<SEC-DOCUMENT>0001193125-15-075224.txt : 20150303
<SEC-HEADER>0001193125-15-075224.hdr.sgml : 20150303
<ACCEPTANCE-DATETIME>20150303165107
ACCESSION NUMBER:		0001193125-15-075224
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		36
CONFORMED PERIOD OF REPORT:	20141231
FILED AS OF DATE:		20150303
DATE AS OF CHANGE:		20150303

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MACROGENICS INC
		CENTRAL INDEX KEY:			0001125345
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36112
		FILM NUMBER:		15669918

	BUSINESS ADDRESS:	
		STREET 1:		9640 MEDICAL CENTER DRIVE
		CITY:			Rockville
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		301-251-5172

	MAIL ADDRESS:	
		STREET 1:		9640 MEDICAL CENTER DRIVE
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>d838054d10k.htm
<DESCRIPTION>FORM 10-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 10-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:17pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:17pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:17pt; font-family:Times New Roman" ALIGN="center"><B>FORM 10-K
</B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(Mark One) </B></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B></B><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT><B></B><B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT&nbsp;OF 1934 </B></TD></TR></TABLE>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman" ALIGN="center"><B>For the fiscal year ended December&nbsp;31, 2014 </B></P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman" ALIGN="center"><B>OR </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B></B><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT><B></B><B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </B></TD></TR></TABLE>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman" ALIGN="center"><B>For the transition period
from&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <U></U> </B></P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number 001-36112 </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:23pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS,
INC. </B></P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant) </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>06-1591613</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(State of organization)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification Number)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman" ALIGN="center"><B>9640 Medical Center Drive, Rockville, Maryland 20850 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive offices and zip code) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman" ALIGN="center"><B>(301) 251-5172 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Registrant&#146;s telephone number) </B></P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman" ALIGN="center"><B>Securities registered pursuant to Section&nbsp;12(b) of the Act: </B></P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:64.15pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title of Each Class</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:156.85pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Name of Each Exchange on Which Registered</B></P></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"><B>Common stock, par value $0.01 per share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>The NASDAQ Stock Market LLC</B></TD></TR>
</TABLE> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman" ALIGN="center"><B>Securities registered pursuant to Section&nbsp;12(g) of the Act: None </B></P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT
STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT> <U></U> </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">Indicate by
check mark if the registrant is not required to file reports pursuant to Section&nbsp;13 or 15(d) of the Exchange Act.&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<FONT
STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT><U></U> </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">Indicate by check mark whether the registrant (1)&nbsp;has filed all reports required to be filed by
Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2)&nbsp;has been subject to such filing requirements for the past
90 days.&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to
be submitted and posted pursuant to Rule&nbsp;405 of Regulation&nbsp;S-T during the preceding 12&nbsp;months (or for such shorter period that the registrant was required to submit and post such files).&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT
STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">Indicate by check mark
if disclosure of delinquent filers pursuant to Item&nbsp;405 of Regulation S-K is not contained herein and will not be contained, to the best of the registrant&#146;s knowledge, in definitive proxy or information statements incorporated by reference
in Part III of this Form 10-K or any amendment to this Form 10-K.&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">Indicate by check mark
whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer&#148; and &#147;smaller reporting
company&#148; in Rule 12b-2 of the Exchange Act. </P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="61%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="19%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">Large&nbsp;accelerated&nbsp;filer</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">Accelerated&nbsp;filer</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">Non-accelerated filer</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">Smaller&nbsp;reporting&nbsp;company</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange
Act).&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT> <U></U> </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">The aggregate market value of the registrant&#146;s common stock, par value $0.01 per share, held by non-affiliates of the registrant on June&nbsp;30, 2014, the
last business day of the registrant&#146;s most recently completed second fiscal quarter, was approximately $437,213,185 based on the closing price of the registrant&#146;s common stock on the NASDAQ Global Select Market on that date. Exclusion of
shares held by any person should not be construed to indicate that such person possesses the power, direct or indirect, to direct or cause the direction of management or policies of the registrant, or that such person is controlled by or under
common control with the registrant. </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">The number of shares of the registrant&#146;s common stock outstanding on February&nbsp;27, 2015 was 29,968,476. </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>DOCUMENTS INCORPORATED BY REFERENCE </B></P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">Portions
of MacroGenics, Inc.&#146;s definitive proxy statement for the 2015 annual meeting of stockholders are incorporated by reference into Part III of this Annual Report. </P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>MACROGENICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ANNUAL REPORT ON FORM 10-K </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD COLSPAN="3" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page<BR>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#rom838054_1">PART&nbsp;I </A></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#rom838054_2">Business</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 1A</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#rom838054_3">Risk Factors</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 1B</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#rom838054_4">Unresolved Staff Comments</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#rom838054_5">Properties</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#rom838054_6">Legal Proceedings</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#rom838054_7">Mine Safety Disclosures</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#rom838054_8">PART&nbsp;II </A></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#rom838054_9">Market for Registrant&#146;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#rom838054_10">Selected Financial Data</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#rom838054_11">Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 7A</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#rom838054_12">Quantitative and Qualitative Disclosures about Market Risk</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 8</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#rom838054_13">Financial Statements and Supplementary Data</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 9</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#rom838054_14">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 9A</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#rom838054_15">Controls and Procedures</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 9B</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#rom838054_16">Other Information</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#rom838054_17">PART&nbsp;III</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 10</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#rom838054_18">Directors, Executive Officers and Corporate Governance</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 11</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#rom838054_19">Executive Compensation</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 12</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#rom838054_20">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 13</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#rom838054_21">Certain Relationships and Related Transactions, and Director Independence</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 14</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#rom838054_22">Principal Accountant Fees and Services</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#rom838054_23">PART IV</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 15</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#rom838054_24">Exhibits and Financial Statement Schedules </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#rom838054_25">SIGNATURES </A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This report includes forward-looking statements within the meaning of federal securities laws. Forward-looking statements include statements
that may relate to our plans, objectives, goals, strategies, future events, future revenues or performance, capital expenditures, financing needs and other information that is not historical information. Many of these statements appear, in
particular, under the headings &#147;Risk Factors&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148;. Forward-looking statements can often be identified by the use of terminology such as
&#147;subject to&#148;, &#147;believe&#148;, &#147;anticipate&#148;, &#147;plan&#148;, &#147;expect&#148;, &#147;intend&#148;, &#147;estimate&#148;, &#147;project&#148;, &#147;may&#148;, &#147;will&#148;, &#147;should&#148;, &#147;would&#148;,
&#147;could&#148;, &#147;can&#148;, the negatives thereof, variations thereon and similar expressions, or by discussions of strategy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All
forward-looking statements, including, without limitation, our examination of historical operating trends, are based upon our current expectations and various assumptions. We believe there is a reasonable basis for our expectations and beliefs, but
they are inherently uncertain. We may not realize our expectations, and our beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements. The following uncertainties and
factors, among others (including those set forth under &#147;Risk Factors&#148;), could affect future performance and cause actual results to differ materially from those matters expressed in or implied by forward-looking statements: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our plans to develop and commercialize our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ongoing and planned clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timing of and our ability to obtain and maintain regulatory approvals for our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our estimates regarding expenses, future revenue, capital requirements and needs for additional financing; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to enter into new collaborations or to identify additional products or product candidates with significant commercial potential that are consistent with our commercial objectives; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the rate and degree of market acceptance and clinical utility of our products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our commercialization, marketing and manufacturing capabilities and strategy; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">significant competition in our industry; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">costs of litigation and the failure to successfully defend lawsuits and other claims against us; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">economic, political and other risks associated with our international operations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to receive research funding and achieve anticipated milestones under our collaborations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our intellectual property position; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">costs of compliance and our failure to comply with new and existing governmental regulations including, but not limited to, tax regulations; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">loss or retirement of key members of management; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">failure to successfully execute our growth strategy, including any delays in our planned future growth; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our failure to maintain effective internal controls. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Consequently, forward-looking statements
should be regarded solely as our current plans, estimates and beliefs. You should not place undue reliance on forward-looking statements. We cannot guarantee future results, events, levels of activity, performance or achievements. We do not
undertake and specifically decline any obligation to update, republish or revise forward-looking statements to reflect future events or circumstances or to reflect the occurrences of unanticipated events. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom838054_1"></A>PART I </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B><A NAME="rom838054_2"></A>ITEM&nbsp;1.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>BUSINESS </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Except as otherwise indicated herein or as the context otherwise requires, references in
this annual report on Form 10-K to &#147;MacroGenics,&#148; the &#147;company,&#148; &#147;we,&#148; &#147;us&#148; and &#147;our&#148; refer to MacroGenics, Inc. and its consolidated subsidiaries.
DART<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, the phrase &#147;Breakthrough Biologics, Life-Changing Medicines&#148; and the MacroGenics logo are our registered trademarks. The other trademarks, trade names and service marks
appearing in this report are the property of their respective owners. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a biopharmaceutical company focused on discovering and developing innovative antibody-based therapeutics for the treatment of cancer, as
well as various autoimmune disorders and infectious diseases. We currently have a pipeline of product candidates in human clinical testing, primarily against different types of cancers. These include two product candidates developed using our
proprietary &#147;Fc Optimization&#148; platform, namely margetuximab, an antibody that we are developing for treatment of certain types of metastatic breast cancers and gastroesophageal cancers, and MGA271, an antibody that we believe has the
potential for broad impact across a variety of different tumor types through multiple potential mechanisms of action. In addition, we created a number of product candidates based on our proprietary <U>D</U>ual-<U>A</U>ffinity
<U>R</U>e-<U>T</U>argeting, or DART, platform and several of these are currently in, or advancing into, human clinical development. For example, we initiated human clinical studies with DART product candidates MGD006, in patients with acute myeloid
leukemia that is refractory to other known treatments, and MGD007, in patients with colorectal cancer. We also recently entered into a collaboration with Janssen Biotech, Inc., or Janssen, with respect to MGD011, a DART being developed for treatment
of various hematological malignancies, and anticipate that this molecule will start clinical trials in 2015. We specifically designed these three DART product candidates with the goal of harnessing the power of the immune system to destroy cancerous
cells. In contrast, the flexibility of the DART platform has also allowed us to create MGD010, a DART molecule designed to moderate the hyperactivity of the immune system seen in various autoimmune disorders, and we expect to start human clinical
studies with that product candidate in 2015 as well. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We develop new therapeutic product candidates ourselves using our antibody-based
technology platforms and also in partnership with other biopharmaceutical companies, when such a partnership is advantageous for strategic or financial reasons. These collaborations have allowed us to expand and accelerate the breadth of product
candidates that can be developed and also have generated a significant portion of the funding we have received to date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our core
scientific expertise is in the field of protein engineering and all of these product candidates have been created through our proprietary protein engineering platforms. These platforms are generally focused on the creation of antibodies, antibody
derivatives, and antibody-like molecules for use as therapeutic agents. Antibodies are proteins produced by specialized cells of the body&#146;s immune system, usually in response to foreign substances such as bacteria and viruses, or to cancer
cells, and they are the primary resource for our product candidates. Many of our cancer product candidates are derived from our library of over 2,000 purified antibodies and we continue to add new antibodies to that library. Our library of
antibodies is targeted to more than 70 different antigens, or components of the foreign substance that induce the production of antibodies. While antibodies can have many different intended effects, the primary ones are to form a complex with, or
bind to, an antigen with the effect of either activating or inactivating it, or to serve as a blocking agent to prevent another molecule from binding to it. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our DART platform enables the creation of potential medicines comprised of a single molecule designed to simultaneously bind to two targets,
each with antibody-like specificity, with the goal of creating a more significant biological effect than binding either one of the targets or even both of them separately. MGD006, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
MGD007, MGD010 and MGD011 have all been generated from this platform and we have several additional DART molecules that are in earlier stages of research and development. To date, we have
identified at least four different mechanistic applications of this platform: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">re-directing natural immune cells, such as T cells, to attack a particular target of interest, such as an antigen found on a specific cancer cell, </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">modulating the effect of the body&#146;s immune cells by binding to two antigens that regulate the body&#146;s immune response, for example in various autoimmune inflammatory diseases, </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">targeting specific immune regulatory control proteins referred to as &#147;checkpoints&#148;; checkpoints may contribute to the suppression of T cell function, and blocking these molecules may serve as an approach for
treating patients with cancer and/or infectious disease, and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">attacking a virus or other pathogen with the goal of neutralizing the pathogen and/or increasing the likelihood that it can be recognized and destroyed by the body&#146;s immune system. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Fc Optimization platform relies on the modification of the constant, or Fc, region of therapeutic antibodies. This region of the antibody
is generally well-recognized by the immune system and our proprietary technology is designed to enhance key characteristics of that recognition system. For example, certain modifications of the Fc region increase antibody-dependent cellular
cytotoxicity, or ADCC, which is the ability of therapeutic antibodies and immune cells to cooperate and destroy targets such as tumor cells. Margetuximab and MGA271 are both antibodies that have been designed using our Fc Optimization platform. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to generating new product candidates using the DART and Fc Optimization platforms, we continue to use our expertise in protein
engineering to expand the existing platforms and develop new ones that may be used to create next-generation medicines. We also have a proprietary Cancer Stem-like Cell, or CSLC, technology that provides a unique discovery tool to identify cancer
targets shared both by tumor-initiating cells and the differentiated cancer cells derived from them. The combination of these technology platforms allows us to customize antibodies, antibody-derived molecules and antibody-like molecules designed to
treat a specific disease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We continue to create new molecules designed for desired therapeutic effect and expect to continue to advance
those programs, either directly or in collaboration with other biopharmaceutical companies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Strategy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Primary Objectives </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our goal is to
be a fully integrated biotechnology company leading in the discovery, development and commercialization of breakthrough biologics for the treatment of patients with cancer, as well as various autoimmune disorders and infectious diseases. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Key elements of our strategy are as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE="font-family:Times New Roman; font-size:10pt"><I>Therapeutic focus, science driven.</I> We create therapeutic biological products primarily for various types of cancers, including both solid
tumors and hematological malignancies. Our proprietary DART and Fc Optimization technology platforms are particularly useful for targeting and harnessing specific elements of the human immune system, allowing us to design molecules that
(1)&nbsp;directly target cancer cells and enhance the ability of the immune system to destroy those cells, (2)&nbsp;re-direct effector cells to attack tumors, or (3)&nbsp;affect mechanisms that regulate the immune response to cancer, either by
stimulating pathways that enhance this response or by blocking pathways that inhibit this response, including checkpoint molecules. This field of scientific discovery, broadly known as immuno-oncology, has been developing rapidly in the last few
years, and most therapeutic products to date are largely focused on affecting individual biological pathways. We believe that cancers are sufficiently </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-family:Times New Roman; font-size:10pt">
complex that effective treatments must simultaneously affect more than one pathway. We believe that we are well-positioned, particularly through the adaptability of our DART platform, to be able
to create and develop therapeutic molecules designed to simultaneously target more than one pathway. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">This same
flexibility in our platforms allows us to create therapeutic molecules that may be useful for other unmet medical needs beyond cancer, such as for autoimmune disorders and infectious diseases. Our core strategic focus is on development of cancer
therapeutics, but we may also opportunistically pursue such possibilities when they arise. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Fully integrated with a deep pipeline.</I> Our objective is to be a fully integrated biotechnology company, in that we intend to continue to grow and establish all necessary functions from early-stage research
through commercialization in at least the United States. At our current stage of development as a company, we have established early-stage discovery, process development, clinical development and clinical-stage manufacturing functions, and we intend
to build commercial manufacturing as well as U.S.-based sales and marketing infrastructure as our development pipeline matures. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">We believe we have a broad portfolio of product candidates and we are not dependent upon the success of any one of them for the overall success
of the company. We continue to augment that pipeline through the discovery and development of new product candidates, primarily through utilization of our internal scientific expertise and strategically seeking external collaborations that can
augment our own skills. In 2014, we advanced two programs into clinical development and expect that we will advance at least two more into clinical development in 2015. Our goal is to continue at approximately that pace to ensure a robust pipeline
and to replace product candidates that fail to progress. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Leveraging partnerships.</I> Throughout our company&#146;s history we have entered into collaborations with other biopharmaceutical companies and intend to continue to do so. We enter into collaborations when there
is a strategic advantage to us to do so and when we believe the financial terms of the collaboration are favorable for meeting our short-term and long-term strategic objectives. We are not dependent upon any one of these collaborations, but in many
cases we have the rights to significant financial payments if the product candidates that are the subjects of the collaborations achieve development milestones and sales. We have also used these collaborations to provide funding for research, to
maintain a broader portfolio of product candidates, and to obtain rights to expand in the future, for example by securing co-promotion and profit-sharing rights under certain circumstances. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Investments in talent and culture. </I>One of our most valuable assets is the quality of our employee base. We invest significant effort in selecting and retaining high caliber, talented individuals who reflect our
values of teamwork, initiative, innovation, corporate responsibility and integrity. As we continue to grow, we continue to seek and develop employees who are strongly committed to delivering life-changing medicines for unmet medical needs through a
collaborative work environment. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Core Therapeutic Areas We Target </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cancer </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cancer is a broad group of
diseases in which cells divide and grow in an uncontrolled fashion, forming malignancies that can invade other parts of the body. In normal tissues, the rates of new cell growth and cell death are tightly regulated and kept in balance. In cancerous
tissues, this balance is disrupted as a result of mutations, causing unregulated cell growth that leads to tumor formation and growth. While tumors can grow slowly or rapidly, the dividing cells will nevertheless accumulate and the normal
organization of the tissue will become disrupted. Cancers subsequently can spread throughout the body by processes known as invasion and metastasis. Once cancer spreads to sites beyond the primary tumor, it may be incurable. Cancer cells that arise
in the lymphatic system and bone marrow are referred to as hematological malignancies. Cancer cells that arise in other tissues or organs are referred to as solid tumors. Cancer can arise in virtually any part of the body, with the most common types
arising in the prostate gland, breast, lung, colon and skin. We believe that our platforms position us very well strategically to actively develop approaches for the treatment of both solid tumors and hematologic malignancies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cancer is the second leading cause of death in the United States, exceeded only by heart disease,
and accounts for almost one of every four deaths. The American Cancer Society estimates that in 2015 there will be approximately 1.7&nbsp;million new cases of cancer and approximately 590,000 deaths from cancer. The National Institutes of Health
estimates that based on growth and aging of the U.S. population, medical expenditures for cancer in the year 2020 are projected to reach at least $158 billion (in 2010 dollars), representing an increase of 27% over 2010. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Autoimmune Disorders </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Autoimmune
disorders including rheumatoid arthritis, Crohn&#146;s disease, systemic lupus erythematosus, and multiple sclerosis, collectively affect more than 20&nbsp;million people in the United States. Autoimmune disorders involve self-reactivity and
destruction by T cells, B cells and antibodies due to a lack of self-tolerance. Anti-inflammatory therapies, such as TNF (tumor necrosis factor) inhibitors, have been able to improve diseases like rheumatoid arthritis. However, in addition to T
cells, more evidence indicates that B cells play an important role in many common autoimmune and allergic disorders by initiating and amplifying the pathological disease processes. Current B cell targeted therapies either cause depletion of B cells,
thus limiting their applicability due to the potential for infections (e.g., rituximab), or exhibit a delayed onset of action and limited efficacy across patient populations (e.g., belimumab). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Product Candidates </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table below
depicts the current status of product candidates that are in or near human clinical development and for which we retain all or some commercial rights: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g838054g02w00.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Oncology </I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE="font-family:Times New Roman; font-size:10pt"><I>Margetuximab</I> is an antibody that targets HER2-expressing tumors, including certain types of breast and gastroesophageal cancers. Human
epidermal growth factor receptor 2, or HER2, is critical for the growth of many types of tumors. Using our Fc Optimization platform, we have engineered the constant region, or Fc region, of margetuximab to increase margetuximab&#146;s ability to
kill tumor cells through an </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-family:Times New Roman; font-size:10pt">
Fc-dependent mechanism, including antibody dependent cell-mediated cytotoxicity, or ADCC. Our preliminary Phase 1 data for margetuximab demonstrated that anti-tumor activity had been observed at
a range of doses tested, including the lowest dose level of margetuximab, even in patients who were heavily pre-treated (frequently with other anti-HER2 agents). In 2015, we plan to commence a Phase 3 potential registration clinical trial with
margetuximab called &#147;SOPHIA&#148; in patients with metastatic breast cancer expressing HER2 at the 3+ level by immunohistochemistry (IHC) or 2+ level by IHC with gene amplification who have failed therapy with other HER2-directed therapeutic
agents. We also plan to commence exploratory Phase 1/2 studies combining margetuximab with other therapeutic agents in patients with gastroesophageal cancer, and we are currently enrolling a Phase 2a clinical trial in patients with lower levels of
HER2 expression. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>MGA271 </I>is an antibody that targets B7-H3, a member of the B7 family of molecules involved in immune regulation, and that is over-expressed on a wide variety of solid tumor types. Inhibition of certain members of
the B7 family has been shown to have powerful anti-tumor effects in several solid tumor types. We engineered MGA271 to utilize the same Fc Optimization enhancements that we incorporated in margetuximab, and to target B7-H3 that is over-expressed on
differentiated tumor cells and CSLCs, as well as on the supporting tumor vasculature and underlying tissues. MGA271 is designed to destroy all of these components of the cancer. We have initiated additional dose expansion cohorts using MGA271 as
monotherapy in other tumor types, including patients with melanoma (who have failed prior therapy with checkpoint inhibitors), renal cell carcinoma, triple-negative breast carcinoma, squamous cell carcinoma of the head and neck and a cohort of
patients with lung or bladder carcinoma that have particularly intense expression of B7-H3. In 2015, we also intend to initiate one clinical study combining MGA271 with ipilimumab and plan to initiate a second study combining MGA271 with another
immuno-oncology agent. Under the terms of a collaboration, Les Laboratoires Servier and Institut de Recherches Servier, or collectively, Servier, has an option to obtain exclusive rights to develop and commercialize MGA271 in all countries other
than the United States, Canada, Mexico, Japan, South Korea and India. If the option is exercised, MacroGenics would still retain exclusive rights in those countries. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>MGD006 </I>is a DART molecule that recognizes both CD123 and CD3. CD123, the Interleukin-3 receptor alpha chain, is expressed on leukemia and leukemic stem cells, but only at very low levels or not at all on normal
hematopoietic stem cells. T cells, which express CD3, can destroy tumor cells. In pre-clinical studies, we have demonstrated the ability of MGD006 to recruit, activate, and expand T cell populations to eliminate leukemia cells. We are currently
enrolling and dosing patients in the dose escalation portion of a Phase 1 clinical trial of MGD006. Under the terms of a collaboration, Servier has the exclusive right to develop and commercialize MGD006 in all countries other than the United
States, Canada, Mexico, Japan, South Korea and India, and MacroGenics retains exclusive rights in those countries. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>MGD007 </I>is a DART molecule that recognizes both the glycoprotein A33 (gpA33) and CD3, and has an Fc domain, which allows for extended pharmacokinetic properties, and convenient intermittent dosing. gpA33 is
expressed on gastrointestinal tumors, including more than 95% of human colon cancers. We have demonstrated that this molecule is able to mediate T&nbsp;cell killing of gpA33-expressing cancer cells and CSLCs in pre-clinical experiments. We are
currently enrolling and dosing patients in the dose escalation portion of a Phase 1 clinical trial of MGD007. Under the terms of a collaboration, Servier has an option to obtain exclusive rights to develop and commercialize MGD007 in all countries
other than the United States, Canada, Mexico, Japan, South Korea and India. If the option is exercised, MacroGenics would still retain exclusive rights in those countries. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE="font-family:Times New Roman; font-size:10pt"><I>MGD011 </I>is a DART molecule that targets both CD19 and CD3 and is being developed for the treatment of B-cell hematological malignancies. CD19, a
lymphocyte-specific marker expressed from early B-lymphocyte development through mature memory B cells, is highly represented in B-cell malignancies. This makes it attractive for targeted interventions. MGD011 is designed to redirect T&nbsp;cells,
via their CD3 component, to eliminate CD19-expressing cells found in many hematological </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-family:Times New Roman; font-size:10pt">
malignancies.&nbsp;MGD011 has been engineered to address half-life challenges posed by other programs targeting CD19 and CD3. Like MGD007, this product candidate has an Fc domain, which allows
for extended pharmacokinetic properties and convenient dosing at a once-a-week or longer interval.&nbsp;In addition, MGD011 and our other DART molecules that redirect T cells against cancer targets are manufactured using a conventional antibody
platform without the complexity of having to genetically modify T cells from individual patients as required by approaches such as chimeric antigen receptor (CAR) T-cells. Under our recent collaboration and license agreement with Janssen, after we
file the investigational new drug, or IND, application for MGD011, Janssen will develop the product candidate, subject to our options to co-promote the product in the United States and Canada and to invest in later-stage development in exchange for
a United States and Canada profit-share. We anticipate that human clinical studies of MGD011 will begin in 2015. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>MGD009 </I>is a DART molecule that recognizes an undisclosed solid tumor antigen and CD3, and has an Fc domain, which allows for extended pharmacokinetic properties. We have demonstrated that this molecule is able to
mediate T&nbsp;cell killing of cancer cells in pre-clinical experiments. We expect to submit an IND for MGD009 in 2015 and initiate a Phase 1 clinical study by year-end. MacroGenics retains worldwide development and commercialization rights to this
molecule. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Autoimmune Disorders </I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>MGD010</I> is a DART molecule designed to address limitations of existing B cell-targeted therapies by binding to the CD32B and CD79B proteins found on human B cells. In pre-clinical studies, this DART molecule
modulates the function of human B cells without B cell depletion. In normal conditions, B cells utilize CD32B as one of the key checkpoints or negative regulators to ensure that tolerance to self is maintained and autoimmune disease does not occur.
MGD010 is designed to further exploit this mechanism by triggering this inhibitory &#147;immune checkpoint&#148; loop. We believe this molecule preferentially blocks those B cells that are activated to produce the pathogenic antibodies that promote
the autoimmune process. We are planning to initiate a Phase 1a clinical trial with MGD010 in normal healthy volunteers in 2015. Under the terms of a collaboration agreement with respect to MGD010, Takeda Pharmaceutical Company Limited, or Takeda,
has the option to further develop the program after completion of Phase 1a clinical development and, if that option is exercised, we would retain the right to co-promote the product in the United States and to invest in Phase 3 development in
exchange for a North America profit-share. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Teplizumab</I> is an anti-CD3 monoclonal antibody being developed for the treatment of type 1 diabetes. Teplizumab has been engineered to alter the function of the T cells that mediate the destruction of the
insulin-producing beta cells of the islets of the pancreas. Teplizumab potentially represents an advance in the treatment of type 1 diabetes by addressing the underlying disorder, rather than merely using insulin replacement therapy. Teplizumab is
currently being evaluated in a Phase 2 clinical trial, called At-Risk, for the prevention or delay of onset of type 1 diabetes in patients determined to be at very high risk for developing the disease. This clinical trial is being sponsored by the
National Institute of Diabetes and Digestive and Kidney Diseases. We are actively seeking a collaborator for further development of teplizumab. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Platforms and Technology Expertise </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We apply our understanding of disease biology, immune-mediated mechanisms and next generation antibody technologies to design specifically
targeted antibody-based product candidates based on our DART and Fc&nbsp;Optimization platforms. Through these platforms and utilization of our CSLC technology, we have designed antibody-based product candidates that have the potential to improve on
standard treatments by having: (1)&nbsp;multiple specificities; (2)&nbsp;increased abilities to interact with the body&#146;s immune system to fight tumors; (3)&nbsp;capacity to bind more avidly to antigen targets: (4)&nbsp;increased potency;
(5)&nbsp;reduced immunogenicity; or (6)&nbsp;the ability to target cancer cells that are resistant to standard treatments. Moreover, these technology platforms are complementary and can be combined. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>DART Platform: Our Proprietary Approach to Engineer Bi-Specific Antibodies </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We use our DART platform to create derivatives of antibodies with the ability to bind to two distinct targets instead of a single one found in
traditional monoclonal antibodies. DART product candidates are therefore bi-specific. An example of a bi-specific molecule is illustrated below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g838054g00a25.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because cancer cells have developed ways to escape the immune system, we have created DART molecules that
improve upon the human immune system, by creating alternative antibody-like structures with more potent immune properties than the parent antibody molecules from which they are derived. The two variable regions of an antibody are mono-specific and
are able to target only a single type structural component of an antigen. For many years, researchers have sought to create recombinant molecules that are capable of targeting two antigens or epitopes (i.e., specific part of an antigen bound by the
antibody) within the same molecule. The challenges in creating such molecules have been the instability of the resulting bi-specific molecules and their inherent short half-lives, as well as the inefficiencies in manufacturing these compounds. We
believe our DART platform has overcome these engineering challenges by incorporating proprietary covalent di-sulfide linkages and particular amino acid sequences that efficiently pair the chains of the DART molecule. This results in a structure with
enhanced manufacturability, long-term structural stability, and the ability to tailor the half-lives of the DART molecules to their clinical needs. This engineered antibody-like protein has a compact and stable structure and enables the targeting of
two different antigens with a single recombinant molecule. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The DART platform has been specifically engineered to accommodate virtually
any variable region sequence with predictable expression, folding, and antigen recognition. To date, we have produced over 100 different DART molecules and have completed numerous in vitro and in vivo proof-of-principle studies on many of these
molecules. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe our DART platform may provide a significant advantage over current biological
interventions in cancer, autoimmune disorders and infectious disease by enabling a range of modalities, including those described below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&nbsp;&nbsp;&nbsp;&nbsp;<I>Redirected T cell activation and killing.</I> In this version of the DART molecule, we are enabling
the cancer-fighting properties of the immune effector cells, such as T lymphocytes to: (1)&nbsp;recognize and bind to structures expressed on a cancer cell (e.g., CD123, the first specificity in the example on the right), (2)&nbsp;enable the
recruitment of all types of cytotoxic, or cell killing, T cells, irrespective of their ability to recognize cancer cells (e.g., CD3, a common component of the T cell antigen receptor, is the second specificity in the example on the right), and
(3)&nbsp;trigger T cell activation, expansion, and cell killing mechanisms to destroy a cancer cell. The outcome is that any of the body&#146;s T cells, in theory, could be recruited to destroy a cancer cell and thus, are not limited to the small
numbers of specific T cells that might have been generated in response to cancer to kill tumor cells. Furthermore, since any T cell could be recruited for this killing process, only small amounts of a DART molecule are required to trigger this
potent immune response. Additionally, the compact structure of the DART protein makes it well suited for maintaining cell-to-cell contact, apparently contributing to the high level of target cell killing.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt" ALIGN="center">


<IMG SRC="g838054g79a80.jpg" ALT="LOGO">
&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&nbsp;&nbsp;&nbsp;&nbsp;<I>Modulation of receptor signaling</I>. In another configuration of the DART molecule, we have taken
advantage of the two different specificities engineered in a DART structure to bind not only to particular cells involved in autoimmune processes, such as autoimmune B cells, but also to usurp the immune checkpoint signaling pathways programmed
within the cells to impede the pathogenic autoimmune responses. Our MGD010 product candidate targets both CD32B, a co-inhibitory molecule, and CD79B, part of the B cell antigen receptor complex, two proteins expressed on the immune system&#146;s B
cells. Using a single DART molecule, we attempt to promote the interaction of these two receptors, a step required to interrupt the B-cell activation and immune response that single antibodies directed against CD32B, CD79B, or both cannot accomplish
independently.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt" ALIGN="center">


<IMG SRC="g838054g92l36.jpg" ALT="LOGO">
&nbsp;</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&nbsp;&nbsp;&nbsp;&nbsp;<I>Simultaneous targeting of multiple co-inhibitory receptors or checkpoints, such as those involved in
inhibiting T cell responses and B cell responses.</I> The immune system generally prevents the development of autoimmune phenomena by regulating activated immune cells that have responded to non-self or foreign antigens. This negative feedback loop
is triggered by the interactions of co-inhibitory receptors, or checkpoint molecules, expressed on the immune cells with ligands expressed by other cells, such as antigen-presenting cells. This phenomenon is exploited by cancer, whereby tumor cells
express checkpoint ligands that block the development of an immune response against the tumor. Antibodies that block the interaction of checkpoint molecules with their ligands have been shown to significantly improve the clinical outcomes of
patients with advanced cancers. Because of the diversity of immune checkpoint pathways, blockade of a single axis, while clinically significant, as shown in the case of the blockade of the PD-1/PD-L1 axis with pembrolizumab or nivolumab, will not
benefit all patients. In fact, combinations of checkpoint inhibitors, such as nivolumab and ipilimumab, a CTLA-4 blocker, have resulted in significantly enhanced benefit compared to ipilimumab alone. We believe that DART molecules targeting two
immunoregulatory pathways, such as two checkpoints in a single molecule, could afford the clinical benefit of the combination together with the potential for synergistic activity, as well as significant advantages in manufacturing, simplified
clinical development, and enhanced patient convenience.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt" ALIGN="center">


<IMG SRC="g838054g44a20.jpg" ALT="LOGO">
&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&nbsp;&nbsp;&nbsp;&nbsp;<I>Targeting multiple epitopes on a pathogen for enhanced neutralization and/or clearance</I>. Infectious
agents with slightly different genetic sequences or structures may perpetuate disease. Sometimes multiple variants may infect one individual and may evade the patient&#146;s normal immune responses. Creating DART molecules that neutralize multiple
infectious variants of a virus or multiple toxins produced by a bacterium could be an advantage for prevention or treatment. Examples of this include targeting the major genetic and serological forms of dengue virus, the cause of a major viral
disease transmitted by mosquitoes, quasi-species of HIV, or different bacterial toxins derived from pathogenic clostridium species.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" ALIGN="center">


<IMG SRC="g838054g38b30.jpg" ALT="LOGO">
&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we have the ability to tailor a DART molecule&#146;s valency (number of binding sites), the
strength by which the binding sites attach to their targets, and its half-life in the blood circulation, after delivery to a patient. Furthermore, when an Fc domain is coupled with a DART molecule, additional changes can be included that can
modulate the DART molecule&#146;s engagement with different immune cells. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have developed proof-of-concept pre-clinical data and are
developing specific product candidates using this technology, including MGD006, MGD007, MGD010, MGD011 and MGD009, among others. We have been able to produce DART molecules in both bacterial and mammalian expression systems. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fc Optimization Platform: Our Proprietary Approach to Enhance Immune-Mediated Cancer Cell Killing
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To enhance the body&#146;s immune ability, we developed our Fc Optimization platform which introduces certain mutations into the
Fc region of an antibody and is able to modulate antibody interaction with immune effector cells. Such interaction enhances the body&#146;s immune ability to mediate the killing of cancer cells through ADCC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ADCC </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g838054g04y47.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Fc region mediates the function of certain antibodies by binding to different activating and inhibitory
receptors, referred to as Fc<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT>Rs, on immune effector cells found within the innate immune system. By engineering Fc regions to bind with an increased affinity to the activating Fc<FONT
STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT>Rs and with a reduced affinity to the inhibitory Fc<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT>Rs, we have been able to impart a more effective immune response, and improve effector functions, such as ADCC.
This is another example in which small changes in antibody structure can confer improvements on normal immune processes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have
established a proprietary platform to engineer, screen, identify and test antibodies&#146; Fc regions with customizable activity. In particular, we have licenses to use transgenic mice that express human
Fc<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT>Rs. These mice can be used for in vivo testing of antibodies that incorporate Fc domain variants, including those antibodies intended for cancer therapy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To date, we have successfully incorporated our Fc variants in two of our clinical-stage antibody product candidates, margetuximab and MGA271.
We have pre-clinical data demonstrating that these Fc variants have substantially improved the therapeutic effects of these antibodies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cancer
Stem-like Cell Technology: Our Proprietary Approach to Discover Cancer Targets </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our CSLC technology provides new approaches to
discover and identify cancer targets that are not susceptible to current cancer therapies. Cancer stem cells represent important potential targets in oncology drug development because they are theorized to be the basis for tumor re-growth,
metastasis and resistance to much standard chemotherapy. Therefore, the ability to specifically target and destroy cancer stem cells could potentially address an unmet medical need in many hard-to-treat cancers today. Using our CSLC technology, we
can create antibodies that could target or kill cancer stem cells. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Building on our expertise in growing stem cells from normal tissues
using proprietary media and culture conditions, we have produced CSLCs from a range of primary human tumor tissues, including those derived from the colon, lung and ovary. We analyze and characterize the CSLCs for the following stem-cell related
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
features: (a)&nbsp;ability for self-renewal, (b)&nbsp;ability to form tumors <I></I>in vivo<I></I> that differentiate with the expected histological characteristics, and (c)&nbsp;genetic and
protein stem cell marker expression profiles. To date, we have created novel antibodies that target antigens on both CSLCs and the bulk differentiated tumor cells, which are derived from the CSLCs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have generated over 2,000 monoclonal antibodies that we have screened by IHC for lower-binding to normal, non-malignant tissues. Many of
these antibodies have been characterized for binding to primary tumors and cancer cell lines and we are developing the most promising of these antibodies into product candidates. This collection of antibodies is selective for both validated and
novel cancer targets. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Collaborations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We pursue a balanced approach between product candidates that we develop ourselves and those that we develop with our collaborators. Under our
current strategic collaborations, we have received significant non-dilutive funding to date and continue to have rights to additional funding upon completion of certain research, achievement of key product development milestones, or royalties and
other payments upon the commercial sale of products. Each of our collaborations has a unique set of terms and conditions, but in general, they fall into two categories: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>MacroGenics-Created Programs</I>. We have a number of collaborations relating to product candidates that we have created from our internal research efforts. These include Janssen for MGD011; Servier for MGA271,
MGD006 and MGD007; Takeda for MGD010; and Green Cross Corp., or Green Cross, for margetuximab. In the case of these product candidates, we have entered into collaborations when we believed that our partner could further enable development of the
program or provide additional capabilities and funding to supplement MacroGenics&#146; investment, or both. In all of these cases, we obtained financial terms that we believed were beneficial to us and retained commercial rights for multiple major
markets or options to other commercial rights. For example, under the Janssen and Takeda agreements, we have the option to co-promote products in the United States as well as an option to share in profits in the United States (and Canada, as well,
under the Janssen agreement) if we invest in the late-stage development. Under the Servier agreements, we retain full commercialization and development rights in the United States, Canada, Mexico, Japan, South Korea and India. Under the Green Cross
agreement, we retain full commercialization rights worldwide except for South Korea. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Joint Research Programs.</I> We have several programs under which collaborators have sought to utilize some aspect of our protein engineering platforms with new product concepts that are jointly directed, and
sometimes employing a collaborator&#146;s own proprietary technology. These collaborations give us the ability to expand the breadth of our potential products, develop greater scientific expertise, and obtain additional funding for research. We have
entered into these types of programs with Pfizer, Inc., Boehringer Ingelheim GmbH, or Boehringer, and Gilead Sciences, Inc., or Gilead. With these collaborators we have more limited development or commercial rights related to the product candidates
that may emerge from joint research programs. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Intellectual Property </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We strive to protect the proprietary technologies that we believe are important to our business, including seeking and maintaining patents
intended to protect, for example, the composition of matter of our product candidates, their methods of use, the technology platforms used to generate them, related technologies and/or other aspects of the inventions that are important to our
business. We also rely on trade secrets and careful monitoring of our proprietary information to protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our success will depend significantly on our ability to obtain and maintain patent and other proprietary protection for commercially important
technology, inventions and know-how related to our business. In addition, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
there is cost and risk to our business in defending and enforcing our patents, maintaining our licenses to use intellectual property owned by third parties, and preserving the confidentiality of
our trade secrets and operate without infringing the valid and enforceable patents and other proprietary rights of third parties. We also rely on know-how, continuing technological innovation and in-licensing opportunities to develop, strengthen,
and maintain our proprietary positions. We currently use multiple industry-standard patent monitoring systems to monitor new United States Patent and Trademark Office, or USPTO, filings for any applications by third parties that may infringe on our
patents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent positions of biopharmaceutical companies like us are generally uncertain and involve complex legal, scientific and
factual questions. In addition, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted by the courts after issuance. Consequently, we do not know whether any of our
product candidates will be protectable or remain protected by enforceable patents. We cannot predict whether the patent applications we are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued
patents will provide sufficient proprietary protection from competitors. Any patents that we hold may be challenged, narrowed, circumvented or invalidated by third parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A third party may hold patents or other intellectual property rights that are important to or necessary for the development of our product
candidates or use of our technology platforms. It may be necessary for us to use the patented or proprietary technology of third parties to commercialize our product candidates, in which case we would be required to obtain a license from these third
parties on commercially reasonable terms, or our business could be harmed, possibly materially. For example, certain patents held by third parties cover Fc engineering methods and mutations in Fc regions to enhance the binding of Fc regions to Fc
receptors on immune cells. Although we believe that these patents are invalid, if they cover margetuximab or MGA271 and we are unable to invalidate them, or if licenses for them are not available on commercially reasonable terms, our business could
be harmed, perhaps materially. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because patent applications in the United States and certain other jurisdictions can be maintained in
secrecy for 18 months or potentially even longer, and because publication of discoveries in the scientific or patent literature often lags behind actual discoveries, we cannot be certain of the priority of inventions covered by pending patent
applications. Moreover, we may have to participate in interference proceedings declared by the USPTO to determine priority of invention. From time to time, we may, in the ordinary course of business, participate in post-grant challenge proceedings,
such as oppositions, that challenge the patentability of third party patents. Such proceedings could result in substantial cost, even if the eventual outcome is favorable to us. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>FDA Regulatory Review Process </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Hatch-Waxman Act permits a patent term extension for FDA-approved drugs of up to five years beyond the expiration of the patent. The length of the patent term extension is related to the length of time the drug is under regulatory review. Patent
extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval and only one patent applicable to an approved drug may be extended. Similar provisions are available in Europe and other
jurisdictions to extend the term of a patent that covers an approved drug. In the future, if and when our pharmaceutical product candidates receive FDA approval, we expect to apply for patent term extensions on patents covering those products. We
intend to seek patent term extensions to any of our issued patents in any jurisdiction where these are available, however there is no guarantee that the applicable authorities, including the FDA in the United States, will agree with our assessment
of whether such extensions should be granted, and even if granted, the length of such extensions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Trade Secrets </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also rely on trade secret protection for our confidential and proprietary information. Although we take steps to protect our proprietary
information and trade secrets, including through contractual means with our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
employees and consultants, third parties may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets or disclose our
technology. Thus, we may not be able to meaningfully protect our trade secrets. It is our policy to require our employees, consultants, outside scientific collaborators, sponsored researchers and other advisors to execute confidentiality agreements
upon the commencement of employment or consulting relationships with us. These agreements provide that all confidential information concerning our business or financial affairs developed or made known to the individual during the course of the
individual&#146;s relationship with us is to be kept confidential and not disclosed to third parties except in specific circumstances. In the case of employees, the agreements provide that all inventions conceived by the individual, and which are
related to our current or planned business or research and development or made during normal working hours, on our premises or using our equipment or proprietary information, are our exclusive property. In many cases our confidentiality and other
agreements with consultants, outside scientific collaborators, sponsored researchers and other advisors require them to assign or grant us licenses to inventions they invent as a result the work or services they render under such agreements or grant
us an option to negotiate a license to use such inventions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>In-Licensed Intellectual Property </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into patent and know-how license agreements that grant us the right to use a certain technology related to biological
manufacturing for margetuximab and MGA271. We anticipate using this technology for future product candidates. This licensor has a business dedicated to licensing this technology and we anticipate that licenses to use the technology for our future
products will be available. The licenses typically include an obligation to pay an upfront payment, yearly maintenance payments and sales royalties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In establishing our Fc Optimization platform, we entered into patent license agreements which grant us the right to use technologies to
generate mutant Fc regions. The licenses include obligations to pay a yearly maintenance payment, development milestones and sales royalties on products we develop and commercialize that include mutant Fc regions generated using the patented
technologies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Manufacturing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
currently have a manufacturing facility located in Rockville, Maryland. We intend to expand our capacity at this location later in 2015. For our Phase 3 clinical trials for our antibody product candidates and for commercial sale quantities of such
candidates, we have supplemented our manufacturing capacity through contract manufacturing organizations and may need to expand further to be able to supply the quantities required. We intend to screen multiple manufacturers to provide the drug
substance for commercial purposes for some of our product candidates prior to the filing of a biologics license application, or BLA. We currently rely on and will continue to rely on contract fill-finish service providers to fulfill our fill-finish
needs for our current and future product candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Commercialization </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not yet established a sales, marketing or product distribution infrastructure because our lead product candidates are still in clinical
development. We believe that it will be possible for us to access the United States oncology market through a targeted specialty sales force. Subject to receiving marketing approvals, we expect to commence commercialization activities by building a
focused sales and marketing organization in the United States to sell our products. We believe that such an organization will be able to address the community of oncologists who are the key specialists in treating the patient populations for which
our oncology product candidates are being developed. Outside the United States, we expect to enter into distribution and other marketing arrangements with third parties for any of our product candidates that obtain marketing approval. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Competition </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are a large number of companies developing or marketing treatments for cancer and autoimmune disorders, including many major
pharmaceutical and biotechnology companies. These treatments consist both of small molecule drug products, as well as biologic therapeutics that work by using next-generation antibody technology platforms to address specific cancer targets. In
addition, several companies are developing therapeutics that work by targeting multiple specificities using a single recombinant molecule. Amgen Inc. has obtained marketing approval for at least one product that works by targeting antigens both on
immune effector cell populations and those expressed on certain cancer cells, and has other product candidates in development that use this mechanism. In addition, other companies are developing new treatments for cancer and autoimmune diseases that
enhance the Fc regions of antibodies to create more potent antibodies, including F. Hoffmann -La Roche Ltd. and Xencor, Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many of our
competitors have significantly greater financial, manufacturing, marketing, drug development, technical and human resources than we do. Mergers and acquisitions in the pharmaceutical, biotechnology and diagnostic industries may result in even more
resources being concentrated among a smaller number of our competitors. Smaller or early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These
competitors also compete with us in recruiting and retaining top qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to,
or necessary for, our programs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The key competitive factors affecting the success of all of our therapeutic product candidates, if
approved, are likely to be their efficacy, safety, dosing convenience, price, the effectiveness of companion diagnostics in guiding the use of related therapeutics, the level of generic competition and the availability of reimbursement from
government and other third party payors. In addition, the standard of medical care provided to cancer patients continues to evolve as more scientific and medical information becomes available. These changes in medical care relate to pharmaceutical
products, but are also affected by other factors, and such changes can positively or negatively affect the prospects of our product candidates as well as those of our competitors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are more effective, have
fewer or less severe effects, are more convenient or are less expensive than any products that we may develop. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours,
which could result in our competitors establishing a strong market position before we are able to enter the market. In addition, our ability to compete may be affected in many cases by insurers or other third party payors seeking to encourage the
use of biosimilar products. Biosimilar products are expected to become available over the coming years. For example, certain products that are trastuzumab biosimilars may be approved in the U.S. prior to margetuximab, if approved. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The most common methods of treating patients with cancer are surgery, radiation and drug therapy. There are a variety of available drug
therapies marketed for cancer. In many cases, these drugs are administered in combination to enhance efficacy. While our product candidates may compete with many existing drug and other therapies, to the extent they are ultimately used in
combination with or as an adjunct to these therapies, our product candidates will not be competitive with them. Some of the currently approved drug therapies are branded and subject to patent protection, and others are available on a generic basis.
Many of these approved drugs are well established therapies and are widely accepted by physicians, patients and third party payors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
addition to currently marketed therapies, there are also a number of products in late stage clinical development to treat cancer. These product candidates in development may provide efficacy, safety, dosing convenience and other benefits that are
not provided by currently marketed therapies. As a result, they may provide significant competition for any of our product candidates for which we obtain marketing approval. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Government Regulation and Product Approval </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Government authorities in the United States, at the federal, state and local level, and in other countries extensively regulate, among other
things, the research, development, testing, manufacture, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing, import and export of pharmaceutical products such as those we are developing. The processes for
obtaining regulatory approvals in the United States and in foreign countries, along with subsequent compliance with applicable statutes and regulations, require the expenditure of substantial time and financial resources. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>FDA Approval Process </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All of our
current product candidates are subject to regulation in the United States by the FDA as biological products, or biologics. The FDA subjects biologics to extensive pre- and post-market regulation. The Public Health Service Act, the Federal Food,
Drug, and Cosmetic Act and other federal and state statutes and regulations, govern, among other things, the research, development, testing, manufacture, storage, recordkeeping, approval, labeling, promotion and marketing, distribution,
post-approval monitoring and reporting, sampling, and import and export of biologics. Failure to comply with applicable U.S. requirements may subject a company to a variety of administrative or judicial sanctions, such as FDA refusal to approve
pending BLAs, withdrawal of approvals, clinical holds, warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties, or criminal penalties. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other Healthcare Laws and Compliance Requirements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, our activities are potentially subject to regulation by federal, state, and local authorities in addition to the FDA,
including the Centers for Medicare and Medicaid Services, other divisions of the U.S. Department of Health and Human Services (e.g., the Office of Inspector General), the U.S. Department of Justice and individual U.S. Attorney offices within the
Department of Justice, and state and local governments. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>International Regulation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to regulations in the United States, a variety of foreign regulations govern clinical trials, commercial sales, and distribution of
product candidates. The approval process varies from country to country and the time to approval may be longer or shorter than that required for FDA approval. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Pharmaceutical Coverage, Pricing, and Reimbursement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States and other countries, sales of any products for which we receive regulatory approval for commercial sale will depend in
part on the availability of reimbursement from third-party payors, including government health administrative authorities, managed care providers, private health insurers, and other organizations. Third-party payors are increasingly examining the
medical necessity and cost effectiveness of medical products and services in addition to safety and efficacy and, accordingly, significant uncertainty exists as to the reimbursement status of newly approved therapeutics. Third-party reimbursement
adequate to enable us to realize an appropriate return on our investment in research and product development may not be available for our products. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Facilities </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our headquarters are located
in Rockville, Maryland, where we occupy office and laboratory space under two leases that each expire on January&nbsp;31, 2020, and each of those leases may be extended for a five-year term. Our manufacturing facility is also located in Rockville
under lease from the same landlord. The lease for a portion of that facility expires on March&nbsp;31, 2018 and may be extended for a five-year term, and the lease for the remainder of that facility expires on December&nbsp;31, 2019. We also lease
office and laboratory space in South San Francisco under a lease that expires on February&nbsp;28, 2018. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employees </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of February&nbsp;27, 2015, we had 211 full-time employees, 180 of whom were primarily engaged in research and development activities and 43
of whom had an M.D. or Ph.D. degree. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Legal Proceedings </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time we may be involved in various disputes and litigation matters that arise in the ordinary course of business. We are not
currently a party to any material legal proceedings. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Available Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our website address is www.macrogenics.com. We post links to our website to the following filings as soon as reasonably practicable after they
are electronically filed with or furnished to the Securities and Exchange Commission, or the SEC: Annual Reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, proxy statements, and any amendments to those reports filed
or furnished pursuant to Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934, as amended. All such filings are available through our website free of charge. Our filings may also be read and copied at the SEC&#146;s Public Reference Room
at 100 F Street, NE, Washington, DC 20549. Information on the operation of the Public Reference Room may be obtained by calling the SEC at 1-800-SEC-0330. The SEC also maintains an internet site at www.sec.gov that contains reports, proxy and
information statements, and other information regarding issuers that file electronically with the SEC. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B><A NAME="rom838054_3"></A>ITEM&nbsp;1A.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>RISK FACTORS </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Our business and results of operations are subject to numerous risks,
uncertainties and other factors that you should be aware of, some of which are described below. The risks, uncertainties and other factors described below are not the only ones facing our company. Additional risks, uncertainties and other factors
not presently known to us or that we currently deem immaterial may also impair our business operations. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Any of the risks,
uncertainties and other factors could have a materially adverse effect on our business, financial condition or results of operations and could cause the trading price of our common stock to decline substantially. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Business and the Development and Commercialization of Our Product Candidates. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>All of our product candidates are in pre-clinical or clinical development. Clinical drug development is expensive, time consuming and uncertain and we
may ultimately not be able to obtain regulatory approvals for the commercialization of some or all of our product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
research, testing, manufacturing, labeling, approval, selling, marketing and distribution of drug products are subject to extensive regulation by the U.S. Food and Drug Administration, or FDA, and non-U.S. regulatory authorities, which regulations
differ from country to country. We are not permitted to market our product candidates in the United States or in other countries until we receive approval of a Biologics License Application, or BLA, from the FDA or marketing approval from applicable
regulatory authorities outside the United States. Our product candidates are in various stages of development and are subject to the risks of failure inherent in drug development. We have not submitted an application for or received marketing
approval for any of our product candidates. We have limited experience in conducting and managing the clinical trials necessary to obtain regulatory approvals, including approval by the FDA. Obtaining approval of a BLA can be a lengthy, expensive
and uncertain process. In addition, failure to comply with FDA and non-U.S. regulatory requirements may, either before or after product approval, if any, subject our company to administrative or judicially imposed sanctions, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">restrictions on our ability to conduct clinical trials, including full or partial clinical holds on ongoing or planned trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">restrictions on the products, manufacturers or manufacturing process; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">warning letters; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">civil and criminal penalties; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">injunctions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">suspension or withdrawal of regulatory approvals; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">product seizures, detentions or import bans; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">voluntary or mandatory product recalls and publicity requirements; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">total or partial suspension of production; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">imposition of restrictions on operations, including costly new manufacturing requirements; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">refusal to approve pending BLAs or supplements to approved BLAs. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA and foreign
regulatory authorities also have substantial discretion in the drug approval process. The number of pre-clinical studies and clinical trials that will be required for regulatory approval varies depending on the product candidate, the disease or
condition that the product candidate is designed to address, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and the regulations applicable to any particular drug candidate. Regulatory agencies can delay, limit or deny approval of a product candidate for many reasons, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a product candidate may not be deemed safe or effective; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the results may not confirm the positive results from earlier pre-clinical studies or clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulatory agencies may not find the data from pre-clinical studies and clinical trials sufficient; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulatory agencies might not approve or might require changes to our manufacturing processes or facilities; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulatory agencies may change their approval policies or adopt new regulations. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any delay in
obtaining or failure to obtain required approvals could materially adversely affect our ability to generate revenue from the particular product candidate, which likely would result in significant harm to our financial position and adversely impact
our stock price. Furthermore, any regulatory approval to market a product may be subject to limitations on the indicated uses for which we may market the product. These limitations may limit the size of the market for the product. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If clinical trials for our product candidates are prolonged, delayed or stopped, we may be unable to obtain regulatory approval and commercialize our
product candidates on a timely basis, which would require us to incur additional costs and delay our receipt of any product revenue. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are currently enrolling patients in clinical trials for margetuximab, MGA271, MGD006 and MGD007, and anticipate initiating or continuing
clinical trials for these product candidates and others in 2015. The commencement of new clinical trials could be substantially delayed or prevented by several factors, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">further discussions with the FDA or other regulatory agencies regarding the scope or design of our clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the limited number of, and competition for, suitable sites to conduct our clinical trials, many of which may already be engaged in other clinical trial programs, including some that may be for the same indication as our
product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any delay or failure to obtain regulatory approval or agreement to commence a clinical trial in any of the countries where enrollment is planned; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">inability to obtain sufficient funds required for a clinical trial; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">clinical holds on, or other regulatory objections to, a new or ongoing clinical trial; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delay or failure to manufacture sufficient supplies of the product candidate for our clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delay or failure to reach agreement on acceptable clinical trial agreement terms or clinical trial protocols with prospective sites or clinical research organizations, or CROs, the terms of which can be subject to
extensive negotiation and may vary significantly among different sites or CROs; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delay or failure to obtain institutional review board, or IRB, approval to conduct a clinical trial at a prospective site. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The completion of our clinical trials could also be substantially delayed or prevented by several factors, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">slower than expected rates of patient recruitment and enrollment; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">failure of patients to complete the clinical trial; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">unforeseen safety issues, including severe or unexpected drug-related adverse effects experienced by patients, including possible deaths; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">lack of efficacy during clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">termination of our clinical trials by one or more clinical trial sites; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">inability or unwillingness of patients or clinical investigators to follow our clinical trial protocols; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">inability to monitor patients adequately during or after treatment by us and/or our CROs; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the need to repeat or terminate clinical trials as a result of inconclusive or negative results or unforeseen complications in testing. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Changes in regulatory requirements and guidance may also occur and we may need to significantly amend clinical trial protocols to reflect
these changes with appropriate regulatory authorities. Amendments may require us to renegotiate terms with CROs or resubmit clinical trial protocols to IRBs for re-examination, which may impact the costs, timing or successful completion of a
clinical trial. Our clinical trials may be suspended or terminated at any time by the FDA, other regulatory authorities, the IRB overseeing the clinical trial at issue, any of our clinical trial sites with respect to that site, or us, due to a
number of factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">unforeseen safety issues or any determination that a clinical trial presents unacceptable health risks; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">lack of adequate funding to continue the clinical trial due to unforeseen costs or other business decisions; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">upon a breach or pursuant to the terms of any agreement with, or for any other reason by, current or future collaborators that have responsibility for the clinical development of any of our product candidates.
</TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any failure or significant delay in completing clinical trials for our product candidates would adversely affect our
ability to obtain regulatory approval and our commercial prospects and ability to generate product revenue will be diminished. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The results of
previous clinical trials may not be predictive of future results, and the results of our current and planned clinical trials may not satisfy the requirements of the FDA or non-U.S. regulatory authorities. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently have no products approved for sale, and we cannot guarantee that we will ever have marketable products. Clinical failure can occur
at any stage of clinical development. Clinical trials may produce negative or inconclusive results, and we or any of our current and future collaborators may decide, or regulators may require us, to conduct additional clinical or pre-clinical
testing. We will be required to demonstrate with substantial evidence through well-controlled clinical trials that our product candidates are safe and effective for use in a diverse population before we can seek regulatory approvals for their
commercial sale. Success in early clinical trials does not mean that future larger registration clinical trials will be successful because product candidates in later-stage clinical trials may fail to demonstrate sufficient safety and efficacy to
the satisfaction of the FDA and non-U.S. regulatory authorities despite having progressed through initial clinical trials. Product candidates that have shown promising results in early clinical trials may still suffer significant setbacks in
subsequent registration clinical trials. Similarly, the outcome of pre-clinical testing and early clinical trials may not be predictive of the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final
results. A number of companies in the pharmaceutical industry, including those with greater resources and experience than us, have suffered significant setbacks in advanced clinical trials, even after obtaining promising results in earlier clinical
trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the design of a clinical trial can determine whether its results will support approval of a product and flaws in the
design of a clinical trial may not become apparent until the clinical trial is well advanced. We may be unable to design and execute a clinical trial to support regulatory approval. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In some instances, there can be significant variability in safety and/or efficacy results between
different trials of the same product candidate due to numerous factors, including changes in trial protocols, differences in size and type of the patient populations, adherence to the dosing regimen and other trial protocols and the rate of dropout
among clinical trial participants. We do not know whether any Phase&nbsp;2, Phase&nbsp;3 or other clinical trials we or any of our collaborators may conduct will demonstrate consistent or adequate efficacy and safety to obtain regulatory approval to
market our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, our product candidates may not be approved even if they achieve their primary endpoints in Phase
3 clinical trials or registration trials. The FDA or other non-U.S. regulatory authorities may disagree with our trial design and our interpretation of data from pre-clinical studies and clinical trials. In addition, any of these regulatory
authorities may change requirements for the approval of a product candidate even after reviewing and providing comments or advice on a protocol for a pivotal Phase 3 clinical trial that has the potential to result in FDA or other agencies&#146;
approval. In addition, any of these regulatory authorities may also approve a product candidate for fewer or more limited indications than we request or may grant approval contingent on the performance of costly post-marketing clinical trials. The
FDA or other non-U.S. regulatory authorities may not approve the labeling claims that we believe would be necessary or desirable for the successful commercialization of our product candidates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We use new technologies in the development of our product candidates and the FDA and other regulatory authorities have not approved products that
utilize these technologies. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our products in development are based on new technologies, such as Fc Optimization, DART molecules and
CSLCs. Given the novelty of our technologies, we intend to work closely with FDA and other regulatory authorities to perform the requisite scientific analyses and evaluation of our methods to obtain regulatory approval for our product candidates. It
is possible that the validation process may take time and resources, require independent third-party analyses or not be accepted by the FDA and other regulatory authorities. For some of our product candidates that are based on these technology
platforms, the regulatory approval path and requirements may not be clear or evolve as more data becomes available for this product candidates, which could add significant delay and expense. Delays or failure to obtain regulatory approval of any of
the product candidates that we develop would adversely affect our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be successful in our efforts to use and expand our
technology platforms to build a pipeline of product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A key element of our strategy is to use and expand our technology
platforms to build a pipeline of product candidates and progress these product candidates through clinical development for the treatment of a variety of different types of diseases. Although our research and development efforts to date have resulted
in a pipeline of product candidates directed at&nbsp;various cancers, as well as autoimmune disorders and infectious diseases, we may not be able to develop product candidates that are safe and effective. Even if we are successful in continuing to
build our pipeline, the potential product candidates that we identify may not be suitable for clinical development, including as a result of being shown to have harmful side effects or other characteristics that indicate that they are unlikely to be
products that will receive marketing approval and achieve market acceptance. If we do not continue to successfully develop and begin to commercialize product candidates, we will face difficulty in obtaining product revenues in future periods, which
could result in significant harm to our financial position and adversely affect our stock price. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may expend our limited resources to pursue a
particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because we have limited financial and managerial resources, we focus on research programs and product candidates that we identify for specific
indications. As a result, we may forego or delay pursuit of opportunities </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
with other product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable
commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable products. If we do not accurately
evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been
more advantageous for us to retain sole development and commercialization rights. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if we obtain FDA approval of any of our product candidates,
we may never obtain approval or commercialize our products outside of the United States, which would limit our ability to realize their full market potential. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to market any products outside of the United States, we must establish and comply with numerous and varying regulatory requirements of
other countries regarding safety and efficacy. Clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not mean that regulatory approval will be obtained
in any other country. Approval procedures vary among countries and can involve additional product testing and validation and additional administrative review periods. Seeking foreign regulatory approvals could result in significant delays,
difficulties and costs for us and may require additional pre-clinical studies or clinical trials which would be costly and time consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of
our products in those countries. Satisfying these and other regulatory requirements is costly, time consuming, uncertain and subject to unanticipated delays. In addition, our failure to obtain regulatory approval in any country may delay or have
negative effects on the process for regulatory approval in other countries. We do not have any product candidates approved for sale in any jurisdiction, including international markets, and we do not have experience in obtaining regulatory approval
in international markets. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, our target market will be reduced and our ability to realize the full market potential of our products
will be harmed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may seek fast-track designation for some of our product candidates. There is no assurance that the FDA will grant such
designation and, even if it does, that designation may not actually lead to a faster development or regulatory review or approval process and it does not increase the likelihood that our product candidates will receive marketing approval in the
United States. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may seek fast-track designation and review for some of our product candidates. If a drug is intended for the
treatment of a serious or life-threatening condition or disease and has an unmet medical need, the drug sponsor may apply for FDA fast track designation. The FDA has broad discretion whether or not to grant this designation, so even if we believe a
particular product candidate is eligible for this designation, we cannot provide assurance that the FDA would decide to grant it. Moreover, even if we do receive fast track designation, we may not experience a faster development process, review or
approval compared to conventional FDA procedures. In addition, the FDA may withdraw fast track designation if it believes that the designation is no longer supported by data from our clinical development program. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may seek breakthrough therapy designation by the FDA for any of our product candidates but that is not assured and may not, in any event, lead to a
faster development or regulatory review or approval process, and it does not increase the likelihood that our product candidates will receive marketing approval in the United States. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may apply for breakthrough therapy designation for some of our product candidates. The FDA is authorized to designate a product candidate as
a breakthrough therapy if it finds that the product is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the product may
demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
early in clinical development. For products designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most
efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Designation as a
breakthrough therapy is within the discretion of the FDA. Accordingly, even if we believe one of our product candidates meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such
designation. In any event, the receipt of a breakthrough therapy designation for a product candidate may not result in a faster development process, review or approval compared to product candidates considered for approval under conventional FDA
procedures and, in any event, does not assure ultimate approval by the FDA. In addition, even if one or more of our product candidates qualify as breakthrough therapies, the FDA may later decide that the product candidates no longer meet the
conditions for qualification or decide that the time period for FDA review or approval will not be shortened. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be unable to obtain orphan
product designation or exclusivity for some or all of our product candidates. If our competitors are able to obtain orphan product exclusivity for their products that are the same as our product candidates, we may not be able to have competing
products approved by the applicable regulatory authority for a significant period of time. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Regulatory authorities in some
jurisdictions, including the United States and Europe, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, FDA may designate a product candidate as an orphan drug if it is a drug intended to treat
a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals annually in the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally, if a product candidate with an orphan drug designation subsequently receives the first marketing approval for the indication for
which it has such designation, the product is entitled to a period of marketing exclusivity, which precludes the European Medicines Agency, or EMA, or the FDA from approving another marketing application for the same drug for that time period. The
applicable period is seven years in the United States, although this may be as long as twelve years if the applicable reference product has a longer period of exclusivity, and ten years in Europe. The European exclusivity period can be reduced to
six years if a product no longer meets the criteria for orphan drug designation or if the product is sufficiently profitable so that market exclusivity is no longer justified. Orphan drug exclusivity may be lost if the FDA or EMA determines that the
request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the product to meet the needs of patients with the rare disease or condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if we obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because
different drugs can be approved for the same condition. In the United States, even after an orphan drug is approved, the FDA can subsequently approve the same drug for the same condition if the FDA concludes that the later drug is clinically
superior in that it is shown to be safer, more effective or makes a major contribution to patient care. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our product candidates may have undesirable
side effects which may delay or prevent marketing approval, or, if approval is received, require them to be taken off the market, require them to include safety warnings or otherwise limit their sales. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although all of our product candidates have undergone or will undergo safety testing, not all adverse effects of drugs can be predicted or
anticipated. Unforeseen side effects from any of our product candidates could arise either during clinical development or, if approved by regulatory authorities, after the approved product has been marketed. All of our product candidates are still
in clinical or pre-clinical development. While our clinical trials for our initial product candidates to date have demonstrated a favorable safety profile, the results from future trials may not support this conclusion. The results of future
clinical trials may show that our product candidates cause undesirable or unacceptable side effects, which could interrupt, delay or halt clinical trials, and result in delay of, or failure to obtain, marketing approval from the FDA and other
regulatory authorities, or result in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
marketing approval from the FDA and other regulatory authorities with restrictive label warnings or potential product liability claims. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any of our product candidates receives marketing approval and we or others later identify undesirable or unacceptable side effects caused
by such products: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulatory authorities may require us to take our approved product off the market; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulatory authorities may require the addition of labeling statements, specific warnings, a contraindication or field alerts to physicians and pharmacies; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may be required to change the way the product is administered, conduct additional clinical trials or change the labeling of the product; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may be subject to limitations on how we may promote the product; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">sales of the product may decrease significantly; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may be subject to litigation or product liability claims; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our reputation may suffer. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any of these events could prevent us, our collaborators or our
potential future partners from achieving or maintaining market acceptance of the affected product or could substantially increase commercialization costs and expenses, which in turn could delay or prevent us from generating significant revenue from
the sale of our products. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if approved, if any of our product candidates do not achieve broad market acceptance among physicians, patients, the
medical community, and third-party payors our revenue generated from their sales will be limited. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The commercial success of our
product candidates will depend upon their acceptance among physicians, patients and the medical community. The degree of market acceptance of our product candidates will depend on a number of factors, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">limitations or warnings contained in the approved labeling for a product candidate; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in the standard of care for the targeted indications for any of our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">limitations in the approved clinical indications for our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">demonstrated clinical safety and efficacy compared to other products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">lack of significant adverse side effects; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">sales, marketing and distribution support; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">availability and extent of reimbursement from managed care plans and other third-party payors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">timing of market introduction and perceived effectiveness of competitive products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the degree of cost-effectiveness of our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">availability of alternative therapies at similar or lower cost, including generic and over-the-counter products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the extent to which the product candidate is approved for inclusion on formularies of hospitals and managed care organizations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether the product is designated under physician treatment guidelines as a first-line therapy or as a second- or third-line therapy for particular diseases; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">adverse publicity about our product candidates or favorable publicity about competitive products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">convenience and ease of administration of our products; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">potential product liability claims. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any of our product candidates are approved, but do not
achieve an adequate level of acceptance by physicians, patients and the medical community, we may not generate sufficient revenue from these products, and we may not become or remain profitable. In addition, efforts to educate the medical community
and third-party payors on the benefits of our product candidates may require significant resources and may never be successful. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are subject to a
multitude of manufacturing risks, any of which could substantially increase our costs and limit supply of our products. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
process of manufacturing our product candidates is complex, highly regulated and subject to several risks, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The process of manufacturing our product candidates is extremely susceptible to product loss due to contamination, equipment failure or improper installation or operation of equipment, vendor or operator error,
contamination and inconsistency in yields, variability in product characteristics, and difficulties in scaling the production process. Even minor deviations from normal manufacturing processes could result in reduced production yields, product
defects and other supply disruptions. If microbial, viral or other contaminations are discovered in our product candidates or in the manufacturing facilities in which our product candidates are made, such manufacturing facilities may need to be
closed for an extended period of time to investigate and remedy the contamination. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The manufacturing facilities in which our product candidates are made could be adversely affected by equipment failures, labor shortages, natural disasters, power failures and numerous other factors. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We must comply with the FDA&#146;s current Good Manufacturing Practice, or cGMP, regulations and guidelines. We may encounter difficulties in achieving quality control and quality assurance and may experience shortages
in qualified personnel. We are subject to inspections by the FDA and comparable agencies in other jurisdictions to confirm compliance with applicable regulatory requirements. Any failure to follow cGMP or other regulatory requirements or delay,
interruption or other issues that arise in the manufacture, fill-finish, packaging, or storage of our product candidates as a result of a failure of our facilities or the facilities or operations of third parties to comply with regulatory
requirements or pass any regulatory authority inspection could significantly impair our ability to develop and commercialize our product candidates, including leading to significant delays in the availability of drug product for our clinical trials
or the termination or hold on a clinical trial, or the delay or prevention of a filing or approval of marketing applications for our product candidates. Significant noncompliance could also result in the imposition of sanctions, including fines,
injunctions, civil penalties, failure of regulatory authorities to grant marketing approvals for our product candidates, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of products, operating restrictions and
criminal prosecutions, any of which could damage our reputation. If we are not able to maintain regulatory compliance, we may not be permitted to market our product candidates and/or may be subject to product recalls, seizures, injunctions, or
criminal prosecution. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Any adverse developments affecting manufacturing operations for our product candidates, if any are approved, may result in shipment delays, inventory shortages, lot failures, product withdrawals or recalls, or other
interruptions in the supply of our products. We may also have to take inventory write-offs and incur other charges and expenses for products that fail to meet specifications, undertake costly remediation efforts or seek more costly manufacturing
alternatives. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We currently have no marketing, sales or distribution infrastructure. If we are unable to develop sales,
marketing and distribution capabilities on our own or through collaborations, we will not be successful in commercializing our product candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently have no marketing, sales and distribution capabilities and we have no sales or marketing experience within our organization. If
any of our product candidates are approved, we intend either to establish a sales and marketing organization with technical expertise and supporting distribution capabilities to commercialize our product candidates, or to outsource this function to
a third party. Either of these options would be expensive and time consuming. These costs may be incurred in advance of any approval of our product candidates. In addition, we may not be able to hire a sales force in the United States that is
sufficient in size or has adequate expertise in the medical markets that we intend to target. Any failure or delay in the development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization of our
products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to certain of our existing and future product candidates, we have entered into collaboration or other licensing
arrangements with third party collaborators that have direct sales forces and established distribution systems. To the extent that we enter into additional collaboration agreements, our product revenue may be lower than if we directly marketed or
sold any approved products. In addition, any revenue we receive will depend in whole or in part upon the efforts of these third party collaborators, which may not be successful and are generally not within our control. If we are unable to enter into
these arrangements on acceptable terms or at all, we may not be able to successfully commercialize any approved products. If we are not successful in commercializing any approved products, either on our own or through collaborations with one or more
third parties, our future product revenue will suffer and we may incur significant additional losses. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We face significant competition and if our
competitors develop and market products that are more effective, safer or less expensive than our product candidates, our commercial opportunities will be negatively impacted. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The life sciences industry is highly competitive and subject to rapid and significant technological change. We are currently developing
therapeutics that will compete with other drugs and therapies that currently exist or are being developed. Products we may develop in the future are also likely to face competition from other drugs and therapies, some of which we may not currently
be aware. We have competitors both in the United States and internationally, including major multinational pharmaceutical companies, established biotechnology companies, specialty pharmaceutical companies, universities and other research
institutions. Many of our competitors have significantly greater financial, manufacturing, marketing, drug development, technical and human resources than we do. Large pharmaceutical companies, in particular, have extensive experience in clinical
testing, obtaining regulatory approvals, recruiting patients and manufacturing pharmaceutical products. These companies also have significantly greater research and marketing capabilities than we do and may also have products that have been approved
or are in late stages of development, and collaborative arrangements in our target markets with leading companies and research institutions. Established pharmaceutical companies may also invest heavily to accelerate discovery and development of
novel compounds or to in-license novel compounds that could make the product candidates that we develop obsolete. As a result of all of these factors, our competitors may succeed in obtaining patent protection and/or FDA approval or discovering,
developing and commercializing products in our field before we do. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Specifically, there are a large number of companies developing or
marketing treatments for cancer and autoimmune disorders, including many major pharmaceutical and biotechnology companies. These treatments consist both of small molecule drug products, as well as biologic therapeutics that work by using
next-generation antibody technology platforms to address specific cancer targets. In addition, several companies are developing therapeutics that work by targeting multiple specificities using a single recombinant molecule. Amgen, Inc. has obtained
marketing approval for one cancer product candidate that works by targeting antigens both on immune effector cell populations and those expressed on certain cancer cells, and has other product candidates using this mechanism in development. In
addition, other companies are developing new treatments for cancer and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
autoimmune diseases that enhance the Fc regions of antibodies to create more potent antibodies, including F. Hoffmann-La Roche Ltd. and Xencor, Inc. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more
effective, have fewer or less severe effects, are more convenient or are less expensive than any products that we may develop. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain
approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. In addition, our ability to compete may be affected in many cases by insurers or other third party payors seeking
to encourage the use of biosimilar products. Biosimilar products are expected to become available over the coming years. For example, certain HER2 biosimilar products are approved in certain countries and others may be approved prior to
margetuximab. Even if our product candidates achieve marketing approval, they may be priced at a significant premium over competitive biosimilar products if any have been approved by then. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Patient Protection and Affordable Care Act, as amended by the Healthcare and Education Affordability Reconciliation Act, collectively the
ACA, created a regulatory scheme authorizing the FDA to approve biosimilars. Under the ACA, a manufacturer may submit an application for licensure of a biologic product that is &#147;biosimilar to&#148; or &#147;interchangeable with&#148; a
previously approved biological product or &#147;reference product.&#148; Under this new statutory scheme, an application for a biosimilar product may not be submitted to the FDA until four years following approval of the reference product. The FDA
may not approve a biosimilar product until 12 years from the date on which the reference product was approved. Even if a product is considered to be a reference product eligible for exclusivity, another company could market a competing version of
that product if the FDA approves a full BLA for such product containing the sponsor&#146;s own pre-clinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of their product. Furthermore,
recent legislation has proposed that the 12 year exclusivity period for each a reference product may be reduced to seven years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Smaller
and other early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific
and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. In addition, the biopharmaceutical industry is
characterized by rapid technological change. If we fail to stay at the forefront of technological change, we may be unable to compete effectively. Technological advances or products developed by our competitors may render our technologies or product
candidates obsolete, less competitive or not economical. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Reimbursement decisions by third-party payors may have an adverse effect on pricing and
market acceptance. If there is not sufficient reimbursement for our products, it is less likely that our products will be widely used. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if our product candidates are approved for sale by the appropriate regulatory authorities, market acceptance and sales of these products
will depend on reimbursement policies and may be affected by future healthcare reform measures. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which drugs they will
reimburse and establish payment levels. We cannot be certain that reimbursement will be available for any products that we develop. Also, we cannot be certain that reimbursement policies will not reduce the demand for, or the price paid for, our
products. If reimbursement is not available or is available on a limited basis, we may not be able to successfully commercialize any of our approved products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, also called the Medicare Modernization Act
or MMA, changed the way Medicare covers and pays for pharmaceutical products. The legislation established Medicare Part D, which expanded Medicare coverage for outpatient prescription drug purchases by the elderly but provided authority for limiting
the number of drugs that will be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
covered in any therapeutic class. The MMA also introduced a new reimbursement methodology based on average sales prices for physician-administered drugs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The United States and several foreign jurisdictions are considering, or have already enacted, a number of legislative and regulatory proposals
to change the healthcare system in ways that could affect our ability to sell any of our future approved products profitably. Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in
healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access to healthcare. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been
significantly affected by major legislative initiatives. We expect to experience pricing pressures in connection with the sale of any products that we develop, due to the trend toward managed healthcare, the increasing influence of health
maintenance organizations and additional legislative proposals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2010, the ACA became law in the United States. The goal of ACA
is to reduce the cost of health care and substantially change the way health care is financed by both governmental and private insurers. While we cannot predict what impact on federal reimbursement policies this legislation will have in general or
on our business specifically, the ACA may result in downward pressure on pharmaceutical reimbursement, which could negatively affect market acceptance of, and the price we may charge for, any products we develop that receive regulatory approval. We
also cannot predict the impact of ACA on our business or financial condition as many of the ACA reforms require the promulgation of detailed regulations implementing the statutory provisions, which has not yet occurred. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If any product liability lawsuits are successfully brought against us or any of our collaborators, we may incur substantial liabilities and may be
required to limit commercialization of our product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We face an inherent risk of product liability lawsuits related to
the testing of our product candidates in seriously ill patients, and will face an even greater risk if product candidates are approved by regulatory authorities and introduced commercially. Product liability claims may be brought against us or our
collaborators by participants enrolled in our clinical trials, patients, health care providers or others using, administering or selling any of our future approved products. If we cannot successfully defend ourselves against any such claims, we may
incur substantial liabilities. Regardless of their merit or eventual outcome, liability claims may result in: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">decreased demand for our future approved products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">injury to our reputation; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">withdrawal of clinical trial participants; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">termination of clinical trial sites or entire trial programs; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">increased regulatory scrutiny; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">significant litigation costs; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">substantial monetary awards to or costly settlement with patients or other claimants; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">product recalls or a change in the indications for which they may be used; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">loss of revenue; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">diversion of management and scientific resources from our business operations; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the inability to commercialize our product candidates. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any of our product candidates are
approved for commercial sale, we will be highly dependent upon consumer perceptions of us and the safety and quality of our products. We could be adversely affected if we are subject to negative publicity. We could also be adversely affected if any
of our products or any similar products </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
distributed by other companies prove to be, or are asserted to be, harmful to patients. Because of our dependence upon consumer perceptions, any adverse publicity associated with illness or other
adverse effects resulting from patients&#146; use or misuse of our products or any similar products distributed by other companies could have a material adverse impact on our financial condition or results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently hold $15 million in product liability insurance coverage in the aggregate, with a per incident limit of $15 million, which may
not be adequate to cover all liabilities that we may incur. We may need to increase our insurance coverage when we begin the commercialization of our product candidates. Insurance coverage is becoming increasingly expensive. As a result, we may be
unable to maintain or obtain sufficient insurance at a reasonable cost to protect us against losses that could have a material adverse effect on our business. A successful product liability claim or series of claims brought against us, particularly
if judgments exceed any insurance coverage we may have, could decrease our cash resources and adversely affect our business, financial condition and results of operation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our business may become subject to economic, political, regulatory and other risks associated with international operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business is subject to risks associated with conducting business internationally. Some of our suppliers and collaborative and clinical
trial relationships are located outside the United States. Accordingly, our future results could be harmed by a variety of factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">economic weakness, including inflation, or political instability in particular foreign economies and markets; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">differing regulatory requirements for drug approvals in foreign countries; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">potentially reduced protection for intellectual property rights; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">difficulties in compliance with non-U.S. laws and regulations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in non-U.S. regulations and customs, tariffs and trade barriers; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in non-U.S. currency exchange rates and currency controls; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in a specific country&#146;s or region&#146;s political or economic environment; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">trade protection measures, import or export licensing requirements or other restrictive actions by U.S. or non-U.S. governments; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">negative consequences from changes in tax laws; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">workforce uncertainty in countries where labor unrest is more common than in the United States; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">difficulties associated with staffing and managing foreign operations, including differing labor relations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">business interruptions resulting from geo-political actions, including war and terrorism, or natural disasters including earthquakes, typhoons, floods and fires. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Financial Position and Need for Additional Capital </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have incurred significant losses since inception and anticipate that we will continue to incur losses for the foreseeable future. We have no products
approved for commercial sale, and to date we have not generated any revenue or profit from product sales. We may never achieve or sustain profitability. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical-stage biopharmaceutical company. We have incurred significant losses since our inception. As of December&nbsp;31, 2014, our
accumulated deficit was approximately $214.0&nbsp;million. We expect to continue to incur losses for the foreseeable future, and we expect these losses to increase as we continue our research and development of, and seek regulatory approvals for,
our product candidates, prepare for and begin to commercialize any approved products, and add infrastructure and personnel to support our product development efforts and operations as a public company. The net losses and negative cash flows incurred
to date, together with expected future losses, have had, and likely will continue to have, an adverse effect on our stockholders&#146; deficit and working capital. The amount of future net losses will depend, in part, on the rate of future growth of
our expenses and our ability to generate revenue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because of the numerous risks and uncertainties associated with pharmaceutical product
development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. For example, our expenses could increase if we are required by the FDA to perform trials in
addition to those that we currently expect to perform, or if there are any delays in completing our currently planned clinical trials or in the development of any of our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To become and remain profitable, we must succeed in developing and commercializing products with significant market potential. This will
require us to be successful in a range of challenging activities for which we are only in the preliminary stages, including developing product candidates, obtaining regulatory approval for them, and manufacturing, marketing and selling those
products for which we may obtain regulatory approval. We may never succeed in these activities and may never generate revenue from product sales that is significant enough to achieve profitability. Even if we achieve profitability in the future, we
may not be able to sustain profitability in subsequent periods. Our failure to become or remain profitable would depress our market value and could impair our ability to raise capital, expand our business, develop other product candidates, or
continue our operations. A decline in the value of our company could also cause you to lose all or part of your investment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will require
substantial additional funding, which may not be available to us on acceptable terms, or at all, and, if not available, may require us to delay, scale back, or cease our product development programs or operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are advancing our product candidates through clinical development. Developing pharmaceutical products, including conducting pre-clinical
studies and clinical trials, is expensive. In order to obtain such regulatory approval, we will be required to conduct clinical trials for each indication for each of our product candidates. We will continue to require additional funding beyond what
was raised in our public offerings and through our collaborations and license agreements to complete the development and commercialization of our product candidates and to continue to advance the development of our other product candidates, and such
funding may not be available on acceptable terms or at all. Although it is difficult to predict our funding requirements, based upon our current operating plan, we anticipate that our cash and cash equivalents as of December&nbsp;31, 2014, combined
with the proceeds from our collaboration with Janssen Biotech and the investment in our common stock by its affiliates, as well as collaboration payments we anticipate receiving, will enable us to fund our operations into 2018, assuming all of our
collaboration programs advance as currently contemplated. Because successful development of our product candidates is uncertain, we are unable to estimate the actual funds we will require to complete research and development and to commercialize our
product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our future funding requirements will depend on many factors, including but not limited to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the number and characteristics of other product candidates that we pursue; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the scope, progress, timing, cost and results of research, pre-clinical development, and clinical trials; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the costs, timing and outcome of seeking and obtaining FDA and non-U.S. regulatory approvals; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the costs associated with manufacturing our product candidates and establishing sales, marketing, and distribution capabilities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to maintain, expand, and defend the scope of our intellectual property portfolio, including the amount and timing of any payments we may be required to make in connection with the licensing, filing, defense
and enforcement of any patents or other intellectual property rights; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our need and ability to hire additional management, scientific, and medical personnel; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the effect of competing products that may limit market penetration of our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our need to implement additional internal systems and infrastructure, including financial and reporting systems; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the economic and other terms, timing of and success of our existing collaborations, and any collaboration, licensing, or other arrangements into which we may enter in the future, including the timing of receipt of any
milestone or royalty payments under these agreements. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Until we can generate a sufficient amount of product revenue to
finance our cash requirements, which we may never do, we expect to finance future cash needs primarily through a combination of public or private equity offerings, debt financings, strategic collaborations, and grant funding. If sufficient funds on
acceptable terms are not available when needed, or at all, we could be forced to significantly reduce operating expenses and delay, scale back or eliminate one or more of our development programs or our business operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish substantial rights. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be
diluted, and the terms of these new securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing, if available at all, may involve agreements that include covenants limiting or
restricting our ability to take specific actions such as incurring additional debt, making capital expenditures, or declaring dividends. If we raise additional funds through collaborations, strategic alliances, or licensing arrangements with third
parties, we may have to relinquish valuable rights to our technologies, product candidates, or future revenue streams, or grant licenses on terms that are not favorable to us. We cannot assure you that we will be able to obtain additional funding if
and when necessary. If we are unable to obtain adequate financing on a timely basis, we could be required to delay, scale back or eliminate one or more of our development programs or grant rights to develop and market product candidates that we
would otherwise prefer to develop and market ourselves. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have broad discretion in the use of the net proceeds from our IPO and follow-on offering
and may not use them effectively. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management has broad discretion to use our cash and cash equivalents to fund our operations
and could spend these funds in ways that do not improve our results of operations or enhance the value of our common stock. The failure by our management to apply these funds effectively could result in financial losses that could have a material
adverse effect on our business, cause the price of our common stock to decline and delay the development of our product candidates. Pending their use to fund operations, we may invest our cash and cash equivalents in a manner that does not produce
income or that loses value. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our ability to use our net operating loss carryforwards and other tax attributes may be limited. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ability to utilize our federal net operating losses, or NOLs, and federal tax credits is currently limited, and may be limited further,
under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended. The </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
limitations apply if an ownership change, as defined by Section&nbsp;382, occurs. Generally, an ownership change occurs when certain shareholders increase their aggregate ownership by more than
50 percentage points over their lowest ownership percentage in a testing period, which is typically three years or since the last ownership change. We are already subject to Section&nbsp;382 limitations due to acquisitions we made in 2002 and 2008.
As of December&nbsp;31, 2014, we had federal NOL carryforwards of $158.9 million, state NOL carryforwards of $103.4 million and research and development tax credit carryforwards of $26.3 million available. Future changes in stock ownership may also
trigger an ownership change and, consequently, another Section&nbsp;382 limitation. Any limitation may result in expiration of a portion of the net operating loss or tax credit carryforwards before utilization which would reduce our gross deferred
income tax assets and corresponding valuation allowance. As a result, if we earn net taxable income, our ability to use our pre-change net operating loss carryforwards and tax credit carryforwards to reduce United States federal income tax may be
subject to limitations, which could potentially result in increased future cash tax liability to us. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Dependence on Third Parties
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our existing therapeutic collaborations are important to our business, and future collaborations may also be important to us. If we are unable
to maintain any of these collaborations, or if these collaborations are not successful, our business could be adversely affected. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have limited capabilities for drug development and do not yet have any capability for sales, marketing or distribution. We have entered into
collaborations with other companies that we believe can provide such capabilities, including our collaboration and license agreements with Janssen Biotech, Inc., or Janssen, Takeda Pharmaceutical Company Ltd., or Takeda, Les Laboratoires Servier and
Institut de Recherches Servier, or collectively Servier, Gilead Sciences, Inc., or Gilead, Boehringer Ingelheim GmbH, or Boehringer, Pfizer, Inc., or Pfizer, and Green Cross Corp., or Green Cross. These collaborations also have provided us with
important funding for our development programs and technology platforms and we expect to receive additional funding under these collaborations in the future. Our existing therapeutic collaborations, and any future collaborations we enter into, may
pose a number of risks, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborators may not perform their obligations as expected; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborators may not pursue development and commercialization of any product candidates that achieve regulatory approval or may elect not to continue or renew development or commercialization programs based on clinical
trial results, changes in the collaborators&#146; strategic focus or available funding, or external factors, such as an acquisition, that divert resources or create competing priorities; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new
formulation of a product candidate for clinical testing; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our products or product candidates if the collaborators believe that competitive products are
more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">product candidates discovered in collaboration with us may be viewed by our collaborators as competitive with their own product candidates or products, which may cause collaborators to cease to devote resources to the
commercialization of our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a collaborator with marketing and distribution rights to one or more of our product candidates that achieve regulatory approval may not commit sufficient resources to the marketing and distribution of such product or
products; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">disagreements with collaborators, including disagreements over proprietary rights, contract interpretation or the preferred course of development, might cause delays or termination of the research, development or
commercialization of product candidates, might lead to additional responsibilities for us with respect to product candidates, or might result in litigation or arbitration, any of which would be time-consuming and expensive; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual
property or proprietary information or expose us to potential litigation; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborations may be terminated for the convenience of the collaborator and, if terminated, we could be required to raise additional capital to pursue further development or commercialization of the applicable product
candidates. For example, each of our collaboration and license agreements with Janssen, Takeda, Servier, Gilead, and Boehringer may be terminated for convenience upon the completion of a specified notice period. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If our therapeutic collaborations do not result in the successful development and commercialization of products or if one of our collaborators
terminates its agreement with us, we may not receive any future research funding or milestone or royalty payments under the collaboration. If we do not receive the funding we expect under these agreements, our development of our technology platforms
and product candidates could be delayed and we may need additional resources to develop product candidates and our technology platforms. All of the risks relating to product development, regulatory approval and commercialization described in this
report also apply to the activities of our program collaborators. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, subject to its contractual obligations to us, if one of
our collaborators is involved in a business combination, the collaborator might deemphasize or terminate the development or commercialization of any product candidate licensed to it by us. If one of our collaborators terminates its agreement with
us, we may find it more difficult to attract new collaborators. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For some of our product candidates, we may in the future determine to
collaborate with additional pharmaceutical and biotechnology companies for development and potential commercialization of therapeutic products. We face significant competition in seeking appropriate collaborators. Our ability to reach a definitive
agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#146;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#146;s evaluation of a number
of factors. These factors may include the design or results of clinical trials, the likelihood of approval by the FDA or similar regulatory authorities outside the United States, the potential market for the subject product candidate, the costs and
complexities of manufacturing and delivering such product candidate to patients, the potential of competing products, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership
without regard to the merits of the challenge and industry and market conditions generally. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether
such a collaboration could be more attractive than the one with us for our product candidate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Collaborations are complex and
time-consuming to negotiate and document. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators. If we are
unable to reach agreements with suitable collaborators on a timely basis, on acceptable terms, or at all, we may have to curtail the development of a product candidate, reduce or delay one or more of our other development programs, delay its
potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to fund and undertake
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
development or commercialization activities on our own, we may need to obtain additional expertise and additional capital, which may not be available to us on acceptable terms or at all. If we
fail to enter into collaborations and do not have sufficient funds or expertise to undertake the necessary development and commercialization activities, we may not be able to further develop our product candidates or bring them to market or continue
to develop our technology platforms and our business may be materially and adversely affected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may also be restricted under existing
collaboration agreements from entering into future agreements on certain terms with potential collaborators. Aside from our agreement with Green Cross, subject to certain specified exceptions, each of our existing therapeutic collaborations contains
a restriction on our engaging in activities that are the subject of the collaboration with third parties for specified periods of time. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Independent
clinical investigators and CROs that we engage to conduct our clinical trials may not devote sufficient time or attention to our clinical trials or be able to repeat their past success. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to continue to depend on independent clinical investigators and CROs to conduct our clinical trials. CROs may also assist us in the
collection and analysis of data. There is a limited number of third-party service providers that specialize or have the expertise required to achieve our business objectives. Identifying, qualifying and managing performance of third-party service
providers can be difficult, time consuming and cause delays in our development programs. These investigators and CROs will not be our employees and we will not be able to control, other than by contract, the amount of resources, including time,
which they devote to our product candidates and clinical trials. If independent investigators or CROs fail to devote sufficient resources to the development of our product candidates, or if their performance is substandard, it may delay or
compromise the prospects for approval and commercialization of any product candidates that we develop. In addition, the use of third-party service providers requires us to disclose our proprietary information to these parties, which could increase
the risk that this information will be misappropriated. Further, the FDA requires that we comply with standards, commonly referred to as current Good Clinical Practice, or GCP, for conducting, recording and reporting clinical trials to assure that
data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial subjects are protected. Failure of clinical investigators or CROs to meet their obligations to us or comply with GCP procedures could
adversely affect the clinical development of our product candidates and harm our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Failure of our third party contractors to successfully
develop and commercialize companion diagnostics for use with our product candidates could harm our ability to commercialize our product candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We plan to develop companion diagnostics for our product candidates where appropriate. Companion diagnostics are used to identify patients who
could potentially benefit from our therapeutic product candidates or for safety reasons to identify patients who might be at increased risk for a potential side effect. We expect that, at least in some cases, the FDA and similar regulatory
authorities outside the United States may require the development and regulatory approval of a companion diagnostic as a condition to approving our product candidates. We do not have experience or capabilities in developing or commercializing
diagnostics and plan to rely in large part on third parties to perform these functions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In most cases, we will likely outsource the
development, production and commercialization of companion diagnostics to third parties. By outsourcing these companion diagnostics to third parties, we become dependent on the efforts of our third party contractors to successfully develop and
commercialize these companion diagnostics. Our contractors: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">may not perform their obligations as expected; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">may encounter production difficulties that could constrain the supply of the companion diagnostic; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">may have difficulties gaining acceptance of the use of the companion diagnostic in the clinical community; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">may not commit sufficient resources to the marketing and distribution of such product; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">may terminate their relationship with us. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any companion diagnostic for use with one of our
product candidates fails to gain market acceptance, our ability to derive revenues from sales of such product candidate could be harmed. If our third party contractors fail to commercialize such companion diagnostic, we may not be able to enter into
arrangements with another diagnostic company to obtain supplies of an alternative diagnostic test for use in connection with such product candidate or do so on commercially reasonable terms, which could adversely affect and delay the development or
commercialization of such product candidate. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We expect to contract with third parties for the manufacture of our product candidates for clinical
testing in the future and expect to continue to do so for commercialization. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or products or such quantities at an acceptable
cost, which could delay, prevent or impair our development or commercialization efforts. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently have a manufacturing
facility located in Rockville, Maryland. We manufacture drug substance at this facility that we use for research and development purposes and for clinical trials of our product candidates. We believe we currently have capacity to produce Phase 2
material for our antibody product candidates and clinical material for our DART therapeutics, but our current facility will be insufficient to support our needs for our Phase 3 clinical trials for our antibody product candidates and for commercial
quantities of such candidates. We do not have experience in manufacturing products at commercial scale. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into agreements
with contract manufacturing organizations to supplement our clinical supply and internal capacity as we advance our product candidate pipeline. We expect to use third parties for the manufacture of certain of our product candidates for clinical
testing, as well as for commercial manufacture of some of our product candidates that receive marketing approval and that are not manufactured by one of our third party collaborators. We plan eventually to enter into long term supply agreements with
several manufacturers for commercial supplies. We may be unable to reach agreement with any of these contract manufacturers, or to identify and reach arrangements on satisfactory terms with other contract manufacturers, to manufacture any of our
product candidates. Additionally, the facilities used by any contract manufacturer to manufacture any of our product candidates must be the subject of a satisfactory inspection before the FDA and other regulatory authorities approve a BLA or
marketing authorization for the product candidate manufactured at that facility. We will depend on these third-party manufacturing partners for compliance with the FDA&#146;s requirements for the manufacture of our finished products. If our
manufacturers cannot successfully manufacture material that conforms to our specifications and the FDA and other regulatory authorities&#146; cGMP requirements, our product candidates will not be approved or, if already approved, may be subject to
recalls. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Reliance on third-party manufacturers entails risks to which we would not be subject if we manufactured the product candidates
ourselves, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the possibility of a breach of the manufacturing agreements by the third parties because of factors beyond our control; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the possibility of termination or nonrenewal of the agreements by the third parties before we are able to arrange for a qualified replacement third-party manufacturer; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the possibility that we may not be able to secure a manufacturer or manufacturing capacity in a timely manner and on satisfactory terms in order to meet our manufacturing needs. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any of these factors could cause the delay of approval or commercialization of our product candidates, cause us to incur higher costs or
prevent us from commercializing our product candidates successfully. Furthermore, if any of our product candidates are approved and contract manufacturers fail to deliver the required commercial quantities of finished product on a timely basis and
at commercially reasonable prices, and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
we are unable to find one or more replacement manufacturers capable of production at a substantially equivalent cost, in substantially equivalent volumes and quality and on a timely basis, we
would likely be unable to meet demand for our products and could lose potential revenue. It may take several years to establish an alternative source of supply for our product candidates and to have any such new source approved by the FDA or any
other relevant regulatory authorities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Intellectual Property </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to obtain and enforce patent protection for our product candidates and related technology, our business could be materially harmed.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Issued patents may be challenged, narrowed, invalidated or circumvented. In addition, court decisions may introduce uncertainty in
the enforceability or scope of patents owned by biotechnology companies. The legal systems of certain countries do not favor the aggressive enforcement of patents, and the laws of foreign countries may not allow us to protect our inventions with
patents to the same extent as the laws of the United States. Because patent applications in the United States and many foreign jurisdictions are typically not published until 18 months after filing, or in some cases not at all, and because
publications of discoveries in scientific literature lag behind actual discoveries, we cannot be certain that we were the first to make the inventions claimed in our issued patents or pending patent applications, or that we were the first to file
for protection of the inventions set forth in our patents or patent applications. As a result, we may not be able to obtain or maintain protection for certain inventions. Therefore, the enforceability and scope of our patents in the United States
and in foreign countries cannot be predicted with certainty and, as a result, any patents that we own or license may not provide sufficient protection against competitors. We may not be able to obtain or maintain patent protection from our pending
patent applications, from those we may file in the future, or from those we may license from third parties. Moreover, even if we are able to obtain patent protection, such patent protection may be of insufficient scope to achieve our business
objectives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our strategy depends on our ability to identify and seek patent protection for our discoveries. This process is expensive and
time consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner or in all jurisdictions where protection may be commercially advantageous. Despite our efforts to
protect our proprietary rights, unauthorized parties may be able to obtain and use information that we regard as proprietary. The issuance of a patent does not ensure that it is valid or enforceable, so even if we obtain patents, they may not be
valid or enforceable against third parties. In addition, the issuance of a patent does not give us the right to practice the patented invention. Third parties may have blocking patents that could prevent us from marketing our own patented product
and practicing our own patented technology. Third parties may also seek to market biosimilar versions of any approved products. Alternatively, third parties may seek approval to market their own products similar to or otherwise competitive with our
products. In these circumstances, we may need to defend and/or assert our patents, including by filing lawsuits alleging patent infringement. In any of these types of proceedings, a court or agency with jurisdiction may find our patents invalid
and/or unenforceable. Even if we have valid and enforceable patents, these patents still may not provide protection against competing products or processes sufficient to achieve our business objectives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent position of pharmaceutical or biotechnology companies, including ours, is generally uncertain and involves complex legal and
factual considerations. The standards which the United States Patent and Trademark Office, or USPTO, and its foreign counterparts use to grant patents are not always applied predictably or uniformly and can change. There is also no uniform,
worldwide policy regarding the subject matter and scope of claims granted or allowable in pharmaceutical or biotechnology patents. The laws of some foreign countries do not protect proprietary information to the same extent as the laws of the United
States, and many companies have encountered significant problems and costs in protecting their proprietary information in these foreign countries. Outside the United States, patent protection must be sought in individual jurisdictions, further
adding to the cost and uncertainty of obtaining adequate patent protection outside of the United States. Accordingly, we </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
cannot predict whether additional patents protecting our technology will issue in the United States or in foreign jurisdictions, or whether any patents that do issue will have claims of adequate
scope to provide competitive advantage. Moreover, we cannot predict whether third parties will be able to successfully obtain claims or the breadth of such claims. The allowance of broader claims may increase the incidence and cost of patent
interference proceedings, opposition proceedings, and/or reexamination proceedings, the risk of infringement litigation, and the vulnerability of the claims to challenge. On the other hand, the allowance of narrower claims does not eliminate the
potential for adversarial proceedings, and may fail to provide a competitive advantage. Our issued patents may not contain claims sufficiently broad to protect us against third parties with similar technologies or products, or provide us with any
competitive advantage. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may become involved in lawsuits to protect or enforce our patents, which could be expensive, time consuming and
unsuccessful. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even after they have issued, our patents and any patents which we license may be challenged, narrowed, invalidated
or circumvented. If our patents are invalidated or otherwise limited or will expire prior to the commercialization of our product candidates, other companies may be better able to develop products that compete with ours, which could adversely affect
our competitive business position, business prospects and financial condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following are examples of litigation and other
adversarial proceedings or disputes that we could become a party to involving our patents or patents licensed to us: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we or our collaborators may initiate litigation or other proceedings against third parties to enforce our patent rights; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">third parties may initiate litigation or other proceedings seeking to invalidate patents owned by or licensed to us or to obtain a declaratory judgment that their product or technology does not infringe our patents or
patents licensed to us; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">third parties may initiate opposition or reexamination proceedings challenging the validity or scope of our patent rights, requiring us or our collaborators and/or licensors to participate in such proceedings to defend
the validity and scope of our patents; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">there may be a challenge or dispute regarding inventorship or ownership of patents currently identified as being owned by or licensed to us; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the U.S. Patent&nbsp;and Trademark Office may initiate an interference between patents or patent applications owned by or licensed to us and those of our competitors, requiring us or our collaborators and/or licensors
to participate in an interference proceeding to determine the priority of invention, which could jeopardize our patent rights; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">third parties may seek approval to market biosimilar versions of our future approved products prior to expiration of relevant patents owned by or licensed to us, requiring us to defend our patents, including by filing
lawsuits alleging patent infringement. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These lawsuits and proceedings would be costly and could affect our results of
operations and divert the attention of our managerial and scientific personnel. There is a risk that a court or administrative body would decide that our patents are invalid or not infringed by a third party&#146;s activities, or that the scope of
certain issued claims must be further limited. An adverse outcome in a litigation or proceeding involving our own patents could limit our ability to assert our patents against these or other competitors, affect our ability to receive royalties or
other licensing consideration from our licensees, and may curtail or preclude our ability to exclude third parties from making, using and selling similar or competitive products. Any of these occurrences could adversely affect our competitive
business position, business prospects and financial condition. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The degree of future protection for our proprietary rights is uncertain because legal means
afford only limited protection and may not adequately protect our rights or permit us to gain or keep our competitive advantage. For example: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">others may be able to develop a platform that is similar to, or better than, ours in a way that is not covered by the claims of our patents; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">others may be able to make compounds that are similar to our product candidates but that are not covered by the claims of our patents; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we might not have been the first to make the inventions covered by patents or pending patent applications; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we might not have been the first to file patent applications for these inventions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any patents that we obtain may not provide us with any competitive advantages or may ultimately be found invalid or unenforceable; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may not develop additional proprietary technologies that are patentable. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our commercial success
depends significantly on our ability to operate without infringing the patents and other proprietary rights of third parties. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
success will depend in part on our ability to operate without infringing the proprietary rights of third parties. Other entities may have or obtain patents or proprietary rights that could limit our ability to make, use, sell, offer for sale or
import our future approved products or impair our competitive position. For example, certain patents held by third parties cover Fc engineering methods and mutations in Fc regions to enhance the binding of Fc regions to Fc receptors on immune cells.
Although we believe that these patents are invalid, if they cover margetuximab or MGA271 and we are unable to invalidate their patents, or if licenses for them are not available on commercially reasonable terms, our business could be harmed, perhaps
materially. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patents that we may ultimately be found to infringe could be issued to third parties. Third parties may have or obtain valid
and enforceable patents or proprietary rights that could block us from developing product candidates using our technology. Our failure to obtain a license to any technology that we require may materially harm our business, financial condition and
results of operations. Moreover, our failure to maintain a license to any technology that we require may also materially harm our business, financial condition, and results of operations. Furthermore, we would be exposed to a threat of litigation.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the pharmaceutical industry, significant litigation and other proceedings regarding patents, patent applications, trademarks and other
intellectual property rights have become commonplace. The types of situations in which we may become a party to such litigation or proceedings include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we or our collaborators may initiate litigation or other proceedings against third parties seeking to invalidate the patents held by those third parties or to obtain a judgment that our products or processes do not
infringe those third parties&#146; patents; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if our competitors file patent applications that claim technology also claimed by us or our licensors, we or our licensors may be required to participate in interference or opposition proceedings to determine the
priority of invention, which could jeopardize our patent rights and potentially provide a third party with a dominant patent position; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if third parties initiate litigation claiming that our processes or products infringe their patent or other intellectual property rights, we and our collaborators will need to defend against such proceedings; and
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if a license to necessary technology is terminated, the licensor may initiate litigation claiming that our processes or products infringe or misappropriate their patent or other intellectual property rights and/or that
we breached our obligations under the license agreement, and we and our collaborators would need to defend against such proceedings. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These lawsuits would be costly and could affect our results of operations and divert the
attention of our management and scientific personnel. There is a risk that a court would decide that we or our collaborators are infringing the third party&#146;s patents and would order us or our collaborators to stop the activities covered by the
patents. In that event, we or our collaborators may not have a viable alternative to the technology protected by the patent and may need to halt work on the affected product candidate or cease commercialization of an approved product. In addition,
there is a risk that a court will order us or our collaborators to pay the other party damages. An adverse outcome in any litigation or other proceeding could subject us to significant liabilities to third parties and require us to cease using the
technology that is at issue or to license the technology from third parties. We may not be able to obtain any required licenses on commercially acceptable terms or at all. Any of these outcomes could have a material adverse effect on our business.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The pharmaceutical and biotechnology industries have produced a significant number of patents, and it may not always be clear to industry
participants, including us, which patents cover various types of products or methods of use. The coverage of patents is subject to interpretation by the courts, and the interpretation is not always uniform or predictable. If we are sued for patent
infringement, we would need to demonstrate that our products or methods either do not infringe the patent claims of the relevant patent or that the patent claims are invalid, and we may not be able to do this. Proving invalidity is difficult. For
example, in the United States, proving invalidity requires a showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents. Even if we are successful in these proceedings, we may incur substantial costs
and divert management&#146;s time and attention in pursuing these proceedings, which could have a material adverse effect on us. If we are unable to avoid infringing the patent rights of others, we may be required to seek a license, defend an
infringement action or challenge the validity of the patents in court. Patent litigation is costly and time consuming. We may not have sufficient resources to bring these actions to a successful conclusion. In addition, if we do not obtain a
license, develop or obtain non-infringing technology, fail to defend an infringement action successfully or have infringed patents declared invalid, we may incur substantial monetary damages, encounter significant delays in bringing our product
candidates to market and be precluded from manufacturing or selling our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The cost of any patent litigation or other
proceeding, even if resolved in our favor, could be substantial. Some of our competitors may be able to sustain the cost of such litigation and proceedings more effectively than we can because of their substantially greater resources. Uncertainties
resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace. Patent litigation and other proceedings may also absorb significant
management time. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to comply with our obligations under our intellectual property licenses with third parties, we could lose license
rights that are important to our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are currently party to various intellectual property license agreements. These
license agreements impose, and we expect that future license agreements may impose, various diligence, milestone payment, royalty, insurance and other obligations on us. For example, we have entered into patent and know-how license agreements which
grant us the right to use a certain technology related to biological manufacturing to manufacture margetuximab and MGA271. These licenses typically include an obligation to pay an upfront payment, yearly maintenance payments and royalties on sales.
If we fail to comply with our obligations under the licenses, the licensors may have the right to terminate their respective license agreements, in which event we might not be able to market any product that is covered by the agreements. Termination
of the license agreements or reduction or elimination of our licensed rights may result in our having to negotiate new or reinstated licenses with less favorable terms, which could adversely affect our competitive business position and harm our
business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to protect the confidentiality of our proprietary information, the value of our technology
and products could be adversely affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to patent protection, we also rely on other proprietary rights, including
protection of trade secrets, and other proprietary information. To maintain the confidentiality of trade secrets and proprietary information, we enter into confidentiality agreements with our employees, consultants, collaborators and others upon the
commencement of their relationships with us. These agreements require that all confidential information developed by the individual or made known to the individual by us during the course of the individual&#146;s relationship with us be kept
confidential and not disclosed to third parties. Our agreements with employees and our personnel policies also provide that any inventions conceived by the individual in the course of rendering services to us shall be our exclusive property.
However, we may not obtain these agreements in all circumstances, and individuals with whom we have these agreements may not comply with their terms. Thus, despite such agreement, such inventions may become assigned to third parties. In the event of
unauthorized use or disclosure of our trade secrets or proprietary information, these agreements, even if obtained, may not provide meaningful protection, particularly for our trade secrets or other confidential information. To the extent that our
employees, consultants or contractors use technology or know-how owned by third parties in their work for us, disputes may arise between us and those third parties as to the rights in related inventions. To the extent that an individual who is not
obligated to assign rights in intellectual property to us is rightfully an inventor of intellectual property, we may need to obtain an assignment or a license to that intellectual property from that individual, or a third party or from that
individual&#146;s assignee. Such assignment or license may not be available on commercially reasonable terms or at all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Adequate remedies
may not exist in the event of unauthorized use or disclosure of our proprietary information. The disclosure of our trade secrets would impair our competitive position and may materially harm our business, financial condition and results of
operations. Costly and time consuming litigation could be necessary to enforce and determine the scope of our proprietary rights, and failure to maintain trade secret protection could adversely affect our competitive business position. In addition,
others may independently discover or develop our trade secrets and proprietary information, and the existence of our own trade secrets affords no protection against such independent discovery. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As is common in the biotechnology and pharmaceutical industries, we employ individuals who were previously or concurrently employed at
research institutions and/or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. We may be subject to claims that these employees, or we, have inadvertently or otherwise used or disclosed trade
secrets or other proprietary information of their former employers, or that patents and applications we have filed to protect inventions of these employees, even those related to one or more of our product candidates, are rightfully owned by their
former or concurrent employer. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Obtaining and maintaining our patent protection depends on compliance with various procedural, documentary, fee payment and other requirements imposed
by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to the
USPTO and various foreign patent offices at various points over the lifetime of our patents and/or applications. We have systems in place to remind us to pay these fees, and we rely on our outside counsel to pay these fees when due. Additionally,
the USPTO and various foreign patent offices require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help
us comply, and in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with rules applicable to the particular jurisdiction. However, there are situations in which noncompliance can result in
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. If such an event were to occur, it could have a
material adverse effect on our business. In addition, we are responsible for the payment of patent fees for patent rights that we have licensed from other parties. If any licensor of these patents does not itself elect to make these payments, and we
fail to do so, we may be liable to the licensor for any costs and consequences of any resulting loss of patent rights. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we do not obtain
protection under the Hatch-Waxman Amendments and similar foreign legislation for extending the term of patents covering each of our product candidates, our business may be materially harmed. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depending upon the timing, duration and conditions of FDA marketing approval of our product candidates, one or more of our U.S. patents may be
eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent term extension of up to five years for a
patent covering an approved product as compensation for effective patent term lost during product development and the FDA regulatory review process. However, we may not receive an extension if we fail to apply within applicable deadlines, fail to
apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. Moreover, the length of the extension could be less than we request. If we are unable to obtain patent term extension or the term of any such
extension is less than we request, the period during which we can enforce our patent rights for that product will be shortened and our competitors may obtain approval to market competing products sooner. As a result, our revenue from applicable
products could be reduced, possibly materially. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Legal Compliance Matters </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we do not comply with laws regulating the protection of the environment and health and human safety, our business could be adversely affected.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our research and development involves, and may in the future involve, the use of potentially hazardous materials and chemicals.
Our operations may produce hazardous waste products. Although we believe that our safety procedures for handling and disposing of these materials comply with the standards mandated by local, state and federal laws and regulations, the risk of
accidental contamination or injury from these materials cannot be eliminated. If an accident occurs, we could be held liable for resulting damages, which could be substantial. We are also subject to numerous environmental, health and workplace
safety laws and regulations and fire and building codes, including those governing laboratory procedures, exposure to blood-borne pathogens, use and storage of flammable agents and the handling of biohazardous materials. Although we maintain
workers&#146; compensation insurance as prescribed by the States of Maryland and California to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of these materials, this insurance may not provide
adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us. Additional federal, state and local laws and regulations affecting our operations may be
adopted in the future. We may incur substantial costs to comply with, and substantial fines or penalties if we violate, any of these laws or regulations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we market products in a manner that violates healthcare fraud and abuse laws, or if we violate government price reporting laws, we may be subject to
civil or criminal penalties. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to FDA restrictions on marketing of pharmaceutical products, several other types of state
and federal healthcare laws commonly referred to as &#147;fraud and abuse&#148; laws have been applied in recent years to restrict certain marketing practices in the pharmaceutical industry. These laws include false claims and anti-kickback
statutes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Federal false claims laws prohibit any person from knowingly presenting, or causing to be presented, a false claim for payment
to the federal government or knowingly making, or causing to be made, a false statement to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
get a false claim paid. The federal healthcare program anti-kickback statute prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving remuneration to
induce, or in return for, purchasing, leasing, ordering or arranging for the purchase, lease or order of any healthcare item or service reimbursable under Medicare, Medicaid or other federally financed healthcare programs. This statute has been
interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers and formulary managers on the other. Although there are several statutory exemptions and regulatory safe harbors protecting certain
common activities from prosecution, the exemptions and safe harbors are drawn narrowly, and practices that involve remuneration intended to induce prescribing, purchasing or recommending may be subject to scrutiny if they do not qualify for an
exemption or safe harbor. Most states also have statutes or regulations similar to the federal anti-kickback law and federal false claims laws, which may apply to items such as pharmaceutical products and services reimbursed by private insurers.
Administrative, civil and criminal sanctions may be imposed under these federal and state laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Over the past few years, a number of
pharmaceutical and other healthcare companies have been prosecuted under these laws for a variety of promotional and marketing activities, such as: providing free trips, free goods, sham consulting fees and grants and other monetary benefits to
prescribers; reporting to pricing services inflated average wholesale prices that were then used by federal programs to set reimbursement rates; engaging in off-label promotion; and submitting inflated best price information to the Medicaid Rebate
Program to reduce liability for Medicaid rebates. At such time, if ever, as we market any of our future approved products and these products are paid for by governmental programs, it is possible that some of our business activities could also be
subject to challenge under one or more of these &#147;fraud and abuse&#148; laws. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our employees may engage in misconduct or other improper
activities, including noncompliance with regulatory standards and requirements and insider trading. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are exposed to the risk of
employee fraud or other misconduct. Misconduct by employees could include intentional failures to comply with FDA regulations, to provide accurate information to the FDA, to comply with federal and state health care fraud and abuse laws and
regulations, to report financial information or data accurately or to disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the health care industry are subject to extensive laws and regulations
intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive
programs and other business arrangements. Employee misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. We have
adopted a code of conduct, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in
protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or
asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Relating to Employee Matters and Managing Growth </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are highly dependent on the research and development, clinical and business development expertise of Scott Koenig, M.D., Ph.D., our
President and Chief Executive Officer, as well as the other members of our senior management, scientific and clinical team. Although we have entered into employment agreements with certain of our executive officers, each of them may terminate their
employment with us at any time. The loss of the services of our executive officers or other key employees could impede the achievement of our research, development and commercialization objectives and seriously harm our ability to successfully
implement our business strategy. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Recruiting and retaining qualified scientific, clinical, manufacturing and sales and marketing
personnel will also be critical to our success. In addition, we will need to expand and effectively manage our managerial, operational, financial, development and other resources in order to successfully pursue our research, development and
commercialization efforts for our existing and future product candidates. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited number of individuals in our
industry with the breadth of skills and experience required to successfully develop, gain regulatory approval of and commercialize products. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or
motivate these key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from
universities and research institutions. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and
advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. If we are unable to continue to attract and retain high quality
personnel, our ability to pursue our growth strategy will be limited. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will need to grow our organization, and we may experience difficulties in
managing this growth, which could disrupt our operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of February&nbsp;27, 2015, we had 211 full-time employees. As our
development and commercialization plans and strategies develop, we expect to expand our employee base for managerial, operational, sales, marketing, financial and other resources. Future growth would impose significant added responsibilities on
members of management, including the need to identify, recruit, maintain, motivate and integrate additional employees. Also, our management may need to divert a disproportionate amount of their attention away from our day-to-day activities and
devote a substantial amount of time to managing these growth activities. We may not be able to effectively manage the expansion of our operations which may result in weaknesses in our infrastructure, give rise to operational errors, loss of business
opportunities, loss of employees and reduced productivity among remaining employees. Our expected growth could require significant capital expenditures and may divert financial resources from other projects, such as the development of existing and
additional product candidates. If our management is unable to effectively manage our expected growth, our expenses may increase more than expected, our ability to generate and/or grow revenue could be reduced and we may not be able to implement our
business strategy. Our future financial performance and our ability to commercialize our product candidates and compete effectively with others in our industry will depend, in part, on our ability to effectively manage any future growth. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Relating to Our Common Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our stock price
may be volatile and fluctuate substantially. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our stock price is likely to be volatile. The stock market has experienced
significant volatility, particularly with respect to pharmaceutical, biotechnology, and other life sciences company stocks. The volatility of pharmaceutical, biotechnology, and other life sciences company stocks often does not relate to the
operating performance of the companies represented by the stock. Some of the factors that may cause the market price of our common stock to fluctuate include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">results and timing of our clinical trials and clinical trials of our competitors&#146; products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">failure or discontinuation of any of our development programs; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">issues in manufacturing our product candidates or future approved products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulatory developments or enforcement in the United States and foreign countries with respect to our product candidates or our competitors&#146; products; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">competition from existing products or new products that may emerge; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">developments or disputes concerning patents or other proprietary rights; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">introduction of technological innovations or new commercial products by us or our competitors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">announcements by us, our collaborators or our competitors of significant acquisitions, strategic partnerships, joint ventures, collaborations or capital commitments; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in estimates or recommendations by securities analysts, if any cover our common stock; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">fluctuations in the valuation of companies perceived by investors to be comparable to us; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">public concern over our product candidates or any future approved products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">litigation; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">future sales of our common stock; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">share price and volume fluctuations attributable to inconsistent trading volume levels of our shares; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">additions or departures of key personnel; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in the structure of health care payment systems in the United States or overseas; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">failure of any of our product candidates, if approved, to achieve commercial success; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">economic and other external factors or other disasters or crises; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">period-to-period fluctuations in our financial condition and results of operations, including the timing of receipt of any milestone or other payments under commercialization or licensing agreements; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">general market conditions and market conditions for biopharmaceutical stocks; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">overall fluctuations in U.S. equity markets. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in the past, when the market price
of a stock has been volatile, holders of that stock have instituted securities class action litigation against the company that issued the stock. If any of our stockholders brought a lawsuit against us, we could incur substantial costs defending the
lawsuit and divert the time and attention of our management, which could seriously harm our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>An active trading market for our common stock
may not be sustained. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2013, we completed our IPO. Prior to the IPO, there was no public market for our common stock.
Although we have completed our IPO as well as a follow-on offering and shares of our common stock are listed and trading on The NASDAQ Global Select Market, an active trading market for our shares may not be sustained. If an active market for our
common stock does not continue, it may be difficult for our stockholders to sell their shares without depressing the market price for the shares or sell their shares at or above the prices at which they acquired their shares or sell their shares at
the time they would like to sell. Any inactive trading market for our common stock may also impair our ability to raise capital to continue to fund our operations by selling shares and may impair our ability to acquire other companies or
technologies by using our shares as consideration. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are an &#147;emerging growth company&#148; and as a result of the reduced disclosure
requirements applicable to emerging growth companies, our common stock may be less attractive to investors. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an
&#147;emerging growth company,&#148; as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, and we intend to take advantage of certain exemptions from various reporting requirements that are applicable to other public
companies that are not &#147;emerging growth companies&#148; including, but not limited to, not being required to comply with the auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley Act, reduced disclosure obligations
regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
shareholder approval of any golden parachute payments not previously approved. In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition
period for complying with new or revised accounting standards. This provision allows an emerging growth company to delay the adoption of some accounting standards until those standards would otherwise apply to private companies. We have irrevocably
elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, we will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies. We cannot
predict whether investors will find our common stock less attractive because we will rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and
our stock price may be more volatile. We may take advantage of these reporting exemptions until we are no longer an &#147;emerging growth company.&#148; We could remain an &#147;emerging growth company&#148; until the earliest to occur of the
following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the last day of the fiscal year in which we have total annual gross revenue of $1 billion or more; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the last day of our fiscal year following the fifth anniversary of the date of the first sale of common equity securities pursuant to the prospectus filed with the Securities and Exchange Commission on October&nbsp;11,
2013; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the date on which we have issued more than $1 billion in non-convertible debt during the previous three years; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the date on which we are deemed to be a &#147;large accelerated filer&#148; under SEC rules and regulations. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We incur significantly increased costs as a result of operating as a public company, and our management is required to devote substantial time to
corporate governance standards. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a public company, we incur significant legal, accounting and other expenses that we did not
incur as a private company. In addition, our administrative staff will be required to perform additional tasks. For example, we are in the process of adopting additional internal controls and disclosure controls and procedures. As a public company,
we bear all of the internal and external costs of preparing and distributing periodic public reports in compliance with our obligations under the securities laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, regulations and standards relating to corporate governance and public disclosure, including the Sarbanes-Oxley Act and related
regulations implemented by the Securities and Exchange Commission and the NASDAQ Global Select Market, have increased legal and financial compliance costs that make some compliance activities more time consuming. We cannot predict or estimate the
amount of additional costs we will continue to incur or the timing of such costs. We must invest resources to comply with evolving laws, regulations and standards, and this investment will result in increased general and administrative expenses and
may divert management&#146;s time and attention from our other business activities. If our efforts to comply with new laws, regulations and standards differ from the activities intended by regulatory or governing bodies due to ambiguities related to
practice, regulatory authorities may initiate legal proceedings against us and our business may be harmed. In connection with our IPO, we increased our directors&#146; and officers&#146; insurance coverage which will increase our insurance cost. In
the future, it may be more expensive or more difficult for us to obtain director and officer liability insurance, and we may be required to accept reduced coverage or incur substantially higher costs to obtain coverage. These factors could also make
it more difficult for us to attract and retain qualified members of our board of directors, particularly to serve on our audit committee and compensation committee, and qualified executive officers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the corporate governance standards of the NASDAQ Global Select Market, a majority of our board of directors and each member of our audit
committee must be an independent director no later than the first anniversary of the completion of our IPO. We may encounter difficulty in attracting qualified persons to serve on our board of directors and the audit committee, and our board of
directors and management may be required to divert significant time and attention and resources away from our business to identify qualified directors. If we fail to attract and retain the required number of independent directors, we may be subject
to the delisting of our common stock from the NASDAQ Global Select Market. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Provisions of our charter, bylaws, and Delaware law may make an acquisition of us or a change in our
management more difficult. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain provisions of our restated certificate of incorporation and amended and restated bylaws that
became effective upon the completion of our IPO could discourage, delay, or prevent a merger, acquisition, or other change in control that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for
your shares. These provisions also could limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. Stockholders who wish to participate in these
transactions may not have the opportunity to do so. Furthermore, since our board of directors is responsible for appointing the members of our management team, these provisions could prevent or frustrate attempts by our stockholders to replace or
remove our management by making it more difficult for stockholders to replace members of our board of directors. These provisions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">allow the authorized number of directors to be changed only by resolution of our board of directors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establish a classified board of directors, providing that not all members of the board of directors be elected at one time; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">authorize our board of directors to issue without stockholder approval blank check preferred stock that, if issued, could operate as a &#147;poison pill&#148; to dilute the stock ownership of a potential hostile
acquirer to prevent an acquisition that is not approved by our board of directors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">require that stockholder actions must be effected at a duly called stockholder meeting and prohibit stockholder action by written consent; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establish advance notice requirements for stockholder nominations to our board of directors or for stockholder proposals that can be acted on at stockholder meetings; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">limit who may call stockholder meetings; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">require the approval of the holders of 75% of the outstanding shares of our capital stock entitled to vote in order to amend certain provisions of our restated certificate of incorporation and restated bylaws.
</TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, because we are incorporated in Delaware, we are governed by the provisions of Section&nbsp;203 of the Delaware
General Corporation Law, which may, unless certain criteria are met, prohibit large stockholders, in particular those owning 15% or more of our outstanding voting stock, from merging or combining with us for a prescribed period of time. This
provision could have the effect of delaying or preventing a change of control, whether or not it is desired by or beneficial to our stockholders. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We do not anticipate paying cash dividends, and accordingly, stockholders must rely on stock appreciation for any return on their investment.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently intend to retain our future earnings, if any, to fund the development and growth of our businesses. As a result,
capital appreciation, if any, of our common stock will be your sole source of gain on your investment for the foreseeable future. Investors seeking cash dividends should not invest in our common stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Future issuances of our common stock or rights to purchase common stock pursuant to our equity incentive plans or outstanding warrants could result in
additional dilution of the percentage ownership of our stockholders and could cause our share price to fall. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of
December&nbsp;31, 2014, we had options to purchase 3,572,116 shares outstanding under our equity compensation plans. We are also authorized to grant equity awards, including stock options, to our employees, directors and consultants, covering up to
1,403,572 shares of our common stock, pursuant to our equity compensation plans. We plan to register the number of shares available for issuance or subject to outstanding awards under our equity compensation plans. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If securities or industry analysts do not publish research or publish inaccurate or unfavorable research
about our business, our share price and trading volume could decline. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The trading market for our common stock will depend on the
research and reports that securities or industry analysts publish about us or our business. We do not have any control over these analysts. We cannot assure you that analysts will cover us or provide favorable coverage. If one or more of the
analysts who cover us downgrade our stock or change their opinion of our stock, our share price would likely decline. If one or more of these analysts cease coverage of our company or fail to regularly publish reports on us, we could lose visibility
in the financial markets, which could cause our share price or trading volume to decline. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B><A NAME="rom838054_4"></A>ITEM&nbsp;1B.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>UNRESOLVED STAFF COMMENTS </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Not applicable. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B><A NAME="rom838054_5"></A>ITEM&nbsp;2.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>PROPERTIES </B></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:62.85pt; font-size:8pt; font-family:Times New Roman"><B>Property Location</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Approximate</B><br><B>Square&nbsp;Footage</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Use</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Lease</B><br><B>Expiration<BR>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rockville, MD</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,597</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Manufacturing</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3/31/2018</TD>
<TD NOWRAP VALIGN="bottom">(A)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rockville, MD</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Manufacturing</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/31/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rockville, MD</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,416</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Office space</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/31/2020</TD>
<TD NOWRAP VALIGN="bottom">(A)(B)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rockville, MD</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,267</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Office&nbsp;and&nbsp;laboratory&nbsp;space</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/31/2020</TD>
<TD NOWRAP VALIGN="bottom">(A)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">South San Francisco, CA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66,127</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Office and laboratory space</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/28/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top">Lease includes one renewal option of 5 years </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top">Lease executed in 2014; lease term begins in 2015 </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that our properties are
generally in good condition, well maintained, suitable and adequate to carry on our business. We believe our capital resources are sufficient to lease any additional facilities required to meet our expected growth needs. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B><A NAME="rom838054_6"></A>ITEM&nbsp;3.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>LEGAL PROCEEDINGS </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the ordinary course of business, we are involved in various legal
proceedings, including, among others, patent oppositions, patent revocations, patent infringement litigation and other matters incidental to our business.&nbsp;We are not currently a party to any material legal proceedings. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B><A NAME="rom838054_7"></A>ITEM&nbsp;4.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>MINE SAFETY DISCLOSURES </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Not applicable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom838054_8"></A>PART II </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B><A NAME="rom838054_9"></A>ITEM&nbsp;5.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>MARKET FOR REGISTRANT&#146;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES </B></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Market Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock has
been listed on the NASDAQ Global Select Market under the symbol &#147;MGNX&#148; since October&nbsp;10, 2013. Prior to that date, there was no public trading market for our common stock. Shares sold in our initial public offering, or IPO, on
October&nbsp;9, 2013 were priced at $16.00 per share. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&nbsp;27, 2015, the closing price for our common stock as reported on the
NASDAQ Global Select Market was $34.57. The following table sets forth the high and low intra-day sale prices per share of our common stock as reported on the NASDAQ Global Select Market for the periods indicated. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>High</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Low</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>2014</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">First Quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;41.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">27.06</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Second Quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 31.11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17.96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Third Quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 22.90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fourth Quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 39.90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17.31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>2013</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fourth Quarter (from October 10, 2013)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">30.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Shareholders </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of February&nbsp;27, 2015, we had 29,968,476 shares of common stock outstanding held by approximately 123 holders of record, which include
shares held by a broker, bank or other nominee. We have never declared or paid any cash dividends. We do not anticipate declaring or paying cash dividends for the foreseeable future. Instead, we will retain our earnings, if any, for the future
operation and expansion of our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Performance Graph </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following graph compares the performance of our common stock to the performance of the NASDAQ Composite Index (U.S.) and the NASDAQ
Biotechnology Index since October&nbsp;10, 2013 (the first date that shares of our common stock were publicly traded). The comparison assumes a $100 investment on October&nbsp;10, 2013 in our common stock, the stocks comprising the NASDAQ Composite
Index, and the stocks comprising the NASDAQ Biotechnology Index, and assumes reinvestment of the full amount of all dividends, if any. Historical stockholder return is not necessarily indicative of the performance to be expected for any future
periods. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Comparison of Cumulative Total Return </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Among MacroGenics, Inc., the NASDAQ Composite Index and the NASDAQ Biotechnology Index </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g838054g10e16.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The performance graph shall not be deemed to be incorporated by reference by means of any general statement
incorporating by reference this Form 10-K into any filing under the Securities Act of 1933, as amended or the Exchange Act, except to the extent that we specifically incorporate such information by reference, and shall not otherwise be deemed filed
under such acts. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Unregistered Sales of Equity Securities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As previously disclosed, in connection with our collaboration and license agreement with Janssen, Johnson&nbsp;&amp; Johnson Innovation &#150;
JJDC, Inc. agreed to purchase 1,923,077 shares of our common stock at a price of $39.00 per share for aggregate consideration of $75.0 million. In January 2015, the transaction closed and we completed the sale of the shares in a transaction exempt
from registration pursuant to Section&nbsp;4(a)(2) of the Securities Act of 1933, as amended. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Use of Proceeds from Registered Securities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;16, 2013, we completed our IPO of 5,750,000 shares of our common stock, including 750,000 shares of common stock sold pursuant
to the underwriters&#146; full exercise of their option to purchase additional shares at a public offering price of $16.00 per share, for aggregate gross proceeds of $92.0 million. All of the shares issued and sold in the IPO were registered under
the Securities Act pursuant to a Registration Statement on Form S-1 (File No.&nbsp;333-190994), which was declared effective by the Securities and Exchange Commission (SEC) on October&nbsp;9, 2013. Merrill Lynch, Pierce, Fenner&nbsp;&amp; Smith
Incorporated and Leerink Swann LLC acted as representatives of the several underwriters. The offering commenced on October&nbsp;10, 2013 and did not terminate until the sale of all of the shares offered. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We received net proceeds from the offering of $83.8 million, after deducting approximately $6.4 million of underwriting discounts and
commissions, and approximately $1.9 million of offering expenses payable by us. None of the underwriting discounts and commissions or other offering expenses were incurred or paid to our directors or officers or their associates or to persons owning
10 percent or more of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There has been no material change in our planned use of the net proceeds from the offering as
described in our final prospectus filed with the SEC pursuant to Rule 424(b) under the Securities Act on October&nbsp;11, 2013. We have broad discretion in the use of the net proceeds from our initial public offering and could spend the proceeds in
ways that do not improve our results of operations or enhance the value of our stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B><A NAME="rom838054_10"></A>ITEM&nbsp;6.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>SELECTED FINANCIAL DATA </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The consolidated statement of operations and comprehensive
income (loss) data for the years ended December&nbsp;31, 2014, 2013 and 2012 and the consolidated balance sheet data as of December&nbsp;31, 2014 and 2013 presented below have been derived from our audited consolidated financial statements and
footnotes included elsewhere in this Annual Report on Form 10-K. The consolidated statement of operations and comprehensive income (loss) data for the year ended December&nbsp;31, 2011and the consolidated balance sheet data as of December&nbsp;31,
2012 and 2011 have been derived from our audited consolidated financial statements which are not included herein. Historical results are not necessarily indicative of future results. The following data should be read in conjunction with Item&nbsp;7,
&#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and the consolidated financial statements and related notes included elsewhere in this Annual Report on Form 10-K. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="54%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2011</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in thousands, except share and per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Consolidated Statement of Operations and</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Comprehensive Income (Loss):</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">47,797</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">58,035</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">63,826</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">57,207</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost and expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,186</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,582</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,433</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,089</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,926</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,087</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,869</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total costs and expenses</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">86,112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57,669</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,621</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,958</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income (loss) from operations</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(38,315</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">366</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,205</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,249</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense)</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(627</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">157</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss)</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(38,313</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(261</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,362</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,716</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted net income (loss) per common share</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.40</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.04</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted weighted average number of common shares</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,384,990</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,847,697</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,083,276</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,025,602</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="54%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2011</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Consolidated Balance Sheet Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">157,591</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">116,481</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">47,743</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">55,218</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">173,886</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">125,782</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,747</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,681</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,720</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,403</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,080</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54,890</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,947</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,947</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; equity (deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">121,286</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78,914</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,237</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,484</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B><A NAME="rom838054_11"></A>ITEM&nbsp;7.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The
following discussion of our financial condition and results of operations should be read together with our selected consolidated financial data and the consolidated financial statements and related notes included elsewhere herein. This discussion
contains forward-looking statements that involve risks and uncertainties. As a result of many factors, such as those set forth under the section entitled &#147;Risk Factors&#148;, &#147;Forward-Looking Statements&#148; and elsewhere herein, our
actual results may differ materially from those anticipated in these forward-looking statements. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a biopharmaceutical company focused on discovering and developing innovative antibody-based therapeutics for the treatment of cancer, as
well as various autoimmune disorders and infectious diseases. We currently have a pipeline of product candidates in human clinical testing, primarily against different types of cancers. These include two product candidates developed using our
proprietary &#147;Fc Optimization&#148; platform, namely margetuximab, an antibody that we are developing for treatment of certain types of metastatic breast cancers and gastroesophageal cancers, and MGA271, an antibody that we believe has the
potential for broad impact across a variety of different tumor types through multiple potential mechanisms of action. In addition, we created a number of product candidates based on our proprietary <U>D</U>ual-<U>A</U>ffinity
<U>R</U>e-<U>T</U>argeting, or DART<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, platform and several of these are currently in, or advancing into, human clinical development. For example, we initiated human clinical studies with DART
product candidates MGD006, in patients with acute myeloid leukemia that is refractory to other known treatments, and MGD007, in patients with colorectal cancer. We also recently entered into a collaboration with Janssen Biotech, Inc. (Janssen) with
respect to MGD011, a DART being developed for treatment of various hematological malignancies, and anticipate that this molecule will start clinical trials in 2015. We specifically designed these three DART product candidates with the goal of
harnessing the power of the immune system to destroy cancerous cells. In contrast, the flexibility of the DART platform has also allowed us to create MGD010, a DART molecule designed to moderate the hyperactivity of the immune system seen in various
autoimmune disorders, and we expect to start human clinical studies with that product candidate in 2015 as well. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We develop new
therapeutic product candidates ourselves using our antibody-based technology platforms and also in partnership with other biopharmaceutical companies, when such a partnership is advantageous for strategic or financial reasons. These collaborations
have allowed us to expand and accelerate the breadth of product candidates that can be developed and also have generated a significant portion of the funding we have received to date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Key ongoing programs include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Margetuximab</I> is an antibody that targets HER2-expressing tumors, including certain types of breast and gastroesophageal cancers. HER2, or human epidermal growth factor receptor 2, is critical for the growth of
many types of tumors. In 2015 we plan to commence a Phase 3 potential registration clinical trial with margetuximab in patients with metastatic breast cancer expressing HER2 who have failed therapy with other HER2 therapeutic agents. We also plan to
commence exploratory Phase 1/2 studies combining margetuximab with other therapeutic agents in patients with gastroesophegeal cancer, and we are currently enrolling a Phase 2a clinical trial in patients with lower levels of expressed HER2.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>MGA271</I> is an antibody that targets B7-H3, a member of the B7 family of molecules that are involved in immune regulation and that is over-expressed on a wide variety of solid tumor types. We have initiated
additional dose expansion cohorts using MGA271 as monotherapy in other tumor types. In 2015, we also intend to initiate one clinical study combining MGA271 with ipilimumab and plan to initiate a second study combining MGA271 with another
immuno-oncology agent. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>MGD006 </I>is a DART molecule that recognizes both CD123 and CD3. CD123, the Interleukin-3 receptor alpha chain, is expressed on leukemia and leukemic stem cells, but only at very low levels or not at all on normal
hematopoietic stem cells. T cells, which express CD3, can destroy tumor cells. In pre-clinical studies, we have demonstrated the ability of MGD006 to recruit, activate, and expand T&nbsp;cell populations to eliminate leukemia cells. We are currently
enrolling and dosing patients in the dose escalation portion of a Phase 1 clinical trial of MGD006. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>MGD007</I> is a DART molecule that recognizes both the glycoprotein A33, or gpA33, and CD3. MGD007 has an Fc domain, which allows for extended pharmacokinetic properties and convenient intermittent dosing. gpA33 is
expressed on gastrointestinal tumors, including more than 95% of human colon cancers. We have demonstrated that this molecule is able to mediate T&nbsp;cell killing of gpA33-expressing cancer cells and CSLCs in pre-clinical experiments. We are
currently enrolling and dosing patients in the dose escalation portion of a Phase 1 clinical trial of MGD007. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>MGD010</I> is a DART molecule designed to address limitations of existing B cell-targeted therapies by binding to the CD32B and CD79B proteins found on human B cells. In pre-clinical studies, this DART molecule
modulates the function of human B cells without B cell depletion. In normal conditions, B&nbsp;cells utilize CD32B as one of the key checkpoints or negative regulators to ensure that tolerance to self is maintained and autoimmune disease does not
occur. MGD010 is designed to further exploit this mechanism by triggering this inhibitory &#147;immune checkpoint&#148; loop. We believe this molecule preferentially blocks those B cells that are activated to produce the pathogenic antibodies that
promote the autoimmune process. We are planning to initiate a Phase 1a clinical trial with MGD010 in normal healthy volunteers in 2015. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>MGD011 </I>is a DART molecule that targets both CD19 and CD3 and is being developed for the treatment of B-cell hematological malignancies. CD19, a lymphocyte-specific marker expressed from early B-lymphocyte
development through mature memory B cells, is highly represented in B-cell malignancies. This makes it attractive for targeted interventions. MGD011 is designed to redirect T&nbsp;cells, via their CD3 component, to eliminate CD19-expressing cells
found in many hematological malignancies.&nbsp;MGD011 has been engineered to address half-life challenges posed by other programs targeting CD19 and CD3. Under our recent collaboration and license agreement with Janssen, after we file the
investigational new drug (IND) application for MGD011, Janssen will develop the product candidate, subject to our options to co-promote the product in the United States and Canada and to invest in later-stage development in exchange for a
profit-share. We anticipate that human clinical studies of MGD011 will begin in 2015. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>MGD009 </I>is a DART molecule that recognizes an undisclosed solid tumor antigen and CD3, and has an Fc domain, which allows for extended pharmacokinetic properties. We have demonstrated that this molecule is able to
mediate T&nbsp;cell killing of cancer cells in pre-clinical experiments. We expect to submit an IND for MGD009 in 2015 and initiate a Phase 1 clinical study by year-end. MacroGenics retains worldwide development and commercialization rights to this
molecule. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We commenced active operations in 2000, and have since devoted substantially all of our resources to staffing our
company, business planning, raising capital, developing our technology platforms, identifying potential product candidates, undertaking pre-clinical studies and conducting clinical trials. We have not generated any revenues from the sale of any
products to date. We have financed our operations primarily through the private placements of convertible preferred stock, the public offerings of our common stock, collaborations, and government grants and contracts. From inception through
December&nbsp;31, 2014, we received $151.3 million from the sale of convertible preferred stock and warrants. We raised $83.8 million net of expenses in October 2013 through the sale of common stock in connection with our Initial Public Offering
(IPO) and exercise by the underwriters of their over-allotment option. We raised an additional $76.7 million net of expenses through a follow-on public offering of our common stock and full exercise by the underwriters of their over-allotment option
in February 2014. In addition, we have received significant non-equity capital from our collaborators in the form of upfront fees, milestone payments, annual maintenance payments and license option fees as well as
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
reimbursement payments through our collaborations and government grants and contracts. Although it is difficult to predict our funding requirements, based upon our current operating plan, we
anticipate that our cash and cash equivalents as of December&nbsp;31, 2014, combined with the proceeds from Janssen and its affiliate, as well as other collaboration payments we anticipate receiving, will enable us to fund our operations into 2018,
assuming all of our collaboration programs advance as currently contemplated. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Through December&nbsp;31, 2014, we had an accumulated
deficit of $214.0 million. We expect that over the next several years we will increase our expenditures in research and development in connection with our ongoing activities with several clinical trials. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Strategic Collaborations and Licenses </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
have entered into several strategic collaborations which provide us with significant additional funding in order to continue development of our pipeline and to extend our technology platforms and on-going programs. Our collaborations have allowed us
to accelerate the progress of our on-going pre-clinical and clinical stage programs. Our most significant strategic collaborations include the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Janssen</I>. In December 2014, we entered into a collaboration and license agreement with Janssen for the development and commercialization of MGD011, a product candidate that incorporates our proprietary DART
technology to simultaneously target CD19 and CD3 for the potential treatment of B-cell malignancies. We contemporaneously entered into a stock purchase agreement and investor agreement, each with Johnson&nbsp;&amp; Johnson Innovation&#151;JJDC, Inc.
(JJDC), an affiliate of Janssen, under which JJDC agreed to purchase 1,923,077 new shares of our common stock at a price of $39.00 per share, representing proceeds of $75.0 million. The effectiveness of these agreements was subject to the early
termination or expiration of any applicable waiting periods under Hart-Scott-Rodino Antitrust Improvements Act of 1976, which occurred in January 2015. Upon closing, we received a $50.0 million upfront payment from Janssen as well as the $75.0
million investment in our common stock. Janssen will be fully responsible for developing MGD011 following submission of the IND, which is planned for 2015. Assuming successful development and commercialization, we could receive up to an additional
$575.0 million in clinical, regulatory and commercialization milestone payments. We may elect to fund a portion of late-stage clinical development in exchange for a profit share in the U.S. and Canada. If commercialized, we would be eligible to
receive double-digit royalties on any global net sales and have the option to co-promote the molecule with Janssen in the U.S. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Takeda.</I> In May 2014, we entered into a license and option agreement with Takeda Pharmaceutical Company Limited (Takeda) for the development and commercialization of MGD010, a product candidate that incorporates
our proprietary DART technology to simultaneously engage CD32B and CD79B, which are two B-cell surface proteins. MGD010 is currently in pre-clinical development for the treatment of autoimmune disorders, and we plan to initiate clinical testing of
MGD010 in 2015. Upon execution of the agreement, Takeda made a non-refundable payment of $15.0 million to us. Takeda has an option to obtain an exclusive worldwide license for MGD010 following the completion of a pre-defined Phase 1a study. We will
lead all product development activities until that time. If Takeda exercises its option, it will assume responsibility for future development and pay us a license option fee that, when combined with an early development milestone, would total $18.0
million. Assuming successful development and commercialization of MGD010, we are eligible to receive up to an additional $468.5 million in development, regulatory and sales milestone payments. If commercialized, we would receive double-digit
royalties on any global net sales and have the option to co-promote MGD010 with Takeda in the United States. Finally, we may elect to fund a portion of Phase 3 clinical development in exchange for a North American profit share. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">In September 2014, we entered into a research collaboration and license option agreement with Takeda for an initial research compound and up to
three additional compounds. Under the terms of this agreement, Takeda received an option to obtain an exclusive worldwide license for each of four product candidates and will fund all research and development activities related to the programs,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">
including reimbursement of our expenses. Assuming successful development and commercialization by Takeda, we could receive up to approximately $400.0 million in program initiation, pre-clinical,
clinical, regulatory and commercialization milestone payments for each of the four potential product candidates. If commercialized, we would receive double-digit royalties on any global net sales and have the option to co-promote each product
candidate with Takeda in the United States. Finally, we may elect to fund a portion of Phase 3 clinical development of each product candidate in exchange for a North American profit share. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Servier.</I> In November 2011, we entered into a collaboration agreement with Les Laboratoires Servier and Institut de Recherches Servier (collectively, Servier) under which we granted Servier an option to obtain an
exclusive license to develop and commercialize MGA271 in all countries other than the United States, Canada, Mexico, Japan, South Korea and India. Through December&nbsp;31, 2014, we have received a $20.0 million option grant fee and a $10.0 million
milestone payment. We may be eligible to receive up to approximately $415.0&nbsp;million in license fees and clinical, development, regulatory and sales milestone payments. In the event Servier exercises its option, Servier must pay a license fee,
which we estimate to be $30.0 million, based on the number of different indications represented within the planned Phase 1 patient population. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">In September 2012, we entered into a second agreement with Servier and granted it options to obtain three separate exclusive licenses to
develop and commercialize DART molecules, consisting of those designated by us as MGD006 and MGD007, as well as a third DART molecule, in all countries other than the United States, Canada, Mexico, Japan, South Korea and India. We received a $20.0
million upfront option fee. In addition, we became eligible to receive up to approximately $1.0 billion in additional license fees, and clinical, development, regulatory and sales milestone payments if Servier exercises all three of its options and
successfully develops, obtains regulatory approval for, and commercializes a product under each license. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">In February 2014, Servier
exercised its option to develop and commercialize MGD006, for which we received a $15.0 million license option fee. We also received two $5.0 million milestone payments from Servier in connection with the IND applications for MGD006 and MGD007
clearing the 30-day review period by the U.S. Food and Drug Administration (FDA). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Additionally, under both agreements, and assuming
exercise of the applicable options, Servier may share Phase 2 and Phase 3 development costs and would be obligated to pay us low- to mid-double digit royalties on product sales in its territories. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Boehringer</I>. In October 2010, we entered into an agreement with Boehringer Ingelheim International GmbH (Boehringer) to discover, develop and commercialize up to ten DART molecules which may span multiple
therapeutic areas. We granted Boehringer an exclusive worldwide, royalty-bearing license and received an upfront payment of $15.0 million. During 2014, Boehringer nominated a lead candidate generated by our DART technology for pre-clinical
development. This formal selection of a development candidate triggered a $2.0 million milestone payment to us under the agreement. We have the potential to earn development, regulatory and sales milestone payments that can reach up to approximately
$210.0 million for each of the DART programs under this agreement. Boehringer provides funding for our internal and external research costs and is required to pay us mid-single digit royalties on product sales. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Financial Operations Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenues
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our revenue consists primarily of collaboration revenue, including amounts recognized relating to upfront nonrefundable payments
for licenses or options to obtain future licenses, research and development funding and milestone payments earned under our collaboration and license agreement with our strategic collaborators, including Takeda, Servier, Gilead, Boehringer, Pfizer
and Green Cross. In addition, we have earned revenues </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
through several grants and/or contracts with the U.S. government and other research institutions on behalf of the U.S. government, primarily with respect to research and development activities
related to infectious disease product candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Expense </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses consist of expenses incurred in performing research and development activities. These expenses include
conducting pre-clinical experiments and studies, clinical trials, manufacturing efforts and regulatory filings for all product candidates, and other indirect expenses in support of our research and development activities. We capture research and
development expense on a program-by-program basis for our product candidates that are in clinical development and recognize these expenses as they are incurred. The following are items we include in research and development expenses: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Employee-related expenses such as salaries and benefits; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Employee-related overhead expenses such as facilities and other allocated items; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Stock-based compensation expense to employees and consultants engaged in research and development activities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Depreciation of laboratory equipment, computers and leasehold improvements; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Fees paid to consultants, subcontractors, clinical research organizations (CROs) and other third party vendors for work performed under our pre-clinical and clinical trials including but not limited to investigator
grants, laboratory work and analysis, database management, statistical analysis, and other items; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Amounts paid to vendors and suppliers for laboratory supplies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Costs related to manufacturing clinical trial materials, including vialing, packaging and testing; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">License fees and other third party vendor payments related to in-licensed product candidates and technology; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Costs related to compliance with regulatory requirements. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is difficult to determine with
certainty the duration and completion costs of our current or future pre-clinical programs and clinical trials of our product candidates, or if, when or to what extent we will generate revenues from the commercialization and sale of any of our
product candidates that obtain regulatory approval. We may never succeed in achieving regulatory approval for any of our product candidates. The duration, costs and timing of clinical trials and development of our product candidates will depend on a
variety of factors, including the uncertainties of future clinical trials and pre-clinical studies, uncertainties in clinical trial enrollment rate and significant and changing government regulation. In addition, the probability of success for each
product candidate will depend on numerous factors, including competition, manufacturing capability and commercial viability. We will determine which programs to pursue and how much to fund each program in response to the scientific and clinical
success of each product candidate, as well as an assessment of each product candidate&#146;s commercial potential. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>General and Administrative
Expense </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expenses consist of salaries and related benefit costs for employees in our executive, finance,
legal and intellectual property, business development, human resources and other support functions, travel expenses and other legal and professional fees. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other Income (Expense) </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other income (expense) consists of interest income earned on our cash and cash equivalents, offset by other expenses, including changes in the
fair market value of the preferred stock warrant liability. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Critical Accounting Policies and Significant Judgments and Estimates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management&#146;s discussion and analysis of financial conditions and results of operations is based on our consolidated financial
statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these consolidated financial statements requires us to make estimates, judgments and assumptions
that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the balance sheets and the reported amount of the revenue and expenses recorded during the reporting period. We base our
estimates on historical experience and on various other assumptions that we believe to be reasonable. We review and evaluate these estimates on an on-going basis. These assumptions and estimates form the basis for making judgments about the carrying
values of assets and liabilities and amounts that have been recorded as revenues and expenses. Actual results and experiences may differ from these estimates. The results of any material revisions would be reflected in the consolidated financial
statements prospectively from the date of the change in estimate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While a summary of significant accounting policies is described fully
in Note 2 in our consolidated financial statements, we believe that the following accounting policies are the most critical to assist you in fully understanding and evaluating our financial results and any affect the estimates and judgments we used
in preparing our consolidated financial statements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue Recognition </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We enter into collaboration and license agreements with collaborators for the development of monoclonal antibody-based therapeutics to treat
cancer and other complex diseases. The terms of these agreements contain multiple deliverables which may include (i)&nbsp;licenses, or options to obtain licenses, to our technological platforms, such as our Fc engineering and DART technologies,
(ii)&nbsp;rights to future technological improvements, (iii)&nbsp;research and development activities to be performed on behalf of the collaborative partner or as part of the collaboration, and (iv)&nbsp;the manufacture of pre-clinical or clinical
materials for the collaborative partner. Payments to us under these agreements may include nonrefundable license fees, option fees, exercise fees, payments for research and development activities, payments for the manufacture of pre-clinical or
clinical materials, license maintenance payments, payments based upon the achievement of certain milestones and royalties on product sales. Other benefits to us from these agreements include the right to sell products resulting from the
collaborative efforts of the parties in specific geographic territories. We follow the provisions of the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 605-25, <I>Revenue Recognition&#150;Multiple-Element
Arrangements,</I> and ASC Topic 605-28, <I>Revenue Recognition&#150;Milestone Method</I>, in accounting for these agreements. In order to account for these agreements, we must identify the deliverables included within the agreement and evaluate
which deliverables represent separate units of accounting based on the achievement of certain criteria, including whether the delivered element has stand-alone value to the collaborator. The consideration received is allocated among the separate
units of accounting, and the applicable revenue recognition criteria are applied to each of the separate units. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31,
2014, we had two types of agreements: 1) exclusive development and commercialization licenses to use our technology and/or certain other intellectual property to develop compounds against specified targets, which we refer to as exclusive licenses;
and 2) option/research agreements to secure on established terms development and commercialization licenses to therapeutic product candidates to collaborator-selected targets developed by us during an option period, which we refer to as
right-to-develop agreements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Exclusive Licenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The deliverables under an exclusive license agreement generally include the exclusive license to our technology with respect to a specified
antigen target, and may also include deliverables related to rights to future technological improvements, research and pre-clinical development activities to be performed on behalf of the collaborator. In some cases we may have an option to
participate in the co-development of product candidates that result from such agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally, exclusive license agreements contain
nonrefundable terms for payments and, depending on the terms of the agreement, provide that we will (i)&nbsp;at the collaborator&#146;s request, provide research and pre-clinical development services at negotiated prices which are generally
consistent with what other third parties would charge, (ii)&nbsp;earn payments upon the achievement of certain milestones, (iii)&nbsp;earn royalty payments, and (iv)&nbsp;in some cases grant us an option to participate in the development and
commercialization of products that result from such agreements. Royalty rates may vary over the royalty term depending on our intellectual property rights and whether we exercise any co-development and co-commercialization rights. We may provide
technical assistance and share any technology improvements with our collaborators during the term of the collaboration agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do
not directly control when any collaborator will achieve milestones or become liable for royalty payments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In determining the separate
units of accounting, management evaluates whether the exclusive license has stand-alone value from the undelivered elements to the collaborator based on the consideration of the relevant facts and circumstances for each arrangement. Factors
considered in this determination include the research and development capabilities of the collaborator and the availability of technology platform and product research expertise in the general marketplace. In addition, we consider whether or not
(i)&nbsp;the collaborator could use the license for its intended purpose without the receipt of the remaining deliverables, (ii)&nbsp;the value of the license was dependent on the undelivered items and (iii)&nbsp;the collaborator or other vendors
could provide the undelivered items. If we conclude that the license has stand-alone value and therefore will be accounted for as a separate unit of accounting, we then determine the estimated selling prices of the license and all other units of
accounting based on market conditions, similar arrangements entered into by third parties, and entity-specific factors such as the terms of our previous collaboration agreements, recent pre-clinical and clinical testing results of therapeutic
product candidates that use our technology platforms, our pricing practices and pricing objectives, the likelihood that technological improvements will be made, the likelihood that technological improvements made will be used by our collaborators
and the nature of the research services to be performed on behalf of our collaborators and market rates for similar services. The upfront payment is recognized upon delivery of the license if facts and circumstances dictate that the license has
stand-alone value from the undelivered elements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upfront payments on exclusive licenses are deferred if facts and circumstances dictate
that the license does not have stand-alone value, and revenue is then recognized throughout the period of performance. We reassess the period of performance over which we recognize deferred upfront license fees and make adjustments as appropriate.
In the event a collaborator elects to discontinue development of a specific product candidate under a single target license, but retains its right to use our technology to develop an alternative product candidate to the same target or a target
substitute, we would cease amortization of any remaining portion of the upfront fee until there is substantial pre-clinical activity on another product candidate and its remaining period of substantial involvement can be estimated. In the event that
a single target license were to be terminated, we would recognize as revenue any portion of the upfront fee that had not previously been recorded as revenue, but was classified as deferred revenue, at the date of such termination or through the
remaining substantial involvement in the wind down of the agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We recognize revenue related to research and pre-clinical
development services that represent separate units of accounting as they are performed, as long as there is persuasive evidence of an arrangement, the fee is fixed or determinable, and collection of the related receivable is probable. We recognize
revenue related to the rights to future technological improvements over the estimated term of the applicable license. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We typically perform research activities and pre-clinical development services, including
generating and engineering product candidates, on behalf of our licensees during the early evaluation and pre-clinical testing stages of drug development under our exclusive licenses. We record amounts received for research materials produced or
services performed as revenue from collaborative research. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our license agreements have milestone payments which for reporting purposes
are aggregated into three categories: (i)&nbsp;development milestones, (ii)&nbsp;regulatory milestones, and (iii)&nbsp;sales milestones. Development milestones are typically payable when a product candidate initiates or advances into different
clinical trial phases. Regulatory milestones are typically payable upon submission for marketing approval with the FDA or other countries&#146; regulatory authorities or on receipt of actual marketing approvals for the compound or for additional
indications. Sales milestones are typically payable when annual sales reach certain levels. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the inception of each agreement that
includes milestone payments, we evaluate whether each milestone is substantive and at risk to both parties on the basis of the contingent nature of the milestone. This evaluation includes an assessment of whether (a)&nbsp;the consideration is
commensurate with either (1)&nbsp;our performance to achieve the milestone, or (2)&nbsp;the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from our performance to achieve the milestone, (b)&nbsp;the
consideration relates solely to past performance and (c)&nbsp;the consideration is reasonable relative to all of the deliverables and payment terms within the arrangement. We evaluate factors such as the scientific, regulatory, commercial and other
risks that must be overcome to achieve the respective milestone, the level of effort and investment required to achieve the respective milestone and whether the milestone consideration is reasonable relative to all deliverables and payment terms in
the arrangement in making this assessment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Non-refundable development and regulatory milestones that are expected to be achieved as a
result of our efforts during the period of substantial involvement are considered substantive and are recognized as revenue upon the achievement of the milestone, assuming all other revenue recognition criteria are met. Milestones that are not
considered substantive because we did not contribute effort to the achievement of such milestones are generally achieved after the period of substantial involvement and are recognized as revenue upon achievement of the milestone, as there are no
undelivered elements remaining and no continuing performance obligations, assuming all other revenue recognition criteria are met. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Right-to-Develop
Agreements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our right-to-develop agreements provide collaborators with an exclusive option to obtain licenses to develop and
commercialize in specified geographic territories product candidates developed by us under agreed upon research and pre-clinical development programs. The product candidates resulting from each program are all directed to a specific target selected
by the collaborator. Under these agreements, fees may be due to us (i)&nbsp;at the inception of the arrangement (referred to as &#147;upfront&#148; fees or payments), (ii)&nbsp;upon the selection of a target for a program, (iii)&nbsp;upon the
exercise of an option to acquire a development and commercialization license, referred to as exercise fee, for a program, or (iv)&nbsp;some combination of all of these fees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accounting for right-to-develop agreements is dependent on the nature of the options granted to the collaborative partner. Options are
considered substantive if, at the inception of a right-to-develop agreement, we are at risk as to whether the collaborative partner will choose to exercise the options to secure development and commercialization licenses. Factors that are considered
in evaluating whether options are substantive include the overall objective of the arrangement, the benefit the collaborator might obtain from the agreement without exercising the options, the cost to exercise the options relative to the total
upfront consideration, and the additional financial commitments imposed on the collaborator as a result of exercising the options. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For
right-to-develop agreements where the options to secure development and commercialization licenses to a product program are considered substantive, we do not consider the development and commercialization licenses to be a deliverable at the
inception of the agreement. For those right-to-develop agreements where the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
options to secure development and commercialization licenses are considered substantive, we have deferred the upfront payments received and recognize this revenue over the period during which the
collaborator could elect to exercise options for development and commercialization licenses. These periods are specific to each collaboration agreement. If a collaborator selects a target for a product program, any substantive option fee is deferred
and recognized over the life of the option. If a collaborator exercises an option and acquires a development and commercialization license to a product program, we attribute the exercise fee to the development and commercialization license. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon exercise of an option to acquire a development and commercialization license, we would also attribute any remaining deferred option fee,
in addition to the consideration received for the license upon exercise of the option, to the development and commercialization license. We then apply the multiple-element revenue recognition criteria to the development and commercialization license
and other deliverables, if any, to determine the appropriate revenue recognition method. This method is consistent with our accounting policy for upfront payments on exclusive licenses (discussed above). In the event a right-to-develop agreement
were to be terminated, we would recognize as revenue any portion of the upfront fee that had not previously been recorded as revenue, but was classified as deferred revenue, at the date of such termination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For right-to-develop agreements where the options to secure development and commercialization licenses to product programs are not considered
substantive, we consider the development and commercialization licenses to be a deliverable at the inception of the agreement and apply the multiple-element revenue recognition criteria to determine the appropriate revenue recognition. All of our
right-to-develop agreements have been determined to contain substantive options. We do not directly control when any collaborator will exercise its options for development and commercialization licenses. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Expense and related Accrued Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As part of the process of preparing our consolidated financial statements, we may be required to estimate accrued expenses. In order to obtain
reasonable estimates, we review open contracts and purchase orders. In addition, we communicate with applicable personnel in order to identify services that have been performed, but for which we have not yet been invoiced. In most cases, our vendors
provide us with monthly invoices in arrears for services performed. We confirm our estimates with these vendors and make adjustments as needed. The following are examples of our accrued expenses: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Fees paid to CROs for services performed on clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Fees paid to investigator sites for performance on clinical trials; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Fees paid for professional services. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The majority of expenses related to clinical trials
performed by our CROs are dependent on the successful enrollment of patients. These expenses can vary from site to site and contract to contract. We base our estimated accruals on the time period over which the services are to be performed and the
level of effort to be expended in each period based on the estimated enrollment of patients in each trial. We will adjust accordingly should the estimates vary from the actual expenses. However, we do not anticipate that our payment of actual
expenses will differ materially from our estimates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Income Taxes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Deferred tax assets and liabilities are determined based on differences between the financial reporting and tax basis of assets and liabilities
and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. The effect on deferred tax assets and liabilities of a change in tax rates is recognized as income in the period
that such tax rate changes are enacted. The measurement of a deferred tax asset is reduced, if necessary, by a valuation allowance if it is more likely than not that some portion </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or all of the deferred tax asset will not be realized. Financial statement recognition of a tax position taken or expected to be taken in a tax return is determined based on a
more-likely-than-not threshold of that position being sustained. If the tax position meets this threshold, the benefit to be recognized is measured as the largest amount that is more than 50% likely to be realized upon ultimate settlement. Our
policy is to record interest and penalties related to uncertain tax positions as a component of income tax expense. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We recorded net
deferred tax assets of $94.3 million as of December&nbsp;31, 2014, which have been fully offset by a valuation allowance due to uncertainties surrounding our ability to realize these tax benefits. The deferred tax assets are primarily comprised of
federal and state tax net operating loss (NOL) carryforwards and research and development tax credit carryforwards. As of December&nbsp;31, 2014, we had federal NOL carryforwards of $158.9 million, state NOL carryforwards of $103.4 million and
research and development tax credit carryforwards of $26.3 million available. The federal NOL carryforwards will begin to expire at various dates starting in 2020. We are already subject to Section&nbsp;382 limitations due to acquisitions we made in
2002 and 2008. Future changes in stock ownership may also trigger an ownership change and, consequently, another Section&nbsp;382 limitation. Any limitation may result in expiration of a portion of the net operating loss or tax credit carryforwards
before utilization which would reduce our gross deferred income tax assets and corresponding valuation allowance. As a result, if we earn net taxable income, our ability to use our pre-change net operating loss carryforwards and tax credit
carryforwards to reduce United States federal income tax may be subject to limitations, which could potentially result in increased future cash tax liability to us. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock-Based Compensation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
recognize stock-based compensation expense in accordance with the provisions of ASC Topic 718, <I>Compensation&#151;Stock Compensation</I>. The fair value of stock-based payments is estimated, on the date of grant, using a Black-Scholes model. The
resulting fair value is recognized on a straight-line basis over the requisite service period, which is generally the vesting period of the option. The use of a Black-Scholes model requires us to apply judgment and make assumptions and estimates
that include the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Fair Value of Common Stock</I><B>&#151;</B>Before our entry into the public market on October&nbsp;10, 2013, our Board of Directors determined the fair value of the common stock. The Board of Directors made
determinations of fair value based, in part, upon contemporaneous valuations to determine fair value. The contemporaneous valuations were performed in accordance with applicable methodologies, approaches and assumptions of the technical practice-aid
issued by the American Institute of Certified Public Accountants Practice Aid entitled <I>Valuation of Privately-Held Company Equity Securities Issued as Compensation</I>. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Expected Volatility</I>&#151;Volatility is a measure of the amount by which a financial variable such as a share price has fluctuated (historical volatility) or is expected to fluctuate (expected volatility) during a
period. As we do not yet have sufficient history of our own volatility, we have identified several public entities of similar size, complexity and stage of development and estimate volatility based on the volatility of these companies.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Expected Dividend Yield</I>&#151;We have never declared or paid dividends and have no plans to do so in the foreseeable future. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Risk-Free Interest Rate</I>&#151;This is the U.S. Treasury rate for the week of each option grant during the year, having a term that most closely resembles the expected life of the option. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Expected Term</I>&#151;This is the period of time that the options granted are expected to remain unexercised. Options granted have a maximum term of ten years and we have estimated the expected life of the option
term to be 6.25 years. We use a simplified method to calculate the average expected term. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Expected Forfeiture Rate</I>&#151;The forfeiture rate is the estimated percentage of options granted that is expected to be forfeited or canceled on an annual basis before becoming fully vested. We estimate the
forfeiture rate based on turnover data with further consideration given to the class of the employees to whom the options were granted. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Results of Operations for the Years Ended December&nbsp;31, 2014 and 2013 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following represents
a comparison of our research and development revenue for the years ended December&nbsp;31, 2014 and 2013: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Increase/(Decrease)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2013&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(dollars in millions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue from collaborative research</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">47.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">56.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9.4</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grant revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.8</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(59</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total revenue</B></P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>47.8</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>58.0</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(10.2</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(18</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)%&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The decrease in collaboration revenue of $9.4 million for the year ended December&nbsp;31, 2014 compared to
2013 is primarily due to a decrease in revenue recognition related to the Servier MGA271 agreement as the revenue related to the upfront fee was substantially recognized prior to 2014 and a decrease in revenue recognition related to the Servier DART
agreement as the estimated development period, and therefore the revenue recognition period of previously deferred revenues, was extended. Additionally, we received less reimbursement under the Gilead agreement as the research and development period
ended in 2014, and we recognized revenue under the Pfizer agreement in 2013, but the development period, and therefore the related revenue recognition period, was completed in January 2014. These decreases were partially offset by the addition of
our collaborations with Takeda, which resulted in $8.0 million in revenue recognized in 2014. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Grant revenue decreased in the year ended
December&nbsp;31, 2014 compared to 2013 due to less activity on the Dengue virus grant. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Expense </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following represents a comparison of our research and development expense for the years ended December&nbsp;31, 2014 and 2013: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="52%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Increase/(Decrease)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2013&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(dollars in millions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Margetuximab</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">211</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">MGA271</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">MGD006</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5.2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(60</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">MGD007</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">MGD010</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">MGD011</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other pre-clinical and clinical programs, collectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total research and development expense</B></P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>70.2</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>46.6</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>23.6</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>51</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2014 our research and development expense increased by $23.6 million
compared to 2013. This increase was due primarily to the initiation of clinical manufacturing activities for two product candidates, preparations for the margetuximab Phase 3 study, expansion of the MGA271 Phase 1 study and preparations for the
MGD007 Phase 1 study. These increases were partially offset by decreased manufacturing costs for MGD006 and reimbursement from Servier for MGD006 which is recorded as a reduction in research and development expense. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>General and Administrative Expense </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following represents a comparison of our general and administrative expense for the years ended December&nbsp;31, 2014 and 2013: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="53%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Increase/(Decrease)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2013&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(dollars in millions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expense increased for the year ended December&nbsp;31, 2014 by $4.8 million
compared to 2013 primarily due to an increase in stock-based compensation expense and increased insurance, professional fees and other costs associated with public company operations in 2014. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other Income (Expense) </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The change
to other income for the year ended December&nbsp;31, 2014 from other expense of $626,813 for the year ended December&nbsp;31, 2013 is primarily due to the change in the fair market value of the preferred stock warrant liability in 2013 (which was
settled in connection with the Company&#146;s IPO). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Results of Operations for the Years Ended December&nbsp;31, 2013 and 2012 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following represents a
comparison of our research and development revenue for the years ended December&nbsp;31, 2013 and 2012: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="53%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Increase/(Decrease)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2013&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2012&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(dollars in millions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue from collaborative research</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">56.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">59.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2.9</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grant revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2.9</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(69</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total revenue</B></P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>58.0</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>63.8</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(5.8</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(9</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)%&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The decrease in collaboration revenue of $2.9 million for the year ended December&nbsp;31, 2013 compared to
2012 is primarily due to the conclusion of teplizumab clinical trial-related reimbursement revenue from our former collaborator, Eli Lilly. Aside from reimbursing us for the continued monitoring expense of one on-going trial, Eli Lilly&#146;s
participation in the development of teplizumab concluded in the first quarter of 2013. This decrease is partially offset by the receipt of a $10.0 million milestone payment under our agreement with Servier, a $5.0 million milestone payment from
Boehringer, and the addition of our collaboration with Gilead. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Grant revenue decreased in the year ended December&nbsp;31, 2013 compared
to 2012 due primarily to the completion of grants to study H5N1 influenza virus, smallpox and West Nile virus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Expense </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following represents a comparison of our research and development expense for the years ended December&nbsp;31, 2013 and 2012: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Increase/(Decrease)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2013&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2012&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(dollars in millions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Margetuximab</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">MGA271</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">MGD006</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">MGD007</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">MGD010</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">225</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">MGD011</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other pre-clinical and clinical programs, collectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12.9</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(46</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total research and development expense</B></P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>46.6</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>45.4</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1.2</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">MGD007 costs were included in other pre-clinical and clinical programs in 2012. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the
year ended December&nbsp;31, 2013 our research and development expense increased by $1.2 million compared to 2012 due to an increase in spending on DART-based product candidates, offset by the reduction in spending on teplizumab-related clinical
development as we ended trial enrollment and began closing down the trials. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>General and Administrative Expense </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following represents a comparison of our general and administrative expense for the years ended December&nbsp;31, 2013 and 2012: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="53%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Increase/(Decrease)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2013&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2012&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(dollars in millions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expense increased for the year ended December&nbsp;31, 2013 by $0.9 million
compared to 2012 primarily due to an increase in professional fees and other costs associated with preparations for public company operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other Income (Expense) </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The change
to other expense of $626,813 for the year ended December&nbsp;31, 2013 from other income of $156,445 for the year ended December&nbsp;31, 2012 is primarily due to the change in the fair market value of the preferred stock warrant liability (which
was settled in connection with the Company&#146;s IPO). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cash Flows </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table represents a summary of our cash flows for the years ended December&nbsp;31, 2014, 2013 and 2012: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="53%"></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2013&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2012&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(dollars in millions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash provided by (used in):</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(32.8</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(14.2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6.6</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3.6</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3.0</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.9</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net increase (decrease) in cash and cash equivalents</B></P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>41.1</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>68.7</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(7.5</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Operating Activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities reflects, among other things, the amounts used to run our clinical trials and pre-clinical activities,
including toxicology studies. The difference between net cash used in operating activities during the years ended December&nbsp;31, 2014 and 2013 was primarily due to the initiation of clinical manufacturing activities for two product candidates,
preparations for the margetuximab Phase 3 study and expansion of the MGA271 Phase 1 study. The difference between net cash used in operating activities during the years ended December&nbsp;31, 2013 and 2012 was primarily due to less teplizumab
clinical trial-related reimbursement revenue from our former collaborator, Eli Lilly, and higher general and administrative expenses, offset by receipt of a $10.0 million milestone from Servier and a $5.0 million milestone from Boehringer. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Investing Activities </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash used in
investing activities in each of the years ended December&nbsp;31, 2014, 2013, and 2012 is primarily due to the acquisition of additional lab equipment needed to further our research and development activities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Financing Activities </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash provided
by financing activities for the year ended December&nbsp;31, 2014 includes net proceeds from the follow-on equity offering and cash from stock option exercises. Net cash provided by financing activities for the year ended December&nbsp;31, 2013
includes net proceeds from our IPO and cash from stock option exercises. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidity and Capital Resources </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have financed our operations primarily through the private placements of convertible preferred stock, the public offerings of our common
stock, upfront fees, milestone payments, annual maintenance payments and license option fees from collaborators and reimbursement through government grants and contracts. As of December&nbsp;31, 2014, we had $157.6 million in cash and cash
equivalents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;16, 2013, we completed the IPO of our common stock, which resulted in the sale of 5,750,000 shares,
including all additional shares available to cover over-allotments, at a price of $16.00 per share. We raised $85.6 million ($83.8 million net of expenses and deferred financing costs). In connection with the closing of the IPO, all of our
outstanding convertible preferred stock automatically converted to common stock at various ratios as disclosed in Note 4 to the financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&nbsp;18, 2014, we completed a follow-on public offering of our common stock, in which
we sold 1,800,000 shares of common stock, at a price of $36.50 per share. Additionally, the underwriters of the offering exercised the full amount of their over-allotment option resulting in the sale of an additional 450,000 shares of our common
stock at a price of $36.50 per share. We received net proceeds of $76.7 million from the offering, net of underwriting discounts and commissions and other estimated offering expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to our existing cash and cash equivalents, we are eligible to continue to receive additional reimbursement from our collaborators
for research and development services rendered, additional milestone and opt-in payments and grant revenue. However, our ability to receive these milestone payments is dependent upon our ability to successfully complete specified research and
development activities and is therefore uncertain at this time. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Funding Requirements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not generated any revenue from product sales to date and do not expect to do so until such time as we obtain regulatory approval of and
commercialize one or more of our product candidates. As we are currently in the clinical trial stage of development, it will be some time before we expect to achieve this and it is uncertain that we ever will. We expect that we will continue to
increase our operating expenses in connection with ongoing as well as additional clinical trials and pre-clinical development of product candidates in our pipeline. We expect to continue our collaboration arrangements and will look for additional
collaboration opportunities. We also expect to continue our efforts to pursue additional grants and contracts from the U.S. government in order to further our research and development. Although it is difficult to predict our funding requirements,
based upon our current operating plan, we anticipate that our existing cash and cash equivalents as of December&nbsp;31, 2014, combined with the proceeds from Janssen and its affiliate, as well as other collaboration payments we anticipate
receiving, will enable us to fund our operations into 2018, assuming all of our programs advance as currently contemplated. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contractual Obligations
and Contingent Liabilities </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table represents future minimum operating lease payments under non-cancelable operating
leases as of December&nbsp;31, 2014: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="59%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Less&nbsp;than<BR>1 year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>1&nbsp;to&nbsp;3&nbsp;years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>3&nbsp;to&nbsp;5&nbsp;years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>More&nbsp;than<BR>5 years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center"><B>(in millions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating Leases</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our current obligations and contingent liabilities are limited to the operating leases at our facilities in
Rockville, Maryland and South San Francisco, California. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with an Asset Purchase Agreement with Tolerance Therapeutics, Inc.
(Tolerance) entered into in June 2005, we may be required to give Tolerance additional consideration as follows: (i)&nbsp;a maximum of $10.9&nbsp;million if certain milestones are met, including the initiation of Phase 3 trials and the filing of
various regulatory product license applications; (ii)&nbsp;36,135 shares of our common stock; and (iii)&nbsp;royalty payments between 1.75% and 4.0% of net sales of products acquired from or patented by Tolerance or other product fees earned by us.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July 2008, we acquired Raven Biotechnologies (Raven). The Raven purchase agreement provides for certain contingent payments that are
based on the achievement of development and commercialization activities for product candidates derived from the acquired Raven technology. We are required to make a onetime payment of $5.0 million to the former Raven stockholders upon the
initiation of patient dosing in the first Phase 2 clinical trial of any product derived from the Raven cancer stem cell program. No payment shall be made if the Phase 2 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
trial start date has not occurred on or before July&nbsp;15, 2018. Other consideration includes a percentage of revenue (excluding consideration for research and development, equity and certain
cost reimbursements) we may receive for each license of a product candidate derived from the Raven cancer stem cell program. The revenue percentage in each case is based upon the execution date of the subject license. No consideration is owed for
licenses executed after July&nbsp;16, 2018. There is additional contingent consideration of one time payments of $8.0 million and $12.0 million, which depend upon the achievement of a specified level of sales of a product derived from the Raven
cancer stem cell program. At our sole discretion, each payment can be made in cash, common stock or a combination thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
contractual obligations table does not include any potential future payments we may be required to make under our Asset Purchase Agreement with Tolerance or the purchase agreement with Raven. Due to the uncertainty of the achievement and timing of
the events requiring payment under that agreement, the amounts to be paid by us are not fixed or determinable at this time. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Off-Balance Sheet
Arrangements </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not have any off-balance sheet arrangements, as defined under the rules and regulations of the Securities and
Exchange Commission. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B><A NAME="rom838054_12"></A>ITEM&nbsp;7A.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our primary objective when
considering our investment activities is to preserve capital in order to fund our operations. Our primary exposure to market risk is related to changes in interest rates. Our current investment policy is to invest principally in deposits and
securities issued by the U.S. government and its agencies, Government Sponsored Enterprise agency debt obligations, corporate debt obligations and money market instruments. As of December&nbsp;31, 2014, we had cash and cash equivalents of $157.6
million, of which $26.0 million was invested in money market funds and the remainder was in our corporate operating account. We do not believe that our cash and cash equivalents have significant risk. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B><A NAME="rom838054_13"></A>ITEM&nbsp;8.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information required by this item is
set forth on pages F-1&#151;F-33. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B><A NAME="rom838054_14"></A>ITEM&nbsp;9.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>CHANGES AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE </B></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B><A NAME="rom838054_15"></A>ITEM&nbsp;9A.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>CONTROLS AND PROCEDURES </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Disclosure Controls and Procedures </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management, including our principal executive and principal financial officers, has evaluated the effectiveness of our disclosure controls
and procedures as of December&nbsp;31, 2014. Our disclosure controls and procedures are designed to provide reasonable assurance that the information required to be disclosed in this annual report on Form 10-K has been appropriately recorded,
processed, summarized and reported within the time periods specified in the Securities and Exchange Commission&#146;s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive and
principal financial officers, to allow timely decisions regarding required disclosure. Based on that evaluation, our principal executive and principal financial officers have concluded that our disclosure controls and procedures are effective at the
reasonable assurance level. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">67 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Changes in Internal Control </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management, including our principal executive and principal financial officers, has evaluated any changes in our internal control over
financial reporting that occurred during the quarterly period ended December&nbsp;31, 2014, and has concluded that there was no change that occurred during the quarterly period ended December&nbsp;31, 2014 that has materially affected, or is
reasonably likely to materially affect, our internal control over financial reporting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Management Report on Internal Control over Financial Reporting
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The management of the Company is responsible for establishing and maintaining adequate internal control over financial reporting.
Internal control over financial reporting is defined in Rule 13a-15(f) or 15d-15(f) promulgated under the Securities Exchange Act of 1934, as amended, as a process designed by, or under the supervision of, the Company&#146;s principal executive and
principal financial officers and effected by the Company&#146;s board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for
external purposes in accordance with generally accepted accounting principles and includes those policies and procedures that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">pertain to the management of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the Company; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of
the Company are being made only in accordance with authorizations of management and directors of the Company; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company&#146;s assets that could have a material effect on the financial statements.
</TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements.
Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. All
internal control systems, no matter how well designed, have inherent limitations. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s management assessed the effectiveness of the Company&#146;s internal control over financial reporting as of
December&nbsp;31, 2014. In making this assessment, the Company&#146;s management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (COSO) in Internal Control-Integrated Framework.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on our assessment, management believes that, as of December&nbsp;31, 2014, the Company&#146;s internal control over financial
reporting is effective based on those criteria. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B><A NAME="rom838054_16"></A>ITEM&nbsp;9B.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>OTHER INFORMATION </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">68 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom838054_17"></A>PART III </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B><A NAME="rom838054_18"></A>ITEM&nbsp;10.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We incorporate herein by
reference the relevant information concerning directors, executive officers and corporate governance to be included in our definitive proxy statement for the 2015 annual meeting of stockholders (the &#147;2015 Proxy Statement&#148;). </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B><A NAME="rom838054_19"></A>ITEM&nbsp;11.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>EXECUTIVE COMPENSATION </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We incorporate herein by reference the relevant information
concerning executive compensation to be included in the 2015 Proxy Statement. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B><A NAME="rom838054_20"></A>ITEM&nbsp;12.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS </B></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We incorporate herein by reference the relevant information concerning security ownership of certain beneficial owners and management to be
included in the 2015 Proxy Statement. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B><A NAME="rom838054_21"></A>ITEM&nbsp;13.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
incorporate herein by reference the relevant information concerning certain other relationships and related transactions to be included in the 2015 Proxy Statement. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B><A NAME="rom838054_22"></A>ITEM&nbsp;14.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>PRINCIPAL ACCOUNTING FEES AND SERVICES </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We incorporate herein by reference the relevant
information concerning principal accounting fees and services to be included in the 2015 Proxy Statement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">69 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom838054_23"></A>PART IV </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B><A NAME="rom838054_24"></A>ITEM&nbsp;15.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>EXHIBITS AND FINANCIAL STATEMENT SCHEDULES </B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">The following documents are filed as part of this Annual Report on Form 10-K: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Consolidated Financial Statements: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="93%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Report of Ernst &amp; Young LLP, Independent Registered Public Accounting Firm</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Consolidated Balance Sheets</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Consolidated Statements of Operations and Comprehensive Income (Loss)</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Consolidated Statements of Stockholders&#146; Equity</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Consolidated Statements of Cash Flows</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Notes to Consolidated Financial Statements</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Financial Statement Schedules: </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">All financial statement schedules have been omitted because
they are not applicable, not required or the information required is shown in the financial statements or the notes thereto. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Exhibits </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">The exhibits filed as part of this Annual Report on Form 10-K are set forth on the
Exhibit Index immediately following our consolidated financial statements. The Exhibit Index is incorporated herein by reference. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">70 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom838054_25"></A>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of Section&nbsp;13 or 15(d) of the Securities Act of 1934, the registrant has duly caused this report to be
signed on its behalf by the undersigned, thereunto duly authorized: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">M<SMALL>ACRO</SMALL>G<SMALL>ENICS</SMALL>, I<SMALL>NC</SMALL>.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Scott Koenig</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Scott Koenig, M.D., Ph.D.</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><I>President and
CEO and Director</I></P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1934, as amended, this Report has been signed by
the following persons on behalf of the registrant and in the capacities and on the dates indicated: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="31%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="28%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Signature</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Date</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Scott Koenig</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Scott Koenig, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">President and CEO and Director</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Principal Executive Officer)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">March 3, 2015</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ James Karrels</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">James Karrels</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Senior Vice President, Chief</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial Officer and Secretary</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Principal Financial Officer)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">March 3, 2015</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Lynn Cilinski</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Lynn Cilinski</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vice President, Controller and</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Treasurer (Principal&nbsp;Accounting</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Officer)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">March 3, 2015</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Paulo Costa</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Paulo Costa</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">March 3, 2015</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Matthew Fust</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Matthew Fust</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">March 3, 2015</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Kenneth Galbraith</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Kenneth Galbraith</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">March 3, 2015</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Edward Hurwitz</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Edward Hurwitz</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">March 3, 2015</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ David Stump, M.D.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">David Stump, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">March 3, 2015</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">71 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INDEX TO CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="93%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">Page<BR>Number</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin838054_1">Report of Ernst &amp; Young LLP, Independent Registered Public Accounting Firm</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin838054_2">Consolidated Balance Sheets at December&nbsp;31, 2014 and 2013</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin838054_3">Consolidated Statements of Operations and Comprehensive Income (Loss) for the years ended December&nbsp;
31, 2014, 2013 and 2012</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin838054_4">Consolidated Statements of Stockholders&#146; Equity (Deficit) for the years ended December&nbsp;
31, 2014, 2013 and 2012</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin838054_5">Consolidated Statements of Cash Flows for the years ended December&nbsp;31, 2014, 2013 and 2012</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin838054_6">Notes to Consolidated Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin838054_1"></A>Report of Independent Registered Public Accounting Firm </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board of Directors and Stockholders </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MacroGenics,&nbsp;Inc.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have audited the accompanying consolidated balance sheets of MacroGenics, Inc. as of December&nbsp;31, 2014 and 2013, and the related
consolidated statements of operations and comprehensive income (loss), stockholders&#146; equity (deficit) and cash flows for each of the three years in the period ended December&nbsp;31, 2014. These financial statements are the responsibility of
the Company&#146;s management. Our responsibility is to express an opinion on these financial statements based on our audits. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements
are free of material misstatement. We were not engaged to perform an audit of the Company&#146;s internal control over financial reporting. Our audits included consideration of internal control over financial reporting as a basis for designing audit
procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company&#146;s internal control over financial reporting. Accordingly, we express no such opinion. An audit also
includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, and evaluating the overall financial statement
presentation. We believe that our audits provide a reasonable basis for our opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In our opinion, the financial statements referred to
above present fairly, in all material respects, the consolidated financial position of MacroGenics, Inc. at December&nbsp;31, 2014 and 2013, and the consolidated results of its operations and its cash flows for each of the three years in the period
ended December&nbsp;31, 2014, in conformity with U.S. generally accepted accounting principles. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-right:21%; font-size:10pt; font-family:Times New Roman" ALIGN="right">/s/ Ernst&nbsp;&amp;
Young LLP </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">McLean, Virginia </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March&nbsp;3, 2015 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. </B></P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin838054_2"></A>CONSOLIDATED BALANCE SHEETS </B></P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands, except share and per share data) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">157,591</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">116,481</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,935</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,004</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">972</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">164,737</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">119,457</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,785</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,035</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other assets</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,064</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">885</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">173,886</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">125,782</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities and stockholders&#146; equity</B></P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,669</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,930</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease exit liability</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,642</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,439</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,248</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,267</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other liabilities</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,605</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">363</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,094</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,822</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease exit liability, net of current portion</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,364</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,006</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred rent liability</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,670</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,904</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue, net of current portion</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,472</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,136</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,868</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; equity:</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.01 par value&#151;125,000,000 shares authorized, 27,995,638 and 25,177,597 shares outstanding at December&nbsp;31,
2014 and 2013, respectively</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">252</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Treasury stock, at cost; 865 and 14,381 shares at December&nbsp;31, 2014 and 2013, respectively</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(58</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional paid-in capital</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">335,071</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">254,453</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(214,046</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(175,733</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; equity</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">121,286</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78,914</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities and stockholders&#146; equity</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">173,886</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">125,782</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>See accompanying notes. </I></P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. </B></P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin838054_3"></A>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) </B></P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands, except share and per share data) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="65%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenues:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue from collaborative research</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">47,264</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">56,753</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">59,646</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grant revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">533</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,282</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenues</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,797</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58,035</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63,826</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Costs and expenses:</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,186</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,582</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,433</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,926</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,087</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total costs and expenses</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">86,112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57,669</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,621</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income (loss) from operations</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(38,315</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">366</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,205</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense)</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(627</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">157</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net comprehensive income (loss)</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(38,313</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(261</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,362</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted net income (loss) per common share</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.40</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.04</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted weighted average number of common shares</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,384,990</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,847,697</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,083,276</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:380pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>See accompanying notes. </I></P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin838054_4"></A>CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#146; EQUITY (DEFICIT) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands, except share amounts) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:5.5pt" ALIGN="center">


<TR>
<TD WIDTH="22%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:5.5pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series A-1<BR>Convertible<BR>Preferred Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series A-2<BR>Convertible<BR>Preferred Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series B</B><br><B>Convertible<BR>Preferred Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series C</B><br><B>Convertible<BR>Preferred Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series D</B><br><B>Convertible<BR>Preferred Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Series&nbsp;D-2</FONT><BR>Convertible<BR>Preferred Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Treasury Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional<BR>Paid-In</B><br><B>Capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated</B><br><B>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Stockholders&#146;</B><br><B>Equity&nbsp;(Deficit)</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:5.5pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:5.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:5.5pt; font-family:Times New Roman">Balance, December&nbsp;31, 2011</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,874,792</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">269</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,364,582</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71,401,237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">714</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">110,952,217</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,446,227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">144</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63,681,176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">637</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,049,030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,381</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(58</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">163,450</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(183,834</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,484</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:5.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:5.5pt; font-family:Times New Roman">Share-based compensation</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">838</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">838</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:5.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:5.5pt; font-family:Times New Roman">Stock option exercises</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,884</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:5.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:5.5pt; font-family:Times New Roman">Net income</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,362</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,362</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:5.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:5.5pt; font-family:Times New Roman">Balance, December&nbsp;31, 2012</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,874,792</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">269</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,364,582</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71,401,237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">714</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">110,952,217</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,446,227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63,681,176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">637</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,098,914</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,381</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(58</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">164,334</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(175,472</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,238</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:5.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:5.5pt; font-family:Times New Roman">Share-based compensation</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">862</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">862</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:5.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:5.5pt; font-family:Times New Roman">Issuance of common stock, net of offering costs</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,750,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83,565</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83,623</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:5.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:5.5pt; font-family:Times New Roman">Conversion of preferred stock to common stock</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(26,874,792</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(269</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,364,582</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(74</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(71,401,237</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(714</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(110,952,217</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,110</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,446,227</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(144</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(63,681,176</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(637</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,060,634</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,637</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,860</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:5.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:5.5pt; font-family:Times New Roman">Stock option exercises</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,268,049</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,055</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,068</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:5.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:5.5pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(261</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(261</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:5.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:5.5pt; font-family:Times New Roman">Balance, December&nbsp;31, 2013</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,177,597</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">252</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,381</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(58</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">254,453</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(175,733</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78,914</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:5.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:5.5pt; font-family:Times New Roman">Share-based compensation</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,244</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,244</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:5.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:5.5pt; font-family:Times New Roman">Issuance of common stock, net of offering costs</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76,694</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76,716</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:5.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:5.5pt; font-family:Times New Roman">Stock plan related activity</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">568,041</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">865</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">738</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">725</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:5.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:5.5pt; font-family:Times New Roman">Retirement of treasury stock</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,381</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(58</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:5.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:5.5pt; font-family:Times New Roman">Net income (loss)</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(38,313</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(38,313</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:5.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:5.5pt; font-family:Times New Roman">Balance, December&nbsp;31, 2014</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,995,638</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">865</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(19</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">335,071</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(214,046</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">121,286</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:5.5pt; font-family:Times New Roman"><I>See accompanying notes. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. </B></P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin838054_5"></A>CONSOLIDATED STATEMENTS OF CASH FLOWS </B></P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="77%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(38,313</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(261</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,362</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments to reconcile net income (loss) to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,822</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,193</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,244</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">862</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">838</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value adjustment of warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">626</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(151</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(931</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,352</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,239</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(834</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(91</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">177</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,179</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(375</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,500</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(570</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,312</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,346</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,347</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease exit liability</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,439</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(629</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(534</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,317</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,676</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,810</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred rent</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(234</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">441</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,242</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(32,759</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,172</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,582</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from investing activities</B></P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases of property and equipment</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,572</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,961</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(940</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,572</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,961</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(940</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from financing activities</B></P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of common stock, net of offering costs</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76,716</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84,771</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from stock option exercises</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">744</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchase of treasury stock</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77,441</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85,871</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net change in cash and cash equivalents</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68,738</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,475</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents at beginning of period</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">116,481</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,743</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,218</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents at end of period</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">157,591</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">116,481</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">47,743</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Noncash financing activities:</B></P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conversion of preferred stock</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,947</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:140pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>See accompanying notes. </I></P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. <A NAME="fin838054_6"></A> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. Organization and Nature of Operations </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MacroGenics, Inc. (the &#147;Company&#148;) was incorporated in Delaware on August&nbsp;14, 2000. The Company is a
clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company generates its
pipeline of product candidates from its proprietary suite of next-generation antibody technology platforms which it believes improve the performance of monoclonal antibodies and antibody-derived molecules. These product candidates, which the Company
has identified through its understanding of disease biology and immune-mediated mechanisms, may address disease-specific challenges which are not currently being met by existing therapies. </P>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Summary of Significant Accounting Policies </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Basis of Presentation and Principles of Consolidation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The consolidated financial statements include the accounts of MacroGenics, Inc. and its wholly owned subsidiaries, MacroGenics UK Limited and
MacroGenics West, Inc. Effective December&nbsp;22, 2014, MacroGenics West, Inc. was merged with and into MacroGenics, Inc. All intercompany accounts and transactions have been eliminated in consolidation. The Company currently operates in one
operating segment. Operating segments are defined as components of an enterprise about which separate discrete information is available for the chief operating decision maker, or decision making group, in deciding how to allocate resources and
assessing performance. The Company views its operations and manages its business in one segment, which is developing monoclonal antibody-based therapeutics for cancer, autoimmune and infectious diseases. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Use of Estimates </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preparation
of the financial statements in accordance with generally accepted accounting principles (GAAP) requires the Company to make estimates and judgments in certain circumstances that affect the reported amounts of assets, liabilities, revenues and
expenses, and related disclosure of contingent assets and liabilities. In preparing these consolidated financial statements, management has made its best estimates and judgments of certain amounts included in the financial statements, giving due
consideration to materiality. On an ongoing basis, the Company evaluates its estimates, including those related to revenue recognition, fair values of assets, stock-based compensation, preferred stock warrant liability, income taxes, pre-clinical
study and clinical trial accruals and other contingencies. Management bases its estimates on historical experience or on various other assumptions that it believes to be reasonable under the circumstances. Actual results could differ from these
estimates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, prior to the Company&#146;s IPO in October 2013, the Company utilized estimates and assumptions in determining
the fair value of its common stock. The Company granted stock options at exercise prices not less than the fair value of its common stock as determined by the Board of Directors, with input from management. Management used contemporaneous valuations
in estimating the fair value of its common stock. The board of directors determined the estimated fair value of the common stock based on a number of objective and subjective factors, including external market considerations affecting the
biotechnology industry and the historic prices at which the Company sold shares of its preferred stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cash and Cash Equivalents </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company considers all investments in highly liquid financial instruments with an original maturity of three months or less at the date of
purchase to be cash equivalents. Cash and cash equivalents consist of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
certificates of deposit and investments in money market funds with commercial banks and financial institutions. Cash equivalents are stated at amortized cost, plus accrued interest, which
approximates fair value. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Accounts Receivable </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accounts receivable that management has the intent and ability to collect are reported in the consolidated balance sheets at outstanding
amounts, less an allowance for doubtful accounts. The Company writes off uncollectible receivables when the likelihood of collection is remote. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company evaluates the collectability of accounts receivable on a regular basis. The allowance, if any, is based upon various factors
including the financial condition and payment history of customers, an overall review of collections experience on other accounts and economic factors or events expected to affect future collections experience. No allowance was recorded as of
December&nbsp;31, 2014 or 2013, as the Company has a history of collecting on all outstanding accounts. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Restricted Cash </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is required to maintain certificates of deposit that serve as collateral for various operating leases and corporate credit card
accounts. Amounts classified as restricted cash on the consolidated balance sheets are $300,000 and $405,000 at December&nbsp;31, 2014 and 2013, respectively. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fair Value of Financial Instruments </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fair market values of the financial instruments included in the financial statements, which include cash equivalents and money market
accounts, approximate their carrying values at December&nbsp;31, 2014 and 2013, due to their short-term maturities. The Company accounts for recurring and non-recurring fair value measurements in accordance with the Financial Accounting Standards
Board (FASB) Accounting Standards Codification (ASC) 820, <I>Fair Value Measurements and Disclosures</I> (ASC 820). ASC 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value, and requires
expanded disclosures about fair value measurements. The ASC 820 hierarchy ranks the quality of reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified
and disclosed in one of the following three categories: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Level 1&#151;Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Level 2&#151;Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or
quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Level 3&#151;Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity&nbsp;&#150;
e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective
judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC 820 hierarchy. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Financial assets and liabilities subject to fair value measurements were as follows (in
thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="43%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair Value Measurements at December&nbsp;31, 2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Quoted&nbsp;Prices&nbsp;in</B><br><B>Active Markets<BR>for</B><br><B>Identical Assets</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Significant&nbsp;Other</B><br><B>Observable<BR>Inputs</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Significant</B><br><B>Unobservable</B><br><B>Inputs</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level 1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level 2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level 3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">131,545</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">131,545</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,046</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,046</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total Assets</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">157,891</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">157,891</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="16"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair Value Measurements at December&nbsp;31, 2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Quoted Prices in</B><br><B>Active Markets<BR>for</B><br><B>Identical Assets</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Significant Other</B><br><B>Observable<BR>Inputs</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Significant</B><br><B>Unobservable</B><br><B>Inputs</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level 1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level 2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level 3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">90,434</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">90,434</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,047</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,047</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total Assets</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">116,886</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">116,886</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s Level 1 securities primarily consist of restricted cash, cash equivalents and money market
funds. The Company determines the estimated fair value for its Level 1 securities using quoted (unadjusted) prices for identical assets or liabilities in active markets. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Concentration of Credit Risk </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Substantially all of the Company&#146;s cash and cash equivalents are maintained with major financial institutions in the United States.
Deposits held with banks may exceed the amount of insurance provided on such deposits. Generally, these deposits may be redeemed upon demand and, therefore, bear minimal risk. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents,
and accounts receivable. The counterparties are various corporations, financial institutions and government agencies of high credit standing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the years ended December&nbsp;31, 2014, 2013 and 2012, the Company&#146;s collaboration revenue relates to agreements with Takeda
Pharmaceutical Company Limited (Takeda), Les Laboratoires Servier and Institut de Recherches Servier (collectively, Servier), Gilead Sciences, Inc. (Gilead), Boehringer Ingelheim GmbH (Boehringer), Pfizer, Inc. (Pfizer), Eli Lilly&nbsp;&amp; Co.
(Eli Lilly) and Green Cross Corp. (Green Cross). Grant revenue is related to contracts and research grants received from U.S. government agencies. The majority of the outstanding receivables are due from the Company&#146;s collaborators and U.S.
government agencies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table includes those collaborators that represent more than 10% of total
revenue earned in the periods indicated: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="66%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2013&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2012&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Servier</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Boehringer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Takeda</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gilead</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eli Lilly</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table includes those collaborators that represent more than 10% of accounts receivable at the
date indicated: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="75%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2013&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Servier</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Boehringer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Green Cross</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gilead</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pfizer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Property and Equipment </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Property and equipment are stated at cost. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are
removed from the accounts and any resulting gain or loss is credited or charged to operations. Repairs and maintenance costs are expensed as incurred. Depreciation is computed using the straight-line method over the following estimated useful lives:
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="55%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Computer equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">3 years</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">3 years</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Furniture</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">10 years</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laboratory and office equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">5 years</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Shorter&nbsp;of&nbsp;lease&nbsp;term&nbsp;or&nbsp;useful&nbsp;life</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Impairment of Long-Lived Assets </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company assesses the recoverability of its long-lived assets in accordance with the provisions of ASC&nbsp;360, <I>Property, Plant and
Equipment</I>. ASC 360 requires that long-lived assets be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of the long-lived asset is measured by
a comparison of the carrying amount of the asset to future undiscounted net cash flows expected to be generated by the asset or asset group. If carrying value exceeds the sum of undiscounted cash flows, the Company then determines the fair value of
the underlying asset group. Any impairment to be recognized is measured by the amount by which the carrying amount of the asset group exceeds the estimated fair value of the asset group. Assets to be disposed of are reported at the lower of the
carrying amount or fair value, less costs to sell. As of December&nbsp;31, 2014 and 2013, the Company determined that there were no impaired assets and had no assets held-for-sale. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Income Taxes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Deferred tax assets and liabilities are determined based on differences between the financial reporting and tax basis of assets and liabilities
and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. The effect on deferred tax assets and liabilities of a change in tax rates is recognized as income in the period
that such tax rate changes are enacted. The measurement of a deferred tax asset is reduced, if necessary, by a valuation allowance if it is more likely than not that some portion or all of the deferred tax asset will not be realized. Financial
statement recognition of a tax position taken or expected to be taken in a tax return is determined based on a more-likely-than-not threshold of that position being sustained. If the tax position meets this threshold, the benefit to be recognized is
measured as the largest amount that is more likely than not to be realized upon ultimate settlement. The Company&#146;s policy is to record interest and penalties related to uncertain tax positions as a component of income tax expense. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenues </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Revenue Recognition
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company enters into collaboration and license agreements with collaborators for the development of monoclonal antibody-based
therapeutics to treat cancer and other complex diseases. The terms of these agreements contain multiple deliverables which may include (i)&nbsp;licenses, or options to obtain licenses, to the Company&#146;s technological platforms, such as its Fc
Optimization and Dual-Affinity Re-Targeting (DART) technologies, (ii)&nbsp;rights to future technological improvements, (iii)&nbsp;research and development activities to be performed on behalf of the collaborator or as part of the collaboration, and
(iv)&nbsp;the manufacture of pre-clinical or clinical materials for the collaborator. Payments to the Company under these agreements may include nonrefundable license fees, option fees, exercise fees, payments for research and development
activities, payments for the manufacture of pre-clinical or clinical materials, license maintenance payments, payments based upon the achievement of certain milestones and royalties on product sales. Other benefits to the Company of these agreements
include the right to sell products resulting from the collaborative efforts of the parties in specific geographic territories. The Company follows the provisions of the FASB ASC Topic 605-25, <I>Revenue Recognition&#151;Multiple-Element
Arrangements</I>, and ASC Topic 605-28, <I>Revenue Recognition&#151;Milestone Method</I>, in accounting for these agreements. In order to account for these agreements, the Company must identify the deliverables included within the agreement and
evaluate which deliverables represent separate units of accounting based on the achievement of certain criteria, including whether the delivered element has stand-alone value to the collaborator. The consideration received is allocated among the
separate units of accounting, and the applicable revenue recognition criteria are applied to each of the separate units. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the periods
presented, the Company had the following two types of agreements: 1) exclusive development and commercialization licenses to use the Company&#146;s technology and/or certain other intellectual property to develop compounds against specified targets
(referred to herein as exclusive licenses); and 2) Option/research agreements to secure on established terms, development and commercialization licenses to therapeutic product candidates to collaborator-selected targets developed by the Company
during an option period (referred to herein as right-to-develop agreements). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are no performance, cancellation, termination or
refund provisions in any of the arrangements that contain material financial consequences to the Company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Exclusive Licenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The deliverables under an exclusive license agreement generally include the exclusive license to the Company&#146;s DART technology with
respect to a specified antigen target, and may also include deliverables </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
related to rights to future technological improvements, research and pre-clinical development activities to be performed on behalf of the collaborator. In some cases the Company may have an
option to participate in the co-development of product candidates that result from such agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally, exclusive license
agreements contain nonrefundable terms for payments and, depending on the terms of the agreement, provide that the Company will (i)&nbsp;at the collaborator&#146;s request, provide research and pre-clinical development services at negotiated prices
which are generally consistent with what other third parties would charge, (ii)&nbsp;earn payments upon the achievement of certain milestones, (iii)&nbsp;earn royalty payments, and (iv)&nbsp;in some cases grant the Company an option to participate
in the development and commercialization of products that result from such agreements. Royalty rates may vary over the royalty term depending on the Company&#146;s intellectual property rights and whether the Company exercises any co-development and
co-commercialization rights. The Company may provide technical assistance and share any technology improvements with its collaborators during the term of the collaboration agreements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company does not directly control when any collaborator will achieve milestones or become liable for royalty payments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When entering into a new collaboration arrangement or materially modifying an existing arrangement, the Company must identify the deliverables
included within the agreement and evaluate which deliverables represent separate units of accounting based on the achievement of certain criteria, including whether the delivered element has stand-alone value to the collaborator. The selling prices
of deliverables under an arrangement may be derived using third-party evidence (TPE), or a best estimate of selling price (BESP), if vendor specific objective evidence (VSOE) is not available. The objective of BESP is to determine the price at which
the Company would transact a sale if the element within the license agreement was sold on a standalone basis. Establishing BESP involves management&#146;s judgment and considers multiple factors, including market conditions and company-specific
factors, including those factors contemplated in negotiating the agreements, as well as internally developed models that include assumptions related to market opportunity, discounted cash flows, estimated development costs, probability of success
and the time needed to commercialize a product candidate pursuant to the license. In validating the BESP, management considers whether changes in key assumptions used to determine the BESP will have a significant effect on the allocation of the
arrangement consideration between the multiple deliverables. Deliverables under the arrangement are separate units of accounting if (i)&nbsp;the delivered item has value to the customer on a standalone basis and (ii)&nbsp;if the arrangement includes
a general right of return relative to the delivered item, delivery or performance of the undelivered item is considered probable and substantially within the Company&#146;s control. The arrangement consideration that is fixed or determinable at the
inception of the arrangement is allocated to the separate units of accounting based on their relative selling prices. The appropriate revenue recognition model is applied to each element and revenue is accordingly recognized as each element is
delivered. Management exercises significant judgment in determining whether a deliverable is a separate unit of accounting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
determining the separate units of accounting, the Company evaluates whether the exclusive license has standalone value to the collaborator based on consideration of the relevant facts and circumstances for each arrangement. Factors considered in
this determination include the research and development capabilities of the collaborator and the availability of relevant research expertise in the marketplace. In addition, the Company considers whether or not (i)&nbsp;the collaborator could use
the license for its intended purpose without the receipt of the remaining deliverables, (ii)&nbsp;the value of the license was dependent on the undelivered items and (iii)&nbsp;the collaborator or other vendors could provide the undelivered items.
If the Company concludes that the license has stand-alone value and therefore will be accounted for as a separate unit of accounting, the Company then determines the estimated selling prices of the license and all other units of accounting based on
market conditions, similar arrangements entered into by third parties, and entity-specific factors such as the terms of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Company&#146;s previous collaboration agreements, recent pre-clinical and clinical testing results of therapeutic product candidates that use the Company&#146;s technology platforms, the
Company&#146;s pricing practices and pricing objectives, the likelihood that technological improvements will be made, the likelihood that technological improvements made will be used by the Company&#146;s collaborators and the nature of the research
services to be performed on behalf of its collaborators and market rates for similar services. Total arrangement consideration is then allocated to each of the units of accounting using the relative-selling-price method. If facts and circumstances
dictate that the exclusive license does not have stand-alone value, then the related payments are deferred and revenue is recognized throughout the period of performance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Management reassesses the period of performance over which the Company recognizes deferred upfront license fees and makes adjustments as
appropriate in the period in which a change in the estimated period of performance is identified. In the event a collaborator elects to discontinue development of a specific product candidate under a single target license, but retains its right to
use the Company&#146;s technology to develop an alternative product candidate to the same target or a target substitute, the Company would cease amortization of any remaining portion of the upfront fee until there is substantial pre-clinical
activity on another product candidate and its remaining period of substantial involvement can be estimated. In the event that a single target license were to be terminated, the Company would recognize as revenue any portion of the upfront fee that
had not previously been recorded as revenue, but was classified as deferred revenue, at the date of such termination or through the remaining substantial involvement in the wind down of the agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upfront payments on exclusive licenses may be recognized upon delivery of the license if facts and circumstances dictate that the license has
stand-alone value from the undelivered elements, which generally include rights to future technological improvements, research services and the manufacture of pre-clinical and clinical materials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognizes revenue related to research and pre-clinical development services that represent separate units of accounting as they
are performed, as long as there is persuasive evidence of an arrangement, the fee is fixed or determinable, and collection of the related receivable is probable. The Company recognizes revenue related to the rights to future technological
improvements over the estimated term of the applicable license. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company typically performs research activities and pre-clinical
development services, including generating and engineering product candidates, on behalf of its licensees during the early evaluation and pre-clinical testing stages of drug development under its exclusive licenses. The Company records amounts
received for research materials produced or services performed as revenue from collaborative research. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s license
agreements have milestone payments which for reporting purposes are aggregated into three categories: (i)&nbsp;development milestones, (ii)&nbsp;regulatory milestones, and (iii)&nbsp;sales milestones. Development milestones are typically payable
when a product candidate initiates or advances into different clinical trial phases. Regulatory milestones are typically payable upon submission for marketing approval with the U.S. Food and Drug Administration (FDA) or other countries&#146;
regulatory authorities or on receipt of actual marketing approvals for the compound or for additional indications. Sales milestones are typically payable when annual sales reach certain levels. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the inception of each agreement that includes milestone payments, the Company evaluates whether each milestone is substantive and at risk
to both parties on the basis of the contingent nature of the milestone. This evaluation includes an assessment of whether (i)&nbsp;the consideration is commensurate with either (a)&nbsp;the entity&#146;s performance to achieve the milestone, or
(b)&nbsp;the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from the entity&#146;s performance to achieve the milestone, (ii)&nbsp;the consideration relates
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
solely to past performance and (iii)&nbsp;the consideration is reasonable relative to all of the deliverables and payment terms within the arrangement. The Company evaluates factors such as the
scientific, regulatory, commercial and other risks that must be overcome to achieve the respective milestone, the level of effort and investment required to achieve the respective milestone and whether the milestone consideration is reasonable
relative to all deliverables and payment terms in the arrangement in making this assessment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Non-refundable development and regulatory
milestones that are expected to be achieved as a result of the Company&#146;s efforts during the period of substantial involvement are considered substantive and are recognized as revenue upon the achievement of the milestone, assuming all other
revenue recognition criteria are met. Milestones that are not considered substantive because the Company does not contribute effort to the achievement of such milestones are generally achieved after the period of substantial involvement and are
recognized as revenue upon achievement of the milestone, as there are no undelivered elements remaining and no continuing performance obligations, assuming all other revenue recognition criteria are met. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Right-to-Develop Agreements </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s right-to-develop agreements provide collaborators with an exclusive option to obtain licenses to develop and commercialize
in specified geographic territories product candidates developed by the Company under agreed upon research and pre-clinical development product programs. The product candidates resulting from each program are all directed to a specific target
selected by the collaborator. Under these agreements, fees may be due to the Company (i)&nbsp;at the inception of the arrangement (referred to as &#147;upfront&#148; fees or payments), (ii)&nbsp;the selection of a target for a program,
(iii)&nbsp;upon the exercise of an option to acquire a development and commercialization license (referred to as exercise fees or payments earned) for a program, or (iv)&nbsp;some combination of all of these fees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accounting for right-to-develop agreements is dependent on the nature of the options granted to the collaborator. Options are considered
substantive if, at the inception of a right-to-develop agreement, the Company is at risk as to whether the collaborator will choose to exercise the options to secure development and commercialization licenses. Factors that are considered in
evaluating whether options are substantive include the overall objective of the arrangement, the benefit the collaborator might obtain from the agreement without exercising the options, the cost to exercise the options relative to the total upfront
consideration, and the additional financial commitments imposed on the collaborator as a result of exercising the options. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For
right-to-develop agreements where the options to secure development and commercialization licenses to a product program are considered substantive, the Company does not consider the development and commercialization licenses to be a deliverable at
the inception of the agreement, and therefore defers any upfront payments received and recognizes this revenue over the period during which the collaborator could elect to exercise options for development and commercialization licenses. These
periods are specific to each collaboration agreement. If a collaborator selects a target for a product program, any substantive option fee is deferred and recognized over the life of the option. For right-to-develop agreements that include multiple
deliverables, the Company determines the selling prices of deliverables under the arrangement using TPE or a BESP, if VSOE is not available. The objective of BESP is to determine the price at which the Company would transact a sale if the element
within the right-to-develop agreement was sold on a standalone basis. Establishing BESP involves management&#146;s judgment and considers multiple factors, including market conditions and company-specific factors, including those factors
contemplated in negotiating the agreements, as well as internally developed models that include assumptions related to market opportunity, discounted cash flows, estimated development costs, probability of success and the time needed to
commercialize a product candidate pursuant to the right-to-develop agreement. In validating the BESP, management considers whether changes in key assumptions used to determine the BESP will have a significant effect on the allocation of the
arrangement </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
consideration between the multiple deliverables. Deliverables under the arrangement are separate units of accounting if (i)&nbsp;the delivered item has value to the customer on a standalone basis
and (ii)&nbsp;if the arrangement includes a general right of return relative to the delivered item, delivery or performance of the undelivered item is considered probable and substantially within the Company&#146;s control. The arrangement
consideration that is fixed or determinable at the inception of the arrangement is allocated to the separate units of accounting based on their relative selling prices. The appropriate revenue recognition model is applied to each element and revenue
is accordingly recognized as each element is delivered. Management exercises significant judgment in determining whether a deliverable is a separate unit of accounting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a collaborator exercises an option and acquires a development and commercialization license to a product program, the Company attributes
the exercise fee to the development and commercialization license. The Company determines the selling price of the option license, upon exercise, through management&#146;s best estimate using the process for an exclusive license as described above.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon exercise of an option to acquire a development and commercialization license, the Company would also attribute any remaining
deferred option fee, in addition to the consideration received for the license upon exercise of the option, to the development and commercialization license. The Company then applies the multiple-element revenue recognition criteria to the
development and commercialization license and other deliverables, if any, to determine the appropriate revenue recognition method. This model is consistent with the Company&#146;s accounting policy for upfront payments on exclusive licenses
(discussed above). In the event a right-to-develop agreement were to be terminated, the Company would recognize as revenue any portion of the upfront fee that had not previously been recorded as revenue, but was classified as deferred revenue, at
the date of such termination. The Company&#146;s right-to-develop agreements have been determined to contain substantive options. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For
right-to-develop agreements where the options to secure development and commercialization licenses to product programs are not considered substantive, the Company considers the development and commercialization licenses to be a deliverable at the
inception of the agreement and applies the multiple-element revenue recognition criteria to determine the appropriate revenue recognition. The Company does not directly control when any collaborator will exercise its options for development and
commercialization licenses. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Costs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenditures are expensed as incurred. Research and development costs primarily consist of employee related expenses,
including salaries and benefits, expenses incurred under agreements with contract research organizations, investigative sites and consultants that conduct the Company&#146;s clinical trials, the cost of acquiring and manufacturing clinical trial
materials and other allocated expenses, license fees for and milestone payments related to in-licensed products and technologies, stock-based compensation expense, and costs associated with non-clinical activities and regulatory approvals. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Comprehensive Income (Loss) </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Comprehensive income (loss) is comprised of the net income (loss) and other changes in equity that are excluded from net income (loss).
Comprehensive income (loss) equals net income (loss) for the years ended December&nbsp;31, 2014, 2013 and 2012. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock-based Compensation
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stock-based payments are accounted for in accordance with the provisions of ASC&nbsp;718, <I>Compensation&#151;Stock
Compensation</I>. The fair value of stock-based payments is estimated, on the date of grant, using the Black-</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Scholes model. The resulting fair value is recognized ratably over the requisite service period, which is generally the vesting period of the option. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For all time-vesting awards granted, expense is amortized using the straight-line attribution method. For awards that contain a performance
condition, expense is amortized using the accelerated attribution method. Recognition of stock-based compensation expense is based on the value of the portion of stock-based awards that is ultimately expected to vest during the period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company utilizes the Black-Scholes model for estimating fair value of its stock options granted. Option valuation models, including the
Black-Scholes model, require the input of highly subjective assumptions, and changes in the assumptions used can materially affect the grant-date fair value of an award. These assumptions include the risk-free rate of interest, expected dividend
yield, expected volatility and the expected life of the award. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Net Income (Loss) Per Share </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Basic income (loss) per common share is determined by dividing income (loss) attributable to common stockholders by the weighted-average number
of common shares outstanding during the period, without consideration of common stock equivalents. Diluted income (loss) per share is computed by dividing the earnings (loss) attributable to common stockholders by the weighted-average number of
common share equivalents outstanding for the period. The treasury stock method is used to determine the dilutive effect of the Company&#146;s stock option grants, potential Employee Stock Purchase Plan awards and warrants and the if-converted method
is used to determine the dilutive effect of the Company&#146;s preferred stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December&nbsp;31, 2012, net income
(loss) per share was calculated under the two-class method under which all earnings (distributed and undistributed) are allocated to each class of common stock and participating securities based on their respective rights to receive dividends. In
the event that the Board of Directors declared a dividend payable in cash or other property on the then-outstanding shares of common stock, the holders of the Series&nbsp;A-1, A-2, B, C, D, and D-2 convertible preferred stock would be entitled to
receive the amount of dividends per share of preferred stock that would be payable on the largest number of whole shares of common stock into which each share of preferred stock could then be converted. Therefore, the Series A-1, A-2, B, C, D and
D-2 are participating securities. All of the outstanding shares of Series&nbsp;A-1, A-2, B, C, D, and D-2 convertible preferred stock converted to common stock upon the consummation of the Company&#146;s IPO in October 2013. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Basic and diluted income (loss) per common share is computed as follows (in thousands except
share and per share data): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="58%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(38,313</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(261</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,362</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: undistributed earnings allocated to participating securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,362</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) allocable to common shares</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(38,313</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(261</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic weighted average common shares outstanding</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,384,990</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,847,697</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,083,276</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic income (loss) per common share</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.40</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.04</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss)</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(38,313</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(261</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,362</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: undistributed earnings allocated to participating securities and other add-backs to net income (loss)</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,362</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) allocable to common shares</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(38,313</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(261</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic weighted average common shares outstanding</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,384,990</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,847,697</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,083,276</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effect of dilutive securities</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted weighted average common shares outstanding</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,384,990</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,847,697</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,083,276</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted income (loss) per common share</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.40</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.04</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following common stock equivalents were excluded from the calculation of diluted net income (loss) per
share because their effect would be anti-dilutive: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="63%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A-1 Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,156,114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A-2 Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">392,274</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,336,037</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series C Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,909,906</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series D Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">769,468</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series D-2 Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,391,991</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effect of Converted Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,189,920</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrants to purchase Series D-2 Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">180,784</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock Options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,094,904</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,313,970</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,249,702</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recently Issued Accounting Standards </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May 2014, the FASB issued ASU No.&nbsp;2014-09, <I>Revenue from Contracts with Customers </I>(ASU 2014-09). ASU 2014-09 will eliminate
transaction- and industry-specific revenue recognition guidance under current GAAP and replace it with a principle-based approach for determining revenue recognition. ASU 2014-09 will require that companies recognize revenue based on the value of
transferred goods or services as they occur in the contract. The ASU also will require additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments
and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. ASU 2014-09 is effective for annual reporting periods beginning after December&nbsp;15, 2016. Early adoption is not permitted. Entities can
transition to the standard either retrospectively or as a cumulative effect adjustment as of the date of adoption. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-17 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Management is currently assessing what effect the adoption of ASU 2014-09 will have on the Company&#146;s consolidated financial statements and accompanying notes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July 2013, the FASB issued ASU No.&nbsp;2013-11, which amended ASC Topic 740 regarding presentation of an unrecognized tax benefit when a
net operating loss (NOL) carryforward, a similar tax loss, or a tax credit carryforward exists. The amendments in ASU No.&nbsp;2013-11 require an entity to present an unrecognized tax benefit as a reduction of a deferred tax asset for an NOL
carryforward, or similar tax loss or tax credit carryforward, rather than as a liability when (1)&nbsp;the uncertain tax position would reduce the NOL or other carryforward under the tax law of the applicable jurisdiction and (2)&nbsp;the entity
intends to use the deferred tax asset for that purpose. The ASU does not require new recurring disclosures. This amendment was effective prospectively for fiscal years beginning after December&nbsp;15, 2013, and did not have a material impact on the
Company&#146;s financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has evaluated all other ASUs issued through the date the consolidated financials were
issued and believes that the adoption of these will not have a material impact on the Company&#146;s consolidated financial statements. </P>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. Property and Equipment </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Property and equipment consists of the following (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="71%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Computer equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,596</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,379</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,683</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,477</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Furniture and office equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">751</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">651</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lab equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,917</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,166</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,193</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,894</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,567</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less accumulated depreciation</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,355</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,532</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,785</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,035</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depreciation expense for the years ended December&nbsp;31, 2014, 2013 and 2012 was $1.8 million, $1.2 million
and $1.0 million, respectively. </P>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. Stockholders&#146; Equity </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During 2002 and 2003, the Company issued a total of 34,239,374 shares of Series A-1 and Series A-2 convertible preferred
stock (Series A preferred stock) for $1.00 per share resulting in net proceeds of approximately $34.0 million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2004, the
Company entered into a series of transactions raising $30.3 million, net of related offering costs of approximately $238,000, from the sale of 71,401,237 shares of its Series B convertible preferred stock (Series B preferred stock). In connection
with the Series B preferred stock offering, 13,604,016 shares of common stock were allocated to holders of Series&nbsp;A-1 preferred stock as an anti-dilution measure. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May&nbsp;2006, the Company raised $44.9 million, net of related offering costs of $101,246, from the sale of 110,952,217 shares of its
Series C convertible preferred stock (Series C preferred stock). In connection with the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-18 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Series C preferred stock offering, 10,003,300 shares of common stock were allocated to holders of Series B preferred stock as an anti-dilution measure. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July&nbsp;2008, the Company issued 12,466,039 shares of its Series D convertible preferred stock (Series D preferred stock) in exchange for
all of the outstanding capital stock and convertible notes payable of Raven Biotechnologies, Inc. (Raven). Subsequently, in March 2011 a settlement was reached with the former Raven stockholders bringing the total Series D preferred stock issued in
connection with the Raven acquisition to 14,446,227 shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September&nbsp;2008, the Company raised $24.8 million, net of related
offering costs of $156,788 from the sale of 38,337,678 shares of its Series D-2 convertible preferred stock (Series D-2 preferred stock). The Company also issued preferred stock warrants for the purchase of 2,875,327 shares of Series D-2 preferred
stock. The preferred stock warrants were exercisable at any time prior to September&nbsp;2018, but expired upon an IPO, and had a stated exercise price of $0.65 per warrant. On May&nbsp;16, 2010, the Company exercised a put notice to Eli Lilly in
accordance with the Series D-2 preferred stock purchase agreement, resulting in the issuance of 6,916,110 shares of Series D-2 preferred stock and a warrant to purchase 518,708 additional shares of Series D-2 preferred stock. On January&nbsp;11,
2011, the Company raised gross proceeds of $12.0 million from the sale of 18,427,388 shares of its Series D-2 preferred stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Due to
certain provisions in the Series D-2 convertible preferred stock warrant agreement, these warrants were required to be classified as a liability. Management believed that the circumstances requiring cash settlement of the award were remote. The
Series D-2 preferred stock warrant liability was recorded at fair value and has been adjusted to fair value at the end of each reporting period using the Option-Pricing Method, with changes in value recorded as &#147;Other income (expense)&#148; in
the accompanying consolidated statements of operations and comprehensive income (loss). Prior to the Company&#146;s IPO in October 2013, all the preferred stock warrants were exercised and subsequently were converted into shares of common stock in
connection with the IPO. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dividends were noncumulative and accrued on the Series A, Series B, Series C, Series D and Series&nbsp;D-2
preferred stock at a rate of $0.08, $0.0341, $0.0324 and $0.0522 per annum, respectively, and were payable when and as declared by the Board of Directors. Dividends had to be declared so that the Series A, Series&nbsp;B, Series C and Series D
preferred stock were paid in like-kind and participated equally to those of the Series&nbsp;D-2 preferred and common stock. No dividends had been declared prior to the conversion of the preferred stock to common stock in connection with the IPO.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s Series A-1, Series A-2, Series B, Series C, Series D and Series D-2 preferred stock were initially convertible into
1.506, 1.00, 1.14, 1.00, 1.00 and 1.00 shares, respectively, of common stock at the option of the holder. The conversion ratio of certain series of preferred stock was subject to change in the event specified dilutive transactions occurred, which
included the Company&#146;s IPO. There were no anti-dilution protections for the Series A-2 preferred stock and no adjustment to the Series A-1 preferred stock conversion price was to be made if a common stock issuance was at a price per share
greater than the conversion price of the Series C preferred stock. Upon consummation of the Company&#146;s IPO in October 2013, all outstanding shares of preferred stock automatically converted to shares of the Company&#146;s common stock at the
applicable conversion ratios then in effect. The conversion price was $12.39, $18.77, $6.95, $7.70, $12.20 and $12.20 for each share of Series A-1, A-2, Series B, Series C, Series D and Series D-2 convertible preferred stock, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;16, 2013, the Company completed its IPO, in which 5,000,000 shares of the Company&#146;s common stock were sold at a price of
$16.00 per share. Additionally, the underwriters of the Company&#146;s IPO exercised the full amount of their over-allotment option resulting in the sale of an additional 750,000 shares of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-19 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Company&#146;s common stock at a price of $16.00 per share. The Company received proceeds of $83.8 million from the IPO, net of underwriting discounts and commissions and other offering
expenses. Upon consummation of the IPO, all outstanding shares of preferred stock automatically converted to common stock at the applicable conversion ratios then in effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with preparing for its IPO in October 2013, the Company&#146;s Board of Directors and stockholders approved a 1-for-18.7739
reverse stock split of the Company&#146;s common stock. The reverse stock split became effective on September&nbsp;26, 2013. All share and per share amounts in the consolidated financial statements and notes thereto have been retroactively adjusted
for all periods presented to give effect to this reverse stock split, including reclassifying an amount equal to the reduction in par value of common stock to additional paid-in capital. In addition, in September 2013, the Company&#146;s Board of
Directors and stockholders approved an amendment of the Company&#146;s certificate of incorporation to, among other things, change the definition of a designated public offering to remove the per share price requirement. The amended and restated
certificate of incorporation also changed the authorized number of shares of common stock from 425,000,000 to 125,000,000, and authorized 5,000,000 shares of undesignated preferred stock with a par value of $0.01 per share. There were no shares of
undesignated preferred stock issued or outstanding as of December&nbsp;31, 2014 or 2013. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2014, the Company completed a
follow-on equity offering, in which the Company sold 1.8&nbsp;million shares of its common stock at a price of $36.50 per share. Additionally, the underwriters of the offering exercised the full amount of their over-allotment option resulting in the
sale of an additional 450,000&nbsp;shares of the Company&#146;s common stock at a price of $36.50 per share. The Company received proceeds of $76.7&nbsp;million from this offering, net of underwriting discounts and commissions and other offering
expenses. </P>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. Stock-based Compensation </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s 2000 Stock Option and Incentive Plan (2000 Plan) allowed for the grant of awards in respect of an
aggregate of 130,725 shares, which was increased to 150,297 shares, of the Company&#146;s common stock in the form of incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock and restricted stock units and
other performance awards. As of December&nbsp;31, 2014, under the 2000 Plan, there were options to purchase an aggregate of 19,705 shares of common stock outstanding at a weighted average exercise price of $0.81 per share. The 2000 Plan has expired,
and no further awards may be issued under the plan. Any shares of common stock subject to awards under the 2000 Plan that expire, terminate, or are otherwise surrendered, canceled, forfeited or repurchased without having been fully exercised, or
resulting in any common stock being issued, will become available for issuance under the 2013 Stock Incentive Plan (2013 Plan) up to a specified number of shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Effective February&nbsp;2003, the Company implemented the 2003 Equity Incentive Plan (2003 Plan), and it was amended and approved by the
Company&#146;s stockholders in 2005. The 2003 Plan originally allowed for the grant of awards in respect of an aggregate of 2,051,644 shares of the Company&#146;s common stock. Between 2006 and 2010 the maximum number of shares of common stock
authorized to be issued by the Company under the 2003 Plan was increased by 1,739,116 shares to 3,790,760. During the year ended December&nbsp;31, 2012, the maximum number of shares of common stock authorized to be issued by the Company under the
2003 Plan was increased by 545,970 shares to 4,336,730. Stock options granted under the 2003 Plan may be either incentive stock options as defined by the Internal Revenue Code (IRC), or non-qualified stock options. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2014, under the 2003 Plan, there were options to purchase an aggregate of 2,008,474&nbsp;shares of common stock
outstanding at a weighted average exercise price of $1.64 per share. Upon the completion of the IPO, the 2003 Plan was terminated, and no further awards may be issued under the plan. Any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-20 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
shares of common stock subject to awards under the 2003 Plan that expire, terminate, or are otherwise surrendered, canceled, forfeited or repurchased without having been fully exercised, or
resulting in any common stock being issued, will become available for issuance under the 2013 Plan, up to a specified number of shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2013, the Company implemented the 2013 Plan. The 2013 Plan provides for the grant of stock options and other stock-based awards, as
well as cash-based performance awards. The aggregate number of shares of common stock initially available for issuance pursuant to awards under the 2013 Plan is 1,960,168 shares. The number of shares of common stock reserved for issuance will
automatically increase on January&nbsp;1 of each year from January&nbsp;1, 2014 through and including January&nbsp;1, 2023, by the lesser of (a)&nbsp;1,960,168 shares, (b)&nbsp;4.0% of the total number of shares of common stock outstanding on
December&nbsp;31 of the preceding calendar year, or (c)&nbsp;the number of shares of common stock determined by the Board of Directors. During the year ended December&nbsp;31, 2014, the maximum number of shares of common stock authorized to be
issued by the Company under the 2013 Plan was increased to 2,967,272. If an option expires or terminates for any reason without having been fully exercised, if any shares of restricted stock are forfeited, or if any award terminates, expires or is
settled without all or a portion of the shares of common stock covered by the award being issued, such shares are available for the grant of additional awards. However, any shares that are withheld (or delivered) to pay withholding taxes or to pay
the exercise price of an option are not available for the grant of additional awards. As of December&nbsp;31, 2014, under the 2013 Plan, there were options to purchase an aggregate of 1,543,937 shares of common stock outstanding at a weighted
average exercise price of $24.22 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following stock-based compensation amounts were recognized for the periods indicated (in
thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,562</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">507</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">472</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,682</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">355</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">366</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stock-based compensation expense</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,244</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">862</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">838</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Employee Stock Options </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model using the assumptions in the
following table: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="58%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0%</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">67%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">53%&nbsp;-&nbsp;67%</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">51%</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">1.8%&nbsp;-&nbsp;2.3%</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">1.2%&nbsp;-&nbsp;2.2%</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1.2%</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected term.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">6.25 years</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">7 years</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">7&nbsp;years</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Expected Dividend Yield</B>&#151;The Company has never declared or paid dividends and has no plans to do so
in the foreseeable future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Expected Volatility</B>&#151;Volatility is a measure of the amount by which a financial variable such as a
share price has fluctuated (historical volatility) or is expected to fluctuate (expected volatility) during a period. As the Company does not yet have sufficient history of its own volatility, the Company has identified several public entities of
similar size, complexity and stage of development and estimates volatility based on the volatility of these companies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-21 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Risk-Free Interest Rate</B>&#151;This is the U.S. Treasury rate for the week of each
option grant during the year, having a term that most closely resembles the expected life of the option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Expected Term</B>&#151;This
is the period of time that the options granted are expected to remain unexercised. Options granted have a maximum term of ten years. The Company estimates the expected life of the option term to be 6.25 years. The Company uses a simplified method to
calculate the average expected term. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the assumptions above, the Company estimates the forfeiture rate based on turnover
data with further consideration given to the class of the employees to whom the options were granted. The forfeiture rate is the estimated percentage of options granted that is expected to be forfeited or canceled on an annual basis before becoming
fully vested. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes stock option and restricted stock unit (RSU) activity for 2014: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="43%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average</B><br><B>Exercise&nbsp;Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Weighted-Average</FONT></B><br><B>Remaining</B><br><B>Contractual Term</B><br><B>(Years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate<BR>Intrinsic<BR>Value</B><br><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding, December&nbsp;31, 2013</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,200,958</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">976,869</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27.06</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(568,906</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited or expired</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(36,805</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding, December&nbsp;31, 2014</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,572,116</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">84,515</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">December&nbsp;31, 2014:</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercisable</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,668,962</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,122</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested and expected to vest</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,341,192</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.03</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80,323</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During 2014, 2013 and 2012 the Company issued 568,906, 1,268,049 and 863,176 net shares of common stock,
respectively, in conjunction with stock option exercises and RSU lapses. The Company received cash proceeds from the exercise of stock options of approximately $0.7 million, $1.1 million and $47,000 during 2014, 2013 and 2012, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The weighted-average grant-date fair value of options granted during 2014, 2013 and 2012 was $17.41,&nbsp;$6.91 and $0.94 per share,
respectively. The total intrinsic value of options exercised during 2014, 2013 and 2012 was approximately $14.5 million, $5.4 million and $271,929, respectively. The total fair value of stock options which vested during 2014, 2013 and 2012 was $3.0
million, $487,603 and $879,024, respectively. As of December&nbsp;31, 2014, the total unrecognized compensation expense related to non-vested stock options and RSUs, net of related forfeiture estimates, was $19.6 million, which the Company expects
to recognize over a weighted-average period of approximately four years. </P>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. Income Taxes </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the years ended December&nbsp;31, 2014, 2013 and 2012 there was no current provision for federal or state income taxes
due to the taxable losses which resulted or use of legacy NOL carryforwards. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-22 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The significant components of the Company&#146;s deferred income tax assets (liabilities)
were as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="71%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred income tax assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Federal U.S. net operating loss carryforward</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">55,358</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">36,561</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State net operating loss carryforward</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,723</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,316</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development credit, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,177</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,786</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Orphan drug credit, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,883</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred rent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,069</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,132</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,989</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,217</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,337</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,438</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">962</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,439</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross deferred income tax assets</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">95,902</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79,772</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valuation allowance</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(94,297</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(79,377</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net deferred income tax assets</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,605</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">395</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred income tax liabilities:</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenditures</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,605</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(395</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross deferred income tax liabilities</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,605</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(395</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net deferred income tax asset/(liability)</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognizes valuation allowances to reduce deferred tax assets to the amount that is more likely
than not to be realized. In assessing the likelihood of realization, management considers (i)&nbsp;future reversals of existing taxable temporary differences; (ii)&nbsp;future taxable income exclusive of reversing temporary difference and
carryforwards; (iii)&nbsp;taxable income in prior carryback years if carryback is permitted under applicable tax law; and (iv)&nbsp;tax planning strategies. The Company&#146;s net deferred income tax asset is not more likely than not to be utilized
due to the lack of sufficient sources of future taxable income and cumulative book losses which have resulted over the years. The net increase in the valuation allowance in 2014 is due to the fact the Company generated research and development and
orphan drug credits and NOL carryforwards which increased the net deferred tax asset. The increase in the credits and NOL carryforwards were offset by the decrease in deferred revenue and resulted in a net current year increase to the valuation
allowance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December 31, 2014, the Company had U.S. federal NOL carryforwards of approximately $158.9 million and approximately
$103.4 million for state that will expire in various years beginning in 2020 through 2034. In addition, the Company has U.S. federal tax credits of $26.3 million which will expire in various years beginning in 2020 through 2034. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The use of the Company&#146;s U.S. federal NOL and tax credit carryforwards in future years are restricted due to changes in the
Company&#146;s ownership and tax attributes acquired through the Company&#146;s acquisitions. As of December&nbsp;31, 2014, $7.1 million of the Company&#146;s US Federal NOLs are limited for use over the years 2015-2027 in which a range of such
amounts could be utilized on an annual basis of $0.2 million to $1.4 million. The remaining $151.8 million of NOLs is not limited and can be offset against future taxable income. Additionally, approximately $7.7 million of NOLs will be recognized as
a benefit through additional-paid-in-capital when realized. Further, despite the NOL and credit carryforwards, the Company may have a future tax liability due to an alternative minimum tax or state tax requirements in which net operating losses do
not exist. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-23 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, the Company recorded $1.6 million of current deferred tax liability and $1.6
million of noncurrent deferred tax asset as a result of the requirement to allocate its valuation allowance against gross deferred tax assets. As such the balance sheet was grossed up but nets to zero deferred income tax assets/(liabilities). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The reconciliation of the reported estimated income tax benefit to the amount that would result by applying the U.S. federal statutory tax
rate to the net income is as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="66%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">United States federal tax at statutory rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13,410</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(91</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,927</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State taxes (net of federal benefit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,608</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">609</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,460</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred income tax adjustments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(855</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(512</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred state blended rate adjustments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,034</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(344</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research credit, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,228</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(226</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transaction cost deduction</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(379</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transaction cost deduction&#151;prior year adjustment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(564</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Orphan drug credit, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(139</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(843</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,896</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other permanent items</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(382</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">756</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">241</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value adjustment of preferred stock warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">219</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(53</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,920</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">787</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense/(benefit)</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows (in
thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Beginning balance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,708</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,592</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,534</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increases/(decreases) for current year tax positions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">242</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">116</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increases/(decreases) for prior year tax positions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Decreases as a result of expiration of statute of limitations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ending balance</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,047</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,708</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,592</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2014 and 2013, of the total gross unrecognized tax benefits, approximately $1.7
million and $1.3 million would favorably impact the Company&#146;s effective income tax rate, respectively. Although, due to the Company&#146;s determination that the deferred income tax asset would not more likely than not be realized, a valuation
allowance would be recorded, therefore, zero net impact would result within the Company&#146;s effective income tax rate. The Company&#146;s uncertain income tax position liability has been recorded to deferred income taxes to offset the tax
attribute carryforward amounts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the years ended December&nbsp;31, 2014, 2013 and 2012, the Company has not recognized any interest or
penalties related to the uncertain income tax positions due to the fact such position is related to tax attribute carryforwards which have not yet been utilized. The Company does not expect its unrecognized income tax position to significantly
decrease within the next twelve months. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-24 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s U.S. Federal and state income tax returns from 2001 to 2014 remain subject
to examination by the tax authorities. The Company&#146;s 2001 through 2010 years remain open for examination, even though the statute of limitations has expired, due to the net operating losses and credits carried forward for use in prospective
years. </P>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. Lease Exit Liability </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;16, 2008, the Company acquired Raven Biotechnologies, Inc. (Raven), a private South San Francisco-based company
focused on the development of monoclonal antibody therapeutics for treating cancer. Raven was considered a development-stage enterprise as defined in ASC&nbsp;915, <I>Development Stage Entities</I>. In connection with the acquisition, the Company
issued 12,466,039 shares of its Series D convertible preferred stock in exchange for all of the outstanding capital stock and convertible notes payable of Raven. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company undertook restructuring activities related to the acquisition of Raven. These restructuring activities included reductions in
staffing levels and the intended exit of leased facilities. All severance-related payments were completed in the year ended December&nbsp;31, 2009. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with these restructuring activities, as part of the cost of acquisition, the Company established a restructuring liability
attributed to an existing operating lease. The terms of the operating lease extend through 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Changes in the lease exit liability are
as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrual balance at December&nbsp;31, 2012.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;10,074</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Principal payments</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(629</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrual balance at December&nbsp;31, 2013</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,445</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Principal payments</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,439</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrual balance at December&nbsp;31, 2014</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,006</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Future principal payments to be made under the lease agreement as of December&nbsp;31, 2014 are as follows (in
thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2015</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,642</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2016</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,866</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2017</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,113</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2018</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,385</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,006</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The purchase agreement provides for a specified total of certain contingent milestones that are based on the
achievement of certain product sales derived from the acquired Raven technology. Also, a onetime payment of $5.0 million will be made to the Raven stockholders upon the initiation of patient dosing in the first Phase 2 clinical trial of any product
derived from the Raven &#147;Cancer Stem Cell Program.&#148; No payment shall be made if the Phase 2 trial start date has not occurred on or before July&nbsp;15, 2018. Other consideration includes a percentage of revenue (excluding consideration for
research and development and equity) received by the Company for license of a product derived from the Raven &#147;Cancer Stem Cell Program&#148; and a onetime payment ranging from $8.0 million to $12.0 million dependent upon a specified level of
sales of products derived from the Raven &#147;Cancer Stem Cell Program.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-25 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The contingent consideration will be accounted for as additional purchase price and recorded
as incremental in-process research and development expense when it is deemed probable that the contingencies will be attained. No additional amounts have been recorded during the years ended December&nbsp;31, 2014, 2013 and 2012. </P>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8. Collaboration and License Agreements </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Janssen Biotech, Inc. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2014, the Company entered into a collaboration and license agreement with Janssen Biotech, Inc. (Janssen) for the development and
commercialization of MGD011, a product candidate that incorporates the Company&#146;s proprietary DART technology to simultaneously target CD19 and CD3 for the potential treatment of B-cell malignancies. The Company contemporaneously entered into a
stock purchase agreement and investor agreement, each with Johnson&nbsp;&amp; Johnson Innovation&#151;JJDC, Inc. (JJDC), an affiliate of Janssen, under which JJDC agreed to purchase 1,923,077 new shares of the Company&#146;s common stock at a price
of $39.00 per share, representing proceeds of $75.0 million. The effectiveness of these agreements was subject to the early termination or expiration of any applicable waiting periods under Hart-Scott-Rodino Antitrust Improvements Act of 1976, which
occurred in January 2015 (see Note 13). The Company is eligible to receive a $50.0 million upfront payment from Janssen after the collaboration and license agreement becomes effective. Janssen will be fully responsible for developing MGD011
following submission of the Investigational New Drug Application (IND), which is planned for 2015. Assuming successful development and commercialization, the Company could receive up to an additional $575.0 million in clinical, regulatory and
commercialization milestone payments. The Company may elect to fund a portion of late-stage clinical development in exchange for a profit share in the U.S. and Canada. If commercialized, the Company would be eligible to receive double-digit
royalties on any global net sales and has the option to co-promote the molecule with Janssen in the U.S. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No revenue was recognized during
the year ended December&nbsp;31, 2014 under this agreement, and no related deferred revenue was recorded as of December&nbsp;31, 2014. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Takeda
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May 2014, the Company entered into a license and option agreement with Takeda for the development and commercialization of
MGD010, a product candidate that incorporates the Company&#146;s proprietary DART technology to simultaneously engage CD32B and CD79B, which are two B-cell surface proteins. MGD010 is currently in pre-clinical development for the treatment of
autoimmune diseases. Upon execution of the agreement, Takeda made a non-refundable payment of $15.0 million to the Company. Takeda has an option to obtain an exclusive worldwide license for MGD010 following the completion of a pre-defined Phase 1a
study. The Company will lead all product development activities until that time. If Takeda exercises its option, it will assume responsibility for future development and pay the Company a license option fee that, along with an early development
milestone, will total $18.0 million. Assuming successful development and commercialization of MGD010, the Company is eligible to receive up to an additional $468.5 million in development, regulatory and sales milestone payments. If commercialized,
the Company would receive double-digit royalties on any global net sales and has the option to co-promote MGD010 with Takeda in the United States. Finally, the Company may elect to fund a portion of Phase 3 clinical development in exchange for a
North American profit share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company evaluated the license and option agreement with Takeda and has determined that it is a revenue
arrangement with multiple deliverables, or performance obligations. The Company&#146;s substantive performance obligations under the license and option agreement include exclusivity, research and development services through the Phase 1a study and
delivery of a future license for an initial research compound. The Company concluded that the MGD010 option is substantive and that the license fee payable upon exercise of the option is not a deliverable at the inception of the arrangement as there
is considerable uncertainty that the option </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-26 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
would be exercised. The Company has determined that each potential future development and regulatory milestone is substantive. Although sales milestones are not considered substantive, they are
still recognized upon achievement of the milestone (assuming all other revenue recognition criteria have been met) because there are no undelivered elements that would preclude revenue recognition at that time. The Company determined that these
performance obligations represent a single unit of accounting, because the exclusivity clause does not have stand-alone value to Takeda without the Company&#146;s technical expertise and development through the pre-defined Phase 1a study. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After identifying the deliverables included within the arrangement, the Company determined its best estimate of selling price. The Company
allocated $10.0 million to the exclusivity clause to its technology and the research and development services and $5.0 million to the exclusive license for the initial research compound. The Company&#146;s determination of best estimate of selling
price for the research and development services relied upon other similar transactions. The Company relied upon the income approach (e.g., future cash flows) to determine the value of the license of the to-be-delivered compound along with other
similar license transactions with differing indications but similar stage of development. The portion of the up-front fee allocated to the MGD010 option is being recognized over an initial 24-month period, which represents the expected period of
development through the completion of a pre-defined Phase 1a study. The portion of the up-front fee allocated to the license for the initial research compound was deferred until the research collaboration and license option agreement was executed
and the license delivered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognized revenue of approximately $3.0 million under the MGD010 agreement during the year ended
December&nbsp;31, 2014. At December&nbsp;31, 2014, $7.1 million of revenue was deferred under this agreement, $5.0 million of which was current and $2.1 million of which was non-current. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September 2014, the Company and Takeda executed a research collaboration and license option agreement, which formalized the license for the
initial research compound. Under the terms of the agreement, Takeda may identify up to three additional compounds, which will be subject to separate research and development plans. The Company determined that it could recognize the entire license
fee as (1)&nbsp;the executed contract constituted persuasive evidence of an arrangement, (2)&nbsp;the delivery of the license occurred and the Company had no current or future performance obligations, (3)&nbsp;the total consideration for the license
was fixed and known at the time of its execution and there were not any extended payment terms or rights of return, and (4)&nbsp;the cash was received. Therefore, the Company recognized $5.0 million in revenue during the year ended December&nbsp;31,
2014 under this agreement. The Company is also entitled to receive reimbursements for research and development services provided to Takeda with respect to the initial research compound, subject to the execution of a separate research plan. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Gilead </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In January 2013, the
Company entered into an agreement with Gilead for Gilead to obtain exclusive worldwide rights for the research, development and commercialization of up to four DART molecules. For each molecule Gilead chooses to develop, the Company is entitled to
receive a license grant fee of $7.5 million and is further eligible to receive up to an additional $20.0 million to $25.0 million in pre-clinical milestones and up to $240.0 million to $250.0 million in additional clinical, regulatory and sales
milestones. Upon execution of the arrangement, Gilead identified one molecule to develop for which the Company granted Gilead a license in exchange for consideration of $7.5 million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company determined that any remaining licenses are conditional deliverables, which are substantive options that were not granted with a
substantial discount. The Company has determined that each potential future clinical, development and regulatory milestone is substantive. Although sales milestones are not considered </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-27 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
substantive, they are still recognized upon achievement of the milestone (assuming all other revenue recognition criteria have been met) because there are no undelivered elements that would
preclude revenue recognition at that time. Gilead also provides funding for the Company&#146;s internal and external research costs under the agreement. Additionally, Gilead would be obligated to pay the Company high single digit to low double digit
royalties on product sales. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company evaluated the research collaboration agreement with Gilead and has determined that it is a
revenue arrangement with multiple deliverables, or performance obligations. The Company&#146;s substantive performance obligations under this research collaboration include a license to its technology and research and development services. The
Company concluded that the deliverables do not have stand alone value and therefore, represent a combined single unit of accounting. Due to the lack of standalone value for the license and research and development services, the combined unit of
accounting (the upfront payment and the expected research and development reimbursements) was recognized ratably over a period of 21 months, which represented the expected development period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company and Gilead have also agreed to establish a joint research committee to facilitate the governance and oversight of the
parties&#146; activities under the agreements. Management considered whether participation on the joint committee may be a deliverable and determined that it was not a deliverable. Had management considered participation on the joint committee as a
deliverable, it would not have had a material impact on the accounting for the arrangement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognized revenues of
approximately $5.5 million and $8.0 million under this agreement for the years ended December&nbsp;31, 2014 and 2013, respectively. No milestones have been achieved under this agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At December&nbsp;31, 2013, $3.6 million of revenue was deferred under this agreement, all of which was current. As of December&nbsp;31, 2014,
there was no remaining deferred revenue under this agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Servier </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In November 2011, the Company entered into a right-to-develop collaboration agreement with Servier for the development and commercialization of
MGA271 in all countries other than the United States, Canada, Mexico, Japan, South Korea and India. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon execution of the agreement,
Servier made a nonrefundable payment of $20.0 million to the Company. The Company is eligible to receive up to $30.0 million in license grant fees, $47.0 million in clinical milestone payments, $140.0 million in regulatory milestone payments and
$208.0 million in sales milestone payments if Servier exercises the option, obtains regulatory approval for and successfully commercializes MGA271. The Company concluded that the license option fees are not deliverables at the inception of the
arrangement. The Company has determined that each potential future clinical, development and regulatory milestone is substantive. Although sales milestones are not considered substantive, they are still recognized upon achievement of the milestone
(assuming all other revenue recognition criteria have been met) because there are no undelivered elements that would preclude revenue recognition at that time. In the event Servier exercises its option to continue development of MGA271, Servier must
pay a license option fee. Under this agreement, Servier would be obligated to pay the Company from low double digit to mid-teen royalties on product sales in its territories. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company evaluated the research collaboration agreement with Servier and has determined that it is a revenue arrangement with multiple
deliverables, or performance obligations. The Company concluded that the option is substantive and that the license fees for this option is not a deliverable at the inception of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-28 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
arrangement as there is considerable uncertainty that the option would be exercised and the additional fee to be paid upon exercise of the option represents its estimated selling price (i.e. no
substantial discount was given). The Company&#146;s substantive performance obligations under this research collaboration include an exclusivity clause to its technology, technical, scientific and intellectual property support to the research plan
and participation on an executive committee and a research and development committee. The Company determined that these performance obligations represent a single unit of accounting, since the license does not have stand-alone value to Servier
without the Company&#146;s technical expertise and committee participation. As such, the initial upfront payment was deferred and was being recognized ratably over the initial 27-month period, which represented the expected period of development and
the Company&#146;s participation on the research and development committee. During 2014, the Company determined that the development period will last longer than originally estimated, and prospectively adjusted its period of recognition of the
upfront payment to a 42-month period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the years ended December&nbsp;31, 2014, 2013 and 2012 the Company recognized revenue of
$0.7&nbsp;million, $21.3 million and $9.1 million, respectively, under this agreement. Revenue recognized in the year ended December&nbsp;31, 2013 included a $10.0 million substantive milestone payment received upon dosing the first patient in a
Phase 1 dose expansion cohort trial of MGA271. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At December&nbsp;31, 2014 and 2013, $0.1 million and $0.9 million of revenue remained
deferred under this agreement, respectively, all of which was current. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September 2012, the Company entered into a second
right-to-develop collaboration agreement with Servier and granted it options to obtain three separate exclusive licenses to develop and commercialize DART-based molecules, consisting of those designated by the Company as MGD006 and MGD007, as well
as a third DART molecule, in all countries other than the United States, Canada, Mexico, Japan, South Korea and India. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon execution of
the agreement, Servier made a nonrefundable payment of $20.0 million to the Company. In addition, the Company will be eligible to receive up to $65.0 million in license grant fees, $98.0 million in clinical milestone payments, including $5.0 million
upon IND acceptance for each of MGD006, MGD007 and a third DART molecule, $300.0 million in regulatory milestone payments and $630.0 million in sales milestone payments if Servier exercises all of the options and successfully develops, obtains
regulatory approval for, and commercializes a product under each license. In addition to these milestones, the Company and Servier will share Phase 2 and Phase 3 development costs. The Company has determined that each potential future clinical,
development and regulatory milestone is substantive. Although sales milestones are not considered substantive, they are still recognized upon achievement of the milestone (assuming all other revenue recognition criteria have been met) because there
are no undelivered elements that would preclude revenue recognition at that time. Under this agreement, Servier would be obligated to pay the Company between high-single digit and mid-teen royalties on net product sales in its territories. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company evaluated the research collaboration agreement with Servier and has determined that it is a revenue arrangement with multiple
deliverables, or performance obligations. The Company concluded that each option is substantive and that the license fees for each option are not deliverables at the inception of the arrangement and were not issued with a substantial discount. The
Company&#146;s substantive performance obligations under this research collaboration include an exclusivity clause to its technology, technical, scientific and intellectual property support to the research plan during the first year of the agreement
and participation on an executive committee and a research and development committee. The Company determined that the performance obligations with respect to the pre-clinical development represent a single unit of accounting, since the license does
not have stand-alone value to Servier without the Company&#146;s technical expertise and committee participation. As such, the initial upfront license payment was deferred and initially recognized ratably over a
<FONT STYLE="white-space:nowrap">29-month</FONT> period, which represented the expected development period. During 2014, the Company and Servier </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-29 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
further refined the research plan related to the three DARTs and as such, the development period was extended. Based on this revised development period, the Company prospectively adjusted its
period of recognition of the upfront payment to a 75-month period. The impact of this change in accounting estimate reduced revenue that would have been recognized in 2014 by $3.7 million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2014, Servier exercised its exclusive option to develop and commercialize MGD006. As a result of the
exercise, the Company received a $15.0 million payment from Servier for its license to develop and commercialize MGD006 in its territories. Upon exercise of the option, the Company evaluated its performance obligations with respect to the license
for MGD006. The Company&#146;s substantive performance obligations under this research collaboration include an exclusive license to its technology, technical, scientific and intellectual property support to the research plan and participation on an
executive committee and a research and development committee. The Company determined that the performance obligations with respect to the clinical development represent a single unit of accounting, since the license does not have stand-alone value
to Servier without the Company&#146;s technical expertise and committee participation. As such, the $15.0 million license fee was deferred and is being recognized ratably over a period of 82 months, which represents the expected development period
for MGD006. In accordance with the agreement, the Company and Servier will share costs incurred to develop MGD006. Reimbursement of research and development expenses received in connection with this collaborative cost-sharing agreement is recorded
as a reduction to research and development expense. During the year ended December&nbsp;31, 2014 the Company recorded approximately $1.0 million as an offset to research and development costs under this collaboration arrangement. No such offset was
recorded in 2013 or 2012. As of December&nbsp;31, 2014 the Company has a corresponding collaboration receivable, which is included in accounts receivable on the consolidated balance sheet, of $0.8 million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the years ended December&nbsp;31, 2014, 2013 and 2012 the Company recognized revenue of $16.7&nbsp;million, $8.6 million, and $2.0
million, respectively, under this agreement. Revenue during the year ended December&nbsp;31, 2014 includes two $5.0 million milestone payments from Servier upon the achievement of clinical milestones related to the IND applications for MGD006 and
MGD007 clearing the 30-day review period by the U.S. FDA. No milestones were recognized under this agreement during the years ended December&nbsp;31, 2013 or 2012. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At December&nbsp;31, 2014, $17.7 million of revenue was deferred under this agreement, $3.3 million of which was current and $14.4 million of
which was long-term. At December&nbsp;31, 2013, $9.4 million of revenue was deferred under this agreement, $8.6 million of which was current and $0.8 million of which was long-term. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Boehringer </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2010 the
Company entered into a collaboration and license agreement with Boehringer to discover, develop and commercialize up to ten DART-based molecules which span multiple therapeutic areas. Under the terms of the agreement, the Company granted Boehringer
an exclusive, worldwide, royalty-bearing, license under its intellectual property to research, develop, and market DARTs generated under the agreement throughout the world. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon execution of the agreement, the Company received an upfront payment of $15.0 million. The Company subsequently received three annual
maintenance payments. These maintenance payments are being recognized over the estimated period of development. The Company has the potential to earn milestone payments of approximately $41.0 million related to pre-clinical and clinical development,
$89.0 million related to regulatory milestones and $83.0 million related to sales milestones for each of the DART programs under this agreement in the case of full commercial success of multiple DART products. The Company has determined that
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-30 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
each potential future clinical, development and regulatory milestone is substantive. Although sales milestones are not considered substantive, they are still recognized upon achievement of the
milestone (assuming all other revenue recognition criteria have been met) because there are no undelivered elements that would preclude revenue recognition at that time. Boehringer also provides funding for the Company&#146;s internal and external
research costs and is required to pay the Company mid-single digit royalties on product sales. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company determined that the
deliverables under the Boehringer agreement include the license, the research and development services to be performed by the Company, and the co-promotion/manufacturing services. The Company concluded that the co-promotional activities were
optional and were subject to further negotiation upon reaching regulatory approval. As such, the co-promotional period is not included in the expected obligation period to perform services. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company concluded that the undelivered element of research and development services had fair value. The Company concluded that the license
does not have value on a standalone basis (e.g. absent the provision of the research and development services) and therefore does not represent a separate unit of accounting. The Company concluded that because the drug candidate has not yet been
developed, the license is of no value to Boehringer without the ensuing research and development activities using the DART technology, which is proprietary to the Company. Likewise, Boehringer could not sell the license to another party (without the
Company agreeing to provide the research and development activities for the other party). Therefore, the upfront license fee and research and development services were treated as a combined unit of accounting and recognized over the expected
obligation period associated with the research and development services through September 2015, which represents the estimated period of development. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company and Boehringer have also agreed to establish a joint research committee to facilitate the governance and oversight of the
parties&#146; activities under the agreements. Management considered whether participation on the joint committee may be a deliverable and determined that it was not a deliverable. However, had management considered participation on the joint
committee as a deliverable, it would not have had a material impact on the accounting for the arrangement as the period of participation in this committee matched the obligation period for the research and development services. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognized revenues of approximately $13.7 million, $14.4 million and $11.7 million during the years ended December&nbsp;31, 2014,
2013 and 2012, respectively, under this agreement. Revenue recognized in the years ended December&nbsp;31, 2014, 2013 and 2012 included milestone payments of $2.0 million, $5.0 million and $2.0 million, respectively, for the achievement of clinical
milestones. At December&nbsp;31, 2014, $5.8 million of revenue was deferred under this agreement, all of which was current. At December&nbsp;31, 2013, $12.8 million of revenue was deferred under this agreement, $7.0 million of which was current and
$5.8 million of which was long-term. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Pfizer </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2010, the Company entered into a three year agreement with Pfizer to discover, develop and commercialize up to two DART-based
molecules. The Company granted Pfizer a non-exclusive worldwide, royalty-bearing license and received an upfront payment of $5.0 million and has received milestone payments and funding for the Company&#146;s internal and external research costs
under the agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is eligible to receive milestone payments of approximately $17.0 million related to pre-clinical and
clinical development and $195.0 million related to commercialization and sales milestones for each DART program under this agreement. The Company has determined that each potential future technical and development milestone is substantive. Although
sales milestones are not considered substantive, they are still </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-31 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
recognized upon achievement of the milestone (assuming all other revenue recognition criteria have been met) because there are no undelivered elements that would preclude revenue recognition at
that time. Pfizer is responsible for all pre-clinical and clinical development costs for the program. In addition, Pfizer is required to pay the Company mid-single digit to low-teen royalties on product sales. Under this collaboration, one DART
program is currently being pursued and the Company completed its research obligations under this program in January 2014. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has
evaluated the research collaboration agreement with Pfizer and has determined that it is a revenue arrangement with multiple deliverables, or performance obligations. The Company&#146;s substantive performance obligations under this research
collaboration include an exclusive license to its technology, research and development services and manufacturing services. The Company concluded that the manufacturing services were optional and were subject to further negotiation upon reaching
regulatory approval. As such, the manufacturing services are not included in the expected obligation period to perform services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Company determined that it had fair value of the undelivered element of the research and development services. However, the Company concluded that the license does not have value on a standalone basis (e.g. absent the provision of the research and
development services) and therefore does not represent a separate unit of accounting. Facts that were considered included the development of the candidate noting that because the drug candidate has not yet been developed, the license is of no value
to Pfizer without the ensuing research and development activities using the DART technology, which is proprietary to the Company. Likewise, Pfizer could not sell the license to another party (without the Company agreeing to provide the research and
development activities for the other party). Therefore, the upfront license fee and research and development services were treated as a combined unit of accounting and recognized over the expected obligation period associated with the research and
development services through January 2014, which represents the estimated period of development. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The $5.0 million upfront payment
received by the Company is non-refundable; therefore, there is no right of return for the license. The Company recognized revenue associated with this non-refundable up-front license fee through the expected obligation period associated with the
research and development services, which ended in January 2014. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company and Pfizer have also agreed to establish a joint research
committee to facilitate the governance and oversight of the parties&#146; activities under the agreements. Management considered whether participation on the joint committee may be a deliverable and determined that it was not a deliverable because
it is a participating right and not an obligation of the Company. However, had management considered participation on the joint committee as a deliverable, it would not have had a material impact on the accounting for the arrangement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognized revenues of approximately $0.1 million, $3.5 million and $5.5 million during the years ended December&nbsp;31, 2014,
2013 and 2012, respectively. Included in the 2012 revenues are milestone payments totaling $0.5 million. No additional milestones have been achieved under this agreement through December&nbsp;31, 2014. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At December&nbsp;31, 2013, deferred revenue under this agreement was approximately $7,000. As of December&nbsp;31, 2014, there was no
remaining deferred revenue under this agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Green Cross </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June&nbsp;2010, the Company entered into a collaboration agreement with Green Cross for the development of the Company&#146;s anti-HER2
antibody margetuximab. This arrangement grants Green Cross an exclusive license to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-32 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
conduct specified Phase 1 and Phase 2 clinical trials and commercialize margetuximab in South Korea. In March 2014, the Company and Green Cross entered into an amendment to the original
agreement, causing the terms of the original agreement to be materially modified. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon execution of the amendment, the Company became
eligible to receive reimbursement for costs incurred for Phase 2 and Phase 3 clinical trials up to $5.5 million as well as clinical development and commercial milestone payments of up to $2.5 million. The Company has determined that each potential
clinical development and commercial milestone is substantive. The Company is also entitled to receive royalties on net sales of margetuximab in South Korea. The Company and Green Cross have formed a joint steering committee to coordinate and oversee
activities on which the companies collaborate under the agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has evaluated the collaboration agreement with Green Cross
and has determined that it is a revenue arrangement with multiple deliverables or performance obligations. As a result of the material modification to the arrangement in March 2014, the Company reassessed the entire arrangement in accordance with
the guidance provided by ASC 605-25, <I>Multiple Element Arrangements (Revenue Recognition) </I>as the original agreement was accounted for prior to adopting ASU 2009-13<I>.</I> The Company&#146;s substantive performance obligations under this
agreement include an exclusive license to its technologies, research and development services, and participation in a joint steering committee. The Company concluded that the license and the reimbursements for research and development services do
not have value on a standalone basis and therefore do not represent a separate unit of accounting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The initial $1.0 million upfront
payment received by the Company upon execution of the original agreement is non-refundable; as such, there is no right of return for the license. Therefore, the upfront license fee and participation on the joint steering committee were treated as a
combined unit of accounting and will be recognized over the term of the agreement through June 2020. Further, due to the fact the research and development services are not deemed to have stand-alone value, revenue for those services should be
recognized over the entire term of the agreement (through June 2020). As a result of reassessing the arrangement in accordance with ASC 605-25, the Company was required to record an adjustment on the date of the material modification to reflect the
revenue that would have resulted had the entity applied the requirements of ASC 605-25 from the inception of the agreement. As a result, the Company recorded an additional $1.3 million of revenue during 2014. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognized revenues of approximately $1.7 million and $100,000 under this agreement during the years ended December&nbsp;31, 2014
and 2013, respectively. No milestones were achieved under this agreement during the years ended December&nbsp;31, 2014 and 2013. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At
December&nbsp;31, 2014, there was a $525,000 unbilled receivable balance under this agreement, which is included in other assets on the consolidated balance sheet. At December&nbsp;31, 2013, $650,000 of revenue was deferred under this agreement,
$100,000 of which was current and $550,000 of which was non-current. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Eli Lilly </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October&nbsp;2007, the Company entered into an exclusive license and collaboration agreement (together, the Agreements) with Eli Lilly to
jointly develop and commercialize teplizumab, a humanized anti-CD3 monoclonal antibody. As part of the Agreements, Eli Lilly acquired the exclusive rights to the molecule. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon execution of the Agreements, Eli Lilly made a nonrefundable payment of $41.0 million to the Company. In May&nbsp;2008, Eli Lilly paid the
Company a milestone payment of $50.0 million and in May&nbsp;2010, Eli&nbsp;Lilly paid an additional milestone of $5.0 million. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-33 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;28, 2010, Lilly notified the Company of its decision to terminate the
agreement after review of one year of clinical data from the Prot&eacute;g&eacute; trial in Type 1 diabetes patients treated with teplizumab. Such data failed to support the primary efficacy end point in the study. In February 2011, the Company
reacquired the commercial rights to the molecule from Eli Lilly. During the year ended December&nbsp;31, 2012, Eli&nbsp;Lilly satisfied its obligation related to the cost of monitoring patients under the Prot&eacute;g&eacute; and Encore trials. The
Company&#146;s obligations continued through September 2012, which represented the follow up period for enrolled patients and the Company&#146;s final reporting of the trial&#146;s results. There is no additional clinical trial activity under the
Eli Lilly Agreements as it relates to such trials. However, Eli Lilly continues to reimburse the Company for monitoring patients in one currently active trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the years ended December 2014, 2013 and 2012, the Company recognized revenue of $0.4 million, $0.8 million and $31.2 million,
respectively, under this agreement. No milestones were achieved under this agreement during the three years ended December&nbsp;31, 2014. </P>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9. Commitments and Contingencies </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Operating Leases </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company leases office and laboratory space for its headquarters in Rockville, Maryland.&nbsp;In 2014, that lease was amended to extend its
term from March 31, 2018 to January 31, 2020.&nbsp;In addition, in 2014, the Company leased additional office space adjacent to its headquarters, also through January 31, 2020.&nbsp;The Company has an option under each lease to continue the
respective lease for five years under the same terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company leases a manufacturing facility in Rockville under a lease that
originally expired on December&nbsp;31, 2014. During 2014, the Company exercised its 5-year renewal option on the manufacturing facility. The Company also entered into a new four-year lease for additional space in the manufacturing facility
effective April&nbsp;1, 2014. This lease also has an option to continue the lease for five years under the same terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company also
leases office and laboratory space in South San Francisco under a lease that expires on February&nbsp;28, 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All of the leases contain
rent escalation clauses and certain leases contain rent abatements. For financial reporting purposes, rent expense is charged to operations on a straight-line basis over the term of the lease. As of December&nbsp;31, 2014 and 2013, the Company had
recorded a deferred rent liability of $2.7 million and $2.9&nbsp;million, respectively. Rent expense for the years ended December&nbsp;31, 2014, 2013 and 2012 was $2.0&nbsp;million, $2.7 million and $2.7 million, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Future minimum lease payments under noncancelable operating leases as of December&nbsp;31, 2014 are as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2015</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,945</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2016</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,364</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2017</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,495</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2018</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,396</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2019</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,873</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thereafter</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">116</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19,189</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-34 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Contingencies </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, the Company may be subject to various litigation and related matters arising in the ordinary course of business. The Company
does not believe it is currently subject to any material matters where there is at least a reasonable possibility that a material loss may be incurred. </P>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10. Product Milestone Payments and Royalty Agreements </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with an Asset Purchase Agreement with Tolerance Therapeutics, Inc. (Tolerance) entered into during June 2005,
the Company may be required to issue Tolerance additional consideration as follows: (i)&nbsp;$10,950,000 if certain milestones are met, including the initiation of Phase 3 trials and filing of various regulatory product license applications;
(ii)&nbsp;36,135 shares of common stock; and (iii)&nbsp;royalty payments between 1.75% and 4.0% of net sales of products acquired from or patented by Tolerance or other product fees earned by the Company. Any additional consideration required to be
paid under the Asset Purchase Agreement will be recorded as research and development expense when incurred. No payments related to the additional consideration have occurred during the three years ended December&nbsp;31, 2014. Additionally, certain
agreements require the Company to pay royalties. Currently, the Company is not obligated to pay royalties, as no revenue from product sales is being generated by the Company. </P>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11. Employee Benefit Plan </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;25, 2002, the Company established the MacroGenics 401(k) Plan (the Plan) for its employees under
Section&nbsp;401(k) of the IRC. Under this Plan, all employees at least 21 years of age are eligible to participate in the Plan, starting on the first day of each month. Employees may contribute up to 100% of their salary, subject to government
maximums. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Employees are 100% vested in their contributions to the Plan. The Company&#146;s contribution to the Plan, as determined by the
Board of Directors, is discretionary. The Company&#146;s contributions to the Plan totaled $318,390, $252,930 and $225,195 for the years ended December&nbsp;31, 2014, 2013 and 2012, respectively. </P>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12. Quarterly Financial Information (unaudited) </B></P>
 <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="55%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>1<SUP STYLE="font-size:85%; vertical-align:top">st</SUP>&nbsp;Quarter</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2<SUP STYLE="font-size:85%; vertical-align:top">nd</SUP>&nbsp;Quarter</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>3<SUP STYLE="font-size:85%; vertical-align:top">rd</SUP>&nbsp;Quarter</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>4<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>&nbsp;Quarter</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in thousands, except per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>2014</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,719</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18,382</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,476</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,108</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,259</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,928</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,018</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.12</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.44</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.14</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.68</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>2013</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,598</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,299</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20,232</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,906</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,366</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(294</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,604</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,205</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) per share, basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2.93</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.24</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.14</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) per share, diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2.93</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.24</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.14</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net income (loss) per share includes the effects of income allocated to participating securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-35 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13. Subsequent Event </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In January 2015, the Federal Trade Commission granted early termination of the waiting period under the Hart-Scott-Rodino
Antitrust Improvements Act of 1976 with respect to the collaboration and license agreement with Janssen and the stock purchase agreement and investor agreement with JJDC (as described in Note 8). Accordingly, the Company issued 1,923,077 shares of
common stock to JJDC and received $75.0 million from JJDC under the stock purchase agreement and received the $50.0 million upfront payment from Janssen under the collaboration and license agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-36 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="91%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:25.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit<BR>No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Restated Certificate of Incorporation of Company (incorporated by reference to Exhibit 3.1 to the Company&#146;s Current Report on Form 8-K filed on October 18, 2013)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Amended and Restated By-Laws of the Company (incorporated by reference to Exhibit 3.4 to the Registration Statement on Form S-1 (File No. 333-190994) filed by the Company on October 1, 2013)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Certificate of Correction to the Restated Certificate of Incorporation of the Company (incorporated by reference to Exhibit 3.3 to the Company&#146;s Current Report on Form 8-K filed on October&nbsp;18, 2013)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Fifth Amended and Restated Registration Rights Agreement by and among the Company, the Founders, and the Investors, dated February 3, 2014 (incorporated by reference to Exhibit 4.1 to Amendment No. 1 to the Registration Statement on
Form S-1 (File No. 333-193648) filed by the Company on February 10, 2014)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Specimen Stock Certificate (incorporated by reference to Exhibit 4.2 to the Registration Statement on Form S-1 (File No. 333-190994) filed by the Company on October 9, 2013)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.3*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Investor Agreement by and between Johnson and Johnson Innovation-JJDC, Inc. and the Company, dated December 19, 2014</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.1+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Company 2000 Stock Option and Incentive Plan (incorporated by reference to Exhibit 10.1 to the Registration Statement on Form S-1 (File No. 333-190994) filed by the Company on September&nbsp;4, 2013)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.2+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Incentive Stock Option Agreement under 2000 Stock Option and Incentive Plan (incorporated by reference to Exhibit 10.2 to the Registration Statement on Form S-1
<FONT STYLE="white-space:nowrap">(File&nbsp;No.&nbsp;333-190994)</FONT> filed by the Company on September 4, 2013)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.3+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Company 2003 Equity Incentive Plan (incorporated by reference to Exhibit 10.3 to the Registration Statement on Form S-1 (File No. 333-190994) filed by the Company on September 4, 2013)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.4+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Incentive Stock Option Agreement under 2003 Equity Incentive Plan (incorporated by reference to Exhibit 10.4 to the Registration Statement on Form S-1 (File No. 333-190994) filed by the Company on September 4,
2013)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.5+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Company 2013 Equity Incentive Plan (incorporated by reference to Exhibit 10.5 to the Registration Statement on Form S-1 (File No. 333-190994) filed by the Company on October 1, 2013)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.6+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Incentive Stock Option Agreement under 2013 Equity Incentive Plan (incorporated by reference to Exhibit 10.6 to the Registration Statement on Form S-1 (File No. 333-190994) filed by the Company on October 1, 2013)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.7+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Nonstatutory Stock Option Agreement under 2013 Equity Incentive Plan (incorporated by reference to Exhibit 10.7 to the Registration Statement on Form S-1 (File No. 333-190994) filed by the Company on October 1,
2013)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.8</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Lease Agreement by and between Red Gate III LLC and the Company, dated May 31, 2011 (incorporated by reference to Exhibit 10.8 to the Registration Statement on Form S-1
<FONT STYLE="white-space:nowrap">(File&nbsp;No.&nbsp;333-190994)</FONT> filed by the Company on September 4, 2013)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.9</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Amendment to Lease Agreement by and between Red Gate III LLC and the Company, dated March&nbsp;26, 2013 (incorporated by reference to Exhibit 10.9 to the Registration Statement on Form S-1 (File No. 333-190994) filed by the Company
on September 4, 2013)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.10</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Second Amendment to Lease Agreement by and between Red Gate III LLC and the Company, dated November 6, 2014</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="90%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.11</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Lease Agreement by and between W. M. Rickman Construction Co. LLC and the Company, dated December&nbsp;2, 2004 (incorporated by reference to Exhibit 10.10 to the Registration Statement on Form&nbsp;S-1 (File No. 333-190994) filed by
the Company on September&nbsp;4, 2013)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.12</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Amendment to Lease Agreement by and between W. M. Rickman Construction Co. LLC and the Company, dated January&nbsp;31, 2006 (incorporated by reference to Exhibit 10.11 to the Registration Statement on Form S-1 (File No. 333-190994)
filed by the Company on September 4, 2013)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.13</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Second Amendment to Lease Agreement by and between W. M. Rickman Construction Co. LLC and the Company, dated June 1, 2011 (incorporated by reference to Exhibit 10.12 to the Registration Statement on Form S-1 (File No. 333-190994)
filed by the Company on September 4, 2013)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.14</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Lease Agreement by and between Britannia Biotech Gateway LP and Raven biotechnologies, Inc., dated November 21, 2006</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.15</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Lease Agreement by and between W. M. Rickman Construction Co. LLC and the Company, dated March 31, 2014</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.16</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Lease Agreement by and between Red Gate III LLC and the Company, dated November 6, 2014</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.17</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Form of Indemnification Agreement (incorporated by reference to Exhibit 10.14 to the Registration Statement on Form S-1 (File No. 333-190994) filed by the Company on October 1, 2013)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.18&#134;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Collaboration and License Agreement by and between Boehringer Ingelheim International GmbH and the Company, dated October&nbsp;18, 2010 (incorporated by reference to Exhibit 10.15 to the Registration Statement on Form S-1 (File No.
333-190994) filed by the Company on October&nbsp;4, 2013)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.19&#134;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Option for a License Agreement by and between the Company and Les Laboratoires Servier and Institut de Recherches Servier, dated September 19, 2012 (incorporated by reference to Exhibit 10.20 to the Registration Statement on Form
S-1 (File No. 333-190994) filed by the Company on October&nbsp;4, 2013)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.20&#134;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Option for a License Agreement by and between the Company and Les Laboratoires Servier and Institut de Recherches Servier, dated November 24, 2011 (incorporated by reference to Exhibit 10.21 to the Registration Statement on Form S-1
(File No. 333-190994) filed by the Company on October&nbsp;4, 2013)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.21+</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Form of Employment Agreement between the Company and Scott Koenig, M.D., Ph.D. (incorporated by reference to Exhibit 10.25 to the Registration Statement on Form S-1 (File No. 333-190994) filed by the Company on October 1,
2013)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.22+</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">2013 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.27 to the Registration Statement on Form S-1 (File No. 333-190994) filed by the Company on October 1, 2013)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.23+</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Form of Employment Agreement between the Company and James Karrels (incorporated by reference to Exhibit 10.27 to the Registration Statement on Form S-1 (File No. 333-193648) filed by the Company on January 30, 2014)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.24&#134;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">License and Option Agreement, by and between Takeda Pharmaceutical Company Limited and the Company, dated May 22, 2014 (incorporated by reference to Exhibit 10.28 to Form 10-Q filed by the Company on August 5, 2014)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.25*</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Collaboration and License Agreement by and between Janssen Biotech, Inc. and the Company, dated December 19, 2014</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.26</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Stock Purchase Agreement by and between Johnson and Johnson Innovation-JJDC, Inc. and the Company, dated December 19, 2014</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>21.1</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Subsidiaries of Company</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.1</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Consent of Ernst &amp; Young, LLP, Independent Registered Public Accounting Firm</TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="88%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;31.1</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Rule 13a-14(a) Certification of Principal Executive Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;31.2</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Rule 13a-14(a) Certification of Principal Financial Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;32.1</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Section 1350 Certification of Principal Executive Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;32.2</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Section 1350 Certification of Principal Financial Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.INS</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">XBRL Instance Document</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.SCH</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">XBRL Schema Document</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.CAL</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">XBRL Calculation Linkbase Document</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.DEF</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">XBRL Definition Linkbase Document</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.LAB</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">XBRL Labels Linkbase Document</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.PRE</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">XBRL Presentation Linkbase Document</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#134;</TD>
<TD ALIGN="left" VALIGN="top">Portions of this exhibit (indicated by asterisks) have been omitted pursuant to a request for confidential treatment granted by the SEC. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">Portions of this exhibit (indicated by asterisks) have been omitted pursuant to a request to the SEC for confidential treatment. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">+</TD>
<TD ALIGN="left" VALIGN="top">Indicates management contract or compensatory plan. </TD></TR></TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.3
<SEQUENCE>2
<FILENAME>d838054dex43.htm
<DESCRIPTION>EX-4.3
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 4.3 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Execution Version </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Confidential Materials omitted and filed separately with the Securities and Exchange Commission. </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Triple asterisks denote omissions. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INVESTOR AGREEMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>By
and Between </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>JOHNSON&nbsp;&amp; JOHNSON INNOVATION-JJDC, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AND </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC.
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Dated as of December&nbsp;19, 2014 </B></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="89%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">1.&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman; ">Definitions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">2.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman; ">Registration Rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">2.1&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Required Registration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">2.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Company Registration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">2.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwritten Registration; Priority in Underwritten Offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">2.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revocation of Required Registration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">2.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effective Required Registrations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">2.6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Continuous Effectiveness of Registration Statement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">2.7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Obligations of the Company</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">2.8</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Furnish Information</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">2.9</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">2.10</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Indemnification</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">2.11</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SEC Reports</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">2.12</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assignment of Registration Rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">3.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman; ">Restrictions on Beneficial Ownership</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">3.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Standstill</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">4.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman; ">Restrictions on Dispositions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">4.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lock-Up</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">4.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Certain Tender Offers</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">5.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman; ">Voting Agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">5.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Voting of Securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">5.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Certain Extraordinary Matters</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">5.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Quorum</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">6.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman; ">Termination of Certain Rights and Obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">6.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Termination of Registration Rights Term</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">6.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Termination of Standstill Term</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">6.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Termination of Lock-Up Term</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">6.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Termination of Voting Agreement Term</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">6.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effect of Termination</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="88%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP>7.&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" COLSPAN="3">Miscellaneous</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">26</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">7.1</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Governing Law; Submission to Jurisdiction</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">7.2</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Waiver</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">7.3</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Notices</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">7.4</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entire Agreement</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">7.5</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amendments</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">7.6</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Headings; Nouns and Pronouns; Section References</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">7.7</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Severability</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">7.8</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assignment</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">7.9</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Successors and Assigns</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">7.10&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Counterparts</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">7.11</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Third Party Beneficiaries</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">7.12</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">No Strict Construction</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">7.13</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Remedies</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">7.14</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Specific Performance</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">7.15</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">No Conflicting Agreements</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">7.16</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Use of Proceeds</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">7.17</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">No Publicity</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">7.18</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Limitation of Liability</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="5"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman; ">Exhibit A &#150; Form of Irrevocable Proxy</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman; ">Exhibit B &#150; Notices</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ii </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INVESTOR AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THIS INVESTOR AGREEMENT (this &#147;<B>Agreement</B>&#148;) is made as of December&nbsp;19, 2014, by and among Johnson&nbsp;&amp; Johnson
Innovation-JJDC, Inc., a New Jersey corporation with its principal place of business at 410 George Street, New Brunswick, New Jersey 08901 (&#147;<B>Investor</B>&#148;) and MacroGenics, Inc. (the &#147;<B>Company</B>&#148;), a Delaware corporation
with its principal place of business at 9640 Medical Center Drive, Rockville, MD 20850. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Stock Purchase Agreement, dated as
of December&nbsp;19, 2014, by and between the Investor and the Company (the &#147;<B>Purchase Agreement</B>&#148;) provides for the issuance and sale by the Company to the Investor, and the purchase by the Investor, of a number of shares (such
shares, the &#147;<B>Purchased Shares</B>&#148;) of the Company&#146;s common stock, par value $0.01 per share (the &#147;<B>Common Stock</B>&#148;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, as a condition to consummating the transactions contemplated by the Purchase Agreement, the Investor and the Company have agreed upon
certain rights and restrictions as set forth herein with respect to the Purchased Shares and other securities of the Company beneficially owned by the Investor and its Affiliates, and it is a condition to the closing under the Purchase Agreement
that this Agreement be executed and delivered by the Investor and the Company; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, simultaneously with the execution of the
Purchase Agreement, the Company and Janssen Biotech, Inc. (&#147;<B>Janssen</B>&#148;), an Affiliate of the Investor, entered into the Collaboration Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the premises and mutual agreements hereinafter set forth, and for other valuable consideration, the
receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Definitions</U>. As used in this
Agreement, the following terms shall have the following meanings: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) &#147;<B>Affiliate</B>&#148; shall mean, with respect to any
Person, another Person that controls, is controlled by or is under common control with such Person; <U>provided</U>, that with respect to the Investor, &#147;Affiliate&#148; shall mean the Investor&#146;s subsidiaries that are wholly-owned directly
or indirectly, by the Investor and any Person that wholly-owns, directly or indirectly, the Investor; <U>provided further</U>, that with respect to the Investor, the term &#147;Affiliate&#148; shall not include any employee benefit plan of the
Investor. A Person shall be deemed to control another Person if such Person possesses, directly or indirectly, the power to direct or cause the direction of the management and policies of such Person, whether through the ownership of voting
securities, by contract or otherwise. Without limiting the generality of the foregoing, a Person shall be deemed to control another Person if any of the following conditions is met: (i)&nbsp;in the case of corporate entities, direct or indirect
ownership of more than fifty percent (50%)&nbsp;of the stock or shares having the right to vote for the election of directors, and (ii)&nbsp;in the case of non-corporate entities, direct or indirect ownership of more than fifty percent (50%)&nbsp;of
the equity interest with the power to direct the management and policies of such non-corporate entities. For the purposes of this Agreement, in no event shall the Investor or any of its Affiliates be deemed Affiliates of the Company or any of its
Affiliates, nor shall the Company or any of its Affiliates be deemed Affiliates of the Investor or any of its Affiliates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) &#147;<B>Agreement</B>&#148; shall have the meaning set forth in the Preamble to this
Agreement, including all Exhibits attached hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) &#147;<B>beneficial owner</B>,&#148; &#147;<B>beneficially owns</B>,&#148;
&#147;<B>beneficial ownership</B>&#148; and terms of similar import used in this Agreement shall, with respect to a Person, have the meaning set forth in Rule 13d-3 under the Exchange Act (i)&nbsp;assuming the full conversion into, and exercise and
exchange for, shares of Common Stock of all Common Stock Equivalents beneficially owned by such Person and (ii)&nbsp;determined without regard for the number of days in which such Person has the right to acquire such beneficial ownership. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) &#147;<B>Business Day</B>&#148; shall mean a day other than Saturday, Sunday or any other day that is designated as a J&amp;J holiday in
the J&amp;J Universal Calendar (a copy of which for the years 2014 and 2015 is attached as Exhibit E to the Collaboration Agreement and a copy of which prior to the beginning of each such year for succeeding years shall be provided to the Company).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) &#147;<B>Change of Control</B>&#148; shall occur if: (a)&nbsp;any Third Party acquires directly or indirectly the beneficial
ownership of any voting security of the Company, or if the percentage ownership of such person or entity in the voting securities of the Company is increased through stock redemption, cancellation or other recapitalization, and immediately after
such acquisition or increase such Third Party is, directly or indirectly, the beneficial owner of voting securities representing more than fifty percent (50%)&nbsp;of the total voting power of all of the then outstanding voting securities of the
Company; (b)&nbsp;a merger, consolidation, recapitalization, or reorganization of the Company is consummated, other than any such transaction, which would result in stockholders or equity holders of the Party immediately prior to such transaction,
owning at least fifty percent (50%)&nbsp;of the outstanding securities of the surviving entity (or its parent entity) immediately following such transaction; (c)&nbsp;the stockholders or equity holders of the Company approve a plan of complete
liquidation of the Company, or an agreement for the sale or disposition by the Company of all or substantially all of the Company&#146;s assets, other than pursuant to the transaction described above or to an Affiliate; (d)&nbsp;individuals who, as
of the date hereof, constitute the Board of Directors of the Company (the &#147;<B>Incumbent Board</B>&#148;) cease for any reason to constitute at least a majority of the Board of Directors of the Company (<U>provided</U>, <U>however</U>, that any
individual becoming a director subsequent to the date hereof whose election, or nomination for election by the Company&#146;s shareholders, was recommended or approved by a vote of at least a majority of the directors then comprising the Incumbent
Board shall be considered as though such individual were a member of the Incumbent Board, but excluding, for this purpose, any such individual whose initial assumption of office occurs as a result of an actual or threatened election contest with
respect to the election or removal of directors or other actual or threatened solicitation of proxies or consents by or on behalf of any person other than the Board of Directors of the Company); or (e)&nbsp;the sale or transfer to a Third Party of
(i)&nbsp;all or substantially all of the Company&#146;s assets taken as a whole or (ii)&nbsp;a majority of the Company&#146;s assets which relate to the Collaboration Agreement, is effected. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f) &#147;<B>Closing Date</B>&#148; shall have the meaning set forth in the Purchase Agreement.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(g) &#147;<B>Collaboration Agreement</B>&#148; shall mean the Collaboration and License Agreement, of even date herewith, between the
Janssen and the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(h) &#147;<B>Common Stock</B>&#148; shall have the meaning set forth in the Preamble to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) &#147;<B>Common Stock Equivalents</B>&#148; shall mean any options, warrants or other securities or rights convertible into or
exercisable or exchangeable for, whether directly or following conversion into or exercise or exchange for other options, warrants or other securities or rights, shares of Common Stock or any swap, hedge or similar agreement or arrangement that
transfers in whole or in part, the economic risk of ownership of, or voting or other rights of, the Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(j)
&#147;<B>Company</B>&#148; shall have the meaning set forth in the Preamble to this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(k) &#147;<B>Demand Request</B>&#148;
shall have the meaning set forth in Section 2.1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(l) &#147;<B>Disposition</B>&#148; or &#147;<B>Dispose of</B>&#148; shall mean any
(i)&nbsp;pledge, sale, contract to sell, sale of any option or contract to purchase, purchase of any option or contract to sell, grant of any option, right or warrant for the sale of, or other disposition of or transfer of any shares of Common
Stock, or any Common Stock Equivalents, including, without limitation, any &#147;short sale&#148; or similar arrangement, or (ii)&nbsp;swap or any other agreement or any transaction that transfers, in whole or in part, directly or indirectly, the
economic consequence of ownership of shares of Common Stock, whether any such swap or transaction is to be settled by delivery of securities, in cash or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(m) &#147;<B>Exchange Act</B>&#148; shall mean the Securities Exchange Act of 1934, as amended, and the rules and regulations of the SEC
promulgated thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(n) &#147;<B>Existing Registration Rights Agreement</B>&#148; shall mean that certain Fifth Amended and Restated
Registration Rights Agreement dated February&nbsp;3, 2014 by and among the Company, the Founders, and the Investors (as such terms are defined therein). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(o) &#147;<B>Extraordinary Matter</B>&#148; shall have the meaning set forth in Section 5.2. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(p) &#147;<B>Filing Date</B>&#148; shall mean (i)&nbsp;with respect to any Registration
Statement to be filed on Form S-1 (or any applicable successor form), sixty (60)&nbsp;days after receipt by the Company of a Demand Request for such Registration Statement and (ii)&nbsp;with respect to any Registration Statement to be filed on Form
S-3 (or any applicable successor form), thirty (30)&nbsp;days after receipt by the Company of a Demand Request for such Registration Statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(q) &#147;<B>Governmental Authority</B>&#148; shall mean any court, agency, authority, department, regulatory body or other instrumentality
of any government or country or of any national, federal, state, provincial, regional, county, city or other political subdivision of any such government or country or any supranational organization of which any such country is a member. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(r) &#147;<B>Holders</B>&#148; shall mean (but, in each case, only for so long as such Person remains an Affiliate of the Investor) the
Investor and any Permitted Transferee thereof, if any, in accordance with Section 2.12. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(s) &#147;<B>Initiating Holder</B>&#148; shall
have the meaning set forth in Section 2.3. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(t) &#147;<B>Interference</B>&#148; shall have the meaning set forth in Section 2.5. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(u) &#147;<B>Investor</B>&#148; shall have the meaning set forth in the Preamble to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v) &#147;<B>Irrevocable Proxy</B>&#148; shall have the meaning set forth in Section 5.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(w) &#147;<B>Law</B>&#148; or &#147;<B>Laws</B>&#148; shall mean all laws, statutes, rules, regulations, orders, judgments, injunctions
and/or ordinances of any Governmental Authority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(x) &#147;<B>Lock-Up Securities</B>&#148; shall have the meaning set forth in Section
4.1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(y) &#147;<B>Lock-Up Term</B>&#148; shall mean the period from and after the date of this Agreement until the occurrence of any
event set forth in Section 6.3. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(z) &#147;<B>Modified Clause</B>&#148; shall have the meaning set forth in Section 7.7. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(aa) &#147;<B>Offeror</B>&#148; shall have the meaning set forth in Section 6.2. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(bb) &#147;<B>Other Holders</B>&#148; shall mean any Person having rights to participate in a registration of the Company&#146;s securities.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(cc) &#147;<B>Permitted Transferee</B>&#148; shall mean (i)&nbsp;a controlled Affiliate of the
Investor that is wholly owned, directly or indirectly, by the Investor, or (ii)&nbsp;a controlling Affiliate of the Investor (or any controlled Affiliate of such controlling Affiliate) that wholly owns, directly or indirectly, the Investor, or the
acquiring Person in the case of a Change of Control of the Investor; it being understood that for purposes of this definition &#147;wholly owned&#148; shall mean an Affiliate in which the Investor owns, or an Affiliate that owns, as applicable,
directly or indirectly, at least ninety-nine percent (99%)&nbsp;of the outstanding capital stock of such Affiliate or the Investor, as applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(dd) &#147;<B>Permitted Transferee Irrevocable Proxy</B>&#148; shall have the meaning set forth in Section 5.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ee) &#147;<B>Person</B>&#148; shall mean any individual, limited liability company, partnership, firm, corporation, association, trust,
unincorporated organization, government or any department or agency thereof or other entity, as well as any syndicate or group that would be deemed to be a Person under Section&nbsp;13(d)(3) of the Exchange Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ff) &#147;<B>Prospectus</B>&#148; shall mean the prospectus forming a part of any Registration Statement, as supplemented by any and all
prospectus supplements and as amended by any and all amendments (including post-effective amendments) and including all material incorporated by reference or explicitly deemed to be incorporated by reference in such prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(gg) &#147;<B>Purchase Agreement</B>&#148; shall have the meaning set forth in the Preamble to this Agreement, and shall include all Exhibits
attached thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(hh) &#147;<B>Purchased Shares</B>&#148; shall have the meaning set forth in the Preamble to this Agreement, and shall
be adjusted for (i)&nbsp;any stock split, stock dividend, share exchange, merger, consolidation or similar recapitalization and (ii)&nbsp;any Common Stock issued as (or issuable upon the exercise of any warrant, right or other security that is
issued as) a dividend or other distribution with respect to, or in exchange or in replacement of, the Purchased Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii)
&#147;<B>registers</B>,&#148; &#147;<B>registered</B>,&#148; and &#147;<B>registration</B>&#148; refer to a registration effected by preparing and filing a Registration Statement or similar document in compliance with the Securities Act, and the
declaration or ordering of effectiveness of such Registration Statement or document by the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(jj) &#147;<B>Registrable
Securities</B>&#148; shall mean (i)&nbsp;the Purchased Shares, together with any shares of Common Stock issued in respect thereof as a result of any stock split, stock dividend, share exchange, merger, consolidation or similar recapitalization and
(ii)&nbsp;any Common Stock issued as (or issuable upon the exercise of any warrant, right or other security that is issued as) a dividend or other distribution with respect to, or in exchange or in replacement of, the shares of Common Stock
described in clause (i)&nbsp;of this definition, excluding </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in all cases, however, (A)&nbsp;any Registrable Securities if and after they have been transferred to a Permitted Transferee in a transaction in connection with which registration rights granted
hereunder are not assigned, (B)&nbsp;any Registrable Securities sold to or through a broker or dealer or underwriter in a public distribution or a public securities transaction, or (C)&nbsp;if the Investor and its Affiliates together own less than
five percent (5%)&nbsp;of the Shares of Then Outstanding Common Stock, Purchased Shares eligible for resale pursuant to Rule 144(b)(1)(i) under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(kk) &#147;<B>Registration Expenses</B>&#148; shall mean all expenses incurred by the Company in connection with any Required Registration
pursuant to Section&nbsp;2.1 or the Company&#146;s compliance with Section&nbsp;2.7, including, without limitation, all registration and filing fees, fees and expenses of compliance with securities or blue sky Laws (including reasonable fees and
disbursements of counsel in connection with blue sky qualifications of any Registrable Securities), expenses of printing (i)&nbsp;certificates for any Registrable Securities in a form eligible for deposit with the Depository Trust Company or
(ii)&nbsp;Prospectuses if the printing of Prospectuses is requested by Holders, messenger and delivery expenses, fees and disbursements of counsel for the Company and its independent certified public accountants (including the expenses of any
management review, cold comfort letters or any special audits required by or incident to such performance and compliance), Securities Act liability insurance (if the Company elects to obtain such insurance), the reasonable fees and expenses of any
special experts retained by the Company in connection with such registration, fees and expenses of other Persons retained by the Company and the reasonable fees and expenses (such fees and expenses not to exceed [***] for the Holders of Registrable
Securities in each Required Registration, selected by the Holders of a majority of the Registrable Securities to be included in such Required Registration. In addition, the Company will pay its internal expenses (including, without limitation, all
salaries and expenses of its officers and employees performing legal or accounting duties), the expense of any annual audit and the fees and expenses incurred in connection with the listing of the Purchased Shares to be registered on each securities
exchange, if any, on which equity securities issued by the Company are then listed or the quotation of such securities on any national securities exchange on which equity securities issued by the Company are then quoted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ll) &#147;<B>Registration Notice</B>&#148; shall have the meaning set forth in Section 2.2 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(mm) &#147;<B>Registration Rights Term</B>&#148; shall mean the period from and after the expiration of the Lock-Up Term until the occurrence
of any event set forth in Section 6.1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(nn) &#147;<B>Registration Statement</B>&#148; shall mean any registration statement of the
Company under the Securities Act that covers any of the Registrable Securities pursuant to the provisions of this Agreement, including the related Prospectus, all amendments and supplements to such registration statement (including post-effective
amendments), and all exhibits and all materials incorporated by reference or explicitly deemed to be incorporated by reference in such Registration Statement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(oo) &#147;<B>Required Period</B>&#148; with respect to a Required Registration shall mean the
earlier of (i)&nbsp;the date on which all Registrable Securities covered by such Required Registration are sold pursuant thereto and (ii)&nbsp;[***] following the first day of effectiveness of the Registration Statement for such Required
Registration, in each case subject to extension as set forth herein; provided, however, that in no event will the Required Period expire prior to the expiration of the applicable period referred to in Section&nbsp;4(3) of the Securities Act and Rule
174 promulgated thereunder; provided, further, however, that (i)&nbsp;such [***] to the period the Holder refrains, at the request of an underwriter of Common Stock (or other securities) of the Company, from selling any securities included in such
registration, and (ii)&nbsp;in the case of any registration of Registrable Securities on Form S-3 that are intended to be offered on a continuous or delayed basis, subject to compliance with applicable SEC rules, such one hundred twenty
(120)&nbsp;day period shall be extended, if necessary, to keep the Registration Statement effective until the earlier of (A)&nbsp;such time as all such Registrable Securities registered on such Registration Statement are sold or (B)&nbsp;all such
Registrable Securities on such Registration Statement may be sold in any three month period pursuant to Rule 144. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(pp) &#147;<B>Required
Registration</B>&#148; shall have the meaning set forth in Section 2.1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(qq) &#147;<B>SEC</B>&#148; shall mean the United States
Securities and Exchange Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(rr) &#147;<B>Securities Act</B>&#148; shall mean the Securities Act of 1933, as amended, and the
rules and regulations of the SEC promulgated thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ss) &#147;<B>Selling Expenses</B>&#148; shall mean all underwriting discounts
and selling commissions applicable to the sale of Registrable Securities pursuant to this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(tt) &#147;<B>Shares of Then
Outstanding Common Stock</B>&#148; shall mean, at any time, the issued and outstanding shares of Common Stock at such time, as well as all capital stock issued and outstanding as a result of any stock split, stock dividend, or reclassification of
Common Stock distributable, on a pro rata basis, to all holders of Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(uu) &#147;<B>Standstill Parties</B>&#148; shall have
the meaning set forth in Section 3.1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vv) &#147;<B>Standstill Term</B>&#148; shall mean the period from and after the date of this
Agreement until the occurrence of any event set forth in Section&nbsp;6.2. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ww) &#147;<B>Third Party</B>&#148; shall mean any Person
(other than a Governmental Authority) other than the Investor, the Company or any of their respective Affiliates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xx) &#147;<B>Underwritten Registration</B>&#148; or &#147;<B>Underwritten Offering</B>&#148;
shall mean a registration in which Registrable Securities are sold to an underwriter for reoffering to the public. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(yy)
&#147;<B>Violation</B>&#148; shall have the meaning set forth in Section 2.10(a). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(zz) &#147;<B>Voting Agreement Term</B>&#148; shall
mean the period from and after the date of this Agreement until the occurrence of any event set forth in Section&nbsp;6.4. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.
<U>Registration Rights</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">2.1 <U>Required Registration</U>. If, during the Registration Rights Term, the Company receives from any
Holder or Holders a written request or requests (each, a &#147;<B>Demand Request</B>&#148;) that the Company file a Registration Statement under the Securities Act to effect the registration (a &#147;<B>Required Registration</B>&#148;) of
Registrable Securities, the Company shall use all reasonable efforts to file a Registration Statement covering such Holders&#146; Registrable Securities as soon as practicable (and by the applicable Filing Date) and shall use all reasonable efforts
to, as soon as practicable thereafter, effect the registration of the Registrable Securities to permit or facilitate the sale and distribution in an Underwritten Offering of all or such portion of such Holder&#146;s or Holders&#146; Registrable
Securities as are specified in such Demand Request, subject however, to the conditions and limitations set forth herein; <U>provided</U>, <U>however</U>, that the Company shall not be obligated to effect any registration of Registrable Securities
upon receipt of a Demand Request pursuant to this Section&nbsp;2.1 if: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) [***]; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) (i) in the event that the market value of all Registrable Securities outstanding is equal to or greater than [***], the market value of
the Registrable Securities proposed to be included in the registration, based on the average closing price during the [***] consecutive trading days period prior to the making of the Demand Request, is less than [***] or (ii)&nbsp;in the event that
the market value of all Registrable Securities outstanding is less than [***], the market value of the Registrable Securities proposed to be included in the registration, based on the average closing price during the ten (10)&nbsp;consecutive
trading days period prior to the making of the Demand Request, is less than the lesser of (x)&nbsp;[***] or (y)&nbsp;the total market value of Registrable Securities outstanding; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) the Company furnishes to the Holders a certificate signed by an authorized officer of the Company stating that (i)&nbsp;within sixty
(60)&nbsp;days of receipt of the Demand Request under this Section&nbsp;2.1, the Company expects to file a registration statement for the public offering of securities for the account of the Company (other than a registration of securities
(x)&nbsp;issuable pursuant to an employee stock option, stock purchase or similar plan, (y)&nbsp;issuable pursuant to a merger, exchange offer or a transaction of the type specified in Rule 145(a) under the Securities Act or (z)&nbsp;in which the
only securities being registered are securities </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
issuable upon conversion of debt securities which are also being registered), provided, that the Company is actively employing good faith efforts to cause such registration statement to become
effective, or (ii)&nbsp;the Company is engaged in a material transaction or has an undisclosed material corporate development, in either case, which would be required to be disclosed in the Registration Statement, and in the good faith judgment of
the Company&#146;s Board of Directors, such disclosure would be materially detrimental to the Company and its stockholders at such time (in which case, the Company shall disclose the matter as promptly as reasonably practicable and thereafter file
the Registration Statement, and each Holder agrees not to disclose any information about such material transaction to Third Parties until such disclosure has occurred or such information has entered the public domain other than through breach of
this provision by such Holder), provided, however, that the Company shall have the right to only defer the filing of the Registration Statement pursuant to this subsection [***] in any twelve (12)&nbsp;month period and, such deferral may not exceed
a period of more than one hundred and twenty (120)&nbsp;days after receipt of a Demand Request; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) the Company has, within the twelve
(12)&nbsp;month period preceding the date of the Demand Request, already effected one (1)&nbsp;Required Registration for any Holder pursuant to this Section&nbsp;2.1; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) at any time during the period between the Company&#146;s receipt of the Demand Request and the completion of the Required Registration,
any Holder is in breach of or has failed to cause its Affiliates to comply with the obligations and restrictions of Sections 3, 4 or 5 of this Agreement, the Company has provided notice of such breach to a Holder and such breach or failure is
ongoing and has not been remedied; it being understood that (i)&nbsp;a one-time, inadvertent and de minimis breach of Section&nbsp;4 shall not be deemed to be a breach of the obligations and restrictions under Section&nbsp;4 for purposes of this
Section&nbsp;2.1(e) and (ii)&nbsp;a de minimis breach of Section&nbsp;3.1(a) hereof, or an inadvertent breach of Section&nbsp;3.1(g) hereof arising from informal discussions covering general corporate or other business matters the purpose of which
is not intended to effectuate or lead to any of the actions referred to in paragraphs (a)&nbsp;through (e)&nbsp;of Section&nbsp;3.1, shall not be deemed to be a breach of the obligations and restrictions under Section&nbsp;3.1 for purposes of this
Section&nbsp;2.1(e). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">2.2 <U>Company Registration</U>. Effective from the expiration of the Lock-Up Term until the [***] of such
expiration, the Company shall notify the Holders in writing at least ten (10)&nbsp;business days prior to the filing of any registration statement (other than the Company&#146;s existing registration statement on Form S-3, SEC File
No.&nbsp;333-200092 and any related Prospectus, amendments or supplements thereto) (&#147;<B>Registration Notice</B>&#148;) and will afford each Holder an opportunity, subject to the terms and conditions of this Agreement, to include in such
registration statement the number of Registrable Securities then held by such Holder that such Holder wishes to include in such registration statement. Each Holder desiring to include in any such registration statement all or any part of the
Registrable Securities held by such Holder shall, within five (5)&nbsp;business days after receipt of the Registration Notice, so notify the Company in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
writing, and in such notification, inform the Company of the number of Registrable Securities such Holder wishes to include in such registration statement. If a Holder decides not to include
Registrable Securities in any registration statement thereafter filed by the Company, such Holder shall nevertheless continue to have the right to include Registrable Securities in any subsequent registration statement or registration statements as
may be filed by the Company with respect to offerings of its securities (either by the Company or by its stockholders), all upon the terms and conditions set forth herein. Each Holder shall keep confidential and not disclose to any third party
(i)&nbsp;its receipt of any Registration Notice and (ii)&nbsp;any information regarding the proposed offering as to which such notice is delivered, except as required by law, regulation or as compelled by subpoena. If a registration pursuant to this
Section&nbsp;2.2 is an Underwritten Offering, the right of any such Holder to include Registrable Securities in such registration shall be conditioned upon such Holder&#146;s participation in such underwriting and the inclusion of such Holder&#146;s
Registrable Securities in the underwriting to the extent provided herein. The Company and all Holders proposing to distribute their Registrable Securities through such underwriting shall enter into an underwriting agreement in customary form with
the managing underwriter or underwriters selected for such underwriting. Notwithstanding any other provision of this Section&nbsp;2 and subject to the prior rights of the parties to the Existing Registration Rights Agreement, if the managing
underwriter for the Underwritten Offering determines in good faith that marketing factors require a limitation of the number of shares of Registrable Securities to be included in such Underwritten Offering and advises the Holders of such
determination in writing, such Underwritten Offering shall include (i)&nbsp;first, the shares held by the parties to the Existing Registration Rights Agreement, (ii)&nbsp;second, all Registrable Securities of the Holders allocated, if the amount is
less than all the Registrable Securities requested to be sold, <I>pro rata</I> on the basis of the total number of Registrable Securities held by such Holders; and (ii)&nbsp;third, as many other securities proposed to be included in the Underwritten
Offering by the Company and any Other Holders, allocated <I>pro rata</I> among the Company and such Other Holders, on the basis of the amount of securities requested to be included therein by the Company and each such Other Holder so that the total
amount of securities to be included in such Underwritten Offering is the full amount that, in the written opinion of such managing underwriter, can be sold without materially and adversely affecting the success of such Underwritten Offering.
Notwithstanding the foregoing, the Company shall have the right to terminate or withdraw any registration initiated by it under this Section&nbsp;2.2 prior to the effectiveness of such registration whether or not any Holder has elected to include
securities in such registration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">2.3 <U>Underwritten Registration; Priority in Underwritten Offering</U>. If, pursuant to
Section&nbsp;2.1, the Holders intend to distribute the Registrable Securities covered by their request by means of an underwriting, the Holders shall so advise the Company as a part of their request made pursuant to Section&nbsp;2.1. The
underwriter(s) will be selected by the Company, subject to approval by a majority in interest of the Holders initiating the Required Registration hereunder (such Holder(s) initiating the registration request, the &#147;<B>Initiating
Holders</B>&#148;), which approval shall not be unreasonably withheld or delayed. With respect to any Required Registration of Registrable Securities requested pursuant to Section&nbsp;2.1 that is an Underwritten Offering, the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Company may also (i)&nbsp;propose to sell shares of Common Stock on its own behalf and (ii)&nbsp;provide written notice of such Required Registration to Other Holders (including, without
limitation the parties to the Existing Registration Rights Agreement) and permit all such Other Holders who request to be included in the Required Registration to include any or all Company securities held by such Other Holders in such Required
Registration on the same terms and conditions as the Registrable Securities. If a registration pursuant to Section&nbsp;2.1 is an Underwritten Offering, the right of any Holder to include its Registrable Securities in the Underwritten Offering shall
be conditioned upon such Holder&#146;s participation in such Underwritten Offering and the inclusion of such Holder&#146;s Registrable Securities to the extent provided herein. All Holders requesting the inclusion of their Registrable Securities in
such Underwritten Offering shall (together with the Company as provided in Section&nbsp;2.7(h)) enter into an underwriting agreement in customary form with the underwriter or underwriters selected for such Underwritten Offering. Notwithstanding any
other provision of this Section&nbsp;2 and subject to the prior rights of the parties to the Existing Registration Rights Agreement, if the managing underwriter for such Underwritten Offering determines in good faith that marketing factors require a
limitation of the number of shares of Registrable Securities to be included in such Underwritten Offering and advises the Initiating Holders of such determination in writing, then the Company shall so advise all Holders which requested inclusion of
their Registrable Securities in such Underwritten Offering, and such Underwritten Offering shall include (i)&nbsp;first, the shares held by the parties to the Existing Registration Rights Agreement, (ii)&nbsp;second, all Registrable Securities of
the Holders allocated, if the amount is less than all the Registrable Securities requested to be sold, <I>pro rata</I> on the basis of the total number of Registrable Securities held by such Holders; and (ii)&nbsp;third, as many other securities
proposed to be included in the Underwritten Offering by the Company and any Other Holders, allocated <I>pro rata</I> among the Company and such Other Holders, on the basis of the amount of securities requested to be included therein by the Company
and each such Other Holder so that the total amount of securities to be included in such Underwritten Offering is the full amount that, in the written opinion of such managing underwriter, can be sold without materially and adversely affecting the
success of such Underwritten Offering; provided, however, that the number of shares of Registrable Securities to be included in such Underwritten Offering shall not be reduced unless all other securities (other than those held by the parties to the
Existing Registration Rights Agreement) are first entirely excluded from such Underwritten Offering. In the event the Company advises the Holders of its intent to decrease the total number of Registrable Securities that may be included by the
Holders in such Required Registration such that the number of Registrable Securities included in such Required Registration would be less than [***] of all Registrable Securities which the Holders requested be included in such Required Registration,
then Holders representing a majority of the Registrable Securities requested to be included in such Required Registration will have the right to withdraw, on behalf of all Holders of all Registrable Securities requested to be so included, such
Required Registration, in which case, such Required Registration will not count as a Required Registration for the purposes of Section&nbsp;2.1(a), and the Company shall bear all Registration Expenses in connection therewith; <U>provided</U>,
<U>that</U>, the right to withdraw a registration and have it not count as a Required Registration may only be exercised once by the Holders (taken collectively). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">2.4 <U>Revocation of Required Registration</U>. With respect to one (1)&nbsp;Required
Registration only, the Holders of at least a majority of the Registrable Securities to be included in a Registration Statement with respect to such Required Registration may, at any time prior to the effective date of such Registration Statement, on
behalf of all Holders of all Registrable Securities requested to be included therein, revoke the request to have Registrable Securities included therein and revoke the request for such Required Registration by providing a written notice to the
Company, in which case such Required Registration that has been revoked will be deemed not to have been effected and will not count as a Required Registration for purposes of Section&nbsp;2.1(i) if, and only if, the Holders of Registrable Securities
which had requested inclusion of Registrable Securities in such Required Registration promptly reimburse the Company for all Registration Expenses incurred by the Company in connection with such Required Registration. Notwithstanding the foregoing
sentence, the parties agree and acknowledge that the Holders may revoke any Required Registration (without any obligation to reimburse the Company for Registration Expenses incurred in connection therewith) if such revocation is based on (i)&nbsp;a
material adverse change in circumstances with respect to the Company and its subsidiaries, taken as a whole, caused by an act or failure to act by the Company or any of its subsidiaries and not known to any Holder at the time the Required
Registration was first made or (ii)&nbsp;the Company&#146;s failure to comply in any material respect with its obligations hereunder, and any such revocation based on an event described in (i)&nbsp;or (ii)&nbsp;above shall be exercisable at any time
and shall not be counted as the one (1)&nbsp;revocation of a Required Registration permitted by the first sentence of this Section&nbsp;2.4. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">2.5 <U>Effective Required Registrations</U>. A Required Registration will not be deemed to be effected for purposes of Section&nbsp;2.1(a) if
the Registration Statement for such Required Registration has (a)&nbsp;not been declared effective by the SEC or (b)&nbsp;become effective in accordance with the Securities Act and the rules and regulations thereunder and not been kept effective for
the Required Period. In addition, if after such Registration Statement has been declared or becomes effective, (i)&nbsp;the offering of Registrable Securities pursuant to such Registration Statement is interfered with by any stop order, injunction,
or other order or requirement of the SEC or other governmental agency or court such that the continued offer and sale of Registrable Securities being offered pursuant to such Registration Statement would violate applicable Law and such stop order,
injunction or other order or requirement of the SEC or other governmental agency or court does not result from any act or omission of any Holder whose Registrable Securities are registered pursuant to such Registration Statement (an
&#147;<B>Interference</B>&#148;) and (ii)&nbsp;any such Interference is not cured within sixty (60)&nbsp;days thereof, such Required Registration will be deemed not to have been effected and will not count as a Required Registration. In the event
such Interference occurs and is cured, the Required Period relating to such Registration Statement will be extended by the number of days of such Interference, including the date such Interference is cured. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">2.6 <U>Continuous Effectiveness of Registration Statement</U>. The Company will use all
reasonable efforts to cause each Registration Statement filed pursuant to this Section&nbsp;2 to be declared effective by the SEC or to become effective under the Securities Act as promptly as practicable and to keep each such Registration Statement
that has been declared or becomes effective continuously effective for the Required Period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">2.7 <U>Obligations of the Company</U>.
Whenever required under Section&nbsp;2.1 to effect the registration of any Registrable Securities, the Company shall, as expeditiously as reasonably possible: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) prepare and file with the SEC a Registration Statement with respect to such Registrable Securities sought to be included therein;
provided that at least five (5)&nbsp;Business Days prior to filing any Registration Statement or Prospectus or any amendments or supplements thereto, the Company shall furnish to the Holders of the Registrable Securities covered by such Registration
Statement, their counsel and the managing underwriter copies of all such documents proposed to be filed, and any such Holder shall have the opportunity to comment on any information pertaining solely to such Holder and its plan of distribution that
is contained therein and the Company shall make the corrections reasonably requested by such Holder or the managing underwriter with respect to such information prior to filing any such Registration Statement or amendment; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) prepare and file with the SEC such amendments and post-effective amendments to any Registration Statement and any Prospectus used in
connection therewith as may be necessary to keep such Registration Statement effective for the Required Period, and cause the Prospectus to be supplemented by any required prospectus supplement, and as so supplemented to be filed pursuant to Rule
424 under the Securities Act, to comply with the provisions of the Securities Act with respect to the disposition of all Registrable Securities covered by such registration statement for the Required Period; provided that at least five
(5)&nbsp;Business Days prior to filing any such amendments and post effective amendments or supplements thereto, the Company shall furnish to the Holders of the Registrable Securities covered by such Registration Statement, their counsel and the
managing underwriter copies of all such documents proposed to be filed, and any such Holder or managing underwriter shall have the opportunity to comment on any information pertaining solely to such Holder and its plan of distribution that is
contained therein and the Company shall make the corrections reasonably requested by such Holder and the managing underwriter with respect to such information prior to filing any such Registration Statement or amendment; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) furnish to the Holders of Registrable Securities covered by such Registration Statement and the managing underwriter such numbers of
copies of such Registration Statement, each amendment and supplement thereto, the Prospectus included in such Registration Statement (including each preliminary prospectus or free writing prospectus) in conformity with the requirements of the
Securities Act, and such other documents as they may reasonably request in order to facilitate the disposition of Registrable Securities owned by them; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) notify the Holders of Registrable Securities covered by such Registration Statement,
promptly after the Company shall receive notice thereof, of the time when such Registration Statement becomes or is declared effective or when any amendment or supplement or any Prospectus forming a part of such Registration Statement has been
filed; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) notify the Holders of Registrable Securities covered by such Registration Statement promptly of any request by the SEC for
the amending or supplementing of such Registration Statement or Prospectus or for additional information and promptly deliver to such Holders copies of any comments received from the SEC; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f) notify the Holders promptly of any stop order suspending the effectiveness of such Registration Statement or Prospectus or the initiation
of any proceedings for that purpose, and use all reasonable efforts to obtain the withdrawal of any such order or the termination of such proceedings; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(g) use all reasonable efforts to register and qualify the Registrable Securities covered by such Registration Statement under such other
securities or blue sky Laws of such jurisdictions as shall be reasonably requested by the Holders, use all reasonable efforts to keep each such registration or qualification effective, including through new filings, or amendments or renewals, during
the Required Period, and notify the Holders of Registrable Securities covered by such Registration Statement of the receipt of any written notification with respect to any suspension of any such qualification; <U>provided</U>, <U>however</U>, that
the Company shall not be required in connection therewith or as a condition thereto to qualify to do business or to file a general consent to service of process in any such states or jurisdictions, unless the Company is already subject to service in
such jurisdiction and except as may be required by the Securities Act; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(h) in the event of any Underwritten Offering, enter into and
perform its obligations under an underwriting agreement, in usual and customary form, with the managing underwriter of the Underwritten Offering pursuant to which such Registrable Securities are being offered; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) use all reasonable efforts to obtain: (A)&nbsp;at the time of effectiveness of the Registration Statement covering such Registrable
Securities, a &#147;cold comfort letter&#148; from the Company&#146;s independent certified public accountants covering such matters of the type customarily covered by &#147;cold comfort letters&#148; as the underwriters may reasonably request; and
(B)&nbsp;at the time of any underwritten sale pursuant to such Registration Statement, a &#147;bring-down comfort letter,&#148; dated as of the date of such sale, from the Company&#146;s independent certified public accountants covering such matters
of the type customarily covered by &#147;bring-down comfort letters&#148; as the underwriters may reasonably request. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(j) promptly notify each Holder of Registrable Securities covered by such Registration Statement
at any time when a Prospectus relating thereto is required to be delivered under the Securities Act of the happening of any event as a result of which the Prospectus included in such Registration Statement or any offering memorandum or other
offering document includes an untrue statement of a material fact or omits to state any material fact required to be stated therein or necessary to make the statements therein not misleading in the light of the circumstances then existing, and
promptly prepare a supplement or amendment to such Prospectus or file any other required document so that, as thereafter delivered to the purchasers of such Registrable Securities, such Prospectus will not contain an untrue statement of material
fact or omit to state any fact necessary to make the statements therein not misleading; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(k) permit any Holder of Registrable Securities
covered by such Registration Statement, which Holder in its reasonable judgment could reasonably be deemed to be an underwriter with respect to the Underwritten Offering pursuant to which such Registrable Securities are being offered, or to be a
controlling Person of the Company, to reasonably participate in the preparation of such Registration Statement and to require the insertion therein of information to the extent concerning such Holder, furnished to the Company in writing, which in
the reasonable judgment of such Holder and its counsel should be included; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(l) in connection with any Underwritten Offering, use all
reasonable efforts to obtain an opinion or opinions addressed to the underwriter or underwriters in customary form and scope from counsel for the Company; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(m) upon reasonable notice and during normal business hours, subject to the Company receiving customary confidentiality undertakings or
agreements from any Holder of Registrable Securities covered by such Registration Statement or other person obtaining access to Company records, documents, properties or other information pursuant to this subsection (m), make available for
inspection by a representative of such Holder and any underwriter participating in any disposition of such Registrable Securities and any attorneys or accountants retained by any such Holder or underwriter, relevant financial and other records,
pertinent corporate documents and properties of the Company, and use all reasonable efforts to cause the officers, directors and employees of the Company to supply all information reasonably requested by any such representative, underwriter,
attorneys or accountants in connection with the Registration Statement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(n) with respect to one (1)&nbsp;Required Registration which
includes Registrable Securities the market value of which is at least [***], participate, to the extent requested by the managing underwriter, in efforts extending for no more than three (3)&nbsp;days scheduled by such managing underwriter and
reasonably acceptable to the Company&#146;s senior management, to sell the Registrable Securities being offered pursuant to such Required Registration (including participating during such period in customary &#147;roadshow&#148; meetings with
prospective investors); </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(o) use all reasonable efforts to comply with all applicable rules and regulations of the SEC
relating to such registration and make generally available to its security holders earning statements satisfying the provisions of Section&nbsp;11(a) of the Securities Act, provided that the Company will be deemed to have complied with this
Section&nbsp;2.7(o) with respect to such earning statements if it has satisfied the provisions of Rule 158; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(p) if requested by the
managing underwriter or any selling Holder, promptly incorporate in a prospectus supplement or post-effective amendment such information as the managing underwriter or any selling Holder reasonably requests to be included therein, with respect to
the Registrable Securities being sold by such selling Holder, including, without limitation, the purchase price being paid therefor by the underwriters and with respect to any other terms of the Underwritten Offering of Registrable Securities to be
sold in such offering, and promptly make all required filings of such prospectus supplement or post-effective amendment; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(q) cause the
Registrable Securities covered by such Registration Statement to be listed on each securities exchange, if any, on which equity securities issued by the Company are then listed; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(r) reasonably cooperate with each selling Holder and each underwriter participating in the disposition of such Registrable Securities and
their respective counsel in connection with filings required to be made with the Financial Industry Regulatory Authority, Inc., if any. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">2.8 <U>Furnish Information</U>. It shall be a condition precedent to the obligations of the Company to take any action pursuant to this
Section&nbsp;2 with respect to the Registrable Securities of any selling Holder that such Holder shall furnish to the Company such information regarding itself and the Registrable Securities held by it as shall be reasonably necessary to effect the
registration of such Holder&#146;s Registrable Securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">2.9 <U>Expenses</U>. Except as specifically provided herein, all Registration
Expenses shall be borne by the Company. All Selling Expenses incurred in connection with any registration hereunder shall be borne by the Holders of Registrable Securities covered by a Registration Statement, pro rata on the basis of the number of
Registrable Securities registered on their behalf in such Registration Statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">2.10<U> Indemnification.</U> In the event any
Registrable Securities are included in a Registration Statement under this Agreement: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) The Company shall indemnify and hold harmless
each Holder including Registrable Securities in any such Registration Statement, any underwriter (as defined in the Securities Act) for such Holder and each Person, if any, who controls such Holder or underwriter within the meaning of
Section&nbsp;15 of the Securities Act or Section&nbsp;20 of Exchange Act and the officers, directors, owners, agents and employees of such controlling Persons, against any and all losses, claims, damages or liabilities (joint or several) to which
they may </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
become subject under any securities Laws including, without limitation, the Securities Act, the Exchange Act, or any other statute or common law of the United States or any other country or
political subdivision thereof, or otherwise, including the amount paid in settlement of any litigation commenced or threatened (including any amounts paid pursuant to or in settlement of claims made under the indemnification or contribution
provisions of any underwriting or similar agreement entered into by such Holder in connection with any offering or sale of securities covered by this Agreement), and shall promptly reimburse them, as and when incurred, for any legal or other
expenses incurred by them in connection with investigating any claims and defending any actions, insofar as any such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon any of the following
statements, omissions or violations (each, a &#147;<B>Violation</B>&#148;): (i)&nbsp;any untrue statement or alleged untrue statement of a material fact contained in or incorporated by reference into such Registration Statement, including any
preliminary prospectus or final prospectus contained therein or any free writing prospectus or any amendments or supplements thereto, or in any offering memorandum or other offering document relating to the offering and sale of such securities,
(ii)&nbsp;the omission or alleged omission to state therein a material fact required to be stated therein, or necessary to make the statements therein not misleading or (iii)&nbsp;any violation or alleged violation by the Company (or any of its
agents or Affiliates) of the Securities Act, the Exchange Act, any state securities Law, or any rule or regulation promulgated under any state securities Law; <U>provided</U>, <U>however</U>, the Company shall not be liable in any such case for any
such loss, claim, damage, liability or action to the extent that it (A)&nbsp;arises out of or is based upon a Violation which occurs solely in reliance upon and in conformity with written information furnished expressly for use in connection with
such registration by such Holder; or (B)&nbsp;is caused by such Holder&#146;s disposition of Registrable Securities during any period during which such Holder is obligated to discontinue any disposition of Registrable Securities as a result of any
stop order suspending the effectiveness of any registration statement or prospectus with respect to Registrable Securities of which such Holder has received written notice. The Company shall pay, as incurred, any legal or other expenses reasonably
incurred by any Person intended to be indemnified pursuant to this Section&nbsp;2.10(a), in connection with investigating or defending any such loss, claim, damage, liability or action; <U>provided</U>, <U>however</U>, that the indemnity agreement
contained in this Section&nbsp;2.10(a) shall not apply to amounts paid in settlement of any such loss, claim, damage, liability or action if such settlement is effected without consent of the Company, which consent shall not be unreasonably
withheld. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) Each Holder including Registrable Securities in a registration statement shall indemnify and hold harmless the Company,
each of its directors, each of its officers who has signed the registration statement, each Person, if any, who controls the Company within the meaning of Section&nbsp;15 of the Securities Act or Section&nbsp;20 of the Exchange Act and the officers,
directors, owners, agents and employees of such controlling Persons, any underwriter, any other Holder selling securities in such registration statement and any controlling Person of any such underwriter or other Holder, against any losses, claims,
damages or liabilities (joint or several) to which any of the foregoing Persons may become subject, under liabilities (or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
actions in respect thereto) which arise out of or are based upon any Violation, in each case to the extent (and only to the extent) that such Violation: (i)&nbsp;arises out of or is based upon a
Violation which occurs solely in reliance upon and in conformity with written information furnished expressly for use in connection with such registration by such Holder; or (ii)&nbsp;is caused by such Holder&#146;s disposition of Registrable
Securities during any period during which such Holder is obligated to discontinue any disposition of Registrable Securities as a result of any stop order suspending the effectiveness of any registration statement or prospectus with respect to
Registrable Securities of which such Holder has received written notice. Each such Holder shall pay, as incurred, any legal or other expenses reasonably incurred by any Person intended to be indemnified pursuant to this Section&nbsp;2.10(b), in
connection with investigating or defending any such loss, claim, damage, liability or action; <U>provided</U>, <U>however</U>, that the indemnity agreement contained in this Section&nbsp;2.10(b) shall not apply to amounts paid in settlement of any
such loss, claim, damage, liability or action if such settlement is effected without consent of the Holder, which consent shall not be unreasonably withheld. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) Promptly after receipt by an indemnified party under this Section&nbsp;2.10 of notice of the commencement of any action (including any
action by a Governmental Authority), such indemnified party shall, if a claim in respect thereof is to be made against any indemnifying party under this Section&nbsp;2.10, deliver to the indemnifying party a written notice of the commencement
thereof and the indemnifying party shall have the right to participate in, and, to the extent the indemnifying party so desires, jointly with any other indemnifying party similarly noticed, to assume the defense thereof with counsel mutually
satisfactory to the parties; <U>provided</U>, <U>however</U>, that an indemnified party (together with all other indemnified parties that may be represented without conflict by one counsel) shall have the right to retain its own counsel, with the
reasonable fees and expenses to be paid by the indemnifying party, if representation of such indemnified party by the counsel retained by the indemnifying party would be inappropriate due to actual or potential differing interests between such
indemnified party and any other party represented by such counsel in such proceeding. The failure to deliver written notice to the indemnifying party within a reasonable time of the commencement of any such action, if prejudicial to its ability to
defend such action, shall relieve such indemnifying party of any liability to the indemnified party under this Section&nbsp;2.10, but the omission so to deliver written notice to the indemnifying party shall not relieve it of any liability that it
may have to any indemnified party otherwise than under this Section&nbsp;2.10. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) In order to provide for just and equitable
contribution to joint liability in any case in which a claim for indemnification is made pursuant to this Section&nbsp;2.10 but it is judicially determined (by the entry of a final judgment or decree by a court of competent jurisdiction and the
expiration of time to appeal or the denial of the last right of appeal) that such indemnification may not be enforced in such case notwithstanding the fact that this Section&nbsp;2.10 provided for indemnification in such case, the Company and each
Holder of Registrable Securities shall contribute to the aggregate losses, claims, damages or liabilities to which they may be subject (after contribution from others) in proportion to the relative fault of the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Company, on the one hand, and such Holder, severally, on the other hand; <U>provided</U>, <U>however</U>, that in any such case, no Person guilty of fraudulent misrepresentation (within the
meaning of Section&nbsp;11(f) of the Securities Act) shall be entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation; <U>provided</U> <U>further</U>, <U>however</U>, that in no event shall any contribution
under this Section&nbsp;2.10(d) on the part of any Holder exceed the net proceeds received by such Holder from the sale of Registrable Securities giving rise to such contribution obligation, except in the case of willful misconduct or fraud by such
Holder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) The obligations of the Company and the Holders under this Section&nbsp;2.10 shall survive the completion of any offering of
Registrable Securities in a registration statement under this Agreement and otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">2.11 <U>SEC Reports</U>. With a view to making
available to the Holders the benefits of Rule 144 under the Securities Act and any other rule or regulation of the SEC that may at any time permit a Holder to sell Registrable Securities of the Company to the public without registration or pursuant
to a registration on Form S-3, for so long as any Holder owns Purchased Shares, the Company agrees to: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) make and keep available
adequate current public information, as those terms are understood and defined in SEC Rule 144; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) furnish to any Holder, forthwith
upon request (i)&nbsp;a written statement by the Company that it has complied with the reporting requirements of Rule 144, (ii)&nbsp;a copy of the most recent annual or quarterly report of the Company and such other reports and documents so filed by
the Company, and (iii)&nbsp;such other information as may be reasonably requested in availing any Holder of any rule or regulation of the SEC (exclusive of Rule 144A) which permits the selling of any Purchased Shares without registration or pursuant
to Form S-3. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">2.12 <U>Assignment of Registration Rights</U>. The rights to cause the Company to register any Registrable Securities
pursuant to this Agreement may be assigned in whole or in part (but only with all restrictions and obligations set forth in this Agreement) by a Holder to a Permitted Transferee which acquires at least 100,000 Registrable Securities (subject to
adjustment in the event of any stock split, stock dividend, share exchange, merger, consolidation or similar recapitalization) from such Holder ; <U>provided</U>, <U>however</U>, (a)&nbsp;such Holder shall, within five (5)&nbsp;days prior to such
transfer, furnish to the Company written notice of the name and address of such Permitted Transferee, details of its status as a Permitted Transferee and details of the Registrable Securities with respect to which such registration rights are being
assigned, (b)&nbsp;the Permitted Transferee, prior to or simultaneously with such transfer or assignment, shall agree in writing to be subject to and bound by all restrictions and obligations set forth in this Agreement, (c)&nbsp;the Investor shall
continue to be bound by all restrictions and obligations set forth in this Agreement and (d)&nbsp;such transfer or assignment shall be effective only if immediately following such transfer or assignment the further disposition of such Registrable
Securities by the Permitted Transferee is restricted under the Securities Act and other applicable securities Law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Restrictions on Beneficial Ownership</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">3.1 <U>Standstill</U>. During the Standstill Term neither the Investor nor any of its Affiliates (collectively, the &#147;<B>Standstill
Parties</B>&#148;) shall (and the Investor shall cause its Affiliates not to), except as expressly approved or invited in writing by the Company: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) directly or indirectly, acquire beneficial ownership of Shares of Then Outstanding Common Stock and/or Common Stock Equivalents, or make
a tender, exchange or other offer to acquire Shares of Then Outstanding Common Stock and/or Common Stock Equivalents; <U>provided</U>, <U>however</U>, that notwithstanding the provisions of this Section&nbsp;3.1(a), if the number of shares
constituting Shares of Then Outstanding Common Stock is reduced or if the aggregate ownership of the Standstill Parties is increased as a result of (i)&nbsp;the participation in any offering by the Company of any securities offered pro-rata to all
stockholders of the Company or (ii)&nbsp;a repurchase by the Company of Shares of Then Outstanding Common Stock, stock split, stock dividend or a recapitalization of the Company, the Standstill Parties shall not be required to dispose of any of
their holdings of Shares of Then Outstanding Common Stock even though such action resulted in the Standstill Parties&#146; beneficial ownership increasing; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) directly or indirectly, seek to have called any meeting of the stockholders of the Company, propose or nominate for election to the
Company&#146;s Board of Directors any person whose nomination has not been approved by a majority of the Company&#146;s Board of Directors or cause to be voted in favor of such person for election to the Company&#146;s Board of Directors any Shares
of Then Outstanding Common Stock; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) directly or indirectly, solicit proxies or consents or become a participant in a solicitation (as
such terms are defined in Regulation 14A under the Exchange Act) in opposition to the recommendation of a majority of the Company&#146;s Board of Directors with respect to any matter, or seek to advise or influence any Person, with respect to voting
of any Shares of Then Outstanding Common Stock of the Company; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) deposit any Shares of Then Outstanding Common Stock in a voting trust
or subject any Shares of Then Outstanding Common Stock to any arrangement or agreement with respect to the voting of such Shares of Then Outstanding Common Stock; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) publicly propose (i)&nbsp;any merger, consolidation, business combination, tender or exchange offer, purchase of the Company&#146;s
assets or businesses, or similar transaction involving the Company or (ii)&nbsp;any recapitalization, restructuring, liquidation or other extraordinary transaction with respect to the Company; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f) act in concert with any Third Party to take any action in clauses (a)&nbsp;through
(e)&nbsp;above, or form, join or in any way participate in a &#147;partnership, limited partnership, syndicate, or other group&#148; within the meaning of Section&nbsp;13(d)(3) of the Exchange Act; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(g) enter into discussions, negotiations, arrangements or agreements with any Person relating to the foregoing actions referred to in
(a)&nbsp;through (e)&nbsp;above; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>provided</U>, <U>however</U>, that [***]would reasonably be expected to require the Company or any third party to be
required to [***]or any Affiliate may [***]of the Company [***]by the Investor or its Affiliates shall [***] nothing in the foregoing clause [***]and not pursuant to the [***]of the Company and its stockholders, and [***]Shares of Then Outstanding
Common Stock and/or Common Stock Equivalents. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Restrictions on Dispositions</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">4.1 <U>Lock-Up</U>. During the Lock-Up Term, without the prior approval of the Company, the Investor shall not, and shall cause its Affiliates
not to, Dispose of (x)&nbsp;any of the Purchased Shares, together with any shares of Common Stock issued in respect thereof as a result of any stock split, stock dividend, share exchange, merger, consolidation or similar recapitalization, and
(y)&nbsp;any Common Stock issued as (or issuable upon the exercise of any warrant, right or other security that is issued as) a dividend or other distribution with respect to, or in exchange or in replacement of, the shares of Common Stock described
in clause (x)&nbsp;of this sentence (collectively, the &#147;<B>Lock-Up Securities</B>&#148;); <U>provided</U>, <U>however</U>, that the foregoing shall not prohibit the Investor from (A)&nbsp;transferring Lock-Up Securities to a Permitted
Transferee or (B)&nbsp;Disposing of any Lock-Up Securities in order to reduce the beneficial ownership of the Standstill Parties to 19.9%, or such lesser percentage as advised in good faith and in writing by the Investor&#146;s certified public
accountants that would not require the Investor to include in its financial statements its portion of the Company&#146;s financial results, of the Shares of Then Outstanding Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">4.2 <U>Certain Tender Offers</U>. Notwithstanding any other provision of this Section&nbsp;4, this Section&nbsp;4 shall not prohibit or
restrict any Disposition of Shares of Then Outstanding Common Stock and/or Common Stock Equivalents by the Standstill Parties into (a)&nbsp;a tender offer by a Third Party which is not opposed by the Company&#146;s Board of Directors (but only after
the Company&#146;s filing of a Schedule 14D-9, or any amendment thereto, with the SEC disclosing the recommendation of the Company&#146;s Board of Directors with respect to such tender offer) or (b)&nbsp;an issuer tender offer by the Company. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Voting Agreement</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">5.1
<U>Voting of Securities</U>. During the Voting Agreement Term, other than as permitted by Section&nbsp;5.2 with respect to Extraordinary Matters, in any vote or action by written consent of the stockholders of the Company (including, without
limitation, with respect to the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
election of directors), the Investor shall, and shall cause any Permitted Transferees to, vote or execute a written consent with respect to the Purchased Shares, in the sole discretion of the
Investor, either (a)&nbsp;in accordance with the recommendation of the Company&#146;s Board of Directors or (b)&nbsp;in the case of a meeting of stockholders, if the Investor or a Permitted Transferee has delivered written notice to the Company at
any time prior to the vote on any given matter (but in any event not less than five (5)&nbsp;Business Days prior to such vote), setting forth its intent to vote pursuant to this clause (b), in the same proportion as the votes cast by all other
holders of all classes of voting securities of the Company (as estimated by the inspector of election immediately prior to the closing of the polls with respect to the vote on any given matter, subject to adjustment for the inspector of
election&#146;s final tabulation of votes cast). In the event that the Investor or a Permitted Transferee does not deliver timely written notice to the Company as provided in Section&nbsp;5.1(b), such Person shall be deemed to have elected to vote
the Purchased Shares of the Company as to which it is entitled to vote as provided in clause (a)&nbsp;above. In furtherance of this Section&nbsp;5.1, the Investor hereby irrevocably appoints the Company and any individuals designated by the Company
(such designated individuals to be limited to the Chairman, Chief Executive Officer, General Counsel or Secretary of the Company), and each of them individually, as the attorneys, agents and proxies, with full power of substitution and
re-substitution in each of them, for the Investor, and in the name, place and stead of the Investor, to vote (or cause to be voted) in such manner as set forth in this Section&nbsp;5.1 (but in any case, (i)&nbsp;in accordance with any written
instruction from the Investor, properly delivered under this Section&nbsp;5.1, to vote as contemplated by clause (b)&nbsp;above, and (ii)&nbsp;excluding any matter that is an Extraordinary Matter described in Section&nbsp;5.2) with respect to the
Purchased Shares to which the Investor is or may be entitled to vote at any meeting of the Company held after the date hereof, whether annual or special and whether or not an adjourned meeting (the &#147;<B>Irrevocable Proxy</B>&#148;).&nbsp;This
Irrevocable Proxy is coupled with an interest, shall be irrevocable and binding on any successor in interest of the Investor and shall not be terminated by operation of law upon the occurrence of any event.&nbsp;This Irrevocable Proxy shall operate
to revoke and render void any prior proxy as to voting securities heretofore granted by the Investor which is inconsistent herewith. Notwithstanding the foregoing, the Irrevocable Proxy shall be effective if, at any annual or special meeting of the
stockholders of the Company and at any adjournments or postponements of any such meetings, the Investor (A)&nbsp;fails to appear or otherwise fails to cause its voting securities of the Company to be counted as present for purposes of calculating a
quorum, or (B)&nbsp;fails to vote such voting securities in accordance with this Section&nbsp;5.1, in each case at least two (2)&nbsp;Business Days prior to the date of such stockholders&#146; meeting. The Irrevocable Proxy shall terminate upon the
earlier of the expiration or termination of the Voting Agreement Term.&nbsp;The Investor shall cause any Permitted Transferee to promptly execute and deliver to the Company an irrevocable proxy, substantially in the form of <U>Exhibit A</U> attached
hereto, and irrevocably appoint the Company and any individuals designated by the Company, and each of them individually, with full power of substitution and resubstitution, as its attorney, agent and proxy to vote (or cause to be voted) such
Purchased Shares of the Company as to which such Permitted Transferee is entitled to vote, in such manner as each such attorney, agent and proxy or his substitute shall in its, his or her sole discretion deem appropriate or desirable </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
with respect to the matters set forth in this Section&nbsp;5.1 (the &#147;<B>Permitted Transferee Irrevocable Proxy</B>&#148;). The Investor acknowledges, and shall cause any Permitted
Transferees to acknowledge, that any such proxy executed and delivered shall be coupled with an interest, shall constitute, among other things, an inducement for the Company to enter into this Agreement, shall be irrevocable and binding on any
successor in interest of such Permitted Transferee and shall not be terminated by operation of Law upon the occurrence of any event. Such proxy shall operate to revoke and render void any prior proxy as to any voting securities of the Company
heretofore granted by such Permitted Transferee, to the extent it is inconsistent herewith. The Investor acknowledges and agrees that it shall be a condition to any proposed transfer of voting securities of the Company by the Investor to such
Permitted Transferee that such Permitted Transferee execute and deliver to the Company a Permitted Transferee Irrevocable Proxy, and that any purported transfer shall be void and of no force or effect if such Permitted Transferee Irrevocable Proxy
is not so executed and delivered at the closing of such transfer. Such proxy shall terminate upon the earlier of the expiration or termination of the Voting Agreement Term. The Investor acknowledges and agrees that it shall be a condition to any
proposed transfer of voting securities of the Company by the Investor to any Permitted Transferee during the Voting Agreement Term that such Permitted Transferee shall agree in writing to be subject to and bound by all restrictions and obligations
set forth in this Section 5.1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event the Company&#146;s stockholders are permitted to act by written consent, the Company and the
Investor shall each negotiate in good faith with the other provisions as consistent as possible with the foregoing to govern the voting of the Investor&#146;s and its Permitted Transferees&#146; Shares of Then Outstanding Common Stock as closely as
practicable to the foregoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">5.2 <U>Certain Extraordinary Matters</U>. The Investor and its Permitted Transferees may vote, or execute a
written consent with respect to, any or all of the voting securities of the Company as to which they are entitled to vote or execute a written consent, as they may determine in their sole discretion, with respect to the following matters (each such
matter being an &#147;<B>Extraordinary Matter</B>&#148;): </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) any transaction which would result in a Change of Control; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) any issuance of Common Stock presented to stockholders for approval (which for avoidance of doubt shall not include the approval of any
stock option or similar equity plan); and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) any liquidation or dissolution of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">5.3 <U>Quorum</U>. In furtherance of Section&nbsp;5.1, the Investor shall be, and shall cause each of its Permitted Transferees to be, present
in person or represented by proxy at all meetings of stockholders to the extent necessary so that all voting securities of the Company as to which they are entitled to vote shall be counted as present for the purpose of determining the presence of a
quorum at such meeting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Termination of Certain Rights and Obligations</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">6.1 <U>Termination of Registration Rights Term</U>. Except for Section&nbsp;2.10, which shall survive until the expiration of any applicable
statutes of limitation, Section&nbsp;2 shall terminate automatically and have no further force or effect upon the earliest to occur of: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) the [***]; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) the date
on which the Common Stock ceases to be registered pursuant to Section&nbsp;12 of the Exchange Act; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) a liquidation or dissolution
of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">6.2 <U>Termination of Standstill Term</U>. Section&nbsp;3 shall terminate and have no further force or effect, upon the
earliest to occur of: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) the date [***] after of the Closing Date; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) provided that none of the Standstill Parties has materially violated Section&nbsp;3.1(d) or (f)&nbsp;with respect to any other Person or
group (an &#147;<B>Offeror</B>&#148;) referred to in this Section&nbsp;6.2, the date on which an Offeror publicly announces a tender, exchange or other offer for the Company&#146;s Common Stock that, if consummated, would result in a Change of
Control of the Company; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) the date that the Company enters into a letter of intent relating to a Change of Control of the Company,
announces its intent to do so or announces that it is pursuing a transaction that would result in a Change of Control of the Company; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) the date on which the Standstill Parties together beneficially own less than [***] of the Shares of Then Outstanding Common Stock; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) the date on which the Common Stock ceases to be registered pursuant to Section&nbsp;12 of the Exchange Act; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f) a liquidation or dissolution of the Company; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>provided</U>, <U>however</U>, that if Section&nbsp;3 terminates due to clauses (b)&nbsp;or (c)&nbsp;above and such agreement is abandoned and no other
similar transaction has been announced and not abandoned or terminated [***] the restrictions contained in Section&nbsp;3 shall again be applicable until otherwise terminated pursuant to this Section&nbsp;6.2. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">6.3 <U>Termination of Lock-Up Term</U>. Section&nbsp;4 shall terminate and have no further force
or effect upon the earliest to occur of: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) the date [***] after of the Closing Date; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) the expiration or earlier valid termination of the Collaboration Agreement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) the consummation by an Offeror of a Change of Control of the Company, which, in the case of a tender offer, shall be deemed to occur upon
the commencement of a tender offer for all outstanding shares of Common Stock; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) the date on which the Investor and any Permitted
Transferees together beneficially own less than [***] of the Shares of Then Outstanding Common Stock; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) a liquidation or dissolution
of the Company; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f) the date on which the Common Stock ceases to be registered pursuant to Section&nbsp;12 of the Exchange Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">6.4 <U>Termination of Voting Agreement Term</U>. Section&nbsp;5 shall terminate and have no further force or effect upon the earliest to occur
of: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) the date [***] after the Closing Date; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) the expiration or earlier valid termination of the Collaboration Agreement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) the consummation by an Offeror of a Change of Control of the Company, which, in the case of a tender offer, shall be deemed to occur upon
the commencement of a tender offer for all outstanding shares of Common Stock; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) the date on which the Investor and any Permitted
Transferees together beneficially own less than [***] of the Shares of Then Outstanding Common Stock; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) a liquidation or dissolution
of the Company; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f) the date on which the Common Stock ceases to be registered pursuant to Section&nbsp;12 of the Exchange Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">6.5 <U>Effect of Termination</U>. No termination pursuant to any of Sections 6.1, 6.2, 6.3 or 6.4 shall relieve any of the parties (or the
Permitted Transferee, if any) for liability for breach of or default under any of their respective obligations or restrictions under any terminated provision of this Agreement, which breach or default arose out of events or circumstances occurring
or existing prior to the date of such termination. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Miscellaneous</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">7.1 <U>Governing Law; Submission to Jurisdiction</U>. This Agreement shall be governed by and construed in accordance with the Laws of the
State of Delaware, without regard to the conflict of laws principles thereof that would require the application of the Law of any other jurisdiction. Any action brought, arising out of, or relating to this Agreement shall be brought in the Court of
Chancery of the State of Delaware. Each party hereby irrevocably submits to the exclusive jurisdiction of said Court in respect of any claim relating to the validity, interpretation and enforcement of this Agreement, and hereby waives, and agrees
not to assert, as a defense in any action, suit or proceeding in which any such claim is made that it is not subject thereto or that such action, suit or proceeding may not be brought or is not maintainable in such courts, or that the venue thereof
may not be appropriate or that this agreement may not be enforced in or by such courts. The parties hereby consent to and grant the Court of Chancery of the State of Delaware jurisdiction over such parties and over the subject matter of any such
claim and agree that mailing of process or other papers in connection with any such action, suit or proceeding in the manner provided in Section&nbsp;7.3 or in such other manner as may be permitted by law, shall be valid and sufficient thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">7.2 <U>Waiver</U>. Waiver by a party of a breach hereunder by another party shall not be construed as a waiver of any subsequent breach of the
same or any other provision. No delay or omission by a party in exercising or availing itself of any right, power or privilege hereunder shall preclude the later exercise of any such right, power or privilege by such party. No waiver shall be
effective unless made in writing with specific reference to the relevant provision(s) of this Agreement and signed by a duly authorized representative of the party granting the waiver. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">7.3 <U>Notices</U>. All notices, instructions and other communications hereunder or in connection herewith shall be in writing, shall be sent
to the address of the relevant party set forth on <U>Exhibit A</U> attached hereto and shall be (a)&nbsp;delivered personally, (b)&nbsp;sent by registered or certified mail, return receipt requested, postage prepaid, (c)&nbsp;sent via a reputable
nationwide overnight courier service or (d)&nbsp;sent by facsimile transmission or electronic mail, with a confirmation copy to be sent by registered or certified mail, return receipt requested, postage prepaid. Any such notice, instruction or
communication shall be deemed to have been delivered upon receipt if delivered by hand, three (3)&nbsp;Business Days after it is sent by registered or certified mail, return receipt requested, postage prepaid, one (1)&nbsp;Business Day after it is
sent via a reputable nationwide overnight courier service or when transmitted with electronic confirmation of receipt, if transmitted by facsimile or electronic mail (if such transmission is made during regular business hours of the recipient on a
Business Day; or otherwise, on the next Business Day following such transmission). Any party may change its address by giving notice to the other parties in the manner provided above. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">7.4 <U>Entire Agreement</U>. This Agreement, the Purchase Agreement and the Collaboration
Agreement contain the entire agreement among the parties with respect to the subject matter hereof and thereof and supersede all prior and contemporaneous arrangements or understandings, whether written or oral, with respect hereto and thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">7.5 <U>Amendments</U>. No provision in this Agreement shall be supplemented, deleted or amended except in a writing executed by an authorized
representative of each of the parties hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">7.6 <U>Headings; Nouns and Pronouns; Section References</U>. Headings in this Agreement are
for convenience of reference only and shall not be considered in construing this Agreement. Whenever the context may require, any pronouns used herein shall include the corresponding masculine, feminine or neuter forms, and the singular form of
names and pronouns shall include the plural and vice-versa. References in this Agreement to a section or subsection shall be deemed to refer to a section or subsection of this Agreement unless otherwise expressly stated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">7.7 <U>Severability</U>. If, under applicable Laws, any provision hereof is invalid or unenforceable, or otherwise directly or indirectly
affects the validity of any other material provision(s) of this Agreement in any jurisdiction (&#147;<B>Modified Clause</B>&#148;), then, it is mutually agreed that this Agreement shall endure and that the Modified Clause shall be enforced in such
jurisdiction to the maximum extent permitted under applicable Laws in such jurisdiction; provided that the parties shall consult and use all reasonable efforts to agree upon, and hereby consent to, any valid and enforceable modification of this
Agreement as may be necessary to avoid any unjust enrichment of either party and to match the intent of this Agreement as closely as possible, including the economic benefits and rights contemplated herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">7.8 <U>Assignment</U>. Except for an assignment of this Agreement by the Investor to a Permitted Transferee, neither this Agreement nor any
rights or duties of a party hereto may be assigned by such party, in whole or in part, without (a)&nbsp;the prior written consent of the Company in the case of any assignment by the Investor; or (b)&nbsp;the prior written consent of the Investor in
the case of an assignment by the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">7.9 <U>Successors and Assigns</U>. This Agreement shall be binding upon and inure to the
benefit of the parties hereto and their respective successors and permitted assigns. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">7.10 <U>Counterparts</U>. This Agreement may be
executed in counterparts, each of which shall be deemed an original but which together shall constitute one and the same instrument. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">7.11
<U>Third Party Beneficiaries</U>. None of the provisions of this Agreement shall be for the benefit of or enforceable by any Third Party other than any Affiliate of the Investor. No Third Party with the exception of any Affiliate of the Investor
shall obtain any right under any provision of this Agreement or shall by reason of any such provision make any claim in respect of any debt, liability or obligation (or otherwise) against any party hereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">7.12 <U>No Strict Construction</U>. This Agreement has been prepared jointly and will not be
construed against any party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">7.13 <U>Remedies</U>. The rights, powers and remedies of the parties under this Agreement are cumulative and
not exclusive of any other right, power or remedy which such parties may have under any other agreement or Law. No single or partial assertion or exercise of any right, power or remedy of a party hereunder shall preclude any other or further
assertion or exercise thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">7.14 <U>Specific Performance</U>. The Company and the Investor hereby acknowledge and agree that the
rights of the parties hereunder are special, unique and of extraordinary character, and that if any party refuses or otherwise fails to act, or to cause its Affiliates to act, in accordance with the provisions of this Agreement, such refusal or
failure would result in irreparable injury to the Company or the Investor, as the case may be, the exact amount of which would be difficult to ascertain or estimate and the remedies at law for which would not be reasonable or adequate compensation.
Accordingly, if any party refuses or otherwise fails to act, or to cause its Affiliates to act, in accordance with the provisions of this Agreement, then, in addition to any other remedy which may be available to any damaged party at law or in
equity, such damaged party will be entitled to seek specific performance and injunctive relief, without posting bond or other security, and without the necessity of proving actual or threatened damages, which remedy such damaged party will be
entitled to seek in any court of competent jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">7.15 <U>No Conflicting Agreements</U>. The Investor hereby represents and
warrants to the Company that neither it nor any of its Affiliates is, as of the date of this Agreement, a party to, and agrees that neither it nor any of its Affiliates shall, on or after the date of this Agreement, enter into any agreement that
conflicts with the rights granted to the Company in this Agreement. The Company hereby represents and warrants to each Holder that it is not, as of the date of this Agreement, a party to, and agrees that it shall not, on or after the date of this
Agreement, enter into any agreement or approve any amendment to its Organizational Documents (as defined in the Purchase Agreement) with respect to its securities that conflicts with the rights granted to the Holders in this Agreement. The Company
further represents and warrants that the rights granted to the Holders hereunder do not in any way conflict with the rights granted to any other holder of the Company&#146;s securities under any other agreements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">7.16 <U>Use of Proceeds</U>. The Company shall use the proceeds from the sale of the Shares hereunder for working capital purposes and shall
not use such proceeds for the redemption of any shares of Common Stock (or Common Stock Equivalents) or for the payment of any dividends on shares of Common Stock (or Common Stock Equivalents). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">7.17 <U>No Publicity</U>. The parties hereto agree that the provisions of Section&nbsp;12.5 of
the Collaboration Agreement shall be applicable to the parties to this Agreement with respect to any public disclosures regarding the proposed transactions contemplated by the Purchase Agreement and the Collaboration Agreement or regarding the
parties hereto or their Affiliates (it being understood that the provisions of Section&nbsp;12.5(a) of the Collaboration Agreement shall be read to apply to disclosures of information relating to this Agreement and the transactions contemplated
hereby). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">7.18 <U>Limitation of Liability</U>. IN NO EVENT WILL EITHER PARTY BE LIABLE TO THE OTHER PARTY (OR THE OTHER PARTY&#146;S
AFFILIATES OR SUBLICENSEES) IN CONNECTION WITH THIS AGREEMENT FOR LOST REVENUE, LOST PROFITS, LOST SAVINGS, LOSS OF USE, DAMAGE TO GOODWILL, OR ANY CONSEQUENTIAL, INCIDENTAL, SPECIAL, EXEMPLARY, PUNITIVE OR INDIRECT DAMAGES UNDER ANY THEORY,
INCLUDING CONTRACT, NEGLIGENCE, OR STRICT LIABILITY, EVEN IF THAT PARTY HAS BEEN PLACED ON NOTICE OF THE POSSIBILITY OF SUCH DAMAGES. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Signature Page Follows) </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed and delivered this Agreement as of the date first
above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="83%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B><FONT STYLE="white-space:nowrap">JOHNSON&nbsp;&amp;&nbsp;JOHNSON&nbsp;INNOVATION-JJDC,&nbsp;INC.</FONT></B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Asish K. Xavier</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">Asish K. Xavier</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">Vice President, Venture Investments</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>MACROGENICS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Scott Koenig, M.D., Ph.D.</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">Scott Koenig, M.D., Ph.D.</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">President and CEO</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF IRREVOCABLE PROXY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to secure the performance of the duties of the undersigned pursuant to Section&nbsp;5.1 of the Investor Agreement, dated as of
December&nbsp;19, 2014 (the &#147;Agreement&#148;), by and between Johnson&nbsp;&amp; Johnson Innovation-JJDC, Inc. and MacroGenics, Inc. (the &#147;<B>Company</B>&#148;), the undersigned hereby irrevocably appoints the Company and any individual
designated by the Company, and each of them individually, as the attorneys, agents and proxies, with full power of substitution and resubstitution in each of them, for the undersigned, and in the name, place and stead of the undersigned, to vote (or
cause to be voted) in such manner as set forth in Section&nbsp;5.1 of the Agreement (but in any case, (i)&nbsp;in accordance with any written instruction from the undersigned, properly delivered under Section&nbsp;5.1 of the Agreement, to vote as
contemplated by Section&nbsp;5.1(b) of the Agreement and (ii)&nbsp;excluding any matter that is an Extraordinary Matter described in Section&nbsp;5.2) with respect to all Purchased Shares, which the undersigned is or may be entitled to vote at any
meeting of the Company held after the date hereof, whether annual or special and whether or not an adjourned meeting. This proxy is coupled with an interest, shall be irrevocable and binding on any successor in interest of the undersigned and shall
not be terminated by operation of law upon the occurrence of any event. This proxy shall operate to revoke and render void any prior proxy as to voting securities heretofore granted by the undersigned which is inconsistent herewith. Notwithstanding
the foregoing, this irrevocable proxy shall be effective if, at any annual or special meeting of the stockholders of the Company (or any consent in lieu thereof) and at any adjournments or postponements of any such meetings, the undersigned
(A)&nbsp;fails to appear or otherwise fails to cause its voting securities of the Company to be counted as present for purposes of calculating a quorum, or (B)&nbsp;fails to vote such voting securities in accordance with Section&nbsp;5.1 of the
Agreement, in each case at least two (2)&nbsp;Business Days prior to the date of such stockholders&#146; meeting. This proxy shall terminate upon the earlier of the expiration or termination of the Voting Agreement Term. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="83%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B><FONT STYLE="white-space:nowrap">JOHNSON&nbsp;&amp;&nbsp;JOHNSON&nbsp;INNOVATION-JJDC,&nbsp;INC.</FONT></B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="right">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT B </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTICES </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">If to the Investor: </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Johnson&nbsp;&amp; Johnson Innovation-JJDC, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">410 George Street </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">New Brunswick,
NJ 08901 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Attention: General Manager </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">with a copy to: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Johnson&nbsp;&amp; Johnson Law Department </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">One Johnson&nbsp;&amp; Johnson Plaza </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">New Brunswick, NJ 08534 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Attention: General Counsel </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">If to the Company: </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">MacroGenics, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">9640 Medical Center Drive </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Rockville, MD 20850 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Attention:
CEO </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">with a copy to: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Wilmer Cutler Pickering Hale and Dorr LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">60 State Street </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Boston, MA 02109
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Attention: Steven D. Singer </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-1 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.10
<SEQUENCE>3
<FILENAME>d838054dex1010.htm
<DESCRIPTION>EX-10.10
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.10</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Exhibit 10.10 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MacroGenics, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Second Amendment to Lease Agreement </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This Second Amendment to the Lease Agreement (&#147;AMENDMENT&#148;) is made and entered into this 6th day of November 2014, by and between
RED GATE III LLC (&#147;LANDLORD&#148;) and MACROGENICS, INC. (&#147;TENANT&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WITNESSETH: </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B><I>Whereas,</I></B> the LANDLORD and TENANT entered into a certain lease dated May&nbsp;31, 2011, as amended by First Amendment dated
March&nbsp;26, 2013 (&#147;LEASE&#148;), covering 46,267 square feet of space located in 9640 Medical Center Drive, Rockville, Maryland. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B><I>Now, therefore</I></B>, the parties hereto, intending to be legally bound, do covenant and agree as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">In the event a lease is executed at 9620 Medical Center Drive, Rockville, Maryland between LANDLORD and TENANT (&#147;SECOND LEASE&#148;), the term of the LEASE shall expire or terminate upon the applicable expiration
or termination of the SECOND LEASE. The parties anticipate the expiration of the SECOND LEASE to occur on January&nbsp;31, 2020. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B><I>Ratification of LEASE:</I></B> Except as expressly modified or amended by this AMENDMENT, all terms, covenants and conditions of the
LEASE shall remain the same. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B><I>In witness whereof</I></B>, LANDLORD and TENANT have caused this AMENDMENT to be executed as of this
6th day of November 2014, and do hereby declare this AMENDMENT to be binding on them, their respective successors and assigns. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP>WITNESS:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">LANDLORD:</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><B>RED&nbsp;GATE&nbsp;III&nbsp;LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/&nbsp;William&nbsp;M.&nbsp;Rickman</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">By: William&nbsp;M.&nbsp;Rickman</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">WITNESS:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">TENANT:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><B>MACROGENICS,&nbsp;INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/&nbsp;Scott&nbsp;Koenig&nbsp;M.D.,&nbsp;PhD</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">By: Scott Koenig</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 1 of 1 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.14
<SEQUENCE>4
<FILENAME>d838054dex1014.htm
<DESCRIPTION>EX-10.14
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.14</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.14 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>LEASE</U> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Landlord: BRITANNIA BIOTECH
GATEWAY LIMITED PARTNERSHIP </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tenant: RAVEN BIOTECHNOLOGIES, INC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: November 21, 2006 </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>TABLE OF CONTENTS
</U></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="96%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">PROPERTY</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">1.1 Lease of Building</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">1.2 Landlord&#146;s Reserved Rights</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">TERM</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">2.1 Term</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">2.2 Condition of Premises</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">2.3 Acknowledgement Of Commencement Date</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">2.4 Holding Over</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">RENTAL</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">3.1 Minimum Rental</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;Rental Amounts</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;Additional Rent (If Applicable)</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;Square Footage of Building</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">3.2 Late Charge</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">TAXES</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">4.1 Personal Property</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">4.2 Real Property</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">OPERATING EXPENSES</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">5.1 Payment of Operating Expenses</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">5.2 Definition Of Operating Expenses</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">5.3 Determination Of Operating Expenses</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">5.4 Final Accounting For Lease Year</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">5.5 Proration</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">UTILITIES</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">6.1 Payment</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">6.2 Interruption</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">ALTERATIONS; SIGNS</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">7.1 Right To Make Alterations</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">7.2 Title To Alterations</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">7.3 Tenant Fixtures</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">7.4 No Liens</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">7.5 Signs</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">MAINTENANCE AND REPAIRS</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">8.1 Landlord&#146;s Work</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">8.2 Tenant&#146;s Obligation For Maintenance</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;Good Order, Condition And Repair</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;Landlord&#146;s Remedy</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="95%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">(c) Condition Upon Surrender</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">USE OF PROPERTY</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">9.1 Permitted Use</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">9.2 [Omitted.]</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">9.3 No Nuisance</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">9.4 Compliance With Laws</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">9.5 Liquidation Sales</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">9.6 Environmental Matters</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">INSURANCE AND INDEMNITY</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">10.1 Insurance</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">10.2 Quality Of Policies And Certificates</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">10.3 Workers&#146; Compensation</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">10.4 Waiver Of Subrogation</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">10.5 Increase In Premiums</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">10.6 Indemnification</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">10.7 Blanket Policy</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">SUBLEASE AND ASSIGNMENT</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">11.1 Assignment And Sublease Of Building</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">11.2 Rights Of Landlord</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">RIGHT OF ENTRY AND QUIET ENJOYMENT</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">12.1 Right Of Entry</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">12.2 Quiet Enjoyment</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">13.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">CASUALTY AND TAKING</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">13.1 Damage or Destruction</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">13.2 Condemnation</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">13.3 Reservation Of Compensation</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">13.4 Restoration Of Improvements</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">14.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">DEFAULT</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">14.1 Events Of Default</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;[Omitted.]</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;Nonpayment</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;Other Obligations</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;General Assignment</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;Bankruptcy</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Receivership</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(g)&nbsp;&nbsp;&nbsp;&nbsp;Attachment</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(h)&nbsp;&nbsp;&nbsp;&nbsp;Insolvency</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">14.2 Remedies Upon Tenant&#146;s Default</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">14.3 Remedies Cumulative</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">15.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">SUBORDINATION, ATTORNMENT AND SALE</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">15.1 Subordination To Mortgage</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">15.2 Sale Of Landlord&#146;s Interest</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">15.3 Estoppel Certificates</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">15.4 Subordination to CC&amp;R&#146;s</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">15.5 Mortgagee Protection</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">16.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">SECURITY</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- ii - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="95%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">16.1 Deposit</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">17.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">MISCELLANEOUS</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">17.1 Notices</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">17.2 Successors And Assigns</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">17.3 No Waiver</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">17.4 Severability</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">17.5 Litigation Between Parties</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">17.6 Surrender</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">17.7 Interpretation</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">17.8 Entire Agreement</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">17.9 Governing Law</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">17.10 No Partnership</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">17.11 Financial Information</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">17.12 Costs</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">17.13 Time</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">17.14 Rules And Regulations</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">17.15 Brokers</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">17.16 Memorandum Of Lease</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">17.17 Corporate Authority</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">17.18 Execution and Delivery</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">17.19 Survival</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">17.20 Parking</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">EXHIBITS </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="88%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>EXHIBIT&nbsp;A</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Real Property Description</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>EXHIBIT&nbsp;B</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Site Plan</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>EXHIBIT C</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Acknowledgement of Commencement Date</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- iii - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>LEASE </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THIS LEASE (&#147;<U>Lease</U>&#148;) is made and entered into as of November&nbsp;21, 2006, by and between BRITANNIA BIOTECH GATEWAY LIMITED
PARTNERSHIP, a Delaware limited partnership (&#147;<U>Landlord</U>&#148;), and RAVEN BIOTECHNOLOGIES, INC., a Delaware corporation (&#147;<U>Tenant</U>&#148;). </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>RECITALS </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A. WHEREAS,
substantially concurrently with the execution of this Lease, Tenant and Amgen SF, LLC, a Delaware limited liability company (&#147;<U>Amgen</U>&#148;) are entering into a sublease (the &#147;<U>Amgen Sublease</U>&#148;) providing for Tenant&#146;s
subleasing of the Building (defined below) from Amgen for the remaining term of the Prior Lease (defined below), which term is presently scheduled to expire on December&nbsp;31, 2013; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">B. WHEREAS, the intention of the parties, in executing this Lease at this time, is to establish a leasing relationship which will be fully
binding on the parties and their successors and assigns as of the date of execution hereof, but which will ripen into an actual possessory interest, with attendant commencement of performance of economic and other obligations hereunder on a current
basis, only upon the Commencement Date as determined pursuant to Section&nbsp;2.1 below; </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">NOW, THEREFORE, THE PARTIES AGREE AS FOLLOWS:
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1. <U>PROPERTY</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.1
<U>Lease of Building</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) Landlord leases to Tenant and Tenant hires and leases from Landlord, on the terms, covenants and conditions
hereinafter set forth, the two-story office and laboratory building which is located on the real property described in <U>Exhibit A</U> attached hereto (the &#147;<U>Property</U>&#148;), is commonly known as One Corporate Drive, South San Francisco,
California (the &#147;<U>Building</U>&#148;), contains approximately 66,127 square feet and is presently leased to Amgen, as successor in interest (by merger) to Tularik Inc., pursuant to a Build-to-Suit Lease dated as of April&nbsp;20, 1995, as
amended by a First Amendment to Lease dated as of February&nbsp;10, 1998 and by a Second Amendment to Build-to-Suit Lease dated as of August&nbsp;12, 2004 (as amended, the &#147;<U>Prior Lease</U>&#148;). The location of the Building on the Property
is depicted on the site plan attached hereto as <U>Exhibit B</U> (the &#147;<U>Site Plan</U>,&#148; on which the Building is designated as &#147;Building B&#148; and is located in the area labeled &#147;Phase I&#148; on the Site Plan). The Property
is part of the Britannia Biotechnology Center, sometimes also referred to as the Britannia Gateway Center (the &#147;<U>Center</U>,&#148; comprising collectively Phase I and Phase II as shown on the Site Plan) on Gateway Boulevard in the City of
South San Francisco, County of San Mateo, State of California. The Building and related improvements presently existing on the Property are sometimes referred to collectively herein as the <U>&#147;Improvements</U>.&#148; The parking areas,
driveways, sidewalks, landscaped areas and other portions of the Center that lie outside the exterior walls of the buildings now or hereafter existing from time to time in the Center, as depicted in the Site Plan and as heretofore or hereafter
modified by Landlord from time to time in accordance with the provisions of this </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 1 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Lease, are sometimes referred to herein as the &#147;<U>Common Areas</U>.&#148; Amgen (as successor in interest to Tularik) also presently leases one other building in the Center, at Two
Corporate Drive, from Landlord pursuant to a Build-to-Suit Lease dated as of February&nbsp;10, 1998, as amended by a First Amendment to Build-to-Suit Lease dated as of August&nbsp;12, 2004. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) As an appurtenance to Tenant&#146;s leasing of the Building pursuant to Section&nbsp;1.1(a), Landlord hereby grants to Tenant, for the
benefit of Tenant and its employees, suppliers, shippers, customers and invitees, during the term of this Lease, the non-exclusive right to use, in common with others entitled to such use, (i)&nbsp;those portions of the Common Areas improved from
time to time for use as parking areas, driveways, sidewalks, landscaped areas, or for other common purposes, and (ii)&nbsp;all access easements and similar rights and privileges relating to or appurtenant to the Property and created or existing from
time to time under any access easement agreements, declarations of covenants, conditions and restrictions, or other written agreements now or hereafter of record with respect to the Property, subject however to any limitations applicable to such
rights and privileges under applicable law, under this Lease and/or under the written agreements creating such rights and privileges. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.2
<U>Landlord&#146;s Reserved Rights</U>. To the extent reasonably necessary to permit Landlord to exercise any rights of Landlord and discharge any obligations of Landlord under this Lease, Landlord shall have, in addition to the right of entry set
forth in Section&nbsp;12.1 hereof, the following rights: (i)&nbsp;to make changes to the Common Areas, including, without limitation, changes in the location, size or shape of any portion of the Common Areas, and to relocate parking spaces on the
Property and in the Common Areas (but not materially decrease the number of such parking spaces in areas of the Property generally adjacent to the Building); (ii)&nbsp;to close temporarily any of the Common Areas for maintenance or other reasonable
purposes, <U>provided</U> that reasonable parking and reasonable access to the Building remain available; (iii)&nbsp;to construct, alter or add to other buildings and Common Area improvements on the Property (including, but not limited to,
construction of site improvements, buildings and Common Area improvements on portions of the Property and/or on adjacent properties owned by Landlord from time to time); (iv)&nbsp;to build in areas adjacent to the Property and to add such areas to
the Property or operate such areas, for maintenance, access, parking and other purposes, on an integrated basis with the Property; (v)&nbsp;to use the Common Areas while engaged in making additional improvements, repairs or alterations to the
Property or any portion thereof or to any adjacent properties owned by Landlord from time to time; and (vi)&nbsp;to do and perform such other acts with respect to the Common Areas and the Property as may be necessary or appropriate; <U>provided</U>,
however, that notwithstanding anything to the contrary in this Section&nbsp;1.2, Landlord&#146;s exercise of its rights hereunder shall not cause any material diminution of Tenant&#146;s rights, nor any material increase of Tenant&#146;s
obligations, under this Lease or with respect to the Improvements. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2. <U>TERM</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.1 <U>Term</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) The term
of this Lease shall commence on the date (the &#147;<U>Commencement Date</U>&#148;) immediately following the date on which the Prior Lease expires, it being the intention of the parties that Tenant&#146;s occupancy of the Building as a subtenant
under the Amgen Sublease </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 2 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
shall be followed immediately, without any intervening gap, by Tenant&#146;s occupancy of the Building as a direct tenant under this Lease. The term of this Lease shall end, unless sooner
terminated or extended as hereinafter provided, on February&nbsp;28, 2018 (the &#147;<U>Termination Date</U>&#148;). Tenant&#146;s minimum rental and Operating Expense obligations under this Lease with respect to the Building shall begin on the
Commencement Date. The parties anticipate that the Commencement Date will occur on January&nbsp;1, 2014, since the presently scheduled expiration date of the Prior Lease is December&nbsp;31, 2013. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) Notwithstanding the foregoing provisions of Section&nbsp;2.1 (a): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i) If the Prior Lease is terminated prior to its scheduled expiration date by either Landlord or Amgen as a result of damage,
destruction or condemnation, then this Lease shall be deemed to be terminated concurrently with such early termination, the Commencement Date shall not occur, and Landlord and Tenant shall have no further obligations under this Lease;
<U>provided,</U> however, that if such early termination is elected by the tenant under the Prior Lease (but not by Landlord) as a result of damage or destruction occurring during the final year of the term of the Prior Lease, then Landlord agrees
to negotiate in good faith with Tenant, if so requested by Tenant, regarding the possibility of causing the Building to be rebuilt for occupancy by Tenant during the remaining term (if any) of the Prior Lease and during the term of this Lease, but
no such rebuilding of the Building and reinstatement of this Lease shall occur except pursuant to a written agreement mutually executed at the time by Landlord and Tenant in their respective discretion; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(ii) If the Prior Lease is terminated prior to its scheduled expiration date for any other reason, then unless otherwise agreed
by Landlord and Tenant at the time in a written agreement mutually executed by them in their respective discretion, this Lease shall be deemed to be terminated concurrently with such early termination, the Commencement Date shall not occur, and
Landlord and Tenant shall have no further obligations under this Lease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.2 <U>Condition of Premises</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) Tenant acknowledges that it will accept and occupy the Building in &#147;AS IS&#148; condition as the Building exists on the Commencement
Date, immediately following the termination or expiration of the Prior Lease and Amgen Sublease and of Tenant&#146;s occupancy of the Building as a subtenant thereunder, and Landlord shall have no obligation to improve, repair or prepare the
Building for occupancy by Tenant under this Lease; <U>provided,</U> however, that the foregoing provisions of this sentence shall be subject to any rebuilding obligations expressly imposed upon Landlord under the Prior Lease (to the extent any such
rebuilding is in progress on the Commencement Date) or pursuant to a future written agreement (if any) as contemplated in Section&nbsp;2.1(b)(i) above. Without limiting the generality of the foregoing, TENANT ACKNOWLEDGES THAT NEITHER LANDLORD NOR
ANY AGENT OF LANDLORD IS MAKING OR HAS MADE ANY REPRESENTATION OR WARRANTY, EXPRESS OR IMPLIED, WITH RESPECT TO THE PHYSICAL CONDITION OF THE BUILDING AND IMPROVEMENTS, OR WITH RESPECT TO THE PRESENT OR FUTURE SUITABILITY </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 3 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">OF THE BUILDING OR IMPROVEMENTS FOR THE CONDUCT OF TENANT&#146;S BUSINESS OR PROPOSED BUSINESS THEREIN, AS OF THE
DATE OF EXECUTION OF THIS LEASE OR AS OF THE COMMENCEMENT DATE. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) Landlord and Tenant shall each use their respective best efforts to
schedule and participate in, and to cause Amgen to participate in, a mutual walk-through of the Building prior to, or within thirty (30)&nbsp;days after, Tenant&#146;s commencement of occupancy of the Building as a subtenant pursuant to the Amgen
Sublease, with the objective of arriving at a list mutually approved by Landlord, Tenant and Amgen describing all material fixtures, trade fixtures, equipment (if any) and tenant improvements to be left in place in the Building by Amgen upon
Amgen&#146;s tender of possession of the Building to Tenant, including (but not limited to) all attached fume hoods and lab benches. Landlord shall have no obligation to enforce Amgen&#146;s obligation to leave any such items in place in the
Building, but hereby assigns to Tenant for enforcement by Tenant, in Tenant&#146;s sole discretion (and subject to any separate agreement on this subject between Amgen and Tenant), any rights and/or claims of Landlord against Amgen, under the Prior
Lease, with respect to the condition in which Amgen is required to leave the Building, including (but not limited to) the leaving of any specific items in place in the Building. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) Landlord shall provide Tenant with a tenant improvement allowance in the maximum amount of One Million Five Hundred Seventy-Five Thousand
and No/100 Dollars ($1,575,000.00, calculated at the rate of $75.00 per square foot for the agreed area of 21,000 for the unimproved area of the Premises as of the date of this Lease) (the <B>&#147;<U>Tenant Improvement Allowance</U>&#148;), </B>to
be available for application towards the construction of tenant improvements by Tenant in the Premises at any time after the date which is six (6)&nbsp;months prior to the scheduled Commencement Date as set forth above. Tenant&#146;s construction of
such tenant improvements shall be governed by the provisions of this Section&nbsp;2.2(c) and of Article 7 hereof, and such tenant improvements shall be constructed in compliance with all of the provisions thereof (including, without limitation, all
conditions relating to Landlord&#146;s approval of plans and specifications). The Tenant Improvement Allowance shall not be used or useable by Tenant for any moving or relocation expenses of Tenant, or for any cost or expense associated with any
moveable furniture, trade fixtures, personal property or any other item or element which, under the applicable provisions of this Lease, will not become Landlord&#146;s property and remain with the Building upon expiration or termination of this
Lease. Any portion of the Tenant Improvement Allowance which has not been claimed or drawn by Tenant within fifteen (15)&nbsp;months after the Commencement Date shall expire and shall no longer be available to Tenant thereafter. Additional
conditions and procedures relating to the disbursement of the Tenant Improvement Allowance shall be as reasonably prescribed in writing by Landlord or its Project Manager (as designated by Landlord from time to time). To the extent the Tenant
Improvement Allowance or any portion thereof is actually drawn down by Tenant, the amount actually drawn down shall result in a rental adjustment pursuant to Section&nbsp;3.1(b) hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.3 <U>Acknowledgement Of Commencement Date</U>. Promptly following the Commencement Date, Landlord and Tenant shall execute a written
acknowledgement of the Commencement Date, Termination Date and related matters, substantially in the form attached hereto as <U>Exhibit C</U> (with appropriate insertions), which acknowledgement shall be deemed to be
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 4 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
incorporated herein by this reference. Notwithstanding the foregoing requirement, the failure of either party to execute any such written acknowledgement shall not affect the determination of the
Commencement Date, Termination Date and related matters in accordance with the provisions of this Lease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.4 <U>Holding Over</U>. If
Tenant holds possession of the Property or any portion thereof after the term of this Lease <U>with</U> Landlord&#146;s written consent, then except as otherwise specified in such consent, Tenant shall become a tenant from month to month at one
hundred ten percent (110%)&nbsp;of the rental and otherwise upon the terms herein specified for the period immediately prior to such holding over and shall continue in such status until the tenancy is terminated by either party upon not less than
thirty (30)&nbsp;days prior written notice. If Tenant holds possession of the Property or any portion thereof after the term of this Lease <U>without</U> Landlord&#146;s written consent, then Landlord in its sole discretion may elect (by written
notice to Tenant) to have Tenant become a tenant either from month to month or at will, at one hundred fifty percent (150%)&nbsp;of the rental (prorated on a daily basis for an at-will tenancy, if applicable) and otherwise upon the terms herein
specified for the period immediately prior to such holding over, or may elect to pursue any and all legal remedies available to Landlord under applicable law with respect to such unconsented holding over by Tenant. Tenant shall indemnify and hold
Landlord harmless from any loss, damage, claim, liability, cost or expense (including reasonable attorneys&#146; fees) resulting from any delay by Tenant in surrendering the Property or any portion thereof (except to the extent such delay is with
Landlord&#146;s prior written consent), including but not limited to any claims made by a succeeding tenant by reason of such delay. Acceptance of rent by Landlord following expiration or termination of this Lease shall not constitute a renewal of
this Lease. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3. <U>RENTAL</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.1 <U>Minimum Rental.</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a)
<U>Rental Amounts</U>. Tenant shall pay to Landlord as minimum rental for the Building, in advance, without deduction, offset, notice or demand, on or before the Commencement Date and on or before the first day of each subsequent calendar month of
the term of this Lease, the following amounts per month (with the counting of such months to begin on and as of the Commencement Date): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="63%"></TD>
<TD VALIGN="bottom" WIDTH="34%"></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:24.40pt; font-size:8pt; font-family:Times New Roman">Months</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Monthly Minimum Rental</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">001&#151;012</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">$185,261.40&nbsp;($2.8016/sq&nbsp;ft)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">013&#151;024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">190,819.25&nbsp;($2.8856/sq&nbsp;ft)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">025&#151;036</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">196,543.82&nbsp;($2.9722/sq&nbsp;ft)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">037&#151;048</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">202,440.14&nbsp;($3.0614/sq&nbsp;ft)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">049&#151;050</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">208,513.34&nbsp;($3.1532/sq&nbsp;ft)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">After Month 50 (if applicable)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Continued&nbsp;pattern&nbsp;with&nbsp;annual&nbsp;3%<BR>escalations on each anniversary<BR>of Commencement Date</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 5 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the obligation to pay minimum rental hereunder commences on other than the first day of a calendar month or if
the term of this Lease terminates on other than the last day of a calendar month, the minimum rental for such first or last month of the term of this Lease, as the case may be, shall be prorated based on the number of days the term of this Lease is
in effect during such month. If an increase in minimum rental becomes effective on a day other than the first day of a calendar month, the minimum rental for that month shall be the sum of the two applicable rates, each prorated for the portion of
the month during which such rate is in effect. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) <U>Additional Rent (If Applicable)</U>. The minimum rental amounts specified in
Section&nbsp;3.1(a) do not take into account the availability of the Tenant Improvement Allowance under Section&nbsp;2.2(c) above. If and to the extent that Tenant actually draws down the Tenant Improvement Allowance or any portion thereof, Tenant
shall pay to Landlord as Additional Rent, payable together with monthly minimum rental as specified above: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i) beginning
on the later to occur of the Commencement Date or the first day of the first calendar month occurring after the date of actual funding of the Tenant Improvement Allowance funds (or portion thereof) drawn down by Tenant and continuing until the first
anniversary of the Commencement Date, an amount each month equal to (x)&nbsp;the aggregate amount of the Tenant Improvement Allowance funds actually drawn down by Tenant up to and including the end of the calendar month immediately preceding the
applicable payment date, (y)&nbsp;multiplied by eleven percent (11%)&nbsp;and then divided by twelve (12); and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(ii)
beginning on the first anniversary of the Commencement Date, such Additional Rent shall be increased on each anniversary of the Commencement Date to one hundred three percent (103%)&nbsp;of the Additional Rent payable for the month immediately
preceding the applicable adjustment date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Thus, by way of illustration, if Tenant draws down a total of $1,250,000 from the Tenant Improvement Allowance
during the four (4)&nbsp;months prior to the Commencement Date, then as of the Commencement Date, Tenant&#146;s Additional Rent obligation shall be $11,458.33 per month; if Tenant draws down the remaining $225,000 of the Tenant Improvement Allowance
during the third (3rd)&nbsp;month following the Commencement Date, then as of the beginning of the fourth (4th) month following the Commencement Date, Tenant&#146;s Additional Rent obligation shall increase to $14,437.50 per month; and on the first
anniversary of the Commencement Date, Tenant&#146;s Additional Rent obligation shall increase to $14,870.63 per month (with additional 3% increases on each subsequent anniversary of the Commencement Date). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) <U>Square Footage of Building</U>. The Building was fully constructed prior to the date of this Lease, has been measured by Landlord&#146;s
Architect and, applying the measurement formula customarily used by Landlord to measure square footage of buildings in the Center, has been determined to contain 66,127 square feet, which measurement is final and binding on the parties, is hereby
accepted by the parties for all purposes under this Lease and is not subject to remeasurement or adjustment unless and to the extent that there is a change in the physical size of the Building. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 6 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.2 <U>Late Charge</U>. If Tenant fails to pay when due rental or other amounts due Landlord
hereunder, such unpaid amounts shall bear interest for the benefit of Landlord at a rate equal to the lesser of fifteen percent (15%)&nbsp;per annum or the maximum rate permitted by law, from the date due to the date of payment. In addition to such
interest, Tenant shall pay to Landlord a late charge in an amount equal to six percent (6%)&nbsp;of any installment of minimum rental and any other amounts due Landlord if not paid in full on or before the fifth (5th)&nbsp;day after such rental or
other amount is due; <U>provided,</U> however, that for the first late payment in any twelve (12)&nbsp;month period, no such late charge shall be due unless Landlord first provides written notice to Tenant that the payment is past due and Tenant
fails to pay the amount due within three (3)&nbsp;business days after Tenant&#146;s receipt of such notice. Tenant acknowledges that late payment by Tenant to Landlord of rental or other amounts due hereunder will cause Landlord to incur costs not
contemplated by this Lease, including, without limitation, processing and accounting charges and late charges which may be. imposed on Landlord by the terms of any loan relating to the Property. Tenant further acknowledges that it is extremely
difficult and impractical to fix the exact amount of such costs and that the late charge set forth in this Section&nbsp;3.2 represents a fair and reasonable estimate thereof. Acceptance of any late charge by Landlord shall not constitute a waiver of
Tenant&#146;s default with respect to overdue rental or other amounts, nor shall such acceptance prevent Landlord from exercising any other rights and remedies available to it. Acceptance of rent or other payments by Landlord shall not constitute a
waiver of late charges or interest accrued with respect to such rent or other payments or any prior installments thereof, nor of any other defaults by Tenant, whether monetary or non-monetary in nature, remaining uncured at the time of such
acceptance of rent or other payments. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4. <U>TAXES</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.1 <U>Personal Property</U>. Tenant shall be responsible for and shall pay prior to delinquency all taxes and assessments levied against or
by reason of (a)&nbsp;any and all alterations, additions and items installed or placed on or in the Building and taxed as personal property rather than as real property, and/or (b)&nbsp;all personal property, trade fixtures and other property placed
by Tenant on or about the Property. Upon request by Landlord, Tenant shall furnish Landlord with satisfactory evidence of Tenant&#146;s payment thereof. If at any time during the term of this Lease any of said alterations, additions or personal
property, whether or not belonging to Tenant, shall be taxed or assessed as part of the Property, then such tax or assessment shall be paid by Tenant to Landlord within fifteen (15)&nbsp;days after presentation by Landlord of copies of the tax bills
in which such taxes and assessments are included and shall, for the purposes of this Lease, be deemed to be personal property taxes or assessments under this Section&nbsp;6.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.2 <U>Real Property</U>. To the extent any real property taxes and assessments on the Property (including, but not limited to, the
Improvements or any portion thereof) are assessed directly to Tenant, Tenant shall be responsible for and shall pay prior to delinquency all such taxes and assessments levied against the Property. Upon request by Landlord, Tenant shall furnish
Landlord with satisfactory evidence of Tenant&#146;s payment thereof. To the extent the Property and/or Improvements are taxed or assessed to Landlord following the Commencement Date, such real property taxes and assessments shall constitute
Operating Expenses (as that term is defined in Section&nbsp;5.2 of this Lease) and shall be paid in accordance with the provisions of Article 5 of this Lease. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 7 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5. <U>OPERATING EXPENSES</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.1 <U>Payment of Operating Expenses</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) Tenant shall pay to Landlord, at the time and in the manner hereinafter set forth, as additional rental, an amount equal to forty-four and
eighty-seven hundredths percent (44.87%)&nbsp;(&#147;<U>Tenant&#146;s Operating Cost Share</U>&#148;) of the Operating Expenses defined in Section&nbsp;5.2; <U>provided,</U> however, that the Tenant&#146;s Operating Cost Share set forth in the
preceding portion of this sentence shall apply only to expenses that are determined and allocated by Landlord on a Center-wide or multi-building basis, subject to any adjustments required under any other applicable provisions of this
Section&nbsp;5.1, and that Tenant&#146;s Operating Cost Share shall be one hundred percent (100%)&nbsp;with respect to any Operating Expenses defined in Section&nbsp;5.2 that are reasonably allocable solely to the Building. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) Tenant&#146;s Operating Cost Share as specified in paragraph (a)&nbsp;of this Section with respect to Operating Expenses which are
determined and allocated on a Center-wide basis is based upon an area of 66,127 square feet for the Building and upon an aggregate area of 147,362 square feet for the existing buildings owned by Landlord in the Center and consolidated with the
Building for operation, maintenance, common area and Operating Expense purposes. If the actual area of the buildings owned from time to time by Landlord in the Center and consolidated with the Building for operation, maintenance, common area and
Operating Expense purposes, as such area is measured in good faith by Landlord&#146;s architect on the same basis of measurement under which the Building has been determined to contain 66,127 square feet, changes from the assumed figure set forth
above as a result of a change in the physical size of one or more of such buildings, then Tenant&#146;s Operating Cost Share as it applies to Operating Expenses that are determined and allocated on a Center-wide or multi-building basis shall be
adjusted to reflect the actual areas so measured as they exist from time to time. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) If Landlord at any time constructs additional
buildings in the Center or on any adjacent property owned by Landlord and operated, for common area purposes, on an integrated basis with the Center, then Tenant&#146;s Operating Cost Share as it applies to Operating Expenses that are determined and
allocated on a Center-wide or multi-building basis shall be adjusted to be equal to the percentage determined by dividing the gross square footage of the Building as it exists from time to time by the gross square footage of all buildings located in
the Center or on any applicable adjacent property owned by Landlord as described above, measured using the same basis of measurement under which the Building has been determined to contain 66,127 square feet. In determining such percentage, a
building shall be taken into account from and after the date on which a tenant first enters into possession of the building or a portion thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.2 <U>Definition Of Operating Expenses</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) Subject to the exclusions and provisions hereinafter contained, the term &#147;<U>Operating Expenses</U>&#148; shall mean the total costs
and expenses incurred by or allocable to Landlord for management, operation and maintenance of the Improvements, the Building, the Property and the Center (or, in the case of items that are determined and allocated on a
stand-</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 8 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
alone basis as described in Section&nbsp;5.1, that portion of the Property and the Center that is reasonably allocable to the Building), including, without limitation, costs and expenses of
(i)&nbsp;insurance (which may include, at Landlord&#146;s option, seismic and environmental insurance), property management fees, landscaping, and the operation, repair and maintenance of buildings and Common Areas; (ii)&nbsp;all utilities and
services; (iii)&nbsp;real and personal property taxes and assessments or substitutes therefor levied or assessed against the Center or any part thereof, including (but not limited to) any possessory interest, use, business, license or other taxes or
fees, any taxes imposed directly on rents or services, any assessments or charges for police or fire protection, housing, transit, open space, street or sidewalk construction or maintenance or other similar services from time to time by any
governmental or quasi-governmental entity, and any other new taxes on landlords in addition to taxes now in effect; (iv)&nbsp;supplies, equipment, utilities and tools used in management, operation and maintenance of the Center; (v)&nbsp;capital
improvements to the Center, the Improvements or the Building, amortized over their respective useful lives as reasonably determined by Landlord&#146;s accountants either for federal income tax reporting purposes or pursuant to generally accepted
accounting principles applied on a consistent basis, (aa) which reduce or will cause future reduction of other items of Operating Expenses for which Tenant is otherwise required to contribute or (bb) which are required by law, ordinance, regulation
or order of any governmental authority or (cc) of which Tenant has use or which benefit Tenant; and (vi)&nbsp;any other costs (including, but not limited to, any parking or utilities fees or surcharges) allocable to or paid by Landlord, as owner of
the Center, Building or Improvements, pursuant to any applicable laws, ordinances, regulations or orders of any governmental or quasi-governmental authority or pursuant to the terms of any declarations of covenants, conditions and restrictions now
or hereafter affecting the Center or any other property over which Tenant has non-exclusive use rights as contemplated in Section&nbsp;1.1(b) hereof. Operating Expenses shall not include any costs attributable to the initial construction of the
Building or of Common Area improvements in the Center. The distinction between items of ordinary operating maintenance and repair and items of a capital nature shall be made in accordance with generally accepted accounting principles applied on a
consistent basis or in accordance with tax accounting principles, as determined in good faith by Landlord&#146;s accountants. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b)
Notwithstanding anything to the contrary contained in this Lease, the following shall not be included within Operating Expenses: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i) Costs of maintenance or repair of the roof membrane for any building, except during periods (if any) in which costs of
maintenance or repair of the roof membrane for the Building are likewise included as an Operating Expense (rather than being incurred directly by Tenant or passed through directly to Tenant); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(ii) Leasing commissions, attorneys&#146; fees, costs, disbursements, and other expenses incurred in connection with
negotiations or disputes with tenants, or in connection with leasing, renovating or improving space for tenants or other occupants or prospective tenants or other occupants of the Center or of any other property owned by Landlord; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 9 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(iii) The cost of any service sold to any tenant (including Tenant) or other
occupant for which Landlord is entitled to be reimbursed as an additional charge or rental over and above the basic rent and operating expenses payable under the lease with that tenant; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(iv) Any depreciation on the Building or on any other improvements in the Center or on any other property owned by Landlord;
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(v) Expenses in connection with services or other benefits of a type that are not offered or made available to Tenant but
that are provided to another tenant of the Center or of any other property owned by Landlord; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(vi) Costs incurred due to
Landlord&#146;s violation of any terms or conditions of this Lease or of any other lease relating to the Building or to any other portion of the Center or of any other property owned by Landlord; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(vii) Amounts paid to any Affiliate of Landlord for management or other services on or to the Center or any portion thereof or
any other property owned by Landlord, or for supplies or other materials, to the extent that the cost of the services, supplies or materials exceeds the cost that would have been paid had the services, supplies or materials been provided by
unaffiliated parties on a competitive basis; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(viii) All interest, loan fees and other carrying costs related to any
mortgage or deed of trust or related to any capital item, and all rental and other amounts payable under any ground or underlying lease, or under any lease for any equipment ordinarily considered to be of a capital nature (except (A)&nbsp;janitorial
equipment which is not affixed to the Building and/or (B)&nbsp;equipment the cost of which, if purchased, would be considered an amortizable Operating Expense under the provisions of this Section&nbsp;5.2, notwithstanding the capital nature of such
equipment); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(ix) Any compensation paid to clerks, attendants or other persons in commercial concessions operated by
Landlord; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(x) Advertising and promotional expenditures; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(xi) Costs of repairs and other work occasioned by fire, windstorm or other casualty of an insurable nature, except to the
extent of any applicable deductible amounts under insurance actually carried by Landlord; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(xii) Any costs, fines or
penalties incurred due to violations by Landlord of any governmental rule or authority or of this Lease or any other lease of any portion of the Center or any other property owned by Landlord, or due to Landlord&#146;s negligence or willful
misconduct; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(xiii) Costs for sculpture, paintings or other objects of art, and for any insurance thereon or extraordinary
security in connection therewith; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 10 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(xiv) Wages, salaries or other compensation paid to any executive employees above
the grade of building manager; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(xv) The cost of correcting any building code or other violations which are Landlord&#146;s
responsibility and which were violations prior to the Commencement Date; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(xvi) The cost of containing, removing or
otherwise remediating any contamination of the Center (including the underlying land and groundwater) by any toxic or hazardous materials (including, without limitation, asbestos and PCBs). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.3 <U>Determination Of Operating Expenses</U>. On or before the Commencement Date and during the last month of each calendar year of the term
of this Lease (&#147;<U>Lease Year</U>&#148;), or as soon thereafter as practical, Landlord shall provide Tenant notice of Landlord&#146;s estimate of the Operating Expenses for the ensuing Lease Year or applicable portion thereof. On or before the
first day of each month during the ensuing Lease Year or applicable portion thereof, beginning on the Commencement Date, Tenant shall pay to Landlord Tenant&#146;s Operating Cost Share of the portion of such estimated Operating Expenses allocable
(on a prorata basis) to such month; <U>provided,</U> however, that if such notice is not given in the last month of a Lease Year, Tenant shall continue to pay on the basis of the prior year&#146;s estimate, if any, until the month after such notice
is given. If at any time or times it appears to Landlord that the actual Operating Expenses will vary from Landlord&#146;s estimate by more than five percent (5%), Landlord may, by notice to Tenant, revise its estimate for such year and subsequent
payments by Tenant for such year shall be based upon such revised estimate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.4 <U>Final Accounting For Lease Year</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) Within ninety (90)&nbsp;days after the close of each Lease Year, or as soon after such 90-day period as practicable, Landlord shall deliver
to Tenant a statement of Tenant&#146;s Operating Cost Share of the Operating Expenses for such Lease Year prepared by Landlord from Landlord&#146;s books and records, which statement shall be final and binding on Landlord and Tenant (except as
provided in Section&nbsp;5.4(b)). If on the basis of such statement Tenant owes an amount that is more or less than the estimated payments for such Lease Year previously made by Tenant, Tenant or Landlord, as the case may be, shall pay the
deficiency to the other party within thirty (30)&nbsp;days after delivery of the statement. Failure or inability of Landlord to deliver the annual statement within such ninety (90)&nbsp;day period shall not impair or constitute a waiver of
Tenant&#146;s obligation to pay Operating Expenses, or cause Landlord to incur any liability for damages. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) At any time within three
(3)&nbsp;months after receipt of Landlord&#146;s annual statement of Operating Expenses as contemplated in Section&nbsp;5.4(a), Tenant shall be entitled, upon reasonable written notice to Landlord and during normal business hours at Landlord&#146;s
office or such other places as Landlord shall designate, to inspect and examine those books and records of Landlord relating to the determination of Operating Expenses for the immediately preceding Lease Year covered by such annual statement or, if
Tenant so elects by written notice to Landlord, to request an independent audit of such books and records. The independent audit </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 11 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of the books and records shall be conducted by a certified public accountant acceptable to both Landlord and Tenant or, if the parties are unable to agree, by a certified public accountant
appointed by the Presiding Judge of the San Mateo County Superior Court upon the application of either Landlord or Tenant (with notice to the other party). In either event, such certified public accountant shall be one who is not then employed in
any capacity by Landlord or Tenant or by any of their respective affiliates. The audit shall be limited to the determination of the amount of Operating Expenses for the subject Lease Year, and shall be based on generally accepted accounting
principles and tax accounting principles, consistently applied. If it is determined, by mutual agreement of Landlord and Tenant or by independent audit, that the amount of Operating Expenses billed to or paid by Tenant for the applicable Lease Year
was incorrect, then the appropriate party shall pay to the other party the deficiency or overpayment, as applicable, within thirty (30)&nbsp;days after the final determination of such deficiency or overpayment. All costs and expenses of the audit
shall be paid by Tenant unless the audit shows that Landlord overstated Operating Expenses for the subject Lease Year by more than five percent (5%), in which case Landlord shall pay all costs and expenses of the audit within thirty (30)&nbsp;days
after Landlord receives Tenant&#146;s written demand for such payment, accompanied by invoices or other evidence reasonably supporting the costs and expenses for which such payment or reimbursement is claimed. Each party agrees to maintain the
confidentiality of the findings of any audit in accordance with the provisions of this Section&nbsp;5.4. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.5 <U>Proration</U>. If the
Commencement Date falls on a day other than the first day of a Lease Year or if this Lease terminates on a day other than the last day of a Lease Year, then the amount of Operating Expenses payable by Tenant with respect to such first or last
partial Lease Year shall be prorated on the basis which the number of days during such Lease Year in which this Lease is in effect bears to 365. The termination of this Lease shall not affect the obligations of Landlord and Tenant pursuant to
Section&nbsp;5.4 to be performed after such termination. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6. <U>UTILITIES</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.1 <U>Payment</U>. Commencing with the Commencement Date and thereafter throughout the term of this Lease, Tenant shall pay, before
delinquency, all charges for water, gas, heat, light, electricity, power, sewer, telephone, alarm system, janitorial and other services or utilities supplied to or consumed in or with respect to the Building (other than any separately metered costs
for water, electricity or other services or utilities furnished with respect to the Common Areas, which costs shall be paid by Landlord and shall constitute Operating Expenses under Section&nbsp;5.2 hereof), including any taxes on such services and
utilities. It is the intention of the parties that all such services shall be separately metered to the Building. In the event that any of such services supplied to the Building are not separately metered, then the amount thereof shall be an item of
Operating Expenses and shall be paid as provided in Article 5. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.2 <U>Interruption</U>. There shall be no abatement of rent or other
charges required to be paid hereunder and Landlord shall not be liable in damages or otherwise for interruption or failure of any service or utility furnished to or used with respect to the Building or Property because of accident, making of
repairs, alterations or improvements, severe weather, difficulty or inability in obtaining services or supplies, labor difficulties or any other cause. Notwithstanding the foregoing provisions of this Section&nbsp;6.2, however, in the event of any
interruption or failure </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 12 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of any service or utility to the Building that (i)&nbsp;is caused in whole or in material part by the active negligence or willful misconduct of Landlord or its agents or employees <U>and</U>
(ii)&nbsp;continues for more than three (3)&nbsp;business days <U>and</U> (iii)&nbsp;materially impairs Tenant&#146;s ability to use the Building for its intended purposes hereunder, then following such three (3)&nbsp;business day period,
Tenant&#146;s obligations for payment of rent and other charges under this Lease shall be abated in proportion to the degree of impairment of Tenant&#146;s use of the Building, and such abatement shall continue until Tenant&#146;s use of the
Building is no longer materially impaired thereby. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7. <U>ALTERATIONS; SIGNS</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.1 <U>Right To Make Alterations</U>. Tenant shall make no alterations, additions or improvements to the Building or the Property, other than
interior non-structural alterations costing less than Fifty Thousand Dollars ($50,000.00) in the aggregate during any twelve (12)&nbsp;month period, without the prior written consent of Landlord, which consent shall not be unreasonably withheld or
delayed. All such alterations, additions and improvements shall be completed with due diligence in a first-class workmanlike manner, in compliance with plans and specifications approved in writing by Landlord and in compliance with all applicable
laws, ordinances, rules and regulations, and to the extent Landlord&#146;s consent is not otherwise required hereunder for such alterations, additions or improvements, Tenant shall give prompt written notice thereof to Landlord. Tenant shall cause
any contractors engaged by Tenant for work in the Building or on the Property to maintain public liability and property damage insurance, and other customary insurance, with such terms and in such amounts as Landlord may reasonably require, naming
as additional insureds Landlord and any of its partners, shareholders, property managers and lenders designated by Landlord for this purpose, and shall furnish Landlord with certificates of insurance or other evidence that such coverage is in
effect. Notwithstanding any other provisions of this Section&nbsp;7.1, under no circumstances shall Tenant make any structural alterations or improvements, or any substantial changes to the roof or substantial equipment installations on the roof, or
any substantial changes or alterations to the building systems, without Landlord&#146;s prior written consent (which consent shall not be unreasonably withheld, conditioned or delayed). If Tenant so requests in seeking Landlord&#146;s consent to any
alterations, additions or improvements, Landlord shall specify in granting such consent whether Landlord intends to require that Tenant remove such alterations, additions or improvements (or any specified portions thereof) upon expiration or
termination of this Lease. Landlord shall receive no fee for supervision, profit, overhead or general conditions in connection with any alterations, additions or improvements constructed or installed by Tenant under this Lease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.2 <U>Title To Alterations</U>. All alterations, additions and improvements installed in, on or about the Building or the Property shall
become part of the Property and shall become the property of Landlord, unless Landlord elects to require Tenant to remove the same upon the termination of this Lease; <U>provided,</U> however, that the foregoing shall not apply to Tenant&#146;s
movable furniture and equipment and trade fixtures. Tenant shall promptly repair any damage caused by its removal of any such furniture, equipment or trade fixtures. Notwithstanding any other provisions of this Article 7, however, (a)&nbsp;under no
circumstances shall Tenant have any right to remove from the Building or the Property, during the term of this Lease or at the expiration or termination of this Lease, any lab benches, fume hoods, cold rooms or other similar improvements and
equipment existing in the Building on the Commencement Date, except with </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 13 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Landlord&#146;s written consent (which consent may take the form of either (i)&nbsp;a separate written consent or (ii)&nbsp;a written approval of plans for proposed alterations or improvements,
if and to the extent that such plans specifically show the removal or relocation of any existing lab benches, fume hoods, cold rooms or other similar improvements or equipment as part of the proposed alterations or improvements), and (b)&nbsp;if
Tenant requests Landlord&#146;s written consent to any alterations, additions or improvements under Section&nbsp;7.1 hereof and, in requesting such consent, asks that Landlord specify whether Landlord will require removal of such alterations,
additions or improvements upon termination or expiration of this Lease, then Landlord shall not be entitled to require such removal unless Landlord specified its intention to do so at the time of granting of Landlord&#146;s consent to the requested
alterations, additions or improvements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.3 <U>Tenant Fixtures</U>. Subject to the final sentence of Section&nbsp;7.2 and to
Section&nbsp;7.5, Tenant may install, remove and reinstall trade fixtures without Landlord&#146;s prior written consent, except that installation and removal of any fixtures which are affixed to the Building or the Property or which affect the
exterior or structural portions of the Building or the building systems shall require Landlord&#146;s written approval, which approval shall not be unreasonably withheld or delayed. Subject to the provisions of Section&nbsp;7.5, the foregoing shall
apply to Tenant&#146;s signs, logos and insignia, all of which Tenant shall have the right to place and remove and replace (a)&nbsp;only with Landlord&#146;s prior written consent as to location, size and composition, which consent shall not be
unreasonably withheld, conditioned or delayed, and (b)&nbsp;only in compliance with all restrictions and requirements of applicable law and of any covenants, conditions and restrictions or other written agreements now or hereafter applicable to the
Property. Tenant shall immediately repair any damage caused by installation and removal of fixtures under this Section&nbsp;7.3. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.4
<U>No Liens</U>. Tenant shall at all times keep the Building and the Property free from all liens and claims of any contractors, subcontractors, materialmen, suppliers or any other parties employed either directly or indirectly by Tenant in
construction work on the Building or the Property. Tenant may contest any claim of lien, but only if, prior to such contest, Tenant either (i)&nbsp;posts security in the amount of the claim, plus estimated costs and interest, or (ii) records a bond
of a responsible corporate surety in such amount as may be required to release the lien from the Building and the Property. Tenant shall indemnify, defend and hold Landlord harmless against any and all liability, loss, damage, cost and other
expenses, including, without limitation, reasonable attorneys&#146; fees, arising out of claims of any lien for work performed or materials or supplies furnished at the request of Tenant or persons claiming under Tenant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.5 <U>Signs</U>. Without limiting the generality of the provisions of Section&nbsp;7.3 hereof, Tenant shall have the right to display its
corporate name and logo on the Building and in front of the entrance to the Building, subject to Landlord&#146;s prior approval as to location, size, design and composition (which approval shall not be unreasonably withheld, conditioned or delayed),
subject to the established sign criteria for the Center and subject to all restrictions and requirements of applicable law and of any covenants, conditions and restrictions or other written agreements now or hereafter applicable to the Property.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 14 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8. <U>MAINTENANCE AND REPAIRS</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.1 <U>Landlord&#146;s Work</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) Landlord shall repair and maintain or cause to be repaired and maintained the Common Areas of the Property and the roof (structural
portions only), exterior walls and other structural portions of the Building. The cost of all work performed by Landlord under this Section&nbsp;8.1 shall be an Operating Expense hereunder, except to the extent such work (i)&nbsp;is required due to
the negligence of Landlord, (ii)&nbsp;is a capital expense, or any other cost or expense, not includible as an Operating Expense under Section&nbsp;5.2 hereof, or (iii)&nbsp;is required due to the negligence or willful misconduct of Tenant or its
agents, employees or invitees (in which event Tenant shall bear the full cost of such work pursuant to the indemnification provided in Section&nbsp;10.6 hereof, subject to the release set forth in Section&nbsp;10.4 hereof). Tenant knowingly and
voluntarily waives the right to make repairs at Landlord&#146;s expense, except to the extent permitted by Section&nbsp;8.1(b) below, or to offset the cost thereof against rent, under any law, statute, regulation or ordinance now or hereafter in
effect. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) If Landlord fails to perform any repairs or maintenance required to be performed by Landlord on the Building under
Section&nbsp;8.1(a) and such failure continues for thirty (30)&nbsp;days or more after Tenant gives Landlord written notice of such failure (or, if such repairs or maintenance cannot reasonably be performed within such 30-day period, then if
Landlord fails to commence performance within such 30-day period and thereafter to pursue such performance diligently to completion), then Tenant shall have the right to perform such repairs or maintenance and Landlord shall reimburse Tenant for the
reasonable cost thereof within fifteen (15)&nbsp;days after written notice from Tenant of the completion and cost of such work, accompanied by copies of invoices or other reasonable supporting documentation. Under no circumstances, however, shall
Tenant have any right to offset the cost of any such work against rent or other charges falling due from time to time under this Lease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.2 <U>Tenant&#146;s Obligation For Maintenance</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) <U>Good Order, Condition And Repair</U>. Except as provided in Section&nbsp;8.1 hereof, Tenant at its sole cost and expense shall keep and
maintain in good and sanitary order, condition and repair the Building and every part thereof, wherever located, including but not limited to the roof (non-structural portions only), signs, interior, ceiling, electrical system, plumbing system,
telephone and communications systems of the Building, the HVAC equipment and related mechanical systems serving the Building (for which equipment and systems Tenant shall enter into a service contract with a person or entity designated or approved
by Landlord), all doors, door checks, windows, plate glass, door fronts, exposed plumbing and sewage and other utility facilities, fixtures, lighting, wall surfaces, floor surfaces and ceiling surfaces of the Building and all other interior repairs,
foreseen and unforeseen, with respect to the Building, as required. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) <U>Landlord&#146;s Remedy</U>. If Tenant, after notice from
Landlord, fails to make or perform promptly any repairs or maintenance which are the obligation of Tenant hereunder, Landlord shall have the right, but shall not be required, to enter the Building and make the repairs or perform the maintenance
necessary to restore the Building to good and sanitary order, condition and repair. Immediately on demand from Landlord, the cost of such repairs shall be due and payable by Tenant to Landlord. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 15 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) <U>Condition Upon Surrender</U>. At the expiration or sooner termination of this Lease,
Tenant shall surrender the Building and the Improvements, including any additions, alterations and improvements thereto (except for items which Tenant is permitted and elects to remove, or is required to remove, pursuant to the provisions of this
Lease), broom clean, in good and sanitary order, condition and repair, ordinary wear and tear excepted, first, however, removing all goods and effects of Tenant and all and fixtures and items required to be removed or specified to be removed at
Landlord&#146;s election pursuant to this Lease (including, but not limited to, any such removal required as a result of an election duly made by Landlord to require such removal as contemplated in Section&nbsp;7.2), and repairing any damage caused
by such removal. Tenant shall not have the right to remove fixtures or equipment if Tenant is in material default hereunder unless Landlord specifically waives this provision in writing. Tenant expressly waives any and all interest in any personal
property and trade fixtures not removed from the Property by Tenant at the expiration or termination of this Lease, agrees that any such personal property and trade fixtures may, at Landlord&#146;s election, be deemed to have been abandoned by
Tenant, and authorizes Landlord (at its election and without prejudice to any other remedies under this Lease or under applicable law) to remove and either retain, store or dispose of such property at Tenant&#146;s cost and expense, and Tenant
waives all claims against Landlord for any damages resulting from any such removal, storage, retention or disposal. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9. <U>USE OF
PROPERTY</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.1 <U>Permitted Use</U>. Subject to Sections 9.3, 9.4 and 9.6 hereof, Tenant shall use the Building solely for a laboratory
and research and development facility, which use may include (but is not limited to) wet chemistry and biology labs, clean rooms, storage and use of toxic and radioactive materials (subject to the provisions of Section&nbsp;9.6 hereof), storage and
use of laboratory animals, administrative offices, and other lawful purposes reasonably related to or incidental to such specified uses (subject in each case to receipt of all necessary approvals from the City of South San Francisco and other
governmental agencies having jurisdiction over the Building), and for no other purpose, unless Landlord in its sole discretion otherwise consents in writing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.2 [Omitted.] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.3 <U>No
Nuisance</U>. Tenant shall not use the Property for or carry on or permit upon the Property or any part thereof any offensive, noisy or dangerous trade, business, manufacture, occupation, odor or fumes, or any nuisance or anything against public
policy, nor interfere with the rights or business of Landlord in the Building or the Property, nor commit or allow to be committed any waste in, on or about the Property. Tenant shall not do or permit anything to be done in or about the Property,
nor bring nor keep anything therein, which will in any way cause the Property to be uninsurable with respect to the insurance required by this Lease or with respect to standard fire and extended coverage insurance with vandalism, malicious mischief
and riot endorsements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 16 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.4 <U>Compliance With Laws</U>. Tenant shall not use the Property or permit the Property to be
used in whole or in part for any purpose or use that is in violation of any applicable laws, ordinances, regulations or rules of any governmental agency or public authority. Tenant shall keep the Building and Improvements equipped with all safety
appliances required by law, ordinance or insurance on the Property, or any order or regulation of any public authority, because of Tenant&#146;s particular use of the Property. Tenant shall procure all licenses and permits required for use of the
Property. Tenant shall use the Property in strict accordance with all applicable ordinances, rules, laws and regulations and shall comply with all requirements of all governmental authorities now in force or which may hereafter be in force
pertaining to the use of the Property by Tenant, including, without limitation, regulations applicable to noise, water, soil and air pollution, and making such nonstructural alterations and additions thereto as may be required from time to time by
such laws, ordinances, rules, regulations and requirements of governmental authorities or insurers of the Property (collectively, &#147;<U>Requirements</U>&#148;) because of Tenant&#146;s construction of improvements in or other particular use of
the Property. Any structural alterations or additions required from time to time by applicable Requirements because of Tenant&#146;s construction of improvements in the Building or other particular use of the Property shall, at Landlord&#146;s
election, either (i)&nbsp;be made by Tenant, at Tenant&#146;s sole cost and expense, in accordance with the procedures and standards set forth in Section&nbsp;7.1 for alterations by Tenant, or (ii)&nbsp;be made by Landlord at Tenant&#146;s sole cost
and expense, in which event Tenant shall pay to Landlord as additional rent, within ten (10)&nbsp;days after demand by Landlord, an amount equal to all reasonable costs incurred by Landlord in connection with such alterations or additions. The
judgment of any court, or the admission by Tenant in any proceeding against Tenant, that Tenant has violated any law, statute, ordinance or governmental rule, regulation or requirement shall be conclusive of such violation as between Landlord and
Tenant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.5 <U>Liquidation Sales</U>. Tenant shall not conduct or permit to be conducted any auction, bankruptcy sale, liquidation sale,
or going out of business sale, in, upon or about the Property, whether said auction or sale be voluntary, involuntary or pursuant to any assignment for the benefit of creditors, or pursuant to any bankruptcy or other insolvency proceeding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.6 <U>Environmental Matters</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) For purposes of this Section, &#147;<U>hazardous substance</U>&#148; shall mean (i)&nbsp;the substances included within the definitions of
the term &#147;hazardous substance&#148; under the Comprehensive Environmental Response, Compensation and Liability Act of 1980, as amended, 42 U.S.C. &#167;&#167; 9601 <U>et seq</U>., and the regulations promulgated thereunder, as amended,
(ii)&nbsp;the substances included within the definition of &#147;hazardous substance&#148; under the California Carpenter-Presley-Tanner Hazardous Substance Account Act, California Health&nbsp;&amp; Safety Code &#167;&#167; 25300 <U>et seq</U>., and
regulations promulgated thereunder, as amended, (iii)&nbsp;the substances included within the definition of &#147;hazardous materials&#148; under the Hazardous Materials Release Response Plans and Inventory Act, California Health&nbsp;&amp; Safety
Code &#167;&#167; 25500 <U>et seq</U>., and regulations promulgated thereunder, as amended, (iv)&nbsp;the substances included within the definition of &#147;hazardous substance&#148; under the Underground Storage of Hazardous Substances provisions
set forth in California Health&nbsp;&amp; Safety Code &#167;&#167; 25280 <U>et seq</U>., and (v)&nbsp;petroleum or any fraction thereof; &#147;<U>hazardous waste</U>&#148; shall mean (i)&nbsp;any waste listed as or meeting the identified
characteristics of a &#147;hazardous waste&#148; under the Resource Conservation and Recovery </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 17 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Act of 1976, 42 U.S.C. &#167;&#167; 6901 <U>et seq</U>., and regulations promulgated pursuant thereto, as amended (collectively, &#147;<U>RCRA</U>&#148;), (ii)&nbsp;any waste meeting the
identified characteristics of &#147;hazardous waste,&#148; &#147;extremely hazardous waste&#148; or &#147;restricted hazardous waste&#148; under the California Hazardous Waste Control Law, California Health&nbsp;&amp; Safety Code &#167;&#167; 25100
<U>et seq</U>., and regulations promulgated pursuant thereto, as amended (collectively, the &#147;<U>CHWCL</U>&#148;), and/or (iii)&nbsp;any waste meeting the identified characteristics of &#147;medical waste&#148; under California Health&nbsp;&amp;
Safety Code &#167;&#167; 25015-25027.8, and regulations promulgated thereunder, as amended; and &#147;<U>hazardous waste facility</U>&#148; shall mean a hazardous waste facility as defined under the CHWCL. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) Without limiting the generality of the obligations set forth in Section&nbsp;9.4 of this Lease: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i) Tenant shall not cause or permit any hazardous substance or hazardous waste to be brought upon, kept, stored or used in or
about the Property without the prior written consent of Landlord, which consent shall not be unreasonably withheld, conditioned or delayed, except that Tenant, in connection with its permitted use of the Property as provided in Section&nbsp;9.1, may
keep, store and use materials that constitute hazardous substances which are customary for such permitted use, provided such hazardous substances are kept, stored and used in quantities which are customary for such permitted use and are kept, stored
and used in full compliance with clauses (ii)&nbsp;and (iii)&nbsp;immediately below. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(ii) Tenant shall comply with all
applicable laws, rules, regulations, orders, permits, licenses and operating plans of any governmental authority with respect to the receipt, use, handling, generation, transportation, storage, treatment and/or disposal of hazardous substances or
wastes by Tenant or its agents or employees (&#147;<U>Tenant&#146;s Hazardous Substances</U>&#148;), and Tenant will provide Landlord with copies of all permits, licenses, registrations and other similar documents that authorize Tenant to conduct
any such activities in connection with its authorized use of the Property from time to time. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(iii) Tenant shall not
(A)&nbsp;operate on or about the Property any facility required to be permitted or licensed as a hazardous waste facility or for which interim status as such is required, nor (B)&nbsp;store any hazardous wastes on or about the Property for ninety
(90)&nbsp;days or more, nor (C)&nbsp;conduct any other activities on or about the Property that could result in the Property being deemed to be a &#147;hazardous waste facility&#148; (including, but not limited to, any storage or treatment of
hazardous substances or hazardous wastes which could have such a result), nor (D)&nbsp;store any hazardous wastes on or about the Center in violation of any federal or California laws or in violation of the terms of any federal or state licenses or
permits held by Tenant. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(iv) Tenant shall not install any underground storage tanks on the Property without the prior
written consent of Landlord and prior approval by all applicable governmental authorities. If and to the extent that Tenant obtains all such required consents and approvals and installs any underground storage tanks on the Property, Tenant shall
comply with all applicable laws, rules, regulations, orders and permits relating to underground storage tanks installed by Tenant or its agents or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 18 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
employees or at the request of Tenant (including any installation, monitoring, maintenance, closure and/or removal of such tanks) as such tanks are defined in California Health&nbsp;&amp; Safety
Code &#167; 25281(x), including, without limitation, complying with California Health&nbsp;&amp; Safety Code &#167;&#167; 25280-25299.7 and the regulations promulgated thereunder, as amended. Tenant shall furnish to Landlord copies of all
registrations and permits issued to or held by Tenant from time to time for any and all underground storage tanks located on or under the Property. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(v) If applicable, Tenant shall provide Landlord in writing the following information and/or documentation within fifteen
(15)&nbsp;days after the Commencement Date, and shall update such information at least annually, on or before each anniversary of the Commencement Date, to reflect any change in or addition to the required information and/or documentation
(<U>provided,</U> however, that in the case of the materials described in subparagraphs (B), (C)&nbsp;and (E)&nbsp;below, Tenant shall not be required to deliver copies of such materials to Landlord but shall maintain copies of such materials to
such extent and for such periods as may be required by applicable law and shall permit Landlord or its representatives to inspect and copy such materials during normal business hours at any time and from time to time upon reasonable notice to
Tenant): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(A) A list of all hazardous substances and/or wastes that Tenant receives, uses, handles, generates, transports,
stores, treats or disposes of from time to time in connection with its operations on the Property. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(B) All Material Safety
Data Sheets (&#147;<U>MSDS&#146;s</U>&#148;), if any, required to be completed with respect to operations of Tenant at the Property from time to time in accordance with Title 26, California Code of Regulations &#167; 8-5194 or 42 U.S.C. &#167;
11021, or any amendments thereto, and any Hazardous Materials Inventory Sheets that detail the MSDS&#146;s. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(C) All
hazardous waste manifests, if any, that Tenant is required to complete from time to time under California Health&nbsp;&amp; Safety Code &#167; 25160, any regulations promulgated thereunder, any similar successor provisions and/or any amendments to
any of the foregoing, in connection with its operations at the Property. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(D) Any Hazardous Materials Management Plan
required from time to time with respect to Tenant&#146;s operations at the Property, pursuant to California Health&nbsp;&amp; Safety Code &#167;&#167; 25500 <U>et seq</U>., any regulations promulgated thereunder, any similar successor provisions
and/or any amendments to any of the foregoing. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(E) Any Air Toxics Emissions Inventory Plan required from time to time with
respect to Tenant&#146;s operations at the Property, pursuant to California Health&nbsp;&amp; Safety Code &#167;&#167; 44340 <U>et seq</U>., any regulations promulgated thereunder, any similar successor provisions and/or any amendments to any of the
foregoing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 19 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(F) Any biennial Hazardous Waste Generator reports or notifications furnished by
Tenant to the California Department of Toxic Substances Control or other applicable governmental authorities from time to time pursuant to California Code of Regulations Title 22, &#167; 66262.41, any similar successor provisions and/or any
amendments to any of the foregoing, in connection with Tenant&#146;s operations at the Property. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(G) Any Hazardous Waste
Generator Reports regarding source reductions, as required from time to time pursuant to California Health&nbsp;&amp; Safety Code &#167;&#167; 25244.20 <U>et seq</U>., any regulations promulgated thereunder, any similar successor provisions and/or
any amendments to any of the foregoing, in connection with Tenant&#146;s operations at the Property. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(H) Any Hazardous
Waste Generator Reports or notifications not otherwise described in the preceding subparagraphs and required from time to time pursuant to California Health&nbsp;&amp; Safety Code &#167; 25153.6, California Code of Regulations Title 22, Division
4.5, Chapter 12, &#167;&#167; 66262.10 <U>et seq</U>. (&#147;Standards Applicable to Generators of Hazardous Waste&#148;), any other regulations promulgated thereunder, any similar successor provisions and/or any amendments to any of the foregoing,
in connection with Tenant&#146;s operations at the Property. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(I) All industrial wastewater discharge permits issued to or
held by Tenant from time to time in connection with its operations on the Property, and all air quality management district permits issued to or held by Tenant from time to time in connection with its operations at the Property. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(J) Copies of any other lists or inventories of hazardous substances and/or wastes on or about the Property that Tenant is
otherwise required to prepare and file from time to time with any governmental or regulatory authority. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(vi) Tenant shall
secure Landlord&#146;s prior written approval for any proposed receipt, storage, possession, use, transfer or disposal of &#147;radioactive materials&#148; or &#147;radiation,&#148; as such materials are defined in Title 26, California Code of
Regulations &#167; 17-30100, and/or any other materials possessing the characteristics of the materials so defined, which approval Landlord may withhold in its sole and absolute discretion; <U>provided</U>, that such approval shall not be required
for any radioactive materials for which Tenant has secured prior written approval of the California Department of Health Services (or other governmental authority then having primary regulatory jurisdiction over such matters) and delivered to
Landlord a copy of such approval. Tenant, in connection with any such authorized receipt, storage, possession, use, transfer or disposal of radioactive materials or radiation, shall: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(A) Comply with all federal, state and local laws, rules, regulations, orders, licenses and permits issued to or applicable to
Tenant with respect to its business operations on the Property; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 20 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(B) Maintain, to such extent and for such periods as may be required by
applicable law, and permit Landlord and its representatives to inspect during normal business hours at any time and from time to time upon reasonable notice to Tenant, a list of all radioactive materials or radiation received, stored, possessed,
used, transferred or disposed of by Tenant or in connection with the operation of Tenant&#146;s business on the Property from time to time, to the extent not already disclosed through delivery of a copy of a California Department of Health Services
approval (or approval by any other governmental authority then having primary regulatory jurisdiction over such matters) with respect thereto as contemplated above; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(C) Maintain, to such extent and for such periods as may be required by applicable law, and permit Landlord or its
representatives to inspect during normal business hours at any time and from time to time upon reasonable notice to Tenant, all licenses, registration materials, inspection reports, governmental orders and permits in connection with the receipt,
storage, possession, use, transfer or disposal of radioactive materials or radiation by Tenant or in connection with the operation of Tenant&#146;s business on the Property from time to time. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(vii) Tenant shall comply with any and all applicable laws, rules, regulations and orders of any governmental authority with
respect to the release into the environment of any hazardous wastes or substances or radiation or radioactive materials by Tenant or its agents or employees. Tenant shall give Landlord immediate verbal notice of any unauthorized release of any such
hazardous wastes or substances or radiation or radioactive materials into the environment, and shall follow such verbal notice with written notice to Landlord of such release within twenty-four (24)&nbsp;hours of the time at which Tenant became
aware of such release. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(viii) Tenant shall indemnify, defend and hold Landlord harmless from and against any and all
claims, losses (including, but not limited to, loss of rental income), damages, liabilities, costs, legal fees and expenses of any sort arising out of or relating to (A)&nbsp;any failure by Tenant to comply with any provisions of this
Section&nbsp;9.6(b), or (B)&nbsp;any receipt, use, handling, generation, transportation, storage, treatment, release and/or disposal of any hazardous substance or waste or any radioactive material or radiation on or about the Property as a proximate
result of Tenant&#146;s use of the Property or as a result of any intentional or negligent acts or omissions of Tenant or of any agent, employee or invitee of Tenant. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(ix) Tenant shall cooperate with Landlord in furnishing Landlord with complete information regarding Tenant&#146;s receipt,
handling, use, storage, transportation, generation, treatment and/or disposal of any hazardous substances or wastes or radiation or radioactive materials. Upon request, Tenant shall grant Landlord reasonable access at reasonable times to the
Property to inspect Tenant&#146;s receipt, handling, use, storage, transportation, generation, treatment and/or disposal of hazardous substances or wastes or radiation or radioactive materials, provided that (A)&nbsp;Landlord shall use reasonable
efforts </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 21 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
to avoid any unreasonable interference with Tenant&#146;s business operations in exercising such access and inspection rights, without thereby being deemed guilty of any disturbance of
Tenant&#146;s use or possession and without being liable to Tenant in any manner, and (B)&nbsp;Tenant may require that the person(s) exercising Landlord&#146;s access, review and inspection rights be accompanied by an employee or representative of
Tenant while such person(s) are in the Building. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(x) Notwithstanding Landlord&#146;s rights of inspection and review under
this Section&nbsp;9.6(b), Landlord shall have no obligation or duty to so inspect or review, and no third party shall be entitled to rely on Landlord to conduct any sort of inspection or review by reason of the provisions of this
Section&nbsp;9.6(b). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(xi) If Tenant receives, handles, uses, stores, transports, generates, treats and/or disposes of any
hazardous substances or wastes or radiation or radioactive materials on or about the Property at any time during the term of this Lease, then no later than thirty (30)&nbsp;days after the termination or expiration of this Lease, Tenant at its sole
cost and expense shall obtain and deliver to Landlord an environmental study, performed by an expert reasonably satisfactory to Landlord, evaluating the presence or absence of hazardous substances and wastes, radiation and radioactive materials on
and about the Property. Such study shall be based on a reasonable and prudent level of tests and investigations of the Property and surrounding areas (if appropriate), which tests shall be conducted no earlier than the earliest of (i)&nbsp;the date
of termination or expiration of this Lease; (ii)&nbsp;the date Tenant shall have vacated the Building; or (iii)&nbsp;the date Tenant shall have ceased operations involving hazardous substances within the Building. Liability for any remedial actions
required or recommended on the basis of such study shall be allocated in accordance with Sections 9.4, 9.6, 10.6 and other applicable provisions of this Lease. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) Landlord shall indemnify, defend and hold Tenant harmless from and against any and all claims, losses, damages, liabilities, costs, legal
fees and expenses of any sort arising out of or relating to (i)&nbsp;the presence on the Property of any hazardous substances or wastes or radiation or radioactive materials as of the Commencement Date (other than Tenant&#146;s Hazardous Substances
and other than as a result of any intentional or negligent acts or omissions of Tenant or of any agent, employee or invitee of Tenant), and/or (ii)&nbsp;any unauthorized release into the environment (including, but not limited to, the Property) of
any hazardous substances or wastes or radiation or radioactive materials to the extent such release results from the negligence of or willful misconduct or omission by Landlord or its agents or employees. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) The parties acknowledge that nothing in this Section&nbsp;9.6 is intended to impose on Tenant any responsibility or liability for any
hazardous substances or wastes or radiation or radioactive materials present on the Property as of the Commencement Date (other than as a result of any intentional misconduct or negligent acts or omissions of Tenant or of any agent, employee or
invitee of Tenant), but also acknowledge that nothing in the preceding portion of this sentence is intended to exculpate Tenant from responsibility or liability for any exacerbation of any such pre-existing conditions as a result of any breach of
Tenant&#146;s obligations under this Section&nbsp;9.6. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 22 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e) The provisions of this Section&nbsp;9.6 shall survive the termination of this Lease. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10. <U>INSURANCE AND INDEMNITY</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.1 <U>Insurance</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a)
Tenant shall procure and maintain in full force and effect at all times during the term of this Lease, at Tenant&#146;s cost and expense, commercial general liability insurance to protect against liability to the public, or to any invitee of Tenant
or Landlord, arising out of or related to the use of or resulting from any accident occurring in, upon or about the Property, with limits of liability of not less than (i)&nbsp;Three Million Dollars ($3,000,000.00) per occurrence for bodily injury,
personal injury and death, and Five Hundred Thousand Dollars ($500,000.00) per occurrence for property damage, or (ii)&nbsp;a combined single limit of liability of not less than Five Million Dollars ($5,000,000.00) per occurrence for bodily injury
(including personal injury and death) and property damage. Such insurance shall name Landlord, its general partners, its property manager and any lender holding a deed of trust on the Property from time to time (as designated in writing by Landlord
to Tenant from time to time) as additional insureds thereunder. The amount of such insurance shall not be construed to limit any liability or obligation of Tenant under this Lease. Tenant shall also procure and maintain in full force and effect at
all times during the term of this Lease, at Tenant&#146;s cost and expense, products/completed operations coverage on terms and in amounts (A)&nbsp;customary in Tenant&#146;s industry for companies engaged in the marketing of products on a scale
comparable to that in which Tenant is engaged from time to time and (B)&nbsp;mutually satisfactory to Landlord and Tenant in their respective reasonable discretion. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) Landlord shall procure and maintain in full force and effect at all times during the term of this Lease, at Landlord&#146;s cost and
expense (but reimbursable as an Operating Expense under Section&nbsp;5.2 hereof), commercial general liability insurance to protect against liability arising out of or related to the use of or resulting from any accident occurring in, upon or about
the Property, with combined single limit of liability of not less than Five Million Dollars ($5,000,000.00) per occurrence for bodily injury (including personal injury and death) and property damage. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) Landlord shall procure and maintain in full force and effect at all times during the term of this Lease, at Landlord&#146;s cost and
expense (but reimbursable as an Operating Expense under Section&nbsp;5.2 hereof), policies of property insurance providing protection against &#147;all risk of direct physical loss&#148; (as defined by and detailed in the Insurance Service
Office&#146;s Commercial Property Program &#147;Cause of Loss&#151;Special Form [CP1030]&#148; or its equivalent) for the shell of the Building and for the improvements in the Common Areas of the Property, on a full replacement cost basis (with no
co-insurance or, if coverage without co-insurance is not reasonably available, then on an &#147;agreed amount&#148; basis or with a commercially reasonable margin clause). Such insurance shall include earthquake and environmental coverage, and shall
have such commercially reasonable deductibles and other terms as Landlord in its reasonable discretion determines to be appropriate. Landlord shall have no obligation to carry property damage insurance for any alterations, additions or improvements
installed by Tenant or by any predecessor tenant in the Building or on or about the Property, except to the extent (if any) expressly provided in paragraph (d)&nbsp;below or otherwise expressly agreed in writing by Landlord and Tenant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 23 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) Landlord shall procure and maintain in full force and effect at all times during the term of
this Lease, at Landlord&#146;s cost and expense (but reimbursable as an Operating Expense under Section&nbsp;5.2 hereof), policies of property insurance providing protection against &#147;all risk of direct physical loss&#148; (as defined by and
detailed in the Insurance Service Office&#146;s Commercial Property Program &#147;Cause of Loss-Special Form [CP1030]&#148; or its equivalent) for the tenant improvements existing in the Building on the Commencement Date and on all other
alterations, additions and improvements installed by Tenant from time to time in or about the Building, on a full replacement cost basis (with no co-insurance or, if coverage without co-insurance is not reasonably available, then on an &#147;agreed
amount&#148; basis or with a commercially reasonable margin clause). Such insurance may have such commercially reasonable deductibles and other terms as Landlord in its discretion determines to be appropriate, and shall name both Tenant and Landlord
as insureds as their interests may appear. The coverage required to be maintained under this paragraph (d)&nbsp;may, in Landlord&#146;s discretion, be added to or combined with Landlord&#146;s master policy carried under paragraph (c)&nbsp;above, in
which event Tenant shall be named as an insured only with respect to the portion of the policy that covers tenant improvements as described in this paragraph (d). Tenant shall cooperate with Landlord in the preparation of a mutually approved initial
list or schedule of such existing improvements as of the Commencement Date, for purposes of identifying the items Landlord is responsible for insuring under this paragraph (d), and Tenant shall thereafter provide to Landlord from time to time, upon
request by Landlord annually or at other reasonable intervals, an updated version of such list or schedule (the intended purpose of such updating being to reflect any addition, modification or removal of any items that would have the effect of
adding them to or eliminating them from the scope of Landlord&#146;s insurance obligation under this paragraph (d)). Landlord, in its discretion, may elect from time to time to obtain appraisals of any or all alterations, additions, improvements and
tenant improvements (if any) which Landlord is required to insure hereunder. Landlord shall have no obligation or liability with respect to any underinsurance of items described in this paragraph (d)&nbsp;that results from Tenant&#146;s failure to
keep Landlord informed from time to time, on a current basis, of the identification and insurable value of such items. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.2 <U>Quality Of
Policies And Certificates</U>. All policies of insurance required hereunder shall be issued by responsible insurers and, in the case of policies carried or required to be carried by Tenant, shall be written as primary policies not contributing with
and not in excess of any coverage that Landlord may carry. Tenant shall deliver to Landlord copies of policies or certificates of insurance showing that said policies are in effect. The coverage provided by such policies shall include the clause or
endorsement referred to in Section&nbsp;10.4. If Tenant fails to acquire, maintain or renew any insurance required to be maintained by it under this Article 10 or to pay the premium therefor, then Landlord, at its option and in addition to its other
remedies, but without obligation so to do, may procure such insurance, and any sums expended by it to procure any such insurance on behalf of or in place of Tenant shall be repaid upon demand, with interest as provided in Section&nbsp;3.2 hereof.
Tenant shall obtain written undertakings from each insurer under policies required to be maintained by it to notify all insureds thereunder at least thirty (30)&nbsp;days prior to cancellation of coverage. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 24 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.3 <U>Workers&#146; Compensation</U>. Tenant shall maintain in full force and effect during the
term of this Lease workers&#146; compensation insurance in at least the minimum amounts required by law, covering all of Tenant&#146;s employees working on the Property. In addition, Tenant shall maintain in full force and effect during the term of
this Lease employer&#146;s liability coverage with limits of liability of not less than One Hundred Thousand Dollars ($100,000) per accident, One Hundred Thousand Dollars ($100,000) per employee for disease, and Five Hundred Thousand Dollars
($500,000) policy limit for disease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.4 <U>Waiver Of Subrogation</U>. To the extent permitted by law and without affecting the coverage
provided by insurance required to be maintained hereunder, Landlord and Tenant each waive any right to recover against the other with respect to (i)&nbsp;damage to property, (ii)&nbsp;damage to the Property or any part thereof, or (iii)&nbsp;claims
arising by reason of any of the foregoing, but only to the extent that any of the foregoing damages and claims under clauses (i)-(iii)&nbsp;hereof are covered, and only to the extent of such coverage, by casualty insurance actually carried or
required to be carried hereunder by either Landlord or Tenant. This provision is intended to waive fully, and for the benefit of each party, any rights and claims which might give rise to a right of subrogation in any insurance carrier. Each party
shall procure a clause or endorsement on any casualty insurance policy denying to the insurer rights of subrogation against the other party to the extent rights have been waived by the insured prior to the occurrence of injury or loss. Coverage
provided by insurance maintained by Tenant shall not be limited, reduced or diminished by virtue of the subrogation waiver herein contained. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.5 <U>Increase In Premiums</U>. Tenant shall do all acts and pay all expenses necessary to insure that the Property is not used for purposes
prohibited by any applicable fire insurance, and that Tenant&#146;s use of the Property complies with all requirements necessary to obtain any such insurance. If Tenant uses or permits the Property to be used in a manner which increases the existing
rate of any insurance carried by Landlord on the Property and such use continues for longer than a reasonable period specified in any written notice from Landlord to Tenant identifying the rate increase and the factors causing the same, then Tenant
shall pay the amount of the increase in premium caused thereby, and Landlord&#146;s costs of obtaining other replacement insurance policies, including any increase in premium, within ten (10)&nbsp;days after demand therefor by Landlord. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.6 <U>Indemnification</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) Tenant shall indemnify, defend and hold Landlord and its partners, shareholders, officers, directors, agents and employees harmless from
any and all liability for injury to or death of any person, or loss of or damage to the property of any person, and all actions, claims, demands, costs (including, without limitation, reasonable attorneys&#146; fees), damages or expenses of any kind
arising therefrom which may be brought or made against Landlord or which Landlord may pay or incur by reason of the use, occupancy and enjoyment of the Property by Tenant or any invitees, sublessees, licensees, assignees, employees, agents or
contractors of Tenant or holding under Tenant from any cause whatsoever other than negligence or willful misconduct or omission by Landlord, its agents or employees. Landlord and its partners, shareholders, officers, directors, agents and employees
shall not be liable for, and Tenant hereby waives all claims against such persons for, damages to goods, wares and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 25 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
merchandise in or upon the Property, or for injuries to Tenant, its agents or third persons in or upon the Property, from any cause whatsoever other than negligence or willful misconduct or
omission by Landlord, its agents or employees. Tenant shall give prompt notice to Landlord of any casualty or accident in, on or about the Property. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) Landlord shall indemnify, defend and hold Tenant and its partners, shareholders, officers, directors, agents and employees harmless from
any and all liability for injury to or death of any person, or loss of or damage to the property of any person, and all actions, claims, demands, costs (including, without limitation, reasonable attorneys&#146; fees), damages or expenses of any kind
arising therefrom which may be brought or made against Tenant or which Tenant may pay or incur, to the extent such liabilities or other matters arise in, on or about the Property by reason of any negligence or willful misconduct or omission by
Landlord, its agents or employees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.7 <U>Blanket Policy</U>. Any policy required to be maintained hereunder may be maintained under a
so-called &#147;blanket policy&#148; insuring other parties and other locations so long as the amount of insurance required to be provided hereunder is not thereby diminished. Without limiting the generality of the requirement set forth at the end
of the preceding sentence, property insurance provided under a blanket policy shall provide full replacement cost coverage and liability insurance provided under a blanket policy shall include per location aggregate limits meeting or exceeding the
limits required under this Article 10. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11. <U>SUBLEASE AND ASSIGNMENT</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.1 <U>Assignment And Sublease Of Building</U>. Except in the case of a Permitted Transfer, Tenant shall not have the right or power to
assign its interest in this Lease, or make any sublease of the Building or any portion thereof, nor shall any interest of Tenant under this Lease be assignable involuntarily or by operation of law, without on each occasion obtaining the prior
written consent of Landlord, which consent shall not be unreasonably withheld, conditioned or delayed. Any purported sublease or assignment of Tenant&#146;s interest in this Lease requiring but not having received Landlord&#146;s consent thereto (to
the extent such consent is required hereunder) shall be void. Without limiting the generality of the foregoing, Landlord may withhold consent to any proposed subletting or assignment for which consent is requested solely on the ground, if
applicable, that the use by the proposed subtenant or assignee is reasonably likely to be incompatible with Landlord&#146;s use of any adjacent property owned or operated by Landlord, unless the proposed use is within the permitted uses specified in
Section&nbsp;9.1, in which event it shall not be reasonable for Landlord to object to the proposed use. Except in the case of a Permitted Transfer, any dissolution, consolidation, merger or other reorganization of Tenant, or any sale or transfer of
substantially all of the stock or assets of Tenant in a single transaction or series of related transactions, shall be deemed to be an assignment hereunder and shall be void without the prior written consent of Landlord as required above.
Notwithstanding the foregoing, (i)&nbsp;an initial public offering of the common stock of Tenant shall not be deemed to be an assignment hereunder; (ii)&nbsp;any transfer of Tenant&#146;s stock during any period in which Tenant has a class of stock
listed on any recognized securities exchange or traded in the NASDAQ over-the-counter market shall not be deemed to be an assignment hereunder; (iii)&nbsp;any transfer of Tenant&#146;s stock in connection with a bona fide financing, capitalization
or recapitalization of Tenant shall </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 26 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
not be deemed to be an assignment hereunder, provided that such financing, capitalization or recapitalization does not result in a material reduction in Tenant&#146;s net worth or materially
change the nature of Tenant&#146;s ongoing business as a going concern; and (iv)&nbsp;Tenant shall have the right to assign this Lease or sublet the Building, or any portion thereof, without Landlord&#146;s consent (but with prior or concurrent
written notice by Tenant to Landlord, except to the extent Tenant is advised by its counsel that such prior or concurrent notice would be in violation of applicable law, in which event Tenant shall give such written notice as soon as reasonably
possible after the giving of such notice is no longer in violation of applicable law), to any Affiliate of Tenant, or to any entity which results from a merger or consolidation with Tenant, or to any entity which acquires substantially all of the
stock or assets of Tenant as a going concern (hereinafter each a &#147;<U>Permitted Transfer</U>&#148;). For purposes of this Lease, an &#147;<U>Affiliate</U>&#148; of a party shall mean any entity in which that party owns at least a twenty percent
(20%)&nbsp;equity interest, any entity which owns at least a twenty percent (20%)&nbsp;equity interest in that party, and/or any entity which is related to that party by a chain of ownership interests involving at least a twenty percent
(20%)&nbsp;equity interest at each level in the chain. Landlord shall have no right to terminate this Lease in connection with, and shall have no right to any sums or other economic consideration resulting from, any Permitted Transfer. Except as
expressly set forth in this Section&nbsp;11.1, however, the provisions of Section&nbsp;11.2 shall remain applicable to any Permitted Transfer and the transferee under such Permitted Transfer shall be and remain subject to all of the terms and
provisions of this Lease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.2 <U>Rights Of Landlord</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) Consent by Landlord to one or more assignments of this Lease, or to one or more sublettings of the Building or any portion thereof, or
collection of rent by Landlord from any assignee or sublessee, shall not operate to exhaust Landlord&#146;s rights under this Article 11, nor constitute consent to any subsequent assignment or subletting. No assignment of Tenant&#146;s interest in
this Lease and no sublease shall relieve Tenant of its obligations hereunder, notwithstanding any waiver or extension of time granted by Landlord to any assignee or sublessee, or the failure of Landlord to assert its rights against any assignee or
sublessee, and regardless of whether Landlord&#146;s consent thereto is given or required to be given hereunder. In the event of a default by any assignee, sublessee or other successor of Tenant in the performance of any of the terms or obligations
of Tenant under this Lease, Landlord may proceed directly against Tenant without the necessity of exhausting remedies against any such assignee, sublessee or other successor. In addition, Tenant immediately and irrevocably assigns to Landlord, as
security for Tenant&#146;s obligations under this Lease, all rent from any subletting of all or a part of the Building as permitted under this Lease, and Landlord, as Tenant&#146;s assignee and as attorney-in-fact for Tenant, or any receiver for
Tenant appointed on Landlord&#146;s application, may collect such rent and apply it toward Tenant&#146;s obligations under this Lease; except that, until the occurrence of an act of default by Tenant which remains uncured following the expiration of
any applicable cure period, Tenant shall have the right to collect such rent and to retain all sublease profits (subject to the provisions of Section&nbsp;11.2(c), below). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) Upon any assignment of Tenant&#146;s interest in this Lease for which Landlord&#146;s consent is required under Section&nbsp;11.1 hereof,
Tenant shall pay to Landlord, within ten (10)&nbsp;days after receipt thereof by Tenant from time to time, one-half (1/2)&nbsp;of all cash sums </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 27 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and other economic considerations received by Tenant in connection with or as a result of such assignment, after first deducting therefrom (i)&nbsp;the unamortized cost of any leasehold
improvements previously made in the Building and paid for by Tenant, (ii)&nbsp;any costs incurred by Tenant for leasehold improvements (including, but not limited to, third-party architectural and space planning costs) in the Building in connection
with such assignment, (iii)&nbsp;any real estate commissions and/or attorneys&#146; fees incurred by Tenant in connection with such assignment, and (iv)&nbsp;any economic consideration received by Tenant as bona fide, reasonable compensation for
services rendered by Tenant to the assignee and/or personal property sold or leased by Tenant to the assignee. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) Upon any sublease of
all or any portion of the Building for which Landlord&#146;s consent is required under Section&nbsp;11.1 hereof, Tenant shall pay to Landlord, within ten (10)&nbsp;days after receipt thereof by Tenant from time to time, one-half (1/2)&nbsp;of all
cash sums and other economic considerations received by Tenant in connection with or as a result of such sublease, after first deducting therefrom (i)&nbsp;the rental due hereunder for the corresponding period, prorated (on the basis of the average
per-square-foot cost paid by Tenant for the entire Building for the applicable period under this Lease) to reflect the size of the subleased portion of the Building, (ii)&nbsp;any costs incurred by Tenant for leasehold improvements in the subleased
portion of the Building (including, but not limited to, third-party architectural and space planning costs) for the specific benefit of the sublessee in connection with such sublease, amortized over the term of the sublease, (iii)&nbsp;any real
estate commissions and/or attorneys&#146; fees incurred by Tenant in connection with such sublease, amortized over the term of such sublease, (iv)&nbsp;the unamortized cost of any leasehold improvements previously made and paid for by Tenant with
respect to the subleased portion of the Building, and (v)&nbsp;any economic consideration received by Tenant as bona fide, reasonable compensation for services rendered by Tenant to the sublessee and/or personal property sold or leased by Tenant to
the sublessee. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12. <U>RIGHT OF ENTRY AND QUIET ENJOYMENT</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.1 <U>Right Of Entry</U>. Landlord and its authorized representatives shall have the right to enter the Building at any time during the term
of this Lease during normal business hours and upon not less than twenty-four (24)&nbsp;hours prior notice, except in the case of emergency (in which event no notice shall be required and entry may be made at any time), for the purpose of inspecting
and determining the condition of the Building or for any other proper purpose including, without limitation, to make repairs, replacements or improvements which Landlord may deem necessary, to show the Building to prospective purchasers, to show the
Building to prospective tenants (but only during the final year of the term of this Lease), and to post notices of nonresponsibility. Landlord shall not be liable for inconvenience, annoyance, disturbance, loss of business, quiet enjoyment or other
damage or loss to Tenant by reason of making any repairs or performing any work upon the Building or the Property or by reason of erecting or maintaining any protective barricades in connection with any such work, and the obligations of Tenant under
this Lease shall not thereby be affected in any manner whatsoever, <U>provided</U>, however, Landlord shall use reasonable efforts to minimize the inconvenience to Tenant&#146;s normal business operations caused thereby, and Tenant may require
Landlord and its authorized representatives exercising Landlord&#146;s right of entry hereunder to be accompanied by an employee or representative of Tenant while they are in the Building, except in the case of emergency (in which event no
accompaniment shall be required). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 28 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.2 <U>Quiet Enjoyment</U>. Landlord covenants that Tenant, upon paying the rent and performing
its obligations hereunder and subject to all the terms and conditions of this Lease, shall peacefully and quietly have, hold and enjoy the Building and the Property throughout the term of this Lease, or until this Lease is terminated as provided by
this Lease. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13. <U>CASUALTY AND TAKING</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.1 <U>Damage or Destruction</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) If the Building, or the Common Areas of the Property necessary for Tenant&#146;s use and occupancy of the Building, are damaged or
destroyed in whole or in part under circumstances in which (i)&nbsp;repair and restoration is permitted under applicable governmental laws, regulations and building codes then in effect and (ii)&nbsp;repair and restoration reasonably can be
completed within a period of one (1)&nbsp;year (or, in the case of an occurrence during the last year of the term of this Lease, within a period of sixty (60)&nbsp;days) following the date of the occurrence, then Landlord, as to the Common Areas of
the Property and the Building Shell (as such term is defined in the Prior Lease), and Tenant, as to the Tenant Improvements (as such term is defined in the Prior Lease) in the Building, shall commence and complete, with all due diligence and as
promptly as is reasonably practicable under the conditions then existing, all such repair and restoration as may be required to return the affected portions of the Property to a condition comparable to that existing immediately prior to the
occurrence. In the event of damage or destruction the repair of which is not permitted under applicable governmental laws, regulations and building codes then in effect, if such damage or destruction (despite being corrected to the extent then
permitted under applicable governmental laws, regulations and building codes) would still materially impair Tenant&#146;s ability to conduct its business in the Building, then either party may terminate this Lease as of the date of the occurrence by
giving written notice to the other within thirty (30)&nbsp;days after the date of the occurrence; if neither party timely elects such termination, or if such damage or destruction does not materially impair Tenant&#146;s ability to conduct its
business in the Building, then this Lease shall continue in full force and effect, except that there shall be an equitable adjustment in monthly minimum rental and of Tenant&#146;s Operating Cost Share of Operating Expenses, based upon the extent to
which Tenant&#146;s ability to conduct its business in the Building is impaired, and Landlord and Tenant respectively shall restore the Common Areas and Building Shell and the Tenant Improvements to a complete architectural whole and to a functional
condition. In the event of damage or destruction which cannot reasonably be repaired within one (1)&nbsp;year (or, in the case of an occurrence during the last year of the term of this Lease, within a period of sixty (60)&nbsp;days) following the
date of the occurrence, then either Landlord or Tenant, at its election, may terminate this Lease as of the date of the occurrence by giving written notice to the other within thirty (30)&nbsp;days after the date of the occurrence; if neither party
timely elects such termination, then this Lease shall continue in full force and effect and Landlord and Tenant shall each repair and restore applicable portions of the Property in accordance with the first sentence of this Section&nbsp;13.1. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 29 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) The respective obligations of Landlord and Tenant pursuant to Section&nbsp;13.1(a) are
subject to the following limitations: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i) If the occurrence results from a peril which is required to be insured pursuant
to Section&nbsp;10.1(c) and (d)&nbsp;above, the obligations of either party shall not exceed the amount of insurance proceeds received from insurers (or, in the case of any failure to maintain required insurance, proceeds that reasonably would have
been available if the required insurance had been maintained) by reason of such occurrence, plus the amount of the party&#146;s permitted deductible <U>(provided</U> that each party shall be obligated to use its best efforts to recover any available
proceeds from the insurance which it is required to maintain pursuant to the provisions of Section&nbsp;10.1(c) or (d), as applicable), and, if such proceeds (including, in the case of a failure to maintain required insurance, any proceeds that
reasonably would have been available) are insufficient, either party may terminate the Lease unless the other party promptly elects and agrees, in writing, to contribute the amount of the shortfall; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(ii) If the occurrence results from a peril which is not required to be insured pursuant to Section&nbsp;10.1(c) and
(d)&nbsp;above and is not actually insured, Landlord shall be required to repair and restore the Building Shell and Common Areas to the extent necessary for Tenant&#146;s continued use and occupancy of the Building, and Tenant shall be required to
repair and restore the Tenant Improvements to the extent necessary for Tenant&#146;s continued use and occupancy of the Building, <U>provided</U> that each party&#146;s obligation to repair and restore shall not exceed an amount equal to five
percent (5%)&nbsp;of the replacement cost of the Building Shell and Common Area improvements, as to Landlord, or five percent (5%)&nbsp;of the replacement cost of the Tenant Improvements, as to Tenant; if the replacement cost as to either party
exceeds such amount, then the party whose limit has been exceeded may terminate this Lease unless the other party promptly elects and agrees, in writing, to contribute the amount of the shortfall. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) If this Lease is terminated pursuant to the foregoing provisions of this Section&nbsp;13.1 following an occurrence which is a peril
actually insured or required to be insured against pursuant to Section&nbsp;10.1(c) and (d), Landlord and Tenant agree (and any Lender shall be asked to agree) that such insurance proceeds shall be allocated between Landlord and Tenant in a manner
which fairly and reasonably reflects their respective ownership rights under this Lease, as of the termination or expiration of the term of this Lease, with respect to the improvements, fixtures, equipment and other items to which such insurance
proceeds are attributable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) From and after the date of an occurrence resulting in damage to or destruction of the Building or of the
Common Areas necessary for Tenant&#146;s use and occupancy of the Building, and continuing until repair and restoration thereof are completed, there shall be an equitable abatement of minimum rental and of Tenant&#146;s Operating Cost Share of
Operating Expenses based upon the degree to which Tenant&#146;s ability to conduct its business in the Building is impaired. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 30 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) Each party expressly waives the provisions of California Civil Code Sections 1932(2), 1933(4)
and any other applicable existing or future law permitting the termination of a lease agreement in the event of damage to or destruction of the leased property, it being the intention of the parties that their respective rights in such circumstances
shall be governed solely by the provisions of this Article 13. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.2 <U>Condemnation</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) If during the term of this Lease the Property or Improvements, or any substantial part of either, is taken by eminent domain or by reason
of any public improvement or condemnation proceeding, or in any manner by exercise of the right of eminent domain (including any transfer in avoidance of an exercise of the power of eminent domain), or receives irreparable damage by reason of
anything lawfully done under color of public or other authority, then (i)&nbsp;this Lease shall terminate as to the entire Building at Landlord&#146;s election by written notice given to Tenant within sixty (60)&nbsp;days after the taking has
occurred, and (ii)&nbsp;this Lease shall terminate as to the entire Building at Tenant&#146;s election, by written notice given to Landlord within thirty (30)&nbsp;days after the nature and extent of the taking have been finally determined, if the
portion of the Building taken is of such extent and nature as substantially to handicap, impede or permanently impair Tenant&#146;s use of the balance of the Building. If Tenant elects to terminate this Lease, Tenant shall also notify Landlord of
the date of termination, which date shall not be earlier than thirty (30)&nbsp;days nor later than ninety (90)&nbsp;days after Tenant has notified Landlord of Tenant&#146;s election to terminate, except that this Lease shall terminate on the date of
taking if such date falls on any date before the date of termination designated by Tenant. If neither party elects to terminate this Lease as hereinabove provided, this Lease shall continue in full force and effect (except that there shall be an
equitable abatement of <U>minim</U>um rental and of Tenant&#146;s Operating Cost Share of Operating Expenses based upon the degree to which Tenant&#146;s ability to conduct its business in the Building is impaired), Landlord shall restore the
Building Shell and Common Area improvements to a complete architectural whole and a functional condition and as nearly as reasonably possible to the condition existing before the taking, and Tenant shall restore the Tenant Improvements and
Tenant&#146;s other alterations, additions and improvements to a complete architectural whole and a functional condition and as nearly as reasonably possible to the condition existing before the taking. In connection with any such restoration, each
party shall use its respective best efforts (including, without limitation, any necessary negotiation or intercession with its respective lender, if any) to ensure that any severance damages or other condemnation awards intended to provide
compensation for rebuilding or restoration costs are promptly collected and made available to Landlord and Tenant in portions reasonably corresponding to the cost and scope of their respective restoration obligations, subject only to such payment
controls as either party or its lender may reasonably require in order to ensure the proper application of such proceeds toward the restoration of the Improvements. Each party waives the provisions of Code of Civil Procedure Section&nbsp;1265.130
and of any other existing or future law allowing either party to terminate (or petition the Superior Court to terminate) a lease in the event of a partial condemnation or taking of the leased property, it being the intention of the parties that
their respective rights in such circumstances shall be governed solely by the provisions of this Article 13. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 31 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) The respective obligations of Landlord and Tenant pursuant to Section&nbsp;13.2(a) are
subject to the following limitations: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i) Each party&#146;s obligation to repair and restore shall not exceed, net of any
condemnation awards or other proceeds available for and allocable to such restoration as contemplated in Section&nbsp;13.2(a), an amount equal to five percent (5%)&nbsp;of the replacement cost of the Building Shell and Common Area improvements, as
to Landlord, or five percent (5%)&nbsp;of the replacement cost of the Tenant Improvements, as to Tenant; if the replacement cost as to either party exceeds such amount, then the party whose limit has been exceeded may terminate this Lease unless the
other party promptly elects and agrees, in writing, to contribute the amount of the shortfall; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(ii) If this Lease is
terminated pursuant to the foregoing provisions of this Section&nbsp;13.2, or if this Lease remains in effect but any condemnation awards or other proceeds become available as compensation for the loss or destruction of any of the Improvements, then
Landlord and Tenant agree (and any Lender shall be asked to agree) that such proceeds shall be allocated between Landlord and Tenant, respectively, in the respective proportions in which Landlord and Tenant would have shared, under
Section&nbsp;13.1(c), the proceeds of any insurance proceeds following loss or destruction of the applicable Improvements by an insured casualty. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.3 <U>Reservation Of Compensation</U>. Landlord reserves, and Tenant waives and assigns to Landlord, all rights to any award or compensation
for damage to the Improvements, the Property and the leasehold estate created hereby, accruing by reason of any taking in any public improvement, condemnation or eminent domain proceeding or in any other manner by exercise of the right of eminent
domain or of anything lawfully done by public authority, except that (a) Tenant shall be entitled to any and all compensation or damages paid for or on account of Tenant&#146;s moving expenses, trade fixtures and equipment and any leasehold
improvements installed by Tenant in the Building at its own sole expense, but only to the extent Tenant would have been entitled to remove such items at the expiration of the term of this Lease and then only to the extent of the then remaining
unamortized value of such improvements computed on a straight-line basis over the term of this Lease, and (b)&nbsp;any condemnation awards or proceeds described in Section&nbsp;13.2(b)(ii) shall be allocated and disbursed in accordance with the
provisions of Section&nbsp;13.2(b)(ii), notwithstanding any contrary provisions of this Section&nbsp;13.3. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.4 <U>Restoration Of
Improvements</U>. In connection with any repair or restoration of Improvements by either party following a casualty or taking as hereinabove set forth, the party responsible for such repair or restoration shall, to the extent possible, return such
Improvements to a condition substantially equal to that which existed immediately prior to the casualty or taking. To the extent such party wishes to make material modifications to such Improvements, such modifications shall be subject to the prior
written approval of the other party (not to be unreasonably withheld, conditioned or delayed), except that no such approval shall be required for modifications that are required by applicable governmental authorities as a condition of the repair or
restoration, unless such required modifications would impair or impede Tenant&#146;s conduct of its business in the Building (in which case any such modifications in Landlord&#146;s work shall require Tenant&#146;s consent, not unreasonably
withheld, conditioned or delayed) or would materially and adversely affect the exterior appearance, the structural integrity or the mechanical or other operating systems of the Building (in which case any such modifications in Tenant&#146;s work
shall require Landlord&#146;s consent, not unreasonably withheld or delayed). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 32 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14. <U>DEFAULT</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.1 <U>Events Of Default</U>. The occurrence of any of the following shall constitute an event of default on the part of Tenant: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) [Omitted.] </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b)
<U>Nonpayment</U>. Failure to pay, when due, any amount payable to Landlord hereunder, such failure continuing for a period of five (5)&nbsp;business days after written notice of such failure; <U>provided,</U> however, that any such notice shall be
in lieu of, and not in addition to, any notice required under California Code of Civil Procedure Section&nbsp;1161 <U>et seq</U>., as amended from time to time; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) <U>Other Obligations</U>. Failure to perform any obligation, agreement or covenant under this Lease other than those matters specified in
subsection (b)&nbsp;hereof, such failure continuing for thirty (30)&nbsp;days after written notice of such failure; <U>provided,</U> however, that if such failure is curable in nature but cannot reasonably be cured within such 30-day period, then
Tenant shall not be in default if, and so long as, Tenant promptly (and in all events within such 30-day period) commences such cure and thereafter diligently pursues such cure to completion; and <U>provided further,</U> however, that any such
notice shall be in lieu of, and not in addition to, any notice required under California Code of Civil Procedure Section&nbsp;1161 <U>et seq</U>., as amended from time to time; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) <U>General Assignment</U>. A general assignment by Tenant for the benefit of creditors; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e) <U>Bankruptcy</U>. The filing of any voluntary petition in bankruptcy by Tenant, or the filing of an involuntary petition by Tenant&#146;s
creditors, which involuntary petition remains undischarged for a period of thirty (30)&nbsp;days. In the event that under applicable law the trustee in bankruptcy or Tenant has the right to affirm this Lease and continue to perform the obligations
of Tenant hereunder, such trustee or Tenant shall, in such time period as may be permitted by the bankruptcy court having jurisdiction, cure all defaults of Tenant hereunder outstanding as of the date of the affirmance of this Lease and provide to
Landlord such adequate assurances as may be necessary to ensure Landlord of the continued performance of Tenant&#146;s obligations under this Lease. Specifically, but without limiting the generality of the foregoing, such adequate assurances must
include assurances that the Building continues to be operated only for the use permitted hereunder. The provisions hereof are to assure that the basic understandings between Landlord and Tenant with respect to Tenant&#146;s use of the Property and
the benefits to Landlord therefrom are preserved, consistent with the purpose and intent of applicable bankruptcy laws; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(f)
<U>Receivership</U>. The employment of a receiver appointed by court order to take possession of substantially all of Tenant&#146;s assets or the Building, if such receivership remains undissolved for a period of thirty (30)&nbsp;days; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(g) <U>Attachment</U>. The attachment, execution or other judicial seizure of all or substantially all of Tenant&#146;s assets or the Building,
if such attachment or other seizure remains undismissed or undischarged for a period of thirty (30)&nbsp;days after the levy thereof; or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 33 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(h) <U>Insolvency</U>. The admission by Tenant in writing of its inability to pay its debts as
they become due, the filing by Tenant of a petition seeking any reorganization or arrangement, composition, readjustment, liquidation, dissolution or similar relief under any present or future statute, law or regulation, the filing by Tenant of an
answer admitting or failing timely to contest a material allegation of a petition filed against Tenant in any such proceeding or, if within thirty (30)&nbsp;days after the commencement of any proceeding against Tenant seeking any reorganization or
arrangement, composition, readjustment, liquidation, dissolution or similar relief under any present or future statute, law or regulation, such proceeding shall not have been dismissed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.2 <U>Remedies Upon Tenant&#146;s Default.</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) Upon the occurrence of any event of default described in Section&nbsp;14.1 hereof, Landlord, in addition to and without prejudice to any
other rights or remedies it may have, shall have the immediate right to re-enter the Building or any part thereof and repossess the same, expelling and removing therefrom all persons and property (which property may be stored in a public warehouse
or elsewhere at the cost and risk of and for the account of Tenant), using such force as may be necessary to do so (as to which Tenant hereby waives any claim for loss or damage that may thereby occur). In addition to or in lieu of such re-entry,
and without prejudice to any other rights or remedies it may have, Landlord shall have the right either (i)&nbsp;to terminate this Lease and recover from Tenant all damages incurred by Landlord as a result of Tenant&#146;s default, as hereinafter
provided, or (ii)&nbsp;to continue this Lease in effect and recover rent and other charges and amounts as they become due. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) Even if
Tenant has breached this Lease and abandoned the Building, this Lease shall continue in effect for so long as Landlord does not terminate Tenant&#146;s right to possession under subsection (a)&nbsp;hereof and Landlord may enforce all of its rights
and remedies under this Lease, including the right to recover rent as it becomes due, and Landlord, without terminating this Lease, may exercise all of the rights and remedies of a lessor under California Civil Code Section&nbsp;1951.4 (lessor may
continue lease in effect after lessee&#146;s breach and abandonment and recover rent as it becomes due, if lessee has right to sublet or assign, subject only to reasonable limitations), or any successor Code section. Acts of maintenance,
preservation or efforts to relet the Building or the appointment of a receiver upon application of Landlord to protect Landlord&#146;s interests under this Lease shall not constitute a termination of Tenant&#146;s right to possession. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) If Landlord terminates this Lease pursuant to this Section&nbsp;14.2, Landlord shall have all of the rights and remedies of a landlord
provided by Section&nbsp;1951.2 of the Civil Code of the State of California, or any successor Code section, which remedies include Landlord&#146;s right to recover from Tenant (i)&nbsp;the worth at the time of award of the unpaid rent and
additional rent which had been earned at the time of termination, (ii)&nbsp;the worth at the time of award of the amount by which the unpaid rent and additional rent which would have been earned after termination until the time of award exceeds the
amount of such rental loss that Tenant proves could have been reasonably avoided, (iii)&nbsp;the worth at the time of award of the amount by which the unpaid rent and additional rent for the balance of the term after the time of award exceeds the
amount of such rental loss that Tenant proves could be reasonably avoided, and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 34 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(iv) any other amount necessary to compensate Landlord for all the detriment proximately caused by Tenant&#146;s failure to perform its obligations under this Lease or which in the ordinary
course of things would be likely to result therefrom, including, but not limited to, the cost of recovering possession of the Building, expenses of reletting, including necessary repair, renovation and alteration of the Building, reasonable
attorneys&#146; fees, and other reasonable costs. The &#147;<U>worth at the time of award</U>&#148; of the amounts referred to in clauses (i)&nbsp;and (ii)&nbsp;above shall be computed by allowing interest at ten percent (10%)&nbsp;per annum from
the date such amounts accrued to Landlord. The &#147;<U>worth at the time of award</U>&#148; of the amounts referred to in clause (iii)&nbsp;above shall be computed by discounting such amount at one percentage point above the discount rate of the
Federal Reserve Bank of San Francisco at the time of award. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.3 <U>Remedies Cumulative</U>. All rights, privileges and elections or
remedies of Landlord contained in this Article 14 are cumulative and not alternative to the extent permitted by law and except as otherwise provided herein. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15. <U>SUBORDINATION, ATTORNMENT AND SALE</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15.1 <U>Subordination To Mortgage</U>. This Lease, and any sublease entered into by Tenant under the provisions of this Lease, shall be
subject and subordinate to any ground lease, mortgage, deed of trust, sale/leaseback transaction or any other hypothecation for security now or hereafter placed upon the Building, the Property, or any of them, and the rights of any assignee of
Landlord or of any ground lessor, mortgagee, trustee, beneficiary or leaseback lessor under any of the foregoing, and to any and all advances made on the security thereof and to all renewals, modifications, consolidations, replacements and
extensions thereof; <U>provided</U>, however, that such subordination in the case of any future ground lease, mortgage, deed of trust, sale/leaseback transaction or any other hypothecation for security placed upon the Building, the Property, or any
of them shall be conditioned on Tenant&#146;s receipt from the ground lessor, mortgagee, trustee, beneficiary or leaseback lessor of a Non-Disturbance Agreement in a form reasonably acceptable to Tenant (i)&nbsp;confirming that so long as Tenant is
not in material default hereunder beyond any applicable cure period (for which purpose the occurrence of any event of default under Section&nbsp;14.1 hereof shall be deemed to be &#147;material&#148;), Tenant&#146;s rights hereunder shall not be
disturbed by such person or entity and (ii)&nbsp;agreeing that the benefit of such Non-Disturbance Agreement shall be transferable to any transferee under a Permitted Transfer and to any other assignee or subtenant that is acceptable to the ground
lessor, mortgagee, trustee, beneficiary or leaseback lessor at the time of transfer. If any mortgagee, trustee, beneficiary, ground lessor, sale/leaseback lessor or assignee elects to have this Lease be an encumbrance upon the Property prior to the
lien of its mortgage, deed of trust, ground lease or leaseback lease or other security arrangement and gives notice thereof to Tenant, this Lease shall be deemed prior thereto, whether this Lease is dated prior or subsequent to the date thereof or
the date of recording thereof. Tenant, and any sublessee, shall execute such documents as may reasonably be requested by any mortgagee, trustee, beneficiary, ground lessor, sale/leaseback lessor or assignee to evidence the subordination herein set
forth, subject to the conditions set forth above, or to make this Lease prior to the lien of any mortgage, deed of trust, ground lease, leaseback lease or other security arrangement, as the case may be. Upon any default by Landlord in the
performance of its obligations under any mortgage, deed of trust, ground lease, leaseback lease or assignment, Tenant (and any sublessee) shall, notwithstanding any subordination hereunder, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 35 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
attorn to the mortgagee, trustee, beneficiary, ground lessor, leaseback lessor or assignee thereunder upon demand and become the tenant of the successor in interest to Landlord, at the option of
such successor in interest, and shall execute and deliver any instrument or instruments confirming the attornment herein provided for. Landlord represents and warrants to Tenant that as of the date of this Lease, neither the Building nor the Center
is subject to any existing ground lease, mortgage, deed of trust, sale-leaseback transaction or any other hypothecation for security. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15.2 <U>Sale Of Landlord&#146;s Interest</U>. Upon sale, transfer or assignment of Landlord&#146;s entire interest in the Building and the
Property, Landlord shall be relieved of its obligations hereunder with respect to liabilities accruing from and after the date of such sale, transfer or assignment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15.3 <U>Estoppel Certificates</U>. Tenant or Landlord (the &#147;<U>responding party</U>&#148;), as applicable, shall at any time and from
time to time, within ten (10)&nbsp;days after written request by the other party (the &#147;<U>requesting party</U>&#148;), execute, acknowledge and deliver to the requesting party a certificate in writing stating: (i)&nbsp;that this Lease is
unmodified and in full force and effect, or if there have been any modifications, that this Lease is in full force and effect as modified and stating the date and the nature of each modification; (ii)&nbsp;the date to which rental and all other sums
payable hereunder have been paid; (iii)&nbsp;that the requesting party is not in default in the performance of any of its obligations under this Lease, that the certifying party has given no notice of default to the requesting party and that no
event has occurred which, but for the expiration of the applicable time period, would constitute an event of default hereunder, or if the responding party alleges that any such default, notice or event has occurred, specifying the same in reasonable
detail; and (iv)&nbsp;such other matters as may reasonably be requested by the requesting party or by any institutional lender, mortgagee, trustee, beneficiary, ground lessor, sale/leaseback lessor or prospective purchaser of the Property, or
prospective sublessee or assignee of this Lease. Any such certificate provided under this Section&nbsp;15.3 may be relied upon by any lender, mortgagee, trustee, beneficiary, assignee or successor in interest to the requesting party, by any
prospective purchaser, by any purchaser on foreclosure or sale, by any grantee under a deed in lieu of foreclosure of any mortgage or deed of trust on the Property, by any subtenant or assignee, or by any other third party. Failure to execute and
return within the required time any estoppel certificate requested hereunder, if such failure continues for five (5)&nbsp;days after a second written request by the requesting party for such estoppel certificate, shall be deemed to be an admission
of the truth of the matters set forth in the form of certificate submitted to the responding party for execution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15.4 <U>Subordination
to CC&amp;R&#146;s</U>. This Lease, and any permitted sublease entered into by Tenant under the provisions of this Lease, and the interests in real property conveyed hereby and thereby shall be subject and subordinate to any declarations of
covenants, conditions and restrictions affecting the Property from time to time, <U>provided</U> that the terms of such declarations are reasonable, do not materially impair Tenant&#146;s ability to conduct the uses permitted hereunder on the
Property, and do not discriminate against Tenant relative to other similarly situated tenants occupying portions of the property covered by such declaration(s). Tenant agrees to execute, upon request by Landlord, any documents reasonably required
from time to time to evidence such subordination. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 36 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">15.5 <U>Mortgagee Protection</U>. If, following a default by Landlord under any mortgage, deed of
trust, ground lease, leaseback lease or other security arrangement covering the Building, the Property, or any of them, the Buildings and/or the Property, as applicable, is acquired by the mortgagee, beneficiary, master lessor or other secured
party, or by any other successor owner, pursuant to a foreclosure, trustee&#146;s sale, sheriff&#146;s sale, lease termination or other similar procedure (or deed in lieu thereof), then any such person or entity so acquiring the Building and/or the
Property shall not be: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) liable for any act or omission of a prior landlord or owner of the Property (including, but not limited to,
Landlord); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) subject to any offsets or defenses that Tenant may have against any prior landlord or owner of the Property (including, but
not limited to, Landlord); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) bound by any rent or additional rent that Tenant may have paid in advance to any prior landlord or owner of
the Property (including, but not limited to, Landlord) for a period in excess of one month, or by any security deposit, cleaning deposit or other prepaid charge that Tenant may have paid in advance to any prior landlord or owner (including, but not
limited to, Landlord), except to the extent such deposit or prepaid amount has been expressly turned over to or credited to the successor owner thus acquiring the Property; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) liable for any warranties or representations of any nature whatsoever, whether pursuant to this Lease or otherwise, by any prior landlord
or owner of the Property (including, but not limited to, Landlord) with respect to the use, construction, zoning, compliance with laws, title, habitability, fitness for purpose or possession, or physical condition (including, without limitation,
environmental matters) of the Property or the Building; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e) liable to Tenant in any amount beyond the interest of such mortgagee,
beneficiary, master lessor or other secured party or successor owner in the Property as it exists from time to time, it being the intent of this provision that Tenant shall look solely to the interest of any such mortgagee, beneficiary, master
lessor or other secured party or successor owner in the Property for the payment and discharge of the landlord&#146;s obligations under this Lease and that such mortgagee, beneficiary, master lessor or other secured party or successor owner shall
have no separate personal liability for any such obligations. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16. <U>SECURITY</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16.1 <U>Deposit</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) No
later than the Commencement Date, Tenant shall deposit with Landlord the sum of Three Hundred Seventy-Five Thousand and No/100 Dollars ($375,000.00), which sum (the &#147;<U>Security Deposit</U>&#148;) shall be held by Landlord as security for the
faithful performance of all of the terms, covenants and conditions of this Lease to be kept and performed by Tenant during the term hereof. If Tenant defaults (beyond any applicable cure period) with respect to any provision of this Lease,
including, without limitation, the provisions relating to the payment of rental and other sums due hereunder, Landlord shall have the right, but shall not be required, to use, apply or retain all or any part of the Security Deposit for the payment
of rental </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 37 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or any other amount which Landlord may spend or become obligated to spend by reason of Tenant&#146;s default or to compensate Landlord for any other loss or damage which Landlord may suffer by
reason of Tenant&#146;s default. If any portion of the Security Deposit is so used or applied, Tenant shall, within ten (10)&nbsp;days after written demand therefor, deposit cash with Landlord in an amount sufficient to restore the Security Deposit
to its original amount and Tenant&#146;s failure to do so shall be a material breach of this Lease. Landlord shall not be required to keep any deposit under this Section separate from Landlord&#146;s general funds, and Tenant shall not be entitled
to interest thereon. If Tenant fully and faithfully performs every provision of this Lease to be performed by it, the Security Deposit, or any balance thereof, shall be returned to Tenant or, at Landlord&#146;s option, to the last assignee of
Tenant&#146;s interest hereunder, at the expiration of the term of this Lease and after Tenant has vacated the Property. In the event of termination of Landlord&#146;s interest in this Lease, Landlord shall transfer all deposits then held by
Landlord under this Section to Landlord&#146;s successor in interest, whereupon Tenant agrees to release Landlord from all liability for the return of such deposit or the accounting thereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) As an alternative to the cash Security Deposit described in Section&nbsp;16.1(a), Tenant may instead deliver to Landlord an irrevocable
standby letter of credit (the &#147;<U>Letter of Credit</U>&#148;) issued in favor of Landlord by a federally insured commercial bank or trust company approved in writing by Landlord (which approval shall not be unreasonably withheld), in form and
substance reasonably satisfactory to Landlord, to be held by Landlord as security for the faithful performance of all the obligations of Tenant under this Lease, subject to the following terms and conditions: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i) The amount of the Letter of Credit shall be Three Hundred Seventy-Five Thousand and No/100 Dollars ($375,000.00), and
Tenant shall maintain the Letter of Credit in that amount in full force and effect throughout the term of this Lease and until thirty (30)&nbsp;days after the expiration of the term of this Lease, unless Tenant elects at any time to replace the
Letter of Credit with a full cash Security Deposit in compliance with Section&nbsp;16.1(a). The Letter of Credit may be for an initial one-year term, with automatic renewal provisions, provided that Landlord shall be given at least thirty
(30)&nbsp;days prior written notice if the Letter of Credit will not be renewed as of any otherwise applicable renewal date and shall be entitled to draw against the expiring Letter of Credit if a replacement Letter of Credit is not furnished to
Landlord at least twenty (20)&nbsp;days prior to the scheduled expiration date, as provided in Section&nbsp;16.1(b)(iii)(A) below. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(ii) Landlord shall be entitled (but shall not be required) to draw against the Letter of Credit and receive and retain the
proceeds thereof upon any default (beyond any applicable cure period) by Tenant in the payment of any rent or other amounts required to be paid by Tenant under this Lease, or upon the occurrence of any other Event of Default (beyond any applicable
cure period) under this Lease. The amount of the draw shall not exceed the amount of the payments (if any) as to which Tenant is then in default and/or the amount reasonably necessary to cure any nonmonetary Events of Default by Tenant, and shall be
applied by Landlord to the cure of the applicable default(s). Following any partial draw under this paragraph (ii), if Tenant fully cures all outstanding defaults and provides Landlord with a new Letter of Credit in
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 38 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
the full required amount under this Section&nbsp;16.1, Landlord shall surrender and return to Tenant, within ten (10)&nbsp;days after Tenant&#146;s satisfaction of the foregoing conditions, the
Letter of Credit under which the partial draw was made. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(iii) Landlord shall also be entitled (but shall not be required)
to draw against the Letter of Credit in full and to receive the entire proceeds thereof under either of the following circumstances: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(A) If the Letter of Credit will expire as of a date prior to the date thirty (30)&nbsp;days after the expiration of the term
of this Lease and Tenant fails to provide to Landlord an extension or replacement of such Letter of Credit, in at least the minimum amount required under this Section&nbsp;16.1(b), at least twenty (20)&nbsp;days prior to the scheduled expiration
date of the Letter of Credit; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(B) If, as a result of a draw against the Letter of Credit by Landlord or for any other
reason, the amount of the Letter of Credit falls below the minimum amount required to be maintained from time to time pursuant to this Section&nbsp;16.1(b) and Tenant has failed to cause the Letter of Credit to be restored to at least the minimum
required amount within ten (10)&nbsp;days after written demand by Landlord or, in lieu thereof, has failed to put up cash in an amount equal to the amount required to be restored (which cash, if put up by Tenant, shall be retained by Landlord as a
cash security deposit in accordance with Section&nbsp;16.1(a) hereof). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(iv) If Landlord draws against the Letter of Credit
in any of the circumstances described in subparagraph (iii)&nbsp;above, Landlord shall use, apply and/or retain all or any part of the amount drawn for the cure of any then existing defaults under this Lease. Any amount drawn that is not immediately
so used or applied by Landlord shall be retained by Landlord as a cash security deposit, subject to and in accordance with the provisions of Section&nbsp;16.1(a). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(v) Any actual or purported withdrawal, rescission, termination or revocation of the Letter of Credit by the issuer thereof
prior to the expiration of the term of this Lease (except when replaced prior to the effectiveness of such withdrawal, rescission, termination or revocation by a replacement Letter of Credit as contemplated in Section&nbsp;16.1(b)(iii)(A) hereof or
by a cash Security Deposit in the required amount) shall be a material breach of this Lease. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(vi) The Letter of Credit
shall provide that it is governed by the International Standby Practices (ISP98), ICC Publication No.&nbsp;590. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17. <U>MISCELLANEOUS</U>
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17.1 <U>Notices</U>. All notices, consents, waivers and other communications which this Lease requires or permits either party to give to
the other shall be in writing and shall be deemed given when delivered personally (including delivery by private same-day or overnight courier or express delivery service) or by telecopier with mechanical confirmation of transmission, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 39 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">effective upon personal delivery to or refusal of delivery by the recipient (in the case of personal delivery by
any of the means described above) or upon telecopier transmission during normal business hours at the recipient&#146;s office (in the case of telecopier transmission, with any transmission outside of normal business hours being effective as of the
beginning of the first business day commencing after the time of actual transmission), to the parties at their respective addresses as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">To Tenant:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(prior to Tenant&#146;s occupancy of Building under Amgen Sublease)</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Raven biotechnologies, inc.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1140 Veterans Boulevard</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">South San Francisco, CA 94080</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: CFO</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Telecopier: (650) 624-2693</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(after Tenant&#146;s occupancy of Building under Amgen Sublease) RAVEN BIOTECHNOLOGIES, INC.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">One Corporate Drive</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">South San Francisco, CA 94080</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: CFO</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Telecopier: (650)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">with copy to:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cooley Godward Kronish LLP</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">101 California
Street, 5th Floor</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Francisco, CA 94111-5800</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: Anna B.
Pope, Esq.</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Telecopier: (415) 693-2222</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">To Landlord:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Britannia Biotech Gateway Limited Partnership</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Slough Estates USA Inc.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">444 North Michigan Avenue, Suite
3230</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chicago, IL 60611</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: Randy Rohner</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Telecopier: (312) 755-0717</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">with copy to:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Britannia Management Services, Inc.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">555 Twelfth
Street, Suite 1650</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Oakland, CA 94607</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Telecopier: (510)
763-6262</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">and copy to:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Folger Levin &amp; Kahn LLP</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Embarcadero Center
West</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">275 Battery Street, 23rd Floor</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Francisco, CA
94111</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: Donald E. Kelley, Jr.</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Telecopier: (415)
986-2827</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 40 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">or to such other address as may be contained in a notice at least fifteen (15)&nbsp;days prior to the address
change from either party to the other given pursuant to this Section. Rental payments and other sums required by this Lease to be paid by Tenant shall be delivered to Landlord in care of Britannia Management Services, Inc., 555 Twelfth Street, Suite
1650, Oakland, CA 94607, or at such other address as Landlord may from time to time specify in writing to Tenant, and shall be deemed to be paid only upon actual receipt. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17.2 <U>Successors And Assigns</U>. The obligations of this Lease shall run with the land, and this Lease shall be binding upon and inure to
the benefit of the parties hereto and their respective successors and assigns, except that the original Landlord named herein and each successive Landlord under this Lease shall be liable only for obligations accruing during the period of its
ownership of the Property, and any liability for obligations accruing after termination of such ownership shall terminate as of the date of such termination of ownership and shall pass to the successor lessor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17.3 <U>No Waiver</U>. The failure of Landlord to seek redress for violation, or to insist upon the strict performance, of any covenant or
condition of this Lease shall not be deemed a waiver of such violation, or prevent a subsequent act which would originally have constituted a violation from having all the force and effect of an original violation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17.4 <U>Severability</U>. If any provision of this Lease or the application thereof is held to be invalid or unenforceable, the remainder of
this Lease or the application of such provision to persons or circumstances other than those as to which it is invalid or unenforceable shall not be affected thereby, and each of the provisions of this Lease shall be valid and enforceable, unless
enforcement of this Lease as so invalidated would be unreasonable or grossly inequitable under all the circumstances or would materially frustrate the purposes of this Lease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17.5 <U>Litigation Between Parties</U>. In the event of any litigation or other dispute resolution proceedings between the parties hereto
arising out of or in connection with this Lease, the prevailing party shall be reimbursed for all reasonable costs, including, but not limited to, reasonable accountants&#146; fees and attorneys&#146; fees, incurred in connection with such
proceedings (including, but not limited to, any appellate proceedings relating thereto) or in connection with the enforcement of any judgment or award rendered in such proceedings. &#147;<U>Prevailing party</U>&#148; within the meaning of this
Section shall include, without limitation, a party who dismisses an action for recovery hereunder in exchange for payment of the sums allegedly due, performance of covenants allegedly breached or consideration substantially equal to the relief
sought in the action. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17.6 <U>Surrender</U>. A voluntary or other surrender of this Lease by Tenant, or a mutual termination thereof
between Landlord and Tenant, shall not result in a merger but shall, at the option of Landlord, operate either as an assignment to Landlord of any and all existing subleases and subtenancies, or a termination of all or any existing subleases and
subtenancies. This provision shall be contained in any and all assignments or subleases made pursuant to this Lease. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 41 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17.7 <U>Interpretation</U>. The provisions of this Lease shall be construed as a whole, according
to their common meaning, and not strictly for or against Landlord or Tenant. The captions preceding the text of each Section and subsection hereof are included only for convenience of reference and shall be disregarded in the construction or
interpretation of this Lease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17.8 <U>Entire Agreement</U>. This written Lease, together with the exhibits hereto, contains all the
representations and the entire understanding between the parties hereto with respect to the subject matter hereof. Any prior correspondence, memoranda or agreements are replaced in total by this Lease and the exhibits hereto. This Lease may be
modified only by an agreement in writing signed by each of the parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17.9 <U>Governing Law</U>. This Lease and all exhibits hereto
shall be construed and interpreted in accordance with and be governed by all the provisions of the laws of the State of California. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17.10
<U>No Partnership</U>. The relationship between Landlord and Tenant is solely that of a lessor and lessee. Nothing contained in this Lease shall be construed as creating any type or manner of partnership, joint venture or joint enterprise with or
between Landlord and Tenant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17.11 <U>Financial Information</U>. From time to time Tenant shall promptly provide directly to prospective
lenders and purchasers of the Property designated by Landlord such financial information pertaining to the financial status of Tenant as Landlord may reasonably request; <U>provided.</U> Tenant shall be permitted to provide such financial
information in a manner which Tenant deems reasonably necessary to protect the confidentiality of such information. In addition, from time to time, Tenant shall provide Landlord with such financial information pertaining to the financial status of
Tenant as Landlord may reasonably request. Landlord agrees that all financial information supplied to Landlord by Tenant shall be treated as confidential material, and shall not be disseminated to any party or entity (including any entity affiliated
with Landlord) without Tenant&#146;s prior written consent, except that Landlord shall be entitled to provide such information, subject to reasonable precautions to protect the confidential nature thereof, (i)&nbsp;to Landlord&#146;s partners and
professional advisors, solely to use in connection with Landlord&#146;s execution and enforcement of this Lease, and (ii)&nbsp;to prospective lenders and/or purchasers of the Property, solely for use in connection with their bona fide consideration
of a proposed financing or purchase of the Property, <U>provided</U> that such prospective lenders and/or purchasers are not then engaged in businesses directly competitive with the business then being conducted by Tenant. For purposes of this
Section, without limiting the generality of the obligations provided herein, it shall be deemed reasonable for Landlord to request copies of Tenant&#146;s most recent audited annual financial statements, or, if audited statements have not been
prepared, unaudited financial statements for Tenant&#146;s most recent fiscal year, accompanied by a certificate of Tenant&#146;s chief financial officer that such financial statements fairly present Tenant&#146;s financial condition as of the
date(s) indicated. Notwithstanding any other provisions of this Section&nbsp;17.11, during any period in which Tenant has outstanding a class of publicly traded securities and is filing with the Securities and Exchange Commission, on a regular
basis, Forms 10Q and 10K and any other periodic filings required under the Securities Exchange Act of 1934, as amended, it shall constitute sufficient compliance under this Section&nbsp;17.11 for Tenant to furnish Landlord with copies of such
periodic filings substantially concurrently with the filing thereof with the Securities and Exchange Commission. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 42 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Landlord and Tenant recognize the need of Tenant to maintain the confidentiality of information
regarding its financial status and the need of Landlord to be informed of, and to provide to prospective lenders and purchasers of the Property financial information pertaining to, Tenant&#146;s financial status. Landlord and Tenant agree to
cooperate with each other in achieving these needs within the context of the obligations set forth in this Section. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17.12 <U>Costs</U>.
If Tenant requests the consent of Landlord under any provision of this Lease for any act that Tenant proposes to do hereunder, including, without limitation, assignment or subletting of the Building or any portion thereof, Tenant shall, as a
condition to doing any such act and the receipt of such consent, reimburse Landlord promptly for any and all reasonable costs and expenses incurred by Landlord in connection therewith, including, without limitation, reasonable attorneys&#146; fees.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17.13 <U>Time</U>. Time is of the essence of this Lease, and of every term and condition hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17.14 <U>Rules And Regulations</U>. Tenant shall observe, comply with and obey, and shall cause its employees, agents and, to the best of
Tenant&#146;s ability, invitees to observe, comply with and obey such rules and regulations as Landlord may reasonably promulgate from time to time for the safety, care, cleanliness, order and use of the Improvements, the Building and the Property,
provided that such rules and regulations do not expressly conflict with the terms of this Lease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17.15 <U>Brokers</U>. Each party
represents and warrants that no broker participated in the consummation of this Lease and agrees to indemnify, defend and hold the other party harmless against any liability, cost or expense, including, without limitation, reasonable attorneys&#146;
fees, arising out of any claims for brokerage commissions or other similar compensation in connection with any conversations, prior negotiations or other dealings by the indemnifying party with any broker, finder or other similar claimant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17.16 <U>Memorandum Of Lease</U>. At any time during the term of this Lease, either party, at its sole expense, shall be entitled to record a
memorandum of this Lease and, if either party so elects, both parties agree to cooperate in the preparation, execution, acknowledgement and recordation of such document in reasonable form. If such a memorandum of lease is recorded, then upon
expiration or termination of this Lease, Tenant agrees promptly to execute, acknowledge and deliver to Landlord, upon written request by Landlord, a Termination of Memorandum of Lease in such form as Landlord may reasonably request, for the purpose
of terminating any continuing effect of the previously recorded memorandum of lease as a cloud upon title to the Property. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17.17
<U>Corporate Authority</U>. Each party to this Lease represents and warrants that the person signing this Lease on behalf of such respective party is fully authorized to do so and, by so doing, to bind such party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17.18 <U>Execution and Delivery</U>. This Lease may be executed in one or more counterparts and by separate parties on separate counterparts,
but each such counterpart shall constitute an original and all such counterparts together shall constitute one and the same instrument. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 43 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17.19 <U>Survival</U>. Without limiting survival provisions which would otherwise be implied or
construed under applicable law, the provisions of Sections 2.4, 5.4, 7.2, 7.3, 7.4, 8.2(c), 9.6, 10.6, 16.1, 17.5 and 17.16 hereof shall survive the termination of this Lease with respect to matters occurring prior to the expiration of this Lease.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17.20 <U>Parking</U>. Landlord and Tenant agree that the Common Areas, taken as a whole, shall include parking in amounts sufficient to
satisfy the minimum parking requirements of the City of South San Francisco applicable to the Property and the Center from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties hereto have executed this Lease as of the day and year first set forth above. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5" ALIGN="center">&#147;Landlord&#148;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" COLSPAN="3" ALIGN="center">&#147;Tenant&#148;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="5"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5">BRITANNIA BIOTECH GATEWAY LIMITED PARTNERSHIP, a Delaware limited partnership</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">RAVEN BIOTECHNOLOGIES, INC., a</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Delaware corporation</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" COLSPAN="3">SLOUGH BIOTECH GATEWAY</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ George F. Schreiner</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" COLSPAN="3">INCORPORATED,&nbsp;a&nbsp;Delaware&nbsp;corporation,&nbsp;General&nbsp;Partner</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">George F. Schreiner</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">CEO</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" ALIGN="center">By:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Jonathan M. Bergschneider</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Jonathan M. Bergschneider</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Senior Vice President</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ John Whelan</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">John Whelan</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">COO &amp; CFO</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 44 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>EXHIBITS </U></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="88%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">EXHIBIT&nbsp;A</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Real Property Description</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">EXHIBIT B</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Site Plan</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">EXHIBIT C</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Acknowledgement of Commencement Date</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 45 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT A </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>REAL PROPERTY DESCRIPTION </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All
that certain real property in the City of South San Francisco, County of San Mateo, State of California, more particularly described as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Parcel
One: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Parcel C as designated on the Map entitled &#147;PARCEL MAP NO. 89-268&#148;, being a resubdivision of Lots 4, 5, 6 and 7 of that certain Map
entitled &#147;FINAL MAP GATEWAY CENTER&#148; (SA-81-74) filed in the office of the Recorder of the County of San Mateo in Book 107 of Maps at Pages 27, 28, 29 and 30, which Map was filed in the Office of the Recorder of the County of San Mateo,
State of California on December&nbsp;12, 1989 in Book 63 of Parcel Maps at Pages 32 and 33. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Parcel Two: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A portion of that certain 0.572 acre parcel of land described in Resolution No.&nbsp;900 by the City of South San Francisco, recorded August&nbsp;6, 1943, in
Book 1079 of Official Records of San Mateo County at Page 77, further described as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A portion of Industrial Way, as shown on that certain Map
entitled &#147;Final Map Gateway Center&#148; filed October&nbsp;1, 1982, in Book 107 of Maps at Pages 27-30, San Mateo County Records, further described as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Beginning at a point on the southeasterly line of said 0.572 acre parcel, also being the northwesterly line of Lot 4 as shown on said Map (104 Maps 27-30),
distant thereon North 38&deg; 42&#146; 41&#148; East, 29.29 feet from the southwest corner of said Lot 4; thence along the aforementioned southeasterly line, North 38&deg; 42&#146; 41&#148; East, 356.97 feet; then northeasterly along the arc of a
tangent, 980.56 foot radius curve to the left, through a central angle of 7&deg; 19&#146; 26&#148;, an arc distance of 125.34 feet to a point of reverse curvature; thence northeasterly along the arc of a tangent, 980.56 foot radius curve to the
right, through a central angle of 7&deg; 19&#146; 26&#148;, an arc distance of 125.34 feet to a point of cusp, being the most northerly point of the aforementioned 0.572 acre parcel; thence along the northwesterly line of said 0.572 acre parcel,
South 38&deg; 42&#146; 41&#148; West, 606.97 feet to a line which bears North 51&deg; 17&#146; 19&#148; West from the point of beginning; thence South 51&deg; 17&#146; 19&#148; East, 16.00 feet to the point of beginning. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>EXHIBIT A</U> to Lease </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT B </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>SITE PLAN </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g838054g39l39.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>EXHIBIT B</U> to Lease </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT C </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>ACKNOWLEDGEMENT OF COMMENCEMENT DATE </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Acknowledgement is executed as
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , by BRITANNIA BIOTECH GATEWAY LIMITED PARTNERSHIP,
a Delaware limited partnership (&#147;<U>Landlord</U>&#148;), and RAVEN BIOTECHNOLOGIES, INC., a Delaware corporation (&#147;<U>Tenant</U>&#148;), pursuant to Section&nbsp;2.3 of the Lease dated November&nbsp;21, 2006 between Landlord and Tenant
(the &#147;<U>Lease</U>&#148;) covering premises located at One Corporate Drive, South San Francisco, CA 94080 (the &#147;<U>Property</U>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Landlord and Tenant hereby acknowledge and agree as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. The Commencement Date under the Lease
is&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. The Termination Date under the Lease shall be February 28, 2018, subject to any applicable provisions of the Lease for early termination
thereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. The square footage of the Building is 66,127 square feet. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. Tenant accepts the Building and acknowledges the satisfactory condition thereof as provided in the applicable provisions of the Lease. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">EXECUTED as of the date first set forth above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5" ALIGN="center">&#147;Landlord&#148;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" COLSPAN="3" ALIGN="center">&#147;Tenant&#148;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="5"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5">BRITANNIA BIOTECH GATEWAY</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" COLSPAN="3">RAVEN&nbsp;BIOTECHNOLOGIES,&nbsp;INC., a</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5">LIMITED PARTNERSHIP, a Delaware</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" COLSPAN="3">Delaware corporation</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5">limited partnership</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" COLSPAN="3">SLOUGH BIOTECH GATEWAY</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" COLSPAN="3">INCORPORATED, a Delaware</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Its:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" COLSPAN="3">corporation, General Partner</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jonathan M. Bergschneider</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Senior Vice
President</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Its:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>EXHIBIT C</U> to Lease </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.15
<SEQUENCE>5
<FILENAME>d838054dex1015.htm
<DESCRIPTION>EX-10.15
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.15</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Exhibit 10.15 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LEASE AGREEMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">THIS LEASE AGREEMENT,
made this 31st day of March 2014, by and between </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>W. M. RICKMAN CONSTRUCTION CO. LLC</B> (&#147;Landlord&#148;) and <B>MACROGENICS, INC.</B>
(&#147;Tenant&#148;). </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>W I T N E S S E T H: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>DEMISE OF PREMISES </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Landlord hereby demises unto Tenant, and Tenant hereby leases from
Landlord for the terms and upon the conditions set forth in this Lease the entire third (3<SUP STYLE="font-size:85%; vertical-align:top">rd</SUP>)&nbsp;floor (approximately 14,597 square feet) in the building located at 15235 Shady Grove Road,
Rockville, Maryland (the &#147;Building&#148;), as set forth on Exhibit A, hereto attached, said space being referred to as the &#147;Premises.&#148; Landlord shall maintain the Building, as required, in accordance with all applicable laws,
including, but not limited to the Americans with Disabilities Act of 1990, as amended (the &#147;ADA&#148;). Landlord hereby represents and warrants that the Building is in full compliance, as required, with the ADA as of the date of this Lease and
the Lease Commencement Date. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>TERM </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The term of this Lease shall be for a period of four (4)&nbsp;years, commencing on
the 1st day of April 2014, and terminating on the 31<SUP STYLE="font-size:85%; vertical-align:top">st</SUP> day of March 2018, with an option for an additional five (5)&nbsp;years on the same terms and conditions in this Lease, provided that Tenant
shall have given the Landlord written notice of Tenant&#146;s intention to do so at least nine (9)&nbsp;months prior to the expiration of this Lease and that Tenant is not in default under this Lease. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In the event the Landlord is not able to deliver possession of the Premises to Tenant on the date this Lease is to commence because Landlord
has not fully completed the Landlord&#146;s Work, or an earlier tenant has failed to vacate the Premises, the commencement date shall be extended to the date said Work is completed and/or the earlier tenant has vacated and the expiration date shall
be similarly extended. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The date of delivery of the Premises by Landlord to Tenant shall be that date on which all required improvements to
be furnished by Landlord as stated in Exhibit &#147;A&#148; have been substantially completed except for punch list items and the occupancy certificate has been issued, unless Tenant&#146;s act or omissions have caused such approval to be denied, in
which case Tenant shall be deemed to have waived this condition. Rent shall be pro-rated for any portion of the initial month in which Tenant is required to commence rental payments hereunder, which does not commence with the first day thereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">At any time prior to delivery of possession of the Premises, Tenant shall have the right to enter upon the Premises for the purpose of taking
measurements, provided such entry does not unreasonably interfere with or obstruct the progress of work being done by the Landlord. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>RENT </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Tenant shall pay to the Landlord an annual rental (herein called &#147;Minimum
Rent&#148;) in the amount of Two Hundred Seventy Seven Thousand Three Hundred Forty Three and NO/100 DOLLARS ($277,343.00), subject to adjustment as hereinafter set forth, payable without deduction or set off in equal monthly installments of Twenty
Three Thousand One Hundred Eleven and 92/100 DOLLARS ($23,111.92) in advance, the first installment of which is due and payable upon signing of the Lease and upon commencement all subsequent installments due and payable on the first day of each
calendar month thereafter during the term of the Lease until the total rent provided for herein is paid. No payment by Tenant or receipt of Landlord of a lesser amount than a monthly installment of rent herein stipulated, or endorsement or statement
on any check or any letter accompanying any check for payment as rent be deemed an accord and satisfaction, and Landlord may accept such check for payment without prejudice to Landlord&#146;s right to recover the balance of such rent or pursue any
other remedy provided for in this Lease. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Tenant&#146;s Minimum Rent shall be abated for the initial eighteen (18)&nbsp;month of the Lease,
Tenant shall still be responsible for any additional expenses as set forth in Lease. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>ADJUSTMENT OF MINIMUM RENT </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">A. The Minimum Rent shall be increased at the end of each
lease year during the term hereby by three percent (3%)&nbsp;of the rent then being paid. There shall be no additional pass-throughs of increases in operating expenses except for real estate taxes or as otherwise provided for herein. For purposes of
clarification, any adjustment of the Minimum Rent under this the Article 4 during the initial eighteen (18)&nbsp;months of the Lease shall be abated. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Additionally Tenant shall pay its pro rata share (33%)&nbsp;of the Building insurance and common area maintenance charges (collectively,
&#147;Operating Expenses&#148;) in addition to its pro rata share of the real estate taxes as identified in Section&nbsp;5. Operating Expenses shall not include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top">Ground rent or other rental payments made under any ground lease or underlying lease or loan payments made on account of any loan; </TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top">Costs of expanding the Building and costs of structural repairs, improvements or replacements to the Building, including structural repairs to the walls, foundation and floor slabs and the maintenance, repair or
replacement of the roof; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top">Costs of leasing commissions, legal, space planning, construction and other expenses incurred in procuring or retaining tenants for the Building or solely with respect to individual tenants or occupants of the Building;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">d.</TD>
<TD ALIGN="left" VALIGN="top">Costs of painting, redecorating or other services or work performed solely for the benefit of another tenant, prospective tenant or occupant (other than for the Common Area); </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">e.</TD>
<TD ALIGN="left" VALIGN="top">Salaries, wages, or other compensation paid to officers or executives of Landlord above the level of Building Manager; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">f.</TD>
<TD ALIGN="left" VALIGN="top">in the case of any offsite or other employees who are not assigned full time to the operation, management, maintenance or repair of the Common Area (as hereinafter defined), Landlord shall reasonably allocate the
compensation paid for the wages, salary, or other compensation or benefits paid to such employees among the properties to which such employees are assigned and Operating Expenses shall exclude the portion of such compensation not reasonably
allocated to the Building. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">g.</TD>
<TD ALIGN="left" VALIGN="top">Costs of advertising and public relations and promotional costs associated with the leasing of the Building; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">h.</TD>
<TD ALIGN="left" VALIGN="top">Any costs, fines or penalties incurred due to the violation by Landlord of any governmental rule or authority; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">i.</TD>
<TD ALIGN="left" VALIGN="top">Any expenses for which Landlord actually receives reimbursement from insurance, other tenants or any other source; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">j.</TD>
<TD ALIGN="left" VALIGN="top">Costs of repairs, restoration, replacements or other work occasioned by (A)&nbsp;fire, flood, windstorm or other casualty (whether such destruction be total or partial) and (B)&nbsp;the exercise by governmental
authorities of the right of eminent domain (whether such taking be total or partial); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">k.</TD>
<TD ALIGN="left" VALIGN="top">Costs incurred in connection with disputes with tenants, other occupants or prospective tenants, or costs and expenses incurred in connection with negotiations or disputes with employees, consultants, management agents,
leasing agents, purchasers or mortgagees of the Building; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">l.</TD>
<TD ALIGN="left" VALIGN="top">Costs incurred in connection with the original construction of the Building or in connection with any change in the Building including but not limited to construction, alteration, improvement, consultation,
architectural or engineering reconfiguration associated with compliance with the Americans With Disabilities Act and the Clean Air Act; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">m.</TD>
<TD ALIGN="left" VALIGN="top">Costs of repairing, replacing or otherwise correcting defects (including latent defects) in or inadequacies of (but not the costs of ordinary and customary repair for normal wear and tear) the initial design or
construction of the Building or the costs of repairing, replacing or correcting defects in the initial design or construction of any tenant improvements; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">n.</TD>
<TD ALIGN="left" VALIGN="top">Costs relating to another tenant&#146;s or occupant&#146;s space which (A)&nbsp;were incurred in rendering any service or benefit to such tenant that Landlord was not required to provide, or were for a service in excess
of the service that the Landlord was required to provide to Tenant hereunder or (B)&nbsp;were otherwise in excess of the Building standard services then being provided by Landlord to all tenants or other occupants in the Building, whether or not
such other tenant or occupant is actually charged therefor by Landlord; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">o.</TD>
<TD ALIGN="left" VALIGN="top">Costs incurred in connection with the sale, financing, refinancing, mortgaging, selling or change of ownership of the Building, including, but not limited to, attorneys&#146; fees, title insurance premiums, and transfer
and recording costs; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">p.</TD>
<TD ALIGN="left" VALIGN="top">Costs, fines, interest, penalties, legal fees or costs of litigation incurred due to the late payments of loan payments, taxes and utility bills and other costs incurred by Landlord&#146;s failure to make such payments
when due; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">q.</TD>
<TD ALIGN="left" VALIGN="top">General overhead and general administrative expenses and accounting, record-keeping and clerical support of Landlord; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">r.</TD>
<TD ALIGN="left" VALIGN="top">Fees for management of the Building or the Project in excess of five percent (5%)&nbsp;of gross collected rents of the Building; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 2 of 12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">s.</TD>
<TD ALIGN="left" VALIGN="top">Increased insurance premiums caused by Landlord&#146;s or any other tenant&#146;s hazardous acts and insurance of leasehold improvements in the premises leased or to be leased to other tenants; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">t.</TD>
<TD ALIGN="left" VALIGN="top">Costs incurred for any items to the extent covered by a manufacturer&#146;s, materialman&#146;s, vendor&#146;s or contractor&#146;s warranty; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">u.</TD>
<TD ALIGN="left" VALIGN="top">Interest on capital invested, bad debt losses, rent losses and reserves for such losses; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">v.</TD>
<TD ALIGN="left" VALIGN="top">Costs incurred by Landlord which are associated with the operation of the business of the legal entity which constitutes Landlord as the same is separate and apart from the costs of the operation of the Building,
including legal entity formation and maintenance charges, legal entity accounting (excluding the incremental accounting fees relating to the operation of the Building) and legal fees (other than with respect to Building operations);
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">w.</TD>
<TD ALIGN="left" VALIGN="top">All amounts which would otherwise be included in Operating Expenses which are paid to any affiliate or subsidiary of Landlord to the extent the cost of such services exceed the market rate for similar services;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">x.</TD>
<TD ALIGN="left" VALIGN="top">Costs or expenses necessitated by or resulting from the gross negligence, misconduct or illegal conduct of Landlord, its agents, or employees; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">y.</TD>
<TD ALIGN="left" VALIGN="top">Depreciation and amortization, and costs which under GAAP are capitalized. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">In no event will
controllable Operating Expenses (i.e., all such charges excluding costs of utilities, insurance, repairs and snow removal) for any year during the term increase by more than four percent (4%)&nbsp;over the amount of such controllable costs incurred
by Landlord during the prior twelve (12)-month period. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">C.</TD>
<TD ALIGN="left" VALIGN="top">Additional Rent Estimates and Adjustments. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">a. In order to provide for current monthly payments
of additional rent, Landlord shall provide Tenant with the Landlord&#146;s estimate of the amount of the charges described in Section&nbsp;5.A. above, together with the amount of Tenant&#146;s additional rent (&#147;Additional Rent&#148;) which is
estimated to result from such charges. Tenant shall pay each month during the term of this lease one-third (1/3)&nbsp;of Tenant&#146;s pro rata share of Landlord&#146;s estimate of the Operating Expenses. Landlord may revise its estimate of
Operating Expenses at any time during a calendar year by written notice to Tenant, setting forth such revised estimate and Tenant&#146;s pro rata share thereof. In such event, all monthly payments made by Tenant after such notice shall be in an
amount calculated on the basis of such revised estimate. Tenant shall, in all cases, continue to make monthly payments of Operating Expenses based on the last estimate received from Landlord until it receives a revised or updated estimate. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">b. If payment of Additional Rent begins on a date other than January&nbsp;1<SUP STYLE="font-size:85%; vertical-align:top">st</SUP> under this
Lease, in order to provide for current payments of Additional Rent through December&nbsp;31<SUP STYLE="font-size:85%; vertical-align:top">st</SUP> of that partial calendar year, Landlord shall provide Tenant with the Landlord&#146;s estimate of
Tenant&#146;s Additional Rent for that partial year, stated in monthly increments, resulting from the charges described in Section&nbsp;5(c)(i) above. Tenant shall make the monthly incremental payments of estimated Additional Rent together with its
installments of Minimum Rent. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">c. After the end of each calendar year, Landlord will as soon as practicable submit to Tenant a statement of
the actual Operating Expenses for the preceding calendar year. Tenant shall pay Landlord, within thirty (30)&nbsp;days of Tenant&#146;s receipt of such statement, the excess, if any, of Tenant&#146;s pro rata share of actual Operating Expenses over
the amount paid by Tenant during the previous year as its share of such charges. If the amount paid by Tenant during the previous year exceeded Tenant&#146;s pro rata share of actual Operating Expenses for the year, the excess shall be credited
toward payment of the next monthly installment of Minimum Rent to be paid by Tenant after Tenant receives said statement from Landlord. If the amount paid by Tenant during the last calendar year of the Lease Term exceeds Tenant&#146;s pro rata share
of actual Operating Expenses for such year, Landlord shall pay Tenant the excess amount within thirty (30)&nbsp;days after Landlord&#146;s submission to Tenant of the aforesaid Operating Expenses statement for such calendar year. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">d. Landlord&#146;s failure or delay in rendering any statement contemplated by this Section shall not constitute a waiver of Landlord&#146;s
right thereafter and during the term of this Lease to render such statement. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">C.</TD>
<TD ALIGN="left" VALIGN="top">Within ten (10)&nbsp;business days after receipt of Landlord&#146;s statement showing actual figures for the year, Tenant shall have the right to request a detailed statement of Operating Expenses prepared by Landlord
and copies of Real Estate Tax bills, which shall be supplied to Tenant within a reasonable time after Tenant&#146;s written request. No such request shall extend the time for payments as set forth in Section&nbsp;5.A. or Section&nbsp;6. Unless
Tenant asserts specific error(s) and supports such errors, in writing, within thirty (30)&nbsp;days after Landlord has complied with Tenant&#146;s request, Tenant shall waive the right to contest the statement of actual figures for the year
submitted by Landlord. If it shall be determined that there is an error in Landlord&#146;s statement, Tenant shall be entitled to a credit for any overpayment. Any payment, refund or credit made pursuant to Section 5.A. or Section&nbsp;6 shall be
made without prejudice to any right of Tenant to dispute, or of Landlord to correct, any item(s) as billed pursuant to the provision hereof. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 3 of 12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>REAL ESTATE TAXES </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In the event the real estate taxes levied or assessed against the
land and Building on which the Premises are a part in future tax years are greater than the real estate taxes for the Base Year, the Tenant shall pay within fifteen (15)&nbsp;days after submission of the bill to Tenant for the increase in real
estate taxes, as additional rent, a proportionate share of such increase, which proportionate share shall be computed at 30.37% of the increase in taxes, but shall exclude any fine, penalty, or interest charge for late or non-payment of taxes by
Landlord. The Base Year shall be July&nbsp;1, 2014, to June&nbsp;30, 2015. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Any reasonable expense incurred by Landlord (including counsel
fees) in contesting any tax increase shall be included as an item of taxes for the purpose of computing additional rent due Landlord. Landlord, however, shall be under no obligation to contest any tax increase. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>UTILITIES </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Tenant shall be responsible for the payment of all utilities used or consumed
by the Tenant in and upon the Premises. Electric and Gas shall be separately metered, with the cost of such separate meters to be borne by Landlord. Utilities shall be either separately metered at Landlord&#146;s expense or an equitable allocation
made between the Tenants in the Building based on the quantity of water consumed. In the event any utility service to the Premises shall be interrupted for a continuous period of more than five (5)&nbsp;days as a result of any cause whatsoever and
Tenant is unable to use all or a substantial portion of the Premises, the Minimum Rent shall abate until such services are rendered. If such interruption continues for a period of sixty (60)&nbsp;consecutive days Tenant shall have the right to
terminate this Lease by delivery of written notice to Landlord while such interruption is continuing. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Landlord shall not be liable to
Tenant for any damage or inconvenience caused by the cessation or interruption of any utility service, or the elevators in the Building, occasioned by fire, accident, strike or other cause beyond Landlord&#146;s control. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>SECURITY DEPOSIT </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">N/A </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>USE OF PREMISES </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Tenant shall use the Premises only for Research Laboratories, Office,
and Manufacturing purposes consistent with Tenant&#146;s business, and for no other purpose, except as approved by Landlord in advance, in writing, which approval shall not be unreasonably withheld. Tenant shall not make any use of the Premises
which would disturb the quiet enjoyment of the Landlord or other tenants in the Building or prejudice or increase the fire insurance premium for the Building, and shall comply with all laws and regulations of all governmental authorities pertaining
to Tenant&#146;s use of Premises. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>WASTE REMOVAL </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Tenant shall be responsible for removal of waste generated by
Tenant&#146;s operation. This includes waste service fees levied by local jurisdictions. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>10.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>HAZARDOUS MATERIALS </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Tenant shall be permitted to store Hazardous Materials on the
Premises and shall comply with all laws and regulations of all governmental authorities pertaining to Tenant&#146;s use of the Premises, including, without limitation, all Environmental Laws (as hereinafter defined) and laws pertaining to Hazardous
Materials and Air and Water Quality. The term &#147;Hazardous Materials&#148; means and includes any petroleum products and/or any hazardous toxic or other dangerous waste, substance or material defined as such in the Environmental Laws. The term
&#147;Environmental Laws&#148; means the Comprehensive Environmental Response, Compensation and Liability Act, any &#147;Superfund&#148; or &#147;Superlien&#148; law, or any other federal, state or local statute, law, ordinance, code, regulation,
order or decree regulating, relating to, or imposing liability or standards of conduct concerning the use or storage of Hazardous Materials. All such materials must be completely removed upon expiration of this Lease, and any de-contamination
certificates required by the Landlord or any government authority must be obtained and delivered to the Landlord. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Tenant shall obtain and
maintain, in full force and effect, all necessary government licenses, permits and approvals legally required for materials used in the conduct of its business. If the presence of any Hazardous Materials on the Premises caused or permitted by Tenant
results in any contamination of the Premises or any portion of the Building or Common Areas, Tenant shall promptly take all actions, at its sole expense, necessary to return the Premises to the condition existing prior to the introduction of such
Hazardous Materials, provided that all such actions shall be subject to the approval of Landlord, which approval shall not be unreasonably withheld. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">At the Commencement Date of the Lease and on January&nbsp;1 of each year thereafter, Tenant shall disclose to Landlord the names and amounts of
all Hazardous Materials which are to be stored, used or disposed of on the Premises. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 4 of 12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>11.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>LATE CHARGE </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If any installment of rent accruing herein shall not be paid within five
(5)&nbsp;days of due date, and other sums not paid within fifteen (15)&nbsp;days after written notice to Tenant, such installment and other sums shall be increased without affecting the Landlord&#146;s other rights under this Lease, by a late charge
of five percent (5%)&nbsp;of the delinquent installment. Anything contained herein to the contrary notwithstanding. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>12.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>REPAIRS AND MAINTENANCE </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Landlord shall be responsible for all structural repairs,
including repairs to the roof and load-bearing walls of the Building, for maintaining the parking area and sidewalks, and the Common Areas (as hereinafter defined) in the Building. Landlord will repair and replace any glass breakage, provided it is
not the result of the Tenant&#146;s willful or negligent act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Tenant shall be responsible for the maintenance and repair of the
Premises and all fixtures, appliances, light bulbs and equipment therein, including, but not limited to, the Heating and Air Conditioning system(s) serving Tenant&#146;s suite. Landlord will pay for major Heating and Air Conditioning component
replacement and all repairs to the Landlord installed heating and air conditioning system(s) in excess of Four Hundred Dollars ($400.00) per occurrence per Heating and Air Conditioning unit. All major replacements or repairs will be performed by
Landlord unless written permission is otherwise given. Landlord hereby represents that the HVAC is in good and proper working order upon the Commencement Date hereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Tenant shall be responsible for removal of waste generated by Tenant&#146;s operation and provide its own janitorial and cleaning service. This
includes waste service fees levied by local jurisdictions. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Tenant, at its sole expense, shall keep all Tenant fixtures and equipment in
the Premises in safe and sanitary condition and good order and repair, together with related plumbing, electrical or other utility service, whether installed by Tenant or by Landlord on Tenant&#146;s behalf. Tenant shall pay for all damage to the
Building and any fixtures and appurtenances related thereto due to the malfunction, lack of repair, or improper installation of the Tenant&#146;s fixtures and equipment. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>13.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>COMMON AREAS </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In addition to the use of the Premises, Tenant, its employees and business
invitees shall have the right to use the Common Areas in common with Landlord and other tenants of the Building, their employees and visitors. The term &#147;Common Areas&#148; shall mean those portions of the Building and the land upon which the
Building is erected which Landlord may from time to time designate for Tenant&#146;s non-exclusive use, which may include the entrance, foyer and lobby corridors, lavatories, stairwells, elevators, and parking areas. All Common Areas shall be
subject to the exclusive control of the Landlord. The Landlord shall operate, manage, light and maintain the Common Areas. Landlord reserves the right to change the size, area, level, location and arrangement of the Common Areas and any such change
or rearrangement shall not affect the obligations of the Landlord and Tenant hereunder. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>14.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>LANDLORD&#146;S WORK PRIOR TO COMMENCEMENT OF TERM </B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A.</TD>
<TD ALIGN="left" VALIGN="top">Landlord shall provide the following improvements at its expense to the Premises prior to the commencement of the term of the Lease: re-paint, re-carpet/tile (floor tiles) and replace all ceiling tiles, ensure all
window blinds and ventilation are in proper working order and remove toilets and showers identified by Tenant within Suite 302, consisting of approximately 2,590 square feet located within Premises. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">B.</TD>
<TD ALIGN="left" VALIGN="top">Tenant shall be entitled to occupy the office areas of the Premises a section at a time during the Term. Prior to Tenant occupying each additional section of office area of the Premises, Landlord at its expense shall
re-paint, re-carpet/tile (floor tiles) and replace all ceiling tiles, ensure all window blinds and ventilation are in proper working order and remove toilets and showers identified by Tenant within such additional section. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">C.</TD>
<TD ALIGN="left" VALIGN="top">Tenant shall be entitled to occupy the laboratory area during the Term a section at a time or altogether simultaneously. Prior to Tenant occupying a laboratory section, Landlord at its expense shall undertake and
complete the following improvements in such laboratory section: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top">re-paint, re-carpet/tile (floor tiles) and replace all ceiling tiles, ensure all window blinds and ventilation are in proper working order and remove toilets and showers identified by Tenant; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top">replace case work (including counter tops) per mutual consent; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">c)</TD>
<TD ALIGN="left" VALIGN="top">ensure all hoods and vents are in working order; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">d)</TD>
<TD ALIGN="left" VALIGN="top">ensure that the cold room is in good working order or remove the cold room at Tenant&#146;s request; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">e)</TD>
<TD ALIGN="left" VALIGN="top">remove or renovate vivarium (if present in the laboratory space being occupied) per mutual consent; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">f)</TD>
<TD ALIGN="left" VALIGN="top">remove warm room (if present in the laboratory space being occupied); and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">g)</TD>
<TD ALIGN="left" VALIGN="top">remove additional equipment and casework upon Tenant&#146;s request. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">D. Additional
modifications and improvements to the Premises shall be conducted at Landlord&#146;s expense according to a separate agreement and mutually agreed upon plan. Which will include the installation of additional electrical outlets and removal or
addition of walls. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 5 of 12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>15.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>TENANT ALTERATIONS </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">All alterations, improvements, or additions to the demised Premises
to be made by Tenant shall be subject to the written consent of the Landlord, which consent shall not be unreasonably withheld, provided such alterations and improvements do not weaken the structural integrity of the Building or detract from its
dignity and/or uniformity. All alterations and improvements and/or additions made by Tenant shall remain upon the Premises at the expiration or earlier termination of this Lease and shall become the property of the Landlord, unless Landlord shall,
at the time of approval of the alteration, provide written notice to Tenant to remove the same, in which event Tenant shall remove such alterations, improvements and/or additions, and restore the Premises to the same good order and condition in
which it was at the commencement of this Lease, reasonable wear and tear and unavoidable casualty excepted. Should Tenant fail to do so, Landlord may do so, collecting the reasonable cost and expense thereof from Tenant as additional rent. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>16.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>TRADE FIXTURES </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">All trade fixtures, telephone equipment, and apparatus installed by
Tenant in the Premises shall remain the property of Tenant and shall be removed at the expiration or earlier termination of this Lease and, upon such removal, Tenant shall repair any damage caused by the removal and shall promptly restore the
Premises to their good order and condition. Any such trade fixture not removed prior to such termination shall be considered abandoned property, but such abandonment shall not release Tenant of its obligation to pay for the cost of removing such
trade fixtures and repairing any damage caused by the removal. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>17.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>QUIET ENJOYMENT </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Landlord covenants that, upon payment of the rent herein provided and
performance by the Tenant of all other covenants herein contained, Tenant shall and may peaceably and quietly have, hold and enjoy the Premises for the term hereof and options. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>18.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>SURRENDER OF PREMISES </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Upon the expiration or termination of this Lease, Tenant shall
quit and surrender the Premises to the Landlord broom clean and shall remove all of its property therefrom. If the removal of any such property shall result in damaging the Premises, or leaving any holes in the floors, walls or ceiling therein, the
Tenant shall make the appropriate repairs with Landlord approved building materials prior to the expiration of this Lease. The obligation of this paragraph shall survive the termination of the Lease. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>19.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>INSURANCE </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Tenant covenants and agrees to maintain and carry, at all times during the
term of this Lease, in companies qualified and authorized to transact business in the State of Maryland, general liability insurance in amounts of $1,000,000.00 per person, $1,000,000.00 per occurrence and $1,000,000.00 for damage to property on the
Premises or arising out of the use thereof by Tenant or its agents. All policies of insurance shall provide that they may not be canceled, except on thirty (30)&nbsp;days written notice to Landlord, and all such policies shall name Landlord as an
additional insured. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Landlord shall procure and maintain throughout the Term of this Lease a policy or policies of insurance , at its sole
cost and expense ( but subject to Section&nbsp;5), causing the Building and any other related improvements to be insured under a Causes of Loss - Special Form property insurance policy in an amount equal to the full replacement value of the Building
and any such other improvements (excluding the cost of excavation) and a policy of commercial general liability insurance with a combined single limit of not less than One Million Dollars ($1,000,000,00). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Prior to commencement, Tenant shall furnish Landlord with satisfactory proof that the insurance herein provided for is at all times in full
force and effect. If either party hereto is paid any proceeds under any policy of insurance naming such party as an insured on account of any loss, damage or liability, then such party hereby releases the other party to (and only to) the extent of
the amount of such proceeds, from any and all liability for such loss or damage, notwithstanding negligent or intentionally tortuous act or omission of the other party, its agents or employees; provided, such release shall be effective only as to a
loss of damage occurring while the appropriate policy of insurance of the releasing party provides that such release shall not impair the effectiveness of such policy or the insured&#146;s ability to recover thereunder. Each party hereto shall use
reasonable efforts to have a clause to such effect included in its said policies, and shall promptly notify the other in writing if such clause cannot be included in any such policy. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>20.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>INDEMNIFICATION </B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">Tenant shall indemnify and hold harmless the Landlord from, and name Landlord as additional insured on policy regarding, any and all liability, damage, expense, cause of action, or claims arising out of injury to
persons or to property on the Premises, except for the negligence or willful misconduct of Landlord, its agents, employees, or servants. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">Landlord shall indemnify and save harmless Tenant from any and all liability, damage, expense, cause of action or claims arising from (i)&nbsp;injury to person occurring in the Building or upon the Land on which the
Building is situated, which arises out of the act, failure to act, or negligence of Landlord, its agents, contractors or employees, or (ii)&nbsp;which arise out of Landlord&#146;s breach of, or default under, this Lease. </TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>21.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>DAMAGE BY FIRE OR CASUALTY </B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">If the Premises are damaged by fire or other casualty, but are not thereby rendered untenantable in whole or in part, Landlord, at its own expense, and subject to the limitations set forth in this Lease, shall cause
such damage to be repaired and the Minimum Rent and Additional Rent shall not be abated. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 6 of 12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">If, by reason of any damage or destruction, the Premises shall be rendered untenantable in whole
or in part and cannot be repaired and made tenantable within one hundred twenty (120)&nbsp;days after such damage: (i)&nbsp;Landlord, at its option and its own expense, may cause the damage to be repaired and the Minimum Rent and Additional Rent
shall be abated proportionately as to the portion of the Premises rendered untenantable while it is untenantable; or (ii)&nbsp;Landlord shall have the right, to be exercised by notice in writing delivered to Tenant within thirty (30)&nbsp;days of
the occurrence of such damage or destruction, to terminate this Lease, whereupon the Minimum Rent and Additional Rent shall be adjusted as of the date of such termination. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">In the event that twenty-five percent (25%)&nbsp;or more of the rentable floor area of the Building shall be damaged or destroyed by fire or other cause, notwithstanding that the Premises may be unaffected by such fire
or other damage, Landlord shall have the right, to be exercised by notice in writing delivered to Tenant within thirty (30)&nbsp;days after such occurrence, to terminate this Lease. Upon the giving of such notice, the Minimum Rent and Additional
Rent shall be adjusted as of the date of termination and This Lease shall thereupon terminate. </TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>22.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>ASSIGNMENT OR SUBLETTING </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Tenant acknowledges that Landlord has entered into this Lease
because of Tenant&#146;s financial strength, goodwill, ability and expertise and that accordingly, this lease is personal to Tenant. Taking this into consideration, tenant shall not assign, mortgage, sublet, pledge or encumber this Lease, in whole
or in part, except with the written consent of the Landlord, which shall not be unreasonably withheld or delayed. Tenant agrees that, in the event of any such assignment or subletting, Tenant shall nevertheless remain liable for the performance of
all terms, covenants, and conditions of this Lease. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In the event the Landlord consents to an assignment of the Lease, any money or
consideration to be paid to Tenant for the assignment shall be paid to the Landlord as partial consideration for the Landlord&#146;s consent to the assignment. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In the event the Landlord consents to a sublease of the Premises, or any portion thereof, Tenant shall pay to the Landlord fifty percent
(50%)&nbsp;any money, rent or other consideration paid to the Tenant by any subtenant in excess of the pro-rata portion of the rent for such space then being paid by Tenant to Landlord under this Lease less Tenant&#146;s actual costs of such
subletting and (2)&nbsp;any other profit or gain realized by the Tenant from such subletting. All sums payable hereunder by Tenant shall be paid to Landlord as additional rent immediately upon the receipt thereof by Tenant. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>23.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>SUBORDINATION AND ATTORNMENT </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">This Lease shall be subject to and subordinate at all
times to the lien of any mortgage and/or deeds of trust and all land leases now or hereafter made on any portion of the Premises, and to all advances thereunder, provided the mortgagee or trustee named in said mortgage or deed of trust shall agree
to recognize this Lease and agrees, in the event of foreclosure, not to disturb the Tenant&#146;s possession hereunder, provided Tenant is not in default under this Lease. This subordination shall be self-operative and no further instrument of
subordination shall be required. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If any proceedings are commenced to foreclose any mortgage or deed of trust encumbering the Premises,
Tenant agrees to attorn to the purchaser at the foreclosure sale, if requested to do so by any such purchaser, and to recognize such purchaser as the Landlord under this Lease, provided purchaser shall agree that Tenant&#146;s rights hereunder shall
not be disturbed so long as Tenant has not committed any event of default as to which the applicable cure period has expired. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>24.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>CONDEMNATION </B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">If the whole of the Premises shall be taken by any public or quasi-public authority under the power of eminent domain, condemnation or conveyance in lieu thereof, then this Lease shall terminate as of the date on which
possession of the Premises is required to be surrendered to the condemning authority and the Tenant shall have no claim against Landlord or the condemning authority for the value of the unexpired term of this Lease. Tenant shall have the right to
claim, however, the unamortized cost of any improvements or additions made to the Premises by Tenant at its cost, the value of any Tenant fixtures and furnishings and any moving expenses. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">If a portion of the Premises shall be so taken or conveyed, and if such partial taking or conveyance shall render the Premises unsuitable for the business of the Tenant, then the term of this Lease shall cease and
terminate as of the date on which possession of the portion of the Premises is surrendered to the condemning authority, and Tenant shall have no claim against Landlord or the condemning authority for the value of any unexpired term of this Lease.
</TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">In the event such partial taking or conveyance is not extensive enough to render the Premises untenantable for the business
of Tenant, this Lease shall continue in full force and effect, except that the Minimum Rent shall be reduced in the same proportion that the floor area of the Premises so taken or conveyed bears to such floor area immediately prior to such taking or
conveyance. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">In the event of such partial taking and continuation of Lease, Landlord shall promptly restore the Premises as nearly as
practical to the condition comparable to that which existed prior to the condemnation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 7 of 12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>25.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>EVENTS OF DEFAULT </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The occurrence of any of the following shall constitute an event of
default hereunder: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">Failure of Tenant to pay installment of rent within five (5)&nbsp;days of the due date, or failure of Tenant to pay within fifteen (15)&nbsp;days after receipt of written notice any other sum herein required to be paid
by Tenant. Notwithstanding the foregoing, Landlord shall be required to deliver to Tenant written notice of the failure to pay Minimum Rent and/or such payments of Operating Expenses one (1)&nbsp;time in every twelve (12)-month period, in which
event Tenant shall be deemed to be in default only if such failure continues for five (5)&nbsp;business days after receipt of such written notice from Landlord. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">Tenant&#146;s failure to perform any other covenant or condition of this Lease within thirty (30)&nbsp;days after receipt of written notice and demand, unless the failure is of such a character as to require more than
thirty (30)&nbsp;days to cure in which event Tenant&#146;s failure to proceed diligently to cure such failure shall constitute an event of default. </TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>26.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>LANDLORD&#146;S REMEDIES </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Upon the occurrence of any event of default, Landlord may, at
Landlord&#146;s sole option, exercise any or all of the following remedies, together with any such other remedies as may be available to Landlord at law or in equity. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">Landlord may terminate this Lease by giving Tenant written notice of its election to do so, as of a specified date not less than thirty (30)&nbsp;days after the date of the giving of such notice and this Lease shall
then expire on the date so specified, and Landlord shall then be entitled to immediately regain possession of the Premises as if the date had been originally fixed as the expiration date of the term of this Lease. Landlord may then re-enter upon the
Premises, either with or without due process of law, and remove all persons therefrom, the statutory notice to quit or any other notice to quit being hereby expressly waived by Tenant. Tenant expressly agrees that the exercise by Landlord of the
right of re-entry shall not be a bar to or prejudice in any way other legal remedies available to Landlord. In that event, Landlord shall be entitled to recover from Tenant as and for liquidated damages an amount equal to the rent and additional
rent reserved in this Lease less any and all amounts received by Landlord from the rental of the Premises to another tenant. Nothing herein contained, however, shall limit or prejudice the right of Landlord to prove for and obtain as liquidated
damages, by reason of such termination, an amount equal to the maximum allowed by any statute or rule of law in effect at the time when, and governing the proceedings in which such damages are to be proved, whether or not such amount may be greater,
equal to, or less than the amount of the difference referred to above, and the Landlord may, in his own name, but as agent for Tenant, re-let the Premises. Any recovery by the Landlord shall be limited to the rent hereunder (plus any costs incurred
in re-letting) less any rent actually paid by the new tenant. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">No termination of this Lease or any taking of possession of the Premises shall deprive Landlord of any of its remedies or actions against Tenant for past or future rent, nor shall the bringing of any action for rent or
breach of covenant, or the resort to any other remedy herein provided for the recovery of rent, be construed as a waiver of the right to obtain possession of the Premises. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top">In addition to any damages becoming due under this paragraph, Landlord shall be entitled to recover from Tenant and Tenant shall pay to Landlord an amount equal to all expenses, including attorneys&#146; fees, if any,
incurred by the Landlord in recovering possession of the Premises, and all reasonable costs and charges for the care of said Premises while vacant, which damages shall be due and payable by Tenant to Landlord at such time or times as such expenses
are incurred by the Landlord. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top">In the event of a default or threatened default by Tenant of any of the terms or conditions of this Lease, Landlord shall have the right of injunction and the right to invoke any remedy allowed by law or in equity as if
no specific remedies of Landlord were set forth in this Lease. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top">If default be made and a compromise and settlement shall be had thereupon, it shall not constitute a waiver of any covenant herein contained, nor of the Lease itself. </TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>27.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>RIGHTS OF LANDLORD </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Landlord reserves the following rights with respect to the Premises:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">During normal business hours, upon 24 hours notice, to go upon and inspect the Premises, and at Landlord&#146;s option, to make repairs, alterations and additions to the Premises or the Building of which the Premises
are a part, provided there is no interference with Tenant&#146;s occupancy. An Agent of the Tenant may be present for inspection, if requested by Tenant. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">To display, within sixty (60)&nbsp;days prior to the expiration of this Lease or after notice from either party of intention to terminate this Lease, a &#147;For Rent&#148; sign, and all of said signs which shall be
placed upon such part of the Premises as Landlord shall determine, except on doors leading into the Premises. Prospective purchasers or tenants authorized by Landlord may inspect the Premises during normal business hours following adequate notice to
Tenant. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top">To install, place upon, or fix to the roof and exterior walls of the Premises, equipment, signs, displays, antennae, and any other object or structure of any kind, providing the same shall not materially impair the
structural integrity of the Building or interfere with Tenant&#146;s occupancy. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 8 of 12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>28.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>HOLDING OVER </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If Tenant holds possession of the Leased Premises after the Expiration
Date or other termination of this Lease, Landlord shall, at its sole option, have the right to treat Tenant as a tenant by the month commencing with the first day after the termination of the Lease at one hundred fifty percent (150%)&nbsp;the
monthly Minimum Rent paid during the last month of the Term, and upon all the other terms of this Lease, including the provisions of this paragraph. Said holdover term shall terminate upon thirty (30)&nbsp;days notice from one party to the other.
Notwithstanding the foregoing, nothing contained herein shall be construed as a requirement that Landlord consent to the occupancy or possession of the Leased Premises by Tenant after the termination of the Lease, and Landlord, upon said termination
of this Lease, if Landlord elects to treat Tenant as a trespasser, shall be entitled to the benefit of all public general or public laws relating to the speedy recovery of the possession of land and tenements held over by Tenant, whether now or
hereafter in force and effect. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>29.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>WAIVER OF CLAIMS </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Except as may result from their negligence, Landlord and
Landlord&#146;s agents, employees, and contractors shall not be liable for, and Tenant hereby releases all claims for, damages to persons or property sustained by Tenant (or any person claiming through Tenant) resulting from any fire, accident,
occurrence or condition in or upon the Premises or Building, including but not limited to such claims for damage resulting from (1)&nbsp;any defect in or failure of plumbing, heating or air-conditioning equipment, electric wiring or installation
thereof, water pipes, stairs, railings or walks; (2)&nbsp;any equipment or apparatus becoming out of repair; (3)&nbsp;the bursting, leaking or running of any tank, washstand, water closet, waste pipe, drain or any other pipe or tank, upon or about
such building or premises; (4)&nbsp;the backing up of any sewer pipe or downspout; (5)&nbsp;the escape of steam or hot water; (6)&nbsp;water, snow or ice being upon or coming through the roof or any other place upon or near the Building or Premises
or otherwise; (7)&nbsp;the falling of any fixtures, plaster or stucco; (8)&nbsp;broken glass; and (9)&nbsp;any act or omission of occupants of adjoining or contiguous property or buildings. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>30.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>NOTICE </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">All notices required under this Lease shall be given in writing and shall be
deemed to be properly serviced if sent by certified or registered United States Mail, postage prepaid, as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If to the Landlord:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">W. M. Rickman Construction Co. LLC</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">15215 Shady Grove Road</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">Suite 201</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">Rockville, Maryland 20850</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If to the Tenant:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">MacroGenics, Inc.</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">9640 Medical Center Drive</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">Rockville, MD 20850</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">or to such other address as either may have designated from time to time by written notice to the other. The
date of service of such notices shall be the date such notices are deposited in any United States Post Office. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>31.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>COVENANTS OF TENANT </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Tenant covenants and agrees: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">To give to Landlord prompt written notice of any accident, fire, or damage occurring on or to the Premises. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">To keep the thermostats in the Premises set at a temperature sufficient to prevent freezing of water pipes, fixtures and HVAC units. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top">To keep the Premises clean, orderly, sanitary, and free from all objectionable odors and from insects, vermin and other pests. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top">To comply with the requirements of the State, Federal and County statutes, ordinances, and regulations applicable to Tenant and its use of the Premises, and to save Landlord harmless from penalties, fines, costs, and
expenses resulting from failure to do so, provided Tenant shall not be obligated to make structural repairs or alterations to so comply. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top">Tenant shall promptly pay all contractors, suppliers of material and persons it engages to perform work and provide materials for construction work on the Premises so as to minimize the possibility of a lien attaching
to the Premises. Should any such lien be made or filed, Tenant shall cause the same to be discharged and released of record by bond or otherwise within ten (10)&nbsp;days of receipt of written request from Landlord. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top">Tenant is responsible for the security of the Premises. </TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>32.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>LANDLORD&#146;S RIGHT TO ALTER SITE PLAN </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">LANDLORD shall, from time to time, have the
right to alter or modify the site plan of the Building and to rearrange the driveways and parking areas, as well as the entrance and exits to the Premises so long as the availability of parking spaces to Tenant under Article 33 is maintained. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 9 of 12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>33.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>PARKING SPACES </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">LANDLORD agrees to furnish 3 1/3 unreserved parking spaces per thousand
square feet of space occupied by the Tenant. There shall be no charge to Tenant for parking space use during the Term and any renewals of the Term. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>34.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>ENTIRE AGREEMENT </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">This Lease contains the entire agreement of the parties. There are no
oral agreements existing between them. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>35.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>SUCCESSORS AND ASSIGNS </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">This Lease, and the covenants and conditions herein contained
shall inure to the benefit of and be binding upon the Landlord, its successors and assigns, and shall inure to the benefit of and be binding upon the Tenant, its successors and assigns, if permitted. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>36.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>BANKRUPTCY </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If Tenant shall make an assignment of its assets for the benefit of
creditors, or if Tenant shall file a voluntary petition in bankruptcy, or if any involuntary petition in bankruptcy or for receivership be instituted against the Tenant and the same be not dismissed within thirty (60)&nbsp;days of the filing
thereof, or if Tenant shall be adjudged bankrupt, then and in any of said events, this Lease shall immediately cease and terminate at the option of the Landlord with the same force and effect as though the date of said event was the date herein
fixed for expiration of the term of this Lease. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>37.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>NON-DELIVERY </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In the event the Landlord shall be unable to give possession of the
Premises because construction of the Building is not complete or for any other cause reasonably beyond the control of the Landlord, the Landlord shall not be liable to Tenant for any damage resulting from failure to give possession. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>38.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>PARTIAL INVALIDITY </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If any term, covenant, or condition of this Lease or the application
thereof to any person or circumstance shall be held to be invalid and unenforceable, the remainder of this Lease, and the application of such terms, covenants, or conditions shall be valid and enforceable to the fullest extent permitted by law. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>39.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>FORCE MAJEURE </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">With the exception of those provisions contained herein regarding the
payment of rent, the inability of either party to perform any of the terms, covenants or conditions of this Lease shall not be deemed a default if the same shall be due to any cause beyond the control of that party. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>40.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>EARLY ACESS </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Landlord will permit Tenant to have early access to premises following
lease execution in order to perform work to ready space for occupancy as long as such work is coordinated with Landlord so as not to interfere with Landlord&#146;s work to make space ready for Tenant&#146;s occupation. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>41.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>ESTOPPEL CERTIFICATE </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Tenant shall from time to time, within ten (10)&nbsp;days
after being requested to do so by the Landlord or any Mortgagee, execute, acknowledge and deliver to the Landlord (or, at the Landlord&#146;s request, to any existing or prospective purchaser, transferee, assignee or Mortgagee of any or all of the
Premises) an instrument in recordable form, certifying (a)&nbsp;that this Lease is unmodified and in full force and effect (or, if there has been any modification thereof, that it is in full force and effect as so modified, stating therein the
nature of such modification); (b)&nbsp;as to the dates to which the Minimum Rent and other charges arising hereunder have been paid; (c)&nbsp;as to the amount of any prepaid Rent or any credit due to the Tenant hereunder; (d)&nbsp;that the Tenant
has accepted possession of the Premises, and the date on which the Term commenced; (e)&nbsp;as to whether, to the best knowledge, information and belief of the signer of such certificate, the Landlord or the Tenant is then in default in performing
any of its obligations hereunder (and, if so, specifying the nature of each such default); and (f)&nbsp;as to any other fact or condition reasonably requested by the Landlord or such other addressee. In the event the Tenant fails or refuses to
provide such a certificate, Tenant shall be liable to Landlord for any loss or damage (including reasonable counsel fees) arising out of or in connection with such failure or refusal. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>42.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>SERVICES TO BE PROVIDED BY LANDLORD. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">During Tenant&#146;s occupancy of the Premises,
Landlord shall furnish the following services, subject to any limitations contained elsewhere in this lease: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top">Air conditioning, both heating and cooling (as required by the seasons) at such temperatures and in such amounts as are comparable to those provided in other similar buildings in Rockville, Maryland, subject, however,
to Tenant&#146;s obligation to pay for or toward certain repairs to the Building&#146;s HVAC system as provided in Section&nbsp;12 above. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 10 of 12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top">Hot and cold water at those points of supply provided for general use of other tenants in the Building through fixtures installed by Landlord, provided, however, that Tenant shall be obligated to maintain and repair at
Tenant&#146;s sole cost the water boiler involved. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top">Routine maintenance and electric lighting service for all common areas and service areas of the Building in the manner and to the extent which is comparable to that provided in other similar buildings in Rockville,
Maryland. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">d.</TD>
<TD ALIGN="left" VALIGN="top">Electrical facilities to furnish to the Premises electricity at the same capacity as that furnished as of April&nbsp;1, 2014. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">e.</TD>
<TD ALIGN="left" VALIGN="top">Replacement of all Building standard fluorescent bulbs in all common areas of the Building and all incandescent bulb replacement in all common areas, stairwells, and other common service areas. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Passenger elevator(s) for ingress to and egress from the Premises. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>43.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>LENDER APPROVAL. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Landlord&#146;s execution and delivery of this Lease shall be
conclusive evidence of approval by any financial institution possessing the right to approve leases for space in the Building </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>44.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>DECONTAMINATION OF PREMISES. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Landlord, at its sole cost, shall obtain and provide to
Tenant a report evidencing the decontamination of the Premises prior to the Early Delivery Date. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>46.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>BROKER PARTICIPATION. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Landlord and Tenant agree, understand and recognize that there
are no brokers other than CBRE, Inc. and J Street Companies (&#147;Brokers&#148;) participating in this transaction and that Landlord will compensate Brokers under terms of a separate agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties have caused this Lease Agreement to be executed on the year and date first written. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">WITNESS:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" COLSPAN="3">LANDLORD:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" COLSPAN="3"><B>W. M. RICKMAN CONSTRUCTION CO. LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ William M. Rickman</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">William M. Rickman</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">WITNESS:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" COLSPAN="3">Tenant:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" COLSPAN="3"><B>MACROGENICS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Scott Koenig, M.D., PhD</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">Scott Koenig, M.D., PhD</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 11 of 12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Exhibit A </U></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Current Layout/Plan </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">15235 Shady Grove Road </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3<SUP STYLE="font-size:85%; vertical-align:top">rd</SUP> Floor </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Rockville, Maryland </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g838054g05q41.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 12 of 12 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.16
<SEQUENCE>6
<FILENAME>d838054dex1016.htm
<DESCRIPTION>EX-10.16
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.16</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Exhibit 10.16 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LEASE AGREEMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">THIS LEASE AGREEMENT,
made this 6th day of November 2014, by and between <B>RED GATE III LLC</B> (&#147;LANDLORD&#148;) and <B>MACROGENICS, INC.</B> (&#147;TENANT&#148;). </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>W I T N E S S E T H: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>DEMISE OF PREMISES </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">Landlord hereby demises unto Tenant, and Tenant hereby leases from
Landlord for the terms and upon the conditions set forth in this Lease approximately 9,416 square feet of space in the building located at 9620 Medical Center Drive, Rockville, MD (the &#147;Building&#148;), as set forth on Exhibit B, hereto
attached, said space being referred to as the &#147;Premises&#148;. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">Landlord&#146;s architect shall provide an accurate measurement of the
Premises based upon a reasonable Building Owners and Managers Association (&#147;BOMA&#148;) calculation. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">Landlord shall maintain the
Building and Common Areas, as required, in accordance with all applicable laws, including, but not limited to the Americans with Disabilities Act of 1990, as amended (the &#147;ADA&#148;). Landlord shall deliver the Premises in compliance with all
applicable laws, including the ADA, and that the HVAC, plumbing and wiring serving the Premises are operational and in good working order. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>TERM </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">The term of this Lease shall be for a period of five (5)&nbsp;years, commencing on
the 1<SUP STYLE="font-size:85%; vertical-align:top">st</SUP> day of February, 2015 (&#147;Commencement Date&#148;), and terminating on the 31<SUP STYLE="font-size:85%; vertical-align:top">st</SUP> day of January 2020 (&#147;Expiration Date&#148;),
with an option for an additional five (5)&nbsp;years on the same terms and conditions in this Lease, provided that Tenant shall have given the Landlord written notice of Tenant&#146;s intention to do so at least six (6)&nbsp;months prior to the
expiration of this Lease and that Tenant is not in default under this Lease beyond any applicable notice and cure period. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">In the event the
Landlord is not able to deliver possession of the Premises to Tenant upon the Commencement Date because Landlord has not fully completed the Landlord&#146;s Work (as hereinafter defined), or an earlier tenant has failed to vacate the Premises, the
Commencement Date shall be extended to the date said Work is completed and/or the earlier tenant has vacated and the Expiration Date shall be similarly extended. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">The date of delivery of the Premises by Landlord to Tenant shall be that date on which all required improvements to be furnished by Landlord as
stated in Exhibit &#147;A&#148; have been substantially completed except for punch list items and the occupancy certificate has been issued, unless Tenant&#146;s act or omissions have caused such approval to be denied, in which case Tenant shall be
deemed to have waived this condition. Rent shall be pro-rated for any portion of the initial month in which Tenant is required to commence rental payments hereunder, which does not commence with the first day thereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">At any time prior to delivery of possession of the Premises, Tenant shall have the right to enter upon the Premises for the purpose of taking
measurements, and/or installing its equipment/casework/security and information technology. infrastructure provided such entry does not unreasonably interfere with or obstruct the progress of work being done by the Landlord. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>RENT </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">The Tenant shall pay to the Landlord an annual rental (herein called &#147;Minimum
Rent&#148;) in the amount of One Hundred Ninety Three Thousand Twenty Eight and NO/100 DOLLARS ($193,028.00), subject to adjustment as hereinafter set forth, payable without deduction or set off in equal monthly installments of Sixteen Thousand
Eighty Five and 67/100 DOLLARS ($16,085.67) in advance, the first installment of which is due and payable upon signing of the Lease and after the Commencement Date all subsequent monthly installments shall be due and payable on the
</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">
first day of each calendar month thereafter during the term of the Lease until the total rent provided for herein is paid. No payment by Tenant or receipt of Landlord of a lesser amount than a
monthly installment of rent herein stipulated, or endorsement or statement on any check or any letter accompanying any check for payment as rent be deemed an accord and satisfaction, and Landlord may accept such check for payment without prejudice
to Landlord&#146;s right to recover the balance of such rent or pursue any other remedy provided for in this Lease. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>ABATEMENT </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">Tenant shall receive a Minimum Rent abatement totaling Sixty Four Thousand
Three Hundred Forty Two and 68/100 Dollars ($64,342.68). Such abatement shall be applied to the Minimum Rent payable by Tenant for the first four (4)&nbsp;months of the initial term. Tenant shall still be responsible for any additional expenses as
set forth in Lease. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>ADJUSTMENT OF MINIMUM RENT </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">The Minimum Rent shall be increased at the end of each lease
year during the term hereby by three percent (3%)&nbsp;of the rent then being paid. There shall be no pass-throughs of increases in operating expenses except for increases in real estate taxes or as otherwise provided for herein (&#147;Operating
Expenses&#148;). </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>REAL ESTATE TAXES </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">In the event the real estate taxes levied or assessed against the
land plot and Building on which the Premises are a part in future tax years are greater than the real estate taxes for the Base Year, the Tenant shall pay within fifteen (15)&nbsp;days after submission of the bill to Tenant for the increase in real
estate taxes, as additional rent, a proportionate share of such increase, which proportionate share shall be computed at 14.66% of the increase in taxes, but shall exclude any fine, penalty, or interest charge for late or non-payment of taxes by
Landlord. The Base Year shall be July&nbsp;1, 2014, to June&nbsp;30, 2015. In the event that the BOMA assessment calculation undertaken by Landlord in Section&nbsp;1 changes the proportion of the square feet of space of the Premises compared to the
total square feet of space to the Building, then Tenant&#146;s share of increases of real estate taxes set forth in the preceding paragraph of this Section&nbsp;6, shall be adjusted to such new proportions. Upon Tenant&#146;s request, Landlord shall
provide Tenant with a copy of each tax bill received by Landlord relating to the land and Building on which the Premises are a part. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">Any
reasonable expense incurred by Landlord (including counsel fees) in contesting any tax increase shall be pro-rated according to Tenant&#146;s pro-rated share of the taxes and included as an item of taxes for the purpose of computing additional rent
due Landlord. Landlord, however, shall be under no obligation to contest any tax increase. If Tenant requests in writing, that the Landlord appeal an increased assessment or tax; Tenant may contest such tax assessments. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>UTILITIES </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">Tenant shall be responsible for the payment of all utilities used or consumed
by the Tenant in and upon the Premises. Utilities shall be separately metered with the cost of such separate metering to be borne by Landlord, or an equitable allocation made between the Tenants in the Building. In the event any utility service to
the Premises shall be interrupted for a continuous period of more than two (2)&nbsp;days due to the gross negligence, willful misconduct, illegal conduct or breach of this Agreement by Landlord, its agents or servants, the Minimum Rent shall abate
until such services are rendered. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">Landlord shall not be liable to Tenant for any damage or inconvenience caused by the cessation or
interruption of any utility service, or the elevators in the Building, occasioned by a cause beyond Landlord&#146;s control. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>USE OF PREMISES </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">Tenant shall use the Premises only for Office and Laboratory purposes
consistent with Tenant&#146;s business, and for no other purpose, except as approved by Landlord in advance, in writing, which approval shall not be unreasonably withheld. Tenant shall not make any use of the Premises which would disturb the quiet
enjoyment of the Landlord or other tenants in the Building or prejudice or increase the fire insurance premium for the Building, and shall comply with all laws and regulations of all governmental authorities pertaining to Tenant&#146;s use of
Premises, including zoning regulations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 2 of 15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>9.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>WASTE REMOVAL </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">Tenant shall be responsible for removal of waste generated by
Tenant&#146;s operation. This includes waste service fees levied by local jurisdictions. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>10.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>HAZARDOUS MATERIALS </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">Tenant shall be permitted to store Hazardous Materials on the
Premises and shall comply with all laws and regulations of all governmental authorities pertaining to Tenant&#146;s use of the Premises, including, without limitation, all Environmental Laws (as hereinafter defined) and laws pertaining to Hazardous
Materials and Air and Water Quality. The term &#147;Hazardous Materials&#148; means and includes any petroleum products and/or any hazardous toxic or other dangerous waste, substance or material defined as such in the Environmental Laws. The term
&#147;Environmental Laws&#148; means the Comprehensive Environmental Response, Compensation and Liability Act, any &#147;Superfund&#148; or &#147;Superlien&#148; law, or any other federal, state or local statute, law, ordinance, code, regulation,
order or decree regulating, relating to, or imposing liability or standards of conduct concerning the use or storage of Hazardous Materials. All such materials must be completely removed upon expiration of this Lease, and any de-contamination
certificates required by the Landlord or any government authority must be obtained by Tenant and delivered to the Landlord. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">Tenant shall
obtain and maintain, in full force and effect, all necessary government licenses, permits and approvals legally required for materials used in the conduct of its business. If the presence of any Hazardous Materials on the Premises caused or
permitted by Tenant results in any contamination of the Premises or any portion of the Building or Common Areas, Tenant shall promptly take all actions, at its sole expense, necessary to return the Premises to the condition existing prior to the
introduction of such Hazardous Materials, provided that all such actions shall be subject to the approval of Landlord, which approval shall not be unreasonably withheld. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">At the Commencement Date of the Lease and on January&nbsp;1 of each year thereafter, Tenant shall disclose to Landlord the names and amounts of
all Hazardous Materials which are to be stored, used or disposed of on the Premises. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">Any Hazardous Materials stored or used on the
Premises must not in any way prejudice the Landlord&#146;s insurance or increase the fire hazards to a greater extent than necessarily incident to the business for which the Premises are leased. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">Tenant shall indemnify and hold harmless Landlord, its officers, members and employees against any and all claims, actions, proceedings or
liabilities of any kind to any third party or governmental authority arising out of or in connection with the presence of any Hazardous Materials on the Premises or used in connection with Tenant&#146;s business, or the violation by Tenant of any
applicable Environmental Laws. In the event Tenant uses and/or stores Hazardous Materials on the Premises, Tenant shall maintain and carry during such use or storage of this Lease a Pollution and Nuclear Waste insurance policy which shall designate
Landlord as a named insured which provides coverage for i) extraction of pollutants from land or water resulting from the discharge, dispersal, seepage, migration, release or escape of pollutants from a specified cause; and ii) radioactive
contamination. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>11.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>LATE CHARGE </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">If any installment of Minimum Rent accruing herein shall not be paid within
five (5)&nbsp;days of due date, and other sums not paid within fifteen (15)&nbsp;days of due date, more than once in any 12-month period, such installment and other sums shall be increased without affecting the Landlord&#146;s other rights under
this Lease, by a late charge of five percent (5%)&nbsp;of the delinquent installment, anything contained herein to the contrary notwithstanding. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>12.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>REPAIRS AND MAINTENANCE </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">Landlord shall be responsible for all structural repairs,
including repairs to the roof and load-bearing walls of the Building, for maintaining the parking area and sidewalks, the Common Areas (as hereinafter defined) and any Building systems and equipment in unleased areas in the Building. Landlord will
repair and replace any glass breakage, provided it is not the result of the Tenant&#146;s willful or negligent act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 3 of 15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">The Tenant shall be responsible for the maintenance and repair of the Premises and all fixtures,
appliances, light bulbs and equipment therein, including, but not limited to, the heating and air conditioning system(s) (hereinafter &#147;HVAC&#148;) serving the Premises except as set forth herein. Landlord will pay for major HVAC component
replacement and all repairs to the Landlord installed HVAC system(s) in excess of Four Hundred Dollars ($400.00) per occurrence per HVAC unit. All major replacements or repairs will be performed by Landlord unless written permission is otherwise
given. Landlord hereby represents that the HVAC is in good and proper working order upon the Commencement Date hereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">Tenant covenants
and agrees to obtain a maintenance, repair and service contract on the HVAC; said contract to be on such terms and with such company as shall be approved by Landlord. Tenant will notify Landlord if costs for repairs will exceed $400.00 prior to
making repairs. Landlord, in Landlord&#146;s commercially reasonable judgment, will make such repairs at Landlord&#146;s sole expense, provided it is not the result of the Tenant&#146;s willful or negligent act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">Tenant shall be responsible for removal of waste generated by Tenant&#146;s operation and provide its own janitorial and cleaning service
within the Premises. This includes waste service fees levied by local jurisdictions. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">Tenant, at its sole expense, shall keep all Tenant
fixtures and equipment in the Premises in safe and sanitary condition and good order and repair, together with related plumbing, electrical or other utility service, whether installed by Tenant or by Landlord on Tenant&#146;s behalf. Subject to
Section&nbsp;29, Tenant shall pay for all damage to the Building and any fixtures and appurtenances related thereto due to the malfunction, lack of repair, or improper installation of the Tenant&#146;s fixtures and equipment. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>13.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>COMMON AREAS </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">In addition to the use of the Premises, Tenant, its employees and business
invitees shall have the right to use the Common Areas in common with Landlord and other tenants of the Building, their employees and visitors. The term &#147;Common Areas&#148; shall mean those portions of the Building and the land upon which the
Building is erected which Landlord may from time to time designate for Tenant&#146;s non-exclusive use, which may include the entrance, foyer and lobby corridors, lavatories, stairwells, elevators, and parking areas. All Common Areas shall be
subject to the exclusive control of the Landlord. The Landlord shall operate, manage, light and maintain the Common Areas. Landlord with prior written notice reserves the right to change the size, area, level, location and arrangement of the Common
Areas and any such change or rearrangement shall not affect the obligations of the Landlord and Tenant hereunder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">Landlord will provide
maintenance and cleaning of these Common Areas consistent with similar office/lab building located in the Rockville/Shady Grove submarkets. In all Common Areas, Landlord will replace all standard fluorescent bulbs and all incandescent bulbs.
Landlord will provide and maintain passenger elevator(s) for ingress to and egress from the Premises. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>14.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>LANDLORD&#146;S WORK PRIOR TO COMMENCEMENT OF TERM </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">Landlord shall make the following
improvements to the Premises prior to the commencement of the term of the Lease: Construction in accordance with Exhibits A and B (hereinafter &#147;Landlord&#146;s Work&#148;). </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>15.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>TENANT ALTERATIONS </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">All alterations, improvements, or additions to the demised Premises
to be made by Tenant (other than cosmetic changes not costing more than $50,000 in any 12 mo. period) shall be subject to the written consent of the Landlord, which consent shall not be unreasonably withheld, provided such alterations and
improvements do not weaken the structural integrity of the Building or detract from its dignity and/or uniformity. All alterations and improvements and/or additions made by Tenant shall remain upon the Premises at the expiration or earlier
termination of this Lease and shall become the property of the Landlord, unless Landlord shall, at the time of approval of the alteration, provide written notice to Tenant to remove the same, in which event Tenant shall remove such alterations,
improvements and/or additions, and restore the Premises to a good order and condition, reasonable wear and tear and unavoidable casualty excepted. Should Tenant fail to do so, Landlord may do so, collecting the reasonable cost and expense thereof
from Tenant as additional rent. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 4 of 15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>16.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>TRADE FIXTURES </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">All trade fixtures, telephone and computer equipment, and apparatus
installed by Tenant in the Premises shall remain the property of Tenant and shall be removed at the expiration or earlier termination of this Lease and, upon such removal, Tenant shall repair any damage caused by the removal and shall promptly
restore the Premises to their good order and condition. Any such trade fixture not removed prior to such termination shall be considered abandoned property, but such abandonment shall not release Tenant of its obligation to pay for the cost of
removing such trade fixtures and repairing any damage caused by the removal. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>17.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>QUIET ENJOYMENT </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">Landlord covenants that, upon payment of the rent herein provided and
performance by the Tenant of all other covenants herein contained, Tenant shall and may peaceably and quietly have, hold and enjoy the Premises for the term hereof and options. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>18.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>SURRENDER OF PREMISES </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">Upon the expiration or termination of this Lease, Tenant shall
quit and surrender the Premises to the Landlord broom clean and shall remove all of its property therefrom. If the removal of any such property shall result in damaging the Premises, or leaving any holes in the floors, walls or ceiling therein, the
Tenant shall make the appropriate repairs with Landlord approved building materials prior to the expiration of this Lease. The obligation of this paragraph shall survive the termination of the Lease. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>19.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>INSURANCE </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">Tenant covenants and agrees to maintain and carry, at all times during the
term of this Lease, in companies qualified and authorized to transact business in the State of Maryland, general liability insurance in amounts of $1,000,000.00 per occurrence which shall include damage to property on the Premises or arising out of
the use thereof by Tenant or its agents. All such policies of insurance shall not be canceled, except on thirty (30)&nbsp;days written notice to the Landlord for all reasons except non-payment, which will be a seven (7)&nbsp;notice period, and all
such policies shall name Landlord as an additional insured. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">Landlord shall procure and maintain throughout the Term of this Lease a policy
or policies of insurance, at its sole cost and expense (but subject to Section&nbsp;6), causing the Building and any other related improvements to be insured under a Causes of Loss - Special Form property insurance policy in an amount equal to the
full replacement value of the Building and any such other improvements (excluding the cost of excavation) and a policy of commercial general liability insurance with a combined single limit of not less than One Million Dollars ($1,000,000,00). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">Landlord shall require the other tenants in the Building to obtain and maintain the same amount and type of insurance as required of Tenant in
this Lease during the terms of such other tenants&#146; leases. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">Prior to the Commencement Date or during the term of this Lease, upon
Landlord&#146;s request, Tenant shall furnish Landlord with satisfactory proof that the insurance herein provided for is at all times in full force and effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">Each party shall employ reasonable efforts to require that their respective insurance policies referenced above will contain the following:
(a)&nbsp;mutual waivers of subrogation rights; and (b)&nbsp;a provision naming the other party as an &#147;additional insured&#148;. Each party shall promptly notify the other in writing if such provisions cannot be incorporated into their
respective policies in which event the parties and their insurers shall thereafter endeavor in good faith to incorporate such alternative policy provisions as may be commercially reasonable in the opinion of Landlord&#146;s insurer. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 5 of 15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>20.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>INDEMNIFICATION </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">Tenant shall indemnify and hold harmless the Landlord from, and name
Landlord as an additional insured on Tenant&#146;s policy regarding, any and all liability, damage, expense, cause of action, or claims arising out of injury to any persons or to property on the Premises, Building and Common Areas, except for the
negligence, willful misconduct, illegal conduct or breach of this Lease by Landlord, its agents, employees, or servants. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">Landlord shall
indemnify and hold harmless the Tenant from, and name Tenant as an additional insured on the Landlord&#146;s policy regarding, any and all liability, damage, expense, cause of action or claims arising out of injury to any persons or to property on
the Premises, Building and Common Areas, except for the negligence, willful misconduct, illegal conduct or breach of this Lease by Tenant, its agents, employees, or servants. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>21.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>DAMAGE BY FIRE OR CASUALTY </B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">If the Premises are damaged by fire or other casualty, but are not thereby rendered untenantable in whole or in part, Landlord, at its own expense, and subject to the limitations set forth in this Lease, shall cause
such damage to be repaired and the Minimum Rent and Additional Rent shall not be abated. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">If, by reason of any damage or
destruction, the Premises shall be rendered untenantable in whole or in part and cannot be repaired and made tenantable within ninety (90)&nbsp;days after such damage: (i)&nbsp;Landlord, at its option and its own expense, may cause the damage to be
repaired and the Minimum Rent and Additional Rent shall be abated proportionately as to the portion of the Premises rendered untenantable while it is untenantable; or (ii)&nbsp;Landlord or Tenant shall have the right, to be exercised by notice in
writing delivered to the other within thirty (30)&nbsp;days of the occurrence of such damage or destruction, to terminate this Lease, whereupon the Minimum Rent and Additional Rent shall be adjusted as of the date of such termination. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">In the event substantially all of the Premises are rendered untenantable for the business of the Tenant as a result of a casualty or other
event not due to Tenant&#146;s acts or omissions and the Premises cannot be substantially restored for the business use of the Tenant within ninety (90)&nbsp;days of such event, Tenant shall have the right to terminate this Lease upon delivery of
written notice to Landlord no later than thirty (30)&nbsp;days following such event. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">In the event that twenty-five percent (25%)&nbsp;or more of the rentable floor area of the Building shall be damaged or destroyed by fire or other cause, notwithstanding that the Premises may be unaffected by such fire
or other damage, Landlord and Tenant shall have the right, to be exercised by notice in writing delivered to other party within thirty (30)&nbsp;days after such occurrence, to terminate this Lease. Upon the giving of such notice, the Minimum Rent
and Additional Rent shall be adjusted as of the date of termination and this Lease shall thereupon terminate. </TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>22.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>ASSIGNMENT OR SUBLETTING </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">Tenant acknowledges that Landlord has entered into this Lease
because of Tenant&#146;s financial strength, goodwill, ability and expertise and that accordingly, this Lease is personal to Tenant. Taking this into consideration, Tenant shall not assign, mortgage, sublet, pledge or encumber this Lease, in whole
or in part, except with the written consent of the Landlord, which shall not be unreasonably withheld, except that Tenant may assign this Lease or its interest therein or sublease the Premises to Tenant&#146;s parent corporation, Tenant&#146;s
direct subsidiaries or entities under common control with Tenant or to Tenant&#146;s successor by way of merger, consolidation, sale of assets, joint venture controlled by Tenant, or partnership of which Tenant is the sole general partner without
the consent of Landlord. Tenant agrees that, in the event of any such assignment or subletting, Tenant and its assignee or sublessee shall nevertheless remain jointly and severally liable for the performance of all terms, covenants, and conditions
of this Lease. Landlord&#146;s failure to deny Tenant&#146;s written request for consent within ten (10)&nbsp;days after receipt shall be deemed consent to such request. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">In the event the Landlord consents to an assignment of the Lease, any money, additional rent or other consideration to be paid to Tenant for
the assignment shall be paid to the Landlord as partial consideration for the Landlord&#146;s consent to the assignment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 6 of 15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">In the event the Landlord consents to a sublease of the Premises, or any portion thereof, Tenant
shall pay to the Landlord fifty percent (50%)&nbsp;any money, rent or other consideration paid to the Tenant by any subtenant in excess of the pro-rata portion of the rent for such space then being paid by Tenant to Landlord under this Lease, less
Tenant&#146;s actual costs of such subletting. All sums payable hereunder by Tenant shall be paid to Landlord as additional rent immediately upon the receipt thereof by Tenant. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>23.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>SUBORDINATION AND ATTORNMENT </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">This Lease shall be subject to and subordinate at all
times to the lien of any mortgage and/or deeds of trust and all land leases now or hereafter made on any portion of the Premises, and to all advances thereunder, provided the mortgagee or trustee named in said mortgage or deed of trust shall agree
to recognize this Lease and agrees, in the event of foreclosure, not to disturb the Tenant&#146;s possession hereunder, provided Tenant is not in default under this Lease. This subordination shall be self-operative and no further instrument of
subordination shall be required. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">If any proceedings are commenced to foreclose any mortgage or deed of trust encumbering the Premises,
Tenant agrees to attorn to the purchaser at the foreclosure sale, if requested to do so by any such purchaser, and to recognize such purchaser as the Landlord under this Lease, provided such purchaser shall agree that Tenant&#146;s rights hereunder
shall not be disturbed so long as Tenant has not committed any event of default as to which the applicable cure period has expired. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>24.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>CONDEMNATION </B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">If the whole of the Premises shall be taken by any public or quasi-public authority under the power of eminent domain, condemnation or conveyance in lieu thereof, then this Lease shall terminate as of the date on which
possession of the Premises is required to be surrendered to the condemning authority and the Tenant shall have no claim against Landlord or the condemning authority for the value of the unexpired term of this Lease. Tenant shall have the right to
claim, however, the unamortized cost of any improvements or additions made to the Premises by Tenant at its cost, the value of any Tenant fixtures and furnishings and any moving expenses (collectively, &#147;Tenant&#146;s Claim&#148;).
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">If a portion of the Premises, Building or Common Areas shall be so taken or conveyed, and if such partial taking or conveyance shall render the Premises unsuitable for the business of the Tenant, then the term of this
Lease shall cease and terminate as of the date on which possession of the portion of the Premises is surrendered to the condemning authority, and Tenant shall have no claim against Landlord or the condemning authority for the value of any unexpired
term of this Lease, but will have the right to make Tenant&#146;s Claim against such public or quasi public authority. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">In
the event that in Tenant&#146;s reasonable judgment such partial taking or conveyance is not extensive enough to render the Premises untenantable for the business of Tenant, this Lease shall continue in full force and effect, except that the Minimum
Rent shall be reduced in the same proportion that the floor area of the Premises so taken or conveyed bears to such floor area immediately prior to such taking or conveyance. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">In the event of such partial taking and continuation of Lease, Landlord shall promptly restore the Premises as nearly as practical to the
condition comparable to that which existed prior to the condemnation. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>25.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>EVENTS OF DEFAULT </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">The occurrence of any of the following shall constitute an event of
default hereunder: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE="font-family:Times New Roman; font-size:10pt">Failure of Tenant to pay installment of Minimum Rent or scheduled payments of Operating Expenses or additional sums due under this Lease within five
(5)&nbsp;days of the due date, or failure of Tenant to pay within fifteen (15)&nbsp;days following written notice any other sum herein required to be paid by Tenant. Notwithstanding the foregoing, Landlord shall be required to deliver to Tenant
written notice of the failure to pay </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 7 of 15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Minimum Rent and/or such payments of Operating Expenses two (2)&nbsp;times in every twelve (12)-month period, in which event Tenant shall be deemed to be in default only if such failure continues
for five (5)&nbsp;business days after receipt of such written notice from Landlord. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">Tenant&#146;s failure to perform any other covenant or condition of this Lease within thirty (30)&nbsp;days following Tenant&#146;s receipt of written notice from Landlord, unless the failure is of such a character as
to require more than thirty (30)&nbsp;days to cure in which event Tenant&#146;s failure to proceed diligently to cure such failure shall constitute an event of default. </TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>26.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>LANDLORD&#146;S REMEDIES </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">Upon the occurrence of any event of default, Landlord may, at
Landlord&#146;s sole option, exercise any or all of the following remedies, together with any such other remedies as may be available to Landlord at law or in equity. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">Landlord may terminate this Lease by giving Tenant written notice of its election to do so, as of a specified date not less than thirty (30)&nbsp;days after the date of the giving of such notice and this Lease shall
then expire on the date so specified, and Landlord shall then be entitled to immediately regain possession of the Premises as if the date had been originally fixed as the expiration date of the term of this Lease. Landlord may then re-enter upon the
Premises, either with or without due process of law (after providing twenty-four (24)&nbsp;hours prior notice), and remove all persons therefrom, the statutory notice to quit or any other notice to quit being hereby expressly waived by Tenant.
Tenant expressly agrees that the exercise by Landlord of the right of re-entry shall not be a bar to or prejudice in any way other legal remedies available to Landlord. In that event, Landlord shall, at its option, be entitled to recover from Tenant
as and for liquidated damages an amount equal to the rent and additional rent reserved in this Lease less any and all amounts received by Landlord from the rental of the Premises to another tenant. Nothing herein contained, however, shall limit or
prejudice the right of Landlord to prove for and obtain an award for damages, by reason of such termination, of an amount equal to the maximum allowed by any statute or rule of law in effect at the time when, and governing the proceedings in which
such damages are to be proved, whether or not such amount may be greater, equal to, or less than the amount of the difference referred to above, and the Landlord may, in his own name, but as agent for Tenant, re-let the Premises. Any recovery by the
Landlord shall be limited to the rent hereunder (plus any costs incurred in re-letting) less any rent actually paid by the new tenant. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">No termination of this Lease or any taking of possession of the Premises shall deprive Landlord of any of its remedies or actions against Tenant for past or future rent, nor shall the bringing of any action for rent or
breach of covenant, or the resort to any other remedy herein provided for the recovery of rent, be construed as a waiver of the right to obtain possession of the Premises. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top">In addition to any damages becoming due under this paragraph, Landlord shall be entitled to recover from Tenant and Tenant shall pay to Landlord an amount equal to all expenses, including reasonable attorneys&#146;
fees, if any, incurred by the Landlord in recovering possession of the Premises, and all reasonable costs and charges for the care of said Premises while vacant, which damages shall be due and payable by Tenant to Landlord at such time or times as
such expenses are incurred by the Landlord. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top">In the event of a default or threatened default by Tenant of any of the terms or conditions of this Lease, Landlord shall have the right of injunction and the right to invoke any remedy allowed by law or in equity as if
no specific remedies of Landlord were set forth in this Lease. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top">If a Tenant default be made and a compromise and settlement shall be had thereupon, it shall not constitute a waiver of any covenant herein contained, nor of the Lease itself. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 8 of 15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>26A.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>LANDLORD DEFAULT. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">If Landlord defaults in the performance or observance of any of its
obligations under this Lease (a &#147;Landlord Default&#148;), Tenant may deliver to Landlord written notice specifying the manner in which Landlord has defaulted (&#147;Default Notice&#148;), and if such Landlord Default has not been cured by
Landlord within thirty (30)&nbsp;days after the delivery of the Default Notice, or (a)&nbsp;such shorter period after delivery of the Default Notice as may be appropriate in the case of an emergency, or (b)&nbsp;such longer period as may be
reasonably necessary to cure such default if it cannot practicably be cured within thirty (30)&nbsp;days, provided Landlord proceeds with diligence to cure such default at the earliest practicable date, then Tenant shall have the right (but not the
obligation) to perform such obligation on Landlord&#146;s account. In the event Tenant cures any such Landlord Default, the reasonable costs and expenses incurred by Tenant therefor, shall be reimbursed by Landlord within thirty (30)&nbsp;days after
receipt of demand and detailed invoice therefor. In addition to the foregoing remedy of Tenant, in the event of a Landlord Default which remains uncured for the duration of the notice and cure period set forth above, and as a result of such Default
the Premises are inaccessible or untenantable for the business of the Tenant for a period of ninety (90)&nbsp;consecutive days, then, in such event, Tenant shall have the right to terminate this Lease by delivery of written notice to Landlord at any
time after such cure period while such Landlord Default remains uncured. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>27.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>RIGHTS OF LANDLORD </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">Landlord reserves the following rights with respect to the Premises:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">During normal business hours, upon 24 hours notice, to go upon and inspect the Premises, and at Landlord&#146;s option, to make repairs, alterations and additions to the Premises or the Building of which the Premises
are a part, provided there is no interference with Tenant&#146;s occupancy. An Agent of the Tenant may be present for inspection, if requested by Tenant. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">To display, within sixty (60)&nbsp;days prior to the expiration of this Lease or after notice from either party of intention to terminate this Lease, a &#147;For Rent&#148; sign, and all of said signs which shall be
placed upon such part of the Premises as Landlord shall determine, except on doors leading into the Premises. Prospective purchasers or tenants authorized by Landlord may inspect the Premises during normal business hours following adequate notice to
Tenant. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top">To install, place upon, or fix to the roof and exterior walls of the Premises, equipment, signs, displays, antennae, and any other object or structure of any kind, providing the same shall not materially impair the
structural integrity of the Building or interfere with Tenant&#146;s occupancy or conduct of Tenant&#146;s business. </TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>28.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>HOLDING OVER </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">If Tenant holds possession of the Leased Premises after the Expiration
Date or other termination of this Lease, Landlord shall, at its sole option, have the right to treat Tenant as a tenant by the month commencing with the first day after the termination of the Lease at one hundred fifty percent (150%)&nbsp;of the
monthly Minimum Rent paid during the last month of the Term, and upon all the other terms of this Lease, including the provisions of this paragraph. Said holdover term shall terminate upon thirty (30)&nbsp;days&#146; notice from one party to the
other. Notwithstanding the foregoing, nothing contained herein shall be construed as a requirement that Landlord consents to the occupancy or possession of the Leased Premises by Tenant after the termination of the Lease, and Landlord, upon said
termination of this Lease, if Landlord elects to treat Tenant as a trespasser, shall be entitled to the benefit of all public general or public laws relating to the speedy recovery of the possession of land and tenements held over by Tenant, whether
now or hereafter in force and effect. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>29.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>WAIVER OF CLAIMS </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">Except as may result from a party&#146;s gross negligence, willful
misconduct, or illegal conduct, or breach of this Agreement, such party, its agents, employees, and contractors shall not be liable for, and the other party hereby releases all claims for, damages to persons or property sustained by such other party
(or any person claiming through such other party) resulting from any fire, accident, occurrence or condition in or upon the Premises or Building, including but not limited to such claims for damage resulting from (1)&nbsp;any defect in or failure of
plumbing, heating or air-conditioning equipment, electric wiring or installation thereof, water pipes, stairs, railings or walks; (2)&nbsp;any equipment or apparatus becoming out of repair; (3)&nbsp;the bursting, leaking or running of any tank,
washstand, water closet, waste pipe, drain or any other pipe or tank, upon or about the Building or Premises; (4)&nbsp;the backing up of any sewer pipe or downspout; (5)&nbsp;the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 9 of 15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">
escape of steam or hot water; (6)&nbsp;water, snow or ice being upon or coming through the roof or any other place upon or near the Building or Premises or otherwise; (7)&nbsp;the falling of any
fixtures, plaster or stucco; (8)&nbsp;broken glass; and (9)&nbsp;any act or omission of occupants of adjoining or contiguous property or buildings. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>30.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>NOTICE </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">All notices required under this Lease shall be given in writing and shall be
deemed to be properly serviced if sent by certified or registered United States Mail, postage prepaid, as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If to the Landlord:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">RED&nbsp;GATE&nbsp;III&nbsp;LLC</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">15215&nbsp;Shady&nbsp;Grove&nbsp;Road</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Suite 201</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Rockville,&nbsp;Maryland&nbsp;20850</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If to the Tenant:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MACROGENICS, INC.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">9640 Medical Center
Drive</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Rockville, Maryland 20850</P></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">or to such other address as either may have designated from time to time by written notice to the other. The
date of service of such notices shall be the date such notices are deposited in any United States Post Office. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>31.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>COVENANTS OF TENANT </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">Tenant covenants and agrees: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">To give to Landlord prompt written notice of any accident, fire, or damage occurring on or to the Premises. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">To keep the thermostats in the Premises set at a temperature sufficient to prevent freezing of water pipes, fixtures and HVAC units. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top">To keep the Premises clean, orderly, sanitary, and free from all objectionable odors and from insects, vermin and other pests. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top">To comply with the requirements of the State, Federal and County statutes, ordinances, and regulations applicable to Tenant and its use of the Premises, and to save Landlord harmless from penalties, fines, costs, and
expenses resulting from failure to do so not caused by Landlord&#146;s negligence, willful misconduct, illegal conduct or breach of this Lease, provided Tenant shall not be obligated to make structural repairs or alterations to so comply.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top">Tenant shall promptly pay all contractors, suppliers of material and persons it engages to perform work and provide materials for construction work on the Premises so as to minimize the possibility of a lien attaching
to the Premises. Should any such lien be made or filed, Tenant shall cause the same to be discharged and released of record by bond or otherwise within ten (10)&nbsp;days of receipt of written request from Landlord. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top">Tenant is responsible for the security of the Premises. </TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>32.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>LANDLORD&#146;S RIGHT TO ALTER SITE PLAN </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">Landlord shall, from time to time, have the
right to alter or modify the site plan of the Building and to rearrange the driveways and parking areas, as well as the entrance and exits to the Premises, provided such alteration, modification or rearrangement does not adversely affect
Tenant&#146;s parking or Tenant&#146;s access to the Premises. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>33.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>PARKING SPACES </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">Landlord agrees to furnish 2.7 unreserved parking spaces per thousand
square feet of space occupied by the Tenant. There shall be no charge to Tenant for parking space use during the Term and any renewals of the Term </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 10 of 15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>34.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>ENTIRE AGREEMENT </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">This Lease contains the entire agreement of the parties. There are no
oral agreements existing between them. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>35.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>SUCCESSORS AND ASSIGNS </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">This Lease, and the covenants and conditions herein contained
shall inure to the benefit of and be binding upon the Landlord, its successors and assigns, and shall inure to the benefit of and be binding upon the Tenant, its successors and assigns, if permitted. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>36.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>BANKRUPTCY </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">If Tenant shall make an assignment of its assets for the benefit of
creditors, or if Tenant shall file a voluntary petition in bankruptcy, or if any involuntary petition in bankruptcy or for receivership be instituted against the Tenant and the same be not dismissed within sixty (60)&nbsp;days of the filing thereof,
or if Tenant shall be adjudged bankrupt, then and in any of said events, this Lease shall immediately cease and terminate at the option of the Landlord with the same force and effect as though the date of said event was the date herein fixed for
expiration of the term of this Lease. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>37.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>NON-DELIVERY </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">In the event the Landlord shall be unable to give possession of the
Premises because construction of the Premises is not complete or for any other cause reasonably beyond the control of the Landlord, the Landlord shall not be liable to Tenant for any damage resulting from failure to give such possession. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">If the Premises are not delivered by April&nbsp;1, 2015 Tenant shall have the right to terminate this Lease. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>38.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>PARTIAL INVALIDITY </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">If any term, covenant, or condition of this Lease or the application
thereof to any person or circumstance shall be held to be invalid and unenforceable, the remainder of this Lease, and the application of such terms, covenants, or conditions shall be valid and enforceable to the fullest extent permitted by law. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>39.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>FORCE MAJEURE </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">With the exception of those provisions contained herein regarding the
payment of rent, the inability of either party to perform any of the terms, covenants or conditions of this Lease shall not be deemed a default if the same shall be due to any cause beyond the control of that party. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>40.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>ESTOPPEL CERTIFICATE </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">The Tenant shall from time to time, within ten (10)&nbsp;days
after being requested to do so by the Landlord or any mortgagee, execute, acknowledge and deliver to the Landlord (or, at the Landlord&#146;s request, to any existing or prospective purchaser, transferee, assignee or Mortgagee of any or all of the
Premises) an instrument in recordable form, certifying (a)&nbsp;that this Lease is unmodified and in full force and effect (or, if there has been any modification thereof, that it is in full force and effect as so modified, stating therein the
nature of such modification); (b)&nbsp;as to the dates to which the Minimum Rent and other charges arising hereunder have been paid; (c)&nbsp;as to the amount of any prepaid rent or any credit due to the Tenant hereunder; (d)&nbsp;that the Tenant
has accepted possession of the Premises (if Landlord has delivered the Premises in accordance with this Agreement), and the Commencement Date; (e)&nbsp;as to whether, to the best knowledge, information and belief of the signer of such certificate,
the Landlord or the Tenant is then in default in performing any of its obligations hereunder (and, if so, specifying the nature of each such default); and (f)&nbsp;as to any other fact or condition reasonably requested by the Landlord or such other
addressee. In the event the Tenant fails or refuses to provide such a certificate, and following five (5)&nbsp;business days&#146; written notice and opportunity to cure, at Landlord&#146;s option: (i)&nbsp;the failure of Tenant to deliver such
statement within such time shall constitute a material default of Tenant hereunder, in which event Tenant shall be liable to Landlord for any resulting loss or damage (including reasonable counsel fees) up to a maximum amount of One Million Dollars
($1,000,000.00); or (ii)&nbsp;it shall be conclusive upon Tenant that (a)&nbsp;this Lease is in full force and effect, without modification, (b)&nbsp;there are no material uncured defaults in Landlord&#146;s
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 11 of 15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">
performance, (c)&nbsp;not more than one (1)&nbsp;month&#146;s Base Rent has been paid in advance, (d)&nbsp;all Tenant improvements to be constructed by Landlord, if any, have been completed in
accordance with Landlord&#146;s obligations and (e)&nbsp;Tenant has taken possession of the Premises. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>41.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>EXPANSION AND RIGHT OF FIRST OFFER </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">Subject to availability and any existing expansion
rights of other tenants in the Building, Tenant shall have the first right to expand into the remaining space in the Building during its term. The Minimum Rent rate would be at the then current escalated rental rate. In the event any additional
office space in the Building becomes available for leasing during the initial Term of this Lease, Landlord shall first offer, by written submission to the Tenant, the terms under which it intends to offer the space for lease. If the Landlord and
Tenant shall not have executed a lease agreement for such additional space within forty-five (45)&nbsp;days after Tenant&#146;s receipt of such notice, Landlord shall have the unfettered right to lease all or any portion of the Building upon such
terms and conditions as the Landlord may desire. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>42.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>SIGNAGE </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">Tenant shall have the right, at its expense, to put Tenant&#146;s name on the
building&#146;s fa&ccedil;ade and/or Premises at Tenant&#146;s expense. Any such signage shall comply with any rules, regulations and covenants applicable and mutually agreeable between the parties and any applicable government agencies. Tenant, at
its expense, shall at all times maintain such exterior signage in good condition. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>43.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>LENDER APPROVAL. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">Landlord&#146;s execution and delivery of this Lease shall be
conclusive evidence of approval by any financial institution possessing the right to approve leases for space in the Building. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>44.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>DECONTAMINATION OF PREMISES. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">Landlord, at its sole cost, shall obtain and provide to
Tenant a report evidencing the decontamination of the Premises prior to the Commencement Date. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>45.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>BROKER PARTICIPATION. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">Landlord and Tenant agree, understand and recognize that there
are no brokers other than CBRE, Inc. and J Street Companies (&#147;Brokers&#148;) participating in this transaction and that Landlord will compensate Brokers under terms of a separate agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 12 of 15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties have caused this Lease Agreement to be executed on the year and date first
written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">LANDLORD:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">WITNESS:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><B>RED GATE III LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ William M. Rickman</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">By: William M. Rickman</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">TENANT:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">WITNESS:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><B>MACROGENICS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Scott Koenig, M.D., PhD</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">By: Scott Koenig, M.D., PhD</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 13 of 15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT A </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To be attached. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The approved floor plan will include the segregation of space from Common Areas and other Building tenants such that entry to all Building tenants space may be controlled and locked. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Re-paint, re-carpet, re-tile entire Premises. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Replace all damaged and discolored ceiling tiles </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Balance HVAC </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Provide building standard lunch room cabinetry and sink as well as adequate electrical installation for a refrigerator and microwave. Kitchen appliances will be supplied by Tenant. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 14 of 15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT B </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>FLOOR PLAN </U></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g838054g98e17.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 15 of 15 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.25
<SEQUENCE>7
<FILENAME>d838054dex1025.htm
<DESCRIPTION>EX-10.25
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.25</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Exhibit 10.25 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Execution Version </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Confidential Materials omitted and filed separately with the Securities and Exchange Commission. </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Triple asterisks denote omissions. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COLLABORATION AND LICENSE AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BY AND BETWEEN </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AND
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>JANSSEN BIOTECH, INC. </B></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Execution Version </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="95%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE 1 DEFINITIONS</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE 2 GOVERNANCE</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.1</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joint Steering Committee.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.2</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional Subcommittees and Working Groups.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.3</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Authority.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.4</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alliance Managers.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.5</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Decision-Making Restrictions.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE 3 LICENSES</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.1</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">License to Company.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.2</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Licenses to MacroGenics.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.3</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trademark License.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.4</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">No Implied Licenses.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE 4 DEVELOPMENT</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.1</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transition of Development Responsibilities.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.2</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Development.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.3</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Decision-Making.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.4</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Compliance with Law.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.5</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Records.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.6</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cooperation.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.7</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Progress Reports.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.8</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Subcontracting.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE 5 REGULATORY RESPONSIBILITIES</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.1</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Initial Data Transfer.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.2</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preparation of Regulatory Materials.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.3</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adverse Event Reporting and Safety Data Exchange.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.4</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Recalls and Voluntary Withdrawals.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.5</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Subcontracting.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE 6 COMMERCIALIZATION</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.1</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commercialization Activities.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.2</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trademarks.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.3</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Decision-Making.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.4</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transparency Reporting.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.5</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Compliance with Law.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.6</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Subcontracting.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE 7 MANUFACTURING</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Execution Version </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.1</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General Supply Terms.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.2</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transition of Manufacturing Responsibilities.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.3</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Decision Making.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.4</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Compliance with Law.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.5</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Subcontracting.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE 8 MACROGENICS OPTIONS</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.1</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Generally.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.2</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Co-Funding Option.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.3</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Co-Promote Option.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE 9 CONSIDERATION</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.1</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Upfront Payment.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.2</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reimbursement of Expenses.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.3</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Milestone Payments.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.4</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Company Royalty Obligations.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.5</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Royalty Term.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.6</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Royalty Rate Reductions.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.7</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Manner of Royalty Payment.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.8</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Currency.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.9</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Allocation of N.A. Profit/Loss.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.10</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Third Party Financial Obligations.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.11</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Taxes.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.12</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax Returns.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.13</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audit. .</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.14</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Late Payment.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE 10 INTELLECTUAL PROPERTY MATTERS</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.1</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ownership of Inventions.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.2</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Disclosure of Inventions.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.3</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prosecution of Patents.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.4</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patent Term Extensions in the Territory.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.5</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Infringement of Patents by Third Parties.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.6</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Infringement of Third Party Rights in the Territory.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.7</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patent Oppositions and Other Proceedings.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE 11 REPRESENTATIONS, WARRANTIES AND COVENANTS</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.1</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mutual Representations, Warranties and Covenants.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.2</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional Representations and Warranties of MacroGenics.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.3</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional Representations and Warranties of Company.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.4</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">No Other Representations or Warranties.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE 12 CONFIDENTIALITY</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ii </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Execution Version </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="93%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.1</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nondisclosure.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.2</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exceptions.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.3</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Authorized Disclosure.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.4</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Terms of this Agreement.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.5</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Publicity.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.6</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Securities Filings.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.7</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Relationship to Confidentiality Agreement.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.8</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equitable Relief.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.9</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Publications.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE 13 TERM AND TERMINATION</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">13.1</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Term.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">13.2</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unilateral Termination by Company.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">13.3</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Termination for Material Breach.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">13.4</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Termination by Company for Safety Reasons.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">13.5</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Termination for [***].</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">13.6</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">HSR Filing; Termination Upon HSR Denial.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">13.7</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Termination for Bankruptcy.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">13.8</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effects of Termination.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">13.9</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Remedies.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">13.10</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Survival.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE 14 DISPUTE RESOLUTION</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">14.1</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exclusive Dispute Resolution Mechanism.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">14.2</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Resolution by Executive Officers.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">14.3</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Arbitration.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">14.4</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provisional Remedies.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">14.5</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Confidentiality.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE 15 INDEMNIFICATION</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">15.1</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Indemnification by Company.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">15.2</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Indemnification by MacroGenics.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">15.3</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Indemnification Procedures.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">15.4</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Insurance.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">15.5</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Limitation of Liability.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE 16 MISCELLANEOUS</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">16.1</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Notices.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">16.2</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Governing Law.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">16.3</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change of Control of MacroGenics.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">16.4</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assignment.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">16.5</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Designation of Affiliates.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">16.6</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Relationship of the Parties.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">iii </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Execution Version </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="93%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">16.7</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Force Majeure.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">16.8</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entire Agreement; Amendments.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">16.9</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Severability.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">16.10</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">English Language.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">16.11</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Waiver and Non-Exclusion of Remedies.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">16.12</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Further Assurance.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">16.13</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Headings.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">16.14</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Construction.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">16.15</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Counterparts.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LIST OF EXHIBITS </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exhibit&nbsp;A</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" ALIGN="center">&#150;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">Commercialization Expenses</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exhibit&nbsp;B</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" ALIGN="center">&#150;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">Global Development Plan</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exhibit C</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" ALIGN="center">&#150;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">MacroGenics Patents</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exhibit D</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" ALIGN="center">&#150;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">MGD011</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exhibit E</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" ALIGN="center">&#150;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">J &amp; J Universal Calendar</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exhibit F</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" ALIGN="center">&#150;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">Form of Press Release</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="5"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5" ALIGN="center"><B>LIST OF SCHEDULES</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Schedule&nbsp;7.1</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" ALIGN="center">&#150;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">MacroGenics&#146; Estimated, Non-Binding Manufacturing Costs</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">iv </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COLLABORATION AND LICENSE AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>THIS COLLABORATION AND LICENSE AGREEMENT </B>(&#147;<B>Agreement</B>&#148;) is entered into as of December&nbsp;19, 2014 (the &#147;<B>Execution
Date</B>&#148;), by and between <B>JANSSEN BIOTECH, INC.</B>, a Pennsylvania corporation, having its principal place of business at 800/850 Ridgeview Drive, Horsham, PA 19044 (hereinafter &#147;<B>Company</B>&#148;) and <B>MACROGENICS, INC.</B>, a
Delaware corporation having its principal place of business at 9640 Medical Center Drive, Rockville, MD 20850 (together with its Affiliates, &#147;<B>MacroGenics</B>&#148;). Company and MacroGenics are sometimes referred to herein individually as a
&#147;<B>Party</B>&#148; and collectively as the &#147;<B>Parties</B>&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, MacroGenics has discovered and is developing
a proprietary program that includes a Compound (as defined below) containing CD3 and CD19 specificities and is coded by MacroGenics as MGD011, with various potential human therapeutic uses; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, Company desires to obtain certain license rights in respect of such Compound, all in accordance with the terms and conditions
of this Agreement, with MacroGenics retaining certain options to co-promote the Initial Product (as defined below) in the U.S. and to co-fund certain development costs and participate in the profits and losses of the Initial Product, all as set
forth in this Agreement; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, MacroGenics and Johnson&nbsp;&amp; Johnson Innovation - JJDC, Inc., an Affiliate (as defined
below) of Company, are contemporaneously entering into that certain Stock Purchase Agreement and that certain Investor Agreement, each as of the Execution Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NOW, THEREFORE</B>, in consideration of the foregoing and the premises and conditions set forth herein, the Parties agree as follows: </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 1</B> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DEFINITIONS
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.1</B> &#147;<B>Accelerated Approval</B>&#148; means FDA approval of a BLA that (a)&nbsp;includes clinical data from a Phase 2 Trial or Phase 2/3
Trial, but no clinical data from a Phase 3 Trial; (b)&nbsp;has been granted expedited review by the FDA (<I>e.g.</I>, such BLA has been granted a Breakthrough Therapy designation pursuant to Section&nbsp;506(a) of the FFDCA or a Fast Track
designation pursuant to Section&nbsp;506(b) of the FFDCA); or (c)&nbsp;has been granted orphan drug status pursuant to Section&nbsp;526 of the FFDCA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.2</B> &#147;<B>Acquirer</B>&#148; means any Third Party that is a party to any Change of Control transaction and any of such Third Party&#146;s
Affiliates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.3</B> &#147;<B>Affiliate</B>&#148; means, with respect to a particular Person, a person, corporation, partnership, or other entity that
controls, is controlled by or is under common control with such first Person. For the purposes of this definition, the word &#147;control&#148; (including, with correlative meaning, the terms &#147;controlled by&#148; or &#147;under the common
control with&#148;) means the actual power, either directly or indirectly through one or more intermediaries, to direct or cause the direction of the management and policies of such entity, whether by the ownership of fifty percent (50%)&nbsp;or
more of the voting stock of such entity, or by contract or otherwise. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.4</B> &#147;<B>Alliance Manager</B>&#148; means the person appointed by each Party from within their
respective organization to coordinate and facilitate the communication, interaction and cooperation of the Parties pursuant to this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.5</B>
&#147;<B>Antitrust Laws</B>&#148; means any law relating to competition that is enforced by (a)&nbsp;the Federal Trade Commission or the Antitrust Division of the U.S. Department of Justice or (b)&nbsp;any equivalent foreign authority, including the
European Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.6</B> &#147;<B>Applicable Law</B>&#148; means all applicable statutes, ordinances, regulations, rules, or orders of any kind
whatsoever of any Governmental Authority, including the FFDCA, Prescription Drug Marketing Act of 1987 (21 U.S.C. &#167;&#167;331, 333, 353, 381), the Generic Drug Enforcement Act of 1992 (21 U.S.C. &#167;335(a) et seq.), U.S. Patent Act (35 U.S.C.
&#167;1 et seq.), Federal False Claims Act (31 U.S.C. &#167;3729 et seq.), and the Anti-Kickback Statute (42 U.S.C. &#167;1320a-7b et seq.), all as amended from time to time, together with any rules, regulations, and compliance guidance promulgated
thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.7 </B>&#147;<B>BLA</B>&#148; means (a)&nbsp;a Biologics License Application as defined in the Public Health Service Act and the
regulations promulgated thereunder, (b)&nbsp;a Marketing Authorization Application in Europe, or (c)&nbsp;any equivalent or comparable application, registration or certification in any other country or region. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.8</B> &#147;<B>Business Day</B>&#148; means a day other than Saturday, Sunday or any other day that is designated as a J&amp;J holiday in the J&amp;J
Universal Calendar (a copy of which for the years 2014 and 2015 is attached as <U>Exhibit E</U> and a copy of which prior to the beginning of each such year for succeeding years shall be provided to MacroGenics). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.9</B> &#147;<B>Calendar Quarter</B>&#148; means a financial quarter based on a Calendar Year; <U>provided</U>, <U>however</U>, that the first Calendar
Quarter and the last Calendar Quarter may be partial quarters as applicable under the relevant Calendar Year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.10</B> &#147;<B>Calendar
Year</B>&#148; means a year based on the Johnson&nbsp;&amp; Johnson Universal Calendar; <U>provided</U>, <U>however</U>, that the first Calendar Year and the last Calendar Year of the applicable period (such as the Royalty Term) may be a partial
year as the case may be. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.11</B> &#147;<B>Centralized Approval Procedure</B>&#148; means, to the extent compulsory or permitted for the Regulatory
Approval of a Compound or Product in Iceland, Liechtenstein, Norway or any country in the European Union, the procedure administrated by the EMA which results in a single marketing authorization that is valid in Iceland, Liechtenstein, Norway and
all countries in the European Union. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.12</B> &#147;<B>CFDA</B>&#148; means the China Food and Drug Administration and any successor agency(ies) or
authority having substantially the same function. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.13</B> &#147;<B>Change of Control</B>&#148; shall occur if: (a)&nbsp;any Third Party acquires directly or
indirectly the beneficial ownership of any voting security of a Party, or if the percentage ownership of such person or entity in the voting securities of a Party is increased through stock redemption, cancellation or other recapitalization, and
immediately after such acquisition or increase such Third Party is, directly or indirectly, the beneficial owner of voting securities representing more than fifty percent (50%)&nbsp;of the total voting power of all of the then outstanding voting
securities of a Party; (b)&nbsp;a merger, consolidation, recapitalization, or reorganization of a Party is consummated, other than any such transaction, which would result in stockholders or equity holders of such Party immediately prior to such
transaction, owning at least fifty percent (50%)&nbsp;of the outstanding securities of the surviving entity (or its parent entity) immediately following such transaction; (c)&nbsp;the stockholders or equity holders of a Party approve a plan of
complete liquidation of such Party, or an agreement for the sale or disposition by such Party of all or substantially all of such Party&#146;s assets, other than pursuant to the transaction described above or to an Affiliate; (d)&nbsp;individuals
who, as of the date hereof, constitute the Board of Directors of a Party (the &#147;<B>Incumbent Board</B>&#148;) cease for any reason to constitute at least a majority of the Board of Directors of such Party (<U>provided</U>, <U>however</U>, that
any individual becoming a director subsequent to the date hereof whose election, or nomination for election by such Party&#146;s shareholders, was recommended or approved by a vote of at least a majority of the directors then comprising the
Incumbent Board shall be considered as though such individual were a member of the Incumbent Board, but excluding, for this purpose, any such individual whose initial assumption of office occurs as a result of an actual or threatened election
contest with respect to the election or removal of directors or other actual or threatened solicitation of proxies or consents by or on behalf of any person other than the Board of Directors of such Party); or (e)&nbsp;the sale or transfer to a
Third Party of (i)&nbsp;all or substantially all of such Party&#146;s assets taken as a whole or (ii)&nbsp;a majority of such Party&#146;s assets which relate to this Agreement, is effected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.14</B> &#147;<B>Clinical Trials</B>&#148; means a Phase 1 Trial, Phase 2 Trial, Phase 2/3 Trial, Phase 3 Trial or Phase 4 Trial, as applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.15</B> &#147;<B>Co-Funding Term</B>&#148; means the time period commencing on the date that Company receives the Co-Funding Option Exercise Notice and
concluding on the Co-Funding Termination Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.16</B> &#147;<B>Co-Funding Termination Date</B>&#148; means the last day of the Calendar Quarter
during which the Co-Funding Termination Event occurs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.17</B> &#147;<B>Co-Funding Termination Event</B>&#148; means the earlier of: (a)&nbsp;the
[***] after MacroGenics&#146; receipt of a GDC Late Payment Notice, <U>provided</U> that MacroGenics has not paid the entire non-disputed outstanding amount due under the applicable GDC Invoice; (b)&nbsp;Company&#146;s receipt of the Co-Funding
Opt-Out Notice; (c)&nbsp;if, Net Sales of the Initial Product in the Northern American Territory are less than [***], the last day of such second Calendar Year or (d)&nbsp;[***] after the First Commercial Sale of the Initial Product in the Northern
American Territory. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.18</B> &#147;<B>Combination Product</B>&#148; means (a)&nbsp;a Product that comprises, consists of or
incorporates two (2)&nbsp;or more active pharmaceutical ingredients or (b)&nbsp;a package that includes a Product and at least one pharmaceutical product that is not a Product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.19</B> &#147;<B>Commercial FTE</B>&#148; means [***] of work devoted to or in direct support of the Commercialization of a Product (other than Detailing)
that is carried out by one or more qualified employees or contractors or consultants of MacroGenics or its Affiliates or Company or its Affiliates, [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.20</B> &#147;<B>Commercial FTE Costs</B>&#148; means, with respect to any period, the Commercial FTE Rate multiplied by the number of Commercial FTEs
expended by a Party during such period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.21</B> &#147;<B>Commercial FTE Rate</B>&#148; means a rate of [***] per Commercial FTE per Calendar Year
(pro-rated for the period beginning on the Effective Date and ending on the last day of the first Calendar Year of the Term); <U>provided</U>, <U>however</U>, that such rate shall be increased or decreased annually beginning on January&nbsp;4, 2016
by the percentage increase or decrease in the [***]. The Commercial FTE Rate is &#147;fully burdened&#148; and covers employee salaries, benefits, travel and other costs not separately accounted for in Commercialization Expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.22</B> &#147;<B>Commercialization</B>&#148; means any activities directed to marketing, promoting, distributing, importing, offering to sell and/or
selling a Product. When used as a verb, &#147;<B>Commercialize</B>&#148; means to engage in Commercialization activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.23</B>
&#147;<B>Commercially Reasonable Efforts</B>&#148; means, with respect to the efforts to be expended, or considerations to be undertaken, by a Party or its Affiliate with respect to any objective, activity or decision to be undertaken hereunder,
reasonable, good faith efforts to accomplish such objective, activity or decision as such Party would normally use to accomplish a similar objective, activity or decision under similar circumstances, it being understood and agreed that, with respect
to the Development, Manufacture, seeking and obtaining Regulatory Approval, or Commercialization of a Compound or Product, such efforts and resources shall be consistent with those efforts and resources commonly used by a Party under similar
circumstances for similar compounds or products to which it has similar rights, which compound or product, as applicable, is at a similar stage in its development or product life and is of similar market potential, taking into account all
commercial, scientific, economic and other factors, including: (a)&nbsp;issues of efficacy, safety, and expected and actual approved labeling; (b)&nbsp;the expected and actual competitiveness of alternative products sold by Third Parties in the
marketplace; (c)&nbsp;the expected and actual product profile of the Compound or Product; (d)&nbsp;the expected and actual patent and other proprietary position of the Compound or Product; (e)&nbsp;the likelihood of Regulatory Approval of the
Compound or Product given the regulatory structure involved, including the likelihood of obtaining Regulatory Exclusivity; and (f)&nbsp;the expected and actual profitability and return on investment of the Compound or Product, taking into
consideration, among other factors, expected and actual Third Party costs and expenses, the pricing and reimbursement relating to the Product(s), and the payments due to a Party hereunder. To the extent that the performance of a Party&#146;s
obligations hereunder is adversely affected by the other Party&#146;s failure to perform its obligations hereunder, the impact of such performance failure will be taken into account in determining whether such first Party has used Commercially
Reasonable Efforts to perform its affected obligations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.24 </B>&#147;<B>Company Applied Technology</B>&#148; means, with respect to any Reverted Product,
(a)&nbsp;any Know-How Controlled by Company as of the Effective Date or during the Term (other than as a result of the licenses granted by MacroGenics to Company under this Agreement) that (i)&nbsp;Company had applied to such Reverted Product prior
to termination of this Agreement, <U>provided</U> that such Know-How is necessary for the continued Exploitation of such Reverted Product as it exists at the time of such termination or (ii)&nbsp;Company had incorporated into such Reverted Product
prior to termination of this Agreement and (b)&nbsp;any Patents Controlled by Company as of the Effective Date or during the Term that Covers the Know-How described in clause (a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.25</B> &#147;<B>Company Inventions</B>&#148; means Inventions Controlled by Company that are necessary or otherwise used to Exploit Compounds or Products
in the Field in the Territory. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.26</B> &#147;<B>Company Know-How</B>&#148; means all Know-How Controlled by Company, during the Term, used to Exploit
Compounds or Products in the Field in the Territory as contemplated by this Agreement, including Company Inventions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.27</B> &#147;<B>Company
Patents</B>&#148; means all Patents Controlled by Company, covering Inventions discovered or invented during the Term pursuant to activities under this Agreement that: (a)&nbsp;Cover the composition of matter of, the method of making or using, or
the sale or the importation of the Compounds or the Products, to the extent included within a Company Invention; or (b)&nbsp;are otherwise used to Exploit the Compounds or the Products in the Field in the Territory. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.28</B> &#147;<B>Company Technology</B>&#148; means, collectively, the Company Patents and the Company Know-How. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.29</B> &#147;<B>Competitive Infringement</B>&#148; means any infringement or misappropriation that involves the Development, Manufacture, use or
Commercialization of a product or product candidate that [***]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.30 </B>&#147;<B>Compound</B>&#148; means (a)&nbsp;MGD011, its derivatives and
variants, including molecules that [***] and are specifically claimed in Patents that specifically claim the amino acid sequence of MGD011; and (b)&nbsp;any other DART derived from the DART Platform that [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.31</B> &#147;<B>Confidential Information</B>&#148; means, subject to ARTICLE 12, all non-public or proprietary Information disclosed by a Party to the
other Party under this Agreement, which may include ideas, inventions, discoveries, concepts, compounds, compositions, formulations, formulas, practices, procedures, processes, methods, knowledge, know-how, trade secrets, technology, inventories,
machines, techniques, development, designs, drawings, computer programs, skill, experience, documents, apparatus, results, clinical and regulatory strategies, Regulatory Documentation, Information and submissions pertaining to, or made in
association with, filings with any Governmental Authority, data, including pharmacological, toxicological and clinical </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
data, analytical and quality control data, manufacturing data and descriptions, patent and legal data, market data, financial data or descriptions, devices, assays, chemical formulations,
specifications, material, product samples and other samples, physical, chemical and biological materials and compounds, and the like, without regard as to whether any of the foregoing is marked &#147;confidential&#148; or &#147;proprietary,&#148; or
disclosed in oral, written, graphic, or electronic form. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Confidential Information shall include: (a)&nbsp;the terms and conditions of this Agreement; and
(b)&nbsp;Confidential Information disclosed by either Party pursuant to the Confidential Disclosure Agreement [***] (the &#147;<B>Prior CDA</B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.32</B> &#147;<B>Control</B>&#148; or &#147;<B>Controlled</B>&#148; means, with respect to any Information, Know-How, Patent or other intellectual
property right, (a)&nbsp;ownership by a Party or, subject to Section&nbsp;16.5, any of its Affiliates, of such Information, Know-How, Patent or other intellectual property right, or (b)&nbsp;possession by a Party or, subject to Section&nbsp;16.5,
any of its Affiliates, of the ability (without taking into account any rights granted by one Party to the other Party under the terms of this Agreement) to grant access, a license or a sublicense to such Information, Know-How, Patent or other
intellectual property right without violating the terms of any agreement or other arrangement with, or necessitating the consent of, any Third Party, at such time that the Party would be first required under this Agreement to grant the other Party
such access, license or sublicense, but excluding, in each case ((a) and (b)), any Information, Know-How, Patent or other intellectual property right that comes into the Control of a Party pursuant to a Change of Control of such Party, except to the
extent, and only to the extent that, such Information, Know-How, Patent or other intellectual property right is either (i)&nbsp;actually used by such Party or its Affiliates, or the Acquirer, to Develop, Manufacture or Commercialize the Compounds or
Products following the consummation of such Change of Control or (ii)&nbsp;made, conceived or reduced to practice by the Acquirer through the use of, or reference to, any Information, Know-How, Patent or other intellectual property right of such
Party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.33</B> &#147;<B>Co-Promote Option Deadline</B>&#148; means [***] after Company delivers the Co-Promote Materials relating to such second
Indication to MacroGenics in accordance with Section&nbsp;8.3 (the [***]&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.34</B> &#147;<B>Cover</B>&#148; or &#147;<B>Covering</B>&#148;
means, with respect to a product, technology, process or method, that, in the absence of ownership of or a license granted under a Valid Claim, the practice or Exploitation of such product, technology, process or method would infringe such Valid
Claim (or, in the case of a Valid Claim that has not yet issued, would infringe such Valid Claim if it were to issue). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.35 </B>&#147;<B>CPI</B>&#148;
means the Consumer Price Index-Urban Wage Earners and Clerical Workers, U.S. City Average, All Items, 1982-1984=100, published by the U.S. Department of Labor, Bureau of Labor Statistics (or its successor equivalent index) in the U.S. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.36</B> [***] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.37 </B>&#147;<B>DART</B>&#148; means a dual affinity re-targeting molecule consisting of [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.38</B> &#147;<B>DART Platform</B>&#148; means MacroGenics&#146; proprietary platform for generating DARTs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.39</B> &#147;<B>Detail</B>&#148; or &#147;<B>Detailing</B>&#148; means an interactive face-to-face meeting between a sales representative acting on
behalf of the applicable Party and a health care professional having prescribing authority within the target audience that occurs after Regulatory Approval of a Product, during which such Product&#146;s attributes (including approved uses, safety,
effectiveness, contraindications, side effects warnings and/or other relevant characteristics) are discussed in an effort to increase prescribing preferences of such Product for its approved uses, in a manner consistent with Applicable Law and
industry standards and with the quality of similar presentations made by a Party&#146;s sales representatives for such Party&#146;s other products, if applicable. Details may include First Position Details or Second Position Details. Detailing shall
not include (a)&nbsp;sample drops made by sales representatives, (b)&nbsp;medical affairs activities or related activities conducted by medical support staff (such as medical science liaisons), (c)&nbsp;activities conducted at conventions,
(d)&nbsp;electronic details or (e)&nbsp;activities performed by market development specialists, managed care account directors or other personnel not performing face-to-face sales calls or not specifically trained with respect to a Product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.40</B> &#147;<B>Development</B>&#148; means all research and non-clinical and clinical drug development activities and processes, including toxicology,
pharmacology, project management and other non-clinical efforts, statistical analysis, formulation development, delivery system development, statistical analysis, Manufacturing Development, the performance of clinical trials (including the
manufacturing of Product for use in clinical trials), or other activities reasonably necessary in order to obtain, but not maintain, Regulatory Approval of Products in the Field in the Territory. When used as a verb, &#147;<B>Develop</B>&#148; means
to engage in Development activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.41</B> &#147;<B>Development FTE</B>&#148; means (a)&nbsp;with respect to Company, [***] hours of work devoted
to or in direct support of the Global Development Activities by one or more qualified employees or contractors or consultants of Company or its Affiliates, as measured in accordance with Company&#146;s normal time allocation practices, or
(b)&nbsp;with respect to MacroGenics, [***] of work devoted to or in direct support of the Global Development Activities, pursuant to Section&nbsp;4.2(c) or providing assistance to Company pursuant to Section&nbsp;5.2 or Section&nbsp;7.1 by one or
more qualified employees or contractors or consultants of Company or its Affiliates, as measured in accordance with MacroGenics&#146; normal time allocation practices, <U>provided</U> that, in each case ((a) and (b)) such employees or contractors or
consultants must be [***]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.42</B> &#147;<B>Development FTE Costs</B>&#148; means, with respect to any period, the Development FTE Rate multiplied by
the number of Development FTEs expended by a Party during such period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.43</B> &#147;<B>D</B><B>evelopment FTE Rate</B>&#148; means a rate of [***]
per FTE per Calendar Year (pro-rated for the period beginning on the Effective Date and ending on the last day of the first Calendar Year of the Term); <U>provided</U>, <U>however</U>, that such rate shall be increased or decreased annually
beginning on January&nbsp;4, 2016 by the [***]. The Development FTE Rate is &#147;fully burdened&#148; and will cover employee salaries and such facilities and equipment and other materials and services, including ordinary laboratory consumables
procured from distributors of relevant products as they may use. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.44</B> &#147;<B>Development Transition Date</B>&#148; means the earlier of (a)&nbsp;the IND Clearance Date
for the IND for the first Phase 1 Trial of the Initial Product submitted by MacroGenics in accordance with Section&nbsp;5.2(a), (b)&nbsp;the date on which the JSC determines that Company shall assume responsibility for the preparation and filing of
such IND in accordance with Section&nbsp;4.1(a) or (c)&nbsp;twelve (12)&nbsp;months after the Effective Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.45</B> [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.46</B> &#147;<B>Effective Date</B>&#148; means the first (1st)&nbsp;Business Day immediately following the date on which the Parties have actual
knowledge that all applicable waiting periods under the HSR Act with respect to the transactions contemplated hereunder have expired or have been terminated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.47</B> &#147;<B>EMA</B>&#148; means the European Medicines Agency or any successor agency(ies) or authority having substantially the same function. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.48 </B>[***] and including, in each case, the territories and possessions of each country. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.49</B> &#147;<B>European Union</B>&#148; or &#147;<B>EU</B>&#148; means the European Union member states as then-currently constituted; <U>provided</U>,
<U>however</U>, that the EU shall always be deemed to include the [***]. As of the Execution Date, the European Union member states are Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece,
Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, and United Kingdom. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.50 </B>&#147;<B>Executive Officers</B>&#148; means (a)&nbsp;with respect to Company, either (i)&nbsp;prior to the first Regulatory Approval, the Global
Head of Research and Development (or his or her designee), and (ii)&nbsp;following the first Regulatory Approval, the president of U.S. oncology commercial operations (or his or her designee) and (b)&nbsp;with respect to MacroGenics, the Chief
Executive Officer (or his or her designee). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.51</B> &#147;<B>Exploit</B>&#148; or &#147;<B>Exploitation</B>&#148; means to research, make, have made,
distribute, import, export, use, have used, sell, have sold, or offer for sale, Develop, Commercialize, register, modify, enhance, improve, Manufacture, have Manufactured or otherwise dispose of a Compound or Product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.52</B> &#147;<B>FDA</B>&#148; means the U.S. Food and Drug Administration and any successor agency(ies) or authority having substantially the same
function. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.53</B> &#147;<B>FFDCA</B>&#148; means the U.S. Federal Food, Drug and Cosmetic Act (21 U.S.C. &#167;301 et seq.), as amended from time to
time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.54 </B>&#147;<B>Field</B>&#148; means all uses, including the diagnosis, treatment or prevention of any
disease in humans. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.55</B> &#147;<B>First Commercial Sale</B>&#148; means, on a Product-by-Product and country-by-country basis, the first sale for
monetary value of such Product under this Agreement by Company, its Affiliates or its sublicensees to an end user for use, consumption or resale of such Product in such country in the Field after Regulatory Approval of such Product has been obtained
in such country in the Field, where such sale results in a Net Sale. Sale of a Product under this Agreement by Company to an Affiliate of Company or a sublicensee of Company shall not constitute a First Commercial Sale unless such Affiliate or such
sublicensee is the end user of such Product. For the avoidance of doubt, the sale of Product for clinical study purposes, early access programs (such as to provide patients with a Product prior to Regulatory Approval pursuant to treatment INDs or
protocols, named patient programs or compassionate use programs) or any similar uses shall not constitute a First Commercial Sale. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.56</B>
&#147;<B>First Position Detail</B>&#148; means a Detail in which a Product is Detailed before any other product and a predominant portion of time is devoted to Detailing such Product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.57</B> &#147;<B>Force Majeure</B>&#148; means any event beyond the reasonable control of the affected Party, which may include embargoes; war or acts of
war, including terrorism; insurrections, riots, or civil unrest; strikes, lockouts or other labor disturbances; epidemics, fire, floods, earthquakes or other acts of nature; acts, omissions or delays in acting by any Governmental Authority (other
than delays incident to the ordinary course of drug development); and failure of plant or machinery. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.58</B> &#147;<B>FPD</B>&#148; means, with
respect to a Clinical Trial, the first patient dosed in such Clinical Trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.59</B> &#147;<B>FTE</B>&#148; means, collectively, Development FTE,
Commercial FTE and Sales Rep FTE. For clarity, no more than [***] per Calendar Year (or equivalent pro-rata portion thereof for the period beginning on the Effective Date and ending on the last day of the first Calendar Year) may be charged for a
single individual contributing work factoring into any reimbursable FTE Costs hereunder, regardless of how much additional work time is contributed by such individual during such Calendar Year (or period beginning on the Effective Date and ending on
the last day of the first Calendar Year), and any individual contributing less than [***] per Calendar Year (or equivalent pro-rata portion thereof for the period beginning on the Effective Date and ending on the last day of the first Calendar Year)
shall be deemed a fraction of an FTE on a pro-rata basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.60</B> &#147;<B>FTE Costs</B>&#148; means, collectively, Development FTE Costs and
Commercial FTE Costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.61</B> &#147;<B>GAAP</B>&#148; means generally accepted accounting principles in the U.S., consistently applied. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.62</B> &#147;<B>Global Development Activities</B>&#148; means the following Development activities relating to the Initial Product: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(a)</B></TD>
<TD ALIGN="left" VALIGN="top">performance of any Phase 2 Trial or Pivotal Trial of the Initial Product in accordance with the Global Development Plan; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(b)</B></TD>
<TD ALIGN="left" VALIGN="top">Manufacturing of the Initial Product to conduct such Phase 2 Trial or Pivotal Trial (and associated Manufacturing Development (except to the extent expressly [***])); and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(c)</B></TD>
<TD ALIGN="left" VALIGN="top"><B></B>preparation, filing and maintenance of Regulatory Documentation directly supporting such Phase 2 Trial or Pivotal Trial and obtaining Regulatory Approval of the Initial Product; </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>provided</U>, <U>however</U>, that Global Development Activities shall specifically exclude: [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.63</B> &#147;<B>Global Development Costs</B>&#148; means all of the following expenses related to Global Development Activities incurred by Company or
its Affiliates (or by MacroGenics or its Affiliates pursuant to Section&nbsp;4.2(c)), regardless of whether such expenses are incurred before or during the Co-Funding Term: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(a)</B></TD>
<TD ALIGN="left" VALIGN="top">Third Party Expenses; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(b)</B></TD>
<TD ALIGN="left" VALIGN="top">Development FTE Costs; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(c)</B></TD>
<TD ALIGN="left" VALIGN="top"><B></B>Product Liabilities arising from the conduct of the Global Development Activities before or during the Co-Funding Term (even if such Product Liabilities are not incurred until after the Co-Funding Term),
<U>provided</U> that any Product Liabilities for which a Party is obligated to indemnify the other Party pursuant to Section&nbsp;15.1 or 15.2 because such Product Liabilities are Losses to which such other Party becomes subject as a result of a
Claim (or would be Losses if such other Party became subject to such Product Liabilities as a result of a Claim) shall be expressly excluded from this definition of Global Development Costs and shall be the responsibility of such first Party to the
extent that such first Party is (or would be) responsible for such Losses pursuant to ARTICLE 15. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of clarity, Global
Development Costs shall not include [***] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.64</B> &#147;<B>Global Development Plan</B>&#148; means the high-level, written plan attached hereto as
<U>Exhibit B</U> covering the planned Development of the Compounds and the Products, as amended from time to time in accordance with Section 4.2(b). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.65</B> &#147;<B>Good Clinical Practices</B>&#148; or &#147;<B>GCP</B>&#148; means the then-current standards, practices and procedures promulgated or
endorsed by the FDA as set forth in the guideline adopted by the International Conference on Harmonization (&#147;<B>ICH</B>&#148;), titled &#147;Guidance for Industry E6 Good Clinical Practice: Consolidated Guidance&#148; (or any successor
document), including related regulatory requirements imposed by the FDA and comparable regulatory standards, practices and procedures promulgated by the EMA, PMDA, CFDA or other Regulatory Authority applicable to the Territory, as they may be
updated from time to time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.66</B> &#147;<B>Good Laboratory Practices</B>&#148; or &#147;<B>GLP</B>&#148; means the then-current
standards, practices and procedures promulgated or endorsed by the FDA as set forth in 21 C.F.R. Part 58 (or any successor statute or regulation), including related regulatory requirements imposed by the FDA and comparable regulatory standards,
practices and procedures promulgated by the EMA, PMDA, CFDA or other Regulatory Authority applicable to the Territory, as they may be updated from time to time, including applicable guidelines promulgated under the ICH. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.67</B> &#147;<B>Good Manufacturing Practices</B>&#148; or &#147;<B>GMP</B>&#148; means the then-current good manufacturing practices required by the FDA,
as set forth in the FFDCA, as amended, and the regulations promulgated thereunder, for the manufacture and testing of pharmaceutical materials, and comparable Applicable Law related to the manufacture and testing of pharmaceutical materials in
jurisdictions outside the U.S., including the quality guideline promulgated by the ICH designated ICH Q7A, titled &#147;Q7A Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients&#148; and the regulations promulgated thereunder,
in each case as they may be updated from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.68</B> &#147;<B>Governmental Authority</B>&#148; means any multi-national, federal, state,
local, municipal or other government authority of any nature (including any governmental division, subdivision, department, agency, bureau, branch, office, commission, council, court or other tribunal). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.69</B> &#147;<B>HSR Act</B>&#148; means the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended from time to time, and any comparable
Applicable Law in jurisdictions outside the U.S. related to the approval of transactions similar to those contemplated under this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.70</B>
&#147;<B>HSR Clearance Date</B>&#148; means the expiration or termination of all applicable waiting periods and requests for information (and any extensions thereof) under the HSR Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.71</B> &#147;<B>HSR Filing</B>&#148; means (a)&nbsp;filings by Company and MacroGenics with the U.S. Federal Trade Commission and the Antitrust Division
of the U.S. Department of Justice of a Notification and Report Form for Certain Mergers and Acquisitions (as that term is defined in the HSR Act) with respect to the matters set forth in this Agreement, together with all required documentary
attachments thereto, or (b)&nbsp;equivalent filings with relevant foreign authorities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.72</B> &#147;<B>IND</B>&#148; means (a)&nbsp;an
Investigational New Drug application as defined in the FFDCA and applicable regulations promulgated thereunder by the FDA; (b)&nbsp;a clinical trial authorization application for a product filed with a Regulatory Authority in any other regulatory
jurisdiction outside the U.S., the filing of which (in the case of (a)&nbsp;or (b)) is necessary to commence or conduct clinical testing of a pharmaceutical product in humans in such jurisdiction; or (c)&nbsp;documentation issued by a Regulatory
Authority that permits the conduct of clinical testing of a product in humans in such jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.73</B> &#147;<B>IND Clearance Date</B>&#148;
means, with respect to any IND, the date on which the sponsor of such IND is permitted to initiate clinical trials following submission of such IND to the applicable Regulatory Authority. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.74</B> &#147;<B>Indication</B>&#148; means a [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.75</B> &#147;<B>Information</B>&#148; means information, inventions, discoveries, compounds, compositions, formulations, formulas, practices, procedures,
processes, methods, knowledge, know-how, trade secrets, technology, techniques, designs, drawings, correspondence, computer programs, documents, apparatus, results, strategies, Regulatory Documentation, information and submissions pertaining to, or
made in association with, filings with any Governmental Authority or patent office, data, including pharmacological, toxicological, non-clinical and clinical data, analytical and quality control data, manufacturing data and descriptions, market
data, financial data or descriptions, devices, assays, chemical formulations, specifications, material, product samples and other samples, physical, chemical and biological materials and compounds, and the like, in written, electronic, oral or other
tangible or intangible form, now known or hereafter developed, whether or not patentable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.76</B> &#147;<B>Initial Product</B>&#148; means the
initial Product Developed hereunder that either (a)&nbsp;contains MGD011 as its sole active pharmaceutical ingredient, or (b)&nbsp;contains a different Compound approved for Development by mutual agreement of the Parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.77</B> &#147;<B>Invention</B>&#148; means any invention, discovery or development, whether or not patentable, made, conceived or reduced to practice in
the course of performance of this Agreement, whether made, conceived or reduced to practice solely by, or on behalf of, MacroGenics, Company, the Parties jointly, or any Affiliate of the same. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.78</B> &#147;<B>Johnson</B>&nbsp;<B>&amp; Johnson Universal Calendar</B>&#148; means the calendar of a particular period of twelve (12)&nbsp;months that
constitutes a financial year for the purposes of Johnson&nbsp;&amp; Johnson, a New Jersey corporation and the ultimate parent company of Company (&#147;<B>Johnson&nbsp;&amp; Johnson</B>&#148;), and its Affiliates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.79</B> &#147;<B>Know-How</B>&#148; means all Information and Inventions Controlled by a Party that are necessary or useful to Exploit Compounds and/or
Products in the Field in the Territory. Know-How excludes any Information contained within a Party&#146;s published Patents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.80</B>
&#147;<B>Knowledge</B>&#148; means, as applied to a Party, that such Party shall be deemed to have knowledge of a particular fact or other matter to the extent that a reasonably prudent person with primary responsibility for the applicable subject
matter (whether an officer or employee of such Party) knew or should have known of such fact or other matter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.81</B> &#147;<B>MAA</B>&#148; or
&#147;<B>Marketing Authorization Application</B>&#148; means an application for Regulatory Approval in any particular jurisdiction other than the U.S. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.82</B> &#147;<B>MacroGenics Inventions</B>&#148; means Inventions Controlled by MacroGenics during the Term that are necessary or useful to Exploit
Compounds or Products in the Field in the Territory. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.83</B> &#147;<B>MacroGenics Know-How</B>&#148; means all Know-How Controlled by MacroGenics as
of the Execution Date or during the Term, including all MacroGenics Inventions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.84</B> &#147;<B>MacroGenics Options</B>&#148; mean, individually, the Co-Funding Option and the Co-Promote
Option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.85</B> &#147;<B>MacroGenics Out-of-Pocket Patent Costs</B>&#148; means all Third Party Expenses incurred by MacroGenics pursuant to the
filing, prosecution and maintenance of MacroGenics Patents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.86</B> &#147;<B>MacroGenics Patents</B>&#148; means all Patents Controlled by
MacroGenics, as of the Execution Date or during the Term that: (a)&nbsp;Cover the composition of matter of, or the method of making or using, the sale or the importation of the Compounds or the Products; or (b)&nbsp;are otherwise necessary or useful
to Exploit the Compounds or the Products in the Field in the Territory. The MacroGenics Patents as of the Execution Date include those set forth in <U>Exhibit C</U>. The MacroGenics Patents include any Patents Covering MacroGenics Inventions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.87</B> &#147;<B>MacroGenics Platform Patent</B>&#148; means a MacroGenics Patent that is a Platform Patent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.88</B> &#147;<B>MacroGenics Product Patent</B>&#148; means a MacroGenics Patent that is a Product Patent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.89</B> &#147;<B>MacroGenics Technology</B>&#148; means, collectively, the MacroGenics Patents and the MacroGenics Know-How. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.90</B> &#147;<B>MacroGenics Trademarks</B>&#148; means the trademark DART<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, trademarks which
incorporate the acronym &#147;DART&#148;, and related logos. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.91</B> &#147;<B>Major Markets</B>&#148; mean the [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.92</B> &#147;<B>Manufacture</B>&#148; means all activities and processes related to the manufacturing of a Compound or a Product, or any ingredient
thereof, including manufacturing of finished Product for Development and Commercialization, labeling, packaging, in-process and finished Product testing, release of Product or any component or ingredient thereof, including Compound, quality
assurance activities related to manufacturing and release of Compound or Product, and ongoing stability tests and regulatory activities related to any of the foregoing. Where the context so requires, Manufacture shall also include obtaining Product
from contract manufacturers. When used as a verb, to &#147;<B>Manufacture</B>&#148; means to engage in Manufacturing activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.93</B>
&#147;<B>Manufacturing Development</B>&#148; means any of the following with respect to a Compound or Product: [***] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.94
</B>&#147;<B>MGD011</B>&#148; means the compound with the chemical structure and amino acid sequence as set forth on <U>Exhibit D</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.95</B>
&#147;<B>N.A. Profit/Loss</B>&#148; means the profits or losses resulting from the Commercialization of the Initial Product in the Northern American Territory, which shall be equal to [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.96</B> &#147;<B>Net Sales</B>&#148; means, with respect to any Product, the gross amounts invoiced by Company or any of its Affiliates or sublicensees
for sales of such Product to unaffiliated Third Party </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
purchasers in arms-length transactions, less the following deductions calculated in accordance with GAAP and standard internal policies and procedures and accounting standards consistently
applied throughout Johnson&nbsp;&amp; Johnson, to the extent reasonable and customary, and specifically and solely allocated to such Product, whether fixed or variable, and actually taken, paid, accrued, allowed, included, or allocated based on good
faith estimates in the gross sales prices with respect to such sales (and consistently applied as set forth below): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(a)</B></TD>
<TD ALIGN="left" VALIGN="top">normal and customary cash, trade or quantity discounts, allowances, and credits allowed, in the form of deductions or fees actually allowed with respect to sales of such Product (to the extent not already reflected in
the amount invoiced), excluding commissions for Commercialization of such Product; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(b)</B></TD>
<TD ALIGN="left" VALIGN="top">charge-back payments, rebates, administrative fees, and discounts (or equivalents thereof) payable to trade customers, managed health care organizations, pharmacy benefit managers (or equivalents thereof), group
purchasing organizations, specialty pharmacy providers, federal, state/provincial, local, or other governments, or their agencies or purchasers or reimbursers; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(c)</B></TD>
<TD ALIGN="left" VALIGN="top">retroactive price reductions or credits actually granted upon rejections or returns of such Product, where such adjustments are limited to recalls or damaged goods, billing errors, reserves for returns, and the actual
amount of any write-offs for bad debt; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(d)</B></TD>
<TD ALIGN="left" VALIGN="top">outbound freight, shipment and insurance costs, to the extent included in the price and separately itemized on the invoice price; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(e)</B></TD>
<TD ALIGN="left" VALIGN="top"><B></B>taxes (other than income taxes assessed against the income arising from the sale of such Product), duties, tariffs, mandated contribution or other governmental charges imposed on the sale of such Product,
including customs duties, VAT (but only to the extent that such VAT are not reimbursable or refundable), excise taxes, use taxes and sales taxes, in each case to the extent included in the price and separately itemized on the invoice price;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(f)</B></TD>
<TD ALIGN="left" VALIGN="top"><B></B>compulsory payments and cash rebates related to sales of such Product payable to a Governmental Authority (or agent thereof) pursuant to Applicable Law by reason of any national or local health insurance program
or similar program, including government-levied fees resulting from healthcare reform policies and annual fees paid pursuant to the Patient Protection and Affordable Care Act (&#147;<B>ACA</B>&#148;), <U>provided</U> that such ACA annual fees shall
be reasonably allocable to the Product; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(g)</B></TD>
<TD ALIGN="left" VALIGN="top"><B></B>amounts payable to patients through co-pay assistance cards or similar forms of rebate directly related to the prescribing of such Product. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All of the aforementioned deductions shall be determined, on a country-by-country basis, as </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
incurred in the ordinary course of business in type and amount consistent with Company&#146;s or its applicable Affiliate&#146;s or sublicensee&#146;s (as the case may be) business practices
consistently applied across its product lines and accounting standards and verifiable based on the Johnson&nbsp;&amp; Johnson sales reporting system. All such deductions shall be fairly and equitably allocated to such Product and other products of
Company and its Affiliates and sublicensees, such that such Product does not bear a disproportionate portion of such deductions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding the
foregoing, amounts invoiced by Company, its Affiliates, or its sublicensees for the sale of a Product among Company, its Affiliates or its sublicensees for resale shall not be included in the computation of Net Sales hereunder unless such Affiliate
or such sublicensee is the end user of such Product and as long as such Product is subsequently resold to a Third Party end user. In addition, the following shall not be included in the computation of Net Sales: (i)&nbsp;transfer or dispositions of
reasonable quantities of samples of a Product at no cost for promotional or educational purposes, (ii)&nbsp;transfers or dispositions of reasonable and customary quantities of a Product as free samples or donations, or for patient assistance,
testing marketing programs or other similar programs at no cost, and (iii)&nbsp;sales of a Product for clinical study or other scientific testing purposes, early access programs (such as to provide patients with such Product prior to Regulatory
Approval pursuant to treatment INDs or protocols, named patient programs or compassionate use programs) or any similar use. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With respect to sales of any
Combination Product in a country, the Parties shall determine Net Sales for such Combination Product in such country by mutual agreement based on the relative contribution of the Product and the other active ingredient(s) in the Combination Product.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With respect to any Product that is sold in combination with services from Company or the selling Affiliate or sublicensee, where the customer receives a
specific discount for the bundling of products or services, the Net Sales of such Combination Product or Product shall be determined by the mutual agreement of the Parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.97</B> &#147;<B>Northern American Territory</B>&#148; shall mean the U.S. and Canada, including in each case the territories and possessions of such
country. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.98</B> &#147;<B>Patents</B>&#148; means all: (a)&nbsp;patents, including any utility or design patent; (b)&nbsp;patent applications,
including provisionals, substitutions, divisionals, continuations, continuations in-part or renewals; (c)&nbsp;patents of addition, restorations, extensions, supplementary protection certificates, registration or confirmation patents, patents
resulting from post-grant proceedings, re-issues and re-examinations; (d)&nbsp;other patents or patent applications claiming priority directly or indirectly to (i)&nbsp;any such specified patent or patent application specified in (a)&nbsp;through
(c), or (ii)&nbsp;any patent or patent application from which a patent or patent application specified in (a)&nbsp;through (c)&nbsp;claim direct or indirect priority; (e)&nbsp;inventor&#146;s certificates; and (f)&nbsp;other rights issued from a
Governmental Authority similar to any of the foregoing; in each case of (a)&nbsp;through (f), irrespective of whether such patent, patent application or other right arises in the U.S. or any other jurisdiction in the Territory. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.99</B> &#147;<B>Person</B>&#148; means an individual, sole proprietorship, partnership, limited partnership,
limited liability partnership, corporation, limited liability company, business trust, joint stock company, trust, incorporated association, joint venture or similar entity or organization, including a government or political subdivision, department
or agency of a government. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.100</B> &#147;<B>Phase 1 Trial</B>&#148; means a clinical trial of the Product that (a)&nbsp;(i)&nbsp;is a
first-in-humans trial on subjects who are patients, (ii)&nbsp;is for the purposes of establishing initial safety, tolerability, pharmacokinetic and pharmacodynamic Information for the Product, (iii)&nbsp;exposes subjects to the Product and
(iv)&nbsp;is designed to provide the sponsor of the clinical trial with sufficient Information about the Product to initiate a Phase 2 Trial; or (b)&nbsp;meets the definition in 21 C.F.R. &#167;312.21(a) or any of its foreign equivalents. Solely for
purposes of determining which activities are &#147;Global Development Activities&#148; that are included in &#147;Global Development Costs&#148; shared pursuant to Section&nbsp;8.2 during the Co-Funding Term, any Phase 1/2 Trial included in the
Global Development Plan shall be treated as a [***]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.101</B> &#147;<B>Phase 1/2 Trial</B>&#148; means a clinical trial of the Product that combines
both a Phase 1 Trial and a Phase 2 Trial of such Product into a single protocol, where the Phase 1 Trial portion is performed first to (i)&nbsp;to establish initial safety, tolerability, pharmacokinetic and pharmacodynamic Information for the
Product as a monotherapy or in combination with another agent or (ii)&nbsp;determine the Maximum Tolerable Dose (&#147;<B>MTD</B>&#148;) of such Product in subjects, and the Phase 2 Trial portion is performed second to further evaluate safety and/or
efficacy of such Product as a monotherapy or in combination with another agent in subjects treated with a selected dose. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.102</B> &#147;<B>Phase 2
Trial</B>&#148; means a clinical trial of the Product (a)&nbsp;with the endpoint of evaluating its effectiveness for a particular Indication or Indications, its short term tolerance and safety, as well as its pharmacokinetic and pharmacodynamic
Information in patients with the Indications under study and is not intended to be pivotal to support Regulatory Approval for the Product; or (b)&nbsp;that meets the definition in 21 C.F.R. &#167;312.21(b) or any of its foreign equivalents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.103</B> &#147;<B>Phase 2/3 Trial</B>&#148; means a Phase 2 Trial involving a sufficient number of subjects that, prior to commencement of the trial or at
any other defined point in the trial, satisfies both of the following ((a) and (b)): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(a)</B></TD>
<TD ALIGN="left" VALIGN="top">such trial is designed to (i)&nbsp;establish that the Product is safe and efficacious for its intended use, and (ii)&nbsp;define and determine warnings, precautions, and adverse reactions that are associated with the
Product in the dosage range to be prescribed, which trial is intended to support Regulatory Approval of such Product or a similar clinical study prescribed by the FDA; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(b)</B></TD>
<TD ALIGN="left" VALIGN="top">such trial is or becomes a registration trial sufficient for filing an application for a Regulatory Approval for such Product in the U.S., as evidenced by (i)&nbsp;an agreement with or statement from the FDA on a
Special Protocol Assessment or equivalent, or (ii)&nbsp;other guidance or minutes issued by the FDA, for such registration trial. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.104</B> &#147;<B>Phase 3 Trial</B>&#148; means a clinical trial of the Product (a)&nbsp;on a sufficient
number of patients, which trial (i)&nbsp;is designed to establish that the Product is safe and efficacious for its intended use, (ii)&nbsp;is designed to define warnings, precautions and adverse reactions that are associated with the Product in the
dosage range to be prescribed, and (iii)&nbsp;is pivotal to support Regulatory Approval for the Product; or (b)&nbsp;that meets the definition in 21 C.F.R. &#167;312.21(c) or any of its foreign equivalents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.105</B> &#147;<B>Phase 4 Trial</B>&#148; means a clinical trial of a Product, possibly including pharmacokinetic studies, which trial (a)&nbsp;is not
required to be completed prior to obtaining Regulatory Approval of an Indication; and (b)&nbsp;either (i)&nbsp;is required by the applicable Regulatory Authority as mandatory to be conducted on or after the Regulatory Approval of an Indication, or
(ii)&nbsp;is conducted voluntarily to enhance marketing or scientific knowledge of the Product (e.g., providing additional drug profile, safety data or marketing support Information, or supporting expansion of Product labeling). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.106</B> &#147;<B>Pivotal Trial</B>&#148; means a Phase 2/3 Trial and/or a Phase 3 Trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.107</B> &#147;<B>Platform Claim</B>&#148; means a Patent claim that Covers [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.108</B> &#147;<B>Platform Patent</B>&#148; means a Patent that includes a Platform Claim and no Product Claims. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.109</B> &#147;<B>PMDA</B>&#148; means the Pharmaceuticals and Medical Devices Agency in Japan and any successor agency(ies) or authority having
substantially the same function. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.110</B> [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.111</B> [***] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.112 </B>&#147;<B>Product</B>&#148;
means any pharmaceutical product, including all forms, presentations, strengths, doses and formulations (including any method of delivery), containing a Compound alone or in combination with other active pharmaceutical ingredients (other than any
active pharmaceutical ingredient that is owned or controlled by MacroGenics or any of its Affiliates that is not a Compound), including any Combination Product. For the sake of clarity, all forms, presentations, doses and formulations of a
pharmaceutical product containing a Compound shall be considered the same Product for purposes of this Agreement, so long as each form, presentation, dose and formulation contains the same Compound and other active pharmaceutical ingredients (and no
other Compounds or other active pharmaceutical ingredients). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.113</B> &#147;<B>Product Claim</B>&#148; means a Patent claim that (a)&nbsp;Covers
[***]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.114</B> &#147;<B>Product Liabilities</B>&#148; means all Losses incurred by Company, its Affiliate or its sublicensee and resulting from or
relating to the use of a Compound and/or a Product in a human (including Clinical Trials and/or Commercialization) in the Territory incurred after the Effective Date. For the avoidance of doubt, Product Liabilities shall include (i)&nbsp;reasonable
attorneys&#146; and experts&#146; fees and costs relating to any claim or potential claim against a Party, its Affiliate, or its </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
sublicensee and all losses, damages, fees and costs associated therewith, and (ii)&nbsp;Losses associated with recalls and/or the voluntary or involuntary withdrawal of the Compound and/or the
Product (except to the extent a Party is obligated to indemnify the other Party pursuant to Section&nbsp;15.1 or 15.2 for such Losses) and (iii)&nbsp;fines, penalties, assessments or other financial sanctions levied by any Governmental Authority
related to such a claim (except to the extent a Party is obligated to indemnify the other Party for such amounts pursuant to Section&nbsp;15.1 or 15.2 because such amounts are Losses to which such other Party becomes subject as a result of a Claim
(or would be Losses if such other Party became subject to such amounts as a result of a Claim)). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.115</B> &#147;<B>Product Patent</B>&#148; means any
Patent that does not include a Platform Claim and includes a Product Claim. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.116</B> &#147;<B>Product Target</B>&#148; means [***]
&#147;<B>CD19</B>&#148; means [***] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.117</B> &#147;<B>Promotional Materials</B>&#148; means all written, printed, graphic, electronic, audio or video
presentations of Information, including journal advertisements, sales visual aids, formulary binders, reprints, direct mail, direct-to-consumer advertising, disease awareness materials, internet postings, broadcast advertisements and sales reminder
aides (for example, note pads, pens and other such items, if appropriate), which, in each case, are permitted under Applicable Law and intended for use or used by or on behalf of a Party, its Affiliates or its sublicensees in connection with the
Commercialization of the Product in the Territory. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.118</B> &#147;<B>Regulatory Approval</B>&#148; means any and all approvals (including
supplements, amendments, pre- and post-approvals), licenses, registrations or authorizations of any national, regional, state or local Regulatory Authority, department, bureau, commission, council or other governmental entity, that is necessary to
market and/or sell a Product in any country or jurisdiction in the Territory for one or more uses, including any pricing and reimbursement approvals that are necessary to conduct a launch of such Product in such country or jurisdiction (even if such
approvals are not legally required to launch such Product in such country or jurisdiction). [***] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.119</B> &#147;<B>Regulatory Approval
Application</B>&#148; means a New Drug Approval Application or Biologics License Application (each, as defined in the FFDCA) in the U.S., or any corresponding application for Regulatory Approval in any country or jurisdiction in the Territory
outside the U.S., including, with respect to the European Union, an MAA filed with the EMA pursuant to the Centralized Approval Procedure or with the applicable Regulatory Authority of a country in Europe with respect to the decentralized procedure,
mutual recognition or any national approval procedure. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.120</B> &#147;<B>Regulatory Authority</B>&#148; means any applicable Governmental Authority
involved in granting Regulatory Approval in a country or jurisdiction in the Territory, including (a)&nbsp;in the U.S., the FDA and any other applicable Governmental Authority having jurisdiction over a Product; (b)&nbsp;in the EU, the EMA or any
other applicable Governmental Authority in the EU having jurisdiction over a Product; (c)&nbsp;in Japan, the PMDA; (d)&nbsp;in China, the CFDA; and (e)&nbsp;in any country or jurisdiction other than the U.S., EU, Japan or China, any applicable
Governmental Authority having jurisdiction over a Product. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.121</B> &#147;<B>Regulatory Documentation</B>&#148; means, with respect to any Compound or Product, all
regulatory filings and supporting documents created, for, submitted to or received from an applicable governmental agency or Regulatory Authority relating to such Compound or Product, and all data contained therein, including all Regulatory
Materials, as well as the contents of any minutes from meetings (whether in person or by audio conference or videoconference) with Regulatory Authorities, registrations and licenses, regulatory drug lists, advertising and promotion documents shared
with Regulatory Authorities, adverse event files, complaint files and Manufacturing records. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.122</B> &#147;<B>Regulatory Exclusivity</B>&#148; means
any exclusive marketing rights or data protection or other exclusivity rights conferred by any Regulatory Authority with respect to a Product in a country or jurisdiction in the Territory, including orphan drug exclusivity, pediatric exclusivity,
rights conferred in the U.S. under the Drug Price Competition and Patent Term Restoration Act (21 U.S.C. &#167;355), as amended (the &#147;<B>Hatch-Waxman Act</B>&#148;), the ACA or in the European Union under Directive 2001/83/EC, as amended, and
Regulation (EC) No.&nbsp;1901/2006, as amended, or rights similar thereto in other countries or regulatory jurisdictions in the Territory, that prevent such Regulatory Authority from granting any regulatory approval under the Biologics Price
Competition and Innovation Act or similar Applicable Law, of a Third Party product that has an amino acid sequence that is the same as or substantially identical to the amino acid sequence of such Product; <U>provided</U>, <U>however</U>, that, in
the event that a Regulatory Authority confers more than one type of exclusivity with respect to a Product in a country or jurisdiction (e.g., the FDA grants both new chemical entity exclusivity and orphan drug exclusivity with respect to such
Product), &#147;Regulatory Exclusivity&#148; will be deemed to apply to such Product in such country so long as any Regulatory Exclusivity granted to such Product prevents such Regulatory Authority from granting any regulatory approval under the
Biologics Price Competition and Innovation Act, or similar Applicable Law, of a Third Party product that has an amino acid sequence that is the same as or substantially identical to the amino acid sequence of such Product. Regulatory Exclusivity
shall not include exclusivity conferred by a Patent right. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.123</B> &#147;<B>Regulatory Materials</B>&#148; means regulatory applications,
submissions, notifications, registrations, Regulatory Approvals or other regulatory submissions, including any written correspondence or meeting minutes, made to, made with, or received from a Regulatory Authority that are necessary or reasonably
desirable in order to research Develop, Manufacture, or Commercialize a Product in a particular country or jurisdiction in the Territory. Regulatory Materials include INDs and Regulatory Approval Applications, and amendments and supplements for any
of the foregoing, and applications for pricing and reimbursement approvals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.124</B> &#147;<B>Royalty Term</B>&#148; means, [***], the time period
beginning with the First Commercial Sale of such Product in such country and continuing until the later of: (a)&nbsp;the expiration of the last Valid Claim Covering the composition of matter or the method of making or using such Product included in
a MacroGenics Patent licensed to Company under the Company License; (b)&nbsp;[***]; or (c)&nbsp;if Regulatory Exclusivity is granted with respect to such Product in such country, the expiration or termination of such Regulatory Exclusivity in such
country. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.125</B> <B>Second Position Detail</B>&#148; means a Detail in which a Product is Detailed in the second
position (<I>i.e.</I>, no more than one other product is presented to or discussed with the applicable healthcare professional before such Product) and the second most predominant portion of time is devoted to the Detailing of such Product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.126</B> &#147;<B>Tax</B>&#148; or &#147;<B>Taxes</B>&#148; means any present or future taxes, levies, imposts, duties, charges, assessments or fees of
any nature (including any interest thereon). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.127</B> &#147;<B>Territory</B>&#148; means any country in the world. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.128</B> &#147;<B>Third Party</B>&#148; means any Person other than (a)&nbsp;Company, (b)&nbsp;MacroGenics or (c)&nbsp;an Affiliate of either of Company
or MacroGenics. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.129</B> &#147;<B>Third Party Expenses</B>&#148; means out-of-pocket expenses incurred by a Party or any of its Affiliates for
services performed by a Third Party on behalf of Company or MacroGenics in the course of such Party&#146;s performance of this Agreement. For clarity, such Third Party Expenses will include the costs of any raw materials and resins used for
Manufacture of clinical trial material. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.130</B> &#147;<B>U.S.</B>&#148; means the United States of America, including its territories and
possessions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.131</B> &#147;<B>U.S. Commercialization Plan</B>&#148; means a plan, prepared by Company pursuant to Section&nbsp;6.1 in the event that
MacroGenics exercises the Co-Promote Option, for the coordination of Detailing activities in the U.S. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.132</B> &#147;<B>Valid Claim</B>&#148;tmeans
(a)&nbsp;a claim of an issued and unexpired Patent, to the extent such claim has not been revoked, held invalid or unenforceable by a patent office, court or other Governmental Authority of competent jurisdiction in a final order, from which no
further appeal can be taken, and which claim has not been disclaimed, denied or admitted to be invalid or unenforceable through reissue, re-examination or disclaimer or otherwise; or (b)&nbsp;a claim within a patent application that has not been
pending for more than [***] from the date of its first priority patent application filing anywhere in the Territory and which claim has not been revoked, cancelled, withdrawn, held invalid or abandoned. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Additional Definitions</U>. Each of the following definitions is set forth in the Section of this Agreement indicated below: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="46%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:34.15pt; font-size:8pt; font-family:Times New Roman"><B>Definition</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:24.85pt; font-size:8pt; font-family:Times New Roman"><B>Section</B></P></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">ACA</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">1.96</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Advertising and Market Research Expenses</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Exhibit A</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Agreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Preamble</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Approval Milestone</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">9.3(b)</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Approval Milestone Payment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">9.3(b)</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Bankruptcy Laws</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">13.7(b)</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Breaching Party</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">13.3(a)</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="46%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:34.15pt; font-size:8pt; font-family:Times New Roman"><B>Definition</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:24.85pt; font-size:8pt; font-family:Times New Roman"><B>Section</B></P></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">CD3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">1.116</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">CD19</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">1.116</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Claim</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">15.1</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Clinical Supply Agreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">7.1</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Co-Funding Approval Milestone</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">9.3(c)</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Co-Funding Approval Milestone Payment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">9.3(c)</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Co-Funding Materials</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">8.2(b)</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Co-Funding Option</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">8.2(a)</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Co-Funding Option Deadline</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">8.2(a)</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Co-Funding Option Exercise Notice</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">8.2(a)</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Co-Funding Opt-Out</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">8.2(e)</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Co-Funding Opt-Out Notice</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">8.2(e)</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Co-Funding Sales Milestone</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">9.3(e)</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Co-Funding Sales Milestone Payment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">9.3(e)</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Commercialization Expenses</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Exhibit A</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Company</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Preamble</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Company Detailing Expenses</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Exhibit A</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Company Indemnitee</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">15.2</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Company License</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">3.1</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Cooperating Party</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">12.5(b)</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Co-Promote Materials</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">8.3(b)</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Co-Promote Option</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">8.3(a)</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Co-Promote Option Exercise Notice</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">8.3(a)</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Co-Promotion Agreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">8.3(c)</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Cost Cap</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">8.2(d)(iii)</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Cost Per PDE</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Exhibit A</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Cost Variances</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Exhibit A</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">14.3</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Cure Period</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">13.3(a)</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Development Milestone</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">9.3(a)</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Development Milestone Payment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">9.3(a)</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Disclosing Party</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">12.1</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dispute(s)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">14.1</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Distribution Expenses</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Exhibit A</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">EAP Expenses</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Exhibit A</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Education Expenses</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Exhibit A</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Execution Date</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Preamble</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="46%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:34.15pt; font-size:8pt; font-family:Times New Roman"><B>Definition</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:24.85pt; font-size:8pt; font-family:Times New Roman"><B>Section</B></P></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">GDC Invoice</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">8.2(d)(ii)</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">GDC Late Payment Notice</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">8.2(d)(ii)</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">GDC Repayment Option</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">8.2(e)(iii)</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Good Faith Dispute</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">10.4</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Hatch-Waxman Act</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">1.122</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">ICH</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">1.65</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Incumbent Board</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">1.13</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Indemnifying Party</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">15.3(a)</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Indemnitee</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">15.3(a)</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Infringement Recovery</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">10.5(d)</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Insolvency Event</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">13.7(a)</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Insolvent Party</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">13.7(b)</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Johnson&nbsp;&amp; Johnson</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">1.78</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Joint Inventions</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">10.1</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Joint Patents</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">10.3(d)</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">JSC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">2.1(a)</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Licensed Patents</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">11.2(b)</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Losses</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">15.1</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">MacroGenics</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Preamble</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">MacroGenics Indemnitee</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">15.1</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Manufacturing Expenses</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Exhibit A</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Manufacturing Process</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">7.1(a)</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Manufacturing Technology Transfer</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">7.1(a)</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Manufacturing Transition Plan</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">7.1(a)</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Marketing Expenses</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Exhibit A</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Marketing Management Expenses</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Exhibit A</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Medical Affairs Expenses</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Exhibit A</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Milestone Events</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">9.3</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Milestone Payments</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">9.3</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">MTD</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">1.101</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Non-Insolvent Party</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">13.7(b)</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Other Costs</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Exhibit A</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Other Costs Not Included in Standard</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Exhibit A</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Party/Parties</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Preamble</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Patent Extension(s)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">10.4</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">PDE</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Exhibit A</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Phase 4 Trial Expenses</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Exhibit A</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Prior CDA</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">1.31</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Protocol</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">14.3(b)(iii)</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">PVA</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">5.3(b)</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="46%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:34.15pt; font-size:8pt; font-family:Times New Roman"><B>Definition</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:24.85pt; font-size:8pt; font-family:Times New Roman"><B>Section</B></P></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Quarterly N.A. Profit/Loss Report</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">9.9(b)</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Recall Expenses</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Exhibit A</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Receiving Party</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">12.1</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Requesting Party</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">12.5(b)</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Reverted Product</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">13.8(a)(iv)</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Sales Milestone</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">9.3(d)</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Sales Milestone Payment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">9.3(d)</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Sales Rep FTE</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Exhibit A</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Sales Rep FTE Rate</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Exhibit A</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Sales Rep PDE Total</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Exhibit A</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Selling Costs</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Exhibit A</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Sole Inventions</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">10.1</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Standard Cost of Goods Manufactured</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Exhibit A</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Term</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">13.1</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Terminated Country</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">13.8</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Terminated Product</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">13.8</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Terminating Party</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">13.3(a)</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Third Party Obligation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">9.10(a)</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Third Party Obligation Expenses</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Exhibit A</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Third Party Patent Challenge</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">10.7(b)</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Transition Plan</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">4.1(b)</TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 2</B> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GOVERNANCE </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.1 <U>Joint Steering
Committee</U></B>. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(a)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Formation and Purpose</B>. The Parties agree to establish and convene a joint steering committee (the &#147;<B>JSC</B>&#148;) within [***] after the Effective Date. The JSC shall consist of representatives from each
Party as further described in Section&nbsp;2.1(d) and operate in accordance with this Section&nbsp;2.1. The purpose of the JSC shall be to provide a forum for the overall coordination, communication and oversight of the Parties&#146; activities
under this Agreement, including the resolution of disputes properly referred to the JSC under this Agreement. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(<B>b)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Responsibilities of the JSC</B>. The JSC&#146;s overall responsibility shall be to: </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> discuss, approve and oversee MacroGenics Development, regulatory and Manufacturing activities with respect to the
Initial Product; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> discuss, approve and oversee the Transition Plan and Manufacturing Transition Plan; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> if MacroGenics exercises the Co-Funding Option in accordance with
Section&nbsp;8.2(a), encourage and facilitate communication and information sharing regarding Global Development Activities and Commercialization of the Initial Product in the Northern American Territory, including review and discussion of
Company&#146;s then-current Global Development Plan, during the Co-Funding Term; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> coordinate the fulfillment of
those rights and obligations arising from MacroGenics&#146; exercise of any of the MacroGenics Options; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(v)</B> decide
matters and resolve disputes referred to the JSC which the JSC has authority to decide or resolve under this Agreement; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(vi)</B> perform other obligations specifically delegated to it under this Agreement. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(c)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>JSC Decisions and Actions</B>. Actions to be taken by the JSC shall be taken only following [***], with each Party having [***]. If the JSC fails to reach unanimous agreement on a matter before it for decision within
[***] from the date that the matter is first presented to the JSC in writing, such matter shall be referred to the Executive Officers for discussion and resolution pursuant to Section&nbsp;14.2. Any resolution of such matter by the Executive
Officers shall be final and binding on the Parties. If the Executive Officers are not able to resolve the matter within the [***] period specified in Section&nbsp;14.2, then [***] with respect to such matter, and [***] on such matter shall be final
and binding on the Parties, subject to the limitations set forth in Section 2.5. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(d)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>JSC Membership</B>. Promptly after the Effective Date, each Party shall designate three (3)&nbsp;such representatives for the JSC. The JSC may elect to vary the number of representatives from time to time,
<U>provided</U> that, unless otherwise agreed by the Parties in writing at the JSC, the JSC shall maintain an equal number of representatives from each Party. Each representative shall have the appropriate level of experience in the subject area of
the JSC, and at least one (1)&nbsp;representative shall have sufficient seniority within the applicable Party&#146;s organization to have the necessary decision-making authority in order for the JSC to fulfill its responsibilities. Either Party may
designate substitutes for its JSC representatives if one (1)&nbsp;or more of such Party&#146;s designated representatives is unable to be present at a meeting. From time to time each Party may replace its JSC representatives by written notice to the
other Party specifying the prior representative(s) and their replacement(s). Each representative shall be bound by confidentiality and non-use obligations at least as restrictive as those set forth in this Agreement. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(e)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE="font-family:Times New Roman; font-size:10pt"><B>JSC Chairperson</B>. The JSC will have a chairperson, to be designated by Company. The chairperson shall be responsible for calling and convening
meetings, but shall have no special authority over the other members of the JSC, </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
and shall have no additional voting rights. The chairperson (or its designate) shall: (i)&nbsp;prepare and circulate an agenda reasonably in advance of each upcoming meeting; and
(ii)&nbsp;prepare and issue minutes of the JSC meeting within thirty (30)&nbsp;days thereafter. Such minutes shall not be finalized until each JSC representative reviews and approves such minutes, <U>provided</U> that any minutes shall be deemed
approved unless a JSC representative objects to the accuracy of such minutes within [***] after the circulation of the minutes. </TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(f)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Meetings</B>. <B> </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(i) </B><B><I>Timing and Frequency</I></B>. No
later than [***] after the Effective Date, the JSC will hold an in-person meeting to establish the JSC&#146;s operating procedures. The JSC shall meet at least once every Calendar Quarter until the later of the Co-Funding Option Deadline or the
final Co-Promote Option Deadline, at which time the JSC shall dissolve; <U>provided</U>, <U>however</U>, that, (A)&nbsp;in the event MacroGenics exercises the Co-Funding Option, the JSC shall meet at least </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">once every Calendar Quarter until the end of the end of the Co-Funding Term, unless otherwise agreed by the Parties, and (B)&nbsp;in the event
that MacroGenics exercises the Co-Promote Option oversight of Co-Promotion activities shall be as specified in the Co-Promotion Agreement. Additional meetings of the JSC may be held with the consent of each Party (such consent not to be unreasonably
withheld, delayed or conditioned), as required under this Agreement or to resolve any matter or dispute referred to the JSC in accordance with this Agreement. In the case of any matter or dispute referred to the JSC, such meeting shall be held
within [***] following referral to the JSC, or as soon as reasonably possible thereafter. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(ii) </B><B><I>Meeting
Procedures</I></B>. Meetings of the JSC shall be effective only if a majority of representatives of each Party are present or participating. Other than the initial meeting, the JSC may meet either (i)&nbsp;in person at either Party&#146;s facilities
or at such locations as the Parties may otherwise agree, at least twice every Calendar Year; or (ii)&nbsp;by audio or video teleconference. Each Party shall be responsible for all of its own expenses incurred in connection with its
representatives&#146; participation in the JSC meeting, including all travel and lodging. All other Third Party expenses incurred by the JSC in furtherance of a JSC meeting, such as expenses associated with off-site meetings, shall be shared equally
by the Parties. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(iii) </B><B><I>Non-Member Participation</I></B>. Additional non-members of the JSC having relevant
experience may from time to time be invited to participate in a JSC meeting, <U>provided</U> that such participants shall have no voting rights or powers. Non-member participants who are not employees of a Party or its Affiliates shall only be
allowed to attend if: (i)&nbsp;the other Party&#146;s representatives have consented to the attendance (such consent not to be unreasonably withheld, delayed or conditioned); and (ii)&nbsp;such non-member participant is subject to confidentiality
and non-use obligations at least as restrictive as those set forth in this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.2 <U>Additional Subcommittees and Working Groups</U></B>. The JSC may establish other subcommittees or
working groups, as needed to further the purposes of this Agreement, including any responsibilities assigned to the JSC under this Agreement; <U>provided</U>, <U>however</U>, that the JSC shall not delegate its dispute resolution authority. In
particular, if MacroGenics exercises the Co-Funding Option, the Parties contemplate establishment of a Joint Development Committee to facilitate communication regarding Global Development Activities during the Co-Funding Term and a Joint Marketing
Committee to facilitate communication and information sharing regarding the Commercialization of the Initial Product in the Northern American Territory. The purpose, scope and procedures of any such subcommittee or working group shall be mutually
agreed in writing by the JSC. Actions to be taken by any subcommittee or working group shall be taken only following unanimous vote, with each Party having one (1)&nbsp;vote. If any subcommittee or working group fails to reach unanimous agreement on
a matter before it for decision relating to the Development or Commercialization of Products for a period in excess of [***] from the date that the matter is first presented to such subcommittee or working group in writing, such matter shall be
referred to the JSC for resolution pursuant to Section (c). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.3 <U>Authority</U></B>. The Parties agree that it shall be conclusively presumed that,
unless otherwise explicitly stated, each voting member of the JSC, or each subcommittee or working group established by the JSC, has the authority and approval of such member&#146;s respective senior management in casting his or her vote. The JSC,
and each subcommittee or working group established by the JSC, shall each have only the powers assigned expressly to the JSC in this ARTICLE 2 and elsewhere in this Agreement, and shall not have any power to amend or modify the Global Development
Plan or the U.S. Commercialization Plan or to amend, modify or waive compliance with this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.4 <U>Alliance Managers</U></B>. Promptly
following the Effective Date, each Party shall designate in writing an Alliance Manager to serve as the primary point of contact for the Parties regarding all collaboration activities contemplated under this Agreement. Each Alliance Manager shall
facilitate communication and coordination of the Parties&#146; activities under this Agreement relating to the Compounds and the Products. The Alliance Managers shall not be a member of the JSC. The Alliance Managers shall be allowed to attend, as a
non-voting observer, meetings of the JSC, as well as any subcommittee or working group established by the JSC of which the Alliance Manager is not a member. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.5 <U>Decision-Making Restrictions</U></B>. Notwithstanding anything to the contrary in this Agreement, to the extent that [***] with respect to any
matter pursuant to Section&nbsp;2.1(c), [***] shall not [***] to: (i)&nbsp;expand [***] or [***], or [***]or [***], under this Agreement; (ii)&nbsp;determine that [***], or [***], under this Agreement; (iii)&nbsp;[***] that is expressly stated to
[***] or [***] or the [***] or [***] and; (iv)&nbsp;resolve any dispute regarding whether a [***] or the [***]. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 3 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LICENSES </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3.1 <U>License to
Company</U></B>. Subject to the terms and conditions of this Agreement, MacroGenics hereby grants to Company an exclusive (even as to MacroGenics), royalty-bearing, non-transferable (except in accordance with Section&nbsp;16.4) license, with the
right to grant sublicenses as provided in Section&nbsp;3.1(a), under the MacroGenics Technology, to Exploit the Compounds and the Products in the Field in the Territory (the &#147;<B>Company License</B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B>Sublicensing</B>. Company shall have the right to grant sublicenses of the rights granted to Company under this Section&nbsp;3.1 to:
(i)&nbsp;its Affiliates through multiple tiers; and (ii)&nbsp;Third Parties through multiple tiers subject to the conditions in this subsection (a)&nbsp;provided below. Any sublicenses to Third Parties [***] that include [***] may only be granted
with MacroGenics&#146; prior consent, not to be unreasonably withheld, conditioned or delayed, unless such sublicense is: (A)&nbsp;in connection with, and only to the extent necessary or useful to enable, a Third Party to perform services for the
Company, its Affiliate or sublicensee in the course of its performance of its Development, Manufacturing and Commercialization rights and obligations under this Agreement; and (B)&nbsp;to one or more Third Party distributors only to the extent
reasonably necessary or useful, to enable such Third Party distributors to Commercialize Products in such countries. Company shall identify each Third Party sublicensee to MacroGenics for which Company has [***]. Each sublicense shall refer to and
be subordinate to this Agreement and, except to the extent the Parties may otherwise agree in writing, any sublicense must be consistent in all material respects with the terms and conditions of this Agreement. Company shall remain responsible for
the performance of this Agreement and the performance of its sublicensees hereunder. Company shall provide to MacroGenics copies of all sublicenses which grant the right to directly [***] to a Third Party in a jurisdiction in the Territory,
<U>provided</U> that Company shall have the right to redact commercially sensitive information from such copies. Information regarding the scope of the license grants, territory and/or term of each such sublicense shall not be considered
commercially sensitive. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(a)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Company Termination of License</B>. Company shall have the right to terminate the Company License with respect to one or more of the MacroGenics Patents included in the Company License, by providing [***] prior
written notice to MacroGenics specifying the MacroGenics Patent(s) to be subject to such termination. Upon the effectiveness of such termination, (i)&nbsp;the Company License will no longer extend to such MacroGenics Patent(s); (ii)&nbsp;such
MacroGenics Patent(s) shall no longer be subject to the provisions of ARTICLE 10, and MacroGenics shall have the sole right to prosecute, maintain, enforce and defend such MacroGenics Patent(s) at MacroGenics&#146; sole expense; and (iii)&nbsp;no
claims of such MacroGenics Patent(s) shall be considered a Valid Claim for purposes of Section&nbsp;9.5 or Section&nbsp;9.6. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3.2 <U>Licenses to MacroGenics</U></B>. Subject to the terms and conditions of this Agreement: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(a)</B></TD>
<TD ALIGN="left" VALIGN="top">Company hereby grants back to MacroGenics a non-exclusive, fully-paid, royalty-free, non-transferable (except in accordance with Section&nbsp;16.4), non-sublicensable sublicense under the Company License for use with
the Compounds and the Products in the Field in the Territory, solely to the extent necessary for MacroGenics to exercise its rights and perform its obligations under this Agreement, including any rights or obligations that arise in the event
MacroGenics elects to exercise any of the MacroGenics Options. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Company hereby grants back to MacroGenics a non-exclusive,
fully-paid, royalty-free, non-transferable (except in accordance with Section&nbsp;16.4), non-sublicensable license under (i)&nbsp;the Company Technology, (ii)&nbsp;any Know-How Controlled by Company, as of the Execution Date or during the Term,
that is incorporated into the embodiment of a Product Developed hereunder, and (iii)&nbsp;any Patent Controlled by Company, as of the Execution Date or during the Term, that Covers technology incorporated into the embodiment of a Product Developed
hereunder, in each case ((i), (ii)&nbsp;and (iii)), for use with the Compounds and the Products in the Field in the Territory, solely to the extent necessary for MacroGenics to exercise its rights and perform its obligations under this Agreement,
including any rights or obligations that arise in the event MacroGenics elects to exercise any of the MacroGenics Options. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(b)</B></TD>
<TD ALIGN="left" VALIGN="top"><B></B>Company hereby grants back to MacroGenics a non-exclusive, fully-paid, royalty-free, non-transferable (except in accordance with Section&nbsp;16.4), non-sublicensable license under the Company License to [***],
<U>provided</U> that MacroGenics shall not [***] without the prior written consent of Company. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(c)</B></TD>
<TD ALIGN="left" VALIGN="top">Company hereby grants to MacroGenics a non-exclusive, fully-paid, royalty-free, non-transferable (except in accordance with Section&nbsp;16.4) license, with the right to sublicense, under any Platform Patent Controlled
by Company by virtue of the use of the MacroGenics Know-How or exercise of the Company License and that claims technology applied to a Product, [***]. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3.3 <U>Trademark License</U></B>. MacroGenics hereby grants Company a non-exclusive license to use the MacroGenics Trademarks in connection with the
Development and Commercialization of the Products, subject to customary and reasonable quality control procedures to be mutually agreed upon by the Parties prior to the launch of any Products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3.4 <U>No Implied Licenses</U></B>. All licenses and rights are granted only as expressly provided in this Agreement and no license or other right is or
shall be created or granted under this Agreement by implication, estoppel, or otherwise. All rights not expressly granted by a Party under this Agreement are reserved by such Party and may not be used by the other Party for any purpose. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 4</B> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DEVELOPMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4.1 <U>Transition of
Development Responsibilities</U></B>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">During the period beginning on the Effective Date and ending on the Development Transition Date,
MacroGenics shall use diligent efforts to perform (i)&nbsp;all Development activities necessary to [***], other than [***], and (ii)&nbsp;any Development activities assigned to MacroGenics in the Transition Plan; <U>provided</U>, <U>however</U>,
that, in the event that MacroGenics does not [***]after the Effective Date, upon Company&#146;s request, the JSC shall discuss and determine whether Company should assume responsibility for the [***]. If the JSC determines that Company should assume
responsibility for the [***], then, promptly following such determination, MacroGenics shall transfer to Company all Information Controlled by MacroGenics that is reasonably necessary for Company [***] and provide reasonable assistance to Company
with respect to the [***]. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(a)</B></TD>
<TD ALIGN="left" VALIGN="top">[***] following the Development Transition Date, MacroGenics shall transfer to Company, and Company shall cooperate in good faith to support MacroGenics&#146; transfer of, all activities and responsibilities related to
the Compounds and the Products in accordance with a transition plan to be approved by the JSC promptly after the Effective Date (the &#147;<B>Transition Plan</B>&#148;). The Transition Plan shall be designed to effect an efficient transfer from
MacroGenics to Company of all Compound and Product-related Development, Manufacturing, regulatory and other related responsibilities and documentation, as well as all Information Controlled by MacroGenics that is reasonably necessary or useful for
Company&#146;s Exploitation of the Compounds and the Products (including copies or tangible embodiments thereof), and may be updated and amended by the JSC as necessary to effect such transfer. The Transition Plan shall include an itemized list of
deliverables and the dates by which such deliverables are expected to be provided by MacroGenics to Company. Any dispute between the Parties regarding the conduct of the activities set forth in the Transition Plan shall be referred to the JSC for
resolution. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(b)</B></TD>
<TD ALIGN="left" VALIGN="top">MacroGenics shall report on the status of any activities conducted pursuant to this Section&nbsp;4.1 at each meeting of the JSC or as otherwise requested by Company. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4.2 <U>Development</U></B>. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(a)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Company Development Activities</B>. Except for Development activities to be undertaken prior to the Development Transition Date by MacroGenics pursuant to Section&nbsp;4.1, Company shall be solely responsible for and
have sole authority with respect to, at its own expense (subject to MacroGenics&#146; exercise of the Co-Funding Option), all Development of the Compounds and the Products. Company shall use Commercially Reasonable Efforts to Develop, and to seek
Regulatory Approval for, [***]. In addition, Company shall use Commercially Reasonable Efforts to [***]. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(b)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Global Development Plan</B>. Except with respect to [***]as specified below, Company shall use Commercially Reasonable Efforts to conduct the Development of the Products for the Territory in accordance with the
Global Development Plan, at its own expense (subject to MacroGenics&#146; sharing of expenses upon its exercise of the Co-Funding Option). Company shall have the right to make amendments to the Global Development Plan, which shall be consistent with
Company&#146;s Development obligations set forth in Section&nbsp;4.2(a), and each amended Global Development Plan shall include all material Development activities anticipated to be required to obtain Regulatory Approval for Products in [***], as
well as timelines regarding such activities, including the plans and timelines for preparing the necessary Regulatory Materials. The Global Development Plan shall include any Development activities with respect to [***] that Company elects to
conduct, <U>provided</U> that Company shall have no obligation to conduct Development or to seek Regulatory Approval for Products in [***]. Beginning with the delivery of the Co-Funding Materials and continuing through the Co-Funding Option Deadline
(if MacroGenics does not exercise the Co-Funding Option) and the Co-Funding Termination Date (if MacroGenics exercises the Co-Funding Option), Company shall update the Global Development Plan to include a then-current, non-binding budget for any
Global Development Costs. During the Co-Funding Term, Company shall update and amend, as appropriate, the then-current Global Development Plan and shall submit such updates and/or amendments for review to the JSC. While the Global Development Plan
shall not require the approval of the JSC, Company shall review and consider all comments to the Global Development Plan received from MacroGenics at the JSC in good faith. Company will consider including, in the Global Development Plan, Clinical
Trials using the Initial Product [***], to the extent that Company reasonably determines that such Clinical Trials are feasible from a medical, scientific, regulatory and commercial perspective. The Parties acknowledge and agree that Company&#146;s
ability to conduct such Clinical Trials may be subject to [***] and that Company shall have no obligation to conduct such Clinical Trials unless the conduct of such Clinical Trials is [***]. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(c)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE="font-family:Times New Roman; font-size:10pt"><B>MacroGenics Development</B>. In the event that MacroGenics, at any time during the Co-Funding Term, wishes to conduct a Clinical Trial of the
Initial Product that is consistent with, but not currently included in, the Global Development Plan, it shall submit a written proposal for the conduct of such Clinical Trial to the JSC for approval, together with a draft protocol, clinical plan and
budget. The JSC shall consider such proposal in good faith. If the JSC approves such proposal, then: (i)&nbsp;such Clinical Trial shall be deemed to be a Global Development Activity and shall become part of the Global Development Plan; (ii)&nbsp;the
costs associated with such </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Clinical Trial shall be Global Development Costs and shared in accordance with Section&nbsp;8.2; (iii)&nbsp;upon Company&#146;s request, the Parties shall enter into a clinical trial agreement
governing the conduct of such Clinical Trial, which agreement shall account for necessary regulatory and other considerations and shall be consistent with the terms of this Agreement; (iv)&nbsp;MacroGenics&#146; agreement with the sites at which
such Clinical Trial is conducted shall be consistent with Company&#146;s form of clinical trial site agreement and with the terms of this Agreement; (v)&nbsp;the Parties shall amend the PVA as necessary to provide for the sharing of information and
data relating to such Clinical Trial; and (vi)&nbsp;MacroGenics shall use Commercially Reasonable Efforts to conduct such Clinical Trial in accordance with the Global Development Plan. If the JSC does not approve such proposal, the JSC shall inform
MacroGenics as to the reasons for such determination and, if the JSC has any specific suggestions for revisions to the protocol that may address the reasons underlying such JSC determination, such suggestions and MacroGenics may submit a revised
proposal to JSC. MacroGenics shall not conduct any Clinical Trial of the Initial Product without the express approval thereof by the JSC. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(d)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Clinical Trial Registries</B>. For all Clinical Trials in the Field in the Territory, Company shall be responsible, in accordance with Applicable Law, for registering in the appropriate clinical trial registry and
posting the results of such Clinical Trials. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4.3 <U>Decision-Making</U></B>. Company shall have sole authority with respect to the
Development of the Compounds and the Products in the Field in the Territory in accordance with this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4.4 <U>Compliance with Law</U></B>.
Each Party shall conduct all Development activities related to Compound and Products in all material respects in a good scientific manner and in compliance in all material respects with all Applicable Law, including applicable national and
international (<I>e.g.</I>, ICH, GCP, GLP, and GMP) guidelines. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4.5 <U>Records</U></B>. Company shall prepare and maintain, or shall cause to be
prepared and maintained, complete and accurate written records, accounts, notes, reports and data with respect to Development activities conducted pursuant to this Agreement (including the Global Development Plan) in conformity with Applicable Law
and Company&#146;s standard practices, <U>provided</U> that in no case shall such records be maintained for [***] following the Calendar Year to which such records pertain (or any longer period required by Applicable Law). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4.6 <U>Cooperation</U></B>. Upon reasonable advance notice, at the request of the JSC, each Party agrees to make its employees and consultants reasonably
available at their respective places of employment to consult with the other Party on issues arising in connection with the Global Development Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4.7</B> <B><U>Progress Reports</U></B>. No later than [***] and [***], Company shall provide to MacroGenics in
writing (or, if the JSC has not yet been dissolved pursuant to Section&nbsp;2.1(f)(i), to the JSC verbally) a report detailing Company&#146;s efforts and progress during the [***] to such date, as applicable, to Exploit each Compound and Product.
Each such report shall describe, among other matters: (a)&nbsp;material Development activities completed since the last report, including the object and parameters of the Development, when initiated, when completed and a summary of all material
results; (b)&nbsp;material Development activities planned to be undertaken before the next report, including the type and object of any Clinical Trials to be conducted and their projected starting and completion dates; and (c)&nbsp;material changes
in Company&#146;s Development and Commercialization plans. In addition, Company shall reasonably respond to reasonable requests by MacroGenics for information regarding Company&#146;s </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Development and Commercialization activities for such Compounds and Products, to the extent such information is necessary to assess Company&#146;s compliance
with its obligations hereunder. In addition, if MacroGenics does not exercise the Co-Funding Option or MacroGenics exercises the Co-Funding Opt-Out in accordance with Section&nbsp;8.2(e), at the request of MacroGenics, the Parties shall meet to
discuss Development and Commercialization progress at either Party&#146;s facilities (or such other location as may be agreed upon by the Parties) on a semi-annual basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4.8 <U>Subcontracting</U></B>. Company may subcontract the performance of any Development activities conducted in accordance with this Agreement to any of
its Affiliates or any Third Party, <U>provided</U> that Company shall oversee the performance of any subcontracted activities in a manner that would be reasonably expected to result in their successful and timely completion and shall remain
responsible for the performance of such subcontracted activities in accordance with this Agreement. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 5</B> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>REGULATORY RESPONSIBILITIES </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5.1
<U>Initial Data Transfer</U></B>.<B></B> </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(a)</B></TD>
<TD ALIGN="left" VALIGN="top">Within [***] after the Development Transition Date, MacroGenics shall deliver to Company electronic copies (unless otherwise required by Applicable Law) of all Regulatory Materials relating to the Products in the Field
in the Territory which are Controlled by MacroGenics. Upon the completion of such transfer, MacroGenics shall, and hereby does, assign to Company all such Regulatory Materials and shall promptly (and in any case within [***] take all steps
reasonably necessary to effectuate the assignment of all INDs, Regulatory Approval Applications and Regulatory Approvals included in such Regulatory Materials, including submitting to any applicable Regulatory Authority a letter or other necessary
documentation (with copy to Company) notifying the Regulatory Authority of the assignment. In the event that any such IND, Regulatory Approval Application or Regulatory Approval cannot be transferred within such [***] period, MacroGenics shall take
all actions reasonably requested by Company with respect to the maintenance or transfer of such IND, Regulatory Approval Application or Regulatory Approval. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(b)</B></TD>
<TD ALIGN="left" VALIGN="top">Within [***] after the Development Transition Date, MacroGenics shall make available to Company separate electronic copies of all remaining Regulatory Documentation, including the study reports from all non-clinical
trials and clinical trials, in each case, whether completed prior to the Development Transition Date or then in-progress, that are Controlled by MacroGenics (to the extent not previously provided to Company). </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(c)</B></TD>
<TD ALIGN="left" VALIGN="top">Notwithstanding Section&nbsp;5.1(a) and Section&nbsp;5.1(b), from time to time after the Development Transition Date, to the extent not done so already, MacroGenics shall, and shall cause its Affiliates to, without
additional compensation, disclose and make available to Company, in whatever form Company may reasonably request, as soon as reasonably practicable after the earlier of the development, making, conception or reduction to practice, all Regulatory
Documentation and other Information Controlled by MacroGenics, which in each case is reasonably necessary or useful for Company&#146;s Exploitation of the Compounds and the Products, including copies or tangible embodiments thereof. For clarity,
MacroGenics will have the right, unless otherwise required by Applicable Law, to retain original copies of the foregoing subject to ARTICLE 12. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5.2 <U>Preparation of Regulatory Materials</U></B>.<B></B> </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(a)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>By MacroGenics</B>. During the period beginning on the Effective Date and ending on the Development Transition Date, [***], in consultation with [***], shall (i)&nbsp;[***]as soon as possible after the Effective
Date, <U>provided</U> that Company shall [***] and provide a [***], and (ii)&nbsp;take all actions necessary to maintain all Regulatory Materials relating to the Products in the Field in the Territory which are Controlled by MacroGenics.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(b)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>By Company</B>. Except for the activities to be undertaken prior to the Development Transition Date by MacroGenics pursuant to Section&nbsp;5.2(a), Company shall, with respect to the Products in the Field in the
Territory, have the sole right and sole authority, at its own expense (subject to MacroGenics&#146; exercise of the Co-Funding Option), to: (i)&nbsp;develop and implement the overall regulatory strategy with respect to obtaining Regulatory Approval
of Products in the Field in the Territory; (ii)&nbsp;prepare, obtain, and maintain all Regulatory Documentation, including all INDs, Regulatory Approval Applications and Regulatory Approvals; and (iii)&nbsp;conduct communications with the relevant
Regulatory Authorities. The regulatory strategy for the Territory shall be consistent with the Global Development Plan and the terms of this Agreement. All Regulatory Materials (including all Regulatory Approvals) generated with respect to the
Products under this Agreement shall be owned by, and shall be the sole property and held in the name of, Company or its designee. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(c</B><B>)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>MacroGenics Assistance</B>. MacroGenics shall assist Company as reasonably requested in connection with the preparation and filing of Regulatory Documentation for the Territory, at MacroGenics&#146; sole expense;
<U>provided</U>, <U>however</U>, that Company shall reimburse MacroGenics for FTE Costs and Third Party Expenses incurred by MacroGenics in providing any such assistance later than six (6)&nbsp;months after the Effective Date. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5.3 <U>Adverse Event Reporting and Safety Data Exchange</U></B>. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(a)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Company Responsibilities</B>. Upon the transfer of ownership of the INDs, Regulatory Approval Applications and Regulatory Approvals in accordance with Section&nbsp;5.1(a), Company will assume responsibility for the
monitoring of all clinical experiences, maintaining the global safety database, safety monitoring, pharmacovigilance surveillance, compliance and filing of all required safety reports to all Regulatory Authorities in the Territory with respect to
Compounds and Products, including annual safety reports, throughout the Development and Commercialization of each Compound and Product. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(b)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Safety Information Exchange; Pharmacovigilance Agreement</B>. In the event MacroGenics exercises the Co-Promote Option, the Parties shall cooperate to develop methods and/or procedures for sharing Information
relating to the clinical experiences referred to in Section&nbsp;5.3(a) with respect to the Initial Product in accordance with safety reporting requirements of the respective Governmental Authorities and as necessary to comply with Applicable Law.
Specific details regarding the management of safety Information, including adverse events reports, related to the Development and the Commercialization of the Initial Product in the Territory, will be delineated in a separate global
pharmacovigilance agreement (the &#147;<B>PVA</B>&#148;). The Parties shall meet to discuss the PVA within [***] after MacroGenics exercises the Co-Promote Option and shall agree upon the terms of the PVA as soon as practicable, but in any event no
later than the anticipated date of the First Commercial Sale of any Product in the U.S.; <U>provided</U>, <U>however</U>, that, in the event the Parties do not reach agreement on all terms of the PVA prior to the First Commercial Sale of any Product
in the U.S., then the Parties shall enter into an interim PVA prior to the First Commercial Sale of any Product in the U.S. and shall agree upon the terms of the final PVA as soon as practicable thereafter. In the event of any conflicts or
inconsistencies between the PVA and this Agreement, the terms of the PVA shall take precedence for matters relating to pharmacovigilance. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5.4</B> <U><B>Recalls and Voluntary Withdrawals</B></U>. Company shall use reasonable efforts to notify MacroGenics promptly, but in no event later than
[***], following its determination that any event, incident, or circumstance related to safety issues or regulatory concerns has occurred that is reasonably likely to result in the need for a recall, market suspension or market withdrawal of a
Product in the Territory, and shall include in such notice the reasoning behind such determination </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and any supporting facts. Company shall have the sole right to make the final determination of whether to voluntarily implement any such recall, market suspension or market withdrawal in the
Territory, <U>provided</U> that, prior to the implementation of such a recall, market suspension or market withdrawal, Company shall, to the extent practical, consult with MacroGenics and shall consider MacroGenics&#146; comments in good faith. For
all recalls, market suspensions or market withdrawals undertaken pursuant to this Section&nbsp;5.4, Company shall be solely responsible for the execution thereof and MacroGenics shall reasonably cooperate in all such recall efforts. Subject to
ARTICLE 15, Company shall be responsible for all costs of conducting any such recall, market suspension, or market withdrawal. For the sake of clarity, during the Co-Funding Term certain [***] associated with recalls and market withdrawals [***] in
accordance with Section&nbsp;9.9. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5.5 <U>Subcontracting</U></B>. Company may subcontract the performance of any activities conducted in accordance
with this ARTICLE 5 to any of its Affiliates or any Third Party, <U>provided</U> that Company shall oversee the performance of any subcontracted activities in a manner that would be reasonably expected to result in their successful and timely
completion and shall remain responsible for the performance of such subcontracted activities in accordance with this Agreement. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE
6</B> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COMMERCIALIZATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6.1
<U>Commercialization Activities</U></B>. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(a)</B></TD>
<TD ALIGN="left" VALIGN="top"><B></B><B>Company Commercialization Activities</B>. Subject to MacroGenics&#146; exercise of the Co-Promote Option, Company shall be solely responsible for and have sole authority with respect to, at its own expense
(subject to MacroGenics&#146; sharing of expenses upon its exercise of the Co-Funding Option), all aspects of the Commercialization of the Product in the Field in the Territory, including: (i)&nbsp;developing and executing a commercial launch and
pre-launch plan; (ii)&nbsp;marketing and promotion (including Detailing); (iii)&nbsp;booking sales and distribution and performance of related services; (iv)&nbsp;handling all aspects of order processing, invoicing and collection, inventory and
receivables; (v)&nbsp;publications; (vi)&nbsp;providing customer support, including handling medical queries, and performing other related functions; (vii)&nbsp;the review and approval of all Promotional Materials for compliance with Applicable Law,
including submission, where appropriate, to the applicable Regulatory Authority and (viii)&nbsp;conforming its practices and procedures in all material respects to Applicable Law relating to the marketing, detailing and promotion of the Products in
the Field in the Territory. Company shall use Commercially Reasonable Efforts to Commercialize Products for which Regulatory Approval is received in the Territory. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(b)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Ordering</B>. MacroGenics shall not accept orders for the purchase of a Product from Third Parties, or make sales of Product to Third Parties in the Field in the Territory for its own account or for Company&#146;s
account. If MacroGenics receives any order for a Product in the Field in the Territory, it shall refer such orders to Company for acceptance or rejection. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(c)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>U.S. Commercialization Plan</B>. In the event MacroGenics exercises the Co-Promote Option in accordance with Section&nbsp;8.3(a), Company shall submit the initial U.S. Commercialization Plan to the JSC, or such
subcommittee designated by the JSC, at [***] for review by the JSC or such subcommittee. Thereafter, Company shall submit an updated U.S. Commercialization Plan to the JSC, or such subcommittee designated by the JSC, at least once each Calendar Year
until the termination or expiration of the Co-Promotion Agreement for review by the JSC or such subcommittee. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6.2 <U>Trademarks</U></B>.
Company shall have sole responsibility, at its own expense, for all matters relating to the use of, and shall own, all trademarks used in the sale of Products in the Field in the Territory (but excluding the MacroGenics Trademarks and any trademark
that is confusingly similar to a MacroGenics Trademark), including the selection, filing, prosecution, maintenance, defense and enforcement thereof. Notwithstanding the foregoing, in the event MacroGenics exercises the Co-Funding Option, costs
related to Product trademarks in the Northern American Territory shall be treated as a Commercialization Expense. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6.3 <U>Decision-Making</U></B>.
Except with respect to a MacroGenics decision to exercise the Co-Promote Option as set forth in Section&nbsp;8.3(a) and MacroGenics&#146; right to conduct [***] upon any such exercise, after the Effective Date, Company shall have sole authority with
respect to all aspects of Commercialization of Products in the Field in the Territory in accordance with this Agreement, including all decisions regarding pricing, discounts and the terms of sale. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6.4 <U>Transparency Reporting</U></B>. Company and, in the event it exercises either or both the Co-Funding Option or Co-Promote Option, MacroGenics, shall
each be responsible for tracking and reporting transfers of value initiated and controlled by its and its Affiliates&#146; employees, contractors, and agents pursuant to the requirements of the marketing reporting laws or research expense reporting
laws of any Governmental Authority in the Territory, including Section&nbsp;6002 of ACA, commonly referred to as the &#147;Sunshine Act.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6.5
<U>Compliance with Law</U></B>. Company and, if MacroGenics exercises the Co-Promote Option, MacroGenics, shall conduct all Commercialization activities related to Compound and Products in compliance in all material respects with all Applicable Law.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6.6 <U>Subcontracting</U></B>. Company may subcontract the performance of any Commercialization activities conducted in accordance with this Agreement
to any of its Affiliates or any Third Party, <U>provided</U> that Company shall oversee the performance of any subcontracted activities in a manner that would be reasonably expected to result in their successful and timely completion and shall
remain responsible for the performance of such subcontracted activities in accordance with this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 7</B> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MANUFACTURING </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7.1</B> <B><U>General
Supply Terms</U></B>. After the Effective Date, except as provided below, Company shall have sole responsibility for and sole authority with respect to, at its own expense (subject to MacroGenics&#146; exercise of the Co-Funding Option),
Manufacturing clinical and commercial supplies of the Compounds and the Products for use in the Field in the Territory. Upon Company&#146;s request, (a)&nbsp;MacroGenics shall transfer to Company, at no cost, all nucleotide molecules, cell lines and
protein material of Compounds, and all Products in finished form or in process on the Effective Date, in MacroGenics&#146; inventory on the Effective Date, <U>provided</U> that MacroGenics may retain reasonable quantities of such materials for [***]
of such inventory; and (b)&nbsp;MacroGenics shall use Commercially Reasonable Efforts to Manufacture, at MacroGenics&#146; facility, and supply to Company (i)&nbsp;[***]; (ii)&nbsp;[***]; and (iii)&nbsp;based on a timeline reasonably acceptable to
MacroGenics, in its sole discretion, clinical supplies of Compound for use in other [***], in each case ((i), (ii)&nbsp;and (iii)), at a cost equal to [***] incurred by MacroGenics in connection with such Manufacture [***] with respect to new
clinical supplies Manufactured after the Execution Date for [***]). A non-binding estimate of such costs are set forth on <U>Schedule 7.1</U>. MacroGenics shall not be obligated to [***] in fulfilling any such Company request pursuant to clause
(b)&nbsp;of this Section&nbsp;7.1, unless otherwise agreed by the Parties. MacroGenics shall continue to conduct and complete [***] that are being conducted as of the Execution Date with respect to [***] through the [***] of the Execution Date, and
Company shall reimburse MacroGenics for any reasonable Third Party Expenses and Development FTE Costs incurred by MacroGenics after the Execution Date in conducting such [***]. Promptly after the Effective Date, the Parties shall enter into good
faith negotiations to conclude a clinical supply agreement (the &#147;<B>Clinical Supply Agreement</B>&#148;) and a related quality agreement within [***] after the Execution Date, which Clinical Supply Agreement shall include specifications and
procedures for delivery and acceptance of Products. Such quality agreement will reflect the findings of any supply qualification audits conducted by Company of MacroGenics and any critical sub-suppliers. Company shall not have the right to [***] to
be negotiated under the Clinical Supply Agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7.2 <U>Transition of Manufacturing Responsibilities</U></B>. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(a)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE="font-family:Times New Roman; font-size:10pt">Subject to the JSC&#146;s approval of a Manufacturing transition plan (the &#147;<B>Manufacturing Transition Plan</B>&#148;), MacroGenics shall effect
a transfer to Company or its designee (which designee may be an Affiliate or a Third Party manufacturer, and which Third Party manufacturer may be a backup manufacturer or a second manufacturer of a Compound or a Product) of all MacroGenics Know-How
and rights under Third Party agreements relating to the then-current process for the Manufacture of Compound and Product (the &#147;<B>Manufacturing Process</B>&#148;) and to facilitate implementation of the Manufacturing Process at facilities
designated by Company (such transfer and implementation, as more fully described in this Section&nbsp;7.1(a), the &#147;<B>Manufacturing Technology Transfer</B>&#148;). MacroGenics shall provide all reasonable assistance requested by Company to
enable Company (or its Affiliate or designated Third Party manufacturer, as applicable) to implement the Manufacturing Process at the facilities designated by </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Company. Company shall reimburse MacroGenics&#146; personnel costs at the Development FTE Rate and reimburse Third Party Expenses incurred by MacroGenics in providing any such assistance.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(b)</B></TD>
<TD ALIGN="left" VALIGN="top">Without limitation to the foregoing, in connection with the Manufacturing Technology Transfer, MacroGenics shall cause all appropriate employees and representatives of MacroGenics and its Affiliates to meet with
employees or representatives of Company (or its Affiliate or designated Third Party manufacturer, as applicable) at the applicable manufacturing facility at mutually convenient times to assist with the working up and use of the Manufacturing Process
and with the training of the personnel of Company (or its Affiliate or designated Third Party manufacturer, as applicable) to the extent reasonably necessary or useful to enable Company (or its Affiliate or designated Third Party manufacturer, as
applicable) to use and practice the Manufacturing Process. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7.3 <U>Decision Making</U></B>. Company shall have sole authority with
respect to the all aspects of Manufacturing of Compound and Product in the Field in the Territory, including CMC development. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7.4 <U>Compliance with
Law</U></B>. Each Party shall conduct all Manufacturing activities related to Compound and Products in compliance in all material respects with all Applicable Law, including applicable national and international (<I>e.g.</I>, ICH, GCP, GLP, and GMP)
guidelines. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7.5 <U>Subcontracting</U></B>. Company may subcontract the performance of any Manufacturing activities conducted in accordance with this
Agreement to any of its Affiliates or any Third Party, <U>provided</U> that Company shall oversee the performance of any subcontracted activities in a manner that would be reasonably expected to result in their successful and timely completion and
shall remain responsible for the performance of such subcontracted activities in accordance with this Agreement. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 8 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS OPTIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8.1
<U>Generally</U></B>. Subject to the terms of this Agreement, MacroGenics may, at its discretion, exercise the Co-Promote Option and the Co-Funding Option. MacroGenics&#146; exercise(s) of the Co-Promote Option and the Co-Funding Option are separate
and independent of each other, such that MacroGenics may exercise: only the Co-Promote Option; only the Co-Funding Option; both the Co-Promote Option and the Co-Funding Option; or neither. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8.2 <U>Co-Funding Option</U></B>. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(a)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE="font-family:Times New Roman; font-size:10pt"><B>Option Grant and Exercise</B>. Company hereby grants MacroGenics an option to fund [***] of the Global Development Costs and share [***]of the N.A.
Profit/Loss (in lieu of royalties on Net Sales of the Initial Product in the Northern American </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Territory), as further described in this Section&nbsp;8.2 (the &#147;<B>Co-Funding Option</B>&#148;). MacroGenics may, at its discretion, exercise the Co-Funding Option by delivering written
notice thereof to Company (the <B>&#147;</B><B>Co-Funding Option Exercise Notice</B>&#148;) at any time before the date that is [***] (the &#147;<B>Co-Funding Option Deadline</B>&#148;). Company shall promptly provide written notice to MacroGenics
of the occurrence of [***]. The Co-Funding Option shall be deemed to be exercised on the date that Company receives the Co-Funding Option Exercise Notice. If the Co-Funding Option Deadline passes without Company receiving a Co-Funding Option
Exercise Notice, the Co-Funding Option shall immediately and permanently expire on the day after the Co-Funding Option Deadline. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(b)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Co-Funding Materials</B>. No later than [***], Company shall deliver to MacroGenics: (i)&nbsp;a projected timeline for the Global Development Activities; (ii)&nbsp;a summary of [***]; (iii)&nbsp;a then-current, [***]
that are included in the Global Development Plan, which [***] of the Global Development Activities and an annual basis thereafter; (iv)&nbsp;a then-current, non-binding [***], which shall be on an [***], and (v)&nbsp;a then-current, [***] (the
&#147;<B>Co-Funding Materials</B>&#148;). After delivery of the Co-Funding Materials, but prior to the Co-Funding Option Deadline, upon MacroGenics&#146; reasonable request and with reasonable notice, Company shall promptly make available to
MacroGenics (i)&nbsp;during normal business hours its employees and consultants who performed the activities on behalf of Company in preparation of the Co-Funding Materials to answer MacroGenics&#146; questions about the Co-Funding Materials; and
(ii)&nbsp;any additional Information in Company&#146;s possession relating to the Initial Product that may be reasonably useful in evaluating the Co-Funding Materials. MacroGenics acknowledges and agrees that nothing in the Co-Funding Materials will
be deemed to be a representation or warranty, either express or implied, that Company will be able to successfully Develop or Commercialize the Initial Product in the Northern American Territory or, if Commercialized, that it will achieve any
particular sales level of the Initial Product in the Northern American Territory. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(c)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Terms of Co-Funding</B>. During the Co-Funding Term: (1)&nbsp;MacroGenics shall be responsible for [***] of the Global Development Costs; (2)&nbsp;the N.A. Profit/Loss shall be allocated between the Parties as
provided in Section&nbsp;9.9; (3)&nbsp;Section&nbsp;9.3(c) shall apply in lieu of Section&nbsp;9.3(b); (4)&nbsp;Section&nbsp;9.3(e) shall apply in lieu of Section&nbsp;9.3(d) and (3)&nbsp;royalties with respect to Net Sales of the Products shall be
payable only under Section&nbsp;9.4(b) (<I>i.e.</I> no royalties shall be payable with respect to Net Sales of the Initial Product in the Northern American Territory). </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(d)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Invoicing and Payment of Global Development Costs</B>. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> Company
shall provide to MacroGenics, no later than [***] before the [***] during the Co-Funding Term, a rolling, non-binding annual forecast of Global Development Costs that Company expects to incur during the [***] (the &#147;<B>Final GDC
Forecast</B>&#148;), with the [***]. In addition, Company shall provide to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">
MacroGenics, no later than [***] before the [***] during the Co-Funding Term, a [***]. The first Calendar Year in each Final GDC Forecast shall be referred to as the &#147;<B>Current
Forecast</B>.&#148; The Final GDC Forecast shall be consistent with the Global Development Plan and with Company&#146;s internal budget for the relevant periods. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> Except with respect to the Calendar Quarter in which the Co-Funding Option is exercised, within thirty
(30)&nbsp;days after the end of each Calendar Quarter during the Co-Funding Term (including the Calendar Quarter in which the Co-Funding Termination Date occurs, if any), (A)&nbsp;Company will provide a written report and invoice to MacroGenics
setting forth in reasonable detail the Global Development Costs incurred by Company during such Calendar Quarter and (B)&nbsp;MacroGenics will provide a written report and invoice to Company setting forth in reasonable detail the Global Development
Costs incurred by Company pursuant to Section&nbsp;4.2(c) during such Calendar Quarter and Company&#146;s share of&nbsp;such Global Development Costs (each, a &#147;<B>GDC Invoice</B>&#148;). The GDC Invoice for the first Calendar Quarter during the
Co-Funding Term shall also include all Global Development Costs incurred by Company prior to such Calendar Quarter (i.e. Global Development Costs relating to Global Development Activities incurred prior to the exercise of the Co-Funding Option).
Within sixty (60)&nbsp;days after the receipt of each GDC Invoice, MacroGenics, to the extent the amounts set forth in&nbsp;such GDC Invoice are not in reasonable dispute and after netting out Company&#146;s share of any GDC Invoice provided by
MacroGenics for such Calendar Quarter, shall pay the GDC Invoice in full, subject to the Cost Cap provisions set forth in Section&nbsp;8.2(d)(iii). If MacroGenics fails to pay to Company the total amount set forth in a GDC Invoice within [***] from
the date of such GDC Invoice , Company shall so notify MacroGenics in writing (a &#147;<B>GDC Late Payment Notice</B>&#148;). MacroGenics shall notify Company of any amount reasonably disputed in a GDC Invoice, including the basis for such dispute.
Company shall notify MacroGenics of any amount reasonably disputed in a GDC Invoice provided by MacroGenics, including the basis for such dispute. Disputes with respect to the amounts set forth in a GDC Invoice that are&nbsp;not resolved by the
Parties [***] after such dispute is first raised shall be referred to the JSC for attempted resolution; <U>provided</U>, <U>however</U>, that such dispute shall not be subject to Company&#146;s final decision-making authority under
Section&nbsp;2.1(c). If the JSC does not resolve such dispute within [***], the provisions of ARTICLE 14 shall apply. The audit rights set forth in Section&nbsp;9.13 shall apply to any payment made pursuant to this Section&nbsp;8.1(d)(ii). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> Notwithstanding Section&nbsp;8.2(d)(ii), during any Calendar Year in which Global Development Costs to be paid by
MacroGenics [***], MacroGenics may elect to [***] by providing written notice of such election to Company within [***] after receipt of the first GDC Invoice for such Calendar Year that [***]. Following Company&#146;s receipt of a [***] during any
Calendar Year, MacroGenics shall not be obligated to [***] Any [***] that have not been paid or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">
deducted from payments due hereunder at the end of any Calendar Quarter shall be carried forward to the next Calendar Quarter; <U>provided</U>, <U>however</U>, that all [***] shall be paid by
MacroGenics or deducted within [***] during which such Excess Costs were incurred. [***] that are carried forward from one Calendar Year to a subsequent Calendar Year [***] for purposes of determining whether the [***]. As used above, [***] means
(a)&nbsp;with respect to [***] during the period beginning [***] and ending on [***] for the period beginning [***] and ending [***] during such Calendar Year, and (b)&nbsp;for each [***] thereafter [***] during such Calendar Year. For example, if
the [***] that became due and payable pursuant [***] during the applicable [***]) </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(iv) </B>Notwithstanding subsection
(ii), during any [***] in which Global Development Costs are greater than [***] of the [***] for such Calendar Year [***], Company shall [***]. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(v)</B> Upon the request of either Party, the finance teams of the Parties will meet and attempt to agree in good faith on
changes to the processes for reporting, calculating and invoicing Global Development Costs (including [***] and [***]) pursuant to this Section&nbsp;8.2(d) to reflect any process improvements identified with respect thereto. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(e)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Co-Funding Opt-Out</B>.<B></B> Notwithstanding the foregoing, at any time during the Co-Funding Term after MacroGenics has paid at least a cumulative total of [***] in Global Development Costs pursuant to
Section&nbsp;8.2(d), MacroGenics may, in its discretion, elect to cease funding [***] of the Global Development Costs and sharing [***] of the N.A. Profit/Loss (the <B></B>&#147;<B>Co-Funding Opt-Out</B>&#148;<B></B>) by providing written notice of
such election to Company (the <B></B>&#147;<B>Co-Funding Opt-Out Notice</B>&#148;<B></B>) on or before [***] of the applicable Calendar Year. If MacroGenics delivers a Co-Funding Opt-Out Notice in accordance with this Section&nbsp;8.2(e), then the
following provisions shall apply beginning on the Co-Funding Termination Date and for the remainder of the Term: </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> MacroGenics&#146; obligation to fund [***] of Global Development Costs shall terminate on the <FONT
STYLE="white-space:nowrap">Co-Funding</FONT> Termination Date and MacroGenics shall have no obligation to fund any Global Development Costs (including Global Development Costs incurred by MacroGenics in performing Clinical Trials in accordance with
Section&nbsp;4.2(c)) incurred after the Co-Funding Termination Date (but, for clarity, MacroGenics shall be responsible for paying any and all invoiced Global Development Costs incurred on or prior to the Co-Funding Termination Date); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> the sharing of N.A. Profit/Loss pursuant to Section&nbsp;9.9 shall terminate on the Co-Funding Termination Date;
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> if MacroGenics exercises the Co-Funding Opt-Out [***], then MacroGenics may elect (in the <FONT
STYLE="white-space:nowrap">Co-Funding&nbsp;Opt-Out&nbsp;Notice)</FONT> to be reimbursed for the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Global Development Costs paid by MacroGenics prior to the Co-Funding Termination Date (the &#147;<B>GDC Repayment Option</B>&#148;), in which case (A)&nbsp;Company shall pay to MacroGenics, in
[***], the Global Development Costs previously funded by MacroGenics, with the [***] to be made within [***] after the Co-Funding Termination Date and the [***] to be made on or before the last day of the next [***] immediately following the payment
of the [***], <U>provided</U> that Company&#146;s obligation to make any such payments shall terminate as of the effective date of the termination of this Agreement by Company pursuant to Section&nbsp;13.3, and (B)&nbsp;beginning with the first
Calendar Quarter after the <FONT STYLE="white-space:nowrap">Co-Funding</FONT> Termination Date, royalties with respect to Net Sales of the Products shall be payable under Section&nbsp;9.4(c)(ii); and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> if (x)&nbsp;MacroGenics exercises the Co-Funding Opt-Out [***]or (y)&nbsp;MacroGenics exercises the <FONT
STYLE="white-space:nowrap">Co-Funding</FONT> Opt-Out prior to the [***] but does not elect the GDC Repayment Option in the Co-Funding Opt-Out Notice, then, in each case ((x) and (y)), beginning with the first Calendar Quarter after the <FONT
STYLE="white-space:nowrap">Co-Funding</FONT> Termination Date, royalties with respect to Net Sales of the Products shall be payable under Section&nbsp;9.4(c)(i). </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(f)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Termination of Co-Funding Term due to Failure to Pay Global Development Costs</B>.<B></B> If MacroGenics fails to pay the entire non-disputed, outstanding invoiced amount set forth in a GDC Invoice within [***] after
receiving a GDC Late Payment Notice (and MacroGenics has not delivered [***] in accordance with Section&nbsp;8.2(d)(iii)), then the following provisions shall apply beginning on the Co-Funding Termination Date and for the remainder of the Term:
</TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> MacroGenics&#146; obligation to fund [***] of Global Development Costs shall terminate on the <FONT
STYLE="white-space:nowrap">Co-Funding</FONT> Termination Date (except with respect to Global Development Costs incurred on or prior to the <FONT STYLE="white-space:nowrap">Co-Funding</FONT> Termination Date), and MacroGenics shall have no obligation
to fund any Global Development Costs incurred after the <FONT STYLE="white-space:nowrap">Co-Funding</FONT> Termination Date (but, for clarity, MacroGenics shall be responsible for paying any and all invoiced Global Development Costs incurred on or
prior to the Co-Funding Termination Date); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> the sharing of N.A. Profit/Loss pursuant to Section&nbsp;9.9 shall
terminate on the Co-Funding Termination Date; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> beginning with the first Calendar Quarter after the <FONT
STYLE="white-space:nowrap">Co-Funding</FONT> Termination Date, royalties with respect to Net Sales of the Products shall be payable under Section&nbsp;9.4(c)(ii); and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> Company may setoff against any amounts that are then owed to MacroGenics or that subsequently become due to
MacroGenics pursuant to this Agreement the amount of any such non-disputed, outstanding invoiced Global Development Costs and any other Global Development Costs MacroGenics subsequently becomes obligated to pay pursuant to Section 8.2(d). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(g)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Expiration of Co-Funding Term</B>.<B></B> If the Co-Funding Termination Event is the result of the application of subsection (c)&nbsp;or (d)&nbsp;of Section&nbsp;1.17, then the following provisions shall apply
beginning on the Co-Funding Termination Date and for the remainder of the Term: </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> MacroGenics&#146;
obligation to fund [***] of Global Development Costs shall terminate on the Co-Funding Termination Date (except with respect to Global Development Costs incurred on or prior to the Co-Funding Termination Date), and MacroGenics shall have no
obligation to fund any Global Development Costs incurred after the Co-Funding Termination Date (but, for clarity, MacroGenics shall be responsible for paying any and all invoiced Global Development Costs incurred on or prior to the Co-Funding
Termination Date); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> the sharing of N.A. Profit/Loss pursuant to Section&nbsp;9.9 shall terminate on the
Co-Funding Termination Date; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> Company shall have no obligation to make any payments to MacroGenics&#146;
hereunder with respect to Net Sales of the Initial Product in the Northern American Territory beginning with the first Calendar Quarter after the <FONT STYLE="white-space:nowrap">Co-Funding</FONT> Termination Date. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(h)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Change of Control</B>.<B></B> In the event of the occurrence of a Change of Control of MacroGenics before or during the <FONT STYLE="white-space:nowrap">Co-Funding</FONT> Term, the following provisions shall apply
until the end of the Co-Funding Term. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(i) </B>Upon the consummation of a Change of Control of
MacroGenics, MacroGenics shall have no further right to [***] pursuant to Section&nbsp;8.2(d)(iii). Commencing within [***] after such Change of Control, MacroGenics shall reimburse Company for all outstanding [***] under Section&nbsp;8.2(d)(iii)
that have not previously been recouped by Company as set forth therein[***]. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> Upon the consummation of a Change
of Control of MacroGenics, (A)&nbsp;the JSC shall be dissolved (except to the extent necessary to perform the activities described in clause (B)&nbsp;of this sentence), and (B)&nbsp;prior to dissolution, the JSC shall establish reasonable procedures
to protect the secrecy of Company&#146;s and MacroGenics&#146; competitively sensitive Confidential Information with respect to such other products, including, for example, limiting access to such information and requiring each Party&#146;s
representatives on the JSC and any employees performing activities in connection with this Agreement to sign individual confidentiality agreements agreeing to comply with the confidentiality provisions of this Agreement. It is understood that such
procedures shall not be established or required in any way that would diminish any of MacroGenics&#146; rights </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">
under this Agreement to information regarding Products, diminish MacroGenics&#146; operational responsibilities under this Agreement in any meaningful way, or otherwise impair MacroGenics&#146;
rights with respect to Compounds or Products. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(i)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Decision-Making</B>.<B></B> For clarity, MacroGenics&#146; exercise of the Co-Funding Option shall not alter either Party&#146;s respective rights with respect to the Development of Compounds or Products, including
Company&#146;s decision making rights as set forth in Section 4.3. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8.3 <U>Co-Promote Option</U></B>.<B></B> </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(a)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Option Grant and Exercise</B>.<B></B> Company hereby grants MacroGenics an option to co-promote the Initial Product in the U.S. for all approved Indications, as further described in this Section&nbsp;8.3 (the
<B></B>&#147;<B>Co-Promote Option</B>&#148;<B></B>). MacroGenics may, at its discretion, exercise the Co-Promote Option by delivering written notice thereof to Company (the <B></B>&#147;<B><FONT STYLE="white-space:nowrap">Co-Promote</FONT> Option
Exercise Notice</B>&#148;<B></B>) at any time before the [***] (in the case of the [***]) or the [***] (in the case of the Indication planned for [***]); <U>provided</U>, <U>however</U>, that MacroGenics shall only have the right to exercise the
Co-Promote Option with respect to the [***] if Company obtains, or seeks to obtain, an [***]. For purposes of clarity: (a) if MacroGenics does not exercise the Co-Promote Option [***]and Company has not obtained, or is not seeking to obtain, an
[***], then the Co-Promote Option shall expire upon the [***], and (b)&nbsp;if MacroGenics does not exercise the Co-Promote Option prior to the [***] and Company has obtained, or is seeking to obtain, an [***] for the [***], then the Co-Promote
Option shall remain exercisable until the expiration of the [***]. Furthermore, once MacroGenics exercises the Co-Promote Option, such exercise shall [***]. Notwithstanding the foregoing, in the event of the occurrence of a Change of Control of
MacroGenics prior to MacroGenics&#146; exercise of the Co-Promote Option, Company may terminate the Co-Promote Option upon immediate written notice to MacroGenics within [***] of the consummation of such Change of Control, if, after such Change of
Control, MacroGenics or the Acquirer or its Affiliates would be conducting Clinical Trials or Commercializing any product that would directly compete in the Field with the Initial Product, whether through the same mechanism of action (e.g., [***])
or for treatment of the same Indication as the Initial Product with such competitive product in the U.S. and, upon receipt of such notice by MacroGenics, this Section&nbsp;8.3 shall be of no further force or effect. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(b)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE="font-family:Times New Roman; font-size:10pt"><B>Co-Promote Materials</B>.<B></B> With respect to [***], Company shall deliver to MacroGenics (i)&nbsp;a non-binding [***] and (ii)&nbsp;a summary
of the key terms of the Co-Promotion Agreement (the <B></B>&#147;<B>Co-Promote Materials</B>&#148;<B></B>); <U>provided</U>, <U>however</U>, that Company shall not be obligated to deliver the Co-Promote Materials for the [***] for which the [***]
unless Company obtains, or seeks to obtain, an [***]. After </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
delivery of the Co-Promote Materials, but prior to the applicable Co-Promote Option Deadline, upon MacroGenics&#146; reasonable request and with reasonable notice, Company shall promptly make
available to MacroGenics (x)&nbsp;during normal business hours its employees and consultants who performed the activities on behalf of Company in preparation of the <FONT STYLE="white-space:nowrap">Co-Promote</FONT> Materials to answer
MacroGenics&#146; questions about the Co-Promote Materials, and (y)&nbsp;any additional Information in Company&#146;s possession relating to the Initial Product that may be reasonably useful in evaluating the
<FONT STYLE="white-space:nowrap">Co-Promote</FONT> Materials. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(c)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Terms of Co-Promote</B>. Promptly following Company&#146;s receipt of the Co-Promote Option Exercise Notice in accordance with Section&nbsp;8.3(a), the Parties shall enter into good faith negotiations for a separate
co-promotion agreement with respect to the co-promotion of the Initial Product in the U.S. (the &#147;<B>Co-Promotion Agreement</B>&#148;). In addition to such usual and customary terms that are typically found within contract sales force
agreements, including with respect to the diligence obligations of MacroGenics, the Co-Promotion Agreement shall include the terms set forth below in this Section&nbsp;8.3(c). MacroGenics shall commit in the Co-Promotion Agreement to employ a number
of sales representatives sufficient to provide [***]of the Details for the Initial Product in the U.S. For the sake of clarity, MacroGenics&#146; exercise of the <FONT STYLE="white-space:nowrap">Co-Promote</FONT> Option shall have no affect on
Company&#146;s authority with respect to Commercialization of the Products under Section&nbsp;6.3 and MacroGenics shall have no right to Detail the Initial Product in the U.S. unless and until the Parties execute the Co-Promotion Agreement.
</TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I></I><B><I></I></B><I></I><B>(i)</B><I></I><B><I> MacroGenics&#146; Detailing Percentage</I></B><I></I>.
Unless otherwise agreed by the Parties, MacroGenics shall contribute [***] of the total Details for the Initial Product in the U.S. for each Calendar Year, as set forth in the U.S. Commercialization Plan; <U>provided</U>, <U>however</U>, that, if
Company increases the total number of Details in a given Calendar Year, MacroGenics shall have the right, but not the obligation, to increase its total sales force efforts within [***] of receipt of notice from Company in order to maintain the
agreed-upon percentage of Details assigned to MacroGenics. Company will have the right to allocate the planned Details for the Initial Product in the U.S. for each Calendar Year between the Parties, which allocation shall be set forth in
Company&#146;s call plan for such Calendar Year. The Parties may agree to treat electronic detailing, such as live video conferencing, as a form of Detail, in which event the Parties shall mutually agree upon the costs of such electronic details and
such costs shall be deemed to be Commercialization Expenses during the Co-Funding Term. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B><I></I></B><B>(ii)
</B><B><I>Fee for Detail</I></B>. Company shall reimburse MacroGenics for the Details of the Initial Product in the U.S. performed by MacroGenics at a Cost Per PDE as measured and approved by the JSC prior to the First Commercial Sale of the Initial
Product in the Northern American Territory. For clarity, Company shall not pay or be responsible for any costs associated with MacroGenics&#146; Detailing of the Initial Product other than the Cost Per
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
PDE agreed upon by the Parties and, in the event the Parties agree to treat electronic details as a form of Detail, such electronic details shall not be reimbursed at the Cost Per PDE, but
instead shall be reimbursed at the cost mutually agreed upon by the Parties as described in Section&nbsp;8.30(i). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> <B><I>Audit Right</I></B>. Each Party shall have the right to audit the other Party&#146;s records regarding
performance under the Co-Promotion Agreement, solely for the purpose of determining the other Party&#146;s compliance with the Co-Promotion Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(iv) </B><B><I>Termination of Co-Promotion Agreement</I></B>. MacroGenics may terminate the Co-Promotion Agreement by [***]
prior written notice to Company. Company may terminate the Co-Promotion Agreement immediately if (1)&nbsp;MacroGenics fails to contribute at least [***] of the Details for the Initial Product in the Northern American Territory that MacroGenics is
obligated to provide under the U.S. Commercialization Plan and fails to remedy such shortfall within [***] after receiving written notice of such shortfall from Company or (2)&nbsp;MacroGenics materially breaches the Co-Promotion Agreement and fails
to cure such breach within [***] after receiving written notice of such breach from Company. The Co-Promotion Agreement shall be subordinate to and coterminous with this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(v) </B><B><I>Promotional Materials and Samples</I></B>. Except for MacroGenics Trademarks, Company shall remain solely
responsible for the production of product labeling and Promotional Materials for the Initial Product, the training and testing materials for all sales representatives (including those acting on behalf of MacroGenics) who Detail the Initial Product,
and restrictions with respect to the ability of such sales representatives to Detail other products. MacroGenics&#146; sales representatives for the Initial Product shall only use Promotional Materials provided by Company, without alteration, and
shall use all such Promotional Materials. Company will provide to MacroGenics, at Company&#146;s expense, reasonable quantities of Promotional Materials and product samples and/or sample vouchers for the Initial Product to support MacroGenics&#146;
Detailing of the Initial Product in the U.S.. Company shall not use the MacroGenics Trademarks in any of the Promotional Materials without MacroGenics&#146; written consent (such consent not to be unreasonably withheld, delayed or conditioned). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(vi) </B><B><I>Training and Related MacroGenics Sales Force Issues</I></B>. Company will be responsible for designing and
providing training materials for the representatives (including those acting on behalf of MacroGenics) who Detail the Initial Product. Company shall provide training to MacroGenics&#146; sales representatives who Detail the Initial Product, at
MacroGenics&#146; expense. Company will ship training materials to MacroGenics as reasonably required for MacroGenics&#146; ongoing training needs at MacroGenics&#146; expense. MacroGenics shall compensate its sales representatives who Detail the
Initial Product in the U.S. using a sales compensation structure similar to that used by Company with respect to its sales representatives who Detail the Initial Product in the U.S. Each sales representative who Details in the Initial Product in the
U.S. on behalf of MacroGenics shall be an employee of MacroGenics or its Affiliate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(vii) </B><B><I>Compliance</I></B>. MacroGenics&#146; sales representatives
performing Details of the Initial Product in the U.S. shall comply with Applicable Law and all of Company&#146;s reasonable instructions, quality standards, policies and guidelines which relate to the Commercialization of the Initial Product and of
which MacroGenics has been given sufficient written notice by Company to appropriately train such sales representatives. MacroGenics shall establish a compliance program and appoint a compliance officer to ensure that MacroGenics&#146; Detailing of
the Initial Product is in compliance with Applicable Law and such Company instructions, quality standards, policies and guidelines. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(viii) </B><B><I>Governance</I></B>. The Parties shall establish a committee to oversee and facilitate communication between
the Parties with respect to the Detailing of the Initial Product in the U.S. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(ix) </B><B><I>Change of Control</I></B>.
In the event of the occurrence of a Change of Control of MacroGenics during the Term, Company may terminate the Co-Promotion Agreement upon immediate written notice to MacroGenics within [***] of the consummation of such Change of Control if, after
such Change of Control, MacroGenics or the Acquirer would be Developing or Commercializing, or assisting a Third Party or its Affiliates to conduct any Pivotal Trial or Commercialize, any product that would directly compete in the Field with the
Initial Product, whether through the same mechanism of action (<I>e.g.</I>, binds to the Product Target) or for treatment of the same Indication as the Initial Product with such competitive product in the U.S. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 9</B> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSIDERATION
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9.1 <U>Upfront Payment</U></B>. Within [***] after the Effective Date, Company shall pay to MacroGenics Fifty Million Dollars ($50,000,000) as a
one-time, non-refundable, non-creditable upfront payment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9.2 <U>Reimbursement of Expenses</U></B>. Company shall reimburse MacroGenics for FTE Costs
and Third Party Expenses incurred by MacroGenics in providing assistance pursuant to Section&nbsp;5.2(c) and 7.1(a) of this Agreement as contemplated thereby. Company shall also reimburse MacroGenics Out-of-Pocket Patent Costs incurred pursuant to
Section&nbsp;10.3(b). Company shall reimburse such FTE Costs, Third Party Expenses and MacroGenics Out-of-Pocket Patent Costs within sixty (60)&nbsp;days after receipt of an invoice issued by MacroGenics describing such costs in reasonable detail
and providing appropriate supporting documentation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9.3 <U>Milestone Payments</U></B>. Company will notify MacroGenics within [***] following the
achievement by Company, its Affiliate or sublicensee of each Development Milestone, each Approval Milestone or Co-Funding Approval Milestone, as applicable, and each Sales Milestone or Co-Funding Sales Milestone, as applicable (collectively, the
&#147;<B>Milestone Events</B>&#148;). Within [***] after achievement of each Milestone Event, Company shall remit the applicable Development Milestone Payment, Approval Milestone Payment or Co-Funding Approval
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Milestone Payment, as applicable, or Sales Milestone Payment or Co-Funding Sales Milestone Payment, as applicable (collectively, the &#147;<B>Milestone Payments</B>&#148;) to MacroGenics. Each
Milestone Payment by Company pursuant to this Section&nbsp;9.3 shall be payable only once. For the sake of clarity, if Development of a first Product is discontinued prior to the time at which a Milestone Payment pursuant to this Section&nbsp;9.3 is
made with respect to such Product, then the achievement by a subsequent Product of any Milestone Event for which the Development of such first Product did not result in the achievement of a Milestone Payment under this Section&nbsp;9.3 shall be
deemed to be the first achievement of such milestone event under this Section&nbsp;9.3. In addition, if for any reason the [***] Development Milestone does not occur prior to the occurrence of the [***] Development Milestone, then the [***]
Development Milestone shall be deemed to occur concurrently with the occurrence of the [***] Development Milestone (e.g., if Development Milestone [***] occurs with respect to [***] Milestone [***] has not previously occurred with respect to such
Indication or any other Indication, then Development Milestone [***] will be deemed to occur concurrently with Development Milestone [***] and Development Milestone Payments [***] and [***] shall become due and payable in accordance with this
Section&nbsp;9.3). Similarly, if for any reason a [***] Development Milestone does not occur with respect to an Indication prior to the occurrence of a [***] Development Milestone with respect to such Indication, then a [***] Development Milestone
shall be deemed to occur concurrently with the occurrence of such [***] Development Milestone, but only if at least one of the [***] Development Milestones has not yet occurred with respect to another Indication (e.g. if (a)&nbsp;Development
Milestone [***] occurs with respect to an Indication (other than [***]) and none of Development Milestone [***],[***] or [***] have occurred with respect to such Indication or any other Indication, then Development Milestone [***] will be deemed to
occur concurrently with Development Milestone [***] and Development Milestone Payments [***] and [***] shall become due and payable in accordance with this Section&nbsp;9.3 or (b)&nbsp;if Development Milestone [***] occurs with respect to [***] and
Development Milestone [***] has not yet occurred with respect to [***], then Development Milestone [***] will be deemed to occur concurrently with Development Milestone [***] and Development Milestone Payments [***] and [***] shall become due and
payable in accordance with this Section&nbsp;9.3). </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(a)</B></TD>
<TD ALIGN="left" VALIGN="top"><B></B><B>Development Milestones</B>. The following payments (each, a &#147;<B>Development Milestone Payment</B>&#148;) shall be made on a one-time basis with respect to the first Product to achieve the corresponding
milestone event (each, a &#147;<B>Development Milestone</B>&#148;): </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom" WIDTH="16%"></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:77.40pt; font-size:8pt; font-family:Times New Roman"><B><I>Development Milestone</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><I>Development</I></B><br><B><I>Milestone</I></B><br><B><I>Payment&nbsp;(USD)</I></B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***] Trial Development Milestone</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1. [***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***] Trial Development Milestones</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" COLSPAN="3" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:77.40pt; font-size:8pt; font-family:Times New Roman"><B><I>Development Milestone</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><I>Development</I></B><br><B><I>Milestone</I></B><br><B><I>Payment&nbsp;(USD)</I></B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">2.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">3.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">[***]<SUP STYLE="font-size:85%; vertical-align:top">1</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">4.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">[***] with respect to which Development Milestone [***] was achieved<SUP STYLE="font-size:85%; vertical-align:top"> 1</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">5.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">[***] with respect to which Development Milestone [***] was achieved or the [***] with respect to which Development Milestone [***] was achieved<SUP STYLE="font-size:85%; vertical-align:top"> 1</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">6.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">7.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">[***]<SUP STYLE="font-size:85%; vertical-align:top">2</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">8.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">[***] respect to which Development Milestone [***] was achieved<SUP STYLE="font-size:85%; vertical-align:top"> 2</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">9.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">[***] with respect to which Development Milestone [***] was achieved or the [***] with respect to which Development Milestone [***] was achieved<SUP STYLE="font-size:85%; vertical-align:top"> 2</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I><SUP STYLE="font-size:85%; vertical-align:top">1</SUP>&nbsp;</I></TD>
<TD ALIGN="left" VALIGN="top"><I>The Development Milestone Payment for this Development Milestone, when achieved, will be due regardless of whether </I>[***]<I>. </I></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I><SUP STYLE="font-size:85%; vertical-align:top">2</SUP>&nbsp;</I></TD>
<TD ALIGN="left" VALIGN="top"><I>The Development Milestone Payment for this </I>[***] <I>Milestone, when achieved, will be due regardless of whether </I>[***]<I>. </I></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(b)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Regulatory Approval Milestones</B>. The following payments (each, an &#147;<B>Approval Milestone Payment</B>&#148;) shall be made on a one-time basis with respect to the first Product to achieve corresponding
milestone event (each, an &#147;<B>Approval Milestone</B>&#148;), if and only if the Co-Funding Term is not in effect when such Approval Milestone is achieved. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" COLSPAN="3" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:64.55pt; font-size:8pt; font-family:Times New Roman"><B><I>Approval Milestone</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><I>Approval&nbsp;Milestone</I></B><br><B><I>Payment (USD)</I></B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">1.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">2.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">[***]<SUP STYLE="font-size:85%; vertical-align:top">1</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">3.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">[***] with respect to which Approval</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" COLSPAN="3" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:64.55pt; font-size:8pt; font-family:Times New Roman"><B><I>Approval Milestone</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><I>Approval&nbsp;Milestone</I></B><br><B><I>Payment (USD)</I></B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Milestone [***] was achieved<SUP STYLE="font-size:85%; vertical-align:top"> 1</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">4.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">5.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">[***]<SUP STYLE="font-size:85%; vertical-align:top">2</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">6.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">[***] with respect to which Approval Milestone [***] was achieved <SUP STYLE="font-size:85%; vertical-align:top">2</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I></I><SUP STYLE="font-size:85%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>The Approval Milestone Payment for this Approval Milestone, when achieved, will be due regardless of whether </I>[***]<I>. </I></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I></I><SUP STYLE="font-size:85%; vertical-align:top">2</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>The Approval Milestone Payment for this Approval Milestone, when achieved, will be due regardless of whether </I>[***]<I>. </I></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(c)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Regulatory Approval Milestones during Co-Funding Term</B>. The following payments (each, a &#147;<B>Co-Funding Approval Milestone Payment</B>&#148;) shall be made on a one-time basis with respect to the first Product
to achieve corresponding milestone event (each, a &#147;<B>Co-Funding Approval Milestone</B>&#148;), if and only if such Co-Funding Approval Milestone is achieved during the Co-Funding Term. For the sake of clarity, this Section&nbsp;9.3(c) shall
only apply during the Co-Funding Term. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" COLSPAN="3" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:107.45pt; font-size:8pt; font-family:Times New Roman"><B><I>Co-Funding Approval Milestone</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><I>Co-Funding</I></B><br><B><I>Approval&nbsp;Milestone</I></B><br><B><I>Payment (USD)</I></B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">1.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">2.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">[***] <SUP STYLE="font-size:85%; vertical-align:top">1</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">3.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">[***] with respect to which Approval Milestone [***] was achieved <SUP STYLE="font-size:85%; vertical-align:top">1</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I></I><SUP STYLE="font-size:85%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>The Co-Funding Approval Milestone Payment for this Co-Funding Approval Milestone, when achieved, will be due regardless of whether </I>[***]<I>. </I></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"><B>Annual Net Sales Milestones</B>. The milestone payments set forth in this Section&nbsp;9.30 (each, a &#147;<B>Sales Milestone Payment</B>&#148;) shall each be payable to MacroGenics one-time only, upon the first time
during the Term that the total aggregate Net Sales of Products in any Calendar Year by Company, its Affiliates and its sublicensees in the Territory during the applicable Royalty Term for the Products in the applicable country exceed the amounts set
forth in the following table (each, a &#147;<B>Sales Milestone</B>&#148;), if and only if the Co-Funding Term is not in effect when such Sales Milestone is achieved. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Annual Aggregate Worldwide Net Sales Milestones </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom" WIDTH="16%"></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:51.65pt; font-size:8pt; font-family:Times New Roman"><B><I>Sales Milestone</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><I>Sales&nbsp;Milestone</I></B><br><B><I>Payment&nbsp;(USD)</I></B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Upon the first occasion that aggregate annual Net Sales of the Products exceeds [***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Upon the first occasion that aggregate annual Net Sales of the Products exceeds [***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Upon the first occasion that aggregate annual Net Sales of the Products exceeds [***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">If more than one Sales Milestone described in this Section&nbsp;9.30 is achieved during the same Calendar
Year, Company shall pay MacroGenics each Sales Milestone Payment that corresponds to such Sales Milestones. For purposes of clarity, only one Milestone Payment shall be owed on the first occasion that aggregate annual Net Sales of the Products
exceeds [***] or [***] under Section&nbsp;9.30 and Section&nbsp;9.3(e). </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(e)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Annual Net Sales Milestones during the Co-Funding Term</B>. The milestone payments set forth in this Section&nbsp;9.3(e) (each, a &#147;<B>Co-Funding Sales Milestone Payment</B>&#148;) shall each be payable to
MacroGenics one-time only, upon the first time during the Co-Funding Term that the total aggregate Net Sales of the Products by Company, its Affiliates and its sublicensees in the Territory during the applicable Royalty Term for the Products in the
applicable country, excluding Net Sales of the Initial Product in the Northern American Territory during the Co-Funding Term, exceed the amounts set forth in the following table (each, a &#147;<B>Co-Funding Sales Milestone</B>&#148;), if and only if
such Co-Funding Sales Milestone is achieved during the Co-Funding Term. </TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Annual Aggregate Net Sales Milestones in the
Territory </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(excluding only Net Sales in Northern American Territory with </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>respect to the Initial Product) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="81%"></TD>
<TD VALIGN="bottom" WIDTH="18%"></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:94.55pt; font-size:8pt; font-family:Times New Roman"><B><I>Co-Funding Sales Milestone</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><I>Co-Funding&nbsp;Sales</I></B><br><B><I>Milestone</I></B><br><B><I>Payment (USD)</I></B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Upon the first occasion that aggregate annual Net Sales of the Products exceeds [***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Upon the first occasion that aggregate annual Net Sales of the Products exceeds [***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Upon the first occasion that aggregate annual Net Sales of the Products exceeds [***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">If more than one Co-Funding Sales Milestone described in this Section&nbsp;9.3(e) is achieved during the same
Calendar Year, Company shall pay MacroGenics each Co-Funding Sales Milestone Payment that corresponds to such Co-Funding Sales </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">
Milestones. For purposes of clarity, only one Milestone Payment shall be owed on the first occasion that aggregate annual Net Sales of the Products exceeds [***] or [***] under
Section&nbsp;9.3(d) and Section&nbsp;9.3(e). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9.4 <U>Company Royalty Obligations</U></B>. As further consideration for the rights granted hereunder,
Company shall pay to MacroGenics royalties on the aggregate annual Net Sales of each Product at the rates set forth in this Section&nbsp;9.4, in each case, subject to Section&nbsp;9.5, Section&nbsp;9.6 and Section&nbsp;9.10 below. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(a)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Royalties if no Co-Funding</B>. In the event that MacroGenics does not exercise the Co-Funding Option prior to the Co-Funding Option Deadline in accordance with Section&nbsp;8.2(a), then Company shall pay to
MacroGenics, with respect to Net Sales of each Product in each country in the Territory during the applicable Royalty Term for such Product in such country, royalties at the following rates: </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="85%"></TD>
<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:58.65pt; font-size:8pt; font-family:Times New Roman"><B>Annual Net Sales</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Royalty&nbsp;Rate</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">On the portion of worldwide annual Net Sales of such Product less than or equal to [***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">On the portion of worldwide annual Net Sales of such Product greater than [***] and less than or equal to [***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">On the portion of worldwide annual Net Sales of such Product greater than [***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(b)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Royalties during Co-Funding Term</B>. In the event that MacroGenics exercises the Co-Funding Option prior to the Co-Funding Option Deadline in accordance with Section&nbsp;8.2(a), then Company shall pay to
MacroGenics during the Co-Funding Term royalties at the rates set forth below in this Section 9.4(b). </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(i) </B><B><I>Initial Product</I></B>. With respect to Net Sales of the Initial Product in each country in the Territory
during the applicable Royalty Term for the Initial Product in such country, excluding Net Sales of the Initial Product in the Northern American Territory, royalties at the following royalty rates: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="85%"></TD>
<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:132.30pt; font-size:8pt; font-family:Times New Roman"><B>Annual Net Sales of the Initial Product</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Royalty&nbsp;Rate</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">On the portion of worldwide annual Net Sales of the Initial Product (excluding Net Sales of the Initial Product in the Northern
American Territory) less than or equal to [***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">On the portion of worldwide annual Net Sales of the Initial Product (excluding Net Sales of the Initial Product in the Northern
American Territory) greater than [***] and less than or equal to [***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">On the portion of worldwide annual Net Sales of the Initial Product (excluding Net Sales of the Initial Product in the Northern
American Territory) greater than [***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">For the avoidance of doubt, the aggregate annual Net Sales of the Initial Product in the
Northern American Territory during the Co-Funding Term shall be excluded from the calculation of the royalty thresholds set forth above and on royalties payable to MacroGenics pursuant to this Section&nbsp;9.4(b)(i). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(ii) </B><B><I>Products other than Initial Product</I></B>. With respect to Net Sales of any Product other than the Initial
Product in each country in the Territory during the applicable Royalty Term for such Product in such country, royalties at the following royalty rates: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="85%"></TD>
<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:201.40pt; font-size:8pt; font-family:Times New Roman"><B>Annual Net Sales of any Product other than Initial Product</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Royalty&nbsp;Rate</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">On the portion of worldwide annual Net Sales of such Product less than or equal to [***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">On the portion of worldwide annual Net Sales of such Initial Product greater than [***] and less than or equal to [***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">On the portion of worldwide annual Net Sales of such Product greater than [***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(c)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Royalties after Co-Funding Term</B>.<B> </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>MacroGenics exercises Co-Funding Opt-Out
and does not elect GDC Repayment Option</I></B>. In the event that MacroGenics exercises the Co-Funding Option in accordance with Section&nbsp;8.2(a), but MacroGenics thereafter exercises the Co-Funding Opt-Out in accordance with Section&nbsp;8.2(e)
and does not elect the GDC Repayment Option, then Company shall pay MacroGenics during any part of the Term after the Co-Funding Term (x)&nbsp;with respect to Net Sales of the Initial Product in the Northern American Territory, royalties at the
rates set forth in the second column of the following table and (y)&nbsp;with respect to (1)&nbsp;Net Sales of the Initial Product in any country outside the Northern American Territory and (2)&nbsp;Net Sales of any Product other than the Initial
Product in any country in the Territory, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">
royalties at the rates set forth in the third column of the following table, in each case ((x) and (y)) during the applicable Royalty Term for such Product in such country: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="19%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="19%"></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:58.65pt; font-size:8pt; font-family:Times New Roman"><B>Annual Net Sales</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(a)&nbsp;Royalty Rate for<BR>Northern American<BR>Territory&nbsp;Net&nbsp;Sales&nbsp;of&nbsp;the</B><br><B>Initial Product</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(b) Royalty Rate for<BR>(i) outside Northern<BR>American Territory<BR>Net Sales of the<BR>Initial Product and<BR>(b) Territory
Net<BR>Sales&nbsp;of&nbsp;each&nbsp;Product<BR>other than the Initial<BR>Product</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">On the portion of worldwide annual Net Sales of such Product less than or equal to [***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">On the portion of worldwide annual Net Sales of such Product greater than [***] and less than or equal to [***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">On the portion of worldwide annual Net Sales of such Product greater than [***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(i) </B><B><I>MacroGenics exercises Co-Funding Opt-Out and elects GDC Repayment Option;
Termination of Co-Funding for Cause</I></B>. In the event that MacroGenics exercises the Co-Funding Option in accordance with Section&nbsp;8.2(a) and (x)&nbsp;MacroGenics thereafter exercises the Co-Funding Opt-Out in accordance with
Section&nbsp;8.2(e) and elects the GDC Repayment Option or (y)&nbsp;the Co-Funding Term is thereafter terminated pursuant to Section&nbsp;8.2(f), then, in each case ((x) and (y)), during any part of the Term after the Co-Funding Term, Company shall
pay to MacroGenics, with respect to Net Sales of each Product in each country in the Territory during the applicable Royalty Term for such Product in such country, royalties at the following rates: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="85%"></TD>
<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:58.65pt; font-size:8pt; font-family:Times New Roman"><B>Annual Net Sales</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Royalty&nbsp;Rate</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">On the portion of worldwide annual Net Sales of such Product less than or equal to [***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">On the portion of worldwide annual Net Sales of such Product greater than [***] and less than or equal to [***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">On the portion of worldwide annual Net Sales of such Product greater than [***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(d)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE="font-family:Times New Roman; font-size:10pt"><B>Examples of Royalty Calculation for Initial Product</B>. By way of example, if global aggregate annual Net Sales of the Initial Product is [***],
MacroGenics did not exercise the Co-Funding Option and no royalty rate reduction under Section&nbsp;9.6 or 9.10 applies, then the royalty payable by Company to MacroGenics for the Initial
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Product for such Calendar Year, subject to other applicable reductions, would be as follows: </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="36%"></TD>
<TD VALIGN="bottom" WIDTH="31%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="31%"></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center">Global Net Sales</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Royalty&nbsp;Tier</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Royalty&nbsp;Due</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(e)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>No Multiple Royalties</B>. For each Net Sale of a Product, only one royalty under Section&nbsp;9.4(a), 9.4(b)(i), 9.4(b)(ii), 9.4(c)(i) or 9.4(c)(ii) shall be payable. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9.5 <U>Royalty Term</U></B>. Royalties under Section&nbsp;9.4 shall be payable on Net Sales on a Product-by-Product and country-by-country basis beginning
upon the First Commercial Sale of the relevant Product in the relevant country in the Territory until the expiration of the Royalty Term for such Product in such country. Following the expiration of the Royalty Term with respect to a Product in a
country of the Territory, subject to the terms and conditions of this Agreement, Company shall have a perpetual, irrevocable, non-exclusive, fully-paid and royalty-free right and license, with the right to grant sublicenses, under the MacroGenics
Technology to Exploit such Product in the Field in such country of the Territory. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9.6 <U>Royalty Rate Reductions</U></B>. The royalty rates set forth
in Section&nbsp;9.4 shall be subject to reduction as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(a)</B></TD>
<TD ALIGN="left" VALIGN="top">the royalty rates shall be reduced by [***], on a country-by-country basis and Product-by-Product basis, in each country in which, at any given time, both (i)&nbsp;no Valid Claim of MacroGenics Patents [***] of the
applicable Product in such country, and (ii)&nbsp;either (x)&nbsp;[***] Product in such country [***] or (y)&nbsp;[***] Product in such country; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(b)</B></TD>
<TD ALIGN="left" VALIGN="top">the royalty rates shall be reduced by [***], on a country-by-country and Product-by-Product basis, in each country in which, at any given time, (i)&nbsp;no [***] of the applicable Product in such country, and
(ii)&nbsp;there is [***] Product in such country and [***]; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(c)</B></TD>
<TD ALIGN="left" VALIGN="top"><B></B>in the event that the royalty rate reduction in Section&nbsp;9.6(b) applies to a Product in a country and [***] Product in such country [***] [***], the reductions set forth in Section&nbsp;9.6(a) shall
thereafter apply to such Product in such country; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(d)</B></TD>
<TD ALIGN="left" VALIGN="top">in the event that Company does not [***] in a country in which [***] and MacroGenics does not elect to [***] in accordance with Section&nbsp;10.3(b) which would have been at its sole expense, the requirements set forth
in clause (i) of </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B></B>&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Sections 9.6(a) and 9.6(b) shall not be deemed to have been satisfied, and there shall be no reduction in the applicable royalty rates until the global expiration date of the family of such [***]; and<B>
</B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(e)</B></TD>
<TD ALIGN="left" VALIGN="top"><B></B>in no event shall the cumulative effect of all reductions available to Company under this Agreement decrease the royalty rate to [***] of the otherwise applicable rates.<B> </B></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9.7 <U>Manner of Royalty Payment</U></B>. Within [***]following the end of each Calendar Quarter after the First Commercial Sale of a Product in the
Territory (but excluding a First Commercial Sale in the Northern American Territory that occurs during the Co-Funding Term), Company shall provide MacroGenics with a report setting forth, on a Product-by-Product and country-by-country basis
(excluding any country in the Northern American Territory during the Co-Funding Term), the Net Sales of such Product in such country, a reasonably detailed statement of the [***] and a calculation of the royalty payment due with respect to such Net
Sales. Such report shall also include the exchange rates and other methodology used in converting Net Sales into U.S. Dollars from the currencies in which such sales were made for purposes of calculating the appropriate royalty rate and the royalty
payment due, and the application of the reductions, if any, made in accordance with the terms of Section&nbsp;9.6 or Section&nbsp;9.10. Company shall pay all amounts due to MacroGenics pursuant to Section&nbsp;9.4 with respect to Net Sales by
Company, its Affiliates and their respective sublicensees for such Calendar Quarter in U.S. Dollars at the time the submission of such quarterly report is due. <B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9.8 <U>Currency</U></B>. All payments under this Agreement shall be payable in U.S. Dollars. With respect to sales of a Product invoiced and
Commercialization Expenses incurred in a currency other than U.S. Dollars, such amounts and the amounts payable hereunder shall be expressed in their U.S. Dollars equivalent calculated using the Currency Hedge Rates described below. For each
Calendar Year during which royalties become due under Section&nbsp;9.4, Company shall provide MacroGenics: (a)&nbsp;the [***]to be used for the [***]of each country in the Territory in which any royalty-bearing Net Sales are expected to occur; and
(b)&nbsp;the details of each such [***], in each case ((a) and (b)), in writing no later than [***] after the [***] are available from [***] or its Affiliates, which is customarily at the [***]. Each [***]will remain constant throughout the upcoming
Calendar Year. Company shall use the [***] to convert Net Sales to U.S. Dollars for the purpose of calculating royalty payments and N.A. Profit/Loss hereunder. <B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9.9 <U>Allocation of N.A. Profit/Loss</U></B>. During the Co-Funding Term, N.A. Profit/Loss for the Initial Product shall be allocated [***] to Company and
[***] to MacroGenics. <B> </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(a)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE="font-family:Times New Roman; font-size:10pt"><B>Expense Report</B>. Within [***] after the end of each Calendar Quarter following the First Commercial Sale of the Initial Product in the Northern
American Territory during the Co-Funding Term, each Party shall submit to the other Party a [***] of [***] Party during such Calendar Quarter. Within [***] after the end of each Calendar Quarter following the First Commercial Sale of the Initial
Product in the Northern American Territory during the Co-Funding Term, each Party shall submit to the other Party a written report setting forth in reasonable detail the <B> </B></P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Commercialization Expenses incurred by such Party during such Calendar Quarter, <U>provided</U> that the Commercialization Expenses incurred by either Party during the Co-Funding Term before the
First Commercial Sale in the Northern American Territory shall be included in the first Commercialization Expense report submitted by the Parties and shall be used to determine the allocation of N.A. Profit/Loss between the Parties for such Calendar
Quarter. Each Party shall have the right to review and submit any reasonable objection to the Commercialization Expenses set forth in the other Party&#146;s report within [***] following its receipt of the Commercialization Expenses report from the
other Party. Disputes with respect to a Commercialization Expense that are not resolved by the Parties within [***] after such dispute is first raised shall be referred to the JSC for attempted resolution; <U>provided</U>, <U>however</U>, that such
dispute shall [***]. If the JSC does not resolve such dispute within [***], the provisions of ARTICLE 14 shall apply. Until the resolution of such dispute pursuant to ARTICLE 14, [***]. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(b)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>N.A. Profit/Loss Reports</B>. Within [***] after the end of each Calendar Quarter following the First Commercial Sale of the Initial Product in the Northern American Territory, and for the remainder of the Co-Funding
Term, Company shall submit to MacroGenics a report setting forth in reasonable detail all [***] (with the detail set forth in Section&nbsp;9.7, <B></B><I>mutatis mutandis</I><B></B>) and an allocation of profits or losses between the Parties (the
&#147;<B>Quarterly N.A. Profit/Loss Report</B>&#148;). Company shall pay all amounts due to MacroGenics pursuant to this Section&nbsp;9.9 at the time of submission of the Quarterly N.A. Profit/Loss Report; <U>provided</U>, <U>however</U>, that if
the Quarterly N.A. Profit/Loss Report indicates a loss for such Calendar Quarter, MacroGenics shall pay the amount due to Company pursuant to this Section&nbsp;9.9 within [***] following its receipt of such Quarterly N.A. Profit/Loss Report. <B>
</B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(c)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Financial Report Formats and Timing</B>. Upon the request of either Party, the finance teams of the Parties will meet and attempt to agree in good faith on alternative financial report formats and timetables to use
in lieu of the reports and deadlines described in Section&nbsp;9.9(a). <B> </B></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9.10 <U>Third Party Financial Obligations</U></B>.<B>
</B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(a)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE="font-family:Times New Roman; font-size:10pt"><B></B>MacroGenics shall be solely responsible for the payment of any royalties, sublicense revenues, milestones or other payments due by either
Party, their Affiliates or sublicensees to Third Parties arising with respect to [***] (each, a &#147;<B>Third Party Obligation</B>&#148;), (i)&nbsp;to the extent such Third Party [***], or (ii)&nbsp;to the extent such Third Party Obligation [***].
If MacroGenics fails to pay any amount of a Third Party Obligation related to the DART Platform, a Compound and/or a Product and such payment [***] or the failure to make such payment [***], upon [***] prior notice, Company may elect, in its sole
discretion, to make such payment <B> </B></P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
to such Third Party on behalf of MacroGenics. If Company makes such payment to such Third Party, Company may deduct the amount of such payment from any payments that are owed or that become owed
to MacroGenics under this Agreement or, if such deduction is not applicable, MacroGenics shall reimburse Company the amount of such payment within [***] after Company makes such payment. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(b)</B></TD>
<TD ALIGN="left" VALIGN="top"><B></B>Except for Third Party Obligations set forth in Section&nbsp;9.10(a), Company shall be responsible for all Third Party Obligations (including any licenses for [***]). Company may credit [***] of any Third Party
Obligation resulting from Patents and/or Know-How owned by Third Parties that is paid by Company pursuant to this Section&nbsp;9.10(a) against any royalties payable to MacroGenics under Section&nbsp;9.4. Company shall take such credit during any
Calendar Quarter for which royalties are payable hereunder, <U>provided</U> that in no event will such credit, together with any reductions under Section&nbsp;9.6, reduce the royalties payable to MacroGenics for such Calendar Quarter by more than
[***]. Any share of such Third Party Obligations that remains uncredited due to the application of such floor may be carried forward to subsequent Calendar Quarters. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9.11 <U>Taxes</U></B>.<B> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Company will
make all payments to MacroGenics under this Agreement without deduction or withholding for Taxes, except to the extent that any such deduction or withholding is required by Applicable Law in effect at the time of payment. Any Tax required to be
withheld on amounts payable under this Agreement will be paid by Company on behalf of MacroGenics to the appropriate Governmental Authority, and Company will furnish MacroGenics with proof of payment of such Tax. Any such Tax required to be withheld
will be an expense of and borne by MacroGenics. If any such Tax is assessed against and paid by Company, then MacroGenics will indemnify and hold harmless Company from and against such Tax. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(a)</B></TD>
<TD ALIGN="left" VALIGN="top"><B></B>Company and MacroGenics will cooperate with respect to all documentation required by any taxing authority or reasonably requested by Company to secure a reduction in the rate of applicable withholding Taxes.<B>
</B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">If Company assigns its rights and obligations hereunder to an Affiliate or Third Party in compliance with
Section&nbsp;16.4 and if such Affiliate or Third Party shall be required by Applicable Law to withhold any additional taxes from or in respect of any amount payable under this Agreement as a result of such assignment, then any such amount payable
under this Agreement shall be increased to take into account the additional taxes withheld as may be necessary so that, after making all required withholdings, MacroGenics receives an amount equal to the sum it would have received had no such
assignment been made. The foregoing sentence shall not apply to any additional taxes withheld to the extent MacroGenics may obtain a foreign tax credit therefor. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9.12 <U>Tax Returns</U></B>.<B> </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(a)</B></TD>
<TD ALIGN="left" VALIGN="top"><B></B>The Parties hereby agree that each Party&#146;s share of Global Development Costs, including amounts paid under Section&nbsp;8.2(d), shall be accounted for by each Party separately for research tax credit and
orphan drug credit purposes.<B> </B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(b)</B></TD>
<TD ALIGN="left" VALIGN="top"><B></B>The Parties hereby agree that [***]of any deductions for tax purposes attributable to amounts paid or incurred by MacroGenics pursuant to this Agreement shall be deductible or amortizable solely by MacroGenics,
and [***]of any deductions for tax purposes attributable to amounts paid or incurred by Company pursuant to this Agreement shall be deductible or amortizable solely by Company. All Tax returns reflecting any such amounts shall be filed (and any
available elections to effect such intent, including a remedial allocation election, shall be made) consistent with the foregoing.<B> </B></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9.13 <U>Audit</U></B>. Each Party shall maintain complete and accurate records in the ordinary course of such Party&#146;s operations in order to permit
the other Party to confirm the accuracy of the calculation of royalties, milestones, profits, losses, Global Development Costs, FTE Costs, Third Party Expenses and other payments under this Agreement. Upon reasonable prior notice, but not more than
[***], such records shall be available during regular business hours for a period of [***] from the end of the Calendar Year to which they pertain for examination by an independent certified public accountant selected by the requesting Party and
reasonably acceptable to the other Party for the sole purpose of verifying the accuracy of the financial reports and correctness of the payments furnished by the other Party pursuant to this Agreement. Any such auditor shall not disclose the other
Party&#146;s Confidential Information, except to the extent such disclosure is necessary to verify the accuracy of the financial reports furnished by the other Party or the amount of payments due by the other Party under this Agreement. Any amounts
shown to be owed but unpaid shall be paid within [***] from the accountant&#146;s report, plus interest, as set forth in Section&nbsp;9.14 from the original due date. Any amounts shown to have been overpaid shall be refunded within [***] from the
accountant&#146;s report. The requesting Party shall bear the full cost of such audit unless such audit discloses an underpayment by the other Party of more than [***] of the amount due (except to the extent caused by improper reporting of the
requesting Party), in which case the other Party shall bear the full cost of such audit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9.14 <U>Late Payment</U></B>. All payments due to a Party
hereunder shall be made in U.S. Dollars by wire transfer of immediately available funds into an account designated by the receiving Party. If a Party does not receive payment of any sum due to it on or before the due date, simple interest shall
thereafter accrue on the sum due to such Party until the date of payment at the per annum rate of [***] over the then-current prime rate quoted by [***] or the maximum rate allowable by Applicable Law, whichever is lower.<B> </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 10</B> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INTELLECTUAL PROPERTY MATTERS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10.1
<U>Ownership of Inventions</U></B>. Each Party shall own any Inventions made solely by its (or its Affiliates&#146;) own employees, agents, or independent contractors in the course of conducting its activities under this Agreement, together with all
intellectual property rights therein (&#147;<B>Sole Inventions</B>&#148;). The Parties shall jointly own any Inventions for which the inventors include at least one employee, agent, or independent contractor of each Party (or its respective
Affiliates) in the course of performing activities under this Agreement, together with all intellectual property rights therein (&#147;<B>Joint Inventions</B>&#148;). Inventorship shall be determined in accordance with U.S. patent laws. Subject to
any licenses granted under this Agreement, each Party will have the right to practice and Exploit any Joint Inventions without the duty of accounting to any other Party or seeking consent (for licensing, assigning or otherwise exploiting Joint
Inventions) from the other Party by reason of the joint ownership thereof; and each Party hereby waives any right such Party may have under the laws of any jurisdiction to require any such approval or accounting and, to the extent there are any
Applicable Laws that prohibit such a waiver, each Party will be deemed to have so consented. In furtherance thereof, at the reasonable written request of a Party, the other Party will in writing grant such consents and confirm that no such
accounting is required to effect the foregoing regarding Joint Inventions.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10.2 <U>Disclosure of Inventions</U></B>. Each Party shall promptly
disclose to the other Party any Invention that is necessary or useful to Exploit Compounds or Products in the Field in the Territory during the Term. With respect to any Joint Invention, each Party shall promptly disclose to the other Party any
invention disclosures, or other similar documents, submitted to it by its employees, agents or independent contractors describing the Joint Invention, and all Information relating to such Invention to the extent necessary for the use of such
Invention in the Development or Commercialization of the Compounds or the Products in the Field and, to the extent patentable, for the preparation, filing and maintenance of any Patent with respect to such Invention.<B> </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10.3 <U>Prosecution of Patents</U></B>.<B> </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(a)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>MacroGenics Platform Patents</B>. Except as otherwise provided in this Section&nbsp;10.3(a), as between the Parties, MacroGenics shall have the sole right and authority to prepare, file, prosecute and maintain the
MacroGenics Platform Patents on a worldwide basis at its sole expense. MacroGenics shall provide Company a reasonable opportunity to review and comment on its efforts to prepare, file, prosecute and maintain MacroGenics Platform Patents in the
Territory, including by providing Company with a copy of material communications from any patent authority in the Territory regarding any MacroGenics Platform Patent, and by providing drafts of any material filings or responses to be made to such
patent authorities in advance of submitting such filings or responses. MacroGenics shall consider Company&#146;s comments regarding such communications and drafts in good faith. <B> </B></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(b)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>MacroGenics Product Patents. </B>The Parties shall jointly prepare, file, prosecute and maintain the MacroGenics Product Patents on a worldwide basis through outside counsel selected by Company and acceptable to
MacroGenics, <U>provided</U> <U>that</U> Company shall reasonably consider utilizing the outside counsel currently prosecuting the MacroGenics Product Patents. Company shall reimburse MacroGenics for MacroGenics Out-of-Pocket Patent Costs incurred
in the filing, prosecution and maintenance of MacroGenics Product Patents. The Parties shall use good faith efforts to agree upon the Patent strategy with respect to the MacroGenics Product Patents, including the scope of protection to be sought in
such Patents and the countries in which such Patents are to be maintained. If the Parties disagree with respect to the preparation, filing, prosecution or maintenance of any MacroGenics Product Patent, such disagreement shall be [***], and such
[***] provide a potential resolution for the dispute; <U>provided</U>, <U>however</U>, that if such disagreement relates to whether or not [***], then such disagreement shall [***] and the Party that desires to file or maintain such [***] shall have
the right [***]. If the Parties agree with such potential resolution, such resolution shall be final and binding. If the Parties do not agree with such potential resolution, [***] with respect to the disputed matter. Each Party shall have access to
copies of all documents relating to the preparation, filing, prosecution and maintenance of the MacroGenics Product Patents and shall be permitted to access such documents in a timely manner.<B> </B></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(c)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Company Patents</B>. Company shall have the sole right and authority to prepare, file, prosecute and maintain the Company Patents on a worldwide basis at its own expense. Company shall provide MacroGenics a
reasonable opportunity to review and comment on its efforts to prepare, file, prosecute and maintain Company Patents in the Territory, including by providing MacroGenics with a copy of material communications from any patent authority regarding any
Company Patent in the Territory, and by providing drafts of any material filings or responses to be made to such patent authorities in advance of submitting such filings or responses.Company shall consider MacroGenics&#146; comments regarding such
communications and drafts in good faith.<B> </B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(d)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE="font-family:Times New Roman; font-size:10pt"><B>Joint Patents</B>. Except as otherwise provided in this Section&nbsp;10.30, Company shall have the primary right and authority to prepare, file,
prosecute and maintain the Patents included in the Joint Inventions (&#147;<B>Joint Patents</B>&#148;) on a worldwide basis at its own expense. Company shall provide MacroGenics with a reasonable opportunity to review and comment on its efforts to
prepare, file, prosecute and maintain Joint Patents, including by providing MacroGenics with a copy of material communications from any patent authority regarding any Joint Patent, and by providing drafts of any material filings or responses to be
made in advance of submitting such filings or responses. Company shall consider MacroGenics&#146; comments regarding such communications and drafts in good faith. If Company determines in its discretion to abandon or not maintain any Joint Patent(s)
in any <B> </B></P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
country(ies) of the world, then Company shall provide MacroGenics with written notice of such determination within a period of time reasonably necessary to allow MacroGenics to determine its
interest in such Joint Patent(s) (which notice from Company shall be given no later than [***] prior to any final deadline for any pending action or response that may be due with respect to such Joint Patent(s) with the applicable patent authority).
If MacroGenics provides written notice expressing its interest in obtaining such Joint Patent(s), Company shall, free of charge, assign and transfer to MacroGenics the ownership of, and interest in, such Joint Patent(s) in such country(ies), at
MacroGenics&#146; own expense, and Company shall cooperate with MacroGenics for assignment and transfer of such Joint Patent(s) in such country. Thereafter, all such assigned and transferred Patents will be deemed MacroGenics Platform Patents and
MacroGenics shall have the right to prepare, file, prosecute and maintain such Patents as set forth in Section&nbsp;10.3(a). </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(e)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Cooperation in Prosecution</B>. Each Party shall provide the other Party all reasonable assistance and cooperation in the Patent prosecution efforts provided above in this Section&nbsp;10.3, including providing any
necessary powers of attorney and executing any other required documents or instruments for such prosecution, as well as further actions as set forth below. Such assistance and cooperation shall include making a Party&#146;s inventors and other
scientific advisors reasonably available to assist the other Party&#146;s Patent prosecution efforts. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> The Parties shall respectively prepare, file, maintain and prosecute the MacroGenics Patents, the Company Patents
and the Joint Patents as set forth in this Section&nbsp;10.3. As used herein, &#147;prosecution&#148; of such Patents shall include all communication and other interaction with any patent office or patent authority having jurisdiction over a patent
application in connection with pre-grant proceedings. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> All communications between the Parties relating to the
preparation, filing, prosecution or maintenance of the MacroGenics Patents, the Company Patents and the Joint Patents, including copies of any draft or final documents or any communications received from or sent to patent offices or patenting
authorities with respect to such Patents, shall be considered Confidential Information of the Party Controlling the relevant Patent and subject to the confidentiality provisions of ARTICLE 12. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> Assignments in the MacroGenics Patents, Joint Patents and Company Patents shall be effected as follows:
(i)&nbsp;employees or agents of MacroGenics (or its Affiliates) that are named as inventors on the MacroGenics Patents shall assign their interest in such Patents to MacroGenics or its Affiliate; (ii)&nbsp;employees or agents of Company or
MacroGenics (or their respective Affiliates) that are named as inventors on the Joint Patents shall assign their interest in such Patents to their respective employer; and (iii)&nbsp;employees or agents of Company (or its Affiliates) that are named
as inventors on the Company Patents shall assign their interests in such Patents to Company or its Affiliate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10.4 <U>Patent Term Extensions in the Territory</U></B>. Company shall decide for which, if any, of the
MacroGenics Product Patents, Joint Patents, Company Patents or other Patents Controlled by Company, its Affiliates or designees the Parties should seek patent term extensions, supplemental protection certificates or their equivalents (each a
&#147;<B>Patent Extension</B>&#148; and collectively &#147;<B>Patent Extensions</B>&#148;) in the Territory and Company shall have the right to seek such Patent Extensions. In the event that the opportunity to seek a Patent Extension, supplemental
protection certificate or an equivalent becomes available for a Product in the Territory based on [***] and if Company, its Affiliates or designees do not seek a Patent Extension for [***], subject to the provisions of this Section&nbsp;10.4,
MacroGenics shall have the right, but not the obligation, to [***] and Company shall reasonably cooperate with MacroGenics in [***]. MacroGenics shall not seek any Patent Extension that is reasonably likely to have a material adverse effect on the
Commercialization of the Product or if there is a good faith dispute between the Parties as to whether a Patent Extension is being sought for a Patent that does not Cover the applicable Product (a &#147;<B>Good Faith Dispute</B>&#148;). In the event
that Company does not intend to seek Patent Extensions for any [***], it shall so inform MacroGenics in writing in sufficient time to permit MacroGenics to seek a Patent Extension. MacroGenics shall not seek any such Patent Extension unless it first
engages in good faith discussions with Company regarding Company&#146;s reasons for not seeking Patent Extensions and MacroGenics&#146; rationale and plans for seeking Patent Extensions, but, unless a Good Faith Dispute still exists, thereafter
shall have the right to seek such Patent Extensions. The Party that does not apply for a Patent Extension hereunder will cooperate fully with the other Party in making such filings or actions, including making available all required regulatory data
and Information and executing any required authorizations to apply for such Patent Extension. All expenses incurred in connection with activities of each Party with respect to the Patent(s) for which such Party seeks Patent Extension pursuant to
this Section&nbsp;10.4 shall be entirely borne by such Party. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10.5 <U>Infringement of Patents by Third Parties</U></B>.<B> </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(a)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Notification</B>. Each Party shall promptly notify the other Party in writing of any existing, alleged or threatened infringement of any MacroGenics Patent, Joint Patent or Company Patent of which it becomes aware,
and shall provide all Information in such Party&#146;s possession or control demonstrating such infringement. </TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(b)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Infringement of MacroGenics Patents or Joint Patents</B>. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(i)</B>
Company, subject to Section&nbsp;10.5(b)(ii) through 10.5(b)(vii), shall have the first right, but not the obligation, to bring an appropriate suit or other action against any Third Party engaged in any existing, alleged or threatened infringement
of any: (i)&nbsp;MacroGenics Product Patent or Joint Patent; and (ii)&nbsp;MacroGenics Platform Patent with respect to a Competitive Infringement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> Company shall notify MacroGenics of its election to take any action
in accordance with Section&nbsp;10.5(b)(i) within the earlier of: (i[***] after the first notice under Section&nbsp;10.5(a); or (ii)&nbsp;[***] before any time limit set forth in Applicable Law or regulation, including the time limits set forth
under the Hatch-Waxman Act. Notwithstanding the foregoing sentence, Company shall not initiate any such suit or take such other action with respect to any MacroGenics Product Patent or Joint Patent without first consulting with MacroGenics and
giving good faith consideration to any reasonable objection from MacroGenics regarding Company&#146;s proposed course of action, and Company shall not initiate any such suit or take such other action with respect to a MacroGenics Platform Patent
without the prior written consent of MacroGenics, such consent not to be unreasonably withheld, delayed or conditioned. Should MacroGenics reasonably withhold such consent, MacroGenics shall keep Company reasonably informed of any enforcement
efforts with respect to the MacroGenics Platform Patents and shall consider Company&#146;s comments regarding such enforcement in good faith. MacroGenics shall cooperate in the prosecution of any suit under this Section&nbsp;10.5 as may be
reasonably requested by Company. In the event that Company elects not to initiate a lawsuit or take other reasonable action with respect to an infringement described in Section&nbsp;10.5(b)(i), MacroGenics shall have the right, but not the
obligation, to initiate such suit or take such other action, after providing [***] notice to Company and giving good faith consideration to Company&#146;s reason(s) for not initiating a suit or taking other action. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> If one Party elects to bring suit or take action under this Section&nbsp;10.5(b) against an infringement, then the
other Party shall have the right, prior to commencement of the suit or action, to join any such suit or action. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> Each Party shall provide to the Party enforcing any such rights under this Section&nbsp;10.5(b) reasonable
assistance in such enforcement, at such enforcing Party&#146;s request and expense, including joining such action as a party plaintiff if required by Applicable Law to pursue such action. The enforcing Party shall keep the other Party regularly
informed of the status and progress of such enforcement efforts, shall reasonably consider the other Party&#146;s comments on any such efforts, and shall consult the other Party in any important aspects of such enforcement, including determination
of material litigation strategy and filing of important papers to the competent court. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(v) </B>Each Party shall bear
all of its own internal costs incurred in connection with its activities under this Section&nbsp;10.5(b). In the event that the Parties are joined in suit or action against the infringement or the non-enforcing Party elects to join such suit or
action and, in either case, elects to be represented by the same outside counsel as the enforcing Party, then the enforcing Party shall be responsible for all expenses arising from such outside counsel, <U>provided</U> that the enforcing Party
consents to such joint representation by outside counsel, such consent not to be unreasonably withheld, delayed or conditioned. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(vi)</B> The Party not bringing an action with respect to infringement in the
Territory under this Section&nbsp;10.5(b) shall be entitled to separate representation in such matter by counsel of its own choice and at its own expense, but such Party shall at all times cooperate fully with the Party bringing such action. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(vii)</B> Neither Party shall settle any claim, suit or action that it brought under this Section&nbsp;10.5 involving
MacroGenics Product Patents or Joint Patents without the prior written consent of the other Party, such consent not to be unreasonably withheld, delayed or conditioned. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(c)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Infringement of Company Patents</B>. For any and all infringement of any Company Patent, Company shall have the sole and exclusive right, but not the obligation, to bring, at Company&#146;s expense and in its sole
control, an appropriate suit or other action against any person or entity engaged in such infringement of the Company Patent. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(d)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Allocation of Proceeds</B>. If either Party recovers monetary damages from any Third Party in a suit or action brought under Section&nbsp;10.5(b), 10.7(a) or 10.7(b) or any royalties, milestones or other payments
from a license agreement with a Third Party related to any alleged infringement related to a Product, whether such damages or royalties result from the infringement of MacroGenics Patents, Joint Patents or Company Patents, such recovery
(&#147;<B>Infringement Recovery</B>&#148;) shall be allocated first to the reimbursement of any expenses incurred by the Parties in such litigation, action or license negotiations, and any remaining amounts shall be allocated as follows:
</TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> with respect to suits or actions brought by Company resulting in an Infringement Recovery
relating to the Initial Product in the Northern American Territory during the Co-Funding Term, [***] to Company and [***] to MacroGenics; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> with respect to suits or actions brought by Company resulting in an Infringement Recovery relating to (w)&nbsp;the
Initial Product outside the Northern American Territory during the Co-Funding Term, (x)&nbsp;the Initial Product in the Northern American Territory after the Co-Funding Term if the Co-Funding Term is terminated, (y)&nbsp;the Initial Product anywhere
in the world if MacroGenics does not exercise the Co-Funding Option or (z)&nbsp;any Product other than the Initial Product anywhere in the world, then (1)&nbsp;if the reward is based on lost profits, an amount equal to the royalty that would be
payable pursuant to Section&nbsp;9.4 on the imputed amount of Net Sales of the relevant Product(s) in the country(ies) where such infringement occurred, or (y)&nbsp;if the reward reflects royalty payments, such reward shall be considered Net Sales
and subject to the applicable royalty in accordance with Section&nbsp;9.4; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> with respect to suits or
actions brought by MacroGenics, the Infringement Recovery shall be retained by MacroGenics. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10.6 <U>Infringement of Third Party Rights in the Territory</U></B>.<B> </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(a)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Notice</B>. If any Product used or sold by either Party, its Affiliates, or sublicensees in the Field becomes the subject of a Third Party&#146;s claim or assertion of infringement of a Patent granted by a
jurisdiction within the Territory, the Party first having notice of the claim or assertion shall promptly notify the other Party. </TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(b)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Defense</B>. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> Company shall have the first right, but not the
obligation, to defend any such Third Party claim or assertion of infringement, other than a [***], of a Patent as described in Section&nbsp;10.6(a), at Company&#146;s expense. If Company does not commence actions to defend such claim within [***
]after it receives notice thereof (or within [***] after it should have given notice thereof to MacroGenics as required by Section&nbsp;10.6(a)), then, to the extent allowed by Applicable Law, MacroGenics shall have the right, but not the
obligation, to control the defense of such claim by counsel of its choice, at MacroGenics&#146; expense. The non-defending Party shall reasonably cooperate with the Party conducting the defense of the claim or assertion, including if required to
conduct such defense, furnishing a power of attorney. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> MacroGenics shall have the first right, but not the
obligation, to defend any [***] at MacroGenics&#146; expense. If MacroGenics does not commence actions to defend or settle such [***]within [***]after it receives notice thereof, then, to the extent allowed by Applicable Law, Company shall have the
right, but not the obligation, to control the defense of such claim by counsel of its choice, at MacroGenics&#146; expense. The non-defending Party shall reasonably cooperate with the Party conducting the defense of the claim or assertion, including
if required to conduct such defense, furnishing a power of attorney. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(c)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Settlement; Licenses</B>. MacroGenics shall not enter into any settlement of any claim described in this Section 10.6 that affects Company&#146;s rights or interests without Company&#146;s prior written consent, such
consent not to be unreasonably withheld, delayed or conditioned. For purposes of clarification, MacroGenics shall not be required to obtain Company&#146;s consent to enter into a settlement of a [***] that it elects to settle under Section
10.6(b)(ii), <U>provided</U> that Company is given prior notice of such proposed settlement with a reasonable amount of time to review and comment and, unless such settlement is likely to detrimentally affect Company&#146;s material rights or
interest, as communicated to MacroGenics by Company. Except for a settlement of a [***] that MacroGenics declined to defend or settle under Section 10.6(b)(ii), Company shall not enter into any settlement of any claim described in this Section 10.6
that detrimentally affects MacroGenics&#146; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
material rights or interests without MacroGenics&#146; written consent, such consent not to be unreasonably withheld, delayed or conditioned. Each Party shall have the right to decline to defend
or to tender defense of any claim described in this Section&nbsp;10.6 upon reasonable notice to the other Party, including if the other Party fails to agree to a settlement that the declining Party proposes. In the event that it is determined by any
court of competent jurisdiction that the research, Development, Manufacture, or Commercialization of a Product, conducted in accordance with the terms and conditions of this Agreement, infringes, or Company determines reasonably and in good faith
that such activities are likely to infringe, any Patent, copyright, trademark, data exclusivity right or trade secret right arising under Applicable Law of any Third Party, Company shall use Commercially Reasonable Efforts to: [***]. To the extent
such a license relates to the Commercialization of a Product, the cost of such license shall be considered a Third Party Obligation and allocated between the Parties in accordance with Section&nbsp;9.10. In the event that Company decides that
neither of the foregoing alternatives is reasonably available or commercially feasible, Company may, at its discretion, terminate this Agreement for the Product affected in accordance with Section&nbsp;13.2. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10.7 <U>Patent Oppositions and Other Proceedings</U></B>.<B> </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(a)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Third Party Patent Rights</B>. If either Party desires to bring an opposition, action for declaratory judgment, nullity action, interference, declaration for non-infringement, reexamination or other attack upon the
validity, title or enforceability of a Patent owned or controlled by a Third Party and having one or more claims that Cover a Product, or the use, sale, offer for sale or importation of a Product (except insofar as such action is a counterclaim to
or defense of, or accompanies a defense of, a Third Party&#146;s claim or assertion of infringement under Section&nbsp;10.6, in which case the provisions of Section&nbsp;10.6 shall govern), such Party shall so notify the other Party and the Parties
shall promptly confer to determine whether to bring such action or the manner in which to settle such action. Company shall have the exclusive right, but not the obligation, to bring, at its own expense and in its sole control, such action in the
Territory. If Company does not bring such an action in the Territory within [***] of notification thereof pursuant to this Section&nbsp;10.7(a) (or earlier, if required by the nature of the proceeding), then MacroGenics shall have the right, but not
the obligation, to bring such action, at MacroGenics&#146; own expense. The Party not bringing an action under this Section&nbsp;10.7(a) shall be entitled to separate representation in such proceeding by counsel of its own choice and at its own
expense, and shall cooperate fully with the Party bringing such action. Any awards or amounts received in bringing any such action shall be first allocated to reimburse the initiating Party&#146;s expenses in such action, and any remaining amounts
shall be allocated between the Parties as provided in Section&nbsp;10.5(d). </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">67 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(b)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Parties&#146; Patent Rights</B>. If any MacroGenics Product Patent or Joint Patent becomes the subject of any proceeding commenced by a Third Party within the Territory in connection with an opposition, reexamination
request, action for declaratory judgment, nullity action, interference or other attack upon the validity, title or enforceability thereof (a &#147;<B>Third Party Patent Challenge</B>&#148;) (except insofar as such action is a counterclaim to or
defense of, or accompanies a defense of, an action for infringement against a Third Party under Section&nbsp;10.6, in which case the provisions of Section&nbsp;10.6 shall govern), then the Party responsible for filing, preparing, prosecuting and
maintaining such Patent as set forth in Section&nbsp;10.3 hereof shall control such defense at its own expense. The controlling Party shall permit the non-controlling Party to participate in the proceeding to the extent permissible under Applicable
Law, and to be represented by its own counsel in such proceeding, at the non-controlling Party&#146;s expense. If either Party decides that it does not wish to defend against such action, then the other Party shall have a backup right to assume
defense of such Third Party action at its own expense. Any awards or amounts received in defending any such Third Party action shall be allocated between the Parties as provided in Section&nbsp;10.5(d). MacroGenics shall have the sole discretion
whether to defend and shall solely control any defense of a Platform Patent which is the subject of a Third Party Patent Challenge, <U>provided</U> that MacroGenics shall keep Company reasonably informed regarding such enforcement and shall consider
Company&#146;s comments regarding such enforcement in good faith. </TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 11</B> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>REPRESENTATIONS, WARRANTIES AND COVENANTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11.1 <U>Mutual Representations, Warranties and Covenants</U></B>. Each of the Parties hereby represents and warrants to the other Party as of the Execution
Date and, as applicable, hereinafter covenants that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(a)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Organization</B>. It is a corporation duly organized, validly existing, and in good standing under the laws of the jurisdiction of its organization, and has all requisite power and authority, corporate or otherwise,
to execute, deliver, and perform this Agreement. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(b)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Binding Agreement</B>. This Agreement is a legal and valid obligation binding upon such Party and enforceable in accordance with its terms, subject to the effects of bankruptcy, insolvency, or other laws of general
application affecting the enforcement of creditor rights, judicial principles affecting the availability of specific performance, and general principles of equity (whether enforceability is considered a proceeding at law or equity).
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(c)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE="font-family:Times New Roman; font-size:10pt"><B>Authorization</B>. The execution, delivery, and performance of this Agreement by such Party have been duly authorized by all necessary corporate
action and do not </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">68 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
conflict with any agreement, obligation, instrument, or understanding, oral or written, to which it is a party or by which it is bound, nor violate any Applicable Law or any order, writ,
judgment, injunction, decree, determination, or award of any Governmental Authority presently in effect applicable to such Party. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(d)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>No Further Approval</B>. It is not aware of any government authorization, consent, approval, license, exemption of or filing or registration with any Governmental Authority under any Applicable Law, currently in
effect, necessary for, or in connection with, the transactions contemplated by this Agreement or any other agreement or instrument executed in connection herewith, or for the performance by it of its obligations under this Agreement and such other
agreements (save for Regulatory Approvals and similar authorizations from Governmental Authorities necessary for the Exploitation of the Compounds and Products as contemplated hereunder), except as may be required to obtain clearance of this
Agreement under the HSR Act. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(e)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>No Inconsistent Obligations</B>. It is not under any obligation, contractual or otherwise, to any Person that conflicts with or is inconsistent in any material respect with the terms of this Agreement, or that would
impede the diligent and complete fulfillment of its obligations hereunder. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11.2 <U>Additional Representations and Warranties of
MacroGenics</U></B>. MacroGenics represents and warrants as of the Execution Date and, as applicable, covenants to Company that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(a)</B></TD>
<TD ALIGN="left" VALIGN="top">MacroGenics (or its Affiliates) is the sole and exclusive owner of, or otherwise Controls pursuant to an existing Third Party agreement, the MacroGenics Technology and the Regulatory Materials. MacroGenics has all
rights necessary to grant the licenses under the MacroGenics Technology and rights of cross-reference under Regulatory Materials that it grants to Company in this Agreement. During the Term, MacroGenics shall not, and shall cause its Affiliates not
to, grant to any Third Party rights that encumber or conflict with the rights granted to Company hereunder with respect to the MacroGenics Technology or Regulatory Materials. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(b)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE="font-family:Times New Roman; font-size:10pt"><B></B>The Patents set forth in <U>Exhibit C</U> (&#147;<B>Licensed Patents</B>&#148;) represent all Patents that MacroGenics or any of its Affiliates
owns or Controls that Cover or disclose any invention necessary or used for the Exploitation of the Compounds or Products in the Territory in the Field as of the Execution Date. The Licensed Patents are free and clear of liens, charges or
encumbrances other than licenses granted to Third Parties that are not inconsistent with the rights and licenses granted to Company hereunder. No Third Party has challenged or threatened in writing to challenge the scope, validity or enforceability
of any Licensed Patent (including, by way of example, through opposition or the institution or written threat of institution of interference, nullity or similar invalidity proceedings before the U.S. Patent and Trademark Office or any analogous
foreign Governmental Authorities). MacroGenics or its Affiliates have timely paid all filing and renewal fees payable </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">69 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
with respect to any Licensed Patents for which MacroGenics controls prosecution and maintenance. The development of the Licensed Patents has not been funded, in whole or in part, by the U.S.
government. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(c)</B></TD>
<TD ALIGN="left" VALIGN="top">MacroGenics or any of its Affiliates owns or Controls all MacroGenics Know-How necessary or useful for the Exploitation of the Compounds or Products in the Territory in the Field. The MacroGenics Know-How is free and
clear of liens, charges or encumbrances other than licenses granted to Third Parties that are not inconsistent with the rights and licenses granted to Company hereunder. MacroGenics and its Affiliates have taken commercially reasonable measures
consistent with industry practices to protect the secrecy, confidentiality and value of all MacroGenics Know-How that constitutes trade secrets under Applicable Law (including requiring all employees, consultants and independent contractors to
execute binding and enforceable agreements requiring all such employees, consultants and independent contractors to maintain the confidentiality of such MacroGenics Know-How). The development of the MacroGenics Know-How has not been funded, in whole
or in part, by the U.S. government. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(d)</B></TD>
<TD ALIGN="left" VALIGN="top">There is no actual or, to MacroGenics&#146; Knowledge, threatened infringement or misappropriation of the MacroGenics Technology by any Person in the Territory. MacroGenics has not received any written notice or threat
of any material suit, legal claim, action, proceeding or investigation against MacroGenics or any of its Affiliates that relates to the MacroGenics Technology, and no judgment or settlement is owed by MacroGenics or any of its Affiliates in
connection with the MacroGenics Technology. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(e)</B></TD>
<TD ALIGN="left" VALIGN="top">The MacroGenics Technology collectively constitutes all intellectual property Controlled by MacroGenics that is necessary or useful for the Exploitation of the Compounds and the Products. To MacroGenics&#146; Knowledge,
except as otherwise disclosed by MacroGenics to Company, or discussed by the Parties, during the course of preparing this Agreement, the Exploitation of the Compounds or Products in the Field in the Territory does not and will not infringe or
misappropriate the Patents (including any Third Party patent application published as of the Execution Date, when and if the claims thereunder issue in their current form) or other intellectual property or proprietary rights of any Third Party in
the Territory. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(f)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE="font-family:Times New Roman; font-size:10pt">All current and former officers, employees, agents, advisors, consultants, contractors or other representatives of MacroGenics or any of its
Affiliates who are inventors of or have otherwise contributed in a material manner to the creation or development of any MacroGenics Technology have executed and delivered to MacroGenics or any such Affiliate a valid and enforceable assignment or
other agreement regarding the protection of proprietary Information and the assignment to MacroGenics or any such Affiliate of such person&#146;s entire right, title and interest in and to any MacroGenics Technology. To MacroGenics&#146; Knowledge,
no current </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">70 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
officer, employee, agent, advisor, consultant or other representative of MacroGenics or any of its Affiliates is in violation of any term of any assignment or other agreement regarding the
protection of MacroGenics Patents or other MacroGenics Technology or of any employment contract or any other contractual obligation relating to the relationship of any such Person with MacroGenics or any such Affiliate. Company shall have no
obligation to contribute to any remuneration of any inventor employed or previously employed by MacroGenics or any of its Affiliates in respect of any such inventions, Information and discoveries and intellectual property rights therein that are so
assigned to MacroGenics or its Affiliate(s). MacroGenics will pay all such remuneration due to such inventors with respect to such inventions and other Know-How and intellectual property rights therein. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(g)</B></TD>
<TD ALIGN="left" VALIGN="top">MacroGenics has (i)&nbsp;prepared, maintained and retained all Regulatory Materials for the Compounds and the Products in the Territory pursuant to and in accordance in all material respects with all Applicable Law,
including, as applicable, GLP, and such Regulatory Materials do not contain any materially false and misleading statements; (ii)&nbsp;MacroGenics has conducted, and has used Commercially Reasonable Efforts to cause its contractors and consultants to
conduct, all studies, tests and pre-clinical trials of the Compounds and the Products conducted prior to, or being conducted on, the Execution Date in accordance with the applicable experimental protocols, procedures and controls pursuant to
accepted professional scientific standards, accepted ethical standards and Applicable Law, including, as applicable, GLP; (iii)&nbsp;except as disclosed in writing by MacroGenics to Company prior to the Execution Date, no adverse event involving
human subjects has occurred in connection with any study, test or pre-clinical trial of the Compounds or the Products; and (iv)&nbsp;MacroGenics has disclosed to Company all material data and other information in its control generated in the design,
approval, undertaking and reporting of any study or pre-clinical trial involving the Compounds or the Products. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(h)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE="font-family:Times New Roman; font-size:10pt">Neither MacroGenics nor any of its Affiliates has been debarred by the FDA, is the subject of a conviction described in Section&nbsp;306 of the FFDCA
or is subject to any similar sanction of other Governmental Authorities in the Territory, and neither MacroGenics nor any of its Affiliates has used, in any capacity, any Person who either has been debarred by the FDA, is the subject of a conviction
described in Section&nbsp;306 of the FFDCA or is subject to any such similar sanction. MacroGenics shall not engage, in any capacity in connection with this Agreement or any ancillary agreements, any Person who either has been debarred by the FDA,
is the subject of a conviction described in Section&nbsp;306 of the FFDCA or is subject to any such similar sanction. MacroGenics shall inform Company in writing promptly if it or any Person engaged by MacroGenics or any of its Affiliates who is
performing services under this Agreement or any ancillary agreements is debarred or is the subject of a conviction described in Section&nbsp;306 of the FFDCA, or if any action, </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">71 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
suit, claim, investigation or legal or administrative proceeding is pending or, to MacroGenics&#146; Knowledge, is threatened, relating to the debarment or conviction of MacroGenics, any of its
Affiliates or any such Person performing services hereunder or thereunder. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11.3 <U>Additional Representations and Warranties of
Company</U></B>. Company represents and warrants as of the Execution Date and covenants to MacroGenics that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(a)</B></TD>
<TD ALIGN="left" VALIGN="top">Neither Company nor any of its Affiliates has been debarred by the FDA, is the subject of a conviction described in Section&nbsp;306 of the FFDCA or is subject to any similar sanction of other Governmental Authorities
in the Territory, and neither Company nor any of its Affiliates has used, in any capacity, any Person who either has been debarred by the FDA, is the subject of a conviction described in Section&nbsp;306 of the FFDCA or is subject to any such
similar sanction. Company shall not engage, in any capacity in connection with this Agreement or any ancillary agreements, any Person who either has been debarred by the FDA, is the subject of a conviction described in Section&nbsp;306 of the FFDCA
or is subject to any such similar sanction. Company shall inform MacroGenics in writing promptly if it or any Person engaged by Company or any of its Affiliates who is performing services under this Agreement or any ancillary agreements is debarred
or is the subject of a conviction described in Section&nbsp;306 of the FFDCA, or if any action, suit, claim, investigation or legal or administrative proceeding is pending or, to Company&#146;s Knowledge, is threatened, relating to the debarment or
conviction of Company, any of its Affiliates or any such Person performing services hereunder or thereunder. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(b)</B></TD>
<TD ALIGN="left" VALIGN="top">Company is not subject to any agreement with any Third Party which would limit or restrict its ability to perform its obligations under this Agreement in any material respect. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11.4 No Other Representations or Warranties</B>. EXCEPT AS EXPRESSLY SET FORTH IN THIS ARTICLE 11, THE PARTIES MAKE NO REPRESENTATIONS OR WARRANTIES OF ANY
KIND WHATSOEVER, EITHER EXPRESS OR IMPLIED, WRITTEN OR ORAL, IN FACT OR BY OPERATION OF LAW, BY STATUTE OR OTHERWISE, AND EACH PARTY SPECIFICALLY DISCLAIMS ANY OTHER WARRANTIES, INCLUDING ANY EXPRESS OR IMPLIED WARRANTY OF QUALITY, MERCHANTABILITY,
FITNESS FOR A PARTICULAR PURPOSE, OR WARRANTY OF NON-INFRINGEMENT OR AS TO THE VALIDITY OF ANY PATENTS. EACH PARTY HEREBY DISCLAIMS ANY REPRESENTATION OR WARRANTY THAT THE DEVELOPMENT, MANUFACTURE OR COMMERCIALIZATION OF ANY PRODUCT PURSUANT TO THIS
AGREEMENT WILL BE SUCCESSFUL OR THAT ANY PARTICULAR SALES LEVEL WITH RESPECT TO ANY PRODUCT WILL BE ACHIEVED. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">72 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 12</B> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONFIDENTIALITY </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12.1
<U>Nondisclosure</U></B>. Each Party agrees that, during the Term and for a period of [***] thereafter, the Party (the &#147;<B>Receiving Party</B>&#148;) receiving Confidential Information of the other Party (the &#147;<B>Disclosing
Party</B>&#148;) shall (a)&nbsp;maintain in confidence such Confidential Information using not less than the efforts such Receiving Party uses to maintain in confidence its own confidential or proprietary Information of similar kind and value,
(b)&nbsp;not disclose such Confidential Information to any Third Party without the prior written consent of the Disclosing Party, except for disclosures expressly permitted below, and (c)&nbsp;not use such Confidential Information for any purpose
except those permitted by this Agreement (it being understood that this Section&nbsp;12.1 shall not create or imply any rights or licenses not expressly granted under this Agreement). Notwithstanding anything to the contrary in the foregoing, the
obligations of confidentiality and non-use with respect to any trade secret within such Confidential Information shall survive such [***] period for so long as such Confidential Information remains protected as a trade secret under Applicable Law.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12.2 <U>Exceptions</U></B>. The obligations in Section&nbsp;12.1 shall not apply with respect to any portion of the Confidential Information that the
Receiving Party can show by competent evidence: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(a)</B></TD>
<TD ALIGN="left" VALIGN="top">is publicly disclosed by the Disclosing Party, either before or after it is disclosed to the Receiving Party hereunder; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(b)</B></TD>
<TD ALIGN="left" VALIGN="top">is known to the Receiving Party or any of its Affiliates, without any obligation to keep it confidential or any restriction on its use, in each case, to the Disclosing Party, prior to disclosure to the Receiving Party
or any of its Affiliates by the Disclosing Party; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(c)</B></TD>
<TD ALIGN="left" VALIGN="top">is subsequently disclosed to the Receiving Party or any of its Affiliates on a non-confidential basis by a Third Party that, to the Receiving Party&#146;s Knowledge, is not bound by a similar duty of confidentiality or
restriction on its use, in each case, to the Disclosing Party; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(d)</B></TD>
<TD ALIGN="left" VALIGN="top">is now, or hereafter becomes, through no act or failure to act on the part of the Receiving Party or any of its Affiliates in violation of this Agreement, generally known or available, either before or after it is
disclosed to the Receiving Party by the Disclosing Party; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(e)</B></TD>
<TD ALIGN="left" VALIGN="top">is independently discovered or developed by or on behalf of the Receiving Party or any of its Affiliates without the use of or reference to the Confidential Information belonging to the Disclosing Party; or
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(f)</B></TD>
<TD ALIGN="left" VALIGN="top">is the subject of written permission to disclose provided by the Disclosing Party. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">73 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12.3 <U>Authorized Disclosure</U></B>. The Receiving Party may disclose Confidential Information belonging to
the Disclosing Party only to the extent such disclosure is reasonably necessary in the following instances: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(a)</B></TD>
<TD ALIGN="left" VALIGN="top">filing, prosecuting, maintaining, enforcing or defending Patents as permitted by this Agreement; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(b)</B></TD>
<TD ALIGN="left" VALIGN="top">as reasonably required in generating Regulatory Materials and obtaining Regulatory Approvals; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(c)</B></TD>
<TD ALIGN="left" VALIGN="top">prosecuting or defending litigation, including responding to a subpoena in a Third Party litigation; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(d)</B></TD>
<TD ALIGN="left" VALIGN="top">complying with Applicable Law or court or administrative orders; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(e)</B></TD>
<TD ALIGN="left" VALIGN="top"><B></B>complying with any obligation under this Agreement; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(f)</B></TD>
<TD ALIGN="left" VALIGN="top"><B></B>in communications with existing or bona fide prospective acquirers, merger partners, financing sources, investment bankers, lenders or investors, and consultants and advisors of the Receiving Party in connection
with transactions or bona fide prospective transactions with the foregoing, in each case on a need to know basis and under appropriate confidentiality provisions substantially equivalent to those of this Agreement; <U>provided</U><I>,
</I><U>however</U>, that the Receiving Party shall remain responsible for any violation of such confidentiality provisions by any Third Party receiving such Confidential Information; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(g)</B></TD>
<TD ALIGN="left" VALIGN="top"><B></B>to its Affiliates, sublicensees or prospective sublicensees, subcontractors or prospective subcontractors, consultants, agents and advisors on a &#147;need-to-know&#148; basis in order for the Receiving Party to
exercise its rights or fulfill its obligations under this Agreement, each of whom prior to disclosure must be bound by obligations of confidentiality and restrictions on use of such Confidential Information that are no less restrictive than those
set forth in this ARTICLE 12; <U>provided</U>, <U>however</U>, that, in each of the above situations, the Receiving Party shall remain responsible for any failure by any Person who receives Confidential Information pursuant to this
Section&nbsp;12.3(g) to treat such Confidential Information as required under this ARTICLE 12. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If and whenever any
Confidential Information is disclosed in accordance with this Section&nbsp;12.3, such disclosure shall not cause any such information to cease to be Confidential Information except to the extent that such disclosure results in a public disclosure of
such information (other than by breach of this Agreement). Notwithstanding the foregoing, in the event a Party is required to make a disclosure of the other Party&#146;s Confidential Information pursuant to Section&nbsp;12.3(a) through
Section&nbsp;12.3(e), it will, except where impracticable or not legally permitted, give reasonable advance notice to the other Party of such disclosure and use not less than the same efforts to secure confidential treatment of such information as
it would to protect its own confidential information from disclosure. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">74 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12.4 <U>Terms of this Agreement</U></B>. The Parties acknowledge that this Agreement and all of the respective
terms of this Agreement shall be treated as Confidential Information of both Parties, subject to the provisions of Sections 12.3(f), 12.3(g) and 12.6. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12.5 <U>Publicity</U></B>. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(a)</B></TD>
<TD ALIGN="left" VALIGN="top">Each Party may, but is not obligated to, make a public announcement of the execution of this Agreement in the form attached as <U>Exhibit F</U> to this Agreement, which shall be issued at a time to be mutually agreed by
the Parties, but no later than [***] after the Execution Date. Except as required to comply with Applicable Law or as set forth in subsection (b), each Party agrees not to issue any other press release or other public statement disclosing other
information relating to this Agreement or the transactions contemplated hereby without the prior written consent of the other Party, such consent not to be unreasonably withheld, delayed or conditioned. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(b)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE="font-family:Times New Roman; font-size:10pt">The Parties acknowledge the importance of supporting each other&#146;s efforts to publicly disclose results and significant developments regarding the
Products and other activities in connection with this Agreement that may include information that is not otherwise permitted to be disclosed under this ARTICLE 12, and that may be beyond what is required by Applicable Law, but in each case
consistent with the need to keep investors informed regarding such Party&#146;s business in accordance with customary investor relations, and each Party may request to the right to make such disclosures from time to time. Such disclosures may
include achievement of milestones, significant events in the Development and regulatory process, Commercialization activities and the like. Except for the initial press release(s) described in subsection (a), whenever a Party (the
&#147;<B>Requesting Party</B>&#148;) elects to make any such public disclosure, it shall first notify the other Party (the &#147;<B>Cooperating Party</B>&#148;) of such planned press release or public announcement and provide a draft for review at
least [***] in advance of issuing such press release or making such public announcement (or, with respect to press releases and public announcements that are required by Applicable Law, or by regulation or rule of any public stock exchange
(including NASDAQ), with as much advance notice as possible under the circumstances if it is not possible to provide notice at least [***] in advance). The Requesting Party and Cooperating Party will discuss such proposed public disclosure in good
faith. Unless otherwise permitted pursuant to Section&nbsp;12.6 or required by Applicable Law, or by regulation or rule of any public stock exchange (including NASDAQ), the Requesting Party will not issue such press release or make such public
announcement without the prior written consent of the Cooperating Party, not to be unreasonably withheld, conditioned or delayed, <U>provided</U> that a Party may issue such press release or make such public announcement if: (i)&nbsp;the contents of
such press release or public announcement have </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">75 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
previously been made public other than through a breach of this Agreement by the Requesting Party, (ii)&nbsp;such press release or public announcement does not materially differ from the
previously issued press release or other publicly available information, (iii)&nbsp;such press release or public announcement does not contain the Cooperating Party&#146;s name and (iv)&nbsp;the Requesting Party notifies the Cooperating Party
reasonably in advance of issuance. The principles to be observed in such disclosures shall include accuracy, compliance with applicable Law and regulatory guidance documents, reasonable sensitivity to potential negative reactions of the FDA (and its
foreign counterparts), the need to protect competitively sensitive information regarding the Products and the need to keep investors informed regarding the Requesting Party&#146;s business. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12.6 <U>Securities Filings</U></B>. Notwithstanding anything to the contrary in this ARTICLE 12, in the event either Party proposes to file with the
Securities and Exchange Commission or the securities regulators of any state or other jurisdiction a registration statement or any other disclosure document that describes or refers to the terms and conditions of this Agreement or any related
agreements between the Parties, or requires the filing of this Agreement as an exhibit to such registration, statement or disclosure document, such Party shall notify the other Party of such intention and shall provide the other Party with a copy of
relevant portions of the proposed filing at least [***]prior to such filing (and any revisions to such portions of the proposed filing a reasonable time prior to the filing thereof), including any exhibits thereto that refer to the other Party or
the terms and conditions of this Agreement or any related Agreements between the Parties. The Party making such filing shall cooperate in good faith with the other Party to obtain confidential treatment of the terms and conditions of this Agreement
or any related Agreements between the Parties that the other Party reasonably requests be kept confidential or otherwise afforded confidential treatment, and shall only disclose Confidential Information that it is advised by outside counsel is
legally required to be disclosed. Each Party acknowledges that the other Party may be required by securities regulators, including the Securities and Exchange Commission, or advised by such other Party&#146;s outside counsel that the financial
terms, including the milestone amounts and/or royalty rates must be included in such filings. No notice shall be required under this Section&nbsp;12.6 if the description of or reference to this Agreement or a related agreement between the Parties
contained in the proposed filing has been included in any previous filing made by either Party in accordance with this Section&nbsp;12.6 or otherwise approved by the other Party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12.7</B> <B><U>Relationship to Confidentiality Agreement</U></B>. This Agreement supersedes the Prior CDA; <U>provided</U>, <U>however</U>, that all
&#147;Confidential Information&#148; disclosed or received by the Parties and their Affiliates thereunder shall be deemed Confidential Information hereunder and shall be subject to the terms and conditions of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12.8 <U>Equitable Relief</U></B>. Given the nature of the Confidential Information and the competitive damage that could result to a Party upon
unauthorized disclosure, use or transfer of its Confidential Information to any Third Party, the Parties agree that monetary damages may not be a sufficient remedy for any breach of this ARTICLE 12. In addition to all other remedies, a Party shall
be entitled to seek specific performance and injunctive and other equitable relief as a remedy for any breach or threatened breach of this ARTICLE 12. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">76 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12.9 <U>Publications</U></B>. Company shall have the right to publish results of all Clinical Trials conducted
with respect to a Compound or a Product; <U>provided</U>, <U>however</U>, that MacroGenics shall have the right to review all proposed publications prior to submission of such publication, solely for the purposes of identifying any relevant
intellectual property or Confidential Information of MacroGenics. Company shall provide MacroGenics with a copy of the applicable proposed abstract, manuscript, or presentation no less than [***] in the case of abstracts) prior to its intended
submission for publication. MacroGenics shall respond in writing promptly and in no event later than [***] in the case of abstracts) after receipt of the proposed material with any concerns regarding patentability or protection of MacroGenics&#146;
Confidential Information. In the event of concern over patent protection, Company agrees not to submit such publication or to make such presentation that contains such information until MacroGenics is given a reasonable period of time, and in no
event less than [***], to seek patent protection for any material in such publication or presentation which it believes is patentable, unless Company reasonably determines that publication of such information is required by Applicable Law. Subject
to Section&nbsp;12.3, any Confidential Information of MacroGenics shall, if requested by the reviewing Party, be removed by Company from such publication or presentation, except to the extent inclusion of such Confidential Information is required to
comply with Johnson&nbsp;&amp; Johnson&#146;s clinical trial publication policy. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 13</B> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TERM AND TERMINATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13.1
<U>Term</U></B>. This Agreement shall become effective as of the Execution Date and, unless earlier terminated pursuant to this ARTICLE 13, shall continue in full force and effect as long as Company continues to Exploit the Compounds or the Products
in accordance with the terms and conditions of this Agreement (the &#147;<B>Term</B>&#148;). The provisions of ARTICLE 1 (Definitions), ARTICLE 11 (Representations, Warranties and Covenants), ARTICLE 12 (Confidentiality), ARTICLE 14 (Dispute
Resolution), ARTICLE 15 (Indemnification) and ARTICLE 16 (Miscellaneous), and Section&nbsp;13.3 (Termination for Material Breach) and Section&nbsp;13.6 (HSR Filing; Termination Upon HSR Denial), shall become effective on the Execution Date; the
other provisions of this Agreement shall not become effective until the Effective Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13.2 <U>Unilateral Termination by Company</U></B>. Company
shall have the right to terminate this Agreement in its entirety, or on a Product-by-Product basis, at any time after the Execution Date, for any or no reason, upon providing [***] prior written notice to MacroGenics. Notwithstanding the foregoing,
in the event that Company provides such a notice of termination, MacroGenics may, in its sole discretion, reduce the [***] notice period to a period determined by MacroGenics by written notice to Company. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13.3 <U>Termination for Material Breach</U></B>. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(a)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE="font-family:Times New Roman; font-size:10pt">Either Party (the &#147;<B>Terminating Party</B>&#148;) may terminate this Agreement in its entirety, or on a country-by-country and
Product-by-Product basis, in the event the </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">77 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
other Party (the &#147;<B>Breaching Party</B>&#148;) has materially breached this Agreement, and such material breach has not been cured within [***] after receipt of written notice of such
breach by the Breaching Party from the Terminating Party (the &#147;<B>Cure Period</B>&#148;). The written notice describing the alleged material breach shall provide sufficient detail to put the Breaching Party on notice of such material breach.
Any termination of this Agreement pursuant to this Section&nbsp;13.3(a) shall become effective at the end of the Cure Period, unless the Breaching Party has cured any such material breach prior to the expiration of such Cure Period (or, if such
material breach is reasonably able to be cured within the Cure Period, the Breaching Party has notified the Terminating Party of its plan for curing such and has commenced and sustained its efforts to cure such material breach during the Cure
Period). The right of either Party to terminate this Agreement as provided in this Section&nbsp;13.3(a) shall not be affected in any way by such Party&#146;s waiver of or failure to take action with respect to any previous breach under this
Agreement. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(b)</B></TD>
<TD ALIGN="left" VALIGN="top">If the Parties reasonably and in good faith disagree as to whether there has been a material breach or a cure thereof, the Party that disputes whether there has been a material breach or a cure may contest the
allegation in accordance with ARTICLE 14. Notwithstanding anything to the contrary contained in Section&nbsp;13.3(a), the Cure Period for any material breach that is the subject of a Dispute will run from the date that written notice was first
provided to the Breaching Party by the Terminating Party through the resolution of such Dispute pursuant to ARTICLE 14 and for [***] thereafter, and it is understood and acknowledged that, during the pendency of a Dispute pursuant this
Section&nbsp;13.3(b), all of the terms and conditions of this Agreement shall remain in effect, and the Parties shall continue to perform all of their respective obligations under this Agreement, except that all payment obligations from one Party to
the other Party under this Agreement which are subject to the Dispute shall be tolled until the resolution of such Dispute in accordance with ARTICLE 14. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13.4 <U>Termination by Company for Safety Reasons</U></B>. Company shall have the right to terminate this Agreement, at any time after the Effective Date,
with respect to a Product in the Territory at any time upon providing [***] prior written notice to MacroGenics: (a)&nbsp;if senior executives responsible for Company&#146;s pharmacovigilance and clinical science functions determine in good faith
that the risk/benefit profile of the Product is such that the Product cannot continue to be Developed or administered to patients safely; or (b)&nbsp;upon the occurrence of serious adverse events related to the use of the Product that cause Company
to conclude that the continued use of the Product by patients will result in patients being exposed to a product in which the risks outweigh the benefits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13.5 <U>Termination </U></B>[***]. MacroGenics may terminate this Agreement with respect to a Product (or this Agreement in its entirety if such Product is
the only Product for which this Agreement is applicable), [***] <U>provided</U>, <U>however</U>, MacroGenics acknowledges and agrees that nothing in this Section&nbsp;13.5 [***] in this Section&nbsp;13.5 and, <U>provided</U> <U>further</U> that
MacroGenics shall not have the right to terminate if Company: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">78 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(a)</B></TD>
<TD ALIGN="left" VALIGN="top">[***] any [***] </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(b)</B></TD>
<TD ALIGN="left" VALIGN="top">[***] MacroGenics, its Affiliates, sublicensees, successors or designers [***] and/or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(c)</B></TD>
<TD ALIGN="left" VALIGN="top">either (i)&nbsp;[***] that [***] </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13.6 <U>HSR Filing; Termination Upon HSR Denial</U></B>. If Company and
MacroGenics determine that an HSR Filing is necessary, each Party shall, within [***] of the Execution Date (or such later time as may be agreed to in writing by the Parties), file with the United States Federal Trade Commission and the Antitrust
Division of the United States Department of Justice, and/or with equivalent foreign authorities, any HSR Filing required of it under the HSR Act in the reasonable opinion of either Party with respect to the transactions contemplated hereby. Each
Party will use reasonable efforts to do, or cause to be done, all things necessary, proper and advisable to, as promptly as practicable, take all actions necessary to make the filings required of such Party or its Affiliates under the HSR Act. The
Parties shall cooperate with one another to the extent necessary in the preparation of any such HSR Filing. Each Party shall be responsible for its own costs, expenses, and filing fees associated with any HSR Filing; <U>provided</U>, <U>however</U>,
that Company shall be solely responsible for any fees (other than penalties that may be incurred as a result of actions or omissions on the part of MacroGenics) required to be paid to any governmental agency in connection with making any such HSR
Filing. If the Parties make an HSR Filing hereunder, then this Agreement shall terminate (a)&nbsp;at the election of either Party, immediately upon notice to the other Party, if the U.S. Federal Trade Commission or the U.S. Department of Justice, or
an equivalent authority in the European Union, seeks a preliminary injunction under the Antitrust Laws against Company and MacroGenics to enjoin the transactions contemplated by this Agreement; or (b)&nbsp;at the election of either Party,
immediately upon notice to the other Party, in the event that the HSR Clearance Date shall not have occurred on or prior to [***] after the effective date of the HSR Filing. In the event of such termination, this Agreement shall be of no further
force and effect. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13.7 <U>Termination for Bankruptcy</U>.</B> </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(a)</B></TD>
<TD ALIGN="left" VALIGN="top">Either Party may terminate this Agreement in its entirety upon providing written notice to the other Party on or after the time that such other Party makes a general assignment for the benefit of creditors, files an
insolvency petition in bankruptcy, petitions for or acquiesces in the appointment of any receiver, trustee or similar officer to liquidate or conserve its business or any substantial part of its assets, commences under the laws of any jurisdiction
any proceeding involving its insolvency, bankruptcy, reorganization, adjustment of debt, dissolution, liquidation or any other similar proceeding for the release of financially distressed debtors, or becomes a party to any proceeding or action of
the type described above (each, an &#147;Insolvency Event&#148;), and such proceeding or action remains un-dismissed or un-stayed for a period of more than [***]. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">79 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(b)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE="font-family:Times New Roman; font-size:10pt"><B></B>All rights and licenses granted under or pursuant to this Agreement, including, for the avoidance of doubt, the licenses granted to Company
pursuant to Section&nbsp;3.1, are, and shall otherwise be deemed to be, for purposes of Section&nbsp;365(n) of Title 11 of the U.S. Code and other similar laws in any jurisdiction outside the U.S. (collectively, the &#147;<B>Bankruptcy
Laws</B>&#148;), licenses of rights to &#147;intellectual property&#148; as defined under the Bankruptcy Laws. Upon the occurrence of any Insolvency Event with respect to a Party (the &#147;<B>Insolvent Party</B>&#148;), the Insolvent Party agrees
that the other Party (the &#147;<B>Non-Insolvent Party</B>&#148;), as licensee of such rights under this Agreement, shall retain and may fully exercise all of its rights and elections under the Bankruptcy Laws. Further, each Party agrees and
acknowledges that all payments hereunder, other than the milestone payments pursuant to Section&nbsp;9.3, the royalty payments pursuant to Section&nbsp;9.4, and the payments pursuant to Section&nbsp;9.9, do not constitute royalties within the
meaning of Section&nbsp;365(n) of the Bankruptcy Code or relate to licenses of intellectual property hereunder<B><I>. </I></B>Each Party shall, during the term of this Agreement, create and maintain current copies or, if not amenable to copying,
detailed descriptions or other appropriate embodiments, to the extent feasible, of all such intellectual property (MacroGenics Technology in the case of MacroGenics and Company Technology in the case of Company). Each Party agrees and acknowledges
that &#147;embodiments&#148; of intellectual property within the meaning of Section&nbsp;365(n) include, without limitation, laboratory notebooks, cell lines, product samples and inventory, research studies and data, Regulatory Approvals and
Regulatory Materials in each case to the extent related to the Compounds and Products. If (i)&nbsp;a case is commenced during the Term by or against a Party under the Bankruptcy Laws, (ii)&nbsp;this Agreement is rejected as provided for under the
Bankruptcy Laws, and (iii)&nbsp;the Non-Insolvent Party elects to retain its rights hereunder as provided for under the Bankruptcy Laws, then the Insolvent Party (in any capacity, including debtor-in-possession) and its successors and assigns
(including a Title 11 trustee), shall (x)&nbsp;provide to the Non-Insolvent Party immediately upon the Non-Insolvent Party&#146;s written request copies of all such intellectual property (including embodiments thereof) held by the Insolvent Party
and such successors and assigns, or otherwise available to them, and (y)&nbsp;not interfere with the Non-Insolvent Party&#146;s rights under this Agreement, or any related agreements between the Parties, to such intellectual property (including such
embodiments), including any right to obtain such intellectual property (or such embodiments) from another entity, to the extent provided in the Bankruptcy Laws. Whenever the Insolvent Party or any of its successors or assigns provides to the
Non-Insolvent Party any of the intellectual property licensed hereunder (or any embodiment thereof) pursuant to this Section&nbsp;13.7(b), the Non-Insolvent Party shall have the right to perform the Insolvent Party&#146;s obligations hereunder with
respect to such intellectual property, but neither such provision nor such performance by the Non-Insolvent Party shall release the </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">80 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Insolvent Party from liability resulting from rejection of the license or the failure to perform such obligations. All rights, powers and remedies of the Non-Insolvent Party as provided herein
are in addition to and not in substitution for any and all other rights, powers and remedies now or hereafter existing at law or in equity (including the Bankruptcy Laws) in the event of the commencement of a case by or against a Party under the
Bankruptcy Laws. In particular, it is the intention and understanding of the Parties to this Agreement that the rights granted to the Parties under this Section&nbsp;13.7 are essential to the Parties&#146; respective businesses and the Parties
acknowledge that damages are not an adequate remedy. The Parties agree that they intend the following rights to extend to the maximum extent permitted by Applicable Law, and to be enforceable under Section&nbsp;365(n) of Title 11 of the U.S. Code:
(A)&nbsp;the right of access to any intellectual property (including embodiments thereof) of the Insolvent Party, or any Third Party with whom the Insolvent Party contracts to perform an obligation of the Insolvent Party under this Agreement, and,
in the case of the Third Party, which is necessary for the Exploitation of Compounds or Products; and (B)&nbsp;the right to contract directly with any Third Party to complete the contracted work upon failure of the Insolvent Party to comply with its
applicable obligations. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13.8 <U>Effects of Termination</U></B>. All of the following effects of termination are in addition to the other
rights and remedies that may be available to either of the Parties under this Agreement and shall not be construed to limit any such rights or remedies. In the event this Agreement is not terminated in its entirety, but rather is terminated on a
Product-by-Product or country-by-country basis with respect to one or more Products as specified herein (each, a &#147;<B>Terminated Product</B>&#148;) in one or more country(ies) (each, a &#147;<B>Terminated Country</B>&#148;), then,
notwithstanding anything to the contrary contained in Sections 13.8(a) or 13.8(b), the consequences of termination described under this Section&nbsp;13.8 shall only apply to the Terminated Product in the Terminated Country, and this Agreement shall
remain in full force and effect in accordance with its terms with respect to all Products other than the Terminated Products, and in all countries of the Territory other than the Terminated Countries. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(a)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Consequences of Termination by MacroGenics or Company</B>. In the event of termination of this Agreement by (i)&nbsp;MacroGenics pursuant to Section&nbsp;13.3, 13.5, 13.7 or Section&nbsp;16.7 or (ii)&nbsp;Company
pursuant to Section&nbsp;13.2, Section&nbsp;13.4 or Section&nbsp;16.3, the following provisions of this Section&nbsp;13.8(a) shall apply from and after the effective date of termination (except to the extent otherwise provided in Section
13.8(a)(vi): </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> Without limiting the effect that such termination shall have on any provisions of
this Agreement, other than those provisions that this Agreement expressly provides shall survive such termination, all rights and licenses granted herein to Company shall terminate, and Company shall cease any and all Development, Manufacturing, and
Commercialization activities with respect to the Products (to the extent such activities were being performed using such rights and licenses) as soon as is reasonably practicable under Applicable Law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">81 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> All payment obligations hereunder shall terminate, other than those
that are accrued and unpaid as of the effective date of such termination and royalties that become due under Section&nbsp;9.4 with respect to sales of Reverted Products made by Janssen following the effective date of termination pursuant to
Section&nbsp;13.8(a)(vii). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(iii) </B>MacroGenics shall have a reversion of all rights previously licensed to Company
hereunder for which the relevant licenses have terminated on a fully paid-up and royalty-free basis, itself or with or through an Affiliate or Third Party, to Develop, Manufacture and Commercialize the Products at MacroGenics&#146; discretion,
<U>provided</U> that any Third Party Obligation arising pursuant to Section&nbsp;9.10(a) is passed through to MacroGenics. <B><I></I></B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> Company hereby grants to MacroGenics, effective as of the effective date of such termination, a non-exclusive,
transferable, fully paid-up, royalty-free, sublicenseable license in the Field in the Territory, under the Company Applied Technology and Company&#146;s right to Joint Inventions and Joint Patents, solely to Exploit any Product that is in active
clinical Development or has been Commercialized by Company at the time of termination (each, a &#147;<B>Reverted Product</B>&#148;); <U>provided</U>, <U>however</U>, that MacroGenics shall reimburse Company for any amounts paid by Company to any
Third Party in connection with MacroGenics&#146; exercise of such license. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(v)</B> At MacroGenics&#146; written
request, Company shall grant to MacroGenics, effective as of the date of such request, an exclusive, transferable, fully paid-up, royalty free, sublicensable license to use any trademarks owned or Controlled by Company or any of its Affiliates which
are solely used in the Commercialization of Reverted Products in the Territory (excluding any Company house marks). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(vi)</B> The JSC (if then in existence) or a committee formed by the Parties for purposes of effecting transition of
responsibilities (if the JSC is not then in existence) shall coordinate the wind-down of Company&#146;s efforts under this Agreement and Company, as soon as reasonably practicable after the effective date of such termination, shall provide to
MacroGenics, as applicable and to the extent permitted under any applicable Third Party contract, any material Information, including copies of all Clinical Trial data and results, Controlled by Company to the extent solely relating to the Reverted
Products, including control of, and all Information relating to, the global safety database. Company will reasonably cooperate with MacroGenics to provide a transfer of such material Information. Beginning on the date that notice of termination of
this Agreement is given by MacroGenics pursuant to Section&nbsp;13.3, Section&nbsp;13.7 or Section&nbsp;16.7 or by Company pursuant to Section&nbsp;13.2, Section&nbsp;13.4 or Section&nbsp;16.3, (A)&nbsp;Company shall have no further obligation to
commence or provide funding for any Clinical Trial that has not yet commenced (for purposes of this sentence, &#147;commencement&#148; means the [***]) </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">82 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">
on or before such date of notice of termination of this Agreement; and (B)&nbsp;at MacroGenics&#146; request, MacroGenics shall have the right, and Company shall cooperate in good faith with
MacroGenics to enable MacroGenics, to commence any such Clinical Trial included in the then-current Global Development Plan prior to the effective date of termination of this Agreement; <U>provided</U>, <U>however</U>, that such cooperation shall
not include any obligation to provide funding for such Clinical Trial. At MacroGenics&#146; request, Company shall use reasonable efforts to (x)&nbsp;assign to MacroGenics any and all Third Party agreements to which Company or any of its Affiliates
are a party that relate exclusively to the Development, Commercialization and Manufacturing activities conducted in connection with Reverted Products prior to such termination (including agreements relating to the sourcing and Manufacture of a
Reverted Product or, to the extent the First Commercial Sale of a Reverted Product has occurred, for sale, promotion, distribution, or use of such Reverted Product) or, (y)&nbsp;if such assignment is not permitted under the relevant Third Party
agreement: (1)&nbsp;grant to MacroGenics other rights to provide to MacroGenics the benefit of such non-assignable agreement, at MacroGenics&#146; expense, to the extent permitted under the terms of such non-assignable agreement; or (2)&nbsp;to the
extent not permitted under the terms of such non-assignable agreement, the Parties shall discuss in good faith an alternative solution to enable MacroGenics to receive, at MacroGenics&#146; expense, the benefit of the terms of such non-assignable
agreement. In the event one or more Reverted Products, or any materials relating to such Reverted Products, are Manufactured by Company or its Affiliate, then, upon the written request of MacroGenics, Company shall supply MacroGenics with such
Reverted Product(s) and/or materials at [***] and for a transitional period to be mutually agreed upon by the Parties and, if necessary, provide technical assistance reasonably necessary to assist MacroGenics in the start-up of Manufacturing of such
Reverted Product(s) and/or materials, and/or obtaining Regulatory Approval of the Reverted Product(s). In addition to the actions contemplated in this Section&nbsp;13.8(a)(vi) Company shall take such other actions and execute such other instruments,
assignments and documents as reasonably requested by MacroGenics as may be necessary to effect the transfer of rights to such Product(s) hereunder to MacroGenics. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(vii) </B>Subject to the payment of all amounts required under Section&nbsp;13.8(a)(ii), Company shall have the right to
sell or otherwise dispose of any inventory of any Reverted Product on hand at the time of such termination or in the process of Manufacturing; <U>provided</U>, <U>however</U>, at MacroGenics&#146; request, Company shall transfer to MacroGenics any
Product that has not been sold or used [***] following such termination, at a cost [***]. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(viii)</B> Company shall
transfer to MacroGenics any and all Regulatory Materials Controlled by Company on the effective date of termination, to the extent such Regulatory Materials relate solely to any Reverted Products, including any INDs, Regulatory Approval Applications
or Regulatory Approvals </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">83 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">
solely related to any Reverted Products. Upon MacroGenics&#146; request, Company shall make available to MacroGenics any other relevant Information Controlled by Company on the effective date of
termination, to the extent such Information relates to such Regulatory Materials, and shall provide a right of reference to any Regulatory Materials Controlled by Company on the effective date of termination, to the extent such Regulatory Materials
are necessary for MacroGenics or its licensees to develop and commercialize Reverted Products and are not transferred to MacroGenics hereunder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(ix)</B> MacroGenics shall have the right to assume all preparation, filing, prosecution, maintenance and enforcement
activities under ARTICLE 10 with respect to MacroGenics Patents as to which Company has assumed the right and authority to prepare, file, prosecute, maintain or enforce. Company will cooperate with MacroGenics and provide MacroGenics with reasonable
assistance with the preparation, filing, prosecution, maintenance, and enforcement activities with respect to such MacroGenics Patents. The step-in rights granted to MacroGenics with respect to Joint Patents under Sections 0, 10.5(b) and 10.7(a)
shall remain in effect, and MacroGenics shall have to the right to enforce the Company Patents, solely to the extent a license is granted under this Section&nbsp;13.8(a), against Third Party infringers. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(b)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Consequences of Certain Terminations by Company</B>. In the event of termination of this Agreement by Company pursuant to Section&nbsp;13.3 or Section&nbsp;13.7, the following provisions of this Section&nbsp;13.8(b)
shall apply from and after the effective date of termination. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> Without limiting the effect that
such termination shall have on any provisions of this Agreement, other than those provisions that this Agreement expressly provides shall survive such termination, all rights and licenses granted herein to MacroGenics shall terminate (other than the
license granted to MacroGenics under Section&nbsp;3.2(c), which shall survive such termination), and MacroGenics shall cease any and all Development, Manufacturing, and Commercialization activities (including any co-promotion activities) with
respect to the Products as soon as is reasonably practicable under Applicable Law. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(ii) </B>All payment obligations
hereunder shall continue, including those payment obligations that are accrued and unpaid as of the effective date of such termination, <U>provided</U> that Company may pursue remedies under Section&nbsp;13.9 and offset damages and costs as provided
in Section&nbsp;13.9. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> Company shall thereafter continue to have all rights previously licensed to Company
hereunder, itself or with a Third Party or through a Third Party sublicensee, to Develop, Manufacture and Commercialize any and all Products at Company&#146;s discretion, in accordance with and subject to the terms and conditions of this Agreement.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">84 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> All licenses granted to Company shall continue in full force and
effect, in accordance with and subject to the terms and conditions of this Agreement, and all rights of MacroGenics with respect to the Co-Promote Option shall cease. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(v)</B> The JSC (if then in existence) or a committee formed by the Parties for purposes of effecting transition of
responsibilities (if the JSC is not then in existence) shall coordinate the wind-down of MacroGenics&#146; efforts under this Agreement and MacroGenics, as soon as reasonably practicable after the effective date of such termination, shall provide to
Company, as applicable and to the extent permitted under any applicable Third Party contract, any material Information, including copies of all Clinical Trial data and results, Controlled by MacroGenics that relates solely to the Products.
MacroGenics will cooperate with Company to provide a transfer of such material Information. At Company&#146;s request, MacroGenics shall use reasonable efforts to (x)&nbsp;assign to Company any and all Third Party agreements to which MacroGenics or
any of its Affiliates are a party that relate exclusively to Development, Commercialization and Manufacture of the Products in the Field in the Territory or (y)&nbsp;if such assignment is not permitted under the relevant Third Party agreement:
(1)&nbsp;grant to Company other rights to provide to Company the benefit of such non-assignable agreement, at Company&#146;s expense, to the extent permitted under the terms of such non-assignable agreement; or (2)&nbsp;to the extent not permitted
under the terms of such non-assignable agreement, the Parties shall discuss in good faith an alternative solution to enable Company to receive, at Company&#146;s expense, the benefit of the terms of such non-assignable agreement. In the event one or
more Products, or any materials relating to such Products, are Manufactured by MacroGenics or its Affiliate, then, upon the written request of Company, MacroGenics shall supply Company with such Product(s) and/or materials [***] and for a
transitional period to be mutually agreed upon by the Parties and, if necessary, provide technical assistance reasonably necessary to assist Company in the start-up of Manufacturing of such Product(s) and/or materials, and/or obtaining Regulatory
Approval of such Product(s). In addition to the actions contemplated in this Section&nbsp;13.8(b), MacroGenics shall take such other actions and execute such other instruments, assignments and documents as reasonably requested by Company as may be
necessary to effect the transfer of rights to such Product(s) hereunder to Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13.9 <U>Remedies</U></B>. Except as otherwise explicitly set forth
in this Agreement, termination or expiration of this Agreement shall not relieve the Parties of any liability or obligation which accrued hereunder prior to the effective date of such termination or expiration, nor prejudice either Party&#146;s
right to obtain performance of any obligation. Each Party shall be free, pursuant to ARTICLE 14, to seek, without restriction as to the number of times it may seek, damages, costs and remedies that may be available to it under Applicable Law or in
equity and shall be entitled to offset the amount of any damages and costs obtained against the other Party in a final determination under Section&nbsp;14.3, against any amounts otherwise due to such other Party under this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">85 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13.10 <U>Survival</U></B>. In the event of termination or expiration of this Agreement, in addition to the
provisions of this Agreement that continue in effect in accordance with their terms, the following provisions of this Agreement shall survive: ARTICLE 1 (Definitions) (as applicable), ARTICLE 12 (Confidentiality), ARTICLE 13 (Term and Termination),
ARTICLE 14 (Dispute Resolution), ARTICLE 15 (Indemnification) (solely as to activities arising during the Term or as to any activities conducted in the course of a Party&#146;s exercise of a license surviving the Term), ARTICLE 16 (Miscellaneous);
Sections 3.2(d), 3.4 (No Implied Licenses), 4.5 (Records), 5.3(a) (Company Responsibilities) (solely with respect to activities undertaken prior to the effective date of expiration or termination of this Agreement), 9.8 (Currency), 9.11 (Taxes),
9.12 (Tax Returns), 9.13 (Audit), 9.14 (Late Payment), 10.1 (Ownership of Inventions), Section&nbsp;10.2 (Disclosure of Inventions) and 11.4 (No Other Representations or Warranties); and any other provisions of this Agreement that are necessary to
interpret or effectuate the intent of the foregoing provisions. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 14</B> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DISPUTE RESOLUTION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14.1 <U>Exclusive
Dispute Resolution Mechanism</U></B>. The Parties agree that the procedures set forth in this ARTICLE 14 shall be the exclusive mechanism for resolving any dispute, controversy or claim between the Parties that may arise from time to time pursuant
to this Agreement relating to either Party&#146;s rights or obligations hereunder (each, a &#147;<B>Dispute</B>&#148;, and collectively, the &#147;<B>Disputes</B>&#148;) that is not resolved through good faith negotiation between the Parties. For
the avoidance of doubt, this ARTICLE 14 shall not apply to any decision with respect to which a Party has final decision-making authority hereunder. Any Dispute, including Disputes that may involve the parent company, subsidiaries, or affiliates
under common control of any Party, shall be resolved in accordance with this ARTICLE 14. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14.2 <U>Resolution by Executive Officers</U></B>. Except as
otherwise provided in this ARTICLE 14, in the event of any Dispute regarding the construction or interpretation of this Agreement or the rights, duties or liabilities of either Party hereunder, the Parties shall first attempt in good faith to
resolve such Dispute by negotiation and consultation between themselves. In the event that such Dispute is not resolved on such basis within [***] (unless otherwise agreed by the Parties), either Party may, by written notice to the other Party,
refer the Dispute to the Executive Officers for attempted resolution by good faith negotiation within [***] after such notice is received (unless otherwise agreed by the Parties). Each Party may, in its discretion, seek resolution of any and all
Disputes that are not resolved under this Section&nbsp;14.2 in accordance with Section&nbsp;14.3. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14.3 <U>Arbitration</U></B>. If the Parties fail to
resolve the Dispute pursuant to Section&nbsp;14.2, and a Party desires to pursue resolution of the Dispute, the Dispute shall be submitted by either Party for resolution in arbitration pursuant to the then current [***], except where they conflict
with these provisions, in which case these provisions control. The arbitration will be held in [***]. All aspects of the arbitration shall be treated as confidential. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">86 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(a)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Arbitrators</B>.<B> </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> The arbitrators will be chosen from the
[***], unless a candidate not on such panel is approved by both Parties. Each arbitrator shall be a lawyer with at least [***] experience with a law firm or corporate law department of over [***] lawyers or who was a judge of a court of general
jurisdiction. To the extent that the Dispute requires special expertise, the Parties will so inform CPR prior to the beginning of the selection process. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> The arbitration tribunal shall consist of [***] arbitrators, of whom each Party shall designate one in accordance
with the &#147;screened&#148; appointment procedure provided in CPR Rule 5.4. The chair will be chosen in accordance with CPR Rule 6.4. If, however, the aggregate award sought by the Parties is less than [***] and equitable relief is not sought, a
single arbitrator shall be chosen in accordance with the CPR Rules. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> The Parties agree to select the
arbitrator(s) within [***] of initiation of the arbitration. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(b)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Procedures</B>. <B> </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> The hearing will be concluded within
[***] after selection of the arbitrator(s) and the award will be rendered within [***] of the conclusion of the hearing, or of any <FONT STYLE="white-space:nowrap">post-hearing</FONT> briefing, which briefing will be completed by both sides within
[***] after the conclusion of the hearing. In the event the Parties cannot agree upon a schedule, then the arbitrator(s) shall set the schedule following the time limits set forth above as closely as practical. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> The hearing will be concluded in [***] or less. Multiple hearing days will be scheduled consecutively to the
greatest extent possible. A transcript of the testimony adduced at the hearing shall be made and shall be made available to each Party. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(iii) </B>The arbitrator(s) shall be guided, but not bound, by the [***] (&#147;<B>Protocol</B>&#148;). The Parties will
attempt to agree on modes of document disclosure, electronic discovery, witness presentation, etc. within the parameters of the Protocol. If the Parties cannot agree on discovery and presentation issues, the arbitrator(s) shall decide on
presentation modes and provide for discovery within the Protocol, understanding that the Parties contemplate reasonable discovery. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> The arbitrator(s) shall decide the merits of any Dispute in accordance with the law governing this Agreement,
without application of any principle of conflict of laws that would result in reference to a different law. The arbitrator(s) may not apply principles such as &#147;amiable compositeur&#148; or &#147;natural justice and equity.&#148; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(v)</B> The arbitrator(s) are expressly empowered to decide dispositive motions in advance of any hearing and shall endeavor
to decide such motions as would a United States District Court Judge sitting in the jurisdiction whose substantive law governs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">87 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(vi)</B> The arbitrator(s) shall render a written opinion stating the reasons
upon which the award is based. The Parties consent to the jurisdiction of the United States District Court for the district in which the arbitration is held for the enforcement of these provisions and the entry of judgment on any award rendered
hereunder. Should such court for any reason lack jurisdiction, any court with jurisdiction may act in the same fashion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14.4 <U>Provisional
Remedies</U></B>. Each Party has the right to seek from the appropriate court provisional remedies such as attachment, preliminary injunction, replevin, etc. to avoid irreparable harm, maintain the <I>status quo</I>, or preserve the subject matter
of the Dispute. [***] does not apply to this Agreement </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14.5 <U>Confidentiality</U></B>. Any and all activities conducted under this ARTICLE 14 shall
be deemed Confidential Information of each of the Parties, and shall be subject to ARTICLE 12 above. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 15</B> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INDEMNIFICATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>15.1
<U>Indemnification by Company.</U></B> Company hereby agrees to defend, indemnify and hold harmless MacroGenics and its Affiliates, and each of their respective directors, officers, employees, agents and representatives (each, a &#147;<B>MacroGenics
Indemnitee</B>&#148;) from and against any and all claims, suits, actions, demands, liabilities, expenses and/or losses, including reasonable legal expenses and attorneys&#146; fees (collectively, the &#147;<B>Losses</B>&#148;), to which any
MacroGenics Indemnitee may become subject as a result of any claim, demand, action or other proceeding by any Third Party (each, a &#147;<B>Claim</B>&#148;), to the extent such Losses arise directly or indirectly out of: (a)&nbsp;the practice by
Company or its Affiliate or sublicensee of any license granted to it under this Agreement; (b)&nbsp;the manufacture, use, handling, storage, sale, marketing, export, import or other disposition of any Compound or Product by Company or its Affiliate
or sublicensee; (c)&nbsp;the breach by Company of any warranty, representation, covenant or agreement made by Company in this Agreement or, if MacroGenics exercises the Co-Promote Option, the Co-Promotion Agreement; or (d)&nbsp;the gross negligence,
illegal conduct or willful misconduct (including to the extent such gross negligence, illegal conduct or willful misconduct gives rise to product liability Claims under any legal theory) of Company or its Affiliate or sublicensee, or any officer,
director, employee, agent or representative thereof; except, with respect to each of clauses (a)&nbsp;through (d)&nbsp;above, to the extent such Losses arise directly or indirectly from the negligence, gross negligence, illegal conduct or willful
misconduct of any MacroGenics Indemnitee or the breach by MacroGenics of any warranty, representation, covenant or agreement made by MacroGenics in this Agreement. Notwithstanding the foregoing, this Section&nbsp;15.1 shall not apply to any Losses
of a MacroGenics Indemnitee that arise during the Co-Funding Term, to the extent such Losses are Commercialization Expenses that are included in MacroGenics&#146; allocation of the N.A. Profit/Loss. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">88 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>15.2 <U>Indemnification by MacroGenics</U></B>. MacroGenics hereby agrees to defend, indemnify and hold
harmless Company and its Affiliates and each of their respective directors, officers, employees, agents and representatives (each, a &#147;<B>Company Indemnitee</B>&#148;) from and against any and all Losses to which any Company Indemnitee may
become subject as a result of any Claim to the extent such Losses arise directly or indirectly out of: (a)&nbsp;the practice by MacroGenics or its Affiliate or its licensee (other than Company or its Affiliates or sublicensee) of any retained or
reverted license right under ARTICLE 3 to Develop, Manufacture or Commercialize any Compound or Product pursuant to the terms of this Agreement or, if MacroGenics exercises its Co-Promote Option, any Co-Promotion Agreement; (b)&nbsp;the manufacture,
use, handling, storage, sale or other disposition of any Compound or Product by MacroGenics or its Affiliate or its licensee (other than Company or its Affiliate or sublicensee); (c)&nbsp;the breach by MacroGenics of any warranty, representation,
covenant or agreement made by MacroGenics in this Agreement, or, if MacroGenics exercises the Co-Promote Option, the Co-Promotion Agreement; or (d)&nbsp;the gross negligence, illegal conduct, or willful misconduct (including to the extent such gross
negligence, illegal conduct or willful misconduct gives rise to product liability Claims under any legal theory) of MacroGenics or its Affiliate or its licensee (other than Company or its Affiliate or sublicensee), or any officer, director,
employee, agent or representative thereof; except, with respect to each of clauses (a)&nbsp;through (d)&nbsp;above, to the extent such Losses arise directly or indirectly from the negligence, gross negligence, illegal conduct or willful misconduct
of any Company Indemnitee or the breach by Company of any warranty, representation, covenant or agreement made by Company in this Agreement. Notwithstanding the foregoing, this Section&nbsp;15.2 shall not apply to any Losses of a Company Indemnitee
that arise during the Co-Funding Term, to the extent such Losses are Commercialization Expenses that are included in Company&#146;s allocation of N.A. Profit/Loss. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>15.3 <U>Indemnification Procedures</U></B>. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(a)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Notice</B>. Promptly after a MacroGenics Indemnitee or a Company Indemnitee (each, an &#147;<B>Indemnitee</B>&#148;) receives notice of a pending or threatened Claim, such Indemnitee shall give written notice of the
Claim to the Party from whom the Indemnitee is entitled to receive indemnification pursuant to Sections&nbsp;15.1 or 15.2, as applicable (the &#147;<B>Indemnifying Party</B>&#148;). However, an Indemnitee&#146;s delay in providing or failure to
provide such notice shall not relieve the Indemnifying Party of its indemnification obligations, except to the extent it can demonstrate prejudice due to the delay or lack of notice. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(b)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE="font-family:Times New Roman; font-size:10pt"><B>Defense</B>. Upon receipt of notice under this Section&nbsp;15.3 from the Indemnitee, the Indemnifying Party will have the duty to either
compromise or defend, at its own expense and by counsel (reasonably satisfactory to Indemnitee) such Claim. The Indemnifying Party will promptly (and in any event not more than [***] after receipt of the Indemnitee&#146;s original notice) notify the
Indemnitee in writing that it acknowledges its obligation (which acknowledgment shall not be deemed or construed as an admission of liability, either under this ARTICLE 15 or otherwise) to indemnify the Indemnitee with respect to the Claim pursuant
to this ARTICLE 15 and of its intention to compromise or defend such Claim. Once the </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">89 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Indemnifying Party gives such notice to the Indemnitee, the Indemnifying Party is not liable to the Indemnitee for the fees of other counsel or any other expenses subsequently incurred by the
Indemnitee in connection with such defense, other than the Indemnitee&#146;s reasonable Third Party expenses related to its investigation and cooperation. As to all Claims as to which the Indemnifying Party has assumed control under this
Section&nbsp;15.3(b), the Indemnitee shall have the right to employ separate counsel and to participate in the defense of a Claim (as reasonably directed by the Indemnifying Party) at its own expense. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(c)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Cooperation</B>. The Indemnitee will cooperate fully with the Indemnifying Party and its legal representatives in the investigation and defense of any Claim. The Indemnifying Party shall keep the Indemnitee informed
on a reasonable and timely basis as to the status of such Claim (to the extent the Indemnitee is not participating in the defense of such Claim) and conduct the defense of such Claim in a prudent manner. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(d)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Settlement</B>. If an Indemnifying Party assumes the defense of a Claim, no compromise or settlement of such Claim may be effected by the Indemnifying Party without the Indemnitee&#146;s written consent (such consent
not to be unreasonably withheld, delayed or conditioned), unless: (1)&nbsp;there is no finding or admission of any violation of law or any violation of the rights of any Person and no effect on any other claims that may be made against the
Indemnitee; (2)&nbsp;the sole relief provided is monetary damages that are paid in full by the Indemnifying Party; and (3)&nbsp;the Indemnitee&#146;s rights under this Agreement are not adversely affected. If the Indemnifying Party fails to assume
defense of a Claim within a reasonable time, the Indemnitee may settle such Claim on such terms as it deems appropriate with the consent of the Indemnifying Party (such consent not to be unreasonably withheld, delayed or conditioned), and the
Indemnifying Party shall be obligated to indemnify the Indemnitee for such settlement as provided in this ARTICLE 15. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(e)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Product Liability Claims</B>. Solely for purposes of coordinating the defense of any claims of a Third Party involving or that could result in Product Liabilities included in the definition of Global Development
Costs, such claims will be treated as if they were Claims covered by this Section&nbsp;15.3 and Company shall be deemed to be the &#147;Indemnifying Party&#148; under this Section&nbsp;15.3 for such claims. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>15.4 <U>Insurance</U></B>. Each Party shall, at its own expense, procure and maintain during the period commencing on the Execution Date through the period
of Commercialization and for a period of [***] thereafter, insurance policies, including product liability insurance, adequate to cover its obligations hereunder and which are consistent with normal business practices of prudent companies similarly
situated; <U>provided</U>, <U>however</U>, that in no event shall such product liability insurance be written in amounts less than [***] and annual aggregate. All such insurance shall include worldwide coverage. Prior to the initiation of any
Clinical Trial, the Party responsible for such Clinical Trial shall secure, and maintain in full force and effect, clinical trial insurance as required by Applicable Law in those territories where such Clinical Trial shall be conducted.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">90 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Upon request, each Party shall provide the other Party with a certificate of insurance evidencing the coverage required under this Section&nbsp;15.4. Such insurance shall not be construed to
create a limit of a Party&#146;s liability with respect to its indemnification obligations under this ARTICLE 15. Each Party shall provide the other Party with prompt written notice of cancellation, non-renewal or material change in such insurance
that could materially adversely affect the rights of such other Party hereunder, and shall provide such notice within [***] after any such cancellation, <FONT STYLE="white-space:nowrap">non-renewal</FONT> or material change. The Parties acknowledge
and agree that Company may meet its obligations under this Section&nbsp;15.4 through self-insurance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>15.5 <U>Limitation of Liability</U></B>. EXCEPT
TO THE EXTENT INCLUDED IN LOSSES RESULTING FROM A THIRD PARTY CLAIM FOR WHICH ONE PARTY IS OBLIGATED TO INDEMNIFY THE OTHER PARTY (OR AN INDEMNITEE OF SUCH OTHER PARTY) PURSUANT TO THIS ARTICLE 15 AND ANY BREACH OF ARTICLE 12 (CONFIDENTIALITY), IN
NO EVENT WILL EITHER PARTY BE LIABLE TO THE OTHER PARTY (OR THE OTHER PARTY&#146;S AFFILIATES OR SUBLICENSEES) IN CONNECTION WITH THIS AGREEMENT FOR LOST REVENUE, LOST PROFITS, LOST SAVINGS, LOSS OF USE, DAMAGE TO GOODWILL, OR ANY CONSEQUENTIAL,
INCIDENTAL, SPECIAL, EXEMPLARY, PUNITIVE OR INDIRECT DAMAGES UNDER ANY THEORY, INCLUDING CONTRACT, NEGLIGENCE, OR STRICT LIABILITY, EVEN IF THAT PARTY HAS BEEN PLACED ON NOTICE OF THE POSSIBILITY OF SUCH DAMAGES. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 16</B> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MISCELLANEOUS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>16.1 Notices</B>. All
notices and other communications given or made pursuant hereto shall be in writing and shall be deemed to have been duly given on the date delivered, if delivered personally, or on the next Business Day after being sent by reputable overnight
courier (with delivery tracking provided, signature required and delivery prepaid), in each case, to the Parties at the following addresses, or on the date sent and confirmed by electronic transmission to the telecopier number specified below (or at
such other address or telecopier number for a Party as shall be specified by notice given in accordance with this Section&nbsp;16.1). </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(a)</B></TD>
<TD ALIGN="left" VALIGN="top"><B></B>If to Company: </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Janssen Biotech, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">800/850 Ridgeview Drive </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Horsham, PA 19044 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Attention: [***] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Fax: [***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">with copies to: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Johnson&nbsp;&amp; Johnson Law Department </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">One Johnson&nbsp;&amp; Johnson Plaza </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">New Brunswick, NJ 08933 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:17%; font-size:10pt; font-family:Times New Roman">Attention: [***] </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:17%; font-size:10pt; font-family:Times New Roman">Fax: [***]
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">91 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(b)</B></TD>
<TD ALIGN="left" VALIGN="top">If to MacroGenics: </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:17%; font-size:10pt; font-family:Times New Roman">MacroGenics, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:17%; font-size:10pt; font-family:Times New Roman">9640 Medical Center Drive </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:17%; font-size:10pt; font-family:Times New Roman">Rockville, MD 20850 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:17%; font-size:10pt; font-family:Times New Roman">Attention:
[***] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">with copies to: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:17%; font-size:10pt; font-family:Times New Roman">MacroGenics, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:17%; font-size:10pt; font-family:Times New Roman">9640
Medical Center Drive </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:17%; font-size:10pt; font-family:Times New Roman">Rockville, MD 20850 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:17%; font-size:10pt; font-family:Times New Roman">Attention: [***] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>16.2 <U>Governing
Law</U></B>. This Agreement and all disputes arising out of or related to this Agreement or any breach hereof shall be governed by and construed under the laws of the State of [***], without giving effect to any choice of law principles that would
require the application of the laws of a different state. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>16.3 <U>Change of Control of MacroGenics</U></B>. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(a)</B></TD>
<TD ALIGN="left" VALIGN="top">MacroGenics (or its successor) shall provide notice to Company of any Change of Control of MacroGenics within [***] after the date upon which the Change of Control closes or otherwise becomes effective.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(b)</B></TD>
<TD ALIGN="left" VALIGN="top">On or before the date that is [***] after the date upon which a Change of Control of MacroGenics closes or otherwise becomes effective, Company may terminate this Agreement in its entirety; or, in Company&#146;s sole
and absolute discretion, Company may require (and MacroGenics, or its successor, shall perform, as applicable) any one or more of the following actions: (1)&nbsp;the Parties shall dissolve the JSC and after such dissolution Company shall solely have
all rights (including all decision-making rights) and shall perform all activities assigned by this Agreement to the JSC; or (2)&nbsp;MacroGenics and its successor shall adopt reasonable written procedures, approved by Company, to prevent disclosure
of Company&#146;s Confidential Information. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>16.4 <U>Assignment</U></B>. Neither Party may assign or transfer this Agreement or any
rights or obligations hereunder without the prior written consent of the other Party (it being understood that neither a merger in respect of which such Party is a constituent corporation or entity, nor a change in the beneficial ownership of the
voting securities of such Party, shall be deemed to be an assignment for purposes of this Section&nbsp;16.4), except that a Party may make such an assignment </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">92 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
without the other Party&#146;s consent to (a)&nbsp;an Affiliate or (b)&nbsp;subject to Section&nbsp;16.3 above, an acquirer of all or substantially all of the property and assets of the Party in
a sale of assets or other similar transaction. Any successor or assignee of rights and/or obligations permitted hereunder shall, in writing to the other Party, expressly assume performance of such rights and/or obligations. Any permitted assignment
shall be binding on the successors of the assigning Party. Any assignment or attempted assignment by either Party in violation of the terms of this Section&nbsp;16.4 shall be null, void and of no legal effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>16.5 <U>Designation of Affiliates</U></B>. Each Party may discharge any obligation and exercise any right hereunder through delegation of its obligations
or rights to any of its Affiliates. Each Party hereby guarantees the performance by its Affiliates of such Party&#146;s obligations under this Agreement, and shall cause its Affiliates to comply with the provisions of this Agreement in connection
with such performance. Any breach by a Party&#146;s Affiliate of any of such Party&#146;s obligations under this Agreement shall be deemed a breach by such Party, and the other Party may proceed directly against such Party without any obligation to
first proceed against such Party&#146;s Affiliate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>16.6 <U>Relationship of the Parties</U></B>. It is expressly agreed that MacroGenics, on the one
hand, and Company, on the other hand, are independent contractors and that the relationship between the two Parties shall not constitute a partnership, joint venture or agency. Neither MacroGenics nor Company shall have the authority to make any
statements, representations or commitments of any kind, or to take any action which shall be binding on the other, without the prior written consent of the other Party to do so. All individuals employed by a Party shall be employees of that Party
and not of the other Party and all costs and obligations incurred by reason of such employment shall be for the account and expense of such Party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>16.7 <U>Force Majeure</U></B>. Both Parties shall be excused from the performance of their obligations under this Agreement to the extent that such
performance is prevented by Force Majeure and the nonperforming Party promptly provides notice of such Force Majeure circumstances to the other Party. Such excuse shall be continued so long as the condition constituting Force Majeure continues and
the nonperforming Party takes reasonable efforts to remove the condition. Notwithstanding the foregoing, a Party shall not be excused from making payments owed hereunder because of a Force Majeure affecting such Party. If a Force Majeure persists
for more than [***], then the Parties shall discuss in good faith the modification of the Parties&#146; obligations under this Agreement in order to mitigate the delays caused by such Force Majeure. In the event a Party is prevented from performing
its obligations under this Agreement due to Force Majeure for more than [***] according to this Section&nbsp;16.7, the other Party shall have the right to terminate this Agreement upon [***] notice after the expiration of such period. A termination
under this Section&nbsp;16.7 by either Party shall be treated as a termination under Section&nbsp;13.3 above and the corresponding provisions for termination under Section&nbsp;13.3 shall apply except to the extent the affected Party is prevented
from performing due to the Force Majeure. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>16.8 <U>Entire Agreement; Amendments</U></B>. This Agreement, including the Exhibits and Schedules hereto,
sets forth the complete, final and exclusive agreement and all the covenants, promises, agreements, warranties, representations, conditions and understandings between the Parties with respect to the subject matter hereof and supersedes, as of the
Execution Date, all prior </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">93 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and contemporaneous agreements and understandings between the Parties with respect to the subject matter hereof, including the Prior CDA. There are no covenants, promises, agreements, warranties,
representations, conditions or understandings, either oral or written, between the Parties other than as are set forth herein and therein. No subsequent alteration, amendment, change or addition to this Agreement shall be binding upon the Parties
unless reduced to writing and signed by an authorized officer of each Party. In the event of any inconsistency between the body of this Agreement and either any Exhibits or Schedules to this Agreement or any subsequent agreements ancillary to this
Agreement, unless otherwise express stated to the contrary in such Exhibit, Schedule or ancillary agreement, the terms contained in this Agreement shall control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>16.9 <U>Severability</U></B>. If any one or more of the provisions of this Agreement is held to be invalid or unenforceable by any court of competent
jurisdiction from which no appeal can be or is taken, the provision shall be considered severed from this Agreement and shall not serve to invalidate any remaining provisions hereof. The Parties shall make good faith efforts to replace any invalid
or unenforceable provision with a valid and enforceable one such that the objectives contemplated by the Parties when entering this Agreement may be realized. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>16.10 <U>English Language</U></B>. This Agreement shall be written in and executed in, and all other communications under or in connection with this
Agreement shall be in, the English language. Any translation into any other language shall not be an official version hereof or thereof, and in the event of any conflict in interpretation between the English version and such translation, the English
version shall control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>16.11</B> <B><U>Waiver and Non-Exclusion of Remedies</U></B>. Any term or condition of this Agreement may be waived at any time
by the Party that is entitled to the benefit thereof, but no such waiver shall be effective unless set forth in a written instrument duly executed by or on behalf of the Party waiving such term or condition. The waiver by either Party of any right
hereunder or of the failure to perform or of a breach by the other Party shall not be deemed a waiver of any other right hereunder or of any other breach or failure by such other Party whether of a similar nature or otherwise. The rights and
remedies provided herein are cumulative and do not exclude any other right or remedy provided by Applicable Law or otherwise available except as expressly set forth herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>16.12 <U>Further Assurance</U></B>. Each Party shall duly execute and deliver, or cause to be duly executed and delivered, such further instruments and do
and cause to be done such further acts and things, including the filing of such assignments, agreements, documents, and instruments, as may be necessary or as the other Party may reasonably request in connection with this Agreement or to carry out
more effectively the provisions and purposes hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>16.13 <U>Headings</U></B>. The headings of each Article and Section in this Agreement have been
inserted for convenience of reference only and are not intended to limit or expand on the meaning of the language contained in the particular Article or Section. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>16.14 <U>Construction</U></B>. Whenever this Agreement refers to a number of days without using a term otherwise defined herein, such number refers to
calendar days. Except where the context otherwise requires, (a)&nbsp;wherever used, the singular shall include the plural, the plural shall include </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">94 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the singular; (b)&nbsp;the use of any gender shall be applicable to all genders; (c)&nbsp;the terms &#147;including,&#148; &#147;include,&#148; &#147;includes&#148; or &#147;for example&#148;
shall not limit the generality of any description preceding such term and, as used herein, shall have the same meaning as &#147;including, but not limited to,&#148; and/or &#147;including, without limitation&#148;; (d)&nbsp;the words
&#147;herein&#148;, &#147;hereof&#148; and hereunder&#148;, and words of similar import, refer to this Agreement in its entirety and not to any particular provision hereof; (d)&nbsp;the word &#147;or&#148; has the inclusive meaning that is typically
associated with the phrase &#147;and/or&#148;; (e)&nbsp;the word &#147;will&#148; means &#147;shall&#148;; (f)&nbsp;if a period of time is specified and dates from a given day or Business Day, or the day or Business Day of an act or event, it is to
be calculated exclusive of that day or Business Day; (g)&nbsp;&#147;Dollar&#148;, &#147;USD&#148; or &#147;$&#148; means U.S. Dollars; (h)&nbsp;references to a particular Person include such Person&#146;s successors and assigns to the extent not
prohibited by this Agreement; (i)&nbsp;a capitalized term not defined herein but reflecting a different part of speech than a capitalized term which is defined herein shall be interpreted in a correlative manner; and (j)&nbsp;any definition of or
reference to any agreement, instrument or other document herein shall be construed as referring to such agreement, instrument or other document as from time to time amended, supplemented or otherwise modified (subject to any restrictions on such
amendments, supplements or modifications set forth herein). The language of this Agreement shall be deemed to be the language mutually chosen by the Parties and no rule of strict construction shall be applied against either Party. Each Party
represents that it has been represented by legal counsel in connection with this Agreement and acknowledges that it has participated in the drafting hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>16.15 <U>Counterparts</U></B>. This Agreement may be executed in two (2)&nbsp;or more counterparts, each of which shall be deemed an original, but all of
which together shall constitute one and the same instrument. This Agreement may be executed by .pdf or other electronically transmitted signatures and such signatures shall be deemed to bind each Party as if they were the original signatures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE PAGE FOLLOWS </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">95 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Execution Version </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the Parties have signed this Agreement as of the date(s) set forth below. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Janssen Biotech, Inc.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Scott White</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">Scott White</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">Vice President, North America Oncology</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">December 19, 2014</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>MacroGenics, Inc.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Scott Koenig, M.D., Ph.D.</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">Scott Koenig, M.D., Ph.D.</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">President and CEO</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">December 19, 2014</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Execution Version </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commercialization Expenses </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Advertising and Market Research Expenses</B>&#148; means all Third Party Expenses related to: (a)&nbsp;conducting and monitoring
professional and consumer appraisals of the [***] in the Northern American Territory, such as market share services (e.g., IMS data), pricing analysis, special research testing and focus groups; and (b)&nbsp;advertising and promotion of the Initial
Product in the Northern American Territory [***] associated with Product advertising. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>&#147;<B>Commercialization Expenses&#148;
means those expenses incurred by either Party (as detailed below) for the purpose of, and directly and specifically attributable to, the Commercialization of the Initial Product in the Northern American Territory, to the extent such expenses are
incurred by either Party or for such Party&#146;s account and are: (i)&nbsp;[***] Expenses, (ii)&nbsp;any fees per-Detail paid to MacroGenics pursuant to the Co-Promotion Agreement, (iii)&nbsp;[***] (xiii)&nbsp;any losses, damages, fees, costs and
other liabilities associated with [***] arising (except to the extent one of the Parties is solely responsible [***] <U>provided</U>, <U>however</U>, that any such expenses incurred by MacroGenics shall be deemed to be Commercialization Expenses
only to the extent that MacroGenics is permitted to conduct the underlying activity pursuant to the Agreement or the Co-Promotion Agreement or to the extent that the Parties mutually agree that MacroGenics may conduct the underlying activity. For
purposes of clarity [***]. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Commercialization Expenses shall not include: (a)&nbsp;any Development expenses including [***] in the Northern American
Territory; [***]. In addition, there shall be no double counting of any expense (or deduction from Net Sales) that could fall within multiple categories of Commercialization Expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company Detailing Expenses</B>&#148; means Selling Costs incurred by a Party in performance of Details, where such Selling Costs
shall be calculated on the basis of [***]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Cost Per PDE</B>&#148; means the [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Distribution Expenses</B>&#148; means [***] of Net Sales of the Initial Product in the Northern American Territory. It is understood
that such amount shall be deemed to cover all Third Party Expenses and FTE Costs identifiable to the distribution of the Initial Product in the Northern American Territory, [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>EAP Expenses</B>&#148; means Third Party Expenses and FTE Costs to conduct early access programs, named patient programs, and
compassionate use programs for the [***] in the Northern American Territory. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Education Expenses</B>&#148; means all Third Party
Expenses specifically incurred to educate health care professionals licensed to practice in the Northern American Territory with respect to the [***] in the Northern American Territory through any means not covered in the definition of
&#147;Advertising and Marketing Research Expenses&#148;, but including [***] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Execution Version </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Manufacturing Expenses</B>&#148; means, with respect to the Initial Product, the reasonable and necessary internal and Third Party
invoiced costs, determined in accordance with GAAP and the terms and conditions of this Agreement, incurred in Manufacturing or acquisition of the Initial Product for sale in the Northern American Territory. Manufacturing costs and acquisition costs
are comprised of Standard Cost of Goods Manufactured, Cost Variances and Other Costs Not Included in Standard, where: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(a)</B></TD>
<TD ALIGN="left" VALIGN="top">&#147;<B>Standard Cost of Goods Manufactured</B>&#148; are budgeted unit costs established to facilitate inventory evaluation, planning and budgetary control as well as to motivate optimal productivity and efficiency,
including [***] </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(b)</B></TD>
<TD ALIGN="left" VALIGN="top">&#147;<B>Cost Variances</B>&#148; are actual costs of manufacturing versus Standard Cost of Goods Manufactured and include [***]; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(c)</B></TD>
<TD ALIGN="left" VALIGN="top">&#147;<B>Other Costs Not Included in Standard</B>&#148; are actual costs of manufacturing which are incurred in the normal course of business but are not included in the Standard Cost of Goods Manufactured including
[***] </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For clarity, royalty payments due to MacroGenics under this Agreement shall not be included in Manufacturing Expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Marketing Expenses</B>&#148; means the sum of Marketing Management Expenses, Advertising and Market Research Expenses and Education
Expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Marketing Management Expenses</B>&#148; means Commercial FTE Costs of either Party arising from the management of
Commercialization activities for the [***] <U>provided</U> that, in each case, such costs may be allocated to the [***] within and across Company&#146;s operating units and, <U>provided</U> <U>further</U>, that such allocation is made no less
favorable to the [***] than to the internal allocation to Company&#146;s other products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Medical Affairs Expenses</B>&#148;
means (a)&nbsp;Third Party Expenses and FTE Costs reasonably necessary and identifiable to the [***] incurred with respect to: medical and scientific information and response [***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Other Costs</B>&#148; means including both product costs and administrative costs that are [***] excluding funding allocated [***]
(to the extent such [***], <U>provided</U> that, if either [***] Commercialization of the [***], then the finance teams of the Parties will align on the inclusion and the appropriate allocation methodology for such [***] legal costs directly related
to, and specifically attributable to, [***] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>PDE</B>&#148; means a primary detailing equivalent, [***] <U>provided</U>,
<U>however</U>, that, prior to the First Commercial Sale of the Initial Product in the Northern American Territory, the JSC shall determine how to adjust the value of [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Phase 4 Trial Expenses</B>&#148; means all Third Party Expenses incurred for the Northern American Territory by Company related to a
Phase 4 Trial for the Initial Product in the Northern American Territory, including expenses arising from: (a)&nbsp;the activities related to the performance </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Execution Version </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of the Phase 4 Trial; (b)&nbsp;Manufacturing Expenses for Product used in connection with such Phase 4 Trial; (c)&nbsp;preparation, filing, and maintenance of related Regulatory Documentation;
and (d)&nbsp;any Product Liabilities relating to a Product being used in the course of such Phase 4 Trial, <U>provided</U> that [***] and shall be treated as the responsibility of such [***], <U>provided</U> that Phase 4 Trial Expenses shall not
include expenses relating to: [***] Phase 4 Trials which address [***] requirements for a [***] in which there are [***] any Phase 4 Trial intended [***] For purposes of clarity, Phase 4 Trial Expenses shall not include [***] for Phase 4 Trials but
shall include the costs for [***]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Recall Expenses</B>&#148; means Third Party Expenses and FTE Costs directly associated with
notification, retrieval and return of the Initial Product in the Northern American Territory, destruction of such returned Initial Product, replacement Initial Product and distribution of the replacement Initial Product, in each case that are
incurred with respect to a recall conducted in accordance with Section&nbsp;5.4 of the Agreement, <U>provided</U> that the foregoing Recall Expenses are limited to recalls that are not caused by the gross negligence, illegal conduct or willful
misconduct of a Party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Sales Rep PDE Total</B>&#148; means the total number of PDEs that one full time equivalent Sales Rep FTE
is planned to deliver in a Calendar Year, which number shall be approved by the JSC prior to the beginning of each Calendar Year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Sales Rep FTE</B>&#148; means [***] hours of work devoted to or in direct support of Detailing the Initial Product in the Northern
American Territory that is carried out by (a)&nbsp;one or more qualified employees or contractors or consultants of Company or its Affiliates or (b)&nbsp;one or more qualified employees of MacroGenics or its Affiliates, [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Sales Rep FTE Rate</B>&#148; means a rate of [***] per Sales Rep FTE per Calendar Year (prorated for the period beginning on the
Effective Date and ending on the last day of the first Calendar Year of the Term); <U>provided</U>, <U>however</U>, that such rate shall be increased or decreased annually beginning on January&nbsp;4, 2016 by the [***]. The Sales Rep FTE Rate is
&#147;fully burdened&#148; and covers employee salaries, benefits, travel and other costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Selling Costs</B>&#148; means the
total number of PDEs delivered by or on behalf of a Party multiplied by the Cost Per PDE. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Third Party Obligation
Expenses</B>&#148; means Third Party Obligations incurred by a Party with respect to the Initial Product for the Northern American Territory, <U>provided</U> that, with respect to any Third Party Obligation that is not specifically allocated to the
Initial Product and/or the Northern American Territory, Company shall use a reasonable method to allocate a portion of such Third Party Obligation to the Initial Product in the Northern American Territory for purposes of determining the Third Party
Obligation Expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Nothing in this <U>Exhibit A</U> is intended to modify or alter MacroGenics&#146; rights or obligations, or to grant additional
rights to MacroGenics, to perform Development or Commercialization activities pursuant to the Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Execution Version </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT B </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Global
Development Plan </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">*** </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Execution Version </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT C </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MacroGenics
Patents </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="90%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Pending&nbsp;Application</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Foreign&nbsp;Rights</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Execution Version </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT D </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MGD011
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Execution Version </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT E </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>J&amp;J
Universal Calendar </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g838054gra14.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Execution Version </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center"><B><I>


<IMG SRC="g838054gra15.jpg" ALT="LOGO">
</I></B> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Execution Version </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT F </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Form of Press
Release </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Execution Version </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g838054g76d20.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Execution Version </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g838054g00y16.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Execution Version </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g838054g28a54.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Execution Version </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 7.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MacroGenics&#146; Estimated, Non-Binding Manufacturing Costs </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Estimated</U></B> fully burdened manufacturing cost for single clinical production lot of MGD011: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="96%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This estimate is based
on expanded capacity that MacroGenics will be creating over [***].&nbsp;Since production under the additional capacity will be a new circumstance, this estimate is still subject to change. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>***&nbsp;=</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission.</I> </TD></TR></TABLE>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.26
<SEQUENCE>8
<FILENAME>d838054dex1026.htm
<DESCRIPTION>EX-10.26
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.26</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.26 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B></B><B><I>Execution Version</I></B><B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STOCK PURCHASE AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>By and Between </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>JOHNSON&nbsp;&amp; JOHNSON INNOVATION-JJDC, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AND </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC.
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Dated as of December&nbsp;19, 2014 </B></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="89%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Definitions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Defined Terms</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional Defined Terms</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchase and Sale of Common Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Closing Date; Deliveries</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Closing Date</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deliveries</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Representations and Warranties of the Company</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Organization, Good Standing and Qualification</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Capitalization and Voting Rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Subsidiaries</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.4</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Authorization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.5</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">No Defaults</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.6</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">No Conflicts</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.7</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">No Governmental Authority or Third Party Consents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.8</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valid Issuance of Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.9</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Litigation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.10</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Licenses and Other Rights; Compliance with Laws</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.11</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Company SEC Documents; Financial Statements; Nasdaq Stock Market</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.12</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Absence of Certain Changes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.13</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.14</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">No Integration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.15</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Brokers&#146; or Finders&#146; Fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.16</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investment Company</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.17</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">No General Solicitation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.18</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign Corrupt Practices</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.19</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Regulation M Compliance.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.20</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Office of Foreign Assets Control</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.21</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intellectual Property</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.22</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Full Disclosure</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Representations and Warranties of the Investor</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.1</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Organization; Good Standing</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.2</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Authorization</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.3</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">No Conflicts</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.4</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">No Governmental Authority or Third Party Consents</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.5</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchase Entirely for Own Account</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.6</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Disclosure of Information</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.7</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investment Experience and Accredited Investor Status</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.8</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquiring Person</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.9</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted Securities</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.10</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legends</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.11</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial Assurances</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.12</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock Ownership</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investor&#146;s Conditions to Closing</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.1</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Representations and Warranties</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.2</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Representations and Warranties in the Collaboration Agreement</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.3</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Covenants</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.4</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investor Agreement</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.5</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Collaboration Agreement</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.6</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">No Material Adverse Effect</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.7</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Listing</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Company&#146;s Conditions to Closing</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.1</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Representations and Warranties</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.2</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Covenants</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.3</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investor Agreement</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.4</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Collaboration Agreement</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mutual Conditions to Closing</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.1</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">HSR Act and Other Qualifications</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.2</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Absence of Litigation</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.3</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">No Prohibition</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Termination</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.1</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ability to Terminate</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.2</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effect of Termination</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="91%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">10.</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional Covenants and Agreements</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.1</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Market Listing</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.2</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Notification under the HSR Act</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.3</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assistance and Cooperation</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.4</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Form D; Blue Sky Filings</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.5</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legend Removal</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.6</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conduct of Business</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">11.</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Miscellaneous</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.1</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Governing Law; Submission to Jurisdiction</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.2</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Waiver</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.3</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Notices</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.4</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entire Agreement</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.5</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amendments</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.6</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Headings; Nouns and Pronouns; Section References</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.7</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Severability</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.8</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assignment</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.9</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Successors and Assigns</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.10</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Counterparts</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.11</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Third Party Beneficiaries</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.12</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">No Strict Construction</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.13</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Survival of Warranties</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.14</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Remedies</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.15</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expenses</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.16</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">No Publicity</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.17</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Limitation of Liability</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="5"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman; ">Exhibit A &#150; Form of Investor Agreement</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman; ">Exhibit B &#150; Notices</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STOCK PURCHASE AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THIS STOCK PURCHASE AGREEMENT (this &#147;<B>Agreement</B>&#148;), dated as of December&nbsp;19, 2014, by and between Johnson&nbsp;&amp;
Johnson Innovation-JJDC, Inc. (the &#147;<B>Investor</B>&#148;), a New Jersey corporation with its principal place of business at 410 George Street, New Brunswick, New Jersey 08901, and MacroGenics, Inc. (the &#147;<B>Company</B>&#148;), a Delaware
corporation, with its principal place of business at 9640 Medical Center Drive, Rockville, MD 20850. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, pursuant to the terms and
subject to the conditions set forth in this Agreement, the Company desires to issue and sell to the Investor, and the Investor desires to subscribe for and purchase from the Company, certain shares of common stock, par value $0.01 per share, of the
Company (the &#147;<B>Common Stock</B>&#148;); and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, simultaneously with the execution of this Agreement, the Company and Janssen
Biotech, Inc. (&#147;<B>Janssen</B>&#148;), an Affiliate of the Investor, are entering into the Collaboration Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE,
in consideration of the following mutual promises and obligations, and for good and valuable consideration, the adequacy and sufficiency of which are hereby acknowledged, the Investor and the Company agree as follows: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Definitions</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">1.1
<U>Defined Terms</U>. When used in this Agreement, the following terms shall have the respective meanings specified therefor below: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Affiliate</B>&#148; shall mean, with respect to any Person, another Person that controls, is controlled by or is under common control
with such Person; <U>provided</U>, that with respect to the Investor, &#147;Affiliate&#148; shall mean the Investor&#146;s subsidiaries that are wholly-owned directly or indirectly, by the Investor and any Person that wholly-owns, directly or
indirectly, the Investor. A Person shall be deemed to control another Person if such Person possesses, directly or indirectly, the power to direct or cause the direction of the management and policies of such Person, whether through the ownership of
voting securities, by contract or otherwise. Without limiting the generality of the foregoing, a Person shall be deemed to control another Person if any of the following conditions is met: (i)&nbsp;in the case of corporate entities, direct or
indirect ownership of more than fifty percent (50%)&nbsp;of the stock or shares having the right to vote for the election of directors, and (ii)&nbsp;in the case of non-corporate entities, direct or indirect ownership of more than fifty percent
(50%)&nbsp;of the equity interest with the power to direct the management and policies of such non-corporate entities. For the purposes of this Agreement, in no event shall the Investor or any of its Affiliates be deemed Affiliates of the Company or
any of its Affiliates, nor shall the Company or any of its Affiliates be deemed Affiliates of the Investor or any of its Affiliates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Agreement</B>&#148; shall have the meaning set forth in the Preamble, including all Exhibits attached hereto. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Business Day</B>&#148; shall mean a day other than Saturday, Sunday or any other day
that is designated as a J&amp;J holiday in the J&amp;J Universal Calendar (a copy of which for the years 2014 and 2015 is attached as Exhibit E to the Collaboration Agreement and a copy of which prior to the beginning of each such year for
succeeding years shall be provided to the Company). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Collaboration Agreement</B>&#148; shall mean the Collaboration and License
Agreement, of even date herewith, between Janssen and the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Collaboration Assets</B>&#148; shall mean the Compound and
any of the Company&#146;s assets and Intellectual Property rights related to the Products or the Compound, each as defined in the Collaboration Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Collaboration Material Adverse Effect</B>&#148; shall mean any effect that, individually or when taken together with all other
Effects, has had, or would reasonably be expected to have, (i)&nbsp;a material adverse effect on the Collaboration Assets, taken as a whole, or (ii)&nbsp;a material adverse effect on the Company&#146;s ability to perform its obligations under the
Collaboration Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>DOJ</B>&#148; means the U.S. Department of Justice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Effect</B>&#148; shall have the meaning set forth in the definition of &#147;Material Adverse Effect.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>FTC</B>&#148; means the U.S. Federal Trade Commission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Governmental Authority</B>&#148; shall mean any court, agency, authority, department, regulatory body or other instrumentality of any
government or country or of any national, federal, state, provincial, regional, county, city or other political subdivision of any such government or country or any supranational organization of which any such country is a member. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Intellectual Property</B>&#148; shall mean trademarks, trade names, trade dress, service marks, copyrights, and similar rights
(including registrations and applications to register or renew the registration of any of the foregoing), patents and patent applications, trade secrets, and any other similar intellectual property rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Intellectual Property License</B>&#148; shall mean any license, permit, authorization, approval, contract or consent granted, issued
by or with any Person relating to the use of Intellectual Property. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Investor Agreement</B>&#148; shall mean that certain
Investor Agreement between the Investor and the Company, to be dated as of the Closing Date, in substantially the form of <U>Exhibit A</U> attached hereto, as the same may be amended from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Law</B>&#148; or &#147;<B>Laws</B>&#148; shall mean all laws, statutes, rules, regulations, orders, judgments, injunctions and/or
ordinances of any Governmental Authority. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Material Adverse Effect</B>&#148; shall mean any change, event or occurrence (each, an
&#147;<B>Effect</B>&#148;) that, individually or when taken together with all other Effects, has had, or would reasonably be expected to have, (i)&nbsp;a material adverse effect on the business, financial condition, assets or results of operations
of the Company and its subsidiaries, taken as a whole, or (ii)&nbsp;a material adverse effect on the Company&#146;s ability to perform its obligations, or consummate the Transaction, in accordance with the terms of this Agreement, except in the case
of (i)&nbsp;to the extent that any such Effect results from or arises out of: (A)&nbsp;changes in conditions in the United States or global economy or capital or financial markets generally, including changes in interest or exchange rates,
(B)&nbsp;changes in general legal, regulatory, political, economic or business conditions or changes in generally accepted accounting principles in the United States or interpretations thereof, (C)&nbsp;acts of war, sabotage or terrorism, or any
escalation or worsening of any such acts of war, sabotage or terrorism, (D)&nbsp;earthquakes, hurricanes, floods or other natural disasters, (E)&nbsp;the announcement of this Agreement or the Transaction, (F)&nbsp;any change in the Company&#146;s
stock price or trading volume or any failure to meet internal projections or forecasts or published revenue or earnings projections of industry analysts (provided that the underlying events giving rise to any such change shall not be excluded),
(G)&nbsp;any breach, violation or non-performance by the Investor or any of its Affiliates under the Collaboration Agreement, <U>provided</U>, <U>however</U>, that the Effects excluded in clauses (A), (B), (C)&nbsp;and (D)&nbsp;shall only be
excluded to the extent such Effects are not disproportionately adverse on the Company and its subsidiaries as compared to other companies operating in the Company&#146;s industry. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Organizational Documents</B>&#148; shall mean (i)&nbsp;the Restated Certificate of Incorporation of the Company, as amended through
the date of this Agreement and (ii)&nbsp;the Amended and Restated Bylaws of the Company, as amended through the date of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Per Share Purchase Price</B>&#148; shall mean $39.00; <U>provided</U>, <U>however</U>, that in the event of any stock dividend, stock
split, combination of shares, recapitalization or other similar change in the capital structure of the Company after the date hereof and on or prior to the Closing which affects or relates to the Common Stock, the Per Share Purchase Price shall be
appropriately adjusted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Person</B>&#148; shall mean any individual, partnership, limited liability company, firm, corporation,
trust, unincorporated organization, government or any department or agency thereof or other entity, as well as any syndicate or group that would be deemed to be a Person under Section&nbsp;13(d)(3) of the Exchange Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Third Party</B>&#148; shall mean any Person (other than a Governmental Authority) other than the Investor, the Company or any
Affiliate of the Investor or the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Trading Market</B>&#148; means The Nasdaq Stock Market. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Transaction</B>&#148; means the issuance and sale of the Shares by the Company, and the purchase of the Shares by the Investor, in
accordance with the terms hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Transaction Agreements</B>&#148; shall mean this Agreement and the Investor Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">1.2 <U>Additional Defined Terms</U>. In addition to the terms defined in Section&nbsp;1.1, the
following terms shall have the respective meanings assigned thereto in the sections indicated below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:45.05pt; font-size:8pt; font-family:Times New Roman">Defined Term</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1.00pt solid #000000; width:23.95pt; font-size:8pt; font-family:Times New Roman">Section</P></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Aggregate Purchase Price</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 2</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Closing</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 3.1</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Closing Date</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 3.1</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Common Stock</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Preamble</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Company</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Preamble</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Company Rights</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 4.21(b)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Company SEC Documents</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 4.11(a)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exchange Act</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 4.11(a)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">GAAP</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 4.11(c)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">HSR Act</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 4.7</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Investor</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Preamble</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">LAS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 4.7</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Permits</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 4.10</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Proprietary Rights</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 4.21(b)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Rule 144</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 5.9</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">SEC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 4.7</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Securities Act</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 4.11(a)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Shares</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 2</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Subsidiaries</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 4.3</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Termination Date</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 9.1(b)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Transfer Agent</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 10.5(c)</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Purchase and Sale of Common Stock</U>. Subject to the terms and conditions of this
Agreement, at the Closing, the Company shall issue and sell to the Investor, free and clear of all liens, other than any liens arising as a result of any action by the Investor, and the Investor shall purchase from the Company, a number of shares of
Common Stock (the &#147;<B>Shares</B>&#148;) equal to the amount obtained by dividing the aggregate purchase price of US $75,000,000.00 (the &#147;<B>Aggregate Purchase Price</B>&#148;) by the Per Share Purchase Price. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Closing Date; Deliveries</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">3.1 <U>Closing Date</U>. Subject to the satisfaction or waiver of all the conditions to the Closing set forth in Sections 6, 7 and 8 hereof,
the closing of the purchase and sale of the Shares hereunder (the &#147;<B>Closing</B>&#148;) shall be held on the third (3<SUP STYLE="font-size:85%; vertical-align:top">rd</SUP>)&nbsp;Business Day after the satisfaction of the conditions to Closing
set forth in Sections 6, 7 and 8 (other than those conditions that by their nature are to be satisfied at the Closing, but subject to the satisfaction at such time of such conditions), at 9:00 a.m. Boston time, at the offices of Wilmer Cutler
Pickering Hale and Dorr LLP, 60 State Street, Boston, Massachusetts 02109, or at such other time, date and location as the parties may agree. The date the Closing occurs is hereinafter referred to as the &#147;<B>Closing Date</B>.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">3.2 <U>Deliveries</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a)
<U>Deliveries by the Company</U>. At the Closing, the Company shall deliver to the Investor the Shares, registered in the name of the Investor, and the Company shall instruct its transfer agent to register such issuance at the time of such issuance.
The Company shall also deliver at the Closing: (i)&nbsp;a certificate in form and substance reasonably satisfactory to the Investor and duly executed on behalf of the Company by an authorized executive officer of the Company, certifying that the
conditions to Closing set forth in Sections 6 and 8.2 of this Agreement have been fulfilled; (ii)&nbsp;a duly executed Investor Agreement; and (iii)&nbsp;a certificate of the secretary of the Company dated as of the Closing Date certifying
(A)&nbsp;that attached thereto is a true and complete copy of the Amended and Restated Bylaws of the Company as in effect at the time of the actions by the Board of Directors of the Company referred to in clause (B)&nbsp;below, and on the Closing
Date; (B)&nbsp;that attached thereto is a true and complete copy of all resolutions adopted by the Board of Directors of the Company authorizing the execution, delivery and performance of the Transaction Agreements and the Transaction and that all
such resolutions are in full force and effect and are all the resolutions adopted in connection with the transactions contemplated hereby as of the Closing Date; (C)&nbsp;that attached thereto is a true and complete copy of the Company&#146;s
Restated Certificate of Incorporation as in effect at the time of the actions by the Board of Directors of the Company referred to in clause (B)&nbsp;above, and on the Closing Date; and (D)&nbsp;as to the incumbency and specimen signature of any
officer of the Company executing a Transaction Agreement on behalf of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) <U>Deliveries by the Investor</U>. At the
Closing, the Investor shall deliver, or cause to be delivered, to the Company the Aggregate Purchase Price by wire transfer of immediately available United States funds to an account designated by the Company. The Company shall notify the Investor
in writing of the wiring instructions for such account not less </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
than five (5)&nbsp;Business Days before the Closing Date. The Investor shall also deliver, or cause to be delivered, at the Closing: (i)&nbsp;a certificate in form and substance reasonably
satisfactory to the Company duly executed by an authorized executive officer of the Investor certifying that the conditions to Closing set forth in Section&nbsp;7 of this Agreement have been fulfilled; (ii)&nbsp;a duly executed Investor Agreement;
and (iii)&nbsp;a certificate of the secretary or assistant secretary of the Investor dated as of the Closing Date certifying as to the incumbency and specimen signature of any officer executing a Transaction Agreement on behalf of the Investor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Representations and Warranties of the Company</U>. The Company hereby represents and warrants to the Investor that: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">4.1 <U>Organization, Good Standing and Qualification</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) The Company and each of the Subsidiaries is a corporation duly incorporated or otherwise organized, validly existing and in good standing
under the laws of the jurisdiction of its incorporation or organization, with the requisite power and authority to own and use its properties and assets and to carry on its business as currently conducted. The Company and each of the Subsidiaries
has all requisite corporate power and corporate authority to own, lease and operate its properties and assets, to carry on its business as now conducted, and as proposed to be conducted as described in the Company SEC Documents, the Company has all
requisite corporate power and corporate authority to enter into the Transaction Agreements and the Collaboration Agreement, to issue and sell the Shares and to perform its obligations under and to carry out the other transactions contemplated by the
Transaction Agreements and the Collaboration Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) The Company and each of the Subsidiaries is qualified to transact business
and is in good standing in each jurisdiction in which the character of the properties owned, leased or operated by the Company or Subsidiary, as applicable, or the nature of the business conducted by the Company or Subsidiary, as applicable, makes
such qualification necessary, except where the failure to be so qualified would not have a Material Adverse Effect. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">4.2 <U>Capitalization
and Voting Rights</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) The authorized capital of the Company as of the date hereof consists of: (i)&nbsp;125,000,000 shares of Common
Stock of which, as of the date of this Agreement, (x)&nbsp;27,954,191 shares are issued and outstanding and (y)&nbsp;4,139,314 shares are reserved for issuance pursuant to the Company&#146;s stock incentive plans, of which 3,630,702 shares are
issuable upon the exercise of stock options outstanding on the date hereof and (ii)&nbsp;5,000,000 shares of preferred stock, par value $0.01 per share, of which no shares are issued and outstanding as of the date of this Agreement. All of the
issued and outstanding shares of Common Stock (A)&nbsp;have been duly authorized and validly issued, (B)&nbsp;are fully paid and non-assessable and (C)&nbsp;were issued in compliance with all applicable federal and state securities Laws and not in
violation of any preemptive rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) All of the authorized shares of Common Stock are entitled to one (1)&nbsp;vote per share. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) Except as described or referred to in Section&nbsp;4.2(a) above and as provided in the
Investor Agreement, as of the date hereof, there are not: (i)&nbsp;any outstanding equity securities, options, warrants, rights (including conversion or preemptive rights) or other agreements pursuant to which the Company is or may become obligated
to issue, sell or repurchase any shares of its capital stock or any other securities of the Company or (ii)&nbsp;any restrictions on the transfer of capital stock of the Company other than pursuant to state and federal securities Laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) Except as provided in the Investor Agreement or as disclosed in the Company SEC Documents, the Company is not a party to or subject to
any agreement or understanding relating to the voting of shares of capital stock of the Company or the giving of written consents by a stockholder or director of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) Except as provided in the Investor Agreement or disclosed in the Company SEC Documents, no Person has any right to cause the Company to
effect the registration under the Securities Act of any securities of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f) The Common Stock is registered pursuant to
Section&nbsp;12(b) or 12(g) of the Exchange Act, and the Company has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the registration of the Common Stock under the Exchange Act nor has the Company
received any notification that the SEC is contemplating terminating such registration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">4.3 <U>Subsidiaries</U>. The Company has disclosed
all of its subsidiaries required to be disclosed pursuant to Item&nbsp;601(b)(21) of Regulation S-K in an exhibit to its Annual Report on Form 10-K (the &#147;<B>Subsidiaries</B>&#148;). The Company owns, directly or indirectly, all of the capital
stock or other equity interests of each Subsidiary free and clear of any Liens, and all of the issued and outstanding shares of capital stock of each Subsidiary are validly issued and are fully paid, non-assessable and free of preemptive and similar
rights to subscribe for or purchase securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">4.4 <U>Authorization</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) All requisite corporate action on the part of the Company, its directors and stockholders required by applicable Law for the
authorization, execution and delivery by the Company of the Transaction Agreements and the Collaboration Agreement, and the performance of all obligations of the Company hereunder and thereunder, including the authorization, issuance and delivery of
the Shares, has been taken. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) This Agreement and the Collaboration Agreement have been, and upon the execution and delivery of the
Investor Agreement by the Company at the Closing, the Investor Agreement will be, duly executed and delivered by the Company, and upon the due execution and delivery of this Agreement by the Investor and the Collaboration Agreement by Janssen, this
Agreement and the Collaboration Agreement will constitute, and upon the due execution and delivery of the Investor Agreement by the Investor, the Investor Agreement will constitute, valid and legally binding obligations of the Company, enforceable
against the Company in accordance with their respective terms (except with respect to the Investor </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Agreement and the Collaboration Agreement as such enforceability may be limited by (i)&nbsp;applicable bankruptcy, insolvency, reorganization, moratorium or other Laws of general application
relating to or affecting enforcement of creditors&#146; rights and (ii)&nbsp;rules of Law governing specific performance, injunctive relief or other equitable remedies and limitations of public policy). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) No stop order or suspension of trading of the Common Stock has been imposed by Nasdaq, the SEC or any other Governmental Authority and
remains in effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">4.5 <U>No Defaults</U>. The Company is not in default under or in violation of (a)&nbsp;its Organizational Documents,
(b)&nbsp;any provision of applicable Law or any ruling, writ, injunction, order, Permit, judgment or decree of any Governmental Authority or (c)&nbsp;any agreement, arrangement or instrument, whether written or oral, by which the Company or any of
its assets are bound, except, in the case of subsections (b)&nbsp;and (c), as would not have a Material Adverse Effect. There exists no condition, event or act which after notice, lapse of time, or both, would constitute a default or violation by
the Company under any of the foregoing, except, in the case of subsections (b)&nbsp;and (c), as would not have a Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">4.6 <U>No Conflicts</U>. The execution, delivery and performance of the Transaction Agreements and the Collaboration Agreement, and compliance
with the provisions hereof and thereof by the Company do not and shall not: (a)&nbsp;violate any provision of applicable Law or any ruling, writ, injunction, order, permit, judgment or decree of any Governmental Authority, (b)&nbsp;constitute a
breach of, or default under (or an event which, with notice or lapse of time or both, would become a default under) or conflict with, or give rise to any right of termination, cancellation or acceleration of, any agreement, arrangement or
instrument, whether written or oral, by which the Company or any of its assets are bound, (c)&nbsp;violate or conflict with any of the provisions of the Company&#146;s Organizational Documents or (d)&nbsp;result in any encumbrance upon any of the
Shares, other than restrictions pursuant to the Investor Agreement or securities Laws, or on any of the properties or assets of the Company or any Subsidiary, except, in the case of subsections (a)&nbsp;and (b), as would not have a Material Adverse
Effect with respect to this Agreement or the Investor Agreement or a Collaboration Material Adverse Effect with respect to the Collaboration Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">4.7 <U>No Governmental Authority or Third Party Consents</U>. No consent, approval, authorization or other order of, or filing with, or notice
to, any Governmental Authority or other Third Party is required to be obtained or made by the Company in connection with the authorization, execution and delivery by the Company of any of the Transaction Agreements or the Collaboration Agreement, or
with the authorization, issue and sale by the Company of the Shares, except (i)&nbsp;such filings as may be required to be made with the Securities and Exchange Commission (the &#147;<B>SEC</B>&#148;) and with any state blue sky or securities
regulatory authority, which filings shall be made in a timely manner in accordance with all applicable Laws, (ii)&nbsp;as required pursuant to the Hart-Scott-Rodino Antitrust Improvements Act, as amended (the &#147;<B>HSR Act</B>&#148;) and
(iii)&nbsp;with respect to the Shares, the filing with The Nasdaq Stock Market LLC of, and the absence of unresolved issues with respect to, a Notification Form: Listing of Additional Shares (the &#147;<B>LAS</B>&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">4.8 <U>Valid Issuance of Shares</U>. When issued, sold and delivered at the Closing in accordance
with the terms hereof for the Aggregate Purchase Price, the Shares shall be duly authorized, validly issued, fully paid and nonassessable, free from any liens, encumbrances or restrictions on transfer, including preemptive rights, rights of first
refusal or other similar rights, other than as arising pursuant to the Transaction Agreements, as a result of any action by the Investor or under federal or state securities Laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">4.9 <U>Litigation</U>. Except as set forth in the Company SEC Documents filed prior to the date of this Agreement, there is no action, suit,
proceeding or investigation pending (of which the Company has received notice or otherwise has knowledge) or, to the Company&#146;s knowledge, threatened, against the Company or which the Company intends to initiate which has had or is reasonably
likely to have a Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">4.10 <U>Licenses and Other Rights; Compliance with Laws</U>. The Company has all franchises,
permits, licenses and other rights and privileges (&#147;<B>Permits</B>&#148;) necessary to permit it to own its properties and to conduct its business as presently conducted and is in compliance thereunder, except where the failure to be in
compliance does not and would not have a Material Adverse Effect. The Company has not taken any action that would interfere with the Company&#146;s ability to renew all such Permit(s), except where the failure to renew such Permit(s) would not have
a Material Adverse Effect. The Company is and has been in compliance with all Laws applicable to its business, properties and assets, and to the products and services sold by it, except where the failure to be in compliance does not and would not
have a Material Adverse Effect. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">4.11 <U>Company SEC Documents; Financial Statements; Nasdaq Stock Market</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) Since October&nbsp;1, 2013, the Company has timely filed all required reports, schedules, forms, statements and other documents (including
exhibits and all other information incorporated therein), and any required amendments to any of the foregoing, with the SEC (the &#147;<B>Company SEC Documents</B>&#148;). As of their respective filing dates, each of the Company SEC Documents
complied in all material respects with the requirements of the Securities Act of 1933, as amended (the &#147;<B>Securities Act</B>&#148;), and the Securities Exchange Act of 1934, as amended (the &#147;<B>Exchange Act</B>&#148;), and the rules and
regulations of the SEC promulgated thereunder applicable to such Company SEC Documents, and no Company SEC Documents when filed, declared effective or mailed, as applicable, contained any untrue statement of a material fact or omitted to state a
material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) As of the date of this Agreement, there are no outstanding or unresolved comments in comment letters received from the SEC or its staff.
As of the date of this Agreement, none of the Company&#146;s Subsidiaries is subject to the reporting requirements of Section&nbsp;13(a) or 15(d) under the Exchange Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) The consolidated financial statements of the Company included in its Annual Report on Form
10-K for the fiscal year ended December&nbsp;31, 2013 and in its quarterly reports on Form 10-Q for the quarterly periods ended September&nbsp;30, 2014,&nbsp;June&nbsp;30, 2014, and March&nbsp;31, 2014 comply as to form in all material respects with
applicable accounting requirements and the published rules and regulations of the SEC with respect thereto, have been prepared in accordance with United States generally accepted accounting principles (&#147;<B>GAAP</B>&#148;) applied on a
consistent basis during the periods involved (except as may be indicated in the notes thereto) and fairly present in all material respects the financial position of the Company as of the dates thereof and the results of its operations and cash flows
for the periods then ended. The interim, unaudited financial statements of the Company for the two-month period ended November&nbsp;30, 2014 and as of November&nbsp;30, 2014, as provided to the Investor have been prepared in accordance with GAAP
applied on a consistent basis during the periods involved (except as may be indicated in the notes thereto) and fairly present in all material respects the financial position of the Company as of the dates thereof and the results of its operations
and cash&nbsp;flows for the period then ended. Except (i)&nbsp;as set forth in the Company SEC Documents or (ii)&nbsp;for liabilities incurred in the ordinary course of business subsequent to the date of the most recent balance sheet contained in
the Company SEC Documents, the Company has no liabilities, whether absolute or accrued, contingent or otherwise, other than those that would not, individually or in the aggregate, have a Material Adverse Effect. There are no material unconsolidated
subsidiaries of the Company or any material off-balance sheet arrangements of any type (including any off balance sheet arrangements required to be disclosed pursuant to&nbsp;Item&nbsp;303(a)(4) of Regulation S-K promulgated under the Securities
Act) that have not been so described in the Company SEC Reports filed prior to the date hereof nor any obligations to enter into any such arrangements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) The Common Stock is listed on The Nasdaq Global Select Market, and the Company has taken no action designed to, or which is likely to
have the effect of, terminating the registration of the Common Stock under the Exchange Act or delisting the Common Stock from The Nasdaq Global Market. The Company has not received any notification that, and has no knowledge that, the SEC or The
Nasdaq Stock Market LLC is contemplating terminating such listing or registration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) The Company has implemented and maintains a
system of internal control over financial reporting (to the extent required by Rule 13a-15(a) under the Exchange Act) that is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of
consolidated financial statements for external purposes, and, to the knowledge of the Company, such system of internal control over financial reporting is effective. For purposes of this Section&nbsp;4.11(e), &#147;knowledge of the Company&#148;
means the actual knowledge of the Chief Executive Officer and the Chief Financial Officer of the Company. The Company has implemented and maintains disclosure controls and procedures (to the extent required by Rule 13a-15(a) of the Exchange Act)
that are designed to ensure that information required to be disclosed by the Company in the reports it files or submits under the Exchange Act is recorded, processed, summarized and reported within the timeframes specified by the SEC&#146;s rules
and forms (and such disclosure controls and procedures are effective), and has disclosed, based on its most recent evaluation of its system of internal control over financial </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
reporting prior to the date of this Agreement, to the Company&#146;s outside auditors and the audit committee of the Company Board (i)&nbsp;any significant deficiencies and material weaknesses
known to it in the design or operation of its internal control over financial reporting (as defined in Rule 13a-15(f) of the Exchange Act) that would reasonably be expected to adversely affect the Company&#146;s ability to record, process, summarize
and report financial information and (ii)&nbsp;any fraud known to it, that involves management or other employees who have a significant role in the Company&#146;s internal control over financial reporting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f) To the knowledge of the Company, as of the date hereof, no employee of the Company or its subsidiaries has provided since January&nbsp;1,
2012 or is providing information to any law enforcement agency regarding the violation of any applicable Law of the type described in Section&nbsp;806 of the Sarbanes-Oxley Act by the Company or its Subsidiaries. Neither the Company nor its
Subsidiaries have discharged, demoted or suspended an employee of the Company or its Subsidiaries in the terms and conditions of employment because of any lawful act of such employee described in Section&nbsp;806 of the Sarbanes-Oxley Act. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">4.12 <U>Absence of Certain Changes</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) Except as disclosed in the Company SEC Documents, since December&nbsp;31, 2013, there has not occurred any event that has caused or would
reasonably be expected to cause a Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) Except as set forth in the Company SEC Documents filed prior to the date
hereof, since December&nbsp;31, 2013, the Company has not (i)&nbsp;declared or paid any dividends, or authorized or made any distribution upon or with respect to any class or series of its capital stock, or (ii)&nbsp;sold, exchanged or otherwise
disposed of any of its material assets or rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) Since December&nbsp;31, 2013, the Company has not admitted in writing its
inability to pay its debts generally as they become due, filed or consented to the filing against it of a petition in bankruptcy or a petition to take advantage of any insolvency act, made an assignment for the benefit of creditors, consented to the
appointment of a receiver for itself or for the whole or any substantial part of its property, or had a petition in bankruptcy filed against it, been adjudicated a bankrupt, or filed a petition or answer seeking reorganization or arrangement under
the federal bankruptcy laws or any other laws of the United States or any other jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">4.13 <U>Offering</U>. Subject to the
accuracy of the Investor&#146;s representations set forth in Sections 5.5, 5.6, 5.7, 5.9 and 5.10, the offer, sale and issuance of the Shares to be issued in conformity with the terms of this Agreement constitute transactions which are exempt from
the registration requirements of the Securities Act and from all applicable state registration or qualification requirements. Neither the Company nor any Person acting on its behalf will take any action that would cause the loss of such exemption.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">4.14 <U>No Integration</U>. The Company has not, directly or through any agent, sold, offered for sale, solicited offers to buy or
otherwise negotiated in respect of, any security (as defined in the Securities Act) which is or will be integrated with the Shares sold pursuant to this Agreement in a manner that would require the registration of the Shares under the Securities
Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">4.15 <U>Brokers&#146; or Finders&#146; Fees</U>. No broker, finder, investment banker or other
Person is entitled to any brokerage, finder&#146;s or other fee or commission from the Company in connection with the transactions contemplated by the Transaction Agreements and the Collaboration Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">4.16 <U>Investment Company</U>. The Company is not, and is not an Affiliate of, and immediately after receipt of payment for the Shares, will
not be or be an Affiliate of, an &#147;investment company&#148; within the meaning of the Investment Company Act of 1940, as amended. The Company shall conduct its business in a manner so that it will not become an &#147;investment company&#148;
subject to registration under the Investment Company Act of 1940, as amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">4.17 <U>No General Solicitation</U>. Neither the Company
nor any person acting on behalf of the Company has offered or sold any of the Shares by any form of general solicitation or general advertising. The Company has offered the Shares for sale only to the Investor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">4.18 <U>Foreign Corrupt Practices</U>. Neither the Company, nor to the knowledge of the Company, any agent or other person acting on behalf of
the Company, has: (i)&nbsp;directly or indirectly, used any funds for unlawful contributions, gifts, entertainment or other unlawful expenses related to foreign or domestic political activity, (ii)&nbsp;made any unlawful payment to foreign or
domestic government officials or employees or to any foreign or domestic political parties or campaigns from corporate funds, (iii)&nbsp;failed to disclose fully any contribution made by the Company (or made by any person acting on its behalf of
which the Company is aware) which is in violation of law or (iv)&nbsp;violated in any material respect any provision of the Foreign Corrupt Practices Act of 1977, as amended, or any applicable non-U.S. anti-bribery Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">4.19 <U>Regulation M Compliance</U>.&nbsp;The Company has not, and to its knowledge no one acting on its behalf has, (i)&nbsp;taken, directly
or indirectly, any action designed to cause or to result in the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of any of the Shares, (ii)&nbsp;sold, bid for, purchased, or paid any
compensation for soliciting purchases of, any of the Shares, or (iii)&nbsp;paid or agreed to pay to any Person any compensation for soliciting another to purchase any other securities of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">4.20 <U>Office of Foreign Assets Control</U>. Neither the Company nor, to the Company&#146;s knowledge, any director, officer, agent, employee
or Affiliate of the Company is currently subject to any U.S. sanctions administered by the Office of Foreign Assets Control of the U.S. Treasury Department. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">4.21 <U>Intellectual Property</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) The Intellectual Property that is owned by the Company or any subsidiary is owned free from any liens or restrictions (other than any
restrictions set forth in any Intellectual Property License relating to such Intellectual Property), and all of the Company&#146;s </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and its subsidiaries&#146; material Intellectual Property Licenses are in full force and effect in accordance with their terms, are free of any liens or restrictions, and neither the Company nor
to the Company&#146;s knowledge any other party thereto, is in material breach of any such material Intellectual Property License, and no event has occurred that with notice or lapse of time or both would constitute such a breach or default
thereunder or would result in the termination thereof or would cause or permit the acceleration or other change of any right or obligation of the loss of any benefit thereunder by the Company except (i)&nbsp;for such failures to be in full force and
effect, such liens or restrictions, and such material breaches that would not reasonably be expected to have a Material Adverse Effect, or (ii)&nbsp;as set forth in any such Intellectual Property License. Except as set forth in the Company SEC
Documents filed prior to the date hereof, there is no material legal claim or demand of any Person pertaining to, or any proceeding which is pending (of which the Company has received notice or otherwise has knowledge) or, to the knowledge of the
Company, threatened, (i)&nbsp;challenging the right of the Company in respect of any Company Intellectual Property, or (ii)&nbsp;that claims that any default exists under any Intellectual Property License, except, in the case of (i)&nbsp;and
(ii)&nbsp;above, where any such claim, demand or proceeding would not have or reasonably be expected to have a Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) Except as set forth in the Company&#146;s SEC Documents: (i)&nbsp;the Company or one of its subsidiaries owns, free and clear of any lien
or encumbrance, or has a valid license to, or has an enforceable right to use, as it is used or held for use, all U.S. and non-U.S. patents, trade secrets, know-how, trademarks, service marks, copyrights, and other proprietary and intellectual
property rights, and all grants and applications with respect to the foregoing (collectively, the <B>&#147;Proprietary Rights&#148;</B>) necessary for the conduct of the Company&#146;s business, the absence of which would not have or reasonably be
expected to have a Material Adverse Effect (such Proprietary Rights owned by or licensed to the Company collectively, the &#147;<B>Company Rights</B>&#148;); and (ii)&nbsp;the Company and its subsidiaries have taken reasonable measures to protect
the Company Rights, consistent with prudent commercial practices in the biotechnology industry, except where failure to take such measures would not have or reasonably be expected to have a Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">4.22 <U>Full Disclosure</U>. As of the date hereof, and other than the transactions that are the subject of this Agreement and the
Collaboration Agreement, no material fact or circumstance exists that would be required to be disclosed in a current report on Form 8-K or in a registration statement filed under the Securities Act, were such a registration statement filed on the
date hereof, that has not been disclosed in an SEC Report filed on or after March&nbsp;20, 2013. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Representations and Warranties of
the Investor</U>. The Investor hereby represents and warrants to the Company that: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">5.1 <U>Organization; Good Standing</U>. The Investor
is a corporation duly organized, validly existing and in good standing under the laws of New Jersey. The Investor has or will have all requisite power and authority to enter into the Transaction Agreements, to purchase the Shares and to perform its
obligations under and to carry out the other transactions contemplated by the Transaction Agreements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">5.2 <U>Authorization</U>. All requisite action on the part of the Investor and its directors and
stockholders, required by applicable Law for the authorization, execution and delivery by the Investor of the Transaction Agreements, and the performance of all of its obligations thereunder, including the subscription for and purchase of the
Shares, has been taken. This Agreement has been, and upon the execution and delivery of the Investor Agreement at the Closing by the Investor, the Investor Agreement will be, duly executed and delivered by the Investor and upon the due execution and
delivery thereof by the Company, will constitute valid and legally binding obligations of the Investor, enforceable against the Investor in accordance with their respective terms (except as such enforceability may be limited by (a)&nbsp;applicable
bankruptcy, insolvency, reorganization, moratorium or other Laws of general application relating to or affecting enforcement of creditors&#146; rights and (b)&nbsp;rules of Law governing specific performance, injunctive relief or other equitable
remedies and limitations of public policy). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">5.3 <U>No Conflicts</U>. The execution, delivery and performance of the Transaction
Agreements and compliance with the provisions thereof by the Investor do not and shall not: (a)&nbsp;violate any provision of applicable Law or any ruling, writ, injunction, order, permit, judgment or decree of any Governmental Authority,
(b)&nbsp;constitute a breach of, or default under (or an event which, with notice or lapse of time or both, would become a default under) or conflict with, or give rise to any right of termination, cancellation or acceleration of, any agreement,
arrangement or instrument, whether written or oral, by which the Investor or any of its assets, are bound, or (c)&nbsp;violate or conflict with any of the provisions of the Investor&#146;s organizational documents (including any articles or
memoranda of organization or association, charter, bylaws or similar documents), except as would not impair or adversely affect the ability of the Investor to consummate the Transactions and perform its obligations under the Transaction Agreements
and except, in the case of subsections (a)&nbsp;and (b)&nbsp;as would not have a material adverse effect on the Investor&#146;s ability to perform its obligations or consummate the Transaction in accordance with the terms of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">5.4 <U>No Governmental Authority or Third Party Consents</U>. No consent, approval, authorization or other order of any Governmental Authority
or other Third Party is required to be obtained by the Investor in connection with the authorization, execution and delivery of any of the Transaction Agreements or with the subscription for and purchase of the Shares, except as required pursuant to
the HSR Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">5.5 <U>Purchase Entirely for Own Account</U>. The Shares shall be acquired for investment for the Investor&#146;s own
account, not as a nominee or agent, and not with a view to the resale or distribution of any part thereof, and the Investor has no present intention of selling, granting any participation or otherwise distributing the Shares. The Investor does not
have and will not have as of the Closing any contract, undertaking, agreement or arrangement with any Person to sell, transfer or grant participation to a Person any of the Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">5.6 <U>Disclosure of Information</U>. The Investor has received all the information from the Company and its management that the Investor
considers necessary or appropriate for deciding whether to purchase the Shares hereunder. The Investor further represents that it has had an opportunity to ask questions and receive answers from the Company regarding the Company, its financial
condition, results of operations and prospects and the terms and conditions of the offering of the Shares sufficient to enable it to evaluate its investment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">5.7 <U>Investment Experience and Accredited Investor Status</U>. The Investor is an
&#147;accredited investor&#148; (as defined in Regulation D under the Securities Act). The Investor has such knowledge and experience in financial or business matters that it is capable of evaluating the merits and risks of the investment in the
Shares to be purchased hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">5.8 <U>Acquiring Person</U>. As of the date of this Agreement and immediately prior to the Closing,
neither the Investor nor any of its Affiliates beneficially owns, or will beneficially own (as determined pursuant to Rule 13d-3 under the Exchange Act without regard for the number of days in which a Person has the right to acquire such beneficial
ownership, and without regard to Investor&#146;s rights under this Agreement), any securities of the Company, except for securities that may be owned by employee benefit plans of the Investor or any of its Affiliates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">5.9 <U>Restricted Securities</U>. The Investor understands that the Shares, when issued, shall be &#147;restricted securities&#148; under the
federal securities Laws inasmuch as they are being acquired from the Company in a transaction not involving a public offering and that under such Laws the Shares may be resold without registration under the Securities Act only in certain limited
circumstances. The Investor represents that it is familiar with Rule 144 of the Securities Act (&#147;<B>Rule 144</B>&#148;), as presently in effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">5.10 <U>Legends</U>. The Investor understands that any certificates representing the Shares shall bear the following legends: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) &#147;These securities have not been registered under the Securities Act of 1933. They may not be sold, offered for sale, pledged or
hypothecated in the absence of a registration statement in effect with respect to the securities under the Securities Act or an opinion of counsel (which counsel shall be reasonably satisfactory to MacroGenics, Inc.) that such registration is not
required or unless sold pursuant to Rule 144 of the Securities Act.&#148;; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) any legend required by applicable state securities Laws;
and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) &#147;The securities represented by this certificate are subject to and shall be transferable only upon the terms and conditions
of an Investor Agreement dated as of December&nbsp;19, 2014, by and between MacroGenics, Inc. and Johnson&nbsp;&amp; Johnson Innovation-JJDC, Inc., a copy of which is on file with the Secretary of MacroGenics, Inc.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">5.11 <U>Financial Assurances</U>. As of the date hereof and as of the Closing Date, the Investor has and will have access to cash in an amount
sufficient to pay to the Company the Aggregate Purchase Price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">5.12 <U>Stock Ownership</U>. As of the date hereof, neither the Investor
nor any of its Affiliates (excluding for this purpose any employee benefit plan of the Investor) own any shares of capital stock of the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Investor&#146;s Conditions to Closing</U>. The Investor&#146;s obligation to purchase the
Shares at the Closing is subject to the fulfillment as of the Closing of the following conditions (unless waived in writing by the Investor): </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">6.1 <U>Representations and Warranties</U>. The representations and warranties made by the Company in Section&nbsp;4 hereof shall be true and
correct as of the date of this Agreement and as of the Closing Date as though made on and as of such Closing Date, except to the extent such representations and warranties are specifically made as of a particular date, in which case such
representations and warranties shall be true and correct as of such date; <U>provided</U>, <U>however</U>, that for purposes of this Section&nbsp;6.1, all such representations and warranties of the Company (other than Sections 4.1(a), 4.2, 4.3, 4.4,
4.5(a), 4.6(c), 4.8, and 4.11 of this Agreement) shall be deemed to be true and correct for purposes of this Section&nbsp;6.1 unless the failure or failures of such representations and warranties to be so true and correct, without regard to any
&#147;material,&#148; &#147;materiality&#148; or &#147;Material Adverse Effect&#148; qualifiers set forth therein, constitute a Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">6.2 <U>Representations and Warranties in the Collaboration Agreement</U>. The representations and warranties made by the Company in Sections
11.1 and 11.2 of the Collaboration Agreement shall be true and correct as of the Closing Date as though made on and as of such Closing Date, except to the extent such representations and warranties are specifically made as of a particular date, in
which case such representations and warranties shall be true and correct as of such date; <U>provided</U>, <U>however</U>, that for purposes of this Section&nbsp;6.2, all such representations and warranties of the Company shall be deemed to be true
and correct for purposes of this Section&nbsp;6.2 unless the failure or failures of such representations and warranties to be so true and correct, without regard to any &#147;material&#148; or &#147;materiality&#148; qualifiers set forth therein,
individually or in the aggregate, has had or would reasonably be expected to have a Collaboration Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">6.3
<U>Covenants</U>. All covenants and agreements contained in this Agreement to be performed or complied with by the Company on or prior to the Closing Date shall have been performed or complied with in all material respects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">6.4 <U>Investor Agreement</U>. The Company shall have duly executed and delivered to the Investor, pursuant to Section&nbsp;3.2(a) of this
Agreement, the Investor Agreement, and (subject to execution by the Investor) such agreement shall be in full force and effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">6.5
<U>Collaboration Agreement</U>. The Company shall have duly executed and delivered to the Investor the Collaboration Agreement, and there shall have been no termination of the Collaboration Agreement that, as of the Closing, is effective. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">6.6 <U>No Material Adverse Effect</U>. From and after the date of this Agreement until the Closing Date, there shall have occurred no event
that has caused a Material Adverse Effect or a Collaboration Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">6.7 <U>Listing</U>. The Shares shall be eligible
and approved for listing on the Nasdaq Global Select Market. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Company&#146;s Conditions to Closing</U>. The Company&#146;s obligation to issue and sell
the Shares at the Closing is subject to the fulfillment as of the Closing of the following conditions (unless waived in writing by the Company): </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">7.1 <U>Representations and Warranties</U>. The representations and warranties made by the Investor in Section&nbsp;5 hereof shall be true and
correct as of the date of this Agreement and as of the Closing Date as though made on and as of such Closing Date, except to the extent such representations and warranties are specifically made as of a particular date, in which case such
representations and warranties shall be true and correct as of such date, in the case of Sections 5.1-5.4, and 5.11, except where any failure to be true and correct would not have a material adverse effect on the Investor&#146;s ability to perform
its obligations, or consummate the Transaction in accordance with the terms of this Agreement, in the case of Section&nbsp;5.5, 5.6 and 5.7, except where any inaccuracy would not result in the issuance of the Shares hereunder failing to qualify as
an offering of securities not involving any public offering under the federal securities Laws, and in the case of Section&nbsp;5.8, except where any inaccuracy would not be material on the Investor&#146;s ability to perform its obligations, or
consummate the Transaction in accordance with the terms of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">7.2 <U>Covenants</U>. All covenants and agreements contained
in this Agreement to be performed or complied with by the Investor on or prior to the Closing Date shall have been performed or complied with in all material respects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">7.3 <U>Investor Agreement</U>. The Investor shall have duly executed and delivered to the Company, pursuant to Section&nbsp;3.2(b) of this
Agreement, the Investor Agreement, and (subject to execution by the Company) such agreement shall be in full force and effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">7.4
<U>Collaboration Agreement</U>. Janssen shall have duly executed and delivered to the Company the Collaboration Agreement, and there shall have been no termination of the Collaboration Agreement that, as of the Closing, is effective. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>Mutual Conditions to Closing</U>. The obligations of the Investor and the Company to consummate the Closing are subject to the
fulfillment as of the Closing Date of the following conditions: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">8.1 <U>HSR Act Qualification</U>. The filings required under the HSR Act
in connection with this Agreement shall have been made and the required waiting period shall have expired or been terminated as of the Closing Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">8.2 <U>Absence of Litigation</U>. There shall be no action, suit, proceeding or investigation by a Governmental Authority pending or currently
threatened in writing against the Company or the Investor that questions the validity of any of the Transaction Agreements, the right of the Company or the Investor to enter into any Transaction Agreement or to consummate the transactions
contemplated hereby or thereby or which, if determined adversely, would impose substantial monetary damages on the Company or the Investor as a result of the consummation of the transactions contemplated by any Transaction Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">8.3 <U>No Prohibition</U>. No provision of any applicable Law and no judgment, injunction
(preliminary or permanent), order or decree that prohibits, makes illegal or enjoins the consummation of the Transaction shall be in effect. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>Termination</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">9.1
<U>Ability to Terminate</U>. This Agreement may be terminated at any time prior to the Closing by: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) mutual written consent of the
Company and the Investor; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) either the Company or the Investor, upon written notice to the other no earlier than March&nbsp;18, 2015
(the &#147;<B>Termination Date</B>&#148;), if the Transaction shall not have been consummated by the Termination Date; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) either the
Company or the Investor, upon written notice to the other, if any of the mutual conditions to the Closing set forth in Section&nbsp;8 shall have become incapable of fulfillment by the Termination Date and shall not have been waived in writing by the
other party within ten business days after receiving receipt of written notice of an intention to terminate pursuant to this clause (c)&nbsp;provided, however, that the right to terminate this Agreement under this Section&nbsp;9.1(c) shall not be
available to any party whose failure to fulfill any obligation under this Agreement has been the cause of, or resulted in, the failure to consummate the transactions contemplated hereby prior to the Termination Date; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) the Company, upon written notice to the Investor, so long as the Company is not then in breach of its representations, warranties,
covenants or agreements under this Agreement such that any of the conditions set forth in Section&nbsp;6.1 or 6.2, as applicable, could not be satisfied by the Termination Date, (i)&nbsp;upon a material breach of any covenant or agreement on the
part of the Investor set forth in this Agreement, or (ii)&nbsp;if any representation or warranty of the Investor shall have been or become untrue, in each case such that any of the conditions set forth in Section&nbsp;7.1, 7.2, 7.3 or 7.4, as
applicable, could not be satisfied by the Termination Date; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) the Investor, upon written notice to the Company, so long as the
Investor is not then in breach of its representations, warranties, covenants or agreements under this Agreement such that any of the conditions set forth in Section&nbsp;7.1, 7.2 or 7.3, as applicable, could not be satisfied by the Termination Date,
upon a breach of any covenant or agreement on the part of the Company set forth in this Agreement, or if any representation or warranty of the Company shall have been or become untrue, in each case such that any of the conditions set forth in
Section&nbsp;6.1, 6.2, 6.3 or 6.4, as applicable, could not be satisfied by the Termination Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">9.2 <U>Effect of Termination</U>. In
the event of the termination of this Agreement pursuant to Section&nbsp;9.1 hereof, (a)&nbsp;this Agreement (except for this Section&nbsp;9.2 and Section&nbsp;11 hereof (other than Section&nbsp;11.13), and any definitions set forth in this Agreement
and used in such sections) shall forthwith become void and have no effect, without any liability on the part of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
any party hereto or its Affiliates, and (b)&nbsp;all filings, applications and other submissions made pursuant to this Agreement, to the extent practicable, shall be withdrawn from the agency or
other Person to which they were made or appropriately amended to reflect the termination of the transactions contemplated hereby; <U>provided</U>, <U>however</U>, that nothing contained in this Section&nbsp;9.2 shall relieve any party from liability
for fraud or any intentional or willful breach of this Agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <U>Additional Covenants and Agreements</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">10.1 <U>Market Listing</U>. From the date hereof through the Closing Date, Company shall use all reasonable efforts to (a)&nbsp;maintain the
listing and trading of the Common Stock on The Nasdaq Global Market and (b)&nbsp;effect the listing of the Shares on The Nasdaq Global Market, including submitting the LAS to The Nasdaq Stock Market LLC no later than fifteen (15)&nbsp;calendar days
prior to the Closing Date. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">10.2 <U>Notification under the HSR Act</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) As a result of the aggregate consideration being paid by the Investor under this Agreement and the Collaboration Agreement, which
satisfies the size of transaction jurisdictional threshold under the HSR Act, the parties shall, as soon as practicable, and, in any event, no later than ten (10)&nbsp;Business Days after the date of this Agreement, file or cause to be filed with
the Federal Trade Commission and the Department of Justice the notifications required to be filed under the HSR Act and the rules and regulations promulgated thereunder with respect to the transactions contemplated by this Agreement. The parties
will use all reasonable efforts to respond on a timely basis to any requests for additional information made by either of such agencies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) Each of Investor and Company shall: (i)&nbsp;reasonably cooperate with each other in connection with any investigation or other inquiry
relating to the transactions contemplated by the Transaction Agreements and the Collaboration Agreement; (ii)&nbsp;reasonably keep the other party informed of any communication received by such party from, or given by such party to, the FTC, the DOJ
or any other Merger Control Authority and of any communication received or given in connection with any proceeding by a private party, in each case regarding the transactions contemplated by the Transaction Agreements or the Collaboration Agreement;
(iii)&nbsp;promptly respond to and certify substantial compliance with any inquiries or requests received from the FTC or the DOJ for additional information or documentation; (iv)&nbsp;reasonably consult with each other in advance of any meeting or
conference with the FTC, the DOJ or any other Merger Control Authority, and to the extent permitted by the FTC, the DOJ or such other Merger Control Authority and reasonably determined by such party to be appropriate under the circumstances, give
the other party or their counsel the opportunity to attend and participate in such meetings and conferences; and (v)&nbsp;permit the other party or their counsel to the extent reasonably practicable to review in advance, and in good faith consider
the views of the other party or their counsel concerning, any submission, filing or communication (and documents submitted therewith) intended to be given by it to the FTC, the DOJ or any other Merger Control Authority; <U>provided</U>,
<U>however</U>, such party shall be under no obligation to reschedule any meetings or conferences with the FTC, the DOJ or any other Merger Control Authority to enable the other party to attend. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) Notwithstanding anything to the contrary in this Agreement, the terms &#147;commercially
reasonable efforts&#148; or &#147;reasonable efforts&#148; do not require that either party (i)&nbsp;offer, negotiate, commit to or effect, by consent decree, hold separate order, trust or otherwise, the sale, divestiture, license or other
disposition of any capital stock, assets, rights, products or businesses of Investor, Company or their respective Affiliates, (ii)&nbsp;agree to any restrictions on the activities of Investor, Company or their respective Affiliates, or
(iii)&nbsp;pay any material amount or take any other action to prevent, effect the dissolution of, vacate, or lift any decree, order, judgment, injunction, temporary restraining order, or other order in any suit or proceeding that would otherwise
have the effect of preventing or delaying any of the transactions contemplated by the Transaction Agreements or the Collaboration Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">10.3 <U>Assistance and Cooperation</U>. Prior to the Closing, upon the terms and subject to the conditions set forth in this Agreement, each
of the parties agrees to use all reasonable efforts to take, or cause to be taken, all actions and to do, or cause to be done, and to assist and cooperate with the other party in doing, all things necessary, proper or advisable to consummate and
make effective, in the most expeditious manner practicable, the transactions contemplated by this Agreement, including using all reasonable efforts to accomplish the following: (a)&nbsp;taking all reasonable acts necessary to cause the conditions
precedent set forth in Sections 6, 7 and 8 to be satisfied (including, in the case of the Company, promptly notifying the Investor of any notice from The Nasdaq Stock Market LLC with respect to the LAS); (b)&nbsp;taking all reasonable actions
necessary to obtain all necessary actions or non-actions, waivers, consents, approvals, orders and authorizations from Governmental Authorities and the making of all necessary registrations, declarations and filings (including registrations,
declarations and filings with Governmental Authorities, if any); (c)&nbsp;taking all reasonable actions necessary to obtain all necessary consents, approvals or waivers from Third Parties; and (d)&nbsp;except as otherwise provided for in
Section&nbsp;10.2, defending any suits, claims, actions, investigations or proceedings, whether judicial or administrative, challenging this Agreement or the consummation of the transactions contemplated hereby, including seeking to have any stay or
temporary restraining order entered by any court or other Governmental Authority vacated or reversed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">10.4 <U>Form D; Blue Sky
Filings</U>. The Company agrees to timely file a Form D with respect to the Shares as required under Regulation D and to provide a copy thereof, promptly upon request of the Investor. The Company shall take such action as the Company shall
reasonably determine is necessary in order to obtain an exemption for, or to qualify the Shares for, sale to the Investor at the Closing under applicable securities or &#147;Blue Sky&#148; laws of the states of the United States, and shall provide
evidence of such actions promptly upon request of the Investor. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">10.5 <U>Legend Removal</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) Certificates evidencing the Shares shall not contain the legend set forth in Section&nbsp;5.10(a): (i)&nbsp;following a sale of such
Shares pursuant to a registration statement </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
covering the resale of such Shares, while such registration statement is effective under the Securities Act, (ii)&nbsp;following any sale of such Shares pursuant to Rule 144, (iii)&nbsp;if such
Shares are eligible for sale under Rule 144, without the requirement for the Company to be in compliance with the current public information required under Rule 144 as to such Shares and without volume or manner-of-sale restrictions or (iv)&nbsp;if
such legend is not required under applicable requirements of the Securities Act (including judicial interpretations and pronouncements issued by the staff of the SEC). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) Certificates evidencing the Shares shall not contain the legend set forth in Section&nbsp;5.10(c) following: (i)&nbsp;a sale of such
Shares pursuant to a registration statement covering the resale of such Shares, while such registration statement is effective under the Securities Act, (ii)&nbsp;any sale of such Shares pursuant to Rule 144 or (iii)&nbsp;the expiration of the
Standstill Term (as defined in the Investor Agreement), the Lock-Up Term (as defined in the Investor Agreement) and the Voting Agreement Term (as defined in the Investor Agreement); provided that any transfer described in clause (i)&nbsp;or
(ii)&nbsp;above shall have been in compliance with all applicable provisions of the Investor Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) The Company agrees that at
such time as any legend set forth in Section&nbsp;5.10 is no longer required under this Section&nbsp;10.5, the Company will, no later than three (3)&nbsp;Business Days following the delivery by the Investor to the Company or the Company&#146;s
transfer agent (the &#147;<B>Transfer Agent</B>&#148;) of a certificate representing Shares issued with such legend, deliver or cause to be delivered to the Investor a certificate representing such Shares that is free from such legend, or, in the
event that such shares are uncertificated, remove any such legend in the Company&#146;s stock records. The Company may not make any notation on its records or give instructions to the Transfer Agent that enlarge the restrictions on transfer set
forth in Section&nbsp;5.10. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">10.6 <U>Conduct of Business</U>. During the period from the date hereof until the Closing, except as
consented to in writing by the Investor, the Company shall not (i)&nbsp;declare, set aside or pay any dividend or make any other distribution or payment (whether in cash, stock or property or any combination thereof) in respect of its capital stock,
or establish a record date for any of the foregoing, or (ii)&nbsp;make any other actual, constructive or deemed distribution in respect of any shares of its capital stock or otherwise make any payments to stockholders in their capacity as such,
except pursuant to repurchases of equity pursuant to the terms of its equity compensation plans. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. <U>Miscellaneous</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">11.1 <U>Governing Law; Submission to Jurisdiction</U>. This Agreement shall be governed by and construed in accordance with the Laws of the
State of Delaware, without regard to the conflict of laws principles thereof that would require the application of the Law of any other jurisdiction. Any action brought, arising out of, or relating to this Agreement shall be brought in the Court of
Chancery of the State of Delaware. Each party hereby irrevocably submits to the exclusive jurisdiction of said Court in respect of any claim relating to the validity, interpretation and enforcement of this Agreement, and hereby waives, and agrees
not to assert, as a defense in any action, suit or proceeding in which any such claim is made that it is not subject </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
thereto or that such action, suit or proceeding may not be brought or is not maintainable in such courts, or that the venue thereof may not be appropriate or that this agreement may not be
enforced in or by such courts. The parties hereby consent to and grant the Court of Chancery of the State of Delaware jurisdiction over such parties and over the subject matter of any such claim and agree that mailing of process or other papers in
connection with any such action, suit or proceeding in the manner provided in Section&nbsp;11.3 or in such other manner as may be permitted by law, shall be valid and sufficient thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">11.2 <U>Waiver</U>. Waiver by a party of a breach hereunder by the other party shall not be construed as a waiver of any subsequent breach of
the same or any other provision. No delay or omission by a party in exercising or availing itself of any right, power or privilege hereunder shall preclude the later exercise of any such right, power or privilege by such party. No waiver shall be
effective unless made in writing with specific reference to the relevant provision(s) of this Agreement and signed by a duly authorized representative of the party granting the waiver. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">11.3 <U>Notices</U>. All notices, instructions and other communications hereunder or in connection herewith shall be in writing, shall be sent
to the address of the relevant party set forth on Exhibit B attached hereto and shall be (a)&nbsp;delivered personally, (b)&nbsp;sent by registered or certified mail, return receipt requested, postage prepaid, (c)&nbsp;sent via a reputable
nationwide overnight courier service or (d)&nbsp;sent by facsimile transmission or electronic mail, with a confirmation copy to be sent by registered or certified mail, return receipt requested, postage prepaid. Any such notice, instruction or
communication shall be deemed to have been delivered upon receipt if delivered by hand, three (3)&nbsp;Business Days after it is sent by registered or certified mail, return receipt requested, postage prepaid, one (1)&nbsp;Business Day after it is
sent via a reputable nationwide overnight courier service or when transmitted with electronic confirmation of receipt, if transmitted by facsimile or electronic mail (if such transmission is made during regular business hours of the recipient on a
Business Day; or otherwise, on the next Business Day following such transmission). Either party may change its address by giving notice to the other party in the manner provided above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">11.4 <U>Entire Agreement</U>. This Agreement, the Investor Agreement (once executed) and the Collaboration Agreement, contain the entire
agreement among the parties with respect to the subject matter hereof and thereof and supersede all prior and contemporaneous arrangements or understandings, whether written or oral, with respect hereto and thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">11.5 <U>Amendments</U>. No provision in this Agreement shall be supplemented, deleted or amended except in a writing executed by an authorized
representative of each of the Investor and the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">11.6 <U>Headings; Nouns and Pronouns; Section References</U>. Headings in this
Agreement are for convenience of reference only and shall not be considered in construing this Agreement. Whenever the context may require, any pronouns used herein shall include the corresponding masculine, feminine or neuter forms, and the
singular form of names and pronouns shall include the plural and vice-versa. References in this Agreement to a section or subsection shall be deemed to refer to a section or subsection of this Agreement unless otherwise expressly stated. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">11.7 <U>Severability</U>. If, under applicable Laws, any provision hereof is invalid or
unenforceable, or otherwise directly or indirectly affects the validity of any other material provision(s) of this Agreement in any jurisdiction (&#147;<B>Modified Clause</B>&#148;), then, it is mutually agreed that this Agreement shall endure and
that the Modified Clause shall be enforced in such jurisdiction to the maximum extent permitted under applicable Laws in such jurisdiction; provided that the parties shall consult and use all reasonable efforts to agree upon, and hereby consent to,
any valid and enforceable modification of this Agreement as may be necessary to avoid any unjust enrichment of either party and to match the intent of this Agreement as closely as possible, including the economic benefits and rights contemplated
herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">11.8 <U>Assignment</U>. Except for an assignment of this Agreement or any rights hereunder by the Investor to an Affiliate,
neither this Agreement nor any of the rights or obligations hereunder may be assigned by either the Investor or the Company without (a)&nbsp;the prior written consent of Company in the case of any assignment by the Investor or (b)&nbsp;the prior
written consent of the Investor in the case of an assignment by the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">11.9 <U>Successors and Assigns</U>. This Agreement shall be
binding upon and inure to the benefit of the parties hereto and their respective successors and permitted assigns. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">11.10
<U>Counterparts</U>. This Agreement may be executed in counterparts, each of which shall be deemed an original but which together shall constitute one and the same instrument. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">11.11 <U>Third Party Beneficiaries</U>. None of the provisions of this Agreement shall be for the benefit of or enforceable by any Third
Party, including any creditor of any party hereto. No Third Party shall obtain any right under any provision of this Agreement or shall by reason of any such provision make any claim in respect of any debt, liability or obligation (or otherwise)
against any party hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">11.12 <U>No Strict Construction</U>. This Agreement has been prepared jointly and will not be construed against
either party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">11.13 <U>Survival of Warranties</U>. The representations and warranties of the Company and the Investor contained in this
Agreement shall survive the Closing and the delivery of the Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">11.14 <U>Remedies</U>. The rights, powers and remedies of the parties
under this Agreement are cumulative and not exclusive of any other right, power or remedy which such parties may have under any other agreement or Law. No single or partial assertion or exercise of any right, power or remedy of a party hereunder
shall preclude any other or further assertion or exercise thereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">11.15 <U>Expenses</U>. Each party shall pay its own fees and expenses in connection with the
preparation, negotiation, execution and delivery of the Transaction Agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">11.16 <U>No Publicity</U>. The parties hereto agree that
the provisions of Section&nbsp;12.5 of the Collaboration Agreement shall be applicable to the parties to this Agreement with respect to any public disclosures regarding the proposed transactions contemplated by the Purchase Agreement and the
Collaboration Agreement or regarding the parties hereto or their Affiliates (it being understood that the provisions of Section&nbsp;12.5(a) of the Collaboration Agreement shall be read to apply to disclosures of information relating to this
Agreement and the transactions contemplated hereby). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">11.17 <U>Limitation of Liability</U>. IN NO EVENT WILL EITHER PARTY BE LIABLE TO THE
OTHER PARTY (OR THE OTHER PARTY&#146;S AFFILIATES OR SUBLICENSEES) IN CONNECTION WITH THIS AGREEMENT FOR LOST REVENUE, LOST PROFITS, LOST SAVINGS, LOSS OF USE, DAMAGE TO GOODWILL, OR ANY CONSEQUENTIAL, INCIDENTAL, SPECIAL, EXEMPLARY, PUNITIVE OR
INDIRECT DAMAGES UNDER ANY THEORY, INCLUDING CONTRACT, NEGLIGENCE, OR STRICT LIABILITY, EVEN IF THAT PARTY HAS BEEN PLACED ON NOTICE OF THE POSSIBILITY OF SUCH DAMAGES. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I></I>(<I>Signature Page Follows</I>)<I> </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed and delivered this Agreement as of the date first
above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>JOHNSON &amp; JOHNSON INNOVATION-JJDC, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Asish K. Xavier</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">Asish K. Xavier</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">Vice President, Venture Investments</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>MACROGENICS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Scott Koenig, M.D., Ph.D.</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">Scott Koenig, M.D., Ph.D.</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">President and CEO</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Signature Page to Stock Purchase Agreement </I></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF INVESTOR AGREEMENT </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT B </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTICES </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">If to the Investor: </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Johnson&nbsp;&amp; Johnson Innovation-JJDC, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">410 George Street </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">New Brunswick,
NJ 08901 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Attention: General Manager </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">with a copy to: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Johnson&nbsp;&amp; Johnson Law Department </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">One Johnson&nbsp;&amp; Johnson Plaza </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">New Brunswick, NJ 08534 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Attention: General Counsel </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">If to the Company: </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">MacroGenics, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">9640 Medical Center Drive </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Rockville, MD 20850 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Attention:
CEO </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">with a copy to: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Wilmer Cutler Pickering Hale&nbsp;&amp; Dorr LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">60 State Street </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Boston, MA 02109
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Attention: Steven D. Singer </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-1 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>9
<FILENAME>d838054dex211.htm
<DESCRIPTION>EX-21.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-21.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EXHIBIT 21.1 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Subsidiaries </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">Entity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">Jurisdiction of Organization</P></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">MacroGenics UK Limited</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">United Kingdom</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>10
<FILENAME>d838054dex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EXHIBIT 23.1 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to the incorporation by reference in the following Registration Statements: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1)</TD>
<TD ALIGN="left" VALIGN="top">Registration Statement (Form S-8 No.&nbsp;333-192277) pertaining to the 2000 Stock Option Incentive Plan, the 2003 Equity Incentive Plan, and 2013 Equity Incentive Plan of MacroGenics, Inc.; and </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2)</TD>
<TD ALIGN="left" VALIGN="top">Registration Statement (Form S-3 No.&nbsp;333-200092) of MacroGenics, Inc. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">of our report dated March&nbsp;3,
2015, with respect to the consolidated financial statements of MacroGenics, Inc.,&nbsp;included in this Annual Report (Form 10-K) for the year ended December&nbsp;31, 2014. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-right:15%; font-size:10pt; font-family:Times New Roman" ALIGN="right">/s/ Ernst&nbsp;&amp; Young LLP </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">McLean, VA </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March&nbsp;3, 2015 </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>11
<FILENAME>d838054dex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-31.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EXHIBIT 31.1 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I, Scott Koenig, certify that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">I have reviewed this Annual Report on Form 10-K for the period ended December&nbsp;31, 2014 of MacroGenics, Inc.; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such
statements were made, not misleading with respect to the period covered by this report; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this report; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">The registrant&#146;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control
over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its
consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of
financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top">Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of
the period covered by this report based on such evaluation; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top">Disclosed in this report any change in the registrant&#146;s internal control over financial reporting that occurred during the registrant&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter
in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal control over financial reporting; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top">The registrant&#146;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#146;s auditors and the audit committee of the
registrant&#146;s board of directors (or persons performing the equivalent functions): </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#146;s ability to record,
process, summarize and report financial information; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#146;s internal control over financial reporting. </TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Scott&nbsp;Koenig</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Scott Koenig, M.D., Ph.D.</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">President and Chief Executive Officer</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Principal Executive Officer)</P></TD></TR>
</TABLE> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: March&nbsp;3, 2015 </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>12
<FILENAME>d838054dex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-31.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EXHIBIT 31.2 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I, James Karrels, certify that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">I have reviewed this Annual Report on Form 10-K for the period ended December&nbsp;31, 2014 of MacroGenics, Inc.; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such
statements were made, not misleading with respect to the period covered by this report; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this report; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">The registrant&#146;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control
over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its
consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of
financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top">Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of
the period covered by this report based on such evaluation; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top">Disclosed in this report any change in the registrant&#146;s internal control over financial reporting that occurred during the registrant&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter
in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal control over financial reporting; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top">The registrant&#146;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#146;s auditors and the audit committee of the
registrant&#146;s board of directors (or persons performing the equivalent functions): </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#146;s ability to record,
process, summarize and report financial information; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#146;s internal control over financial reporting. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ James Karrels</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">James Karrels</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Senior Vice President and Chief Financial Officer</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Principal Financial Officer)</P></TD></TR>
</TABLE> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: March&nbsp;3, 2015 </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>13
<FILENAME>d838054dex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-32.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EXHIBIT 32.1 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certification of Principal Executive Officer Pursuant to 18 U.S.C. 1350 (Section 906 of the Sarbanes-Oxley Act of 2002) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I, Scott Koenig, President and Chief Executive Officer (principal executive officer) of MacroGenics, Inc. (the &#147;Registrant&#148;), certify, to the best
of my knowledge, based upon a review of the Annual Report on Form 10-K for the period ended December&nbsp;31, 2014 of the Registrant (the &#147;Report&#148;), that: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">The Report fully complies with the requirements of Section&nbsp;13(a) of the Securities Exchange Act of 1934, as amended; and </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Scott Koenig</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name: Scott Koenig, M.D., Ph.D.</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Date: March&nbsp;3, 2015</TD></TR>
</TABLE></DIV>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>14
<FILENAME>d838054dex322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-32.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EXHIBIT 32.2 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certification of Principal Financial Officer Pursuant to 18 U.S.C. 1350 (Section 906 of the Sarbanes-Oxley Act of 2002) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I, James Karrels, Senior Vice President and Chief Financial Officer (principal financial officer) of MacroGenics, Inc. (the &#147;Registrant&#148;), certify,
to the best of my knowledge, based upon a review of the Annual Report on Form 10-K for the period ended December&nbsp;31, 2014 of the Registrant (the &#147;Report&#148;), that: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">The Report fully complies with the requirements of Section&nbsp;13(a) of the Securities Exchange Act of 1934, as amended; and </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ James Karrels</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name: James Karrels</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Date: March&nbsp;3, 2015</TD></TR>
</TABLE></DIV>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>15
<FILENAME>mgnx-20141231.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- RR Donnelley Xcelerate Instance Document, based on XBRL 2.1  http://www.rrdonnelley.com/ -->
<!-- Version:  6.22.4 -->
<!-- Round: 8 -->
<!-- Creation date: 2015-03-03T16:02:26Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2014-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:mgnx="http://www.macrogenics.com/20141231" xmlns:us-types="http://fasb.org/us-types/2014-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:country="http://xbrl.sec.gov/country/2013-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2014-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:utr="http://www.xbrl.org/2009/utr">
  <xbrll:schemaRef xlink:type="simple" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xlink:href="mgnx-20141231.xsd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" />
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="eol_PE179294--1410-K0014_STD_0_20030228_0_1280964x1610346" unitRef="shares" decimals="INF" id="id_6848266_D28E7557-DDA7-4B6D-9607-D6CA79D3147F_1001_0">2051644</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <us-gaap:SharesIssued contextRef="eol_PE179294--1410-K0014_STD_0_20041031_0_1276400x1427952" unitRef="shares" decimals="INF" id="id_6848266_CDB623D9-E3EB-42CD-B55D-C0607E460EFE_2001_3">13604016</us-gaap:SharesIssued>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="eol_PE179294--1410-K0014_STD_0_20100516_0_1276400x1610343" unitRef="shares" decimals="INF" id="id_6848266_7426FC99-BD79-4D02-BB8F-F1DB176047AC_2003_6">518708</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="eol_PE179294--1410-K0014_STD_0_20131031_0_1280964x1332409" unitRef="shares" decimals="INF" id="id_6848266_914CBE22-E452-498E-A124-A2D404D04BB2_1001_0">1960168</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <us-gaap:SharePrice contextRef="eol_PE179294--1410-K0014_STD_0_20140228_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_6848266_65716240-1ACD-4151-B726-0CB414642F18_1001_3">36.50</us-gaap:SharePrice>
  <mgnx:NonRefundableUpfrontPaymentReceivable contextRef="eol_PE179294--1410-K0014_STD_0_20150131_0_1271378x1273350_1272072x1605598" unitRef="iso4217_USD" decimals="-5" id="id_6848266_38B29B67-8FE5-479C-9081-21997680B4E2_2001_2">50000000</mgnx:NonRefundableUpfrontPaymentReceivable>
  <dei:EntityCommonStockSharesOutstanding contextRef="eol_PE179294--1410-K0014_STD_0_20150227_0" unitRef="shares" decimals="INF" id="id_6848266_0E6F3311-D183-4200-9E69-FFDB3EB2AE27_1002_8">29968476</dei:EntityCommonStockSharesOutstanding>
  <mgnx:AdditionalPaymentUponAchievementOfMilestone contextRef="eol_PE179294--1410-K0014_STD_0_20050630_0" unitRef="iso4217_USD" decimals="INF" id="id_6848266_5AC0A3D5-9392-4E9F-ADBF-602155A2C90D_3001_0">10950000</mgnx:AdditionalPaymentUponAchievementOfMilestone>
  <mgnx:NumberOfPotentialSharesToBeIssuedAsAdditionalConsiderationUnderAssetPurchaseAgreement contextRef="eol_PE179294--1410-K0014_STD_0_20050630_0" unitRef="shares" decimals="INF" id="id_6848266_5AC0A3D5-9392-4E9F-ADBF-602155A2C90D_3001_1">36135</mgnx:NumberOfPotentialSharesToBeIssuedAsAdditionalConsiderationUnderAssetPurchaseAgreement>
  <us-gaap:SharesIssued contextRef="eol_PE179294--1410-K0014_STD_0_20060531_0_1276400x1281157" unitRef="shares" decimals="INF" id="id_6848266_D9BC4B9F-9FBE-443F-B550-EB15EEB45E03_2001_3">10003300</us-gaap:SharesIssued>
  <mgnx:OnetimeMilestonePaymentToBePaidUnderAgreement contextRef="eol_PE179294--1410-K0014_STD_0_20080716_0" unitRef="iso4217_USD" decimals="-5" id="id_6848266_DC520CC2-DEE8-4887-9180-BDAD4D552524_1_0">5000000</mgnx:OnetimeMilestonePaymentToBePaidUnderAgreement>
  <mgnx:OnetimeMilestonePaymentToBePaidUnderAgreementUponSpecifiedLevelOfSalesOfProducts contextRef="eol_PE179294--1410-K0014_STD_0_20080716_0_1269523x1275948" unitRef="iso4217_USD" decimals="-5" id="id_6848266_DC520CC2-DEE8-4887-9180-BDAD4D552524_1001_2">12000000</mgnx:OnetimeMilestonePaymentToBePaidUnderAgreementUponSpecifiedLevelOfSalesOfProducts>
  <mgnx:OnetimeMilestonePaymentToBePaidUnderAgreementUponSpecifiedLevelOfSalesOfProducts contextRef="eol_PE179294--1410-K0014_STD_0_20080716_0_1269523x1277596" unitRef="iso4217_USD" decimals="-5" id="id_6848266_DC520CC2-DEE8-4887-9180-BDAD4D552524_2001_1">8000000</mgnx:OnetimeMilestonePaymentToBePaidUnderAgreementUponSpecifiedLevelOfSalesOfProducts>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="eol_PE179294--1410-K0014_STD_0_20080930_0_1276400x1610343" unitRef="shares" decimals="INF" id="id_6848266_7426FC99-BD79-4D02-BB8F-F1DB176047AC_2001_3">2875327</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:SharePrice contextRef="eol_PE179294--1410-K0014_STD_0_20131016_0_1271382x1272538" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_6848266_CF8BFD7F-B642-4113-81AE-4982E2833ECB_1002_1">16.00</us-gaap:SharePrice>
  <us-gaap:SharePrice contextRef="eol_PE179294--1410-K0014_STD_0_20131016_0_1271382x1280942" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_6848266_CF8BFD7F-B642-4113-81AE-4982E2833ECB_2002_3">16.00</us-gaap:SharePrice>
  <dei:EntityPublicFloat contextRef="eol_PE179294--1410-K0014_STD_0_20140630_0" unitRef="iso4217_USD" decimals="0" id="id_6848266_0E6F3311-D183-4200-9E69-FFDB3EB2AE27_3_9">437213185</dei:EntityPublicFloat>
  <us-gaap:SharePrice contextRef="eol_PE179294--1410-K0014_STD_0_20031231_0_1276400x1269676" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_6848266_EC69272C-D3C5-43AD-8833-6DB1DCB18EE3_2001_2">1.00</us-gaap:SharePrice>
  <us-gaap:StockholdersEquity contextRef="eol_PE179294--1410-K0014_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_BFB39C8D-DAF1-408E-872B-38367E4AE90D_1019_1">-17484000</us-gaap:StockholdersEquity>
  <us-gaap:UnrecognizedTaxBenefits contextRef="eol_PE179294--1410-K0014_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_C276425F-9994-4C60-9006-051FF560D19C_2001_0">1534000</us-gaap:UnrecognizedTaxBenefits>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE179294--1410-K0014_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_436CCE6F-4336-4B5F-8F07-5F706B0B6ECB_2001_27">55218000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:StockholdersEquity contextRef="eol_PE179294--1410-K0014_STD_0_20111231_0_1276401x1269588" unitRef="iso4217_USD" decimals="-3" id="id_6848266_BFB39C8D-DAF1-408E-872B-38367E4AE90D_1018_1">-183834000</us-gaap:StockholdersEquity>
  <us-gaap:SharesIssued contextRef="eol_PE179294--1410-K0014_STD_0_20111231_0_1276401x1270422" unitRef="shares" decimals="INF" id="id_6848266_BFB39C8D-DAF1-408E-872B-38367E4AE90D_1013_2">1049030</us-gaap:SharesIssued>
  <us-gaap:StockholdersEquity contextRef="eol_PE179294--1410-K0014_STD_0_20111231_0_1276401x1270422" unitRef="iso4217_USD" decimals="-3" id="id_6848266_BFB39C8D-DAF1-408E-872B-38367E4AE90D_1013_1">10000</us-gaap:StockholdersEquity>
  <us-gaap:SharesIssued contextRef="eol_PE179294--1410-K0014_STD_0_20111231_0_1276401x1273409" unitRef="shares" decimals="INF" id="id_6848266_BFB39C8D-DAF1-408E-872B-38367E4AE90D_1015_2">14381</us-gaap:SharesIssued>
  <us-gaap:StockholdersEquity contextRef="eol_PE179294--1410-K0014_STD_0_20111231_0_1276401x1273409" unitRef="iso4217_USD" decimals="-3" id="id_6848266_BFB39C8D-DAF1-408E-872B-38367E4AE90D_1015_1">-58000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE179294--1410-K0014_STD_0_20111231_0_1276401x1273630" unitRef="iso4217_USD" decimals="-3" id="id_6848266_BFB39C8D-DAF1-408E-872B-38367E4AE90D_1017_1">163450000</us-gaap:StockholdersEquity>
  <us-gaap:SharesIssued contextRef="eol_PE179294--1410-K0014_STD_0_20111231_0_1276401x1291665" unitRef="shares" decimals="INF" id="id_6848266_BFB39C8D-DAF1-408E-872B-38367E4AE90D_1009_2">14446227</us-gaap:SharesIssued>
  <us-gaap:StockholdersEquity contextRef="eol_PE179294--1410-K0014_STD_0_20111231_0_1276401x1291665" unitRef="iso4217_USD" decimals="-3" id="id_6848266_BFB39C8D-DAF1-408E-872B-38367E4AE90D_1009_1">144000</us-gaap:StockholdersEquity>
  <us-gaap:SharesIssued contextRef="eol_PE179294--1410-K0014_STD_0_20111231_0_1276401x1296600" unitRef="shares" decimals="INF" id="id_6848266_BFB39C8D-DAF1-408E-872B-38367E4AE90D_1001_2">26874792</us-gaap:SharesIssued>
  <us-gaap:StockholdersEquity contextRef="eol_PE179294--1410-K0014_STD_0_20111231_0_1276401x1296600" unitRef="iso4217_USD" decimals="-3" id="id_6848266_BFB39C8D-DAF1-408E-872B-38367E4AE90D_1001_1">269000</us-gaap:StockholdersEquity>
  <us-gaap:SharesIssued contextRef="eol_PE179294--1410-K0014_STD_0_20111231_0_1276401x1310046" unitRef="shares" decimals="INF" id="id_6848266_BFB39C8D-DAF1-408E-872B-38367E4AE90D_1003_2">7364582</us-gaap:SharesIssued>
  <us-gaap:StockholdersEquity contextRef="eol_PE179294--1410-K0014_STD_0_20111231_0_1276401x1310046" unitRef="iso4217_USD" decimals="-3" id="id_6848266_BFB39C8D-DAF1-408E-872B-38367E4AE90D_1003_1">74000</us-gaap:StockholdersEquity>
  <us-gaap:SharesIssued contextRef="eol_PE179294--1410-K0014_STD_0_20111231_0_1276401x1421015" unitRef="shares" decimals="INF" id="id_6848266_BFB39C8D-DAF1-408E-872B-38367E4AE90D_1011_2">63681176</us-gaap:SharesIssued>
  <us-gaap:StockholdersEquity contextRef="eol_PE179294--1410-K0014_STD_0_20111231_0_1276401x1421015" unitRef="iso4217_USD" decimals="-3" id="id_6848266_BFB39C8D-DAF1-408E-872B-38367E4AE90D_1011_1">637000</us-gaap:StockholdersEquity>
  <us-gaap:SharesIssued contextRef="eol_PE179294--1410-K0014_STD_0_20111231_0_1276401x1493912" unitRef="shares" decimals="INF" id="id_6848266_BFB39C8D-DAF1-408E-872B-38367E4AE90D_1005_2">71401237</us-gaap:SharesIssued>
  <us-gaap:StockholdersEquity contextRef="eol_PE179294--1410-K0014_STD_0_20111231_0_1276401x1493912" unitRef="iso4217_USD" decimals="-3" id="id_6848266_BFB39C8D-DAF1-408E-872B-38367E4AE90D_1005_1">714000</us-gaap:StockholdersEquity>
  <us-gaap:SharesIssued contextRef="eol_PE179294--1410-K0014_STD_0_20111231_0_1276401x1559024" unitRef="shares" decimals="INF" id="id_6848266_BFB39C8D-DAF1-408E-872B-38367E4AE90D_1007_2">110952217</us-gaap:SharesIssued>
  <us-gaap:StockholdersEquity contextRef="eol_PE179294--1410-K0014_STD_0_20111231_0_1276401x1559024" unitRef="iso4217_USD" decimals="-3" id="id_6848266_BFB39C8D-DAF1-408E-872B-38367E4AE90D_1007_1">1110000</us-gaap:StockholdersEquity>
  <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE179294--1410-K0014_STD_0_20121231_0" unitRef="shares" decimals="INF" id="id_6848266_C9A3D9AC-840C-4E73-A009-17EE683770D1_3_0">425000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:StockholdersEquity contextRef="eol_PE179294--1410-K0014_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_BFB39C8D-DAF1-408E-872B-38367E4AE90D_3019_7">-8238000</us-gaap:StockholdersEquity>
  <us-gaap:UnrecognizedTaxBenefits contextRef="eol_PE179294--1410-K0014_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_C276425F-9994-4C60-9006-051FF560D19C_1003_0">1592000</us-gaap:UnrecognizedTaxBenefits>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE179294--1410-K0014_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_436CCE6F-4336-4B5F-8F07-5F706B0B6ECB_1003_27">47743000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:StockholdersEquity contextRef="eol_PE179294--1410-K0014_STD_0_20121231_0_1276401x1269588" unitRef="iso4217_USD" decimals="-3" id="id_6848266_BFB39C8D-DAF1-408E-872B-38367E4AE90D_3018_7">-175472000</us-gaap:StockholdersEquity>
  <us-gaap:SharesIssued contextRef="eol_PE179294--1410-K0014_STD_0_20121231_0_1276401x1270422" unitRef="shares" decimals="INF" id="id_6848266_BFB39C8D-DAF1-408E-872B-38367E4AE90D_3013_8">1098914</us-gaap:SharesIssued>
  <us-gaap:StockholdersEquity contextRef="eol_PE179294--1410-K0014_STD_0_20121231_0_1276401x1270422" unitRef="iso4217_USD" decimals="-3" id="id_6848266_BFB39C8D-DAF1-408E-872B-38367E4AE90D_3013_7">10000</us-gaap:StockholdersEquity>
  <us-gaap:SharesIssued contextRef="eol_PE179294--1410-K0014_STD_0_20121231_0_1276401x1273409" unitRef="shares" decimals="INF" id="id_6848266_BFB39C8D-DAF1-408E-872B-38367E4AE90D_3015_8">14381</us-gaap:SharesIssued>
  <us-gaap:StockholdersEquity contextRef="eol_PE179294--1410-K0014_STD_0_20121231_0_1276401x1273409" unitRef="iso4217_USD" decimals="-3" id="id_6848266_BFB39C8D-DAF1-408E-872B-38367E4AE90D_3015_7">-58000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE179294--1410-K0014_STD_0_20121231_0_1276401x1273630" unitRef="iso4217_USD" decimals="-3" id="id_6848266_BFB39C8D-DAF1-408E-872B-38367E4AE90D_3017_7">164334000</us-gaap:StockholdersEquity>
  <us-gaap:SharesIssued contextRef="eol_PE179294--1410-K0014_STD_0_20121231_0_1276401x1291665" unitRef="shares" decimals="INF" id="id_6848266_BFB39C8D-DAF1-408E-872B-38367E4AE90D_3009_8">14446227</us-gaap:SharesIssued>
  <us-gaap:StockholdersEquity contextRef="eol_PE179294--1410-K0014_STD_0_20121231_0_1276401x1291665" unitRef="iso4217_USD" decimals="-3" id="id_6848266_BFB39C8D-DAF1-408E-872B-38367E4AE90D_3009_7">144000</us-gaap:StockholdersEquity>
  <us-gaap:SharesIssued contextRef="eol_PE179294--1410-K0014_STD_0_20121231_0_1276401x1296600" unitRef="shares" decimals="INF" id="id_6848266_BFB39C8D-DAF1-408E-872B-38367E4AE90D_3001_8">26874792</us-gaap:SharesIssued>
  <us-gaap:StockholdersEquity contextRef="eol_PE179294--1410-K0014_STD_0_20121231_0_1276401x1296600" unitRef="iso4217_USD" decimals="-3" id="id_6848266_BFB39C8D-DAF1-408E-872B-38367E4AE90D_3001_7">269000</us-gaap:StockholdersEquity>
  <us-gaap:SharesIssued contextRef="eol_PE179294--1410-K0014_STD_0_20121231_0_1276401x1310046" unitRef="shares" decimals="INF" id="id_6848266_BFB39C8D-DAF1-408E-872B-38367E4AE90D_3003_8">7364582</us-gaap:SharesIssued>
  <us-gaap:StockholdersEquity contextRef="eol_PE179294--1410-K0014_STD_0_20121231_0_1276401x1310046" unitRef="iso4217_USD" decimals="-3" id="id_6848266_BFB39C8D-DAF1-408E-872B-38367E4AE90D_3003_7">74000</us-gaap:StockholdersEquity>
  <us-gaap:SharesIssued contextRef="eol_PE179294--1410-K0014_STD_0_20121231_0_1276401x1421015" unitRef="shares" decimals="INF" id="id_6848266_BFB39C8D-DAF1-408E-872B-38367E4AE90D_3011_8">63681176</us-gaap:SharesIssued>
  <us-gaap:StockholdersEquity contextRef="eol_PE179294--1410-K0014_STD_0_20121231_0_1276401x1421015" unitRef="iso4217_USD" decimals="-3" id="id_6848266_BFB39C8D-DAF1-408E-872B-38367E4AE90D_3011_7">637000</us-gaap:StockholdersEquity>
  <us-gaap:SharesIssued contextRef="eol_PE179294--1410-K0014_STD_0_20121231_0_1276401x1493912" unitRef="shares" decimals="INF" id="id_6848266_BFB39C8D-DAF1-408E-872B-38367E4AE90D_3005_8">71401237</us-gaap:SharesIssued>
  <us-gaap:StockholdersEquity contextRef="eol_PE179294--1410-K0014_STD_0_20121231_0_1276401x1493912" unitRef="iso4217_USD" decimals="-3" id="id_6848266_BFB39C8D-DAF1-408E-872B-38367E4AE90D_3005_7">714000</us-gaap:StockholdersEquity>
  <us-gaap:SharesIssued contextRef="eol_PE179294--1410-K0014_STD_0_20121231_0_1276401x1559024" unitRef="shares" decimals="INF" id="id_6848266_BFB39C8D-DAF1-408E-872B-38367E4AE90D_3007_8">110952217</us-gaap:SharesIssued>
  <us-gaap:StockholdersEquity contextRef="eol_PE179294--1410-K0014_STD_0_20121231_0_1276401x1559024" unitRef="iso4217_USD" decimals="-3" id="id_6848266_BFB39C8D-DAF1-408E-872B-38367E4AE90D_3007_7">1110000</us-gaap:StockholdersEquity>
  <us-gaap:RestructuringReserve contextRef="eol_PE179294--1410-K0014_STD_0_20121231_0_1277830x1270443" unitRef="iso4217_USD" decimals="-3" id="id_6848266_0D44A515-B00A-4367-8453-713228457EE3_1001_1">10074000</us-gaap:RestructuringReserve>
  <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE179294--1410-K0014_STD_0_20131231_0" unitRef="shares" decimals="INF" id="id_6848266_B705D980-35B2-4892-9FBB-34A97DC9992A_2_26">25177597</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE179294--1410-K0014_STD_0_20131231_0" unitRef="shares" decimals="INF" id="id_6848266_B705D980-35B2-4892-9FBB-34A97DC9992A_2_25">125000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="eol_PE179294--1410-K0014_STD_0_20131231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_6848266_1A1F7457-4446-4854-A71F-326EE5804095_1001_1">4.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:TreasuryStockNumberOfSharesHeld contextRef="eol_PE179294--1410-K0014_STD_0_20131231_0" unitRef="shares" decimals="INF" id="id_6848266_B705D980-35B2-4892-9FBB-34A97DC9992A_2_28">14381</us-gaap:TreasuryStockNumberOfSharesHeld>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE179294--1410-K0014_STD_0_20131231_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_6848266_B705D980-35B2-4892-9FBB-34A97DC9992A_2_24">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="eol_PE179294--1410-K0014_STD_0_20131231_0" unitRef="shares" decimals="INF" id="id_6848266_7B0A02FA-85DB-43CF-BC04-01FAA356A7C5_1001_1">3200958</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:OtherLiabilitiesCurrent contextRef="eol_PE179294--1410-K0014_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_B705D980-35B2-4892-9FBB-34A97DC9992A_2_16">363000</us-gaap:OtherLiabilitiesCurrent>
  <us-gaap:DeferredTaxLiabilitiesPrepaidExpenses contextRef="eol_PE179294--1410-K0014_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_17ABEAB7-223F-4A9F-9F4A-306BF437B850_1002_13">395000</us-gaap:DeferredTaxLiabilitiesPrepaidExpenses>
  <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="eol_PE179294--1410-K0014_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_17ABEAB7-223F-4A9F-9F4A-306BF437B850_1002_10">79377000</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:DeferredRevenueNoncurrent contextRef="eol_PE179294--1410-K0014_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_B705D980-35B2-4892-9FBB-34A97DC9992A_2_20">7136000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="eol_PE179294--1410-K0014_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_60C93174-EF0F-4892-ACF6-2D7A2CCA3EFF_1002_6">15532000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE179294--1410-K0014_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_B705D980-35B2-4892-9FBB-34A97DC9992A_2_17">28822000</us-gaap:LiabilitiesCurrent>
  <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="eol_PE179294--1410-K0014_STD_0_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_6848266_3B574C8A-3C81-4AA8-BD7F-9FE5A340DBA2_2_0">0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
  <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate contextRef="eol_PE179294--1410-K0014_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-5" id="id_6848266_DCBA6BD2-9822-4BD7-92DE-E17C73CB0F31_1002_0">1300000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
  <us-gaap:RestructuringReserveCurrent contextRef="eol_PE179294--1410-K0014_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_B705D980-35B2-4892-9FBB-34A97DC9992A_2_14">1439000</us-gaap:RestructuringReserveCurrent>
  <us-gaap:CommonStockValue contextRef="eol_PE179294--1410-K0014_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_B705D980-35B2-4892-9FBB-34A97DC9992A_2_23">252000</us-gaap:CommonStockValue>
  <us-gaap:AccountsPayableCurrent contextRef="eol_PE179294--1410-K0014_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_B705D980-35B2-4892-9FBB-34A97DC9992A_2_12">3169000</us-gaap:AccountsPayableCurrent>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="eol_PE179294--1410-K0014_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_B705D980-35B2-4892-9FBB-34A97DC9992A_2_30">-175733000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:AccruedLiabilitiesCurrent contextRef="eol_PE179294--1410-K0014_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_B705D980-35B2-4892-9FBB-34A97DC9992A_2_13">3584000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:StockholdersEquity contextRef="eol_PE179294--1410-K0014_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_B705D980-35B2-4892-9FBB-34A97DC9992A_2_31">78914000</us-gaap:StockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE179294--1410-K0014_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_B705D980-35B2-4892-9FBB-34A97DC9992A_2_32">125782000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:DeferredIncomeTaxLiabilities contextRef="eol_PE179294--1410-K0014_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_17ABEAB7-223F-4A9F-9F4A-306BF437B850_1002_14">395000</us-gaap:DeferredIncomeTaxLiabilities>
  <us-gaap:AdditionalPaidInCapital contextRef="eol_PE179294--1410-K0014_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_B705D980-35B2-4892-9FBB-34A97DC9992A_2_29">254453000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:DeferredRevenueCurrent contextRef="eol_PE179294--1410-K0014_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_B705D980-35B2-4892-9FBB-34A97DC9992A_2_15">20267000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:UnrecognizedTaxBenefits contextRef="eol_PE179294--1410-K0014_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_C276425F-9994-4C60-9006-051FF560D19C_1002_0">1708000</us-gaap:UnrecognizedTaxBenefits>
  <us-gaap:RestructuringReserveNoncurrent contextRef="eol_PE179294--1410-K0014_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_B705D980-35B2-4892-9FBB-34A97DC9992A_2_18">8006000</us-gaap:RestructuringReserveNoncurrent>
  <us-gaap:Liabilities contextRef="eol_PE179294--1410-K0014_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_B705D980-35B2-4892-9FBB-34A97DC9992A_2_21">46868000</us-gaap:Liabilities>
  <us-gaap:DeferredRentCredit contextRef="eol_PE179294--1410-K0014_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-5" id="id_6848266_81731F1A-1997-4BE2-B6DC-1FBA78F4CD34_1002_0">2900000</us-gaap:DeferredRentCredit>
  <us-gaap:DeferredRentCreditNoncurrent contextRef="eol_PE179294--1410-K0014_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_B705D980-35B2-4892-9FBB-34A97DC9992A_2_19">2904000</us-gaap:DeferredRentCreditNoncurrent>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE179294--1410-K0014_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_B705D980-35B2-4892-9FBB-34A97DC9992A_2_2">116481000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE179294--1410-K0014_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_B705D980-35B2-4892-9FBB-34A97DC9992A_2_7">5035000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE179294--1410-K0014_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_1488D3AB-3CD2-47A3-A84E-215813CCCADC_1001_5">116886000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:DeferredTaxAssetsGross contextRef="eol_PE179294--1410-K0014_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_17ABEAB7-223F-4A9F-9F4A-306BF437B850_1002_9">79772000</us-gaap:DeferredTaxAssetsGross>
  <us-gaap:RestrictedCashAndCashEquivalents contextRef="eol_PE179294--1410-K0014_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_B705D980-35B2-4892-9FBB-34A97DC9992A_2_6">405000</us-gaap:RestrictedCashAndCashEquivalents>
  <us-gaap:DeferredTaxAssetsOther contextRef="eol_PE179294--1410-K0014_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_17ABEAB7-223F-4A9F-9F4A-306BF437B850_1002_8">1439000</us-gaap:DeferredTaxAssetsOther>
  <us-gaap:DeferredTaxAssetsDeferredIncome contextRef="eol_PE179294--1410-K0014_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_17ABEAB7-223F-4A9F-9F4A-306BF437B850_1002_6">8217000</us-gaap:DeferredTaxAssetsDeferredIncome>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic contextRef="eol_PE179294--1410-K0014_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_17ABEAB7-223F-4A9F-9F4A-306BF437B850_1002_1">36561000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="eol_PE179294--1410-K0014_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_17ABEAB7-223F-4A9F-9F4A-306BF437B850_1002_3">3786000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE179294--1410-K0014_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_60C93174-EF0F-4892-ACF6-2D7A2CCA3EFF_1002_5">20567000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment contextRef="eol_PE179294--1410-K0014_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_17ABEAB7-223F-4A9F-9F4A-306BF437B850_1002_7">1438000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent contextRef="eol_PE179294--1410-K0014_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_17ABEAB7-223F-4A9F-9F4A-306BF437B850_1002_5">5132000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent>
  <us-gaap:Assets contextRef="eol_PE179294--1410-K0014_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_B705D980-35B2-4892-9FBB-34A97DC9992A_2_9">125782000</us-gaap:Assets>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="eol_PE179294--1410-K0014_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_1488D3AB-3CD2-47A3-A84E-215813CCCADC_1001_2">90434000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="eol_PE179294--1410-K0014_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_17ABEAB7-223F-4A9F-9F4A-306BF437B850_1002_15">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
  <us-gaap:DeferredTaxAssetsNet contextRef="eol_PE179294--1410-K0014_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_17ABEAB7-223F-4A9F-9F4A-306BF437B850_1002_11">395000</us-gaap:DeferredTaxAssetsNet>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsOther contextRef="eol_PE179294--1410-K0014_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_17ABEAB7-223F-4A9F-9F4A-306BF437B850_1002_4">19883000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsOther>
  <us-gaap:AccountsReceivableNetCurrent contextRef="eol_PE179294--1410-K0014_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_B705D980-35B2-4892-9FBB-34A97DC9992A_2_3">2004000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:OtherAssetsNoncurrent contextRef="eol_PE179294--1410-K0014_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_B705D980-35B2-4892-9FBB-34A97DC9992A_2_8">885000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:TreasuryStockValue contextRef="eol_PE179294--1410-K0014_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_B705D980-35B2-4892-9FBB-34A97DC9992A_2_27">58000</us-gaap:TreasuryStockValue>
  <us-gaap:AssetsCurrent contextRef="eol_PE179294--1410-K0014_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_B705D980-35B2-4892-9FBB-34A97DC9992A_2_5">119457000</us-gaap:AssetsCurrent>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal contextRef="eol_PE179294--1410-K0014_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_17ABEAB7-223F-4A9F-9F4A-306BF437B850_1002_2">3316000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
  <us-gaap:PrepaidExpenseCurrent contextRef="eol_PE179294--1410-K0014_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_B705D980-35B2-4892-9FBB-34A97DC9992A_2_4">972000</us-gaap:PrepaidExpenseCurrent>
  <mgnx:MoneyMarketFundsFairValueDisclosure contextRef="eol_PE179294--1410-K0014_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_1488D3AB-3CD2-47A3-A84E-215813CCCADC_1001_3">26047000</mgnx:MoneyMarketFundsFairValueDisclosure>
  <mgnx:NumberOfImpairedAssets contextRef="eol_PE179294--1410-K0014_STD_0_20131231_0" unitRef="Assets" decimals="INF" id="id_6848266_67DBCEB7-F98C-4A6D-A6E0-A97F7017FCB5_1002_0">0</mgnx:NumberOfImpairedAssets>
  <mgnx:NumberOfAssetsHeldForSale contextRef="eol_PE179294--1410-K0014_STD_0_20131231_0" unitRef="Assets" decimals="INF" id="id_6848266_67DBCEB7-F98C-4A6D-A6E0-A97F7017FCB5_1002_1">0</mgnx:NumberOfAssetsHeldForSale>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE179294--1410-K0014_STD_0_20131231_0_1269038x1272304" unitRef="iso4217_USD" decimals="-3" id="id_6848266_1488D3AB-3CD2-47A3-A84E-215813CCCADC_1002_5">116886000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:RestrictedCashAndCashEquivalents contextRef="eol_PE179294--1410-K0014_STD_0_20131231_0_1269038x1272304" unitRef="iso4217_USD" decimals="-3" id="id_6848266_1488D3AB-3CD2-47A3-A84E-215813CCCADC_1002_4">405000</us-gaap:RestrictedCashAndCashEquivalents>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="eol_PE179294--1410-K0014_STD_0_20131231_0_1269038x1272304" unitRef="iso4217_USD" decimals="-3" id="id_6848266_1488D3AB-3CD2-47A3-A84E-215813CCCADC_1002_2">90434000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <mgnx:MoneyMarketFundsFairValueDisclosure contextRef="eol_PE179294--1410-K0014_STD_0_20131231_0_1269038x1272304" unitRef="iso4217_USD" decimals="-3" id="id_6848266_1488D3AB-3CD2-47A3-A84E-215813CCCADC_1002_3">26047000</mgnx:MoneyMarketFundsFairValueDisclosure>
  <us-gaap:DeferredRevenueNoncurrent contextRef="eol_PE179294--1410-K0014_STD_0_20131231_0_1272072x1370805" unitRef="iso4217_USD" decimals="INF" id="id_6848266_5A5F5357-667E-4030-90D0-FDF5BC9B5938_2_3">550000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:DeferredRevenueCurrent contextRef="eol_PE179294--1410-K0014_STD_0_20131231_0_1272072x1370805" unitRef="iso4217_USD" decimals="INF" id="id_6848266_5A5F5357-667E-4030-90D0-FDF5BC9B5938_2_2">100000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredRevenue contextRef="eol_PE179294--1410-K0014_STD_0_20131231_0_1272072x1370805" unitRef="iso4217_USD" decimals="INF" id="id_6848266_5A5F5357-667E-4030-90D0-FDF5BC9B5938_2_0">650000</us-gaap:DeferredRevenue>
  <us-gaap:DeferredRevenueCurrent contextRef="eol_PE179294--1410-K0014_STD_0_20131231_0_1272072x1444876" unitRef="iso4217_USD" decimals="-5" id="id_6848266_5ADF1F89-DB4B-4AF2-97E3-1E7D2B3FAC60_2_0">3600000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredRevenueNoncurrent contextRef="eol_PE179294--1410-K0014_STD_0_20131231_0_1272072x1503196" unitRef="iso4217_USD" decimals="-5" id="id_6848266_AED8F272-20FC-4F1A-82AB-7856839A71BD_1002_3">5800000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:DeferredRevenueCurrent contextRef="eol_PE179294--1410-K0014_STD_0_20131231_0_1272072x1503196" unitRef="iso4217_USD" decimals="-5" id="id_6848266_AED8F272-20FC-4F1A-82AB-7856839A71BD_1002_2">7000000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredRevenue contextRef="eol_PE179294--1410-K0014_STD_0_20131231_0_1272072x1503196" unitRef="iso4217_USD" decimals="-5" id="id_6848266_AED8F272-20FC-4F1A-82AB-7856839A71BD_1002_1">12800000</us-gaap:DeferredRevenue>
  <us-gaap:DeferredRevenueCurrent contextRef="eol_PE179294--1410-K0014_STD_0_20131231_0_1272072x1538608" unitRef="iso4217_USD" decimals="-5" id="id_6848266_DD806EFD-88BF-43D4-A4C5-E550AEDED6C9_2_0">900000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredRevenueNoncurrent contextRef="eol_PE179294--1410-K0014_STD_0_20131231_0_1272072x1538608_1279908x1439878" unitRef="iso4217_USD" decimals="-5" id="id_6848266_2843D6A1-C5DF-40EC-8091-B7217826CD0B_1002_2">800000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:DeferredRevenueCurrent contextRef="eol_PE179294--1410-K0014_STD_0_20131231_0_1272072x1538608_1279908x1439878" unitRef="iso4217_USD" decimals="-5" id="id_6848266_2843D6A1-C5DF-40EC-8091-B7217826CD0B_1002_1">8600000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredRevenue contextRef="eol_PE179294--1410-K0014_STD_0_20131231_0_1272072x1538608_1279908x1439878" unitRef="iso4217_USD" decimals="-5" id="id_6848266_2843D6A1-C5DF-40EC-8091-B7217826CD0B_1002_0">9400000</us-gaap:DeferredRevenue>
  <us-gaap:DeferredRevenueCurrent contextRef="eol_PE179294--1410-K0014_STD_0_20131231_0_1272072x1545620" unitRef="iso4217_USD" decimals="0" id="id_6848266_DF05BECD-1327-4B39-94D5-76BD1E434554_2_0">7000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE179294--1410-K0014_STD_0_20131231_0_1276136x1273964" unitRef="iso4217_USD" decimals="-3" id="id_6848266_60C93174-EF0F-4892-ACF6-2D7A2CCA3EFF_2002_3">11166000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE179294--1410-K0014_STD_0_20131231_0_1276136x1275434" unitRef="iso4217_USD" decimals="-3" id="id_6848266_60C93174-EF0F-4892-ACF6-2D7A2CCA3EFF_3002_0">2379000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE179294--1410-K0014_STD_0_20131231_0_1276136x1277482" unitRef="iso4217_USD" decimals="-3" id="id_6848266_60C93174-EF0F-4892-ACF6-2D7A2CCA3EFF_4002_4">4894000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE179294--1410-K0014_STD_0_20131231_0_1276136x1277975" unitRef="iso4217_USD" decimals="-3" id="id_6848266_60C93174-EF0F-4892-ACF6-2D7A2CCA3EFF_5002_1">1477000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE179294--1410-K0014_STD_0_20131231_0_1276136x1424108" unitRef="iso4217_USD" decimals="-3" id="id_6848266_60C93174-EF0F-4892-ACF6-2D7A2CCA3EFF_6002_2">651000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PreferredStockSharesOutstanding contextRef="eol_PE179294--1410-K0014_STD_0_20131231_0_1276400x1312914" unitRef="shares" decimals="INF" id="id_6848266_C9A3D9AC-840C-4E73-A009-17EE683770D1_1002_4">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockSharesIssued contextRef="eol_PE179294--1410-K0014_STD_0_20131231_0_1276400x1312914" unitRef="shares" decimals="INF" id="id_6848266_C9A3D9AC-840C-4E73-A009-17EE683770D1_1002_3">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:StockholdersEquity contextRef="eol_PE179294--1410-K0014_STD_0_20131231_0_1276401x1269588" unitRef="iso4217_USD" decimals="-3" id="id_6848266_BFB39C8D-DAF1-408E-872B-38367E4AE90D_5018_17">-175733000</us-gaap:StockholdersEquity>
  <us-gaap:SharesIssued contextRef="eol_PE179294--1410-K0014_STD_0_20131231_0_1276401x1270422" unitRef="shares" decimals="INF" id="id_6848266_BFB39C8D-DAF1-408E-872B-38367E4AE90D_5013_18">25177597</us-gaap:SharesIssued>
  <us-gaap:StockholdersEquity contextRef="eol_PE179294--1410-K0014_STD_0_20131231_0_1276401x1270422" unitRef="iso4217_USD" decimals="-3" id="id_6848266_BFB39C8D-DAF1-408E-872B-38367E4AE90D_5013_17">252000</us-gaap:StockholdersEquity>
  <us-gaap:SharesIssued contextRef="eol_PE179294--1410-K0014_STD_0_20131231_0_1276401x1273409" unitRef="shares" decimals="INF" id="id_6848266_BFB39C8D-DAF1-408E-872B-38367E4AE90D_5015_18">14381</us-gaap:SharesIssued>
  <us-gaap:StockholdersEquity contextRef="eol_PE179294--1410-K0014_STD_0_20131231_0_1276401x1273409" unitRef="iso4217_USD" decimals="-3" id="id_6848266_BFB39C8D-DAF1-408E-872B-38367E4AE90D_5015_17">-58000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE179294--1410-K0014_STD_0_20131231_0_1276401x1273630" unitRef="iso4217_USD" decimals="-3" id="id_6848266_BFB39C8D-DAF1-408E-872B-38367E4AE90D_5017_17">254453000</us-gaap:StockholdersEquity>
  <us-gaap:RestructuringReserve contextRef="eol_PE179294--1410-K0014_STD_0_20131231_0_1277830x1270443" unitRef="iso4217_USD" decimals="-3" id="id_6848266_0D44A515-B00A-4367-8453-713228457EE3_3001_3">9445000</us-gaap:RestructuringReserve>
  <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0" unitRef="shares" decimals="INF" id="id_6848266_B705D980-35B2-4892-9FBB-34A97DC9992A_1_26">27995638</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0" unitRef="shares" decimals="INF" id="id_6848266_7B0A02FA-85DB-43CF-BC04-01FAA356A7C5_3001_7">3341192</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
  <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0" unitRef="shares" decimals="INF" id="id_6848266_B705D980-35B2-4892-9FBB-34A97DC9992A_1_25">125000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_6848266_1A1F7457-4446-4854-A71F-326EE5804095_3001_5">11.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0" unitRef="shares" decimals="INF" id="id_6848266_7B0A02FA-85DB-43CF-BC04-01FAA356A7C5_3001_6">1668962</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_6848266_1A1F7457-4446-4854-A71F-326EE5804095_3001_6">3.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:TreasuryStockNumberOfSharesHeld contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0" unitRef="shares" decimals="INF" id="id_6848266_B705D980-35B2-4892-9FBB-34A97DC9992A_1_28">865</us-gaap:TreasuryStockNumberOfSharesHeld>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_6848266_1A1F7457-4446-4854-A71F-326EE5804095_3001_7">11.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_6848266_B705D980-35B2-4892-9FBB-34A97DC9992A_1_24">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0" unitRef="shares" decimals="INF" id="id_6848266_7B0A02FA-85DB-43CF-BC04-01FAA356A7C5_3001_5">3572116</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:OtherLiabilitiesCurrent contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_B705D980-35B2-4892-9FBB-34A97DC9992A_1_16">1605000</us-gaap:OtherLiabilitiesCurrent>
  <us-gaap:DeferredTaxLiabilitiesPrepaidExpenses contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_17ABEAB7-223F-4A9F-9F4A-306BF437B850_1001_13">1605000</us-gaap:DeferredTaxLiabilitiesPrepaidExpenses>
  <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_17ABEAB7-223F-4A9F-9F4A-306BF437B850_1001_10">94297000</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:DeferredRevenueNoncurrent contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_B705D980-35B2-4892-9FBB-34A97DC9992A_1_20">16472000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_60C93174-EF0F-4892-ACF6-2D7A2CCA3EFF_1001_6">17355000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_9B3A4714-9D41-4994-BBD5-F46F44FB8483_1001_5">116000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter>
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_B705D980-35B2-4892-9FBB-34A97DC9992A_1_17">27094000</us-gaap:LiabilitiesCurrent>
  <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0" unitRef="iso4217_USD" decimals="0" id="id_6848266_3B574C8A-3C81-4AA8-BD7F-9FE5A340DBA2_1_0">0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
  <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-5" id="id_6848266_DCBA6BD2-9822-4BD7-92DE-E17C73CB0F31_1001_0">1700000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
  <us-gaap:RestructuringReserveCurrent contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_B705D980-35B2-4892-9FBB-34A97DC9992A_1_14">1642000</us-gaap:RestructuringReserveCurrent>
  <us-gaap:CommonStockValue contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_B705D980-35B2-4892-9FBB-34A97DC9992A_1_23">280000</us-gaap:CommonStockValue>
  <us-gaap:AccountsPayableCurrent contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_B705D980-35B2-4892-9FBB-34A97DC9992A_1_12">1669000</us-gaap:AccountsPayableCurrent>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_B705D980-35B2-4892-9FBB-34A97DC9992A_1_30">-214046000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_9B3A4714-9D41-4994-BBD5-F46F44FB8483_1001_3">4396000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
  <us-gaap:AccruedLiabilitiesCurrent contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_B705D980-35B2-4892-9FBB-34A97DC9992A_1_13">7930000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:StockholdersEquity contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_B705D980-35B2-4892-9FBB-34A97DC9992A_1_31">121286000</us-gaap:StockholdersEquity>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_9B3A4714-9D41-4994-BBD5-F46F44FB8483_1001_6">19189000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_9B3A4714-9D41-4994-BBD5-F46F44FB8483_1001_4">1873000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_9B3A4714-9D41-4994-BBD5-F46F44FB8483_1001_2">4495000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_B705D980-35B2-4892-9FBB-34A97DC9992A_1_32">173886000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:DeferredTaxLiabilitiesGrossCurrent contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-5" id="id_6848266_E0E6B925-9E6C-4A5F-8119-FFBEE4B9541F_1001_0">1600000</us-gaap:DeferredTaxLiabilitiesGrossCurrent>
  <us-gaap:DeferredIncomeTaxLiabilities contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_17ABEAB7-223F-4A9F-9F4A-306BF437B850_1001_14">1605000</us-gaap:DeferredIncomeTaxLiabilities>
  <us-gaap:AdditionalPaidInCapital contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_B705D980-35B2-4892-9FBB-34A97DC9992A_1_29">335071000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:DeferredRevenueCurrent contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_B705D980-35B2-4892-9FBB-34A97DC9992A_1_15">14248000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:UnrecognizedTaxBenefits contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_C276425F-9994-4C60-9006-051FF560D19C_1001_4">2047000</us-gaap:UnrecognizedTaxBenefits>
  <us-gaap:RestructuringReserveNoncurrent contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_B705D980-35B2-4892-9FBB-34A97DC9992A_1_18">6364000</us-gaap:RestructuringReserveNoncurrent>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_9B3A4714-9D41-4994-BBD5-F46F44FB8483_1001_1">4364000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
  <us-gaap:Liabilities contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_B705D980-35B2-4892-9FBB-34A97DC9992A_1_21">52600000</us-gaap:Liabilities>
  <us-gaap:DeferredRentCredit contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-5" id="id_6848266_81731F1A-1997-4BE2-B6DC-1FBA78F4CD34_1001_0">2700000</us-gaap:DeferredRentCredit>
  <us-gaap:DeferredRentCreditNoncurrent contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_B705D980-35B2-4892-9FBB-34A97DC9992A_1_19">2670000</us-gaap:DeferredRentCreditNoncurrent>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_9B3A4714-9D41-4994-BBD5-F46F44FB8483_1001_0">3945000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_B705D980-35B2-4892-9FBB-34A97DC9992A_1_2">157591000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_B705D980-35B2-4892-9FBB-34A97DC9992A_1_7">6785000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_8736C8C4-3746-4F80-82B8-11768B6E1563_1001_1">84515000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_E424C480-B269-4D7E-8163-82DADFAD094B_1001_5">157891000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:DeferredTaxAssetsGross contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_17ABEAB7-223F-4A9F-9F4A-306BF437B850_1001_9">95902000</us-gaap:DeferredTaxAssetsGross>
  <us-gaap:RestrictedCashAndCashEquivalents contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_B705D980-35B2-4892-9FBB-34A97DC9992A_1_6">300000</us-gaap:RestrictedCashAndCashEquivalents>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_8736C8C4-3746-4F80-82B8-11768B6E1563_1001_3">80323000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
  <us-gaap:DeferredTaxAssetsGrossNoncurrent contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-5" id="id_6848266_E0E6B925-9E6C-4A5F-8119-FFBEE4B9541F_1001_1">1600000</us-gaap:DeferredTaxAssetsGrossNoncurrent>
  <us-gaap:DeferredTaxAssetsOther contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_17ABEAB7-223F-4A9F-9F4A-306BF437B850_1001_8">962000</us-gaap:DeferredTaxAssetsOther>
  <us-gaap:DeferredTaxAssetsDeferredIncome contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_17ABEAB7-223F-4A9F-9F4A-306BF437B850_1001_6">3989000</us-gaap:DeferredTaxAssetsDeferredIncome>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_17ABEAB7-223F-4A9F-9F4A-306BF437B850_1001_1">55358000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_17ABEAB7-223F-4A9F-9F4A-306BF437B850_1001_3">7177000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_60C93174-EF0F-4892-ACF6-2D7A2CCA3EFF_1001_5">24140000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_8736C8C4-3746-4F80-82B8-11768B6E1563_1001_2">53122000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
  <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_17ABEAB7-223F-4A9F-9F4A-306BF437B850_1001_7">1337000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_17ABEAB7-223F-4A9F-9F4A-306BF437B850_1001_5">4069000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent>
  <us-gaap:Assets contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_B705D980-35B2-4892-9FBB-34A97DC9992A_1_9">173886000</us-gaap:Assets>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_E424C480-B269-4D7E-8163-82DADFAD094B_1001_2">131545000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_E0E6B925-9E6C-4A5F-8119-FFBEE4B9541F_1001_2">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
  <us-gaap:DeferredTaxAssetsNet contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_17ABEAB7-223F-4A9F-9F4A-306BF437B850_1001_11">1605000</us-gaap:DeferredTaxAssetsNet>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsOther contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_17ABEAB7-223F-4A9F-9F4A-306BF437B850_1001_4">19287000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsOther>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-5" id="id_6848266_6FF767FB-8AC0-4D45-89E1-7828051C94DC_1001_5">19600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
  <us-gaap:AccountsReceivableNetCurrent contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_B705D980-35B2-4892-9FBB-34A97DC9992A_1_3">2935000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:OtherAssetsNoncurrent contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_B705D980-35B2-4892-9FBB-34A97DC9992A_1_8">2064000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:TreasuryStockValue contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_B705D980-35B2-4892-9FBB-34A97DC9992A_1_27">19000</us-gaap:TreasuryStockValue>
  <us-gaap:AssetsCurrent contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_B705D980-35B2-4892-9FBB-34A97DC9992A_1_5">164737000</us-gaap:AssetsCurrent>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_17ABEAB7-223F-4A9F-9F4A-306BF437B850_1001_2">3723000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
  <us-gaap:PrepaidExpenseCurrent contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_B705D980-35B2-4892-9FBB-34A97DC9992A_1_4">4211000</us-gaap:PrepaidExpenseCurrent>
  <mgnx:MoneyMarketFundsFairValueDisclosure contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_E424C480-B269-4D7E-8163-82DADFAD094B_1001_3">26046000</mgnx:MoneyMarketFundsFairValueDisclosure>
  <mgnx:OperatingLossCarryforwardsNotSubjectToLimitation contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-5" id="id_6848266_DAFDF779-4E13-4F8C-BCD2-10752D7C8927_1001_5">151800000</mgnx:OperatingLossCarryforwardsNotSubjectToLimitation>
  <mgnx:NumberOfImpairedAssets contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0" unitRef="Assets" decimals="INF" id="id_6848266_67DBCEB7-F98C-4A6D-A6E0-A97F7017FCB5_1001_0">0</mgnx:NumberOfImpairedAssets>
  <mgnx:NumberOfAssetsHeldForSale contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0" unitRef="Assets" decimals="INF" id="id_6848266_67DBCEB7-F98C-4A6D-A6E0-A97F7017FCB5_1001_1">0</mgnx:NumberOfAssetsHeldForSale>
  <mgnx:UnrecognizedTaxBenefitsResultingInNetOperatingLossesCarryforward contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-5" id="id_6848266_DAFDF779-4E13-4F8C-BCD2-10752D7C8927_1001_6">7700000</mgnx:UnrecognizedTaxBenefitsResultingInNetOperatingLossesCarryforward>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0_1269038x1272304" unitRef="iso4217_USD" decimals="-3" id="id_6848266_E424C480-B269-4D7E-8163-82DADFAD094B_1002_5">157891000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:RestrictedCashAndCashEquivalents contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0_1269038x1272304" unitRef="iso4217_USD" decimals="-3" id="id_6848266_E424C480-B269-4D7E-8163-82DADFAD094B_1002_4">300000</us-gaap:RestrictedCashAndCashEquivalents>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0_1269038x1272304" unitRef="iso4217_USD" decimals="-3" id="id_6848266_E424C480-B269-4D7E-8163-82DADFAD094B_1002_2">131545000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <mgnx:MoneyMarketFundsFairValueDisclosure contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0_1269038x1272304" unitRef="iso4217_USD" decimals="-3" id="id_6848266_E424C480-B269-4D7E-8163-82DADFAD094B_1002_3">26046000</mgnx:MoneyMarketFundsFairValueDisclosure>
  <mgnx:OperatingLossCarryforwardsAnnualLimitationAmount contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0_1269523x1275948" unitRef="iso4217_USD" decimals="-5" id="id_6848266_DAFDF779-4E13-4F8C-BCD2-10752D7C8927_2001_4">1400000</mgnx:OperatingLossCarryforwardsAnnualLimitationAmount>
  <mgnx:AdditionalPotentialClinicalAndCommercialMilestonePaymentsUnderAgreement contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0_1269523x1275948_1272072x1370805" unitRef="iso4217_USD" decimals="-5" id="id_6848266_E08C9C97-0AE9-4E28-82AE-4DD5B9295905_2001_1">2500000</mgnx:AdditionalPotentialClinicalAndCommercialMilestonePaymentsUnderAgreement>
  <mgnx:AdditionalPotentialRegulatoryAndSalesMilestonePaymentsUnderAgreement contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0_1269523x1275948_1272072x1444876" unitRef="iso4217_USD" decimals="-5" id="id_6848266_B20C8915-6C26-4325-8243-BD8CB702C60D_2002_6">250000000</mgnx:AdditionalPotentialRegulatoryAndSalesMilestonePaymentsUnderAgreement>
  <mgnx:AdditionalPotentialClinicalMilestonePaymentsUnderAgreement contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0_1269523x1275948_1272072x1444876_1279908x1560227" unitRef="iso4217_USD" decimals="-5" id="id_6848266_B20C8915-6C26-4325-8243-BD8CB702C60D_3002_4">25000000</mgnx:AdditionalPotentialClinicalMilestonePaymentsUnderAgreement>
  <mgnx:AdditionalPotentialSalesMilestonePaymentsUnderAgreement contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0_1269523x1275948_1272072x1538608" unitRef="iso4217_USD" decimals="-5" id="id_6848266_DB33E3E0-DB0D-48E7-B64B-61B8090A36D2_1001_4">208000000</mgnx:AdditionalPotentialSalesMilestonePaymentsUnderAgreement>
  <mgnx:AdditionalPotentialRegulatoryMilestonePaymentsUnderAgreement contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0_1269523x1275948_1272072x1538608" unitRef="iso4217_USD" decimals="-5" id="id_6848266_DB33E3E0-DB0D-48E7-B64B-61B8090A36D2_1001_3">140000000</mgnx:AdditionalPotentialRegulatoryMilestonePaymentsUnderAgreement>
  <mgnx:AdditionalPotentialLicenseGrantFeesUnderAgreement contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0_1269523x1275948_1272072x1538608" unitRef="iso4217_USD" decimals="-5" id="id_6848266_DB33E3E0-DB0D-48E7-B64B-61B8090A36D2_1001_1">30000000</mgnx:AdditionalPotentialLicenseGrantFeesUnderAgreement>
  <mgnx:AdditionalClinicalMilestonePotentialPaymentsUnderAgreement contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0_1269523x1275948_1272072x1538608" unitRef="iso4217_USD" decimals="-5" id="id_6848266_DB33E3E0-DB0D-48E7-B64B-61B8090A36D2_1001_2">47000000</mgnx:AdditionalClinicalMilestonePotentialPaymentsUnderAgreement>
  <mgnx:AdditionalPotentialMilestonePaymentsReceivableUponNewDrugApplicationAcceptance contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0_1269523x1275948_1272072x1538608_1279908x1439878" unitRef="iso4217_USD" decimals="-5" id="id_6848266_2FB55827-09AB-416E-B47F-893BEB50C154_2001_3">5000000</mgnx:AdditionalPotentialMilestonePaymentsReceivableUponNewDrugApplicationAcceptance>
  <mgnx:AdditionalPotentialSalesMilestonePaymentsUnderAgreement contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0_1269523x1275948_1272072x1538608_1279908x1439878" unitRef="iso4217_USD" decimals="-5" id="id_6848266_2FB55827-09AB-416E-B47F-893BEB50C154_2001_5">630000000</mgnx:AdditionalPotentialSalesMilestonePaymentsUnderAgreement>
  <mgnx:AdditionalPotentialRegulatoryMilestonePaymentsUnderAgreement contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0_1269523x1275948_1272072x1538608_1279908x1439878" unitRef="iso4217_USD" decimals="-5" id="id_6848266_2FB55827-09AB-416E-B47F-893BEB50C154_2001_4">300000000</mgnx:AdditionalPotentialRegulatoryMilestonePaymentsUnderAgreement>
  <mgnx:AdditionalPotentialLicenseGrantFeesUnderAgreement contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0_1269523x1275948_1272072x1538608_1279908x1439878" unitRef="iso4217_USD" decimals="-5" id="id_6848266_2FB55827-09AB-416E-B47F-893BEB50C154_2001_1">65000000</mgnx:AdditionalPotentialLicenseGrantFeesUnderAgreement>
  <mgnx:AdditionalClinicalMilestonePotentialPaymentsUnderAgreement contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0_1269523x1275948_1272072x1538608_1279908x1439878" unitRef="iso4217_USD" decimals="-5" id="id_6848266_2FB55827-09AB-416E-B47F-893BEB50C154_2001_2">98000000</mgnx:AdditionalClinicalMilestonePotentialPaymentsUnderAgreement>
  <mgnx:OperatingLossCarryforwardsAnnualLimitationAmount contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0_1269523x1277596" unitRef="iso4217_USD" decimals="-5" id="id_6848266_DAFDF779-4E13-4F8C-BCD2-10752D7C8927_3001_3">200000</mgnx:OperatingLossCarryforwardsAnnualLimitationAmount>
  <mgnx:AdditionalPotentialRegulatoryAndSalesMilestonePaymentsUnderAgreement contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0_1269523x1277596_1272072x1444876" unitRef="iso4217_USD" decimals="-5" id="id_6848266_B20C8915-6C26-4325-8243-BD8CB702C60D_4002_5">240000000</mgnx:AdditionalPotentialRegulatoryAndSalesMilestonePaymentsUnderAgreement>
  <mgnx:AdditionalPotentialClinicalMilestonePaymentsUnderAgreement contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0_1269523x1277596_1272072x1444876_1279908x1560227" unitRef="iso4217_USD" decimals="-5" id="id_6848266_B20C8915-6C26-4325-8243-BD8CB702C60D_5002_3">20000000</mgnx:AdditionalPotentialClinicalMilestonePaymentsUnderAgreement>
  <us-gaap:UnbilledContractsReceivable contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0_1272072x1370805" unitRef="iso4217_USD" decimals="0" id="id_6848266_5A5F5357-667E-4030-90D0-FDF5BC9B5938_1_1">525000</us-gaap:UnbilledContractsReceivable>
  <us-gaap:DeferredRevenueCurrent contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0_1272072x1444876" unitRef="iso4217_USD" decimals="INF" id="id_6848266_5ADF1F89-DB4B-4AF2-97E3-1E7D2B3FAC60_1_0">0</us-gaap:DeferredRevenueCurrent>
  <mgnx:AdditionalLicenseGrantFeesUnderAgreement contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0_1272072x1444876" unitRef="iso4217_USD" decimals="-5" id="id_6848266_B20C8915-6C26-4325-8243-BD8CB702C60D_1002_2">7500000</mgnx:AdditionalLicenseGrantFeesUnderAgreement>
  <us-gaap:DeferredRevenueCurrent contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0_1272072x1503196" unitRef="iso4217_USD" decimals="-5" id="id_6848266_AED8F272-20FC-4F1A-82AB-7856839A71BD_1001_2">5800000</us-gaap:DeferredRevenueCurrent>
  <mgnx:AdditionalPotentialClinicalMilestonePaymentsUnderAgreement contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0_1272072x1503196" unitRef="iso4217_USD" decimals="-5" id="id_6848266_D8A60150-BE03-466F-8DF8-E45FA6E46220_1001_2">41000000</mgnx:AdditionalPotentialClinicalMilestonePaymentsUnderAgreement>
  <mgnx:AdditionalPotentialSalesMilestonePaymentsUnderAgreement contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0_1272072x1503196" unitRef="iso4217_USD" decimals="-5" id="id_6848266_D8A60150-BE03-466F-8DF8-E45FA6E46220_1001_4">83000000</mgnx:AdditionalPotentialSalesMilestonePaymentsUnderAgreement>
  <mgnx:AdditionalPotentialRegulatoryMilestonePaymentsUnderAgreement contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0_1272072x1503196" unitRef="iso4217_USD" decimals="-5" id="id_6848266_D8A60150-BE03-466F-8DF8-E45FA6E46220_1001_3">89000000</mgnx:AdditionalPotentialRegulatoryMilestonePaymentsUnderAgreement>
  <us-gaap:DeferredRevenueCurrent contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0_1272072x1538608" unitRef="iso4217_USD" decimals="-5" id="id_6848266_DD806EFD-88BF-43D4-A4C5-E550AEDED6C9_1_0">100000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredRevenueNoncurrent contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0_1272072x1538608_1279908x1439878" unitRef="iso4217_USD" decimals="-5" id="id_6848266_2843D6A1-C5DF-40EC-8091-B7217826CD0B_1001_2">14400000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:DeferredRevenueCurrent contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0_1272072x1538608_1279908x1439878" unitRef="iso4217_USD" decimals="-5" id="id_6848266_2843D6A1-C5DF-40EC-8091-B7217826CD0B_1001_1">3300000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredRevenue contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0_1272072x1538608_1279908x1439878" unitRef="iso4217_USD" decimals="-5" id="id_6848266_2843D6A1-C5DF-40EC-8091-B7217826CD0B_1001_0">17700000</us-gaap:DeferredRevenue>
  <mgnx:OptionExerciseFee contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0_1272072x1538608_1279908x1439878" unitRef="iso4217_USD" decimals="-5" id="id_6848266_04591BAC-6897-476B-88E9-DCED4AA4B34E_2001_0">15000000</mgnx:OptionExerciseFee>
  <mgnx:CollaborationAgreementConsiderationReceivable contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0_1272072x1538608_1279908x1439878" unitRef="iso4217_USD" decimals="-5" id="id_6848266_04591BAC-6897-476B-88E9-DCED4AA4B34E_2001_3">800000</mgnx:CollaborationAgreementConsiderationReceivable>
  <us-gaap:DeferredRevenueCurrent contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0_1272072x1545620" unitRef="iso4217_USD" decimals="INF" id="id_6848266_DF05BECD-1327-4B39-94D5-76BD1E434554_1_0">0</us-gaap:DeferredRevenueCurrent>
  <mgnx:AdditionalPotentialClinicalMilestonePaymentsUnderAgreement contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0_1272072x1545620" unitRef="iso4217_USD" decimals="-5" id="id_6848266_BCD36912-D7FB-475E-807A-BEEA09E6D473_1001_0">17000000</mgnx:AdditionalPotentialClinicalMilestonePaymentsUnderAgreement>
  <mgnx:AdditionalPotentialCommercializationAndSalesMilestonePaymentsUnderAgreement contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0_1272072x1545620" unitRef="iso4217_USD" decimals="-5" id="id_6848266_BCD36912-D7FB-475E-807A-BEEA09E6D473_1001_1">195000000</mgnx:AdditionalPotentialCommercializationAndSalesMilestonePaymentsUnderAgreement>
  <us-gaap:DeferredRevenueNoncurrent contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0_1272072x1565531" unitRef="iso4217_USD" decimals="-5" id="id_6848266_39E3AD4D-78FF-4EA3-ABF5-D7E3361199B7_1001_3">2100000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:DeferredRevenueCurrent contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0_1272072x1565531" unitRef="iso4217_USD" decimals="-5" id="id_6848266_39E3AD4D-78FF-4EA3-ABF5-D7E3361199B7_1001_2">5000000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredRevenue contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0_1272072x1565531" unitRef="iso4217_USD" decimals="-5" id="id_6848266_39E3AD4D-78FF-4EA3-ABF5-D7E3361199B7_1001_1">7100000</us-gaap:DeferredRevenue>
  <mgnx:PotentialLicenseOptionFeeAndEarlyDevelopmentMilestoneFee contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0_1272072x1565531" unitRef="iso4217_USD" decimals="-5" id="id_6848266_5BD21674-263F-4556-AF29-4A17D34968DD_1002_2">18000000</mgnx:PotentialLicenseOptionFeeAndEarlyDevelopmentMilestoneFee>
  <mgnx:AdditionalPotentialDevelopmentRegulatoryAndSalesMilestoneUnderAgreement contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0_1272072x1565531" unitRef="iso4217_USD" decimals="-5" id="id_6848266_5BD21674-263F-4556-AF29-4A17D34968DD_1002_3">468500000</mgnx:AdditionalPotentialDevelopmentRegulatoryAndSalesMilestoneUnderAgreement>
  <us-gaap:SaleOfStockPricePerShare contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0_1272072x1605598" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_6848266_5D514CAD-48D3-4D6A-AF91-9AF832FEA310_1001_3">39.00</us-gaap:SaleOfStockPricePerShare>
  <us-gaap:DeferredRevenue contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0_1272072x1605598" unitRef="iso4217_USD" decimals="INF" id="id_6848266_868640A9-E7A9-43E8-8868-1C279F076DB5_1001_1">0</us-gaap:DeferredRevenue>
  <mgnx:NonRefundableUpfrontPaymentReceivable contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0_1272072x1605598" unitRef="iso4217_USD" decimals="-5" id="id_6848266_5D514CAD-48D3-4D6A-AF91-9AF832FEA310_1001_4">50000000</mgnx:NonRefundableUpfrontPaymentReceivable>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0_1276136x1273964" unitRef="iso4217_USD" decimals="-3" id="id_6848266_60C93174-EF0F-4892-ACF6-2D7A2CCA3EFF_2001_3">13917000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0_1276136x1275434" unitRef="iso4217_USD" decimals="-3" id="id_6848266_60C93174-EF0F-4892-ACF6-2D7A2CCA3EFF_3001_0">2596000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0_1276136x1277482" unitRef="iso4217_USD" decimals="-3" id="id_6848266_60C93174-EF0F-4892-ACF6-2D7A2CCA3EFF_4001_4">5193000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0_1276136x1277975" unitRef="iso4217_USD" decimals="-3" id="id_6848266_60C93174-EF0F-4892-ACF6-2D7A2CCA3EFF_5001_1">1683000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0_1276136x1424108" unitRef="iso4217_USD" decimals="-3" id="id_6848266_60C93174-EF0F-4892-ACF6-2D7A2CCA3EFF_6001_2">751000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0_1276400x1279561" unitRef="shares" decimals="INF" id="id_6848266_D49DD8E9-EE62-4E2A-9623-E6C0D7C833BF_1001_3">1.00</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
  <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0_1276400x1281157" unitRef="shares" decimals="INF" id="id_6848266_D49DD8E9-EE62-4E2A-9623-E6C0D7C833BF_2001_2">1.14</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
  <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0_1276400x1281158" unitRef="shares" decimals="INF" id="id_6848266_D49DD8E9-EE62-4E2A-9623-E6C0D7C833BF_3001_4">1.00</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
  <us-gaap:PreferredStockSharesOutstanding contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0_1276400x1312914" unitRef="shares" decimals="INF" id="id_6848266_C9A3D9AC-840C-4E73-A009-17EE683770D1_1001_4">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockSharesAuthorized contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0_1276400x1312914" unitRef="shares" decimals="INF" id="id_6848266_C9A3D9AC-840C-4E73-A009-17EE683770D1_1001_1">5000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0_1276400x1312914" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_6848266_C9A3D9AC-840C-4E73-A009-17EE683770D1_1001_2">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesIssued contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0_1276400x1312914" unitRef="shares" decimals="INF" id="id_6848266_C9A3D9AC-840C-4E73-A009-17EE683770D1_1001_3">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0_1276400x1369166" unitRef="shares" decimals="INF" id="id_6848266_D49DD8E9-EE62-4E2A-9623-E6C0D7C833BF_4001_1">1.00</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
  <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0_1276400x1481307" unitRef="shares" decimals="INF" id="id_6848266_D49DD8E9-EE62-4E2A-9623-E6C0D7C833BF_5001_0">1.506</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0_1276400x1610343" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_6848266_7426FC99-BD79-4D02-BB8F-F1DB176047AC_2002_4">0.65</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0_1276400x1610343" unitRef="shares" decimals="INF" id="id_6848266_D49DD8E9-EE62-4E2A-9623-E6C0D7C833BF_6001_5">1.00</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
  <us-gaap:StockholdersEquity contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0_1276401x1269588" unitRef="iso4217_USD" decimals="-3" id="id_6848266_BFB39C8D-DAF1-408E-872B-38367E4AE90D_7018_27">-214046000</us-gaap:StockholdersEquity>
  <us-gaap:SharesIssued contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0_1276401x1270422" unitRef="shares" decimals="INF" id="id_6848266_BFB39C8D-DAF1-408E-872B-38367E4AE90D_7013_28">27995638</us-gaap:SharesIssued>
  <us-gaap:StockholdersEquity contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0_1276401x1270422" unitRef="iso4217_USD" decimals="-3" id="id_6848266_BFB39C8D-DAF1-408E-872B-38367E4AE90D_7013_27">280000</us-gaap:StockholdersEquity>
  <us-gaap:SharesIssued contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0_1276401x1273409" unitRef="shares" decimals="INF" id="id_6848266_BFB39C8D-DAF1-408E-872B-38367E4AE90D_7015_28">865</us-gaap:SharesIssued>
  <us-gaap:StockholdersEquity contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0_1276401x1273409" unitRef="iso4217_USD" decimals="-3" id="id_6848266_BFB39C8D-DAF1-408E-872B-38367E4AE90D_7015_27">-19000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0_1276401x1273630" unitRef="iso4217_USD" decimals="-3" id="id_6848266_BFB39C8D-DAF1-408E-872B-38367E4AE90D_7017_27">335071000</us-gaap:StockholdersEquity>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0_1276960x1336998" unitRef="iso4217_USD" decimals="-3" id="id_6848266_3BC1CC65-808A-4FE2-9D0F-D1B069F5CFEF_1001_3">2385000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0_1276960x1336998" unitRef="iso4217_USD" decimals="-3" id="id_6848266_3BC1CC65-808A-4FE2-9D0F-D1B069F5CFEF_1001_4">8006000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0_1276960x1336998" unitRef="iso4217_USD" decimals="-3" id="id_6848266_3BC1CC65-808A-4FE2-9D0F-D1B069F5CFEF_1001_2">2113000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0_1276960x1336998" unitRef="iso4217_USD" decimals="-3" id="id_6848266_3BC1CC65-808A-4FE2-9D0F-D1B069F5CFEF_1001_1">1866000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0_1276960x1336998" unitRef="iso4217_USD" decimals="-3" id="id_6848266_3BC1CC65-808A-4FE2-9D0F-D1B069F5CFEF_1001_0">1642000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
  <us-gaap:RestructuringReserve contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0_1277830x1270443" unitRef="iso4217_USD" decimals="-3" id="id_6848266_0D44A515-B00A-4367-8453-713228457EE3_6001_5">8006000</us-gaap:RestructuringReserve>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0_1280651x1276398" unitRef="iso4217_USD" decimals="-5" id="id_6848266_F8C8395C-C469-4205-A2C8-BE58E73B5783_3001_1">103400000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0_1280651x1280458" unitRef="iso4217_USD" decimals="-5" id="id_6848266_F8C8395C-C469-4205-A2C8-BE58E73B5783_4001_0">158900000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
  <us-gaap:TaxCreditCarryforwardAmount contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0_1280651x1280458" unitRef="iso4217_USD" decimals="-5" id="id_6848266_F8C8395C-C469-4205-A2C8-BE58E73B5783_4001_4">26300000</us-gaap:TaxCreditCarryforwardAmount>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0_1280964x1332409" unitRef="iso4217_USD_per_shares" decimals="2" id="id_6848266_557DC2D9-226E-49B4-A8EE-7F0F1D34CDEB_1001_1">24.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0_1280964x1332409" unitRef="shares" decimals="INF" id="id_6848266_557DC2D9-226E-49B4-A8EE-7F0F1D34CDEB_1001_0">1543937</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <mgnx:CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0_1280964x1332409" unitRef="shares" decimals="INF" id="id_6848266_914CBE22-E452-498E-A124-A2D404D04BB2_2002_1">1960168</mgnx:CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0_1280964x1365667" unitRef="iso4217_USD_per_shares" decimals="2" id="id_6848266_B3CF7651-2E5D-49CD-B6AD-918C0C89A412_1001_1">0.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0_1280964x1365667" unitRef="shares" decimals="INF" id="id_6848266_A343CD6A-8A35-4D63-97CC-755B3CB56B63_2001_0">130725</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0_1280964x1365667" unitRef="shares" decimals="INF" id="id_6848266_B3CF7651-2E5D-49CD-B6AD-918C0C89A412_1001_0">19705</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0_1280964x1610346" unitRef="iso4217_USD_per_shares" decimals="2" id="id_6848266_A1F5B38D-F36E-450A-8309-AC3D7DAF8A2D_1001_1">1.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="eol_PE179294--1410-K0014_STD_0_20141231_0_1280964x1610346" unitRef="shares" decimals="INF" id="id_6848266_A1F5B38D-F36E-450A-8309-AC3D7DAF8A2D_1001_0">2008474</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE179294--1410-K0014_STD_1_20100516_0_1276400x1610343" unitRef="shares" decimals="INF" id="id_6848266_7426FC99-BD79-4D02-BB8F-F1DB176047AC_1003_5">6916110</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesAcquisitions contextRef="eol_PE179294--1410-K0014_STD_1_20140716_0_1276400x1491160" unitRef="shares" decimals="INF" id="id_6848266_C7788A55-8DC2-470E-BCED-AB5EACFD9B3E_1001_0">12466039</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
  <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent contextRef="eol_PE179294--1410-K0014_STD_1_20020925_0" unitRef="pure" decimals="INF" id="id_6848266_3D6479E8-FC85-4E73-B9C2-F899F5DFB6A0_1_1">1.00</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
  <mgnx:EmployeesEligibleAgeToParticipateInBenefitPlan contextRef="eol_PE179294--1410-K0014_STD_1_20020925_0" id="id_6848266_3D6479E8-FC85-4E73-B9C2-F899F5DFB6A0_1_0">P21Y</mgnx:EmployeesEligibleAgeToParticipateInBenefitPlan>
  <us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="eol_PE179294--1410-K0014_STD_1_20131016_0" unitRef="iso4217_USD" decimals="-5" id="id_6848266_CF8BFD7F-B642-4113-81AE-4982E2833ECB_1_4">83800000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE179294--1410-K0014_STD_1_20131016_0_1271382x1272538" unitRef="shares" decimals="INF" id="id_6848266_CF8BFD7F-B642-4113-81AE-4982E2833ECB_1001_0">5000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE179294--1410-K0014_STD_1_20131016_0_1271382x1280942" unitRef="shares" decimals="INF" id="id_6848266_CF8BFD7F-B642-4113-81AE-4982E2833ECB_2001_2">750000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE179294--1410-K0014_STD_1_20110111_0_1268687x1421015" unitRef="shares" decimals="INF" id="id_6848266_EDEA8EEE-6294-4B35-90B2-9B2244E9EF89_1001_0">18427388</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="eol_PE179294--1410-K0014_STD_1_20110111_0_1268687x1421015" unitRef="iso4217_USD" decimals="-5" id="id_6848266_EDEA8EEE-6294-4B35-90B2-9B2244E9EF89_1001_1">12000000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
  <mgnx:AmountOfAdditionalConsiderationPaidUnderAgreement contextRef="eol_PE179294--1410-K0014_STD_1096_20141231_0" unitRef="iso4217_USD" decimals="INF" id="id_6848266_5AC0A3D5-9392-4E9F-ADBF-602155A2C90D_2_4">0</mgnx:AmountOfAdditionalConsiderationPaidUnderAgreement>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized contextRef="eol_PE179294--1410-K0014_STD_1826_20101231_0_1280964x1610346" unitRef="shares" decimals="INF" id="id_6848266_D28E7557-DDA7-4B6D-9607-D6CA79D3147F_1002_1">1739116</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
  <mgnx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease contextRef="eol_PE179294--1410-K0014_STD_1826_20101231_0_1280964x1610346" unitRef="shares" decimals="INF" id="id_6848266_D28E7557-DDA7-4B6D-9607-D6CA79D3147F_1002_2">3790760</mgnx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE179294--1410-K0014_STD_28_20140228_0" unitRef="shares" decimals="INF" id="id_6848266_65716240-1ACD-4151-B726-0CB414642F18_1_0">1800000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="eol_PE179294--1410-K0014_STD_28_20140228_0" unitRef="iso4217_USD" decimals="-5" id="id_6848266_65716240-1ACD-4151-B726-0CB414642F18_1_4">76700000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
  <mgnx:StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption contextRef="eol_PE179294--1410-K0014_STD_28_20140228_0" unitRef="shares" decimals="INF" id="id_6848266_65716240-1ACD-4151-B726-0CB414642F18_2_2">450000</mgnx:StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption>
  <mgnx:NonRefundableUpFrontPayment contextRef="eol_PE179294--1410-K0014_STD_30_20111130_0_1272072x1538608" unitRef="iso4217_USD" decimals="-5" id="id_6848266_DB33E3E0-DB0D-48E7-B64B-61B8090A36D2_2_0">20000000</mgnx:NonRefundableUpFrontPayment>
  <mgnx:RoyaltyPaymentAsPercentageOfNetSalesUnderLicensingAgreement contextRef="eol_PE179294--1410-K0014_STD_30_20050630_0_1269523x1275948" unitRef="pure" decimals="INF" id="id_6848266_5AC0A3D5-9392-4E9F-ADBF-602155A2C90D_1001_3">0.040</mgnx:RoyaltyPaymentAsPercentageOfNetSalesUnderLicensingAgreement>
  <mgnx:RoyaltyPaymentAsPercentageOfNetSalesUnderLicensingAgreement contextRef="eol_PE179294--1410-K0014_STD_30_20050630_0_1269523x1277596" unitRef="pure" decimals="INF" id="id_6848266_5AC0A3D5-9392-4E9F-ADBF-602155A2C90D_2001_2">0.0175</mgnx:RoyaltyPaymentAsPercentageOfNetSalesUnderLicensingAgreement>
  <mgnx:NonRefundableUpFrontPayment contextRef="eol_PE179294--1410-K0014_STD_30_20100630_0_1272072x1370805" unitRef="iso4217_USD" decimals="-5" id="id_6848266_DCDEA1B2-D101-4A1F-8E1E-3BDF24348197_1_1">1000000</mgnx:NonRefundableUpFrontPayment>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE179294--1410-K0014_STD_30_20080930_0_1276400x1610343" unitRef="shares" decimals="INF" id="id_6848266_7426FC99-BD79-4D02-BB8F-F1DB176047AC_1001_2">38337678</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock contextRef="eol_PE179294--1410-K0014_STD_30_20080930_0_1276400x1610343" unitRef="iso4217_USD" decimals="-5" id="id_6848266_7426FC99-BD79-4D02-BB8F-F1DB176047AC_1001_0">24800000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
  <mgnx:StockIssuanceCosts contextRef="eol_PE179294--1410-K0014_STD_30_20080930_0_1276400x1610343" unitRef="iso4217_USD" decimals="0" id="id_6848266_7426FC99-BD79-4D02-BB8F-F1DB176047AC_1001_1">156788</mgnx:StockIssuanceCosts>
  <mgnx:NonRefundableUpFrontPayment contextRef="eol_PE179294--1410-K0014_STD_30_20120930_0_1272072x1538608_1279908x1439878" unitRef="iso4217_USD" decimals="-5" id="id_6848266_2FB55827-09AB-416E-B47F-893BEB50C154_1002_0">20000000</mgnx:NonRefundableUpFrontPayment>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE179294--1410-K0014_STD_31_20041031_0_1276400x1281157" unitRef="shares" decimals="INF" id="id_6848266_CDB623D9-E3EB-42CD-B55D-C0607E460EFE_1001_2">71401237</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock contextRef="eol_PE179294--1410-K0014_STD_31_20041031_0_1276400x1281157" unitRef="iso4217_USD" decimals="-5" id="id_6848266_CDB623D9-E3EB-42CD-B55D-C0607E460EFE_1001_0">30300000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
  <mgnx:StockIssuanceCosts contextRef="eol_PE179294--1410-K0014_STD_31_20041031_0_1276400x1281157" unitRef="iso4217_USD" decimals="0" id="id_6848266_CDB623D9-E3EB-42CD-B55D-C0607E460EFE_1001_1">238000</mgnx:StockIssuanceCosts>
  <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued contextRef="eol_PE179294--1410-K0014_STD_31_20080731_0_1276400x1281158_1276960x1336998" unitRef="shares" decimals="INF" id="id_6848266_EFD560C7-410B-4135-92D3-40CD85265EF1_1001_0">12466039</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
  <mgnx:NonRefundableUpFrontPayment contextRef="eol_PE179294--1410-K0014_STD_31_20101031_0_1272072x1503196" unitRef="iso4217_USD" decimals="-5" id="id_6848266_D8A60150-BE03-466F-8DF8-E45FA6E46220_2_0">15000000</mgnx:NonRefundableUpFrontPayment>
  <mgnx:NumberOfMoleculesToBeDevelopedAndCommercializedAsPerCollaborations contextRef="eol_PE179294--1410-K0014_STD_31_20101031_0_1272072x1503196" unitRef="Molecule" decimals="INF" id="id_6848266_5540EA28-6FEE-4A0D-A0A6-9B2A48528279_2_1">10</mgnx:NumberOfMoleculesToBeDevelopedAndCommercializedAsPerCollaborations>
  <mgnx:NonRefundableUpFrontPayment contextRef="eol_PE179294--1410-K0014_STD_31_20101031_0_1272072x1545620" unitRef="iso4217_USD" decimals="-5" id="id_6848266_8CF91BB7-8196-4F41-8150-141308C6D5B2_1_3">5000000</mgnx:NonRefundableUpFrontPayment>
  <mgnx:NumberOfMoleculesToBeDevelopedAndCommercializedAsPerCollaborations contextRef="eol_PE179294--1410-K0014_STD_31_20101031_0_1272072x1545620" unitRef="Molecule" decimals="INF" id="id_6848266_8CF91BB7-8196-4F41-8150-141308C6D5B2_1_2">2</mgnx:NumberOfMoleculesToBeDevelopedAndCommercializedAsPerCollaborations>
  <mgnx:NumberOfMoleculesToBeDevelopedAndCommercializedAsPerCollaborations contextRef="eol_PE179294--1410-K0014_STD_31_20130131_0_1272072x1444876" unitRef="Molecule" decimals="INF" id="id_6848266_B20C8915-6C26-4325-8243-BD8CB702C60D_1_1">4</mgnx:NumberOfMoleculesToBeDevelopedAndCommercializedAsPerCollaborations>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE179294--1410-K0014_STD_31_20150131_0_1271378x1273350_1272072x1319668" unitRef="shares" decimals="INF" id="id_6848266_38B29B67-8FE5-479C-9081-21997680B4E2_1001_0">1923077</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE179294--1410-K0014_STD_31_20150131_0_1271378x1273350_1272072x1319668" unitRef="iso4217_USD" decimals="-5" id="id_6848266_38B29B67-8FE5-479C-9081-21997680B4E2_1001_1">75000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued contextRef="eol_PE179294--1410-K0014_STD_31_20110331_0_1276400x1281158_1276960x1336998" unitRef="shares" decimals="INF" id="id_6848266_EFD560C7-410B-4135-92D3-40CD85265EF1_1002_1">14446227</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE179294--1410-K0014_STD_31_20060531_0_1276400x1279561" unitRef="shares" decimals="INF" id="id_6848266_D9BC4B9F-9FBE-443F-B550-EB15EEB45E03_1001_2">110952217</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock contextRef="eol_PE179294--1410-K0014_STD_31_20060531_0_1276400x1279561" unitRef="iso4217_USD" decimals="-5" id="id_6848266_D9BC4B9F-9FBE-443F-B550-EB15EEB45E03_1001_0">44900000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
  <mgnx:StockIssuanceCosts contextRef="eol_PE179294--1410-K0014_STD_31_20060531_0_1276400x1279561" unitRef="iso4217_USD" decimals="0" id="id_6848266_D9BC4B9F-9FBE-443F-B550-EB15EEB45E03_1001_1">101246</mgnx:StockIssuanceCosts>
  <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="eol_PE179294--1410-K0014_STD_31_20080531_0_1272072x1569517" unitRef="iso4217_USD" decimals="0" id="id_6848266_D572F75F-D2EF-4A0B-B1FB-EA0E1523E794_2_500001">50000000</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
  <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="eol_PE179294--1410-K0014_STD_31_20100531_0_1272072x1569517" unitRef="iso4217_USD" decimals="-5" id="id_6848266_D572F75F-D2EF-4A0B-B1FB-EA0E1523E794_3_600001">5000000</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
  <mgnx:NonRefundableUpFrontPayment contextRef="eol_PE179294--1410-K0014_STD_31_20140531_0_1272072x1565531" unitRef="iso4217_USD" decimals="-5" id="id_6848266_5BD21674-263F-4556-AF29-4A17D34968DD_1_0">15000000</mgnx:NonRefundableUpFrontPayment>
  <us-gaap:EarningsPerShareDiluted contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_6848266_06A157FB-CCF1-440F-8ABC-76F98DD1AADC_2_11">-0.04</us-gaap:EarningsPerShareDiluted>
  <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0" unitRef="shares" decimals="0" id="id_6848266_06A157FB-CCF1-440F-8ABC-76F98DD1AADC_2_9">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
  <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_6848266_C038B40A-B436-460B-B84E-355BF772C2D9_2_11">-0.04</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_6848266_6FF767FB-8AC0-4D45-89E1-7828051C94DC_2_0">6.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_436CCE6F-4336-4B5F-8F07-5F706B0B6ECB_2_17">-14172000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0" unitRef="pure" decimals="2" id="id_6848266_5078EE5D-09E5-4168-A034-4E6683B2BE49_6_0">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0" id="id_6848266_5078EE5D-09E5-4168-A034-4E6683B2BE49_6_3">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0" unitRef="shares" decimals="0" id="id_6848266_C038B40A-B436-460B-B84E-355BF772C2D9_2_12">6847697</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0" id="id_6848266_17746F23-4AA2-4BB3-9A89-FCE1187AF996_1001_1">P6Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0" unitRef="shares" decimals="0" id="id_6848266_06A157FB-CCF1-440F-8ABC-76F98DD1AADC_2_10">6847697</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:EarningsPerShareBasic contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_6848266_06A157FB-CCF1-440F-8ABC-76F98DD1AADC_2_4">-0.04</us-gaap:EarningsPerShareBasic>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0" unitRef="shares" decimals="INF" id="id_6848266_01C3FF41-5B4B-4782-A3E1-45AFC051D57A_2_0">1268049</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0" unitRef="shares" decimals="0" id="id_6848266_06A157FB-CCF1-440F-8ABC-76F98DD1AADC_2_3">6847697</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_BFB39C8D-DAF1-408E-872B-38367E4AE90D_6019_10">83623000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_6848266_6FF767FB-8AC0-4D45-89E1-7828051C94DC_2_4">487603</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
  <us-gaap:RevenueFromGrants contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_C038B40A-B436-460B-B84E-355BF772C2D9_2_2">1282000</us-gaap:RevenueFromGrants>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_06A157FB-CCF1-440F-8ABC-76F98DD1AADC_2_7">-261000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
  <us-gaap:LicenseAndServicesRevenue contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_C038B40A-B436-460B-B84E-355BF772C2D9_2_1">56753000</us-gaap:LicenseAndServicesRevenue>
  <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_436CCE6F-4336-4B5F-8F07-5F706B0B6ECB_2_10">375000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_BFB39C8D-DAF1-408E-872B-38367E4AE90D_6019_14">1068000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_C038B40A-B436-460B-B84E-355BF772C2D9_2_8">366000</us-gaap:OperatingIncomeLoss>
  <us-gaap:IncomeTaxReconciliationTaxCreditsResearch contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_6F5E51EF-C8FC-4FD4-AB59-C423FE9A715A_2_4">226000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
  <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_C276425F-9994-4C60-9006-051FF560D19C_2_1">116000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_C038B40A-B436-460B-B84E-355BF772C2D9_2_9">-627000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_BFB39C8D-DAF1-408E-872B-38367E4AE90D_6019_12">1860000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:Revenues contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_C038B40A-B436-460B-B84E-355BF772C2D9_2_3">58035000</us-gaap:Revenues>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_436CCE6F-4336-4B5F-8F07-5F706B0B6ECB_2_19">2961000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_06A157FB-CCF1-440F-8ABC-76F98DD1AADC_2_2">-261000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLoss contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_C038B40A-B436-460B-B84E-355BF772C2D9_2_10">-261000</us-gaap:NetIncomeLoss>
  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_436CCE6F-4336-4B5F-8F07-5F706B0B6ECB_2_7">-42000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:IncomeTaxReconciliationTaxCreditsOther contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_6F5E51EF-C8FC-4FD4-AB59-C423FE9A715A_2_7">843000</us-gaap:IncomeTaxReconciliationTaxCreditsOther>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_BFB39C8D-DAF1-408E-872B-38367E4AE90D_6019_9">862000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_436CCE6F-4336-4B5F-8F07-5F706B0B6ECB_2_8">834000</us-gaap:IncreaseDecreaseInPrepaidExpense>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-5" id="id_6848266_FA11B785-8CBF-4BB6-ADA5-597BE5495B8F_2_0">1200000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_436CCE6F-4336-4B5F-8F07-5F706B0B6ECB_2_14">-16676000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_C038B40A-B436-460B-B84E-355BF772C2D9_2_5">46582000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:IncreaseDecreaseInRestructuringReserve contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_436CCE6F-4336-4B5F-8F07-5F706B0B6ECB_2_13">-629000</us-gaap:IncreaseDecreaseInRestructuringReserve>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_436CCE6F-4336-4B5F-8F07-5F706B0B6ECB_2_26">68738000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:FairValueAdjustmentOfWarrants contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_436CCE6F-4336-4B5F-8F07-5F706B0B6ECB_2_5">626000</us-gaap:FairValueAdjustmentOfWarrants>
  <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_6F5E51EF-C8FC-4FD4-AB59-C423FE9A715A_2_0">-91000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_6F5E51EF-C8FC-4FD4-AB59-C423FE9A715A_2_12">0</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:OperatingLeasesRentExpenseNet contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-5" id="id_6848266_81731F1A-1997-4BE2-B6DC-1FBA78F4CD34_2_1">2700000</us-gaap:OperatingLeasesRentExpenseNet>
  <us-gaap:Depreciation contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_436CCE6F-4336-4B5F-8F07-5F706B0B6ECB_2_3">1193000</us-gaap:Depreciation>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_436CCE6F-4336-4B5F-8F07-5F706B0B6ECB_2_25">85871000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_436CCE6F-4336-4B5F-8F07-5F706B0B6ECB_2_22">84771000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ConversionOfStockAmountConverted1 contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_436CCE6F-4336-4B5F-8F07-5F706B0B6ECB_2_30">2947000</us-gaap:ConversionOfStockAmountConverted1>
  <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_6F5E51EF-C8FC-4FD4-AB59-C423FE9A715A_2_9">241000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
  <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_436CCE6F-4336-4B5F-8F07-5F706B0B6ECB_2_12">2347000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_436CCE6F-4336-4B5F-8F07-5F706B0B6ECB_2_20">-2961000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_436CCE6F-4336-4B5F-8F07-5F706B0B6ECB_2_23">1100000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0" unitRef="iso4217_USD" decimals="INF" id="id_6848266_21E5900F-6C26-4A8D-A5FF-3358DB02959F_2_0">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
  <us-gaap:CostsAndExpenses contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_C038B40A-B436-460B-B84E-355BF772C2D9_2_7">57669000</us-gaap:CostsAndExpenses>
  <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_6F5E51EF-C8FC-4FD4-AB59-C423FE9A715A_2_1">609000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_C038B40A-B436-460B-B84E-355BF772C2D9_2_6">11087000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_436CCE6F-4336-4B5F-8F07-5F706B0B6ECB_2_11">-570000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_436CCE6F-4336-4B5F-8F07-5F706B0B6ECB_2_4">862000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-5" id="id_6848266_6FF767FB-8AC0-4D45-89E1-7828051C94DC_2_2">5400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0" unitRef="iso4217_USD" decimals="INF" id="id_6848266_AC57A800-8787-4A43-9539-9C416E3C9097_2_0">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
  <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_6848266_3D6479E8-FC85-4E73-B9C2-F899F5DFB6A0_3_3">252930</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
  <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_6F5E51EF-C8FC-4FD4-AB59-C423FE9A715A_2_11">1287000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:IncomeTaxReconciliationOtherReconcilingItems contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_6F5E51EF-C8FC-4FD4-AB59-C423FE9A715A_2_8">3000</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
  <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_C276425F-9994-4C60-9006-051FF560D19C_2_3">0</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
  <mgnx:IncomeTaxReconciliationStateDeferredTaxesAdjustments contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_6F5E51EF-C8FC-4FD4-AB59-C423FE9A715A_2_3">344000</mgnx:IncomeTaxReconciliationStateDeferredTaxesAdjustments>
  <mgnx:IncomeTaxReconciliationFairValueAdjustmentOfPreferredStockWarrantLiability contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_6F5E51EF-C8FC-4FD4-AB59-C423FE9A715A_2_10">219000</mgnx:IncomeTaxReconciliationFairValueAdjustmentOfPreferredStockWarrantLiability>
  <mgnx:IncreaseDecreaseInDeferredRent contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_436CCE6F-4336-4B5F-8F07-5F706B0B6ECB_2_15">103000</mgnx:IncreaseDecreaseInDeferredRent>
  <mgnx:IncomeTaxReconciliationDeferredTaxAdjustments contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_6F5E51EF-C8FC-4FD4-AB59-C423FE9A715A_2_2">-855000</mgnx:IncomeTaxReconciliationDeferredTaxAdjustments>
  <mgnx:LiquidInvestmentMaturityPeriodToBeClassifiedAsCashEquivalentMaximum contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0" id="id_6848266_E33C22AD-216A-4963-A3D6-46A51E324042_2_0">P3M</mgnx:LiquidInvestmentMaturityPeriodToBeClassifiedAsCashEquivalentMaximum>
  <mgnx:ContingentConsiderationRecordedAsIncrementalInProcessResearchAndDevelopmentExpense contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0" unitRef="iso4217_USD" decimals="INF" id="id_6848266_D9A01372-2F1E-4894-98FA-D2AE7AF3ADC1_2_0">0</mgnx:ContingentConsiderationRecordedAsIncrementalInProcessResearchAndDevelopmentExpense>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0_1268687x1270467" unitRef="shares" decimals="INF" id="id_6848266_2EA8D3D9-9412-48E8-9B1C-0BA0E09F80DD_1002_6">13189920</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0_1268687x1281225" unitRef="shares" decimals="INF" id="id_6848266_2EA8D3D9-9412-48E8-9B1C-0BA0E09F80DD_3002_8">2313970</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0_1269523x1275948" unitRef="pure" decimals="INF" id="id_6848266_5078EE5D-09E5-4168-A034-4E6683B2BE49_5_2">0.022</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0_1269523x1275948" unitRef="pure" decimals="INF" id="id_6848266_5078EE5D-09E5-4168-A034-4E6683B2BE49_5_1">0.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0_1269523x1277596" unitRef="pure" decimals="INF" id="id_6848266_5078EE5D-09E5-4168-A034-4E6683B2BE49_4_2">0.012</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0_1269523x1277596" unitRef="pure" decimals="INF" id="id_6848266_5078EE5D-09E5-4168-A034-4E6683B2BE49_4_1">0.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0_1272045x1351512_1277042x1272910" unitRef="pure" decimals="3" id="id_6848266_75317A27-B598-4883-ACA0-8C9C5785D6CA_1002_3">0.138</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0_1272045x1351512_1277042x1275282" unitRef="pure" decimals="3" id="id_6848266_7EC2521A-795D-493C-9187-6371803B072D_1002_3">0.534</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0_1272045x1503196_1277042x1272910" unitRef="pure" decimals="3" id="id_6848266_75317A27-B598-4883-ACA0-8C9C5785D6CA_2002_1">0.248</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0_1272045x1503196_1277042x1275282" unitRef="pure" decimals="3" id="id_6848266_7EC2521A-795D-493C-9187-6371803B072D_3002_1">0.122</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0_1272045x1538608_1277042x1272910" unitRef="pure" decimals="3" id="id_6848266_75317A27-B598-4883-ACA0-8C9C5785D6CA_3002_0">0.516</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0_1272045x1538608_1277042x1275282" unitRef="pure" decimals="3" id="id_6848266_7EC2521A-795D-493C-9187-6371803B072D_4002_0">0.064</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0_1272045x1545620_1277042x1275282" unitRef="pure" decimals="3" id="id_6848266_7EC2521A-795D-493C-9187-6371803B072D_5002_4">0.123</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0_1272045x1569517_1277042x1272910" unitRef="pure" decimals="3" id="id_6848266_75317A27-B598-4883-ACA0-8C9C5785D6CA_5002_4">0.014</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0_1272072x1370805" unitRef="iso4217_USD" decimals="INF" id="id_6848266_3E7F58A9-4394-4CDC-8DCF-ED0CEFE40CF7_2_500001">0</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
  <us-gaap:LicensesRevenue contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0_1272072x1370805" unitRef="iso4217_USD" decimals="0" id="id_6848266_3E7F58A9-4394-4CDC-8DCF-ED0CEFE40CF7_3_600000">100000.0</us-gaap:LicensesRevenue>
  <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0_1272072x1444876" unitRef="iso4217_USD" decimals="INF" id="id_6848266_FC960917-5ACF-4C3E-8677-73447D268A07_2_1">0</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
  <us-gaap:LicensesRevenue contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0_1272072x1444876" unitRef="iso4217_USD" decimals="-5" id="id_6848266_FC960917-5ACF-4C3E-8677-73447D268A07_2_0">8000000</us-gaap:LicensesRevenue>
  <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0_1272072x1503196" unitRef="iso4217_USD" decimals="-5" id="id_6848266_AED8F272-20FC-4F1A-82AB-7856839A71BD_2_4">5000000</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
  <us-gaap:LicensesRevenue contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0_1272072x1503196" unitRef="iso4217_USD" decimals="-5" id="id_6848266_AED8F272-20FC-4F1A-82AB-7856839A71BD_2_0">14400000</us-gaap:LicensesRevenue>
  <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0_1272072x1538608" unitRef="iso4217_USD" decimals="-5" id="id_6848266_4FE942DA-BDC1-4D22-A8C8-0DBE3DDFD663_2_1">10000000</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
  <us-gaap:LicensesRevenue contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0_1272072x1538608" unitRef="iso4217_USD" decimals="-5" id="id_6848266_4FE942DA-BDC1-4D22-A8C8-0DBE3DDFD663_2_0">21300000</us-gaap:LicensesRevenue>
  <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0_1272072x1538608_1279908x1439878" unitRef="iso4217_USD" decimals="INF" id="id_6848266_D09A039D-38C1-4E9F-AFCC-87FCE28B8EF2_1002_4">0</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
  <us-gaap:LicensesRevenue contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0_1272072x1538608_1279908x1439878" unitRef="iso4217_USD" decimals="-5" id="id_6848266_D09A039D-38C1-4E9F-AFCC-87FCE28B8EF2_1002_0">8600000</us-gaap:LicensesRevenue>
  <mgnx:CollaborationArrangementOffsetToResearchAndDevelopmentCosts contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0_1272072x1538608_1279908x1439878" unitRef="iso4217_USD" decimals="INF" id="id_6848266_04591BAC-6897-476B-88E9-DCED4AA4B34E_1002_1">0</mgnx:CollaborationArrangementOffsetToResearchAndDevelopmentCosts>
  <us-gaap:LicensesRevenue contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0_1272072x1545620" unitRef="iso4217_USD" decimals="-5" id="id_6848266_D3A79C34-1D3F-47B7-B198-6DACB4B91533_2_0">3500000</us-gaap:LicensesRevenue>
  <us-gaap:LicensesRevenue contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0_1272072x1569517" unitRef="iso4217_USD" decimals="-5" id="id_6848266_9A5607AA-73D8-4654-BE4E-3E38374EEC8A_1_0">800000</us-gaap:LicensesRevenue>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0_1274159x1269133" unitRef="iso4217_USD" decimals="-3" id="id_6848266_0C47355F-C953-4F92-9309-B77CCD08112A_1002_1">355000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0_1274159x1269570" unitRef="iso4217_USD" decimals="-3" id="id_6848266_0C47355F-C953-4F92-9309-B77CCD08112A_2002_0">507000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:NetIncomeLoss contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0_1276401x1269588" unitRef="iso4217_USD" decimals="-3" id="id_6848266_BFB39C8D-DAF1-408E-872B-38367E4AE90D_6018_16">-261000</us-gaap:NetIncomeLoss>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0_1276401x1270422" unitRef="shares" decimals="INF" id="id_6848266_BFB39C8D-DAF1-408E-872B-38367E4AE90D_6013_11">5750000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0_1276401x1270422" unitRef="shares" decimals="INF" id="id_6848266_BFB39C8D-DAF1-408E-872B-38367E4AE90D_6013_13">17060634</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0_1276401x1270422" unitRef="shares" decimals="INF" id="id_6848266_BFB39C8D-DAF1-408E-872B-38367E4AE90D_6013_15">1268049</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0_1276401x1270422" unitRef="iso4217_USD" decimals="-3" id="id_6848266_BFB39C8D-DAF1-408E-872B-38367E4AE90D_6013_10">58000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0_1276401x1270422" unitRef="iso4217_USD" decimals="-3" id="id_6848266_BFB39C8D-DAF1-408E-872B-38367E4AE90D_6013_14">13000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0_1276401x1270422" unitRef="iso4217_USD" decimals="-3" id="id_6848266_BFB39C8D-DAF1-408E-872B-38367E4AE90D_6013_12">171000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0_1276401x1273630" unitRef="iso4217_USD" decimals="-3" id="id_6848266_BFB39C8D-DAF1-408E-872B-38367E4AE90D_6017_10">83565000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0_1276401x1273630" unitRef="iso4217_USD" decimals="-3" id="id_6848266_BFB39C8D-DAF1-408E-872B-38367E4AE90D_6017_14">1055000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0_1276401x1273630" unitRef="iso4217_USD" decimals="-3" id="id_6848266_BFB39C8D-DAF1-408E-872B-38367E4AE90D_6017_12">4637000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0_1276401x1273630" unitRef="iso4217_USD" decimals="-3" id="id_6848266_BFB39C8D-DAF1-408E-872B-38367E4AE90D_6017_9">862000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0_1276401x1291665" unitRef="shares" decimals="INF" id="id_6848266_BFB39C8D-DAF1-408E-872B-38367E4AE90D_6009_13">-14446227</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0_1276401x1291665" unitRef="iso4217_USD" decimals="-3" id="id_6848266_BFB39C8D-DAF1-408E-872B-38367E4AE90D_6009_12">-144000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0_1276401x1296600" unitRef="shares" decimals="INF" id="id_6848266_BFB39C8D-DAF1-408E-872B-38367E4AE90D_6001_13">-26874792</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0_1276401x1296600" unitRef="iso4217_USD" decimals="-3" id="id_6848266_BFB39C8D-DAF1-408E-872B-38367E4AE90D_6001_12">-269000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0_1276401x1310046" unitRef="shares" decimals="INF" id="id_6848266_BFB39C8D-DAF1-408E-872B-38367E4AE90D_6003_13">-7364582</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0_1276401x1310046" unitRef="iso4217_USD" decimals="-3" id="id_6848266_BFB39C8D-DAF1-408E-872B-38367E4AE90D_6003_12">-74000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0_1276401x1421015" unitRef="shares" decimals="INF" id="id_6848266_BFB39C8D-DAF1-408E-872B-38367E4AE90D_6011_13">-63681176</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0_1276401x1421015" unitRef="iso4217_USD" decimals="-3" id="id_6848266_BFB39C8D-DAF1-408E-872B-38367E4AE90D_6011_12">-637000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0_1276401x1493912" unitRef="shares" decimals="INF" id="id_6848266_BFB39C8D-DAF1-408E-872B-38367E4AE90D_6005_13">-71401237</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0_1276401x1493912" unitRef="iso4217_USD" decimals="-3" id="id_6848266_BFB39C8D-DAF1-408E-872B-38367E4AE90D_6005_12">-714000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0_1276401x1559024" unitRef="shares" decimals="INF" id="id_6848266_BFB39C8D-DAF1-408E-872B-38367E4AE90D_6007_13">-110952217</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0_1276401x1559024" unitRef="iso4217_USD" decimals="-3" id="id_6848266_BFB39C8D-DAF1-408E-872B-38367E4AE90D_6007_12">-1110000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:PaymentsForRestructuring contextRef="eol_PE179294--1410-K0014_STD_365_20131231_0_1277830x1270443" unitRef="iso4217_USD" decimals="-3" id="id_6848266_0D44A515-B00A-4367-8453-713228457EE3_4001_2">629000</us-gaap:PaymentsForRestructuring>
  <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" id="id_6848266_A1488B41-B58D-4673-9608-D4918F54DDFF_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 &lt;b&gt;&lt;i&gt;Basis of Presentation and Principles of
 Consolidation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The consolidated financial statements include the accounts of
 MacroGenics, Inc. and its wholly owned subsidiaries, MacroGenics UK
 Limited and MacroGenics West, Inc. Effective December&amp;#xA0;22,
 2014, MacroGenics West, Inc. was merged with and into MacroGenics,
 Inc. All intercompany accounts and transactions have been
 eliminated in consolidation. The Company currently operates in one
 operating segment. Operating segments are defined as components of
 an enterprise about which separate discrete information is
 available for the chief operating decision maker, or decision
 making group, in deciding how to allocate resources and assessing
 performance. The Company views its operations and manages its
 business in one segment, which is developing monoclonal
 antibody-based therapeutics for cancer, autoimmune and infectious
 diseases.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" id="id_6848266_14D6AA70-4D23-4093-B119-0781A263032A_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;9. Commitments and Contingencies&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;&lt;i&gt;Operating Leases&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 The Company leases office and laboratory space for its headquarters
 in Rockville, Maryland.&amp;#xA0;In 2014, that lease was amended to
 extend its term from March 31, 2018 to January 31, 2020.&amp;#xA0;In
 addition, in 2014, the Company leased additional office space
 adjacent to its headquarters, also through January 31,
 2020.&amp;#xA0;The Company has an option under each lease to continue
 the respective lease for five years under the same terms.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 The Company leases a manufacturing facility in Rockville under a
 lease that originally expired on December&amp;#xA0;31, 2014. During
 2014, the Company exercised its 5-year renewal option on the
 manufacturing facility. The Company also entered into a new
 four-year lease for additional space in the manufacturing facility
 effective April&amp;#xA0;1, 2014. This lease also has an option to
 continue the lease for five years under the same terms.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 The Company also leases office and laboratory space in South San
 Francisco under a lease that expires on February&amp;#xA0;28, 2018.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 All of the leases contain rent escalation clauses and certain
 leases contain rent abatements. For financial reporting purposes,
 rent expense is charged to operations on a straight-line basis over
 the term of the lease. As of December&amp;#xA0;31, 2014 and 2013, the
 Company had recorded a deferred rent liability of $2.7 million and
 $2.9&amp;#xA0;million, respectively. Rent expense for the years ended
 December&amp;#xA0;31, 2014, 2013 and 2012 was $2.0&amp;#xA0;million, $2.7
 million and $2.7 million, respectively.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 Future minimum lease payments under noncancelable operating leases
 as of December&amp;#xA0;31, 2014 are as follows (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt &apos;Times New Roman&apos;; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="84%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 2015&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,945&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 2016&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,364&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 2017&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,495&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 2018&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,396&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 2019&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,873&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Thereafter&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;116&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;19,189&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 18pt &apos;Times New Roman&apos;; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;&lt;i&gt;Contingencies&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 From time to time, the Company may be subject to various litigation
 and related matters arising in the ordinary course of business. The
 Company does not believe it is currently subject to any material
 matters where there is at least a reasonable possibility that a
 material loss may be incurred.&lt;/p&gt;


 &lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <us-gaap:EarningsPerShareDiluted contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_6848266_06A157FB-CCF1-440F-8ABC-76F98DD1AADC_1_11">-1.40</us-gaap:EarningsPerShareDiluted>
  <us-gaap:EarningsPerSharePolicyTextBlock contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" id="id_6848266_4F330D26-A18B-4CCA-9D2C-F8C3EA148B5B_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Net Income (Loss) Per Share&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Basic income (loss) per common share is determined by dividing
 income (loss) attributable to common stockholders by the
 weighted-average number of common shares outstanding during the
 period, without consideration of common stock equivalents. Diluted
 income (loss) per share is computed by dividing the earnings (loss)
 attributable to common stockholders by the weighted-average number
 of common share equivalents outstanding for the period. The
 treasury stock method is used to determine the dilutive effect of
 the Company&amp;#x2019;s stock option grants, potential Employee Stock
 Purchase Plan awards and warrants and the if-converted method is
 used to determine the dilutive effect of the Company&amp;#x2019;s
 preferred stock.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 For the year ended December&amp;#xA0;31, 2012, net income (loss) per
 share was calculated under the two-class method under which all
 earnings (distributed and undistributed) are allocated to each
 class of common stock and participating securities based on their
 respective rights to receive dividends. In the event that the Board
 of Directors declared a dividend payable in cash or other property
 on the then-outstanding shares of common stock, the holders of the
 Series&amp;#xA0;A-1, A-2, B, C, D, and D-2 convertible preferred stock
 would be entitled to receive the amount of dividends per share of
 preferred stock that would be payable on the largest number of
 whole shares of common stock into which each share of preferred
 stock could then be converted. Therefore, the Series A-1, A-2, B,
 C, D and D-2 are participating securities. All of the outstanding
 shares of Series&amp;#xA0;A-1, A-2, B, C, D, and D-2 convertible
 preferred stock converted to common stock upon the consummation of
 the Company&amp;#x2019;s IPO in October 2013.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"&gt;
 Basic and diluted income (loss) per common share is computed as
 follows (in thousands except share and per share data):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="58%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;Year Ended
 December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Net income (loss)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(38,313&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(261&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,362&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Less: undistributed earnings allocated to participating
 securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(8,362&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Net income (loss) allocable to common shares&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(38,313&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(261&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Basic weighted average common shares outstanding&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;27,384,990&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,847,697&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,083,276&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Basic income (loss) per common share&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1.40&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.04&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.00&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Net income (loss)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(38,313&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(261&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,362&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Less: undistributed earnings allocated to participating securities
 and other add-backs to net income (loss)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(8,362&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Net income (loss) allocable to common shares&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(38,313&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(261&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Basic weighted average common shares outstanding&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;27,384,990&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,847,697&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,083,276&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Effect of dilutive securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Diluted weighted average common shares outstanding&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;27,384,990&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,847,697&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,083,276&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Diluted income (loss) per common share&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1.40&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.04&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.00&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The following common stock equivalents were excluded from the
 calculation of diluted net income (loss) per share because their
 effect would be anti-dilutive:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="63%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;Year Ended
 December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Series A-1 Preferred Stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,156,114&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Series A-2 Preferred Stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;392,274&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Series B Preferred Stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,336,037&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Series C Preferred Stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,909,906&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Series D Preferred Stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;769,468&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Series D-2 Preferred Stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,391,991&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Effect of Converted Preferred Stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13,189,920&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Warrants to purchase Series D-2 Preferred Stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;180,784&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Stock Options&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,094,904&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,313,970&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,249,702&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
  <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" id="id_6848266_5AF50911-6594-4248-A588-43616CA1CB9D_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The reconciliation of the reported estimated income tax benefit to
 the amount that would result by applying the U.S. federal statutory
 tax rate to the net income is as follows (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="66%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;Year Ended
 December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 United States federal tax at statutory rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(13,410&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(91&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,927&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 State taxes (net of federal benefit)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1,608&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;609&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,460&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Deferred income tax adjustments&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(855&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(512&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Deferred state blended rate adjustments&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,034&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(344&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Research credit, net&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2,228&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(226&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Transaction cost deduction&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(379&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Transaction cost deduction&amp;#x2014;prior year adjustment&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(564&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Orphan drug credit, net&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(139&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(843&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(4,896&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Other permanent items&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(382&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Equity-based compensation&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;756&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;241&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;279&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Fair value adjustment of preferred stock warrant liability&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;219&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(53&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Change in valuation allowance&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;14,920&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,287&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;787&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Income tax expense/(benefit)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
  <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" id="id_6848266_24F8C4DA-713F-4DF2-8950-B88903C71C83_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 The fair value of each option award is estimated on the date of
 grant using the Black-Scholes option-pricing model using the
 assumptions in the following table:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt &apos;Times New Roman&apos;; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="58%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="5" align="center"&gt;&lt;b&gt;Year Ended December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expected dividend yield&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;0%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;0%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;0%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expected volatility&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;67%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;53%&amp;#xA0;-&amp;#xA0;67%&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;51%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Risk-free interest rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;1.8%&amp;#xA0;-&amp;#xA0;2.3%&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;1.2%&amp;#xA0;-&amp;#xA0;2.2%&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;1.2%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expected term.&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;6.25 years&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;7 years&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;7&amp;#xA0;years&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;


 &lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" unitRef="shares" decimals="INF" id="id_6848266_7B0A02FA-85DB-43CF-BC04-01FAA356A7C5_5001_2">976869</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" id="id_6848266_17746F23-4AA2-4BB3-9A89-FCE1187AF996_3001_4">P7Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_6848266_1A1F7457-4446-4854-A71F-326EE5804095_5001_3">1.31</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <dei:DocumentType contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" id="id_6848266_FAA44042-8554-4DED-B4FD-D076A21A6C07_1_0">10-K</dei:DocumentType>
  <dei:EntityRegistrantName contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" id="id_6848266_0E6F3311-D183-4200-9E69-FFDB3EB2AE27_1_1">MACROGENICS INC</dei:EntityRegistrantName>
  <dei:EntityWellKnownSeasonedIssuer contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" id="id_6848266_0E6F3311-D183-4200-9E69-FFDB3EB2AE27_1_4">No</dei:EntityWellKnownSeasonedIssuer>
  <dei:TradingSymbol contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" id="id_6848266_0E6F3311-D183-4200-9E69-FFDB3EB2AE27_1_0">MGNX</dei:TradingSymbol>
  <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" unitRef="shares" decimals="0" id="id_6848266_06A157FB-CCF1-440F-8ABC-76F98DD1AADC_1_9">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
  <us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" id="id_6848266_66A55710-6664-4F1E-A6D5-DD83B64E9DB2_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Stock-based Compensation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Stock-based payments are accounted for in accordance with the
 provisions of ASC&amp;#xA0;718, &lt;i&gt;Compensation&amp;#x2014;Stock
 Compensation&lt;/i&gt;. The fair value of stock-based payments is
 estimated, on the date of grant, using the Black-Scholes model. The
 resulting fair value is recognized ratably over the requisite
 service period, which is generally the vesting period of the
 option.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 For all time-vesting awards granted, expense is amortized using the
 straight-line attribution method. For awards that contain a
 performance condition, expense is amortized using the accelerated
 attribution method. Recognition of stock-based compensation expense
 is based on the value of the portion of stock-based awards that is
 ultimately expected to vest during the period.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company utilizes the Black-Scholes model for estimating fair
 value of its stock options granted. Option valuation models,
 including the Black-Scholes model, require the input of highly
 subjective assumptions, and changes in the assumptions used can
 materially affect the grant-date fair value of an award. These
 assumptions include the risk-free rate of interest, expected
 dividend yield, expected volatility and the expected life of the
 award.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
  <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" id="id_6848266_07FE58B5-D415-4ED1-9D27-5AEBA74886D1_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Comprehensive Income (Loss)&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Comprehensive income (loss) is comprised of the net income (loss)
 and other changes in equity that are excluded from net income
 (loss). Comprehensive income (loss) equals net income (loss) for
 the years ended December&amp;#xA0;31, 2014, 2013 and 2012.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
  <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_6848266_C038B40A-B436-460B-B84E-355BF772C2D9_1_11">-1.40</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
  <us-gaap:IncomeTaxPolicyTextBlock contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" id="id_6848266_6048F9B5-E046-4D73-8714-D1421EB92BFF_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 &lt;b&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Deferred tax assets and liabilities are determined based on
 differences between the financial reporting and tax basis of assets
 and liabilities and are measured using the enacted tax rates and
 laws that are expected to be in effect when the differences are
 expected to reverse. The effect on deferred tax assets and
 liabilities of a change in tax rates is recognized as income in the
 period that such tax rate changes are enacted. The measurement of a
 deferred tax asset is reduced, if necessary, by a valuation
 allowance if it is more likely than not that some portion or all of
 the deferred tax asset will not be realized. Financial statement
 recognition of a tax position taken or expected to be taken in a
 tax return is determined based on a more-likely-than-not threshold
 of that position being sustained. If the tax position meets this
 threshold, the benefit to be recognized is measured as the largest
 amount that is more likely than not to be realized upon ultimate
 settlement. The Company&amp;#x2019;s policy is to record interest and
 penalties related to uncertain tax positions as a component of
 income tax expense.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
  <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" id="id_6848266_FE49A87A-4715-40B6-B191-77A5DE30C9B6_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The following common stock equivalents were excluded from the
 calculation of diluted net income (loss) per share because their
 effect would be anti-dilutive:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="63%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;Year Ended
 December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Series A-1 Preferred Stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,156,114&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Series A-2 Preferred Stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;392,274&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Series B Preferred Stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,336,037&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Series C Preferred Stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,909,906&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Series D Preferred Stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;769,468&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Series D-2 Preferred Stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,391,991&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Effect of Converted Preferred Stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13,189,920&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Warrants to purchase Series D-2 Preferred Stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;180,784&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Stock Options&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,094,904&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,313,970&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,249,702&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
  <us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" id="id_6848266_E9731952-4A2A-4B3C-A75E-0325F4F0516D_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Changes in the lease exit liability are as follows (in
 thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="84%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Accrual balance at December&amp;#xA0;31, 2012.&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#xA0;10,074&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Principal payments&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(629&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Accrual balance at December&amp;#xA0;31, 2013&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9,445&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Principal payments&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1,439&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Accrual balance at December&amp;#xA0;31, 2014&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,006&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_6848266_6FF767FB-8AC0-4D45-89E1-7828051C94DC_1_0">17.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <dei:EntityFilerCategory contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" id="id_6848266_0E6F3311-D183-4200-9E69-FFDB3EB2AE27_1_7">Accelerated Filer</dei:EntityFilerCategory>
  <dei:EntityIncorporationDateOfIncorporation contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" id="id_6848266_5D0AE233-2605-4855-969A-F0516A2D9E93_1_0">2000-08-14</dei:EntityIncorporationDateOfIncorporation>
  <dei:EntityVoluntaryFilers contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" id="id_6848266_0E6F3311-D183-4200-9E69-FFDB3EB2AE27_1_6">No</dei:EntityVoluntaryFilers>
  <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" id="id_6848266_929BD157-34BF-4115-9456-AFF0C5D8DCA4_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Restricted Cash&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The Company is required to maintain certificates of deposit that
 serve as collateral for various operating leases and corporate
 credit card accounts. Amounts classified as restricted cash on the
 consolidated balance sheets are $300,000 and $405,000 at
 December&amp;#xA0;31, 2014 and 2013, respectively.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" id="id_6848266_6FF767FB-8AC0-4D45-89E1-7828051C94DC_1_6">P4Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_436CCE6F-4336-4B5F-8F07-5F706B0B6ECB_1_17">-32759000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" id="id_6848266_95C8F256-297F-445E-87AD-EBDD40750717_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The following stock-based compensation amounts were recognized for
 the periods indicated (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="74%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;Year Ended
 December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Research and development&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,562&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;507&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;472&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 General and administrative&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,682&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;355&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;366&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Total stock-based compensation expense&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,244&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;862&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;838&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
  <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" id="id_6848266_287DD34B-6F25-4E6D-A8A2-A733C5B81A8E_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Revenues&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 2%; MARGIN-TOP: 6pt"&gt;
 &lt;i&gt;Revenue Recognition&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The Company enters into collaboration and license agreements with
 collaborators for the development of monoclonal antibody-based
 therapeutics to treat cancer and other complex diseases. The terms
 of these agreements contain multiple deliverables which may include
 (i)&amp;#xA0;licenses, or options to obtain licenses, to the
 Company&amp;#x2019;s technological platforms, such as its Fc
 Optimization and Dual-Affinity Re-Targeting (DART) technologies,
 (ii)&amp;#xA0;rights to future technological improvements,
 (iii)&amp;#xA0;research and development activities to be performed on
 behalf of the collaborator or as part of the collaboration, and
 (iv)&amp;#xA0;the manufacture of pre-clinical or clinical materials for
 the collaborator. Payments to the Company under these agreements
 may include nonrefundable license fees, option fees, exercise fees,
 payments for research and development activities, payments for the
 manufacture of pre-clinical or clinical materials, license
 maintenance payments, payments based upon the achievement of
 certain milestones and royalties on product sales. Other benefits
 to the Company of these agreements include the right to sell
 products resulting from the collaborative efforts of the parties in
 specific geographic territories. The Company follows the provisions
 of the FASB ASC Topic 605-25, &lt;i&gt;Revenue
 Recognition&amp;#x2014;Multiple-Element Arrangements&lt;/i&gt;, and ASC Topic
 605-28, &lt;i&gt;Revenue Recognition&amp;#x2014;Milestone Method&lt;/i&gt;, in
 accounting for these agreements. In order to account for these
 agreements, the Company must identify the deliverables included
 within the agreement and evaluate which deliverables represent
 separate units of accounting based on the achievement of certain
 criteria, including whether the delivered element has stand-alone
 value to the collaborator. The consideration received is allocated
 among the separate units of accounting, and the applicable revenue
 recognition criteria are applied to each of the separate units.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 For the periods presented, the Company had the following two types
 of agreements: 1) exclusive development and commercialization
 licenses to use the Company&amp;#x2019;s technology and/or certain other
 intellectual property to develop compounds against specified
 targets (referred to herein as exclusive licenses); and 2)
 Option/research agreements to secure on established terms,
 development and commercialization licenses to therapeutic product
 candidates to collaborator-selected targets developed by the
 Company during an option period (referred to herein as
 right-to-develop agreements).&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 There are no performance, cancellation, termination or refund
 provisions in any of the arrangements that contain material
 financial consequences to the Company.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 2%; MARGIN-TOP: 18pt"&gt;
 &lt;i&gt;Exclusive Licenses&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The deliverables under an exclusive license agreement generally
 include the exclusive license to the Company&amp;#x2019;s DART
 technology with respect to a specified antigen target, and may also
 include deliverables related to rights to future technological
 improvements, research and pre-clinical development activities to
 be performed on behalf of the collaborator. In some cases the
 Company may have an option to participate in the co-development of
 product candidates that result from such agreements.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Generally, exclusive license agreements contain nonrefundable terms
 for payments and, depending on the terms of the agreement, provide
 that the Company will (i)&amp;#xA0;at the collaborator&amp;#x2019;s request,
 provide research and pre-clinical development services at
 negotiated prices which are generally consistent with what other
 third parties would charge, (ii)&amp;#xA0;earn payments upon the
 achievement of certain milestones, (iii)&amp;#xA0;earn royalty
 payments, and (iv)&amp;#xA0;in some cases grant the Company an option
 to participate in the development and commercialization of products
 that result from such agreements. Royalty rates may vary over the
 royalty term depending on the Company&amp;#x2019;s intellectual property
 rights and whether the Company exercises any co-development and
 co-commercialization rights. The Company may provide technical
 assistance and share any technology improvements with its
 collaborators during the term of the collaboration agreements.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company does not directly control when any collaborator will
 achieve milestones or become liable for royalty payments.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 When entering into a new collaboration arrangement or materially
 modifying an existing arrangement, the Company must identify the
 deliverables included within the agreement and evaluate which
 deliverables represent separate units of accounting based on the
 achievement of certain criteria, including whether the delivered
 element has stand-alone value to the collaborator. The selling
 prices of deliverables under an arrangement may be derived using
 third-party evidence (TPE), or a best estimate of selling price
 (BESP), if vendor specific objective evidence (VSOE) is not
 available. The objective of BESP is to determine the price at which
 the Company would transact a sale if the element within the license
 agreement was sold on a standalone basis. Establishing BESP
 involves management&amp;#x2019;s judgment and considers multiple
 factors, including market conditions and company-specific factors,
 including those factors contemplated in negotiating the agreements,
 as well as internally developed models that include assumptions
 related to market opportunity, discounted cash flows, estimated
 development costs, probability of success and the time needed to
 commercialize a product candidate pursuant to the license. In
 validating the BESP, management considers whether changes in key
 assumptions used to determine the BESP will have a significant
 effect on the allocation of the arrangement consideration between
 the multiple deliverables. Deliverables under the arrangement are
 separate units of accounting if (i)&amp;#xA0;the delivered item has
 value to the customer on a standalone basis and (ii)&amp;#xA0;if the
 arrangement includes a general right of return relative to the
 delivered item, delivery or performance of the undelivered item is
 considered probable and substantially within the Company&amp;#x2019;s
 control. The arrangement consideration that is fixed or
 determinable at the inception of the arrangement is allocated to
 the separate units of accounting based on their relative selling
 prices. The appropriate revenue recognition model is applied to
 each element and revenue is accordingly recognized as each element
 is delivered. Management exercises significant judgment in
 determining whether a deliverable is a separate unit of
 accounting.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 In determining the separate units of accounting, the Company
 evaluates whether the exclusive license has standalone value to the
 collaborator based on consideration of the relevant facts and
 circumstances for each arrangement. Factors considered in this
 determination include the research and development capabilities of
 the collaborator and the availability of relevant research
 expertise in the marketplace. In addition, the Company considers
 whether or not (i)&amp;#xA0;the collaborator could use the license for
 its intended purpose without the receipt of the remaining
 deliverables, (ii)&amp;#xA0;the value of the license was dependent on
 the undelivered items and (iii)&amp;#xA0;the collaborator or other
 vendors could provide the undelivered items. If the Company
 concludes that the license has stand-alone value and therefore will
 be accounted for as a separate unit of accounting, the Company then
 determines the estimated selling prices of the license and all
 other units of accounting based on market conditions, similar
 arrangements entered into by third parties, and entity-specific
 factors such as the terms of the Company&amp;#x2019;s previous
 collaboration agreements, recent pre-clinical and clinical testing
 results of therapeutic product candidates that use the
 Company&amp;#x2019;s technology platforms, the Company&amp;#x2019;s pricing
 practices and pricing objectives, the likelihood that technological
 improvements will be made, the likelihood that technological
 improvements made will be used by the Company&amp;#x2019;s collaborators
 and the nature of the research services to be performed on behalf
 of its collaborators and market rates for similar services. Total
 arrangement consideration is then allocated to each of the units of
 accounting using the relative-selling-price method. If facts and
 circumstances dictate that the exclusive license does not have
 stand-alone value, then the related payments are deferred and
 revenue is recognized throughout the period of performance.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Management reassesses the period of performance over which the
 Company recognizes deferred upfront license fees and makes
 adjustments as appropriate in the period in which a change in the
 estimated period of performance is identified. In the event a
 collaborator elects to discontinue development of a specific
 product candidate under a single target license, but retains its
 right to use the Company&amp;#x2019;s technology to develop an
 alternative product candidate to the same target or a target
 substitute, the Company would cease amortization of any remaining
 portion of the upfront fee until there is substantial pre-clinical
 activity on another product candidate and its remaining period of
 substantial involvement can be estimated. In the event that a
 single target license were to be terminated, the Company would
 recognize as revenue any portion of the upfront fee that had not
 previously been recorded as revenue, but was classified as deferred
 revenue, at the date of such termination or through the remaining
 substantial involvement in the wind down of the agreement.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Upfront payments on exclusive licenses may be recognized upon
 delivery of the license if facts and circumstances dictate that the
 license has stand-alone value from the undelivered elements, which
 generally include rights to future technological improvements,
 research services and the manufacture of pre-clinical and clinical
 materials.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company recognizes revenue related to research and pre-clinical
 development services that represent separate units of accounting as
 they are performed, as long as there is persuasive evidence of an
 arrangement, the fee is fixed or determinable, and collection of
 the related receivable is probable. The Company recognizes revenue
 related to the rights to future technological improvements over the
 estimated term of the applicable license.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company typically performs research activities and pre-clinical
 development services, including generating and engineering product
 candidates, on behalf of its licensees during the early evaluation
 and pre-clinical testing stages of drug development under its
 exclusive licenses. The Company records amounts received for
 research materials produced or services performed as revenue from
 collaborative research.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company&amp;#x2019;s license agreements have milestone payments
 which for reporting purposes are aggregated into three categories:
 (i)&amp;#xA0;development milestones, (ii)&amp;#xA0;regulatory milestones,
 and (iii)&amp;#xA0;sales milestones. Development milestones are
 typically payable when a product candidate initiates or advances
 into different clinical trial phases. Regulatory milestones are
 typically payable upon submission for marketing approval with the
 U.S. Food and Drug Administration (FDA) or other countries&amp;#x2019;
 regulatory authorities or on receipt of actual marketing approvals
 for the compound or for additional indications. Sales milestones
 are typically payable when annual sales reach certain levels.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 At the inception of each agreement that includes milestone
 payments, the Company evaluates whether each milestone is
 substantive and at risk to both parties on the basis of the
 contingent nature of the milestone. This evaluation includes an
 assessment of whether (i)&amp;#xA0;the consideration is commensurate
 with either (a)&amp;#xA0;the entity&amp;#x2019;s performance to achieve the
 milestone, or (b)&amp;#xA0;the enhancement of the value of the
 delivered item(s) as a result of a specific outcome resulting from
 the entity&amp;#x2019;s performance to achieve the milestone,
 (ii)&amp;#xA0;the consideration relates solely to past performance and
 (iii)&amp;#xA0;the consideration is reasonable relative to all of the
 deliverables and payment terms within the arrangement. The Company
 evaluates factors such as the scientific, regulatory, commercial
 and other risks that must be overcome to achieve the respective
 milestone, the level of effort and investment required to achieve
 the respective milestone and whether the milestone consideration is
 reasonable relative to all deliverables and payment terms in the
 arrangement in making this assessment.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Non-refundable development and regulatory milestones that are
 expected to be achieved as a result of the Company&amp;#x2019;s efforts
 during the period of substantial involvement are considered
 substantive and are recognized as revenue upon the achievement of
 the milestone, assuming all other revenue recognition criteria are
 met. Milestones that are not considered substantive because the
 Company does not contribute effort to the achievement of such
 milestones are generally achieved after the period of substantial
 involvement and are recognized as revenue upon achievement of the
 milestone, as there are no undelivered elements remaining and no
 continuing performance obligations, assuming all other revenue
 recognition criteria are met.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 2%; MARGIN-TOP: 18pt"&gt;
 &lt;i&gt;Right-to-Develop Agreements&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The Company&amp;#x2019;s right-to-develop agreements provide
 collaborators with an exclusive option to obtain licenses to
 develop and commercialize in specified geographic territories
 product candidates developed by the Company under agreed upon
 research and pre-clinical development product programs. The product
 candidates resulting from each program are all directed to a
 specific target selected by the collaborator. Under these
 agreements, fees may be due to the Company (i)&amp;#xA0;at the
 inception of the arrangement (referred to as &amp;#x201C;upfront&amp;#x201D;
 fees or payments), (ii)&amp;#xA0;the selection of a target for a
 program, (iii)&amp;#xA0;upon the exercise of an option to acquire a
 development and commercialization license (referred to as exercise
 fees or payments earned) for a program, or (iv)&amp;#xA0;some
 combination of all of these fees.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The accounting for right-to-develop agreements is dependent on the
 nature of the options granted to the collaborator. Options are
 considered substantive if, at the inception of a right-to-develop
 agreement, the Company is at risk as to whether the collaborator
 will choose to exercise the options to secure development and
 commercialization licenses. Factors that are considered in
 evaluating whether options are substantive include the overall
 objective of the arrangement, the benefit the collaborator might
 obtain from the agreement without exercising the options, the cost
 to exercise the options relative to the total upfront
 consideration, and the additional financial commitments imposed on
 the collaborator as a result of exercising the options.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 For right-to-develop agreements where the options to secure
 development and commercialization licenses to a product program are
 considered substantive, the Company does not consider the
 development and commercialization licenses to be a deliverable at
 the inception of the agreement, and therefore defers any upfront
 payments received and recognizes this revenue over the period
 during which the collaborator could elect to exercise options for
 development and commercialization licenses. These periods are
 specific to each collaboration agreement. If a collaborator selects
 a target for a product program, any substantive option fee is
 deferred and recognized over the life of the option. For
 right-to-develop agreements that include multiple deliverables, the
 Company determines the selling prices of deliverables under the
 arrangement using TPE or a BESP, if VSOE is not available. The
 objective of BESP is to determine the price at which the Company
 would transact a sale if the element within the right-to-develop
 agreement was sold on a standalone basis. Establishing BESP
 involves management&amp;#x2019;s judgment and considers multiple
 factors, including market conditions and company-specific factors,
 including those factors contemplated in negotiating the agreements,
 as well as internally developed models that include assumptions
 related to market opportunity, discounted cash flows, estimated
 development costs, probability of success and the time needed to
 commercialize a product candidate pursuant to the right-to-develop
 agreement. In validating the BESP, management considers whether
 changes in key assumptions used to determine the BESP will have a
 significant effect on the allocation of the arrangement
 consideration between the multiple deliverables. Deliverables under
 the arrangement are separate units of accounting if (i)&amp;#xA0;the
 delivered item has value to the customer on a standalone basis and
 (ii)&amp;#xA0;if the arrangement includes a general right of return
 relative to the delivered item, delivery or performance of the
 undelivered item is considered probable and substantially within
 the Company&amp;#x2019;s control. The arrangement consideration that is
 fixed or determinable at the inception of the arrangement is
 allocated to the separate units of accounting based on their
 relative selling prices. The appropriate revenue recognition model
 is applied to each element and revenue is accordingly recognized as
 each element is delivered. Management exercises significant
 judgment in determining whether a deliverable is a separate unit of
 accounting.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 If a collaborator exercises an option and acquires a development
 and commercialization license to a product program, the Company
 attributes the exercise fee to the development and
 commercialization license. The Company determines the selling price
 of the option license, upon exercise, through management&amp;#x2019;s
 best estimate using the process for an exclusive license as
 described above.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Upon exercise of an option to acquire a development and
 commercialization license, the Company would also attribute any
 remaining deferred option fee, in addition to the consideration
 received for the license upon exercise of the option, to the
 development and commercialization license. The Company then applies
 the multiple-element revenue recognition criteria to the
 development and commercialization license and other deliverables,
 if any, to determine the appropriate revenue recognition method.
 This model is consistent with the Company&amp;#x2019;s accounting policy
 for upfront payments on exclusive licenses (discussed above). In
 the event a right-to-develop agreement were to be terminated, the
 Company would recognize as revenue any portion of the upfront fee
 that had not previously been recorded as revenue, but was
 classified as deferred revenue, at the date of such termination.
 The Company&amp;#x2019;s right-to-develop agreements have been
 determined to contain substantive options.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 For right-to-develop agreements where the options to secure
 development and commercialization licenses to product programs are
 not considered substantive, the Company considers the development
 and commercialization licenses to be a deliverable at the inception
 of the agreement and applies the multiple-element revenue
 recognition criteria to determine the appropriate revenue
 recognition. The Company does not directly control when any
 collaborator will exercise its options for development and
 commercialization licenses.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" unitRef="pure" decimals="2" id="id_6848266_5078EE5D-09E5-4168-A034-4E6683B2BE49_3_0">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" id="id_6848266_B17DC221-39E0-441F-896B-6A1583FF1F73_1_1">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" unitRef="shares" decimals="INF" id="id_6848266_7B0A02FA-85DB-43CF-BC04-01FAA356A7C5_5001_4">36805</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
  <us-gaap:StockholdersEquityReverseStockSplit contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" id="id_6848266_A6088308-BD9B-4CD3-8B23-B276AB4CBE4A_1_0">1-for-18.7739</us-gaap:StockholdersEquityReverseStockSplit>
  <us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" id="id_6848266_49A0970A-683E-4EEF-A0A3-CCDCD3A7E197_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Future minimum lease payments under noncancelable operating leases
 as of December&amp;#xA0;31, 2014 are as follows (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="84%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 2015&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,945&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 2016&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,364&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 2017&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,495&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 2018&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,396&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 2019&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,873&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Thereafter&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;116&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;19,189&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock>
  <us-gaap:UseOfEstimates contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" id="id_6848266_003E53A8-63EF-4E7E-B012-985AD609116E_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The preparation of the financial statements in accordance with
 generally accepted accounting principles (GAAP) requires the
 Company to make estimates and judgments in certain circumstances
 that affect the reported amounts of assets, liabilities, revenues
 and expenses, and related disclosure of contingent assets and
 liabilities. In preparing these consolidated financial statements,
 management has made its best estimates and judgments of certain
 amounts included in the financial statements, giving due
 consideration to materiality. On an ongoing basis, the Company
 evaluates its estimates, including those related to revenue
 recognition, fair values of assets, stock-based compensation,
 preferred stock warrant liability, income taxes, pre-clinical study
 and clinical trial accruals and other contingencies. Management
 bases its estimates on historical experience or on various other
 assumptions that it believes to be reasonable under the
 circumstances. Actual results could differ from these
 estimates.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 In addition, prior to the Company&amp;#x2019;s IPO in October 2013, the
 Company utilized estimates and assumptions in determining the fair
 value of its common stock. The Company granted stock options at
 exercise prices not less than the fair value of its common stock as
 determined by the Board of Directors, with input from management.
 Management used contemporaneous valuations in estimating the fair
 value of its common stock. The board of directors determined the
 estimated fair value of the common stock based on a number of
 objective and subjective factors, including external market
 considerations affecting the biotechnology industry and the
 historic prices at which the Company sold shares of its preferred
 stock.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:UseOfEstimates>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" unitRef="shares" decimals="0" id="id_6848266_C038B40A-B436-460B-B84E-355BF772C2D9_1_12">27384990</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <dei:DocumentPeriodEndDate contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" id="id_6848266_FAA44042-8554-4DED-B4FD-D076A21A6C07_1_2">2014-12-31</dei:DocumentPeriodEndDate>
  <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" id="id_6848266_4D6B304E-AA50-4BB0-AD12-9681B4A5969A_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Cash and Cash Equivalents&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The Company considers all investments in highly liquid financial
 instruments with an original maturity of three months or less at
 the date of purchase to be cash equivalents. Cash and cash
 equivalents consist of certificates of deposit and investments in
 money market funds with commercial banks and financial
 institutions. Cash equivalents are stated at amortized cost, plus
 accrued interest, which approximates fair value.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
  <us-gaap:DescriptionOfLesseeLeasingArrangementsOperatingLeases contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" id="id_6848266_4B2FF989-2059-4FC7-89D2-70B1D6317EB2_1_3">During 2014, the Company exercised its 5-year renewal option on the manufacturing facility. The Company also entered into a new four-year lease for additional space in the manufacturing facility effective April 1, 2014. This lease also has an option to continue the lease for five years under the same terms.</us-gaap:DescriptionOfLesseeLeasingArrangementsOperatingLeases>
  <us-gaap:NumberOfOperatingSegments contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" unitRef="Segment" decimals="INF" id="id_6848266_29E8473B-161E-4D1A-9837-724A35C72B5C_1_0">1</us-gaap:NumberOfOperatingSegments>
  <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" id="id_6848266_3FC6146B-8ABB-4106-B6FB-ADFAC4DE48E7_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Property and Equipment&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Property and equipment are stated at cost. Upon retirement or sale,
 the cost of assets disposed of and the related accumulated
 depreciation are removed from the accounts and any resulting gain
 or loss is credited or charged to operations. Repairs and
 maintenance costs are expensed as incurred. Depreciation is
 computed using the straight-line method over the following
 estimated useful lives:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="55%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Computer equipment&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;3 years&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Software&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;3 years&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Furniture&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;10 years&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Laboratory and office equipment&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;5 years&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Leasehold improvements&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 Shorter&amp;#xA0;of&amp;#xA0;lease&amp;#xA0;term&amp;#xA0;or&amp;#xA0;useful&amp;#xA0;life&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
  <us-gaap:QuarterlyFinancialInformationTextBlock contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" id="id_6848266_6467ACFF-28C1-42C5-A119-6B5AFCF4667D_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;12. Quarterly Financial Information (unaudited)&lt;/b&gt;&lt;/p&gt;
 &lt;!-- xbrl,body --&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="55%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;1&lt;sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top"&gt;st&lt;/sup&gt;&amp;#xA0;Quarter&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2&lt;sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top"&gt;nd&lt;/sup&gt;&amp;#xA0;Quarter&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;3&lt;sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top"&gt;rd&lt;/sup&gt;&amp;#xA0;Quarter&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;4&lt;sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top"&gt;th&lt;/sup&gt;&amp;#xA0;Quarter&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;(in thousands,
 except per share data)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;2014&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Revenue&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;14,719&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9,220&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;18,382&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,476&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Net loss&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(3,108&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(12,259&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(3,928&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(19,018&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Net loss per share, basic and diluted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.12&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.44&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.14&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.68&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;2013&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Revenue&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,598&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;12,299&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;20,232&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;14,906&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Net income (loss)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(3,366&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(294&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,604&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(3,205&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Net income (loss) per share, basic&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2.93&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.24&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.14&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.14&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Net income (loss) per share, diluted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2.93&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.24&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.01&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.14&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Net income (loss) per share includes the effects of income
 allocated to participating securities.&lt;/p&gt;


 &lt;/div&gt;</us-gaap:QuarterlyFinancialInformationTextBlock>
  <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" id="id_6848266_A8A36FDB-555C-48DD-AC20-1DDB52DACD89_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Research and Development Costs&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Research and development expenditures are expensed as incurred.
 Research and development costs primarily consist of employee
 related expenses, including salaries and benefits, expenses
 incurred under agreements with contract research organizations,
 investigative sites and consultants that conduct the
 Company&amp;#x2019;s clinical trials, the cost of acquiring and
 manufacturing clinical trial materials and other allocated
 expenses, license fees for and milestone payments related to
 in-licensed products and technologies, stock-based compensation
 expense, and costs associated with non-clinical activities and
 regulatory approvals.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" id="id_6848266_17746F23-4AA2-4BB3-9A89-FCE1187AF996_3001_2">P7Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_6848266_1A1F7457-4446-4854-A71F-326EE5804095_5001_4">9.76</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" id="id_6848266_A6EAC5D5-0710-4FBF-BED9-FE2C9CC52FE3_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;4. Stockholders&amp;#x2019; Equity&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 During 2002 and 2003, the Company issued a total of 34,239,374
 shares of Series A-1 and Series A-2 convertible preferred stock
 (Series A preferred stock) for $1.00 per share resulting in net
 proceeds of approximately $34.0 million.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 In October 2004, the Company entered into a series of transactions
 raising $30.3 million, net of related offering costs of
 approximately $238,000, from the sale of 71,401,237 shares of its
 Series B convertible preferred stock (Series B preferred stock). In
 connection with the Series B preferred stock offering, 13,604,016
 shares of common stock were allocated to holders of Series&amp;#xA0;A-1
 preferred stock as an anti-dilution measure.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 In May&amp;#xA0;2006, the Company raised $44.9 million, net of related
 offering costs of $101,246, from the sale of 110,952,217 shares of
 its Series C convertible preferred stock (Series C preferred
 stock). In connection with the Series C preferred stock offering,
 10,003,300 shares of common stock were allocated to holders of
 Series B preferred stock as an anti-dilution measure.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 In July&amp;#xA0;2008, the Company issued 12,466,039 shares of its
 Series D convertible preferred stock (Series D preferred stock) in
 exchange for all of the outstanding capital stock and convertible
 notes payable of Raven Biotechnologies, Inc. (Raven). Subsequently,
 in March 2011 a settlement was reached with the former Raven
 stockholders bringing the total Series D preferred stock issued in
 connection with the Raven acquisition to 14,446,227 shares.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 In September&amp;#xA0;2008, the Company raised $24.8 million, net of
 related offering costs of $156,788 from the sale of 38,337,678
 shares of its Series D-2 convertible preferred stock (Series D-2
 preferred stock). The Company also issued preferred stock warrants
 for the purchase of 2,875,327 shares of Series D-2 preferred stock.
 The preferred stock warrants were exercisable at any time prior to
 September&amp;#xA0;2018, but expired upon an IPO, and had a stated
 exercise price of $0.65 per warrant. On May&amp;#xA0;16, 2010, the
 Company exercised a put notice to Eli Lilly in accordance with the
 Series D-2 preferred stock purchase agreement, resulting in the
 issuance of 6,916,110 shares of Series D-2 preferred stock and a
 warrant to purchase 518,708 additional shares of Series D-2
 preferred stock. On January&amp;#xA0;11, 2011, the Company raised gross
 proceeds of $12.0 million from the sale of 18,427,388 shares of its
 Series D-2 preferred stock.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Due to certain provisions in the Series D-2 convertible preferred
 stock warrant agreement, these warrants were required to be
 classified as a liability. Management believed that the
 circumstances requiring cash settlement of the award were remote.
 The Series D-2 preferred stock warrant liability was recorded at
 fair value and has been adjusted to fair value at the end of each
 reporting period using the Option-Pricing Method, with changes in
 value recorded as &amp;#x201C;Other income (expense)&amp;#x201D; in the
 accompanying consolidated statements of operations and
 comprehensive income (loss). Prior to the Company&amp;#x2019;s IPO in
 October 2013, all the preferred stock warrants were exercised and
 subsequently were converted into shares of common stock in
 connection with the IPO.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Dividends were noncumulative and accrued on the Series A, Series B,
 Series C, Series D and Series&amp;#xA0;D-2 preferred stock at a rate of
 $0.08, $0.0341, $0.0324 and $0.0522 per annum, respectively, and
 were payable when and as declared by the Board of Directors.
 Dividends had to be declared so that the Series A, Series&amp;#xA0;B,
 Series C and Series D preferred stock were paid in like-kind and
 participated equally to those of the Series&amp;#xA0;D-2 preferred and
 common stock. No dividends had been declared prior to the
 conversion of the preferred stock to common stock in connection
 with the IPO.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company&amp;#x2019;s Series A-1, Series A-2, Series B, Series C,
 Series D and Series D-2 preferred stock were initially convertible
 into 1.506, 1.00, 1.14, 1.00, 1.00 and 1.00 shares, respectively,
 of common stock at the option of the holder. The conversion ratio
 of certain series of preferred stock was subject to change in the
 event specified dilutive transactions occurred, which included the
 Company&amp;#x2019;s IPO. There were no anti-dilution protections for
 the Series A-2 preferred stock and no adjustment to the Series A-1
 preferred stock conversion price was to be made if a common stock
 issuance was at a price per share greater than the conversion price
 of the Series C preferred stock. Upon consummation of the
 Company&amp;#x2019;s IPO in October 2013, all outstanding shares of
 preferred stock automatically converted to shares of the
 Company&amp;#x2019;s common stock at the applicable conversion ratios
 then in effect. The conversion price was $12.39, $18.77, $6.95,
 $7.70, $12.20 and $12.20 for each share of Series A-1, A-2, Series
 B, Series C, Series D and Series D-2 convertible preferred stock,
 respectively.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 On October&amp;#xA0;16, 2013, the Company completed its IPO, in which
 5,000,000 shares of the Company&amp;#x2019;s common stock were sold at a
 price of $16.00 per share. Additionally, the underwriters of the
 Company&amp;#x2019;s IPO exercised the full amount of their
 over-allotment option resulting in the sale of an additional
 750,000 shares of the Company&amp;#x2019;s common stock at a price of
 $16.00 per share. The Company received proceeds of $83.8 million
 from the IPO, net of underwriting discounts and commissions and
 other offering expenses. Upon consummation of the IPO, all
 outstanding shares of preferred stock automatically converted to
 common stock at the applicable conversion ratios then in
 effect.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 In connection with preparing for its IPO in October 2013, the
 Company&amp;#x2019;s Board of Directors and stockholders approved a
 1-for-18.7739 reverse stock split of the Company&amp;#x2019;s common
 stock. The reverse stock split became effective on
 September&amp;#xA0;26, 2013. All share and per share amounts in the
 consolidated financial statements and notes thereto have been
 retroactively adjusted for all periods presented to give effect to
 this reverse stock split, including reclassifying an amount equal
 to the reduction in par value of common stock to additional paid-in
 capital. In addition, in September 2013, the Company&amp;#x2019;s Board
 of Directors and stockholders approved an amendment of the
 Company&amp;#x2019;s certificate of incorporation to, among other
 things, change the definition of a designated public offering to
 remove the per share price requirement. The amended and restated
 certificate of incorporation also changed the authorized number of
 shares of common stock from 425,000,000 to 125,000,000, and
 authorized 5,000,000 shares of undesignated preferred stock with a
 par value of $0.01 per share. There were no shares of undesignated
 preferred stock issued or outstanding as of December&amp;#xA0;31, 2014
 or 2013.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 In February 2014, the Company completed a follow-on equity
 offering, in which the Company sold 1.8&amp;#xA0;million shares of its
 common stock at a price of $36.50 per share. Additionally, the
 underwriters of the offering exercised the full amount of their
 over-allotment option resulting in the sale of an additional
 450,000&amp;#xA0;shares of the Company&amp;#x2019;s common stock at a price
 of $36.50 per share. The Company received proceeds of
 $76.7&amp;#xA0;million from this offering, net of underwriting
 discounts and commissions and other offering expenses.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <dei:AmendmentFlag contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" id="id_6848266_FAA44042-8554-4DED-B4FD-D076A21A6C07_1_1">false</dei:AmendmentFlag>
  <dei:CurrentFiscalYearEndDate contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" id="id_6848266_0E6F3311-D183-4200-9E69-FFDB3EB2AE27_1_3">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:DocumentFiscalYearFocus contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" id="id_6848266_FAA44042-8554-4DED-B4FD-D076A21A6C07_1_3">2014</dei:DocumentFiscalYearFocus>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" unitRef="shares" decimals="0" id="id_6848266_06A157FB-CCF1-440F-8ABC-76F98DD1AADC_1_10">27384990</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:EarningsPerShareBasic contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_6848266_06A157FB-CCF1-440F-8ABC-76F98DD1AADC_1_4">-1.40</us-gaap:EarningsPerShareBasic>
  <us-gaap:IncomeTaxDisclosureTextBlock contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" id="id_6848266_E341EAAC-A138-466E-A509-18CDE4F1464C_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;6. Income Taxes&lt;/b&gt;&lt;/p&gt;
 &lt;!-- xbrl,body --&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 For the years ended December&amp;#xA0;31, 2014, 2013 and 2012 there was
 no current provision for federal or state income taxes due to the
 taxable losses which resulted or use of legacy NOL
 carryforwards.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"&gt;
 The significant components of the Company&amp;#x2019;s deferred income
 tax assets (liabilities) were as follows (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="71%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Deferred income tax assets:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Federal U.S. net operating loss carryforward&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;55,358&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;36,561&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 State net operating loss carryforward&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,723&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,316&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Research and development credit, net&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,177&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,786&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Orphan drug credit, net&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;19,287&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;19,883&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Deferred rent&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,069&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,132&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Deferred revenue&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,989&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,217&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Depreciation&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,337&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,438&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Other&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;962&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,439&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Gross deferred income tax assets&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;95,902&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;79,772&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Valuation allowance&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(94,297&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(79,377&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Net deferred income tax assets&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,605&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;395&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Deferred income tax liabilities:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Prepaid expenditures&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1,605&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(395&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Gross deferred income tax liabilities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1,605&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(395&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Net deferred income tax asset/(liability)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company recognizes valuation allowances to reduce deferred tax
 assets to the amount that is more likely than not to be realized.
 In assessing the likelihood of realization, management considers
 (i)&amp;#xA0;future reversals of existing taxable temporary
 differences; (ii)&amp;#xA0;future taxable income exclusive of reversing
 temporary difference and carryforwards; (iii)&amp;#xA0;taxable income
 in prior carryback years if carryback is permitted under applicable
 tax law; and (iv)&amp;#xA0;tax planning strategies. The Company&amp;#x2019;s
 net deferred income tax asset is not more likely than not to be
 utilized due to the lack of sufficient sources of future taxable
 income and cumulative book losses which have resulted over the
 years. The net increase in the valuation allowance in 2014 is due
 to the fact the Company generated research and development and
 orphan drug credits and NOL carryforwards which increased the net
 deferred tax asset. The increase in the credits and NOL
 carryforwards were offset by the decrease in deferred revenue and
 resulted in a net current year increase to the valuation
 allowance.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 As of December 31, 2014, the Company had U.S. federal NOL
 carryforwards of approximately $158.9 million and approximately
 $103.4 million for state that will expire in various years
 beginning in 2020 through 2034. In addition, the Company has U.S.
 federal tax credits of $26.3 million which will expire in various
 years beginning in 2020 through 2034.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The use of the Company&amp;#x2019;s U.S. federal NOL and tax credit
 carryforwards in future years are restricted due to changes in the
 Company&amp;#x2019;s ownership and tax attributes acquired through the
 Company&amp;#x2019;s acquisitions. As of December&amp;#xA0;31, 2014, $7.1
 million of the Company&amp;#x2019;s US Federal NOLs are limited for use
 over the years 2015-2027 in which a range of such amounts could be
 utilized on an annual basis of $0.2 million to $1.4 million. The
 remaining $151.8 million of NOLs is not limited and can be offset
 against future taxable income. Additionally, approximately $7.7
 million of NOLs will be recognized as a benefit through
 additional-paid-in-capital when realized. Further, despite the NOL
 and credit carryforwards, the Company may have a future tax
 liability due to an alternative minimum tax or state tax
 requirements in which net operating losses do not exist.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"&gt;
 Furthermore, the Company recorded $1.6 million of current deferred
 tax liability and $1.6 million of noncurrent deferred tax asset as
 a result of the requirement to allocate its valuation allowance
 against gross deferred tax assets. As such the balance sheet was
 grossed up but nets to zero deferred income tax
 assets/(liabilities).&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The reconciliation of the reported estimated income tax benefit to
 the amount that would result by applying the U.S. federal statutory
 tax rate to the net income is as follows (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="66%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;Year Ended
 December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 United States federal tax at statutory rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(13,410&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(91&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,927&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 State taxes (net of federal benefit)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1,608&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;609&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,460&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Deferred income tax adjustments&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(855&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(512&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Deferred state blended rate adjustments&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,034&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(344&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Research credit, net&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2,228&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(226&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Transaction cost deduction&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(379&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Transaction cost deduction&amp;#x2014;prior year adjustment&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(564&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Orphan drug credit, net&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(139&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(843&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(4,896&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Other permanent items&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(382&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Equity-based compensation&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;756&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;241&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;279&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Fair value adjustment of preferred stock warrant liability&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;219&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(53&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Change in valuation allowance&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;14,920&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,287&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;787&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Income tax expense/(benefit)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 A reconciliation of the beginning and ending amount of gross
 unrecognized tax benefits is as follows (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="70%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;Year Ended
 December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Beginning balance&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,708&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,592&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,534&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Increases/(decreases) for current year tax positions&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;242&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;116&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;58&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Increases/(decreases) for prior year tax positions&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;97&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Decreases as a result of expiration of statute of limitations&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Ending balance&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,047&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,708&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,592&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 As of December&amp;#xA0;31, 2014 and 2013, of the total gross
 unrecognized tax benefits, approximately $1.7 million and $1.3
 million would favorably impact the Company&amp;#x2019;s effective income
 tax rate, respectively. Although, due to the Company&amp;#x2019;s
 determination that the deferred income tax asset would not more
 likely than not be realized, a valuation allowance would be
 recorded, therefore, zero net impact would result within the
 Company&amp;#x2019;s effective income tax rate. The Company&amp;#x2019;s
 uncertain income tax position liability has been recorded to
 deferred income taxes to offset the tax attribute carryforward
 amounts.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 For the years ended December&amp;#xA0;31, 2014, 2013 and 2012, the
 Company has not recognized any interest or penalties related to the
 uncertain income tax positions due to the fact such position is
 related to tax attribute carryforwards which have not yet been
 utilized. The Company does not expect its unrecognized income tax
 position to significantly decrease within the next twelve
 months.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"&gt;
 The Company&amp;#x2019;s U.S. Federal and state income tax returns from
 2001 to 2014 remain subject to examination by the tax authorities.
 The Company&amp;#x2019;s 2001 through 2010 years remain open for
 examination, even though the statute of limitations has expired,
 due to the net operating losses and credits carried forward for use
 in prospective years.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
  <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" id="id_6848266_F886155F-4E3D-40FB-B141-BBE0E9C1D7BD_1_0">&lt;div&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;1. Organization and Nature of Operations&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 MacroGenics, Inc. (the &amp;#x201C;Company&amp;#x201D;) was incorporated in
 Delaware on August&amp;#xA0;14, 2000. The Company is a clinical-stage
 biopharmaceutical company focused on discovering and developing
 innovative monoclonal antibody-based therapeutics for the treatment
 of cancer, as well as various autoimmune disorders and infectious
 diseases. The Company generates its pipeline of product candidates
 from its proprietary suite of next-generation antibody technology
 platforms which it believes improve the performance of monoclonal
 antibodies and antibody-derived molecules. These product
 candidates, which the Company has identified through its
 understanding of disease biology and immune-mediated mechanisms,
 may address disease-specific challenges which are not currently
 being met by existing therapies.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
  <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" id="id_6848266_81CA2BC2-161C-47DA-AA41-8F0C41231ABF_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"&gt;
 The significant components of the Company&amp;#x2019;s deferred income
 tax assets (liabilities) were as follows (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="71%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Deferred income tax assets:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Federal U.S. net operating loss carryforward&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;55,358&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;36,561&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 State net operating loss carryforward&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,723&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,316&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Research and development credit, net&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,177&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,786&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Orphan drug credit, net&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;19,287&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;19,883&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Deferred rent&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,069&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,132&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Deferred revenue&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,989&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,217&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Depreciation&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,337&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,438&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Other&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;962&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,439&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Gross deferred income tax assets&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;95,902&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;79,772&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Valuation allowance&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(94,297&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(79,377&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Net deferred income tax assets&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,605&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;395&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Deferred income tax liabilities:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Prepaid expenditures&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1,605&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(395&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Gross deferred income tax liabilities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1,605&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(395&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Net deferred income tax asset/(liability)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
  <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" id="id_6848266_1476740B-011E-4B83-B5CF-0229831740ED_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"&gt;
 Basic and diluted income (loss) per common share is computed as
 follows (in thousands except share and per share data):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="58%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;Year Ended
 December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Net income (loss)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(38,313&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(261&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,362&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Less: undistributed earnings allocated to participating
 securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(8,362&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Net income (loss) allocable to common shares&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(38,313&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(261&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Basic weighted average common shares outstanding&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;27,384,990&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,847,697&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,083,276&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Basic income (loss) per common share&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1.40&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.04&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.00&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Net income (loss)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(38,313&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(261&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,362&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Less: undistributed earnings allocated to participating securities
 and other add-backs to net income (loss)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(8,362&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Net income (loss) allocable to common shares&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(38,313&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(261&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Basic weighted average common shares outstanding&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;27,384,990&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,847,697&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,083,276&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Effect of dilutive securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Diluted weighted average common shares outstanding&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;27,384,990&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,847,697&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,083,276&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Diluted income (loss) per common share&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1.40&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.04&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.00&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
  <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" id="id_6848266_E8F92511-D38E-491B-A1E5-BFFC7743CEE9_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Future principal payments to be made under the lease agreement as
 of December&amp;#xA0;31, 2014 are as follows (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="86%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 2015&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,642&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 2016&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,866&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 2017&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,113&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 2018&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,385&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,006&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
  <us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" id="id_6848266_CDA37EC4-71AF-48AA-8FEA-AD550109F4D7_1_0">&lt;div&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="55%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;1&lt;sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top"&gt;st&lt;/sup&gt;&amp;#xA0;Quarter&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2&lt;sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top"&gt;nd&lt;/sup&gt;&amp;#xA0;Quarter&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;3&lt;sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top"&gt;rd&lt;/sup&gt;&amp;#xA0;Quarter&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;4&lt;sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top"&gt;th&lt;/sup&gt;&amp;#xA0;Quarter&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;(in thousands,
 except per share data)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;2014&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Revenue&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;14,719&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9,220&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;18,382&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,476&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Net loss&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(3,108&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(12,259&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(3,928&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(19,018&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Net loss per share, basic and diluted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.12&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.44&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.14&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.68&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;2013&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Revenue&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,598&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;12,299&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;20,232&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;14,906&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Net income (loss)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(3,366&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(294&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,604&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(3,205&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Net income (loss) per share, basic&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2.93&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.24&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.14&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.14&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Net income (loss) per share, diluted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2.93&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.24&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.01&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.14&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" id="id_6848266_17746F23-4AA2-4BB3-9A89-FCE1187AF996_3001_3">P5Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_6848266_1A1F7457-4446-4854-A71F-326EE5804095_5001_2">27.06</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" id="id_6848266_816FA5DB-59E8-4E04-A680-8338EA5F3D9C_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;2. Summary of Significant Accounting Policies&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 &lt;b&gt;&lt;i&gt;Basis of Presentation and Principles of
 Consolidation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The consolidated financial statements include the accounts of
 MacroGenics, Inc. and its wholly owned subsidiaries, MacroGenics UK
 Limited and MacroGenics West, Inc. Effective December&amp;#xA0;22,
 2014, MacroGenics West, Inc. was merged with and into MacroGenics,
 Inc. All intercompany accounts and transactions have been
 eliminated in consolidation. The Company currently operates in one
 operating segment. Operating segments are defined as components of
 an enterprise about which separate discrete information is
 available for the chief operating decision maker, or decision
 making group, in deciding how to allocate resources and assessing
 performance. The Company views its operations and manages its
 business in one segment, which is developing monoclonal
 antibody-based therapeutics for cancer, autoimmune and infectious
 diseases.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The preparation of the financial statements in accordance with
 generally accepted accounting principles (GAAP) requires the
 Company to make estimates and judgments in certain circumstances
 that affect the reported amounts of assets, liabilities, revenues
 and expenses, and related disclosure of contingent assets and
 liabilities. In preparing these consolidated financial statements,
 management has made its best estimates and judgments of certain
 amounts included in the financial statements, giving due
 consideration to materiality. On an ongoing basis, the Company
 evaluates its estimates, including those related to revenue
 recognition, fair values of assets, stock-based compensation,
 preferred stock warrant liability, income taxes, pre-clinical study
 and clinical trial accruals and other contingencies. Management
 bases its estimates on historical experience or on various other
 assumptions that it believes to be reasonable under the
 circumstances. Actual results could differ from these
 estimates.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 In addition, prior to the Company&amp;#x2019;s IPO in October 2013, the
 Company utilized estimates and assumptions in determining the fair
 value of its common stock. The Company granted stock options at
 exercise prices not less than the fair value of its common stock as
 determined by the Board of Directors, with input from management.
 Management used contemporaneous valuations in estimating the fair
 value of its common stock. The board of directors determined the
 estimated fair value of the common stock based on a number of
 objective and subjective factors, including external market
 considerations affecting the biotechnology industry and the
 historic prices at which the Company sold shares of its preferred
 stock.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Cash and Cash Equivalents&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The Company considers all investments in highly liquid financial
 instruments with an original maturity of three months or less at
 the date of purchase to be cash equivalents. Cash and cash
 equivalents consist of certificates of deposit and investments in
 money market funds with commercial banks and financial
 institutions. Cash equivalents are stated at amortized cost, plus
 accrued interest, which approximates fair value.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Accounts Receivable&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Accounts receivable that management has the intent and ability to
 collect are reported in the consolidated balance sheets at
 outstanding amounts, less an allowance for doubtful accounts. The
 Company writes off uncollectible receivables when the likelihood of
 collection is remote.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company evaluates the collectability of accounts receivable on
 a regular basis. The allowance, if any, is based upon various
 factors including the financial condition and payment history of
 customers, an overall review of collections experience on other
 accounts and economic factors or events expected to affect future
 collections experience. No allowance was recorded as of
 December&amp;#xA0;31, 2014 or 2013, as the Company has a history of
 collecting on all outstanding accounts.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Restricted Cash&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The Company is required to maintain certificates of deposit that
 serve as collateral for various operating leases and corporate
 credit card accounts. Amounts classified as restricted cash on the
 consolidated balance sheets are $300,000 and $405,000 at
 December&amp;#xA0;31, 2014 and 2013, respectively.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Fair Value of Financial Instruments&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The fair market values of the financial instruments included in the
 financial statements, which include cash equivalents and money
 market accounts, approximate their carrying values at
 December&amp;#xA0;31, 2014 and 2013, due to their short-term
 maturities. The Company accounts for recurring and non-recurring
 fair value measurements in accordance with the Financial Accounting
 Standards Board (FASB) Accounting Standards Codification (ASC) 820,
 &lt;i&gt;Fair Value Measurements and Disclosures&lt;/i&gt; (ASC 820). ASC 820
 defines fair value, establishes a fair value hierarchy for assets
 and liabilities measured at fair value, and requires expanded
 disclosures about fair value measurements. The ASC 820 hierarchy
 ranks the quality of reliability of inputs, or assumptions, used in
 the determination of fair value and requires assets and liabilities
 carried at fair value to be classified and disclosed in one of the
 following three categories:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;Level 1&amp;#x2014;Fair value is
 determined by using unadjusted quoted prices that are available in
 active markets for identical assets and liabilities.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;Level 2&amp;#x2014;Fair value is
 determined by using inputs other than Level 1 quoted prices that
 are directly or indirectly observable. Inputs can include quoted
 prices for similar assets and liabilities in active markets or
 quoted prices for identical assets and liabilities in inactive
 markets. Related inputs can also include those used in valuation or
 other pricing models, such as interest rates and yield curves that
 can be corroborated by observable market data.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;Level 3&amp;#x2014;Fair value is
 determined by inputs that are unobservable and not corroborated by
 market data. Use of these inputs involves significant and
 subjective judgments to be made by a reporting entity&amp;#xA0;&amp;#x2013;
 e.g., determining an appropriate adjustment to a discount factor
 for illiquidity associated with a given security.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company evaluates financial assets and liabilities subject to
 fair value measurements on a recurring basis to determine the
 appropriate level at which to classify them each reporting period.
 This determination requires the Company to make subjective
 judgments as to the significance of inputs used in determining fair
 value and where such inputs lie within the ASC 820 hierarchy.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 18pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"&gt;
 Financial assets and liabilities subject to fair value measurements
 were as follows (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="43%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;Fair Value Measurements at
 December&amp;#xA0;31, 2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Quoted&amp;#xA0;Prices&amp;#xA0;in&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Active Markets&lt;br /&gt;
 for&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Identical Assets&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Significant&amp;#xA0;Other&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Observable&lt;br /&gt;
 Inputs&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Significant&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Unobservable&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Inputs&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Assets:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Cash and cash equivalents&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;131,545&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;131,545&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Money market funds&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;26,046&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;26,046&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Restricted cash&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;300&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;300&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Total Assets&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;157,891&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;157,891&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1pt"&gt;
 &lt;td height="16"&gt;&lt;/td&gt;
 &lt;td height="16" colspan="16"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;Fair Value Measurements at
 December&amp;#xA0;31, 2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Quoted Prices in&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Active Markets&lt;br /&gt;
 for&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Identical Assets&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Significant Other&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Observable&lt;br /&gt;
 Inputs&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Significant&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Unobservable&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Inputs&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Assets:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Cash and cash equivalents&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;90,434&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;90,434&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Money market funds&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;26,047&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;26,047&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Restricted cash&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;405&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;405&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Total Assets&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;116,886&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;116,886&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company&amp;#x2019;s Level 1 securities primarily consist of
 restricted cash, cash equivalents and money market funds. The
 Company determines the estimated fair value for its Level 1
 securities using quoted (unadjusted) prices for identical assets or
 liabilities in active markets.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Concentration of Credit Risk&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Substantially all of the Company&amp;#x2019;s cash and cash equivalents
 are maintained with major financial institutions in the United
 States. Deposits held with banks may exceed the amount of insurance
 provided on such deposits. Generally, these deposits may be
 redeemed upon demand and, therefore, bear minimal risk.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Financial instruments that potentially subject the Company to
 concentrations of credit risk consist principally of cash and cash
 equivalents, and accounts receivable. The counterparties are
 various corporations, financial institutions and government
 agencies of high credit standing.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 For the years ended December&amp;#xA0;31, 2014, 2013 and 2012, the
 Company&amp;#x2019;s collaboration revenue relates to agreements with
 Takeda Pharmaceutical Company Limited (Takeda), Les Laboratoires
 Servier and Institut de Recherches Servier (collectively, Servier),
 Gilead Sciences, Inc. (Gilead), Boehringer Ingelheim GmbH
 (Boehringer), Pfizer, Inc. (Pfizer), Eli Lilly&amp;#xA0;&amp;amp; Co. (Eli
 Lilly) and Green Cross Corp. (Green Cross). Grant revenue is
 related to contracts and research grants received from U.S.
 government agencies. The majority of the outstanding receivables
 are due from the Company&amp;#x2019;s collaborators and U.S. government
 agencies.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"&gt;
 The following table includes those collaborators that represent
 more than 10% of total revenue earned in the periods indicated:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="66%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"&gt;
 &lt;b&gt;Year&amp;#xA0;Ended&amp;#xA0;December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;2014&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;2013&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;2012&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Servier&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;36.4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;51.6&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;17.3&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Boehringer&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;28.6&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;24.8&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;18.4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Takeda&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;16.8&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Gilead&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11.4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13.8&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Eli Lilly&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.9&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;48.9&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The following table includes those collaborators that represent
 more than 10% of accounts receivable at the date indicated:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="75%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;2014&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;2013&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Servier&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;33.3&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Boehringer&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;21.2&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;12.2&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Green Cross&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;17.9&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Gilead&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;53.4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Pfizer&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;12.3&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Property and Equipment&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Property and equipment are stated at cost. Upon retirement or sale,
 the cost of assets disposed of and the related accumulated
 depreciation are removed from the accounts and any resulting gain
 or loss is credited or charged to operations. Repairs and
 maintenance costs are expensed as incurred. Depreciation is
 computed using the straight-line method over the following
 estimated useful lives:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="55%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Computer equipment&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;3 years&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Software&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;3 years&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Furniture&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;10 years&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Laboratory and office equipment&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;5 years&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Leasehold improvements&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 Shorter&amp;#xA0;of&amp;#xA0;lease&amp;#xA0;term&amp;#xA0;or&amp;#xA0;useful&amp;#xA0;life&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Impairment of Long-Lived Assets&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The Company assesses the recoverability of its long-lived assets in
 accordance with the provisions of ASC&amp;#xA0;360, &lt;i&gt;Property, Plant
 and Equipment&lt;/i&gt;. ASC 360 requires that long-lived assets be
 reviewed for impairment whenever events or changes in circumstances
 indicate that the carrying amount of an asset may not be
 recoverable. Recoverability of the long-lived asset is measured by
 a comparison of the carrying amount of the asset to future
 undiscounted net cash flows expected to be generated by the asset
 or asset group. If carrying value exceeds the sum of undiscounted
 cash flows, the Company then determines the fair value of the
 underlying asset group. Any impairment to be recognized is measured
 by the amount by which the carrying amount of the asset group
 exceeds the estimated fair value of the asset group. Assets to be
 disposed of are reported at the lower of the carrying amount or
 fair value, less costs to sell. As of December&amp;#xA0;31, 2014 and
 2013, the Company determined that there were no impaired assets and
 had no assets held-for-sale.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 18pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 &lt;b&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Deferred tax assets and liabilities are determined based on
 differences between the financial reporting and tax basis of assets
 and liabilities and are measured using the enacted tax rates and
 laws that are expected to be in effect when the differences are
 expected to reverse. The effect on deferred tax assets and
 liabilities of a change in tax rates is recognized as income in the
 period that such tax rate changes are enacted. The measurement of a
 deferred tax asset is reduced, if necessary, by a valuation
 allowance if it is more likely than not that some portion or all of
 the deferred tax asset will not be realized. Financial statement
 recognition of a tax position taken or expected to be taken in a
 tax return is determined based on a more-likely-than-not threshold
 of that position being sustained. If the tax position meets this
 threshold, the benefit to be recognized is measured as the largest
 amount that is more likely than not to be realized upon ultimate
 settlement. The Company&amp;#x2019;s policy is to record interest and
 penalties related to uncertain tax positions as a component of
 income tax expense.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Revenues&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 2%; MARGIN-TOP: 6pt"&gt;
 &lt;i&gt;Revenue Recognition&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The Company enters into collaboration and license agreements with
 collaborators for the development of monoclonal antibody-based
 therapeutics to treat cancer and other complex diseases. The terms
 of these agreements contain multiple deliverables which may include
 (i)&amp;#xA0;licenses, or options to obtain licenses, to the
 Company&amp;#x2019;s technological platforms, such as its Fc
 Optimization and Dual-Affinity Re-Targeting (DART) technologies,
 (ii)&amp;#xA0;rights to future technological improvements,
 (iii)&amp;#xA0;research and development activities to be performed on
 behalf of the collaborator or as part of the collaboration, and
 (iv)&amp;#xA0;the manufacture of pre-clinical or clinical materials for
 the collaborator. Payments to the Company under these agreements
 may include nonrefundable license fees, option fees, exercise fees,
 payments for research and development activities, payments for the
 manufacture of pre-clinical or clinical materials, license
 maintenance payments, payments based upon the achievement of
 certain milestones and royalties on product sales. Other benefits
 to the Company of these agreements include the right to sell
 products resulting from the collaborative efforts of the parties in
 specific geographic territories. The Company follows the provisions
 of the FASB ASC Topic 605-25, &lt;i&gt;Revenue
 Recognition&amp;#x2014;Multiple-Element Arrangements&lt;/i&gt;, and ASC Topic
 605-28, &lt;i&gt;Revenue Recognition&amp;#x2014;Milestone Method&lt;/i&gt;, in
 accounting for these agreements. In order to account for these
 agreements, the Company must identify the deliverables included
 within the agreement and evaluate which deliverables represent
 separate units of accounting based on the achievement of certain
 criteria, including whether the delivered element has stand-alone
 value to the collaborator. The consideration received is allocated
 among the separate units of accounting, and the applicable revenue
 recognition criteria are applied to each of the separate units.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 For the periods presented, the Company had the following two types
 of agreements: 1) exclusive development and commercialization
 licenses to use the Company&amp;#x2019;s technology and/or certain other
 intellectual property to develop compounds against specified
 targets (referred to herein as exclusive licenses); and 2)
 Option/research agreements to secure on established terms,
 development and commercialization licenses to therapeutic product
 candidates to collaborator-selected targets developed by the
 Company during an option period (referred to herein as
 right-to-develop agreements).&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 There are no performance, cancellation, termination or refund
 provisions in any of the arrangements that contain material
 financial consequences to the Company.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 2%; MARGIN-TOP: 18pt"&gt;
 &lt;i&gt;Exclusive Licenses&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The deliverables under an exclusive license agreement generally
 include the exclusive license to the Company&amp;#x2019;s DART
 technology with respect to a specified antigen target, and may also
 include deliverables related to rights to future technological
 improvements, research and pre-clinical development activities to
 be performed on behalf of the collaborator. In some cases the
 Company may have an option to participate in the co-development of
 product candidates that result from such agreements.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Generally, exclusive license agreements contain nonrefundable terms
 for payments and, depending on the terms of the agreement, provide
 that the Company will (i)&amp;#xA0;at the collaborator&amp;#x2019;s request,
 provide research and pre-clinical development services at
 negotiated prices which are generally consistent with what other
 third parties would charge, (ii)&amp;#xA0;earn payments upon the
 achievement of certain milestones, (iii)&amp;#xA0;earn royalty
 payments, and (iv)&amp;#xA0;in some cases grant the Company an option
 to participate in the development and commercialization of products
 that result from such agreements. Royalty rates may vary over the
 royalty term depending on the Company&amp;#x2019;s intellectual property
 rights and whether the Company exercises any co-development and
 co-commercialization rights. The Company may provide technical
 assistance and share any technology improvements with its
 collaborators during the term of the collaboration agreements.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company does not directly control when any collaborator will
 achieve milestones or become liable for royalty payments.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 When entering into a new collaboration arrangement or materially
 modifying an existing arrangement, the Company must identify the
 deliverables included within the agreement and evaluate which
 deliverables represent separate units of accounting based on the
 achievement of certain criteria, including whether the delivered
 element has stand-alone value to the collaborator. The selling
 prices of deliverables under an arrangement may be derived using
 third-party evidence (TPE), or a best estimate of selling price
 (BESP), if vendor specific objective evidence (VSOE) is not
 available. The objective of BESP is to determine the price at which
 the Company would transact a sale if the element within the license
 agreement was sold on a standalone basis. Establishing BESP
 involves management&amp;#x2019;s judgment and considers multiple
 factors, including market conditions and company-specific factors,
 including those factors contemplated in negotiating the agreements,
 as well as internally developed models that include assumptions
 related to market opportunity, discounted cash flows, estimated
 development costs, probability of success and the time needed to
 commercialize a product candidate pursuant to the license. In
 validating the BESP, management considers whether changes in key
 assumptions used to determine the BESP will have a significant
 effect on the allocation of the arrangement consideration between
 the multiple deliverables. Deliverables under the arrangement are
 separate units of accounting if (i)&amp;#xA0;the delivered item has
 value to the customer on a standalone basis and (ii)&amp;#xA0;if the
 arrangement includes a general right of return relative to the
 delivered item, delivery or performance of the undelivered item is
 considered probable and substantially within the Company&amp;#x2019;s
 control. The arrangement consideration that is fixed or
 determinable at the inception of the arrangement is allocated to
 the separate units of accounting based on their relative selling
 prices. The appropriate revenue recognition model is applied to
 each element and revenue is accordingly recognized as each element
 is delivered. Management exercises significant judgment in
 determining whether a deliverable is a separate unit of
 accounting.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 In determining the separate units of accounting, the Company
 evaluates whether the exclusive license has standalone value to the
 collaborator based on consideration of the relevant facts and
 circumstances for each arrangement. Factors considered in this
 determination include the research and development capabilities of
 the collaborator and the availability of relevant research
 expertise in the marketplace. In addition, the Company considers
 whether or not (i)&amp;#xA0;the collaborator could use the license for
 its intended purpose without the receipt of the remaining
 deliverables, (ii)&amp;#xA0;the value of the license was dependent on
 the undelivered items and (iii)&amp;#xA0;the collaborator or other
 vendors could provide the undelivered items. If the Company
 concludes that the license has stand-alone value and therefore will
 be accounted for as a separate unit of accounting, the Company then
 determines the estimated selling prices of the license and all
 other units of accounting based on market conditions, similar
 arrangements entered into by third parties, and entity-specific
 factors such as the terms of the Company&amp;#x2019;s previous
 collaboration agreements, recent pre-clinical and clinical testing
 results of therapeutic product candidates that use the
 Company&amp;#x2019;s technology platforms, the Company&amp;#x2019;s pricing
 practices and pricing objectives, the likelihood that technological
 improvements will be made, the likelihood that technological
 improvements made will be used by the Company&amp;#x2019;s collaborators
 and the nature of the research services to be performed on behalf
 of its collaborators and market rates for similar services. Total
 arrangement consideration is then allocated to each of the units of
 accounting using the relative-selling-price method. If facts and
 circumstances dictate that the exclusive license does not have
 stand-alone value, then the related payments are deferred and
 revenue is recognized throughout the period of performance.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Management reassesses the period of performance over which the
 Company recognizes deferred upfront license fees and makes
 adjustments as appropriate in the period in which a change in the
 estimated period of performance is identified. In the event a
 collaborator elects to discontinue development of a specific
 product candidate under a single target license, but retains its
 right to use the Company&amp;#x2019;s technology to develop an
 alternative product candidate to the same target or a target
 substitute, the Company would cease amortization of any remaining
 portion of the upfront fee until there is substantial pre-clinical
 activity on another product candidate and its remaining period of
 substantial involvement can be estimated. In the event that a
 single target license were to be terminated, the Company would
 recognize as revenue any portion of the upfront fee that had not
 previously been recorded as revenue, but was classified as deferred
 revenue, at the date of such termination or through the remaining
 substantial involvement in the wind down of the agreement.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Upfront payments on exclusive licenses may be recognized upon
 delivery of the license if facts and circumstances dictate that the
 license has stand-alone value from the undelivered elements, which
 generally include rights to future technological improvements,
 research services and the manufacture of pre-clinical and clinical
 materials.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company recognizes revenue related to research and pre-clinical
 development services that represent separate units of accounting as
 they are performed, as long as there is persuasive evidence of an
 arrangement, the fee is fixed or determinable, and collection of
 the related receivable is probable. The Company recognizes revenue
 related to the rights to future technological improvements over the
 estimated term of the applicable license.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company typically performs research activities and pre-clinical
 development services, including generating and engineering product
 candidates, on behalf of its licensees during the early evaluation
 and pre-clinical testing stages of drug development under its
 exclusive licenses. The Company records amounts received for
 research materials produced or services performed as revenue from
 collaborative research.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company&amp;#x2019;s license agreements have milestone payments
 which for reporting purposes are aggregated into three categories:
 (i)&amp;#xA0;development milestones, (ii)&amp;#xA0;regulatory milestones,
 and (iii)&amp;#xA0;sales milestones. Development milestones are
 typically payable when a product candidate initiates or advances
 into different clinical trial phases. Regulatory milestones are
 typically payable upon submission for marketing approval with the
 U.S. Food and Drug Administration (FDA) or other countries&amp;#x2019;
 regulatory authorities or on receipt of actual marketing approvals
 for the compound or for additional indications. Sales milestones
 are typically payable when annual sales reach certain levels.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 At the inception of each agreement that includes milestone
 payments, the Company evaluates whether each milestone is
 substantive and at risk to both parties on the basis of the
 contingent nature of the milestone. This evaluation includes an
 assessment of whether (i)&amp;#xA0;the consideration is commensurate
 with either (a)&amp;#xA0;the entity&amp;#x2019;s performance to achieve the
 milestone, or (b)&amp;#xA0;the enhancement of the value of the
 delivered item(s) as a result of a specific outcome resulting from
 the entity&amp;#x2019;s performance to achieve the milestone,
 (ii)&amp;#xA0;the consideration relates solely to past performance and
 (iii)&amp;#xA0;the consideration is reasonable relative to all of the
 deliverables and payment terms within the arrangement. The Company
 evaluates factors such as the scientific, regulatory, commercial
 and other risks that must be overcome to achieve the respective
 milestone, the level of effort and investment required to achieve
 the respective milestone and whether the milestone consideration is
 reasonable relative to all deliverables and payment terms in the
 arrangement in making this assessment.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Non-refundable development and regulatory milestones that are
 expected to be achieved as a result of the Company&amp;#x2019;s efforts
 during the period of substantial involvement are considered
 substantive and are recognized as revenue upon the achievement of
 the milestone, assuming all other revenue recognition criteria are
 met. Milestones that are not considered substantive because the
 Company does not contribute effort to the achievement of such
 milestones are generally achieved after the period of substantial
 involvement and are recognized as revenue upon achievement of the
 milestone, as there are no undelivered elements remaining and no
 continuing performance obligations, assuming all other revenue
 recognition criteria are met.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 2%; MARGIN-TOP: 18pt"&gt;
 &lt;i&gt;Right-to-Develop Agreements&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The Company&amp;#x2019;s right-to-develop agreements provide
 collaborators with an exclusive option to obtain licenses to
 develop and commercialize in specified geographic territories
 product candidates developed by the Company under agreed upon
 research and pre-clinical development product programs. The product
 candidates resulting from each program are all directed to a
 specific target selected by the collaborator. Under these
 agreements, fees may be due to the Company (i)&amp;#xA0;at the
 inception of the arrangement (referred to as &amp;#x201C;upfront&amp;#x201D;
 fees or payments), (ii)&amp;#xA0;the selection of a target for a
 program, (iii)&amp;#xA0;upon the exercise of an option to acquire a
 development and commercialization license (referred to as exercise
 fees or payments earned) for a program, or (iv)&amp;#xA0;some
 combination of all of these fees.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The accounting for right-to-develop agreements is dependent on the
 nature of the options granted to the collaborator. Options are
 considered substantive if, at the inception of a right-to-develop
 agreement, the Company is at risk as to whether the collaborator
 will choose to exercise the options to secure development and
 commercialization licenses. Factors that are considered in
 evaluating whether options are substantive include the overall
 objective of the arrangement, the benefit the collaborator might
 obtain from the agreement without exercising the options, the cost
 to exercise the options relative to the total upfront
 consideration, and the additional financial commitments imposed on
 the collaborator as a result of exercising the options.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 For right-to-develop agreements where the options to secure
 development and commercialization licenses to a product program are
 considered substantive, the Company does not consider the
 development and commercialization licenses to be a deliverable at
 the inception of the agreement, and therefore defers any upfront
 payments received and recognizes this revenue over the period
 during which the collaborator could elect to exercise options for
 development and commercialization licenses. These periods are
 specific to each collaboration agreement. If a collaborator selects
 a target for a product program, any substantive option fee is
 deferred and recognized over the life of the option. For
 right-to-develop agreements that include multiple deliverables, the
 Company determines the selling prices of deliverables under the
 arrangement using TPE or a BESP, if VSOE is not available. The
 objective of BESP is to determine the price at which the Company
 would transact a sale if the element within the right-to-develop
 agreement was sold on a standalone basis. Establishing BESP
 involves management&amp;#x2019;s judgment and considers multiple
 factors, including market conditions and company-specific factors,
 including those factors contemplated in negotiating the agreements,
 as well as internally developed models that include assumptions
 related to market opportunity, discounted cash flows, estimated
 development costs, probability of success and the time needed to
 commercialize a product candidate pursuant to the right-to-develop
 agreement. In validating the BESP, management considers whether
 changes in key assumptions used to determine the BESP will have a
 significant effect on the allocation of the arrangement
 consideration between the multiple deliverables. Deliverables under
 the arrangement are separate units of accounting if (i)&amp;#xA0;the
 delivered item has value to the customer on a standalone basis and
 (ii)&amp;#xA0;if the arrangement includes a general right of return
 relative to the delivered item, delivery or performance of the
 undelivered item is considered probable and substantially within
 the Company&amp;#x2019;s control. The arrangement consideration that is
 fixed or determinable at the inception of the arrangement is
 allocated to the separate units of accounting based on their
 relative selling prices. The appropriate revenue recognition model
 is applied to each element and revenue is accordingly recognized as
 each element is delivered. Management exercises significant
 judgment in determining whether a deliverable is a separate unit of
 accounting.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 If a collaborator exercises an option and acquires a development
 and commercialization license to a product program, the Company
 attributes the exercise fee to the development and
 commercialization license. The Company determines the selling price
 of the option license, upon exercise, through management&amp;#x2019;s
 best estimate using the process for an exclusive license as
 described above.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Upon exercise of an option to acquire a development and
 commercialization license, the Company would also attribute any
 remaining deferred option fee, in addition to the consideration
 received for the license upon exercise of the option, to the
 development and commercialization license. The Company then applies
 the multiple-element revenue recognition criteria to the
 development and commercialization license and other deliverables,
 if any, to determine the appropriate revenue recognition method.
 This model is consistent with the Company&amp;#x2019;s accounting policy
 for upfront payments on exclusive licenses (discussed above). In
 the event a right-to-develop agreement were to be terminated, the
 Company would recognize as revenue any portion of the upfront fee
 that had not previously been recorded as revenue, but was
 classified as deferred revenue, at the date of such termination.
 The Company&amp;#x2019;s right-to-develop agreements have been
 determined to contain substantive options.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 For right-to-develop agreements where the options to secure
 development and commercialization licenses to product programs are
 not considered substantive, the Company considers the development
 and commercialization licenses to be a deliverable at the inception
 of the agreement and applies the multiple-element revenue
 recognition criteria to determine the appropriate revenue
 recognition. The Company does not directly control when any
 collaborator will exercise its options for development and
 commercialization licenses.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Research and Development Costs&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Research and development expenditures are expensed as incurred.
 Research and development costs primarily consist of employee
 related expenses, including salaries and benefits, expenses
 incurred under agreements with contract research organizations,
 investigative sites and consultants that conduct the
 Company&amp;#x2019;s clinical trials, the cost of acquiring and
 manufacturing clinical trial materials and other allocated
 expenses, license fees for and milestone payments related to
 in-licensed products and technologies, stock-based compensation
 expense, and costs associated with non-clinical activities and
 regulatory approvals.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Comprehensive Income (Loss)&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Comprehensive income (loss) is comprised of the net income (loss)
 and other changes in equity that are excluded from net income
 (loss). Comprehensive income (loss) equals net income (loss) for
 the years ended December&amp;#xA0;31, 2014, 2013 and 2012.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Stock-based Compensation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Stock-based payments are accounted for in accordance with the
 provisions of ASC&amp;#xA0;718, &lt;i&gt;Compensation&amp;#x2014;Stock
 Compensation&lt;/i&gt;. The fair value of stock-based payments is
 estimated, on the date of grant, using the Black-Scholes model. The
 resulting fair value is recognized ratably over the requisite
 service period, which is generally the vesting period of the
 option.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 For all time-vesting awards granted, expense is amortized using the
 straight-line attribution method. For awards that contain a
 performance condition, expense is amortized using the accelerated
 attribution method. Recognition of stock-based compensation expense
 is based on the value of the portion of stock-based awards that is
 ultimately expected to vest during the period.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company utilizes the Black-Scholes model for estimating fair
 value of its stock options granted. Option valuation models,
 including the Black-Scholes model, require the input of highly
 subjective assumptions, and changes in the assumptions used can
 materially affect the grant-date fair value of an award. These
 assumptions include the risk-free rate of interest, expected
 dividend yield, expected volatility and the expected life of the
 award.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Net Income (Loss) Per Share&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Basic income (loss) per common share is determined by dividing
 income (loss) attributable to common stockholders by the
 weighted-average number of common shares outstanding during the
 period, without consideration of common stock equivalents. Diluted
 income (loss) per share is computed by dividing the earnings (loss)
 attributable to common stockholders by the weighted-average number
 of common share equivalents outstanding for the period. The
 treasury stock method is used to determine the dilutive effect of
 the Company&amp;#x2019;s stock option grants, potential Employee Stock
 Purchase Plan awards and warrants and the if-converted method is
 used to determine the dilutive effect of the Company&amp;#x2019;s
 preferred stock.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 For the year ended December&amp;#xA0;31, 2012, net income (loss) per
 share was calculated under the two-class method under which all
 earnings (distributed and undistributed) are allocated to each
 class of common stock and participating securities based on their
 respective rights to receive dividends. In the event that the Board
 of Directors declared a dividend payable in cash or other property
 on the then-outstanding shares of common stock, the holders of the
 Series&amp;#xA0;A-1, A-2, B, C, D, and D-2 convertible preferred stock
 would be entitled to receive the amount of dividends per share of
 preferred stock that would be payable on the largest number of
 whole shares of common stock into which each share of preferred
 stock could then be converted. Therefore, the Series A-1, A-2, B,
 C, D and D-2 are participating securities. All of the outstanding
 shares of Series&amp;#xA0;A-1, A-2, B, C, D, and D-2 convertible
 preferred stock converted to common stock upon the consummation of
 the Company&amp;#x2019;s IPO in October 2013.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"&gt;
 Basic and diluted income (loss) per common share is computed as
 follows (in thousands except share and per share data):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="58%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;Year Ended
 December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Net income (loss)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(38,313&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(261&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,362&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Less: undistributed earnings allocated to participating
 securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(8,362&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Net income (loss) allocable to common shares&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(38,313&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(261&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Basic weighted average common shares outstanding&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;27,384,990&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,847,697&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,083,276&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Basic income (loss) per common share&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1.40&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.04&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.00&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Net income (loss)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(38,313&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(261&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,362&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Less: undistributed earnings allocated to participating securities
 and other add-backs to net income (loss)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(8,362&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Net income (loss) allocable to common shares&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(38,313&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(261&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Basic weighted average common shares outstanding&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;27,384,990&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,847,697&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,083,276&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Effect of dilutive securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Diluted weighted average common shares outstanding&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;27,384,990&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,847,697&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,083,276&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Diluted income (loss) per common share&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1.40&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.04&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.00&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The following common stock equivalents were excluded from the
 calculation of diluted net income (loss) per share because their
 effect would be anti-dilutive:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="63%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;Year Ended
 December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Series A-1 Preferred Stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,156,114&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Series A-2 Preferred Stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;392,274&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Series B Preferred Stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,336,037&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Series C Preferred Stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,909,906&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Series D Preferred Stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;769,468&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Series D-2 Preferred Stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,391,991&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Effect of Converted Preferred Stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13,189,920&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Warrants to purchase Series D-2 Preferred Stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;180,784&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Stock Options&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,094,904&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,313,970&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,249,702&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Recently Issued Accounting Standards&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 In May 2014, the FASB issued ASU No.&amp;#xA0;2014-09, &lt;i&gt;Revenue from
 Contracts with Customers&lt;/i&gt; (ASU 2014-09). ASU 2014-09 will
 eliminate transaction- and industry-specific revenue recognition
 guidance under current GAAP and replace it with a principle-based
 approach for determining revenue recognition. ASU 2014-09 will
 require that companies recognize revenue based on the value of
 transferred goods or services as they occur in the contract. The
 ASU also will require additional disclosure about the nature,
 amount, timing and uncertainty of revenue and cash flows arising
 from customer contracts, including significant judgments and
 changes in judgments and assets recognized from costs incurred to
 obtain or fulfill a contract. ASU 2014-09 is effective for annual
 reporting periods beginning after December&amp;#xA0;15, 2016. Early
 adoption is not permitted. Entities can transition to the standard
 either retrospectively or as a cumulative effect adjustment as of
 the date of adoption. Management is currently assessing what effect
 the adoption of ASU 2014-09 will have on the Company&amp;#x2019;s
 consolidated financial statements and accompanying notes.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 In July 2013, the FASB issued ASU No.&amp;#xA0;2013-11, which amended
 ASC Topic 740 regarding presentation of an unrecognized tax benefit
 when a net operating loss (NOL) carryforward, a similar tax loss,
 or a tax credit carryforward exists. The amendments in ASU
 No.&amp;#xA0;2013-11 require an entity to present an unrecognized tax
 benefit as a reduction of a deferred tax asset for an NOL
 carryforward, or similar tax loss or tax credit carryforward,
 rather than as a liability when (1)&amp;#xA0;the uncertain tax position
 would reduce the NOL or other carryforward under the tax law of the
 applicable jurisdiction and (2)&amp;#xA0;the entity intends to use the
 deferred tax asset for that purpose. The ASU does not require new
 recurring disclosures. This amendment was effective prospectively
 for fiscal years beginning after December&amp;#xA0;15, 2013, and did
 not have a material impact on the Company&amp;#x2019;s financial
 statements.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company has evaluated all other ASUs issued through the date
 the consolidated financials were issued and believes that the
 adoption of these will not have a material impact on the
 Company&amp;#x2019;s consolidated financial statements.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
  <us-gaap:SubsequentEventsTextBlock contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" id="id_6848266_F619F4A5-E290-48DF-B197-E35967A843F3_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 &lt;b&gt;13. Subsequent Event&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 In January 2015, the Federal Trade Commission granted early
 termination of the waiting period under the Hart-Scott-Rodino
 Antitrust Improvements Act of 1976 with respect to the
 collaboration and license agreement with Janssen and the stock
 purchase agreement and investor agreement with JJDC (as described
 in Note 8). Accordingly, the Company issued 1,923,077 shares of
 common stock to JJDC and received $75.0 million from JJDC under the
 stock purchase agreement and received the $50.0 million upfront
 payment from Janssen under the collaboration and license
 agreement.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
  <dei:EntityCentralIndexKey contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" id="id_6848266_0E6F3311-D183-4200-9E69-FFDB3EB2AE27_1_2">0001125345</dei:EntityCentralIndexKey>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" id="id_6848266_F5CFB28F-CFD7-4B3F-A7FD-049723FD67C5_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;5. Stock-based Compensation&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 The Company&amp;#x2019;s 2000 Stock Option and Incentive Plan (2000
 Plan) allowed for the grant of awards in respect of an aggregate of
 130,725 shares, which was increased to 150,297 shares, of the
 Company&amp;#x2019;s common stock in the form of incentive stock
 options, non-qualified stock options, stock appreciation rights,
 restricted stock and restricted stock units and other performance
 awards. As of December&amp;#xA0;31, 2014, under the 2000 Plan, there
 were options to purchase an aggregate of 19,705 shares of common
 stock outstanding at a weighted average exercise price of $0.81 per
 share. The 2000 Plan has expired, and no further awards may be
 issued under the plan. Any shares of common stock subject to awards
 under the 2000 Plan that expire, terminate, or are otherwise
 surrendered, canceled, forfeited or repurchased without having been
 fully exercised, or resulting in any common stock being issued,
 will become available for issuance under the 2013 Stock Incentive
 Plan (2013 Plan) up to a specified number of shares.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 Effective February&amp;#xA0;2003, the Company implemented the 2003
 Equity Incentive Plan (2003 Plan), and it was amended and approved
 by the Company&amp;#x2019;s stockholders in 2005. The 2003 Plan
 originally allowed for the grant of awards in respect of an
 aggregate of 2,051,644 shares of the Company&amp;#x2019;s common stock.
 Between 2006 and 2010 the maximum number of shares of common stock
 authorized to be issued by the Company under the 2003 Plan was
 increased by 1,739,116 shares to 3,790,760. During the year ended
 December&amp;#xA0;31, 2012, the maximum number of shares of common
 stock authorized to be issued by the Company under the 2003 Plan
 was increased by 545,970 shares to 4,336,730. Stock options granted
 under the 2003 Plan may be either incentive stock options as
 defined by the Internal Revenue Code (IRC), or non-qualified stock
 options.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 As of December&amp;#xA0;31, 2014, under the 2003 Plan, there were
 options to purchase an aggregate of 2,008,474&amp;#xA0;shares of common
 stock outstanding at a weighted average exercise price of $1.64 per
 share. Upon the completion of the IPO, the 2003 Plan was
 terminated, and no further awards may be issued under the plan. Any
 shares of common stock subject to awards under the 2003 Plan that
 expire, terminate, or are otherwise surrendered, canceled,
 forfeited or repurchased without having been fully exercised, or
 resulting in any common stock being issued, will become available
 for issuance under the 2013 Plan, up to a specified number of
 shares.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 In October 2013, the Company implemented the 2013 Plan. The 2013
 Plan provides for the grant of stock options and other stock-based
 awards, as well as cash-based performance awards. The aggregate
 number of shares of common stock initially available for issuance
 pursuant to awards under the 2013 Plan is 1,960,168 shares. The
 number of shares of common stock reserved for issuance will
 automatically increase on January&amp;#xA0;1 of each year from
 January&amp;#xA0;1, 2014 through and including January&amp;#xA0;1, 2023, by
 the lesser of (a)&amp;#xA0;1,960,168 shares, (b)&amp;#xA0;4.0% of the total
 number of shares of common stock outstanding on December&amp;#xA0;31 of
 the preceding calendar year, or (c)&amp;#xA0;the number of shares of
 common stock determined by the Board of Directors. During the year
 ended December&amp;#xA0;31, 2014, the maximum number of shares of
 common stock authorized to be issued by the Company under the 2013
 Plan was increased to 2,967,272. If an option expires or terminates
 for any reason without having been fully exercised, if any shares
 of restricted stock are forfeited, or if any award terminates,
 expires or is settled without all or a portion of the shares of
 common stock covered by the award being issued, such shares are
 available for the grant of additional awards. However, any shares
 that are withheld (or delivered) to pay withholding taxes or to pay
 the exercise price of an option are not available for the grant of
 additional awards. As of December&amp;#xA0;31, 2014, under the 2013
 Plan, there were options to purchase an aggregate of 1,543,937
 shares of common stock outstanding at a weighted average exercise
 price of $24.22 per share.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 The following stock-based compensation amounts were recognized for
 the periods indicated (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt &apos;Times New Roman&apos;; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="74%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;Year Ended
 December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Research and development&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,562&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;507&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;472&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 General and administrative&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,682&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;355&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;366&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Total stock-based compensation expense&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,244&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;862&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;838&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;i&gt;Employee Stock Options&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 The fair value of each option award is estimated on the date of
 grant using the Black-Scholes option-pricing model using the
 assumptions in the following table:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt &apos;Times New Roman&apos;; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="58%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="5" align="center"&gt;&lt;b&gt;Year Ended December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expected dividend yield&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;0%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;0%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;0%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expected volatility&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;67%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;53%&amp;#xA0;-&amp;#xA0;67%&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;51%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Risk-free interest rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;1.8%&amp;#xA0;-&amp;#xA0;2.3%&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;1.2%&amp;#xA0;-&amp;#xA0;2.2%&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;1.2%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expected term.&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;6.25 years&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;7 years&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;7&amp;#xA0;years&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;Expected Dividend Yield&lt;/b&gt;&amp;#x2014;The Company has never declared
 or paid dividends and has no plans to do so in the foreseeable
 future.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;Expected Volatility&lt;/b&gt;&amp;#x2014;Volatility is a measure of the
 amount by which a financial variable such as a share price has
 fluctuated (historical volatility) or is expected to fluctuate
 (expected volatility) during a period. As the Company does not yet
 have sufficient history of its own volatility, the Company has
 identified several public entities of similar size, complexity and
 stage of development and estimates volatility based on the
 volatility of these companies.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt &apos;Times New Roman&apos;; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;Risk-Free Interest Rate&lt;/b&gt;&amp;#x2014;This is the U.S. Treasury rate
 for the week of each option grant during the year, having a term
 that most closely resembles the expected life of the option.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;Expected Term&lt;/b&gt;&amp;#x2014;This is the period of time that the
 options granted are expected to remain unexercised. Options granted
 have a maximum term of ten years. The Company estimates the
 expected life of the option term to be 6.25 years. The Company uses
 a simplified method to calculate the average expected term.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 In addition to the assumptions above, the Company estimates the
 forfeiture rate based on turnover data with further consideration
 given to the class of the employees to whom the options were
 granted. The forfeiture rate is the estimated percentage of options
 granted that is expected to be forfeited or canceled on an annual
 basis before becoming fully vested.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 The following table summarizes stock option and restricted stock
 unit (RSU) activity for 2014:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt &apos;Times New Roman&apos;; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="43%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Weighted-&lt;br /&gt;
 Average&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Exercise&amp;#xA0;Price&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;Weighted-Average&lt;/font&gt;&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Remaining&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Contractual Term&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;(Years)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Aggregate&lt;br /&gt;
 Intrinsic&lt;br /&gt;
 Value&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;(in&amp;#xA0;thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Outstanding, December&amp;#xA0;31, 2013&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,200,958&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4.90&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.9&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Granted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;976,869&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;27.06&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Exercised&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(568,906&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.31&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Forfeited or expired&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(36,805&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9.76&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Outstanding, December&amp;#xA0;31, 2014&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,572,116&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11.40&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7.3&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;84,515&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 December&amp;#xA0;31, 2014:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Exercisable&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,668,962&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3.24&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5.3&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;53,122&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Vested and expected to vest&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,341,192&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11.03&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7.2&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;80,323&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 During 2014, 2013 and 2012 the Company issued 568,906, 1,268,049
 and 863,176 net shares of common stock, respectively, in
 conjunction with stock option exercises and RSU lapses. The Company
 received cash proceeds from the exercise of stock options of
 approximately $0.7 million, $1.1 million and $47,000 during 2014,
 2013 and 2012, respectively.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 The weighted-average grant-date fair value of options granted
 during 2014, 2013 and 2012 was $17.41,&amp;#xA0;$6.91 and $0.94 per
 share, respectively. The total intrinsic value of options exercised
 during 2014, 2013 and 2012 was approximately $14.5 million, $5.4
 million and $271,929, respectively. The total fair value of stock
 options which vested during 2014, 2013 and 2012 was $3.0 million,
 $487,603 and $879,024, respectively. As of December&amp;#xA0;31, 2014,
 the total unrecognized compensation expense related to non-vested
 stock options and RSUs, net of related forfeiture estimates, was
 $19.6 million, which the Company expects to recognize over a
 weighted-average period of approximately four years.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" id="id_6848266_C6216F2A-8891-45F8-AE33-DCDA887F114E_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"&gt;
 Financial assets and liabilities subject to fair value measurements
 were as follows (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="43%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;Fair Value Measurements at
 December&amp;#xA0;31, 2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Quoted&amp;#xA0;Prices&amp;#xA0;in&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Active Markets&lt;br /&gt;
 for&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Identical Assets&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Significant&amp;#xA0;Other&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Observable&lt;br /&gt;
 Inputs&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Significant&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Unobservable&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Inputs&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Assets:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Cash and cash equivalents&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;131,545&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;131,545&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Money market funds&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;26,046&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;26,046&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Restricted cash&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;300&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;300&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Total Assets&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;157,891&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;157,891&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1pt"&gt;
 &lt;td height="16"&gt;&lt;/td&gt;
 &lt;td height="16" colspan="16"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;Fair Value Measurements at
 December&amp;#xA0;31, 2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Quoted Prices in&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Active Markets&lt;br /&gt;
 for&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Identical Assets&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Significant Other&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Observable&lt;br /&gt;
 Inputs&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Significant&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Unobservable&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Inputs&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Assets:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Cash and cash equivalents&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;90,434&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;90,434&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Money market funds&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;26,047&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;26,047&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Restricted cash&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;405&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;405&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Total Assets&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;116,886&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;116,886&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
  <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" id="id_6848266_D56B35B5-B6C6-4CF7-A9DF-5D56EFA0A9B8_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Impairment of Long-Lived Assets&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The Company assesses the recoverability of its long-lived assets in
 accordance with the provisions of ASC&amp;#xA0;360, &lt;i&gt;Property, Plant
 and Equipment&lt;/i&gt;. ASC 360 requires that long-lived assets be
 reviewed for impairment whenever events or changes in circumstances
 indicate that the carrying amount of an asset may not be
 recoverable. Recoverability of the long-lived asset is measured by
 a comparison of the carrying amount of the asset to future
 undiscounted net cash flows expected to be generated by the asset
 or asset group. If carrying value exceeds the sum of undiscounted
 cash flows, the Company then determines the fair value of the
 underlying asset group. Any impairment to be recognized is measured
 by the amount by which the carrying amount of the asset group
 exceeds the estimated fair value of the asset group. Assets to be
 disposed of are reported at the lower of the carrying amount or
 fair value, less costs to sell. As of December&amp;#xA0;31, 2014 and
 2013, the Company determined that there were no impaired assets and
 had no assets held-for-sale.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" id="id_6848266_8D0E052A-305C-4974-9FD4-E0BD4A96E160_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Recently Issued Accounting Standards&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 In May 2014, the FASB issued ASU No.&amp;#xA0;2014-09, &lt;i&gt;Revenue from
 Contracts with Customers&lt;/i&gt; (ASU 2014-09). ASU 2014-09 will
 eliminate transaction- and industry-specific revenue recognition
 guidance under current GAAP and replace it with a principle-based
 approach for determining revenue recognition. ASU 2014-09 will
 require that companies recognize revenue based on the value of
 transferred goods or services as they occur in the contract. The
 ASU also will require additional disclosure about the nature,
 amount, timing and uncertainty of revenue and cash flows arising
 from customer contracts, including significant judgments and
 changes in judgments and assets recognized from costs incurred to
 obtain or fulfill a contract. ASU 2014-09 is effective for annual
 reporting periods beginning after December&amp;#xA0;15, 2016. Early
 adoption is not permitted. Entities can transition to the standard
 either retrospectively or as a cumulative effect adjustment as of
 the date of adoption. Management is currently assessing what effect
 the adoption of ASU 2014-09 will have on the Company&amp;#x2019;s
 consolidated financial statements and accompanying notes.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 In July 2013, the FASB issued ASU No.&amp;#xA0;2013-11, which amended
 ASC Topic 740 regarding presentation of an unrecognized tax benefit
 when a net operating loss (NOL) carryforward, a similar tax loss,
 or a tax credit carryforward exists. The amendments in ASU
 No.&amp;#xA0;2013-11 require an entity to present an unrecognized tax
 benefit as a reduction of a deferred tax asset for an NOL
 carryforward, or similar tax loss or tax credit carryforward,
 rather than as a liability when (1)&amp;#xA0;the uncertain tax position
 would reduce the NOL or other carryforward under the tax law of the
 applicable jurisdiction and (2)&amp;#xA0;the entity intends to use the
 deferred tax asset for that purpose. The ASU does not require new
 recurring disclosures. This amendment was effective prospectively
 for fiscal years beginning after December&amp;#xA0;15, 2013, and did
 not have a material impact on the Company&amp;#x2019;s financial
 statements.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company has evaluated all other ASUs issued through the date
 the consolidated financials were issued and believes that the
 adoption of these will not have a material impact on the
 Company&amp;#x2019;s consolidated financial statements.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" id="id_6848266_F094D6C9-B6D5-4877-BB7B-8B927F1533BA_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;11. Employee Benefit Plan&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 On September&amp;#xA0;25, 2002, the Company established the MacroGenics
 401(k) Plan (the Plan) for its employees under Section&amp;#xA0;401(k)
 of the IRC. Under this Plan, all employees at least 21 years of age
 are eligible to participate in the Plan, starting on the first day
 of each month. Employees may contribute up to 100% of their salary,
 subject to government maximums.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Employees are 100% vested in their contributions to the Plan. The
 Company&amp;#x2019;s contribution to the Plan, as determined by the
 Board of Directors, is discretionary. The Company&amp;#x2019;s
 contributions to the Plan totaled $318,390, $252,930 and $225,195
 for the years ended December&amp;#xA0;31, 2014, 2013 and 2012,
 respectively.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
  <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" id="id_6848266_F92EA1E1-7264-45DB-B6E5-8E7A9081A082_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;3. Property and Equipment&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Property and equipment consists of the following (in
 thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="71%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Computer equipment&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,596&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,379&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Software&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,683&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,477&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Furniture and office equipment&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;751&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;651&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Lab equipment&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13,917&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11,166&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Leasehold improvements&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,193&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,894&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Property and equipment&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;24,140&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;20,567&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Less accumulated depreciation&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(17,355&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(15,532&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Property and equipment, net&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,785&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,035&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Depreciation expense for the years ended December&amp;#xA0;31, 2014,
 2013 and 2012 was $1.8 million, $1.2 million and $1.0 million,
 respectively.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" unitRef="pure" decimals="2" id="id_6848266_5078EE5D-09E5-4168-A034-4E6683B2BE49_3_1">0.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <dei:DocumentFiscalPeriodFocus contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" id="id_6848266_FAA44042-8554-4DED-B4FD-D076A21A6C07_1_4">FY</dei:DocumentFiscalPeriodFocus>
  <us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" id="id_6848266_A9BFB8B5-4804-48FB-9C2D-AFE9C9E5BA9F_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Accounts Receivable&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Accounts receivable that management has the intent and ability to
 collect are reported in the consolidated balance sheets at
 outstanding amounts, less an allowance for doubtful accounts. The
 Company writes off uncollectible receivables when the likelihood of
 collection is remote.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company evaluates the collectability of accounts receivable on
 a regular basis. The allowance, if any, is based upon various
 factors including the financial condition and payment history of
 customers, an overall review of collections experience on other
 accounts and economic factors or events expected to affect future
 collections experience. No allowance was recorded as of
 December&amp;#xA0;31, 2014 or 2013, as the Company has a history of
 collecting on all outstanding accounts.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
  <us-gaap:ConcentrationRiskCreditRisk contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" id="id_6848266_CEC85403-C6D3-4609-A58A-4E700E199CA1_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Concentration of Credit Risk&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Substantially all of the Company&amp;#x2019;s cash and cash equivalents
 are maintained with major financial institutions in the United
 States. Deposits held with banks may exceed the amount of insurance
 provided on such deposits. Generally, these deposits may be
 redeemed upon demand and, therefore, bear minimal risk.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Financial instruments that potentially subject the Company to
 concentrations of credit risk consist principally of cash and cash
 equivalents, and accounts receivable. The counterparties are
 various corporations, financial institutions and government
 agencies of high credit standing.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 For the years ended December&amp;#xA0;31, 2014, 2013 and 2012, the
 Company&amp;#x2019;s collaboration revenue relates to agreements with
 Takeda Pharmaceutical Company Limited (Takeda), Les Laboratoires
 Servier and Institut de Recherches Servier (collectively, Servier),
 Gilead Sciences, Inc. (Gilead), Boehringer Ingelheim GmbH
 (Boehringer), Pfizer, Inc. (Pfizer), Eli Lilly&amp;#xA0;&amp;amp; Co. (Eli
 Lilly) and Green Cross Corp. (Green Cross). Grant revenue is
 related to contracts and research grants received from U.S.
 government agencies. The majority of the outstanding receivables
 are due from the Company&amp;#x2019;s collaborators and U.S. government
 agencies.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"&gt;
 The following table includes those collaborators that represent
 more than 10% of total revenue earned in the periods indicated:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="66%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"&gt;
 &lt;b&gt;Year&amp;#xA0;Ended&amp;#xA0;December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;2014&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;2013&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;2012&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Servier&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;36.4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;51.6&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;17.3&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Boehringer&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;28.6&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;24.8&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;18.4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Takeda&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;16.8&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Gilead&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11.4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13.8&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Eli Lilly&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.9&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;48.9&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The following table includes those collaborators that represent
 more than 10% of accounts receivable at the date indicated:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="75%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;2014&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;2013&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Servier&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;33.3&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Boehringer&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;21.2&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;12.2&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Green Cross&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;17.9&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Gilead&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;53.4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Pfizer&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;12.3&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
  <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" id="id_6848266_AA70A4D4-25AF-4667-BB33-243648DEB5FE_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Fair Value of Financial Instruments&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The fair market values of the financial instruments included in the
 financial statements, which include cash equivalents and money
 market accounts, approximate their carrying values at
 December&amp;#xA0;31, 2014 and 2013, due to their short-term
 maturities. The Company accounts for recurring and non-recurring
 fair value measurements in accordance with the Financial Accounting
 Standards Board (FASB) Accounting Standards Codification (ASC) 820,
 &lt;i&gt;Fair Value Measurements and Disclosures&lt;/i&gt; (ASC 820). ASC 820
 defines fair value, establishes a fair value hierarchy for assets
 and liabilities measured at fair value, and requires expanded
 disclosures about fair value measurements. The ASC 820 hierarchy
 ranks the quality of reliability of inputs, or assumptions, used in
 the determination of fair value and requires assets and liabilities
 carried at fair value to be classified and disclosed in one of the
 following three categories:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;Level 1&amp;#x2014;Fair value is
 determined by using unadjusted quoted prices that are available in
 active markets for identical assets and liabilities.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;Level 2&amp;#x2014;Fair value is
 determined by using inputs other than Level 1 quoted prices that
 are directly or indirectly observable. Inputs can include quoted
 prices for similar assets and liabilities in active markets or
 quoted prices for identical assets and liabilities in inactive
 markets. Related inputs can also include those used in valuation or
 other pricing models, such as interest rates and yield curves that
 can be corroborated by observable market data.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;Level 3&amp;#x2014;Fair value is
 determined by inputs that are unobservable and not corroborated by
 market data. Use of these inputs involves significant and
 subjective judgments to be made by a reporting entity&amp;#xA0;&amp;#x2013;
 e.g., determining an appropriate adjustment to a discount factor
 for illiquidity associated with a given security.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company evaluates financial assets and liabilities subject to
 fair value measurements on a recurring basis to determine the
 appropriate level at which to classify them each reporting period.
 This determination requires the Company to make subjective
 judgments as to the significance of inputs used in determining fair
 value and where such inputs lie within the ASC 820 hierarchy.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 18pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"&gt;
 Financial assets and liabilities subject to fair value measurements
 were as follows (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="43%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;Fair Value Measurements at
 December&amp;#xA0;31, 2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Quoted&amp;#xA0;Prices&amp;#xA0;in&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Active Markets&lt;br /&gt;
 for&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Identical Assets&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Significant&amp;#xA0;Other&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Observable&lt;br /&gt;
 Inputs&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Significant&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Unobservable&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Inputs&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Assets:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Cash and cash equivalents&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;131,545&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;131,545&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Money market funds&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;26,046&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;26,046&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Restricted cash&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;300&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;300&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Total Assets&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;157,891&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;157,891&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1pt"&gt;
 &lt;td height="16"&gt;&lt;/td&gt;
 &lt;td height="16" colspan="16"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;Fair Value Measurements at
 December&amp;#xA0;31, 2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Quoted Prices in&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Active Markets&lt;br /&gt;
 for&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Identical Assets&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Significant Other&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Observable&lt;br /&gt;
 Inputs&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Significant&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Unobservable&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Inputs&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Assets:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Cash and cash equivalents&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;90,434&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;90,434&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Money market funds&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;26,047&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;26,047&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Restricted cash&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;405&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;405&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Total Assets&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;116,886&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;116,886&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company&amp;#x2019;s Level 1 securities primarily consist of
 restricted cash, cash equivalents and money market funds. The
 Company determines the estimated fair value for its Level 1
 securities using quoted (unadjusted) prices for identical assets or
 liabilities in active markets.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
  <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" id="id_6848266_B6669AB2-99F4-4558-9ADF-5DF30AA5DCE3_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Property and equipment consists of the following (in
 thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="71%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Computer equipment&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,596&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,379&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Software&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,683&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,477&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Furniture and office equipment&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;751&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;651&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Lab equipment&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13,917&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11,166&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Leasehold improvements&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,193&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,894&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Property and equipment&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;24,140&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;20,567&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Less accumulated depreciation&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(17,355&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(15,532&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Property and equipment, net&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,785&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,035&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
  <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" id="id_6848266_8D44353C-F428-4458-97DD-F9E92BBC4C1C_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;7. Lease Exit Liability&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 On July&amp;#xA0;16, 2008, the Company acquired Raven Biotechnologies,
 Inc. (Raven), a private South San Francisco-based company focused
 on the development of monoclonal antibody therapeutics for treating
 cancer. Raven was considered a development-stage enterprise as
 defined in ASC&amp;#xA0;915, &lt;i&gt;Development Stage Entities&lt;/i&gt;. In
 connection with the acquisition, the Company issued 12,466,039
 shares of its Series D convertible preferred stock in exchange for
 all of the outstanding capital stock and convertible notes payable
 of Raven.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company undertook restructuring activities related to the
 acquisition of Raven. These restructuring activities included
 reductions in staffing levels and the intended exit of leased
 facilities. All severance-related payments were completed in the
 year ended December&amp;#xA0;31, 2009.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 In connection with these restructuring activities, as part of the
 cost of acquisition, the Company established a restructuring
 liability attributed to an existing operating lease. The terms of
 the operating lease extend through 2018.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Changes in the lease exit liability are as follows (in
 thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="84%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Accrual balance at December&amp;#xA0;31, 2012.&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#xA0;10,074&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Principal payments&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(629&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Accrual balance at December&amp;#xA0;31, 2013&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9,445&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Principal payments&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1,439&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Accrual balance at December&amp;#xA0;31, 2014&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,006&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Future principal payments to be made under the lease agreement as
 of December&amp;#xA0;31, 2014 are as follows (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="86%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 2015&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,642&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 2016&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,866&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 2017&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,113&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 2018&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,385&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,006&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The purchase agreement provides for a specified total of certain
 contingent milestones that are based on the achievement of certain
 product sales derived from the acquired Raven technology. Also, a
 onetime payment of $5.0 million will be made to the Raven
 stockholders upon the initiation of patient dosing in the first
 Phase 2 clinical trial of any product derived from the Raven
 &amp;#x201C;Cancer Stem Cell Program.&amp;#x201D; No payment shall be made if
 the Phase 2 trial start date has not occurred on or before
 July&amp;#xA0;15, 2018. Other consideration includes a percentage of
 revenue (excluding consideration for research and development and
 equity) received by the Company for license of a product derived
 from the Raven &amp;#x201C;Cancer Stem Cell Program&amp;#x201D; and a onetime
 payment ranging from $8.0 million to $12.0 million dependent upon a
 specified level of sales of products derived from the Raven
 &amp;#x201C;Cancer Stem Cell Program.&amp;#x201D;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"&gt;
 The contingent consideration will be accounted for as additional
 purchase price and recorded as incremental in-process research and
 development expense when it is deemed probable that the
 contingencies will be attained. No additional amounts have been
 recorded during the years ended December&amp;#xA0;31, 2014, 2013 and
 2012.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
  <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" id="id_6848266_1B892D1E-FB9D-488B-9ACA-E9A4EB27D279_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 A reconciliation of the beginning and ending amount of gross
 unrecognized tax benefits is as follows (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="70%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;Year Ended
 December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Beginning balance&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,708&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,592&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,534&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Increases/(decreases) for current year tax positions&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;242&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;116&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;58&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Increases/(decreases) for prior year tax positions&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;97&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Decreases as a result of expiration of statute of limitations&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Ending balance&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,047&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,708&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,592&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" unitRef="shares" decimals="INF" id="id_6848266_01C3FF41-5B4B-4782-A3E1-45AFC051D57A_1_0">568906</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <dei:EntityCurrentReportingStatus contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" id="id_6848266_0E6F3311-D183-4200-9E69-FFDB3EB2AE27_1_5">Yes</dei:EntityCurrentReportingStatus>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" unitRef="shares" decimals="0" id="id_6848266_06A157FB-CCF1-440F-8ABC-76F98DD1AADC_1_3">27384990</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_C276425F-9994-4C60-9006-051FF560D19C_1_2">97000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_BFB39C8D-DAF1-408E-872B-38367E4AE90D_9019_20">76716000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-5" id="id_6848266_6FF767FB-8AC0-4D45-89E1-7828051C94DC_1_3">3000000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
  <us-gaap:RevenueFromGrants contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_C038B40A-B436-460B-B84E-355BF772C2D9_1_2">533000</us-gaap:RevenueFromGrants>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_06A157FB-CCF1-440F-8ABC-76F98DD1AADC_1_7">-38313000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
  <us-gaap:IncomeTaxReconciliationDeductions contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_6F5E51EF-C8FC-4FD4-AB59-C423FE9A715A_1_5">379000</us-gaap:IncomeTaxReconciliationDeductions>
  <us-gaap:SalesRevenueGoodsNet contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" unitRef="iso4217_USD" decimals="INF" id="id_6848266_5AC0A3D5-9392-4E9F-ADBF-602155A2C90D_3_5">0</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:LicenseAndServicesRevenue contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_C038B40A-B436-460B-B84E-355BF772C2D9_1_1">47264000</us-gaap:LicenseAndServicesRevenue>
  <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_436CCE6F-4336-4B5F-8F07-5F706B0B6ECB_1_10">1179000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_C038B40A-B436-460B-B84E-355BF772C2D9_1_8">-38315000</us-gaap:OperatingIncomeLoss>
  <us-gaap:IncomeTaxReconciliationTaxCreditsResearch contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_6F5E51EF-C8FC-4FD4-AB59-C423FE9A715A_1_4">2228000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
  <us-gaap:IncreaseDecreaseInRestrictedCashForOperatingActivities contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_436CCE6F-4336-4B5F-8F07-5F706B0B6ECB_1_9">-105000</us-gaap:IncreaseDecreaseInRestrictedCashForOperatingActivities>
  <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_C276425F-9994-4C60-9006-051FF560D19C_1_1">242000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_C038B40A-B436-460B-B84E-355BF772C2D9_1_9">2000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:Revenues contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_C038B40A-B436-460B-B84E-355BF772C2D9_1_3">47797000</us-gaap:Revenues>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_436CCE6F-4336-4B5F-8F07-5F706B0B6ECB_1_19">3572000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_06A157FB-CCF1-440F-8ABC-76F98DD1AADC_1_2">-38313000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLoss contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_C038B40A-B436-460B-B84E-355BF772C2D9_1_10">-38313000</us-gaap:NetIncomeLoss>
  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_436CCE6F-4336-4B5F-8F07-5F706B0B6ECB_1_7">931000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:IncomeTaxReconciliationTaxCreditsOther contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_6F5E51EF-C8FC-4FD4-AB59-C423FE9A715A_1_7">139000</us-gaap:IncomeTaxReconciliationTaxCreditsOther>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_BFB39C8D-DAF1-408E-872B-38367E4AE90D_9019_19">3244000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_436CCE6F-4336-4B5F-8F07-5F706B0B6ECB_1_24">19000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
  <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_436CCE6F-4336-4B5F-8F07-5F706B0B6ECB_1_8">3239000</us-gaap:IncreaseDecreaseInPrepaidExpense>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-5" id="id_6848266_FA11B785-8CBF-4BB6-ADA5-597BE5495B8F_1_0">1800000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_436CCE6F-4336-4B5F-8F07-5F706B0B6ECB_1_14">3317000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_436CCE6F-4336-4B5F-8F07-5F706B0B6ECB_1_16">1242000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_C038B40A-B436-460B-B84E-355BF772C2D9_1_5">70186000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:IncreaseDecreaseInRestructuringReserve contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_436CCE6F-4336-4B5F-8F07-5F706B0B6ECB_1_13">-1439000</us-gaap:IncreaseDecreaseInRestructuringReserve>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_436CCE6F-4336-4B5F-8F07-5F706B0B6ECB_1_26">41110000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_6F5E51EF-C8FC-4FD4-AB59-C423FE9A715A_1_0">-13410000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_6F5E51EF-C8FC-4FD4-AB59-C423FE9A715A_1_12">0</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:OperatingLeasesRentExpenseNet contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-5" id="id_6848266_81731F1A-1997-4BE2-B6DC-1FBA78F4CD34_1_1">2000000</us-gaap:OperatingLeasesRentExpenseNet>
  <us-gaap:Depreciation contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_436CCE6F-4336-4B5F-8F07-5F706B0B6ECB_1_3">1822000</us-gaap:Depreciation>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_436CCE6F-4336-4B5F-8F07-5F706B0B6ECB_1_25">77441000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_436CCE6F-4336-4B5F-8F07-5F706B0B6ECB_1_22">76716000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_6F5E51EF-C8FC-4FD4-AB59-C423FE9A715A_1_9">756000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
  <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_436CCE6F-4336-4B5F-8F07-5F706B0B6ECB_1_12">4346000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_436CCE6F-4336-4B5F-8F07-5F706B0B6ECB_1_20">-3572000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_436CCE6F-4336-4B5F-8F07-5F706B0B6ECB_1_23">744000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" unitRef="iso4217_USD" decimals="INF" id="id_6848266_21E5900F-6C26-4A8D-A5FF-3358DB02959F_1_0">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
  <us-gaap:CostsAndExpenses contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_C038B40A-B436-460B-B84E-355BF772C2D9_1_7">86112000</us-gaap:CostsAndExpenses>
  <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_6F5E51EF-C8FC-4FD4-AB59-C423FE9A715A_1_1">-1608000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_C038B40A-B436-460B-B84E-355BF772C2D9_1_6">15926000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_436CCE6F-4336-4B5F-8F07-5F706B0B6ECB_1_11">-1500000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_436CCE6F-4336-4B5F-8F07-5F706B0B6ECB_1_4">3244000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-5" id="id_6848266_6FF767FB-8AC0-4D45-89E1-7828051C94DC_1_2">14500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" unitRef="iso4217_USD" decimals="INF" id="id_6848266_AC57A800-8787-4A43-9539-9C416E3C9097_1_0">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
  <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" unitRef="iso4217_USD" decimals="0" id="id_6848266_3D6479E8-FC85-4E73-B9C2-F899F5DFB6A0_2_3">318390</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
  <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_6F5E51EF-C8FC-4FD4-AB59-C423FE9A715A_1_11">14920000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:IncomeTaxReconciliationOtherReconcilingItems contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_6F5E51EF-C8FC-4FD4-AB59-C423FE9A715A_1_8">-382000</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
  <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_C276425F-9994-4C60-9006-051FF560D19C_1_3">0</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
  <mgnx:ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" id="id_6848266_F6086DEA-4108-4345-9687-C741738EB53D_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The following table summarizes stock option and restricted stock
 unit (RSU) activity for 2014:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="43%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Weighted-&lt;br /&gt;
 Average&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Exercise&amp;#xA0;Price&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;Weighted-Average&lt;/font&gt;&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Remaining&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Contractual Term&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;(Years)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Aggregate&lt;br /&gt;
 Intrinsic&lt;br /&gt;
 Value&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;(in&amp;#xA0;thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Outstanding, December&amp;#xA0;31, 2013&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,200,958&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4.90&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.9&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Granted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;976,869&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;27.06&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Exercised&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(568,906&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.31&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Forfeited or expired&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(36,805&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9.76&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Outstanding, December&amp;#xA0;31, 2014&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,572,116&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11.40&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7.3&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;84,515&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 December&amp;#xA0;31, 2014:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Exercisable&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,668,962&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3.24&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5.3&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;53,122&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Vested and expected to vest&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,341,192&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11.03&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7.2&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;80,323&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</mgnx:ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock>
  <mgnx:PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" id="id_6848266_207EFCF1-701A-4DF6-BE55-0D4800661B73_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Repairs and maintenance costs are expensed as incurred.
 Depreciation is computed using the straight-line method over the
 following estimated useful lives:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="55%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Computer equipment&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;3 years&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Software&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;3 years&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Furniture&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;10 years&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Laboratory and office equipment&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;5 years&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Leasehold improvements&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 Shorter&amp;#xA0;of&amp;#xA0;lease&amp;#xA0;term&amp;#xA0;or&amp;#xA0;useful&amp;#xA0;life&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</mgnx:PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock>
  <mgnx:IncomeTaxReconciliationStateDeferredTaxesAdjustments contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_6F5E51EF-C8FC-4FD4-AB59-C423FE9A715A_1_3">-3034000</mgnx:IncomeTaxReconciliationStateDeferredTaxesAdjustments>
  <mgnx:DefinedContributionPlanEmployeesContributionAnnualVestingPercentage contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" unitRef="pure" decimals="INF" id="id_6848266_3D6479E8-FC85-4E73-B9C2-F899F5DFB6A0_2_2">1.00</mgnx:DefinedContributionPlanEmployeesContributionAnnualVestingPercentage>
  <mgnx:BusinessMergerEffectiveDate contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" id="id_6848266_E6816035-D3BF-4170-9184-CEA849A43957_1_0">2014-12-22</mgnx:BusinessMergerEffectiveDate>
  <mgnx:CollaborationAndLicenseAgreementsDisclosureTextBlock contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" id="id_6848266_4A039608-0476-414D-A21E-CEF7E0F9919E_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;8. Collaboration and License Agreements&lt;/b&gt;&lt;/p&gt;
 &lt;!-- xbrl,body --&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 &lt;b&gt;&lt;i&gt;Janssen Biotech, Inc.&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 In December 2014, the Company entered into a collaboration and
 license agreement with Janssen Biotech, Inc. (Janssen) for the
 development and commercialization of MGD011, a product candidate
 that incorporates the Company&amp;#x2019;s proprietary DART technology
 to simultaneously target CD19 and CD3 for the potential treatment
 of B-cell malignancies. The Company contemporaneously entered into
 a stock purchase agreement and investor agreement, each with
 Johnson&amp;#xA0;&amp;amp; Johnson Innovation&amp;#x2014;JJDC, Inc. (JJDC), an
 affiliate of Janssen, under which JJDC agreed to purchase 1,923,077
 new shares of the Company&amp;#x2019;s common stock at a price of $39.00
 per share, representing proceeds of $75.0 million. The
 effectiveness of these agreements was subject to the early
 termination or expiration of any applicable waiting periods under
 Hart-Scott-Rodino Antitrust Improvements Act of 1976, which
 occurred in January 2015 (see Note 13). The Company is eligible to
 receive a $50.0 million upfront payment from Janssen after the
 collaboration and license agreement becomes effective. Janssen will
 be fully responsible for developing MGD011 following submission of
 the Investigational New Drug Application (IND), which is planned
 for 2015. Assuming successful development and commercialization,
 the Company could receive up to an additional $575.0 million in
 clinical, regulatory and commercialization milestone payments. The
 Company may elect to fund a portion of late-stage clinical
 development in exchange for a profit share in the U.S. and Canada.
 If commercialized, the Company would be eligible to receive
 double-digit royalties on any global net sales and has the option
 to co-promote the molecule with Janssen in the U.S.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 No revenue was recognized during the year ended December&amp;#xA0;31,
 2014 under this agreement, and no related deferred revenue was
 recorded as of December&amp;#xA0;31, 2014.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Takeda&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 In May 2014, the Company entered into a license and option
 agreement with Takeda for the development and commercialization of
 MGD010, a product candidate that incorporates the Company&amp;#x2019;s
 proprietary DART technology to simultaneously engage CD32B and
 CD79B, which are two B-cell surface proteins. MGD010 is currently
 in pre-clinical development for the treatment of autoimmune
 diseases. Upon execution of the agreement, Takeda made a
 non-refundable payment of $15.0 million to the Company. Takeda has
 an option to obtain an exclusive worldwide license for MGD010
 following the completion of a pre-defined Phase 1a study. The
 Company will lead all product development activities until that
 time. If Takeda exercises its option, it will assume responsibility
 for future development and pay the Company a license option fee
 that, along with an early development milestone, will total $18.0
 million. Assuming successful development and commercialization of
 MGD010, the Company is eligible to receive up to an additional
 $468.5 million in development, regulatory and sales milestone
 payments. If commercialized, the Company would receive double-digit
 royalties on any global net sales and has the option to co-promote
 MGD010 with Takeda in the United States. Finally, the Company may
 elect to fund a portion of Phase 3 clinical development in exchange
 for a North American profit share.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company evaluated the license and option agreement with Takeda
 and has determined that it is a revenue arrangement with multiple
 deliverables, or performance obligations. The Company&amp;#x2019;s
 substantive performance obligations under the license and option
 agreement include exclusivity, research and development services
 through the Phase 1a study and delivery of a future license for an
 initial research compound. The Company concluded that the MGD010
 option is substantive and that the license fee payable upon
 exercise of the option is not a deliverable at the inception of the
 arrangement as there is considerable uncertainty that the option
 would be exercised. The Company has determined that each potential
 future development and regulatory milestone is substantive.
 Although sales milestones are not considered substantive, they are
 still recognized upon achievement of the milestone (assuming all
 other revenue recognition criteria have been met) because there are
 no undelivered elements that would preclude revenue recognition at
 that time. The Company determined that these performance
 obligations represent a single unit of accounting, because the
 exclusivity clause does not have stand-alone value to Takeda
 without the Company&amp;#x2019;s technical expertise and development
 through the pre-defined Phase 1a study.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 After identifying the deliverables included within the arrangement,
 the Company determined its best estimate of selling price. The
 Company allocated $10.0 million to the exclusivity clause to its
 technology and the research and development services and $5.0
 million to the exclusive license for the initial research compound.
 The Company&amp;#x2019;s determination of best estimate of selling price
 for the research and development services relied upon other similar
 transactions. The Company relied upon the income approach (e.g.,
 future cash flows) to determine the value of the license of the
 to-be-delivered compound along with other similar license
 transactions with differing indications but similar stage of
 development. The portion of the up-front fee allocated to the
 MGD010 option is being recognized over an initial 24-month period,
 which represents the expected period of development through the
 completion of a pre-defined Phase 1a study. The portion of the
 up-front fee allocated to the license for the initial research
 compound was deferred until the research collaboration and license
 option agreement was executed and the license delivered.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company recognized revenue of approximately $3.0 million under
 the MGD010 agreement during the year ended December&amp;#xA0;31, 2014.
 At December&amp;#xA0;31, 2014, $7.1 million of revenue was deferred
 under this agreement, $5.0 million of which was current and $2.1
 million of which was non-current.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 In September 2014, the Company and Takeda executed a research
 collaboration and license option agreement, which formalized the
 license for the initial research compound. Under the terms of the
 agreement, Takeda may identify up to three additional compounds,
 which will be subject to separate research and development plans.
 The Company determined that it could recognize the entire license
 fee as (1)&amp;#xA0;the executed contract constituted persuasive
 evidence of an arrangement, (2)&amp;#xA0;the delivery of the license
 occurred and the Company had no current or future performance
 obligations, (3)&amp;#xA0;the total consideration for the license was
 fixed and known at the time of its execution and there were not any
 extended payment terms or rights of return, and (4)&amp;#xA0;the cash
 was received. Therefore, the Company recognized $5.0 million in
 revenue during the year ended December&amp;#xA0;31, 2014 under this
 agreement. The Company is also entitled to receive reimbursements
 for research and development services provided to Takeda with
 respect to the initial research compound, subject to the execution
 of a separate research plan.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Gilead&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 In January 2013, the Company entered into an agreement with Gilead
 for Gilead to obtain exclusive worldwide rights for the research,
 development and commercialization of up to four DART molecules. For
 each molecule Gilead chooses to develop, the Company is entitled to
 receive a license grant fee of $7.5 million and is further eligible
 to receive up to an additional $20.0 million to $25.0 million in
 pre-clinical milestones and up to $240.0 million to $250.0 million
 in additional clinical, regulatory and sales milestones. Upon
 execution of the arrangement, Gilead identified one molecule to
 develop for which the Company granted Gilead a license in exchange
 for consideration of $7.5 million.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company determined that any remaining licenses are conditional
 deliverables, which are substantive options that were not granted
 with a substantial discount. The Company has determined that each
 potential future clinical, development and regulatory milestone is
 substantive. Although sales milestones are not considered
 substantive, they are still recognized upon achievement of the
 milestone (assuming all other revenue recognition criteria have
 been met) because there are no undelivered elements that would
 preclude revenue recognition at that time. Gilead also provides
 funding for the Company&amp;#x2019;s internal and external research
 costs under the agreement. Additionally, Gilead would be obligated
 to pay the Company high single digit to low double digit royalties
 on product sales.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company evaluated the research collaboration agreement with
 Gilead and has determined that it is a revenue arrangement with
 multiple deliverables, or performance obligations. The
 Company&amp;#x2019;s substantive performance obligations under this
 research collaboration include a license to its technology and
 research and development services. The Company concluded that the
 deliverables do not have stand alone value and therefore, represent
 a combined single unit of accounting. Due to the lack of standalone
 value for the license and research and development services, the
 combined unit of accounting (the upfront payment and the expected
 research and development reimbursements) was recognized ratably
 over a period of 21 months, which represented the expected
 development period.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company and Gilead have also agreed to establish a joint
 research committee to facilitate the governance and oversight of
 the parties&amp;#x2019; activities under the agreements. Management
 considered whether participation on the joint committee may be a
 deliverable and determined that it was not a deliverable. Had
 management considered participation on the joint committee as a
 deliverable, it would not have had a material impact on the
 accounting for the arrangement.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company recognized revenues of approximately $5.5 million and
 $8.0 million under this agreement for the years ended
 December&amp;#xA0;31, 2014 and 2013, respectively. No milestones have
 been achieved under this agreement.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 At December&amp;#xA0;31, 2013, $3.6 million of revenue was deferred
 under this agreement, all of which was current. As of
 December&amp;#xA0;31, 2014, there was no remaining deferred revenue
 under this agreement.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Servier&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 In November 2011, the Company entered into a right-to-develop
 collaboration agreement with Servier for the development and
 commercialization of MGA271 in all countries other than the United
 States, Canada, Mexico, Japan, South Korea and India.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Upon execution of the agreement, Servier made a nonrefundable
 payment of $20.0 million to the Company. The Company is eligible to
 receive up to $30.0 million in license grant fees, $47.0 million in
 clinical milestone payments, $140.0 million in regulatory milestone
 payments and $208.0 million in sales milestone payments if Servier
 exercises the option, obtains regulatory approval for and
 successfully commercializes MGA271. The Company concluded that the
 license option fees are not deliverables at the inception of the
 arrangement. The Company has determined that each potential future
 clinical, development and regulatory milestone is substantive.
 Although sales milestones are not considered substantive, they are
 still recognized upon achievement of the milestone (assuming all
 other revenue recognition criteria have been met) because there are
 no undelivered elements that would preclude revenue recognition at
 that time. In the event Servier exercises its option to continue
 development of MGA271, Servier must pay a license option fee. Under
 this agreement, Servier would be obligated to pay the Company from
 low double digit to mid-teen royalties on product sales in its
 territories.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company evaluated the research collaboration agreement with
 Servier and has determined that it is a revenue arrangement with
 multiple deliverables, or performance obligations. The Company
 concluded that the option is substantive and that the license fees
 for this option is not a deliverable at the inception of the
 arrangement as there is considerable uncertainty that the option
 would be exercised and the additional fee to be paid upon exercise
 of the option represents its estimated selling price (i.e. no
 substantial discount was given). The Company&amp;#x2019;s substantive
 performance obligations under this research collaboration include
 an exclusivity clause to its technology, technical, scientific and
 intellectual property support to the research plan and
 participation on an executive committee and a research and
 development committee. The Company determined that these
 performance obligations represent a single unit of accounting,
 since the license does not have stand-alone value to Servier
 without the Company&amp;#x2019;s technical expertise and committee
 participation. As such, the initial upfront payment was deferred
 and was being recognized ratably over the initial 27-month period,
 which represented the expected period of development and the
 Company&amp;#x2019;s participation on the research and development
 committee. During 2014, the Company determined that the development
 period will last longer than originally estimated, and
 prospectively adjusted its period of recognition of the upfront
 payment to a 42-month period.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 During the years ended December&amp;#xA0;31, 2014, 2013 and 2012 the
 Company recognized revenue of $0.7&amp;#xA0;million, $21.3 million and
 $9.1 million, respectively, under this agreement. Revenue
 recognized in the year ended December&amp;#xA0;31, 2013 included a
 $10.0 million substantive milestone payment received upon dosing
 the first patient in a Phase 1 dose expansion cohort trial of
 MGA271.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 At December&amp;#xA0;31, 2014 and 2013, $0.1 million and $0.9 million
 of revenue remained deferred under this agreement, respectively,
 all of which was current.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 In September 2012, the Company entered into a second
 right-to-develop collaboration agreement with Servier and granted
 it options to obtain three separate exclusive licenses to develop
 and commercialize DART-based molecules, consisting of those
 designated by the Company as MGD006 and MGD007, as well as a third
 DART molecule, in all countries other than the United States,
 Canada, Mexico, Japan, South Korea and India.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Upon execution of the agreement, Servier made a nonrefundable
 payment of $20.0 million to the Company. In addition, the Company
 will be eligible to receive up to $65.0 million in license grant
 fees, $98.0 million in clinical milestone payments, including $5.0
 million upon IND acceptance for each of MGD006, MGD007 and a third
 DART molecule, $300.0 million in regulatory milestone payments and
 $630.0 million in sales milestone payments if Servier exercises all
 of the options and successfully develops, obtains regulatory
 approval for, and commercializes a product under each license. In
 addition to these milestones, the Company and Servier will share
 Phase 2 and Phase 3 development costs. The Company has determined
 that each potential future clinical, development and regulatory
 milestone is substantive. Although sales milestones are not
 considered substantive, they are still recognized upon achievement
 of the milestone (assuming all other revenue recognition criteria
 have been met) because there are no undelivered elements that would
 preclude revenue recognition at that time. Under this agreement,
 Servier would be obligated to pay the Company between high-single
 digit and mid-teen royalties on net product sales in its
 territories.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company evaluated the research collaboration agreement with
 Servier and has determined that it is a revenue arrangement with
 multiple deliverables, or performance obligations. The Company
 concluded that each option is substantive and that the license fees
 for each option are not deliverables at the inception of the
 arrangement and were not issued with a substantial discount. The
 Company&amp;#x2019;s substantive performance obligations under this
 research collaboration include an exclusivity clause to its
 technology, technical, scientific and intellectual property support
 to the research plan during the first year of the agreement and
 participation on an executive committee and a research and
 development committee. The Company determined that the performance
 obligations with respect to the pre-clinical development represent
 a single unit of accounting, since the license does not have
 stand-alone value to Servier without the Company&amp;#x2019;s technical
 expertise and committee participation. As such, the initial upfront
 license payment was deferred and initially recognized ratably over
 a &lt;font style="WHITE-SPACE: nowrap"&gt;29-month&lt;/font&gt; period, which
 represented the expected development period. During 2014, the
 Company and Servier further refined the research plan related to
 the three DARTs and as such, the development period was extended.
 Based on this revised development period, the Company prospectively
 adjusted its period of recognition of the upfront payment to a
 75-month period. The impact of this change in accounting estimate
 reduced revenue that would have been recognized in 2014 by $3.7
 million.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 During the year ended December&amp;#xA0;31, 2014, Servier exercised its
 exclusive option to develop and commercialize MGD006. As a result
 of the exercise, the Company received a $15.0 million payment from
 Servier for its license to develop and commercialize MGD006 in its
 territories. Upon exercise of the option, the Company evaluated its
 performance obligations with respect to the license for MGD006. The
 Company&amp;#x2019;s substantive performance obligations under this
 research collaboration include an exclusive license to its
 technology, technical, scientific and intellectual property support
 to the research plan and participation on an executive committee
 and a research and development committee. The Company determined
 that the performance obligations with respect to the clinical
 development represent a single unit of accounting, since the
 license does not have stand-alone value to Servier without the
 Company&amp;#x2019;s technical expertise and committee participation. As
 such, the $15.0 million license fee was deferred and is being
 recognized ratably over a period of 82 months, which represents the
 expected development period for MGD006. In accordance with the
 agreement, the Company and Servier will share costs incurred to
 develop MGD006. Reimbursement of research and development expenses
 received in connection with this collaborative cost-sharing
 agreement is recorded as a reduction to research and development
 expense. During the year ended December&amp;#xA0;31, 2014 the Company
 recorded approximately $1.0 million as an offset to research and
 development costs under this collaboration arrangement. No such
 offset was recorded in 2013 or 2012. As of December&amp;#xA0;31, 2014
 the Company has a corresponding collaboration receivable, which is
 included in accounts receivable on the consolidated balance sheet,
 of $0.8 million.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 During the years ended December&amp;#xA0;31, 2014, 2013 and 2012 the
 Company recognized revenue of $16.7&amp;#xA0;million, $8.6 million, and
 $2.0 million, respectively, under this agreement. Revenue during
 the year ended December&amp;#xA0;31, 2014 includes two $5.0 million
 milestone payments from Servier upon the achievement of clinical
 milestones related to the IND applications for MGD006 and MGD007
 clearing the 30-day review period by the U.S. FDA. No milestones
 were recognized under this agreement during the years ended
 December&amp;#xA0;31, 2013 or 2012.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 At December&amp;#xA0;31, 2014, $17.7 million of revenue was deferred
 under this agreement, $3.3 million of which was current and $14.4
 million of which was long-term. At December&amp;#xA0;31, 2013, $9.4
 million of revenue was deferred under this agreement, $8.6 million
 of which was current and $0.8 million of which was long-term.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Boehringer&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 In October 2010 the Company entered into a collaboration and
 license agreement with Boehringer to discover, develop and
 commercialize up to ten DART-based molecules which span multiple
 therapeutic areas. Under the terms of the agreement, the Company
 granted Boehringer an exclusive, worldwide, royalty-bearing,
 license under its intellectual property to research, develop, and
 market DARTs generated under the agreement throughout the
 world.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Upon execution of the agreement, the Company received an upfront
 payment of $15.0 million. The Company subsequently received three
 annual maintenance payments. These maintenance payments are being
 recognized over the estimated period of development. The Company
 has the potential to earn milestone payments of approximately $41.0
 million related to pre-clinical and clinical development, $89.0
 million related to regulatory milestones and $83.0 million related
 to sales milestones for each of the DART programs under this
 agreement in the case of full commercial success of multiple DART
 products. The Company has determined that each potential future
 clinical, development and regulatory milestone is substantive.
 Although sales milestones are not considered substantive, they are
 still recognized upon achievement of the milestone (assuming all
 other revenue recognition criteria have been met) because there are
 no undelivered elements that would preclude revenue recognition at
 that time. Boehringer also provides funding for the Company&amp;#x2019;s
 internal and external research costs and is required to pay the
 Company mid-single digit royalties on product sales.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company determined that the deliverables under the Boehringer
 agreement include the license, the research and development
 services to be performed by the Company, and the
 co-promotion/manufacturing services. The Company concluded that the
 co-promotional activities were optional and were subject to further
 negotiation upon reaching regulatory approval. As such, the
 co-promotional period is not included in the expected obligation
 period to perform services.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company concluded that the undelivered element of research and
 development services had fair value. The Company concluded that the
 license does not have value on a standalone basis (e.g. absent the
 provision of the research and development services) and therefore
 does not represent a separate unit of accounting. The Company
 concluded that because the drug candidate has not yet been
 developed, the license is of no value to Boehringer without the
 ensuing research and development activities using the DART
 technology, which is proprietary to the Company. Likewise,
 Boehringer could not sell the license to another party (without the
 Company agreeing to provide the research and development activities
 for the other party). Therefore, the upfront license fee and
 research and development services were treated as a combined unit
 of accounting and recognized over the expected obligation period
 associated with the research and development services through
 September 2015, which represents the estimated period of
 development.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company and Boehringer have also agreed to establish a joint
 research committee to facilitate the governance and oversight of
 the parties&amp;#x2019; activities under the agreements. Management
 considered whether participation on the joint committee may be a
 deliverable and determined that it was not a deliverable. However,
 had management considered participation on the joint committee as a
 deliverable, it would not have had a material impact on the
 accounting for the arrangement as the period of participation in
 this committee matched the obligation period for the research and
 development services.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company recognized revenues of approximately $13.7 million,
 $14.4 million and $11.7 million during the years ended
 December&amp;#xA0;31, 2014, 2013 and 2012, respectively, under this
 agreement. Revenue recognized in the years ended December&amp;#xA0;31,
 2014, 2013 and 2012 included milestone payments of $2.0 million,
 $5.0 million and $2.0 million, respectively, for the achievement of
 clinical milestones. At December&amp;#xA0;31, 2014, $5.8 million of
 revenue was deferred under this agreement, all of which was
 current. At December&amp;#xA0;31, 2013, $12.8 million of revenue was
 deferred under this agreement, $7.0 million of which was current
 and $5.8 million of which was long-term.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Pfizer&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 In October 2010, the Company entered into a three year agreement
 with Pfizer to discover, develop and commercialize up to two
 DART-based molecules. The Company granted Pfizer a non-exclusive
 worldwide, royalty-bearing license and received an upfront payment
 of $5.0 million and has received milestone payments and funding for
 the Company&amp;#x2019;s internal and external research costs under the
 agreement.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company is eligible to receive milestone payments of
 approximately $17.0 million related to pre-clinical and clinical
 development and $195.0 million related to commercialization and
 sales milestones for each DART program under this agreement. The
 Company has determined that each potential future technical and
 development milestone is substantive. Although sales milestones are
 not considered substantive, they are still recognized upon
 achievement of the milestone (assuming all other revenue
 recognition criteria have been met) because there are no
 undelivered elements that would preclude revenue recognition at
 that time. Pfizer is responsible for all pre-clinical and clinical
 development costs for the program. In addition, Pfizer is required
 to pay the Company mid-single digit to low-teen royalties on
 product sales. Under this collaboration, one DART program is
 currently being pursued and the Company completed its research
 obligations under this program in January 2014.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company has evaluated the research collaboration agreement with
 Pfizer and has determined that it is a revenue arrangement with
 multiple deliverables, or performance obligations. The
 Company&amp;#x2019;s substantive performance obligations under this
 research collaboration include an exclusive license to its
 technology, research and development services and manufacturing
 services. The Company concluded that the manufacturing services
 were optional and were subject to further negotiation upon reaching
 regulatory approval. As such, the manufacturing services are not
 included in the expected obligation period to perform services.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company determined that it had fair value of the undelivered
 element of the research and development services. However, the
 Company concluded that the license does not have value on a
 standalone basis (e.g. absent the provision of the research and
 development services) and therefore does not represent a separate
 unit of accounting. Facts that were considered included the
 development of the candidate noting that because the drug candidate
 has not yet been developed, the license is of no value to Pfizer
 without the ensuing research and development activities using the
 DART technology, which is proprietary to the Company. Likewise,
 Pfizer could not sell the license to another party (without the
 Company agreeing to provide the research and development activities
 for the other party). Therefore, the upfront license fee and
 research and development services were treated as a combined unit
 of accounting and recognized over the expected obligation period
 associated with the research and development services through
 January 2014, which represents the estimated period of
 development.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The $5.0 million upfront payment received by the Company is
 non-refundable; therefore, there is no right of return for the
 license. The Company recognized revenue associated with this
 non-refundable up-front license fee through the expected obligation
 period associated with the research and development services, which
 ended in January 2014.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company and Pfizer have also agreed to establish a joint
 research committee to facilitate the governance and oversight of
 the parties&amp;#x2019; activities under the agreements. Management
 considered whether participation on the joint committee may be a
 deliverable and determined that it was not a deliverable because it
 is a participating right and not an obligation of the Company.
 However, had management considered participation on the joint
 committee as a deliverable, it would not have had a material impact
 on the accounting for the arrangement.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company recognized revenues of approximately $0.1 million, $3.5
 million and $5.5 million during the years ended December&amp;#xA0;31,
 2014, 2013 and 2012, respectively. Included in the 2012 revenues
 are milestone payments totaling $0.5 million. No additional
 milestones have been achieved under this agreement through
 December&amp;#xA0;31, 2014.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 At December&amp;#xA0;31, 2013, deferred revenue under this agreement
 was approximately $7,000. As of December&amp;#xA0;31, 2014, there was
 no remaining deferred revenue under this agreement.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Green Cross&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 In June&amp;#xA0;2010, the Company entered into a collaboration
 agreement with Green Cross for the development of the
 Company&amp;#x2019;s anti-HER2 antibody margetuximab. This arrangement
 grants Green Cross an exclusive license to conduct specified Phase
 1 and Phase 2 clinical trials and commercialize margetuximab in
 South Korea. In March 2014, the Company and Green Cross entered
 into an amendment to the original agreement, causing the terms of
 the original agreement to be materially modified.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Upon execution of the amendment, the Company became eligible to
 receive reimbursement for costs incurred for Phase 2 and Phase 3
 clinical trials up to $5.5 million as well as clinical development
 and commercial milestone payments of up to $2.5 million. The
 Company has determined that each potential clinical development and
 commercial milestone is substantive. The Company is also entitled
 to receive royalties on net sales of margetuximab in South Korea.
 The Company and Green Cross have formed a joint steering committee
 to coordinate and oversee activities on which the companies
 collaborate under the agreement.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company has evaluated the collaboration agreement with Green
 Cross and has determined that it is a revenue arrangement with
 multiple deliverables or performance obligations. As a result of
 the material modification to the arrangement in March 2014, the
 Company reassessed the entire arrangement in accordance with the
 guidance provided by ASC 605-25, &lt;i&gt;Multiple Element Arrangements
 (Revenue Recognition)&lt;/i&gt; as the original agreement was accounted
 for prior to adopting ASU 2009-13&lt;i&gt;.&lt;/i&gt; The Company&amp;#x2019;s
 substantive performance obligations under this agreement include an
 exclusive license to its technologies, research and development
 services, and participation in a joint steering committee. The
 Company concluded that the license and the reimbursements for
 research and development services do not have value on a standalone
 basis and therefore do not represent a separate unit of
 accounting.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The initial $1.0 million upfront payment received by the Company
 upon execution of the original agreement is non-refundable; as
 such, there is no right of return for the license. Therefore, the
 upfront license fee and participation on the joint steering
 committee were treated as a combined unit of accounting and will be
 recognized over the term of the agreement through June 2020.
 Further, due to the fact the research and development services are
 not deemed to have stand-alone value, revenue for those services
 should be recognized over the entire term of the agreement (through
 June 2020). As a result of reassessing the arrangement in
 accordance with ASC 605-25, the Company was required to record an
 adjustment on the date of the material modification to reflect the
 revenue that would have resulted had the entity applied the
 requirements of ASC 605-25 from the inception of the agreement. As
 a result, the Company recorded an additional $1.3 million of
 revenue during 2014.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company recognized revenues of approximately $1.7 million and
 $100,000 under this agreement during the years ended
 December&amp;#xA0;31, 2014 and 2013, respectively. No milestones were
 achieved under this agreement during the years ended
 December&amp;#xA0;31, 2014 and 2013.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 At December&amp;#xA0;31, 2014, there was a $525,000 unbilled receivable
 balance under this agreement, which is included in other assets on
 the consolidated balance sheet. At December&amp;#xA0;31, 2013, $650,000
 of revenue was deferred under this agreement, $100,000 of which was
 current and $550,000 of which was non-current.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Eli Lilly&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 In October&amp;#xA0;2007, the Company entered into an exclusive license
 and collaboration agreement (together, the Agreements) with Eli
 Lilly to jointly develop and commercialize teplizumab, a humanized
 anti-CD3 monoclonal antibody. As part of the Agreements, Eli Lilly
 acquired the exclusive rights to the molecule.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Upon execution of the Agreements, Eli Lilly made a nonrefundable
 payment of $41.0 million to the Company. In May&amp;#xA0;2008, Eli
 Lilly paid the Company a milestone payment of $50.0 million and in
 May&amp;#xA0;2010, Eli&amp;#xA0;Lilly paid an additional milestone of $5.0
 million.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"&gt;
 On October&amp;#xA0;28, 2010, Lilly notified the Company of its
 decision to terminate the agreement after review of one year of
 clinical data from the Prot&amp;#xE9;g&amp;#xE9; trial in Type 1 diabetes
 patients treated with teplizumab. Such data failed to support the
 primary efficacy end point in the study. In February 2011, the
 Company reacquired the commercial rights to the molecule from Eli
 Lilly. During the year ended December&amp;#xA0;31, 2012, Eli&amp;#xA0;Lilly
 satisfied its obligation related to the cost of monitoring patients
 under the Prot&amp;#xE9;g&amp;#xE9; and Encore trials. The Company&amp;#x2019;s
 obligations continued through September 2012, which represented the
 follow up period for enrolled patients and the Company&amp;#x2019;s
 final reporting of the trial&amp;#x2019;s results. There is no
 additional clinical trial activity under the Eli Lilly Agreements
 as it relates to such trials. However, Eli Lilly continues to
 reimburse the Company for monitoring patients in one currently
 active trial.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 During the years ended December 2014, 2013 and 2012, the Company
 recognized revenue of $0.4 million, $0.8 million and $31.2 million,
 respectively, under this agreement. No milestones were achieved
 under this agreement during the three years ended December&amp;#xA0;31,
 2014.&lt;/p&gt;


 &lt;/div&gt;</mgnx:CollaborationAndLicenseAgreementsDisclosureTextBlock>
  <mgnx:RoyaltyAgreementDisclosureTextBlock contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" id="id_6848266_2521B15A-7DC1-40A3-8B7A-EF9CDE0483DC_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;10. Product Milestone Payments and Royalty Agreements&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 In connection with an Asset Purchase Agreement with Tolerance
 Therapeutics, Inc. (Tolerance) entered into during June 2005, the
 Company may be required to issue Tolerance additional consideration
 as follows: (i)&amp;#xA0;$10,950,000 if certain milestones are met,
 including the initiation of Phase 3 trials and filing of various
 regulatory product license applications; (ii)&amp;#xA0;36,135 shares of
 common stock; and (iii)&amp;#xA0;royalty payments between 1.75% and
 4.0% of net sales of products acquired from or patented by
 Tolerance or other product fees earned by the Company. Any
 additional consideration required to be paid under the Asset
 Purchase Agreement will be recorded as research and development
 expense when incurred. No payments related to the additional
 consideration have occurred during the three years ended
 December&amp;#xA0;31, 2014. Additionally, certain agreements require
 the Company to pay royalties. Currently, the Company is not
 obligated to pay royalties, as no revenue from product sales is
 being generated by the Company.&lt;/p&gt;
 &lt;/div&gt;</mgnx:RoyaltyAgreementDisclosureTextBlock>
  <mgnx:IncreaseDecreaseInDeferredRent contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_436CCE6F-4336-4B5F-8F07-5F706B0B6ECB_1_15">-234000</mgnx:IncreaseDecreaseInDeferredRent>
  <mgnx:OperatingLossCarryforwardsLimitationsOnUseAmount contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-5" id="id_6848266_DAFDF779-4E13-4F8C-BCD2-10752D7C8927_1_0">7100000</mgnx:OperatingLossCarryforwardsLimitationsOnUseAmount>
  <mgnx:LiquidInvestmentMaturityPeriodToBeClassifiedAsCashEquivalentMaximum contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" id="id_6848266_E33C22AD-216A-4963-A3D6-46A51E324042_1_0">P3M</mgnx:LiquidInvestmentMaturityPeriodToBeClassifiedAsCashEquivalentMaximum>
  <mgnx:ContingentConsiderationRecordedAsIncrementalInProcessResearchAndDevelopmentExpense contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" unitRef="iso4217_USD" decimals="INF" id="id_6848266_D9A01372-2F1E-4894-98FA-D2AE7AF3ADC1_1_0">0</mgnx:ContingentConsiderationRecordedAsIncrementalInProcessResearchAndDevelopmentExpense>
  <mgnx:IncomeTaxExaminationYearUnderExaminationRangeStart contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" id="id_6848266_65038A39-0FF2-4AFF-9C88-A6B848C2CFE9_1_0">2001</mgnx:IncomeTaxExaminationYearUnderExaminationRangeStart>
  <mgnx:OperatingLossCarryforwardsLimitationsOnUseYearStart contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" id="id_6848266_DAFDF779-4E13-4F8C-BCD2-10752D7C8927_1_1">2015</mgnx:OperatingLossCarryforwardsLimitationsOnUseYearStart>
  <mgnx:TaxCreditCarryforwardExpirationYearRangeStart contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" id="id_6848266_F8C8395C-C469-4205-A2C8-BE58E73B5783_1_5">2020</mgnx:TaxCreditCarryforwardExpirationYearRangeStart>
  <mgnx:TaxCreditCarryforwardExpirationYearRangeEnd contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" id="id_6848266_F8C8395C-C469-4205-A2C8-BE58E73B5783_1_6">2034</mgnx:TaxCreditCarryforwardExpirationYearRangeEnd>
  <mgnx:OperatingLossCarryforwardsLimitationsOnUseYearEnd contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" id="id_6848266_DAFDF779-4E13-4F8C-BCD2-10752D7C8927_1_2">2027</mgnx:OperatingLossCarryforwardsLimitationsOnUseYearEnd>
  <mgnx:LeaseExpirationYear contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" id="id_6848266_5FD1DC97-33FA-4A54-A1B6-44794A68686D_1_0">2018</mgnx:LeaseExpirationYear>
  <mgnx:IncomeTaxExaminationYearUnderExaminationRangeEnd contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" id="id_6848266_65038A39-0FF2-4AFF-9C88-A6B848C2CFE9_1_1">2014</mgnx:IncomeTaxExaminationYearUnderExaminationRangeEnd>
  <mgnx:StockIssuedDuringPeriodValueStockPlanActivity contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_BFB39C8D-DAF1-408E-872B-38367E4AE90D_9019_22">725000</mgnx:StockIssuedDuringPeriodValueStockPlanActivity>
  <mgnx:ChangeInAccountingEstimateCurrentYearImpact contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-5" id="id_6848266_D62CA802-BA63-4468-AE9D-8E8E4337AF6D_1_0">3700000</mgnx:ChangeInAccountingEstimateCurrentYearImpact>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1268687x1281225" unitRef="shares" decimals="INF" id="id_6848266_2EA8D3D9-9412-48E8-9B1C-0BA0E09F80DD_3001_8">2094904</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1269523x1275948" id="id_6848266_B17DC221-39E0-441F-896B-6A1583FF1F73_1001_0">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1269523x1275948" unitRef="pure" decimals="INF" id="id_6848266_5078EE5D-09E5-4168-A034-4E6683B2BE49_2_2">0.023</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <mgnx:AggregatePotentialFutureCostReimbursement contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1269523x1275948_1272072x1370805" unitRef="iso4217_USD" decimals="-5" id="id_6848266_E08C9C97-0AE9-4E28-82AE-4DD5B9295905_1001_0">5500000</mgnx:AggregatePotentialFutureCostReimbursement>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1269523x1277596" unitRef="pure" decimals="INF" id="id_6848266_5078EE5D-09E5-4168-A034-4E6683B2BE49_1_2">0.018</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1269523x1277596_1277042x1272910" unitRef="pure" decimals="2" id="id_6848266_3038785B-3D7A-47B1-8652-A1B9FAC3D8E5_1001_0">0.10</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1269523x1277596_1277042x1275282" unitRef="pure" decimals="2" id="id_6848266_91F125CD-A799-4B94-B823-3F07BAB673CC_1001_0">0.10</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1272045x1275481" id="id_6848266_B0F4DC45-F5BC-437B-BF8E-1FEC81F6835D_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"&gt;
 The following table includes those collaborators that represent
 more than 10% of total revenue earned in the periods indicated:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="66%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"&gt;
 &lt;b&gt;Year&amp;#xA0;Ended&amp;#xA0;December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;2014&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;2013&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;2012&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Servier&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;36.4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;51.6&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;17.3&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Boehringer&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;28.6&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;24.8&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;18.4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Takeda&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;16.8&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Gilead&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11.4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13.8&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Eli Lilly&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.9&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;48.9&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
  <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1272045x1277073" id="id_6848266_6FBE9CDB-16D8-4BEF-BAF9-2AF97B1B6CE2_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The following table includes those collaborators that represent
 more than 10% of accounts receivable at the date indicated:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="75%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;2014&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;2013&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Servier&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;33.3&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Boehringer&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;21.2&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;12.2&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Green Cross&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;17.9&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Gilead&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;53.4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Pfizer&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;12.3&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1272045x1351512_1277042x1272910" unitRef="pure" decimals="3" id="id_6848266_75317A27-B598-4883-ACA0-8C9C5785D6CA_1001_3">0.114</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1272045x1370805_1277042x1275282" unitRef="pure" decimals="3" id="id_6848266_7EC2521A-795D-493C-9187-6371803B072D_2001_2">0.179</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1272045x1503196_1277042x1272910" unitRef="pure" decimals="3" id="id_6848266_75317A27-B598-4883-ACA0-8C9C5785D6CA_2001_1">0.286</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1272045x1503196_1277042x1275282" unitRef="pure" decimals="3" id="id_6848266_7EC2521A-795D-493C-9187-6371803B072D_3001_1">0.212</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1272045x1538608_1277042x1272910" unitRef="pure" decimals="3" id="id_6848266_75317A27-B598-4883-ACA0-8C9C5785D6CA_3001_0">0.364</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1272045x1538608_1277042x1275282" unitRef="pure" decimals="3" id="id_6848266_7EC2521A-795D-493C-9187-6371803B072D_4001_0">0.333</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1272045x1565531_1277042x1272910" unitRef="pure" decimals="3" id="id_6848266_75317A27-B598-4883-ACA0-8C9C5785D6CA_4001_2">0.168</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1272045x1569517_1277042x1272910" unitRef="pure" decimals="3" id="id_6848266_75317A27-B598-4883-ACA0-8C9C5785D6CA_5001_4">0.009</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1272072x1370805" unitRef="iso4217_USD" decimals="INF" id="id_6848266_3E7F58A9-4394-4CDC-8DCF-ED0CEFE40CF7_1_400001">0</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
  <us-gaap:LicensesRevenue contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1272072x1370805" unitRef="iso4217_USD" decimals="-5" id="id_6848266_3E7F58A9-4394-4CDC-8DCF-ED0CEFE40CF7_1_400000">1700000</us-gaap:LicensesRevenue>
  <mgnx:CollaborationAndLicenseAgreementEnteredDate contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1272072x1370805" id="id_6848266_5665E16B-AFF5-4DCF-92E5-45969B568CE8_1_0">June 2010</mgnx:CollaborationAndLicenseAgreementEnteredDate>
  <mgnx:AdjustmentToRevenueUnderAccountingStandardsCodification contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1272072x1370805" unitRef="iso4217_USD" decimals="-5" id="id_6848266_CD1E98AB-F08D-4B79-8E85-DC4E46EEDE24_1_0">1300000</mgnx:AdjustmentToRevenueUnderAccountingStandardsCodification>
  <mgnx:UpfrontFeeAndParticipationRecognitionEndDate contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1272072x1370805" id="id_6848266_DCDEA1B2-D101-4A1F-8E1E-3BDF24348197_2_0">2020-06</mgnx:UpfrontFeeAndParticipationRecognitionEndDate>
  <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1272072x1444876" unitRef="iso4217_USD" decimals="INF" id="id_6848266_FC960917-5ACF-4C3E-8677-73447D268A07_1_1">0</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
  <us-gaap:LicensesRevenue contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1272072x1444876" unitRef="iso4217_USD" decimals="-5" id="id_6848266_FC960917-5ACF-4C3E-8677-73447D268A07_1_0">5500000</us-gaap:LicensesRevenue>
  <mgnx:CollaborationAndLicenseAgreementEnteredDate contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1272072x1444876" id="id_6848266_B20C8915-6C26-4325-8243-BD8CB702C60D_2_0">January 2013</mgnx:CollaborationAndLicenseAgreementEnteredDate>
  <mgnx:UpfrontPaymentRecognitionPeriod contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1272072x1444876" id="id_6848266_BA5752B5-0385-4C37-91DD-C48825C03757_1_0">P21M</mgnx:UpfrontPaymentRecognitionPeriod>
  <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1272072x1503196" unitRef="iso4217_USD" decimals="-5" id="id_6848266_AED8F272-20FC-4F1A-82AB-7856839A71BD_1_4">2000000</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
  <us-gaap:LicensesRevenue contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1272072x1503196" unitRef="iso4217_USD" decimals="-5" id="id_6848266_AED8F272-20FC-4F1A-82AB-7856839A71BD_1_0">13700000</us-gaap:LicensesRevenue>
  <mgnx:NumberOfAnnualMaintenancePaymentReceived contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1272072x1503196" unitRef="Payments" decimals="INF" id="id_6848266_D8A60150-BE03-466F-8DF8-E45FA6E46220_1_1">3</mgnx:NumberOfAnnualMaintenancePaymentReceived>
  <mgnx:CollaborationAndLicenseAgreementEnteredDate contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1272072x1503196" id="id_6848266_5540EA28-6FEE-4A0D-A0A6-9B2A48528279_1_0">October 2010</mgnx:CollaborationAndLicenseAgreementEnteredDate>
  <mgnx:ResearchObligationCompletionDate contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1272072x1503196" id="id_6848266_730B731A-21F4-470D-AFCC-CDEC74713CEF_1_0">2015-09</mgnx:ResearchObligationCompletionDate>
  <us-gaap:LicensesRevenue contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1272072x1538608" unitRef="iso4217_USD" decimals="-5" id="id_6848266_4FE942DA-BDC1-4D22-A8C8-0DBE3DDFD663_1_0">700000</us-gaap:LicensesRevenue>
  <mgnx:CollaborationAndLicenseAgreementEnteredDate contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1272072x1538608" id="id_6848266_AC0CD568-461A-4CB3-AD58-348183F777C1_1_0">November 2011</mgnx:CollaborationAndLicenseAgreementEnteredDate>
  <mgnx:UpfrontPaymentRecognitionPeriod contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1272072x1538608" id="id_6848266_2D23F0E4-C0FB-4EB1-A909-519005243AD9_1_0">P27M</mgnx:UpfrontPaymentRecognitionPeriod>
  <mgnx:UpfrontPaymentRecognitionPeriod contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1272072x1538608_1273334x1269610" id="id_6848266_2D23F0E4-C0FB-4EB1-A909-519005243AD9_1001_1">P42M</mgnx:UpfrontPaymentRecognitionPeriod>
  <mgnx:UpfrontPaymentRecognitionPeriod contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1272072x1538608_1273334x1269610_1279908x1439878" id="id_6848266_29BB417A-FBA4-49DB-BC20-F354FD5385FF_1001_1">P75M</mgnx:UpfrontPaymentRecognitionPeriod>
  <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1272072x1538608_1279908x1439878" unitRef="iso4217_USD" decimals="-5" id="id_6848266_D09A039D-38C1-4E9F-AFCC-87FCE28B8EF2_1001_1">5000000</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
  <us-gaap:LicensesRevenue contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1272072x1538608_1279908x1439878" unitRef="iso4217_USD" decimals="-5" id="id_6848266_D09A039D-38C1-4E9F-AFCC-87FCE28B8EF2_1001_0">16700000</us-gaap:LicensesRevenue>
  <mgnx:ReviewPeriodByRegulatoryAuthority contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1272072x1538608_1279908x1439878" id="id_6848266_D09A039D-38C1-4E9F-AFCC-87FCE28B8EF2_1001_3">P30D</mgnx:ReviewPeriodByRegulatoryAuthority>
  <mgnx:CollaborationArrangementOffsetToResearchAndDevelopmentCosts contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1272072x1538608_1279908x1439878" unitRef="iso4217_USD" decimals="-5" id="id_6848266_04591BAC-6897-476B-88E9-DCED4AA4B34E_1001_1">1000000</mgnx:CollaborationArrangementOffsetToResearchAndDevelopmentCosts>
  <mgnx:CollaborationAndLicenseAgreementEnteredDate contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1272072x1538608_1279908x1439878" id="id_6848266_7E53B876-B31C-4A36-8DDC-2308CDAFE76A_1001_0">September 2012</mgnx:CollaborationAndLicenseAgreementEnteredDate>
  <mgnx:NumberOfMilestonesAchieved contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1272072x1538608_1279908x1439878" unitRef="Milestone" decimals="INF" id="id_6848266_D09A039D-38C1-4E9F-AFCC-87FCE28B8EF2_1001_2">2</mgnx:NumberOfMilestonesAchieved>
  <mgnx:UpfrontPaymentRecognitionPeriod contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1272072x1538608_1279908x1439878" id="id_6848266_29BB417A-FBA4-49DB-BC20-F354FD5385FF_2001_0">P29M</mgnx:UpfrontPaymentRecognitionPeriod>
  <mgnx:OptionExerciseFeeRecognitionPeriod contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1272072x1538608_1279908x1439878" id="id_6848266_04591BAC-6897-476B-88E9-DCED4AA4B34E_1001_2">P82M</mgnx:OptionExerciseFeeRecognitionPeriod>
  <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1272072x1545620" unitRef="iso4217_USD" decimals="INF" id="id_6848266_D3A79C34-1D3F-47B7-B198-6DACB4B91533_1_1">0</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
  <us-gaap:LicensesRevenue contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1272072x1545620" unitRef="iso4217_USD" decimals="-5" id="id_6848266_D3A79C34-1D3F-47B7-B198-6DACB4B91533_1_0">100000</us-gaap:LicensesRevenue>
  <mgnx:NumberOfPrograms contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1272072x1545620" unitRef="Program" decimals="INF" id="id_6848266_BCD36912-D7FB-475E-807A-BEEA09E6D473_1_2">1</mgnx:NumberOfPrograms>
  <mgnx:NonRefundableUpFrontPayment contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1272072x1545620" unitRef="iso4217_USD" decimals="-5" id="id_6848266_B9D4CCF5-215C-4E58-BFF5-B69E659E8B75_1_1">5000000</mgnx:NonRefundableUpFrontPayment>
  <mgnx:CollaborationAndLicenseAgreementEnteredDate contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1272072x1545620" id="id_6848266_8CF91BB7-8196-4F41-8150-141308C6D5B2_2_0">October 2010</mgnx:CollaborationAndLicenseAgreementEnteredDate>
  <mgnx:CollaborativeAgreementPeriodOfContract contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1272072x1545620" id="id_6848266_8CF91BB7-8196-4F41-8150-141308C6D5B2_2_1">P3Y</mgnx:CollaborativeAgreementPeriodOfContract>
  <mgnx:ResearchObligationCompletionDate contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1272072x1545620" id="id_6848266_BCD36912-D7FB-475E-807A-BEEA09E6D473_1_3">2014-01</mgnx:ResearchObligationCompletionDate>
  <mgnx:UpfrontFeeAndParticipationRecognitionEndDate contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1272072x1545620" id="id_6848266_B9D4CCF5-215C-4E58-BFF5-B69E659E8B75_2_0">2014-01</mgnx:UpfrontFeeAndParticipationRecognitionEndDate>
  <us-gaap:LicensesRevenue contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1272072x1565531" unitRef="iso4217_USD" decimals="-5" id="id_6848266_39E3AD4D-78FF-4EA3-ABF5-D7E3361199B7_1_0">3000000</us-gaap:LicensesRevenue>
  <mgnx:CollaborationAndLicenseAgreementEnteredDate contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1272072x1565531" id="id_6848266_5BD21674-263F-4556-AF29-4A17D34968DD_2_1">May 2014</mgnx:CollaborationAndLicenseAgreementEnteredDate>
  <mgnx:UpfrontPaymentRecognitionPeriod contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1272072x1565531" id="id_6848266_2A3ABCD3-AEBB-4451-B3D4-E9FBD726C3BE_1_0">P24M</mgnx:UpfrontPaymentRecognitionPeriod>
  <mgnx:UpfrontFeeAllocatedToAgreement contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1272072x1565531" unitRef="iso4217_USD" decimals="-5" id="id_6848266_8AB4D6EC-908B-4111-BABA-E69D739E1753_1_0">10000000</mgnx:UpfrontFeeAllocatedToAgreement>
  <us-gaap:LicensesRevenue contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1272072x1565531_1279908x1600194" unitRef="iso4217_USD" decimals="-5" id="id_6848266_F04E6CDE-7718-4C16-8A52-E45C330CFE5A_1001_0">5000000</us-gaap:LicensesRevenue>
  <mgnx:CollaborationAndLicenseAgreementEnteredDate contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1272072x1565531_1279908x1600194" id="id_6848266_FCFCAF09-AF01-49BC-91F2-FBB53CC9B7C4_1001_0">September 2014</mgnx:CollaborationAndLicenseAgreementEnteredDate>
  <mgnx:UpfrontFeeAllocatedToAgreement contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1272072x1565531_1279908x1600194" unitRef="iso4217_USD" decimals="-5" id="id_6848266_8AB4D6EC-908B-4111-BABA-E69D739E1753_2_1">5000000</mgnx:UpfrontFeeAllocatedToAgreement>
  <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1272072x1569517" unitRef="iso4217_USD" decimals="INF" id="id_6848266_9A5607AA-73D8-4654-BE4E-3E38374EEC8A_3_1">0</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
  <us-gaap:LicensesRevenue contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1272072x1569517" unitRef="iso4217_USD" decimals="-5" id="id_6848266_9A5607AA-73D8-4654-BE4E-3E38374EEC8A_3_0">400000</us-gaap:LicensesRevenue>
  <mgnx:NonRefundableUpFrontPayment contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1272072x1569517" unitRef="iso4217_USD" decimals="-5" id="id_6848266_D572F75F-D2EF-4A0B-B1FB-EA0E1523E794_1_400000">41000000</mgnx:NonRefundableUpFrontPayment>
  <mgnx:CollaborationAndLicenseAgreementEnteredDate contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1272072x1569517" id="id_6848266_C5533AEF-2AF5-4A03-AF4E-1148119ACBE6_1_0">October 2007</mgnx:CollaborationAndLicenseAgreementEnteredDate>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1272072x1605598" unitRef="shares" decimals="INF" id="id_6848266_5D514CAD-48D3-4D6A-AF91-9AF832FEA310_1_2">1923077</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1272072x1605598" unitRef="iso4217_USD" decimals="-5" id="id_6848266_5D514CAD-48D3-4D6A-AF91-9AF832FEA310_1_1">75000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:LicensesRevenue contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1272072x1605598" unitRef="iso4217_USD" decimals="INF" id="id_6848266_868640A9-E7A9-43E8-8868-1C279F076DB5_1_0">0</us-gaap:LicensesRevenue>
  <mgnx:CollaborationAndLicenseAgreementEnteredDate contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1272072x1605598" id="id_6848266_5D514CAD-48D3-4D6A-AF91-9AF832FEA310_1_0">December 2014</mgnx:CollaborationAndLicenseAgreementEnteredDate>
  <mgnx:AdditionalPotentialClinicalRegulatoryCommercializationPaymentsUnderAgreement contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1272072x1605598" unitRef="iso4217_USD" decimals="-5" id="id_6848266_5D514CAD-48D3-4D6A-AF91-9AF832FEA310_1_5">575000000</mgnx:AdditionalPotentialClinicalRegulatoryCommercializationPaymentsUnderAgreement>
  <us-gaap:LeaseExpirationDate1 contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1273333x1394675_1279380x1509307" id="id_6848266_4B2FF989-2059-4FC7-89D2-70B1D6317EB2_1001_7">2018-02-28</us-gaap:LeaseExpirationDate1>
  <us-gaap:LeaseExpirationDate1 contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1273333x1605760_1279380x1509307" id="id_6848266_4B2FF989-2059-4FC7-89D2-70B1D6317EB2_2001_0">2018-03-31</us-gaap:LeaseExpirationDate1>
  <mgnx:AmendedLeaseExpirationDate contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1273333x1605760_1279380x1509307" id="id_6848266_4B2FF989-2059-4FC7-89D2-70B1D6317EB2_2001_1">2020-01-31</mgnx:AmendedLeaseExpirationDate>
  <us-gaap:IncomeTaxReconciliationDeductions contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1273334x1271232" unitRef="iso4217_USD" decimals="-3" id="id_6848266_6F5E51EF-C8FC-4FD4-AB59-C423FE9A715A_1001_6">564000</us-gaap:IncomeTaxReconciliationDeductions>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1274159x1269133" unitRef="iso4217_USD" decimals="-3" id="id_6848266_0C47355F-C953-4F92-9309-B77CCD08112A_1001_1">1682000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1274159x1269570" unitRef="iso4217_USD" decimals="-3" id="id_6848266_0C47355F-C953-4F92-9309-B77CCD08112A_2001_0">1562000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1276136x1274094" id="id_6848266_72FCCFC1-583F-444A-80AF-B789F584D4D2_1001_2">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1276136x1275434" id="id_6848266_72FCCFC1-583F-444A-80AF-B789F584D4D2_2001_0">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1276136x1277482" id="id_6848266_72FCCFC1-583F-444A-80AF-B789F584D4D2_3001_4">Shorter of lease term or useful life</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1276136x1277975" id="id_6848266_72FCCFC1-583F-444A-80AF-B789F584D4D2_4001_1">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1276136x1479456" id="id_6848266_72FCCFC1-583F-444A-80AF-B789F584D4D2_5001_3">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PreferredStockDividendRatePerDollarAmount contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1276400x1269676" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_6848266_B654834F-0ECF-43A4-ACE7-754065B49B90_1001_0">0.08</us-gaap:PreferredStockDividendRatePerDollarAmount>
  <us-gaap:PreferredStockDividendRatePerDollarAmount contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1276400x1279561" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_6848266_B654834F-0ECF-43A4-ACE7-754065B49B90_2001_3">0.0324</us-gaap:PreferredStockDividendRatePerDollarAmount>
  <mgnx:ConvertiblePreferredStockConversionPrice contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1276400x1279561" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_6848266_469AEE3F-B279-4E6E-9151-F534E9EE7450_1001_3">7.70</mgnx:ConvertiblePreferredStockConversionPrice>
  <us-gaap:PreferredStockDividendRatePerDollarAmount contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1276400x1281157" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_6848266_B654834F-0ECF-43A4-ACE7-754065B49B90_3001_2">0.0341</us-gaap:PreferredStockDividendRatePerDollarAmount>
  <mgnx:ConvertiblePreferredStockConversionPrice contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1276400x1281157" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_6848266_469AEE3F-B279-4E6E-9151-F534E9EE7450_2001_2">6.95</mgnx:ConvertiblePreferredStockConversionPrice>
  <us-gaap:PreferredStockDividendRatePerDollarAmount contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1276400x1281158" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_6848266_B654834F-0ECF-43A4-ACE7-754065B49B90_4001_4">0.0522</us-gaap:PreferredStockDividendRatePerDollarAmount>
  <mgnx:ConvertiblePreferredStockConversionPrice contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1276400x1281158" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_6848266_469AEE3F-B279-4E6E-9151-F534E9EE7450_3001_4">12.20</mgnx:ConvertiblePreferredStockConversionPrice>
  <mgnx:ConvertiblePreferredStockConversionPrice contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1276400x1369166" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_6848266_469AEE3F-B279-4E6E-9151-F534E9EE7450_4001_1">18.77</mgnx:ConvertiblePreferredStockConversionPrice>
  <mgnx:ConvertiblePreferredStockConversionPrice contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1276400x1481307" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_6848266_469AEE3F-B279-4E6E-9151-F534E9EE7450_5001_0">12.39</mgnx:ConvertiblePreferredStockConversionPrice>
  <us-gaap:PreferredStockDividendRatePerDollarAmount contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1276400x1610343" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_6848266_B654834F-0ECF-43A4-ACE7-754065B49B90_5001_5">0.0522</us-gaap:PreferredStockDividendRatePerDollarAmount>
  <mgnx:ConvertiblePreferredStockConversionPrice contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1276400x1610343" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_6848266_469AEE3F-B279-4E6E-9151-F534E9EE7450_6001_5">12.20</mgnx:ConvertiblePreferredStockConversionPrice>
  <us-gaap:NetIncomeLoss contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1276401x1269588" unitRef="iso4217_USD" decimals="-3" id="id_6848266_BFB39C8D-DAF1-408E-872B-38367E4AE90D_9018_26">-38313000</us-gaap:NetIncomeLoss>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1276401x1270422" unitRef="shares" decimals="INF" id="id_6848266_BFB39C8D-DAF1-408E-872B-38367E4AE90D_9013_21">2250000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1276401x1270422" unitRef="iso4217_USD" decimals="-3" id="id_6848266_BFB39C8D-DAF1-408E-872B-38367E4AE90D_9013_20">22000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <mgnx:StockIssuedDuringPeriodValueStockPlanActivity contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1276401x1270422" unitRef="iso4217_USD" decimals="-3" id="id_6848266_BFB39C8D-DAF1-408E-872B-38367E4AE90D_9013_22">6000</mgnx:StockIssuedDuringPeriodValueStockPlanActivity>
  <mgnx:StockIssuedDuringPeriodSharesStockPlanActivity contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1276401x1270422" unitRef="shares" decimals="0" id="id_6848266_BFB39C8D-DAF1-408E-872B-38367E4AE90D_9013_23">568041</mgnx:StockIssuedDuringPeriodSharesStockPlanActivity>
  <us-gaap:TreasuryStockSharesRetired contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1276401x1273409" unitRef="shares" decimals="INF" id="id_6848266_BFB39C8D-DAF1-408E-872B-38367E4AE90D_9015_25">-14381</us-gaap:TreasuryStockSharesRetired>
  <us-gaap:TreasuryStockRetiredParValueMethodAmount contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1276401x1273409" unitRef="iso4217_USD" decimals="-3" id="id_6848266_BFB39C8D-DAF1-408E-872B-38367E4AE90D_9015_24">-58000</us-gaap:TreasuryStockRetiredParValueMethodAmount>
  <mgnx:StockIssuedDuringPeriodValueStockPlanActivity contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1276401x1273409" unitRef="iso4217_USD" decimals="-3" id="id_6848266_BFB39C8D-DAF1-408E-872B-38367E4AE90D_9015_22">-19000</mgnx:StockIssuedDuringPeriodValueStockPlanActivity>
  <mgnx:StockIssuedDuringPeriodSharesStockPlanActivity contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1276401x1273409" unitRef="shares" decimals="0" id="id_6848266_BFB39C8D-DAF1-408E-872B-38367E4AE90D_9015_23">865</mgnx:StockIssuedDuringPeriodSharesStockPlanActivity>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1276401x1273630" unitRef="iso4217_USD" decimals="-3" id="id_6848266_BFB39C8D-DAF1-408E-872B-38367E4AE90D_9017_20">76694000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1276401x1273630" unitRef="iso4217_USD" decimals="-3" id="id_6848266_BFB39C8D-DAF1-408E-872B-38367E4AE90D_9017_19">3244000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:TreasuryStockRetiredParValueMethodAmount contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1276401x1273630" unitRef="iso4217_USD" decimals="-3" id="id_6848266_BFB39C8D-DAF1-408E-872B-38367E4AE90D_9017_24">58000</us-gaap:TreasuryStockRetiredParValueMethodAmount>
  <mgnx:StockIssuedDuringPeriodValueStockPlanActivity contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1276401x1273630" unitRef="iso4217_USD" decimals="-3" id="id_6848266_BFB39C8D-DAF1-408E-872B-38367E4AE90D_9017_22">738000</mgnx:StockIssuedDuringPeriodValueStockPlanActivity>
  <us-gaap:PaymentsForRestructuring contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1277830x1270443" unitRef="iso4217_USD" decimals="-3" id="id_6848266_0D44A515-B00A-4367-8453-713228457EE3_7001_4">1439000</us-gaap:PaymentsForRestructuring>
  <us-gaap:LesseeLeasingArrangementsOperatingLeasesTermOfContract contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1279380x1610417" id="id_6848266_4B2FF989-2059-4FC7-89D2-70B1D6317EB2_3001_5">P4Y</us-gaap:LesseeLeasingArrangementsOperatingLeasesTermOfContract>
  <mgnx:LeaseAgreementInitiationDate contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1279380x1610417" id="id_6848266_4B2FF989-2059-4FC7-89D2-70B1D6317EB2_3001_6">2014-04-01</mgnx:LeaseAgreementInitiationDate>
  <us-gaap:LesseeLeasingArrangementsOperatingLeasesRenewalTerm contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1279380x1621777" id="id_6848266_4B2FF989-2059-4FC7-89D2-70B1D6317EB2_4001_2">P5Y</us-gaap:LesseeLeasingArrangementsOperatingLeasesRenewalTerm>
  <us-gaap:LeaseExpirationDate1 contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1279380x1621777" id="id_6848266_4B2FF989-2059-4FC7-89D2-70B1D6317EB2_4001_4">2014-12-31</us-gaap:LeaseExpirationDate1>
  <mgnx:OperatingLossCarryforwardsExpirationYear contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1280651x1613553" id="id_6848266_F8C8395C-C469-4205-A2C8-BE58E73B5783_1001_2">2020</mgnx:OperatingLossCarryforwardsExpirationYear>
  <mgnx:OperatingLossCarryforwardsExpirationYear contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1280651x1613554" id="id_6848266_F8C8395C-C469-4205-A2C8-BE58E73B5783_2001_3">2034</mgnx:OperatingLossCarryforwardsExpirationYear>
  <mgnx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1280964x1332409" unitRef="shares" decimals="INF" id="id_6848266_914CBE22-E452-498E-A124-A2D404D04BB2_1002_3">2967272</mgnx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease>
  <mgnx:PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1280964x1332409" unitRef="pure" decimals="3" id="id_6848266_914CBE22-E452-498E-A124-A2D404D04BB2_1002_2">0.040</mgnx:PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan>
  <mgnx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease contextRef="eol_PE179294--1410-K0014_STD_365_20141231_0_1280964x1365667" unitRef="shares" decimals="INF" id="id_6848266_A343CD6A-8A35-4D63-97CC-755B3CB56B63_1001_1">150297</mgnx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease>
  <us-gaap:EarningsPerShareDiluted contextRef="eol_PE179294--1410-K0014_STD_366_20121231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_6848266_06A157FB-CCF1-440F-8ABC-76F98DD1AADC_3_11">0.00</us-gaap:EarningsPerShareDiluted>
  <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="eol_PE179294--1410-K0014_STD_366_20121231_0" unitRef="shares" decimals="0" id="id_6848266_06A157FB-CCF1-440F-8ABC-76F98DD1AADC_3_9">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
  <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare contextRef="eol_PE179294--1410-K0014_STD_366_20121231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_6848266_C038B40A-B436-460B-B84E-355BF772C2D9_3_11">0.00</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="eol_PE179294--1410-K0014_STD_366_20121231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_6848266_6FF767FB-8AC0-4D45-89E1-7828051C94DC_3_0">0.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="eol_PE179294--1410-K0014_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_436CCE6F-4336-4B5F-8F07-5F706B0B6ECB_3_17">-6582000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="eol_PE179294--1410-K0014_STD_366_20121231_0" unitRef="pure" decimals="2" id="id_6848266_5078EE5D-09E5-4168-A034-4E6683B2BE49_7_0">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE179294--1410-K0014_STD_366_20121231_0" id="id_6848266_5078EE5D-09E5-4168-A034-4E6683B2BE49_7_3">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE179294--1410-K0014_STD_366_20121231_0" unitRef="pure" decimals="3" id="id_6848266_5078EE5D-09E5-4168-A034-4E6683B2BE49_7_2">0.012</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="eol_PE179294--1410-K0014_STD_366_20121231_0" unitRef="shares" decimals="0" id="id_6848266_C038B40A-B436-460B-B84E-355BF772C2D9_3_12">1083276</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="eol_PE179294--1410-K0014_STD_366_20121231_0" unitRef="shares" decimals="0" id="id_6848266_06A157FB-CCF1-440F-8ABC-76F98DD1AADC_3_10">1083276</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:EarningsPerShareBasic contextRef="eol_PE179294--1410-K0014_STD_366_20121231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_6848266_06A157FB-CCF1-440F-8ABC-76F98DD1AADC_3_4">0.00</us-gaap:EarningsPerShareBasic>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE179294--1410-K0014_STD_366_20121231_0" unitRef="pure" decimals="2" id="id_6848266_5078EE5D-09E5-4168-A034-4E6683B2BE49_7_1">0.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="eol_PE179294--1410-K0014_STD_366_20121231_0" unitRef="shares" decimals="INF" id="id_6848266_01C3FF41-5B4B-4782-A3E1-45AFC051D57A_3_0">863176</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="eol_PE179294--1410-K0014_STD_366_20121231_0" unitRef="shares" decimals="0" id="id_6848266_06A157FB-CCF1-440F-8ABC-76F98DD1AADC_3_3">1083276</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="eol_PE179294--1410-K0014_STD_366_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_6848266_6FF767FB-8AC0-4D45-89E1-7828051C94DC_3_4">879024</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
  <us-gaap:RevenueFromGrants contextRef="eol_PE179294--1410-K0014_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_C038B40A-B436-460B-B84E-355BF772C2D9_3_2">4180000</us-gaap:RevenueFromGrants>
  <us-gaap:LicenseAndServicesRevenue contextRef="eol_PE179294--1410-K0014_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_C038B40A-B436-460B-B84E-355BF772C2D9_3_1">59646000</us-gaap:LicenseAndServicesRevenue>
  <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="eol_PE179294--1410-K0014_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_436CCE6F-4336-4B5F-8F07-5F706B0B6ECB_3_10">-1000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE179294--1410-K0014_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_BFB39C8D-DAF1-408E-872B-38367E4AE90D_4019_4">46000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE179294--1410-K0014_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_C038B40A-B436-460B-B84E-355BF772C2D9_3_8">8205000</us-gaap:OperatingIncomeLoss>
  <us-gaap:IncreaseDecreaseInRestrictedCashForOperatingActivities contextRef="eol_PE179294--1410-K0014_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_436CCE6F-4336-4B5F-8F07-5F706B0B6ECB_3_9">-177000</us-gaap:IncreaseDecreaseInRestrictedCashForOperatingActivities>
  <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="eol_PE179294--1410-K0014_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_C276425F-9994-4C60-9006-051FF560D19C_3_1">58000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="eol_PE179294--1410-K0014_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_C038B40A-B436-460B-B84E-355BF772C2D9_3_9">157000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:Revenues contextRef="eol_PE179294--1410-K0014_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_C038B40A-B436-460B-B84E-355BF772C2D9_3_3">63826000</us-gaap:Revenues>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE179294--1410-K0014_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_436CCE6F-4336-4B5F-8F07-5F706B0B6ECB_3_19">940000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:NetIncomeLoss contextRef="eol_PE179294--1410-K0014_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_C038B40A-B436-460B-B84E-355BF772C2D9_3_10">8362000</us-gaap:NetIncomeLoss>
  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="eol_PE179294--1410-K0014_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_436CCE6F-4336-4B5F-8F07-5F706B0B6ECB_3_7">-1352000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:IncomeTaxReconciliationTaxCreditsOther contextRef="eol_PE179294--1410-K0014_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_6F5E51EF-C8FC-4FD4-AB59-C423FE9A715A_3_7">4896000</us-gaap:IncomeTaxReconciliationTaxCreditsOther>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE179294--1410-K0014_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_BFB39C8D-DAF1-408E-872B-38367E4AE90D_4019_3">838000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="eol_PE179294--1410-K0014_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_436CCE6F-4336-4B5F-8F07-5F706B0B6ECB_3_8">91000</us-gaap:IncreaseDecreaseInPrepaidExpense>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="eol_PE179294--1410-K0014_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-5" id="id_6848266_FA11B785-8CBF-4BB6-ADA5-597BE5495B8F_3_0">1000000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="eol_PE179294--1410-K0014_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_436CCE6F-4336-4B5F-8F07-5F706B0B6ECB_3_14">-10810000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE179294--1410-K0014_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_C038B40A-B436-460B-B84E-355BF772C2D9_3_5">45433000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:IncreaseDecreaseInRestructuringReserve contextRef="eol_PE179294--1410-K0014_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_436CCE6F-4336-4B5F-8F07-5F706B0B6ECB_3_13">-534000</us-gaap:IncreaseDecreaseInRestructuringReserve>
  <us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic contextRef="eol_PE179294--1410-K0014_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_06A157FB-CCF1-440F-8ABC-76F98DD1AADC_3_6">8362000</us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE179294--1410-K0014_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_436CCE6F-4336-4B5F-8F07-5F706B0B6ECB_3_26">-7475000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:FairValueAdjustmentOfWarrants contextRef="eol_PE179294--1410-K0014_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_436CCE6F-4336-4B5F-8F07-5F706B0B6ECB_3_5">-151000</us-gaap:FairValueAdjustmentOfWarrants>
  <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="eol_PE179294--1410-K0014_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_6F5E51EF-C8FC-4FD4-AB59-C423FE9A715A_3_0">2927000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="eol_PE179294--1410-K0014_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_6F5E51EF-C8FC-4FD4-AB59-C423FE9A715A_3_12">0</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:OperatingLeasesRentExpenseNet contextRef="eol_PE179294--1410-K0014_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-5" id="id_6848266_81731F1A-1997-4BE2-B6DC-1FBA78F4CD34_3_1">2700000</us-gaap:OperatingLeasesRentExpenseNet>
  <us-gaap:Depreciation contextRef="eol_PE179294--1410-K0014_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_436CCE6F-4336-4B5F-8F07-5F706B0B6ECB_3_3">960000</us-gaap:Depreciation>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="eol_PE179294--1410-K0014_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_436CCE6F-4336-4B5F-8F07-5F706B0B6ECB_3_25">47000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic contextRef="eol_PE179294--1410-K0014_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_06A157FB-CCF1-440F-8ABC-76F98DD1AADC_3_1">8362000</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
  <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="eol_PE179294--1410-K0014_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_6F5E51EF-C8FC-4FD4-AB59-C423FE9A715A_3_9">279000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
  <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="eol_PE179294--1410-K0014_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_436CCE6F-4336-4B5F-8F07-5F706B0B6ECB_3_12">185000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="eol_PE179294--1410-K0014_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_436CCE6F-4336-4B5F-8F07-5F706B0B6ECB_3_20">-940000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="eol_PE179294--1410-K0014_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_436CCE6F-4336-4B5F-8F07-5F706B0B6ECB_3_23">47000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="eol_PE179294--1410-K0014_STD_366_20121231_0" unitRef="iso4217_USD" decimals="INF" id="id_6848266_21E5900F-6C26-4A8D-A5FF-3358DB02959F_3_0">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
  <us-gaap:CostsAndExpenses contextRef="eol_PE179294--1410-K0014_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_C038B40A-B436-460B-B84E-355BF772C2D9_3_7">55621000</us-gaap:CostsAndExpenses>
  <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="eol_PE179294--1410-K0014_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_6F5E51EF-C8FC-4FD4-AB59-C423FE9A715A_3_1">1460000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE179294--1410-K0014_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_C038B40A-B436-460B-B84E-355BF772C2D9_3_6">10188000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="eol_PE179294--1410-K0014_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_436CCE6F-4336-4B5F-8F07-5F706B0B6ECB_3_11">-7312000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE179294--1410-K0014_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_436CCE6F-4336-4B5F-8F07-5F706B0B6ECB_3_4">838000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="eol_PE179294--1410-K0014_STD_366_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_6848266_6FF767FB-8AC0-4D45-89E1-7828051C94DC_3_1">271929</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense contextRef="eol_PE179294--1410-K0014_STD_366_20121231_0" unitRef="iso4217_USD" decimals="INF" id="id_6848266_AC57A800-8787-4A43-9539-9C416E3C9097_3_0">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
  <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount contextRef="eol_PE179294--1410-K0014_STD_366_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_6848266_3D6479E8-FC85-4E73-B9C2-F899F5DFB6A0_4_3">225195</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
  <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="eol_PE179294--1410-K0014_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_6F5E51EF-C8FC-4FD4-AB59-C423FE9A715A_3_11">787000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:IncomeTaxReconciliationOtherReconcilingItems contextRef="eol_PE179294--1410-K0014_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_6F5E51EF-C8FC-4FD4-AB59-C423FE9A715A_3_8">8000</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
  <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations contextRef="eol_PE179294--1410-K0014_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_C276425F-9994-4C60-9006-051FF560D19C_3_3">0</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
  <mgnx:IncomeTaxReconciliationFairValueAdjustmentOfPreferredStockWarrantLiability contextRef="eol_PE179294--1410-K0014_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_6F5E51EF-C8FC-4FD4-AB59-C423FE9A715A_3_10">-53000</mgnx:IncomeTaxReconciliationFairValueAdjustmentOfPreferredStockWarrantLiability>
  <mgnx:IncreaseDecreaseInDeferredRent contextRef="eol_PE179294--1410-K0014_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_436CCE6F-4336-4B5F-8F07-5F706B0B6ECB_3_15">441000</mgnx:IncreaseDecreaseInDeferredRent>
  <mgnx:IncomeTaxReconciliationDeferredTaxAdjustments contextRef="eol_PE179294--1410-K0014_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_6F5E51EF-C8FC-4FD4-AB59-C423FE9A715A_3_2">-512000</mgnx:IncomeTaxReconciliationDeferredTaxAdjustments>
  <mgnx:ContingentConsiderationRecordedAsIncrementalInProcessResearchAndDevelopmentExpense contextRef="eol_PE179294--1410-K0014_STD_366_20121231_0" unitRef="iso4217_USD" decimals="INF" id="id_6848266_D9A01372-2F1E-4894-98FA-D2AE7AF3ADC1_3_0">0</mgnx:ContingentConsiderationRecordedAsIncrementalInProcessResearchAndDevelopmentExpense>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE179294--1410-K0014_STD_366_20121231_0_1268687x1273442" unitRef="shares" decimals="INF" id="id_6848266_2EA8D3D9-9412-48E8-9B1C-0BA0E09F80DD_2003_7">180784</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE179294--1410-K0014_STD_366_20121231_0_1268687x1281225" unitRef="shares" decimals="INF" id="id_6848266_2EA8D3D9-9412-48E8-9B1C-0BA0E09F80DD_3003_8">3249702</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE179294--1410-K0014_STD_366_20121231_0_1268687x1296600" unitRef="shares" decimals="INF" id="id_6848266_2EA8D3D9-9412-48E8-9B1C-0BA0E09F80DD_4003_0">2156114</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE179294--1410-K0014_STD_366_20121231_0_1268687x1310046" unitRef="shares" decimals="INF" id="id_6848266_2EA8D3D9-9412-48E8-9B1C-0BA0E09F80DD_5003_1">392274</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE179294--1410-K0014_STD_366_20121231_0_1268687x1343554" unitRef="shares" decimals="INF" id="id_6848266_2EA8D3D9-9412-48E8-9B1C-0BA0E09F80DD_6003_4">769468</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE179294--1410-K0014_STD_366_20121231_0_1268687x1421015" unitRef="shares" decimals="INF" id="id_6848266_2EA8D3D9-9412-48E8-9B1C-0BA0E09F80DD_7003_5">3391991</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE179294--1410-K0014_STD_366_20121231_0_1268687x1493912" unitRef="shares" decimals="INF" id="id_6848266_2EA8D3D9-9412-48E8-9B1C-0BA0E09F80DD_8003_2">4336037</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE179294--1410-K0014_STD_366_20121231_0_1268687x1559024" unitRef="shares" decimals="INF" id="id_6848266_2EA8D3D9-9412-48E8-9B1C-0BA0E09F80DD_9003_3">5909906</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE179294--1410-K0014_STD_366_20121231_0_1272045x1503196_1277042x1272910" unitRef="pure" decimals="3" id="id_6848266_75317A27-B598-4883-ACA0-8C9C5785D6CA_2003_1">0.184</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE179294--1410-K0014_STD_366_20121231_0_1272045x1538608_1277042x1272910" unitRef="pure" decimals="3" id="id_6848266_75317A27-B598-4883-ACA0-8C9C5785D6CA_3003_0">0.173</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE179294--1410-K0014_STD_366_20121231_0_1272045x1569517_1277042x1272910" unitRef="pure" decimals="3" id="id_6848266_75317A27-B598-4883-ACA0-8C9C5785D6CA_5003_4">0.489</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="eol_PE179294--1410-K0014_STD_366_20121231_0_1272072x1503196" unitRef="iso4217_USD" decimals="-5" id="id_6848266_AED8F272-20FC-4F1A-82AB-7856839A71BD_3_4">2000000</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
  <us-gaap:LicensesRevenue contextRef="eol_PE179294--1410-K0014_STD_366_20121231_0_1272072x1503196" unitRef="iso4217_USD" decimals="-5" id="id_6848266_AED8F272-20FC-4F1A-82AB-7856839A71BD_3_0">11700000</us-gaap:LicensesRevenue>
  <us-gaap:LicensesRevenue contextRef="eol_PE179294--1410-K0014_STD_366_20121231_0_1272072x1538608" unitRef="iso4217_USD" decimals="-5" id="id_6848266_4FE942DA-BDC1-4D22-A8C8-0DBE3DDFD663_3_0">9100000</us-gaap:LicensesRevenue>
  <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="eol_PE179294--1410-K0014_STD_366_20121231_0_1272072x1538608_1279908x1439878" unitRef="iso4217_USD" decimals="INF" id="id_6848266_D09A039D-38C1-4E9F-AFCC-87FCE28B8EF2_1003_4">0</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
  <us-gaap:LicensesRevenue contextRef="eol_PE179294--1410-K0014_STD_366_20121231_0_1272072x1538608_1279908x1439878" unitRef="iso4217_USD" decimals="-5" id="id_6848266_D09A039D-38C1-4E9F-AFCC-87FCE28B8EF2_1003_0">2000000</us-gaap:LicensesRevenue>
  <mgnx:CollaborationArrangementOffsetToResearchAndDevelopmentCosts contextRef="eol_PE179294--1410-K0014_STD_366_20121231_0_1272072x1538608_1279908x1439878" unitRef="iso4217_USD" decimals="INF" id="id_6848266_04591BAC-6897-476B-88E9-DCED4AA4B34E_1003_1">0</mgnx:CollaborationArrangementOffsetToResearchAndDevelopmentCosts>
  <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="eol_PE179294--1410-K0014_STD_366_20121231_0_1272072x1545620" unitRef="iso4217_USD" decimals="-5" id="id_6848266_D3A79C34-1D3F-47B7-B198-6DACB4B91533_3_1">500000</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
  <us-gaap:LicensesRevenue contextRef="eol_PE179294--1410-K0014_STD_366_20121231_0_1272072x1545620" unitRef="iso4217_USD" decimals="-5" id="id_6848266_D3A79C34-1D3F-47B7-B198-6DACB4B91533_3_0">5500000</us-gaap:LicensesRevenue>
  <us-gaap:LicensesRevenue contextRef="eol_PE179294--1410-K0014_STD_366_20121231_0_1272072x1569517" unitRef="iso4217_USD" decimals="-5" id="id_6848266_9A5607AA-73D8-4654-BE4E-3E38374EEC8A_2_0">31200000</us-gaap:LicensesRevenue>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE179294--1410-K0014_STD_366_20121231_0_1274159x1269133" unitRef="iso4217_USD" decimals="-3" id="id_6848266_0C47355F-C953-4F92-9309-B77CCD08112A_1003_1">366000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE179294--1410-K0014_STD_366_20121231_0_1274159x1269570" unitRef="iso4217_USD" decimals="-3" id="id_6848266_0C47355F-C953-4F92-9309-B77CCD08112A_2003_0">472000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:NetIncomeLoss contextRef="eol_PE179294--1410-K0014_STD_366_20121231_0_1276401x1269588" unitRef="iso4217_USD" decimals="-3" id="id_6848266_BFB39C8D-DAF1-408E-872B-38367E4AE90D_4018_6">8362000</us-gaap:NetIncomeLoss>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="eol_PE179294--1410-K0014_STD_366_20121231_0_1276401x1270422" unitRef="shares" decimals="INF" id="id_6848266_BFB39C8D-DAF1-408E-872B-38367E4AE90D_4013_5">49884</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE179294--1410-K0014_STD_366_20121231_0_1276401x1273630" unitRef="iso4217_USD" decimals="-3" id="id_6848266_BFB39C8D-DAF1-408E-872B-38367E4AE90D_4017_4">46000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE179294--1410-K0014_STD_366_20121231_0_1276401x1273630" unitRef="iso4217_USD" decimals="-3" id="id_6848266_BFB39C8D-DAF1-408E-872B-38367E4AE90D_4017_3">838000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized contextRef="eol_PE179294--1410-K0014_STD_366_20121231_0_1280964x1610346" unitRef="shares" decimals="INF" id="id_6848266_D28E7557-DDA7-4B6D-9607-D6CA79D3147F_1003_3">545970</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
  <mgnx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease contextRef="eol_PE179294--1410-K0014_STD_366_20121231_0_1280964x1610346" unitRef="shares" decimals="INF" id="id_6848266_D28E7557-DDA7-4B6D-9607-D6CA79D3147F_1003_4">4336730</mgnx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE179294--1410-K0014_STD_730_20031231_0_1276400x1269676" unitRef="shares" decimals="INF" id="id_6848266_EC69272C-D3C5-43AD-8833-6DB1DCB18EE3_1001_0">34239374</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock contextRef="eol_PE179294--1410-K0014_STD_730_20031231_0_1276400x1269676" unitRef="iso4217_USD" decimals="-5" id="id_6848266_EC69272C-D3C5-43AD-8833-6DB1DCB18EE3_1001_1">34000000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
  <us-gaap:EarningsPerShareDiluted contextRef="eol_PE179294--1410-K0014_STD_90_20130331_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_6848266_B4A3C0A0-0CA7-40A4-9088-B96E6FDD78FC_1_3">-2.93</us-gaap:EarningsPerShareDiluted>
  <us-gaap:EarningsPerShareBasic contextRef="eol_PE179294--1410-K0014_STD_90_20130331_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_6848266_B4A3C0A0-0CA7-40A4-9088-B96E6FDD78FC_1_2">-2.93</us-gaap:EarningsPerShareBasic>
  <us-gaap:Revenues contextRef="eol_PE179294--1410-K0014_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_B4A3C0A0-0CA7-40A4-9088-B96E6FDD78FC_1_0">10598000</us-gaap:Revenues>
  <us-gaap:NetIncomeLoss contextRef="eol_PE179294--1410-K0014_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_B4A3C0A0-0CA7-40A4-9088-B96E6FDD78FC_1_1">-3366000</us-gaap:NetIncomeLoss>
  <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare contextRef="eol_PE179294--1410-K0014_STD_90_20140331_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_6848266_1387E7D8-A32C-4BE9-A199-5150C9F9FDB0_1_2">-0.12</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
  <us-gaap:Revenues contextRef="eol_PE179294--1410-K0014_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_1387E7D8-A32C-4BE9-A199-5150C9F9FDB0_1_0">14719000</us-gaap:Revenues>
  <us-gaap:NetIncomeLoss contextRef="eol_PE179294--1410-K0014_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_1387E7D8-A32C-4BE9-A199-5150C9F9FDB0_1_1">-3108000</us-gaap:NetIncomeLoss>
  <us-gaap:EarningsPerShareDiluted contextRef="eol_PE179294--1410-K0014_STD_91_20130630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_6848266_B4A3C0A0-0CA7-40A4-9088-B96E6FDD78FC_2_3">-0.24</us-gaap:EarningsPerShareDiluted>
  <us-gaap:EarningsPerShareBasic contextRef="eol_PE179294--1410-K0014_STD_91_20130630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_6848266_B4A3C0A0-0CA7-40A4-9088-B96E6FDD78FC_2_2">-0.24</us-gaap:EarningsPerShareBasic>
  <us-gaap:Revenues contextRef="eol_PE179294--1410-K0014_STD_91_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_B4A3C0A0-0CA7-40A4-9088-B96E6FDD78FC_2_0">12299000</us-gaap:Revenues>
  <us-gaap:NetIncomeLoss contextRef="eol_PE179294--1410-K0014_STD_91_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_B4A3C0A0-0CA7-40A4-9088-B96E6FDD78FC_2_1">-294000</us-gaap:NetIncomeLoss>
  <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare contextRef="eol_PE179294--1410-K0014_STD_91_20140630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_6848266_1387E7D8-A32C-4BE9-A199-5150C9F9FDB0_2_2">-0.44</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
  <us-gaap:Revenues contextRef="eol_PE179294--1410-K0014_STD_91_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_1387E7D8-A32C-4BE9-A199-5150C9F9FDB0_2_0">9220000</us-gaap:Revenues>
  <us-gaap:NetIncomeLoss contextRef="eol_PE179294--1410-K0014_STD_91_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_1387E7D8-A32C-4BE9-A199-5150C9F9FDB0_2_1">-12259000</us-gaap:NetIncomeLoss>
  <us-gaap:EarningsPerShareDiluted contextRef="eol_PE179294--1410-K0014_STD_92_20130930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_6848266_B4A3C0A0-0CA7-40A4-9088-B96E6FDD78FC_3_3">0.01</us-gaap:EarningsPerShareDiluted>
  <us-gaap:EarningsPerShareBasic contextRef="eol_PE179294--1410-K0014_STD_92_20130930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_6848266_B4A3C0A0-0CA7-40A4-9088-B96E6FDD78FC_3_2">0.14</us-gaap:EarningsPerShareBasic>
  <us-gaap:Revenues contextRef="eol_PE179294--1410-K0014_STD_92_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_B4A3C0A0-0CA7-40A4-9088-B96E6FDD78FC_3_0">20232000</us-gaap:Revenues>
  <us-gaap:NetIncomeLoss contextRef="eol_PE179294--1410-K0014_STD_92_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_B4A3C0A0-0CA7-40A4-9088-B96E6FDD78FC_3_1">6604000</us-gaap:NetIncomeLoss>
  <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare contextRef="eol_PE179294--1410-K0014_STD_92_20140930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_6848266_1387E7D8-A32C-4BE9-A199-5150C9F9FDB0_3_2">-0.14</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
  <us-gaap:Revenues contextRef="eol_PE179294--1410-K0014_STD_92_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_1387E7D8-A32C-4BE9-A199-5150C9F9FDB0_3_0">18382000</us-gaap:Revenues>
  <us-gaap:NetIncomeLoss contextRef="eol_PE179294--1410-K0014_STD_92_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_1387E7D8-A32C-4BE9-A199-5150C9F9FDB0_3_1">-3928000</us-gaap:NetIncomeLoss>
  <us-gaap:EarningsPerShareDiluted contextRef="eol_PE179294--1410-K0014_STD_92_20131231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_6848266_B4A3C0A0-0CA7-40A4-9088-B96E6FDD78FC_4_3">-0.14</us-gaap:EarningsPerShareDiluted>
  <us-gaap:EarningsPerShareBasic contextRef="eol_PE179294--1410-K0014_STD_92_20131231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_6848266_B4A3C0A0-0CA7-40A4-9088-B96E6FDD78FC_4_2">-0.14</us-gaap:EarningsPerShareBasic>
  <us-gaap:Revenues contextRef="eol_PE179294--1410-K0014_STD_92_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_B4A3C0A0-0CA7-40A4-9088-B96E6FDD78FC_4_0">14906000</us-gaap:Revenues>
  <us-gaap:NetIncomeLoss contextRef="eol_PE179294--1410-K0014_STD_92_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_B4A3C0A0-0CA7-40A4-9088-B96E6FDD78FC_4_1">-3205000</us-gaap:NetIncomeLoss>
  <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare contextRef="eol_PE179294--1410-K0014_STD_92_20141231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_6848266_1387E7D8-A32C-4BE9-A199-5150C9F9FDB0_4_2">-0.68</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
  <us-gaap:Revenues contextRef="eol_PE179294--1410-K0014_STD_92_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_1387E7D8-A32C-4BE9-A199-5150C9F9FDB0_4_0">5476000</us-gaap:Revenues>
  <us-gaap:NetIncomeLoss contextRef="eol_PE179294--1410-K0014_STD_92_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6848266_1387E7D8-A32C-4BE9-A199-5150C9F9FDB0_4_1">-19018000</us-gaap:NetIncomeLoss>
  <context id="eol_PE179294--1410-K0014_STD_92_20141231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
    </entity>
    <period>
      <startDate>2014-10-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_92_20131231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
    </entity>
    <period>
      <startDate>2013-10-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_92_20140930_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
    </entity>
    <period>
      <startDate>2014-07-01</startDate>
      <endDate>2014-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_92_20130930_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_91_20140630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
    </entity>
    <period>
      <startDate>2014-04-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_91_20130630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
    </entity>
    <period>
      <startDate>2013-04-01</startDate>
      <endDate>2013-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_90_20140331_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_90_20130331_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_730_20031231_0_1276400x1269676">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2002-01-01</startDate>
      <endDate>2003-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_366_20121231_0_1280964x1610346">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:EquityIncentivePlan2003Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_366_20121231_0_1276401x1273630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_366_20121231_0_1276401x1270422">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_366_20121231_0_1276401x1269588">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_366_20121231_0_1274159x1269570">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_366_20121231_0_1274159x1269133">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_366_20121231_0_1272072x1569517">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:EliLillyMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_366_20121231_0_1272072x1545620">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:PfizerIncMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_366_20121231_0_1272072x1538608_1279908x1439878">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:SecondRightToDevelopCollaborationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_366_20121231_0_1272072x1538608">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_366_20121231_0_1272072x1503196">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:BoehringerIngelheimMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_366_20121231_0_1272045x1569517_1277042x1272910">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">mgnx:EliLillyMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_366_20121231_0_1272045x1538608_1277042x1272910">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">mgnx:ServierMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_366_20121231_0_1272045x1503196_1277042x1272910">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">mgnx:BoehringerIngelheimMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_366_20121231_0_1268687x1559024">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mgnx:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_366_20121231_0_1268687x1493912">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mgnx:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_366_20121231_0_1268687x1421015">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mgnx:SeriesD2ConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_366_20121231_0_1268687x1343554">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mgnx:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_366_20121231_0_1268687x1310046">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mgnx:SeriesA2ConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_366_20121231_0_1268687x1296600">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mgnx:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_366_20121231_0_1268687x1281225">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_366_20121231_0_1268687x1273442">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_366_20121231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_365_20141231_0_1280964x1365667">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:StockOptionPlan2000Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_365_20141231_0_1280964x1332409">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:StockIncentivePlan2013Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_365_20141231_0_1280651x1613554">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">mgnx:EndingYearMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_365_20141231_0_1280651x1613553">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">mgnx:StartYearMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_365_20141231_0_1279380x1621777">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">mgnx:ManufacturingSpaceMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_365_20141231_0_1279380x1610417">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">mgnx:AdditionalManufacturingSpaceMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_365_20141231_0_1277830x1270443">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:ContractTerminationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_365_20141231_0_1276401x1273630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_365_20141231_0_1276401x1273409">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_365_20141231_0_1276401x1270422">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_365_20141231_0_1276401x1269588">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_365_20141231_0_1276400x1610343">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mgnx:SeriesD2PreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_365_20141231_0_1276400x1481307">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mgnx:SeriesA1PreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_365_20141231_0_1276400x1369166">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mgnx:SeriesA2PreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_365_20141231_0_1276400x1281158">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_365_20141231_0_1276400x1281157">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_365_20141231_0_1276400x1279561">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_365_20141231_0_1276400x1269676">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_365_20141231_0_1276136x1479456">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mgnx:LaboratoryAndOfficeEquipmentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_365_20141231_0_1276136x1277975">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_365_20141231_0_1276136x1277482">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_365_20141231_0_1276136x1275434">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_365_20141231_0_1276136x1274094">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_365_20141231_0_1274159x1269570">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_365_20141231_0_1274159x1269133">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_365_20141231_0_1273334x1271232">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioPreviouslyReportedMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_365_20141231_0_1273333x1605760_1279380x1509307">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">mgnx:OfficeAndLaboratorySpaceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">mgnx:RockvilleMarylandMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_365_20141231_0_1273333x1394675_1279380x1509307">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">mgnx:OfficeAndLaboratorySpaceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">mgnx:SouthSanFranciscoMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_365_20141231_0_1272072x1605598">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_365_20141231_0_1272072x1569517">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:EliLillyMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_365_20141231_0_1272072x1565531_1279908x1600194">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:TakedaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ResearchCollaborationAndLicenseOptionAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_365_20141231_0_1272072x1565531">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:TakedaMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_365_20141231_0_1272072x1545620">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:PfizerIncMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_365_20141231_0_1272072x1538608_1279908x1439878">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:SecondRightToDevelopCollaborationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_365_20141231_0_1272072x1538608_1273334x1269610_1279908x1439878">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:SecondRightToDevelopCollaborationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_365_20141231_0_1272072x1538608_1273334x1269610">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioAdjustmentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_365_20141231_0_1272072x1538608">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_365_20141231_0_1272072x1503196">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:BoehringerIngelheimMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_365_20141231_0_1272072x1444876">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:GileadMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_365_20141231_0_1272072x1370805">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:GreenCrossCorporationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_365_20141231_0_1272045x1569517_1277042x1272910">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">mgnx:EliLillyMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_365_20141231_0_1272045x1565531_1277042x1272910">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">mgnx:TakedaMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_365_20141231_0_1272045x1538608_1277042x1275282">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">mgnx:ServierMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_365_20141231_0_1272045x1538608_1277042x1272910">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">mgnx:ServierMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_365_20141231_0_1272045x1503196_1277042x1275282">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">mgnx:BoehringerIngelheimMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_365_20141231_0_1272045x1503196_1277042x1272910">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">mgnx:BoehringerIngelheimMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_365_20141231_0_1272045x1370805_1277042x1275282">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">mgnx:GreenCrossCorporationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_365_20141231_0_1272045x1351512_1277042x1272910">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">mgnx:GileadSciencesIncMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_365_20141231_0_1272045x1277073">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_365_20141231_0_1272045x1275481">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_365_20141231_0_1269523x1277596_1277042x1275282">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_365_20141231_0_1269523x1277596_1277042x1272910">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_365_20141231_0_1269523x1277596">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_365_20141231_0_1269523x1275948_1272072x1370805">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:GreenCrossCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_365_20141231_0_1269523x1275948">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_365_20141231_0_1268687x1281225">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_365_20141231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_365_20131231_0_1277830x1270443">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:ContractTerminationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_365_20131231_0_1276401x1559024">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mgnx:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_365_20131231_0_1276401x1493912">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mgnx:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_365_20131231_0_1276401x1421015">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mgnx:SeriesD2ConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_365_20131231_0_1276401x1310046">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mgnx:SeriesA2ConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_365_20131231_0_1276401x1296600">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mgnx:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_365_20131231_0_1276401x1291665">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mgnx:SeriesD1ConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_365_20131231_0_1276401x1273630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_365_20131231_0_1276401x1270422">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_365_20131231_0_1276401x1269588">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_365_20131231_0_1274159x1269570">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_365_20131231_0_1274159x1269133">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_365_20131231_0_1272072x1569517">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:EliLillyMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_365_20131231_0_1272072x1545620">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:PfizerIncMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_365_20131231_0_1272072x1538608_1279908x1439878">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:SecondRightToDevelopCollaborationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_365_20131231_0_1272072x1538608">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_365_20131231_0_1272072x1503196">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:BoehringerIngelheimMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_365_20131231_0_1272072x1444876">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:GileadMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_365_20131231_0_1272072x1370805">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:GreenCrossCorporationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_365_20131231_0_1272045x1569517_1277042x1272910">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">mgnx:EliLillyMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_365_20131231_0_1272045x1545620_1277042x1275282">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">mgnx:PfizerIncMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_365_20131231_0_1272045x1538608_1277042x1275282">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">mgnx:ServierMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_365_20131231_0_1272045x1538608_1277042x1272910">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">mgnx:ServierMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_365_20131231_0_1272045x1503196_1277042x1275282">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">mgnx:BoehringerIngelheimMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_365_20131231_0_1272045x1503196_1277042x1272910">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">mgnx:BoehringerIngelheimMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_365_20131231_0_1272045x1351512_1277042x1275282">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">mgnx:GileadSciencesIncMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_365_20131231_0_1272045x1351512_1277042x1272910">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">mgnx:GileadSciencesIncMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_365_20131231_0_1269523x1277596">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_365_20131231_0_1269523x1275948">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_365_20131231_0_1268687x1281225">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_365_20131231_0_1268687x1270467">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_365_20131231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_31_20140531_0_1272072x1565531">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:TakedaMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-05-01</startDate>
      <endDate>2014-05-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_31_20100531_0_1272072x1569517">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:EliLillyMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2010-05-01</startDate>
      <endDate>2010-05-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_31_20080531_0_1272072x1569517">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:EliLillyMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2008-05-01</startDate>
      <endDate>2008-05-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_31_20060531_0_1276400x1279561">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2006-05-01</startDate>
      <endDate>2006-05-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_31_20110331_0_1276400x1281158_1276960x1336998">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mgnx:RavenBiotechnologiesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-03-01</startDate>
      <endDate>2011-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_31_20150131_0_1271378x1273350_1272072x1319668">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:JohnsonAndJohnsonDevelopmentCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-01-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_31_20130131_0_1272072x1444876">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:GileadMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-01-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_31_20101031_0_1272072x1545620">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:PfizerIncMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2010-10-01</startDate>
      <endDate>2010-10-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_31_20101031_0_1272072x1503196">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:BoehringerIngelheimMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2010-10-01</startDate>
      <endDate>2010-10-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_31_20080731_0_1276400x1281158_1276960x1336998">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mgnx:RavenBiotechnologiesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2008-07-01</startDate>
      <endDate>2008-07-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_31_20041031_0_1276400x1281157">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2004-10-01</startDate>
      <endDate>2004-10-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_30_20120930_0_1272072x1538608_1279908x1439878">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:SecondRightToDevelopCollaborationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-09-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_30_20080930_0_1276400x1610343">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mgnx:SeriesD2PreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2008-09-01</startDate>
      <endDate>2008-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_30_20100630_0_1272072x1370805">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:GreenCrossCorporationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2010-06-01</startDate>
      <endDate>2010-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_30_20050630_0_1269523x1277596">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2005-06-01</startDate>
      <endDate>2005-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_30_20050630_0_1269523x1275948">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2005-06-01</startDate>
      <endDate>2005-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_30_20111130_0_1272072x1538608">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-11-01</startDate>
      <endDate>2011-11-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_28_20140228_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
    </entity>
    <period>
      <startDate>2014-02-01</startDate>
      <endDate>2014-02-28</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_1826_20101231_0_1280964x1610346">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:EquityIncentivePlan2003Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2006-01-01</startDate>
      <endDate>2010-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_1096_20141231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_1_20110111_0_1268687x1421015">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mgnx:SeriesD2ConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-11</startDate>
      <endDate>2011-01-11</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_1_20131016_0_1271382x1280942">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-10-16</startDate>
      <endDate>2013-10-16</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_1_20131016_0_1271382x1272538">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-10-16</startDate>
      <endDate>2013-10-16</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_1_20131016_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
    </entity>
    <period>
      <startDate>2013-10-16</startDate>
      <endDate>2013-10-16</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_1_20020925_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
    </entity>
    <period>
      <startDate>2002-09-25</startDate>
      <endDate>2002-09-25</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_1_20140716_0_1276400x1491160">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mgnx:ConvertiblePreferredStockSeriesDMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-07-16</startDate>
      <endDate>2014-07-16</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_1_20100516_0_1276400x1610343">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mgnx:SeriesD2PreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2010-05-16</startDate>
      <endDate>2010-05-16</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_0_20141231_0_1280964x1610346">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:EquityIncentivePlan2003Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_0_20141231_0_1280964x1365667">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:StockOptionPlan2000Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_0_20141231_0_1280964x1332409">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:StockIncentivePlan2013Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_0_20141231_0_1280651x1280458">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_0_20141231_0_1280651x1276398">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_0_20141231_0_1277830x1270443">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:ContractTerminationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_0_20141231_0_1276960x1336998">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mgnx:RavenBiotechnologiesIncMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_0_20141231_0_1276401x1273630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_0_20141231_0_1276401x1273409">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_0_20141231_0_1276401x1270422">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_0_20141231_0_1276401x1269588">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_0_20141231_0_1276400x1610343">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mgnx:SeriesD2PreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_0_20141231_0_1276400x1481307">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mgnx:SeriesA1PreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_0_20141231_0_1276400x1369166">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mgnx:SeriesA2PreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_0_20141231_0_1276400x1312914">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mgnx:UndesignatedPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_0_20141231_0_1276400x1281158">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_0_20141231_0_1276400x1281157">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_0_20141231_0_1276400x1279561">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_0_20141231_0_1276136x1424108">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mgnx:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_0_20141231_0_1276136x1277975">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_0_20141231_0_1276136x1277482">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_0_20141231_0_1276136x1275434">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_0_20141231_0_1276136x1273964">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_0_20141231_0_1272072x1605598">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_0_20141231_0_1272072x1565531">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:TakedaMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_0_20141231_0_1272072x1545620">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:PfizerIncMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_0_20141231_0_1272072x1538608_1279908x1439878">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:SecondRightToDevelopCollaborationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_0_20141231_0_1272072x1538608">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_0_20141231_0_1272072x1503196">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:BoehringerIngelheimMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_0_20141231_0_1272072x1444876">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:GileadMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_0_20141231_0_1272072x1370805">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:GreenCrossCorporationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_0_20141231_0_1269523x1277596_1272072x1444876_1279908x1560227">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:GileadMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:PreclinicalMilestonesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_0_20141231_0_1269523x1277596_1272072x1444876">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:GileadMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_0_20141231_0_1269523x1277596">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_0_20141231_0_1269523x1275948_1272072x1538608_1279908x1439878">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:SecondRightToDevelopCollaborationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_0_20141231_0_1269523x1275948_1272072x1538608">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_0_20141231_0_1269523x1275948_1272072x1444876_1279908x1560227">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:GileadMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:PreclinicalMilestonesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_0_20141231_0_1269523x1275948_1272072x1444876">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:GileadMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_0_20141231_0_1269523x1275948_1272072x1370805">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:GreenCrossCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_0_20141231_0_1269523x1275948">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_0_20141231_0_1269038x1272304">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_0_20141231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_0_20131231_0_1277830x1270443">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:ContractTerminationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_0_20131231_0_1276401x1273630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_0_20131231_0_1276401x1273409">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_0_20131231_0_1276401x1270422">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_0_20131231_0_1276401x1269588">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_0_20131231_0_1276400x1312914">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mgnx:UndesignatedPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_0_20131231_0_1276136x1424108">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mgnx:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_0_20131231_0_1276136x1277975">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_0_20131231_0_1276136x1277482">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_0_20131231_0_1276136x1275434">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_0_20131231_0_1276136x1273964">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_0_20131231_0_1272072x1545620">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:PfizerIncMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_0_20131231_0_1272072x1538608_1279908x1439878">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:SecondRightToDevelopCollaborationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_0_20131231_0_1272072x1538608">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_0_20131231_0_1272072x1503196">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:BoehringerIngelheimMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_0_20131231_0_1272072x1444876">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:GileadMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_0_20131231_0_1272072x1370805">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:GreenCrossCorporationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_0_20131231_0_1269038x1272304">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_0_20131231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_0_20121231_0_1277830x1270443">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:ContractTerminationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_0_20121231_0_1276401x1559024">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mgnx:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_0_20121231_0_1276401x1493912">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mgnx:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_0_20121231_0_1276401x1421015">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mgnx:SeriesD2ConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_0_20121231_0_1276401x1310046">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mgnx:SeriesA2ConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_0_20121231_0_1276401x1296600">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mgnx:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_0_20121231_0_1276401x1291665">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mgnx:SeriesD1ConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_0_20121231_0_1276401x1273630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_0_20121231_0_1276401x1273409">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_0_20121231_0_1276401x1270422">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_0_20121231_0_1276401x1269588">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_0_20121231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_0_20111231_0_1276401x1559024">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mgnx:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_0_20111231_0_1276401x1493912">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mgnx:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_0_20111231_0_1276401x1421015">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mgnx:SeriesD2ConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_0_20111231_0_1276401x1310046">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mgnx:SeriesA2ConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_0_20111231_0_1276401x1296600">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mgnx:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_0_20111231_0_1276401x1291665">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mgnx:SeriesD1ConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_0_20111231_0_1276401x1273630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_0_20111231_0_1276401x1273409">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_0_20111231_0_1276401x1270422">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_0_20111231_0_1276401x1269588">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_0_20111231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_0_20031231_0_1276400x1269676">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2003-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_0_20140630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
    </entity>
    <period>
      <instant>2014-06-30</instant>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_0_20131016_0_1271382x1280942">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-10-16</instant>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_0_20131016_0_1271382x1272538">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-10-16</instant>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_0_20080930_0_1276400x1610343">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mgnx:SeriesD2PreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2008-09-30</instant>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_0_20080716_0_1269523x1277596">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2008-07-16</instant>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_0_20080716_0_1269523x1275948">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2008-07-16</instant>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_0_20080716_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
    </entity>
    <period>
      <instant>2008-07-16</instant>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_0_20060531_0_1276400x1281157">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2006-05-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_0_20050630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
    </entity>
    <period>
      <instant>2005-06-30</instant>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_0_20150227_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
    </entity>
    <period>
      <instant>2015-02-27</instant>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_0_20150131_0_1271378x1273350_1272072x1605598">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-01-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_0_20140228_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
    </entity>
    <period>
      <instant>2014-02-28</instant>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_0_20131031_0_1280964x1332409">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:StockIncentivePlan2013Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-10-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_0_20100516_0_1276400x1610343">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mgnx:SeriesD2PreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2010-05-16</instant>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_0_20041031_0_1276400x1427952">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mgnx:SeriesAOnePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2004-10-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1410-K0014_STD_0_20030228_0_1280964x1610346">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:EquityIncentivePlan2003Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2003-02-28</instant>
    </period>
  </context>
  <unit id="shares">
    <measure>shares</measure>
  </unit>
  <unit id="iso4217_USD_per_shares">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="iso4217_USD">
    <measure>iso4217:USD</measure>
  </unit>
  <unit id="Assets">
    <measure>mgnx:Assets</measure>
  </unit>
  <unit id="pure">
    <measure>pure</measure>
  </unit>
  <unit id="Molecule">
    <measure>mgnx:Molecule</measure>
  </unit>
  <unit id="Segment">
    <measure>mgnx:Segment</measure>
  </unit>
  <unit id="Payments">
    <measure>mgnx:Payments</measure>
  </unit>
  <unit id="Milestone">
    <measure>mgnx:Milestone</measure>
  </unit>
  <unit id="Program">
    <measure>mgnx:Program</measure>
  </unit>
</xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>16
<FILENAME>mgnx-20141231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- RR Donnelley Xcelerate Taxonomy Schema, based on XBRL 2.1  http://www.rrdonnelley.com/ -->
<!-- Version: 6.22.4 -->
<!-- Round: 8 -->
<!-- Creation date: 2015-03-03T16:02:26Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<schema xmlns="http://www.w3.org/2001/XMLSchema"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:us-gaap="http://fasb.org/us-gaap/2014-01-31"
  xmlns:us-types="http://fasb.org/us-types/2014-01-31"
  xmlns:mgnx="http://www.macrogenics.com/20141231"
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xmlns:country="http://xbrl.sec.gov/country/2013-01-31"
  xmlns:currency="http://xbrl.sec.gov/currency/2014-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31"
  xmlns:exch="http://xbrl.sec.gov/exch/2014-01-31"
  xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31"
  xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31"
  xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31"
  targetNamespace="http://www.macrogenics.com/20141231"
  elementFormDefault="qualified" attributeFormDefault="unqualified">
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/DocumentandEntityInformation" id="DocumentandEntityInformation">
        <link:definition>101 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/StatementOfFinancialPositionClassified" id="Role_StatementOfFinancialPositionClassified">
        <link:definition>103 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical" id="Role_StatementOfFinancialPositionClassifiedParen">
        <link:definition>104 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/StatementOfIncomeAlternative" id="Role_StatementOfIncomeAlternative">
        <link:definition>105 - Statement - Consolidated Statements of Operations and Comprehensive Income (Loss)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome" id="Role_StatementOfShareholdersEquityAndOtherComprehensiveIncome">
        <link:definition>106 - Statement - Consolidated Statements of Stockholders' Equity (Deficit)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/StatementOfCashFlowsIndirect" id="Role_StatementOfCashFlowsIndirect">
        <link:definition>107 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
        <link:definition>108 - Disclosure - Organization and Nature of Operations</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock" id="Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock">
        <link:definition>109 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock" id="Role_NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock">
        <link:definition>110 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock" id="Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock">
        <link:definition>111 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
        <link:definition>112 - Disclosure - Stock-based Compensation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock" id="Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlock">
        <link:definition>113 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsRestructuringAndRelatedActivitiesDisclosureTextBlock" id="Role_NotesToFinancialStatementsRestructuringAndRelatedActivitiesDisclosureTextBlock">
        <link:definition>114 - Disclosure - Lease Exit Liability</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsCollaborationAndLicenseAgreementsDisclosureTextBlock" id="Role_NotesToFinancialStatementsCollaborationAndLicenseAgreementsDisclosureTextBlock">
        <link:definition>115 - Disclosure - Collaboration and License Agreements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock" id="Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock">
        <link:definition>116 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsRoyaltyAgreementDisclosureTextBlock" id="Role_NotesToFinancialStatementsRoyaltyAgreementDisclosureTextBlock">
        <link:definition>117 - Disclosure - Product Milestone Payments and Royalty Agreements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsPensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="Role_NotesToFinancialStatementsPensionAndOtherPostretirementBenefitsDisclosureTextBlock">
        <link:definition>118 - Disclosure - Employee Benefit Plan</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlock" id="Role_NotesToFinancialStatementsQuarterlyFinancialInformationTextBlock">
        <link:definition>119 - Disclosure - Quarterly Financial Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock" id="Role_NotesToFinancialStatementsSubsequentEventsTextBlock">
        <link:definition>120 - Disclosure - Subsequent Event</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies" id="Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies">
        <link:definition>121 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables" id="Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables">
        <link:definition>122 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables" id="Role_NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables">
        <link:definition>123 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables" id="Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables">
        <link:definition>124 - Disclosure - Stock-based Compensation (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables" id="Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables">
        <link:definition>125 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsRestructuringAndRelatedActivitiesDisclosureTextBlockTables" id="Role_NotesToFinancialStatementsRestructuringAndRelatedActivitiesDisclosureTextBlockTables">
        <link:definition>126 - Disclosure - Lease Exit Liability (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables" id="Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables">
        <link:definition>127 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlockTables" id="Role_NotesToFinancialStatementsQuarterlyFinancialInformationTextBlockTables">
        <link:definition>128 - Disclosure - Quarterly Financial Information (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformation" id="DisclosureOrganizationAndNatureOfOperationsAdditionalInformation">
        <link:definition>129 - Disclosure - Organization and Nature of Operations - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation" id="DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation">
        <link:definition>130 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfFairValueMeasurementFinancialAssetAndLiabilities" id="DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfFairValueMeasurementFinancialAssetAndLiabilities">
        <link:definition>131 - Disclosure - Summary of Significant Accounting Policies - Summary of Fair Value Measurement Financial Asset and Liabilities (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfCollaboratorsThatRepresentMoreThan10OfTotalRevenueEarned" id="DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfCollaboratorsThatRepresentMoreThan10OfTotalRevenueEarned">
        <link:definition>132 - Disclosure - Summary of Significant Accounting Policies - Summary of Collaborators that Represent More Than 10% of Total Revenue Earned (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfCollaboratorsThatRepresentMoreThan10OfAccountsReceivable" id="DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfCollaboratorsThatRepresentMoreThan10OfAccountsReceivable">
        <link:definition>133 - Disclosure - Summary of Significant Accounting Policies - Summary of Collaborators that Represent More Than 10% of Accounts Receivable (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLives" id="DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLives">
        <link:definition>134 - Disclosure - Summary of Significant Accounting Policies - Estimated Useful Lives (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesComputationOfBasicAndDilutedIncomeLossPerCommonShare" id="DisclosureSummaryOfSignificantAccountingPoliciesComputationOfBasicAndDilutedIncomeLossPerCommonShare">
        <link:definition>135 - Disclosure - Summary of Significant Accounting Policies - Computation of Basic and Diluted Income (Loss) Per Common Share (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromTheCalculationOfDilutedIncomeLossPerShare" id="DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromTheCalculationOfDilutedIncomeLossPerShare">
        <link:definition>136 - Disclosure - Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from the Calculation of Diluted Income (Loss) Per Share (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipment" id="DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipment">
        <link:definition>137 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformation" id="DisclosurePropertyAndEquipmentAdditionalInformation">
        <link:definition>138 - Disclosure - Property and Equipment - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureStockholdersEquityAdditionalInformation" id="DisclosureStockholdersEquityAdditionalInformation">
        <link:definition>139 - Disclosure - Stockholders' Equity - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformation" id="DisclosureStockBasedCompensationAdditionalInformation">
        <link:definition>140 - Disclosure - Stock- based Compensation - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpense" id="DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpense">
        <link:definition>141 - Disclosure - Stock- based Compensation - Schedule of Stock-Based Compensation Expense (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureStockBasedCompensationScheduleOfFairValueOptionAwardEstimatedOnTheDateOfGrantUsingTheBlackScholesOptionPricingModel" id="DisclosureStockBasedCompensationScheduleOfFairValueOptionAwardEstimatedOnTheDateOfGrantUsingTheBlackScholesOptionPricingModel">
        <link:definition>142 - Disclosure - Stock- based Compensation - Schedule of Fair Value Option Award Estimated on the Date of Grant Using the Black-Scholes Option-Pricing Model (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockOptionAndRestrictedStockUnitActivity" id="DisclosureStockBasedCompensationScheduleOfStockOptionAndRestrictedStockUnitActivity">
        <link:definition>143 - Disclosure - Stock- based Compensation - Schedule of Stock Option and Restricted Stock Unit Activity (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation" id="DisclosureIncomeTaxesAdditionalInformation">
        <link:definition>144 - Disclosure - Income Taxes - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureIncomeTaxesComponentsOfTheCompanysDeferredTaxAssetsLiabilities" id="DisclosureIncomeTaxesComponentsOfTheCompanysDeferredTaxAssetsLiabilities">
        <link:definition>145 - Disclosure - Income Taxes - Components of the Company's Deferred Tax Assets (Liabilities) (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureIncomeTaxesReconciliationOfReportedEstimatedIncomeTaxBenefit" id="DisclosureIncomeTaxesReconciliationOfReportedEstimatedIncomeTaxBenefit">
        <link:definition>146 - Disclosure - Income Taxes - Reconciliation of Reported Estimated Income Tax Benefit (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureIncomeTaxesReconciliationOfTheBeginningAndEndingAmountOfGrossUnrecognizedTaxBenefits" id="DisclosureIncomeTaxesReconciliationOfTheBeginningAndEndingAmountOfGrossUnrecognizedTaxBenefits">
        <link:definition>147 - Disclosure - Income Taxes - Reconciliation of the Beginning and Ending Amount of Gross Unrecognized Tax Benefits (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureLeaseExitLiabilityAdditionalInformation" id="DisclosureLeaseExitLiabilityAdditionalInformation">
        <link:definition>148 - Disclosure - Lease Exit Liability - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureLeaseExitLiabilityChangesInLeaseExitLiability" id="DisclosureLeaseExitLiabilityChangesInLeaseExitLiability">
        <link:definition>149 - Disclosure - Lease Exit Liability - Changes in Lease Exit Liability (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureLeaseExitLiabilityFuturePrincipalPaymentsUnderLeaseAgreement" id="DisclosureLeaseExitLiabilityFuturePrincipalPaymentsUnderLeaseAgreement">
        <link:definition>150 - Disclosure - Lease Exit Liability - Future Principal Payments Under Lease Agreement (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformation1" id="DisclosureCollaborationAndLicenseAgreementsAdditionalInformation1">
        <link:definition>151 - Disclosure - Collaboration and License Agreements - Additional Information 1 (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformation2" id="DisclosureCollaborationAndLicenseAgreementsAdditionalInformation2">
        <link:definition>152 - Disclosure - Collaboration and License Agreements - Additional Information 2 (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformation3" id="DisclosureCollaborationAndLicenseAgreementsAdditionalInformation3">
        <link:definition>153 - Disclosure - Collaboration and License Agreements - Additional Information 3 (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformation4" id="DisclosureCollaborationAndLicenseAgreementsAdditionalInformation4">
        <link:definition>154 - Disclosure - Collaboration and License Agreements - Additional Information 4 (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformation5" id="DisclosureCollaborationAndLicenseAgreementsAdditionalInformation5">
        <link:definition>155 - Disclosure - Collaboration and License Agreements - Additional Information 5 (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformation6" id="DisclosureCollaborationAndLicenseAgreementsAdditionalInformation6">
        <link:definition>156 - Disclosure - Collaboration and License Agreements - Additional Information 6 (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformation7" id="DisclosureCollaborationAndLicenseAgreementsAdditionalInformation7">
        <link:definition>157 - Disclosure - Collaboration and License Agreements - Additional Information 7 (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation" id="DisclosureCommitmentsAndContingenciesAdditionalInformation">
        <link:definition>158 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMinimumFutureLeasePayments" id="DisclosureCommitmentsAndContingenciesScheduleOfMinimumFutureLeasePayments">
        <link:definition>159 - Disclosure - Commitments and Contingencies - Schedule of Minimum Future Lease Payments (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureProductMilestonePaymentsAndRoyaltyAgreementsAdditionalInformation" id="DisclosureProductMilestonePaymentsAndRoyaltyAgreementsAdditionalInformation">
        <link:definition>160 - Disclosure - Product Milestone Payments and Royalty Agreements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureEmployeeBenefitPlanAdditionalInformation" id="DisclosureEmployeeBenefitPlanAdditionalInformation">
        <link:definition>161 - Disclosure - Employee Benefit Plan - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureQuarterlyFinancialInformationCompanysConsolidatedQuarterlyResultsOfOperations" id="DisclosureQuarterlyFinancialInformationCompanysConsolidatedQuarterlyResultsOfOperations">
        <link:definition>162 - Disclosure - Quarterly Financial Information - Company's Consolidated Quarterly Results of Operations (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSubsequentEventAdditionalInformation" id="DisclosureSubsequentEventAdditionalInformation">
        <link:definition>163 - Disclosure - Subsequent Event - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:href="mgnx-20141231_cal.xml" xlink:title="Calculation Links, all"/>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:href="mgnx-20141231_def.xml" xlink:title="Definition Links, all"/>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:href="mgnx-20141231_lab.xml" xlink:title="Label Links, all"/>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:href="mgnx-20141231_pre.xml" xlink:title="Presentation Links, all"/>
    </appinfo>
  </annotation>
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <import namespace="http://fasb.org/us-types/2014-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2014/elts/us-types-2014-01-31.xsd"/>
  <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <import namespace="http://fasb.org/us-gaap/2014-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/country/2013-01-31" schemaLocation="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/currency/2014-01-31" schemaLocation="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/exch/2014-01-31" schemaLocation="http://xbrl.sec.gov/exch/2014/exch-2014-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/naics/2011-01-31" schemaLocation="http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd"/>
  <element name="AdditionalClinicalMilestonePotentialPaymentsUnderAgreement" id="mgnx_AdditionalClinicalMilestonePotentialPaymentsUnderAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AdditionalLicenseGrantFeesUnderAgreement" id="mgnx_AdditionalLicenseGrantFeesUnderAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AdditionalManufacturingSpaceMember" id="mgnx_AdditionalManufacturingSpaceMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AdditionalPaymentUponAchievementOfMilestone" id="mgnx_AdditionalPaymentUponAchievementOfMilestone" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AdditionalPotentialClinicalAndCommercialMilestonePaymentsUnderAgreement" id="mgnx_AdditionalPotentialClinicalAndCommercialMilestonePaymentsUnderAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AdditionalPotentialClinicalMilestonePaymentsUnderAgreement" id="mgnx_AdditionalPotentialClinicalMilestonePaymentsUnderAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AdditionalPotentialClinicalRegulatoryCommercializationPaymentsUnderAgreement" id="mgnx_AdditionalPotentialClinicalRegulatoryCommercializationPaymentsUnderAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AdditionalPotentialCommercializationAndSalesMilestonePaymentsUnderAgreement" id="mgnx_AdditionalPotentialCommercializationAndSalesMilestonePaymentsUnderAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AdditionalPotentialDevelopmentRegulatoryAndSalesMilestoneUnderAgreement" id="mgnx_AdditionalPotentialDevelopmentRegulatoryAndSalesMilestoneUnderAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AdditionalPotentialLicenseGrantFeesUnderAgreement" id="mgnx_AdditionalPotentialLicenseGrantFeesUnderAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AdditionalPotentialMilestonePaymentsReceivableUponNewDrugApplicationAcceptance" id="mgnx_AdditionalPotentialMilestonePaymentsReceivableUponNewDrugApplicationAcceptance" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AdditionalPotentialRegulatoryAndSalesMilestonePaymentsUnderAgreement" id="mgnx_AdditionalPotentialRegulatoryAndSalesMilestonePaymentsUnderAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AdditionalPotentialRegulatoryMilestonePaymentsUnderAgreement" id="mgnx_AdditionalPotentialRegulatoryMilestonePaymentsUnderAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AdditionalPotentialSalesMilestonePaymentsUnderAgreement" id="mgnx_AdditionalPotentialSalesMilestonePaymentsUnderAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AdjustmentToRevenueUnderAccountingStandardsCodification" id="mgnx_AdjustmentToRevenueUnderAccountingStandardsCodification" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AggregatePotentialFutureCostReimbursement" id="mgnx_AggregatePotentialFutureCostReimbursement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AmendedLeaseExpirationDate" id="mgnx_AmendedLeaseExpirationDate" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AmountOfAdditionalConsiderationPaidUnderAgreement" id="mgnx_AmountOfAdditionalConsiderationPaidUnderAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="BoehringerIngelheimMember" id="mgnx_BoehringerIngelheimMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="BusinessMergerEffectiveDate" id="mgnx_BusinessMergerEffectiveDate" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ChangeInAccountingEstimateCurrentYearImpact" id="mgnx_ChangeInAccountingEstimateCurrentYearImpact" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CollaborationAgreementConsiderationReceivable" id="mgnx_CollaborationAgreementConsiderationReceivable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CollaborationAndLicenseAgreementEnteredDate" id="mgnx_CollaborationAndLicenseAgreementEnteredDate" type="us-types:dateStringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CollaborationAndLicenseAgreementsDisclosureTextBlock" id="mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CollaborationArrangementOffsetToResearchAndDevelopmentCosts" id="mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CollaborativeAgreementPeriodOfContract" id="mgnx_CollaborativeAgreementPeriodOfContract" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance" id="mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ContingentConsiderationRecordedAsIncrementalInProcessResearchAndDevelopmentExpense" id="mgnx_ContingentConsiderationRecordedAsIncrementalInProcessResearchAndDevelopmentExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ConvertiblePreferredStockConversionPrice" id="mgnx_ConvertiblePreferredStockConversionPrice" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ConvertiblePreferredStockSeriesDMember" id="mgnx_ConvertiblePreferredStockSeriesDMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DefinedContributionPlanEmployeesContributionAnnualVestingPercentage" id="mgnx_DefinedContributionPlanEmployeesContributionAnnualVestingPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DocumentAndEntityInformationAbstract" id="mgnx_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="EffectiveIncomeTaxRateReconciliationLineItems" id="mgnx_EffectiveIncomeTaxRateReconciliationLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="EffectiveIncomeTaxRateReconciliationTable" id="mgnx_EffectiveIncomeTaxRateReconciliationTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="EliLillyMember" id="mgnx_EliLillyMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="EmployeesEligibleAgeToParticipateInBenefitPlan" id="mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="EndingYearMember" id="mgnx_EndingYearMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="EquityIncentivePlan2003Member" id="mgnx_EquityIncentivePlan2003Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="FurnitureAndOfficeEquipmentMember" id="mgnx_FurnitureAndOfficeEquipmentMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="FutureMinimumLeasesPaymentsUnderLeasesTable" id="mgnx_FutureMinimumLeasesPaymentsUnderLeasesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="GileadMember" id="mgnx_GileadMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="GileadSciencesIncMember" id="mgnx_GileadSciencesIncMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="GreenCrossCorporationMember" id="mgnx_GreenCrossCorporationMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="IncomeTaxDisclosureLineItems" id="mgnx_IncomeTaxDisclosureLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="IncomeTaxDisclosureTable" id="mgnx_IncomeTaxDisclosureTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="IncomeTaxExaminationYearUnderExaminationRangeEnd" id="mgnx_IncomeTaxExaminationYearUnderExaminationRangeEnd" type="xbrli:gYearItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="IncomeTaxExaminationYearUnderExaminationRangeStart" id="mgnx_IncomeTaxExaminationYearUnderExaminationRangeStart" type="xbrli:gYearItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="IncomeTaxReconciliationDeferredTaxAdjustments" id="mgnx_IncomeTaxReconciliationDeferredTaxAdjustments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="IncomeTaxReconciliationFairValueAdjustmentOfPreferredStockWarrantLiability" id="mgnx_IncomeTaxReconciliationFairValueAdjustmentOfPreferredStockWarrantLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="IncomeTaxReconciliationStateDeferredTaxesAdjustments" id="mgnx_IncomeTaxReconciliationStateDeferredTaxesAdjustments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="IncreaseDecreaseInDeferredRent" id="mgnx_IncreaseDecreaseInDeferredRent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="JanssenBiotechIncMember" id="mgnx_JanssenBiotechIncMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="JohnsonAndJohnsonDevelopmentCorporationMember" id="mgnx_JohnsonAndJohnsonDevelopmentCorporationMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LaboratoryAndOfficeEquipmentMember" id="mgnx_LaboratoryAndOfficeEquipmentMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LeaseAgreementInitiationDate" id="mgnx_LeaseAgreementInitiationDate" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LeaseExpirationYear" id="mgnx_LeaseExpirationYear" type="xbrli:gYearItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LicenseAndCollaborationAgreementsLineItems" id="mgnx_LicenseAndCollaborationAgreementsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LicenseAndCollaborationAgreementsTable" id="mgnx_LicenseAndCollaborationAgreementsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="LiquidInvestmentMaturityPeriodToBeClassifiedAsCashEquivalentMaximum" id="mgnx_LiquidInvestmentMaturityPeriodToBeClassifiedAsCashEquivalentMaximum" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ManufacturingSpaceMember" id="mgnx_ManufacturingSpaceMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="MoneyMarketFundsFairValueDisclosure" id="mgnx_MoneyMarketFundsFairValueDisclosure" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NonRefundableUpFrontPayment" id="mgnx_NonRefundableUpFrontPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NonRefundableUpfrontPaymentReceivable" id="mgnx_NonRefundableUpfrontPaymentReceivable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NumberOfAnnualMaintenancePaymentReceived" id="mgnx_NumberOfAnnualMaintenancePaymentReceived" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NumberOfAssetsHeldForSale" id="mgnx_NumberOfAssetsHeldForSale" type="xbrli:integerItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NumberOfImpairedAssets" id="mgnx_NumberOfImpairedAssets" type="xbrli:integerItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NumberOfMilestonesAchieved" id="mgnx_NumberOfMilestonesAchieved" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NumberOfMoleculesToBeDevelopedAndCommercializedAsPerCollaborations" id="mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedAsPerCollaborations" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NumberOfPotentialSharesToBeIssuedAsAdditionalConsiderationUnderAssetPurchaseAgreement" id="mgnx_NumberOfPotentialSharesToBeIssuedAsAdditionalConsiderationUnderAssetPurchaseAgreement" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NumberOfPrograms" id="mgnx_NumberOfPrograms" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OfficeAndLaboratorySpaceMember" id="mgnx_OfficeAndLaboratorySpaceMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OnetimeMilestonePaymentToBePaidUnderAgreement" id="mgnx_OnetimeMilestonePaymentToBePaidUnderAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OnetimeMilestonePaymentToBePaidUnderAgreementUponSpecifiedLevelOfSalesOfProducts" id="mgnx_OnetimeMilestonePaymentToBePaidUnderAgreementUponSpecifiedLevelOfSalesOfProducts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OperatingLossCarryforwardsAnnualLimitationAmount" id="mgnx_OperatingLossCarryforwardsAnnualLimitationAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OperatingLossCarryforwardsExpirationYear" id="mgnx_OperatingLossCarryforwardsExpirationYear" type="xbrli:gYearItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OperatingLossCarryforwardsLimitationsOnUseAmount" id="mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OperatingLossCarryforwardsLimitationsOnUseYearEnd" id="mgnx_OperatingLossCarryforwardsLimitationsOnUseYearEnd" type="xbrli:gYearItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OperatingLossCarryforwardsLimitationsOnUseYearStart" id="mgnx_OperatingLossCarryforwardsLimitationsOnUseYearStart" type="xbrli:gYearItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OperatingLossCarryforwardsNotSubjectToLimitation" id="mgnx_OperatingLossCarryforwardsNotSubjectToLimitation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OptionExerciseFee" id="mgnx_OptionExerciseFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OptionExerciseFeeRecognitionPeriod" id="mgnx_OptionExerciseFeeRecognitionPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" id="mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PfizerIncMember" id="mgnx_PfizerIncMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PotentialLicenseOptionFeeAndEarlyDevelopmentMilestoneFee" id="mgnx_PotentialLicenseOptionFeeAndEarlyDevelopmentMilestoneFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PreclinicalMilestonesMember" id="mgnx_PreclinicalMilestonesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" id="mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RavenBiotechnologiesIncMember" id="mgnx_RavenBiotechnologiesIncMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ResearchCollaborationAndLicenseOptionAgreementMember" id="mgnx_ResearchCollaborationAndLicenseOptionAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ResearchObligationCompletionDate" id="mgnx_ResearchObligationCompletionDate" type="xbrli:gYearMonthItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ReviewPeriodByRegulatoryAuthority" id="mgnx_ReviewPeriodByRegulatoryAuthority" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RockvilleMarylandMember" id="mgnx_RockvilleMarylandMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RoyaltyAgreementDisclosureTextBlock" id="mgnx_RoyaltyAgreementDisclosureTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RoyaltyAgreementLineItems" id="mgnx_RoyaltyAgreementLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RoyaltyAgreementTable" id="mgnx_RoyaltyAgreementTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="RoyaltyPaymentAsPercentageOfNetSalesUnderLicensingAgreement" id="mgnx_RoyaltyPaymentAsPercentageOfNetSalesUnderLicensingAgreement" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock" id="mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SecondRightToDevelopCollaborationMember" id="mgnx_SecondRightToDevelopCollaborationMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SeriesA1ConvertiblePreferredStockMember" id="mgnx_SeriesA1ConvertiblePreferredStockMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SeriesA1PreferredStockMember" id="mgnx_SeriesA1PreferredStockMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SeriesA2ConvertiblePreferredStockMember" id="mgnx_SeriesA2ConvertiblePreferredStockMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SeriesA2PreferredStockMember" id="mgnx_SeriesA2PreferredStockMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SeriesAOnePreferredStockMember" id="mgnx_SeriesAOnePreferredStockMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SeriesBConvertiblePreferredStockMember" id="mgnx_SeriesBConvertiblePreferredStockMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SeriesCConvertiblePreferredStockMember" id="mgnx_SeriesCConvertiblePreferredStockMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SeriesD1ConvertiblePreferredStockMember" id="mgnx_SeriesD1ConvertiblePreferredStockMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SeriesD2ConvertiblePreferredStockMember" id="mgnx_SeriesD2ConvertiblePreferredStockMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SeriesD2PreferredStockMember" id="mgnx_SeriesD2PreferredStockMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SeriesDConvertiblePreferredStockMember" id="mgnx_SeriesDConvertiblePreferredStockMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ServierMember" id="mgnx_ServierMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease" id="mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SouthSanFranciscoMember" id="mgnx_SouthSanFranciscoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="StartYearMember" id="mgnx_StartYearMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="StockIncentivePlan2013Member" id="mgnx_StockIncentivePlan2013Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="StockIssuanceCosts" id="mgnx_StockIssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="StockIssuedDuringPeriodSharesStockPlanActivity" id="mgnx_StockIssuedDuringPeriodSharesStockPlanActivity" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption" id="mgnx_StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="StockIssuedDuringPeriodValueStockPlanActivity" id="mgnx_StockIssuedDuringPeriodValueStockPlanActivity" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="StockOptionPlan2000Member" id="mgnx_StockOptionPlan2000Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="TakedaMember" id="mgnx_TakedaMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="TaxCreditCarryforwardExpirationYearRangeEnd" id="mgnx_TaxCreditCarryforwardExpirationYearRangeEnd" type="xbrli:gYearItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="TaxCreditCarryforwardExpirationYearRangeStart" id="mgnx_TaxCreditCarryforwardExpirationYearRangeStart" type="xbrli:gYearItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="UndesignatedPreferredStockMember" id="mgnx_UndesignatedPreferredStockMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="UnrecognizedTaxBenefitsResultingInNetOperatingLossesCarryforward" id="mgnx_UnrecognizedTaxBenefitsResultingInNetOperatingLossesCarryforward" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="UpfrontFeeAllocatedToAgreement" id="mgnx_UpfrontFeeAllocatedToAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="UpfrontFeeAndParticipationRecognitionEndDate" id="mgnx_UpfrontFeeAndParticipationRecognitionEndDate" type="xbrli:gYearMonthItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="UpfrontPaymentRecognitionPeriod" id="mgnx_UpfrontPaymentRecognitionPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>17
<FILENAME>mgnx-20141231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- RR Donnelley Xcelerate Taxonomy Calculation Linkbase, based on XBRL 2.1  http://www.rrdonnelley.com/ -->
<!-- Version: 6.22.4 -->
<!-- Round: 8 -->
<!-- Creation date: 2015-03-03T16:02:26Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#DocumentandEntityInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DocumentandEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#Role_StatementOfFinancialPositionClassified" roleURI="http://www.macrogenics.com/taxonomy/role/StatementOfFinancialPositionClassified"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#Role_StatementOfFinancialPositionClassifiedParen" roleURI="http://www.macrogenics.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#Role_StatementOfIncomeAlternative" roleURI="http://www.macrogenics.com/taxonomy/role/StatementOfIncomeAlternative"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#Role_StatementOfShareholdersEquityAndOtherComprehensiveIncome" roleURI="http://www.macrogenics.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#Role_StatementOfCashFlowsIndirect" roleURI="http://www.macrogenics.com/taxonomy/role/StatementOfCashFlowsIndirect"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#DisclosureOrganizationAndNatureOfOperationsAdditionalInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfFairValueMeasurementFinancialAssetAndLiabilities" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfFairValueMeasurementFinancialAssetAndLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfCollaboratorsThatRepresentMoreThan10OfTotalRevenueEarned" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfCollaboratorsThatRepresentMoreThan10OfTotalRevenueEarned"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfCollaboratorsThatRepresentMoreThan10OfAccountsReceivable" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfCollaboratorsThatRepresentMoreThan10OfAccountsReceivable"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLives" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLives"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesComputationOfBasicAndDilutedIncomeLossPerCommonShare" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesComputationOfBasicAndDilutedIncomeLossPerCommonShare"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromTheCalculationOfDilutedIncomeLossPerShare" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromTheCalculationOfDilutedIncomeLossPerShare"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipment" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipment"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#DisclosurePropertyAndEquipmentAdditionalInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#DisclosureStockholdersEquityAdditionalInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureStockholdersEquityAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#DisclosureStockBasedCompensationAdditionalInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpense" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpense"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#DisclosureStockBasedCompensationScheduleOfFairValueOptionAwardEstimatedOnTheDateOfGrantUsingTheBlackScholesOptionPricingModel" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureStockBasedCompensationScheduleOfFairValueOptionAwardEstimatedOnTheDateOfGrantUsingTheBlackScholesOptionPricingModel"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#DisclosureStockBasedCompensationScheduleOfStockOptionAndRestrictedStockUnitActivity" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockOptionAndRestrictedStockUnitActivity"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#DisclosureIncomeTaxesAdditionalInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#DisclosureIncomeTaxesComponentsOfTheCompanysDeferredTaxAssetsLiabilities" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureIncomeTaxesComponentsOfTheCompanysDeferredTaxAssetsLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#DisclosureIncomeTaxesReconciliationOfReportedEstimatedIncomeTaxBenefit" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureIncomeTaxesReconciliationOfReportedEstimatedIncomeTaxBenefit"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#DisclosureIncomeTaxesReconciliationOfTheBeginningAndEndingAmountOfGrossUnrecognizedTaxBenefits" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureIncomeTaxesReconciliationOfTheBeginningAndEndingAmountOfGrossUnrecognizedTaxBenefits"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#DisclosureLeaseExitLiabilityAdditionalInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureLeaseExitLiabilityAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#DisclosureLeaseExitLiabilityChangesInLeaseExitLiability" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureLeaseExitLiabilityChangesInLeaseExitLiability"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#DisclosureLeaseExitLiabilityFuturePrincipalPaymentsUnderLeaseAgreement" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureLeaseExitLiabilityFuturePrincipalPaymentsUnderLeaseAgreement"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#DisclosureCollaborationAndLicenseAgreementsAdditionalInformation1" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformation1"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#DisclosureCollaborationAndLicenseAgreementsAdditionalInformation2" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformation2"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#DisclosureCollaborationAndLicenseAgreementsAdditionalInformation3" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformation3"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#DisclosureCollaborationAndLicenseAgreementsAdditionalInformation4" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformation4"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#DisclosureCollaborationAndLicenseAgreementsAdditionalInformation5" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformation5"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#DisclosureCollaborationAndLicenseAgreementsAdditionalInformation6" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformation6"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#DisclosureCollaborationAndLicenseAgreementsAdditionalInformation7" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformation7"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#DisclosureCommitmentsAndContingenciesAdditionalInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#DisclosureCommitmentsAndContingenciesScheduleOfMinimumFutureLeasePayments" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMinimumFutureLeasePayments"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#DisclosureProductMilestonePaymentsAndRoyaltyAgreementsAdditionalInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureProductMilestonePaymentsAndRoyaltyAgreementsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#DisclosureEmployeeBenefitPlanAdditionalInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureEmployeeBenefitPlanAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#DisclosureQuarterlyFinancialInformationCompanysConsolidatedQuarterlyResultsOfOperations" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureQuarterlyFinancialInformationCompanysConsolidatedQuarterlyResultsOfOperations"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#DisclosureSubsequentEventAdditionalInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSubsequentEventAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#Role_NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#Role_NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#Role_NotesToFinancialStatementsRestructuringAndRelatedActivitiesDisclosureTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsRestructuringAndRelatedActivitiesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#Role_NotesToFinancialStatementsRestructuringAndRelatedActivitiesDisclosureTextBlockTables" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsRestructuringAndRelatedActivitiesDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#Role_NotesToFinancialStatementsCollaborationAndLicenseAgreementsDisclosureTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsCollaborationAndLicenseAgreementsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#Role_NotesToFinancialStatementsRoyaltyAgreementDisclosureTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsRoyaltyAgreementDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#Role_NotesToFinancialStatementsPensionAndOtherPostretirementBenefitsDisclosureTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsPensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#Role_NotesToFinancialStatementsQuarterlyFinancialInformationTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#Role_NotesToFinancialStatementsQuarterlyFinancialInformationTextBlockTables" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#Role_NotesToFinancialStatementsSubsequentEventsTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock"/>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DocumentandEntityInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/StatementOfFinancialPositionClassified">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestructuringReserveCurrent" xlink:label="us-gaap_RestructuringReserveCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestructuringReserveNoncurrent" xlink:label="us-gaap_RestructuringReserveNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="us-gaap_TreasuryStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_RestrictedCashAndCashEquivalents" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.0600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="1.0700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="1.1300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_RestructuringReserveNoncurrent" order="1.1400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DeferredRentCreditNoncurrent" order="1.1500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="1.1600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="1.1700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="1.2200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="1.0800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1.0900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_RestructuringReserveCurrent" order="1.1000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DeferredRevenueCurrent" order="1.1100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="1.1200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1.1800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_TreasuryStockValue" order="1.1900" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="1.2000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="1.2100" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/StatementOfIncomeAlternative">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LicenseAndServicesRevenue" xlink:label="us-gaap_LicenseAndServicesRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueFromGrants" xlink:label="us-gaap_RevenueFromGrants"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="1.0700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="1.0800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_Revenues" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_CostsAndExpenses" order="1.0600" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_LicenseAndServicesRevenue" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_RevenueFromGrants" order="1.0200" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/StatementOfCashFlowsIndirect">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_IncreaseDecreaseInDeferredRent" xlink:label="mgnx_IncreaseDecreaseInDeferredRent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInRestructuringReserve" xlink:label="us-gaap_IncreaseDecreaseInRestructuringReserve"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="1.1500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" order="1.1700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" order="1.2100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1.1800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="1.1900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" order="1.2000" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_NetIncomeLoss" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_Depreciation" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_ShareBasedCompensation" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="1.0500" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense" order="1.0600" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities" order="1.0700" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="1.0800" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="1.0900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="1.1000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInRestructuringReserve" order="1.1100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="1.1200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="mgnx_IncreaseDecreaseInDeferredRent" order="1.1300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" order="1.1400" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfFairValueMeasurementFinancialAssetAndLiabilities">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_MoneyMarketFundsFairValueDisclosure" xlink:label="mgnx_MoneyMarketFundsFairValueDisclosure"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="mgnx_MoneyMarketFundsFairValueDisclosure" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_RestrictedCashAndCashEquivalents" order="1.0300" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfCollaboratorsThatRepresentMoreThan10OfTotalRevenueEarned">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfCollaboratorsThatRepresentMoreThan10OfAccountsReceivable">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLives">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesComputationOfBasicAndDilutedIncomeLossPerCommonShare">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic" xlink:label="us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:label="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLoss" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" order="1.0200" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_NetIncomeLoss" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic" order="1.0400" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" order="1.0600" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromTheCalculationOfDilutedIncomeLossPerShare">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipment">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1.0300" weight="-1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureStockholdersEquityAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpense">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureStockBasedCompensationScheduleOfFairValueOptionAwardEstimatedOnTheDateOfGrantUsingTheBlackScholesOptionPricingModel">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockOptionAndRestrictedStockUnitActivity">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureIncomeTaxesComponentsOfTheCompanysDeferredTaxAssetsLiabilities">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" order="1.0600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" order="1.0700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOther" order="1.0800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet" order="1.1100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="1.1300" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="1.0900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1.1000" weight="-1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureIncomeTaxesReconciliationOfReportedEstimatedIncomeTaxBenefit">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxReconciliationDeductions" xlink:label="us-gaap_IncomeTaxReconciliationDeductions"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_IncomeTaxReconciliationDeferredTaxAdjustments" xlink:label="mgnx_IncomeTaxReconciliationDeferredTaxAdjustments"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_IncomeTaxReconciliationFairValueAdjustmentOfPreferredStockWarrantLiability" xlink:label="mgnx_IncomeTaxReconciliationFairValueAdjustmentOfPreferredStockWarrantLiability"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:label="us-gaap_IncomeTaxReconciliationOtherReconcilingItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_IncomeTaxReconciliationStateDeferredTaxesAdjustments" xlink:label="mgnx_IncomeTaxReconciliationStateDeferredTaxesAdjustments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsOther" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsOther"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="mgnx_IncomeTaxReconciliationDeferredTaxAdjustments" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="mgnx_IncomeTaxReconciliationStateDeferredTaxesAdjustments" order="1.0400" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" order="1.0500" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationDeductions" order="1.0600" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsOther" order="1.0700" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationOtherReconcilingItems" order="1.0800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" order="1.0900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="mgnx_IncomeTaxReconciliationFairValueAdjustmentOfPreferredStockWarrantLiability" order="1.1000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="1.1100" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureIncomeTaxesReconciliationOfTheBeginningAndEndingAmountOfGrossUnrecognizedTaxBenefits">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureLeaseExitLiabilityAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureLeaseExitLiabilityChangesInLeaseExitLiability">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureLeaseExitLiabilityFuturePrincipalPaymentsUnderLeaseAgreement">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" order="1.0400" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformation1">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformation2">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformation3">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformation4">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformation5">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformation6">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformation7">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMinimumFutureLeasePayments">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" order="1.0600" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureProductMilestonePaymentsAndRoyaltyAgreementsAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureEmployeeBenefitPlanAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureQuarterlyFinancialInformationCompanysConsolidatedQuarterlyResultsOfOperations">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureSubsequentEventAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsRestructuringAndRelatedActivitiesDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsRestructuringAndRelatedActivitiesDisclosureTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsCollaborationAndLicenseAgreementsDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsRoyaltyAgreementDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsPensionAndOtherPostretirementBenefitsDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock">
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>18
<FILENAME>mgnx-20141231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- RR Donnelley Xcelerate Taxonomy Definition Linkbase, based on XBRL 2.1  http://www.rrdonnelley.com/ -->
<!-- Version: 6.22.4 -->
<!-- Round: 8 -->
<!-- Creation date: 2015-03-03T16:02:26Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#DocumentandEntityInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DocumentandEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#Role_StatementOfFinancialPositionClassified" roleURI="http://www.macrogenics.com/taxonomy/role/StatementOfFinancialPositionClassified"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#Role_StatementOfFinancialPositionClassifiedParen" roleURI="http://www.macrogenics.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#Role_StatementOfIncomeAlternative" roleURI="http://www.macrogenics.com/taxonomy/role/StatementOfIncomeAlternative"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#Role_StatementOfShareholdersEquityAndOtherComprehensiveIncome" roleURI="http://www.macrogenics.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#Role_StatementOfCashFlowsIndirect" roleURI="http://www.macrogenics.com/taxonomy/role/StatementOfCashFlowsIndirect"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#DisclosureOrganizationAndNatureOfOperationsAdditionalInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfFairValueMeasurementFinancialAssetAndLiabilities" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfFairValueMeasurementFinancialAssetAndLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfCollaboratorsThatRepresentMoreThan10OfTotalRevenueEarned" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfCollaboratorsThatRepresentMoreThan10OfTotalRevenueEarned"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfCollaboratorsThatRepresentMoreThan10OfAccountsReceivable" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfCollaboratorsThatRepresentMoreThan10OfAccountsReceivable"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLives" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLives"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesComputationOfBasicAndDilutedIncomeLossPerCommonShare" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesComputationOfBasicAndDilutedIncomeLossPerCommonShare"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromTheCalculationOfDilutedIncomeLossPerShare" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromTheCalculationOfDilutedIncomeLossPerShare"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipment" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipment"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#DisclosurePropertyAndEquipmentAdditionalInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#DisclosureStockholdersEquityAdditionalInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureStockholdersEquityAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#DisclosureStockBasedCompensationAdditionalInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpense" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpense"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#DisclosureStockBasedCompensationScheduleOfFairValueOptionAwardEstimatedOnTheDateOfGrantUsingTheBlackScholesOptionPricingModel" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureStockBasedCompensationScheduleOfFairValueOptionAwardEstimatedOnTheDateOfGrantUsingTheBlackScholesOptionPricingModel"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#DisclosureStockBasedCompensationScheduleOfStockOptionAndRestrictedStockUnitActivity" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockOptionAndRestrictedStockUnitActivity"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#DisclosureIncomeTaxesAdditionalInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#DisclosureIncomeTaxesComponentsOfTheCompanysDeferredTaxAssetsLiabilities" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureIncomeTaxesComponentsOfTheCompanysDeferredTaxAssetsLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#DisclosureIncomeTaxesReconciliationOfReportedEstimatedIncomeTaxBenefit" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureIncomeTaxesReconciliationOfReportedEstimatedIncomeTaxBenefit"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#DisclosureIncomeTaxesReconciliationOfTheBeginningAndEndingAmountOfGrossUnrecognizedTaxBenefits" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureIncomeTaxesReconciliationOfTheBeginningAndEndingAmountOfGrossUnrecognizedTaxBenefits"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#DisclosureLeaseExitLiabilityAdditionalInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureLeaseExitLiabilityAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#DisclosureLeaseExitLiabilityChangesInLeaseExitLiability" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureLeaseExitLiabilityChangesInLeaseExitLiability"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#DisclosureLeaseExitLiabilityFuturePrincipalPaymentsUnderLeaseAgreement" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureLeaseExitLiabilityFuturePrincipalPaymentsUnderLeaseAgreement"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#DisclosureCollaborationAndLicenseAgreementsAdditionalInformation1" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformation1"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#DisclosureCollaborationAndLicenseAgreementsAdditionalInformation2" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformation2"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#DisclosureCollaborationAndLicenseAgreementsAdditionalInformation3" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformation3"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#DisclosureCollaborationAndLicenseAgreementsAdditionalInformation4" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformation4"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#DisclosureCollaborationAndLicenseAgreementsAdditionalInformation5" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformation5"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#DisclosureCollaborationAndLicenseAgreementsAdditionalInformation6" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformation6"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#DisclosureCollaborationAndLicenseAgreementsAdditionalInformation7" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformation7"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#DisclosureCommitmentsAndContingenciesAdditionalInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#DisclosureCommitmentsAndContingenciesScheduleOfMinimumFutureLeasePayments" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMinimumFutureLeasePayments"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#DisclosureProductMilestonePaymentsAndRoyaltyAgreementsAdditionalInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureProductMilestonePaymentsAndRoyaltyAgreementsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#DisclosureEmployeeBenefitPlanAdditionalInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureEmployeeBenefitPlanAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#DisclosureQuarterlyFinancialInformationCompanysConsolidatedQuarterlyResultsOfOperations" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureQuarterlyFinancialInformationCompanysConsolidatedQuarterlyResultsOfOperations"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#DisclosureSubsequentEventAdditionalInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSubsequentEventAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#Role_NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#Role_NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#Role_NotesToFinancialStatementsRestructuringAndRelatedActivitiesDisclosureTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsRestructuringAndRelatedActivitiesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#Role_NotesToFinancialStatementsRestructuringAndRelatedActivitiesDisclosureTextBlockTables" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsRestructuringAndRelatedActivitiesDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#Role_NotesToFinancialStatementsCollaborationAndLicenseAgreementsDisclosureTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsCollaborationAndLicenseAgreementsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#Role_NotesToFinancialStatementsRoyaltyAgreementDisclosureTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsRoyaltyAgreementDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#Role_NotesToFinancialStatementsPensionAndOtherPostretirementBenefitsDisclosureTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsPensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#Role_NotesToFinancialStatementsQuarterlyFinancialInformationTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#Role_NotesToFinancialStatementsQuarterlyFinancialInformationTextBlockTables" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#Role_NotesToFinancialStatementsSubsequentEventsTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DocumentandEntityInformation">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/StatementOfFinancialPositionClassified">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/StatementOfIncomeAlternative">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_SeriesA1ConvertiblePreferredStockMember" xlink:label="mgnx_SeriesA1ConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_SeriesA2ConvertiblePreferredStockMember" xlink:label="mgnx_SeriesA2ConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_SeriesBConvertiblePreferredStockMember" xlink:label="mgnx_SeriesBConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_SeriesCConvertiblePreferredStockMember" xlink:label="mgnx_SeriesCConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_SeriesD1ConvertiblePreferredStockMember" xlink:label="mgnx_SeriesD1ConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_SeriesD2ConvertiblePreferredStockMember" xlink:label="mgnx_SeriesD2ConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_StockIssuedDuringPeriodSharesStockPlanActivity" xlink:label="mgnx_StockIssuedDuringPeriodSharesStockPlanActivity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_StockIssuedDuringPeriodValueStockPlanActivity" xlink:label="mgnx_StockIssuedDuringPeriodValueStockPlanActivity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="us-gaap_TreasuryStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TreasuryStockRetiredParValueMethodAmount" xlink:label="us-gaap_TreasuryStockRetiredParValueMethodAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TreasuryStockSharesRetired" xlink:label="us-gaap_TreasuryStockSharesRetired"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="mgnx_SeriesA1ConvertiblePreferredStockMember" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="mgnx_SeriesA2ConvertiblePreferredStockMember" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="mgnx_SeriesBConvertiblePreferredStockMember" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="mgnx_SeriesCConvertiblePreferredStockMember" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="mgnx_SeriesD1ConvertiblePreferredStockMember" order="1.2100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="mgnx_SeriesD2ConvertiblePreferredStockMember" order="1.2200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="1.2300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_TreasuryStockMember" order="1.2400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1.2500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="1.2600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssued" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mgnx_StockIssuedDuringPeriodValueStockPlanActivity" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mgnx_StockIssuedDuringPeriodSharesStockPlanActivity" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TreasuryStockRetiredParValueMethodAmount" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TreasuryStockSharesRetired" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/StatementOfCashFlowsIndirect">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformation">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_BusinessMergerEffectiveDate" xlink:label="mgnx_BusinessMergerEffectiveDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:label="us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_LiquidInvestmentMaturityPeriodToBeClassifiedAsCashEquivalentMaximum" xlink:label="mgnx_LiquidInvestmentMaturityPeriodToBeClassifiedAsCashEquivalentMaximum"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_NumberOfAssetsHeldForSale" xlink:label="mgnx_NumberOfAssetsHeldForSale"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_NumberOfImpairedAssets" xlink:label="mgnx_NumberOfImpairedAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:label="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsReceivableMember" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:to="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:to="mgnx_BusinessMergerEffectiveDate" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:to="mgnx_LiquidInvestmentMaturityPeriodToBeClassifiedAsCashEquivalentMaximum" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:to="us-gaap_RestrictedCashAndCashEquivalents" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:to="mgnx_NumberOfImpairedAssets" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:to="mgnx_NumberOfAssetsHeldForSale" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:to="us-gaap_RangeAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="2.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfFairValueMeasurementFinancialAssetAndLiabilities">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_MoneyMarketFundsFairValueDisclosure" xlink:label="mgnx_MoneyMarketFundsFairValueDisclosure"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="mgnx_MoneyMarketFundsFairValueDisclosure" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalents" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="1.0100" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfCollaboratorsThatRepresentMoreThan10OfTotalRevenueEarned">
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_BoehringerIngelheimMember" xlink:label="mgnx_BoehringerIngelheimMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_EliLillyMember" xlink:label="mgnx_EliLillyMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_GileadSciencesIncMember" xlink:label="mgnx_GileadSciencesIncMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_ServierMember" xlink:label="mgnx_ServierMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_TakedaMember" xlink:label="mgnx_TakedaMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="mgnx_ServierMember" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="mgnx_BoehringerIngelheimMember" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="mgnx_TakedaMember" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="mgnx_GileadSciencesIncMember" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="mgnx_EliLillyMember" order="1.0700" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfCollaboratorsThatRepresentMoreThan10OfAccountsReceivable">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_BoehringerIngelheimMember" xlink:label="mgnx_BoehringerIngelheimMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain_2"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_GileadSciencesIncMember" xlink:label="mgnx_GileadSciencesIncMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_GreenCrossCorporationMember" xlink:label="mgnx_GreenCrossCorporationMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_PfizerIncMember" xlink:label="mgnx_PfizerIncMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_ServierMember" xlink:label="mgnx_ServierMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsReceivableMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="mgnx_ServierMember" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="mgnx_BoehringerIngelheimMember" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="mgnx_GreenCrossCorporationMember" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="mgnx_GileadSciencesIncMember" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="mgnx_PfizerIncMember" order="1.0700" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLives">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_LaboratoryAndOfficeEquipmentMember" xlink:label="mgnx_LaboratoryAndOfficeEquipmentMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="mgnx_LaboratoryAndOfficeEquipmentMember" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesComputationOfBasicAndDilutedIncomeLossPerCommonShare">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromTheCalculationOfDilutedIncomeLossPerShare">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_SeriesA1ConvertiblePreferredStockMember" xlink:label="mgnx_SeriesA1ConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_SeriesA2ConvertiblePreferredStockMember" xlink:label="mgnx_SeriesA2ConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_SeriesBConvertiblePreferredStockMember" xlink:label="mgnx_SeriesBConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_SeriesCConvertiblePreferredStockMember" xlink:label="mgnx_SeriesCConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_SeriesD2ConvertiblePreferredStockMember" xlink:label="mgnx_SeriesD2ConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_SeriesDConvertiblePreferredStockMember" xlink:label="mgnx_SeriesDConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="mgnx_SeriesA1ConvertiblePreferredStockMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="mgnx_SeriesA2ConvertiblePreferredStockMember" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="mgnx_SeriesBConvertiblePreferredStockMember" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="mgnx_SeriesCConvertiblePreferredStockMember" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="mgnx_SeriesDConvertiblePreferredStockMember" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="mgnx_SeriesD2ConvertiblePreferredStockMember" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_StockOptionMember" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipment">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_FurnitureAndOfficeEquipmentMember" xlink:label="mgnx_FurnitureAndOfficeEquipmentMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="mgnx_FurnitureAndOfficeEquipmentMember" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformation">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureStockholdersEquityAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_ConvertiblePreferredStockConversionPrice" xlink:label="mgnx_ConvertiblePreferredStockConversionPrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockDividendRatePerDollarAmount" xlink:label="us-gaap_PreferredStockDividendRatePerDollarAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_RavenBiotechnologiesIncMember" xlink:label="mgnx_RavenBiotechnologiesIncMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_SeriesA1PreferredStockMember" xlink:label="mgnx_SeriesA1PreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_SeriesA2PreferredStockMember" xlink:label="mgnx_SeriesA2PreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_SeriesAOnePreferredStockMember" xlink:label="mgnx_SeriesAOnePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_SeriesD2ConvertiblePreferredStockMember" xlink:label="mgnx_SeriesD2ConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_SeriesD2PreferredStockMember" xlink:label="mgnx_SeriesD2PreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="us-gaap_SeriesDPreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_StockIssuanceCosts" xlink:label="mgnx_StockIssuanceCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption" xlink:label="mgnx_StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_UndesignatedPreferredStockMember" xlink:label="mgnx_UndesignatedPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="mgnx_SeriesD2ConvertiblePreferredStockMember" order="1.2300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="mgnx_RavenBiotechnologiesIncMember" order="1.2200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="1.2100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mgnx_SeriesA1PreferredStockMember" order="1.2500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mgnx_SeriesA2PreferredStockMember" order="1.2700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="1.2800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" order="1.2900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesDPreferredStockMember" order="1.3000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mgnx_SeriesD2PreferredStockMember" order="1.3100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mgnx_UndesignatedPreferredStockMember" order="1.3200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mgnx_SeriesAOnePreferredStockMember" order="1.3300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharePrice" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="mgnx_StockIssuanceCosts" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssued" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockDividendRatePerDollarAmount" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="mgnx_ConvertiblePreferredStockConversionPrice" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="mgnx_StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="1.2400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="1.2600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="4.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_2" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformation">
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance" xlink:label="mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_EquityIncentivePlan2003Member" xlink:label="mgnx_EquityIncentivePlan2003Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" xlink:label="mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease" xlink:label="mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_StockIncentivePlan2013Member" xlink:label="mgnx_StockIncentivePlan2013Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_StockOptionPlan2000Member" xlink:label="mgnx_StockOptionPlan2000Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="mgnx_StockOptionPlan2000Member" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="mgnx_EquityIncentivePlan2003Member" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="mgnx_StockIncentivePlan2013Member" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_RangeAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="1.1600" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpense">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensation" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureStockBasedCompensationScheduleOfFairValueOptionAwardEstimatedOnTheDateOfGrantUsingTheBlackScholesOptionPricingModel">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_RangeAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="1.0600" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockOptionAndRestrictedStockUnitActivity">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsGrossNoncurrent" xlink:label="us-gaap_DeferredTaxAssetsGrossNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGrossCurrent" xlink:label="us-gaap_DeferredTaxLiabilitiesGrossCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_EndingYearMember" xlink:label="mgnx_EndingYearMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_2"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_IncomeTaxDisclosureLineItems" xlink:label="mgnx_IncomeTaxDisclosureLineItems"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_IncomeTaxDisclosureTable" xlink:label="mgnx_IncomeTaxDisclosureTable"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_IncomeTaxExaminationYearUnderExaminationRangeEnd" xlink:label="mgnx_IncomeTaxExaminationYearUnderExaminationRangeEnd"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_IncomeTaxExaminationYearUnderExaminationRangeStart" xlink:label="mgnx_IncomeTaxExaminationYearUnderExaminationRangeStart"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_OperatingLossCarryforwardsAnnualLimitationAmount" xlink:label="mgnx_OperatingLossCarryforwardsAnnualLimitationAmount"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_OperatingLossCarryforwardsExpirationYear" xlink:label="mgnx_OperatingLossCarryforwardsExpirationYear"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount" xlink:label="mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_OperatingLossCarryforwardsLimitationsOnUseYearEnd" xlink:label="mgnx_OperatingLossCarryforwardsLimitationsOnUseYearEnd"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_OperatingLossCarryforwardsLimitationsOnUseYearStart" xlink:label="mgnx_OperatingLossCarryforwardsLimitationsOnUseYearStart"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_OperatingLossCarryforwardsNotSubjectToLimitation" xlink:label="mgnx_OperatingLossCarryforwardsNotSubjectToLimitation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_StartYearMember" xlink:label="mgnx_StartYearMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_TaxCreditCarryforwardExpirationYearRangeEnd" xlink:label="mgnx_TaxCreditCarryforwardExpirationYearRangeEnd"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_TaxCreditCarryforwardExpirationYearRangeStart" xlink:label="mgnx_TaxCreditCarryforwardExpirationYearRangeStart"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_UnrecognizedTaxBenefitsResultingInNetOperatingLossesCarryforward" xlink:label="mgnx_UnrecognizedTaxBenefitsResultingInNetOperatingLossesCarryforward"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="1.2200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="mgnx_StartYearMember" order="1.2400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="mgnx_EndingYearMember" order="1.2500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="mgnx_IncomeTaxDisclosureLineItems" xlink:to="mgnx_IncomeTaxDisclosureTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_IncomeTaxDisclosureLineItems" xlink:to="mgnx_OperatingLossCarryforwardsExpirationYear" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_IncomeTaxDisclosureLineItems" xlink:to="mgnx_TaxCreditCarryforwardExpirationYearRangeStart" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_IncomeTaxDisclosureLineItems" xlink:to="mgnx_TaxCreditCarryforwardExpirationYearRangeEnd" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_IncomeTaxDisclosureLineItems" xlink:to="mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_IncomeTaxDisclosureLineItems" xlink:to="mgnx_OperatingLossCarryforwardsLimitationsOnUseYearStart" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_IncomeTaxDisclosureLineItems" xlink:to="mgnx_OperatingLossCarryforwardsLimitationsOnUseYearEnd" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_IncomeTaxDisclosureLineItems" xlink:to="mgnx_OperatingLossCarryforwardsAnnualLimitationAmount" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_IncomeTaxDisclosureLineItems" xlink:to="mgnx_OperatingLossCarryforwardsNotSubjectToLimitation" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_IncomeTaxDisclosureLineItems" xlink:to="mgnx_UnrecognizedTaxBenefitsResultingInNetOperatingLossesCarryforward" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_DeferredTaxLiabilitiesGrossCurrent" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsGrossNoncurrent" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_IncomeTaxDisclosureLineItems" xlink:to="mgnx_IncomeTaxExaminationYearUnderExaminationRangeStart" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_IncomeTaxDisclosureLineItems" xlink:to="mgnx_IncomeTaxExaminationYearUnderExaminationRangeEnd" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mgnx_IncomeTaxDisclosureTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mgnx_IncomeTaxDisclosureTable" xlink:to="us-gaap_RangeAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="1.2100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.2300" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureIncomeTaxesComponentsOfTheCompanysDeferredTaxAssetsLiabilities">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureIncomeTaxesReconciliationOfReportedEstimatedIncomeTaxBenefit">
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_EffectiveIncomeTaxRateReconciliationLineItems" xlink:label="mgnx_EffectiveIncomeTaxRateReconciliationLineItems"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_EffectiveIncomeTaxRateReconciliationTable" xlink:label="mgnx_EffectiveIncomeTaxRateReconciliationTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxReconciliationDeductions" xlink:label="us-gaap_IncomeTaxReconciliationDeductions"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_IncomeTaxReconciliationDeferredTaxAdjustments" xlink:label="mgnx_IncomeTaxReconciliationDeferredTaxAdjustments"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_IncomeTaxReconciliationFairValueAdjustmentOfPreferredStockWarrantLiability" xlink:label="mgnx_IncomeTaxReconciliationFairValueAdjustmentOfPreferredStockWarrantLiability"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:label="us-gaap_IncomeTaxReconciliationOtherReconcilingItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_IncomeTaxReconciliationStateDeferredTaxesAdjustments" xlink:label="mgnx_IncomeTaxReconciliationStateDeferredTaxesAdjustments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsOther" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsOther"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioPreviouslyReportedMember" xlink:label="us-gaap_ScenarioPreviouslyReportedMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="mgnx_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="mgnx_EffectiveIncomeTaxRateReconciliationTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="mgnx_IncomeTaxReconciliationDeferredTaxAdjustments" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="mgnx_IncomeTaxReconciliationStateDeferredTaxesAdjustments" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxReconciliationDeductions" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsOther" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxReconciliationOtherReconcilingItems" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="mgnx_IncomeTaxReconciliationFairValueAdjustmentOfPreferredStockWarrantLiability" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mgnx_EffectiveIncomeTaxRateReconciliationTable" xlink:to="us-gaap_StatementScenarioAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioPreviouslyReportedMember" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureIncomeTaxesReconciliationOfTheBeginningAndEndingAmountOfGrossUnrecognizedTaxBenefits">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureLeaseExitLiabilityAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_2"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_ContingentConsiderationRecordedAsIncrementalInProcessResearchAndDevelopmentExpense" xlink:label="mgnx_ContingentConsiderationRecordedAsIncrementalInProcessResearchAndDevelopmentExpense"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_ConvertiblePreferredStockSeriesDMember" xlink:label="mgnx_ConvertiblePreferredStockSeriesDMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_LeaseExpirationYear" xlink:label="mgnx_LeaseExpirationYear"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_OnetimeMilestonePaymentToBePaidUnderAgreement" xlink:label="mgnx_OnetimeMilestonePaymentToBePaidUnderAgreement"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_OnetimeMilestonePaymentToBePaidUnderAgreementUponSpecifiedLevelOfSalesOfProducts" xlink:label="mgnx_OnetimeMilestonePaymentToBePaidUnderAgreementUponSpecifiedLevelOfSalesOfProducts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mgnx_ConvertiblePreferredStockSeriesDMember" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="mgnx_LeaseExpirationYear" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="mgnx_OnetimeMilestonePaymentToBePaidUnderAgreement" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="mgnx_OnetimeMilestonePaymentToBePaidUnderAgreementUponSpecifiedLevelOfSalesOfProducts" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="mgnx_ContingentConsiderationRecordedAsIncrementalInProcessResearchAndDevelopmentExpense" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_RangeAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_2" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureLeaseExitLiabilityChangesInLeaseExitLiability">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ContractTerminationMember" xlink:label="us-gaap_ContractTerminationMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsForRestructuring" xlink:label="us-gaap_PaymentsForRestructuring"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestructuringReserve" xlink:label="us-gaap_RestructuringReserve"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain_2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringReserve" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_PaymentsForRestructuring" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_RestructuringCostAndReserveAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_ContractTerminationMember" order="1.0400" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureLeaseExitLiabilityFuturePrincipalPaymentsUnderLeaseAgreement">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_FutureMinimumLeasesPaymentsUnderLeasesTable" xlink:label="mgnx_FutureMinimumLeasesPaymentsUnderLeasesTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="us-gaap_OperatingLeasedAssetsLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_RavenBiotechnologiesIncMember" xlink:label="mgnx_RavenBiotechnologiesIncMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="mgnx_RavenBiotechnologiesIncMember" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mgnx_FutureMinimumLeasesPaymentsUnderLeasesTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="mgnx_FutureMinimumLeasesPaymentsUnderLeasesTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" order="1.0500" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformation1">
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_AdditionalPotentialClinicalRegulatoryCommercializationPaymentsUnderAgreement" xlink:label="mgnx_AdditionalPotentialClinicalRegulatoryCommercializationPaymentsUnderAgreement"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_AdditionalPotentialDevelopmentRegulatoryAndSalesMilestoneUnderAgreement" xlink:label="mgnx_AdditionalPotentialDevelopmentRegulatoryAndSalesMilestoneUnderAgreement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_CollaborationAndLicenseAgreementEnteredDate" xlink:label="mgnx_CollaborationAndLicenseAgreementEnteredDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_JanssenBiotechIncMember" xlink:label="mgnx_JanssenBiotechIncMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:label="mgnx_LicenseAndCollaborationAgreementsLineItems"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_LicenseAndCollaborationAgreementsTable" xlink:label="mgnx_LicenseAndCollaborationAgreementsTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="us-gaap_LicensesRevenue"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_NonRefundableUpFrontPayment" xlink:label="mgnx_NonRefundableUpFrontPayment"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_NonRefundableUpfrontPaymentReceivable" xlink:label="mgnx_NonRefundableUpfrontPaymentReceivable"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_PotentialLicenseOptionFeeAndEarlyDevelopmentMilestoneFee" xlink:label="mgnx_PotentialLicenseOptionFeeAndEarlyDevelopmentMilestoneFee"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain_2"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_ResearchCollaborationAndLicenseOptionAgreementMember" xlink:label="mgnx_ResearchCollaborationAndLicenseOptionAgreementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_TakedaMember" xlink:label="mgnx_TakedaMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_UpfrontFeeAllocatedToAgreement" xlink:label="mgnx_UpfrontFeeAllocatedToAgreement"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_UpfrontPaymentRecognitionPeriod" xlink:label="mgnx_UpfrontPaymentRecognitionPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="mgnx_ResearchCollaborationAndLicenseOptionAgreementMember" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_LicenseAndCollaborationAgreementsTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_CollaborationAndLicenseAgreementEnteredDate" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_NonRefundableUpfrontPaymentReceivable" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_AdditionalPotentialClinicalRegulatoryCommercializationPaymentsUnderAgreement" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="us-gaap_LicensesRevenue" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="us-gaap_DeferredRevenue" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_NonRefundableUpFrontPayment" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_PotentialLicenseOptionFeeAndEarlyDevelopmentMilestoneFee" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_AdditionalPotentialDevelopmentRegulatoryAndSalesMilestoneUnderAgreement" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_UpfrontFeeAllocatedToAgreement" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_UpfrontPaymentRecognitionPeriod" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="us-gaap_DeferredRevenueCurrent" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mgnx_LicenseAndCollaborationAgreementsTable" xlink:to="us-gaap_CounterpartyNameAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mgnx_LicenseAndCollaborationAgreementsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="mgnx_JanssenBiotechIncMember" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="mgnx_TakedaMember" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformation2">
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_AdditionalLicenseGrantFeesUnderAgreement" xlink:label="mgnx_AdditionalLicenseGrantFeesUnderAgreement"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_AdditionalPotentialClinicalMilestonePaymentsUnderAgreement" xlink:label="mgnx_AdditionalPotentialClinicalMilestonePaymentsUnderAgreement"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_AdditionalPotentialRegulatoryAndSalesMilestonePaymentsUnderAgreement" xlink:label="mgnx_AdditionalPotentialRegulatoryAndSalesMilestonePaymentsUnderAgreement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_CollaborationAndLicenseAgreementEnteredDate" xlink:label="mgnx_CollaborationAndLicenseAgreementEnteredDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_GileadMember" xlink:label="mgnx_GileadMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:label="mgnx_LicenseAndCollaborationAgreementsLineItems"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_LicenseAndCollaborationAgreementsTable" xlink:label="mgnx_LicenseAndCollaborationAgreementsTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="us-gaap_LicensesRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedAsPerCollaborations" xlink:label="mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedAsPerCollaborations"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_PreclinicalMilestonesMember" xlink:label="mgnx_PreclinicalMilestonesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_UpfrontPaymentRecognitionPeriod" xlink:label="mgnx_UpfrontPaymentRecognitionPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="mgnx_PreclinicalMilestonesMember" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_LicenseAndCollaborationAgreementsTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_CollaborationAndLicenseAgreementEnteredDate" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedAsPerCollaborations" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_AdditionalLicenseGrantFeesUnderAgreement" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_AdditionalPotentialClinicalMilestonePaymentsUnderAgreement" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_AdditionalPotentialRegulatoryAndSalesMilestonePaymentsUnderAgreement" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_UpfrontPaymentRecognitionPeriod" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="us-gaap_LicensesRevenue" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="us-gaap_DeferredRevenueCurrent" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mgnx_LicenseAndCollaborationAgreementsTable" xlink:to="us-gaap_CounterpartyNameAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mgnx_LicenseAndCollaborationAgreementsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mgnx_LicenseAndCollaborationAgreementsTable" xlink:to="us-gaap_RangeAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="mgnx_GileadMember" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformation3">
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_AdditionalClinicalMilestonePotentialPaymentsUnderAgreement" xlink:label="mgnx_AdditionalClinicalMilestonePotentialPaymentsUnderAgreement"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_AdditionalPotentialLicenseGrantFeesUnderAgreement" xlink:label="mgnx_AdditionalPotentialLicenseGrantFeesUnderAgreement"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_AdditionalPotentialMilestonePaymentsReceivableUponNewDrugApplicationAcceptance" xlink:label="mgnx_AdditionalPotentialMilestonePaymentsReceivableUponNewDrugApplicationAcceptance"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_AdditionalPotentialRegulatoryMilestonePaymentsUnderAgreement" xlink:label="mgnx_AdditionalPotentialRegulatoryMilestonePaymentsUnderAgreement"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_AdditionalPotentialSalesMilestonePaymentsUnderAgreement" xlink:label="mgnx_AdditionalPotentialSalesMilestonePaymentsUnderAgreement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_ChangeInAccountingEstimateCurrentYearImpact" xlink:label="mgnx_ChangeInAccountingEstimateCurrentYearImpact"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_CollaborationAgreementConsiderationReceivable" xlink:label="mgnx_CollaborationAgreementConsiderationReceivable"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_CollaborationAndLicenseAgreementEnteredDate" xlink:label="mgnx_CollaborationAndLicenseAgreementEnteredDate"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts" xlink:label="mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:label="mgnx_LicenseAndCollaborationAgreementsLineItems"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_LicenseAndCollaborationAgreementsTable" xlink:label="mgnx_LicenseAndCollaborationAgreementsTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="us-gaap_LicensesRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_NonRefundableUpFrontPayment" xlink:label="mgnx_NonRefundableUpFrontPayment"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_NumberOfMilestonesAchieved" xlink:label="mgnx_NumberOfMilestonesAchieved"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_OptionExerciseFee" xlink:label="mgnx_OptionExerciseFee"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_OptionExerciseFeeRecognitionPeriod" xlink:label="mgnx_OptionExerciseFeeRecognitionPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_ReviewPeriodByRegulatoryAuthority" xlink:label="mgnx_ReviewPeriodByRegulatoryAuthority"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioAdjustmentMember" xlink:label="us-gaap_ScenarioAdjustmentMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain_2"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_SecondRightToDevelopCollaborationMember" xlink:label="mgnx_SecondRightToDevelopCollaborationMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_ServierMember" xlink:label="mgnx_ServierMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_UpfrontPaymentRecognitionPeriod" xlink:label="mgnx_UpfrontPaymentRecognitionPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="mgnx_SecondRightToDevelopCollaborationMember" order="1.2400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_LicenseAndCollaborationAgreementsTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_CollaborationAndLicenseAgreementEnteredDate" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_NonRefundableUpFrontPayment" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_AdditionalPotentialLicenseGrantFeesUnderAgreement" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_AdditionalClinicalMilestonePotentialPaymentsUnderAgreement" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_AdditionalPotentialRegulatoryMilestonePaymentsUnderAgreement" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_AdditionalPotentialSalesMilestonePaymentsUnderAgreement" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_UpfrontPaymentRecognitionPeriod" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="us-gaap_LicensesRevenue" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="us-gaap_DeferredRevenueCurrent" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_AdditionalPotentialMilestonePaymentsReceivableUponNewDrugApplicationAcceptance" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_ChangeInAccountingEstimateCurrentYearImpact" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_OptionExerciseFee" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_OptionExerciseFeeRecognitionPeriod" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_CollaborationAgreementConsiderationReceivable" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_NumberOfMilestonesAchieved" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_ReviewPeriodByRegulatoryAuthority" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="us-gaap_DeferredRevenue" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mgnx_LicenseAndCollaborationAgreementsTable" xlink:to="us-gaap_CounterpartyNameAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mgnx_LicenseAndCollaborationAgreementsTable" xlink:to="us-gaap_RangeAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mgnx_LicenseAndCollaborationAgreementsTable" xlink:to="us-gaap_StatementScenarioAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mgnx_LicenseAndCollaborationAgreementsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="4.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.2200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="mgnx_ServierMember" order="1.2100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioAdjustmentMember" order="1.2300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformation4">
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_AdditionalPotentialClinicalMilestonePaymentsUnderAgreement" xlink:label="mgnx_AdditionalPotentialClinicalMilestonePaymentsUnderAgreement"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_AdditionalPotentialRegulatoryMilestonePaymentsUnderAgreement" xlink:label="mgnx_AdditionalPotentialRegulatoryMilestonePaymentsUnderAgreement"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_AdditionalPotentialSalesMilestonePaymentsUnderAgreement" xlink:label="mgnx_AdditionalPotentialSalesMilestonePaymentsUnderAgreement"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_BoehringerIngelheimMember" xlink:label="mgnx_BoehringerIngelheimMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_CollaborationAndLicenseAgreementEnteredDate" xlink:label="mgnx_CollaborationAndLicenseAgreementEnteredDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:label="mgnx_LicenseAndCollaborationAgreementsLineItems"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_LicenseAndCollaborationAgreementsTable" xlink:label="mgnx_LicenseAndCollaborationAgreementsTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="us-gaap_LicensesRevenue"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_NonRefundableUpFrontPayment" xlink:label="mgnx_NonRefundableUpFrontPayment"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_NumberOfAnnualMaintenancePaymentReceived" xlink:label="mgnx_NumberOfAnnualMaintenancePaymentReceived"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedAsPerCollaborations" xlink:label="mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedAsPerCollaborations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_ResearchObligationCompletionDate" xlink:label="mgnx_ResearchObligationCompletionDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_LicenseAndCollaborationAgreementsTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_CollaborationAndLicenseAgreementEnteredDate" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedAsPerCollaborations" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_NonRefundableUpFrontPayment" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_NumberOfAnnualMaintenancePaymentReceived" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_AdditionalPotentialClinicalMilestonePaymentsUnderAgreement" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_AdditionalPotentialRegulatoryMilestonePaymentsUnderAgreement" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_AdditionalPotentialSalesMilestonePaymentsUnderAgreement" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_ResearchObligationCompletionDate" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="us-gaap_LicensesRevenue" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="us-gaap_DeferredRevenue" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="us-gaap_DeferredRevenueCurrent" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mgnx_LicenseAndCollaborationAgreementsTable" xlink:to="us-gaap_CounterpartyNameAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="mgnx_BoehringerIngelheimMember" order="1.1400" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformation5">
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_AdditionalPotentialClinicalMilestonePaymentsUnderAgreement" xlink:label="mgnx_AdditionalPotentialClinicalMilestonePaymentsUnderAgreement"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_AdditionalPotentialCommercializationAndSalesMilestonePaymentsUnderAgreement" xlink:label="mgnx_AdditionalPotentialCommercializationAndSalesMilestonePaymentsUnderAgreement"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_CollaborationAndLicenseAgreementEnteredDate" xlink:label="mgnx_CollaborationAndLicenseAgreementEnteredDate"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_CollaborativeAgreementPeriodOfContract" xlink:label="mgnx_CollaborativeAgreementPeriodOfContract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:label="mgnx_LicenseAndCollaborationAgreementsLineItems"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_LicenseAndCollaborationAgreementsTable" xlink:label="mgnx_LicenseAndCollaborationAgreementsTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="us-gaap_LicensesRevenue"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_NonRefundableUpFrontPayment" xlink:label="mgnx_NonRefundableUpFrontPayment"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedAsPerCollaborations" xlink:label="mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedAsPerCollaborations"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_NumberOfPrograms" xlink:label="mgnx_NumberOfPrograms"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_PfizerIncMember" xlink:label="mgnx_PfizerIncMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_ResearchObligationCompletionDate" xlink:label="mgnx_ResearchObligationCompletionDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_UpfrontFeeAndParticipationRecognitionEndDate" xlink:label="mgnx_UpfrontFeeAndParticipationRecognitionEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_LicenseAndCollaborationAgreementsTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_CollaborationAndLicenseAgreementEnteredDate" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_CollaborativeAgreementPeriodOfContract" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedAsPerCollaborations" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_NonRefundableUpFrontPayment" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_AdditionalPotentialClinicalMilestonePaymentsUnderAgreement" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_AdditionalPotentialCommercializationAndSalesMilestonePaymentsUnderAgreement" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_NumberOfPrograms" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_ResearchObligationCompletionDate" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_UpfrontFeeAndParticipationRecognitionEndDate" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="us-gaap_LicensesRevenue" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="us-gaap_DeferredRevenueCurrent" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mgnx_LicenseAndCollaborationAgreementsTable" xlink:to="us-gaap_CounterpartyNameAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="mgnx_PfizerIncMember" order="1.1300" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformation6">
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_AdditionalPotentialClinicalAndCommercialMilestonePaymentsUnderAgreement" xlink:label="mgnx_AdditionalPotentialClinicalAndCommercialMilestonePaymentsUnderAgreement"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_AdjustmentToRevenueUnderAccountingStandardsCodification" xlink:label="mgnx_AdjustmentToRevenueUnderAccountingStandardsCodification"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_AggregatePotentialFutureCostReimbursement" xlink:label="mgnx_AggregatePotentialFutureCostReimbursement"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_CollaborationAndLicenseAgreementEnteredDate" xlink:label="mgnx_CollaborationAndLicenseAgreementEnteredDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_GreenCrossCorporationMember" xlink:label="mgnx_GreenCrossCorporationMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:label="mgnx_LicenseAndCollaborationAgreementsLineItems"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_LicenseAndCollaborationAgreementsTable" xlink:label="mgnx_LicenseAndCollaborationAgreementsTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="us-gaap_LicensesRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_NonRefundableUpFrontPayment" xlink:label="mgnx_NonRefundableUpFrontPayment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnbilledContractsReceivable" xlink:label="us-gaap_UnbilledContractsReceivable"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_UpfrontFeeAndParticipationRecognitionEndDate" xlink:label="mgnx_UpfrontFeeAndParticipationRecognitionEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_LicenseAndCollaborationAgreementsTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_CollaborationAndLicenseAgreementEnteredDate" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_AggregatePotentialFutureCostReimbursement" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_AdditionalPotentialClinicalAndCommercialMilestonePaymentsUnderAgreement" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_UpfrontFeeAndParticipationRecognitionEndDate" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_NonRefundableUpFrontPayment" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_AdjustmentToRevenueUnderAccountingStandardsCodification" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="us-gaap_LicensesRevenue" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="us-gaap_DeferredRevenue" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="us-gaap_UnbilledContractsReceivable" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="us-gaap_DeferredRevenueCurrent" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mgnx_LicenseAndCollaborationAgreementsTable" xlink:to="us-gaap_CounterpartyNameAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mgnx_LicenseAndCollaborationAgreementsTable" xlink:to="us-gaap_RangeAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="mgnx_GreenCrossCorporationMember" order="1.1300" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformation7">
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_CollaborationAndLicenseAgreementEnteredDate" xlink:label="mgnx_CollaborationAndLicenseAgreementEnteredDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_EliLillyMember" xlink:label="mgnx_EliLillyMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:label="mgnx_LicenseAndCollaborationAgreementsLineItems"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_LicenseAndCollaborationAgreementsTable" xlink:label="mgnx_LicenseAndCollaborationAgreementsTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="us-gaap_LicensesRevenue"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_NonRefundableUpFrontPayment" xlink:label="mgnx_NonRefundableUpFrontPayment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_LicenseAndCollaborationAgreementsTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_CollaborationAndLicenseAgreementEnteredDate" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_NonRefundableUpFrontPayment" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="us-gaap_LicensesRevenue" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mgnx_LicenseAndCollaborationAgreementsTable" xlink:to="us-gaap_CounterpartyNameAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="mgnx_EliLillyMember" order="1.0500" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_AdditionalManufacturingSpaceMember" xlink:label="mgnx_AdditionalManufacturingSpaceMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_AmendedLeaseExpirationDate" xlink:label="mgnx_AmendedLeaseExpirationDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRentCredit" xlink:label="us-gaap_DeferredRentCredit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DescriptionOfLesseeLeasingArrangementsOperatingLeases" xlink:label="us-gaap_DescriptionOfLesseeLeasingArrangementsOperatingLeases"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_LeaseAgreementInitiationDate" xlink:label="mgnx_LeaseAgreementInitiationDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm" xlink:label="us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:label="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_ManufacturingSpaceMember" xlink:label="mgnx_ManufacturingSpaceMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_OfficeAndLaboratorySpaceMember" xlink:label="mgnx_OfficeAndLaboratorySpaceMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="us-gaap_OperatingLeasedAssetsLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="us-gaap_OperatingLeasesRentExpenseNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_2"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_RockvilleMarylandMember" xlink:label="mgnx_RockvilleMarylandMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="us-gaap_SegmentGeographicalDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="us-gaap_SegmentGeographicalDomain_2"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_SouthSanFranciscoMember" xlink:label="mgnx_SouthSanFranciscoMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="us-gaap_StatementGeographicalAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_ScheduleOfOperatingLeasedAssetsTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="mgnx_AmendedLeaseExpirationDate" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_DescriptionOfLesseeLeasingArrangementsOperatingLeases" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="mgnx_LeaseAgreementInitiationDate" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_DeferredRentCredit" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_OperatingLeasesRentExpenseNet" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:to="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:to="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:to="mgnx_OfficeAndLaboratorySpaceMember" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:to="mgnx_ManufacturingSpaceMember" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:to="mgnx_AdditionalManufacturingSpaceMember" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="us-gaap_StatementGeographicalAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentGeographicalDomain" xlink:to="mgnx_RockvilleMarylandMember" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentGeographicalDomain" xlink:to="mgnx_SouthSanFranciscoMember" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementGeographicalAxis" xlink:to="us-gaap_SegmentGeographicalDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementGeographicalAxis" xlink:to="us-gaap_SegmentGeographicalDomain_2" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMinimumFutureLeasePayments">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureProductMilestonePaymentsAndRoyaltyAgreementsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_AdditionalPaymentUponAchievementOfMilestone" xlink:label="mgnx_AdditionalPaymentUponAchievementOfMilestone"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_AmountOfAdditionalConsiderationPaidUnderAgreement" xlink:label="mgnx_AmountOfAdditionalConsiderationPaidUnderAgreement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_NumberOfPotentialSharesToBeIssuedAsAdditionalConsiderationUnderAssetPurchaseAgreement" xlink:label="mgnx_NumberOfPotentialSharesToBeIssuedAsAdditionalConsiderationUnderAssetPurchaseAgreement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_RoyaltyAgreementLineItems" xlink:label="mgnx_RoyaltyAgreementLineItems"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_RoyaltyAgreementTable" xlink:label="mgnx_RoyaltyAgreementTable"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_RoyaltyPaymentAsPercentageOfNetSalesUnderLicensingAgreement" xlink:label="mgnx_RoyaltyPaymentAsPercentageOfNetSalesUnderLicensingAgreement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="us-gaap_SalesRevenueGoodsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="mgnx_RoyaltyAgreementLineItems" xlink:to="mgnx_RoyaltyAgreementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_RoyaltyAgreementLineItems" xlink:to="mgnx_AdditionalPaymentUponAchievementOfMilestone" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_RoyaltyAgreementLineItems" xlink:to="mgnx_NumberOfPotentialSharesToBeIssuedAsAdditionalConsiderationUnderAssetPurchaseAgreement" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_RoyaltyAgreementLineItems" xlink:to="mgnx_RoyaltyPaymentAsPercentageOfNetSalesUnderLicensingAgreement" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_RoyaltyAgreementLineItems" xlink:to="mgnx_AmountOfAdditionalConsiderationPaidUnderAgreement" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_RoyaltyAgreementLineItems" xlink:to="us-gaap_SalesRevenueGoodsNet" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mgnx_RoyaltyAgreementTable" xlink:to="us-gaap_RangeAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureEmployeeBenefitPlanAdditionalInformation">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureQuarterlyFinancialInformationCompanysConsolidatedQuarterlyResultsOfOperations">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureSubsequentEventAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_JanssenBiotechIncMember" xlink:label="mgnx_JanssenBiotechIncMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_JohnsonAndJohnsonDevelopmentCorporationMember" xlink:label="mgnx_JohnsonAndJohnsonDevelopmentCorporationMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_NonRefundableUpfrontPaymentReceivable" xlink:label="mgnx_NonRefundableUpfrontPaymentReceivable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="mgnx_JohnsonAndJohnsonDevelopmentCorporationMember" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="mgnx_JanssenBiotechIncMember" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="mgnx_NonRefundableUpfrontPaymentReceivable" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_CounterpartyNameAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="1.0500" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CreditConcentrationRiskMember" xlink:label="us-gaap_CreditConcentrationRiskMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:label="mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CreditConcentrationRiskMember" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsRestructuringAndRelatedActivitiesDisclosureTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsRestructuringAndRelatedActivitiesDisclosureTextBlockTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsCollaborationAndLicenseAgreementsDisclosureTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsRoyaltyAgreementDisclosureTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsPensionAndOtherPostretirementBenefitsDisclosureTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlockTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock">
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>19
<FILENAME>mgnx-20141231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- RR Donnelley Xcelerate Taxonomy Labels Linkbase, based on XBRL 2.1  http://www.rrdonnelley.com/ -->
<!-- Version: 6.22.4 -->
<!-- Round: 8 -->
<!-- Creation date: 2015-03-03T16:02:26Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" id="id_6848266_1276885_1_1">Accounting Policies [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" id="id_6848266_1276885_2_1">Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" id="id_6848266_1282972_1_1">Accounts Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" id="id_6848266_1282972_2_1">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableMember_lbl" xml:lang="en-US" id="id_6848266_1275282_1_1">Accounts Receivable [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableMember_lbl" xml:lang="en-US" id="id_6848266_1275282_2_1">Accounts Receivable [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US" id="id_6848266_1288279_1_1">Accounts Receivable, Net, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US" id="id_6848266_1288279_2_1">Accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" id="id_6848266_1283401_1_1">Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" id="id_6848266_1283401_2_1">Accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" id="id_6848266_1282041_1_1">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" id="id_6848266_1282041_14_1">Less accumulated depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_AdditionalClinicalMilestonePotentialPaymentsUnderAgreement" xlink:label="mgnx_AdditionalClinicalMilestonePotentialPaymentsUnderAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_AdditionalClinicalMilestonePotentialPaymentsUnderAgreement_lbl" xml:lang="en-US" id="id_6848266_1595085_3_1">Additional Clinical Milestone Potential Payments Under Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_AdditionalClinicalMilestonePotentialPaymentsUnderAgreement_lbl" xml:lang="en-US" id="id_6848266_1595085_1_1">Additional Clinical Milestone Potential Payments Under Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_AdditionalClinicalMilestonePotentialPaymentsUnderAgreement_lbl" xml:lang="en-US" id="id_6848266_1595085_2_1">Clinical milestone payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_AdditionalClinicalMilestonePotentialPaymentsUnderAgreement" xlink:to="mgnx_AdditionalClinicalMilestonePotentialPaymentsUnderAgreement_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_AdditionalLicenseGrantFeesUnderAgreement" xlink:label="mgnx_AdditionalLicenseGrantFeesUnderAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_AdditionalLicenseGrantFeesUnderAgreement_lbl" xml:lang="en-US" id="id_6848266_1592653_3_1">Additional license grant fees per under agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_AdditionalLicenseGrantFeesUnderAgreement_lbl" xml:lang="en-US" id="id_6848266_1592653_1_1">Additional License Grant Fees Under Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_AdditionalLicenseGrantFeesUnderAgreement_lbl" xml:lang="en-US" id="id_6848266_1592653_2_1">License grant fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_AdditionalLicenseGrantFeesUnderAgreement" xlink:to="mgnx_AdditionalLicenseGrantFeesUnderAgreement_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_AdditionalManufacturingSpaceMember" xlink:label="mgnx_AdditionalManufacturingSpaceMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_AdditionalManufacturingSpaceMember_lbl" xml:lang="en-US" id="id_6848266_1610417_3_1">Additional manufacturing space.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_AdditionalManufacturingSpaceMember_lbl" xml:lang="en-US" id="id_6848266_1610417_1_1">Additional Manufacturing Space [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_AdditionalManufacturingSpaceMember_lbl" xml:lang="en-US" id="id_6848266_1610417_2_1">Additional Manufacturing Space [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_AdditionalManufacturingSpaceMember" xlink:to="mgnx_AdditionalManufacturingSpaceMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" id="id_6848266_1283855_1_1">Additional Paid in Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" id="id_6848266_1283855_2_1">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" id="id_6848266_1273630_1_1">Additional Paid-in Capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" id="id_6848266_1273630_2_1">Additional Paid-In Capital [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_AdditionalPaymentUponAchievementOfMilestone" xlink:label="mgnx_AdditionalPaymentUponAchievementOfMilestone"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_AdditionalPaymentUponAchievementOfMilestone_lbl" xml:lang="en-US" id="id_6848266_1408978_3_1">Additional payment upon achievement of milestone.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_AdditionalPaymentUponAchievementOfMilestone_lbl" xml:lang="en-US" id="id_6848266_1408978_1_1">Additional Payment Upon Achievement Of Milestone</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_AdditionalPaymentUponAchievementOfMilestone_lbl" xml:lang="en-US" id="id_6848266_1408978_2_1">Additional consideration of asset purchase agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_AdditionalPaymentUponAchievementOfMilestone" xlink:to="mgnx_AdditionalPaymentUponAchievementOfMilestone_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_AdditionalPotentialClinicalAndCommercialMilestonePaymentsUnderAgreement" xlink:label="mgnx_AdditionalPotentialClinicalAndCommercialMilestonePaymentsUnderAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_AdditionalPotentialClinicalAndCommercialMilestonePaymentsUnderAgreement_lbl" xml:lang="en-US" id="id_6848266_1610405_3_1">Aggregate potential clinical and commercial milestone payments available to be earned under collaboration agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_AdditionalPotentialClinicalAndCommercialMilestonePaymentsUnderAgreement_lbl" xml:lang="en-US" id="id_6848266_1610405_1_1">Additional Potential Clinical And Commercial Milestone Payments Under Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_AdditionalPotentialClinicalAndCommercialMilestonePaymentsUnderAgreement_lbl" xml:lang="en-US" id="id_6848266_1610405_2_1">Clinical and commercial milestone payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_AdditionalPotentialClinicalAndCommercialMilestonePaymentsUnderAgreement" xlink:to="mgnx_AdditionalPotentialClinicalAndCommercialMilestonePaymentsUnderAgreement_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_AdditionalPotentialClinicalMilestonePaymentsUnderAgreement" xlink:label="mgnx_AdditionalPotentialClinicalMilestonePaymentsUnderAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_AdditionalPotentialClinicalMilestonePaymentsUnderAgreement_lbl" xml:lang="en-US" id="id_6848266_1330138_3_1">Aggregate potential clinical milestone payments available to be earned under collaboration agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_AdditionalPotentialClinicalMilestonePaymentsUnderAgreement_lbl" xml:lang="en-US" id="id_6848266_1330138_1_1">Additional Potential Clinical Milestone Payments Under Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_AdditionalPotentialClinicalMilestonePaymentsUnderAgreement_lbl" xml:lang="en-US" id="id_6848266_1330138_2_1">Clinical milestone payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_AdditionalPotentialClinicalMilestonePaymentsUnderAgreement" xlink:to="mgnx_AdditionalPotentialClinicalMilestonePaymentsUnderAgreement_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_AdditionalPotentialClinicalRegulatoryCommercializationPaymentsUnderAgreement" xlink:label="mgnx_AdditionalPotentialClinicalRegulatoryCommercializationPaymentsUnderAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_AdditionalPotentialClinicalRegulatoryCommercializationPaymentsUnderAgreement_lbl" xml:lang="en-US" id="id_6848266_1610366_3_1">Additional potential clinical regulatory commercialization payments under agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_AdditionalPotentialClinicalRegulatoryCommercializationPaymentsUnderAgreement_lbl" xml:lang="en-US" id="id_6848266_1610366_1_1">Additional Potential Clinical Regulatory Commercialization Payments Under Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_AdditionalPotentialClinicalRegulatoryCommercializationPaymentsUnderAgreement_lbl" xml:lang="en-US" id="id_6848266_1610366_2_1">Clinical, regulatory and commercialization milestone payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_AdditionalPotentialClinicalRegulatoryCommercializationPaymentsUnderAgreement" xlink:to="mgnx_AdditionalPotentialClinicalRegulatoryCommercializationPaymentsUnderAgreement_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_AdditionalPotentialCommercializationAndSalesMilestonePaymentsUnderAgreement" xlink:label="mgnx_AdditionalPotentialCommercializationAndSalesMilestonePaymentsUnderAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_AdditionalPotentialCommercializationAndSalesMilestonePaymentsUnderAgreement_lbl" xml:lang="en-US" id="id_6848266_1610404_3_1">Aggregate potential remaining commercialization and sales milestone payments available to be earned under collaboration agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_AdditionalPotentialCommercializationAndSalesMilestonePaymentsUnderAgreement_lbl" xml:lang="en-US" id="id_6848266_1610404_1_1">Additional Potential Commercialization And Sales Milestone Payments Under Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_AdditionalPotentialCommercializationAndSalesMilestonePaymentsUnderAgreement_lbl" xml:lang="en-US" id="id_6848266_1610404_2_1">Commercialization and sales milestones</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_AdditionalPotentialCommercializationAndSalesMilestonePaymentsUnderAgreement" xlink:to="mgnx_AdditionalPotentialCommercializationAndSalesMilestonePaymentsUnderAgreement_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_AdditionalPotentialDevelopmentRegulatoryAndSalesMilestoneUnderAgreement" xlink:label="mgnx_AdditionalPotentialDevelopmentRegulatoryAndSalesMilestoneUnderAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_AdditionalPotentialDevelopmentRegulatoryAndSalesMilestoneUnderAgreement_lbl" xml:lang="en-US" id="id_6848266_1591112_3_1">Aggregate potential development regulatory and sales milestone payments available to be earned under agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_AdditionalPotentialDevelopmentRegulatoryAndSalesMilestoneUnderAgreement_lbl" xml:lang="en-US" id="id_6848266_1591112_1_1">Additional Potential Development Regulatory And Sales Milestone Under Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_AdditionalPotentialDevelopmentRegulatoryAndSalesMilestoneUnderAgreement_lbl" xml:lang="en-US" id="id_6848266_1591112_2_1">Development, regulatory and sales milestone payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_AdditionalPotentialDevelopmentRegulatoryAndSalesMilestoneUnderAgreement" xlink:to="mgnx_AdditionalPotentialDevelopmentRegulatoryAndSalesMilestoneUnderAgreement_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_AdditionalPotentialLicenseGrantFeesUnderAgreement" xlink:label="mgnx_AdditionalPotentialLicenseGrantFeesUnderAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_AdditionalPotentialLicenseGrantFeesUnderAgreement_lbl" xml:lang="en-US" id="id_6848266_1543714_3_1">Aggregate potential license grant fees available to be earned under collaboration agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_AdditionalPotentialLicenseGrantFeesUnderAgreement_lbl" xml:lang="en-US" id="id_6848266_1543714_1_1">Additional Potential License Grant Fees Under Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_AdditionalPotentialLicenseGrantFeesUnderAgreement_lbl" xml:lang="en-US" id="id_6848266_1543714_2_1">Additional license grant fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_AdditionalPotentialLicenseGrantFeesUnderAgreement" xlink:to="mgnx_AdditionalPotentialLicenseGrantFeesUnderAgreement_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_AdditionalPotentialMilestonePaymentsReceivableUponNewDrugApplicationAcceptance" xlink:label="mgnx_AdditionalPotentialMilestonePaymentsReceivableUponNewDrugApplicationAcceptance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_AdditionalPotentialMilestonePaymentsReceivableUponNewDrugApplicationAcceptance_lbl" xml:lang="en-US" id="id_6848266_1476996_3_1">Additional potential milestone payments receivable upon new drug application acceptance.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_AdditionalPotentialMilestonePaymentsReceivableUponNewDrugApplicationAcceptance_lbl" xml:lang="en-US" id="id_6848266_1476996_1_1">Additional Potential Milestone Payments Receivable Upon New Drug Application Acceptance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_AdditionalPotentialMilestonePaymentsReceivableUponNewDrugApplicationAcceptance_lbl" xml:lang="en-US" id="id_6848266_1476996_2_1">Clinical milestone payments under agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_AdditionalPotentialMilestonePaymentsReceivableUponNewDrugApplicationAcceptance" xlink:to="mgnx_AdditionalPotentialMilestonePaymentsReceivableUponNewDrugApplicationAcceptance_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_AdditionalPotentialRegulatoryAndSalesMilestonePaymentsUnderAgreement" xlink:label="mgnx_AdditionalPotentialRegulatoryAndSalesMilestonePaymentsUnderAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_AdditionalPotentialRegulatoryAndSalesMilestonePaymentsUnderAgreement_lbl" xml:lang="en-US" id="id_6848266_1463867_3_1">Aggregate potential regulatory and sales milestone payments available to be earned under collaboration agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_AdditionalPotentialRegulatoryAndSalesMilestonePaymentsUnderAgreement_lbl" xml:lang="en-US" id="id_6848266_1463867_1_1">Additional Potential Regulatory And Sales Milestone Payments Under Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_AdditionalPotentialRegulatoryAndSalesMilestonePaymentsUnderAgreement_lbl" xml:lang="en-US" id="id_6848266_1463867_2_1">Regulatory and sales milestone</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_AdditionalPotentialRegulatoryAndSalesMilestonePaymentsUnderAgreement" xlink:to="mgnx_AdditionalPotentialRegulatoryAndSalesMilestonePaymentsUnderAgreement_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_AdditionalPotentialRegulatoryMilestonePaymentsUnderAgreement" xlink:label="mgnx_AdditionalPotentialRegulatoryMilestonePaymentsUnderAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_AdditionalPotentialRegulatoryMilestonePaymentsUnderAgreement_lbl" xml:lang="en-US" id="id_6848266_1489594_3_1">Aggregate potential remaining regulatory milestone payments available to be earned under a collaboration arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_AdditionalPotentialRegulatoryMilestonePaymentsUnderAgreement_lbl" xml:lang="en-US" id="id_6848266_1489594_1_1">Additional Potential Regulatory Milestone Payments Under Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_AdditionalPotentialRegulatoryMilestonePaymentsUnderAgreement_lbl" xml:lang="en-US" id="id_6848266_1489594_2_1">Regulatory milestone payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_AdditionalPotentialRegulatoryMilestonePaymentsUnderAgreement" xlink:to="mgnx_AdditionalPotentialRegulatoryMilestonePaymentsUnderAgreement_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_AdditionalPotentialSalesMilestonePaymentsUnderAgreement" xlink:label="mgnx_AdditionalPotentialSalesMilestonePaymentsUnderAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_AdditionalPotentialSalesMilestonePaymentsUnderAgreement_lbl" xml:lang="en-US" id="id_6848266_1484137_3_1">Aggregate potential remaining sales milestone payments available to be earned under collaboration agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_AdditionalPotentialSalesMilestonePaymentsUnderAgreement_lbl" xml:lang="en-US" id="id_6848266_1484137_1_1">Additional Potential Sales Milestone Payments Under Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_AdditionalPotentialSalesMilestonePaymentsUnderAgreement_lbl" xml:lang="en-US" id="id_6848266_1484137_2_1">Sales milestone payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_AdditionalPotentialSalesMilestonePaymentsUnderAgreement" xlink:to="mgnx_AdditionalPotentialSalesMilestonePaymentsUnderAgreement_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" id="id_6848266_1284706_1_1">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" id="id_6848266_1284706_2_1">Share-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" id="id_6848266_1278564_1_1">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" id="id_6848266_1278564_2_1">Adjustments to reconcile net income (loss) to net cash used in operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_AdjustmentToRevenueUnderAccountingStandardsCodification" xlink:label="mgnx_AdjustmentToRevenueUnderAccountingStandardsCodification"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_AdjustmentToRevenueUnderAccountingStandardsCodification_lbl" xml:lang="en-US" id="id_6848266_1591115_3_1">Adjustment To Revenue Under Accounting Standards Codification</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_AdjustmentToRevenueUnderAccountingStandardsCodification_lbl" xml:lang="en-US" id="id_6848266_1591115_1_1">Adjustment To Revenue Under Accounting Standards Codification</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_AdjustmentToRevenueUnderAccountingStandardsCodification_lbl" xml:lang="en-US" id="id_6848266_1591115_2_1">Adjustment to revenue from contract material modification</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_AdjustmentToRevenueUnderAccountingStandardsCodification" xlink:to="mgnx_AdjustmentToRevenueUnderAccountingStandardsCodification_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_AggregatePotentialFutureCostReimbursement" xlink:label="mgnx_AggregatePotentialFutureCostReimbursement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_AggregatePotentialFutureCostReimbursement_lbl" xml:lang="en-US" id="id_6848266_1591114_3_1">Aggregate Potential Future Cost Reimbursement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_AggregatePotentialFutureCostReimbursement_lbl" xml:lang="en-US" id="id_6848266_1591114_1_1">Aggregate Potential Future Cost Reimbursement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_AggregatePotentialFutureCostReimbursement_lbl" xml:lang="en-US" id="id_6848266_1591114_2_1">Aggregate potential future cost reimbursement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_AggregatePotentialFutureCostReimbursement" xlink:to="mgnx_AggregatePotentialFutureCostReimbursement_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" id="id_6848266_1285222_1_1">Allocated Share-based Compensation Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" id="id_6848266_1285222_2_1">Stock-based compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xml:lang="en-US" id="id_6848266_1282511_1_1">Allowance for Doubtful Accounts Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xml:lang="en-US" id="id_6848266_1282511_2_1">Allowance recorded</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_AmendedLeaseExpirationDate" xlink:label="mgnx_AmendedLeaseExpirationDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_AmendedLeaseExpirationDate_lbl" xml:lang="en-US" id="id_6848266_1505439_3_1">Amended Lease Expiration Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_AmendedLeaseExpirationDate_lbl" xml:lang="en-US" id="id_6848266_1505439_1_1">Amended Lease Expiration Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_AmendedLeaseExpirationDate_lbl" xml:lang="en-US" id="id_6848266_1505439_2_1">Amended lease expiration date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_AmendedLeaseExpirationDate" xlink:to="mgnx_AmendedLeaseExpirationDate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" id="id_6848266_1276506_1_1">Amendment Flag</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" id="id_6848266_1276506_2_1">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_AmountOfAdditionalConsiderationPaidUnderAgreement" xlink:label="mgnx_AmountOfAdditionalConsiderationPaidUnderAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_AmountOfAdditionalConsiderationPaidUnderAgreement_lbl" xml:lang="en-US" id="id_6848266_1491766_3_1">Amount of additional consideration paid under agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_AmountOfAdditionalConsiderationPaidUnderAgreement_lbl" xml:lang="en-US" id="id_6848266_1491766_1_1">Amount Of Additional Consideration Paid Under Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_AmountOfAdditionalConsiderationPaidUnderAgreement_lbl" xml:lang="en-US" id="id_6848266_1491766_2_1">Payments related to the additional considerations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_AmountOfAdditionalConsiderationPaidUnderAgreement" xlink:to="mgnx_AmountOfAdditionalConsiderationPaidUnderAgreement_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" id="id_6848266_1280165_1_1">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" id="id_6848266_1280165_2_1">Antidilutive securities excluded from computation of earnings per share, shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US" id="id_6848266_1268687_1_1">Antidilutive Securities [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US" id="id_6848266_1268687_2_1">Antidilutive Securities [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" id="id_6848266_1278584_1_1">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" id="id_6848266_1278584_2_1">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" id="id_6848266_1268688_1_1">Antidilutive Securities, Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" id="id_6848266_1268688_2_1">Antidilutive Securities, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" id="id_6848266_1275318_1_1">Arrangements and Non-arrangement Transactions [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" id="id_6848266_1275318_2_1">Arrangements and Non-arrangement Transactions [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" id="id_6848266_1287793_1_1">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" id="id_6848266_1287793_6_1">Total assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" id="id_6848266_1273668_1_1">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" id="id_6848266_1273668_2_1">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" id="id_6848266_1288812_1_1">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" id="id_6848266_1288812_6_1">Total current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" id="id_6848266_1276921_1_1">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" id="id_6848266_1276921_2_1">Current assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US" id="id_6848266_1285757_1_1">Assets, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US" id="id_6848266_1285757_6_1">Total Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xml:lang="en-US" id="id_6848266_1270294_1_1">Assets, Fair Value Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xml:lang="en-US" id="id_6848266_1270294_2_1">Assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_6848266_1268714_1_1">Basis of Accounting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_6848266_1268714_2_1">Basis of Presentation and Principles of Consolidation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_BoehringerIngelheimMember" xlink:label="mgnx_BoehringerIngelheimMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_BoehringerIngelheimMember_lbl" xml:lang="en-US" id="id_6848266_1503196_3_1">Boehringer Ingelheim International GmbH.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_BoehringerIngelheimMember_lbl" xml:lang="en-US" id="id_6848266_1503196_1_1">Boehringer Ingelheim [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_BoehringerIngelheimMember_lbl" xml:lang="en-US" id="id_6848266_1503196_2_1">Boehringer [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_BoehringerIngelheimMember" xlink:to="mgnx_BoehringerIngelheimMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xml:lang="en-US" id="id_6848266_1268730_1_1">Business Acquisition, Acquiree [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xml:lang="en-US" id="id_6848266_1268730_2_1">Business Acquisition, Acquiree [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xml:lang="en-US" id="id_6848266_1276960_1_1">Business Acquisition [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xml:lang="en-US" id="id_6848266_1276960_2_1">Business Acquisition [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl" xml:lang="en-US" id="id_6848266_1275350_1_1">Business Acquisition, Equity Interest Issued or Issuable, Number of Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl" xml:lang="en-US" id="id_6848266_1275350_2_1">Shares issued to acquire entity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_BusinessMergerEffectiveDate" xlink:label="mgnx_BusinessMergerEffectiveDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_BusinessMergerEffectiveDate_lbl" xml:lang="en-US" id="id_6848266_1335672_3_1">Effective date of merger of subsidiary into parent.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_BusinessMergerEffectiveDate_lbl" xml:lang="en-US" id="id_6848266_1335672_1_1">Business Merger Effective Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_BusinessMergerEffectiveDate_lbl" xml:lang="en-US" id="id_6848266_1335672_2_1">Effective date of merger</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_BusinessMergerEffectiveDate" xlink:to="mgnx_BusinessMergerEffectiveDate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" id="id_6848266_1285262_1_1">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" id="id_6848266_1285262_4_1">Cash and cash equivalents at end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" id="id_6848266_1285262_5_1">Cash and cash equivalents at beginning of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" id="id_6848266_1285262_2_1">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US" id="id_6848266_1287836_1_1">Cash and Cash Equivalents, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US" id="id_6848266_1287836_2_1">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US" id="id_6848266_1286290_1_1">Cash and Cash Equivalents, Period Increase (Decrease)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US" id="id_6848266_1286290_6_1">Net change in cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" id="id_6848266_1275397_1_1">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" id="id_6848266_1275397_2_1">Cash and Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xml:lang="en-US" id="id_6848266_1272014_1_1">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xml:lang="en-US" id="id_6848266_1272014_2_1">Restricted Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_ChangeInAccountingEstimateCurrentYearImpact" xlink:label="mgnx_ChangeInAccountingEstimateCurrentYearImpact"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_ChangeInAccountingEstimateCurrentYearImpact_lbl" xml:lang="en-US" id="id_6848266_1621776_3_1">Disclosure of the effect of a change in accounting estimate on current year operations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_ChangeInAccountingEstimateCurrentYearImpact_lbl" xml:lang="en-US" id="id_6848266_1621776_1_1">Change In Accounting Estimate Current Year Impact</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_ChangeInAccountingEstimateCurrentYearImpact_lbl" xml:lang="en-US" id="id_6848266_1621776_2_1">Change in accounting estimate, current year impact</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_ChangeInAccountingEstimateCurrentYearImpact" xlink:to="mgnx_ChangeInAccountingEstimateCurrentYearImpact_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US" id="id_6848266_1277017_1_1">Class of Stock [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US" id="id_6848266_1277017_2_1">Class of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US" id="id_6848266_1268790_1_1">Class of Stock [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US" id="id_6848266_1268790_2_1">Class of Stock [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" id="id_6848266_1275410_1_1">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" id="id_6848266_1275410_2_1">Exercise price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" id="id_6848266_1277021_1_1">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" id="id_6848266_1277021_2_1">Purchased shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_CollaborationAgreementConsiderationReceivable" xlink:label="mgnx_CollaborationAgreementConsiderationReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_CollaborationAgreementConsiderationReceivable_lbl" xml:lang="en-US" id="id_6848266_1556268_3_1">Collaboration Agreement Consideration Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_CollaborationAgreementConsiderationReceivable_lbl" xml:lang="en-US" id="id_6848266_1556268_1_1">Collaboration Agreement Consideration Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_CollaborationAgreementConsiderationReceivable_lbl" xml:lang="en-US" id="id_6848266_1556268_2_1">Collaboration receivable, included in accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_CollaborationAgreementConsiderationReceivable" xlink:to="mgnx_CollaborationAgreementConsiderationReceivable_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_CollaborationAndLicenseAgreementEnteredDate" xlink:label="mgnx_CollaborationAndLicenseAgreementEnteredDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_CollaborationAndLicenseAgreementEnteredDate_lbl" xml:lang="en-US" id="id_6848266_1523477_3_1">Collaboration and license agreement entered date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_CollaborationAndLicenseAgreementEnteredDate_lbl" xml:lang="en-US" id="id_6848266_1523477_1_1">Collaboration and License Agreement Entered Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_CollaborationAndLicenseAgreementEnteredDate_lbl" xml:lang="en-US" id="id_6848266_1523477_2_1">Collaboration agreement date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_CollaborationAndLicenseAgreementEnteredDate" xlink:to="mgnx_CollaborationAndLicenseAgreementEnteredDate_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock" xlink:label="mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock_lbl" xml:lang="en-US" id="id_6848266_1348589_3_1">Collaboration and license agreements disclosure.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock_lbl" xml:lang="en-US" id="id_6848266_1348589_1_1">Collaboration And License Agreements Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock_lbl" xml:lang="en-US" id="id_6848266_1348589_2_1">Collaboration and License Agreements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock" xlink:to="mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts" xlink:label="mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts_lbl" xml:lang="en-US" id="id_6848266_1496661_3_1">Collaboration arrangement offset to research and development costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts_lbl" xml:lang="en-US" id="id_6848266_1496661_1_1">Collaboration Arrangement Offset to Research and Development Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts_lbl" xml:lang="en-US" id="id_6848266_1496661_2_1">Offset to research and development costs under collaboration arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts" xlink:to="mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_CollaborativeAgreementPeriodOfContract" xlink:label="mgnx_CollaborativeAgreementPeriodOfContract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_CollaborativeAgreementPeriodOfContract_lbl" xml:lang="en-US" id="id_6848266_1556640_3_1">Collaborative agreement period of contract.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_CollaborativeAgreementPeriodOfContract_lbl" xml:lang="en-US" id="id_6848266_1556640_1_1">Collaborative Agreement Period Of Contract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_CollaborativeAgreementPeriodOfContract_lbl" xml:lang="en-US" id="id_6848266_1556640_2_1">Period of agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_CollaborativeAgreementPeriodOfContract" xlink:to="mgnx_CollaborativeAgreementPeriodOfContract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" id="id_6848266_1272029_1_1">Commitments and Contingencies Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" id="id_6848266_1272029_2_1">Commitments and Contingencies Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" id="id_6848266_1268805_1_1">Commitments and Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" id="id_6848266_1268805_2_1">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance" xlink:label="mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance_lbl" xml:lang="en-US" id="id_6848266_1334617_3_1">Common Stock Capital Shares Minimum Increase In Shares Reserved For Future Issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance_lbl" xml:lang="en-US" id="id_6848266_1334617_1_1">Common Stock Capital Shares Minimum Increase In Shares Reserved For Future Issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance_lbl" xml:lang="en-US" id="id_6848266_1334617_2_1">Stock reserved for future issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance" xlink:to="mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" id="id_6848266_1270422_1_1">Common Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" id="id_6848266_1270422_2_1">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" id="id_6848266_1278675_1_1">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" id="id_6848266_1278675_2_1">Common stock, par value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" id="id_6848266_1270423_1_1">Common Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" id="id_6848266_1270423_2_1">Common stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" id="id_6848266_1268809_1_1">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" id="id_6848266_1268809_2_1">Common stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" id="id_6848266_1282921_1_1">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" id="id_6848266_1282921_2_1">Common stock, $0.01 par value-125,000,000 shares authorized, 27,995,638 and 25,177,597 shares outstanding at December 31, 2014 and 2013, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xml:lang="en-US" id="id_6848266_1273758_1_1">Compensation and Retirement Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xml:lang="en-US" id="id_6848266_1273758_2_1">Compensation and Retirement Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US" id="id_6848266_1270400_1_1">Compensation Related Costs, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US" id="id_6848266_1270400_2_1">Stock-based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xml:lang="en-US" id="id_6848266_1268815_1_1">Components of Deferred Tax Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xml:lang="en-US" id="id_6848266_1268815_2_1">Deferred income tax assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_lbl" xml:lang="en-US" id="id_6848266_1280286_1_1">Components of Deferred Tax Liabilities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_lbl" xml:lang="en-US" id="id_6848266_1280286_2_1">Deferred income tax liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_6848266_1270405_1_1">Comprehensive Income, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_6848266_1270405_2_1">Comprehensive Income (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US" id="id_6848266_1275434_1_1">Computer Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US" id="id_6848266_1275434_2_1">Computer Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xml:lang="en-US" id="id_6848266_1270409_1_1">Concentration Risk Benchmark [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xml:lang="en-US" id="id_6848266_1270409_2_1">Concentration Risk Benchmark [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US" id="id_6848266_1277042_1_1">Concentration Risk Benchmark [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US" id="id_6848266_1277042_2_1">Concentration Risk Benchmark [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xml:lang="en-US" id="id_6848266_1272045_1_1">Concentration Risk Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xml:lang="en-US" id="id_6848266_1272045_2_1">Concentration Risk Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" id="id_6848266_1280278_1_1">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" id="id_6848266_1280278_2_1">Concentration of Credit Risk</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskLineItems_lbl" xml:lang="en-US" id="id_6848266_1277045_1_1">Concentration Risk [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskLineItems_lbl" xml:lang="en-US" id="id_6848266_1277045_2_1">Concentration Risk [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US" id="id_6848266_1273765_1_1">Concentration Risk, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US" id="id_6848266_1273765_2_1">Percentage of all significant revenue earned</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US" id="id_6848266_1273765_12_1">Significant Accounts Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskTable_lbl" xml:lang="en-US" id="id_6848266_1268823_1_1">Concentration Risk [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskTable_lbl" xml:lang="en-US" id="id_6848266_1268823_2_1">Concentration Risk [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xml:lang="en-US" id="id_6848266_1270418_1_1">Concentration Risk Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xml:lang="en-US" id="id_6848266_1270418_2_1">Concentration Risk Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_ConcentrationRiskTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_ContingentConsiderationRecordedAsIncrementalInProcessResearchAndDevelopmentExpense" xlink:label="mgnx_ContingentConsiderationRecordedAsIncrementalInProcessResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_ContingentConsiderationRecordedAsIncrementalInProcessResearchAndDevelopmentExpense_lbl" xml:lang="en-US" id="id_6848266_1381021_3_1">Contingent consideration recorded as incremental in process research and development expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_ContingentConsiderationRecordedAsIncrementalInProcessResearchAndDevelopmentExpense_lbl" xml:lang="en-US" id="id_6848266_1381021_1_1">Contingent Consideration Recorded As Incremental In Process Research And Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_ContingentConsiderationRecordedAsIncrementalInProcessResearchAndDevelopmentExpense_lbl" xml:lang="en-US" id="id_6848266_1381021_2_1">Additional amounts recorded</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_ContingentConsiderationRecordedAsIncrementalInProcessResearchAndDevelopmentExpense" xlink:to="mgnx_ContingentConsiderationRecordedAsIncrementalInProcessResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ContractTerminationMember" xlink:label="us-gaap_ContractTerminationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractTerminationMember_lbl" xml:lang="en-US" id="id_6848266_1270443_1_1">Contract Termination [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractTerminationMember_lbl" xml:lang="en-US" id="id_6848266_1270443_2_1">Contract Termination [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractTerminationMember" xlink:to="us-gaap_ContractTerminationMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xml:lang="en-US" id="id_6848266_1287356_1_1">Conversion of Stock, Amount Converted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xml:lang="en-US" id="id_6848266_1287356_2_1">Conversion of preferred stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountConverted1" xlink:to="us-gaap_ConversionOfStockAmountConverted1_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_ConvertiblePreferredStockConversionPrice" xlink:label="mgnx_ConvertiblePreferredStockConversionPrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_ConvertiblePreferredStockConversionPrice_lbl" xml:lang="en-US" id="id_6848266_1376666_3_1">Convertible preferred stock conversion price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_ConvertiblePreferredStockConversionPrice_lbl" xml:lang="en-US" id="id_6848266_1376666_1_1">Convertible Preferred Stock Conversion Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_ConvertiblePreferredStockConversionPrice_lbl" xml:lang="en-US" id="id_6848266_1376666_2_1">Conversion price of preferred stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_ConvertiblePreferredStockConversionPrice" xlink:to="mgnx_ConvertiblePreferredStockConversionPrice_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xml:lang="en-US" id="id_6848266_1270467_1_1">Convertible Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xml:lang="en-US" id="id_6848266_1270467_2_1">Effect of Convertible Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_ConvertiblePreferredStockSeriesDMember" xlink:label="mgnx_ConvertiblePreferredStockSeriesDMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_ConvertiblePreferredStockSeriesDMember_lbl" xml:lang="en-US" id="id_6848266_1491160_3_1">Convertible preferred stock series D.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_ConvertiblePreferredStockSeriesDMember_lbl" xml:lang="en-US" id="id_6848266_1491160_1_1">Convertible Preferred Stock Series D [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_ConvertiblePreferredStockSeriesDMember_lbl" xml:lang="en-US" id="id_6848266_1491160_2_1">Series D Convertible Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_ConvertiblePreferredStockSeriesDMember" xlink:to="mgnx_ConvertiblePreferredStockSeriesDMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xml:lang="en-US" id="id_6848266_1278689_1_1">Convertible Preferred Stock, Shares Issued upon Conversion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xml:lang="en-US" id="id_6848266_1278689_2_1">Convertible preferred stock series</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpenses_lbl" xml:lang="en-US" id="id_6848266_1287875_1_1">Costs and Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CostsAndExpenses_lbl" xml:lang="en-US" id="id_6848266_1287875_6_1">Total costs and expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpensesAbstract_lbl" xml:lang="en-US" id="id_6848266_1275457_1_1">Costs and Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostsAndExpensesAbstract_lbl" xml:lang="en-US" id="id_6848266_1275457_2_1">Costs and expenses:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CounterpartyNameAxis_lbl" xml:lang="en-US" id="id_6848266_1272072_1_1">Counterparty Name [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CounterpartyNameAxis_lbl" xml:lang="en-US" id="id_6848266_1272072_2_1">Counterparty Name [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_CounterpartyNameAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CreditConcentrationRiskMember" xlink:label="us-gaap_CreditConcentrationRiskMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CreditConcentrationRiskMember_lbl" xml:lang="en-US" id="id_6848266_1277073_1_1">Credit Concentration Risk [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CreditConcentrationRiskMember_lbl" xml:lang="en-US" id="id_6848266_1277073_2_1">Summary of Significant Accounts Receivable[Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditConcentrationRiskMember" xlink:to="us-gaap_CreditConcentrationRiskMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" id="id_6848266_1276508_1_1">Current Fiscal Year End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" id="id_6848266_1276508_2_1">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" id="id_6848266_1287874_1_1">Current Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" id="id_6848266_1287874_2_1">Provision for federal or state income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xml:lang="en-US" id="id_6848266_1275481_1_1">Customer Concentration Risk [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xml:lang="en-US" id="id_6848266_1275481_2_1">Summary of Significant Revenue [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US" id="id_6848266_1283784_1_1">Deferred Tax Liabilities, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US" id="id_6848266_1283784_14_1">Gross deferred income tax liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRentCredit" xlink:label="us-gaap_DeferredRentCredit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRentCredit_lbl" xml:lang="en-US" id="id_6848266_1284639_1_1">Deferred Rent Credit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRentCredit_lbl" xml:lang="en-US" id="id_6848266_1284639_2_1">Deferred rent liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCredit" xlink:to="us-gaap_DeferredRentCredit_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRentCreditNoncurrent_lbl" xml:lang="en-US" id="id_6848266_1284640_1_1">Deferred Rent Credit, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRentCreditNoncurrent_lbl" xml:lang="en-US" id="id_6848266_1284640_2_1">Deferred rent liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCreditNoncurrent" xlink:to="us-gaap_DeferredRentCreditNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenue_lbl" xml:lang="en-US" id="id_6848266_1284641_1_1">Deferred Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenue_lbl" xml:lang="en-US" id="id_6848266_1284641_2_1">Deferred revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenue" xlink:to="us-gaap_DeferredRevenue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US" id="id_6848266_1284239_1_1">Deferred Revenue, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US" id="id_6848266_1284239_32_1">Deferred revenue, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US" id="id_6848266_1284239_2_1">Deferred revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US" id="id_6848266_1284239_12_1">Deferred revenue current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xml:lang="en-US" id="id_6848266_1281965_1_1">Deferred Revenue, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xml:lang="en-US" id="id_6848266_1281965_32_1">Deferred revenue, net of current portion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xml:lang="en-US" id="id_6848266_1281965_2_1">Deferred revenue non-current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xml:lang="en-US" id="id_6848266_1281965_12_1">Deferred revenue, Long-term liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueNoncurrent" xlink:to="us-gaap_DeferredRevenueNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xml:lang="en-US" id="id_6848266_1286875_1_1">Deferred Tax Assets, Deferred Income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xml:lang="en-US" id="id_6848266_1286875_2_1">Deferred revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" id="id_6848266_1285845_1_1">Deferred Tax Assets, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" id="id_6848266_1285845_6_1">Gross deferred income tax assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsGrossNoncurrent" xlink:label="us-gaap_DeferredTaxAssetsGrossNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGrossNoncurrent_lbl" xml:lang="en-US" id="id_6848266_1286338_1_1">Deferred Tax Assets, Gross, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsGrossNoncurrent_lbl" xml:lang="en-US" id="id_6848266_1286338_2_1">Noncurrent deferred tax asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGrossNoncurrent" xlink:to="us-gaap_DeferredTaxAssetsGrossNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US" id="id_6848266_1287893_1_1">Deferred Tax Assets, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US" id="id_6848266_1287893_2_1">Net deferred income tax asset/(liability)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US" id="id_6848266_1287893_6_1">Net deferred income tax asset/(liability)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" id="id_6848266_1287895_1_1">Deferred Tax Assets, Net of Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" id="id_6848266_1287895_6_1">Net deferred income tax assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xml:lang="en-US" id="id_6848266_1286880_1_1">Deferred Tax Assets, Operating Loss Carryforwards, Domestic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xml:lang="en-US" id="id_6848266_1286880_2_1">Federal U.S. net operating loss carryforward</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xml:lang="en-US" id="id_6848266_1288926_1_1">Deferred Tax Assets, Operating Loss Carryforwards, State and Local</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xml:lang="en-US" id="id_6848266_1288926_2_1">State net operating loss carryforward</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl" xml:lang="en-US" id="id_6848266_1287390_1_1">Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl" xml:lang="en-US" id="id_6848266_1287390_2_1">Net operating loss carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US" id="id_6848266_1286340_1_1">Deferred Tax Assets, Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US" id="id_6848266_1286340_2_1">Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xml:lang="en-US" id="id_6848266_1287391_1_1">Deferred Tax Assets, Property, Plant and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xml:lang="en-US" id="id_6848266_1287391_2_1">Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther_lbl" xml:lang="en-US" id="id_6848266_1287899_1_1">Deferred Tax Assets, Tax Credit Carryforwards, Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther_lbl" xml:lang="en-US" id="id_6848266_1287899_2_1">Orphan drug credit, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US" id="id_6848266_1286884_1_1">Deferred Tax Assets, Tax Credit Carryforwards, Research</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US" id="id_6848266_1286884_2_1">Research and development credit, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_lbl" xml:lang="en-US" id="id_6848266_1287392_1_1">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Deferred Rent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_lbl" xml:lang="en-US" id="id_6848266_1287392_2_1">Deferred rent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" id="id_6848266_1281963_1_1">Deferred Tax Assets, Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" id="id_6848266_1281963_14_1">Valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGrossCurrent" xlink:label="us-gaap_DeferredTaxLiabilitiesGrossCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesGrossCurrent_lbl" xml:lang="en-US" id="id_6848266_1283781_1_1">Deferred Tax Liabilities, Gross, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesGrossCurrent_lbl" xml:lang="en-US" id="id_6848266_1283781_2_1">Current deferred tax liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesGrossCurrent" xlink:to="us-gaap_DeferredTaxLiabilitiesGrossCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:label="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_lbl" xml:lang="en-US" id="id_6848266_1281961_1_1">Deferred Tax Liabilities, Prepaid Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_lbl" xml:lang="en-US" id="id_6848266_1281961_14_1">Prepaid expenditures</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:to="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:label="us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract_lbl" xml:lang="en-US" id="id_6848266_1273856_1_1">Defined Contribution Pension and Other Postretirement Plans Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract_lbl" xml:lang="en-US" id="id_6848266_1273856_2_1">Defined Contribution Pension and Other Postretirement Plans Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_DefinedContributionPlanEmployeesContributionAnnualVestingPercentage" xlink:label="mgnx_DefinedContributionPlanEmployeesContributionAnnualVestingPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_DefinedContributionPlanEmployeesContributionAnnualVestingPercentage_lbl" xml:lang="en-US" id="id_6848266_1315356_3_1">Defined contribution plan, employees contribution, annual vesting percentage.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_DefinedContributionPlanEmployeesContributionAnnualVestingPercentage_lbl" xml:lang="en-US" id="id_6848266_1315356_1_1">Defined Contribution Plan, Employees Contribution, Annual Vesting Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_DefinedContributionPlanEmployeesContributionAnnualVestingPercentage_lbl" xml:lang="en-US" id="id_6848266_1315356_2_1">Percentage of employee vested contribution</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_DefinedContributionPlanEmployeesContributionAnnualVestingPercentage" xlink:to="mgnx_DefinedContributionPlanEmployeesContributionAnnualVestingPercentage_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xml:lang="en-US" id="id_6848266_1288941_1_1">Defined Contribution Plan, Employer Discretionary Contribution Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xml:lang="en-US" id="id_6848266_1288941_2_1">Defined contribution plan, employer discretionary contribution amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xml:lang="en-US" id="id_6848266_1272135_1_1">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xml:lang="en-US" id="id_6848266_1272135_2_1">Percentage of employee contribution to salary</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US" id="id_6848266_1286908_1_1">Depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US" id="id_6848266_1286908_2_1">Depreciation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US" id="id_6848266_1285354_1_1">Depreciation, Depletion and Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US" id="id_6848266_1285354_2_1">Depreciation and amortization expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DescriptionOfLesseeLeasingArrangementsOperatingLeases" xlink:label="us-gaap_DescriptionOfLesseeLeasingArrangementsOperatingLeases"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DescriptionOfLesseeLeasingArrangementsOperatingLeases_lbl" xml:lang="en-US" id="id_6848266_1275561_1_1">Description of Lessee Leasing Arrangements, Operating Leases</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DescriptionOfLesseeLeasingArrangementsOperatingLeases_lbl" xml:lang="en-US" id="id_6848266_1275561_2_1">Lease agreement description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DescriptionOfLesseeLeasingArrangementsOperatingLeases" xlink:to="us-gaap_DescriptionOfLesseeLeasingArrangementsOperatingLeases_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US" id="id_6848266_1273909_1_1">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US" id="id_6848266_1273909_2_1">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" id="id_6848266_1278832_1_1">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" id="id_6848266_1278832_2_1">Stock-based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_DocumentAndEntityInformationAbstract" xlink:label="mgnx_DocumentAndEntityInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US" id="id_6848266_1430739_3_1">Document and entity information.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US" id="id_6848266_1430739_1_1">Document And Entity Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US" id="id_6848266_1430739_2_1">Document And Entity Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_DocumentAndEntityInformationAbstract" xlink:to="mgnx_DocumentAndEntityInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" id="id_6848266_1279677_1_1">Document Fiscal Period Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" id="id_6848266_1279677_2_1">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" id="id_6848266_1276510_1_1">Document Fiscal Year Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" id="id_6848266_1276510_2_1">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" id="id_6848266_1274889_1_1">Document Period End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" id="id_6848266_1274889_2_1">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" id="id_6848266_1269867_1_1">Document Type</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" id="id_6848266_1269867_2_1">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US" id="id_6848266_1280458_1_1">Domestic Tax Authority [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US" id="id_6848266_1280458_2_1">U.S. Federal Government [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" id="id_6848266_1277213_1_1">Earnings Per Share, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" id="id_6848266_1277213_2_1">Basic income (loss) per common share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" id="id_6848266_1277213_12_1">Net income (loss) per share, basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" id="id_6848266_1268986_1_1">Earnings Per Share, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" id="id_6848266_1268986_2_1">Diluted income (loss) per common share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" id="id_6848266_1268986_12_1">Net income (loss) per share, diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" id="id_6848266_1268988_1_1">Earnings Per Share, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" id="id_6848266_1268988_2_1">Net Income (Loss) Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_EffectiveIncomeTaxRateReconciliationLineItems" xlink:label="mgnx_EffectiveIncomeTaxRateReconciliationLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_EffectiveIncomeTaxRateReconciliationLineItems_lbl" xml:lang="en-US" id="id_6848266_1550895_3_1">Effective Income Tax Rate Reconciliation [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_EffectiveIncomeTaxRateReconciliationLineItems_lbl" xml:lang="en-US" id="id_6848266_1550895_1_1">Effective Income Tax Rate Reconciliation [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_EffectiveIncomeTaxRateReconciliationLineItems_lbl" xml:lang="en-US" id="id_6848266_1550895_2_1">Effective Income Tax Rate Reconciliation [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="mgnx_EffectiveIncomeTaxRateReconciliationLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_EffectiveIncomeTaxRateReconciliationTable" xlink:label="mgnx_EffectiveIncomeTaxRateReconciliationTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_EffectiveIncomeTaxRateReconciliationTable_lbl" xml:lang="en-US" id="id_6848266_1440317_3_1">Effective Income Tax Rate Reconciliation [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_EffectiveIncomeTaxRateReconciliationTable_lbl" xml:lang="en-US" id="id_6848266_1440317_1_1">Effective Income Tax Rate Reconciliation [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_EffectiveIncomeTaxRateReconciliationTable_lbl" xml:lang="en-US" id="id_6848266_1440317_2_1">Effective Income Tax Rate Reconciliation [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_EffectiveIncomeTaxRateReconciliationTable" xlink:to="mgnx_EffectiveIncomeTaxRateReconciliationTable_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_EliLillyMember" xlink:label="mgnx_EliLillyMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_EliLillyMember_lbl" xml:lang="en-US" id="id_6848266_1569517_3_1">Eli Lilly &amp; Co.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_EliLillyMember_lbl" xml:lang="en-US" id="id_6848266_1569517_1_1">Eli Lilly [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_EliLillyMember_lbl" xml:lang="en-US" id="id_6848266_1569517_2_1">Eli Lilly [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_EliLillyMember" xlink:to="mgnx_EliLillyMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan" xlink:label="mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan_lbl" xml:lang="en-US" id="id_6848266_1412525_3_1">Employees eligible age to participate in benefit plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan_lbl" xml:lang="en-US" id="id_6848266_1412525_1_1">Employees Eligible Age To Participate In Benefit Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan_lbl" xml:lang="en-US" id="id_6848266_1412525_2_1">Eligibility of employee participation Plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan" xlink:to="mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US" id="id_6848266_1270610_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US" id="id_6848266_1270610_2_1">Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US" id="id_6848266_1287944_1_1">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US" id="id_6848266_1287944_2_1">Unrecognized compensation cost related to non-vested stock-based compensation arrangements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" id="id_6848266_1272251_1_1">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" id="id_6848266_1272251_2_1">Unrecognized compensation expense recognition period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_EndingYearMember" xlink:label="mgnx_EndingYearMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_EndingYearMember_lbl" xml:lang="en-US" id="id_6848266_1613554_3_1">Ending Year [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_EndingYearMember_lbl" xml:lang="en-US" id="id_6848266_1613554_1_1">Ending Year [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_EndingYearMember_lbl" xml:lang="en-US" id="id_6848266_1613554_2_1">Ending Year [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_EndingYearMember" xlink:to="mgnx_EndingYearMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" id="id_6848266_1278115_1_1">Entity Central Index Key</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" id="id_6848266_1278115_2_1">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" id="id_6848266_1276513_1_1">Entity Common Stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" id="id_6848266_1276513_2_1">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" id="id_6848266_1281311_1_1">Entity Current Reporting Status</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" id="id_6848266_1281311_2_1">Entity Current Reporting Status</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" id="id_6848266_1271511_1_1">Entity Filer Category</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" id="id_6848266_1271511_2_1">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:label="dei_EntityIncorporationDateOfIncorporation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationDateOfIncorporation_lbl" xml:lang="en-US" id="id_6848266_1271512_1_1">Entity Incorporation, Date of Incorporation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityIncorporationDateOfIncorporation_lbl" xml:lang="en-US" id="id_6848266_1271512_2_1">MacroGenics incorporated date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationDateOfIncorporation" xlink:to="dei_EntityIncorporationDateOfIncorporation_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US" id="id_6848266_1284726_1_1">Entity Public Float</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US" id="id_6848266_1284726_2_1">Entity Public Float</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" id="id_6848266_1269875_1_1">Entity Registrant Name</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" id="id_6848266_1269875_2_1">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US" id="id_6848266_1271521_1_1">Entity Voluntary Filers</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US" id="id_6848266_1271521_2_1">Entity Voluntary Filers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US" id="id_6848266_1269876_1_1">Entity Well-known Seasoned Issuer</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US" id="id_6848266_1269876_2_1">Entity Well-known Seasoned Issuer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:label="us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EntityWideRevenueMajorCustomerLineItems_lbl" xml:lang="en-US" id="id_6848266_1277234_1_1">Revenue, Major Customer [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EntityWideRevenueMajorCustomerLineItems_lbl" xml:lang="en-US" id="id_6848266_1277234_2_1">Revenue, Major Customer [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:to="us-gaap_EntityWideRevenueMajorCustomerLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquipmentMember_lbl" xml:lang="en-US" id="id_6848266_1273964_1_1">Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquipmentMember_lbl" xml:lang="en-US" id="id_6848266_1273964_2_1">Lab Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US" id="id_6848266_1269012_1_1">Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US" id="id_6848266_1269012_2_1">Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" id="id_6848266_1272258_1_1">Equity Component [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" id="id_6848266_1272258_2_1">Equity Component [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_EquityIncentivePlan2003Member" xlink:label="mgnx_EquityIncentivePlan2003Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_EquityIncentivePlan2003Member_lbl" xml:lang="en-US" id="id_6848266_1610346_3_1">Equity Incentive Plan 2003 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_EquityIncentivePlan2003Member_lbl" xml:lang="en-US" id="id_6848266_1610346_1_1">Equity Incentive Plan 2003 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_EquityIncentivePlan2003Member_lbl" xml:lang="en-US" id="id_6848266_1610346_2_1">Equity Incentive Plan 2003 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_EquityIncentivePlan2003Member" xlink:to="mgnx_EquityIncentivePlan2003Member_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US" id="id_6848266_1286409_1_1">Fair Value Adjustment of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US" id="id_6848266_1286409_2_1">Fair value adjustment of warrant liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" id="id_6848266_1280493_1_1">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" id="id_6848266_1280493_2_1">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US" id="id_6848266_1277254_1_1">Fair Value Measurements, Recurring and Nonrecurring [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US" id="id_6848266_1277254_2_1">Fair Value Measurements, Recurring and Nonrecurring [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xml:lang="en-US" id="id_6848266_1278908_1_1">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xml:lang="en-US" id="id_6848266_1278908_2_1">Summary of Fair Value Measurement Financial Asset and Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US" id="id_6848266_1269038_1_1">Fair Value, Hierarchy [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US" id="id_6848266_1269038_2_1">Fair Value, Hierarchy [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" id="id_6848266_1272304_1_1">Fair Value, Inputs, Level 1 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" id="id_6848266_1272304_2_1">Quoted Prices in Active Markets for Identical Assets Level 1 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" id="id_6848266_1270691_1_1">Fair Value Hierarchy [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" id="id_6848266_1270691_2_1">Fair Value Hierarchy [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US" id="id_6848266_1280532_1_1">Fair Value of Financial Instruments, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US" id="id_6848266_1280532_2_1">Fair Value of Financial Instruments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US" id="id_6848266_1274094_1_1">Furniture and Fixtures [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US" id="id_6848266_1274094_2_1">Furniture [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_FurnitureAndOfficeEquipmentMember" xlink:label="mgnx_FurnitureAndOfficeEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_FurnitureAndOfficeEquipmentMember_lbl" xml:lang="en-US" id="id_6848266_1424108_3_1">Furniture and office equipment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_FurnitureAndOfficeEquipmentMember_lbl" xml:lang="en-US" id="id_6848266_1424108_1_1">Furniture And Office Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_FurnitureAndOfficeEquipmentMember_lbl" xml:lang="en-US" id="id_6848266_1424108_2_1">Furniture and Office Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_FurnitureAndOfficeEquipmentMember" xlink:to="mgnx_FurnitureAndOfficeEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_FutureMinimumLeasesPaymentsUnderLeasesTable" xlink:label="mgnx_FutureMinimumLeasesPaymentsUnderLeasesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_FutureMinimumLeasesPaymentsUnderLeasesTable_lbl" xml:lang="en-US" id="id_6848266_1308602_3_1">Future minimum leases payments under leases.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_FutureMinimumLeasesPaymentsUnderLeasesTable_lbl" xml:lang="en-US" id="id_6848266_1308602_1_1">Future Minimum Leases Payments Under Leases [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_FutureMinimumLeasesPaymentsUnderLeasesTable_lbl" xml:lang="en-US" id="id_6848266_1308602_2_1">Future Minimum Leases Payments Under Leases [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_FutureMinimumLeasesPaymentsUnderLeasesTable" xlink:to="mgnx_FutureMinimumLeasesPaymentsUnderLeasesTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" id="id_6848266_1288487_1_1">General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" id="id_6848266_1288487_2_1">General and administrative</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" id="id_6848266_1269133_1_1">General and Administrative Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" id="id_6848266_1269133_2_1">General and Administrative [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_GileadMember" xlink:label="mgnx_GileadMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_GileadMember_lbl" xml:lang="en-US" id="id_6848266_1444876_3_1">Gilead [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_GileadMember_lbl" xml:lang="en-US" id="id_6848266_1444876_1_1">Gilead [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_GileadMember_lbl" xml:lang="en-US" id="id_6848266_1444876_2_1">Gilead [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_GileadMember" xlink:to="mgnx_GileadMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_GileadSciencesIncMember" xlink:label="mgnx_GileadSciencesIncMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_GileadSciencesIncMember_lbl" xml:lang="en-US" id="id_6848266_1351512_3_1">Gilead Sciences, Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_GileadSciencesIncMember_lbl" xml:lang="en-US" id="id_6848266_1351512_1_1">Gilead Sciences Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_GileadSciencesIncMember_lbl" xml:lang="en-US" id="id_6848266_1351512_2_1">Gilead [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_GileadSciencesIncMember" xlink:to="mgnx_GileadSciencesIncMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_GreenCrossCorporationMember" xlink:label="mgnx_GreenCrossCorporationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_GreenCrossCorporationMember_lbl" xml:lang="en-US" id="id_6848266_1370805_3_1">Green Cross Corporation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_GreenCrossCorporationMember_lbl" xml:lang="en-US" id="id_6848266_1370805_1_1">Green Cross Corporation [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_GreenCrossCorporationMember_lbl" xml:lang="en-US" id="id_6848266_1370805_2_1">Green Cross [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_GreenCrossCorporationMember" xlink:to="mgnx_GreenCrossCorporationMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US" id="id_6848266_1279053_1_1">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US" id="id_6848266_1279053_2_1">Impairment of Long-Lived Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_lbl" xml:lang="en-US" id="id_6848266_1270814_1_1">Income (Loss) from Continuing Operations, Per Basic and Diluted Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_lbl" xml:lang="en-US" id="id_6848266_1270814_2_1">Basic and diluted net income (loss) per common share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_lbl" xml:lang="en-US" id="id_6848266_1270814_12_1">Net income (loss) per share, basic and diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" id="id_6848266_1272476_1_1">Income Statement [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" id="id_6848266_1272476_2_1">Income Statement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" id="id_6848266_1274159_1_1">Income Statement Location [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" id="id_6848266_1274159_2_1">Income Statement Location [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" id="id_6848266_1270824_1_1">Income Statement Location [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" id="id_6848266_1270824_2_1">Income Statement Location [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US" id="id_6848266_1280651_1_1">Income Tax Authority [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US" id="id_6848266_1280651_2_1">Income Tax Authority [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US" id="id_6848266_1279066_1_1">Income Tax Authority [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US" id="id_6848266_1279066_2_1">Income Tax Authority [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US" id="id_6848266_1272478_1_1">Income Tax Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US" id="id_6848266_1272478_2_1">Income Tax Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_IncomeTaxDisclosureLineItems" xlink:label="mgnx_IncomeTaxDisclosureLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_IncomeTaxDisclosureLineItems_lbl" xml:lang="en-US" id="id_6848266_1551029_3_1">Income Tax Disclosure [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_IncomeTaxDisclosureLineItems_lbl" xml:lang="en-US" id="id_6848266_1551029_1_1">Income Tax Disclosure [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_IncomeTaxDisclosureLineItems_lbl" xml:lang="en-US" id="id_6848266_1551029_2_1">Income Tax Disclosure [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_IncomeTaxDisclosureLineItems" xlink:to="mgnx_IncomeTaxDisclosureLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_IncomeTaxDisclosureTable" xlink:label="mgnx_IncomeTaxDisclosureTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_IncomeTaxDisclosureTable_lbl" xml:lang="en-US" id="id_6848266_1331088_3_1">Income Tax Disclosure [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_IncomeTaxDisclosureTable_lbl" xml:lang="en-US" id="id_6848266_1331088_1_1">Income Tax Disclosure [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_IncomeTaxDisclosureTable_lbl" xml:lang="en-US" id="id_6848266_1331088_2_1">Income Tax Disclosure [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_IncomeTaxDisclosureTable" xlink:to="mgnx_IncomeTaxDisclosureTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" id="id_6848266_1277417_1_1">Income Tax Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" id="id_6848266_1277417_2_1">Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_IncomeTaxExaminationYearUnderExaminationRangeEnd" xlink:label="mgnx_IncomeTaxExaminationYearUnderExaminationRangeEnd"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_IncomeTaxExaminationYearUnderExaminationRangeEnd_lbl" xml:lang="en-US" id="id_6848266_1566755_3_1">Income tax years subject to examination by taxing authorities, range end.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_IncomeTaxExaminationYearUnderExaminationRangeEnd_lbl" xml:lang="en-US" id="id_6848266_1566755_1_1">Income Tax Examination Year Under Examination Range End</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_IncomeTaxExaminationYearUnderExaminationRangeEnd_lbl" xml:lang="en-US" id="id_6848266_1566755_2_1">Income tax examination year subject to examination, Range End</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_IncomeTaxExaminationYearUnderExaminationRangeEnd" xlink:to="mgnx_IncomeTaxExaminationYearUnderExaminationRangeEnd_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_IncomeTaxExaminationYearUnderExaminationRangeStart" xlink:label="mgnx_IncomeTaxExaminationYearUnderExaminationRangeStart"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_IncomeTaxExaminationYearUnderExaminationRangeStart_lbl" xml:lang="en-US" id="id_6848266_1403313_3_1">Income tax years subject to examination by taxing authorities, range start.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_IncomeTaxExaminationYearUnderExaminationRangeStart_lbl" xml:lang="en-US" id="id_6848266_1403313_1_1">Income Tax Examination Year Under Examination Range Start</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_IncomeTaxExaminationYearUnderExaminationRangeStart_lbl" xml:lang="en-US" id="id_6848266_1403313_2_1">Income tax examination year subject to examination, Range start</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_IncomeTaxExaminationYearUnderExaminationRangeStart" xlink:to="mgnx_IncomeTaxExaminationYearUnderExaminationRangeStart_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" id="id_6848266_1286481_1_1">Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" id="id_6848266_1286481_6_1">Income tax expense/(benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" id="id_6848266_1270827_1_1">Income Tax, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" id="id_6848266_1270827_2_1">Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" id="id_6848266_1289034_1_1">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" id="id_6848266_1289034_2_1">Change in valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxReconciliationDeductions" xlink:label="us-gaap_IncomeTaxReconciliationDeductions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationDeductions_lbl" xml:lang="en-US" id="id_6848266_1281837_1_1">Effective Income Tax Rate Reconciliation, Deduction, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxReconciliationDeductions_lbl" xml:lang="en-US" id="id_6848266_1281837_14_1">Transaction cost deduction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationDeductions" xlink:to="us-gaap_IncomeTaxReconciliationDeductions_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_IncomeTaxReconciliationDeferredTaxAdjustments" xlink:label="mgnx_IncomeTaxReconciliationDeferredTaxAdjustments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_IncomeTaxReconciliationDeferredTaxAdjustments_lbl" xml:lang="en-US" id="id_6848266_1376192_3_1">Income tax reconciliation deferred tax adjustments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_IncomeTaxReconciliationDeferredTaxAdjustments_lbl" xml:lang="en-US" id="id_6848266_1376192_1_1">Income Tax Reconciliation Deferred Tax Adjustments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_IncomeTaxReconciliationDeferredTaxAdjustments_lbl" xml:lang="en-US" id="id_6848266_1376192_2_1">Deferred income tax adjustments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_IncomeTaxReconciliationDeferredTaxAdjustments" xlink:to="mgnx_IncomeTaxReconciliationDeferredTaxAdjustments_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_IncomeTaxReconciliationFairValueAdjustmentOfPreferredStockWarrantLiability" xlink:label="mgnx_IncomeTaxReconciliationFairValueAdjustmentOfPreferredStockWarrantLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_IncomeTaxReconciliationFairValueAdjustmentOfPreferredStockWarrantLiability_lbl" xml:lang="en-US" id="id_6848266_1306821_3_1">Income tax reconciliation fair value adjustment of preferred stock warrant liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_IncomeTaxReconciliationFairValueAdjustmentOfPreferredStockWarrantLiability_lbl" xml:lang="en-US" id="id_6848266_1306821_1_1">Income Tax Reconciliation Fair Value Adjustment Of Preferred Stock Warrant Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_IncomeTaxReconciliationFairValueAdjustmentOfPreferredStockWarrantLiability_lbl" xml:lang="en-US" id="id_6848266_1306821_2_1">Fair value adjustment of preferred stock warrant liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_IncomeTaxReconciliationFairValueAdjustmentOfPreferredStockWarrantLiability" xlink:to="mgnx_IncomeTaxReconciliationFairValueAdjustmentOfPreferredStockWarrantLiability_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" id="id_6848266_1286480_1_1">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" id="id_6848266_1286480_2_1">United States federal tax at statutory rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xml:lang="en-US" id="id_6848266_1287511_1_1">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Compensation Cost, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xml:lang="en-US" id="id_6848266_1287511_2_1">Equity-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:label="us-gaap_IncomeTaxReconciliationOtherReconcilingItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationOtherReconcilingItems_lbl" xml:lang="en-US" id="id_6848266_1289042_1_1">Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationOtherReconcilingItems_lbl" xml:lang="en-US" id="id_6848266_1289042_2_1">Other permanent items</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:to="us-gaap_IncomeTaxReconciliationOtherReconcilingItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" id="id_6848266_1288018_1_1">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" id="id_6848266_1288018_2_1">State taxes (net of federal benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_IncomeTaxReconciliationStateDeferredTaxesAdjustments" xlink:label="mgnx_IncomeTaxReconciliationStateDeferredTaxesAdjustments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_IncomeTaxReconciliationStateDeferredTaxesAdjustments_lbl" xml:lang="en-US" id="id_6848266_1304043_3_1">Income tax reconciliation state deferred taxes adjustments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_IncomeTaxReconciliationStateDeferredTaxesAdjustments_lbl" xml:lang="en-US" id="id_6848266_1304043_1_1">Income Tax Reconciliation State Deferred Taxes Adjustments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="mgnx_IncomeTaxReconciliationStateDeferredTaxesAdjustments_lbl" xml:lang="en-US" id="id_6848266_1304043_14_1">Deferred state blended rate adjustments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_IncomeTaxReconciliationStateDeferredTaxesAdjustments" xlink:to="mgnx_IncomeTaxReconciliationStateDeferredTaxesAdjustments_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsOther" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsOther_lbl" xml:lang="en-US" id="id_6848266_1284545_1_1">Effective Income Tax Rate Reconciliation, Tax Credit, Other, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsOther_lbl" xml:lang="en-US" id="id_6848266_1284545_14_1">Orphan drug credit, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsOther" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsOther_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xml:lang="en-US" id="id_6848266_1283210_1_1">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xml:lang="en-US" id="id_6848266_1283210_14_1">Research credit, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" id="id_6848266_1288515_1_1">Increase (Decrease) in Accounts Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" id="id_6848266_1288515_2_1">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US" id="id_6848266_1284543_1_1">Increase (Decrease) in Accounts Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US" id="id_6848266_1284543_14_1">Accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US" id="id_6848266_1287513_1_1">Increase (Decrease) in Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US" id="id_6848266_1287513_2_1">Accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_IncreaseDecreaseInDeferredRent" xlink:label="mgnx_IncreaseDecreaseInDeferredRent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_IncreaseDecreaseInDeferredRent_lbl" xml:lang="en-US" id="id_6848266_1373765_3_1">Increase decrease in deferred rent.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_IncreaseDecreaseInDeferredRent_lbl" xml:lang="en-US" id="id_6848266_1373765_1_1">Increase Decrease In Deferred Rent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_IncreaseDecreaseInDeferredRent_lbl" xml:lang="en-US" id="id_6848266_1373765_2_1">Deferred rent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_IncreaseDecreaseInDeferredRent" xlink:to="mgnx_IncreaseDecreaseInDeferredRent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US" id="id_6848266_1285447_1_1">Increase (Decrease) in Deferred Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US" id="id_6848266_1285447_2_1">Deferred revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" id="id_6848266_1279090_1_1">Increase (Decrease) in Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" id="id_6848266_1279090_2_1">Changes in operating assets and liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_lbl" xml:lang="en-US" id="id_6848266_1285451_1_1">Increase (Decrease) in Other Current Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_lbl" xml:lang="en-US" id="id_6848266_1285451_2_1">Other liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xml:lang="en-US" id="id_6848266_1282772_1_1">Increase (Decrease) in Other Operating Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xml:lang="en-US" id="id_6848266_1282772_14_1">Other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US" id="id_6848266_1284979_1_1">Increase (Decrease) in Prepaid Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US" id="id_6848266_1284979_14_1">Prepaid expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities_lbl" xml:lang="en-US" id="id_6848266_1283656_1_1">Increase (Decrease) in Restricted Cash for Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities_lbl" xml:lang="en-US" id="id_6848266_1283656_14_1">Restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInRestructuringReserve" xlink:label="us-gaap_IncreaseDecreaseInRestructuringReserve"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInRestructuringReserve_lbl" xml:lang="en-US" id="id_6848266_1285990_1_1">Increase (Decrease) in Restructuring Reserve</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInRestructuringReserve_lbl" xml:lang="en-US" id="id_6848266_1285990_2_1">Lease exit liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInRestructuringReserve" xlink:to="us-gaap_IncreaseDecreaseInRestructuringReserve_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US" id="id_6848266_1272538_1_1">IPO [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US" id="id_6848266_1272538_2_1">IPO [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_JanssenBiotechIncMember" xlink:label="mgnx_JanssenBiotechIncMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_JanssenBiotechIncMember_lbl" xml:lang="en-US" id="id_6848266_1605598_3_1">Janssen Biotech Inc. [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_JanssenBiotechIncMember_lbl" xml:lang="en-US" id="id_6848266_1605598_1_1">Janssen Biotech Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_JanssenBiotechIncMember_lbl" xml:lang="en-US" id="id_6848266_1605598_2_1">Janssen Biotech Inc. [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_JanssenBiotechIncMember" xlink:to="mgnx_JanssenBiotechIncMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_JohnsonAndJohnsonDevelopmentCorporationMember" xlink:label="mgnx_JohnsonAndJohnsonDevelopmentCorporationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_JohnsonAndJohnsonDevelopmentCorporationMember_lbl" xml:lang="en-US" id="id_6848266_1319668_3_1">Johnson And Johnson Development Corporation [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_JohnsonAndJohnsonDevelopmentCorporationMember_lbl" xml:lang="en-US" id="id_6848266_1319668_1_1">Johnson And Johnson Development Corporation [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_JohnsonAndJohnsonDevelopmentCorporationMember_lbl" xml:lang="en-US" id="id_6848266_1319668_2_1">Johnson &amp; Johnson Innovation JJDC, Inc, [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_JohnsonAndJohnsonDevelopmentCorporationMember" xlink:to="mgnx_JohnsonAndJohnsonDevelopmentCorporationMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_LaboratoryAndOfficeEquipmentMember" xlink:label="mgnx_LaboratoryAndOfficeEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_LaboratoryAndOfficeEquipmentMember_lbl" xml:lang="en-US" id="id_6848266_1479456_3_1">Laboratory and office equipment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_LaboratoryAndOfficeEquipmentMember_lbl" xml:lang="en-US" id="id_6848266_1479456_1_1">Laboratory and Office Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_LaboratoryAndOfficeEquipmentMember_lbl" xml:lang="en-US" id="id_6848266_1479456_2_1">Laboratory and Office Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_LaboratoryAndOfficeEquipmentMember" xlink:to="mgnx_LaboratoryAndOfficeEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_LeaseAgreementInitiationDate" xlink:label="mgnx_LeaseAgreementInitiationDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_LeaseAgreementInitiationDate_lbl" xml:lang="en-US" id="id_6848266_1457102_3_1">Lease Agreement Initiation Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_LeaseAgreementInitiationDate_lbl" xml:lang="en-US" id="id_6848266_1457102_1_1">Lease Agreement Initiation Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_LeaseAgreementInitiationDate_lbl" xml:lang="en-US" id="id_6848266_1457102_2_1">Origination date for additional space in manufacturing facility</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_LeaseAgreementInitiationDate" xlink:to="mgnx_LeaseAgreementInitiationDate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xml:lang="en-US" id="id_6848266_1280723_1_1">Lease Expiration Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xml:lang="en-US" id="id_6848266_1280723_2_1">Lease expiration date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_LeaseExpirationYear" xlink:label="mgnx_LeaseExpirationYear"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_LeaseExpirationYear_lbl" xml:lang="en-US" id="id_6848266_1555557_3_1">Lease expiration year.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_LeaseExpirationYear_lbl" xml:lang="en-US" id="id_6848266_1555557_1_1">Lease Expiration Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_LeaseExpirationYear_lbl" xml:lang="en-US" id="id_6848266_1555557_2_1">Operating Lease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_LeaseExpirationYear" xlink:to="mgnx_LeaseExpirationYear_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US" id="id_6848266_1277482_1_1">Leasehold Improvements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US" id="id_6848266_1277482_2_1">Leasehold Improvements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm" xlink:label="us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm_lbl" xml:lang="en-US" id="id_6848266_1275869_1_1">Lessee Leasing Arrangements, Operating Leases, Renewal Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm_lbl" xml:lang="en-US" id="id_6848266_1275869_2_1">Lessee leasing arrangements, operating leases, renewal term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm" xlink:to="us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:label="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_lbl" xml:lang="en-US" id="id_6848266_1274221_1_1">Lessee Leasing Arrangements, Operating Leases, Term of Contract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_lbl" xml:lang="en-US" id="id_6848266_1274221_2_1">Term of additional space lease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:to="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" id="id_6848266_1284515_1_1">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" id="id_6848266_1284515_6_1">Total liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" id="id_6848266_1283630_1_1">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" id="id_6848266_1283630_6_1">Total liabilities and stockholders' equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" id="id_6848266_1275871_1_1">Liabilities and Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" id="id_6848266_1275871_2_1">Liabilities and stockholders' equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" id="id_6848266_1282281_1_1">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" id="id_6848266_1282281_6_1">Total current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" id="id_6848266_1272565_1_1">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" id="id_6848266_1272565_2_1">Current liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:label="mgnx_LicenseAndCollaborationAgreementsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_LicenseAndCollaborationAgreementsLineItems_lbl" xml:lang="en-US" id="id_6848266_1534348_3_1">License and collaboration agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_LicenseAndCollaborationAgreementsLineItems_lbl" xml:lang="en-US" id="id_6848266_1534348_1_1">License And Collaboration Agreements [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_LicenseAndCollaborationAgreementsLineItems_lbl" xml:lang="en-US" id="id_6848266_1534348_2_1">License And Collaboration Agreements [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_LicenseAndCollaborationAgreementsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_LicenseAndCollaborationAgreementsTable" xlink:label="mgnx_LicenseAndCollaborationAgreementsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_LicenseAndCollaborationAgreementsTable_lbl" xml:lang="en-US" id="id_6848266_1345378_3_1">License and collaboration agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_LicenseAndCollaborationAgreementsTable_lbl" xml:lang="en-US" id="id_6848266_1345378_1_1">License And Collaboration Agreements [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_LicenseAndCollaborationAgreementsTable_lbl" xml:lang="en-US" id="id_6848266_1345378_2_1">License And Collaboration Agreements [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_LicenseAndCollaborationAgreementsTable" xlink:to="mgnx_LicenseAndCollaborationAgreementsTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LicenseAndServicesRevenue" xlink:label="us-gaap_LicenseAndServicesRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LicenseAndServicesRevenue_lbl" xml:lang="en-US" id="id_6848266_1282734_1_1">License and Services Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LicenseAndServicesRevenue_lbl" xml:lang="en-US" id="id_6848266_1282734_2_1">Revenue from collaborative research</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseAndServicesRevenue" xlink:to="us-gaap_LicenseAndServicesRevenue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="us-gaap_LicensesRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LicensesRevenue_lbl" xml:lang="en-US" id="id_6848266_1282735_1_1">Licenses Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LicensesRevenue_lbl" xml:lang="en-US" id="id_6848266_1282735_2_1">Recognized revenue under agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicensesRevenue" xlink:to="us-gaap_LicensesRevenue_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_LiquidInvestmentMaturityPeriodToBeClassifiedAsCashEquivalentMaximum" xlink:label="mgnx_LiquidInvestmentMaturityPeriodToBeClassifiedAsCashEquivalentMaximum"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_LiquidInvestmentMaturityPeriodToBeClassifiedAsCashEquivalentMaximum_lbl" xml:lang="en-US" id="id_6848266_1380127_3_1">Liquid investment maturity period to be classified as cash equivalent maximum.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_LiquidInvestmentMaturityPeriodToBeClassifiedAsCashEquivalentMaximum_lbl" xml:lang="en-US" id="id_6848266_1380127_1_1">Liquid Investment Maturity Period To Be Classified As Cash Equivalent Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_LiquidInvestmentMaturityPeriodToBeClassifiedAsCashEquivalentMaximum_lbl" xml:lang="en-US" id="id_6848266_1380127_2_1">Original maturity of financial instruments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_LiquidInvestmentMaturityPeriodToBeClassifiedAsCashEquivalentMaximum" xlink:to="mgnx_LiquidInvestmentMaturityPeriodToBeClassifiedAsCashEquivalentMaximum_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_ManufacturingSpaceMember" xlink:label="mgnx_ManufacturingSpaceMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_ManufacturingSpaceMember_lbl" xml:lang="en-US" id="id_6848266_1621777_3_1">Manufacturing space.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_ManufacturingSpaceMember_lbl" xml:lang="en-US" id="id_6848266_1621777_1_1">Manufacturing Space [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_ManufacturingSpaceMember_lbl" xml:lang="en-US" id="id_6848266_1621777_2_1">Manufacturing Space [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_ManufacturingSpaceMember" xlink:to="mgnx_ManufacturingSpaceMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MaximumMember_lbl" xml:lang="en-US" id="id_6848266_1275948_1_1">Maximum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MaximumMember_lbl" xml:lang="en-US" id="id_6848266_1275948_2_1">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MaximumMember" xlink:to="us-gaap_MaximumMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinimumMember_lbl" xml:lang="en-US" id="id_6848266_1277596_1_1">Minimum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MinimumMember_lbl" xml:lang="en-US" id="id_6848266_1277596_2_1">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinimumMember" xlink:to="us-gaap_MinimumMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_MoneyMarketFundsFairValueDisclosure" xlink:label="mgnx_MoneyMarketFundsFairValueDisclosure"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_MoneyMarketFundsFairValueDisclosure_lbl" xml:lang="en-US" id="id_6848266_1336791_3_1">Money market funds fair value disclosure.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_MoneyMarketFundsFairValueDisclosure_lbl" xml:lang="en-US" id="id_6848266_1336791_1_1">Money Market Funds Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_MoneyMarketFundsFairValueDisclosure_lbl" xml:lang="en-US" id="id_6848266_1336791_2_1">Money market funds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_MoneyMarketFundsFairValueDisclosure" xlink:to="mgnx_MoneyMarketFundsFairValueDisclosure_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl" xml:lang="en-US" id="id_6848266_1287111_1_1">Net Cash Provided by (Used in) Financing Activities, Continuing Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl" xml:lang="en-US" id="id_6848266_1287111_6_1">Net cash provided by financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" id="id_6848266_1269355_1_1">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" id="id_6848266_1269355_2_1">Cash flows from financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl" xml:lang="en-US" id="id_6848266_1287595_1_1">Net Cash Provided by (Used in) Investing Activities, Continuing Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl" xml:lang="en-US" id="id_6848266_1287595_2_1">Net cash used in investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" id="id_6848266_1277599_1_1">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" id="id_6848266_1277599_2_1">Cash flows from investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xml:lang="en-US" id="id_6848266_1272684_1_1">Net Cash Provided by (Used in) Operating Activities, Continuing Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xml:lang="en-US" id="id_6848266_1272684_6_1">Net cash used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" id="id_6848266_1269356_1_1">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" id="id_6848266_1269356_2_1">Operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" id="id_6848266_1284477_1_1">Net Income (Loss) Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" id="id_6848266_1284477_2_1">Net income (loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" id="id_6848266_1284477_6_1">Net comprehensive income (loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" id="id_6848266_1284477_12_1">Net income (loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US" id="id_6848266_1284476_1_1">Net Income (Loss) Available to Common Stockholders, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US" id="id_6848266_1284476_6_1">Net income (loss) allocable to common shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xml:lang="en-US" id="id_6848266_1281749_1_1">Net Income (Loss) Available to Common Stockholders, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xml:lang="en-US" id="id_6848266_1281749_6_1">Net income (loss) allocable to common shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_6848266_1279254_1_1">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_6848266_1279254_2_1">Recently Issued Accounting Standards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US" id="id_6848266_1272694_1_1">Noncash Investing and Financing Items [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US" id="id_6848266_1272694_2_1">Noncash financing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_NonRefundableUpFrontPayment" xlink:label="mgnx_NonRefundableUpFrontPayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_NonRefundableUpFrontPayment_lbl" xml:lang="en-US" id="id_6848266_1494102_3_1">Non-refundable up front payment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_NonRefundableUpFrontPayment_lbl" xml:lang="en-US" id="id_6848266_1494102_1_1">Non Refundable Up Front Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_NonRefundableUpFrontPayment_lbl" xml:lang="en-US" id="id_6848266_1494102_2_1">Nonrefundable upfront payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_NonRefundableUpFrontPayment" xlink:to="mgnx_NonRefundableUpFrontPayment_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_NonRefundableUpfrontPaymentReceivable" xlink:label="mgnx_NonRefundableUpfrontPaymentReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_NonRefundableUpfrontPaymentReceivable_lbl" xml:lang="en-US" id="id_6848266_1610364_3_1">Initial fee receivable from collaboration or license agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_NonRefundableUpfrontPaymentReceivable_lbl" xml:lang="en-US" id="id_6848266_1610364_1_1">Non Refundable Upfront Payment Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_NonRefundableUpfrontPaymentReceivable_lbl" xml:lang="en-US" id="id_6848266_1610364_2_1">Nonrefundable upfront payment receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_NonRefundableUpfrontPaymentReceivable" xlink:to="mgnx_NonRefundableUpfrontPaymentReceivable_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_NumberOfAnnualMaintenancePaymentReceived" xlink:label="mgnx_NumberOfAnnualMaintenancePaymentReceived"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_NumberOfAnnualMaintenancePaymentReceived_lbl" xml:lang="en-US" id="id_6848266_1290658_3_1">Number of annual maintenance payment received.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_NumberOfAnnualMaintenancePaymentReceived_lbl" xml:lang="en-US" id="id_6848266_1290658_1_1">Number Of Annual Maintenance Payment Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_NumberOfAnnualMaintenancePaymentReceived_lbl" xml:lang="en-US" id="id_6848266_1290658_2_1">Number of annual maintenance payments received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_NumberOfAnnualMaintenancePaymentReceived" xlink:to="mgnx_NumberOfAnnualMaintenancePaymentReceived_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_NumberOfAssetsHeldForSale" xlink:label="mgnx_NumberOfAssetsHeldForSale"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_NumberOfAssetsHeldForSale_lbl" xml:lang="en-US" id="id_6848266_1534567_3_1">Number of assets held for sale.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_NumberOfAssetsHeldForSale_lbl" xml:lang="en-US" id="id_6848266_1534567_1_1">Number Of Assets Held For Sale</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_NumberOfAssetsHeldForSale_lbl" xml:lang="en-US" id="id_6848266_1534567_2_1">Number of assets held-for-sale</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_NumberOfAssetsHeldForSale" xlink:to="mgnx_NumberOfAssetsHeldForSale_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_NumberOfImpairedAssets" xlink:label="mgnx_NumberOfImpairedAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_NumberOfImpairedAssets_lbl" xml:lang="en-US" id="id_6848266_1529599_3_1">Number of impaired assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_NumberOfImpairedAssets_lbl" xml:lang="en-US" id="id_6848266_1529599_1_1">Number Of Impaired Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_NumberOfImpairedAssets_lbl" xml:lang="en-US" id="id_6848266_1529599_2_1">Number of impaired assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_NumberOfImpairedAssets" xlink:to="mgnx_NumberOfImpairedAssets_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_NumberOfMilestonesAchieved" xlink:label="mgnx_NumberOfMilestonesAchieved"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_NumberOfMilestonesAchieved_lbl" xml:lang="en-US" id="id_6848266_1541400_3_1">Number of clinical milestones achieved during period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_NumberOfMilestonesAchieved_lbl" xml:lang="en-US" id="id_6848266_1541400_1_1">Number Of Milestones Achieved</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_NumberOfMilestonesAchieved_lbl" xml:lang="en-US" id="id_6848266_1541400_2_1">Number of milestones achieved</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_NumberOfMilestonesAchieved" xlink:to="mgnx_NumberOfMilestonesAchieved_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedAsPerCollaborations" xlink:label="mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedAsPerCollaborations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedAsPerCollaborations_lbl" xml:lang="en-US" id="id_6848266_1526272_3_1">Number of molecules to be developed and commercialized as per collaborations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedAsPerCollaborations_lbl" xml:lang="en-US" id="id_6848266_1526272_1_1">Number Of Molecules To Be Developed And Commercialized As Per Collaborations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedAsPerCollaborations_lbl" xml:lang="en-US" id="id_6848266_1526272_2_1">Commercialization of molecules</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedAsPerCollaborations" xlink:to="mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedAsPerCollaborations_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" id="id_6848266_1276002_1_1">Number of Operating Segments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" id="id_6848266_1276002_2_1">Number of operating segments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_NumberOfPotentialSharesToBeIssuedAsAdditionalConsiderationUnderAssetPurchaseAgreement" xlink:label="mgnx_NumberOfPotentialSharesToBeIssuedAsAdditionalConsiderationUnderAssetPurchaseAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_NumberOfPotentialSharesToBeIssuedAsAdditionalConsiderationUnderAssetPurchaseAgreement_lbl" xml:lang="en-US" id="id_6848266_1559574_3_1">Number of potential shares to be issued as additional consideration under asset purchase agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_NumberOfPotentialSharesToBeIssuedAsAdditionalConsiderationUnderAssetPurchaseAgreement_lbl" xml:lang="en-US" id="id_6848266_1559574_1_1">Number Of Potential Shares To Be Issued As Additional Consideration Under Asset Purchase Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_NumberOfPotentialSharesToBeIssuedAsAdditionalConsiderationUnderAssetPurchaseAgreement_lbl" xml:lang="en-US" id="id_6848266_1559574_2_1">Common stock shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_NumberOfPotentialSharesToBeIssuedAsAdditionalConsiderationUnderAssetPurchaseAgreement" xlink:to="mgnx_NumberOfPotentialSharesToBeIssuedAsAdditionalConsiderationUnderAssetPurchaseAgreement_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_NumberOfPrograms" xlink:label="mgnx_NumberOfPrograms"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_NumberOfPrograms_lbl" xml:lang="en-US" id="id_6848266_1307567_3_1">Number of programs being pursued under collaboration agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_NumberOfPrograms_lbl" xml:lang="en-US" id="id_6848266_1307567_1_1">Number Of Programs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_NumberOfPrograms_lbl" xml:lang="en-US" id="id_6848266_1307567_2_1">DART program</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_NumberOfPrograms" xlink:to="mgnx_NumberOfPrograms_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_OfficeAndLaboratorySpaceMember" xlink:label="mgnx_OfficeAndLaboratorySpaceMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_OfficeAndLaboratorySpaceMember_lbl" xml:lang="en-US" id="id_6848266_1509307_3_1">Office and laboratory space.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_OfficeAndLaboratorySpaceMember_lbl" xml:lang="en-US" id="id_6848266_1509307_1_1">Office And Laboratory Space [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_OfficeAndLaboratorySpaceMember_lbl" xml:lang="en-US" id="id_6848266_1509307_2_1">Office and Laboratory Space [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_OfficeAndLaboratorySpaceMember" xlink:to="mgnx_OfficeAndLaboratorySpaceMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_OnetimeMilestonePaymentToBePaidUnderAgreement" xlink:label="mgnx_OnetimeMilestonePaymentToBePaidUnderAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_OnetimeMilestonePaymentToBePaidUnderAgreement_lbl" xml:lang="en-US" id="id_6848266_1522455_3_1">One-time milestone payment to be paid under agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_OnetimeMilestonePaymentToBePaidUnderAgreement_lbl" xml:lang="en-US" id="id_6848266_1522455_1_1">Onetime Milestone Payment To Be Paid Under Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_OnetimeMilestonePaymentToBePaidUnderAgreement_lbl" xml:lang="en-US" id="id_6848266_1522455_2_1">Onetime purchase payment under purchase agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_OnetimeMilestonePaymentToBePaidUnderAgreement" xlink:to="mgnx_OnetimeMilestonePaymentToBePaidUnderAgreement_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_OnetimeMilestonePaymentToBePaidUnderAgreementUponSpecifiedLevelOfSalesOfProducts" xlink:label="mgnx_OnetimeMilestonePaymentToBePaidUnderAgreementUponSpecifiedLevelOfSalesOfProducts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_OnetimeMilestonePaymentToBePaidUnderAgreementUponSpecifiedLevelOfSalesOfProducts_lbl" xml:lang="en-US" id="id_6848266_1361394_3_1">One-time milestone payment to be paid under agreement upon specified level of sales of products.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_OnetimeMilestonePaymentToBePaidUnderAgreementUponSpecifiedLevelOfSalesOfProducts_lbl" xml:lang="en-US" id="id_6848266_1361394_1_1">Onetime Milestone Payment To Be Paid Under Agreement Upon Specified Level Of Sales Of Products</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_OnetimeMilestonePaymentToBePaidUnderAgreementUponSpecifiedLevelOfSalesOfProducts_lbl" xml:lang="en-US" id="id_6848266_1361394_2_1">Onetime payment paid under license of product</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_OnetimeMilestonePaymentToBePaidUnderAgreementUponSpecifiedLevelOfSalesOfProducts" xlink:to="mgnx_OnetimeMilestonePaymentToBePaidUnderAgreementUponSpecifiedLevelOfSalesOfProducts_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" id="id_6848266_1283121_1_1">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" id="id_6848266_1283121_6_1">Income (loss) from operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="us-gaap_OperatingLeasedAssetsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasedAssetsLineItems_lbl" xml:lang="en-US" id="id_6848266_1280907_1_1">Operating Leased Assets [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasedAssetsLineItems_lbl" xml:lang="en-US" id="id_6848266_1280907_2_1">Operating Leased Assets [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_OperatingLeasedAssetsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xml:lang="en-US" id="id_6848266_1283561_1_1">Operating Leases, Future Minimum Payments Due</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xml:lang="en-US" id="id_6848266_1283561_6_1">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xml:lang="en-US" id="id_6848266_1284896_1_1">Operating Leases, Future Minimum Payments Due, Next Twelve Months</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xml:lang="en-US" id="id_6848266_1284896_2_1">2015</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl" xml:lang="en-US" id="id_6848266_1283562_1_1">Operating Leases, Future Minimum Payments, Due in Five Years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl" xml:lang="en-US" id="id_6848266_1283562_2_1">2019</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xml:lang="en-US" id="id_6848266_1283125_1_1">Operating Leases, Future Minimum Payments, Due in Four Years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xml:lang="en-US" id="id_6848266_1283125_2_1">2018</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xml:lang="en-US" id="id_6848266_1283564_1_1">Operating Leases, Future Minimum Payments, Due in Three Years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xml:lang="en-US" id="id_6848266_1283564_2_1">2017</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xml:lang="en-US" id="id_6848266_1284469_1_1">Operating Leases, Future Minimum Payments, Due in Two Years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xml:lang="en-US" id="id_6848266_1284469_2_1">2016</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_lbl" xml:lang="en-US" id="id_6848266_1282235_1_1">Operating Leases, Future Minimum Payments, Due Thereafter</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_lbl" xml:lang="en-US" id="id_6848266_1282235_2_1">Thereafter</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:label="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_lbl" xml:lang="en-US" id="id_6848266_1274379_1_1">Operating Leases of Lessee Disclosure [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_lbl" xml:lang="en-US" id="id_6848266_1274379_2_1">Schedule of Minimum Future Lease Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:to="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="us-gaap_OperatingLeasesRentExpenseNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesRentExpenseNet_lbl" xml:lang="en-US" id="id_6848266_1286571_1_1">Operating Leases, Rent Expense, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesRentExpenseNet_lbl" xml:lang="en-US" id="id_6848266_1286571_2_1">Rent expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesRentExpenseNet" xlink:to="us-gaap_OperatingLeasesRentExpenseNet_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_OperatingLossCarryforwardsAnnualLimitationAmount" xlink:label="mgnx_OperatingLossCarryforwardsAnnualLimitationAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_OperatingLossCarryforwardsAnnualLimitationAmount_lbl" xml:lang="en-US" id="id_6848266_1456179_3_1">Operating loss carryforwards annual limitation amount.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_OperatingLossCarryforwardsAnnualLimitationAmount_lbl" xml:lang="en-US" id="id_6848266_1456179_1_1">Operating Loss Carryforwards Annual Limitation Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_OperatingLossCarryforwardsAnnualLimitationAmount_lbl" xml:lang="en-US" id="id_6848266_1456179_2_1">Net operating losses limited for use utilized on an annual basis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_OperatingLossCarryforwardsAnnualLimitationAmount" xlink:to="mgnx_OperatingLossCarryforwardsAnnualLimitationAmount_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_OperatingLossCarryforwardsExpirationYear" xlink:label="mgnx_OperatingLossCarryforwardsExpirationYear"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_OperatingLossCarryforwardsExpirationYear_lbl" xml:lang="en-US" id="id_6848266_1521077_3_1">Operating Loss Carryforwards Expiration Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_OperatingLossCarryforwardsExpirationYear_lbl" xml:lang="en-US" id="id_6848266_1521077_1_1">Operating Loss Carryforwards Expiration Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_OperatingLossCarryforwardsExpirationYear_lbl" xml:lang="en-US" id="id_6848266_1521077_2_1">Net operating loss carryforwards expiration ending year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_OperatingLossCarryforwardsExpirationYear" xlink:to="mgnx_OperatingLossCarryforwardsExpirationYear_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount" xlink:label="mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount_lbl" xml:lang="en-US" id="id_6848266_1377544_3_1">Operating loss carryforwards limitations on use amount.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount_lbl" xml:lang="en-US" id="id_6848266_1377544_1_1">Operating Loss Carryforwards Limitations On Use Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount_lbl" xml:lang="en-US" id="id_6848266_1377544_2_1">Net operating loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount" xlink:to="mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_OperatingLossCarryforwardsLimitationsOnUseYearEnd" xlink:label="mgnx_OperatingLossCarryforwardsLimitationsOnUseYearEnd"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_OperatingLossCarryforwardsLimitationsOnUseYearEnd_lbl" xml:lang="en-US" id="id_6848266_1503531_3_1">Operating loss carryforwards limitations on use year end.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_OperatingLossCarryforwardsLimitationsOnUseYearEnd_lbl" xml:lang="en-US" id="id_6848266_1503531_1_1">Operating Loss Carryforwards Limitations On Use Year End</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_OperatingLossCarryforwardsLimitationsOnUseYearEnd_lbl" xml:lang="en-US" id="id_6848266_1503531_2_1">Net operating losses limited for year maximum</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_OperatingLossCarryforwardsLimitationsOnUseYearEnd" xlink:to="mgnx_OperatingLossCarryforwardsLimitationsOnUseYearEnd_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_OperatingLossCarryforwardsLimitationsOnUseYearStart" xlink:label="mgnx_OperatingLossCarryforwardsLimitationsOnUseYearStart"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_OperatingLossCarryforwardsLimitationsOnUseYearStart_lbl" xml:lang="en-US" id="id_6848266_1446509_3_1">Operating loss carryforwards limitations on use year start.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_OperatingLossCarryforwardsLimitationsOnUseYearStart_lbl" xml:lang="en-US" id="id_6848266_1446509_1_1">Operating Loss Carryforwards Limitations On Use Year Start</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_OperatingLossCarryforwardsLimitationsOnUseYearStart_lbl" xml:lang="en-US" id="id_6848266_1446509_2_1">Net operating losses limited for year minimum</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_OperatingLossCarryforwardsLimitationsOnUseYearStart" xlink:to="mgnx_OperatingLossCarryforwardsLimitationsOnUseYearStart_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_OperatingLossCarryforwardsNotSubjectToLimitation" xlink:label="mgnx_OperatingLossCarryforwardsNotSubjectToLimitation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_OperatingLossCarryforwardsNotSubjectToLimitation_lbl" xml:lang="en-US" id="id_6848266_1427571_3_1">Operating loss carryforwards not subject to limitation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_OperatingLossCarryforwardsNotSubjectToLimitation_lbl" xml:lang="en-US" id="id_6848266_1427571_1_1">Operating Loss Carryforwards Not Subject To Limitation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_OperatingLossCarryforwardsNotSubjectToLimitation_lbl" xml:lang="en-US" id="id_6848266_1427571_2_1">Remaining portion of net operating losses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_OperatingLossCarryforwardsNotSubjectToLimitation" xlink:to="mgnx_OperatingLossCarryforwardsNotSubjectToLimitation_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_OptionExerciseFee" xlink:label="mgnx_OptionExerciseFee"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_OptionExerciseFee_lbl" xml:lang="en-US" id="id_6848266_1304911_3_1">Payment from collaborator upon exercise of option to develop and commercialize product.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_OptionExerciseFee_lbl" xml:lang="en-US" id="id_6848266_1304911_1_1">Option Exercise Fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_OptionExerciseFee_lbl" xml:lang="en-US" id="id_6848266_1304911_2_1">Option exercise fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_OptionExerciseFee" xlink:to="mgnx_OptionExerciseFee_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_OptionExerciseFeeRecognitionPeriod" xlink:label="mgnx_OptionExerciseFeeRecognitionPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_OptionExerciseFeeRecognitionPeriod_lbl" xml:lang="en-US" id="id_6848266_1610421_3_1">Option exercise fee recognition period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_OptionExerciseFeeRecognitionPeriod_lbl" xml:lang="en-US" id="id_6848266_1610421_1_1">Option Exercise Fee Recognition Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_OptionExerciseFeeRecognitionPeriod_lbl" xml:lang="en-US" id="id_6848266_1610421_2_1">Option exercise fee recognition period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_OptionExerciseFeeRecognitionPeriod" xlink:to="mgnx_OptionExerciseFeeRecognitionPeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" id="id_6848266_1276020_1_1">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" id="id_6848266_1276020_2_1">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US" id="id_6848266_1277652_1_1">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US" id="id_6848266_1277652_2_1">Organization and Nature of Operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" id="id_6848266_1288618_1_1">Other Assets, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" id="id_6848266_1288618_2_1">Other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US" id="id_6848266_1281714_1_1">Other Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US" id="id_6848266_1281714_2_1">Other liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" id="id_6848266_1284001_1_1">Other Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" id="id_6848266_1284001_2_1">Other income (expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xml:lang="en-US" id="id_6848266_1280942_1_1">Over-Allotment Option [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xml:lang="en-US" id="id_6848266_1280942_2_1">Over-Allotment Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic" xlink:label="us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic_lbl" xml:lang="en-US" id="id_6848266_1286106_1_1">Participating Securities, Distributed and Undistributed Earnings (Loss), Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic_lbl" xml:lang="en-US" id="id_6848266_1286106_14_1">Less: undistributed earnings allocated to participating securities and other add-backs to net income (loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic" xlink:to="us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsForRestructuring" xlink:label="us-gaap_PaymentsForRestructuring"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRestructuring_lbl" xml:lang="en-US" id="id_6848266_1283087_1_1">Payments for Restructuring</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsForRestructuring_lbl" xml:lang="en-US" id="id_6848266_1283087_14_1">Principal payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRestructuring" xlink:to="us-gaap_PaymentsForRestructuring_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xml:lang="en-US" id="id_6848266_1284842_1_1">Payments Related to Tax Withholding for Share-based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xml:lang="en-US" id="id_6848266_1284842_14_1">Purchase of treasury stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" id="id_6848266_1284434_1_1">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" id="id_6848266_1284434_14_1">Purchases of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xml:lang="en-US" id="id_6848266_1279337_1_1">Pension and Other Postretirement Benefits Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xml:lang="en-US" id="id_6848266_1279337_2_1">Employee Benefit Plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" xlink:label="mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_lbl" xml:lang="en-US" id="id_6848266_1381037_3_1">Percentage of shares of company's common stock outstanding for increase in shares reserved for issuance under stock plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_lbl" xml:lang="en-US" id="id_6848266_1381037_1_1">Percentage Of Shares Of Companys Common Stock Outstanding For Increase In Shares Reserved For Issuance Under Stock Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_lbl" xml:lang="en-US" id="id_6848266_1381037_2_1">Percentage of common stock share outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" xlink:to="mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_PfizerIncMember" xlink:label="mgnx_PfizerIncMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_PfizerIncMember_lbl" xml:lang="en-US" id="id_6848266_1545620_3_1">Pfizer Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_PfizerIncMember_lbl" xml:lang="en-US" id="id_6848266_1545620_1_1">Pfizer Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_PfizerIncMember_lbl" xml:lang="en-US" id="id_6848266_1545620_2_1">Pfizer [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_PfizerIncMember" xlink:to="mgnx_PfizerIncMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US" id="id_6848266_1280964_1_1">Plan Name [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US" id="id_6848266_1280964_2_1">Plan Name [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" id="id_6848266_1279330_1_1">Plan Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" id="id_6848266_1279330_2_1">Plan Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_PotentialLicenseOptionFeeAndEarlyDevelopmentMilestoneFee" xlink:label="mgnx_PotentialLicenseOptionFeeAndEarlyDevelopmentMilestoneFee"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_PotentialLicenseOptionFeeAndEarlyDevelopmentMilestoneFee_lbl" xml:lang="en-US" id="id_6848266_1591111_3_1">Potential license option fee and early development milestone fee.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_PotentialLicenseOptionFeeAndEarlyDevelopmentMilestoneFee_lbl" xml:lang="en-US" id="id_6848266_1591111_1_1">Potential License Option Fee And Early Development Milestone Fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_PotentialLicenseOptionFeeAndEarlyDevelopmentMilestoneFee_lbl" xml:lang="en-US" id="id_6848266_1591111_2_1">License option fee and early development milestone</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_PotentialLicenseOptionFeeAndEarlyDevelopmentMilestoneFee" xlink:to="mgnx_PotentialLicenseOptionFeeAndEarlyDevelopmentMilestoneFee_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_PreclinicalMilestonesMember" xlink:label="mgnx_PreclinicalMilestonesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_PreclinicalMilestonesMember_lbl" xml:lang="en-US" id="id_6848266_1560227_3_1">Preclinical milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_PreclinicalMilestonesMember_lbl" xml:lang="en-US" id="id_6848266_1560227_1_1">Preclinical Milestones [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_PreclinicalMilestonesMember_lbl" xml:lang="en-US" id="id_6848266_1560227_2_1">Pre-Clinical Milestones [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_PreclinicalMilestonesMember" xlink:to="mgnx_PreclinicalMilestonesMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockDividendRatePerDollarAmount" xlink:label="us-gaap_PreferredStockDividendRatePerDollarAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDividendRatePerDollarAmount_lbl" xml:lang="en-US" id="id_6848266_1280975_1_1">Preferred Stock, Dividend Rate, Per-Dollar-Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockDividendRatePerDollarAmount_lbl" xml:lang="en-US" id="id_6848266_1280975_2_1">Accrued noncumulative dividends on preferred stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendRatePerDollarAmount" xlink:to="us-gaap_PreferredStockDividendRatePerDollarAmount_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" id="id_6848266_1280976_1_1">Preferred Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" id="id_6848266_1280976_2_1">Undesignated preferred stock, par value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" id="id_6848266_1279344_1_1">Preferred Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" id="id_6848266_1279344_2_1">Undesignated preferred stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" id="id_6848266_1280980_1_1">Preferred Stock, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" id="id_6848266_1280980_2_1">Undesignated preferred stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" id="id_6848266_1276106_1_1">Preferred Stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" id="id_6848266_1276106_2_1">Undesignated preferred stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US" id="id_6848266_1289180_1_1">Prepaid Expense, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US" id="id_6848266_1289180_2_1">Prepaid expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US" id="id_6848266_1288681_1_1">Proceeds from Issuance Initial Public Offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US" id="id_6848266_1288681_2_1">Proceeds from initial public offering net of expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" id="id_6848266_1287188_1_1">Proceeds from Issuance of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" id="id_6848266_1287188_2_1">Proceeds from issuance of common stock, net of offering costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xml:lang="en-US" id="id_6848266_1287673_1_1">Proceeds from Issuance of Convertible Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xml:lang="en-US" id="id_6848266_1287673_2_1">Proceeds from issuance of convertible preferred stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US" id="id_6848266_1287667_1_1">Proceeds from Issuance or Sale of Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US" id="id_6848266_1287667_2_1">Proceeds from sale of shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" id="id_6848266_1287696_1_1">Proceeds from Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" id="id_6848266_1287696_2_1">Cash proceeds from exercise of stock options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" id="id_6848266_1287696_12_1">Proceeds from stock option exercises</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US" id="id_6848266_1277741_1_1">Property, Plant and Equipment [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US" id="id_6848266_1277741_2_1">Property, Plant and Equipment [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US" id="id_6848266_1276136_1_1">Property, Plant and Equipment, Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US" id="id_6848266_1276136_2_1">Property, Plant and Equipment, Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US" id="id_6848266_1279373_1_1">Property, Plant and Equipment Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US" id="id_6848266_1279373_2_1">Property and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:label="mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock_lbl" xml:lang="en-US" id="id_6848266_1295304_3_1">Property plant and equipment estimated useful life.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock_lbl" xml:lang="en-US" id="id_6848266_1295304_1_1">Property Plant And Equipment Estimated Useful Life Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock_lbl" xml:lang="en-US" id="id_6848266_1295304_2_1">Estimated Useful Lives</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:to="mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xml:lang="en-US" id="id_6848266_1279374_1_1">Property, Plant and Equipment, Estimated Useful Lives</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xml:lang="en-US" id="id_6848266_1279374_2_1">Leasehold improvements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" id="id_6848266_1287207_1_1">Property, Plant and Equipment, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" id="id_6848266_1287207_2_1">Property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" id="id_6848266_1269502_1_1">Property, Plant and Equipment [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" id="id_6848266_1269502_2_1">Property, Plant and Equipment [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" id="id_6848266_1285626_1_1">Property, Plant and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" id="id_6848266_1285626_2_1">Property and equipment, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" id="id_6848266_1285626_6_1">Property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US" id="id_6848266_1276143_1_1">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US" id="id_6848266_1276143_2_1">Property and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" id="id_6848266_1281009_1_1">Property, Plant and Equipment [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" id="id_6848266_1281009_2_1">Schedule of Property and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US" id="id_6848266_1274491_1_1">Property, Plant and Equipment, Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US" id="id_6848266_1274491_2_1">Property, Plant and Equipment, Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US" id="id_6848266_1276144_1_1">Property, Plant and Equipment, Useful Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US" id="id_6848266_1276144_2_1">Estimated Useful Lives</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_lbl" xml:lang="en-US" id="id_6848266_1279380_1_1">Property Subject to or Available for Operating Lease [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_lbl" xml:lang="en-US" id="id_6848266_1279380_2_1">Property Subject to or Available for Operating Lease [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:to="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_lbl" xml:lang="en-US" id="id_6848266_1277745_1_1">Property Subject to or Available for Operating Lease [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_lbl" xml:lang="en-US" id="id_6848266_1277745_2_1">Property Subject to or Available for Operating Lease [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:to="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract_lbl" xml:lang="en-US" id="id_6848266_1277772_1_1">Quarterly Financial Information Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract_lbl" xml:lang="en-US" id="id_6848266_1277772_2_1">Quarterly Financial Information Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_QuarterlyFinancialInformationDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock_lbl" xml:lang="en-US" id="id_6848266_1276165_1_1">Quarterly Financial Information [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock_lbl" xml:lang="en-US" id="id_6848266_1276165_2_1">Quarterly Financial Information</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_QuarterlyFinancialInformationTextBlock" xlink:to="us-gaap_QuarterlyFinancialInformationTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RangeAxis_lbl" xml:lang="en-US" id="id_6848266_1269523_1_1">Range [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RangeAxis_lbl" xml:lang="en-US" id="id_6848266_1269523_2_1">Range [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RangeMember_lbl" xml:lang="en-US" id="id_6848266_1279402_1_1">Range [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RangeMember_lbl" xml:lang="en-US" id="id_6848266_1279402_2_1">Range [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_RangeMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_RavenBiotechnologiesIncMember" xlink:label="mgnx_RavenBiotechnologiesIncMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_RavenBiotechnologiesIncMember_lbl" xml:lang="en-US" id="id_6848266_1336998_3_1">Raven Biotechnologies, Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_RavenBiotechnologiesIncMember_lbl" xml:lang="en-US" id="id_6848266_1336998_1_1">Raven Biotechnologies Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_RavenBiotechnologiesIncMember_lbl" xml:lang="en-US" id="id_6848266_1336998_2_1">Raven Biotechnologies Inc. [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_RavenBiotechnologiesIncMember" xlink:to="mgnx_RavenBiotechnologiesIncMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US" id="id_6848266_1276212_1_1">Counterparty Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US" id="id_6848266_1276212_2_1">Counterparty Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" id="id_6848266_1285664_1_1">Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" id="id_6848266_1285664_2_1">Research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" id="id_6848266_1269570_1_1">Research and Development Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" id="id_6848266_1269570_2_1">Research and Development [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" id="id_6848266_1276218_1_1">Research and Development Expense, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" id="id_6848266_1276218_2_1">Research and Development Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_ResearchCollaborationAndLicenseOptionAgreementMember" xlink:label="mgnx_ResearchCollaborationAndLicenseOptionAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_ResearchCollaborationAndLicenseOptionAgreementMember_lbl" xml:lang="en-US" id="id_6848266_1600194_3_1">Research Collaboration And License Option Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_ResearchCollaborationAndLicenseOptionAgreementMember_lbl" xml:lang="en-US" id="id_6848266_1600194_1_1">Research Collaboration And License Option Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_ResearchCollaborationAndLicenseOptionAgreementMember_lbl" xml:lang="en-US" id="id_6848266_1600194_2_1">Research Collaboration And License Option Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_ResearchCollaborationAndLicenseOptionAgreementMember" xlink:to="mgnx_ResearchCollaborationAndLicenseOptionAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_ResearchObligationCompletionDate" xlink:label="mgnx_ResearchObligationCompletionDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_ResearchObligationCompletionDate_lbl" xml:lang="en-US" id="id_6848266_1562048_3_1">Research obligation completion date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_ResearchObligationCompletionDate_lbl" xml:lang="en-US" id="id_6848266_1562048_1_1">Research Obligation Completion Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_ResearchObligationCompletionDate_lbl" xml:lang="en-US" id="id_6848266_1562048_2_1">Research obligation completion date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_ResearchObligationCompletionDate" xlink:to="mgnx_ResearchObligationCompletionDate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_lbl" xml:lang="en-US" id="id_6848266_1286186_1_1">Restricted Cash and Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_lbl" xml:lang="en-US" id="id_6848266_1286186_2_1">Amounts classified as restricted cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_lbl" xml:lang="en-US" id="id_6848266_1286186_12_1">Restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalents" xlink:to="us-gaap_RestrictedCashAndCashEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract_lbl" xml:lang="en-US" id="id_6848266_1281074_1_1">Restructuring and Related Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract_lbl" xml:lang="en-US" id="id_6848266_1281074_2_1">Restructuring and Related Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_RestructuringAndRelatedActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl" xml:lang="en-US" id="id_6848266_1281075_1_1">Restructuring and Related Activities Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl" xml:lang="en-US" id="id_6848266_1281075_2_1">Lease Exit Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringCostAndReserveAxis_lbl" xml:lang="en-US" id="id_6848266_1277830_1_1">Restructuring Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringCostAndReserveAxis_lbl" xml:lang="en-US" id="id_6848266_1277830_2_1">Restructuring Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_RestructuringCostAndReserveAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringCostAndReserveLineItems_lbl" xml:lang="en-US" id="id_6848266_1274563_1_1">Restructuring Cost and Reserve [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringCostAndReserveLineItems_lbl" xml:lang="en-US" id="id_6848266_1274563_2_1">Restructuring Cost and Reserve [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringCostAndReserveLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestructuringReserve" xlink:label="us-gaap_RestructuringReserve"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringReserve_lbl" xml:lang="en-US" id="id_6848266_1282122_1_1">Restructuring Reserve</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_RestructuringReserve_lbl" xml:lang="en-US" id="id_6848266_1282122_4_1">Accrual Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_RestructuringReserve_lbl" xml:lang="en-US" id="id_6848266_1282122_5_1">Accrual Beginning Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringReserve" xlink:to="us-gaap_RestructuringReserve_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestructuringReserveCurrent" xlink:label="us-gaap_RestructuringReserveCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringReserveCurrent_lbl" xml:lang="en-US" id="id_6848266_1282592_1_1">Restructuring Reserve, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringReserveCurrent_lbl" xml:lang="en-US" id="id_6848266_1282592_2_1">Lease exit liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringReserveCurrent" xlink:to="us-gaap_RestructuringReserveCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestructuringReserveNoncurrent" xlink:label="us-gaap_RestructuringReserveNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringReserveNoncurrent_lbl" xml:lang="en-US" id="id_6848266_1284378_1_1">Restructuring Reserve, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringReserveNoncurrent_lbl" xml:lang="en-US" id="id_6848266_1284378_2_1">Lease exit liability, net of current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringReserveNoncurrent" xlink:to="us-gaap_RestructuringReserveNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" id="id_6848266_1283021_1_1">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" id="id_6848266_1283021_2_1">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" id="id_6848266_1269588_1_1">Retained Earnings [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" id="id_6848266_1269588_2_1">Accumulated Deficit [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueFromGrants" xlink:label="us-gaap_RevenueFromGrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromGrants_lbl" xml:lang="en-US" id="id_6848266_1281624_1_1">Revenue from Grants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromGrants_lbl" xml:lang="en-US" id="id_6848266_1281624_2_1">Grant revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromGrants" xlink:to="us-gaap_RevenueFromGrants_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_lbl" xml:lang="en-US" id="id_6848266_1282115_1_1">Revenue Recognition, Milestone Method, Revenue Recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_lbl" xml:lang="en-US" id="id_6848266_1282115_32_1">Milestones achieved</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_lbl" xml:lang="en-US" id="id_6848266_1282115_2_1">Milestone achieved</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_lbl" xml:lang="en-US" id="id_6848266_1282115_12_1">Milestone payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:to="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US" id="id_6848266_1272964_1_1">Revenue Recognition, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US" id="id_6848266_1272964_2_1">Revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US" id="id_6848266_1284373_1_1">Revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US" id="id_6848266_1284373_2_1">Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US" id="id_6848266_1284373_6_1">Total revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US" id="id_6848266_1271283_1_1">Revenues [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US" id="id_6848266_1271283_2_1">Revenues:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_ReviewPeriodByRegulatoryAuthority" xlink:label="mgnx_ReviewPeriodByRegulatoryAuthority"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_ReviewPeriodByRegulatoryAuthority_lbl" xml:lang="en-US" id="id_6848266_1314337_3_1">Review period by regulatory authority.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_ReviewPeriodByRegulatoryAuthority_lbl" xml:lang="en-US" id="id_6848266_1314337_1_1">Review Period By Regulatory Authority</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_ReviewPeriodByRegulatoryAuthority_lbl" xml:lang="en-US" id="id_6848266_1314337_2_1">Review period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_ReviewPeriodByRegulatoryAuthority" xlink:to="mgnx_ReviewPeriodByRegulatoryAuthority_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_RockvilleMarylandMember" xlink:label="mgnx_RockvilleMarylandMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_RockvilleMarylandMember_lbl" xml:lang="en-US" id="id_6848266_1605760_3_1">Rockville Maryland [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_RockvilleMarylandMember_lbl" xml:lang="en-US" id="id_6848266_1605760_1_1">Rockville Maryland [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_RockvilleMarylandMember_lbl" xml:lang="en-US" id="id_6848266_1605760_2_1">Rockville, Maryland [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_RockvilleMarylandMember" xlink:to="mgnx_RockvilleMarylandMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_RoyaltyAgreementDisclosureTextBlock" xlink:label="mgnx_RoyaltyAgreementDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_RoyaltyAgreementDisclosureTextBlock_lbl" xml:lang="en-US" id="id_6848266_1365015_3_1">Royalty agreement disclosure.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_RoyaltyAgreementDisclosureTextBlock_lbl" xml:lang="en-US" id="id_6848266_1365015_1_1">Royalty Agreement Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_RoyaltyAgreementDisclosureTextBlock_lbl" xml:lang="en-US" id="id_6848266_1365015_2_1">Product Milestone Payments and Royalty Agreements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_RoyaltyAgreementDisclosureTextBlock" xlink:to="mgnx_RoyaltyAgreementDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_RoyaltyAgreementLineItems" xlink:label="mgnx_RoyaltyAgreementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_RoyaltyAgreementLineItems_lbl" xml:lang="en-US" id="id_6848266_1466934_3_1">Royalty Agreement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_RoyaltyAgreementLineItems_lbl" xml:lang="en-US" id="id_6848266_1466934_1_1">Royalty Agreement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_RoyaltyAgreementLineItems_lbl" xml:lang="en-US" id="id_6848266_1466934_2_1">Royalty Agreement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_RoyaltyAgreementLineItems" xlink:to="mgnx_RoyaltyAgreementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_RoyaltyAgreementTable" xlink:label="mgnx_RoyaltyAgreementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_RoyaltyAgreementTable_lbl" xml:lang="en-US" id="id_6848266_1426785_3_1">Royalty agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_RoyaltyAgreementTable_lbl" xml:lang="en-US" id="id_6848266_1426785_1_1">Royalty Agreement [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_RoyaltyAgreementTable_lbl" xml:lang="en-US" id="id_6848266_1426785_2_1">Royalty Agreement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_RoyaltyAgreementTable" xlink:to="mgnx_RoyaltyAgreementTable_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_RoyaltyPaymentAsPercentageOfNetSalesUnderLicensingAgreement" xlink:label="mgnx_RoyaltyPaymentAsPercentageOfNetSalesUnderLicensingAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_RoyaltyPaymentAsPercentageOfNetSalesUnderLicensingAgreement_lbl" xml:lang="en-US" id="id_6848266_1496030_3_1">Royalty payment as percentage of net sales under licensing agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_RoyaltyPaymentAsPercentageOfNetSalesUnderLicensingAgreement_lbl" xml:lang="en-US" id="id_6848266_1496030_1_1">Royalty Payment As Percentage Of Net Sales Under Licensing Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_RoyaltyPaymentAsPercentageOfNetSalesUnderLicensingAgreement_lbl" xml:lang="en-US" id="id_6848266_1496030_2_1">Maximum royalty payments percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_RoyaltyPaymentAsPercentageOfNetSalesUnderLicensingAgreement" xlink:to="mgnx_RoyaltyPaymentAsPercentageOfNetSalesUnderLicensingAgreement_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US" id="id_6848266_1279494_1_1">Sale of Stock [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US" id="id_6848266_1279494_2_1">Sale of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US" id="id_6848266_1281096_1_1">Sale of Stock, Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US" id="id_6848266_1281096_2_1">Common stock price per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="us-gaap_SalesRevenueGoodsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueGoodsNet_lbl" xml:lang="en-US" id="id_6848266_1282106_1_1">Sales Revenue, Goods, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SalesRevenueGoodsNet_lbl" xml:lang="en-US" id="id_6848266_1282106_2_1">Revenue from product sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueGoodsNet" xlink:to="us-gaap_SalesRevenueGoodsNet_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xml:lang="en-US" id="id_6848266_1272910_1_1">Sales Revenue, Net [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xml:lang="en-US" id="id_6848266_1272910_2_1">Sales Revenue, Net [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioAdjustmentMember" xlink:label="us-gaap_ScenarioAdjustmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScenarioAdjustmentMember_lbl" xml:lang="en-US" id="id_6848266_1269610_1_1">Scenario, Adjustment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScenarioAdjustmentMember_lbl" xml:lang="en-US" id="id_6848266_1269610_2_1">Scenario, Adjustment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScenarioAdjustmentMember" xlink:to="us-gaap_ScenarioAdjustmentMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioPreviouslyReportedMember" xlink:label="us-gaap_ScenarioPreviouslyReportedMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScenarioPreviouslyReportedMember_lbl" xml:lang="en-US" id="id_6848266_1271232_1_1">Scenario, Previously Reported [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScenarioPreviouslyReportedMember_lbl" xml:lang="en-US" id="id_6848266_1271232_2_1">Prior Year Adjustment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScenarioPreviouslyReportedMember" xlink:to="us-gaap_ScenarioPreviouslyReportedMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US" id="id_6848266_1272914_1_1">Scenario, Unspecified [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US" id="id_6848266_1272914_2_1">Scenario, Unspecified [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioUnspecifiedDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" id="id_6848266_1269612_1_1">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" id="id_6848266_1269612_2_1">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" id="id_6848266_1271235_1_1">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" id="id_6848266_1271235_2_1">Schedule of Antidilutive Securities Excluded from the Calculation of Diluted Income (Loss) Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" id="id_6848266_1277849_1_1">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" id="id_6848266_1277849_2_1">Components of the Company's Deferred Income Tax Assets (Liabilities)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US" id="id_6848266_1277853_1_1">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US" id="id_6848266_1277853_2_1">Computation of Basic and Diluted Income (Loss) Per Common Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" id="id_6848266_1269624_1_1">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" id="id_6848266_1269624_2_1">Reconciliation of Reported Estimated Income Tax Benefit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US" id="id_6848266_1276285_1_1">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US" id="id_6848266_1276285_2_1">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" id="id_6848266_1272939_1_1">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" id="id_6848266_1272939_2_1">Schedule of Stock-Based Compensation Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:label="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_lbl" xml:lang="en-US" id="id_6848266_1277858_1_1">Schedule of Revenue by Major Customers, by Reporting Segments [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_lbl" xml:lang="en-US" id="id_6848266_1277858_2_1">Schedule of Revenue by Major Customers, by Reporting Segments [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:to="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xml:lang="en-US" id="id_6848266_1277866_1_1">Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xml:lang="en-US" id="id_6848266_1277866_2_1">Future Principal Payments Under Lease Agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfOperatingLeasedAssetsTable_lbl" xml:lang="en-US" id="id_6848266_1276303_1_1">Schedule of Operating Leased Assets [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfOperatingLeasedAssetsTable_lbl" xml:lang="en-US" id="id_6848266_1276303_2_1">Schedule of Operating Leased Assets [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="us-gaap_ScheduleOfOperatingLeasedAssetsTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US" id="id_6848266_1272974_1_1">Property, Plant and Equipment [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US" id="id_6848266_1272974_2_1">Property, Plant and Equipment [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_lbl" xml:lang="en-US" id="id_6848266_1277899_1_1">Schedule of Quarterly Financial Information [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_lbl" xml:lang="en-US" id="id_6848266_1277899_2_1">Company's Consolidated Quarterly Results of Operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:to="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_lbl" xml:lang="en-US" id="id_6848266_1274647_1_1">Schedule of Restructuring and Related Costs [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_lbl" xml:lang="en-US" id="id_6848266_1274647_2_1">Schedule of Restructuring and Related Costs [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:label="us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_lbl" xml:lang="en-US" id="id_6848266_1271272_1_1">Schedule of Restructuring Reserve by Type of Cost [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_lbl" xml:lang="en-US" id="id_6848266_1271272_2_1">Changes in Lease Exit Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:to="us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" id="id_6848266_1271276_1_1">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" id="id_6848266_1271276_2_1">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock_lbl" xml:lang="en-US" id="id_6848266_1295136_3_1">Schedule Of Share Based Compensation Stock Options And Restricted Stock Units Activity Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock_lbl" xml:lang="en-US" id="id_6848266_1295136_1_1">Schedule Of Share Based Compensation Stock Options And Restricted Stock Units Activity Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock_lbl" xml:lang="en-US" id="id_6848266_1295136_2_1">Schedule of Stock Option and Restricted Stock Unit Activity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" id="id_6848266_1269652_1_1">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" id="id_6848266_1269652_2_1">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US" id="id_6848266_1281133_1_1">Schedule of Stock by Class [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US" id="id_6848266_1281133_2_1">Schedule of Stock by Class [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xml:lang="en-US" id="id_6848266_1281137_1_1">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xml:lang="en-US" id="id_6848266_1281137_2_1">Reconciliation of the Beginning and Ending Amount of Gross Unrecognized Tax Benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl" xml:lang="en-US" id="id_6848266_1272993_1_1">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl" xml:lang="en-US" id="id_6848266_1272993_2_1">Summary of Percentage of Customer Concentration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_SecondRightToDevelopCollaborationMember" xlink:label="mgnx_SecondRightToDevelopCollaborationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_SecondRightToDevelopCollaborationMember_lbl" xml:lang="en-US" id="id_6848266_1439878_3_1">Second right to develop collaboration.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_SecondRightToDevelopCollaborationMember_lbl" xml:lang="en-US" id="id_6848266_1439878_1_1">Second Right To Develop Collaboration [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_SecondRightToDevelopCollaborationMember_lbl" xml:lang="en-US" id="id_6848266_1439878_2_1">Second Right to Develop Collaboration [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_SecondRightToDevelopCollaborationMember" xlink:to="mgnx_SecondRightToDevelopCollaborationMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="us-gaap_SegmentGeographicalDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentGeographicalDomain_lbl" xml:lang="en-US" id="id_6848266_1276336_1_1">Geographical [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentGeographicalDomain_lbl" xml:lang="en-US" id="id_6848266_1276336_2_1">Geographical [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentGeographicalDomain" xlink:to="us-gaap_SegmentGeographicalDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_SeriesA1ConvertiblePreferredStockMember" xlink:label="mgnx_SeriesA1ConvertiblePreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_SeriesA1ConvertiblePreferredStockMember_lbl" xml:lang="en-US" id="id_6848266_1296600_3_1">Series A1 convertible preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_SeriesA1ConvertiblePreferredStockMember_lbl" xml:lang="en-US" id="id_6848266_1296600_1_1">Series A1 Convertible Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_SeriesA1ConvertiblePreferredStockMember_lbl" xml:lang="en-US" id="id_6848266_1296600_2_1">Series A-1 Convertible Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_SeriesA1ConvertiblePreferredStockMember" xlink:to="mgnx_SeriesA1ConvertiblePreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_SeriesA1PreferredStockMember" xlink:label="mgnx_SeriesA1PreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_SeriesA1PreferredStockMember_lbl" xml:lang="en-US" id="id_6848266_1481307_3_1">Series A-1 preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_SeriesA1PreferredStockMember_lbl" xml:lang="en-US" id="id_6848266_1481307_1_1">Series A 1 Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_SeriesA1PreferredStockMember_lbl" xml:lang="en-US" id="id_6848266_1481307_2_1">Series A-1 Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_SeriesA1PreferredStockMember" xlink:to="mgnx_SeriesA1PreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_SeriesA2ConvertiblePreferredStockMember" xlink:label="mgnx_SeriesA2ConvertiblePreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_SeriesA2ConvertiblePreferredStockMember_lbl" xml:lang="en-US" id="id_6848266_1310046_3_1">Series A2 convertible preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_SeriesA2ConvertiblePreferredStockMember_lbl" xml:lang="en-US" id="id_6848266_1310046_1_1">Series A2 Convertible Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_SeriesA2ConvertiblePreferredStockMember_lbl" xml:lang="en-US" id="id_6848266_1310046_2_1">Series A-2 Convertible Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_SeriesA2ConvertiblePreferredStockMember" xlink:to="mgnx_SeriesA2ConvertiblePreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_SeriesA2PreferredStockMember" xlink:label="mgnx_SeriesA2PreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_SeriesA2PreferredStockMember_lbl" xml:lang="en-US" id="id_6848266_1369166_3_1">Series A-2 preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_SeriesA2PreferredStockMember_lbl" xml:lang="en-US" id="id_6848266_1369166_1_1">Series A 2 Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_SeriesA2PreferredStockMember_lbl" xml:lang="en-US" id="id_6848266_1369166_2_1">Series A-2 Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_SeriesA2PreferredStockMember" xlink:to="mgnx_SeriesA2PreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_SeriesAOnePreferredStockMember" xlink:label="mgnx_SeriesAOnePreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_SeriesAOnePreferredStockMember_lbl" xml:lang="en-US" id="id_6848266_1427952_3_1">Series A- 1 preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_SeriesAOnePreferredStockMember_lbl" xml:lang="en-US" id="id_6848266_1427952_1_1">Series A- One Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_SeriesAOnePreferredStockMember_lbl" xml:lang="en-US" id="id_6848266_1427952_2_1">Series A-1 Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_SeriesAOnePreferredStockMember" xlink:to="mgnx_SeriesAOnePreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xml:lang="en-US" id="id_6848266_1269676_1_1">Series A Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xml:lang="en-US" id="id_6848266_1269676_2_1">Series A Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_SeriesBConvertiblePreferredStockMember" xlink:label="mgnx_SeriesBConvertiblePreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_SeriesBConvertiblePreferredStockMember_lbl" xml:lang="en-US" id="id_6848266_1493912_3_1">Series B convertible preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_SeriesBConvertiblePreferredStockMember_lbl" xml:lang="en-US" id="id_6848266_1493912_1_1">Series B Convertible Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_SeriesBConvertiblePreferredStockMember_lbl" xml:lang="en-US" id="id_6848266_1493912_2_1">Series B Convertible Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_SeriesBConvertiblePreferredStockMember" xlink:to="mgnx_SeriesBConvertiblePreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xml:lang="en-US" id="id_6848266_1281157_1_1">Series B Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xml:lang="en-US" id="id_6848266_1281157_2_1">Series B Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_SeriesCConvertiblePreferredStockMember" xlink:label="mgnx_SeriesCConvertiblePreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_SeriesCConvertiblePreferredStockMember_lbl" xml:lang="en-US" id="id_6848266_1559024_3_1">Series C convertible preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_SeriesCConvertiblePreferredStockMember_lbl" xml:lang="en-US" id="id_6848266_1559024_1_1">Series C Convertible Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_SeriesCConvertiblePreferredStockMember_lbl" xml:lang="en-US" id="id_6848266_1559024_2_1">Series C Convertible Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_SeriesCConvertiblePreferredStockMember" xlink:to="mgnx_SeriesCConvertiblePreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesCPreferredStockMember_lbl" xml:lang="en-US" id="id_6848266_1279561_1_1">Series C Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeriesCPreferredStockMember_lbl" xml:lang="en-US" id="id_6848266_1279561_2_1">Series C Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesCPreferredStockMember" xlink:to="us-gaap_SeriesCPreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_SeriesD1ConvertiblePreferredStockMember" xlink:label="mgnx_SeriesD1ConvertiblePreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_SeriesD1ConvertiblePreferredStockMember_lbl" xml:lang="en-US" id="id_6848266_1291665_3_1">Series D1 convertible preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_SeriesD1ConvertiblePreferredStockMember_lbl" xml:lang="en-US" id="id_6848266_1291665_1_1">Series D1 Convertible Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_SeriesD1ConvertiblePreferredStockMember_lbl" xml:lang="en-US" id="id_6848266_1291665_2_1">Series D-1 Convertible Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_SeriesD1ConvertiblePreferredStockMember" xlink:to="mgnx_SeriesD1ConvertiblePreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_SeriesD2ConvertiblePreferredStockMember" xlink:label="mgnx_SeriesD2ConvertiblePreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_SeriesD2ConvertiblePreferredStockMember_lbl" xml:lang="en-US" id="id_6848266_1421015_3_1">Series D2 convertible preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_SeriesD2ConvertiblePreferredStockMember_lbl" xml:lang="en-US" id="id_6848266_1421015_1_1">Series D2 Convertible Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_SeriesD2ConvertiblePreferredStockMember_lbl" xml:lang="en-US" id="id_6848266_1421015_2_1">Series D-2 Convertible Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_SeriesD2ConvertiblePreferredStockMember" xlink:to="mgnx_SeriesD2ConvertiblePreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_SeriesD2PreferredStockMember" xlink:label="mgnx_SeriesD2PreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_SeriesD2PreferredStockMember_lbl" xml:lang="en-US" id="id_6848266_1610343_3_1">Series D-2 preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_SeriesD2PreferredStockMember_lbl" xml:lang="en-US" id="id_6848266_1610343_1_1">Series D-2 Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_SeriesD2PreferredStockMember_lbl" xml:lang="en-US" id="id_6848266_1610343_2_1">Series D-2 Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_SeriesD2PreferredStockMember" xlink:to="mgnx_SeriesD2PreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_SeriesDConvertiblePreferredStockMember" xlink:label="mgnx_SeriesDConvertiblePreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_SeriesDConvertiblePreferredStockMember_lbl" xml:lang="en-US" id="id_6848266_1343554_3_1">Series D convertible preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_SeriesDConvertiblePreferredStockMember_lbl" xml:lang="en-US" id="id_6848266_1343554_1_1">Series D Convertible Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_SeriesDConvertiblePreferredStockMember_lbl" xml:lang="en-US" id="id_6848266_1343554_2_1">Series D Convertible Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_SeriesDConvertiblePreferredStockMember" xlink:to="mgnx_SeriesDConvertiblePreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="us-gaap_SeriesDPreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesDPreferredStockMember_lbl" xml:lang="en-US" id="id_6848266_1281158_1_1">Series D Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeriesDPreferredStockMember_lbl" xml:lang="en-US" id="id_6848266_1281158_2_1">Series D Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesDPreferredStockMember" xlink:to="us-gaap_SeriesDPreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_ServierMember" xlink:label="mgnx_ServierMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_ServierMember_lbl" xml:lang="en-US" id="id_6848266_1538608_3_1">Servier.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_ServierMember_lbl" xml:lang="en-US" id="id_6848266_1538608_1_1">Servier [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_ServierMember_lbl" xml:lang="en-US" id="id_6848266_1538608_2_1">Servier [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_ServierMember" xlink:to="mgnx_ServierMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" id="id_6848266_1288753_1_1">Share-based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" id="id_6848266_1288753_2_1">Share-based compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" id="id_6848266_1288753_12_1">Stock-based compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US" id="id_6848266_1273028_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US" id="id_6848266_1273028_2_1">Options granted, maximum term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" id="id_6848266_1273029_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" id="id_6848266_1273029_2_1">Expected dividend yield</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" id="id_6848266_1273030_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" id="id_6848266_1273030_2_1">Expected life of option term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" id="id_6848266_1273030_12_1">Expected term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" id="id_6848266_1279587_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" id="id_6848266_1279587_2_1">Expected volatility</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" id="id_6848266_1274709_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" id="id_6848266_1274709_2_1">Risk-free interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" id="id_6848266_1269692_1_1">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" id="id_6848266_1269692_2_1">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US" id="id_6848266_1274711_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US" id="id_6848266_1274711_2_1">Increase in aggregate number of shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" id="id_6848266_1276359_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" id="id_6848266_1276359_2_1">Share-based compensation, number of shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease" xlink:label="mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease_lbl" xml:lang="en-US" id="id_6848266_1336201_3_1">Share based compensation arrangement by share based payment award number of shares authorized after increase.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease_lbl" xml:lang="en-US" id="id_6848266_1336201_1_1">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized After Increase</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease_lbl" xml:lang="en-US" id="id_6848266_1336201_2_1">Increased number of shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease" xlink:to="mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US" id="id_6848266_1287262_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US" id="id_6848266_1287262_2_1">Aggregate Intrinsic Value, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" id="id_6848266_1273034_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" id="id_6848266_1273034_2_1">Shares, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_6848266_1273035_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_6848266_1273035_2_1">Weighted-Average Exercise Price, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" id="id_6848266_1277951_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" id="id_6848266_1277951_2_1">Weighted-Average Remaining Contractual Term, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US" id="id_6848266_1288760_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US" id="id_6848266_1288760_2_1">Share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" id="id_6848266_1273037_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" id="id_6848266_1273037_14_1">Shares, Forfeited or expired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xml:lang="en-US" id="id_6848266_1269694_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xml:lang="en-US" id="id_6848266_1269694_2_1">Shares, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" id="id_6848266_1271328_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" id="id_6848266_1271328_2_1">Weighted-average grant-date fair value of options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" id="id_6848266_1285691_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" id="id_6848266_1285691_2_1">Aggregate Intrinsic Value, Outstanding, Ending Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" id="id_6848266_1281183_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" id="id_6848266_1281183_4_1">Shares, Outstanding, Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" id="id_6848266_1281183_5_1">Shares, Outstanding, Beginning Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" id="id_6848266_1281183_2_1">Share-based compensation arrangement by share-based payment award, options, outstanding, number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_6848266_1271330_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_6848266_1271330_4_1">Weighted-Average Exercise Price, Outstanding, Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_6848266_1271330_5_1">Weighted-Average Exercise Price, Outstanding, Beginning Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_6848266_1271330_2_1">Weighted average exercise price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" id="id_6848266_1276363_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" id="id_6848266_1276363_2_1">Weighted-Average Remaining Contractual Term, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US" id="id_6848266_1286208_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US" id="id_6848266_1286208_2_1">Aggregate Intrinsic Value, Vested and expected to vest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US" id="id_6848266_1269697_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US" id="id_6848266_1269697_2_1">Shares, Vested and expected to vest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_6848266_1277958_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_6848266_1277958_2_1">Weighted-Average Exercise Price, Vested and expected to vest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" id="id_6848266_1269698_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" id="id_6848266_1269698_2_1">Weighted-Average Remaining Contractual Term, Vested and expected to vest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xml:lang="en-US" id="id_6848266_1281600_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xml:lang="en-US" id="id_6848266_1281600_2_1">Fair value of shares vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_6848266_1269701_1_1">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_6848266_1269701_2_1">Weighted-Average Exercise Price, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_6848266_1276367_1_1">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_6848266_1276367_2_1">Weighted-Average Exercise Price, Forfeited or expired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_6848266_1277960_1_1">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_6848266_1277960_2_1">Weighted-Average Exercise Price, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US" id="id_6848266_1273051_1_1">Share Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US" id="id_6848266_1273051_2_1">Price per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US" id="id_6848266_1273053_1_1">Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US" id="id_6848266_1273053_4_1">Ending Balance, Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US" id="id_6848266_1273053_5_1">Beginning Balance, Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US" id="id_6848266_1273053_2_1">Shares of common stock allocated</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" id="id_6848266_1277972_1_1">Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" id="id_6848266_1277972_2_1">Summary of Significant Accounting Policies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl" xml:lang="en-US" id="id_6848266_1277975_1_1">Software and Software Development Costs [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl" xml:lang="en-US" id="id_6848266_1277975_2_1">Software [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_SouthSanFranciscoMember" xlink:label="mgnx_SouthSanFranciscoMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_SouthSanFranciscoMember_lbl" xml:lang="en-US" id="id_6848266_1394675_3_1">South San Francisco [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_SouthSanFranciscoMember_lbl" xml:lang="en-US" id="id_6848266_1394675_1_1">South San Francisco [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_SouthSanFranciscoMember_lbl" xml:lang="en-US" id="id_6848266_1394675_2_1">South San Francisco [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_SouthSanFranciscoMember" xlink:to="mgnx_SouthSanFranciscoMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_StartYearMember" xlink:label="mgnx_StartYearMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_StartYearMember_lbl" xml:lang="en-US" id="id_6848266_1613553_3_1">Start Year [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_StartYearMember_lbl" xml:lang="en-US" id="id_6848266_1613553_1_1">Start Year [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_StartYearMember_lbl" xml:lang="en-US" id="id_6848266_1613553_2_1">Start Year [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_StartYearMember" xlink:to="mgnx_StartYearMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US" id="id_6848266_1276398_1_1">State and Local Jurisdiction [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US" id="id_6848266_1276398_2_1">State and Local Jurisdiction [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US" id="id_6848266_1276400_1_1">Class of Stock [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US" id="id_6848266_1276400_2_1">Class of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" id="id_6848266_1276401_1_1">Equity Components [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" id="id_6848266_1276401_2_1">Equity Components [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="us-gaap_StatementGeographicalAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementGeographicalAxis_lbl" xml:lang="en-US" id="id_6848266_1273333_1_1">Geographical [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementGeographicalAxis_lbl" xml:lang="en-US" id="id_6848266_1273333_2_1">Geographical [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementGeographicalAxis" xlink:to="us-gaap_StatementGeographicalAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" id="id_6848266_1279599_1_1">Statement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" id="id_6848266_1279599_2_1">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" id="id_6848266_1281214_1_1">Statement of Cash Flows [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" id="id_6848266_1281214_2_1">Statement of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" id="id_6848266_1271363_1_1">Statement of Financial Position [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" id="id_6848266_1271363_2_1">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US" id="id_6848266_1281215_1_1">Statement of Stockholders' Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US" id="id_6848266_1281215_2_1">Statement of Stockholders' Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementScenarioAxis_lbl" xml:lang="en-US" id="id_6848266_1273334_1_1">Scenario [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementScenarioAxis_lbl" xml:lang="en-US" id="id_6848266_1273334_2_1">Scenario [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_StatementScenarioAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" id="id_6848266_1274733_1_1">Statement [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" id="id_6848266_1274733_2_1">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" id="id_6848266_1283431_1_1">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" id="id_6848266_1283431_4_1">Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" id="id_6848266_1283431_5_1">Beginning Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" id="id_6848266_1283431_6_1">Total stockholders' equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" id="id_6848266_1276413_1_1">Stockholders' Equity Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" id="id_6848266_1276413_2_1">Stockholders' equity:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" id="id_6848266_1276414_1_1">Stockholders' Equity Note Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" id="id_6848266_1276414_2_1">Stockholders' Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xml:lang="en-US" id="id_6848266_1273339_1_1">Stockholders' Equity, Reverse Stock Split</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xml:lang="en-US" id="id_6848266_1273339_2_1">Reverse stock split</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_StockIncentivePlan2013Member" xlink:label="mgnx_StockIncentivePlan2013Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_StockIncentivePlan2013Member_lbl" xml:lang="en-US" id="id_6848266_1332409_3_1">Stock Incentive Plan 2013 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_StockIncentivePlan2013Member_lbl" xml:lang="en-US" id="id_6848266_1332409_1_1">Stock Incentive Plan 2013 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_StockIncentivePlan2013Member_lbl" xml:lang="en-US" id="id_6848266_1332409_2_1">Stock Incentive Plan 2013 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_StockIncentivePlan2013Member" xlink:to="mgnx_StockIncentivePlan2013Member_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_StockIssuanceCosts" xlink:label="mgnx_StockIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_StockIssuanceCosts_lbl" xml:lang="en-US" id="id_6848266_1566187_3_1">Costs related to the issuance or offering of stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_StockIssuanceCosts_lbl" xml:lang="en-US" id="id_6848266_1566187_1_1">Stock Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_StockIssuanceCosts_lbl" xml:lang="en-US" id="id_6848266_1566187_2_1">Related offering costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_StockIssuanceCosts" xlink:to="mgnx_StockIssuanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xml:lang="en-US" id="id_6848266_1271369_1_1">Stock Issued During Period, Shares, Acquisitions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xml:lang="en-US" id="id_6848266_1271369_2_1">Shares issued in connection with acquisition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US" id="id_6848266_1279601_1_1">Stock Issued During Period, Shares, Conversion of Convertible Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US" id="id_6848266_1279601_2_1">Conversion of preferred stock to common stock, Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" id="id_6848266_1274739_1_1">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" id="id_6848266_1274739_32_1">Stock issued during the period for new issue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" id="id_6848266_1274739_2_1">Issuance of common stock, net of offering costs, Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" id="id_6848266_1274739_12_1">Number of shares issued or sold</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" id="id_6848266_1281224_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" id="id_6848266_1281224_2_1">Common stock, shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" id="id_6848266_1281224_12_1">Stock option exercises, Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" id="id_6848266_1281224_14_1">Shares, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_StockIssuedDuringPeriodSharesStockPlanActivity" xlink:label="mgnx_StockIssuedDuringPeriodSharesStockPlanActivity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_StockIssuedDuringPeriodSharesStockPlanActivity_lbl" xml:lang="en-US" id="id_6848266_1620794_3_1">Number of shares issued due to stock plan related activity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_StockIssuedDuringPeriodSharesStockPlanActivity_lbl" xml:lang="en-US" id="id_6848266_1620794_1_1">Stock Issued During Period Shares Stock Plan Activity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_StockIssuedDuringPeriodSharesStockPlanActivity_lbl" xml:lang="en-US" id="id_6848266_1620794_2_1">Stock plan related activity, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_StockIssuedDuringPeriodSharesStockPlanActivity" xlink:to="mgnx_StockIssuedDuringPeriodSharesStockPlanActivity_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption" xlink:label="mgnx_StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption_lbl" xml:lang="en-US" id="id_6848266_1312479_3_1">Stock issued during period, shares to underwriters for exercise of over allotment option.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption_lbl" xml:lang="en-US" id="id_6848266_1312479_1_1">Stock Issued During Period Shares To Underwriters For Exercise Of Over Allotment Option</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption_lbl" xml:lang="en-US" id="id_6848266_1312479_2_1">Additional shares sold under over-allotments option to underwriter</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption" xlink:to="mgnx_StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US" id="id_6848266_1284348_1_1">Stock Issued During Period, Value, Conversion of Convertible Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US" id="id_6848266_1284348_2_1">Conversion of preferred stock to common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" id="id_6848266_1281592_1_1">Stock Issued During Period, Value, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" id="id_6848266_1281592_2_1">Issuance of common stock, net of offering costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" id="id_6848266_1281592_12_1">Stock issued during period value, new issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" id="id_6848266_1283001_1_1">Stock Issued During Period, Value, Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" id="id_6848266_1283001_2_1">Stock option exercises</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_StockIssuedDuringPeriodValueStockPlanActivity" xlink:label="mgnx_StockIssuedDuringPeriodValueStockPlanActivity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_StockIssuedDuringPeriodValueStockPlanActivity_lbl" xml:lang="en-US" id="id_6848266_1620793_3_1">Value of shares issued due to stock plan related activity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_StockIssuedDuringPeriodValueStockPlanActivity_lbl" xml:lang="en-US" id="id_6848266_1620793_1_1">Stock Issued During Period Value Stock Plan Activity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_StockIssuedDuringPeriodValueStockPlanActivity_lbl" xml:lang="en-US" id="id_6848266_1620793_2_1">Stock plan related activity, value of shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_StockIssuedDuringPeriodValueStockPlanActivity" xlink:to="mgnx_StockIssuedDuringPeriodValueStockPlanActivity_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US" id="id_6848266_1281225_1_1">Equity Option [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US" id="id_6848266_1281225_2_1">Stock Options [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_StockOptionPlan2000Member" xlink:label="mgnx_StockOptionPlan2000Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_StockOptionPlan2000Member_lbl" xml:lang="en-US" id="id_6848266_1365667_3_1">Stock option plan 2000.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_StockOptionPlan2000Member_lbl" xml:lang="en-US" id="id_6848266_1365667_1_1">Stock Option Plan 2000 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_StockOptionPlan2000Member_lbl" xml:lang="en-US" id="id_6848266_1365667_2_1">Stock Option Plan 2000 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_StockOptionPlan2000Member" xlink:to="mgnx_StockOptionPlan2000Member_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US" id="id_6848266_1269753_1_1">Subsequent Event [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US" id="id_6848266_1269753_2_1">Subsequent Event [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" id="id_6848266_1273350_1_1">Subsequent Event [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" id="id_6848266_1273350_2_1">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US" id="id_6848266_1279606_1_1">Subsequent Events [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US" id="id_6848266_1279606_2_1">Subsequent Events [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" id="id_6848266_1278000_1_1">Subsequent Events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" id="id_6848266_1278000_2_1">Subsequent Event</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US" id="id_6848266_1273352_1_1">Subsequent Event [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US" id="id_6848266_1273352_2_1">Subsequent Event [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US" id="id_6848266_1271378_1_1">Subsequent Event Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US" id="id_6848266_1271378_2_1">Subsequent Event Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US" id="id_6848266_1276407_1_1">Subsequent Event Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US" id="id_6848266_1276407_2_1">Subsequent Event Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US" id="id_6848266_1271382_1_1">Sale of Stock [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US" id="id_6848266_1271382_2_1">Sale of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_TakedaMember" xlink:label="mgnx_TakedaMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_TakedaMember_lbl" xml:lang="en-US" id="id_6848266_1565531_3_1">Takeda [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_TakedaMember_lbl" xml:lang="en-US" id="id_6848266_1565531_1_1">Takeda [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_TakedaMember_lbl" xml:lang="en-US" id="id_6848266_1565531_2_1">Takeda [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_TakedaMember" xlink:to="mgnx_TakedaMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US" id="id_6848266_1288257_1_1">Tax Credit Carryforward, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US" id="id_6848266_1288257_2_1">US Federal Tax credits carry forward</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_TaxCreditCarryforwardExpirationYearRangeEnd" xlink:label="mgnx_TaxCreditCarryforwardExpirationYearRangeEnd"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_TaxCreditCarryforwardExpirationYearRangeEnd_lbl" xml:lang="en-US" id="id_6848266_1503197_3_1">Tax credit carryforward expiration year range end.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_TaxCreditCarryforwardExpirationYearRangeEnd_lbl" xml:lang="en-US" id="id_6848266_1503197_1_1">Tax Credit Carryforward Expiration Year Range End</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_TaxCreditCarryforwardExpirationYearRangeEnd_lbl" xml:lang="en-US" id="id_6848266_1503197_2_1">Federal Tax credit expiration ending year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_TaxCreditCarryforwardExpirationYearRangeEnd" xlink:to="mgnx_TaxCreditCarryforwardExpirationYearRangeEnd_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_TaxCreditCarryforwardExpirationYearRangeStart" xlink:label="mgnx_TaxCreditCarryforwardExpirationYearRangeStart"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_TaxCreditCarryforwardExpirationYearRangeStart_lbl" xml:lang="en-US" id="id_6848266_1461684_3_1">Tax credit carryforward expiration year range start.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_TaxCreditCarryforwardExpirationYearRangeStart_lbl" xml:lang="en-US" id="id_6848266_1461684_1_1">Tax Credit Carryforward Expiration Year Range Start</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_TaxCreditCarryforwardExpirationYearRangeStart_lbl" xml:lang="en-US" id="id_6848266_1461684_2_1">Federal Tax credit expiration start year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_TaxCreditCarryforwardExpirationYearRangeStart" xlink:to="mgnx_TaxCreditCarryforwardExpirationYearRangeStart_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TextBlockAbstract" xlink:label="us-gaap_TextBlockAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TextBlockAbstract_lbl" xml:lang="en-US" id="id_6848266_1276429_1_1">Text Block [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TextBlockAbstract_lbl" xml:lang="en-US" id="id_6848266_1276429_2_1">Text Block [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TextBlockAbstract" xlink:to="us-gaap_TextBlockAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xml:lang="en-US" id="id_6848266_1279899_1_1">Trade and Other Accounts Receivable, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xml:lang="en-US" id="id_6848266_1279899_2_1">Accounts Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" id="id_6848266_1269880_1_1">Trading Symbol</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" id="id_6848266_1269880_2_1">Trading Symbol</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="us-gaap_TreasuryStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockMember_lbl" xml:lang="en-US" id="id_6848266_1273409_1_1">Treasury Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TreasuryStockMember_lbl" xml:lang="en-US" id="id_6848266_1273409_2_1">Treasury Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockMember" xlink:to="us-gaap_TreasuryStockMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TreasuryStockNumberOfSharesHeld" xlink:label="us-gaap_TreasuryStockNumberOfSharesHeld"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockNumberOfSharesHeld_lbl" xml:lang="en-US" id="id_6848266_1274790_1_1">Treasury Stock, Number of Shares Held</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TreasuryStockNumberOfSharesHeld_lbl" xml:lang="en-US" id="id_6848266_1274790_2_1">Treasury stock, shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockNumberOfSharesHeld" xlink:to="us-gaap_TreasuryStockNumberOfSharesHeld_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TreasuryStockRetiredParValueMethodAmount" xlink:label="us-gaap_TreasuryStockRetiredParValueMethodAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockRetiredParValueMethodAmount_lbl" xml:lang="en-US" id="id_6848266_1287282_1_1">Treasury Stock, Retired, Par Value Method, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_TreasuryStockRetiredParValueMethodAmount_lbl" xml:lang="en-US" id="id_6848266_1287282_14_1">Retirement of treasury stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockRetiredParValueMethodAmount" xlink:to="us-gaap_TreasuryStockRetiredParValueMethodAmount_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TreasuryStockSharesRetired" xlink:label="us-gaap_TreasuryStockSharesRetired"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockSharesRetired_lbl" xml:lang="en-US" id="id_6848266_1273392_1_1">Treasury Stock, Shares, Retired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TreasuryStockSharesRetired_lbl" xml:lang="en-US" id="id_6848266_1273392_2_1">Retirement of treasury stock, Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockSharesRetired" xlink:to="us-gaap_TreasuryStockSharesRetired_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="us-gaap_TreasuryStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockValue_lbl" xml:lang="en-US" id="id_6848266_1288788_1_1">Treasury Stock, Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_TreasuryStockValue_lbl" xml:lang="en-US" id="id_6848266_1288788_14_1">Treasury stock, at cost; 865 and 14,381 shares at December 31, 2014 and 2013, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockValue" xlink:to="us-gaap_TreasuryStockValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US" id="id_6848266_1279908_1_1">Type of Arrangement and Non-arrangement Transactions [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US" id="id_6848266_1279908_2_1">Type of Arrangement and Non-arrangement Transactions [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfRestructuringDomain_lbl" xml:lang="en-US" id="id_6848266_1278340_1_1">Type of Restructuring [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TypeOfRestructuringDomain_lbl" xml:lang="en-US" id="id_6848266_1278340_2_1">Type of Restructuring [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_TypeOfRestructuringDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnbilledContractsReceivable" xlink:label="us-gaap_UnbilledContractsReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnbilledContractsReceivable_lbl" xml:lang="en-US" id="id_6848266_1288782_1_1">Unbilled Contracts Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnbilledContractsReceivable_lbl" xml:lang="en-US" id="id_6848266_1288782_2_1">Unbilled receivable balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnbilledContractsReceivable" xlink:to="us-gaap_UnbilledContractsReceivable_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_UndesignatedPreferredStockMember" xlink:label="mgnx_UndesignatedPreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_UndesignatedPreferredStockMember_lbl" xml:lang="en-US" id="id_6848266_1312914_3_1">Undesignated Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_UndesignatedPreferredStockMember_lbl" xml:lang="en-US" id="id_6848266_1312914_1_1">Undesignated Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_UndesignatedPreferredStockMember_lbl" xml:lang="en-US" id="id_6848266_1312914_2_1">Undesignated Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_UndesignatedPreferredStockMember" xlink:to="mgnx_UndesignatedPreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:label="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_lbl" xml:lang="en-US" id="id_6848266_1287283_1_1">Undistributed Earnings (Loss) Allocated to Participating Securities, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_lbl" xml:lang="en-US" id="id_6848266_1287283_14_1">Less: undistributed earnings allocated to participating securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:to="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" id="id_6848266_1284319_1_1">Unrecognized Tax Benefits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" id="id_6848266_1284319_4_1">Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" id="id_6848266_1284319_5_1">Beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xml:lang="en-US" id="id_6848266_1288785_1_1">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xml:lang="en-US" id="id_6848266_1288785_2_1">Unrecognized interest or penalties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xml:lang="en-US" id="id_6848266_1283872_1_1">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xml:lang="en-US" id="id_6848266_1283872_2_1">Increases/(decreases) for current year tax positions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xml:lang="en-US" id="id_6848266_1281565_1_1">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xml:lang="en-US" id="id_6848266_1281565_2_1">Increases/(decreases) for prior year tax positions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:label="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_lbl" xml:lang="en-US" id="id_6848266_1289286_1_1">Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_lbl" xml:lang="en-US" id="id_6848266_1289286_14_1">Decreases as a result of expiration of statute of limitations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:to="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_UnrecognizedTaxBenefitsResultingInNetOperatingLossesCarryforward" xlink:label="mgnx_UnrecognizedTaxBenefitsResultingInNetOperatingLossesCarryforward"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_UnrecognizedTaxBenefitsResultingInNetOperatingLossesCarryforward_lbl" xml:lang="en-US" id="id_6848266_1604789_3_1">Unrecognized tax benefits resulting in net operating losses carryforward.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_UnrecognizedTaxBenefitsResultingInNetOperatingLossesCarryforward_lbl" xml:lang="en-US" id="id_6848266_1604789_1_1">Unrecognized Tax Benefits Resulting In Net Operating Losses Carryforward</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_UnrecognizedTaxBenefitsResultingInNetOperatingLossesCarryforward_lbl" xml:lang="en-US" id="id_6848266_1604789_2_1">Net operating losses, recognized as a benefit through additional-paid-in-capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_UnrecognizedTaxBenefitsResultingInNetOperatingLossesCarryforward" xlink:to="mgnx_UnrecognizedTaxBenefitsResultingInNetOperatingLossesCarryforward_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_lbl" xml:lang="en-US" id="id_6848266_1282545_1_1">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_lbl" xml:lang="en-US" id="id_6848266_1282545_2_1">Gross unrecognized tax benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_UpfrontFeeAllocatedToAgreement" xlink:label="mgnx_UpfrontFeeAllocatedToAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_UpfrontFeeAllocatedToAgreement_lbl" xml:lang="en-US" id="id_6848266_1601006_3_1">Portion of upfront fee allocated to agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_UpfrontFeeAllocatedToAgreement_lbl" xml:lang="en-US" id="id_6848266_1601006_1_1">Upfront Fee Allocated To Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_UpfrontFeeAllocatedToAgreement_lbl" xml:lang="en-US" id="id_6848266_1601006_2_1">Amount allocated to agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_UpfrontFeeAllocatedToAgreement" xlink:to="mgnx_UpfrontFeeAllocatedToAgreement_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_UpfrontFeeAndParticipationRecognitionEndDate" xlink:label="mgnx_UpfrontFeeAndParticipationRecognitionEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_UpfrontFeeAndParticipationRecognitionEndDate_lbl" xml:lang="en-US" id="id_6848266_1592662_3_1">Upfront fee and participation recognition end date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_UpfrontFeeAndParticipationRecognitionEndDate_lbl" xml:lang="en-US" id="id_6848266_1592662_1_1">Upfront Fee And Participation Recognition End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_UpfrontFeeAndParticipationRecognitionEndDate_lbl" xml:lang="en-US" id="id_6848266_1592662_2_1">Term of the agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_UpfrontFeeAndParticipationRecognitionEndDate" xlink:to="mgnx_UpfrontFeeAndParticipationRecognitionEndDate_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_UpfrontPaymentRecognitionPeriod" xlink:label="mgnx_UpfrontPaymentRecognitionPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_UpfrontPaymentRecognitionPeriod_lbl" xml:lang="en-US" id="id_6848266_1559634_3_1">Period over which upfront payment is to be recognized.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_UpfrontPaymentRecognitionPeriod_lbl" xml:lang="en-US" id="id_6848266_1559634_1_1">Upfront Payment Recognition Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_UpfrontPaymentRecognitionPeriod_lbl" xml:lang="en-US" id="id_6848266_1559634_2_1">Expected period of development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_UpfrontPaymentRecognitionPeriod" xlink:to="mgnx_UpfrontPaymentRecognitionPeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" id="id_6848266_1274809_1_1">Use of Estimates, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" id="id_6848266_1274809_2_1">Use of Estimates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US" id="id_6848266_1273442_1_1">Warrant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US" id="id_6848266_1273442_2_1">Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_lbl" xml:lang="en-US" id="id_6848266_1270058_1_1">Weighted Average Number Diluted Shares Outstanding Adjustment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_lbl" xml:lang="en-US" id="id_6848266_1270058_2_1">Effect of dilutive securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" id="id_6848266_1276710_1_1">Weighted Average Number of Shares Outstanding, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" id="id_6848266_1276710_6_1">Diluted weighted average common shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US" id="id_6848266_1274823_1_1">Weighted Average Number of Shares Outstanding, Basic and Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US" id="id_6848266_1274823_2_1">Basic and diluted weighted average number of common shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" id="id_6848266_1281555_1_1">Weighted Average Number of Shares Outstanding, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" id="id_6848266_1281555_2_1">Basic weighted average common shares outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" id="id_6848266_1281555_12_1">Basic weighted average common shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>20
<FILENAME>mgnx-20141231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- RR Donnelley Xcelerate Taxonomy Presentation Linkbase, based on XBRL 2.1  http://www.rrdonnelley.com/ -->
<!-- Version: 6.22.4 -->
<!-- Round: 8 -->
<!-- Creation date: 2015-03-03T16:02:26Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#DocumentandEntityInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DocumentandEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#Role_StatementOfFinancialPositionClassified" roleURI="http://www.macrogenics.com/taxonomy/role/StatementOfFinancialPositionClassified"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#Role_StatementOfFinancialPositionClassifiedParen" roleURI="http://www.macrogenics.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#Role_StatementOfIncomeAlternative" roleURI="http://www.macrogenics.com/taxonomy/role/StatementOfIncomeAlternative"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#Role_StatementOfShareholdersEquityAndOtherComprehensiveIncome" roleURI="http://www.macrogenics.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#Role_StatementOfCashFlowsIndirect" roleURI="http://www.macrogenics.com/taxonomy/role/StatementOfCashFlowsIndirect"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#DisclosureOrganizationAndNatureOfOperationsAdditionalInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfFairValueMeasurementFinancialAssetAndLiabilities" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfFairValueMeasurementFinancialAssetAndLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfCollaboratorsThatRepresentMoreThan10OfTotalRevenueEarned" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfCollaboratorsThatRepresentMoreThan10OfTotalRevenueEarned"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfCollaboratorsThatRepresentMoreThan10OfAccountsReceivable" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfCollaboratorsThatRepresentMoreThan10OfAccountsReceivable"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLives" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLives"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesComputationOfBasicAndDilutedIncomeLossPerCommonShare" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesComputationOfBasicAndDilutedIncomeLossPerCommonShare"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromTheCalculationOfDilutedIncomeLossPerShare" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromTheCalculationOfDilutedIncomeLossPerShare"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipment" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipment"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#DisclosurePropertyAndEquipmentAdditionalInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#DisclosureStockholdersEquityAdditionalInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureStockholdersEquityAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#DisclosureStockBasedCompensationAdditionalInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpense" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpense"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#DisclosureStockBasedCompensationScheduleOfFairValueOptionAwardEstimatedOnTheDateOfGrantUsingTheBlackScholesOptionPricingModel" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureStockBasedCompensationScheduleOfFairValueOptionAwardEstimatedOnTheDateOfGrantUsingTheBlackScholesOptionPricingModel"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#DisclosureStockBasedCompensationScheduleOfStockOptionAndRestrictedStockUnitActivity" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockOptionAndRestrictedStockUnitActivity"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#DisclosureIncomeTaxesAdditionalInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#DisclosureIncomeTaxesComponentsOfTheCompanysDeferredTaxAssetsLiabilities" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureIncomeTaxesComponentsOfTheCompanysDeferredTaxAssetsLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#DisclosureIncomeTaxesReconciliationOfReportedEstimatedIncomeTaxBenefit" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureIncomeTaxesReconciliationOfReportedEstimatedIncomeTaxBenefit"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#DisclosureIncomeTaxesReconciliationOfTheBeginningAndEndingAmountOfGrossUnrecognizedTaxBenefits" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureIncomeTaxesReconciliationOfTheBeginningAndEndingAmountOfGrossUnrecognizedTaxBenefits"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#DisclosureLeaseExitLiabilityAdditionalInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureLeaseExitLiabilityAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#DisclosureLeaseExitLiabilityChangesInLeaseExitLiability" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureLeaseExitLiabilityChangesInLeaseExitLiability"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#DisclosureLeaseExitLiabilityFuturePrincipalPaymentsUnderLeaseAgreement" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureLeaseExitLiabilityFuturePrincipalPaymentsUnderLeaseAgreement"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#DisclosureCollaborationAndLicenseAgreementsAdditionalInformation1" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformation1"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#DisclosureCollaborationAndLicenseAgreementsAdditionalInformation2" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformation2"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#DisclosureCollaborationAndLicenseAgreementsAdditionalInformation3" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformation3"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#DisclosureCollaborationAndLicenseAgreementsAdditionalInformation4" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformation4"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#DisclosureCollaborationAndLicenseAgreementsAdditionalInformation5" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformation5"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#DisclosureCollaborationAndLicenseAgreementsAdditionalInformation6" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformation6"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#DisclosureCollaborationAndLicenseAgreementsAdditionalInformation7" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformation7"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#DisclosureCommitmentsAndContingenciesAdditionalInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#DisclosureCommitmentsAndContingenciesScheduleOfMinimumFutureLeasePayments" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMinimumFutureLeasePayments"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#DisclosureProductMilestonePaymentsAndRoyaltyAgreementsAdditionalInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureProductMilestonePaymentsAndRoyaltyAgreementsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#DisclosureEmployeeBenefitPlanAdditionalInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureEmployeeBenefitPlanAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#DisclosureQuarterlyFinancialInformationCompanysConsolidatedQuarterlyResultsOfOperations" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureQuarterlyFinancialInformationCompanysConsolidatedQuarterlyResultsOfOperations"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#DisclosureSubsequentEventAdditionalInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSubsequentEventAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#Role_NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#Role_NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#Role_NotesToFinancialStatementsRestructuringAndRelatedActivitiesDisclosureTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsRestructuringAndRelatedActivitiesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#Role_NotesToFinancialStatementsRestructuringAndRelatedActivitiesDisclosureTextBlockTables" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsRestructuringAndRelatedActivitiesDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#Role_NotesToFinancialStatementsCollaborationAndLicenseAgreementsDisclosureTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsCollaborationAndLicenseAgreementsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#Role_NotesToFinancialStatementsRoyaltyAgreementDisclosureTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsRoyaltyAgreementDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#Role_NotesToFinancialStatementsPensionAndOtherPostretirementBenefitsDisclosureTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsPensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#Role_NotesToFinancialStatementsQuarterlyFinancialInformationTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#Role_NotesToFinancialStatementsQuarterlyFinancialInformationTextBlockTables" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20141231.xsd#Role_NotesToFinancialStatementsSubsequentEventsTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock"/>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DocumentandEntityInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_DocumentAndEntityInformationAbstract" xlink:label="mgnx_DocumentAndEntityInformationAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentType" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_DocumentAndEntityInformationAbstract" xlink:to="dei_AmendmentFlag" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentPeriodEndDate" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_DocumentAndEntityInformationAbstract" xlink:to="dei_TradingSymbol" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityRegistrantName" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCentralIndexKey" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_DocumentAndEntityInformationAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityVoluntaryFilers" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityFilerCategory" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityPublicFloat" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/StatementOfFinancialPositionClassified" xlink:title="104000 - Statement - Statement of Financial Position, Classified">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestructuringReserveCurrent" xlink:label="us-gaap_RestructuringReserveCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestructuringReserveNoncurrent" xlink:label="us-gaap_RestructuringReserveNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="us-gaap_TreasuryStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalents" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_RestructuringReserveNoncurrent" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRentCreditNoncurrent" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_RestructuringReserveCurrent" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="1.2600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="1.2700" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="1.2800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1.2900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_TreasuryStockValue" order="1.1400" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TreasuryStockNumberOfSharesHeld" xlink:label="us-gaap_TreasuryStockNumberOfSharesHeld"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TreasuryStockNumberOfSharesHeld" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/StatementOfIncomeAlternative" xlink:title="124100 - Statement - Statement of Income">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LicenseAndServicesRevenue" xlink:label="us-gaap_LicenseAndServicesRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueFromGrants" xlink:label="us-gaap_RevenueFromGrants"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpenses" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_RevenuesAbstract" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_CostsAndExpensesAbstract" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_LicenseAndServicesRevenue" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromGrants" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_Revenues" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome" xlink:title="148600 - Statement - Statement of Shareholders' Equity">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_SeriesA1ConvertiblePreferredStockMember" xlink:label="mgnx_SeriesA1ConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_SeriesA2ConvertiblePreferredStockMember" xlink:label="mgnx_SeriesA2ConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_SeriesBConvertiblePreferredStockMember" xlink:label="mgnx_SeriesBConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_SeriesCConvertiblePreferredStockMember" xlink:label="mgnx_SeriesCConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_SeriesD1ConvertiblePreferredStockMember" xlink:label="mgnx_SeriesD1ConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_SeriesD2ConvertiblePreferredStockMember" xlink:label="mgnx_SeriesD2ConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_StockIssuedDuringPeriodSharesStockPlanActivity" xlink:label="mgnx_StockIssuedDuringPeriodSharesStockPlanActivity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_StockIssuedDuringPeriodValueStockPlanActivity" xlink:label="mgnx_StockIssuedDuringPeriodValueStockPlanActivity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="us-gaap_TreasuryStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TreasuryStockRetiredParValueMethodAmount" xlink:label="us-gaap_TreasuryStockRetiredParValueMethodAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TreasuryStockSharesRetired" xlink:label="us-gaap_TreasuryStockSharesRetired"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="mgnx_SeriesA1ConvertiblePreferredStockMember" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="mgnx_SeriesA2ConvertiblePreferredStockMember" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="mgnx_SeriesBConvertiblePreferredStockMember" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="mgnx_SeriesCConvertiblePreferredStockMember" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="mgnx_SeriesD1ConvertiblePreferredStockMember" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="mgnx_SeriesD2ConvertiblePreferredStockMember" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_TreasuryStockMember" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="1.2600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssued" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mgnx_StockIssuedDuringPeriodValueStockPlanActivity" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mgnx_StockIssuedDuringPeriodSharesStockPlanActivity" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TreasuryStockRetiredParValueMethodAmount" order="1.1000" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TreasuryStockSharesRetired" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_2" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssued_2" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/StatementOfCashFlowsIndirect" xlink:title="152200 - Statement - Statement of Cash Flows">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_IncreaseDecreaseInDeferredRent" xlink:label="mgnx_IncreaseDecreaseInDeferredRent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInRestructuringReserve" xlink:label="us-gaap_IncreaseDecreaseInRestructuringReserve"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="1.0400" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense" order="1.0500" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities" order="1.0600" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="1.0700" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInRestructuringReserve" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="mgnx_IncreaseDecreaseInDeferredRent" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" order="1.1600" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1.1800" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetIncomeLoss" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_ConversionOfStockAmountConverted1" order="1.3100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" order="1.2600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" order="1.2700" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.2800" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_2" order="1.2900" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="1.3000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:label="dei_EntityIncorporationDateOfIncorporation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="dei_EntityIncorporationDateOfIncorporation" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_BusinessMergerEffectiveDate" xlink:label="mgnx_BusinessMergerEffectiveDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:label="us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_LiquidInvestmentMaturityPeriodToBeClassifiedAsCashEquivalentMaximum" xlink:label="mgnx_LiquidInvestmentMaturityPeriodToBeClassifiedAsCashEquivalentMaximum"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_NumberOfAssetsHeldForSale" xlink:label="mgnx_NumberOfAssetsHeldForSale"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_NumberOfImpairedAssets" xlink:label="mgnx_NumberOfImpairedAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:label="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsReceivableMember" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:to="mgnx_BusinessMergerEffectiveDate" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:to="mgnx_LiquidInvestmentMaturityPeriodToBeClassifiedAsCashEquivalentMaximum" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:to="us-gaap_RestrictedCashAndCashEquivalents" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:to="mgnx_NumberOfImpairedAssets" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:to="mgnx_NumberOfAssetsHeldForSale" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:to="us-gaap_RangeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:to="us-gaap_EntityWideRevenueMajorCustomerLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfFairValueMeasurementFinancialAssetAndLiabilities">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_MoneyMarketFundsFairValueDisclosure" xlink:label="mgnx_MoneyMarketFundsFairValueDisclosure"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="mgnx_MoneyMarketFundsFairValueDisclosure" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalents" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfCollaboratorsThatRepresentMoreThan10OfTotalRevenueEarned">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_BoehringerIngelheimMember" xlink:label="mgnx_BoehringerIngelheimMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_EliLillyMember" xlink:label="mgnx_EliLillyMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_GileadSciencesIncMember" xlink:label="mgnx_GileadSciencesIncMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_ServierMember" xlink:label="mgnx_ServierMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_TakedaMember" xlink:label="mgnx_TakedaMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="mgnx_ServierMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="mgnx_BoehringerIngelheimMember" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="mgnx_TakedaMember" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="mgnx_GileadSciencesIncMember" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="mgnx_EliLillyMember" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfCollaboratorsThatRepresentMoreThan10OfAccountsReceivable">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_BoehringerIngelheimMember" xlink:label="mgnx_BoehringerIngelheimMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_GileadSciencesIncMember" xlink:label="mgnx_GileadSciencesIncMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_GreenCrossCorporationMember" xlink:label="mgnx_GreenCrossCorporationMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_PfizerIncMember" xlink:label="mgnx_PfizerIncMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_ServierMember" xlink:label="mgnx_ServierMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsReceivableMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="mgnx_ServierMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="mgnx_BoehringerIngelheimMember" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="mgnx_GreenCrossCorporationMember" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="mgnx_GileadSciencesIncMember" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="mgnx_PfizerIncMember" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLives">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_LaboratoryAndOfficeEquipmentMember" xlink:label="mgnx_LaboratoryAndOfficeEquipmentMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="mgnx_LaboratoryAndOfficeEquipmentMember" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesComputationOfBasicAndDilutedIncomeLossPerCommonShare">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic" xlink:label="us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:label="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" order="1.0200" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NetIncomeLoss_2" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic" order="1.0700" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromTheCalculationOfDilutedIncomeLossPerShare">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_SeriesA1ConvertiblePreferredStockMember" xlink:label="mgnx_SeriesA1ConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_SeriesA2ConvertiblePreferredStockMember" xlink:label="mgnx_SeriesA2ConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_SeriesBConvertiblePreferredStockMember" xlink:label="mgnx_SeriesBConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_SeriesCConvertiblePreferredStockMember" xlink:label="mgnx_SeriesCConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_SeriesD2ConvertiblePreferredStockMember" xlink:label="mgnx_SeriesD2ConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_SeriesDConvertiblePreferredStockMember" xlink:label="mgnx_SeriesDConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="mgnx_SeriesA1ConvertiblePreferredStockMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="mgnx_SeriesA2ConvertiblePreferredStockMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="mgnx_SeriesBConvertiblePreferredStockMember" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="mgnx_SeriesCConvertiblePreferredStockMember" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="mgnx_SeriesDConvertiblePreferredStockMember" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="mgnx_SeriesD2ConvertiblePreferredStockMember" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_StockOptionMember" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipment">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_FurnitureAndOfficeEquipmentMember" xlink:label="mgnx_FurnitureAndOfficeEquipmentMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1.0700" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="mgnx_FurnitureAndOfficeEquipmentMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureStockholdersEquityAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_ConvertiblePreferredStockConversionPrice" xlink:label="mgnx_ConvertiblePreferredStockConversionPrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockDividendRatePerDollarAmount" xlink:label="us-gaap_PreferredStockDividendRatePerDollarAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_RavenBiotechnologiesIncMember" xlink:label="mgnx_RavenBiotechnologiesIncMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_SeriesA1PreferredStockMember" xlink:label="mgnx_SeriesA1PreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_SeriesA2PreferredStockMember" xlink:label="mgnx_SeriesA2PreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_SeriesAOnePreferredStockMember" xlink:label="mgnx_SeriesAOnePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_SeriesD2ConvertiblePreferredStockMember" xlink:label="mgnx_SeriesD2ConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_SeriesD2PreferredStockMember" xlink:label="mgnx_SeriesD2PreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="us-gaap_SeriesDPreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_StockIssuanceCosts" xlink:label="mgnx_StockIssuanceCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption" xlink:label="mgnx_StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_UndesignatedPreferredStockMember" xlink:label="mgnx_UndesignatedPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="mgnx_SeriesD2ConvertiblePreferredStockMember" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="mgnx_RavenBiotechnologiesIncMember" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mgnx_SeriesA1PreferredStockMember" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mgnx_SeriesA2PreferredStockMember" order="1.2700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="1.2800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" order="1.2900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesDPreferredStockMember" order="1.3000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mgnx_SeriesD2PreferredStockMember" order="1.3100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mgnx_UndesignatedPreferredStockMember" order="1.3200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mgnx_SeriesAOnePreferredStockMember" order="1.3300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharePrice" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="mgnx_StockIssuanceCosts" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssued" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockDividendRatePerDollarAmount" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="mgnx_ConvertiblePreferredStockConversionPrice" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="mgnx_StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="1.2600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="13.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformation">
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance" xlink:label="mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_EquityIncentivePlan2003Member" xlink:label="mgnx_EquityIncentivePlan2003Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" xlink:label="mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease" xlink:label="mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_StockIncentivePlan2013Member" xlink:label="mgnx_StockIncentivePlan2013Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_StockOptionPlan2000Member" xlink:label="mgnx_StockOptionPlan2000Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="mgnx_StockOptionPlan2000Member" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="mgnx_EquityIncentivePlan2003Member" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="mgnx_StockIncentivePlan2013Member" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_RangeAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpense">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensation" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureStockBasedCompensationScheduleOfFairValueOptionAwardEstimatedOnTheDateOfGrantUsingTheBlackScholesOptionPricingModel">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_RangeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockOptionAndRestrictedStockUnitActivity">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="1.0300" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="1.0400" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsGrossNoncurrent" xlink:label="us-gaap_DeferredTaxAssetsGrossNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGrossCurrent" xlink:label="us-gaap_DeferredTaxLiabilitiesGrossCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_EndingYearMember" xlink:label="mgnx_EndingYearMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_IncomeTaxDisclosureLineItems" xlink:label="mgnx_IncomeTaxDisclosureLineItems"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_IncomeTaxDisclosureTable" xlink:label="mgnx_IncomeTaxDisclosureTable"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_IncomeTaxExaminationYearUnderExaminationRangeEnd" xlink:label="mgnx_IncomeTaxExaminationYearUnderExaminationRangeEnd"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_IncomeTaxExaminationYearUnderExaminationRangeStart" xlink:label="mgnx_IncomeTaxExaminationYearUnderExaminationRangeStart"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_OperatingLossCarryforwardsAnnualLimitationAmount" xlink:label="mgnx_OperatingLossCarryforwardsAnnualLimitationAmount"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_OperatingLossCarryforwardsExpirationYear" xlink:label="mgnx_OperatingLossCarryforwardsExpirationYear"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount" xlink:label="mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_OperatingLossCarryforwardsLimitationsOnUseYearEnd" xlink:label="mgnx_OperatingLossCarryforwardsLimitationsOnUseYearEnd"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_OperatingLossCarryforwardsLimitationsOnUseYearStart" xlink:label="mgnx_OperatingLossCarryforwardsLimitationsOnUseYearStart"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_OperatingLossCarryforwardsNotSubjectToLimitation" xlink:label="mgnx_OperatingLossCarryforwardsNotSubjectToLimitation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_StartYearMember" xlink:label="mgnx_StartYearMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_TaxCreditCarryforwardExpirationYearRangeEnd" xlink:label="mgnx_TaxCreditCarryforwardExpirationYearRangeEnd"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_TaxCreditCarryforwardExpirationYearRangeStart" xlink:label="mgnx_TaxCreditCarryforwardExpirationYearRangeStart"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_UnrecognizedTaxBenefitsResultingInNetOperatingLossesCarryforward" xlink:label="mgnx_UnrecognizedTaxBenefitsResultingInNetOperatingLossesCarryforward"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="mgnx_StartYearMember" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="mgnx_EndingYearMember" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="mgnx_IncomeTaxDisclosureTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_IncomeTaxDisclosureLineItems" xlink:to="mgnx_OperatingLossCarryforwardsExpirationYear" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_IncomeTaxDisclosureLineItems" xlink:to="mgnx_TaxCreditCarryforwardExpirationYearRangeStart" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_IncomeTaxDisclosureLineItems" xlink:to="mgnx_TaxCreditCarryforwardExpirationYearRangeEnd" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_IncomeTaxDisclosureLineItems" xlink:to="mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_IncomeTaxDisclosureLineItems" xlink:to="mgnx_OperatingLossCarryforwardsLimitationsOnUseYearStart" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_IncomeTaxDisclosureLineItems" xlink:to="mgnx_OperatingLossCarryforwardsLimitationsOnUseYearEnd" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_IncomeTaxDisclosureLineItems" xlink:to="mgnx_OperatingLossCarryforwardsAnnualLimitationAmount" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_IncomeTaxDisclosureLineItems" xlink:to="mgnx_OperatingLossCarryforwardsNotSubjectToLimitation" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_IncomeTaxDisclosureLineItems" xlink:to="mgnx_UnrecognizedTaxBenefitsResultingInNetOperatingLossesCarryforward" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_DeferredTaxLiabilitiesGrossCurrent" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsGrossNoncurrent" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_IncomeTaxDisclosureLineItems" xlink:to="mgnx_IncomeTaxExaminationYearUnderExaminationRangeStart" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_IncomeTaxDisclosureLineItems" xlink:to="mgnx_IncomeTaxExaminationYearUnderExaminationRangeEnd" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_IncomeTaxDisclosureTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_IncomeTaxDisclosureTable" xlink:to="us-gaap_RangeAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_IncomeTaxDisclosureTable" xlink:to="mgnx_IncomeTaxDisclosureLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureIncomeTaxesComponentsOfTheCompanysDeferredTaxAssetsLiabilities">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:label="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1.1000" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" order="1.1200" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="1.1300" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureIncomeTaxesReconciliationOfReportedEstimatedIncomeTaxBenefit">
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_EffectiveIncomeTaxRateReconciliationLineItems" xlink:label="mgnx_EffectiveIncomeTaxRateReconciliationLineItems"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_EffectiveIncomeTaxRateReconciliationTable" xlink:label="mgnx_EffectiveIncomeTaxRateReconciliationTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxReconciliationDeductions" xlink:label="us-gaap_IncomeTaxReconciliationDeductions"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_IncomeTaxReconciliationDeferredTaxAdjustments" xlink:label="mgnx_IncomeTaxReconciliationDeferredTaxAdjustments"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_IncomeTaxReconciliationFairValueAdjustmentOfPreferredStockWarrantLiability" xlink:label="mgnx_IncomeTaxReconciliationFairValueAdjustmentOfPreferredStockWarrantLiability"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:label="us-gaap_IncomeTaxReconciliationOtherReconcilingItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_IncomeTaxReconciliationStateDeferredTaxesAdjustments" xlink:label="mgnx_IncomeTaxReconciliationStateDeferredTaxesAdjustments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsOther" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsOther"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioPreviouslyReportedMember" xlink:label="us-gaap_ScenarioPreviouslyReportedMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="mgnx_IncomeTaxReconciliationDeferredTaxAdjustments" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="mgnx_IncomeTaxReconciliationStateDeferredTaxesAdjustments" order="1.0500" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" order="1.0600" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxReconciliationDeductions" order="1.0700" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsOther" order="1.0800" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxReconciliationOtherReconcilingItems" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="mgnx_IncomeTaxReconciliationFairValueAdjustmentOfPreferredStockWarrantLiability" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_EffectiveIncomeTaxRateReconciliationTable" xlink:to="us-gaap_StatementScenarioAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_EffectiveIncomeTaxRateReconciliationTable" xlink:to="mgnx_EffectiveIncomeTaxRateReconciliationLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="mgnx_EffectiveIncomeTaxRateReconciliationTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioPreviouslyReportedMember" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureIncomeTaxesReconciliationOfTheBeginningAndEndingAmountOfGrossUnrecognizedTaxBenefits">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:label="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" order="1.0400" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits_2" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureLeaseExitLiabilityAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_ContingentConsiderationRecordedAsIncrementalInProcessResearchAndDevelopmentExpense" xlink:label="mgnx_ContingentConsiderationRecordedAsIncrementalInProcessResearchAndDevelopmentExpense"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_ConvertiblePreferredStockSeriesDMember" xlink:label="mgnx_ConvertiblePreferredStockSeriesDMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_LeaseExpirationYear" xlink:label="mgnx_LeaseExpirationYear"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_OnetimeMilestonePaymentToBePaidUnderAgreement" xlink:label="mgnx_OnetimeMilestonePaymentToBePaidUnderAgreement"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_OnetimeMilestonePaymentToBePaidUnderAgreementUponSpecifiedLevelOfSalesOfProducts" xlink:label="mgnx_OnetimeMilestonePaymentToBePaidUnderAgreementUponSpecifiedLevelOfSalesOfProducts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mgnx_ConvertiblePreferredStockSeriesDMember" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="mgnx_LeaseExpirationYear" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="mgnx_OnetimeMilestonePaymentToBePaidUnderAgreement" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="mgnx_OnetimeMilestonePaymentToBePaidUnderAgreementUponSpecifiedLevelOfSalesOfProducts" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="mgnx_ContingentConsiderationRecordedAsIncrementalInProcessResearchAndDevelopmentExpense" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_RangeAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_RestructuringCostAndReserveLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureLeaseExitLiabilityChangesInLeaseExitLiability">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ContractTerminationMember" xlink:label="us-gaap_ContractTerminationMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsForRestructuring" xlink:label="us-gaap_PaymentsForRestructuring"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestructuringReserve" xlink:label="us-gaap_RestructuringReserve"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestructuringReserve" xlink:label="us-gaap_RestructuringReserve_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringReserve" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_PaymentsForRestructuring" order="1.0200" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringReserve_2" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_RestructuringCostAndReserveAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_RestructuringCostAndReserveLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_ContractTerminationMember" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureLeaseExitLiabilityFuturePrincipalPaymentsUnderLeaseAgreement">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_FutureMinimumLeasesPaymentsUnderLeasesTable" xlink:label="mgnx_FutureMinimumLeasesPaymentsUnderLeasesTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="us-gaap_OperatingLeasedAssetsLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_RavenBiotechnologiesIncMember" xlink:label="mgnx_RavenBiotechnologiesIncMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="mgnx_RavenBiotechnologiesIncMember" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_FutureMinimumLeasesPaymentsUnderLeasesTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_FutureMinimumLeasesPaymentsUnderLeasesTable" xlink:to="us-gaap_OperatingLeasedAssetsLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="mgnx_FutureMinimumLeasesPaymentsUnderLeasesTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformation1">
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_AdditionalPotentialClinicalRegulatoryCommercializationPaymentsUnderAgreement" xlink:label="mgnx_AdditionalPotentialClinicalRegulatoryCommercializationPaymentsUnderAgreement"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_AdditionalPotentialDevelopmentRegulatoryAndSalesMilestoneUnderAgreement" xlink:label="mgnx_AdditionalPotentialDevelopmentRegulatoryAndSalesMilestoneUnderAgreement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_CollaborationAndLicenseAgreementEnteredDate" xlink:label="mgnx_CollaborationAndLicenseAgreementEnteredDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_JanssenBiotechIncMember" xlink:label="mgnx_JanssenBiotechIncMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:label="mgnx_LicenseAndCollaborationAgreementsLineItems"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_LicenseAndCollaborationAgreementsTable" xlink:label="mgnx_LicenseAndCollaborationAgreementsTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="us-gaap_LicensesRevenue"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_NonRefundableUpFrontPayment" xlink:label="mgnx_NonRefundableUpFrontPayment"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_NonRefundableUpfrontPaymentReceivable" xlink:label="mgnx_NonRefundableUpfrontPaymentReceivable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_PotentialLicenseOptionFeeAndEarlyDevelopmentMilestoneFee" xlink:label="mgnx_PotentialLicenseOptionFeeAndEarlyDevelopmentMilestoneFee"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_ResearchCollaborationAndLicenseOptionAgreementMember" xlink:label="mgnx_ResearchCollaborationAndLicenseOptionAgreementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_TakedaMember" xlink:label="mgnx_TakedaMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_UpfrontFeeAllocatedToAgreement" xlink:label="mgnx_UpfrontFeeAllocatedToAgreement"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_UpfrontPaymentRecognitionPeriod" xlink:label="mgnx_UpfrontPaymentRecognitionPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="mgnx_ResearchCollaborationAndLicenseOptionAgreementMember" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_CollaborationAndLicenseAgreementEnteredDate" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_NonRefundableUpfrontPaymentReceivable" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_AdditionalPotentialClinicalRegulatoryCommercializationPaymentsUnderAgreement" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="us-gaap_LicensesRevenue" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="us-gaap_DeferredRevenue" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_NonRefundableUpFrontPayment" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_PotentialLicenseOptionFeeAndEarlyDevelopmentMilestoneFee" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_AdditionalPotentialDevelopmentRegulatoryAndSalesMilestoneUnderAgreement" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_UpfrontFeeAllocatedToAgreement" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_UpfrontPaymentRecognitionPeriod" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="us-gaap_DeferredRevenueCurrent" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsTable" xlink:to="us-gaap_CounterpartyNameAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsTable" xlink:to="mgnx_LicenseAndCollaborationAgreementsLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="mgnx_LicenseAndCollaborationAgreementsTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="mgnx_JanssenBiotechIncMember" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="mgnx_TakedaMember" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformation2">
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_AdditionalLicenseGrantFeesUnderAgreement" xlink:label="mgnx_AdditionalLicenseGrantFeesUnderAgreement"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_AdditionalPotentialClinicalMilestonePaymentsUnderAgreement" xlink:label="mgnx_AdditionalPotentialClinicalMilestonePaymentsUnderAgreement"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_AdditionalPotentialRegulatoryAndSalesMilestonePaymentsUnderAgreement" xlink:label="mgnx_AdditionalPotentialRegulatoryAndSalesMilestonePaymentsUnderAgreement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_CollaborationAndLicenseAgreementEnteredDate" xlink:label="mgnx_CollaborationAndLicenseAgreementEnteredDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_GileadMember" xlink:label="mgnx_GileadMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:label="mgnx_LicenseAndCollaborationAgreementsLineItems"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_LicenseAndCollaborationAgreementsTable" xlink:label="mgnx_LicenseAndCollaborationAgreementsTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="us-gaap_LicensesRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedAsPerCollaborations" xlink:label="mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedAsPerCollaborations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_PreclinicalMilestonesMember" xlink:label="mgnx_PreclinicalMilestonesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_UpfrontPaymentRecognitionPeriod" xlink:label="mgnx_UpfrontPaymentRecognitionPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="mgnx_PreclinicalMilestonesMember" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_CollaborationAndLicenseAgreementEnteredDate" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedAsPerCollaborations" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_AdditionalLicenseGrantFeesUnderAgreement" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_AdditionalPotentialClinicalMilestonePaymentsUnderAgreement" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_AdditionalPotentialRegulatoryAndSalesMilestonePaymentsUnderAgreement" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_UpfrontPaymentRecognitionPeriod" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="us-gaap_LicensesRevenue" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="us-gaap_DeferredRevenueCurrent" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsTable" xlink:to="us-gaap_CounterpartyNameAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsTable" xlink:to="us-gaap_RangeAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsTable" xlink:to="mgnx_LicenseAndCollaborationAgreementsLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="mgnx_LicenseAndCollaborationAgreementsTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="mgnx_GileadMember" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformation3">
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_AdditionalClinicalMilestonePotentialPaymentsUnderAgreement" xlink:label="mgnx_AdditionalClinicalMilestonePotentialPaymentsUnderAgreement"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_AdditionalPotentialLicenseGrantFeesUnderAgreement" xlink:label="mgnx_AdditionalPotentialLicenseGrantFeesUnderAgreement"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_AdditionalPotentialMilestonePaymentsReceivableUponNewDrugApplicationAcceptance" xlink:label="mgnx_AdditionalPotentialMilestonePaymentsReceivableUponNewDrugApplicationAcceptance"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_AdditionalPotentialRegulatoryMilestonePaymentsUnderAgreement" xlink:label="mgnx_AdditionalPotentialRegulatoryMilestonePaymentsUnderAgreement"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_AdditionalPotentialSalesMilestonePaymentsUnderAgreement" xlink:label="mgnx_AdditionalPotentialSalesMilestonePaymentsUnderAgreement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_ChangeInAccountingEstimateCurrentYearImpact" xlink:label="mgnx_ChangeInAccountingEstimateCurrentYearImpact"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_CollaborationAgreementConsiderationReceivable" xlink:label="mgnx_CollaborationAgreementConsiderationReceivable"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_CollaborationAndLicenseAgreementEnteredDate" xlink:label="mgnx_CollaborationAndLicenseAgreementEnteredDate"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts" xlink:label="mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:label="mgnx_LicenseAndCollaborationAgreementsLineItems"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_LicenseAndCollaborationAgreementsTable" xlink:label="mgnx_LicenseAndCollaborationAgreementsTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="us-gaap_LicensesRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_NonRefundableUpFrontPayment" xlink:label="mgnx_NonRefundableUpFrontPayment"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_NumberOfMilestonesAchieved" xlink:label="mgnx_NumberOfMilestonesAchieved"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_OptionExerciseFee" xlink:label="mgnx_OptionExerciseFee"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_OptionExerciseFeeRecognitionPeriod" xlink:label="mgnx_OptionExerciseFeeRecognitionPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_ReviewPeriodByRegulatoryAuthority" xlink:label="mgnx_ReviewPeriodByRegulatoryAuthority"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioAdjustmentMember" xlink:label="us-gaap_ScenarioAdjustmentMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_SecondRightToDevelopCollaborationMember" xlink:label="mgnx_SecondRightToDevelopCollaborationMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_ServierMember" xlink:label="mgnx_ServierMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_UpfrontPaymentRecognitionPeriod" xlink:label="mgnx_UpfrontPaymentRecognitionPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="mgnx_SecondRightToDevelopCollaborationMember" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_CollaborationAndLicenseAgreementEnteredDate" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_NonRefundableUpFrontPayment" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_AdditionalPotentialLicenseGrantFeesUnderAgreement" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_AdditionalClinicalMilestonePotentialPaymentsUnderAgreement" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_AdditionalPotentialRegulatoryMilestonePaymentsUnderAgreement" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_AdditionalPotentialSalesMilestonePaymentsUnderAgreement" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_UpfrontPaymentRecognitionPeriod" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="us-gaap_LicensesRevenue" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="us-gaap_DeferredRevenueCurrent" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_AdditionalPotentialMilestonePaymentsReceivableUponNewDrugApplicationAcceptance" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_ChangeInAccountingEstimateCurrentYearImpact" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_OptionExerciseFee" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_OptionExerciseFeeRecognitionPeriod" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_CollaborationAgreementConsiderationReceivable" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_NumberOfMilestonesAchieved" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_ReviewPeriodByRegulatoryAuthority" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="us-gaap_DeferredRevenue" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsTable" xlink:to="us-gaap_CounterpartyNameAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsTable" xlink:to="us-gaap_RangeAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsTable" xlink:to="us-gaap_StatementScenarioAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="13.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsTable" xlink:to="mgnx_LicenseAndCollaborationAgreementsLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="mgnx_LicenseAndCollaborationAgreementsTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="mgnx_ServierMember" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioAdjustmentMember" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformation4">
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_AdditionalPotentialClinicalMilestonePaymentsUnderAgreement" xlink:label="mgnx_AdditionalPotentialClinicalMilestonePaymentsUnderAgreement"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_AdditionalPotentialRegulatoryMilestonePaymentsUnderAgreement" xlink:label="mgnx_AdditionalPotentialRegulatoryMilestonePaymentsUnderAgreement"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_AdditionalPotentialSalesMilestonePaymentsUnderAgreement" xlink:label="mgnx_AdditionalPotentialSalesMilestonePaymentsUnderAgreement"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_BoehringerIngelheimMember" xlink:label="mgnx_BoehringerIngelheimMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_CollaborationAndLicenseAgreementEnteredDate" xlink:label="mgnx_CollaborationAndLicenseAgreementEnteredDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:label="mgnx_LicenseAndCollaborationAgreementsLineItems"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_LicenseAndCollaborationAgreementsTable" xlink:label="mgnx_LicenseAndCollaborationAgreementsTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="us-gaap_LicensesRevenue"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_NonRefundableUpFrontPayment" xlink:label="mgnx_NonRefundableUpFrontPayment"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_NumberOfAnnualMaintenancePaymentReceived" xlink:label="mgnx_NumberOfAnnualMaintenancePaymentReceived"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedAsPerCollaborations" xlink:label="mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedAsPerCollaborations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_ResearchObligationCompletionDate" xlink:label="mgnx_ResearchObligationCompletionDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_CollaborationAndLicenseAgreementEnteredDate" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedAsPerCollaborations" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_NonRefundableUpFrontPayment" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_NumberOfAnnualMaintenancePaymentReceived" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_AdditionalPotentialClinicalMilestonePaymentsUnderAgreement" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_AdditionalPotentialRegulatoryMilestonePaymentsUnderAgreement" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_AdditionalPotentialSalesMilestonePaymentsUnderAgreement" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_ResearchObligationCompletionDate" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="us-gaap_LicensesRevenue" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="us-gaap_DeferredRevenue" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="us-gaap_DeferredRevenueCurrent" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsTable" xlink:to="us-gaap_CounterpartyNameAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsTable" xlink:to="mgnx_LicenseAndCollaborationAgreementsLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="mgnx_LicenseAndCollaborationAgreementsTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="mgnx_BoehringerIngelheimMember" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformation5">
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_AdditionalPotentialClinicalMilestonePaymentsUnderAgreement" xlink:label="mgnx_AdditionalPotentialClinicalMilestonePaymentsUnderAgreement"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_AdditionalPotentialCommercializationAndSalesMilestonePaymentsUnderAgreement" xlink:label="mgnx_AdditionalPotentialCommercializationAndSalesMilestonePaymentsUnderAgreement"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_CollaborationAndLicenseAgreementEnteredDate" xlink:label="mgnx_CollaborationAndLicenseAgreementEnteredDate"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_CollaborativeAgreementPeriodOfContract" xlink:label="mgnx_CollaborativeAgreementPeriodOfContract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:label="mgnx_LicenseAndCollaborationAgreementsLineItems"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_LicenseAndCollaborationAgreementsTable" xlink:label="mgnx_LicenseAndCollaborationAgreementsTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="us-gaap_LicensesRevenue"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_NonRefundableUpFrontPayment" xlink:label="mgnx_NonRefundableUpFrontPayment"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedAsPerCollaborations" xlink:label="mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedAsPerCollaborations"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_NumberOfPrograms" xlink:label="mgnx_NumberOfPrograms"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_PfizerIncMember" xlink:label="mgnx_PfizerIncMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_ResearchObligationCompletionDate" xlink:label="mgnx_ResearchObligationCompletionDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_UpfrontFeeAndParticipationRecognitionEndDate" xlink:label="mgnx_UpfrontFeeAndParticipationRecognitionEndDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_CollaborationAndLicenseAgreementEnteredDate" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_CollaborativeAgreementPeriodOfContract" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedAsPerCollaborations" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_NonRefundableUpFrontPayment" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_AdditionalPotentialClinicalMilestonePaymentsUnderAgreement" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_AdditionalPotentialCommercializationAndSalesMilestonePaymentsUnderAgreement" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_NumberOfPrograms" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_ResearchObligationCompletionDate" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_UpfrontFeeAndParticipationRecognitionEndDate" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="us-gaap_LicensesRevenue" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="us-gaap_DeferredRevenueCurrent" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsTable" xlink:to="us-gaap_CounterpartyNameAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsTable" xlink:to="mgnx_LicenseAndCollaborationAgreementsLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="mgnx_LicenseAndCollaborationAgreementsTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="mgnx_PfizerIncMember" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformation6">
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_AdditionalPotentialClinicalAndCommercialMilestonePaymentsUnderAgreement" xlink:label="mgnx_AdditionalPotentialClinicalAndCommercialMilestonePaymentsUnderAgreement"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_AdjustmentToRevenueUnderAccountingStandardsCodification" xlink:label="mgnx_AdjustmentToRevenueUnderAccountingStandardsCodification"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_AggregatePotentialFutureCostReimbursement" xlink:label="mgnx_AggregatePotentialFutureCostReimbursement"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_CollaborationAndLicenseAgreementEnteredDate" xlink:label="mgnx_CollaborationAndLicenseAgreementEnteredDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_GreenCrossCorporationMember" xlink:label="mgnx_GreenCrossCorporationMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:label="mgnx_LicenseAndCollaborationAgreementsLineItems"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_LicenseAndCollaborationAgreementsTable" xlink:label="mgnx_LicenseAndCollaborationAgreementsTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="us-gaap_LicensesRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_NonRefundableUpFrontPayment" xlink:label="mgnx_NonRefundableUpFrontPayment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnbilledContractsReceivable" xlink:label="us-gaap_UnbilledContractsReceivable"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_UpfrontFeeAndParticipationRecognitionEndDate" xlink:label="mgnx_UpfrontFeeAndParticipationRecognitionEndDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_CollaborationAndLicenseAgreementEnteredDate" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_AggregatePotentialFutureCostReimbursement" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_AdditionalPotentialClinicalAndCommercialMilestonePaymentsUnderAgreement" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_UpfrontFeeAndParticipationRecognitionEndDate" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_NonRefundableUpFrontPayment" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_AdjustmentToRevenueUnderAccountingStandardsCodification" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="us-gaap_LicensesRevenue" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="us-gaap_DeferredRevenue" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="us-gaap_UnbilledContractsReceivable" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="us-gaap_DeferredRevenueCurrent" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsTable" xlink:to="us-gaap_CounterpartyNameAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsTable" xlink:to="us-gaap_RangeAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsTable" xlink:to="mgnx_LicenseAndCollaborationAgreementsLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="mgnx_LicenseAndCollaborationAgreementsTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="mgnx_GreenCrossCorporationMember" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformation7">
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_CollaborationAndLicenseAgreementEnteredDate" xlink:label="mgnx_CollaborationAndLicenseAgreementEnteredDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_EliLillyMember" xlink:label="mgnx_EliLillyMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:label="mgnx_LicenseAndCollaborationAgreementsLineItems"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_LicenseAndCollaborationAgreementsTable" xlink:label="mgnx_LicenseAndCollaborationAgreementsTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="us-gaap_LicensesRevenue"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_NonRefundableUpFrontPayment" xlink:label="mgnx_NonRefundableUpFrontPayment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_CollaborationAndLicenseAgreementEnteredDate" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_NonRefundableUpFrontPayment" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="us-gaap_LicensesRevenue" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsTable" xlink:to="us-gaap_CounterpartyNameAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsTable" xlink:to="mgnx_LicenseAndCollaborationAgreementsLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="mgnx_LicenseAndCollaborationAgreementsTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="mgnx_EliLillyMember" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_AdditionalManufacturingSpaceMember" xlink:label="mgnx_AdditionalManufacturingSpaceMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_AmendedLeaseExpirationDate" xlink:label="mgnx_AmendedLeaseExpirationDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRentCredit" xlink:label="us-gaap_DeferredRentCredit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DescriptionOfLesseeLeasingArrangementsOperatingLeases" xlink:label="us-gaap_DescriptionOfLesseeLeasingArrangementsOperatingLeases"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_LeaseAgreementInitiationDate" xlink:label="mgnx_LeaseAgreementInitiationDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm" xlink:label="us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:label="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_ManufacturingSpaceMember" xlink:label="mgnx_ManufacturingSpaceMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_OfficeAndLaboratorySpaceMember" xlink:label="mgnx_OfficeAndLaboratorySpaceMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="us-gaap_OperatingLeasedAssetsLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="us-gaap_OperatingLeasesRentExpenseNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_RockvilleMarylandMember" xlink:label="mgnx_RockvilleMarylandMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="us-gaap_SegmentGeographicalDomain"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_SouthSanFranciscoMember" xlink:label="mgnx_SouthSanFranciscoMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="us-gaap_StatementGeographicalAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ScheduleOfOperatingLeasedAssetsTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="mgnx_AmendedLeaseExpirationDate" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_DescriptionOfLesseeLeasingArrangementsOperatingLeases" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="mgnx_LeaseAgreementInitiationDate" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_DeferredRentCredit" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_OperatingLeasesRentExpenseNet" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:to="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:to="mgnx_OfficeAndLaboratorySpaceMember" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:to="mgnx_ManufacturingSpaceMember" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:to="mgnx_AdditionalManufacturingSpaceMember" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="us-gaap_StatementGeographicalAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="us-gaap_OperatingLeasedAssetsLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentGeographicalDomain" xlink:to="mgnx_RockvilleMarylandMember" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentGeographicalDomain" xlink:to="mgnx_SouthSanFranciscoMember" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementGeographicalAxis" xlink:to="us-gaap_SegmentGeographicalDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMinimumFutureLeasePayments">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureProductMilestonePaymentsAndRoyaltyAgreementsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_AdditionalPaymentUponAchievementOfMilestone" xlink:label="mgnx_AdditionalPaymentUponAchievementOfMilestone"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_AmountOfAdditionalConsiderationPaidUnderAgreement" xlink:label="mgnx_AmountOfAdditionalConsiderationPaidUnderAgreement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_NumberOfPotentialSharesToBeIssuedAsAdditionalConsiderationUnderAssetPurchaseAgreement" xlink:label="mgnx_NumberOfPotentialSharesToBeIssuedAsAdditionalConsiderationUnderAssetPurchaseAgreement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_RoyaltyAgreementLineItems" xlink:label="mgnx_RoyaltyAgreementLineItems"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_RoyaltyAgreementTable" xlink:label="mgnx_RoyaltyAgreementTable"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_RoyaltyPaymentAsPercentageOfNetSalesUnderLicensingAgreement" xlink:label="mgnx_RoyaltyPaymentAsPercentageOfNetSalesUnderLicensingAgreement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="us-gaap_SalesRevenueGoodsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="mgnx_RoyaltyAgreementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_RoyaltyAgreementLineItems" xlink:to="mgnx_AdditionalPaymentUponAchievementOfMilestone" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_RoyaltyAgreementLineItems" xlink:to="mgnx_NumberOfPotentialSharesToBeIssuedAsAdditionalConsiderationUnderAssetPurchaseAgreement" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_RoyaltyAgreementLineItems" xlink:to="mgnx_RoyaltyPaymentAsPercentageOfNetSalesUnderLicensingAgreement" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_RoyaltyAgreementLineItems" xlink:to="mgnx_AmountOfAdditionalConsiderationPaidUnderAgreement" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_RoyaltyAgreementLineItems" xlink:to="us-gaap_SalesRevenueGoodsNet" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_RoyaltyAgreementTable" xlink:to="us-gaap_RangeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_RoyaltyAgreementTable" xlink:to="mgnx_RoyaltyAgreementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureEmployeeBenefitPlanAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:label="us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_DefinedContributionPlanEmployeesContributionAnnualVestingPercentage" xlink:label="mgnx_DefinedContributionPlanEmployeesContributionAnnualVestingPercentage"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan" xlink:label="mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:to="mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:to="mgnx_DefinedContributionPlanEmployeesContributionAnnualVestingPercentage" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureQuarterlyFinancialInformationCompanysConsolidatedQuarterlyResultsOfOperations">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_Revenues" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_NetIncomeLoss" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureSubsequentEventAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_JanssenBiotechIncMember" xlink:label="mgnx_JanssenBiotechIncMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_JohnsonAndJohnsonDevelopmentCorporationMember" xlink:label="mgnx_JohnsonAndJohnsonDevelopmentCorporationMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_NonRefundableUpfrontPaymentReceivable" xlink:label="mgnx_NonRefundableUpfrontPaymentReceivable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="mgnx_JohnsonAndJohnsonDevelopmentCorporationMember" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="mgnx_JanssenBiotechIncMember" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="mgnx_NonRefundableUpfrontPaymentReceivable" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_CounterpartyNameAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CreditConcentrationRiskMember" xlink:label="us-gaap_CreditConcentrationRiskMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:label="mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CreditConcentrationRiskMember" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsRestructuringAndRelatedActivitiesDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsRestructuringAndRelatedActivitiesDisclosureTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:label="us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsCollaborationAndLicenseAgreementsDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock" xlink:label="mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TextBlockAbstract" xlink:label="us-gaap_TextBlockAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TextBlockAbstract" xlink:to="mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:label="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsRoyaltyAgreementDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="mgnx-20141231.xsd#mgnx_RoyaltyAgreementDisclosureTextBlock" xlink:label="mgnx_RoyaltyAgreementDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TextBlockAbstract" xlink:label="us-gaap_TextBlockAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TextBlockAbstract" xlink:to="mgnx_RoyaltyAgreementDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsPensionAndOtherPostretirementBenefitsDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_QuarterlyFinancialInformationTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g838054g00a25.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g838054g00a25.jpg
M_]C_X``02D9)1@`!`0$#P`/```#_[1Z^4&AO=&]S:&]P(#,N,``X0DE-!`0`
M``````\<`5H``QLE1QP"```"````.$))300E```````0S<_Z?:C'O@D%<':N
MKP7#3CA"24T$.@``````Y0```!`````!```````+<')I;G1/=71P=70````%
M`````%!S=%-B;V]L`0````!);G1E96YU;0````!);G1E`````$-L<FT````/
M<')I;G13:7AT965N0FET8F]O;``````+<')I;G1E<DYA;65415A4`````0``
M````#W!R:6YT4')O;V93971U<$]B:F,````,`%``<@!O`&\`9@`@`%,`90!T
M`'4`<```````"G!R;V]F4V5T=7`````!`````$)L=&YE;G5M````#&)U:6QT
M:6Y0<F]O9@````EP<F]O9D--64L`.$))300[``````(M````$`````$`````
M`!)P<FEN=$]U='!U=$]P=&EO;G,````7`````$-P=&YB;V]L``````!#;&)R
M8F]O;```````4F=S36)O;VP``````$-R;D-B;V]L``````!#;G1#8F]O;```
M````3&)L<V)O;VP``````$YG='9B;V]L``````!%;6Q$8F]O;```````26YT
M<F)O;VP``````$)C:V=/8FIC`````0```````%)'0D,````#`````%)D("!D
M;W5B0&_@````````````1W)N(&1O=6)`;^````````````!";"`@9&]U8D!O
MX````````````$)R9%15;G1&(U)L=````````````````$)L9"!5;G1&(U)L
M=````````````````%)S;'15;G1&(U!X;$!S<2\@````````"G9E8W1O<D1A
M=&%B;V]L`0````!09U!S96YU;0````!09U!S`````%!G4$,`````3&5F=%5N
M=$8C4FQT````````````````5&]P(%5N=$8C4FQT````````````````4V-L
M(%5N=$8C4')C0%D````````````08W)O<%=H96Y0<FEN=&EN9V)O;VP`````
M#F-R;W!296-T0F]T=&]M;&]N9P`````````,8W)O<%)E8W1,969T;&]N9P``
M```````-8W)O<%)E8W12:6=H=&QO;F<`````````"V-R;W!296-T5&]P;&]N
M9P``````.$))30/M```````0`\`````!``$#P`````$``3A"24T$)@``````
M#@`````````````_@```.$))300-```````$````'CA"24T$&0``````!```
M`!XX0DE-`_,```````D```````````$`.$))32<0```````*``$`````````
M`3A"24T#]0``````2``O9F8``0!L9F8`!@```````0`O9F8``0"AF9H`!@``
M`````0`R`````0!:````!@```````0`U`````0`M````!@```````3A"24T#
M^```````<```_____________________________P/H`````/__________
M__________________\#Z`````#_____________________________`^@`
M````_____________________________P/H```X0DE-!`@``````!`````!
M```"0````D``````.$))300>```````$`````#A"24T$&@`````#-0````8`
M`````````````D@```6P``````````$``````````````````````````0``
M```````````%L````D@``````````````````````0``````````````````
M```````0`````0```````&YU;&P````"````!F)O=6YD<T]B:F,````!````
M````4F-T,0````0`````5&]P(&QO;F<``````````$QE9G1L;VYG````````
M``!"=&]M;&]N9P```D@`````4F=H=&QO;F<```6P````!G-L:6-E<U9L3',`
M```!3V)J8P````$```````5S;&EC90```!(````'<VQI8V5)1&QO;F<`````
M````!V=R;W5P241L;VYG``````````9O<FEG:6YE;G5M````#$53;&EC94]R
M:6=I;@````UA=71O1V5N97)A=&5D`````%1Y<&5E;G5M````"D53;&EC951Y
M<&4`````26UG(`````9B;W5N9'-/8FIC`````0```````%)C=#$````$````
M`%1O<"!L;VYG``````````!,969T;&]N9P``````````0G1O;6QO;F<```)(
M`````%)G:'1L;VYG```%L`````-U<FQ415A4`````0```````&YU;&Q415A4
M`````0```````$US9V5415A4`````0``````!F%L=%1A9U1%6%0````!````
M```.8V5L;%1E>'1)<TA434QB;V]L`0````AC96QL5&5X=%1%6%0````!````
M```):&]R>D%L:6=N96YU;0````]%4VQI8V5(;W)Z06QI9VX````'9&5F875L
M=`````EV97)T06QI9VYE;G5M````#T53;&EC959E<G1!;&EG;@````=D969A
M=6QT````"V)G0V]L;W)4>7!E96YU;0```!%%4VQI8V5"1T-O;&]R5'EP90``
M``!.;VYE````"71O<$]U='-E=&QO;F<`````````"FQE9G1/=71S971L;VYG
M``````````QB;W1T;VU/=71S971L;VYG``````````MR:6=H=$]U='-E=&QO
M;F<``````#A"24T$*```````#`````(_\````````#A"24T$$0```````0$`
M.$))3004```````$`````SA"24T$#``````42`````$```"@````0````>``
M`'@````4+``8``'_V/_M``Q!9&]B95]#30`"_^X`#D%D;V)E`&2``````?_;
M`(0`#`@("`D(#`D)#!$+"@L1%0\,#`\5&!,3%1,3&!$,#`P,#`P1#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`$-"PL-#@T0#@X0%`X.#A04#@X.#A01
M#`P,#`P1$0P,#`P,#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,_\``
M$0@`0`"@`P$B``(1`0,1`?_=``0`"O_$`3\```$%`0$!`0$!``````````,`
M`0($!08'"`D*"P$``04!`0$!`0$``````````0`"`P0%!@<("0H+$``!!`$#
M`@0"!0<&"`4###,!``(1`P0A$C$%05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"
MT4,')9)3\.'Q8W,U%J*R@R9$DU1D1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6T
ME<34Y/2EM<75Y?569G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_<1``("`0($!`,$
M!08'!P8%-0$``A$#(3$2!$%187$B$P4R@9$4H;%"(\%2T?`S)&+A<H*20U,5
M8W,T\24&%J*R@P<F-<+21)-4HQ=D154V=&7B\K.$P]-UX_-&E*2%M)7$U.3T
MI;7%U>7U5F9VAI:FML;6YO8G-T=79W>'EZ>WQ__:``P#`0`"$0,1`#\`['KO
M7LC=U'IV)2\,Q:`,W.K?%U'VAEGIY&'B!F_+^RUM^TV?IJ/H;,?U[_T2YWH?
M4J^BQF8^QF'1MIZUC42^O:&M?5U?%+??=^B<S+^T?3S^F7?I-^3C,76]>Z?E
M>I7UCIC`[J&(TMLIB#DXT[[,/?\`FWL=^GP+/\%E?\#DY"Y#+8S#MQ>K=)L;
M9TC(81B44LU>;'^M9TR/;Z=E;_M.3T>AS?9F?;^B_H_M&'6JO,C+<98SZX'B
MQBZCE_SF"?\`?_R;+C,=1+:6DCUC^[,/HS'LL8VRMP>QX#FN:9!!U:YK@JO5
MNJ8W2<"S-R=SFLAK*V#<^RQYV4X]+/S[;K'-K8N>^JG4V8EU72"\VX&6TW='
MOY:UNWUK.G;_`*6VNK]8P-W_`&D]7'_[1K-ZOUH]1R!U4!S\.@NJZ/C%P8VZ
MPAXMZG:3[:Z?1;=Z-]O]$Z6S+S_^U",N;A[$<L!QG)Z<>/\`2EE/^3_P?TU#
M#+C,#IPZREVA^\U+LBQO5<;,SK'6=7]>K)OMI!)K87.;B]#P(=7N^W^_"KI<
M_P!.ZK]H=6S/YI=MT;K-O4+<K$R\<8F;A&LW5,L%U>VYOJ4/KO#*=WT7[V.J
M9L_XOT['\GTUEF)55FES<W/S['CHE%C"PV66L;]HZGD5^ZRBK[/7_P"@'0:<
M?%_IN9?ZO9=&Z6.F8?HNM.3DV.-V7E.`:ZZY_P#.WN8WVL^CLJJ_P%#*J/\`
M!H\M&<8D2EQFS*<_WLLOF]O]W'#Y$9""=!0VB/ZO];^LWEP_UG^L-W4L#J/3
M:JCB8AN.$SJ'JC6^JRMCJ,JAFUV+@9MS7]/^UNO_`,/7;D8_V6W>NX7*_6KI
MK,.RWK36FS"N8*^L8VW>TU[?2'4-C?=^KU?H<YG^&P/?_P!HZU9C5ZL1V>;^
MH/UE?TS-'1\WU&8659Z=#+!!QLF=CL9['>ZFN^S]%Z7^!S?_``S:O3EXU]8.
MF6UW6OM><H/9N<\B3;BL:RO[79?N_6,K#W58^<_V>I@_8NI?^6%R[3ZG?7&F
M_I-]/6+A7D]*J]2Z^PR;<=O&7^^ZVO\`FLK_`(;T[?\`M576ILT1(>[$5K62
M(_0R?]Y-CQRH\!-]8']Z'_?1=?ZU_6.KH'3#>-MF;?->%0Z8?9'TG[?=Z%#?
MTM__`&W_`#MM2\]^JV9U&CK#NL"QV7=87TOK=9L=E7.:VRWUG0]M>'T^MS+\
MB_T_U9]F'AXM?Z?T56ZIU3)^LG67Y=[SCU;3Z+7-G[-BM+?\$S^=S,BQ];/2
M_P"U6??BX7\WZ2W>E],RVG'Z=B!M/5<BAC++-#]CPZR=UAV>VS*?<ZVSV^S/
MZU=?E?T3$_1N,!CAPR'KE4I_ZN'Z,/\`:30)&<N(?+'2/]>7Z4O[D7N>B]5;
MU7!^T^D:+:[+*,BDG=LMJ<:KF-M;[;F;V^RQO_@=GZ-8.=TW&PLFK`R>N=19
M=U%[_3`)<'&RUNZG<RM_I?S^VKW?HJ_4_P`%ZBZ7`P,3IV'5A8=8JQZ&[:V#
M[W.<?I/L>[WV6.]]EGZ1ZL*LS/!U]2Z2^BX9/7.H54V&IHJL8[U*GL-E[VB_
M'993NR&#U*6U?S-=7^%K_15&KLQ;\G'Q6=9ZJZW*@2X!C"/4OH`<VVMGI^H_
M$O=L_GO1K70YUC_^<'2ZI_1NJRGEG(W-^SMK?_78VRQK7?\`"6+%^L'USLIZ
MPSH/3*[79`=&5D5MK<6?H_M(JQVY5M-&_P!+WW9-WZ''_P!!DV_S!`)V%J)`
MW=VWH[[>CGI9SLD.)$Y@?^L1ZGKEOK-#?S?T'_%+F\BSI];LE[NL]4L_9S_3
MR*V0TUE]GV8VM<^ME;J_9^;ZGZ+U;*O\(@8W6?K'D6LKKR\FZTOO;;@,KPV9
M%#:35MNOS;V-Z?EML^TXOZ+&JQ]_VO\`1Y/ZI=ZFS]5OK3=U3;B9]#J,QPN?
M59#6MM918W'NW4MMO?BY5-EC&9.*]]G_``-UO^#:91!$20)$T!>M_-_W*:-6
MY567TVVS&J/7\^W.#:ZP::K&&SU;7O:]U5U=K&-L^T55L]3_`$-/^#_1JYT:
MFGJ658W%ZOU*UF$ZMY]1S`TQ9<W:?;ZSFW>@Y_Z5C/4Q;:O\%8Q:_P!7WNM;
MGV6'?9]MR*]Y^ELKL<VJO=^Y4W^;6LBA_]#U5<SUCZM]0M=FT],^S?8NJM<<
MBF\N9Z&28_REA^C7;ZECH;D64?J_Z[15EUY5=MERZ9)`@'0JNGS2]K6V6UCZ
M%?5\AK1V&F0YT`>UN^QS[?9^?8I=/Z=9U._#Q:A6][.EU6LKN)%3@V_#??CV
M[6V[:LRFG[/<[TW_`*/_``=M7J4V-E?S^3_Z>,K_`*G(6G]4?^6\3_TSC_SY
MCK.QC^D1_P!OS7_I.+:E_-G_`&>+_I/0='Z5F59-W4^JNK?U"\>E5742ZO'Q
MP=[<:FVQM=EK[G_I\O(].KUK?3_1^ECT+7226B``*&@#5W>;Z#]:<SJG7.H]
M-NZ=?C58IK])]C&M<P.K9:YN:6WW?I+GNWXWHL_F/YQ=(H-JJ8][VL:U]D&Q
MP`!<0-K=Y_.VM4T5/(N^I^;7F58V/92>CUY#,BOU"[UZ:P7.R.FU5-9Z61BW
MUNLPV/MOK]'`R[\2RG)KKJ7G'2X.#FS_`.5__NWTY>ZKPKI/]`S/_3</_;OI
MJL823#+Y0_\`2D6+)\T/.7_0D]%]4.D9?4,>Z_#939=AYK7OKO>ZMKV_9W5T
M'UJZLES+,.V^VVC]"]GZQ=_A?1MK[_H/11TO'>ZXMMZAE.%F;D-!`<X#;757
MNES,;&K_`$.-5^Y^D_GK;5S?^*S^B=3_`/##/_/3%W"9S!/NY!_7E^:<0_5P
M_NQ_)!FY)Q,6W)%-F1Z32[T:&[['1^;4PENYZQ.A_6?)ZCUK*Z9=A7TMKK;D
M5OLJ]-U;7$UC'S&^K=MNL<QUN,__`+44^I^AK]#]+T2'5CX])L=34RLW/]2T
ML:&E[R&L]2S;].S8QC=[E$R.9U5N55U?IV;5BVY553,BJT4[-S3;]G]-SFW6
MT_H_T5GT%R7H?:?KAF]1>&M)I-;P--K_`+3DX%;W:N_2?8.F5>HO1%YCUGJ6
M+BM^L-SWU8V;?DW5-QR0RP>RO!Q[?1.VS;97OZEZNW9Z=WK)^/YELMF[T:_&
M&#T'KC7[3U//S<:T01/VQU[JF:_Z&[IF!3_UM'Z?]HZ;]<,U[:S=4YP]"EL&
MPMSJLGJ>6:=SZJVN=G]+V?I/^%7'=.RVNZ>^@7-J9@G(R^GV/>&UNRP,2RNB
ME[]M;K\;T+;+6;_4V=07>]/ZETKJ'UIZ=F=/LKR_M6#=O;66O=2UKJKL6ZYK
M=SL;;]HS,3W[+/4N]/\`TBKY`!S4HU9@3$FM.+]&8_P>-DB;Q"6PD+K_`+EV
M?J[3DUXN0_)I?C.R,O(O959MWAEECGU[_2?8QOM_EK5224JU_]'U5)5Z^H8%
MMGI59-5EL..QKVET-><9_M!W>S(;Z#_^&_1?31+,C'JK?;98QE=32^Q[G`-:
MT3+WN/T6>UR2GSC)<'=2R.GM.[./5LI[<3_"EAJR+V6>C_.>D^ES+&V_S:T/
MJ3?1E=8HLQ;&WUT])K9:^L[@QSWUFNNUS?YNU_HV_HG_`*3]&NVVXWJ^O#/5
M+=@LTW%L_P`WO^EM]1WT?WT'&RNEN>&8EM!?D-^TAM3F2]KB&?:=K/YQKW^S
MUE7CRT8Y!/B.D\F2O]N.$C_!9#E)B8UO&,?_``MMI*O5U#!N>ZNG(JL?6W>]
MK7M)#3^>Z#]%$9?38]];+&N?4[98T$$M<6BW8\?FN]-[+/ZBL,:1)1>]E;'6
M6.#&,!<YSC``&I<XE"Q\_!R6N=C9%5S6AI<ZM[7`![!?67;"?YRA[+F?\%^D
M24G7A72FO^Q=1K#7>IC]/(O9!W5EF7T]UOK-^E7Z;:K=^_\`T5G^C7N-F1CU
M`&VUC`7MK&YP'O>6MKKU_/L<]FQJ@ZW"QV6Y+G55,(]2ZXEK1M:W=ZEC_P"3
M4SZ;O\&GPR&(D`+XJ_YLN-;*'$8G]V_Q'"\=_BK]V!U*UONK=E`->-02VJK=
MM=_)E=PJU>1T^EME%5E-;<32ZMKFM%4M]?\`2,;_`#/Z+]-[O\'^D4Z<S$R-
MWH75V[';';'!T.C=L=M/T]ON0G+CG*6W$3+_`!DQCPQ$?W0!]B9)#IOHO8+*
M+&VL)<`YA#A+":[!N;^Y8W8]$34J67U=^=3?19T_IS,VZP.KMM<6M+*]/9ZC
MRUVUSG>I_P!:]/\`PN]7;L["Q[647Y%=5UHFNM[VM>X`[26,<=SOI(?4,2G.
MH^SV7/J`>VR:G!KIK+7CZ0?^=L24\M?A]6KSQ;3TNZP"Z&LL.&*S4QUCZVUF
MK&]1GZ)OL]:RA_\`-U?;+?471=%LR[JKKLSIS>FWOL.YC7->;!#7-NL?4/Y7
MI^[]S_!K(M^KO1V7_9:NL96/E6`15]K)<6U`&S]$\[G;*/\`MK>MG"OZ7@5#
MI[<YMEF.]M5GKWA]WJ7%SZF7N>[U/6R'?S3'?SG^#24Z"2JXO5>EYEGI8F91
MD6;/4V56,>[9.SU-M;G?H]WMWJTDI__2[:SZC_5ZRU]KJK-]EAM>18_4N.^P
M?2]C7OWO]G^$LLNK_3?I%@.H^HN)E/JOKOP_3+JJWDDL<&V9&!DFEE9M=Z7Z
M&WUWOJ97B_H;JO0R<C?;WRQ>M8EF-73D],P*+[FY0ON::@]W%QLNJ_2X^S)W
M6OV6_I/YZS]%[TE/*Y#?J`W&%F/7E9(N]A=5ZC7AOZ.UU3O7]']$VF^JVW]^
MOTK[?4O_`$JMV.^HF7>RNP9#VUT5557?IG5NI!J&+3L;N_G,F^FZGU*?TN3Z
M7Z3^95QG6NKC(JH'U:;7;;4QVW?HQF\5;++F8WH_H=]UOI;_`%/3_P`']-2=
M=UQ[\3U.CT"@UXU^2X5ESFY3LNK[976S>Q_ZO0S[=Z^RS]-379^F22U<+H?U
M*ZCG6]/QQ<W+H%S75$N;M]&[[+8\'::7[7_1:[^>JN]6^NRS^;V^F_5/I'3,
MYF9B->U];;0UKG;Q-OI^XN?[]U-=3JJ7;O\`M1D^IZGJJWT?==T_&S,C'91F
MY%+'9`:S8=SAZCP0[](S](YS_3L^@KZ2$>117D468]D^G<QU;X,':X;705@.
M^HOU9K;N=0X5U[G.87N<TCP<UV[V5L;Z>S_0_H/YG]&NC224^>5._P`7[*WO
MR/M.(7M;NIL+W.-;F49E)W8_KN8VQWI^A9ZE=][_`%*/TF/7Z3&RJ_J!2::B
MS)-%GNMR&%[&PSU<5UN2T^G9MKM9=77Z=/LL]2JC]'^C71=7Q\CIUV,_I?2:
M,S'91;592RIHLASL>IM++C8UE55M7NM_5K_Z*J=G6^NE^53C?5QAR*V[G.<X
M[-[J3D,#G?9ZVY'YN.[T;/YZOT][/U;U4EKNI^I74NI93<BO(.9=;8U[;/5(
MLM:'O?Z/TZV6T8]5E7^!]/&_0_OJ?1^A_4OK9?;ABY[F-JLMK<7UD![7[!H&
M-^DU[/T#_P!!91Z='H_X0G4\OK^+FVOQ>CTC&Q"_[!<*38\M;C6.$>A:UU#[
M<M[,2G]!_,W9'\U_A>KJHHH!%-;:@Z"0QH;,`,;]']UC&L20YW1OJWT[HUMU
MN'NFYE=9#B"`*][MS=![[GV[K?\`K7^C6JDDDIYKZV4]#KR,7.ZE3??;4RS8
M*';=M=>RVZVSWU>RK_">_P#FO4]3]'6L6RG_`!?Y>=8_[1==9<?;0UMFT6.M
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M.$))300A``````!5`````0$````/`$$`9`!O`&(`90`@`%``:`!O`'0`;P!S
M`&@`;P!P````$P!!`&0`;P!B`&4`(`!0`&@`;P!T`&\`<P!H`&\`<``@`$,`
M4P`V`````0`X0DE-!"(``````7Y-30`J````"``,`0```P````$%W````0$`
M`P````$"H0```0(``P````,```">`08``P````$``@```1(``P````$``0``
M`14``P````$``P```1H`!0````$```"D`1L`!0````$```"L`2@``P````$`
M`@```3$``@```!X```"T`3(``@```!0```#2AVD`!`````$```#H```!(``(
M``@`"``O=U0``"<0`"]W5```)Q!!9&]B92!0:&]T;W-H;W`@0U,V("A7:6YD
M;W=S*0`R,#$U.C`S.C`S(#$Q.C,U.C,Y``````20```'````!#`R,C&@`0`#
M`````?__``"@`@`$`````0``!;"@`P`$`````0```D@`````````!@$#``,`
M```!``8```$:``4````!```!;@$;``4````!```!=@$H``,````!``(```(!
M``0````!```!?@("``0````!``````````````!(`````0```$@````!.$))
M30/]```````(``````````#_X0&`34T`*@````@`#`$```,````!!=P```$!
M``,````!`J$```$"``,````#````G@$&``,````!``(```$2``,````!````
M``$5``,````!``,```$:``4````!````I`$;``4````!````K`$H``,````!
M``(```$Q``(````>````M`$R``(````4````TH=I``0````!````Z````2``
M"``(``@```/``````0```\`````!061O8F4@4&AO=&]S:&]P($-3-B`H5VEN
M9&]W<RD`,C`Q-3HP,SHP,R`Q,3HS-3HS.0`````$D```!P````0P,C(QH`$`
M`P````'__P``H`(`!`````$```6PH`,`!`````$```)(``````````8!`P`#
M`````0`&```!&@`%`````0```6X!&P`%`````0```78!*``#`````0`"```"
M`0`$`````0```7X"`@`$`````0`````````````#P`````$```/``````?_A
M1GUH='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O`#P_>'!A8VME="!B96=I
M;CTB[[N_(B!I9#TB5S5-,$UP0V5H:4AZ<F53>DY48WIK8SED(C\^/'@Z>&UP
M;65T82!X;6QN<SIX/2)A9&]B93IN<SIM971A+R(@>#IX;7!T:STB6$U0($-O
M<F4@-2XQ+C(B/@H@/')D9CI21$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S
M+F]R9R\Q.3DY+S`R+S(R+7)D9BUS>6YT87@M;G,C(CX*("`\<F1F.D1E<V-R
M:7!T:6]N(')D9CIA8F]U=#TB(@H@("`@>&UL;G,Z>&UP34T](FAT='`Z+R]N
M<RYA9&]B92YC;VTO>&%P+S$N,"]M;2\B"B`@("!X;6QN<SIS=$5V=#TB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+W-4>7!E+U)E<V]U<F-E179E;G0C
M(@H@("`@>&UL;G,Z<W12968](FAT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N
M,"]S5'EP92]297-O=7)C95)E9B,B"B`@("!X;6QN<SID8STB:'1T<#HO+W!U
M<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B"B`@("!X;6QN<SIP:&]T;W-H;W`]
M(FAT='`Z+R]N<RYA9&]B92YC;VTO<&AO=&]S:&]P+S$N,"\B"B`@("!X;6QN
M<SIX;7`](FAT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\B"B`@('AM<$U-
M.D1O8W5M96YT240](GAM<"YD:60Z03`Y0S!",3$V.$,Q130Q,3DV.#!&,C5!
M0S8Y13-$-#<B"B`@('AM<$U-.DEN<W1A;F-E240](GAM<"YI:60Z03(Y0S!"
M,3$V.$,Q130Q,3DV.#!&,C5!0S8Y13-$-#<B"B`@('AM<$U-.D]R:6=I;F%L
M1&]C=6UE;G1)1#TB-40T0D%"14-!.48Q-T0R0D5%1$$T-T0V,T,S-$$P040B
M"B`@(&1C.F9O<FUA=#TB:6UA9V4O97!S9B(*("`@<&AO=&]S:&]P.D-O;&]R
M36]D93TB-"(*("`@>&UP.D-R96%T941A=&4](C(P,34M,#,M,#-4,3$Z,#$Z
M-3,K,#4Z,S`B"B`@('AM<#I-;V1I9GE$871E/2(R,#$U+3`S+3`S5#$Q.C,U
M.C,Y*S`U.C,P(@H@("!X;7`Z365T861A=&%$871E/2(R,#$U+3`S+3`S5#$Q
M.C,U.C,Y*S`U.C,P(CX*("`@/'AM<$U-.DAI<W1O<GD^"B`@("`\<F1F.E-E
M<3X*("`@("`\<F1F.FQI"B`@("`@('-T179T.F%C=&EO;CTB<V%V960B"B`@
M("`@('-T179T.FEN<W1A;F-E240](GAM<"YI:60Z1#$Y.$0S14,V,D,Q130Q
M,3DV.#!&,C5!0S8Y13-$-#<B"B`@("`@('-T179T.G=H96X](C(P,34M,#,M
M,#-4,3$Z,#0Z,C,K,#4Z,S`B"B`@("`@('-T179T.G-O9G1W87)E06=E;G0]
M(D%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I(@H@("`@("!S=$5V=#IC
M:&%N9V5D/2(O(B\^"B`@("`@/')D9CIL:0H@("`@("!S=$5V=#IA8W1I;VX]
M(F-O;G9E<G1E9"(*("`@("`@<W1%=G0Z<&%R86UE=&5R<STB9G)O;2!I;6%G
M92]J<&5G('1O(&%P<&QI8V%T:6]N+W!D9B(O/@H@("`@(#QR9&8Z;&D*("`@
M("`@<W1%=G0Z86-T:6]N/2)D97)I=F5D(@H@("`@("!S=$5V=#IP87)A;65T
M97)S/2)C;VYV97)T960@9G)O;2!I;6%G92]J<&5G('1O(&%P<&QI8V%T:6]N
M+W!D9B(O/@H@("`@(#QR9&8Z;&D*("`@("`@<W1%=G0Z86-T:6]N/2)S879E
M9"(*("`@("`@<W1%=G0Z:6YS=&%N8V5)1#TB>&UP+FEI9#I$,CDX1#-%0S8R
M0S%%-#$Q.38X,$8R-4%#-CE%,T0T-R(*("`@("`@<W1%=G0Z=VAE;CTB,C`Q
M-2TP,RTP,U0Q,3HP-#HR,RLP-3HS,"(*("`@("`@<W1%=G0Z<V]F='=A<F5!
M9V5N=#TB061O8F4@4&AO=&]S:&]P($-3-B`H5VEN9&]W<RDB"B`@("`@('-T
M179T.F-H86YG960](B\B+SX*("`@("`\<F1F.FQI"B`@("`@('-T179T.F%C
M=&EO;CTB<V%V960B"B`@("`@('-T179T.FEN<W1A;F-E240](GAM<"YI:60Z
M.48Y0S!",3$V.$,Q130Q,3DV.#!&,C5!0S8Y13-$-#<B"B`@("`@('-T179T
M.G=H96X](C(P,34M,#,M,#-4,3$Z,S4Z,S,K,#4Z,S`B"B`@("`@('-T179T
M.G-O9G1W87)E06=E;G0](D%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I
M(@H@("`@("!S=$5V=#IC:&%N9V5D/2(O(B\^"B`@("`@/')D9CIL:0H@("`@
M("!S=$5V=#IA8W1I;VX](F-O;G9E<G1E9"(*("`@("`@<W1%=G0Z<&%R86UE
M=&5R<STB9G)O;2!A<'!L:6-A=&EO;B]P9&8@=&\@87!P;&EC871I;VXO=FYD
M+F%D;V)E+G!H;W1O<VAO<"(O/@H@("`@(#QR9&8Z;&D*("`@("`@<W1%=G0Z
M86-T:6]N/2)D97)I=F5D(@H@("`@("!S=$5V=#IP87)A;65T97)S/2)C;VYV
M97)T960@9G)O;2!A<'!L:6-A=&EO;B]P9&8@=&\@87!P;&EC871I;VXO=FYD
M+F%D;V)E+G!H;W1O<VAO<"(O/@H@("`@(#QR9&8Z;&D*("`@("`@<W1%=G0Z
M86-T:6]N/2)S879E9"(*("`@("`@<W1%=G0Z:6YS=&%N8V5)1#TB>&UP+FEI
M9#I!,#E#,$(Q,38X0S%%-#$Q.38X,$8R-4%#-CE%,T0T-R(*("`@("`@<W1%
M=G0Z=VAE;CTB,C`Q-2TP,RTP,U0Q,3HS-3HS,RLP-3HS,"(*("`@("`@<W1%
M=G0Z<V]F='=A<F5!9V5N=#TB061O8F4@4&AO=&]S:&]P($-3-B`H5VEN9&]W
M<RDB"B`@("`@('-T179T.F-H86YG960](B\B+SX*("`@("`\<F1F.FQI"B`@
M("`@('-T179T.F%C=&EO;CTB<V%V960B"B`@("`@('-T179T.FEN<W1A;F-E
M240](GAM<"YI:60Z03$Y0S!",3$V.$,Q130Q,3DV.#!&,C5!0S8Y13-$-#<B
M"B`@("`@('-T179T.G=H96X](C(P,34M,#,M,#-4,3$Z,S4Z,SDK,#4Z,S`B
M"B`@("`@('-T179T.G-O9G1W87)E06=E;G0](D%D;V)E(%!H;W1O<VAO<"!#
M4S8@*%=I;F1O=W,I(@H@("`@("!S=$5V=#IC:&%N9V5D/2(O(B\^"B`@("`@
M/')D9CIL:0H@("`@("!S=$5V=#IA8W1I;VX](F-O;G9E<G1E9"(*("`@("`@
M<W1%=G0Z<&%R86UE=&5R<STB9G)O;2!A<'!L:6-A=&EO;B]V;F0N861O8F4N
M<&AO=&]S:&]P('1O(&EM86=E+V5P<V8B+SX*("`@("`\<F1F.FQI"B`@("`@
M('-T179T.F%C=&EO;CTB9&5R:79E9"(*("`@("`@<W1%=G0Z<&%R86UE=&5R
M<STB8V]N=F5R=&5D(&9R;VT@87!P;&EC871I;VXO=FYD+F%D;V)E+G!H;W1O
M<VAO<"!T;R!I;6%G92]E<'-F(B\^"B`@("`@/')D9CIL:0H@("`@("!S=$5V
M=#IA8W1I;VX](G-A=F5D(@H@("`@("!S=$5V=#II;G-T86YC94E$/2)X;7`N
M:6ED.D$R.4,P0C$Q-CA#,44T,3$Y-C@P1C(U04,V.44S1#0W(@H@("`@("!S
M=$5V=#IW:&5N/2(R,#$U+3`S+3`S5#$Q.C,U.C,Y*S`U.C,P(@H@("`@("!S
M=$5V=#IS;V9T=V%R94%G96YT/2)!9&]B92!0:&]T;W-H;W`@0U,V("A7:6YD
M;W=S*2(*("`@("`@<W1%=G0Z8VAA;F=E9#TB+R(O/@H@("`@/"]R9&8Z4V5Q
M/@H@("`\+WAM<$U-.DAI<W1O<GD^"B`@(#QX;7!-33I$97)I=F5D1G)O;0H@
M("`@<W12968Z:6YS=&%N8V5)1#TB>&UP+FEI9#I!,3E#,$(Q,38X0S%%-#$Q
M.38X,$8R-4%#-CE%,T0T-R(*("`@('-T4F5F.F1O8W5M96YT240](GAM<"YD
M:60Z03`Y0S!",3$V.$,Q130Q,3DV.#!&,C5!0S8Y13-$-#<B"B`@("!S=%)E
M9CIO<FEG:6YA;$1O8W5M96YT240](C5$-$)!0D5#03E&,3=$,D)%141!-#=$
M-C-#,S1!,$%$(B\^"B`@/"]R9&8Z1&5S8W)I<'1I;VX^"B`\+W)D9CI21$8^
M"CPO>#IX;7!M971A/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H\/WAP86-K970@96YD/2)W(C\^
M_]L`0P`!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!_]L`0P$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!_\``$0@`M`'!`P$1``(1`0,1`?_$`!\``0`"`@(#`0$````````````(
M"0<*!08#!`L"`?_$`%80``$$`P`"``0#`@<*!PL-``4#!`8'`0((``D1$A,4
M"A4A%A<B,3@Y>+:W&",V05%U=WFU\!DR-3="88$D)28S5W%VD:&TN"<T1V9T
MAI66I:>QL\'_Q``>`0$``@(#`0$!````````````!P@&"0,$!0(!"O_$`%L1
M``$$`0(#`P4)"@@)"@<```$``@,$!081!Q(A$S%!"!0B46$5%C(V-T)Q@;4)
M(R0S-5)U=I'P-&)R=(*AM+8E)CA#4['!T?$71$945F65HK+A)T5WA(62I?_:
M``P#`0`"$0,1`#\`W^/")X14,>_/KJ^J!HOGZ@N7Y@O6%W]OWX'H45<#7XZD
M:K@_Y<L6GDJCJVO]^;RK9LH)%"7;;*)!BR(&"(5Z//LQ+U#$=?:NJ:!T5JK6
MMZO-<JZ7P62S<M2!P9-;\PK23LJQO<'-C=8D:R$2N:YL7/VCFEK2#[>FL)-J
M7/X?`5Y6039?(5:#)Y!S,@\XE:QTSF@@N$3"Y_(""_EY002%0$]]5P^!B]['
MYTZ9Z<K;KT.A^=ANB75T2\@;E<T:Z_=8S8#++O+4A'S[_7*1AFU1UVPT<;X=
M:F$='#)]J/TU]T(XJ5]:0Y'56/P%_1=F\&WM.X[&BK;QV-DE`<_%91TQM3WJ
MD1YF^Z+YZ]MS71N;6$K98+L9;R9=&RX%]7#V<E6ST5<FOE+5HS0V;3&$@7*@
M8(65YG^B[S5L4D+2'-,A:6OV6?33[*W??U#2"*W$/0A79_,9=K575%>*:-6*
MRDJ8)K,AUG@AK?":2<3L7(P@^0T9I:L!9YF;$L<K"&X<@1W$8'.XG4^%Q6HL
M%=AR.&S5"MDL;>KNYHK-.W$V:&1O<YKBQP#XWALD4@=%(ULC'-%&<ECKN(OW
M,7D:\E6]0L2U;=>0;/BGA>6/:?`C<;M>TEKVEKV$M<";B_/6723PB>$3PB>$
M3PBASWKVU4/KVY>LCJ"YG>^X"%,4VD<BK%=%*06+/2_SM8A7\836^;*I>1$L
M8T57U172"AFY:1D$]109^JF)`!).P'4D]``.\DHM.4)RWT'WX@OU![%>@^A=
M;-M!5:5P>CJWLR05O77-\3*J;NXQ$HU&ANVS=O(1HI1AL5<.&R+O#O7Z,CP<
MD")(T]U0\<_+VU1BM<7M/<(H=/OT[I^W)1L9[*4WY5VH[M=P9:DI-99KPUL.
MR5LD%66(RV+K&>>LLQ13Q0QW.X>>3?A[>GJ^2UL_)#*9.%MB+'5)Q3&*@E;S
M0LG)CDDFO%A;),U_)'`YWFYB>^-\CK7_`$?=+='5]U1T/ZO>BKBEG1@2MJAC
MG1W-5P6$\4*60UJI_)!\)D->3DZXV</9"L#.&!68^0?NUW**+(WA+=`.["!`
M5\/)[XP,XX<-,9K=V-;B,CYY<P^:Q\4CYJL.6QW9&=]*60=JZG:@L5K<+)2^
M6N)S5DEG?`9Y:X\3=#NX?:LMZ?;;=>J]A!?H67M#)I*5KG$;9V-)8)H9(I8)
M',V9*8^V:R,2=FW:!\FY1^GA$\(GA$\(GA$\(J_?:CUV;X0]?73_`%7%AK4K
M+ZN@376$M7R/W(Y.<SF4Q^N(41*-,_H\%!I3+Q)<HQSLGAZ/8N6GUD?K?5T(
MOF5R!K;]TR3%V7IT+>$_OPXIB0N;/<V7)FIN.%7F</4FT1^U>Z-P`T.HIJ@+
M'BT6@YD@@FB+8C6>C=FWO;IKR:M&NTS4&?FR=G.W:45BQ?J6_-X:,]B%LHAI
MUPU\,L=8N#.TM-F=8<UTG+"U[8HZL9OC5J)F<L>Y45*'%U++X8JD\`FDM10R
M%AELS<S9(WS`<X97=&(0X,YI7-,C]Q/\.][=)U=CTUZ[^R9Z3F'25>BR$IHN
MVY8[T4,7U4C%/19V%,$7.^79RRH$AJY=N7CA9Z7D<4;OGS]5V_B!XR3J)KS1
M>2T%J2[I_([RB$B:A=$9CBR./E)->W&TEW*7`.CGC#W]A9CFAYW\G.ZPFE=2
MTM5X6KF*8[/M08[58O#Y*=N/;MJTA`;ORDA\;RUO:POCEY6A_*-L/S#5D:>$
M3PB>$3PB>$74I[.X?5T(EUDV%(A<1@D"C9J7S&4FW.C,1'HU'A[@J:,$72G\
M%%H/'M5W*V_Z[?(GG&FNV^==<D7S/N_?9=T+[5KNF<V9VA;E0<7@BZX"A*-B
M<K*PG24@Q&^S7-EV8B"<-OSR2R-WHN1;MB6S_2,H+Z@`[C1N/=$#EFN#/`VK
MK+'.U-JQ]ZOAI9'PXFC4>*\^1[(EDUR6=S7NCILD!AA;$T26)62O[2.*-O;P
MGQ)XHS::N-PF!96FR3&-EOV;#3-%2#P'15F1-<P/LO81+(Y[BR&-T;>1\DA,
M,M_1MW]TARMWC0W)4KM^P+=Y4ZI,&J['0BR)(1F#^HK'U#N"D3D,$*F%')`6
M))E6R`,R!9N6P5RQ,/BSQ@N8&#GFV.<;N%%+AS<Q=W"VIY\+FC9CBKW'MDM4
M;=40ODB[9K8^WKRQSM="]S!*QT<C)2[T'O\`8X8Z^LZRJWJ^2KQ0Y+&]@Z26
MNTL@M03F1K)!&7/[*5CXG-E:'EC@YCXPW=S&_0W\@A2HGA$\(J_O9_?MK<X\
M:6%.*$VWVOR2RRG:>I%L@+CAQZ[LV[;A@U5QU,<&F#AI%23]MF5N2+9M(W34
M%\[+ZIATV').7"1%33`_;?>L!K;:7V\;G5G2"F97[)IW*81J*I:NIG+H#RA)
MJVYVJVF+J7@\'GU>?MM,^@KJC;)A-.>Y*TBC=VQ%(K%IHFS/A7I%(&9>[>SX
MW'[@!*<C0L+=%,R;K92<@I#U"@SK"-5)Q_6E,SBR)\I9NE).')B<*26]H95`
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MZUW(LBS/W?/(.QDL[(<Q-"-0.(3W&8J(X+N]-:RK`E7"IUM7\R;RFM,5:H.K
M>OK-N%56L*VFVL_F)I4KL&>G(,/Q(6;%`BX-;WASZ"3*4#[XXS85U`:ZL[J*
ML[(F$2Z-:V0;#D.8.17?7LN7C<1_<[$4)1^3QU!E7$XV6DH$7'K%-"QL7+3Y
MG@@Y8D7C=^V^UI838U].J>;\XR^-]!<Z@Y<1JV]XA="7[&F:`M+MNWXI(G4M
MH(6.$N87S[5(P%9[`2QP7;%[$5;1*:A,!QLJ+$4S?77[#I_W";L(1.N:=.?M
MHG2O*UY@_I6XE:3DE'>IXG-9?'8]*$D:\@K>*R\$%B#0X[$LG<H35`2V.NB#
MD&54<ADB*TCPBU'Q/MO[#&V)TA8$QDTGTHMW3/LEMOGR'KP2CQJ,MB-"W;%Z
M#YI=TC-(RQF4Z0E1"9G]4I>4Z+B&8H:7?B=(3&YNEJ]RD13+D7NQ-427D4;L
MKGHQ,JSJX+UK#MKR:6_&WMAV_8O#\;K,/8IA&K054QR)!@,[N"?L*L:R)O*Q
M3%A-UUUT(@QCB:>$R+#!/VE=-1NWKOD]UMV]9QFJ[L6A9JG*:M*O[4A$6CO&
MO#UG]F]4H+VO*J##&90K/'DPI6HIBP'@(N8ADM;(#XI*V>[`KM*B+/0#W56@
M5?F:\-<=1*#7CI*HBR"1*7=1Z,ZW$0I]R%_=G63);5M=M13G>"FZEK)40*DL
M7`PB>(N97*`+)L?T%X*EQY%F"Z>V[OM;E?UJ2^DG6>8+5]C%OTBP0W>LHI;!
MFJ*?E-5S>_K"+H(S"--HL8+#:PA/TOORD9T'CR!I+&4OFT1<[$4*JU]U=WP2
MI[V;2*%P+K@[S@OU_:Q"^EYJ/YJA-M<C\X6H'JB(V##6D<@EL!I?;5K6`YEU
M?0N-Q0;'J]/$H&Z)J2T+@L.:/2+.=J^ZZT(C+9Z.@?%HF40F+/>PA0683CI5
MO710HOQ#64.L6]I%(HBTI::[Q6%Q4A(WU9N"38Y)#BMD,Q89./:C2KHR((NR
MQWW4$Y-8=8"VG,0\95<TGT9J"5S.07TS&6#$+.0Y):]EW;J+J=&K7V937-"U
MFY3C<KGKJ:194K8;L6$9QMF*?X.I$6/N;O;W;1IYR[7!Z@SEBHVM-.0H'9=Q
M36X8>!F<2L#N.I)KU%%X.)KF#49'X],G%'TNW`.YDOA>`;:Q[+;=;).0(OW3
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M6\H>U+(B`!ETLU9?FM<68RW*`A<LPP&-F<C:!B<A#-/R3<2][U^CA=6X&[C;
ML=7,8#4&-LT+D/,V:ID,;D('U[$1<P[.CFAD>PEK@YI/0M<-QP5K&0PF2KVZ
M[IJ.2QEN&S`_8LFK6JTC98G[.'1S'M:[8@AP[P6GK%KBKJ5+J&J5B$D"JP:[
MZU-/JWZ"JLDBNP.5U:<:<.!9\:^$O,8(,&)!ZQ=/12;K&ZC;3#H.X76)B".$
M_P"?#RB."65X&\0LAIR9MBSIR^Z3):1S,K/1R6&D>.6"61K1&<EBWO%+(L:&
M$RLCM,BCKW*_-LTX8Z_I<0],ULK&8HLI6#*N;H,=UJ7VMZO8TGF%6V&FQ5<>
M;9CG0E[I8)=L-=,H6SQ5T%`_:IRN*<%9K48_$;ZJJ4:LHR:=`\VJJ(?M,U()
MMM=M',CAK)!$L,(O&[O8?J'"G_E7S"&8PC:;R%/*(&E\Q'P<U=>+=/ZAN%^C
MKUF7[WA]067#GPSG2.VBH9V3K4:W9L&9/*&.]U)9(8?\HGA@<S1=KG"5]\IB
MX`W.5HF>G>QD(]&\T-&[[..;TEWW,E'<\P\T8R3<RYQZ&JCJZCZUZ'I"3M9?
M6%JQEG)XN9;9UU5U27RHW(""K7&^^XV01XJW?`9&'<9PZ#G1I`:ZUU7:J8QN
M"5'%FSPB>$3PB>$7H%2HL$+)'#9%B'"AF#PJ7+E';=@,%BQS=1V_(D7[I1)J
MR8L6B*KEV[<JIMVS=)19931/3;;!%I#6A=9;W.=P9Z"(Z.MO7=QI+3,9Y/BC
MY)5,/?UOCE\L9+?Q@:YUT_,0HUVU3UB&KQOJFS9HA6"6B!+-@L'6OGRXO**&
MAM/OX4Z0O\FL-44]]17*DI;/IW3=ENWFXD808<GGXRZ*-O-VM;%=O8<R-UW'
MSFS7D]\+SJ#)-UGFZW-@\1/_`(*@F:#'D\K"[\:6.!YZF-<`\G;DENB.,.>*
M]F-2YO&Z8#SQ54TN*S3"0:'P@,N5(*YV3^[?N,?!(<$$H*;I_>FSA!1L+$,M
M-L;.G[I!/YM-<[J::E-!Z'U#Q'U;A-%Z7INNYG.7(ZL#0'=C6B^':OW)&M=V
M%&A6;+;N3D$1P1/(#G<K773U'J#&:6PN0SV7G$%#'0.FE/3M)7_!AK0-)':6
M+,I9#!'N.>5[02!N1P'K:=A>!^?^C/>E[,"3NM)QU-'XU&Z<I]LRT>2V)4(B
MZU*535T0!+*,GARQK?>,A,BV%+[L4&00,-EDD<`$W,NW!_T4\)N&>#X0Z"P6
MA<"72UL3`Y]R_*T,GRN5LN[;)92PT$ACK5ESG1PASFUJS8*K'&.!I6KW6NK<
MCKC4F1U%D0&2W)`VO68=XZ=.$=G4J1G8%PAB`#W[`RRF29P#I"%G3;\0U>T'
M8,[@Z"]/G6%-<AN5FCI_>VLT!R^9Q.+/ETDT9?.:0TA,>+Q4,@BND[?*OI=G
M1)#;Y62Q!?=LBXR*IK+2U[(^Y53.X^Q?YC&VO'.#VL@WWCAE($,\@V/H0R2/
MZ'IT*\J;!9>O5\\FQUJ.MRAQD=&1R-/SI&?C(V_QI&M'=UZK8ZJFU*^O"M8-
M<%42H7-ZVLF,")C"98&4W4''8\<:)O1SY#"R:+EOONBKC1RR>(-W[!UHNQ?M
MFSQNN@GDR\E9`\(GA$\(GA%K[=Q>]7:D.BI5R!Q;RC+.X^@*S;LE;J5%3T55
MM2T\\)):.&4<D%@E0D@:%)C]#;XO@":0AHQ6RH._/')T<9"C>[1QUW(R.CI5
MWSN8.9Y;RM8P'N+Y'EL;=^O*'.!=L>4'8KKV+=>HT/L2MB:X[-WW)<1W\K6@
MN=MTWV!VW&^VX6-:F]A]-^Y"&=!>JKM7G^<<1=$VU4AK0;74IE`B<AYV#0QL
M^;3ZE)\F'C@R5R*O9`':3+6/*!]DMD0*ST<1D#$))]PWQ;I6J,O86X'P2[<P
M:\#TFGIS-<"6O;N".9KB-P1ON%]06(;+.T@D;*S?;F:>X]#LX'8M=L0=G`'8
MCIU6EU-*BM[D>]+,XOZ,8X&VY2)+(\>6UUWT$V97"O\`#AED19=7^$_#'PFS
M)YIOG;+QMA;5F73;'6AABROOP`XFMU9@VZ7RT[??#@*T<<#GN^^97$0M;%!.
M!ON^S2')7MG8N>PU[#BYTLQ;4_BWH@X')G/8^)WN1E9GOG:UN[*.0D)?+$3M
MZ$-H\TU?J`UXFA`:UD0=U@[B=QB10>XJ:D;V$7G3$G&6!54Q%J:(OATC!NDW
MJ3!7=3^\N!I7Z/VCU@\PH.=Z;_;D$7`]9XV7RWC#PXBXAZ9?%5CC;J+%"2WA
M+)Y6F5X9O-C)7G;:O=:T-:YS@R&TV&<GD;*'X_PYUI)I#--=.Y[L/D"R#)Q#
MF(C;S;17HV#?>6J27.`!=)7=+&!SNC+?I#^IGV0P;V;<E16ZA28^-VU&M](-
MT-5J*^WWU<VL(2^D50U9.-MGJ<7E&J69)#'B^5OJAWF13ETH<"&V[36O8@GJ
MSS5;,4D%BM+)!/!*TLEAFB>8Y8I&.`<R2-[7,>UP!:X$$;A72BECGBCFAD9+
M#-&R6*6-P<R2.1H>R1CAN',>TAS7`D$$$=%9QYPKD3PB>$3PB>$6BI^(V]F3
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MT498UIQWQFRL#]S!V6JIAPDVG`^/DAD_M@@[?X3T3@U:A5WV$".NF-'DPU&M
M&"WWT2DC+?7'QIXD.X@:F+:+S[W<&9ZF&;Z0%HO<T6LF]KNH===$SL6N`,=6
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MYA!!((V(Z$'H01W@A=Q3$\(L86[2=.]`0U>N[SJVO[A@+D@P*N(79D1!3:+K
MDQ:FRHTBJ"D3$B-W>L%-]]V;K9ME9OMOMLEOIG;/Q(NE(\F\LL8^'C#;G.C&
M$6C,88PX#'VM60=F!!0\3-1-EL(R+%H!$AXZ/,K"`!9VB*;(),$Y<('2/Z'Y
MLR0=ID76Y?QIQ?<C$6^G',O.EFC-SDYGPEW(ZIK^6#W$BM_+=]8DP:+/@KYL
M[*6,HDR(2@WKLJXDJ[9@^(.':S5HLD18QM0KZQ:JF)"%78>X<K:P)4/GCTG$
MK1D%&0R8R`7?(\3&+)>NP,K?#31)C;HJ(!8]+G2C15&;#XT.$DU"+<4@@@1=
M=`^L/G()VTW[O_[\/;6"H+Z0D`G%:7CD3A2SBK&U+ZN6!:%U1&;2DVH^N$WT
M;`C;!LB8!H^S+OM0XUIAN&P*(I)[<D<L;W2XZ/5YPHQ;H)TX9O%[N7JJ$+VO
MN\'B68%B]_;]8)O*-'C,&/9!VSO0GJX0%M4&":NK5/5+PBZ^SX]XS`R:?%6?
M-G.XJ77H^R7LAXG5T`:G;4?")&QFZKZ3[_D^KV5*,Y<V'2]YN\^[UUDB+20.
MOB4U2=^$7YD58<6:2I:%2R$<U:3>5$)NY7B4A"UKI*I$4Z8#RAE82Z@$BA@N
M5?WP`KB:,Y0IEHNXL</!)2W(9+LHP7T9$76ZFYGX!(PQX)H^D.42L!$')O'"
M32L(-5A2,,)03A.M1V.&)8C`]R.0DA"OOA7<V9O-M2SJ,[[QL[HHP54:[D4D
MXA65<U^Z-/H)`X?#7LD1C3:0.XO'!`)R;;PR.L8C$&Y588T;*/T(O%1@Z.1]
M%SLHF'",6HL?JW9H)HZD7>/"*+$-X:XOKIE+Q\!Y-YQA;*P'(=Y.FT7I>NP2
M<R<1Z0LI:!4E&!L>;Y._DLI&L)&+T)Y<Z,#K-L5:ZI/D=%\$7-O>7^4I"U.Q
M-_0U%F&JX&QHW(X\O7D)>Z9CE\2-*<6H(+#MA:F=!EM2P<A+9HV<I:HS$^Q2
M-E</W[71SH18MG=">N?GRK<I6?5''=)TPGK)XIMM/XK3]<UOC-J!@,=F(!1>
M2-`\;RM8@"%1P-(AZBF5Y6+C`IB13?-A3=-$BP+?/#7"GLZK)L[B,Z@!BN"-
MB2*6RV:\U,N9)^PL*=NH,(K(P^-SN05C;>!LX#088)B[*7PHK%["CPEN/9-I
M`V18BM&9%,F=\?\`+%K5_7-5VSSW3]LUY48\4,K6)6E7\8L,-#6H4(UC@[`)
MG+QIA)DNB#9-AFSE+7#A=JEJDNHIK\<9(O!..3N1),M6\IL/G?G\MM0`_3]U
M)J4UC`UF]0B!*S0F@E#7)`/]M#A`ET*8$VK<9EB/&/!K,BW3;N6:*Z9%^I=1
M?(HH:IO.ZIY_&")?FR(.HI*XC`6`^3*=*R1M(;8B?U"S)%N77O26M6A><!<;
M.%K#.H(.S#<J]3TWP18,#0[U9R^^548\%X6E'3%M5_K)<M`R=&F[HL&KI+6*
MD7U/MF;'9U,I%!I'3I=0-DHU2<@SE=O\M]EW<>6^&2*40CG6@0!,::!TI50<
MN&EPZ?""8R`Q=B_%S@17:51"9>/=-A::S.2BZK11K@<:;[ID64(3TB[9PD&U
MPSP19E\(H^]:UW+;?Y5Z9J:`/-1\[M#GVYJ[A3_=S]GJQELVKB21J./-G>=M
M,-=6Q@FS6RYSOI]#&F5?FU^7XX(M>3T3VQ!I3P'7%'#1*T'MWE)<W2/0-4F6
M.X>6P2RA$E/N2#LZ%<:(O&^)>ML].:/5$<)JF,R`3LKN2!DTT*8<6,1D,=K+
M)6K@>Z#*R"Y0L'<LE@$<<1A#NNSJC@(71][&"*38,D83.VC;M:U@ZL4!:)*;
M>PL1#HYLG,YP>1^;,"7AW<7<[=]VN`Z][%Z3M[F*YXA[?>(X\H7O^BPV`/35
M0L?KI#NG>8]-4/VK#%&S))95Q+H:.8MB0DCHT=OM!P@<102?$81'!3S)^$.O
M/<FVS3.5G`Q=Z4G'3R.V;1O2N_$EQ.S:UQQVZGECLEK]FMFE</)UKIWSV$Y:
MG'O;KL_"8V#<V*[`?3`'?+"/4-W1;CJ6,"C'W\-A*+*JOQ#7KP:.YW1-UQX`
M%]@-4Q]'7<@XB/SLPV]JNP#3?=(19=2&V&\5LK37;;"!)BQ-+*8`D)R=>9IY
M0G!3$\<^'U[3-HQU,[1,F4TGF'-]+&YN*%[8XYG`%YQN1:?,\E$`X&)T=IC'
M6:E9S/$X8Z_N\/-35\K%SS8VSR5,W1:>EJ@YX+GQM)#1;JN^_P!5YV],.A<1
M%/*#+>'R^(V="X]-H@6'2F%38`Q.`BS3.KD<9!&6>CEJMKKOKGXZ+MEL:+M5
MT]54=_JMG22:NBJ>O\]>:PV8TIG<C@\Q4LXK.8+(3T;]28&*Q2OTIC'(W<'O
MCD9S131N+'MY)HGN8YCCLUH7J.8Q]7(49HKN/R-:.Q6G9L^*Q7G8'-=L1W.:
M[9S'`%IW8]H<"!%+@+H53TY]JH\V35XHP]</<T[4(57(B:ZF`?+W3!=-)LM%
M'A!7.R`N`6+LBP8I;/MD6HW70,4PX0;1B<$R.\7R/_*%;QET5[A:CN1NXAZ0
M@AK9@/<UDV>Q0Y8J.HXX^A?*_P!&IF.SYFQWPRRX0QY&M"W7OQQX8G0F?]TL
M5`\:8SDCY*7*"YF.NG=]C&/=\U@]*>CS;%U;FB:9'597G=0\N&H-3PB>$3PB
MU3?=_P!CRWJ&W&7IMY:DKD:I)A@N6=_6]'EM5/W64LKNV((TXS=Z:[I)S*Q6
MRHY0VRVW_P"1288`]2<BI!*]1$,<>.,F&X(</LGJ[(]C9RCP['Z8PTCRU^9S
MT\;S5KD-(D%.L&NN9*9I!BI0R!CC8DKQR9[PXT)>X@ZFJ82MVD-)I%G+WVMW
M;1QT;AVL@)]$V)B1!4C._//(TN'9,E<W]5O7<,J"OXE6<!#MHY"8*`8QZ/"6
M_P#XID,&H833V66WS]1PZ7VQN[(/G&V[E\]6<O72BCA=53;^>74^I,WK/4>8
MU/J"Y+DL[G\A/D,A;DZ.FLV7EQ;'&/1BAC;RPUJ\8$<$$<4$36QL:T;.<3BJ
M&"Q='$8R!E7'XVM'5JPM[F11-VW<X]7R/.\DLCMWR2.?(\ESB3"?FFI(][=.
MM9%:UJ/68GU2>N>0O)5+)&<=H#X-TC?L/'Y-/4RQ5[LD+<5-68?5P8E#C=5P
MP<1Y1%-TKEA8F%`&ZCR,O)W'";2/OSU/3Y.(&LJ43YH)X^6;3>GY',L5,,`[
M=T=ZX6PWLSOR&.9M7'E@=0DEL4)X\<3_`'YYKW`Q$_-IK!6'M9+&[=F5R;0Z
M*:]N.CJT`,E>CL7![#-9#B++&QR'K(B:]WG:8_M^P@I45ZZ^.Y<6C?"=8&F:
MC%E>EG!2.&LBZ0EH=VBDHX$#GPQBG%QCAOJW9N6`L#M\CP!/FT@F7B]KSW+K
M/TOBI@,C=A/NI/&[TJ5*5O2NTCX-BXPGFZ\T54\W+O8B>S`=$Z=\\E;E[D?X
M+7?^"1N'2>=AZRD'OB@=MR^#YAMOM&]IMC[&NRG.>>9+IM:^G0U.K0,!D+62
M"B?TU-9=J<'.`K.#,62OS?F12:/7R,;'C\:[X<N".N%OIMM5U4ZZ:=QN1R^:
MQU#%!YO2VX3#)'N#7[-[9'6GN'P&5FM,SW].5K.F[MMY0R=NM2H6K%PM\W9"
M\/:[_.\S2T0@?.=*3R-;XEW7IN5Q_P"'?J:T:8]0?(\1MP<4!R4B'G\\%1PT
MFND2C\(L>SYC.8*Q<I.<8<H9>18\,.)-7&B:[)$NFS5224;[):7_`%6U77>$
M3PB>$3PBT4>76SCGKO/V:<GW&P6`7W)>N+7Z:C1<PGNBO<E*VF<V,P^8`'J^
M,:E$1[)ZBZ(LVJRV!CL\]:8^=T,.89R7H6W7->W0]%MHS><C?8&:'D:P[;]_
M8N&Y;X"0$#X1&(:E@E,D%CJ8>3LO8Q_,YW7U<X(V/K;L3W+*W;G+YZ]HK#[&
MIR1.:[ZLYVD2-I<W68,62:/@\W"*MR2<;).5==D5(Y*5QS)H^3=:J-6KQ%@^
M<HNV")`81R'4&&CS%(QMV%R`%]20]/3(W="\[D=G+L`3WM?RO[FN!\K%9%U"
MQN[<P2[-F;U)`\)&C\YF^^WSF[M[R"/0Z8APG\05Z^!W6E.Q%.O/;)Z^L$H?
M;M+-D<M3ALH$4=+S>J'8MQ\";F-S]$>>E]+Y=;.<C93F2UNH_P!WCN3%V\7X
M+-972>=I9G&R.JY/$VQ*P.!VYF$LFK3LW'/#/&9*]B,D<\3WMW&^XS'*8VCG
ML7:QMU@GHY"N8W\I&_*[9\<T3MB&R1/#)H7['ED8UVQVV6L]7TX'V!&F9UHD
MHS<_,HQ,B'.-M7H0VS^"9(2]24T3537:K_'Y?JII;J(;(K9TT^I\F-G^AM8X
M[7>FZ.HL:0P3M[*[4YPZ7'9"(-\ZI2D<I/9N<'0R%K3/6?#.&M;*`*.:JTW=
MTKFK6(N;N[)W:5;'+RLN4WD]A98-W;<P:6R,#CV4S)(RYQ829/\`$';<W]5_
M7H+K"),R1^DYY^60'K>LQN_QQ(Z^<O=-6D\#--OBC^V<"=J8-AULX1V>*:O0
M:[QB,E!]YBLWE'<+^1TG$+!USL\QLU/5B;N&N(9%!F6M;W!YY8+^WSS#:+?2
MM2*;>#6N>T:W2&3F',P/=A)Y#U<T<TDN.+CWE@YIJN_S1+`#LV!B^GI6]BPB
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MKHG(I*2W^N6,/W;C=5RX7=.=MLXW7546SIC7*JBJ^RJJFS_A]HC':`TU3P./
MVDF_A&3O;%K\ADI6,;/8<#U;&.5L->(D]E7CC82YW,]]'-7ZIN:MS5C*6MXX
MOQ-&KN"VI3:]QBA!'PI#N7S/V^^2O>1LWE:V0O)/(%B^S;K2(\9UJN3"P!MA
MG,^I[4&(X41K:HF3QOL0%M72J>[/$PF&=D@<:'K:JY7)D&JCELL%9R)5A7SR
MC.*'FL,O#W!S@SV&,?J:U$_K!7<`^+#M+>Z2PTMFO;'I7,5<\PGG:R7>#>AN
MVD9J_*0_>X7.;A()&]))6^C)D2#WLB=S15=QUE$DX`,4+G7N]Z6%%.P[(B7I
M<XJ0Q`O7+Q.VB07KN;PIRMHUG<K@R^-H]S?'#Z>VV"7Y28'ZD[`.*NGA,O.4
M#1DEMEY$&RDKJ?I["/S%O9X<VE!L^S(WIN/FPL/Y\AZ$CJQG,[OY0;`97(MH
M0;MV-B3=L+#Z_&1P_-9TZ?.=LWUD3,8,8G740:#6"(>(0B#QU%HU0URW%`(S
M&(Z.U32T^939)J/%"!;3'QW4WT1;-4,[J;ZZ:9V\F=H9#&`P-BAAC`#>C61Q
M1MV'7H`UC1MOOT`[^FZCXE\KRX\SY)'$D]2YSW']I))^DE>7\-`&+2PA[-NH
M8P')A><.C.J`R]$[O&3D8/ER\`&RMC8UA@6#K1';87*BTB")[ODT==-R8DB*
M6VP^"O&[>"<O/!:R=ZQ6'WF6Q(^,[<O,">K]O#M#N_8]?2Z]5)=&.2&G6BE_
M&1PL:[V$#X/TM&S3MN-QT)"VF//.7:3PBBKW1";(LGC#JROZ<&DS%MS+GRVX
MY6`H-,75?%"%@%H.:9P]HRFC,N`6CJR\@5'I_F.QL6V3USMH\>MV:B^^"*AV
MJ>(.[(E;O.==02'=.532E*R7B![2LWDW5[)S7])<TUS#&TJZQI^SZPCM\S%[
M:ET6E8S@[5HP*2B]DU9%ZV<Q4=`9W$X=!1HA8BF_[)>6.FKIO`;<//->QI])
MZ$X1[(THZ7$G<"1>%NP;DTKF$U:'RVDKQ)=-S$((%GIR.GY`V2B`N0FQJ+HH
MVPN^UU(HD4=P=VK*)F!AEA/.RJ9Y/DG2JDNE$9F?=4AF5Q#*#K3C=W&8]'Y+
M8<,NZ6R06\Z#ZDM:;S.QHK7TE>LH_K"6K-$BQ%"($9P15Z\^/?8WTRPZ7/<^
M2KH@A9\>I&(1:YI6(Z<Q8<%LBV+I[,8F[>(\XAUKS$4;`9-4_)E:OX-6\6&3
M2G9]&@4G8Y/+P68FPQM\16K\O\!V[%.R>/K7MD/UO+(+57._1!`%)+*Z!0^G
M3ESVE>;.5,J[E\$`=.V:^(0<?6@W`&)"=)9T$B6:%PPFSI:1_=]&=HR18V`^
MNSJ(O[%KK[JZ$K#%GP`-(;RF=<4K"YD<1D]C(-Q[[G6AX4,:S7L%.G17RU$C
M8-KO$IA'8[&6R71LYA;])JH8Q%:T(K(O4!2-D\]\21>M;AI%S05FZ6A>DVF$
M%R3K,J(P1M&VY;9;=U%%:HE<MB[:(C1<L81$`/W<B2+%G%]4%03!EJPW<D5G
MWA$\(GA%K+6AQYUV&Z`ZYMV-4AU!*HW=W>D%,6L%JCK,7"CUW<01CFW["%1&
MHGQSHN&ZP%4=TF'8/;2R[<57,15921Q`ZU)&(6D:!MB*6D[Y,Z_/^D@SR'*]
MD[=ZYG%(O:N+KR:<,)<XC>;:F3@(926LN?/T<RE]2-23(B&TF+XDN=EG[$Y>
ML%R9<NWU=D4."?)'L5BW3\[E=45U=D;A]5S+HI]4JT;Z?B\+YYFM(Q'D<E#^
M-:0B=`A[4'!\FY!?KII-[>G=D0"/$6$I8M]]Y`<C#]]^2D44NE:OZ)I*Z.:N
M)0]N]8V'95@U+QB'!S2.=IV(K-(A=]E7+B+=N7]9D:96LC9,MCS.DH$*%01J
MUC1ND*^#.)X>^M%9.]W=GR+*5C\%>Q.^*;[3>W\RZSF%J66:6@Q.HHI=T$B-
M(6M3<I[$A$A))U8GCK,F*?/J^Y<B;\)#!,AK_ED,]'RR20Z?H64<D!HS@BF3
M[6?7]U3U?&N5Z'YPV=1NG*E@9A(G*YU8]EGI_'IQ*G-?T*")FI0SZ>A,CL,[
M6-0S^U[R7D<LS/'I*45*UC.2<Q5M0D%7(NT\U<KVH0[P@,IN'CV04S2'$,1E
M]7\4RF.2*D3\4E:&M?1VF']XV]*-+QFG0\CF<VK@"E%:L@,DB+P;6T(3RO-Y
MG)IJ[:KQXBOE\(GA$\(M8;VX\S6'P_T"R]T?(4;>EV8<<-BWL<HF.I_(E<5&
MME&;;]\PH<GLDV_;^M&2"*Q<FI^N!H\5(G2K80)G6)%B>L]*5-7X6?&SAD=I
MG-/CK9&[JMQK2&.)`+C!+^+L,&_/&>8#M&1N;[."S$V$OQVHRYT3MH[4(/2:
M`D%PV/3M&?#C=TV<-B>5S@;(Z9M^N>A*I@ESU1(F<NKBRHVPDT6.-<9QH]&$
M$LYV0=ME<868$A[C5P,,BGFB3T45:/1C]!%VT72TH_DL?;Q-^UC;\+J]RE,^
M&>)W7E>P][2.CV/!:^-["6R1N:]I+7-)L!5LPW*\-JN\203QMDC>/%KO6.\.
M!W:YIZM<"T@$$*C[1^(])G7LDS+A38QZ=O8Q*7T2MZ#OQR9:%\J7Y-F"PYT<
M7`N--AK.G;(&[OQ\E'(M\,4HXDX9[M-M8+&1DAM7PHUW[XL>,+DY>;-8R!O+
M*\^ED:+"&-GW)W=8K[LCL[^E(#'/NYSY>2'=9:=]S+/G]1FU"V\\S6CT:MAV
M[C'ZA%+U=%MT:0Z/9H#.:NBH+JH?@GV+7MZW*\NT1;7*Y:PMG'.4O&$GQT92
MEC2]1R5*\QR&6N=/RHFX8/\`[H6*>!R19M^T""+<@NG)STF8@J@>77Y._OFQ
M$O&31]!KL_@*@;K6E6CVER^`JLVCS;6,;O-?P<0Y+CG;OFPS0\O`Q<<<LY>3
MMQ0]RKK="9RR1CLE/OI^Q*[T:62F=N_'ESCLROD'GFK@;!EXEH!-PN9:+T?S
M_`>H*:FM*60R^YCTP&[((OD4T]B4<.-L_<`I0%54QG"!<$2T0?-=O_%.-=%F
M+S59@[=-UM7G#+B+J'A5K;!ZXTU/V>1P]GFEKO<X5LE0E'9W\7=:T[OJ7ZY?
M#)TYXG&.Q"YEB&*1EO-6:7QFL<!D-/9:/GJWH2ULK0#+4LL]*M<KD_!GK2AL
MC/FO`=%('12/:Z7?HK]@$]F@Z8>M/L,_LX[,Y'%)H1N5$EEE,]$\ZM,L6<*L
MX22>;Y<&SP%@]%A)9LO\2CEHH%,E%'9]66_EW]%'#3B'I[BIHK!ZXTS.9,;F
M:PD=7D+?.L;>B/97L7>8TD1VZ-EKX)0-V2M#+$#I*\T,C]7NK=+Y/1N?R.GL
MM'RVJ$W*V5H/8VZSQSUKE<D>E#9B+9&_.82Z*0-EC>UNQ=YG:QQ/"*ICW`>R
M-CZ\><4%8(S0F?6E^$E:KY,JE-'5^]E%E%MF0W]J2`WYM=E8E7^3`\R;^KLD
MW)$%P<9V<M-S^KUKYV7RV-P.*R.;S%R#'XG$4K.1R5ZR_D@J4J<+[%FQ*[KL
MR**-SSL"X[;-!<0#VJ-*WDKE7'T8)+5V[8AJU:\3>:2:Q.]L<4;!XN>]P`\!
MON2`"51#Q+R\_P";ZW+D;#D+BP^C+DD+VS^C;8*.U2IJ<65(5W!$CKN9=::O
M7@<&N]=,Q?U<):.7"A(UELV<F'2.O\^OE)\<\CQTX@VLTUUFMI/#]KC-'8B;
M=AJXP/!DOV8&N=&W*9>1C;5YP+W1QBK1$DD5&)YV9<*N'E7AWIF''[12YF[R
M6\Y=9U[:V6[-K1/(#C4I-<8:X(`<XS6.1K[#PH->V'L[,,&(<H5O(Y%'I!,V
ML?*],6K$(P<F"O-O-TADP.*2&;&64>TV=M7YK,B8LFJ65FSC\M>HM$%F1:51
M1TM87R'?)T]^^>CXL:PQ[9=(::MD:;I6F`PZ@U+5>TBTZ)P(FQF!>!(XD=E9
MRW80;RLI7X%&/E"<4/>]C7:-P=HLSF6AWRD\+O3QF)E:X&(/!^]W,BW=C0/3
MBI]K(0QT]:132L\G4W9`VB_1YZJYCJ/]>U(06#3GN_I6OW^JR,YB9[+65!ZB
M!2]DBDT.3RW":[^462^PWRFYD;MTP=M=!L'FL6>[7]>:RK:.PS[1Y9<E;#X,
M55/7M+`;UGE;N#YM5YFR3$$%Y,<+2UTK7"F&G<'+G+[8?295AY9+DP^;%OTC
M8>[M9MBUF_P1S2$$,(.PS!X3`J;KV-0&#A0T&KFN8PP`1X*QU38!(W&(\QU;
MM4--U=\:I-F3)OA1P[=+;**;:K.W:ZBNZJVU)[-BUD;<UJS)):N7)WRRR.W?
M)--,[=Q('>YSW$!K1L.C6@#8*?(HH:T+(8FMBAAC#&-&S6,C8-@/8`!U)^DE
M4G4+`7_O:[70MR1(K//4SPU8>Z%?`'Z2Z(7LGIR.Z:;JR=^,63P@<JJ"8>:_
M3T?ZY9D1Z[81AJYUFLS81ZW7"[0@TKC/=#(PM&>R,8,_-LYU"J2U[*+3X2$A
MLELCX4H;%N6PM<Z%=7:B.8M>;57GW.JN(CVW`LRCHZPX>+1U;"#W,)?L#(0-
MN[77737733773337&NNNN,:ZZZZX^&NNNN/AC777&,8QC&,8QC'PQY*JPY?K
MPB>$3PB>$5'/NM]:<J[$K.(='<N[M8IWUR<LZF-$2A#9)BI8T<2^JZEE%2ES
MG&J)(-+V>SS]FVQ;?`YK(G"PMRZ&`)9*7"O8JVIZ5B*U6>8YH7!['#]A:X?.
M:X;M>T]'-)!Z%<4T,=B)\,K0Z-XV<#_40?!S3L6D=00".H547'74\8ZUIT?/
MQC%Q&9F#>KP^VZZ)I+-3M<68$T31DL7)LG>J;Q)%)W\S@4X<I)*N1RJ/W*38
MBB_8M)NQ.4@R]-EJ'T3T9/%ON89@T%S/Y))YF.^<P@]#N!'-^E)1L.A?U;\*
M)_@^,D\I]CNFSAX.![QL3@&\'EJ>O3IN.^T[F$4^,,0C1G&>Y*2#*Y0:7?1*
M:K5!]+$6&OR-=IS`&26";(TM_#9?E8HJXV_*!LF9G<5UA@NW8[+56??8VCSV
M-H.\D;0`VP`!\.-O23UQM#NG(=_;P&2Y"*,[O1<?P=Q[FN)ZQ$_FO)W9ZG;C
MYPVK(]U9'B*#=951V1Q/;\1EE:]Y5PG=]T4W%$'RI&MCQ$BD,Q;I,8T9;,89
MM-S:[QM*(>8<M),QG8B9**#MTC#),;ZG!OB5-P]U(SSR64Z;RSHZV:KMYGB#
MKM!DX8V[GMJ;G??>1I?-4=-$&ND[$L\SB/HN+5^%>((V#,T&OFQDIY6F0[`R
M4I'NZ=G9#=F%Y#8IQ'(2&=H'0WWT'&QFR:F&Q$649YUVUS\CAF^8O$,XSC.,
M_,FNW<MU?U_XVBB>_P#'G7/Q\V0.;3RE%['-@OX[(U2UX/)/6N4[D6VQ'5DL
M%B%Y'BU\;^[TE3`.LX^V'-,E2[3G!:?2BFK6:TF^X[G1RQ2-!VZ.:]GLZ7S_
M`(<SV7.N6[>;>L?H25N,TM;9MV4XNEYURHLVAD_-/]G)RB7;]?;.C,7,2#S8
ME#4=]DT$9HX<,DOK/)ZW1'ZUN+W#BQP[U+)!"U\FG\HZ6U@K3MW;0!P,U"9Y
M'\)H.D;&XDDRP.@L='2N8RZO#W64.L,(R:1S69:B(Z^5@`#?OO*>SMQ-!Z06
MPUSVC8".5LT(W$;7OWN?(H6>IX11D[%ZUI[AOG&S>G;T-;"*_K,)D@X;-/I*
MG).<>*Z,(W#(NR651U?R65&G#,.);;*I-TUG.STBX9BVCYZV(OF(6;=]P]I]
M"V1VQT6XV5LFV7'TX=%,.'"P>HJH9J;_`+'5U&&[G]6#$:.4TV=;:))."#Q=
MZ9)_,=-G5G-^/)]X7^]?$^^W-5PW4&;KCS&&5OWS%8B9HD8""/O=S(#EEFZ\
MT5<0P'D>ZRPU/XNZY]V[YT]C)2<5C)CYU(QWH7\A&2QQ!:3SUJ9+HX_FOF[2
M4![6P.6*K-F1B.L!X&%@BTOLR;.\Q^OH='Q3T\=.'7&-=$_L`HU%R0(_:?53
M5RU:-EE7*^[=IIK\7'SZ9_Q:XBU>'6FI+;'LDSN2$M7`U';.#K+6CM;LS-^M
M6@'MDDWV$LKH:^X[;F;B7#[1LVL<TR%[7,Q5(QSY6<;M(A+CV=6-WA/;+',;
MMU8P2S=>SV=>CS;UK1W)'J^I;DGU96.VMWV4^R/+XW?UPI,W0R34&IC#X39$
MGGF5]=C40S5@S8S&:E8*:J86VQ([@#ZK.3#!"2:VV-R.?RCW22RW,AD;$D]B
MS,YSY))97.EGLSR'<GJ722./4]P!)`5T2:F+I-:QC*]2I"R**&)H:UD<;0R*
M&)@V`Z!K&#H!XD`$JPCE+F>"\ETM&*?@VN[O`[50K+92\TQ@U.YP4T1WD<Q.
MK9W555?%726NB"2JZ_Y<+;#Q2*V[=@CGR:,=CJ^*J14ZXW:P;RO(V=-,?QDK
M_:[8`#<\K`U@.S0H^NVY+MA\\A[^C&#NC8">5@^@=Y'PB2X]25&*?1&P_:CU
M>U]9_/T@*QNG(/N,EWL'O`#G.B<0KW5TCNRI:-E?E5:JSB<K)+CEV&=%M=7"
M:B3Y%T%C<[':X5K#.[!V(J/Z[_ATC3];:P(/7OWFV[ND?C*#D.`QG07IVCK_
M``9I'=UZS$?U1^S=WYA6Z]4=35W1%80.FJEBHR$5K6D8$PZ%14.EE)@&`A6N
MC1DVTSOMNLY<;ZZ9</G[M5=^2?+.2!!PY>N7"ZD<K+%D7PB>$3PB>$3PBA1[
M([=G]`\`]EW;5)O6-6757-MO3R!R'8<,,8!RN-0HN4!E?RLTS(""&S!^W0<Z
MM";%XP7V3PFZ:KHYW3V(LT<RS60V3S=S[8LM=)/I5/J0JB:R9\BV09(O)#*8
M&`.FG23-KHDU:)."3]RLFV;)IH(:;X21TT3TUUP19O\`"+^9SC7&=MLXQC&,
MYSG.?AC&,?KG.<Y_3&,8_7.<_P`7A%4=:_NUX8@=CF:7JXM;O8UTQU95L?J[
MB>G9CT8<".4-U$G#8M(8DU3KU@Z9K)+($6;B::/!BR*R9%NUW14QJ18EF/OD
MI:G0^9ETOP_[/.6JN0=,69.WKNY$=#ZX!*DW23(?^>F(5.)L_&?>NUD6K1-8
M3E=TZ52:MD57*FB6Q%Z\7_$"\EW,1D+7C_G[O7N83$W;8?)IARURI)I'#@3]
MVWRZ;,"AFPS-:[,WR[?519NT7::+ND4]UVVBR&,*Y(NY#?>UQS')&&BW45>]
M<<%DI&\2'Q]_VGS3-ZEAQAZKO\F$D+#$YF4!9HI[?'"Y`O)1HQOC&<KO$\8S
MG!%<6`D`&6`Q,FBQL1)8V?'M2P*0`"3,P$-"GR.CAB3$E1RSE@1'O&ZFB[5X
MS76;N$=]5$E-]-L;9(N7\(GA%6=ZB^B;:ZGXBBER7=(T978):X>HHR],MPP8
M`EN"K[I>V('#V&@P`Q'#4]0\3C@41JOJUPZ>:,=79!=V06<NUB*S'PB>$3PB
M>$3PB>$7I$AHXR.?B"[!D5$E63H:4%DFJ#X>2'/D%&KU@_9.=%6SQD\;*JMW
M35PFH@X04W25TW3WVUR1:B"D7*>BGN)*FS;EPW]5/<L]?O>?)$]<;;@.1>BS
MF^7Q:HC)%THIL%KV6_*HM'EWRZ;%)AHT*X5PO&+(+O(8XM:$]WJ)S^+@WS&.
MB/G,4;=WY&A&"2T-;\.U5&[X>G/+%SP#G<(&MSK1FHO<ZP,;;DVHVG[1.<?1
MK67$`.W/P8ICLV3KRM?RR=!VA-SEZ4A6?251SRD;?C;*75U9$?=QZ1!GFFFV
MVS=SC&[4D.<[:;[CC85\DV+@2[;Y78DNR9$F:B3ELEMBK>+R=W#9"KDL?*^O
M<IRB:&5FX',WX3'-!'/%*TNCEC.[9(W/C<"TE2[;JU[U::K98V6"=A8]I]1Z
MAS3\US3LYCAU:X!PZA:VO)_(-.I0+HK\.QUZ`AM?65(I!).FO79UT'C(X(8M
M8HDF0<QZ5NBK+5J_>V[7"8YV,-"OS54B9KK290)L\;BX\#)';P:4U+CM:8&.
M_$R,]JPU<G0E#91!8,8%BM*QXVD@D:[FC<YO+-`\<S0[G8V`<SBK6!R+J[G/
M'(X35++-V&2,.WCE8X;%DC"-GAIW9(T[';E<>[<2WI:)5S9G)'58[:+=G<FF
M=8+;X=WOIC]N0:?RZQ*W(ZIG1'4N#EXC<>]<%6266KI5Z..IZ-&$G$MM=)?E
M?^3V[@SK;W;T]4<WA[K"Q/9PG9M<Z+!9,??;^G97G<,CCYC:Q!>09<<70-,L
MF.M2'8!P0XFC7FG_`##)S`ZFP<<4.0YB`[(53Z%;*,;\YS]A#=Y00RR!(>1E
MF)H\?:](VDH1K7LGDYWB-]G\G%L36L2C5+;.]B1-KJZWE]-R)%%1')D)+1#L
MJT:B76^R+Q1^2`8W9MI.0>)<WD>^4*_@[K5NG=1W7MX>:PLPU\KVLF]?`9B3
MDAI:B8UW2.%H#*>8Y"SGHEEI_:OQU>)W'QQX8MUU@#D\7`TZGPD3Y:1:W[YD
MJ3>:2?%N(ZN>=W34>8.Y;(,(Y&VI'C:2]='=]7^QCE6ONDZUQ^4.S*"L?LNO
MW;C"IRK+4`ZI-IG`CB>VJ3C&XQ_MAV%>N6S3<W&7X4[JU;:D<-TMZ['LE8R2
M-[9(Y&M?'(QP>Q['@.:]CFDM<US2'-<TD$$$$@K78YKF.<Q[7->UQ:YK@6N:
MYIV<US3L0X$$$$;@]"I&7Q>%9\U4W9%]W))6L0K&J(F5F4R/N_X6&@H4AE3[
M=FVQG"I$P4<[-Q0,0UQN^,F7K`4P26>O$$M_I?*TN*"?V?[!NEI5[5.G`3L'
MM)V3J'\2TX74W70I#G])5\D.D66V^<-]IC/V[UT1?&4T=-GVI,L98[:ACH1B
M(U(>7;Y17NQ?FX*Z.ODXG%SL?KV]5D!CR65@D9-7TXR1F_-6Q,L;9\H`[:3*
M".H]K'8V82W7\G7A?YA6CU]G*VUVY&X:<K3,(=5I2-<R7*.:X=)KK'.CJ'8%
MM3FF:7-ML+,[]F=2AN3J;>SC\H<3&PY*3906FJT&).'ARQ[0D>^6D:C@T<QU
M4(.D,.=M7A7[))1UA@@HV9:+%'@YHYIQP%X-YGC?Q"QND<>Z6KBHMLCJ?,L9
MS,P^"KR,%B9I<"QUVTY[:>-A=OVEN9CY`VM%8ECG7B-KJAP^TS;S=H-FMN_!
M<31+N5U[(R-<8HSMZ0@B`,]J0=601N#=Y7QL=BDC")KZP.3-><!P"-7_`.\W
MW*ID$;*:G&(:6#ZAKB3MGS8YK*6#]$H!'UA4D:<F!;9H[:;Q60S1I(B^43T%
MKA$2S_H)QV/TQPUT?2Q>.KPX;3&EL7#3IUHATBK5VAD;!N>>Q;M2GF?(\NGN
M7)GRRO?-*]YUG6K67U9G9[EN62]E\Q;?//,\]7RR'=SC\V*"%@V:UH$<$$;6
M,#6,`%R7KPX2K#UZ\U1&B*^09D#FB2)ZTI]JTPV)V18SUJ@F;DCW.^V[A(>E
ME+05&A:BJF@:/,F#+YE76'CMS3K5VJ+VK,S/E+9<R(DQ4:G,7,ITVDF.%FPV
M+COVDSP`99G/=T'*T3?A<17PM&.I"`Y_P[$VVSIYR/2>?'E'P8V[^BP`=^Y,
M%>[+!MGV!=)B?3UQ](G@#!P:PE7L$OT)\JS.BZ!=*MLO:Y9N]-\:+6!8K%RB
MR4!X52W<M"@L$ZSD06F+R-RSP>T'YU+'JW+0[UH'D8:O(WI/8C.SL@YI&QBK
MN!;6[^:PUTOHB&,OPS6^HNQ8[#4I-I9&_ATC#^+B<.E8$=>:4=9>[:,AG7M'
M!NSMS]0=4<NTS7E`TA$F$(JVKHXTC,2CK#&VV&[-OG=5R^?NU,[.2ALR06=F
M#YIZHL0-&G[\H_76>.UE=K,J*%F+PB>$3PB>$3PB>$6HG[C^1Y1Z_NA''MLY
MBB+HC2-@NQL>]C-,Q1KMGZR!`G]$5TV!$)[8:?G@]^_PA-5VZ;93)-?0R\V^
MSF$\.L/<P&9DPUULO5U:7:.U$/G1[]'M'=VD75S#XCF9N`\KSLE09?KF/HV5
MF[H7GYKOS2>_D?W.^IW4M"R3%Y-$+.A8261@B+EL'G$?:%PY%O\`2?"3T>.L
MM5T%/IJZ[)K-GC-Q\B[9PG\<8V4;N4M=]5$\33')%/&R6-S9896->QPV+'L>
M-QT[MB#U!^@@=RCM['PR.8\%DD;BUP[G-<T[?M!'0_6%5;R]7O,GK+[8M2F^
MB:;KZ0>O#VCQ_%&+61(`K+9]S]-C:SIPC5IV8+?`L!J>6D%\.6SQ$@PP"=L8
MI*OOT%:X*E=XDU1@CBK(L5V_@%IV\>W402D;O@/J;WNB)[V;LZEA)SO#9(78
M>SE</.81Z?KD9OL)`/7W!_?Z6SNG-L*M.ON.K!]8W6\KX[L)P0.UJ7U?3KE*
MTWR>?M[!J9Z[64:@73S&FC?,PA6WU0<C8)YTRD_8J.FJ"8,I&U7UI/)QXH&>
M./A[F[&\T+))-,V9G=9(&!TL^&<YW4NA:'ST`3L81-6!`BK1N@?C+H81N?J_
M&0^@]S&9N",=&2.(9%D6M`V`D);%;(V/:&.;J9)GB.M@0M&;`<L4GK@.='.V
MYJ+2-@LLU*1N3#-\.!)D<[;;IN6SAHYTTVSNW436^GG;*2B:VJ:FEAN(&B<=
MK[3-S`WPV.8M\XQ=TL#GX[),8X5[3=MG.C/.Z*S&".U@DD9N'.:YD/Z1U1<T
MEFZ^4JESX@>QO50=FVZ;W-,T#M^@>-A)`\_`E:QVQ:'!V^]Z$_:HX]A/.Y*L
M+J>HL.R^8T1,.NT:XW21<V("PE]E%+M$-]<)Z.&TL3;;-I;ADG]L.EJ2SO1!
M@&DD;15U?YO#9'3V6OX7+5W5<AC;#ZUF%W<'L/1\;M@)(9F%LL$K?0EA>R1A
M+7`J\F,R-/+T*F2Q\S9Z=R%DT$C=NK7#JUP!/))&X.CEC/I1R-<QP#FD*^9P
MX;M&Z[ITNBV:MD57#ERX5T1;MVZ.FRBRZZRFVJ:2*2>NRBJJFVNB>FNVVVV-
M<9SYY:[R^;U[F/8X[]I75VU>UP84<\)\I2@@-A.B"NV0]]W*QT6&G[2=IIY^
MB1C`;7=<-`L+Y<(YC^SDPE]+><%AX^Q7`'A?[[<P-3YJL'Z:P=@=E#,S>/+Y
M5@#XZ_([825:?,RQ;WW9(\P5BV1DE@1P]Q9US[WL=[B8V?ES64B//)&[:3'T
M'$M?/N.K+%G9T-;;9S&B6<%KF1%U;\A/"8J$)2`TYT9"Q#-5V[7V^'\%)+7]
M-$]/CC*JRV_R(MT=/X:R^Z:*>,[[ZXS>S-9C'X#$W\UE;#:N.QM9]FU,X]S(
MQTCC;T+YI'%L4$3=W2S/9&S=SV@U5QF-N9?(5,;0A=/<N3-@@C'BYYZN>[J&
MQL:'22R.Z,C:][M@UQ5TWK8KR!^M/EB7>\WN&'ZF;FLH3F!^MSG5_CX2I\E,
M![UO'#8EALFLX:R&T6ZZ[C8XV'KNXQ4R$BDS5,BK,QH9'6%Q!UODN(.IK>;N
M=HR%SC6Q-#F+VT,>R1QKUF`='2NYC)8D:/OUB1[ALWD:V\>DM,TM(X2OBZW*
MZ1H[:_:VY76[CFM[:=V_41C81PL/XN%C&G=W,YV9/7[R4>JO]Y?3U\@XHEUK
MU+*#ECVCF,QX1'PU>L986WD6E:Q<6';H#1#5N]7P1DVHU+31\:U;M'+@HF!8
MDG&5::P8Q-7M9VM-ZRT&;H"8(]]VUVN[]P0'2[='2;#TFL:5Y.9R1NS=G$3Y
MM$=F#N[1XW!E(_\`*P'J&]>A>0NZ=J]$V+#5:ZYAY>"YG?:G49C6#4=#V?VR
MVT90>940-VK)\.=5&8J,Q%FF]?)D3&FHK#AB\)/L+!(](<M_O4>;;AZG+$1Y
M_8#FUV]"8F]S[#@?!O=&'`ATG0;AK]OG#XTWIN:0'S:(@R'J`]V^XB:>AW/S
MB/@M\0XMWV5O6!Z\*]];?,,?IF.ND9?9\B<9G'0=Q.45=I!<%O&=,N)%)23Y
M[LJ35$,7"RHJ*,'JZBC`(@DLZ^J9(&'SZ&W.<]SGO<7.<XN<YQ)<YSCN7$GJ
M22223U)6?@!H#0`T````;``#8``;``#H!MW*Q?SY7ZGA$\(GA$\(GA%6][A_
MYJKV'?T/K[_L[.^$4A^*?Y&W)7]&6AO[+(KX19_DTEC\,CA^82TT,C<5BH4I
M))+(C3Q`<'`@`;%<F8,EB#K=-LQ&C!S5P]?/'"B:#9J@JLKOKIIMG!%HC>UK
M\14T[!A3_G+BFH;H?\ZKV()0ORZ]IR-HXU>M+1YTZVG-5U@0<#31^!QVR$DV
M[0A/R&NDA3CNCT,1@B30P1:[9MI_ASK;5%&;*833]NUC8&R.DORR5:-/EB#G
M2F.SD+%6*81!I[4POD$1&TA:L:RVL=-8.U%1R>6KP79BP,J,9/:L[R$",/@J
M13RQ]IN.S[1K>TW')S;A2+XY]]^&E#1"">M7TB289`(JBJPD(MA=,!JRK1!M
MIO\`2=(@Y\[KU3>U9$[;Z(.3I\RF*DZK]?98PB_W4U>N,<IX;)WVN?4J23,8
MXM,@=&R(N;WALLCV1O(_B.<O9L9"G5+1/.V-S@"&$.+]CW$L:TO:/:X!=AXS
MZ,K/VO\`LYD\9]JL#EE86=7#!H<X9]<UJML2#F_08%!;.IK;:D@43'1?HFYE
M5T#SEHG((>T`A(F/?.XRE(?RURC#NK;IVJ,I@MP25Y0-^61NVX/<YIZM>T_G
M,+F[@C?<%<\,\-A@D@D;*P_.8=]CZB.]KAXM<`1XA91]Q\MH[AGJV@[&]=$8
MDX#VRS4N#)$N?N;8(F2A/2=!8+Z-)6)ZUA8)T+`#8^[9LR*L/L?48]G0XH(W
M?Z9;BA*,LB7E7LA2QE66[D;4%*I"-Y+%F1L4;?4.9Q&[G'HQC=WO=LUC2X@+
MMUZUBW,R"K#)/,\[-CB:7O/K.P!V`[W..S6CJ2`%WVW/>-?]65](R/LC])=M
MP[F<V+=,I4<A5JU%U1'T1[Y#=-`59$&6C\9CXL._<[(,'9"4GAX["KG1'#)P
MXRFV5Q_$:ZTEG;0I8O-U;%L[AD#FSUI)B.I$#;44';G8$\L/.[E!=ML-UZ=W
M3V:Q\)GMT)8X1MS2-,<K&;]W:&%\G(.X;OV&_3?<[*LW@3V@]%<8$[@LVB/6
M7>)3U?W2Z`6A3]&A.@H;/I3S\LZ0<*SV3T_'\B'A]:$6#LJG(-JARBQ%Q8PW
M6<"),DV=$-7$?6_*.X(X_5]K0F1XA8?&ZHI7G8RW0R4.2Q]>O?8_D=5FRMRC
M!AXY><AHYKX:XEH:XD@+*(>%?$&SA(=15=,7K6(GKMMP6*LE2S++6<.831TH
M+,EYS"WKTK$@;D@`+<0X@[AY]]A%!@.BN<)(]-0PJ_?`#04\PU#32!3(1HV4
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MSJ14<GHM-7#:J/%O0GN'==J+%Q;8G(SGSN&-@#,?>DZ[@#HVM;=S/CV`;%-S
M0^B'P-,R:+U%[H0#&6W[W*L8[%[CZ5FNWIU)^%+"-@[Q>S9_4B0J27LGX73[
M6IP.I!)$I6G4-%R)O;'+%SC5MAIF`VF`4;D!S-8LVTV>MXO*'(Y@R.IH_5U9
MNFH:1Z-'KR/,VJN%Z#UC9T=FH[8YY<=:Y*^4JM)/:U^;<31@]/.:I+I(7';F
M!DA+FMF<X>[J+!Q9R@Z$\K+4/-)3F/S)=NL;CW]E-L&R#PV:_8E@"I]N&16!
M[(Z"%>R>F(-K6WN`]7.SJKN[.9&K-0>0NRL0:CO]J6&P5O\`.3?C"8AK))9`
M,ZZ/EFRZ,UA`I4Z6`0@MO9SB)H32_&3A_E=)9GL[6&U%0;)2R$#62S4+@';8
MW,4'.^#:I3\DS!NT2,$M6?>&:9CHGTOJ+,:$U-3S5'FAO8NP66*LA<QEF`GD
MMT;('?#8CYF$['D=R31_?(XW"7?.M^P'IVFX1=E;/ONHU-!>CK+-91+8E'S"
M&?MS<8-)H[[ZH&`!+1<>]TQG*2NR6KMHHLR<MEU?YX.)7#W4'"S6F<T/J6#L
MLGA;3HFSL:\5<E1D'/0RE%SP#)3R%8LL0DCF9SN@F:R>*6-FSW2FI\9K#`X_
M4&)DYZE^$/,;BTS59V^A8IV`TD-GK3!T4@'HNY0]A=&]CC'ZA9J:]9OM:I";
MUZ[S_<W^S^UH]SS>U3I?42'@;^D2^C2L+=BS1+;5JV?DI$3W2DVVZ6V,CR<Q
M55RLL5$;A=KWD%\;\EKG2U_ACJ$S6LGH''U)\+E9'F1]S3,L[JD-"VYQ+NWP
MLI@JUI`=I<=+5AY6OIO?-3/RC^'U33V7JZNQ89#4U)9FBR%-H#6PY9D8F?9A
M`V'9WV"2:9O>VTR63<B<-9FSW(SJ4]Y>Q6%^MAR46"<K<K0>#=,])A6BZR;J
MZ+'E#G"U<5P6PBKKK^R(4"\8F5D]_P""Y6*GU%$M"8R,$&<Q^5MQLN<%N&$E
MS!M/OJU7;ETYI^SN`W$R24YI[N;(/227'5V`4X^XW[%221KX(Y6.P;@IH"#7
MNKFPY`CW&PL+,IDXMMS=:V=D=?'C\UEJ4DSO[_-HIF-+9'L<,MR*0Q2N(>8D
MTB("XI"H2`>%BQ%SE)@'`1X$QW<.5]\::ZI-F3!BVV^1)+3&-4T]4D4\Y^33
M.AG&XW,:HS5/%XVO;R^=SN1AJ5*\?-8NY#)9"<1QLW<2^2:S8E'-(]W5SB][
MN\K8W:M4<30GN6Y8:6/QU5\\\K]HX*M6M&7/<=@`V.*-G1K1W`-:.X*N'FB;
MP5B.G_XA#N((2;4%1VQJM?5[S4:PDUD%IV`X7<AQ]HLQ3S1TVWE<N/MR+.-O
MD&1%2.HB3TU5^H(K2-EWW]!'DX<#L;P*X>U<$?-K6J,J8\IK#,1-!%K)NCV;
M2KS.:V0XO$QDU:37\K9'&S>,44MV5@UG\5.(5KB)J:7(#M8</3#JF$HO)^\U
M0[=UB5@):+=UX$T^W,6-[*L'O978XV8>M#E6V7$KLOV1]LI_F/<'7J2!9X`>
M)*Y8\Y4PM]%Q":0B#-_]5X$59AFX;]J4-E,.&VX\6"=X4)C#I4]@O%779U+D
M?<C'2[X/&3.V>PGER-QF['VB0>5T$.[HZ@Z\S3)/N>U8V/(-'Z=]R:OGEIG^
M$+;&DM<.M6`^DV$>(D?T=-ZB&Q].1Q=DSV:=R'^4X!"ZMH:-;6?VKU#(,59R
MY4P[1-Z^=2HME)@ZL(XQVS\J<1@VSUN^=J/<HL'Q+9BQ?.F0?!LN)\/AWHJ;
M6.8#)@^/#T#'-D[#1MSM+MXZ43NX3VN5P+A^*B;)+L7"-C_0U-GF8.B7,+77
M;`<RI&>NQ`]*=X_T<6X.WSWEK.XN+;`_5+ZXHYZY>=EHD5/9LGHVWSN]J=3W
M>0V4>&[-MPYJHZ*8T+/$]"CB)1AP]?CXJW?;:JJY<EY&[;-S4E,?/=.""&M#
M%7KQLA@@C9##%&T,CBBC:&,C8T;!K6-`:T#H`%`TDCYI'RRO=))(YSY'N.[G
MO<2YSG$]22222K/O.5?">$3PB>$3PB>$3PBX.31J/32.'X?+@@N2Q65!B<=D
ML=-LFY(,=`FF2PXN'*CW6BK9\.),'+AF]:.$U$7#991)73;3?.,D6D#)Z@/^
MF#LUKQ]+7Y0IP=U3(SDKXLLTXX76;U/-R+W9U).=)43<YV23^D1>M?V<>;KZ
MX(_F@<VIJH_D,L_9_.M(9WS>08JT[[Q,_P#!)''I#,[J8CN=A'.[;E\&2G?8
M]H2W&\]C>V8;L+=Y8V_?F@=9(V_/&W>Z,=^_?'[6`&7]_P!%5_TG4<TIBS1G
MYE$YJ*48N%$M4<$0Y!/;#@3(0BZR2VC,V"(IMR0QSE-335RWU3727:J+H*R+
M=IP7ZLU.PWFAF!:>[F:[H6R,W'HR,<`YA/3<;$$<P.)5K$E6>.>([/C=OL=]
MB.YS7`;>BX>BX>KVJ$%;08C[*>;YKZ2>Q90TCWL*XQ#JV?Z[>G3VRB:ET5S'
MFV^L;0R6<[*$G2B,>9M(A8+%HY?OMHZP'RM5D9E53GG*D+VJ]_3N588II*]R
ME/%:I6X7.C>#'()*]J%X])CVN:'#8[LD:6D[M*D**2KEJ+@^-DU>S$^"Q!(`
M]I:]A9-!*T]'-<UQ!!Z.8X';8K7SBI.5MB,NKBSHX_A%R5-)2L`M:#F$?M"D
M>E\?>KC"2:K;/Q^5!=TT<91W2VW0^JFND@LNBFFX5V0\)>(U;B+IF.W(8XL]
MC1%4SE1AV+;'9GDO1,W)%2^UCI(_]%,V>ON_L0^2F'$'1D^C\V^!@?)B;O//
MBYW;NWAYASU9';`><57.#']_:1F*8\O:<K>Y5]T)9G"7059=U4B]^VFE0$6C
M2=Q?=PNT#6Q5!A\T'RV`275OGY7#0BQ7VRT<+IK;"GJ3$VSQ@J##JMXS\I#A
M[5RV!=KJDV.#*8&*&+)``#W1Q<MED,9<0-S9H2SA\;W?#JNFC<XF*!HS?@OJ
M^>CE&Z5LETM'*.EEI.)_@=Z.%\KPT$](;<<1:YH^#8;&X`"25QVWOQ(WL2F$
M/Y$YJYPY_)$(P4]DH8X[,V`ENHU)1SGL%&X?(9L'';(+)[HFYVPG04$\VPIN
ME^R^DJ%YQHN6:/&M.]%Z9FUCJG"Z:@F;7=E;@A?8<.;L*\4<EFW,&].=\56&
M:1C"0'O:UA<T'<6,U)FHM.X+)YJ6,S-H5C*V%IV,LSWMA@B+NO*V2>2-CG[$
ML:2X`[;'4%B\;$P^/BXV$;ZMA8EJFU:IX^7Y]\:X^*JZVV-=,*.7*VRCARK\
MN,JKJJ*9Q\=OAYM*P&"QNFL/CL#B(!7H8RLRM"S8%[N4DR3RN:!VEBQ*Y\T\
MA&\DTCWGJ3M1++Y6[F\E<RN0D,MN[,Z:5W7E&_1D48)<60PL#(HF[GDC8UHW
MV&\T?6=Q9$>_[VFEO="%VD,];W"FO[R^E)R>5RRBUF2F,M=I"SJO!/?'T7`!
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M.S02,9J59+D[((AZ3CU<0>5C1\)[MO!OT[D[``D[*9WH[]=<\K].5^R;LP+G
M/:G5(=%Q'(>4;*?3YDH1_A%W$ZN!,2&F7@24&1FC!]-<JY1(L6VH^-O46QA.
M8+FX/R%^?)6YKE@[OE=T:/@QL'P(F>IK!T'B3NX[N<29'JUHZD$<$0V:P=3X
MO<?A/=ZW./4^KH!T`6Q3YTEV$\(GA$\(GA$\(GA%6][A_P":J]AW]#Z^_P"S
ML[X12'XI_D;<E?T9:&_LLBOA%$;W?PF<6#ZEN]8Y7CYTPDFG/THDJF67U,N7
M\8A#@?-9V#2T2VU45S(8/'Y$"V;Z?-ESH1V;_(IA7.FQ%\R*8FM7'.D>80YM
MKJ^G@2'0J-"VGPQNJ0DWV(W<8CKI_"W7^AL_0SKKC.VZNF_S8S\=O-@6M]1T
MZ/`"E8Q#65F9W3V`P>-KPD,#'9.&O#<JMY=B9(Z<=YC]MR2QW-N=RJDZ8PUF
MUQ<M19`NG=BLQELI<FD!)<*4LTE:P=]]F/L/IN9OL&M<T-^:MV.C:L!TA3M9
MU''&C5F)KV%1^+I:,T=$$G+H8.01)$M]$\8QN[+DL.RCY?;XJ.7KQPX5VW55
MWVS7ZI694JUZT8:&011Q#8;;\K=B[8;#=SMW./>7'KU*F2Q,ZQ/+,XDF61S^
MOJ))`^AHV`'@``%$OH4.M.?8[Z:Z\A&B;:V=NSF5GMSK/&/S@94-2#V4PN`7
MOLE_?L!Y'&VF4WB*VV&;O02LDMHHEHOKC"M>/B%;'QD-,SIYGM=TYVQ,C:UX
M\2&O<^,^`WC\2.F1Z8:_M+3]SV89&TCP+RXEI^EK0X?TCW;]9H5,/3@WXAWV
MD@;":)D9Q;-`\R6I2LF?Z8R\;4Y'(I&83-(Z$W7URH@._;90(U((,U-473J)
MZNED]MT\93ISQZAM.Q&!L,D>*<60LQ6(QOR.L3UVOJR.'<71QP6VL)[NU=M\
M(@SKPZ?"+N1C<T=N^M$^-Y^$(F2D3-'L<Z2$G;OY1OW*Y&21T',(\=B<G%,3
MD;DX8G'I`%)-DW8TN$,LEAQ0<_:K:[HN6;]DY6;.$%=-DUD5=]-]<Z[9QFLD
M,TM>6*>"1\4T,C)H96.V?'+&X/8YC@=PYCF@@@@@C<'?J)7DC9*Q\4C0^.1K
MF/8X;M<QP+7-(/0@@D$+57]4S<O6->=!\AR9PX4D7'?3EJU*VT=J9W<K0EX;
M7D,2,?#.<[:M3+AY(%V/Z83V:I)Y3QC7/RZU/\NO`1P<4M/ZZJ1-93XC:)P^
M7E>QO*PYC%M.)R$(V]$R0TX<2Z4[[\\QYO2V)FSR=LF^71^2T].\FQI?/7J+
M6N.[A1N'SVL_J2>62:2ZU@[N5FPZ*S3\.2#>D[M]P]MQG.&%+2KKJ'UQ$03/
M7.@;%EU/&)+^^&4,$T_@T^XE;F:Q%\^70TQNO])MLKNIKJEG&UOR<J.7QW`K
MA55SEB:SD?>9A[#WV'.=-'5NP>>XVI(7DOWHXVQ4I<KNK17#=AML*:<4[-*U
MQ%UC-CXHX:ON[=B#8@`QTU=_F]N9H:`/PBW%/.2.CC(3UWW6TIY-2P%4P>@3
M^;1@7^G_`+5_^,:\O"*Y_P`(GA$\(GA$\(GA$\(GA%3?[B?7'(>U*IAER<[%
M]:_[QY)+N+0Y:L9FHW8KERC'&C\S3LF>+[)MG$1L/1DBRT3*[[#!QS#15_C:
M.D92/+=2_0J9.E:Q]Z%MBI<A?!8A?W/CD&QV(ZM<WHYCVD/C>&O80YH(YZUB
M:I/%9KO,<T#VR1O;WM<T_P!8/<YIZ.:2T@@D+!?KL[KBO=-'ZRE<9^P5Z5R3
M7KOI&DR>J["3U1;4?44'204\"D?D+-@1`BS>.8Z[>I9W^AJY#O5?ST(::M*0
MZUTC=T?F9:$P?)2E+IL;=+?0M52[T0XCT18AW[.Q&-B'@/`$4D9=/V!S4&;H
MLL1EK)V`,M0;[NBF`Z[`GF,;_A1./>/1)YFN`B/5*X$C^)9ARW/2J+IZQX;G
M++NA>*[ZK`T\ID5$*J93Q1GG++$Z0*:5VEHB_P`Y+)Q]$"CIIJW;K83L-P2;
MDVZ4G\]$K:3LE,[%"4$;UW1Q&=T._P#S9UGM"PCT3,9R.I*C/7QJ',1]@6&P
M*K!<Y"/Q@<\1A^W^=$0:';]1'V8/<%"7A\(%C71WMLC45%,8[$8Y[/NE`,<C
M`AJD/"`6(@]JSU9B!;75)B-8:IIHZ-FC-%)%%!%)'5/31%/776O]T@$8XFZ#
M(C:)#H1W/(&@.<WW?R@C#G#TG!AY^4.W#><[?"*M?Y*_-[T=1;N)8-1[-:2=
MFGW,I%Q`[AS;MWVZG8;]P3M/^5?Z;_\`6K<K_P!>17G+]S>^4?B#^I-?[=HK
MC\JGXJZ:_6"3[.LK-5P_S_7L6_H\\H_U%C_DN?=)OB;PR_6;-?9==83Y*?Y=
MU;^B<?\`VR51K]S:JJ?KKO+5)55+"Y*IVJWTE-TLJMG%OP5-=!3*>=<[)+)[
M9T43SGY-]<YQMC./*=^1%&R3RDM!A[&/Y*^JI&\[6OY9&Z2S98]O-\%[=_1<
M/2:>H(.P4Z>4`YS>%.I.5Q;S289IV)&[3FL?NT[=X/B#T/CT4^?:/'('"_9=
MZ.(5:X@/$N+XE#K.&5>`5:-@]1A>C`$1%M*K$DF2>B((>Z%9;0-"OVKA-%-`
MCC9!EC#/8IIG=GQ*.3]Y&<]RA*;+J\0E[#F[;S(SQ>?]F&^D?P3M1)MU[$R[
M==EK_P!*>:>[V/\`/.01=H\L[3;D\X[-_F_-OT_'<G)O_G.16>=2]/5)QY1L
MYO\`NN0H@(3!QBCK*6-TLEY,<6UV3!1&,,5-]-BDDD1#Z8\6R3SC37=15Z]6
M:#&;YZVIQ@\)D-0Y.KB<;"9K-IX;OL>S@B!WFL3.&_9PQ,W>]Q]0:T.>YK73
MCD,A6QE26Y:>&11-[NG,]Y'H11CYTCST:/K.S02(K^FCB^V;#L"6>WSN8)NS
MZ<Z-CV@SG6I2FJZ[7E7F1[KNK&8^*9O=-/RJ9SD0LF0-N-&S4FU#$7>Q+#.0
M3:<"T[QZ9T[1TMAZN(H-]"%O//.6@2V[3P.WM3;?.D<`&MW(BB;'"T\D;57[
M+92QE[TUVR>KSM'&"2R"%N_9Q,W\&CJ3L.=Y<\CF<5L9^>^O-3PB>$3PBB%V
MEW=R[Z^*M"W-UE8R]9UY(IN,KH,:;0Z;3==]+RX@Z>9"]!,#CLE+I:[AXT<?
MJ/G#)%@DFPV24<X<KM4%R*5@<L//"19T2XP[%&AS(L,=ZZ*I:NAY%LD\9.,)
MKZ)K)X7;+)J8T6335TQM\JFFN^,ZX(N1\(GA$\(H9]^<05'[#.7;&YBN!ME`
M5+F29"(S!FV17D%:6&&^HYA]A1A13*>Z14`2SC[ILFX;:'`3HQ&WZWY69?:;
MD6J#Q_<-LP*>V'Z^^S540_8G,[C\F5(N7"N6=\U6D@DK#K@AS]ZFW4D"90&H
MS7+K:Z9(*I*-C!-%L3<G!P>7=+9T9.N*EAX\_K-`W<0#9A'02]3Z4@'HRCJ2
M0'[;//+@N:QAJ2F>%OX-*=]@.D,AW)9T[F'O8?#JWP!/3.UEM'/97JG'4XK]
M7KM#N*J'D';QY3XREM3?YBJI;:YU-I\724`59-F&TBV)8P)5!-I+]7&[!$UC
M7S]=FMYI2#N7ST6"8QT[05NS>)=QWAAD$6V^WI`[>*[6F1-VU@CF\W[,<V^_
M*9>=O)MX;AG:;[>!&_>%&_\`$&1P!'O==)G8(*+#N9?QM5$HE2XUB@R5D4DT
MF4CCFITQNWT3R1+X`@0@?[]U]5UD<*8M?J91;):ZR;Y+#G>_G.-!=RNTK:):
M">5Q;E<2&DM\2`YP![VAS@-N98'QV`]ZN.=L-QG8`';=0#0R!(!]O*"1X[=>
MX*E'HG_F8GN?\7Y0C_M-A_O_`!?^ORT7&GY+-9CKTQL/]OJ?OTZ;;;;G=07P
MR^/>G#X&Y+U'=_!+'^_Z=]]QMMM?Q^('5W5U]#+/;&N$D>3K)<Z;8QGY\J+U
M/1.N^-L_'X9UQAFE\N,8QGX[;_'.?CCY:0\!0'<6=)`[]),P_I_$T_EG`=QZ
M$MV/LW[E9WBLXLT!J`CQ9CF]?4_+T&']@<2/:J497MLG%Y%NGMLGOH#+;:;Z
M;9UWUVT'N<Z[:[8SC.NVN<?'7.,_'&?AG&<9\V*Z@>YN`SKV.<Q[<-DW-<TE
MKFO%*8AS7`@AP(!!&Q!VV[@J=X9H=E\4UP#FNR5%K@X`AS3:B!#@>A!!((.^
MX[^\A7B75&5(M^$^X._98*J!J>6]`57(^N7,29*LW1JL"UR6AI(3\H7&IZN7
M^SF:L*T:*/W>ZSC[EG'&"6^&[5HBEJ1@[,SP]OOV/:Q]MMW]GSCM-CW[\NZV
M"2<_9R=G^,Y'<F_=S\IY=_Z6RL[#G*YC5;BY""+10-5(&'LB8@T.>#6<+%P8
M:(378/F+Y!304VCS,*BDJV724U9I,4]-M-L):X\L`UT+(&O8^)E6.,.:]KFB
M%D+6`M<T@AHC#`-CT&PWZ=5%SFROE+7![I72$%I!,AD)V(([R\GIMWD]%@#U
MA\P%O;3U<+]@=S`R#?@SE68/!O&U;R!BLV8WW<<>>_2+WO(A3S&N'L7AA5HC
MH`0<-MF[D^S8AL;)J1N=,#4/:DSCLO;Y8G.%*N2VNT[CM#W.G>/SG]S`>K(]
MA\(OWS[$XX4(/3`-B78RN'7E'S8FG\UOSOSG;GJ`W;<Q\QM>LGA$\(GA$\(J
MWN0_:MR+VE>70_-M62:1Q^\.;IS)H?+:TLZ..('+Y&+BA+0&5GT+`E5OS(K#
MT3WUA3K[ML-DH93#%Q(XZ%:FPBK\BLA\(GA%6][A_P":J]AW]#Z^_P"SL[X1
M2'XI_D;<E?T9:&_LLBOA%Q_3W0%,U;BLZ:M,3,YB8ZPDAVEH57<!A)N=GI0@
MYBI,E/")(>&05U$PJ)0Q,@:FDD)*H,`XC&5=_K**)H[D7RZ^8Z!/#O9%5_$<
MI0<N5^4.KKE5F.726WTU1U`'2Q6.O7.N?FT49&#(K=BECX[I*($6N,?,@MIG
M,PTM629S26@]$O<YPT]G\YD[(=S$&LQD%K%G?J"!-<RE<-^8UL8Z-+5'TV`9
MB]0:IU*T-;[KXK%TX2W8$3ETL%X;=X)CKT)>;IS.+S\)I*W1O,H/[=N\CK]?
M_O\`N?(4</6I$?[H;WTW/9:R?WL4X)Y#!0$8OICZC9A;-^D-B.KC53/QT3=K
MP(E.`[G&F<;8R*U2SC&4U?(DUI9[;,F$'T:E>*(CP[20&=Y]7=*QIV_,V6>:
M?A[+'B0CK/(^3V\K3V;1_P"0D?RE*#V_M,<Y^TSU)=IH)?;QZSCMB\$6T1S_
M`'E!1E9Z.#5,M7;K&,XU19S,W+3V^JV,I_(&_3=+&=U-(4XF8GW7T5FHFMWF
MIP#)P;#<AV/<+$NP\2^LV>,;=?3Z;]QS_2=SS+/4'D[,GD-23?ITLCLV=?XL
MIC=_1\.]6P?[_P"_^7_?_%Y2/]_W]7[^*GU:G79$W:<*>UOK>;OM$64*ZAXA
M;=(C=-\Y29D;5YX"'(XY"-]<?*FH0(`XX8*NTM/BNHY-L]L?JY_7R>-?#B7B
M[PQX4UZC'R9/3/%?&Z0L2,;S/K:=UW<J5K5J0[%PBKW?<S9Q]!K(92>H7H\/
M]5,T5JS63YG-95RNC+6<B:XD-ERFG()Y881X%TE;SO<?"+GL`^%UN!_#Y3&O
M^:N,.,.5["83X#?_`%_75H]H"I*;@YQO`;36E\C4E)`>"L+#?<&2G4:J=[71
MD_'W"S=\B$<-7R6R^NVR>FRFO7AJ5X*M:-L->M#%7@A8.5D4,+&QQ1L:.@:Q
MC6M:!W``*J4LLD\LDTKW22S2/EE>X[N?)(XO>]Q\7.<22?$E;)?G,N-4P>@3
M^;1@7^G_`+5_^,:\O"*Y_P`(GA$\(GA$\(GA$\(GA$\(J:^O/1/PCU_<I'HD
MJUN.@+UD2.6\VM'ERSW=0R*P$LIIH[;S-MH*/1XJ_71231?FD0C,Z6231T+D
MW^K9KA'@L5:UMG96ZT%J(.#A'8ACF8'#N=R2-<WF'@=MQX+DBFEA=SPRR1/V
M+>:)[HW;'O',P@['Q&^Q4K>%?7'R7ZYH&>@W+]=JQQ:9D6YFPYY)3+^7658Q
M=GASAD^F4P+[[O7R;#[U]L.$,$QL?&+/R3H<(:NB9%=US`!H#6@-:T`-:```
M`-@`!T``Z`#H`O@DDDDDDG<D]22>\D^)*U8N-_Y4?N%_UKG5W]:_-.GW2#Y3
MM!_J&?[P9=7H\ECXGZB_64_9=!<;VG_*O]-_^M6Y7_KR)\YON;WRC<0/U)K_
M`&[17%Y5/Q5TU^L$GV=96:KA_G^O8M_1YY1_J+'_`"7/NDWQ-X9?K-F_LJNL
M)\E/\NZM_1./_MDJC/[G<_'UY7&C_C=2&GV^FW_1UWWM^$;XSM_C^7X)YQGX
M8SG]<?#]/U\I_P"0\WF\I/0YW^#1U:X]_P#V3S+0/VN!]6W[%./E!.VX5:A'
MYT^&:/\`QFB>OU`K<-Z=XSYT[HYYUY_Z?KH=8]>$F@,HV;JN7HHW&I*-';("
MY9#Y&+7:&(W)!J;MVBW)#G265V+Q^)(I/@Y(B/=;ZEK@58-1?AQN":[LF#V'
M8\QZFZK:56^0(576?4MW+695$`<,MTU!OY5"F<<C;0BU';(HZH"#ZY4`X301
MT(AWN$]<XZ=;'T*;Y9:=&G5DL.YIY*U:&!\SM]^:5\3&ND=N2=WEQWZKGELV
M9VL9-8GF9&-HVRRR2-C&VVS&O<0T;=/1`Z=%?KC&,8QC&/AC'Z8QC],8QC^+
M&,>=Q<">$3PB>$77I:6)@8I)S@0&XDYD-'C181&V:N$7<A)CAKEXP!M5MM%-
M4G!9TBDP05V3WPFJXUWSIMC'RY(OFV>^3V;=^=G\EUU675/JZM;B:``>@(U-
MP]HSE"S$Q)^6CX!901E!F^TRK&%C,OR(F0&3J>$"CA[E"/.?IL5$,+KH$6S+
MZN/:C[%.D[IIKGV]O4O<'--*.JX(:N^C)/K9B$9&IQ"`JOXPX6_:FK(P#7TF
MC\</$,4D)!];"YA!9KAXDCOC8BV3_")X1/")X15L=\>IOC#V/;10WT)"#XZS
MH$WPR@MW57)W=?6]%1F'2[[`=E*6*+MJ3#)O73MZS%240<8"WSQZ^$H,'CUX
MNO\`37.8X.8YS7-.[7-):X$>((V(/M"_"`X$.`((V((W!![P0>A"Z/PGZ7^'
M?7Y/3-Q5/&Y]8E[G!SH,YO6^YT[L^SF85ZGJB]%A"*S(0"CR;YOIAF_?A(\P
M,D1^=AK\FY';;-<_KY'RN+Y'OD>>][W%[C]+G$D_65^-:U@#6-:UH[FM`:!]
M`&P"U*_Q$G\]-O\`T&:J_M,G/^_^^/A97R6?CUF_U3M_:N']JA;CK\5,=^GJ
M_P#8,C^_54:]%[?+2\\SC]?B+;8_7^+X;%AVF?A_V9^/_G\M!QL=R<*]9$`=
M<?5;]/-DZ3">_P#C;CPWZ>"@WA@WFUYIW<]UJP[Z.6A:<!U'3X.Q\=CN>_IL
M"?B%VFC`[Z,&*>VV^C+E2SFFF^_PQMOHVK"F4==MOAC&OS;8TQG/PQ\,9SGX
M8QCRD_`3Y6M)?RLU_=S,*S'%GY/]0?1B_MG'*D:7?X*R3_,)C_9SG_?_`-O^
M/S8EJ'XO9_\`0F4]7_49]_;^_P!"I]A/RSB?TG1]?_6X=MM_9W^WN[UOV^CB
MNX-;?HRX^K&S8H#G-?3RD)K%IC#Y*P1*`I%'S%CV`S(BR;%QKLFNW<MU-M<_
MIJHEO\BR*B:R::FNHU;!E@;7\+EZW]3_`-'$SZ__`'*?GGY]MR]_=$E?W$[+
M8>8>?E^PS`'$XR,^;&NGS_MU^=_#7"GYW]7^'YS><V.Q\W[>;L-]^Q[5_8[]
M^_9\W)OOX\JX^RBY^U[./M.[M.1O/MMMMS[<W=T[^Y;!==UW!:C@L4K*L8D!
M@E?04&/C4/A\8'-Q("/`A:&K=B-&#VNFB+=N@EKC^+7*BJFVZZVZBRBBFW"N
M1=S\(GA$\(OPIOE--13&FZN=--M\)IXURHIG77.V-$\;;::YWW^'RZXVWUU^
M;./CMKC]<$6KTI^(6ZRT4WTQZ$_9-G&NVVN,YA4YQG.-=LXQG.-:5WUQ\?A^
MN-=]]<9_3&VV/US^;CUCU(M?3V[]JV!9LN@OL+KWU:=X^MKL*F)/%MV_7AX!
M((U!92-^HF!81FUT#-81H,<(K,%OV>"$'1#9P9"KK063,)-%W+,<*_=QZT6Z
MWZ@>W;.]A/"-3=+6_3YBGIY(OS`"8:NF*H^+V$I'M6;;>U:U0=KK$=:^F+A5
MQL*2(_%9D4'FAK1V9$LAQ\L16<>$4*O9!4$_Z`X"[*I"J0J<DLNU^;;>@4#C
MZI,6&T-RR2PHN+!B<EC;P>'&Y($'"#75Z5?LA[?97"KQVW;ZJ+:$5<]`]6>U
MFIZ>I2GR7I0GY'-:UK7%;/Y*CW5R4V;OLPV+AHNZ.I#-BZZR"+K\N4?Z,=G:
MRB6F^&^7"FVOU<D6>.A"A&4>W?UR1(Z`?PF/UQ4'85G0Z;&EVSH/<4WDL%B,
M`.U3"T0VY)P.D%=14FYL&4NIGB,-B0A8>E#/VEW;2+8,1:Z48AU<V![R?;1T
M)7H71B`A$E@]$X=?-JLB]M!*-1IO>+]G\,9U;N,3:NUL/===\J?4*+[[9TPZ
MW2UD#0=7>:_<</Q<4=>,^V5_:2?1L(XQO_&^E8OJ:;:*O7'SWNE=]#`&M_:7
MN_9[%9"]>-1S-V0>KIMF3%LN\=N5=L:)-VK9+=9PNKMG]-4TDM-U-]L_IC77
M.<_Q>20=@"20``22>@`'>2?9^_58@`20!U)(`^D]`H\_A1^AX'>AKVDF$F^J
M5JS/IF-6Z2(+9QHZ*5)+!\K%5F(0TVQA3=M"W824HJ:_';5KB2LM=L:9<:_-
M`>1LFY>MVC_G[$L@_D.>2P?4SE`]@4H5HA!7@A'^;B8P_2&CF/UNW/UJQC\2
MS78^6>I>Y["_.V,;EW.$]I>_JW//U?M]6,WC%E`(LU1:+8UWVP5*A9H<#A4L
M:YPY,OQ[??.FBFRJ?GS11SQ2P2M#XIHWQ2-/<Z.1I8]I]A:2/K798]T;V2,.
MSXW->TCP<TAS3]1`*D70%L"KXHNG;L![)Y$VU6$&L5CHCM\^B",QC8T]EGG/
MS;9U49*/MVJVFV<[)K([Z;?PM<^:^LK0?B\ID<;+^,Q]ZU3>2-MS7F?#S#^4
M&@@^HJRM.PVW4JVF?!LUX9Q[!+&U^WU;['Z%KI?B=>9U+0JGDJY1A1O&7,-O
M/2C9=)E556S4-!.@V[$:Y-''+?X;9`AC,49-':6^=M<(R5TGJGMHY7UVF/@;
MD8FY?*X6PUDD5ZK7R$#96A[6V\58#XW,:\':5K9S,QX',UU9CP0YK2L&X@UG
MFE3OQ.<U]>66K(6$M)@N1EK@XC8EA,?9N:>A$I!&Q.]^O7,=9<\=+^F5K4\2
M5F:5;3ZV^=X=2D?=MF$O>5M(^:74;*3H&0,[,HH@`I"-0AA(YFE(CH'+\"ME
MC'5R4H<!P)2TRB%=UM'M/V41"QYS%:]].D\M>"QV5'`T0LUGVMR[$&D_C@\@
MNV$2]K%9`0R>CK>0,DT2:(8UC4J.3<ZM2":3M)5/4BY[TTT+=O-G`-;5?T1`
M/W76UI8W1DXD<!S)XQ,E(TUM#H>S['CS%>20TF8CA)?,<E`I=90<06U3W5RB
MXT;NDUVR)%:3X1/")X1/")X1/")X1/")X1/")X1:/?&_\J/W"_Y?^%<ZN^'_
M`.:_-.?W2#Y3M!_J&?[P9=7I\ECXGZA_65WV7CUQO:?\J_TW_P"M6Y7_`*\B
MO.;[F[\H_$#]2:_V[17%Y5/Q5TU^L$GV=969K84U=>_CV2[I_'&!U#<EL%_G
MQ\/BNO7,=>Z93^'Q^9/Z.V,;9VSKM\^,ZXTSC^%F6_NDQ'O/X8M\3J3..^IN
M+J@_^H?UK"O)3'^'-7'U8K'#]MR;_<HT>YW^;[M7_P!+:;_M<AOE0_(;_P`I
M'1GZ.U;_`'7RW=]2F[RA/DJS_P#.<-]KTUO:!?\`D83_`)L8?^ZI>;YUKB7)
M^$3PB>$3PB>$3PBI3][/K'M/VL<EU_S_`%%84`KB3PV_8M;;DQ8^DBV`O0P:
M#V)$'HQ#>,B31!,GLI-FSYK]1CEJJFQ7057;[*IJ8(K@X-'UHG"H?%7#A-VO
M&8M'X^N[1TV31=+!A+0<HX23WSG?1-?=MLIIIOG.VNNV,;9SG&?"+M/A$\(G
MA$\(GA$\(OGA_B&EMEO=25UVQK\&?$U2-TOE_3.VBD]ESK;._P`<Y^.WU%]L
M8^'RX^3&OQQ\<9VS9KR6`/?OG7'PTK8`]77*XGP\>[ZE"?'8_P"*V-'KSL!]
MO2AD/:/6?ZOI5'O1O_,M//\`-K/^/_/`W_M_[/\`^/+-\;_DJUC_`#.G[>GN
MK1\0=MOJ[]E"'"[X^:=_G%GV?_+[F_?U_:?]ZV#_`,1+_A5Z//Z+UK_V;4Y_
MO_ZO*5<!/E:TEZN;-?W<S"LMQ9^3_4'T8O[9QRH\EW^"LD_S"8_V<Y_R_KYL
M2U%\7\_^A,I_51F'_#V>"I]@_P`L8C])T>_OZVXC_P`?;XKZ$'X?/^9MX0_T
M7R+^U">>:C5L&5R7A$\(GA$\(GA$\(GA%JLG?6YV][9._P"9V3[30J=5^OKE
MJSS0OF_C^-3%$N%O5X(4PB%LV6$@*K?8G'9`+62(G#AC0=(G6KQU7@`-&@Z<
MD<NB+:3"A0\;#BH]'A0T$`!#6(<($#L6PP0'$#&R3(<+%CF22+-@.8,T46K)
MDU12;-6R2:"">B>FNN"+D_")X1/"*JGV*QVRH%:_'G<T.@[2QX)Q,\Z8E-YQ
MK6:1V$G!5463112/G;#"NY6JT#&-*_W"(F#,>T(-S104JOH#;OGVFJ'A%K/^
MI0%(G?+92]9QIG-@=97-;/2<P<JYSNY</9[*'#=DJHMM_#W1>#@[<PVU^/RZ
MZEM]_AA157XS%I"KYMA(7D`.MRRV7>L!Q;'']1CB:X>'I'N*P'/S]MD'M!W;
M`QD(]6XW>[_S/()]GL"RU[*;:S2W#71\S0<[-2KNO7\'`*)[9U<ZG;(<-H$-
M7:?#^%EPP5D62>OR_'.FC%17./E3V\]#.V34Q%^5OPW0.ACV[^TL;0-Y=NI(
M,FX`\1[%U,7#V]^LP_!$@D=OW<L0,AW]AY=OK58GX;:P]N7O:I3=:O%\L(_U
MCS+,:C*([[939*V3!V+>V1SQ;XYPG][LE$7P(?G?XJ;*G]VR7\)UC7/7XQZ&
M.C6Z$>R'LAD-'8^*Z0W8/S=``Y,D@#J6W*O?Z70G<]P<.]4#49U2UTO:&GJ*
MV^L"=RW&6NE$`=^V]>Q[/#O!WV(_Q/DK<S:@./.&0Q!PS*]J=>08%)-6BF-7
M&*GJS"<CG+_"?R[_`#X#'3<$,XSOIE+78?\`';]<:^5?XDZOBT#H#66M)1&_
MWLZ<RV7ABE.S+%RI3E?1JN.[?X7=["L-G`[RC8A33I/!OU+J;`X!A<WW6RM*
ME(]GPHH)IV-LS#<'\17[67N/1G<5B?\`#\V6:/\`!SBC9@[^O.>/[NM?FV1)
MJYSJZT:Q@[B1`-\I;YSOJQ0%RC`-@IMCY<Z`U$=-MOMM\8JSQ#DIY/*XO5.,
MZXS6FG<)JJBX$.:Z+)THWCJ.][N1LS]O]+N1Z04O::9/4J7,-;_A>`RE_#V`
M1L>>I.YN^QZ\O4L;_((\%+3VR43MT9ZZ>M:R:L_O3?[I3DZBB&NF=G*LMJS=
MO94;;,\Z_P`)-V0*Q1N+2WUSCXX?;Z;[83WW\Z.@LK[CZOP%XNY8_/XJT[M^
M@@O`TYG.W^:R.P9/Z(/>NQJ*GY]A,E`!S.\V?+&/7)7VGC`]KG1AOJZ^K=>W
MPO,KP]@Z_IV[)UAS/6IJ6Y4M.0VK<A69QUP\G-^3VO!E!2V"1J"L5W,I9N0<
MPB,NDQV1'6[`+NP<,APUR\(9<I:7J5>5L&^$3PB>$3PB>$3PB>$3PB>$3PB>
M$3PB>$6CWQO_`"H_<+_K7.KOZU^:<_ND'RG:#_4,_P!X<NKT^2Q\3]0_K*[[
M+QZ]#LU/=?K;TWMTL?.MGVG<Q.L)X_3/V[&:"EW2GQV^&OP22^.^=?C\VV,?
M#37;/Z>=C[FZTGB+Q!=MZ+=%UFD].A=G*1`]?4,=[!M[>O%Y5)'O6TR/'WP2
M';V#'6=_]8_:LM61_/Z>T'_1!Q__`&21CR5OND_Q3X7_`*Q:@^S:2POR4_RU
MJ_\`1>,_M=A1R]SW\WY:O_I=3G^7_P`K<,_]G^3RHWD-_P"4CHS]':L_NOE?
M]JFWRA/DJS_\YPWVO36]F%_Y&$_YL8?^ZI>;YUKB7)^$3PB>$3PB>$3PB>$3
MPB>$3PB>$3PB>$3PB^=]^(4_GJY!_0NJ'^NDH\LWY+.WOVSOZKS_`&IB_P!_
MJ*A+CM\5\9^G8?[!?5(/1W_,M._\VL_]LC/^K_?_`*OX_+-<;ODJUCT/\"I^
MK;\JT-OK]?\`L4(\+_CYIW^<6?[!<^GITZ?Z_%;"'XB7_"KT>?T7K7_LVISR
ME7`3Y6M)?RLU_=S,*RW%GY/]0?1B_MG'*CF9_P""$JS_`(\1PWG'_5_WM<^;
M#=3DC36H=CM_@'+]1OT_P?8\1UZ'PV\-QW[JH&"_+F'_`$KCO[7#^_\`4>[9
M?0Q]`FNNOIUX,QKC&N/W0/MLXQC&,9VWGLPVWVSC&,8^;;;.=ML_QYVSG.?U
MSGS4DM@BN$\(GA$\(GA$\(GA$\(GA$\(GA$\(GA%1;^(YO8G2WJBO:.QC?/[
M==*F(/RS"FNBFVBA%[<!W1I*QJ>NF<*K*/:T$SI#1)/YOFWWU^KKLCA77/TQ
MCI'M8P;N>YK&@>+G$`#ZR0%^.<&M+G'8-!<3Z@!N3^Q04J"O1]2U16E6BL)_
MEU=0*(PAGLGKC311"+@6`75?Y<?])Q]GE??.?UVW4VVV^.V<Y\L!6@;5KUZS
M/@UX8H![1%&UF_?X\N_11;/*9II9G=\LCY#[.=Q=M]6^RIA]X\^U?1OE_G-J
MKME>S[=7G\B;IYQGYXC58O.[AJZTQGXX1?OY,DY;YVQG39<)OG_C)8^')0QP
MU!J_16G.7GCR.H*MJXS;??'XO>Y=:X;G=KJ[)-B[INS?;HN&]=]R-.ZES&_(
M^IB9H*[M]MK=W\&K$'UMF?'_`/L/6JH75K%^<+5YRZICVJNY?FR_JRM'=)#]
M-WP$3)6'[0!=_P!=<;-3K/Y!;Q+.==56KA5/?/R[9\GGRF<'[I:!KY:-@,VG
M\O5L/>`-VT\@TX^=N^VX#K4M%Q._7D'L41\$<IYGJN;'/=M'EL?/$QN_0V:A
M%N(^KI7CM`?RMEM0]X6<(ZN]Z-=!(\^0.UYPIQDA*FC]!7#P?^]/I[#`P@\:
MYQC*:/YM4D@B3UOMG&%M_P`JRKG;Y?I83T-_=`-7G`<$(M/02EEG6VIL7BY&
M-=RN=C,5VF<N/Z'<QBW1QD,@^"18`=W['9WY-.#&2X@2921G-%I_$V[;'$;A
MMN[RXZ`=VP<8+%M[?'[V2.Y=/];A/6AO;3W-SZHIEI'.HJCKGK.$M5LX3;YD
M,6+/(/8&K''PU3W?&3$B*E'F$\944:A$U%<Y^VSG$:\(-0'6ODU\/,F]W:WM
M"93+\/\`(N#N9S8(!'?PX>-RX-AQ,F/A9OL`7D-&Q65:ZQHP'%74U1HY*^HJ
M=+4E4;``R2<]:]R@#;=]QEF1WB=MRMCMRW0=MUVKI%-PV<HJMW""VN%$UT%]
M-DUDE=-L9TW343VV34TVQ\-M=LXSC.,^>NTEI:YI(+2'-(Z;%O4$>(V.Q!WZ
M$=Z\X@$$$;@C8@^(/>%69^'-+XJB`]W^OD@[WV?\/=IV*+A3!PKG+E"B[C56
MF-7OLH;XUW3T,$!LV+?-ICZ&^7V,Z9VS\V^]_--909O3^'RNX+[V/K33;=PL
M&-K;+!_(L-E9_1\.Y5PRM3S#)7J>VPKV98V;]YC#R8C_`$HRT_6MD#SW%YZ>
M$3PB>$3PB>$3PB>$3PB>$3PB>$3PBT>^-_Y4?N%_UKG5W]:_-.?W2#Y3M!_J
M&?[P9=7H\E?XGZB_60_9=!>'KK^69Z;?]9E0W]8!GG<^YN?'_B+^I]#[:A7#
MY5/Q8TQ^GIOL^991L?\`G]?:#_UU!Q_C_P#:2,>2E]TG^*?"_P#6+/\`V;26
M&^2G^6M7G_NO&?VNQ_N4<O<[_-]VK_E_:VF_[6X9_C__`,\J-Y#?^4CHS]':
ML\?7I?*_\/'JIM\H3Y*L_P#SG#?:]-;V87_D83_FQA_[JEYOG6N)<GX1/")X
M1/")X1/")X1/")X1/")X1/")X1/"+YWWXA3^>K/_`-"ZH?ZYRCRSGDL$>_7/
M;_\`9>?;_P`5Q?U?7^SO4)<=OBOB_P!.P_V"^J0>CO\`F6GG^;6G^V!O_F\L
MUQN^2K6/J\RI_0/\*T3_`.V^W>?4H1X7?'S3W<#YQ:WZ]_\`@^V!^WP'7_6M
M@/\`$.9VS/\`TH:_-GY,<CV%MKK\?X.-MH)6&NV<:_Q8VSC&N,Y^'ZXUQC.?
MTQCREO`';_E9TMOZLWX;_P#1_*_[/'<*RO%KY/\`/[?]V?;&/_W>WZ%2+,_A
M^R$JS_\`5PW\/_PUUYL(U1\6M1_H+,?9UGH?;WC]NRJ#@MO=S#'IO[JX_;N_
MZW%W?\5]#3T#?S.O!?\`H?>?U[E_FI-;!%<%X1/")X1/")X1/")X1/")X1/"
M)X1/"+5F_$S.GD=>^K"P)UARUYC@/;")ZYSV45%0D:EZ809O4!B2[Z:*:-0;
M?=">_?.7&GT/MLKM\YRJX125]+#O@BRE"2TX-@CM0OD<?@MY7@M<X]=F-<&E
MYV.S05U+S97T[3(1O*Z&1K0.\\S2"&_QBTD-_C;+DV10:2'-C`X@Q?B7K1(@
MS*,G:#H<[8+I8<(O6SU!3=LNT50VU62<I*[(J);84UWSIG&?)V!#AS-+7-(Y
M@\$$$'N<""00?6"1U[^XJ,R""6D$.!V((((/J(/4'V+4P[GO6%]%^Q0ZZATL
M"R>'T75`ZN(^^$DFSP:6E+PD^,S`@%434VT):,%S+F.D7[#ZK3*@=#":JB.R
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M;86@Z^18@L!B)`,WD#=OE1VRRHPT(IZN6KKZ'\O'W2'":KMCAOFX*-FQH[$P
M9^M;NUXWR08_-Y*?&.;[HN8"(&W*E.)M&64!CY(+D37A[@U^Z+R5K^&A&JL?
M)8BBSER7'30P2O:V2SCZL=H'S4.V,A@FG>ZRUFY#9('D%K26RB[2G@KE#M?U
MR=QF2&@&$PRTI-0MSG-\Y^W:5M<`)<=H6*HI8W<N!,1T4E,@6U226PFYU;[:
MIY<[(:*1[Y"^6DS6'XP<+^LMC(XG%ZRP4'I`>?X:P:>0CC<?0;-<;/B(F[EK
MG1PO(W:UY;DWE$46T+NB-7=&1U;MS!9&3ITK7XA-6<\#TC'`Z.Z\[`@.D'B6
M@[5860@9(#'2>.FQ!Z-F&"!43(`Q)D3"E!;E+"[<D/*,EEV+QBNAG"R+QLNH
MW52SC?13;7/Q\GB2*6&5\$T4D4\;BR2&1CV2,D!V+'L<`YK@>A8X`CU!1JU[
M'L;(Q[7L<T.:]K@YCFD;AS7`D%I'4$';94_^L*3!K3]\OLFM&@2*<LH)OR]3
ME?W/.H^IJ_A);IJ.'(H.C8L0;:YW&%7P2!AIJ+);,EE_H$V!7&^_RJIJ+W.X
M44\E1T5C8,E#)7>9KDU6&5I9*RG/8=-$9&.`<PR/?+*P$;]E)&=AOLH*UE/5
ML9ZU)4>V1O)"R9[#S,=/'&&/Y7#H0UK6,<1TYVNZE;3_`)(ZQ9/")X1/")X1
M/")X1/")X1/")X1/")X1:.W$^^SCHCVY/5/U<.?:YUIA;;&/AKGY)*SWU^&F
M/X.OPV7W_BQCX_''^3'FFS[H](X\5]$Q';D9P\@D:-NO-)J34+7=>_8B)G3P
MV/K5[/)8:/>7GW>)U1*T_0W%8LCI_2/]7J7\ZZ_EF>FS_694-_6`9_O^GGI_
M<W/C_P`1?U/H?;4*ZOE4_%C3'Z>F^SYEE*Q_Y_3V@_'_`,D''_\`9)&/X_)2
M^Z3_`!3X7_K%J#[,I+#?)3_+6K_T7C?[784</<WGYN!;';Y_B>3BF&N=\?\`
M0^>V(CMC?&/^E\,Z?#Y<YU_C_CQY4GR&6AWE(:.];,9JUW@0?\6<HWZOA$[[
MGN`[E-GE#';A7G?;:PH__K4S_L6]R,3^B-'H_'YOI,6B?S?#X?-\C=/7X_#]
M?A\?A\?AYOD6N->]X1/")X1/")X1/")X1/")X1/")X1/")X1/"+YWWXA3^>K
M/_T+JA_KG*/+-^2S\=<]UV_Q7F_9[J8Q0EQV^*^,_3L/]@OJC[I+;;6E)WG&
M<8_[A'Z_Q?XMCHK7;X_'_+KG/^3X?Y?\?EF..)(X4ZQV/_-<>/#J#E\>T[?4
M>_O\5"?"P;Z]T]O_`*>X=O'IC;IZ_7X>'<MA+\1:BFVM+TPMDL9PDWY2LI%/
M&<YVSA-*&5JGI\=L_KG/RZXQG;/ZY_Q_Q^4OX`_*QI;Z,UX[?]'\I["K)\6O
MD_SW_P",^V,>J.9G_@A*O_1PW_LUU_'YL*U1\6=1=WY"S'0?HZS_`+OWZ*H.
M!_+F&'7\J8[K_P#=Q=_[]_T';Z&GH&_F=>"_]#[S^O<O\U)+8(K@O")X1/")
MX1/")X1/")X1/")X1/")X18UN&G*LZ!K674[=4#C5F5A.Q2@:6PJ6CDB@0RP
MW4363PL@I\-T';-TB@_&$F:C8D))-FA,8[:$&C9RD14#O?PMGK>W(.FH.>]H
M0^L'KW=TZH>-=)/TZB7;J*Y4W&+#S$5,S%9CMKG"6VRTT4(93QC.7^5?BKGF
M%BPV,PMGF$)[XA*\1GZ6!W*?V+X,49<'F-A>.YY8TN'T.VW_`*U(JY/P[OJ8
MN"J8'5"?,K*IT:Q'KC(/8--R4[#;5&MG;Q<@[V.S9TZ-N[#<N'SEP[PZLYM-
M'#-=PON/49_64^;YBEE@D9-!))#+&X.CEB>Z.1CAW.8]A#FN'@6D$+]>QDK'
M1R,;)&\%KV/:'L<T]X<UP+7`^(((4'*B_#G^O2N+,'W-RG:$_N/H/D"WWKPC
M&.@Y[#[4@Y6R@=:*22*TS:`U&MVS.&C=B<TKF9NY2*BY:8QX=HW?1S*)M1B1
M&=BYD+^1D$N0O7+TK6\K9;EF:U(&CN:'SO>X-'J!V7#7J5:C#'4K5ZL9/,65
MX8X6%WK+8VM!/M(W62+H]5]W^W4U%I![0*-ICDR2T?)(<\KRS^0+7<3FXK)B
M:3>:XGE?2*826$L,1"$*F'\1DT+53_.C``FUD6OV.-S2KM+SYH8;$4D%B*.>
M"9CHY89HVRQ2QN&SF21O#F/8X='-<"".A"[<<DD3VRQ/?%(QP<R2-SF/8X=0
MYKVD.:X'N(((7,<S?A[_`%(GW:%R.9#<7>8L84F4-`DNCKV>6Q#`)N(GS,$F
M0EB(B@>#`R3J.R(,:`N6L@:G&PXL.W<M4DR#-H\1\W$X#!8&.6+!X7$X6*=_
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MUMGX?_>(=\?\OP^/FFG[H[\KFB__`*<U/[S:D5[?)9^)6>_6F;[)Q2_O77\L
MSTV?ZS*AOZP#//6^YN?'_B+^I]#[:A_?]^G4\JGXL:8_3T_V?,LESG?9Q[[_
M`&M;*?KEE6_&C-O\,?#X(+4A%76^-OA_Q]LK;9SC;/ZXQ_!_B^'DG?=*'$:8
MX5L^:[/:E<?I;C\8&]?9SNZ>*Q#R4@/=;6)\1CL2!]!LW"?_`$C^M1U]S7\@
MV=?K_P#2'2?]JT4_3RIWD+_Y2&D?T5JS^[624S^4/\E>;_GF%^U:BWP&?_S-
MI_\`9D/_`.K7S?&M<J]GPB>$3PB>$3PB>$3PB>$3PB>$3PB>$3PB>$7SOOQ"
MG\]6?_H75#_7.4>6<\ECXZY[H/BM/W_I7%GI[>G]2A+CM\5\9^G8?[!?5'G2
M?ZTI._\`)]D-Q_\`KXGX^66XY'_X4ZO]M7'=WLS./]OT?[>_<PGPL^/VGNN_
MWZ[]F7=_W\/ZAL,_B-/^=GTS_P!%BSO^S_P/K?RF/`'Y6=+?1F_[OY7V%63X
MM?)_G_#\F?;%!4:3/_`^5?Y/V;-_[-<^;"-4'_%G47=^0LQW?HZQU^CQ]G7N
M50<#^7,-^E,=W_SR+_5_7Z^B^AIZ!\9QZ=N"\9QG'_R/.\_#/\?PS.I?G7/Z
M_P"+.,XSC/\`CQG&?-2:V"*X+PB>$3PB>$3PB>$3PB>$3PB>$3PB>$3PBBYV
M)TLGR?23FU6\'>6=)2-AT[4\"K<>>:1A[-K`NZUX=4D/"(GW[$FT%):F)B@4
M(/%1[SZ`L<^4T;J*:Z:Y(HL5)[+$K%MD5SQ+*@0J'H,7TA*:$LVM979*1]F'
M%Q3G=KT<^LBN)K"H6>C\]#[0^20-'89*\U8LR=R)VU?O6Q5D*$R$BC]UI7?I
M/F]T]"SKIJIH^;M*G8M&95TE:H*LNB=0<=06BT8>0QA/;/J$$C!S%D/X4<B+
MF,Q!4\4LDE'78/\`+!#AGHSTT(H(7I3?J,Y_DF`MC5Y:?:2T-GG4(>YYQ;UM
M](325<W5ORWST.O!6N(2,VRJC-8E7`.8T;4XA$-E1JU0E[J0V#/C<NC\KT<D
M4L>&_:_R9`N>PL>EM60_CZOZ_9UK#8E2%4PKIR;S()/+)C,[N4E7B%1O.4*W
MG!=:)52.#65-K&AX>;1`DM()*?<2'8"T%RR6$4N.7?;3SE?45YSTF;QY6%M]
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ME>*>.>7:>4MB9)&UKW-$@<HC=X6E`^V4J=]?/+4LCMXWET=<U8-_MZR,,)L%
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MTCK1E]\\1NJ!D_V;KJ@(O:%>R4X\(Q`P]T3W0$Y(1UV%/#-G2B7YC]X96;:*
M(`BZS6<>`.L\-HW6DTN>G;3H9C%38H7Y!]YIV'VJEF"2R[OBK2&NZ&27X,3G
MQR2ED+9)&1AQ9TWDM2:9CCQ41L6\??CO^:-/WRS"VO8@D9"WN?,SMFR,9\)[
M6/9&'2.8QU`LC'D>E2T0YAH9!*T+BO:51N$0N,Q)=,WMHX?&F#AP6,.!NSE$
M4%&,VRS\H1=[IMQPQ!V6>;)#6+QRA83CQQ*T@[0>1T[BLWC<UE,]YG#%%BK=
M>]'6K07JUV:S;EJR210@L@[.%CGB:625CFQNB9*]L1<*=$ZACU54S%_&W<91
MQ0LR/?D*\U1\\TU6>K'!7CG8R20ATW:2/#>SC9&YI>'OC:[:5_%#\WV!7,=]
M<73#040D]/\`-D=F%!6Y)!+!RZVASJ9@(8,A<L,-VR:N[2.&'H`PQ<$%M=&[
M0KJ&$YWV('AJ"U3.%6I<?I'7^G,_E>=N.J6+,5N1C7/=!#?H6L>;/(T%[FUC
M:$\C6!SW1QO:QKGEH,_:\PMK4.DLSB:(:;=F&%]=CR&MEDJ6Z]P0\SB&M=-Y
MN8F.<0QKWM+R&@K5@GMK0YY$'PF+F&,TDTP9*1N)Q:)N$Y`>/FY"ED8,8LA(
MK[M^HJLZ=)Z?2PAA7=3.&J6BCQ5%NI>/B'Q4T/CM%YJ:IJ+$9>WE,3=HXRCC
M+]:[:L6+]:6LQTD5>9\E>"$R]I8EG:P1L86`.G+(WU>TAH'5%K4V,99P^0Q]
M:CD*UJ[:NU)JT$,-6>.9S8Y)6-9-+((^2%D3G\[G!QVB#GL^H'ZJ*%G/,/KE
MXWHFS67Y78=>T7#V$U#;?#*H"3%&ZDA,1USMKG;3=Y'7I=8(\43VV24=,%E$
MMMD]M<YUM*YZL"\(GA$\(GA$\(GA$\(GA$\(GA$\(GA$\(HC=B\E,^OH;6,7
M6N&SZ0*U)>,`O^(32J6E:D3B4WK1(YO$TR0FV*_LN&%0X\P8;R31D0C#C.#H
M$(ZPKA-JJ@N11X@7J3Y9B<P!368[S:_"B0._V]BZ=`N(=9+2\9MTD2J1:Q+0
MML>XA@\2:EB4=I:$P.+B@0V.0.,PAGD$*AZ":355N18NM7TM4/:9N[#>+.L*
MN/WI55`J7B`:HX1S_6T>J6OJRM2M+=@0,<'BM/CF]E-X:;JB*Q6):7#^W6L<
MK94]#!N$D#CU]L18KNWTTKNZN.1"FK9E<YL"V1W1E86U9W1,U&I/VM=]JVS`
MK'ZEM`:+K>HFJ4MN`I&ZQC%50>-IN*WA+*(+[X>$&V12#9\19LMKT\5)9<ZD
M]F@+\Z$J.?S"S+HG9J55X^J[\U0CMY\_UOS;*JQCNTLK*3-XS%A-;U5&&,/,
MB4$9U%EG<D<")4V<F=7#(B[?SYZGZ+YGZ,;=`UM*3N<-HK`8ZG!Y+75`239L
MO7%#1#G6//`ELE*A7O6(B\02#1X@\B4,LN.QIS*TR9+9A@4=-`GY%:5X1/")
MX1/")X1/")X1/")X1/")X1/")X1/"+`=_<L<V=51QG$>DJ*JJ\8\,<*.Q`ZS
M80`EV`CQ77715Z!<EV+EZ">+:::IK.Q#ADX52Q])179/.=?"+VJ'YEYWY=BR
M\*YRI"K:/BSQQH\(AJPA$?AK4L^3UV33(&M@C%HN:(::;[Z8?E57CS&FV=/K
M_+GX>$78;@I"F^@X2^K>]:KKZX8`253</8=941!32.*ND-5-&[[`F0,7[1(@
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M=+;9-5/?3.<>$4/:?]:WK]Y_L+6V*5XUYQK*R455EQ\TB%3Q`2?!JN,;ZN-X
MT^1&?4B^5M%-TE<1W\LQNCME';&4OX'A%-SPB>$3PB>$3PB>$3PB>$3PB>$3
MPB>$3PB>$3PBUJC7<?[Q1WL9KL#=^DPN"QO993_(]3TJUM>;!#E0THI,N=.:
M)=-P+6N)I#YY70=^79WM9JDDC1R.MR931(H]>/&:[W1P11QN[V8=VW%0704/
M'":_%">A^3GC[F9G2L<L2*W?%'_17=_]QAS"N[L>16<3&E9K857N)/9*S\4%
MA6D>*1IJ:'DT&ZCE-L1<TW]T_6)1"H(G7&>8XO-98`YAVBU.V#6US2JP)T=Z
MBZ5D7/#&I!)#][L,**&.0A$+,.^E;C>Q_6.R.T_MX2PB<$0?"B1LBY-'WI]*
M.F=YV%&Q/-T\B\.I.Q;,TJ43&)@(F_.$C>=A0WE&AXGT3:!BXVD*4>/0Y:4W
M7<HU_&ZIWAD>C>[)8Z!"/FTKU(KV_7W<%W7QSF.M&]"E+GC,BFLZ3A4AHPH`
M*Q8[6X<\N%CA`VK#K2NV"M)IAT/+LY&/@]M3R.,U6C=)(W^8?F+!D13;\(GA
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M'PUUUQC&,?IC'A%Y/")X1/")X1/")X1/")X15;&O:U34;]F`[UF'X#8@V>&8
M[&GPJWE=8_M5J\NF$!EUEQB`.5?S;4\R.GXI`I@J'54&;-WY0(L-2Q\54E]B
M+T*0]N//]Y]M].\8A([*HWCERO9E8DLOJ6$(H*I\\*K2:@*ZLO`8FH:R1:M(
M1-BQ:/ES1AHQ$Z.HA)=\N4T&J"CDBDU#/8%PW8E=3FW8)USSM+:OK(H##6+/
M0%MPDG%H.2DY5L"C+:5&&QA1F"_:,N]:CX^L14;H&G*^B8Q5U\?C@BYV)=M\
M=SRNK)M^&=1T%)ZJITB[$VM8P2UX20A-=D66-,KMIA)FYG<0`WVU43V:[$7:
M";[51/9ENXU4TSL1>J$[HXRD=''NF`/4]!E>?8J_V$R>XV5IPY:O8Z9U69-\
M`SDFU+?EHHZHN2&HH!'RR!5RJ2')MV:N[YIA8BP/#O9;3-@]=,^?(02@<KIP
MAPT[[?8]4`;4`$JX<14;<A&I"X+Y6P_<(F-#;BGYHM,%9IHW&*,GP<@&;+,G
M#O0BS/"_8!P[8U=3>W('UOSO+JPK0L#!V'/0%MPHE%805E!=H!C+24F6QC=F
M#VDAE^R&Q]4BJW0-.G*28Q5UG;PB\@SOOB`S65@72)ZXYT)5'54B3B-CV2RN
M""N87"I0NNFV9`)#(DC>PP<6)N%D40[%9QA<RHLEH*T>94TQL18+L/V;4P/D
M_";:BW\'Z1KOM[H(]0HJTZWL\,_C4(?1V"R28D2V=PPJ1MI(_:.0&`C^,J$H
MX]'JNMG#EWJHAAFL1<E[+/9%6_K1IV+VG.*_G5MEIG+"4<C=;5K@;O+R(R*P
MB4658<OQJ560:)1NOH'#S4BD;O;?_N=#1MIGY-5]EDB+,TU[PXVK&#UY8MI]
M+TO5T2M>MVUN5X4L:P8U#=9;7CE&+K:R8&B>(LEB;#3,TBK=3++1??5V>&M<
M:97=):;$6`;']P7KMJ>ZX%2$]Z@J..%+(I52^(S8!:R:[&U)O"W+H(C%V[Z=
MOY:V:MCL_8&]9!!&*3-RVDD<&&"[1]A!CC54BCK#/=O3+>7\V">B1]/\Y03H
M#E^U.C'%MF.JJJL"M(F\KZ[A5.A:_$SV'-E8!8;V9Z$\R)`O&IAHJ(7:NHVN
M#>/V1%RR(K%+7[DXTHH97!JY>IZ!K$/<#!J7JPI-;7A4?'V"$>HLW#4_$GA`
MPBW-QU5`B/6_:%BHL%T2?,U%'VFCE'.Y%A7O/V8<T\(5)/)=,;,J4S;XBF)=
M<E6\_%[<B\*G-T#(R*($6K6(Z.DS1+=F>5&/&8TRQCIE)TLU>:CVA%9FNAJ1
M9:A_</,I^FB=TR&ZJFA<=A#:NV=Q[E[&C?V%-S:R0L2+`('/"R[ABD%D#Q6:
MQY@-;%&XUT56)L,MF>N[K1'4BEQX1/")X15=>Q?VK4YZU97S,!N*`6+*0G1D
MAF@]S+X0F"<"JIC-?D*W82N=35J5*#R#B/B-+,$DGFH-!\\1&#2[G9'YD4$G
M!%[%X>T^F*4[SYYX!5A4ZFUC7Q@!J0FT6R`W@M5N9L-L$M7HZ:.'A1`DH4F8
MVKIJ4'L1;)PHB(%ID5,J)ND=,D4G8;VUQ[8EH3>E('T_0\QMRMFAM]/*XC=I
M0XQ,8JSC._TI.X,`F)=9^V3C*W]XDF<HY_9]Q\$"^&2V<:>$7\J7MOCR^I61
M@M)]04-:\R$PL98I.+P"TX;*CK""F&K%\/ECL:'+NW2`-9F4%NE'^Z>$&J!0
M8H[V0U(,\K$7\J3MWCF^W-@,Z4ZDH*U'-4LG92R4H':\*DV80&8;+:/#TDV%
MF7.@R/-MV[C1:0.-M`VFZ"^F7WS)*8U(HR3/VI\Z+2'DMASK,*QZEB_376;?
ME`S-*IMN.F!-5R%6MYG8BA<I^0L),D9>:-8JU01CJSR/;/&!IN:;%MVJ:*3T
MBE!"NUN0;(M.:4?7_3E%32X:Z;F'<XK2,VA#S,TC#>.*X0DBI4`P++D&^L;<
M9PWD?]YVR!<YPW+X9K9QIX1<96_>'%-PFCD<JOK'GFPCL8KU&V9&*B-NP8X]
M`UFLQ:E/V[,(L#2VPV+MQKY@0?&'?T68YD0'NB"K9!\TW6(HQ=`^VSEF!<<=
M)=<<W61478;3FEG$EI?":GN.,N-]',PF0*)"VY:0`V<QVCR#O4L[)"R"X)ZT
M,Z"'C<?NI\BSAL12QZDZH@G)7*MI]8V2S).8=5E=[3E\!#;-E#9Y^ZT9M(Y#
MPF[O=LTW.2F2%!$8#[NE&[78F4:[+[I(_/MJ183YO]E/.-Z<HP7K&<R03S/%
MY98,AIT[&+YE,:AQF!7-&)K((&4JV3OWY!L(0EFQB./%V+#5SHL\&K-7NB6F
MBFV-"+I]N^XGUTT["*,LPKT_54NKKH&Z?W&PN<0"?P*1Q<9(F**:\MDTO,;R
MH>T`P*NTWH+:P9)\[O,7TE456>,<H'F"JI%'Z9^[*G8RR#SH*.IJ<4*>[XJ/
MC$=?<,ZRJ*7P-")V17):?G;VE#F&I25*OVD$_)GS`A7T]>QTH_')?M)^?#A>
MZ7U"*PE;N[BUO1#;J!?JF@T>=WI;>/L[G4M*(:5V[D2;I=CO'&LFV*X'.)%J
M[;.&^0**VY?ZB"N/L_[WMG!%[$H[DXTA5206^Y=U/0,<I.SR38/75K%[7A;*
M`S<JYW=::CXQ*%C&H@R\1V8/\/D&+I90;@>_V(:M=63K*1%@KA'V44QVI3<8
ML)T5@M46!((U;=BN*<?6>$DTG%U#5-S3&FG=M*+;#HT[7@A`S$LK+R#(1`0)
M>/L"52+I1##MP13KKRQ(';4(C%E5A+X[/Z^F@EL>B,SB19F=C4D"O,9RU*!B
MX]5=D08KXUV^DX;+*)[_``SC&WQQGPB[EX1/")X1/"*#/<_;"7%H&B7#*EIW
M?<VZ*O\`BW.E;5[`#T%C!0A.)=&I?)1:CP]8L@C,7'#]D8@Z9[N'Y9LGHX>-
M]U54D-55-2+`]*^U&+7VPY\>1&FS,/?VIU7<'(5IQ"X;3J>O9O35ITG'9"7F
M#`$$UD9]C?2^K\(DR:CZD,EG/Y:]6..,H)BR#-$BG3?/3W.G+<>#ROH^\*MH
MV-R$QB/@#-HS8!"V)LUE#=UN,$K'7S/!!V@T34>.DFF%<LV22CQU]%LGNKJ1
M=!EO>G$T"FXJM9KUESS%;`.2"+14/##UN0@7)"4@F\>`RR'C&@AV:2>++2:-
M2F,FPF^J642(Z1`G#5530LP^X(NU&^NN6HU>87F20]#TR$Z'D;=JY!4H4L6+
M,K,*Z/VBK\<FSA[@FF:5=$AZ"S\8QPT^](L$57K)!=LGNK@BC_T'[)N;*DBW
M2#.N[9H*XK_YIA!":S?GG;HZJ*SD@MJ**"!)-*8R68%\A:]:B7)IBD8)29)-
MN)>.QPXAHW>E&*2Q%7[=OOVJ6K^B+EH".1_G@\_H^G(5,9$4L?N:DZ-5E]Q3
MM@X),Z.K3::C'$/D[J*M6^$[!E[V<@T8N\=CV^0#[5^S5<$5OZ_7',XNXHGS
MC(KYIV/]&S,&S/`J*?67$<V81:O!BI9/\MB^I3!4CA5@U>O6.[9IMDH.8O"3
M#1=DW663(HE=+>R"0TCUFCQ[5O'5Y=3V6UYC9]9276I)334?R$JQQ9DBJQQA
MB/M2?P9>421M(`">4H\`5=$R*9<>F.0<*ZN\-B+#]X>\'F6K^#*J[V@L(M*Y
M(G<4K.0R)U(`%#X_;C$_!`D_DEO#Y6!,/%&X)>H`573E]-M\.GS%#4.DJP?/
M1Y)@07(LM=`^SL'6+[AL'2//UE]72CV`PR?V#1,?K>55="MW43KVN(;:I,B5
M-6M+XA'&N[V&3)N1'M\E]=UE!SUIC;+M1D@Y(HM3CWK!@_/E%=35[Q!TA9E(
M7C+!-1MI,E,*`A96%]"D[8EM-[4=)HI*;3;']S[>7Q-3XR\0S(5WL/+#G*LI
M;[Z$$61%<]34TF]AUI%IE8]12:AYJ;;OU3M33&1P66R2'K-2Y!@U;$Y%6LCE
ML()[DA[1H;;J`9"1219DV[5YNW(H/&C<BR=X1/")X1/"+6][C]8W5-SWWWWT
MC2*$."VZ[6];5T<'RTO(QR7T;XX]>6WB;CY,Q6SKJ'#&XK8)"(X_.L_DYM"2
M*_<XRU:.-DR**DL]$/3>U>2VJ())8@R=3+TVLN9I5:!V5*:*33LZ0=K9ZUMQ
MM)$F#9U(E(58;Y](PKV8[-7>N@DWJT49K_;Y:9(O>Z:]5_<'7\.[FLE3FRB>
M5I?=O)?*O*=;<SP>VHS*`,I>4UTA#[@E]FRZ5`HI%(6#8#8N&5A=>"=DB1K>
M.LL,27Y5G5HS7(LI]2>H+H26V[V]-J$KBDQ==2^X/5=>-/TJ\-!X175X(<6A
M9<A;=13(2#!$!L,82-8H(1#OS,?=ABKT:-R]U18I+.VA%TF<^K/M^P)39W8R
M5&4;$)](O8UR/V2+]?V;9%/X')X#S)4DNJTV(D]H#X8A7K6UK&*S+><X>8C9
M&+,%X^S_`#5Z5*+Z?0(N[]8>K_L[LF3WA,6]7TKRRYN?U9'.;64(B=E-9+#H
MM=6>WG?0K6#&2D;B$7=$0U@P%HW2LJ9"(GJ)UE$NE"#;0^BEA\2(L5=,^JWM
M_KZ%]QV1OS=1G+$RNODGE+E"N.:87;48E(25O*7Z6AEQR^TIC+0,4BD+#-&$
M6#.(77XG9`@:WCK#1D2_*L_9L52*1%W^NCM6!W-[`+$XLA%202(WM*?6T[@<
M>CJM21DX6@7/$6E4<O\`'5LTFT&F%=57:OVQ,2S@4YE40=M6B.'CX;ND_2:;
MZ$6)N6?5/VI7LQYYEM@10`,TAON5Z![FE[4E;L8GDA$4C:_-\5A(1R3D82,P
MP7*IUI-F),=)6@**!$7#[5<VR8:"G:2V2*=W<WKPZ:[A[E@<]9W>ISCS[0O,
M5@0:OI0#AM4V](YO9_1ZY>%7N-?0"T0DC`!(]FFF`&+ZR!R,P:64,%6P-TU0
M6?J;D4-N1O5'U7%;+]:@3JN"55:=7<"USWM02LFD1:*S!.75]/R8!GS%*V\+
M)-R&6KM2$IKQEX,W2R]BS4"GJ]SI]ZG]0B_O(GK#ZPYJE'JSE,KH&G+;;TUR
MI<_)O2X(K8D5:+5FC8=\@K$C=H!EB<9D#*S6T6B`]X-91D1LR)X<JZ#4"`UF
MNJ[1(L+5EZM^\:"CW#4B:\H<\]+F^>^$^J.<)W5]BV_$X\*'3N\[[D$LC9J)
M%RL2E@8EN-AQE/\`/-MT0R+B,D98!:FD2R[-@1(N2C7J0[BYH@H")1>H*+[1
M=61ZI8]P%*'EB6LQA+;G2QD9'8Y\O(@'[60<^XF--)YLA#3[",)"9B36AK//
MY8/TW9;X(NK6]Z:NWX)7U_4A6]34!UR/Z(];'*G*(V[K4LEC"#?/UC<NUZ5B
MYC,0CDCADG,%0]@EORZ3P=<47CZ8B8-0+N6D1;02J1P1<K;G#\L5]OG%/.`P
MT"_=9?\`0_+?5?=U5L\+$\J2SUK#34/K.1&<:8T$+0NS9H;@$&WT^538^^@A
M!R^QLBU;IK$6WMX1/")X14_>Q[U]R'N7HSCY4J)$/J"AM-^P:JKS(.RK5L:"
M)]-TA#J]K\E'0ZN=719\SD`AX1PX9;:;!7(]D^4WUSE/;!%6/RUZA^XHJ/Y!
MMCHP]%Y;U(([?B]D]'3P9+Q[E6/\]T5R38/+-$I1Y[\B.LB-,VKUC+WC)C]-
M[N9G9AZ^22=($<ID7AYM]4O:8';@JH;"I:AZHCGKK1ZK>N^F8/:#"1RWK$C<
ML'G,+C#$;$6D,"R:%-9*O+&QZTG-A''6SI1AMH/1<J[Z)Z$7&03TD=&":/X0
MK,)&JLIJ:0+UP>P+E[HFP8L5!MWK"W.EX0Q"UP6(/8TS3+S]@WD3HP4+&&V2
M"HS.[UREG=P[3^L1==*>G[N+HZO\1>55/0_%96H?51+N`(J]KVTVLUTZ)L,P
M]A#IM)I-O#H2&5AU./M(4]W<#Y!D],6;^7OUE!9#71RJH134<<>]DW<R]>3N
M5<F45R6ZY9ZNKB63QA5]NQ:9$BE<0?FFQ*K<V#AV%A,1'Y5:261!QT%AJ3N0
MG!\>3^N2>,L:;M$2*-_+GJM[/C!#U]519%,T7547]<2W3Y-_TU![.8266]8/
M;@B,WB4;8"X@TAX:3PII(UI8VD-HN+!..]W;D=OH/1=*JIYT(O0I;U!]=4C4
M_K>UJRN^?H+>?.O#WL.J6X9`4S#R\9?7I?\`!TFE([3AHV#/T[8BNTQW6<RC
M8@/D`YHSW?8?,'[=WNU<D6#RWJ2]E-J5UW0[L*(M$[&Z0X7YLHD'I.[VJ.5$
M9!;M5=``I_-72ZE85M6,&@\)V",RSF"!4!)?(H-L.&NCN"#M<($(KP?9OQYT
M-VE6O*?-582QG6%;I7I"++Z/M35*+20E&(W2$>?S&O0@>O)>U>@K#_:.Y6,*
M<N198>^!MF\>PX.,G8]11JL15)RCTX=Q#GUV465/P[I_G^S/9CQAWWM/Y[I6
M5?OI.[;%'N>TA\MJ.-"AT-9X,Z,X^^&`P`1H#DS'1ZGJQV(D'C?!%D&V_5'T
MZ-)W-/:JI"FYCJ`]U55^P6J*9=S**P@18U%QNI`$,F\79E5@12.P,[)9&EN[
M?BS@W5F_;!<O7:3QQ@8U=D7KWGZMNO)*;M"9P6@Z+D*!7V[\R]WQVE938<?#
M5](ZFJ+EQI#Y?$"I%O%"K,:L3L9LO%&>B\->?<).=9.Y![B_K(Y(N,AWK&[?
M@TBKWKS7GZD9%-A'LMZ?[3.^OY*W`(^#AH+?M&QNE8R@$LQW#EJY>VU7I*+[
M6%][L`'@'B\A=_EKX:5;[)JD7XA?JR[4I,QR9T4-H'GN\Y3"^D_8U<]B<5%K
M5&QJJJG"]WXC6L,"0">2"OBT8+(TTVBV&TIRT@R>I'61EFT+&K):Y>+D4'NJ
M_7[T_P`C<%^M.O8R6@=8=G32]>G_`%UF`,$?+'HW*Z.]B,JM=X1:AG@YNP7<
M!ZS'-@%A@_OD1ND14V>/GGVI!ID>Y(MUJJ:UBE,UA750P1AH*A56P:*5[$AV
MFNFN&4;AH)C'@K;/R:Z:YW2'CV^JF^-<?44QMOG]=L^$7?O")X1/")X14Z>Y
M+CNV>PJ[Y+'594D5O5"D>QH#>-CU-++0VIYG.*ZCD!LR/&`;.=I,G[@0^>D)
M0);Z+-&^[I)%19REKM]#;7)%7]SSZG>O*Z>\@;E14-KBLZO]D5[]/BZ*A=RE
MK";<D\_6?0\KA0B!0NR)D%$EYS($[$-/I.[0&#-Q@PC(UWS#ZZ>2.VA%GKNK
MUKW\I6=5Z\PR_J/H?I6M)-<,NIKINW.O(,"GW/\`*+"A$-AVD<-A)C4I*&6O
MSS-$0"BEDP5<5M)FR31TC'?N_P!JGJ@DBJIMGD3K?JOJOW)<KQ&C>=[/L2V8
MCZIJQN#I8_)QT!TY\D8'F:LI'*Y_7,.<0<B8DD2*/XY('X2/Q,U&S`$P-B^Z
M@DFS^?0>13I_X*7H5AV_:QV>0B<7=0UI=Y4UV5%+1BW4\%JL;`5X(C7R3/:Q
M:N/4_*;,E<JJI:*$TXDSA,\9`I=&G+*.+$(=L\*O]2+IRWK<[L'<%=J>OE+F
M/GZ0D)@VZM-5=V;O<8%.P+J*7I>"=G1H8=B+Z"(R&(G%@A'8)/#4DF^HK5"%
M1M@-U.H[(NV9%W+HWU+=#6<*]KW[/US6#\WU/R!PY5-`OGYN,(.U+/I2,&1=
MKJNWKEME:)_.\<,M43J^Z.#^OR;X5WU2V^0BE-R_R1U9S/W%TL8)\Z49=E+=
M0]$1'H5#J226<+'6328L-5(B&+URWKDA`CDDD)B)$PBS&N7H&3A@#,-(R3YX
M48+;N!.Q%SG35*]YP3VEZ=O<I<_5/?45.^O(5R0LRL:_4:72B<^1Z*EUN[2<
MDW2@DY+R&.,!;D$BNP$M&3TAL]>I-W[59EK]<BK]J?TC=NHS+GV)3?IN/U;$
M:4JKIVT)3:]<0*L;38SSKKN2QY-K?<9!53<T:-B&E91ZE'[2#!Y2?CK8R]5(
M&%PS$)J:)MT2+PP#TO\`2\Z`^L;G;J1M^T-'\(2KV+U6=LJ%7.3@L_D=#VA%
MP0[D^<`',"-AY0'.(J,FH8M$D"'T@@Z--&4B:$P9!RR<D6;EO7)V67]5G'_%
MQB#U8RM3E#M>CCZK^*G8I&HC/J#I*[WTG8VN@S$-&;$;,)+!W;4G)0#Q',D-
MRY$T7)*N"QI390BV5O")X1/")X1/")X1/")X15RV_P"SWG&B;0ZK@]FKG@$1
MXPH^J[CONU$V>A*-QLG=A\J'K"J!H<;NZDINQ):T%IEQ@YB-V;*HEPC3#C+I
M_P#*D19UYQZRA_1D,)S#%;WK0:@J3YBB\0ZAJLU1\R>/=@#23M7P07)5=V<C
M#/0KK=T@3`$R2*2H\LR?8:/A3]N@19_WFD.3C>)BI+(SI$-DM5]95N>%ZQO9
M#=?#;1;!S+K`S*6[G.&^JF'7R;+YPEC.5,_+X1>P0E,8$,QQ$K(P(P>8<,V@
ME\0+CV3,H[(8^9@U'.G+A-!ZX?:_PF:+;=51SC]4==\>$5;70?M1J_G.(6E(
MYA1W0S@S!NH8+R/`8=B-0H$5Z!M.QD0ZT9(4Z3D\]#QXC`E<%=L/I=)RL8;,
M=A[O15ME7+=-8BE'0_4T<NZ,V?+"=?651X:J[#(5V5?7<PB\6%R-8:#CIE>7
M0L\(E<C`2"!JJR+4,QDR11!L]+"RB+=+=!%%=<BZ;9W>%)4C(KO1N9K.ZTK"
MA*KKVVY9T"?BJSZF#8.QC!4(-#P@U&7)Z2RF3B78Q/<X('Q7.6K<BQ7;K.T]
M]]M"*58^;0XJP=%!LJCKT<Q&(&G[UL9'J-QXAR@LY;DB"FKCY6+%5NW<+:.7
M>44LIMU]OF^"*GRD6-+BZ5HN@&U6O;@L<'"6=U6;%*=J]V^3)/FTML6;H/G,
M7`M%PS$DDS0)MQKM;)XKNPC;%/1+8D79X<M?K$65%)5%TC(^.JR0"E("S/<B
M+!*&!VADD/3QG.[X>+V<8>O&>F-=L[N6Z"B.N-<YSOCX9\(N>\(GA%XOH(?7
M^Z^BE]SE+"&7'T]/KY0QOE3"/UOA]3Z6%,YWPG\WR8WSG;X?-GX^$7E\(GA$
M\(GA$\(GA%$>]NQ(!0][<O\`/AL08-3;I\A;;@0X'.!;0+`8#1]>.;!L>R9N
M](NV^6<;$-]@8-OJV36<OS,@9HHXQJBOG!%C+DWV3T/V4X,OJIAO00*MFT:+
M32'7M:E(S"M:*MB(!)*A%"4AK2RI&BB&+MT2SE'*8TUB/GW0_94JT$+CVCUP
MW(IV,)''BN2N!AX,2R!=*,3F&!1B\R&>HI8669E<-UU,CG22.VJJC=Y]%71+
M.%-M,:YQGPB]1K,H@^CZTL92J-NXJW3<K.)*U.#'$?019[;:.U5C*3K<<DFU
MWTWT<J;N==4-M=M5<ZYUSC!%%.X^Y:NHTY:B,WB=FYKZH>2)%V))+O"@`Y.G
M2$'C)<L,?P..2O61)+&+8<-Q&YP9%DQB3!^&?#G")WZ[K5MJ1=)Y!]@@7KEU
M%6S'G;H2H6LLH1AT(TE%F":\<0-E&C<U(1>/1`C,8%8<S&M+*,@6P^R,0U;5
M-V+@YI@Y-+#B^KH0@19WF'3<-BMCT3`F,<F<Y#7JK:>C:VH$R!R&H:S3J>(*
M2\LYM:8Z'V^(TV/I(K`XNHQ8&OOI"@LP>X')I[.?"+G:(Z6HGIJN85;%&67'
MI_`[$9E"$,,,LO13LXT"O51Y91&/2%F(DK;8>Z1VT=HOQ#59%+=NYV3PV=-E
MEB+E[5O>H:2J2>7O9T\"QJI*Q!&Y).9KKET;'`A$=^K@TKNVCK8N3?NV*B"K
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MF-4TQ,2D7-W,O%XL[^T"00F/:!Y0,W)%4RSD7)A+5B/?D=7S9J16;`;5@AZ-
MQ:39/-8\VEXF)%Q8F9_&&RAMB<#=2D:$FXM)/RT\!DC]OE5']G"S!H91?-'S
M!5EJ[9.4DB+LCD]%A9QD%>&8^.DDBU45'"7)$<S.'=&"?P549,%5DWY/5DCC
MX*;H)+X;IX^&V=-<>$70+>NF,5%!+.F*S$Q/3=75S);,(5776HH_:\C#1L4[
M*[,(K$')48L0+&/M,CPB3MTP9/"*R#;9\C\^=]2*OFPO;G5D'MF.TP*Y]Z3L
M&=NN1&G8\ZCT/`5OB15;"CH"1%(974GC4@LP&:+7/+CD<4A8^!PQK)5&LB+A
M5'Y!$(Y=EV)%9-&;(CTA`P,J\^XB!FPHJ,E06!3%0<%GR"3\.U,.@SZ.9(.%
MOST$FZPS/,V*SY$<_171V=*)Z86V(HM5-[">?+(;T$-EB\OH"SNDHO9\SK:D
M[ZCFT-LS:.U`>3`S4A(VXUW(8I&L-U'8T@*;EY6V='1I)!40B[7;$FS$BRK1
M?3,4NJGAESEHE/*'!E91*HLVC_0`X+7TJPYC4M+1)N0W98/EAWY9*EA.Q:)K
MIE5%2X9ZQ=ZH);K_`$=2+.KV21T81$B")\*/+'ME=`0MZ58M")K=#3"BV@ED
MNNFY([(IYQNKJS26RGIG&V^,:_KX18LF_1U(UO;U14-.;##1NV[W83LG4\-?
MI$LNY>QK1F&?S1=`@@Q6"BORIM(!.6Z9TD+6-+.=VH%,FZ:/$6Y%E%O)XT[.
M/8PTD(-U)1C=)X2CS<LP6.#VB_R_1=/1*;C9^T;K?/I])==NFDI\^OR;9^;'
MQ(N<\(GA$\(GA$\(GA$\(GA%K"&X!&SO7'X@BD;BYGF768BZT_7W9G[B807!
M1VP[,HHA6+2ORDDK5_)9'#V#HS3\IB,A/BT&4G#$%I+'V@T41:'G[+YR*J_H
M.J^HHG3/*\#Z.J/JJXN2G7N;YO"\@<U=52BOS'7TMH7;GF[F5EU?,R@R7)!E
M@LF)*KQFO(G.9DR<O`23L.?=,A1C594BR4OZ[^PFU3U!+!7*%D0GD!A[-^PN
MAT^%=J]JN\IM5U#VG6$9A_/QHIS3-)X.KF3(1*>#)Q(G-5IR4AF#)SA(X'8$
M=FN^V"++;#U^S"J"_#[^V^%.H/8#QI".3>G*DB?.<_BM+,+/HV_+-Z/-SJ*R
M>656YN)Q!X1%2%7.&\#A$H'S@T_K.)I`\E,QTL-1$L2+W[G]8-M7+/[F>SKC
MYQ+8])_>YRM<0IE)@L<D397D)U7T!C=[FDW#EZXT>5RLS!(`)LCKMMJ:1#)I
MK,WB;?7.I%UDWZW;CJ;$B9)\+RBTN)ZY]X%]W[)N-JX!0O*5G<T'N>H)!:6L
M"$UF9D,>C$UA<#FK%^LA"'+Q#+WY<ZJBOR]L]<M"+NG5GKBMF_(I[!6M:<+G
M*ZA<W]8W'<;Y>IF4)PAPXAUI5%9%F2A2L8\N/D9N.C+$A,3)I,TV0HVX8#7)
MI$&.,.$UM-]R+&?>',,D$SWBJ#<BT<5Y'K[VXTN(]=-^<^&P<6K^=U#$J[N4
M+<1^U/W>1`O(@F2R5*;W2%.*-"#QJ,C$A8*%_M3)%(?DBMW]TG%@>W:*X<6A
MG)6>F8YR;V)0,EEE11.+Q:43-?E82-*QRU8-#P,K)AF)\:;9L8$W,1/<LU:F
M&H-@X([Z-!*CEL15'VOZ^>C9A;G0\<&\(65_=46K[&**Z&Y+[VQO7+6$<T<=
M1!Y5+T#79";H3_,C@CVE(5%YC`GM1QX$03D9`FW6"IFD6`5VJ1;IWA$\(GA$
M\(GA$\(GA$\(GA%17V$D]B7N@]?\S,1G69`++XQ[LI>`1EVY9,AT@M@,/A-H
MN8;L1*X_)QI&<P<,3%M%">VK=PU8$-E,*-V3G7!%15=]"]!T?RQ[)A=%47V1
MR;ZV5."+0>RKG'L.6P.31V"]0%)['GP\=RJV!3NPI2/@"('<X\-%%#V\5*NW
M+Q3&5WJX75B1?O\`X/3K2W*4[9/\8<:V1Q]!K1X)XSJDQ5$EDT'#&.L[N@MT
M1RRKSFL9>C)^9'21O)Z:TDT-TG4H,B%K35DJK4HJD[DT@U9$673'KTMG%)%9
MC7O+O4,XI@O["./K\Z=X;EE#4+S&&L>GZAK^8Q6PV=)T+`[>/1.3(D2+NO3,
M]B4@>Q<78T@BC(@RT):-GC],BS->/!,QN@AT^ZK#U[2RE:.F_HHZ$I^E*%E(
M:"JJ1CI'/65FW/4$+0`QV3R2-1BQ2!O]E+BC4;%%EV<!)%!(M)ZP?@LM6I%@
MRW?4ET'#H]=L:X_Y62JW]Y_I-Y*KV<CH$A'*W96KT?'>I(_..EZK)F63Y@AO
M:-@4S'B<;-$WV^$"Z!%B-=%?IK_,F13?`<>1RWKW];A*J_6),>2^4XU97L`'
M=`4U9L/KD**7`W#PS#Z?;2V=0&)2^8!1<>LPVT<5:DP>*_F4IWBCF3F12*$F
M2>OB*LQ[05F>N3U.<W=<P[E$CS/VOZR>ER>]F*3,-"8ZTZC"WV3>T7.]XN:C
M$A-NK&$R>,RZJ1X<Z3:MB:BD)W:`A9#0>U<*$5WLX]:QH5Z!)=P:*@`VS;N5
MY-D)K>/F-!:SJ3=7G6#VU3)QF]+J),D91O=1(@]C9=X[;Y9D$QBNSYMJCA9,
MBJJL_BLX9>57*#7J0N6RN;2WJYF?-M%<TL8540HQS!VJ7M&8$YC84JKE:RF8
M&N-;86>CY@A?(=^_D(Q@LV6?-6!'15FV(MH7@"K+:H_B'E"G[W+Y.7'6E!UC
M"[&?[%,'-M92`BHT>1';'-5%M#>P;='`?8SHNOH5V89?Z+K:N,*;$4O?")X1
M/")X1/")X1/"+#/1L1D5@<]7O`H>KLA+9O3-H1&++:J?1V1D4DA!P,$5U6^.
M/I;)DWK7?"GQQ\F<?-\<?#X^$6IVRK1K?'JH]7,EJ[ECMN4]#TGR21B//G4'
M#LS@\3G=%=$PY'6K9W6%J,Y3.HFY90*2SB$;8FSLH$D0I)L./BOG!$E%=R!%
M$/HF@K\O;HCM.I>A>,I5VCW1(_6+PK!F<SK5>`_D?/?7,J@DG8;VP;W(2^)A
MX\T0DC!\2>V3#!Q)@'VBY,"V3$QB=;:N"*7%L>N'JV0]GV,XZ,B?0UBOIF4X
M+,T3U/0%(4G;AN#+4+$H*WE+!G<-DVC!I=S:@%M`')CDNT#BU65C`9(8-NDR
MY)R@T6(N\J\86VRBWMGKFQO7?9EI=IW;K[*Y+4O>;)K79**2RK+MH*;1BC8!
M'9VZG*$\W*%6I`)4S"E48ID)&7#A.1/%F'V*JR!%B2VO3[*K#%=!R*0<0"I7
M.U_0MS=`JU,DX9%GYS7N^#0DS#BC&/O7"VRS:X0`$%#@&YK11)9(<,"M$B6R
M#=OKJ12KY[Y'L:MN]7\RZE]>UC=+/YS"O7"ARAT2/Q79>+<BLZ-J&*QVW1<C
M+2*=!C]1/()8S0O-G0V'AC3RV%D5F/VK[)+Z:Y%$ZA/5U(XT+]+<@ZG]<1:^
M`D)@W9E$=1Q%Q`JXFI^!NK)O!:4<Z22T`DID0Q!U7\2_:*<RM$RV=E,Q%H<,
MNT&62)9LP(D6,&GK/ZVC-&\"1RR.9[*D%!5/O[)8;.:4A]*U1?\`(:OD5V]#
MS(K5%A)T18D[B$>,,I/5KQ`=%IF'(/C%;);)E6B8E<BBNH12[9<(7)470OK?
MFE0\^=$WO.J_K7CFH)\][1I#GZ:UO"Z4KF?DI>ZG(BW0UM&ICS)T91(Y\JHZ
M$P5>5B9J5#QEFT:2S'WJCDBL+]D_)8Z=^QWU<=4O>-GW3L'K)W?-<W23B$.@
M\JDL1?25G7Y+FF7RAE+3D>RM#*ML%.?R]$ZD[=;09T_)E&+50D5;M7Q%5[R!
MP'TG'+[X3:%.+[%JKKGG?M*_;H[@]AQQU!](7T73$Q)6@MH'!S\9-B,TM+][
M`J308.SAQ",M\0'4([V>-1:"I%;PBW(?")X1/")X1/")X1/")X1=6Q!H5B:[
M63B'Q;%B[1?$(VGV(^)Q-=H7J5R=UB&TJ^T_/<Q?4WG)G`#+_P#*L%<Y(8:?
M=Y^MX10Q[?ZQ]?G,*M.$.ZIC5\253ECZR*2?V7`2DVR!G->H-![B<P]V/B4H
MQ$95&FLT1:,I$BH)+-T#KE$<[V36>:ZD6>N;NHJ%Z\KK:V><K%&VA7>A\E%]
MI,+&2`4UP>$(,')$=]K)1`4CE1L@38J;+89Y;*:N-<)+*9UWQJ19]\(GA%TH
MY9->1B80:O9).X?'Y[9W[2XK>%&I('%RN?YA@Q`U+\0N//7B!:3YBP=RW*R'
M`5H]_)ARZ+TC]NV4T4R1=;L^]*FIAY`!]GS49$'EI2@C#("W((D5]Y')1$-D
M]A%!K7\O9/-6^6$,ADG/NG;_`"T8(LQ*VN[K#A5LBN118D_7_KG)S'B^Q9A9
M='$[0Z"18:<0&Y!'T7UM2$;>`YB,T)5>T?@%;`AD=GXY0:&.'UFD;!/-%686
M0/\`115%IL12$@/2E5V/>5\\YQXD43MCG%&LW]D1\L(=#$\`[=C3F3P:21I^
MO\6LD`$6X\N*=$!V^^!A\*3$/TT'"*7UB+/GA$\(GA$\(GA$\(GA$\(GA$\(
MNJR."PB8/XH5EL-BLI*0.08ED&)2./"#;^&2G4:_#ZR6*/";-TXCL@U$%2@K
M!D.HS(X&DG['#G[5XX24(L'=?VSRW3U#RV0]E/X4SY].;,(7-6MB1%U.X8<U
MDR_VC(">BK4#)<%V9)?3Z>S=T'<LOCIC9Q\FNN-L$70N0^^^)NRM#\=Y`NB)
MVDUK,,!W,C(E'94!&QH&04>BH^DUT/1J/L/LL[!GC%JU%96U9Z,OI;I()X2Q
MDBFQX1/"+ID\L>OJL!)RBS)S$*\C2QN/1I&03:1B(L%5D4M-,HY%P290V\8L
MMR\B/DAX4(.U7R[*%'K5BR26<KII[$7$7%<-:T!64RN2X96R@]9U\(V.S"5D
M6Y!VS"BM%T&OW2K42S($W.=G+ENW2;L63IRLLLFFDCOMMC'A%!WJ3O/UAQ.O
M3;[K2U*:?5_`;\?5>_$65!"TZ;#N@*?:`IN1'!H<M#I"1+22MD#`(^YDL>#$
M&$7<.6ZVQEF\24PD19QB7=/,D^GO.D!@]C,Y8MUG5\_MOGN6`FR[Z"67&JPW
MC^TW'A)/IC#;65@F,D9%GL7>)-BK<:T,*.$45Q#]LB12[\(GA$\(GA$\(GA$
M\(GA%B>\;RJGFVK)5==W3!G`:OA"8I64RU^Q+DF@A,V=&1H5LLR!#RI5?[PX
M9&#],-&#C.BCO55;";?155,BCCRU[*^'.UY:=@O+?0<:N"5QF/.96=$@@4V&
M[#P#,L.!.B"CN21@*P4P@6+#V*C9!TJ\U5<XSEO]--7=,BE]$(/"J^%N`<"A
M\7A`5X;/25V'B$?$QH6ZD<J+O)!*#[@>&:,FBYN2'B#\V>*JH[/C!=\\)$%W
M#URLMN1>F-K>O0TXD]G"(+#Q=D382``S*?CHT'9325@XI]]^S`>22=LS3-&Q
MD=_,R/Y&Q)/7+85A\[PR30PNIC8B_5@V+7]30XW8=I3>)5O`8TBW<R*;3N1"
M(G$P+=V];#6BYB0G7;`2-2=$7K-@W4>.T=5GKMLU3SLNNEIL1=QUVUVUQMKG
M&VNV,;:[:YQG7;7./CC.,X_3.,X_7&<?IG'ZX\(L0VC?=04L1A(FT9P,AY&Q
M7$T;0ML0;DU]CBE=U]);4FN4MQ[%XDT1CT`A\BD;YR0W:-LMQV6B"JQ%TQ9N
M2+$!7OKCD)(>;(@5Z`@K*8=?C(P;YPARJQ/,OL\%,QB1>+GQT6T&[GPH`RR7
M3^U.2D<#%8>9V&+/$B>BC34BE]X1/"+AY$>%Q6/G90;7V:A8V')GB[G1%9QN
MW%AV2Y!^OJW;Z*+K[(M&ZJFJ*":BRN=<:)Z;;[:ZY(L*P'J*DK'YE"]@QZ8?
M2Y].5.O=Z$Z-"#(;#.LF<?<RE_)"@1\P3.L-&`)FZ?NV2H[[]/1#?35MNI\N
MFQ%A:?\`LRX3JV"S:R;!Z.AL4A=>':XBTK+E!\LT49RBVZY'6Y74:'"D8\J9
MD<BDU;%64P;@XV.+E&8C9=0FU8K,GJ+<B\D+]D/'EE_W+3ZM+:86#%.QY/8,
M'HV?18<2=PLO.:UCC^4R"$R0JZ;LG$,EK@4(-?DL?DK$<3)O@[\>FWT=ZH)+
MD4Y_")X1/")X1/")X1/")X15/>\Z*R:;>I;N*+0V-G9=*#-1)M@T<C(<@?/%
M7.LQBZ^S<8(%-W9!\OJ@BJMLDU;JJ82244SK\FFV<$5$WMGL&\V-Q%`50U/T
M?"+LJ&M>)Y%2%I161=S2):P$W,DCQ"T_W0P"HTM.6(&!KX*U,1RYW5RZ/C,O
M5(KLVS#=UH&^F1>[UO$K?AE;^[SJ<I8G5D8LN,]GU_0O,X_2V;JB\$3JBV)'
MRV*FP^KX$".C=#'[QD#1>)OY%70B2SQH/9;-:O8?M,DLR*$49&S^S1]#G5:^
MFUR8C2OL:B#WN[F]H_\`9A)'G(W/1.DY$1Y^JB;"I8%KGK@A3Q:6K/)S-I/7
M4*C:,H5-1L4]4.1^/BD]2+-8NA\#+(],-[W[->J.AJB`7CVS7^EIQ&*=X1,I
M7<.D>6Q/E6O2$=DJC&]4(\TGKL]%6=DRX4W6L6N!@8'.C1ZO(^/1:D4P?Q"]
M/W3:-L<X%ZXI!.TP54<O=\VX\?M+(OZ*DF\ABE)KQL2&;BJFB!H7M+<O9^)+
M52/V)H%+0DK4W`)&XCD'U(D21%BOK"*P#D*E/2'3!JAIOF\.9K[XHMZZ#U+4
M?T%T*G&Z#J[2W=9AKO=#*JG9LHU&3@^3D"%/[.4"D==R)?2+PY&/?EKE<BLH
MJ8TWFGOXN:70?#[]CO\`@D.?=;`^X'/PZZ4WE?1L[E%;(2(03;LR0N1:UUL6
M4P/+LVA-DS4V:.&R*B*R6I%>1X1/")X1/")X1/")X1/")X1/")X1>@5TRH+(
MZ:ZYWVV8N]==,:_-G;;+=3&N-=<8SG.V<Y^&,8Q\<Y_3'A%I`QA.P*\]3'JP
MH^<<]WPW=2.(]O[$)4F0[ABP:M;`96W+2=;Q63U%R&U'SN76G8NY/1:FWEDJ
MBX?&]6ATDA]_J7<[-B*27*T%Z#N^Y^)9WU1,^N1`&D?295_0A]P]L*SZTC)7
MJJI;ZDR@(G<BKTU%8W,9L(C6WYP>C%F%M6DD9IH$+`;D0Z6RVA%61S7+^F9I
MSG=E@5C9?0,9[AE?K1$R*FJL3F/>YBP>F2Q*RXJ9Z4Z]ACN[(Y$JJ.V1BGI&
M[B<5C//9>SFC8Q]"6UJ<0V9@7>Q%(2S:+)VUP;U++PLSOVWJ3@G2'KZM0)2$
M'AGL<CCFF]8]8B$<Z-/19?HYYI:=EOB\#=;RR:`X>ZE@FNY>'2G8C`(]^4%6
MY%=I[:*L(7]ZK**J#F&NY!8T7M2U>*(;"QUGS'H6)38/7,GL*$BQQV<K.8])
MK5)K8CCQ,99BEP)I$(Q&RLFL`WDE.8D'$D"*K6"SVZ^!O6G8^`W)TD8="=^]
M>=?Q2*RB.B.G>FP//M7&+&D,`,V_:@@Q6A6Q4T(U%V:"=<A`T>)F+WCP^$3.
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M*.B\DEBP90LT)/W_`-:*#O*%C=#6F\G-H1&TKICO7DLY']C!+E1D2F':)@KV
M[?*Y*6/@=BQ?$R`C^.G,DH&HU3,>@L2I:=VE&%BKZ/R$=JP5CH-481=D.4/9
M-_>NGO5**S3H*QV@GF/FR7&.9FT,]B@DV)Z.@=CZO)_894]TN[^G.;#+P%U+
M&MI5I6S^10<B6C4=FF06"`R-ODR*?$B/BXSW9P5->;/[J?H>FI6.YK@<'YNL
MT?[(Z\FM(15:Q922DW346M@\[2JZ>QQ#1XNYOF$=0_?F"<3C8Z-_FK:*DF#-
M`BY;\1%35XVE<E?FZQHO%EB:RX([4F>LC&V5T-'SC"7OV<6JX`P&Q2KX<5BI
M*9AG-IMY'74;W-HN[<3UGD:L%:.PF)#5I`1>IVV+KCE`QZ3JU=T3/-+4Y4MW
MG&R.A)%2=$]"]`#HW3,'K:VXJNR0O`?53P_/!,>GILLH#@CAQF1A&IS+QI#A
M`UYI\2*S#W.6)L%H_G=FI4ME6%`K&O<(+FDJCDLZPAL/J<"Z@<N>#Y5<L6Y!
M;8O2=Q=Z0W:!AD%TT'`\S1T!?GWC-V+'(+D5(/*%1]0=0-_4/2W2A[MH/6A`
M#[:HS=FC:=='U)(G,9A-C!G%!1FTY<J2#6&T8-6PH6TA3.<FT3Q(.-3`Y</A
MRA1BZ?O^_P"_BBQ6$)],3&EO7LR[E0]C$DJHEZW.BXM6[6DD.C=+*+>P`1?T
MNBE9-[9TK+#.1NY%M1(^,-X4YN'.T,?Y4>OS6ZPAQ)G"A%9C8%<7$K^%QKJJ
M(Y51PY:)3C6FJ]>5\5<V1#)F%(RAU'8GEXU"0X&]E!,]&21AD6<0PVU'1PR/
M9D&<O<Z@?OFKHBC1SE([@]6',GL+OS3BXO*;IL+NI6@^=(M`2W3/1@0`5K.K
M=ZP'61)M)=724V3H."-H[*C`6T(U''<WLUC('%;ZL(\*2A^<$7]A-=4W5?"7
MJ.I^@CUHS"PV?NRYQD$NF-GTE97/\HF-P$D9Q9%^2Z-5S9\4A\@95J/KXP5`
MCGXX2L#2`-&XU^^7,IE?"+<=\(GA$\(GA$\(GA$\(GA$\(GA%B"]:"I[IFMB
M]17K`P]C5V<>!R3Z.F-WS;70K'2K0X`,C"@EX.-`S@0PQ:$A)L(2'E1SM#19
MH\1W^.<D76N?.5.?^6!<K%T37+&%9GAU&33LXX,R:83.<GVS%,8R*S2?3DU)
M9O+'8X:BF.&*2"0$<#&.OV@_#9OMLGDBD)X1/")X18KA])55`;&MNW8C#!H:
MR[V>0U[;4R35?NC4U4KV-:1"$($%WSQUHU'QB/:;L!(H6FP%MMW9%]JSR0)D
M7;HBRIX1/")X1/")X1/")X1/")X1/")X1/")X1<1(``25@3<7DPD>>CDD$$@
M$@!%FB+\4:"&&:PXJ))L7&BC=X/(L'*[-ZT73W1<-EE$5=-M-]L9(HE\]>OG
MCSE:5_MU15*BX=+T8?\`N\$R!])YW-R,4K[[YN2V@4$6L"4RG%?PA1^S9.E8
ME"=0$?569,ME1V_V;;"1%,OPB>$3PBQ:5I2K#MOQ"_#,-&$[>K^&2NOH3-GR
MCYP_BL2G)`&3F`P&S4=["!ZTB=1L'J4*MQ^AERS'(C=B'Y=LJT4(LI>$3PB>
M$3PB>$3PB>$3PB>$3PB\:R*3A)5!=)-9!9/=%9%7351)5)37.BB2B>^,Z;IJ
M:;9UWTVQG7;7.==L9QG./"*$]&^N+BCFV>";,I:A@,,F,:&20+"WV9#.)(,K
M@/,5]7$K%57&);*#T6JH=(M]<)F&5<AHPV(-<[,W*:C3?=#8BFYX1/")X1/"
M)X1/")X1/")X18JF-(558-C5);4TA@Z0V'1#J9/ZCD;]<CLI""-@1_2*RXD+
F'I/4Q"Q,K'--@^A$@/>O1K)R^2$KL?S%_EP195\(GA$\(GA%_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g838054g00y16.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g838054g00y16.jpg
M_]C_X``02D9)1@`!`0$!+`$L``#_X@Q824-#7U!23T9)3$4``0$```Q(3&EN
M;P(0``!M;G1R4D="(%A96B`'S@`"``D`!@`Q``!A8W-P35-&5`````!)14,@
M<U)'0@``````````````````]M8``0````#3+4A0("``````````````````
M`````````````````````````````````````````````!%C<')T```!4```
M`#-D97-C```!A````&QW='!T```!\````!1B:W!T```"!````!1R6%E:```"
M&````!1G6%E:```"+````!1B6%E:```"0````!1D;6YD```"5````'!D;61D
M```"Q````(AV=65D```#3````(9V:65W```#U````"1L=6UI```#^````!1M
M96%S```$#````"1T96-H```$,`````QR5%)#```$/```"`QG5%)#```$/```
M"`QB5%)#```$/```"`QT97AT`````$-O<'ER:6=H="`H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0``9&5S8P`````````2<U)'0B!)14,V,3DV
M-BTR+C$``````````````!)S4D="($E%0S8Q.38V+3(N,0``````````````
M````````````````````````````````````````````````````6%E:(```
M`````/-1``$````!%LQ865H@`````````````````````%A96B````````!O
MH@``./4```.06%E:(````````&*9``"WA0``&-I865H@````````)*````^$
M``"VSV1E<V,`````````%DE%0R!H='1P.B\O=W=W+FEE8RYC:```````````
M````%DE%0R!H='1P.B\O=W=W+FEE8RYC:```````````````````````````
M``````````````````````````````````!D97-C`````````"Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92`M('-21T(`````````
M`````"Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92`M
M('-21T(`````````````````````````````9&5S8P`````````L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0``````````
M````+%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$``````````````````````````````````'9I97<``````!.D_@`47RX`
M$,\4``/MS``$$PL``UR>`````5A96B```````$P)5@!0````5Q_G;65A<P``
M```````!`````````````````````````H\````"<VEG(`````!#4E0@8W5R
M=@````````0`````!0`*``\`%``9`!X`(P`H`"T`,@`W`#L`0`!%`$H`3P!4
M`%D`7@!C`&@`;0!R`'<`?`"!`(8`BP"0`)4`F@"?`*0`J0"N`+(`MP"\`,$`
MQ@#+`-``U0#;`.``Y0#K`/``]@#[`0$!!P$-`1,!&0$?`24!*P$R`3@!/@%%
M`4P!4@%9`6`!9P%N`74!?`&#`8L!D@&:`:$!J0&Q`;D!P0')`=$!V0'A`>D!
M\@'Z`@,"#`(4`AT")@(O`C@"00)+`E0"70)G`G$">@*$`HX"F`*B`JP"M@+!
M`LL"U0+@`NL"]0,``PL#%@,A`RT#.`-#`T\#6@-F`W(#?@.*`Y8#H@.N`[H#
MQP/3`^`#[`/Y!`8$$P0@!"T$.P1(!%4$8P1Q!'X$C`2:!*@$M@3$!-,$X03P
M!/X%#04<!2L%.@5)!5@%9P5W!88%E@6F!;4%Q075!>4%]@8&!A8&)P8W!D@&
M609J!GL&C`:=!J\&P`;1!N,&]0<'!QD'*P<]!T\'80=T!X8'F0>L![\'T@?E
M!_@("P@?"#((1@A:"&X(@@B6"*H(O@C2".<(^PD0"24).@E/"60)>0F/":0)
MN@G/">4)^PH1"B<*/0I4"FH*@0J8"JX*Q0K<"O,+"PLB"SD+40MI"X`+F`NP
M"\@+X0OY#!(,*@Q##%P,=0R.#*<,P`S9#/,-#0TF#4`-6@UT#8X-J0W##=X-
M^`X3#BX.20YD#G\.FPZV#M(.[@\)#R4/00]>#WH/E@^S#\\/[!`)$"800Q!A
M$'X0FQ"Y$-<0]1$3$3$13Q%M$8P1JA')$>@2!Q(F$D429!*$$J,2PQ+C$P,3
M(Q-#$V,3@Q.D$\43Y10&%"<4211J%(L4K13.%/`5$A4T%585>!6;%;T5X!8#
M%B86219L%H\6LA;6%OH7'1=!%V47B1>N%](7]Q@;&$`891B*&*\8U1CZ&2`9
M11EK&9$9MQG=&@0:*AI1&G<:GAK%&NP;%!L[&V,;BANR&]H<`APJ'%(<>QRC
M',P<]1T>'4<=<!V9'<,=[!X6'D`>:AZ4'KX>Z1\3'SX?:1^4'[\?ZB`5($$@
M;""8(,0@\"$<(4@A=2&A(<XA^R(G(E4B@B*O(MTC"B,X(V8CE"/"(_`D'R1-
M)'PDJR3:)0DE."5H)9<EQR7W)B<F5R:')K<FZ"<8)TDG>B>K)]PH#2@_*'$H
MHBC4*08I."EK*9TIT"H"*C4J:"J;*L\K`BLV*VDKG2O1+`4L.2QN+*(LURT,
M+4$M=BVK+>$N%BY,+H(NMR[N+R0O6B^1+\<O_C`U,&PPI##;,1(Q2C&",;HQ
M\C(J,F,RFS+4,PTS1C-_,[@S\30K-&4TGC38-1,U336'-<(U_38W-G(VKC;I
M-R0W8#><-]<X%#A0.(PXR#D%.4(Y?SF\.?DZ-CIT.K(Z[SLM.VL[JCOH/"<\
M93RD/.,](CUA/:$]X#X@/F`^H#[@/R$_83^B/^)`(T!D0*9`YT$I06I!K$'N
M0C!"<D*U0O=#.D-]0\!$`T1'1(I$SD42155%FD7>1B)&9T:K1O!'-4=[1\!(
M!4A+2)%(UTD=26-)J4GP2C=*?4K$2PQ+4TN:2^),*DQR3+I-`DU*39--W$XE
M3FY.MT\`3TE/DT_=4"=0<5"[40914%&;4>92,5)\4L=3$U-?4ZI3]E1"5(]4
MVU4H5755PE8/5EQ6J5;W5T17DE?@6"]8?5C+61I9:5FX6@=:5EJF6O5;15N5
M6^5<-5R&7-9=)UUX7<E>&EYL7KU?#U]A7[-@!6!78*I@_&%/8:)A]6))8IQB
M\&-#8Y=CZV1`9)1DZ64]99)EYV8]9I)FZ&<]9Y-GZ6@_:)9H[&E#:9II\6I(
M:I]J]VM/:Z=K_VQ7;*]M"&U@;;EN$FYK;L1O'F]X;]%P*W"&<.!Q.G&5<?!R
M2W*F<P%S77.X=!1T<'3,=2AUA77A=CYVFW;X=U9WLW@1>&YXS'DJ>8EYYWI&
M>J5[!'MC>\)\(7R!?.%]07VA?@%^8G["?R-_A'_E@$>`J($*@6N!S8(P@I*"
M](-7@[J$'82`A..%1X6KA@Z&<H;7ASN'GX@$B&F(SHDSB9F)_HIDBLJ+,(N6
MB_R,8XS*C3&-F(W_CF:.SH\VCYZ0!I!ND-:1/Y&HDA&2>I+CDTV3MI0@E(J4
M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY`
MGJZ?'9^+G_J@::#8H4>AMJ(FHI:C!J-VH^:D5J3'I3BEJ:8:IHNF_:=NI^"H
M4JC$J3>IJ:H<JH^K`JMUJ^FL7*S0K42MN*XMKJ&O%J^+L`"P=;#JL6"QUK)+
MLL*S.+.NM"6TG+43M8JV`;9YMO"W:+?@N%FXT;E*N<*Z.[JUNRZ[I[PAO)N]
M%;V/O@J^A+[_OWJ_]<!PP.S!9\'CPE_"V\-8P]3$4<3.Q4O%R,9&QL/'0<>_
MR#W(O,DZR;G*.,JWRS;+MLPUS+7--<VUSC;.ML\WS[C0.="ZT3S1OM(_TL'3
M1-/&U$G4R]5.U='65=;8UUS7X-ADV.C9;-GQVG;:^]N`W`7<BMT0W9;>'-ZB
MWRG?K^`VX+WA1.',XE/BV^-CX^OD<^3\Y83F#>:6YQ_GJ>@RZ+SI1NG0ZEOJ
MY>MPZ_OLANT1[9SN*.ZT[T#OS/!8\.7Q<O'_\HSS&?.G]#3TPO50]=[V;?;[
M]XKX&?BH^3CYQ_I7^N?[=_P'_)C]*?VZ_DO^W/]M____VP!#``,"`@,"`@,#
M`@,#`P,#!`<%!`0$!`D&!P4'"@D+"PH)"@H,#1$.#`P0#`H*#A0/$!$2$Q,3
M"PX4%A02%A$2$Q+_VP!#`0,#`P0$!`@%!0@2#`H,$A(2$A(2$A(2$A(2$A(2
M$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A+_P``1"`,^`Q`#
M`2(``A$!`Q$!_\0`'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`
MM1```@$#`P($`P4%!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*Q
MP152T?`D,V)R@@D*%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA9
M6F-D969G:&EJ<W1U=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*S
MM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ
M_\0`'P$``P$!`0$!`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#
M!`<%!`0``0)W``$"`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1
M"A8D-.$E\1<8&1HF)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI
M:G-T=79W>'EZ@H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZ
MPL/$Q<;'R,G*TM/4U=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1
M`Q$`/P#]4Z***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`***
M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH
M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`
MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B
MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`***
M*`"BBB@`HHHH`*3-!.T9-<)>:G=^,O%RZ;H5S+;Z1H<RR:E=1/M\^88*VZD=
MAU;\J`.\HI!TI:`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@#.7Q!8/K;Z0+A1J"0B;R6!!9"<9&>O3G'2M&N:\9
M^$?^$CMX;C3IA8ZUIS&33[T#F-^ZMZHW0BL:#XIP6WAV\DU^W>VUW3G6WN-,
M!R\L[<((_P"\KGD'T^E.P%WQUXCNHYK?P_X88-KNK`[&QD6D/\<S>F.@]36Y
MX9\.VGA;1K?3M-4B.$99V.6E<_>=CW8GDFL;P+X8N--2XU;Q"RRZ]JY$EXXY
M$*_PPI_LJ/S.:ZZ@`HI,TM("*=6"[X@"Z\X]?:BVN$NHA)'T/8]0>X-2UD+-
M]@U_R&XBU",N@["1>OY@Y_"@#7HI,TM`!1110`4444`%%%%`!1110`4444`%
M%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`44
M44`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!111
M0`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`
M!1110`4444`%%%%`!1110`4444`<'\8-=U'0?#D,NA7;6=S+>11>8%!^5B<]
M?I7%1Z[;W/A67Q%KMM'<>+-`E>PBF88<S$[4.WH>N1GISBNS^,6E7FL^'[6#
M2K62ZF34()"J8R%#')_"N3U3X?ZG<?$P+;V\I\/WUU%?W#C[BRHI^4_4_P`Z
M^$S>IF-/,ISP_,XM1A;6R<N;WEZ-*[/H\!#!U,)&-6R:;EY^[;3SNKV7D:/P
MW\8:I'H7B.?QE>-=-HLQ#.0%P`F2./<5J^"OBDOB:'4'U2T.F2:=&LTD;2[L
MPE=P?G'^37&W_AKQ`=.\3Z;::;<(VO:Z!YQ`VK`>2YY^[4DO@7Q'IWB-!=_9
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M]/O_`+)#:2G=MN7!7!/=1R??%:=LFM>"/%NO7</A^_U>QUMEN(GM2"T;8Y5\
MGCJ?RK@?&G@W4+OP9#H-X@M_$/B?5WU"QAW`B&2/YE1S[Y89[$C/>NV&.S6=
M6482DY6J7CRV44OA<797;6N[N9PP^7IP=1+EO#6^KO\`%=7V3\D;L,?BG2+R
MQ;Q#\7M.M==D:*2?1KF"(0D,1F,#(;D<`UNWGQB\03>-M;\.>%?#-IJ)T.2-
M9I[G6%M2X<`@A6'/?H>WO7F?C/0?$7Q%O=#>Y^&>HZ;XEM+RV;4-7)3RI(HS
MR`V>G?\`"K'B7X?W$WQ@\1ZUX@\$>)?$%C/=02Z9/IMP(E5E"Y+?,,C('Y5K
M'$XJ.E'F4>9:OF>EG>_,G9K2]D=/U?#5/>KN+ERR=ERI)\RM;EE&Z>MKNZ1Z
M)=_'U-,^*B>$-5TLV]NTD4!U+[1E5FDCW(I7'0GC.:@U#X_3:?X:U+53HX<V
M'B<Z((OM)&X9_P!9G'Z5S?C#X6ZQXQ\0?$.Z2PN+2:>.PN]#G?`$EQ"I)4'U
MZJ?K7-+X$\7ZE\)[B"_T"]CUF]\9)J,UH%&\1D#=)U^[DFM)X[,XRE%7:]YI
MV\[);?/YF=+!Y9*$)-I/W5+7NKM[_)]K>9ZQK_Q?U@^,[SPS\/\`PVWB&_TJ
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M-]NN_P`SYJ:2DT@HHHK0D****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B
MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`***
M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH
M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`.)^*\L
MD&@V;P2/&QU2T4E&(.#*./I790+B,9ZDDUQ7Q<./#]F?^HK9_P#HT5V\9R@Q
M7E8=O^T*^O2'_MQUU$OJU-^<OT%Q1@>E+17JG()BC%+2%@#R10`'`!S@5Y-X
M6E_X3_XLW^O(-^D^'(C96+X^5Y3G>P_,_F*F\;>-+SQ=J+^$?AV_G7,ORZEJ
M2',5G'_$`W]X]./I7=^$?"]GX/T&VTO3%(BMUY=OO2.?O.?<FFM$!LT444@$
MQ1@>E+10`F,=*,8Z4M%`"8Q2T44`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!1110!C^)=`A\1VD5M=^8(XIXYP4.#N1MP'TK3MP1$-P(/<&I:*S5*"FYI:
MNU_EM^93E)I1;T17NWN8TW6<4<Q'5'D*9^AP:R9?$UQ:G%WH>L;O^F$:3`_B
MK5O45H2<A=^-M38[-&\):[<R'H;CR[9!]2S$_I6-=^%?&'C<;/%>I6^@:8W^
MLL-)8O+*OH\QQ^@KTBBG<#)\.>%M+\)Z<MCH%I':6ZG)"CYG/JQZD_6M:BBD
M!QWQ,^)EE\+-%_M;7--UZ^T]`S3RZ5IYNOLRJ,EI`#E5YK5L_%]@WAJ'7-;,
MGA^SD0/(NLA;-[?)P!(&.%.>Q/<51^*7A&X\>_#S7O#UA/#:W&KV;01S3`E$
M)QR0.<5D_%/P%J/C9O#EQI8T:X;0-5-Y)I^L1-):WJ-!)"5;:#AE\S>IVGE>
MG>@#=U[Q]H>A:5K5Y)J-K<MH.G/J-[;6LR2SQVZH7W^6#G!4'&>#57P[\3="
M\1R2)!?16LBZC+IT45VZPR7$\:J[")2<O\KJ>*\GM?V;-2@C\31RR:&9M9L=
M8@M+^*6:-K?[?$H\LPA=K1HX*KECB-$``.:MZ5\`=<T3QE9ZY87FB>?'K#75
MQ=R"21_L;F,R6ZPLI3<?+XE!5E+<$CB@#VE_$6E1ZL-+DU/3UU,PF861N4$Y
MC_O^7G=M]\8K/3XA^%9;-[R/Q-X?>TCG6W>==3A,:RMTC+;L!C@X'6O(OBG\
M&O%'B?Q/JGB!;K3+ZULK*^_LFR2'R[DK+ILMM]G)"C=F61GWE^A"X&,UQFE?
M`GQ1XJ\#ZUH6GVNG:#9:K(WV^;4K(02ZF[Z=%`DWE"/,)A92,*!YG)W#G(!]
M)/XVT>TDOEU:_M--2PN5MWEO9TA1W948;2S<C]XH[')^E-\0_$3POX4MK^?Q
M)XAT;38]*B2:]^T7J(;='.$9U)R`QX&1SVKRB\_9ODU;Q1>7^O2Z-J.G79O2
M;.XMC("TVG6=HK$$8RK6KMGT<8YS5;7?V=]7UBW\:6,$WAZUT_Q3I31%)HWN
MFEOAY6RX<NNZ-0L1!C1BI+!@`1R`>VS^*-&M;&TO;K5],AL]09$M+B2[18[A
MG^Z(V)PQ/;&<T1^*M%FEOHH=8TMY=,8+?(MY&6M6/02#/R$^^*\^\3?#+5];
MUWPKJ\-GX2F_L;3;FQNM)O[9Y;.+SFA836X`X9##M`*C*N1E:XR?]G+Q)K.I
M>)+WQ-J^AW4^N1VD#O%:[!/'!JOVS,B!%`S#B+'S9()+$'%`'N*^+]">WL+A
M-:TEH-5D\NPE%[&5NW_NQ'.'/LN:=_PEFB;+Y_[8TK9ICF.];[9'BU8#)60Y
M^0XYP<<5Y9'\#+G2/&EMJNAV_A:72E2ZB&G7MFVVP$MZ;GS[8*,+(0S!A\HR
ML9!X(KG=`_9@N=-T^RLM2.C77V*]T]I[MY9)#J5M:WK3[9H2@0.ZMRQ+$L6R
M=N!0![7-X^\-0:_8Z'-KVD)K&I6AO+.R:\02W$`QF1%S\R\]1UY/8U-#XT\/
M7&G#4+?7=&EL#)Y8NDOXVB+Y`V[PV,Y(&,]2*X;QM\+M4U7QKIWB/P@?#ME=
MV7AZ_P!)BFO;$2O:-,8VAFB`&#L:,@H<#:YQU(/*^$?V=]0TJ_L+OQ))H=ZE
MOXBFUFXLTAWQN7TQ;0`915W>8@ESM`&>.1F@#V`>.O#9_M#'B'0S_9/_`"$,
M:A%_HG./WOS?)R"/FQR*@A^)'A2XUB\TJ'Q)HCZCI]DE]=6POH]\-LX)65AG
MA,#.[IC!Z$9^9_`'P%U[5=+2"ZT5-*O;'^R;F:[OX_LZWKVSW(:R=`AWJJSF
M19OGW-LSG;7<6O[-DUBFJ00Z9X7DL-7T*RL)8#=W"30RVUU+-E;D)O9&$B]1
MUC5=I7@`'MUSXKT2RTB/5KS6-+@TN8*8[Z6\C2!PWW<2$[3GMSS2W7BC1K*5
MH[W5M,MY$@:X9);M$(B4`M(03]T!E);H-P]:\L\4_"CQCX@^%FA^&'U;0);R
M&.2/6BUBL4%TK12JGEA8SY91WC;Y57<$(^7=6->?LTWLVB:E$E]I4NI2KH7V
M2:6`@.NGQ0K)#*<$^5*T1.!G&02#B@#W1-8L)--344OK-M/DC$B78G4Q,AZ,
M'S@@^N:J1>+]!GCED@UK29(X+5;N5TO8R(X&SME8@\(<'#'@XZUP5S\'7NOA
M"G@Z%-/LMVK17DL1FDNH2BZ@MU(F64$[E##&T*"V`-HKD9_V<]9TN."?P3?>
M']*U&.36A/)]@&VZ@O;Z.>.%_E(PD2/'RK!2P*CC%`'M1\8Z`+.TNSKFCBUU
M!E6TG-]'LN"QPHC;.&)((&,YJMXI\=Z'X0\/:GK>N:I9V^G:/%++>2F53L\L
M9=<9Y8<#;UR0.]>/Z+^S(\&FV]KK[:'J"6^F:Q;Q0R6YD2">]OUNHW0D#'E@
M%=P`.>0!G%6M:^`^OZQ:>,]*GO/#K:1XBDUF>T,MO(\J37\:A?,!^4"-@3QD
MG@C:1R`>G^$OB'H_BRRT^2WO+.VO=2LEO8M-EO8'N5A/\16-V!'NI(]Z1OBI
MX-75+#3CXJ\/&^U,3&SA748BT_E$"3;AN2I(!'^!KR?Q+^SOKWB7Q(\W]L:/
MINEVUC=V>F-968BFLXI].-KL"JJYVRN\NXOR"%P,9JS>_`35-5D\.W,VG^`]
M-N=,T[4--NDT^P94\NZ@@C$\9V@^:K0L0#@;7QNR,D`]GNO$>DV-FUW>ZGI]
MO:JJLT\MRB(%894[B<8(Y![BDB\2:1/)?)!JFG2/I8!OE2Z0FU!&09!GY.`3
MSCBO(M*^!^N7=IX8A\9S^'+J/0-1TZ:2VMX))(IX+6QFMPI$G5R\JN,@`;<<
MD9.#;_LQZG::+J]C!<Z-)=3"06NH7$DKF\C_`+02\6&ZA"A2K!/+=MS'!.,`
MD4`>Y:5XNTS5[.[OK6\M_P"SK6;RC=F5?*?Y58,K@X*G>,'-6KWQ!IEA+;PW
MFHV%O-=S_9X(YKE$:67&?+4$_,V/X1S7F=W\']2OOA)XH\+)_P`(]I=[K]U-
M=0I80.MG;LS(X7:?FQN0Y(`SN)`'2J6H?"+Q1J?B+1]?EF\-0:U9ZH]S-=Q^
M;(D-M)+`TL"0NI5V:.';YAV,K$,N!E:`/2]+\;Z1J4=@6OK6TGU3<+2TNIXX
MYY2I.0J;B6.!GC/%7-,\3Z/K=W=VNC:MIE_=6#;;N&UNTE>W.2,.JDE3D$<X
MZ&O&/!_[-\GAQTN-7;1M3N[.+3/L,IMSOMWM;JXF<HS<KO6=5X(Z'/&*S_V<
MO`&N^%;#6XYM%.BZG>>'[&V&KW5L(V%S$)U$)AVCS%B+AO,W'?OP2<9H`]ZT
MKQ#I6NV\L^B:GI^HP02-%++:7*3*CKU5BI(!'<'I54>-O#K6D-TNOZ*;6YN#
M;0SB_BV23`X,:MNP7S_".:\I\&_`G7-)\$^/]*US5["+4_'-LD;7>G1$+;RB
MR6W:7:%C'S.I?:`,`XR<9K-\0_`/Q#K=C;^78_#FWE_L.]TB6P6PD-I";A(1
M]LC&W/G`Q$8P,J57=QD@'MUQXIT6TO7L[O5]+AO$B,KV\EVBR+&#@L5)R%!(
M&>E+>^)M'TZ58M1U73;65IT@5)[M(V,KC*1X)^\000.I!KR;2_V;;"/^T5UX
M:?J+:A=RAKUK?%U]DDTI+%HRYSR60R8SMY]:Y0_LN:Y>6MK=>*-2TGQ'K-U!
MJ$&MM/+-:Q7/G>2L$D;*K.CK%;1(V,'DX8=P#WS5_&_A[0?M?]M:YI-DUA;/
M=723WD:-#"GWY&4G(4=SBJ5E\2?#M_`;RVU?3WTG[!'?KJGVF,6IA=V13YN[
M&=R'.?Y\5P&H?L^0ZK>^)[R^31Y+S7M1NYH;J2U\R2"WGTQ;/RBQ&6`==Y&<
M$>]<_-^SMKLM[X9U#?X4\SP]IFF6<NDM;R&QO3:R7>_=\O`9;I77Y3B2/)!'
M-`'NDOB?1X)+*.?5M-CDU$J+-7NT!N2P)7RP3\^0#C&<X-9.N_$C0=$M9IO[
M0MKTVFHVNGW<5E,D\EM-<3+#&LB@Y7YW&<]!GTKRKPM^S1+I<D,VO2:#>S06
M-NENL=FRI8W":K/?O]GSDI&!,L:8P?W8S@<5#9?L]^*)]6UC4_$&M:+/?ZI+
MI1DFM[<QB866J/>%V154*S1L(POS8*Y+'-`'N<WB+2K?58],N-3T^+4IHC+'
M9O<HLSH,Y<(3N*C!YQCBL?5OBEX/T.%)=5\4^'[5)+Y;!6DU&(#[2PRL1.[A
MR.<'MS7"^*_A%XA\4?%;3O$<^HZ3_9&DW:SV,)@VW$*_8YH)(B0OS[I)O,W%
M^`-NWO6$O[,YT_PIX>L]*M_"SZGHJ:&]RUQ98AOY[`R^:[D*3F19>&P3\O.:
M`/2T^+?AY?%,.@7]XEA?7*3-;F[=(DG,4RPLJ,6Y8NRX7J0<XKI(_$6E2WUW
M91ZGI[7MA&)+NV%RADMT(R&=<Y48[D"OG_Q+^S)K>KZAJD]I=>%I1K!U>/S;
MZTDDDTY+Z\2X$T&!_KHPF!ROS8.>*9K/[+VNZNMS;?VGX<MQ#)J\UOJJV3M>
MZ@;V3>D-X<C=&NYE;#'<`F`N,4`>Z:/XXT77)KT:=J5E+%9<F9;B-DE3RTD,
MB,&Y0"106Z`YJ]?^)-)TJWAGU35-.LX+@J(9;BZ2-9"Q`7:20#DD8QUR*^?O
M&OP/UNXTZR@TRST/3M0USQ$8M2&AVSI:VND75O%'?(=Q'+"W4AL<N4X')KH/
MCE\+]6\?^)/#MCX:TO19K$>'=9L)Y]6MS);6)G%JD;!5Y\P*LA4<?=(R,YH`
M]*T_XDZ!>7VH6=QJ%O87&GZLVE%+V5(//N1'')LBW'Y\K*G3GGI6!K?[07@C
M2TLUT[7=,UF[OM:_L:*TL+Z!I/M0+;T.YU"[0K$DGL`,D@'S?Q!^S5XHU%+S
M3[/7]'ET>]U!+LK=6Q\Z.2-;)4EW[6);;:R`J&49D4Y.,5NV?[/,L6KQ//#X
M96SM/&E[X@@EBLOW[17,-POEME<!T>="I!((C!X.*`/7HO%6BSI>O#K&ER)I
MLACO62\C(MG'59#GY#['%0R>-_#L4;22Z_HJ(D"W#,U_$`(6.!(3N^Z20`W2
MO"-*_9@U=;2PMM6G\*I'INGZ9ISFRLG7^U8[:_BN9)[H-UD=(0NWYANDD)8@
MXKH9OV<+>[\83ZM>0:!<6L^L7]XUO+8AR8)[".VBA.1C".C/CH`W'-`'L]SJ
MEG9HSWEW;0(L;2EI950!%QN;D_=&1D].16%XH^)'A[P6CS>)M4L["S@5S<W4
MLZ+':A8Q)^])/RDJ1@8R<CUKS/Q?^SQ>^,?`/@;P_J&KPK<:#8QZ5KUR5=CJ
M>GO"B7<*'((,C11L"V<8Y!K#U']ES5=;\#V^EZUJ^E7NLR1ZJ=1OI[8R+<RW
M-H+6W?;@?ZM(X<\#[IQS0![#I/Q3\-:UXHN-!L-5LGOHH+>>`?:(]MY',K,C
M0'=^\&$;.WIQZUM6_BC1KS[1]DU;3)_L=P+:X\N[1O)F)`$;X/RN20`IYYKR
MZ'X$F]\2W6O:Q:^'K>_ECTC[(;*W.=.:S\T2"%RH(5A+\N,=\BN0T[]FCQ%8
MV-F4N?"-O?:+IVEV=JUI:RQ+J;V=_'=>?=G&0[B%5XWD&20Y.<4`>[MX[\.+
MXHB\-MKFE#7YX&N(M-^U)Y[QJVUF"9R<$$?@?0UNUY%X?^$NLZ7\0])\5ZB/
M#-S=I8W]KJ+1V[HZ&>\-PCP,03P&,9#$<$D'G%>N#@"@!:***`"BBB@`HHHH
M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`
MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`//_BQ\0=;\"7'A.+PU
MX?BUYO$6N)ILP>_6U-NK12/N7<"&/[L\>Q]17!:1^T1J>C:?XCN?'6A7OV#2
M]0U2/3M3M982M\+?45M8X/+!W(^9H5W-P<,3C'/L7BGP?I7C*UMK;Q%9K=Q6
M=U'=V_[UXVAF3.UU9"&!`)'!Z$@\&LZX^&'AR[TJZTVZTFUDL;W[4;B$LP#F
MYD$DYSG(+.`V01@@$8H`P;/XSPGX:7_BG5]%U.PFTZ[^Q/IY*LTUPTR11K%(
M=JNCO+&`_`Y/H:R+GX\WFE7TEOKOA#4[-=*FLH/$$L>HV\PTR2\E$=N%`(,P
M.Y&8KC:&Z$@@=U<?#O0[SPW?>']0LS?:1J>?M=M>W4MQYF<<[W8L,%01@C!`
M(P:R1\#_``6-0M[]M"ADO+=X9/,DN9I/-DBD:2)Y0SD2LCNS*9`Q!Z8P,`'"
M-^T_&ZW=PWA'6!IUG#]MENS>086Q6Z:UEN-F=V5E1\1_>91GC@4[QS^T)<Z1
M#XHM=(T.^M?L$6K6>G:S))%)$VI6=H]P4,.=^S8A(8\$J5QT)]#_`.%0^$_L
M5Q:?V'9?9KJR>QFCR^'MVF:9HS\W0RNS^N36)I?P)\)_VOXAU/4[1=9N]?N[
MV6:2Y=BL,=TBQS1(H;:N53:6`#$$@F@#F++]IV&XCU*5/#FK7=CI%I<2RZA;
M%2DK6C(MWE?^687<Y3<<R>6P`SC-'Q'^TIJ,&G0ZOX/\/3ZK%>Z;87UE8W5S
M':B:VNM2-K%<>9R070HX0C@.,G@BO3G^#OA-VN]VDKY-])YMS;?:YQ;RO^[)
M9H=_EDGRH\_+SCG.3E+KX-^$+VSN[6YT*T:"^@,$R*SH#']H-R%7#`H!,QD&
MW&T],8%`&=X/^+Z^*_$D/A]])N]/UJ**\?5;:29'&G&"5(E#,/O"4ON0CJH)
MKSWX@?M-ZKIW@_5KSPCX9NC-=V%]-X<U"XNX/*NQ:2K%<2,F=T>TN&56SO`Y
MQTKU3PO\,=-\(^*_$OB.RR]_XD^R).S`DQPVT(CBCSDEOXV+'DEAGH*J0_!+
MP+*U_/%X?L6_M*.XAN%\V1XPDTHDG5%W;8P\BAFV!<D<T`<IXW^)?B_X>7?@
M6VBT>Z\17%]HVHW&M6/VBW2X9K:*!MXDPL>X;WX0`,6&`!TE\1?M&6GA[Q'=
MZ:ND3:E!;://J8N+*_BD?;;K"\\<D0YC=8Y@V">=IZ9%>F:IX3TW6K^VO=4M
M(;F[LX)X()7SF..<*)5&#T8(H/TK'T[X2>%=)UV76-/T6UBU"83!Y#)(RYF1
M$F(0L4!=8HPQ"Y;8,YH`X/Q!^T=8Z3<&_@MK^YT6V&K`/;K&XU`67V96>,DC
M`\R9T'J4.<<5#XF_:2O_``MIT7VWP/JIUTS7:3:0=3MP=MNT*DQ2<B5F^T1%
M449(W>G/:Q?!WP3%X?T_0;?P_8+I.B6D]E9VBLVRWAF*M+&#NSABB$Y.>!6=
M\0/@=:>/-4BOX=2FTB8VMS!-):H?,/GF$M-'(&4QRCR5`;D>U`%+XB_&G4?A
MSXSAL+[PV;G0$\.W.LWVI0Z@@EA,,D<?EK"1\V6E1<Y'+@]`:V=!^++76C^+
MIO$VA:AHVI^"HO-U/3A-'=,4,'GH8I$.URR=N,$$>];7BCX9>&_&<MK+XITN
M'5);2SFLU>X=_G@F"B6-P"`ZML4D,",J",$9JF/A5X?L/"7B'P_H=LVF1>)[
M>6*]N5E>>9V>'R0[/(69BJ!0`3@``4`>:Q?M42-8"2?P??+?SW<T=E:PZG#/
M'>00V\,\LT<RC:0%N(T"C)+Y7C!(W)OVBK>VO=0EN?#VM0^']*CE%[J\IC0P
M3)8"^\IK<GS,F%L9[.-OO6KX;^`^D:39-%K5S<ZK*+M;FV:.>:T6Q<6X@;[.
M$D+1AU!+@-ABV<<"NI@^'>@VZ7*)IENR7LWGW*R,TGG2?9Q;%FW$[B80(SGJ
M/?F@#R_2OVA]>U_Q)X8TS2O`EVBZWJCVEY+=:FB+!&+4W"R1-MQ*=@.Y1]TJ
M5R20:TO`'QTG\818M-*GN;'3(6?7-9N;J"SCL6/F-&I0M\PV(I+`X4,#S\V.
MMMOA'X6M5TV"+3YB-&N([G3S)J-S(UJZ1^4NQFD)5?+)4J#M(/(-0GX&>!\R
M;?#UDJ3VIM)XEDD$<\)\P;9$#;7XFE`+`D;S@CC`!Y/XI_:0UJ^\-27_`(9M
M8]&NK"?6+2\BEDCO8WDM]):]ADC=0`RY,9/'/S#T->E^!OC!%XQUVVT)-/NX
M-5CMKJ75$D90+'R9EB3=CJ)B2Z8ZJI-:"_!3P<NG26)T2WEMY9)I)!-/+*SM
M-;_9I"SLY8EH`(^3]T#&*M>$_AIIOA/Q;XH\16@#ZAXIDM?/;8%$45O"L448
M]<89B3R2WL*`//K[]I8VLVJ&W\(:O<6>F17UTUU]MMT#VMC<_9[R8*6W#8^"
MJ]7&<8Q4VH_M,Z?I'G7VHZ%JR>'99+Z#3-5CEB?[?<6F\2Q^5D/'EHW"LW!Q
MSM&,]X_PI\+R0W4+Z-:&*\M;RUG7+XDANY?.N4//223YC[],50?X%^!I;J\G
MG\-Z?*U_'<1SQR%WB(N`HG*Q%MB,X1=S*`3SSR:`.'UWXU>)]&M[R2ZT">SU
M9;J_BM]'N)874FWTH70!G4X*%LD,.?X2!3_A?\;M3NM-\-:-XVT[46\6ZR]H
M0CRP$3P7,$EP;I#&JKY4:Q2H1C<"@!))R>^L_A!X4L;9+>WT:`QQRS2@RSRR
ML7F@^SRL69BQ+0_(22>*;;_"O2++QYI'BJ*-$F\/Z`VBZ9;JF%MX&=68[NI.
M(T4`]`&Q]XT`<SI5]XX7X[7V@W_BJPN?#]KH\6KK9KH:1R,LT\\0A\[S#PHB
M4[MN3STIOB#X^_V')J\T7AS4+S2=/U0:+!J"WD,8NM3,B1^0(S\R(&8@R'CY
M&XZ9]&@TO2W\0W&MV\$+:G):I8372MEO*1V=8SSCAY'..N6-<]J/PA\(:I?:
MG>7>B1&;5YA/=E)Y8P\P\L^<`K@)+F*/]XH#?*.>M`'F7B?X]:^TV@W.AVLF
ME6^HV<3W-E?6P>1)1K-I9R;3QN5HY9=K`88%6%;^I?&W4[WX,>-?&'A;0A;Z
MGX?M;B2VTV^O4$R[(]RM<1\&%P/F,3<D#@G(-=E>_#;PI=):#4]/BNGA!BMY
M+J\DED/^D+<[0[.68^=$C]3C8.W%/L?AIX7T_1];TV#38VLO$B[-66>ZEF>\
M7RA$`[NY<CRU"`9X`XH`X#3?CEJVB62Z5K7A_5=4UG3OL%A=SO?6J&YU*\2-
MX(`4"I@K)EG`"J%Z$G%2ZM^TM#I.CQ74_AC5VO8#JIU2Q2YAS8KIK1B[;?G;
M)@2`IMY?@?+V]"U/X8^&M9M]1AU/2+6=-7GM[B\.YU9Y;=56"0,#E601IAE(
M(VCFJ+_"+P;:Z9#IS:)9"S6"\M51W<EDO64W(9BVYS*RKN+$L2.M`&)+\9'F
M\">/=2N=+O=$U3P7;RR3VSO%<MM-L+B&12IV'=&ZG:3P00?4YDO[1<-A+J\V
MH^'=731](%Y"-36:%A<W=JZ(\*QYRNXR+M8X!PV<`9/H#^!-`U&TUR)]/MI;
M?Q/$L6K+N8B\01"%0Q!_YY@+QC@5%/\`"_PS<Z9>:?=:-9366HO<O=02!F29
MKC'G$@GJV!]",C%`'FFL_'C6/"LGVKQ7H6HV/EZG<Q7.E*T$S100:?'<2.)5
M.&4`O(".3C;@8JSK/[1EKIVHV4UI9WUW87=QJ-E8K$(R-4GM[BUMD*.2-BF>
MX*`GCY68X`&>]T[X2^%M*6!;/1X/]'EFF1II9)F\R6$02,S.Q+%H@$.[/`JJ
MWP1\$R>'M,T)_#FGG2=&L9;&PM<OBV@D9&=4.[():*-MV=P*`@@T`<_HWQDO
M(;EK3Q3HU]8ZA.NKW(MFDB;[+'8+;EHRR\/N\_*N.HY..E8WQ!_:#FT9O%6D
M:#:Q+?Z=X8U#5=.U)+N*YC$UK'&SQ2Q#E&4S)P2<X.0.*[>[^!W@N_LK:TN]
M"AEM[1[AX@US-N)N`OG[FW[G#[5W!B02H)Z4]_@IX-DNM2N'T*V:35XKF*\!
MFE*2I<A1<`+NVKYGEIN*@%MH)YH`H_$KXN3?#Y-,2TT&]U^\O=,N]2DAM;B*
M`1V]JL33L6<X)`E&U1U/''6N,\9?M/'14UE?"^@QZW)9^'+C6=/E&JQ(DX@2
M%Y8IE`)A91.IP<D[2,#(KT#QY\'="^(VMZ)>>)TDN;+1K*\M/[/$CQQW"7'D
M[MY1@2`(0-IR&#'(-"_!+P6MSJ$R^'[('58;F"ZCWR>4\=R%%PJQ[MJ>8$3=
MM`SM%`'GVH_M*7'A[5M1TS5O#U_<:[$Z/_8\%Q$?L\2V4%Q/MF&?-8>>@4;0
M69L#CFM^]^.MV?$%UIV@^$M5U&&S$<,MY+=16JQW,MC]LAB=&^<!E(1FQA6(
M&#SCHQ\%O"(VLNDF.=)!(MS'?7"3[A`+?/G"02?ZD!#\W(49Y`-;%OX#T2UN
M;BX@T^'S[N>*>>1F9C+)%"(8V8DG)$0"^XZY/-`'G/@?X[ZCXE3P+%X@\*MH
MUWXQTJ/4))7U*/[-$L@_=I%(0!-*V-QB&'52IYYQ?\3_`!RM_"GCJ3P\VCW6
MI*MA<W"SZ7=1W,QF@@\][<VZ_,'*#Y><DD<8(-=!8?!?PCIG]C+8Z24B\/2)
M)ID+7UQ)%:LA<H5C9RN5WMMR#M!P,`#$MQ\(O"UUKE[K$NE(-2OVE>>XCNIH
MR7EA6&210K@([1(J%U`;"CGB@#&/QC,?PS@\63:4TTMU=PV<>FV.H17#>?-.
ML$<9EX53O==P."O((!%<U+^T]:V5YJ::GX;UB.WTGS[>>>WD2<?;H2JR6YQ@
M*/,;RUD8@,P/`&#7I%G\-/#UCH(T:VTN%=._M$:D87D>0O=^>)_.9F8LS^:`
M^23R*KZA\(_"VJS:M)J&E1SKKI=M1@:XF\BY9XQ&[M"'\O<551NVYR`<YYH`
MP]/^,,[ZE8:7K_AW4='U2[N[NUEMY+F*40O;VBW18.O#HRN`I&.>H%9;?'&>
M+5[RRL-)OM7O+G6++3M-LEDB@`DGTU;TYE)QM";\DC.>`#Q6ZGP'\(O:RVFH
M::+NT-^U[#')<S;H7>W2"0>9OWN'1/F#$@[L'-;EO\-?#UI?Q7MMI5K'=P7<
M=W'*"V5FCMOLJ/UQD0?NQ[>_-`'FNG?M06NL(S:5X:UBX%_+%%H!$J*FIO),
M855G/RP-E2^&).P$XR,5I>(OB;XDT[X21>(K'395UR3Q-!8_V7/Y0DV/J@MC
M`6SL#;#M#YQT:NHG^"WA"XL[FTETG=:W,YN#`;VX\N*4S>=YD2;\1/YOS!H]
MI!S@X)%:%Q\,_#=UX/\`^$7FTN)M$$OG"U$LBXD$OG!PX;>&\SY]V<YYH`X*
MP_:,MKD_9;_0-1LM7>Y2RBL3<1OYUY]N:SG@20?*QB<+(S#^!U/J![(IRH.<
M^]>?+\#_``W;ZWX/O=.M([.W\%2WMQI]JBELW-TN))GD8EV;F0G).YGW$Y45
MZ$HPH!Z@4`+1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1
M110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%
M%`!1110`4444`>8_'WQ1JWAKPE`OAAM<M]0U&X:&*^TNV6;[(RQ22`RAHI?D
M8H$&$)+,HR,YKRVP^*?CR_\`'&D:>^H:FFH0+H'VW18M#W0R1W5J)+^2>79^
MY,>&91O7!&,-N`KZ@JC'HUG!>WEY;6T$5UJ`074R1@-/L&U-Y[X!P,]*`/ES
MP3\3_B-XNTJSFTO6M8O+?6X-&-WJ!\/+&FE7%S=&*XCMR8P)$6#$FX[PI`8M
MAMM='8?$+QQIGC"9+Z3Q1JXL;G5HM2T1=`4+'8VL+M:W,,X10\T[>1QO96,S
M`*NPX^A-+TNTT73[>QTJWAM+.TC$<$$*!$B0=%4#@`5:H`^6M"^(?CRZM+>'
M7-8\4:=HEUK<Z#7TT%;F[CA%E!-#"RBV5=K3-<(7\KK%LW9()72IOB)X'\)>
M*-4\.WVKW@O+W7)[?2;C1U_T'&JKBXCPAD8F"6>0(VX,0H4<8/U)10!\XIXX
M\::;'X4^V>(+S6;0ZU-!<)IFDR?;KZ$S0)#YC/:K$5022&7:(LJ`R,=C`ZOQ
M+\9^,M&\<:Y:>&KG4[R,^&[IM(L=,TTR);7:6KR"6Y9XB'W.J+'Y<GWCM9#G
M->\TE`'SYK'Q,\0ZQ/I'V&_\2Z'X<O;IH[K6;;PZ\DT4B64,B1K')$Q$<DIG
M!<IUCV`C(J]\#M,\3Z/K-V^K:IJDFBZKJ.OS#2[O3DA6S==1S#(C[0^)$DD.
M&)!R-N`*]VI*`/FO5_B)XZO?&7BZ'P]>ZMI.F16%S%`VL:47BL;J*\@A1XS%
M;DXEB:9T),PQM<@!2*Z+6?&WB&X^'/@.ZMKOQ5H5MK=SY6MZO+I"7&H648AE
M,;O"L11?,E2-2WE8`<<+GCW.B@#YNTS3O%MGXE\<:O8ZIK$FF:EJ<D;:3<:.
M@CO0="B9;D97>K>=&J%0=N=R8S5;PWJOQ*UBXT6R&KZOX>L+EHM-=(-!AQ:1
M+HT5SYZET.'^TEH>?D&"N-W(^FJ*`/FKP!\0OB3XA\6Z,_BFX;1898+/S=)G
MTR54NX9;'S))580$K.+D,N&E54";2N64G,N_$WQ#T[3_``CK%_/K$UYK>@B;
M6;Y-`5YM"6:[LEE6*-8R?W<9E8(P9N"Q!VX'U110!XE\3?%^M:#\*](/AC4?
M%-YJ6HEXX-;ATQ%E#1Q2R(]Q$8'"B0QA!B(;BR_=W9K+TK5OB1XFUF.2\U?5
M=%M88]-@FM(=(C`F-UIV^XD#NI(:.X(Q@[5(*L#GCZ!I,4`?'_AWQ;XXT'PK
MH[RZGXDOM4NO#^CV-WJ5_I"K?K=RZB\=S`C/$`TB(?EW*_\`>(;.:V_AMX]^
M(6J^(M"MM5\5I?V4,ULCSMIK>5JB/--'=*Q2V&V>%T\K&Z((8]S`ALU]+:YH
M&G>)=.:QUZSM[ZT=U<PSH&7<K!E8>A!`((Y!%2Z7I5IHNGPV.E6T%I:6Z[8H
M84"JH]A0!Y9\$]1\::G=?;O'>I7US!JVG-.-/N-,2V&GS)<R1A48*&(:,1DA
MR3D%A@'`\YU+QA\4H-&\/74^MWVF/K<.HW<L]QI'[JTN8)%6WM72.WD<1-&'
M<Y`=SD*Z\"OJ2B@#YIU+Q_X[&C^(KN'4-=M]8BU?[)<Z8-!(@TG3A>)&+RW?
MR6:5FMV$G)D^\QV#RR*SO%OQ-\=:5I>C6%KXENY=9DT+4KRS.EZ`UT^K7D%X
MD5K!*KPJ55UD"R.$C4D;E91C/U/51])M)-3CU%K>$W\4#0)<[!YBQ,RLR!NN
MTLJDCU44`?+5IXG\=>'-3U;3]>\5^.;>TD\0:H]U?_\`"/K>O8*B+)900@0$
M&*4&7D!O]4J`J6Y].^#>L>.?%&L7=Y\0Y;W35LM.TY?[(-@L,,EQ/:12W#EB
M"Q*2EU"JV%Y!R>GL5-==RD4`?*?AZ33HX/"K_$[3]9U+PI?:5=R0&+3)YU77
M#J$C7#7$=NK,LI4IY;L.-LG()K>U*37%^)]MXXLM,\0_V'!<_P#",JA,G_(/
MDB"F8VY^<L+W:3(1]Q2<XKZ#TW1[31TE33((;6.:9YY(X4"*TCL6=R!W9B23
MW)S5V@#XK^''AG6/"'@^TM_$FG-H]V]MX3O-+BTZVF,4DQO@LLDBS?=O<NR2
M[3RC`[3S7MGQ0^%6@:_\7OA]J]_X<MK^62^NO[2O&MB_RQV<A@\UAQ@.%VY_
MB`QS7KFHZ19ZK]G_`+0MH+@V<ZW%N98PWE2J"%=<]&&3@]LU;`PH!YP*`/'O
MB#XK\4V_B[0;&:?4?#6DS074WVK1['^T_MES')$(;:5C"?*5T:1B,#.,!QBO
M.=,UOQWXO\(S_P#"775Q>W;ZGH-U-I8TZ6.?3+E=607**1!&OD*D8Q\TC85G
M+;6!KZGQCI2T`?,7P4\4^(/"NHZ'IOB>;6_[$ATBX<6%OI4@6P*;Y7>[+0[F
M9L@1^5(>H4ID9KZ:BD$L:NO1AD4^B@`HHHH`****`"BBB@`HHHH`****`"BB
MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****
M`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`
M****`"BBB@`HHHH`****`"DS7EO[2/Q8F^#_`,,+S5]*NM'L]9O+JWT[29=8
ME$=HEU<2!%>9LC$:+O=N1PAKQ+2?VSM9N7\(Z['X>N/$FAW?@"[UGQ!;:`L3
MO9W-K>)!<S!W<;HDVRX122VX'F@#[`HKP7Q+^USHOAR_U8GP]KMYH>CW$MA<
M:U$81"-12Q-[]EV%]^3$-HDV[=YQGO6-XN_;#FTO5M#T_P`(>!M6UV;4[O0(
M[C-[!!Y4>K1221!<M\SJ(F!Z+GO0!])T5X/\7/C]J'PG^,'ARPU9=-3P'=6,
M9UR]E0B:QEGEEB@F#[@HCWQJC`@_ZP'/%<%X)_;-UE=#\6ZQ\0?#UH(;"]BG
MTNRL[N*UF33Y;!;U0_GR#S9A$V[;&,DY&!B@#ZUHKY_\3_M>Z;H=AXDU32/"
M7B77="\+6>GSZAJ%JUO'MEO8XI8(5CDD#LQ2:/)`P"V,U=M/VHHF\0V^E:KX
M+\2Z7Y6H66F:S<SR6SKH]]>)OMX)520E]RF/+(&53*H)ZX`/<Z*^4=`_:PU:
MWAM?&?Q#U+P]H_A+6])U'4]+\.0Z/=RWS6MKYG/V[/D-/^[RT6!M##GH3T5Y
M^V+%;KIUK;?#_P`67FNZA=75N--@EML*(+5;II5G:01/&8G^\I.&4J0#0!]&
M45\V:!^U[!KEU=2>']&U7Q$-;U;3+'PQID,$5I-(;G3!?-YDDDNP!8PY).WD
M;0#UKTSX8_&>#XE^(?$FD1Z'J>B7'AJX%O<1:E)"L[/T)\E6+A,_=D(VN`2I
M.*`/1Z*\#^,G[2=U\'?B?!I%UHEQKNDW6@6]S#;:>J_;)+R?4H[2-5+LJ;3Y
MH)!YR.M6/"?[4D/C3Q'IOA[0/!GB2;79&NQK5FTELO\`8R6MVMI,SN9-LN)&
MX$9)*@F@#W2BD!!SCMUI:`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`
MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B
MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`***
M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH
M`Y_Q3X!\/^-KG29_%NE6NK-H=TUW8)=`O'#,8VCW[/NL=CL!N!QN)'-<)J/[
M*'PKU2:YENO"<*F[-SYR6][<0(RW$@DGCV)(%\MW4$IC:?2O6Z*`//V^`?@!
M_%DWB1_#=FVJW!+RLTDAA>0P&`RF#=Y7F&$F/?MW;21FLK3OV7?AEI-G);:=
MX9$,<MQ97!<:A<M(LEGN^RLLAD++Y8=@H!``..G%>JT4`<=XY^$'A#XE6FHV
MWCG1+?5H-6L$T^\29W`EMTF\Y4.TC&)/FR.?>L3Q#^S9\-_%5Y/=ZYX8MYKF
MYE$LLJ7,T+,1;"U*Y1Q\I@58ROW2HY!KTRB@#S#5/V9_AKK%S)-J'AB%VFL[
M:TF1+N>..:.W55@WHKA69%15#D%L#&<5KWGP3\%:AXZ7QA>:%#)XA6:&<W7G
M2!9)H49(IGB#>6\B*Q"NRE@.AX%=Q10!Y@?V9OAFVK7>H/X4LWDOA=^=;O/,
MUMFZ7;<LMN7\I&D7AF503G/6M2P^"'@_3UTS;IUW<MHQNOL$E[J=S=/;BYA$
M,RJTDC':T8"XS@=1@\UW=%`'EP_9D^&B:)_94/AB&"S6>UN(_)NYXY(I;:`6
M\+I(KAT*PCR_E(RN0<Y--U7]G+PE=VUW%I2:GI;:E-:?VA+!J,SRW%M;S><M
MJKR.QBA+]1'MX)'>O4Z*`.,\4_"#PAXXUVUUKQ5HL-_JEG%#'#.\LBE%BN%N
M8QA6`^69%?IU'IQ6:_[/?P_;6[;6%\/11:G:W]Q?I=0W4T;M-/,LTN\JXWHT
MJJ^QLKD9`%>BT4`9'A;PKIG@S1TTOPY!);6,<LDJQO/),0TCL[G<[%N68G&>
M,X'%:]%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`<K\0OB9H/POT
MZPO_`!E<RVEIJ6IP:;#*D#2`3S$A-VT':ORDECP`,G`J";XL>'+;Q[>>$+J[
M>#5M/T@ZM=/+&4MX;<.%.Z8_*&&Y6(SPK`]ZK_%CX:1_%'3M&T^\FCCLK+5?
MM5[&ZDF>$V\\+(N.C'SLY]J\WTS]GCQ7I.F1W,7B^RNO%;Z3>6=]JTUAQ=R2
MSVA1BA+!0+:T$)P#@MN`XQ0![(OCKPX]KIURFO:*UOJ\GEZ?,-0B*7CYQMB;
M=ASGC"YIEQ\0/#-IO^U^(-#@$=PENYDU&%=LS#*QG+<.1R%ZD5Y-X-_9\U?P
M=K&EW\=WX;U)8A?)<VM_9/*ELMQJ!NP]N2?O@,4)(&[:C<8Q4%Q^S?J-GHFF
M0:+<>%KJ[M['6;.\35-,:2"7[?-YJW``.?-0*J'/WE+#(H`],O/BKID/BF30
M]/T[7]7EM9$BO[O3=.>XMK&1PI6.5QT;:ZL0H;:""VT5MQ>,=#G^W?9]8TN8
M:7((K\QWD;"T?^[+AOD/LV*\/D_9EUS3H++2-`\16YT:VU2RU)+R9[FWO;66
M-;=+@)Y,@CE65;<\2`A?-8<C%2:1^S#<6'AB_P!&N+C2)7FCLK==08S.]S;V
M^HK=;9HC\F60$$C)+,QZ'%`'L2_$+09?L\L&I64VGW%C+>KJ4=W$UJ(8V568
MR;L8RXYZ<')!ZVM/\9:%JUU%:Z5K.E7ES/;"ZBAM[V.1Y("<"555B2A/&[I7
MD7C#]G&?5[^RN?#=WHMA%IDUU<0:?-8EK:=I=2M[T12HI'[L^0P;'=@0.,5O
M^#/A5K'AWXC3>(2?#>F6%];R?VE9:7;R8NYMD2Q,!)Q#L5&!V$"3(+*"*`.X
MM_'&C37HL[B^M;.[DOI;&W@N;B-'NI8P"PC7=EN".,9]0*N-XETE==716U/3
MQK#P^<NGFZ3[08_[XCSNV^^,5Y';_`?5].^(H\2Z3?Z/!)-X@FO[FZ:*1YC9
MRR*[VHC.8\G:,2<,I)(/:M>[^$VNZE\9]/\`%^I:S8S:7H]W)-86HMRLT4;V
M30-"2!AOWCO)O))P=N`!F@#KO&'Q-\/^";+5)M6O[>6XTBT%Y=:?;S(]TL.X
M+O$6[=C+#GI5A?'^A1P++J6HV6EK)>R640OKN*$RRI(T>U<MR2RG`Z^P/%>:
M:Y\"M7U2'Q[8QWOAXVOB^XGNH-0FL7-];M*L(\IGS@QKY9`QV*C`QDI)^SHM
M]<7#:Q/I5]#+;:_'''-9[_+DU#4%NHY!GH8PNTD<DGC%`'IJ>/-$68PW^H6F
MGS-J+Z?!'>7,<37,Z8RL0+98\CCK[53O/BEX<MK[3K2TU*UU*?4-971RMA/'
M.;:Z,4L@64*V4^6%^O.<<5Y_IWP)U?1?B-J/B:TO/#NH0ZM=W3R6VI6#2FS2
M6X299(3G'FX5E;.`=L9S\N#F>&/V=O$-IXIM=>\4>(=.O+]-3L+N[EMK9HS<
M_9HK]&<`8",YO5.`,+Y9Y.:`/9-?\<>'_"H)\3:UI>E$6\ESMN[M(F:*,9D<
M*3DA1R2!Q5;1OB5X4\1#3/["\1:)?-K-N;C3HX+^-GNXAU:--VY@,'.!Q@@X
MP:X+Q7\#KW6_%T%_IE_9PVLVFMI^IW5_OO;F]MS'<!8F5_D&V2=6$BX;"LIR
M#QR8_9[\7!?#AU35/#US:>$K6'[%8V5HT(+165Q;L@SC/FM,)"S-\IRH&#F@
M#VF+XF>$I[.\NX?$_AY[73G$=[.NJ0%+9R2`LC;L*200`>N#3?%WQ&T/P/!I
M%SXDNXK2RUF_6RAO))$6&-VADE#.Y("H5B;YL]2/6OG7P%\!-:U/2K);S2TT
MJXTRYTVYDEU$&W.ILE@]K+"\<>=AB5@4E&=Q+9'>O6/$_P`'[S4O`?@?1M%3
M0%F\&7UK=QV>H1RW-G*(;>6$1Y8ER!YNX,V3E1F@#M[CX@:%9-=/J.HV5G96
MEM;W#W]Q=11V[)/N\LB0MCG8>N`<C!/.+<GB_1(;VRLY]7TR*\U+'V*WDO(Q
M)=9&1Y:[LOQSQGBO"M+_`&8]9T&\T"_M=6T'5;C0[6SB-EJ5@YM+DQI>JX*@
MG:J_;1Y77:(\=^,S0OV;]=L]?MM(D.B?V3IMAH!DUF6P/FF2TO;FZDCLE#?N
MAN:-/FZ(PQN(H`]L\*_%_P`)^+O#LVM:?K.G06MFI:_6ZO(HWL`'9/WXW?N\
ME3C=C-;!\:Z`%LV.MZ1MU%-]FWVZ/%RN"VZ/YOG&%8Y&>`?2O)M._9[U#PWX
M7@M?"U]HEEJS0I!J%R+`*+^'[>]S)&[8)&Y9&4/@L&)(JGI'[,=Q8>%;W3+G
M4M+GNIO`\OAVUN#:$_9II)KF0S*2<A<7"K@8)V?2@#V2S\;^']1FBAT[6](N
MY9XY)(HX+^*1G2,[9&`#9(4\$CH>M1+\0_"[Z0FJIXBT(Z6\WD+?#4H?(,N<
M>6'W;=V>V<UY9J'[.MW`UY=^$-0T71-6;Q"=4L;V+2U)MH_[*^Q"';T9?-_>
ME?ND<$9K.T/]G/7=#O+;5/MWAG4+Y=5O+N>PU"S>>T=;FSMH"PZ'S5:U#`[0
M-LKKQG-`'MC>,="6[O;5]9TI;G3462^A-['OM5;[K2+NR@/8G&:IZW\2/#'A
MK5=.TS7]<TS3]1UB9X+"VN+I$>YE1=S(H)^\`1QZD#J17C=]^S!>W%MXFMXK
MS26EU4:DUAJ4IG\V'[7/%/Y<D0.QE#Q[=V20JI@`@YZG4OA#KVKZCH.L:E=>
M&I]6TS7+N_G1K*0P^3<6Q@*QDDL'3Y6!/!(Z#C`!WVG_`!`T"_CM<ZII]K<W
M=@+];.XO(EG6WQDR,@8_*!U897WJ&U^).@ZCK>AZ;I%[#J9\0VMY<V-W8RI/
M;LML8A*#(I(SF9<?0^E>2^$OV>_%/@?PUJ>DZ#K7AC[3>Z?`EOK%QI)DNK2>
M.RBM2B[B083Y6X9Y`D<8.<UN_#;X%WW@GQ#H^J7>HV4BV%SKEQ+;PQL<G4)+
M=U56.,[/(()(&=PX%`'I-WXY\.:?-J$-]K^BVTNDHKWZ3:A$C6BM]UI06^0'
ML6QFGR^,M"@-H)]9TF,Z@N^TWWT8^T+@MF/+?,,*QR,\`^E>07'P"UU9X_L]
MSX1NHM.\4SZ[:R7FF.TVH":61VM[I@>0@F;:PW<Q0G`VUGV7[+$RV2)J=[H-
MQ,8+,%5TW$4#IK,NHSI"I)VQ,LODJ/11GCB@#VJ?QYX<M=,MM2NM>T:'3KW'
MV:\DU")89\D*-CEMK<D#@]3BICXOT3^U+K3?[7TS^T;*$37-G]LC\Z",XP[I
MNW*O(Y(QR*\"\9_`#7KC6+'3?#\&@7.FWI\3N9K^S+VNF)J#VQB58@?]8`)2
M,#!(;IG-7+[]FGQ%J5WJ?]H^)=/N83X<U+0]-G>T*RK#<PV\<8D"X'[OR"2<
MDOOSQB@#V_3_`!GH.K0F72]9TJ\B59&:2WO8Y%`C($ARK'A"0&],C.*PM5^,
M'AW2_'&B>%?M<$^J:U92WZA;N%%@M4&?.;<X+!CT"!B0"V-JDUYO\2_@//=V
MEG:>"+>TLIM5UR.&_DM+98DATN>TB@U!6`(&72W4@@'Y_+XZD=)\3_@4/'^H
M75S87.GZ<7\+3Z-;,]D)#$[3Q2H3R,Q[8BA7(RKD4`=X?'_AD:1%JI\0Z'_9
M<\HABOO[1B\B20G`19-VTMGC`.:O'Q#IHCED^WV?EP&02O\`:$VQF/\`U@8Y
MXV_Q9Z=Z\0MOV>]>M_%<GB@2^"S>75[/)-HC:6[:=''):06X=!G)F'V<,20`
M1(Z\=:OW'P)UFY7Q'I]_<^']0T'5KW4[N&TDCN())&O71BLDB-E%0JP!3DY4
M\8((!ZK!XX\/73Z:MMKFCRMK*EM-"7\3&]`ZF$!OW@&/X<T:7XRTG6]<NM+T
M>\M[Z>RB+W#6TZ2K"P<J8VVD[7!'(/K7B]I^SAK<FKV6H>)-5TK69C;6<5P2
M)+4VIMKR6:%H3&!NPD@!W;=SQAFSN85UWP9^$6H_#:93JTOAZ;[-H]OI4<^F
M6#6\UVL+N5FN"6(:1@_./XMQR<\`'?1^+]#FN+Z"'6-*DGTQ@M]$E[&6M23@
M"0`Y3/OBGVGBG1[_`$<ZM8ZIIUSI01G-_#=QO;[5)#'S`=N`0<\\8KP23]EO
M5KW33IU[J?AT06>FWEA;74.G,+C4%N;V&X9[PD_,0D`7`SN9V8D=*]!\3?!S
M^T/`6M^'_#CZ7IOV_6EU6VB:TS:EEGBG\J6-2-R.T9#XZAS0!T=K\3M!NFWK
M>0+9%;E_[0:XB%MY<`C+2>9NQL(E4AAQP<D<9THO&>@SW-G;0:UI$EQJ-N;F
MSA6^B+W,(&3)&N[+)CG<,BO']6_9UO-8@L6O5\,G[/)J4LFGVL4]I;A[JXM)
ME,;(=RE#;$YQAF8$C&14=K^SWXEDT_7[/7-=\/7TOBK1HK6]U;^R=EU8SK9M
M;G[,%(41'Y7Q\N"TO'SY`![)IGC/0=:1'T;6=)OTD:14:UOHY0QCQY@&UCDK
MD9],\TMKXRT*^NI+:RUG2;BYBM5NWABO8W=8&&5E*ALA"""&Z<UX;JW[,VN:
MW::K?1ZKX=\/>(;Y[.*W;1=.:.V@MDMI+:Y&"0Q>6*>7!Z*4A^]M.="U_9I;
M3-2\0#3I=-^Q7ZZE_9=Q)),)[`7=IY/EE%^1U0\`D\(%``(S0!ZJGQ(\.//<
M@:MIWV2T@$TU^;V'[,OSR(RE]_#*T3YS@#'7(($\WC[PU;S:=%/X@T2.76%5
MM.1]1B5KU6("F$%LR`D@#;G->8WO[.BW.M:!<13Z1'I^DV6B6\]E]B^28V$]
MQ+(=O3#^>,9'!4DYS7'W7P@U/1/BEI+:7X<BU'2=-FTDV@2%8;6)8;BY9Y/,
MSF-H4F!5,8?"COP`?1$WBK1[;6(])N=4T^'59H3-%8R72+/)&,Y=8R=Q7@\X
MQP:K+X]\-M9WMVNOZ(;3391%>W`U&+R[60XPLC;L*W(X.#S7GWBGX.Z]XH^*
MECXBN]:T]M(TNY$]C;&V*S0`V4UN\>0,,"\QDW$Y'W0,<UBQ?LW3:1H7A>+0
M9/#GV_P_!I0NXKK3B;759;2"XA=IE7DDBXWJQR0R`G-`'M.@ZU!XBTJ'4+$,
M()RVS=C)VL5SP<8XK0KGOA]X8D\&^#=+T6=K-GT^$H?L<)AA'S$X1"2549P!
MDX`KH:`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`.5\>>.T\%QZ;#%IFH:UJ6M71M=/T^P,8EG=8WE<[I&5%"
MQQNQ);L`.37G^A_M&V!O=#T:[TO5+G4]02V%X\<<<0LIKHM]GB>(OYF3M&XJ
MI5,@L>N/2?%_@?1_&\5BGB&*9GTVZ%U93V]R]O-;RA67<DB$,,JS*0#@AB#6
M7I_PE\-Z1J%G>:+'?Z=-9V\%L!:ZE-&L\4#%HEE4-B3:6;ELD@X)(XH`XN\_
M:E\/Q06']G:9JE]>:C;0/%:B2"$I/)YY-O(\CJB.BVLS-D\84#)85%%^T$TW
MBY+72=(U#6(M>T;3+O0=,AB2"ZEEN%O))1(TK*B*L=KD[B,'(&<BNM3X->"8
M;B^%A9BRO-0US^VI9;2]DBF6^V;3(C*P*90ME5PI#-Q\QS+J/P7\*:G=6UY?
M6]\VI6<=LEOJ(U*=;J+R!*(R)@^[=B>8$YRP<@YXH`YA/VFM&N&L);+0/$4V
MGS+9MJ%V8HD&EBZNI+2(2J9-S'SXG0B,-@#=TIOAK]H.'4[G3[1=$UO4FGEB
M&H7UM;Q1PV"3WD]K`SH9"Q!D@8';NP/F.,XJY8?L[>%+/Q/'?>5+_95E8Z?;
MV.D+<2K!&UI--,DDHWXG/F3!_P!X#AEW<DUU&C_"GPOH`G_LBQ^SFX6%'/GN
MV1#<27$?4]I9I&]]V#Q@4`8?PU^.%K\3]4U>VTO0]3L;73K.&[BO;F6%DN8Y
M7E5`%1V9'_<N2CA67C(!-9'@;]H.'Q/<:#91Z)K=X=2CLQ>:I'!%%;VDEU;M
M-"'3S"X#!2#MW!25!/(K5^$_P=;X9M<*^N2WUJ]E%:)9QQ-#"2CNWGLC._[Y
M@X4LNU<*/E]-[PY\+?"WA=$C\/V(MQ$UK@"X=\&VC\N`<D_=0X]^^:`.0L_V
MD+"]MKFX7PQXD2&0Q)H[,L/_`!-Y7NC:B.+]Y\A$PP?,VC:=W2G0?M)Z,QN[
M>^T;6['5+,B`Z?.L1DEN_M26SV\95RK,LDT)W`[=LJMGKCIKCX.^$;G08M'E
MTXBPMQ^X5+J1'@;[1]H#HX;<KB;YPP.0?;BH;?X(^#+>719?[+$MSX?U.?5+
M*XFN)))1=S`^;+(Y;,A;=D[LC*J0!M7`!QFN?M,O:7U[8>'_``?J&LW]AK>G
MZ=)'!JMGLDBO)9(HIDD$A7.Z)AL;!&1G`Y%V/]H?3M.U7Q%8:Q:7[W>F7S6]
MG''`B?;&^TQ6_DQ_.=SK)-%D\<2`X&*V[']G[P/IFES:?96%U#!+]D*%=2G#
MVXM)&DMA$^_,8C=W*A2/O&M&7X.^#[C5=.U.;3$DOM*U>;5[29YG)2[E0)(Y
MY^8$!3M.1E5.,@$`%+X8?&W2OBGJ-Y;:+8ZA;1PVR7EK<3F-DN[9W9%D!1FV
M$E"=C[7P5..:YF/]J/2I3+(/#/B46-NB7,MZRVXCCLC<-;-=$>;NVK,CC;C>
M54L!BO0O"?@70_`LDD>@2W=O"R$1V<NHRR00(9"Y$43,50;G(X`P,*.`!6;_
M`,*7\&K87%D-+`MKK3SITR?:9/FMS.\^S.[(_>R.V>O..E`',W?[2^BZ?%=W
M6H:'K\.E_9;RZTR^$<3IJD=I*D4YC4/N4AG7:)`NX<BIKC]H#[-;K'+X+\4'
M6(?MLM_I*FV\ZTMK4Q^;.6,H1U(FCVA6);=C'%:O_"@O`V^],FE.\5[#<0^0
M]],T5O'<2B6=84+XB#R*K-L`SC'3BKGB;X1^$O&EQ)<:O;S/<-]HCFFM=0EM
MW>.=$6:%FC8$HZI'E#Q\H/6@#C?$G[0$FH>"?$FM?#_1[Z6PTBS#P:Y=)&+5
M[C]TQA\O?YN0LN,[0,AAGCFS-^TKHNFP75S?:)K\6E_9;R[TN_\`+B9-4BM9
M4BG,:A]R$-(NT2!=PY%=*WP0\&[=3BBTZ2"SU>/;=V,%[+';,=L:EQ$&V*Q6
M*,%@`?E]SFN/@#X&W7N[2GDBO8;B'R'OIFBMX[B433K"A?;$'D56.P#.`.G%
M`&/KO[1%MX9\+IK/B'PSK&GO%J4EC?Z?/=VBW%J$90957S<3+AT(\LL<'M6O
MX9^(=U/H/C/5M9CMY1X=U[4+&WB26.V$D4+`1J7D8(&.<9)`J[XH^#7A'QE?
M?;-?L9)KAEE21H[N2+SDE:)I(W"L-R%H(CM/&4^M6K_X:^%]4T#6='N[96T_
M5]1.H7Z+<LI^UF1)?-#`Y1@Z(PP1@@4`<3;_`+3&GWNC:;>Z=X8\0WTMY!=W
M%U;6Q@D:RAM;H6UQ(S>9M<+(01L+%@<CH:S[[X_ZM/I6JS3>';CP])8^);[0
M[22XEAO$O'@M;F7?A'!C&8%)R#UP,Y)7T'3OA)X5TB'9:63KMM+NT:22ZD=F
MCNIA/<;F+$DO*`Y8\YSC%5X_A5X,UD7%]#`+VUU/4GU5O+OY)(&N7ADA>5`&
MVC<DL@.W@DYZ@4`<9X2_:.DU31M*M=1\)Z]_PF6I6]G)!HBM;HUXDULT_P!H
M1S+Y:1XBFX9@P*8QR*M0_M"6_BS^SSX'T+7KR%[FQCOKM[>)4L9)Y5`MY5+[
M@Y7<"R@JI9.>:V[3]GOP/86Z+9V5]%/!/%+!?#5;@W5N8HFAC2.<OO5%C=T"
M`[<,W'-6-*^!O@C1;RQO-$TQK1K".V$,=O?3+%(;8DP/(@?;(ZY.'8$G/)/%
M`#O"/QJT'QG=1V]IYUEYEC9SLUX5CV37)DVVI&<^<HC)9>V1ZUQ_PP_:#N==
M\,._B_0[NQU6+2[C4;:66:W@@U6**X:%FB9I<1X;RQ^]*9\Q2/;O/AQ\-K#X
M>Q>(&L9!+=>(]=NM7O91'L!DE;Y449.%50HZ\D,>-QK(C_9]\`VEE?0G393!
M=PK&3+J4[_98TG^TA82S_N0)@)/DQ\RC/04`86C?M3>']5A6>?2]4L;:WTR[
MU#4IKB2`+:);R31NJ8D_T@[K>3_4[\`J3@-5G3?VB['6K"-;#PUX@GUFXU#[
M';Z1$UN\LW^C_:#(LHE\HJ(>2-^0WR8S6W%\#/!,BV<<EG<7MK8//+#:7.HS
M3P>;.)1+*8V<J9'%S-EB,G?],69/@QX8FTVQLKLZQ<)I<Z3V$TVLW+36;+%Y
M0$<N_>JF,E6`.&!.<F@#"OOC!J^B^'OAO<V_AB\UV?QM>16EP8YXK0V1>!Y=
MS)(1DXC;Y1TVMSG`.#X<_:0>PT?6[KQYH.JV\6GWE_'8ZA"L(@U,0ZD;-(XA
MYF5?<\"DOM!RS9`%>FWWPW\/ZEH6AZ1);S1V?AN>&?2_(NY(Y+:2)"B$.&W'
MY&93DG(8@YS5>[^$_A6\T6?2;C3\V,YNBT8N'4JUS.+B5E8-N5C,JN"""I`V
MXH`YS0?C_9^(;O3;2Q\/ZP+NZBNIKU9);=8K"*VE$4TCRF38ZAV3!0L&#9'`
M.,^P_:4M=5TM'TOPKKE]JTNJ7.FQZ7:7%K*SRP6Z7+D3"7RBODN&!W]?EZUU
M]Y\*O"TUO=)KT=SJ`O\`3;G2[B34M1EF:6UN&#2Q%F;."57&.F.,5S.H?`#P
MMJ=SI$6G7E_!;6%[<WU\D.I3&>]>>U^RY:<2!U`15'!P0F*`*-G^U3X8U2[4
M:5IVKW5@UGYWVU4C&V7[%]L$+1[_`#`?)QERNP,0N[)K2\0_'*>RNO"$/AWP
MKJ.LIXIOK6VD=;N&`VBSVCW*,0[?,0L;9`_NGG.`=^T^#7A/3YI/[+LI[&UN
M+=(+BPM;V6*UGC2`VZAX0VQL183)'(5<Y*@BO9_`_P`(:?8VUE;07Z_8+RWO
MH)6U6=IXI88S#$PD+[@!$6CQG!4D$&@#$\,?'=-9N+FTLM$UK6!I4MTVKWMI
M;QQI81)<W,,68S(7D9OLS\1AC@`X&=HI>+?CIJ$WP'U/QQX+T&:2]4*MG:37
M5O(R!Y%02N%DV@J'#&-B&!&"!766OP5\(V&I-J&F6EU8W4OF"9[349X1/OFD
MG_>!7`?;+-*RY^[N...*LVOPF\,6OAS5M#:UFN+#7;K[7J7VF\EEENY_D_>/
M(S%B?W48Z]%%`'->'_C@GVW3]+UK1M=P]R^D/K4J6XAFU2"!I)X2D<A*D>5*
M-P7864@'&"6:S\=[VV^%VG^--"\%ZOJ$&K:C8V]C937EO;RS6]U+&D=QDN0H
M)D&%)#9(R%&2.DC^#OA./Q.^O)8RB^>[FO0GVR4P)=31>5+.L.[8LK)D%@N>
M6/4DF[=?#7P[>>";7PE-;.NAV,5O%:PQW+H\(@96A*R`APRLBD'.<B@#S/0?
MVC9=*'BE_B!X?U6RT_1+_5$M]3A2%H9EM9D008$F[S?WJ+N("L0V#@9KH+WX
M[D?"3Q3XRTGPWJ%S>>%EG%SI$ES"C,\2J[;9E9HV38ZMN4GN/O#%=-)\)_"L
MND7FF7&G^=9:@]V]RDEP[&1[K'G,6W9W,0#G.01D8-7%\!:.?"^I>']0:^U+
M3-8BDAO$U"_EN'DC=`C+O9BP&T=B.YZG-`'%:S^T%;^'5N?[=\,ZW;2:;86=
MSJ2B:W86LMVVRVM]WF`.[R`KD?*N,LP%0/\`M)Z6FGZ!=MHNH@:SJG]F7$7V
MNU$EG/\`:%MP=OFYFC,K`"2+<N.<UU<WPC\+W.FZE97EM<7,>K6EM:WDLU[*
M\LB6Q8P-YA;<'1F)#@ALX.>!56Y^"/A2_P!5MM3U*/4KZ_MO*Q<7.J3R-*(K
MC[1"),O\ZI,2Z@\`GTXH`X_3_P!IB4>$[?6/$'@C7+&XO-1U.VM[*"[MKAGB
ML6D\^8MO"@*D3G!Y)4A<Y!,]Y^U#H]E`4N-`UR'59I8OL.F3O;1275O);M<)
M<;VEV(AC23Y68.&7;MY%=<OP7\(K'+&;&9H9+B^N!$]Y*R1/>HZ7.P%OD#B1
MR5&`"Q(P:=>?!OPI=W,-V+2XMKVU6U$%W:WLL,T(MXY(H@KJP(`2613_`'@W
M.<"@#$'Q]M+S5["ST'PUXBU.*]M[&>2ZCCBB2U%ZC-:B19'5@6*%3P=AQNQF
MHO#'QVEU?X4Z/XOUOPKJ6FWFNW4=IIVBQW4$\MW/(^V,)(&"`$AB2Y7`4D]L
M]E9>`-"L[V:ZACEDO)DLEFGFNGEDD^R;OLY8L22068Y/+9.<UGQ_!_PK%X57
MPY':W`TF"]6]M(OMTV^SG5]Z-`^[='M89`4@#)'0F@#A=!^->M>//BWH>A:)
MH>I:7HL%C?S:VUR+9I$N;>?[.\#?O"0B2<[HPV[<N/EW5T]S\:47^WYM.\.Z
ME=:9H<\MF-2DO+2U@NKR*01R0(995((8D;F`!*L!GC.WX9^&'AGP;=P76@69
MM[N.WGMQ,]R\KRB>;SYBY9B7=Y!O+')]\5F:C\#/!VIWUS=SVM['+=:D-4VP
M:E/%'%?`J3<QHKA4D)0$L`,\YZG(!A:;^T?INLGP\VD>'?$%W!K=A8W]Q-&L
M.W38+N=[>-I<R9;$J,#LW8`W=*6Y_:+LK?0X=7'AS6C8ZM>K:>'II)[6)=88
MB0ED+2CRE"PNV9=I*X(&3BNHT7X6^$=!$<&D6:0_9["UT]5^TLQ6""9YX4.6
M)XD=VSU.><BJUO\`!#PC:68M;*VO;>"&\6\M$AU*=18RK(\@-O\`/^Y&Z23*
MK@$,5(V\4`,\#_&.T^(.M0V7A_1M8^SG3+?4+J\N%CB2U6=6,4;*6WER4D&%
M!`VY)P14WC_XM67P^UK0+'4+*6[37+V&T,L%W`&MFFE2*-FB9Q(ZEW`)13@9
M)JQ)\+M+BM;Q-)O=6T^ZU);.*\OX[YWN9HK9RR(9').2&=2W4ASSTJ/Q%\-/
M"/B?QA:ZEK<:R:['!`8T6^>,S16T_G0EHU8!UCF;<"00"U`$WPV^)5M\2[/4
M+O3K"[L;>RO'MT^U21^9*%)&YHE8O$<@_+(%;&#BNRKF_"O@#2/!]_JE]I"W
MDE]K+1&^NKR\DN99A$I6-2SL3M4$@`>IKI*`"BBB@`HHHH`****`"BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB
M@`HHHH`****`"BBB@`HHHH`****`"BBB@#S3XZ:]XJ\+^';+5/A]:7.I7,=Y
M]FN;&WMQ,\J3QO%'(!U`CG>&1B,?(KYX%>5/XF^*]QX:M'UFYU'3776(-"U.
M[MK`+)&(()1-?1@0RD)/<>4-WELJJ.,`[J^B_$/B/2/"U@]_XGU*RTJRB'SW
M%Y.L48X)QN8@9P#^59TGQ#\)P_9#)XDT1/MUH;NU)U","6W"%S*ISR@4$[NF
M!0!X1X-TKQ)?_%[P_K&NVUS>22WUA->ZC!82P6\C#0[J.20*ZJ47S&5<,!AF
M`(!P*TO%WC7QU)\4=>M_#$NN:/I=KIFHV['4M-:ZLX9XH8&MKJ-8X-Y5VDD`
M`DD+;&^08Q7L#?$[P@-`AUV/Q/H1TJYE$$%]_:,?DRRGI&K;L%O;K5S1?%^E
M:Y96TT5["D\\-N[VS3+YD33IOC5E!X8KR/7'%`'E,_B_7!\$]-GV>-8]5O=1
M.G/J!CC-W;`2NOVM\6Q_<,$&&\C<5D3*@DD9W@WQYXYD&CV/C!-?CO\`6-`T
M!E>/1CB*Z>YD74&=A'MC81^66#XQD$#DUZ0GQR^'DWBC3_#UMXQT&XUK5)I(
M;6T@O5E>62/&Y/E)`;YA@$C/.,X-;]YXU\-Z?K7]C7^MZ7;:J;9[K[#+=HLP
MA4$M)L)SM`!.?0'TH`^:-&UGQWX=\%:98:EXA^(RS0+K<EWJ+Z*MY=G4(9E-
MI9D&`Y@DC+."!AS\HD48`O:CK/Q40ZL]G#J.C7S0W>HW!L='C?S[NWTBPDB@
MR48,CW)GC."68*R!ACCWAOBSX(30K?6G\6^'TTBZD:.&^;4HQ#(ZL%90^<$@
MD`CMFEUGXCZ!I6MQ:/%J=C<ZJ07EL(;R,S0QB&242.A;(4B,\\?>4]#F@#QS
M4-2^)L>IW&B6^K^(#`UWY_\`:ZZ7#YNQM+DN3"O[ORP@NHUC!VE@)"F2<&GV
M'BOXAZ'IT5SKMQKM_%*?#6I7LIT<;K9+J1EU&VC2.//EQJBG&&=-YR>E>M6_
MQ/\`#UYJ&DV$&I63ZCJ<<<S6*7D3S6\4D#S+)(JL<+A.HR.0<X.:K-\<_AV+
MG1H4\8Z#++X@O9++3?*O5D%Q<(`7C!4D!AE>#CEE'4B@#SZ[UKQ[XBUJSFTF
M^U_1-,M+"/4!"VCHIO)#J<D9@F$B;@#:A?E7:PRK9XP=#X1Z[XVU7QGK`\:W
MTH0K>J^C363HMK)%<[(&@D\A$\LPD$YDD+DAA@!A7HDOQ.\&Q6NJ7,GBC05@
MT280:E+_`&C'MM)"<!)#GY23Q@^A':LCQC\9=!\&>+/"OAZXN;>74?%K.]HK
M7D42);(`7GR[#</F`"KDMSCH:`/&=,U#QGK6E7&HZK_PD>HZW)!IBWUC?^'A
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M+DJD?FE,`H2!7NWQ"^)_AOX80P77CG48-*T^6&65KN>50D8C*`C;G>Q)D4?*
MI]\9&='3/&_AO6=1CL-'UW3;V_FLUO4MH+M9)&MVQME"@YV'(P?<4`>%>*M?
M^(%GI>L:U+K/B&)(/$<]M%H^G:6!+<V$",Z"T8V\F))'(&Z7Y650H*'YCT?Q
MD\6>*M.\1^%['P7;^)+:8RV=S<R06RRVMW%)=Q13V\H\ESO2$R2'YX@!R"QX
M'IL7Q#\)O?W]A%XCT4WNE0B6^@%_'OM8]VW=(,Y49XR>AJ.P^)7@_4K^SLM.
M\3Z'<7FI6_VBTMH]0C:2XBY^=%SEAP>GH:`/&]2UKXEZ;I.NZY;W^NW37$NH
MV\>FKI$;_P!G6\&IQQ1W-NH3=)(;-I9`K%A(5!`XP=*4:TOP/\;R:6VKZYJ4
MM]*UA-J.CB*YO8\PA7:W*`-P#SL`;;NVCH/3X?B?X+GM-0N8/%6@26VD.J7\
MJZE$5M6()42'=\I(!QGT/I45M\3_``O)+"+W6=,L3>W[V-BMQ?Q!KR5<?ZL!
MB3G<..",C(&:`/&/B!8?$'Q-H/Q$W:UXEM[2YM]?T^QTNTT^)<QQ(K6DD3^6
M7+.=Z9R0X?`P5S5-;WXD>#=4O-)\,W5U+%X>L5@T32[G3`8=6A.GM(K_`+FV
M6-9_M0*DF5%4)M*9<$^T6GQN^'U_8:Q?0>+M#%GH%^=/U*>2[6-+6X!(\MBV
M`#D''8X..E;47CSPQ+K<&BQ>(-(DU:Z3?#8K>H99%V[LA,Y.5R?<#-`'ANGM
MX@N_&GP_U&+Q?\2-1T>6'48]02\TA;:*6Z:.V>*&>-;=<(29E#$`+L*AL@DY
M/@'Q3\18SX7M+T>(;+4$GTNS&AC042PDTY[-'N;EY/+'ER))YRX#KM**NP[N
M?HJ^\<>&]+T6'5]1UW3+;2KF010WLUXBQ2N6*A5<G!.01QZ&FZGXST6PTK4+
MU;ZWN4TY;@S1Q7*`EX%W2IEF"AE[[B,9YQ0!X-<_$/QOJ?PTL+E+CQ%IFJ66
MF:<=8=M"EBN;JY"W#7<-L3`ZK*3'$NXQF,<+D;P:Z'XP:]XEN+31K33G\3Z-
MIVJ>'+N>1[+15OYIM0V1^59W*A&V@H\I.W9EEP'&!7=Z3\<?A_K&E:GJ5KXN
MT/[)HEX;+4)I+U8UMI\D>6Q8@9)!QC(.#C.*Z'7O&?AWPQIL.H>(];TO3-/N
MG5(+JZNTBCE+<J%8G#9'/';F@#P:;6_&6A>.62W35H=)/B2-!INFZ9Y<U^C6
MMA&DC3F%XV@1FF\S+(^%)5SLVU7\.^-/'Z>%=7G\77NO37M_'9Q2VUEIS17.
MAW4ER\4\B.UIL%LBA3@+.V`7R0P->P:=\7]"UCXIW7@;19X+R_T_2TO[V2.\
MCQ$LA_=JJ;M[Y7YB0,*"N3\PK6C^)?@^=-5>'Q1H3IH2+)J;+J,9%DK?=,GS
M?*#@@9ZD8H`\#T_QM\48=/\`#LTQUK4]:N/#,P32TTPP`:@([EEGOBT`5HV\
MJ%0$>-@[#*$/P6OC'Q]9:9I5Q<>(-=U:U&J1RRV=IHTL>IW"/'!^X,CV:PA5
MDDD9D*I\GR^9E#GWV7XD>$8=,?49/$FC"Q6&*9I_MR%/+EW>6V<]&\M\>NP^
MAIWACXB>&/&7A&+Q1X:URRO?#\\+3KJ"S;8E11EBQ.-N.X.".]`&)\4-"TGX
ME?#'Q%;ZAI,>LK!9WGV2WNK)BPNHTD161'&=V[.U@.<@@D$&O'_#WP\UCPOX
MGT"Z\"_VCX6L].\$Z%]IL[+38S;W\QO93<PRAD)#;'<MM*L"X8DXP?;[3XO^
M!;O3K>_M/%_AV6QO+PV5O<+J4926X&,Q*V<%QN7(ZC(SUK03Q[X7?5[S24\0
MZ.=3T^![B[M/MR>;;Q(<.[KG*JIZD].]`'F/P8USQKJWBO4V\>7TH5X[D3Z1
M-9.@LIHKK9'Y$GD(GE&+'620OPP(&:XFRU>YT/PQJ<\?A_Q&GQ8M+N5-9U9-
M#GN'%LUX1)/#*5\J9%MV+Q1@MC"C;D$5[\GQ)\(3:+;:K'XET1M+O9?)MKL7
MZ&*:3<%V(V<%MQ`P.>:R-9^.7P\T*#S=3\8Z%#&-332F(O5;R[ML[8GVYVMP
M>N`,&@#QG4O$OQ/?2;Y/#FI>)[BSTQ-;N-+U*?0XUNM56TBM#:),AC`P\SW*
M<(C2(G&.M/\`%WC'QMX:UK_A']8\2^)[:SN=6F6WUFTT2.>]GB.EK=>7%&L+
M*RI<!DR$)"Y4G/S5[G:?$_PM*]A!J&M:7I][JEQ/!96MUJ$*RW+12M$VP!SG
MYD.,<]C@Y`M0^(O">M^*DTN#4]%O?$6D+),EHMQ&]U:`_NW8+G<O7:?K@]:`
M/`K;Q]\3KSQ!IYN+'Q'8WMOX=G76=/EL%-J]ZNF"XCGA"P_+FY81X\YB65UV
M``&K6N>+?B'\./!O_"0:AJNJ>(9#<6B_8;O3HHW::_M5CCB4(J_+%>M&<=0C
MN"3MS7N@\?>%FU+5-/\`^$AT@7NB*KZE;F^0/9J3PT@S\@R1R?45S]Q\7/AM
MK6JZ#I;^(_#VIWVLF2\T6%;A)O/>W?:7C/*AU?('(.0V.AP`>>?'O7_%_A30
M/"^D:-XEU#3M1DT6_N-3UBUMHW<2VT,7^D2#RI/W(=V9U5`2",,,8;&O/&OQ
M(2\\57>EZI<SFSLK\:1I_P#9;S1WL26JRV5S`5MPK.[$,Q,I!):,(I`QZ3IG
MQ$^'WQ5\1C0M<CTF;6=/$,UC9ZD\$DDR3VL=P7A`9MR^6^&*Y!V'J!FNJ@^)
M_@N72;W4;3Q5X??3=+E\F[N4U*(Q6\A.`K,&PI)X`[]J`/&/&-W\2O#D5MI5
MGXDUB>REOKMCX@ETU3-&PM()K>"18;>0&'S6N`2(P3L5-P)R=+6?$/C2*;Q1
M=ZA>>)EM(9M+TW3DT6Q2&*/[3;6[SWN9())"J2M(OW6V`L"I/(]9T/X@:#J^
MEB]&IV<*B9(75[E,JTCE(@<''[PXV_WLC%4M1^*WAS1OB'%X.UO4(-.U6ZL8
M+JR%U<)$+OSI98A'&"<M(&B.0!_$OK0!\[IK?Q2L(XM<N]4\:'5;SP3IS&P;
M3@UJLZWLJ7DOEK`=MPEMME"D99F'RL,(.RM?$WC73[KP8M]KFK:W:'5)X+F'
M3M,DCN;Q&NDCADGDDM5C:..-F,F!"6QO0D#!]BD^)W@Z./67D\3Z(B^'G"ZL
M3?QC["Q)`$O/RDD$#/<$5:@\<>&[K6(M(MM>TJ;5+BT%W%9)>(TTD!&1($SD
MJ0<Y].:`/$OB3:^)W^-=E=Z?J/BK1O#UKJVDI=S:+8JR7,3VUZ'$K")VD02B
M!#V3S<\$@C7\(>,O$\/@OXE7.OWNIWFJ:';7%W9:C-9?9[-CY,CHEM&\4<@$
M>U`ZOOY/#G)QZ+IOQ/\`#.J?VS<:=K6GW6EZ':+<7FH6]VDL$*[I0X+*3@KY
M1)SZBJVG_%;P!XPT'2+BV\2Z#?:9XM5H=.6:Z0"_!&&C5&P6/.TKCJ<'GB@#
MP6W\<^/)M$&L+=:UK6FV,J:A!J>J:$D!@E;1;R6=4'EKB!)Q;A7QU<IO:DLO
M&_Q)U+3H1I^L^)9?#^HW5H9?$%SHHM[BVEDLGEDBB46SG[,)Q$N_RFQN*;SU
M'M7BSXO>`_#.FM97FJ:-<Z?;ZA!HNIP1W431Z?YP90LZDX6/"E2#],5T$/Q"
M\&V::+;P>(M!A768XAH\2WT:B[1N(Q",_,IVX&WTQ0!X#K+^-;+Q1)KEA8S7
MVIW&G:9-)>6^DOY,L\>CZD6:-'7<G[\PKC`8;U0_>Q6EJ]]\3-'T:PM6U_6Y
M8=5OX);W5FTU$GTY9+#S!"HCMY,1?:05),9*@A"W\5>N^(OB]X5T33]:N+75
M;+5KKP_)%'J%C87<<L\!DE2+YDW<89QG/ICK6@GQ(\);M71O$VA^;H`)U51J
M,>;(`\F3GY>>.>_'6@#@/&VO>)X?"W@)IM1U?3K;5$'_``D>M>'](:6:%Q:E
MTV0R1.T:23#!W1DCA3@FL;]G_P`.>*+[X@ZSXO\`B+)K*:I?^&M(C-O=V44,
M,;LDIE2,!-R%2J%D#X#2'<"=N/6M)^)GA'7M+EO]%\3:)?6,`0R7-O?HZ('D
M,:DL#W=60?[0(ZBNF50.1GGUH`=1110`4444`%%%%`!1110`4444`%%%%`!1
M110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%
M%`!1110`4444`%%%%`!1110`4444`>;_`!G\+:WXJ7P@/"<-E+=:5XGM[Z5K
MU/,ABB2"=2[IN4L`SH,`YR0>U<78_LP26/A75-,37+<WE_H]C:1W7]G+LBN+
M:^GO2WE[N8'DG"&+/W%QDYS7I/Q,\:W?@JUT<Z-ID>KZEKNJQZ996\MU]FC$
MKQR.&>3:V%`B.<*3SP#7E=I^T+J&HZI:W]G%:01ZEX922TT2^N]JR:D+^6W>
M-)HHW=SB)]NU#N"YP.<`&LWP"UEM9?7_`.V-!_MJ\U:\N[NVDT<R6!BN;2&U
M*+%O#%U2!&WD_,6D!`#<6K'X$:I8:LQ@UZR32KJVTV.\C33RL[/:6KVP\I]^
MU%8,'^Z2"N.AS7G/BK]HKXA^(O#=_<>!]`T33["[T+0;ZWO)=89;NV.HW)@8
M;3"R$@JR@X^7A\-]T>@Z3\=+Z"ZM;/4M#SICSZAIEMJ(U=9IYKW3H96N/-B\
MM<(3;RA7!R<`E5#"@"?PU\%M?T&]\#W,^K>'IW\%6TFGIY6DM$;NT>*.,LQ\
MPXF_=*<_=&3QS5[5_A1XC;6/&5UX6\1V&EKXM(N4N9--\Z[T^Z6U6W'EON`,
M>$1L$9!+@'YN.9N_VD-8L;'2KN?P<C+J6EV>K-''K2[HK2[N5M[<9,8!E+R1
MEER%4;OF)`!UM(^.VHWWB#3-)U/P['I;2:K/I>K7T^H,;2VNHY`B002B+$LK
MAD8*_EY!(!)&*`*NB_LXR6T\<VMZE97Y:;6IIX'MFE1CJ,4,>-TC,QV"(\MD
ML&/2K-E\!=0L]2O<ZQI4VFW-[<WT1DTO-Y'+<6)M703;\>6,A@-N2`%/0&MC
M]H6_\1:+\-=5U[P1XDNO#UYH5L\_[JRM[E;KH`KB5&P!R?EP>:Y73OB3XL\'
M?$?7M"\0>;XH\.Z3+80W&L230V]S;O+9R2LP@CC"R`M&,X*XW#`/.`!WAC]G
M;6_"ME'9:;XFTV..T:2XLK\:,&O;:YDT_P"R$K(7QY:L%D"[<D`(3@`U/X=^
M`&L:'?:?JDVN:?=ZI;^)#J]R9K661)5?3ULI$#-(7#[5\P,3@,<8P!6EX+^.
MEQX@\&Z]XF\0^&]0T;2=(T=-9MYE=Y%N[5XGD"AG1!YRJGS*NY1O7#'/%;4/
MC5XFTZWLX9O">F'5[G3;K66M5\1KY2:=`(2S"7RN9CYZ@)MV\$[\8-`&':?L
MR7FFZ#'86=WH4]YIL4<.DZO<)>?:K=8GF:&3Y9MJR)YN?E&UCOR,-@=YXA^%
M-UXBNO#ES?:JDUUHF@ZAID\\EL`UW)=0PQF?`("X,1;:/[V!C%<C#^T5J>N:
MM;6O@_PF-0AU%UMK"6[UA;4R7+:<FH!74(VU!`^"P)._C&.1GVG[0>KR^*X]
M4M]-2Y\%ZAHWAVZF$UXL4^FR:A<30@H@0F8EO+R-R@!"1DG%`%[5OV;KVZTU
M-+T[6=,ATZ^\-Z7H6I^=I?F2*EE(6\VV.X!&<.X(8$`[6Y(P;-W^S>+J'6%;
M4;+S-4TOQ#9B0V(+1/JEV+A9.O)C`V^IZY'2J_A#X]:OK<^G6EMH,FH6ZM;'
M5]1N-1CADMH[J]N+:)DC6,"3:T!+#Y<*1U.:SM3_`&D/$5Y=RVO@OP_X?U!T
MUO2+>WNI=9F%O>65_-+%'*C^0#OS">@9/F!!;!%`'9?%?X*3?$JRTV&/58K.
M33]#OM.#RVWF[GN!;[9"-PX4V_(ZG=U&*M>'/AOK6C_$6?Q+-J&DVEKJ%LW]
MJV&G6\JIJ%SY<*),_F.P4QB)@"@!964-G;D\=)^T5J&G:=JK6NB?VO+H$6JZ
MEK!N-2CMC!8VM[/;XAQ'B1_W#84[>%&YLMSU/A'XO:AXN\:2Z7%H'D:(MS>V
M<>J'4`TC7%MY;,&@V\(RR<'<3E6!`!!(!Y[9_LWZYXKT_5AXEO--TA&F\00Z
M=!%8B25DO]0$WFSOO(<>7$FU0!]_YNF*['7/@;?7_BR\OX-4T]-%N_$5GXA>
MW;3MUW'<6T"Q)!'+NVB)C%&<[<@%U'WLCG/'_P"T7KVD^'M>N?"N@601H]9M
M="U"?5%W/=Z='*T[30;#L3]S(5PS$E5#!0P-3?$#XA>,_AEX)^&UP)HKFXFG
M>?Q-'<.+R2YLH;62>=8Y0D8W[5+!@@^[C%`%#X>?LWZS_8?A>\\97>EVFH:5
M9:%`=.M[`;4CL)VN&65MY#RL\A7</E&,@'-:VI?LSRW'BC5]7BU#3[R+79[H
MWEC?13K$(I;E9T`\J5264AP<\-E.FWFEI'QZU>Z\;^+;B&\TBY\*OI=K)X2@
MF)A6[E:[EM=XF17=Q-(C;`J-D*N!\U=#X&^.^H_$.33?[!\.P1Q#3(+_`%MK
MG51&UDLTL\2+"OEYF.ZVD)SLX('7B@"'7?@7XCO;'Q!IVC>)[.QTW7=<O-1E
MA6SD1I8[J%T>*5T<$[)&5UVXSMVMP:S?$/P&U30/AGK]AX-NH;KQ3<ZC87NA
MWXMUC:QG@M;:T$C9;E0D4C-S]V1E`)ZB_M*ZM+H(U:+PE`;>+P]_PDUS$^N*
MDD>E'(1ES'AKABDA\O(4!0"^6`JE_P`+MU#^T(?$FKZOK-KX=FU^YTE-+T_0
MH;J"W\B8QA;N8GS4FEV[EVG:!(ORGJ0#N?&'P:EU'P3X<T'P9=V>DW/A>)8]
M+U.>.1YK%A`81-$$=07P3E7#*P)!'-8U]\!-8OK7Q7ITGB&Q_LOQ`-7>$?V<
M1-'+J$2HS.WF;2J$,0`HSNY(Q4.E?M!ZSJ7AF/4V\&W$$NI7NFV^CI)>.D%V
M+_(A+3/$N&0@>8%5P`PVENE5YOC[J\'B'2M-_L)AKFNZ=:I:Z1-J<:VL=Z]Q
M=HX:X$9;:%M'.0#N&T!02:`)YOV>M25@UKJ^GG['XEGUJR0V\L.\7$+Q3PRM
M'("<!R4=<8Q@@YK9UGX.:D;#P8?"MYH>GW?A'2[G3DM;FP>XLGBGACC)5#)O
M!0Q(5RQRI=2?FS3&\>>(_%WB._\`!ZVL?@^_:SBEMM0ENS+)<D>2]PUHICV3
M1HLACW[LAOO(`036\>?&G6_`7C[Q'9ZAHEC=>%O#_A6+6GN8+U_MDDDDLL2Q
MB/9MVEXPO7@9;G[H`-[X8_"!?AI>%[:^6^A7P_I6D1[[<))BR65?,)''S^:.
M!TV]ZY1_V;#%X.T[2['4K./4M+2V:.\%JT8GD@OFNU$FQ@Q0EV7`;()W#FKU
MI\;/$-W)I>E)X.$'B;4KF\6.TO=1>VM9+>U2%Y9HYGA#N"+A%`\L?,K\[5R>
M=\-_'KQ+I'AGQ!J7C+01?6.GRZO+IM[;:E&)+Q+;4_LPA>,(!&0LD85LMN"D
MG!-`&M8?LY-!XKT#Q`]UI-K/X?2:.&SMK1Y(9$N)9Y+EG:1V=Y#YRE&)PC>8
M0,2$4[7/@_J^G_`&?PG#.-6U;3M#&FV0LF:WBN(TVA&:%GV&;:,[B1\V,$<&
MEU#X[>(=.CDM+CPA:_V]IUMJ-]JMF=>588;.S:,-)%*8_P!X[B5"JE5`YW$<
M5FZ/\=-9O=4U.RT;3XM=O=2U6>;1[6]O5L$MM/ATZPN9`\@5LN&NQ@8ZL<D*
MN:`,[3?@!JOB*WENM2M["R+2ZK:RV>HM/_Q,[6\:*1IYQ%-E)3)&05#E63'W
M3TZ;5OV<8=7T#7]/EU"""?6KK59UNXK7$D(O#&RIG=DJIB0$9&X`#BN=C_:I
MU+5IH;GPCX*EU31ULTO+UVU/9=6T)LX[MG\M8V0KLD"+F0%G!&!QGO9OC5%_
MPK;Q%XVL=.>\TK2+V:WL!'<@?VE''*L1E5B,*K2;P.O"@]^`"IHGP3GL]7T3
M4[Z;2H;K2]6N]2N!:Q32BZEGLA;!R9G8AQ@'TPJC'4GGM/\`V=_$,"W%]JOB
MFRU37GO]'O%N[JRD=)GL))6S(IDR/,\YLA,*F!@8JO<?'S6(?%MI;ZQ;Z=H4
MVF+K-EJFG2ZCYUK<7L(T]K79<"/?AA>*N!'NW.5VD@52/[0_CG7())?#/A?0
M8(E\*:OJ4OVS5I1)!=V-RULP`\GYH]Z@@,%)#<[2,$`NO^S#J*1ZQ:6_B#36
ML/$TJ-J?G:7OF@5-2GO%^S-OPI(N"AW`X*AQSQ7H/A'X3Q^&/$,NK-/;3W$N
ML:KJ'F"V"R!;UT;R]V<_+L4$]]HX&*\Y\#?'#7]+\/Z3!XCTHZF;%]*M?$.I
M/K2/-'=:D8V@\J/R4$B`7$1/W<`E5W["3:O/VEM5L_#=EK3>$4>UU&QU'5+=
M!K"AQ86/E">1OW>!*3(=D8)!P-S+DX`)]:_9TUGQ+J7B.Z\0^*8KYM8LI[&W
M>6U9C'!)?1W2JRE]H")$L0"@`@;CDYKI[SX/3Q^,=.US1+K3+5+:?5#<6SV7
M#Q7P@+E2K#$BM`#D@@[VR*PIOV@-4M-2>PU3PO%83V6KI9ZI>3:H6L;""2&&
M:&1YUB.)'6=5"E0N]6&_E2>@\;?%X^$O'GA_P_;VEIJ$6JWMM:7S)>NMQ8-<
M,ZPN8Q&4V,4;[SJ3@[0<&@#@K+]E:_M[>WTR;Q'9KI!336NI8-.*7IEL]/%F
MHCE+D*C8#D%21EES\V:MVO[.&NQ:GI&MW&O:"=9\/0:9:6,<>BE;.>&S2X0F
M=/,W%W%TY&T@(43`/-6M-_:)U74-+AO'\)I`NM-9Q^'=VL+B]DN+AX`LYV?N
M=K1[L@/E6`'S9%=(OQ,U'P]\)-3\6^(=.DFO=/OKJ.734NT8J1>M"L2R@;2!
MP`WH.<'-`'-6_P`"[VS\?^"")(#HFCZ?+)KCVMNMM%=W,,CFP6.,,2GEFYN&
M'8;4YR!6EX]^`M[XK\3-=Z7K5O:Z=>Z78Z;??;+=[N\6.VO'N@T,[/E78OLR
MP;&`1T`JB/VAM1BO)-/U'PO#!JVF3ZD-96/5Q+!:PV,=O++)$XC#2L8KJ,JA
M53N!!(`S65JO[1/C!;W0].TGPAHD>I:Q<:5<(MSKQ>)M/OWF2,[TBRLP,)R,
M%0"""U`%H_LZZ_=W&KW^O^(=/US5KZ&UBMKJ\AG1H6M[JXGBG!24%)%,X`"8
M0;.AW&K%E^SE?+J-Y)KFMP:PNI@37-_-'+%=Q7;:=]BEGB5)!$"P^=<H=NYE
MYX(KI^T1J6M>%=:U>U\.ZIINF00)/IFIHVX3+]L2W9)/,B")(=Q8*"_RYR01
M79_#WXK:CXU\27-I=>'AI^DLMZ+"_&H"9YWM+O[+,KQ;1Y>6PRG)RO7!XH`=
M\//A?J/A6ROHM?O=&NY;S2+33-VFZ7]D4I;I(BR."[;V*R#T`Q@<5Q=G^S;J
M%O;>'H[[4M&U+^R?#]KH5S#+;W$4,\-K.)8)@L<HQ)][>I)4G8>-N#/8_M*7
M5[X?UK7QX0U$:):6PN=,N1,RB\7[4MOY<C/&JQREF#A5+C:#D@C%1>(/VA?$
MNA)8V*^"8;CQ+-/<QSZ<NM%HV$-S%!^X=869V83))AE3"AN<C%`&MHWP+U*R
MT70M%U+5M)N]-\-ZY;ZA9NNF;9[B.*:67;.VXAG/F*-P&,J6QEL"W:?`B"UU
M=KL36#1IIMA96T'V(!;?[+J,MX&7GC/FJH`Q@H#[##_X7SK$.JWVG:1H$FMR
MV&HZD]V\^HQVWD6=K?BV;RP(_G8;U95."0#ELXS'=_M,7-LNKW:^$=3GT:VN
MYK'3KZ-Y-L]U'>I9^7/^ZVQ!Y7W+M,AVHQ(!P"`5A^S%J,^GVVGWWB#3VM=&
MTZ>PTN6+3"D\D<U]#<L]RV_YW"VZ)\N`26<]<#)\3_LY>(++P_8"TU"VU4^&
M4^SZ2ECIZPWDD,FI07,DTLC2!7E1(%"@%=S;FR"V!W$'QDUV\.@V#>$Y['5]
M6CU&6ZCN[QH([:&RDC22:,O$'D5Q*K1@HN1UVUB>$_VA=4U6RL)6\-SWFE0:
M?:-J6I-J42W`GGTM;]`L(158%3L)RH#,,#&<`&9H/P6UR\U?P')=Z9;:/9:?
M?7T^OQQL&^W6T=VUU8"4%V(F:X?SF4%E7,@SR*^C4!50#U%>;_!;XF:K\3K3
M5+W5M`M]'M+62!;&X@O7N4O4D@28L"T4>"GF*C``_,K#/%>E4`%%%%`!1110
M`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!
M1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110!ROC[X<Z
M3\2+?2K;Q,C3VFE:E'J"V_&V:1(Y$"OD<KB0GC!R!S45U\)O"%Y:VEM<^'-&
M:WT^WBM[-!:JHMXHR6C1,8VA221CU/K6!\=-.\2:GI>AP^$GU1;)M54:VNE2
MO'=&U,4@!1D='VB4Q%@C!B`>O(/GEQ8?$:QUK2[Z>_\`%$WAVQ\.H=4EN#';
MRS:DMI/LG,08[(@,>:@8YE\H@':Q(![(WPI\)-);.?#NC[K.TBL[?%JH$<$4
M@DCB`'\*N`RCL>14D?PQ\+0ZY=ZS%H&DKJM\LJW-V+5=\OFJJRY/JZHH8]2%
M&<U\U^&;#XE>(?#6EW]G/X\/AK6(M)GU0W6H,][/+):SM<S6WERK)';^:]H2
MJ.OW6VKC(.MXN^&7C7QCX0ULZ_>>.]0FT^WT)],AMM1;39+S8T+WS&&*4*9<
M(QPS'#`;3DYH`]]3P=X6U(O:IIFCW']G006#1B)'^SQ0LLT,)'\(5@CJO;Y3
M2S_#+PM<ZO'JD^A:6^H171NTN#`-PG)SYOH7SSN/(->,:GHWCJU\;?;-,M_%
M]UI*Z];/9:9]J:&.:W-M8QF6XN%DW#RF%RQC<.LA$F>=IKIO@'I7C/3]3U*7
MXAWWB*6ZN+4"]M[^,O:F[6:0&6WD,K!49-N(T55"[21NS0!Z-8:1X?\`$'A-
M--L;?3;_`,.30^0ENF)8)(U."OH0"I&/4&KO_"+Z9_:%Q??8;3[;=RQ33S^7
M\TCQ*5C8GN54D#T%?/7A7X?^+_`7@>Y6UM?%E_)K*2QWVEKK#J+`R:FY,UL$
M<-&RV\A?;&RE@HYW<U?^'VF?$'3==\`OXG3Q;J/DV;VVI0W-TT<%DIDN6%S+
M()2+B0QBW0QR*Q&58-G?0![#9>"_"W@72M2EL=-TK2-,>V;[?E0L`@7>Q#`_
M*$`=SCH,FL>R^$_PYU[14L;+P[X;O=.TZ>6)8HH5D6!R@CDCR.F4"*5Z8"C&
M`*\L^(&B>/O%/C#QE%8:1KT.D7?AO6M,6#^T&EL[]FM8A9R(C2>6CLYF&%0$
M8.YCD5@WG@[XC:/)XCCTW3_%UO%=O?W7A_\`L.^2W"ZHQB6&2Z&\!H2H&`X9
M<))E<E<@'TQ'X)T."\6[@TG3H[I;DW*S+;J&$QA$!<$=_)`CS_=`'2LW_A4O
M@_\`M#2[[_A&M%^UZ+'%%I\WV1=ULD6?*5/0(22O]TDD8KQ'5]$^-'_"47EK
M#=:F=%$[Z5#=PW*9D@OF$SWPQRIM-ODKD`X8X!ZTFJZ)\48=2\53V-[XN:\:
MXNXXK:W;-O=:?]IA:$VTCR[(IUM?-5<(K-(6WGA20#W;1_!_ANT>ZCT/3-+@
M,;QPSB"(##1.9HU;']UY6<#L7)[UDZ?\,O`$D.JZ)IV@:!Y:R6_]HV<4*_(R
M'S8-PZKMW%TZ8W9'6O.O$'@#6O$'P!\<:+86WC!+Z_N99]+@O=2\O49D41%%
M:9'R<A"H#MD@`,<YJ+3/AMXCC^(.K^)?#LOBK2_-DTQ-/BOM19HKF%=/>.0W
M<99O,99"FYFRV4&#UR`>KZA\(?!NJ+;KJ7AG1+E;1Y7A62T4A3+()9/J&D`<
M@Y!8`XS5C18/#+ZK>1>'CHS:C9W4DU[':2(TL$\P'F-(JG*LP"YSUKSSX):'
MXRB\,Z[#XJU+Q)#JU_ID`VZQ&SK:7Y219I893*Y92^QMBA44*NT?,0.2L-/\
M0Q>`?#6BV/@'Q/X?OM'EM++Q9>Z<T$-S>VJJRSFTN4D\V4-,(Y2PVL4W?Q'%
M`'M;?"CPC)J>H:C)X<T5K[58YXKV<VBDSI,JK,&_WPBAO[V!G-;-YX9T[4&M
M&U"RM+DV`<6OFQ!O)#QF-PN>@*,RGV)%?.:^&/BMJ-C:23WGC*S^QVUNUA&-
M303!9-8D5EN=IVR2IIK+NW;@",\N`1E>+K?Q[8ZO+X4LKKQ[<745GK4WAL6.
MJ@2NR7=N+&>ZF9\O"OG.#O)RN`RM@4`?1+_"GPD^FP:>?#FBK96MI!:6\"6B
MHL,,#^9#&F/NJC_,N,8/(I;?X6>$[2ZTVYM?#NCPSZ/#Y-B\=J%-O'N+A5QV
M#DL`>A)(YKP_5K'XIW^M^,[O2['Q)I<MQHMS;V\<>I--`]XEU"MO-;[W*(7@
M$S_(B@;MK9(JUXUT?Q?X'ETC1O"^N>);I/%.M7&@0->ZDUQ/:V\^RX%ZKL=Q
M\A(KI03D@2+GH*`/8]2^$OA#5X--@U/PWHMS!H\`M[".2T4K;PAE81J/[F40
M[3QE1QQ3[CX5>$KSQ,GB*Y\.Z.^N)*DPOC:KYGFH"%D)[N`2`QY'K7E/QL\&
M>*IO'UKX@^'T/B>>_C\)7]A9/9:HR6\5WYD31^;&SA,M'YVUF4C>$ST!JSH\
MOB;PO\.?B;?-)XKT_3;2VDG\,_V]<BYOX-EF#(Y+%VV^?N*AR>AP`,"@#T[2
M_A=X6T6)8M*T+3+:*.>&XCC2'Y8Y(6+1,HZ*4+,5QC&33]3^&GAC65==7T'2
MKO>L:EI;<%@$E:5,-U&V1W<$<@L3WKYDT*R\8:QI$EMH.O>-KRS35I3JYL]0
MGO9;*1]/@>T$$WG[I8!()795?&^559=H->@?\(G\1YY]:U>QU?Q$NMI)/:Z1
M%=7*QV4D+:2A262V!**WV[)SR0<C.V@#U_2?AUX;T+6$U71]%TZTU".#[.EQ
M%"`Z1812BG^$$1Q@XZ[%STJ76?`N@^(=3_M#6M(T^]O/L4EB9YX`S-;2`AX2
M>Z'+94Y')KQ#PAX2\;7DN@6VH:CX[72)=4:YU2&]N7MIK=18[A%YYE>22-KI
M5S@A025`V&N5N_!/COQ;:7E[XETSQY9VD?B#1-472;;7IO.@999OMRP.9LLJ
MJT)`!53C**,4`?0[_"/PA+I\%E-X=TJ6VM;@W$,<D6_RY#&(RRDG(R@"'G!7
M@\5?;P#X?DTY]/DT?36L9/.W6YMP8SYLHEE^7I\TBASZD`UYG\,M(\:6OQ.U
M&[\7WGB00//J"/!*ADL)K?S4:R:-C*5C98B5PB!F;?O)PI/`7,_Q#\0^)/&E
MSX'F\7RW-A=^(K,RO>J+#8D9%C#!$S8\Y9RIW;00`P9B,"@#Z$\1?#+POXMV
M_P#"3:!I6IE'D<&YMPYS(`LG/HP50PZ':,CBF:S\*_"?B"*2/6_#VCWB2W+7
M+B2U7F5H1"SY'.3$!&?50`>*\=O_``OX[TKQA!;Z1+XXNEM[W23H]ZVL>;9+
M:,X;4A>AV^=^)@-RDX:(1XP<95EX,^*<.GSWTVH>,GU.'2[6_M[=]6S')J8O
MY5>)D#8,?V58<Q_<())RY)H`])B^#'AJ;7[KQ-IVJFVMX[B:=%MA`L-K*MK]
MC9=X7)C1$/[IB4#+R.,5L)\(O#M[\'K;P!IC/#X:738;.$P,K%H$*L"#@J=V
M,DXP=QKR1=!^(MMJ]P#!XJOC<QZW!!;_`&G[/:V"R2WSP7&Y9-D[,IM4$<B9
M3*%6&&%:D'AWQU8O=:]K&I>*+(Z%;68M+>*]!MWB&D@71>'E7(N<G+`D,@QP
M3D`]8/PA\&MIL>GGPSHGV.'SBD/V1<*TKI)(P/7<SQQL3URBG/`J9?A9X31+
M%$\/Z2JZ;#<0V@%L!Y,=P<SJ/9R26!ZDY/->'?!G6=2A^'7Q#OKK7=?O]731
M(;Y?M=_)>0V3-IY<&"5I'&6D#R,@QLRHQC;5?P'H/CSQ/:Z23=>.[;PQK%_I
MDU[+?:MMNW0V%PUY)&ZN7CMWF-J`JD<AMH44`>\R_"[PK-K-EJLOA_2&U'3H
MX8[6Y-JN^)801#C_`'`S;2>5R<8I(O!'A74[/[!'I&CSVFFP7&G+`(`4ABFV
MF>''8/A"P[X%?/[:3\6DBFDLH/'`OC:W'_"3+)JD9BN3]NA$?]F;G(1_LJW&
MTKL'S)N^?D;\-AXV\.K92Z'I?CB[L)X]>C^S7-U%)=>;*EO]ADG8R`$`)*`[
M$LO\7))H`]BU3X7>%M;O&NM7T'2[NY>9)GDE@R7=`BHS=F($40&<_<7TJS>^
M`/#^I^(8==U'1].N=9M_+\J]D@#2+Y98QG/JI=]IZC<<=:^>_'W@3Q;XMMM>
M77K/XC3ZC:Z_:W5M_9.N-;V<NF17-NZK"B2J#,(O-R"`V]6).-M>D^.K#7+K
MQAX5$-OXQD\,1:>Y==%O_)GCOQ)%Y)NCO#/'Y8D!R67=G<#D4`=M<_#;PS>Z
M+_9%WH6E2Z7Y2Q"T-L/+5%?S%`';#_,,=#S6?XK^&WAV_P#ASJ'A:X2#1O#D
MT?[Y+55B2)?-$K<$;1N8'/'.XUXU:Z5\3]6U/Q3.+3Q5H=OJ\VEK]D_M9I?L
MSC4Y%O#;.[G:ILRAR@1?[J[A4_B/P?XW@GAT=F\>:MHMM97$>DS6VIH[M/\`
M;YO^/XNP,L9M3`JEMW"O_'@T`>QZ1X6\&Z!I_P!JT73M"LK;23=Q-)#$F(&E
M<&Y5CV+,B[P>25&>E16GP:\$6FEW%A9^%=#ALKN2&26%;4`,T/\`J3ZC9_#C
M&WG&*\7UKPS\0KS7]<MM4M/&,VD7-[?RZ)_9-]$D0D:^<C[4C,`T+6QBV!@0
M`),`-M-9WQ`\&_$#QY<^/$?3/&%AI]W92>386^N2A9IX-0C,+6[>;A2]LCOM
M0(OS!6RPS0!]"1?"SPK"UZ8M!TQ1J)8W2B'Y9BTHE8E>G,@#G`Y89K8TOPUI
MNC,ITRQM;79YQ3RHPNTS2>;*1_OR?,?4\U\_7V@>/7\4ZK/;ZGX\TJT6#R]%
M:W@-\/L3:?A4D1YPGVE+D%F9P79@H#;6)'5Z4?%5A\#[BW?0=>GUA+B2U6WE
MU>8WDUL;C8;H2&0RJWEEI1'YFX`;`W2@#OD^%OA6-[]H]!TL#4V9KM/)RLQ:
M42L2O3F0!S@<MS7-_$'X-^'_`!KK=L^J7LMA<7=K/;M!;+&'N$:2.61T9E+1
MR`HO[Q""`?ICSC0?!7Q&U+2-&@UW4O&5DNEZ5>SQM#J9262Z74LVB3G>S2?Z
M(<%7+`@X8E@#72^`-&\4_P#"RVU#Q=:^*Q+#<ZLMU-=7<<NF&)YA]C-J@8E/
MW&T'"KR&WY.#0!ZE#X"T"WGGGATC3TFNEF6>18`&E$T@DE#'OND`8^I&:I7'
MPJ\)W<^IRW6@:7*^L"47^^#*W/F%3(77H2Q123C)*@]:\1NM`^*!N/%DL6H>
M+8]8N9;N*&.#FTDA-]";:2WD:4I$5MBXPL:ECOWY(&;>I?"_Q+I'CGP[?:3=
M>--1.E0:[::?>76LRSQ6\DK12637*EQYD(/FKN8,<*@;.!0![?IW@/0M),!L
M-+LXFMDN$B?9N9%G*M,`Q).'*J6]=HK.D\!>%FL[_P`/Z?8Z=8-=6:":*S"Q
MRQQ^0;:*0`<KMB4QJV.`F.U>-^#O"7CS4;30K+6-1\>0VE]JMM)KR75PT$ML
MGV*X\\)<>:[E&N!!D)M5>-@`8XZ[XEZ#XSOO&.J?\(N^KPZ9=Z?H5NMQ97`B
M*8U*7[<4;.586S`D^F,<B@#L?AM\++'X:K>G3[NXNY=06W69G1(D`@B$:;8H
MPJ*Q`RS`98]>@`[>OF/6?AMXTT/Q0NH>&)?&>HZG;^%=8TW1[VZUEY8DN1=.
MUG]I5GVMF$KM=E;+*I;D9KT7X(6.OV=_XC.K1^*[?P_(;0Z1#XFO!<WBR^43
M='=N9@A=D`!;&5?:`N*`/5Z***`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@#$\5>,='\$V"7WBG4;73+2258DEN&QO=NB@#
MDG@].P)K*NOBMX0@U#4M-N_$6CI>:5$)+^%K@9MT8A<OV'+*#Z;AG&:K_%;X
M?7/Q!TBUMM+U"#2+^RF::TU(VKRSV,IB>,2P,LB%)`'/)RI&5*D&N2TO]GBS
MMK[5DU:Z@U;2]5.IG%U;2?:X/MZKYZK+YNP9;<V1&#@J,_*,@';:A\4?"/AZ
M\CT[4_$.CV=U]L%BMN]P%99MJ-L([8$D>>@&Y<D9J+6/C%X.T"34TU?Q%I5L
MVB[1J`,I;[*68JH?`.#D'CKQGIS7FUE^R]]CM+(W>NPZSJ,EA<VFMW&J:>[Q
MZL9K@3^:\<<J;6!&W!+*1@$?**Z#7O@G?WVFZO9Z/XHN=+CUKQ#>:M>*ENVR
MX2XMS%Y#[)$8A3MD!W#)0`@CB@#K-*^)^E:KJ/B2$2PP67AN"UN)M2DF7[/+
M#/!YRR*V?NA>Y]JR[#]H'P%J?B"/1;'Q)8RWTNEG5%!5U3[*"P9RY&!C8Q(.
M"`,UG:+\$+?1/#OB#2C>6VHP:]H^GZ:T6H6/F0A+6U$`+HK@N'`W$`KCL:R?
M^%":K<6=]#?^+Y[YM6\-7V@WTES9&1O)GEEDB,3-(6`B\W8`Y<LJ#)!R:`.S
M/QM\#B2S4>)M)SJ,,TUI^]/^D)#O\PH<?-CRY#QR0IQFJWAKX^>`O%NGZ%>:
M+XFTQX_$AQIB2L8I)SG&-C`$'/R\XR>!DUCZC\%[_4?&VAZQ<^)KQ]+\/W%G
M<6FE&W)2*2"VE@.PAPJJXFW'*%@4`!QQ6'H/[-D^CRZ7]JUNSU6'3].L=-EB
MO-,DV30V5R9K9PJS@"1=S`DAE+;6"C;@@';M\</!\NO/H>E:[I6H:Q!>0VUQ
M9172J\)DF$0)W8!PYVX!))X&36WH7Q#\.^)I=4C\/ZUIM^VB2&/4#!-D6[#.
M=QZ8^5N<X^4^E>'^"O@5XB;643Q'%#IUI:WRWIN6999&>+4WNXH+?;(5$#*[
M%LHA5B,`\@>B^'?A#<Z9\.+[P/K.MM?Z--I$FDV4L%BMO/;V[+(N7?<0\@5U
M&<`$IG&6-`&BOQX\`/:6MR/%^@BWO;EK:WE:Z`5Y%QN'/0#<OS'Y?F'/(JC;
M_'72&\02:;?6T]G%#<ZM!->2.ICC&GB$R.<<[6$X(QS\IKF]8^`?B#7K>Y&H
M>,;03ZIX:/AO46CT!`KV1(^:-3(=DO,N22R_./E^04[5?V=;AI3<Z!XLOM'O
M([W4;F">&URT8NVMBT>X.#@+:["002)&P5(!H`W[S]HKP18ZMH,%QK>G+IOB
M6RN+C3]5:Y`@E:&>.%HO4-NE[\#:<XKHS\5/":ZYJ&C-XAT==5TJ)IKVT-TH
M>!%&7+?[HY;^Z.N*\QN?V:;QM%CL-.\5+:F>QUBPU"5M*\XRV^IW0N)Q%NE)
M1U*[59B_')!-/U#]F>74K&XTN?Q+(=%C?6)=.@_LU//@EU&)XW,DV[]XJ":8
M@;5)W*"3M&0#O6^-W@=7M%/B;2<W\$T]K^\/[^.'?YC)Q\V/+D.!R0IQFJ.A
M_'_P7XBT:RUO3-:L3H-[ILNH+J$\P@"1QR1HP,;X?.Z51P,9('4C.=J7P8U#
M4_'.C:U=^)KQ]+T*YM;FTTDP$I#)#;2P$(0X55<3%SE"V5`#8XK!;]FZ\DTS
MPG"WBDB^\%64=KI=R-+&QA%=6\\+2QE_FP+<*P!&=V1MP*`._N/C7X&M=-TW
M4+CQ7H4=EJ[A+*9KM0)V+;2!Z88A3G&"<'%:=IXY\.ZCJFL066J6$]WX=4C4
MPCY-HN"2';MC:<@'C;SS7G^E?L_+9W>HWVJZO]OO=7M=5CO2-/2.-I;^>&9F
M1=QVJGD*H!))ZDYKH?"'PTG\,^)?$-Y+J,4FDZ[O;^P[>U:&VCE>:222=E:1
MP99!(%<J%5MN=N2:`-__`(6-X=+-''K.F23++;0F-+E2WF7";X%P.\B_,OJ.
M:\VG_:H^'KQ"<:C;SW-E=6$.H(K`C3A>;0LGFXV.HWKDH3UXS57P#^RW9^!_
M$.GZJ->O=2:T68S17%NJ_:'"O%9,2#C-O;2/"#@E@0201S/X<_9RE\/C3[6/
MQ&;BQL9]$N6B?3P'>;351%(;?@*ZQC(P2I.03TH`]-?XA^&X/!L/BF36M._X
M1Z:%98]2$P,+JW"E2.N3P`.<\5RD?Q_\%W\TS_VO8-H2:/%J::R9@;:9)+B6
MW\L=RV^%A@#G.*@^(GPYU&[^'5CHOAE'FGL->MM0!MBD$J1K>>>QBW,JAU!.
M/F7..O.*Y30?V?-7F3PYK=U?V>@:]X>C@6SM+>T^T6X$-S=.IF!D)9GBNV#A
M7^5_F5CB@#L;3XX>!M*\5Z=X;M]2T>U@UG3X+[2KJ&:-;>],T\D(CCV\;]\?
M/NP'6M'6_C7X;TP:G'I][!JM]HNH65EJ5C;2`36K7-RENC,#CY0SGG_9(ZUP
M#?LPW)A:!/%)6+5+,VVO-_9*;[H-J$M](T!W@09>9T`(?"X/)&:O6W[.U]+?
MZG=^(/%M[JUUJ7V!!<36I+K'::DU\@;=(1D[O*^4*H500N<T`>E:S\2/#.@>
M(['0=8UW2[/6-294M;*>X"RRLWW0![X(&>I&!DUS/@O]H7P;XS\-7VKPZM9V
M?]D1>9JMK),'DL%\QXP9`N>K(P&/IUK&\5_"+6/%WQ1U>_N+^#3O#5]%H4DJ
MI:K-/>R6%S/<"-7+#R@',63M;()Q@\U+:_`JZTKPW8:=X>\1SZ=>V$,<)O8K
M4H;F);QKEHI-CJVQ][(0K`\DYYH`ZT_%_P`'B+39#XDT;9K%J;NQ87(Q/`%9
MC*/1`$?).`-I!YIGA_XK^"_$&IP6/AKQ'HE[>WXFEAMK:X4O+Y?^L.!SD=>>
M2.>1S7#Z7^S?!I?A;4](.N32?VEX-;PR9VLQE`TUQ*9L;CGFYQM)_@')S6M/
M\$%DO9;FSUJ:TN)/$G]N)+#:J'B<:9]A5`2>PQ(#ZC;C%`&__P`+N\#?V)>:
MP/%&CC3=/O!97,[3X$5P1D1$$;MQ7Y@`.G/2K2_%KPA)<ZK;Q^(]':;1+4W>
MH*+D'[/`!EG;'&`",XZ9&<9KSG0OV>]6T'4H-9M_&,EUXDMM2BO3>W.GM-',
M5L?L3^8CREBSK\^X.-K$@#;Q4L/[-J)I^OZ?<ZK;SV^LVNK0073:>WVJR_M$
MAYMA,IC"^9EL",$C8"?ER0#N/$GQG\(^$]>TC1=<UFVM]4UV=H+"WVLWF.(U
MDVE@,+E70C./O"BU^,/A6XBTN.]UK2K6]UC3!J,-FUVLC^04+ELKE2-H8@YP
M=IQFN>_X4_K4E]I.I7OB:"?5--U22\=UTD)#)%)8K:-"J"3*G8NX,6)R>016
M/I/[/FM>%]!O=*\'^-KC2XM2TJPLY[E=+5KB.:TMA`LL3AQL5E5-RX)!#;6!
M8X`.N\/?$WPQK&I:#I7@PV>HV'B6VU"XAN[%56!&M&A65'7`.XF8#I_"<UJ+
M\4?"5MJ&K:8VO:7!>>'XA+J4$DPC-I&2%#-G`"Y*C(X!(KE_`WP1/@_7=,U6
M75WO9[&XUB>1/L[*LK:A)`[`%G9@$\C`R6)W<GBL34OV=+W7K_7KGQ!XKO+]
MM9LKBRA::U+M;PRWL=TJG,A4A!$L2A50%1D@F@#LM0^.O@JR\+PZ[%XCT:XL
M[TSI8$787[5+#G?$N>C`C:<C@D9ZBCQC\:O#_P`/M9\.V7C2YATB#Q':7$\%
M[<S!(HVA\G*-WR1.#GH-AS6%XK^"-QK.M7NIZ-K<.EOJ=KJ%E?13:4EU'+!=
MF)FVJ6`$@>$'<<@Y.1T-6_B9\)[WQ[)I,FD:['HT^G:/?Z5(TNG"[\V"\2))
M"`77:X$(P>1R<@BBX&UJ/QC\*Z#-=Q^)M9TK1_L^HFP0W5ZG[V011R$\$[0!
M*N=V,`@G`(S3/Q_\!)JGB+3IO$FGPW7A62--5$Q9%A:159`K$8?.]1A<\UQE
MS^S7<6U[J]QX8\326+:W87.F7(O--6Z`M)K>UA.WYU_>C[*&W'*G>05X%6]1
M_9VDDU$SZ5K[6]M!J&FZA9P36C.8I[2T%GAG21"R/`",#:5<[@>,4`=EXC^,
M_A3PYI\4\NLZ;<7%]ILNH:;:17*F2^B2-G!C[8;:0">"01VJKH_Q]\"ZSX/'
MB:/Q+H\6EJ4CGD>Y'[B9HA+Y+8_CV'.!G(Y&17-P_`J[TN._M=%URQTRQUW0
M(M(U*T@TC,8$?G['@W2DQY^T-N5B^2,@@DUM6_P8@M[SP[<"\&=`O;.ZVBT4
M"X-O8268!YXRLF[/.-H%*X'0CXK>$3JFEZ:/$FC?;M;@CN-.@^U+FYCD&8V7
MG!WC[O\`>[9K)\/_`!T\*:OI7ARXU35+'1+[Q1#YMCI]]<JLK#>4'MRRD`G&
M3P.>*Y:/]GR6"\$5MXA\O1;F\T>]OK$Z8ID>731&(A%)N_=HWDPY7:Q&UMI&
M[BG;_LSSV>F'2K;Q.XTN_L=/L]6C?2U>2X6SN7G0PN7_`'1;S"AR&QC<,&F!
MZ#IOQI\$:QXBET'3/$VD7.KP3+#):)/\PD9F55Z8)+(P&#R5('2KNI_$_P`+
MZ-H`US5==TRUTAKAK=+R2;Y))59E9%/\1#(PXS]T]A7@FE_!/QM;^$O$=G'I
MUM;:M+I2+I-]+.C2VNHQ7TL]L8")&06T9D,F"J-EBH'.!ZO<_!Z6RT3P)#X1
MU==+O_`:LEI-/9_:8KA7MV@E\Q-RG<=Q<,&R#UR":`.A_P"%K>$O[=GT8>(M
M'_M6VMS<RVOVI=ZQ!-Y;TX3YR.H7G&*K:7\9_!.MW]M9:3XHT.[N[UY4MX8;
MH,TC1`LX`]@"?<`D9%<-J/[.EUJC75K=^)2VD2:GJ.JP6ZZ6BS)=WMK)`Y:7
M?@QJ9YG"A0>54MA1FVWP"CMH9S;ZK)YK:IIFHH!:*F38V*6JQ9W<!Q'NSVW$
M<T`=5'\;O`TVDZGJ4'BG1I['194BOYX9]ZV[/]S=C)P><$<'!YX-7?\`A:WA
M'^UM*TO_`(2/1_[0UU$?3;<7(+W2NF]"@[AEY7U[9KR#PC^SMXFA\,Z))JOB
MTZ=K5KH6EZ3/:V5ELMUM;6*8&VD,<H>4^9<,V]64'RT&W!.>V\'?`V#PDMN!
M?M>"ULM#M4,EJH(&F*ZJ^<]7WG_=YQG-`'0Z)\7O#&M3:19_VQI<&JZU;?:+
M6P-XDDCISR"I*G.TD<\X.,X-;'A?QKHWC6WGN/"NHVNJ6UM.T$LUNVY5D7JN
M>_4<C@YXKRCP;^S1'X,O[:2WU.TU.VC:SGFBU#3W<_:;>-HEECVS!%)0H,,K
M8*L1]XXZ_P"&'PZU7X>6YL6UNWN=,:XWQ:;%8M'!8PB!(U@M@TKM&F]6D()8
M9<JH4`4`7?&WQ*F\*>*-!T#3/#^H:]?Z[%<3J+:Y@@$$,#1"1V,KKDYF7"KD
MGFK8^*OA)M6U/2QXCT4:CHT;27]N;M0UNJ_?+?[O\7]WOBJ?B_X3Z1XY\<^'
M/$'B6WM+^/PS;W26MI<VRR+YLSP,LP)^ZR>1@<?Q'I7!:O\`LTRZU976EWOB
MAGTF./6UTV(:8GG6[:FS&0RR;OWH3S)`H`7.X;B=M`'L?AWQ%I_BK2X=3T"[
MAOM/N03#<0DE9`&*G!/7D$9]JTZB@A$,:*,\*!CIT%2T`%%%%`!1110`4444
M`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`
M4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`'%?$[QOJ/@RUT2/P]8
M6>H:EX@U>/2[2.\N3!"DCQ2R!W958[0(CP%).:\TT_\`:9U*YTNWN+WP[IUK
M<:]I^F7F@QG52T9%[<_95%U)Y8\O;(0V5#94XZU[I?:=9ZA);MJ%K#<O:2B:
MW,D8;RI`"`ZYZ-AF&1SR?6LR?P3X;N+)K.XT'29;0V@LS"]DC)]G#;A%C&-@
M;D+T!YH`\EC_`&BM9,MS:R>'=->\T&+5YM<-OJ32QF/33")OLN(]TCOYZA58
M+@A@QXYT]-^+FO:S\*_&6OZ]H9T:;1=(DO[&:TN&\NZC-JTR&-Y8P0RXVEBA
M7."-PKT32]!\,Z1=)8:1I>EV<]G:ML@@M40QP32$MC`X5W0D^I7)K%\&/\.-
M2L]5TKP"?"MU;$M;:G8Z9Y+K\O[LI)&O89*8(P.1[4`<-JGQE\5SR:S;>&]%
MT9[32D>R%_>ZBXD%Z=,%]&S1K&08\'83G.><8KF/A]\=/$F@>$='77[33M6:
MR@T9_$%W<:V[74LNK.ODM;HT0#*OF`E25`PR)G;D^RWWB3X?:/H\NJW^H>&+
M32Y]0-K+>/+$L4EVJF`QE^AD"HT9'4!2O08K%UGQ/\'](\0:0->O_`MKK-I!
M`-)-P]N)HXL'R/))YV@$E-O`R<4`<=J/[1WB.ST"VU>#PSHTMOJ$.KWUM&VJ
MNK"STS'GESY1'FOAMBC(Y7<PYIOB?]IG5/#6BZ\+W2=!B\1:*/MB:;]OGE6\
ML?L@NBR.D)(D5"%;<H0'!W8(KVEO"6@/:QP/H^FFWABGA2(VB[4CF_UR`8P%
M?^(?Q=\U7U+P#X6UN3=J_A[1[U\J2UQ8)(3M38.2.R?+]..E`'C=Q\;_`!/;
M2^)KSQ';:3#I&B^+=,L+(:5=/]J>">.WE83*Z%3\DW\.,G*@C`8RVG[26N3Q
MV<+^']"?4-?M=*O=%6VUEI(?(U&<PPK<-Y0*.K`,VT,",[>17LLG@SP[_:$E
M\^B:6;V9H6DN/LB%W,./*+-CDI@;2>F!BH--\`>%M%61=(\.:-9B6>.X<6^G
MQQYEC):-^!U4DE?0GC%`"^!?$5]XE\+65[KMG;:=JTGF1W=I;W'GI%)'(T;;
M7(!924)!('!KPC6?VC->UG2"L5C8Z*+\VUYIES9:A]HG$,6LV]E<1SQE`%+^
M8=N"V06!P17NNF:'H<?B74-5T9(3J<4*6%T8FSY*AC-Y>WHI)F+GN=P)K-\&
M_"3PAX.TA[+1]'LIA/)YEQ<SP1R2W+"9IE,CA1NVR,2N>A`[C-`'`>'/VA=6
MUSPY?:O=:!9Z/97<-N_AVYNY;@Q74L\S0QVLNV'?Y^0#B)7'S!<Y!JI9_M.W
MXT31-;UKP_;V&DW^C7%Y+*;B1S=W40N";.UQ'@R;;5GQ+L)5N,E6%>LGX<^$
M2MXO_"-Z*5U)@]THL$Q,PD,@+#')\PE\_P!XD]>:8_@_P?I%[IUTVA:):W,)
M6TL)19(ICR'Q''Q\N0\G`_O-ZF@#DO"WQ8\3ZSX$U_6K_P`(2'4=,@6?3;2R
MG8QZJLD0D18GE1&R,["=N"1E<Y%<]I7[1.L:UKFE:9H>@66M2)#;RZW)I\UQ
MB+SKN2V980\*\PM"YD\W9C!49->JV'@7PMINEWFE:;H6DV^GWH5+JSAM$6.4
M!0%#(!@@*``,=!Q3#\.?"0-CCPWHP.F#;9D6*#R!YGF$+QQ^\&__`'N>O-`'
M'?#3XP:W\1-8OT3PW]BTAX[IM,OWDDP7@G,!BG#(`KL1N`C+X`(/.,^9Z=\:
M?B9J6G^!M9%EX6N=0U+3_$%S>Z9;:C+#:W$-FT`0EFC9EE!WJ!]WY\DCD#Z"
MT?0/#5GKFI7FA:9IL&K>84OY[:V5)=\@61M[`9RV58^O!/-2V7@OP[I[L^GZ
M'I5LSM.Y,5FBY:;'G'@=7VKN_O8&<T`<#X0^-&J^,/B%<Z19>')%T"VNYK"7
M4=[^9!<1PK+OD!0((VW;%PY8G#8`/&5I?Q*N#I_BWQOK/B*:&W\+WNJVTOA:
M!(`IBLRX4-N7S?/=4$N[=C:ZC;CD^I0^$/#T.M?VS!HVG1ZK@`WR6JB7A-@^
M?&<[/E^G'2J$OAKP6WC<W4^CZ`?%=Y9O*;A[&,W<UNNV-F+;=S*-R*>>A`H`
M\R/[0/B6*^70I?#_`(<E\1W-U81VIMM;>6R\N\M[J>-GD\K>&5;1L@*=V]2#
M@U7L?VE]8O+&Q9O#>EP7GB&UTB[T2)M68Q^3J$KPI]H?ROD9)(\D(&RIX.1B
MO7]+\!>%M!ACAT;P_H]C''<"YC2WLDC"RA#&)!@<,$)0'LIQTXKFOB%X/\`O
MI^B6?BNUT^PMQJ-C!80QP*OVAX9#)!:[0I+1!MQ*`8`R>.30!Q.F_M,76H7?
MA6WCT[17GU'5TTK7+:"^EF>RE>[FM(YHG$7EO$SP2,N]E9@#@9%3Z-^T+KEQ
MI?\`;NN>'M*L_#;BWN1=QZH7D@LS=/;3RRJ4`4QLJ2<$C8QY!4UZ1;^%_`T6
MNV=I::5X936=&M(FM+>*VA%Q:6ZNWELJ@;E0/OVD#`)..2:JWOACPE\0O!6I
MZ-HKV$FAZC;7&E74NCM$0J;V6>$,H(!W;PPQP2>]`'$ZA\7M>TSP5IWC4Z7`
M-.\12+*1>W$BVVB6"+*XNIRB,^'C$9.$(4L-Q`!-:?QC^.LGPHCL?*T?^V)M
M9LY6TB.*X"&\O$>+_1AD=3%(\H/7$3\'%=Y?^"_#^M:=9Z?K>BZ;?65@`+2W
MN;99$A4+M`4,"!\O'TJ_>Z5IE\;2;4;.TG.G2F:UDGB5C;R;2I="?NMM9AD8
MX)%`'B"?M+:KK6L10>#O"AUFQE#7L$J32"2\L!<?9_,B`C*A_,64D.RJ%5<G
M+<9'A?X[^+M(BO[&\T:T\37=W=:XVA?9+]GNI$L]3\@BXCV?*BI*A7879A$1
M@L1GUC0[+X9^-X(+3PW#X0UN'P]NA@ALE@G%B"P)50N=BED'`X)7VK7/PW\(
M--J$O_",Z'YVK$?;Y!I\8:YP^_YSC+?.`W/?!ZT`>+ZM\>/$UQ>V4G@3_A&-
M0^WW'A^*:2ZOIC9;;Z2YC<P8B$@.Z'!+^GW000>Y^%'Q@UCXD:M<&X\.M8:'
M-%-)I]^'<Y,4YA:*8.B@2$@N`A8``ACGKUMOX1\':QH\EM:Z+H5UIA"6SQ)9
MQM%_HSL$3`&/W;[\#^$YQBK^E^#-`T;4[C4-'T?3K&_N]QGN(+98WDW,&;)`
MR<L`3ZD9-`'A'B;]I3Q+--KMOX"L_"5X+&XTN73M0N;JY%O<VMUJ+V3;LQ*=
MX>/[R%DP3@DK@]K\6/C9?_"R&Q6?2(-2N]3L'>R2"XPMQ>H\8>W3(R1Y;O(#
MUQ&>/3K=/\&^![^TU>'2=#\.7%O>3/;ZHD%E$R22(Y9HY0!@E7);!Z,2>M4/
M$OPSB\0WUI<#7O$&E16(46=K8+;>5;L%*;T\R%V5BK%<ANG&*TH.DJB=7X?G
M^@I<W+[NYYIJO[5LNG6IO4T-)]/U%R^@3).=VHVT4VR[DVXX,<8:4`9R!R!S
M3KW]JR32WMY-3T2*.TU"YCGT^5+G<;C2O.FCFO-N,CRTA60@9XE3.*[&/X"V
M<-I:6L7BOQ2EOI\;QVD06Q"VZ.I5U0?9?E#*2"!U%#?`6S:U@MG\5>*6M[:S
M>RAC*V)6*V<`-"H^R\(0J@KT.!7H*67Z:?B_ET]+_,Q_>_U8RO'WQ(\2WWP+
MC\0^%FMM"U_6+JR73A(BSB**XO$CB9E8<[HW4GT+''2N*F_:,U*\\4>'=9LK
M^TTSPO'I]S:ZO;W:@QMJ:6K3/&[J&=?*<11G:,Y=A@\5Z=)\#8)@HF\7^+9`
ML442[OL1PD3[XE'^C=$;YE'8\BH)_P!G[3[J%H;KQ/XFFB>265DD2Q92\H(E
M8@VO5\G<>^>:FE4PD8N,K/5]]$^FW3IV*?/?1?E_F87A7X]^(O%4ECI]KH^@
M6VKBXOAJ0O-1EMX(X;2X2%S%NCWESO!VNJ[<<]:2/X\>*-2\O^RM$\-QB^N=
M26P-]JSQ!H=/D,=P[D1D!F."BC/&2Q&*V?\`AG32!;VL'_"1>(_)L96FMH_*
ML<0R-@LZ_P"B\$D`D]\<T^^_9ZTS4[".QU+Q+XENK.*9YD@F2Q=%D<DNX!M>
M"Q9LGON.>M$I8)O2UOGY_P#`^ZPKU+;?D<*/C1?^*1/XF?5M=T?3=*N;*(:1
MI,%I*8HKBWAE$]WYWS.C--L7R\8VYY.:V+O]I#6+:#Q)J,7A8RZ-I$EQ!:7#
M2R1EYX+I+=EE+)L7>6+*$+$!?FQD5T.H?L[Z5JUY;7>I^(_$=U=6:JMO-+%8
M,\04Y4`_9>`"`0.@[4LG[/.ERW5U<R^)?$KW%\2;J5H[$M.25)+_`.B\DE5/
M/]T>E4ZF!:5[?CY==&_7_AQ+VE_^&.7\0_'K7?#%[I/_``D>E6<&J/+J%C+:
MVVHYLWG2XM(8)&=HPP0_:0Q/!4;N&XQU6F?%;Q%'XYT?0/%6G:#IT-Y`PEOH
M+V2:*YN<2GR;9A'C*K$682;#@G&=IJ6^^!%IJBR+J?BSQ3>"5)4<3K8R;EDV
M^8#FUY#;%SZ[1Z55B_9STB"=)H?$7B-)HX3"CB*QRL9#`J/]%Z$.X_X$?4UD
MW@Y0LVD]=K_+[OF7S3OM^16\6?'/5="U+77T_3=#FTG1M1@T@-<ZH8KB6^G$
M/EL4V$+`#,N6SNPK,!@5E:I^T7KFF6,MO_8.D3:Y87^H6=\$U)C:#[%:+=2O
M$_E[FS&Q4!E!#C!XR:W[K]G;2KZ:26]\1^(KB6:W%M(\D-@Q>$+M"'-KRH7C
MZ<5+!^S_`*?;6D5K;^)_$T=M`)1%"J6(5/-!67`^R_Q@D-Z@G-7&6"44G9_?
MV_S%>=]OR-3X<?$K4?%]UJ-KK]A8Z9<V\%G>6RV]T9Q);749>+<2JXD&UPP`
M(X!!YKG?VAOB)X@^'VH>";KPW<1)IWVVZNM?MF@5VNM/M[<R3*I/*%5S(".?
MDQWK57X'0I/#.GC#Q:L]N4,,@^Q!H]BLJ8/V;C:KLH]`Q'>NDT+P)'92.^N:
MGJ7B=QN^SR:RD$C6P92CB,I$F`ZG#9SD<5Q5E1YG*$NVFOSW+BY/1H\<T/XZ
MZU/XN\67\>J:7<:#JFGZ?+X,L[J-EBE,MW<VR.KPH\DGG_9S(H"G@K@`9K4\
M&_M):KXTT"^UVRT/1K;3-!T=;O5XI]587)N'LS<JENGEX:/``W,5)^;`^4UZ
M[<?#_P`,W5FEI<>']&DM8K>&WCA-E'M2*$EH4`QPJ$DJ!]TDXQ35^'7A6.>.
M:/PYHBRPVOV2-UL(P5@PP\H<?<P[C'3#,.YK(H\EN/VA_$&GJTVH>']`6#3+
M73;W5XTUE_.$.H3%+9;=3$!(ZJ`7R5!;Y5)ZUDZ!\:;V&YT?Q)XDU/Q/<PZ\
MVH`:3I]G9OI]G):I<N;%\XN1<JMNQ+<@L,<`X'NMWX#\-W]_8WU]H.D7%YIB
MHEG<2V:.]NJ'*!&(R`IY`'0\BF1?#WPQ!XA?78/#VBQZU(6+:@MC&)R67:Q+
MXSDC@G.2.*`/)=+^/GB_5M+TH6_A#3HM3\27T,&C/<7\L5G,DMI-<@F1H@Y*
M+`5;:A4EUVDC.(HOCSK5SXLMM'T?2[`:UK^GZ=<6MOJFJ^59VADM)KB==Z1%
MB0(]HZ[NOR@'/K^E?#[PSH9C.C:!I%B8I1+']GLTC\MPK(&7`X(5W48Z!B.Y
MHU#X?^&=5B,6I^']'NHSY7RRV2-_JE98^H_A5F`]`Q'<T`<YX&^)6H>)O'&N
MZ#KFGV.D&PC\VP@-R\EQ>0!MC7(^01M"S'"E7)'1@IXKT.L?2?"&AZ#J%U?:
M)I&FV-[>C%Q<6]LD<DHR6PS`9(R2<>IS6Q0`4444`%%%%`!1110`4444`%%%
M%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444
M`%%%%`!1110`4444`%%%%`!1110`4444`>8_'S2M>U[PI#I?A;2[C4OMT[+=
MO;7KVTUHHBD:.1-DL1;]Z(U(W@`,6(;&*XC1/ASXZDU6SU;6;[6(]5TFSTF.
MR8ZNQMS(+!H[TRQ!ML@,Q4DLI)*@KWS]"$`]0#1M'H/RH`\9^`WA77=`NKFZ
M\6Z?K]E=W&CV4-ZVJZNM_P#:+]&E-S)#AW*1LS!L<`Y&%7!%<'X?\%^-[33]
M#72_!MQI&L>#FUIDU*>[MA_:)NWG6"*/9(6:/,R3L9-N/)&`21CZBVCT'Y4;
M1Z"@#Y;/P,\8:++I_AKPP;?3='MO$6GZU;ZQI\4,BV4BV<]O=,89L[G9Q#*<
MJ03.Y'(KL?!_P^U>RT?X0Q7^C1V\_A.]N_[:!9&"DVES%YR\G*R2R*X4?=$@
M&!MP/<]H&<`<]>*-H]!^5`'A_C30?&6L_&OP]?Z1IUW:Z+HUW`9-1M]2=8[J
MT>WN!.DL7FA,K*T.!Y3%A\VX8Q7&/\+O'T&G^%?MEYXM$W]C"XU&2QU(W-Q;
M:UYD>Z5E>XC1E,8VJOSQKM;Y/FR?J(HIZ@?E2[1Z"@#QGXL>#/&'B7Q'J][X
M3O+ZT^Q^$W70WCU!H8DU4R2C+(K`%O*8`,X*@D'J,CR#XDZ-K6A>%--T:^OO
M%NG:=J$NJW"P7NHM;RVFVRB*"&1;IGE=)#*Z*\WS,9!L*[<?8N!Z"D>-)``Z
M*P!R`1GF@#YI/A#Q?<Z_9:C8VGB?4=&?5K6>PT^YU!K6'[(]I81M-.RSK+'+
M'LN6"%75FWAERP:N?TSX.^+]`\':%H>F6GBO2K#3Y-7^UK8:F;B87K2JUG>1
M[KI-\8C#`*S;0QRT9R37UOM'H*38OH/RH`^</$7PV\:7RW=W<3>(+E;_`,5R
M_;X(=4<22Z0(G^S^6B3QJBK,P=E5E8XYR`!4OACP1XR7QEH]SXKA\5ZD;"]L
M)+?5KK58HX%L4LPLD=Q:K(5\_P"T!W)56)+*0Y`(KZ+P/04;1Z#\J`/G3Q%\
M+=>B\;?$B^\+66N07/BRXT:2VU.WUED3R$E@6\C53+^[?8LA!"CY>%/.*S_$
M/@;XCCQAK<_@2PO]&M[70]0TW39/[=EDCO$"6PLI,RS-MF.V<;O+4HV"S-G-
M?3>T>@_*C:/0?E0!\P:M\-_%MS8PPZ+8^,M*\/7&J7$T]@^K"ZU",&RA6VEW
MBY0LD<T<HV-*QRRD@J,#4C^%7B[7?$Z7'B2^\4OIMW?/;7CKKC6K2:>-*CVY
MCAD"HS7P=CL^;/?9U^B]H]!^5&T8Z"@#YMTSPQ\3-0\6^`+K7-.O;:?0[2SC
MU;4(]4)2[C-E.+E)HQ,$+"X:(8$3%L;MXQBJ-G\)_'>F:G\/-4V:G=FVT1T\
M:QR:P6NKN>66V9XXI6<[<-$)-B;498V3(W<_4&T9Z#\J-H]!0!X#X:\-^/=/
M^%'CK3+&+58M?GW-H^I:GJ&V\U&1XE,DCKYLD=N^XM&I0JN0&"K6)H/P;UC5
M?B'X<U?5-+\2V/AS0M?FN-+L]2\12S7%A`=.VNS%9F)5[K^$LW&[("L17TSM
M'H/RHV@=`/RH`^=?B?\`#GQJ?BWJ?C?X:6%NVIOIEAH\,TMRD7FVLOVI+D\]
M?)>2VN`I^]Y9`Y-<Q;?"'QIX4GL=#\(Z'=6>DZ5XH;4=.U&SU/RB86O8?-66
M-947:ULCMEDD+%RN%/)^L-BGJ!Q[4;%]!^5`'SK8^`?%^H:.UGJUIXG@UJ_\
M0VS>(M1'B%A!?6(NY-YM@LN8D^SE1A%C;!"\D9K!UWX6?$367U?3],CUFRN[
MH:Q!>ZA>:^9-.U"R((TZW2+>Q0[61&8(I7;(6+;AGZIVCT'Y4;1Z#\J`/F'6
M?#WQ*\1:A=K9Z/J^C>%B^G+-I`CLK:Y2$/.MQ;6\MK*CO`@-N_S2*2`X'7%;
M<'PV\6W]]HTNI:CXJE@T'1-.:QDFU(6TCW\=_(TWGQQR,KG[-Y:G<6!4GDMR
M/H/:/0?E2%%/51^5`'SEH'@GQK;>*+J;Q=9>*+NW22[DT"YTW6U1=.=[Z\=F
MEB,BK(6@DMB@<.,)LPN*[#X'SZQX5L(O#/BG2-<2YEEN9X-0NI6G:>&,0CS[
MDM+((99)))`(T<K^[9@%!Q7KVT>@HVC&,#'IB@#YO?X2>*[WQ!KAG.LZ?ISW
MVL:GI_\`9VKFV#WCWL4EK(P1ANS$)>&RN"01G%=A\/-*UW0O$.NW_B?1?$5W
MK%WJ-PKWPU=9;2YM&NO]%\F!I=L?EP,-WR*1Y;#YBPS[!M'H*-HSG`S]*`#`
MHP*6B@!,"C`I:*`$P*,"EHH`3`HP*6B@!,"C`I:*`$P*,"EHH`3`HP*6B@`H
MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB
MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****
M`"BBB@`HHHH`****`$S17D/[17C[6?!]OX,TCPIJ5CH%[XY\2PZ(=<O(!.NF
M*\4LGF+&V%:1C$(T#';ND!(/2N5\2_M!WGP:OO#WAOQ#J&E^.[MI+./4]2MY
M1;7C)=7IM(IC;Q1M"NURH8F1-Q#;5R,4`?1-)G/2OD#QO^VQXBA^'MKJO@;P
MKHS:O=>&O[<EBU#5&\NU5=52P:(A4!9B7!Y*XY],'H;+]I+Q#IVO:SH46D6N
MJ>);KQ=>:5IUE?ZM':V=HMKID%W,OV@19*Y=E7<I)+9)`'`!]/T5\KZ!^VU=
M>(-9LYHO!*VWA6XU#2M.EU*?656>*XU"R^TQCRMF"B'AGW8*D,N>11!^VEJ&
MIV$L?AKPEIVN:O-K.C6.FI:ZT\=I>Q:HDS02":6!2-I@;<=A4@@J30!]44F:
M\-^&/[1FH^.OB))X$U?PS#I7B;0S>GQ-!%J!GBT](C"+9T<HID$XFRO`P(W]
M*\<O_P!IWQOX.\=6FC^+;RW-AKWQ!>/0+M+),W.D075Q;WMD0/\`EK%Y<+AN
M&(D]C0!]JY`ZTM?'WB/]LKQE<>&-,U#PCX,\/+=:V-$U#31=:Z9D?3=1NC;H
M)=L8\JX#[01RH#$@ML(KU?X>_'W5/''Q#OM#M?!]XN@6FIZAI9UN&1Y%M[JR
MVB03@QA%21BZHRNQ.WY@-PH`]JHKY>\;?MH3^$5\2:A%X2@O=#TBZUG3K*9=
M747-Q>Z;'YDHDAV?NX7`<*X9L84L`'%=[X#^-&L>.?#_`(_@U[08?#/B/P4H
M$T,%^M]%F6R6ZA97VKDA9%##&,@X)%`'L=+7QM\,?VE/&^A?#+PI=>(DO?&?
MB?Q;H%UXC_XJ`6NA0P6=K;P23K`\*L)`S3#RRX4X#%BH%=99_MA:K>:-XE\5
MMX)BMO`?AC6+*PN]5GU?;<!)_LS/*T'E_(L4=R&;+<[2!Z@`^G:*^5?#G[<2
M>*K>[-AX?TZPETV+.H-J6K,B6LD]VL.GH1'$[LUQ&WFA0N<<#/6JD'[<>I7V
MG:KJ5EX!272O#7AF76M>F?6A%);F.YNK8Q1(8\R;I;7@G;A6)(!&"`?6F12U
M\R?!_P".VM7WCKQQIGQ+BO$O;KQ#:6&D6.CI)JUGIN[3H)F#7,<0$:,TF_=)
MM`+$9XIWA#]I/Q#_`,*A^%EPVGZ;XB\:^/K&\F#7=\NFVO\`HD;RRL[A&"L5
M50`%QDDD@`T`?3&<=:,U\UO^V#_:CV=QH7A</H\=GH5QK$EUJ:Q75L=6)6W%
MO!M/VC8=N[##(/R@XK@_A-^U9K_BSP7X&MKZ2Z;4%\3:/I.L7\[QQW%_)="Y
MD<^0T9_T8I&@652"S!@N-AR`?:-)G'6ODC2?VY]2?0+:]\0^!(M.FUS2K74=
M!6+6#=)-'-??8\S[(2\>'P^$60E3C&>*[;QW\1/B9X@_9]T?Q+X*T<^'?%&H
MW,4NH:=#Y4]W!8;G\TVJW0C1[CRU5U5U&1D8SB@#Z!R/44M?(GA[]KC7;C77
M$%OX>U'P>?">C:AINLZM=26%W>75].]NGG01Q/AGECD'E1J<%1@D-A;MK^V!
MX@U+6?"VI)X6TZ#PA>^%-=UK6`]^QO89-+F,4RQ#:`R[@-H(!829.W800#ZN
MHKY6N?VO?&D4NA6,'PO!U'7;6ZO;::YU=[:SFM8;-+IGCE>`,S*&*,NSA@""
M0<B_:?M?ZK=:#!=S>"HK2\U^XT-?#<+:J9TNH=4BEDB><QQ,T;(()0RJKY.,
M=<T`?35)G-?+=E^V'XAG\2?8M:^&ESHVGV&H:-I^L/?:J([JTN-2D:*'9`8_
MG4.N[<2N4((&>*9X4_:E\;1:.M[XX\':)%;MXUU+0I]4L]3D^QZ?!:RB)7G(
MB9E9G)C5B`A(!8H&`H`^J**0=*6@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`RO$WA71_&>D3:7XLTRQU?39RIDM+V!
M98V*D,I*D8R"`0>U<Y'\#OA]"VFM%X+\,HVCJ%L"NF1`VP$GF`)QQ^\)?_>)
M/6NXHH`XK_A2G@$2ZM*/!OAD2:[')'JC?V9%F]21Q(ZR_+\P9P'(/\0SUI^H
M?!OP+JVFR:=J?A+P_=V,MVMX]O-81NAN!&(Q+@C[_EJJ;NN`!7944`<R?AGX
M3+$_\(WHF6N8+H_Z#'@S01^7#)C'WD3Y5/8<"J>D?!OP+X?5%T/PCX=T]8[J
M&Z06VG1Q[9XBQBD&!]Y-[[3VW''6NRHH`Y#P_P###1O#GCWQ1XPLA,^M>+4M
M(KV5]N%CMD*1HF%!Q\S,<DDD]<``7[CX?^&KN6PDNM!TF:32KV2_L6DLT8VU
MU(6,DR9'RNQ=B6')R:Z"B@#BK;X*>`;/2M2TRU\&^&X=.UB19;^UCTV)8[EU
M;<K.H&"5;YAZ$Y%:&G_#;PMI/B2X\0:5H&E6>N749CGU""U5)I5(`(9@.<A5
MSGK@5TM%`''7/P=\#7FIZKJ-WX2\/37^N0O!J5R^G1E[R-P`RR''S`A5!SUV
MC-;5KX2T:QDU.2STRQ@?6MO]HM'`JF[VQB-?,_O80!1GL`*UZ*`.1U;X1^"M
M>TC2]*UOPKH-_INAJ%TRTN+"-X[-0NT+&I&%&T8P.,<5=F^'WAJ?2M7TR;0M
M*?3O$#O)JUH;5/*OF=0K&5<8<E54'/90*Z&B@#D;GX2>"[RUU*VNO"VA2P:P
M+==0C>QC*W0MU"P;QCYO+``7/W<#&*FTOX7>$-$@N8='\,Z'9PWEG]BN(H;"
M-5FM]SOY3#&"FZ21MIXR['O7444`<_X6^'_AKP/:36O@S0M*T.VN=OG1:?:I
M`LI5=JE@H&2%XY[5SX_9^^&HTZ33QX%\+?899UN&M_[,BV&50P#XQP<.PR/[
MQ]:]`HH`Y:[^%OA"_P!<T_6;WPSH4VK:5$L-C>OI\9EMHUSL1&QD!<G`[=L5
M%;_"/P5:3Z?-;>%=!BFTE(DL72PC!MEB9FC"$#C:TCE?0NV.IKKJ*`/+_'W[
M-_@?Q]X<L]'FTFWTB/3?)%E-IMO%&T$<4OFI%M9&1HO,^8QLI4G!QD`B]X>^
M!'A#1?AKIW@74M/'B/0=-=I(X]<VW;-(SLY8Y&!@NP````.``.*]"HH`XS5/
M@SX$UM85U;PAX=NUM[%+"(2Z=&PCMD8,D(XX16`('8C(Q5F#X5^#[5=,6V\,
M:%$NBB<::$L(P+039\X1\?*'R=P'!SS7544`<=H_P<\#>'P@T3PGH-B(O.\O
MR;%%V>;&(Y<<<;D`4XZ@`5/=_"SPA?:0=*N_#6B3::;>WMC:/9(8_*@SY"8Q
MP(]S;?[N3BNJHH`Y2U^%/@ZQ@\FT\,Z)%%OM9"BV28+6IS;MTZQGE#_#VJO<
M_!KP->79NKOPGH$UP;]M1,CV$9)NFV[ICQRYV)D]]HS79T4`(.!2T44`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`'.?
M$#QI;_#_`,):CKEY:WE_]BC7R;*R0//=RNP2.&-20"[NRJ,\<\UD3?&KP;IG
MA_0M6U[7K+3;;Q';17-A]J?:TB2!<9`SC!=03T!/)%:7C3P/'XUN=%%]>7$%
MEI-\+UX+=VC:>5498OWBL&4*S[^.I5?2N,TG]GZVTE!!'J\TUE;Z7JVEV5O+
M;*WV>VOIXY@A8G+^48RH)ZAAGD4`=_8^-]"U*YM;;3]4M;BXO3=+;Q(^6<VS
MA)QCML<A6ST)Q7*7/[0WP_MM5TG3_P#A((IKC6]1DTZS,%O+(CSHNXKO"[<=
M`&S@D]>N*?@SX6W.A_%KQIXFNV5++4Q%%HUJ2K+!O57O)0!]WS953(/.8R>C
M#%#1/@)?Z%=:7<V/BA;?^Q]8%_8V-OIFRRM8FMI+>6&*(RL8]XE=\AL!NBXR
M"`;7B#]HGX?>&8[EM6\0Q(;/5(=,N8X[:61X;B5F5`RA<[24?YON_*>>*V6^
M+G@U-2U&PD\1:8EUI$!GOD>7:((QC<68\?+N7<,Y7<,XS7GVG_LXW]FE]<7/
MC2\OM8N)]*FBU"ZLC*VZPN9)XVE5I#YA<RL&P4'`V@4[4/V:(-1B\0VTFK6O
MV;76OY(Y&TTO<V;WKI),(Y#+MVF16.-@)#!2<**`.WTKXV^!-;G\G3/%.DS2
M?9)KQE\[;LABQYK-G&W;D$@X(!!Q@YILWQO\"V_AM=>N/$NG1:2TSPK<.6&9
M%&639C=N"_-C&=O/3FN4\5_LW6'BZPU&SO\`6+J.#4M:U'5)/+@4,K7=JUOL
M!ST3<'![[<'BM/2/@H+*^TF^OM0LI+S3=4FU"5[33C"+QY;$VA\S?(Y)VG=G
M/0!<8%`%A?VC/AXVJ:Q8-XCMUGT-+=[HF&38RSJK1>6P7$F58'"9..>@-='J
M_CS3-&U#38[ZZMX;;4;*YO1<2SJ@2&!4=WVGDKMD!)'W1UZUY[JW[/,]T;Y=
M,UZT@BO;>P5!<Z3YKV=S:6[01W-O(DJ-&X4@C'0@\D$BMSQC\&/^$TT[3+?4
MM=NS-I_AS4=%DNI(5DDN?MD$<+SN>!O'E;L#@ECTH`U)OC7X+3P/K?B^#7+>
M[T#P[Y@U&YMD>4PL@!*[`-Q.&4C`Y#`C@YK&TS]H;P?J?C.U\/KJL-O+JUC9
M7>CS3;D&H"Y:951%*@JP,)'S8R6`'-;=]\,X;_PMXIT1[QXX_%-C]DFGCB`:
M(?9%MMP'0G"@\_3I6?I?PEEMM4FU/5]72_O[FTTB"9UL1$A;3[B2975=S$%_
M,P1DXQD'F@#0\*_%GP]XHO+2PMM2L_[5O())UL89A.5C21D)+J-HSL)P2#[<
M5,_Q?\&1:_>Z)+XCTR/5-.AFFNK9Y=K0I%S*23QE!RPSD#DC'-<EX'^`DG@7
MQ!IE_IFO[;>QCF6ZA@L?(DU0.9"BW+B0JZQF5BGR;@0/FQD'G?\`AGC4_%5[
MXI'BO64LM.OM6UNXTRTM;5'9?MUO]G$\DF<MB-Y,1X')&20`*`/3+#XR>"M4
MU#3;&P\1:?-=ZN&-E$&(,P#,O<8&2C!<XW;3MS3$^-/@F2WCGB\16+PS7YL(
MF0,WFSC&53`^8<CYQE>1S6#-\#(3XX_X2""]M)(YO[.>XL[VR:<&:S!6.6,B
M151BNT<JVTKN')-8:?LXWT-E'!8^*H].:VNQ-ISV.E-%_8R%8U=+']\?)$FQ
MRZ_,AW_<`49`/3==^(WAGPQJD&G>(-:L;"]N86GCAFDVGRE#%I#V5`$;YC@<
M8S7-/\>?"LFHZ1]BU*VGTC4K34+B;4_-\N.S^R>3O616`8$B=2..PZ[A2^.O
M@Q9>/=0\0W&HWT\">(/#*Z%)'$@S"JS22K*K=SND'R]#M]ZY37/V8X?$MFBZ
MIK%M;7J?:9#<:?IQB$UQ*+,I-('E=G96LHSC<`5.W@*#0!WL_P`9O!5MH>G:
MQ<>(+*/2]5N#;6MTP<*90=I1N/D(.`=^,9YJ6\^+W@ZP76&N]?L8QH$R0:@<
ML?*E8D",8'SOD$;5R<@C&:X+Q'^SG<^)-'733XE72[*X>Z?4+33[!T@NI)I8
MI//93,29E\HKO<N")&^4$"I-5_9VEU35[N_7Q"MDAU>+5K'3[2Q:.TANEDF:
M262,2Y>26.=HW=3'G:'QNH`]"U7XE^&-$\)P^)M2UBVCT"=4:*_4-)&RMT/R
M@G'!SQQ@YQBL#2?CIX7U#X@7_A*XU*UMM2A^SM8;Y05U".:V%PKQD#`^4MP3
MSM)&:H^(?@I<:QX"T?PQI>NKH-MIPF2YCTZR:.VNXY8Y$*-$)0P"M()!ER-R
M@L&R16)<_LSK=77D2>)KI="F.FO=V4=BBS326-J+>(K/N^13M5V&T\C`(!-`
M'>Z-\8_!7B'?_8OB33+LI>0V9$<O)EF8K$`#U#L"%8?*V#@G%-L_C!X4U+Q\
MW@NPU/SO$0L?MHMU@DVM%N=3B3;MR#&V1FN$A_9QO@EG<7?B]I]5T>VTBTTJ
MY&DHD<,.G3-+&)(P_P"\9RY#$,HZ8`[]3X7^%-YX9\5VFMC7VO'&DG3M0AEL
M57[5_I$UPLBE6`C(>=P1@@@#I0!4\`?'S0/'WB+7-.LKBWMX]*U673+5I96$
MM[-#&SSD1E!M50C$?,Q(!)"\`Z6F_'?P/JVN:UI%IKD7VS0)+:.]\R&1$5K@
MQB':Y7:VYI8U&#U:L>_^!UP;B*\T3Q')87\/B'4=8CFDL%G5?ML3Q21;"P'R
MA\JQ[CD$<56OO@'<SVNM6UGXE:&'5UTF4"33ED,-UI_D>7)G>-R,+==R8'WC
MAJ`.ZU/XE^%]&O;:TU76[&UN;R62*&*1\%FC8K)]%4J0S'@8Y(I_ASXB>&_%
MVD76J>'=8L[W3[)F6YN%?:L.U=Q+;L8&W#9/!!R,BN-F^!4>J"\/B/6Y]0?4
M]"U32+QX[98"Z7]PLSNN"=NW;M`YR.2<U8T3X+Q6G@OQ'X=UR[M+M/$]F+2^
MO+*R:UFE7[.(-SEI'W-@<<@`84#`H`UK3XV>!;ZP-[;>)]+-L%G;S&D*<0JK
MR\,`>$=6]P01D5,/C!X*_MN]TAO$NE)J.G6\MQ=023;##'%_K22>,IP6&<@$
M$C%>?7W[,JZQIME;:OKEH9=/O8=1CN+32!&\]]!"D5O/,7D<N$VL3&"%8,%X
M`YRW_9LO_&;>(8O'.LBVT^XUG6;O3+2RMDW*UX-BW#R[LG"[CY>!R<$D`4`>
MG?\`"[O`O]G:??'Q+IXMM4N6M;0DL&DE7&Y=F-RXW+DL`!N4D\C.=I?[17P^
MU;PQ+XA@\01Q:1!J,FG2W-Q:S1!)T9@P.5X7Y2=QXQU(K-TCX(:AH7B2W\0:
M-X@L;#5C'/!?O!HV8[V*;R"Q8/*S"4&W7#[B-I"E<**R_$7[.FI:_P"&KGP]
M_P`)K>6VC7%UJTAM4LB`T>H2-(ROMD'F/$[N48_+ASE#UH`ZG3/CSX2U[Q)<
MZ+H6I1W5YIVL?V5?+(&@$,WDO+\I<`2#:C?=)Z$]!FKEO\<O`5UI=]J-OXIT
MF2STZ18[F02GY&?.S`QE@VU@I`(8@A2:YS4?@"-7U.^>_P!>F;2[W6?[6-FE
MJ%D25M-:PD42[ONE"&'RY4CN#Q5TO]GB>+4-+O\`7_%$FIW>C)H\%HT>FI;K
M]FTZ222-&4,<N[2L6<8`XPHH`[O2_BKX2UN]TBTTC7;&\N-=M!>:>D+%_.@(
M)#Y`PH.UL;L9VG'0U9\8_$3PY\/K&.\\9ZO:Z3;2L5C><G]X1R0H`))`Y.!P
M,GH#7$7GP;U/3-;MM;\':Q9V-]I]M*JPI9&'^T"1<&*&YD5\-`LDX<+L+`IP
MPW&I?B3X$\3>*=5\#2Z)J-G87>BM>?VEJ1LQ,L1FLWAW)"S#.7?@;N!USR*`
M+S?'?PK87.NOKVH0Z=IFCWEK;1ZD\GF077VBUCN4=2H.$V2<L>.,YP:V9OBU
MX.MO$4^A7'B/2XM6M8)9Y[9YL&..-=\A8]!M0[B,YV\].:\NU#]E!9=%N=(T
M;QAJEEI5]81V%S:O!O66)+"&S1VVNFZ15AW@G*@R,"IXQVDWP6M9(==1KJVN
M1K>ISW[1WE@LT2&73ULVC9,C>FU=Q&1G./>@#I8/B1X<N?"+^)X-25]"C4LU
MV(9,`!MI^7;NZ\=*H/\`&GP/&^B(WB;2]_B1(GTH"7/VI96*1LO'`9P5!./F
MXZ\5C1_"76(?`,'AZ'QAJ"W,&J"]6\".%\@3;Q9;?,W_`&<)B,#S-V`.>U4/
M"?[/=KX4M[:*/5Y;O[-HEAI8:6U49%K>RW8DQD\LTNW';:#G-`'6:/\`%'0/
M$?B^;0?#FHVNI75C#.]Z+>4,;=HWC3:1CG+.1D'`*,.HX9'\:/`TE[JMHOBC
M2!<:)$9=01I]OD('V,Q)X(5R%;&=I(!QFLKX=_"2?X?7EJ6UTZGI^EVES9Z;
M;R:?'%+#!-.LV))0<R,I4+G"@CG&<D\'I'[-NIZ[I$T7C37$MECEU:/3;.TL
MT86L=YJ@NV=Y-V92RQ1#&%V[F^\:`/3[/XT^!K_4[33K?Q-I?VV]MUN((9)#
M&60J7&2P`5B@+;3AMO.,<U#<_';P#9Z-;ZM>>*--M]/NY)(X)Y2R"0H5#D`C
M.U=RDMC`!!SCFN?UWX"R:WKVH3OKX&BZEKR:]-I<^FI/F\2V$`4R%AF$[$8H
M5R<%=P!KE+_]GCQ(U[I>FZ9XGCCTM=,UFRN+HV(D73[>[6T1+6UA>1BJ!89"
M"68*3TP0M`'KR?%'PE)KEWHZ>(-,.HV%NUQ<Q><,1QJH9F+?=X4AB,Y`()&*
MYO3?VDOASJ_B--$T[Q+;2WLEC+>[O)D6)88_OLTC*%7`^;D].?2N<B_9=TV&
MVUK34U%3H^JQWJ0B2T+WED;JW$,IBF+[!DY;_5YPVW.*V;SX.:SJVH1WVO>)
MM/U.=]!N=%O8;C0$-M=6\OED9B\WC#1Y89(8,0-O&`"SX^^/GASP=\.(O&-G
M<+J5A>W<5E8`;X5GN))/+56)0LB@Y+,5.`IP"<`ZVG_&;P;=75Y92^)-(34-
M,MC<7\/VCB!5`,GS$`,$S\V.5_B`K/M/A'=+X%M/#NI^(KN]>TUR#4X[MXB?
M+2&\2YCMD5G8B)0BQKEF(4=37+ZM^S.=:LKO3;[Q1<-I"QZU_9MN-/3S+5]3
M+&5I)-W[T)YDNT87[PR3M%`'9^(?CAX,\-:!H>M:IK&S2_$=\MCIMS%;2R":
M5B0.`N0/E/)&*H>#OVA/!OBK3=6FFU>STVZT![D:I:W$WS6R0W+V^\G`!#,@
MQC)!=0>3BMSQUX$G\7Z9I4-CJ8TR[T;4[74;:<VPG4R0DX5TRN5()'!&.#VK
MD-1_9XM=1\(+HCZQ*DL$MU/;W@M1N2:745OU8J&&Y5D0+MR-PSR#0!Z7X;\3
MZ5XOTF#4_#=[#?V%SGRYHLX)4D,I!Y#`@@@@$'K6I7.>!/"0\&Z,]D/L!:6[
MGNI&L[5H$9Y9"[,0SNQ8D\L6)8\\5T=`!1110`4444`%%%%`!1110`4444`%
M%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`44
M44`%%%%`!1110`4444`%%%%`!1110`4444`>=?&#Q7<Z"_A;3+?4SH-MXGUD
M:==ZN`NZS0P32*$9P4621HUC5F!`+="<5Q7BOXU7WP_>[L='N--\4VGA72X-
M1U:_U+5$ANKR&:XDA2.W$2>6\JF/#$A0257`+9KVG7=!T[Q)I\UAX@L;+4[&
M<#S;2\MUFCDP<C*,"#@@'IVK#TOP9X2U6QTJZL="\/RV^G+C3'CTZ/%LH;/[
MKY?E`=0>`.0#UH`\FU3]H7Q/;7.MR:?X=T&2STNVUB\1Y]3E21[?2KH076Y1
M&0'?<#&`<#!W'I4MS^TM+I_B*Y_M>VT*P\,I>7]A'>3ZC(;F*6VM?M/G2Q*A
MQ`5(0[26#%>""*]J/A722)`=-T[$T<T<G^BH=Z3-NE4\<AV&6'\1Y.:Y;0/`
M'@G3O$OB2TLK#2KK6-1+7FJI<6\<LPANOEV'*Y$+>00$R1\AH`\UM?VA?%VH
MZ9#;:=X>T*7Q&+S6()HI[Z>WMMNGI#(Q7='Y@9UE"@,!M(R>*Z[P[\9[K6_'
MR^%I].MK2\A$]Y?.UT2L&G"*)K:?IUD><)@\9BE]*]"M/!NB:='''IVDZ7:Q
MPB01)#9H@C\P`28P.-P`#>N!FL;4/A)X<U?4M:O=4M/M4FOVEI97JNV%:VMF
M9XX%VX(3<[$C/.X]N*`.:^+GQ3N/ASK;RP6SWD5EX4O]5:V-T(DE:&XM8PI&
MTG/[XX;.!SP<\9<?Q<\61Z[8^&M0TSPG9>(C-?2W<L^KRI9&TM6M\F)C'O,K
M+<J<,`%V,3QBO7=1T+3]6).IV-E=EX6@8SP+(3$Q!9.1]TE5)'0E1Z53U/PI
MHFK3V_\`;.FZ7>RQ3FX@^TVJ2,LF`"Z[AD-@`$CMB@#Q;X=_'*^CT:SLM?EM
M[RX_LEKX7MW=!))W?5IK1(L=#A57&.2<"J6L_'76M0TC6-;@CLK32;;2=4GT
M^&RU?_2R;>[AMS]H0H1&^=Y!`8#>5/->YS>!]`F>UDFT31Y9;#=]D=["(F#<
MVYMAV_+EOFX[\]:QO#UEX)\46-]J_AW3]#N8-3GD@N[I=.51>ON`;+,@\T%E
M'S<AB`03UH`\ZU7X^^(=*L?$&JS:#H_]C63W]MITBZC(9FGM-0CLW:=-G$9\
MSS`$+-A"N"6%;=E\3?&3_"&7Q)<^'M.N->.H26]O:64\I@>`7!B6Z^91*4V`
MR[%7>5X`S75W_A/PS\1_"=U8V30?89KJ5'GL%1'BN([D-+@E2-WGQ?.""&*G
M<#3]-^&WAKPUX8O-+N+.VO-,N+R;4;U=1CC='F=O,>5EP$4`\\``8H`\AT_]
MH+Q-=WWB-UO/`EQIY&EQ^&/(>\9KZ:[MA.%PJ;F4HLK`[01MYXS5;3?VD_%+
MVVJ^(+[3/#IT"'PEHNKV>GP7$WVM9[^1XQO?;M,*NI+,!E4`(R20/7]%TCX?
M^/[1KO0['PGKEO`J6AGM[:"81K$?DBR!P%_A'0#IP:WG\#Z!*09=$T=\61L?
MFL(S_HIZP=/]7_L?=]J`/'/$'Q]\5^'-`M)=0\*V$6K"VU>[O8Y[V2&)[;3E
MB=Y(05+@R++A0X&"/FXZP:I^T5XHLM5?PY;^&=-N/%#7#-%'#=S2VSVWV2.Z
M1=RQ[C.RR%,8"Y5FS@8KVFW\"Z!:6WV:VT72(K<+*OE)91A=LN!*,8Z.%`8?
MQ8&>E.U#P1H&K(R:KHNDWJO(DC"XLHY,NJ%%;D=0A*@]@2.E`'D.H?&KQE=-
MK;:!X?T2TMM,6:TWZEJ$C3PWPTQ;]-\<:[3&`3&V&SN&1Q5KP+\8_$E]J'@.
MT\96?A^UA\4:1!.^I6T\S17=Y-')(MM;C:=KK''O82$`@G:3M->M)X>TO3X'
M-O8V,$:GS&"6ZJ"1'Y>3@=1&-G^Z,=*SO#_@WPK"NFZIH.AZ'`T4`-C<6UA'
M&8HV!(\LA05!#MTQ]X^IH`\?^*'QYU&TU+QEH7AN2P%O:>&M:FM=4M))5GLK
M^P@B:2-]Z>62#.OW2=N!GKBF:=^T'XDN;]/#+67A$^*HWD:6Z?6)!IIMX[2&
MZ;]YLW>=MG`*[<`*S]!BO7[G2O"5MXB7[38:%'JWB(RP+(UI&9;XJA,J%L?/
M\B'<">B\]*E/PV\*G2AI9\-^'_[-68SK9_V9%Y0E(VE]FW&XJ2,^AQTH`\S\
M,?M"7'C*P=M*L-.L;VZ&FC38+Z^)+M>6'VKY]HR0IX^4<J">*SV^+7CW_AF[
MPWXUA/@S_A)=5FTOSRSS_8A%<SQ1GC[RO^]&1G"\XS@9]H_X0[0QJ<6I#2-+
M_M&%%CCO/L<?FHB@A5#XR``2`,\`XI%\%Z%'HTVCQZ/I2Z3<EC+8"SC$$A8Y
M),>-IR>>G6@#Q2#XN^+_``MXC\=76NV=AK'AC2-4N8E%O>/]K@EBTB&[,4*;
M-K1%ED`);=F3.,#%:Z?&3Q0OPB\8>)M4T*UL;_0K07-A)`TDUM<PR1+(LH5@
M'(C#'=P`VPE3@UZW;^'-.M%*VUC91*TGF,$@4;F\L1[CQR?+&S/]T8Z50T[2
M?#7A"!;+2+'1]+AU.?[.(;:W2)9Y0A^0JHP2$4C![#%`'G-]XTO?!J:+I7A?
MQ59>,]6\67S)9W6NW\,=M:8@DG=BUO'NVLL9")@G_:P#7/67[2VNZ^='D\/^
M'-),.HII:2FZU9QMGU":>&'84C(:)7MV8MP61EVC->PP?"_PA:Z6^F6_A;PW
M#ITLPFDM(]*A2)I!T<J%QN&>O6M)/"FD1F,Q:9IR>2(1%MM4&P0Y\D#`XV9.
MW^[DXQ0!X/??M.:U:6J2KH>BE]*M!/KL<FJ.C.5U*:PDCLQL_>-YD!==^,A@
MIY-7&_:2OFU+Q/#I5AI&K6=DFGR:)=6]Q/$ETMUJ+V($I>,?<D0DL@(."!G%
M>HO\)_##>+5\22Z193:E':I;P"2W1HX-LTD_F1J5^60R2NQ<<GCN,TNB:/X/
MNKJYAT33=!6>ZQ=7*064:M+MF;;(XVC.)D<@GHRD]>:`//)OCIXAT2?3=+\3
M:%I2:[K<_P!ATN.TOWD@N[Z._-M<("5#!%A,=QR,[2X/W<UO:5XWUC1_B18>
M#-;^RBS:QQ::I=22&XUBX6+S)/*"@HNQ?O*[!OX@"*ZE_">A>)]<TC6MBSS^
M&+R\-H$`$<=U(##-(1CF0#S%SG^-^N<UJ1^&-&;66UJ'3M-.K%3$=0%LAGP!
MM*^9C=_"`1GMCM0!XE\1?CCXRT&_US3M`LO#&F7NGZG81:?%K4T[/>6<EY#;
M2W68UV>67F51AMR<[AG`,OB'X_>(-)T'Q!J"6?AB*?3M3N].TNTFN;J5]0EL
MEDDNB!'&=J^6F5)/`#%L<"O8)/`'AN=]0>?0M%E;5QB_9["-C=C.[$A(^?YN
M>>_/6I+KP-X?OK)+.^T32+BTCF,Z02V,;(LI&"X4C&X@D$]2#0!X7;_M!^+8
M)_%%U?:;X>N-/AN]&M-"MH)I_/BDU""!U:Z(4YC7SCDJ,D@*!SFKG_"^/'%[
MXGT/0-.\*Z3:ZK<_9O[2MK^ZFW*DMQ/$TT01"%15MS)ME*OB11C(->H^([3P
M5I-Q(OB:S\/Q3:C;PVLGVFTC)GA,J1Q1M\O*>:\:@'@$KC%9M[\!_"M_KD.I
M?9I+1(GM)/L%J(XX#);2O-"X`3<A#NS'8RAN^><@%;X4?%Z3XD76I*UA#I\.
MC06UM?[KG<T6JOO-Q:#/!\K$8SU)?IQ7$'XC>*=!^,GBV3Q!+IUSH4/B+2/#
MVG6RWTJ"TCNHHI3*T9789/G)+9SGY<[<5ZGIOPM\.6$;0P6_G,FORZ]*TDF6
M?4)&+^:^W&2NX;01P%3T!K;OO"6CZI#=1:II>FWD=^Z27:7%HD@G=``C."#N
M*A5P3R,#'2@#Q#Q9\>?$^BZR]]HT'A6Z\,0>#=3UQHY+J3[1/):S^6OENN4*
M'*?@6.>!GJ]:^+NH+XATW1_"EGI5_<:AJLMF9I;U_+B6*RCNY2=@)+[69`H[
M[22!FO0)_!6@W*VBW.C:1*MA')%:A[&,B!)!AT3CY58<$#@]Z=IO@_1=&2W3
M1]*TRQ2T=GMUM[1(_)9EVLRX`P2ORDCD@8H`\_\`@W\7M9^(EI>:AK7A[^S=
M)FTZ'4=,N8I6<R1.7!@<.%S,NP%BHV?/@'(-<9:_M,ZRVFV]U+HWA^3^WM,L
M=4T86^LLPA@NKR*U1+LE/D<-,&)7(^1U'*\^Z:5X/T;0;F>YT+2M-TZXNL^?
M+:VJ1-+\Q;YBH&?F9C]6)[FL36?A!X4UG2[K3I-%TZTM;Z\M[N[%E:QPFY>"
M<3H),+\R[P20>NYO4T`>3Z=^TAXCU;4X-)TWPM9:AJ6G23C6397LDD,Z17SV
MC-9N4`/*&0F0J%!53R14GBC]H[6M"\'7VOQ6'AP;+K4O[/TV2YN7GN[33I7B
MNY24C*HVY4(R=H#C)SQ7KFH>$?"%MH]O/J&D>'TTS1(7>V9K&+RK./(=BG&%
M&5#''<`]15RZ\$>'M7M;>/4-$TB[@@D>:!)K&-U1Y"6=U!&`6)R3WZF@#Q*_
M^-OBC1SXGO?%::2^FZ#XVM],LX=%N'6Z:W-NL["8.I#$JPZ8R<C(`!,UI^T-
MXBF>WL/[&\,SZQK":3/ICV>KR2VJ1:D\RQ+.WE[@Z>3N.T$,&^7%>W#PAHPO
MY;[^RM,^VSO')+<&T3S)'C&(V9L9)4<`GD=JBT[P+X>T>,II&AZ/8HTZ7!6V
ML(XP94&$DP!]Y1P#U':@#S?0/C#KMWXJ\,Z7XITO2="MM8L_WMRUY),MQ?@3
M%[>V95V_((&<^;M)4Y&<&NB^)'Q!U'P[KOAW0_#$.B2:CKL%W="?6+YK:V2"
MV$9E`9%8M(1*"!T`5F/`K>U;X;^&];%P=0T;3FENK62UDN$ME280NK*ZK(`&
M4$.XX(^\?6KVH>$-%U:QLK/4])TV\M=.*FTAN;5)5@*KM!0,#M(7CCMQ0!X!
M;?'#6?#-YXIDOC-K1TN?67MH)KP11[8]8BM8H^$)&U9<!L\`8P>M:7B3XYZ_
MX2N='7Q/ING0ZO,^HV4D%MJK+8-.E[96\$KNT>\1XN@S'@J`PPV1CVN7PKHA
M9Q-IFE%KMG#[[2/,I9_,8'CDEUWGU*YZBFZQX=T.>TN9M=L-*FMUAF^T/=V\
M;((WP9=Q88VML4MG@[1GI0!Y+XF^-^LZ!K>A:%./#5WJ%Y*EEKBZ9=7$AL)I
M_/$,D;F,)@F!CM8ALJP[9/H_P>U:[U[X3>#-3UBX>\OM1T"RN+FX?&Z61X$9
MF..,DDFH_"^@>#?$>G:9KOAW1M&EM_)VZ?=#2Q$RQAFQLW(&5<ER./XB1UR>
MLLK.#3K2&ULHHH+>WC$<442!$C0#`55'``'``H`GHILDB1(SRLJ(@)9F.`!Z
MDU2M-;LKW5;[3;:YADO=-6-KJ!6^>$2`F,L/1@K8^AH`OT444`%%%%`!1110
M`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!
M1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`'FWQH\/ZUXAMO
M#\6C6>H:II46J;]<T[3]2^P3W-N89%3;+N3A)C$Y7>N0O?&#YKHOPM\:V_BK
MPY-KI\0II^G6NG+;?8]1CE%IM9Q>0W&9D5_,4@M((W+`X7:0*]L\;^-!X0BT
M^*VLI=4U36;K[)IEA$XC-Q-L>0[G/"(J1LS,<X`Z$D`Y-]\8M#\-?V?:_$">
M/PUK%\@=K*5S<K;@OL5Y)HP42-FX5W*@DXX.0`#QBY^%7Q+O(A!K\VI7FF:3
MJ4&E);6NJ'S-4TB))V2Z8^=&?,,DT&]2ZL?L_?(!MZG\+?&<FO:3=WUCKNMZ
M&VDZ19Z];_VO'::AJ`@2^#!WCD4$I+-;NP$@#8."V"*]3U']H'P'I5[>6FH>
M(K:*XT^1H[E!;S/Y;*^Q^0A!"-PY!(CR-Q&16A'\8_"4OB:X\/1ZU!)K%JLQ
MDMD@E/,2[I8U8+M:15(8HI+;2#C'-`'S]IWA'X@WWB?3-(OU\07'B'1-/T.Z
M2^_M\BWTD-?W3W'G'<!<N;1$@/RR9([9W5JCX->/TLM0NS-K9U?^S6N[,'Q%
M)L.K)J$C0L5\S9@6OE+@C9MR""<UZU-\?_`=EH<6LW>OK!9333PCS;*X659(
M<&96A,?F+L#!FRHPIR>.:U+SXIZ.T:1Z!<PZKJ,]Y+9VUE"&WRS0[6F7IP$1
M@Q/3!7!^84`>-Q?#7XB1V'C=EN?$8\1:I:7T,-RFH1I:WDANU:UEC)F9HF6'
M*J!'&%&X-D[:U3\#I-%^)_@[5[+2]8U+2?#^IZD(6EUV61[**X2W:)\22@O&
MLJ3Y4[CR.",8]B\->/-$\7'4O^$?OENX])F:&YG$,B0AU)#;)&4+(`58$H2`
M003D5S#_`+0W@*.P%X^OI]G>5HT<65P=X50S2J/+R80&!,P_=X/WJ`.%\8_#
MKQ?K_P`2+R86>K26MUK-I]EU2#7F@M;?1?(47=H]NK@EW=9!D(23*C;UV<4)
M_@'/;_L]>`?##:#=WFH>&M1TN^O]-AUF178QR*;D1RF4`G;NP-X7^[@XKOX?
MCC;3>)QIB60DM&UJ73EOX)O-1T33%OQ.JJ"6!1MH`R3U&<XJGJW[3?A#2KC0
M)GNY7T?6CJ$<M]]CN`]G-:",O')!Y?F`XD).0`H7)X.:`.$7X)>*]"\,^([K
MPB-5T_Q!K<NKO-"FM.4EBDU-)X$13)LCD:W\Y`Z[2ID.XYYKJ9?AKKUS\#-;
M\.:8NHM?R7AGL+#6YUP\"3QR_8RZRRD0NJ/'EW8@.<\<5W3_`!D\'IK[:,VO
M6?\`:`4L%VN8V(B\THLNWRVD\L;]@8MMYQBJT?QQ\'S0Z3-%JLC0:[,8=.N!
MIUSY-RX.`%D\O;\Q^X2</_#F@#SCXA:1XU\>/:WB^!M>TVQBTV]CCTRU\16]
MG<IJ9$?V2ZD:"4*T:;9%&78KN!V&H+7X->,-5\0VTWC:\UB\@FO/LVIS6VOS
M0)/9#28U^5(W7:&U!7?@!^_W>*[G2/VE?`>K^%;+Q#_:EU9Z?J$TT4`O-,N(
MI3Y)Q*YCV%A&N06DQL7<,D'BM74OCEX+TJYN+>ZUR)YK;RMZVMM-<[FE4-&B
M&-&WNR,'"+EBF6QM!-`'B*>'?B!K/BK2-.N8M<G\2Z%HOAJ:6_76_(M=.F\^
M?[<\JA\3F2&+RR`KYR.F<UH:%\,?B#J4NL-K5A?:):Z_J^C3:A8VVNN45%GG
M_M'RG\]V"-$\2Y4H6`X52*]W\8^.M*\!^#-2\4ZR]R=)TRS-W<-;VSS2^6!G
MB-1N)Y]..^!FN.\,_M'>%O$7C";P\T\EC<2BU?3'NK::+[8L]L9P&W(!$P5)
M/E<@ML)'2@#A_P#A#/$.A>./!?A.PN]7ET;5XVGUCS]1>9[6UTVX=X?G))/G
MB>WB;G)6+!SR1V6A>%-;TCXUZCJ$.GW\OAR[T\PBYN[P)%8K''`L4%K#'*08
MV(E9M\:LK*<,0P%=?X<^)_A;QA9ZC>^']7AN8=)3S+IFC>+9$5++*`Z@M&P5
MBKKE6VG!.#6+I_QEB70_^$@\5:1<>'_#EY'%)I-]-.L\M\)0#&OV>,&59&!R
M$`8XZX/%`'DFB_LYW+0:9HU]H6J6&FV7B[7-0O)XM?D#3PW$5T+62)UE,B@>
M;$I7Y3N!)!Y)T3\-_'W_``E=Q>W<_B.6>*QBBTRZ@OT,/E?V88GMYPTPQ_I0
M,A=8F9F9"&`#8]/N?CYX$M(M/EN/$NGB+5(O-MI`LC+LWM'ER%_=_O$:/Y\?
M/A/O$"FW?[0/@*PTVRU"]\16\-K?^9Y3-;3!E$<GERM(FS=$J/@.7"A<C)&1
M0!YB/AEXTM-?^'T.G:9>QQ:(^F7>I:N=<EEDFF=R=328//@@@+@"-PV\@%0!
M7&^%?!?Q#\4>&SJN@1>(;>"^ME361=ZX2^N%-2Y6!#*/(VVJ2)G,6X.%]Z^C
M[SXP>%=.U/5]/U+5X[*YT.T^V7WVFWEB1(,JID61E"R*"Z`E"<%AFJVG?&SP
M7J.G75_9Z["+:TM;B[N#-;RPM'%!((YB4=0P*NR@KC=\Z\?,,@'G47A'QSH-
MOH\6C6/B+5K<:!J>G%;S4X89+2:2\CDMV?\`>L"JPJRJP9W"@!CDDUB2_!KQ
MCH-IXBMOAS8W>C:I>^-;W5(=1DU@O#/;36ETL#8:1BNV:6+<I4<X.&"Y'M\7
MQ*TZ'6[31=89[/6=2FF%E9""21W@21D29]JD1(^.&?`)R`217-:?\>]+O?BE
MKWA*<+90Z#-:6+W5Q#.K7-]<[?+BC_=["F'`W;\D]!M^:@#'?PAX@B^"E_I?
MA#0];T35IIH))+"]\0&>YN%WPM=HER9'\LR*)D4[AR=WRYXYZ+P%XPD^(?AB
MXT3PWJ6@:!H$^R)Y=?>YDEL7@N1)'.#<,"PF>(JNQL*`=_RX'H]U\?/"%CXL
MU#P_>7UU%=:7I#ZM=7!T^<VT=LC2*Y,H7;E?*?(SVP,GBMO6OB=X>\//`NKZ
ME'#)<W2VL$2PR2/+,T:R!%55))V.K<#@9)P`<`'BMK\(_&.C^$=(22+7M5?4
M%TF?QAIR^(W$U[*B7"W0AE:0!#O>V9@CHKK%@>A6\^&_C^*PCCL[+5I-.&E:
M=!>Z;_;ZK/=(NIW,MU")@RCS6MY(P9,KNY7<*]H\,_%'PUXQFU"+PYJUO=OI
M:A[GY'C41DL!*K.`'C)1QYBY7*D9XK/T[XX^"=4M#=6WB"T2V%TEJ9KB.2!=
M\B,\9RZCY'5'VR?<;&`2>*`/(-5^''CN1/"]CI6A:A:6NE:I]OBO7U\RW-N&
MU/?+#,RS*KJ;,=2LI)8IQC<<.V^!7BW0[4:9HVG>(M-TJ+4M:N"VF:P)9#<R
MW7FV5[&)+E0=L.4VOPKY+(V2U>]1?'+P5+K&GZ6-?M4O=42-[97AD52)(O-B
M#N5"HSQ_,JN06P<`XJ)/CYX&DTN74(]>C>WBN$@VI9SM+(SJ60QQ!-\B,JNP
M=%*D(Q!P#0!RN@VOB'P9\2O$&JZEHWB#5M,UN:&**\EN%DF$CS)&D4422F,6
MR1[Y2[)&R@$$OFG?%OX>>*_%GC@ZAH,VJ16-I8Z4EB;35VM`DW]H/]N;8KC+
M&S;;E@>"0OS=.BTKX_\`A'6$\326=QJIB\(W26VI2'1;HC<RJRF,+&3(,,/N
M@D#DC!!-)?VC_"-[J]SIFBW<MY<V\.G7'G/:S0VLL%](J0LDY0HQ.\$+W)P.
MC;0#SK4?A%X\DE&GV<=Q+HUA?.--2YU3SO+MTUNTN8"V]RS%;>.8@L2P`V]2
M!4&D?"KQO#X+UBUUU_&4NKW\5F=0B@OHI(-0N8IY#-(K-=!PDJ[`X5H<)M"@
M,#7L-O\`'CP-<PZC+%XCLQ'I85IVDBE3<C2")9(\J/-0R$('CW*6(&<U;T;X
MR>$=?N='M](U874^NI(]G%':3%PJ.T;&4;,P@2(Z?O-OS(PZ@B@#PBW^#?BJ
MS\0:GJ,WA34$3Q%>:3=:];Z9XF<"XM4L5BN;2-WF#;DN0LF<KOC0@/SM.]8_
M";QMJ^F:+%XJFUR,:9H][+;11^(7\RVO3J`DLHY)%8>:T=L3&6;<IP02<@U[
M1JWQ%T+0_%%AX?U2]:WU/5$9K.-K67RYB%9RHE"^7OVQN=A;<0I.*P[3X^^!
M+[2[W4+/Q!#-:Z?+#%*Z6LQ9VF!,7E)LW2APKX,88'8W/!H`Y3X:>"/%>C?$
M[5=6\6S:Y(;BXU%7F%PDEC>V[SJ]G\IF+(T<6455B3&'W$Y4GAS\-/B<]O?B
MSAURQU>YT^\BUG4#XCWQ:M=/>PFWEMTWGR0ENDISMCVAPF"1Q[A%\5]$A\#6
M?BK6+ZWL]*U"0I;3)NF$Q+LL80("SLX48`&23@<UC6WQ^\.7-]=/!+)<Z'!H
M5MJR:G:02W!=9KF>`Q^0B&0,K0'=QD9((&#0!C_%?X?ZFT'A?3_"VDZQK'AG
M2;6\CN-,L->>SN/M&Q/L<IF>56=599`<N2#(K8;;QYTWA#QKKOC>QTC4_P"W
M-1UG0]-\-&]U6+7&@M+4GS!J3,H9?.::.,IPC')!^3K7N`^-O@Q]2TC3TU^T
M>ZUZ."6P58Y&65)TWPL7"[4#@';N(W$$#D$5I>'O'WA_Q/H-WK>@WKW>FV1?
M?<I:R@2!5#%HP4!E4CD,@8-V)H`\D\&?"?Q/X6_9VU7PKH%K<:+JR:7?VT5F
MUYYSW-VP813Q7)E/EH?DP"!C!)`KH_AU\.M=T;QM+XAU^753=7-_JL4@DU5Y
M8#8O*C6@\G<44J%.,`,-S9ZUM77[0?@6QT*UUB]UY(;"\DGCB9[*=9%:!PDX
M>+9O3RRR[RR@*#DX'-:2?%C0;KQQ:>%=,O[>\U62:2.XB0.!#LA:0X;;L=AA
M`RAB5W@G&10!XO?:5XWU?XG>*M4\%Z9JEY>:'KU[$EQ>ZZUO8W-H=+0QV`AW
MY^:ZD5_,"C;@G?QBLFX\&>//"'AFVM]..JZ??>(O$L^BV=D^HO)]FTZ^@B\R
M<9EEVM!)#-*H+D@%^?FQ7T#J7Q8\*:1XQ7PU>ZS!#K<C"/[,8GPKF/S%1G"[
M%=DRRJ6!8`X!Q63)^T%X!^S6L[^(H%MKQCY4_P!EF\O8"!YQ;9A8<L`)20A/
M`8XH`\QU#X*^+;V]U=WFUXQW4>OB'R_$4T:DK)&=&P%D`7:/-/'0D[\\4NE?
M#SXC#6=?U'7)]>?7+NPOX[>YM[R,6<ZR6@^S1,#-^[,<W`VQ+\ZEBQ5J]<N?
MC1X/M+749Y-:3[/I-V+*XF6UF=&N"6`BB8(1,^Y&7$98[AMZ\5':_'+P3?2Z
M1':>(+25M=C1[(K'(5P[LB>8VW$):160"0J2RE0,C%`'DNI_`6_A;PK=3:9K
M^M_V1X@MM3N83XAD,L;OIS17,D;/*!_Q\^6Y7.#\Y488@[_A?X::_>?!;QYX
M5\2:;?--J=O<Q:?-?ZD3=ZH\EJN99RDSI$YF+*0C*I"[MJAL5TU[^TIX%M+S
M2K>/4KR[_MC4O[/MIK72KF2(R^6S[]XCP8R$;$BY4X/.`Q'6Z!\1-!\3>'[O
M6]#O7N],LR^^X6TF`D"KN+1@J#*I!R&0,&[$T`>(S?!GQ1I>BW\6A6^J?\2[
M2-%M=*LX_$$L9:-6SJD,;&3"R21@('8\9&UEY-9VI_"7X@WNCWD.EIKVG6=O
M%K<WAVP?Q&QFL)2+4:<LD@D.[#QW,@5F=4#@,>U>PW7Q[\$67AFWU^[UU(M,
MNIIX8V>SG$ID@)$R&'9Y@9,,6!48`)/`)JS-\8?#S>*],\.Z9J%M>ZIJ$\:&
M)-X"(\+3`A]NQFV!6V9W;6#8Q0!Y]XD^#^LZI\-/BSX16"]N]/UL>9X:@NM6
MDD=I&LXC(#*SET!NED.&.WD\;346E_!B_P#^$Z?Q)8V&KZ$UK;Z)%I,3:T[^
M3'"LZW,<Z"1EEPLBY+[BW&#Q7H_B'XU^#_"^M7FDZOK$<>HV49:2!+:63YQ'
MYGE!E4J9BGS"('>1R!7*:?\`M2^#[[4/#9EFNK/2/%6CC4-/OKJQGB;<;A(?
M+DCV909D7YVPGN<@T`-_9[\%>)_"7VU_&[:Z+V[L;<7XO+M+BWN+U&D$MQ$?
M.D?,@*$\(NT(`H(:O9ZX6?XU^#;:[U:VN=>LX9=$5VO6D218TV2+')M<KMDV
M.RHVPMM9@&P:ZK0M9M_$.E6VHZ<TC6MY$)83+`\+%3TRC@,I]B`?:@#0HHHH
M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`
MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`X_XC>`6
M\<V^ER6&J7FA:QH5\M]I>IVL:2-!+L:-@T;_`"NC1R.I4_WLCD"N0U[X"77B
M5[MM7\8:O(VN:9;Z;X@*65NG]HPPS-(@4!?W)Q+*A*Y^5O4`UN?&KX@ZG\.?
M#UKJ6CQZ:(?M7_$QO+\EX[&U6-WDF\I65Y<;,80DC.[!`(KRY/CSXKTG1/&,
MVLZSX,GU.U\2W&G^'[6/3K@[XHK<W!651(#DQ*6#$J.&)SP*`.]E^`5A-;ZE
M"=4U!5U+3M=L7PJ?(NJW`GE8<=4*X7U'6N9LOV;]1OY=;76O$^J:=:-JM_=Z
M-'I?EI);O<6RVZW+2;=V\)YGR=,MG/3'/VO[0_C&(^)-4OAX9DT\6.@2Z5IZ
MQ2++9-J*19EG??\`/"AD;)`&2%`*\UI:O^T%XTTA+6.?0_#L=W:VD4^I)+<O
MB;S-2-A&8MC-Y8)9)2'+%1E#D\@`Z_P_^SY8Z%<0SG4[N>9)=5EDQ!'&CM?Q
MQ))A><!1"NT9/4YS5OPI\(GT/XOZQXKGFS8-H]M8Z=;;@<3[56YN2`!M9T@M
M4ZGB(GC-<#/^T3XQCUE]!MM$T.YUK1YKP:FPD>.WOA;SQQE+9G<>6VR5&9I"
MP4D#!!!JUXR^,WCR*S\=3^&(/"]K9:#'K-K8W%RLTLZW5E"LPD=`0K(R%AM'
M1E!)()``/1?!_P`)X_#4OBC[3J<]U9^)EVOI\%NEI;6V3)O>.-.!(_F_._&[
M:I(SDGF%_9_U&*PTR"V\<ZS%/I.B3Z#;W']GVS'^SY%C4HR[<&0&&-A)ZCD8
M)%+\//BUKVL^-+/0/%UQX8`NM(%S9S:8))/[3D6.)YI(V#L(D3S54QN-QX8$
M@X&)J/Q_U[[7/_9TO@NU@OO$TOAS3H;^>7S[&>*5T:XNP&`\MM@VJNTYFA&X
M[^`#;O?V:]/?37L]'U[7=("7!GM9[61/.MC_`&8FG*%?&>(T#YZEB1TJN?V;
M!!9PKH_BC4M-OEGU266ZAL8&#+?I&DR*C9"X$2%3DD'.<UBZ3^T)XL\12V::
M)IWA9ULX3<:M,;F9X[F%-3DL7:T8=F$?FJ6R/X><[ADW?[0WB[PM\/=9U#7=
M4\%W_B2UUK6H[*R@L+@+):Z?)+YB/B3Y'VJF&8_=8':QS0!VEK^S7I]@(=/L
M]?U9/#UI>O?VVDF*)O*NFLS:[_.(WLH1F?8?XCUP`*N7/P"@NM6\+3/X@U9K
M3PK;Z7';V+JC1L]@Y9)%_N-)\H?`Y"+@C'/*ZE\:?%4?B;6M+\'66CRW[W5W
M-$=7NIGACBMM-L+EHU"8VEC=%>.`?F(.2#<NOB]XEDUR_P!-\'VVDOJ>H^(6
ML;1M7N)I((`FCPWI^5,$`Y9-HP,G=Z@@&HO[/$]I8P6^C^+]7LGMK34M.BF^
MQ02$6-[(LKQ$,,%U=05DZ]B#5RZ^`.GP^%M3T/2-2FM(-1OH+N*:XM([E[(P
MV45I&8B<%9`L*.)`0P;/8XK$\-?&SQ7XI^)^E:%:6/A^WTHB'^U58RO<1!]/
M6Z\R*3<J$>9(L6S:6Q\QX/',^)_B'\1KOQS=Z1INM>%(Y;#XC6VEZ7;>3/&1
M;2:7)/MN@'S(AW*>`N70\@`8`/8O^$#U+6/!'B#POXKU:2[L]5M9-/M;F-1]
MHBM6MUAW2.?]9,Q#R%L8R^.0.<[3/@O!"VHR:]JEWJT^K26DEZ[01PB0V]L;
M<`!?N[D/..AZ5R6A_'3Q7K7B_1])71-(CC6WTPZROGD,6NPVZ6W=F4>5&RD8
M*LSD,HP1S)\3/VBKGX:>/1H&HZ9#):QFVU"XN@[;HM'96CN+K&/O17'E(0,C
M;("?8`Z[X>_!VT\!Z+=:7+/!JMK<:?#I[,^GQP2R6\2NBK+(G,GRN1V`Y(`+
M&L.U^!.IV>D:-I[^.]<GM_"EY!<^'/-L+9FLA$K1JDIVYG'DNT>6(.#G[V#7
M.:%^T+XFO=;TN'6;#PS9QS:SIVCWNE"XE&H"6\@CG6>('@QHDN""N6\J4Y7&
M*SK_`./_`(KU+PY`Y_X0W2#KFE:IJ-H][=S0`6UHZPM"LF<&X9G+@@855QAN
MM`'8V?[.6FV]I)Y^N:K<3W45O]KN)(XP9I8]4?4GEV@`+OF=EVC@+C'/-9FO
M_L]7NL>+=1?3=>N=/T/Q#8ZM%J\D<43SR"^GMWD@C#*0J;(F&_[PXX/;H_AY
M\2-3USQSJ?AG7!IEJEG8K-ID"%I;B[A3RU>Y>56*`%WV^60KJ>N[K6%\6/'N
MH_`CPJ\MCJ]IJVM3Q3WEO;:M;S2>?!:6R&=4*.`A^ZVYB>9/NM0!//\`LSV=
M[<:[)J'B+6;H:Q8W-C&941WMX9KF.?;O/+A#$D:9P`@Q@]:O_$+X,'QGK7A^
M:VE,5O;^)#J6KN2%,UIY:E[3&/F22:"V)Y'W,\]*Q-<^+OC>ZNO$W_"+V_AF
MWT[2'N;"&6[$TMPMVNEB^CE*J0K1\^65ZY&[/:N:M/CQXELI_"D%Y>>&KK6?
M%7A[2F&HF:5-+M[BYENOG>(.2/E@"<,"SLJY`Q0![!XH^&S>*/&6B:_%JDFG
M2:+)&S+:6J+-<*K,QA>?[_DN2-T?(.W/!)-4/$GP9CUR_P!8O[75[VPOM4UC
M3=5CE2&.1;6:R1%C`5N&5@G(/KQ7G\WQNU_39[VUL;KPFEY=>(I;!=1U*^E?
M381%I,%XSH000C$N%4'^(-SR#0G_`&G?$&OKIZ^$(]!ADU;P]//)#=6L[R:7
MJ":;]N"NVY1*FTI\JJ#AP=W44`>@77P$2]BO(KCQ#JSQZMX;N-"U/=!#NN8Y
M))I%E!``1U:XDZ#!X!'%:.D_"`VNKZ3JFM:]?ZMJ&EWTUWO>VBA63S+(6FS:
M@`50@W#'.3R:\^^'GQZ\9>(=;\/Z7>6GAW5%^RZ6VL75F3#YXO8RPG@+2%0D
M>-I7#%W5U7;@"O:CI;ZKK]KK-AK$K6480?9H7#0R[%G4G(..3*I/O"OX`''>
M`_@E8>!=)O-*^T1W^GW6E?V6JM8QPSK:@R%8WG7YG`63:.G3=U)-8\7[-&F7
MG@I_"VN:F]]HUTEG%=B"PBM9[N"U#^5'+*OS-AF1LC&"G`&YLS_')-;\&^#]
M6U_0]?:"YEU334MUNY6CM[8/J%NK;V!R(]I96Q_"S5QUG^TEXKO[^VTS2='\
M/ZA>V#7)U">&9DM=32&]-LWV.1Y`$P`'9G+A2P7!R#0!O+^S]?Z]XKUN3QCK
ML]WX?N;S3KDVD$44;ZE+;62P%YF"YC^<%MJ<'`Z#(J]I'[.K:#_8D^D>(WM=
M5\.F-;#48M(MQ(\2P20%)^TN8Y3@\;2,@#)SP%U\<==\&^)-:@C+ZG)+K6J6
MMH]Y<.T%F#JEM;QF1`1F-!,>X/(4$`UU=S\?/$^CMH&GZYH6F1:UXJ46VCQQ
M2LZ7%Y'>&*Y4A6.U1;[+@+NW`!U8_*30!T6K?`VYU%]7,/BS5[:'5]8@U6:#
M[/$RM.ELMO(KXQOC=41]AX#J"..*I0_LXV4%C;:=;Z[J8TN+3-&L)[=H(F,W
M]F3>9!)OQE2V65@..<C!J;X+_&#6_B)YMWXDL-*TW3+VT@NM-DBG"NK2R2(;
M65&<LTJE!EP%4DE0,J:[G3?"-[8Z!J&GRZY?7$]XBK'=OG?`1$B$CGN5+?5C
M0!Y[8_LW6\5OIT&H>)=7U"#0[6SL=(62"%#:6MM>172HQ4?O&8P0QESCY4X&
M22>@U#X/+<^*M*UNVU:>P?3+Z2[<6]K&LUP))Y9G@:8?-Y#-+@Q\@[<\$DUS
MWC;XF>)/`/B_3?"OAVRM=89+'^U+N?47\MKJ&2[:,Q0N754:,$$LVX`%!CYJ
MY>Z^.7C:_P#$.BV%M>^"M%ED\6II^IV-U!+.8;*6"YD@_?K+Y;M)]G8ADQR5
M!4<@@'H>M_!:/Q#\1+?Q3?:YJC):W$=S;Z>RJT<#K;2VY$;'E4996<J!R_.>
MU5V^!$,&D>&+;2-<U&POO"%MI\.F7ZP12'_1(YH@71AM;?'<RJ1QC((QBN!M
M_C]XGM"UMHMAH]Q#9W9^TOJ5W,\D@N-=NM-B5&'W0IB5SG/RC8!T(LWG[26M
M65QIFF2+X=?7K37O[+UZS2WN"CQ-J*V27$#[L("Q8[7WG*D<#YJ`.Y\7_"S5
M[SP3X8T/PYJK&[T3Q!::@^I7,4>_;',TCOL`V%OF^[@`^U83?LR00K;26?BK
M7(;I($CNY6CC9+YOM-W<2M+&,`J\M[(VP?*"D>.G/)Z?\?/']GX>L(;P>$M:
MU_4]9UR")[>"2*&&/3YF46\BF7B:0`E22`$4LP;!S[C<VD_C2STRZM-2ETJ:
M"-6N[:VG678[".0QLRG!(`QGN'ST-`'-^%?@II_A.WCBL]0O9DCL-'LD,L:'
MY=-W^4QXQE]YW=N.*9I7P3ETKP1XC\.V_B75+5=?D5X9K")+1-+`C1-EM$AV
MQJQ0LRC`)D;IFNF\2Z?=:9=77B6*YOIH=*LFF.DVXR+DQ1SG:!G[S&1.W6-?
MP\3E_::\6Z9X,M]>U'0]`NX]0EMS9):W3(9(KBWDD!V[F;;`R!II"`#'O90"
MA!`.^T+]GVPT5$_XF=Y+(L6M(Y$$:(QU-XWE(7L$,0VC)X/.:U/#/PA;PSXH
M_M&UU_4)=,&J7.J1:5);PE([BXC9)CYN-Y4LS.%SP6(Y&,><^)?VEM=\+ZYJ
M2-8^'=5L-+N[JP:QL;B0W]Q+#IGV[[2B\KY!XCZ$_,&W=JGT[X\>+[RXTO2K
MV+P7IE]JCSW%OJ][<.EC/:Q003%502%UD(G(!9L%8FD"D8%`'0WOP3O]<^)/
MB+6];UB6VT*[UNRU2ST^UC0F>6WL8X%:5R-RA9`QVC@[5YY(,=_^SO;W&CV6
ME6/B75["S_X12V\,:FJ01.U_8P,2O+#]U)AY5++VD/&54B;X6^+?$GC?1?&5
MEXXUOP\EW%K^H:1ISZ3&T,MNJ/(J;@SDLVT;EQ@D*2<]:]`B\-72Z')8_P!J
M71EDNS.+LYWJIG\WR^O3;^[^GY4`>6Z_\!=5^W+=>%->^S23>(K'4#;K9QP6
MUDL,LTCS+",K).WFA68X+A%SSS5K2?V9=-T6\AN8-4EO7FCB_M7^T+"&X^VS
M)=27!G7H(G+S2@;00N5(&5!K/U?X@^)?"?CE_!WAE[#4-4F;2]/MKS69YFA$
MDEI>S-*T:'.3]EP0I^8MR>*PY/C]XUTFZ\2ZAJ__``BLMC9Z%H=W9:7"DHEM
MIKYO+>620L-\$;;BQ"CY57!7F@#O[+X)7UAH'AK2X_%NIR)X.NHI-%DEL;=C
M##'!+;B*08`DS%,5+'!^53CKE^F?!:32?`_B'PW!XEU6U77I%>":PA2U32P$
MC79;1(=L:,8RS*,`F1^F:Y7_`(77X]>:SL4T;PQ#J%M97.H:FUQ<2;)[:"]2
MW)A5&8QLZN'`=F*D;6SGC0\(?%B_\8_$&!K^[\/V>BP2:S$EG#?,+RW%I.("
MUW&WRX.TN",!0P'.<T`:_A[X&Z=H*:65U*ZG?3-0U6^SY"(DLFH*XE7;V5=Y
MVC/89)JUX=^#@\/^(4O;+Q!J7]F-J,>IOI4EM"5:[6U%L7\PKO"E%5M@/#`\
MX.*ZS2_#]S;:G=WLFIW%W#=;MEM)G9%E]WR\]AQ]*X;Q?JWB#X76&B6.A7=I
MK&I^(M2%G'<:R9/*MQ%I[R,Y5#N;=]E<X!',IYXY`+.H_`^.^\4W&H-KVIKI
M%UKJZ[+I"11;3>K;B$,)<;PF%5]G]Y>N"13-!^!L>CZ?IUO>:W?:@VE^&O\`
MA'H)'MHD)MEEC>-B%X+J(U7/?D]:X5?VDM?_`+'4ZC'X:TW5M=T;3-8\.Q^3
M<7431W:3N;>;#(3*JVTK;P53!]1SM>$_V@M5\0ZUX6TB]TW3+.]\36%GK2'S
M6*1:2]EYMQ,2>C1W`,(SQAT)ZXH`OO\`LX::\.K6<>HLECJ%Q<3Q#^SXFN+7
MSKN.Z=%G/S%/,C/&.0PR3M%>R*H!)YR:P]-T2>/7[C5SJDUQ:WB,8[0',2!D
MA`*G/./*8CC_`):M^.]0`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%
M%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`444
M4`%%%%`!1110`4444`<_XPN?#]M9Q2>,K>RGMDD9HOM5J)E5UC=R0"#@A$<Y
M]J=JFB^'C:WE]J^DZ9)#M^T7<LUDC[O+4X=L@Y*KG'<#I6K?6%K?Q;-0MH;F
M-<D++&''*E3P?568?0D=Z^;-9\"^)/%_QB\3WFCZ?=1)IVN%!J]QJCQ1FQ;1
MT5K..#HRO/(K%L;05))RH%`'OUE9^'O$6G6^IV=AIM]9ZI81B*X^RJPGM7`9
M%Y&2A!!"GCVJ232=#T>PD?\`LS3[:TMXF=PEHBJJ*3(>`.@8%OKSUKYLTOX,
M_$2*X$QLM.TR\LO!=YH<5U8ZEM%VQT^WCM2YW$[TG27)VJJX4KG)KUGP%X7'
MPTNFT*TT:\N=.\17?G3.+EKB&T(LXQ/)(9&.!)*N-HSN9RV,;C0!T]S<>$-8
MTO\`M*^LM,N[..\V"6>Q5\3NZQY`*YW%B@)^F>E;-@-,U.PCN[*VMY+:_C^T
M*X@`$HD498\=6!&<]>]64TNR6U^SQVELMN7$AB$2[=X(8-C&,Y`.?45\\:[X
M'USQ!\=]1ET'3+F*WT'5-&DM=4;4'MX+&T6W)N8(H1Q)YJ@1D`8YY(VB@#WO
M3O#6BZ3.9M(T?3K&;9L\RVLTB;;Q\N5`..!Q["J&N0^%].DGEU[3M-#ZE$[W
M#R6*R&X2%0[;\*2VT*"`<]!CI7@'_"@O$]OI_A1;A=1FE@T?=J;6&KH+BVUD
M21DWBR3-AF9%V;AG:$P%PU:=_P#"/Q;=ZGXMN6T__B;:C;Z[%;:X->8"[2YC
M86,?D?\`+,Q!ECW<;=I(SO.`#WQ+71[&SBE6UL+6V$4<,3&)(T6,L-B#.`!N
M(POJ1QFLO6XO"5C>0PZWINE?:-1G\Y!+8(YEEWQQ;R=I^;=+&N3S\WIFO`_$
M'P#UCQ-X1\1:?XH\+6VN:[/J<-W%JLVNG;J-O%>PS16X0D",K`)(OF`4%<@G
M>2/?_"7DZWI:F_\`#TNE#2YWM+2&]5';RXF7#H1G"%D7!ZG8K>AH`F-]X>3Q
M#_9OD6?]JR(24%L-Q#)SEL=TC`//10/2M,:;8+()!8VXDW[PP@&[=M";LXSG
M;\N?08Z5E^-;"(>&M<N[6W3^T%TRX$4\<690WE,!M(YSS@8KYR^'OP:\2:UH
M^ARZGI=QIGA_5+C1;O5]-N=<EEDO=EE<B[N)!G*F62:W!CSEO)RP[4`>V:G\
M-/"FE^('\7:E'<1M:7:Z@%,C-#!<"#[.)DC`R&\KY<#CG.,UV/\`8VF_;3>'
M3K,WK%<W)MU\PE00OSXR<`D#GC)KY6\4?#;QGX9T35[VXM+FUNY+'4+2_O[/
M6)+A_$-Q<7D0L-D*G*>7&",L%V;MHXR:WD^#?C:WL?%ABDOYM<U43K/<_P!K
M)#;:S%]O2958J3)'(UL'A4X41AF'(((`/H231]"NM3B>73]+FU#3T1HF:WC:
M6W4DE"O&Y!D,1TY!Q55-3\.^(KB_MGBM+V6SA>*[2:V#;8O,=&0[ARN^)N.G
MRY]*\9\)?#4?"_Q_KGC'1_AU)%%?Z):VEG;V.JBYN(95N)5:(AF(PZR0MD$J
M@1AD8R?H"'3;2WDEDM[6WBDGSYK)&`9,DL<GORS'ZD^M`&%I5]X7\07T.I:=
M%IL]^J;(+AK=1/M"*Q"$C=@)*N<<#?[UIW&@Z3=Q0076EV$T5JQD@CDM498F
M/5E!'RGD\CUKR_XD_"HWWQ.\#^*O#7AS2[Z?P[:W\&7N!;?9I95B^SRX!&Y5
M,3`@?-AA@'''!^$?@AXKFB6V\46%M8Z7J?BBQU+5-+MM2(B\D:?+'=*H1SE&
MN60[=V6`!;G(H`^CK31]-TZ[FN]/TZSMKJZ_UT\-LJ/+_O,!D_C4>I6.CZO.
MEOJ]KI][/;@3)#<Q)*\8.5#A6R1G!&?;%?(/A/P#K'B6Y\0_V1:ZHVN7T,9U
M`M</&EQ:Q:J[2VMP\C#;<20[5!`"LD0!P#D]_P"%OA3<_#3QJOC,^%=2UEK/
MPU+9P%K^*6^AE2ZN)(H%16VE&BECC0`G8J@,>":`/=])U/0]6OKRUTQ+=[FU
M<O<H(-I#!GA))QR<Q.F?1?2J6A1>$O$6F3Q:)IVE7%B@2*6%;!0F"!*JE2N"
M/G#@8ZG/6MZQL;:`&>&TAMI[A09BB*&))+$$CK\S,?J2>]>.?'WPO)J%YX+T
MO1/#<FM6-[?7@O\`2[2Z-C%<!;&3R_-D4@!0Z1D9/5%QR`*`/1-<^'GAO7KK
M2[C5-(LY5T>>2>"%H5\K>\)A)=,;6Q&<#/3`]*U;73-&N+A-4LK'3I9YXALO
M8H$9I(]N!B0#)7;P.<8KYPTOX&^-9;W2K?Q=%'JU\EQIZ7?B0Z[)M&FQV:1W
M=BT.0S^9*DG;#>=O)!7%5-!^`'B32-`\%Z8NEW>FV7A_14MOLNDZO"'L]2CG
M5GO8V=MI\U.,X+($(V_-0!](3^&_#>GPQW,FDZ/9K8+B&<VL47V<;B1M?`V?
M,Q/!')]:E\+VVD:)8_V%X;@CM;?10D)M8D($(8;@,GJ2#DG)Y)SS7S[XM_9S
MU#Q)X.\41WUA%J&N:_'JHF2XU60QW(_M%)]/4@MM7;`K*"`-N[!ZU#\1_A!X
MW\0VNOZ?X=T2QCT?5XH7TZ"751YVD3PZ='#`8SO"J%F\S<PW'A2H.2:`/H&[
M\2>'M5L=<BOI+6\M-$F-OJL4L/F)#($20HZD<_)(C=_O"J-_+X,@T"QO+^PT
MDZ7;220V>^P5D@92V\(NWY>8FZ#^'Z5SW@/2-2T'Q;XGTW7-'DN[/Q3J4NI?
M;05D@BB2SLH`DN?XWD27"C/$9)ZBO1I-)LIK86\MG:O;JQ81-$I4,<Y.,8R=
MS?F:`*ATC1[^W=GTVPGAO(R7WVJ$2JY#'=D<@D`G/4@5SFI^,/`GA&2*SU&3
M2]-;36GEAB^Q[!;LGE"5TPN!C[5'DK_ST^M>5_$GX6_$B\\?ZCJ?P_U*.'2;
M9EOM,MVORA>[N(4L[F)DX"QQPH9DYQYDAP,@&LCQ+^S]XJFGO[71EAN=/1+Z
MWTYKK4-SB*2#24CSGIEK*X)'K@_Q4`>X:OHW@VVU_3X+W3=,AU-KR*]@"6@0
MR3[G$<C%1\S!C(1NSAN>O-;P\4::=:_LD7'_`!,,9\G:<XV[NO3[IS4&AW,7
MB3S[V_T66QFM+V6WMVO8E\R5(G95F7N%;EES@X.>]4?B)X-_X2KPIK5KI+1V
M.L7EFZVE_'^[DBF`S&V\<XW*N?49%`&SJ6C:7K,D+ZOIME?O;G,+7-LDIC)P
M<KN!QT'3T%0+X7T*&"2"/1-+2&683R1K91A6D'1R,8+#L>M?-EO\&?BC?:=J
M,FOW:7-Q*#JZV<6L.B27EW-";^P608*Q+##+'&^T#_23TY-:UE\,O'6@S_:=
M!T=8]/8ZY;V&AR>(.-+M[J&U2WRYW`J'MYI"J;MGG`#O0![GI]WX;U-]533K
M>PF;1[G[/J`2V&89EVS[6XZCS%D^KYZU7U2Y\)65K8:SJ=IIFRYW3VET]DK/
MDH9F<';D$JI8GKQZUXSXD^$'BJ]UW49WTV/6M&O]:N[M].AULV+EWL+.&VNB
MX[QR6\XVYR/,#@$@5[#X,1[_`$E='\0Z))'_`,(_#;VBSW2K)'=O]F3S'BSR
M5!=HRQ`R0V.*`)=4A\)1:BNEZKINDO<ZC.L_DR6".)I7W()#\N"Q"L-QYQ6I
MH6@:=X=^V#1K)+0:A<M=7/EI@RRL`"Q_X"JJ.P"@#@"H_%6C-J>D7PTP6\&L
M26DD=C>21@M!,4;RWSC/RLV?SKY\D^$/B#_A'-`MW\%>;:VD5R=:T@>*FW7^
MI-;Q"*_\W=C"R1R#DAOWHDVY&*`/IB>ZC@B>27<J1J68XZ`#)KE]'/@Z72],
MU30K+1ULO$(0V-Q;V**+D2QDJ>%_B0MU[$@]:\L\'^`O'V@:A]CU\1:M!<MI
MD]WJ[ZOG+P:6MM,HC8;F+3H6SP"&W'GBL/X;_"3Q7X,O=!NO%6C_`&V?0%LW
M&J6VM,XBLX=-6)[);4<.1.KL,#!WA@<\4`>S:%HG@_P[XLU6'3;6U77M6G:>
MZ9H=SG,,8**Q'RIY<<?R`X]JM:39^#]2-QINE:3H[K9RB:6V33D"I(KR0A\;
M<;@T,BYZ_+Z5K:%Y>K6-EJ]YI']F:C=VZ2S07"(9[=F0;HW9<@L/NG!QQ7'?
M&/P,_B?P==V&@6$SW-Q<PR2Q64L-O]I5)&D*3%R`\+,S;ER"=Y((-`&W9Z;X
M6\1:_-?V-G8W6H^']2=)I4@VM!>"$`EC@;G$4P`8YP'.#R:ZKS`.JL/PKYHT
MGX#>*(K+7];@ALM!\<:L;E8;JQU24P0))I,4"H`2?D6YCR"06&T-DFK&D_##
MQ=HEO-=>'M!.CV-OKVC7]MX=_P"$A\XL(%;[8XD8E%,C2+\N?F\K<<%L4`>[
M"^T*[\3S:;MM)-<MK:&]DC,(\U8G:2..3=CIE95'.1SZU3NKGPO)IR:I=VFG
MO;7"?8!,]FK;D+E/*/&=FX$8Z5XEXC^$OC/5==T[5+[2[:_L&T^Q@UK1H]:\
MIKU4N;^1X1+A<JAN;>3G:&\LCVKU+X8V-WI^BVGA?Q#H=P@TBQBF>ZGG^UP-
M*\LI$*RL-TCHJHQ?'\8[YH`USJ/A/0;/3VCMM.L[?4XLV@BLP@D1V0D8"\`M
M(A(/<U<UCP5H.N07\&I:/8RQ:HNV_P`6X5KI>,K(P`+`X`()Y'!XK5ETFQFC
MA6:SM72V4"%6A4B(#&`HQQ]U>GH/2OG*V^$?B==`M[;6/#BZA=_VTL_BIU\1
M$?\`"40`W"AAD@)M\R&78VP';Y?110!]**5C&U%V@=@.!6;/J6DW=S8QSFWN
M9KB246G[L2_.@8288`@$#<#R.X]J\#\-_`WQ)-)I=SXS\V1]'L;)],C77)9?
ML$ZZG<3/%NR/,VVDD,)<YW!2HXK(MO@)XGT#P2^B>!=+M]!N;:\\1R>;;ZMM
M6Z-VDHLI1SE2`\:X."I3/N0#Z3N/#VC7D"Q7FDZ=-$J(@CEM$8*J9V+@CHN3
M@=!DXK)U+X<:#K>I7-]J%@DSW6CMHS(7*HMFS%GB11]T,<!L=0BCL*\PO?A=
MKO@[4=.?X<Z;]JTVSU._G&GR:TT85;G3XXMVZ0M\HN%D8KR1N+`'-4-/^'_B
MCPMX\NO%FM6NM:J=.1);1]+OHF,MLNG",V+1L=Y7SU+`*N&9E<D8(H`]ST[7
M-*.I/H>GR1I<Z?'M-LB%1$J+$<#C&`LT73^]6O5&PM(7$=^]C':7US$&FRJF
M1257*LPZD;%!Y_@'H*O4`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1
M110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%
M%`!1110`4444`%%%%`'/^./&=MX"\/7.L:C9:E?6UJ`9(]/@$LH7NVTD#``R
M>:Y:'X_>%;C6].TZV&K2KJ,-O+]N73W^RVRW%N;B#SI.B;XU8C/0C!QD9VOB
M+\,=)^)MI86^OS7T(TVX>>!K255.YHGB8,&5E8%)&ZC(."""`:I:5\&/#>D1
MRQ6J7C0SPV,,D4EP65DM(#!$OKCRR0WJ>>*`(O`GQ4L_B!KEZND6E_;6%OIU
MO=P27]B]L]RDS2;)4W<-$RH&4CGDY`K%;]H#0+G3-/UJU^UV^@W=U>(+NZLG
M`N8K:VEG>6#:3E=L+<M@\$8!Q73>!/A=IWP]A,>E:GKEXBV4%C`-1O?/^S6T
M);RHX^!@+O(R<DX&2<5S\O[.7A>\74/[3N];O9M3EEEN9I;I$9FDLI+-N$15
M!\J5SG&2QW$G%`#8/VA_#E^_V6&TUZSG+2PB34-*DAABN%MS<1Q2-V:2$>8J
MC)*D="<50TO]H6UM?"NO>(_$6GW<VE:-<VJ"72K=I6\B;3[>\:9T<@JJ^<P]
M<`<$YKIKOX)^&[[SA,VH?O\`5(]3?;<_\MTLOL2]ON^3V_O<U@ZG^S!X-U/3
M5L99M9C@5&C;9=J2Z-8Q63*0R$<PP1_,`&#9((R:`.OTCXFZ/KFN:OINGQW[
M+H4(DO[][4I:PDQI*$,AZOY<B/@#@'FN3M_VH/`TNGRW]S/J5E9Q/%F>YLF5
M3'-'(]O-QG"3>4ZIG!9\+@%AGN-"\":3X>&N+:+++'XAF66^2>3>K%;>.WP!
MV'EQ("/7)[UQT?[.OA=O#MOH-_<ZQJ&B6GE^1I\T\:QKY22+%DI&K.4\P,I8
ML0T<;=5H`L3?'[PS;Z\FDWEMK=O,6$4EQ-IKK!!<FU^U"V=^BS&'+;?8C.<5
M5@_:3\)2S:4CPZY;KJP@DCEN-/,:PPW$OE6T\F3E8YGX0X)/4@#FJVG_`+/M
MG<^)=8U3Q1K&K:E!=:D+RRLOM6V-)!I\=D9Y0%&^?:)3NSM^<';D5N)\$]`M
M-2TF^TZZU*QN-)TNTTQ6B>)OM%M;-NA$F^-CN'S#<NTX=AGD8`*1_:&\,O:B
M>TM-=O$GUEM(T_R+'=_:-RN_S!!EAN">5)G.T_+P#D9JWG[0N@:'=ZQ%J\6H
MW3Z1>7:WO]F:=+/]@M8"%:XN.ZH"2,C.<'`.TXFU3]GG0=9BU];_`%?Q$_\`
MPDVQ=287$`\U$60*@Q%A2/.;YP!)POS_`"BFZE^S?X5U&XU26*[U^Q;7(YX-
M56SU$H+VWF=6>!\@G9E2!MPP$CC=\U`$UW^T3X1L-0U>WN_[6BMM%M[J6ZU%
MM.?[(3;!#-&LO1G"R(<=PW7@X[KPUX@C\2Z);:G'9WVGQW4?F""^B$<J#_:`
M)`]1@D$'-<]!\)]&L+:]BTRYU&Q-Y=W5V9(9E+127"*LFT.K+C:HP""!SUH\
M`?#A/`3RV>EZK?3:((&6'3KC8P6:2>6::8L`.6,@4*H555``*`,F/X^Z#<:;
M'>V.D^*+N*]N1!I"0Z0Y?6,H[^9:@D;XPD;L6.W``/<9+7]H7PIJ&HZ1:Z8N
MM7JZNMLPN8-,D,-F+AWCA^T,0/+W2121X(X93G`YI+;X":)8Z?I-G8:UXHME
M\/7'FZ)(FI`OIB[9$,464(,9CE9"'#':%&?E%:'AGX*^&_"47EZ)_:"`VUC`
MQDNS(SBTFDFC<D\ES)*[,?XL]J`.>7]I+1]0N?#":%X>\5ZG9>++^>TL=1@L
M%\G$41D,V2^3&0I[9`5B0,8JKX;_`&EM)U&?[/J.C:[%!%I6E7S:O'8G[',=
M0D$4*H2=XRY`^8=F_N\[=E\`=!T_4(]0BU3Q!_:::H-2-Y]JC5WD%L;=E*K&
M$VM$2&^7))SG/-1/^SMX9^P)8VE_K]I;+I%AIFR"^`REE*9;67E3^]1R3GH<
MX(-`$VK_`!YTC1/&Z^'[[2M=%JFFWU_=ZT+8?8[2.TDV3>8V[.`>X!ZK_>JG
MJ/[0&DW7PR\8>*?#>F:O>W'A&T>>XTN6U\JX),7FQDKGA&0A\YR%R2,C%:<G
MP-\/SO;M>WFMW92RU"RN_M%Z'_M"WO7$DZ3Y7Y@7`(V[<8P..*N:?\(M*M/!
M>K>%Y[_5;[3-9LC93F>2)9%B,7E':T<:_,5Y+'))YS0!SWA#XZV-P-&T_P`4
MV^K0ZO>-;V=Y=+HTD%G;7\ZJ\5JY+.8Y"KH0"2/F7+`D"GS_`+3/@JTTB]U7
M46U>STVUM9;J*YN-/=$O8HI8X9&@[R;9943`&23QD<UJO\$?#[^)1JYNM8"_
MVE;:G+IPO<6DU[;Q"**=DQG<%6,X#!28T)4D5%=?`3PA?:3X7TS4(+JYM?"%
MW+=:>DER<L9=^])<8\R,EPVP\91#_"*`%U3XZ^&]*F@\R#5Y[.;6AHYOX+/=
M;QW!:)!N;.=A>9$W`'D-V&:J:A^T'X=MA<QVMAXBO)([FYMH?LVE/)]H:V)6
MY>,#EHX6&'8="0!N)Q52#]F3P=;PZ'%%-K'EZ%!%#"INU;SA%=_:T9R4^]YW
M)9-I8?*<C`K8O?@?H-Q#IZV=]KFF7.FWFHW,%W8WWE3#[?(TEU$3@@HS,#C&
M5V+@@C-`%?Q#\45T#PIX8UECI[OJFH:9#?HTF!:PW6W?)C.5P"6&?2J\'[1W
MA:X@?99>)%OI!`]AIKZ0ZW.I1S^9Y,MNA^^CB*4Y)&`A+`5T>M_";PYXAT&Q
MT?4[5I+2QDM7W*VV2?[.,1B5P,N,<'GGVKF;3]F_PY:-9S#5?$\NHZ8MG'I>
MHRZD&GL(K7S!%'$=NTKMFE5MZL6#G)/&`"'1OC_I'B'Q_9Z'IL<TMOJFDQ7-
ME$+=UO#<"[N+>Y22(XV)"8/G8\*<\G*YF\/_`+0N@ZB=&M)8=3N;K4_)$MQ8
MZ;*UK:>=))'`97/*!VB=1GNIS@8-6M'_`&=_">AZQI&KV+:M_:^BQ!+:_>]+
M3$F>:>5G./F,KW$WF`C#!A@#:I%W0/@OX?\`"-O+'HCWZ&:*TBS+<;\"VFEF
MB[#^.9\^HP.,4`1^"OCGX=\=3:R-*MM8M;?1+&+4)KN^L3#%-:RB0QS1')+*
MPA<]`<#IVK,TC]H;3=>\1^$M,TCPSXKFM_&-M<W-EJ+62+`D4)C'F,=Y.QA*
MIR.@(R,G`@^#/P@U3X=6=]9:CJUN;2XTVWM4AL5Y$T?F;[KS&0,'8.HV'<`4
MSDY-7;/]GKPW8S13Q:AKPN4N+V6:9;Q(S<"[BBCGC940*J,L$1P@4@KG.2<@
M%"Y_:8T9-0LK*R\-^+[NZN/$`T2ZA33U#V<IMS<+(XWX*-&,C!)P&R!MQ5W3
M_P!I+P=JFG:E>VK:HT.G+;2*OV)B]Y#<S&&WE@49+H\H*#H<]L8--T;]G+PQ
MH-A!;Z9>ZY%+;ZE:ZA%=K<QB42V]L;6,<(%*F$LC`KEMQ).>:NZ3\!_#VCZ(
M-&MKK57TJ.:TEMK5I(@+?[-<BXB566,,0&"K\[-\J@>]`%&/]I3P?]FFN+V/
M6]/CCMY)8S>:8\7VB2*=;>:WBS]^:.9TC91T+#!(R0MW^TAX4M-$L]1%KK]R
M;LW@:RM=-::YMOL;*MUYJ*2%$6]2Q!/!XSTJQK7[/?A+7=,@L;\:B8K1M1DM
MW6Y`>*2]NDNI)`2/O+-&C)QA<8P:U8_A)HYDLYKN[U&[FL;34+2&5WCCQ%>>
M7YPVQHJ\>4FTXXYZYH`YJW_:3T5];U32[OP_XJM[JRUX:-9*;!6_M.;R5F+0
M?-R!&V\@X.W!`.<5TWC/XQ^&/`%X]MXHNI;29([.3'D,VY;FY-O&1CKB0?,!
M]T$$\&LC7?@'H6OQZ[;W&K>((+#Q'.MQJ%C#=1>4\@@2$NNZ,LC%(TY5@05R
M".:U/'7P8\+_`!$OM*O/%$%Q++HUK=6MN([@HICN(O+<2+T?``9=V=K`,.:`
M.2\7_M):5X5NH9++2-:UVVFE>W$.GV1:=I$U".R:1=Q"F(2.0.['&.#FEM/C
M["=>\6Z3JNDZG8S:'<7265ZVGR-:2"&QBNS'+(.DH5WRH[)P<\5LWG[/WA>Z
MTC2[#S]6@&CZ7%IUI<Q7865%CN8KE92VW!E\Z!&+$8/.1S6R_P`)M%DMM7@G
MEU"0:Y=375X[3C<\LMF+1R.,#,0Z8^]S[4`9?A3XUZ)XCUZRT2UM]5EO;I`K
M7BZ=(MDMP+=+AH/-/1_*=7`/8]<\5S.O_M&FRGU,:?X3\29T+Q?:^'[D366?
MMOF@$M:A6RS?,I`.."I/!X[[PS\+M%\([?[(:\4+?B]`EGW9E%HEJ.W3RD7C
MUR:JO\'M$DUJ]U%[K52;W7;;7&M3<CR8[V!%174;<@,J)N7.#CC'-`&3'^T7
MX1:ZT2W_`.)K&^M16TA,EBR"P-Q(T4"7(/,;O*K(%P3D<X'-7_%7QO\`#_A#
MQ*="U&VUNYU!?(5A9:<\Z+).&^SQEAQOD*.JCU4YP.:=_P`*9T1/$46MV%YJ
M5G?+%'%.87B87*QSO,F_?&Q!#22+E2IVL1GIBYJGPJT/5_$<FMWC7GVZ6[T^
M[;9/A/,LC(8>,=/WK[AWXH`P+G]I#P9:Q:/)-+J(&JPK-*/L9#:<AG-OFY!.
M8\3JT1')W(W&`35J^^/'AW3-0\06&I6FMVMWX=>V6:%[`EKD7$[00-`%)WAY
M5*#H<XXP<TV'X#>'+/4;6_TNZU.QO+=9U,T4D3F9);M[LJWF1MP)9)-I&"!(
MPSS531?V;O".A_:?LLNKR_:)+1LRW2DH+6\:\A4$*"0)G8DL68@X+=*`$/Q^
MT.W>VNKJ#4K:TNM/>;['-ILHOEG6]2S\DQ]-WG.$V]22"..:2[_:3\,V4>DE
M]-\4/-JCQQO;+I+"6P:2[-F@N%)&S-PK)QGE2>F"=K6/@QX=UO58M0OVOS<P
MOO7;<;1D7R7W3'_/>-?^`Y'O7*>,?@CJ.K>.[77?#>J6^GB-(PLTR^;-;2"^
M>ZF9$9&1@XD*8)4KA3DX&`#K?%OQFT#P;KATO5XM5E:%(7OKJTL7G@T]9W,<
M)G=?N;V4@=>F3@<USOPW^(OBOXF^"M<UC2-'M-)OX]9N+32;36[66W00PS&)
MC(ZLY=B4<DJ%`;Y<':6._P"*?@OH7BW7KC5-0NM8@^WK:)J5G:WGEV^H+;2F
M6`2K@GY6)'RE<@X.172^%?"UCX.T<Z;H[3?9_M5S<_OGWMOGF>:3GTWR-@=A
M@4`>'Z'^TEKECIGA/5OB%X?@>Q\3:9?ZCM\-17%[)9PVS0#?(K`?*!+(6('1
M5QD\5Z=H_P`9_#.N>.9/"MA+=-?K)-#'.UN1;SSP`&:%'[N@.6X`X(R2"*+#
MX->'=-L-(M+9K\0Z'H]YI-IFYR1;W10R[CCEOW:X/;FI_#WPKTCPMXFO-9T2
MZOH#?W4MW-9YB,+2R*%D8'9Y@R1O(#XW$G'-`':8'I1BC</44;@.I'YT`+12
M4M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`444
M4`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110
M!Y)^T/876KV'@S3[*">[6\\6VR3VT5_-9K-&(+AMLDL7S*FY5)[9`KA/$VK?
M$#PUX8\0:/K6J6NI2>%/"-O>W)2PDE.I7-Q+<*(Q-N5]L2Q1C(^=^K8S7T+J
M>J0Z9<62W*RG[=<+;QE(RV'*LPW8Z+A3S]/6D?7-+:*ZE74;`I8_\?+_`&E,
M0'`/SG/R\$'G%`'@VN?&;Q/I>N>(]%U/S=./AIVAN=3@TI9%D-[<QIIDB^8R
MQA%B,AE8G"E,G'2N5TOXN_$56BUV[U0W<C>!+J^M/#W]D+''J-[!<SQF16'S
M;O+1)2BGE3@<$&OI"P\9Z5?>8))C!!%!+-)/.HCB5$F:)B7)V_>0]^F#WJ]=
M^)-$L4=KS5].@$5J;QR]VBX@`R93S]S'\72@#QJ'7M=\9?!7Q6-;\8Z79313
MHEGXBL.`L+"&0"=8&/E9+M&VQMPC8,2K9QQ]C\6O$VFZ9X=TWPO!H_AZRAM[
MMUN-0OGN[+5)K>[$+PPW5P1((2AWJ<%SN`4$*2?I+2_%&@ZU:6$^CZMIMY!J
ML1FL6M[E&^TIC)9,'Y@`><=.]+;:YI]YK<FDP3)/<Q0M+((V5UCVL%*G!^5A
MN4X/8T`>'6?QFUU-,N-9U+6;&(IXFM;+4=#?2&1M!L_[0-O(TLI.6W1@-N8`
M#.Y?EI/%/Q'\3>(+#6FT&XA32++P;J.L8;2Y-^H,LUU#%""2K1@K'&YP-YP,
M8S7L?A#QUH7C73$OM$OX7CDE:+RGD"2JZNZ%63.0<QM@=P,BMF;4]/M;26[N
M;VUBM86(EGDG54C(."&8G`.>.>_%`'RY9^/?&VCZ;?RWFI2>+M7TWQL\5GH[
MZ;]F>VMQIUS-"H*$%D=E15+9'!ZD\6H/C=XQM_#^G:AJ7B'P_<:>]]#-<3Z?
M:Q3:C+!)%&WD1VF[:2)),$;O-"8.,@BOIV.[LY&/E7,+-N$?RR@\XW!?KMYQ
MZ<USLWQ"\,Q^(K+16U2R^TW]O-/`XG3RF\J1(W0/G'F;I4&WJ<GTH`XW6/&%
MGX?_`&@TT_6]3-G%J_A**/3K661O+N+K[7+D(/N[]NWWQBO'/!WCKQ@_AW6'
MUW6C=!;/PS<:=X?DTQHA;1W$ML)G1PWFLJDNIRQY^]TP?I+6_B%H^B>,]&\*
MS2/-J^NQRSQ6\+)F*&/&Z:3<P(3<0HP"23P,`D;:ZUI$VGB\.I:>UF^5^T"Y
M0Q'G:1NSCJ<8]:`/F30/CIXLO]'U:_UWQ%;VK:JFGII$-OI%OOTZ:=YR\CAY
M,&UVPJB2R8RS$8W8%5E^(_C?5=)U[4?$6N!C>_#[2=5L_#AT@PK]IE9UN'C<
M$2?*RJ67/'F*#C`S]&^'/"'A/P:96\/V]G9,T$4+.;EI"D&YC%&"['9'N9MJ
MC"Y)P*V8M:TB5+B6+4K%TLG9+EUND(A8#)#G/RG`)P:`/FR\^/?C2$:O<V$E
MC?W(T_5;B?13H\BOX>EM;J.&!)7!S)YH9CA@"VW<GRUUWQ&E\4)^S[\1+;7-
M175=<T\W%K:WEC;O8-<(3&T?$9)1L/M+(>V1S7K<WB73/[5M-.MKF*XN[Q6=
M4AD5]JA-P+8/`*]/6JUKXVT5]5UO3[F]2TGT":WBO&NF$2*T\8DC`8G!R#^=
M`'SK!X]\:>"M'.A6<EKH-T/$6H6MPU_=&_MM)$-M%+:VR7%P5+13J6D#O@KE
MT`R!4&D^(/%6@>*O$6M:MXDL=./BCQ';Z;-KDFB_:(-&MUTN.Z1(V+`-$TKF
M)6?"Y+,?F?%?4]Q?Z?#<&TEN;;[686E6U,J^8Z+U8)G)&>]8>B^.]&U[1]#U
M33I99K/7XXGMAY>&1)8VD1I5ZH"$;D\9H`\0MOC'\0=4\)ZGKR)8V;Z-X6L]
M26S.C2$:A<7,T\8;YFWH@6%)-@^;]Y@GI72>!O'?C>/QQIFG^)[ZRU'3;C7-
M4T*41:0;5F-K$98[LL&(!;:R;`-IW`@Y!S[%)X@T>&UFNI=5T]+:WE\J:=KM
M`D<G3:S9P&SV/-23:MID%M!<SW]G%;W3*D,SW"JDK-]T*Q."3VQUH`\#\5^,
MM?TOXJR^,["VUV[\.Z9=R>&Q:1-FSN"\6?.*`EC)]M$4._;@+GG%9^F?$'Q5
MK>H?#743\0[:/3]9U4KK5O;^'%BB@>2S:5+*1G)(8.I09PP+#/(`KWO3?''A
M?5;%[W2_$&C7-FETUFT\5_&4$ZL5,6<XW;E(QUXI8/&?AFZ?5(K?7M(=]%G$
M&I*+V/\`T24X(63GY3\PZ^M`'D?B'XI^)H/BM-HFF7]I;JGB&TTB#0GTAY9K
MFTGMUD?4EFS]V,F7ML'DE6.6%97@*TN/#'[*FO:GXN\1WMMJ.IPW][<:M#%]
MBNA.SLBDL,L79E4;NN&`&,"OH*;4=-MI5CN+VUAE=&94>=58J!EB`3G`')]N
M:%U;32]F!?V9:_YM!]H7-P,9_=\_-QSQF@#Y:\8:YJ'B'PIX-UKPSXA.I7/_
M``C.G+I=C::O/;7JZD;A8YKA8E4BXRH>-A)PNQ\X#$BL=,U?41XQTQO%L*0Z
MCX;NGU7Q##K5W/8B\?4%%LSKA?LSB$/'LB;(4'.`%)^GM7\9>&="@EN]:US2
M+*&WFB@EEGO8T$<DI`C5B3P6)&`>M:-OJ.G7%R]O:W=K+<1HLDD,<RLX5ONL
M5'.#V)ZT`>>?`OQ-;W7@NTTU+>UL)K.:[CMTANIYXKR"*;:;J%YB9#$S-P6)
M]B1BO-(OB%XFT#Q7K_C&.QU[4;#QCIFHKHEC/E[;SK!6>R$,:DLAGB6=FRJ[
MCL`YQ7T.VOZ,;:ZG;5=.^SV;^7<R_:TV0-TVN<X4\@8.*FNM4T[3Q;_;KZUM
M_M;B.W\Z=4\YNRKD\GV%`'S=9_$#Q<?&5C<6GQ&M?$&F7/A34;RUL[?PXL$-
M[?1K$Z0*V23(HDS@'.%*D9W$6O$O[0.HS_#W[=X=U)H=4N+:V%M=PZ2LL`NQ
M8O<S1.92J@,R;!@D[OD'S<#Z*NKRRL]@O;J"W\UPL?FRA-S$X`&>I)('XU`^
MNZ.+9[A]3T];>&?R'E-TFQ)<XV$YP&R1QUS0!XCHGC+7=-T'XN^*1!)_:EKI
MFGZE:6TL<AB$_P#9$,C(J'G:9,@@<Y]Z9;_$'QUIWQ*M/#^KZKHCP6K6/F"\
MM4L_[6ANE9GEB^8L&C8&-40')C)<_,*]F\3>*],\+Z!J6M:E.'LM(MIKBZ\D
MB1PL0W284=2`.G6E\.>*M"\70SOX=U33]4%G,T,_V6=93!(/O(V#\K#G@T`>
M#>&OCSK4"Z7)XMU.SFB;5[NUUB[M=.WV<;?V>;FWBM9DR95W%0"0'))0KN%9
M,7BCQ9#\9;.[C\2W&A:)J^LV2ZC!/IWF6]TS:)#*L>YN8PT@90%Q\Q[D8KWC
MQ;\4/#OA&TTR>>^CO#K&HKIUA!8S1R-<7!R649<+\H#,Q)&,>I`/4+?6:[@]
MS`&641,#*.'.,*?]HY&!UYH`\0\+?%KQ!>?"/Q[K=Y<6NK>(_#$,TR+:V8-E
MYOV=9DBMY$),\8#*"QPX)*L`164_Q6\;>$+BXO?%M['JVDZ5K=SI-U'8^'BM
MQ.@TTWJW2@.>48>4$'##J0U>]+KVCR6<EW;ZIISVT3E))UND,:L.H+9P#ZU%
MIOB33M16`^>ML]U+-#;PW+"*69HW*OL4G+#*D\=L&@#YTMOCMXWTKPG<:G=2
MVNM1R:W<>'].G&G*C3WD\%N^GR'RF9"GG22Q.5.#\O.0<]I\=O&^O>'19:$F
MJ6>DPWGAV]N)=0GTJ2Y74KJ,(GV1-A'ELRN[_+EOE&T<&O5]5L]!U1;.ZU=K
M*:/2+@WEO)+*-D$D893)UQ\NYAD\`GL:FO->LXETXQR>?'J<PCMY8!YB$E&<
M,6'`7"GYNG(]:`/D[XA6WB[Q)X]U3^R=:N-'M-`AURYL8UTHW(^T0:?I[1SA
MG;`E_?R*K*!MPVT9+&M_X>^+O%W@^]\/^%8[O18-/TRPT]C!=VJ6LFK1W4#2
MRSQ_,6,B2[DV*#ED8N1N%?2\>L:7+(D46H63R22F%$6Y4EI%&XH!GE@.2.N*
M:-8TF1;EEU"Q9;`;KEA<(1;@C.7.?EXYYQQ0!Y/;^,O&$?P.T3Q)->6DGB/Q
M+<:64']E[8[!+V:&-D\K=E_+$CMEB"2O.!7,V?Q>\7Z!8'4/&EU]ML9]+UL*
M;#0MLMG-IUXELD^TN0_FJ_F%#M5=I(.W->\:GXHT+1--.I:OK&FV=AY7FBYG
MNT2,I@G<&)P1@$\>E+9^)M#U..RDT_5].N$U2/S;(Q7:-]I3'WH\'YA]*`/F
MS0/B=\0;[7/#%Y?^(!):X\16G]GQZ3$D>O3V<T?V1?-!(1Y48[2AVG8Q7.3C
M4\(_%+Q[XHL=#MTUK06F\1ZK:1&]@L%EETV.6SN)Y8W@#84J\"HID.[YFW#(
M&?=M5\9>&=#MI)]8UW1[*"*XBMY))[V-%CEE($:')X9LC`/6L_4_B-HFF^-=
M*\+>=Y^KZO;27B1PM'MAMTQF:0E@=I)"C`8D\XP"0`>'^'_C'XAC\3^%]%T]
MY('?Q'/:ZM82Z:"ES;3:A>1I-'([F3*K`"VT;%R,D!@*YWP#\0=;^&GA6\\4
MZB;RYT?2-)T5]9@N8Y))'A<7L9,>>0XE-OG_`&1SVQ]6CQ!HSZ>E]_:NG&R=
M_+6Y%VGE%B<;0^<9R,8S61+K7@OQSX?:275-#U?1EOTC:3[:CP_:8I050D'!
M82(/E/4CH:`/)_'FE>+M8UCX/'Q!J,45Q&+F_P!9L8],62"6\AM#,N<GY=K9
M53S@_,.17-ZG\:/'FD>'],O[[5=.M]0O?"UOXBL[)_#SD:O<SOM_LJ+#;@T>
M8P6&9#YRD@*IKZ9O=:TRQ>1=0U"RMFBC,DBS7"H50$98Y/"C<O/N/6G7=Y;6
M^G37Y8RP6\+3[HAO)4+G*XZDCICK0!\[ZK\3?B-<:CK9TN^T^RMH5\02VD4F
MAM,T2Z7-&(UW;QN,XD()QP$!7)R:Z#XG>*/$+:S\-+O3M>?P[HVOP7(U2Q^P
M+,EQ(UIYD432-RA+91<8YYY/%>Q6.M:?>M%''=P"XFA$ZV[2@2^7ZE,Y`'0^
MAK*;QYH`U_3]+CU"&674[6YN;>:*17A*P/&DN9`<!@TT8Q]:`/!_"/C/QSX,
M^$.A+KFMVUP+S3_#RQ:K-HS9T2"Z1HYGG7<?-\LQI\[D8,F7XIVF_'3QBUYH
M[3SV.IV\C7]M8VVG:=MN=?ECEN4MIVB=MT-O(D"MYL>X;B<@*5-?0NNZ_INA
M:9<WE_=Q)'`CY7S%W2%5+,B@GYGP#\O6H[?Q-I<AG-U<1V8MIQ;%KLB'<Y52
M`A8_,#O4<=3Q0!P7[/OCC7_&^F7]SXIU'1]24PVMS;/9*L<L'G1EI(98E)V!
M&&%W'>?FW`$<^MUG)K6E)J4EBM_8C4%7>]KYZ^:!C.2F<XQSG%:`.1Q0`M%%
M%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444
M`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`''_$#P
M==^+;SPG+8RV\2>'_$$6ISB;.9(T@GC*+@?>S*IYXP#7D]M^S->:1X5T.VTJ
M'PM-J-@FEMJ\%S$XM=<DM6N-XN"%)8$7`9696.Z-<C&,>G?$[XF2?#FX\,QP
M^'M7U\^)-833%&G-$#;,T;OO;>RYXC/`]#R.,\=X?_:2LX+7Q"WCG2M7TY-$
MO=2CAU!+/_1;^.VOA:JD3;R3*3)"I!"@LQP<`X`.=O\`]F_79Y]!N8/^$3>'
M1H(4FT219OL5VJWUQ.8#E6(B"3J5R&^>)<KCI<U/X`^(/$OC2RU#75\&P:/8
M6LUM;VEG9@>3!+I[VYM]IB!=%FD:0%GQM``0$9KT&R^-6A7GP\U;Q@T&I06.
MA/-'J%J\2-/#)$0'3Y7*,?F4Y5R#GKUIOC;XU:1X(F-O<:9KVJWGF7*BUTRT
M6:1EMXHY9G`+*-JI*IZY/(`)P"`>7^#?V9]5T'6-`N]5M_#KII5II42#3[R2
MW^PRV>X.\.(,LLH/F,FY`79@Q8'-=C\%/@_JGPXU(3ZS!X9#PZ5]@>_TP2BX
MU1A,7%Q<A@!YA!YY8[BWS$8`T-6_:%T#2CJ,K:;X@N=/TZ:.T;48;1/L\U[(
M8PEHA9P?-)E09("`Y!88-5+[]HW2#H=G>^']#\2:W>WMG?72Z=9P1"2);.3R
MKCS7:01@)(57*LP.05W"@#S-_P!G?Q#X/T/6-2L[7PZ-4T?3KN?1?[%@E>YU
M74OMXO;:6Y!5.491'C+<32\@<5Z!K/P5O[[X,:%X7@CTZZUC3Y([Z>6\NVCA
M:_(D>29@(Y!*IFD8F-T*L#V(%:.E_'VPGTGP->Z[H&NZ4?'7V=;:.4V[_9))
MRHB$F)=Q#%EPRJV`06V]!#H7[0VFZ@VG6ITS7=2NKUT$\^G:=BWLQ-<S6\!D
M+297?)`R\9YY.T'@`Q6^"OC&<:]92:IX?M;37I#=2:A:)+'<07#:.+$^7$`$
M51(/,'S_`'3MP",U3'[-KZW]B;Q)H'@*R2P\.WFG16FFV[M&MW*;4I=*6C4J
MP-NWS`;@"HR>36AH'[3]A?Z-:ZUXET?5O#5E+I][=&SO(DEGE,%W#;+Y;I(5
M^:295"D`ECU`&3T7AS]H7P_XIUK2M(TJQUEM3U%YUGMWCB'V#R7V.9&\S:XW
M$?ZHR<'/`YH`SOB]\#9OB3KL^J6+Z19WI\*W^D6]Y/:^9-%/-+"\;A@,A`L<
MJ'#`XE;'4UBZ#^SS>?\`"66VK^(;#P?:Z8-;%_-X>TZ%GLT5=/:V4HK(JES*
MPD.4`&U>K#-=AKWQILO#/B#6=/O+34-3FL]0L["RL=-L]\]Q/<6SSJ@+.%.5
MC8Y^4+CGUK&TW]H-;OQY!ISZ%KDF@ZGI>DW=K?16&#8/>R3QA;S+Y3YHT7Y0
M<$MGCF@#E/"O[,.NZ%XPLK_4->LKW2(+]4EM#YF6TVS?S=*AP<@O%*7+G*@@
M]Z=HO[.'B*:XU"X\8S^%[J75]2T6ZU.*U@VP7HL[B:6<M&(D4>:LH4(0W0AF
M85UUC^U#X3U.VN9=.M->N2CVPL8HK5'?4EN96B@>$!^`\BE0)-AY#$!3FGM^
MT[X1AN=5BO(-9MUTBWN9993;(XD:V=$N8D".6WQO(JG(`8@[2V#0!0\'?`_4
M_#GC6?4)5\.P6RW.J/#J^GJ\>IRPW;AXXGRNP"(#8O+#:B8"\@YWB[X!Z]JG
MC^\\1VI\->(;.<@#2/$0=HIC]B2`32%8V'FH\>1A#E97Y4XKHY/CYYVK>%["
MR\&^+3-XAU>ZTNXCFBAADTV6",R%I%,F&4I\P*$_+D]1M-_7/C19^%]=UG3;
MZSU'4[FRU&STZRLM-L]\]Q//:O<*@+.%/RQN<G:!C!]:`/-_#G[,NOZ%>:+%
M=7GAO45TW4-+O#KTL<HU**.TM$A>TCX/[IWB!YD'RRR94G&7>%_V9_$?A[P!
MHWAR?5M'O)]+U-;XZBXD$T@.GW%L86;;EEC>9?+/&(QMP"N6]$\1_&N/2=+\
M"ZCI/AOQ!K%KX[OHK2%($CAELO,A>4&5)'&"!&P*@\;6YX`/,^#/VG;*[\(2
M:AXTT?6=/OH=HB*VBI#J;/>26T:VK-)R2Z`'>4QG=]WF@#BO'OP%D\.>'/#^
MGZ1HME<6\C0KJXL-,:YCEFBTR:W:62(1ODR,R`2%"00I)!YKM]<^$^K>*?`_
MP]&@Z1I.AZGX:L81#;:K=&XBTPF.%7C,0B:.X(5&7)V$,`589-==/\6=-U#X
M;V_BW15DCM[G4;>Q,=U!O>*5[U+5T94;!(<D;E8KQN!8=<5?VA]*U+3+RXT?
M3]:M([:6S\B[O]._<7L<]\MHQAVODD2%E.[;CAL,IY`.%\0_LU^)+WP1JGA/
M0H_`]EI.H:IK%TY6UVR2_:V=K:5CY#;'A\QE*K]Y0N'7&*M:U^S3J5UX@U&[
ML[7PK)97?B&+5I(R/)DO4-@MK)%-^X=<JX:9&(;+.V0I.ZND\._M"MK\L+77
MAO6M%#/K2"SO%A:6Z_LZ5(V:.02A$^9B"'QSP#@9,=A^TM:Z]J-G;:'X:\0F
MSO-#U'4WU.9(3%9M9S-#+'*JRY;#KC*$@[EP2"2`#-N/V:Y+_4=*N+V+1)8=
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M,L,YW;DE,3$]"%)7)&1D`\X3]FOQ7<:?KD^LGPE>:WJLEC<(\3FWMA>6R70-
MP\2VVQU9KA,PNC`A3ER0IKK_`(P?![Q5\2=&T/2K>]\."UM+)5O'GM1&R7BO
M"PG@(C<JNU)5V*4.60[N,5U.M?''P[X?\=1^%+Q;Z6_\V""XGAC5H;:>=2T,
M3Y8/N=1G*J5&1N*YK+LOVC]!O]%?4H-%\5"*1[$:=$^G*LFJ+>EQ;/`-^"K-
M&R_,5(X)`!S0!I?$+X6-X]\6Z!J-R]HEGI&G:G`1(F^6*XN1`(9X@1M#Q^4Y
MR<$$C'>O)[;]F'7-/\+V]MIUGX9CUVS%LT-Y+J,DMH;B&"6(3O:&U\N3/F9*
ML"QZ^8"JFNU\6_M(V.G^']<FT;2]8M[NTL-1?2[N_LP+.]N[*-VG@#JY.4,;
M@DA02C;2V*)OVC+3PW>Z_!XML+Z?^S=1N$@_LJU\TI9V]G9W%Q/+EA@)]KYQ
MR0``">"`9VH_!'Q9?:?XPTD7GAU=/UXZW+9W&Z;SA+J"*%$B[=JJAW9VEB1C
M&.16IX;^"-_H/@SXB>';$Z%I'_"6SWTMCJ6F0F.5/M*,!YRA5YC9B!M8Y!/W
M3Q4^J?M.^%]&@E74=/\`$$&I07,L<FERVT<=RL4<,<[7!#2!?+\J6-A\VX[@
MNW=Q6A>_'W1DUAM-T?2/$FL/Y<9%U962^0)9;3[5!$6=E(:2/ID8!(#%<C(!
MPVB?LU73>*M*UK7=)\#6,-AJUA='2M-M6DMT2WLKB&21"\:_O9)9T/W1\L"9
M8L!CJ?%7P:UC5/BHOB+0M3T^UT>6#[;/93PL['6(;>2WM;C'W6C$<N64G.88
M\=\:F@_&ZTU'X4Z+XUU;0M<TTZ\+=;+1V2.:ZGEG($4<>UMK;LY!)7CD[:Y[
M2?CM?^,_BMH'AWPQHFL6>DO9WL^LW%[8IO@FMY1`ULW[T;-KL"742`Y0+D$L
M`#"\(_LWZO9S0R>+CX:NHIO%%IK.H65O#FWF$6FO:R`((D3+3$2@%<`#DDC)
MSI_V8?$33:C'YWA2ZCU6Y62&_N4E-SHBC5+B[+6N%^\T<X!^9/G3JRUV'PZ^
M.=[X@\4ZO9^+-*U/2HIM>O\`2]%@>TCP191N\KO(LK%BP0G&U0I(`W<D7]+_
M`&A+*\UGQ%;W_AWQ!8:?H5[IMG'J,BPM'=O?>1Y.U0^Y>;A"<C[H)Z\4`<^W
MP.\17>AZEHFM+X?O=*^T:C)9K#?W%O+-]JU-+P&1O*8)L"[=NUU8CGY20.F/
MPQ\0:AX9^'UKK%WH@U/PK>_:=1>SM_(MY?\`1+B#;"BJ`N#.O91A3P.!6EXB
M^.&@^&;XVU_;:JXAM[V[NYH;<-'9VMI*8YYY"6&$#@``98[A@=<1Z)\>/#FL
M^$M>\021:II]OX;=4O[:Y@5IE+HCQ!1&S*Q=9$P`V<M@@$$4`>>>'/V7Y_#]
ME9-`/#B:G90^'#%>Q0,'CGL92U[*K;=P:="5W=6SA^*Y3P7^SEXHU+0=+U.\
MT[PQHUS;6UND^E74<N=:\N_-PXU`[/[@"KQ)RQ)XXKU'6OCC?6/B/2[6?1[O
M1+6_LHI)+?5K3-S'*^I6UH`1'(5VLMQD$,<<$YP5J:W_`&A-+U>R>XT73M:L
MX1<:<+>ZU#3L0WL5U>"UW1;7R<.&7YL8^5L%2,@'+:7^S#//;WT?BB/PO/#>
MZ3K5O;V,=J9K;2[B]NA+%Y"NH&R)<KD!3DG``-.M?@/XKFU?P$]\/!MAIG@T
MZ=)'!IT6UX7@:7[0(V\@,RR[HV'S(%._(;.:[*]_:#TFT\+ZGXCCT#Q-/HFG
MDF&]6""-+^)2X>6#S)EW*OEL<'#$$%0P-,M_C+-)IWQ%U>#3I=2T[P?#;W5C
M;6@"7%W#)IT-U@[R%#9D/I@>IZ@'$']EIH?`T&G16/A*ZUI(=/:[FNK<F*_F
MM=0-S^\8H6^:-GCWE2?G(P1Q7;>*_A+?ZQXP?Q1H4/AJQUF'P?<Z1837-B)_
MLUV[JT;\KS$H#+CKAB,8)%5=0_:'MH/#'VO^P-?L=2_X1@^(+B&XM4E33K8B
M78TY20;MS0L`J$L<CISAOC?]H&#0QXBTS1["Y77="LX+R-KQ8S;7<+7,,+E3
M'(67!E'#A3SD`@&@#DM$_9OUW2);6XNK3P7K$"ZIJ%W-HFH(SV:BYM[:-)5"
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M57D[5!P,XK(NOVF?"PT2VU?1['Q%K>GWT5W<6DVG6`<7%I:^7]HN5W,N8E\T
M#/5BK!0>,R1_M+^"FU/4+99KY;.PM[J<ZEY`-O*;:/S)T4!O,W*O]Y`"00"2
M,4`<LO[-%U)HVMAKC2+;Q!J7VJ*UUF&)FFMX)=,CM!'NP&VB5"^T'&#D?-FF
M^)_@#KWB/1[)-/L_!7ANXM-,N[?[%I8E6U::2:QE1R1&IP39N&.W(#)]X@UU
MFD_':;5?'UOX;G\"^,=+6729M2:\U".WB6-(V"X*B4G!W*,]BP!`Y(HZ5^TC
M:>(/$/A[2]#\*^);@ZWJEWIMU*3;`:;-;Q)*Q?;*RNI216RA.!GJ?EH`PO%G
MP)\5>+;A[S5XO!.H37MIJ5O+97AG>"P>YEC>.X@;9N,JB/:3A">""!\M3:Q^
MS?/XB\2ZU>>(/[#U+3=1.KR0VUS&SF.:ZM[*.&3!7`9&M9#N'(WC;SFMSPO^
MT?HNKVNE&XL]7N$NGM+>]U2UT\BSLKFZ*BWBDRY=6;?'T#!=Z[B,TJ?M.>&W
MT>XU,Z3XGCM@+4V#36*1#4A<2/%&86:0*!OC8$R%,<'HRD@'`>%_AQJ,?Q:U
MV]O_``A;:A+=3:[%%>:C"T$,4,[Q&,22^43/'*(P``[&,;@%`R!].(,*!@#`
MZ"H;.5;RTAG,+P^?&KF.4`,F1G#8)&1GG!-6*`"BBB@`HHHH`****`"BBB@`
MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B
MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@#G?&/@BP\;06,6KO=Q'3+Z.^L
MYK2Y:"6&=`P#!E_V7=2.A#&L+4/A%X7O=(N=#O()#::D][(R-=LKF2ZG%Q*R
M'.0PD574C[A48JI\:O$FK>'[70(M'U"YT.RU75/LVIZW;Z>+UM.B\F5U;RV5
ME&^18X][*0N[W%><?"^T\4^./BYX9\5^-[F^B6W\&O)%:2Z,D,(=KN6(2+O4
MO#))"(Y&4,&PVT_+Q0!['<_#;3M1\&:EX8UBXU+4M,U:.2.Y-U=LTI5P,A7&
M"N,9&.AYJI8_!_0K*XM[ESJ=Y=VPO-MQ>:C+/(YNHXXYBS,><K$@'9<<`5XO
M_P`+3^)FSQ!=07%O+JL%Q-'8^&9-/S(+B*_CBA@5A&"(9H6.^9W.TLKKA585
M%<_&#QN=:T6RM-9FEU1;'1;IM(7P[EM2ENKR:*\AD.W,*0QQ,0P*G]WN)8<$
M`]<O?@%X8OAJ2,=7@M]4GCNIK:#4Y4A2Z3R]MS&F<+,/)C.X=P3C).=B/X:Z
M/:W,%W?27U_<0:?=Z>)KV\9BUO<R(\J'H.J*!Q\H&!7BNB_%/QYXCN=<&B7>
MLQ6-[J>C1:=-J.B1>?ID=W=317,95452T4:QMA]Y4D;F(.*=XA\5^-7N+/0/
M$>M7:F&VMBDL7ALNOB*3^T98IMQ1<0%(HX7PI49D+'*C%`'I-C^SMX4T^]T>
M[C;69IM#BLXK7[1J<D@9+.1I+4/G[PC9SCU&`<X%;7A_X/\`ASPNTK:/;W$9
ME6V5B]T[9$%S+<Q]?26:0GU!`Z`5Y'IGB3Q_<Z_>VFD7+Z-I^F7]Y?/&-$5Q
MJ`_MJ:$PLS#(#6X#;DPV2'SC(.G\&/B!XI\7^/M87Q)XA2;3Y;*ZET_16LHH
M"6BO9(?-@<)O>$(L8)9R=\A[8H`[-?V>O"/V"XLI8=1FMI[>[MXXY=1D86L=
MQ/'<.(3G*8FB1U(Y4CBK\_P<TF^NM(FU74?$%^NBWZ7]M#<:DS1_:$8LCLH`
MSM)X'`X`.:\8T[XO?$.30]:O;:>[U+44\,S:C<V%QX=,(T'45N8XDLU(`,P*
M^><-N8^4&#`,*D^)7CGXB^#D31(_&0@N;;^T;E]?ET6W4""%K7RVN%*,BPJL
M\H9T4$E%.>N0#W*Z^%NA7OB,Z[<03-J1U*WU'>+A@OVB"!X(SMZ8$<K@CH<Y
M[46?POT+3[N:YM()EEN(+*"0M<,P9+25Y81@^CR,3Z@X-?/FK?$_QUJND:U#
M'-=:O)<:5JDE]I$OAXJNC207,<=J%D"@R^:A9L$ONQN7:!BNH\3^/OB#HB^-
M-?34T33=)DU>TL-,FT=0BF!8VMKCS>&9F+.N"=K97`R#D`](TOX(>'M(M;:S
MMI-5?3[&]@O+*QDOW:&UDAG,T?EKV4,<8)/R@+T&*CN/@GX<OUUVW>35$L=?
M>:2_TZ*_9;=GF96D=4'*DLF[@X!9R!\QKA-%\=^+[#X.>+M3EUR;Q#X@TG6F
MMT8Z7&;G3+4O"#YUO"BAI8X7><J`<C;U%8:7VLQ^+KN\L;[4/%$<UUX7@_M6
MXTDPBX07UZ)9!&JJ@*KMRZJ!C#="*`/<-7^&NEZU?V-].U[;WFFZJVIV]Q:W
M;Q.)FB\IP<<%&C)4KTIMY\+]!N_$;:]/!,=1.IV^IF07#!?M$%N]O&=O3`CD
M88Z$G/45XM#XI^(LG@W1]6UIWU^]U2;0=2@TUM%%O]ADEFD$]N"HS@;(SN?Y
ME)))P1C/U_XO^+++X5VM[H_B#Q%J'BC4X9;Q6C\,10PV%Q';"1M.=7B).9&"
MJ`#(=K#?0![OJ?PWTC7M'T;3YC>00^'[V*\TZ6UO'CE@FC#J"'')&V1U(/4,
M:HR?!/PS+X<AT0V]TEE;(!;.EVXE@87'VA71^H99>0WIQTXKS#Q+_P`)4GPX
M^,]_X;O]:T/6/[9AN[.YL;3S)=@L+$R>4CJV5.)`=HSD-WJ3Q%XB\77L6O2V
MVIW>L:-H=SX?BL(FT5`=4^T2VKS73$(#E09,!`JJ221P,`'L5]X$TV\\*QZ%
MJ\U]?6:7<5T'N+HF5I([A9X_F&.`Z+A>F!CI6='\'O#BZ%;:0EM<"PM?*,2&
MZ?</+NQ=KENI_?*#]..E>#OX^\6^-1>3R2:O/IEGXFT"_P!*&HZ6(9+$/<3&
M:&80HI*QK'$6!W,H8Y8Y%>K?`[XC3Z]I46G^,M6FO?$<US<*KRVJ017@B2%I
M7M=B)OMT,Z*&=0V25.2":`+>I_LZ>$=869-0359(WNKNZA0:E)MM9;F>.>8Q
M#^$&:)'QR`<]CBK=K\"?#-DEF+3^U(3:6U_;,4U"0&YBO9/-N%E_O[I/G']T
M],#BO,M0^*/CJ]\=^+5\)MJ\VF:/97%TFF7VDQ!EDL[R))(8V5`V)X?/*;F9
MC\C+CI5?5?C!XUFM?"%QIYUNTO-=O8M26S?1H_(DTRXU!(H[:3<AD$T=L?,?
M!0KG+$@8`!Z?H?P'\*:%JEK=Z9'J*KIT_P!JM["34I&MHKDVXMS<"+./,,0(
MW>K,V,DFM[0_AYHFC:(-(TZ!Q81:/%H_E27#.?LL:N%0G.<XD;YNIS7SJWBS
MQ#X?\3:W>B/7-(FU&WETZUO['35,=LPUO4BDD@E1HPIB1<L58GS$('S`T_1O
M&OC2#QQH>M7-YJEKK'B#0O"RW>A+H):+5)))9EO=SE#]G,,<AD.TKC`W9&!0
M![7X8^!/A/PDUDNE17TDVGWUO?0R3WSR,LD%JUK#GU587*X[\$Y/-68/@GX>
MM=<BU6S_`+4MIXS:-)#!J<R07#VQ_<22Q@[791@9/4``YP,>"Z!+XIN8GGAM
M;VPO]0E\.VXF32R1;9OM05Y8XW&T,B^6Q)&!E2>"*T?!_P`1/'FE>&/ASID^
MOZCK^H^.;6WT\7FH:4D<^FZA#()+WS@$4$"U\T`L#\T.226H`]YO?AAI=WXL
MF\113:C9:A=I"EX+2[,<5V(@P3S$Z$X8J3P2H`.0!4-M\(?#UKINBV$5O.+7
MP^M@+!3=.2GV)F:WR?XL%VSG[V>>E<'XS^(OB&V^->BZ%X:DUB/3H[F.WU6U
METZ-K>>*2UGE%Q')L,GR.D49;>%#';M).:YFW\=_$:P\(Z/J'B'7+J*/Q,FD
MW%[?Q>'$+^&TN([CSE6,*=ZB2*!,R!BGFDMQC`!Z3-^S_P"#]1N=0:>+4IK>
M]74`+,ZG*;>U>]&V[>&/.$=\OR.F]\8W&KVH_`SPIJMSJ<]Y:W3R:O!>0W1%
MY(-R7<%O!-CGC,=K"`1T()'4UYQXGOO$MO\`!CP7?Z/XCUC09D\26YU>^L-'
M^>2VDNW$CO!*CLD?(8J1P.#Q6+K7CCXAZ5<^(E\*-)90:=>:K?(!H?G"_,=]
M!#%&Q(SM>.9W)7#'8""`#D`]AU7X(^'-4UJ36,:A9:M),LOVVTO6CD4BW6WV
MCJ`IC1,C&"R*W4`UK6GPWT>SO[R]2.>2YU"ZM[FYDEN7<R200"!&/_;,#/J>
M>M>*>+O&GCSP]%<@+-KFI>&-3UN*SU&31P&ND32?M,#;(P%'[R3R<K]_9C[Q
M-4OB/XX^(W@[3QI-MXMD%]*VH74>M'0X%:***SMIHQ,A1HQ`DL\BNZKNVA><
MJV0#V=/@UH*^!K#PF7U1M+TF:&;39#J$AN+)X6#0^5+G<-A4!?;@Y%2>%/A=
MX<\&:O%<Z*MRVIQVURDL]Q>O/),+F<3322;CEF:1`=Q],#`XK@/B[X_\1>'D
MT<>'M;N;*RF\/7.HQ:K::,-175;Z(1F&TVA2$64,[_*%9NBD8K)^'EIXM\/6
M'Q@\87J7FK>*YY?,L=.GTV-"'CT^"5((W51))&LDC1A2Q&4)'S,Y(!Z5J7P6
M\-ZKMC9M3M98M6N]4$MGJ4L$OGW2LLXW*<A'5V&WMVQBFWOP+\-WBZD@;5H(
M]5CLA<)!J4B`26?E_9YUY^65?)B&X=0G.:\8U+XD^(M(\):[>Z'X@U_5=5U6
MXB&G:Y#X92W&Z.Q>;RIHY(BF"X,8*)DG:F=V6-NR\=^+M%O_`!I/XG\1>*UF
MU$:-_9=E!H\/E:4+FWM_,N$9XB!$DK2(V[?MY)!/-`'L9^$7ABRMY?MT5Q=1
M3:9>:;<O?7SS>;;W4WG3B1G/)9^=Q.1T&!4T7PET=O!VH^&=2N-6U72-4A6&
M5+Z_>1T1455V.,,I&T-N!SN&[.:\B\36GBKXI?`_X:?V[?7]EJ6IZ_IPUU(]
M*B<7$?G,&\Z"1"H3Y58@J%]1CBDU+Q]XZL;&PNM9\1:CH6G:K?ZRANX/#*7`
MT\6,KI:VX38Q/VA$9RS#DIM3;N%`'J\WP5T"]FLY]5EU?4KNR5%2ZO-2DED8
M)=172[CWQ+!&?HN.A-31?!WPY!HMCI,-O<+8Z;]G^SI]J?(,%R+F/)ZG$H!]
MQQTKR/2O&GQ3\3:OI45Y=S^&Q?7>GZ==6T>@K(+1I](^USW`:3)W)<+Y0!)0
M;B&#'&.BU'Q_XJD^$?@G4KN:ZT+4->O(;37M6ATOSGTU-LH,_D,I"[Y$C7+*
M53S<]!0!N7O[-?A&^M(;25M=6SM)+A[.U35YA%:+.LBS1Q*20J,LSC'4#`!&
MT8ZK3/AAH.DV.N6=I;2?9_$4$5OJ$;SLPDCCMDME`YX_<HHXZD9ZUXYX:\=?
M$OQ//I4KWTVG6EC8VE[(&\/A/[8CDU6XM_G#C="7M(XI=JX*EP>%^4\II'QB
M\>ZEJ\;:AXLDL-,UF2)7\O0X99-(A-Q<HUW"GEDO;DQVL0>0OM:9BW0&@#WJ
M+X(^'$T>\TZ?^T[N*_T"/0+B2YU"225[%&E94W]<CSG&[KC`[50MOV<_!EL^
MI%+:_9-426.6-[^0K&DET+IU3GY<SJ&_3IQ7F*_$#Q_?6_A_48H)8=1U+2?L
M_P#:)T)E?RY-;@MTN#$WW"UJWG[#@`\D``BF>)OB%X_T3Q#I.A7?B];!--:)
MM1U>71X(X[J)M6DMMUQN1A'O@C`0QA09"2>",`'L.E?"BU\-^(FUK2M8UN.X
MO+M+C56GO#,=0$<+Q0Q2,W2-/,9L`9+!<GBI=0^#^C:CJNLZA'=:Q8OXA!.H
MQ6&H/!%<,8/(+X'(8Q[1E2,E5/4`US'BOQ/K3_%*[T.;4[S1M*M]+AEL+./2
M/M*:X\OG"96G*DQ^7MCX4J1NW'(.*\K^'NJ_$!=%TC0?#]S=^')+JRL8Y-2D
MT47$L?D^'[:8;O-!!)G#1DGGJHPP!`!ZMK/[->@ZEJ&EPV%SJ&D^'+&TU*WE
MTG3[R2!76\,&^-&4C9"?);,8X)D)X-;8^"?A>W.K6XBO(]+UY)4OM)2\9;.7
MSHA%)B/L2J@\$?-ENI)KRJX\>^+;;QU>6M]>W?A72M1N+>6?7+;P^;HO,NEV
M<BV^UE8`.[W`W8S^ZV`@UE>,O'GBGQC/XXTZU&O2Z&EHCV]I<Z8L4ME<P:K#
M#M1HT#;70/(`[.Q7#<#B@#V2\^`/AS4X1'JMUXAU`OI=QI4\ESK,SO<VDRJK
M12'/(&Q2IX(8$YR3F?2_@;X=T>73Y["35H[O3=5DU2.Z&H/YKSR1+#('(X9&
MC1%*8Q\HK@OB5XD\7^$OB;XRO=$U[5Y;2#P*+[0M";3%FLY[V-[@/M<)N+C;
M$Q7<"?,`Z`8YWX@^,_&7@2Z\365GJ&N7.L26%DUAKEOH=OB>=;>[F:*4&-DP
MQ5(U55W9(&06S0!ZAI?[//@S2;^T;3H=3BALI;2=K(:G+]GN9[7_`(]Y9H\X
M=T^7!/7RX\@[16N?@YH4?AJ'0K"35+&P@L5L5-M?,LA@#,VQF.<@EVSGKQZ5
MXKJOC/Q9X9O_`!-K,,]]IJW^M:9<7T-MIWG7=V@T:U+Q6<<B-&6\WY64X)P0
MK!A7TGH/B"P\0VTLNCW4=W':W,MI,Z$D)/$Y21#[JP(/N*`)-`T2S\,Z%IVD
M:/&8;#2K2*UM8RY<I%&H506/)P`.3S5^BB@`HHHH`****`"BBB@`HHHH`***
M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH
M`****`"BBB@`HHHH`****`"BBB@`HHHH`I:OK.G^'["2^UZ^L]-LHL>9<W<Z
MPQIDX&68@#FF-X@TM7"-J6GARR*%-RF<NI=!UZE06'J`3TKC/B]\.;GXA1^'
MS83P)+H.JK?&WN2PAN5,4D3*Q4$A@)=RG!P5'%>?W'[/-]8:OIFN:>VF)_8'
MAO\`L>WTJ!995D46\R&3S)#N:97D"1.WW4:4'[_`![.?'/AL:?>7[>(-$%CI
M\WDW=R=0B\JWDX^21]V%;D<$@\UF:YXM\%>#+W4-9UW6/#^EWDFFK/>7$]W&
MDKV<.XJY&=S(ID?!`ZN<=:\(\*_LRZ]-I/AW4]6&@:9J5C::0LFCVUN\,$B6
MUI/%(;AP#FX)NGPP!`\I>N<UTEA^SG>V>C>)=%5/"QTSQ)I(M5FGLY;JZTQQ
M8?91'%))DO""J2`L0PW2#&3D`'KZ?$7PO+#9RQ>(]!=-0M6O+4C48OW]NH):
M5!NRR`*<D<#!STJCH?Q<\)>(K`:EHVNZ9=:,;$7O]K)=QBU$9<I\SEOE((Y!
M`QD=^*\X?X&^)-7\5^%+_P`07_AU=*\-R6LJ:?9V958C';SPRQIE1N60S*^6
M/R[2-ISFL+3OV8-<TZ'PNZWGA9Y?"EG9VL5I]AD^RZBMO/*V9U[%DEW<!L2(
MIY`H`]^E\7:%`+'S]:TF/^U"@L=U[&/M1;.T1\_/G!QC.<5B:!I7@G0+S6;S
MPX=!MKC3RXU62"=";/),KK)\Q\H$DN1\HSR17F7A[]FM[%_.UZ;0;J4VCB**
M+3RL5E<OJCWY,`.=B+O5%Q@_("?2NP^&OPRU'P;=>)H[TZ2NB:O)OLM,MD>;
MR7=Y6F=Y)!O8.9%_=DLJX.#AL``U?`?QF\,>/]!TW5M/U&RM+?6[B2+2DNKZ
M`27P4_>C57)R1SL/S#/S`'BKNMZ/X.\:7\C:TNB:I=:)&5G#S([6L;\E90#P
MC;,E6X.WIQ7C4O[+>I)X>M-&LKSPRT$WAS3M&O;F?36\VS:UG:1KBTQP'<2-
M][&&1&R<8KT&V^#[6WPQ\;>'8)K&/4?%TFL.;Y+<KC[9+,T?F$?,^Q90O_`>
M*`.WLO%_A^ZFLK2QUS1[BXO@_P!CABOHF>X$9(?RU!RVT@@XZ8.>E4KO7_"'
MC%+[0+C5O#VK>8QM+W3OML4S;CN_=N@;(;Y6X(S\I]*\TD_9^-IXZ@UJPCTJ
M>PC33&6V=I+8VDUGN&Z$1C:4;=NVDJ-Q;.0<5Y]\,_@KXJMY-*N8M(L=)U+0
M9--NS?:K"8A<20+>QM:;(^65%NBZR@DL2%.<9`![OHGB;P?X0O\`6](LY;'1
MK72+:VU"\NYI5BMV6Y:1$<S,WS,3`P)8]E'I6G#\4?"$^L7VE)XFT$ZCIME'
M?7=O]OC#0VS@E9FYQL(&<]`"">HSYI=_!+Q0(I'TS6]($MW8:39W\3VC+'=1
MVK7;2H"0YC#M<HRD`D>61GYLU@0_LRZKIMAIMOI]YX8N&L=&T.UEDO+!S]HG
MTR=Y-CXZP3*X5@3D;%X;%`'O$_C?P[:V-K>W.OZ+#9WV/LMQ)?Q+'/GIL8MA
MLX/3TK1.J62FZW7=J/L*AKK,R_N`5W`OS\HV\\]N:\3\,_LYPVNK37?C!=#O
MK2]MM92YTZULBL4#7\\+[8-W0*D3*3@$LY/&<58^&WPX\76'P6U>UO=0CT[Q
MWXG$L\U_=6RS"!MJPVZR)\P)6WBB5AR-Q;K0!ZB?'GAD:3!JA\1:$-,N6V0W
MO]HQ>3*VX+A7W;2=Q`P#U.*M/XFT>/5/[,DU;3%U+RFF^QF[03>6OWGV9W;1
MW.,"OFS5/V=O$MM<:5IMC;>'=1COF\1W%W/?VS3V=@;Y;98QMP&>0;'P0H!P
MP^7-6]+_`&=]<OO$&IPSG3++3=+U426.JW%J6U"_5=$BL5PX.%A+M(S#KE",
M<YH`^@%\<>''FM8D\0:(TM[,\%L@U"(M/(APZ(-WS,IX('([U'>>(O#6FA=7
MU/5M#MT-L62]N+J)`("Z@D2$_<WE1UQDCOBO%M7_`&9KV>QCT[29O#,=G=>'
M]*TF[EFTPF:R>SE+O/:$<!I-['G&&5&).,5,W[/&OZ=>:Y)H6MZ;]DO+^--.
MM+BT(%OI/F37$MF6PVTFYG+!U'W(HUXY-`'JX^)GA]-5U:SO-0M;.'1[*SO9
M[^XG2.V,-T9!$RRD[3DQ-^8]:Z2:]M[>T>[GGABM4C\QIWD"HJ8SN+'C&.<U
M\^M^S7JMMX9MK"UO='O+VPT71K&RN+A9HEMKFPBND%P%7<'R;E<1N"I`8'L:
M[CQ+X.\2^/OAQJGAS67TRSO8KBV6QN6B\R&^2W:&0M/"I`6.62.13&I.(V'?
M(H`Z74/BMX0TYM'6?Q-H6[Q"TBZ2!?QD7[(,L(B#ACVX/4@=2*9X6^*_A7Q;
MX0C\2Z?K>F1:7]GBFN))[R)#9>8H8)/\V(WP1D,:\VL_@'J=IJMCK/\`Q2PU
M"/Q3=ZQ+9QV#+:P0SV8M?+A.-V\!$E+$`,Y;@<&JJ?LR'3_"GAS3]'DT>WOM
M"BTC[28[4P0ZE+9BX5S+M!)W+<LRD@D.JDYH`]Q/B/25GLH&U33A-J:AK*,W
M2;KD%2P,8SEQM!/&>`363JFM^$8=:CO=9U30(]3T2-D22YO(EDLUF8(>K97>
MR!>>I7%<?X!^#*>$/$UAJTT6F+%IWAN'2;:VC$DYM9%N9YG>.63YMK+,%['Y
M?3`KG-0_9K35-<U/4KQ]$N6U&3Q"[&:P\QLZ@(1`6)')B$3#_@7&.:`/5O$'
MQ'\+>%HM4?Q!XBT6P_L6V^U:BD]ZBO:P\?.Z9W`'(QQR2`.M5-.^+O@G5K^\
ML]/\6>'+BYT^R2^NDCU*,^5;ODK*3G&SCKGC(SC(KQV[_9F\1Z[->GQ5X@TC
M4%;PWJ&BVDS61+@7-O;QQEUP,^6T!;<2S-NS\I%7?$/[/&L:]?7-Y&_A6QEO
M++1_-CMK62-1<V$[R>6"!DP2*X!R,@HIP0*`/;SXJT18K*5M8TH1:EM^Q.;R
M/;<[@2OEG/SY`)&,YP:S-8^)WA/0O#D/B#5/$FAV^AW%PEM%J3W\?V=Y7?8J
M"0$@G=QUXP<]#7G%O^S_`!K'"+RRT2>WA\/:KIHT^22>6,37ER)C()B!(H(W
M`E,$;SMP`!5B?X.ZQJ/P@;PKJ5WH=WJ%MJ\-]8--9[[>**&[2:*!R%#.=B>6
MTA&X[B3GN`=WX>^)_AWQ'K>KZ19:G9KJ6C7!BFMI+A!)(HBCE\U%W9:+9,GS
MXQG-8?BCQ)\,/%=YX>M_$>L^%-1GU2:>WT;=J$;_`&E]H$T495L-D`!ES@\`
M@G`K`?X)7D.HZ_K.FW&A6'B35-3N+ZPU)=-$K61DTM;-4^89=%==^T\%>,9K
M&\+_`+/6K^'M6TC5Y[CP[=W]EXGGU>>.6U=T\J:QCM65'V@APT8D!V@9..,9
MH`]K_MW1=-OQI#:EIEO?1VYG%B;F-)5A7J_EYR$&.N,"ET[Q3HNKV]O<:3J^
MEWL%VSK;RV]Y'(LQ0$N$*DABH!)QTQS7D?BKX%ZOX@N?'D-O=^'Q;>,9#<PZ
MA<V#O?6;_9HX?(W`X:`F$9&0=LDBXYS5"#X$>);+Q`?$>EW/A.PU:76);TV%
MO92K8P1/IPLOD"X9I./,.0`<[>,9H`]1'Q1T`7^NVMQ>P6AT&YM[::6ZF2*.
M>2>!)HEB8G#EE<`#KFM67Q?I%AX?M-9UO4++2+"[CB=9;^Y2!5,B@JI9B!NY
MZ9KQ/5/V<=9N/$LFLP7WAK45F@6V?3]6T^2:W*'3K>U:7:#_`*Q6M\K_`+$C
MKD9S75_$GX6:_P"+O`.C^&-"U;3K2*VLVM-2CN;<E+I#:M"K(V&9-KE7P,;@
M-I(SF@"'Q7^U#X+\*>(M6T6:[AN[[29K:U=(K^UC\V[GVE(%$DJG(1@[.0$4
M<%MW%>D#QCH6S4&;6M(7^QP#J6;Z/_0LC(\WYOD_X%BO'[7]FY+>Z6>YDT2=
MAKFB:@7?3P6:.QM8H94R1UD:(L.PW<UC6?[,6HV-K&EM<:)<7.G7JSVMU>>?
M(+^);X7(@NHL;?F'WG&X[E!`QD4`>V:-\2?"OB'7+O1M#\1:+?ZK96T=U/:6
MUZDDB0R#*28!Y4CG(]1ZBL"U^/W@.^U'3+:P\3Z+<PZHUW'%>QWT7V=);:2)
M)(F<L,2%I5VK_$,D<8S4\&?#2_\`#/Q`U+Q#-:^%X[?6=)M+6YAL+)H7MYH&
MER(CC!C82C.<'*#CTXVS_9I:3;:ZY%X7NM-LT\1):1KII+.-3F22-W!&`\>&
M3*]5QC'2@#W%->TRXU6;2H-2L7U2"(32V27*&>.,]'*9W!?<C%<UH-EX$\'Z
MW?6VA3>'M-U9$7[9;QW4:S1([Y4%"V41GDR```2PXR:X[PA\$[CPQ\1;C7[E
M["_CDU*[OK>Y>>9;F'[1"J/&4`V.H((4L>$V@#(S67K/[/VK>+O&^M:IXMUB
MQGLK^QU*RLS;VY2>"*Y,#09&T+NA:W!#98L2"<8Q0!['=^+M#LKZ&QNM9TF&
M^NIS;P6TM[&DDLH`)C52<E@&4X'.&'J*X34M=\!Z_P"*X9_%=G:07MIILUVN
MH:EL2&*WMKP1$.^_;@3$,H;.,YX.17#)^SKXKGA\/1ZUXAT>\-K?P:MK$BV;
M(9M274!=SS1G!8JZ*D*HS`($!^:KTWP#\2V1M)="US2HI(5OHKB*6U8K<PW.
MK&^:/)#;/D.S<`2&&10!Z=#\4_#3>+H?#C:K8I?7>G6]_8NUS&([Z.9Y400M
MN_>-F%CA<\$'O52+XPZ&^M2:7(MU#/#'%(\DHC6-4>XN(`Q;?@`/:R$]P,''
M4#R./]ES6;>ST&R@U'PZZ6.A:?I-U>S6,C7-K]EOI+HRVAS\K-Y@7DC!4'G&
M*V-/_9RO[7Q!9ZA=:KITEO;:C#=/`;=OG5-3O[PKSQDK>JGU0GH:`/6/#/Q,
M\*>,M&;5O"_B/1-3TU`I>YMKU&2/<<+NY^7)X&<9K6O?$.E:;J-I8:CJ>GVM
M]J!(M+6:Y1);C'78A.6Q[`U\]:7^SYJ^A:M\/M*2/33I>G22IXAN;&W,<=]9
MVLHN;%9`3D3?:3D@`C:9.>F>J^(OP.U/QKXMU._MKK0A8ZY%I<<\M]9O+=Z<
M+.X:4FU8'`WAN^-K#=STH`]>L=:T[4[BY@TR_LKN>R95N8H)UD:$L,J'`.5)
M'(SUJ[7&_"_P%'\/_#\UC(+*2[N=3OKR:XMX1&9?/N99DW'JQ59`N3_=XXKL
MJ`$89'!(^E5[+3[?3HQ%8PQ6\0)(CBC"*"3DG`[DDD^I-6-PSC(SZ4M`!111
M0`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`
M!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`<
M?\0?'=QX._LFTT;2GUO6M?NVM=-L!=);+(ZQ23.7E8$*HCB8]"2<`#FN/N/V
M@FLM8:*\\,WT>E)J3Z/)J`O(F*:DELUP\!B'.P*C)Y@)!8?=QS7HGBKP?HGC
M.VM[;Q/8QWJ6=PMS;$LR/!*H(#HZD,IPS#((X)'0UA6/PG\!W6I?VQI^B:9-
M<JSIYL3ED601?9G;:&VB01KY9;&[`()H`XGP_P#M*2ZU=6(NO".H:?8W5U81
M37<FH0R?9TOX]]DVQ>6+Y4.H^YN'+<XBTC]IJ34UMKJ7PAJ-MI<JZ;<S7;:A
M"WD6=_,T%O,4'S%C*I#1CE5PV3G;7I4?PR\*VD"QPZ):1QJ]DRJH;AK,`6IZ
M_P#+,*,?2JVE_#[P3=::8-'TO2Y['R+6S/D/O3R[.4R01Y!/^KD)('8]:`."
MC_:=@EAUB[@\,:O/IMD^RPNHI%VWKB^2R*MD!86,L@*AF)9`QXP14^J_''6?
M^$:\5:DGAJ?3[/PO#)!>ZA'J$-P8K^,1F2!(B!O4>9M$AP"0?EQ@UWA^%'A1
MGNRVD1E+ZX-Q/`9Y3"TIF2<N(]VQ6,L:/D`<CW-)??";PCJ6H:K>WNAVLD^N
M*1J/S.$N<JJEF0';N*H@+8W$*.:`/,O%W[05T;SQ'I6@6MK!=:)/ILEIJ<%Z
MEY!=V\VIQVDH*A1L<?O%VY;&>H(Q75^-_C6_@SQ=)I(\/7>H6-A_9S:KJ4=W
M'&+-+ZX:W@*QM\TA\Q3N`(PO//2MNT^#/@JP-W]D\/V:"]96F7<Y!VW/VE0H
M+851/F3"X&XDXJKJ?P=T#6_B%-XN\1VPU&Z%M9QV\,Y/DV[6LDTB2!0<,VZ;
M/S`X*J1@T`>=^,OVH]2T7P]?:EH'@Q[M)K6]N-`GN=4CCCU!+.9(K@R*`6BP
M7W*.=P'.T\5T&E?M!RW_`(BOM+N_"VH01Z6MS#>W4-P)T@O+>W\^6)L(`(\9
M1920&?`V\@UTT/P:\`74=_=P^'M,FAUNUGCG8%FCDAN&$DH09VH)&PQV`9.#
M4-EX9^'6GZCJ)LYM,CNK<>3J<7]KN0I,`B/GH9,%_*906<;L%23T-`'$-^T1
MXGO?^$8.C>`-H\1:S:6R+?:U$FZSNK62XBG4JIP^(G#(?NE<9.0:MZ=^T(H@
M\&17-DNH_P#"3:@+.XE^VQ17%F9+N2WA=K=0<H60_-E>`<9((KT*3X=>$=:T
MRTMO[+LY[33I+?[*(I6'V=[4-'%M96RI0%UX.<$@]ZAA^#?@NWU&ROK?P_9Q
M7.GF)K=D9U"F*5YHR5#88K)+(RD@X+G&,T`<=X9^,&K_`/"M_"-U)IW_``D7
MBGQ1?7=G9VD<R6:2F!YV9GD8%4"Q0]@23C`YXR_AQ\6?$OQ/^)]])IVES6/A
M2P\.07,%M)?0;YKJ:6=")E",P(>V=%*OM`4L0V]=OIUY\+?"M_H5CH]SHUN=
M.TNY-U8Q([H;:8EB7C=2&4DR/D@\AB.AJQH'A#PUX(EB3P]I]AI4DUI#81)#
M\A>&#>T<:C/.WS)#QS\Q)H`\+M_VA/'=]I_@S6&\%0,VKVNN3WFC6>KQ,9(;
M-H0LR3.HP1F0;,?,2.0.GH7ASXZQ^)_'\GA[3="U%[!+B6S.K#YD2YBB65UD
MC"_)'AMH<MRPQCD&NBTCX<>#--NG@TC2[&.>S^TN85E9C;K>8\["EOD63RQP
M`!\IQWJ>/P;X6\.ZI+KZ6\6FW!=9)I_M3Q1,PC$(=TW",ML"KN(SP.:`..7X
MCZM=7'C'Q)-J=GIWA?P%?7=I?:8+#SY[I+>%))96DW@QN=QV*`05VDYSQ2D_
M:%U"UD_LR_\`!5[!XFGN;.*TTL:I`T<R745S+"YG'"<6DP8%3M(&-P(KM=3^
M#O@O7/$D^OZIH%G<ZI=(([J1R^RX`78/-BSLD(7C+*3@`9X%06'PN\!>$#:F
MWTK3;%Q?0RVTD\[%VN(X6AA"N[$DK$SHJYP`QP.:`.)LOVF#?V4,L/A/45N=
M6@TVYT.U>^AW7T-](T43.PR(<2H0P.2%(;GD5-;_`+2,=Q<^%H&T,12ZYJO]
ME:E!_:D3SZ5=?:7M>8U!\R,RQ.`^5R!D`D$#IO$OP,\*>)-,TJS@L4T^'2FL
M$B-ME2UM:3&6*WSG(3<3R#D9X-7K#X*>"-,NM.N;#PY8V\VEB$6K1EU"F&1Y
M(F8;L.RO+(P9LG+L<\F@#CM&_:*EU&(7]_X4O]/T*66V\G47O8G#02736KS.
M@Y01RJI(/\#ALC!`GO/C)?6/@RV\:V>C7%YI.M-%#86CS"(0@RS?Z7<3;6$,
M#1+$VX@A2R@XR371^)OA?X9U?P;J/@^TAM]*M]9TNXT[;"H9UMI&+2A%;.>7
M)SV+`^E:U]X'\-:_X?B\-W=K'-IFFQ)!]BBNGC\I!$45&V,#@QL1@\$'O0!S
M?Q#^,-QX*@T@:1X?E\17FKZ==ZDL-O?Q11QV]JD3S-YK95CME7;C[Q[@'(Q/
M^&B9-0E9?#/A>ZU)+F^MM-TUYM0BMC>7L]HMXL9!!\M%MVW,YSRI4`FNG\9?
M!7PWXWU'P[)K=IYFF^'+&ZLH-,0F.&2*=85*MM(.%6$+MS@AB"#6O??"_P`*
MZA97%I<Z+:>1<W\6H.L>Z,BZB1$CE4J0494C105(P!CUH`\T;]H2\\3VTEOX
M4\-ZDD]A)#%KTSW,&=)D>]DM=H7)\X;[>;++T7#8).!T-W\=;2Q\-'53I-Z^
M^\OK*VMEE3=-/;Z@EBB;C@`22R*03PHSFM:3X,>`-,2RNG\/:9:1Z-`D<,@9
MHU2..0RKOPP#[9"S@ODAF)SDFJNJ_#;X9Z=)?IKNG:%:OXC\Y+B.\NO+^T^;
M*LL@16;@F4*_R8^?#=>:`*/AKXG^+]6^*C>%=>\&VFCV<.@0ZE<78UI+B2&2
M2::,(%5`'4F+@Y!&<D=J@N_CG>KI6L:KI_AN%]*M+R6PTJZO-;AMCJEU#.T,
MT:IM9D(,<A7ABP0\+Q7:Z7\./#>DZM9ZKINF+#J-A;R6T-SYTAD\IW9V5R6^
M?YW9OFS@L2,9K'F^#W@#5=3O7_L:Q>^6^^V7`@N9$:"Z=<F0!''E.ZMDE<%@
MV3G-`'-:/^T,VOW>B?V3X7U";3M1L-+OM0O&O(E_LZ+4`WD93K)AD8/MQ@8(
MSG%9;?'35+[0M6\0II%_H^D?V%;:EI+M)!<&\AFN`B2@9^1MI&8VZ!EY))QZ
MKIGP[\-Z-&L>EZ/9VR);VENJHIP(K4DVZ8ST0L<?6LW3_@OX)TJSU"TT_P`.
MV,-KJ<:Q74(+E7C60R+&`3\J!R6"K@`DX%`'&6WQPN]5G;54T;^S_#PTZ^N-
M+NK[4888]5:*>&&/+<F!B[,`I!R'7^+Y1SR?M5Z@'M-1N?!XA\.#0K_4=1N%
MU57N+>6TO/LC1I'L&]3)M`)*\.#QM(KT\_`_P+B_QX<LE&HLSSA6<`$S+.2@
M#?N_WR+)\F,,,]:CA^%?P_U*"*VM](TRZCTQ+NS*1S,_EBY;?<128;G>QW$/
MGYCGKS0!S$?[05T+/2FOO"=]8W-]JTFGW4EU=B*RM0BQMY@NF0*P82J$!"AG
M61<Y7G=\;?%]?!GC7P[H+6-O?KKEY!:3RQ:@JS6+SL5B9H-I)1BI^8LO0XS@
MUK7?PA\)W]C#9:AIDEW:03>:L-Q?7$JLW[O&X,YWC]S'\K9'R].3FYJ/PU\,
MZOXFA\0:EI,$^L0&!DNF9@2T#.T+,H.UBAD<J2"1N.*`/-]._:0N-1TTW8\'
MZC$NI&UC\/!]0A_XFDD]P\`1C_RPP\9)+9^4@]?E&Y!\4K[2?`$6M:OH]U)K
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M`PO`GQ6G\?Z]>66F^'[^RLM.M+:6[N[^189(IKBWBN(X#!][<$E^8G&TKCGM
MQ\?[0]Y=6VG:PGAG5UT_4-*U2_L+&V:.ZGU".U-NH8JHW1G?*P"C=\H+'L*]
M7\.>'-#\/SWX\.V\$%Q.81?%)2\C&.%(XO,)).1$J`$\D`'FLZ[^'?A&RTFU
MCN=.M+*QT:SGM[>03M`+2"5D>4+(&!4$QH2<_P`/6@#S;1/CW<ZI\5M&\/O!
M:2-XB\-VU_:6-I>QSQ02K=7273FY``?;'$G[L#<2",##E8+GXP^*M&\?_$63
M5M.LFTGPS/::=HM@^LPVZWLLD$<Y;)B,AE*.S!02`JXVY!:O2]-^$7@S3WLI
MM.T"PBET_9]EF7<7B*2RS*0Y.<^9/,Q.<MYC9)!-&L>`/!GB&_N4U:QL)[Z[
MOX[J;%PT<S74=N(U<%6#!A`0O&/D;G@T`<&W[0^IZWX8U/6?`7@^75;;2?#\
M6IWDMYJD5J+>::R6[B@*X)?]VZ;F'`W``'G!'^T3J-IIUG<ZSX0F06NGZ?>>
M(WM=3BD&EK>N4@$88`SYV[FQMV@C[QXKO8?@]X,MKJ.XMO#]C$\=C'8;8]RH
M]O'$T2(Z`[7VQNR`L"0IP#BJ9^"O@*W^PRR>'[0C2(88X3))(P$<,AEB5\MB
M14<EE#YV]L4`<N?V@KMI[!U\*3PZ7J6LW.FP:G=ZG'#;C[-,89GD?:1&QD4B
M-&(,F#RIX.GXX^*&HV'B670?#>CW-XVG/IIU;4EGC1;!;NX"1CRVYDRJ/N*_
M=!!&3P.BF^&/@_7M)L86TRVNM+BF>\MHH[A_(D>687#.55ML@:4"3YLC/(JQ
MK'PR\+^(/$,.NZQH]M<ZM`L2K<DLK$1/YD6X`@-L<EEW`[23C%`'F,/[4!OM
M,U#4-*\':S=V*!7TVZ5CY-Q$9_),D\@0BV`/SG._"<G&#C9D^/4BZ?XCUBW\
M/2WGAKPK9O)J&JVVI0R!KA+:.X:&%!_K%V2J!*"`3T&.:ZMOA#X3,5U$FF2Q
M0WDDDDL,-_<11[I',DA5%<!=S,Q.T#.35"/X3?#N&6YM(=%TF`W=JFGW%I'*
MT:21_9_+5#$&"EO(7;G&[8O7`H`\]\1?&GQG;>,=+TW2/#V[59-1LXKC0GOH
M`K1SV=]*%%SC`.;:-R<'&-HSDFM;P[^T[8>*]9TVUT;0=5EL+B*V_M"]7YSI
M\T\'G*K1J#N15P'DW``D8W=O0/$/PH\)^*II9M>T6WN9YGA=YA(\<FZ%'2,A
MU8$%5ED7@]'([T67PH\)Z9>6MUI6C06,EG;P6\2VDDD,?E0!A$K1JP5PH9@-
MP/!H`Y[X:?$G4_B!KAN;C1KK1M(O=%M]1TLS7$4PNX)G;RY<H<HVP#,9Z9')
MR<<]X'_:!O?$LFA6MMX=U"_ANH[(ZGJK7$,0M/MGF"!O*'+_`#1$-M(VY!YR
M<>D>$_AGX8\"RSR>$M'M],>XC$3F)F.(U8LJ*"2%0%F(48`R<`4W3O`7A3PC
M:L^G:78Z=!&EL&<$JJK;EC#DD_P%VQ]:`.H4Y4$]Q2U"MU"9Q;B6/S]F\1%A
MNV@XW8ZXSQFIJ`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`***
M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH
M`****`"BBB@#R7X_>']1UG_A"[G1[GQ7##I7B:";45\/7#I*;4Q2JS.J\NH<
MQY&#@,3CT\\MO"/Q!\'^'O%FH^$+OQ(M]JE[KDJ:3)L:&%6U1'CEMD*Y65[=
MKAEY.YF&1P*]V\9_$;PO\/I-+'C?6+#1SK5V+.P-W($$\Q!;8#]`>3QT]16;
MX8^,/A+Q6VL1P:KI]M>>'I[N+4K2ZNHDEM4MYFB>5UW96,E,ACC@CI0!PEWI
M/B[4/@)XCTZSO-9UO5?M#_8X[R*6TN[BR66-WMO,E"N[M$)8Q(0N2XZ8S7/>
M*+^^FCMG^''A7Q]X-T&2QO99$T30DL;F;5$6/[(LD1!/E$>:,E0C-M#'%>Z+
MXUTB]\-#7?#]Q!K>G,%,4VG2+.LN7"_*0<'!//T-<I=?';1[#7HM-U#2->A0
MV]G-=7_V5#;V1N[A[>W24[]X+21MT4@#&2*`//K31?B?K_B*S7Q/J_BS2H;N
M[CL=1_LQXHH88/[(CEDEC.QMK&_#()`?]D<&N<T+Q=\2]5\6Z?%/)XNFU[11
MH;7VEV\,<=B(Y;4O?"Z)&!(P4[><ARNT<FO?HOBEX<EM"?MUFM^UE<WD>F?:
MHFN988&=7955B",H><_7!!Q2N/BIX:L/A_?>-X(9)[>#3(-1O;>UC1[M5>)7
MCC=<@>9L=<`MWZXH`\?\*1_$WQ!"]K>/XWT;2]:\26!E:>8M=Z?9R64S7:)+
M)&&"I.(DW!<`_<."#6UI%[XWM/B'X2\'ZGJ^KWEMJNGPZOJ5W.(P\$5FK0S0
MO@9'VB5[5^@!_?`>E>K6OQ,TF*TTMO%H;PC?ZS<-;V6FZY/!#<3R`@!4"R,K
M$Y7&&/4=ZS=<^-/PW\+:]%9:[XI\,V6LSW2:;Y+7<9F64AG6)\9*CAOO8`)]
M30!@^'8=<TCXS7.GJ-?NO"_]F^198C>WL=*2*.$+'AE*W#NS.5D5MR[65A@`
MUXYJ7PG\6:7X-U'3M,L_$VJ+JUQXIENHKXK<N2]Y&;0AB`1YB!G'/S')/8#Z
M?7X@>%Y+W4;*+7=$>\T<9U&W6^B+V@Z?O%SE>?7I5(_%/PM<QXT35]-UB[:V
M2ZCM+"[CFFD@:01B55!R5R>OM0!Y%<Z)\0=3DDM[>^\3:';0-XAOH7T^..+S
MKA=3!L$?*G<CP,YV\;QR22*XZ^\2>+M=\:Z\+3QAXJLIKNYU2WL;"RAENHKJ
M&VOXD/EI$A-LR0@Q[P68^;YF"017TS-XZT73_#MKK7B2[M="LKIE57U*98`K
ML<*I+'&XXX%0V&O>#+?Q%J]OIEWX=BURUB\_5D@DA6XCCZ[YL?,!T.6H`X7Q
MUJ7CY?A3X4U7P-IVL0Z\T<,6H:/<2QSW"+<6[1;Y7.T,T$KQRL1C(C?CM7EW
MB;PY\5_%W@R6VUB;Q'_:44=_I8:Q*P22?9M,G1+M'P"GVFY*\C&054'!KW)/
MV@/A[>7MW8:/XJT/5M1M--DU+['9WT;L\$>[<58L$R-C=6&!R<#FN@@^(/AB
MXU"YT]-<T8:C8VXN+NR^VQ>=;1XSN=`V0`#R>@H`\5\->!?$!\>0:_IFH^.;
M*VM=(\.PXOGPVI!;FY%TEVKKN=DCDSS@KN!'-5/C%X#U[5_$WQ/73O\`A-;R
M/Q#X0LHM)MX96ET\SK+*)@B$%4E4>4R@]=S'GM]`Z#XIT/Q3837OAS5--U2R
MMYGBEN+2Y2:-)$^\I93@$=\UP_B_]H?P1X8TO2[JPUK1];DUC5ETJRBL]4M]
MKW!R6#2,X50J@DDGNH&2PH`\]\9Z-\1=#DM-)T7Q#XOETBWFU*2'5O(:[N5G
M`A>T$PB0M+",W"A2`&("L1Q6Y\=/#EWJ.H^&->TG3+[6?$6CVLJ6UG)H(U"P
MO/,>'?%*"0;:0E5*S`C8`_WAE3V/BWX\>"O",WB.RO=6M+G5_"U@E_J>E0NO
MVB*W8X#[6(&!U//`(SC(SLK\4?!G]F66I+XG\/?V?J5R;6SNO[1B\JXF!VF-
M&W8+`\$#I0!X.D_Q5CAU2;4[SQ8+BYO?+UFQL;)Y#;VHOU5IM/E9!&"+4G"I
MN9P2V`RUV^E:SXHTOQ:FG0VWCB^T:\M-$&GW5_;!C$$NYOMC7#\;',7E;@1N
M((XSG'H'BCXAV7AG4;338=-U;6M5NH6N18:7;K++';JRJTS!F4!`6`'.6.0H
M)!JY:>/?#=YJ=SIMOK.EG5;*`3W>GFZ07%LF,DR1YW+@=<CCO0!\U>.O!7Q'
MU_P#823W7CB;6-0TO6;C4%M9UBGM9EFMA;01%0#&&BC<A%/SG.22:U/%-K\0
M5\1WD7AV?Q;8^&+MX`FHBTD:^W)IT?DO+L0RNOG"42`C);8IP":]ZL?B9X0U
M:\M[33/$F@WEW=22QV\$&H1.\KQ#,BJ`V25`)/H!49^*7@P6&I7W_"3^'C9Z
M+(J:A<#48BEH[?=$A!^4GMGK0!PO@J\\6I\6)%\0S>(=5TZZTE,W+VKV%EI\
MB16^4,)!62221Y6#JV4PR,,*#7$P7_Q0U74_%\]C;>,-'MM1.G+;VUS)Y[64
MIU1H[HP,Z!0/L>V3Y-R`$$$D&O=I_B)X4@N-/M[C7]#2XU9!)81-?1[KM"N\
M-&,Y<%>01UI\WC?1X[K3X;:YMKHZ@@G5X)D<1V[1R.MPQ!XB/E,`W0F@#PKQ
M9H_CNV9=!N+WQ]J>DV]A>)IEW:0Q7#WMQ]MD41WS$#<GV5HMI.T'YSDN!71?
M%72/,^-?A#5M0\.WNMZ3#HUS;&:'PY_:JP3M=6[*&_YXDJC'?V`KU6/QUX?F
M\(W?B:PU*SOM#LX)9Y+RRD6=&6,$OM*YR1@C`YSQ63I7Q@\)W_@;3/%M]J=M
MH>CZI#YD;:Q(MF\3`[6CD#'Y75LJR]B#0!XP)OB=OU*/7)/&ZZ)-K<$4$MA"
MOVV'1#)<YD^4%OM7F^2'V@L(/+8#<6QJZ+X1\4Z7\0]=\6:5+XS\DW.F^7IM
MR\:+J\*Z6$D,ZE<>:)0BELC:R].3GVB3QYX:BUJVT>36]'75;R,R6UD;R/SI
MD";RRIG)&TALCMS1?^//#>FZ.VKZCK6DVVE+!%<&^ENT6'RI"1&^XG&UB#@]
M#CB@#P3PE;?$CQ!:FQU"X\<:/IFK>*+4R22S$W=E8OIKO<(LTD88*MT$3=MX
M/W>"#63/XB\;1_$#2++4/%&NVUSI!TVR2*1ML-]>2Z?*P@N88TP?,G\MVE)`
M`#+@#!KZ`7XGZ++=>(8[?S+F'P[I$&K2W,&V2.XMIDE=#$P/S<0-[<KSS6!X
M9^*W@OQ#;77B76-/C\+WFEVEM-<W'B"""VG@M[A&,#>:&8%6&\##]<@C/%`'
M)_#ZP^(6J?#+QA;7>K:V/$6HZ(AL$U>VDA>RU%X)!+MF90"OF;,*@*IC()W5
MG^;*WA#28O`G@GQEX*1KVRM?%,UEI`MK\6HCD#&)^6F*R^7OE4,=K,02>GM3
M?$+PQ'?Z;8OK^BK>:RH;3K<WT8>\!7<#&N<N".1CK3(/B/X2NDU%[;Q%H,R:
M,_EW[)J$3"T;.,2<_+SQSWXH`\%MXOBWJEKI\UQ>^,;(V=K9FW410)),LNKS
MQ.;E0I!E33C"[#C:WS$;A3M9L?BQ';7EII5_XP":`NH_V7<@1O+J#)J$26IF
M++B7-M),<8`8("<D5[=X+^+'@[XBSZG#X$U_2M<ET>58[Y;*</Y)*AE)/<$'
MJ.,@C.0:FB^*/@^XTV]O[?Q-H$MCILIBO+E-1B:.W<`G:[!L*>#^1H`\7U#3
M/B'I^M:C8VVH>(A8:8FMP:;KMS8"_N!'+'I[V[':`SXD:[1=N#B/N5%4H[SQ
M]=+8?Z%XYE2X\/WEFFG7+.PM)A'=[+JXE>,+<^:5@"QOMD0NF0<M7MGBSXGZ
M1X:\*:;K]A;W7B.TUF[M[734T;RIFNWG;;&49G5"IZY+8Q5VW^(.A_:],T[5
M[RUT;6]6@$T&BZA<Q1WASU7RPQR0<C@D<<$T`?/VF7/Q4@>,HGC*+6XENH9[
M5K:/^RTT]-.8VSQ\8\\W!A&`=^\2`@*!7IWPRN]5\%^18>.]6\0ZK=^)9[8V
M0U&,2O!.UGYER@**-D2O&YYX4L%'4"NN;XI>#8MWF>)_#R!;E;5B=1B`$QVD
M1YS][YTXZ_,*O6/B_1-6TN[U/1+ZSU6SLVE2>;3G%UM>/[\?R9)<8^Z.:`/'
M?%>@^.=:^(VN6&E7?B/0_#^I:J6_M'2UCB<0II$90K(5)Q]J7;SR2"O0UB>*
M=.\:>)=!\?V'B&+QK=:I<^'Y;31[*"!/[-NH7T],LV!C[0;CS@02&!V@#;7I
M\OQVT!_"V@:WI6FZ]JG_``D=M-=6.G6ED/M?V>$CSI6C=EVA-RY&=V64`$G%
M;>N?%+PYX>\-:-X@OKM?[%UNXMHK6]7`C`G&4D8L1M3')/;TH`\HNM>^)$&B
M>)=/T73O$S:K8W.K26<[6J>4UL9(_LR0NQVO((BY0<@,N&YX./JNG^.=/TFX
MN_`T/C&[N5N=6FL[G6;%/MK?\2B-+4OD9/[]=BD@,V,-7J/BWX\:!X0\#:1X
MDUBUNK)?$%Y'9Z38ZBT5E+<22.0A)D8+&I4>9EB,*1D`\5=MOC7X9:_U"#5K
MB+2(--L$O9[V^N(4MU1KJ>VV^8'(W>9;/QG/('7(`!XE\6YO%_@ZQ&@P>,?%
M\-M(NIWZ:F]ROVJ"..TM7#[TC+2QQ2RS_N@!NZ9^5:[[QKH5_JGQ(^'^M:;=
M^,;C1QH-_;S"QFD^RRS.L#0-=1`=''FY9AU51QW[CQ;XQ\&1+I2Z]+H.I7-\
MT<NDVLLD$LMPLCJGFPJQY'S9RO8&NCN?$6E6MR;>]OK&&?SHH/+DG4,9)<^6
MF,YW/@[1WQQ0!\X>&/"7CGP/\.?">E-J/CV72KFTT4:XEN4DO=)3[-.D\5MA
M-RHLJ6H95!95W$=2:2UU+XN10V<\8\57^KSZ)?1Z?:75M]FCL7Q=-;3WA"F*
M>5D6U0IE620C@@M7LVM?'#P/X<NQ'XAU[2]/BENX+."YENHRD\\ID41C:Q((
M,3@E@`"#R<'%KP)\6?#'Q#CO8]!U"S:^TV>>*^TYKB,W%MY4[PEW0$E5+1D@
MGL10!PGA"7QQ9_"GQB^F7NMZIKXMGET"#6K-X[B&9K56\HM,%\W]\6/0*I.P
M$A:Y+^S/&$>G"Y\,R^.4,NM"4:CKNCI<WMO%_9$Z[S$`&=5N60`8#$_*,KC/
MI8_:3^'4J:5=VGB329]*U6^N[$:I]I1+>WGMT+.DC,1M)`./7@]"#7:Q^,]`
MDUY-$BU;2WUJ2W^TIIZW:&=HN#O"`YVX.<^G-`'A_@N[\97'B'P[#XJB^(UC
MHUG"5LY(9?/^W7:WLB.]XSH'6%X?*D19`N$+\EE%5TUCXB:I\.X[2^_X3/2]
M5T^PMX]0N/[.<R7LZW$AECB:,%UW1J@\]5(`9<9R<>O6'Q5T?4O%.N:-;6E^
M(?#;&+5=5DB2.SM91$LIC=V8,"(W5MVW9SC=G(J\_P`3?!Z:)9ZQ)XET%=)O
MYO(M;XW\8AFDSC8CYP6R.@H`\)U;5?B>S:Q+HMKXS:>^TFTE6.52HT>)6M!<
M6R#9LN+HJ]RRS1G.48%>%J*]L_'UW'#IFJ7OCO4M,2S?^RIK332HN)?MD@>&
M^\Y0[*MOY061@N_YV'S`"OHH^+=$6S-X=3TX6:ARUP;E-B^7((WRV<?*YVGT
M/'6N8G^._@2UOK*UU#Q%I5M_:U['9Z7*]W&R7\CP+,OEE6.!L8<MMR2,9RI(
M!S'Q?B\:+XDO)_`,>HJI\-+%#<6D".R7+:C!N"E@?F\CS6P>,`G%=W\-=*U+
M0M#NM.UO4=5U9K34KE;6[U-P\\EN9"8MS@#=A3M#=2`,T[3?B7X<U`:-'/J>
MGV5[KT9DTZQN+V'SK@#.=@5R&Z'E21Q6KX?\3Z-XHAN)?#.I:?J<-K.T$\EG
M<+*L<J_>1BI.&'I0!K4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`
M!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%
M%%%`!1110`4444`<9\2O`UUXTC\/RZ5=6=K>^'M;AU.'[7;&:*78DD;(P#`C
M*RD@@]5%</K'[-\6J^&-5TU=1MK>]O[C5+A+Z.RPP:ZOXKR-7PP+(K0HK#(W
M#/2NW^*GQ!?X=^'#?6=O8WU_*Y6TL;F\>W-R51I'5"D<C%@B,V`O0$D@`FN+
ML/VB+C4]4L_L?A>0Z)]EL+C4KYM0426@O+,W,06+;^\QM*L=PY92`><`'>?#
MOP<W@S2[N">.PCGOK^6\G-FTS+([A<L3*[,6.WGD#I@5QWCKX"0^+OB(?&L%
MY!;ZY9)I?]DRO&Y%LUK<2R2AP&`=)8YBF"/EP".:O_"_X@:Q\0-7DN]6TH:-
MI]UHEEJ.FPK?I=":&X:4K(2%!1]JJ&4Y`QP6Y->?>%_C'K_A#X<7_P`0OB'>
MZSKFD)J,D$UJ;*TMDLX!>30B2V\L"28C;&"KG)!)'/%`&YX9_9YU/PO?YTW7
M+"UM9[.\@U)X;63S-2$OG^4LJM(4`B:?<&4!CMVDX-6="_9XET3X$:M\,CK<
M=U97UE]FM[R6U_>('5?,$A#9D&X-M).X*0I)V@UD>.OCCXIG\">+[SPUX?MM
M.F\-:;&;N[?5HY'M[^2VBN5A2/85D39*BERP&2<`@$UM>*OCWJ?@WP1?:IKW
MAO3K;7M-N[J.713K1<W$%O$)I)8)$A8O^[9#AD4`GYF'!(`[QG\`9M8&C:7X
M2U:'1/"FFM!(VD>5)(JS17L=UYJMO!8MY?ED/D`'<!FJ\'P(UNQL](MK76-`
ME3PUXC?5],FN-)8S3K))<,\=PXD&2%N"`RXR4!([5=O/CW=VNLZJ(O"LT^@Z
M,9(;K4$U&,3>>-.%^J+"1RIC.S=O&&QQCFN6L_VI=>N0L*^`)+J]F6:YM(['
M499TO;.&*W>1X6^S@M)NN5C"%0-RN"ZXH`DU#]EV_P!5TV73+[7],-E:6&K6
MFFRII9%Q(+^X29VN6+X?8$VC:!N)W'TKT/2?AK>:1\4[SQ+IMY8:=H]]"XO-
M.M('W7\WEPQQ2R[F**T:QL`8U7<&4-G;DU?&GB?5=2\9>&O"F@:C_P`(Y-KV
MF7>HO?/;1SS`0-"/(CCD!3>?.W-D'"H<=<C"E^/=SHFHM;WFC)J&CVVK3:$V
ML0WB1R3:C#:O</\`Z-@[8B(V4-O)SSMQS0!U?Q;^'E[X_P!+LH]"NK'3=5TZ
MX:>QU*>.1Y+"4Q/&)8@CJ"P#G*OE6&017!77[,LMY#XCL[C5K22+6$U3[)J3
MQ3-=VC7S))(-GF>4R[U.?E!*;5XP29_#W[2>H:M<V1U'P?\`8+"XO-.@N+@:
MNDK0C4(A)9D($&XG<BR#(";L@N`:CT7]IG4-4BM[VY\&_9=)=-*NI[G^V$=X
M;/49F@MY/+"?-)YBG<F0`N#N)XH`T-:^".N>(KK6+K4-4\.6\_B+PK<:#?)9
MZ2Z)$&,ACEBS)DG,AW!NH``(K%N_V8]1OK&XTJX\0:;_`&;$-:DLIETO%V9M
M1@>(B:3?AHX_.D(``+`1@D;.=#2?CY?QZM-9S>'[V[A^U:K'#=S3+$]_-;7%
MRB6=HJQ[)9MMOG8S(VUE/SX8U1E_:'N8[G03)I4+ZCK=O-`FDV^H`Q)?&]MK
M>.*:5X5DB=3/\X*_+\PVL=IH`]#D^%-N_A/Q;H5O<I80^*K0V\DUG`(VA)LT
MMC(!T+80'\A7':/^S_J(\3:;K_B/5=%>]L+[3)3!IVE>1"\-E:W4(&"Y.]VN
MV8GHJHJ@'&:BE_:-U5G>ST_P8+K5M-^WMK%L-918[=+*:**<Q2;/WI/GHR@A
M,X8':172?%#XRS^`-3O+32]#36#HNA/KVL-)J*VIALE=ES$"I\R0E'^4E1P,
ML"10!5^(/P5NO&>K>+Y;;4=.MK+QAH%KIERDUB9)87MY975PP8!D82D,I'\(
MYJAXU_9[37]8>_TJ;3$AN%U&"ZTZXBECMYH;Q8-V?)=&W;X`3_>#D<'!K:T?
MXNWVO>/'T:S\.$:%%J!TV;5VU!0ZW)LEO$'D;<E#&VTMNR&[8YK@]1^.>NZ!
M\2/'VA:LUC<0-<+8>"84AVR27P@M2]NYS^\)>]BD'0A$D["@#T/Q'\/-?3QC
MIWB?P#J^E:??QZ2-)U"UU*RDN;>XMUD\R-D"2(RR(S28Y((D(/0&N3MOV>=4
M&H*-1U_3)[&SGUJ[M98]*\NZDGU*-U<2OO(*(9I2`.2!&"1LYS/AW^T-JKV/
M@/2_$T6FZ[J6ML;'5M0LYS`]O=[;EXV:W$915=+8MCS`?FX4@9KH?"'QRUKQ
MO>Z+;:;X2M8_[6TZ'6I//UM5,&F3/Y<<F/+PTQ99"8P0`%&7RP%`%2P_9T71
M84:UU"T\Z"^T.ZC:.Q"-C3K=(6C!!X\S:WT#D<\YY?P'^SWXPMO"VBW%WK>F
MZ%J\&AZ9I=SIUK9,BR6MOYSO%/*DFYI#)/G<A`_=#LQKM/V?/B5XE\9Z;';>
M-M+CB9K.2ZL]62\23[<BW4L)WQ*J^4P"(<9;(;KG(K"U;QYXRTS5];L[+7+?
M4M'OM;TO1]-UU["*,V-Y<W#QW,<2`;)EA3RL%\_O&926VD``WO!W[/</AA+$
M7=]9ZBVGZ7H%E#))8@,ITR21RX))QO\`,QCMCO5;X9_!JYTCPWX\LM?BM)1K
M\]QIFE6EXFZ.#1H@Z6MO($8$I^\E;`8';(.AKL?A%XBU'7_#VI)X@N%OKW1=
M:O=*:_6)8A?"WE*++M7Y58CA@O&Y6P!T'FVJ>._&>F:MK-E8Z[;ZGHM_K>EZ
M/INNOI\4;6-Y<SO'<QQ*!LF6%!%@OGYV926P0`#L;7X2:M/\.8O"NN>(O.BE
MU037$D,;`QV*RB1+2-V8L<!43>Y8D;LYXJC:_`$P:U;O=:M'J.CV6MZAJ=O9
MWMMYL@^VVC131LY.&_?222@[1PY7WK(TCXA^+//\'P3ZA8W$(\<WOAK5KIK`
M"34XX8KAHYDP0D1S"`^T$%@<;1Q4?PH^//\`PLGXW^)M(M=:TJ?18-(CGTG2
MH4`NH7CNIH)I)B1NW-L1MG15*'JQH`Z71?@5#I>K7%]+=VDLCW6FS0,+,!X!
M:V/V0A6SQN!8CT#$<UB:=\#/%NE^$].TBV\6Z='_`&9::?IZB#3Y(5NK.U6<
M;)6$I<%S*CDH5P8]O()ITO[2NS4O$EM;:':ZC%I2V,FEW-CJA>+4%NKYK)<L
MT2A"LJG)4NN,\Y&*CUOXYZ_<:;<:=9>%Q::_8:?-=ZRJZO&1IR+=2VJO"S(!
M/EX7?!"87&?F(4@&WX/^!TOA3P[JVE?VPEP-1\'Z?X>27[-LV&UAGC\XC<<[
MO/!V]MO4YKE]-_997PUI$&G>%-4M[2SLM0TS5;>V=)MAO+>W:WN,L)-PCDC*
MLH!^1QNYSBN@^)'Q#\4:)XWN]!T33=+_`+(_X0W4-8;4VO&6YMYH"%4K%L*L
M`SIP2,Y)R-N#@Z1^T-XDL_">AQ>(/""/XHU8VT=G#%J1DANU>Q^U-,SQPL4.
M%==@1OFZ';S0!GV_[/&K7?B6XT]1HNC^&X[70BT\%H\TKO97-Q<-';-)(6C^
M=HPS/N.&./:]8_LQWYM-.M=9US29H=#TZQTRQ:WTGRVN+>WU"&[9[C+G=(RP
M(G&`"SMSNP.V\6_%Z]\-^#/#VO)X:NXQK1B:\74I3:QZ+&T1D=KMPCF/&"F2
MNW<1N*CFL#QI\;KIOA[XSN]`MOL.I:1'KD%G/YRR?O+"/(E`(P0Q(X/`[YH`
MZ?2?A?/I]WX_A>_M5TOQI.\\9MK8Q7-H\EK';N-^2K`"(,O`(+'-<5I/[.&H
M?;]+O/$.L:--+I"Z);116.DF&*:WTV624-("YS*[2GI\J@#`-3VO[06JV<\>
MG:]X5M[#4+/5(K/6KI]5+6&GQR00S12/<+$<.ZSA55E5=RD;QE28K+]IF[U*
M(S6/@V^:VU2[CM/#]S)<M%%=S/=?9U2=VB"PL3E\*9#M!Z-Q0!U/B?X(Z?XH
M\!Z+X3O6MAI6EZW#J$T"P%8YHHYVE\D!2-N=P&0>,=*QM7^`$]UXEN'TG4M.
MM/#U]J&CWLMM+8&6ZM3IVSRXH)2V%1_)BSD$KF0C._C2L?C=++-]FU70&L+R
M/2+^_GB.H)*(WM;Q;5HPX&#N+;@WIQC-9*?M'2,/%-\?"FI/H'AZUU.:+4(W
M;]\]A(8Y8Y`T82,NP;R\.Y(4Y"T`5;[]FA;SP9I.A'5+)6TSPWK6D&8Z>"'D
MU`QXGQNX*>6<\Y.[J*[OP]\/[KPE?>,;W0;RQ6?Q%-;SV4,EL1#:R16<4`W*
MK#<"T08XVG!Q[UQ1^,?C:X\9>%=%?P=HUB-5U>ZL]2\[7#*T<4=HETDD)6+#
M$QR<A@/F4KG!W56\;^//%$4/C_7/#VLVNDVOPYNA$NCR64<W]K$6\4[>:[?.
MGF>;Y<?ED<C)W9VT`.\/?`OQ=H6@>%(D\3:%_;'A>TU'3DGCTJ00RVEX$);8
M921*CQJP.=I&01SFMCQ9^SEHOB?X?:)X-GNKR31M+GT[S8KF>242P6B[0J#=
MB-SP=R]"`:UX_C):+-K0U&UAT^#1=7GT^:XNKP)&!%8+=M*Q(^5<-M/7&,^U
M<KHO[0>L^((K2PTSPC:R>(;S6[K2EMGU=HK8&"UCNC*96@#[3%(,#R\[AZ'-
M`'7ZA\-]3U[PSX5T_P`2ZS!J%_X<UJUOYKYK/;]L2!V*@KN.UV0J&8'&[)`Y
MQ7G\_P"R_=+JMKJ=KX@A-UI]V+FWA>"2..0F_O[EE<HX;'EWY0$'AHPW.<57
MT#]I;Q+)X2\-W&I^"8K[7M:T^YU22QTB]EF7['#*D9,7[DEIF+\1G"\<N,U:
M\7?'#Q(EY:7WAS0#_9]AXIO-):W%XK3ZL;:UO'EC";,1?-"A4Y))!!`')`+]
ME^SU=Z;>VS:=>^'[:P>TTN&ZM&TR2<VS6-P\R&UD>4L@;S&!W;B"-PZXJW\6
M?V?&^(_BV'7M.UTZ1-!8+MA6VWAM1MV=K"[+9!!A,TV0/O!EY&T4_P`0_&>;
M7/@]\0_%/@;;!'X>L[K^Q]2&V=;J2*V5VD5",865F3!SDQFN+\.?M$>(-+L9
M;.YT?5?%.KG4+N&S@OK+^S;_`,BTM[>2<3PPQNHF9YQY:J`KJRL2HR:`.E'[
M.,NFI`_A_5+"*:QDT.:W2YLB\;R6'G>87PP/[TSLV1C!]<UU_P`._A+#X%N;
M>Y,MI<748U02S1V@C:47E]]J`)R3\OW>>O7BN6\1?M('PWKETNH>&+F/0=,N
M[:SU"^DO52XAGN+);N-1;;<L`IVM\X(/0$`X@3]HO54>"QN_!T<>MZFFF3Z7
M;1ZTDD,T%^TR0-)*(_W;!H&W@*PP<J6H`NZ7\`I8?[)M]8OM*O=/T75-:NK>
M(:=@S1:@LWRR`L1N0SL,@8*@#`S3_#7P'D\-^.4UC[5I]_:+>PWT8G6<36DZ
MV(M&\L+)Y9!501N4[0S#G@C$\._'[Q:L6_QCX1T>PMW\3WNDR:C!K,C6=G';
MS^43-*8?ED9B%0$*KD'E.`>H\>?&^;P;XAU*TM-!_M+3?#D5A+KMV;]8)+=;
MR5HX?*B*GS2-I+99>.!D\4`8OQ._9XNOB5XAO[Z34])T<7-G+;B]L+!TO+I#
M&HBANG$@66))!OQ@,0%4%>29[;X'ZK8ZKIFM:7=^'K;5+6XOVNX9;2>[M[H7
M44"-*?,E+"9?LZ8.=I4E<#.:W?"7Q9O_`!7XVN](/A[[)HT5WJ-C!JO]H*[2
M7%E,L<BM#M!56W$J=Q^Z<@<$^=^'OC%XELO$'BF?4VUS6#_PEEQX?T+3;BPM
M['36D^UM%"%O%4R,51#OW!N<@`G%`&\?V>]6N?#6I:!?Z_ICZ9,UT+)4TQ@Z
MK/J27K>:3(0WW3'@`#&#[5LZM\%;J;QG/XCTC4=.CG;Q1:ZS#;W-B714CTT6
M+Q$A@<D9D##H0`0>M5M,^/5]J]SI-A9^&5&IW,^JQ:E%)J:B*S_LV=(;ED<(
M3+DR`H-JD]]O-9?A[]I34-8>QGO?!QLM+N9-)>>Y_M=)'@M]4.VS?RPGS/O(
M#KD!0<AFY``*VB?LR3:'+I8?4--U>VM]/TZVNH;V*=%\RSG>6.6-8Y0/^6A^
M5LC<H;G)%>A?"+X?ZA\.M%N].U"_M;BS,Z?V98VD;B'3+=8D3R8VD9I&7<KN
M-S';OVC@"N[!R`>E+0`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`<_XR\+^'?$VGH/&]GI]W9V3F9&O,!86*LA;<2,95V4\\
MAB.]5(M'\':'J5K8QQ:%8ZAJ"Q&UM2T<<MPMLFV/8F<L(TX&`=HKE?VFM$F\
M0_!_7-.L/#U_XFOKM%2RL[.%)66<'*2$.R@!2,YSP<<5Q'BCPEK_`(M\9ZQ<
MV_AG4[>;Q'/X?O-&U:[2,'1X[:4/<I(=Q:)P%;Y5R&,O!.6P`>M6'ASP/\*;
M6:[L+?P_X4MKEDCEG+1VJ.=Q*(68@<%FVKVW'`J+1_@YX$T.YEU#1?#6C6LM
MS<"\>6*`8:7+L)<=,YD<Y_VB:X_QQIVL:=X]T[7?%7A>?QOHW]BW-DEGI-G'
M,+*X,HDWF&:09\R-1'O!."F#@,:T/V>KJ?\`X5=IFCWNGZK876EV[I+#>VC0
M"U9I9"MHN[!)A38F0-F-I4D'@`W;7X5_#_488[JRT#P_<P3V4=LDL4*/'+;J
MI5%R.&`4E0><`X!Q6IX@^'7A;Q65_P"$DT73=1*RO*/M$(;YG0(Y]PR*%(Z$
M``YQ7B_P]^'?C2QL_"\6H3>)-'@\,Z'H"V]A:WPCMY+C[1*M_'-&"1(!#Y>0
M>!U7FMKXAVWCR]^+FC'PAI^LVEAILL8:\34&^PWL#VUSYGG0[@@*3^0.59SD
M$$`&@#T?5O`WAO6K#6=%$%M;2:M`SW9M@J3#S(&MA-_O>6IC!(Z+CM7*^%?@
MQX)@6>WO)+3Q#=S-Y^)#''Y`6,6K&**+:(U81E7V@!F!ST`'F6F^'_'R:)#=
M3V?Q&$ET-)B\3";48OMK@&Y^VBQ=9-RIYKPM@,OR%O+QTJEXH^&GC+5K?0/M
M-IXX;3=+%E=7$=IJ:V][(RZQ*\I8PNH>7[.ZN0#CN.10!]#>(O!'A+XB6$=E
MXET[2M=M=+N3Y<<RK+]EF5=I`(Y5@IP1G.#S4=O\)?!=MJG]HVWAG18KWRVC
M$R6JJ0#&(C@#C)C`3.,[>,XKPKQ/HOQ-34_$PM;;QJ+:6349O"[:1?1P[+YG
MC%NUUEP&@VD$!]R_++N&=M=AHMKXH\(>(=6\8^.+_P`32V-C=:FDNGI<>=;/
M9+'&UN8K<'[YD$@4CYCOP>,``'J*>`?#-M%L31M,CC1K:3`@4`-;*!;M]8U4
M!?0"J^F>"_!]YI$+:/I>CSZ9<VMHD+6\:M%+!;OYEL%(X*HQ++CH3D5Q/Q&\
M)WVM?%?X=^([6W\2RV-C;W\%VEA?/#%#)*L)A-Q"'`9,K(&)!Z`$8Q7G.A?#
M+Q[X,^%^A:;H]UXN\J>UT;^W+$ZBTDUH@,Z74=H5=6BQFV++&P^1#MY)R`>T
M>)?`GP\T2VN-<\5Z9H5E;VOFR37=T`B1M,9`[DDX#,9Y1GJ?,;UJVOPD\$3:
M;]E_X1S1Y+25)!M:W#;A+(DKG)Y):2.-R<YRJG/`KSWQ9\.=:\9_"WP+IVJW
M?B:_U'3?$FFW-Y="=].NO(CN?GDD"2$Y2/G.XMD!OO5QT^D_%E8=4.D#QG%K
M3:=J@U*2YOHY+22X^TQBP-BK,0N(1(>`HP?GRU`'T#IWP\\*Z5#'#IFB:9;Q
MPV\ULJQP`?NIG$DRD]][@,V>I&33O%'P^\+^,[FVN/%NB:9JL]FA2&2Z@#E4
M+*Q3GJI9$.TY&5!Q7B'C3P_\6/"/BJ6#X>2:WJ_AS1E34+1[N_%Q)?O/&MJ]
MF[.2Y\I@]WEN,LHR<8JI=:)\4;3Q#J\>CQ>*O^);X7U/3XKJ75&GAU*ZCMK<
M6-TBN^Q97E$YPJ@@YW$Y%`'T)_8>AZ3<27AM;*UFNKY)Y)MH4R7+((%<G^^4
MVQCVP*HW'A/PG<>(8?M>GZ/)K2W?]LPB2)#.+A8Q`;I<\A@A6/<.Q`KR#_A#
M_%]GXXLK.Z_X3F_TZSN=)GTVY.IK/:&,2K)>_;`[Y:02`D<$A0@3`#"K7Q>\
M-^.[GQAHVJZ-:W=U'!I,EIJMSH+_`&><6KW]H\L<!=]PE,,<A!!!^4X(.*`/
M3K+X4>#=-U.'4;#PYI%O?6F#%-';A3&0'`8?[0$D@!ZX<CH:@F\'^`G6TGFL
M/#ZKX."VEO*0BC3`/+<1$Y^0#$3;3Q]TXZ5X/?Z/\53IUXB1_$%H%M;\^$!!
MJ<8N;>Z^TE;7^T27^=/**,/,+C:'WY;%7=<\&?$BVU_XFO9V6HO9:Y(LVB-I
M\Z1AKP6MFDLDRD_.K+&RQD\*8Y,C+*:`/HG3/#.CZ+%'%I%E:V4<430QK"@0
M*C.7*CV+$GZFN:TKX&?#[0[#4-/TKPIHMK9ZH$%W;I!\DNQRZ$@]"')8$8(/
M->0^+].\;>%/"OB#Q#>:UXGM[O4KF]M'@FU/;;P0G5X4LS$,X@+6KN-ZD':Q
M)(8`C4T*WU?4O@+>6GA_7/&%YJ<.O7,5Q<@RW5V42[8M;+,90YB"`1":-\X&
MX<Y%`'L>F>`M$T;4[>]TNW-K]DT]K"WMXG*PQ1-)YCX0<;V8`ECDG'N<XVE_
M`OX?:)IU_8:5X3T6VL=4""[@CM_DEV.70D=B')8$8(//6O&M+\,>+M%O/%^I
M3>'/'37OBNUT8M`/$LTR6,310QW7ENLH8S1.'X7:S*#AL&L2/P%\3;".#62O
MC>7Q+<>"[>S,RZLSHLD5]*9XW3S=HG:T9=C'.9#G<&R:`/HC5/@[X'UU-'CU
M;PWI-VGA\E]+62'/V1BVXLGH2>2>IR>>372#1-/35Y-46V@74YK9;9[M4`D:
M%69U0M_=#.QQZDU\]:WX6^(D_A>RM?#VI^-9/L%AKUQ;R/*;6X-TGDMIL,C/
M(SRH&\T`NQW@8?C@P>*?"?Q+M=5N=,L=1\9/X7^W/*M[!=O<7JRR6,3J05D1
MV@2Y68>7D+N91C9T`/;K'X5^#=-:Y-CX?TB#[9)')/LMP!(T<QG3Z!929`!P
M&)/4FIM:^&7A+Q#=P7>OZ!I-]/:F0Q2SVZL5\QP[\]P7`;!_B&>M>9Z+X(\8
M:OXAOK_Q+JWBP0R7DEC'`+[[+!+8R:4F9?)1L1R?:]Q#`[E;@':*YCX.>&?%
M_A2^^']E<6/CV:TLM)BL=3M=5OW$&GSK'*9KCS/-87"LZQHL;+\H*LA`R*`/
M>-2\+^&?%.II=:I9Z;J=_I2RV@E8*\ENLJCS(F(Y`92I*GM@XZ5!KW@_P@FC
M(OB"PTJ'3;!H'1YP(TMVB'EPL&R-I4-M!R.&QWKS#7_!GC37_$^I6`N_$>EZ
M'J/B>\D>YTR^%M(+,:5#Y!5U.X+]K0\#DD$'Y2<\WXM\(^-_$6E>*;'7++QC
MJ&J3VEI'I/EWJ#39;806YD\R+>%-QYZSDDKNY4@[:`/>-8^'?AG7=(L])UO2
M;.\TW3T$=M:3*62--NW;C/(V\8.015.+X;^"+G5=7N8="T26_OA)!JCBW5FE
M$J+YB2?[Z;"P_B&"<UY=K,GQ.^S>+K#1-/\`$+:A#?:Q/IM\\\0ADMY&C-K'
M"S/]\(9-F5`1ASBL+5O"OC?[%$GAUOB#I^A7>J74DTEQ<>=JJ'[#;BU=S'*'
M>)98YEVLY).P/E:`/9!\(_A_86]E8#P[HD,!NVEMK<Q`+)/A7)(_C;$*'G.!
M&/2I6^&'@35#JT/]B:+="ZG;^T854./.9UF8LH.$<OMDR`#G#=\UYUX'T7QE
M<?$FSN_&<?B^:6TU.<O<S2PIICV1LV6W980Y\N;<Q#!1G<S[B5VTNO\`@SQM
MK_B;4[%;OQ)I6BZCXGOI6NM-OA;2+:#2X?LY5U.X+]K1N.I((/RDY`/0X?@O
MX,6UL[>\T#3+R/39;A[(36RG[.)YO-=%`&-N_!QZJ#U&:%\'>`[V"\U@6>AS
M6WB%9([JZWJ8;W[1M1P>=C&0JBGNQ`')KC?&7@W6=2\2_"'6;U/$]R=#N&76
M/[-U!HMKR6N!)/&KJ'7S0`W!X)&,$UQ?A+X7^-O"'P]M;73I?$S75T=-DN-/
MGO5FCLW35M\WDH3M0?9F.5'!"C^+.0#W[4O`_A_5[BVN-4TNRN)[*[6\MY7C
M&Z*=4$:R*>H.P!?<`"LCQ?\`!CP1X\OVO?%OAW3M0OY$C0W;(4FQ&2T9WJ0<
MH22IZJ>017F&GWWB[PG\"/B3=:P_B*+5=)L[FXT[6=4F/VB\<6HD,RP,[BW"
MR$KY:G9E"5`!Q53PGX5\=ZKK5G;R7/CFR\)3:]+/&=3U3%X(%L$8"617+B%K
MU6(7=]W(P$.*`/7H_A#X-6XGN;K0K"]O;NV-O=WE['Y\UTAA$+>:[9+LT8",
MQY8=2:O:/\//#'A\VQT71]/LY+.>2X@DCC&Z.62,1O(">=S(`I/H`*\"T?P_
M\1QX(U9==U3QU'K%S%9M?6L=N\N^Z2:3[0+><3AHXI5"+^YV!%V,!DL*[7X,
M0^+E\7:G+XRT_P`3);WVGQ3[]5OB\6GR@JHLHTWLDVT;C]H4*7`^<$G-`'<G
MX0>"9+6*W7P]IBP02SRQ)''L$;38$Q7:1@/@;@.#@<5>LO#GABY9UTNVTMYM
M,U2:Z)A5&:UOW0^9(1VE*RG.>2']Z\,U_P`'_$5M+L9VU+QG$=2U36#JGV*\
M>66UV2R#3'CB21,0B)>4!P[-'O!&<9VJ>#?B/;^(M7DMI?$VG:9J6H7-XE[I
M,`\Y[T6EBL5Q+"DJ[D)CG`C8E-P(88P:`/>O"GPP\.^$?A];>"[.TBN="AM7
MMIH+A%9;H2$M*9```=[,Q(``^8\8J75?ACX3URZGN=5T/3[BYN)5FEF*8D9U
MA\D-N!!!\H^7_N\=*\9U_3_B+JOC_P`23Z?%XL\.Z:^F7]GYUK.U[&[!K86M
MS!`TH179?M!*QA67)RQ;%0:-I?Q&N_$/AR;54\7Z%IUI;V?V2&.YDU`96[E6
MY6[W2@L98?*8&7?Y:-P=ZG(!ZUIWP8\)67C+4_$LFGV][JE_+"\3W,2R"S$=
MJML%BR.`8U.<Y/S-S@XK0T;X5>#?#J!-#\.Z19!+B&X7RK<#;)""(6'IL!(4
M#A<G`&:\Z^)WAOQU>ZSXQU#PK<Z_%'9V.FKHUM9WOEI*KR-_:'EH&`:;R54*
M6(VL05())KSOQ(/'4-W8^&M#U+X@7NJ+H=_=Z,D4OV22*Y6_1+5KMI)&:2!$
M<J3(6WKRRDXH`^A+GX1>";^_EO;KP[I<UU<7?VN9VBXEGW*WF,O1FW(K9(ZJ
M#UJ[K/PZ\+>(M:M]8UW1-+O]3M/+$5W/;JSCRWWID]]K_,N<X/(Q7D/C#PIX
M\N+C7+ZWN_%'V>X\616SVUE?NA&B_9T):W2-U*G[2Q+,I$FQ6`XP*P[S2_BG
M:I<C0KGQ?K6I2^&?)AN[U!I\=E)'$A.V(2M'-/*2X#,`Z/U8K0!]$V/AG2=-
MF:33[*UMY3//<%HXPI\V9MTS_5VY8]ZJ7O@/PWJ.DW.EW^D:=/I]]>->3VSP
M@K)<M)YAFQVDW_-N'.>:\.C\$>.-5L;>PMM9\>P:;#::O<0RO<-:7,-R%M6L
MH7D>1Y)E#FX(+G!R5(V@9Z?X??#R^T_4/BO9:G'XKB?Q%J,D]I<W&K2-"\,M
MM&!]F;>?*<2>8#@*0`HZ`4`>A:9X1\(Z'=V>F:3I^CV=UI]E.+6UB1%>*VF=
M?.(7KM=U7<>[`9.:G@^'WAF"!8;;1=-2%5M%5%@&`+0YMA_VR.-O]WM7SMX/
M^$'B7^S_``7-$/'>BWGAOP2+:6675CY\FHI=0.\,C%V\V$[)-JDE-G8<8]"^
M%FD^,[7XDZO=>,[SQ`$EFU%'MY(S)I\T7VA39O"QD*Q[83MVH@+$MOY4$@'M
M(X%+110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444
M`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`
M4444`<OXX\:?\(C%I\5I9S:IJVM77V32]/B=8S<3>6\ARYX1%2-V9B#@#H20
M*S+WXPZ%X8_LVU^(=Q%X:UB_C#O8S.;A;<%]@=YHP42-FX5W*@GCKQ5SXB^`
M&\=6^ER6.JW6A:OH5\+[2]3M8TD:WEV-&P9'!5T:.1U*GUSP0*Y'7O@+=>)V
MNVUGQCJTK:YIMOIWB`K96Z?VA!#,\J!0%_<G$LJ97/ROZ@&@#:U'X_?#[3;V
M\LM0\26T=Q82F*X003-L97V/R$((1N'()"9&XKD5?C^,'@Y_$UQX?BUN%]8M
M5F,ELL,K<Q+ND16V[6D52&**2VWG&.:YZ7X`Z?+;ZG$VK7X&IZ=KMBY")\B:
MK<+/*P]T*X7U'7-<Q9?LWZE?S:VNM>*=1TRT.JW]UHD>E;$DMFN+9;=;@R[=
MV\)YGR=,MG/3`!W%S^T%\/[/08M9N_$*0V,TT\"F2RN%E$D&/.5H3'YB[`RL
MV5&%.X\<UHWOQ2T5XXX_#]W%JFHW%Y+9V]E$&WS31!6F4<<;$.XD\8*\_,*Y
M?P]^SU8:#-#.=5NKB9)=5E?]PB([7\<22`+S@*(5P,GJ<DU8\+?"*70_B_J_
MBN2?-@VCVUEIUMO!S/M47-R0`-K.D-JG4Y$1/&<4`=;I/Q(\.Z[:ZQ<Z1J'V
MJVT%G6^G2WE\M2F[?L<KB0#:P)0L,@CKQ61J7QH\+6-_8P+K&FM#<P+=3SO.
M46&W:VEN$DSM(;='$S8R"%Y]`9/`?PQ'@K4M?NFU)[R#7)%<:?':I;6ML0TC
M,Z1)\OF.9/G;C=L4D9R3PA_9-\/OX:ET2XU759K22_N[D.VSS$BEM&M88`<?
M<@B*A.YV#.<G(!WEO\;/!-QI4FHC7[>&UAANII3<120/$ELBR3EXW4.NU)$;
M!`)5U(R"*DD^,7@Y=9MM)36XI]1NY(TBM[:"6=CYD:2*QV*0J;)8B7.%'F+D
MC<*Y+5/V<M-\0Z%9Z;X@O]_V?6HM3GGL;"*T-X!"L4T$P&[>DJ+M<GG&`,!1
M46F_LVVNC:?HUKI>OWL$FDZ@UY_:`MD^VN#+$PA6?.Y(_*AC@9>0R#D9P0`>
M@:Q\1O#GAO7].T36]0^Q7^J*QM!+;RB*3"NQ7SMOEAML;G:6!PI.*BL?BEX7
MU'PE<^)[;5%70;0,9;Z:WEA3`Q\RAU!93D;2H(;(VDYKFO$WP17Q1X_MO$U[
MKVH!+*XAN;;37C66&&6.":'Y-W1&$[,RX^9E'..*BLO@3'!\/=6\*SZ[?F+4
M+R*\M9H(8X4TR2%HGA6WAY1(UDA5]G0EGZ`XH`J7?[2'A^\\8>$?#WA"7^U;
MCQ/=3QRR26US$+%(=F]9%\HLDO[Q,)($`!RQ4%<IXL_:8\,>%]:U72I/[1EO
M/#^JZ?8:MNTZ98X1=LJK)&^PB7&]?E7D]L]:UO#?P871/%\?B?4-<O=3U@W5
M]<W3O"D4<[7,5M#M"*/E5([2(#DD\DDYI=8^#,>K^,;O7&UJ\AAO=2TS4I;%
M88ROVBQ*^60Y&0K*H4K^(H`T8?C?X(N#HHAU^W?_`(2"-)+`B"7#*[F-#(=N
M(MT@*#S-N6!4<\4[QU\6M!\#7EOI^H7L/]KW?EFWL2'RX>41J68*53)R%W$;
MBI`R:P+SX!6$WBA=:MKV,2O'%'<P7>GQW,<PBNWN8F`;&QU:610W/53C<H-:
M7B;X2-K_`(LNM;L]>O\`35U2VL[?5+*.WAECNEM9FEAPSJ2AS(ZMCJ#V(!H`
MK>,?VB/!7@D:J-7U"_,^BW%M;WMM!I-R\J&>4Q1NJ^7\\>\$%UR,C&<X!Z#3
M/BCX9U?Q(/#UAJT<FM-'O%NT$B9^02%-S*%\P(P8QYW@<E17`K^S3&6UR:X\
M5:Q<W^KQP)%>SQ))+!Y%^;V(L6SYA$A"<X&Q0,#K70>'/@O!X;\:7/B&"^AN
M'NK^74)(I]/C9TN)81%*T<N<QAB"Y`'\17.WB@"/P[^T#X7U/7?$NCZS?Q:1
MJ/AF[OH[B*X#A'@M2F^82;0G21"4#%AN'J*UH_C9X+ETRUOTUH>3>7ALH8S9
MSB=K@`,8O)*>8&VL'P5'RG=]WFL?6/@+I6MZ+KVF:A>W;P:_=ZE<RD*H:)KP
M+N"G'\!12,]<<U/HGP9ATR_T:]N;^*6YTC49[[=:Z?':BZ>:S^RMY@4DD[>=
MV<]!P`!0!8F^-_P^OM-U)Y]<M;FUL72*XC-I+(9O,9E3RH]A,ZLR.H,8<$JP
MSP:Q?#OQUT'Q!\2=,\&^!!;WEG-HS:C)>Q13)%''O=$BC`BV;@T;APS)M^[R
MP*BAI'[-%KH%KI<>BZVUI/X>N()='O$TR$SP+"9@L4KG_71^5<21X^7^]][)
MK>\'_!7_`(0JYN+W2?$&H2:G=Z:UK-=W%O$^Z5[R>[EGV8"@M)<2#;T`QB@"
M3XD?$KQ+X&U_0K'1_!\6O6OB"]2QMKLZW':;;AHY92K(T;':$A8[L\D@8JKX
M1_:*\)>(+;6QJU_'I%]X>FO%U"VF60B..WNFMRZOL"R98)\J;B#(H(R1GL_%
M7@^'Q5>>';BXN)8&\.:NNIPJ@!$KB":+8V?X<3$\<Y`KB=7_`&?]-U?PG-H4
MVI7@C>>_N(K@1H6AEN;Y+T,`1@^7+&F`>"`0:`.EN?BQX=3P-/XKT^ZEO]-A
MD$"I#`RS/<&01+!Y;A664R,J;6`()&<5F7/QALO"EE#)\5H%\)75Q))Y-OY_
MV\21)@M-NA4E8U#+N9@JJ3R<$$OG^#]EJ'P\U3PIJ%RL*:E<M="\TVT2S>"X
M\Q98YE`R#(DB*VYLDE><UA:I\#]<UMOM>K_$#5)M7ETN[TFXO$TJUC62SN-A
M=%B"X5PT:L'R><Y!'%`&]J_Q[\`Z'?7%GJ/B.V6YMH_,DCB@EFR-@DPI1"';
MRV#[5RVP[L;>:MCXS>"V\16&AIK]H^I:GY7V6-$=DD,L?FQ#S`NP,Z?,H+`M
MV!K&T/X$Z9X?U:SO-.U"^5+#4I;V"!MI`+Z;'8!"<9($<0;/7<3VKBO#W[,=
MYI^HW5E=^([Z#PU93:5+I\5HL:SW$EE8I`DLDFW,;+(N_"\$HO3D4`>BM\=_
M`R:7>:A+K9B@T^^%A<))87"3+<&,R+&(3&)&+("R[5.X#(S6CIOQ7\):Q#;R
MZ9K=K<+=W5K:P;%?,DMS")H%`QD[XB'!Z8R21@XXWP?^SQ:^%KJSNYM=U#4;
MRUUFUU62:2)5,\D%B]FH;J?F1R[-G);)X!Q3[#X*/8?%?P_K\,X_LCP]H'V4
M1%@#=WH+I%,R`<&."290<\^=C`VB@#L]3^)_AK1O$8T+5M1-IJ;6DETL<UK,
MJ/%&A>0K*4\LE44L5#;@`3BN4N?VE_`*2Z4MEJ]W?+J^KC2H&L]+N90MP8?.
M7?A,A&3#*_(8'(R`2(M>^`47B+QI?:_J7B'5)%NDNE@M'16%H+BR^R.J,>B`
M%I`H`^=F))S5^Y^#$?DZ%_9>LW=E=:!=V-S;SBWCDWFVM9+;#J>"'CE?/H<$
M=*`+6G?&GPW=W-O87&H6Z:K>3W,4%K;B2X`\F>6',DBIMC#/"X&_`R"`6Q3-
M"^.W@[5[G1-/EUJSBU?7+>"6"UC\R5-TT0EC3SM@3<R'*AMI8#@5G>%O@9_P
MAFN7U_X?\1ZC!#K+2'5;5[:*1;D&ZN+A0K$93!NI$.,Y4#H>:Y/P]^S->V.H
MW=E>^)+ZW\-V<VER:=':+&MQ<26>GQV\<TDFW,;+(N_:O!V+TY!`.NO_`-I'
MP/97FG6R:AJ-Q-J6L_V.D<6CW1>"Z\KS0LJF,,BE,$,1@@Y&0"1JR?'3P-;C
M4A-XA@+Z2XCN`MO*QD8R>5B$!,SGS/D_=;_FXZURWA_]G,>'8X)K7Q1J,FJ0
M:W::M]MDMHV\R2"S-GM=#G=OB9BS9SO.1CI4=M^S58Z=I5UIVG:A9"U<R+:-
M=:)#<36L;7'GA!*QW'8V-I&T@JK9)&:`.Q\3?%KPSH6L^%-%U=[]KCQNS)I@
M33)I8W`3<?-(0^6,$#YL8SS@`D8GP^_:(\*^./#%UJ:W,UM<Z7;+-J5A'9SS
MR6RF5X@5"QYE!>-ES&&&01U!K9N?AA))'X&DAU_4C?\`@EAMO+I5N)-14VY@
ME\XG^)U).X<@\UAGX"PVWA73=&TG7]3LCID4$2W*(N9TCN6G\N51C=&Q8JRY
M&10!I^&?CMX3\8>,8?#?AR^N[V]N=(BU:"=-/F%O+;2%@I$I4*&^1LJ<<\=0
M0-:U^+/A.^O)[:UU=)'M]3CTMG%O*(VNW9D6))-NQVW*RG:2%((.#6!X!^"<
M7PZU/2;G1=:O98=/T&/1Y[>>",K=1QS2S1R$@`HP:>3..",>E9EU^S\T^H7]
M[;>);NPFN-5MM3M8;2PBCMK:XAGEE\TP\J\CB78[\%@BD\Y)`-2_^/?AK2?B
M);^&-5NA;)?Z=;75E>F.1HYI);F:W\IL*1'AX@-SD`EP.M:,WQQ\$P:;/?MK
M6ZT@O39"2.RN)//F`8D0A4)F`"L2T890%.3P:Y;5?V=5U6:'SO%6K"WETZVL
M-6C^S0;M1B@O)+I<MM_=,7E=25'W3P`>:A;]FNWDO1>R:[)]H@U'[;:6Z:=&
MEE;;HI(ID6V!VYE$I9V!!+*I]<@';0_&3P7<ZY;Z1:^(+.>_NHDE@2(.Z2!X
MO-4"0#86,7[S;NW;2&QCFI;WXL^$[#0K?6+C5XSI]Y;VUQ;/%!)*]Q'<!C"8
MXU4NY<(Y"JI/RGBN0TSX%W'AS4;0Z)K;_P!COJ4-[>Z4+.&&%95L_LK/$57<
MBE4C(C!`!!P<<55MOV;HTT/1K&]\2WU_-X<-@ND3SV4(6VCM$FC5&10-^^.>
M16).<G(Q0!U]W\;O`]E<:/!/X@M3)K\4,NGB..2031S.4B8E5(0,X*`MCYOE
MZ\53\+?&GP;XM\):CXNLKR>VTC2KF:TN;F_T^:U='CE*%55U#."P&`N<D@8W
M<"/2O@M9Z9=+<+>X<:38::8K:SCMX0MI=R7*.D:\*2TA7`X`&1S4%Q\$(KWP
M#JWA*]UF[FLKW5I=3L9V@C\RPE:[-VH'&)`LQ)^;J.#ZT`;=M\9_!EUI\M[%
MKL`MX;)[V7S(9(WCB27R7+(RA@RR80H1N!(!'(ID7QL\$2KJ[KX@M%CT--]]
M))')&B)YGEEU9E`D42?(60L`W!(-<[J'[/>FZLOAPWMZL,N@:O+J#C3[)+6.
M_CDE69[>9!G*&6.%RV=Q:(9/)S3L/V:].L=!O]&BU(+874?E6[KI\8N;:+[6
MMRL?G=74%0H!`R,$Y(S0!IM^TM\/QJNDV@UFX":O:WEQ'<OIMPD,*VKA)Q,[
M(/**MG(?&,<XRN>NB^(FA3>$3XFBGO&T<*6\P:;<>:1NV\0>7YIY]$]^E<UX
MD^#0US5H[^SU=K.15U**:&:PBNH+B*^\KS8WC<8(!AC/O\P.<U&OP9GC\`VO
MAN/Q/JP:UU7[>MW@8*><9!:&//\`Q[`$((]W"J.>*`-*\^.G@6PL]$NKKQ#;
M+;^(H8Y]-=896\Z)W"+(0%)1=[*I9\`$@'!(J?3?BOH6N>.?^$8T*^AOKZ!;
MC[8JAU\DPE58*2NV3#,5;:3M88.#Q6#H'P#T[P_I^F6EOJ5[,FF>&FT&-I(T
M^:,SI-YAP/O;D`P.,5H^"_A,W@[7$NH]>O[S3;6:_EL--FMX@MJ;R;SI1Y@7
M>X#[MN3P#@YP#0!Z%1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%
M%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`44
M44`%%%%`!1110`4444`>?_%GQ[>^"AX>MM&;1[>]\1:F;**[UF9H[.VVP2S$
MR%<$EA%L49'+#TP?-M,^-GBE)/#.E:)I^F:E+/H]GJ-_-<WV[[2ES=/"?L\I
M9%*Q;=Q<@[@44`%A7O\`J.EV>KVQM]6M+:]MRP8Q7$*R(2#D'#`C(-8SP^&=
M6\0-I$UCI=UJ>B6\-P(9+1&:TBD9O+9<K\H+0MC'=/I0!X<W[3'B'4I(++0M
M&TV&_%[#HFH2W1D>&QU?9<23PD!E+`)!'M&X$F=3GC!6X^-7B6U\?V=F&TK2
MK[Q5HVCB*WU>],NGZ5<21ZA+,2T;#>SBW5%VL`QV\\<^_P"H:-HQL;S^T]/T
MU[263[3=B>"/8[J!^\?(P2`H^8],#GBH+O1-`-C#:WFFZ.UK<"."&"6WBV2!
M,M&BJ1@X^8J!TY(H`\$MOVH-:U`:1=6MAX;@M98M+DO+66_D:>]^V7\UG_H6
M``P7R?.!93E&`P/O4+^TAXO:UO\`46TGPR--T^P;5Y$\^?SC91WTEI)&/X?.
M8Q,ZM]T9"D'[U>Y6OP^T"W\3OXA33+4ZFUI;VL4C1J1;Q0&3RQ$,8CQYSC*X
MR,#L*UO[#TWRVC_L^RV/&8V7[.N&0L6*D8Z;B3CU.:`/!T_:)\2C1?%NNRZ!
MIHTK1K6^ELXVN3'-'+:W0MS#.-Q)+@E\J@"8P=V0:FN/B=\1+'X@^&-&U>;P
M7:Q2SZM#J4,8E5;XVZ6\D(AD=QY3%)\8;<,AB<C@>T76@Z%8B_U&XTO3(VEB
M=KVX^QINE3[S;R!EA\H/.>@IUQ:Z/J5A'?ZA:Z?-;1C[6DUS"A6/*?ZW+#Y3
MMZGTH`\KT3XTZM=?"77O%&I6VF3ZMX9N0=8TVS\Q5L8@(I9HR^YA(Z02,X=&
M*-A>F2!Q]M^TKJWB[3+@V.EPV<5E>VTEQ*ES(C-9W6HVL>G2HPX_?6\KR,.1
M\A7O7T5IFCZ;I^GFUTK3[&TLI<DP6\")&VX<_*!@Y%9FKWGAKPY;7-QJ2:5;
M0I):6]RWE(2K-(J6RN`,_?=0N>F>,4`>.?`KQUK-])XDN-?U+4-7BTOPY;WB
M0M)O8N+W4U;:/[S)!&O_``!?2JFN?M':UH_PPMO$2W_@BXUC5+)]5T[3;7[1
M<*;2.V$\D,K!QME4%1O)`.3A#C%?0]GIUK9%FL[2WMF90K&*)5)`)(!P.F68
M_5CZU1/@[0&A$)T/1S$)C.(_L,>WS3P7QM^][]:`/,Q\<;B2\UVRM[?29-3T
M[4S:V6GMJ"PRW4?]DK>AF+'Y?WC!-Y&T+R:Y&#]H[Q/>2:;9:1INAZEJD5O/
M<:NF7M8RT5PL,MI$TDFU98]P+R%G3E,`AN/:/%MSX6\*QKJ7B2QLA+J4L=@K
M)IWGSW3."JQ!54N_R[N,'"AB>`:TG\'Z#):V]M)HFD-;VC,UO$UC&4A+'+%1
MMPI)`)QUQ0!XK\9?B#XOT7Q3XWT?3=8T:QT6S^'=SJUF@C>._%T//7?')NQ\
MK1J2-IP,=^:AU+XT>/?#UGIVD7^F>&[OQ'>W,R0W<+S"TDBBLH+D(0[J1,_F
MLHRV,1L^,#;7O=YHNG:A.D]_865S-'&\:230*[*CC#*"1D`C@CO3+_P_I>JP
M>1JFFV%Y`7#^7<6R2+N"[0V"",A>,^G%`'E'C?QK+>>(/!>C^)-;F\$:3XAT
M>YO[BZ@OHXG>[C\@K:+<G*#"R2.<??$?'`.<RX^/%_I_BU-,T^XT#5='L]<L
M=`<S71_M*^DN+=)1>QA/W9B`<G`7YA'(P9=N*]?\0:?H,]E8V'B/3].NK&2X
MCAM;>YM%EB$N"$`4@@'&0#VJ%1X;?Q@+%+73/^$AL]/2X7_15\Z*U9GC4AL9
M"Y5UP#Z\<T`>)>'?V@O%VIVUIJ6H:9X9CTMH="OKE(9YVG%IJL[6\4:9^4RQ
MNN]F/RL#M`!&:ATC]IS5KUY(]4;PI9MJMD9=&\AI[IK6X%\+1(;M%89,K'<A
M!0#:P)XW5]##1;!(]D5C9H@6-=HMUQMC.8QC'13R/0]*XKPKHW@/P]X7O=/T
M.STZ;2K34&L-0,MMYS/<B;[DI*DN1))P3D#/I0!YSX?_`&@/%GB>UT&?3-+\
M/1A]&M-4UGSIILF.6_DM'6W`/!`B,@+$_P!WG.X=1X'^(FM?$GQ1>Z/)';Z7
M+X,93KYMY&8&^$TJK;*2>(VA19B3DXFCKU2#1["!%$%C:1*(A$%2!5`0'<%X
M'0$DX]:IZ#X2TWPW=:S<Z9"1<:_?&^U"5VW--*45!DGL$C10.@"XH`\N\-_&
M'Q#K/P^\6ZO]ATF?Q+X9;S)M"M#(_DIY:S"%I0S++(8B2KQG:<KP.17&ZG^T
MQJ;W=GK/AVRM;G1]:AN(]"G>Y?R'@^WVMI'=SKD`J6DD8$$?+L&?F)KZ)T73
M]*TV*XM_#]GI]G''+B>*SB2,+)M!PP4<-M*]><$>U0KI.B3(VFC3M+=(8!$]
MIY$9$<+G.TICA"5SC&"5]J`/#/%'[2'B3P7IFBKK?AJRDUC6[>1K2WM[LNMP
M]K=,M[@*6VA;0"X5<LP.5;E>=KPE\<M6\0^,M`MM1@T?3?#?B9I3H]R7DFGU
M(%K@P*H#?NF,,`FRZ;6#X4@KS['!H&F6UO#!;:=8106^_P`F*.V15CWYW[0!
M@;LG..N3FF0^&])M[NWNK?2].BNK2$0V\Z6J*\,8!`16`RJ@$C`XYH`\,E^,
MGC'1_$7BO3=2O_!DKCQI!H&B&9)85T]);1;A9;OY\NI'R+C;ND;&0,8UQ\<=
M3O?AMX<UFTBT"TU3Q)XADT.*ZN+F1]-B>.2=/M&X;6:-_L_R#(R94&[O7K.H
MZ#HTRWL^I:;IDHNT7[9)/;1GS5CY7S"1R%QD9Z5)_9&EW^C1636-A/I;1H([
M8PH\!08*X7&W`P",<=,4`>&:-\2_%>G_`!(\1S:E?Z!>^$8;S3H[YHYYG-KY
MFEB9Y;0C@Q;E#8();>Q&,?-7\/\`[0?B?Q-$]IHL'AFXU&]\26NEZ9>ND\5J
M\%SISWL<TD>XOD!-N-PSD'Y:]\ELM-TVVDE>VLK>!%#2N8T155%P"3T`51C)
MZ`4VQ\.Z3IL21Z9IFG6D<<GFHL%JD85\$;@`.#@D9]":`/!HOV@?%]WXHTRQ
MM-(T-HH;.VN-9M4>:6=Q)927,AMGRJ</&L2HP9CO#=.!V?P8^*.M>/[!KKQ7
M::/80WD-K<Z7-9W0Q.LZ,_DE"[,70(<MP&R<*-IKH+OX.^'+WQ9'X@N8)FNH
M[NWO!;B7$`N($,<,H3'#*IQP0#@9!KI++POHVFR>9IVD:9:OY@EW0VD:'>`0
M&R!UPS#/^T?6@#PWQC\0/%6D^)O'EIIEQ-]AL?%/ANSAN#<H/L<5S]C$T:H1
MDA_,?/\`OG'2J:_M.ZO"HU&XL/#]UI-U97NI&WM+N3[9I-E97<4-R;I3D;_+
MDD<8V@-$R\]:^B9-,LY6E,MK;.9W224M$IWLF-C'CDC`P3TP*KP^'M*MY[R:
M#3-/CFU$$7DB6R*UP#G(D(&6ZGKGJ:`/GJR_:FUK4?#^JZC;>'K2)]&MQ-=)
M+*^Q([JZB339BW`\M[>0SR')QL(!'6M=?CUXITV_TG1O$>BZ5#K7B2Y6RT1H
M)6:*[GCN_+N"RAV**MLRW`0L6`5P>F:]FCMM%N;[4=.2RLFG>"(7\7V48DB(
M98U?Y<,,!@!S@<<4^RT?1;65+73]/TR%M.?SXXH8(U-NT@8;PH'REAN&>,\^
M]`'A5E^T-XLO]+O]3AT'2([.>[AM=+$URR/;3/J*67E7*[BS,#)YA*JH7:4.
M20:]7\5^)]4\+^`-4U:&.PU?6-#L_/O;>V=EB9XU#S*HR67Y-Q4$YY7/7-:^
MEZ7X?U&2XU'3=,TQI+B=UFN5LE5Y9(Y/FW$J"2)$SD]P".QJG+-X<\!6&O7M
MQ]CL+<F75=7<MN8AAAYY!RQ&(]OIA,#@8H`^>/$7[2VO>-O!7B,>#+:#3)+-
M)+ZTU$3R#S-.:>W&G7"D#_EX\Q\XSA8WP,]-?XG?%#Q=IVCQVFKSVFEZW'%J
MB2W.CW4J0?Z->:>L<BH^3EH[C!#$[?F`SFOHF/0M+*$QZ=8!98(X6Q;)\T2<
MQH>.57)P.@SQ67K^J^'M,U?2M-UJ""6_UR62.RA%D9WDQM:1CM4[4&(]SMA0
M2F3DB@#@_A[\6?$/C?QQJEA/I5A:Z%#<ZC:P3"?;<6TUI.(L3*7R_F`EP%4;
M!MR3N!KS>R^)WQ-UBU\)3VNK^$;O79=?\16LEM&D\-K)#:).$CG0.6WYB!4\
M8!!.3G/TFVEZ-INJ?VA]BTRUO[MO+-YY,:2S,V!MWXRQ.T<9YP/2IX="TVVF
M>:WT^QBFEE:9Y$MT5FD889R0.6(X)ZD4`>0>%OC5XB\4_$,:5!HNGQ:-!<06
MEZ6N-MS"\MBMT)U+,`T>6\L($+'!;(`(%:_^(42>,O&]SXC\57FDW?@>Z`TW
MPY!=Q0?VA;?9(Y@[1N"9S,[2(I'W=N%P037LI\.Z4=0BOSIFGF^@4+%=&V3S
M44`@`/C(`!(Z]":BU#1]&DU6SU#4+#3)=3C/E6=U/!&9E.&;9&Y&X<;C@'U/
MK0!X18?M#>)[U[;3[6'P=?ZGJPT>6QN[&ZFDM+==1:=4BG&=QDC$(?Y2-X8<
M)UJ"W_:3\2C1;.]U/3/#<#:[IMG>:5B[E$=OYM_'92?:'/4!IDD&W'`93T#'
MW'PE%X:U?1+;4?"-EI7]F7SBZ@EM;5(TD<<"3&T?,,8SC/%5/'/A;PM?>'=O
MBRVL+?2+"2"X=WVPI&(9DF12?[GF(I*]&Z8YH`\:@_:9U65M"ME/ANYU(Z\-
M-UB"U$[QSV[:E]@2[M92VU5+*[!6WGY2.GS5LVOQM\7?8;_6[S2_#Q\/6S7<
MJB*>7[3%;6.HBUNY)"?E)\O=,N,8V;3G.:]0\+_\(EXNTRPU/PS:Z->VEEF.
MRFAM$'V;!R44%08R#@XP*T]9\+:;KF@W^D7,`AL]2MIK:;[-B)O+FSYFUAR"
MV221WYH`\ZD^+.L3_"2P\7Z=8Z>)]>U:WMM(BGDD6(VUU>K;VLTA'S<QR1RD
M#UP*Y.U_:&UVRM;>;Q;'X:TZ/6+74(=,FMUN9PM]9W\=B1(F03'+)*A0*05Z
M,W<>]6FBV5EIEKI\%K;K9621I;P>6-D2QX\L*.@V[5QZ8%-N/#^EW<!@N]-L
M)H2KJ8Y+9&7#L&<8(Q\S`$^I&30!X/H/[17B"_LO#<-]I6DC5?&$QL]'\F23
MRIKJ"_DM[S*Y)"I`@N!R>-PR<9/T,ARHQD_6L*7P-HTVM:+J9LHDF\/+.--C
MC4)%;F90KLJ#C=M!4'L&8=S6_0`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`'E_QW\$ZOXYTK1+31$>[LK;54EUC3EE
M6/[9;&*10/F95;9(R2;2P!V=<@5YAXA^"/B[4KW2W5+V^TJ/2]'L]5L[V_B>
MZU!;=;T2"5@RHY1[B"3&X*^TXY'/OGC+QYI7@6&RDUV2XW:E<BUL[>UM9+F>
MYE*LVV.*,%F(568X'`4D]*Y^Y^/'@RQUR\TK4-7%I<V"W'VB6>TF2!'@3S)H
MO.*[#*L?SF,$MMYQ0!Y'=_`C7==T/Q/I7BK19]>N=5\/"PT;5]4UW=)8I]A$
M7V>9$.&;[2F\LH*MYFXG*8KI_%_P9'B#P!\,K:/PA;N_@S6+:[FT234%!@B$
M4L<@27=M8AG1^3R%(Z\5V@^//A(Z4EZMSJ+O)>-9BQ32+DWHE5!(P-L$\U0(
MV60DKC:RG/(KC_$G[3$6E>-&T'3M/6=+&'4[O4;YX+MH(8+.-"5,B0D(Y,BE
MLY50`,EF4$`@^&GPS\6Z!\1[75M<M3;"(:K_`&YJHUAIUUXRS@V9$'\/EQY^
M\%V_=7(-8?C3P[XZT/X?>-HY=/NU2SBURXL+VTU0R37375['-;K'&HWH5CW+
MD\J1@#'->N6/QCT'46U)+#^T[Y](MS+=&QTFYN(V*E0\<4BQ[99%+`%$R1W`
MP<<?KG[3&FV5YILNBV9U'1=0M+&Z^V'S(I$2>]>UD!B*[MR%"=IY)!6@#@I?
M@EXO/VI%\.,?#=Q<:BVE^&T\4O&VCS216RP7/FY(/SQ7+[5+;/M&0#SA_C'X
M%^+O'&O>(%U71]*AL;WPSJ.D+)'>E4OM]M`+(S`.6++,DA/RJJ\$;LFO?M)^
M)/AW6H;^:PU."2WTW3K?4;JX(*QQ6T\;21N6/'**6QU`P2!D5R$?[0OAZ=VN
M4N([;24O(+:2ZU&*>S:/S+>><L4>,$#RX`X)PI5LYZ`@'#:'\'O$%GXX\.Z@
MVFZAIFE:5;Z8-.MK/4H6_L@1%A=6[$O\T<F0[%`Q<-MR-HI?''[/]SK/BKXD
M7&G>'[5U\:R:+*NI"_\`*+QV]Q`US$ZY#*Q6)F##C@`$&O4;?XT^&[O^QEA?
M5O-U[YK2`Z+="41;P@GD39F.$LR@2/A3G@UG^%/CEI>MV/AL:U;W>F:AXGDN
M(;)1:32VS2Q23+Y?V@)L#LL#L%)!P/S`/-_$7P*UZ'4]+M=$34G\.:4MY_9E
MM9:FJSZ7,U[YT4T;3.!S&VP'YB@3:!AJI:A\&/&5X^H6QTV630KKQ"E]?1W6
MH1R7VKQNEP'\UA((W2)G@:-3L8A<,"47/IMG^T?X/>UTW[;?N+S4+2"<06=C
M<W2EIHO,BB5EC^:1T#%$(#,$;`X-=!X=^+WAOQ;JMOI_AJ[GU*:YL8[WS+>R
MF:*WCD&4$TFW;$[`'".0W!XXH`XOQ5\&Y/%WAKX5VVM6<NJ7'A'5;>YO7U2[
M#SI&MI*CLSQD+(_F&+..N"1Q7`Z=\$O'AT^6!K1]-N;C3[:WU^Z7Q$\G]O78
MU&"26Z4`_N_]&BFY.UOW^P#"U[EK'Q;\/>'_`!%=:-KL]W87=GITVHR27%A,
MD#VT*JTSQS%=CE%=2P4DC-4--^//@[5(Y7BU.6V6".[EE^VV$UL52VCCEF;$
MB@X$4T<@_O*V1GF@#R?Q3\$?']OXGO4^'VH+9>&+)FAT>V&I.&2"_B6&^5E)
MX\CRTEB^8\NP`&!3+_X.^.KG6O&-QH]A;:,+_0[G3+&2SU(Q_:MMS!]CD+;R
MWF"WB?<Q"[6<A1@YKV;Q)\9O"WA&&PEU^\N;==0LQ?+LL)Y3;6O&9YPB'R8P
M2`6?`!R.QQQTO[3&E1VOC>%K65=8\*'5#:P/#*MOJ*6<8D(2X*>7O*,K%`20
M.<8!H`R['X.ZKH_Q.CN=.T;&DV6JP2Z3J::TX6QT];78UH;9B=Y$X:3G(/F!
MMV5Q4WQ*^%GB_6O$=Q?Z>8M9MY-'TVSO4%R+%]2BBU"2:XMAM^X&A<#.0#R"
M1DUT>K?M%>&/#*ZD?%$TT#:=,%EAL;.XO988_(@E:258X_D0&YC4MROS+SDX
M$_C?]H/PSX`36UUR#Q`UUH5FMY/;0:+<,TT)=$+PDJ%D56D0,5.%W#-`'C]]
M\$?'DNG7<"Z6\]M+:WR>%[(>)70^%+B2Y)MY2^?G"Q,I^0L4\LHH(;-:]K\&
M?'=EK/BR6:2&\CUGQ!!?Z5*FH&%K")=0MY;@%!@'SXHRV>6!38?E(KT>7]H/
MPQI[7G]LS75O]FN3&((M.N9KB.);>":26>$1;H51;A-Q(PN1DY)`UA\9_"LG
MBJQ\/0:BT^H:B8A`8+662'=+"9XE:8+Y:EX@S*"1N"G'2@#QCQO\+M:\,>#O
M$>NLMVNKZK/>PZC*FH32K+:2ZM"]J'0'_5I;%U8*!A"RYY)JSIG@"YUOX!1Z
M)X1T?6&DMO$5Y<I9RW:16]]B69E#;W!DLBS(J@,'VJA'*\^EW/[07ABP\1^(
M]$U"+7K>\\-7$%M,3HMPZ7<TR!TCMBJDRN0<[5&2`6'`)K=_X6KX</@Q/%4>
MH>;HTDGE))';R-*\WF>5Y`A"^89?,!39MW;N,4`>(K\$]?TJW\9P:=X)T.5_
M&.M65WJ,R:AO66V^R1B5(D>12'2YC9@7."KD\D`5G6W[/GBO2[#5)[/2X/\`
MA)]4\%:-I\VLQZK^\EN+5S]KMF)(/[Z,(@D'`QSCOZ];_M$>$X-*AO\`6KR:
MWAN9;ID,5C<2_9[6&9HC<7`"9@0,I!,FT`@CL<=5J_Q'T+1O$5CH=U=R/J-_
M:F[6."VDF6&W!(\Z9U!6*,D$!W(!((SQ0!X/JOP'\3WNBK:Z,FJ6D>GZ?>G2
M8+G6%A:RO'O(7@,?DN0J+#]H"99BNXC/-)XG^`_B@ZM=6FF1WS^$8+Z_ET>Q
ML=359[!Y8K5XKF-IG`#B9+H#<6V&3<`0<5[?X+^*OA[X@7-U;^&;N:6XM88[
MAH;FRFMFD@D+".>,2*N^)BK!77(.TUS_`(H^)?BW0?B3I7ANS\+:/=:?K,%S
M<V^H2:XT4BPVPA\XM#Y!^;,PV@/S@Y*T`<CK_P`![WQ3JGBR^UN![FXU>YO+
M:S:?4Y"ATZ;2UB$3H#M`^U@N0!G/S55^'_PHUWPKXB\`7-IX:_L^TT;1XM/O
MX;K4XY[?3PL<WFR6H1]_FO(R;MP965A]TK75^#/VE_"_BGP3:Z[=&_L;E[>S
M:;3O[,N7F>6Y1FC2W7RPUP&,<@#("#Y;'M70VWQN\(WLUNEEJ9N$GTLZH\\5
MK*T-I:X?]Y<2!=L.?+D`#D$E&'44`>._$?X(^+/B)XK\9SZAH^E0Z?J^A:MI
MD+)>E8]0WI;_`-GM*-Y;<KQR$DJH4D8W`FNM^('P[U;5?AGX6TSPGX;DAN=#
M=98="DU*,60=8F"1W3;P9(PQ!!C;<I`(SC%=+J_Q[T"U^'/BGQ=HT>HZE#X5
MMGEN[#^SYH;D-Y8=`8G0.%=65@Q7&T[N@-1^&/CQH=^FD6/B&Y:SUR_CA6=$
MTVZCMH;F1/,2V,DD8"3%"&$;X8@CCD4`>8:E\'?B!<7FMSZ=;&SUJZAUU;G7
M8]??;JJ3HXT^$19S'Y1D3E@`GD94G?5N_P#@%XGT]+Z3P+.^C:E_:]U'IEX=
M5ED%IILVEE&4*S$<WQ\PC&[/S`UZ7;_M#>!KBP>].M?9[51;,DUS9S0K,ES-
MY$$D991YB-)\H9<CJ>G-:-]\8_#>GBS>>XO6MKW59-)CO(M.GDMTNTF$!1Y5
M4J@,QV!F(!.<'B@#S&S\&:YX#^`WQ%A@M-;TW4+G2)KBSM%NTG\FX%F`QMO*
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MU"]9H3#Y5K_9-RMS=K-N\EX(#'OF1_+?:R`@[&.>#46D_'O0=<\:0:-IDR7%
MKJ.EVUWIUQ&KF6XFDN;B"2(P[=R^6;<ER<;?FW8Q0!P6F?`_Q+>:^U]XG,LO
M]FR?:-'9-7D'D7']M75R7P&QS:20H<Y&,IZU9^+'P1O/$_CKQEK>@Z#:75SX
MG\`R:+;ZB;T1/!=`W`PRD_==)8E#`'&TYQU/:Z-^T#X5U&31[2XO@FH:QY>Q
M;>VGF@B,K.(M\WEA4#F-PN_;DJ0.E:GA#XT>%?&TFL+HE[=>7H=I'>7=Q=6$
MUK#]FD#F.9))%"O&PC=@RD@@9Z4`>2^+_P!G_58K>STSPG;WO_"+QWMU/)I5
MOJ69(Y);.!8[B-II`,I/',0I;AIMX!QBNTU_X1G7OB+X&\27=DMQ<>&_#U]9
MRWMU<DW$=Q(+?R2=IPYRLY+`8R?<8T;/]H3PWJ'B#P[I-C:>)YI/%%K<W6GW
M(\/W*PM%"4RY8H/E8.I5@"""#GYES'%^T;X5N=:T/3+2#Q'-<ZYJ%QIZC^PK
ME/L<\,:R.MP&0&+Y'5LD?=.XX&2`#S*_^#'B?Q9X*\)VGC7PK;W]UX1?01]E
MEUM9&O/LAF%U*K9"J6$BD;CE@.<'BM=OAWX_O/!^KZ"+(V<B_P!I+:WZZWEK
MH7&JQW";=OS1A;<,N200<J!C!/H=M\?O!EW8:C?0ZI*+73!"SL]C.AG2>0QP
MR0J4!ECDD!170$,P(%1VG[0G@B\@GECU6>..VM3<,9].N(MX640O'&&0&25)
M66-HURRLRJ1DT`<3I7PGU7P?\4[G7(K74Y-$TR</I+V%TA$>GBRV&R>-F,C*
M)E+!54[F96SP16_\3O`4WQ,@^&NOW?A;[7=:#K$6I76EW=VL4UI');2*Z[@V
MUG21HF(SSY9QZ'6F_:%\%06UC-+J-TIOW9%B_LRX,EN4F$,AG0)NA"2E48N!
MM+#/6H-(_:+\*ZO'<E8?$%M-!KDVBQ6LVB7'G7=Q"S"0PH%)=%",S$#Y0/FQ
M0!Y=IW[.NO\`AOX?06.A0-#J%]%8GQ!91ZFS1ZEY5Y(\L8W.%4M%)C(*A@H0
MX%=Q?_#K7X?A'H6F:)!<7>J^&M9M]2ATW5[N/_3(H+II%M6D3**-A'E\D*4C
M!)P37?ZU\1]*T;Q!#H#///K=Q9/>);06DLHBA&X"29U4K$C,C*&<@$@@=*XW
MP;^TOX6\4>";/7;@ZA:7,L%F9=-73+EYVFN8C(B0)Y8:=3MDPR`@B-CT%`''
M?$?P/X^^(U_+J+>%_P"S[B;11;:+&/$HC?0-1$S9OG,6%<F-T/R;V`@VX^<U
M!JWP!\0ZUJ6MWFHK+--J:^('WC694WR/-&^DG:&``C_>D#&$+9/)KV+1?B[X
M7\0@'2-32Y!M8+HD0R+MCFN'MTR"`0WG12(5/*E3D"N5T[]HG2;JPM8[J(P:
MW=:D]F+-(Y98X@-0DLT:295V1F3RG9%8@L00,]:`/+]-\$^/M3\8:UJ^DZ3Y
MNO:-J=U')J6IZO)';WT1TJ-18B%2,Q-=R>87`"@JQ!SQ6CH/[/\`K]YI%KH_
MB:S:#P^VM:I=R:;%JAC$4,ME&ENH$;G&+E7<*&(4D-UKVOQK\6/#G@#4K.P\
M1WDT-W?*KQQQ6<L^R,R"/S7**0D8=E4NV`"P]:YWQ5^TGX+\)6NMS7MQJ=VV
MAQ7#O'9Z7/)]K-N<3I;OM"2M&?O[6^7!)P`<`'->#?"/B"#XU?V=?2WDGAS0
M].BUN21YW93JMS`+9H,GAE5899N"1NGSQW]X`P`.N*\X\:?&BS\':7X0U6?3
M]4FT[Q3?BUV+ITYNX0;::93]F"&0MF(*5V@C=GM5JR^.'A#4=7TK3;'5?M$^
ML1PO;316LI@S-'YD,;R[=B2.F2L;$,<=*`.^HI`<@'UI:`"BBB@`HHHH`***
M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH
M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@#COB=\.HOB9H(TF[O
MI].A+,QFM[>&252490T;2*3%(N[*R)A@>_4'SL?LTQ:]<>(4\=:M?WFDZAJF
MH75AIMO(@CB^TVRV_G.Q3>TH3?P25!;.#7=?%7Q9K/AF#P];>%/L"7_B+7(=
M+2>^B>6*W#Q32&0HK*6(\KIN&<]17BNO?&?Q?XG\#^/6NAINEP6FGWXMA9W"
MP7^GSVMVL(5E$K.V]3O+;$"?*OS;@:`/3[;X&1VYTN\L/$%]8ZQI,TTD&HV6
MGVENSI-`D,J21K'L?<(T?<1N#*,':-M.F^`ND3W6OR-J&K;_`!#9:K:7)WH=
MJZ@(/.9?E^\/LZ;<^K9SQ7GFE?'3Q8?%\FB:3::2L%IJ]R9O[3N]C7T!U::T
M989)9EV&)$5L!9,ET0*H(KJ/AA\3M3^('Q%A:_OM"6V%MJRII%HTBWE@8+N*
M`+=*6()(7<#A<;B`".:`-0_`*&+1+W1;'Q+XAM]&N-0&H06(\ET@F,R3R`Y3
M,D;NK9C<E<2N.F,-TG]F_0=(_L40WNJN-#2U6$$Q@2""^:]!8!0.9'((&!MP
M!BN?U7]HN[T[PSXEO(CH<VK>'O[<>6P,A!2.RO4@A,@!+*&1MQ)Z\$<5S\_[
M1_B2";4=,DU?P)')I#ZE*/$,D,PT_4TM(;:7[/"/-XE_TAT8B1\>0Q"DY``/
M1_AO\$;;PW\/O$WAOQ&S7*>*[N^:\6*8GRK6;,<-NCX!VQVXC0''&*4_`J.Y
ML[2/6/$NNZI=V-U!<0W=W#;,08;::WC4H(PC+MG9F#`[F'/!(K'\#_%CQ?XP
M\66KW%KHNG:#]MM["[L9(I3>QS3:7'?!@Y(7"LYB*E<G!.0>*R_$WQ^UNS^)
M.LZ'X2.AZG:V6G:DJ6]^GV$V]_:1P/M>=I<&-O/'S&-%X&'/)`!T_A;X!P>#
MM7MM3T'Q'KUM=*LL5T$2`13V[SB<0+%LVPHC;@HC`P)''<$4]&_9GT;1/$>D
MZK!J^MSC1KI;JVMY_*=$E`N!\K;=R(1=2$HI`)"D\CE3\6]8N_A3H6M:#<Z5
M?:QJVNP:(]S-8206\4[W1MG?RA(Q(1@?NR%6V\-@@US<'QY\803>,;B^M-`>
MS\,V.L`VY=8+B.XL%!1F0S,[),#OP(UV*R?,V[-`'8^&_P!GK1?#,FDM97VJ
MR'1[O3[J'S63YGL[.2UC#87H4E8MCN!C`XJ;PG\!M/\`"?B31]4L]6U)UT2.
MX6"#R88S,)BY832(@>5`9&948D*V".E</X;^./C#Q'K5MH.GW7A*_N+O6TM$
MUFRMI9+41-IYO6C5!)\TJ;3$3OQ\ZL0""M95K^T5XXOO"EYK7D>$[*UE$4ZM
M-<1>=I4>^99XGMS<AKB6,0],Q$GS`%)3!`/0=6_9STC6O$FOZO?ZMK,LFNVN
MHVI1C&3;I>Q1QS!'*[BH$2E%)*J2W!S3OB7\$$\<Z78:?;7$D,;:[97E_*\F
MU_LD,(AFA7`Y\V)1&P.!B1CG@"N9T7X^>(]<\3:K]BMM$.A6$-PJQ3,+>[;R
M[$745R$:7S&27(Q&(LJIW%S@BLJ[^*_Q(EMO!ES>:UX.T6#7-<TPW$HTV1XQ
M9WEE-,('+RC:RR1;0X(W;DX7E2`>I?$'X-V?CW4[F\76=8T=M2T9M$U2.P,>
MV\L6DWF,[U.QOFD`=<'$C>Q&#J'[->E:I<ZFM[KFNMIE^=0EATU3$([2>]@^
MSRRJVS>Q$98*&)`+D\\8Y+PO\8/%]_;Z/#HD>C1PP6$>IZF=0$\\D\3ZI-:M
M%&Y?*L$3<&;=R`N,'CH/A!\5_%7Q%\9:_;7\WAZ'2+6UF^R0Q0,+B"X6[EA`
M8F7,L>R-6+A$&7V\8H`SOB#^SQJ&I>)GU3P?/;2R7L<[/_:;(\=K=-'9Q1R&
M)HF66,+9J60[223\W/&Y-^S5I%]<>(KC4M9URXG\165W:22GR@\"W,Z3L58H
M6;;)&@0.2%0;>17E/A/XD_$K59]!U;_A)O#&J:G:^'M8N=4@>PEB@D6VOK=!
M$T:2_).%+X<]`V-IR2?5OA_\6?$GBWXDZIIE[:Z1!HEM=ZC9B#S42]M9+25$
M1F4REI!*C[^(T"`H<MNH`EU#]GNUO-4U/5+;Q1XALM;UJ*X@U.]@6WS<0SP6
M\,J;#&54_P"BQNK*,JQ;L<5T6B?"/2O#M]-<Z5)>(LD]A*D+.&6/[';BWB4'
M&2"@&<G.:\JN/B[;:':>-/$FN^(K@^-?#5_J,$/A-]3,,0MXF(@S:\ET:+RY
MS,!N.XX;`Q1/\?/&"R7>E:7=>#M8O+*_FA_MRSMYFL[B./33?,$C$I^<;3$<
M2$?,&."-M`'HGB/X(P:WXIN?$%IKNLZ9>S7]GJ426ZPND%W;1-`L@#H20T+O
M&R$X.XD8.#4S?!>R'@*T\-Q:KK"3V.J#5X=7W1M<_;_M)N3.05V',K-E-NW#
M8Q7FL_[0/BRVCLK34Y_".F7>MRZ3+;ZC<12BUTZVO[2ZF"RAI`9'C>T(W;D#
M"0<+BD\-?M+ZSXCUSP+;P#2<ZUY5OK5D+*13&\MO<S17$$K2@M&RP(P'EL`)
M,%\XH`[;5OV>;75TNO-\3^)(9-7TZXTW6ID:#=J-K-</.R-^[Q&0TLRAD`(6
M0CD@$;7C?X/:=X[U32)[Z^O(+324$?V>UBB1YD`8&-KC;YHC8-AD#;3M''7/
MG.G_`![\6:1X-MO&7CB/PX/#DEEINKWHLX9DEL;"Z69'!+,0[QRI"=P`!5WX
M&T&M3Q;\0?%'@7P)H_BO5)M)TZ\UR.WGUU;E3(FEPI`\CB"W,J/,_P!U6"MN
M&"P5L8H`ZWP5\'O^$+OX[]/$NN:A=PV%EI<4UVD'R6%JSLD&%0`EB[;I#\QX
MP171ZWX,M==\5:1KTTMPMSHUE>VD,:8V,EUY6\L",Y'DKC'J<YKA_B)\6-9\
M)>+=#T33K:SG/C..W@T&62)R!=B=?M*R8/W5MG\X#@_NI`:X/PM\=?%EY<>&
M]-TBUT<1R6=O=7(U.[P]\D]]-;MY4LLP(\H1JWW9"S,J87(H`]$O/V?]'NO#
MF@Z2MW?`^&H-/BT^YE2*5D-F)51F1E*-O2>1&!&,-Q@\U#JO[/&E>(#IT6LZ
MA<M96&G26+V]I8VUG]IBDBFC='>*,-Y>)RWE`[-R*V,YSP.A_M.^*?$&M+I-
MMH.FVUW-(EC#)<-(D/VZTRVKH['[L<2%-C>I8DG&*[7PA\:IKGX2:_XH\77V
MGI>^'6ECU(V-BTD-G,$1Q&NV5Q.J^:G[Q'`8?W""``;FF?!FULO`OB#PM=:A
M/<6OB*R-G<745C;6LP0P"$L3&BAW*\[F!YZ8'%5[OX&65UXADOVUK6ETZ?5H
M-9GTD-'Y,E]#`L*2[MN\#$<;%`VTM&#T)!X#0?V@?$\\>@-XAE\.VMI)XBN]
M*U&^B@\R2X9+F."!8K9;@LH<R\RJTRH0,C!R-OQU\;-=T/Q_?Z-H\WAV!-,U
M#2K!--OHI&O=3-^5'GP%7`V1;G)`5MWDR`LN,T`:NK_LV>&?$&C^$M.U*XU:
M2'PAI,NEP;9E7[9"\(C4SC'S%&594Q@!QFH[G]FO2+G_`(1I9=7UIHO#EO:Q
M+&YB<7$D%T+H3G<IV2O*/G9,;A\O0"N7^&?B[6/!7[/5MKOBC7;6?7_$FJ$0
MZC)8RS(US/<>4@D1YP`,KC.^-%&.G))X:^.WC7Q9;^'YK"#PW;(=#T_5=8$T
M$K&<3W\MJZ08?"86+S`3OYPO0[J`.[G^!=HD.E_V-KFN:5=Z5<ZK)'=VQA9W
MBU&8RW,)5T9=N_85.-R^6O)YS>\1?!K0/$NA6>CWL4B16\EK)/-$%26\%NNU
M%D<#N"0<8([8K'^&/Q6UOQIXAU[2]4M+**3P=;_9-;^S*V6U/S9"(XR3]PVZ
M12]SBX3GCGS_`$'X]ZGJ=E<:]J.N>&X;G4](L!IUO96\EP-,N;JZ>-+>[B:5
M1YBE2I<O&,@Y"@#(!W%M^SE;07=AJ,OBGQ'<:WHL=C#I&I2"#=9P6BRJD>P1
MA)`RW$P<L"3NZC`J70OV<-$\/>)='\0V.I:V^N:+;>1'>R3)NG$ES/<7/F`*
M`PF>YDW+C:-J%0"@->4VW[1OCN-$UZ^O?#0L;GP;8:A%H[6)0_:);V6VFN!*
M9<F.,*)G7)`0`;A]\^L1?$3Q</A%?ZR\'AN;Q%:7CVD+K?0I:S`3B,2G]\45
M]AW>29L[@$W#.0`7/"WP,TSP?:S1:5>:C*TD-C&K3,OR_9)99(CP!U:9@?8#
M&*QO@K\(==\`:7J5AJT^G06UUI5M:`6Z1W$K7$8D62<R&-<H0Z[8G#[2&R3N
M-5O"'[0(U[5+:SEU'1YEO[;0Y-.D-N]I)?\`VR69)V2%W9@!Y60,G'.2>*\U
M^'_QV\8:;X*6PM]3\+ZW>)IB78NY9")=*3[:\+I=>9,JS3%,ND>Z(MY3@9P"
M0#U6+]FVQBLDAM_$OB*SE"ZC&TMD(+<+#>QQ)+%#&J;85'D1LOE@8;<?XC5W
M0OV>].T!M.FL-6U)+JQUF;4WD6"!$G,UJMM+"8PFU4:)%Y7#`Y.>:X*3]ICQ
M')<ZIJ6C6.D:EH>DV`E%M(OV2[O5;3?MD=U&CR^9L=OD$0B8[0QWY4BMS1_C
MUJ,$FE_V]K7@G4=/N/$<&GW6KZ7(Z6R6\VGRW0)+NP1PZ(GWB"".A.``=!H7
M[/.E:!H<>CVM_<FPMIK![7;9VT4T:6=T+B%&E1`\@!54^8GY1G[Q)+-=_9OT
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MTK5M$FT-_#.JW]UISV)9]5N;5861(90^5+"0[5`8X#'YN,:GP_\`B7X@\86?
MC*P_M7PQJ=[H=C;S6&N:1;R-:/)<P/*L;1F1MS1X0D!_F6120I-`'2>*?A9;
M^+O$VD:O<:C>6IT;'EQ6T,2/+C>"KSE?,\MMXW1[MIV#CKG./P,L8M+\-V^F
M:MJUA>>$H+"+2[]/+9T^R131*75E*OOCN)58$8Y!&",UY!\./B1\0=7UKP_K
M+^(_#FLI<>#M!NM<B%I(D<K7%_/%((E20K%.JMAB0<E%&U1T]*^"_P`6/$GQ
M$UV^_MVTTBTTN2&:2W@AF1;NPEBN3"UO-'YK.YP,LY2,*PVX.0:`)])_9[T_
M0[RPGT_7_$,;16\,6H;C"W]IM'>R7N^0E,J6GFE+!-H(;'&!4FE?L^:?H6J3
M76CZ]X@LX=0NDN-2M$:%H[QTO);N/<60L@#S.AVD;EQGD9K@=,^/M]J'G^(-
M7UGPY:1MI5RMG8VL$L\^E7#WT%M'%>1&10S!R`6W1@$N#A1N.?I7Q_\`'4EQ
M9ZQ?7>@36*>$-8OSH=O8%9-3N[&[>`>3)YK8W*JOM&\!2W7A@`>]>(?AY9:_
MXCEUFYGNXYY-&DTHI'MV^4\R2EN1G=E`/3!-<5>?LXZ5JD%Y9WVMZ_+I$L6J
MK8V`>)4L&U'=]H='V;G(WR;`Y(7>>O&,#4OB)XG\0_L_?$?4M4NM)2_TW2II
M=*U+1;E0)5>T69'*)+*8F5GP,OE@H?`SBJWB7XQ?$#P@EKHEVOA2XUI[N\`U
M,Q&WLYDAM8+F.#$LZA)7$S@L7("Q,P4]``>H>)OAO=>)M*\/0R^(=4L]5\-7
M0N[75H((/,>;R9(27C9#&04E<8"CG!'2N=\*?LYZ'X(U>RO?#=U<(ELEF)8K
MNU@NFGDMXS&LOFNF^-V3:&*$?=&,<YYKQ5\</%^FW6OS:?;:#;Z?I6HZ5I(:
M2-I_(FO;>WF-S))YJ(8HS,4`R-Q*G<HZY5U^T3XNM&6.]7PC:7VEQ6`N=-:0
MSRZV]U>26V;1HY2J[0BL5'FD,Q0D8S0!]*(PP%SR!3Z\;_9NN-2C\*W]SXUU
MNRU36]<UW5)@\:R1/)'!=/`<(\C_`"J$0#8%55*@@G+'V2@`HHHH`****`"B
MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`***
M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`CD@CE96D17*'*EA
MG:?4>_-0?V18^?+-]BM/.G7;+)Y*[I!Z,<9/0=:MT4`4YM'L+GR_M%E:2^2Q
M>/?`K;&)R2,C@YYS4L5E;P2R2PP0I+*<R.J`,YQC)/4\`5/10!B>(_!ND>*=
M&U'2]7L89;/5XS'>JG[MIE..K+@]ASGM5\Z/8/;1P265HT$3;TB,*E$;D[@,
M8!Y//O5RB@"(6L(<N(HP[-N+;1DMC&?KCBH'T>PEDF>6RM'>X7;,S0J3(O3#
M''(]C5RB@"O'I]K%#'#%;P)#%CRXUC`5,=,#H,>U9VN>#]'\1:=J5EJFGVTL
M>K6DEI=L$V22Q2+M=2X^;E>.M;-%`%'3]&L]-LX+:RM8(8;88B5$`V\8R/?'
M4]Z:_A[2I#(9-,T]S,P:0M;(=[#D$\<GD\^]:%%`%1M)L6NOM+6=JUSMV^<8
M5+[<8QNQG&.*?+IUK-%Y<UM;R1G;\CQ@CY?N\>W;TJQ10!`MC;IREO"I`P,1
M@<9SC\SGZURWA?X6:!X0U,ZAHUK*MT()+>)I[EYA;P22^:\408G8AD^;`]!Z
M"NPHH`JQZ99PL[16ELC2$ERL2@L3U)XYS@9^E"Z79I=M=):6RW3C:TXB4.1Z
M%L9[#\JM44`53IEF;HW)M;8W)3RS-Y0WE/[N[&<>U$.E65O"D5O:6T449)1$
MB557/7``P,Y.?6K5%`&'KW@O1O$C:<VKV%O<'2KM;NU##`658Y(U)`X8!97&
M#D<UIC3;3STG-K;&>--BR^4NY5]`<9`]JLT4`8OB+PCI?BC2)-*UFTCGTZ?R
MQ-;@E%D5'#A#CJF1RO0C(/!-:-SIMI>A!>6UO<")@Z"6,/M8=QGH?>K-%`$3
MVL,K(TL4;M&VY"R@E3TR/0X)J"71M/F:%IK&SD:W.82T"DQG.?EXXYYXJY10
M!7;3K5R"]M`Q&[!,8)^;[WY]_6FP:99VUJ;:VM;>*V((,*1!4(/4;1QSFK5%
M`%)=%T]&@9+"S5K7_4$0*#%_N\<?A4KZ?:R7,=S);0-<1`B.9HP70'J`W458
MHH`K2Z;:3VYMYK:"2W;@Q-&"A[_=Z=:7[!;JN$@A4;0H`08`!R!],\U8HH`R
M=#\+Z=X??49-,MQ%-J]Z][>R%RS33,%7<2>>%55`Z`*`.!5MM(L7BFB>RM&C
MN&+3(85(D).26&.3GUJW10!4DTFREV^;9VK[$9%W0J=JMPRCCH>X[T@T>P6R
M-FME:"T/)MQ"OEGG/W<8ZU<HH`K#3;021N+6W#Q)Y<;",91>H4'L,CH*B?0]
M-DCEC?3[)DG8/*IMU(D8="PQR1ZFKU%`%1M*LFN$N&M+8W$2[8YC$N]!Z!L9
M`Y-5+/POIEHUTT=C;`7CH\L?E@IE!A2%Z#'L.O-:U%`%1])L9+B*>2SM7G@_
MU4K0J6C_`-TXR.O:G/IUI)`87MK=H678T9C!4KZ$=,>U6:*`('L;:3RO,MX7
M\AMT6Z,'RSC&5]./2DM=/M;&+RK&W@MHLEMD,81<GJ<#O5BB@"M#IEG;@BWM
M;:(,<D)$JY.<]AZDGZTD6F6<%S)<06MM'<3?ZV9(@KO_`+S`9/XU:HH`JMI5
MDZS*]I:LMR29@85(E)QG=QST'7TH73+-#"4M+93;Y\G$2_N\C!V\<<>E6J*`
M*EOI-C9PR0VEG:P12DF2..%55R>#D`8-+<Z797L1CO;2VN(RVXI+$K@G&,X(
MZXXJU10!7?3[62*2.2V@:.88D1HP0XQC!'?@`5''HUA%]G\JQM$^R9^S[8%'
MDYZ[>/E_"KE%`$"V5NC*R0Q*R@A2$`(R<G'U/)]:GHHH`****`"BBB@`HHHH
M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`
MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B
MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"D)P,TM-9=RD>M
M`'SU)^U>)-1\7P0>#_$!_P"$6TZ]O%1H&5KORKG[/"%.-H$CK+DDY7R^AK,O
MOVQOLNG6US#X+\02+?W5[;6S-;2(H>&[AM8U<8R"\LK*<9"E0.=U=]!^RM\-
MK;3=:L(O#=@+7Q"@74$$"`S`7+W)RP7/,C]ST50,8I5_98^&ZW.E7!\-Z:T^
MC'-HQLXL(/M(N2-NS:,R`<@`XX&,F@#UE&W(IP1D`X(P?QIU(.!2T`%%%%`!
M1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%
M%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`444
M4`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!16=K
M6N6VA6JS7GFNTLBQ00PH7DFD;.U%7N3@]<`8))`!-8-O\1[:Y\Q(=-UE[RWF
M:.XL1:#SX`H4L[#=@I\PP03N.=H.*`.OHKA;CXM:5&NIFW@U"[;2FA,J6\*L
M98Y0I26/+`,GS*#SE21D"C3?BM:ZI?QVD&CZ_&\V!%)+:H$<E964`^9D;A#)
MC(`SC.,B@#NJ*Y'2/B3IFL>'7UF)+R"!+DVQMYX,3F7<%5512=Q;*E<'!#`]
M,UGW'Q;MK:[>T?0_$AO(9(XYH!9(#&TC1JG)D"D%ID`*DCKZ&@#OJ*S-#UZ#
M7-*M+^$20Q7J!HXYUV2#U4C/48-:=`!1110`4444`%%%%`!1110`4444`%%%
M%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444
M`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`
M4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1
M110`4444`%%%%`!1110`4444`%%%%`&-XDT2;6$LWL;@6MWI]R+FVE:,2('"
MLA#+D9!5W'!'7/:LAO#>O+<+J-MJ&FQZO-"+>Z8VC&`Q!BR;%W[MREF()/.X
M@]!7844`>6'X.W9@O+9=3@@A::WDM)XK<^<H18UE27+;663R\\`8."/NBMZ_
M\,>(IK_Q+<:=J&E6O]L64=O9L;:1GMF3<`['?AN)&/&.0/>NUHH`\UTWX4WF
MD32K8ZJRVNRSEM1-ON'M[JW&T/EF`,9CPFW@X`.<ULZSH'B35M$2V-]HRW@O
MX+AG-I)Y2I#*DBJH#[LDH,DGN<#@5V-%`&+J^@MJ=UHTP^Q?\2R\^T-YUMYK
M?ZMT_=,2/+;Y_O<\9&.<UM444`%%%%`!1110`4444`%%%%`!1110`4444`%%
M%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`444
M4`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110
M`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!
M1110`4444`%%%%`!1110`4444`9FKW4B>7;6-U:6VH70(M1<HSJY49;Y003A
M<]Q7*Z/XQU231/#EUJL=N9M9OQ!*]I"?)B4EP`0TF[)VXW#//45I>.!H@FT9
M?$DUS;37-\+;3)[>26)TN9$;"B1/N[E##YN#TZD5GV>E^&O&ND61TN]NH[#1
M;Z2VM_LEW+:J+B%BC8.1O(8,`W(/.,T`3ZU\4K'0]8O-/NM-UB0V)/G7$449
MBP(1,Q!+@D+&=QX[8&20#T'B+4)[#P]?WNG&'[1;6LDT7G*2A95+`,`0<<=C
M67JG@71=2NIY=35C/?AQ)FZ=#)N@\EN,_P#/,XX]CUYK7O[&UU;2IM-N9F:*
MYC:"3RYRLA&,,`P.0<=QS0!Q7AWXD74WAJX\1Z[]D;2\1QP16\30S&3"ARXE
M<!%WD[0<';ACUK4'Q2TR71=.U2RM-2OK74+TV/\`HD:2M%."5VL`W/S*5RNX
M=R0.:@U3PKX<T>Q6ZNKB^CBB\F"-H+V9G\U!LC9`I):;;\FX#<1P>*IZ+X6\
M*:YI4D>BW&K6]KI^K//(IOKFW>&\(!;=O(;.6S@\98GO0!MWGCP6-_864VA:
M\UWJ5M)-#%'#&V#&RB1&(DPI&]3DG:<\$GBHK+XEZ/JWB*70K*:1+W,D44C!
M2K2H#O7:&W`K@\L`#@X)J]?>&+&\UZQU.YO+U+VP0PP+'?NB%6P2&C!PV[8N
M<CG:*@LM`TN;7+J6T-]'<6K>8\:7$BVZ22*P+J@.S>1NSQP6SU.:`*ND^+YM
M+\*ZEJ'BJ873Z7?W%L\MO!Y?F!)BBG:6(7/&23@<DD"M7PCXPLO&FEB_TE)1
M;M(45G9&#X`.Y61F5EYX()S@UG6O@#18--O[`7.H7%M=7`N+E9M4E=EE602;
MPV[*'>`3@C/>IHO`FFIHLNGZ=+-%;7DZ374BREY+C!4D%\YP0JKD=N!0!TSJ
M64@'%<"OBO71JJZ27TC^T%UIK>1!#*`+$1"7S1\_W]K*,]-QQBN^0%5^8[CZ
MUQRW>A2_$&Z,5K?CQ!%8K#+.UI,L2VY9F4[R/+Y96&X')VX[4`7--\7J+'6K
MO6EEM8=,OG@*21C>H"IM'RLP8L7&,==P&`:K7OQ*M-)L;FXUW3=4TIK>6.)(
MKM8D\]I`2H1PYC/"G.6&W'.*L:5X*TJTCU&.*:[O8]5.^\BNKY[E79@/FPQ.
MTD`<C'05)#X/TN;3GMHKB[N$:42+</?2231.HPI24L64@9`P>A/J:`-#PYXB
ML_%6D0ZCI#E[>;(&X8*L"0RGMD$$<9''!(KC=8\>ZEI/C*[TKSM'F2!K-H;`
M!Q>7*3,0Y0[L$KM)^[@@<D=:[C2-)AT6S^S6C3/'N9BTTS2NS,<L2S$DDDDU
M2MO"MM::]=:O#+>?:[V-8YU:Z<Q$*,+B,G:".>0.Y]:`,^U^(EK/-J2W.FZM
M9P:-)+'?W<\*B&$H@?.X,=P*D'*YQT;!XK,7XU>'3HUUJ+/*B6DJ1R(\D0VA
MPS*QDW^6JD(Q^9AC&#@D`[^F>"M/TMM2,3WMPFK2-)=Q7=T\Z.S#!PK$@9``
MP.P%4YOAKI%Q'MN7U28K(LD<DFI3EXRJNJA3NX4+(XQTYYS@4`,E\<B\L?#]
MWIEM=1VVMWRP>9+&A\M?FP"`_&[;P1N'KUJIXF\975G?VD.B)=211:M:V=_<
M?9A)"#+(BF,MN#*P60'<%*@X!/-7[CX<:5/96%HC7]M!ILQG@%M?20GS222[
M;2-S9).3ZFI=6^'^DZU<">^%X'$T4^V&\DB1IHV!24JK`%QM7YCV&#0!F3?%
M[0XK[4;.#[3=3Z=%,^V#RR9S"I:5%!8$$!6^\%!P<$U'?_$[&F"XT_0]6EN4
MO;*%[*0Q12^7<N%23E]O0GY20<C!`ZUJWOP]TJ_:Z\TWT<=XDBO#!?2Q1J9%
M*NRHK!59@S9('<GKS1%\/=+A%V,WL@O8K>.0R7LCE?(_U3(2?D=3SN'.>:`-
MZPNWO+6.6>VGLY'7+0S%2Z>QVDC\B:L$9!Q6)-X4AEL+.R6XO!;6MTEP^^=I
M'G*-O`=V)8C?M)YYQCI6VPRI`.,CK0!Q=KKGB/5W@N])@TH:5+>RV[),SF=(
MT9T,V<A3\ZCY,9P?O9XKE_"GQ5U;78K1@^CWKW02WE6WMY[<6=W)@QHY=CO3
M:)22HZH!GYJ[Y/!6GQ7\EW;F[ADE=I&CCNY%B\QNL@CW;0_)Y`ZG/7FG:=X-
MTW3O#L>B1K<36,2A8_M%P\LB`'*XD)W#:>ASQVH`3P[J]W=WE]I^L"`WVF&/
MS9+<,(I5D7<K`$D@\$$$GIUYK>K+T3P_;:"DBV1F8SOOFEGF:629\`;F=B23
M@`>P`K4H`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`***
M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH
M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`
MHHHH`****`"BBB@#DOB#X2D\96^G6181VL=VTMQ(LQCEC7R)45XB`?WBNZ,"
M<8*YS7#:A\(M8GTAM-L)M/AC1[L6DAD*F#S#E)3^Z)9L!<JI7!&0QS7??$C[
M+'X/U.74+ZZT]8[=RDUM<O`^_!V@,A#<G'`ZTS1?$%W=^%]&N?#MK'K2SP1B
M>5KL0["%`8_,#N.<Y%`&)/X%OM1DMWUZST?5?.AM5GDNY9&>QDB"[C`P7+*S
M+NZH=S$G(XJ$_#N>ZUKQ1=7%CIEDVL2+)97]O.SS0LL:H24V*%+X;<5;)#8)
M/!JUXJNH8O&6D'3Y9FU7[7$MU;QW$S.;8@@A8L&,KDAG)P0!G).!5>P%\?&U
MRMU/J,;>?>?;P97$4=F4'V9E!^53QP5YSYF>]`!!X%U*.]@U'3[31]&N=/D2
M2#3K25VMKE@KJ7D8(I5MDC*"%)'4EN@K7_P\UW5=*5=7OWO9A?2W'V-[L!1&
MZ(JJ9O).XIM8@F/^/'&`:O\`PYUV.3P]JT7ARYFUZXL-2N!#'=7KM(\1E.S,
MLF3C;D@G/2I/'VNV5MI&G?\`"61SV-[=,XMK>*]E2-)0/OO+&!PH.<GUP`30
M!A:A\,]5F:2>*UT:[OH](LK2"_N+J3S5E@F9W8L8V895L!L[N.V:Z?2]%U:W
M\1^(;F2TT[3K/6X$1+BRNF:=9$5@)&4Q`;B''.XXVCKVYC4KO[-X@T"^>_CU
MHMIEFD-H[W$-Q<R%V+3(@(3+!E8AP2`F#@5N:/J5A:_%#6["WU:ZN)[BQ@<6
ML]U)(J3"28NL:GY4PNS(7MB@#/F^'%[+I-Y;V]CH%EJ,UM%:_;+=Y5-Y&LRN
M[2_+PQ"GJ'R3R2I(-_PGX<UKP5X4FL[2.UN]1N+P/$I5=L88JKO*R)$&.`6.
MU%Z`<]:N>*[O4]2\%ZQ%J<5OX>E9`L4[7C2KMW#)8Q@,H/(XYYZUS&LW]F?A
M'J,\EU<:4MGYRV5QI][.BW<@1BAC8GS&0L2-I)R4/4`4`>M1?<'>N4%AK(\:
MW]_/8Z:VEW-C%:1G[8QD8QM*X)0Q[<-YF"-QQC//2LCQEIVF^)H]+GTZ>\GN
MM:FBM+.XM;N5$BB!:2610K!0P17&XCKM'M42ZSI5S\1TM=+O[R*_AN7COEEE
MF*W)\IB(%C/R!%X;?@`%0H)+&@#-\-_#+5-)L([.&'2=)C?16L[F;3YW+-/Y
MV\,1Y:[E*Y4G((#$"NETCP_?:-8:M-I&E^'M*U:]51%%;F0VSNBD(TF%4@')
MSM7('4GK74:9J\&IR7<=HS.;&<V\S;"`)``2`3P<;@#COD=0:Y/XN:HFE>%O
M-EO8[/\`TN#Y70OYZB12R<'(XR<CD;?K0DY245U&=O')E1O*[L<X/>G&0#N.
MN.O>O)_'?C>]TO5)Y="UNS6PAT%M46![#SC.5D`50X(PK@^A/`([T7\-IJ?Q
MAB>YU>&<6VF6T^GZ?);JP:0M,W[MST8@(Q(YQ@=*M4I<MV^E_P`O+S%H>KF0
M8ZC/UI/.4*22N!U.>E>,:GX\\2+8&32YX]0O)Q_Q,M,MK`QSZ)&#^\;>2=S*
M,K\PY8AE&`17':/KGB+7[/3)-,EOS-;ZRLEE'<RSJMS*EO<NT!9R2T4BK""6
M)"LYQ@C`T6$J-<UTD)M(^FA(I`P1S06`Z8_.OG6T\6^(/!_A=H;"XGO[ZWN=
M1N+E[J$R->2K._[J,G<3C'W$'RJ5(.*[B^\7ZGJ.HVXL=1MM)%Q':R6%O-I[
M7`U-90K2%7'*[=S*`.1MW-P:B5"<7:_?\!H]1\SUP/QI&E"XZ$GH`:\ETSQ=
MKMVWB2;3=4L-9&@W4D45E'8%))H\*0[D'G82PP@^8(1U(Q6O/$=[J7EPW>JG
M6?#T=S$VI:KI]N]KY:,DF8&V$D+O$1++R%.&ZYI>PGW_`*_K_(>A[(),]1M]
MB:4N.Q!_&O"H/%6KZ+X>+^'('L+*XU6X`O=2OS=Q1HJ)L6*1UYC9MP7/]Q@#
MR*MZC\1=8M[TW,VI6-G##INGWEQIQL&<EYYC')&)"`P4+AN5W#([57U>I>R_
MK\Q:'M6\=R!^-&_FO-M%\0Q/XM\706%W#JM]!%'+9VZ?NVDVH^8L_=.&P-V,
M_-SVK'D\:ZU:Z)J%_;:M:ZC+'!`/L_\`94D+6%Q)*%96X.0JGHPR,9;@UG[*
M=[>GX_+_`"'H>Q!@?2@L`<$C/UKSKP-XYO+GP?)K/BL.'BNO*+1VF05)4+M\
MHN)/F;!=<#.>%P:9XQ\1ZO;ZW):6>IVVAE8HS8^?IK72:C*QPR97E=O`P/FY
MSTH<)*?(!Z/N`ZD#CUHWC'!!KRF?QEK9U.XB@N;87OVF2`Z&+(F6WA!(%QYF
M>?E`DY&T@[1SS4?@/Q=X@U#6]/MO$%Y;W5O=0C<(]/\`(PYM8;@'.3WD=,>B
M>N:I49V;OL!ZY1114""BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH
M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`
MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B
MBB@`HHHH`****`&E`3G)!]C2JH48%9^L>(+'0?LG]J2O%]NN4MH-L+R;Y6^Z
MOR@XSCJ<"DT3Q%8>(M.2^TB9IK65BJ2-"\>\@X.`P!(]^A[4`:&WYMV3],T-
M&&/.?SIOG)C.>AQTI3*@!)8<=:`%"8.<D_6G4T.&8J.HK.USQ+IOAN**36;D
M6XG8B,"-I&;`RQ"J"<`#).,`=:`+_E#GEL$\C-+Y8XY/';-9>E>*M.UJ[,&G
M2R2DV<%Y')Y3!)89MVQT8C!SL;CJ.]:AF13@G!QG\*`%:,,V3G(I!$`<Y;\Z
M/.3.-PYZ4GGIS\W3J:`%6,*<C/YTYE##!H!##(Z5%=74=E;2SW!810H7<JA8
MX`R<``D_04`);6<-F"MK&L2$LQ55`!9CDGZDDD_6N<\8?"[PMX^FM9?&&D0:
MG)9!EMVDD=3&&QN`VD=<"KMAXWT;4YM,BLKIW?6;5KJRS;2J)8EQN;)4!<;E
MX;!^8>M:=GJ4%]9Q7,!<13+N7S(V0X]P0"/QJHRE%WB[,#SX?LV_#4=/"ED.
M<_ZZ7K_WW2?\,V?#3;M_X12RQZ>=+_\`%UZ2LJ-T/T]Z?TK7ZUB/^?C^]BLC
MS/\`X9K^&G'_`!2=CQT_?2\?^/T']FSX:'KX3L3]9I?_`(NNLTOQYH>LZ@UE
M87CM<K)+'LDMI8@SQ'$BJ74!BIZX)K=\Y.<G&WDT?6J_\[^]A9'FW_#-?PT_
MZ%.QY_Z;2_\`Q='_``S7\,^?^*2L.>O[V7_XNO2?-3.,]3CIWJ$W\(O8K7+F
M6:-Y%PA*X0J#EL8!^<8!Z\XZ&CZU7_G?WL=CSP_LU_#1@`?"=B<=/WTO'_C]
M!_9L^&C')\)V.?\`KK+_`/%UW-QXAM+77+72IQ<+<WL4DD+>2WEMLQN7?T#8
M(.#VJ_YR9`#`D],4?6J_\[^]BLCS<?LU_#0?\RG9?]_I?_BZ!^S9\-`,#PG8
M\?\`3:7_`.+KT.34K6&XA@EGB2:X#&)&;!DVC+8]<`BIU<.,KTH^M5_YW]["
MR/-#^S5\,R,?\(G8X_Z[2_\`Q=*/V;/AH,8\*67'3]]+Q_X_7IE%'UFO_._O
M861YG_PS7\-/^A3L?^_LO_Q='_#-?PS_`.A3L?\`O]+_`/%UZ911]:K_`,[^
M]A9'F?\`PS7\-,8_X1.QQZ>=+C_T.M3PU\$_!/@_6(M5\,Z!;:?J$*,D=Q')
M(656&".6(Y!/:NXHI2Q%:2LYNWJQA1116(!1110`4444`%%%%`!1110`4444
M`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`
M4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1
M110`4444`%%%%`!1110`4444`%%%%`'(?$?PM=^+=.L;*S17@_M"&2[/VQK9
MUA7=NV,JD[N>G&>>:Y?Q5X`\3>)M.M[65=)CGLK:6VMKE)@NUL82X(,+8R`O
MR+@J0<,0>-GXL3ZC;Q^'6\.W,L6I+JX>WMTN#$MZ4MYW^SOV*OM"\@@$@]JX
M6V\>:YX2\-3@WKW^I17VH370NR)&E=9"1;Q%G'W>5V("54*<8H`Z_P#X0?4-
M2\6:3?Z_H^F74,6D);7T[7[%GG!5MY38!)M*D*6((W$C%,3X>ZM!XJO=0:1;
MV*Y^T&1IKP*+B.1&"0/&(B=JDJ.7*@+D#/%27/CC4-0FM?[+U#3-,-S#:S6<
M5Y`\PU(2A6?RV4C[N2N`"<C)`6N?T[7UM;J]G\*W]_K&L0Z[?";34U&2X#VJ
M&0[2C,RQ@84*0!S@#.<4`=-\-?!>H^$;J%+C3].LK0:':6TWV6[:0R741?>Y
M!09R&'S$Y^7&.E:WCC0]4U:XTZ70XH2;995DE74'LYTW;,!'5&!4[26!'.U<
M=*YL^/=20J]CJFD:O;(\,U]<V=LRI91F:-)(WRYQ\CNX)P5\IMPP:BA^)-]?
MV$DEI>VPBBO;Z'^T(]-EN8V,4@$4)C0Y4NC!MV>0/EZT`)K7@+Q%=WCWOV;2
M;W4[?2;.WM+\W;0,DT<[/(RJ$(0%6P".3@C`!I[^!M>B\<6^MP)8&(WLCWBB
MX"?:[=XG41[?*W?*3&2&<@E<@#H,[4OBYJNDZ=HM[-]DE66PLKF^B,7E&0S;
M3(R9<OY:!LY"D*00QKH].U+0(/B=KUI;7EF)[O2[=[BW%R"7D#S[SMSP=FTG
M';!/:@#)TGX6RMX6>RU+0M(MKPZG%,P6]:=9+<7BSF+)0;5"#:$`V_0$U1C^
M$FLV]@EFD.EO:LL1EA$^-TR^8IDR\3J1M9<C;D\`$;1GJOA1JNE3Z3J-IH%W
M;7-O::O=K&D-QYOE1F5M@ZDA2.GMTJK\7M0BL6\-FXNHX!+JI1XY=9DTV.6/
M[/,6#2)S@,(SR#SCIF@#2\+VWB/0]#\.:3J*P7=W`ABU*\\UI$$:*0&!(4EV
M.S`(P!N]!GL0OR@/R17E<7BU--M_!!UO6+6!KN]E$D-U+B1D,<_EN'+`L@PJ
M!F!#[E;@D5H2>-]2_M"2(7.GBZ%TUN-#$3&ZCC#%1.6W<C;^\^Z%V\`YH`NZ
M'X,OM&FUI[F*QU"#8UMI%HTA"BU9VD9')4A26?9P"-L:?04].\)ZR/`FE:5J
MEKIHFTN11)8F[:2WOHE5@(W;8"HRP(&TC,:YR":P-)^)?B;REDNQ8:I+-9[X
M[:UM7A+2FSCN!@EVXR[KCN$)ZU=L?B#J.I:7(FISZ5;P"Y\F;6-RS6\2,F[#
MA&VAB?D^_@=\'`(`S6/AAJ%Q:V0TF.*Q6(2LMC!?^7'8S22E_-1VB<D_,!\H
M0C'R\'%>J01R);*D[;G"`%LYR<<FO'/#/BNRTS2/!45QJ^F01MJMY#);R2.A
M`'VH(P+L&"@A5VN#]]>X%==?>*-2_P"$F^PPWUCIYBNXHTT^ZM7DEOH#M+RQ
MN#QP6`P"`5^;&:`*OA_P3J<4VJ3^)8ENE74+N[TZQ-\LEN3,9!\P\E64['93
MDN/G;CI65IOPNOHO`=MI[6=I8:G`Z"[6"^,POXD!Q&TCQG"Y8$*48#:!C!X?
MX=^)$FM^)9M'\1/9G3;VQN9MYVQ>2(R@:)\.V&V.258AEV'(].C^%.K:??>$
MX8=&NH+J&UN;F(>5/YGEJ)Y-BDY)^YMQGMB@#D->^%?B'5='TFR$EM)'9Q3(
MR3WWFE`\N57+0;2HC^7*A&'13BNL&A:S;>--(OX-.TQ[>TTU[*[O$NS'))N,
M3`B/8<JIC?`+_P`?;FCQG?10Z_9P^(;ZYTW0FM9&\V&=[=7N0RX$DJX*@+DJ
M,@,<YS@"L2V\5ZAHL<5E#JL5T]C''':66H1,;[6D*J1*K;@06)('RG!4EL=@
M!K_#C6O[;MI[9=.@EBMKRWN-:6X?[5<F=,),4V[=RD#@L>ORD`8-2+X7:JFC
M2V,UE975O)J=C<?9;C4LHHAEW2R+L@4*SJ`N,9/\3>N=K7Q1\4Z58WUP+O1Y
M/(#>6IL'&W,]U"N[]YSM^SH3TR9,<<5KV_C[7X;Z:+4+K3I(+2[_`'TB6;(!
M;QW@@E<_.<?NV$F[HH'<'-`$J_#6[>*QGOM#T"\DTC4;]K.QFFW1"VN&R@#&
M/Y-@Q\@4CC@UZ9:JT$,:3*BO@`A#E0<=![5Y2/B;?7QT]+'7M$@6>ZU6*6::
MT)+);,3&RJ9!@E,9SD$'<.U:,'CRTOM>\$SW&JZ9$-7TUY6MO.PRR/&A4J=W
M()R@!!Y'!S0!Z;17G1\9Z@=3GW7EG']E:Y-SHOV*22[2*-'V2*P;YMS!#T"D
M,0#FN;3XBZ]KNE:]96=];6VHZ?!:7D%[;1),K1/,5F"JKE6"*ARP;C=SS0![
M0S!1DT`AAD5YMXO\606O@6*];Q#IEPIO(E:YV&*.[`F7<L>'R..=P)'RGJ,U
M/KWCJYM+^<6%_ID$<2))IUI+&9)-;#(&_<L&&`2=@VACN&3P10!Z'17ENG?$
M6^_X2(P:AJND2V\NLW&G1V:0[9HREN9AN8.<L&`C("X.?6IOAA\1M3\7ZI>1
MZJMO]G6W2:#R(E."Q&0S"1BO#`!9$1SM8XP.`#TRBN5\;>(+C19;&**]LM(M
MKH2&;4[V/?%"R[=L>-RC<^YB"3C"-W(KA]5^*&K6DMQ++J.C6,5EH[7[02P-
MNN=MPT:LA+@K'(H5AD$C<.M`'L).!D]!0#D9Y_&H(Y4GM=ZNLD3KD.#D,I[@
M^F*\?\)>-[_3?#>S07MM=$/VSR]/@1Q+:1I+(8Y'=B2R,`H'`R""I(!H`]E,
M@!(.>.IIP.X`CO7B]UXMN_$%GHKW=[I-KJ%MXC@@MK]91+%*KPN6^5'VD@';
MMWD9`S@\5)K?QAOK7P[::CH[6=P\=M<331H@*W312.FR(E\DG8254,5#*3QU
M`/8PV20`>.^*0R`=CCUQ7GT.OZ%_PLK2);6]LDOM7T68S1K=@F8E[8PC;G!.
MTN5XR1NJIX`^SW_C/Q1>7&L6&HW\.HSP1PHN)K>`;`%_UA^0'CA1SGWH`]/I
MI<`@'.37/^--:N-%LK9[66WM$GG$<]]<J6BLTVL?,<`C.2`HR0`6&>*\^\8>
M()=9T#24U/6]-LK*77X[9K\QE;?4H!$S;@OF#"[OE/S%24.."*`/8@P;IVI:
MI:7%';Z;!%:M&T,4:+&4'R[0!C')X_&O#]"U?7;&^T.YOM3U"ZT6"ZU&:R<7
M+S-?,Z73>3(N=SB$PC:"<8D7NM`'OM%>2>'_`(HZI?QZS;W)M;BYL(K::.Y@
M4/&(II'1Y-L;,'6+9N.ULG.#BI-4\>:GIEMILB>)O#$\6H:P+2*Z>W:..6`Q
M99_OXW(X/W25.5!(.:`/5Z*\YU?QAJVDWDUO/?Z6ES9HGV>SDMV$NM$H&)A^
M?Y<L2@`#8923QBL:UUJ1O$.CB\GUV37I=3F%[9P:AM6%!YNQ'MR<&#;M(=1R
M=O))H`]?II<!@#U/2O&9/BQKJZ;>R3RZ+I]Q$]NR^>PE%L7N$C:"55?((5R<
ML5;*GY2.FAJWCU/^$7N9M3UK2/.TWQ#'932`^6+E4GCR``^4;:VXX)&%.1@F
M@#UBBN#\6^+[RWN1%HVI:9I:262SV-U>P-<0W\K%@(D*,.F%)QEF$@V@X-9<
M/Q(U6;XD)HJK;?84NC!*$B#N<)DD`R+(/F(.\1L@`/S9H`]0HJCIVLVFJO<K
M8R&3[).\$QV$!9%QN7)ZXSC(XSD=C5Z@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`,#QOJ5_H?AR_U/1X;*XFT^W>=
MHKMV171%+$`J"0>!CBJ&H^-XO"YLK7Q'9W4M_<6TMR3IEI)/"JQE?,.['&`Z
MGYL9SQGI6OXG\.1>*=(N=.NKN^M(+M#'*UG*(W9""&7)!X(/-9FH?#^WU,V[
M7FJZV\EO87%EO%RH,B38WLWR\M\JX/&,4`.U#Q]I>G-'L@O[R/$32265FTRP
M"3&PO@?+D,#[`Y.!73*JCD*`3UXKFX/`-G:M:M:WNK0F".*.8QW17[6(U"H9
M<#YB``,C!(&#D<5L6VDI;:G=7JSW3O=(B-$\Q,2!,X*)T4G<<D=<#/2@"YL7
MGY1@]>.M9VL^';'7DC348Y2(B2OE7$D)Y&""48$C'8\5IT4`1PV\5M#'%;QI
M'%$@1$10`JC@`#L.*=Y29SL7/TIU%`#515^ZJCZ"AD5_OJK?49IU%`##$C'+
M*I/N*78N[.T9QC.*=10`FT9S@?E2;%V[=J[?3'%.HH`:8U)R54Y]J7:..!QT
MXI:*`&^6IZJOKTH5%7[H`^@IU%`"%0<Y`.>N12%%)!(!(Z''2G44`-V+_='Y
M4NT>@_*EHH`:8U;JJGZBCRT/55_*G44`)M`.0!G&.E($48PH&.!@4ZB@!OEK
M@#:N!T&.E'EKQ\J_+TXZ4ZB@!OEIG.U<_2EVKSP.>O%+10`C*&&&`(]"*0QJ
M3DJI/TIU%`#0B@8``'IB@(HZ`#Z"G44`-\M,`;5P.@QTH"*,84#'3CI3J*`&
M>4@.0BY]<4HC53E54'U`IU%`"%0PPP!'O2&-2,%5(],4ZB@!,`#``QZ4FQ1V
M''M3J*`&A%&,*!CI@=*#&A&"JX'M3J*`&E%)!*C(Z''2EVC.<#.,=.U+10`W
M8O\`=7DYZ4AB0]47\J?10`FU>.!QTXILD8=3@`'&,T^B@""SLX;&`16L<<48
M9FVHN!EB23]2223W)J>BB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`
M****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H
MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB
MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****
M`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`
M****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H
MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB
MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****
M`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`
M****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H
MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB
MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****
M`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`
M****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H
MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB
MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****
M`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`
M****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H
MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB
MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****
M`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`
M****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H
MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB
,B@`HHHH`****`/_9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g838054g02w00.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g838054g02w00.jpg
M_]C_X``02D9)1@`!`0(!>@%Z``#_X?-W:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87`O,2XP+P`\/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z
M;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N,RUC,#$Q(#8V+C$T
M-38V,2P@,C`Q,B\P,B\P-BTQ-#HU-CHR-R`@("`@("`@(CX*("`@/')D9CI2
M1$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S`R+S(R+7)D
M9BUS>6YT87@M;G,C(CX*("`@("`@/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O
M=70](B(*("`@("`@("`@("`@>&UL;G,Z9&,](FAT='`Z+R]P=7)L+F]R9R]D
M8R]E;&5M96YT<R\Q+C$O(CX*("`@("`@("`@/&1C.F9O<FUA=#YA<'!L:6-A
M=&EO;B]P;W-T<V-R:7!T/"]D8SIF;W)M870^"B`@("`@("`@(#QD8SIT:71L
M93X*("`@("`@("`@("`@/')D9CI!;'0^"B`@("`@("`@("`@("`@(#QR9&8Z
M;&D@>&UL.FQA;F<](G@M9&5F875L="(^4')I;G0\+W)D9CIL:3X*("`@("`@
M("`@("`@/"]R9&8Z06QT/@H@("`@("`@("`\+V1C.G1I=&QE/@H@("`@("`\
M+W)D9CI$97-C<FEP=&EO;CX*("`@("`@/')D9CI$97-C<FEP=&EO;B!R9&8Z
M86)O=70](B(*("`@("`@("`@("`@>&UL;G,Z>&UP/2)H='1P.B\O;G,N861O
M8F4N8V]M+WAA<"\Q+C`O(@H@("`@("`@("`@("!X;6QN<SIX;7!'26UG/2)H
M='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O9R]I;6<O(CX*("`@("`@("`@
M/'AM<#I-971A9&%T841A=&4^,C`Q-2TP,RTP,U0Q-#HP-#HS.2TP-3HP,#PO
M>&UP.DUE=&%D871A1&%T93X*("`@("`@("`@/'AM<#I-;V1I9GE$871E/C(P
M,34M,#,M,#-4,30Z,#0Z,SDM,#4Z,#`\+WAM<#I-;V1I9GE$871E/@H@("`@
M("`@("`\>&UP.D-R96%T941A=&4^,C`Q-2TP,RTP,U0Q-#HP-#HS.2TP-3HP
M,#PO>&UP.D-R96%T941A=&4^"B`@("`@("`@(#QX;7`Z0W)E871O<E1O;VP^
M061O8F4@26QL=7-T<F%T;W(@0U,V("A7:6YD;W=S*3PO>&UP.D-R96%T;W)4
M;V]L/@H@("`@("`@("`\>&UP.E1H=6UB;F%I;',^"B`@("`@("`@("`@(#QR
M9&8Z06QT/@H@("`@("`@("`@("`@("`\<F1F.FQI(')D9CIP87)S951Y<&4]
M(E)E<V]U<F-E(CX*("`@("`@("`@("`@("`@("`@/'AM<$=);6<Z=VED=&@^
M,C4V/"]X;7!'26UG.G=I9'1H/@H@("`@("`@("`@("`@("`@("`\>&UP1TEM
M9SIH96EG:'0^,30T/"]X;7!'26UG.FAE:6=H=#X*("`@("`@("`@("`@("`@
M("`@/'AM<$=);6<Z9F]R;6%T/DI014<\+WAM<$=);6<Z9F]R;6%T/@H@("`@
M("`@("`@("`@("`@("`\>&UP1TEM9SII;6%G93XO.6HO-$%!45-K6DI29T%"
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M03MQ8FY*,F5N-4MJ<$M7;7`V:7!Q<75S<F$V=F]204%)0T%1241"455%0E%9
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M,7IF.$%#9CA!3D=+;V4O93`P*S%E.'8X059$85=K5E!5=4HU25EO,35%2T]4
M=6]55EEG1$953%DV>F]&+V9.<#EJ-6=H)B-X03MU-SE):&-085%81G9*34E7
M0VQ:1$=O3&-$-FDP86Q.>#0T<6U8,4M4+VQR;2]W0T4O=T-A359D.5-K+S5A
M-78K12\U;WA6,S%+5"]L)B-X03MR;2\T5"]M:D989E5P4#A!;')M+S14+VUJ
M1EAF57!0*U=U8B]!250O04IO>%8S,4M4+VQR;2\T5"]M:D989E5P4"M7=6(O
M:%`K84U6)B-X03MD.5-K+W=#5W5B+VA0*V%-5F0Y4VLO-6$U=CA!:%`X06UJ
M1EAF57!0*U=U8B]H4"MA359D.5-K+S5A-78K12\U;WA6,S%+5"]!2F$U)B-X
M03MV*T4O-6]X5C,Q2U0O;')M+W=#12]W0V%-5F0Y4VLO-6$U=BM%+S5O>%8S
M,4M4+VQR;2\T5"]M:D989E5P4#A!;')M+S14+VUJ1EAF)B-X03M5<%`K5W5B
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M57-R341*3G=M-#$T8U8K03%9<4\K2W9$=D](+T]25VQA,W`P;6AA<#5A=DER
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M;4Q.1WE+=W1+35%1:DM7-4)L0BM(9F-+)B-X03MS9#`W.'9F>FIS<F4P:FPX
M>7A8,'%756QT9'IY-FIF;WI3=4QX1FM596TV2&ET>$%E4EAN>6HV:G5Q:"]-
M6#58+VY09'AQ9$@X-D<P)B-X03MK;&IJ:75O,W9B>F=Q>#(Q;W9+2F=H64\Q
M>F)337IB17$O.$%L34-Q;4AL8CAU9GI1=%I8;C$W>D]B:'5B=&)W5S)O86=9
M;U5E,G59)B-X03LO5$AR;&I*>&YK:&-.3'E0=R]E<6Q6-RM6+S4P0T-*=$\X
M,5)X>C%#,T5-*W%A=$I'-D=/1V]$,35Q>7EW=#A3,$Q",BMZ.6Y&6'`S)B-X
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M03MA>$M*>'AM,THU,7`Q1TMV6#A6961F;4M0>F5'='=3950K5&%125E6=5EO
M;7-"2UI4335M6E!R:6YC47%Q9SAQ07-0:&)F:7%X=4UF)B-X03LX-4E45TQ4
M5&@W3V5+,$IH=&]:3DIM:VUU4')9;W-Z=D5K84XY5THS5#1D9S(W2&AI<C)K
M5F]+.64K2W9)4$TO+U%W;R]-1S4O46=$)B-X03ME5%=K5#9R>$]M:&Q!:%=V
M3#%H-C-!>FLX+S)U25!':'!I<6IP0V8X-4544U)7*W%03&)21DEL=7)Y3G1)
M3&E74S5I37)W;TDU0C9C)B-X03M6=$A)0GI(27,O43`R5E)V:V(O;&98*TM,
M1"]%-'`U931.*VMF5D]N1U5Y+U9J.6HV<4MI4#9X.6XY<FIX-69T67$Y67A6
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M03LY54@R9G)D+VEB55`K5T=B+VM82B]W03!9+WDQ<78X055*9F(K<&8U3WAF
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M03LQ3%`O04US9E!8;4QZ4DIQ,%=T-D]D26TP,#(V3$5Y5'AS5VQ2:2]*8FA9
M,D(K04]">&]&9%)6=75+<S=X5C54*UDY,7)%,$5C6&U#)B-X03MU;6%A;"]/
M='!C,GEH:3A3>'8V0EER3DDQ5W`X44U9>D9Z6#$U3VTQ,#56*S@Y165)-VIU
M;S$Q4#--=CAN6&9M2U=#,FIV3%99=$M7)B-X03MW='IB6$(T:5(U94E$06A:
M6F1U3D-#5D=7-&I+="M4;C9E57IZ2'`T4BM/8DER;31G=')E5S5N8U)W44DP
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M0S)R9W`K-RM,-&I4:W97=4M60V(X,G9..$5J23-K<31L)B-X03ML95-C5SEU
M;VU%;F\R-%5'56HV<V53<S=$9%)T565)<7%M9&PK6DAM3V94,75:+TM&,V)Z
M=3!I3&)'3U9I1U))1TA)+U9X>$1E=316)B-X03MQ52]D;F5U=U91*W0O;6PU
M;'-P43)N95-B+U5B2GE"1DXV57--<$IJ5C(U46TS9&LT<S-'<F)(96Y41E=4
M5U!M:'(S4E`P;4Q->"]V)B-X03MP;U)!5DEF.7I-.$Y30VES<%!#<%5R<V1U
M,EEE=C%5<T=,:FI(:E!C,S9B04UK*T5M;%`O04)23"]W07-49F,S+TY'84PO
M4D)N+S%!)B-X03LO32\X4S=(*U-O+WIX.6XV,V8T;VPO-5EM*S5V*V%-9CE%
M1V8O540X>B]X2R]W06Q2+VYJ-U`Q=2]W0553+SA!3$4S,TXO>E)J+V]G)B-X
M03MZ+S9G9FUF*TI8*U-O+WIX.6XV,V8T;VPO=T-72G9U8B]M:D@O4D)N+W="
M45!Z4"]!0DLO>59(*V50<R]7-R]&178X07EX3CEZ9CA!)B-X03M.1U`K:410
M+T%+9V9M9CA!:58O:W%0.$%02#)F<F0O:6E8+VQI8B]G5R\U;W@O,%%:+SA!
M540X>B]W05-V.&Q2+VYJ-U`Q;WI49%EE)B-X03LY:V1$8D=)2TLX:414.%%U
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M5'`R:39.<&YQ9F\R=W0W3#%1;VPK<E)*)B-X03M&>459-'!Y-$)A.%)S4$1&
M5TAA,RM:;FY#>'9D47,W2'E:9%A1=%AE3S%U*T5H:FPT=$=I>69"8G5#<F5O
M5S)F;W`V9&Q+1FLO3G)Z)B-X03MU:%94-4%V;6)J25=)5GET56A754%%5WIF
M85II9W(K=6]#<6AC+VY8-6MT.5!M,4M4>5I-3$-'5S5I831-;$98-G-$5G!'
M3G1W54TY)B-X03M%5VI(96\V:6A6<&MF:S=Z-S5H,3=5-W$P,41Y=F-A3$)!
M<G1&9#-#:W!*=V1654QY:&I8-&=X3WI(<&EH:S)O-FI,8E<O<4Q$-G)C)B-X
M03MG06E2,4\O*V]P3UE7=C%-.$]0:6A(:DXX;DDP=45:2E54=VA++SA!16PU
M+S%B-5`K4E0O05!.1V%4*UA.5"]Q0BLS.51S9C5.>"\V)B-X03MO4',O5S<O
M16PU+S%B-5`K4E0O.#!9+WDU<68Y45`R+W%8*U1C9CA!<6<K>CEB=CA36&XO
M049B-5`K4E0O=T1.1U`X04QM<"\Q02]B)B-X03LK<&8U3G@O-F]0<R]7-R]%
M;#4O,6(U4"M25"\X,%DO>35Q9CE14#(O<5@K5&-F.$%Q9RMZ.6)V.%-8;B]!
M1F(U4"M25"]W1$Y'4#A!)B-X03M,;7`O,4$O8BMP9C5.>"\V;U!S+U=U:CAW
M6&-J:%!Q5'@Q<BLX84YG1C(V;FMG1UAA9G1J551Y0TIW:T%N;BM!,35E>CAC
M66MI64YE)B-X03LW.6)X6%$O>G`X>C)6,5I487@U<3!E-S!E5G=J5'HR1C-(
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M=&-O;4IO:6Q3-CAW-E9A5"]6-W4Y=$QE-#1E<C9-<E%O+W`X6&9N>&%H)B-X
M03LT.%E:1%AW5G9!-%=+3&IU+U526DEZ1SAB9TUJ<7%%14AC145$1E8S<G8T
M2B]W04%N.4U69#8W*T-F.$%!2B]41EAE=2]G;B]!04-F)B-X03LP>%8S<G8T
M2B]W04%N.4U69#8W*T-F.$%!2B]41EAE=2]G;B]!04-F,'A6,W)V-$HO=T%!
M;CE-5F0V-RM#9CA!04HO5$970C9L*UI8)B-X03MM<3`Q;65W:#AM,U8Q8G<S
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M03ME2$AX46IX>3=N23`R25I*,4DX25-R+T5D.2]Y=U-F.&EN+S5O>E(O>3%Q
M+SE14#(O<61J+THR3"]60CEN-C-F-&IV=BM70U0O:U4O)B-X03LO3D=0.'1A
M=B]51#EV-FPO:S=&+W%G*WHY8F8K23<W+T%*64I0*U)4+W=$3D=0.$%,5W(O
M04Y14#(O<5@K5'-8*W%$-U`Q=&8T:G9V)B-X03LK5T-4+VM5+R].1U`X=&%V
M+U5$.78V;"]K-T8O<6<K>CEB=CA2,S,O04-W4V8X:6XO=T-A368U83%F.$%Q
M0BLS.5,O>61I+S%19EHK)B-X03MT>#AX6'!&1'`W:TAQ1$4Y4"M)62]W071A
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M,S`Q9T]Z;T1R3&PK3VI/6&%U46EI23@W)B-X03LO5#,Y*S9596,O>64P1'I5
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M57%D+UI15&U*<G,K5$9J-'-C94]88S,V)B-X03MB2$=C-FME14I8+VE$5E`K
M5T-4+T%*1E-F.#`U<%`U5S%V.$%Q0BLQ,D@U1$(O<6<K660O:4164"M70U0O
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M=7)+8E=03F5K6&5J>75%865E>'4T-7`T234S13AS4S)S)B-X03M.16M#,%9"
M249"1D-6<E5N9D]T5%0O;&-N;2LY:6$R,&$X,'4T;FAT5G5:5$IA,V$S33!"
M5TM->E%B0T)737I/55=7;7A1159R:%9.)B-X03LO2S-N=CAX+T]-54UU:7EA
M6F)24GA*3F9R8WAZ4GE&2C5P5F@Y2&%B9C!O-G5757%81D8R2D]+<WHX=4@X
M>#!U,%AZ1DQP53%I='5W)B-X03ME4WI765A$6%!Q2&DS>&A9>$@V5DYQ5C5D
M-F11:&MV<5`T+V=-5F0V:BM0-$1&56%X2FDP.&YR-C,O1VHT<%)D=C%M+S1Y
M2#E1>%8U)B-X03LU<E!M8GIJ8F%X3&$R3VUI87E6:T-84FAL8V-7:D1-9F=)
M<GA9;G`X=75A-U!Q33!::U)J8V4K:3=85#985'EX:55P,4QU<V0V16HX)B-X
M03LS*V5M4TEN4TYN-65Q5&)Z2UDV16=F0U16<4-J8F1E9S-'5FI6-3EV4CEH
M8E1O=$YV-B]T:G8X06IL-6,P<#AY9FU,*UE7;G1P34YT)B-X03MP0TIC6#EZ
M8WAZ0C=79350<'=22S9*2$A$26IL<$AE;E`W2W%'66EI;DTS5%I*>D)->'=M
M,U@V=D9J:$E#175)56PY:"MC2#5M439,)B-X03MA>F%N-4=U<FI52EE*2G!"
M8E$S<T,X;$9W5FI-2G1B;&]N2F=22TY)82MO<F1.:&M/26IF3E`U;&9M3&)W
M>DYP2&PR5T4R*W!Z,D)K)B-X03ML<TPS56979VEA,T-82U(R-'175DA3858K
M44QO9E,T<7A,1$95,R],>CAW4$Y0;5!69%AS3F(P3G1%8E1)8DYK16EY07I0
M4#9W;&M8)B-X03LQ:VE0<#AO=4LX5EE65G9J6459<7E45F1#<SE3-'1-.'E3
M4FM.1S!C<VEH5UAO46]014@S1R]V;#),35EC<6$U-'A*:#`O-60S;'1.)B-X
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M868K=5`U<E5F>E!S2R]K9$HO<6XR:'-E9F90=&%F-&1M,R\U9'`O-C0O;712
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M151I3G!8:RM)>4QW5E%35W!X8DXP-'E595`Y2#0U=74Q2GA74$1',W@W+U!Y
M4U-W.#,O.$%/56-I4S-H.'4R:G)D>'=Y)B-X03LR,71,-D-P1%<R2EI/3%AL
M=D]H33-(;4IE4D97<%1I03)1-'%C96%D4R]0,F4V8CE&5S<R=')&9C-C55IS
M5'`S3U=W53(U9VQK*W93)B-X03M41&UY;6-*>#1F1E1M:6I&53@O3%179GI1
M=7)J5UEF3S!!=&UT6&=3=V%.5E=/46-'.5)K6D=K1&AQ27A03#=41557;D5+
M<S)X5C)+)B-X03MU>%8R2W5X5C)+=7A69S)T82\X06Y*0F8S365J-E!A6$9M
M:E-I,656:TA*1E9V4TI9,U-(8VAF.3%J8VQF:$-H,U5O0S0X>&9N-F94)B-X
M03M-3VE724M/<&-#4TUI4F5#0G=E5C%69FI:>4ME2%@K9%8V2'!T,W%S;6Y7
M<VPK0D1F4$1',3-%:'%Q5$916D95,6)93E5$8S1O4E`Q)B-X03MI9CA!;E`S
M-'%K9FTW5V1D<TY,5V93;TAV3&MY<7!I5TYP:GA)66LX5C,W9&-X.59/8UDS
M05=B8W9263AC-3%K3E)P:'8K3U!Z22\V)B-X03MS<S,O045H>B]W0F,Q+S5J
M5F9Z9G-,=&9Y96DO;B\W24\O>'@K6D@O049:6G8K:T]F*W50-6I69GIF<TLO
M:SE&+U`X03EK1C!F;F(X)B-X03MY2&161VI3:FM12W1A5$%B*TI,8EDO;4Y6
M+TXK>&9Y96DO;B]!1V@V3D).8W1"1S!W.4]6;$)K44=O5FE.>%A.=D5M="MB
M;UIG06UU)B-X03M3+S%(+VU/1FDS-FHO=T%X>%9R,4@O;4]+=3E2+W=#631Q
M-S%(+VU/2W0K;R]W1$UC5F$Y4B\U:FER=E5F*UDT<6IM2DU/;FLY9E<O)B-X
M03LT,&9&2TQT*W,S+T=1+W%'2W90=%HX,65D3&)72F)7>#`O,7)*5U%*9$='
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M;&M2<$E)2EI):F5X1#`P9%=L;5AI8F-S1$94:GED4FER3B]W079F3BMT)B-X
M03ME6F9+;'1R1W`R8F%897IY,TM3-F4Q9550;S--:TEJ8FM!,TY22%(V<79X
M5BM%9$U52CED,S@X1G).3T$P<&E2;D530W).>$)016)D)B-X03M4:V]I>4%G
M;&IR96,O35E:,4AL,C9B:GHT2&MO1&-!0TM66&)L53!R;58K6&@O4$18-&MV
M-7)B-C4U:6XQ:E-5='EB3DQH<#)V<D]E)B-X03M.6E`S15%(1U%%8T=1<U=!
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M8E1/9W9:6$1S<U!R1E5K85`V>$%A*VPX4E9A+U)7:7%Q)B-X03M'<"M:+W=!
M.%5U5D=N95@W3U,R3G9!-TY*2D57.60P:DTX9BLY4V))>&MO93E":7%!,'9Z
M<"MF3B]D>5(O;T,P=')A3S5.=DIC5'AT)B-X03M&>$,Q-5-+:C-3=$MG*T5H
M:S)B96YS<6UE:V59+W=!-W!D53`V4%4Y1G-O3D]K;$DQ1V1'5#%)-'1Q1E9&
M,4HW+W=!,WE'2W-N.#$V)B-X03LW<E=N85ET>'`Q<3DO8T=654U#4G9)47!"
M2F)I;2LQ37@Y5&MN0TYW1FQY9$AI>'IN57IW:6U)+SAR03@K+SA!575Z+T%0
M4TQC6F<O)B-X03MM.5(O32MW=7HO2394+U90=$1V*U9G969F*W!D;B\V4F)J
M2#@S<5`U;C)&9GE/:R\Q5#=1:71/.#9E9F)Y85-%84,X5&U+5F]M;6EL)B-X
M03MH5#%&46Q!5VM)6&1Q0VQ2;'5(55HU4T%L1V@X5VI5-E14>&=41V1Y*T,W
M4U!-;C5T0S9T-U16+TLY=$ER.#%U9%)T8GE+2S-J2TTT)B-X03M6,6ID<%IN
M5U%+<F1!5G(S3V)*,4M(=F9.4#5X>'=)3%AY;$),37-S85-T.6-G-'9(.$Q3
M=6ET2VY(8FMI9W-D+VDS1S)+<F(W>FPK)B-X03MB-3!Q15=8:W5/2%=P95)+
M5%@P371U:7@W<U-Y1TU69F]Q.'@Q<G5&3TM5679M8C@Q6C4P4655-$Q+265M
M6DHU3E%H=4,S269'<6]G)B-X03MI<'=0-U)B9G-..6Q#079F378U,T\W4U=0
M;&EZ9VEA>&%55S@Y>D9--EAO:TE73#%5;FE$<5DV369G54$W8VI48TIE:%%4
M6$114G1+)B-X03M/17)+1$EM,GI%8FI9<TYJ-S1O5E!6:R]M>%8S<5`T-'$W
M,4@X8U92<D5M3%1Y979R9CA!1VHT<%)D=C%M+S1Y2#E1>%8U-7)0;69Z)B-X
M03ML8F%X3&$R3VYE=%I+>4),;W=Y=4],4FAM4'=%5C1S5#`K6%A.9&XQ1V%-
M>4EX=5!F4F1R<#E,<#59>$M5-FPS5T\Y0U(K8V908DI%)B-X03M4<$]Z.'96
M2G0U;$UD0U%0:$IQ,4)2='5V46)J2WAQ."LS;RMW='`P5VTS+T%(;BMY:G8K
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M03M+>6=Y2G1S>$<T,DQ$62LK2T8O<5`T-'$W;3-J:7)U8F5/2V\U:51$<#50
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M07ED-D50*RLQ*S19<3<P268X069A+V--5F0V15`X079T9G5'2W4Y0T@O9F$O
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M2W4T2B]+4'5X5E9N04,R3E`Y+T0O:40T)B-X03M&4D9V,6TO-'E(.5%X5FE'
M<"]M3"MJ3EAL<TQU,2]D<$(V.&,P5EA,04MZ1494>$,O65`W6#EM1FPQ;VA-
M>&M/;'5F:#!%<VU-5&EE)B-X03MT555V:2]/0WI-5'EZ5V-I24I84TE*>%II
M<6-F:5I79$-#968R4E@U-5-/,#166D)C:5A9*U,V0DA,>B]!1R]O5G)V.#)T
M3W1X9$E,)B-X03ME5G`W6GI'27EN14\T-41:9WI55W$Y858S-F1C;E!T3$=,
M,DYH:&HW2GEY<F-55TIE8W8K8VIJ-68Q;3`P-DA324IL=7)33S=&>&58)B-X
M03M:<S%":W5*3&-Q2U)80W-Q96QZ6G<Q3T\O8DUZ1FM%-&E1-G5";7A(2$UX
M4%)K;C5C9FY#=FYH9%%A1%1*9$\O4B]O:&QU0W)&:DM()B-X03M$9V5M>DPX
M16M4<C%R,TE",D9J57I4.4LS2#AQ9F-F-C1O9"ML8FHK5E!U4#EC5F0K;&)J
M*U90=5`Y8U9D*VQB:BM64'50.$%81EAF)B-X03MP5S0O;%0W:B]81EAN;"\O
M04TU0RM83$A63#=46G)'*TYX65A45V-R3$1'55HP-3=Q>&U(=VXP:E-T1#=D
M84M53$PO>FMR-5=I=4=G)B-X03MF5'1156=K0FI"14%W179O:VES-$Y/9FE-
M5EHS-6,X-7@K64Y%=$Y:<V]J2&$S:6,T:VU8:DE!0U8K24)M2%5D:FEH2F11
M+TYY>#`K)B-X03M8530W<7=U12]26EE3=5)!16LT=D%L55EZ9T%F-EA'87EC
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M<DY.+V]N>&9Z2B]:*W1Z+T%/4CAN95!T9"]J5W<O>DLO=T1.5U`X06]N>&9Z
M2B]:*W1F-4AY9#0K,7<X)B-X03LW5T$W9FEV+T%$5FHO;VYX9GI*+UHK=&8U
M2'ED-"LQ,RM.8D0O37(O04TQ62]W0VEF1B]-;CEN-C$O:V9*,VHW6&8T,7-0
M.$%-<B]Z)B-X03M6:B]O;GAF>DHO6BMT9C5(>60T*S%W.#=704E.3VYU=B].
M5U`K:69&+TUN.6XV,2]K9DHS:C=89C0Q<U`X>78O0416:B]O;GAF>DHO)B-X
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M03M.04A"3C=J22LX+U`W43=84T4Q<7<X=C(X5GAD,VAS9%)..61,6G(Y66A3
M,54O=C1L=796-')D<CES2U%I3U-">'!I<48Q;B]!2GEJ)B-X03LP3WA.=&%W
M95=,>515<"]467=4=7-52E9Y>4@P-5EN=4=:+U989T9E3DXO=$9A67$Y93!8
M5C1.5C!E>#%/3S)%8V0Y8GA82U)V>C5+)B-X03M*:T1H5'5.>'EX5E%B>DI9
M4U!E4C)58TUZ5TQ'3S5N:V0T<F%/66-F,U14170X9$@S0TLS1VQ'-&UL87IL
M1SED4&PX,TY':&U"17IS)B-X03MC931!1GE),SE1:C-B9%-,-7AS5S!F375N
M<WE.82]5-WE";$940F1+6F5B54Y&5FU60V]J-4]4>D)O3FQ/0352,$E0>%-.
M1$U!.%%L)B-X03M#6&Y%,5AV-3-D1#9E6C-)53E:.#0V3G!8;#(U,2M323-&
M:F%!1UI)1EEY9SAW:DM9,V1#<DE4.%-T47)V6&9,0DE(:S1U6$1,2$QH)B-X
M03MK2U`T,TAE1#!),E!22712+TXO>7)9-F9C,WHR<W-S5G)E9E5(5TUX8VDU
M9TTT8V-R:%8T36])5W!"2C9$0W=P03-8-39E5G)D1FMB)B-X03M33E%-3%)*
M34IM:5-+3VIX<DQX1%1Z>$%L438Y2VAU4SA3=UI35F%4;GER-3-M.'I8<5A&
M:'!P9S!.64<K<U!D0E9N5S5947EW2U!4)B-X03MU6E!H94-B;CEJ-F$W66]3
M+W=!>69N3C56,%!68G93<&)6-3<V>6QG:6Y25VI2851P>C5Q.&MY0VE$6G$P
M;WA!4&II;6MV<R\K8V=V)B-X03M*9#%E=U=I-F1F4FTT;&AH17IX>&E.5%`P
M6FU&=V9H6#EO:D9A4D=S9FYN-5(P<3EU-U,T<TQP-4Q/-"MQ>4Y&-D)"8T=1
M5D9B;%=!)B-X03LO9$@W44(V1VTK2S!H<F8O04IY0SAM>G8V83989DLO<7A1
M149)9&UM2E9A:UA*06]6,S-R:71-,#@P*UDW1%$Y3E<X=3=D6&EA5EEW)B-X
M03MO3DXR0E`W8E4O6GI(,5=9630R4F4W;&%05'EZ5#1183)9;B]!37)C.',O
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M2S=K4#52*U`Y8U9D>4@X;R](*W5+;S5J)B-X03M72%0Y<69V=6XK=V9&2TQT
M*W,S+T%":U`V:&ER13=$>B]W1&QZ<49R<DXQ6C9M2F)F>2]#3&Y6<$)(3T)&
M17E.27)I<40Q3U-X:VHP)B-X03LK5F9P1TLP:$Q4.#)F>6)U,FE%6&UR5$8Y
M5T),;%=L=6QH54DY3TMU,'!12DIV=D4Q2$<Y5C)/2W)B:CAX+WEC64QE>6$S
M67IZ5U5T)B-X03MZ1V=1;6$U:&MT,&PK<T5224=M4F5%1"]!0CA1<D-N16M-
M=%959F$K9F9Y>75.3VDQ2#E05U9V6GI35%)24UAK-'1#>C(P9VEM05,U)B-X
M03M-5"]!-TM$=#-(:4U685`U:&9L3496>C5T,%5),5%R2%5R5VAP,6]F57A6
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M26DO=T-T)B-X03MK-S<O04HO9G8W.3`W2#5G9FMX<'1Y;'%N;512-'!T461P
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M<C!K>5!',&]C6#!*:4-O44-$2T@Y3E<K3%I3,TEI<$%O1%)69F1F;5`K571T
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M*TIA9U4S4%1)949$=410>'`O=T$T+TXR;V9M3"M1,6=O:VQV-T=A07ET0CEA
M=$QE4SAG1&])5UE'93)I;&E!2#%Q249U)B-X03M62W14<4-!*T9(=4,K3E`K
M8V9M<U0X,U`K8V8W4RM32TA89$]J=5=U1W,Q;&A2>6]K2$5%;5I%2TQ%9E5&
M2E,S<&YE:F9#,4I$2$5C)B-X03MG15-Y4TEO:W`Q9&9M:"M55G1E5U9M+VUF
M5&YN,4)U3G%)8FQ:,4I,2V\U=D584TU%<TM&>4%D-F1$:VU#1V<O3T0X;#4Y
M4V)4:S@P)B-X03LV971W<5!)6&QN.4M$:DA)66I3-&LT=VML:%912'%Y+T=T
M5DE/2W,R:S!N5'`P55-23$MG6EI%-69%3U-K37)#=F-%5D)X5F8K:G)4)B-X
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M,V9A1S$Q>GEY4T(V:F(W)B-X03MB<31'161V-E%M=5`W1"MP0C=/>D1P.6]4
M4S573F9Q26HK>#9W2R])>'5C,T%C2EAT*W,S+T=1+W%'2W9'9GDY<V9/03`S
M>G=*9DE6)B-X03MJ<$YX3G`V4F%,6GI2=4ET44%&,F]G=2]6;FMJ:U5317)1
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M1%-+,W!Q=C=S;%98-&$P53`K,$]+<50V=G!(;E$V1F-*92]K3F]6>F-E)B-X
M03MN5S=U-U=F5#%,>$%6:T5%15%.>4I"1E9%2U-L9SE'54@W3TMO,SE%*V)+
M=T=Z+TE,46]B14MP=6]*-VY35VUM<6\T:$=#04IW8713)B-X03LV<U<X1D]+
M<3DY;U@U9S-54S(K:69K+S58,%I:8F1)-W<V;3%J95)/1&-2;C!/1G`V0C12
M54UX<E5'9V]/44%+<6IO5FHK6C!K0S9B)B-X03LU:2]*:GDX,6<P>71#8E8Y
M3E-+,4QX<$1.3V):-5IH33-P<6\T<3AD5E5*>39%2V]04U!+9FTW4UEF<3AV
M-4<V1'%53GEV,7$W<&0R)B-X03M%65<Y9#--;D)B<#<S:$=%2W%K4VYI:')X
M3D112W%S1VDV+V4K<G`R;R]K2F]Y,TM*.6)-.$XQ65=S5$)*1V5#1EIO;UI+
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M-$=!1$]Q<5AM;"MC;C!R)B-X03LP-U`X:5!,.$Q7.#='1WEM=71+;5%M84IG
M8FE-3$9#:3A8:6DU,4E:;&]"+TUQ<6AF-DPU;C%B4V11:E`U2F%(3G)Z>'AW
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M5S9H:FU#,4MS84)W,4ML1E`P1$98;%!N)B-X03M56&UI*V,W6%0Y12],-G<Q
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M2W4K<WAF-5@O05`O5$989E=9=CAR+T%)0B\V67$W-GI&+VQF.$%!4#A!)B-X
M03LP>%8S,6U,+T%#=BM!9CA!<&ER=G)-6"M6+W=$+W="359D.5II+WEV*T%F
M*VU+=2MS>&8U6"]!4"]41EAF5UEV.'(O9T@O<&ER=G)-)B-X03M8*U8O=T0O
M,'A64VQR8U118T9B:D4O<4UX0D$K>59P=B]R67$O=T0O,E$]/3PO>&UP1TEM
M9SII;6%G93X*("`@("`@("`@("`@("`@/"]R9&8Z;&D^"B`@("`@("`@("`@
M(#PO<F1F.D%L=#X*("`@("`@("`@/"]X;7`Z5&AU;6)N86EL<SX*("`@("`@
M/"]R9&8Z1&5S8W)I<'1I;VX^"B`@("`@(#QR9&8Z1&5S8W)I<'1I;VX@<F1F
M.F%B;W5T/2(B"B`@("`@("`@("`@('AM;&YS.GAM<$U-/2)H='1P.B\O;G,N
M861O8F4N8V]M+WAA<"\Q+C`O;6TO(@H@("`@("`@("`@("!X;6QN<SIS=%)E
M9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+W-4>7!E+U)E<V]U<F-E
M4F5F(R(*("`@("`@("`@("`@>&UL;G,Z<W1%=G0](FAT='`Z+R]N<RYA9&]B
M92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C945V96YT(R(^"B`@("`@("`@
M(#QX;7!-33I);G-T86YC94E$/GAM<"YI:60Z-C1#-#)$,C1$.$,Q130Q,4$W
M,$5%-T8Y-T0W,C=!034\+WAM<$U-.DEN<W1A;F-E240^"B`@("`@("`@(#QX
M;7!-33I$;V-U;65N=$E$/GAM<"YD:60Z-C1#-#)$,C1$.$,Q130Q,4$W,$5%
M-T8Y-T0W,C=!034\+WAM<$U-.D1O8W5M96YT240^"B`@("`@("`@(#QX;7!-
M33I/<FEG:6YA;$1O8W5M96YT240^=75I9#HU1#(P.#DR-#DS0D9$0C$Q.3$T
M03@U.3!$,S$U,#A#.#PO>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/@H@("`@
M("`@("`\>&UP34TZ4F5N9&ET:6]N0VQA<W,^9&5F875L=#PO>&UP34TZ4F5N
M9&ET:6]N0VQA<W,^"B`@("`@("`@(#QX;7!-33I$97)I=F5D1G)O;2!R9&8Z
M<&%R<V54>7!E/2)297-O=7)C92(^"B`@("`@("`@("`@(#QS=%)E9CII;G-T
M86YC94E$/GAM<"YI:60Z,4$V0S(V-3E$,4,Q130Q,4$W,$5%-T8Y-T0W,C=!
M034\+W-T4F5F.FEN<W1A;F-E240^"B`@("`@("`@("`@(#QS=%)E9CID;V-U
M;65N=$E$/GAM<"YD:60Z,4$V0S(V-3E$,4,Q130Q,4$W,$5%-T8Y-T0W,C=!
M034\+W-T4F5F.F1O8W5M96YT240^"B`@("`@("`@("`@(#QS=%)E9CIO<FEG
M:6YA;$1O8W5M96YT240^=75I9#HU1#(P.#DR-#DS0D9$0C$Q.3$T03@U.3!$
M,S$U,#A#.#PO<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/@H@("`@("`@("`@
M("`\<W12968Z<F5N9&ET:6]N0VQA<W,^9&5F875L=#PO<W12968Z<F5N9&ET
M:6]N0VQA<W,^"B`@("`@("`@(#PO>&UP34TZ1&5R:79E9$9R;VT^"B`@("`@
M("`@(#QX;7!-33I(:7-T;W)Y/@H@("`@("`@("`@("`\<F1F.E-E<3X*("`@
M("`@("`@("`@("`@/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^
M"B`@("`@("`@("`@("`@("`@(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T
M.F%C=&EO;CX*("`@("`@("`@("`@("`@("`@/'-T179T.FEN<W1A;F-E240^
M>&UP+FEI9#HQ039#,C8U.40Q0S%%-#$Q03<P144W1CDW1#<R-T%!-3PO<W1%
M=G0Z:6YS=&%N8V5)1#X*("`@("`@("`@("`@("`@("`@/'-T179T.G=H96X^
M,C`Q-2TP,RTP,U0Q-#HP-#HR.2TP-3HP,#PO<W1%=G0Z=VAE;CX*("`@("`@
M("`@("`@("`@("`@/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@26QL=7-T
M<F%T;W(@0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*("`@
M("`@("`@("`@("`@("`@/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E
M9#X*("`@("`@("`@("`@("`@/"]R9&8Z;&D^"B`@("`@("`@("`@("`@(#QR
M9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@("`@("`@("`@("`@
M("`@("`\<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B`@("`@
M("`@("`@("`@("`@(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z-C1#-#)$
M,C1$.$,Q130Q,4$W,$5%-T8Y-T0W,C=!034\+W-T179T.FEN<W1A;F-E240^
M"B`@("`@("`@("`@("`@("`@(#QS=$5V=#IW:&5N/C(P,34M,#,M,#-4,30Z
M,#0Z,SDM,#4Z,#`\+W-T179T.G=H96X^"B`@("`@("`@("`@("`@("`@(#QS
M=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E($EL;'5S=')A=&]R($-3-B`H5VEN
M9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B`@("`@("`@("`@("`@("`@
M(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B`@("`@("`@("`@
M("`@(#PO<F1F.FQI/@H@("`@("`@("`@("`\+W)D9CI397$^"B`@("`@("`@
M(#PO>&UP34TZ2&ES=&]R>3X*("`@("`@/"]R9&8Z1&5S8W)I<'1I;VX^"B`@
M("`@(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B`@("`@("`@("`@
M('AM;&YS.FEL;'5S=')A=&]R/2)H='1P.B\O;G,N861O8F4N8V]M+VEL;'5S
M=')A=&]R+S$N,"\B/@H@("`@("`@("`\:6QL=7-T<F%T;W(Z4W1A<G1U<%!R
M;V9I;&4^4')I;G0\+VEL;'5S=')A=&]R.E-T87)T=7!0<F]F:6QE/@H@("`@
M("`\+W)D9CI$97-C<FEP=&EO;CX*("`@("`@/')D9CI$97-C<FEP=&EO;B!R
M9&8Z86)O=70](B(*("`@("`@("`@("`@>&UL;G,Z>&UP5%!G/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C`O="]P9R\B"B`@("`@("`@("`@('AM;&YS
M.G-T1&EM/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O<U1Y<&4O1&EM
M96YS:6]N<R,B"B`@("`@("`@("`@('AM;&YS.G-T1FYT/2)H='1P.B\O;G,N
M861O8F4N8V]M+WAA<"\Q+C`O<U1Y<&4O1F]N=",B"B`@("`@("`@("`@('AM
M;&YS.GAM<$<](FAT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]G+R(^"B`@
M("`@("`@(#QX;7!44&<Z2&%S5FES:6)L94]V97)P<FEN=#Y&86QS93PO>&UP
M5%!G.DAA<U9I<VEB;&5/=F5R<')I;G0^"B`@("`@("`@(#QX;7!44&<Z2&%S
M5FES:6)L951R86YS<&%R96YC>3Y4<G5E/"]X;7!44&<Z2&%S5FES:6)L951R
M86YS<&%R96YC>3X*("`@("`@("`@/'AM<%109SI.4&%G97,^,3PO>&UP5%!G
M.DY086=E<SX*("`@("`@("`@/'AM<%109SI-87A086=E4VEZ92!R9&8Z<&%R
M<V54>7!E/2)297-O=7)C92(^"B`@("`@("`@("`@(#QS=$1I;3IW/C@N-S4P
M,#`P/"]S=$1I;3IW/@H@("`@("`@("`@("`\<W1$:6TZ:#XQ,2XR-3`P,#`\
M+W-T1&EM.F@^"B`@("`@("`@("`@(#QS=$1I;3IU;FET/DEN8VAE<SPO<W1$
M:6TZ=6YI=#X*("`@("`@("`@/"]X;7!44&<Z36%X4&%G95-I>F4^"B`@("`@
M("`@(#QX;7!44&<Z1F]N=',^"B`@("`@("`@("`@(#QR9&8Z0F%G/@H@("`@
M("`@("`@("`@("`\<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*
M("`@("`@("`@("`@("`@("`@/'-T1FYT.F9O;G1.86UE/DAE;'9E=&EC84YE
M=64M365D:75M0V]N9#PO<W1&;G0Z9F]N=$YA;64^"B`@("`@("`@("`@("`@
M("`@(#QS=$9N=#IF;VYT1F%M:6QY/DAE;'9E=&EC82!.975E/"]S=$9N=#IF
M;VYT1F%M:6QY/@H@("`@("`@("`@("`@("`@("`\<W1&;G0Z9F]N=$9A8V4^
M-C<@365D:75M($-O;F1E;G-E9#PO<W1&;G0Z9F]N=$9A8V4^"B`@("`@("`@
M("`@("`@("`@(#QS=$9N=#IF;VYT5'EP93Y4>7!E(#$\+W-T1FYT.F9O;G14
M>7!E/@H@("`@("`@("`@("`@("`@("`\<W1&;G0Z=F5R<VEO;E-T<FEN9SXP
M,#$N,#`P/"]S=$9N=#IV97)S:6]N4W1R:6YG/@H@("`@("`@("`@("`@("`@
M("`\<W1&;G0Z8V]M<&]S:71E/D9A;'-E/"]S=$9N=#IC;VUP;W-I=&4^"B`@
M("`@("`@("`@("`@("`@(#QS=$9N=#IF;VYT1FEL94YA;64^2&QM8U]?7U\N
M4$9".R!(;&UC7U]?7RYP9FT\+W-T1FYT.F9O;G1&:6QE3F%M93X*("`@("`@
M("`@("`@("`@/"]R9&8Z;&D^"B`@("`@("`@("`@("`@(#QR9&8Z;&D@<F1F
M.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@("`@("`@("`@("`@("`@("`\<W1&
M;G0Z9F]N=$YA;64^2&5L=F5T:6-A3F5U92U";VQD0V]N9#PO<W1&;G0Z9F]N
M=$YA;64^"B`@("`@("`@("`@("`@("`@(#QS=$9N=#IF;VYT1F%M:6QY/DAE
M;'9E=&EC82!.975E/"]S=$9N=#IF;VYT1F%M:6QY/@H@("`@("`@("`@("`@
M("`@("`\<W1&;G0Z9F]N=$9A8V4^-S<@0F]L9"!#;VYD96YS960\+W-T1FYT
M.F9O;G1&86-E/@H@("`@("`@("`@("`@("`@("`\<W1&;G0Z9F]N=%1Y<&4^
M5'EP92`Q/"]S=$9N=#IF;VYT5'EP93X*("`@("`@("`@("`@("`@("`@/'-T
M1FYT.G9E<G-I;VY3=')I;F<^,#`Q+C`P,#PO<W1&;G0Z=F5R<VEO;E-T<FEN
M9SX*("`@("`@("`@("`@("`@("`@/'-T1FYT.F-O;7!O<VET93Y&86QS93PO
M<W1&;G0Z8V]M<&]S:71E/@H@("`@("`@("`@("`@("`@("`\<W1&;G0Z9F]N
M=$9I;&5.86UE/DAL8F-?7U]?+E!&0CL@2&QB8U]?7U\N<&9M/"]S=$9N=#IF
M;VYT1FEL94YA;64^"B`@("`@("`@("`@("`@(#PO<F1F.FQI/@H@("`@("`@
M("`@("`\+W)D9CI"86<^"B`@("`@("`@(#PO>&UP5%!G.D9O;G1S/@H@("`@
M("`@("`\>&UP5%!G.E!L871E3F%M97,^"B`@("`@("`@("`@(#QR9&8Z4V5Q
M/@H@("`@("`@("`@("`@("`\<F1F.FQI/D-Y86X\+W)D9CIL:3X*("`@("`@
M("`@("`@("`@/')D9CIL:3Y-86=E;G1A/"]R9&8Z;&D^"B`@("`@("`@("`@
M("`@(#QR9&8Z;&D^665L;&]W/"]R9&8Z;&D^"B`@("`@("`@("`@("`@(#QR
M9&8Z;&D^0FQA8VL\+W)D9CIL:3X*("`@("`@("`@("`@/"]R9&8Z4V5Q/@H@
M("`@("`@("`\+WAM<%109SI0;&%T94YA;65S/@H@("`@("`@("`\>&UP5%!G
M.E-W871C:$=R;W5P<SX*("`@("`@("`@("`@/')D9CI397$^"B`@("`@("`@
M("`@("`@(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@("`@
M("`@("`@("`@("`@("`\>&UP1SIG<F]U<$YA;64^1&5F875L="!3=V%T8V@@
M1W)O=7`\+WAM<$<Z9W)O=7!.86UE/@H@("`@("`@("`@("`@("`@("`\>&UP
M1SIG<F]U<%1Y<&4^,#PO>&UP1SIG<F]U<%1Y<&4^"B`@("`@("`@("`@("`@
M("`@(#QX;7!'.D-O;&]R86YT<SX*("`@("`@("`@("`@("`@("`@("`@/')D
M9CI397$^"B`@("`@("`@("`@("`@("`@("`@("`@(#QR9&8Z;&D@<F1F.G!A
M<G-E5'EP93TB4F5S;W5R8V4B/@H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`\>&UP1SIS=V%T8VA.86UE/E=H:71E/"]X;7!'.G-W871C:$YA;64^"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.FUO9&4^0TU92SPO>&UP
M1SIM;V1E/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIT>7!E
M/E!23T-%4U,\+WAM<$<Z='EP93X*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@/'AM<$<Z8WEA;CXP+C`P,#`P,#PO>&UP1SIC>6%N/@H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`\>&UP1SIM86=E;G1A/C`N,#`P,#`P/"]X;7!'
M.FUA9V5N=&$^"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.GEE
M;&QO=SXP+C`P,#`P,#PO>&UP1SIY96QL;W<^"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@(#QX;7!'.F)L86-K/C`N,#`P,#`P/"]X;7!'.F)L86-K/@H@
M("`@("`@("`@("`@("`@("`@("`@("`\+W)D9CIL:3X*("`@("`@("`@("`@
M("`@("`@("`@("`@/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.G-W871C:$YA;64^
M0FQA8VL\+WAM<$<Z<W=A=&-H3F%M93X*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E
M/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIC>6%N/C`N,#`P
M,#`P/"]X;7!'.F-Y86X^"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX
M;7!'.FUA9V5N=&$^,"XP,#`P,#`\+WAM<$<Z;6%G96YT83X*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@/'AM<$<Z>65L;&]W/C`N,#`P,#`P/"]X;7!'
M.GEE;&QO=SX*("`@("`@("`@("`@("`@("`@("`@("`@("`@/'AM<$<Z8FQA
M8VL^,3`P+C`P,#`P,#PO>&UP1SIB;&%C:SX*("`@("`@("`@("`@("`@("`@
M("`@("`@/"]R9&8Z;&D^"B`@("`@("`@("`@("`@("`@("`@("`@(#QR9&8Z
M;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`\>&UP1SIS=V%T8VA.86UE/D--64L@4F5D/"]X;7!'.G-W
M871C:$YA;64^"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.FUO
M9&4^0TU92SPO>&UP1SIM;V1E/@H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`\>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@/'AM<$<Z8WEA;CXP+C`P,#`P,#PO>&UP1SIC>6%N
M/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIM86=E;G1A/C$P
M,"XP,#`P,#`\+WAM<$<Z;6%G96YT83X*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@/'AM<$<Z>65L;&]W/C$P,"XP,#`P,#`\+WAM<$<Z>65L;&]W/@H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIB;&%C:SXP+C`P,#`P
M,#PO>&UP1SIB;&%C:SX*("`@("`@("`@("`@("`@("`@("`@("`@/"]R9&8Z
M;&D^"B`@("`@("`@("`@("`@("`@("`@("`@(#QR9&8Z;&D@<F1F.G!A<G-E
M5'EP93TB4F5S;W5R8V4B/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\
M>&UP1SIS=V%T8VA.86UE/D--64L@665L;&]W/"]X;7!'.G-W871C:$YA;64^
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.FUO9&4^0TU92SPO
M>&UP1SIM;V1E/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIT
M>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@/'AM<$<Z8WEA;CXP+C`P,#`P,#PO>&UP1SIC>6%N/@H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`\>&UP1SIM86=E;G1A/C`N,#`P,#`P/"]X
M;7!'.FUA9V5N=&$^"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'
M.GEE;&QO=SXQ,#`N,#`P,#`P/"]X;7!'.GEE;&QO=SX*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@/'AM<$<Z8FQA8VL^,"XP,#`P,#`\+WAM<$<Z8FQA
M8VL^"B`@("`@("`@("`@("`@("`@("`@("`@(#PO<F1F.FQI/@H@("`@("`@
M("`@("`@("`@("`@("`@("`\<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U
M<F-E(CX*("`@("`@("`@("`@("`@("`@("`@("`@("`@/'AM<$<Z<W=A=&-H
M3F%M93Y#35E+($=R965N/"]X;7!'.G-W871C:$YA;64^"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIT>7!E/E!23T-%4U,\
M+WAM<$<Z='EP93X*("`@("`@("`@("`@("`@("`@("`@("`@("`@/'AM<$<Z
M8WEA;CXQ,#`N,#`P,#`P/"]X;7!'.F-Y86X^"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@(#QX;7!'.FUA9V5N=&$^,"XP,#`P,#`\+WAM<$<Z;6%G96YT
M83X*("`@("`@("`@("`@("`@("`@("`@("`@("`@/'AM<$<Z>65L;&]W/C$P
M,"XP,#`P,#`\+WAM<$<Z>65L;&]W/@H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`\>&UP1SIB;&%C:SXP+C`P,#`P,#PO>&UP1SIB;&%C:SX*("`@("`@
M("`@("`@("`@("`@("`@("`@/"]R9&8Z;&D^"B`@("`@("`@("`@("`@("`@
M("`@("`@(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIS=V%T8VA.86UE/D--64L@
M0WEA;CPO>&UP1SIS=V%T8VA.86UE/@H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`\>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.F-Y86X^,3`P+C`P
M,#`P,#PO>&UP1SIC>6%N/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\
M>&UP1SIM86=E;G1A/C`N,#`P,#`P/"]X;7!'.FUA9V5N=&$^"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@(#QX;7!'.GEE;&QO=SXP+C`P,#`P,#PO>&UP
M1SIY96QL;W<^"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.F)L
M86-K/C`N,#`P,#`P/"]X;7!'.F)L86-K/@H@("`@("`@("`@("`@("`@("`@
M("`@("`\+W)D9CIL:3X*("`@("`@("`@("`@("`@("`@("`@("`@/')D9CIL
M:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@(#QX;7!'.G-W871C:$YA;64^0TU92R!";'5E/"]X;7!'.G-W
M871C:$YA;64^"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.FUO
M9&4^0TU92SPO>&UP1SIM;V1E/@H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`\>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@/'AM<$<Z8WEA;CXQ,#`N,#`P,#`P/"]X;7!'.F-Y
M86X^"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.FUA9V5N=&$^
M,3`P+C`P,#`P,#PO>&UP1SIM86=E;G1A/@H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`\>&UP1SIY96QL;W<^,"XP,#`P,#`\+WAM<$<Z>65L;&]W/@H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIB;&%C:SXP+C`P,#`P
M,#PO>&UP1SIB;&%C:SX*("`@("`@("`@("`@("`@("`@("`@("`@/"]R9&8Z
M;&D^"B`@("`@("`@("`@("`@("`@("`@("`@(#QR9&8Z;&D@<F1F.G!A<G-E
M5'EP93TB4F5S;W5R8V4B/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\
M>&UP1SIS=V%T8VA.86UE/D--64L@36%G96YT83PO>&UP1SIS=V%T8VA.86UE
M/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIM;V1E/D--64L\
M+WAM<$<Z;6]D93X*("`@("`@("`@("`@("`@("`@("`@("`@("`@/'AM<$<Z
M='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@(#QX;7!'.F-Y86X^,"XP,#`P,#`\+WAM<$<Z8WEA;CX*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@/'AM<$<Z;6%G96YT83XQ,#`N,#`P,#`P
M/"]X;7!'.FUA9V5N=&$^"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX
M;7!'.GEE;&QO=SXP+C`P,#`P,#PO>&UP1SIY96QL;W<^"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@(#QX;7!'.F)L86-K/C`N,#`P,#`P/"]X;7!'.F)L
M86-K/@H@("`@("`@("`@("`@("`@("`@("`@("`\+W)D9CIL:3X*("`@("`@
M("`@("`@("`@("`@("`@("`@/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O
M=7)C92(^"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.G-W871C
M:$YA;64^0STQ-2!-/3$P,"!9/3DP($L],3`\+WAM<$<Z<W=A=&-H3F%M93X*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@/'AM<$<Z;6]D93Y#35E+/"]X
M;7!'.FUO9&4^"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.G1Y
M<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`\>&UP1SIC>6%N/C$T+CDY.3DY.#PO>&UP1SIC>6%N/@H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`\>&UP1SIM86=E;G1A/C$P,"XP,#`P,#`\
M+WAM<$<Z;6%G96YT83X*("`@("`@("`@("`@("`@("`@("`@("`@("`@/'AM
M<$<Z>65L;&]W/CDP+C`P,#`P-#PO>&UP1SIY96QL;W<^"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@(#QX;7!'.F)L86-K/C$P+C`P,#`P,CPO>&UP1SIB
M;&%C:SX*("`@("`@("`@("`@("`@("`@("`@("`@/"]R9&8Z;&D^"B`@("`@
M("`@("`@("`@("`@("`@("`@(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S
M;W5R8V4B/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIS=V%T
M8VA.86UE/D,],"!-/3DP(%D].#4@2STP/"]X;7!'.G-W871C:$YA;64^"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.FUO9&4^0TU92SPO>&UP
M1SIM;V1E/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIT>7!E
M/E!23T-%4U,\+WAM<$<Z='EP93X*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@/'AM<$<Z8WEA;CXP+C`P,#`P,#PO>&UP1SIC>6%N/@H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`\>&UP1SIM86=E;G1A/CDP+C`P,#`P-#PO>&UP
M1SIM86=E;G1A/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIY
M96QL;W<^.#0N.3DY.3DV/"]X;7!'.GEE;&QO=SX*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@/'AM<$<Z8FQA8VL^,"XP,#`P,#`\+WAM<$<Z8FQA8VL^
M"B`@("`@("`@("`@("`@("`@("`@("`@(#PO<F1F.FQI/@H@("`@("`@("`@
M("`@("`@("`@("`@("`\<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E
M(CX*("`@("`@("`@("`@("`@("`@("`@("`@("`@/'AM<$<Z<W=A=&-H3F%M
M93Y#/3`@33TX,"!9/3DU($L],#PO>&UP1SIS=V%T8VA.86UE/@H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`\>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D
M93X*("`@("`@("`@("`@("`@("`@("`@("`@("`@/'AM<$<Z='EP93Y04D]#
M15-3/"]X;7!'.G1Y<&4^"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX
M;7!'.F-Y86X^,"XP,#`P,#`\+WAM<$<Z8WEA;CX*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@/'AM<$<Z;6%G96YT83XX,"XP,#`P,#$\+WAM<$<Z;6%G
M96YT83X*("`@("`@("`@("`@("`@("`@("`@("`@("`@/'AM<$<Z>65L;&]W
M/CDT+CDY.3DY.3PO>&UP1SIY96QL;W<^"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@(#QX;7!'.F)L86-K/C`N,#`P,#`P/"]X;7!'.F)L86-K/@H@("`@
M("`@("`@("`@("`@("`@("`@("`\+W)D9CIL:3X*("`@("`@("`@("`@("`@
M("`@("`@("`@/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.G-W871C:$YA;64^0STP
M($T]-3`@63TQ,#`@2STP/"]X;7!'.G-W871C:$YA;64^"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIT>7!E/E!23T-%4U,\
M+WAM<$<Z='EP93X*("`@("`@("`@("`@("`@("`@("`@("`@("`@/'AM<$<Z
M8WEA;CXP+C`P,#`P,#PO>&UP1SIC>6%N/@H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`\>&UP1SIM86=E;G1A/C4P+C`P,#`P,#PO>&UP1SIM86=E;G1A
M/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIY96QL;W<^,3`P
M+C`P,#`P,#PO>&UP1SIY96QL;W<^"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@(#QX;7!'.F)L86-K/C`N,#`P,#`P/"]X;7!'.F)L86-K/@H@("`@("`@
M("`@("`@("`@("`@("`@("`\+W)D9CIL:3X*("`@("`@("`@("`@("`@("`@
M("`@("`@/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.G-W871C:$YA;64^0STP($T]
M,S4@63TX-2!+/3`\+WAM<$<Z<W=A=&-H3F%M93X*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP
M1SIT>7!E/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIC>6%N
M/C`N,#`P,#`P/"]X;7!'.F-Y86X^"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@(#QX;7!'.FUA9V5N=&$^,S4N,#`P,#`R/"]X;7!'.FUA9V5N=&$^"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.GEE;&QO=SXX-"XY.3DY
M.38\+WAM<$<Z>65L;&]W/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\
M>&UP1SIB;&%C:SXP+C`P,#`P,#PO>&UP1SIB;&%C:SX*("`@("`@("`@("`@
M("`@("`@("`@("`@/"]R9&8Z;&D^"B`@("`@("`@("`@("`@("`@("`@("`@
M(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`\>&UP1SIS=V%T8VA.86UE/D,]-2!-/3`@63TY
M,"!+/3`\+WAM<$<Z<W=A=&-H3F%M93X*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E
M/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIC>6%N/C4N,#`P
M,#`Q/"]X;7!'.F-Y86X^"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX
M;7!'.FUA9V5N=&$^,"XP,#`P,#`\+WAM<$<Z;6%G96YT83X*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@/'AM<$<Z>65L;&]W/CDP+C`P,#`P-#PO>&UP
M1SIY96QL;W<^"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.F)L
M86-K/C`N,#`P,#`P/"]X;7!'.F)L86-K/@H@("`@("`@("`@("`@("`@("`@
M("`@("`\+W)D9CIL:3X*("`@("`@("`@("`@("`@("`@("`@("`@/')D9CIL
M:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@(#QX;7!'.G-W871C:$YA;64^0STR,"!-/3`@63TQ,#`@2STP
M/"]X;7!'.G-W871C:$YA;64^"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`\>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@/'AM<$<Z8WEA;CXQ.2XY.3DY.3D\
M+WAM<$<Z8WEA;CX*("`@("`@("`@("`@("`@("`@("`@("`@("`@/'AM<$<Z
M;6%G96YT83XP+C`P,#`P,#PO>&UP1SIM86=E;G1A/@H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`\>&UP1SIY96QL;W<^,3`P+C`P,#`P,#PO>&UP1SIY
M96QL;W<^"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.F)L86-K
M/C`N,#`P,#`P/"]X;7!'.F)L86-K/@H@("`@("`@("`@("`@("`@("`@("`@
M("`\+W)D9CIL:3X*("`@("`@("`@("`@("`@("`@("`@("`@/')D9CIL:2!R
M9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@(#QX;7!'.G-W871C:$YA;64^0STU,"!-/3`@63TQ,#`@2STP/"]X
M;7!'.G-W871C:$YA;64^"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX
M;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`\>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@/'AM<$<Z8WEA;CXU,"XP,#`P,#`\+WAM
M<$<Z8WEA;CX*("`@("`@("`@("`@("`@("`@("`@("`@("`@/'AM<$<Z;6%G
M96YT83XP+C`P,#`P,#PO>&UP1SIM86=E;G1A/@H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`\>&UP1SIY96QL;W<^,3`P+C`P,#`P,#PO>&UP1SIY96QL
M;W<^"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.F)L86-K/C`N
M,#`P,#`P/"]X;7!'.F)L86-K/@H@("`@("`@("`@("`@("`@("`@("`@("`\
M+W)D9CIL:3X*("`@("`@("`@("`@("`@("`@("`@("`@/')D9CIL:2!R9&8Z
M<&%R<V54>7!E/2)297-O=7)C92(^"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@(#QX;7!'.G-W871C:$YA;64^0STW-2!-/3`@63TQ,#`@2STP/"]X;7!'
M.G-W871C:$YA;64^"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'
M.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`\>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@/'AM<$<Z8WEA;CXW-2XP,#`P,#`\+WAM<$<Z
M8WEA;CX*("`@("`@("`@("`@("`@("`@("`@("`@("`@/'AM<$<Z;6%G96YT
M83XP+C`P,#`P,#PO>&UP1SIM86=E;G1A/@H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`\>&UP1SIY96QL;W<^,3`P+C`P,#`P,#PO>&UP1SIY96QL;W<^
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.F)L86-K/C`N,#`P
M,#`P/"]X;7!'.F)L86-K/@H@("`@("`@("`@("`@("`@("`@("`@("`\+W)D
M9CIL:3X*("`@("`@("`@("`@("`@("`@("`@("`@/')D9CIL:2!R9&8Z<&%R
M<V54>7!E/2)297-O=7)C92(^"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M(#QX;7!'.G-W871C:$YA;64^0STX-2!-/3$P(%D],3`P($L],3`\+WAM<$<Z
M<W=A=&-H3F%M93X*("`@("`@("`@("`@("`@("`@("`@("`@("`@/'AM<$<Z
M;6]D93Y#35E+/"]X;7!'.FUO9&4^"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`\>&UP1SIC>6%N/C@T+CDY.3DY-CPO>&UP1SIC
M>6%N/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIM86=E;G1A
M/C$P+C`P,#`P,CPO>&UP1SIM86=E;G1A/@H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`\>&UP1SIY96QL;W<^,3`P+C`P,#`P,#PO>&UP1SIY96QL;W<^
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.F)L86-K/C$P+C`P
M,#`P,CPO>&UP1SIB;&%C:SX*("`@("`@("`@("`@("`@("`@("`@("`@/"]R
M9&8Z;&D^"B`@("`@("`@("`@("`@("`@("`@("`@(#QR9&8Z;&D@<F1F.G!A
M<G-E5'EP93TB4F5S;W5R8V4B/@H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`\>&UP1SIS=V%T8VA.86UE/D,].3`@33TS,"!9/3DU($L],S`\+WAM<$<Z
M<W=A=&-H3F%M93X*("`@("`@("`@("`@("`@("`@("`@("`@("`@/'AM<$<Z
M;6]D93Y#35E+/"]X;7!'.FUO9&4^"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`\>&UP1SIC>6%N/CDP+C`P,#`P-#PO>&UP1SIC
M>6%N/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIM86=E;G1A
M/C,P+C`P,#`P,3PO>&UP1SIM86=E;G1A/@H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`\>&UP1SIY96QL;W<^.30N.3DY.3DY/"]X;7!'.GEE;&QO=SX*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@/'AM<$<Z8FQA8VL^,S`N,#`P
M,#`Q/"]X;7!'.F)L86-K/@H@("`@("`@("`@("`@("`@("`@("`@("`\+W)D
M9CIL:3X*("`@("`@("`@("`@("`@("`@("`@("`@/')D9CIL:2!R9&8Z<&%R
M<V54>7!E/2)297-O=7)C92(^"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M(#QX;7!'.G-W871C:$YA;64^0STW-2!-/3`@63TW-2!+/3`\+WAM<$<Z<W=A
M=&-H3F%M93X*("`@("`@("`@("`@("`@("`@("`@("`@("`@/'AM<$<Z;6]D
M93Y#35E+/"]X;7!'.FUO9&4^"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`\>&UP1SIC>6%N/C<U+C`P,#`P,#PO>&UP1SIC>6%N
M/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIM86=E;G1A/C`N
M,#`P,#`P/"]X;7!'.FUA9V5N=&$^"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@(#QX;7!'.GEE;&QO=SXW-2XP,#`P,#`\+WAM<$<Z>65L;&]W/@H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIB;&%C:SXP+C`P,#`P,#PO
M>&UP1SIB;&%C:SX*("`@("`@("`@("`@("`@("`@("`@("`@/"]R9&8Z;&D^
M"B`@("`@("`@("`@("`@("`@("`@("`@(#QR9&8Z;&D@<F1F.G!A<G-E5'EP
M93TB4F5S;W5R8V4B/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\>&UP
M1SIS=V%T8VA.86UE/D,].#`@33TQ,"!9/30U($L],#PO>&UP1SIS=V%T8VA.
M86UE/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIM;V1E/D--
M64L\+WAM<$<Z;6]D93X*("`@("`@("`@("`@("`@("`@("`@("`@("`@/'AM
M<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@(#QX;7!'.F-Y86X^.#`N,#`P,#`Q/"]X;7!'.F-Y86X^"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.FUA9V5N=&$^,3`N,#`P
M,#`R/"]X;7!'.FUA9V5N=&$^"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M(#QX;7!'.GEE;&QO=SXT-"XY.3DY.3D\+WAM<$<Z>65L;&]W/@H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`\>&UP1SIB;&%C:SXP+C`P,#`P,#PO>&UP
M1SIB;&%C:SX*("`@("`@("`@("`@("`@("`@("`@("`@/"]R9&8Z;&D^"B`@
M("`@("`@("`@("`@("`@("`@("`@(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB
M4F5S;W5R8V4B/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIS
M=V%T8VA.86UE/D,]-S`@33TQ-2!9/3`@2STP/"]X;7!'.G-W871C:$YA;64^
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.FUO9&4^0TU92SPO
M>&UP1SIM;V1E/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIT
M>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@/'AM<$<Z8WEA;CXV.2XY.3DY.3D\+WAM<$<Z8WEA;CX*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@/'AM<$<Z;6%G96YT83XQ-"XY.3DY.3@\
M+WAM<$<Z;6%G96YT83X*("`@("`@("`@("`@("`@("`@("`@("`@("`@/'AM
M<$<Z>65L;&]W/C`N,#`P,#`P/"]X;7!'.GEE;&QO=SX*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@/'AM<$<Z8FQA8VL^,"XP,#`P,#`\+WAM<$<Z8FQA
M8VL^"B`@("`@("`@("`@("`@("`@("`@("`@(#PO<F1F.FQI/@H@("`@("`@
M("`@("`@("`@("`@("`@("`\<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U
M<F-E(CX*("`@("`@("`@("`@("`@("`@("`@("`@("`@/'AM<$<Z<W=A=&-H
M3F%M93Y#/3@U($T]-3`@63TP($L],#PO>&UP1SIS=V%T8VA.86UE/@H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIM;V1E/D--64L\+WAM<$<Z
M;6]D93X*("`@("`@("`@("`@("`@("`@("`@("`@("`@/'AM<$<Z='EP93Y0
M4D]#15-3/"]X;7!'.G1Y<&4^"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M(#QX;7!'.F-Y86X^.#0N.3DY.3DV/"]X;7!'.F-Y86X^"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@(#QX;7!'.FUA9V5N=&$^-3`N,#`P,#`P/"]X;7!'
M.FUA9V5N=&$^"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.GEE
M;&QO=SXP+C`P,#`P,#PO>&UP1SIY96QL;W<^"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@(#QX;7!'.F)L86-K/C`N,#`P,#`P/"]X;7!'.F)L86-K/@H@
M("`@("`@("`@("`@("`@("`@("`@("`\+W)D9CIL:3X*("`@("`@("`@("`@
M("`@("`@("`@("`@/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.G-W871C:$YA;64^
M0STQ,#`@33TY-2!9/34@2STP/"]X;7!'.G-W871C:$YA;64^"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E
M/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIT>7!E/E!23T-%
M4U,\+WAM<$<Z='EP93X*("`@("`@("`@("`@("`@("`@("`@("`@("`@/'AM
M<$<Z8WEA;CXQ,#`N,#`P,#`P/"]X;7!'.F-Y86X^"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@(#QX;7!'.FUA9V5N=&$^.30N.3DY.3DY/"]X;7!'.FUA
M9V5N=&$^"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.GEE;&QO
M=SXU+C`P,#`P,3PO>&UP1SIY96QL;W<^"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@(#QX;7!'.F)L86-K/C`N,#`P,#`P/"]X;7!'.F)L86-K/@H@("`@
M("`@("`@("`@("`@("`@("`@("`\+W)D9CIL:3X*("`@("`@("`@("`@("`@
M("`@("`@("`@/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.G-W871C:$YA;64^0STQ
M,#`@33TQ,#`@63TR-2!+/3(U/"]X;7!'.G-W871C:$YA;64^"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E
M/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIT>7!E/E!23T-%
M4U,\+WAM<$<Z='EP93X*("`@("`@("`@("`@("`@("`@("`@("`@("`@/'AM
M<$<Z8WEA;CXQ,#`N,#`P,#`P/"]X;7!'.F-Y86X^"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@(#QX;7!'.FUA9V5N=&$^,3`P+C`P,#`P,#PO>&UP1SIM
M86=E;G1A/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIY96QL
M;W<^,C4N,#`P,#`P/"]X;7!'.GEE;&QO=SX*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@/'AM<$<Z8FQA8VL^,C4N,#`P,#`P/"]X;7!'.F)L86-K/@H@
M("`@("`@("`@("`@("`@("`@("`@("`\+W)D9CIL:3X*("`@("`@("`@("`@
M("`@("`@("`@("`@/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.G-W871C:$YA;64^
M0STW-2!-/3$P,"!9/3`@2STP/"]X;7!'.G-W871C:$YA;64^"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E
M/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIT>7!E/E!23T-%
M4U,\+WAM<$<Z='EP93X*("`@("`@("`@("`@("`@("`@("`@("`@("`@/'AM
M<$<Z8WEA;CXW-2XP,#`P,#`\+WAM<$<Z8WEA;CX*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@/'AM<$<Z;6%G96YT83XQ,#`N,#`P,#`P/"]X;7!'.FUA
M9V5N=&$^"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.GEE;&QO
M=SXP+C`P,#`P,#PO>&UP1SIY96QL;W<^"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@(#QX;7!'.F)L86-K/C`N,#`P,#`P/"]X;7!'.F)L86-K/@H@("`@
M("`@("`@("`@("`@("`@("`@("`\+W)D9CIL:3X*("`@("`@("`@("`@("`@
M("`@("`@("`@/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.G-W871C:$YA;64^0STU
M,"!-/3$P,"!9/3`@2STP/"]X;7!'.G-W871C:$YA;64^"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIT>7!E/E!23T-%4U,\
M+WAM<$<Z='EP93X*("`@("`@("`@("`@("`@("`@("`@("`@("`@/'AM<$<Z
M8WEA;CXU,"XP,#`P,#`\+WAM<$<Z8WEA;CX*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@/'AM<$<Z;6%G96YT83XQ,#`N,#`P,#`P/"]X;7!'.FUA9V5N
M=&$^"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.GEE;&QO=SXP
M+C`P,#`P,#PO>&UP1SIY96QL;W<^"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@(#QX;7!'.F)L86-K/C`N,#`P,#`P/"]X;7!'.F)L86-K/@H@("`@("`@
M("`@("`@("`@("`@("`@("`\+W)D9CIL:3X*("`@("`@("`@("`@("`@("`@
M("`@("`@/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.G-W871C:$YA;64^0STS-2!-
M/3$P,"!9/3,U($L],3`\+WAM<$<Z<W=A=&-H3F%M93X*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.G1Y<&4^4%)/0T534SPO
M>&UP1SIT>7!E/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIC
M>6%N/C,U+C`P,#`P,CPO>&UP1SIC>6%N/@H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`\>&UP1SIM86=E;G1A/C$P,"XP,#`P,#`\+WAM<$<Z;6%G96YT
M83X*("`@("`@("`@("`@("`@("`@("`@("`@("`@/'AM<$<Z>65L;&]W/C,U
M+C`P,#`P,CPO>&UP1SIY96QL;W<^"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@(#QX;7!'.F)L86-K/C$P+C`P,#`P,CPO>&UP1SIB;&%C:SX*("`@("`@
M("`@("`@("`@("`@("`@("`@/"]R9&8Z;&D^"B`@("`@("`@("`@("`@("`@
M("`@("`@(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIS=V%T8VA.86UE/D,],3`@
M33TQ,#`@63TU,"!+/3`\+WAM<$<Z<W=A=&-H3F%M93X*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.G1Y<&4^4%)/0T534SPO
M>&UP1SIT>7!E/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIC
M>6%N/C$P+C`P,#`P,CPO>&UP1SIC>6%N/@H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`\>&UP1SIM86=E;G1A/C$P,"XP,#`P,#`\+WAM<$<Z;6%G96YT
M83X*("`@("`@("`@("`@("`@("`@("`@("`@("`@/'AM<$<Z>65L;&]W/C4P
M+C`P,#`P,#PO>&UP1SIY96QL;W<^"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@(#QX;7!'.F)L86-K/C`N,#`P,#`P/"]X;7!'.F)L86-K/@H@("`@("`@
M("`@("`@("`@("`@("`@("`\+W)D9CIL:3X*("`@("`@("`@("`@("`@("`@
M("`@("`@/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.G-W871C:$YA;64^0STP($T]
M.34@63TR,"!+/3`\+WAM<$<Z<W=A=&-H3F%M93X*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP
M1SIT>7!E/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIC>6%N
M/C`N,#`P,#`P/"]X;7!'.F-Y86X^"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@(#QX;7!'.FUA9V5N=&$^.30N.3DY.3DY/"]X;7!'.FUA9V5N=&$^"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.GEE;&QO=SXQ.2XY.3DY
M.3D\+WAM<$<Z>65L;&]W/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\
M>&UP1SIB;&%C:SXP+C`P,#`P,#PO>&UP1SIB;&%C:SX*("`@("`@("`@("`@
M("`@("`@("`@("`@/"]R9&8Z;&D^"B`@("`@("`@("`@("`@("`@("`@("`@
M(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`\>&UP1SIS=V%T8VA.86UE/D,],C4@33TR-2!9
M/30P($L],#PO>&UP1SIS=V%T8VA.86UE/@H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`\>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y
M<&4^"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.F-Y86X^,C4N
M,#`P,#`P/"]X;7!'.F-Y86X^"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M(#QX;7!'.FUA9V5N=&$^,C4N,#`P,#`P/"]X;7!'.FUA9V5N=&$^"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.GEE;&QO=SXS.2XY.3DY.3@\
M+WAM<$<Z>65L;&]W/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\>&UP
M1SIB;&%C:SXP+C`P,#`P,#PO>&UP1SIB;&%C:SX*("`@("`@("`@("`@("`@
M("`@("`@("`@/"]R9&8Z;&D^"B`@("`@("`@("`@("`@("`@("`@("`@(#QR
M9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`\>&UP1SIS=V%T8VA.86UE/D,]-#`@33TT-2!9/34P
M($L]-3PO>&UP1SIS=V%T8VA.86UE/@H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`\>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.F-Y86X^,SDN.3DY
M.3DX/"]X;7!'.F-Y86X^"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX
M;7!'.FUA9V5N=&$^-#0N.3DY.3DY/"]X;7!'.FUA9V5N=&$^"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@(#QX;7!'.GEE;&QO=SXU,"XP,#`P,#`\+WAM
M<$<Z>65L;&]W/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIB
M;&%C:SXU+C`P,#`P,3PO>&UP1SIB;&%C:SX*("`@("`@("`@("`@("`@("`@
M("`@("`@/"]R9&8Z;&D^"B`@("`@("`@("`@("`@("`@("`@("`@(#QR9&8Z
M;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`\>&UP1SIS=V%T8VA.86UE/D,]-3`@33TU,"!9/38P($L]
M,C4\+WAM<$<Z<W=A=&-H3F%M93X*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIC>6%N/C4P+C`P,#`P
M,#PO>&UP1SIC>6%N/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\>&UP
M1SIM86=E;G1A/C4P+C`P,#`P,#PO>&UP1SIM86=E;G1A/@H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`\>&UP1SIY96QL;W<^-C`N,#`P,#`R/"]X;7!'
M.GEE;&QO=SX*("`@("`@("`@("`@("`@("`@("`@("`@("`@/'AM<$<Z8FQA
M8VL^,C4N,#`P,#`P/"]X;7!'.F)L86-K/@H@("`@("`@("`@("`@("`@("`@
M("`@("`\+W)D9CIL:3X*("`@("`@("`@("`@("`@("`@("`@("`@/')D9CIL
M:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@(#QX;7!'.G-W871C:$YA;64^0STU-2!-/38P(%D]-C4@2STT
M,#PO>&UP1SIS=V%T8VA.86UE/@H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`\>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.F-Y86X^-34N,#`P,#`Q
M/"]X;7!'.F-Y86X^"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'
M.FUA9V5N=&$^-C`N,#`P,#`R/"]X;7!'.FUA9V5N=&$^"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@(#QX;7!'.GEE;&QO=SXV-"XY.3DY.3@\+WAM<$<Z
M>65L;&]W/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIB;&%C
M:SXS.2XY.3DY.3@\+WAM<$<Z8FQA8VL^"B`@("`@("`@("`@("`@("`@("`@
M("`@(#PO<F1F.FQI/@H@("`@("`@("`@("`@("`@("`@("`@("`\<F1F.FQI
M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@/'AM<$<Z<W=A=&-H3F%M93Y#/3(U($T]-#`@63TV-2!+/3`\
M+WAM<$<Z<W=A=&-H3F%M93X*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIC>6%N/C(U+C`P,#`P,#PO
M>&UP1SIC>6%N/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIM
M86=E;G1A/C,Y+CDY.3DY.#PO>&UP1SIM86=E;G1A/@H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`\>&UP1SIY96QL;W<^-C0N.3DY.3DX/"]X;7!'.GEE
M;&QO=SX*("`@("`@("`@("`@("`@("`@("`@("`@("`@/'AM<$<Z8FQA8VL^
M,"XP,#`P,#`\+WAM<$<Z8FQA8VL^"B`@("`@("`@("`@("`@("`@("`@("`@
M(#PO<F1F.FQI/@H@("`@("`@("`@("`@("`@("`@("`@("`\<F1F.FQI(')D
M9CIP87)S951Y<&4](E)E<V]U<F-E(CX*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@/'AM<$<Z<W=A=&-H3F%M93Y#/3,P($T]-3`@63TW-2!+/3$P/"]X
M;7!'.G-W871C:$YA;64^"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX
M;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`\>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@/'AM<$<Z8WEA;CXS,"XP,#`P,#$\+WAM
M<$<Z8WEA;CX*("`@("`@("`@("`@("`@("`@("`@("`@("`@/'AM<$<Z;6%G
M96YT83XU,"XP,#`P,#`\+WAM<$<Z;6%G96YT83X*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@/'AM<$<Z>65L;&]W/C<U+C`P,#`P,#PO>&UP1SIY96QL
M;W<^"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.F)L86-K/C$P
M+C`P,#`P,CPO>&UP1SIB;&%C:SX*("`@("`@("`@("`@("`@("`@("`@("`@
M/"]R9&8Z;&D^"B`@("`@("`@("`@("`@("`@("`@("`@(#QR9&8Z;&D@<F1F
M.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`\>&UP1SIS=V%T8VA.86UE/D,],S4@33TV,"!9/3@P($L],C4\+WAM
M<$<Z<W=A=&-H3F%M93X*("`@("`@("`@("`@("`@("`@("`@("`@("`@/'AM
M<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`\>&UP1SIC>6%N/C,U+C`P,#`P,CPO>&UP
M1SIC>6%N/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIM86=E
M;G1A/C8P+C`P,#`P,CPO>&UP1SIM86=E;G1A/@H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`\>&UP1SIY96QL;W<^.#`N,#`P,#`Q/"]X;7!'.GEE;&QO
M=SX*("`@("`@("`@("`@("`@("`@("`@("`@("`@/'AM<$<Z8FQA8VL^,C4N
M,#`P,#`P/"]X;7!'.F)L86-K/@H@("`@("`@("`@("`@("`@("`@("`@("`\
M+W)D9CIL:3X*("`@("`@("`@("`@("`@("`@("`@("`@/')D9CIL:2!R9&8Z
M<&%R<V54>7!E/2)297-O=7)C92(^"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@(#QX;7!'.G-W871C:$YA;64^0STT,"!-/38U(%D].3`@2STS-3PO>&UP
M1SIS=V%T8VA.86UE/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\>&UP
M1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@(#QX;7!'.F-Y86X^,SDN.3DY.3DX/"]X;7!'
M.F-Y86X^"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.FUA9V5N
M=&$^-C0N.3DY.3DX/"]X;7!'.FUA9V5N=&$^"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@(#QX;7!'.GEE;&QO=SXY,"XP,#`P,#0\+WAM<$<Z>65L;&]W
M/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIB;&%C:SXS-2XP
M,#`P,#(\+WAM<$<Z8FQA8VL^"B`@("`@("`@("`@("`@("`@("`@("`@(#PO
M<F1F.FQI/@H@("`@("`@("`@("`@("`@("`@("`@("`\<F1F.FQI(')D9CIP
M87)S951Y<&4](E)E<V]U<F-E(CX*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@/'AM<$<Z<W=A=&-H3F%M93Y#/30P($T]-S`@63TQ,#`@2STU,#PO>&UP
M1SIS=V%T8VA.86UE/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\>&UP
M1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@(#QX;7!'.F-Y86X^,SDN.3DY.3DX/"]X;7!'
M.F-Y86X^"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.FUA9V5N
M=&$^-CDN.3DY.3DY/"]X;7!'.FUA9V5N=&$^"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@(#QX;7!'.GEE;&QO=SXQ,#`N,#`P,#`P/"]X;7!'.GEE;&QO
M=SX*("`@("`@("`@("`@("`@("`@("`@("`@("`@/'AM<$<Z8FQA8VL^-3`N
M,#`P,#`P/"]X;7!'.F)L86-K/@H@("`@("`@("`@("`@("`@("`@("`@("`\
M+W)D9CIL:3X*("`@("`@("`@("`@("`@("`@("`@("`@/')D9CIL:2!R9&8Z
M<&%R<V54>7!E/2)297-O=7)C92(^"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@(#QX;7!'.G-W871C:$YA;64^0STU,"!-/3<P(%D].#`@2STW,#PO>&UP
M1SIS=V%T8VA.86UE/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\>&UP
M1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@(#QX;7!'.F-Y86X^-3`N,#`P,#`P/"]X;7!'
M.F-Y86X^"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.FUA9V5N
M=&$^-CDN.3DY.3DY/"]X;7!'.FUA9V5N=&$^"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@(#QX;7!'.GEE;&QO=SXX,"XP,#`P,#$\+WAM<$<Z>65L;&]W
M/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIB;&%C:SXV.2XY
M.3DY.3D\+WAM<$<Z8FQA8VL^"B`@("`@("`@("`@("`@("`@("`@("`@(#PO
M<F1F.FQI/@H@("`@("`@("`@("`@("`@("`@("`\+W)D9CI397$^"B`@("`@
M("`@("`@("`@("`@(#PO>&UP1SI#;VQO<F%N=',^"B`@("`@("`@("`@("`@
M(#PO<F1F.FQI/@H@("`@("`@("`@("`@("`\<F1F.FQI(')D9CIP87)S951Y
M<&4](E)E<V]U<F-E(CX*("`@("`@("`@("`@("`@("`@/'AM<$<Z9W)O=7!.
M86UE/D=R87ES/"]X;7!'.F=R;W5P3F%M93X*("`@("`@("`@("`@("`@("`@
M/'AM<$<Z9W)O=7!4>7!E/C$\+WAM<$<Z9W)O=7!4>7!E/@H@("`@("`@("`@
M("`@("`@("`\>&UP1SI#;VQO<F%N=',^"B`@("`@("`@("`@("`@("`@("`@
M(#QR9&8Z4V5Q/@H@("`@("`@("`@("`@("`@("`@("`@("`\<F1F.FQI(')D
M9CIP87)S951Y<&4](E)E<V]U<F-E(CX*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@/'AM<$<Z<W=A=&-H3F%M93Y#/3`@33TP(%D],"!+/3$P,#PO>&UP
M1SIS=V%T8VA.86UE/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\>&UP
M1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@(#QX;7!'.F-Y86X^,"XP,#`P,#`\+WAM<$<Z
M8WEA;CX*("`@("`@("`@("`@("`@("`@("`@("`@("`@/'AM<$<Z;6%G96YT
M83XP+C`P,#`P,#PO>&UP1SIM86=E;G1A/@H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`\>&UP1SIY96QL;W<^,"XP,#`P,#`\+WAM<$<Z>65L;&]W/@H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIB;&%C:SXQ,#`N,#`P
M,#`P/"]X;7!'.F)L86-K/@H@("`@("`@("`@("`@("`@("`@("`@("`\+W)D
M9CIL:3X*("`@("`@("`@("`@("`@("`@("`@("`@/')D9CIL:2!R9&8Z<&%R
M<V54>7!E/2)297-O=7)C92(^"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M(#QX;7!'.G-W871C:$YA;64^0STP($T],"!9/3`@2STY,#PO>&UP1SIS=V%T
M8VA.86UE/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIM;V1E
M/D--64L\+WAM<$<Z;6]D93X*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@(#QX;7!'.F-Y86X^,"XP,#`P,#`\+WAM<$<Z8WEA;CX*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@/'AM<$<Z;6%G96YT83XP+C`P
M,#`P,#PO>&UP1SIM86=E;G1A/@H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`\>&UP1SIY96QL;W<^,"XP,#`P,#`\+WAM<$<Z>65L;&]W/@H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`\>&UP1SIB;&%C:SXX.2XY.3DT,#(\+WAM
M<$<Z8FQA8VL^"B`@("`@("`@("`@("`@("`@("`@("`@(#PO<F1F.FQI/@H@
M("`@("`@("`@("`@("`@("`@("`@("`\<F1F.FQI(')D9CIP87)S951Y<&4]
M(E)E<V]U<F-E(CX*("`@("`@("`@("`@("`@("`@("`@("`@("`@/'AM<$<Z
M<W=A=&-H3F%M93Y#/3`@33TP(%D],"!+/3@P/"]X;7!'.G-W871C:$YA;64^
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.FUO9&4^0TU92SPO
M>&UP1SIM;V1E/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIT
M>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@/'AM<$<Z8WEA;CXP+C`P,#`P,#PO>&UP1SIC>6%N/@H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`\>&UP1SIM86=E;G1A/C`N,#`P,#`P/"]X
M;7!'.FUA9V5N=&$^"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'
M.GEE;&QO=SXP+C`P,#`P,#PO>&UP1SIY96QL;W<^"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@(#QX;7!'.F)L86-K/C<Y+CDY.#<Y-SPO>&UP1SIB;&%C
M:SX*("`@("`@("`@("`@("`@("`@("`@("`@/"]R9&8Z;&D^"B`@("`@("`@
M("`@("`@("`@("`@("`@(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R
M8V4B/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIS=V%T8VA.
M86UE/D,],"!-/3`@63TP($L]-S`\+WAM<$<Z<W=A=&-H3F%M93X*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO
M9&4^"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.G1Y<&4^4%)/
M0T534SPO>&UP1SIT>7!E/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\
M>&UP1SIC>6%N/C`N,#`P,#`P/"]X;7!'.F-Y86X^"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@(#QX;7!'.FUA9V5N=&$^,"XP,#`P,#`\+WAM<$<Z;6%G
M96YT83X*("`@("`@("`@("`@("`@("`@("`@("`@("`@/'AM<$<Z>65L;&]W
M/C`N,#`P,#`P/"]X;7!'.GEE;&QO=SX*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@/'AM<$<Z8FQA8VL^-CDN.3DY-S`Q/"]X;7!'.F)L86-K/@H@("`@
M("`@("`@("`@("`@("`@("`@("`\+W)D9CIL:3X*("`@("`@("`@("`@("`@
M("`@("`@("`@/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.G-W871C:$YA;64^0STP
M($T],"!9/3`@2STV,#PO>&UP1SIS=V%T8VA.86UE/@H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`\>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@/'AM<$<Z='EP93Y04D]#15-3/"]X
M;7!'.G1Y<&4^"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.F-Y
M86X^,"XP,#`P,#`\+WAM<$<Z8WEA;CX*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@/'AM<$<Z;6%G96YT83XP+C`P,#`P,#PO>&UP1SIM86=E;G1A/@H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIY96QL;W<^,"XP,#`P
M,#`\+WAM<$<Z>65L;&]W/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\
M>&UP1SIB;&%C:SXU.2XY.3DQ,#(\+WAM<$<Z8FQA8VL^"B`@("`@("`@("`@
M("`@("`@("`@("`@(#PO<F1F.FQI/@H@("`@("`@("`@("`@("`@("`@("`@
M("`\<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@/'AM<$<Z<W=A=&-H3F%M93Y#/3`@33TP(%D]
M,"!+/34P/"]X;7!'.G-W871C:$YA;64^"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`\>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP
M93X*("`@("`@("`@("`@("`@("`@("`@("`@("`@/'AM<$<Z8WEA;CXP+C`P
M,#`P,#PO>&UP1SIC>6%N/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\
M>&UP1SIM86=E;G1A/C`N,#`P,#`P/"]X;7!'.FUA9V5N=&$^"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@(#QX;7!'.GEE;&QO=SXP+C`P,#`P,#PO>&UP
M1SIY96QL;W<^"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.F)L
M86-K/C4P+C`P,#`P,#PO>&UP1SIB;&%C:SX*("`@("`@("`@("`@("`@("`@
M("`@("`@/"]R9&8Z;&D^"B`@("`@("`@("`@("`@("`@("`@("`@(#QR9&8Z
M;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`\>&UP1SIS=V%T8VA.86UE/D,],"!-/3`@63TP($L]-#`\
M+WAM<$<Z<W=A=&-H3F%M93X*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIC>6%N/C`N,#`P,#`P/"]X
M;7!'.F-Y86X^"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.FUA
M9V5N=&$^,"XP,#`P,#`\+WAM<$<Z;6%G96YT83X*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@/'AM<$<Z>65L;&]W/C`N,#`P,#`P/"]X;7!'.GEE;&QO
M=SX*("`@("`@("`@("`@("`@("`@("`@("`@("`@/'AM<$<Z8FQA8VL^,SDN
M.3DY-#`R/"]X;7!'.F)L86-K/@H@("`@("`@("`@("`@("`@("`@("`@("`\
M+W)D9CIL:3X*("`@("`@("`@("`@("`@("`@("`@("`@/')D9CIL:2!R9&8Z
M<&%R<V54>7!E/2)297-O=7)C92(^"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@(#QX;7!'.G-W871C:$YA;64^0STP($T],"!9/3`@2STS,#PO>&UP1SIS
M=V%T8VA.86UE/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIM
M;V1E/D--64L\+WAM<$<Z;6]D93X*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@(#QX;7!'.F-Y86X^,"XP,#`P,#`\+WAM<$<Z8WEA
M;CX*("`@("`@("`@("`@("`@("`@("`@("`@("`@/'AM<$<Z;6%G96YT83XP
M+C`P,#`P,#PO>&UP1SIM86=E;G1A/@H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`\>&UP1SIY96QL;W<^,"XP,#`P,#`\+WAM<$<Z>65L;&]W/@H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIB;&%C:SXR.2XY.3@X,#,\
M+WAM<$<Z8FQA8VL^"B`@("`@("`@("`@("`@("`@("`@("`@(#PO<F1F.FQI
M/@H@("`@("`@("`@("`@("`@("`@("`@("`\<F1F.FQI(')D9CIP87)S951Y
M<&4](E)E<V]U<F-E(CX*("`@("`@("`@("`@("`@("`@("`@("`@("`@/'AM
M<$<Z<W=A=&-H3F%M93Y#/3`@33TP(%D],"!+/3(P/"]X;7!'.G-W871C:$YA
M;64^"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.FUO9&4^0TU9
M2SPO>&UP1SIM;V1E/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\>&UP
M1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@/'AM<$<Z8WEA;CXP+C`P,#`P,#PO>&UP1SIC>6%N/@H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIM86=E;G1A/C`N,#`P,#`P
M/"]X;7!'.FUA9V5N=&$^"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX
M;7!'.GEE;&QO=SXP+C`P,#`P,#PO>&UP1SIY96QL;W<^"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@(#QX;7!'.F)L86-K/C$Y+CDY.3<P,3PO>&UP1SIB
M;&%C:SX*("`@("`@("`@("`@("`@("`@("`@("`@/"]R9&8Z;&D^"B`@("`@
M("`@("`@("`@("`@("`@("`@(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S
M;W5R8V4B/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIS=V%T
M8VA.86UE/D,],"!-/3`@63TP($L],3`\+WAM<$<Z<W=A=&-H3F%M93X*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@/'AM<$<Z;6]D93Y#35E+/"]X;7!'
M.FUO9&4^"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.G1Y<&4^
M4%)/0T534SPO>&UP1SIT>7!E/@H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`\>&UP1SIC>6%N/C`N,#`P,#`P/"]X;7!'.F-Y86X^"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@(#QX;7!'.FUA9V5N=&$^,"XP,#`P,#`\+WAM<$<Z
M;6%G96YT83X*("`@("`@("`@("`@("`@("`@("`@("`@("`@/'AM<$<Z>65L
M;&]W/C`N,#`P,#`P/"]X;7!'.GEE;&QO=SX*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@/'AM<$<Z8FQA8VL^.2XY.3DQ,#(\+WAM<$<Z8FQA8VL^"B`@
M("`@("`@("`@("`@("`@("`@("`@(#PO<F1F.FQI/@H@("`@("`@("`@("`@
M("`@("`@("`@("`\<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@/'AM<$<Z<W=A=&-H3F%M93Y#
M/3`@33TP(%D],"!+/34\+WAM<$<Z<W=A=&-H3F%M93X*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.G1Y<&4^4%)/0T534SPO
M>&UP1SIT>7!E/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIC
M>6%N/C`N,#`P,#`P/"]X;7!'.F-Y86X^"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@(#QX;7!'.FUA9V5N=&$^,"XP,#`P,#`\+WAM<$<Z;6%G96YT83X*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@/'AM<$<Z>65L;&]W/C`N,#`P
M,#`P/"]X;7!'.GEE;&QO=SX*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M/'AM<$<Z8FQA8VL^-"XY.3@X,#,\+WAM<$<Z8FQA8VL^"B`@("`@("`@("`@
M("`@("`@("`@("`@(#PO<F1F.FQI/@H@("`@("`@("`@("`@("`@("`@("`\
M+W)D9CI397$^"B`@("`@("`@("`@("`@("`@(#PO>&UP1SI#;VQO<F%N=',^
M"B`@("`@("`@("`@("`@(#PO<F1F.FQI/@H@("`@("`@("`@("`@("`\<F1F
M.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*("`@("`@("`@("`@("`@
M("`@/'AM<$<Z9W)O=7!.86UE/D)R:6=H=',\+WAM<$<Z9W)O=7!.86UE/@H@
M("`@("`@("`@("`@("`@("`\>&UP1SIG<F]U<%1Y<&4^,3PO>&UP1SIG<F]U
M<%1Y<&4^"B`@("`@("`@("`@("`@("`@(#QX;7!'.D-O;&]R86YT<SX*("`@
M("`@("`@("`@("`@("`@("`@/')D9CI397$^"B`@("`@("`@("`@("`@("`@
M("`@("`@(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIS=V%T8VA.86UE/D,],"!-
M/3$P,"!9/3$P,"!+/3`\+WAM<$<Z<W=A=&-H3F%M93X*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.G1Y<&4^4%)/0T534SPO
M>&UP1SIT>7!E/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIC
M>6%N/C`N,#`P,#`P/"]X;7!'.F-Y86X^"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@(#QX;7!'.FUA9V5N=&$^,3`P+C`P,#`P,#PO>&UP1SIM86=E;G1A
M/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIY96QL;W<^,3`P
M+C`P,#`P,#PO>&UP1SIY96QL;W<^"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@(#QX;7!'.F)L86-K/C`N,#`P,#`P/"]X;7!'.F)L86-K/@H@("`@("`@
M("`@("`@("`@("`@("`@("`\+W)D9CIL:3X*("`@("`@("`@("`@("`@("`@
M("`@("`@/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.G-W871C:$YA;64^0STP($T]
M-S4@63TQ,#`@2STP/"]X;7!'.G-W871C:$YA;64^"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIT>7!E/E!23T-%4U,\+WAM
M<$<Z='EP93X*("`@("`@("`@("`@("`@("`@("`@("`@("`@/'AM<$<Z8WEA
M;CXP+C`P,#`P,#PO>&UP1SIC>6%N/@H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`\>&UP1SIM86=E;G1A/C<U+C`P,#`P,#PO>&UP1SIM86=E;G1A/@H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIY96QL;W<^,3`P+C`P
M,#`P,#PO>&UP1SIY96QL;W<^"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M(#QX;7!'.F)L86-K/C`N,#`P,#`P/"]X;7!'.F)L86-K/@H@("`@("`@("`@
M("`@("`@("`@("`@("`\+W)D9CIL:3X*("`@("`@("`@("`@("`@("`@("`@
M("`@/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@(#QX;7!'.G-W871C:$YA;64^0STP($T],3`@
M63TY-2!+/3`\+WAM<$<Z<W=A=&-H3F%M93X*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT
M>7!E/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIC>6%N/C`N
M,#`P,#`P/"]X;7!'.F-Y86X^"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M(#QX;7!'.FUA9V5N=&$^,3`N,#`P,#`R/"]X;7!'.FUA9V5N=&$^"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.GEE;&QO=SXY-"XY.3DY.3D\
M+WAM<$<Z>65L;&]W/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\>&UP
M1SIB;&%C:SXP+C`P,#`P,#PO>&UP1SIB;&%C:SX*("`@("`@("`@("`@("`@
M("`@("`@("`@/"]R9&8Z;&D^"B`@("`@("`@("`@("`@("`@("`@("`@(#QR
M9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`\>&UP1SIS=V%T8VA.86UE/D,].#4@33TQ,"!9/3$P
M,"!+/3`\+WAM<$<Z<W=A=&-H3F%M93X*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E
M/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIC>6%N/C@T+CDY
M.3DY-CPO>&UP1SIC>6%N/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\
M>&UP1SIM86=E;G1A/C$P+C`P,#`P,CPO>&UP1SIM86=E;G1A/@H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`\>&UP1SIY96QL;W<^,3`P+C`P,#`P,#PO
M>&UP1SIY96QL;W<^"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'
M.F)L86-K/C`N,#`P,#`P/"]X;7!'.F)L86-K/@H@("`@("`@("`@("`@("`@
M("`@("`@("`\+W)D9CIL:3X*("`@("`@("`@("`@("`@("`@("`@("`@/')D
M9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@(#QX;7!'.G-W871C:$YA;64^0STQ,#`@33TY,"!9/3`@
M2STP/"]X;7!'.G-W871C:$YA;64^"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`\>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@/'AM<$<Z8WEA;CXQ,#`N,#`P
M,#`P/"]X;7!'.F-Y86X^"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX
M;7!'.FUA9V5N=&$^.3`N,#`P,#`T/"]X;7!'.FUA9V5N=&$^"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@(#QX;7!'.GEE;&QO=SXP+C`P,#`P,#PO>&UP
M1SIY96QL;W<^"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.F)L
M86-K/C`N,#`P,#`P/"]X;7!'.F)L86-K/@H@("`@("`@("`@("`@("`@("`@
M("`@("`\+W)D9CIL:3X*("`@("`@("`@("`@("`@("`@("`@("`@/')D9CIL
M:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@(#QX;7!'.G-W871C:$YA;64^0STV,"!-/3DP(%D],"!+/3`\
M+WAM<$<Z<W=A=&-H3F%M93X*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIC>6%N/C8P+C`P,#`P,CPO
M>&UP1SIC>6%N/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIM
M86=E;G1A/CDP+C`P,#`P-#PO>&UP1SIM86=E;G1A/@H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`\>&UP1SIY96QL;W<^,"XP,#,P.3D\+WAM<$<Z>65L
M;&]W/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIB;&%C:SXP
M+C`P,S`Y.3PO>&UP1SIB;&%C:SX*("`@("`@("`@("`@("`@("`@("`@("`@
M/"]R9&8Z;&D^"B`@("`@("`@("`@("`@("`@("`@(#PO<F1F.E-E<3X*("`@
M("`@("`@("`@("`@("`@/"]X;7!'.D-O;&]R86YT<SX*("`@("`@("`@("`@
M("`@/"]R9&8Z;&D^"B`@("`@("`@("`@(#PO<F1F.E-E<3X*("`@("`@("`@
M/"]X;7!44&<Z4W=A=&-H1W)O=7!S/@H@("`@("`\+W)D9CI$97-C<FEP=&EO
M;CX*("`@("`@/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*("`@("`@
M("`@("`@>&UL;G,Z<&1F/2)H='1P.B\O;G,N861O8F4N8V]M+W!D9B\Q+C,O
M(CX*("`@("`@("`@/'!D9CI0<F]D=6-E<CY!9&]B92!01$8@;&EB<F%R>2`Q
M,"XP,3PO<&1F.E!R;V1U8V5R/@H@("`@("`\+W)D9CI$97-C<FEP=&EO;CX*
M("`@/"]R9&8Z4D1&/@H\+W@Z>&UP;65T83X*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@(`H\/WAP86-K970@96YD/2)W(C\^_]L`0P`!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!_]L`0P$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!_\``$0@!40)5`P$1``(1`0,1
M`?_$`!X``0`"`@,!`0$````````````&!P4(`P0)`@$*_\0`9A```00"`0$!
M"0D(#@8(!``/!0(#!`8!!P@`$0D2$Q05%A=55B%4DY25EM/4U1@B,5=F<Y&2
M&38W.$%14W:7LK2VTM8C,C58<=$D4F%T=;&SUR4S0I@F-&-R@<$G0T5B9&6A
MHN'_Q``=`0$``@(#`0$``````````````0(#!@4'"`0)_\0`8!$```4"`@0'
M"0P'!@0#!@4%``$"`P0%$08A!Q(Q41-!88&1H=$4&%9QE9:QU/`(%187(C)2
M55?!U>$9(U23E-/6)$)RDM+Q4V*7HB8S-0DT-H*RXR5#14=T1G.SM.+_V@`,
M`P$``A$#$0`_`/[SK+:H%<C+?E.H1WB<YSWV<8_!CM_A]S_CG^#^+\':$%<_
M%Q=M[Y=61YB@Y^^G5]\X+$ER,;OE)2_`%SYC&5)SG&<)=CQW&\]F?<5C"LYQ
MGW/X.IM[<UQ-B+9;F]O8QB<[\,X]SS8LOR`6_P#UQ.ECY.DNT!^>GTS[,67Y
M!*_5>ECY.DNT`]/IGV8LOR"5^J]+'R=)=H!Z?3/LQ9?D$K]5Z6/DZ2[0#T^F
M?9BR_()7ZKTL?)TEV@'I],^S%E^02OU7I8^3I+M`/3Z9]F++\@E?JO2Q\G27
M:`>GTS[,67Y!*_5>ECY.DNT`]/IGV8LOR"5^J]+'R=)=H!Z?3/LQ9?D$K]5Z
M6/DZ2[0#T^F?9BR_()7ZKTL?)TEV@'I],^S%E^02OU7I8^3I+M`/3Z9]F++\
M@E?JO2Q\G27:`>GTS[,67Y!*_5>ECY.DNT`]/IGV8LOR"5^J]+'R=)=H!Z?3
M/LQ9?D$K]5Z6/DZ2[0#T^F?9BR_()7ZKTL?)TEV@'I],^S%E^02OU7I8^3I+
MM`/3Z9]F++\@E?JO2Q\G27:`>GTS[,67Y!*_5>ECY.DNT`]/IGV8LOR"5^J]
M+'R=)=H!Z?3/LQ9?D$K]5Z6/DZ2[0#T^F?9BR_()7ZKTL?)TEV@'I],^S%E^
M02OU7I8^3I+M`/3Z9]F++\@E?JO2Q\G27:`>GTS[,67Y!*_5>ECY.DNT`]/I
MGV8LOR"5^J]+'R=)=H!Z?3/LQ9?D$K]5Z6/DZ2[0#T^F?9BR_()7ZKTL?)TE
MV@'I],^S%E^02OU7I8^3I+M`/3Z9]F++\@E?JO2Q\G27:`>GTS[,67Y!*_5>
MECY.DNT`]/IGV8LOR"5^J]+'R=)=H!Z?3/LQ9?D$K]5Z6/DZ2[0#T^F?9BR_
M()7ZKTL?)TEV@'I],^S%E^02OU7I8^3I+M`/3Z9]F++\@E?JO2Q\G27:`>GT
MS[,67Y!*_5>ECY.DNT`]/IGV8LOR"5^J]+'R=)=H!Z?3/LQ9?D$K]5Z6/DZ2
M[0#T^F?9BR_()7ZKTL?)TEV@'I],^S%E^02OU7I8^3I+M`/3Z9]F++\@E?JO
M2Q\G27:`>GTS[,67Y!*_5>ECY.DNT`]/IGV8LOR"5^J]+'R=)=H!Z?3/LQ9?
MD$K]5Z6/DZ2[0#T^F?9BR_()7ZKTL?)TEV@'I],^S%E^02OU7I8^3I+M`/3Z
M9]F++\@E?JO2Q\G27:`>GTS[,67Y!*_5>ECY.DNT`]/IGV8LOR"5^J]+'R=)
M=H!Z?3/LQ9?D$K]5Z6/DZ2[0#T^F?9BR_()7ZKTL?)TEV@'I],^S%E^02OU7
MI8^3I+M`/3Z9]F++\@E?JO2Q\G27:`>GTS[,67Y!*_5>ECY.DNT`]/IGV8LO
MR"5^J]+'R=)=H!Z?3/LQ9?D$K]5Z6/DZ2[0#T^F?9BR_()7ZKTL?)TEV@'I]
M,^S%E^02OU7I8^3I+M`/3Z9]F++\@E?JO2Q\G27:`>GTS[,67Y!*_5>ECY.D
MNT`]/IGV8LOR"5^J]+'R=)=H!Z?3/LQ9?D$K]5Z6/DZ2[0#T^F?9BR_()7ZK
MTL?)TEV@'I],^S%E^02OU7I8^3I+M`/3Z9]F++\@E?JO2Q\G27:`>GTS[,67
MY!*_5>ECY.DNT`]/IGV8LOR"5^J]+'R=)=H!Z?3/LQ9?D$K]5Z6/DZ2[0'.Q
MODPM:<*K-EQC.<?_`,`+8_3G,3'2WBZ2[0M[?E[=0LRH[=&6!_,-Q6692%80
M['?2II]I>?=[UQIS"7$*QVX[<+3C/\>,=1L#5W9<>77EL/HWGRBYVW$NH2XC
M/:E6.W&>@@NLO:_MRD-7;6N/9ML4VHD^UX40GD'YD7.<^#E-B1!`NF,\GMSA
M;$AV"VU(;S[CC"W&\^XKIO\`;D$C:%IIIAMMEEMMEEI"6VFFD);;;;1C"4-M
MH1C"4(0G&$I2G&$IQC&,8QC'0!R=`#H`=`#H`=`#H`=`#H`=`#H`=`#H`=`#
MH`=`#H`=`#H`=`#H`=`#H`=`#H`=`#H`=`#H`=`#H`=`#H`=`#H`=`#H`=`#
MH`=`#H`=`#H`=`#H`=`#H`=`#H`=`#H`=`#H`=`#H`=`#H`=`#H`=`#H`=`#
MH`=`#H`=`#H`=`#H`=`#H`=`%"[U'P88D-;FF4,&AAT9!Q-:3A#T@>0<<8=A
M25X[/#,(=4W(9PYWV6'&U^"RA+[^''MT%[>(/;VN+3J$M4P)$>5GMSEI&<Y_
M[<I]W_\`S_V=!19F5K<8UN>SG[HB@X__`"UH_NC8.K%\U7-Z1<;<=5`5-M7?
MFBM%,`I6[]TZFTW&M$N2/K,C:NQJ?KUBQ3X2&')D($[;C(ALO+B-RHJY,8>J
M0\PB2PIU"$O-Y4`8\5R1X['=G/Z3";[TL8W-&:4_)U(*VE1B&SH["!+1Y;S]
M"B'7K4TT@&^P94XX*2A(EYHCG.(;B'L@&&$<M.*Q^E;"V2!Y,<?3>NM2$'1.
MUK\(W-KDE2M9%6'$,OC-A6F'9'@=+(,O.MM.PK)/&R6W'$(6WA2TXR`=65S"
MXD0LZ\Q,Y2<<XF=NC8)G5&)6[M9L9V<(*$7!`PKKS#MG1YZ#2)9IT7!G5ORE
M%ED6W(4=UR2A36`">'-WZ7K$G8,*R[>U?7IFI0(FU;4B'+_5!,G6=8/-2I`.
MQ[!8GEH[M,`F6(,UX28L:!H\BU$E.0Y#R([JD`'>&[<U09M`*D!]G:]*W2TT
M5G:%9J`VZ5N=:+'K21*9@Q]B`@$4DZ6+T5^;)CPV;:/B2`#LI]F.@@IUU"%`
M%:[%YA\1]/V273=M<I>.>KK>/4RF?5=B[NUG2;)"5)@0"L=,L'9;.,)QE/BR
MHPDSAZ*C+L`C`F([Z/,CN.`&Q#3K3[33[#K;S#S:'67FEI<:=:<3A;;K3B,Y
M0XVXC.%(6G.4J3G"DYSC.,]`')T`121?*-$L<:GR[G5(UMF3(0^'5I%B$,V.
M7/)!;'9!T&,$<F))OS)]=IUN/0HS453TH+5K&480Y!!DWXH!*^@!T`.@!T`.
M@!T`.@!T`.@!T`.@!T`.@!T`.@#P+[J%LB[@=E\GI$/<&R]8RN.O<T5<D^,P
MVC;-N5`&V3DGG;FQP[TLU6JL>"C-O*BR:?IJC(I%U@VNN9'[/(B/(.7KDO,A
M_N+I(OD\JK'EQ9<?%M/ER&G_`"1Y+[[%:3V8X)WIM6NWD)OSN[\>=#!;4MT*
MP5NO:FXH\J+3J8;VP#S1*!7=5GDZ[.ZT9_T0ZF$F:47JZ1LI(.1@+I)-RN19
MDWUK(CZ2ZK\H]->Y;G=F8NW+2@;(*;2'YITGC69K>MMH[[OO)Z56!NP-(#[`
M1N0+<FS#IZX/#=DGFB<N3KZ7)0-HI*O2EB4^+6'*6PHJUDGEQYD1)X]Q>GL'
MK_T%`Z`'0`Z`'0`Z`'0`Z`'0`Z`'0`Z`'0`Z`'0`Z`'0`Z`'0`Z`'0`Z`*LN
MF\]):VLU;I6Q-Q:LH5RN7@L5"I738-2JUFM7AYF!S/FV!.%X)4YX8AG$%KR9
M$E>$F9Q&1VO9[SH)L9E>QV+:=LB$8F\J>,`VZS=;$>1^A8&Q1I>)7R-!F[?U
M[%NL`]/(P0\$)-JS]B;.Q2\TN3&BX@U^`W,DD2$&"RRN3+CM.`U3M>QVWV.W
M2%UY4\8-;%9`+8O(_0M!.1"LH%*#77;^O:L5C'((X&8FAI`XY8H$MDK$$V>M
ME)0YQE,R..L(.:ZRB,6@.R`$1GL(S\1'[<0GDW:VKAM(.;,([)H,#6]9<L#-
MDV!-N->BTBONU(U.K=J:.6M\BV!$N5FQ"R8&P(GSXZ@QH=.%D<1IT20PV$6]
MO'LZ1`I7*OB]`&T$S.Y(Z$AA]JLN2=7%I6X=>1QNR([,YH8](H,YZQ(BW!EH
ME(8'N.UYTBVB<\U$4K#[B&U!-CSR/+;D>7CW"12-]Z+B"K$>E;HU-&!U"^.:
MKMAF1L:GLBJOL]J5%@.ZXL1%PPF&$OC<Z="AN4\D]&L*)4R+'4.P](90L%CW
M'O$63RTXJJ*VP$GDSQ]4<H2W&[R&3N;7.2M,<9M(FC.HM@[%D\;KJVKJ>!T]
MQ)AF'E%I,B:^K&"Q&'$>!JJR.QV/9D>?'D.Q>.5/&#6).2%V3R/T+KTQ#)RP
MLL3>-P:]J9.*8@#09F<)DP#UB@2F"<,/9JV6EP'6DRHXVP@YSS2(I:`[(`23
M/81GXB,QGKUR`T/JX93S>S-V:CUV&V')BPZ`6O6R*;41EYESF(TJ%%I\\^9'
MQ;-)EQID21%8"NS79#$J,ZTE;;[2E`(C/81G;<5Q&XG++BO/L%CJ4#DOQ_FV
MJGQ+1/MM9B;EUU)L%6@T>-,F76;8PS-C62"1*?$'$)5HDDXT5FOQH$Q\LN(U
M%?4@&JJU['8]AV.V>P2*Q<@]"4^/KF7;=WZAJT3<3D!K4<JQ;*I@2/M-TJQ`
ME"V]<O$S45N[N$HQ47(@(K*B:IC!*`]'PXW,CJ<"+'NV;>0?M=Y`Z&N%_-:G
MJ6[=16C:=;<+LV+6M=V333=_`/`):8!YHU31AJ38A;@2<M$(NB<.84-EK3'F
M89>5A&0FQVO8['QVRZ1;O00'0`Z`'0`Z`'0`Z`'0`Z`*,Y"_N?M_SGKG]OQU
M);>8_08"?4']KL+\TW_5Z@4=V\ZAKX]^^)H/YZT?W1L'5B^:KF](N-N.J@/'
M3NDO&G<')3DSP6KFM9F:E64U+FY5-F[2*:9]-%/HU>V1IZH5B/#-AYYD!6!1
MJV)\I#:=/LY"2.R7BKSD!86V)`UP`\@IG<Y.3&N;%9Z+JJO[+,ZHHW=%Y^O]
M-AS>KID6Z($0^XO5;CGJWE^1Y`18S1A_6]>V.,%T6RI@"!=!*7=DFX8L\9^%
M+"]`'U%U-M@X3XS[FIG%WD11M-<5]+]QOUGR1U^7XS[;"VT]=>,NXMS'+W'I
MVF'*?"NN_A7%[-OJ%O(6C5`"[5\_#=7Z-#EK>!R\00"F]H\;.:F_:-RFMK7'
M*PTL(KAGRG&R==U/A=L+6?W4H9[NA.U-J0ZM2J'?#]PN>B=V<D*(2SM-<8/+
ML>PJN<OBRHFN0BT5AI@`S_(W0//"YF.9/(&1P_MQ&L]T-K7/74$L=78VU+GO
M.15:,6U0,X<RMV:)D:/`L:="L:BXJ'A=&<3LK8<>VE-_QV)PNH6(VP-)@&V_
M<W>)W)76O=&=3[#V]J38@&K:$X^\W.YZZYO9BN'<@"'&?C!<N#@WBE99UBE0
MTPXJ-PNE]^VBBLS)7AK**KQXJ/<FK@F/$P"S@NJ[=L6H\9+'(U25V9M37_=X
MN;ULY!K&U1H^2`U`64[H2#UQ/LT^5!EL!*'Z+C/','4R5D=8K[0DSKMAUW&9
MHY+@!J?Q1`<\]M[&T#KZ_P`SNE5!TW>]T<6+KMENRG.<5)LM.K\GA5S]QO>B
MWG>^R6ZD0D-1M_U?C\$V;.U>)TQI>7?B5)*Z9UG4!1RH6`X`4C3MF<XK19HU
M%K^S>;4PMG7/&V[<U$%#O+G:0QDT<YB\D:SMZ^\>ZMIZ_#MJNZA*,U/6E?1)
MX>'*W37=3@S<*HNMLB=ELI`+6I>G]VZ]O$*\[+C\MC/(O9Q3N#LK4FRMX@MX
M@HEU+4_F`1K>_1EH$E[WLW552VI6>.$XFK8U%*W29M\52;!M.T28C3EQV],(
M`']AW0`Z`'0`Z`'0`Z`'0`Z`'0`Z`'0`Z`/AQQMEMQYYQ#332%..NN*2AMMM
M"<J6XXM6<)0A"<94I2LX2E.,YSG&,=`'G^%[I_PZL(0D=%7:\/--C];&J@,?
MTKN.%8MP5[<EMGT35%ET76YM&CF]RUW8%L&315>,:]A'H2FVD&"#L`!)B%7P
MMJF77QEE;;?/*U^/Q"44WNBG$&]7>A:X!;5<:N^Q]=['V?7:Z>I-^K,R/6]/
MV:S4W:<.S+L-8&Q:?;J#::5;PEFHUID";>/EU@WE05;`]]Y(-4]VRW&7'LMO
MO?:0I>N\[>YD<KK'J":HU0=F65&G;WRSTT9V3HRSXGUC6^MKU9]?7;8-6-;#
MU]&72;`&MNM;*PX)9EA[K+A5=P]"%R0T>.0R$FE:;[2SL=CY".UB//:7)GO&
M,H'+?N:N[MA!S^LM9.;4V'R8U36B1R\T[@_N"X%+)IK9ESNFGPJ-Y7T3I&>F
MIT4[8M7W0`0'[C-`P\</59I`Q'CUZ,B;D!I419Y$1GD:BVE8SL5\SS+8)90^
MZ1<`RH:V;-J)\Q7L/Z\H5V>)D>.&Z*#9MJ:^GW:)J/6,O7$<_JX";W9`=V%:
MQ>NZB-H"+:["L5L$!8D2(NQ04S`@TJ+(^7C([6S/8>66>=A90#NC'$BP"+Z6
M1L0R$7JK66U]M[/!VK6^R:M:-?U'2%EQ4-H(M59.5.$9&V:LV!;,--/S#<LQ
MUF7`)UL68%$8$Z2#5/++;8BV9WV"VM4<J=%[N*4P-K.Z+L1&_P"C:QR.JT95
M<M`C,W45P+O@`=AE+-!AR!)%PS%E#9]3+*@VT-+COLF`D%;2\)"#(RYCMSC8
M;H(&K[O-'BZQLB#J%_<=:8V23/[AJPVI/QS;)&?8=`UBN73<(B&MT4F')FT6
MJ6VOGB;3,E?C`Z>IX9F=XG/Q%"=4[7MD5CZ=G2*JSW3GA#B=@?G<\KPN=7^F
MO$GT5;G\DYU'YJ8NWI&\N8UWY%\T/-I6)V3?C_B6)&?)67,&/^@=!.J>[CMQ
M;=EA.*/SRXH[#L>L*C6]IJ:LFZ35HKNJ`]JH>RZ#+OY>F5*+>K)%K*;Y3:V@
MB@?5)L4NF6VOQ*<AW$4=(ESDKBI"+'GR;=F7%Z1B*SW1+AE<+'1ZO7=XAYY+
M9`[5I.FRUUJ]P*T5:W<.;*Z@AO7,C5HE0$&]E1'FDTRNFS@X^?FNM"QXQXFX
MB)D)U3W;+]6W+DXQC(W=)N&4T$6M$/;!:771%@%5-PW&U%NU\85M!RX8H`>O
M568UKA;-U,D;EGS>BC:>LY+=GX6E+7@T+<2$:I^QEVC:+56VM<[OI`W8VJK8
M-N=-+2C`^*8&XE,^!*UTQ.KUB"%!Q"/#*A#]>/C"(0^!,P8!D(7@3!I2#%FQ
MGF4!&P6+T`.@!T`.@!T`.@!T`.@!T`.@!T`.@!T`>"O=.Z+:;+N7>HN!H3;>
MX4;K[E;NSCGJURBZ8O.PZPYOR[[#6[1@E@O`.MDZ7JQZ$^Y$LJKA?;!5!("%
M`R726;DL14.AD0=K9D5E$9WW>+:?B(:KP./6[K#3^Z/Z+/,[\C[3N=RWQLC3
M@6=P]N+^K+ALRCTG7]\U'LH5RSD:V2,D.&MIZY'^1ZXSL)&"DYAIB".=(3F6
M7@970>5LB/Y1&=LR,K7+BY.H86E:\W=6MS:`Y3;&UYR9TR7Y"4'GEN#;;5+X
M67;E+9*1:-W<H]`V+4>DM@T<7K/8,RBG8.@-;U@4\=)BA92&_KZ8,CRXZ)ZX
M;@#L9*26KEJEM(KV)5U$9F7&?+M%WAG+I]RK!T40T-R<=M.C>Z76_E'M:K2^
M,&]TURZZ"%]U8M>YG2&O[-*U^BE;D)(H%PJNVA%`H!FTVVU!*^3\W:^7("I,
M)L%LR.Y9I(BS+;J6L97N6>1F>1<8J^K\'MS<GM]W\;)"7C0_';DKKKNH\>78
M+SQ_*2"XO4/(#DKQB\0K(^N[`Q64:2VSME@#?=P45=XKTRV`QF"IJ7KQ1',Y
MP2#6)/C(T<>1F1*XRVD5R+;U#5+87!KE"V:W_KRNZ&VY.T]=.5V_.9'A54^T
MSGSNS=5<UN0FG*-'=2H<Y(/9V1I#=^F=STR6C"W30'2,NY0GR`>$N1%"Q*++
M,OFDGI2DS\5C(R/QVL-@'>/^P=E<9N4'%Z[4/DH<>V#S8*ES.G2G"Z]U&F)U
M#:>[(T/8Q^YUGDUG6,"-L6`5TN4F;$>%1KT;C#*;*.'VXC(BC29`H(O8R45O
MF6N2B,[\';9?+/+9M%IZ1X_<EBNNC,3?.EKJ<V?7^[9<=YQZT%Z"2FKV1J?3
M6F.+>G[)R1'.OC'<.ZMV/(U<5ND^P,J5782I4X=.E(?%2FF0&:>(RMJ'S&:C
M.W-<;8]U2IMB1;*C=M=ZPVI:[S#XL\DM7UD8%XX&.57'C=4"ZD-83YW$G>NM
M*<`GVK6\+;DRJU]ZN[H8L^MZQ6AP*S0K)99L3+(=P*H/B.UKD>W5,K7^41\A
M7RSVY$8I+D9I'?1S8/+FNZ[XPJ>-\I1'<R=0)\,+.@M5P:PP3W/9.50@UMNM
M4&[H!TV+KP>5UO<[J/K5E0+)7JHXG!#,XR("%`DC++/9K<6?)8CY;']XTXDT
MCEQIW6>QJI;.)]FM]OHO#'<G#_25$1QVW5RHTM=9NI>4%^O%/UI`+U,-J\P+
MU]M'15BT6*JVY;-'U^`++U>7D1Q.;-5V:;'"<KE8[%K$9GK$1YD69%GL.]RN
M>67*/3;N<@J^4OD3RGK]^A[VK+]HY1<R;T`IUHX>VVK:K>K]PWF4LU;O('E6
M0US#$V1-D!R,30M7;V'.BSHI-:H<!W(YKP(57F23*WS4EM*]R+,K7OU<X]M.
M@H'0`Z`'0`Z`'0`Z`'0`Z`*,Y"_N?M_SGKG]OQU);>8_08"?4']KL+\TW_5Z
M@4=V\ZO2-?'OWQ-!_/6C^Z-@ZL7S5<WI%QMQU4`Z`'0`Z`'0`Z`'0!AAE=KX
M2;8"08$&$$;:79L%JGC!D*!-LQZ.##UF.;L$J*PT^:+L5NNU^OLDB3DF8T#!
M!Q*'DP!D*.P`9GH`K+7^E--:F(W$OJO4FLM9EMB&<V/8!37]"JM,(WJPY=F/
MY.W&;7!0V39S.7R)![)0V[.FY=GS'/#]_*?RL`FI.NU\U-KY(R"#EB-2+/'Z
MK/)C(4^;63L@(8K,@U7Y4IAU\,6?K=AL%?>)#G(TQT(<,"5O*@$YL=\`S'0`
MZ`'0`Z`'0`Z`'0`Z`'0`Z`'0`Z`([;@";74[/5ERG(*;+730!4UE/?NPTF!L
MD=F4TCOD=\Y'Q)R\A/?H[Y2,8[Y/;VX`/"NL\;^>2=/</*4;T5K0;%[GR/X;
MM"P$*_529=^2=KT/%L>N=F$Z#<<%&:_4-=R];$(%MUQ7-H,5,[/O[CPVQYJX
MZ$V:EA<S3=1E?Y6MQ;"/9EX]MMA;+[!K+L7N4O,:_E;#LX-"J="V1L$EN:U*
MCM787,?UG&Y=\G^2<';U,8,05-,%#M$XF\G+$;?,#</5\QM($J,!=+9:%2Y0
M3K)V9VRS_P`*2Y>,RZ.@<!WN1/*0BJN1ZR)IE-9&"CVIY#\6V#<)8TEO/ESW
M1"#O`'#1!>2^UY.XI\PJY>04=I25JO%<$BX??&P26N@G7*V_FXR2BW6DR\1[
M!>'&K@AR3T+R)UC>K)IR_P!@JPO4VLZ%F;IWEQ/TU7*B9J?,?ESN"<[LK7M7
MO-6&;NI;%#W/1)[-/L8BU!7D)LU90*SDB4BS`@U$9'G;,SS21[4I+;G;8?4?
M$*NH'<J^56K]?\?9(F#FXV_5NE.+EEL=.NVW(MC&QMP<7><.I>1;NH-7F3KT
MYG7E-V9K\!:X;C0)R)KZ3<P5(E65`_`N*1;"361F>XS5;Q*2:;GXMN_<+@WM
MQ![H#R=VQB[E*+J?3`/;%?8U=9L1R-?LA75^FQW+K6VZVXVQ@(FV-B]I7RUZ
M^U@Z%O;--LC=?FIO"J[!-Y2+D'5!4C216S.V?/:W4>R^Z_()-Q/XT\XN(O(>
M09,Z=";YU^-H^R=*UF[U'8-!UKEFE6SE7?>0->L3E%L]B+3Q(FO!-E2ZG`J<
M8J5(#8=6APFYDYM4>9(`9D9;;'MMF>PK;>7>/?+H*#^9O=G<Z.6UTW7N;;--
MUQ%B62L73N@>Z^/EAF76@LL&;_>;'W/4]IRK2$)M*B(07ORJZ2WMJ>Q32<."
MU6:N6.9M3]=\LU]\B&36*UCX]0CRXB)5^BY"\L\+.3&=%MT[T:9\Y$]P-=X6
M9'>>%!]SDPJGLBTZT\<\Z?$.W,]"F//#QKS!QV>%S:?`YPYD&L6M>^7":W'L
MOM]LQ51KAERKV@#XRDA&G^2U.V!Q>IFY[G2SG*W=/'"]3Q>_ZZ"XVVK1PFGD
M=/[FV*H?J:Y7?41BE'(DW$.7#K)>U,V&`R&.M8F@N5SS+.Q9$>PS.^TBS(C]
M`KG0G!CFG4=.A^-]GXW6`,YL2E]Q\A6+;;NR-#3:!J9_A87U_<-X1CL,7MF?
ML<U:!KM.E`:2BD42QU\\?E0YBK0/"-.E.@DU)N9WXW,K'<]:]N*UL\[GLXCV
M"3:QXN<P:)H'6NOIO&+E\=M^GN7NE-[%*Y8-[\/3>G;!3->\PWMMFX_'X)GD
ME$(5ZR2J+,\JJB;'9HD&?*9FC\DF)[D:.^"Z;F=TYI,MBKYE;/+T7'L;P2U;
MLC6VN=M&=IU-6O;1NSE!R#WZSKF2:KM@+4.N;/OLTG5Z_9"U/*GZA)M:P<:$
M;M#=5L%A`PSIB?"@'C"(V2$@**,KE;.Q$5]]BY<^0N0N8;M=!4.@!T`.@#`F
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M[PD_"-=-0^3K[`URY>KM#S[A^\)/PC734/DZ^P-<N7J[0\^X?O"3\(UTU#Y.
MOL#7+EZNT//N'[PD_"-=-0^3K[`URY>KM#S[A^\)/PC734/DZ^P-<N7J[1^X
MO</.<8\1D^[_`/E&NFH?)U]@:Y;C':GW"-`F2(:X;[BH[G>*6E;>$JSV8SVX
MQGW<?A_AZ@D&97R`UD66?MSCJ>?</WA)^$:ZG4/DZ^P-<N7J[0\^X?O"3\(U
MTU#Y.OL#7+EZNT//N'[PD_"-=-0^3K[`URY>KM#S[A^\)/PC734/DZ^P-<N7
MJ[0\^X?O"3\(UTU#Y.OL#7+EZNT//N'[PD_"-=-0^3K[`URY>KM'<7;XR(+,
M[,-_*'I#T?"._;[Y*F4-+RK.?P=F<.XQC&/=]S/;TU#V9>U^3D#7+;G[6Y>4
M=/S[A^\)/PC734/DZ^P-<N7J[0\^X?O"3\(UTU#Y.OL#7+EZNT//N'[PD_"-
M=-0^3K[`URY>KM#S[A^\)/PC734/DZ^P-<N7J[0\^X?O"3\(UTU#Y.OL#7+E
MZNT//N'[PD_"-=-0^3K[`URY>KM&2%6F.5F)AMQ7FE*0XO"UK1E./!I[[..Q
M/N^[_!U!I,LSL))1&=BZQ6O(7]S]O^<]<_M^.H+;S'Z#%A/J#^UV%^:;_J]0
M*.[>=7I&OCW[XF@_GK1_=&P=6+YJN;TBXVXZJ`UTWENFRZW.Z\I5%I@FYW78
MC%^*#XMBL\FI@H(36]=9L)]^23@UZSS72$SQP8*$0VQB6%RY_C$V;%BQG,N9
M$()1*,S,B3JED5S,U'8N,N4^88W%J2:22DE*5K'F=B(DE<\R(]NPLK;S%$63
MGF&!M:>(,T&2^&V]H6T[EB3Y5@Q%S7B0*OJ*C:>40V%E-N)-F/`U9D\V\A#1
M::/PV,DIE)2FQ,F>N6MFE9)V;2,]I9\19VW7W#&<@BU/DY+;-S;LL5R+8>W9
M?>99"7F>45ZD&:H%USIQ%[G/Z9UYNZ[BV[>Z.,CJ_L(]@#$!4R*FLS8]GL`U
M,8P:E8*RZQ!=&"TMM2,3)J&F8)LK'K+U?EF@CME\DLS/,K%L+*_'D)-U1FDD
MHUOU:7%%K9D2CM9.69EF>=M@YKORL*U/;!ZGQ:!`)4.C[#TSJ^]6YZUOPK!"
MLN[8T&4`E@JLW6YD(H$`M&07EYZ79!DYQ1)Q(V%(S!<\,2V1IO<]8TJ4DK7(
MR1MN=]IV.V7I!3QI69:MTI4VE1W.]W-EBM8R*Y7N9;1;5`W7&N`W=Y<D$4#@
M:7V9>*%+<8G^5'3,&D@09V0=2VJ%`Q!>ELEW&DB^_EI95%2KR@[X?*6JJ1JZ
MF=]=)*W6N9E;CW;>H9"7<EG:VHI1>.Q$=^L4+1^99`C7[38MAZXAU2)!XVQ>
M5548KMN=M+YG6LU)C+0<QF;6JV@/<&O)T'+D>)DN*=P7:[P@A41U+ES:*Y$E
M5_UG!G<K65EF69W3GR'EQC$E^Y&:DZI<'PI6.]T[CR*RNDAG!W)?9F-2[5V$
M:T_7'CNM*_5[HBL5':D&RLG*J<$LV$XPN2BMQ#@*U4\.T8;G!B]99B&R@Q+`
M,I)ARES8E30G6))*.QF97--K'>Q<=C(\LR/(LS+B`G5ZBU&A-TDE5B5<C(RN
M?$1D9%?:5C,MMLQ<VB-P8WE42M_&@O)5.D7&SA:`55/=EN76IUT@H,Q=<Q'A
MHYP/&-E(A7`X:YF:YY.BQ9RY7;-\78JM.H=KYV(SY#/.VT[VYL^(9&U\(DU$
M5BUC))[TEE?IOT"Z^JC('0`Z`'0`Z`'0`Z`'0!_.63[JGR@JY?E.=R,U_?*9
MJ:Y<^]:P!+&CMHT@3J>ZZ/WFO2'$)BZ;Z+76=K38+N]K?/"UNQU,",`V:%*=
MG'1RX@X&7A]!DU"R*]KZI[2.]RN=BM<K<7BY1#MJ=UTY&U?7%*."+7I4-=*O
MQBY=7;9J&M";1VS2KQR,XE\@1&AGZ2T6I.RQ,?16I=BE,%#/I6OY^=4J2#*@
M3)FQJ'.H?E!)((]^9E8KE>QIUK\IEED5K\@N?>?+[NB6K/NWWZ[?N--D+<>`
MW$Q[6M+(:)M8^,8LO+>]0ZX'"6>\0N01".^-U\T\H=)."P#";@XZDRU%K;+6
M![P5(D_)OK9WO8RXMQ6%>S^ZU[PV5L:OA-:3A&N*+;]S(I<:8/XE;SY=;/J(
MN/P%XV\EC50,Z?T;:!]V,7"M[>VE>:1;"HX<P.JHP,RR6'MN!YY*6$ZA6Y;7
MS,DE\Y1<?(0N+2G=#>0]OYJU_0)RR:[L5<*<I=H\?R=2D<<MM:E-L4+7G%S.
MZD[7#[=M]\F4>3?7;JB$$+\>$@"VQ1E3+SS4N/`A5<N>8"#21%?_`)2,LR.]
MSMLM??GR<H]WN@H'0`Z`/-ONA?*O8O&@CQ:"T2UTF@P-X;:OM(NE\N>CMG\B
M<U4%4-`;7VU"E`]5ZCNU&N)X@3L%"$@Y;D,C*:%B"<\L_$RS!<=;"R2(]:_$
M5]I%QD6T_&//S6/=5.36WI6I:%(B:*U5;=T`^,!UF_M52T;,J&OJ]?.'?)#E
MKN2UX`B=EP7;CXR(T-!#:ZKK%C@OUU%LD*L)&W3@>8T\+&DBO:]BOMR/)1)W
M<O\`L.<OW8+9]9$[!%38^LM@VT3JG@K8*'=M)::Y&[$T6:N.\>0NU=/;SFW#
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M!`=`'A+>NZT['U_R:@ZE-:PHZ]8(W=R_U):+PU*/-E:K%TS%XKU32!V8TX2S
M`?3L'=?)ZI:\M*<-,MQ&3`<B,S$5$G(F!?4ROQ_)RWWUO01#CU'W4#D/>%5'
M8Q_7VF&M-O7[N;NJKP#$HN\+8T"P=T"TUQ_M3%OKI^8?*UR4!H&R=\"Q*ZM.
MK2"1.GP),OSF:+,X3+"30197._R_^PS])%TB4\0.Z!<O>9<"FW+6FJM()K%4
MKO$<COFGS95IAVXPKD6-1;M@GM6VDA;85=K(O2^NR@6TPZ]9P=T+;,G,&Z[!
M*5:8@6_."%))-\SVJ(O_`)3L5_'GXLA6QONIG)<_KKDWL#6]*T*$CZ:V#1K!
MK.'?(&PC*ML\6]O[^O'&W5.RV%@;8`3`/EKIJZZVR>J,J:&S5)=:'HBPBLAZ
M4Z#5*Y;;&7_<22,R\69$+@;YS<LCG(NS<,:Z$X[Q-YA=P3Z(SL<O7MDS-6XK
M%+X7Z+Y)W(L]2HE[@6J25-7[=P2BUUI%SAQP-9\8L1%FQD1611<&J5KG>UK\
MOSC3Z"OXQK?5N[>7NT.OR'-,5"NBK5I;AAL'64@@5-3D.[!W?=]/U_=NKK!-
M8E0VIY"K5[:TNS:QFCHHE9T70K:2*0Y#$%Z/'"=3E/:9;+9%>Q]76/Z+N@QA
MT`.@!T`5U??PBO\`A-_\XG61OCYOO&-SBY_N'D-W0CEGM;C=9]!U?6)_7U87
MM07OJ?/*7G3>R]XR)QC5M("V6GU.NTW5MZH]C5,MY@BL+)FLN%W(Z7H[D8>M
MY'@WK*5:W/U`A!*)1G?+5M8R+:>=S,CV$-$`/=3^5<BX%!5FKNHZO9HENV#3
M3/'XWJ3:8BST5NE<%4<GRMBF;Z(;)8US:;!4]E]]0SFGQM0AW@M5TRS\!P<Q
M`F%8U=<]V>>5C[1DX)-BS.QD1ZURL=W-7)-KE<K&1F>W*QC>?B'SC#VK45$O
MW*/D/J.N'MNKU^/H0>QZ"VKPQC2;C;*P.-3*'27.1NQ+"YOR5XX7AQ1-HUDI
ML-,;2TIAB6HG&RU8E$>TR]'I/,46V9&9)2HR*]SN2\B/:>J1:OB/,4:+YI\R
M7-1:KY/.M\?26FM];0U14@-0\UK>)ONK8&QN<&I-`!ADF<O8,Z+LIXUIF[6H
MZ9LS8JF,4_9@@'AJOG*V6<$QZDI61Y6/JSL)-#=U)+6NDE'>Y6.R#5NRL9;.
M,KYY7'<YL]T1WSQLWA=J/0*-1+G5-?E.&ADJ*FAK'+NAFA[:'<T;=O2(!DCK
M-$AOW"-3N,@9&L&L!GV&3\\E'+0;"@G`9&2:C*_(9=97,$-I41&9F1GKER7+
M4)/6K/,;\<.]]E>2&K;?L4DY69,0?R(Y1:SJI"I-2VQ!>A:@Y";'UC0365RR
M114LD8I]5"DC!",^Q`(%)4N:.'C(3[$"/*3O?QV+Q"BTZID6]*3.^\R(SZQN
M,&_`7_\`!9O]=CHK^[_B(0G^]_A,87JPJ/$C>'=`>2=#Y5;[U-KP9KFY5W3]
MXHE:1KA.F-J%KFBA6CBY!W3:-R63<X78#>O:R%H5MF-Q)-=.4J$NQ`U,@AYN
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M:Z3M_>OQVV6&Q?`GE3M_DM9]DR]A6VLY$UVX;^J@S7E;XE;]U]#!L:NY"6G5
M-9,)Y2W.]V#3&V9A"M59$\]5J$`'EH!PW*9>='XIQJ!(LE5^/FM]_MM%7$$D
MBL1YZN9K2>U-S^217+,\C,]A<HOOC3O;:FUMI\O=>;2I]%ILCCYN*FT"L1*-
M8SMO;)5NUZ/UIMB$6.V,V!J69AJ9B^=])@P*H(A`<8P";EV3(_-G+B,S,R/*
MUNL54DB))D9GK$=[E;89EET?[;!N%C\./^./_/JPH,S8O]MDO^\9_J)ZJCYI
M<_I,2>T_&?I'G9S^Y)WKC;6^.\FBV>B4=6X.28C3MHNNP-9W/;XNJU>=IK=F
MQ'"@Z@T*ZT*Q&S+Q[6X`4PB.=RTS!(D'%PWG,-.QRCM;QBR$DHSN1G9)F5C(
ML[EQF1D//>N=U?WZP-E5S:&H\4G;DFU=SM!B`;6A>0$BG"X')[;%3INV9FP[
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MC;$6?`4?8`^>*P77`E0&4M;.URV;;&>=]V5C/_8.#*RKI41D99&M*;7*^TR,
ME%NM8S(QNES%Y#<A-%7;62=;C]/E:K<;+JRF`:#9!MHL6X=ZWNZ[0A@;Q3];
M,U^XUR+K\?JO4:2FUK!L`]6MB!$0X\C!@57`P(D7E6,S(^+BMO,[^V8HA*5$
M=]:Y$9W(R(DD19&>1WN>1$1ESCT(ZL,8S;W[7X/_`(G._P#0B=1QGXB])B>(
MO&?H(1J:\N-#ER$83E;$5]Y&%8SE.5M-+6G"L8RG.4YRG';C&<9SC\&<?AZD
M0/YS=*=ULY*F*MQNV#L2N4^^:TW'.XP*O=QU'Q>Y&Q)5%L&Y*SN<U?M)4ZLP
M[;M$YNF[U9FAU$\/M.N!Q%@<',3&#M.<R4"D&<9+/+E,KY;.3GV](^A322-1
M%D9:Q%K+3G:WRC/(DEG:Q\=N46Y`[JQLF<&XJ61L+KN*#V)MS>"]]><-9N=1
M.U+0=9YZC^%6JB(2K64^,LE:O\OSK@WFZQ;4)GNPH&LMEH?JU>?Q&A#&L=D]
M?BO81P1&:]N5M6QW(U:AJ,KYWV6+/:9;1T=H]T3Y4:Q$\GRMDFZ2I%YU>%W"
M4KG'O8FE=U!MA!@=3W[3=>ZEV=0[`U:T5;ECK6Z:OL+MKV"0UN0ILRH7(S3Z
M\/:=S)*#XS6,K[+[CXO$?'[&60DFTGJ_.,CM\HC*QW29F1_0,C*Q7([E>X]%
MZ1LG?EMXP6&[U"UT;8.VTE9#("P7?B[R*XQU,>(BFQ$4Y.+:&V!9;1N@_+K%
M<58#HF`*.!V]E%(@NN""-<:G.GX]KW(S*Q\QE^8Q&DB58R,B_P`25'L^D1$G
M,^3+C$BX3;WMO(S0L/9%V:K*;`UL;<M$=F50,<J0\V.UEMFXZ_!V29KRUFK%
M<M6'+($KH\V=UA=#4^VT8I.D@C[C,^*[&8).Y7]OR!:22JQ;DGGRD1[;%?QD
M68W>IW^W&?S$C_T^H7LY_N,$;>;[R&+Y"_N?M_SGKG]OQUC+;S'Z#&43Z@_M
M=A?FF_ZO4"CNWG5Z1KX]^^)H/YZT?W1L'5B^:KF](N-N.J@*!W7I"7M0G1K1
M7KS,U]=*`BYP0IYD%`LL1P-L``BOV<?+#$)$-MQYV/'@3!LY$QO,"=!:<<8F
M,K<85="]6Y&6L2K7*YEFD[D>78,:T&O5,E:JDWL=KE916.Y9<VX4[<>#%!ME
M.`T?%F.#@]8X_P"-$A'DQ8DDE$\5ME&N0N\*EX7%QDY",T6$Z]$8:C1):9TQ
MO"X[64M=7)TR,U6S->N?0HM7Q64**CI,B*YE9O@RRO;Y25$KQW2,M;.(GER3
M6WZ]M>TTG$;4M&TK=G00Z&DG;*70CK1\4L463+CRZ<>D25E(4PM#R32H64=B
MHB(=89D]03MB.Z2/Y9K*^PC,K'<N,MG.0&Q>UEFGY"4*L174E.>5_FF?/D,I
M<>*<*V[5*7WS\+#*Q:;OJC8UXH3009);L-MTTQ&CT]^-8W74S0XI]H8$2>&-
MPICA'`IOQ:>.\.]VP3ADDDV*Y$I*57/(E[<N,]MCXK\>0E31*6:M8R)1H4I-
MBS-'S3OM+85]]AG*;Q],5"V;2FIV9,)Z[VW;;I<K/KA^I!64^5;H'AA9F(UM
M1(6:;CQ8H^'EMI#:&W%-+[Y"?"KST4LE$DM7Y22(B5<]A&9[-G&))M1*6>O=
M"S49HU2_O%;YVT06E<,Q((#;*[;]AG;S"-:$8XSUUQ0417I-6U-%082Q#[^#
MF4V9LN,E6E.6"0S%;7Y,A82+:QAWOY-VYD9)(K+X0^.ZLN@LM@JE@B2:5*-1
M&WP99$5DY[MIY[>38)5I;C*K5#VS"!:_/74QL^IT2I%YWFD&J[$>-0`UD`#I
MZ80M]],T@2''T.F)4Y]YZ62BO2DNM1Y;4&#"UZUK%JV,SVF>TR/FMQ6XND[(
M:U-8]:YJ2E)Y$7S=8BR+D//?87%I_7,34.KJ)K"`2?,0Z+6AE;CE9,9J)((-
MC6$LXEOQF5N-,NOYQEQQ"'%IPI6?OL_AZJI6LHU6M<[V%T)U$)1>^J1%?9>P
MLCJHL'0`Z`'0`Z`'0`Z`'0!J"4X.<?SFN2&ICH(L<UX;Y-F>65CJI@K@D'M&
MTCNYR&_IT.R09<1V*9HJMG3TFDTZ:RX-7'@#ATG,B)'6VZ%M8[WX[6YK:OH%
M:1>Y@\21LW>KX6HFJ\*Y":PWOI^[5.NF\`Z>)HG)`=KR!M451Z\-@QH51P8>
MUH#+PLC<8;%FB%AGQ6<++NH;!K'D6XR/G*]L^<698.$.C+/'VE',1;5(QN*)
MQTAW=U%B<9=EM\7#40_JM<'+45*(#K!*$RX?4RWWIEO*VEH80K'8$7/+DO;G
M%,/]RPXSP[G8MAT0ON34=VLN^]H\DIMDU7LJ752479VYJ<"H^QI0QSR=.1!"
MV$)7XN7@K;>8S,V40D,*;3)PTV$ZQ\=CL1%GN+,NBXN"L\'=)5<I5#\9V\D[
M%4.213E=!/G+6\2*D-QG=)%=`'2YI]<1MLB-,Z^-$FYXQ;+:%G)'EEIUF0A"
M4A%SSY2MS7(_N&XG00'0`Z`*DONE:5L?8&C=EV-)7-EX]7.UWO7N8,_$6`D]
M<M6WC4!G)N)EAW).'FH;!L"8L=+L;+!/,*=EQS$;+#@3>U^4K'TD?I(:45CN
M4?&BB!:]!UZ?W%0[%2B.H2^O]A5RZBO/>A$=*4C9.M*G(KTHO52P)YN?KS;E
M]IMI@6$`=&GPQK.9$-LA$B3F0G6/DX[\MSOZ2*UAG*=W+OB_1J#L'6X1.R%U
MS98'2=<LRRMX>+%W1V@=S["WQ05L%YP]Z;F=Y^;-L[A^?-<FRC0M4&&^XA^.
MY,?!K'M\9[.,R(C]!<@M6\\)-1WE_<Y11G8U4M.Z]T:HY!%KG3;6V(LE/VQI
M:BZVUU0K)1W9(H@*A,PJUJRMQR@*PBK*`/*DG&C`R9`*N0FP:QY<A&GF,S/[
MQ;.A-$4OCK0%Z_I$FQ%8Y"WWO8=GL]P*H-VZZ;`V;;C%ZOERLQ-F(.A/%[':
M#I(@\P+&"@P]IQD:&%#1<.)"8"#.YW%T=!`=`'FK=^Y7\<=AF-SF;0?VK,<W
MB$Y2AK/#:/U6/$"N<L'N/4RXG*DXW2?*`FP40MQGUT<U82E3B7F\9<.33;-F
M4\'0%"VL>6S+5_[;V])W&'U_W*33&N['4)P_</(,Q1*D;XLVY6FSA?42M>6>
M]\.-5:]U1HR[6>>(TV(V=*)@8>L*?<2(09L832BUZ&H+/U9`YN.&8"369\17
M^5GG<M8S,^.W&9;-@C];[D-IFD5VJ4BB;SY)TVAAJWH(/;*L%L>KT(V:>XOS
MI!31]\MQJ3J:0>'VBJDO(LDM&I)"I5.YM5&JC;762@F$1@E@C7.][%M4>SZ6
MWV.]AV0W<;N&M/J\.HZW$VO58IS1NO\`15P7KSS!`SMH#]9;+UOM2I[%V9+5
MK^6NT[8CV'72HLVWN8C-D15YO3<L4X0(!20`&NHSN>>=\^*Y6,BY-G00M:^]
MSPU_:MJW??%0V]NO46Z[EMKTN,;&H<W6DTA4I\WCG1^+]DJE;#7O6=QK;M1M
M&O->UDP0CV418C<"_#XMF`G1+$.&)8!K;"L1D16MGGF:L[&7&?0*K,=QVXE%
M:77J%'E[3!`:=:.)MNIF0]FKJ255*</*K)I.OTC21*G$I,J/<JN0,"=HY-**
MRK,T:)R!DJOS'69#`22SO?(]O/K'<^O,AZK]!0.@!T`.@"NK[^$5_P`)O_G$
MZR-\?-]XQN<7/]PUHM>G:?<MH:FVZ9P4S;M+L;`CTS,6=A@9AO904<!LOE6%
MEAS,]68`N+XAE+['BKWA',X=[_O4WMF1[K]8H1F1&7$JU^;,A0ETX':(OD>S
MQSB+CC%MY`VCDL4<A6)N.ZC95PT(5XW',P\K&O)8`/ZQ-$8C0I2'5L%WL%42
M_"-H:3!I(^F_2+$XHK6MDDD\Q*UBY[BS>/G'@1QWJ35'";(VUL.N#AM<"UJ%
MMBT"[5FG!*L,R(%!ZPY!KH)4*"F`F,T^B3XZZ[XE$5AY&6U^$DBMQF?C$*5K
M'>Q%XN.^^YF-63'<L..1IF1$?L^ZHT$7,7*U3"A7Z&U'T$W*WW2.2Y2#ISPE
M;>>#Q2VW=;T@W)7:';?-@B:X-JP.8(K3/DO,:A<O)GL\0OPJMR=ECR^=\G5N
M>>VU]VTQ8X;@+J&'>Q.SK-;MN;)OXHSJDXNT[#N`XV1+RM,8WXU16#28=<%1
M)L*%"Y';"'3(Z8S.)L!FN,K6E0EQR:U2WF>9'GR"O"':Q$1%GD5_[VK?C_Y2
M$RXN\.-4\0*Y#I.F"NQ(%"&#K%`$4$[<Y9NG"7;1L:W;-+&!X1V,PPT?=,7&
M<'P96IR:JKC089]QY(U,AT22+9?VXP4LUG=5KY9VSR*VWK\8W)#?@+_^"S?Z
M['17]W_$0A/][_"8PO5A447&X\:\BE^19MI)OQWE$H4K:/?$TY:7D/J\-J&'
MYO-^+8\D?_@@"@)=[Y4OOR>'IOWN'/`IBVWEV^@6UCLDOH[.DU9\YC7\SW-[
MC#93FIB]J`'+7!T]KW1^L`=0LQ(><I5DJ?'D=M>#K.'>JV0#/P[0H;)W#9C<
MY$K+4,B<'5@@[$3D*AI^-4LN2Q=&\6)Q1:ULM:YF?'\JU[9Y;/2(?GN6'&6*
MX>'UV?M.F4*Y$IKU\U)4+C!"ZMNE<D;BM.]X-!(U=NNNY`TH%L>\W*>'@46=
M4B;0:RD:M-,3JTF$+B-0N7/BX@X565R29EL,RN99$F]]]B+;<KYV%_:"XGU7
MCD9L4NB[*W,3JI\IL8ZSJ^W7$::UQ7#NTMC3]IVTS6@K-;'D8$]^V&#ST1<@
MS-:BPCQ2+X%SPK+C`DVXS\1[!52M;:22/+,B.YV*V\6G2-/T_7U[W/L6OI)X
ML6^+;5[K?,S9V),%1JHZUIVJ1&0\7##>1T3%4HH+$F/EV1E\CB9,PXC$C#+<
MVS,]]NH09W(BW7MSG<6IC\./^./_`#ZD0,S8O]MDO^\9_J)ZJCYI<_I,2>T_
M&?I%([)T[3MJF=/G;4DIF?H_:D?<5'\G3L0V4W&-0K]KAI1=O+#WE`7YN;(L
MF%0<*CYS.S`E>'QB+EIV3*]N0[@1VORE;T']PJF^\.M0;%,[4/GE6MHGN"X<
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M3DVE-N-#Y(TK6#KK:[.2CBH]GD#9@YTT,``(4I64BHRTC3<[W,N+(5)9DDTV
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MER=9*16VR,&79;=6A<IM5I(6QBN#4O@JDP`"2'(&6H7+R9[/$!.J*QV3?*YV
MVV*Q7YMUAL=)XT"RNF#6F+-MS>EKC%CXBT1-CG+Y%QM6NFZY8:_;*S*`6D0`
M$PV&*_8JR,)1!L\*1%D$YG"S\(P%(S1KS5RM<S\>T5UK*UB))<5B++,C(^/E
MW^(3'1VD:EH*ES*;4YUB-Y-7&Z[$MEIMY&.5M5ROFP[(0M=PM1^7`@"129Q8
MP2?6B$%#A@8R$W$&B!4`?$CQFY(K"%*-1W.VPB(BR(B+(B&Q=._VXS^8D?\`
MI]57LY_N,61MYOO(8OD+^Y^W_.>N?V_'6,MO,?H,91/J#^UV%^:;_J]0*.[>
M=7I&OCW[XF@_GK1_=&P=6+YJN;TBXVXZJ`@5JO3%7GL071SLS+\1$O#C<A#6
M$X4\^SWF4J;7G.<99RKONW_ZNSL]SMR%5*U<K7$9]+\/U))^.-?0=!7A.3K_
M`"#TOP_4DGXXU]!T#A.3K_(/2_#]22?CC7T'0.$Y.O\`(/2_#]22?CC7T'0.
M$Y.O\@]+\/U))^.-?0=`X3DZ_P`@]+\/U))^.-?0=`X3DZ_R#TOP_4DGXXU]
M!T#A.3K_`"#TOP_4DGXXU]!T#A.3K_(/2_#]22?CC7T'0.$Y.O\`(/2_#]22
M?CC7T'0.$Y.O\@]+\/U))^.-?0=`X3DZ_P`@]+\/U))^.-?0=`X3DZ_R#TOP
M_4DGXXU]!T#A.3K_`"#TOP_4DGXXU]!T#A.3K_(/2_#]22?CC7T'0.$Y.O\`
M(/2_#]22?CC7T'0.$Y.O\@]+\/U))^.-?0=`X3DZ_P`@]+\/U))^.-?0=`X3
MDZ_R#TOP_4DGXXU]!T#A.3K_`"#TOP_4DGXXU]!T#A.3K_(/2_#]22?CC7T'
M0.$Y.O\`(/2_#]22?CC7T'0.$Y.O\@]+\/U))^.-?0=`X3DZ_P`@]+\/U))^
M.-?0=`X3DZ_R#TOP_4DGXXU]!T#A.3K_`"#TOP_4DGXXU]!T#A.3K_(/2_#]
M22?CC7T'0.$Y.O\`(/2_#]22?CC7T'0.$Y.O\@]+\/U))^.-?0=`X3DZ_P`@
M]+\/U))^.-?0=`X3DZ_R#TOP_4DGXXU]!T#A.3K_`"#TOP_4DGXXU]!T#A.3
MK_(/2_#]22?CC7T'0.$Y.O\`(/2_#]22?CC7T'0.$Y.O\@]+\/U))^.-?0=`
MX3DZ_P`@]+\/U))^.-?0=`X3DZ_R#TOP_4DGXXU]!T#A.3K_`"#TOP_4DGXX
MU]!T#A.3K_(/2_#]22?CC7T'0.$Y.O\`(/2_#]22?CC7T'0.$Y.O\A&;#L&.
M;S$RV,>C^+8?[>_DH7W_`(;P/9V=C2>SO?!?]O;V_P`'9U9*M6^5[BJE:ULK
M6$;\XV_>J_A4_P"#JW"<G7^0J'G&W[U7\*G_``=.$Y.O\@#SC;]ZK^%3_@Z<
M)R=?Y`'G&W[U7\*G_!TX3DZ_R`/.-OWJOX5/^#IPG)U_D`><;?O5?PJ?\'3A
M.3K_`"`=Z#;VHF)G;!<7XU!?B8['DX[S+V6\X7GM;SVX3WGNXQV9SV_AZ@UW
MMEL,CV[N821VORD9=(Z/G&W[U7\*G_!U/"<G7^0@/.-OWJOX5/\`@Z<)R=?Y
M`'G&W[U7\*G_``=.$Y.O\@#SC;]ZK^%3_@Z<)R=?Y`'G&W[U7\*G_!TX3DZ_
MR`/.-OWJOX5/^#IPG)U_D`_<61O&<9\47[G_`.53_@Z<)R=?Y`.Z3M[4^?*F
M)@N-ID.9<PC+R593[F,=F<X;QC/X/XNH)=BM;K_(#S,SWCH^<;?O5?PJ?\'4
M\)R=?Y`'G&W[U7\*G_!TX3DZ_P`@#SC;]ZK^%3_@Z<)R=?Y`'G&W[U7\*G_!
MTX3DZ_R`/.-OWJOX5/\`@Z<)R=?Y`'G&W[U7\*G_``=.$Y.O\@&`OVZ:EKBA
M3[1<E2A5=KCR9A(A&@E3<C'E.5`$P8T0,`&DS1*9*(2(L2-#&P)DN3(DM-,L
M+5GIKYWMNX]U^3E$E<[$6VY_=V"HZ?S&X[7N!8B5=VG3<QZA*%0K6V=--U&?
M6I9H97RHV,=%6UD(4$O/,VD)"<;G0V%13LIZM3,,6(<2%PW"<G7^0DT*+^Z?
MIV>+VMGL,61&W5KB80:$1+E3Y1:0?*U-@9&MH)\@]:049$PW6FH34M4EP^'A
MN-RBH9#2B(^,XA^7&9:4E67"<G7^0BQ[CV7V<6_Q")C>3NI"[UMC#[`M]^BV
MH!3+0RH18H[@TW9[C(U^"6VF2$9R2`S[E"*`,6T5X]4X\T)8/&S;#->-NP'"
M<G7^0G55EEM*Y;,[%?T<6W9O&"-<Q^/(&8.@3]F5AV093_\``_)$U^PL'W\1
M+Y.?@5^8`ADXAXK!BZRNSA0.(?FE!*@S;)*'$>+!6R+A.3K_`"`D*/B/T;LS
MOL+,LSR,967RMT3$LXRF9V14)EH,))+A!0YV,=F>""FAE=-/S<!43VQ<<,:,
MC1YB03<AL"W9&53W([3$AQIPG)U_D&JK;JGER;]G2)F!W7K>TSH@RL7*G6,D
M0#9L<`>!MP$O.FU[#L9C)V)$'RY#\D-A^9$9R49;7!P[*C-^'[]]K"G"<G7^
M0@R,MI&7%F0N>A&D3+)&CXCJ1E<>7]]ES"L8[QA2_P`&$X_#WO9^'JJE:Q6M
M;G$H^=X_]_N'/R%_<_;_`)SUS^WXZ@MO,?H,9A/J#^UV%^:;_J]0*.[>=7I&
MOCW[XF@_GK1_=&P=6+YJN;TBXVXZJ`U[VW_M\?\`^#M?VV=T&)>WF^\Q5?04
M#H`=`#H`=`#H`=`#H`=`#H`=`#H`=`#H`=`#H`=`#H`=`#H`=`#H`=`#H`=`
M#H`=`#H`=`#H`_GIU'R!Y##MG$Q%/V<HX6O6R[;KXTNS7;87($)KN9/YQ$M;
MB"M\U\?/5X=I6SQM6G(;6JZ#33C`2[5*N&;78<QO)(YMX+V*W,1EL*^5SXL_
M:^\2VU]T6Y&`J;LDJ_+UJ+L8DT3A5D+FJLSGP=K"!>4A5_5=UF2MA"0P@K-3
MIO7J8@C$LIN`W-+6$6)UM!CWC79T6$6Y.+9?Q9]=\\BY=@F6.8>YM@;-!!4;
M3IE;JP?E#J\=.GTROL2JSG6]GO6W:8+JUHM<B]M&!I<_'K]1AE0=TIM<9,61
MW%IUJ:N]!L(!V""V5^0\CRZ-]BSY=PLO=/-7?E.);<53*>#F!*J\3C!Y4L6J
M2Y6GZY>-^Z_=0?8R:B3SJKA)U$*LP?R3#:2)&'6VIV5LR(DMT(_V+;F=_;L$
M;7S;W('(BR16W41K6:ZNA9W9,BL5>Y5N`<D4[>5P<BCY&K-J&,%K8RG6`^*)
M"PUO59^.T7%6&R!KE*&!G`FW3LL5^3?X^3,;)3^2>Q@@[B7,(EM<%3.V8T-R
M_4^G0&[80L#$J`A<\KK<L$ODZ`137IBHT,K!JR-APXLPJT5G'8=,&2C\H(MM
M\7'S>F_YB17OF)(JFBZANB%J@WE=HL)X)FIV\J]4)D?R!K_8%\;1"FX`&E$R
MENDT5BA4<=Y/B8.WJV`0Z9+3CJ4OA)%<[>VTBZK^VT84GOW>%J@<<"U1J(ZL
MHVM)OAVTB(#\*YR15-JC(V0-D2BEG]'C$%Z3&EN23D4</*DHRE)A@D&EL9DO
M`L5CWE8L\LS]-O8AJ'6^>_(>;``.I'U*YVDX!AFYU0K%9C0X(*'GCCMC9"\D
M#!2[QCU8L+=LJ(6=/K-TJ@^%90$>5+U;9[4,(K6,"=4N7DSVV.UMGY=8W>&<
MH+`36`@8HEA'31UUT=6+1/+`Y$0/:H^W&0X>=(JDA3N,PUU\K9HEI3X3RCB;
M6*\5RK$;#^7XH5MV^+T^+??;RV+R*N3U/@U)UNT/5A,Z6;;6XT9<#XEJ89%*
M0A2VY,?P^6<.+4E.<J[SOU9QC'?9[?SK_P#:`8LQ[A>#HL/`V)L6X<<FRL8E
M4CPK6JO1US$1V<-=RE-.DR8YR$L*??X#A]<FC>>X/5-Q=_4ON9<-4K$<C&":
MG0*=7>Y&:(IA,^EQJGW-PRZH3BFBDL/$SPO!MDLT:NOP:"5?5*VK7ILD?C7E
M?/>1]I=?FO\`&S[H#[3=+WGIC'\3'K+XLL*?9_AWS5IGJ(>FR1^->5\]Y'VE
MT^-GW0'VFZ7O/3&/XF'Q984^S_#OFK3/40]-DC\:\KY[R/M+I\;/N@/M-TO>
M>F,?Q,/BRPI]G^'?-6F>HAZ;)'XUY7SWD?:73XV?=`?:;I>\],8_B8?%EA3[
M/\.^:M,]1#TV2/QKROGO(^TNGQL^Z`^TW2]YZ8Q_$P^++"GV?X=\U:9ZB'IL
MD?C7E?/>1]I=/C9]T!]INE[STQC^)A\66%/L_P`.^:M,]1#TV2/QKROGO(^T
MNGQL^Z`^TW2]YZ8Q_$P^++"GV?X=\U:9ZB'ILD?C7E?/>1]I=/C9]T!]INE[
MSTQC^)A\66%/L_P[YJTSU$/39(_&O*^>\C[2Z?&S[H#[3=+WGIC'\3#XLL*?
M9_AWS5IGJ(>FR1^->5\]Y'VET^-GW0'VFZ7O/3&/XF'Q984^S_#OFK3/40]-
MDC\:\KY[R/M+I\;/N@/M-TO>>F,?Q,/BRPI]G^'?-6F>HAZ;)'XUY7SWD?:7
M3XV?=`?:;I>\],8_B8?%EA3[/\.^:M,]1#TV2/QKROGO(^TNGQL^Z`^TW2]Y
MZ8Q_$P^++"GV?X=\U:9ZB'ILD?C7E?/>1]I=/C9]T!]INE[STQC^)A\66%/L
M_P`.^:M,]1#TV2/QKROGO(^TNGQL^Z`^TW2]YZ8Q_$P^++"GV?X=\U:9ZB'I
MLD?C7E?/>1]I=/C9]T!]INE[STQC^)A\66%/L_P[YJTSU$/39(_&O*^>\C[2
MZ?&S[H#[3=+WGIC'\3#XLL*?9_AWS5IGJ(>FR1^->5\]Y'VET^-GW0'VFZ7O
M/3&/XF'Q984^S_#OFK3/40]-DC\:\KY[R/M+I\;/N@/M-TO>>F,?Q,/BRPI]
MG^'?-6F>HAZ;)'XUY7SWD?:73XV?=`?:;I>\],8_B8?%EA3[/\.^:M,]1#TV
M2/QKROGO(^TNGQL^Z`^TW2]YZ8Q_$P^++"GV?X=\U:9ZB-AMA006Q>-EB';\
M--5&EE/-SRM9'G&FG9@>+9P$X6Y.9>8=;;6=)QX8=/>(4^1:G)=8::??9>>_
M:WW*^*=*>,-$E%K&E6FIBU1RS=$JCZE-5;$=`2RUW%6ZO3S:0F)(DF:TM2-<
MEU6.A%25&92^V_,_/O2[2,)4/&LZ#A"2IZ.BZI\-LB5$I=2-:RD0(<G74IUM
MJQ*6T:;0W#5&)U9MJ;9\[=B:@X';-D[#;`\A4Z8K\Y5S'O,U)%:KE/74;OQ9
MXEV8YBL3HT)I**Y$TUJ"L6@>_(FPTRS$S844H/L=>#&0,CT=Q^++IL8ZR)3A
M6^3<\MNWYROO.WBMR&)%4=;\-:SL0#LESEP@N1I%GMFSGJTXZ/BA4P;%<-)F
M)(UNJ-17(XN>+OH373Y`:/&(R.(6J3)AU:MVJ=#L8^1%UVMJ;2MU**]^/*^9
M[;;3$RN!#C9/&\M[`0W3;MBL-6OC+L&_$Z!6JB[%CS:;R1MV-65`(X!@#@5N
MN>;IKZ3J&W6L@IF4W2:M1!M@,I*5LD=<C(\O$?7VD!:WR/DD62B*YG]$K[S(
MB([D7*('6N*_#RU/%@^ON1Y>RE7*Y79\H%4X82RF7*OJ[36XM?.RA8(2!D$)
M#)RI\CLV>!,@QGTFW7:-/K6"(NPQ4E9X^KVZ1.LLCN:;9\9Y7-2?O3Z106-4
M\1C<*TU:X;<Y**=)C=C1-@Q2&NHY&UB)^*)$KCU2?0"'VDBU;FJ7P5V`=@"Z
MM`,5X6L%9!^8=.ANTBF-!-U%:Q)MD99Y;;WSME=9%O\`'M&[O%#7VAV^05T*
M4:]VRT[,JR#FPKTV5@TT*,40Y)P`.XI6(8&!.=M`T7X+8$&:(COPW!,!+[H7
M)XN3%S'%!19JU<R(B.Q<=_DW+C\7W\8]AM:?MNA?]WG?V5SH*(^<7/Z#$GY"
M_N?M_P`YZY_;\=26WF/T&,PGU!_:["_--_U>H%'=O.KTC7Q[]\30?SUH_NC8
M>K%\U7-Z1<;<=5`:][;_`-OC_P#P=K^VSN@Q+V\WWF*KZ"@=`#H`=`#H`=`#
MH`=`#H`=`#H`=`#H`=`#H`=`#H`_GSVSW:B\:WVILS7<71%4*1J%L"Y4N.3?
MNA>,^18JUC)`VI[T=L(ZVP[,;@ID.,H<<0TMS*$K6E.%9TF3BQYB3(8*&VHF
M7W6B4;JB-1-N*01F6ID9VO8>+L2>ZJJU"Q#7J(W@^G2&Z/6JI2D2%U62A;Z*
M?.?B)>4A,124*=2R2U))2B2:C(C,BN/:7COM.7N_1^L=MSQ$<!,O]3'620%B
M2G9T8:[.PO*HK,MYIAV0VWWON.+9;4KM]U..MK@R3F0X\HT$@WVTK-!'K$DS
MXB,R*_0/5&",1.8LPE0,2/140G:S36)RXK;BGFV%.WNVAU24*6DK9*-*3Y!<
M_7UC:0Z`'0!QNN(9:<><5WK;3:W'%=F<]ZAM.5+5V)QE6>Q.,Y[$XSG/X,8S
MGH`IT%R(T=9GQ<:O;2IIF0;CZWEB6!QAB4]/C;@#%;#K!^,VUE2UM7@$#,%Z
M\OLPF<.&S):,X986O`38^B_5M%CV>U5VF"%GK48@@0R"`04LD1>PQ%21L9L?
M7`4/+F>W&'RITL-%0T?A=F36&L>ZO'00/V)::]/LANH0S$&39ZV+`&CP-I["
MB`H3:7SL:NSYC'X6HQA^LGVH+F<]CRQ,W&/_`).>@?>/F1::_$*$PTDFPP2#
M5]BTE([J7D8A5^3()Q62;K^6O%O`*?#DD92EY3S?BBUN-(;4VI8!V@!T/:00
M6S5TC%,5^QB1QT$7@N8>A%`Y>&R0&$8;V/<=BSH4AB3'<Q[BVG4*Q^'H`RW0
M!W!\)TE.B0&,MI?F2&HS2G<J2WAQY>$)RM24K5A.,YQWV4H5G&/P)S^#H!9Y
M"PO1/9??(?XU+^H]!?4/DZ^P/1/9??(?XU+^H]`U#Y.OL#T3V7WR'^-2_J/0
M-0^3K[!T(6DB0UTD^/8K<%XS/\JEG8F78[A(GXE"&Y(3E-#DYE3,CQT"%F2]
ME;N8T.,SE?>,MI2#4/>77V#O^B>R^^0_QJ7]1Z!J'R=?8'HGLOOD/\:E_4>@
M:A\G7V!Z)[+[Y#_&I?U'H&H?)U]@>B>R^^0_QJ7]1Z!J'R=?8'HGLOOD/\:E
M_4>@:A\G7V#H3=)$B+PR008K<U\+/R5$/2LNONC">8$X7DA`6Z.4J+,R-)D8
M'C+.4.^*3I;'?^#?<2H&HK>72?8,/9-7O-)AMGH=>*(4I]<9$EA)!+*DX:2Z
MI*9D#.&E+PIO&<MX[583V*S][CKX)U&I57)HJG3*=4B8US9*H0HTPF3=U>$-
MHI#3O!\)P:-?4MK:B=:^J5OLAU*ITPUG3ZA-@&\22=.%+?BFZ2+ZI.&PXV:R
M3K&:25<DZQVM<Q%?1B!]FJE\BCOL_KC_`(&84\&,.>1:;ZJ/N^%&)O"*N^5Z
MAZP'HQ`^S52^11WV?T^!F%/!C#GD6F^JA\*,3>$5=\KU#U@/1B!]FJE\BCOL
M_I\#,*>#&'/(M-]5#X48F\(J[Y7J'K`>C$#[-5+Y%'?9_3X&84\&,.>1:;ZJ
M'PHQ-X15WRO4/6`]&('V:J7R*.^S^GP,PIX,8<\BTWU4/A1B;PBKOE>H>L!Z
M,0/LU4OD4=]G]/@9A3P8PYY%IOJH?"C$WA%7?*]0]8'9C:G#2O&/!UNGX\6C
M.RW._##\=K;64X5A/8-5VKSE>.S&>S&?=[58Z@\&X4*W_A?#F9V_]%IOJHDL
M3XF._P#XBKN17_\`5ZAZP.MZ,0/LU4OD4=]G]3\#,*>#&'/(M-]5$?"C$WA%
M7?*]0]8#T8@?9JI?(H[[/Z?`S"G@QASR+3?50^%&)O"*N^5ZAZP'HQ`^S52^
M11WV?T^!F%/!C#GD6F^JA\*,3>$5=\KU#U@/1B!]FJE\BCOL_I\#,*>#&'/(
MM-]5#X48F\(J[Y7J'K`>C$#[-5+Y%'?9_3X&84\&,.>1:;ZJ'PHQ-X15WRO4
M/6`]&('V:J7R*.^S^GP,PIX,8<\BTWU4/A1B;PBKOE>H>L!Z,0/LU4OD4=]G
M]/@9A3P8PYY%IOJH?"C$WA%7?*]0]8'9F:G#093T1ZMT_+K"^\7EL,/4C.>S
M&?O<J&ISG'N_PIQ_PZ@L&X4,K_!?#GD6F^J@>*,3%E\(J[Y7J'K`ZWHQ`^S5
M2^11WV?U/P,PIX,8<\BTWU4/A1B;PBKOE>H>L!Z,0/LU4OD4=]G]/@9A3P8P
MYY%IOJH?"C$WA%7?*]0]8#T8@?9JI?(H[[/Z?`S"G@QASR+3?50^%&)O"*N^
M5ZAZP'HQ`^S52^11WV?T^!F%/!C#GD6F^JA\*,3>$5=\KU#U@/1B!]FJE\BC
MOL_I\#,*>#&'/(M-]5#X48F\(J[Y7J'K`>C$#[-5+Y%'?9_3X&84\&,.>1:;
MZJ'PHQ-X15WRO4/6!&-T:(([<U>3IN;,NI-FR]:D1[`):;F%14FH6NO6]EZ%
M&FL>)8?<=#LQX[TA,AF,X[XPY#E(9\6>V!+>J1(224I21$1%DDB+(B(B+(B(
MK$5K$1#A=8];749J-1JN9F9F9F1W,S.]S.]S/.XT^E]RMX\S'(JW7KSWK$5Y
MEYM5M8D)ES)>GQ6C21CPDRO29`PJ:H`U<,X\`>$1S1&<HD3BRGP]5Q7[<&?)
MU]@GA5\G1RWMMW[^V^>/]S,X_6))G,Z$?Q),V2U6U<I1N(2\3/7$]KFPFID4
M<>`%PCJ5S-7UIF-&)"R$6-%632AGP\MN1':A\G7V!PJN3=:W%8RW\HGE3X*:
MJI@V^A0Z[&H+L"969$P5-L:Y$4#$J>V+WNX2'K;B1C4R*+QLC9=U./H(RBLQ
M;)G`AN:R('BX,)J'R=?8(USN1Y97Y[D2<^8B+*P[6IN$6MM*N6631)MI@D;/
M4!U$?*OV5:R(NL`*M5Z-4H(1Z,+BH@R*A3*34*Z$**:?*O,`(Q0[-,V&65,D
M&H?)U]@@UF>TBVWZS,^/C,S/\A%*WW//4M<S7.PG;R[=8IZZ6/9)&`L9EV"W
M7-P5$24FM@*F#Q(L`2L[]W`*CE<>#<,9N\PK;&[&=%5XJ':A\G7V"QN&?$6?
MCY#XSX]4NC*V8MNC\6ZO0KVC8`LM9B)2#2_,*N#3UB=)A*C7)0_7L`]%KD3(
M]F5&\Y_170YIAN;.(0V"(-R6"BA5FC^"K4/DZ^P5-1F5LM^1>/T7,;5:]#RH
MEGBON+8RA$>9VX0M>5??1UHQV8RVG'X58[?=Q[G4&DRS.P(^=XO]ADN0O[G[
M?\YZY_;\=06WF/T&,PGU!_:["_--_P!7J!1W;SJ](U\>_?$T'\]:/[HV#JQ?
M-5S>D7&W'50&IG)TM.``;0=%NI8)!=<6`L.?4VV\EF<.A&YD1U3+R5M.I;D,
MMKRVZA;:\8[U:5)SG&>*KLIZ#1*S-C*)$B'2JA*86:4K)#T>(\ZTHT*(TJ)*
MT),TJ(TJM8R,CL.6P["CU'$F'Z?+0;D2?6J5"DMDM39KCRI[##R"6@TK0:FU
MJ22T*2I-[I,C(C'C96.6.[C(KCP*>/C\V4K?@[&W)F*^$1Y1J=QLFKUTZ&Q&
MQ!Q&%R"-;V/][)'-17UH%.24NJ>RXYCSE3M)V,947`D94Y@ZA)K<1&*'NX8:
M>Z*75:AAPZ4RAHF>#C./T_$!?K&$M+,HRUDLUZRAZTJVAG`$&9I-EHILDJ5#
MPY.<P6Q[YSU=RUFATO%R:X^XZ<CA9C<:JX7S:E+=;2<Q#1H)&JD;"&>;XFOS
M-A0BFOW\R:17I%F:@"KM73923`B;&!:[>@6"&,;D,U.P./6`>=BA9$TDZL4X
MCQMZ%(<0WG>Y>F*-!>KK,FAK-VC07*BEB-6($R2XPU7X5!6Q.:CI6BESE+G,
M36HCCLA1Q5%PJV5J)(ZT@>Y_FU-C#4B)B5LFJ_4FJ4N1,H%3@1&I#V%ZAB=$
MFFORUMKK--2BFR:<]/:8BH*8A7`(D-(4H2$CRO+AK0JL&-/&!\@0=U95[FZJ
MX5^3FJV';A%YJM0LMPF9#1F.R(;:(DIHV4I$>7)9&);<1WY!/W/Z3942I'39
M6%)3"XLW#5-JRU56"Y[V3\4R%(IS.JRAQ,M"(I)D2'H[ADVZXF.25%=\N,BZ
M&H,ZD)JT'',&2W.IV+ZO04%0ZDT58IF"HJ%U:02WW&EP7%S5+BQ6)3)*=8:7
M+-25:L8Z:NG/&07HFQ9NLZW#AG`E7G6NM%Y=B"G/!!0][@4XE)M%<98P\`,/
M^/1"0H!*D2USA$[$[QQAR-F.YJ58TUN2J)7G\.T]IJ7#IKU3ITMV?$F:L2+6
MF*2^Y4J>A&O!E+X9J1&@N..J?B/$^3J#;-![S0?<ZM0L188CXKJKS\"?5X]'
MJT%FESZ?KSYV'9-<BM4BJ+<-%2AM]SO19E1::91'FQ^YS9<2Z3B=@$<GN\*,
MUZ=0I42P>F*I:6EP_.*(_$BV*T4-ZZJG>/LC<X>'C7&'!#F6F,KDJ[)S7>MY
MPQG>BTC:LE,%ZB.-3?A92\(.M=WM+;:GU*B+K!O<,B.9+8CJ0<16J@S</]>C
MY/R!ULK1)K0UU./B-EZF_`>LX\9>]['FWG:72<1HH!1^YURKMR927$SDDIS5
M:*\==U?K!`7.6$ZX#Q\@%6+32$!]QZOU?;I,OR%,?;N%@LKXRUT'Q8D,E,/1
MPD9J+Y8.05Q)N&RD/R3EE_+CS?!JTFOU5AA<*G5*CE$Q9AO#E4<=[B=6FK3Z
M@N-4Z'P<B,ZA3<-M+7=<UDVGM62UW+J+,UIV5&AF/1)4EJHU>CU]4[`^+L74
M5EGWQ8;70Z92VI='Q'PL66RXV[4'5O%!I\A+S&M$?[L)QO50K%_=RS7`[AZ+
MI0P^,71[?L&#(5>`+69-=H-O>J%LDOLJ@*?B+B3&<K',>"?DDUJ2WX"+'[9O
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M*FQ3UQGL4M8=E0XN(G#9CR:HWKE*?BQ6%)CQW6[RTO&2!E^.'(8SL,6*`;%`
MN`+3&T_2=HNV-X@)=&VNOGFI4*=8_$QK$9BN8P5'2G<#'/">#A/-/*S&SA49
M'V:/,;SL1LPJ;6H#D6K'A>BXA*9PT9QJK1*CPD=<U+$9"$P5'+8<-,4]8R:6
MA1\&=VT\=I7T;TW"3]0K&':HU-H18TQ#A55/X"8V_0YU*-J4U3ER9CKJZD10
M9+6M,+4(WFW$EPI:KJM"@?=BZT4-4>ND->A`=AV[9>Y]/ZAK4^Y$L'[5K'GG
MM]-1%VN;&34O%A)_7&M2==O!NMKE/-33LR?5T%(K$%!B1V@.F=7JOU$*QK'=
MFK)8-*ZEV_.&<,JK&VYN6HZK=;L_*&ZA@.E&K#I7DKM]Z;OJQD=%18M3+2'-
M!PJC6Q5>;M+)@Q99N')T18J$P9"=4KVSO;LV=?;QBZ<=TYW@_5./UU3P]A#!
MO)#4KEXUU5RV\6,[,-'8'%:U\E[$2@T@?K:4N-I2KDP`/3!O9UL*5&Q1KM>Z
MU/SK7$"8*B'0@T[<[F6[QD7W\H]9=>WFO;/H-'V549*YM4V'3ZU>:Q,=;\$Y
M+KUM"PCX62XUA2\-K?&D(SJV\+7WBEY3WRNSMR%1,.@!T`.@#^7;1'.KD7LQ
MR^#]C<V%:N,#C0F!2F)%(T_WI;,M1QF5'DQBNOXD1</QAL3X0TFR1E`FX\A,
M\5/;,19PSKJ+6J@^;J7JKP"B61-$;,7Y7S[D9*8(K7U?E:Y:ECNDR41I_/'"
M^F3'U955&:QI0.AR&9+#5-2ND89L_KG*2M"T/T5#9MZZ8]Y/=B#BDA9.L.E(
M0XSI#4=4AMW4;;&[[C:S!2\Q+/MFT6V7&.:RJXF>XS0BMT$$LBK`5#V-^?:K
M]*1E42NUF1$6(A$0HV+',2XSHSAT,)E-R);KBE.\(^XZ9*8;29\$ITE:JU(7
M=QT]B&[:I*0DB496ZEA45C%%.K^*:G/D2*J4_$%0J3J)-$@QW5^]<BI,O]SR
MGXTM3L^K.D9MPX*F^YVWHS#:)#B#8VCUWS'VQKOBP!BT?E"?KUFHFM"SL'7<
M,5I<]"%S(VVZ-3Z4%Q!-ZXBV3,>;2R]R/&V\6:RE!BH5<*Y>=BS"H8=R+%6E
ML4]"69ZT*98/59)$19),I#3;:;+8X0R-M3BU?+6I-D*N9*4E/8=$TJXJH>`X
M<>D8]EPI5(HKYL4=N)A>6TPMNOTRGTV*3<JB)FFERFR*C*DD<Z:^R;4-_64A
MQ^.S[S=SJVSL'=_$G7&R=HV)RU74X0O3)4XZ.$"ERVA%ZL0@<G,$$/&#&O%A
MT*+&QEB$TIS#6''LN/*6XK=:')?F4QB1(7PCRU/$I>JA-]5YQ*?DH2E)621%
MD1;,\Q[-T(XDK6+-&U"KN(9IU&JRWJNB1+4Q&C&XF-6)T9@C9ALQXZ>#8:;;
MNAI)JU=91J49J/=[KEQVP'0`Z`/`)KN8?(F!(.-!K/2!D.;'W9!@JC6(S`>\
MET;4-BT!PY#KEPA*I@^$UKN_74E;7XGAGZ8?DLS`K)*1A'07N7'Q_>9&=_NM
MG;(7)$X$[.)$+'8)U:HM?C>5M>F-141JR+EBM-#17,0KN&Q5H"S!&,@1RT:L
ME8B1E@H>($,@6*4T,\@"WF?-!K%LY#N>\[6ZS^XQ6(/N<N^,BXP\BS2Z9(GH
MTCKC;-F`7XDLKMJ@1Q'(^D<D]A39<<'!D0+A?1>W*S>0D6<X_/E6$)A!4I"E
MJD.]`UBXK\>W;Q6\>96XSZAED<#^3LR'235Z10-HF$^33&X*00OI.-6[Q9GB
MO+9N-#S*F@9C&(5`:W'H^W"Y<H<E^3.U?AR#%9+P0ZW@B^Z_)O(OD]ABT>-7
M&#D#QKV/6;Y8@B[^^U5*!J@D\$O@*,-Q6;(.XR428I8B+JIVWFH>F8U`V!9(
MN+3>T5V$*AL-TR$-(;(N+P0%R.^?+GOSY;%EEQW\>0]@.@J&,]GNX]S./=QG
M'\'0!YIZ_P"Z9Z_L-ENH:Y5M0&#6C!8".=UU8#>[;2X>B[PL.B:]4KA0*;18
M]EIUXOMA`*.4JM1&;4@M7)"IKI2(N/X)X+:IV(RSRN?%;9QGXQ<TWGUQM@BK
M@:7:[=)'T3&)ED='ZTV01S$KV&]E..W1I$*L/YE4AC.GMF,JM3'?B'I=5<A1
M)$F6;K#)L(L9^UO3S=)#A+\Z]1,GJ\`JL2_W9TUNT5HV24"T*\HKT"QRS5TK
M):;&L#U<\CFHM8LU#/!#K(Z8MZ&ZTQ/7E(F:.GS06]%_1VY">W'EUHJA3+G!
MLUUD0WZ#XEYR>`!V&>RSF:NSLXP/?@CGVC*H<VFV884P*7,R+*AY8V?XO,1X
M'(0,9GF3I=DK""$)>PQ)8E!CS(`XAJK9:)DN1.'VLN+",18]9D/KL1D-2+.7
M#`<-^4B@\8I^&P[F1$0^$V\727M[>,64'WOK0\G5"A=EDR,[M03<UNAP+8HK
MAKR+7B=H*M3&Y8MA=?E0`X<B[(AV+`J6F3%<@885-3F/@(MMY!VAFZM?%;I:
MZ`R?EP[+3(T68::,A;``%*B2IK(Q,D-8C8V!7[&Q'*R&!,UT`3)(@E7FQTI3
M4Q6&>@"`W;ECJ#7]IMM/L)6T>5J&$)6*Y.":7;3@NN!A-<"6N=-*%1(J7!CM
MMA;&%?;3E[*Y#T]N)'2Y*0\TV$V/+EV>@8Z#S(T7.;0^FRV")$E1SLX1/)TJ
MYC!UB%UVST2G$BU:GS@K$0Z/38MCU4<TZ->D.+<DSE*:0@22S&!8_;I&P$*V
M""%C/5*-/7FPUJ`!+%AKC<AIY@39U%V@11I3B$M28!&57S\%B3'6XC$X(4BK
M[QV*M/00(_L*_P"*$/'SW!;ACQ^8Y$PU@EXAX'P;'ALN=^J#.\)WW9WO>]ZW
MV?A[[/X.O-WND?="%[GNA8;K1X1/%WPAJTJE]S%7O>'N3N:'W7P_#>\U9X?7
M_P#+X+@F=7YW"*^:.T=%VC4])4^J02K)4;WLALR^%.G^^'#<*]P/!ZG=L'@]
M7YVOKN7V:I;14WW2#7L8]\Y4_P"7^O(7Z3!'V+*_ZBE_0H[I[U5?ATGS9/\`
M'P^Z0:]C'OG*G_+_`$_28(^Q97_44OZ%#O55^'2?-D_Q\/ND&O8Q[YRI_P`O
M]/TF"/L65_U%+^A0[U5?ATGS9/\`'P^Z0:]C'OG*G_+_`$_28(^Q97_44OZ%
M#O55^'2?-D_Q\/ND&O8Q[YRI_P`O]/TF"/L65_U%+^A0[U5?ATGS9/\`'P^Z
M0:]C'OG*G_+_`$_28(^Q97_44OZ%#O55^'2?-D_Q\/ND&O8Q[YS)_P`O]/TF
M"/L65_U%+^A0[U5?ATGS9/\`'P^Z0:]C'OG*G_+_`$_28(^Q97_44OZ%#O55
M^'2?-D_Q\/ND&O8Q[YRI_P`O]/TF"/L65_U%+^A0[U5?ATGS9/\`'P^Z0:]C
M'OG*G_+_`$_28(^Q97_44OZ%#O55^'2?-D_Q\/ND&O8Q[YRI_P`O]/TF"/L6
M5_U%+^A0[U5?ATGS9/\`'P^Z0:]C'OG*G_+_`$_28(^Q97_44OZ%#O55^'2?
M-D_Q\/ND&O8Q[YRI_P`O]/TF"/L65_U%+^A0[U5?ATGS9/\`'P^Z0:]C'OG*
MG_+_`$_28(^Q97_44OZ%#O55^'2?-D_Q\/ND&L^[FFO9S_.9/^7^GZ3!'V+*
M_P"HI?T*'>JK\.D^;)_CXEM+W6,MAID'*$.`GYB<I'O.%4D&94OMQWL)78.@
M98=>3WWBZLY<2\[A,?&$N.-]]W!H0]W/AO2SCF'@:MX.5@2766U,T">[B9%=
MB5*KD9&W2'KT&BG!D3&]<H#AJD(E2DHA$2)#\=+NEX]]S[5,'8?D5^!6TXA:
M@J)=1C(I2J>]&A6/7FH__$)W#MLJU>Z$D39LLFI\S4VVX:+J[<_QY_3GKW</
M/(=N?X\_IST`.W/\>?TYZ`';G^//Z<]`#MS_`!Y_3GH`=\K\'?9[/P]G;GH`
M=N?X\_IST`.W/\>?TYZ`';G^//Z<]`#MS_'G].>@!VY_CS^G/0`[<_QY_3GH
M`GVM,Y\[87NY_P#Q>=_#_P#TKG061\XN?T&)-R%_<_;_`)SUS^WXZDMO,?H,
M9A/J#^UV%^:;_J]0*.[>=7I&OCW[XF@_GK1_=&P]6+YJN;TBXVXZJ`UCWX$B
M67QRN3UR&X)^GS0DUR*MMN4W$*^5(,E<9QUIYI$A++ZU,K<9=;2YA*EM.)QE
M&?EGPVJA!F0'S6EF=%D0WE-&27":DLK9<-M2DK2E9(69H-2%$2K&:5%D?TT^
M>]2JG3JI&2VN139L2>PEY*E,J>AR$2&DNI0MM:FS6VDEI0XA1I,R2M)V46C@
M[B!JD7-A$8LFUXG0<:2PB4LB)RZ[Z!XT.'4LO]Z"2E62L<<.1:/!I;\?\0C9
M'>2.\5W_`%^QHKPS'=:?;<J?#-?`^SAR(QJ5\"6VFJ7KVA$1]U(CQRJ5B3P_
M`-]S]RV._9\K3=C*7'?BO-48X\CX?:S28LPDH^,5YY^M<'>H&9%#<DRCI!*-
M7<W=#O=7=MTZL=3PBUCD7/"R+9LF4+E5TI4H,-PK6$M@ZZ5V$'V:]`&N-U!#
M[KB+.&;6D@7>*$'84N7$DR7\)@+@_"6A[#O<S\1=4Q`Y&<@2:6RRJ3323"@2
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M#*CCU\ZJQ*@P4/$<RH1#H\V3)?0AN/-8CN/-"9-<1*"FK6VCO6W9,FFV4`4K
M(VLNV`8D12Q)BU>>DQ%8BL@6DNS,'L)<C$[-YQ$(H]"134C$!3S+O+)T6T,J
M;4Z,NJ8@<I-0@R:<Q3E3XY1:1%EU/WW>*G-H@I)3W=ME-R:C[X/ML$49#A,&
MM"^"7ILQ(=8HN($47"K5=I52AU:55D4R6<VO38-']XF%5=U=16:6#IUTNQ:3
M[UQG9*CF+:.02'$<WW)]25:V+>]?=G/D6+75KZN.X4JN1\R]56K9J+%LFQL4
M['A29(?E4DDRTM@9F<X\N"/@Q'/$TV^+*EG4T55=;Q$N0BJ4VN&VJ33.`=K5
M,IGO6BJ.M^]7RI$AB[DA"5(C<,I1LL,M*X(J?'+6BH[E$1AO"3<5=&K&&R<3
M$K/=+.':Q6/?IRC,.G7/D1(LHB:BN+)R7W.A!2),AY/#GP!>'FL*^W$8%F;V
MQ&:L5!N1&.X:%2&S]RUZ8FFA]K-*D`'7G3AQ^<['L\B$[!9*1&HJ&H\-Z*R^
MBD/15AR"EI$:76D-HJ%#JSZ%2XKA3JM0I;TQBIRS7!4M4R:MY3=26RIE$EI+
M1);:6VEPKS].&+:DMYR7!PZXZNEXCH49U,"6TJG4+$T)B#)HT$FJBAM%/@-Q
MT.TEI]$A<1Y;RENOH=<;5R,<0=8QZ\S6D%KMF`SKS8&LTN**!<RL@-D6URYG
M9*G,5W#62L8JZID7(PQB+'@]C4J%-?QF3F4:*\.(@HIY2JQP"*#7<.DHY,3A
M>XL05156FN&KN#5[J;DJ-,9>H32&?DN,O+_6"KFFW%KE37550J`4ES$V&\5F
MDH<_@2J6%J*BA4YHDG4S7W&Y#02Y;1N&\Y(,UM/L-V:+B1Q`U\@V\61:-@)B
MN'25F:`I)5S(F.=-456O3!!*UU599Y4X#X)28\@H]$@36<.C(\..]+C2(+19
M0BF*E%4JX3:ILFHIA%(I_<J)LRBG0I;Y&=-.4HWH6J9(<DK:9>02HZ&D+=;<
MR'INQ,J`W#.D8:-Y-/BTI=1.)5.['*=`Q"6)H,4TIK"8;:8]1UR-QJ(AZ1'7
MJ2G'W&V76Y1J_C72=7.E'(AJX6WRC1PFMF$W,D,GI$4<$F;EBO#?)(8)WL23
M((RI,I4KQI[OU-MQG(S#>&L\KA;`=+PG(<DQ)U6J#QTJGT2.NJR(S_<5*IIN
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M:*GJ_<NH&CQ=A(<=.1N[Q%G3QK#<;:96=D^@JU:ZBT^DT,W5-?!2Q;[GMW<`
M6IBK`:=V%8:_KG8U.B6:W(7-F-H;<0TR#6SS+COE?;T^D>D>K->`M1:QUQJ>
MK>'\V=84.H:\KOC2DKD^0J57QU;$>,K0E*%O^3QD?PRDI2E3G?92G&,XQT%1
M/.@!T`.@#'>2!/JL=\2C?1=5U$?13_E+L&#N:-^SL?NF_P#2/Y#N0'<_^8=H
MWSNRRUK0EL)5RQ;<V0=`$(K]?;BSPA:Y&9XJ;&0X8:<1'E09##[*%M-K2VM.
M%-H5C*<=8S:)5')DMQN$XI#DE]:%$;=E(4ZM23*ZR.QD9'F0_-/&>AC2?4,8
M8KGP,'5%^#.Q+79D-]MR"3;T635)3T=U!*E)42'&5H6DC2DR297(CR']+O#O
M712A<7M'4V\U=H);JY0`XNP"2$:"[-@$HZ7,/QI+C.9#2W49SCOE-O.)SV^X
MK/6_4J.IFG0VGFR0ZVRE*TJ))FE17N1F5RZQ[QT84.11M'^$J75Z>F)4X-&C
M1YL9YME3K+Z-;70XI!K2:BN5S2M1<HV@999CMX:CM-,-)[<I;9;0TVGOLY4K
ML0C"4X[<YSG/9CW<YSG/NYZY(B(LB*Q;BR'8"4I0DDH2E"2O9*2)*2N=SL16
M(KF9F?*=QR]!8.@#07G:]R00(UZQH$G=PK<A6P?+177E1EW6PLW5JI]]J6/*
M!Q"86.[7I%DR0417:C8/7"R#`6+L(R-KDF1(P$E;._1[7ZL]PU2+%>9Z#=^Q
M:7.4\?7BMJ7Y>OW]9UT+-V#Z*O-_>JM),X9R)F1TV>3ME@:U8<VMEH1'UVCC
MRO:[T(%.V4\^%LLBRV;;].WJW;K[()<+SR^K5L\#LFY<APH2Z<A+)3"`77U#
MG((K&-CN89^DC=3F,9*O65N=1:MJ,F48UQ6G0T<6.`S"AK.RGKE&P$;2+(LM
MN_GSXS\5LL["9A-2<DBW$;GO6[T!OY#?^VH>K;/'A%8,DJ`.6PQQ/XZB+1(I
M2(>&`4YL;M>O;#KI8."FH4.AUH/!=:B0_)4F6"Y73:V7:?W<=O&,(%K?,K6Z
M1=$KXC:\2XUNT1&"5QK(!U^B[XOA3?!(OR"W=L`JY%)PV6[UQS)UD_0!AXI#
M'5&_8,:UH.'I]-A0F@DM7CM;+HW%;<?49F=[CEF8Y[5%L"K)SD;;9D7CR*/R
MA8L".EE;#9CW'W;1:^PB-PEAGJ#3+I7]]2Z9$K(_%'N]\@^2*.$K-&+4DA>Y
MC0,N3(SY>,NG+[]FT>CO#J=M&9IU]G;N;8[9QNR=JP14NYA;`$-3:#Y^G9NM
MI66+9CSGE0\T6:`9B3+*MRS90SF+9\1[%$*PXP4/V]K$-JD(6XM+;:%.+6K"
M4(0G*EJ5G/9A*4IQG*E9S[F,8QG.<_@Z`-)07<[M?A[37;7+M6Z+%(I5R+7*
MAC#3]*9%4QRQ[Q@\AK.!%IK^MP1$J#L6QA0F1-5;B5E/00XYD4!.AVWY[DP+
M:Q[BS*W'XM_%Q"#'NY6:</`C-9<.;='`2YLH32*'0=8X@#AQ<1MH+(!1X<[4
MTZ(17&B;EM.1=VL3!O:0EX94G!]\CJKD7OPB_MR[;^V7()P&[GC2@UO<OC=S
MW-*MZKI1+PV>?CZWCS5$*!8+2?%PRF1FJA[-HAR&KD;K'C-M:/&Z_3?)U;I)
M>JPAD3O`7_VS[1^6KN=^MK_,O<RZ-VN7(M1:P2`A$4/$13-4$6FT[)OIZ"+*
M%:\;DL2R5MW!><SI4=;,:6`8J8MV#AT-+E$P&=^KJR'PKN=&N$-LRQ1W:=5M
ML4*[68>P:,)U90KA`K$BO;'KLVN#':9J0$!%!R"-EDC<^*,`Q,R[6!JMI><4
M;&29A`%SYMW%[9=`V!7QQKTH#J6ME(9\F*T\@BQ7X?D:N!!Y6"3UQ:M5R!1H
M)5:J`KS`ENIV\DQ%&5<16H<61''Y991#8=AR`7V\OY']PKB;PEI1-V_-E26T
M9P:]O47*0")@@1$IPS6\>)$IU8IIJO5,/<8=.#1F)F8E2-6<]7XY$[8K#&'L
M68W.,N@OV\?;Q\8XC_!75%H39%G@EI*D['4-ATOS@),"BUC!#-D%I4TG.KQP
MO6R!&`<$AWH=,"%7GY;Z:@'%"R^##[+\Z2"YE;D$*_8X=1RK"3M)U>Q;,:(R
MBLYJ49ATCL&DRMDUM95'X;8S7@U#UP8?U<"&.7TI@C>30B>8BV>QG7<B)(@&
ML=K<7^_MS$8V,H6B(6O+K;;16PZA(L_3Z)21M9&"9<>`)%TJQ;0N"IF7'%NJ
M>(&+%MNS/2N\0RPW&C0,)2MY4A>0;O3[;AWMK:K(;#$"Q>3AJH.0"*YZ9L,/
M#G.2D9C+CKBJ9*LJ:2COG&W<N-I\)A2$I[<)4K&>B-.^@6AZ>J30:17:M-I3
M%`J,FHLJA,(?4\[)C%&-*]9YG52A!*,K&=S5F61&.S]%^DQ_1G4*G/9HD2M^
M^<-J&IF7+DQ$,\$^3Q.H7%^6M1YH-*ODV.^VPHK[DTI^-RV?-*K?5>O,WZ.C
M1YX7U[^`:]?'='?7SO`"B^6:L'W)I3\;EL^:56^J]/T=&CSPOKW\`UZ^'?7S
MO`"B^6:L'W)I3\;EL^:56^J]/T=&CSPOKW\`UZ^'?7SO`"B^6:L'W)I3\;EL
M^:56^J]/T=&CSPOKW\`UZ^'?7SO`"B^6:L'W)I3\;EL^:56^J]/T=&CSPOKW
M\`UZ^'?7SO`"B^6:L'W)I3\;EL^:56^J]/T=&CSPOKW\`UZ^'?7SO`"B^6:L
M/I/$LLOON]VU;E=ZG*U=[4:OGO4X_"I79$SV)QVX[<Y]S';[N>GZ.C1YX7U[
M^`:]?#OKYWV?T7RS5Q\_<FE/QN6SYI5;ZKT_1T://"^O?P#7KX=]?.\`*+Y9
MJP?<FE/QN6SYI5;ZKT_1T://"^O?P#7KX=]?.\`*+Y9JP?<FE/QN6SYI5;ZK
MT_1T://"^O?P#7KX=]?.\`*+Y9JP?<FE/QN6SYI5;ZKT_1T://"^O?P#7KX=
M]?.\`*+Y9JP?<FE/QN6SYI5;ZKT_1T://"^O?P#7KX=]?.\`*+Y9JP?<FE/Q
MN6SYI5;ZKT_1T://"^O?P#7KX=]?.\`*+Y9JP?<FE/QN6SYI5;ZKT_1T://"
M^O?P#7KX=]?.\`*+Y9JP^E<2RR%90O;5N0M.>Q255&KI4G/\64YB8SC/_''3
M]'1H\\+Z]_`->OAWU\[P`HOEFKBQM::'1K\O(-$+.9N4SP*&QF"@86.:$N9P
MZF1*82,9;R_(>:<PTA3^5)CIPI;6,.+PM/:6A_W&FCW1'C*/C>-.J&(:M3XD
MEBD-U*,VW&ILJ426W*FTV3KYN3FXO#1HRS-*&$2I#A(4^4=UC0M(FGNLX\H?
MO`S1(6'(;SR5U!4&;-E.U!ELTJ:BN*E'9N.3J2=<2V6LZI*$J5P9*2N]?`/_
M`,B[\&O_`)=>O['N/H,="!X!_P#D7?@U_P#+I8]Q]!@'@'_Y%WX-?_+I8]Q]
M!@'@'_Y%WX-?_+I8]Q]!@'@'_P"1=^#7_P`NECW'T&`^LQ9.$X7F._A"LY3A
M>67.]RK'9G*<*[WLSG&,XSG&,]N.W';TL>RQW`?/@'_Y%WX-?_+I8]Q]!@'@
M'_Y%WX-?_+I8]Q]!@'@'_P"1=^#7_P`NECW'T&`>`?\`Y%WX-?\`RZ6/<?08
M!X!_^1=^#7_RZ6/<?08!X!_^1=^#7_RZ6/<?08">ZU:=3;(2E-N)3B/.[<J0
MK&,=L5S'NYSCL_#[G2QEM(Q9'SBY_08D?(7]S]O^<]<_M^.A;>8_08S"?4']
MKL+\TW_5Z@4=V\ZO2-?'OWQ-!_/6C^Z-@ZL7S5<WI%QMQU4!KWMO_;X__P`'
M:_ML[H,2]O-]YBJ^@H'0`Z`'0`Z`'0`Z`'0`Z`'0`Z`'0`Z`'0`Z`/S..W&<
M=N<=N,X[<9[,X[?X<9_@SC^#/0!JA`XG!(4L/.=V=M`I)#RWGVTE"PB1#F,*
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M72$YGR\4AR6'QI"P1Q<^3#<8&HA/4][4V,BDRB(]7_\`,(_E)(OE9IL>LHM=
M1&1I4LDJ,C)-C^5>CJ,:%H1B+$K:5I9/_P!00O5?92@CD$2F-12GWD]V26G$
M+COS41WG6E(8)I=ZZ]HS&O0+E?BFS9V-DG/(L2#TEN9,C(G+0M41,K#2)$AO
MPJ7);S\YV5*?G2YCWAFX[D>)&^QEDF$:A+6LM8U$:SN97XKVN>\S,S,U&9W(
MC(BVZBTE%%AG";ERY;?#O/(7,<2ZZV3ID9MDX226LM8C<4MY3CBWG'5:Y(-#
M;<YZS#E@Z`'0`Z`.%V-'D*86^PR\N*]XS%4ZTAQ4:1X)UCP["EI5EE[P#[[/
MA6\I7X)YUOON\<7C(!S=`#H`=`#H`[4*8\/F1IT;*4R(C[<AG*DX6G#C2\+1
ME2<^XK'?8QVXS^'H!99C"T_EW5+_`&VST6G7^LG[93G"#1\/"BK\+'4&-2:T
M<5"D/,-0C+5?LL.56K$^$DD6:_8V'0)ER"63F'T%]=6XNOM$VL>]9=0%*.6B
MP@@`=$X.,62*HBPH22-@,0*^#A9?>4EO$DJ<*#A4!KM[^3/FQHS>%..H3D&N
M>XNOM&<])]K]\0_B370-<^3K[0])]K]\0_B370-<^3K[0])]K]\0_B370-<^
M3K[1'JQON1=!D@S53X<X+BV"V561-@Q4.,,V*B6HS2+>)6I24YQ+K]MKQL"0
M1V92W/&R6TJ6E.%J!KGN+K[1(?2?:_?$/XDUT#7/DZ^T1ZW;[D4.JV2[W$^'
MKU3J`(K9K,>(Q4-P`H$'!?)%BDUQ*5J1%@0(S\J0M*%92TTK.$YSCLZ!KGN+
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ML$?`ROJW3OM/<[_:KA_]Q5OPT/B;TF^"-1_SQ/60]-M.]K!'P,KZMT[[3W._
MVJX?_<5;\-#XF])O@C4?\\3UD/3;3O:P1\#*^K=.^T]SO]JN'_W%6_#0^)O2
M;X(U'_/$]9'8C[WJD;P_@K:'QXQ'<C.]L>4KM:=RG*\8[8WN9SE&.Q6/=QT[
M[3W.Q_\`[JX?RS_\BK?AHDM#FDTO_P"D:CF5OGQ/61U_3;3O:P1\#*^K=.^T
M]SO]JN'_`-Q5OPT1\3>DWP1J/^>)ZR'IMIWM8(^!E?5NG?:>YW^U7#_[BK?A
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MB/T#0202DZQJL9ZQVXCL5_'Z?0,&'[JIJLZJO9'Z\VXN%8X6H"K!A0K7GD`0
M(V_3)5TB%+,?;V.X&K46ELQV:_>,&9T1X39B86!%:(1"\$@\UU;_`$".#,N-
M.5]_$=LLL[\0L(+SO1>]%`][:^UG<&P9;;6D=>.A]GP<Z\,8KNZ;1JP2+O@A
ME#%C0;&L@MLU\V/CLN1F2LAJ>.R2AYB.2%-=6_T=@C4^5JF9;#/+/9?+BW&.
MU3N8=VL^U4U95#`+U\NO;&N,BW!K&1*V`!2:A;[C6*I>+'7VJSY(@5O9Z*EB
M7KY/G/Y>MR)AF6!"31%&LI-MKJW]1=@DT6*^=\MQ$=R([%G>Y7S$"D=T]HD+
MS4:G:IW#%FW)O630<?B/J29)\K[E=OSNM`,MT?MF7!B$+$$UG;;"^^],2*!0
M8T&$<(P#9&,+RUU;^HNP."/>G+6W_P!VQ'Q<HKU_NNE%A0F;@2U'M07KB+17
M+A92DIC7DBT5_P`I473&RZ9E5?%[!(1B8RUU3=M6CMNBBTPH'L.7XAP6-%Q9
M1AIKJW]1=@G@C/C*][<>\R/BXK'Q>(7/>>Z$`J0,H1N1KR_$DW1[=`%RI#XM
M(S;AMUTMNBDZ+L()Z5.O@^G9CMW.S$.])1[',@S10SRC#E=\XS$EM=6_J+L$
M$V9W*Y96.^=K&DU;K["W"I1G=7X9(O$&N:NLV:5*G1E5XZS(I[!>QS#UGY75
M04#B`R5NA8AEI<OC)'8&^&)RG[`4LKXB"(ARVPN#365O]'+VBW!G;(\RS/;Q
MD@_0?)Z1C1G=;JK)>D%"6HMD0:O/KD^W4UMAJDR;58:N-XY:NY/DRI,?+N@T
M569H?6UXL,B:`E%ILB5)K,6&.GR#1A`..UU;^HNP1P1VVE>]CVV^<:;;+[2V
MVL-T]"<JPO(--W76:Y:ZVFD'60[^+=#KC*C<:5B6F&=#XKUDL7>#)CXX@RTP
M8R*,M>*X<EBHR'V<J:ZM_478**3JVS([[KY=(V$\O$/^LU\%C_GTUU;^HNP5
M#R\0_P"LU\%C_GTUU;^HNP`\O$/^LU\%C_GTUU;^HNP`\O$/^LU\%C_GTUU;
M^HNP!-]>%IDJT1&'5-Y;7'F=]A*,)S]['6K'N]O\>,=0:C/:8LCYWC_W&5Y"
M_N?M_P`YZY_;\="V\Q^@QF$^H/[787YIO^KU`H[MYU>D:^/?OB:#^>M']T;!
MU8OFJYO2+C;CJH#7O;?^WQ__`(.U_;9W08E[>;[S%5]!0.@!T`.@!T`.@!T`
M.@!T`.@!T`.@!T`.@!T`.@!T`.@!T`.@!T`.@!T`.@!T`.@!T`.@!T`.@#QA
M+\.^5RV6*&U'UJ?U*$(7Z-,#'+2&**N\6S\IPVYJ_:A@*SZCL06NV`?2)!B%
M91-U](5/,6J-EYRK$DP`!9X+7+V+(LK;S.U[;.PA60ON<N^W:K%$V^I:@N):
M'J7C_7K*]<;<U;VKM;M-*XFL3&@ITAK*+:`HFTB](;`A&Q=VFW:MPY!>OEJ@
M.KDJY[+84$W+>?&6[+/:6P[7RV<V0M8;W/[:(&=K*8!A:[%6&-:`-JL&P8IJ
M9YPZZLH3E#$VQ;K?7,NUY4RS&=LZ-$A-&&%8GA5Q0(,+5R*YM)C^*1@B][WO
MR%V^(\^GC,02@=STWS48.GGWH-1G6.D6^L%R\@W?*Z9K'EH..X[#[3?55@5I
M*JJ\?M3FK;83'6VO%@N\6"<:LR[+L`O&V+M04R"^WQW\>[CY<RW;,]M7V;@+
MR(A#*IK[T>T6RS[)J>UZ[DE&K.;548VY1&CI=,D<OK>=9I3WD38EYOA,+=H>
M'XKMP61I<4A&L:K5'&X9!>Y[3V^(RSZ3L5_%?IN"Q]SNW.ALSD&*U*9>OEUW
M85V?)(SXL:?;H5VY3[RV[KNP3F#E#MM4+6"LU+8-2;D8M]6MD6OH;M$"L0G3
MD.MG&P:Q9<G(5]A%8CXN/9O%*O\`$'DE8MB*UZ]5$HN4*D`I5YW(YBXX@VP,
M&U7P^"3].R[Y=-4RM<VP"4G:\VC7J\R@IL"!G%OLLVUT`(S*N<<F%KD5\]NS
MI.QY9[K\?CXIM>^YT\ESP-8$!#UU"93J/;.O1<XC>X#A.,#V?I/DK3AU&.$Q
MFGA<UT/4+YM6D2X0&EN4O5(RN@FG1]"+6$*'*0@C6+[^N^R^[??<60]].@H'
M0!0F^ZU>+*(KK-'KD2QRHI&:[/8E'X`#$9AR,REEU#L]"TR,K<2I&6V\84CL
M[[.>S/7BSW9VA;'&F>@8'I^"*<50D4.KU:9/2<RDP^"9EPHK#)WJM3IB%ZRV
MUE9E;JDVNI*2,C/T+[G[&N$L&5+$;^+*NY26)T&$U#6W39M1-YUI]Y;B31";
M6IHDH41ZSEB5>Q9D8UB]%F__`,5X?^D:O?0=?G[WBFGSP:1Y:P?_`%6/4/QZ
M:&O#.5YKUWU</19O_P#%>'_I&KWT'3O%-/G@TCRU@_\`JL/CTT->&<KS7KOJ
MX>BS?_XKP_\`2-7OH.G>*:?/!I'EK!_]5A\>FAKPSE>:]=]7#T6;_P#Q7A_Z
M1J]]!T[Q33YX-(\M8/\`ZK#X]-#7AG*\UZ[ZN'HLW_\`BO#_`-(U>^@Z=XII
M\\&D>6L'_P!5A\>FAKPSE>:]=]7#T6;_`/Q7A_Z1J]]!T[Q33YX-(\M8/_JL
M/CTT->&<KS7KOJX>BS?_`.*\/_2-7OH.G>*:?/!I'EK!_P#58?'IH:\,Y7FO
M7?5P]%F__P`5X?\`I&KWT'3O%-/G@TCRU@_^JP^/30UX9RO->N^KAZ+-_P#X
MKP_](U>^@Z=XII\\&D>6L'_U6'QZ:&O#.5YKUWU</19O_P#%>'_I&KWT'3O%
M-/G@TCRU@_\`JL/CTT->&<KS7KOJX>BS?_XKP_\`2-7OH.G>*:?/!I'EK!_]
M5A\>FAKPSE>:]=]7#T6;_P#Q7A_Z1J]]!T[Q33YX-(\M8/\`ZK#X]-#7AG*\
MUZ[ZN'HLW_\`BO#_`-(U>^@Z=XII\\&D>6L'_P!5A\>FAKPSE>:]=]7&:KNH
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MFHK9PBMAGQ["M?\`O<OB/>.Q9^Z15*EZEN`77_%;4E':%U5N\AH5CN%4%ZQ"
M;,'<>&N3XXE9JL*I88J_';/"P]<UN<C0!4K8E^@B8>"NO",L5-:!P9WN:U'Q
M;#O:^J>=]VW<7$8OO:O(6L<>.5!D2[QQTG,@UZI:4I>N+J%C"ZCLV$$L!.-4
MS=2'FE4PC@@[$:N('%`U2"EB8C]0JVP2[IMGP#`5L*DG63\Y7&9D>9<>>WDS
M,^,R$`W=NRJ:<UOH6_:^T'P_K%VMVA-@;D"Z:)U420L#-:JP)&UXD6FW:+&U
ME&%MP[$1!N*KPBGV2QW/8]D:9K`>$-`V?8(UZ=P$DU&HE*69$JU[Y7O;9GMZ
M"+;Q$.B8VVRH&.-,:;X4R'Q@'9T&G[!.Z\KPFHNHH_+>B\,/.8:]8;N%#U^E
MVW1:1#P40SLAQ)=F/6:M$L<FMP!0PH$D7_,O:61&=\T&O=MUN3?E<>F^HZ]J
MO8^FM*VYG5U+AABNMZM:JJ"FZV`5U%3A7@97;G+'C:FIT\S3%O%&!,\D!@F"
M28A85"\.4*2AD<@H,1FHC45SO<R/,\[7+;E<227H'1$]M#,_2FI)K3<54%#4
MO6].DMH@KG'B:X:$/!EI3%62M5H(*CXQAE4ZR'I>49?,$')`1K*^D?2?)V%T
M$.#[G?C_`.+/0O07IWQ.0T.8?B>C*E>+/LAX08:(9>8\B>"<:%#JY7H`YM:%
M(@P@(:+&PTP+@ML`UE?2/I,6$"J=6J^9F:S6J_7<D%MN$,@@PX1F<XTIY;3D
MSR?&C^,K;7)D*;4]WZD*D/*3G&75Y4$7,]IW$@Z`'0`Z`'0!/M:?MNA?]WG?
MV5SH+(^<7/Z#$GY"_N?M_P`YZY_;\=26WF/T&,PGU!_:["_--_U>H%'=O.KT
MC7Q[]\30?SUH_NC8.K%\U7-Z1<;<=5`59>251AE(K=@"2B4M4!"VGF'%(2B/
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MW.,.6)4Z3X#R2`F1,(\+X?PCBE^$RKP?@NS_`*:]V=YV.=O^KV]]C\/\%BU>
M,K[O:Y"#U>(K;_:YC#^,!O5LC]*OI^INC<?MSBH>,!O5LC]*OI^ET;C]N<`\
M8#>K9'Z5?3]+HW'[<X!XP&]6R/TJ^GZ71N/VYP#Q@-ZMD?I5]/TNC<?MS@'C
M`;U;(_2KZ?I=&X_;G`=J-+KJ/&?&0\IWOXKJ(_>J5CP4E64>"=5_TE/:E.,*
MQG'WWX?]7/\`!!FG*Q'MS\72)*V=]V7C'5\8#>K9'Z5?3]3=&X_;G$!XP&]6
MR/TJ^GZ71N/VYP#Q@-ZMD?I5]/TNC<?MS@'C`;U;(_2KZ?I=&X_;G`/&`WJV
M1^E7T_2Z-Q^W.`>,!O5LC]*OI^ET;C]N<`\8#>K)'Z5?3]+HW'[<X#&J"Z]B
MV4]:`]/8'EK$@:P5)(CHP2(10S3C0IB=*\.MU]$!#SR8R5N*PUA>>]_@[((T
MVS([^W*),^C.W..XE5=92E"`ZFD)PE*4I0E"4X;3WB,)3A[&,80C[U.,8^]3
M][CLQ[G4W1N/VYQ`^%9K2LJRH/A65^![_*D(SE7BZLKC]]G+WWW@%YRMGM[?
M!*SE2.]SG.>ET;C]N<!]K>KR\H4L6I:FUX<1E>,*RAS"5(PM&<O9RE>$+6C"
ML=F<)6I/;V*SC*Z-Q^W.`_<O5_.4YR+7G*/<1G/9G*/_`,W.7_O?_P!'9TNC
M<?MS@./MK66,1O(^/%L->`Q'[Q'@,,=F$^!PUX;P?@N]QA/@^][SLQC'9V8Z
M71N/VYP'/XV#]7O?K9^GZ71N/VYP':5.K68;3:1,C$M+[JG7^_SWJV5(;PTW
MC'C6<=J%8<SG/>8]Q6/OL_@Q%T7V';[^D,K<OW#J^-@_5[WZV?I^INC<?MS@
M'C8/U>]^MGZ?I=&X_;G`/&P?J][];/T_2Z-Q^W.`>-@_5[WZV?I^ET;C]N<`
M\;!^KWOUL_3]+HW'[<X!XV#]7O?K9^GZ71N/VYP$WUX^+=LT9,:&XT]B-,RE
M:E9SC&/`YPKW/"K_``ISG'^KGJ#U>(C(_;E%D?.+G&0Y"_N?M_SGKG]OQU!;
M>8_08S"?4']KL+\TW_5Z@4=V\ZO2-?'OWQ-!_/6C^Z-@ZL7S5<WI%QMQU4!K
MWMO_`&^/_P#!VO[;.Z#$O;S?>8JOH*!T`.@!T`.@!T`.@!T`.@!T`.@!T`.@
M!T`.@!T`.@!T`.@!T`.@!T`.@!T`.@!T`.@!T`.@!T`>&$C9&S-;[TVPJLF]
MDDE6'8]UB7C;4V-L)<[1&N2G+'5];GQ+[JBZP[=J2:BNZ[L1N5QEVK6G?)?H
M:`GK1;M?21D<Y/<"]BL6S86[;8SWWVY'?F,5[!WQR[AD36QYP^ZCSQ>$+(DC
M4BDV:4,J=?FZAXBC;'L`)19[4D&-<A`C5^V.Y6)@>;#AV2"7B2!BW8AB$\$'
M:Y$6?;<]QVW$?58;$R*E8]D<0]2%;`;VQ:K)CGA*%8LT0]L:C60[JBZ=T=)U
MPU.*#*N3KTN-53.FGF_%8TN*V+J]-?;4!2'&L,N-A.Q6666S_P"6XK-/*GET
M;#!*Q39QVORPE`!Q;*48U+DI/#7RN:A[H5;;'7UJM8*?&E2'+1H7CY72674S
MW8[AM8^/*:-VM#J@6+[O_I+[SY.83&'R6YA#KA`K1HD6E>)[%KP^L*5J:!&3
MMU^S$N),\WKZ<]%!K9!":=4]O[?GC2P=\0<;A5%L]8+"8@Z]NZ"P18MO(?'L
MMEOOF=NGCXI?Q]WSRE)[&XGC-K7(D>B;DT]KZ[76I#]4#JY,KEAMVO-L6:Q-
M6.+(K0R1!JP$I6J:+CVZMWF?.JMH\-5;]KA4?9=,.UX!VSRV'MSSXBY]IB5#
M^97(3!$:F+IV%;0LFPQ6)_B\*RQS[+9O;>JJC*K,-R!`>"I)T<5M2>,DORTK
M7*FZU-R2OBRG)ZX0#(N(RZ;\1]G7L'3A<YM\261TWT)AGP;Z*D/FVB+&O&`K
M,FXB]^EYUQ1X<>AQJFZM1IJ$,O<60ZDC,GGGG(T\&AH:P1!J\OMELWWOEO&U
M6F]Z6+95LI$">+2-;L^C\76U`L09T=5'NHLK4>\BIE$84*?*'W8+?D31*9K7
M?1V*>^VA+1#RVRV$&6W=>WM]XVLZ"!KER2M$>K5JN2Y)I01N2<?C8?3*>B^&
M7X@MW#65,J3E7WJ%+PG/N?>YS^'K\^/_`&@\_$D'!FCU6&ZA5Z?(<Q/4BD+I
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M-O."L>O!\!Z?X+4SR5!_DB]=`W4M:+AX.OG5GQ<=C/G)A^;)E1(D!S"LLNYR
MZI>&YV7T83`RC'?N.96VO.(JI*D^L/<8U[3=(TUTN'!J-;JN'WH$E>-F<1U*
MHS:5'PZV:+RT'(=D$Q5VYRHR*.;*4O/27%1WE)ISM06CH[3_`(<PA2L"/NU:
MF1:34E/H^#JX$.+'F2*D7SF;-);X2%P!K5.)P]1MLD.((Y*8R5;N]?M8/`(=
M`#H`=`#H`=`#H`=`#H`=`#H`=`%@ZQ_;9&_[I-_]'/061\XN?T&))R%_<_;_
M`)SUS^WXZDMO,?H,9A/J#^UV%^:;_J]0*.[>=7I&OCW[XF@_GK1_=&P=6+YJ
MN;TBXVXZJ`UDWVM;:I;C:U-N-U":M"T*RE:%IR44E:%)SA25)5C&4JQG&<9Q
MC.,]O7RSC-,*8I)FE28L@TJ(S(R,FEF1D99D9'F1EF1CZ:>E*JG3DJ(E)5-B
M)4E1$:5).0@C(R/(R,LC(\C+(Q_.J"V%LM[6M`I;MXN;I&LV:H;>)&EV`QXX
M2J%Y(:8K04--(JE^,S(6;'=[PRF"Z\XSE(7OLM=ZWWV?&$*O8B5AZATA59JZ
MI%/J-*Q5(F'/E\-(I59?PC3XD1Z0;O"/,G/K-903"EF@RA7--DD9_H74,,X4
M1BO$E>1A^A(C5:E5O!,6`FFP38BUK#T;'E5GSH\4F>"CR"IF'\/N*D(;2LCG
MV)9&LQM'KJ]1ANPP.Q[J:V<@[8MY[TJA$I#MT=ZBQQ-:;,-CZ/9*>3-97%%U
MT"*0;%RPH!+D:;AE<HDIUUAKKL>@5EJ/7H5?J\S$139^,\:4R1)9JB%T5N-3
MBF$Q1JA2I,PU-18$*,F;&=AP24V[J&](-2D)'46*,/.RL,5'"U`@X353Z9H]
MT>UF+$?HKB,0NS:JN"J1B&EUR)`)+TNIU&:=/ELSZD:78^N3,4D(<6*_TKM_
M-I&;J@V_<UPIL/8%#:W80L_?GV9NOFXNRSK=CJ=,<))B9P@A3RM-&PUU5Z0A
MMR<OR(XJ<VEAG@\(XK.IQ\7LU7%M5I+-<HB<8/5&\Y#M"2UB&8FH4RD'()HR
M2_2I-(CLG3%+)*GC[C,WTDE.R8\P25'EX"D43`M#KK^&L1KP#&I&K3EL8E4]
MA6G*I=9KJ8IO$:HU<AUV4\580TI2(Y>^""CJ4XN='@5VA:0F60C8]TU0[?\`
M;#E9XWTU_:]V'&Q(K9,D(-J,6]R&#<DG/<'(@%[6V'+$B$D3!R\,7+;<ER41
M^:FPZPS@YVH/U#%U,FUS$YT[1_27,3UB/,BQ<0N0X]*:K3B)BY+ZHY,RZFF)
M)D/N1637&-U)N.$WKU.J.'Y&/V:5&I6`ZQ3L-X-35M*==:P;095/F3,+-3Y5
M:>PZTY`:B1D2CDPJ,J;#B1FIL@FY26%)9:-R^H(VX4GD]INES-F7*W5I6EK8
MAL4>DQLM9GUQBHB'C1)^*RS-L)@Q(:>+2R-BE%9<67+DM#GHL9Q;2MV8CU6C
MZ1L)TAW$56JE//"%4(HTYQLTF_3TTF*N6^XTA#TZ5+<2N2X_/<DNM.NK2PMM
MM1I/KB1*H=?T28ZKS&$Z'1:J6/**I4RG-.ZY1JHY6YK<"*V\M;%,A06E(ALQ
MJ8U#8>99:7);==2E9:=\VN6_(&J;PE:HTH8LP`97-@\.M;E(^OJGJRS;+M)C
MD;*W\<MGFRC<N44./(`5;5E&BUE9B:.'/3K)<LE5NNP`BX_;PZ&(B/;RGT6\
M>69W/D\8A>B>4O*O:)#@X3D[T#S)>QZ#M;:');5X?0$2?-J^N.,QN7K[:[JG
MA+\^W-;8L.W2]$U=FEU(9/$)L^=D%-?2+,'J0Z`8`9$5^0_8O3G?QD,7RS[I
M7N"G6[8*]!4S;!+7ZN,&C-C5XS9]+L:Q(ZKM]IY9;$T[;[1M*@\C\ZIW%#KY
M^NU6,(K<`;KVS//K9:M`\2V(*P3DT)))'MWVR,MU_;\AGC/,GDQJC?%VK=VV
M'4;W1@=JXBVF`P-H0(*%MU!Y)\NC?&&UP=/V($7L4JPTO4H2^:Q*G"EP)C]B
MR=O4TI!8CN4&X1QT<(MD1VW^B_YE;*VVX]Q.@J'0`Z`'0`Z`'0`Z`'0`Z`'0
M`Z`'0`Z`*E";WU!8[-,IH*_@2=I'[`/ZKG`XKSZY\3857J:;T?JTAK+"?`D1
MM15@\[WZL1W(/:IA]US&6\`L?W\PG5EM5<IPC)^TFAX$+B>%%Y)DI"(\/RC8
MS(^O`H?AEY[W+Y4V5'"X2,>Z_,F1VD^ZYCH`XJG<*S>@$6T5$S$.U^:Z18BE
M(>7/%GG1)*8')(3EY#2\9B$Q\V&[WR$X\+'<[W*D=BL@&(UIL^@;BI(78^L+
M6)NM&L2B2`EF"O+>&$EAR\\"33&<<;:6I4(P+(#WL*;3E,B(ZG';C&,Y!L$[
MPI.>SL5C/?8[Y/9G&>^3CL[58_CQ]\GW<>Y[N/X\=`&'&GQ1::?'0)#CLNLE
MF`9EMR'-BHCDY(,19&6(\B7'8CDFU!SHR0J6,=F0VWGGA[LA!&#/B1@#,8SC
M/;V9QGLSG&>S.,]F<?AQGL_!G'\./PXZ`.Z/88E3HD:3)3#COR667Y2^S*([
M3CB4K>5A2D)[UM.<KSVJ3CLQ[JL?AZ`0L7S+J/MY`_4B_7N@OJE](NKM#S+J
M/MY`_4B_7N@:I?2+J[0\RZC[>0/U(OU[H&J7TBZNT/,NH^WD#]2+]>Z!JE](
MNKM#S+J/MY`_4B_7N@:I?2+J[0\RZC[>0/U(OU[H&J7TBZNT=6)KZB#VEL0+
M@&A,.2ITYQF)$@1FES2<V02)2UMLRT(5*($9<J?.D9QEV7-DR)3ZW'WG'%`U
M2^F7MSCM>9=1]O('ZD7Z]T#5+Z1=7:.JC7U$1-?(HN`9!"5%B0I,]$2`F;(A
M0'9K\&(_*Q+P^]%A/DB+T2.XM34=V?-<90A<I_*P:I?3+VYQVO,NH^WD#]2+
M]>Z!JE](NKM&#-5FNQ<1T1K-"*(<RZIQ.&X^4LJ1WF$9SC$EW':YA:\8SG&,
M]B,]G;VY[*K99>*SR&UDD[D3B$K(CV7(E$9$=N,A9+CC)W9>6@S*QFVM2#,L
MCL9I,C,KYYC`^0@OOZ%\!'^DZQ]P0OV>+^X:[!D[LF?M<G]^[_J#R$%]_0O@
M(_TG3N"%^SQ?W#78'=DS]KD_OW?]0>0@OOZ%\!'^DZ=P0OV>+^X:[`[LF?M<
MG]^[_J#R$%]_0O@(_P!)T[@A?L\7]PUV!W9,_:Y/[]W_`%!Y""^_H7P$?Z3I
MW!"_9XO[AKL#NR9^UR?W[O\`J#R$%]_0O@(_TG3N"%^SQ?W#78'=DS]KD_OW
M?]0[46M@'O&?"E8#'@HKKS7?,1O],\C*,(83VNI^^<PK.<=G?9^]]Q.>H.#"
M*W]FBGG;_P`AK+E^:)*9+S_M<DLO^.[T?/'5\A!??T+X"/\`2=3W!"_9XO[A
MKL$=V3/VN3^_=_U!Y""^_H7P$?Z3IW!"_9XO[AKL#NR9^UR?W[O^H/(07W]"
M^`C_`$G3N"%^SQ?W#78'=DS]KD_OW?\`4'D(+[^A?`1_I.G<$+]GB_N&NP.[
M)G[7)_?N_P"H/(07W]"^`C_2=.X(7[/%_<-=@=V3/VN3^_=_U!Y""^_H7P$?
MZ3IW!"_9XO[AKL#NR9^UR?W[O^H,`@OOZ%\!'^DZ=P0OV>+^X:_TAW9,_:Y/
M[]W_`%#M3:Y7X\I]E@K`DLMK[UM]+$;O74]F,]]CO758_#GL]Q6?P=04&$97
M[FBER<`U_I`YDS]KD_OW?]8X4"!3>,X;)QF\*SC*L(0TC&<X[>S.<)=QVYQV
MY[.W\';G^/K*W'89OP2&6M:VMP;:$7MLOJVO:YVOLN,;CSSUN%===U;VX1Q:
M[7VVUC.U^.P^_)@[ULS^AOZ;K+JE](NKM&(/)@[ULS^AOZ;IJE](NKM`/)@[
MULS^AOZ;IJE](NKM`/)@[ULS^AOZ;IJE](NKM`/)@[ULS^AOZ;IJE](NKM`=
MI041B&U(P>CJ?6^ZTN-V-=\VVA#:D.Y_T_?=CBE*3CM3C':C/9G/X,1JE>VL
M7MSA[>@=7R8.];,_H;^FZG5+Z1=7:`>3!WK9G]#?TW35+Z1=7:`>3!WK9G]#
M?TW35+Z1=7:`>3!WK9G]#?TW35+Z1=7:`>3!WK9G]#?TW35+Z1=7:`>3!WK9
MG]#?TW35+Z1=7:`G&O(,-BS1W&2#<A>(LO&&DX1VYQEK.,Y]QQ6?<_#^#J#(
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MCH->+"ZZ!:K`2#*BJ\7&UYAP8\R&CH;<;[![3P44ZW'7E2$.08ZTXPI';GZ)
M^#L+U2/#B5"B0)4:!"33H;+C1ZD>`A4=2(B"2I/ZA*HD926SNDE,MF17(?+2
M](&-*+*GSJ7B2IPI=4J*ZM4)#+Q<+*J;B9:%SG5*2J\E:)TQ"G"LI29#J3R5
M8<0'16H*Q&&0@&OZ\+BAK1'N@N/&C.8:@VN+"4.C'F$K=7A)!B$M49I[/;WC
M:LX3C&<YSU6%@S"M.;CLPJ'`C-1*BBKQFVVSU6:FVR<=N:@C49%(0R9MI7_=
M29V%ZCI#QM5G9;]1Q)4Y;TZDN4&8XZZDUR*.\^4IVG.*2A)G%<D))U;>6LHB
M,SRL)S)JM=F609<)(B&]9PPZ>(%FEMYS.@C"CC#I"$PYWW8EB6Y&CK>3E.>^
M4TC.,X[.N9<IL!VH1ZJY%9748D=^+&F*3=YF/)4A;[*%7R0ZIILUE;,TD->:
MK%48I4NB-37VZ3.E1ILR`E1%'D2XB7$1GW$VN;C*77$MG?(EJRS&N^RN'&C=
MO['/;#V/6O.E5HK&M01ZMSGWXX>07TX?OYW6%V@R!CL`R(MU63M780G!.`2:
MR3$FX,6<AS``5EG[AQU_;V]MPLF@Z`TKJR>")ZXUC3Z3-K&OV=65]VMB(XI(
MC7S)Z1:?-:"S%PVPR.?LLN2>FY2UXR0+OND)[\F2O+G01<S]O;</J[Z$TYL@
MC9"U[UW6[02N%1K5"L\PK$4^\;IU.M<^\UBNSE8=1AP:$MQ0@?@M8PG+1&6\
M[E2L*[W`3<]E^44M(X'\:6"T<M5M>":0[)VI0=KVQJN,]ZU;2.L+^5W)2*T\
MD@J<FM4T/O&="W"JLTY``1-NPS,^5$<R6+^.`N?MT>@;C=!`=`#H`=`#H`=`
M'PVXV\VV\RXAUIU"7&G6U)6VXVM.%(<;6G.4K0M.<*2I.<I4G.,XSG&>I4E2
M5&E1&E23-*DJ(R4E1'8R,CS(R/(R/,CR,0E1*(E),E)41*2I)D9*(RN1D99&
M1EF1ED9".6ZZTZ@!7+'>K57:;7VI4*$Z<M)D<!$-3",EN'`C.D2DB+$;>ERG
M6V&&UO84XXK&$XSV9[/MIU+J58E%"I,"94IBFW74Q8$9Z7(4VR@W'5I980MP
MTMH2:E&23(B(?)/J-/I<<Y=3G1*?%2MMM4F;(9BQTN.K)MI"GGUH;)2UF24D
M:B,S/(9N#/@E(<8B,F1"(^8RB1#G09#,N'*8<QWS;\:3'6XR^RO'NH<:6I"L
M>ZE6<=?*ZRZPXME]IQEYI1H<:=0IMQM9;4K;61*0HN-*B(RXR'TM.MO-H=9<
M0ZTXDEMNM+2XVM)YDI"TF:5),LR-)F1\1CM]8Q<.@!T`.@#Q/VYW.7=]KV==
M;W2K1K\>,V'<^0%FNH`H9L$-L_'L%6M0/449;T&N2TQ'#8_8E[I>U'O`2G&Z
MN_6UPLV%`)H5D+ZQ6YB+81\>?H*P^B'<VK78!6RBEDU]H<T4(0=;3-/4(S(R
M4K>L&*]S2WER$M&MP9.70)$2N`2&J=@U?7[1$!7?$E2O+U<;#L4^)$=)A&M]
M]^6Y6O\`?GQ\>ZTM7\-MLZJI?)`9KZ;JRN;`VQQ]CZXB%`A.?'9A;9E;0Y,V
M=N]VQ4.MQY4R0&HFY-?X&$)#$@M.57%`.\AA1PF:\"^P^(E&?-ED*A<[F5LQ
M)F172I'4M\UM4B4HCJEXT.D!)X)%CVIP\V'964U1H&<%5^8VG4.\XC!02;D2
M"4>]#Q\C$2,=L&8@-8L[%:__`/UVE[$(C:NYD;W)A+H`%%Z"RV0U'O"AZY?8
MM#845KZ+=*IRSJ=2I$:.QJ0A;DT_+.[J'(EB05S!5`<S#L;\NHGBU.HSQ,)U
MB]B*Q[+GU';+CXAL,9X*VP3O0W<JE0M*G]3RMCRC-(UZ<-6*LCM9IEZVX,U<
M5M4&.K=>2J/>Z42XV[88#PPA<01D1[Z,?;M<&*>N4%(1?+;;+IS,[<]R]BSE
MG"S1W(+C:?*B+U3M?3`VV)E3FVHGKZT8P*J!^IZZ/0K/8V`#.KJ='DC[5:QM
M<'B7#AVR;%GBS<$C<K1:C00Z0P$'GG?VOL+FY+>+(>FW00/+5OF3M:F[>MU2
MO\*MDI5EOMJHNC=:Q@,T$(N4=CD)2-,TJY@-^"2MYJI02$%7.#*Y!UDI7HFQ
M=>7.2P%"TF9%BK;(A:Q<5^*_1<\CMS;<A7PSNF)N78R9C-+7(K4N:-$5&BI\
M1@EW+(>HG&]$&O62YKDSHL9B'M'<Q`>_8Q@*7%56V$STC'EQ&FIH+;"WYWV[
M+[A:IWD!R--\>-?[/!'J%KRZ%N81?CO:@TZDOWX2P$*\WR7&$*]`EMVVKY44
MJ%;CME)D]*51+8886\F("B2$LM`L5[<E_P#MN,80[I*V-K]54,U$2M=D.:[J
M]YRR_;1M6@/,D]>\OMA&._?\D'<PG8@CAY:\1HS;,Q$F?<`4/P[#$&=-6`TY
MGU=5MV\AFQ?=%F)I=X-,TP4'R:Y91$+8>?/<;+36:G:36@P]5L(;P0)";69E
M(Y#58@=K"5AHX6-7;<U!L9Z6S76+("W+OZ"OGQ[O&)+I?G25VM:M$!2^D2&O
M0>_Z#6]@4ZQ';W!DM3!ULJ=YMXL<&4BN0Z[8K".&TC#]GJ$*ULWL0,M=;L4*
MI&J_'MY&IA!E;EMM]MO5;E%A,<W-59$$S+X2_NPATR;#1+"52<<&39")$<B(
M&,E6,,0F+$8UZ3![-9!3W(CV:N0G-P)!0I7CL."`R,O;V]N2UXR4[H+II,O(
MRKA+];2CUV`T@4U$K;HV#8IIG<#NFUO5\C/<2B8K!\-=)`J/*9@X+-4Z:E3X
M]@Q7II0)U3Z+Y<>S_;I(3&E<U-/[&L5!!4SSA(,;`GAH@LR0#2PL##)NAE+J
MS):3-;\/)4,E1!-0L$-QN)*%66Q#HZ6Y<9@C(A@ME>_YYV^Z^P;>=!453MBZ
MF*2*%3`Z(*WII!V,]XZPX^C#:(RG<=XEMYGO5=]CW<YRKW/<[.O'ONPM..-M
M!V&<'U;!*:,J77*[-ITWWY@.SVBCQZ?W2WP*&I<0VW.$^<HU+(TY:I;1W=H2
MT?T#']4K<.O'.)JGP&)+'<,E,=?".2":5KFMEXE)U=A$1&1YWXA17I]O'\@`
M^3I'U_KP'^D%T^?\+`OFY+_&1Z,[VW1S]+$'E-GU$/3[>/Y`!\G2/K_3](+I
M\_X6!?-R7^,AWMNCGZ6(/*;/J(>GV\?R`#Y.D?7^GZ073Y_PL"^;DO\`&0[V
MW1S]+$'E-GU$/3[>/Y`!\G2/K_3](+I\_P"%@7S<E_C(=[;HY^EB#RFSZB'I
M]O'\@`^3I'U_I^D%T^?\+`OFY+_&0[VW1S]+$'E-GU$/3[>/Y`!\G2/K_3](
M+I\_X6!?-R7^,AWMNCGZ6(/*;/J(>GV\?R`#Y.D?7^GZ073Y_P`+`OFY+_&0
M[VW1S]+$'E-GU$/3[>/Y`!\G2/K_`$_2"Z?/^%@7S<E_C(=[;HY^EB#RFSZB
M'I]O'\@`^3I'U_I^D%T^?\+`OFY+_&0[VW1S]+$'E-GU$/3[>/Y`!\G2/K_3
M](+I\_X6!?-R7^,AWMNCGZ6(/*;/J(>GV\?R`#Y.D?7^GZ073Y_PL"^;DO\`
M&0[VW1S]+$'E-GU$/3[>/Y`!\G2/K_3](+I\_P"%@7S<E_C(=[;HY^EB#RFS
MZB'I]O'\@`^3I'U_I^D%T^?\+`OFY+_&0[VW1S]+$'E-GU$26I[V.2SD*#8!
MT.3!G.MQ,9#PY"9[$A]Q+;#K3/C$CQM/?JPAR,A&'EI5WS"E.(PR[V=HA]WW
MI!J6.Z+1=(="I57P_7)4>D$6$:+-;KT*?.?:8A2XD-,V<JK()Y9-/TUEDI;S
M;G"0U.2&D1)6J8T]SGAJ+AZ?.PU4)D*I0&7)EZS/853WX[#:G'V7GC8CE#4:
M"-;<I;G`H4G5>)+:S>:UNY%\,)FSMXF=W$;BQ64L6;B</I^(5B@TZ3-C5+<$
M%^^"RUOA!&KM'=+!RGBM"JP.W0A)O82ZR3D04V(17R,+]<!XV)6J6KQEKD?&
M6S++,CSVG;9?B,Q6`30_=(8D^JK,[0'3TC&-#-FG6MQ7;`\T6HVN\@[\5.0/
M)\9^5`LMI)/E2$.MNU2&8)AX)VUUJ_1QTD!>`:S6>7TO[I<9\7B+9?9?(RVE
M<P#1_(!'%J#6=];)C$MCU3<FC]K&;A/V2?B5V-6M67745LV9*GF5-P76ZT73
M4-EV8=5;'*,5R,DZ+0IBHBV!M3HX1K)U[D66JHK6+C(R+GS(KY?>>/WYKKE3
M==G[2'ZDVBQ!PH=&+!08W>12FS0%7.Z\"UJ@P)M'%UDI(!RA6\:S?-HSM@MS
MX7GC3D3=8S(-W@J<$5,"3022UB_[;\9WSX_DV+CL>>68I#9''[E'BQ,Q[KOF
M`6BVC:8J[P:&;Y!V>EKM%<U]R0'[CGCJ+">:2FKE0VK*I3H$"95D1G:A*BS%
MLDQK10Z;*A8E)_NIV$97U;[4V*^V^9G>^WCOD)=K>E<C(.D-C-[IY$ZTN4BW
MZ6UN@)>BFUH9ZA6&R`23,:SWD2@L(B@ZM6V(Q6MU8F2&1%P[G9EL6`E"A$Y[
M#Q`(,TW3JI,C)1W*V97V$>_>6XLA5-HX7\R-@U,=,([0!WPABMP)((M/VS9Y
MR)96R<<*13C[RC>`TC)RAO[EE[$OJ*>07/IY4`0C-M`\,R88:"$DM!'LW[$V
M_O&9;L[6*_%UB9&N*G.*T[-:N!F[5W$,-LQXS2T2-FW(V%J]>?WSIF]YFJIQ
MF%/#%$1*/J:6R+KCC$<4(L1P=.K0RL269<B`]NO,1K-VROLSR(O[IE:Y9YWZ
MLS%VZ&T=S'J^R*%:=G;2G$::$<KL$O3Y6U+1<<>0LU#DVQ>&R:B(N)$MQ<QL
M.Q<>;($-%DY*`0%?(5P3+%#1$D;8`JI2+&1%SZI%]&W5K#THZ#&'0`Z`'0`Z
M`+!UC^VR-_W2;_Z.>@LCYQ<_H,23D+^Y^W_.>N?V_'4EMYC]!C,)]0?VNPOS
M3?\`5Z@4=V\ZO2-?'OWQ-!_/6C^Z-AZL7S5<WI%QMQU4!3.QJP=-F(<D6/5+
M8:&ML+<2]&:PEW$J6YE'8^\VK/8AQ"NW&,I^^[.WMQG&`QK29GD7$*_]']P]
M3.?&X'UOH*ZBMW67:'H_N'J9SXW`^M]`U%;NLNT/1_</4SGQN!];Z!J*W=9=
MH>C^X>IG/C<#ZWT#45NZR[0]']P]3.?&X'UOH&HK=UEVAZ/[AZF<^-P/K?0-
M16[K+M#T?W#U,Y\;@?6^@:BMW67:'H_N'J9SXW`^M]`U%;NLNT/1_</4SGQN
M!];Z!J*W=9=H>C^X>IG/C<#ZWT#45NZR[0]']P]3.?&X'UOH&HK=UEVAZ/[A
MZF<^-P/K?0-16[K+M#T?W#U,Y\;@?6^@:BMW67:,`5#$PC[<8I%5$?=9P^AM
M3C+G?-*6MO"^^9<<3CM6VM/9E6%?>]O9V9QG(09&6T:V\GZWLJUZ3O`?4A:0
M%OCHF1(`SHTI$-UB;`:7/CR([R!!8EY3BR8S,D$T'R,FO'FAK2S`V$J7*;W#
M`DVB4_%%*DXACHE4E,A");2T&XE;;IDRM"TG(CL<`XAQ2):I/#-(B*?44=YT
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MTZN0V.5M+?(1E.=B3US&P.']_`3;'):4I#3:I!"`!AJ<@#W7U/$B)7M[">#Z
M5A.D&TI$&HUB:VA52FNJT?U-#*R*YQ*8^]I%I$QJ$VHB4I1(9=EN$3KR4:K+
M+'5V)L55/$U5)Q*YD&DQ%J33XC:,<TY3R#4=I5199P#5(KDM99$1J>:BMF;3
M2E:S[SU\:;W=;ZI%BBV['(CAFW%.*&R[+;\15..=F5O*27[G34"6'7>]QA[+
MAE*LYQA2EY5G'6IXEPM3:@XX^J$VN29$DGFX5.-PB*]DWC:9Z@P:4W^3:*9$
M6PBSOLV'\25&$A#)2UICD9J-IR94-0S/:JTC1+`>N=L[R=USXQO_`%'?%:,H
M808+T\6I2&\+>Q:YCBLKSV84IQ)JGU#LS[N,_>QVNW/?8\$WA.<8ZAJ.$9L8
MUG&8J+Y7.R?>]HB(N(DG&J=2.WC6JQ?WC,QVG`Q/$D$DI#T!D[$1J*<X9WWF
M4FGT_J2G_"0N8?8`)?&,BC8@GA7^KD>2AS>WM[?P>+/.=OX,_@_BS_%GK6'H
M<R-<I$62P9;>&8=:_P#K2D;"U*C/_P#D2&'O_P"T\VY_]"C&7Z^89PZ`'0!P
MR5O-1Y#L=CQJ0VRZMB-X5+'C#R&U*:8\,O&4,^&7A+?A5XREOON_5C.,9Z`/
M#2^9Y?F+K?=K:XU#OK6F=F;`!7M(>'+PB=`,Z\U!Q4K,ZMVFLU\P)S88\R2*
MW($K)\^=D:V*L4T^M=%OA&X:ODQ@MER'8C+,O\7Y<O+M%=#;!S:OVLBYG7+W
M):PC+4*@,1[0Y:"&,QMN"V.7["I]5ABS88_,UO)7$XX@I,41:*31AUNS7CMV
MD%A@G;E8LP,LMG5QVX[96.YY^+8-QM'GN1VO]D#-A;L:W44I^P)FR*B2`%I;
M$\37K!<^2NFZ5Q_DPZJ^2B0:O$A5"Z70J<?%-)FIJP\F[/CD'@(0:T$':W1Z
M,[\_B'JAT$!T`<\6*_-DL1(K>79$EU###>%)3EQUQ6$H1A2U)0GOE9QCM4I*
M<?PYQCH`J:9P1U-/*VHY*T?7EF+G*ED#A%N5F/*03(6T-?R1<"[',M*J1DK?
M:Z`O)8Q4_(A,K<@8BTD)4DZ.B3V0OJK]C+Q;Q\N\#=//#7A"]!4U(U\+BO*B
M,QX,=M`E%=JM3:C1\L$&UQ'(P"CU"!#F15,SH>:Z*EQ9+,Z*B3T#57MW<I":
M"N*=9"4H'KH7JT1%I-;MT*_!*[AZ,[!'W0??<[1AV5K+Y%U]9=G8><V_$MYY
MQ:S2E2G._P`JRG(1JJW<G%NMZ!!AG`C3H:1/E#=#56,^2>F/2UX6T[WWCP+9
MM8?892^6=1$@XKNY=HA(P^(EB!"&74U"A1H[#K2&0FR_8RY.7D(961PCUE*,
MB[`_I.M*,AK!%M,&=A4=MS!R#'HL:#,F(;)H9)MPO1AKJ9$@DVY@^,5H]5,L
M14%P8^:P"RRV>DN7M,=L)PRH%;.4:Q@=/`Q1?6M;!5*COPY#;4>O`:L(/@*Q
M%B#L%?)KTBM@K7:`P`I,B22H879#T`;-C12Y!J0#55NV\I>WMR"-HX%:O5'G
M,3]20RJY[9:,Y*G%,(EL#BUC:L2QD!T>3@X'QXN806OLR(:&2<FHUNN5@J0)
M"1$6.D&JN]^/QD,U/X2:T))<3)TK7$Y<)X,I=AN,C9$<NFU'KPT2@R1Q2+('
MSH]NLY^PQ),%V.]$*$Y$F*ME7@^\!9?L9>WCW\8^`?">AU8]5['5-6P*Q/J$
MP/,$,A94*,.1BO4<QKX'$R/<F/16((VNF7>\CCVX6)A2`&+DE39XB"\R$:JO
M8R[>0A?'H_N'J9SXW`^M]`U%;NLNT5OLC1L.[#QPN]@)ST2+,<GP$Q#\L2YB
M0EG,=Q2GPA2*ZXC#3_9EIY:F^^RE>$]\G&<=<Z1M$^!]+$*FT_'%)<JT6DRG
M9D%MN;,A<#(?:)AQ9JAO,J7K-EJD2S419F1$9F-TP7I`Q3H]ES)N&)<>'(J$
M=,62N1`A5!*V4.)=2E*)K+Z&S)9$>NA*5&61G;(5!]Q]J?V7/_/ZW?YBZZE[
MS;0!X&2/+M;]='8O?+Z7/KNF>;=`_#P^X^U/[+G_`)_6[_,73O-M`'@9(\NU
MOUT.^7TN?7=,\VZ!^'A]Q]J?V7/_`#^MW^8NG>;:`/`R1Y=K?KH=\OI<^NZ9
MYMT#\/#[C[4_LN?^?UN_S%T[S;0!X&2/+M;]=#OE]+GUW3/-N@?AX?<?:G]E
MS_S^MW^8NG>;:`/`R1Y=K?KH=\OI<^NZ9YMT#\/#[C[4_LN?^?UN_P`Q=.\V
MT`>!DCR[6_70[Y?2Y]=TSS;H'X>.9GAMJU_PO@:I8%^`97(=_P#P_MF.\9;R
MG"U_?6/';WN5)]Q/:K/;[F,^[T[S?W/_`(&R/+M;]=$]\MI=/_\`6Z9EG_\`
M#=`_#QP_<?:G]ES_`,_K=_F+IWFV@#P,D>7:WZZ([Y?2Y]=TSS;H'X>'W'VI
M_9<_\_K=_F+IWFV@#P,D>7:WZZ'?+Z7/KNF>;=`_#P^X^U/[+G_G];O\Q=.\
MVT`>!DCR[6_70[Y?2Y]=TSS;H'X>'W'VI_9<_P#/ZW?YBZ=YMH`\#)'EVM^N
MAWR^ESZ[IGFW0/P\/N/M3^RY_P"?UN_S%T[S;0!X&2/+M;]=#OE]+GUW3/-N
M@?AX?<?:G]ES_P`_K=_F+IWFV@#P,D>7:WZZ'?+Z7/KNF>;=`_#Q,*5QXI.O
MRRC=8KDY@GF.N,B01LA@WAA#F<=^N,P7+36&)&4XRWXPTVE_#2W&TKPEQ6,[
M9@GW-6AW1]B&+BG#.$&XU=@MOMP)LN;4*B<$Y*.">?BM39#S+,I3)K83*2V3
M[;+SS;:T)><UM9Q9IITB8UI*Z)7JRRY3776W7F(5,IM-.0;=S0V^[!BL.NL$
MHR<-A:S:4XAM:DFIM!EICOGA5OW;/(PQ<X%I'42G@R6A3H5^89-EY)R9K38U
M-V"9K+U8$G(`X>$<FU"(4\IXD0B[UDB`UQW%0T2)D'O2QF6P^+BW&.KR422(
MC*Y_*N65LR,MO&>=O%?9QTU7.YF\@H\:N8L6\VG'PIZ@K=CCB]J\372A,WD*
M:V!3XZ(3M;@M0[B8VS0ER%,!XB)R=7BYQ1"YB1Z(4ZJMQ]`GA$YV3Q'NVV21
M'Q[+'TC`V_N6_(:RU6RU:1OB,='&*5'I21%F*VM0`@->XWO:,BQC,0:ZR0D1
M==6]WTU4ULB4L&"5I_Z$PFBSI)ZTV%8]Q]!APJ?H\9GQ7S5?:>\LCV<^5MDM
MW\$]C;$W<;V]2;W!IR[0_K!!:.V^;@$(J]>E0D]JT,2`TYIHK88X04=HH@?/
M2P+37=BVQP@_(::4%-+'N/H,0E9$G5,K[=VP[WZ[';D&$W5W/Z];2U/J[3,8
MK2&Z[5]&7#6MPM!EHK*O!:]6"HM`@MW:L+J2)\T"`664;V#*ILZQ!D6:Y+`%
M39A]L%XG-6/<?08$LB,SL>:KER$1WMNOD17W;!^S>Y_6Z7"DF7V]>3+<9:V,
M1L4!!&[U:)-)WCFB&Y<"`<38U")5;8,,?0LQBU6JMD82T\P8?CV214GA<HO4
MIBQ[CZ#`G"+?:Y;CV(U-AY7XQOSK&A7"F:VU[3[4?D7>SU2CU.M6.Z2FF(4F
MWG@0&`+,6B1#Q*?Q$?/D(L@L]&P^]AAR6IK#KF$=_E8]Q]`QF=S,RV&9F)]F
MOF$L(DYAJPPXXME#GAH_8IQM*5+3V>&[['>I6G/;G&,9[?<SG.,]BQ[CZ!`X
M?(Y+WMGX5GZ3I8]Q]!@'D<E[VS\*S])TL>X^@P#R.2][9^%9^DZ6/<?08!Y'
M)>]L_"L_2=+'N/H,`\CDO>V?A6?I.ECW'T&`>1R7O;/PK/TG2Q[CZ#`3O7`Z
M;&M$=UYC*&\19F,J[]M7NY9SC'N)6K/NY_[.EC+:1BR/G%SC+\A?W/V_YSUS
M^WXZ%MYC]!C,)]0?VNPOS3?]7J!1W;SJ](U\>_?$T'\]:/[HV'JQ?-5S>D7&
MW'50%`[@LA:O2\R8$^?'9BUYT@N+%FO1$/N1W)[F>^RWG*4K<2REOPF4+RG&
M$_>JPG&.L,AW@&'G]76X%EQW5OJZW!H4O5UK':]K7L=MMCV"[#)R9<:,2S;[
MH?98U[7U.%=)O6U;IUM76O:Y7M:Y;1Y:0.Z1'9^N:/=DTT\V5MNQ_,:=6%;!
MDYR!&YBU>8W9UD_-U*IS#S-UJV68/DV'A:BB$^/X[S'?]',:;FWZ!1JP6&UI
MDU2O^\SU..JE>%'-NFNE43D>]Q&\A2*Q3=5DH[1&<DOUY6S])2/<Y.Q\4X@H
M!XO2J%1<+_""/5BHJB*HRB>J["J2F)[[&4=Q"Z#5R7([J?-)1#_L_P`KY-O@
M.6FTK(;.3!-"L<[5XNQ[%J35[B7B0].05UU"ENR21JN>2$H$UH\2AOAA!%LS
M/F-R$H>FC64/(;QM4''M4J,R8[%PLX]AR-4*_2T5IJHDMXI-!9=4Y(F4_N(B
MBT^;(9<B19"9;[J7"2MZ.A*R(:14M&%&I4"GL3<;-1\72Z7A>M.8=?I2FXZH
M>)WV4-1:?5/?`U3:K3HK[<Z;%5!C,*:-3<>4XI!J.NA_=![-`J^+3L"F'ZM#
M,:I7M:D8"[#5:4V:`DV+KV`$I;H.O.@S2B1L9G[^.0AXB///^,>$92P]P#&F
M+@::52KF&W*:U+PR>)Z.42K-U(JBP4R/`*$X:H,!4*6<B9&/-$AK@EK7KZR"
M;7M$G0"<BKG2,-8P15WH.,4X.Q`<^AO4@Z3(.GS*F=292BI5)%0@%%@2R^2Y
M&>-]"&^#U5FXB0R.<-Y8,O:_\R#2]NP[':`\^F>DG&`;(VJ4>%?IYQBX^0U9
MDMR1!&'$@PLUYAQTHXIAYZ/&1B6O[G-*4E$M="^#)JQ2U/J,1ZD>_#10D1Z9
M1F:X_,15NX#X1+D60TTRT<%"E25&A2D-D3I\8WH7BN048D^&9)P4_2Z1.C5W
MW@?.H.2JSB"1AN-3W*)[YD32FIL5]Z0^53<2B&E+J&W'3-E/[2^>DO8=HK8:
MH#2TT47>H<$G,);(#!+'`)7@"Q8'6PM0GN)?MD*H1945NU2AA1J7'>=5@8-*
M8;[5S2-+,2O5*GQ*522>C2ET1F2[(K%/ASV)%9@HGJ3#I3Q$NJ,TMIQI-3<C
MR4.MK491X\DDYQ7M!E0PQ2*K.K==7'F0D8BD1&(M`JL^ER8N'ZBY34+GUN,9
MMT9^M/,O+H[4N(MEUM!'*E1#5\F=;MYO4/0AEFK7*UWPK<9HZGS!=-I8H[:K
M*7F[&O\`$UEK8!!@0%=Y@W?[>X8B5IB8_$AN#J=>#Y.<,!5,R1C=NCH<M8^,
M^FWI]LR%&5[NLO'^QGP8*-9]U0&B3FLQQ^PEM:[!@UC6UEV_MR^:$H%1VD75
M!6W13QK=&M;AK;.3+30:'9!S29AAD<0@$)`/E;SRXK[K']Y"<R^Z5Z&P$MIR
MO[.N]_;J6_)7&1P9K:K7N]G;%ND;J,=O4U4:>'K@R=,LJ0.K)LNV&C0Y"P8^
M(!L++I',L4ZPH'RMY[+[>(=W6_='=%[<OU"U]K[9]XL$O:0$2<UY:44[9$#7
MMO=-Z?KO(`?7`M[*`H5;D6U>E+8`V0_753FR$0#-<9E(9,0"0N(#Y6\^D_%S
M9Y9C9P7N08<GNB@NT1I@HP@ZZ^-%W*&0GLMU<ZY5[,X[#B$7I#:*[967JZ=6
MMO"1!UIP00S'((5'P$7/>?28T('=UXT.9C5MX++Y"F)&P)FNLZG%P-5WEPIN
M&K[9&;.,:[V%K*(XAK-CI%G&Z?ODV*14N$2B11PV63$0HECKKY0+?*W[^,^*
MW;VB4I[JKQUDM4F2'V%M6P0=@UH38*Z3#:SVO(%8(V,1L,Q6*`:)OUV-!K>T
M+"C5-^&0=?'WQUDB'P38$U"%%3E=BEPCY6_KZ3YOSV#=JJ[1<O%7K=UJ-VF6
M"J7`"'M%8/#BLMX>;KU@'1RP4O`>\(GPL,D-EQID5SLQW[#R%=F.WLZ"+GO/
MI,=R:0G$7$O$)DF:ZA&&D.2GW'UI;PI2L(2IU2LX1A2U*PG&>SM5G/9VYST$
M7OM$4)UH46POQE,Y"U]]VKA&#0M7?9Q_K94*(P5Y]WW<]BTYS_`K&<]O7VQY
M\B/;4-M1%;)V/%?R+B+NAAXBZ#Y2,?*_#8?OKDX1G?-M^0R=]]V'6CZ#(^4A
MKI?]#E)T61*K]@/>&^^4F'&MF]52E]N<J^]4.Y.Z[B]O\'WLEI6<_P"JG\">
MMTH^+8S3B&YD.*2<B-UR!A/@RV%F3V`ZRYTH,K;3XQJ-5PQ(=0M<67)OG9IN
M=B;A#O?C9QI26_\`N2>XAYN[9KFS:<[*;8=WDAQCOLNK$D>?D]"/<RI*W,U7
MD;L^(RWWN4J[]"5MX0KOL=\GLSGNO#\RA5-+9K+"IDNQ$F0SHC9-7$9$4[!E
M!<6=[E8[*OEEL'45=B5JGJ623Q(1IS-3#VE-PBX]8S@XNK3:2MQE<B+.^^Q-
M71K5QIUU'Y1[W.;DMWE(B*#4+7</:>\B045"M#3\?%JV>$W38HL6MICL)?=R
MY8X>859BJ8F2,23\^!&$<+7E4[&]:7@/"43#=.X!F1)J]:<H.%F94AV`I"_>
M^A2L,PW')NNO5+5AN<+.<);2-2(RZN3RU%3/P=2$XUQ/*Q%4.&>8CTRD-UO$
MK\9AJ:E22FUJ-B*6VB)J))1F<QO@X2-5Q6O*=:1'MF3W3&A-0K278UA;Y`.F
M@ZD5/%TV?7[L)N9<PE.(B!8^8/LA`87_`/BE[K0!XF.(R!J),U4WP_B++CN-
M>1H-JRG8$===IR)53E5"/$CG!JZ7#;ILJHLR'WFWH3+\;^STJ;+2P\RAXT-$
MUJ\*I*3YU>F.EDW.D(HT]<:G1H#\E\IM*-LG*C'I[K##3C4MUE_]?4X<53S+
MJV26X;FMP25*+(@^Z2:\,17%.ZXO`TB\';LH."Y/JD^/9:I!/[.%6VY!"HHS
M.@RZA3Q6I;;9"1]*_%)@YJ`T-Q)DDX").&5H2K$99$FMTMYE,@X4MU+-0:7!
MJ#L2A2*=394>1&:>;J-2?Q#3H3$35X1MY3RG]1##QHRQM+])D-J-5(J33JHY
M3(K1NP7438+4JLL3ZA&?8D.-+@4]BA3YCTJ^HXREM+)+6\T2\7^R8T?R+8S_
M`**[HR-K&:?").3CU.&K2?MS])@9"83.+L(0H"6NJ!QL@ZZB!%4!.R<.JCQ,
M+5G^(ZJ%*A0_A!35/SRJ+K*68=2?+N.GHJ;O=5VF%*,I<>F*>BLI2;KA2HB-
M4G'#26'XXZ:<:9*]Y*@EF%W`V\;LJGLF4J<NFM=S?K7TI(XK]1)J2ZI1-([E
MDKOJ-W/=G1VV(6\=6U7:8ROF*R.MC1*1!%''1DB;XK`,$!+)!J4'FD!TT873
M`P5#3HLI;<X3,A3$I1A_"<=78JP\[A6O3Z`_,C3GJ>IA#LB*E]#7"/1F9"F5
M-R6F7FGXYO<!):<02FI#;C9W--QV-AJN-XEHD&MLQ9$-F<EY;3$E3*G-1J0Z
MPEU*V''6G&7R:X>.ZA9DZPXVX1$2K"V>M>'.AT`?S_:JY(<B:2\<=VQL8I3'
M[5L,\"UU?[[/.VW6U,X[#MM[YAV&^6$::(AQ$G:+.S*[1=:3I5DG2(-5US?M
M+BZFMI9`ZV0"YEQVXBN6S/Q>DBW'LL)<5YM\Q(NKF]B3XFN=<2"]C'UIFN6:
M@F1XVD6:'Q`I^^7JV;GR3LPT?G6W:-METR%708)=OE#*L0J]2BF+X>&OC@BQ
M<V^_%K6ON^ZVX;1\=.9AJ];^VGKO8UAK<&NLEIH#7T%T&Q7K'#NHO<FT==3*
M3*@0SUBG(R@)5JH19=MN`ME+>58ER?KM0KUWJU<B@,BM<O21<1'S[>+9LSVC
MTPZ"H=`'(R\['=;?8=<9?96EQIUI2D.-N(SVI6A:<X4E2<XQE*DYQG&<=N,]
M`&EFV^Z:ZSTT_P`B&+,O<9-?&J7J"%<LUL>-()LTC<1ZMUL<WK[QNW#E6%5,
M*VZO1K\B4D0X'>(M0Q:#A%+D)`6+6.UE;;\9\0E5-[H-1;YO^P<=:[-V?)M=
M?M,RHKLRT#,44J2'467>R,@*79M;Q6:.@QQY*NR)2P4=6+0-FPFV7(#22BP?
M*(B.^WE,;A^=-E]?F/E&7]+T$7/>?28>=-E]?F/E&7]+T"Y[SZ3#SILOK\Q\
MHR_I>@7/>?28>=-E]?F/E&7]+T"Y[SZ3#SILOK\Q\HR_I>@7/>?28>=-E]?F
M/E&7]+T"Y[SZ3#SILOK\Q\HR_I>@7/>?28>=-E]?F/E&7]+T"Y[SZ3&L?)7E
MR%XZPJC.O4>[V1NURC40:@"]!E+AK$-#7I2I/E<P.2A+Z2#&&O`9=RK+2_"8
M1C".^Z]Q]I'I6CQJF/52%49B:JY*;9*GE&,VSB)84LW>Z)$<K**0G4U#4=R5
M>V5^UM%VB2N:5WJRQ1:E2J>JBM0G9!U14Q*74SER4-DSW)%E'=)QEZ^N2"LI
M.J:L[:G?LK^H?8W;?P-7_P`V==:]\OA/ZDQ)_DIOXB.X.\]QWX2X2_>5C\*#
M]E?U#[&[;^!J_P#FSIWR^$_J3$G^2F_B(=Y[COPEPE^\K'X4'[*_J'V-VW\#
M5_\`-G3OE\)_4F)/\E-_$0[SW'?A+A+]Y6/PH/V5_4/L;MOX&K_YLZ=\OA/Z
MDQ)_DIOXB'>>X[\)<)?O*Q^%!^ROZA]C=M_`U?\`S9T[Y?"?U)B3_)3?Q$.\
M]QWX2X2_>5C\*#]E?U#[&[;^!J_^;.G?+X3^I,2?Y*;^(AWGN._"7"7[RL?A
M0Y&^ZR:F:[_P=1V\WX1M33G>-UA/?M+[.^;5V6W[Y"NS':G/N9[,=N/<Z=\O
MA+ZCQ)_DIGXB'>>X[\)<)?O:Q^%#:7CWRTH')"&8539QP2;`N)43JUD5%BG$
M#W<H3',QFH)`A&F"W7E^*N/L25.0Y>$,SF8^)4!<OLO`FDS#^D!J7[U*DQ)L
M)1'(IL_@6YA,*U21+;2R\\V[&4L^#4M"S4TZ1)>0@G&3=Z>TFZ'L5Z+'H/OW
MW).I]1291JO2SD.P#E)UC<@O*D,1W6):6T\,A#C9(?:,UL+<-J0EG9'Q^=[[
MD_#.?XNNPKGO/I,=4AX_.]]R?AG/\72Y[SZ3`/'YWON3\,Y_BZ7/>?28!X_.
M]]R?AG/\72Y[SZ3`/'YWON3\,Y_BZ7/>?28!X_.]^2?AW/\`%TN>\^DP'(Z4
M)/N*=>GS'75Y[Y;CDEU:UY_C4I2\YSG_`+<YZ7/>?2`X_'YWON3\,Y_BZ7/>
M?28!X_.]]R?AG/\`%TN>\^DP#Q^=[[D_#.?XNESWGTF`>/SO?<GX9S_%TN>\
M^DP#Q^=[[D_#.?XNESWGTF`>/SO?<GX9S_%TN>\^DP')DH2RTEG,^9EE"U.)
M:S(=[Q*UXQA2TI[_`+,*5A*<*5C';G"<8S^#'2Y[SZ0''X_.]]R?AG/\72Y[
MSZ3`/'YWON3\,Y_BZ7/>?28!X_.]]R?AG/\`%TN>\^DP#Q^=[[D_#.?XNESW
MGTF`>/SO?<GX9S_%TN>\^DP#Q^=[[D_#.?XNESWGTF`GVM9<IVU1T.R'G$9B
MS<Y2MQ:D]N&<YQGL5G./<_@Z7,]IF+(^<7/Z!G.0O[G[?\YZY_;\="V\Q^@Q
MF$^H/[787YIO^KU`H[MYU>D:^/?OB:#^>M']T;!U8OFJYO2+C;CJH#6S>$1<
M^8J"VI*')M8>B-K7V]XE<ATDRE2^]QE7>I4O&5=[C.>S&>S&<^YUADM&_'D,
MI,B4\RZTDSO8C<;4@C.USL1G<[%>PR1GDQIL20HC4F/(8>4E-M926G4K,DW,
MBN9)L5S(K[3'D0.X+6R#`BMYME:<EQZ/JX&AG.2N1[%FJESU^5MYN/C([#B4
MF:KK2LAX#V6\2''V%-2FHT;'AG//S&ABILL-).J4]3C='PU#)']IX!%1IE6H
M<FJS$?J-8BETW#U.BL+U2<4M!H=2VV6NKU))]T-1I$EY?O-5DLNX@Q?4%.%W
M'W2Y2:S0L2PZ)3W/[5J&<&L8KJTZ2@E&TEM:5LK==,T)D2>(5]:N(^4T6UWF
MKUO8^R[G72RVCZ+PX$V1`-Y=JQ+O82A3$4,8*^->%CR)/E5.$2%)&N1$QI?(
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M>&<'^$B8;Q,=Y%W1SBE59<Q>B70"Q)(J%8=>@*>J/O.U`JF'XM"0AJ;W$<QV
M1&.&W+/6A--O:RH^LT22=5Q3.EO!2,/-8"<@XI/",2EX?:CU-+%).O.U.B8I
MFXE<6]3CJ)0&H<U,]V`6I4G78Y(1)U'C4;*8Q5N#!^GD@@T<<I<VMXLFD;B:
MM$N(28O@PMJ<8U&*C*NRW!D0O)MKG,YE,RI1N$\&9E/L.02JD-N9XVF:&9M)
MDPX\>;27J<50P=5I=1=:D(K<>7AB.EN5'IR$LK9[FJCR.$2ZY,97$0XM"F91
MI2H^7K'NA:;6XL^5)I]>8JATO']#@4AEZ*YAR7"QG+6[#EU=:I#;_==&CN$R
MMEJ`^B<MIMQ,B&2E(*#<CN*FX[_RPLVS]>QP3\O-=X0;3UM/NLTL+H<VZ\/M
MS\AB%[U1=+(`"VDU38=\HG(R%-I)Z#5+*[#/1;27\WC,<++A.^A!Y5(R(NDN
MFW9GLYQ6YG@ES+V1>+F5VWLK1)H7OIKAI(W3:0KELA6:F0^)G*_<7)*#K[5]
M3BT`/7[6*GU?8%4TT(V':;#4SK,.J3-@G:B8/EUBT@N5N/CMSD17X^4Q:FW>
M(?*.57>68;2UZUT-;Y7<RZQN*Z1BETO6N3$GCK%XK:)TG==9#M@U.A7,]1KS
M<K=I=+$JS5D1(F#=;V`FJMV2N7=X>5!`(RROQ%UW/E+>,Q4.)F]V^2O&?9AT
M9Q[UYK#C75YU:J`34UAV1+*C=<'>/436TOCC%IE@J8JCOU"K;<RYLJN[NA2Z
MS=252K5-UO*UP%AMGBQ0(N5MYGO(M^V^W9Q>,2'CGPSO&I.4/,7?%K+:ZGU[
MEUXJ[*KE6CF(Q;6WF6?MH>JCJS-F"XT:4-V/1["SL+;"58'KC;VD6DL+18AE
MAP3@@,\BY.O_`&V>(:SU;A1SQJNN^(%`S=>-IZM\$R''85J2ENV"\@QFSQVD
M-2;MT\9V??+BQIXM8J%<;M6+WKAIK60,;?ZA7I%.L<YF[3W[)&0,";EGO/6Z
M]GMD/L5P:Y(ZN%<7$SSNKK]5N)]I*\AUV&G8V*+VT[?+&_N*W[[U70M6N0CE
M#V(`V_,O8VG4.SVJR5>U:Y"I,X'@SA@M&EQ`7+/EW]1\W)EGN*P]&>%NI++H
M/B%Q@TE<W8[MOU/H/4^O[3B$^F2.CV*JT@*'-013Z<J2Z('$8DF`(6E6<9&Q
MHO9G..@@\S,;-=!`=`#H`K*[Z6U%LHD&,[`UG1[B8KL^$2!E[#61!0J+F#I"
M)<1<,E*BN36FFY#3;BXN'_%7^]PE]EU'WO7.TO$^(J(Q)BTBN56FQIC+K$J-
M#G2&([[;Z#;<)QA#A-*4I"C(G-3A$7,T+2>8X:I8=H-8>CR*I1J;4)$1UMZ-
M(EPV'WV'&5DXV;;RT&XE)+(C-!*X-5K*2HLA][,U!KC<(X4*V-66;'#!DEEQ
M&<SRPF8-(/#Y@F2]$)`YXPDRB8+(3ATZ,B7B+/A2GHLQE]E>4=5H>(ZUAMZ1
M(HLY<)R4P4>39J/(;>92\W(0EQB4R^RHVGV6GF5FWPC+J$N-*0HKB:Q0:37V
M6&*M#3+;C/'(8_6OL.,NJ:<86IMZ,ZR\DG&'G6G4$YJ.MK4AQ*DG80,/Q/X[
MU\AY2":KKXM[!4$<3&A/%F!+9:L$P9>OS602".`C+H<A60#L##0]#;#8J'%2
MCQ1KP&>7D:0L9RV>`E5^8^DX\J*:W4QU2%1YS,J/,:5+-GNI29#4V6ETU/&:
MCD.+,^$5K#BX^!L)Q7>&C42*PHGXTDD-*?0PE^&]&?BN)C$]W,E3#L**INS1
M$DF&T$6HG5&3QQHT,EB3&QK"LX:ETBT:V?[&9/A546ZGB%GM=92_XSX=H:=.
ME21">AIQ#CCDV0TEQ,=Q3/6`\<8M-:'#KL[6;JD"MH^4WJE5:7$9@4^<:.#U
M%/Q(D=AEHU)-)):0HTFM)*&<L'88)*T%189)<ILVCK^2NYTRHRG9LZ&2M?62
MS*E/O/.DDR-1N+*Y),TCA$<8M#@3*K`)UP'A%5VYF^>&1+,+83<(Y*079L#<
M!XDX/9((*27IV%M14(S)RVYE&<LL^#M)QWBV7&*)(K<EU@J>JDZIMQDK.G*9
M1&5#4\EA+RF380EHR4X9ZERO\I5ZQ\&88BR#E,4B.V_W>FIZQ.2#2500\J0F
M4EI3QM)=)Y1NW2@BU[';Y*;6G3:;6-?5@-3*8&B5ZK5Z)B`%"P?"8B#HF'''
ML,,>&<==[SPCKB_OW%Y[59]WK@*G4Y]8GR:G4Y+DR?,<X65*=U>$><U23KKU
M22F^JDBR(BL0YNGT^%2H4>G4Z.W$A1&^"CQVK\&TV1FK53K&I5KF9YF9YB3=
M?"/L#H`\[]_\M=BZ9Y(1=75NF@+^/L^N=>2JV!-6=VAQH%M.M<HK(;,E+7"J
M%X(K'+K^BQPF.+9`/>#F3E3DNI['6G@FQ6+GZB(:[SNZ,[%NA;7-CJ5(@TO5
MUF<C">^7:!QV[FS\FZ\-1TWQX61HV!=7#@XG(,Z)BO02EBEVR)'<*.MTR7Y%
M7D)U;>/T9&>_D\1<HW/XU<D!?*>7=62NNQ(9.MB-'L]6)M%B=M$'!ER%G958
MM0,B?H=*:5,:C#B*6C-41::A.8E,SJE>;#`?S*2$&5K;]PW)Z"`Z`'0!YDG.
MYH5$]9XEPG[5N$TV9V68O^TXY=)<W6-@0"7*35O)J%51U0(VUT!0(@5[58?7
ML4A68:9$ZNS),\PR1(H1A06UO1ER6*W/M/(QA=8]S:-Z1-4*VZMY`>"N=(8=
MPZ;V#J[STC6,@6&7R':3!<>,V)39'E`]/OQ,LE3!1+(]YEJ.EF4RK_1@UKE8
MRRXK'8_SRR'J8SAU+327W$.O);1AYUMO++;CN$XPXXAK+CN6D+7VJ2WEUW*,
M9PG+B\X[[(5')T`.@!T`.@!T`.@!T`:$\Z^*FR^48C6\#6^P*90I--)6:85>
MN-:,6-DDP;BA68K4!`@L*7%<C.#'E/K?4\EU+S6&\(RA65=6Z3='/QALT=DY
MR814MV:Y<TJ5PG=:(R;%JI5\WN?CM\X=XZ%=+L?10_B!]^E/U3W[9IS24LNM
MM<#W"N8LS5PGSN$[J(BMLU#OM(><W[$CRD_WB=(?T873_.'74G>U)^OD?NW/
MY8[][\2!X)3OXJ-VA^Q(\I/]XG2']&%T_P`X=.]J3]?(_=N?RP[\2!X)3OXJ
M-VA^Q(\I/]XG2']&%T_SAT[VI/U\C]VY_+#OQ('@E._BHW:'[$CRD_WB=(?T
M873_`#AT[VI/U\C]VY_+#OQ('@E._BHW:'[$CRD_WB=(?T873_.'3O:D_7R/
MW;G\L._$@>"4[^*C=H?L2/*3_>)TA_1A=/\`.'3O:D_7R/W;G\L._$@>"4[^
M*C=H?L2/*3_>)TA_1A=/\X=.]J3]?(_=N?RP[\2!X)3OXJ-VCTBX;\+HO&J'
M.L-Q/B;WM,I%P,>L8@5*#A!`C.&ER88,;.ESY;+Q.2WATA,D27'?%VHL&-AE
MK$Y9#LS1GHDI^`'YU2>DIJ=7E&MB/)X,T-P:>9I4;#*5&9J??6DE29!DFZ$M
MLM(0DG3>Z1TRZ=ZEI18I](APW:+A^'J2I,);R77ZC4R):4R)*VR2DH\9M1IB
MQDZQ$XMU]Y;B^`3'WMZ[A'G\.@!T`.@!T`.@!T`.@!T`.@!T`.@!T`.@!T`.
M@!T`.@!T`.@"P=8_MLC?]TF_^CGH+(^<7/Z#$DY"_N?M_P`YZY_;\=26WF/T
M&,PGU!_:["_--_U>H%'=O.KTC7Q[]\30?SUH_NC8.K%\U7-Z1<;<=5`5/L"^
M2ZC-;;;C#7(B1>2$A^:U(<6TE#LI+N<>!?;_`-&AMCO^SO%*[>^[,Y[<8Q5:
MTMH6XL]5"$J6M1[$I21J49VSR(C,$)6XZVRVC7<=4AMM)&1&I:U:J4E?+Y2C
M(BO8MYC6)KG/JM^L`;DU<:6Y6K/9<T\$43!/^#(V1.,J4*:8[WQMM]*>Q2G'
MX[4=.%MYR]C#K??:@G2!@Y=.A59->B*I]1J!TJ%)),C5D5`BN<5*.!X4ED5C
M,UH2@B-/ROE)OOB]%^D!NK5&A+PO.35J32BKE1AF[$UXU*,[%,4YW1P*VS.Y
M$EMQ;AFE1$BZ%6R#7-+7;]Q(T!JS4]=L%+,LS!F(1SP:9=<@^4CXZ.3SV")Q
M8+`PJ44$09\DG`:0YF3$;RTYA.=.-L*KJTBAIK,8ZI&5+0]&)#]B=@,]T3H[
M<C@>Y7I4-F[DF*R\Y(821FXTG5.WRKT>8W10XN)%X<F)HTQ,%QB6;D76-BJ2
M.Y:;*=B</W;'ASY!DS$FR([420M22:>5K)OTZSSBU9;XAN<`NE$DQ:X"59S3
MLMLL(\1KB%^#6=4@PN`X\);=[UER?&0]&0^XRPMS#K[*%XZ=CW!U5:F/0:_!
M<:I\,ZC+4ZIR+P,!)V5-,I;;"EQ4JLE3[9+;2M24&HEJ21YZMHSQ_1'H$>I8
M5J33U4J!4F`ADF9W=%44G633R5!=DI1,4BZTQG5(=4VE;A)-#:U)^W.;VKVJ
MVW;7+G0T@73$D`B5E)3QGRU#A^4I@U8O#GE9J5$&Y22E(=@H\7'+;GO91$=;
M>5*L=X033TU15?@%"5+<@DYKN<)W6RSW0['.-P?=*7&HYE(=2IDN#CFE]=FE
M)6=4Z-<?+JBZ,G"M3.HH@M5)3.JUP7<#[_<K$I,LW.XULORB.*RI$A7"RDJC
M(UGDJ07&YSFU*U8(%55L#6F;"5<!M#1;<R0\_/798T&8`\44S+6R^DO$)CY$
M%QMQ3;[,MAQ*N]7C/5%8_P`%IGL4P\2THY\E4),>,F02UOG46V7H/!&@E(64
MIJ2PXRI*C2M+J#([&+HT8:1%TR16$X.KGO9#34%RIBHBD-QTTIV0Q4N&)>JM
MLX3T22U(2M)*;6RXE1728NGTLF<*PC(X%A:DJ4E/@97?*2C*<*5A/CO;E*<K
M1A6<8[$Y6G&>SOL=NX#0>$Y.O\A]>E<WZL"?%Y?UWH'"<G7^0XT;<+.)[]N"
M`6COLH[]#4E2>_2O+:D=\F=G'?)<QE&4]O;A>,ISCMQV=`X3DZ_R'WZ6#7;G
M'DT'VX[.W'@)?;CM_!VX\=]SM[,]G\?0.$Y.O\A^^E<WZL"?%Y?UWH'"<G7^
M0Z#&[7Y32'XV*K(9<D.Q6WF'5NM.2F'%,O1D.-D5(7(9>2IIUE.<N-N)4VM.
M%8SCH&OR=?Y#N*VV81_KCP*?]7_69E)_UU80G\,['^LO.$)_C5G"<=N<]G0.
M$Y.O\A]^E<WZL"?%Y?UWH'"<G7^0AMBL4NRS&9LQB)'<9C)BI1$0XAO*$NNN
MX4K#KKJLK[YY6,YPK&.]PGW.WMSD*J/6.^P8#H*AT`.@!T`.@!T`.@!T`.@!
MT`0,YJW6UFL<.X6*B5(Y:Q\>'$@V,J!&SC4.*/BVF%!CQB4F.Y+99AP[Q<HL
M9M#J4,L6D^TWA*"LS#P!!8O%_CE"+J/P]&ZKBFE0@`[RFQ1Z\U,3!JV:GFNQ
M4/(@86VR'S0J/X@EO*?`>9]8[W_8(OQ4)N>_?UWOZ1*==Z7U'J1PP[J_6M)U
M^[8&1L<XY4*X+`K+1PKQ5\-'(*'1H^94<.HX5;$L.Y4T,C378<%#$3#;*`@6
M;T`.@#N#YK@Z=$GM(;<=AR&I+:'<*4TM;*\+2ES"5)5E&<XQA6$J3G./P9QG
MW>@%D9'N$A@\B1A2PF*B,+T`C;*\Q&DGZQ!*1Y=A!QIJ4+AR#`6.7<)#&):'
M&UQG9L9AM]*T*:4O"L9R&37Y.O\`(9>/NB7+DSX41NKRI@IYF,4B1U.O21LB
M3$8GQV)[#9!3L-Y^#)C3&6I"&UNQ)#$A"5,NMK4#7Y.O\AW?2N;]6!/B\OZ[
MT#A.3K_(<"]PDFY#$1R)742Y+;[L:*M+Z9$AJ+EG$EQAE4_#CK<?,AC#ZVTJ
M2UE]G#F4^$1WP.$Y.O\`(<3>Z);L^4*:;K#I2#$@SYHUM3JY\."3=GL#9DJ&
MDAF1'B$'Q1-F#(>;0S+=&SVV%N+AR,-@X3DZ_P`AW/2N;]6!/B\OZ[T#A.3K
M_(/2N;]6!/B\OZ[T#A.3K_(/2N;]6!/B\OZ[T#A.3K_(/2N;]6!/B\OZ[T#A
M.3K_`"#TKF_5@3XO+^N]`X3DZ_R$(N>Y!<!(YVVEZ;5VW%2FX*RQ2*%1-6G$
M=4A+"BA)K$A3&,LY7AG.<MX=3E>,=^GKXIE5IM+)M51J$"`3QJ)HYTMB*3IH
ML:R;-]QLEFDE)-1)OJZR;VN0Y"!1ZQ63=*DTFI5,XY(-\J=!E3C9)PU$V;I1
MFG#;)9H42->VL:56O8[03T\:V_&-K+YYU[[9Z^'X6X9\(Z!Y7I_K(Y+X%8R\
M$L3>0:KZJ'IXUM^,;67SSKWVST^%N&?".@>5Z?ZR'P*QEX)8F\@U7U4/3QK;
M\8VLOGG7OMGI\+<,^$=`\KT_UD/@5C+P2Q-Y!JOJH>GC6WXQM9?/.O?;/3X6
MX9\(Z!Y7I_K(?`K&7@EB;R#5?50]/&MOQC:R^>=>^V>GPMPSX1T#RO3_`%D/
M@5C+P2Q-Y!JOJH>GC6WXQM9?/.O?;/3X6X9\(Z!Y7I_K(?`K&7@EB;R#5?51
MVHO(/7,7QGO-B:O5XS%=B+[^Y5_/>H=RC*E([#6.Q>.\QV9SVX]W/;C/4'BS
M#)V_\1T#([_^KT_UD26"\9%?_P`)8FS*W_H-5]5$J@7!HK#C$1;XDF.F-X>B
M3Q[Z)L*4SG.<8=C2XTEUA]K.<9QAQIQ:,YQG&,]N,]<RQ+9E,MR(KS$F.ZG7
M:?8<0\RZG9K-NMJ4A:;D>:5&66T:_*BRH4AV)-COQ)3"M1Z-)9<8?978CU'6
M74H<;58R/56DCL99#M^<$K^0B_J.?2]9M<^3K[1@#S@E?R$7]1SZ7IKGR=?:
M`><$K^0B_J.?2]-<^3K[0#S@E?R$7]1SZ7IKGR=?:`><$K^0B_J.?2]-<^3K
M[0#%AEX]WP$7]1SZ7IKGN+VYP':FVN=.E/RW(T)"WU]^I+;;V$)SV8QV)PI]
M6<8]S^%6>H)9D5L@/,S/>.KYP2OY"+^HY]+U.N?)U]H!YP2OY"+^HY]+TUSY
M.OM`/."5_(1?U'/I>FN?)U]H!YP2OY"+^HY]+TUSY.OM`/."5_(1?U'/I>FN
M?)U]H!YP2OY"+^HY]+TUSY.OM`=I5KG*AM0LQH6&V7W9"5X;>\)E3R&T*2K/
MAN][W&&TY3C"<9QG.>W.?<QB-<[WL5_;E$WR(MU^NPZOG!*_D(OZCGTO4ZY\
MG7VB`\X)7\A%_4<^EZ:Y\G7V@'G!*_D(OZCGTO37/DZ^T`\X)7\A%_4<^EZ:
MY\G7V@'G!*_D(OZCGTO37/DZ^T`\X)7\A%_4<^EZ:Y\G7V@)QKPN_,LT=AQI
MA*519:NUM*\*^]:SG'NJ6K'9_'[G4&HSR.PLCYQ<X[_(7]S]O^<]<_M^.H+;
MS'Z#&83Z@_M=A?FF_P"KU`H[MYU>D:^/?OB:#^>M']T;#U8OFJYO2+C;CJH#
M67?3;CRI;32%NNNU&8VVVVE2W''%Y*)0A"$XRI:UJSA*4IQE2E9QC&,YSU\L
MU*EPI:4I-2E19"4I21FI2C:61)217,S,SL1%F9Y$/H@*2BIT]:U)0A$R(I:U
M&24I2F0@U*4H[$E*2(S,S,B(BN>0_GO":/VI&J-;!/:^N+0*OB=6[.&PO-DW
MF6W?+;:M+5"T#UQ%0/"LS`(2@VL\7B][B2.BGGILYIB*XEY?CN'@W$S=*IT)
M5!JR84&-AK$<=GWNF<*FMU.I80I528-HV-=#L*'0ZG-EM6X2.W.4\\EMM1*/
MW[/Q_@]VMU6HHQ+0U5"IS<7X3E2/?6`3"L.T6CX\K=(DI>*1J+8J4_$E'IT)
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MF_<4;8+NKRUNVK`'MHH%O6;<D&M%5RJ"##E-2&S98PTV?'3P$8G*#LQ<27,>
M,OLQG/#=<Z_%J/PTD8W]Y:ZK#<JJXF982FAU54Q2Y>"Z?3(LM5)*(=1;CS)T
M=^"B2Y$0UPJBX1:&U:PUJ-,I7Q=P]''P@PTC%T*B8.DR5*Q)1$P$M0-(54K$
MZ$BNG/\`>EZ5`ITJ-478C,UQXVD?J4..IX,KHU'K^[2#/%O7USK!F!6M0:<:
MV4>>G"Y:0\O9TM]%=J=:G$5L^).'J0-DDS2!J)*GX$K,9]QO_0QU(V["U"K#
MDO1M0JO3I;-.PIA-&(9JWHSG<CF(W5E`IE.>?4C@53:-'<DS"CI<-;+AMN*3
M9#9EH>-<2T!J!I>Q-0:O!DU7&V.5X4IR(\MDYK.$F6SJE:JL>,3G#HIU?E-1
M(!RC:2B2T3K:5?K'2/4KF5=]H5OEQL!T6=V1608^A=SWK48UJ:NSK=LX/I?:
M7([DG%Y)S=3UP36[E8R]FL9JCZ,!;#B4VK'K/"I8>M%88^.\B*0;[U'F@B(_
M'8_%LRSV;SN/.C07.KG`7#U79(2S\G.0]]IM<J-IL>H@VG7K%1+AK4IP%VCL
MTM+L$^BZS2(@;,LW(*#IR)6!,.W#BSQ>P#A%8KSM:L=ARX$V+Q7OF?\`BMLX
MLOSV7$?)<<-E:OX;;TX?;NXQ;;G;(J`ZQ77C/?JYK#9_*?7*=@[<XOU2%L%8
MLUKQ``2#Y#[-WM4MU6/6VWI=&N4'CS>]EPBT]EB05#1KZ$Y7N1EN/87&?5R7
MN99&/4/BW3&HG=(3U^IVB=J:T@&-$\B06])5YUQL"NSXNVW=VZ,+`SUWWO9C
M5KJ'*,;L\=!LY;C:JE&0K.B]55^T5Q=4$,W)ZOU(*GLMXN/D/BXMN>\QB=9$
MN;6U^,G=0:A;GM\YV22UMNZN<(,WN@JUQ,*ZJL%6W0*X_P!KP4;'BE*WH;M:
M9,.^CBCHFS5ZK!-,G3M4J<ZU.8(`RN1\I7V\E^;=SC3RU:KXN%;=I(Y7>YZ;
MMB\;!)#8<+8]:<XA;KL(&Y;&D\*@5/"%07'9O6$XW2#`4PU7];3MDXHX(78M
MB`Y,K-GF$*W+)Q@DC.QYYY<9%Q[_`&+<*XO6HCU=IVK2.S=2[@K^[=<<![\#
MYH;4LFNMBMFG;>`[F&%;'[C%\J7[%;*!8M5U;9=4K.NZ_H:KXI%D'\K(MAWR
MU#=,@R)6QA/BMMR(CM<KGQ%S7/896W#^IO6<JUS]<:_G7R-B'>)E(JDJYP\-
MI9Q%M<@#`>L4;#2,)0UA@NN8UAM"<)1WO>IQC&,8Z#&8F_0`Z`'0`Z`'0`Z`
M'0`Z`'0`Z`'0`Z`'0`Z`'0`Z`'0!XX%M/;Q#DCX<-H&W9+B^0V\=@7'>].O@
M*G7FVZ)W)R^HNTW]<:I,U^YAKA,)G].-X$V]).?2B-=CZDC5VMDI!"P`4OA:
MY;^(K%XBX\C+:708J(9HGGL'BG2;L/;#5FM@R-(&DJYM86--(W#"T9QQJ>H;
MAMPJ-O@Y5UJ%!EU7:->VA!+R[8)LYSO2LD!;XLP854"Y=O2=[9%:]R,MEMXL
M?.E.<XXQJ>2(N&Y&)T\T2LUEEE-EFK>-#VE&_P!J3/B6B,3W2*JPN@$^/X@`
M'$UYJA[,#1V4VE0&L5G9UDDV@F$W3GD6WI+BY?&>5LMI9"#%=(\H/)VI[V.U
MKRJ(WFJZ_P!HTLVJV<F9!BPCK?<=<\;XUHM(E<#;D$A$IA:Q57;RA5?@6Z60
M*6^!$)U>=KX6:H)6K@WYIVD>6SC[2YK\=QM]P:UMOVIW?9UKWJ%M,2:9U3K"
MBB3MO/#CIDSB@\B>;1H;#D2&KWL4SGR3K#8VJ'FGCUJ/SE12\:%*L1PN.,2&
MP@S+BW\67$7WW'I!T%0Z`'0`Z`'0!Y)]U;#W<M7=*>9>K=K;.<CFKSY0CZMU
M[9;_`"!"'8-7\6>,,UR#-6,9F*;>1#=EX;1)7'D(:RK+*^SSQI_PQ7,2Q<,(
MHE.E5!42155R"C,/O\$EYN`39KX%IS5US;62=:U]4[7L=O6_N5,68<PM-QHY
MB&M4RCHF1:(B*JHSHL(GU,NU-3I-'*>9)PVR<0:R1K:NNG6MK%?Q?\S]Z_[I
M_+C_`.W+9_V#UYH^*O'G@Y5/X"=ZL/97QNZ-/#?#'EVD^N!YG[U_W3^7'_VY
M;/\`L'I\5>//!RJ?P$[U8/C=T:>&^&/+M)]<#S/WK_NG\N/_`+<MG_8/3XJ\
M>>#E4_@)WJP?&[HT\-\,>7:3ZX'F?O7_`'3^7'_VY;/^P>GQ5X\\'*I_`3O5
M@^-W1IX;X8\NTGUP/,_>O^Z?RX_^W+9_V#T^*O'G@Y5/X"=ZL'QNZ-/#?#'E
MVD^N!YG[U_W3^7'_`-N6S_L'I\5>//!RJ?P$[U8/C=T:>&^&/+M)]<#%/WKG
MW/N4.7'_`.GCEL_[!Z?%9CSP<JG\!.]5#XW=&GAOACR]2?71_0AW/;5VW=::
MH)HV;)*"AATIB?4=>FH;L<K4HZ%2$DY\Q$M*)@M5BDJ;D)K[C;:(F(WE1;;<
MPQ*1CU9H(PWBG#V&I)8A<DQ8TV3PU+H4MI2)--01K*0^Z3MG8QSG#2LH1I23
M?!]TF1.RG"+PG[IK%V"L58PB?!5F),F4Z)W/6L30'T.Q*NXHFSBQF39-3$LJ
M:T2FSJ*5*4[PI1$J4S#:4-_.N\AYJ#H`=`#H`=`#H`=`#H`=`#H`=`#H`=`#
MH`=`#H`=`#H`=`#H`L'6/[;(W_=)O_HYZ"R/G%S^@Q).0O[G[?\`.>N?V_'4
MEMYC]!C,)]0?VNPOS3?]7J!1W;SJ](U\>_?$T'\]:/[HV'JQ?-5S>D7&W'50
M%6WD=4)A2*Y8#4H;+3`0AIEAO*T+C8D25)=SG$*3]]EU3J,X[_'N(Q][C\*@
MHHDWS.V7;R&(5Y#UG[5D?@5?9705LC>?MS!Y#UG[5D?@5?970+(WG[<P>0]9
M^U9'X%7V5T"R-Y^W,'D/6?M61^!5]E=`LC>?MS!Y#UG[5D?@5?970+(WG[<P
MKV^Z'XN[4B.#]GURG;'@/#7@ST*^T6O7"(Z'D%PE@D"7(UAK!%E8U\]6:X;>
M@J1F*Z7KX0DMI4P5`>8!\CZ1^W,,Q6-4<?*2B0W3&`U11,B@X$M%8JXH`B5!
MK`>+7JW#D)%5Z)A^+7@$&$#!QW<*9$AX<49`1'A1VF$`LCZ1^W,)5Y#UG[5D
M?@5?970+(WG[<P>0]9^U9'X%7V5T"R-Y^W,'D/6?M61^!5]E=`LC>?MS!Y#U
MG[5D?@5?970+(WG[<PQ9JCZ9L8U\/82:#PB4N,Y)%&A,8H-D+ARF)T-;\&<%
M?BO+BS8T:9&4XTK+$J.Q(:REUIM:061O/VYAE/(>L_:LC\"K[*Z!9&\_;F#R
M'K/VK(_`J^RN@61O/VY@\AZS]JR/P*OLKH%D;S]N8/(>L_:LC\"K[*Z!9&\_
M;F#R'K/VK(_`J^RN@61O/VY@\AZS]JR/P*OLKH%D;S]N88PHG3@-J,^9ORA3
M$R8R/C/D7&X;#TZ0EQ4>(E^0-;:\/(\$M+#>5X4\YA+3>%.K0A7V0J=/J*WF
MZ?#DS7&([DIYJ*RX^XW&:-"77S;:2I?!-:Z3<623)M!FM9DA*E%QE4K%%HC<
M9ZL52%2V)<QFGQGZA)9AL/3I"7%1XB7GU-M</(X):6&S62GG"2TV2G5H0K)8
M!ZRSC&<6LAG&<=N,X95G&<9_!G&?)7NXSU\9E;(\C+(R/B')%P9D1DJY'F1E
MF1D>PR.P_?(>L_:LC\"K[*Z";(WG[<P>0]9^U9'X%7V5T"R-Y^W,'D/6?M61
M^!5]E=`LC>?MS!Y#UG[5D?@5?970+(WG[<P>0]9^U9'X%7V5T"R-Y^W,'D/6
M?M61^!5]E=`LC>?MS!Y#UG[5D?@5?970+(WG[<P>0]9^U9'X%7V5T"R-Y^W,
M./(C5R74,9N$W#[C;KS;.4=CKC3"F4/.H;R+[];;*Y#"'5IQE+:GV4KSC+B,
M*!9&\_;F')Y#UG[5D?@5?970+(WG[<P>0]9^U9'X%7V5T"R-Y^W,'D/6?M61
M^!5]E=`LC>?MS!Y#UG[5D?@5?970+(WG[<P>0]9^U9'X%7V5T"R-Y^W,'D/6
M?M61^!5]E=`LC>?MS!Y#UG[5D?@5?970+(WG[<P>0]9^U9'X%7V5T"R-Y^W,
M'D/6?M61^!5]E=`LC>?MS!Y#UG[5D?@5?970+(WG[<P>0]9^U9'X%7V5T"R-
MY^W,,*7%TR/XOY).RYF%^%\/X5O*?!][X/P7>]L%GM[_`+7.W_6_U<?@_AL6
MKQG;=[6,0>KQ'??[6(8;Q0'ZP>_5S]!U-D;S]N85#Q0'ZP>_5S]!TLC>?MS`
M'B@/U@]^KGZ#I9&\_;F`/%`?K![]7/T'2R-Y^W,`>*`_6#WZN?H.ED;S]N8`
M\4!^L'OU<_0=+(WG[<P#M1H-:7XSXR5D-=Y%=7'[U&<^$DIRCP32O^BK[$KQ
ME?;G[W\&/O\`'\,&2<K&>W/Q=`DK9WW9>,=7Q0'ZP>_5S]!U-D;S]N80'B@/
MU@]^KGZ#I9&\_;F`/%`?K![]7/T'2R-Y^W,`>*`_6#WZN?H.ED;S]N8`\4!^
ML'OU<_0=+(WG[<P!XH#]8/?JY^@Z61O/VY@#$0'_``D'NS_\W/U?I9&\_;F`
M=J;!K3<I]$,K(?BI7V,NK1G"EH[,??9QXJWV>[V__0G_`(=01)MF9W]N0#VC
MJ^*`_6#WZN?H.ILC>?MS`'B@/U@]^KGZ#I9&\_;F`/%`?K![]7/T'2R-Y^W,
M`>*`_6#WZN?H.ED;S]N8`\4!^L'OU<_0=+(WG[<P!XH#]8/?JY^@Z61O/VY@
M':5!K.(;3B2LC,M3[J76<HSWB&$H;RTYC/BN/OEJRYC.._5[B<?>X_#F+)OM
M.WB_+[@]/^WYCJ^*`_6#WZN?H.ILC>?MS`'B@/U@]^KGZ#I9&\_;F`/%`?K!
M[]7/T'2R-Y^W,`>*`_6#WZN?H.ED;S]N8`\4!^L'OU<_0=+(WG[<P!XH#]8/
M?JY^@Z61O/VY@$XUXP+;LT=466X\]XK+QA"DYQC.,M9[[/\`\I'X,?\`\W4'
MJVR,S/VY!9'SBYQW^0O[G[?\YZY_;\=06WF/T&,PGU!_:["_--_U>H%'=O.K
MTC7Q[]\30?SUH_NC8>K%\U7-Z1<;<=5`:S;X>=CN27V5J:>9J4MYIQ&>Q;;K
M:BBVUISCW<*0M.%)S_!G&,]?--4I$.6M!FE:(SZDJ+(TJ2TLTF1[R,B,A]$%
M"':E`;<22VW)D5"T**Z5(6^A*DF7&2DF9&6XQ_/T$W[NR3K>@UU[8]H=M@FX
M5W8-D.X(N^42NN+:_IP0#%SY>?\`2.P7C^RSD!+&<Y2XJNN?P,]F/($3&^+W
M,/4.`O$%255(U5@5VH3>'7W1*H%47A.+#C/.Y&IE<[$4U@D9DHZ>KZ)V]ZS]
M&^`6L58DJ;>%Z.BC3*)5,-4JG=RH[FAXIHK>.9M0F1F?FHD-TW"E/D&X5C25
M43QKN>PE<VA:)%BS=#NS=GP"=IV7OFFC*M&'ME-8K'5:">A5FL83F?`14SX1
M`=-B8-Q8A`F24VXW/\*T^M>-ZI^(ZBY4/?>;B+$;$FIXBQM28U,;83)PZ<>F
M,S6:=3K&\P5+G0TQ"GHF-MO29)I6E_62LS+K2J81I#5,*@T_">$9,2CX5T<U
MV76'9*XF+"E5>137ZM5K]S255FFU!4U5,73W7XT2*2D+CZJVR2=5S-T;AUKK
M2LV(;LRW6,ALOC8JYSO.R9%/^:UN7>JA6F[(`7)A>&@LH'V.:A,&2Y)@JE-,
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MR/`C-)CHG0F&GV>ZU)D*4MM>SMKL.P1/*W4=:7;T.:_MU2V3/;J$(/B!EB97
M!%?3XP:+J(S%GW')LUZ4.2B"(9%-9S'RU.=6N7GL6ISZ[&TFX6IQU4E4.J4O
M$#Z:4S$X#4=@18)<),E&^Z<Y2GGENL$3,5$9)ZFH\HS=/J6C4S#4S0YC6JIH
MBDXEHM:PK&76WYW=).,52;4CX*!"**PFFI3'CH9DF<B:N8O]9KQT$E@M:.4O
M,;:]'WPQQ\TW'H8LK*F<2Z=.N][KINV1`5JY9[7VH!'E60`BVT[RI'H6M^/^
MPB#H1\K"38;9?M?*P:@C:\?%G.RQU!;*^?HRR^\QKL8YP\T-=7:^P;V4XJ6>
MO<><<*8.V1FNZ;L$C(V<GE1S#W7QF,&Z%>Y&VTC];'J=6=?UBX2J";I&R4PK
MV];M;RK2\Q$@VAH%B].9[B(C]NGD$HO?/WDS76-PAR=2TCK(O1>Z!R.)N=A+
M#[6WMK#6FME<':1RAJ5TO\(%)TW;;5:-C;&M074`U`YJAU^MG]AUD*A=OG@X
MY"^@(BRVYE?EVVR]/-Q<5P,=TG&!.*G!3D9;]/W$G.YP5G3@BJ5NB.CIT81O
M;=='"V>A:RDR34V`_##6PG(L0L7=R"4!!#(-F18WH7E6%A8+9F1<7H$LW=OG
MD8CE"=TKH\OHBK`M0Z/T5OC8#V[!=D5'V$-W+O/9.M9-/#78-;@D76CX"HZ<
MN9*`?F56^>4[E8J;"D"HPF(29*A%LN/CV<A#4[2'.#FMLV%41CV..,^P;HX\
M[,Y%T0F.U#NO+6K*OHSDOKW4>U@YZAU39NP;?ORS2M<;$CVG6-:I;VJB-LO@
M)^G29,*$;8+B0DR(CX[%;CWEEQ=(V4X%<T]A\E9D>O[4!4H2>,:#HN[`<BDP
M#8=G.9FU]TZ7O]:L%=/V"R%:K8*]8-3!#Q&IEB2[!2"%[):RL_C=CUZ4,EP&
M5NFWH/[^H>F/05#H`=`%9WS:M;UY.&C3;4MR67`V2P0<-RZ\,AKBU>?51LZ.
M^5LQVOB(<V5+N`AH:W,GL,RW/#L^,-R/%F9/-TF@S:PT^]&4VEN/*A1'=9N8
M\X3DYJ>\TM+$&++D.-H;IT@WE-M*4V6HK4-&NI'$5*M1*6XRU()9K?C2Y3=G
M(K+9HANPF7$*?F28K#;BW)["62<=2E9ZR=8E:B5TPUS&UL^,P:CUO8;XE0[+
MS<U@.!=PX>1K>?M9RG8B-V=1!!QFGB2DM\B]$:IC$@?(9>M:$^!==V16CFM)
M?.*N92$2">U5-+D2TZL4ZRU04U'A#@DT<5=1D,-H92XJI+0\A28!GK)3KR<?
M4A;/="(E54P;1F3B8\8[RBI#M<.GDV4SA2DII[+SBG5-E3TJ:4E4XODFK+3.
M5^MX2IK+L,MXY'E4N".B9.:T938I=XHKVQ1BP1.5L&.#DAF*U",*5;I16%2C
M)8";!5&QV4O`<AJ^=O`-9=)M27(_!J14G7G.Y:THX;=+JB:.^4MAND+E(D+F
MN1[4]##E3C1Y<654(<*.Z3A?0YC:DMFXE3;W")73FVD=TT=)2UU*FJJS)QGE
MU1$9<=,-M\SG./MT^0_%DQH$N8^T;8S%7W1KG<YF7KA54/31QNNGB://&OB4
M5VQC*\QKA^Q070\PE*-Q9(STJ4YN3`LU=$*=D2)J(N)"ALG**2*#7\)-L5^/
M5&8DR#.B-(=I$^4BH4^3+5640WVI;#33!I>]XJD:'H$U_50ALW-0GT$>-51P
MWC1N9AFIT7WTI=3@2NZ85=IL.32JI$CII"YD:3`E+?6K@O?FGDXQ/A,DI:EZ
MA+-E1EYAJH>QJ9W1TWIKC*6U]J(:YIUK8<LV5JMQN\856)$H`),`/-!C8==K
M4MZ387F"`M^2S!\GH>CMH?7EIM+WHR=7J7B#0/3L7Z045O$\\\4/4(F6I]+I
MCDJH,IF28LXZBJB2YZ"1`(V)*$NO<.M#BS26NK5\I8<PK+P=[HNMX$T:-T#"
M5$;PA$Q$FT&KU%N%39"H42734TTJ[&IIZ]2_M,51QV.YVG6VR4K@T:_MS#;D
M,Q(K4R2F9+:CL-RI:6$QDRI"&DI?DIC)6XF.E]W"G<,)<6EK"O!X6K">^SY"
M<-"G'%-HX-M2U&ALU&LVT&HS2@UF1&O539.L9$:K7,BO8>WT$M*$)6OA%DE)
M+62=0EK(B)2R01F2=8[GJD9ZM[7.P['5!8>=NO\`D=L@WO2L48V9$XK1/?',
M&A3F,BQT5[-=U"U4L4"-B9A"'6I$9\XXB3*PK#Y5<J.W(4YG+6,A:VWD(CYS
MMV]0[O$#=^R+U=KM5]P7M@I8YE9#W>KUR"!H,J@SZZ3N6PA<*YZ/VKKLV2AW
MG69L*&#0V`%[8QM*MF0A>>>D9@&8D(<`RW%R<?)MN6WQ9"O2O*79U0L5ZV"3
MO-5+BON@;MQQHO'$Q$%5E14K"V%K'5E%M0N\P`1:W05,';:Y;]FSR[5H$QZ3
M88"ZW5H4X4TX8!8CV;KF?3?CWV+I';VAS4M)CC\R?HM8V'0=I.[8U1KTU*":
M^+76IP\$>9E*XR;'%ZYV3<Z:'U7=;3.;G6)ZCBR.8A9^._`-DZX/8AST1`6L
M>\K&?5<N4AC*%S!Y-BW(^M-A:1J4[9,*W4_731FS[-:I$HQ8MF.V^XZ]?N%=
MI=`V'7ZCEC352DE[Y)K]D/L,;'DC*M702A)2:4K(+%OWWL6XKY7//=UB$0^Z
MEVH[76;Y6^/0-VB.TIZ]>,F]R$!=L2+#ZAXT;GLD;->AZC*BO'&*]R/'A@>,
M6C+!4W6)KLUT.-GQI#8-7LV<ID5\^3E'HZ]K5N;OZM[K'N@\1ANHK]K`PME*
ME&B4LU=]=V`+VR665,/#07FC98[S+\M+T2<6PF/'5AV:MH*\71]XNGH`\=BG
M=%=CTN]/"K-K8N5KL+:?*O74"9#!)9'7LG2>4.KN/^E1=7F5R;<[EET5)V)&
M8V.\UKR<4FNJ\:JH(]*:9%R@M;T%S9&9\^77T3DCW1^U->3F1W&LDW/>C,PR
MHRX[`(40F,M3FM-^[14,\DE]8/&O(6`''.[X:-EQ8(R\LS3%^:+:2AE->!J\
MOBM;/9R\I<?0+NY9<@-ETOAY&W?H08*7L6WDN.L6B!K;`66@+>W5M?6=-2+)
MPX,R*MV2L9=7XC;L:5V1Y^6I+>'TM8:<""(KVXL\^8\QIB'[J<=C0N0NTY%1
M!WO4E>)-V'3H8.0EU^VRM55.C;1+WHZM`X/=BEO*$BNIC!,&]'`!J>'!FH!6
MYW&IU:,_8^@G5V<1YWV;RY>6PL@/S^O8NZVRHE*=`O)]6P]J4RG`XQ.)10B8
M%!WWW0,,F>4LCP^RRVR$?3G#E25,K&+A&;BZ.92Z%C')\X6#5^[T%]Y[]@S5
M?[I:JPPX)-K2K(T78P$N53917:##3Q2S#CW&<%.`E!T.BSI\6*ZYR>JV0&:L
MQ=KK;"5=.5VN:](V`C51Y\&KQ7S[2,RVVW=8Q6.ZE0&P,6WR]&F6:JX+<CRI
M";LR@^U>U<>;WR"A5>/7B52%JR(D#M=6"L2+(8(@YHXE*!S)=72Q)+,`P:IY
M9[=GBN1%TWV??D)'?N>UWUC?9=+LFF992\S`E6'!=;4VRR;^+?M+Q#ER7+DA
M]PU[0[7<YXXM1^,\J<-'SM8C2P<D3%0[@&IT=-G+A`6_WY,N([;RSO8;"Z'Y
M4N;KV/<:%+UJ7UUD!7XEF"(MQ.1!MYP.](@0WB3]/(UX2RD5B41989,T^QWT
M5!F-R0-PF4^VM)K;@096X[YVR]NKHN-N^@@>=O/OD?M'CZC4N=:D10_-N5?L
M&O*86"7\-@!BE>3?`^.(7XOX/RV0\)X/L\-X1OO^WP2.SH/3AC_$F!O@Q\'I
M$=CWT]^NZ^Z(C,K7[B]Z>Y]3A2/4U>ZWM;5^==-_FD/4/N;M%V$-)18R^%<2
M5*]Y3P]W!W+.D0M3WQ]_.ZM?@%)X76[ACZNO?4U5:MM=0\Z/V1_E'[15;YEA
M/H>NA/C^TD?6%.\DQ/\`2/4'>N:(?JFJ^7*A_,#]D?Y1^T56^983Z'I\?VDC
MZPIWDF)_I#O7-$/U35?+E0_F!^R/\H_:*K?,L)]#T^/[21]84[R3$_TAWKFB
M'ZIJOERH?S`_9'^4?M%5OF6$^AZ?']I(^L*=Y)B?Z0[US1#]4U7RY4/Y@?LC
M_*/VBJWS+"?0]/C^TD?6%.\DQ/\`2'>N:(?JFJ^7*A_,#]D?Y1^T56^983Z'
MI\?VDCZPIWDF)_I#O7-$/U35?+E0_F#:[AWSGVQM';<+6VRH$:S0[3$DI$DZ
MX`C#Y-;G#8TB<[,*-P<(:>!28S:V)LEY&78$C$)]M>&%2FW.S=%&F;$^(L4L
MX?Q"RBHM5-MPHLB!";8<I[T=M;RGI"62)*X;C:30\M1:S*^"61ZAN$?3FG#W
M/6#,)X+D8HPJ^Y2'Z.\VJ9%J=1=DLU2/)<;82Q%7(-2VY[3BDN,-MGJR&S>0
MI)K)I2<SGG;O6N7HB_;=/UPAIQ[=FV-8`K.-<D5DV_!U5N/;VKSZAN)MLM.+
M20"BZ32+-/*20-&$E"ML*U$5$1YOR;%CU4/$VHFV1GK6(^(]I$>XK;3W[`']
MU<H)%IE^-K,S(CRR(D'`EPCLLG&('+?3(%^HL:,T-J$HHF"3K1%N:7GR1<=V
M2U!/$-40=P@JS8#`T)X'_F+HW'8^/HYKVN0VY"\A3EG+\4)`BI"X-/Y'50Y9
MB4@F>=E66L28>N,7L6'@PAD!8,I'>[Y;$T_@[WG>QVT0@\AN?B?`#&:;:V>:
M3MR;;#3JP]TO+08=]&A=:QI=AJ%HV;6AA<C)S&`V`KK6Z:2!3`\H+&+22@&/
M.';_`*2W'M#9<[GQL5922ZFVV@:$E!DX+/,\K$?B(R,]V?S3XBXACE]U!(-C
M*Z'CZ^JY385AD"TY:\YR(FH"E3]MFZ+)AR":!9[,B!#KM4LQ>%9G)@Z::E,B
MY3='@"9)5P&#@MN=B\5SV7Y+;2RZ]@[['=41$2K!"<S4Q8Z2G4>5;WG!QP;7
MFI#%0XV$.2NQ'I`.6[8I=7\'5QK@W7XV<:-9N!)QW+Q@2)@K-2&P1P1[^/=O
M5JETF+1Y!]T%%Z0V19->.4R.^BG%`RCMCGV,<EI0-C&D3%O?4%\)!EA&&*UN
MH?@%9B<UT(LZ$)Q"3++28WC8$MZQ7OM([%_F_P!(B8SNFPLS-K@P7IHO)FV6
M[`]6Q%/6]`R(ULBQ;YLFA!PZ0T6JD`]"K*#53,'R!HJ`&6,>*6,AR*1@O(GP
MA0#:M?Y6\]G$1$9\?+RERB#&>ZQAR%#G6&C:D(1S!"GB[%5%7JPQ@X=,J?HV
MX[JG13J$18SLQZ!$J+P4'`JY`MYXR9.%-$Z\MB0TT$DUF5SWWZ2++ISN1<^T
M6UM[GR3T;MK;M2N6NH1JF4A\`BM3JX=5&LTV&N%H.#8IA*.49\GS)Z[?R6UY
M%%`QZ82(-/KM^M,XW/G015<FA"6]8DF1YG?BRX[?_2?.9$.[R$YD;&U/`U\5
MK]6UR[-L^IK'L^Q:_.'"Q"TUD*/JMA)XMI8\/4&K@NH5RP-4T1*CLMGK%>W#
MEG37X8`10#UIZ"$H([E<\C(KD66W=M.Y7MLM;/;80LOSDV_%KMBD1:9K+$X+
M7!TT:=\OP6H=GE"^1E_TK<3@NM7N^ZM!MC2=>U[-N6OJNC;\XJ;R:'0<GI*X
M^$D0L3:>,U;3+Q?))69D1[+V,[$60]*Z59(MQIM2M\%QQV%:JR!LD-UT?($N
MN13@J(3CN."Y;\J4-<6U*0I8^3)D2(:LYCO/NN-J<4&(RL9EN,R$FZ"`Z`'0
M`Z`'0`Z`'0`Z`+!UC^VR-_W2;_Z.>@LCYQ<_H,23D+^Y^W_.>N?V_'4EMYC]
M!C,)]0?VNPOS3?\`5Z@4=V\ZO2-?'OWQ-!_/6C^Z-@ZL7S5<WI%QMQU4!26T
M*B7LQ!M,,:Y.@NALP)64/LLXSAU^;AYKM6^RYC.67L??H[,X[[&4JPK'N4<;
M2ZVMI970XA3:RN972M)I45R,C*Y&97(R,N(P0XXR\T^T=G&5H=;58E:KC:R6
MD[&1D=E$1V,C(]AD9#4EKA)K]B&W`9U@XW';KU0JJ>RRE_#>0J)8FK55X2I.
M;!F0O(XY'CRW)*W52R"(\>&2?EPF6XZ=,3HZP<AI+":01-I@4JF%_;:AK]Q4
M2>FITUDW.ZN$/@)B$.J<-1NODA#4A;K2$H+L!>EG2"X^J0NNJ4ZNIUNL'>G4
MS4]\<14Q='J\@FNXN"3W53W76$M$@F8RG7'XK;+[BG3^5<):,NU2[BK7Q3RQ
M,L!>U9:1<C[06-9+#!?&V$U!KK5D0#A$#L60I!5^./0J6MMAU?8XPRI$'H[P
MB=3=JQTU[NMV=*J>J53JB8C=0G,N1YTQF`F84)E^:TX925ML%PIDA9_*0DRD
MM+&/$T=BA%56.X6*;"HY+51J,J>[2Z9(:E4R!(J:H"JA(C4YYI)PVW9*B92I
MQ!72XLE=8'P7UM7Q)T'"U=)DCK%5O,DBV:M]BL3S=3\91.2`$RCUG(R@`Y$]
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M5X-2TJX]>DK&1X@I6)FI\:)4Z'`D4NCIA4BDQ*=3($N/-C28T.D,044QI#S=
M1FFXKN0UFZ^I[6X5+:D3TEHA\O;ZS?"%3??M5/@'1E>)X*J:Q`A65N(T:9S"
M9)MCY?C:(,7&')D60['\%VQ5LY6YE7-R*-3955I];?CFNITIB;&@2.&?23#-
M0)I,M/`H<2P[PI,MEK/-N*;U?U9H,U7UR+B"L0J)5L.1I/!T>MR:=+J<3N>.
MLY+]*4^N`LI"V526>`5(>,TL/-(=U[/)<)*2+6_:G<]`&XMI6?8ER&'%P[M0
M-256QB`9TI4K!%MO'K9]FVGH;9U*V%3[57[12+9K\WL'8;$B2(=5)L44T%BR
MI\06`E"SW*#ABUBXCX^(^,L_N$.K_<E^--9L%9L@G3]N;F5CT>OI&R-W[@FU
M6U%]5;(N6XJ!9]ETJ7LUZH;7M]<VUL*Y;,B6K982U'G+V>DVF5/?,-1)<<'R
MMQ\?%O*PL^X=S^UU=(U_9F4^]U^9L[<4/?=P/4+<.Q]>6:;M.'J6MZ)Q88-C
MI5Z!&`D65J6IA:;/KH:7`K4V*S(*2!"S\R46=!9661Y<GC[1P;![G;I7:%+U
M;KJXZ93+H^D*QYIZAK(JUV*M#-<P(X8%7@I.IM5NT"EB+=40M='#J+=X[F+A
M1HZRF*D;#K-F53@?*+.QWO?8?M8^,=K</<_]8;XO-=V+LS71\O9:^/KP5_`O
M8EPJH*X5ZH7:'LFIUC9-7JUN#5S9=9K=]@M6D,!O(LZ,A$7RK2(WD\Z=A$@%
MK%L(^C\A4P3N2/&RNB"8@/JJ^Q\S&Z^R%,RM^;I,637K-5V;%W+7X^H[";VB
M2*ZBAP-HP(%U>@:VDUB`7+0("#D4G`AQH;0#UCXCZ.2WMU"QM"\!`G'>[VBV
M4(*08'$M>4G5U7`2R$LL]6:O6+EL_9]A($[19++8+)<KKLC:6X;O<[U<#4Y$
M\X]FOL3&9$X3*,%@'K'Q'XK<WH&U_F#;_4KWQB%]9Z"+'N/H,/,&W^I7OC$+
MZST"Q[CZ##S!M_J5[XQ"^L]`L>X^@Q5EUXS2=A6<!8+4&(SHM:!%A8L/&(-C
M$-$BEGHUL8LB2PTC%,Q#0`MKROR:W*&31[@N5XY.RN3+R/='<[3,03:1!EQ(
M'!M+FRH[[\A:$/FIEB#5("H9QWD+C.1I<>KRT3$/MO$^WP;1$AOADO<-4*#%
MJDR-*FDXXB)&?89CI4MDDNOS:;.3+)]I2'T2(K]*BKAK9<:-A?".76YP2F>K
M!XEUH7#BPA>OY@M,$BV7A31EJ.#S,0NU3YU!05CGH=D9-LD_-$G/#J(-D$RU
MHE.RUO*GJ\;QD=Q577W''7YJ7S=9..ZV]#@O1G(YU%JK''7$<C*BJ8]\&&9!
M,FR;9&VELDDS^K&-K#-&9;0VS"6R33Q2&W&94UJ0A\J>Y2B?1*1(3)2]W`\[
M'X4G269+-PU<+\L=)KAW46&X:(^OR<58L;7Q`&7%NMGBDJL/K,=<45'II2/:
MVR5,[YAV0@N]590A^Q9ES5V%THY.EK>R*Q?B%9N&N<VX3[TN1*;<I]-<9G/3
MEDX^NHL+AJ9J5EI0<=,]N0B%P;10TL$TV2:)PK1$D@D0G4&RU%8C+1-J*'83
M4-!H813WDRB>I]TFHGSA+CJEZ[ARS>-QPU2T?Q_:K)5VVB:)(S88\.RI\?04
M7/*RTV=-1=L3>721EW$J6<<H%0\.]+<RZX^'CK\.TI^:N1\+E6J4]I%.D34I
MANO02-"VVF8S)PCJ"(:U$PSK-M1"JU0,DM),B1(66HO4:)/U>]D&GJ=J4>`Z
M[+98G++@5./2Y'=282Y33?=#Q(<?EG2X"2-UQ.LXPB[B-=Q2J)T=Q.V4$VSM
M[DALL$VULW;>18$57XA$;.CZ[UE6VV&`55\HQY2HLXX45#AE[?)@./"EEH\=
MH6\^RP[-F[[CG&5.EX;PIH_PRMU[#>$T2)4FI.M+CKQ#B.H+<=J%53&=)+T>
M`P;SL6DM24HEIAJ4J4AM:R99ZJT9X#KD+$^-=)^-&68N+L<OQ8T6BQWVYC6$
M\)TMMN/2:&N:P:H\NJ/ML,3*\_#6Y3U5!)(@NO--G)D;9^8-O]2O?&(7UGKJ
ML=UV/<?08>8-O]2O?&(7UGH%CW'T&*AE<0=<SK6;O<[06MYETLBQ[M@M4NG4
MZ2?,OBB5=,#I!(H]'7,ER8A:H5(DS)>=6^F=5:U*RYEX"*7$";*W*ZQ^5OA_
MKBGG56>J:!UM6[(JQ+MWEX)3J:,,-V=8ZV"%GF2,2,U+CE<B[[>8'CC#K;V(
MMTMK.%818S&)H+*_YNL?I3B!KDX?MEJ,Z#UP5LU\$N`KI8"%0I\LS:@[S8AI
M\>>(OQURRD:0U7Z^W(1+==\.BO@4NY6D*,Q%!96Y76)2QQX%Q:H#HD?5E89I
M58FULE7:DV&KJ:X#(TXZ/M%3("@V,>3X$^M642,L(.9&CMR19P?"+0W69\9F
M0@(LK<?08Z%HXR5J[Q;'"N&GZ=9XMP?!2K4R=`5DFFQ2ZQA&*U*-9EH=41E5
M_"$8"29677A>$XQ!6QC'0+*W'T&,>YQ-H;L>5$<T1KE<2=&(0ID55.IGBTJ&
M6"5:M%(C['BO@G8Q&NT>E@9K"T9:DAZE6AKR%PP@UF,$V5N5UB=@=/D*L.\D
M5FE#Z\*\?,%?)H2.'%P/*=A,3K`>(^*0G&6/'C1XH2-%97@_#D"I":0EK=E2
MGG5A%CW'T&,SY@V_U*]\8A?6>@6/<?08IHSP[U_8(SL0SIBLSV'9MY)YP[%@
M)=:*[*LPRZ7DM%D-2VY$(K8K>$#V>83B.L3VSPL>5B2(\V&P\V"RMQ]!\0Z\
M/AAK4?'A1(6CZE'CCVX;<1MN`-QX+$&J72CQW%+S*RX])Q4]C7P(]+?4Y*E1
M+:>S*>>?(R'5A-E;CZ/;<0D,'BY6QM?Q58&J@<6N8ME5O6`S3$#$#%PHY*LF
M*A8DL9E92DI72E,JL\7(QV9C20(YU..^8QVA%E;CZ!6Y#N?NBRH:+7IW'&@.
M@X0Z.'CBD"!<>"D-%"F:ZV&7'C2F4/!UA+":&R1+V'!\R-/=3+C/J2TIL)^5
M_P`W0?M[7$:VEW.?6^S:E.JC-";HGE,HDJ1.U0+K<H:FN*L6Q;=+9D8V'6;T
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M+L(3BG\5ZOK^R&K=2=4`JQ83[#D4D1$,P(F<Q)$IF=-B0(J)?B0>*3(1XY(O
M&#QH#!@G'CDBC<N<PU(0$65N/K%H>8-O]2O?&(7UGH%CW'T&-8N2'"#4')1-
M,1R!UK.MF*6JQ+J7B][NU1S`S8\`L'N_S0K?7/*&)7D$-WN"OCGBGBZO$O%_
M&9?AM>KV$Z#B?N3W[IY3NX>'[EN])9X+NK@>'_\`=WFM;7[G9^?K6U/DVNJ^
MY82T@8NP)[X%A>JG2_?7N7N[^Q0)?#]P]T]S?^_19/!\%W7(_P#*U-?A/EZV
MJC5U?_8>^"'XA2_]-^^O_=;K7OBHP']0)_C:EZV-R[X#2UX5GY'H/X8'[#WP
M0_$*7_IOWU_[K=/BHP']0)_C:EZV'?`:6O"L_(]!_#`_8>^"'XA2_P#3?OK_
M`-UNGQ48#^H$_P`;4O6P[X#2UX5GY'H/X8'[#WP0_$*7_IOWU_[K=/BHP']0
M)_C:EZV'?`:6O"L_(]!_#`_8>^"'XA2_]-^^O_=;I\5&`_J!/\;4O6P[X#2U
MX5GY'H/X8'[#WP0_$*7_`*;]]?\`NMT^*C`?U`G^-J7K8=\!I:\*S\CT'\,&
MQO'S@]HKC/*LT_1>KEU.?8H49!^?+N-SN,YT<.=4ZW'C2[W:[)(&1,O.H=EQ
MA+D-N>ZS#<FMR5P8BF.;H6"\-8:D/2Z-26H<J0RF.X_PDA]TV"7PG`H7)==-
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M>SP?WO2Q[CZ#$#'8U\)PM3F*D#PXM]^4MS`L5A:Y,EV"])D*5AKOE/R'A8UU
M]W.<N.NCH+CBE*B1\MK'N/H,+GO&+]$5.[UE'HZI_>1H'DJ.CS;K_>L"^]F)
M\FLI\5[&H'>D2"?$T83'[V?,QX/LE/\`?K'N/H,3<]Y]([B=:5]"Y#J*36T.
M2XT:%*<2%#)7)APADX+#B2%X8PIZ-$#DR0F,PYE33`PA.@-(1%EOM.+'N/H,
M+GO/VS](QK&G*A'/VBTHH@%RQW60/DVDS)@09D\TX*%B0HY,I^7X=6&(@T$(
M89BL^"C85`9DY9S*[]Y35/<?0%SRS/+9U]IC+LZJ!@_`P(M%K8O`Q^*Y&BPP
MH.,U!D07?&83L9$9E+3#L-]7AXKC/>JCO9RZRI"^U72Q[CZ`N>\]PZ;FJ:JZ
ME]#M`JCJ)*Q+DE+E?!+3(<`0U#@2WTJC9PZL*/6N")4YA2AT-2HL/++"LHRL
M>X^@PN>\^D9&=01920W+)U0*1E,R7)C,F<,%RY#4MX<L.[*;>D-N.(DNB7%B
MW'TJPZL<M<)2LQE9:RL>X^@PN>\_;/TYC@(:X!EY<0@6IM>)SX$-X?!FD`X>
M;+A0)#3K#\&))DLNO1X;[+[[+T9E:&7&GG6UH4AQ>,K'N/H,+GO/>/F1K4#+
M%)!2J57)(1`Z"(0&D!0SPI(D6\B0-%I'N,*B)'#I#33\&%AG$:(\VAV.TVM"
M586/<?08BY[Q)<!R./<Q%5C&/<QC"VO<_P#]^ECW'T&`>2"/O57Z[7TG2Q[C
MZ#`<V0!=+").82\,..+:0YX1GL4XVE*EI[/"]]C*4K3GMSC&,]ON9SV9[%CW
M'T`.'R01]ZJ_7:^DZ6/<?08!Y((^]5?KM?2=+'N/H,`\D$?>JOUVOI.ECW'T
M&`>2"/O57Z[7TG2Q[CZ#`/)!'WJK]=KZ3I8]Q]!@'D@C[U5^NU])TL>X^@P$
M\UP/F1[1'=>8RAO$69C*LJ;S[N6<XQ[B59S[N?\`LZ6,MI&+(^<7/Z!E^0O[
MG[?\YZY_;\="V\Q^@QF$^H/[787YIO\`J]0*.[>=7I&OCW[XF@_GK1_=&P=6
M+YJN;TBXVXZJ`H3;EF*UV9XQ"(3HT>*`<(.QXDE;.'51W9ZUY[$JPGPBT,I1
MA6?XD]ON8ZQ/NDPR\\9&HF6G'326TR;0:S(KY7,BL0NPTJ1)CQD*)!R'FF24
M97)*G7";)1\=B-1&=N(AYL0NZ-CYVOJ7?&A-[QFX;"50,`5%XGCXAQ,<)*\M
MS7O"^`4-4Q9:\MO#>,.K\K1N]_UL95TXSIJH[U"I%;32*B7OM7CH90C<C\/%
M43<-WNQY=]0XYHJ,`TZORC[J;MM*_?\`(]SQB&/B:O8<77Z294/#)8D]\28D
M]S3DF[4&?>^.W;A$RB<I-32HU70GN)V^P[62)YB68U9"T0=3=E3**//WVIL;
M'AS8\T,]8=>0),LR@B.BOND`8.=(AR184^0QB+/(I:84S'\+E2-ABZ0N[*A*
M:CX<K#M&8G5NEHK[7`O1%3Z"PX[+*0PTI;\.&\XRY&ASG[-OODE!I;UKIU6;
MHJ5`I<)Z5B^@L8ADTW#E9<PL^3[$Y%,Q/):8@JBRGDHC5"H1VGVID^FQKO1X
MQK<)3FJ6M#!/=!&\5Z19+H`V)2H$G6:]K553Q<*<Q<*V@M`!>*BU"RV?$SKA
M4H.CM"RZ8*O!RL27W6&4]\KB(NE^F=P+J%7HE5I##F'CQ-3#6Y`F%5:>4IB%
MP<8XTD^!FJDR8[:8TLF#U72<6M""N?.S=`U:]\VZ70<242O2&L6)P=6"0Q4J
M>=#JBH4BH<-+3+B?KZ<F'#E.*EPCD%KM&TVAQ9V+,O\`.4A'E+JZJILI6SXU
MBL(&;K=)FM9(Q&ZQ4(M[+&LG?.'S>>%HKLV*N+X*>J;*).X'MQ.WL?S]B]*,
M5#BJ<>'ZP>(VY\^"]A\G:7W0V5.I3=:E2^[.[NX%QB@/-&V:7S>=D+)A+5[+
M/X&]#$]QI-7+%=!+"3M,IM1CXI./6.Y7EU:MO8>A0"IY4TZDB8JIQWB=UXY,
M,Q4')4]:[9?`?GR$L!`&H*UL*94B9?7-:)754H4P-KUHVD*:+5<*1'.&\F)&
M66Y$>*=GCX<J`)G.^!R])2AQU-8FEJA3WX9PX%4>I<F50*?(JYIAMQX%2Q+&
M3*IL.1'5+[J6:4N-M37V&G6(KRM37<(E**T[09B>F1J@F?5:,Q6HD'%%5BT$
MCGN2JG2<(3%PJM/BRDP>XFR<6VX]3H\E]F1,83PG!M&I*3DO(/G?J+BW$?F[
MKV=<@$:#6Y=S-+K.OMN[175Z;"?=B/W"YL:II=V?I54S+CRXL>R6QL,%F2H)
M"/$G/O#YJ&.U!TCK*W^@O2(G6NZ2:#M.QP6IH6T=E"+Y8BM>KP\3=M+\@]<P
MH]JMU4FWBJTL[8]@:SK-8J][LE2'33P*BV8R(MY6`PI<$*^M2$*";KVW]!BX
M=/<L*#OX/>;!J';*KH&UML>W:DNY&(LX-C@=@T54/SG`OJ-PAF92(+)$=.BF
M1Z98$P+(02P0H1&3(\MP(UE;^HAGMI<B`>EJ&?V7LG8!(#3JR^(A%)\9H_8I
MZBMB-"JU6P`FNUB"9LEALUEL9T)7JW6*^()V"P'3`L0'&S2$^+'=!K*W]1#5
MZ'W5/BU-)`1*-YV^+,.>+IE9*:JWN'A461)VK8='-#]PE2NNH8K1I7TNU2P:
M^<$[DFT4DS91RH+L5&9$1<@)NO?Z/'Z!/JQW0C05RN\G75=WNY-MC%N9H[,-
M\7>!@TL?D'[I4&?-RR%:_!K-I!+NVO;A0/.VMF"M3QL03C7ZC>+F1%`YP+K+
MCW;N,;5>=MG]?%?CK_\`CZ"-=6_J+L#SML_KXK\=?_Q]`UU;^HNP/.VS^OBO
MQU__`!]`UU;^HNP/.VS^OBOQU_\`Q]`UU;^HNP/.VS^OBOQU_P#Q]`UU;^HN
MP/.VS^OBOQU__'T#75OZB[`\[;/Z^*_'7_\`'T#75OZB[`\[;/Z^*_'7_P#'
MT#75OZB[`\[;/Z^*_'7_`/'T#75OZB[`\[;/Z^*_'7_\?0-=6_J+L#SML_KX
MK\=?_P`?0-=6_J+L#SML_KXK\=?_`,?0-=6_J+L&GV.Z*:AR<36?/VXXL*HJ
M9.`RA19,[OE<EL<1\PO!Y5A.)[>],XJKL7*^_;:S@DK.(F>^Z";JW^C=?=QV
MR$XN'.#2E+UZ>V=/Y$4DK50-<OMF\+6=BURQ3ST3609H[=8%4'C#3[]E-@H,
MD?B:'$XDSH\DJ)CR&F7"4/#H-9?L1=@R3?,;5[NS).HVMW`'+Q`#DBQ48W<Q
M*T!GA#\=N?7S+R2F?)5K8C/J*JK4Y#);`6)/+9C8@PI#R`77MSMXB[!WB/+7
M70J>S&G[KK,86JED;],M;VP*TS40]:@.ZY3'G&3KQYN,/:-1=JT@H"DNI\0)
M"S<":B8ALD(\H@UE\N[9^0_=<<LJ#M6/5\T_;XR65N88E8ZS595I'P[D7KHH
MN5!R[!"JKA')J2#\?"D4-%H\1V`ZW'6ZF1WN%=Z`U*+CZOR%T>=MG]?%?CK_
M`/CZ"-=6_J+L#SML_KXK\=?_`,?0-=6_J+L&M83F[1#!Z\#)-QME7KU`D7B$
M8V==(TNJ:G?(:RO4/6>PAL38!B1&!L$*I?9S%9E1#+PETK,Q)DUI)L9!FSHX
M3K*W\V5_;V/B';9YK:V>LA^O*VJB+%K$-PF:N)"Q"QU#BAT4*D[*0=;MDXNP
M,F`7ZCL"MDFS<)<@6C$AW$B4PA#;CP+JW\UL^,MW((L>Y\4H1KJJ;6%3]I7J
MC7399G4@$WK\#+M,>3=!6V).DX43OX<]#68%IV+&R&J)5EQZ"<:>CSV'D0WD
M.]`NO?R\6ZXM*;RMUJ'`0;-8]]TBJ!YXT*51*M.RZP":8BV%BP/B,R7YYQJ,
MTJ>FI6U$7L?6W*<JEE3&<>P")YC`UE;-O-^0[</E'K8BJOH'\@M?SEVRQ$:A
M54P]H5B2JS6T._%BEJO7TL&EY,V(7)G0HY$(.Q))0GYD5F3&:<D-)6$:R_8O
MR'Y7.4>MK@:%5NI<@]?6FQ'8\B6$`US:%7-FC,6)&?F2I(H6,-2IQ"/&B19,
MJ0]$8>;9C1WWW%)::<4D&LK?U%V"UO.VS^OBOQU__'T#75OZB[`\[;/Z^*_'
M7_\`'T#75OZB[`\[;/Z^*_'7_P#'T#75OZB[`\[;/Z^*_'7_`/'T#75OZB[!
MKUOKEA2]#8J:MI'K1_\`A7D]@%Y-@R3/^P<!<D_#=Z^WXM_MH=X+M[[PW^D_
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M?LFW''U]?/FK+^N=.^%T>?M-7\E+_F!WJFE?]GH/EEO^2+FTMS`U/OLT4KE`
MLIE9P4/25<&'($@1)F#_``V(\B2.2ZZZF6F"ZY&3-0A276<2X[F$+;RXMK;<
M(:4L*8VF2:?1)D@YD9@I)QYD8XKCK&N3;BV"4I1.DRI39.D1DI!.H58R-1IT
M3'NAC'6CBGQ*KB*%%][Y<DX92J?+3,:8D:G"-MRC2E!LF^E+G`*,C2LVG$FI
M*B22MEFRQ-KPG@I\I'A6U,N=Z\O'?M+[,J;5V9]U*LIQVX_!GLQUV%K&?'LS
MXAU0*0`\G=.6:XS]?A=K@)=T&G2=:E5Q<^1#)^6@YBRUTC$BLSFHV)Z(UBIM
MMKV9D%<F"Z>K)X*Q)<)BIT5AKJW]1"VJJU[9"T_/$=WO?^<X_O,-DGN^\L1>
M]\"&<PT7=[[QCL\&*=SALDOM[V"YG")66E9[.FNK?U%V"MCW#%S=F5@=9*Q3
M9UV#Q;9=(I2=4JTZ;BI.6(>$B8G%R(@7X?,R<.&15-NSI[#*X<;P\9#KR7),
M=#C75OZB[`L>9\1;1BR.Y*4(!3+*5N\(<$'/RHY&?,DR(Z!N81%T3,?(LNMI
MDP($6<RXB02ELLCVF,8F+E)A+1(4UU;^HNP3JJW'T>WMD.'TW:^Q74VUW8P*
M-6G'F&&34TPU`@/YE'H=7AO1GIBV,28<ZP$1XF!/8PY!G2Y\)$20]B4PIQKJ
MW]1=@G55>UL_8_0)"-V$#+#(1>%:HBAY"&+(1G9$[Q%S,4W&5,$K?BSE1I<1
M9",A;L9B6PP^XEMW&&N^:<PEKJW]1=@BQ[C_`-A^'-B`JTN*V=MD$6[,+!`<
M5F410A]TO8R,42"@X8PM3J7BA*=#AQ,K0E#CTEE/?XPO&>FLK?Z`(C/87L69
MC(.7H?)[V6[;A[V)47))$E1N(M,B#X1EC,]#OC.<.Q/#2([.92<Y9\(^RWW_
M`'SJ,*$HRR(_0&9GLS\0P]CV=6*@"-V:RW44&`UP?DL=)S2[*(PP=B$\2Q+E
M92ZI:&W($=^8QV(RJ1':<=82XA.<]-=6_J+L`DF>1$8XH>U*J0LMDIT.Z#WK
M+3W!#%F$8(=Y(#RCPF2?%0I2G,H8\H2@41TUF`VZY-CB51R,IAB'+B//M=6_
MJ+L"QY';;LZ;>G(1FZ<B-4:Z(0!=YVO5:M.)A2UBA,F;!&B)="!!Y<J1)K?6
M[XNQ%:'5\_+87(=:S.:`F\P,2<B"&(S75OZB[!))4>PC/V+M+I(85?*K1K8^
M42]-%/=CP!-;.$&HU@:ED1PVX6)=1K#Q$1&4\5@/&[2T_7H$*9"9G.F8LP=X
MMB5#E-LM=6_J+L#55NWET%<^H7;&,R)D>/+C3WW8\IEJ0P[AQU.'&7VTNM+Q
MA7>JQA:%)5C"DX5CM[,XQGW.FNK?U%V"HYO*$[WW(^%7_P`^FNK?U%V`.3)8
MGEI+&9\K+*%J<0WE]?>)6O"4J7A/;V84K"4XSG^'&,=OX.FLK;?T`./RA.]]
MR/A5_P#/IKJW]1=@!Y0G>^Y'PJ_^?375OZB[`#RA.]]R/A5_\^FNK?U%V`'E
M"=[[D?"K_P"?375OZB[`#RA.]]R/A5_\^FNK?U%V`'E"=[[D?"K_`.?375OZ
MB[`$]UK+E/6J,AV0\XC,69G*5N*4GMPSGLSV9SV>YU!J,]IBR/G%SC.<A?W/
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M#3:(_=+G`MUB'5<.JK<I"NYKV<I&&8+3#AE=UQ2T*2V1FL_7$O3]A.1,D.)C
MU=*9%>Q@ZY*[D9X=[#\ZAXL1AV&M/=9V4U7L85!^2UK&EEIM#B7'#)+13F)Q
MIW*-M$6`/Q78]3![+VG:8MCCWFQ19UAJ6QH9V5!KA2F,C$A?&@QHDVZ0(RY4
MAU[LCH'=D=A_+W--:/<61JDTRQW`BEPL18EJ;<]NM5!MZ=2Z^U-=9I\BD)CE
M#X2',D)4_(==<4NR"CV0A>OK[VE?`LJD/29)U1RM5#"F$*.]2W</4QZ/3:UA
M=^G,R*I$KJY9S^!G0(JT18K+32&[N*D_K7$$B*O<0]S7+7HZKVM=$K<N@Z/]
M&=)0,L14]BP6-%MKEIR;.ON5L4V#$O-UJ.+3!BH,2FG);LQ3ZT,I9<XQ>BS%
MM7H4>FU,Z+3W:)@WX.T@H]0E32G5`JI3ZD<R:X=.BE#BK33FXQ,ME+<0IU3I
MK4E.HKET:;,"T+$LNKT8L155G$FD`\5U]4NEPZ<=,I:J+5*.5/IS::K,54)B
M%55V6<ATX+2TLI9)M*EFM,KF<>=UN;(F;\9"T[-S+62^*?UZNX2<0H%=MFK@
MVOQTGSJ\V\L228\B%05FQ$"D,O#G_`,2_&^^0GDWL"8O5B!W&Z(E)]]Y-0K9
MKH1U5S@&8%3PW#H4=SWS][]5R0S(AE*>:3&2E;"R0AWA=8D\,SI-P"G"S&CA
MR?7"H,*E8<)O$R:(T<B15*-B^=B24U[S^^A.-19$2>J''?.6I:)2.$=9X'54
M<=$<+;B((Z^!-0JTT'#$]*G[1<15YN,-LC-UQ#:S84S]>/-.`#)^5(94(JEA
M2@<B"`DN.$(R2:GW'?@BZ(JM%?H4)+-/3$B2,(3JE5HM:JS*7WL/LI.?PU!6
ME4&7.=<0<2F3R3')F"X:GVRDFXI?*3=/-"FQL2U%;]57-G1,>TVD4.9A^B/K
MBL8I?65-./B9"TU&#3F6EE-K%,-4DWZDTE,9XXA-H3"^7'&O:^Y[KW0C7]4&
MI<D<KNY\:BU;J.UG4D8M+%W'6%WY.1K?4;%888XDQ7L=N]Z#9!33K2IY]@C:
M7QL&8U4R3D?T8/)1'LY%7]'8*HY`\'>5EAYB;)Y%:9%T/$MS:>G]S:SLMTWG
M?XU48EZJXX%]6$ZA8>.K-6.ZR.6FWG2#H4#M8HANU:Y!$Y5DKYEJ:,9KQ4!&
M6P]UNN^WDR$QXF<"-Y<5=6<F]26,EK/DC3MN<9=/A@P"SQGZ,)N&]*CIZT:0
MV-6]F,1&3JYU1V#3*SI>,;V0VMZQ&<,VEV?6428<#QX!F1F7C/=L,[^U[C]U
M_P`#-\ZYX!`..;I6D7W>.HN5.K.18N^E;+88D/D=)T_RJU[R2AD=CFRP^QGJ
MS<;I7:JK64B1*\Y1P`@&!$A^8U58@`A0#,KW+C(\MV5OS%:;8X;<Y-Y6K;I*
MTT_CO687)[2]7TU;)0*_&H&=(U0#RQVOM=B6H?#U[-SMW83&G[B"9GF8LJE"
MC6UTD4YF0ZZPR>D`(RM;/;?BW;.GJ'UMKBUREM>[#FP;%1ZJ`E;)VCPRHD!R
M@7*Y[&$JB\>N<H#DBG;E=&64+E'&ZGA./U#/2K=31AR#6M@[XL"&I,,@?EB+
M+;`@ON/=QE;G]LA[P=!`=`#H`=`#H`=`#H`=`#H`=`#H`=`'D[:.YB-6K;UC
MV-*VNY##63<MMN\@%"KF43XFN;2TO8*Z!$***Y;1+A<EW%;G9,*B98R[A`_R
M?B5CRAT%K\F[Q7*V=N6WI'68[FS92`K9:K/LRF/6&_\`%[?7'.,L)0Y\0#79
M.T-+\5](U>\0(,ZQ39>)H@'QNE%+!#:EL.S$71FN#R#$&N9(&@:VS+89'T&9
M\A<8Z]S[FG;KA'O@S.W:P(B3R.U)>NST"CD\V\`C<O)B;R!N3MD(JM"8Q>9'
M#6N\ZP".0(XY+(PE$/R\OR7)@S`-8K=%]G$5BL=N?D,<L/N9QJO/5LM6=HU[
M!FD6HS9JQ&*TZ=D"]$`;LX<7G3%3+Q81]J1Y#I>JN'%-U:3>A.MOR)<]FT"V
M(:1*`\L&MR>UCOTW/\Q-]!<`#6G-J4+81>_@;4S4YSEJDQ8L"_`V8UN50=H:
MU4W5:HSL-^A#1+P#9+\ILH<KMBLPS+!<+!G>)GDSA0+Y&6_MONS'IOT%0Z`/
M,6R<%-C%]K']H#-F4$$^F_-[('APE"+5T5M"P"=[Z[W%1)&]08.S1*J<L&MJ
M[1YVKJ_L,!78=W,PK&NWV8B0(#W0Q4+$>5K7].[+JZ.45BQW+FPCQC+,'<0-
MTD/P',P%2Z1.P(=M`&O<>VX<:4/:LV7FZ?*L^C7?#B&9CDN-4K&T':FORQ:I
MDX%[G?Q]=^/GW#;(3Q7L+6B:?JDO<P"CP+E+`Y)EC06MS!X"2IKF+*Y4S:H'
M"2#$N6.CJCRUTV!+D$YF(RT-E'&'V\9AY"+Y\UO^VPUA']S6N:WH6#VV:C+A
M@*DFA5UF!1BK3JJZ.U/SKUF'FFE3;1+:?.+=YBP3I#,)J)!0BDRQ<5K*BK)*
M,$ZW';V^3V"3?L=M@C6XB<'[-KK0FU6.FOV>"_3YV9PVLTV7Q2.1VZ;)8/-1
MAUBGFN-#S#TZ;&D0F8ML$DT1G)M-3#L`+VYN;?N\?YB7Z?X,G]26SC(8%7BK
M-#-&ZEUMKNX*%5LY`(;'E:^HFT:GE^:&?LLVEM^4"^RG+.&MCE?SL*I)8M5;
MB60D$V`5;'`,]O+?H/\`(K<_3Z/]!4.@!T`.@#S;[H7QAWSR0;U!C2$G4\=5
M,7L#-GQM"P6T%A:;&FD>1<@\U>HVKQK*<@2WE+$[Q'P';`\6\9\,_P"+],Z7
M-&U0TA?!_N"7%B^]'OMPO=+CB-?N_P![>#U-2._?5[B7K7U+:R;:USU?1>@+
M2]0M%18L*M0ZE+]_3H7<WO>Q'?X/WL]^.&X;AYD35UO?!K@]7A-;57K:EBUO
M-;]C!Y[>L>)W](.VO_:+KIKO;<0?6M,_?O\`J`]$]]Y@7ZHQ)_`P/Q@/V,'G
MMZQXG?T@[:_]HNG>VX@^M:9^_?\`4`[[S`OU1B3^!@?C`?L8//;UCQ._I!VU
M_P"T73O;<0?6M,_?O^H!WWF!?JC$G\#`_&`_8P>>WK'B=_2#MK_VBZ=[;B#Z
MUIG[]_U`.^\P+]48D_@8'XP'[&#SV]8\3OZ0=M?^T73O;<0?6M,_?O\`J`=]
MY@7ZHQ)_`P/Q@;L<'.!VY-,[,E[+W^4U@],KT!;-`':IL5Q+M.D2\6<-,S[*
M]9*K4\ML0Q;ZHXZ!%00:FOD'9,M4;`YAJ9V!HUT(R,(8D;Q#5I[$E4&.\FGL
M0W7C_M4E"F''GU&S'(VVXRWD)9^63CCQ+5JDR27.IM,ONC:9CO""\*X;ILZ,
MBI2F5U>35(T5!E#AN-R68\-+<J8?#/2VVG')!FTIEI@VT:YR#4SZZ]>BQY$'
MGG8NYTZML#OE59A]NUR-K[2VF1M4X3Y<(OO[`VI?]I`J^.:+EY,>N"M?D=BV
M&.";KZ1\>1/(&+(["CFCY5]\,G"'S6(MNXB+=QV^X46,[DV)ALIQ+W(S)E8E
MBISTN#K>8%S+6#H(BFPQ:XT#9F(@>OEB`MRP6&'3V:L5AQ"1:CZR.ZQHQRQ@
M386X7_EYK]>STWWG<[&6^U4X[AZE`XS#H)Q[$;C769-:#L-P7<,'XTG7GH_Q
MW^9Q0C-%QXT?LG1(RYQ=YM*&H3LQ_",RE!C-5];_`)COXL[[NP:>SNY;T(D4
MN967L2>Y(O%GV4>+NYIH94IP=L:S:`LSM<>E.D'%S!@1_17@8+<I*V',W4Q(
M5$:7&[R<%^%/=Q$7'Q$HK]?4(^ON5XMZ;69LC;(>3YMPH6&H#NHHR1#Q"#?+
MGL9F/D<Q?66W:DFQ6B!XK7"ZS)$1!#RXX&S"7+$3D)">%_Y>ODMNVVOGR[,B
M''([DU2)PQ@,2VC)G08%++5."Z[0!*R4F2:XQG.."CECFR#DAL](J^"`V[:Z
M9Q%'+I4J"0!QY9!DLT3%#SR`W3XBMG?;_P`VMNX^/?N$_P!P=S[F;LW)M;9A
MK882H1+4[`33\@Z,-LEF:;Q6="P)RKE-LKF`Q@-$-:7R^'H[P@H#5Y8>,%9D
MMV0X$BA"7-5)$17,K\?^+G_O;Q&0'<L:0.F58@9OS!J17MC5B]R&,4-"H146
M`WW:M^2J&^NRVZVFW:L4,6I\`MDP=./I&#X,R>LL1P\\Z`W3,K6W\>\M6^1$
M6S=81-GN1M0B5YD'&VP]*>C`JG6VBU@HTFPOO#06CK;I*9(E#9U_P"9-0X5M
MDG]=EP8L$[0Y,5N!,:M[3STG(LLA/#'NW\>\R/=S'OY!=^^.YY5/>%]NE\=N
M_FS/OLMMTYXO2QQ(@Q&BL<?G861!=18>]$+-%./`%AXK,CD4/4ZY7^J-#XSY
MJ(?&A5+AI(BM>VS/Q[?\Q]!"7;AX7M;2&4*HP;L!JVNM?ZT)TD)34:Z5+8&V
MF0`GUX-L@(X'NM6%13-='3Y0\6(/`+0&A"R]H9$LB25@<,1`)<L9G:YF=[WX
MMV9'R;+;"W6&"-\$(!>KEA+MZ"$#)X"[",O6K64&U4Z98"V\+QO:QF\4V7:(
MLIB$]9[^8CU@4U:?'ZNU!!R<V`P]!DIG!/"9WMQ\1V/81$5['Q%Z1O'4P&*I
M5:S5\%"IS%;KX8!@T=E>.FS&`XZ,.P4,3.]1XV5(>+>-D)7>)\/+>>=[U/?]
MF`Q'T>(2#H`=`#H`=`#H`=`#H`=`%@ZQ_;9&_P"Z3?\`T<]!9'SBY_08DG(7
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M`]Z,?!XZ:B=W6?:`>3H'O1CX/'343NZS[0#R=`]Z,?!XZ:B=W6?:`>3H'O1C
MX/'343NZS[0&6%"!CV"?A8,9?@A,MYOOFDY[QU"F>]<3[GN*3VY[,_\`;GJI
MI(K9;5$7&+)X_P#"8Q/DZ![T8^#QU;43NZS[14/)T#WHQ\'CIJ)W=9]H!Y.@
M>]&/@\=-1.[K/M`/)T#WHQ\'CIJ)W=9]H!Y.@>]&/@\=-1.[K/M`/)T#WHQ\
M'CIJ)W=9]H#]P-@=N/\`HC'X<?\`[O'353N](#*G!`N.7GLLP8S33;^4H;0T
MG"4I[U.>S&/X,>[U5*2,B,R].\2>T_&8Q/DZ![T8^#QU;43NZS[1`>3H'O1C
MX/'343NZS[0#R=`]Z,?!XZ:B=W6?:`>3H'O1CX/'343NZS[0#R=`]Z,?!XZ:
MB=W6?:`>3H'O1CX/'343NZS[0&7=$"\!(;^($;#RR$QM;F&D]^IM#,92$9S_
M``I3E2LXQ_!G.>HU4W/+B+C/E$\1>,_N&(\G0/>C'P>.IU$[NL^T0'DZ![T8
M^#QTU$[NL^T`\G0/>C'P>.FHG=UGV@'DZ![T8^#QTU$[NL^T`\G0/>C'P>.F
MHG=UGV@'DZ![T8^#QTU$[NL^T!+:3#BLGF7&H[3:\1Y.,*0C&,]F6\XSCMQ_
M'U5:2(LBXQ=&WF[!U.0O[G[?\YZY_;\=4+;S'Z#&43Z@_M=A?FF_ZO4"CNWG
M5Z1KX]^^)H/YZT?W1L'5B^:KF](N-N.J@-%.>N][1I77=4CT&\A=?7BY6`XD
M78#T<%)'M#*;2;);Y\%;=BC2QGA;"7'5RH1U*8S(3(LK68:T2_`=]F902E'=
M)J(B*Y$>\R+B,CR*Y\P^>0X:$EJJ)*E&=C.VQ*3,]N\[%OSRS$#V]R8O>,%+
M)KJS^2*T7[G[L+D)6HR18`CB%>(IND^;1S+Y(7,??=&#3DR(L5)<=#OK<4N<
M,>?:;6W9#99$HL^&)!YGLL=RR/>6WK%5NJVI.Q''4X61'\JZ;'Q[",\KF0G!
MPYM^1R!XV`H.ZK4'J&TM>V>ZV>IPZMK"1`5,UV*UQ)<'Q"1&C3;#'@VUZQE%
M'<H,8E1?"H37Y`=+36$4(DZBSU",TJ(B.ZO[VMQ7ME8K9>,6NO7:+A#(EI-1
MD24?W20>TTF?RKG?/Q6$&IF[-MS]Y5V81N\R;4;=REW]Q_=UFH)6&@@:KZOJ
M]AFUJP#",<(W;<6)9.M*)&Y1"P3QLV"8\48'0FXT5[%C0G4/*QDVA>MG<S49
M7*U[6SL5B*QD*DM>NDS5DIYQO4L5M5)'8RRO>Y7O<]MMPK(YR>WD+U)Q<OB+
MLGQBP;?W:[M=YVNU7P=BUCJ>_7-\D)<3@(EH,F#0JQ(CX*!4#2/;%3,E3'9*
MGI"[\&C6=+5V)1JYGDI9$5]N?RCV'XA4W7"0TK6VK<U\BS0A:LMA6LDMI6/(
M8:!R2Y)VG0>]K2%OOB-UD;YTZ$U$0Q5:<M-:HFZW-=G*T$Q!E5]R$50W7[U%
MC>4#L<B57A7AU3O#]ZXEP;9+01E<M11JS45U)N1GMN69;"R$$ZZ;:U$KY7"(
M)!V3DE>H9%LML5M,C,?M=Y?;FO,?DM=PUNP/J`?BA*V;J@8BNUES-=MX`"*%
MV`TY*E!79A-]J^Q+7%<$F79XR+XEB*J%_HU-H@VT%P96S-PDJN9E<C/(K7R^
M3;/:!/+43JB58B;UD%8LC+(SS+/Y1'D>7(+#V+OS>C%+Y2*J5X;&V6F#^',;
M71!\!5I+%?+;?748UOD/,R04J.0:,OF)#CJ"L<B@<V]GR0W![QG"*DE%V[ED
M9N:V9YDF]O8A9;B]5W558T\!J'8CMKFF_%G>_'<1)[E=N*Y::OMUKU@/A#B.
M3VEM7#Q5:KE%(6BL#K/5M9-WZA@XEL%O5\C8HEO-6D;`EVAR1ALKX-ATHP-9
M;\#;@T$I)&5RX-:C,S.QVUK'D=[6(CRMD*\,M2%*(S(^%;1D2;E=*=9):Q6O
MK&97/CX[#TSU.Y8'M>UIVTR+O*/N1I:R+VQQM*#W;*U$IN64'ANNDIID60S&
MRRS'2#QEE<%N*[)4N<Y*6K`JVL=K6_Y3,RYC5GTCZT7U2UM:^=]8DDK:>TD?
M)Z.+E%B=5%@Z`'0`Z`'0`Z`'0`Z`'0`Z`'0`Z`'0`Z`'0`Z`'0`Z`'0`Z`'0
M`Z`'0`Z`'0`Z`'0`Z`'0`Z`'0!75]_"*_P"$W_SB=9&^/F^\8W.+G^X5YUD&
M,.@!T`.@!T`.@#-!OP%__!9O]=CJJO[O^(A9/][_``F,+U85#H`=`#H`=`#H
M`_<?AQ_QQ_Y]`&9L7^VR7_>,_P!1/54?-+G])B3VGXS](PO5A`=`#H`=`#H`
M=`&;>_:_!_\`$YW_`*$3J.,_$7I,3Q%XS]!#"=2(#H`=`#H`=`#H`E-._P!N
M,_F)'_I]47LY_N,71MYOO(8OD+^Y^W_.>N?V_'6,MO,?H,91/J#^UV%^:;_J
M]0*.[>=7I&OCW[XF@_GK1_=&P=6+YJN;TBXVXZJ`B9:BU([9J_<3`.(2LE5'
M'Q5>)2\O.J%P+2B`U86(\93OB7_Q5H7`9E.N1G'LLQDM(<0VIQ*YN9$:;Y':
MY;[;.@5-*3,E&5S(C(CW$>WDXA5ACBUH(^"I]9+:W%RP5"%2@-6'Y('F&X-?
MG28\N9793L8LS(-5V5)B177P!QTD'=S':PN%E*$XQ;A%D9GK'<SN>S;O\?*6
M8J;+9D1&@K)R(L]E[VVYE?B.Y<@M692:J0LU9N4L+%=LM-&G1%8*]KS;H<99
M4C$'(<5EIU$7+)!`88ES#K#BFTPV\,*:QE??UN=C*^1V,^4RO;TF+ZI7)5LT
MD9$>XCM?IL0APW1&I!&Q)6UQU)&Q;]+E$R#AQ$@DIMHH;@L"S1F&&<G+`CSI
MD=&9@ESD`9&+E(B5,3ILAMQU*YUU6U;Y;N0MA&>TR+B(\BYA4FT$K7)/RC,S
MO<]IY&=KVN9%F=KC@<T!IUVOA:L[1!+E>KR;\@,*<>(KC04;1BG85^0C"IN7
M'4V:+9CK,Y,A;N&T$GO%,1LI9RVUUW,]8[GJW/\`PVU>BQ!P:+$6J5BUK%Q?
M+OK=-SZ1V8^B]2Q!TT1&I`M@:0.4>R3(;3I!#+QO6L.O#Z-/[W$SM;77(=4K
MT>$TUE$=;8MCQII_*GLNM=6\\B,N95[]-S#@T6,M4K&:3MGM38DGS6+H'$&T
M'IRO1Y\,/K\##A%:H>HQ*#AN0_!G5&SV`Q:K`!E0I,AZ*]`*G[`9(2D+:RM2
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MJ.YYF8N1$DB(LB+QGUGF)-U`D.@!T`.@!T`.@!T`.@!T`.@!T`.@!T`.@!T`
M.@!T`.@!T`.@!T`.@!T`.@!T`.@!T`.@!T`.@!T`5U??PBO^$W_SB=9&^/F^
M\8W.+G^X5YUD&,.@!T`.@!T`.@#-!OP%_P#P6;_78ZJK^[_B(63_`'O\)C"]
M6%0Z`'0`Z`'0`Z`/W'X<?\<?^?0!F;%_MLE_WC/]1/54?-+G])B3VGXS](PO
M5A`=`#H`=`#H`=`&;>_:_!_\3G?^A$ZCC/Q%Z3$\1>,_00PG4B`Z`'0`Z`'0
M`Z`)33O]N,_F)'_I]47LY_N,71MYOO(8OD+^Y^W_`#GKG]OQUC+;S'Z#&43Z
M@_M=A?FF_P"KU`H[MYU>D:^/?OB:#^>M']T;#U8OFJYO2+C;CJH"B]LW*PU1
M]QX-DA)3&K[Q/`@8P/>GDY,=<Y:8D'!!3,?,V9AAN-%1(EQ8V7E-^&?91E;J
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MUB%=-A)DJF5!-'J)PHJ83QQYAR)11^`9*(^E3,KA%I[G=2I#NHI)D58T_FN,
MMR6)CIR34@;@.T')!ZYD=?@H8]JJ7_.N9;,Z,LZ\191..82L<2Q#6'6R[&BR
MB$0O)9&KUVE:0Z%5"0\HU4N$J%4IKDVKS*3"9813*Z=`=0\V=17(03TPB4Q(
MX(XAH6VTX^W*<1'/;:YHIQ/1#<83JUFH)J%(I[5.H4"NU%^2NL8<+$[*X[J:
M2W%6J/3S-,F+PY3DK0Z\S&>A-.2TV3"Y*UTE&>F#MQT:?#CCB!B1+A6>GRHS
M`@0XRT5*//L/N--#ACLF.V0G+4F-"<?91)=;4ZC"N?9Q-AN0VMZ/B&AOM-QW
MY:W6:M`=;1%BJ0F5)6M$A24QXRG&TOO&9-LJ6@G%)-2;ZJ_@_&$5U#$K"V)8
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MT>F0A]_'@6E+<^]ZRGB;#B7*>TJOT5+M70VY2FSJD(EU)MU6HTN`@W]:6AU?
MR&U,$X2U_)29JR&).#\7J:JKR<,8B4S0G'6JVZFC5(VZ0ZRCA'FZFLH^K!<9
M;_6.HDFVIMO]8LDHS$=UGRR%[4=)#Z]<FHMA%%;(-F5$I(J[5K0S6#DFOS3/
MD.#*GS$A),^,K,*>XAO#C3C/AFV'5^"Q\&'L94+$JI#$"6VW/BR:A'=I<F1#
M34THILUR`]+[C9DONE#<?;/@7U$DE)4C72A:M0N3Q9H^Q/@Y$634X3[U,F0Z
M5*8K42-/51U.5>GM5./`]\)$2.P=0:C.EW1'0I1H6E>HIQ"=<XEM?GQIS1SI
M&/M3>]:J4L.2;$%8#[.21$=/S4W;[*;FC0@<E.C,AZ*VFZ628['3#J]2DP+)
M8I`L,2'S9.U#2+JWGTF,0,[HUQY+VBTTV%R<UK@]2Q5I.6-J:;#BQL(/1@,.
MU70FP?*18=?*0JE5R$*S660)*3FP=>D-FR:HPS.96`FZBVFKK$XU;S.UQNQU
MJ/JC=M3O<IV":(IA@)8V3-3%K96`$L7AH2XC4J/(`$RX2,;A/LMS!.+!79$^
M/'C6$*]."+JWGT_F+L\_[?ZZ=^+0?JO0+GO/I,//^W^NG?BT'ZKT"Y[SZ3#S
M_M_KIWXM!^J]`N>\^DP\_P"W^NG?BT'ZKT"Y[SZ3#S_M_KIWXM!^J]`N>\^D
MP\_[?ZZ=^+0?JO0+GO/I,//^W^NG?BT'ZKT"Y[SZ3#S_`+?ZZ=^+0?JO0+GO
M/I,//^W^NG?BT'ZKT"Y[SZ3#S_M_KIWXM!^J]`N>\^DP\_[?ZZ=^+0?JO0+G
MO/I,//\`M_KIWXM!^J]`N>\^DP\_[?ZZ=^+0?JO0+GO/I,:\IYW:I5-2-3ND
M5DBJ$V02/\E3?'LQ'=Q?<_MK\3\@^,>$5N7_`/9]B/X/QG!W[W+.(G_2>@FZ
MMZNOQ^C,6M<-_(H--M.P;=>X@:FTNO6&U6<ZZS$DQA0"IP91*Q$'&H,*5+D8
M%0X4IV3'AQY$OOVLL-1W)"D-*"+JWGTC];WZEVX^8#=YCKN'FZJV9!IC1\R4
MU],YH:H@MWQ#Q1OLF/LM9BKD)F]ZXE_Q;P&?"]`N>\^D=Z3NDE#-PZ])LTAL
MC/!F;(PO(A2A:!`"6`A$GYAY`M0(=(0_9@^88X@2BDBD9V9-%Q)L,07?@@NK
M>?2.I3]\JOP0;8JA=F#8<N@@Z-EL18["I;0HG)#$'6XLR!&F8:BE(DB&XZN.
ME'A48[U2D+;4L%U;SZ1+//\`M_KIWXM!^J]`N>\^DP\_[?ZZ=^+0?JO0+GO/
MI,:K3>Z+:9#O;.;LFV2U,9TVTZO8Y._:QV%K\%7Y"&H<B(*;L5UH($$<L!R&
M0A$:K6JZ1+6"WBI3)6KC2XU>)703\K+,\]F=_O$^VYS'J&BY(&+M'8!*O.6,
M5:[!`7$H]GM$:+6Z(@(Y<[18)E2J9V'4ZK5FK($>/6>TOA@`Q@@T_+(M,H>6
MT"ZCXSZ?S$SC<AV90TB63=51X(R79(;[A`0X*=E+J*77#\@/$)B8DL^-ALLK
ME,EP3!$42A]Y-%S)L5UIY8+JV7/BX]^P9.G[ODWZLA+C3KDR>K=B%CC(<I#C
MQ<-RAY6#'(P75L/PF941YV%+CO+AS6(\V-X7#<J.R[A3>`BY[SZ3%6ZMYL4#
M<SQ6-K[:#I&0'A#2DE@Y4C](>EA3$T^-%6`$U>:O6UV6MD2-5LD"'9*ZDJ"?
MF!"<9L@IZ(ZA(3\HN,^GG%R,[9+R$+<8N$%YMM4E#BV70[B&U0I"8DQ*U(:4
ME*HDI:(TG"LXRQ(6EEW"7%83D(N>\^DQQJV^10VX\NZ#4LLS'!SSJI(5+;1!
MEYJ.]!<7EO"43&I#S+#D96</(>=::4C"W$IR"ZMY])B#UWE,!MDLM$KVQ62:
M0,BU0S1)H4\U7Q<^DVR51K2,FV:2'9KK!8/:(4H:^*<*8(NI:R0C1GQBD35`
MNK>?2?C%A-[2/.S%#VK3'<GH:4^J"WD4N8EA/@.^>5&2SE[#2?&8W?.91A&/
M&&.W/^E;[X%SWGTF.[Y_V_UT[\6@_5>@7/>?28A]NVK@.U!?MMD\5;><D-05
M.0''N_6E+*W\8P.'/93V)RUG.7<)QG\",Y^^ZZUTCZ8M'6B*/2I6D+$B,.,5
MMZ5'ICBZ76JGW4]"0RY)02:-3:BMK@D2&5:SZ6DKU[(-1DHBVK"^"<48T<EM
M8:IBJFY`0TY+24N%%X%#ZEI:5>;)C$O74VLK-FLRU?E$1&5X1Z=:1[9-_)!G
M[&ZZI[]/W-/VG,^:F./Z8&X?$5I4\%5^5J%^*!Z=:1[9-_)!G[&Z=^G[FG[3
MF?-3''],!\16E3P57Y6H7XH'IUI'MDW\D&?L;IWZ?N:?M.9\U,<?TP'Q%:5/
M!5?E:A?B@>G6D>V3?R09^QNG?I^YI^TYGS4QQ_3`?$5I4\%5^5J%^*!Z=:1[
M9-_)!G[&Z=^G[FG[3F?-3''],!\16E3P57Y6H7XH'IUI'MDW\D&?L;IWZ?N:
M?M.9\U,<?TP'Q%:5/!5?E:A?B@YF=^TYCPO@;JVCP[*X[O\`\&+Y[]ES*<K1
M]\%SV=]E*?=3V*QV>YG'N]._2]S0?_[G,Y9__"F./Z9#XB]*G@JORO0OQ0</
MIUI'MDW\D&?L;IWZ?N:?M.9\U,<?TP'Q%:5/!5?E:A?B@>G6D>V3?R09^QNG
M?I^YI^TYGS4QQ_3`?$5I4\%5^5J%^*!Z=:1[9-_)!G[&Z=^G[FG[3F?-3'']
M,!\16E3P57Y6H7XH'IUI'MDW\D&?L;IWZ?N:?M.9\U,<?TP'Q%:5/!5?E:A?
MB@>G6D>V3?R09^QNG?I^YI^TYGS4QQ_3`?$5I4\%5^5J%^*!Z=:1[9-_)!G[
M&Z=^G[FG[3F?-3''],!\16E3P57Y6H7XH'IVI/MDW\D&?L;IWZ?N:?M.9\U,
M<?TP'Q%:5/!5?E:A?B@YI&_:=*><D/W5#CSJN^<7D.7QE2NS&.WL2%2G'N8_
M@QC'0O=I>YH+(M)S/FICC^F0^(O2IX*K\K4'\4'#Z=:1[9-_)!G[&Z=^G[FG
M[3F?-3''],!\16E3P57Y6H7XH'IUI'MDW\D&?L;IWZ?N:?M.9\U,<?TP'Q%:
M5/!5?E:A?B@E@&^0[1%=F`#C9*/'>\`^IMA;#C+N4]^E+K$N+'D(PM/;EMS+
M6&W.]7AM:LMKPGN#1WI9T?Z6*;-JVC[$\3$<*G2R@SU,QI\&3#D+;)YM,B!5
M8<&>TV\V9G'D*C%'D&V\EAUQ3#R6])Q-@_$F#I3$/$E*>IC\IDY$<EN1Y#3S
M1+-"C;D1'GXZU(41$XV3IN-DI!N(23B#5G/*Y'WTK]1KZ/KL+75OZB[!K0>5
MR/OI7ZC7T?375OZB[`#RN1]]*_4:^CZ:ZM_478`YLGRZF$1LS5Y8;<6\AOP;
M'8EQQ*4K5V^"[[/?)0G'9G.<8[/<QC.<]K6.][@.'RN1]]*_4:^CZ:ZM_478
M`>5R/OI7ZC7T?375OZB[`#RN1]]*_4:^CZ:ZM_478`>5R/OI7ZC7T?375OZB
M[`#RN1]]*_4:^CZ:ZM_478`>5R/OI7ZC7T?375OZB[`$\UP0F2+1':>?RMO,
M69G*<I;Q[N&<YQ[J4XS[F?\`MZ@U&>TQ9'SBY_0,OR%_<_;_`)SUS^WXZ%MY
MC]!C,)]0?VNPOS3?]7J!1W;SJ](U\>_?$T'\]:/[HV#JQ?-5S>D7&W'50&O>
MV_\`;X__`,':_ML[H,2]O-]YCQ[LW'#;2IID_#!NE4IY+[PV(Q7@MIK@@L8J
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MW7FVWY:W$*G==XR7R/;`!@S6`+\>)R&KM\(/OS0\MU5+%ZD9K#JE84IQQ[P-
MF1GP0S[YS.<8G(:[WL<ZYN!H[K3=3@RY=.@K0UCRGUM]Q;T1U1T>-A9--69W
M,U+U:B7R8V:KEPQ)M90UZIZ6L..T:I08-7J3;K^C*J8=C-ML3F4%7I>,W*LV
M1&1)2WKTI7RY>22N<=2[_)%6#N,'(&+4:#4I54$):KP/6^'98@U2(:\3:SML
MQ:S4&SDY$1VS'DQ`TR/*JXX86B5R&X_.>D)=+=XRYK<?1SCENET.E.4V*28$
M/#^N[$F4=D^&IV*9=3ELU*0MI51G$U$>;<IK$:4U`96IY:R5)LA6WRM+>C1Z
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M2FP(L$N]98@D9:8M<!V"0$R(F=[#S/EEQ;,\SV&?1O\`]Q&Z]P]Y=P[3&BD>
M.>F2`W5_)#DWRE@QY]RJPG1^X'=F<)KCQMJ.@JS4HJ;E;:I1S]PO<J0?7>JM
M&%5VCUP>PEBQSY"8C`3<KY&?S2(CX^?[[7%A\5]$;LI?+REV"X4^W5)HG<^;
MN[B+EX/52Y[&%ZNVU5^(U)K5.W+>]>$#=&,72W;6H-DL-'&A#YAD?J;4U6#S
M)F"52>90$&>ZW%LRSSV%MMGNVCV_Z"H=`#H`=`#H`=`#H`=`#H`=`#H`=`#H
M`\8K3W-/:E@W=8]@0MB4H)5S6Z+<:@IB/V/-E#:;/V]7)D:,BQT`V8'GH*YD
MY3>&XJ"K0E%5;219.X.Y\BI"U\N/TY\7-;(_0(Q'[F%L(M6]@0S8?C\#D&N+
MG);3]!J@F<>,U6B[7VKHSB3IVI[+%S).M`[@U9>7HG8E@NQ@8";L`:-;@T<?
M'MA.;89T<&MX]I=!&9_?L'9LO<V=U%W-FS`4[2M7M\\KL*?2=H1CEI5;+3-V
M1R0N.QR%BV)&8UTPX/+@-*;(M.M!*8IZW*>*PX"43!=:D-1Q8+E<KW,BXN;M
M]C'*WW-#:XED"]')ZCM+%8)$H_F:?,6B/7;EKND;EX(R]-:VL$AZBF\,"9N@
M.&B:[>E2!)P>,OA^.B**N(*67*)!K>/Q\?\`>\=LSZ!8G&O@1M34&Z-6["M<
MW6\@/1V'9B6:K8R:\U9MRB[<IGH]JL"7JX&9+5),S8L2T1W2=W#UEJ?@N\]K
M*18X=?M48%RL>V^?/F71L_,>N705#H`T4VMQ;NM]IO/RN#353CR^5U;BAZ$\
M1D%DQJ_+8T17]6^&MBF`\EV*UY=$OST+#-&G<"G&7>\Q,RN&@)(]G(=SZNP=
MKEOH';>X#]6,:L=URG#6D.3&D["K8%@L@3R0QO\`'ZR'0K>'A5^F6M-H=JZ:
M00DRJO/G5%LPJ5#C-V4<E3\AD!'OWD?1?+GO^0TTL'<Y-XX.AFZ[8=0D*T!V
M!(MHDD8)$@MNBPG]Q3;=*9G3V-2V<P1R2HLQJ%Y#%6^J@8=ECS\%D6R(3&%*
MN%B41;]M]^73MOQ_[#:OA'QKVOQL:/AK.*TT%JMD"TIB:'U><LLUJ+9=::IU
M%JX798T4G0:9!>D[%Q6+M8KFM]I,\([%I`QB?;W)1HN."#._7UG?VS/F%3U;
MN:X855N.$8VY7CMVUU>9U@VA8K%8+G>X$D&/TYR>I]`&:R#7),X576*9LC>P
MF]CP8T93P[,V`5-86\:A!VWP7V\O:7W%SBMM>]S0V'7`>IHI`YK@(1KNQ:*Q
MM)H&;L)N'=-+UVMZ!D6X9!<51*</:LEZO?&S7+$D(Y688^)1DR6RUNLMGCJ)
M$`7V[>.W)M[;WVD(1![E3LE[4Q2B'R>GR1WT,[-UQ!,DBMA/L&+V:XY>AZF;
M@(H<UR&CU^Q.VK*+$8\0%';2`'PX;Z[YL(XTR_&!K9WSV])7V<G6+-_8\]EC
M;H7LXT3H4H`@[>V!L,=KXD6/BZYM`-;N0Y'<HL1LC$?59>)7Y`(,:9"L(CA]
MAQ$%*!3WVEX@3,LUH)UB,K'<]G-EQ9]FWIL#BEP'M_'Z]Z]NM@/4&Q%JFQ*$
M&[0-9*HM1VO?<N\:-*CA*IDX*B4X.AW;3%IL+`F:8D188@L&FH?D&Y)2/$"#
M._MRJ/[QZF=!44/O:J7:U#JXU2@HTU(A32+D]LB=:!I89>8BI86TX[$EXD*6
MMMQ*D)PCO,)QG.<]]V8\9>[$T%8STX4K`L/!Y0C=P]4*Y*G=V2F(Q$W4(U-:
M8X,WWFB6>M%=UB2:C+*]KE?T%H$QYA3`TW$;V*9\N"U48M/:AG$ISM1-Q<=V
M2IXEI:<0;1)2Z@TJ5?6,S(MAC6ST0[X]A:Q_2!#^Q^O"/>`Z;?H43RK3_7!Z
M5[X#1#X05GS:F>L!Z(=\>PM8_I`A_8_3O`=-OT*)Y5I_K@=\!HA\(*SYM3/6
M`]$.^/86L?T@0_L?IW@.FWZ%$\JT_P!<#O@-$/A!6?-J9ZP'HAWQ["UC^D"'
M]C].\!TV_0HGE6G^N!WP&B'P@K/FU,]8#T0[X]A:Q_2!#^Q^G>`Z;?H43RK3
M_7`[X#1#X05GS:F>L!Z(=\>PM8_I`A_8_3O`=-OT*)Y5I_K@=\!HA\(*SYM3
M/6`]$.^/86L?T@0_L?IW@.FWZ%$\JT_UP.^`T0^$%9\VIGK`>B'?'L+6/Z0(
M?V/T[P'3;]"B>5:?ZX'?`:(?""L^;4SU@/1#OCV%K']($/['Z=X#IM^A1/*M
M/]<#O@-$/A!6?-J9ZP'HAWQ["UC^D"']C].\!TV_0HGE6G^N!WP&B'P@K/FU
M,]8#T0[X]A:Q_2!#^Q^G>`Z;?H43RK3_`%P.^`T0^$%9\VIGK`>B'?'L+6/Z
M0(?V/T[P'3;]"B>5:?ZX'?`:(?""L^;4SU@/1#OCV%K']($/['Z=X#IM^A1/
M*M/]<#O@-$/A!6?-J9ZP'HAWQ["UC^D"']C].\!TV_0HGE6G^N!WP&B'P@K/
MFU,]8#T0[X]A:Q_2!#^Q^G>`Z;?H43RK3_7`[X#1#X05GS:F>L!Z(=\>PM8_
MI`A_8_3O`=-OT*)Y5I_K@=\!HA\(*SYM3/6`]$.^/86L?T@0_L?IW@.FWZ%$
M\JT_UP.^`T0^$%9\VIGK`V-TCKNRU1H@9N#$<6:FH7`:"C"_E6`W"2XV[B9*
ME-,16I$EU:<)CL^"SB(C#R\Y6X\C+7LOW(GN6L2Z%*MB3%N,JL95>IPTT.G4
M.ESC73?>_A&);]1JQ,.*CS)AR&R8IS)FM$%E,I]1K>F-E%\\:=-+%`QLS3:'
MA="YE,BNE4)%6GT_N28<HT.,IAQ&G5..L,);4;DETE$<E9LH(DH84;M_=>\!
MYO#H`=`#H`=`#H`=`#H`=`#H`L'6/[;(W_=)O_HYZ"R/G%S^@Q).0O[G[?\`
M.>N?V_'4EMYC]!C,)]0?VNPOS3?]7J!1W;SJ](U\>_?$T'\]:/[HV#JQ?-5S
M>D7&W'50%1[`*5F`4C)-@%%'_)J'42<3WHB6H^)$K'@E);6E.>]6EQS+F?=[
M%]F<]B<=#.V9Y$69F?$**S41:IJ,[$1%>YF9V(B(MIW%88ONI\QF)N`@[,.3
M(\4C2\6C&8TB5]]_T9A_QKP3LC[U7^A;6IS[U7WON9Z^7NV'P:'NZXO!.+X)
MMWAVN#6YG^K0O7U5+R/Y"3-61Y9#ZO>^>3KC!TZ:3[3?#.L]SR.%:9R_6N-\
M'KH;S+Y:B).99YC[Q>=5YGR!6`$')2)'Q+E#<6;MGQHN<)5B3(AXD^,,Q\I4
MG.'G&TMYPI.>^[,XZL4N(;[D8I4<Y+2.%=CD\WP[;=B/A'&M;A$(L9'KJ22;
M&1WS%3@S2C-33@2RAON<"S+-A\HSSUS+@FG]3@G'+D9:B%FJY&5LC'W`NVKB
MB'7!E>B$6V,X2\Y`LBI:&<JQE2<.JCR'$MYRG&58PO.,YQC.<>YCJ694:22E
M1Y##Z46):F76W229E<B4:%*)-R*Y7MD*R(<J(I"9<*3%4X1FVF0R\RI9$9$9
MH)Q"341&9$>K>QF1#E3;M:JB^/)J[*H79G/CB;`[F+V87X/.?&,/^"[,+^\S
MGO\`LPO[W\/N=6)]DV^&)YHV<SX4G$&W8CL9Z]]7(\CSVY;10X[Z7NYSBO%(
MV<`;;A/7,M8BX(TZ^:?E?-V9[!R*M&NT/MQ5U)*9+R%N-1U''TONMM]GA%ML
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MG0+I^CUF/I)RBJ[>]I+N>S\/_P`8E8_#_P`7.@73]'K,?7EJC^Q#ORQ)^EZ!
M=/T>LQ5YKD'QT`%'0,WR5*L4?/8_601V?:+0SGW?_FUJM8+'6_\`5S[JQZ<>
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M+$GZ7KD!JUT_1ZS'QD]1,9SC-*=[<?\`]WE?2=`NGZ/68_/+]$]BG?E>7])T
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M/`^3JVN!A'A/#=\0??\`"]]WG@^SOU9[WO.]7^#_`%N_]W\&.K%J\97W>UR$
M';B*W/<8KQP5ZKS\87U-T;C]N<0'C@KU7GXPOI=&X_;G`/'!7JO/QA?2Z-Q^
MW.`>."O5>?C"^ET;C]N<`\<%>J\_&%]+HW'[<X!XX*]5Y^,+Z71N/VYP'8CD
M`2/#^'"J>[^.XVSV2W4>"?5E/@WL]F<=]A&,*QWF?<5WWNX]SJ#-.5B/;GXN
MD25N/=UCK^."O5>?C"^INC<?MSB`\<%>J\_&%]+HW'[<X!XX*]5Y^,+Z71N/
MVYP#QP5ZKS\87TNC<?MS@'C@KU7GXPOI=&X_;G`/'!7JO/QA?2Z-Q^W.`8F"
M?X1>>S_O"_\`GTNC<?MS@.Q+(`G9#KD4*J/'4KM:8S+=<RVGLQ][E:LYRKW>
MW/;G/\/4$:;9D=_;E`=?QP5ZKS\87U-T;C]N<`\<%>J\_&%]+HW'[<X!XX*]
M5Y^,+Z71N/VYP#QP5ZKS\87TNC<?MS@'C@KU7GXPOI=&X_;G`/'!7JO/QA?2
MZ-Q^W.`["B`+,5MM(56)*7G%N2/&W<X6TI*,-M8;[>]QWBDK5WV,=N>_[,_@
MZBZ;[#MX_P`_O`=?QP5ZKS\87U-T;C]N<`\<%>J\_&%]+HW'[<X!XX*]5Y^,
M+Z71N/VYP#QP5ZKS\87TNC<?MS@'C@KU7GXPOI=&X_;G`/'!7JO/QA?2Z-Q^
MW.`G.NI$!RSQTQX.6'/%9F<.>&4OLQAG/;CO<^Y[N/<_[.H/5XB,C]N461\X
MN<9/D+^Y^W_.>N?V_'4%MYC]!C,)]0?VNPOS3?\`5Z@4=V\ZO2-?'OWQ-!_/
M6C^Z-@ZL7S5<WI%QMQU4!K%O[\$[^9T[_P`BO7R3_P#W&;__`!)/_P#A6/JI
MW_JM-_\`YT/_`/V4#^:X`.)XUO1:.MN3@#3INN-\PI3F5>`<?V38=*46%!;[
M,][G+9AS9TK&%8[U*%8PG/?=N$^'H,>06'Z+1C2X4*E/8?QJRZJ^HIS$,_!]
M&993G:Z91XC<+*Q$>1W.Q?I%4I,7X58AQ`E;7OC7(^*-'4AE.KPA-X5IF/<0
MOR%97(E04X39R.YJ(S,K6,]@:\>J@NWHP6KU3*[3+;PY+"#IO-DG#-EU^5)%
M6-MIR>%B0<^6J6]76XD&"R6(H'QY;[?DV"I2'GF]Z@3J9&JR2DP*7)Q)*QEI
M"BS9GO@]&Q#!=7&J!(4_$99,IE(73TM,,HEODPAU:>YF3,EK3UI4Z;6)E%4<
M*IUF'@^'H^T53J=`*EQI>%*DRU+I:EHC3WI!=P5Y%44_(DKA1527&6U]UR")
M2&U4[*<!Q]3B'M2+%LD\\1%(W:NDYBI7VO['I;#OGCD/G",610EP_B1DIV&_
M)'C67O\`H6%=:DZJ$WAB*K"QQ4R3T6&G&"J.;9&1KK]';5[[=R9%4#BJG\)W
M3_;#B\*:_P!21VWEE-0<QE.;QHF8N)\=9*P`FO$Z:?D87KSB/>+NXM8Z64U-
M-X(HG]@*;P/!_KS(73LBOUI_5'+6=1Y;D'7=4W/J]=%@4HW)'4*1,+NZL&VU
MCR2"E,UXW%:<DH=3&DL2HT`FYX\PAJ;_`*7K<,00:>O#&E!ZC.J9H-,Q=APZ
M*S2)CD>B./2CPU'JJ.YH3B(,QI*W"43;B'6V9"N&0E+WRAH.%JE56\8Z%X^(
M&$2,3UC`>+TXBD5ZGM2L1M,P48OE45SNVH,KJ<!Y:&30;K3C+LB(G@'%+8^0
M)=M/,5?(6^29&8>=FP^2'%6#KY;N6/.-BFR`$=PM'KW?Y\>16I>'CCED;@]@
MQ][QI1?"G&\][RF)3;5CNMN+X(\1-8_T:,T(U&CN]%(7";7*;@W_`%R:>[KS
M55!+/]F6OA>ZKJ3EPV#^%3HSPXRV3Y83?T6:89&)DH)?O6Y76JBZF$[4[?V=
M559U*>FEKD%W4VC@BAF259TURBW/=#?+QG5EKVQ=]3:`3RAXVZ"O\JI;(L.H
M_%*0=XA\H^1:CR=A54U6K)39&T]W1M0ZM(64/8P\U^%185.%3X:[0<9+^FQX
MV(LK\A\N9&7%;=X]^0T^H7)8NSLP(>H7-C<^TIT3?O<_M;:KQ<;:<95N#COL
M_2X"?N>\EN/4_P`$#L,I5->LVX)FQ(='0?40K35H:.)'SIK4X%N2WR3/Q9G_
M`+9^+:,`<Y+6&#7MS:Y$\YMIV@@3MVL(/$DF+WO6D0=T67;G&"R'*7MJ_<C"
M#%/3J&ACC0(IR*W#I#`=JEZ\9'5FDU81?H&P*MKTZ$VV':^_+EXB+([[+EE;
M;;:+JXF[WW@_W0H'3[OOLE?Q%EW_`,G]3F(83>!B["[;%HG'NE;!J\MWC60B
M,5+2>KAY49:;#6MR4(L3E&K&;`:X,AXPZUPR#`09%;+<1^GKY-F1CT5XV<OM
MG;BYC<O^.MA1JGS/XX^+)HQVKB[E!/;;58SL_P`.X-F'#4NN89T.N!Z']QJ!
M^75$-LR?'\IUW`;B54H$':Q;;]7MQ^(>1%`WF/L6LN#4^S<Z-]9OW(B3P^MG
M-.F*WEL*O`M<']A5WDA,O:X>Q(=E@.:`47V#6BE!G:1J%@I=?@#]3"9K=0C3
M8I4B0"3X\LBV'XS+IMOY=UA;6L[SO[<P3BA(H_*;<4'9R]0\K]\6*VG]@LL:
MAM&A^-VQK=JSC?9+M6D!,A#4K?1JTZAM]JN*FIC%JUS3=D3VHK<\R-+Q`FUC
MV;BX^,N7=Q;#V#167RGY4GI`^G,[GV$&J+`Z88&'=C\YPM%AS=FO\"1NS;4^
M[R1T.:VK53=88V+Y!V]K_6LP[-K#@^\C!1(90Z\::JX$)U2S/Q6RSVF6P]^7
M%TC^@#N<N[KUMH=M6%;[1;;N.@`N+.R:O8[R':K]IAL[UXH:DV':*L;`,29S
M%>(Q[J_8;N_5VI\R/4D[!:JPQ[`(,(:;"AE;VRV\0]+>@@5SMK<6OM$4`_LO
M9I^/7ZL!92IYYSL<F$)CF%XAB`\+"DO$BY%W'@84%CM6XKOG'%-1VGWVN,J]
M8I]"@/5*I/I8C,EF>UQUP[ZC+*+D;KSAE9"$\JE&E"5*+?-&NC7&6EO&%*P-
M@6D/5BOU9W5;;1=$6%%09')J53E&DVX--A-GPDJ6]9*$ZJ$$X\XTTYY:>E_=
MG*G6=VY)7&":UKQ#J#!(E6=4U^Y(H5TW$$!/.H-G;WL-MI^</K,=,25'CURK
MIB*L)#*@S,F2AA)6;U,]5JYBFF3L1S&WZ=A"&3CC%)C34T^;6&65&3SLRHFD
MUHCI-*F^`C$DY+MV&CUD\,K]`TZ-]%ON?\<X7T(8:ETS''NCL2NPH-=T@UG#
M*L787T:U2K--JI=)PG@Q;C,697'CD,/O5NO+D)HL,DU-UAE3QT^+M'ICD_I"
MFTET63I-:X_Q@]<)62+1PTILX]'@5^G-W2SQ[%,`UZ$$#VP`'>A9/!BI:2=8
MG3X<<EX.;/A-R]EH6+*!"A+87`C8>2S'<DMP6%E(6I$>$4R2F0Y'CH9:FLLF
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MA2:HS1UH]^#I7<T]V`RU,CDNE]R;/XF;=N@:GF%N2BS00B8B;MI+IFMVNE34
MD5!:M&H%J"B\V"VE;.5BGLB1U869"2X-5L<V<S-A#)3.."KE7P96)K$5\S-U
M++KJ:_!X:-+@N)<X&(B!*99-^<[)>)\VFH_#QE(BR'5I<0THB[0T9X#]T3HX
MPQ4\2TTD,4YRIP:;(T68I13*WA_%$54,JG7WL7T"J3O>?#E/H-/?I'OA-KB:
M95&)=?HL6&[%E3F'!2%*YPV?CC<J10^2EGQLS16UX?E31/*J&&>#ODPOC"(O
MB>RA*HD)M4@=X:&J:>@0V',09D`V]'(CR>9L#C*=C>7AZ7"@8DD^^=#JB.%H
M6*4,J9-Z.2M2T]HT(NINZ.%=2DEH2M#Y\,PZEQ/:F*?<IT'37AK%.+="%!/`
MVEG1])[@TM>Y^DU)JI-0*KP"I'=."*@E^2M+$W@Y!1:3,D.-G*C3*6T]"FP>
MY97KC'F1"$>//@2H\Z!.CL3(4V&\W)B3(DII#\:5%D,J6T_'D,K0ZR\TM3;K
M:TK0I258SGN!"T.(0XVM+C;B4K;<0HE(6A1$I*T**Y*2I)DI*BR,C(R'YN28
MTF%)D0YC#T67$>=C2HLAI;$B-(86II]A]EU*7&GF7$J;=:<2E:%I4E1$9&0\
ME:5NL^&Y/PJC;]BW!,:J[[Y8O7>JSS5G(-A*%;9NL06@Y%@`MN2O%:<5,V^!
M"UD_,B)!X?G$55];:(!AR)88K7V%M(K<696O;K'<X.[79B[3O%'M>PKIL(U:
M&Q48?<R5[V18@A&X+L.[K$]3+KJB\CY:>.6]0]3J1ERRTBMV)ZE%:97*M,'#
M*]ED*-F`,LK^W%RYE<\CZ17MIW(?H6P=S6!K86V6M_"MUWNN$*G),G['J'77
M&TI?M-58-MN\ZQ*D\5>M5FB:RL"MC4>VA1X5%DLK-Y2;+%X&;?&9!ES9<1W,
M]U[<?Y[;B:;(V_R2V=Q3KLIFI3XSUCW)H2N"=KTG:%BU*O9@.1SIUUK-K#2M
M?1B.P]=U+;FGU.V<Y=JR^4BP:K8R#P@9-@OQ8JP6(CZ<C+/YM_%S"."]B<LM
M&LF]?[#W)61E1H5UUG23NR3P`WL%&OZ_MURV;`\Y#.T]@%AQ*\#]=P(%6TB)
ML=R$#YAR2>Q;[<M9IV)`8!D?$>_;;+?X]NS(K;#S%<Q^9O-TK57+U+BUVGRX
ME`+6DGKF1J(K*?@G:CH;B!M@C7E$IM@:*L+-6[=FQ*E*1(C.2QPL(S$B-HL`
MV420`TELY2+IOV7MRYCU8"4T?>=NP=^BK](L(`17K!KD%4I@/&15<*![*;"W
M<K7I<I<24..%C@QL-822QTIZ>-K`T>-G,B'9.)X1E:UL]XV"Z"!X9N\FM]Z^
MY"[,V83$[,"Z7W+MVH5:LGKVX/+ZHKFO-&\G]1\?KT:I("+:BIF@1KCK>W[)
MV6>L=LJ=(CE6Q4:UCY%B"AV9L,+6N1>V9D9D5^;KMQ"'PN6'*"`5L-Q,[+)U
M:)>ZKKLVAD_K]4NN46-$U-R:."LURLDV&TP'-B[4USKRAF'WD9EDR%KCU6%X
MM;R]/E0`:M[VWGT%;Q%QWYA8-:Y"<OR)[`J!X?7#9+;%:C6,5/H1:XR(;FT>
M68G35A9C$+84G+&PZ33;%-LPR%!\$'BSP8Z6Y$:K""8DB#+Q[>38667+_MF(
MSGEESC+T=RS1340(0'44NIT>C2[4Q1&Q5OAY9]\9,YQ,?4XPX>V538=3<%L-
M>)1AUG,"83>#>:_,"A-BO;:66SEL749W+H.XWDY5;$@V?C[2[!%LMFKH7'(K
MCU6MIE*J7N]"G!Z^SN2G#=JC9!X#)!64<`C"7"\,R3'$6X;@G$EU)!V+WSV0
MJ6WF/T';K'G:+Y(\DM7UNWDH%DM4,1"S'=IAS802YW:_W;5K6T.?,K4`^NP]
MBSV*S:[T:UW3-'3_`#?L5AUYL3<0-]-?A;%;V`:J;S06^3EQ^+DM?85]^_+,
MBXAL&&Y.\KKAMP#KT,8'C(UFW.6J=R4O5[<N3I2`+/\`*R,)I$AR3)C,R"=N
MH^IM96F&;LCDEYB0=Q:([,FGW6L`V@BQ%8]M[VYK???+KXSUC"\PN74<20O`
M^Z0)5BO%"U49LDJW4^QBZ/K7;T;2NQ[>5T"-JL(!;)<@IG9K*:0:$U<$YLNV
M>:S-*'3?2+)C$UA:Q;M^9&1Y99[=W1ML-L!G)/DS"ONH%VRXBT`-C\@-L4A=
M`$:N:1:6*K5^66-'5A$7!EX:W<J^S0(DNTW*Q5FSB+I189*'M.32+IKVO'!4
ML*V+JXSX[7["V6/>/7CH*CRC[JUMI[4U"U).9V'/UZHQ;[!$S*@62=6UDL1@
MT9[Q=QZ%+BJE)8ROPF&UJ6EO*^^QC&<]O7GGW0DFMQJ3APZ)*J45U=1F$^=-
MDR8RUME&;U2=.,XVI224=TDHS(C.Y9CUI[D^FT&HUS%R:]3J54&6J5`4PFJP
MHDQMMQ4QPE*:3*:=2A:DE92D$1FDK&=AXB_=E3_]Y>Q?TI'_`+8Z\K^^F/OK
M;%7E2J>L#V]\&-'?@U@_R%1_5`^[*G_[R]B_I2/_`&QT]],??6V*O*E4]8#X
M,:._!K!_D*C^J!]V5/\`]Y>Q?TI'_MCI[Z8^^ML5>5*IZP'P8T=^#6#_`"%1
M_5`^[*G_`.\O8OZ4C_VQT]],??6V*O*E4]8#X,:._!K!_D*C^J!]V5/_`-Y>
MQ?TI'_MCI[Z8^^ML5>5*IZP'P8T=^#6#_(5']4#[LJ?_`+R]B_I2/_;'3WTQ
M]];8J\J53U@/@QH[\&L'^0J/ZH/03N</(/;&S-[)"TW8,_:=1;&]_LY@W:R=
M@&5NOKR_X@::D2I$_(XWY0;\7#-,HQDNMR2/D>"AJDSX';6A>KZ1%8TC1%/5
M2HTN2PX=916)<MZ-'@M6_M;+CZGC:EM/+;1'2V5Y"G38<U&E+>9Z&]T5AK1=
M'T=RYRX=(HM9C26BPZ[0Z?!BS)E2=OK07FHR(_#P78Z''):G%6BI:1(;UWDM
MQY&SCMM[H;4[M.O+;Y"U:^+;TW*$$:S*ZXF68A'UU3-U[C``R,E-8I&NS=+%
MVG6B]9+UT3F6O9,0NBO,WY^60B6J;77O:@_.S]7:W'JIN>19F1'M,SV'>^1<
M1<0CHSFQSG(L8D)XT$&VWWT1HJ)_''D$%(1(Q&BA[?FQV6"0/JB#1=+DDY]=
M/B:J7OIRRV\"[4P3([!>#8F`G4;O\[_N2?'LY;\UAL[L#:_)H+K[1.SAM7+R
M#$[2NQ[?MC7%.U39[1$7L$?I:9:JJ.P#-)`;#&,+O;+0H31IQ2I6HO,D,5H@
M49,)4G`4)*3,R_YB(C,R+(SMXO&>>_(KBOK9R#YDJI>B[/3M1.IN-NHFZT;#
M$SM0;4)5:NVVJ;1U16:;/FU19.LW,0W8JQ)O)ZLC3-C@OD!69A*.X3A#ER$A
M))1=1&>1&5CUBO:Q\VVU]PI2!R4YZC+).,&=9WEP'.)R/(]67QSV,;@U>(6W
MCOZD12)LD'?#%K$+@5,/K:S2X4:?!+"J<L+9H8TK'*HS:`MJ-G8B,O\`,1'L
M3ON69WXM^SBZ=<Y6]T(9B3[.6TK8"DTQ"B%XM2G\=]M#1%2?)Z)1LD5K^(B+
M('F2I`ILY@;J)RZDB#\:F$K;+GVT4XJJS@[`#2WL(RMOUBOMM?HSL19VL6>8
MO(ORIY2UC1=IO%PUR#K%^]*FO*A21[^E-ODV9@"\TRNF'XZ=>CKBNZW:PAK3
M.,5IR762PV.Z]&2R^"ARAL[#X5U$:Q$2KE8[_*+B.VW81'MSZ17=8Y2\[UG*
MW3I6C#42;:+D7'E#MST-L\R/H<6V<R2]'"37+#43M7K%@IM"X]NNG.\GYJ9&
M5`KX2Z3+>=$&ILC`N7E].74)-+>9ZWB(E%<[(ON/,U>/;:P^0/+SN@9"OTPN
M4XSBP\ZW/T!<P83TUOB#YG)*BMP2+0&/*@DK`77+EEZ=K\6..K`#!U*Q<D2+
M./,-$!2T@-#?$J^W^\GDSYB,[EQVRML&9&;HYT6GC[<MB1ZE8AFV(O(C4TH=
MK9.D;96N\URUI#2=NV)JD'%MSBR\P&WMB3L'7IO=.99@3/E-6:=6UB1Z1,&O
MA&J@E$5RMJGGK$>>L97RRV9DGQ;>.TJ1O7DY;-;[[LU_I]FJ(^C:\+RZ%.UE
MQVV!&VO?SR+?LP9#.:]U[LT[8D.%GJM5*K)#4"P5TRZDW:QQLZ5\V9,4;)`:
M4$:;9W/.ZBL16(\S(MY[2/BRN->*]L[G_*&[2COEMF3BH;4EN/5:4YQ]D#XC
MY<=7>*92BL`TV'4%%*V"[G+';>3M0.1Y(.'B<F@P;'&UM4(K8R*1"UF[ED6T
MK_*Y57XS*V2>FUQO/QON&Y#VQN10'9N;B3KE=O,Q_7A\_3'*2`C!9^P]M"H=
M#K$>;K2C$;/YITRLT$T1O3=@V"!L\:[!G@EA\)%).3@QJ))$FUKVSL=\[%F>
M9EMOE8MGB&WG04#H`=`#H`=`#H`=`#H`L'6/[;(W_=)O_HYZ"R/G%S^@Q).0
MO[G[?\YZY_;\=26WF/T&,PGU!_:["_--_P!7J!1W;SJ](U\>_?$T'\]:/[HV
M#JQ?-5S>D7&W'50%7WBBSK21CRXTJ"RRT/3#<:E8>SE></R759[&VG$Y;4E[
M">Q6>W.<*QG'9V=HR(R,C*Y'D9'F1D>TC(5,E:Q*2=C*QD9&9&1D=R,C+89<
M1BN<:%3AO#6&*KAI+,6.EK`_&&TQX+^94)C"/$>]PS#DJ5(BM8QWD=]67FDH
M<SE77S=Q0]4D]R1M4D-MDG@&M4D,K-QE!%J6U&G#-;:=B%F:DD2LQ]7=U2-1
MK.?,-9K==-?=3^L;C[9-/N&K7N:WFB)IU=]9QLB0LS25A\YT$TJ:^25&J:B,
MI32Y)#(U.9LA;#+D=A3\K,#P[RF6'G6&E..*RVRZXVC.$+4G,'`@F\N0<.*;
M[AI-Q\X[/#.&A"FT&MS4UU&E"UH2:E&:4*4DK$HR.2J%3*.W$*HS2BLDM+48
MI<@H[27'$NN);9)?!H)QU"'%DE)$IQ"5JNI)&7W#T-@='DQ![-6@Q9B<IEQH
M8_Q:/*2I"FU)DLLP4-OIRVI2,X=2K&4*4G/WN<XZEJ'#80XVQ$C,MNE9UMIA
MIM#A&1I,G$H225D9&9641Y&9;#%7YM1DN-/29\N0\P9&PZ_*?=<9,E$HC:6X
MM2FS)1$HC09&2B(]I$/EC0:(PS`6-'JD</A6%8$L#L-#,*P]B3A6(#<!,7"L
M2$I?QGP7;AY.'?\`7QA74(@PFXY1&X<5N(1W**B.TF.1DLG",F4H)N_"$2_F
M_/(E;<Q+D^I.R^[W:A,<G6U>[7)<A<NQMFU;NA2S>MP1FW;7MP9FCYIV'*[H
MI;Q*.:>1673$1E<>*6=@Y<)1H[G?=^Q'G*A9E,LK[]??M-NI0KOU=J<]]GML
MJ)%7(;EKC1U2VD&VU)4RVJ0VVJ^LAMXTFXA"M95TI41'K'<LS%$2Y[<1R`B;
M)1!><)UZ&B0\F(ZZG5U7'(Y*)E;B=5-EJ0:BU4V/(A7Y/AQ23=LN5S.`*D=+
M;#J5-I%WBG(KYD!:*_KTS:3],9,5HG%E`I4P`2NED<B$U#\$'&9[465)D1Q@
MEJ#]`^745O+I/L$JB\;`T$VBS0@=#AV1$%D6BP10,2.;0,CQVXC`Y!5H8B>F
M"Q%99C,Q,2,1VX[3;*&TMH2G`-16\ND^P8!?$#7C@[(AS7VI%B<EIQ_(M='!
MJ'9.E$MI)FLPE`\QLEB*66DSB/@O'):6F\2'G,(3V`U%%L,ND^P9X/QI!UTG
M+-U\#0@9DA';ASRX>OPQA.;$9PSAJ++GPA;$J3':Q'8PVP\ZMI&&&<)3CP:.
M]"=16_K/L&0AZ`9'2D3A\2I09K:2Z43(8Q$64A-@)H-GDHD,0$.I2;,MMER^
M,+Q@D3;1/F>&E(2[@(U#WEU]@C;W$ZDR(YF)(I6KGXMB-^<M@C/4\2['.V/O
M5H\X#+*PRFR9OO'7$>59J7Y_>N+3X?L6K&0G45OZS[!*V=%*C2FIT=%9CS6!
MK89B8S!RU*9#M.8>:%-2&X27FQK3V,.MP4+Q%0YC"TM85C&>@C4/DZ^P0]/$
M>AH%0@2*)JE`0:3E&AP9-,#)%0#$YSPLTM"'X"XB12<QW_22I[#+<J0Y]^\Z
MM7N]!.HK?UGV#MT_B\,HA"^%JWY-B%=FW1[8%Y)/RRLV;8+2NNURGQY\I^6E
MY2&QE0J%5JXF%'\##'`Z^,@QF$(8SE81J*WE[<PF_HC->LQ?Z9?U?H&H?)U]
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M\*!T6<'#3ZV.<:Y:$TMQJT1G2B,BMM1__P`7:KZ94Z:J.&9;;'16ILN,Q';C
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M(+VTH#1Y9$%C9FP[`(-P2$J87B`AM7BB1N'60U=69;8-R)!=CR/S"<%M5J+'
MBU^"W#IM.:2S2:7%J,F:_'(WFGI#\JHNI0M;CZ66XJ&6R4EB,;I-OZ[J>!TJ
M/[IFMZ*:Y6\0:(,53JUC7&<^34\?8[K6$Z-AV!5E>]M1I]*IE&P?#?EPX\:F
MR*M.KS]1FFAVIUI--6]2VF:<[[Y;YU702:E6PE8K,4!6*\`&Q!`6OP$.M0Q`
MV`TF/$A1D,,N-):99;1A/>K7G/X5*RO*L];]%BQX4=F)$91'C1VTLL,ME9#;
M:"LE"2S.Q%QF9F9YF9F9F/)]=K59Q/6:GB+$%1DU>N5J=(J55J<YTWI<Z=+<
M4](DR'#+Y3CKBC4JUDEL21)(B+/^B,UZS%_IE_5^LXXK4/DZ^P/1&:]9B_TR
M_J_0-0^3K[`]$9KUF+_3+^K]`U#Y.OL#T1FO68O],OZOT#4/DZ^P/1&:]9B_
MTR_J_0-0^3K[`]$9KUF+_3+^K]`U#Y.OL#T1FO68O],OZOT#4/DZ^P/1&:]9
MB_TR_J_0-0^3K[`]$9KUF+_3+^K]`U#Y.OL#T1FO68O],OZOT#4/DZ^P/1&:
M]9B_TR_J_0-0^3K[`]$9KUF+_3+^K]`U#Y.OL#T1FO68O],OZOT#4/DZ^P/1
M&:]9B_TR_J_0-0^3K[`]$9KUF+_3+^K]`U#Y.OL#T1FO68O],OZOT#4/DZ^P
M/1&:]9B_TR_J_0-0^3K[`]$9KUF+_3+^K]`U#Y.OL&**Z%2=;::.,54RU'6I
MQAHL.P1;8<6G"5N,HF0'DM+4G&$J4C"5*3C&,YSC'6)UAA\B)]EIXDF9I)UM
M#A),]ID2R.QGQV'T1Y$R(:CBRGXQK(B6<=]UDU$69$HVU)-1$>PCO883[F"M
M>S&N?FP.^R.L'O=3_P!AA_PS/^@?5[[5GZVJ/\=*_F!]S!6O9C7/S8'?9'3W
MNI_[##_AF?\`0'OM6?K:H_QTK^8'W,%:]F-<_-@=]D=/>ZG_`+##_AF?]`>^
MU9^MJC_'2OY@?<P5KV8US\V!WV1T][J?^PP_X9G_`$![[5GZVJ/\=*_F!]S!
M6O9C7/S8'?9'3WNI_P"PP_X9G_0'OM6?K:H_QTK^8'W,%:]F-<_-@=]D=/>Z
MG_L,/^&9_P!`>^U9^MJC_'2OY@S`G0+('QCR%%J07QKP7C7D@8@;XSX#PG@/
M&/$H#/AO`^&=\%X3OO!^%<[SL[]7;F:CQV-;@&&6=:VMP32&]:U[:VHDKVN=
MK[+F/FD2ITO4*7,D22;N:"D2'GM36MK:G"*5JZVJ5[6O8K["&8]$9KUF+_3+
M^K]9A\VH?)U]@>B,UZS%_IE_5^@:A\G7V!Z(S7K,7^F7]7Z!J'R=?8'HC->L
MQ?Z9?U?H&H?)U]@>B,UZS%_IE_5^@:A\G7V!Z(S7K,7^F7]7Z!J'R=?8.-W3
MA1[O,/30[N&G$/-^%1(<\&\WGM;=1WT7/>.-Y]U#B>Q2<^ZG.,]`U#Y.OL')
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MTBXVXZJ`XG'V&5,(>>::7)=4Q&0XXA"I#R6'I*F6$JSC+KJ8T>1(4VWA2\,,
M/.YQX-I:D@''%FPYR%.PI<:8VG*$J<BOM2$)RZPS*;PI;2UIQER-(8D(QG/:
MMA]EU/:VXA2@#J2S@2`1%AYY@7"+',R\!1<LA$C$2^8#6'YV!<)YY$DAF&PI
M+TO$1IWQ=I6''N\1G&>@#LS9\$;'7+(S8D"*WWOA),V2S%CH[]Q#2._>?6VV
MGOW7&VT]\K'?..(1CM4I.,@';Z`.G@B/R04)Q/AY*IAI(J&8E,>4$CUOKC(G
MJA=_XSB&N2VY'3*RWX!3Z%M87EQ*DX`.1Z5%C*C(D28\=<R1XK$0\\VTJ5*R
MR](Q&C)<4G+\CQ>/(?\``M84YX%AYWO>\:6I(!B9%IK$3R-XU8P,;SCE8@5[
MQ@N/9\O3E8RI,,-X20GRI*4E*E8CP?#O9QC.<([,9Z`,]T`.@!T`.@#\RI.,
MIQG.,95G.$XSG&,JSC&59PG'\.<)QG.<8_@QG/X,=`'[T`.@!T`<&)494E<)
M,EC,QIAJ4Y$P\WF2W&?<>:8DK8PKPJ&'G8\AIIY2,-N.,/(0K*FEX2`<V5)Q
ME.,YQC*L]ZG&<XQE2NS*NQ/;^'/>I4KLQ[O9C.?P8ST`,*2KMRG.%8QG*<]F
M<9[%)SV*QGL_A3G&<9Q^'&<=F?=Z`.I'(CY<J="BSX<F:+<89)Q(\IAZ4.=D
ML(E1FIT=M:G8CDB*XW)81(0VIUAQ#S>%-J2K(!RR94:$PY*F26(D9G&%.R)+
MS;##2<JPG&7'G5(;1C*E)3C*E8QE6<8_#G'0!S]`'!)E1H3#TJ9(8B18[3CS
M\F2\VPPPRRVIUYUYYU2&VVFFD+=<<6I*$-H4M6<)3G.`#[:=:?::?8=;>8>;
M0ZR\TM+C3K3B<+;=:<1G*'&W$9PI"TYRE2<X4G.<9QGH`Y.@#%CS84LAAP47
M%DVY4;,V,L?/B342(:7U1LRV%1G7$NQL24+CY?;RIK#Z%-97X1.4X`,GA25=
MO>YQGLSE.>S.,]BL?AQGL_!G'\.,^[CH`*4E.,J5G"4X_#E6<8QC_CG/N8Z`
M/WH`=`'`Q*C2O#>+26)'B[[D61X!YM[P$EGL\-&>\&I7@GVN^3X1E?>N([<=
M\G';CH`_9,F/#COS)C[,6)%9=DRI4EU#$>-'80IU]]]]U26F666DJ<==<4E#
M:$J6M6$XSGH`Y<9PK&%)SC.,XQG&<9[<9QGW<9QG'N9QG'NXSC\/0!^]`#H`
MZBY\%N3$AN38C<N>F0N#%7)93)F(AX0J6J(PI>'9"8J76U2%,I7AC#B,NY3A
M:>T`[?0!\K6AM"G'%)0A"5+6M:L)0A"<94I2E*SC"4IQC.5*SG&,8QG.<]G0
M!\,/L2F&945YJ3&DM-OQY##B'F'V'D8<:>9=;RIMUIUM25MN(4I"T*PI.<IS
MC/0!R]`'$\\S&9=D2'6H\>.TX\^^\XAIEEEI&5NNNNKRE#;3:$J6XXM24(0G
M*E9QC&<]`'Q$EQ9\6-.@R8\V%-CLRX<R(\W)BRXLEM+T>3&D,J6R_'?96AUE
MYI:VW6UI6A2DJQG(!P(*BW'D1VR4!<AR3)A-L(F1U/+F0F\O3(B&DN96J3$:
MQEV2PE.76&\96ZA"?=Z`.`2?!'DSE@C0DTD80D"22A)&&12/*Q.]\;&3LPWG
ML1"$7OT>,0W_``<EGOT^$;3WV.T`RW0!TUD(#2Y;;DZ&VX/BMS9[:Y+*%PH;
MWC/@9<M*EX5&BN^)R_!OO80TOQ63WJ\^`=[T`X1!D18!L4P!*C38B<A3L(J(
MG120V8VE:VE.19T-UZ-(0EUM;:ELNK3A:%HSGODYQ@`R70!P-2HS[LIEB2P\
M]">1'F--/-N.Q'W([,MMF4VA65,/+BR8\E#;N$+5'?9>2G+;J%*`.?H`Q)H^
M"K<%1.Q&A(`:AQ#*B!HC#%P4NN]O@VE2YSS#&''.]5WB,N84OO<][C/9GH`R
MB5)7CODJ2K';G':G.,X[4YRE6.W';CMPK&<9Q_!G&<9]W'0!Q1I4::PW*AR&
M)<9W&<M2(SS;[#N$JRA66W6E+;7C"TJ3G*59[%)RG/NXSCH`Y^@!T`.@!T`.
M@!T`.@#22I]T`X\6"[<DJA8#[VL1_&*STNKW"^[,EUVKT*R/WFZV?5HLC33K
MIV1F:-B[=I5KU3/67BA9+=X#.C&(TAJ5"DR0#`S^Z2\7'K?`I%'NXC8Q@M3Z
M7>1!"O6N@C:L3#7#=\'0SL*-9;7;J_!39JY;I,ITO6I"6";^!S]?#-E+I(@U
MF2`2#57=#.)^T]>FMA,[:J=-9JJFDW*L7.Q5Z!;*BJ??C&M:^@R*'E2B5/6F
MWAG0U=BCI$^41*2X(5+*#DCR8D`_=E]T+XFZT7K%F1MZFVN7M@IK)%8AT^TU
M@L^FH[6.3`==V3-RX9B,HHK*Q9DA,(QG9,YP6".RQHTA@.03'`-G:?L_76PG
M2+-%NU9M[HD7531-%<,02V8(F\`VK-3B$G,-YU+46SUU]@X$>7G""(I]B=&R
MN,\VXH`J*=RTT\.FS!\N>;:EP)4B'*;P#E.8;D175L/(PMO*FUX0XA2>_0I2
M%=G:E6<9QGKR]6_=D^YZP]6:O0*MC67&JM#J<^CU..G"N*WTL5"F2G84UDGV
M**XP\34EAQ!.LN.-.$G7;6I!DH^V(&A'234H,.HPZ&R[$GQ8\V*X=7I#9N1I
M3*'V%FVY.2X@UM.)4:%I2M-[*21D9#J_=@:6]9'/D";_`,NN,[^'W-7AW,\T
M,8_@0^OXA-*/@^QY:HOKX?=@:6]9'/D";_RZ=_#[FKP[F>:&,?P(/B$TH^#[
M'EJB^OA]V!I;UD<^0)O_`"Z=_#[FKP[F>:&,?P(/B$TH^#['EJB^OA]V!I;U
MD<^0)O\`RZ=_#[FKP[F>:&,?P(/B$TH^#['EJB^OC8&K6D'<PD&PUZ<W/&3V
ML.LO-YQWR,__`%,OM]N5,OM*[4.M+[%(7C.,X]SKTQAK$M"QC0:7B?#-3C5B
MA5F*B93JC$4:F9#"[D=R427&7FG$K9DQGT-R(LAMV/(::?:<;3U95*74*)4)
M=*JL1V%4(+RF),9XK+;<38]I&:5H6DTK:=;4IMUM2'&UK;6E1U;R%_<_;_G/
M7/[?CKG2V\Q^@QQXGU!_:["_--_U>H%'=O.KTC7Q[]\30?SUH_NC8.K%\U7-
MZ1<;<=5`>7O-S4=EV]R'T=6"H,[8-4V/BOSJHP:,)*F0,(?R@LL3CZ3T_-('
M0Q`4^!(3]15?DH`#''BHV"V**VZMD7WXUL\4=`(?W,O4>T].V6^4VWUZ=5@%
M*X?]S6U/;Q+CC$@4[ROU9HFW@]^3Q)*`[(#63Q36$OC#3IMI`S28>>[3VQ$8
MG(<`/LQ0"F^=?$+?VT>2NS+Q1=0>??I&K7<YHVF]_-V'6D!WB:3XH\N-B;LW
MI.>C6FUB=FBEW"CV()/JSFFJQ<9&P+''=IU];K0(=`,/@'DC6>'W=1^1='XH
M;ZDTGE!87%\9]!.08^[^3U=FVL1NV_:AU.?Y`[A,TRW[[2T*U1>CH"'`9U88
M&Q;A7[8,+//:6J4:7B6@`V@5Q7[M&;K!AE=OY(U\J'X.W&*EN9R^`-S;GW2D
M1K^E=NU*P0K^Y)K0WC_L39,*1-UGK.Q/52@5>$+M<2X:BH-<M:0YT`O#F;PL
MYPS>:O)SDAQI#[BR.VQH"NZ^I9;5_)2#K<TSN>M:@VD/U!:S0RS[=IXV+IC4
M^V20`_?**D<2&VF=8&3+.L=E1//,>^`7:)XU\QZYHGA+?-FA-G\A^0NE.>UO
MY([UJ"]P4VP68G19^ON5VDJK$U`]L[955U-7A(.I[3U<:8H\2Y5"+@-"L4^8
M@AL)\E',`&E#/!3F%&U%Q#`*X:RR^X-!Z1$ZCQ-NVQ>*FS=`%Y4S;&K-QEH6
MS:+9+6-V11J]7RC+B@>[.-VP&]NM7#69^&2UK;:?C6)*S`'HES"J7/O;%CUK
M<-(4_>6OGB^@82:K6*CR&U5K@;Q]Y.D-GT<P1L/)B)'MMHJ.\->B=<ME0$JK
M52K;Y#E4"KB'K<6HG;?6=EB0#5ZUU#NH.J^$?+*R,WC95%'PAX"?K?5.P)A3
MD+S->D-:,T=7+O.UYR0H_)RVUVAPCW(.#M>X5X"=`[9D1JZ5>CP$:W"$1%=J
M8!#Z5QA[J([>]M7._3^82]%0-UZGD:=X_C^:(B-NB3QCD[?Y2$=JTB;>Q/(R
M(,E[4A!2'&XRBVV_>KAK&KH+M#K>Q)-FC600H`A5:X@]V;D:@D$]@[7WW.W]
M'U/O9B*]7>6R`M9E[)$::X>/<:\+KX;8H2BK<3N0'R5799ZP(\79US3#&QT3
M:">J@IP`K7='"KNP%U)ZYOX9C>Y+8^I8$Q<<F2Y55AQM[D9;=1<Y*7M;?VH`
MV>0P0)4]+6=JZ\6*O2]?D9=(,5:/%L3`O4--#3-DS[@`>A=/U_STQQ?Y@:CB
M3>4$+DM.U7&+:.L-VV-4HM>!1KIO3D8[3*K0+M)W+N@B+VG5*B*&2[U-N>_=
MF3!FNSNB0LZY3#(XNTD`H"_\7.ZE5.YMQM;&.2=UUG8MA<GPEDC3>8YHR6KF
MKD\G0MAXIF@K5EY+ZQN9"2/TR]81YML#N/7=XG`)*(VR+':YU;#:WL0!Q<-`
M?=5;;K[FE1;CM+8:=U:4X9YUGH^Q7ZUPBX4OSHW[Q]H5QV)BQGH2RU!L+_&C
MD)1I@>F'@A"RU8#0]MN#(.8F,F0S(!KF5X7=V):V[<-GUR5N^)6;?1*C1%HS
MN"IL;R@5RKA.9A.L56*<<YY3+.D'4MR;,U]L%K-EY:WQC+%E"XGB;K5*G8-,
M#0#:"B\2>>IW<7#:\<B*KR8V);-!\V2>S=SWU7+NEMZ:N-3-C>;='H^R--:,
M%[1"9J=;U]3=FZ"';+K7B-`(6*C><U.&Z5VE/DWF=;0#ATSQ'[H5J'DK>FZD
M#WM6M0EN:V=J4D^YR=!'-3,:_N'.O;NW>3=IV/KTKO0Q:+A!W5P]M>K]::W`
MD]=6`]3]W5B]6^6`H<\X[M"W@$1M7#[NE.HMR\UBW&RK;<B@N4O(FD[&K5KK
M_(JD(&5^)6^6&@+;=;79HFP=R0K*%:NO&@+LK7PH93P)DB\('JI)L.!$R*_X
M<`J78/![NL5I%$=>WUKD=N355NXQZSB,UI?,"L2V`7,611N'DS9]VV=YZ[P#
MOVS4K5HI/(P=`H(URWT,-;3[AVDZSBP#H*WU\`V"Y25#NE^U>7O(B'Q??Y,0
M:7KWEEJ>+;"D+>(G7>JK+P_E\(M`G-L:1TC5K-LRKX@;WNNX3A@M2=Q@ZZ"&
M4RPXMD:5NNDS\%!TH`H#:G`/NG.VM=74[L>'R*V#8ZCR7.V/C!JPCRYKR9](
MT'8J%REK%!1<UYWF*H=QV=KF%>-!5O:5DN-PN)JQ1`5_\VC&P(EGM\B]@%H4
M+BAW7(A8]%UB[V7D%6:4-M.XF.4A8-RO$U^OWL%)'<HE<9WM$PJ%N%-HU?4M
M=5<OHBB[%KM:#:NG'[FU7+$^.OZ:G8=D(`+GWAQX[I_L>C:#JV2>X95CF\.^
M%]#V&7J/(:O42IU3=0BR7']D-<W1``[0JDS9)G<^GR54HNF[9406QHU-V*,)
M6P&8UIX5-RF`%,[*X)\\=:5KA<`XQZXNH5JA\!]8<<=KE:%OL56+-1+X'K>R
MK,6AXF)W]IVUW0".V](HRY>*OMX0%@1I+%@AQ-E5BIS]27``@7'?AYW7*@;!
M"2^\W/K(=;MQ53;]Z.$]VU/8U=7L&S[#T+:MNV?8-9#\R0`\S42=`%7Z@G:F
MSKW:L:=('6\?0*Y39EBH>X&`"Y.=G$/NGF\CNUJA((V[>-+N.NT0)N-47]_B
MQIB<_7:P1L0$3K_7!?F?<"4:Q&+X.K0&P`]D5ES),PN1?V^3E<UYA_0W0!J'
MN=KNL&E@UXN>TQ?,2H:JM5'*>9%$J');%PV0(Y'P=;<\9%5=8O\`5^2NSC1Z
MKPCA;BN1D5<6O6M2VR2K0NO@.-]@MHLA3]B`&[6D-(=V"3H3F'B]WK:$?=MV
MX][1$:CD&-BU^,,*[++;3V`:U3.UA.([QV'C6EM$:2FUND2CDG6_&L0&L\D!
M(M`:]V:L&=H.@%#US@SW4EW9NWZ]KH[R-XP:)W!L4Y:M<E'M_P!8N.R=42+M
M<=H8VA<=QVD'RO..6RQV#7$W4(^ISB-1Y66B%8:M,E"[%JDXS.OMK`(MN[B3
MW;W?NI]Z#M@SKU@]R)XW[<@-:BK^Y*%)U?KBW7RM\P*.<TA8UR.0U6I,D5;M
M?F.,H\>49U!N<&.NTDB;KMXTOY%N%CLH!D;_`*Q[J]3]@:=JE@B<RCP&_E-V
M4^_!=5\H:Z'SLW;<#5W/>Z:IOFI3\/>@(7H/2-8'(XVM3JG9[!HT28-5VL!<
MZ_MMAAFHMN`+6J/$CNQ\:E![):]N;CF;^8*G[`5FM<HW_12_;A?=)J<<ILYK
M7<:_QZ<O7TK@M.V.U.H*ZLD`3`2(%:LM6?V<#I0\*`1&E\3^[-E`#B[ML/D;
M!(B^.MCE#Q:>30^J*D\MH9O@FF&<Q)`\H=IS+!1K(,K?*N6/#V&U@]8-R'K.
MIG3&JQURJ%3F`%E(X1<\*IQ]X`ZLU#7-H:]*:>WA<1_($@WR$KWG:SJ&V\V^
M/]GN)RI[#7M@Y:D5ZY\;0^W9$<16SXVVM#Y,X%/K(BUF8(J8`6=L[0O=4WM,
M\3J?2;IMADY2T\M!&SB(K;8@SL)BP3N05(E\.KQ=;J8Y#:QQ?*M5=#C+Y#MV
M+26WTJ;(/"6;UHG9-D<P1J8!0PWCEW7*;-M0[;@_E/?:?8`NPH^IA%&YI:EJ
MTG7"+,5XY9T0%WF2FV@:.V(K3^O`V_:9R!D/U#>(K<-O/S+6-B73%IJ)/5@!
M!Q/$ONOFE:IJK6VI!>]I-(H&F./<T&R.Y5UTS'K.VJ-J7AZ(V90D@K1R5US%
M:IA2P4S?HNNC2,O9NC0TF05$C-(,A+Y7MB4X`ICD/3.ZO\;--0R-YO/,"P3[
M5P4@P1@;7O).Q6N_Y[I4UQ[VS%P>'E`FP)SLRG`+W%I:).G:^3DU3:EN+5XG
MK_6FQ"8:V2!P!O#GB3W2O:G#?NH6H-\E-B7"_P"]^*.VM=ZAKI#:HH75+ENH
MT=Y'.U@CKLJUR'O>*13[#5CVHJS81)87QSUX3K+8FKV73[F1E]-GP#LZ:XB]
MT@#<C>.=2/67D13^*="VI?XO(1]'*Q,H-L"EUT5S8^Y[G:A@#-N6#8M0U2'#
M%.)U)N-&0,U_8#Y**!+6&JGY=6N]^6`3>)QHY8TSE3#L<'C79+I1J9S4YC<@
M6+P,VQINK5FYT+EIK:N:FKD(`[*V.SL\%8J`[<+%;-A>5M?",PZUKRPJU[-O
M-L*TFN64`F?<O-!\C>+$R[Z_+\22VM-9%=&:5KE)N=QLO%-S:HFZZ@K=V$S-
M9[-NG'JR9$;GU^&C'JJ%TIO,KIRK[>L>&MA3]Y5>,ZBISC(!HK4>-7=L#J[/
MFQD.2-+A"^-][M5`'R>6H!#B>5T^'PD8J0`R1'<I=I%+@)&F:!R>)/)LA$'H
MXO!M4R7$UIKZ%>O1H(`+&USP8YWV7C]S?&;BHFPBF\-U<1>"FMK//VOO:B;!
MC\D-PZ#V]R>O')@)0YT?9MRAZ[TWMNM["#5V@5&Z(UO510F_O!9=3J(F"?@"
MP"$\C-`=U3EEMU$N#G%/8?#ZLV:,=-:RI>NN3&I`\8K;;O7=Z4^ZW6_T@)R=
MK^F]8['('2&G[R_&KU7WV&DA1@&R4Z]:IV?7[O7KJ`=_=7'/NUH6[[9!\>B^
M\G*Z,V13C?'C8-EY3!KF-C5BR0M9QMJB[H%O7(@!-=$A3&;^=$L;"H.^5R1;
ML^OZU!:?6#K$Z[`$<H_%ONJE#VE8KAK?4W)FCUZZ[XX[;?-2+ORXUSL&]6'S
M#U[W.G6VZH6T7V>7+0JSIM=7TGR*"TY^\D>0H9X!)168U`U.JPUVVA@"V-L:
MW[I;O'EELB)I`YRGJ&JJSW0*H5;;-UQO^)K_`%S.X>L&.!]CM5*TK2R>QH!P
M5;0H)WD'99E]J&O!KYBO3+C11VP[,>*AJ'``-7^2W<W.Z?;]HPFO'0^YKT2U
MC4=KSQS>SN5X>RA;;R@D<2NZAT.K;LUB.+;M,0:_K<]L'8W!VI@ZO=854?%L
MXL"CFM:Y5'MSFK@`;GE.)O/'5W#@?JOC]6=^U_9]9YC\_-CK%".2`;,'8=3V
MOMW>M_T)9B%[(<FZC:Z]33`B\4>=(<F';+.J^THIRZ;;XI;Q9(&VC8!K#,X6
M=UVU)J@=K'1`[=`L6:XWBEJB5OEB-;%ZQY4M3>?2US:Z$D<BM4*$4QUFW<37
M3+%2LSNLVRD`1:CFD=SE@][#1P"\Z/H'NOE6NNI-HV8QR*M2GKB3V/L#7".0
M%'-8&J!\W-HW`AK8E!(\I*;IH/7=E<*TZGUG5!8W7V]*^$/^7U.OZ:N+CVST
M@'])XV3)F#X$N8/?$S)4*+)E"I3T.1*&27V$.OCY,@?(EP'WX3JE1GGH,N5#
M=<;4N-(>94AQ0!W>@!T`.@!T`<;N7<-.Y82VM_#:\LI=6IMI3N$Y\&EUQ"'5
MH;ROLPM:6W%)3G*DH7G&$Y`/"L/W)7;%>QJ$LQR(3:K!E=`.<AX-QBH<JA>Y
M5CG%IGFZ7*ZFCA*P-,P8,^Y@-YP6(][)G9CK^SX<Y<R'A@BTX`2J5W,K;S90
MAD=L76[@>R6JS'3N9D:SLD1T61W3XGSXKS0AMB`_%G/NU0Q)H1E,QR`W$L,5
M@A!=G#9#F6`".5?N8_(((8UE;IU^TO+L'&[%;5ID1`;NT`#L'Q?DT6Y!6)K:
MTU8:5+JCGD^=%J->G5H9<\QC;,N[RH6<2DU=D`^Z3W,3<6LBE?6B]:LM=();
M$XX;SW!$E`[8]9T6_1>T=G[)LU&U>(1&ECB5/M,78ZP]<D'Y@\D-P$>@R0LQ
MNU.20`!M!W+#CS;M`<<#$>_#;`)M%YV*;GB15OB-PK@#T]K8%7-"<<P-DAMS
M2/DPM%T)J779,F'5->=&&C)9N=AHLX21@`IVT<:.3!*RV(C`H55<@SSA:;"<
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M8WRQQ=UN_I7=N_\`9FY,:YKFS[`2':IW-Q#TP,T[0ZU;8\P$J^;*5RD(MT@K
M(ASVP6RQ&NIYH%<:5FWTJP@'!W,+DIR%W"7W!K[D'?*AM0E7-?:7W=4;M39^
MK3D8)5MU["Y-:_#:DLMITFTWJNT[(H-?XX@#VV"U,=FUY&T=@7(;593=%'U`
M8-`*;YS<S-[Z:Y.[$K%.W`W16]6@.YQ%M-\?5@-934<M9W)_EWL+3N_1\R1:
MZD8V8734*%6@D``C3=FI\C7)N2]=;XNQ`B4`4R`>:UK[NKRCNB]&F*W)T=2*
MC=-#:FW/:,ZH/C;:2)'=[4G6MT%:.&638E5M085N'4GCMD:MP?S=F.%P-C%O
M/@P<UB,1B@%[/=WBWU)K<TV!T;HLLL=P7/<_3*HU[N4N'5ZT'U_3]C$^+]@7
M#&.+B\@J1$-2JUL"?+4-&A9ANJGGJ;#;\-720!;W+[NF7)WBISCY/T],[59W
M2.MN-(K:-"IU]<9IP-P]2M1[3W)9JDW<(`&1:RVY=UN4[-/H41RQ2ZK7P`$B
M>AZZLQH>29)`%X@NZ"[MM^H>"W(B[JUWQ_USOGG[;=.7H<J:S,BBM$UK6'+0
M$-@;-M5_$PH-/L]AW/J6C3<RJXZ*\0F3@E)C'B:B9!)@`T91W3[=933?#G:A
M#E^":8F:.$73D)5]0"^-QC<Q*_'-P:S9"%2VJ]E5&""V)19NL[F!A&=5Z$V+
MJ_D`('[+J%\KE=NZ+;1FVP#TIY@=TUSHFPTV1J1.B]CZ^-\?X'(P'8K!LPA&
M8Y$@S>UZ-K,'K;C,<HP:Y#K9L`M%N,8^`DL#K0&L!8YKJJNMU\3=95^K0!2,
M+NO&T8G&GD?N&1Q^!;(DZ'8K,STQZJNU;7Q2RFW<?=([YC#;I;K!<$;'"SZV
MYN)>O3LBF4G8<51`!#LL]-9:.S*Y6@"IZ5W9+D%?-G[2UN.H/&`55M2[UU9Q
M\.<AI]\NLK4I4OM?;/)ZA!ML"T,MQH+.MH4/C@X`E1)=]\9D;6ML*F1+`Y&B
MK)N`%>U?NZ')6[:B<WD*XXZ:`55C5&[MGR*H?N]]DV=,?CYI_B)N>U0XI6-7
M8(Z8Q>!G)V56:9-=%P$C$5D;=BC9-DR[3H0!7NZ.[N<D*B5U;;Z]1-*1J3BM
MRMK7BFLV&5*(JC7+5'.0E3N-6R+2:Q'BZ]W%KJQ\38MIV"3@>3G7&K2/'NUD
M8%`DEVX`])`7=+=L9XE<K-_6*@<?W[OQNJ)TN-UU5M]5RTV6TS`>Y-R:RBV2
M]5C7$_:0;5E`MD;6\)BL3QVT]G$G=@!-T4>6TTO5[1*R@&LMT[L;R#UO=&]<
MWC7W',8<L=ZY/ZPHYYJQWUB`5M?%CD<,TS8''!M@<K]:BN7ZNF/.0`,N6T]<
MU>KN5TNHYM`A)*!*\Z`3;CGW9S8F[].<B=L2>-XMJ1Q@X,%.9FPJE5;>6-/F
M5[$TE1>1'%W7M/-N5]#!)W8NOI>TP-M-H'R'`EZUZ^+@B'%X(PH@!I\7[N-R
MUKF]KW4I>I]3DH$/7M6AUD=C:>AV-4-V$+6N9FV[/L`EL6%NB;7:W.NM>TG5
M-7NTT_OTJFH(K%GV4,`F2*<T"Q@&S5&[JQR$W1MKA7"%2N,NGJ?NKF38=/;2
MU*0N!.X[WHE2KX[G!3H5%V6VH8Q4`5@O]OXU@S=%L->.""<RZ38VOH`&SUJ&
M0LML`.#3/=8^0*.0>P-$;)@Z3O#]/YG1=+*;#D)];V&<IFXN>^Y.)=0`T*LQ
M<OQIQCC94=<"=T[9EEHQ$@7U%<*B3GK"3)3UI*@$',]UYW[Q^W+SIJ.VW=;;
M$8I'(C7-0X[U69.%T14>IV?E+HCC0>IP&/`!,6.XDZS6-G3]N'21,O:RGE=M
M<3'D"HYB1X@!5NP^[?<I"@$_18-:T!HR\R>+^MN4E?V/,L94I%(C-F5;AQ:Q
M6F->@KL%>$VG;`AODT:\J3R$62.+AJJ-R.J`B187S%9`-M^8'=B]A\:.2%\T
MJ%UUIBTC0')W6/%N"P4OIP=?JKC:G%S67(9ODWLL%&A/117'G6I&Z$ZE>B$=
M45QY,>#);L@20T^Q,`-2]M]V<Y>6&@WVX4,;HC4-.TAR4N/'Z[7V*9E663MU
MZNT+E6L;;M7OW&M%J=5J3L$KH81<=7&B;=XF%%W.E"7X1X,R4S<`"SZ%W:_D
M#=2O'ZAUK5&G"%GWZ?W/58$BRVZQ2S^G5:#;Y.B);^^P]5"B(V;?N-SCNWL&
MAA@`VC"_-\O9P\5J9%KT6T2P"Y]V=UUVW7J#IBPZ_P!::P#F]O<0^$_("(#N
M=C.3[`8M/.2VW/7L03JT=!C#L6L/Q;EU>+M#=;LB*_():Y-#^]13UJP6?`*Q
M9Y!]TTO6.&-&U)N(W9MHWSN<VH^5%].KJ?&,)K`O>K-MFC^=EDW2Q8]<L71B
MAMZW-FP$:K<=8(*TN'4C7X_B>/&32`"BZ'W=OD+KK46A8.ZZYHR[;))\.^*W
M*.XV)9LG2C>QJ=M76/'XK=R+(R1`I^L*M81MBVQ**6.2#.294.04K(/6NA[P
M$Q;;!1P"TZMW=7=]AM5*I$;0VE3%H-B(>P[!&![GJ$6MQ:>2L'&L$*I57V79
M+Z&U;?3]C9W[*.4N[:XN=\L9\<"K$6P\=Z&6N<Z#3P#?4[RHV)7^Z85#2@7?
M0_96M;6G<P*WZ.!5;6R"6JK3K[05!VE5Z7(@0V'MW^=IJ/+)[%F[>LUB9TT4
M`["I6JPU)A7!T9:"(!Y35SN[O)]RPRK#$H6C=GC]A\6=)<F:QKZO;.H-5J.H
M'RFL+/LF[:#M6R=C6;6JFMW6!PS6*N04:/6"16W*#8K,!U'*9G%:P(`+W*=W
M$Y!(M:JD&XLT5Z=3)6V*%L^6;VI7:8&;Y`\8;=JFJ\@]+5X_LZU:X"MO$?3K
MKLEJX_$FW&PSXPVT+1KBTPT/SP`!3.HN[N\@86EM.E+[5]*VFUVO:^C^/EB.
MW:T/4:Q@"6QSG#9@SR;V@"JX:'7JMH[Q'E9,$"T!PXZ.P8J59(.V*6W=I8*L
M`%HU+NV_)W8(.W&:II'CVW"J&RM^:;26FW/8)$7;K#H7BMNKDZ]LJKK'#6VG
M]:;'$Z&,P*/'\>DSW@VQ:I9G#<F/7)<2V`&3K7=NN1>R=D4"D4CC?J>N0=O;
M1WAK6J$[WM0//*4ES1@3D-+DEK;1JA;)VSR\#8^=&*LM-(&=?ZF#M`2>($4E
M:&)P>VR0",C.[`\C,<$-R<S+)BDRC57Y,:D53]2TR6$&R:[JG87%S6W((?K6
M_ESM0M$XH&).VN0+=M0\-5[D60DO*`64(Q''M1`#<HKW3K=@#26PK*6U'KN3
MLZJ\W-;<1XCX6SMQ=;#1VS^.&H.2HV^V&;LBU:R'L^1Q6U&M:>)&-@4L=8[C
M'#SXA8/Y?CUID`U-H?=V-N;!LE-HLW5O&O3A6V,T3#VSMB[F,']&C9=WXR;.
MY-&G!]]JHID!<0&G"6K%\8MIV2JV(@-B[QV109`W.6'FJD<`(53>[8\E*A0J
MJ[L89Q_M1S<MPYCDM0V228L(]M072'+SEA0!.N_<KVK*0=7!U?IL1`J5KNU@
MTC&FUNM$[5<3I_9A890[0`3"E]W:V]=V>/9YW5''^A4'E#-V@+J5^MFQ[.[4
M]--:FWQQ5U.9N&WK#F`$#SZP?A\G(L0&V+EUQ+%OKX:).-YBW'$>O`%\]SM[
MKQNCG=L:N51S0^NM?`K30K)+8(IV?6RQ81;P.EM"[:AV-%3EVT5M"T:U.R]V
MMUQN7$U4#@CAT*I67SY)2KQ(J]1`-'>.O=O.7@_06C7MBU;4&[-N[+VGHW3C
MN39IW7]O07Y#!N*^T`VY;/6:%36!-=T*"$\K(NEZ^X+JD\L]::17BI6W6DM;
M28N``7YST[HSS3XH\G-@UV&9A&]3QF^YF:SA`*/KVOF)U6WOO_D,N5L%H-/,
M@R9J32MTZ2UWNS7D61;Y4]ZGW).L$U.0)LMD?FK`*QO_`';/EI=-<;;$:<IW
M'&O6ZI<"-D\VW]S"[-9;Q3:>,KNN^(=X9UF*#2Q,D58=H45_E"H1<E6.<*`+
M'AJ_;Y(,+@\[2XP!=>G.ZO\`(@/QHY"W#;S&M]FW2H\>=S;@T5;M;PIF7=@[
M`=YJ<@>)FCM7.UL4,R),QK=<*IJP'3)]<CO$R$,RU'+)M1Z4Z;G@$0T?W6SE
M?F?CCR6`TO9^W=+[<TOHK=>R=T4V[Z*NMB-<D^9AOC[I:XS=,BJ545460]IB
MWZ.WO8Z_,KH#R@@P8JH:"-8+#+2,`,#6^[S<C;='#J"<7-3-RYVT-%:%DL']
MQAP36;[M>1Q88F[''AG#TO;I+5K)'D:]7(C`C39>(*E`AI:9L8O*G&:F!`,U
MKGNTFY15&O[NR)/'`78=:;VO''^9%VS>+2*V#L6WS]D[5$U6^:MK&LM50QI?
M5`&97!&L!`FSBJ:P\\&.S=C<@@Y2NECUA`+:V1W:*^4[BYIG?@Z@Z.:.7+5/
M="=CVBM6S92X4.QG>`FQ`]*=U9JN;5IUK&%-A[W;=(XIHJ-8;="`E)8]$`EL
M*#"\8-@%86+NT/*%=&/'HNI="T\J7IFO;'K>OSK/<RUWL<+=6Z.2G'P&5`AI
MD`7%/3=!G..4O<.]!D*(1'Q=?7@.$;GAW@;UHL8!%^Y_]TLYDV4KMZ)O3:>O
M=J0]2\+]H[QCP-B.ZSU:4O6R=?UW7]L>D(M])UUKNMTF@1XMK:@G')M9L>*@
M+E2SY@N3;1!1%`,=&[MOR+`7_>=]M`K2$S4&DJ%Q"![)HLI=Q#-T6];CW?S;
MI%LMT>STJK;4GS7X5>U?K"3<(='LW(>BY#4]4C54TK9K?8((P`D%6[NGR&MQ
MO;%<`Z+TD85I.V<?Z;=+%!O[.$SY')/:6N=7TRPC`ZKP[1P`:N2-IBCI=F[[
MMKZ2.*N_7C17796V37=;@'NGPJY*Q^5_'BD[;DIH@ZXRV7`^R*GKW9%,VF&I
M5VA-1YCP1VS40_9P:'BE>)5VZC1OEJ=+C5FV`'W9<YF7'(2P#:WH`=`#H`=`
M#H`=`#H`=`&L',K=MIX[<=;OMJDB:^<M0(OK8(%'6KRCFOKE7_:5*UYF242)
MDPR+D<<Q:G2.&8DIAQYV(VUEQ*%JST`:`[A[I5N#3&OMGC2NJZ#;-]:3Y$VK
M6%W!U@G9DTVQ:EUQQ=@\RKYM>L1):5V`5,CZ;(1*W!K1&<7PULR<*'*(D!Y2
M+G(`*=T=VJ9Y86?CEK!/'@_*>W[$T70ZL1FW9[9+P$SQ0`<AH7(,TV)*.")V
MK09LYBN'!\:&#ESQT1S(>P^6WHL"0`;E\&=T[OY!:E)[/W+`U4(Q*V!M&CUD
M7K*+;F,L>B#;FQ=0V*<=?M14GA_RV3HS9H*V/Q'\2@3EQ9V9$AM+O0!YU7CN
MSQZFW6WU#''T01Q5;18*W@AG9$R)X_Y#+2Q?CGBGF7)\6\:\5\/XOXS(\#W_
M`(/P[O>^$5Y>K'ND%4JK52E_`Y+_`+VU&;`X?X0&UPW<<EV/PO!>\KG!\)P>
MOJ<(O4OJZZK:Q^S*![DA-<H5%K7P_5%]]Z33JIW-\%B>[G]\(;,O@.&^$37"
M\%PO!\+P3?":NMP:+ZI1?]G"/?[N(C^E"9_D3KCN^?7X$I\XS_`ARW>:H^T9
M7FD7]3!^SA'O]W$1_2A,_P`B=.^?7X$I\XS_``(.\U1]HRO-(OZF#]G"/?[N
M(C^E"9_D3IWSZ_`E/G&?X$'>:H^T97FD7]3!^SA'O]W$1_2A,_R)T[Y]7@0G
MSC/\"#O-4?:,KS2+^IA[&\:N1U"Y/:S&;$H\GP:E93!LE?DK3DG5S[3+3DP0
M00G\*F\.H>BR48\#,ANL2F5*:>3G/HK"&+J3C6B1ZU2'+MN?JI499EW1`F(2
ME3T20DMCC>NE2%E\AYI;;S=T+(>4,>X%KFCS$4K#M=:(G6BX:%,:)7<M3@+6
MM+$Z(I69M.:BD+0K]8P^AUATB<;4._R%_<_;_G/7/[?CK:2V\Q^@QI@GU!_:
M["_--_U>H%'=O.KTC7Q[]\30?SUH_NC8.K%\U7-Z1<;<=5`0*VZNU]>SM,LU
MOJ@D^=U[,-3J@1(-+6Z)<L89\"=C90AQ#)$65'O-+FA2K4X0\3&@3JH/ERN`
M2(T`_:?K#7]`+W4[3*H)KI;8A@8>N,T<TMM9DB&KPJJBLJ0MQ;4&"/"!H;$0
M2,;A"69;I,LB%@N;-3B`!)2-?!%Y$.84#C"$T<W.9'3I<*._.'-DX_BA%(Z:
MXWF5`\>B_P#1Y>8CK*GV>QMS*DXQC`!`]>:1U'JC7E%U1K[7M7K>O=:5^LU>
MCUF.,:F1``:G5H=3JTRQ()>.D),L76!(T*V5GRY99^#$:;E3G\]\I0!-FJM6
M6$2T,5T$R@@^3DST-"![:)LDUX')F1+2B/C$E\MF.QDFZ]A;D_P+/C2G?!H[
MT`YI]?`E%863"""*TRQ\]*YXV'+4F<)6MT7-PJ0RYG$L:ZXXX/DXSX:&M:UQ
MUMJ4K.0#\G5X`3$O@20,.0!RNWQD-.&PI8F1WTCQM7AQS[+D-[OI?_2L^$95
MVR/]-G_2??=`'"[5:P^_`E/UP"])%3O*8R0Z''N/CB7BS,+RA`>7'RY#G>)Q
MV(GC<=3<CQ9AECPG@FT(2`<RZ\`<4'4X##K575977U+&0E*!+5'5#4L/G+&<
MC%9B*5%RJ%X#.8ZE,9SX+.4]`$-O&G=8;'US8]1W&E!"NMK=&?B6.H,L+$"2
MC$J>@I)2Z@(Z.?:7)(MIFR'HSS+S\COW77%*<<RH`E'F?4O)<@'YKUWR++BM
M098?R(,\ER83#S\EB'('^+>*/169$F3(:CN,J:;>D/NH1A;KBE`'=6"".8<2
MX&%+2\F0AW"Q\16'43&X[,M+F%,YPM,IF'$:D)5VX?;BQT.X4EAK"0#JYJE6
M5B4G-:`93-*K.S$Y##LXEG'6,QG#,K&8W8^5<C9S'61=[^8MC.6E/9;SWO0!
MB1FMZ"&*E#8FGUT<3-UBL4LI(ABXC")E2ID^T%*K77(S;:8B0X$C=;9-'06F
M$,,2#Y)W",JD*ST`9J76JY/3A,ZOA)J<2/&\)EBH$E.)7E".6\9QAYA>/&/*
ML2*3\-_\SRA&CS.^\99;<2`037^D-7:NL6R+=1ZJV(LVW#0P[L$U(+'3D\[)
M!BDA*^.;>L!0ID+6*V*PY"K5,K^!51KC4LAD(#@.$B"Y(!+DTBEH'L"45"KH
M%1O%?%AB0`I(^/XC.>*0O`0\1,1FO$R<B01B^#;3XO.?>EL]Y(=6XH`[GFS6
M_&94SS>!^-SB4$Q-E>28'C,PN+2A`PK*?\7\+()#D-MH@SGE+DQ$MH3'=;PA
M.,`'[BLUM))HSBOA,%V)4R:P5P)@8),S2,1B`0EM3L1_&FY4^#%C0YDA#N'9
M42.Q'?6MEEM"0#\E5>M39+4R970<N8PY)>8E2A,!^2R],<ANRW6GW8ZW6W)3
MH^`[)6A6%/N08:W<J5&9R@`^'ZI5I68JI5:`250EMN0LOAASV8CC,%0QI<7+
MD968ZVAJUCFU-=YE$%:HB<XCJRWD`B`/3&JZY;=F7L110$>W[C*Q#6S#ST7,
MZ=;2$*C4[6K"I^2"Y33,15'U]3*])&P&X@V;&K\)^9$?F^'E/`$P55:NJ`D4
MJM@5"TI'H2-4''9@)0)0VV*0F'F/XOA(QMII`].&^R&AMM,;#:4)Q@`^V:U7
M(TF1,CU\)'F3'X\F7+9%0&I,J3#@."HDB0^AA+K[\48\Z.CNNJ4XQ`=<AM*3
M'6IO(!]NUX`\\+D/`P[KX./)B!7W1D)QX/%F1DPI<86XMC*Q\>5#0B))9B*9
M;?C(2PZE32<(P`=QH?`86TXS!ALK9AI'LK:C,MK:@(RE2(+2D(QEN&C*4Y3&
M3G#*<I3G",9QCH`Q,BGU*9XOB75Z[*Q#CYB1/&`@Q_Q6+D>\)S&C^%C*\!'R
M+D/C<LM=ZWD>^]#[WQ=Q;:@#Y9IM0C^+^+U6ML>*&G[)%\"#&->+6&4E:9)Z
M/WD5/@34A+CB7RC?>SG4K7AQ]6%9[0#(H"AFRSQ]L2,;.R838V0:1`BI+/CF
M7<OLP'B26L3'833V<O-Q5O*80[G+B6\+SV]`&-Q3*>G"$IJE:2EHLV>;3@$+
MQALXS)E36C*,8B]B"S4R=.EMD4]DQ$F9*?2]AV0\M8!W)%<KTM4=<L$&E*B%
MTV"(J0+A/*C'D)4E!N/EQA662Z$J4E))O*9B4J5C#V,9ST`02_:/U'M`*U7;
MYKZM6`.T?UI9T1'H"8:LF=/;'K>W=:/N2AJH4QV+4=D5"NVL>+=D+%.D!J&Y
ML*5"D2XL@`G3%;KL6.S%C``L>+':;8CQF!4%F.PPT.R':999;82VTTT(4H4V
MVA*4('*S!3C$;.6N@#Y9K-;CRY,^/7P;$Z8[%>ES61,!J7*>@P7A<)V3)1'2
M\^[#&2'QT5QU:EQX+[T1G*([BVU`#S9K?@I#/F^#\#+\4\::\DP/!2?$(B8$
M#QAOQ?O'O$H*$0XGA,*\6B(3'9[QE.$8`.2;7@!&!/%$`8>>,*J;63&S1D*5
M`)+:1&::7/AOL+CS%-MPH;;:I#;F4(B1D)SA+#6$`'7FU.JD8V81"LU^?#5E
M]2HDT,.E1LJDD&"TG.6'XRVLYD%8L4F_G*.UTA&8FN=])9;<2`<DBLUN9AK$
MNO@Y6&)29K&)`F`_AF8DEY83+:P['5X.4DO_`/%4OH['<$O^G87XU_I>@"#W
MW2FL]DU+S(LM==C`&Y4";#\S3UDUN<$RQI0<:B2`-LUT8JMKKSJ20D=(?6#-
MC\S$Q6X\SP\7*V5`&2USJ?6NHJQ6*;K2D5RF5RFU(%1*T/"#6(ZAE0K,9,0$
M`3.4EPC)@CF4YRTF;+DN+?<>EON.RI#[S@!)$5:L-R$S&ZX!;EHA0AJ)2!`]
M,A(X;,20'#TOICX=3"'ST(G0HN%88BS$IDL-MO)PO`!WWQ0N2MQV2-@2''G(
M3KKC\..ZMUT:]F0.=<6XVI2W![ZLOPEJSE45[.7&,MKSE70!T8]7K,1F1&B5
MT%%CS$E42V(X@>RS*2=>;D&TR&FXZ4/I,OM-/E<.I5@@\VVY+P\M"58`.1BN
M5Z,PQ&C`0T>-&1';C1V!<%IB.W$F^4HB&&FV$MM(C$?_`(A'2VE.&9O_`$IO
M"7_])T`<N0854N1/4'%JG3'83\N;D?$S+E/#5-+'/2).6?#/NP%L,*A..+4N
M*IEI3&6\MHS@`ZJ*M6&Y7CR*X!1-\4BP/'$"!Z97B,&=@I"A^,8CX=\4AD\8
M(Q8_?^!CSL8EM(1(QX3H`XI-.J,U;[DRK5R6N2-FAI*Y(08^N0((RU3R`I]3
ML5>71L^<M<V;!<RJ+*EK5)?:6\K*\@$2-:4U18KI1]A&Z%72-PUM!N0^CEWX
M?N5V-L$E4S%QS#'H6@6Y*-EJ-4R3TZ5"D3HTX+&E09$5Y<A;P!-EUNO.O0)+
M@$*Y(%-$&!DA8N"MX:R61WA5F`ZIC*X;1-'WA!N.IM$U'WLG#F/<Z`/MJO@6
M'FY#(00S(9:E,,OM#83;S3,U$9N:RVZAG"VVI;<.&W*;2K")"(D9+N%I8:PD
M`ZT*I54;#:'CJS7X$!AMAEB#"##8L-EF+)E38K349B,VRVW&F3ITMA"$82S)
MF2GV\)=D/+6`<+-+IT>%,&QZG66!Q`>R)GCV0(MJ%.%QXZ(C`V9%1%2Q)'L1
M&VXK,-YM<=N.A#*&TMIPG`!FH0X>,:RP-@PQ["E(4IF%%8B-*4U'9B-JRVPA
MM&5-Q8T>,C.<=J(\=EE/8VTA*0#N=`#H`=`#H`=`#H`=`#H`I#D;HH#R4T[:
MM-66Q6>I"K1+J)'-DIJ@2;*'(TJZUV^!)@OSG!V4`M:#=8'ID,E01**_#5(8
M4QA3B7$`&HF>Y7\;K-:9ERW9-NG(XX:<VT9M*]RHH!$=9;WN`3J*J&-AR@=0
MH5.!B;-5M?:3I.NJ$W6QH8'6JHDSWHB8>,SSCH!G=5=S?U-JBO4@$/V%MJS/
MT3?FI>1(X_:BE0E&R-TT_P`;ZEQ="0##XVF"HT@(;UW4(LVR8CQ8I>;9B)2?
M$+01[S(I@`VLT1I:M<?M<Q]95(D<+!(]RVG=D3;&_`D%<D]M;3N>VK!&4Z,'
M"XGB,"P7@G`#HQ#Q(9#QH#,V3.FMR)TD`\6KWW#0U=[Q<KI]V?>0_G=:[%9_
M)$;4^NY4<5Y?+S"ODUB5):S)DLP?&_%6I$C/AWD-)<=_TBE=="5+0!ANI5&?
M47JA)2[4)LJ:ZDFEF1.2GW'UD1E+25B4X9%9*2Y"V#U51O=58DHU(I5'9PY3
MW&:538--:<5,6E2VX,5J*A:B[C592DM$HRUE6,[7/:(I^P&&O]^&_P#]#^M/
MHNOB[W/"_P!8ROW*_71R7?>8H\&:;_&K]1#]@,-?[\-__H?UI]%T[W/"_P!8
MROW*_70[[S%'@S3?XU?J(?L!AK_?AO\`_0_K3Z+IWN>%_K&5^Y7ZZ'?>8H\&
M:;_&K]1'ZGN!IG&<9SS@OZL8SC.4YU!K7'?8QGW<=N&L9QV_@[<>[C^#IWN6
M%_K&5^Y7ZZ'?>XH\&:;_`!J_4A[GZ)T?1>/6MP6LZ`/3$$B&,*F3G4HR2/%G
M4IS/-EY"$IS)(3GL9<6KL2TPWX.-&;9BLLLH[JPUAREX4HT.AT=@F8D1&:CL
M;TE]5C>ER5D1<+(?46LXNQ$1:K;:4-(;0GS3B_%M:QO7Y^(Z]).1/G.7)*=8
MH\2,BY1X4-HU*X&+&0>HTBYJ4>LZZIQ]QUQ>-Y"_N?M_SGKG]OQUSY;>8_08
MUD3Z@_M=A?FF_P"KU`H[MYU>D440B>*;YH,]]7@F/'#S'A%_>HR]-K!J)&;[
M<_@4_(?:9:Q^%3BT(QCMSU/$?+;Q"_%[6&U74`'0`Z`'0`Z`'0`Z`'0`Z`'0
M`Z`'0`Z`'0`Z`'0`Z`'0`Z`'0`Z`'0`Z`'0`Z`'0`Z`'0`Z`'0`Z`'0`Z`'0
M`Z`'0`Z`'0`Z`'0`Z`'0`Z`'0`Z`'0`Z`'0`Z`'0`Z`'0`Z`'0`Z`'0`Z`'0
M`Z`'0`Z`'0`Z`'0`Z`'0`Z`'0`Z`'0`Z`'0!1_(!*7:/#B]^G#TJT@$1V\Y^
M^>6T^Y)6A&/PJREAAUW/9^!#:LY]S'4E]Q^BP%T[?1]VT6#1V5,@(:%8SC/@
MF_P__F?_`/>H&-SBY_N$6V'046=C#K"G&9;*T/QI#"U-/QY#*L.,O,NMYPXT
M\TXE+C3C:DK0O&%)SA6.W`7(^(_][;#+IS+F%8OEM]"4)B1204FAK[Q$LH$P
M[,6A/N)\*Y#D06G%8QC'?.*9\(O/WSBEJRI69R_V^ZXD8[SLY#_]:J?-^5]J
M],MQ])=@G+<?3^0>=G(?_K53YOROM7IEN/I+L#+<?278'G9R'_ZU4^;\K[5Z
M9;CZ2[`RW'TEV!YV\A_XZI\WY7VKTRW'TEV!EN/I+L'[YV\A_P`D_F_+^UNF
M6X^DNP,MQ])=@>=O(?\`)/YOR_M;IEN/I+L#+<?278'G;R'_`"3^;\O[6Z9;
MCZ2[`RW'TEV!YV\A_P`D_F_+^UNF6X^DNP,MQ])=@>=O(?\`)/YOR_M;IEN/
MI+L#+<?278'G;R'_`"3^;\O[6Z9;CZ2[`RW'TEV!YV\A_P`D_F_+^UNF6X^D
MNP,MQ])=@>=O(?\`)/YOR_M;IEN/I+L#+<?278'G;R'_`"3^;\O[6Z9;CZ2[
M`RW'TEV!YV\A_P`D_F_+^UNF6X^DNP,MQ])=@>=O(?\`)/YOR_M;IEN/I+L#
M+<?278'G;R'_`"3^;\O[6Z9;CZ2[`RW'TEV!YV\A_P`D_F_+^UNF6X^DNP,M
MQ])=@>=O(?\`)/YOR_M;IEN/I+L#+<?278'G;R'_`"3^;\O[6Z9;CZ2[`RW'
MTEV!YV\A_P`D_F_+^UNF6X^DNP,MQ])=@>=O(?\`)/YOR_M;IEN/I+L#+<?2
M78'G;R'_`"3^;\O[6Z9;CZ2[`RW'TEV!YV\A_P`D_F_+^UNF6X^DNP,MQ])=
M@>=O(?\`)/YOR_M;IEN/I+L#+<?278'G;R'_`"3^;\O[6Z9;CZ2[`RW'TEV!
MYV\A_P`D_F_+^UNF6X^DNP,MQ])=@>=O(?\`)/YOR_M;IEN/I+L#+<?278'G
M;R'_`"3^;\O[6Z9;CZ2[`RW'TEV!YV\A_P`D_F_+^UNF6X^DNP,MQ])=@>=O
M(?\`)/YOR_M;IEN/I+L#+<?278'G;R'_`"3^;\O[6Z9;CZ2[`RW'TEV!YV\A
M_P`D_F_+^UNF6X^DNP,MQ])=@>=O(?\`)/YOR_M;IEN/I+L#+<?278'G;R'_
M`"3^;\O[6Z9;CZ2[`RW'TEV!YV\A_P`D_F_+^UNF6X^DNP,MQ])=@>=O(?\`
M)/YOR_M;IEN/I+L#+<?278'G;R'_`"3^;\O[6Z9;CZ2[`RW'TEV!YV\A_P`D
M_F_+^UNF6X^DNP,MQ])=@>=O(?\`)/YOR_M;IEN/I+L#+<?278'G;R'_`"3^
M;\O[6Z9;CZ2[`RW'TEV!YV\A_P`D_F_+^UNF6X^DNP,MQ])=@>=O(?\`)/YO
MR_M;IEN/I+L#+<?278'G;R'_`"3^;\O[6Z9;CZ2[`RW'TEV!YV\A_P`D_F_+
M^UNF6X^DNP,MQ])=@>=O(?\`)/YOR_M;IEN/I+L#+<?278'G;R'_`"3^;\O[
M6Z9;CZ2[`RW'TEV!YV\A_P`D_F_+^UNF6X^DNP,MQ])=@>=O(?\`)/YOR_M;
MIEN/I+L#+<?278'G;R'_`"3^;\O[6Z9;CZ2[`RW'TEV!YV\A_P`D_F_+^UNF
M6X^DNP,MQ])=@>=O(?\`)/YOR_M;IEN/I+L#+<?278'G;R'_`"3^;\O[6Z9;
MCZ2[`RW'TEV!YV\A_P`D_F_+^UNF6X^DNP,MQ])=@>=O(?\`)/YOR_M;IEN/
MI+L#+<?278'G;R'_`"3^;\O[6Z9;CZ2[`RW'TEV!YV\A_P`D_F_+^UNF6X^D
MNP,MQ])=@>=O(?\`)/YOR_M;IEN/I+L#+<?278'G;R'_`"3^;\O[6Z9;CZ2[
M`RW'TEV!YV\A_P`D_F_+^UNF6X^DNP,MQ])=@>=O(?\`)/YOR_M;IEN/I+L#
M+<?278'G;R'_`"3^;\O[6Z9;CZ2[`RW'TEV!YV\A_P`D_F_+^UNF6X^DNP,M
MQ])=@>=O(?\`)/YOR_M;IEN/I+L#+<?278'G;R'_`"3^;\O[6Z9;CZ2[`RW'
MTEV!YV\A_P`D_F_+^UNF6X^DNP,MQ])=@>=O(?\`)/YOR_M;IEN/I+L#+<?2
M78'G;R'_`(ZG\WY?VMTRW'TEV!EN/I+L'YYV<A_^M5/F_*^U>F6X^DNP,MQ]
M)=@>=G(?_K53YOROM7IEN/I+L#+<?278'G9R'_ZU4^;\K[5Z9;CZ2[`RW'TE
MV#F9M/(1:\86NJXQG/N]@"5C/9[G;G_:F?X/_P!'3+EZ2Y^(,O%[>+[C&=&4
MNY6LQ",WDFH@Y![[,&$TPW$'0<+[WPN8L1E.$>%<[W&')#ZGI2D)2C+V4(0E
M,"-GYC8J'&1#CML-X[,(3C'N?]F.SH(M?,^8CXB_/L'9S^#/_#/_`)=!"O[O
M^(AAY'^OG_CG_P#5T$EL+Q%Z!P=!(=`#H`=`#H`=`#H`=`#H`=`#H`=`#H`=
M`#H`=`#H`=`#H`=`#H`=`#H`=`#H`=`#H`=`#H`=`#H`=`#H`=`#H`=`#H`=
M`#H`=`#H`=`#H`=`#H`=`#H`=`#H`=`#H`=`#H`=`#H`=`#H`=`#H`=`#H`=
H`#H`=`#H`=`#H`=`#H`=`#H`S$?_`%,__H_\N@J?SD\_H'8Z"P__V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>g838054g04y47.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g838054g04y47.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`)D%D
M;V)E`&3``````0,`%00#!@H-```8=0``77$``'UN``"A;__;`(0``0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0("`@("`@("
M`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"`@(!`@(#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#_\(`$0@`ZP$@`P$1
M``(1`0,1`?_$`2X``0`"`@,!`0$````````````&!P4(`P0)`@$*`0$``04!
M`0$``````````````0($!08'`P@)$``!!`$#`@0$!0,$`P`````%`@,$!@$`
M$`<@$3!`$A-0%!4U,306-C<S%PA@<"$R(B,D$0`"`@$"!`(&!@8#"@H+```"
M`P$$!1$&`"$2$S$405$B,A4'$"!A<4(C,(&1,R060*%2\+%B<I)#-"5VML'1
M\8*BLW1UM7?ALE-S1)2D-287"!(``0,!!0(("P8""`<``````1$"`P`A,4$2
M!%%A$"!Q@2(R$P5`D:&QP=%"4F)R%#!0\",S<^$5@/&"HK(T="62PD-3D[,&
M$P$!``("`0,#!`,!`0$!```!$0`A,4%1$"!A,'&!0/"1H;'!T5#A\7#_V@`,
M`P$``A$#$0```:#YQ^M^/IN0!\31B_;`9?PV(``#O56_5CVXXJ`'//GP1Z<%
M5KB/?7,];;:.>?/B5R*O%QOSRH%MW>E?T%[U^:$B],6(SYY7P+T?](Z1LN@0
M3)<FF^/ZG\*,)<:K(K7<Q#K_`)K)K3>NWYY".W6F=/TQOH7=Z)G_`$QL:\LM
M./?7LC5:ZNXWKU@^^LSCVU_K3YX3TQ&:\=AUSQ_4=@[_`)GS318WOJWF?KOU
M@![7[C\"[LYC@('RGP5TC]'=8\;UH``#XGS^X]`!(_3%SGWU[F>=I76H5':;
MK#/+/6)[ZOU8]HSYY:5^N&XHKJ2UW6W[O2.M'KAJ+ZOK?9AM]EN(^RNV_"<U
M]L"`,?3<_P`V7/?U6@4T][SRW)3Z@<<^27U%?7JL^U1?!*+7>A2FSWV"9+DT
MWQ_5.2GU`C]UI_9HO<OX;'CO7#=BF[[-%\`,[Z8[^DKH/Y5R'TQ@`Z--QXYZ
MG]S4!YY:B,7VCL47@&%N-8_4]NC(X;WUJ3V>]`86XUC-6^S@<=7C#+[F4WQ_
M4Q\S3]15A[C6^WYY'N^>3`MBZTSVXW'\_P"^+[G0``%26NZZ%X/Z-\S==^LN
M"/0``````?$T?<5B"Y'E$XQ_5?J*@+)N=5VLR?&_4[9?CW.UXZ4>N(```$;\
M\I1%GT#R5U;[6U\Q_3@`,!=:AG[7;P`(A?<YEMET3ZBH#KUV?8HO`![4[A\$
M;OYGY^`````QQ_/5'I[Y>69\_<']*>-^+[3/L9UX#`W.I9ZVVT<57AA+C5I!
M:[AT/7$]_P`LL!\S3"[_`)A-L?U$3;WP&T&1Y%Z8[%\F[`W_`#4````1@\T(
MK].)HSQYP:_]3>8FN?6\?\\GT:;@`=>NSY(]\'<:I(+7<``(=?\`-9=8]&^X
M]+6NM-]VMU_.SIW6FP@K!-IH^2T$62``?)1":=3NVI$"\-CD?IBO"72OT4H*
MQZ3DZK2*^68$1ON=2ZQZ*``!.+K3(A,82B\L&]YW[D;I^>G(0\ZYK]%4^1DY
M;&(G2)>`:TIU)BKT@FB6``P7GD==[#IWB/J?W/F;KY5C?.>NQ_<N_P#Y*-Y7
MB4EQ/;<I9<DZ.(T^ZNBX&A\/WO>;-?/.XN6X9V)\]L+[F\MGRUB32L33*=^I
MITDBJS9CJPO:8V50!YFJMYE-F```&G.*SNI^%B+?&O=8I]:YN!W7T#[/[=\&
M_P`[VD?HIO1\J?(%&?3>H;U[5H.ZF?O;4NM/```````IU,$-G4```"EO*O53
MC>[Z8Y[RL[Y;ZKZ/?<_#[QN,+XW?+O<ZVR>`W0VO!SCI6K;KYJP```````&A
M*K8A%W(````TXQ5[6G+=LU4UC-V?C[BY>L:;K=\Q=9L?Z9Y-/LG:>BN[X"ET
M66GOE((OU-/EI&,.0SI718H`!Y6Q7ZBS1W0````>=NGYRE_:BHOC;NFP._:W
M4/9]%ORFGT.ZAJ4J/,!$1EFS"&KJ*X-A$Y(ZIQ%-(_HTBH`#R`BOU_F@````
M#\*+3Y3?`_T?>F_:W>_?.<;L[]K7:!61ECN&O2,Z7.F!EF&,.P?)*0`#SUBK
MT*FD`````4>GRB^!_H^\]^UN]^^<XWCW[6@/,:8T_*^1F"9)SY7AL2>Q<2``
M!7QI>J]$5(`````H]/@Q\\T;+;#.WG0Y]!=B`<!USX.([!Q'R5D7&```#2I5
MMBID@````!2*?!SD7SYLKE]@VXV_H?H)E\^````````!YYJIF;LJ0```,$8I
M$>AY'VEAD)JV5N+NZJJMC9F3@```````&O"==HGT0FD``#@*-B-;T8Z`Z)$)
M3*&+E)#:69FB1$4X@GJ-8E5U(_2($L.^74@`"/'DA%?J1-%D``'2-,XIU93-
M$3&`$.EEBBTV&B7&0)HG8N9ZR8@5LF;Q%;IL:8PZ;)1L(@``4`GS^BKU[FCE
M`.J::Q37,(E+.G?A^@J29EB)=#]`/LW/F;(F0`````!TROC0R*O2&:<^"E8C
M4^(BLL]#N&GLSMTB)2[!(H1V4GAS0%-S,E1O4F[YD``````#3].N45;XS3DX
MIU"1$RI$V0B5PC\H%6PJ!]GP=HEU,R6'Z<IE8;L3-@S(``````%2)E2-88IT
M^BK3R9W,1C3NHK2J>M,0V)@Z>R6_-,/3)D2V$FIG)%>)WK1N_(```````5E$
M:<1&M:K]E#TBI*G9.B25'-*,Q/Z2.8C$39\T]>)R-,_AMFI]$IG,@``````&
MF44Z/IV`1DX:P35G)BFZIO!10"OF.4ZI^$1B9"C*RQT+ZB(_#81&VB=AYD``
M````#5F(U31-(<AK3-50U,<67,<IC#B*RB<P6),1XC*9^B_J%D1`W/F;+F0`
M`````*EB-/X@`0:I`:H`````G5,SVD-S9FS9D```#__:``@!`0`!!0*4Y*>D
M]&<X3B).B3D]:(LEU*DJ0KHRTZE&G'$,H@$HA)&WM.^WC&<YD!B\-.]&K'ZP
MLPD5!!C=B(807;Y#36F;7HTP8>TC"L)<;0Z@>+AC$[&BN1,=AWWF=%437((1
MN>V/XKLQ]B$(K4.SPVJK5%1<4FE$C%6%T1NWBV01CD:WV*Y%K.3I%;^2-T:H
M38<&A4==WB52BF#[C5>GW"\';7(N=IJ]("8Y&^U;\24^CM"]\XQG')W'\JE&
MNO.,*QT#BQ$3J)>[;!@`[A,'FK-R8X3B3+Q:9\PH8(F24[D2ZDHDZ^VTEAZR
MG)#<SD&YS\OWVV29RE*6J9R#<IXPC>K67BS[58";>W%Y:D?-!:Z$KK71+=CL
M13I))<S*EQX3*5)6G=2DH2E25ISG&,-/-2$;Q#$"=(T9C%Y&DXSA.Y2&Y/@P
M8RXD74J5'A,LO-2&^@7`<*DQ(]`D9T28S$R-<^$+`.+W/B"P`P#33;#>Y"$@
MA%@0TCXDF.W+8%BV!3&\<?$BO;J5Z4B#/U56W?&TZ#&(,1X[45G>FVJ14C(J
MO4`^QUWL"NRU$%P1$%P7,X6YXV,8QN4#9(R<?\8WJ]3-W"?3N%;#FS_I"J?+
M"@HH&QX!<7%-C;)0J^S2+CQL=I,/IC$X4Q_I(FH0QS&>^-T.M.9Z.!!4&)2_
M#E_-?+$O[B\E<HFZ\%L<3G&EUD16!+)IN3O&&0H;^RUI;1`)PR2=/1H\C.^?
M^<#`<<9(VKM?)6@L0X$O4-GC&L2JG3_",&15?'#O\@7K[R0@6-;5K_(UY_`<
M6`.'-28LF$_T9=:PXI*5I@#(@Q'2LW#:))4E6-47V_UH,H]6#&;U:W:>$>Y;
MID,9(YO&.'F.6Z5)U+Y=HT)@7;`QDMTYSC&&+V"*%*9PJ*I]KVL5:#VJ#`'0
M!46SB35OOT"!,*3#8EX$5V?#1'R/75JXBS6,O75AR28#_II<AV+<!'(:B4^\
MAZR3*L\.`F!4SB)A\J`X?F#*S.`<<P@8^=QX"/N<B4MJ<#.0+#`WY3>EMURL
MP9%U:!-%F`W0@=$CQ.-^,Q]'AV*<HB9K!.IFZ58*^6J3^T=%E9EZ?$FOJ]G'
MS:3)H8,7=:4Y@@W*$<7W^H7&\<.2+QFA\)@ZQ$%@`03&KS%E?JCC:CVVC1Z`
MP28NT]TK:`1/ABPX&%*#:;/IJL7IY_C".^@;OR&TKD%JIB"(<1U\AS9`8C-`
M.C8S*4V@5Q=QW#-$`5#(R[]=J=!MU;+)="N"FG1L6Q4PM;7..XYCB\V4I-6,
MD/'OMLQ2:L+J_%EJ,>!>Z>S<P@U^-R#7;%/E@BDQ4F6BG$:W<V%K2VF>L9R!
M>BMD#RCP&$NOP^-P,XX1\AS"2L295"AR&@W@\DUDA%EEXR+F&@3X0N6(.*XV
MM'+MDDF9Q5Q_*J*"AF7(,'^ZEDU:>1*127AA*`9'R9,:%'KW*?'=L)Z.7VHU
M\)&D,S(Q8K`!"QA*$9&ZLEJ"5-CILLI1^TQF$18_A6")_:JPNM!+A.L[KC_%
M)57KY10-Q)J$JQ-7UP(%&UP1KDF-8)?.TXZM?*'-LKD8IQ=>3]'M]F"7<PX[
M+AQZX,LI"VEY"S-NKS\ZPX+%@=IO9VZ%3GZ@1TUTLUGD#Q.24(;XTMO\7DOY
M/X,^WM,LL8VM!ZKU&`TQ7[$T9-AJ_#G7/CFBD>/*%5ZL*<`@WI!4U5!-C4,&
MKR[7P,A2P@9PA]#"YD]($7<Y5@\3DW^-[=_&!+^3^#/M^_,TJ99+Z-/V-OCS
MD2#(12;"Y#BN@[$7#S*_8I,0M25`+!?.)#5QL=XZ[.S9'A-:OEU8L?B<F_QN
M?,6]VDWHE8X/*W^.KTN17=_;;PY\K&RMR'$>0F!!0EJ+&CKCPH</+,"#'S6J
M0*JY;P)W%Y9\@*,"3L3P^3,9SQP?SC-(O'\K?X[?MWR?,(.1$)\'`Y`FN^#.
M)0AK;-A"OZ-V(-'CS*96JNN1-`\CEJX4@UT1#NY1C0DK'+Q?(\F0A<^O\?V"
M4)/];CC;*"MVCLZE2Y$U[:3&9EL!ZX/"+=88?Q],B8T+E%`T@=8"4W7U:<UK
M]2ADZN%TAU>JL<B!66PULKU@<JG-PH\AWDJF,Q'^2Z5&=F<PTJ.WGDVD8=%<
MA50Y-Z2T)PB-R,G5]^L6#Z_!Z9$AF*R?//&9%ILL@$L$5^LCMS)R$$8'D(Q.
M)=9QZ&\"49F"OE']9:=7JM11>"]CHH0]7W:4EJS<7T-5(@IX(`M!(_%WR"3/
M##30M7%KCBE<-PW6)=`CR[3U74<W$"5-BQA'T8RE.[SS<=JP6!XR]HF#&E\Q
M8L>$QO8ZM@\\#$I"C_QZ$JRA0"Q,&&_&D1V)<=P<FL`*=8W:'*&%!QJ#M=I_
MRX_1,T.$8COLRF='0-C6:]7MM*--Z:+L+RX^TTVV8CJRA:'$[6NQR0>JF=EE
M8=?MK<WR%IXO61J[*;Z7NE+N$*["+!8F0J9DR3/?^H0OG+359)J2$'+%"]$)
M2XK<B>_)3MZE9QIIYUA2#2M1Y\>3F8/A$$1(46`U^&JV6^JCO'N(8L7!U\",
MK`6W2/?.2K:Y`M4:T#DV"1R#6HT(?R94RDF5?PC$<GR0!7,FV\+`EW"Y.`V2
M]Q-0AP.]+?F_K`(F"3O\6`Y,NP&#)A6H2FR';,8_42[6L)',7:2HGPH5E%0/
MD+&?0(86M;JS=0)$30NGD81:N<?F`^F./S#8F=3K+\W,IA.0-F4B6LM<:<^=
M;?`&R&IU&(2XKE-(.CR@BT$VIE1L*VPP%\6>)"#+-D+TVR%B4NF/,/<?YFTP
M5`GQB4;Q[>GTGC5SGC#,*4B=$T0M.1=A!7I)S4.YJGGM2[M)8F8NCOT^-<GB
M2EW=[&579]"G[86FE97(+3(B1=?0:'7)NRN\<S99>MVFNG2)<2U*8&T)A?H\
M>\PEMS2%=$$Y"$);3JSU27)?!5:<PR*J)F`6'@LP"&:V,RMRHBEN8IH=&#M5
M;P\[2/>BP:J)'N9H8+Y;-1,-GXU::%-5&`T)KFU10A('Q[IV^B=!K\/#"_CM
M4/L/@__:``@!`@`!!0+/?OTK;6WX';/@8QG.7&EM9Z,I5CH9;]UQ*<(3LI*5
M:?\`;]S3"F,;8SG&7'EN[L,^\I6/2K3.6\.2,MY<C.+[);PYCVVNWLLJ4VEG
MW4^A4AUQU3BF6^RFF]+PEZ1AME2__#+KRW,NN-LHU(_Z[Q6F?3T2&,LK\1*E
M)UAYW&$.Y2MR1ZL9><SE2E*5E]Y6,O.JU[B\ZR^[G67W<YUE]W*5/.*QEQ:M
MXRF>Z$(1TY[=EJ]2D(4YG\.C\=?AME.4YW6PXVG3"F4]+*\-N.*PM>D(4XK.
M,IST)QZE)QZ4]&<=\.PUI5[;\76<Y5G=MS+:W%^XM*LH4\\IY6ZG%K3T/,>S
MTMN*:4I65JW:<RTI*&%^`\CW&D0L)QY)E_VD]#;2W<M0U^Y[3?9*$H\%2<+2
MMA/M.QULXZ5M+0GI:CN.XZ,XSCIA)QAKQ5H2YB8TVEM[+&4[J=<6G;&.^G&E
MM;84I/2[(4ZG9"%.*S">QJ.WEIKQI_\`U2A:]9QG'3VSV_#3CJW<].(Z\M;,
M_P!5++:5>06VES&$X3AQ*W7\8RK*T^A6R7UI:ZV\9<5E3J,^KOIA*5.^3].,
M8CQ\,X[9==G?+#(`4]$.8V?9;;;U-DL#(H,LQ8&OD<^GT8QE,;V77F$NZ99]
MK'EI3J8C,:6P59*P)E3-"'XIF&AE67WFL.M^C/JL1=^QE!8EFNBQT_YS2F6U
M9\RM"7$R&71DLH.C68572[]9*I]M>UZ/);U1Z_B(S.E+(2(,1,-GS<R*B6S$
MD.#I5W`8FQZ)8?6FS'4`Q]4!.'B!>=H1`]E/G2L#YE(II]N,)0ENX\D*_P#J
MK3?HK`\8ZI[X`%_=W)'YVK_M_P"`A?W=R1^=J_[?^`P0`=DQ9A`TD^)CLQ1W
MP&-]Q-_U8'Y/X#AAG#CK+3V,8[8_V-[?">W^U>/$SXO_V@`(`0,``04"92RA
MKH4I*$CBP\LWUJ=:3G&<*QT>M.5:>>:C-"#@TXUMZT^K\--3H3^=["7^AB9L
MR00E;19TV$JL9*K#:L\2RR=-X6EMYEJ0T'`#`2-K/8%5Z'$?S*C:L#95T35F
M3#`>XB1KC\TJ^)?68,X=R?/Q()B78E!):R,&K!!8*$)B6`K[\4T6]0YV77:L
M\9L4$:E1..$KXX,T"#E[!/S5_P`YO=#E@7,W_#52LK)^!UJ2E:>B3"BS-/5T
M+(D$`;$F`)J:8CS%>#QV(D&+!BQZN`BO1ZX%BZ0*'M*8K(*-INN!FH^,83AB
MM`HTN+7@T)Z.'&Q%;6Z%8/9GE)Y1?0RAQQX=%S"@D",,7&0M#J-UK0VAMQ#J
M,YPG$>3'F-;C;*(*S=6>#8YFF\*2C<\->+"A,)T</U/(0Q<:-)CS&>B7)3#B
M3)*ILOH:=<8=`\@C),+ZO6+HY'CLQ6-S`MLP/#C&PXZ=#8(1``")7HF\,,-@
M2MW%^VW7+-]?7MWQC8J)@F8D.''@1=SH=LU!F$[*-<ZZZ12)-$>17I<A./2G
MQL)2G<]65&IN,=L;ES,`'&.7X9@3];,^[,GS"#G@0ICP^4.L\])T#;!MB=Z8
M)T82E])JT"P+^,X5C=N0P\KHY'F2'CWBCR<X4]0#QB:5KT:T,SMX(,6-E;.N
MMLMB#HTXWJ3!AS,[YQWP#JD(%,V)DX@B%&Y'KKZ[:69-'/#[;\6H;S.F$AX_
M33K3[?0J0PEYQM#J`X(<#;Z7;2,8-H6AQ.K%ZOH,NP&)T#;MX??<65G!Y$F5
M(F/")L`)6Y$AB(P/FH(P]I58'RS768D1A,6/%"DF<PE-9M$Z5""^35*><>M5
MLDV!]#T<$">Y`-D"0FS343MJU8"Y<IHU9VXK<.X/05KY(8^=23<>9FV]%A!U
M^T3`FK&?P9>4M:NKOY!$B9*PZTY$7#DLF(,F]$AS1"QQ6:V`.2`A6:8A0AD"
M,F"PP>9<<(87G,,^8@QO,I5E.6UHDM19KHV03A-E8:ILS$/0)N:]%/DO>6PT
MF.W(>R\OS;#V65O-IDM`".6'+$,[:$CLD))@@D=&AL:F2/5GSL21[>9:VU.S
M,Y4$JV/_`$E5=RTF4E*/@$[[-5ORYC[E\!G?9JM^7,?<O@.+T[,SFV.5W7SV
M2?P*#]ZL_P#6%_;O*9\5,6.EY^-'DXQC&,?#.V_;X#WV[[=_]=]M=M=MNVNV
ML:[:[:[:[:[>:[Z[Z[Z[Z[ZQMWUWV[]'?S';;MKMKMKMKMKMKMKMKMYKOOWU
MWV[[=_BG_]H`"`$"`@8_`K;^,CPG@""^D?Q;0>(&5E;=P](+1$75X#VPJRE%
M]=/A14I.`=KU:_*ZM.:M@8:63KD*JV^*HPAS/IK+G*<5LIJ(O+0"(Q:,7LK=
M5R'.!>M'LU#FN`6NS*V8TT#&^V@!8Q:,-S+N:B!UP=M]2?,/-Q!*SK<7X#]K
M9B*R@V4USK0VAE7,"JF^E)M%9G=:D)JTT;;Z"FZLRVC@RDV4CC14W\.24#EK
MH!.+;=1=65M](>*AX$=?Q`]UQX#VH7BAY"BBX!!P96WTCK^*&[:#=G%0W5^7
M:VNUI3?Q,XHO-9A>*S'B!KC8.*+05XN9E]9G7\1<*$C0/L"W&L\Q\#+4!7BY
M65^:.A290E(VP?8Y3=1CC`%*Y.,'.%AXQ+;AQ;>+FQ/VR/M%!S0EM-[(=+B!
MKC8.%!?73X.B;^*&G#AR-OJQ#0:;_MVC!:Z()I#?Q5PI12OXW:B[A;RUG:$=
MX#E?=2-NIV0+;2"^LIO'"8A=]@(ELK(ZK6C\<E-0.O\`!$%*?U*Z-Y-2:W4Y
MG-C:MGF'/3VQ,,6J9;D+LRMV@H+L0G"US3:>!VMUJB%N&+B;FC>?(*>[31NC
MEC<`YI*V.5""@V%;*/OX4CC;33:12V9Z*HO)X.[495(I^FU#1:$+<"#39-.3
MD!S1.VMV'_"X>NAK]/U77M]QWM#FPW(:[([:R5E-B7[MJTW2Z($Z9KLD3?>/
MO<_D'/36EWYO6D(O<_8-PN&ZW;3FY<I&]:S$=+PHL?:TUF9=>T_CRT8[I[VG
MW'CT''=;3M/K`6Z<NRRM]TCVO[/E;S4)F(5%^[@/<^C_`%'#\TC9@SGO=N08
MFOYUK0D[V]!?99[W*[_#RT&1?IJC1Z:R>V;SX9V;NM@=AHLDZMSAZ:_G6B"S
M,;TT]IGO<K?\/)7\DU9Z0_2.[%G->W<HP%&1J?6261C?[W(WU#&CK=:KM&QR
MO)]M]^7TNW68U]'#U1UO5ZZ^IE_5-VX?Q\.[:+]<>45DU`L6P'93(V!&-U;@
M!N5U:5FR-WE(]50#3`"0Q$_VBMM=KJFD,;MQ/W#'_JG><UIOVCYZTO[7W%'_
M`*IWG-:;]H^>M+^U]Q-U<1U/U(E)M<S*MOP*G/4;]<9\S6D#(6C'',UU1:?3
MYNQ:U!FOYT3S?<0^<TSDJ/Y?N+M@T=IMI)6@I2"[^CW_`/_:``@!`P(&/P)K
M-.&B$"S+<FY.*7O(#`+33I.[Y6R,8[*4V^HX&XX?8(YS0>6E;=Q<H(S<#IYW
M!D+`I)N`ITW=[\P:4(N(V*-^']?#D49]E*;J8(9HGF1I+4<TY@+RU#:!B1Q)
M>\<N=S4`&]Q0+NVT_6ZHYM1(Y2?QY.'/HY9(G?"XCS5%-WR_/K'C-<`0T]4%
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M>DG25IN3`BI&.E,NG=W?)/&YT`BM;<6A2K"OM5ICWJZ+4:+6Z*63L^S3+V;,
MR+;FS8J$ML%.[YTSH2R=N=L09U'OD:T'-F+G-8"B.N*!:UNHG#\L4;'1R21-
M8<Q<`]N5I<TC8:EU&HD;-W@(7O&5N4+E5K0+50V+>:A[_<P2]XACI3)F.=TE
MN9JK;BW+Y%J*>=KG:#412%_Y;6LCZ)+.S<'%S@>J<U=S_P"AG_\`8>)+W-WC
MD9I0Y0UC;'B]KE*N\J+8EG$6@)"!WE&$D;M^,;CY#9L7CY7@%O%C^I9F[*42
M-W/;<[F6G:N:!IG<X.-KNL+G(J9OB1<#6KTND2&?5]9UZG>"=EEE2OU?8?2R
MP=F88VN$9M7.[.YQ+\!L&^I--'#^3*W*X%SG*W`=)Q0#!$2FZ'2MRZ5H0"TW
MVGK*3?C1U$&F8)"'#$A'!'(TG*%%A0"RRB8(`"8W,O<>@Z]MKC9L&&"5`]D0
M#M,PLCOZ+2$(WV;5J00Z9@;*W*X6D9250`E&A0"C4M`-2:1L/Y$H`<"YY4-*
M@*7$@`X!*RBZOKH-,QNI5<4!VAJY0>05V^EA#'VXN09K\K5RM7X0*B?IX@UT
M+"QE_1:XJ1?B>'^8=PZB4.8.G$,1[S-^UN.%M[9.\)72O:$!.SBMCA7MG.`"
M;3=46D<XO='&`2;5*6GG-?5ZYX9`"`N\^?U4)(R'1N"@BXCB&20@1M"DFX`8
MT)8R'1N"@BXBLSK`*$^E>V2$XM*CR<270:*3-/'XG;2PX@?Q"BW@@/<4XB:U
MXS"XW]9?::,68_%8`&O.9X%IN4[4XDN@@E,4KQ?_`,KL<KKBGEN,>CFF?/(P
M==UY_@,%4ICP'6:YX9`W'T`7D[A3=3I7M?`ZXBT<675OZD4;GGD:%J35N#6N
MD>7(VP!3AQ6SPDME8X$'81:#7^\O$&M8+;"C_B;E!MVM\5EQ[D1[T&<%,O53
MJGK+;LN6FZ;3M#(&!`!@.(_N^5SV,?BT_A1M!O\`+4?=T;G/;&+W>/F&P85)
MHM2O82-0H4/C'XVV4=+IB7%SLSG&\[/$/7Q)M9I(FLU$YZ1]6Q3:4O-O$,B$
MH%06D\@VU.SZ>6'L7);=R'8_:W#;PVX\!T>O;FCPVM.UIP/X-E,T>E;E@C"`
M?C';Q#IB2S4"V-XO:[U'VAB-Z5-W3K-1/BQ[7.+@A%O66QP-A&!4?8:?7/*1
M,?TOE=T7>0TW0?\`ST2/D>&B22]24&5GI<3\M!I*G;M^WZ(`4\.GU;=3+"(3
M:&^-6>Z_#-;9R6IQ!JN\'98RY`EI)Y*>[N2=>\2@;T7#+M=TFH4'EHS_`%>H
M$KKR)'CS&A-K9'2R@(KK2G+]BS6:=.WC*A0MNU-U]0=Z=ZS2RLC?;;@06G*V
MQHL."5)!HFRMDC:O3#0HNL1SKN:_C3:+1R!\\%^_>WW@#83MYN-%I]:7]I)[
MH7*WWCN7`*=U9A<>(YL+VN<QR.0KE.P[#Q?I)/\`+PQC*/F"N/HYOMCJ.[Y#
M%,6Y20EQ0I;R"I='JI7S1NB+^F2[(6D"S<<R$!,*U3N_)6OTA=T`-NUF+6`6
M93CSD\,NMT<09/-UO4WW03:0,>;A,TI#8FA23<`*=)W>]<CD(-AW%-CKP?2H
MX&.U4;'NC=F:HN(Q'$2I]9`][W2W9O9;>1\5OM&U+-I/`[7ZTD0,2ZTVE`@K
M)+VT(VN;9_<+CY*EU>F_RX1C3[P;[7/AN3'[?52D_FB)H'(76^9M#ZZ:*+-=
MF<&KXZ$T#FOB-Q!4'G'%;IG/:-0\$AJVD"]!NHQ2`.C<$(-Q%/B[O8F=RDFT
M[@NQMS?222>*>Y)SDD#%SFQBWY5Y+5NPOK/&06[N#6%A1PTTA7D:30[NUDSI
M-*'!W2M*@$=;K&_$^`G5=WNR3EA:J+8>7F/**.HU;W23NO+BIK1?7RMB!@9?
M>2X*@%YOP%.U.I<&0,"DG"H]=$"(I`H6],/&+>&/OR4R?4QI9F*$CJG<FP(#
MCBO'E[Z,+7S1L`)09BS,%"\ZI=3>\-(R/+(%#V=!W_$W*Y1LP-!L&JF8MP);
M(O\`Y`Y_B=6JCGFTKR^%S4MC?T^C8,S\QMV-YO!&SSN<][4O.#;AR;-E=E&K
M.ZVGHLV_$_?NN;RVF-^K.6#3Z=@/,T!.4FRF1]VAD$%V4@/7>XHMV#4YZ9H^
M^3&Z&:QDC6Y4?@UP4CI>R=MAOLX-9I=7#&S30.2QUK2J9,0^XE0B<X'`V'NL
MLE[PD<X#W69'%KW.Q0."#WC=3H^_S&8NS<YCV#*26IT,JFTKT4Y]HTSPPC0.
M8[M6V%S3F1I";$NQ#KNK0GTVGD,!;F#W.C:TMO7KEW]RM9`SLH)&QGH$ESGM
MVLL8/.1LHZ?-(=`ZW*TM!S;07,>F]$7;4;M.)F0QMN?*Z3IF\A2@P`0"@'$D
M#P8:22:0P+U2XEMFY4H2Q$V&^DDZUSAL.T><5!H)F9M1$>F__NM'4Y,W_4Y#
MM-.[]TQ5CH^A\YL`/([K<AINO!)83^8/?:;^?$;Z_FSG9M-D!:GMYNJ&[W4_
M5:I/J'J]YV8I^,:U/::5L\DL>2/.>C&U5)R^\;"H<""`E"1V6Y+&AJ)N'GO-
MY)-/T>FG>-(]A:6WA'6%%ZO*U/"LPOJWGIE@[-MA2]P)6W:1AXJ$D-L@"M.W
M=S^>OY6YQ^D$N?+L>F5>!GU;WNT43B8F$V`F]WJWDD5]#!U`>EO.SF\_)2NO
MQI?9\,S84K;\*^@GZA/1W'9S^?EKZ^$6>WZ_764_H-M=ZN>NP@LG<$'PC;ZO
MX5VS[\*[)O5\.R/ZE+'?1<[K&$>BI3\0I_:VM#O)66(VG[A=^T/14GS#S5+\
MWW$[]H>BI/F'FJ7YON+^5&)H:[H+R<]=BR,/[2WT;17UY&4RVI]Q-_=/IJ+Y
M3YZA^3[B^H:QO;G'&@W4,#@-M(+&C^CW_]H`"`$!`08_`GNNF]MMK".PRR1E
M8-Q3J9.)OYA,*?'7G]62*8$1B9F9G2(B.<S,SX1'!G5<+A6<K/IUY%'V3I/2
M7HGPG]!UKKO8,^!`IA#R\>8C,<2)B0%'*1*)$H^^)YQ]46$LX6?(62!0!?XI
M::3X?036D(+`9(S*=!$8\9F>"949U]$])C,2)AKKT]0SST/3E],-[9]J9TAG
M07;F?5!Z=.O+B(B)F9G2(CG,S/A$1Z9GBT=O%9*J%%RZUTK%&RD:=AP]Q*+4
ML4,5W-#F(EI)1]3'8&;/E%69<Q[X'K,:]9)V'0D?=[Q@O0=>43.OV<4\3C4]
MBC00**Z]9*8$><D93S-C"F2*?&2G7Z95E<90R*Y&1Z;M1%GE/]F6@4C/W>$\
M9*KM2KY;%4S\K/2]UA3[BI*+CD2\V$%?O>P,1,C,#K'*=/HK?"[`J@6QW1UZ
M"\>1D4ZP:0CQ#T_;P,&744#$$6G3U%IS+I]&L\&I@P:S&1,"C42&?&)CA@U%
MR/=+J,B+K.><](=4_@7KR_X_I!T5CL=;('^RL(Y:]P]"Z9+\/V\*;*S5W`$^
MVS2&!U1KTE$3.D_0\<><!9D?9G\4C^(5EX`PH\)_Y>%#D2ZG?AB>;05I'0#B
M_$R/[N?&\<<K*6@HX?Y?[HRN,K04=NED%,JN7:1'3[+!:\R]6I3Q%O=5(HSN
M<P>3S5?,V=RR68O330XJMRO@4U.P&/[=:`_.+4A&9CT<?+K'GCLB>4WH&.*W
MD$WF=%)0Y7M7&)I]ML-;:K%(S,Z`F`@])]KC;FW55J>/R-[*9IN0^%;G+.M'
M"8BL^Q4'6.]639RT!SC]X$!U:>(QM$Z*<;:O6[>6IVL32S%K+4*O14-]#)R=
M^BIK2[8,6:B]GJF"C332<96#'1B\';W!0KEC6VYO#`0Y*FH.RU:)-=ZP,\NF
M.@6=,>&O&>VF^;CL8S.*QB]OI37%:JJ,LE6)52DD$%,V_E"#AT[G7SU$M.*+
M5XY.-O5M\8C;64I4MQMSOY%TB&RB\Z:U==;(I)4Q/9Y1S\)Y1N:CB*%O'7-N
M;JQ&`9>NY#SR,DK,7RHLEM0U`NJFJ1>SH1$0C'5.LSP&P,1A<EB%8_+6@R&6
M9E#LORR*>-N7&K\NVM"ZUBR=6.U(:QV>J>GEQM*C3;3AF2OY2IE\5BLS>R:`
MK*HNLT+:[=JO5M*;UATL'G$S'+3C&TJ-)^*P9Y7'8ZR-J[-MY)\Z%:W=:^14
M*B>KVY"/9"?">,OLH+1X[`NM5<*C$C51\-J8B65@JV@3V>E(],BWNC(E&NFL
M1RXR=.G9K5LWA,IB$XY8Y>U=R.7$K:*^1C*474TU:3E@??#L%TS'+[_FG_ME
MMC_P>O\`4QN[,$-JWD6H-;+5^UW+%"R0=J]2\N@:]4.B2F(F5R4A,3$Z3]28
MGG$QI/W3PTD*,]OY!AMQ=F((A3$SU%C[!?A?6UT'6?S`T+QZHCZ^A1!1/HF-
M8_9/U;WP^T5;XGCK.)O=(K+S&.N='F:I=8%TBWMQK,:%R\>$8VKF7*IUD.JI
M7V:AF%2P)BVIYAE<K)5)[DZ*DY`9TF(B8CC;&1R<'E:>UR&*-&3&MVJ\$;(6
MMJUZZ@XNN.KJUF-)Y<8Q.,/,_$L;F&9A.XLQ:HLS%?J0=<<;4+'TJBUX_0^L
MHG7K/T:<N*&0L94O-XRP5NDVO5HTNS:9T0U\A3K(6YK87'7)P75'CXSP_,9&
MS+\C9-;&V16JO,FI8*5(A66E2N@%#$=(QX<+I7-PW6H4RJZ.2%.-E)P6*AOM
M)2NU9*O87!CW#+0XU\>%C<S#&BJ]5R8`-:BD(R-+7L79!%98E9U+VCGFS\?5
MQEU.R+37GK:;^7'I3'G+==I/2XIA<2L@:<S['3'&/*UG[AGB["[5-HPA+ALJ
M6:5V'.0E;;;A2T@ZG2<])3'A,\4,DS+3%W&->^DY-+'5H4^RJ$V'RJO44ESG
M+C0B,2*>",IU(RDBF?213K,_KGB</<S]Q]"5BHP.$=]J@D9%3KL)B\Y<2/ND
MR8XBGD<N=I.M>3(ZU(;+YJF+*_FKH5AN6^T81,=TSYQQD4W\DVPO+VZ]_(B2
MT#YJW55":[CZ%#(RI4:1`Z1](X/>F#QCEVF_P&<>$C-=K)_T;(%!B/EC+W&S
M^[GD7L<P<C"8Y&-389#7*K]<`;1'HADB1%'5T\M?3]6P^W(152AKK),B)6*%
M!)M(XGE(P$3KQD\H"%U5WKUBRJLI8*772QA2E(@OV([2M(XE]ED*7$B.L^F2
MG2(B(YS/_!P)@4$)1!"0SJ)#/.)B8Y3$Q]0C.8$1B2(BG2!&(UF9F>41$<"8
M%!`400D,ZP0SSB8GTQ,<:SRB.<S/A$<0U#0<N?`UE!C.GCS'6.7U'5:[>IB?
MLT%L1R(DE^,1G^[3Z*WPRU"8!HRT?<+QY,D^<,6$>(>G[>!@BZBB(@BTZ>J=
M.9:1RC6?J/JJ=*#9'(X\)T_S;-/:[9^$Z?\`HX378]EDUCI+F>]/V>F>D?1K
MK.GT%8LLA2A],ZSK,^`B,:D13ZHX%J6"U9QJ)A.HS_R?5QV+3,"[)7JE!13$
MS`LN/77"9@?:F()G%#&*:]Z\?414!UEA->T4+%<&TRYR1=/W1Z.7U;%.TH'U
M;:&UK*&1JMR'@2G*./2#%E,3Q_\`BE0\QB;IF5<(<E=C'3S+RML[+E`2ACW&
MZ\_Q:3XKR>XZU.*AW4UNS7M]^Y6<P'&#3E*Y0"Y[4CK#)YE$>G@$J"%K6,"`
M#X",?4;5,V+%D>\LM)B8YQK'@8Z^,3X\)J`9LA43[9SSF9F2GE^$=9Y1Z.&U
MG:]MPR!])2,Z?9,<2E,D<F<F;#]XI\!Y1RB!'ZEBPA(K;9G5I1_>&/`(*><Z
M>,_4(M"+I&2Z1CJ*=(UT&/24\61\HZOY<^G4^8SSTZ2G2.A\>D?1],?;RC[9
MTUY?JCZ)KV@Z@GF,QR-9>@UE^$HX770/0I0](C_PSZYF?'ZB;XI"[19(JRF-
M<(&B]3F?:"19!`-A>NJCT]DO\&2B<5N;%8+"E!%6R./O4Z**;EOK-ABY9-45
M%YBK87H0'KTD/3/A^@SN&2`LM6J1%2`I$.J]6(;5,>X<B"^NPD1UF8B->+.:
MWSD>XFC4?>=B\49"L4UDD]GFL@8"PM%C.HJ$=)CDR>&&"X6)$10L.J16)%R"
M)*2+I'73G.OZ?E$1K.LZ1IK,^,_?/TU'Q<?7\N7,`GT1,EUIYQVW^CJY\ONX
MT_O^/U#QV#KB]ZJYV7$U@I0E0R(ZL:7LQ)F40,>,S^OBDO=V'E6!4+K%HPO5
M6KM=L)A-6#HVR>ONO*-?=GHB>%4YVU@3JI'H4AF)H-6,:Q/@Q!<Y*-9GQF>?
M!U<11KXZLQLO*O5#M([Q``$P51[`$0KC72(UT_0V\3>[LT[RNQ9%+22;$R42
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ME<3CJ.'N5LBN@`TJRD!>"VE[9"S"X`G-3Y;J$IF9@>J/3RNSDG@Q$G^2,:3$
ME.D]2?Q*5`\NF?3^V?I?8KI%;;$^W,>$>L5QX+$BYS$>GZ2890``,D1%.@B,
M<YF9]$1'!E59U=LY$Q*.DXYSTGTSSZ&1&L3_`,/T+EZ5ME)PQ4F.L@<>!#]3
M3U^J9B?VQSCBS84QC)?R&&3^Z7[TAKK^9,GZ9YZ?KF?HK87$K!EVUW9#NG"E
M`"5&YK&LG6``0#]<\HYSP+:WPG*ETZFBE>E;@+TC_K!%%1_J+C'XR^4^>83K
M]Q6HR-5UN8/R@R'*>P$1!3J6K.K2=-/T=G+9O(5<7C:@]=BY<:*4KUF!$>HO
M>8PY@1&-2,ITB)GC;FR]BTI3A+&1)F5SF11$VKV.QU=U^XJI29J%"M:55E?<
M;JZ8.-!6?%$UT:BBQBVIQW:0M?D5/`5N55@!B$+8`1$P.D<OHVU7$"\LW)7'
M-9RZ!>BJ`5P+T]1KLMT_Q9X=\'Q&1RGEQZG>1IOL]N/1U=H"T*?1'C/#*MRN
M^I93/2VO94Q#U%I$Z,4T18$Z3Z8^J*98$-9!$"Y*.LQ#WI$?&8'7@@,8("B1
M(2C6"&>4Q,>F)CA@50Z>Z<F9%/4<\YZ0ZO'H7$Z#_P`?UIQK9E9PN"[Q^RKK
MGVH7,SX>Q.NOAZ..H9@HGPD9UB?UQ]&U!:L7+;N#$H-9Q!`8V+R43!B42)#^
M9SCT\-SV*Q%?'Y%U9M1DU>M5:5.8IIR%,2\JEDDJ.8",Z<1D:F*9GLI;R%+%
MXC"*L^39DKUQFLJBU->W"8124YY3VR]E4_?QA,G>MW5*SFWJ^YDC6Q64R?EL
M2SLC8M7F8ZG9"FC'L=`N-O0(3X\1MZAC[:K(;]PNSRMY3'9M6.MHR)5A?8J7
M*^,973?(K'\,IY`+0CN]7;F)XLRFUE"%%?&V4%_+^<B,HK-72QV&^#1-#KRI
M9>X!#7A,%W>DICV1*818L7\B(NK7K;`#`9QSZ",5D2Q.7/*UTX\W8J,5?"0L
M>8A<!I]L:Y/#XT[EJQB")5ZT&-R$8I=@`J-.H&7*M&-=;%5Y9=L624C,S&O0
M?3]69F8B(C69GE$1'C,SZN+VT^[8PNY)7<71QVYL3;I#DP7!@-[&A8FO7SE"
M=.J00[N=O7J@.,?NY5R;F4_EW(T,VTU"D<AGLCD*]QN:K5UQV:*R43T0@-`6
MGMC'@4S]`8W-UO-4UVT787#&*GO5^KI_,5(L@369`6DQ/24\*HXVG7HTTQHJ
MM54"5#ZYZ`B(ZBGG,^,SX\;N^"X^SD95FLD+&)#\A**;F5Q8^R4Q70N5U_9Z
MBC7T<^*^/Q]=MN[;:*:]=(]3&L+T1Z(B(YS,\ACG/+B[A[+%LLX]OE[))GJ5
M%@0'OK`OQ0ILR.OIT^E.2.6]Y6GLPR8`B#]V7K'I]4:1/[=?KT<2!JJVLD-B
MLNX:X+I)=6Q80MD^]V3>N(G[^+>.R>/\ED:;238$8[+H*/"8>B1EBS&>H2B9
M@AG6.7!E7L78!403/"TL(F>D9:;UM:(S,Z>_'&W&.NX*/+96K='XI>/!UNJ@
M?G1A]SHR4KZR1IK"2UF=.GA6//:6Z([K(7\8H8\LCMJ-2@8.,Q,4S(.>LSV(
MB!Y\;*/<IW7].8N8_#8BMU=B]E\ECFE%NUV>BR$8K'4K!P<&`C!EU:\HXR.%
M5D\N./N;>W#MBNJ3JG.-Q.X,Q.9)%5AUY,_(.GH3W.O1?*=>&Y)6XLF%<MT[
M7WDO$'7H34C.;7K5JB&3:&N.0[%U%,!8,'H/.8YZ:9?&;WMXVI@*N/PN3?;J
MAB,Q;^+[7=8NLR!]W:5$+FW?*R4>2R(Y)I=QFIZE,DZG=W+%&I?^66:@VT,/
MCL17_E/,9FG<LYU&.P^%JT$-5:O)6(BJ"*"U,2/J+B-^GN?(]>6HWL%5K?RX
M^CYE>-7C[EQEU&.V]5RV6/&5E+[;[?<A*S+0I]&$QYY^KYC<8T2PA`NTVI?^
M)Z_#@7D5(/'K=?Z?R0-HFST1Q\0QQ'*8MWZ#0:';?7NXRZ_'W:SU:SVVIM5B
MC[8Y^$_4Z$GM=]*T^:>6P6Z<A\&3N2A82T&8G&YKS*1QN59[R3D2CK&/=C7B
MQLRVS(9/!8TI8INX&QC?F?\`*;-J2YN))C3YYNFQBOX&Z@Y(AY')!$\8M&>L
M5KF:31KJR=NF)!6MW%K@'65`8+((><=6FD:3/U7TZ5=%)5CS!'%=(+&76NJ7
M6#$.CN-89:E,\RGQG@;+X5<W%95I<R&FH5Q/22I4.KF"!F/:/2#;/.=(T&-P
M945NL>9R&6RDC745ADJ.Q8ML,03$ZB"N<S'LP,:\HX<NOB;=G?>1W)6P5-M]
MUQ&&Q*+5:[=5D1;3D$W>BI09UH.>[+=-(Z.<T_B%M.3QN0+L*R::A4O+7_$:
MEI'?LA`V!_='!<YB8F(^EJ\UA+.+K,6%BDVRAR(<IRU.3-=C![=Y;$.$^L.4
M04>N/HH[>KU.WE\A6K7QBU!=FIBK5=5H<G9Z/:['8>.D>,G/3[W+BNK,W:MZ
MI>K6GTKM9!56DZG*(L56U"<^.K^)#H*#Y^GC-Y)`9:-P)R()Q5>GA\SEE%Y2
MOW;-2XS$T+M>I%WS0=!NE?281^"9X.E.*NA;6^:QHL=I!C8$^T235+"L@T6<
MM)#77C:5MPX<$.R"8C)H"[G*5"R8,@49!`E@G1/5,1$]8K.9T@]>7"K][=;*
M^:2`(%U/"X^MCV5HF2)+$:OR1%!3JLBMET<XTG7ED%YWM;DLWK'.;17&49H`
M$0NNW'6;+:K9)A&1P0D/.(]',QPN%Q.(AO[R,7CJ="&>'OQ52KK]V/'U?1\M
M,HH736JYO.XQ[5*)WD+.>VOE*6-R#!`)(5KMA"9/41'O\^,E;;C`NYQM'"XV
MP'QG%U\7G7*R9SDLXQM/#*ONR`5;+6]Z]W++N2IG\4;ES2=J'D]S]G?/PQM@
M#Q4*AV[R=71NK*W,3YI=VY3(`H%+'E%-1+Z8'G&_L0.'9CYA6:V[A+%MTC&:
M[N&%7Q`5G73-2I\2LF@9U9!PKKB=)CAU;&OM6WV_E"_:;QS.Y<ADU(W$S*;;
MN>5Q\9!]D:&+[6,;I">A4:#&G&U(:66VO.*C>R;-W^;V[@R]7XWA:]3&V$Y2
MPF'.45N)@T_A"/'GQ\M,9D-J8B-K;+JX*V['8[/*K#_-.,'RJ<G)-18LOQN&
M7J]%>"@W-+5ISIIQN;(-6U5?.[]W?F,<MP$L_ASLH=5#NT7M`%PJ9/'E&HMU
M].L_3.8QYXI%/;.Z,A\OK.,W(W6KN*;F>P%&\A#J-3)7-MWKF6QWDEME7<.J
MXBZE"?5PI.9N*R&8<RU9OV*XF-1)6KEFVK%XV'?G!A\.%GR]42TT4'A&NGZ#
M;&'VE6PF$W%O&YDZA;F=B:=E^-QF-I?$<CY=)`(V[UG0(6#>I7*9*.6L)^7>
MXKU!>&W#D2R6R=YX[!X[;[=N_,$#:^HC*T\,FKC&!DH80)9`!)CU)](R.7VU
MN>E%7,8]AXC<F,\"JW@CK3=IR6L^6M#`V*K8UB8TTF=.-T;<W#D8'/XFJH<6
MN5_Z;B+K.S_,JA.9&P:%:KD(U[-B8DIUZ.*^S,@DEMKY"1R<QK$1CZW\0^PL
MIT_+LU(U47XNL?7Q9PA*2IRU=>(?T1_`7$C_``\KTC4$E$=LXCQ7,_9Q;KWD
M-7;IV#ILI],S8FZ#)1Y0%QK).)T=,1'&2W9NIZUY:]778R3"*21AL713T8_!
MT_'2KC*P]/L\VMU*>J9CC`7+;1#<6\^]_+VTK=0C';VQU2)ENC.."Q$T6VCB
M#Z.B389`L"U$AC:OR_9D:6<VWN?XV-%@XQ6)R6*R^.QSLR]A]AS@OT+E>N8^
MW^:!]'M3'C4RM_#5&9.E:KW$WEC->R3JK`8GS+$2N;BXE<>RWK'3^@9+<GDC
MR$T/+]-,/-?G=VPI1];:E.\RNM:B(Y.5R,=//A'S!PE3"9C*0\+`YC%WF,05
MU4?EV+E.I:B@S)HU]]Z9>LO5,?H?(Q8+'9:C87E-O9A7[[$9JIU34MC_`&TE
MU2#@\#44QZN,QMG=5'R><QQ_!]U8F)Z78[)A'<K9&@?.8K6>D;5)\:Q,>$ST
MSPFUE&9"[\QL*=/#W:M>M9M#\QMBQ7<=;.4DUTLA.7PB*1'9(YT@P/4O;$>,
M+O39]E19S$1\2PKNJ8K96D\(FYA+L:A,U,HB.B8G0E,TGV9CBEO_`!56%Y&Y
MC9Q%ON\KU"46(9<P]X/PV:5P-)Y<XTGW>G@F,(0`!DS,Y@1`1C4B(IY"(QQ9
MWO6H5U8/%$5#;K@3VSW!<KD2;.Z+7AW0C3M4Y*->V/7RG3BM&<IY6YLS"6WQ
MVZ./LV:N]-]8\4/Q>R1LJ`TB(FZ&F)Z@TPZ9C2->,WOG>]JN&XLNOXEN"WU:
MU,)CJP25+;V.][IH8E/L^SU$]VI:E,CP7S-W)7;6M7:S*FR\+8CVMO[:?TEY
MUZ_=7F]P#$,=XRM/2O7QB/Z!BT;>LY]U;'+&UG:6R<A7C<5`[65Q44<CE,6M
MD9.WABP];)0H%Z`VSTP?+F+<ED,)4P.4SV4RN5M4DT*5&VNH_(VO@:<MY$1"
MQE*V"BN#B+4^N)B9U_15_F+M2L5C/X6OY?.XA'CNO;`EW+%&!CWLOC>;J9^]
M,Q*_:ZACC![RV5>2&>Q?^N=J92?W3I(9"WA<E&L%Y')!$U[*YTE9QKXCIQ7R
M6/KGCMI;JR5FF[$MCI/8/S`">K+[4M#H,(HY%W4ZG.@QZ(&(GB<[K,;/W-8K
M5=W(B)[>)R)%%>ANE8Q[@3)PJ[I[P=)^T4<#\L\,YB5V*R;V^,BF2`JF"L27
M8P2&CIT7<_T3U\_9J]7*>OBCL[;C$8V];I,8[(3$!1VEM?'A$9/<%R>I8(31
MK1TH@B&#=I&O+C%9Q%1M39>V4LI_+C$68F&VH9K&0WWEA(1)V5SK.HJ_5$=I
M)=41J4%P2SCK^7.T,C'G)GFC>6Z*9"8T1CW;&`P#8@G3/L/LZ#H0CK'%2ONO
M<F-P;[RF.J*NL(3>I10!L$0`YZ(,M.?%++8NTJ[CLC65<I6T3U)LUGA#%.7/
M*>DPGA]RY834J55,L6;5EH(KUT)&3:][FD*U*4`S)$4Q$1Q.&V[O#"9;*0+"
M&C6MQWW"D>MI519`><%:_:GM=>@Q,^$?1GMPW\Y3/&;8L#2SS,<?Q5V+O'8K
MU1HW*N-\U91<[]M<2LA@@ZM2T'GQ7MUS[E>TE5A#.DAZTO`6*/I.!,>H"\)B
M)XR.:RMB*F,Q-*SD<A:E;6Q7ITTG8LN[2`:]G;4$ST@)%/HB9XQ^7QKO,X[*
MT:F2H6.AJO,4KR%V:KNT\%N7W4-B>DQ$HUYQ$_1CK.<M'53ELUCMOTB"O8L]
MS*95A*II(:ZV$L#()U.=!'T_6W74V]9^8F*Q&X[<;-WA:J_+ZIN/;N2L8\6[
M=NSC,M-L;F&FNGKKML,4:(+V])Y<(JJZNU62I"^LI,NA(0L.HIYD72/C^CM9
MH`9'RYW3;*QE82EC5;,W*V/;R';0!FG`YZ1_,Y="+7/V1/2?FED\(KXCM)OR
MUOQG<@H6AB<AO3$L\WM^U2=(@%K)8BA79U.3,P.H1,\6GN,FN=M>BUK#GJ-C
M&5ZIF9E/.2,IUGCYF%X=I^T:OW]&UJ5KK_7YW33_``>-^YEM6W<1_P#MC#XO
M>#*D.?<9L#$4<%:=0%:>JQ\.K6<A+'`F(DE]4ERCBGLGY<9);1R"H^/[CQ8S
M-/:>W!&!=V70$)#-WP_(J)CVUSJ<]$#U<8_!X>J%/&8RLNI4KAX`M?XB+WF.
M:<R1G/M&<R4\Y^CY?)VT6W1RG\D;G(9W10NY+%=F+:N]UUJ%RC8EVGN3UZ1Q
MN#"_,7YCW=A)VKMS8S=KT=N9MFU\+N.]>J=_<%^KC'-L,S%=685-55-OF#['
M+QCJXW\G-[5IXK%TK6$>LL%G&YF]EL`C/I/*R]"ZN/.B"Z"@:SF4=OKUTB)G
MCY#X[Y;7\)E\QB]\8?)@.W#JM+![(H5R9G*MT*8%.)KG7A<>7;VI]C3I]6U[
M]?YG[DR.]H^=<[5/9#<\=FD[9]G,W9L>=P'[ZXJ`L:#<;)=E?2L)'MAT?/SX
M7\RM_8O=^U-V7+6-QJ-[9&F_,8WS^)QYYO+I5*GYBW,V9%ECJ@O<UX^:MI>_
M=Z8<-E?+78NZ\74PV;?2KNS%C;(6GG<T@FG6L,2<M4!`#C;U'U2(Z9K7?&[<
MO.Z__P":-P_,%_Q/*D08?=8U#L+O;<55765@TU^J84M$#T>.LS`Z?(O'L^:F
MX=L9:UL;9.Y-\6KN^SPN"9BUXNK9BM-)]RJO*[JW5?L3!R1,/LQUD!#X6[3-
MWX_"9K'_`#;+#V<+F?F58QZ)P"\HO&AM6G\M&8CR-^;]4_R+H/E[73K!04<M
MNY//[^S%G>[?GU1I9'Y>6,R+,;A,;CL^=>IY7;DCK1"B`!`VQ@(;+B`I,O#Z
MM%N.Q&Z=O8W/Y^OENM?S1>VCE/C.8W$A%O([/N8RQKY]VUK`M2IO6B)`"((+
M4?TF_P`%@*P'8^ZX$`&!$8^`W^4#&D1QD/\`9NK_`-36X^:/_>6U?]R\)Q\P
M/_,G*_[N[6XD4J6D2*3D5`*XDITB2F!B(DIB/I/=.Z+-+&4\?T5OBMFN36H\
M\Y:!0F4I=;T>THU$(^V>4<8C/A4QF6`Z]?)83*-IHL,"O;2-BM:HO>J7(AR6
MP42/3.D\>?SN3HXFB3TU?-9&PJM7E]D^VA'<<0A+''.D1Z>-UU!QRL3=V]@$
M[IW`>*V^*(9CK5@*ZS\S60H+MDW3'L]4S^R=$6L0OXBR_9R.=J9C)5*7Q9*M
MR-^(-JILKK*<BKH[W-?OXMW&X;$MMWTA7O6F8ZF=B[762S6BV\DRRPD"4,P)
MS,1(QZN-O[5OU$QE]_)R]>@L<:MJ<@C;&.&[<1D'0'3V:])VBQ9K$ZZ1QJ>/
MI'/DRQVI54%/P\_?H<P_T,O2KW)]7"C?A,0XT*4E)MQM-A)2B-$J41IF5J3'
MNC'(?1P.79B,8S*@,"&3.A5+(`,::"-V539$8Z8_%Z.'W9P^+\Y:-#+-OX?4
M\S8.L4'6-[^UW7'7,8D)*9Z9CE];8X9K9"*F2VMD,\S/[V:O:DX_)8^\C+SV
M\"FDN<I5G(Y*ZEX](5S5`E#>N3.?TOS!_P!B-U_^`W^,A_LY5_ZJMQ\T?^\M
MJ_[EX3CY@?\`F3E?]W=K?4V'L/';7L;TKX95[Y@[GV_6O8K&RZLD'8+;W<N9
MBW3HB(9*XUAKDI,H$>F/3&P?EX_(YS:NX-L?/O;_`,M<S-#(+1F5;>S5;.^4
MUMTC?2;TT[?;28=:NNJ#`UT$N/F9AKF=W-DL3L#YM8*MBF9/,WL@^GC,HBO%
MH;EEDDQZ4M*)3U_NVGK'M%S^<F*V[NG<&XMH.^3='-8LLON#)9M)NMYK%B=I
M,WVSI/O#$],3$3/&X4_*_=>Y=VC5^1;\QF:^1O7LV&$WO7L*4GL5;J>UC<M6
MK=?31`(]SHE?LZ#MUGRMWKN'?%[(?*C=^9WM2R>>R&XDU-Q4\#YO;UQR+AVU
MXS,7-RGV"1H&B_1[7M?('R6^=R[FS>7V[O\`/>L7L]D;SL!GLML>U%J:+&SK
MAKS70X.E1Q/132S2)]H]O;+S>1RO7\EL?NJKNRUYFV*=R9:SDFX+;0Y"9<<W
M0#"KFR$F1B9#)<_1]<XVG:QU7-KM8]Z/BPG..M5T7D-O4+3$U[3ZZ[U(35W%
MK)@=6HZ3SC&[5WCNWY55\J60=7O89+,C9W(^&W;'DZR'U;%+#5K3Z?;E`&J7
M$!!UA#)G]+\P?]B-U_\`@-_BW6M'MOX=.'0LX12R87>Q"T]/2UF28B':1'/H
MT^SCYCCA"P@J.YM@G_%:MZPSN1L["0/:FI>JB(=/KB>-Z.O^6FXSYAY0K$TP
M:NMW/Y>VO^Y!S'-$-/64_4EO;#ND,`3.F.Y(1.L#)Z=4C$SX<2R:Z.Y+`=)]
MI?7+5Q(K;)=.O<`9TB?&(X>IU6NU5J-+2V(6868TZ='@0R+HZ8T]K7CMA2J"
M'9&OT#73`^7#3H1TP&G9#3D/A'#V(KH2RTSO634I:SL-T@>Z\@&):SIC34M9
MTX=-2I6JS8;+K$UT*1+W3XM=VQ'NMG^U.L\=2*=5!2YEB9374N9>Z.EK]0"/
MSFC.A%XSQN[-U+&1NY/>F8#+Y:SDFUVDOL)\O1QM+R]2KV\9C43(I$^XR(GF
M9?H<DA>YZ-39^6W=6WIDL?&"'X^=ZO>J94J@;@F^()J3D*0F+.QWE+_+B=./
M/X7)X_+TI8Q,7,9<KWJLM272U</K,8J3`O&-?TGS`B(F9G9.ZXB(YS,S@K^D
M1'KXM:3[V'KZ?;U`B!T]?5,\?,?_`+7M>?U?R?A8U_;'&]/_`#$RO]6`VQ$_
MLF/Z)4WH.=QN'QXU,=BKKLOF=QU*M5U7)MMB2L#A8<C=!YK'6K%!M5@07;/4
M9\9&U9=:MM5=G$UJZ;6UW;3U#"X>GBXR(X^Q9?8LGD5I'6R8I)\*&9`9_10R
M[8%(E.@Q.I&7^(L()A:>G2.7'L9*M&O_`+4^Q_U\+X=5;VLGYA)J92#MN0U3
M@D379*>M4*8!:3'M3,3X<!FNC+9/&8^\BSCMIWLHQF"2X;$,J*9,)^(6*E(A
M@A6YQA/3H6NO%G+[A3E]NYY=-*2R6S;/85E*27=*T9>KD:>92+*BV]*K,:%'
M5ISB!'A&WMJO12I(8QY]-H;N3N6[)]RQ<R5MTDUURPR=2GI"/PP,#$1Q$6@1
M='TS(]AO^6J.W_T)XBRCV9]UR9F)-+/[):>,3Z)],?T*M7OY:<'>^.XAFV<J
MNFS(6ZFYTV.YB_(40:D;=Y_2:EK.>V4GI,3X3V-P6,]45NJ$JQS_`)C;E1_-
MV:R*S+RL8?8N.3-/;F(Z&.@]>T9%V^KPY_7)C3!2PC4C84``QZY(M(C@TXL/
M,-YQYED2*`GU@'(W:?\`-C[^"L6G&YI>)'/]0QX",>J.7TMK65PU#AZ&`7@4
M?JYQ,3X3XQ/#F5.\371TRQS.J15U=4+&!$!TB8CGIKQTO2IP^IJP9'[#B>/R
MA;6].E6Q8JAK_P"Z0T%3^N./,4,H_G'0Q%M->S78'J.`"L\ICT3W-8X@:[<#
MD&S_`)AQW]OOB?\`!5(Y\6_\T^/XK;V3"-?:=4;CKZ/O$5W5WS_^7X_B;1XW
MEK_K>G=PX_J/*5Z@%S]4Z:\7]SU@1FUTW8I`UZ^00E;3RV7HXA,E=Z;"D+!E
MWKDIB>0SQB4YQBZ&:RJ76`Q6'F[NQ::P9!V/39;D<%CG5U5[#5=(FV%#W>I<
M3)!/"E8?)+O&_"8S<2X6JR.N'S)VEXZT4M2L5D\Z38E1:.7T^V(\N"LY;'+P
M-#^6AW1%Y>65F@34+)HQ*Z.1KU*BK=+,6K=D8KUX6PK'.`UF-)JW&92P(W+U
M['*J?!,\66&YC.F<DFS@QQDYFE\/%@RXG(`5"8R4Q!#KE5/S,K^#(RMB\Z<9
ME_)]O!&"\T-&]%":65?BF,@;"JK',5/(ACBJVO9R62%^?K[?<%'!9QMJG9M4
MSOIL.HSCANLJOK#!)-:S\P,ZJZX@M,DJ<WI\*J9N]9<6-RXTW5MMQ)9XL7>F
MAY+.,Q,#/>728]@:>'%3'XJ]=NV;B(M*[>!W!"`K&VZE%BY<9BPJ8]%P\<[R
MYO-8V8#575$Q,_5NTDW;F.=9KM4J_C_+Q>IL,9@7U"M*?7%X?ADAG3@''4RV
MV+F9M'71BL&\=X?.K>5E`KLL^.[M.;-':M%M8E.8*#@5K*=2\.&D]**.8QMB
M,?N#$(NCD8PV7\K6NLQQ7UI2BVQ5:XN2-<2'5,CKJ,_698L,%25#U&9>$1_?
MF9GPCQF>.74NDHOX='K]'>;IREI?]&.7KUJJK(2T[`&R2?U](P!",1`@03,E
MS]/"KO:[)D3%L7K)#!K+3V2F(U$ATG[/#Z@MM21&R9A*%Q$M;,:=6FLP(@.O
M.9X7<J%));KIU#TF)#,B0$/H(2CA,U6-K8Z1'1U:9@BL:\QL'$=2_P#!'W2^
MWT5'7+0I883_`/":V)`3(1-IL=(2;`B)]R/'CVLG=^X1H!'ZI&EW(_RN/S<A
MEV_?ELB&OWBFPH/ZN*X7ZB;J;/\`"S&0UO#!'^Y+2Y+HF>]I_E3Q=V\JM5P]
M:_:PUFR>.H5%2WX+F*672IBQ6"V@PZ?;GJ\!.=.*FX\)E6X&`QE/#9#%4L?C
M3H9#&T<O9S"DB#J\S08Q]^P#&+]J0=.G2<0?&;&S[=W)9S(2H^]#@3MZG>N#
MMJA7T$>S6K4'RSMSK(M>SGPG"5\K=K(G;E3`9,T5:8_%VXG.5MP87+W42$H9
M?QUVO(:E!=VNTESRTTPC\1GYP>5PK,]TWL3@<-6K64;C3CU9`&XMB7U9L06)
MKF#2ZY@E^U!#[/&^?@3JUJ]N+&;I#&HO8['+MU;VY6,M/5\?A<7/)0]I0(S&
ML!,01%IQ;R#MV91VXK6XL%N'XZ>/Q4$);<Q[<7CJA8Y5=5$US4L,[I=(R9GK
MR\.+5!^XLF[%AC=\8[`TBK41G"?S\-@<PXK(+%^3)'FSBO#-.@2Y]7*8VYN;
MXBRJS;M959:Z=*I7N7E*K6Z_D[V6"(N/Q#/-=PJI:AW!B8TY_7SU["X7-/SN
M:;BP<S:%E&'S]^W6)57'G8R[/834JJB`8QL,%5?J]F8XN[;V]NNQN#?NX'WV
MY9>,L#D=H_+Y6;OQ=R6X=Q7^T"L_NU8ATIEG01E^6*X7[XB1290,1)S`Q)S$
M<RF!@1B2^R-/J,>XNA20)C"G\(!&I3RYSRXZ1ZE45%^2GTG/AWG:<I9,>$>`
MQ^N9X45]$M)'5"YAKEZ0>DE'Y9C$Q/3PNK55"4*C1:QUTC69*>93)3,E/IXT
M]/TU[`W/*L2J4EJGO"P.OK'_`#RNB0DB]>NO`48=YCI-C";T=KJ)A:_N^MG3
MH.D>/'/^[3G'[)^H)#.A#,$,QXQ,3K$Q]T\=L]$W@'\Q/H9$?YU/]H?7'B/]
M?Z=]6TE=BM92RO80X(8IZ'!*VI:!:B:V+*8F)\8XL(V7M[%`RJ,.J82F%;$5
M;<B:^^H"4"T+MNKB4`9Z#+>GKF(UGB*VX;6;9DLE\4R^\Z6:SBK=;:6&'-9(
ML/NG,..YE*^/S&8HVJM6,=39I8F(*(UB.JOD\3<KY"A:&21:JLAJ6=)$LX@H
M\#6P9$AGF)1,3S^E=()_,O'[7KA"9$R^[J9TQ]L:_0N;S^W+?W8"),841,=1
M=`1,](Z^/"[%=D-2X8-;!\"&?OTF/H?:4MUF&NEE:P@O94N9]A?,^I/:&=/M
MT]/'4XH]@(EA>$:Q'M3$?;/'L(,O\8H#^]!\1!@2M?Q>\,??II/]7'=,XZ/1
M,<^KU=/KUXT,37]OO1I]NG/^KCJ64&/K&=?IJKJ)6;;,-*6/$Y6(ATQH'08=
M3-2]?+]?'Q`^BO:KW"2)5NL(B5K2T3'J,RB?S?7P%/(R*;<Z"M_NIL3Z(+T*
M=/\`DE_5_0,AA,)F#19RD6_C5[+T*^:R&X.[,LH.O71LX:XS*;>,5_#'%8@$
M]H0."#PQ>!LH#;]"MA<MOR[M+#Y;X3F,Q>3974PUC=VY,/\`E)N[DSG4QBJW
M6E2U3K+"CV6Y2G5MTBJ9&[A\A4MPHIKY/&F*KJD6ZK'TLC5!D^P]!DL_LF)&
M(4(]ZZT.M2IU@`#61AK9_L]0SI$<YT]'!V;32:T_3/@,>@`'P`(]4<?#_,I\
M[T=SR_5'<Z?N_M:<]/'3GX<)N4WH!@)%!K?+!&8%AE!B0"S28[GAIQ5H,8+C
M1#>I@Q,#,M>UVD1//0>YI]`2OIZB/3VHUY1$Z^F/3Q`'TP.NN@1,:_?SGP^F
M(F9F!\(UY1KXZ1Z-?HZE'(3]GA/WQX3Q^8F)]<@73_T9B?[_`!`C,BR?P%'/
ME&LZ3&HSP(7:RK(A.H0P=>F9\9&?$=>.Q30%=75)]"_#K+2)+T\YTXUCE,<`
M1EK:KZ)M>N2B/8=]SAC7_&U_H&3J;;MTL/G<G71BYSCE%YBGBV68\]-=J5DZ
M;*JCG37C6!%Y1.H^/&-V_AT>6QN*JKJ55>)=`<R8TM([CWLF38?B9E,^GBU'
MX4"JN/\`S5P1_L8<\9K%W`0.'PVT/YE<]:G'>ZE66C8C]]VC4-=>L#`=75Z>
M!M3:ONZ;(Y-+@Q]X[&5IC9U:['KBO,VM`$NK3\O02Y],<86_-BTY.X*]M^)&
MK1LV+%J:4H!]<:ZPEWF898@>G3T3Z(UXQM6I9N$65;Y6NX\=<76"]/5ICWV#
M5"UW?9]SGRF)\)X79"7,6></;\SVC&1R(63J]/3I,]N6+GVO5Q-%QV%'4OEC
MK#!J665JUDC%0>:LP':4#61,!/ITGT<.J/99_A&5DWK:J=AU#'NMS$5UW;@!
M*D$R2C[M>>G`!CAJS:G(5J;'Y$3F@D'=7<8?8>EOY6G/U<^,:,7\-:MY7,15
M#);:IV<O2KT5K&7B*V66#8RG=+V5]7,/MY\9RUEK5A.-QYA1J4?@C5-?8DZR
MEEW-6/\`B5AA%_"<YB"U\!XN7G-LUXH65TK52Q3L*R"[;M/+UXIR'>,[$%J'
M3K$QSUY3QAX#&95HY&TZO8!N/NU[=7LCS$:IU^MUB9F)Z/[//AU=S+<C5-*K
MUQ5"TVACVV-.TJ];!<J0R>KG$^$^/"\%!O*^IH"Z`K,-"`=4"T#GV(CM*22W
MC$$4QJ?+C'[4VLG%NR5C',S-Z]E9L,H4,:M_EAGLTF*<][G^S$=8Q$]/HG6*
M-7<ZA=N&PNX\Z.V*E_)@5.F9=60!$K*Q7K=KIU[D^_RCJXQY8*XEN(O[*W#G
MDGY<2EEJBDCJ,_-"&AVC'0@G3GK$QQ2NW3@[>2P>,O63$(6)NZ?;*`"(`=2?
MX1_0>TF1.^X?R@\84/AWV1_ZL>F>"8PB-AE)F93J1$4ZR13/C,SQNC(H?1%.
M;V):VQ5%K'BU>0<5B1:^`K&(TXAL:D,D?^#QLJ\U](D[;VA&`NBMCY8VY%>L
MGN58*N(E6U3/,I`O\'CY;^9LXT_Y._G#XEV&VB[_`/,'>\GY'KJ+[G:[OYG7
MV]/1U<8&B5G&]W%_,96\+!0VUVRQR[-MTH3/E((KLB^/9F!#77V^+&/&QA9Q
M"=Z'N5+B.Y%\UE>*P54A%!(`EP9>OJ+3G$<;GJ`^C#<UN9>9JR3+';"J#ZK)
M"Q,5I(7]*9Y#!#X<^,PX:>(RF/S-P;G^L,CEZC:9D(>8`ZU*)1<7)#JOF,^B
M9X4>,957:"_6MM5=)@570GJZO:2EYB1Z\_9F)XP)648"A.(W%7RAIQK;<H93
M6DA/I[E%/\7+"\-('3\7&:'S%'OVMW#N;'"3;<(,%AVXJWC2M;TR8D6LJZM.
M6D\==>IA\5E49K$YJL`7\ID:]EN*$Q!>2LVE]W21<6D`$Q$:<8.^?P0<OB,L
M5X:@MNQ0FL:.SVBL]DWD\)YS,!`^KPY[AQ%1V(^$[FR992S<?-F;U([,USNI
M57[1*>,DC\J9,>F/5QN3)$:2J99>!52`385A88G'E3;YGJ4`1)G/L])%K'CI
MQC]U;=;CO/IHGBKM/*2]56Y1-TO'1]8&,6T&SZM.4>K2<7N2V.WLGD0QC\5D
M<:K(YO%8[RY7V7*;<??JPRT;4=S1G<&!9'X==-,-TMP&)6G:>?VZ%%=R[VOB
M69[O:BE-I+'NJ"QOM$4]?J'T<8.FR4/?C\75QUV$R4H?"P7#82QBULB.M>HE
M(Q/+G'HX"U5/K6?C'XUG^);!_"8_W<OZ!;GG[85B_P#IE!R^SV.+%-=:L=:L
M2XF&"T7,ZDK,OS.YTCS+V?9\/7Q7N+$Q"RD'")QH40<:Q$_1O;(W&6BQFT-O
M80!QR63"[-O,LM6I?VY+MS8+LJ3!E[@ZZ>,ZY-'DTHMT/*_F4L@.5QS0N+8:
MS3>BM3ZVIE1"P.CV2CQF)UX^#JQP2)7,K6)_Q("MH^$GV[%BYCHK]=93VS'9
MU/V]?1]%JNC;[K:*F;3@#LCD*RI.[;!?DX4A@1J+&L@3DB&`B8G4N<0ZP6.I
MU;M3+V\-;J7\Y7J5PM5`6V>Q=\LP[?=6T=(!/KUTB->,4K$X8[EB_B!S=A3K
MR:D4Z162J1`,)3!LO)X%`C^7&D:S,<7Y#!M-5;.GMJFSSZ!^(9J+T5%H$)5K
M7KFN>Y+2]WW=)\>(IG@SG+QFHPC*"\@DDP]M(KU9X7C0L3KL7'/4!(.?*?"=
MM_#L<[S7F-VXW)8+XBI5=E[%+I#HR\2NTQ5?N20ET>GPXQ^851K$F[1*\=>S
MEZ]2[$*:27JIU>PYETEFN>?Y03RYZ\N`Q%?&@^2O8^AJS(K1<Z[],;WF5X[R
M[6,HUZY>VWJB.J-/#GQ.,KH*JK+5,H%"]6R'7<1Y<27#;B%(66,8P9ZTS#&3
MR]$\8C*/8?YU(!=K.OF+*=:[6SK_`&S5U3]L\,M54^:K2I(IGOUE=F!'VD]+
M7++]YJ6NGXN*2;Q]=I:`%Q:P7M1^&2CWY`>4SZ=->,A:F2[9&I`CK/1)A$L.
M9CPDA@Q_;_0*]Z/W5A,)F?[+4Z\I_P`991I]T\!:MUNMP:01"PU]T1]T70$Q
MUQ'[?U<"`1`@`P`#'*!$8T&(CU1'T;FN5!39I[BPF-HY&A,'-IEK&VS[+Z_2
M/3_H-@H\>L2"-/LZ,BW-+I^9K6T#;NVENFS29UA`CJ$Q7F"_,B8_-Y:ZZ<BL
M%DA729<RUFY%6]D-<@O(E8-:?AI@-+'%7-T%W%F1S(\!9&Y9.I5Q"<33JM>Y
MW*+!67VK),*8;8*8`!G\(1/KX>?2[JL9JKGV?FS_`/<*<IE)1RY*CL#J/IX)
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MTTY"/WA6#/[3BRU>O^2N/Z`6O:_TE&G<ZNK7VOW'3R[NGKY='5]6OX^+?N_S
M?]?Z1_O?@]71Z?U]7TU/'W[/C_VEOA]GZ+__V@`(`0$#`3\A=&7[4]*&K<^T
M[('AVC`!5<=G`06(48!>)X?H%*R%TJ`81,?(=6/@0GM8KU49:*'VX>O0[*D@
M%0X#(^5WLJ:0FKAGD0]$$G10V3F&S5ZP$SAE!`-HX,^:`&[.6'_03V<N=.-2
M"E'YPH41S<:"H;4>T6WU=[)@/$/)10@)LPX=J&<&PG20YC*%'2"J3:6-7V:@
M!@RY``@H=TZP.>D`,0Y$RL`4P!.8A)_+4KZ)*$4492&38)O[(HZ;AP"$!NR_
M?TV5J&O(LTU^'PZ2WO<Y$-Y5["#:RY>-NXB1IMH3>!+3-;UR6JPM@I)OLSI?
M.GXKC=B-\#5OT@N#<9PY6Z*4XJM]B;;!1Z!*[N0D*>^8_P"O[R6(K$?5=\B8
M**NA`P;Y-E'3MFY,^!//C_M5NGAJC'K5>+6W;R(T40BT7$H&1Y'"!<ML+AI:
MA\."%!PD-;K46H!8@>T-7E[E-O0@2=JOJ"=('A")^3+)L^+GB,L2(/T!><TC
M)N[H._;Y3;H#\2O)P&\J-MVDQ*I25F/&LW[&']L793(TI(VOWQY>"<#9S_`)
M_:76+*:*=7.4\L*?+(SGG6LR).8>V-CKBPS?T2+Q2"/LV$FS;1'U2`8:-#>W
M4O6[_$]U8*`Y'5&%N\=ESFF%?*9#L[>1&-M>[3;FHE",*7SX4'K!<],DD'!8
MU[%]5PL-%4;SM"M2C#6J)@P')B$0%X/:`KT27HIZNLT*97`USP?*6MN;T]26
M(<]Z`L+UA@/F$=O(*)[``_(<HX&JO!AL-D"0=I"CB!`"@`"JKH`R]";]*`:B
MY\>S>;[6E;`VXNKR7;T<=.#1D6HZS^QP-7*91@^2:''L`#\HWJP:?E3R5=S%
M6ML<%H$`Y](DY&QP`]$!<@>HTOW.UI.1T^T(8:NIY$E#;UB_4[.U2/3/``![
M?%C1%:/%=CF^-2(/`(M=9-%SJO>26Z>;QH="-61"(!V_=VOL!NK><_#%TAX8
MAP?MJ;-)Q#H>><"AE%.\L2)]GA$IDWJ?5:'1,-<M>_8/>P/,V^`6CE?9W;*=
M=%W)`[<Y`;'%H_/1QV^J"%!4%!HCR:/V/2JF4HHD1VOD32)K`HD&Z#E.5JG:
MM]F@)193/E;C4W!'*RLT\+8X6/#Z!8T(V[U"A`JRY\@9J7%`U$`Q<'?+A:T0
M%EVK]>ON21R23E.7U':$MS8(I.R.#X(A2P"JJ$J]K[`&B53ODWT7@1OSJK%)
MV.NERCA`(P8TR^*BCI7>;G97@(^]J*=[^B.D,AMDEV@2`G.%=/"X-"Q4`\,W
M^\XN-=T)'!J^TBE!X3JG-=-'P1?:[ZA0MZ)=#["8!'`!1&)2@$]D1G?R!$U`
M>'?M8!=N\P4'!Y&X?J`S<\8_*!F5>#G)YS)ZR!KE&,IK:*[&YQ\K6F:Z26^A
M5_Y.`.=%85X<-/EY^5]@0\3Q#GX$@#]A/0-5'"*NT!O.M]E,'\DA&F!#!&'P
M;U#LV?9GL`BL".@)-()\FS$T74*B*\W2@!SZ@>:1)X,A^E@"`EHV;XV"2G#5
M;KBIN:@OXW#N*$U?2')<>5V!*G$.`P<ZN7KSIE%%8C,4'&C,MD#K1Z.TEXK3
M++B22G6.#BCEI#+3_##A2RKT!>6;`8^T773<BZ]XAK#8;($J[2$3&A]@&C(X
M*=&VI7VM)7Z<R%B2#W>5P'MT(;R(CZ/0]?XU!>P0:S3WV-"R0MTIPX)L&+2N
M2HZ-JQ<HA]LHP9"FR&(:8<!RZ0/R.)OQQD'Q4-B;>+5$2:W$]<IJIB@G&25A
MH.^4>X(F<@`*AH!G;0ZE+@!9#D$"->W@S@(@%]0?_9M0.1HR#"+<W-M#?9+M
MYUU2MR=/$.4^<1QYLF=%]1@`T`5@J@%PO7+`:AX]SGA8>@I8S-38&6]=?)]`
M?;'F$5C%XJ"06&",Y\BXQD'H10XBN8)/@.$Y7O'H6K80T4X4$%9BC'D%4G3P
M@6QP<HBBJAS%QN+DK,?Q\IC7>AI$+2(3WGD.%AI8Z2`>!TY#2F5(^R[@I#W5
MK95\#8/7'H1'=ARRSWTBX0*TTU,Y!=7=]:3+P&@OKL9@#NZ[(HJ$$G%0"+=(
MV5%S$O>7U>Z.N9H$#VZY$:U`PH>YE,G;8EJ\`&D`8-,LWJ.(]$@42*G*7-@Z
MM;X/79F-N3Y+HWO@>#U($""(6V+[#@_18HOA8?HT.G'PX`<D%F)B-=6Z104Q
MRGB$GNB*B4QCL/L(PV7@Q"K@JS``((*P4G(9)%HF+LJ\T^<3:*YT`0&SA-/5
MU-:54['#QZ;4#SINE).2MF,^I)ARBIENOQ;63A#4ZN2IB59(AM0NBPDS[!-;
M*EX+H8L!)..%G>7#;@7P3(L'BRS3/6:3R-C'SH)!0*DE]@@'SXVC4].X7'8;
MN]2?1,$W1]]/`&`?=OXM7&%)CEOZHJ+W)C<1^B$#24'*J#@S+T!J[AU1.%,A
M6Z$_K_:OZ3-#I)]&[P"JQNC1`9DR!&`.]\8"HS)5.SZ*>S`#TV$)BI0$EE9*
M/,ACI9KOAB02.XY&.>(3]`GAZ(*F(CFO87'82W2]*L`3D4^@[&?5*`&[BWE:
M@Z*$[.U;F&)3@&[J4W`R\G'`"S$/;55G:2:EQZC^);C!^\)`KPEET)1M"*JL
M#)Z+RB?A;>-Q&3IEPY,=E5+D3^XMT%&ZB1HMB(+Q!,I6HL\/7]#H9^_#9C3N
M]&9%=`O\7)19/`5^C#;!(XUEWB0@!E9HB3[#?A7-ZH'.BN6V6[J@[EZEJ+:<
M1SC0`R@31=!EC+F/1@L1]U/$(W$%L&ICG;;<>JT%S'/^H@]FA`3$MZ8%9*U^
MN$J!;+'%),M1B1"4H/G#(1+^LGI!U4,L*)@[-LE8(-B9'5^O;5#&X2L/&&'G
M*?\`8B[!Q[P<,P<,L+B`81\(R`N#\##4#T5\RTE&<01&W%]L_.$\&`Z2426?
MA\%AL^*MKOZ>S-V^/0##N:B9$CMEW2N2:7"XNN;^QS#:/*XS@0!S-8]*^%M=
MPW.7@MNA)Q;'ABAKX#]CR(*$'&V?1;5M!JN5EQP0LHN--.)7D<90>2NRN("3
MNN.FD845F+#B6TZ4T3,=+*+>7&EM(D+.I!^3XUILBWV]MG(RULF-+NH(D#5Q
M4YUF+/*U^F!>[2,?Y18EZ=B(T"!*Q8%'-&7&FQI5`_JG![FOUBS%0KVIPOJ"
M"(@B1'8CR)V.<?Z\7%1_8PP#0"!UZA60).!-P)01>=>O1'SCA/):$(T1[M8*
MPZ1!@Z:J97<P`'<;8M&]KO3\S<E!@[M-L^',[M<>F9ID)-[,`HR8&4E6MA[1
M#,ZDIW.4=F?R6)U^-]..,D#@8'BSG9*PR""/&+L5$C_>P&!&$]T+E88+G.$)
M$7Z-XN*R'W?3&!6X`ACOZW37AV-T3JMP3_D8U'LC-HX,VD;8^4(0`L7%:W[=
M)F`FMX<!81,.X7_&<%CP(=XM39%4EB&4T$^PU*BKE4GT"6]J\*XKTHT&5'87
M(^DPG(,OK/%`IBY`W(!.[BO\4)Y$2`R]XD:4%H'3D-/^?8&8A4U6W#$3!<5!
M)%DJ%7:Z$'-7C1N=%@:-"9UT/MHF)CIU$,ZH:3KH/:H)<UR])CO>'FIYQ"N`
MO52*AP-BN6"@-[YRP_WC3Z"[#/QWR"*S2:C.&7`-&B"C\GU`?/`@(#:G$($&
MQ$8!'(`>;G#\D^XWV*GW,W4V,'ITI^4/R?I7`[D)<CH"T&1)EVX_$P)0^E+9
MC'Z6(;V3RR'Q2#/90C1_WK!8>>$J97+.11QNG-";O3B:2(!=3RG1!4`WA`B_
MRU>,Z/F*`HPE/9)X(/Y3%]B^3&^X4P\30_0MX:^".$G6-5<B9M@H?8\1A*1]
M!\]<#8(+[N%?8)!+JOEY:-8DI^4AT2=<`.CU3)&E3OE`@00`F\MEHU(EYW`F
MG/6?_GSNS[SY:1PZVP><*?&`0N0$[6O:EG#+D:;*LDHGQ9$'R<'&*("@.BB2
MNJGRS`PVMDL6Q5$J+07(Q;1Z!@T2_.*OA):*&\1RD@K9*H$PP2.:H[0EK>I8
M)/*L!;085W)X[S!82J-E2(4S%]`0&_+\30O4F[EE;S/&7?T!$0V)A0IG?]\7
MXY7NT0(EZQ6SNA+QR3,9J#6B)HT$)2^F3/UUB1%+[40`?@OY20*B&\8#34TZ
M:*1..1([8N7Y36@U-IDX<-V)-B;<]0;/*7V;$TGAR*)N`NJH,ED:F,JT!I1Y
M%$</<1?(2;J*0O*F-!VSH283R1L+@[5[%O8TG&/W:YYPS:,J;'EVN_#K!<*\
MIG*Z`+Q3G.Q1?0!L$#OV;=V^'W1)BZ167^4VA^Y`YL`874FCV<.N"4P*<6E$
MF0EHA"+_`/.<(*(W1H-T$2RV&8.(9"!+DB7#EQJ)06P&&W5MFX.1:[KW$@<'
MY^6!W:)CIFN;6Z%P*`,C95\T%M!4`70>PK-G2(R!@.`5ZS8,B[`78*#L5#?H
M`THGKFQZCD4FDQ6%F$.T"JJE5WE*454+M"6'++ZK4.B\10V8:TN)B"DM[HTT
MQ<FR]XAH!*,2[0F^PI\^Q(SXH.4Z0P/NL[U"KM?N'DB^L20UE+D%'(B./Y?Z
M%=:YB@5$]1DPY7LA_GR9$GL.!X#0]`3UUH\&^#%M7@@]`YM060`=S%#HKK*O
M*DZQ`(\B".GTFA3>$U4R,=41QK6P$J3D$.`YZPCJ/WQAX2TI'?("?.&0$5!L
M*)Y])B#;F2>,\-3H6&FS@@^VN$\>MW<K^F')%L&4</0\*GEG_?AB341A/7:G
M@TFB*+Z['L[Q();!&[G%<)[:$*4SSU$X3UMAZ[-_>*\AOP(,XJ!M*WRQ23;X
MS8$LZ`,_^I//P^5\;EFZ@EX9JP&-#FYN>B&H5>R/,L./0YESD+4!LTQ*PUH9
MQO8Z>K0VKIY53*<ST\XEK\#T_N80!WM:^<-<O$F5.``/-F/GK9#`'&!N.\:(
MKR239.@?XP5"*!$8B;$38CAD4>4YQ&OA`03C]`\(<2Q4;GY80@[OD;`;7_%+
MVLAC53[6^(^*%;N@`B0QK\.LT>`90KC7B%4KDX&E-,?+=ZT?!&TB6FN.5MR:
M#C-^(P"]I3KJ]S*0H4B^:B#HDBXWH"\:>M/:C-8\FF?VF+%T`:..@X?*EH./
M/@"(5:$W2$A--FB.;R%@!XJQ!4T(!#+H]V8S"B\V;0=^MX]`(NJ$0=AWBC#'
MP!)J.2)!1MG:34*MN/1TGA-H.$:70Q`*Z4-6S(781JPK@4LU*'0%T3]#?`UM
MWM5P;IQ^!QSZHFRI*E7-JQZT(\P!K'WLRQ0NU?FNSRG$7<J=;3H>.R1;;6>#
MEU^S0*K:A%*J\<H@V'#2P[*]6XZ;RJ/4`\>`OR$Z`")8]E*GO]B-RNGGFF.W
M*MNM:34.L"8!FZ[6QPNJ;%=)5C'O(%`%>36%\W\6K;&&<#F5%*;H9X&Y"U),
M3"AB1$'0EIK.6D6I`C=JUM8L(*=X;B>;C!01P*::O;6J=/W[00%+)QU`FDS0
MN`'@B0`&V=_9PFRH7Z[K<+IJ'W"OY84;^MOXGO0S1<0$,J_)J6/)1Y->BX^4
M/3H@DW2F(JKQX2,!'"-!@O!EE4/FI.FFX.)P+6>H8#`TP*!Z4I*:P5@7:L[`
M][<"-?!V'!!`,2A2;K00A<#A+F[&-FHJL&"Q!9)7!4-GK!3FA:VL7Y^&!B7#
M/PAOV,)'1(<+^T'.4`^6YSEE=W0XD]H*D)P><?SQ5:RTC70][<V\/X0@DD2U
MO8W#$7(X#;(PR@O/Z`B+M%MKP!\TRTOU%$@BZ;J27A@7U3BA;0*'H3V;)_&Z
MW&R%4Q"0.!!7J`>;:7CN#GAE^<Q2$6XW-IIHWYPQ"O`7/4KIF\AT.WG#OR.?
M8%@P=NXP%0:R:W5\2A5F'TF]0M:2GH4WO%A@;EB'2VH3QA/#9\Z"&U331-8T
M9)>-R-&G(O."H:2:(&@2)7$,H$Z$2E`%4VJ.3E!YH:*F&^'KU=H+=Y8=.@!\
M'Z#S#^]V:O\`-3V_NCAR_P`/S]2O!E>6S?ZYJ6]>O_YB_9?F_2__V@`(`0(#
M`3\A23?M`K#G$!"2_0$X'./;'GKT!'5AX)?6,O7I6@G.N/O[-L0<*:B>H\`?
M)DB(-?GOTYF*:_Y\/S_C&+T,!/!C8K@_?\^I.Q!^?P?YRI8QY./1`%_?GXQ*
M_P#"_'QA3*V?#YR5=OLIPZ<??#J(5O&]Z^?ZR"@E)Q./YPJV:B"0UIV?U@V@
M'5O[N)Z\/V74\=;R"D*0[//S]L@[GCFL_$PD=.-<@+Q(+\9'^I`)ZTUCB';`
M;;WMP*.TB:.C_NY<("FR[;I(>=>TX5!CE>/)X]NH?%_SZ`ILY]M6YH?LX+T9
M.N/'VSP@`Q0=H!^!`UA?<*:#?XQ4U67'G_.-\Y]\QZY.\0!T=?ES?G:G[[_.
M`5X6CO\`&<Y3=_?OG-NA^.O+RX<+"K]SUX1GC_K_`+@L`/M03T9HR"Y"MRBN
M!/8"H<N(KL,YR4D^7L*F?U??TY[DU_SX?G_&,6FCV11'[I\X*1NCT@&O'A(?
M:H'*#^<,BH)[0;8C-=U_K[_]R;@=>?YZQP]?L)`*><<@"X8Y[.!,-'L>(\?L
M"LR1ZC]_CY]M(3_+[XT:OV=Y]SR?OC#?)Q"?0</D:^_)B'2"P_V_\_G';]>K
MSZC]VC_?D^/;(E9DL^5LW_#GA5\&$1/@^BPY^+<"?NO.'E0O5_X>Z.;]V_=!
M/Y.WQG&O8,(0>/GVRKFW^/K1ELN#D1&M6X=,1O\`^^7Y]ETW%_\`?/JBY%CX
M#D_?\>E\0!'VEJ!X=O\`KU-\O#[^`_\`9GS$WXO7UV_,/\?_`+G21X,1BGM#
MHC/>"KL,/)P?O^?=R?KCO[XB,>?2=_$_YR'T)K_G'Z&7+5R6@^&7$V_UATZ\
M5?6(A7\?S]"\`G\68R1IT[/X:9.R/Y/]#^L="2O)K?@G]_I!`0'_`'G+1<O^
MC%<V?_G(^K/9Z.C:E='.`T>@?=YJ^)1%W/1,"?\`/S\>CW`D'%6W[CX%>,D,
M=!X&_!'2=W"/=$^#K?[_`/N,B[R`K_B?WC/4//`/SSG"8=M_TF2%D]`UD#C]
M,=`+K7*&WQYS<#ZMZ9_X^--P&2F<=T^4'A4;`.+!!G(]K_EU5X,$<YM]O_SC
M%G;KX<*(FJ=`.2Z#MR:[P[&+^>MXSAMY\CL$:9^TSLP7!I5M^2_+W_7B8'/#
M;]O\_G]4!0*)\845A^0>'_`_[EB!;70X>^KR1%#+UK3E$#.6GBV9=L*:1P;%
M;$>QY'TO<"=XY5\Z?<-`(M(3VC;O`<>/N@-2CY!>WW_H_.#1O=YG_AP?SW^L
M5ZN7[#7GXPL4O_@?;D\GWS5,D](T/(<^?LC(U]4>1O\`8.@!EDEF_#:/F%\K
MHVSN'/%NSNO^D2X7+.0?X_;_`(\Y!#3IY._O_0UV_KE$=/']7W.OX\8_<6[`
MN:>%NGYPN1L:`$!\!HRT')_A84`>2%39\KV_XRZ06<O^1R^>-[_\,RG_`%W^
M7_Q**?\`7?Y?_"B\%HHU0/)\OG#6)1T:\E]DRCC;0S7D`OV'_A%GW_VS^S_S
M_P"&#\=^&_V]N#A*U>L`CA-'_P##T])^O#)[T_5S#7I?2^ERX_K9D])[7]2'
MK?6Y?2^K^H/HSU?_`$3_V@`(`0,#`3\A%(\(`C@&@'4U[70*48`;570!M7$G
M)VM#X0>SB=IW]#X=R@?\X<87V;/:*,'DI3[GH]:JT!RKFPF2&NTFY*KACV`]
M*_R`7^.<4'`,&,1N*E19J@'3[(#SYP26<PMC:$)R4-EQMO0=`0'0!ZCPUM_F
MZ+^>>,[<!)6T8>801Y"7&"J[!ZDH`W5Y34Q,&$AH&_D.YUQC]DC5&D3&!.B'
M*[6Y,/Y2*]"?RUH]6!0:$W7P=)Z;D5B*">+?,=>BK%N=+RB&T^A\IE(E\7<Y
MO-&[V$1#D2@3V@V;0OL&/C,E4]6-/@)$<X-8"#6AT@@E5M#&P'D,K>0:><4@
MZZY!@)1%>,"QV)BE;-@9*S=:M+,(QTHP12G95NA0<"$IG&]F"<W6TVJ052/F
M!4Z(!1`,/QV3&@WDZ:.<JQ6VCI2$&ZDN[K%X$<2MI#47E2YQ&#$UIL5V*/-;
M8JGL6NR4AJVQYX]D]H@4`5Y?6"@1:J#U%4<F$--H#T![YV=_"OH'S'R)1_#[
M=2MZJ;DHE:::?&.14("HPDZ;`941190%UNJ%[`5I!IO!OF:M=EI"A/)RP%4\
M5EVMH8?@D,+BDETIHJA2T\YT.?$43%=W1=-8^DY5WEV&NC7SG'I1-TH&]$!R
M8$Q)5@$P1`#V`9]_G^5&@!`>)AD82'V,C1$$WEO93D7.E$PUQ+7(H\)<?O\`
MHO0*J\E:_/K8W.NRZ(LGV.^O.B`8:)LH&KO^?/MI*[!+0'S>,5X32BV%WR.+
MJD#M(`&UW`6%X'#O@0J-B)I$V)['6(0@%4N@#:O!@>P(5!1$Y$V./4!570!V
MYQU^(TYVDUWX]GV6AAFJ&YI=7T$@B=W7!N@U9_8\$;:D-`W#17<../9J1*/#
M&L/Y"CTN45QW^`.7H"``KTYS;*M7@%1T"]\#@D%JQ/R=G"<CIC[2CI!Y2^?@
MQQYX*F8#HOW>7?M/21N5P?(@F:$"'3J@@7@US6`S;;>=!LQ.Y([L#4'A@Z_Z
MNUV[]@:UZB)LIQ?PAX8$%\+;550XHZ=#6W:+25<D^-G^G@*18U_D7C0T$#7+
M>WL),!+_``.#HHY74]:$-X=`L[%P';K-DQ:W192$_GCMZK@0*A\L6'G0OV'T
MJA=HUU>H?D304F$B-%X\OE.T[55]E;+))UFD7BI]@(,'0=U-%#=04$W?H.>%
M&5A*0JQF`K-;R&Q,"A2%#:2@<AQD(P*E4YU"O.B?7N[@6$J\K\O;ZG]G5T+R
MC;LC@UQQ+M8<O/Y]BP0B%2NAO0*O!]TMKG$LIX"D,Y*.>,T)551_AZT'`:-9
M)%6VDJ#R8K+9P:^CS'3@"-4TJTNJ&*(\C:3E=AT`X=##+`[=LEO1+N>ULX!/
M'DGP$T?!3[7"-\Y0G7P3R*+LSP%.N?AV?GV2V>B7+$?P._;9D\+:OO5FG1.;
M]70:YQ),P$K)H>TIO7.7WO(R#3KB,6J)OBJP"*C_`)D&GD]A<U=1P=H<<``_
M`!Z([&M`*JO`'.;U&,CMVMR/A:80P_:W)>,G7^&%-'L)W8DTH_A(GW-F,BN!
M7=LW=WC`.7K=R@D40#L5?P5=#CG9=7K^"_/Y886K870J^==";C;ZFA7U$1/.
MURSX&WW,Y"N?PI1KR\'>'A.C&^$1_#[5[4($VJ5*W#6)[`!4$1'D328G`NY7
M;Y4F'15?<@K8Q<I(:DW`]WGP0"7PH1^R:]-O#\:1UJ;'6GK!7[-(@K(1:3<>
ML-Y'T1R/T)WC6O7A:AG!NJ-(%$AISDVPB?EZ.`X#1K*63@M68]UWI.76\=?5
M:`/W`-K`%<A2/Z56TZT1U97GUEXV@)/R<M=>P_0R+$ZE+3L**Y&_.,]3FL?,
M5**;08W%0:TXCJN:\+Y<U,PO1<T^2@'/RR89<N7QF\WQD?:9QOW0YI++HBM@
M"`T.#%R_.YG$N7UL&BU@F31-75@Y8!>W:;<35%[(K0!(\B[K296M/MV7$4ZG
M+T/&N<0/.[5BDH;I4/0,"]O-0)8E`=.PAF^^ZH*;)AI'XW"?_C4%$MRU<5.U
M)YG*&$<63>^&\X;8_2-OR35%8WAMFT=:=D#@7H\-U_8JJ53#`G%5Y`!#"%5A
MS#QO?H8HX\>G^V69K\X^PU]':RZ&(8CV!0UWE7H$["8G(HB_!X/+TZY'-\(:
MR/CW0+[@:((_1_B]YU#KX\G/[?D<_(YWJ?.*1+R90^^H3QRP%Q4@OR:P^"OW
M\M8-6E=D(E4(0!3E38"0H<`$/E5:J%52"UF##=;>1>_T`5S?'T0>D9!_:/GS
M_P`P6US!.6'_``?AC1GPF/[-\<N\[&Z^*%Y&M3S\WT97`8ZX!\;#P!!56MW>
M'_ZCMYP<]>KQ\?OO/"#@_0F/T@@^X\F#.A5_K]]Y<LWC^T8*.4X'GK\^/E'M
MPI0@GQT/G@>-O6'(04Z=?9X^>^V+\_\`9_Y_.;ITY^7_`(?HNOJ'2V_I_?[Y
MP@_R3SCZ*FOE2G(>>/\``_\`<K4BGX37VR%#XNC_`+_C]'U]4YS]^\?IACZ^
MJ<Y^_>/THQ_OD.K]4YROH=MZ7GX\80%^5NI\,)@XM77]OCS^DO\`/U3G"Q[_
M`-WH4UMX?Y?TAX^L2ETI.W+]WMY<1AE(X^SSOLX>\!&`@&@#@#P?I#']*;R9
M/1'(Y61R?K#67%OHOHOHNO>9_C_Q/OCO_P`2YJ8D_P##/6:RLK*R.5E8+@,?
M#*PQ61EP"5R7CC)K>=_HQ_SETX\OG/\`3(_,R*?;.&*93^L_TS^F"'VR.>\7
M4P21RG'H7=_2S1B3.%]AISZ/Z9$SE,X7--XD?T]Q<1ERN5E8/HKE929;SBUO
M_H__V@`,`P$``A$#$0``$&VWNVVV\6V\^F\6VR`*61NV`U%%"2ZQ@$VX`!&V
MVWVVV''&Y,8:V:``&(V^+FQF(VPVFVV<``F2V^3&VVV>W6.VWP```&VVVVVV
MV\WJVR=@```+`VVRVV]&V6VR`````(^:VTW4ZV[FX^````!5!;FVP(VVZFP"
M+2``(`!;GFXVVV_5X3=Y"`)J``NDW`\.\R!5@HB`#0```4K.#[P``````!*`
M``!T^)N&````````(````(EA]19&%!!``!@`````'[20I(V),P`!P`````))
M(!('QH````P`````(9``4[E@```*0`````)4P`)))(```!*`````(W``````
M````8````(65P`````````.```!S_P`LVP"$240``!D``2R_\W&T4$?$0```
M>`"'VO\`%?\`^P``````!?`/[_R@1?Y>```````*@Z0>A^^TJ>P``````!*=
MY?)FS:I)````````&^1:DBD5<80```````#CZ9Q)9G'\4```````(7Q'!;.+
M8O\`@``````#_P#Z_P#_`/\`_P"OV````/_:``@!`0,!/Q!R,>O:QA>45;[7
M31>UJ2J0`"N47!@:"J@$=EHSWJ9YA<,Q.$'23(CSL""FI'A!]JA,Z0E6?8([
M>'T2RX!4F``^ZZ-Y*P8(!,FTS%&O4"HKG`K)!T(JKPX?8F9PA6(`*K#.0V/'
MN^WGM,>SP&66NP&T\+<3%">RK276KRGJ&5[M,H46?80""&;0P0N;>F]!5GA&
M6O:VH7E3"'1L0^04H*@968[/W2D\1+&<O$Q<OM<V5?6*I:R5QN2<RS8\)16;
MCHK?8'`&ADH"M&[<N0%.)8S#A0WBI!%*<M(+'FMRO#;9&C$X'[NTAVJ4#CF)
M>:!:;!3V!+1#_JL3T^A!IO*HNP6RV!CW/R6ZNP],8]N!',5K9IX;G<;4O-*B
MHUEW_"=",6.P:Y4,88*$X4":T&WMI)3)'_VTT#BH-59`C`Y069>M0RP*/O.3
M?$3#BE5)\92%449.'MRO0SZV':YC63V;-KRGD/\`A$<'BG:W0M_1P?0N?Z`K
MP`)$!*<GM".[#CT6JUF01H`V:!&5Y)/@C[-:W<@\"A5-P%?8@D(XR[@`8/!U
M9!R=+;D$830R*=/<Q*E#9:F^&J"I+ZS1R))3`#IR-R@>`M#S5#*>0J)`#HXC
M?X5_%D`&W)7J.Y^ZQ75(?PRP6`+*_+FACMS8]\:%0HD$S"H4*52/"A&T#J/\
MW.1`B7UF'9/Z:^1I36#@TE7B@?((.DE[`TK*(PV]!$M,!TR/X;%"[VI$FT'3
M$RHLJ$1(D#@Z&"F!Q!$:>QV)]*3Y)H`"N)&'HS!I8!1'$7_`1+P.55@8UBRC
M@8H6"U:?50%6!M70!VX_0R@'HZ"1;#TZ4;U!UB62!"+5B[)GCF*8#5*AH]C0
M\E`#<(;04XR)5PP*D!41&8"YZ.H,NE1I&-`!9!08UK+*,=A%4$@(GM/#Q=*X
M#8I$%F1F]U)C\BBT@/8>B"+N'!<>EF7E+V_XP&FS8X6Q_P"K=FF,EUE8TXJ\
M1,JG:BA557V"7AF";@GN%.0P7+D4Q"17&,)54XGH;<:O@,:94I+_`":ZQA)`
M`1%!ZM0#P&CA848)L0GJ3X$!&AT^GM`.<"O@_B6`-8ZB;IZ(CV($LE$YA6CP
M/H/&12V)H&6+*E6Y3>NTH[8M++;[+K4+'&4)J+A3L'5\#D?'`71]X-1^TYK.
M&>+(5H"?/,<`=4.)C&HW5YZQ`H*_6)(QPI.CG.)M>?4L_;L`&&PA:3#\)/83
M1&E5[?9VL:`!E^.H(9E**4;;M]F4)/"$MH=YC.;Z!+@C_@1TPF0AK5]![0%U
M26P$TX(-;>??-,L9L:(!*:--IR.?:F_=FOLK17#E*Q<^XB^]?8JB1=E!5A;1
MKZF-1''8@G9[&>D!206DLQX]ODJ6#&P]$;^3Z9?^VB;*'5V`F.*B=8M>A2>+
M3`$2"[5G\MFEU*WP65^!]YCN"H=HD+2`89+5`'LM(.GHT8+H$PKH?4\.5T]6
M-BE@&,_JS"C([@IL#T&/0%R415`4M!1A/55"E`E).\=()L1P95Q*EA).FV!Z
M@,_NVLU<QI<R:7?2Y("9%,PG;-OI0XU8XZ*)I^FM7!!L)BCI4T67-.]\XY=;
MJ(^)M2CGZ.O`QL&2K:,EC1WA`H*#O;#LL:TNHP&FF3:L"U!,B>W7O#LA)B+0
M&WAP(P]&8-;$"(X=?5X2*9-)K1/<=$J(PCJ:@AG1$%+"6'`AOD?3=R^S@KQJ
MP5<XA8+R""TV\G5P'J(UD8:1TC!$8I+>4D)F"#*]A\5\2RK>5BY;?33@3^G8
MH7D+.-L&2\H>1UXP52&N:<4]Q^`/SC""E50`R^U-A7@]R$FX>#]0NPL(UJOU
ML'>N&_$)5MIA<W\C[MIE%3,2>7G\+%`EX92&4$@>=N_#@$?H]"9<-?)557KZ
M5M>C5J!HD2K7Z!/I@I&D\A#?33TJV-=ZJ7^1JDY-A$#HVPIAEC4U=!UHX!4K
M1F;KOB2A9$:;KF^S3KO<T(D2F82>"7UM%\"[9'7B2BK'\A"K+93[\5Z.$KY.
M1],9W0E9K\VL7YLM2+#CE$!KZ\4'$9<&$H_J'\_B@&^Q1O@Y4^]7V+(ESH3^
M9[<>R9LL*E<7(-7AB>V6D9EK6GU.H5Q,S#,!MZ`(7H"RUZ@RV[XQB``32MW(
M<*(FV=70=E;],U5TMQ4%"H*%E9HKQ<8VN+[`CD*8^BW2B=,\@$!:0:]%+*[9
M60(AA8.;_1=S>ZS76ZX,="F`G4,4C7":(4BL!QEY'YT6K0'0$&#@>BE83]9`
MQL,JKHF?C3:*A3P)B]9>U,-7`Q.+U5F5,4:JXA#%*@!$KJS>3K<&G9G<'0S4
MN&'4.B8#@%6@CP9`N:W"7'7>>RMIH-"YGILKA/-.I6B&7<+V&8_LY*>:.JH-
M7(_=TH=[2W^@]V+-?_[18\PM7LW\\P)U2"\'MPH:CPYCE^N3;B3P'.CK;.`F
M4-"I]0@`3@H1TJK(9`3DX"`8`K5,;RN7`/@+C8.:-PE40*03"`&F3Z;06EF3
MMDUO"66J."=X#>'"CE(Q<*"/Z`ES3U71_`U"!PSML,HLW1D6X^B2[+D!JL#I
M/@\<(4$`X!-'?],>D$$WZW_,:!8PI0)<.FH#K;YW3I\S.CE6!PK;W9I+PE4#
M"J6^:+$5.H`1BZB&4;NU$3:R3Y93\6_51S8);7@[/@#6N?T,][>Y(4;8<MOT
M^I3&>^;%\$U>@N?NZ(T`F"7(!J#!+:#/8!,<Z.C6%'C4,FHRH51^>M<IX]S?
M]F,VTABE.473AZ\BVIEF?0OX:\%%PGC+0>CU/Y#]$D'M9-&RZK>!&EJ2GQ_\
M!JPJ&P")@"KP1<QTZ5A<W;I/=.TOTZ/0BOMZ&9NIV*8S?AQ>CU.!EB$)87U#
M16_0*X#VMW3J,;"(P&)^#Q#H*%H:*CW)8YVNH0ZIJ&7RRQDS)V16I;?I[0UR
M!.?<+%'4GQ$XY.,`OZ"^=WERPJ$E4NW"8!?4AM030&!3*XVJV/YKG)8C-TL/
M+^&._A)(T@12AV?T$^[=UD7S?@=UM*IT#*O<@8!F,*/F9U^WW<`;O+'O01'4
M68L&5F-BQ@JE)*;06>'\E;&21LD[;<SJRI1SP,+XQ%>`N0$O33!5Q@WF3K0=
MW9Q=N(EV@FL1#8Y-Y?&0ETR*MK*3[KJYGU`D?"7ZL9$SA@!$*`8CSAK`.-0'
MBKH#```$````&@#U3-W_`/2RY>(D4`6!ZT(Q&-1Y6EF3/KV3^J@.13L!4PP.
MAS>S2`"74%!^7_>R<W6`7A7@_P`A)KV=4U3`_IU.E'Y%L)$203"ULV'!BF,F
M]JP!38PM`VX5=&U,9`&3(#"=&S=?0*>`!I&BL.'$+.*YD3VL.L7Q/TC(0.MS
MWFDS=PV6AR>*#/N\K/?2Z&?M04&%;Q9B$6WF<)XCJ]/Y3.1%,).#4]U]M\?U
MK!NFB4EQ0<0)C*$5[N_8L:,,]6Q$CDYVU`P!]#!`PCAP:+G1XTLTU`'PJP,6
M_5WODVN3-26=Z`(`%#Q8,*SG'N`UC^5T`#J4%3>$]AAF3SO0Y$,(5<>+IL/*
M*<QH"F>,_+7VB@!+@3(\\97K1H>I2(9\8W"PSP5$T`862W<(%P(D7.$5PTRY
MV(VL(S(/Q8S.+!@'97T0O2)[J1^.SC&DML"D\15-!D1^F.`+YU"J@`%5QBG*
M@91`!+8"TS5FD<Z4$#M(GA4Y'$(@6.T-AI?#S#L?TD[V0V]Y`'53@&I^3B)9
M'TL"I#6[`3).800:BEE7=D=K&@:B#\FL35HNQF@G&)2]10!JD8"?O#ER$CA[
MQ?"DBM7/A/F<\7LP74FB,=J.J=U-WFI."-E+IHR;8('Z),>[E+2!764Y!6"R
M-6',C0&?0*GH<GI&FO(&*1,'?8@40Q-8-I;AZ]%4U6PZZ`]8<=>I@C-B0``0
M9EG5$8:3M=EQI7B:@1$U%%UWE]W$..`-83J^BX7Z%2AW>,9T`00BX0`'*]KE
MQNX#@4]C@`#Q``))BHF#T%`-4GJ@@BOD-S!E-7PF`]+)8$U?J[%J!H=()T&#
MC%:J6]>5KA0$]&FS)VZ;A4<>%9FW+$>U$5B<3U@VY3"JLX?!L6Z-C<.5?8H"
M-D.$$VP^Z\4,[EH_0M9;L&1QT$M\:QM@.!%FMGPC(>55CW-%]P"@``*$A#4#
M3OS1@FEC8NW*XEV1?S\$P0&.28!Q#)=*^![%*:]2^JZ10T"`P#"4MO1-;>JD
M%%(XII0M360MR7%VW-,CM9A4-"%`E&$$TI+DW@"K28/1NR*UX:,J```Y'Y+U
M(@1%DM-KW%Y%%50%@*B#C#5%Y&=NS.4`AZ_],YKT`99MAP&>+]#P1>>2[XE!
M./)GQ=Q%6O+RZ3P5Z/XD!'@<"-^S7OVCO>-.WGF)&2'5`@XU\1^^,(K<'Z3C
M^$02'8N[&K)RP^$([J-NSYE(!`]0>4,T-9DQ"T%0SHNJ%0:%-B!U>@2GA5J)
MYJ]R!K&LS;BL$>N4KB;#%,&]483LXIZK@*EQ/81HTUYU`I]06ZB4"IZ,!P%#
M$`X@0!3D`FSV/5S\#*;$(])G%!_NR7X!WNC]=`S-:5:=:0\(IG)+%!N[SC6;
MZ65FSGQKF(_T)E^9--I=!@_^G7I.=$92]=#=$])OVF\OA]M/`KEA01.(HB#,
M@(GIL$\U@K8EF0BN,94G[S.*L[L"N25$[5G2<O\`?+OC2967!8;`NX;R?;ZE
MR)L_P3:@+@H>31B[,G%!&E>7MF2![2G:VHG9ZG79U/MWRT`Q";RJX$X,=B<)
M.1!NZ%#B11L&OZ';MO/10EV*.@]]RX%'0^MK+,JO*.QP'I;,*`90W0^TJ#`(
M9WXP`&%NZTQJRJMF6%];)OPVS>00&SZ-H012<#9*27,BLG![Q&,^FRGJ2[-[
MQUA<]A0W.UFQHNVH3TYBI;N4"18%>?0"<301.MV?#%WSA?>!5`;`M?$&!&5M
M[XH1;K4L,)8+)Z8&8B@+88O(:O3`Z'=],>R!Y<)@`HFQPLQLA3$%33T%7^@V
M*&B$Z;3H[N(@='AK.!>6S<SD2N+U)QHK?%[A&AQ@!Q":SYH-17VJEL`B#1F0
M!@HG/>;@R!G]KED4\X!5+<L`LO>RS[0F%`+V^I/!T`2A`.*_5$.3-1AL4`G3
M8F%D%IX])D3.,R)],IE9`NP!"4S8#.PE+13\"E+TT^,J0:<0)R':J2C@+HX&
MJ2>:,2QSBHNFE^!!Q*+ROJL+%F0@KP!)L5"S$ZU'?/,[Y/`U:(<C16$"H@RA
MMT`UW4_07<'.+DR(X.9-.=Y(S_#!:(55R/<KIOH\Q01`X;IK`0M0W:/,C'(<
M/YBQU-[3IA+3B#X,118,8*=0%S7R_P"*F(+?_11K/M:AG!B!42=E-F1!\"',
M>9'0WZTDVSJ(9$#V*0.V$$G(D":_5FC>8ZG&*;O53D6>(YO$%*;MO-DN`0E6
M\9?("(H\K@V#&="S6;19#B&7J2!N<&PVOP\O01VC.6,\-"A!8@G@*E3`6MP6
MLQY?`2I[^!)5`%0=B@?]`!H*5L4^WNJGD=8^>A3Y'(<Z2`X-ISXKFD:4'$4/
MIL"&^,JB5L07E'PJ=Z&\"_@P)\E^O9CHS=>@W.7D_GZ,F''(C^/)4BJ;=\4<
MSA5,-.X`]1C3.ZYF8\U,Z"-Y#D?`E;KAE]`89(>0+6TRHBG":OX&HKH".0Y=
M1/D1[(1DU@T2KEB?A5PV%E*<-@^T@NU$,!CLXC&KOS;#L!#[75XGJO)IDE(L
M((>T,*Z1X05^NU0@!59-J@\KP8[8B!/.,4AJ&QD"M8X6(&P-`>AX>IM"*A,J
M'!G;4)#0*&N"PV5AR%0Z5I[M7D$"!N$,H7:49;CI@6AF)L:"G`>6D(-XZ/Y+
M"$!R:/X?4E3`MR7"0U\1)T%0@)`MIGF@L&)FA<UB'W'`$)G#@H%1C@X?\Z51
M9"B57S1?%%5"\HBA`I63KQ*5:EK"[5/8M&M.W;UA\=*DBD\@HW=_0?[%$O;D
M)_ZY_<OZ?4<3XY]\/3?Y$]7[[/V#]*__V@`(`0(#`3\0;)-JMJ]V[OM!&J8!
MM5Z,/D`7L_'9V<CS]`2H/@<14=/M0*&N_1T"H!M5R@<*(T>+$[+LZ^R/KT#\
MNL!6'."HQA2*=A1I3@=OLLNT5[@*SY9#K!$T0?OMY7M]=*TZ'_)@O1]E$<BK
MJZ-S5-/I+*S7)QL!M.JUYY+:BJPMAT7N><=`JB:1.\+TZ@"'RSS%7\$`/4PK
M3RGK84.=M'WT086.Q'DLUZ,4%WX'I'8>0_LTC_.TY=D]?Y-2$P5(;Z!$'S5?
MSE5Y)<`P,:$VV%.L4E"D4&J(:C7B!CO!-IMY%?('^9+.@Z8*1$Z1="*U8DD3
MQ'K\@)4*+XT,ZRPM@D(`ATV=`<WL9D2$2=.0H`9\.>.HT!1-[:0V<16!6W`S
M;):V&A`MY%9CM29F"0`&D3CQ,3"W[$@1U*;AHZQ["`EN&B:ZA$XH:P(0,\`%
MP0X5,_:O#V%2I#0J2!!^2I&Q]B4CQCA*HK\?+Y.O)OFA[T:H.S7MV&HXMRIO
MS#C>.2$`E5S27EQ8.PH9:5_)(<P0Z=[OAUC-T0P-)J!V3M^,7;N!`I6`%9M;
M>\ND`K`V`&@`@'!@E,H]#54@%$$JQWS@@(@70\6@;\O?=QY2/AT-'C47J93/
M230T$%0%12UI3O-AD5`Q$6`%3E1<55>7-?MB,J>&*/A<I3IZIY$#0G:XZ8/2
M;"#HZ/&O798FPX7KX/73O6Q4PJAPOGVR3E+>(%;^,(T)H!`%T0\&L,O86?!V
MO!^>T.\>@JB.D3D3S[#)JP`;5>`/+CT$:(Z1.1P%0VN-@OD"/\/L_M0A=`Z4
MX_ACKT'#(UR<<#L>+UY%5I&JPMAT7N>?8$!NQY/Z(Y+_`$Q')C3@/_KRP"]>
M@Q_4^.U70'EQVB1$B?OKSU[=:93[H#_.*4!I:L)5]H1B`CPB1'[F;IMUL'XT
MFO%;[WS!+=L'L+I-->=,Q*R:KRK[&>+P*1YGA\)L^2B_1>#@A#[L-O;_`!DO
M=@H)_#_^G)'>$1``'!Y^=N]_!U[!%!`_[\H:%X-'LEV%0JP+VO1Y<[]M#D^0
MW7UI?'J"U.#T&=03D'@=G]G(CO*B#5_?`<!T>P20;3[/R:IRNGX45."A!"-+
M)L2(\)'Z`-W^"=CQ4"Y?`Y/J!7LXZ!]V(1"%X\?7>06$_'CU1[3I'XG\GAN^
M:+5>+[$<#36`?+\NC$Q1%A"#1:%9X8.:R4M"Q_9B=X;-"\6<=?1K)&,8IV7Y
MX?C)03C.41.1;#;<888+40N[R=2\/N7P'7D^!TIL'KY$/:3'R$[(^9VP^<12
MN3V`C&I$CR7D^3V][W7W('V#?W7ZQT8@#>02Z3I?YP\'8)`*CK:2BV;_``/`
M;72'CJCN.ON!ZL(+_P#I=@T+P?=OH'-0`&U7@,F7W";'R7SP3\E$7#&$`,H]
M/L&-.3\YRM)_`&=`Z-6O$#T,`:<L`"JO6C_6&:<X@_U']YSQZ'EM_`EYW8R?
M7.0:1>J0?R,?9RQK&Z,_C%)%R(B?<=GM4J8&&"\"\%ZPZB-1-(G"9<%J`('%
M9YBK^"`![0@#,C<&M#YU.>Y,BE!TZ?31`4:/R#_>+TA+@11?`ZY`_0GX$Q4V
M?)OA1^%PJ%\``_K^_.40"J<`DJ\!#5=XZ9L`Y7]_QRXFPI&<7L_#KU#"]VB@
M\/#?**=/$]Y99D*Q:,XK`7F98O8Z[^@>1")'`#%\H1_D/Y6&E1K6]R2+4Y_+
M])2HG`&^3KE>5[P-`GV/]'EY?M`'^E/&TU?`;^W&4(&&K:`NQ."-0')C=0;1
MOR@;28OJ5%\B0$%ACS`&K?A?0S#,/AQD*CJ!B@%J1F+HD9B+$0+0RT&P-@WS
M9=@G/#%8(H"(R<$W$(TZ@A="O[.A=#<?(-`")X2CX6S>MZ91SXF#0PKNK5Y_
MD0H!>?G],%4P`$I!&E(K>C0LQKH6\LSL9N'-!MKD[S*J:P:<!LE)_N9`#@EI
MJ&E0<&FG\2VI\/)W3$0`3><'$\'3\98M$\KU1`8J(`82QF@3B61`-94M@A_`
M#-(AGE9&U!D))71#38""233@"8SJ(#34)4D:XH_5)1&CA1$_^\G)O!D+1Q>/
M$*#Q*(Z!@O0<PQ=1HLRP&G"\,RH#:H1U;'23,:N0Y"@$!I$W)Z53L<<&1N.B
MC",`%-`,']A']+N\R0;0Y9$'OK9,L;9AQ"\/`\[T==P*_62'#A;`T_*X/:9$
M$\J.5H=="AJ:=!@049P`>D73>7;F+8=PXBE>R/)P:9<M)QLK7(AR.W0'^KE3
M4I<6OMH4,JD@-`IQ+00:=AK"Z!]N-DY>"Y[7@B9%]8GI/;S^B'&Q(A^1#G5=
MEV=4F+5D`C9$(W;HB8<:,0:,:``&@`SY\'>=%)J;6[O!-IJ<A0%.&3DX!TF,
MYDCY-*-5MCIS0SZ'&=:PE^<V6Y_B9XP,T_SGG(?U@?Q^D:L[7!_8_'Z%_;B_
MJS/['X^V^<9W?C!W\S/%\Y]_./SC8X^?/Z=VL2O8"W2@&)5N\YA97$(:X03D
M7>(,71,4-CB[!\?3OZ?4#&K[-_QW@:=?Z^%`?#_+^E/ITRY1@=`Y<MZ>AMK5
MKEU#(;7<=(,*6,*,P(!0```0`-`&@-!E_6WVWUN7]4N!<?9+Z$S7J?IU]+[1
MGO']*^D]1/2L7@*S+R3GU#'6#^C6>H^M'`'M0><^&*/8?HGGVE;ZR,4Q\,5P
M\LICB,5)WGW]3]"L]P,/&1C]\Y8ULR/]Y_MD_G$7[Y'CIP(K@O'Z1YR>RC\9
M=SU7+>/1_;*TSA<NYENL1/G!]#]`Y?4S;`<F0R&0Q-ZR9#(R-R3C!'U./T#Q
M[>WUQQ]+_]H`"`$#`P$_$#8$<FDH40"#CVA6`D?4P`*``*H&,D!(+4%F`2CP
M0CWJS.44NRB'9Q@$4H@AY$H_CVEE&BA:V#3DY.ST.^!(C4-`'Y715#)LK7LN
M,Q;F(4]="I8%=":VU!LW)LQZ@!56`&U5T`<N0JV378CRL,#KV:,VQ2-XAY;P
MB<'<R``P`&CA=&-!ZBG#L5/`02B!`J$4QI49"!&TAD4#Z01,F"`3!"4+V6<*
M`UD$!!0$@J!A9<!QQ(BI-(C^.2.*YP>`O<)YLOK'%@A%`U.BY<RQ8L6N]0@D
M"D[T.`",_.EL#<5(+I"V,U%33LRT<\Y;6XUHIJD:`0>ABNL%%>,?!!C972-@
M[4?C3((0C;,;*[R0D:Z"HJ8,R)=4YI#=`5P/N&!9&$:L:O5!^NOR84%>;L'5
M^^DP%MH!(8AQB,>W!WIW`;NUK\P'+'82C#PXQ5OL.X'!(J(/UBF:Y0`U9!),
M:P=8#CG2+/:%BKZXQ^-9IV"I]K^>OT!+40@$1#>P,K&$?";''9#A1#9B$B"S
MGT.B'&-,B4$8@E.0?;_B=G)Y`U;M0FAP:]*<J1,\%Q>RQVB9".)6#".:&)=7
M6U)[IB3AN^YJK!C&,*)2`,R2H659HMH6:QH>6H1<Z67);X1S%GR`8(!0-"`3
M#$A8CEB43HHBJO-'A8?]IT@+@)2P;0(MYX6B`8$@(#@"`?8)@IR3P`3;A$H0
M$`CB<!&>Q&7$0<+C6C`BA1`BAJH`UZGI\`@>U2;4PH!<VR-J;@4'8!H*B5?8
M6(5I"+)$3"&UP/,M:QO;0V00``#<]:"PGGF(0N5!AJF$1>4@@B(C/8'-/C`K
M`90`%4#`!%<(EQ$`"B(F()(@`*HP`!56!MQX=H_2@+!:%JT@^J@5T&;<+:T;
M;ELB@@IZ#N5-'0*0,)"+;BT>HG$&XC-4J-'L'_D:DR`8AH-A!R=[1.E7D`G6
M8`])'.`II%4]H`,4$"3?CPQ-(*H),$/8V(N$$*CH*H+H=NL.GI5`2@-`6\@I
M7V(2<^&5>EAT@YL:8CH%!!L][6ABF_WQ$H^@I)TA$L=F0F`Y7RA0HI7U+[':
M=\MI#A3D\NUF4#LT1N,8:ID*+@UP=@"(,:8Y(IE8R$:71L0`#`L/4&ADZ9%[
M1!@FU/8%:!1JHVY(]H#;@3"0^&..E8ZB;IZ26D5!!(/+0%:.!?0MK;4X2*HE
M+%EL>C<5`VH[:;2R5?82]199H6("@V&/H.[;:(H:"6HCZ`"S1)$+ANP`#&<J
MKV0X16`2<,EL(`!"P!!0`W`-?7*($$4K$%3:;7E]6<-(AL&`T$+?89\!&*50
ME7:\KV^QX562D-P:S`;8,$9DQEK3A=K=`.%[*H"B;8`2"(@:8%,>R$TUIU@Z
M(/HPK3*>C<(")#$0C<:5PL2(^#`Z7*4/<KK;=&<=I[@[-3$G5.<LL17W;6D8
MD6\DH)LH`@,6=2T%04H"1V`3A!]CK5'8`F2`BS'9I]IQD'")?+IO73IE?4*W
MH_.:\1]@I,LP`F#-22=@+Q8$$B0SI<#G#@I$LEB![)B[?2@;#T282GJD-?,F
MA>`!4L`Q[^J+P&;E"EH_2M7K[%A0VA!2T1-'JJX<F"2-:/"";$0<MZ$E(&'P
M8-A>ML/84CRB)/L`4,&U%(9^G\\(!'M!@D=`-BV*DK"8;](%8<XT\F5]#M4+
M9#DD=;1F(L'9O*X[Y(?P%%,VNE&@E(=$J%$Y/;M\A=H>)BT!5T,`$5QB'$04
M"(HYR\E'U9@G4U]PPTBM]D:`DL(;U\!<?1&\H4?(^@H?"HC*"C414>L'.MP1
M&`T38"(P5O1FY#IRI7Q?6D0K[Z#PQ!X7U'*V(4EI*SL$H"+4$L3M`JH&E!``
M#.-*)R<2/5Y%`.._@IY2O*K`%0P&&'6T\PPMA\(KT!(C;Y:!ER"16'T`[H4`
M--,W"BT*#],<&U$P!LQ@&-`T%D*P>4I&+`P4B$(E:'14((00P6F)!F7;W<XR
M=3&V\O\`OYRUQW_>-&F:+.,2<^SGW^,7[G].,NN/;?5L'2,8H5Q($RUQE`JE
M!"*W4,33;'E%D]``BE)`)7W:-'@<+`X4P6\=PGY>2`*`>@D2+&CS\8D)\0MV
MPG8R?H1^24P(=2SRSI7H!X1YT\3=$%8@\^O#^2T*-#PMJ?0%,4[*/ET!)UH5
M>V)K%<=/.*.4G<`?R$<(PURZEFTM')<0:,%6&A,94*H%*"%5Y7TX)\9]HR(+
MK7^.LT(X"[^6`KOCK+LW;_&<S['LZ'LN*+KCZ`7B"*`5JB0(($%P!@!:6IYW
MJG3L36Y"!U".^4A0W(;.)%B;G5)0K"T5-.&+/\6*O*7?1\:,3FT]<>FVQR\`
MY8AMQ5,82\M`AHLW(O<7%%YMJ,JS$!`&4;L8)[4;UCA?8GC<0!VUSP&@.[NB
MMQ<;HS2?H-!BDJSZ*0JQ$\F.B%3X'0>+RNG7(XO;"UGJT2M()*6\BZB]`!6L
M@`#1(T)6IC>$"02EJ>BD!)P'LLB*]`[%F13>\+Q)T9R^'AUHJ(`_@!N/@[G/
MD2-]C3XCR_+R_@X#]#/<OSG*#0^EN)>OY@^_8]/Q:C0_]`O`\/@7J8BOCR-V
M[P]GC[R4]Q`7"0B=.?R%<"&">N6QTX]@-^KT'H4!8#D!+P=@$&A=H?GE_+_M
MV$J;7N='7W/Y=]#Z4/6CZ7Z9H64V;^HBB>C_`'?9X?&GY`,2'00Z1[0FSX\8
MIY`-42/:JJ^<WCTGBNWY_P`/G#WR$5@"/`.CYFW(C!+P^+PN";%=,Q5:\^CS
MG>\;,8R8/\YY]/\`F>,W?SG^;[D[10\?[_/U>/[YH!QF?MWEG]E_@]]#`#ZB
MPQT];^KQ_<]!G[=Y9_9?X/8\S.I\X^A\>,^V')AX^@2^&,*(^KQ_<P3>J"1Y
M)5^<WQ@0A6-)Z':YX?OFZ(&D;2%3\E]_ISZ(9QPF(FGZG']S->LW)LE*?$WX
MP->LY0A'_,A_)O\`2/6F_P!_QBK^WZ=,L^^:-#%$B4X`H(`HK6\X#Z+98("#
M9H(88#\```@$```"!HRN#?T5CY)@IJ:\<?S]&^VWUN4]14RNN/XQ1SBCC;?6
M/\'I*.?<:<H_/]!^,2/Q[UN!<?8%]"9KTN#BJYPCO+,JWYS?DIAL7K/MU,\I
MO7]9R'GWK>^/G&.T@_E_^>Y;Z7VC,=^X;^@M=L'23KYQ)I]7TE]1/2Y?2^P+
MCK!_0$M?W^^\TKGJ_P#,HF+/49C]&^T_0('?&*K7G'G"PG*S-'6;$\8F*]9N
MGQ<J7XN"%,%;LF(72`=Z_9D0.3\_O^<V3SE;LU@Q=9]IRA:6:SN_DP-=A#$!
MAQ?T*ST$`\5B4/+<!TO#^L0J[W&=N^#`$WJ,#!40\&"MV3`K*V-X$3GID7=8
M3KO*1NC#2K!,!/8O]YR'+<"$4+>LB)NT<HAPOZ%YP/4H#E7^LU/G&-GC^_GT
M+*O5SE+I+QCLK0S.N]R_C/*\+@"KK6_OANK=\8<AZQC\/C+(<8)Z'Z!RSU)`
M['-M`N(.-Z_=QHDW;G^*9HFI)G)8W%Y\$_&$+KJ'C%J/#/ZS==<W.(G7]_?'
3Q/\`>4/+U./T#Q[7ZAZG'TO_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>g838054g05q41.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g838054g05q41.jpg
M_]C_X``02D9)1@`!`0$`@@"#``#_X@Q824-#7U!23T9)3$4``0$```Q(3&EN
M;P(0``!M;G1R4D="(%A96B`'S@`"``D`!@`Q``!A8W-P35-&5`````!)14,@
M<U)'0@``````````````````]M8``0````#3+4A0("``````````````````
M`````````````````````````````````````````````!%C<')T```!4```
M`#-D97-C```!A````&QW='!T```!\````!1B:W!T```"!````!1R6%E:```"
M&````!1G6%E:```"+````!1B6%E:```"0````!1D;6YD```"5````'!D;61D
M```"Q````(AV=65D```#3````(9V:65W```#U````"1L=6UI```#^````!1M
M96%S```$#````"1T96-H```$,`````QR5%)#```$/```"`QG5%)#```$/```
M"`QB5%)#```$/```"`QT97AT`````$-O<'ER:6=H="`H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0``9&5S8P`````````2<U)'0B!)14,V,3DV
M-BTR+C$``````````````!)S4D="($E%0S8Q.38V+3(N,0``````````````
M````````````````````````````````````````````````````6%E:(```
M`````/-1``$````!%LQ865H@`````````````````````%A96B````````!O
MH@``./4```.06%E:(````````&*9``"WA0``&-I865H@````````)*````^$
M``"VSV1E<V,`````````%DE%0R!H='1P.B\O=W=W+FEE8RYC:```````````
M````%DE%0R!H='1P.B\O=W=W+FEE8RYC:```````````````````````````
M``````````````````````````````````!D97-C`````````"Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92`M('-21T(`````````
M`````"Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92`M
M('-21T(`````````````````````````````9&5S8P`````````L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0``````````
M````+%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$``````````````````````````````````'9I97<``````!.D_@`47RX`
M$,\4``/MS``$$PL``UR>`````5A96B```````$P)5@!0````5Q_G;65A<P``
M```````!`````````````````````````H\````"<VEG(`````!#4E0@8W5R
M=@````````0`````!0`*``\`%``9`!X`(P`H`"T`,@`W`#L`0`!%`$H`3P!4
M`%D`7@!C`&@`;0!R`'<`?`"!`(8`BP"0`)4`F@"?`*0`J0"N`+(`MP"\`,$`
MQ@#+`-``U0#;`.``Y0#K`/``]@#[`0$!!P$-`1,!&0$?`24!*P$R`3@!/@%%
M`4P!4@%9`6`!9P%N`74!?`&#`8L!D@&:`:$!J0&Q`;D!P0')`=$!V0'A`>D!
M\@'Z`@,"#`(4`AT")@(O`C@"00)+`E0"70)G`G$">@*$`HX"F`*B`JP"M@+!
M`LL"U0+@`NL"]0,``PL#%@,A`RT#.`-#`T\#6@-F`W(#?@.*`Y8#H@.N`[H#
MQP/3`^`#[`/Y!`8$$P0@!"T$.P1(!%4$8P1Q!'X$C`2:!*@$M@3$!-,$X03P
M!/X%#04<!2L%.@5)!5@%9P5W!88%E@6F!;4%Q075!>4%]@8&!A8&)P8W!D@&
M609J!GL&C`:=!J\&P`;1!N,&]0<'!QD'*P<]!T\'80=T!X8'F0>L![\'T@?E
M!_@("P@?"#((1@A:"&X(@@B6"*H(O@C2".<(^PD0"24).@E/"60)>0F/":0)
MN@G/">4)^PH1"B<*/0I4"FH*@0J8"JX*Q0K<"O,+"PLB"SD+40MI"X`+F`NP
M"\@+X0OY#!(,*@Q##%P,=0R.#*<,P`S9#/,-#0TF#4`-6@UT#8X-J0W##=X-
M^`X3#BX.20YD#G\.FPZV#M(.[@\)#R4/00]>#WH/E@^S#\\/[!`)$"800Q!A
M$'X0FQ"Y$-<0]1$3$3$13Q%M$8P1JA')$>@2!Q(F$D429!*$$J,2PQ+C$P,3
M(Q-#$V,3@Q.D$\43Y10&%"<4211J%(L4K13.%/`5$A4T%585>!6;%;T5X!8#
M%B86219L%H\6LA;6%OH7'1=!%V47B1>N%](7]Q@;&$`891B*&*\8U1CZ&2`9
M11EK&9$9MQG=&@0:*AI1&G<:GAK%&NP;%!L[&V,;BANR&]H<`APJ'%(<>QRC
M',P<]1T>'4<=<!V9'<,=[!X6'D`>:AZ4'KX>Z1\3'SX?:1^4'[\?ZB`5($$@
M;""8(,0@\"$<(4@A=2&A(<XA^R(G(E4B@B*O(MTC"B,X(V8CE"/"(_`D'R1-
M)'PDJR3:)0DE."5H)9<EQR7W)B<F5R:')K<FZ"<8)TDG>B>K)]PH#2@_*'$H
MHBC4*08I."EK*9TIT"H"*C4J:"J;*L\K`BLV*VDKG2O1+`4L.2QN+*(LURT,
M+4$M=BVK+>$N%BY,+H(NMR[N+R0O6B^1+\<O_C`U,&PPI##;,1(Q2C&",;HQ
M\C(J,F,RFS+4,PTS1C-_,[@S\30K-&4TGC38-1,U336'-<(U_38W-G(VKC;I
M-R0W8#><-]<X%#A0.(PXR#D%.4(Y?SF\.?DZ-CIT.K(Z[SLM.VL[JCOH/"<\
M93RD/.,](CUA/:$]X#X@/F`^H#[@/R$_83^B/^)`(T!D0*9`YT$I06I!K$'N
M0C!"<D*U0O=#.D-]0\!$`T1'1(I$SD42155%FD7>1B)&9T:K1O!'-4=[1\!(
M!4A+2)%(UTD=26-)J4GP2C=*?4K$2PQ+4TN:2^),*DQR3+I-`DU*39--W$XE
M3FY.MT\`3TE/DT_=4"=0<5"[40914%&;4>92,5)\4L=3$U-?4ZI3]E1"5(]4
MVU4H5755PE8/5EQ6J5;W5T17DE?@6"]8?5C+61I9:5FX6@=:5EJF6O5;15N5
M6^5<-5R&7-9=)UUX7<E>&EYL7KU?#U]A7[-@!6!78*I@_&%/8:)A]6))8IQB
M\&-#8Y=CZV1`9)1DZ64]99)EYV8]9I)FZ&<]9Y-GZ6@_:)9H[&E#:9II\6I(
M:I]J]VM/:Z=K_VQ7;*]M"&U@;;EN$FYK;L1O'F]X;]%P*W"&<.!Q.G&5<?!R
M2W*F<P%S77.X=!1T<'3,=2AUA77A=CYVFW;X=U9WLW@1>&YXS'DJ>8EYYWI&
M>J5[!'MC>\)\(7R!?.%]07VA?@%^8G["?R-_A'_E@$>`J($*@6N!S8(P@I*"
M](-7@[J$'82`A..%1X6KA@Z&<H;7ASN'GX@$B&F(SHDSB9F)_HIDBLJ+,(N6
MB_R,8XS*C3&-F(W_CF:.SH\VCYZ0!I!ND-:1/Y&HDA&2>I+CDTV3MI0@E(J4
M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY`
MGJZ?'9^+G_J@::#8H4>AMJ(FHI:C!J-VH^:D5J3'I3BEJ:8:IHNF_:=NI^"H
M4JC$J3>IJ:H<JH^K`JMUJ^FL7*S0K42MN*XMKJ&O%J^+L`"P=;#JL6"QUK)+
MLL*S.+.NM"6TG+43M8JV`;9YMO"W:+?@N%FXT;E*N<*Z.[JUNRZ[I[PAO)N]
M%;V/O@J^A+[_OWJ_]<!PP.S!9\'CPE_"V\-8P]3$4<3.Q4O%R,9&QL/'0<>_
MR#W(O,DZR;G*.,JWRS;+MLPUS+7--<VUSC;.ML\WS[C0.="ZT3S1OM(_TL'3
M1-/&U$G4R]5.U='65=;8UUS7X-ADV.C9;-GQVG;:^]N`W`7<BMT0W9;>'-ZB
MWRG?K^`VX+WA1.',XE/BV^-CX^OD<^3\Y83F#>:6YQ_GJ>@RZ+SI1NG0ZEOJ
MY>MPZ_OLANT1[9SN*.ZT[T#OS/!8\.7Q<O'_\HSS&?.G]#3TPO50]=[V;?;[
M]XKX&?BH^3CYQ_I7^N?[=_P'_)C]*?VZ_DO^W/]M____VP!#``@%!@<&!0@'
M!@<)"`@)#!,,#`L+#!@1$@X3'!@='1L8&QH?(RPE'R$J(1H;)C0G*BXO,3(Q
M'B4V.C8P.BPP,3#_VP!#`0@)"0P*#!<,#!<P(!L@,#`P,#`P,#`P,#`P,#`P
M,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,##_P``1"`)9`E,#
M`2(``A$!`Q$!_\0`'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`
MM1```@$#`P($`P4%!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*Q
MP152T?`D,V)R@@D*%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA9
M6F-D969G:&EJ<W1U=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*S
MM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ
M_\0`'P$``P$!`0$!`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#
M!`<%!`0``0)W``$"`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1
M"A8D-.$E\1<8&1HF)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI
M:G-T=79W>'EZ@H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZ
MPL/$Q<;'R,G*TM/4U=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1
M`Q$`/P#W^BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB
M@`HI"<#-<)XD^)]CI.JG3[.V-_(AVNRR!5#?W<GJ:B4XPW.BAAJN(;5-7M_6
MYWE%>:?\+8D_Z`;_`/@2E'_"V)/^@&__`($)4>VA_29T_P!FXCR_\"C_`)GI
M=%>:?\+8D_Z`;_\`@0E'_"V)/^@&_P#X$)1[:'])A_9N(\O_``*/^9Z717F%
MQ\7Q;PF6;165`0,_:%/).!T]S1;_`!>%S"LT&C,\;=#]H7FCVT/Z3#^S,1Y?
M^!1_S/3Z*\T_X6Q)_P!`-O\`P)2C_A;$G_0#;_P)2CVT/Z3#^S<1Y?\`@4?\
MSTNBO-/^%L2?]`-O_`E*/^%L2?\`0#;_`,"4H]M#^DP_LW$>7_@4?\STNBO-
M/^%L2?\`0#;_`,"4H_X6P_\`T`V_\"4H]M#^DP_LW$>7_@4?\STNBO++CXRQ
M6UQ#!/I)26<XC4W"Y8U8_P"%L2?]`-O_``)2CVT/Z3#^S<1Y?^!1_P`STNBO
M-/\`A;$G_0#;_P`"4H_X6Q)_T`V_\"4H]M#^DP_LW$>7_@4?\STNBO-/^%L2
M?]`-O_`E*/\`A;$G_0#;_P`"4H]M#^DP_LW$>7_@4?\`,]+HKS3_`(6Q)_T`
MV_\``E*@O?C)%80^=>:28H\A=QN%ZT>VA_28?V;B/+_P*/\`F>I45YH/BPY`
M/]AMS_T\I1_PMB3_`*`;?^!*4>VA_28?V;B/+_P*/^9Z717FG_"V)/\`H!M_
MX$I1_P`+8D_Z`;?^!*4>VA_28?V;B/+_`,"C_F>ET5YI_P`+8D_Z`;?^!*5'
M<_%\6T#S3Z,4C099C<)Q1[:'])A_9N(\O_`H_P"9Z?17F%O\7A<PI-#HS/&X
MRK"X3D4R[^,D5F8Q<Z08S*VU,W"\GTH]M#^DP_LS$>7_`(%'_,]2HKS3_A;$
MG_0#?_P(2C_A:\G_`$`V_P#`E*/;0_I,/[-Q'E_X%'_,]+HK@-#^*-G?:I'9
MZA9M8+*=J2M(&7=Z$CIUKO0X(R.<U<9QGL<U?#5<.TJBM?;JOO0ZB@'-%6<X
M4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1
M110`4444`%%%%`!1110`4444`%%%%`!1110`444&@`I#QDYH)`ZUY?\`$GQX
MRF;1]!EP_P!RXN5/W#TV+CJQZ<5$YJ*.G"X6>)GRQT2U;Z)=V'Q'\>D&71]$
MF(8?)<7*\[,\;5QU8].*YGP;\/QXM4G5(BNDJ2&.>7;NJG^]G[SCI]U>Y./;
M:?/#81:E<:?.]CYZH95<*C#HZ;_[[=/,^Z#E01DM7O7AB_TR_P!$MY=%"):*
MNQ8E7:8B.J%>Q'0BE"+OS2W.C$XF/)]7P^D%]\GW?Z(X?_A0O@3_`)\KO_P+
M>C_A0O@3_GRN_P#P+>O3,BJ.H:S8:<1]LE9,H7XB9\*.YV@X]L]>U:'G'`_\
M*%\"?\^5W_X%O1_PH7P)_P`^5W_X%O7;6_B;2KAF6.>4;$#L9+>1``1D<LHY
MQVZU/:ZU97=Z+.%IO/\`+$Q1[>1,+[EE`!]CS[4`>3>-OA)X3\,Z`=8TFUN(
M[NVNK7RV>X9@-UQ&IX/LQKM?A%;0/\.])9X8V8B7)*@G_6O4OQ=_Y$.Z_P"O
MJR_]*XJ/@]_R3C2?I+_Z->@#J?LEM_S[Q?\`?`H^R6W_`#[Q?]\"IJ*`(?LE
MM_S[Q?\`?`H^R6W_`#[Q?]\"IJ*`(?LEM_S[Q?\`?`H^R6W_`#[Q?]\"I<BE
MH`\=^+L$2?%3X=*D2*K7;A@%&#\\=>N?9+;_`)]XO^^!7D_Q@_Y*M\./^OQ_
M_0XJ]>H`A^R6W_/O%_WP*/LEM_S[Q?\`?`J:B@"'[);?\^\7_?`H^R6W_/O%
M_P!\"IJ*`(?LEM_S[Q?]\"O)_P!I^"&+X<P-'$B'^T8AE5`_@DKUZO)?VH_^
M2<0#_J(Q?^@24`>H6UI;?9X_]'B^Z/X!Z5)]DMO^?>+_`+X%+:D&WCQ_='\J
MEH`A^R6W_/O%_P!\"C[);?\`/O%_WP*FHH`A^R6W_/O%_P!\"N/^,MM`GPO\
M0,D$:L+;@A0"/F%=M7'?&?\`Y);XA_Z]?_9A0`GPCMH'^&GAYG@C9C9H22H)
M-6_&/@/0?%\5O#K-JS);L73R7,?)&.2.M1?"#_DF/AW_`*\DKK*`/G7XK?#K
MP[X+N_#-QH5O-%)<ZFD<GF3%P5!![U]!_9+;'%O%_P!\"O*/VB^OA#_L++_2
MO70PH`YKQ;X3M-<L9$$*I+C(V@+N/;Z$=C_2N8\(>*+KP_?)X>\3.WE$[+6Z
M?\MK>A[?_6P:]-ZBN:\8^%;;Q!8NK1KY^.#T)].>Q]#_`$K.<;OFCN>AAL3%
M1]A7U@_O3[K]>YTB'(SVI:\Q\'>*;OP_>)X?\3LPC)VVMV__`*`WI_GMBO2U
M.0"#D'H:<)\R,<5AI8>26\7LULU_7W#Z***LY0HHHH`****`"BBB@`HHHH`*
M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HH
MHH`****`"D)P,T'`YS7E_P`1_'AS+H^AS88?+<72\[,\;%QU8]./I43FHHZ<
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MZ/<,%=&;CV1R>C#HKG_=;L:])T+5K/6].COM/DWQ/P5(PR,.JL.Q!X(H`>^D
MV#JX:UCQ)C=@8S@;1T]J99Z+96EX+N$3F?RQ%ODN)),K[AF()]SS[UH49H`Y
M#XN_\B'=?]?5E_Z5Q4?![_DG&D_27_T:]1?%JY@D\%7,$<T;2FZL\(K`GBYB
M)X^@)^@-2_!__DG.D_27_P!&O2N!U^:*SM834'2(:9((VWC>Q`.%SSUJ&<:N
MUK;>4R),0PF'&`<9!''J,?C3`UZ;("4('7%<C>?VP-86TM/$4:S[_.:UF,)<
MQ87@*`&`SOY]AS5NQGU.[T**2"Z>YD\_#O!)`SE!PPW8V?>_'''6@#SWX+?#
MWQ;X5\47.H>(YT>V:T:%$%R926+J<XZ#`4_G7LXZ5@WEEK,A+PZA.A623;&B
MQ8*;3LR64G.['<5HZ.+M;"(7Y<S<YWE2V,\;MH"YQZ<4`>7?&#_DJWPX_P"O
MQ_\`T.*O7J\A^,'_`"5;X<?]?C_^AQ5Z?K*WAM/]`,HDW+GRB@<KGG:7^7/U
MH`OT5S1M_$DEW<%+QX8LL4W+&V>NT+@9'&.N><]L59UE=9EFTUM,>2&,2_Z2
MH6,Y7CKN/3K]WF@#<HKE[8>)]@BD63)E!\V1HB0@/S`[1WYQ@<`<\];ME;ZW
M#H4\%U>FXU%HV,=QY:*$8CY1@<'!]J`-NO"?VK+#49=/TB_CD(TV&1HI4\SC
MS6Y4[>_"MS7JFD6OB*V9#J5^+L*^"HB12R[>N1COVKAOVHN/AO;_`/81B_\`
M0)*`/1O"=M-9>&=*M;K_`%\%G#'*<Y^94`//?D&M6H[;_CWC_P!P?RJKJ$%W
M)=VLMM<S1Q1$F6*/9B48X!W*3U]"*`+U%9FG&_%S=?:TG*M)F,L8]BKV"@?-
M]<YYZ<5D:C)XKEM`FGVPADCBD1WDECW2.5PC(,$<'G#%:`.JKCOC/_R2WQ#_
M`->O_LPKH=#^WKIENFJ!FNE0>8YVC<?HIP#]./K7/?&?_DEOB#_KU_\`9A0!
M)\(?^28^'?\`KR2NMKAOAM)=1?"CPV]C"]Q*MM$3&A4%ESR,L0.GO5YQXM;5
M8'952S\]G9(WC<F/`PC9`(/!^[NY/7T`.#_:?CGFT[PW%:,4N'U`K$P;;ARH
MP<]N<58^"7@;Q9X5UO4+KQ-(KQ7%N(X\7/F_-N!/'TH_:*_YD_(Q_P`39./R
MKUZ@`'2@J#2Y%&1ZT`<WXR\+6NOV;J8QYV,@]-V.G/8CL?Z5RW@[Q1=>'[Y/
M#_B:0F+.RUO'X_X`WH?\],&O3#S7F/QOT'5+ZPM]0TN/S;>T;?=P1+^\=1_$
M#SG`R,=><]L5E.#?O1W._"XF,8NA75Z;^]/NOU74]-#Y''.:<#FO)/AIX^$2
MP:;JUSYUG+\MI>-QC_8?T(_SQ@UZTIR,YS50FI>IEB<++#R2;O%ZIK9H6BBB
MK.4****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB
M@`HHHH`****`"BBB@`HHHH`#2$X'-!.`37E_Q)\>$&71]$FPZ_+<7*C.S/&Q
M<=6/3BHG-11TX;"SQ,^6.B6K;V2[L3XD>/=LDNC:'/M?[MQ<KSM&<;%QR6).
M./6L'X?^"9-?G%S=AHM.B8AB&^:0]"JD=2>C..GW5[FE^'_@J77IUN+M6ATV
M)B&(;F1NZJ1U/9G'3[J]R?:K:WAM8(X+:-8HHU"HBC`4#H`*4(._-+<Z,3BH
M<GU?#Z07WR?=_HN@6MO%:V\=O;QK%%$H5$48"@=`!6?XCT&S\0:<UI?*>NZ*
M5.'B<=&4^O\`/H:U:*T/./)-"UF_^'6KG1=>!?27):.51\L2YYD3_8Y^9/X.
MH^4\>FW5]&MM$\#"0W'$!7YE8XR#D=N,YJ'Q'H5EK^FM:7JD8.Z*5>'B?LRG
ML17FVD7L_@J^?P[XGC$FDR$O#(`=D8[NGHG/S+_`3D?*>`#T.S>;4K9K35+)
M9;>961V=<!Q@<%>>#D\Y[>]>?ZC8ZE\-M:_M'3"UQH]PP1T<]1V1R>C#HCGK
M]UNQ'JMOY9A0P[3&5&W;TQVQ4&KK`=+NA=6QNH?*<O`%W&08Y4#N3TH`CT/6
M++6].CO=/D+Q/D$$89&'56'9AW%.FS<W1M\D0HH:3:<%B>BY_4_A7BOASPIX
MGU])+SPOK5QX<LF8_,2S&7IM3'!;8."YZ].0N:]*^'GAS7_#\5ZOB/Q"VN/.
MR-&[(5,>`<]2<YX_*EN-:&9\46\O1A;C"QBY@9%`QCDYQZUI?!__`))SI/TE
M_P#1KTSXM:=J%_X44Z1%)/<6]W!,T$2!GF0.`RKGO@D_A3_AHLVC^"=,L=5@
MEL[F,/O25<;2TC$#/3H1WK.,>63?<TE+FBDEL=?12`YZ4M:F16EM%DN/.WLK
M;=AQCE<Y(Z4W3;(V,"P_:9IT0;5\P+P.P^51T''X>O-6\44`%%%!H`\A^,'_
M`"5;X<?]?C_^AQ5Z]7D/Q?Y^*GPZ/I>/_P"AQ5ZZ.E`"T444`%%%%`!7FW[0
MF@ZIXC\#PV.B64M[<K?1R&./&0H1P3S]17I-&*`([?B&-2""%`(/TJ2D`Q2T
M`%%%%`!4=Q#%<0M#<1)+$XPR.H96'N#4E%`$=O!';Q+%!&D<:#"HBA0H]@*D
MHHH`\A_:+Z^$/^PLO]*]=KR+]HOKX0_["R_TKUX4`<[=Z+JEUJ3R'4&AM?-$
M@"7$N6`'"[00%_`D'J1Q3(=#U2W@2,7K70WJ[A[N9"3EB<-\QQRO'0XQP*Z6
MBD!D>%['4+"PDBU6599FE9PRSR2C:>G+\CZ#BM5V4*Q8@`#DFAV"*68@*!DD
M]J\MU[6+_P")&KR^'?#$K0:)`<:AJ('^L]8T]1_/Z=6!S,NA6WBKQW?IX*@`
MT=1F^D<X@>4=XO0^G;KVZ]7X/\4W/A^_3P[XED)C)VVMVXQ_P%O0_P">F#7>
MZ!HEAH.EPZ=I<`@MXAP!U)[DGN3ZUF^,O"UKX@LW1HQYV.#TW8]^Q'8_ATK.
M4&WS1W/0PN*C&/L*ZO3?WI]U_6IT2D'&#P:=7F7@[Q1=:!?)X?\`$KDQ$[+6
M[<8_X`WH?\^AKTL-D?6G"?-ZF.)PTL/)7=T]4^C7]?<.HH'-%6<H4444`%%%
M%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`444&
M@`I"0.2:"<#)KR_XD>/"&ET?0Y<,/DN;E<G9GC8N.K'IQ43FHHZ<+AIXF?*M
M$M6WLEW8GQ)\>,/.T?0Y?G'RW%PO.W/&Q<=6.>U87@#P5-K\RW-TK0Z="Q!8
M'F0]"JGUZAG'3[J]R3X?^"9-?G%S=AH=.B8@L#S(>ZJ>YZAG'3[J]R?:K6WB
MM+>.WMXUBBC4*B(,!0.@`J80=^:6YT8G$Q4?J^'T@OOD^[_1=!;:"*UMXX+>
M-(HHE"HB#`4#H`*DHH-:GG!56[U"ULY8H[F98VE.%ST/X]NH_.B[O8()$B:6
M-)I0?+5CC<:R5T9;_57O;Q)XU&,0M)\I<`@D<],?3/.:`-]65U#*<@]#69XD
MT*S\0Z<;.]4C!WQRH</$XZ,I[$5IJ,<#I2T`>4Z%K.H^`=3_`+#UZ*6?3^6@
M>WC+D#^]&HY*^J=5)R/EZ>D:=JUCJ5G!=V=S'+#<*'C8'&1_DU#XBT*TU[3S
M:W@92#OBFC.'A<='4]B*\DM9M0^'VM-8:I'YFGM\X*#A5S_K(_0#^)>J]?N]
M)DVMBX)2=F>Q1`1:A+&OW9%$F/0YP?SXJ[69H[_:XEO59GBDC41,W5EZ[C]<
M_I6F>!36PI;B&D?9MP^W!XY[UR7Q(\4'0]*-OIMS%'JT^TQ%TWB&/<-\K#L`
MN<9ZM@8/2O+[CQA\4KAU;_A%+Z9%.486Q`;T;&VE)M;*XX13>KL>XV^+6Y$*
MG,$H)3G[C#J/IW_`U>R*\&L?&OQ/MYH&G\$7T\$))\KR2F>#W"Y[U[5H%Y<:
MAHEE>7EM]EN+B%))(,Y\MB,E<^QXI1;ZH))7T=R_D49KFO'OB1_"^B?;H8%G
ME:58T1C@<Y.3^`-<P_C;Q?&L;2Z1I,/FH)$$M]&A93T.&<&HE6C&7+U.NC@:
MM:G[5-);:M+\STRBO,/^$\\4_P#0.T3_`,&4/_QRC_A._%7_`$#M$_\`!E#_
M`/'*7MEV?W&G]FS_`.?D/_`X_P"9Z=D4M>:6_C3Q?<S+#;:1I,\K9VI'J$3,
MV.>`)/2JD/Q,\3.)%C\*K<&&1HI&25\!U.&7A2."/6CV\5O=?)E+*J\E>#C+
MTE%_J>K45Y;_`,+)\5?]":W_`']D_P#B*M:?\2=:9I!J'A&[7&-OD,S>N<Y4
M>U'MX=Q?V3B_Y?QC_F>D$XHKS36?B?=V=F\R^&KN$KSON3M0#U)Q6-+\7]3A
M<I-#HD3CJDE_&K#Z@OD4>W@W97?R'_96(BKU'&/K**_4]DKS_P".7BO5?!_@
MQ=1T.6.*ZDNXX-[QA]JD,QP#QGY<<]B:YI/C#J,CA$3069C@`:C'R?\`ONL'
MXA>([[QSH::5J":;;Q).L^^&]CSD!ACEO]JAUXKH_N8++*C^W#_P./\`F>_V
M[%HD+')*@G\JDKQZ/XIZS&BJ+31\*,?\?J?_`!=,D^,.HQNR2)H*LIP0=1CR
M#_WW1[>/9_<Q?V94_GA_X''_`#/9**\9_P"%R7_IH'_@QB_^+H_X7)?^F@?^
M#&+_`.+H]LNS^YB_LV?_`#\A_P"!Q_S/9J,BO'(OB]JDS%88-$F<*6V1WZ.Q
M`!)P`^3P#3U^*/C:91)8_#RYO;=AE)XI'VN/4?(:J%52=M3*O@JE&'M&TU>V
MC3U^1[!G-&:P_!6L76N^'X-0U"S6QN9"XDMU<OY9#$8R0.>.>.M+XSU6_P!%
M\/7-_I.FMJEY$4$=HK%3)E@#@@'H"3T[5I=-7.-IIV///VB_O>$/^PLO]*]=
M%?.7Q'\2>*O$AT277?!EYHEGIU_',\[;W'+`8/RBOH&.2[N$WHL<"GE?,!8X
M]P",?G1<+%W--=@JEF(`'))[5FS:H+%F-])#Y:$!Y$.-A/3(/;\:\WUO5]1^
M)VLRZ!X8E>W\/V[XO]17(\X?W$]1U^O7I]XN#318UW6-1^)&JR^'?#$K0:)`
MVW4-17_EH.\:>H/Z_3KZ'H&C66@:7#IVF0B&VA&`!U)[D^I-'A_1+#0-*@T[
M2X1#;PC``ZL>Y)[D^M7W=4`+$#G')Q3$,N9X[>%I96VHO)-,M+N"\A66VE61
M&&0169K=E+JCI:,LD:+('$T;8&S!#*WOR>.G0]JTM/LHK&V6"`$(O<G)/U-`
M&)XQ\*VWB&RD5HQYV.#G&?3GL1V/X=*Y7P;XHN]`OD\/>)F;RRVRTNG]!QM;
MW_SZ5Z8Q`4DG&!7BGQ)UV7Q/=7,?A?2_[1L],&^_NE'W\<80^HY((R3CH1UR
MG'[4=ST,+B8QBZ%?6#^]/NOU74]K5@1D$<]*=7D'PP^(:"*#3-6N/,MI/DM;
MINJG^X_H1P/\1@UZZA!P1@@^E5":D8XG"RP\DGK%ZI]&AU%%%6<H4444`%%%
M%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!2$X!)/%!(
M'6O+_B1X\(:;1M#FPP^6XN4Y*=MJXZL>G'TJ)S44=.&PT\3.RT2W?1+NP^)'
MCP@RZ/HDWS#Y+FY3G9GC8N.K'IQ7G^D0V=OJ&GMK:W45A+*_F2!.-HZ[7Z,>
MSD<@9VY^8UT7@#P3-K\XNKL/#IT3<G/,AZ%5/<]0SCIRJ]S7J^L>&]-U;1?[
M)N+=8[9`!#Y0"F`C[K(1]TCM2A%I\TMSHQ.)AR_5\/I!??)]W^BZ&AIZ6J64
M(L!&+4(!$(L;=N.,8[5.3BO*-`U34OAWJYT376:?2I"6@F"X4+U+(.P'\4?;
MEEXR!ZI#-%/"LL,BR1N`RNIR&![@UH><>=Z#\3KO5?B?=^$Y-#E@@AWA9SG>
M-H^\PZ!3V^H]:[[4+E[>UD>*)II%&=B#)_+_``J801"9IEB02,,%PHW$>F:R
M[32;J+6)KV>_FE0\1QY`4`]B,=/QH`JZ?IT^H2_;;Z9GBE561`I1NN<$>G3(
MP,$?4GH<4"EH`****`"LSQ%H-AX@T\V>HQDH&#HZ':\;#HRL.0?\:TZ#[T`5
M=+T^UTO3K>PL(A#;6R".-`>%45A^-O%\'ANU\N/9-J$JEHHF.%5>\CGLH_,G
M@<T>-_%L'ANVV1>7-J$JEHX6;"HHZR.>R#\R>!DFL#P3X2N;Z[_M_P`3;YIY
M6$L<4ZX9B/NNZ_PX_@CZ+U^\>``\$>$I[V[_`.$@\2AY9I'$L44R\L?X9'7M
MC/R)T7K]X\>B`"@"EH`:PXXJG:O]FE:UD.`6+1'L0><?A_*KU17$*3ILD4,O
MH>WN/>DT-,\X^-<<BZ(LA7]V\Z8.>I"MVK+T?P_8ZYJ^NBZLK2XN(Y--2-[B
M!)"%^R(2F6!P">N*Z7XM::)/!EQ(UQ*PMF6158@Y/3KU[U1\!_\`(PZ[_P!=
M]-_](TKFIQ<:TGY(]:M-2R^DNTI?DC8L?`7A*[@$@T.Q5@2KH;2'*,.H/R4Z
MY\`>$+:%YIM&L%1!DG[)%_\`$5NW\;VLYOK=688Q/&HSO7^\!_>'ZCCTIEK(
M-6G2Z!#649S!SD2M_?\`H.WY^E=1Y!YXN@66C?$KPJ;73[:S,\TSA8H(T9%-
MM<?*2H&?N@GKS74_"_\`Y!FM?]AW4/\`TH:K'B'PQ9>(];5KN>]MI;**.2":
MSN&@D0MYRG#+SR"1^-:?AG0+/PWIK6-@\\D;2O.[W$IDD=W.68L>22>:`-0B
MJ=T'@G%S&I="-LJJ,G'8CZ9-7**30TSSGXSXF\$ZC<0E'C\@J64\CZT?!*"&
M7P]J;21(Y_M*09903_JHJZ'XB6-K-X(U]YK6&1ETZX969`2"(F(/UK"^!W_(
MN:G_`-A.3_T5%4QC9M]RY3YDEV.\^R6W_/O%_P!\"L.XABWWI\M.-1MP..V(
M:V=1N?L=C<7.W?Y,;2;<XS@9QFN'D\22L9S_`,2@>;<QW'_(37C:$&/N]]GZ
M^U85YQ6C*I1<M4;)6..Z)5%W&6X5>.Y*@?SK?BL;9(E46\6%`'W!7%Z?K4,V
MJ0O?W6EVT$<LDS%+Y9"2<8&,#H0#^%=./$^A?]!BQ_[_`*_XT4:D+7N.I"2T
M-#[);?\`/O%_WP*/LEM_S[Q?]\"F6.H6>H1M)8W4-RBG:6B<,`?3BK-=*::N
MC#8\T^-L$46F:*T42(3?2#*J!_RZSUT_PZ_Y$?2?^O<5S_QJADN+#0H85+R/
MJ#JJCN3:SUE>&_B!)HGA*P$^@W[VD42JMV!B-P>A!Z<YK"<E"?-+L>QAZ$\3
MA'3I:RYEI==O,[+P,DB6LSE?W;SSX.>XE;K6RS_:[M53F*`Y9AT+]`/PSGZX
MJCX?L(3H\#PRW'D7&;D(S`$>8=Y!(_WJV88TBC"1HJ*O0*,`5=.-H*+/-JRO
M-BLBLNUE!'H:J:Q?VVE:=/>WLRPV\*EGD8\*/_UU=J"]M8+VVDMKJ%)X)5*2
M1N,A@>Q%:F*/$B^J?$[6&TO29)+?0[=L7EYS\_\`LKZD_P">/O>Q>']%L-`T
MN'3M,@6&WA&``.6/=B>Y/K7G;17OPIU=YHDEO/"E]+ND`RSV;GO[_P!?K][T
MZPO;;4+.*[LIDFMYE#I(AR&![TDDMBI2<G=C[B>.VB,DSK&@ZLQP*YI)KG7[
MLNL4R608B)SNC((RI;G![GC^G-=#J%I%?VDMM,"4D&#CJ/0CW!YHLK2WL;=8
M+6-8HUZ*HQ^-,D?;0BWMTC5F;:,;F.2WN:\]\<?$Z[\,^.=,T"+0IKN"["EY
MQD%LG'[L=#M[Y_\`KUZ.S``DG`'>O+O$>K77Q`UH^'_#!$>GVYQ>ZH%S@'JB
M'W_7Z=0!_B'7-0\?:I)X<\*3&'2XSMU#4EZ8[HOKG]?IU[OP[H5AH&EQ:=IT
M02",<YZN>[,>Y-'AW0K'P]I<-AID`BACY)_B=N[,>Y/K6H2!0!Y)XY^$TUSK
M!O?"DL5I%>-F\MW.$!!SO08Z]1CCKU`R*O>#O%%UX?OD\/\`B9SY6=EK=N"/
M;8WH?\^AKT?[1"TSQ"5#)&`S+GE0>A/IT-8/C'PK;>(+%PT:^=C@]-WISV/H
M?PZ5E.%WSQW/0PV*BHNA7U@_O3[K^M3H@V0",8/2G"O,O!_BBZ\/WZ>'O$SM
MY9.RUNY,CVV-GH?\],&O2U8%000<U4)J7J8XG#2P\M[Q>SZ-?U]PZBBBK.4*
M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHI#0`III.!DTI.!FO
M+_B3X]*^;H^ARG</EN+E.=F3C:N.K'IQ43FH[G5AL+/$SY8Z);M[)=V'Q(\>
M$-+I&ARX;[EQ=)SLSQL7'5CTXYK`^'_@F37[D75VK0Z?"Q!;^*0]U5NY[,XZ
M?=7N:/`'@J77K@75TK1:;$Q!;/S2'NJGN>S..GW5[FO:[:WAM+>."VB6**)0
MB(@P%`Z`"E"#OS2W_(WQ.)CR?5\/I!??)]W^BZ!:VT-I;QV]M&L4,2A41!@*
M!T`%2$U6U.:>"SDDM(_-E`X&,_CCO].]9OAJVO\`R7N=2GD,L[^84Z*.`!@=
MNG3\:T/.)/%6E6&KZ0]KJ,1D5B#$4.)$D_A9&[,#WKS?PMXCO_!&KMH?B%6^
MR9)5L<*.OF)_L]V0=.6'&0/5)_FU"W1L;0DDGX@J!^C&L'Q=X0B\0PF.21@V
M=R2%COA8<AE(Z5#;6J-(*+T9T\$L<\*2P.LD;@,KH001Z@CK3Z\@\)^(M0\$
MWYT;Q#%.MIYC+DPLJ+CGS(FQAE(.61?N]0,9`]<AECGB26%UDC<!E93D$>H-
M69CZ***`"BBB@`)P,US7C?Q=:^&;`EMDEY(I,41;``'\;>B@XY[D@#)-8GQ:
M^)D?P_ALE6P%_/>B3:OG;/*V@8)&"2"3[=#6=\./#TWB7[/XP\2-]H:Z"SVT
M#G(![2-CCCG:HX4<\L2:`)_`G@^ZU"\_X23Q5YDEQ(PDA@G7#9'W9'7MC^%.
MBCU;)KTD#%``Q2T`%%%%`!61XOOY]+\-:A?6I4300LZ$C(!K7KG_`(A_\B5J
MW_7NU14TBSHPL5*O",MFU^9Y/J^M>--;\"SZO>B"317!WLNT/A9-AXZ_>%=M
MX3M_L?B[Q);EMWDW>GIN]<6B#-<_!_R;=/\`[LW_`*5M5O4_$ECX<\9^)QJ%
MP+6:ZNK.6#S(V(=!;JK.,#!P01]1BHI027-U9U8_$RG-T;)1BW9)6\OT/1+M
MS?W!LXF(A3_CX=3^/ECW/4^@^M-4#2KA4"[;&4X7'2%_3V4_H?K7)VOQ2\'6
MD"PI>R8'))C8ECW)..II\WQ6\'31-%+=LZ.""#$W(_*MCS#2\2>*!H'B""WB
MTR[U.ZU&-(H8;8H&)43.3EV`Z`]ZU/"7B"/Q+IDEY'9SV317$MK)!/MWH\;%
M6!VDCJ#WKSBQ\26'B#XD^&%L+O[4()IE!*L&V"VGP6R.N6`]\9KL/A?_`,@S
M6O\`L.ZA_P"E#4#.OHHHH`P_'_\`R(GB'_L&7/\`Z*:N9^!O_(N:G_V$Y/\`
MT5%5WXK>*M$T;PUJNF:IJ$=M>7VG7"V\3`YD)1E&,#UXKA/`GQ`T[PCI]W97
M,2WGVBY^U)+;7UIMVM''@'?*I!&TY&*`/;F4,I#`$'@@]ZYV>TMPU[^XBXU&
MW`^4=,0\?J:Y5OC3I)X33I@>VZ_L@,^^)C_(UAR?%Q',Y_L>(>;<QW'_`"%K
M3C8$&/O]]GZUC55^AI#3J>BV5G;G5$'D18\ZX&-H_P!FH+>UMS8V9,$63I+L
M?E'7"<UP4/Q<2*[6;^QXCAY'Q_:UI_'C_;[8J*+XL(EO#%_9,68K-K7/]K6G
M.0O/W_\`9_6L5'R-+ON>R:=$D5E#Y2*@**2%&,\4D]Q(\I@ME&\#+NPR$_Q/
MM7F]K\8K*WMHXK[29(I`BX5-0LVRN`0>95ZC!^A%=IX(UFW\1>'+?6+:.2.*
M\,C[9,;AAV7G!(_AXYZ8KICLD8O=MG'>/-0GE\7>$[)I-\)O'E.Y-K!Q%*OY
M=:S;\?\`&/>BG_IVMOYBG_$>:VT[XC>&8Y[B*&*(2W;RW$R1HB8=<98C)RPX
MY-)?_P#)O6B_]>UM_,5E*_LY7\ST,#R_7*7+W7YGIWA?_D6],_Z]8O\`T$5I
M5F^%_P#D6],_Z]8O_016E6T=D<-7XWZA15;4[K[#IMU=[-_V>%Y=N<;MH)QG
M\*X#X5_%A/B#JEY91Z.VG_981,7-P)-V6QC&T8ZU1F>A7EI!>VTMM=Q)-!,I
M1XW&0P/8BO.])T?7?`OB:.ST:"74_#NHR'$>239.?XB>R^_?Z_>]%@GBN%)A
ME20*Q5BK`X(ZCZU)@>E`%2.VE;FXN)"3U"?(H_K^M5;VX33EDE^V8$0W-',<
MY'L>N?SJ[J5[;:;8S7E[*L-O`A>21C@*!WKQF>YU+XB:U)IFA2O%IJ,7N+SD
MJJDDX'JQ!X'].N;;5DC6%G=R9N:UK^H_$*_/A[PJSVNG+C^T+_T'>-?7T]_I
MU[_P[H5CX?TN/3],A$,*=>Y<]V8]R?6E\.Z'8>'],BT[3(1'!&/Q=N[$]R:T
MP,=*LR]`Z"L?7M6>U4VUE&9+ME+`;2VT<\XXST_ST*ZYJ[64<D5I&;B\VY2-
M<<>YR1QW^@JW:1M-Y<]W$BSH,`J<XSUY]#3`S-#TJX0_:+Z64,V#Y7G%PQQC
M<V><^V2![\8WB,BC`I:`.:\9>%;77[-@T:^?C@]"?Q['T/Y\5R_A#Q1=>'[U
M/#WB9V,6=EK=OQW^XV>A_P`^AKTP@&N<\9>%K;Q!9R*T8\[&0>F['3GL?0_@
M>*SG"_O1W/0PV)C&/L*ZO3?WI]U_EU.B4@]#GZ4ZO,?!WBF[T"^7P_XF=O+!
M*6MW(,9_V6]*],4Y%.$^;U,<3AI8:23=T]GT:_K[AU%%%6<H4444`%%%%`!1
M110`4444`%%%%`!1110`4444`%(303@9KSOXD^/DTS=I.D2K]N;B28_=A&/Y
MUG.:@KLZ<+A:F*J>SIK_`("[L9\3_&JV<,NC:5/B[8?OYE;`@7OD^M<?X$\(
M7'B&_#,C0V-NP$TC9!_VE'^VPX/]Q>,Y)`;X'\)7?B/4&\PR0VT$F;B9OOAN
MN.?^6F#_`,`!S][[ON.FV%MIEE%9V,*PP1+M1%[?_7]ZF$7?GEO^1U8G$0A#
MZKA_@6[ZR??T[(DM+>*TMH[>WC6**)0J(@P%`Z`"JFLZM!I=N&D5Y)'.V.)`
M2SGT%7I-VQO+QNQQGIFN:T73K^]NY;S6F<*6^2W.S:".O&T'`/0ECD5L>82>
M'[+5C=2SWM\[V_F,51D"LXR=N<8Q@$#U)'.:Z(9QS0!CI3+B>.V@DFG=8XHU
M+.['`4#J2:`*NJR"VB6\=@L=OEI&)QA,<_EP?PJQ:SQ74"3V\B2Q2#<KH<JP
M]C7D_B/6KWQ[K5KHNERI;:;.Q*-*0/-"X)=E[\$%(_XOO'@<^F^'-&M/#^CV
M^F:>K""`'&\Y9B22S$^I))_&@"/Q-H5MXATB6PO!C<-T<HX:%Q]UU/8@UY[X
M/UN[\$ZM+X=\2DI`Q#1RC_5IV\Q?^F;'J/X&.,8(->KUB^+/#5GXETW[-=YC
MFC.Z"X0#?"^.H]1V(/!!(-`&PK*5!!!!YR*7(]:X;P!8>)[!;K2M9`BL;4@0
M3HX8OUR$SR$QC&>1DCG`-=:UI:QQ$R+QW9F/\R:5QV+F16+XL\26?AO3C<W)
MWRL"(800#(0,]3T4=2QX`K(\2>+K'PU#$\;O<-,"5MF;D``_-N/W5X[\8YKG
M_"OAR\\8:C_PD?B@%[1L-;V[`@3`'*DJ>1&.H4\L?F;L`D[C<7'<K>$?!?\`
MPF&IGQ+XOM8[R!U?[/%<)DREB/GV_P`*!1M53U'S$`FO5;.UALK:.VM8DAAB
M4(B(,*H'0`5*J@#CI2U1(4444`%%%%`!6!\0@/\`A!]<=CQ%8S2GWVH6Q^E;
M]8'Q$_Y$#Q)_V"KK_P!$M2:YE9EPFZ<E..ZU/'O!/P_O/%WA&TU2VU06]G=[
MR+:3<0-LC*<@''52?QKM?^$)\9@?\CA)^;_XU#^S_(MKX!MHB2(1NF)8DA20
M">2>F><#UKT'3;IYX'$_RS*6;!&/E))4_EC\0:Y(TJ;6C?WL]FIFN*3]Y1_\
M!C_D>.^'/^$JU[Q7KF@0^)KN*;1V"R2.[;9,DC@9XZ5U'_"$^-/^AQE_[Z?_
M`!KG]-^#S:Y&->C\5:C87&H@RRBW4*22Q;E@06Y)Z]L#M5S_`(4A=_\`0_:]
M_P!]G_XJJC1A)*2;U\V1+-\1%M-1_P#`(_Y%V_\`"7C*RL+BZ?Q?,RP1M(5#
M/D@#..OM6M\%I7G\(O+(2TDMW+*['JS,=S$^Y)-<GJOP8NK33+NY/CG7)1#"
M\AC9SAL*3@_-T-=1\#?^1*'_`%W?^E"@J=1<OGU+J8N>*P=1U$KIQVBEO?LC
MOZ***ZCPSQ[XFPQ7'QR\$17$:2QO&X9'4,I&6Z@UZ?\`V!HG_0(L/_`9/\*+
M[0=+O]1@U&\L89KRW7;#.R_/&/0'M3F\RR=6#M);Y`96.2F>X/<4KC2N-_X1
M_1?^@/8?^`R?X5Y1XATO3T_:2\.6B6%JML^ENS0B%0C'%QR5Q@G@?E7M`.:\
ML^(_@7Q?JOQ#L/%/@_4--LIK.R%LK71)8-NDW';L8$;9*8CT+_A'M%_Z`]A_
MX#)_A36\/Z+D#^R+#G_IV3_"O-?[#^.7_0U:#_WZ7_XQ1_8?QQ[^*=!_[]#_
M`.,4@+7P(TC3;OP1))<Z=:3/]ON5W20JQP'X&2*].MK>&UA6&VACAB7[J1J%
M4=^`.E<I\)O#.H^$?"8TS69;>:[-S+,[V[$H=YSW`_E78TP/'OVH((CX6T>9
MHD,G]IQQ[]HW;=DAQGT]JZ;XP0QV_P`/YHH(TCC22(*B#"J-PX`[5SG[4'_(
MGZ/_`-A:/_T7)6[\9[^`>&?[,#[KRZE3RHEY9L-GI6-9VIL]#+(N6,I6[HZ_
MPO\`\BWIG_7K%_Z"*TJS_#L;P:'80S*4DCMHU93U!"CBM"M8[(XJFLWZF#XF
MU6X@EM](TNWCN-1OU?8LQQ''&H&YWX/`R!CN2!7G&L>%O$'@70=1N]&&E2->
M@1375M:+;2VJ%ADC:/F4>IY'7M71^)O%5II?Q(TN*UBN-1G6VEANX;6/S&@0
M[6#\=P5Y'H?H#=\0:VOBC3)M#T*VN9I;Y?)EFEMWCBMXSPS,6`R<9P!SG':F
M0<7I=GJWPAU&*YO[F75/#VH!1=21K_Q[S''S[?3KCU'7D#/L=E=V]_:175G,
MDT$RAXY$.0P/0BHYM/MKG3FL;J)9K=X_*='&0RXQ@UY=NO?A%JPR9+SP?>RX
M`^\]BY/ZCG\?KU`/5+VUAO;:2VNHEF@E4H\;#(8'J"*\ITYKCX3^(YK?4B\O
MA?4I=T-PHR+60]G[]."<\@`^M>K6%Y;ZA9Q7=G*DUO,H>.1#D,IZ$5'JNFVF
MK6$UCJ$*SV\R[71AU_P^M`%B&:.>-)(761'4,K*<AAZ@U#J$DT5M(]L@DE5<
MJI[FO+=,U'4/A3JZ:3K<DEUX7N7(M+PC)MB>=K>WM^([@>KQ2)/$LL;JZ.`R
MLIR&'8@T`8FF:=;WEQ)?SAYF+_NS*K(0O'R[3V!R1GU]A6^*3;R*"<4`+17,
M>._'&E^"[%)]0W2SS'$-M&0'?U//``]36GX;U_3_`!)I$.I:5,)8)1WX9#W5
MAV(]*`-2D(ILDL<8S(ZJ#W)Q2A@PRI!'M2`YCQQX7BU_3W_=J90#GCD\<$>X
M[>O2L#X?>*);"=?#?B*0BX4G[-<.?EE7LN3W[<_2NXU[6;#0M+FU#59U@MH1
M\S'J3V`'<GL*\0UZW\8^,P?$%CHP73;EQ':6PQYJ^DQZ=>A.<>QP#6<X/XH[
MK\3T<+B(<CP]?X'UZQ?=?JNI[\#Q2YKSKP)XON8;E/#_`(F.V]'$%P?NS+Z9
M/?\`SUKT-:J,U)'/B<-/#SY9:IZI]&NZ'44459S!1110`4444`%%%%`!1110
M`4444`%(:"<5P7COQA+'<-H?AYA)J,@Q+*/NVZ^I/K43FHJ[.C#8:>)GR0^;
MZ)=V+X[\82Q3MH7AYA)J+C$LO\-NO<D^M4]*^&EE=:')'J)D^T3?,LQ^^&/\
M1_P]/?II^!?!T>E1"YN@9+ASO)D'S,W7<W]!V^O3M`N!VK)4N;WJF_Y'?5QJ
MPZ5'!NR6\NLGW].R/&+"]UCPGXB-O<@'42`I#'$6HQC@<]I0/NMWZ'M7JND:
M[8ZKI/\`:-M/BW4'S-_RF(C[RN#T([U!XL\,V?B;36M;U=KCYHI5^]&WJ*\M
M@FU3PYK4NGZC$LMU,GE/$YQ%J<.,8)Z"0#HW?[I[4*3I/EEMT8ZE.&.@ZU%6
MFOBCW\U^JZ'IOA7QCH?BP7)T*_6Z^ROLE&TJ1[X/4>AK?P.N*XKX7>&_"^C6
M%S>>%5E`O7_?><Q+Q,/^69'\.TYXKLIYHX('EF=8XXU+.S'`4#J2:Z#QPN9X
MK:"2>>18HHU+N['`4`9))KRS5=1U'XC:Q_9>D;H-'A(>21UX<=G<=_5$[_>;
MC`)JNI:A\1M8_LO2,PZ/"P:21EX<=G<'KGJB=_O-Q@'T;0M&M-#T]+*P0K&O
M+,QR\C'DLQ[DGO0!R'B'X;VATR)_#ZF#4+8`[V<@W)!)^=NN_))#]0?;(JSX
M#\9MJ3?V1K.8=5B)0%UVF4KU!'9QW'<<C(KL[B:*"%I)Y%C1>K,<`?C7GOBW
M1K+Q7#+JFC9@U&W.%E.42Y5>GS#[I!SM;JIXY!P0#T4=*6L#P//K4_A^%O$<
M`AO`2HR1N=!]UF`X#'N!6_0`8KCOB+XGM=%M4LBK37UPK2PQ*.`J$$NYZ!1Q
MDFNQK$\6^&;+Q/IC6MX"DBY:&=`-\38QD9Z@C@@\$9!I-7'%\KN<!X&\'W'B
M*Z'B#Q'N>U=A+#$XQ]HP<AF!Z1C`*KQNZGL!ZRJ@#I7EOA/Q#>^#M1_X1KQ0
M=L"<03\[43.`P)ZQ]O5#P>"#7J*LI4%2"#R".]"5@;N[LBO4FDLITMGV3-&P
MC;^ZV.#^=9+:;J4K0M->RJT3@YCE90P&[)8#KGY>*W:*8CGM-M-<AG@:6=/(
M1?WL+R-*SM\V2)#C`Y4XVGIVQSK3K=[KAX64'R]L*MTW<\G]/RJW10!RZZ=X
M@FM!:7ET``I/VB"X=7+=`.`/3).?PI[:=K0NR5N'DM_-!"FZ925YP?N\8XRN
M<-UXKI:*`.<,/B662%RUK;B.%D*"9GWOV8_*.X''H3ZUC^)K/5[;PEXRDU*X
M6:WDTJ;R`)&8C$#;L@G`Y]`*[NL#XB?\B!XD_P"P7=?^B6H`Y;X"V-O-\,=$
MNY8@\Q\WYFYQB5E&!VX1?RKT*>VAGQO7YAT(."/Q%>5?LZWES<^`+>T%V$^R
MLXBCV`C!=F.>YY/K7J%M<MYWDW*!)2,J1]UQWQ_A6<>5K0TDI)ZL?IUG#I]E
M%:6JE(8EVH"<X'UJQ0#FBK2LK(SO?4S_`!'_`,B]J7_7K+_Z`:Y#X&_\B4/^
MN[_TKK_$?_(O:E_UZR_^@&N0^!O_`")0_P"N[_TK&7\2/S_0]&C_`+G5]8_J
M=_1116YYQP/CKX@OX<UZ/3(K/ST>'?+(&(>,DX&!C!_.L(?$VS".G]GS$,A3
ME.@/7OWK9N;2"]^+T\-Q#%*O]F`@2('`.[K@UT$^@:=;1'%I:RR./+C4VZ<N
M>_3M_(5P2C6G)N+T/>O@\/3A&=-MN*;UMO\`(Q+?XFVAA0MHVKN=HRRVW!]Q
MS3_^%FV?_0$UG_P&_P#KUVL$2Q1)&@`5`%`QV%2;1Z"NE0J?S?@<7M\)?^"_
M_`O^`</_`,+.L_\`H":S_P"`W_UZ/^%G6?\`T!-9_P#`;_Z]=QM'H*-H]!1R
MS_F_`7M\)_SY?_@7_`.&/Q/LE!+:+K``Y)-M_P#7J.V^*^F7<7FVNEZI/'G&
M^.$,,_4&NRUE1_9%[P/]1)_Z":\X_9F&[X9J3S_IDW_LM')4_F_`?M\)_P`^
M7_X%_P``P?B[K!\<:)86&GZ7J<+V]\ERQEMC@@(PP,9YRPKMO!/A2Y-Z?$7B
M@^?JMQRD;<K`O8`>O\J[K;["BCV;<KR=QRQL(TW3P\.2^[O=M=O)`,"N$\>>
M,KJ*_3PSX2476O7(P6'*6J]V8],XY]OR!3QYXSNHKU/#/A)!=Z_<C#$?=M5[
MLQZ`XYYZ?D#J>!O!MIX3L'8R&ZU&X.^[O).6D;J1D\A?_P!9K8\T/`G@ZU\)
MV,A+FZU*Z^>ZNWY:1NI`[A<G^IJ?4M1U";58].L$\C:ZM),020N?3&,'D=?7
MTJ'6M4;4;H:58.3YF4E900P&`<JV<=".><].,YK0U+4;+PUHSW^KW6V*W7YI
M'Y8G^Z.Y)/0=:`)=9UFTT#2);_5KA8H81EF]3V51W/8"N!T;2]0^).IPZ[XD
M@:VT"W??8:>?^6QS_K)/4?SZ=.K-$TC4/B3JT7B'Q+"UOH=NV[3]/8_ZW_;?
MU_KT''7U)%5%"HH55&``,`"@#DKNTG\(7,FH:3`TNC2L7O+&,9-N>\L2CMW9
M!UZCG.>CAU.SFM(;F&YCDAG4-&RG.\'N*ML,U2T[2;+3%E%C;I")7,C!1QN)
MR<>G.3^-)WZ#7F0ZG;:9KUC-IM^B3Q3+AHFR"?<=\CKD=*\WTN_U#X4ZHFD:
MU))=>%KE\6EX1EK9C_"WM[?B.X'922RZA/<2RR^39VQ/FS`\#:2<+SU]3VZ4
MW4,^(1?:7>6<5S97$8$(/*D==Y/48./3D<4D[E3ARNQU,4J30I+$ZNCJ&5E.
M00>X-<UX_P#&EGX1TT.ZFYU"X^6UM%Y:5NG;H,G^@YKSY=3UWX/Q2Z=>Q-K.
MBNC/8SD[3$^"=A]!QT_$=P-'P[X0NKFW?Q=XKOF?6[W:UJL>'%NIY5$'.202
M.#P#ZY-405_!VC7*ZG/XQ\6$WVJF3RVM"N1`&'"QCNPY&/KCG)-KPMX>NM-\
M>S7'A^Z2TTN_C\V\M`I\N/(^41GH6]^,#(&>,=YHVD""0WETB"Z<=%'"9Z_5
MCW/X#BH-;TEMWGVDLT418M,D&-XSU=/?N1WP._4W!&Q':6\(+"-=V.7;EC]2
M:Y7QKXNT#PEIQOKFX6VF>0QQ+&O,K#KD#JH[FKWBWQ#:>'_",NISO)=Q!%0,
MA7=(6^4'L.]>9Z'X$N?B;<#6O%8FM-*0%;*",A9)!T+$X.%X[=>WJ9>]C2-N
M6[W-?P_I=]\4=2@\0^)8C!H$!W:?I^>)3_ST?U_R!QDGUA$5%"JH`'``JMI6
MGVVE:?;V-C"L-M;H(XT7HJCH*MTS,Y+QSX0@UZU>2)-MPIW`KP<^H]^/Q^N"
M,CP-XON(+M?#WB5]MVORV]P>DP[`GU_P]:]#P<UR7CGP=!KUJ98U*7*?,I3@
MY]1[_P`_R(B<7?FCN>AAL3!P^KXCX'L^L7W7EW1U@)IU>=^!_%\]M=+X>\2L
M$ND^6WN#TG`XY]__`-76O0P13C)21AB<-/#SY9:I[/HUW0M%&:*LY@HHHH`*
M***`"BBB@`I"<"C-<'XZ\8313-H7AYA)J$@Q+,#\MNO<GWJ)S4%=G1AL-/$S
MY(?-]$N[#QUXRDCG.A^'R)-0D&)9@?EMU[DGUJ?P+X0BTN`7-WF2XD.]B_WF
M;^\W]!V^O1?`W@^+3(?M-VK2W#G>6D^\S==S?T';KUZ=H`,5$(-OGGO^1UXC
M$PA#ZMAOAZOK)_Y=D`&.E+116QY@'D5A^+/#=EXDTUK6\7;(.8IE'S1MZC_"
MMRBE**DK,TI59TIJI3=FCQ;3[W6/"7B(P70_T[A2"V(]2C'`YZ"0#HQZ_=/8
MUK:KJ>J?$#5!I&F0S66G0[6N3,F&'?,BG_QU#U^\W&`>W\7>&[+Q+IS6MVH6
M11F*8#YHV]17ENEZMJ/ACQ//9R2QR:E$5CE3S!LU!`/E#'^&4#[K'KT/8UA&
M3I/EEMT9ZE2E#'0=>BK37Q1_5?JNGH>NZ#HUGHFG1V=C'M1>6<G+2,>K,>Y)
M[U?9@@YZ"L_1-9LM9TU;ZSE_=\B16^5HF'WE8=B.X-9%]?/KMZMCITMPD$;@
MRNL3H'"L"0LA7'IT/X^G0>.7I;S3-?B>TBN=S$Y4Q\D<?>^GUJR+.*UBM;.!
M<1>9D@DG(`)_F!4VF:?#I\/EPH.22S$#<Q)[TNH!E2.:,$F%]Y4=Q@@_H<_A
M28UN3/(B,H9@&;A03U-8]OXNT>?Q`^BQW6;M./ND(SXR4#="P&#@5Q?CWQ@R
M:A)8Z).TMPX5#+&"_E9R,*`?F<]@.N/0$BK;_#'4O^$=-S]JDBU4N)UM/-Q'
MGT9A_P`M?^F@Z8``VC%3&3D_(J45%+74]:%+7">`/&K7[_V-KI:'4XB8U>0;
M#,5ZJP[2#N.A'(X-=T#Q5D&-XL\-6?B73?LUUF.:,EH+A`-\+XZCU'8@\$<&
MN$\.^*+SP3>MH/BQ)!;QC,,L:/+M7L4`!9HSZ<E#P>"#7JM9'B+PWI/B2*&+
M6;-;E(&WQ_,RE6QC@J0>AH`Q_P#A9WA/_G^N_P#P677_`,;H_P"%G>$_^?Z[
M_P#!9=?_`!NC_A5_@[_H$'_P*F_^+H_X5?X._P"@.?\`P*F_^+H`/^%G>$_^
M?Z[_`/!9=?\`QNC_`(6=X3_Y_KO_`,%EU_\`&Z/^%7^#O^@.?_`J;_XNC_A5
M_@[_`*`Y_P#`J;_XN@`_X6=X3_Y_KO\`\%EU_P#&Z/\`A9WA/_G^N_\`P677
M_P`;H_X5?X._Z`Y_\"IO_BZ/^%7^#O\`H#G_`,"IO_BZ`#_A9WA/_G^N_P#P
M677_`,;K(\9_$'PWJ7A#6K"RNKN6YNK"XAB3^SKD;G:-@HR8\#DCK6O_`,*O
M\'?]`<_^!4W_`,71_P`*O\'?]`<_^!4W_P`70!QO[.=E(/":M(A1H)W5E<$%
M3D_K[>]>H:_<06.FRWUU*L,=KB4R,<!<?X]/QIOA_0=-\.V;6>CVHMK=I#*5
M#,V6.,G+$GM5G5+"UU33Y[&_@2XMKA"DL3C(9341ARJQ<IN339S(^)WA,=;Z
M[_\`!;=?_&Z7_A9WA/\`Y_KO_P`%EU_\;I!\+_!W_0(/_@5-_P#%UGW?PK\*
M2WS*ME/$/*!1([N4`D$YZL?5:IDI7)=;^(_ABZT:^MX+R[>66WD1%_LZY&25
M(`R8\5'\#P1X+`/!\]_Z55@^$>@?>GMIPH4DA;R4D'L.O:K_`,&%">$Y%'1;
MJ0#\Q6#;=2.G<].FE'!U4G?6/ZG=4445T'EGEVN:I/IWQJLHK=(R;Z!+9F<$
M[0=QR`".?E%>CQ6JQR>=*[2R8QN;L/0#M7E?BW_DN6A?[T?_`*#)7KKC*D5A
M27Q>K/3Q^BI?X%^I1&LZ4&V_VE9DYQCSUS_.KK.JJ69E51R23P*\M\1>&=-L
M/%46IWOA'3X=`L,3>?8VT6]I.[R@`-L7T&?4]*ZGQ0L>LZKHVBR-OL+OS+FX
M4'Y9HT`VH?52S*2.X%;K4\PZ:">*XC$D$B2QGHR,&!_$55?6M,1F5M1LU93@
MJ9U!!].M8&EV-KX=\8C3]*A2UL-1M&G%K$H6..2-@"RJ.%R'&<?W:YWQGX5L
ME\0P7TOA"P?1;8FZN9[.VB^T329SEA@,5'4@$EOT*[`>BZH#-I%T(AO+P/M"
M\YRIQBO.OV;(I+?X=&">-XI8[V8,KJ5(Z>M>@O<QSZ5%-8R!HKA8Q$Z=-KD`
M$?@<U.GD6D<<0*Q+]U1TR:8TKEBN5^)>J:WI7AB6;P[:BXN6;8SY&84(.7`/
M!/0?CFKUCXLT6_UV?1;2^26^@7=(@!P.F1NQ@GD<`UJW,/GPF,L5!ZD4F]-`
M2UU/.O@6VB2Z)-);.SZXS'^T6N/]=NS[\[<]/?.>:](FA2>!H9!E'&"/:O(O
M%G@G5?#^I1^(O";F*]C8*40Y\X'^%AQD'_/8CJM`^)NBZAX<N-4U"4:?/9#;
M=VLA.]'Z8`ZMD\#CVI1=UJ5.*B]-C9NYM,\):7=ZGJ4ZQQCF24J`S?W5`'4\
M]/4UQ.AZ1J'Q)U>+Q!XFB:WT*W;=8:<QXE']]QWS^O0<=31-(U#XD:O%X@\3
M0O;:%`Q-AIS=)?\`IH_K_7ITZ^I(BHH5%"J!@`#``JB`C14140851@`=A1+(
ML4;/(RJJC)9C@`4.ZQHSNP55&23V%<^-1&NW<]C#;RFU51NF/R,KYX(4\D#W
M`_'-`%_3];MM1GECM,R+&VT2#E6X&<'VS@BM+J*JZ981:?;""$'`QDDDY..O
M-6Z`.$\16][X5GFO]&M'O],OF/VZP"%A"3]Z9`.W]Y._4=ZZ?P[%8_V7%/IL
MR7$,X#B=,8DXZ\=!VQVZ4GB?7M.\-Z1+J6JS+%!'T'=V[*!W->=>"[SQ/I\=
MYXF?3/L_A^^F\X:3&#YL*'K.@]^I7OR1Z4`>F:SI-EK.FS6&I0K/;3+M9&'Z
MCT(Z@UP?@?PIXC\,^(+G3I9A>:"$+V5W+(&>VR>8U4GJ1U.,<>Y%>A6%[;:A
M9Q7=G/'/!,H9)$.0P-3\4GJ%[%5;&$#,F^1O[SN3_P#J_"L/Q'XAT_PS8_;Y
M[S]QGF)F+[AG!QGG/MW/'4T_Q]X@M/#VAO<WLCH)&$<>Q&8LW7''TKR;1M-O
M_'NJQ:IJRNFFJP-M:GD,.S$=#QT'3!],ELY.VAO3AS=3>\.Z#=_$;7/^$AUZ
M)K7P_%*9++2R>)&[R./?J?7/U)]=C141410JJ,``8`K,M+*#2C`EHGEPM^[9
M??&0?KG^=:@Z5HC%^0M%%%,04C=*6B@#D?'/A"#7;5I(5*7*_,I7@Y]1[_S_
M`"(R?`WC">"\'A[Q(X6[0[(+AC@3CT/O_D\UZ)@>E<EXY\(0:[:O+$FRY3+*
MR#G=ZCW_`)X^A&<HN_-'<]'#8F#A]7Q&L'L^L7W7EW74ZQ:6O//`_B^XM[M?
M#_B5]MTORV]RW`G'8$GO_P#JZUZ"#[TXR4D<V)PT\-/EEJNC6S7=#J***LYP
MHHHH`*0G%!Z5P?CGQC+'.=#\/$2:C(/WLPY6W7N2?6HG-05V=&&PT\3/DA\W
MT2[L/'?C"6*<Z)X>/FZ@X_>RJ<K;KW)/K7`>#-9N/"^MQS>*]$NK/3[J9HA>
M7$9!$H/WW)ZC^74;L$CT;P-X0BTN$7-V#)<2'>QD'S.W]YL_H.WUZ=1K>DV.
MMZ9-8:G`L]M,N&4_H1Z$=B*B$&WSSW_(Z\3B(4X?5L-\/5]9/_+LBU!(DL2R
M1.KHX#*RG((/<&I*\ETG4M1^%FKQZ-KTDEUX:N7VV5Z1G[-_LMZ#_P#6.,@>
MKPRI-$LD3JZ.`593D$>H-;'F#Z***`"D9@HR:4]*\]^(WCY].E_L'PUMN=<G
M&"PPRVH_O-[^@/J/8%`E?1$_CSQA<PWR>'/"D?VO7[D8)7E+1>[OV!QZ_7T!
MS++X;6$.G3Z;?2F?49U^T2W[?ZR2;U!/102>/K6Y\-/#-KH&EO*YDGU:Z/F7
MMQ,/WCN><=3QW'^-=3=6<%T!YT>[;T()!'XBLZD?:1L5&I4I24Z;M)'C>F7^
MI^&M=DM;H*]X1Y;J6_=ZG&.`,G@2`<!N_P!UO6O3_!S:3+I*SZ*H"N<2[EQ(
M''!5QU##ICM2>)?"NG:[I'V&:/8R9,,H^]&WKGO7FNGWNL>$O$1@NA_IW`8$
MXCU*,=!GH)0.%;OT/8UG!RI>[/;O^AZM2G''0]M15IKXH_JOU70]H)KC?'_C
M-=%3^S],Q-JLN``J[_)W=#M'WF/\*=^O`!-4_$7Q(M!I42Z`3/J%R-NPQDM;
M,21ADZ^9D$!.I//0$U8\`^"SIS?VQK@\[59LN`[;_)W=23W<]V[=!@"ND\@3
MP!X).ED:MK($NIRDNJL0_D;NI)_BD/=OP&`*[<\4IZ52N[J%UEMUNEBEV_>!
M'R]OS'I2`Y+X@>%K36Y'N=-EBAUJ"-9"F_9YZ`G;D]58$':XY!]B15CX;>)+
M[68+FPU:VN$O-.*QO/)$4$GL>P<8Y`R.A'!K1T[1O[*MKBZEV2WDI'SG+'.2
M!\Q))^]WK;MH$@A5$'3DGU/<FF,FHJO/>VMO/#!/<P133DB*-Y`&D(Y(4'D_
MA4X.:!"T450US6=/T+3WO]7NXK2U3@R2'C/IZD_2@"_17%#XN>`\<^)+7/\`
MN/\`_$T?\+<\!_\`0R6O_?#_`/Q-`':T5GZ!K>G>(=.74-&NDN[1V*K*@(!(
M.#U]Z?K6K6.AZ;-J.JW"VUG!@R2L"0N2`.GN10!=HKBO^%M^!02&\16P(XY2
M3_XFC_A;G@/_`*&2U_[X?_XF@#M:*R/#?BC1?$\$L^@W\=[%"P21D!&TD9QR
M!VK1O;J&RM)KJZ<1P0(TDCGHJ@9)_(4`357N[8S;71MDL9W(WI['V-97AOQC
MH/B:66+0]1CO7A4.X16&U2<`\@>AK4U._M=+T^>^U"98+6W0R2R-G"J.IXI-
M7#8@FOUM[>1KV.2'8I9FVEEP!R<@=/KBN5^#+!O"DC*<JUU*0?49JOK7Q4\#
MW.CWL$'B&V>62WD1%"OR2I`'W:?\#O\`D2E_Z[O_`$K&5_:1^9Z5'_<JK\X_
MJ=_1116YYIY%XM_Y+EH7^]'_`.@O7K%T)3;2B`J)=IV%AD;L<9]LUY/XM_Y+
MEH7^]'_Z"]>NUA2^UZL]/'[4O\"_4X74?$NH7NBS:0?#^HC6KB)H&C-NWV96
M*X+^=]W9SGKGMC-7=6TV[TFWT._L89;^71T\F6&,9DFA9`K%1W8$*V.^#76`
M`48%;'F'*:&]UKWB"36Y+&ZT^V@MC;6J7D1CE=F.YW*'D#A0,]>:K2^*]12Q
MDT^\\/ZC)K)4Q!(;=FMY3R`XE^Z$[G)R,XKM,48%,#&T329=/\*6&FNX:>UM
MXDW=MZ`'\LBN%\;^)[V[UE=`\-1R3:I.H1N,?9N/F)/;KR?YY&=CQYXQNHKU
M?#/A-!=:[<C:S#E;1?[S'L<?E^0.IX"\&VOA6RD+2&ZU.Y^>[NWY:5NO&>V?
M\34M7+A-PV(_!/@:R\-::R2;;N_N/FN;IQ\S-UPO<`?_`%^M=#]EF7B.[D"^
MC`-^M6P,44[(F[*T=FJR>:[-+(/NLYSM^@Z"O.OBE\.%U23^WM!MH6U2`K)+
M;.@*784YP1_>[>XX->G4F*+6$]3E_A]XQL?%>F9AC%I?6W[NYLFX:)AQP.NW
MWQ[=JZFO._'O@R[CU`>*_!K?9M;MQF6(?=NU[@CINQ^?UP:W/`/C2S\7:<S(
MOV:_M_DNK1^'B?OP><9SS^!YI@/\075S>:DFC007$7F#S!<J2H&#[$9'8@9^
M]6QI6FPZ;;+##EL#EV`W-]<`5<P,YI:`"LOQ-X@T[PUI,VHZK,(H8QP,\NW9
M5'<T>)O$%AX:TF74M4F$<,8X'\3GLJCN:X#PUH.H^/M9B\4^,83%IL9W:;I;
M]`.TCCOZX/7KTP*`#PSH&H?$#5H_%'C"%H=.C.=.TI_N@=I''?/7!Z]>F!7J
M.WC';I2@`<`8%+0!RT>AWVAZUYWA_P`HZ=>.3=64C;5B<_\`+6/TR<;E[]16
MM=L]I#YDUX=YSA0JC<?0`_XUI$=ZYSQNT\%K;W:VLEU9PR9O$A)\WRL<E0.H
M'4@<XSBIE>VA<+7][8M"*V\1Z5<VFHVZW%J_[LDCY91_>7TY[CN.#5G3-%L=
M*M;:WL8!%%;)LC&22![GOT[U/IES:7FGP7&GR1R6LD8:)HS\I7'&*LGI32[D
MW[%2\(DN+>$?>W^8?8`?XD5;'2O.KSQ#JG@WQ=-_PDS"ZT+4Y`MM?(F/LI[1
MOCM[_CZX]#A=9(ED1E=6&0RG((]10@8^BBHYVD6-C"JO)M)57;:"?<X.![X-
M,1)16&NO2"VTYKB*T@FO"NY'NL+'D9`#%`68CHN!G!YJQ?:]9V,T<<\T0,L+
M31#S!NEQCA!U8X.>*`-2DQ7,Z%XO75=6:Q-J+8K$KGS)"'#'`*E"H(]CW]*Z
M<=*`.1\=>#X==LVEA4+=+\P*\'<.X]_Y_D1D^!O&%Q;W*^'_`!.VR[3B"Y;I
M./3/KV_#'6O0VKDO'/A"WUVU:2%=EROS`KP=W]X>_P#/\B,Y1=^:.YZ.&Q,'
M#ZOB-8='UB^Z\NZ.M#"E!S7GG@?Q?<07:^'_`!,^R[7B"Y8X$XZ`9/?_`#UK
MT):<9*2.?$X:>'GRRU3V:V:[H6BBBK.89+_JV(["O*/@_;1W5TTTZB1Y/.E<
MMSN=60`GZ;C7J\O^K;Z&O+O@M]\?]<[C_P!#BK&6M2/S_0]*@VL%6MWC^IZF
M!@4N117EWQQ\,^,/$4&DKX/GD00/*;A([OR"V0NP]1D##=^];'FGH>MZ39:Y
MILVGZE`L]M,NUE/;T(/8CL:\STK4M0^%FKQZ+KTCW7AJY?%E>D9-N?[K>W_Z
MQQD#T+P9:7EAX3TBTU3=]N@LXH[@L^\F0(`V6[\YYJUK6D66MZ=-8:G")[>9
M<,I[>X/8CL:`+<4B2QK)$P='`964Y!![T^O)=)U._P#A9J\>BZ]*]SX9N7VV
M5Z1DVY/.UO;KQ^(XR!ZQ%(DL:R1L'1QE64Y!'K0!F>*8]6ET"\3P])%%J)3]
MRTO0'OZX.,XSQFN)^'OP]ETFPCN]63=J=TQ>Y9V#L"1W/.3]/\:]+[4USM4G
M!.!T'>DU?<J,G%W131!%J**@P#`01]",?S-.O=5L+":VAO;N&"2[?RH%D8`R
M-C.!ZURWA?QM9:U-J`G@GL]2MI?):SF&'"@_+CZYY^H[8J7Q-X8M?$UGY&KR
M#SY`6B93_J&'3;_6LW-1T1C.HD[+5G3:BLDEE*L!(D*G!%<-X\ATJXT9X[J.
M>3:A,*9_>QS8X"ECSGN.E9MCX^NO!\-UHWC&.6>ZM8RUG<QKG[6HX`)['IR?
MQYZ\K\.O!/C-_%8U[Q%;R-ILB/*L%Q=;R=QRJ[<DC&<\@=/PK.M!SCS1&JE2
MG)5J#M);%C1]0U#2]<L9M0M4_M2WC)B$R@+>1MC(#$<2X&`W?H:]FT+6+36]
M/2]L9"T;$J588>-AU5AV(/:L77?#$'B>T,-[";=(TVP,/O(W8_\`UJX'3KW6
M/"GB-K>Y`.H$!2"V(M1B'3D])0/NMWZ'L:BE.4$HU-NC/9E"&/INO15IKXH]
M_P"]']5T/3-?UV"SD^PV]S`+^881'<97/0E0=V#ZTNC:#%;N+R]"SWCA6:1D
M"_-@`G`XR<?I5?PC'IM[#)JFGSR3+,[#9(2#"<Y*,IZ,&SG-='79L>25]01F
MM)-@RP`8#U(.?Z5@>,?$$&D:;%<S2GRI1E8TY>5N-JCOUK:US5K/1-.EOM0E
M\N&/`X&2Q/15'<D\`5Y(FDZEX\U:?5_*-IIZ2;."247)W*GJW7<PX'(7/)K.
M5[:&E-I/4J:?::KX]\1-<7$P@&?+\XC/V8`@[8C_`'P5&6[$8YY->X0C9$JE
MF8J`,MU/N:R?#>D:?IEL$TXJ84`5`#]W`P1]:NWUZ((W6%?/N0I*0J>6..,^
M@]S1&Z6HZEF_=&ZWJ]GHNG27M_)LC3@`#+.QZ*H[DGH*\YTS3;[XDZF=2UD&
M/1H6*1P!N&'0HI'7/1G^JKQDGS[QZOC#X@:Q9V=L0MY#YA^S"46Z0OC!C`8Y
M9P,DG/(/`Q7O?@;3KS2?".E:?J15KNVMDCE*G(W`8(SWK0R*`^&W@K'/A?2_
M_`=:#\-O!0&?^$7TO_P'6NJH/-`&5X=T^RT>TDT_3K:*TABD)6*)=J@-R#C_
M`#TKF/C3,?\`A7^N0$`HUGNY7N'7O79W5L9&$L+".=1@,1D$>A'I7'_%J.XG
M^&^O1M9Y=;-W,BLI4!<,3S@]`>U9RO:QI"U[LPOAGX-\-ZWIFJ7FKZ)8WMR=
M6NU,LT(9L"3@9-=9_P`*V\%?]"OI?_@.M4/@U_R+^I_]AB\_]&5W-:&9B:%H
MNE^'KF:TTBPM["&<"0)#&$!(X/3OR*7Q?,8]#NEQE9(9$8%<Y!0_@*TKJV%P
MO+%64[D9>JGU_G^=9^K0W=QI=U:-;+.\L3HC(P`R00"0Q&/UK.=^5I&D&N9-
MGAO[/MY-'XJU;YV95S$`Q)"IO&`/0#)_.O>=:BAO;)]/GC29+K]VT;#(9?XL
MCTQ7AO[/NF7W_"5>(R8$$$$CPRRL0P63>,+MSD]&.?:O<3-9V/F3W$Y=U<1L
MY&6R0"%`'U'`%3335TRZDHNUCA_B'X!\*6'@;6[NR\/:=!<06<DD<J0`,C!3
M@@U;^!W_`")2_P#7=_Z5L?%`@_#CQ"1_SX2_^@FL?X'?\B4/^N[_`-*)?Q(_
M,ZZ/^Y5?6/ZG?T445L>:>1>+?^2Y:%_O1_\`H+UZY7F'CWPSXBG\=6>O:#;1
M3FV52F]Q@,-PY!(XPW:I_P"TOBEG_D%:9^0_^.5RQGR.2:>_8]ZMA?K4*4X5
M(JT4M9).^IZ1^-'XUYO_`&E\4O\`H%:9^0_^.5S?C#PY\1O%<MM)=H]D;<,J
MBQN1"&SC[WSG/2J]NOY7]QS?V9/_`)^0_P#`D>V$CUKA/'GC*ZBOD\,^$U%U
MKUT,%AREHO=F/KCGVZ^@.!+=_$W2_#XM_L5L(K6W$8G`$DV%7&[[YRW?..M:
MOP7@T9=#ENK.1IM6F8-J$DW,N\\_]\YSCUYSS5QJJ3ML_,PKX&K1A[2ZE'O%
MIV];;&]X#\&VWA6R=BYNM2NCON[Q^6D;KQ[9)_F>:ZBD!R*7-:G"%%%%`!2$
M@#).`*&(49-85[-<ZI(T%H%6,;9$9\[95SZCMGMZ?44`;$-Q#<1[X7#J>XK@
M?'O@V\CU%?%?@T_9M;M_FEB7[MVO<$=,X_/ZX-=8='>'1+NVMI`MS/#(JL"5
M1&8'&WT`)KSCX(^$_&OAW6M0F\723R6TMN$A+W@G&[<#P-QQQ0!V_@'QG9^+
MM.+*IMM0M_DN[1^&B?H>.N,@_P`CS6GXG\0:=X:TB;4=5G$4,8.!GYG;^ZH[
MFN0\>^#+Q-1'BOP:PM];M_FEA'"W:]U(Z$X'X_7!KG/`UN?B9XGN=9\5W$,@
MTF79;Z2F0L;?WV4\D9'?J1ST`H`U/#>@:CX_U>'Q5XOB,>FQ'?IFEMT`[2..
M_K@]>_&!7J0&`!TQ0HP,#I3+B>.WB:69MB*,EJ`',1CJ*YVY_M6_UZ.$,UM:
M6S&3*#ECM8*<YP1STQ_*BYU!M5NI=/6V!*$.N'!*X.`9%/0'TY_PW;.%H+6.
M)W,C(H4L>_O0!*@(4!B6/J>]*PXI:P/&GBO3O">C/?:@Y+GY88%^_,_95'\S
MVH`YWQ+?VWPWO$U1)U32-0GVW-AGYDD/66$?JR]._7KW.GWMMJ-G%=V4R3V\
MRATD0Y#`U\W^.O!OCGQ?J-AK>K>3''?`B.U\[:;6/((7:<=1CGUZXX%>X_#G
MP_;>&_#,%I:^=B0F5Q*Y;#'KCDX%3=7L5ROEYC;U?3+35]/EL=0@6>VF4JZ-
M_/V/O7G.G7]]\,=3CTC6Y9+GPQ</ML[P\M:L>=CGTZ_S'<#U+-4]6TRTU>PF
ML=0A6>VF7:Z-_/V/O5$EI)$D17C<,KC*E3D$>HIU>6:9?WOPOU./2M;DDN?#
M%RVVSO6Y-J3_``/[=?YCN!ZC%(LJ!XR&1AE6!R"/44`.HHHH`,"BBL[Q+;WM
MYX<U.VTN7R;Z:TECMY-VW9(4(4Y[8..:`-'@T8KROX$^&/%_AV76#XP:9A<+
M#]G\R[$_(W[L?,<=5KU2@#RWXT6,*1P3HNR3RI)L@8RZR0J#^4C?7C/05Z1I
M9+:=;,QR3$I)_"N`^-?_`!YP?]>D_P#Z.MJ[_2?^07:_]<D_D*S7\1^AZ-1M
MX&G?I*7Y1+5%%%:'G#9?]6WTKRWX+??'_7.X_P#0XJ]2E_U;?2O+?@M]\?\`
M7.X_]#BK&7\2/S_0]*C_`+E5]8_^W'JE)@4M%;'FA1110!1UO2;+6M,FT_48
M%FMIEPRG]"#V(/(->9Z3J6H?"O5DT77I'N?#-PV+*](R;<G^%O;V_$<9`]:J
MCK>DV>MZ=+I^I0+/;3##*>WH0>Q'K0!;BD26-9(G#HX!5E.013B,UY-I.I:A
M\*]6CT77I'NO#-PV+.^(R;<_W&QT'M^(XR!ZO%(DL:R1,'1P&5E.00>^:`.3
M\;^%7OY5UC1"(-9MU^7LMPH_@?WZX/;Z9K%B^(NDPZ))?:K!Y%]9;H9;9H\/
MYO\`=QV.?\]*[ZYN',WDVRAI<98M]U![_P"%>*_'6*/3]0TG6]-VOJGVD1LV
MP*&=&7;QWP3P3FN>I%7YD2Z+D^:.YT?A70I=5UE/%?C8+'.<26&G;?EMDSP[
MCUZ'!Z=^>GIZ;2H*G((XKA?"'B'^WVN;"<BUU,<7D$O$J8X(4>GZ#/?-=+XD
MUW3O"^C/?ZG+Y<$(VJHY9V[*H[DU5)NVVAG3;:VT-9L8KE/'NC0>(K%K292G
MDX9)53<RN1P/ICK^%7/!OB"37],2ZN[%].N'RWV>1LG;_"V?<8K3A"B[NXG`
M)D828(ZJ5"_^RFJ?+4C;HSKP]=TIJK3>J/'M$U?5?#FOM%.N-2P%:-CB/4$'
M0$]!(!]UN_0]C7J*>+M(/AUM;-P1:K\K*5/F"3IY>WKOSQCUJOXI\%Z;XBL!
M;RJUM)&2T<T6-RGTYZCVKRC4M-N+/518:U`QU&-E*.LA1;^(<$`]%D*_*'/.
M/ER.M8P<J3Y9[='_`)GJUZ5/'1=?#JTU\4?U7ZKH=-866I?$C6AJ.IAK71[5
MBL:(WYJI'5CT9QT^ZO<UZC:VT-I;16]M$L4,2A(T08"J!@`"J'AG4--U#1H)
M-(VI;(OEB(+M,)7@H5_A(Z8J_=7$5M`TLSA%'<G%=1XHDUI;2OOE@C=\8W,H
M)Q]:YV#3K^ZUC=/FTM;9BT:0!4&X@@-T);@^P]1QR0P:EKE^EU(T^GV\;$!5
M=2QP>,C)P3DY]L=*Z:"/RHEC!)"C&2<G\Z5@O<X[QWX+76$&H:5B'5(0,'=M
M$X7H">S#^%NQ]02*;X#\9G46_LG6<PZI$2@+KM,I7J".SCN.XY'!KM6(`KR+
MQ\UMXA\6V]IX;A:74HR4GN(FVJY7H,]MA()D_A^Z,DX#`]='2EJOIL<\-A;Q
M7<PN+A(U624#&]@.3CMDU8H`*YKXGC_BW7B0_P#4-N/_`$6:Z6N0^+%_;V_@
M?5K*20?:=0M9;>WBSR[%"/P`SDD\`4`5?@U_R+VI_P#88O/_`$97<UQ?PBM;
MBV\,W,MS"\(O-0N;J$.,%HW?*MCJ,CGFNJO[N.TB#NV"QVKP>6]\=N.M`%JD
M(JAH][)>VPDFB*..&XX)]O7\./>EUK5K/1M/>\OI=D2D``#+.QZ*H[D]A0(\
MP_9^YU7QQ_V%F_\`0GKTS^P[01,@>X!:3S2_GMO#>H;.1P,?3BO"O`/C)/!>
MH^('G@LKY=5N_M2>5JULGE@[CM8,X.1NP>W!ZUU__"[;;_H#0_\`@ZL__CE(
MJS.O^)J"/X;^(5!)_P!!FZG/\)K)^!W_`")0_P"N[_TKDO%?Q2'B/P]>Z1:Z
M4D9O8S`SIJ$%P5##!(2-B2?3M74?"^\L-`\*Q6NH7L<<[.TA3DE0>@/'6L6T
MZJ2Z(].$'#`SE+3FDK>=KW/1**Q_^$IT3_H(1?D?\*/^$IT3_H(1?D?\*W/+
M-<CF@5D?\)3HG_00C_(_X4?\)3HG_00C_(_X4`;%%8__``E.B?\`00B_(_X4
MC>*M#52S:E$%'))!P/TI`;#8(P1D&O-?&7A>^T+4O^$H\)?),A+7%LOW9%[\
M=P>X_$5Z2C!U#*001D$=Q2L,C%1."FK,ZL-B98>5UJGHT]FCG_!OBJS\4:<)
M[;]W/&`)X"?FC;^HZX-=`*\U\9^%KW0M4_X2CPE^[F0EKBV`^61>IX[@]Q^(
MKJO!GBFR\4:=]HMF\NXCXG@/WHV_J/0U,)N_)/?\S?%86/)]8P^L']\7V?Z/
MJ=#2,<`FCJ*P=3>XU"Z:TBBW0#Y75E'7((8J<97C'Y^H(U/.+-Y+#JL$MI!<
M+YJ,,C)`;N,D<X(]*GT;3UT[3X[8-NV\D^YJ33++[%;[&*/(S%W9$V*6/)PN
M3@>V:MTP`C(Q2;12T4`)@5YYX^\&WB:DOBSP<PM]<MOFEB'W;M1U4CUP/Q^N
M#7HF::V,8H`YGP#XTL_%^G,\:_9[^W^2ZM&X:)NGY5TD\,=Q$T4RAD88(->/
M>,_#%UHOB&?Q/X1EGBOUD,TL4A.V7)^88/53C_\`5P1WO@'QI9>+]-\R,>1?
M0?+<VC?>B;U]Q[_@>:E23+E!QW.AL[2.T@$41=@"3EW+,2>I)/-3T9K!\8^*
M=/\`"VF->7[EG;Y884^_*W8`?U[51`GC3Q9I_A'27OM0;<Q^6&!?OS/V51_,
M]A7)^"O"NH:]K"^+_&RYNSS8V!^Y:Q]1D'OT///<]@%\&^%-1U[65\7^-E#W
M6/\`0;$_<MDZ@D'OWYYSR><`>DCB@#+N-.`O)9]GV@2[=RLV&4#LO;'L:L^?
M<,NV.S:,^LK+@?\`?)-6R0*\T\;>+=0US5V\'^"&\R];*WMZ#\EJG0X/K_\`
MJ'/16L5S7W,:Y^(<_A;XBZC;W.H/K&CRE6N?+C)^P.<+A3TP.X_KP?7[*Z@O
MK2*ZM)4F@F4.DB'(8'N*Y[PMX&TCP]X=?2$@6Z6X7%W),H)N"1SN]O0=JXS_
M`$_X1ZMSYM[X.NY/=GL7)_EU^OUZLD].U;3;35M/FLM0@6>WF7:Z-W_P/O7G
M&FW]]\+]2CTC69'NO#%P^VSO3R;4G^!_;_\`6.X'IME=V]]:Q75G,DT$RATD
M0Y#`]Q4.KZ9::O82V.H0+/;3+M=&_P`\'WH`M1.LD:NC!U89#*<@CU%.KRS3
MKZ^^&.J1:1K<LESX8N'Q:7S<M:L>D;^W_P"L=P/4(98YXUDA=9(W`964Y#`\
M@@T`/HHHH`0`#I2T44`>;?&P@6<&?^?6;_T=;5W^D_\`(+M?^N2?R%<!\:_^
M/.#_`*])_P#T=;5W^D_\@NU_ZY)_(5FOXGR/1G_N,/\`%+\HEJBBBM#SALO^
MK;Z5Y;\%OOC_`*YW'_H<5>I2_P"K;Z5Y;\%OOC_KG<?^AQ5C+^)'Y_H>E1_W
M*KZQ_P#;CU2BBBMCS0HHHH`****`*.MZ19:WILUAJ<"SV\PPRMV]"/0CL:\4
MLO'-[\+O%5_X0N+:[U[3K=5EMC",S1*P!"X_NX/X'IUP/;'GFFF:*VPJH<-*
MPR`?0#N?Y>_2L.T\$V=MXYF\6_:KA[^>V^RNC;=A7Y><`9S\H[TKW'8G\"ZV
MGB70AJJ6EQ9^?*^8KA<.,'%>:_M"HEJ^@(TC,;B^+J"I./F3(S^/2O:UZ5Y%
M^TG_`,@SPS_V%D_D:EQ4MRHS<;VZG4^/?!;:K)%K>@R_8M?L_FBE7Y1,!_`_
M]"?7TKD?",5QXV\4/J'C"19+G3&\N'2T&U(7'WF92>3D>_;M7L745Q?CCPC-
M>72Z[X<86NN6XSP=JW:C^!_?T;M]*51-KW3":;6AL3O&8[B9T:W>UD.)"0-O
MR@^O3!Z5R.G:GKWC7Q9;W&F3'3]"TQOWMQ&,F[?^*,9_A['T^O3*T"^U'XF7
M$]FLDECIUM*/[1*\.TFT`Q+_`-\\GMVS7J^G6-MIUG%:64"06\*[4C08"BLJ
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MVDZ-<A&P4DG5B#(_3RD8<*<G!<X`/`.X\;/@*QTRQT2)M"DCNKNY4>=<[-OE
MX_A*]5"G("=<]>YI^@>$K#1=,ETPPP7]]>1!;N22,%!&?X=O9!SA>_)/<UO^
M&M`T_P`.:6+#3(BD.XNQ=BSR,>K,QY)Z#Z`4`2VMU)!,MI?,&=O]5-C`E'I[
M-[?B/;0S5'5S;BS<70RAQM"_>+=MO^UZ5E:MXC3PWH27&KL'NV!$4(8!I#[G
MH,#EFZ#!-`%KQ7XDL_#>G&XN2'E<$0P!@&D8?R`ZDG@"N.\+>';SQ5J0\1^*
M`6@8AK>V885USE?E/1!P0#RQ^9NP$'@[29/&>IR>(/$,HFA5_P!U:D':P!R.
M#TC!Y`_B(RW8#TFXGC@`0,@E8?NXRV-Q["B]]AM6W(]0O[33T3[7<1P!SA=S
M`?Y%8_\`9=UJ-\CW[SQI""&*R`)-DY7:%/`'J1GGK3;6UGUC4$N[LD01``PN
M@(#C((&>@/?!/3O6KK6JVFBZ>]Y>R>7$@P`!EG;LJCN3T`%`A-5U.QT#2VN+
MMA%!$`B*HR6/95'<GTKP_P`3^(;[Q7J:R2HS0L3';6D3;MV>"JXZ_P"TXZ\J
MO&24\3^(K[Q9JRM(DC0L2EM:Q$D-G@JI'7/1G'7[J\9)]+^'O@A-%0:AJBI+
MJ<BXP%&V!?[JCH./3Z5C.3D^2&_?L>IA\/3I06)Q*TZ+K+_@=V<UIGP6M;RT
M6XUBX,-Y)\SQPQ)M3VZ5:_X4;HG_`#^S_P#?I/\`"O4@,"EI>PI]4#S?%WTE
M9=DE_D>96GP4T2WG5VO+AT!^9`JKN'ID"M(?"+PB/^76?_O^U=W1731E*@FJ
M3M<XL3B*F+:==WML<+_PJ+PE_P`^L_\`W_:C_A47A+_GUG_[_M7=45M]:K?S
M,Y/90['"_P#"HO"/_/I/_P!_VI@^#_A$2%_LUSD@#'VAL?E7>T4/$UGO)C]G
M'L<+_P`*B\)?\^L__?\`:H[CX1>&O*)LEN+:X7YHY1*6V,.AP:[ZDI_6ZR^T
MQ>RAV.%\,Z]=:1?-HFOH(9HQE6'W63^^G^SZC^'Z=.Y5PP!!!!Z$=ZR?$_A^
MVUZR$<A:&YB.^"YCX>)O4'T]1WKF?#7B2?2=5?P]KX\NYB7>&`^0IT#I_LGN
MO\/TZ*<8U%SPWZK]5Y?D-76C.\*@]<$5YMXR\*WFA:D?$_A(&.9"6N+91\KK
MU/`Z@]Q^(KTI2&4$$$$=1WI&`(QZUR3@IJS.W#8F6'E=:I[KHUV,#P;XKLO$
M^FB>V_=W"8$]N?O1M_4>AK?"KN#8Y]:\V\8^%K[0M2_X2?PEE)D.ZXM4'RR+
MWX'4'N/Q%=5X-\56?BC3Q/;D1W"`">W+9:-OZCT/]:B$W?DGO^9OBL+%1^L8
M=W@_OB^S_1]3H!2T@I:V/."BBN)^(/C9M'DBT708A?>(;WY88%Y$0/\`&_ZG
M!]/04`+X_P#&S:+)'HVA0?;_`!!>?+!;KR(L_P`;^@[X]O2K_@_2M:T71DCU
M34'U6[E9I9S*WW&8Y*H?[HZ8_+'2J7P_\%)X>CEU'4YC?Z[>G?<W3\D$]54G
MM_/`]`!K:YK<=JSVEN\37&T[E+X9>,@`>I&<?3\*3&B26YBNKKR#;Q^>O&92
M,<@]/7CM7&>+?`5WI\T7B+P5(8=:M<M+$.%NTZE2/TQW`'<`UV.AZ&EG_I%S
M)+/<L=Q:5@2#ZX``S_\`7]:9XP\46'A72VO+Y\N?EAA4_/,_]T?X]J+!S-JQ
MS5G\6=%D\+2:C=@P:A"WE2Z>3B3S?09[<'GMSGI4?@_PO?Z]JJ^+/&B9N6YL
M[`@[+=.H)![]\'G/)YP!7\"^"9=4UF7QCXKLX8[VZ82068B`$0P,,PQR>!U^
MIYQCTX4Q!B@G%*>G%>9^-?%VH:[JA\(^!G\R[DXN[]#\EJO?!]??\!ST`%\;
M>+=0US5V\(>"#OO7RM[>J?EM5Z'!]??\!STZOP1X1T_PAI*V=B/,E?#3W##Y
MYG]2?3T':CP1X2T_PCI"V=DN^9\-<7+#YYG]3[>@[5T%`!4%[9V]_:RVMY$D
MT$RE'C<9#`]B*GHH`\C>2]^#^I%G,MYX-NI.YW/8N3_+^?UZ^K65U#?6<-W;
M/O@G198VP1N5AD'!YZ&O/OVBP/\`A4^I_P#76#_T:M=AX+_Y$_1/^O"W_P#1
M:T`97Q<C23X:^(?,17VV4C`,,X(&0?K5[X?#'@3P\?73+;_T4M5/BS_R33Q'
M_P!>$O\`Z#5SX?\`_(A^'?\`L&6O_HI:`-VBBB@`HHHH`\V^-?\`QYP?]>D_
M_HZVKO\`2?\`D%VO_7)/Y"N`^-F?L<&!G_19O_1UM7?Z3_R"[7_KDG\A6:_B
M?(]&?^XP_P`4ORB6J***T/.&R_ZMOI7C'PU\1:3X?>T_MB\6U^UF>&#<K'>^
M^+C@'U[U[--_JF^E?*/B$C/A3_K]N3^L585)<LE+LG^AZ>&CS82JN[A_[<?6
M`]:Y36?B7X/T34IM.U76XK:[@($D31R$J2`>H4CH16WH]UYFEJ\T@)0$,2>F
M/7TK*?P=X<UFXEU#5M!T^ZN+AMV^>W5GV]!DD>@%:IGG2C9M,S?^%O\`@(]/
M$4!_[92__$T?\+?\!?\`0Q0?]^9?_B:DU7P-X6L_LS67A_3;=Y)UC+Q6Z*<'
MKVJPOAG0993:KHUBKI]Z7R5P1[<=?Y5E*JU+E2.>51J5K%/_`(6_X"'7Q'!_
MWZD_^)I#\8/`6#CQ'!G_`*Y2?_$UQ?P=\+:!K-_XL.K:/8WQM]3,<1G@5]BX
M/`R.*]&'P[\&'_F5])_\!$_PK9:JYJG=7.&C^./AF.&*..69=HRY"?>;O^!.
M373^!/B=H/BW5&TK3I)WNEB:;YTP"H(!Y'^\*T_^%=>#/^A7TG_P$3_"O//"
M^F6.C_M(ZE9:59P6=JFE`K%"@102(B>![U*BT]S64TU:Q[37EWQ]TC4=8L/#
MR:78W%XT.IK)(((F?8H4_,<#@>]>HTTC`JS,B@NX9B51L,.JLI5A[X/-3BLV
M::"[(2/>)%)\N0*<`COGT_G5RRE,UK'(PVL1\P]#T(_.I3*<;'D_[.?_`#-_
M_86;^M>O5Y#^SG_S-_\`V%F_K7KU42%%%%`!6'XL\-67B73VMKP;9%YBF4?-
M&WJ/\*W*3%3**DK,TI59TIJI3=FCPRZ.KZ&^M6EQ>S65[:V,MQ-)#TU"&-"0
M"<_(^!C>,G!(/(!KTOX>^&K30]&AN$`EO+N)'EF(QP1D(H_A49Z?B<GFN(^*
M?_(Q:U_V+EY_Z*>O4=`_Y`6G_P#7M%_Z"*SI-V:?1G;F*BYQJ15N:*;MM?J%
M]92&7[79LL=R@QR?ED7^ZWMZ'M^)!8FIVYLVFEW(Z-L>%A\X?LN/7T]1STK2
MJN;*V-TMT85,ZC:),<@5L><>=>)+WQ/H7BB'6KC9=Z=,!%%:LX2.`GC:SXPK
MDXPYX/*\<$X>DZ9J?CG4#K>J;I+)G"*,$*XSPJC'$8//J2,GL![%=V=O>6TE
MO=Q)/#*NQXY%#*P]"#1:VD%E;1V]I$D,,2A4CC4!5'H!4RCS*Q<)<CO8HPV@
ML+>RV[1Y.V$[0`"#QV]\4^]TI+NY$K2,JE0LB@`^8H.0,]1SZ=:FNF$EQ#;J
M<X82/[`<C]<?E4>LZQ::-I\EY?2;(TX`'+.QZ*H[D]A0E84FWJQFK:E8Z#I;
M7-VXB@C`554?,[=D4=2Q["O$/$_B&^\5ZFKR(S0LQCM;2-B=V>"JD=<]&<=?
MNKQDE/%/B"_\5ZFCL&,3,8[6UC.[<"<%01UST9QU^ZO&2?3/A[X(71HQJ.J!
M9=3D4=!\L"]E4=N.*SG)M\D-_P`CT</AX4H?6<3M]E?S/_+NQ/A[X(71474=
M3"RZG(H[?+`O95'TQ7<4`8HK2,%!61QXC$3Q$_:5/^`O)>044451@%%%%`!1
M110`4444`%%%%``:QO$_AZVU^T"2$PW,1WV]RGWXF]1[>W>MFBJC)P?-'<32
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M\TBUMO#=E+<>(+X^6EJ5R(6[L3W`ZC]<8-3";;Y)[_F;8K"PY/K&'U@_OB^S
M_1]39^(/C9M&DBT70(?M_B&]^6"!.?*S_&_X9./;/0&G_#_P4GAU9=0U.7[?
MKM[\]S=OR03U53V'\\?0`^'_`(*7P[')J&J3?;]=O#ONKMN2"?X5/8?S_(#H
M-2O5$,T4$ZB=5R<,,KZX[9'I6QYY'KMU<II\ATS:\P.QF`W>7^&1^>>.O:DT
MC3F79=ZC#&;P*$W?>(`[Y_R<8R31H6E-9&6:5WS*Q81[RP7/N>3Z\^OUJ'QC
MXIL?"VDM>7S;G;Y885/S2OZ#^I["@`\8^*=/\*Z8;R^?<[?+#"I^>5O0?U/0
M5RO@[PM?Z[JJ^+/&:9N&YL[!A\MLO8D'OW_4\X`7P?X7O]?U5?%GC--UPW-E
M8D';;+U!(]>_/U/.`/1L4``&*6BB@`->/_LP1I_PB^M2[5\PZHZ%L<D!$(&?
M3D_G7L%>0_LO_P#(HZU_V%Y/_1<=`'KU%%%`!1110!YQ^T7_`,DGU/\`ZZP?
M^C5KL/!G_(GZ)_UX6_\`Z+6N/_:+_P"23ZG_`-=8/_1JUV'@S_D3]$_Z\+?_
M`-%K0!F_%G_DFGB/_KPE_P#0:N?#_P#Y$/P[_P!@RU_]%+5/XL_\DT\1_P#7
MA+_Z#5SX?_\`(A^'?^P9:_\`HI:`-VBBB@`HHHH`\W^-?_'G!_UZ3_\`HZVK
MOM)_Y!=K_P!<D_D*X#XU_P#'G!_UZ3_^CK:N_P!)_P"07:_]<D_D*S7\3Y'H
MS_W&'^*7Y1+5%%%:'G#)O]4WTKY]\(>`+?Q?J5E=7.H3V_V1962-`"I*R+Z^
MN_\`05]!R_ZMOI7EGP8.&!_Z9W'_`*'%6,TG-)]G^AZ5!M8.JUWC_P"W'H\=
MAD*MU*TRIC"[0J\>H'7\:O``=*@2YAD<HDJ,R\%0P)%3UJK=#S;W.6^(B^(V
MTRU_X12R@O+I;A7D6:4(%0`\@D]<XKD_MWQ9\D1#PQI"@="+M<CWSNKU0U2D
MU2S20JTAX.TD*2`?3-9RC!.\C.2C>\CR[]G.:>Y3Q5-=(L<[:EF5%.0&P<@'
MZUZ^*\D_9\B>WN/&,4HPPU9B1^=>MUHK6T+5K:!7D.F?\G/ZK_V"%_\`08J]
M7N+N.!E5MS.WW449)_"O/].\+ZNGQNO?%4MJ(]+N-/%NKF12P<!!@J#G^$T7
M*L>CUY5^T3JNJZ9H>C)HM])9RW5^(6*-@,"IP&]1G!KU6N?\7^$--\6+8+JW
MFE+"X%S&L;!0S`8PW!X^F*'J@6AY-_PK+XK=O%FE_P#?Z3_XU6I8>$OC586J
M6UKXPT5(4SM#1ACR23R8"3R37JTGVBTS)YC3PCEU8#<H]01U^G6KL;!T5E.0
M1D'UJ8QBME8J4I/=G`?!OP3K/@RSU9=>NK2YN-0NOM&ZV+$9QSG*KCGT%>@T
M459`4444`%%%%`'C_P`4_P#D8M:_[%V\_P#13UZEH'_("T[_`*]HO_017EOQ
M3_Y&+6O^Q=O/_13UZEH'_("T[_KVB_\`016%/[7J>CC]J7^!?J7J***W/."D
M8X%+5#6M6L]'TZ2\OI"D28``&6=CT51W)/`%`'G6KG6O`?BN34HY)]3T[5KC
ME&?)+,21%SPI'.PC`(^4XX-<CXG\0WWBS4D>5':(L8[:TC.=V>"H(Z^C..OW
M5XR2>)_$%[XKU-9)49HBQBM;6,YW9X*@CKZ,_?E5XR3Z3\._`R:'&-0U)4DU
M*5>`!\L"_P!U1^GZ"L93;?)#?\CU,/AX4J?UG$[=%_-_P.['?#WP0NBH-0U1
M4EU.10!@?+`N.%4=.G'\J[8#`I:*TA!05D<6(Q$\1/VE1_Y+R7D%%%%48!11
M10`4444`%%%%`!1110`4444`%%%%`"&L?Q-X>MM>LA'(3#<PG?;W"</"_8C_
M``K9H-5&;@^:.XFDU9G">&]>NM)O6T37U$4T0R&'",O]]/\`9]1_#].G=*RL
MH(((-8GBWPU:>)M/6"X9X9X6$EO/&VUXG'0Y]/4=ZP/#>OW.DWS:)KZB.:(;
M@P^XR_WT_P!GU'\/TZ;2BJB<X+U7ZKR)3Y=&=RW(Q7FGC+PE>:%JJ^*?"2A+
MB+)GMPN0ZG[V!Z'N/Q%>EH01QTZTI&>M<<X*:U.W#8F6&E=:I[I[->9S_@WQ
M39>*-.%Q;$1SQX6>`GYHV_P]#5]=(M%U#[8J?/R=IY&XG)/UKA?&7A>\T#4S
MXH\)GRY8_FN;8?==>YQW'J/Q'-9L_P`?_#MHODW.FZH+P*-RJD9CW8[-OSC/
M?'X5,)N_)+?\S;%8:"BL10=X/[T^S_1]3T#Q?XHL?"VE/>7SY<_+#"OWY7_N
M@?S/:N5\'>%K_7=53Q9XS7=<'#6-DP^6V7J"1Z]#Z]SS@`\&^%[[7]53Q;XQ
M4-.V'L;(_<MTZJ2/7I_,\X`]''%;'G@*6D)Q1N%`"T4F12@YH`*\A_9?_P"1
M1UK_`+"\G_HN.O7J\A_9?_Y%'6O^PO)_Z+CH`]=/>N6.MZ_(7^SZ8&6-968F
M,C!`^5/F9<G/&1D'VKJJ*`.9N=:U>VMU,MEMG6)W*B%GWN$#!!M)`.3U+8XQ
MFMC0;N:_TBVNKJ)H9I5RR,FPJ<^F3C\ZO44`><?M%_\`))]3_P"NL'_HU:[#
MP9_R)^B?]>%O_P"BUKC_`-HO_DD^I_\`76#_`-&K78>#/^1/T3_KPM__`$6M
M`&9\6?\`DFOB+_KPE_\`0:N?#\C_`(07P\N1D:9;`CT_=+6S<6\5S$\5Q&DL
M3C#(ZAE8>A!ZU`VG6P0"*)8"H`5HAM*@=,8I._0>A<HJI9S.'>WN.9$Y#`8#
MJ>_^-6Z$[@T%%%%,1YM\;!FS@YQ_HLW_`*.MJ[_2?^07:_\`7)/Y"N!^-?\`
MQYP?]>D__HZVKOM)_P"07:_]<D_D*S7\3Y'H3_W&'^*7Y1+5%%%:'GC)N(F^
ME>"^#?%6F:-ML+FZ:&\N(IMB"-FR#(G<#'1'_+Z5[W+_`*MOI7BWPYT.SU>V
M8365O-.(IPKR1*S8$D?&3[%A^)]:Y:Z;=EV?Z'?#7`5[=X_^W'17'CS0O)B:
M`R0&$[S(8ST"D]O?%9_B']H#PIIR0G24N-7=R=ZHC0B,#U+@9S[>E=,_A;2K
MC[/%!HRQ&-N3)$"JC;CC-7=0^'_A+4(U2Y\.::54[AY=NL9S]5QFIPJFK\YX
MV'4M>8YVS^-W@J6PMI[Z^GM)IHP[1-:3-L/==P3!P<C(XXJH?BIX'>-HX=?N
M?LZ$2$"PF)3#9Z[.F<=:[6'PAH-M;QP0:7!'%"H1$1<``5AZEI^FV^EW<ZV5
MANVE#;2P[SU[@_GTHKS<5>:T7GT"M/EUDM#G?V>;]-5/BR^BQY=QJ7F*0",@
M@X/->MYKP'X8>%M8U:_\2G0_%%SX>AAO]K0VULC*Y(SG&1C'3`KMS\/_`!?@
M_P#%R]3/_;FG_P`573!IP31T0:<4UL=I:W"(B7#J[R7(WDJN<+V'T`J]%()(
MPQ4KGLPYKQG_`(5[XD$<3MXM=1*H90;.'.#Z\<5J?#OP!K^A^.VUW4=434+)
M[-X%+#8ZL2O\`&`/E-3!N]C>4=+GJZ]*Y3XB^.K/P-8V5WJ%N\T-U.8<H<;#
MM+9Z'/3'XUU8Z5Y#^TLJOI7AM'4,K:L@((R"-IK5ZF2T*J?'KPZ'WN;M^2=N
M,`^WW>E/\-?M`^&Y)Q9ZG:7.G6R*VRX.90<'@%5&>G>O2CX/\,X_Y%S2/_`&
M+_XFJ5E\.O!]E<//!X;T[S)`0V^$..3GHV0/PJ(Q<=W<TG/FZ6,7_A>/P^_Z
M#;_^`<__`,11_P`+Q^'W_0;?_P``Y_\`XBNI_P"$.\,?]"YI'_@#%_\`$T?\
M(=X8_P"A<TC_`,`8O_B:LS.6_P"%X_#[_H-O_P"`<_\`\11_PO'X??\`0;?_
M`,`Y_P#XBNI_X0[PQ_T+FD?^`,7_`,31_P`(=X8_Z%S2/_`&+_XF@#EO^%X_
M#[_H-O\`^`<__P`12?\`"\/A_P#]!I__``#F_P#B*ZK_`(0[PQ_T+FD?^`,7
M_P`32?\`"'^&/^A<TC_P!B_^)H`\A\5^+-"\3ZS?W6EZ@&M;K2+BQ29X9%`E
M=&49&W=C)'.*T[+XJZI9V4%LMOH3"&-8PQN;D9P,9_U'M47B_2=-M/COX0T^
MTTZTM[*XMG:6WB@58Y"!+RR@8/0=?2O51X9T'_H"Z=_X#)_A7/R5$WRM69Z[
MQ."JP@JT)7BDM&DM/DSRR_\`C1K=J$,&BZ5>[LY$%W*-OUWQK^F:F@^,.KR0
MH\EAHD#,,F.2ZN"R^QVPD?D37H6H>"/#5_L%QHEG\F=NR/R^O^[C/XU9B\+:
M!&BHNBZ?A0`,VR$X^N*=JW=?<_\`,GGR[^2?_@4?_D3S?_A;VJ_\^N@_^!5U
M_P#&*Y;Q#XFO_%>IK]L,<A'[N&VM&<HV[C:I8!N?XF(!(^48&2?=/^$9T+_H
M"Z=_X#)_A7EVN65M9?%2PCL[>&W0:D`%B0*`/)MSC`]V)_$U%1U8QNVOZ^9U
M82.7U:MHPEHF]9*VBOK9+L=?\//!*Z-&-1U0++JDB@8&-L"X^ZOX<?I7;`8H
M48I:Z(1459'CXC$3Q$W4J;_EY+R"BBBJ,`HHHH`****`"BBB@`HHHH`****`
M"BBB@`HHHH`****`#%8_B;P_;:]9".5FAN(3OM[B/AXG'0@_S%;%(13C)P?-
M$35U9G!>%_$EQI>K?\(YKBA+M`NT(I*E68*KK_LDD#'8^W3O0<C->7>(^/C/
M!_UXVG_I6*]2K:NE=26EU<F%]GT*&O#_`(DE_P#]>\G_`*":\X^!GBFWO(+G
MPTMO*MQ8+]H,I(*NK-T]01D5Z1KW_($O_P#KWD_]!-<1\%=&T^'P\-6AM42_
MN&:*6<9W.H;@'Z5QZ^T7H>M3_P!PJ?XH_E(]$'2LW4QJ/VB/["L9B:*1'+RE
M-C'&U@-IST/IUK3'2BM3S#F#9>('CF:2Y0&9RWDI.1L']U7VY&>><<5/'8ZT
M;&\BFOHP\L;+;E0V8<L<;FSEB`1R-O\`6M_`]*/PI=+`<_I&FZQ:21O=ZD;H
M*V#'DA2NS&><GKS@D_6N@%+13`*\A_9?_P"11UK_`+"\G_HN.O7J\A_9?_Y%
M'6O^PO)_Z+CH`W/B=\5['P!J=I87.FW%[+<0F?*.%"KN('7.3D&N]LYQ<VD-
MP%VB5%<`]LC-8WB7PCX<\1SPS:_I=M>R0J4C>48(4\D9&./\]ZV8C##$D<;(
MJ(`J@'H!TH'9DM,EE6)&>1@JKR2>U'FQ_P!]?SK(UG5]-M+V&/4+R&&-5,H5
MV`WL#Q^7/Z5,IJ*NV5&$I.R1B?%#0=0\;>"KS1M,2."2=HV22Y8H#M<-T`)[
M=ZZ7P[9RZ?H&G6,Y4RVMK%"Y0Y!94`./;BLZU\8Z+-(JM>P1AAG+RK^`ZUOQ
MR)(BO&RNC#(93D$4HSC+X7<<Z<X.TE8S?%&LKX?\/W^KR1&9+*%IFC4X+`#.
M`:\YN?C+9SE"FF:K"!R0MN_)]/N=*[#XK_\`)-O$7_7C+_Z#4VC^&-`GTBRE
MGT/3)9)($=W>TC+,2H)))')I3BY=;!3DHZM7.1TSXMZ/+=PB]M=3MXXU8&:2
MTE<MG'&%3_.*V+CXN>%HK>22)]1GD1"RQ+IMP"Y`X4$H`">G)`KH?^$2\.?]
M"_I7_@''_A0_A'PVRD'P_I7(QQ9Q_P"%.,7%;W%*2D[VL<5X>^-6E7[3_P!L
M:3J6D!`OEEK:2;S,YS]Q#C&!U]:U_P#A;'A+_GYO_P#P67/_`,16EIOP_P#"
M6G%S;>'K`>9C=YD0DZ?[V<=>U7?^$3\-_P#0OZ5_X!Q__$U9.AY=\2O&FC>(
MH8H]+>Z<K;RH3)9S1`$R0,.74#HC?E7K^D_\@NU_ZY)_(5YG\6=%TK3;>)].
MTRSM&:TG),$"(3B6W`Z#W/YFO3-)_P"09:_]<D_D*R5_:/T/1J6^HT[?S2_*
M):HHHK4\T;+_`*MOI7EOP6^^/^N=Q_Z'%7J4O^K;Z5Y;\%OOC_KG<?\`H<58
MR_B1^?Z'HT?]RJ^L?_;CU2BDI:V/."JFI6OVJQN85"AY8F0,1T)&*P_B#JGB
M32M,MY?".FVVI7CSB-H9VV_*0>1\R\Y`[UQ!\5_&3_H1=-_[_C_X[4R2DG%B
M:4E9B_L[Q+!_PED*2^<(]3*[\8S@'M7KF*\<_9H:>2U\4/=QB*=M2S(@/"M@
MY'YYKV2FE96!*RL9RG["QCF4^1DE),9VY['T^M6(KVU>;R8[B)Y<;MBN"V/7
M'6K!4&O(=+`'[3FJ*.`-)&!^$5%BF[GKXY%>0_M)_P#(,\,_]A=/_037KU>0
M_M)_\@SPS_V%T_\`033$>O"B@44`)FE!S7%_$N673=+.K#7]4TU(5\M8+)(F
M\YSTSO1L?7@`5=\"O=V_A1+K5M;&L3,&FDN%9&11_=!4`''3/<^E'F!T^:,U
MY_\`;?$2Z,GB]]2?R"HN6THQ+Y0MB<_>QNWA><YQGC%=!KFHSQ:OX<CMI2L-
M[=.L@`X=/(D8#\P#3MT`WP<TM)VI:0'D/CG_`).'\%?]>DG\I:]>KR'QS_R<
M/X*_Z])/Y2UZ]0`4444`%>0>)_\`DK-C_P!A,?\`HBVKU^O(/$__`"5FQ_["
M8_\`1%M6%?X/FOS/2RS_`'C_`+=E_P"DL]?%%`HK<\T****`"BBB@`HHHH`*
M***`"BBB@`HHHH`****`"BBB@`HHHH`*2EHH`\M\1G_B]$'_`%XV?_I6*]1K
MRWQ(/^+U0')_X\+3CM_Q]BO4ZWK;1]#.&[]2CKO_`"!+_P#Z]Y/_`$$US'P:
M_P"1&M_^NLG_`*%76ZC!]JL+BWSCSHVCSZ9&*\=\(Z5XI.CG^R_$<.FVL<TD
M:Q2``D@\MRIX-<,Y<LKGL8;V4\).E.HHOF3UOV?9,]JHKS2/P[\09$WQ^+H6
M4]"%!_\`9*8^@_$$.(U\5QO)U*A1P/?Y*3K-:\K_``(^I4O^?\/_`";_`"/3
MJ*\TC\-_$9ERWBB)#GIM!_\`9*=_PC/Q$_Z&N+_OD?\`Q%-56_LL?U&G_P`_
MX_\`DW^1Z317E<FE>/HVF4^*E+0G#!8Q_=!S]S_:I6TCQ\J%CXJ4D9R@C!88
M&>FSWJ?K"[,GZI1_Y_P_'_(]2XKR']F$X\(ZSG_H+2?^BXZN'2?'WE[O^$J!
M8'!01C=TSTV>E<[IF@>(_!-UINFZ3J\<"ZS>L/+"97S/+W%FR,X(4#BA5[Z*
M+&L'2>BKP_'_`"-7X[3/'J-@R*KE8#M1V8*6,B+D[2#W_2HO^%4^(_\`GYT/
M_OJZ_P#BJI_$S2->ABANO$-_;W3!5\OR4Q@">+(/'^T*]P]Z(4U-N4X]3JQ&
M,JX>%.EAZNB6MMKW9XW_`,*H\1_\_.A_]]77_P`72-\)O$#<M/H1(]3<_P#Q
M5>RYHJW1IO3E.3^T\8O^7K^\\%\2^!+_`,.Z6U[J?]F21NPB7[*9@P8]SN8C
M&`?TKV#P22?">EDDD_9DZGVK`^,__(HQ_P#7W'_)JW_`_P#R*.E_]>Z?RJ(P
MC&K[JMH=&(Q%7$8)2JR;:EU]"A\5_P#DFWB+_KQE_E6YH/\`R`]/_P"O:/\`
M]!%8?Q7_`.2;>(O^O&7_`-!K<T'_`)`>G_\`7M'_`.@BND\CH7J***!!1110
M!YQ\:?\`CT@_Z])__1MM7>Z3_P`@NU_ZXI_(5P7QI_X](/\`KTG_`/1MM7>Z
M3_R"[7_KBG\A62_B/T/1J?[C3_Q2_*):HHHK4\X;+_JV^E>,>`YI;?P[?RP2
M-'(EI=%70X(.^+D&O9IO]4WTKYY\.7?B4LFF:%HHO[2[AEBGGW8,0:10QZ]@
M$/\`P*N:LFW9=F>IA;?5:C>W-#]3W2Q,[VD5Q#)(WR_-%*<Y^AZ_CS6C!,D\
M2R)T8=#U'L:BL;9+6V6-,XZ\DGGVSVKSOQ+XE^(.E:]>6WA[P:FHZ>LFZ.X>
M3&_(!.!N'?-;*Z1YTFFW8]`U+_6V?_7<?^@FK@->/R>+_BE,5:?P!&IB.]-L
MHY;IS\_3DT[_`(3;XL?]$^@_[_?_`&="5FV9):L7]G3[WC#_`+"S?UKUZOGG
MP(?B=X-.J&T\$"Y_M*Y-R_FR@;"<\##=.:ZC_A-_BQW^'UN/^VW_`-E5E'KV
M:\ATS_DY[53_`-0E?_08JQ/^%R>.C_S*%IC_`'W_`,:;\+=3UC7OC7<ZUK6F
M#3Y+G3'0(F2ORF,<$_2I4XMV3*<))7:/>Z\A_:3_`.09X9_["Z?^@FO71R.*
M\T^.WA_5O$%AH2:-8R7CVNHK/*$(&U`#D\D51)Z8**K17L;R>60R2=E=<$_3
MU_"K(Y%(#+?6;$:R^D3R"*Y\H3*).!*I.#MSUP>OID>M<YI$%OJ&K^*K;2&0
M:?-$D1:+_5_:"C!]N.,X*9QWKI]8T/3-:B6+5;&"\1#N42H&VGU![5/IUA:Z
M;:):V%O%;6\8PL<2!57Z`4V!P\NN6LWPP%F)(QJ,MJ--^R[AO$^/+*[>O7GZ
M<UJZY%]GU;P?"3GRKIDS]+:05MC0=)&K'51IUJ-0*[?M/E+YF/\`>ZU:FM8)
MY(99HD>2!B\3,,E&(()'IP2/QIWZBMT1,.E+2`4M(9Y#XY_Y.'\%?]>DG\I:
M]>KR'QS_`,G#^"O^O23^4M>O4`%%%%`!7D'B?_DK-C_V$Q_Z(MJ]?KR#Q/\`
M\E9L?^PF/_1%M6%?X/FOS/2RS_>/^W9?^DL]?%%`HK<\T****`"BBB@`HI'8
M*"20`.22>E5!JM@P!6[B((R"&R"*`+E%4SJMB!DW46![U:1U=%="&5AD$'((
MH`=1110`4444`%%%%`!1110`4444`%%%%`'EOB3_`)+1!_UXVG_I6*]2KRWQ
M)_R6B#_KQM/_`$K%>I5O6VCZ&<-WZC6Z&O/_``)<)_99F,]M$\5Q/&(YSU&_
M[PYZ<5Z`V-IS7!>`IOLVE>5'<"WADN)Y'<C(W[^F?Z>U>?7MH*K;EU.HL;NQ
MM8G#7UNS.Q<A6``)[`9K/@\5:="K;TG+L<L1&2"?KZ5M:;,\]NS2<X)"OMV[
MQZXHCC%R3))AH_X%[$>M3*-1I>SDE\O^"9M3:7([?+_@BZ5J,&IVOVBV+%,E
M2&&"".U6Z;#&D:D1JJ@G.`,4^NF'-RKFW-XII>]N94^G71NI9K:>./S&W#,9
M)'R@8SG!^Z.U-_LZ^QQ<PA\Y+B-MQ/\`WU["M>BH]E$GV:,C^S[_`&\7,`?=
MN\P1-NST_O5RGC&WG@\5^#/M,B2,^IN0RJ0<^0_7)/;Z5Z%7#_$+_D;/`_\`
MV$Y/_1#TU32=RHP2DF8_QY9DT!64E2L3$$=OWT%=;::\PM809M*XC7.;\YZ=
M_DKDOC[_`,B\/^N+?^CH*ZVSO)A9P#[;<`>6O']G.>WKBHJ.S.A+W487BV\7
M4YH4DDM6$5I=R@6MV7PPC!!.`O0BMK3==9-/ME,VE9$2CYK\@]!U&RLCQ//)
M-<QAYY)L6-[C?;-%C]T/4<UKZ9>3+IUL!>W`Q$@P-/<XX'?'-<<'^]D[_P!:
M&TE^[B<A\5]1-[IMJOF6;*K$D6USYO=>HVC%=5X"U:&7PM9I'',RVT:PR,J9
MPP4$\=>XKE/BO.\NFVV^>6;#'[]LT6.5]1S6I\)E?^RRX4E#*5+`\#]VG7_Z
MU7&;5:RZG>X)Y?=])?YFM\4Y8Y?AGXA:-PZFPE(*G(/%;V@_\@/3_P#KVC_]
M!%<K\5MMKX&U\`A4N+&;Y<X&\+U'U'\JZG0#_P`22P'_`$[1_P#H(KO1XS6A
M?HHHIDA1110!YQ\:?^/2#_KTG_\`1MM7>Z3_`,@NU_ZXI_(5P7QI_P"/2#_K
MTG_]&VU=[I/_`""[7_KBG\A62_B/T/1J?[C3_P`4ORB6J***U/.&R_ZMOI7E
MOP7&7&?^>=Q_Z'%7J4O^K;Z5Y;\%OOC_`*YW'_H<58R_B1^?Z'I4?]RJ^L?_
M`&X]4HQ116QYHA`-+BBB@`I",\4M%`&5;6Z/MMIF=7MQM"AL97^%O?@5HQ0I
M$@10=H]3FFSVT<^/,7+*?E8'!'T(KS?2]=U3_A?6H^'VO97TR+35F6!CD!\1
MG/\`X\>G7O4*-F4Y-H].`Q2.0%);`'O0!@8KR3]I.>[BT+0XK*ZEMFN-1$)9
M&(R"IZ@=1FJ>VA/J>DS75I>#R5<[MQ"N!]UAW!JY8RF:UC=B-V,-CID'!_45
MX@?@7XG/_,ZK_P"`[?\`Q5:>G_"WQW80I;P?$.XCMX\XCBC9<9R>/F]36<>?
M[5C2;A;W;GL5+7BDW@+XH0HSR?$%DC'4M(_'Z5B>+;'QOX<\//J3_$*ZN9XA
ME[=2P##(Y#=N#W%#JP3LW8YW5BM&SZ&%&*1?NBEK4T"BBB@#R'QS_P`G#^"O
M^O23^4M>O5Y#XXY_:'\%8_Y]9/Y2UZ\*`"BBB@`KR#Q/_P`E9L?^PF/_`$1;
M5Z_7D'B?_DK-C_V$Q_Z(MJPK_!\U^9Z66?[Q_P!NR_\`26>OBB@45N>:%%%%
M`!378*N2<#N3VH=U4$D@8&23VKF=0OGU>8VMF-T`4.PQG>N?O$=U]!U8^W4O
M8:'W=W+K5Q]FL\?9\`DL.&']YO\`9]!_%WXZSR>'-"MX3)=6R-W>65R2Q)Y)
M.?6F1)'IL0:.0!S\R3GG[1G^%\?Q?Y'I5ZQ/VUS<7(VR1G`A/_++Z^Y'?\JC
MF*Y;:E<^&-%*!DLD4GD,C,"/<'-103SZ/<_9[DEX')*.!U]2!V/J/Q'<"^V=
M/8E.;0GD?\\CZC_9_E].EBYMXKRW,<HWHW<'IZ$'L:I,FQ.CJZJR,&4C(([T
MZN9^WOH-]%9W>Z9)V41E0.0TJ1[O08:5-P]\CN*Z51@<TQ"T444`%%%%`!11
M10`4444`%%%%`'EOB3_DM$'_`%XVG_I6*]2KRSQ(R_\`"ZH%R-WV"T./;[6*
M]2K>L](^A$=V(V=IKSOP(DZ:+(L=[/:^9=3L(HH5DW#?][)!->B$<5X-IGQ:
M\/\`AEKC3M3CU5;VVN)5W6D,31E2V?XF!)_"N"M!SLE^J%4BY1LCUZWM;^YC
MW1:Y-CH1]GC!!]",5"/#ETHP-<O![#`%>>VG[0?@VVC*K9ZZ[,VYF:"+)/\`
MW\J;_AHOP>?^7#6_^_$7_P`<J?JT)+WK_>_\S/V$6O>O][_S/2M-MKW3K=DE
MN#?#<6#.</CT]ZT8I5E0.AX/J*\KE^/WA5=A59]KJ&`=3N7/8[00#^-55_:!
M\)6\KL]OJ$HD(8"WB4@'H<[F7]*JG*,7R1O]S_,J$DGRJ_X_F>Q56U.=[;3[
MF>/&^*)G&?4`FO*O^&C/!W_/AK?_`'XB_P#CE07W[07A&]LY[:.SUA'FC:,,
M\$04$C&3^\Z<UM*_*[&\=U<],TC4KJZTZWNF\J?=$C2K&"&5BH)P._7I7.^/
M)%F\4^!70Y5M2D(/_;!ZZ#PA%C0K*=)/,CGMH9$.>WEC]*\W^)OC/2=%\?Z#
M9732;M-NVOIL*H55:%AM!)'S$GV'/6IA?E5]S227/[II_'W_`)%X?]<6_P#1
MT%=99'4/L<.TZMC8N,?9<=/>O+_'/Q`T7QC8^5I?F*]NJEDF,9W!IX>FQF].
M<XZUZLOA'2@`!]K`'87DO_Q51-2;O$:<4DF8'B<W/VB,W1N_^/&]Q]H\G'^J
M'3R_ZUK:6=1_LVVVG5<>4N-OV7&,#IGFII?!FCRD&2.Y?`(^:[E/!ZC[W>M"
M+0]/BC6-;?`48'SMT_.L(4:BFY/\RY5(<BBCS#XQSWT-OHZRM=A9KAXR+D0$
M$;">-G0Y`_SFNY^'NEV=GX3L3:Q&'SXUFDVNPW.0`3U]A7'_`!QTN&VT[1;F
M!!&JWQC(R223$Y'7_=/Z?AJ:9KVHZ=I>D6UG%:O"=.20M,^W#[@`.,G&,]NU
M:4XVJ6?8ZYRO@%;^;]"Y\7])L+CP#JUW<VR3S6%K)/;F7YQ&X'7!X/XUN^!Y
MI+GP9H5Q,VZ673K=W;&,DQJ3P*XGQOXC;4/!?B6PGF@\T:7-*(E`#[=S+NX8
M_+P,'@GT%=G\/S_Q0?AW_L&6W_HI:ZK6/,;?4W:***!!1110!YQ\:?\`CT@_
MZ])__1MM7>Z3_P`@NU_ZXI_(5P/QI_X](/\`KTG_`/1MM7?:3_R"[7_KBG\A
M62_B/T/1J?[C3_Q2_*):HHHK4\X;+_JV^E>6_!;[X_ZYW'_H<5>I2_ZMOI7E
MOP6^^/\`KG<?^AQ5C+^)'Y_H>E1_W*KZQ_\`;CU2BBBMCS0HHHH`****`"O(
M=,_Y.?U7_L$+_P"@Q5Z]7D.F?\G/ZK_V"%_]!BH`]>KR3]HR*2XL?#$<*,[M
MJZ;549)^4]J];IKJC8W`''(SVH`9!/'.NZ)U8#K@]*E'(JA=>2[YAD5+E3M4
MCN<9VGU%6K:436Z28V[AD@]CZ4DQM$6HVS75ML4KD,&PPR#@]#7E/Q\1[3PM
M+/-%$@DC,(6+W88/ZUZW=2^3;22XSL4MCUQ7E7QL$DW@FYENYUE+INCC\GA!
MZAO7('O7%BU'2_=?F<>(47:_E^9ZP#TIU<KX2=KVWN0TTHFBN)0)!(2<>8V`
M0>.WY5T-E.\F^.;`ECQNQW!Z,/K_`$-=4)\Z3.Z<'!V99K+\1Z_8>'=+FU#4
MY?*AC&`/XG;LJCN:/$NNV/AW2Y=1U*81P1C@#[SMV51W-<+X>T._\=ZM%XF\
M61-%I\;;M.TX_=*]G<=^WU^F!6A`WPGX?U'QAXMM?'?B!7LEM5(TRU3&3&0P
MR_M\Q/8DG/`QGU`#`I`H7H`.U+0`44F?>B@!:\@\3_\`)6;'_L)C_P!$6U>O
MUX[XMEC@^*EI+,ZQQIJ0+,QP%'V>VY)K"O\`!]WYGI99_O'_`&[+_P!)9[$*
M*S1XAT7_`*#&G_\`@2G^-'_"0Z)_T&-/_P#`E/\`&MSS32IKMMK.;Q#HN.-8
MT_\`\"4_QK.O]1;5"MK8.KP2?\M`^!+[!A_#ZD=>@[F@+":OJ+WTWV/3P75@
M2=IP9`.#@]D!X)[G@=S2VL$-C")5E4$\I=;<`GO&P[#L!VQZ]7PPVUK;.\A*
M*I!DD(`>!P,#I_#Z=L'TIJPR7,AFN(@W&XVV,+,,?ZP#^][=N_8UDW<V45:X
M1QF\!EN$>.&-MWV<'YHF_P">G_UOZ\5%J6HR6\I6W<?:<8DD0`JZXR#@D#?C
MGG@#D\8HO+TAA%:3%GC'_'R"-R*>J,#U;Z].I]\Z&V2[E6..(%(2)"=N[RP?
MXR#SZD#J>I["FEH2W?8Z31+\:G;,DR9D55+_`"D*RL,@X/3CJIY'Y$S(QL)4
MA=B\$AVQD\E#_=/J/0U0A"Z<`(<"7J.<B[![Y_O_`.>G2[8C[4?M<QW/RH3I
MY7J,>OJ:=[L5K(P/&W_(<T?_`(#_`.EUC785R'B5)=2UW3OL49F^SLJO@@<"
MZMI&;GL%A;)]<`9.<=<M60+1110`4444`%%%%`!1110`4G>EHH`\K\21I_PN
MR"3:-XT^T4'V^UBO4Q7EWB3_`)+/!_UXVG_I6*]1K:JK*/H1%[@>E8Z>&=`G
M42SZ)ILDC\L[VD9)/N2*V&Z4RW_U"?2L33H9G_"*>'/^@!I7_@''_A2'PIX<
M_P"@!I7_`(!Q_P"%;%)0(R!X4\.?]`#2O_`./_"E_P"$4\.?]`#2O_`./_"M
M<44`9'_"*>'/^@!I7_@''_A2?\(GX<_Z`&E?^`<?^%;%&:`&1QI!"L4*+''&
MH5$48"@=``.@K-OM$T2]N1-J.F6%S._R[Y[='8X[9(S6H>E9.JZ!9ZI?V5[<
MF7S;)MT>U\`G(/([]!2=^A4%%OWG9'(>._AHFM75A)X?&FZ0L*NEP%M<&4%X
MG'W,<@Q=\]37<M/<6PWW(22(=7C!!7W(.>/QK,\4>,="\*O:IKUX;4W>XQ8@
MDDR%*@YV*<<NO7'6JDOC;2&=PFHVOED@#<KDX[]J4FENQQBV=4K;AD8(-0W5
MR(-JA3)(YPJ#J?\`ZWO61I/B+1C9*/[6LE`+!0\ZJ=NXXR"<],55OO%6CVUY
M,ZZG:O)M54(;>H'?E<]^WM2<K*XE&[L97Q8T6_UCPPDHN((/[/G%Z4V,VX*C
MK@'/7Y_2F"QM%^'":K,[Q36VE$HYE*JA"$@XZ=>/<<4WQ?XWT-O#5[;RZC$T
MUTA@@2.*0EG*GCIQT//2NC\'113^#-.BGC22*2U561P"&!'(([UFFO::=CT)
M)K`V?\WZ'':GIEK>_!RZU.SA^U:E>Z(`TJ#>[DH"4&.V[/RCI77>!9E@\'Z#
M:3!HIX]/MT9)%*D$1J".:L#4[#3[RVL(VAB@8+#"D2'"MV7C@#BK]X]H5,5R
MR8(SAC^M:\R?4X.1JUUN6@<BEJIISL8WB=MYB;`;^\I&03[X-6Z:(>@4444P
M/-_C5_QZ0?\`7I/_`.C;:N^TG_D%VO\`UQ3^0K@?C0?]$@_Z])__`$;;5WVD
M_P#(,M?^N*?R%9+^(_3_`#/1J?[C3_Q2_*):HHHK4\X9-_JF^E?/OA.+QW)/
M%_PA,]A$GDR[_M0'7S%W=C_L?K7T'+_JV^E>6_!;[X_ZYW'_`*'%6,OXD?G^
MAZ5'_<JOK'_VXJ_9?CC_`,_V@_\`?*__`!-8'C'0OC;J4%N&O(W\MC\NEW:V
M[<CJQ^3(_'OTKWVDQ6QYIXUIMI\<DT^W7[;I"E8U!$^UI!Q_$0I!/KR:L?9O
MCE_S_:#_`-\K_P#$UZZ!BEH`\A^S?'+_`)_M!_[Y7_XFC[-\<O\`G^T'_OE?
M_B:]>HH`\A^R_''_`)_M!_[Y7_XFL7X<+X@3X_7Z^+I+>351I9\QK?[A'[O;
MC@=L5[Q7D.F?\G/ZK_V"%_\`08J`/7JXCXKCQC_9]@W@2-IKM;@F=!(B`Q["
M.2Y'?'0UV])CG-#5P6AX'&/C=&04T6,$9Q_I$'_QRJ/AG2_C9H&L/J"Z?<7Z
MN&!M;W44DA^8YR%\W@@],5]%T5$81CL7*<I;GC[^(_C5(C(_@C2"K#!'GK_\
M?KGM?T_XM^(M-ETW4O#,,=I*N-L5S$=G'&,RU]`T42IQG\2,90C+='/>!["]
MM?#]M)J]LMMJ4P:6XB5P1&S,6*C!((&?6LGX@W_C;3[RSD\$:':ZKOC87!N)
M%4)R-H&77/?UKMZ0#FFHI*R-&VW=GF'AKPQXD\5ZNNL_$FSBM?L;;;73(W5H
MB>#O.&88]B<DCGC%>GJ,*````,8%+15""BBB@#RSX^6OBV?2K";PG-=PP6IF
MGOWMKD0%45002=P)&-_`S].E9_@OPIK/B;08M2_X2_5+8NS+Y?FR/C!QUWBO
M5]7M(K[2;RTN`3%<0/$X!P=K*0?YUP7PG@NI/!\!@>X5?,D'R2*HSN/8@US5
M4I3BGY_H>Q@JLJ.%JU*=KWCJTG_-W3%/PUU@?\SQJG_?4G_QRBQ^%&S5H;W4
M]>NM0\M][*^Y68X`^_O)'`7IZ"NVL(W2\G0W,TZ(J@^80<-UQP/3'YUI52H0
MWM^)G+-,4TX\RU5M(Q6_R,$>#]'[Q77_`('S_P#Q='_"'Z-_SRN__`^X_P#B
MZWJ*W/+.:OO!6ESVS)`;J&0D%6-Y.Z\'."I?D'H1Z$U)%#'8V\JLH&U1Y\?L
M.CIZ8[`?SK=N/,\A_)"F3:=H;H3VS7.V4%[J-P\>K0/'-9R%H)AC:<],\8/T
MZ?C4M76A46EN/B22ZFBGE8=/]'+#Y9AZ/_M>GIU]14%[=<&VMB4VG<Q/#6S#
MJH/3D9]@.3QBEU"[(:6VC`CD8XG`^ZC8SN0]F[^W4^]"&-[J1;>``;AD&0G!
M/7YB1R3U`/+?>/``J$K:LN3OH@AB>[E\BV7=@;R.Y7.=W/7/4`]3@MQ@5KJ(
M;&W1HW(&3Y,^,L['JC]R2?7^=`^SV%OG#K$'Y).98I3WSWS_`%]*$@D>Y>6Y
MB5IV&3;_`,+ITW+_`+7K^`]#2;NQQ2ZBQ1B7S)+E60@Y:)3S;G^\OKGO_P#K
M%0S7$T]T+>T(:5LJ[H<+*!_$?3'<_@/9D]Q)=31V]D6F;^"7)5BG=6]@>IZY
MX'.<;FF:?%8P;5^:1L;WQC..P]`.P[5:1$I!IFGQV$>%.Z1^7?&,^@`[`=AV
MJ[115D!1110`4444`%%%%`!1110`F:BN;B&V@>:>18XXP69V.`H'<FBZN(K6
M!Y[B18XHU+,['`4>I-><WES>_$#4!;V@>'0HVW#.0;H@XW-T^3.<#N1]2NM*
MESWE)V2W?]=2)2MHMRM9K/XJ^(8U[3H"+%(H8$>3(+K','+@=@>0/4_CCU0=
M.*H6%I::19")-D2#JQPN3_GC'I4PO[;C,H4'HS`@'\3Q2JU%.6FB6PXQ:0:L
M+@Z7=BRS]I,+^5C'W]IV]>.N*\%\+1?%BZU34[OP]?*U@\AC#:C<"2,,AP0B
MG)7!SV`->YZWK%GHVFR7M]*J1(,]>OTKE?@K>0ZCX.DN[<DQ2WUPR$C&1OX.
M*R-+:"^`1X]BU.9/'-UI\L#PDP+:J,A@PR2<#L:W?&NL2:1X<U"XM'5;N.!F
MB+#(5CP&QT."0<=ZU+RW:0(\3`2Q'<A/0^H-<I\12USX5OSLDCE$.WRBA.[Y
MA]T]*SJ2:B[%4XJ4DF0?!'Q/J?B[P8=3UJ2.6Y^U21;D0(-H"XX'U-=W7S]\
M$_AUH7B[P8=2U8WBW`N7AQ;7!A3:JJ!\J\9]3U/4UW?_``I+PE_?U7_P.>M3
M-GHIZ5Y5\"/%WB;QC;W]]X@N;>6U1O)@6.((V\8+$X[89?UK0_X4EX2_OZK_
M`.!SUSW[,L3R?#VZEB($L>J2E<]"/*BRI]C_`$%)C1Z3XTU.ZTW0;EM,D1=0
M=0MN7&5#,P4$]N"U>=^&?$/Q!\06#W-E>:?MA?RI#*JI\V`?3WKM_&3&ZTI3
MMDBE26',3(3N_>IT/0XQVKD?@Y;/-I%U*D4,@CO&RLG&<HOM7#5G)U5%;'L8
M5PHX.K74%*2Y=U?=F+XV\._$767MYY[*+5'2-XE%M/'&JHV-P;<5R&P..0=M
M;<'P9C>"-I;ZSC=E!9/[+A.TXY&>]>EZ;:M;I)O"(';<$3[J_2F:WJ]OHUE]
MKNPQCW!?E(SD_4@?K6T:,6KN]_5F"S7$22Y5&/DHQ_5,\Y_X4O;_`/01L_\`
MP4Q4O_"EX/\`H(V?_@JBKNF\36>YA!%-<!)1#(8MI\LD9RV2..OY&KVEZI:Z
MK;?:+&59H<XWJ<@G`/\`6K]C#^FQ?VGB>Z_\!C_D>/\`C#X=CPIH,^JV]_;N
MZ%8]L=A'$2'.T_,.1P:]*\-PB30=+M`Q\E+2*23GELCA?IUS6'\:KF67P!J"
M:;$UW<1O$Y2-2V`'!.2.!QFJ.@?#^>[T6QNSXDUBW:>VBD,2RD!,J#M_#.*R
MY)0GS05U;N=KQ-/%854\14Y9*3?P]+*VR7F:'QB'D^$5EMV:"5)U"20ML=.&
M^ZPY%<EI/AOQOJ^G0:A;ZL3'<(&4O=/NQVS6AX[\#-I7A'4]2EU_4[W[%;O.
M(9Y-RL5'&:Z;P#?WT7@O1@=*GD#VD<@973!W*&XR?>N:K3YJG-5NEY?\`VIX
MFCA<.H8=QG.^K:Z?/S.;T[3/B%IE[):VVH6TTTD:R-Y\ADPH)`P6'%7+ZW^*
M364ZB>Q),;#$+*KGC^$D``^AS6]!K\$^N23^;:V[*GV3RY[A02X;+`;<\CC(
MK5BUM98UDBN-.>-QN5A=<$9`)^[ZD#ZU=&'NZ.5KZ'/5S%J6M*G?K[J/*_#%
ME\3](::",7;&4;P-0NTN#@<':2S8ZC(KHK4_%"YB\Q9M.7YF4AMN002#V]17
M5:EJ'DW$)FO;"SF\MBNZYP63@L<%>GR]?:K>F-=BUQ`;6X&]R7$Q.6+$GHN.
MIJE"7-O*Q+S'W?X5._\`A/*/'EIXR_L_S_$4UFT4<;+^ZQG:SIGL.ZI7L6CY
M_LJTW=?)3/Y"N"^+ES<#1S;W,4:F2!W4HY;A9(0>H']X?E7>Z1_R"[7_`*Y)
M_(5I134W>_S#&5O;8.G+E2]Z7PJRV1;HHHKK/%&R_P"K;Z5Y;\%OOC_KG<?^
MAQ5ZE+_JV^E>6_!;[X_ZYW'_`*'%6,OXD?G^AZ5'_<JOK'_VX]4HHHK8\T**
M**`"BBB@`KR'3/\`DY_5?^P0O_H,5>NDXKR+3/\`DY[53_U"5_\`08J`/7J,
MT`YKRG]HG5M4TK1-%_L?4KK3I;F_$+R6SLK%2IXXY/TH`]6HKQ"Q\$>*[Z[^
MS0?%36UF*&0)-97$65!`)&]QG!9>GJ*T?^%5^.<?\E3U/_OW)_\`':`/72?>
MC\:\R\.>`_%&AZ]97VL>/M1U6T23#6S;U5^#C=ER",]L5Z)=SBWAWE'8$[?E
M&2/>DQI7=D6<^]&?>O(?AWH5QXITVZN;[7=45X9S$"MP>0`#DY[\UU7_``KM
M/^A@UC_O_6$*LIKFC'3U/4K8&A0FZ=2K:2W]UG:9]Q1GW%<7_P`*\3_H8-8_
M[_UC>(M$TCPZ81J7B76@TISMCD+E$'61@.B#(RQX%5SU/Y?Q,OJ^%_Y_?^2L
M]-S[BC/N*XB#P#!/$LL'B359(W`976XR&!Z$&G_\*[3_`*&#6/\`O_1S5/Y?
MQ#ZOA?\`G]_Y*SI?$%[_`&=H.HWVSS/LMM+-LSC=M4G&>V<5R'PB^TOX'MT@
M"(OF2?O"<G[QZ#_$_G4\WPWAFB>.77=6>-U*LK3Y#`]0:T/AC:1V?A"WBBSM
M$DO7VD8?TJ;2E--JQK.6'I865*G/F;:>UMK_`.9T=O"L,851[DGJ3ZFI:**Z
M#R@HHHH`*,444`8.N:,LA>ZMX0[$EVCVY^;&-X'=A@<'AL`'L:IVTJG2YOL,
M(EF$9=[<L3YK8XD4]<DCGOGT(KJJP]8TMXW^VV.5D4[F1.I/]Y??U'\0]\&I
MDKH:=F5K'SKIH[R4;9R"(3(!M=?[K8_B]_R[BF7,\EW(MI9(2"<@'*M&0<$!
MAT7U/X#.>*5_K2;K>U4;);YPGE*>'8NJ[QW5<L-QX.3CK74Z9IT=A'A3ND;E
MWQC=_@!V%*,;;E2E<32[".PB*CYI&QO?&,^P]`.P[5=HHJR`HHHH`****`"B
MBB@`HHHS0`E174\5M;O-/*L448+.['`4#J2:+FXBMH))IY%CCC4L[L<!0.YK
MSB>[N_B'J"P68>'0HFSA@0;@@_>;N$!'`ZDCM@E=J5+GO*6D5N_ZZDRE;;<3
M49+KXBWPM8!)#H43AAR5-R0?O-C'R9S@=\?4KZ!I>GP:9:K#`F`!RV`"Q_S^
M5&EZ;!IUJL%L@4`<G&"Q_P`]!V%7&Y0CVI5:BEI%62",;;E.SC$Y^U3#<6.8
MP>BKVQ]>N:CUW5;/1["6ZOI$2-1DAB!FI-/F1-/C4_>B7RB.^X<8K*UCPO:Z
MWJEI?:K,\D%J-WV,D>4S`Y5F[G'ITZ9Z5ATT->NIS7A[0[GQ=?IK6NPO#I,;
M;[/3WR/-[B1U/1<\A>_4]A2_L]<?#F,`8`O+C_T8:]`2>(@>6ZLI.T;>1QVK
MYY^'FF_$5O#8D\-^*]-TG3GN)3';W$:E\[SEN8FX)]Z+J*U9$IZWD?1M5=3_
M`.0;=?\`7%__`$$UY1%X>^-$R!XO'6CNIZ%85(_]$4LOA7XT2QM')XUTED<%
M6'DKR#_VPI[@6_V8O^2:'_K^E_DM>JUQ7PO\+7'@/PJFE73K=.96F>2$Y4$@
M9QD`XX]*[*.19%#(<J>A%"=Q)ICCTXKS?]GWPWJWA?P7=6.O636=R^H23+&S
M*Q*&.,`\$]U/Y5Z313&-<?*>.U>0?"""UEL-2>\X$<VY&\PKM;'IWKV!ONGZ
M5\\^$;7QM-;2R>#]/TJY@28^8]X!O5\#IDCC&#7%B(.<X)>9Z5&+E@,0E_<_
M-GOFDR/+81-(220<$]2,\'\L5)>V5K?0&&]MXKB(D'9(H89'3@UY.+CXX`8%
MCH(`]U_^*H^U?''_`)\M!_,?_%5V)65CS(JR2/5HM.L8<^59P)G!.V,#.,X_
MF?SJ&YC3S%MH@(48;Y2O'RC``_'@?05YA]J^./\`SY:#^:__`!58FOZC\7XI
ME6^TRQE=XSG[+YA&W/?8_P#.IG+E5RX*[L>X6TUL2(H-H`!(4#``!Q5@8[5\
MVW&I_%F\MWM[2SEMI)/^6EL9@X[<%F(]LGI[5]!^'5NDT#3DU#?]K6VB$^\Y
M;S-@W9/<YS1":DKE5(<K,OXFVMQ>_#_7K:S@DN+B6RD2.*)"SN2.``.2:=X*
M<VGA/0[*\CDMKB*PMXV25"AW"-05Y[\=.M="352\N+?#13#?D9*@9^GY]JIL
MA*^AD1^#=(6XFN&B:2229YP6"_([')(P/U.31;^#=+B2$$7#^3@*#)M7`;=@
MHN%//?&?>M?3I'V/%(2QB;`8]2I&1GW[5<H3!K74R;[P_I]])')=P^;)%'Y2
M.W+!>0?SS5VTLXK0,MNOEQDY$8`"CZ"K-%,1YQ\:?^/2#_KTG_\`1MM7>Z3_
M`,@RU_ZY)_(5P/QI/^B0?]>D_P#Z-MJ[[2?^07:_]<4_D*Q7\1^AZ-3_`'&G
M_BE^42U1116QYPV7_5M]*\M^"WWQ_P!<[C_T.*O49O\`5-]*\+^'WB^V\-W<
M$5UINIW*RI+F6U@#QQ[I$&68D8`VG/ID5C+2HO1_H>E05\'5]8_^W'N]%-1@
MR!@<@C.:XG7_`(EVNB:O<:=+X<\27C0,%,UI8B2)L@'Y6W#/7TK:YYIW%%>=
M#XNV)&5\+>*6'J+%"/\`T95>3XV:1'>)9OX<\3_:I%+K"+%"[#N0OF9Q4J<7
MLR5*+V9Z;2$XKSG_`(7!9?\`0H^+_P#P6#_XND/Q?LCT\(^+_P`=,'_Q=44=
MR-U](3O9+=25`4X+D=3GL/I3(-!TJ#5#JD-A`E^R>6;D+^\*\<%NN.!^5>:K
M\3'\J%#H&M_NE"_\>ZJ2?4CS>M7_``-\2IO$'C>7PT='FL4AM6G+W.5E)!7C
M;D\?,><]JQA5C-VB[CYH27NRN>FUY!^TJ2-+\-$`L1JR$`=_E/%>O+TKR+]I
M/_D&>&?^PNG_`*":V$=_:F]O?$=M>3:7<64%O:3Q%IWB.YG>$C`1V[1MUQVK
M>'2@4M`$5S"DT+1N.#^A]15"YCF>W,-Y$TRCD2Q'!SZD=C]*U*1ONGZ4FKE1
ME9GGOP2C>+1M3CD4JZ7S*P/8A5S7H7:N&^$_^IU[_L*2_P!*W_$>N_V8(K.R
MB^V:K=Y%M;`XSCJ['^%!W/X#)-8X=6II'?FCYL9-OR_)"^(]=_LTPV=E#]KU
M6[R+:V!QG'5V/\*#J3^`R<"N*DOKK3C>S:<UIJ5^K@:I?W8/E3/GBUA`Z8R1
MW"]\DFI(XY9;B[MK6\DGN9G$>JZM&/G9^UK;#L1R/]D9.<Y(Z:VT:*PM;*'R
MHXB)8TAB3[L"JV\J#W)VG+'DUN><<SX<UV'0;<WM@)7\-,Y6YM6&9=&E[@C_
M`)Y=_P#9ZCY>GI$,J3PI+"ZO&X#*RG((/0@UQ/BCP[=:9>-KWAQ$$P7;<VK?
MZNXC[JP].N#_``D^F16;X=UV+0K?[;8>8_AIY-MS:L,RZ/*>N1_SRYS_`+.<
MCY3P`>EUSWP^_P"16@_ZZS?^C7K>BD2:)9(G5T<!E93D$'H0:P?A]_R*T'_7
M6;_T:]`T=#1110(****`"BDSGO2T`%!&:**`.*\86L$'B30Y(8D1Y9<NP&"Q
M^T6W6NUKD/&__(P^'_\`KH?_`$HMJZ^@`HHHH`****`"BBB@`HHI*`%-0W-Q
M';0O-.ZQQ1J6=V.`H'<T7,\5M`\T\BQQQJ69F.`H'>O-KJZU#X@:N+:V'E>'
MHCD9R&N6!^\W_3/C@=2?Q*ZTZ?-[TM(K=DMVT6XFJ:A/XVNW`D%IX=M3YCO*
M=@G`_C<]H^#@<9_,KUCK9:?9Q65FY0,`ZS*X19#CY06]#C`QTX`[5J6.DVMG
MIYLTB#PLNUPP!WC&.1TQCMTQQ7&:A9-X/_T>Y:23PO,Q$4@)+:8[<8/K"<_\
M!^E.K5Y[1CI%;+^NH1C;5[G7:#JIU"WQ/$8+A!\\98'OC/!/I]:@\6>);+PS
MIC7=\V6/$40/S2-Z#_&L35K^U\.:9]OU9TE<'%HL#G=,!G;_`)]#^%<QX$LE
M^(.M7'B#7KF*X2TD\N*Q!XC(Z;AZ>GJ?RKCJ3=^2&_Y'IX;#0Y/K&(T@OOD^
MR_5]!FD^*O$&G:S;Z_XE@FBTC4`4150!8\D;6(QGH._)!KTN^W:E81FSE62V
ME`+%#RZGIM/3W]^E6M2L+74[*2SO81-!(,,AKSJUN;[X:ZJMG?,]UX=N7_=2
MXRT!/8_Y]QWK-7H_%JOR.F4:>8K]U%1J+HMI+R\U^)Z#8:<EHN\XDG(P7QCC
M_/?J:\V^$6HP0>#K-Y;J.VFC>9`CH6W*7Z\=.E>IP3Q7-ND]NZRQ2*&5E.00
M>XKS/X..(/!5G''.887DGD=@N[#[^F2..IIUW[JM_7Y'SU=6TZ_UZ'96.N:3
M;1L&OT9G8LQ"D#/L*LGQ-I`'_'ZGY&K.FR/+`6F&[#$*Y3:7'KBDAB6Y)FE`
M9&^XO;'J?K22JI*S7W?\$2Y[+E:^[_@D5MK5K>*9+9)IT5BNY(R1D5/8R%WE
MVQ21QE@5WKCGOC_/>K,,4<2D1(J`G)"C&35?4YW@M6>(@-N502,@98#^M:+F
M2O-[&GO)7DRY16&+F_(WFZ@V<<!,M@G`.,T?:-0(W_:H-N>FSYL9QG&?6E[;
MR9/M5V-MONGZ5YQ\"/\`D!:E_P!?A_\`0%KK3<7^&;[5`4&>"GS$`X)QFN2^
M!97^PM2(X!O#C/\`N+4<_-5CIW/8PD^;!5_^W/S9WFKPW,^GS)8W$EM<%?W<
MD80D'_@0(_,5S\47B5-1F$LUY);"Y01D"V4&+G))QG'0G@'/3BNK'(I:ZCS3
M"DBU6VT=4%Q>7=X91F4"`.%W>A"IC'MG\:O7R$,LVSS%`*2H!G*'_#_&K]%)
MJXT[,K6BVS+YENJ;6[KWJP`!7G7Q\G;2_AOJ%Y8S-:79EA59(G*,<N,X([XS
M78>$':7PGHTDCEW>Q@9F8Y))C7))H2!NY4^(-O>W?@K6;;2UE>^EM'6!8CAB
MY'&#ZUX,_ACXJ1$"2]925SR><#_@-?3)P.M5+LVT1,DJJ7?```RS8.0`.]9U
M(<QI2GR,\0\+>'/C$IN?L?B"RL2=F_[6H??UQC,3>OMU%;O_``CWQP_Z'/0_
M^_"__(]>JV$3*CR2C$DK;F']WL!^`JS505E8B;YG<\A_X1[XX_\`0YZ'_P!^
M%_\`D>C_`(1[XX_]#GH?_?A?_D>O7J*LD^<_&1\=:;J\&G^-M;L]2$]E*\0M
M8E4*-\><D1H>JKZ]*^@M)_Y!=K_UQ3^0KQWX[_\`(X:5_P!@V?\`]&)7L6D_
M\@NU_P"N2?R%8K^*_1'I5/\`<:?^*7Y1+5%%%;'FC)O]4WTKQ7P4/^*7U+_K
MSN__`$**O:Y?]6WTKR?X16\-W"]O<H)(98;A74]""\5<]5<TK+JG^AZF&ERX
M2H_[T/U/1M-N?(TN,W!8,/E5<'<WH!GDU9M(V2$F3B21B[#T)[?A3X;."`[D
M3Y@,!F)8@>F32W<<DEI*D+[)'1E5O[I(X-:I6/-E*[;1CZ>9([&W^Q#<[1@R
MKV`]?K[=ZXW5UC3XNV4MLS&=='E:%ARQ?=Z=_?\`I60OPQ^(R#$?C\(/15<"
MJGA7P]KGAWXTZ-!XBUD:O/-87$B2X(VKR,<^]8JE*R1R*E*R3/7+*:5[M%BF
MGFC()D\U,!?3!P/RK6[4@I:VA'E5KFT(\JLSGSI4D<$EL+039:1DFW@;-Y.?
MYFO._#MO]E_:3U*'.XKI()/N1$3_`#KV/%>1Z9_R<]JO_8(7_P!!BJ*=&-/6
M),*2AJCUX5Y#^TG_`,@SPS_V%T_]!->O"O(?VD_^09X9_P"PNG_H)K8U/7A1
MF@5!<S>5A5&Z1^%7^I]J3=@2OL39I&/&,=JY[6-9L="G3^T+B2&:2-I5D,3,
MDFWDH,`\XY"CG`[X-<YKGBVY\3LNC>#'+F1-UU?1GY8D(^ZC="Q]>V?7I#FE
MN6H7>A1\$ZY_9D.LVEE#]LU6ZU286]J#C/3+L?X4'<_@.2*LQQRR375M:WCS
MW,S"/5=7C'SL_:UMAVQ^2@DGYLD5[OPG/X7CM-8\*3F2\B7;-;L<BX7OQZ_Y
MZUGZ5J-OIIBU:Q$T^@(62YM-Y$FF.QRV,8.PGOV^G3*C.WN2T9ZF84O:OZU2
M=XO?NGMKY=F>E:%HT.GVT/[I(?)3RXHD^Y`GH/4GNQZFG7^HV0U&RB:ZARKL
MY4."00I`X_&I+"TTF^M8KF"&"YC<;DD<;_U;)J0Q(-6B2-%58H'.`,`$LN/Y
M-72>0*=5M6!\LRR8_P"><3-_(5PGBBW.EZK_`&UH$;02F)FNH;@".&6$`DB0
M$Y`[`XX)[@D5W=]>-$RV]L@ENI!E$/0#^\WH!^O05Q-W%*WBN6UU>"6?R=DU
ME$$.R]D_ONW0!#P$[=>:!I7'^';F?07L&T^UN'T/5D\R/3WP)]/<C<0H)YC/
MIU4GCC@=+X(MYK3PY!#<Q-%*'E8HW49D8C]#5C2=.:!VNKMA+>S#]X^.%']U
M?0?SK3`Q2!V6B%HHKFO%WC*Q\,K&DZO<W<W^KMHAER/7V%*4E%79I2HSK34*
M:NSI"<5GR7DLJ/);[4@3/[UE+9QZ*.H]ZX6X^)\D\+Q)X;U(%QM!V^OX5/)X
M^NVMC"/"FJ(NW:-HQBLG7@]F=ZRO%+>/XK_,Z[PWJ$VHV]S).4)BNI85*+@%
M5;`/7K6M7D^B^/I]&BN+>;P]J+L]Q)-G801N.<'BNJ\*^/;+7[U[&2WFL+P#
M*Q3\%Q[5-*M%I*3U%B,MQ%/FGR^ZNUGI\CKJ*0&EKI/,./\`&_\`R,/A_P#Z
MZ'_THMJ["N9\:^%#XDEL)$O3:M9,S+Q)AB=I'W)$/!4'KCVX%9(\`ZE_T,3_
M`/DW_P#)-:PC3:]Z5OE?]29.2V1WE%<'_P`(#J7_`$,3_P#DU_\`)-'_``@.
MI?\`0Q/_`.37_P`DU7)1_F?W?\$GFGV_$[RBN#_X0'4O^AB?_P`FO_DFC_A`
M=2_Z&)__`":_^2:.2C_,_N_X(<T^WXG>4F:X3_A`=2_Z&)__`";_`/DFFCX?
M:B'+_P#"129(QUN\?^E-)QI?S/[O^""<^WXG?5#<W$5M#)-/(L<<8+,['`4>
MM<3_`,(#J7_0Q/\`^37_`,DU#=_#B\NXC%<ZZ)8\@E)$N74X]0UR15*%'K)_
M=_P0O/M^)5N[J\^(&H+;6H:+0HFS@Y!N2#]YNX3(X'4G\2._TO3H-.M%@MU`
M4`9..6.,?T_"DTG3H--M5@MUPH`R<8).,?Y':KP&*FI5Y[1CHELOZZE1C;?<
M3H*P_&7B#3]!T>6740L@E4HD!P3,2/NX]/6G>+/$EGX;TYKF[;=(V1#$/O2-
MZ"N:\*>'+W6]17Q+XL7=,WS6MH?NPKV)'K7)*3ORQW_(]+#8:/)]8Q&D%LNL
MGV7ZLJ^`/!<R[-6U98\>7_Q+[0L76T4DG')]Q@=JR/%'AG5_#&LMXH\*IMN$
M.+B!1^[G0GIM![^G;M7JWV)%),+R0@]D/'Y=*<EG&'$DC/*PZ;SG'T'04E3Y
M5IN16Q<JTFY;=%V79&-X(\6Z?XMTD7EB2DJ86>W<_/$_H1Z>A[UKZEI]MJEE
M+:7L2RP2KM96%<!XW\):CHVKGQ?X'79?IS=V0^Y=)U)V^OMWZCGKU'@CQ=8>
M+](%Y8-ME3Y9[=OOPOZ$>GH>]:VNK,XU)Q?-'<Y>+X>^(]/WV^C>*9+6R#$Q
M1$'*@^M5M)^&WB;1K,6>E^*/LEN&+^7&K`9)R3^=>B0ZK;2WAMU+=2JN5^1V
M'50>Y'^>AQ>%8^P@MK_>STWFN(>LE%^L8_Y'G/\`PA?C7_H<Y/R:FKX%\6KT
M\4)T_N-_C7I-%3+"TY?%K\V1+,JLMXQ_\`C_`)'G)\%^-``$\8,B@8`56`IK
M>"?&;C#^,&<>A5C7I%%/ZO!*VOWLK^TZUK<L?_`(_P"1YG_P@7B_S/,'BTA^
MN=AZ^M+_`,('XO\`,\S_`(2T[NN=ASGUKTNBCZM3\_O8?VG6_EC_`.`1_P`C
MS0^`_%V_>?%N6SG.P]?6L1_"?C'P-C5=$U6._M+9O-N=.12/.!&"Q'?`].>,
M\XQ7JVIZ@(`\$1/V@QEEPN0H]??Z5GZ!I=REW-?7UQ=,[DA$ED4_+[A3M]QC
M']*J%&$)<R,ZN85JM-TG9)VO:*6WHB3PAXGT_P`4:0E]ISDD866)OOQ/C[I_
MQZ'M6Y7F'C#PWJ'A36I/%W@Y2P)W:A8#[LBYR6`'XDCJ#R.X/9^#_%%AXKTF
M.^TZ3T$L+?>B;^Z?\>AK8X#<K-\1:[8>'=*FU'5)A%;Q#ZECV4#N31XCURP\
M.Z5+J.J3B&"(?4L>R@=R:\_\/Z)J'Q"U>'Q-XLA,.DQ'=IVFD\,.SN.^<?C]
M.H`>'M$O_B%J\7B7Q7"8=*A.=.TUNA':1QWS^OTZ^HJH48%``48`P*CNIX[6
M!YYY%BBC4L[N<!0.I)H`YGXL?\DV\1_]>,O\J3X9W5E=^$M.2#8;NSMH[2[&
M!O25$"L&_$'%<9?W5_\`%S5WT[3FEL_"-I)MNKD#:UVP_A7/;I].IYP!I:_X
M0N?!MRGB'P#;[1!&$O-,!.RXC'<#^]CG]>N058#TP=*P[OQ,EK=_9YM,O@3<
M"W5QY1#'&=P^?.W&.H!YZ4_PEXFT_P`4Z0E_ILF0>)(FX:)^ZL*T+K3K*[9&
MN[.WG:-_,0R1JVUQ_$,C@^],"G8ZY]LN881I]W$)49_,=HMJ;2`0V')SR.@/
M6M&UG6Y@6:,$*V<9Z\'%,M+*TLT"6EM#;HN<+$@4#)R<`>IYJ9$6-=J*%4=@
M,"@#Q;X[_P#(X:5_V#9__1B5[#I/_(+M?^N2?R%>/?'?_D<-*_[!L_\`Z,2O
M8=)_Y!=K_P!<D_D*Q7\5^AZ=7_<:?^*7Y1+5%%%;'F#9?]6WTKRSX,??'_7.
MX_\`0XJ]3E_U;?2OG_PCX\T;PFZ6VJ2S133PS"-D3*@NZ@$G/'W#6$W::?D_
MT/1I:8*L_./_`+<>^"XA+[!(A;TS4V:\@_X6CX<&FQ+OMDG&S=*)XR^X$;C@
M'IU[]ZDN_P!H'PG:VP,,6H7<P(!18@N?4Y)I4:WM>AX]*K[0]2N+R&!U1V;>
M1D*JECCUXKR?XBZ/)XH^)NAI8:G>Z<#83*+FT<Q2@JWS*#P>AJ23XY^"I)EG
M2?4H)2H5@+8,#['GWKGI_B?X=/C_`$N_BFN8[.VM9B\EQ`5;?*0P.!U&,'\:
M)NITV%-U/D=#+\,M0$):'X@^)Y'VEMOVUAC'KSQ7HWA*UEL/#&G6UU>2WLT<
M"A[B4DO(<=3DDY_&N!;XO^!XUD,&IRF64$2;H&P_'7VI+'XS>$KO[)HL$UXU
MS,T=H&6'Y220O#9Z>]%-RYK,JFVY:GHSWSR*7@"+`#CSI#P?H._Z5Y!X,OY=
M1_:.UB:X5%=;!XOD!`(4QJ#R3Z5[/=6PEM'A0A,K@<<#\*\#\`ZA9V7Q^U22
MYNK=$E2:U0[P`9=Z_+U_V2/KQUK35378Z[1<&^I]!CI7EW[0NE7VH:#I-U8V
MSSQ:=?K<W!7'R1@'G'U_^OQ7J*G(I'170JZAE88((R"*T,C*TC7K#6=,AOM*
MF6XCG'R8X(/<,.Q'<5-<V1D42+(5N%^829ZGT^E>=>(-$O?A]JDFN^'8Y)]$
MF;=>V*G_`%'^VGIC]!P>/NYD7Q3E\?:BGACPI%/9W,Q827DV%Q$.K*`>#BLI
MK>ZN:4]U9V+/Q"O+GQMJ=GX:T&.1KZW<F[N%8B&%>,Y[$@X((Y!Z=Z]$\-Z#
MI_A;24M;1%``&]]OS2-_GM4&B^&+/PUI21Z:=DT0W23.>9CWW'_.*U-/<7\2
M7;=#]Q>H7W_^O4Q>J4MRYVU<=A\-J#,;AXPLC=`.W_UZY#Q?X8NK.];Q!X:C
M7[5M(NK0CY+I.X(Z$UW0''6@CBKE34E8JAB9T)\T=5LT]FNQY)X=UQ=`5M2T
MD22>'W?%Y9L29--D^G]S/?MT/'3M9O$%DCW6H6UQ%(I@CPS-A$4;F+L>P&_Z
MYXZUE^+_``S<V=ZWB#PTB_:@"+JS(^2Z3N"/7^=8'AJ#0YF6:SG:1))?,BT%
MD`,<X`^^W5D7'R@\+^6)C.SY9[_F=%;"QG'V^&UCU76+[/R[,Z_PKKT5W<RP
M365W;W<Z^?%)<)@W470.,?='^R<$`CBNFCCP=S8+GOZ50TC3C`[W5XXFO91\
M[]D']U?0?SK4K8\]Z:(*1L=Z"<5R_CGQA#X=MEA@3[3J4_RP6Z\DD]R!V_G4
MRDH*[-:%">(FJ=-7;$\<>+X/#MN(;=?M.IW'RP6Z\DD]SCM_.J'@?P?/;73:
M]XC;[3J\_(#<B`'L/?\`E1X'\(3P7+:]XDD-SK%Q\PW\B`'L/?\`ETKN,5E&
M+F^>?R1WUZU/#0>&PSO?XI=_)>7Y@`/048'H*6BMSRA-H]!7,>-O",7B"!;B
MU;[+JEM\UO<)P<CH"1VKJ*0C-3**DK,VHUIT)JI3=FCC/!/BV6[G;1/$"?9=
M9MOE96X$P]179@@US'C?PC%X@@2YM7^RZI;?-!<)P<CH"?3^5<[I'Q+_`+/5
M],\265R-5M3ME$*;MPX^8CMU'YUBING[L_O/1GAHXQ>VPJUZQ[>:\OR/2J*\
MYL?C#H]W,\:V%[\O*E%5RPSUP#Q5W_A:.D_\^&I?^`YJO;T^YA_9F+7_`"[9
MW-%<-_PM'2?^?'4O_`<T?\+1TG_GQU+_`,!S3]M#N']F8O\`Y]L[FBN&_P"%
MHZ3_`,^.I?\`@.:/^%HZ3_SXZE_X#FCVT.X?V9B_^?;.YHKAO^%HZ3_SXZE_
MX#FC_A:.D_\`/CJ7_@.:/;0[A_9F+_Y]L[FBN&_X6CI/_/CJ7_@.:IZA\8-(
ML]G_`!+[YBV>'4)Q^)H]M3[C668M_P#+MGHAK%\5^)++PWIYN;MMTC<10C[T
MC>@KG)/BIIC6QD@T_4)&*[D'DX#<<<TSPKX<O=;U)?$OBI=TIYM;1AE85[$C
MUI.IS:4_^&-(8!T/WN,5HKIU;[+]6'A3PW>ZUJ0\3>*E+3,=UK:'[L*]CCUZ
M5VEY=^7')%;-&]T$W)&3UI+^\-L@$<>]CU.>$'JW?%9FDZ9?7-V]YK,D98,&
MC2.,IC:3C)+-D?EW[&KC%15D<>)Q,\1+FELM$NB78?X=M+]I9;_4)I?,GQ^[
MX"@`<#;V_//8YK>I%&!R<TM6<P&O/M7\#Q?\)[;ZGH]]-HWVF)A>"#A;G/8=
M@W<_F.<UZ#45S;QW,9249!].H/8@^M`&;;I$\7]E7T21NB_($&U74=&3T(].
MH_6IK2YDMYQ9WK99O]3-VE'H?1A^O4=\5M1ECAM)5U-F4VZ--'<)]X[03D>C
M8!X[CV)%<E\.OB5I/Q#:ZTL6D\%Q;()"9,`2#.-RX)((X/MZT`>C`\4M9UI<
MRV\JVE\=S'_4S=I1Z'T8?KU'MHYYH`****`"LK6M56S4QQ21K(0<N[86/C//
MOZ"KM[.((TR2IE<1J^,A20<$_C@?C65I.CS+*]QJ+[Y68YP>&`Z;O7].V>@H
M`?X>LG6&26[C8M++YH$F"5./_P!?/>MKI2=!7$_$/QP=%\O1]$B^VZ_>86&!
M!N\K/\3#^0]L]`:`.VX(KS#Q=X9U+PEJS^+/!<65.6O]/4?+(N<D@#\3@<@\
MCN#AI\4-6^'5W_8WCZTN+Z21!-!<1.K,5)YR3C(SGZ8Q7M$$J7-M'-'G9*@=
M<^A&:`/,/#FAZG\0=4B\2^+H&M],A.[3]+8_*?\`;<'KT[CGZ=?4E````P!0
MJA>E,GGCMXGEF=8XXU+.['`4#J2:`'MTKR74Y=5^*FMRZ58F?3_"ME+MNKC!
M1[IU/W1G_(ZGG`'I>FZUIVK645WIUY%<6\WW)$;AO\\TZ-5M]1VQ@*LZ%BHX
M&X8Y^N"/R%)OL.W<?I6FVFDZ?!8Z=;I;VT"[4C08`'^/O5HTHZ44Q'G'BWPS
MJ/AO5G\6^"T)E/S:AIR\)=+U+`#^+J?Y<YSU?@_Q1I_BO2DOM.DY&%FA;[\+
M?W2/Z]ZVVYKS+QUX>NO"=_/XV\);8C"C2ZE9#Y8[B,<LV!T.,D_F.<Y`/3LT
M5Q/PS^).F^/TO?L%I<VLMD(S(DVT@A\X((/^R:[8<T`>)_'C_D<=*_[!LW_H
MQ*]BTG_D%VO_`%R3^0KQ[X[_`/(X:5_V#9__`$8E>PZ3_P`@NU_ZY)_(5BOX
MK]#TZO\`N-/_`!2_*):HHHK8\P;+_JV^E>3?!^TMKEQ]IMXIOW=Q]]`W\<?K
M]:]98;E(]:\HU'3[WX=ZL+NU+RZ-,Y(<#+6S$\@^JGC_`/6`:PJ/EDIO8]3!
M1]O1J8>+]YV:7>U]/770],_LG3?^@?:_]^5_PK"\7_#[PWXKM(H-4T]$,#[H
MY;?$3KGJ,@=#@<>PK6T76[35+$3QR*N%#.-V0!Z@]U]_Y5;M;NVO[5+BSGCG
MAD&4DC8,K?0BME8\R47%\K1Y%<VL7C2^3PGX0LX[/P]I@6"\U'RP3(%X\M2>
M3T]>>IXZ^G:3X8T;2=.@LK/3K=8H5VKNC#,?4DGJ2><U/:VL5C>E+:)(XK@&
M0JB@`.,9/X@_I6CVHN*UBE_9.F]]/M?^_*_X4Y-+T]&#+8VP93D$1*"#^56Z
M*8`>:Y[Q7X.TCQ)IDMI<VT<,K'?'<1H`\;_WL]_<=ZZ&B@#SKPAXHU#0]57P
MGXS?;=#Y;*^<X6Z3H`2>_OZ\'GKZ+6'XP\+V'BK2FLKY-KK\T,Z_?B;U']1W
MKE_!GB;4-&UE/"/C`DW@^6QO>JW2#ISZX'7\#SU`/0955T*,H96&"",@BO'-
M:\$#X;^)3XO\-61N;%MPNK?JUNK')9#V'\NAX.1[,#FFN@=2KJ&5A@@]"*`.
M?TB^B\5V<-Y!,CZ<PSA&YD8=0P_AP>"IYS6^@"+M4``=A7E^MZ/?_#K5Y/$'
MAN)KC1)FS?:>O_+(?WU]`/TZ'C&.YTGQ'8:O8076E2?:EG7<JJ<%<<'=GH0>
M*A14=2FW+0VJ0]*J^9>!=WDP'_9$A_GBN/\`&_C.ZM)HM"\/6LDVOW@PB,O$
M"_WSV/MV[GWJXK#O'GC&>RNH_#_AJ/[;K]U\JJN"+8?WF]\<X/U/'7#N/A?=
M6>BQ7MAJ,LGB*%C</,6P)G/)4>G.<'OWZ\=5X#\&0>&;5Y[B3[9JUT=]U=OR
M68\D#/;/YUU53*"FK,WP^)J8:?/3=OU]>Z.&\"^.CK41T^]@\K6("4DB<[-V
M.IYY!]1@FNMDFNH5#N(""<;=Y7GT!(Y_2L3Q;X1@UB,7=CMLM6A;S(;E!@[O
M]K'4<5Q>I>/;^WMVT^]LY/[=A(A$0'RL_:0#OGTK!U'25I_?W_X)Z:P<<=+G
MPJMWCV\U_=_(ZSQ=XWMM%M##;(9]5E/EQV@Y8,>A(';I]:K>!_"$T%RVO>)&
M^TZQ<?-A^1`/0>_\J9X`\%O8RG6M?_?ZM/\`,`_/DY_K7=BJA%S?//Y(RKUZ
M>&@\-AG>_P`4N_DO+\Q`./2G445T'DA1110`4444`(>E<I?>"--EUZ]UV!KJ
M'4[U5266*?9\H"K@8'3"@X[D5UAZ5Q]EXV%[\0]4\'06&+G3[=+GSVE^5U(C
M)XQD$&0>N<'I4R2DK,J+<7=%/2?AYHWA^]CN=.C>VNI'$8,+;2RY!8''4';G
M%=SL7^Z/RJ""U99#+,_F2D8!`P%'H!5JE&"CL5.;D]6-\M/[H_*CRT_NC\J=
M15F=V-\M/[H_*CRT_NC\J=10%V-\M/[H_*CRT_NC\J=10%V-\M/[H_*O)OVB
M-!L=0T[0;J>-A-_:D-GO1B/W<F=P_P#'1S7K=><_'C_D`Z!_V'[/_P!GH'=G
M>6%C;V-G!9VT02"WC6*->NU5&`,GV%-U2:XMK&62SMS<3*I*Q@XR:N44K!<Y
MSPY87<LO]IZ@\T4DOS"W9R0N0,\'D9Z[>,'J,UT0`'2DDW>6VS&[!QGIFN!/
MB'QI'XFM='-MX?N'D.^?[-+,S6\.?OOD`#/0#N?:GN["\ST"BL3Q'J\^FK:V
MVGVZ7>HWSF.WB=]B#`RSL0"0H'7'M4?AS6+ZZNKG3=:M8;;4K15=A`Y:*5&Z
M.A(!QD$$$<$4`;]%<;>:]XH=;B_TO1;-M,M2^4NIWCN)PO5D7;M4<'&X\_C7
M4:3?1:GIEK?6^?*N8EE3/7##(_G1Y@+J-C;ZC92VEW&'AE4JPSC@^A[&N%\'
M_#G0/!][<1V<4\5U=@"&Z:4L<`YPO8-ZCN!Z9%>AU#=VT=W`T,RY4^AP0>Q!
M['WH`H(WVI3I^IH!,!E6'`D`Z.A[$<<=0?P)DM;B6VG6SOFW,?\`53$8$H]#
MZ,/3OU'<"NZ,SK8ZBY$H.;:Y7@DC^3#N.A&>V0)8R+M7L-30><!D,!@2`?QH
M>Q''N#^!H`TQ69K.JQV:/"D\4=TR'R_,^ZIQP6I]K<R6\PL[YMS-_JIL8$H]
M#Z-[=^H]I;G3K6YNH;F6,&6(_*V<?@?7GF@"'1GNKJS5[]5*M@H"F"1P02,]
M>O\`@*TJ3I69K5S<M')9:2Z+?NA*R.NY(<]&8?R'?]:`.9^(_CQ?#J#3-)`N
M];N1B.(<B$'^)OUP/;)X!-5?AGX;AT<3ZIKIDDUZY!FEGN1@A#UV$]O7H>G`
M&!7+>"+:'2/$]W#XFC+>)!,TRR73@)<ICHK'`!X+`]#C'&,#M[R2]NS]HD`>
MXD($,!!P`3UQCH,@\C)QD\`"@"CXH\&^&_B!KUO<ZV'5[6(QPHDI1IESG)'I
MUP.N"2>U>@PQI#"D40VQHH51GH`.*Y.RLI+T7$-M<A9E<B69"01G(.,=#GJ>
M,_2NCC2#3-//F2^7!;H6:260G:HY))8GB@"Q<31V\+S3R+%$BEG=C@*!U)->
M77MWJ'Q2U5]/TN26S\,6LF+B['!NF'\*_P"<=SV%075[J7Q8U:33M*DFL?"=
MJ^VYN@,->$?PK_GCJ><`>HZ7IUII6GPV.G0);VT*[411P!_4^]`'C`34/AEK
M2V&IAKK1;AB;>Z(P%YS@]@1^G7ID#US19OM\<-VKN\0CVH[K@N3R3CTX`J;7
M=&LM=TR:PU.!9[>4<J3@@]B#V(]:\TTC5-1^%^K)HGB&5[KP]<,?L=[C_4>Q
M]!ZCMU'&0)Y;.Y;FVK,];%(S!1DG'O38I8Y(T>-U='`*LIR"/4&N=U.6ZU2Z
M;3X@D<1+Q31R*<LNW(<'L`<>O6J(+']H?VR&;1[L*]M(1U!27CKD9X!/]#C-
M:US:PWMC+:WL23PSQF.6-AE74C#`CT.346D6$>FV:V\3.V#N9G8L2QZGD\?0
M<"KE`'D=_P##N?X?S'Q!\/1<.T?_`!^:?)(7$\><X7W'IU]/0]_X/\4V'BO2
M4OM/?#=)8&/SPMZ,/Y'O6XW2O)OB%ITG@G7;?Q5X7N(;>>\E6"ZT]CA;K/5@
M/;J>..OJ"#2;=D9OQW_Y'#2O^P;-_P"C$KV+2?\`D%VO_7)/Y"O%])TC4_B-
MX@>_U!MMLGR23J/E5,Y\J+^I[]3V%>W01K#$L2#"H`H'L*PIOFFYK8]7&0]A
MAZ>'F_?3;:[7M9/ST)****W/)$Q4-[:07ML]O=1K+%("K(PR"*GI#2:N--IW
M1XEXY\,7OAI'MK>\N(]`NY,,\8RT`)Y4^JG]<#KW[30[*QBT.W;P]&RV\$:^
M;;*Y)88XD4YR2>3[_6NSN[6&\MI+>YC66*52KJPR"*\LU"ROOAYJBW-LSR:)
M(YVM]XVQ)Z'U4_YY`KE<?9?X?R/;A-9@NU9?^3__`&WYGHFD3M>F.<2"6.-"
M-X7:&8GT]@,?4FM;M69H&JVVK6:RVY4'`9E!R!GH0>X/.#_7(K3KICL>+--2
M::L%%%%42%%%%`!6?%;0W&H/=S1(\D#%(6902@Q\Q'IFM"N>U_4TT6SNY+B7
MR58^:C^H_B&>V,9^AJ6[%07,[&M<ZC96GE?:;J&'SW$<>^0#>QZ`9ZGVJT#D
M9KP^TT34?BG>-(TCV&AV;$12@?,[\_='H#U^OKPO5>#O%6H:'JZ^$?&C;;Q<
M+8WQ^Y=)T`)_O=!^AYZB;>X223LF>BN@9"K`$$8((ZUY#XO\,7G@?4I/$'AI
M7.E2'-W:H>8?5E_V?QX^F"OKYQ374,I5E!!&"",@BFU=68HMQ=T<QX$\0V>O
MVK-9W<4@4`M""2T9/KDYQ[$`BND%K#]I^TF)#.$V"3:-P7.<9],UC^'/"&B^
M&[F[N-(LQ!)=MESG.!_='HOM6]0E96'*7,[@*,444R1".*\W^+&DVE@(?$MI
M<K8ZK;NNP]?/(Z#'<X_3K79>*/$%EX=TM[V^DP!PB#[TC>@%<9X:T&^\7:HG
MB/Q2A%N#FSLC]U1V)'^<US5FI?NX[_EYGL9;%T']<J/E@M/\7]U=[]>QV'A'
M5;K6/#]I?7UHUM/*N60]_P#:'L>M;0IH4```8`I16Z32LSRJDE*;E%63Z=A:
M*,UX]\0+W6]5^,^B^&M(\1WNE6-YIY>1[1@0)%\YCQTSA%!]L51![#17@WC7
M3_%7AOQ=X8T6+QYK-PFMSF)Y&(!BPR#(&>?O?I76S>`?$4+Q(?B+KK&9]@.%
M&W@G/7GIC\:3=E=B;L>F45YQ_P`*X\1_]%)U[_OE?\:DM?`^O:9?VEY<>/M:
MO(8IXVD@D"A9%W#*GGH>A]C3&>AUY#X:_P"3G_%/_8)3_P!!MJ]8N)A!$7*L
MPSCY17AOPGDFE^/_`(EDN+B6Y<V$G[R5LL1YD&!GT`P![`5/,K\I7*^7FZ'O
M%%`HJB0HHHH`****`"BBB@`KSGX\?\@'0/\`L/V?_L]>C5YS\>/^0#H'_8?L
M_P#V>@#T:BBB@".XFCMX))IW6.*-2[NQP%`Y)-<CXNT+3(--U'Q-IN++5(X#
M="\A<KYA125#C.'4],$'K77S1I-"\4JAT=2K*1D$'J*Y5/`5B'BBDO\`4YM,
MA8/'ILD^;=2.0,8W%1CA22*0!+<,_B_P[=7*[%N;"X1,_P`,I\IL?7"M^1J=
M?WGQ%8Q](=+VRX[%I04!_!6K3UO1;76K);:[\U-C"2*2%RDD3CHRL.AJ+0?#
M]KHD$RV\ES//<-NFNKF3S)93C`+'V'`&,4[BL8\BW'C.ZNH%GDMO#\$C6[^4
M<27KKPXW=5C!RO')(/:NLMX8[>!(845(XU"JJC`4#H!7&VGPZ2SA$-IXI\2V
M\0)(CCO$"C)).!Y?J:[*VB\BWCB,CR%%"[W.6;'<GUH6PR2BBB@"&ZMHKJ$Q
M3KN4_@0?4'L?>LW#;UL;YB)@<VUSTW$?H&'<="/;(K8J&[MH[J!HI5RK>^"#
MV(/8^]`%,%;I'L+]!YH&<J<!AV93V(X]P?P-+:W,MO,MG?-N8_ZJ;H)1Z'T;
MV[]1WQS'CB'Q;%I\%SHGV>X;39A</&1^\NT`^[_LG'7!Y_0Z?A;Q)I7CC1#-
M;$AE^6>W8XD@?^G3@T`:U]>N)!:605KIQG)^[$O]YOZ#O^>*UW<V?AW3)+FX
M<M_$[,1NE;U/^<"FZE?V'AG2WNKR1B,]3\TDSGL/4FN&B-YXGU.*YUH^6C-F
MWM%0L%YXW^HXS6U.E=<\](_GZ$RET0_0_#MYXV\2+XE\5*JV5HVW3[)5(#J"
M&#MW(S@X/<>@Q7>:II"7*N]L(XIY,!V*??'H2.?R]*HSWLNHR"PTN0V^S;OE
M5,A<$Y49'3Y2,^XKH$R%`8Y-92:;NE8I:(AABCMXRJ@#/+'`&X]R?>DU"SMM
M2L9K*^A6>VG0QR1MT93U%<1\9]`U?7M#ACTJ_-O#$6>>#'$_0KDCG`(_7.#B
MLKX>>-);]ETW4)#;ZE:@1M'*YVG'].1SS^6#6;DD[&D:;:N>A:!8V^E6?]F6
M<20V]K\L:(,`*>1^/7GO6F.E4[!O-DGN!]QV`4^H`QG\\U<JEL0]PK/UW1['
M7-,ET_4X1-;RCD9P0>Q![$=C4NJZC;:7I\UY>2K%%$I8EF`S[#)`S4%K>75S
M=HT,2263KN\TMM9#T*E>YS]/TIB/-M'U34/A?J\>A^()'N?#MPQ^R7N,^1_L
MGT'J.W4<9`]6A:.95EC*NKJ"KK@AAU&#537-'LM=TR73]2@$UO,.1T((Z$'L
M1ZUYIHVJ:C\+]730]?D>Y\/7+'['>XY@_P!D^@]1VZCC(`!ZW2$XIL,BRQ+(
MCAT<!E8'(8'H16-XM\267AG33=WA+R.2L$"'YYG_`+H_J>@%`TFW9"^+/$UE
MX:TPW5YEY'.V"!/OS/CA1_4]`*\HT;2]6^(WB"2^U&7;;+\LDB_<C3_GE%_4
M]S^`HT;2M7^(WB"2_P!2D*VRG;+(GW(TS_JHL_J>_7T%>SZ9I]MI=C%9V40B
M@B7:J@5SW=9V7P_G_P``]I*.61YGK6?_`))_]M^0:9IMKI=E%9V,2Q01#"JM
M6Z**W2LK(\64G)N4M6PHHHIB"BBB@`J"]MH;RVDMKB-9(I%*NK#@BIZ,4FKC
M3:=T>3:E8WWP[U1+FU9Y=%EDRK?>-L2>0?53^N.Q`KT?0]8M]7M%F@8;L`LH
M.<9Z$'N#V/\`7(JW>6D%[;R6]U&LL4BE61AD$&O+=0LK[X>:JMS:M)+HDC_*
MV-QMB>H/JI]/Y$5SZT7_`'?R/93CF4;/2LO_`";_`.V_,]9HK-T/6(-8M5F@
M9=V`64'/7H0>X/K_`%!%:0KH3OJCQFG%V>X445#>W<-C:R7-U*D,$2EI)'.`
MH'<TQ!>7<%E;2W-W*L,$*EWD<X"@=\UY@?MWQ4U8JOFV?A.TEZ_=>]<'^7'X
M?7[H7OOBMJI"F6S\)6<O)Y5[Q@?Y<?A]?N^G6-G;V%K#:V<2PP0J$CC0850.
MP%`!8VD%C:QVMI$D,$*A(XT&`H':LKQCX7L?%>DO97Z[6&6AF7[T3XZC^H[U
MN44`>=>#_%%_H>KKX3\9MMNUPME>D_+=+V!/KT'Z'GKZ(#GI7.^.O#MAXETD
M6%['F5G_`-'E7AXGQ]X'Z9R.]:NAV3Z;I-M9RW<U[)#&$:>;&^0CN<4K@7J*
M3-%,!:R/$WB"Q\.Z;)>7[X`X1!]Z1O04>*/$-GX<TU[R^<``81!]Z1NP`KQ^
M_P!:NCXETWQ'XVT^5M%G<B((<K;<_*63J>Q]^O;%8U*EGR1W9Z.%PL91>(Q#
MM37WR?9?KV.M\-:!?>+M43Q)XI3;;J=UE9G[JKV)'Y?6O2%`4`#@"HK*>"ZM
MHY[5TDAD4-&Z$%64]"*GQ54Z:@C'%8J6)E=JT5HDMD@H-%%:'(9FH21F9UN"
M1!&!N4`G>QZ#CKQV]ZMVLD4BGR/NJ=O`P*J:EX?TK4[@3WUE'-*!MW'.<?Y-
M>+?$/58O`WQKT";3].GN;2'3FF-E:Y+.[^>A8#GMC\%K-<_-JE8TO#EW=S>^
M,/\`R53X<?\`7XW_`*'%7J5__P`?%C_UW/\`Z`U>`Z_XW/C+XF^")6T2_P!*
M%E>9Q=K@R99#\O'.-O3W%>ZSWL4]W8HBS`^<3\\+J/N-W(I5))*S\OS,)-+0
MU:CGC$L;(P!5@00>XJ2BM2S,GAF$/V>6-IXN-KH1O&.F<_S'Y5X[\++>:U_:
M!\217$;QR#3G;:XP<%X""?P(KW3%>1>&O^3GO%(_ZA*?^@VU1R+FYB^=\O*>
MO"BBBK("BBB@`HHHH`****`"O.?CQ_R`=`_[#]G_`.SUZ-7G/QX_Y`.@?]A^
MS_\`9Z`/1J***`"BBB@`HHHH`****`"BBJFKZE:Z182WVH3+#;PC+NWZ`>I/
MI0!//<0VZ;YY4B7(7<[!1D\`9-.+@#).,=3Z5Y,^EZG\6)Y+N_EFTO0(MRV:
M)C?(W0/SD''KT[#N:ATGQ3K'AK6(?#7C0)<-$NVSN&SLNES\K$]R.F#S^."4
MW8J*YG8]8^W6K$`7$7/`^8<_2O-?B7H[>$[UO''ARXBLKQ&"W=LYQ'>*3TQ_
M>_\`U]:]$TVZAU"WW;5/'(`)4@].HYK!U7P)9:OXDM=1U&XEN+&T3]SIS8,*
MR9^][C';^G%).X-6=F<]X2TW6/&VK+XG\2C[)IX0K9:>O.5_OD]>?7@GV%=Q
MJ^GW$XBCLA;I&W[N8LO/EXZ#M6JJA1A1@#L*CNKB*U@>>XD6**-2SNQP%`ZD
MFK<FTD^A%BM#!8Z19.RK#:P1J6D<`(``.2:XWPSXWU/Q3XGNFT73U?PW9JT3
MW3@B2:3_`&.>1[>GN<5BW]Q?_%C5&T_3I);+PI;2`7%P!M>Z8<[1G\..W4\X
M`].TG3+/2=/AL-.@2WMH%")&@X`_Q]ZEC*]XUE>QE9S@KTRGS+^8KAO%?P]?
M69#J>BRFTU&W7=`[KM$KY/RD=E//4=_0G/IFT9H*BIY;N[-%-I61QOP\\:)K
MJ2:5JL/V#7;$;;FU(VYQ_$H].G';/H0:ZVYN$MK=YI-VQ%+'`R<5R/Q`\%'6
MC%JVBS?8=?L_F@N%.!)C^!_;W]_0D4G@/QLNO)+IFLQ"PUVS^2YMGXW8_B7V
MZ?GW!!-F9==;[7+S:K_9[>-@=\;Y#QLH/((^]D>XP?I73JNU<5';V\-L@2WC
M6-!DA5&!S4M`!6?KVCV6N:7-I^I0B:WF&"#U![$'L0>AJ^3BL7Q9XFLO#6F&
MZO27D<[8+=/OS/\`W1_4]`*!I-NR/.;+5]7^%FH?V)J<,NJZ/.KMITB8WK@9
MV<\`=,CMU''`SM&TK5OB+X@EOM1D*VJG9)(GW(T_YY1?U/?KZ"C1M+U;XC>(
M)+[49"EJIVRR)]R-<Y\J+/ZGOU/85[1IFG6NEV,5G91+%#$N%45SN]9V7P_G
M_P``]I*.61N]:S_\E_\`MOR$TK3[;2[&*SLHEBAB7:JJ*MT@&*6MTK:(\64G
M)N4GJPHHHIB"BBB@`HHHH`****`$-0W=K#>6TEO<Q++%(I5E89!!J>BDU<:;
M3NCR;4+&_P#AYJBW-JTDFB2/A7Y8VQ)Z$=U/I].X%>CZ%K%OJ]FLT+KNP"RA
MLXST(/<'U_KD5;O;6&]MI+:YC66&0%61AD$5Y;J-C??#O4UN+5Y)=$E;Y7P6
M-L3U4CNI]._'0@5SZT7_`'?R_P"`>S>.91L]*R_\F_\`MOS/4[RZM[.UEN;N
M9(8(E+/(YP%`[DUY7>)JGQ;NY8;>6;3?"UN2HE`P]U(.AP>P.#CM]?NN!U+X
MIZN;>82:;X;LF!EC5_FNW^H_A]#VQGK]WU&QLX+"UCMK2)(8(E"I&BX50.P%
M=*=]CQI1<6XRW//_`(,>`]9\#VVI0:MJ*W,,\V8(8V)50/X^>A/&1[5Z/110
M(***0TF!6N2%NK9F^Z69?H2./Y$?C7+^+/&D6AQ3,"H<`HBG!);UX_E6MXNU
MO3]$T>2XU%R,\1HI^=W[;?>N(\%^$KKQ!?+XA\3J3&3OM[63G/\`M-_GFN>K
M*5_9PW?X'K8+#4^1XG$Z07XOLOZT+7@3QU>F>'2_%B/!<W`WVUQ(FP2@]`>W
MT-=EXF\0V/AW3'O;Z4`#A$!^:1O0"H/%GA>R\2Z8;6Z`CD3F&91\T9]O;VKR
MN&PN/^$O&F>.+V826T`-D\@W0S#.`<_EV^M1.=6E%K?S_P`RY?4*R>(?N);Q
M[]N5^?6^VYT'AS2-0\8ZG_PDGB*(M;Q-FTLV^[C_`#CZFNSN].BU:T.GSPQ3
M6;`JX9.WH1Z_UYI^E*(;B%+:*6)"I$J$'8/1@>GY5M*`.<=:=&G[NKUZGEXG
M%3QK3>D5HDMDOZW/);:;4OA+JOV>]:6\\(7<O[N;&6L6)S@C^[S^F1SD'U:T
MN8;NUCN+>5)895#)(AR&!Z$&F:E8VNI6,UG?0I/;S*4>-QD,#7#>"=!UKPGX
MGN-(M)OMOAEU,L9E?Y[1SR$'J#SQTZ'C//496/0J***8%6ZG>.18X5\R5^0N
M<`#N2:YBZ\$&]^(VE^,)]0`GT^V:V^SI#@.")!][=Q_K#V[5NW]M?O/(UJ(2
MD@52S2LC`#/`PI]>N:YM_&D^F_$?3/!MW8!YM2MVNS=+<EEC4+)@!2HS_JCZ
M=<UG>[V+LK',_&'_`)*I\./^OQ__`$.*O4;\?Z38_P#7?_V1J\N^,/\`R53X
M<_\`7XW_`*'%7J-^P^TV/_7?_P!D:G/;[C*6Q=HHHJR@KR'PU_R<_P"*?^P2
MG_H-K7KU>0^&O^3G_%)_ZA*?^@VM`'KU%%%`!1110`4444`%%%%`!7F/[1$T
MMMX2TF>"$W$L6M6SI$O61@'(4?4\5Z=7G/QX_P"0#H'_`&'[/_V>@#'_`.%I
M^.O^B6:G_P!_)/\`XU1_PM/QU_T2S4_^_DG_`,:KUZB@#R'_`(6GXZ_Z)9J?
M_?R3_P"-4?\`"T_'7_1+-3_[^2?_`!JO7J*`/$]2^-OB?2Y[2#4OAW=6LMZ_
ME6Z2W#J9GR!M4&/DY(_,5>_X6GXZ_P"B6:G_`-_)/_C5'QW_`.1R^'/_`&%A
M_P"C(*]=R*`/(O\`A:?CK_HEFI_]_)/_`(U1_P`+3\=?]$LU/_OY)_\`&J]=
MW>U&Z@#R+_A:?CL_\TLU(?\`;23_`.-53\*W]]\7?$-Y_;\#Z98:$ZI+IH<D
MF0[AAC@<Y5@>!CH.I->U5X[\$8O.\8?$N,L5#:J5R.HS)/0!Z7>WJZ6EO';6
MT9ME'ED(<;<8`10!UYX''2L;XG6N@W?A*>3Q*XMTA!>*48,D<F.-GJ3TQT/>
MMJRTU-.5YII(V,8^4(GEHB@<?+DC..K?H.E<U=^%X?%OBZ+4M7N)9K'3XT\O
M3F'[H3'DL?7C'&.>.W%*_0:BVKE/X)P^(_[&>ZUIR+"95^R1R+B0CNY]`>WK
MU]SZ/2(H10J@`#@`5'<W$-M!)-<R+%%&I9W<X"@=230@;;U87,\5M;R3SRK%
M%&I9W8X"@=R:\6\;:WKWQ!M+X>&K*:30+`@NX)1KI@03QU(`YVCGOUP*TKF]
MU'XKZR]AI32V?A2SD_TBZ'!NV'\*_P">.IYP!ZCI>FVFE6$5CI\"6]M"NU(T
M'`']3[TQ&!\-M;T75_#D"Z%$EJELHCDM!]Z%O0^N>N[O755YGXT\)ZAH.JGQ
M;X*79<IEKNQ1?DG7N=HZ^X]>1SUZSP5XLT_Q9I0N[)MDR86>W8_-$WH?4>A[
MT`=!3)75(V=V"JHR23P!ZT/(L:%Y"%51DL>@%<WK$DVN7)TZPGE@5&VS;D9`
MRD`AU88)Q@C`/?F@#62[N3?K&8DEM90#'+&22.,DGC'TYK@?C5\-KSQC%:7W
MA^2*WU.V;#ECL\U.V6'=>WU->D65K'9VZ0Q`*B#``S@?3TJ>@#A/A9XK.I:>
MFA:TTD.OZ:GEW,4Y^>3'&\'O[_X$$]UD>M<9X_\`!)ULQ:MHT_V#7[/YH+E/
ME\S'\#'T]^V>X)%9FF?%&U@T:X7Q!;O:Z[:'RGL0,-,_8I[=SZ#GD8)!I-NR
M.L\6^)++PSIQNKQB\CG;!;H?GF?T']3T`KRC1M*U?XC>(7O]1D9;53MDE0_)
M&O\`SRB_J>_Y"C1M*U?XC>('O]1E9;93LDE3.R).OE19_5N_4]A7L^E:?;:7
M916=E$L4,2[5517/_&>GP_G_`,`]I*.61N]:S_\`)?\`[;\@TS3[;2[**SLH
MEBAB7:J@5;%%%;I6T/%E)R;E)W;"BBBF(****`"BBB@`HHHH`****`"BBB@`
MJ&\M(+RW>"ZB66*12K(PR"*FI"*35QIM.Z/*;RUO_AUJ@GMC+-H4K\'&XVQ/
M8CNO^>M>D:-JMOJUHL]LZG(!(#9Z]"#W'O5F[M8;RVDM[F)98I%VLC#((KRW
M4;'4/AWJBW-FSRZ)(W!Y;[.2?NM_LG_/-<^M%_W?R_X![*<<RC9Z5E_Y/_\`
M;?F>L"BL[0]8MM7LEGMW4G`W*#G'^(]ZT,C%="=U<\9Q<79K4,UD^)_$-GX<
MTY[N^<>D<8/S2-_=`I/%/B"R\.:8]Y>R#C(CC!^:1O05QWAGP_?>+-47Q)XJ
M0B`<V=F>BCL2/\Y_*LIU&GR1W_(]#"X6+BZ^(TIK[V^R_5]`\,>'[[Q9JB^)
M/%2$0=;2R8?*H[$@_P"37I`4```8`[4*`````!2U5.FH+S,<5BI8F5VK16R6
MR7]?>&*P?&?A73_%6DM9WRE9%^:&=1\\+>H_J.];U-D8(A9C@*,FM#DL>8^"
MO$.K>'=:_P"$4\6G+C_CUO'8*LR=!@GKS@?7CZ^GKT%<#X]\+1>(=*22YB?[
M0WSK)NQY1/0#GC'Z_P`LWX=^.;BSOU\+>+9?]+CPMK>,>)UY"JQ[-QQGK]>N
M<-&T/V3@N9;'J!'>J%O)'!:M/(P!:1R>>2=Q&/KQC\*OD@\"L?4M.N9G\F&0
M1V\DGFNX/S(>X4>_7/;FJEW14;-V9D>)O']IX?>TDN+*XDL991%<7:#*6Y(X
MSZ^^/_K5U5I<PWEO'<6TJ30R*&21&W*P/0@UX;\8;S4O$US!X4^'L=W=+8*Y
MOQ:/B)L[=JL<X)!!_'/H:]2^&6B3>'O`VDZ;=Q&*YBA!G0ONQ(QRW.?4TU>V
MI+M?0Z:O"?BMX?C\4?'WP_H\UW<6:7.DG,UN0'7:;AN#[[<?C7NU>0^)O^3G
M_"W_`&"7_P#0;JF(CD_9\TF21))/$FM.\9RC,Z$K]#CBIT^`]BBN%\5:YAQM
M.9$/&<^G'2O6Z*`/(?\`A06G_P#0U:]_W]7_``H_X4%I_P#T-6O?]_5_PKUZ
MB@#R'_A0>G_]#5KW_?U?\*R/A3H$?A?X^:_H\-W<7B6^DY$UP07;<;=N?^^L
M?A7NM>%ZPMI+\:?$\<%MXCFU?R8&0Z+<)"1!Y,.[<68<;MGZ4`>Z45\Z^$M,
M^)L6INWBU/&$]CY1"I8Z@H?S,C!.YP,8W?I7MG@.WU6V\(:7%K[ROJ2P#[09
M7WONZ\MW-`&]1110`4444`%%%%`!7G/QX_Y`.@?]A^S_`/9Z]&KQ#]IVVUUT
MT";3'G%G]H\O;')@?:21Y1QGKPV#VH`]N8X%8>N^(VT=IC)IMQ-%$BOYD15M
MVY@N`H.[]*N>'(;V#0=.BU-V>]CM8DN&9MQ,@0!B3WYSS5V>WAN$*7$,<J-P
M5=0P/YT`8T'B)KB9(X=/E;=.(6_>("@QG<1G..#[\5?M-0,^IW5DT#IY"JPD
M)&V0'/3!SQCG-6(K:"$L8H(HRQW$J@&3TR:>J1JS.JJ&;JP')I`>0_'S>?%G
MP]$9`?\`M3Y2>Q\R'%=LL7B`26RBZDBW+AO/>)@2"2PX'S$C&,8^4'/-<9\=
MB#XQ^'..?^)L/_1D%=UXJOC;/%F#4`+=6N1-:>4<@?*4VMDG.\=!^-,"A+J%
MZUK<W>GZW9S/M3<LEW&(82"=_P`P0GL!SZGI5ZS%_*D-[/?SI`LQD;;)&\<L
M14[=N%)QG'?/6L2R&B1$V5O]J>\(20(7B22/>"<$<#C@_,.3CJ:Z#1[RWOTM
MK>!KIXX,[FN4*L[+C!Y`R.<Y`QP,47`V;2ZBNX5F@;<C?F/K7BWPMURQ\.^(
M/B;J.J3B&"/53]7/FSX51W)KT?5+'5[1+Y],)D::)P`N$^8J<,/0@D<_Y/D/
MP9^&NL7WB"ZU7QK872VV[[0$NCC[3.6/S.IY.,D\^OO4Q;>Y<XI;,],\#ZGX
MF\0/>:UJD*6^D7B@66GNN)`G/[S=CN,=>O48&,]3H%JUK9MYB&-Y)&?:QR5&
M<`9[\`5HJ`J@```#&!0>E%M;BYG:P&N?\<>&H_%FBG39;J>V3S%E;R7V^8!G
MY&]CG\P#VKCOBGXI\3Z!X@L9;.%X-&MV$DTJ`/YX/#`CL!Z?CZ5UOA;Q*FN6
MZ7$++-%(N<Q_P=>O/2ES+8I0;5S5T"QLM.TFVM=,MDM;6)`J1(,!?7\<]36A
MTJKIIW6JL.C%F'T)R*M52(8$9%>9^-?"=_H&JGQ;X)79<IEKNQ0$K<+U8A1U
M]2/Q'/7TMFP#C%4[:^$E]-:2((Y(P&4;LEE.?F]N0:8C(\)>)=,\:Z(98``V
M-ES;,?FB8]C[>A[UM6%E'91[$9G.`-S'G`Z"O/?&OA._T'5F\7>"EV7"9:\L
MU'RW"]20O\Q^(YZ]9X*\66'BW2UN[)MDR86>W8_/"WH?;T/>@#H*0G%&1ZUB
M^+?$EEX:TTW=X2\CG9#`A^>9\=!_4]!0-)MV0>*_$MEX9TPW5Z2\CG;#;H1O
MF?\`NK_4]`*\ET/1]4^(7B*XU&^810/A+B>,?(JKTBC]<9.3WS^%/T;2M8^(
MVOR7VHRE+9?EDE3[D:9_U47]3W_(5[/IFG6VEV4=I8PK#!$,*JUSW=9V7P_G
M_P``]I*.61YGK6?_`))_]M^0NEZ=:Z78Q6EC"L,,0PJJ/U^M6L4#I16Z5M$>
M+*3D^:6X4444Q!1110`4444`%%%%`!1110`4444`%%%%`!1110`5!>6T-[;2
M6]S&LL,@VLK<@BIZ*35QIM.Z/)]1L;_X=ZJMS:,\VB2O\I^\;<G^$^JG_//7
ML;SQMI5KX?.J32#.T;858%G8C@+Z@^M=#=VL%Y;R6]U&LL4B[61AD$5XSXE\
M*#PCKUMJ$T;W6BK)F//SBW8G(##N,_YS7+/GH_#M^7_`/H,/[#,I+V^E1=OM
M^7E+SZ^IT?AGP_?>+-33Q)XI4B!3NLK(_=5>H)'Y?6O2%`50```.PK-T'5K?
M5K)9;=E!"C<@.0,]"#W!QP?ZY%:8Z5O3@HJZUOU/*QF)G7G:2Y4M$NB\O\PH
MHHK0XPIDR+)$R-RK`J?I3ZXKXD>/;;PI:_9K?;<ZO.A:&W`W;1_?8#G'!X[D
M>F2$!U-E,L\'E2%3+$-DJ^A^GH>HK"\6^`=#\3Q2R7=JD=ZT>R.[CR)(R.01
MZ\U3^&7AR6PL&US4[F:ZU76(TFG>0D;%(W*FTXQC/I[=!7:]J+#N><>"_%.H
M:'JR^$O&CXO!\MC?'[ETG0`G^]T^O0\]8_&/B;4O$NK2>$_!+?O!\NH:B/N6
MR'@@$?Q=1QSG@=R.M\9^%-.\6:0UCJ";6'S0SJ!OA?\`O#^H[U-X3\-:=X7T
MB/3],BVJ/FDD;[\K=V8^O\J8B/P=X6T[PGI"6&FQ]]TLS??F?NS'^G0#@5N4
M44`%>0^)O^3G_"W_`&"7_P#0;JO7J\A\3?\`)S_A;_L$O_Z#=4`>O4444`%%
M%%`!7D/AK_DY_P`4_P#8)3_T&UKU*2XEEE:*U"X4X:1N0#Z`=S7/Z5X)AL?B
M'?\`C`WKR75_:"UDAV`(`/+PP.<](Q^=(=CK****8@HHHH`****`"BBB@`KS
MGX\?\@'0/^P_9_\`L]>C5YC^T0UROA+26L55[H:U;&%7^Z7P^T'VSB@#TZBO
M(?[5^.7_`$+^@_\`?Q?_`([1_:OQR_Z%_0?^_B__`!V@#UT]*H`R7C.5D:.W
M!VC:<&3'4Y[#Z<UY!'XS^+<^O3:`FD:,VJ00BXGA``"Q'`4A_-P223QVXZ]O
M8-"^U'1K+^T+=;:[\E/.A1MRQO@9`(ZX-)H:T/#/BK*S_%3P8AR%6_@^7>67
M/G)D@GZ5[[/;0W",D\22JPVE74,".XP:\<^+?@GQ5JWC;2]6\+:7#.FG-'<*
M\EPBJTBL&P5+`XRH_.K7]J_'+_H7]!_[^+_\=J*::6O=_F75:E*\?(]5;3[1
MH1"UM`8@,!#&-H_#\!^59GBC4[#P[IO]J7DL=O%;$>V_/&T>I/;Z5Y[_`&K\
M<O\`H7]!_P"_B_\`QVKN@^$O$OBG58=6^)J6\8LFQ;Z;;L#"3_?;!;/7IGG'
MIP;9"T/1]+OX=4TVVOK8.(;F-94WKM;!&1D=C5D#%`````P!VJ.ZGCMH'GGD
M6**-2SNQP%`ZDFF(+BXBMH9)KB18HHE+.['`4#DDFN:\(>.=/\53W_V*">*V
MM9A#%<R@!+@]]OT]#ZBN,OKS4?BUK+Z=ICRV?A.RDVW5R!M:[8?PK_GCJ><`
M>H:9I5CI>FQ:;8VT<5I"FQ8@.,>_K0!2\1:4NHV[!W#(1RDC84>_\Z\HDTB^
M^'NHMJUM%+=^&7EVW$<+<Q@_QK_L=CV[=,$>T#3[0'/D(?8\@?A4LL,<L312
MHKHP*LK#((]"*CEUN:>T=K%?1]0M-5T^&]TZ9)[:9=R.O0^WL?:K3,$&6X'K
M7E-_9W_PIU635-(C>Z\*7+@W5HO+6C'^)<]O_P!1[&O1(YK/Q)HJ3V-UYEO<
M*&CFC/3G^A'0U9F8^JW5UKTXL=.WI;ERLY8%&&T\@Y!X(/&!^(KIK>$0QJNX
MMM&T,W)Q]>]1V%L;>+;(P9R<LP&,G&/Y`5:H`3%>:>-?"=_H&JMXN\%#9<IE
M[VS4?+.O4D*/U'XCGKZ636+XI\1VGAS3C<WA+R/E884^]*^.@_J>PH&DV[(P
M+;XGZ'/X6&K!F^T9\O[""/-,N/NCV[[NF.:X?1M*U?XC>()+_49"ENIVR2K]
MR-/^>47]3U/7T%5O#/ABX\:>(KN],,5M;33%[F:%-JC.,QQ_ER>Y)/>O<-*T
MZUTNPBL[&%8H(AA5%<[O5=E\/Y_\`]I*.61YGK6?_DO_`-M^0:5I]KI=E%9V
M,2Q01#"J*MT8HK=*VB/%E)R;E)W;"BBBF(****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`0BH;RUAO+66WN8UEBE4JR,,@BIZ*35QIM.Z/)M
M1L;[X=ZHMS;,\NB2O\C?>-L3_"1W4_K[&O1]"UBVU>R6:!UW8!90<XST(/<'
ML?ZU;O+6&]MI+>ZC62&12K*W((->57]O=_#SQ#"())#HUP_[J5^1;L>JG'5?
M4=_J,US:T7_=_+_@'LJV9QL]*R_\F7_R7YGKE-?\/QJEH^I1:E:),A4,1\Z`
MYVG_``]#WKG_`(E>,T\*:2@M52XU:Z81VEKRQ8DXW$#G`_7IU-=1XK33LSR?
M_A*?B/H'Q&U>TNV@O995S':N3Y3!B1$8E'.>.GL<D=:Z[P+X/N5O/[8UI_MN
MK7Q\UY9,'C(S@>@[#^E;_P`-O!;Z2C:YK[O=>(;\;YY9<$PY_@7'`Q[?0<5U
MYL(Q(7A>2%FY.P\$_0\5,E<TA)1)+FYAL;22XNI!'#"I=W/10.]5]#UG3]>T
MZ._TFZ2ZMI,X=.Q'4$'D'V-2&PC=@;AGN,=I#D?D.*\N\36-W\+]=_X2+PY"
M\NA7<F-1L0/DBY^^OIUXX[8[C#1F>N454TK4K35K""^T^=)[:=`\<B'((-6Z
M8!1110`5XMX\U2QT;]H_PUJ&JW4=I:1:2P>:4X5<_:0,GZD#\:]IKG_$'@CP
MWXDO4O-<TB"^N$C$2R29R$!)`X/JQ_.@"G_PL[P1_P!#/IW_`']H_P"%G>"/
M^AGT[_O[4/\`PJCP)_T+5E_X]_C1_P`*H\"?]"U9?^/?XT`3?\+.\$?]#/IW
M_?VHY_B=X*\MBGB;3BP4X`E')IO_``JCP)_T+5E_X]_C0?A1X%[>&K+_`,>_
MQI,#G(OC/X6@ABBANCA5&XLHY/?^+UYKIO!7Q%\/^+;Y].TN[:6^BA,[QF,@
M;`54MNY'5AQG-1GX4^!1S_PC5E_X]_C7#_#_`$JPT3]HOQ'I^E6R6MI%I*[(
MDSA<_9B>ON2:B,6GJS24TUHCVNBBBM#,****`"BBB@`HHHH`*\Y^/'_(!T#_
M`+#]G_[/7HU><_'C_D`Z!_V'[/\`]GH`]%=@B%F.`!DFJ6GZE#J'F-;%C&F`
M2R,ISZ<CZ?G5F[(6VD8]E)KG_!FGV]G%-);P10"<(S+'`8]QY^8DJ,DYZ<@?
MC0!RD&H6FF_';7+F_N$MX3I$$>]S@;BP./R!_*NV'BW0&8*-5MB2<`;JTY[=
M9HV4G:2/O*!D51FM8H7B@B)=Y67=N.2$4Y/^'XUE+GOHU8TBH-:[FIUI:1>!
M2UJ9A1110!%<SQ6]O)-/(L44:EG=S@*!U)KR:^NM0^+6KOINEO+9^$K23%U<
MCY6NV!^ZO^>.IYP!W7Q"T!?$?AN:Q>ZFMAN$@,;A=Y'(4YX(_KBN$^%?B>7P
M[J(\&:YY<4(R=/N2NSS`3G8>V>?Z>E*^MA\KMS'J>DZ;::1IT%AIT"6]M;J$
M2-1P!_C[U<H'2BF(*0D#J<4$XKFUUN;4?$4FFVUO%/8I$?-9G7+DL%("YR,?
M-G(YH\@.BE1)XFCD571P596&01W!KP;Q7:^*/A=XL6Z\+13GPK*ZSS0@>9%'
MGAPW=?;\/2O>((A#&J!F8*,`L<G\Z6:))HVCF17C<%65AD$>A%`%?2=2L]6T
M^&^T^=9[>9=R.O?_``/M5HD"O(]0BNOA/XA2[TU9)O"FH2_Z3"V2+-R0,J1T
M'IQSC'7%>AZSXDT_3M`.KF9)H&0-!L;/GDCY57U)H#T$\5^(K/PYIYNKLEY&
M^6&!?O2MCH/ZGH!7E>DZ9JOQ%UZ2[O9"EHIVRRK]U5SGRHL_J>_4]A46EVFJ
M?$/Q.SWTC"%1_I#Q_=@0\B),_J><D9]*]ITO3[72[**SL8EB@B7:JBN:[K.W
MV?S/:266Q4I:UGM_=7?_`!=NP:9IUMI=C%9V42Q01+M515L445T)65D>-*3D
MW*6["BBBF(****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`JGJVFVNJV4MG?0K+#*,,I'ZCWJY24FDU9E1DX-2B[-'D%_)K'PV
MNW6-3>6#@BTED.!GJ(Y#Z>A[=1W%:GPS\,/?7LGB[Q/.M[K<Y^6,\K:+V"CL
M<=,=CWR37H&J:;:ZI92V=]"LT$JX96'Z_6O,?^)C\/-72&>1YM(E.V"X;.$[
M^6_M[]NH[@\^M%V^S^7_``#UVHYE'FCI66Z_F\U_>_,]9`XI:IZ7J5OJ-JLL
M#>S+W4U<S72>,TT[,*CN8(KF"2&>-98Y%*LC#(8'J"*DHH`\EN[74/A1JSW^
MFI+>>$[N3-S;#YFLB3]Y/;^?3K@GU#2M1M-6T^&^T^=)[:==T<B'(85+=017
M-N\%Q&LD4BE61QD,".017BVKZK_PJ#Q6+?2W?4]'U'=*^E1MNEM6_O*/?]0/
M;-`'MU%>0_\`"_+#_H5->_[]+_C1_P`+\L/^A4U[_OTO^-`'KU%>0_\`"_+#
M_H5->_[]+_C1_P`+\L/^A4U[_OTO^-`'KU%>0_\`"_+#_H5->_[]+_C0/CW8
MD@#PIKN3Q_JE_P`:`/7J1CBHK>3SX$EP5WJ&P>HR.E<!\0/BK9>#]971[G2-
M0NYIH@\<EN%*MG/`&<Y%*X[':H&OCYDCLL!.$121N'J2/Y4RR\/Z19:O<:M:
M6$,5_<QB*2=1\Q08POL.!TZX&:\0/QKU-A&#X:NOW8"@"*0#C\:[/X4?$35O
M%VO7.G76A/8V-O:>:DY1UPX<+L.<@Y!)'.?E/X1%W>Q<HI+1GI]%%%:&8444
M4`%%%%`!1110`5YS\>/^0#H'_8?L_P#V>O1J\Q_:(NA9>$M)NV1I!!K5M*43
M[S;0YP/?B@#TN5=Z%3T/%4=)TF#33(T;2.\@56+D<A<XZ#T./P%>9?\`"_+#
M_H5->_[]+_C1_P`+\L/^A4U[_OTO^-`'46WB#4[KXJ:IX=\]4L;;3HKF,!!N
M#%@#S^-=?;VR0LS#<SM]YV.2:\!LOBC#;?$6_P#%3>']6:WO+)+-;=8OWB%2
MIW'M@]N<\5T__"_+#_H5->_[]+_C2L._0]>HKS3PO\7[7Q)KMKI4/AW5[5KE
MMOG3HH1."<GGVKTEF`4D],47$#MM7<2`!R2:X%/&6J>(O%D=AX/CBETRR?-]
M>2KE'_V%/\B/KTZ\Y>^+-2^*&L7'A;PTDNEV-LQ&HWDA!8QYP`H'][T_/I@^
MH>'-"L/#NDPZ=I4`AMXA]2Q[LQ[D^M"=]@M9DK7,<B&.YMY4/=6C+#\"`0:Y
M3Q+X%L?%$/E.LMNJ\I.5PZ$#"[1P1CW^E=S12:N6I-*R/./!?BS4-&U<>$/&
MQ$=ZG%E>L?DO$[<_WOY]^>OH]8'C3PG8>+=*:SOEV2+\T%P@^>%_4'^8[UR_
M@KQ7J&BZL/"/C=ME\GRV5\Q^2\3MS_>__4>>M$'7>(1/.GV39*(+A"AEA/S*
MQZ?3^7T[W--T^*R#,H#32G=)(0,L>_\`GWJZ#FB@`I#2YK-\0:U9Z#ISWM_)
MM1?E50,M(QZ*H[DT!N0>+;[2K#0[A]<5);21?+,++N,Q/1`O<FO#_"'AR^\1
M7QL+%[B*PBE=R9)?,6S1C]Q#T+$<$_Y.R!K/Q(\1GDP6T7REE.8[5#_"O8N1
MU/\`05Z_H.C6FA:='96$2QQ(.W5CW)/<USW=5V6WYGLQA'+HJI45ZKV7\OF_
M/L@T#1K+1-,CL;"$1Q(.?5CZGU)K1HHK=))61Y$YRJ2<Y.[84444R0HHHH`*
M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HH
MHH`#5/5=.M=4L9;.^A6:"0896'^>:N48HWW'&3BU*+LT>2G^TOAWJ\<4\K3:
M3*<07#=$S_RS?V_EU'<'T[2M1AU*V$T!X_B7(RI_SW[BC5=.M=5LI+.^A6:"
M48937F0_M'X=ZPD,TC3:3*<07#<A!_SS?V_EU'<5S:T7K\/Y?\`]AJ.91YHZ
M5ENOYO-?WN_<]9HJAI&J6VJ6YEMI58J<.FX$H<9P<?G[BN9^(?CC_A'Q%I>D
M1?;M?O?DMK9!NVY_B8>GMWQZ9-=)XS33LP^(GCD>'UBTO2(?M^OWOR6ULGS%
M">`[#T]N^/3)IOP\\#G1&EUG79OMWB"]^:>=SN\O/\"_U/MZ<4?#KP.=#,NL
MZ[+]N\07OSSSOSY6>J+_`%(]/3%=O0`4444`%%%%`!2.H92K#((P:6B@"A;R
M&-#:2\2*NU23CS!V(_KZ5YAXH5U^*W@5)00PN+@$$_\`3%*]:F@BF3;+&KCT
M89KS;Q]:0VWQ1^'K0IM,ES>%N2<XB0#K46=T7S:-'IM(!BEHJR`HHHH`****
M`"BBB@`HHHH`*\X^/'_(!T#_`+#UG_[/7H]><_'C_D`Z!_V'[/\`]GH`]&HH
MHH`3;SFEI,CUHR/6@"O?1M)%F/!="'7/<CM^/2JE]/\`:=.=H-XD3&44D,I'
M8@?R[UI\'TJ&:T@F.YXP6QC<.#^8J6M-"HNSN>(?LZ\^-O%O^[%_Z$U>[5XW
M\';6&Q^+/CVUM4\N&*1%1<DX&YNYYKV2E"/+%1[#G+FDY+J%%)D>M+D>M60%
M8'C7PGI_BW2&LK]2DB?-;W"_?A?LP/\`3O6_D>M''2@#SCP7XLO]%U9?"'C9
MME\GRV=\Q^2\7MR?XO\`]77KZ/VK`\:^%-/\6Z4;.^79(GS07"??A?L1_4=Z
MXS0/'5[X5FF\.^.UE:[M4+6EY&A87J#H!_M?Y/-`'H&OZU9Z#ISWNH2;8UX5
M1RTC'HJCN37D.-9^(_B(DDP6T/#,/FCM4/\`"I_B<]S_`$H`UGXD^(B<F&WB
M.&(Y2U0_PKZN>Y_I7K^@:-9:'IL=E80B.)/S8]R3W-<[;JNR^'\SVH1CET54
MJ*]5[+^7S?GV0:%HMEH>GQ66GQ".*,?BQ[DGN:T:**W225D>/.<IR<I.[844
M44R0HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`***
M*`"BBB@`HHHH`****`"BBB@!*J:KIMKJEC+9WT*S02C#*U7*0TFKZ,<9.+YH
MNS/"];TO6OAUKAN])N-L,P*13.NZ.1>T<HXY'9NWTR*[3X5^%X+..37M4N/[
M1U^].ZXG8Y\G/.Q?;W'48QQ7:ZKIUKJEC+9WT0F@E&&4_P">M>8_\3#X=:Q'
M#/(9M)E;;;SGD(,_ZM_;G\.H[BN=7HNS^'\O^`>RU',H\T=*RW7\WFO[W?N>
MM453TK48=3MA/`>PW*>JGT/^>:N5TGBM-.S.<\9^.-"\%QVKZ_<20K=EEBV1
M,^2N,].G45LZ3J-KJ^FVVH:?+YMK<QB6)\8W*>G%8'C[P!HWCNVM(=::Z3[(
M[/$]O(%8;A@@Y!!!P.V>/K6YH>E6NB:1:Z98*RVUI$L489LG`&.3ZT`7:***
M`"BBB@`KSGXC_P#)4/AU_P!?%Y_Z+2O1J\Y^(_\`R5#X<_\`7Q>?^BTH`]&I
M&(4$GH*6D8!@0>AH`Y+PA\2_#/B_5'T[0[J::YCB,S*\#(-H(!.2/5A775Q7
M@CX6>'/!6L7&J:-]L,\\9AQ--N6-"P)"C`]!UR>*[6@`HHHH`****`"BBB@`
MKR;]HG7]/T[3]`LKJ5EF_M2&]P$)'E1D[SGVW#BO6:\C_:-\/6.J:=H%Y<>:
M)_[3BL=R/C]W+G=QTS\HP:`/4]-OH-2L+:]M&+07,231L1C*L`0<?0U7U[3I
M-2M$AAD2-ED#Y8$^O3!'/.1[BK.G6,&FV%M96BE(+:)88U))PJ@`#)Z\`58H
M`Q/#^A3:/;2P&^>Y$Q+L\B@,&('3``QUZY/J35'_`(0]I483W[JWEO&@B48&
M[@M\^XY[\$#.<@UU-%`%"'3FAL(;2*7"0E-K8Y*J1UQ@9.#T`%7Z**`/(?A3
M_P`ED^(7_79/_0FKU74K9KNQF@1E5I$*@L#C\<=J\J^%/_)9/B%_UV3_`-":
MO7J`.9T[0VT"2ZU2YU!Y4$1:2,I\B(HS\O\`$<`8&2:YCPMKOA_Q[KUT-'U:
M>3R"+IH_L[(2,X`8N"#@\<`''>O2+JWCN[66VG7=%,AC<9QE2,$5R?@/X9Z!
MX&N[NZT8W;S72"-C<2AMJ@YP``._KGI1N!NZ3I+:7IILX9O-!!.^51DN>N=H
M`QT]_>I]'M)+'3H+>9D9XUPQC!`SGL"2:N]!574+V&PMFGN&PHZ`=6/H!ZT`
MET#4+V"QMFGG;"C@#NQ]!7E.IM>?$/Q`MI8JJ6]JW[V[QD0J>"J'N3W/?'H*
MFOKW4O'VLOI^F.8K.(XN+@?=C7NJGN3SSW^E>D:#HUEH>FQ66GQ>7#'^;'N2
M>YKG;=5V7P_F>S&,<NBJE17JO9?R^;\^R^\70=%L]"TZ.QT^(1PH/Q8]R3W-
M:-%%;I65D>1.<IR<I.[84444R0HHHH`****`"BBB@`HHHH`****`"BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"J>J
MZ=:ZK8RV=]$)8)1AE-7*3%)J^@XR<6I1=FCR?.H_#O6(X9Y&ETF5MMO<-R$&
M?]6^.W/7MU'<'TS2M1@U&T6:!O\`>4GE3_GOT-+JNFVNJ6,MG?1+-!*-K*:\
MPET_Q'X-OI+73HKZ]L&Y@FM@ID09^XVY6&.>X^F.:Y]:+_N_D>PU#,8\UTJJ
MWZ*7GV3[]SUNBO)_^$E\6_\`/CXA_P"_=O\`_&*/^$E\6_\`/CXA_P"_5O\`
M_&*OVT//[F8?V7B>R_\``H_YGK%%>4?\)+XM_P"?'Q#_`-^K?_XQ2?\`"2^+
M?^?'Q#_WZM__`(Q2]M#S^YA_9>)[+_P*/^9ZQ17E'_"2^+?^?'Q#_P!^K?\`
M^,4?\)+XM_Y\?$/_`'ZM_P#XQ1[:'G]S#^R\3V7_`(%'_,]7KSCXC_\`)3_A
MU_U\7G_HM*S_`/A)?%O_`#X^(?\`OU;_`/QBL36V\2ZOKNC:I-9:]YFDO*\8
M:&$GYU`.,1`#IW#?A3]M#^DP_LO$]E_X%'_,]RS17D__``DOBW_GQ\0_]^K?
M_P",4O\`PDOBW_GQ\0_]^K?_`.,4O;0\_N8?V7B>R_\``H_YGJ]%>3_\)+XM
M_P"?'Q#_`-^K?_XQ2_\`"2^+?^?'Q#_WZM__`(Q1[:'G]S#^R\3V7_@4?\SU
M>BO*/^$E\6_\^/B'_OU;_P#QBD_X27Q;_P`^/B'_`+]6_P#\8H]M#S^YA_9>
M)[+_`,"C_F>L45Y1_P`)+XM_Y\?$/_?JW_\`C%'_``DOBW_GQ\0_]^K?_P",
M4>VAY_<P_LO$]E_X%'_,]7HKR?\`X27Q;_SX^(?^_5O_`/&*/^$E\6_\^/B'
M_OU;_P#QBCVT//[F']EXGLO_``*/^9ZQ7G/QWYT'0?\`L/6G_L]9W_"2^+?^
M?'Q#_P!^K?\`^,5B>*V\2^)+6T@N;+7@MK=QW:[X83\R9Q]V)>>>^1[&CVT/
M/[F']EXGLO\`P*/^9[E17E'_``DOBW_GQ\0_]^K?_P",4?\`"2^+?^?'Q#_W
MZM__`(Q1[:'G]S#^R\3V7_@4?\SU>BO*/^$E\6_\^/B'_OU;_P#QBD_X27Q;
M_P`^/B'_`+]6_P#\8H]M#S^YA_9>)[+_`,"C_F>L49KRC_A)?%O_`#X^(?\`
MOU;_`/QBD_X27Q;_`,^/B'_OU;__`!BCVT//[F']EXGLO_`H_P"9#\*O^2R?
M$+_KLG_H35Z[GG%?,VH^$O%%QK^H:O9R>(K&:_D,DIACV,WU*;0?R%.M-!\?
M6-_:W4&I>)Y?)E5V65G((!Z8)(/X@BG[:'G]S'_9>)\O_`H_YGTQ2&O*?^$E
M\6_\^/B'_OU;_P#QBD/B;Q;_`,^/B'_OU;__`!BCVT//[F+^R\3V7_@4?\ST
MZ_O(K"W,]PV%'``Y+'L![UYA?7FI^/M;?3M,<QV41Q<7`Y6-#_"OJ3CD]_I4
M36_BKQ==1V5Q#?V=L?\`77-X$#*G<*$51S],^^*]-T'1;/0M.CLK",1Q1C\6
M/<D]S4MNJ[+1?F;PC#+H\\[2JO9;J/F^E^R#0-&L]#TV.QL(A'%'W/5CW)/<
MUHT"BMTDE9'D3G*I)RF[MA1113)"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`I"!FEHH`3%+BBBD`8HQ110`8HQ110`8HQ110`8HQ110`8HQ110`
M8HQ110`8HQ110`8HQ110`8HQ110`8HQ110`8HQ110`8HQ110`8HQ110`8I"*
M6BF`F/:EHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`
*****`"BBB@#_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>g838054g10e16.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g838054g10e16.jpg
M_]C_X``02D9)1@`!`0(!>@%Z``#_X5^0:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87`O,2XP+P`\/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z
M;65T82\B('@Z>&UP=&L](EA-4"!#;W)E(#4N,2XR(CX*(#QR9&8Z4D1&('AM
M;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN
M=&%X+6YS(R(^"B`@/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*("`@
M('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+R(*("`@
M('AM;&YS.GAM<$=);6<](FAT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]G
M+VEM9R\B"B`@("!X;6QN<SIP9&8](FAT='`Z+R]N<RYA9&]B92YC;VTO<&1F
M+S$N,R\B"B`@("!X;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE
M;G1S+S$N,2\B"B`@("!X;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D;V)E+F-O
M;2]X87`O,2XP+VUM+R(*("`@('AM;&YS.G-T179T/2)H='1P.B\O;G,N861O
M8F4N8V]M+WAA<"\Q+C`O<U1Y<&4O4F5S;W5R8V5%=F5N=",B"B`@("!X;6QN
M<SIS=%)E9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+W-4>7!E+U)E
M<V]U<F-E4F5F(R(*("`@('AM;&YS.G!H;W1O<VAO<#TB:'1T<#HO+VYS+F%D
M;V)E+F-O;2]P:&]T;W-H;W`O,2XP+R(*("`@('AM;&YS.G1I9F8](FAT='`Z
M+R]N<RYA9&]B92YC;VTO=&EF9B\Q+C`O(@H@("`@>&UL;G,Z97AI9CTB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]E>&EF+S$N,"\B"B`@("!X;6QN<SIX;7!44&<]
M(FAT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]T+W!G+R(*("`@('AM;&YS
M.G-T1&EM/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O<U1Y<&4O1&EM
M96YS:6]N<R,B"B`@("!X;6QN<SIS=$9N=#TB:'1T<#HO+VYS+F%D;V)E+F-O
M;2]X87`O,2XP+W-4>7!E+T9O;G0C(@H@("`@>&UL;G,Z>&UP1STB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]X87`O,2XP+V<O(@H@("`@>&UL;G,Z17AT96YS:7-&
M;VYT4V5N<V4](FAT='`Z+R]W=W<N97AT96YS:7,N8V]M+VUE=&$O1F]N=%-E
M;G-E+R(*("`@>&UP.D-R96%T941A=&4](C(P,34M,#,M,#-4,3(Z,3@Z,3$K
M,#4Z,S`B"B`@('AM<#I#<F5A=&]R5&]O;#TB061O8F4@26QL=7-T<F%T;W(@
M0U,V("A7:6YD;W=S*2(*("`@>&UP.DUO9&EF>41A=&4](C(P,34M,#,M,#-4
M,3(Z,3@Z,3$K,#4Z,S`B"B`@('AM<#I-971A9&%T841A=&4](C(P,34M,#,M
M,#-4,3(Z,3@Z,3$K,#4Z,S`B"B`@('!D9CI0<F]D=6-E<CTB06-R;V)A="!$
M:7-T:6QL97(@,3`N,2XY("A7:6YD;W=S*2(*("`@9&,Z9F]R;6%T/2)A<'!L
M:6-A=&EO;B]P;W-T<V-R:7!T(@H@("!X;7!-33I);G-T86YC94E$/2)X;7`N
M:6ED.C(Q.4%#-S(S-41#,44T,3%"03(R.$(X-4(S.#8R0D-$(@H@("!X;7!-
M33I$;V-U;65N=$E$/2)X;7`N9&ED.C(Q.4%#-S(S-41#,44T,3%"03(R.$(X
M-4(S.#8R0D-$(@H@("!X;7!-33I/<FEG:6YA;$1O8W5M96YT240](GAM<"YD
M:60Z-D$T,C-$13(X1D)$130Q,3E$0D9$1C,S0D-$,41%,S0B"B`@('AM<$U-
M.E)E;F1I=&EO;D-L87-S/2)D969A=6QT(@H@("!P:&]T;W-H;W`Z0V]L;W)-
M;V1E/2(T(@H@("!T:69F.D]R:65N=&%T:6]N/2(Q(@H@("!T:69F.EA297-O
M;'5T:6]N/2(Q.3(P,#`P+S$P,#`P(@H@("!T:69F.EE297-O;'5T:6]N/2(Q
M.3(P,#`P+S$P,#`P(@H@("!T:69F.E)E<V]L=71I;VY5;FET/2(R(@H@("!E
M>&EF.D-O;&]R4W!A8V4](C8U-3,U(@H@("!E>&EF.E!I>&5L6$1I;65N<VEO
M;CTB,3$S,2(*("`@97AI9CI0:7AE;%E$:6UE;G-I;VX](C<W,2(*("`@>&UP
M5%!G.DY086=E<STB,2(*("`@>&UP5%!G.DAA<U9I<VEB;&54<F%N<W!A<F5N
M8WD](D9A;'-E(@H@("!X;7!44&<Z2&%S5FES:6)L94]V97)P<FEN=#TB5')U
M92(^"B`@(#QX;7`Z5&AU;6)N86EL<SX*("`@(#QR9&8Z06QT/@H@("`@(#QR
M9&8Z;&D*("`@("`@>&UP1TEM9SIW:61T:#TB,C4V(@H@("`@("!X;7!'26UG
M.FAE:6=H=#TB,3<V(@H@("`@("!X;7!'26UG.F9O<FUA=#TB2E!%1R(*("`@
M("`@>&UP1TEM9SII;6%G93TB+SEJ+S1!05%3:UI*4F=!0D%G14%304))04%$
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M,4]4,%I85T9L85<Q>&18;#E76C)H<&%M='-B5S5V63-2,61N9#1E6'`W9D@Q
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M,5)L6FUD;V%7<')B1S%U8C)2,61N9#1E6'`W9D@Q*V8S3T5H66%(:4EM2VDT
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M<G-69&ER<U9D:7)S5F1I<G-69&EQ6&5:9BM58S%8+VU$=5`K5%19<6=T1S%V
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M,T1&540U;"]W0U5C,5@O04IG-VHO:S`R2W4X=&8X04M/858O=T%W9'8X03AM
M;'A6139J+W=!8RLV+S1X4V8X4D]+;R8C>$$[:D9867$W1EA9<3=&6%EQ-T98
M67$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T98
M67$W1E9/831G9U5.2R8C>$$[-%%-94LQ-G-X-DMO-FMN<T)G36=/8DM-1$QK
M:UAL8GIF1'(Y,W%K0U<P='5,0V8P-$=L4C`Y84=L0DMV34PQ8TYT,D902$M-
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M<5$S2E9#<VTK='HO05!,1DXY.%`O5E1&6&97-2]W1&QI;2LK2"]Q<"8C>$$[
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M>%8R2W!4-6AU<F=X439:6E-'3R\Q2FI(2$MV,F]95D%-."]88F=P;W`O;EI2
M,WDS14(Y4C5$.%8K3R8C>$$[:7!L83(P1G)B43)T=6=J=#1%5TM'361&4D)X
M5E(X9TUR2DI.;%5&-6PO-5)Z5F8K64\T+S5.3F=6,VQR+VQ(3DLO-6<W9CA!
M-4Y,:28C>$$[<4HQ2"]J;C-8+T=+5"]I2GA615EQ-T9867$W1EA9<3=&6%EQ
M-T9867$W1EA9<3=&6%EQ-T9867$W1E5&<D]S5T=J85AC86YF>65L828C>$$[
M5W%&-4<W;6Y25DAD;4]W2&IK36MX05=7+U1A865B24UC0F-P3V@Q84<V=#!U
M3$=/4S=I:U534G5Q.$9:5U5S<D)P9E1$0G%F<S$V:B8C>$$[=&='44573B]X
M-7),5&U%=4=:15-0:CDQ<B\X06-N24YV4G0O0W9+63`K2')4,&=$.6]D*W@Y
M<U!Q4&-0=%(K-TAE9G,O6#5/*V]"="8C>$$[<'`U<&@T1G5!-G0Q15%J0C)A
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M;6UY-7I(95=V*U5C,'(O;41T+RM44S1Q:612+S0U.3$O=T%9<%`X06E*>%9%
M67$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T98628C>$$[<7!Z,T9V06Y/
M95)9:S,K2GE&1W=Q979S34)K0GI:4F=:1V=,569R<GEB5S!$>4-T1$DT.4I"
M=5`U+VE/>'%#<6ME*U(T-S5"<SA)1"8C>$$[-FE".78W4&U896AE4V<K=DU)
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M=%-4,T-L3&4S="M,<F%Y:&YM:TPQ;VIV2'AI54PT<4A0>G<K<%!R2E!)1'`Q
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M.$%,8DXY,%`X03%4>%8S,5-F+VQT;28C>$$[*S9(+T%+<#1Q-S9P4"]Y,GIF
M9$0O=T)5.%9D.55N+S5B6G9U:"\V<#1Q-S9P4#A!.'1S,S-1+SE5.%9A93-L
M4D,W,S!Q;V]Q>D519R8C>$$[041U4UDX4V%305-A0T@Y94-P0S9N2DEW-G)%
M25I'2'A"9G-P1W@V<TUH-&ME.7,X0V9D6'8R*SE*9$$X,E<O;4-F56].2G5,
M:5=45"8C>$$[6GIB>7,O;U)Q9&I2.31Y-%5S<$@R8W%X-F=42D52>6,W5CEL
M>C`T9V-H;U1J9F8X3S<W53=45#E48T5Z-FQ)=&1W:U-1:6<R3D,W4B8C>$$[
M:W13:#-!6'(P1U<P5'I,9VU54GE(>B]6+V%U:#!H65<U2F-Z96]E<W)#2C5$
M4W1+=3!:63`U1VQ4:$511TUS:W!C>G0Y;GE66'0U528C>$$[4FYE*VQ61D),
M35)#04%.>5-42&MR649!4V%R<#97-'5%,5=7-6E:>D5R5W%2,TI,9U9+,&=I
M:TYA6D1X2712>G=Q-W-E5R\S2E0U=28C>$$[,69Z4'`K;FE44DQ7.79B:SA'
M-4Y$13A95G5O36%"6G58*WAO3RM6-6-K9U!33&-B5V%J2D-&-#1M4CDS-DQT
M6#AU,U!M*R\P5F)M+R8C>$$[:DYP9DUL56IC<D=#,TEI:GAT07IX9T%E2G)H
M>'IM63)24EHV8DIL;FI";$5#6#0K4T]E>C@Q4&)2.$PV1T<U<3-R0FM%,&10
M,F5.128C>$$[:%!Z<FLO5EA2=5!I5C!"*V8V;&1D4#%V-C1(8E9F.$%205!I
M9T5%66-N:G8K.$Y2.7)F-TA48C-W,&(X;593=FYT-W8R=$IP5W`K;"8C>$$[
M2VLR<S-,1U-N1C!J=&M+8C<X9C-49&9F04EN=EDX17%0<5`R3%ID06MM:6EJ
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M56XO-28C>$$[8EIV=6@O-G`U5W%T16I);D9P1VQ0.'HX468X06A1;R]$1E5$
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M2G%4+U9O6C)K=FE,9R8C>$$[='=&=EI/<%5)=TAX>'EX=DEN43`U9%%D=7AX
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M2#!%97$S>51S,EA2.4UB-FY99G`O57%D6E-R<U9D:7%895IF*U5C,28C>$$[
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M;E0T928C>$$[04AV6$QX;$%&0T509G=G:V4T;2]X>6-82F]C8SAK8V@K<5`T
M2'E49V569DQT879P.%4S9TIH-G=(>45N241"-#`K.7I'+SA!0W9L:B8C>$$[
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M=R\X028C>$$[27AF-C1Q-SE*-F(O04UT8U`O27AF-C1Q-SE*-F(O>3%W+SA!
M27AF-C1Q-SE*-F(O04UT8U`O27AF-C1Q-SE*-F(O>3%W+SA!27AF-B8C>$$[
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M*UE">%9F<5AL3'EU9$9V3%)D2G1)-R8C>$$[6C`Y4C19;U5J5FYH47)'>$-"
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M>4]E-T\U3$XW;D)/6$5B5D9:1EA9<3=&6%EQ;#-M6"]L2$Y6+S5G-VHO:S`R
M2W4X=&8X;S5P6"]-2&(O=T1*<&-64B8C>$$[3V\O.&,K-B\T>%-F.%)/2V]J
M1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&57(Q2%)7:W50
M,&AP,&]S.55!04TS2"8C>$$[;$A-<3E)-VA!4GI8=TY1>3EJ,4)S:FLR;S=J
M.&-L6&%B<E,S33=75C-#8DQ626AY:W1(4$E-9TY056AK;V]L:CEW2VIO=U4W
M67IX,"8C>$$[3$<T5DUS<E8R2W5X5C)+=7A6,DMP3'!N*S505G`Y5T\Y<&$X
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M=#`O=T%U86I9,D5.<DAR.3E)64EW:79-=')*56=D5TQ1;5%J+UHQ.3A'5$U*
M4THT4G8W+S%T;4Q(=R8C>$$[4D5B2G)Q55%,5'I/=G=R<59O-FIO,&QM-6,W
M.7EL>6DO8W52-&]D>"MF-T=X>7EE831X>&$S<V)K+S<X13@Q=B]W04HV3G@O
M>$Q';R8C>$$[9#4O2'A#=2]35W5235)0;S=3:G,Q;F-24T0O:W8Y5D]00DAP
M3#5J.59Q-#8Y2D=F.4LP=2MT,5`W9G!P8V4S4S%E9'9W>#A0=4DO2"8C>$$[
M=G!5:#AW*V9.4#A!<C%L-6-T1&1W86YR3$-+2V0W865(,%5:9W)31#%54G58
M2&QW2V=G3CEQ9WI*=S9/4FEC:')H:C5J.&9J6GA-=28C>$$[<VA$2DA'8C1P
M*U@T+TA.;#ET8E%7='1&8E<V0TM#0D9J:&I8;W%)3TMQ4&M";4534V),;'%M
M0EA9<3=&6%EQ-T95=3AY+SA!2T]A<B8C>$$[+W=!=V1X+WEA8D95:G5R5'I6
M9&52=$EI.',S<V1H<5AP5U1.4$U&2VU!2W9Q<CAC531Q5C9F1#DR2W)02VUK
M+VU*86%,9E<O;6Y63"8C>$$[9E=R*U-%3&)34G%K23E1<2]Q5CE/0T5+=%=6
M5DA&:G-46&9I<7))9E@Q+R]!2EDW6"]P2VLO-THX5F0V*W8X02],2&$O=T13
M5DHO,B8C>$$[5#1Q-S$Y9B]!3U=/,2\V4W!0.$%S;GA6,W(V+R]W07-D<B\P
M;%-F.6LK2W4Y9E@O05!L:G1F.$%P2VLO-THX5E=M-#AW.'=0<4YR>"8C>$$[
M24I,9E<U3FE+5490<2]F1E8S<C8O=T0X<V1R+T%.2E5N+UI0:7)V6#$O.$$U
M63=8+W!+:R]W0WEF1EAE=G(O+T%#>#)V+U-62B\R5"8C>$$[-'$W,3EF.$$K
M5T\Q+W=#:W%4+W-N>%8S<C8O+T%-<V1R+S!L4V8X05I0:7$Q8FIZ0U-W3FIA
M9T$P52]7-4YX44=V.$%V4#A!4FEQ-R8C>$$[,3EF+T%/5T\Q+S93<%`X07-N
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M:U`Q:V95=UE8:5=/2R8C>$$[;#!O2S%:6%E%535,.$E3=4MQ1W%F;&@U=W9B
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M=T%E,U4P<E8Y2EI98FE72U`X03!A94)A2E!E5$9Q4$UK<#5S87-G=TMZ,U),
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M>%8R2V]A.3%#,W-W:&U36G5D865H0DY0,#AF4E(K4#`U2TU35E-$45!Z2#AU
M-C1B<U=36&I',&U-3"8C>$$[+W=#:5A$,2]L9CA!9&\O14Y1-U!2=D5$37)0
M;W`T<31Q,TAE2$4P=71H;C1U1R]383-(-"]7:U,O;C,K6'-D>&91-FA.8S99
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M6%(Y4#`W5&(Y<E<X=4ET5&Q71TY)26=8:EIK1%9D6D=J8F@X44)D428C>$$[
M44\K,BM846M*0W<U94Q+2GA%9W@R*R\U>4,X9U<P9G%13F-8.%9:;#E7,RMR
M:5!L1&12,G4X:S`P4TM(.61*5EEK3#9:-45J<&MM>"8C>$$[14HK96YK96(Q
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M5E!H;$U.4D=224A4>6,S561M-6-567EK04)-5TYX*R8C>$$[4%`T:$IF33,U
M=6569DQ/='1P5W-R8U<S17=J-CA55#9S5$UY9VIN>C56:E=13S0T,316659!
M3UAU06M0+U%X=FM*3#(Y=&)I0RMT:B8C>$$[665O2G!:571W<&%.6E=65554
M;5)V54U"5D1W-#AM445J;75+<'!R2#4R*U1T3G1T574O5'4W>3`P=4,S=5AU
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M4T]E>6<Q1S!U6F)E9C`U<F4T-6-'44MJ4TMF:$)P228C>$$[:3%$2U8U5GA6
M2&544'IA.&HK8TQP3$A2<C$R,4IR55AS;&I,1$Q'.&-2-%9$4'A-3$UP;%5%
M2DDS-%EQ>DA&574X>2\X;S5Q=B]-2"8C>$$[8V8X04IP<U9D-6$O-5)Z4W8K
M64\S+S5.3&EQ631Q-T9867%P=U=T=&(K<#9%4U)E<35L;#1+1C533CEP,G`Q
M63EZ:$UI96%"141K<28C>$$[645U>%8R2W)6:6E2,V155EAK24UJ04%&:4)1
M1FHS,D9-5E=Z5W1T3S!45%),23!$*W)!>D%%;S1"6&MP-TAI>$92,DI(9D96
M5$963R8C>$$[83%T<'I%6F]L:TU$:5=%<T%E3&=%0FQR,$Y'3RM+<58Y<&5M
M86=I<&8R:TXR:4=Q3%!':V]5;F%O1&<P>4UO9SAX8EAK>%%M2VM!9B8C>$$[
M9G5R>'AX>%)R2$=O4TY!1E)&04-Q;T9!04(P07E11DUW2S)#-T9+2'9T4#`K
M+V=&=F8R,%8S04A745)4;W-I8S0R1$DS1G=25E=!228C>$$[4%DT<6E-5E59
M8DMY9VYU3&E',VII=4QT;&4V;5)&5C574D)'<E--0E9I<4M&1F5W<&EQ=&ER
M<U9D:7%#<TY$,%A4<%I:=%`P*S)S-28C>$$[6B\W-E-#1T]*;C-R.%)1071U
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M5FY',C)+;W8Y2S,S+U9M=E`K1',O=T1S;WA6,S96=G8K<DYE9CA(6B]W1%I2
M:7)V,')F9CE783@O=T-$<R\X07-O>%8S-E9V=BMR3B8C>$$[968X04(R9B]!
M1U59<3<Y2S,S+U9M=E`K1',O*WEJ1EAF<%<K+W=#<DYE9CA(6B\Y;$=+=2]3
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M4V,W8C1Q+R]:(B\^"B`@("`\+W)D9CI!;'0^"B`@(#PO>&UP.E1H=6UB;F%I
M;',^"B`@(#QD8SIC<F5A=&]R/@H@("`@/')D9CI397$^"B`@("`@/')D9CIL
M:3YR<C$W-C,V,CPO<F1F.FQI/@H@("`@/"]R9&8Z4V5Q/@H@("`\+V1C.F-R
M96%T;W(^"B`@(#QD8SIT:71L93X*("`@(#QR9&8Z06QT/@H@("`@(#QR9&8Z
M;&D@>&UL.FQA;F<](G@M9&5F875L="(^36EC<F]S;V9T(%=O<F0@+2`R,#$T
M(#$P+4L@1')A9G0@87,@;V8@,BXR-2XQ-2!T;R!24D0N9&]C/"]R9&8Z;&D^
M"B`@("`\+W)D9CI!;'0^"B`@(#PO9&,Z=&ET;&4^"B`@(#QX;7!-33I(:7-T
M;W)Y/@H@("`@/')D9CI397$^"B`@("`@/')D9CIL:0H@("`@("!S=$5V=#IA
M8W1I;VX](G-A=F5D(@H@("`@("!S=$5V=#II;G-T86YC94E$/2)X;7`N:6ED
M.C9!-#(S1$4R.$9"1$4T,3$Y1$)&1$8S,T)#1#%$13,T(@H@("`@("!S=$5V
M=#IW:&5N/2(R,#$U+3`R+3(V5#$T.C(W.C4Q*S`U.C,P(@H@("`@("!S=$5V
M=#IS;V9T=V%R94%G96YT/2)!9&]B92!0:&]T;W-H;W`@0U,V("A7:6YD;W=S
M*2(*("`@("`@<W1%=G0Z8VAA;F=E9#TB+R(O/@H@("`@(#QR9&8Z;&D*("`@
M("`@<W1%=G0Z86-T:6]N/2)S879E9"(*("`@("`@<W1%=G0Z:6YS=&%N8V5)
M1#TB>&UP+FEI9#HR,3E!0S<R,S5$0S%%-#$Q0D$R,CA".#5",S@V,D)#1"(*
M("`@("`@<W1%=G0Z=VAE;CTB,C`Q-2TP,RTP,U0Q,CHQ.#HQ,2LP-3HS,"(*
M("`@("`@<W1%=G0Z<V]F='=A<F5!9V5N=#TB061O8F4@26QL=7-T<F%T;W(@
M0U,V("A7:6YD;W=S*2(*("`@("`@<W1%=G0Z8VAA;F=E9#TB+R(O/@H@("`@
M/"]R9&8Z4V5Q/@H@("`\+WAM<$U-.DAI<W1O<GD^"B`@(#QX;7!-33I$97)I
M=F5D1G)O;0H@("`@<W12968Z:6YS=&%N8V5)1#TB>&UP+FEI9#HR,#E!0S<R
M,S5$0S%%-#$Q0D$R,CA".#5",S@V,D)#1"(*("`@('-T4F5F.F1O8W5M96YT
M240](GAM<"YD:60Z,C`Y04,W,C,U1$,Q130Q,4)!,C(X0C@U0C,X-C)"0T0B
M"B`@("!S=%)E9CIO<FEG:6YA;$1O8W5M96YT240](GAM<"YD:60Z-D$T,C-$
M13(X1D)$130Q,3E$0D9$1C,S0D-$,41%,S0B"B`@("!S=%)E9CIR96YD:71I
M;VY#;&%S<STB9&5F875L="(O/@H@("`\>&UP5%!G.DUA>%!A9V53:7IE"B`@
M("!S=$1I;3IW/2(T,C0N,3(U,#`P(@H@("`@<W1$:6TZ:#TB,C@Y+C$R-3`P
M,"(*("`@('-T1&EM.G5N:70](E!O:6YT<R(O/@H@("`\>&UP5%!G.D9O;G1S
M/@H@("`@/')D9CI"86<^"B`@("`@/')D9CIL:0H@("`@("!S=$9N=#IF;VYT
M3F%M93TB5&EM97-.97=2;VUA;E!3+4)O;&0B"B`@("`@('-T1FYT.F9O;G1&
M86UI;'D](E1I;65S($YE=R!2;VUA;B!04R(*("`@("`@<W1&;G0Z9F]N=$9A
M8V4](D)O;&0B"B`@("`@('-T1FYT.F9O;G14>7!E/2)4>7!E(#$B"B`@("`@
M('-T1FYT.G9E<G-I;VY3=')I;F<](C`P,2XP,#$B"B`@("`@('-T1FYT.F-O
M;7!O<VET93TB1F%L<V4B"B`@("`@('-T1FYT.F9O;G1&:6QE3F%M93TB351"
M7U]?7RY01D([($U40E]?7U\N4$9-(B\^"B`@("`\+W)D9CI"86<^"B`@(#PO
M>&UP5%!G.D9O;G1S/@H@("`\>&UP5%!G.E!L871E3F%M97,^"B`@("`\<F1F
M.E-E<3X*("`@("`\<F1F.FQI/D-Y86X\+W)D9CIL:3X*("`@("`\<F1F.FQI
M/DUA9V5N=&$\+W)D9CIL:3X*("`@("`\<F1F.FQI/EEE;&QO=SPO<F1F.FQI
M/@H@("`@(#QR9&8Z;&D^0FQA8VL\+W)D9CIL:3X*("`@(#PO<F1F.E-E<3X*
M("`@/"]X;7!44&<Z4&QA=&5.86UE<SX*("`@/'AM<%109SI3=V%T8VA'<F]U
M<',^"B`@("`\<F1F.E-E<3X*("`@("`\<F1F.FQI"B`@("`@('AM<$<Z9W)O
M=7!.86UE/2)$969A=6QT(%-W871C:"!'<F]U<"(*("`@("`@>&UP1SIG<F]U
M<%1Y<&4](C`B+SX*("`@(#PO<F1F.E-E<3X*("`@/"]X;7!44&<Z4W=A=&-H
M1W)O=7!S/@H@("`\17AT96YS:7-&;VYT4V5N<V4Z<VQU9SX*("`@(#QR9&8Z
M0F%G/@H@("`@(#QR9&8Z;&D*("`@("`@17AT96YS:7-&;VYT4V5N<V4Z4&]S
M=%-C<FEP=$YA;64](E1I;65S3F5W4F]M86Y04RU";VQD(B\^"B`@("`\+W)D
M9CI"86<^"B`@(#PO17AT96YS:7-&;VYT4V5N<V4Z<VQU9SX*("`\+W)D9CI$
M97-C<FEP=&EO;CX*(#PO<F1F.E)$1CX*/"]X.GAM<&UE=&$^"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@(`H\/WAP86-K970@96YD
M/2)W(C\^_]L`0P`!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!_]L`0P$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!_\``$0@!@`(W`P$1``(1`0,1`?_$`!X``0`"`@,!`0$`````
M```````'"`8)`P4*!`(!_\0`2Q````8"`0$#!PD'`P,"`PD```,$!08'`0((
M"1A8EQ$2$QE6T=44%2$Y=YBWUM<*%A<B-7BU(S$R)"A!0E$S5Y8T0U)356%Q
ME=/_Q``=`0$``04!`0$``````````````@$#!`4'!@@)_\0`4!$``00!`@(&
M!0H%`@(&"`<``0`"`P0%!A$2(0<3,6&1T11!45*2"!4B,C-"<7*!L18CH;+!
M)/!BH@D7)29#<S135(*4H^'Q5H.5L]+3U/_:``P#`0`"$0,1`#\`WG]+'I8]
M.JV^G5PWLNR^&]#S:?S:AX1();+9!"$"][D#VO0>D6.;FL,_G4K%._\`,:;M
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M<2#OR))]16ZKHV_58\#_`.V^O?\`'9!6W_7=^9W[E;+@44!$!$!$!$!$!$!$
M!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$
M!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$
M!%Y_OVG#ZH>[/M#HO\4XX"N1?:-_7^TJZ?1M^JQX'_VWU[_CL@HO^N[\SOW*
MV7`HH"("("("("("("("("("("("("("("("("("("("("("("("("("("("
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MY%]HW]?[2KI]&WZK'@?_`&WU[_CL@HO^N[\SOW*V7`HH"("("("("("("("(
M"("("("("("("("("("("("("("("("("("("("("("("("("("("("("("(
M"("("("("("("("("("("("("("("("("("("("("("("("("("("("("("+
MS_?M.'U0]V?:'1?XIQP%<B^T;^O]I5T^C;]5CP/_`+;Z]_QV047_`%W?F=^Y
M6RX%%`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`
M1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`
M1`1`1`1`1`1`1`1`1`1`1>?[]IP^J'NS[0Z+_%..`KD7VC?U_M*MKTEG9>P]
M(KAB^M3"X2IS9>*,5=FZ+M)J4EUDB]NCRE8C86PY><G0E.#PH)+;T9JP\A*6
MI4%[*#BR<;[ZE%_UW?F/[E8U6W5%_B-4M2V<VU?'-E5A\TX!P\F,(WL"0LT]
MI20S62;,;BGL^$R2L6F01ZPX;G3.SE`78AJ+=6U6RR1%(4R=WW:&XJENQ(W[
M&\6_J/X<^8[U^CNK+5SW(7")P)G(<9.[\DXKQNJ]BD)LE9%LY^=+QDM`2RZM
M51\7*8MZOB=@UY9;,A)BCU+W=\5QUG(DAM>'2IM*T*G"?Z;_`(<MP/#;Q[E>
M?C'R+C/)?C!3'*!M;SH;&;=JB+6D8T/BT@TV)D/K$0[.C4XNN"DB55JP*-E:
M(UVT(2IEI23Y?H204=J7H5'#A)!]1(\$>N7/%J..:IE?^0],LSNB]#A8V.5C
M15&N2Y4)RE1&%"4]TT.)R<F/)4%X,TUSN2<4;KC.F^N<MMNU4`WYCF.[FNK[
M:G$+O-47XGQ#XL"KL?8?`IVU.(7>:HOQ/B'Q8$V/L/@4[:G$+O-47XGQ#XL"
M;'V'P*=M3B%WFJ+\3XA\6!-C[#X%.VIQ"[S5%^)\0^+`FQ]A\"G;4XA=YJB_
M$^(?%@38^P^!3MJ<0N\U1?B?$/BP)L?8?`IVU.(7>:HOQ/B'Q8$V/L/@4[:G
M$+O-47XGQ#XL";'V'P*=M3B%WFJ+\3XA\6!-C[#X%.VIQ"[S5%^)\0^+`FQ]
MA\"G;4XA=YJB_$^(?%@38^P^!3MJ<0N\U1?B?$/BP)L?8?`IVU.(7>:HOQ/B
M'Q8$V/L/@4[:G$+O-47XGQ#XL";'V'P*=M3B%WFJ+\3XA\6!-C[#X%.VIQ"[
MS5%^)\0^+`FQ]A\"G;4XA=YJB_$^(?%@38^P^!3MJ<0N\U1?B?$/BP)L?8?`
MIVU.(7>:HOQ/B'Q8$V/L/@4[:G$+O-47XGQ#XL";'V'P*=M3B%WFJ+\3XA\6
M!-C[#X%.VIQ"[S5%^)\0^+`FQ]A\"G;4XA=YJB_$^(?%@38^P^!3MJ<0N\U1
M?B?$/BP)L?8?`IVU.(7>:HOQ/B'Q8$V/L/@4[:G$+O-47XGQ#XL";'V'P*=M
M3B%WFJ+\3XA\6!-C[#X%.VIQ"[S5%^)\0^+`FQ]A\"G;4XA=YJB_$^(?%@38
M^P^!3MJ<0N\U1?B?$/BP)L?8?`IVU.(7>:HOQ/B'Q8$V/L/@4[:G$+O-47XG
MQ#XL";'V'P*=M3B%WFJ+\3XA\6!-C[#X%.VIQ"[S5%^)\0^+`FQ]A\"G;4XA
M=YJB_$^(?%@38^P^!3MJ<0N\U1?B?$/BP)L?8?`IVU.(7>:HOQ/B'Q8$V/L/
M@4[:G$+O-47XGQ#XL";'V'P*=M3B%WFJ+\3XA\6!-C[#X%.VIQ"[S5%^)\0^
M+`FQ]A\"G;4XA=YJB_$^(?%@38^P^!3MJ<0N\U1?B?$/BP)L?8?`IVU.(7>:
MHOQ/B'Q8$V/L/@4[:G$+O-47XGQ#XL";'V'P*=M3B%WFJ+\3XA\6!-C[#X%.
MVIQ"[S5%^)\0^+`FQ]A\"G;4XA=YJB_$^(?%@38^P^!3MJ<0N\U1?B?$/BP)
ML?8?`IVU.(7>:HOQ/B'Q8$V/L/@4[:G$+O-47XGQ#XL";'V'P*=M3B%WFJ+\
M3XA\6!-C[#X%.VIQ"[S5%^)\0^+`FQ]A\"G;4XA=YJB_$^(?%@38^P^!3MJ<
M0N\U1?B?$/BP)L?8?`IVU.(7>:HOQ/B'Q8$V/L/@4[:G$+O-47XGQ#XL";'V
M'P*=M3B%WFJ+\3XA\6!-C[#X%.VIQ"[S5%^)\0^+`FQ]A\"G;4XA=YJB_$^(
M?%@38^P^!3MJ<0N\U1?B?$/BP)L?8?`IVU.(7>:HOQ/B'Q8$V/L/@58YK=&U
M[;&YZ9UR1T:'="D=&IS0'EJD+BVKTY:M"N1*B=MR5*16F-*4)SRM]BSB3-#-
M-MM=L9R5%]P(@(O/]^TX?5#W9]H=%_BG'`5R+[1OZ_VE7!Z0S2A?^DUPD8G/
M0\QM>N+L+:7`M*M6MJG="XLAJ-7HG<6Q0C<D!^Q!QFI*UO5I5J4S.IZ100>6
M6;J47_7=^8_N5/Y?!+C;J47Z>*2!:Y=H"-\H%DA63Z;F29XNJ%FZ[0N5/[]H
M_%N+\GBR8I.A;(\[G+(ZH()R>\M;HXJW%<L*FY_IMV#L*Z\OI\<2R'E]D22K
M2D3Z\RDF:H71)(I.4JALG+N%SY`G.E>^5XV)@^7&Z'IXL)Y1QTI"WO;JXJ&Y
MV2+(Y@EE*)Q'V]W]-OV5GZZKV%U+`855U<QY#$X!7<6883"XPV>F^0,$7C+8
MF9V-I2[*33U)A2%N1IT^IRI0H5G^CR<J//4&&&[E0\^9[2NG@/\`7K=^THK\
M-JZ%3V#\/\E1;][\Q4E"BD@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(
M@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(
M@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(O/]^TX?5#W9]H=%_BG'`5R+[1OZ_VE
M73Z-OU6/`_\`MOKW_'9!1?\`7=^9W[E;+@44!$!%&L!_KUN_:45^&U="I[!^
M'^2HM^]^8J2A120$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$
M0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$
M0$0$0$0$0$0$0$0$0$0$0$7G^_:</JA[L^T.B_Q3C@*Y%]HW]?[2KI]&WZK'
M@?\`VWU[_CL@HO\`KN_,[]RMEP**`B`BC6`_UZW?M**_#:NA4]@_#_)46_>_
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M[OS._<K9<"B@(@(HU@/]>MW[2BOPVKH5/8/P_P`E1;][\Q4E"BD@(@(@(@(@
M(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@
M(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(L-G]B0.JHHZ
M3FRIA'()#V4O4UTDDJ=T3*T)//V\PDK=8N.)*W5*C<ZD(T963%:U3N6F2$G'
MF:%[8]JW6I0/LW+$-:",;OFGD;'&W?L'$X@<3CR:T;N<=@T$D!>@TOI34VML
MW3TWI#`Y;4N>R#RRGB,+1L9&]/PCBD>VO6CD>V&%F\EB=X;!7B:Z6>2.)KGC
M5CU#.85],-&/[7QAXXVK8;7;4);&6*WI'4ZD\I`59$8,=B7R'0)A;'ZP5IS1
M&C%>BMZE+7`F^.292TDE*'99DM$=S_7&H\M6PEAF!P^0NG(UF05LC7C>_JQ=
M@+^O@JPQRVG&*#BWDG969#.Z,`R.^B?M/Y*W0+T8Y+I)Q=WIEZ6M$Z4NZ&U'
M<R&:Z-LM+%&^T_2.891DQN>U/D[F,TM69>R[8'08[#7=36LMAX;TCXJ,`?8C
MA[H;6/>+55$JXRWE5MK0G^&IYLIJM_G<!E\:;%L/?W#.S]$2'5^:$*+99'9(
ML^=FY%\IW6*6V2*BDA&J&/F>CTO1%?R\>-L8#+X_(U/F\FQCIKE*S7C?5F?_
M`#JPDFC8TO@G=UC&[ESHYW!HX(3M[W_I(=)]&][7&%Z8>C;6FB-1?Q?&S"ZU
MQ>F=48',7*V?Q=4#&9V2EC+UFPVOEL1!Z#;L=4V"&YB8'SR&SE6\6^$=B7YG
MH"+S_?M.'U0]V?:'1?XIQP%<B^T;^O\`:5=/HV_58\#_`.V^O?\`'9!1?]=W
MYG?N5LN!10$0$4:P'^O6[]I17X;5T*GL'X?Y*BW[WYBI*%%)`1`1`1`1`1`1
M`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1
M`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`18[)Y;&X:U+7J3.Z1I;
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M?/+6#`SC=&\.:#UV;0G1[T>W]38GI6U%>SFHL?AZ;\'@.B7+:9SN+?GK\60$
M]'4^NI)LCBL6[3<]>F,K1P>)U+)=?<-6#(4I*T\K<YAW'6'1M_F<IDK_`#NW
M7Z:R-%(3U%O2/]\&B,_,CFXND6:8)#L(FZ#PM!$SG-5JS*X_&D3^9Y=5+N].
MBW7"H9%?$UX9;$\TMJ_+8E;*3?FZ]D/5O>^&.M7X65J[8"]W5NBA;*>V21[N
M:\WG^E?/Y?&:?PN(Q>FM"8S3V)L8J.+0F(^8;^8^<:=6EFKVIL^;%O4FH;6;
MCIPG(0Y3,6,8W8PT,?2K'J5/HVBY@@(@(@(O/]^TX?5#W9]H=%_BG'`5R+[1
MOZ_VE73Z-OU6/`_^V^O?\=D%%_UW?F=^Y6RX%%`1`11K`?Z];OVE%?AM70J>
MP?A_DJ+?O?F*DH44D!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!
M$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!
M$!$!$!%'5BVY6%1HFA?9L]BL'3R!W1Q^/8D;PC;E,@?'!2G2)&AA0G&X6O3D
M:>J(Q\C;$ZH\LO?TYNFA&FYFN+:O4Z+8W7+,-82R-BBZZ1K#+*X@-CB:3Q2/
M)(^BP$@<R`-RO6:3T)K+75B_6T=IC-:DEQ5"?*94XFA8MPXO&U8I9Y[^3LQL
M-?'U&1PR;6+DL,3WMZICG2N:PPNX2[D/;I%EQ:NH@X<;B&-Z1,$2N:U66.3=
M;*BT;PL0RYYB%3M4I(,1MY:%*6IA<DG#L4E>=UI"Q3##F_3_`%=<Z?*WA<AJ
M0/Q`CD;%!D+L<-ETX;(YL\D%%DX+6AK0:\UEX$G$'&N6CGT*M@>BK0DFC\UJ
MO/5.EN3)8Z?*9WH_T3D<MIVOA'6,?!9P6/SVM[N%E98M.LSNAU#B--T738\5
MY((M0QVCLS,XIQRKABF[#;LC;][%O1FAS3#M[DF>I*V4&)T#1\T.*]B:4A:2
M'P!5)2C%9DB+KR.19,[Y7*BUY2DLW?7;(@Q-2.S%?E9Z7DHZ[(/G"QLZ8AL?
M5O?&QO#7JNF!=UHJPPB3B(<""O/9SI9U;DM.9/0F)M-TIT;9#/WL^W0&GS)7
MPS9;-_T^I5R=Z=T^?U1#B'M@9B7ZKRV:FHBM`^L^)\;2)Z&S7,D!$!$!$!$!
M%Y_OVG#ZH>[/M#HO\4XX"N1?:-_7^TJZ?1M^JQX'_P!M]>_X[(*+_KN_,[]R
MMEP**`B`BC6`_P!>MW[2BOPVKH5/8/P_R5%OWOS%24**2`B`B`B`B`B`B`B`
MB`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`
MB`B`B`B`B`B`B`B`B`B`B`B`B`B`B`BC:T[<@%,1)SFMA/>[4R->S<4:6@:W
M>1/:Q6\K]&IE;FF-QU"ZR!X<7AS,T;VU$VMJH]4JVR7IIY-#-M,2[>JX^!]B
MW)U<;.$'A9)+(YSW<$;60PM?+(][_HL:QCBX\@%Z[1>A-4=(.<IZ>TKCFW<C
M=%M['VKM'$XVO!CZSKN0MW\OEK-+%T*E"FUUJW8N6X8H(`'.=])@=%A$GY`V
M=(F3,4C+-5%(R"O]W1?-)ELZ%W^0_P`IC*_YG;V"KW-AVC<'>8,]G-JY\/L%
M3*"5VY!K1I$\XV.6$8(FRER6/J(8Z.-EJ\;[%CC&4$LT+^!D5-\1AK25I"QT
MAM&<.V,?4=KA[63#]%NCL3D1F\QD-;](V+U2VG5T]@!2?T72XO"YBMZ?:RFL
MZ>3&7U'0U)CH[E;&QZ5APTE9LC+[LX"(X),HK+C[":Y;V'+BNDULS*/.,@>&
M^TKF=M+!LA&YRLEK(DAC'(7-)II#6MV)96HHZ,P9%&8N66@3X(9B]\&;F7Z>
M+KU&Q<;IKUB)TKVW<@_TJVU\X8)C'*]NU=D@C8##6;#"`T;1CGOI=8]*6HM6
M6LGZ)6P^A]/Y6IBZ%K1?1_1.EM(ST\))=EQ#<EBJ<SG:@N49,C>DCS&I+&8S
M+WVI3)D'-+6MG0;)<V0$0$0$0$0$0$0$7G^_:</JA[L^T.B_Q3C@*Y%]HW]?
M[2K:])9R=V;I%<,7>/L!LK?FKBC%7)DBQ#@D:3Y*[H8ZI5-K`2Z+_P#H6TUX
M6%$MQ;@M_P"D1[J<*%/^B7N"B[Z[OS']U'];=3Z1SNJZKFQ<`BG[U2[G16_#
MBTZ[>%4R@%BT$[3>0_-;HV6#7T@8W1;K/HZET+/)2DR$B+O[<Z-TC:W<PLM2
MQ`J\.WP\0/:#V>OQ7+-.JY'2^0T]H.M&:&RO+9.N&U6069ERQ*]I7>6\D[;O
M"NI^]O3"R+"UB:-58CI_50@287(5TH<WQG,W7-4=DL>>E!4X#MO^;E^`!_KO
M^GX\E?3BIR,:^37%2CN4&C$IA[=;U0Q.T5L;/.-=CHT8^,"=U=F<M60D(.>"
M6E9E6D1KR6].:ZIB"5FB%/NIPFT*CAPD@GL)&_X'984Q\H*2BDMMIL?96YI%
MIE@I5FI14$L)PURG.KBOM"]\GML55I]=MMBC,9*V-P;KY,9WTUQMKG,B-M@?
M9_DJ+!N">6Q<=N8'[K+.V+QX]M7CPVM+\E"*EL>[Q'FG;%X\>VKQX;6E^2@3
M8]WB/-.V+QX]M7CPVM+\E`FQ[O$>:=L7CQ[:O'AM:7Y*!-CW>(\T[8O'CVU>
M/#:TOR4";'N\1YIVQ>/'MJ\>&UI?DH$V/=XCS3MB\>/;5X\-K2_)0)L>[Q'F
MG;%X\>VKQX;6E^2@38]WB/-.V+QX]M7CPVM+\E`FQ[O$>:=L7CQ[:O'AM:7Y
M*!-CW>(\T[8O'CVU>/#:TOR4";'N\1YIVQ>/'MJ\>&UI?DH$V/=XCS3MB\>/
M;5X\-K2_)0)L>[Q'FG;%X\>VKQX;6E^2@38]WB/-.V+QX]M7CPVM+\E`FQ[O
M$>:=L7CQ[:O'AM:7Y*!-CW>(\T[8O'CVU>/#:TOR4";'N\1YIVQ>/'MJ\>&U
MI?DH$V/=XCS3MB\>/;5X\-K2_)0)L>[Q'FG;%X\>VKQX;6E^2@38]WB/-.V+
MQX]M7CPVM+\E`FQ[O$>:=L7CQ[:O'AM:7Y*!-CW>(\T[8O'CVU>/#:TOR4";
M'N\1YIVQ>/'MJ\>&UI?DH$V/=XCS3MB\>/;5X\-K2_)0)L>[Q'FG;%X\>VKQ
MX;6E^2@38]WB/-.V+QX]M7CPVM+\E`FQ[O$>:=L7CQ[:O'AM:7Y*!-CW>(\T
M[8O'CVU>/#:TOR4";'N\1YIVQ>/'MJ\>&UI?DH$V/=XCS3MB\>/;5X\-K2_)
M0)L>[Q'FG;%X\>VKQX;6E^2@38]WB/-.V+QX]M7CPVM+\E`FQ[O$>:=L7CQ[
M:O'AM:7Y*!-CW>(\T[8O'CVU>/#:TOR4";'N\1YIVQ>/'MJ\>&UI?DH$V/=X
MCS3MB\>/;5X\-K2_)0)L>[Q'FG;%X\>VKQX;6E^2@38]WB/-.V+QX]M7CPVM
M+\E`FQ[O$>:=L7CQ[:O'AM:7Y*!-CW>(\T[8O'CVU>/#:TOR4";'N\1YIVQ>
M/'MJ\>&UI?DH$V/=XCS3MB\>/;5X\-K2_)0)L>[Q'FG;%X\>VKQX;6E^2@38
M]WB/-.V+QX]M7CPVM+\E`FQ[O$>:=L7CQ[:O'AM:7Y*!-CW>(\T[8O'CVU>/
M#:TOR4";'N\1YIVQ>/'MJ\>&UI?DH$V/=XCS3MB\>/;5X\-K2_)0)L>[Q'FG
M;%X\>VKQX;6E^2@38]WB/-.V+QX]M7CPVM+\E`FQ[O$>:=L7CQ[:O'AM:7Y*
M!-CW>(\UB#YU`N)<?7;L:VU,[RS=F<'UL@Z>&3[>;R)$VIU*D_$:BIL8)=WU
M1MHD4:E%-Z8[SMB3<[[:%DG&%X=B_4K2,@EGC%F9DCX*C7-=:L"*-\KQ!`#U
MDI#8W;<+=BX!N^Y`/K\!H'5VI<=>SN+P60?IG$V\;3SNK)JT\.EM/R97(5,9
M3?G<^^/YNQD3[5ZL'.LSM<R)[IBPQ,>YM=B^;;A>3!%'>*RZ2<1F;,N=3),A
ML*C))85PO\(0:L9\=-8V]`B>('7BR2F;R!&^)9.EF3RS)"&\Y.A2+CC=2=<)
M,ODH8)(&NP49G>9FVX(+5^2LT1F(QL;-)6J.E)E;(V=L\D;0TAC7$[='DQ_1
M#T:Y;.X[.2U>G7(LP=./$6=)Y[-:7T!C-1V'9*'+,R%V?$4=2:MK8AK,78QE
MC"6,!C<C-+:;):L561NDE>O;*X15?+)[/H@M>")W9KH>ZS>:/,.N^4RIZ]*N
M4KTS1\_2>.N[DWQ=I.5&%L43:U"*-LB?4HAL:TVA>N,9U7&4J4]FS!#M9N/+
M[%B222:>3=Q<(^MF?(]L,9<1%`PMAC&P8P+PVJNDW6^L\'IG3&>S0ETUHZE%
M2TYI['T<7A<)CN"M#5EO?-F&J4*EK,WHX&.R6<NQ6<OD92^2Y=F<\J8>V+QX
M]M7CPVM+\E#/7@MCW>(\T[8O'CVU>/#:TOR4";'N\1YIVQ>/'MJ\>&UI?DH$
MV/=XCS3MB\>/;5X\-K2_)0)L>[Q'FG;%X\>VKQX;6E^2@38]WB/-.V+QX]M7
MCPVM+\E`FQ[O$>:IWSEZE[!1=!O\NH1C?K+L56=AE;#U,&FC=%X%HK2*S3)U
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M=%_BG'`5R+[1OZ_VE7!Z0K0W2#I-<(V%W386-+WQ=A;0Z(]C#B=53<Y,AJ-:
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M<YSC.<E18Y`?Z];OVE%?AM70J>P?A_DJ+?O?F*DH44D!$!$!$!$!$!$!$!$!
M$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!
M$!$!$!$!$!$!$!$!$!%P95)=51:+921JM-(-5%),G%X5&)4YA))ZDM/G;TNY
M!)JE.4:=KIDLLQ03IOMKL;IC:G$WB#>(<1!<&[CB+00"X#M(!<T$]@)`/:%=
M$$QA=9$,IKLEC@?.(WF%DTK))(H72[<#99&0ROCC+@][(I'-!#'$1!;=^UE2
M>T41SEV<\O\`/'8UC@\/BT:D4UFDN<TOR+9>2PQ6*-CN\JR&HEQ1*7AQV2E-
MC0E5)SW%8FT/)R9@7LG3QW4-LO?UMEYCK00PRV+$[V\/'U<,#))"V,/:Z1Y:
M&1M(+W#<;^\T+T8:QZ11F[&FZ-,8O3-%F2U)G\UE\5IW3V!IS>D-JR9/-9NY
M1Q\$EV2K8AH5!,^Y>FAECJ5YG12<$>N;3R1MPRTHF^*4O&Z!9<2&.OIO74I:
M)A=;\V-K_GYYDIVCW$7&"P-OET=*PE84I.DCEK`8M,<U*EM<DQ"0O%?'E[WI
ML$CFXBMQ".K9J3LL9&1C9?YDQ$D#JU9L\0X8P.NGB+N,N8\!H]33O=$>A6:+
MSF.AFZ7-3BI+D=4Z<U9A;V!Z.\9<MXL?-^'C=CL[3U+J:W@LL\S9.>1V)P64
M;794AAN5)I9W2M!::KZOST+NTL93K-D\598:Y6C*<Z26UI2R,!.2F\F7V*Z%
MGRF2&:[;&'[Y<G$XO)YN^Y91>OF::YM;'U:I;)'&'V!#'7?<F_G79HXALP3V
MG@S2GM/TW$;GD`-@O$ZEZ0-4ZICLT+N2?2TY-FLCGZFB\+Q8C1&%R.3DX[4F
M!TG2?'A<2T@-B:*E1C^J8UKWO/$YTI#-7BT!$!$!$!$!$!$!%K0Y;GG\H+RK
M7@1'CS]X-\E9+^YEN2$XPO1'2L>?\[5Q3"A8FV+,3.=_V$R^A=D92M*X8JV%
MS??T>Z9X3;&=.T<3I3"Y#I!E_EY%DDN"T4UWUSG9H`<AFXVG?>/3V/F#X9"U
MT?SK=H@$/A=MJ\C6KY1DF(M016J5J%[<E7GC;-!/3D:Z-U2>)X+)([8+F21O
M!#X1(US2'*]E5U-7%(09DK6IX@SP:#QTLTMIC[*3N6F(V4';J%2D\\\P]8O7
MK5!ABA<Y."E4O6G[['*E)IFV=AXG/9_,ZGREG-9_(V,IE+CFFQ<M.!D>&-#(
MV-:QK(XHHV`,BAA9'%$P!L;&M&RQ]-Z9P.D,/4T_IK%U</AZ+7-K4:C"V-AD
M>9))'O>Y\LTTLCG233SR233/)?)(YQW4AC3K>("+S_?M.'U0]V?:'1?XIQP%
M<B^T;^O]I5T^C;]5CP/_`+;Z]_QV047_`%W?F=^Y6RX%%`1`11K`?Z];OVE%
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M<TC3U5TO"BV"I&G5''WQ>;+U[RH>W:5/4Q?'Q$WZ+)A(I=('!V?).\O*)`VX
M/>')R5FG)$J(@G?1&F3$E?2.-H4<?6$=!@;%*[TATAD?/)8DE:S>Q+/*]\DT
MDC6LWD>]Q+0T#9H`'XB](NOM:](6H7Y375YUC*8VLS`U<?%CJ.$QV`QN.L6G
M08'%8+%U:.-PV/Q]BS;,="G3@9'/-8ED:ZQ--(^8!GKP2`B`B`B`B`B`B`B`
MBB6^+HA?':G;$NVPE1R:)5Q&5TB<BDFF#G)U/)QHG:(ZR)<YQE=(9.]*&^.Q
MUNTSZ1Q?'1O0E?ZBC4;?`X6[J+,X["8YK76\E:97B+SM%$T[NFLSN^Y7JP-D
MLV9#RC@BDD/)I5N65L,3Y7_58TN.W:?8T>USCLUH]9("@#@S2\TKRN)':MU)
M2M.2O)R4[W5>WF[Y4?NNZNR!,AA%/MBHS&3OW;I.!)6*O6M/Z8Y.:Y-C\^$[
M9-?5.^_H-=9JED<E6Q6$>3IK3%083`\N'TJ*&1TE[,2L&S?2<W?=/D97<+7"
M.6O`X;0-`LU8G,8Z27[>=W6S>OA)&S(P?=B8`P>K<./WE=D>(64@(@(O/]^T
MX?5#W9]H=%_BG'`5R+[1OZ_VE73Z-OU6/`_^V^O?\=D%%_UW?F=^Y6RX%%`1
M`11K`?Z];OVE%?AM70J>P?A_DJ+?O?F*DH44D!$!$!$!$!$!$!$!$!$!$!$!
M$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!
M%%MI7A3M(M:-ZMZSH-6[:Y*C$+4?,9*U,1CPN*U)W-0,J5<I*5O"XK1008:B
M;"%:DLHXLW<K4O?&V<*[D:&.8V2_<K5&/<6L-B9D?6.&V[8PXATCAN"6L#B`
M02%[31?1QK[I&NV,?H/1VI-76Z<+;-V/`8B[DFT*SS(UEG(3UH7P4*SW12L9
M8N2P0O?&]C7ES2%@:WD(J7R:Q817M+7--I/`&1R6E.#C#5E<5M*Y`@/;B"HC
M&K.L'YBC[PXK?G'"HET9RW6/X0HEZCYUWV+3$JL9V4<^:W6JX_(6)JL;W!SZ
M[JE2>5I:!!#<M".*1SN+B#XP^+A:X\9Y!WIJ_19!5P^D]1ZJZ0NC_3N'U1D:
M==]6IGX-6ZNPF*M1VY9,[E]':6^<\I0JUO1.IDI9!]'*^DV*T7H36NEDAZC7
MM?SEOKIRTWIKC]MLXKUMGQ=8E?K[D.6M(])]V5FB\H1N-4QIO5O3$6J*D"Y6
MPOY;,M4D_,^[GJGW.-M_]O6657_]GXL\;G7(7"7)R\#9`8XX9FNHQ-=)'Q"5
MSHI>K<1U?&!N<YW_`%#:;M:KJ$=('2D!4JU]&YJO-C.C'%"Y/CY6Y'(9G#6*
MFM\O:AQ^2?"_%5H,GBW9"O#)Z>VFZ5K&<Y_%Q@DO\3DEKV=<ER1JT%&F%\&F
M<S)983&6A))"Y(U,,28ZV:()LWHT)J9$W*5C@K=7A\:TVR!^<7%*L6DJ)'#1
M3>F-O7+]^&X[Z5:Q8$=>&-LO6LB@CJ,K<+6D-87.+Y)&#@E>]KG`VX^F?*8C
M^#I]$:.T!H#+Z,B=Z-J33^GI,AJ+,7Y\0[$7<GG,CJZ]J46K%ADUFW#7JP4J
M&-NS"SC*M2>"M)%,,'JRMZT9V)@K^"Q6(-$89_W?8$;"R(&_5I9,K53ENUHS
MB2=5!:,UR6K7$\GTN=5#@L5K3L&*E)QN^?7I5*C(XZM:"!D,?51-BC8S@CXG
M/X&D#<-+WN>1OS<YSCNYQ)\#J36FKM87\ED]4:DS6>O9B_\`.F4GR>1M6C>R
M(KPU&W9V22&)]AE2O7J1R<`=%5KP5H^&&&-C<]&2O,H"("("("("("("("("
M("("+678G_>#S2C=+)_^NX_\)'6+7!=IFO\`J-4\Y.N:+#O1=4J-L>9HN0U*
MQ*,W5,$6IBI,7)W*J4C@FT-3GZ:]-QW_`'/T59S3OH:@UO%:P^#'9-0TQ$_J
M<[EF]I8_+SM^9*;R&.-6/+/C<6O:5@O_`-39$7;#5+9)?8^P1O%'ZMQ&T]:[
MM'$8P>86S0<R6<@(@(@(O/\`?M.'U0]V?:'1?XIQP%<B^T;^O]I5T^C;]5CP
M/_MOKW_'9!1?]=WYG?N5LN!10$0$4:P'^O6[]I17X;5T*GL'X?Y*BW[WYBI*
M%%)`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`
M1`1`1`1`1`1`1`1`1`18;/+$@%6QQ9,++FT3K^*(-BBULDF<@:HTR)C5&=L)
MR#7-X5(T>JA3MIOHF3^E].I,UR6069O_`"C'LVZM*)T]RQ!5@;MQ2V)60Q@G
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MT\[@QC\3U?N95CP<\QF@U4\99>=*DZ5/_$9\57\L)@VS4HV6.QC'7R^`Q]#,
M"WG9&2A:L3B2,>4):L]4OV-R0GVL];G[=<F.M2P\YG#1Z7(<FX5N`\3^JJOJ
MQ-L"3A#6>DRQ<(<2[?8'>'&?)_TEJ.-E_4FM^F+`QX26:7^$\;#T7UY-2"[$
MVO1;DM4UM496S@'8]L\EF[_#>(R0L/@B@K-8)91EAM!NS],765SZ[[>E+0\P
MXZ'K*K:GAJ@=4)R7:)%1F3.;>U1%I;YS\YNRK=R?VY<\6&]N,7<7'7YA7I/F
MYO,(O'%OEL/GM9*_.R2N:[J3)&5J($D`AF>QE>-EGC>>.5CI+<CH7O\`Y3F\
M#2-&SI/HXS`4L)ICHYT)A;V/S\>>@UK=Q]W4VMY9*.=DS&'IVKN=O6M-^AT8
M13QENM0TKCJN9J5#\YUI_2[3),IK/C]2M.,:".5M6L5C#6V/+E(T?H&_"]QT
MD3PF0HW>0&O;ONX/:I]=$;8W)7!X5.!SBL3($9"A284F)UTOT\7CJ$;(JE.&
M%C)'RMV;Q/$L@:V24R2<4CI'M8QKY'/+W!K020T;:76'2ETAZ^R5K+:NU?FL
MS=N8^IB;'66C5J.Q-":S8HXMF.HMJXZ'&T[%RW/5H0U8ZE>:S/)%"Q\TA=,0
MSUX%`1`1`1`1`1`1`1`1`1`1`1`1`1`15FY=<@\<:J/D=@-;+F7V&ZKF:O:7
MKTG?R+;)NJ?KRXY6L(2::F%F[%.DB5IU3XH)V\]JBZ!]>S,83MAVVOIM(:>_
MB7.5L?+/Z'CHHY\CFLB1NS&X3'QFSD[SSL1O%78YD#7<I;4D$`^E*T*Q9FZB
M(O`XGDAD3/?E>>&-GZN/,^INY]2_/$/CYGC71\?@;N]?O?8[VXO5C7;81FGF
MJ[(NRP%V\BLF:*=MBRS<IU[\J-0,"8[7SVJ*MC"R:>0AL)UQ75^H?XESEB_#
M#Z'C8(X<;@\>#]#&X/'L%?&4FC<CBCKM$EAP/\VW+8G/TI2E:'J(@PGB>27R
MO]^5YW>[\">31ZFAH]2LV/,*^@(@(@(O/]^TX?5#W9]H=%_BG'`5R+[1OZ_V
ME73Z-OU6/`_^V^O?\=D%%_UW?F=^Y6RX%%`1`11K`?Z];OVE%?AM70J>P?A_
MDJ+?O?F*DH44D!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!
M$!$!$!$!$!$!$!$!$!$!%Q'GDIB35"DXI.G(+W.///,T*)))*USN::::9G70
MLLO37;?<S?;&NFN,[;9QC&<BA(`))``!)).P`',DD\@`.TJ<<<DTD<44;Y99
M7MCBBC:Y\DDCW!K(XV-!<][W$-:UH+G.(`!)6KKJ(]12M>-O&F0R2LI\R2BT
M;"1R2&TXNB.<2]@3RYN4HV>2NRR2M!#K$4#A7I3GL\;L;TX%K%[HC3-OS:I)
MV793>`USK2II_3]BS2M139"X):F,=!M/$+0(CFE=*P20-=3:XS&*1W$][&LX
M""[;[.^2E\E'5_2[TOXK$:QTQD<-HS2MC$:@U_6SH.!RDF"MPV+^(HP8>_)2
MSMFKJF2F*#<ECZKJ]:E8EM^EQ2"L)?JX=<P^0'-CCNIL:N*ZJV!/:9H:(XAF
ML[FBV7L3E:30L9T]AIG6KX6C9I!'V$EM.7/<:T73A(ZK]7"/X.1$MBO=S%W2
MVILGJO!-R%.I2JS=7'`9[-AT\3LA$Z-MUKZ5=L<L40:72P<5EKWM?#NT,<7J
MST^=`?1=\G;I6BTGJW5FM-3X^6_?RUG3NFM/5\#DJFB[]>_+I6:EK/4,^0Q>
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MQC&/)C&,?1C&,8^C&,8_VP-FN8$[\SS)YDGUK^@B`B`B`B`B`B`B`B`B`B`B
M`B`B`B`B`B`B`BUEP#_O"YIR*X%'_7<?>#[O)JEIDK;_`%&J><I71ORTW=:)
M6F?,+7(J=CRO%,Q%9N4I3DRUWM54WJM3D1&^O3<A_P!SM%5L.W^7J'7$-7+Y
MDC<34-+12=;@\6[MX'YFPPYFXP%KC4AQ3)&%KR%@L_U-HR]L-4NCB[-GV"-I
M9/PC:1$W_B,A'8KXS6W:IK?).MA67`H.8IW*+2DRR7,$?4*C#]L:$%)$[JO2
MGJC3]]M="2DY9AAN^V-2]=LYQ@<IGNTZNWI-JO7WV`$TT<1)/8`'N!)/J`W)
M6KS>K]*::+!J'4N`P;I2QL3,MEZ&/DE=(X-C9#';L1/E?(XAK&QM<YY(#025
MJYZQ-WVW2%9TZ[5)/Y'`')\G3VW.ZR.+?D1[@A3Q_P"4DIE._F;^>46?_JZZ
M^3'DW^D>`Z2,ID<71QLF.N34WRVY62.@=P%[1#Q!KCZP#S_%?+7RQM<:NT/I
MG1MO2.H,EI^S>SMZO<FQL_4/L01X\2,BD.QXF-D^F![>:J#TD^4O(>Y^3K]$
M[4MZ:3N-IJ@E3V0S2%TRL0E.R.2PE(E7Z%>CT\B@A,O6DE[^7Z-%)N/)_,/.
M]'F>S.3SLU>_D;5N`8ZQ*(II.)@D;/5:UX&WU@U[@#['%<@^21TI](FM.D^_
MB=5:OS6>QL>C\K>CI9"T9H&VX<GA(HK`9PC^8R.Q,QKO4V1P]:](X[4OTF0$
M7G^_:</JA[L^T.B_Q3C@*Y%]HW]?[2KI]&WZK'@?_;?7O^.R"B_Z[OS._<K9
M<"B@(@(HU@/]>MW[2BOPVKH5/8/P_P`E1;][\Q4E"BD@(@(@(@(@(@(@(@(@
M(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(N%2I3HTYZM6>2E2
MIBC#U*E2;H0G3D%:YW-./.-VU+**+TUVW,,,VUTTUQG;;.,8SD4)#07.(:T`
MDDD``#M))Y`#UDJY##+8EC@@BDGGF>V*&&%CI)99'N#61QQL#GO>]Q#6L:"Y
MSB``25!"_DQ4A%@LE4LCP[SBP)#'L2IL8X%&)#+&_6/J&IP=FIV>9FU-QT"B
MS<_%MVZ1B<)3*65"Y+5*,LE1Z(_!VNL?F*(M1THGR6;4L77,CJPRSLZHL?)&
M^2PQIK0LE#"V)\TT;7N+0#L=UTNKT/ZZDTKD=;9&A1TYI;%90X6[D=3YG%8.
MT<I%=JT;M''Z?NVX]3YJWC'6VSY*KA<+D+-2O#8<^+K(NK.`_/G+RVX/J='(
MI#>)K^JE6R;8VSOFZ]Y67`OFK4[1Y2QV!2B.PUCF)SOOA)HT.4OF#4D0$FJE
M.YJHTM$5C=9GKU8&&&O@Y73EI],X<E.*O5[B1L5::*O'8,AX>K?/.QK07.))
M#5ZCYMZ!]#:C,>6S>H.G'&0X03!FC?2NC3".U-Z:Z-V/FRVI\-E=09+`1T&]
M>Z_3P.!NSVI&0PM;`QUB3+S>-$/?9A+YA8TGL.U"IK&5$1=*\G,N7KZ60L#F
MWMR%];6FH$F$<*,(>MV[58K521NDCP4>H4:)G8DC;0K2^<1!+///;FMW18A,
M#ZEF=SL>V)[&-D8R@WAKD2<'$XS,FD!)V>!R6@9TP9[&X'`X'2>&TIHI^G<Q
M%G:6JM-X*K6Z0K.3J6K=G&V[VO)_2-1-DQS;;J\$.)MXC'OBBB=-1?*'/=@5
MW=/_`(D\AF:!QJSJD1*HO61+P1!(I$I#+*XBT<U?]T.[MNACE>/L79LG+,MJ
M+78\Y$:<461Z,G<O0PW4S79C1NG,]'4AR>.$L%`2BI7@L6J5>#KBPREL-*>O
M$7.X&?2<TD`;-(!._I^CKY4/3IT59#4V8T;KJS!FM8R4)-2YO.8K!ZNS66=B
MVV6T6V<OJO&9K(=7`+E@B*.RR-[I..1KW,86YCQKX@T#Q%:I0QT##W*%,TR<
M&]U?VM3-9Q+$*ES;$QZ-.O2IIA(GXIL5F)3_`).M/;-4ACB2F0%K\J-6]#A/
MD8'3&%TS'8APM5]2*T]DLT9MW++'2,:6M>UMJQ.(W%IX7&/A+PU@?Q<#-M!T
MN]/'2ATZW<-DNE#/U-19#`5;5+%W8M.Z;P=F&G<ECGEJS38#$XM]R!LT?6UX
M[AG;4DELNK"(VK/6V8&_7'T!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!%\3BY-
MS.C/<79P1-;>ETR8I7N*HA$C3EX_W,/5*3"B"=,?^=C-]=<?^XBY[6-+GN:Q
MHYESB&M'XDD`?JK%FS6IPR6;=B"K7B;Q2V+,L<$,;?>DEE<UC&][G`+`IY;M
M?UQ63M<,E?M-Z\9FA&^J)#'T:Z5DJ6IQ/2)V]:UIXTG=%3JG6FKDF2%#>2H(
M]`=A88:6C+-4%X]F[6JU'WI9/]-&QLADB:Z8%CBT-<P1!Y>'%S=BT$;'B)#=
MRM#G]7Z?TWIBYK')WP=.TJ<-^3(8^&?*LEJ6'Q1UYJL>-CM2VXYWSP]7)79)
M'P/ZYSVPM?(VM=3<V$EW6#'HK`>._)$N$N^[AAPN29UUO"Z[;"DK2O7HSTRQ
MT7[N#MJXK$R1KT++1)3DYKB2H,+V)+W&JI9YN0LQ0UL9E/1W\?%>GJFO58&L
M<YI#GNXG\;@U@`:""X$C8+FFDNFV+7&H<?BL!T==)+<);=8](UGFM..PNG*S
M(JD]B%\4UJ<V;8LS1150UL$3XW6(Y'-+`Y0[U!;@Y90&3TG6?'-\JML4<B)0
MW51'$CBW/[G;^LI6?/;K-YHRZ%[&Q=KKNKZW;SII)Y$N1'.+8I1E(DFBM:[M
M*7;U>.TYJ/.RY*WC;^(Q.%T_BGY;+9+)U9[CF2-F;#2HP5VEM>Q8R=J2O4JU
MI71]8]\KWO$,4A;L>D6OTSW<GCZ71SF]#Z?PEBFUE[)9S'9/*:CCR1GGZPXZ
MI&3B'T(J0@D<;;6S"?K`'/8YC6V-X6<97/B10[)1KA8YEG-T=<'%0Q.1L521
M31I:W31,H5LNJ4AU>U3MNH?,O,B<I`].:U^?7F0.C@[JE"D_8S.-->SF4MW,
MGJ/+OSF6R%CTBS=?4K4F["**&."&K4:RM#7@CB;'!%#'''%$&Q1L9&QK1Z7H
M_P!-ZHTS@YL?J_6DNN\I/?GN?.TN$HX!E>O-!6C&-KT*$LL/H\,L,T[97.ZV
M1]J7CY!H&.07IU\,*_6Y=&RA8B_O&ZC96<[6!LZ60L.6;;^DRKSI.7!^1$'X
MW\F^FR1(FP7MC&Y>NNV/.'GJ^F,%6=QLQT$DA/$9+/':<7>W_4.D`/Y0-EXW
M!?)SZ%M/S>E5=`XC(7#(97W-0FUJ29\Q/%UI&=L7X6/!Y@PQ1AI`+0#S4M7Y
MQBI3DZSL##=<1-ES5&')2[LB8J12>.Y1N"M+\B//R?&'AG4*<;IO]/T2HTXG
M7_GH7KO_`#"_E\%B\['##E*QLQP/=)$T33P\+W-X2=X)8B[=O+9Q(]>VZ];K
M_HPT3TGT\?0UMAW9>IB[,ENC$S(Y3'=38FBZF1Y?B[E.23BC^CP2N>P=H:'<
MU@=&<%N,'&Z9*9_3E=*(I*UC"MC*AS-F<ZD&IC*XK&Y>K2?(9))'9OTR:J:4
M!F%&B7527Z'.A9VA9INN^)BM*X+"V76\;2->PZ)T#GFS;FWB>YCW-X)YY&#=
MT;#Q!O$-M@=B0=#H7H*Z+^C;,RZ@T;IR3$Y::A/C)++LUG<@'4K$U:Q-#U&2
MR5NN"Z6I`[K&Q"5O!PM>&N>'6X'HEUU`1>?[]IP^J'NS[0Z+_%..`KD7VC?U
M_M*NGT;?JL>!_P#;?7O^.R"B_P"N[\SOW*V7`HH"("*-8#_7K=^THK\-JZ%3
MV#\/\E1;][\Q4E"BD@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@
M(@(@(@(@(@(@(N(\\E,28H4G%)R"=-C#CSS-"B2B]<>7;<PPS.NFFFN/IVVV
MVQKC'TYR*$@`DD`#F23L`/:2>Q3CCDFD9%%&^661P9''&USY'N<=@UC&@N<X
MGD``23V!5V=.5%38D-CP2"K7FX;/JQE5N\KK.J6DR2R-(<B<FQJ/CQCLJ-:H
M*WRS58[),;1E\E[2\Z)M%RS=)JE;EQJ?5/S5'K;=:LZ2_<I1N?/3I,ZZ5I:]
MC#$9'%E9D_%(W^3).R38.=P[,>1U>ET*ZX.*TEJ74E?'Z"T;K7(0T,'K#6UY
MN(Q,\<]2Y>CRK*,++NI+>#->C/MF,;@;V/=*ZM`V<S6ZS)>N2/?*R>[U>]L\
M4KBBHRL4[N-J1:S]E=E6DD0(9(;HGCL<UKN3MU>MRN1Q=,4I/D"F523]VUKI
M\E_=]T-;C-SX-DS=DTI(X*F-A<[CNPW"ZW=:QLIVBA]$F958Z6$`F5T\O5.?
MP]4_@W.7/CNA/3+=9XZ_F]6])68KPMJ:*S6C6P:0T7/9LXACI<MEG:KP]O55
MJ'$YF9\,6*APF)^=Z]+KOG6DRVUL?"3Q-A#\WS9JNR6V!R2:)T_,[\NC5UNS
M0]0=EWCKDX.3&W1B`1QBC$,:&])NOP2LURR*E;Z4B0ZOJMQU2E:Z4&#K2-L,
MR,]K+QV98Y70Y&1DE:,Q/<^-D-6**&O&QI=L[^6YT@:WK'/V"N2=..H\9:T[
M=Z.\%I;HBOZ;Q=_&5LOT=T+V.U'D6Y6I4J9*WF=49;)9G4-^U.VJ7UR,C#!C
M7V+)QL%0S2.=9)E9&:-M#9'XZTMC`PLJ%,V,[(RH$K6T-+:B)U3HV]L;4)1"
M-`A2$::$IDB4DI.03IJ647IIKC7&WCCCB8R*)C(HHVAD<<;6L8QC1LUK&-`:
MUK0``UH``Y`+D60R.0R]^YE,M>N9/)Y&S-<R&1R%J>[?O7+$CI;%JY;LOEL6
M;,\KG233S2/EED<Y[W.<25V8FL-`1`1`1`1`1`1`1`1`1`1`1`1`1`11Q_&*
MH_\`YIUQ_P#7$9^*#"^<L=_[?2_^*@__`+%YO^,M(?\`XJTW_P#KF,__`-2D
M%.H3JTY"I*>2I2J22E"92G-T.3J$YVFIA)Y!Q>VQ9I)I>VIA1I>VVAFFVNVN
MV=<XR,P$.`<TAS7`%K@0001N"".1!',$<B%Z&.2.:-DL3V2Q2L;)')&YKXY(
MWM#F/8]I+7L>TAS7-):YI!!(*X3G!$G2K5IJDKY*W:*#%QNFWIL)M4A63E.#
M=2?/WP827C.^Y6-<FXQY,8TSG.,9H7-`<XD;-!+CV[<(W.^WL'J[5!]B".*>
M9TK.JK-D=.]IX^J$+>.4.#.)P<QHW<S;B[MR%05+U,.-\GD:&+U(AN"]W)6[
M(FE2=4=1S!^;&C=8J*3F+G-Q=D3"GPV(-#<JURQORX8T1E&FD:*-M<:;><;J
MO%S2MAI-NY%SGM832I32,CW(!<][Q$.!N_$XMXOH@D`\@>`1?*:Z-LID8,7I
M&#6&O+,MJ"I(_2&D,Q?JU'32LC=/:LVX*$8JUP[KIYJ_I`;"USXVR$!IL7?S
MMR0;&%C+XTQ2KY+*7!W,2/2FUWM[:8Y'FGY&::2[93Q_S75VS\LT+3&HD9NA
M^-#M3=-=]=3,Z;3)/RC(XQBH:DLSG\,AN22,BB9PDA^T7TW_`$M@6MY['<+H
M_2!;Z2:U"BWHSQ.ELGE;%QT-V75MZ]4QN.J=2]S+?5X[:U;/7-;$^&%PD`>'
MM!`<6XWQ_BW+)H<I(\\EK4J^7$NJ%`4P0JKH2M9&.*+B#U!BY81)GHW20O12
MT@TI-\E=$NV"?DQ1Y)I6^Y^AUK&PYECI7Y6Y4GXVM$<%2NZ..%P)+B)9#UD@
M<"!L]O+A!!&Y!UG1]BNEJG9R5WI,U5I;+LMP5V8_":6P<]&CBIV22.GF9D[K
MFY&ZV9CV1=5:B(9U39&/8XR-?'TVZ>7&BT;&?[,M=FFUGN[X[;O!#),;'F*F
M(1XXS333*2.QMK=6I"C;-?,VV+;E>%R4O)IFNA>I7HRR\:QIG%6[4MNXRQ<?
M(_C$<]J=T$1.WT8HF/8UK.7U3Q`>KDO/9OY._1GJG4>0U/JREF]47+UMUQE'
M,ZDS,N'QSW-:TPX[&5;56"&J-B6UI>OB:7N#6AG"UMP(K%8Y"(VR0^(LZ&/Q
MB-MR5H8F-M)P0WM;8B+U*2(DA.,YP6007KKJ7KY<^3&/]_+](W<,,5>*."!C
M8H8FAD<;!LUC&C8-:/4`%V+%8K&X/&T</B*<&/Q>-K14Z%&LP1UZM:!H9%#"
MP?5CC:`&CU+OM]]"M-S3=]2RR]=MS#-]L:::::8SMOOOOMG&NNNNN,[;;;9Q
MC7&,YSG&,"Z`20`"23L`.9)/8`/62M@M:'$G0SE->EC\]WO3937Q*5]H#A@B
M4Z[93%4VPO\`KK9MW(B#<8]$OOVP&33#&X_)TRW:JX1#<ZF&)7U3C?I>KB-+
M8+&Z!@/#D2Z#4&M'M/TCF9X#\V8-[AVQX#'S_P`^/B?'\ZWKFX#Z[-L&O_J)
M7W#S9L8:W;MU37?S)1ZOYSP-CMOU;&\]B5LQ',UG("("("("("+S_?M.'U0]
MV?:'1?XIQP%<B^T;^O\`:5;3I,.#VT](CAFZQIF3R*1MG%"+.#!'U;J0QI7U
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M=9[K%4)+@^FLBY]CR9U=VIH+2)#'5\2IENRHIEW3H-G!W181FEHOE*G!`*+A
MPD@^HD;_`(+%&/DK7,7EMM-SFP7RH4;V"E5ZF1[BKR@ER'!1M<5]IKINZ12G
MGIM+4XV*VR:B,5ZK"-<E[G$%Z'$[;U/J_#_)46C?<\N;CZP/W66=KBJ/9CDM
M]RWF-^A`HI;'N\1YIVN*H]F.2WW+>8WZ$`FQ[O$>:=KBJ/9CDM]RWF-^A`)L
M>[Q'FG:XJCV8Y+?<MYC?H0";'N\1YIVN*H]F.2WW+>8WZ$`FQ[O$>:=KBJ/9
MCDM]RWF-^A`)L>[Q'FG:XJCV8Y+?<MYC?H0";'N\1YIVN*H]F.2WW+>8WZ$`
MFQ[O$>:=KBJ/9CDM]RWF-^A`)L>[Q'FG:XJCV8Y+?<MYC?H0";'N\1YIVN*H
M]F.2WW+>8WZ$`FQ[O$>:=KBJ/9CDM]RWF-^A`)L>[Q'FG:XJCV8Y+?<MYC?H
M0";'N\1YIVN*H]F.2WW+>8WZ$`FQ[O$>:=KBJ/9CDM]RWF-^A`)L>[Q'FG:X
MJCV8Y+?<MYC?H0";'N\1YIVN*H]F.2WW+>8WZ$`FQ[O$>:=KBJ/9CDM]RWF-
M^A`)L>[Q'FG:XJCV8Y+?<MYC?H0";'N\1YIVN*H]F.2WW+>8WZ$`FQ[O$>:=
MKBJ/9CDM]RWF-^A`)L>[Q'FG:XJCV8Y+?<MYC?H0";'N\1YIVN*H]F.2WW+>
M8WZ$`FQ[O$>:=KBJ/9CDM]RWF-^A`)L>[Q'FG:XJCV8Y+?<MYC?H0";'N\1Y
MIVN*H]F.2WW+>8WZ$`FQ[O$>:=KBJ/9CDM]RWF-^A`)L>[Q'FH1WZFW&I^B4
MCE%--/('D@IBRWYL>8I0_&>])A)$#EG51G"!SU7P1B9617M\F-\Q*^/+:K/Q
MH9LD3J<%&^9I7YZBZ*=]`RYA]>:."2'$M;;>V61KW-:YX>V!C0(W<;Y)FLC.
MS7N:YS0>STN@?74&2PU'7;<7T04\[B+^>QN9Z5[5C2-&UB\;/2@LRU:DM.UG
M+UA[\A7=3HT,1:NWXNMGIP305YY8\=QS&LB72TG5)7UF5-4SA!\'&.#SP_YK
MS6]&Z8OL/V-(3_NZV\?RZJ8MH),%A2=PSM*;(;)0E9U&$>R,AS)4);G%F9YQ
MM'4HT7U]RZ1[[&29/+7W`ZI@%*(UK#@'_P`ZVR9L9X2T/!&&:O0W@<'(9\CJ
M[7.N*FH^K95Q]6GIWHUMX#&9\,EE^=K<[];9(:EP-=\M0#"Z1N8:;(1&P)Y:
M<D4^.:)N-$NB;#'>12?F#RF6L4I<IF2YW'PTY8Y:-GEU1M2,]'B`0KCI$Z^4
MQI#\TEJ&)@>XT]DLRA8XG)U.QRY09O9^8:L\$<65EGS3HYGV`^^8^#K)&L:6
M^BUF053"W@!BBDAD$9<XAV[B5MG=/.J<%G,GENBC&8/H5KY+"T]/R4]`,N"\
M,?1L7;$=@ZHU#=SFJHLQ9].=%D\ICLOCI,A%!4CEA;'6B8VUQ7+&HB,;X(B7
M)$G!AFQQF"N%/,0O!AN_D\\W?&E#8\XS?R8\[?;R[;>3'ESGR#=@`=@`W.YV
M&VY]OXKB+WRREIDD=(6-#&E\G&6L;OPL;Q..S6[G9HV`W.P7+VN*H]F.2WW+
M>8WZ$"JAL>[Q'FG:XJCV8Y+?<MYC?H0";'N\1YIVN*H]F.2WW+>8WZ$`FQ[O
M$>:=KBJ/9CDM]RWF-^A`)L>[Q'FG:XJCV8Y+?<MYC?H0";'N\1YKKUG,ZE&[
M;31P:^0R'<S7.Y>BSAUR^2[&:XSY,[::GT9IG;7&?HSG7&<8S]'E\H@Z2-FW
M&]C-^SB<&[_AN0L>:U5KEK;%JM`7#=HFL0Q%P'(EH>]I(!Y;A?I%S,I5QR9A
MO:>1"_)/FY-PBX<\OE62L;^=YF3,$49OYGG^9MYOG>3SO-V\GE\F?(;(Q^_`
M]C]NWA<';;]F^Q.RK#9K6>+T>S7GX-N/J9XI>'BWX>+@>[AWV.V^V^QV[%]W
M:XJCV8Y+?<MYC?H0)J_L>[Q'FG:XJCV8Y+?<MYC?H0";'N\1YIVN*H]F.2WW
M+>8WZ$`FQ[O$>:=KBJ/9CDM]RWF-^A`)L>[Q'FHYD?49XFP\]0EETKM"+*4F
MVVBI/(^,G*!D/3;Z_P#+502YTVE,)VU_]6IFNN<?^<#%EO4H"1-;JPD<B);$
M49!]A#WC;]5YS):PTCAY)(LOJK3>*EB)$L>2SN+HR1D=HD9:MQ.81ZPX`A=]
MISQXX;Q,N?;.-Q$0$UM+>M9ZLXL\ID,&U93===BWDV8+:9(CA+1OKMKMJYG.
M9:'.-M<_*/)MCRR?;K1UC<=/%Z*V/K38#PZ+J_?#V<0<T[\BW<'U*[;U/IVC
MI^75EC-8T::AI#)/SD5N&SC#0(!%R.W6=-%-7<'`MEA=(UP(+25B;=U,N$SX
M[M<?C=Q+)=(7L_5*SQZ&57<LQ?W-3MKMOJF0,D8KUU=%:G.FF^V$R=(8HSKK
MMM@O.,9SC50:EP=FQ%4@R$<MB=W!$QD5@ASMB=N/JNK'8>;G`=ZYKAOE"]#>
MHL_C-,836]/)YO,6?1,=3JX[-O98L<#Y!'Z8<8VC%NUCB'3V8V$@-#BX@'[I
MSS[JB%'MR0FK^5<J7.92@U,A:.+%V1U9MA/N7IOJ419L1@&ZW.<FZ>7=MPN)
M)SG752:1N85J9?R67AQCHF2UK]ETP<YC:55]D[,+0>+A(#3](;`GGZEN>D#I
M4Q'1W8QE3(Z?UGGK.6ALS58=(Z<L9]S6U7Q1R-L.AEB9`]SIF=6R1X,@XB.3
M2OK@O.2&2Q.XJ9!1',:L]4IY);<3+^)EWOISZ087MN8N0;U5$+(1)DQ&^-2M
MM'A:VK#=M]=TZ4TG&QFMS'9'YQ9*\4<A2$;FM`R%;T9TO$">*)O&_B:-MG'<
M;'ELL[H_U^.D"KD;C-':ZTA%0L001QZZP'\/V,BV:-\GI&.A-JUZ16CX>"23
MC:6O<T%OT@33Z6]4F]DDGD#!`^FMRQE+8UO3FVM<M?*TO>(M;VW(UIZ9$_)D
M*OCVL6%I'-,46O)1FFZ+""C]"E&NAVNVN-;-E<X)I8ZVFY)F,D>QD\N2JUV2
M-:XM$C6N:7<+P`]H//A/J*Y]E.DOIG;D\C0T_P#)\OY2K4OVZE7+Y'I"TSA*
MUZ"O8DABOQ5K,$DX@M1L;8B87=8(Y&@\P59:?<S'HRF]G:L:OMPB[%;-&5)<
M1L#B1S5,A;4ZKE#5F5MCD_1NA]52S1D0GO&J!:WXP2XK$27./-3J,YQM;+\A
MZ`7U(:XOF.(]39D=U#'N+.N8Z2+Z1ZMI?PN;R<YH]173]06=<NT8;>F,5@6:
MWEI8R5N'U!?F=A:MJ>2I\[5;-_&_S9A1@?<%>:N."S-!%MM'(O%X9G.=]\Y_
MWSOMG/DQG'T^7/E^C;&,X_\`XSC&?_?'E'R.>T_B5^!;OK.W[>([[?BO5$L:
M*,O&%TNMG\ZZ@S3'V*DJVBJ^KZPHGF&SU6^.#4R:;K'];M&:&<4TA4+RU12$
MMV97WYL6-R!&I0*%!1_R@WZ=BPD63HXJ2>[DHX6XNBPTZUMT%9Y$#29)&-;Q
M.<X.#20YO)H]I7[.-Z'<=TB:=T'D,WK#7U+%1:"TK2DTI@-3S8;3MV2/',E?
M>O5((C/-:FCGCKO='8A`BKQ[#B+R;54I8?%?CS"-*ZJ2M>3,9B6'-<]&-Q_$
M?G)(#5#LYZ)RW%>>OD=-.R_<U9A*3L:5JIT2Z[Z[;$IRO/W\[>T,=3QE?T6E
M%U,'&Z3@,DDI+W[<3BZ5[W;NV&XWV]@"ZYHG06E^CO!C3FD<:<9B!9GNNKOO
M7L@^2W:;&VS8DL9*U;G+YNJ87M$@B!!+(V\3MY20<J*::TA#>V0OD6W($I>"
MDR)!PDY@(TB<K'^Q9"9/0I9))>/_`!H7IKKC_P`8&6UK6-#6-:UHY!K0&M`]
M@`V`_1>I@K0588Z]6&"M!$T-B@@9'##&T=C8XXPUC&CU!K0%]?:XJCV8Y+?<
MMYC?H0)*]L>[Q'FG:XJCV8Y+?<MYC?H0";'N\1YIVN*H]F.2WW+>8WZ$`FQ[
MO$>:=KBJ/9CDM]RWF-^A`)L>[Q'FJ&<XN8$=M%CBW#RI2.0S),^1:S+7:C^B
MXM\H&J95?Q<1FX*N2PV&.+*>)E;FXOZ(U+4L5=6)D<43++)XA=7)<V8;"S#.
MB:#J5L<,CKK*PLFQVE!"['59AO%EM56@\X/'\)V$L-:2*3+Y!K22VG1ZM[2+
M+=\*V7NZNI&=GV.(/<"-XZ[=NM?OOR<01&SL^D_<'Z*NE$>1E"P**1F#PZ`<
MB8]$H<P,\6B[`V\*.8Q#>RQY@;T[4S-2$G^!&?1I&]O2ITB?3RYSJ45KC.<Y
M\N<^#N6[-^W9O7)GV;EVQ-:M6)3Q23V+$CI9II#ZWR2/<]QV',E9C6!C6L:&
MAK6AK0"-@UHV`'/U`;+(>UQ5'LQR6^Y;S&_0@8ZKL>[Q'FG:XJCV8Y+?<MYC
M?H0";'N\1YIVN*H]F.2WW+>8WZ$`FQ[O$>:L<UN*=X;&YV2%KBDKHA2.*8IS
M;')D<BTZU.6I)+<&9Y2('AH7:%FZZJVQV0HG)`HP8E7)$RHHTG0J+[@1`1>?
M[]IP^J'NS[0Z+_%..`KD7VC?U_M*N'T@VIM?>DYPA8WE$F<VAYXOPIJ=6U85
MJ<D<&UQ934:Y$J)WQG4U,K2G&D'E;8SJ849MKG'DSD%%_P!=WYC^Y5LBN)7'
MDIN0-N:V0J2FZV6V]25B][E#B]GV\RGX4,4_=)$O?%+^]2%AVT*)85+PY+M&
M1&G3(&LI(B2ITY94W/M]6WZ>Q=(U<).*K(\6%(FNEHLDD5J25JF<\D6IST:_
MOLO8Y?F?LTIP]GNIKHUR%KFOFRA"\,JIN<$ST40N*4:G)R-BR;GES[%8J+QB
M.0F-1Z&0]C:HQ$HDQM4:B\;8D*=L9(_'F)"0ULS(SMJ0LI(WM;4W)4R%`B3%
M%ITJ4@H@G30O377!46)0'^O6[]I17X;5T*GL'X?Y*BW[WYBI*%%)`1`1`1`1
M`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`11_(;8JV);OI<HLB"1TZ+L:Z3
M20AZEK"V*6".MFA)CB^O"98O)/;FA#HH3[*W%664D(].1Z0W7)Q?G8LMVE`9
M!-;K1&&-TTHDGB88HF`%\L@<X%D;01Q/<`T;C<\PO48K0^M,XW&/PNDM396/
M,Y*MA\1+CL%D[D64RUQSVU,90EKU9([=^RZ*405('/GEZN3@8>!VVL*N^KO4
MED\J;,X^PF*2VTVAMVB+?4$AJ%EUEI]A+]4:H^S'54<I<VIG:HK%C#D6Z)^4
M+B&]4V-;RXX4&X.;23^?X_I(QV1U+DL%6@FNQP"NW&ST(^O-V1K7'(.)+V1L
MAKN<S@D+@US(YI-S]`'[*U7\A'76D>A31_2EJ+-X+15^V,[:UYBM>9$X*+2M
M4SP1:/I0QPT[M^[FLTR.P+&,BK2VH;EW'U.J9U=N2*\"S/*V>*;182"*WX_L
M!9N6FJK#2N1US3Q?\ADJ;Y3+'F!KF2(PMD1/\5)5EL[0HDLD7,KJN3K'=.N*
M1&-BKV3OGNR;L0%3%Q`]72M-><A9=PS#>>2LZ."O&V6$$1QF:9T;W!T@<&\!
M^<8!T):9BT7DY)=7=*.3>P7M;:4GJ1]'VF:WI.(EZK!T-35LCG=0Y&QC,W)`
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M>OG;[;;9\NV<Y&TCCCB:&1,9&QO8R-K6-'X-:`!^@7++^1R&5M2WLI>N9*[/
MPF:Y?LS7+4Q:T,:9;%A\DTG"T!K>-YV:`!R`"[,36&@(@(@(@(@(JN3GFUQ'
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MK-1Z4NZGT!D=`=3A+<6,J97+4,E=R55U\ODMRUZ+&G&F.0]3Z/8+Y'[%[7</
M(93TE&/D^^NEZD<;9U5D$W+05UF9K[(C3Q)E!Y.ZB:X8L1U*V[:)BS"-]7?9
MRRX9\TS!B#!'_`X9'1O'EY'Y<8JQ3K[-H]>ZU$^8D<5OJ^J#"`-OYG'Q=N[=
MO6MI\DFCTH7[.NX^C7.Z5P+FP:<^>K&I<9<R<CV.DS7H'S=%6(B:Z,BV;/I'
M)P=`(^QZ]+T,BUP%4SM$[$LQJ<[A5L4J;E5HQ.)I&EN0.SLJ>/W:?&N)*C#$
M.YL80*VC3*149\G=5;5N<JQKJL,UQVV"&Z*/4V;;'W3',UUN&%K&M>\OZJ1D
M));O$TL^BX[/<PD_6*_3+"XK6+=%G$ZBU/5M:QFH96M+JG$XF&I6@MVY;GS;
M>JXB5[H"[%P34V]3*[J[<M1SY>$3.`K)$^(%ZM\JC4FFW/&_)F5'Y`S/JJ.-
M[5$X9')"6TN*=P-9'IO:B%?IV1VU3Y0.:/0S7TZ$\\C&^OGXVQJ8<)D&S12V
M-19*<1RQR&)K(((I0QP<8Y&L!WC?MPO:"-VDC?GNN8XCH>UW6RN,RF<Z>M?Y
MIF/R%*_+C:]3$87&Y%M2S'8=1NUZL<W64K8C,%J$.'6022,#AQ;J>[^XWQ#D
M6@C;9,)79\:11I8XK"B:VG3E"/G?+D2E(-3O^[:7L8YI2-4FFZ0K;<K*<PP_
M;3;_`%ML#99+%P91L3)YK<38G.<!5L/K\?$`")"SF]HVY#<;$GVKWW2!T;8?
MI&KXVKF<MJC&08R:S,V/36>LX/TPV61,='D'5FEUJ*,1`PL);U;G2$'Z975T
M!Q,I[C4JD[A6:66X<YBG:DLB<I7-Y-+U2\EE,7G-V,:OKBJ3)-B3'-;ML8C3
MIS#?3>:;MOKIIC6&-PU+%&5U03\<X8)'36)IRX1\1;MUCRUNQ>XGA`)W]BQ>
MC_HDT=T9RY2QIB++^E9F.K%D;.6SF3S$L[*3IWUP!?L2Q1%CK,Q+H8XW/X]G
MEP:T#XI#PFXG2Z8/T_E="U[)Y?)W(UW?GJ0M.ST<YN)V-<&JCTSD>I1:[&8T
MU\[0I,65G./+YGESG.8RX##33R69L=5FGF<7R22Q]87N/:2'DM]7J`"L9'H1
MZ)<OF;^H,MH'3N4S&4LNN7[N1IFZ^S9>`'ROCLOE@!=PC<,B:T]O#N2I\;81
M#&>)I($U1..-\(0-NC.BB"1E;B8RE:2L>0ML)8]$^&TM!ICZ,)-4V",?_@&Q
M;7@9"VLR&)M=K0QL`C:(@P=C!'MP!H]3=MNY>_K8/"T\3#@*F)QM?!UZS:<&
M'BI5V8R*HT;-K,HMC%9L`'9$(^#_`(5]K3&HXP:8+8F!D92\8\W!;2U(6W3&
M/_;&B,@G7&/_`-O)Y!)D440VCCCC'L8QK!_R@*]4QF-Q[>&ACZ-)HY!M2I!6
M;M[-H8V!=V+BSD!$!$!%U7S$R?\`Z,U?_P!>D_\`\1;ZF+_U4?P-\EB^@TO_
M`&.K_P##Q?\`\%V>NNNFNNFFNNFFFN-=--<8UUUUUQY-===<>3&NNN,8QC&,
M8QC&/)CZ!<62`&@-:`````!L`!R``'(`#D`.Q?H%5`1`1`1`18[+I9&X%%)-
M.9B\(H]$H:P/$IE#^Y&^A;V6/L#>H=7AU7&^3/HTC>WI5"I1OC&V=2BMLXUS
MGR8SD5*EF_;K4:<,EFW<L0U:M>(<4D]BQ(V*&&-OK?)(]K&CUDA4<YK&N<X@
M-:"YQ/8&@;DGN`&ZH?P0B4DL'>QN=%ILZUHL7E;NS*:[C#T5YCI4_%>+Y6[4
M;7NQ!GG[-;S)$+FXVW8*8C<K!TOG)C>M(P9'4FI7O->6ZV/&-T+BIF38[2@F
M;D;4+MXLMJJUP?/F1!&W6PUGQ1XC'N<"6TZ(D8[:R_?$J-+^.U("'V-N!KAS
MCKMWZIG<2"9'_P#$_8_5"V)#G:S$!$!$!$!$!$!%Y_OVG#ZH>[/M#HO\4XX"
MN1?:-_7^TJZ?1M^JQX'_`-M]>_X[(*+_`*[OS._<K9<"B@(@(HU@/]>MW[2B
MOPVKH5/8/P_R5%OWOS%24**2`B`B`B`B`B`B`B`B`B`B`B`B`B`B`BQN4S*(
M0=KW?)K*HW#V0LW4@QXE+XV1]K+/W+,-T)W<'94D2:F[E%&F:E['8WV++,WQ
MC.NFV<69K$%9G66)H8(P=C)-(R)@.Q.W$]S6[[`G;??8$^I;?"X#/:DNMQNG
M<)E\]D7L,K:&%QMS*771M<UCI&U:,,\Y8U[V,+Q&6ASVM)W<`8F4\I./A$^+
MJTFUXH[V,='#)<3"XTI42J1&QS2+&S8ET+;8TF=3]R7"*%?/C,7KKD]\1')-
MF<I<8N1Z'X)S6*%KT(787V^IZ\5XB9I3%U)L!X9"UY(?`.LC`YR-+>K#BYH/
MN(>A?I3ETP_6DFB,W1TG'EF8*34.7ABPF*9EG9IFG'TG7,Q-1B$E7-O^;;[B
M>KQUB.P+[ZS:UAT6%9Y:-SS!M9S6]#\FK-3GRK>*(V-MJ%QKN0*M]6G5VTDN
MB&\G"JM<0PS&^K?B1X.W3_.F-T."=C2C,:X_SXR2MZ34QF8N`S]0V)E%]24_
M0ZSKN').I?Z?[G6[[<?T=M]UZ+_J-MX_4ATWJ[I,Z'M'2QX1N;L9*WKRIJO%
MP`WG478=UGHWJZV/\0L+3:.)+&R>A<-GK`Q[=\L,G_(1PFSJP,O'UG:H67%E
M#@S6+-[@9$.RN5GQ0IS:H^M@\1CTR=4R$B5GXB\B>-7C;"),D7/C(DD)'R!,
MNOFUE76'Q1XN-E<0E\=NS?C;Q3F`/9$ZM!%8D:T3GJ99.,\(:Z2-LHX`[1LT
MOT65=.TLID>E*_=U"_-15<AI/3F@\C9;!A(\X^G=RE?4F=RNGZ4UF3"1',XJ
M@:`](EGK8W(SXN7TF:MB9L>YKRJ$($JZRN/=/SW,G7G.SA#ZXFUP,F(;EM0:
MM:!JS+IC6IA<E+=\.AC@Z+6I2V'M^[<6F:4Z@A5NJL=5J&:NT.MXNA9ZYQ>Z
MO4L7X^HX&\#&=?/3(E#^,N>YA86\`$8(<3NV97Y.^%U'9FK:0Z5->Z8&&JQT
M:N>U9IW061.H!<LF[:NC!8#5['8A]#T)M6E6O17([3;;IKTT4D`ARM32T^=Y
MC+G]^Y)VZ9%I)&'.--=<1I!6T/C\1W=V1.UJ9"QR%J@^]A[21`N+4OD?<ETR
M4_-"]5@O)*Q*G*)%\X^U)/8DER]_J9H7PLJ0MIP10=9$&&6*5E8V^N:[>6)[
MK!ZMQVV<``M)#TA:8H8#!8O&=$6A&YG$9FGE[NK,Q9U=GLIG6T,C+=AQ62Q5
MW4C=*MQ%JLZ'&Y2G6T_#Z?6A+Q)7FF>]8LIX6T:_P]@A5CDV-<C7''YXDB%5
M;UOV?.G,]U?26U.ORYJ7*58*<VW4II1X;V):F.8V@S*PYJ;D9[DXF*K+M/XV
M6"*O;%K(,BDDE:Z]>N67E\H8'\9?-L]FS&\,;@8V?2+&-+WEVZA^4)TD8O/9
M346DI-)Z`N9?&4,19@T'H/1NFJ<=+&R6Y:WH<-/"E].V7WIS:R5>6/)7FBO'
M=MSQTZC()05T55Y"F?2*(0.!06Q["97MK>[/CT!B!4U5*GE#\DRZ.KONT_*I
M"<G.+1K,I7L]:C6&HD^BPHTK7S1EOQE/_5RUZ]:I<N12QR7H:M<6>*1G")'O
M,>\I:0U_#*7-<6-#@0O&P=)6LY(=,8G.ZFU/J32>E<AC;F-T;E=3YZ33T$./
ML]>*5*B+W4XJ.6-\]<38Z.O/799E=`]CSNM3=,=#NKJ*N""W=".1=UES:!RE
M)*4*A8EAII3F;H;OAU;'C;1F+4*FR1-ZA>SOA6#RS5C:XK2?3:;F^DQS/%=$
M>.P^4J9>IG,L+=.PVPUSQ5(D.YZR.7:$.='.QSXY1N"YCW#<;[K[BZ0?^D?U
MGTE:"U)T<ZCZ)NCQ^G=386?"V8J\^?8^FQS&^A7*`=?=%#<Q-J*M?QKS&YD%
MNI7DZMS6<)WB#KB_.!`1`1?GSM?.SIYVOGXUQMG7RX\[&NV=L:[9U_WQKMG7
M;&,YQY,YUVQC_;(*FXWVW&X`)&_/8[@';MV)!V/<?8J:6GU!>(E.R%TATRN!
MMWFC,X'M#A#XPQR>8R!,\)]\E'-*A+&65T)1N!9N,E&)URE+DLS'F&9UV^@:
M*YJ7"497P3WF>D,<6.@ACFGE#QVL+88W\+M^6SB-CR*XQJKY0G1!HW(VL-F=
M85G9NE8?4L8?%T<IF,A'<C/"^I)%C*5ID-AKAPNCGEBX7<G$%3,\6N[+J0*N
M"J:\?[*<WB+,<HB5=*%)$'D;Z6^9;S"VQ:>_D&$1YQ1(UIJA>4X$[_)]T1Z?
M/EVSKN,]]Q[J`NTZTMI[X8YH:I(KRR=9PD,<91M$YK7$N#QRX2%[2YJRW/H=
MFL-*:=R&IK5S%4<IB-.22QX+)7VWC7<VK._(,<S'6((9G26&6&'JW0OC//8J
M"JFL#GA-;!CRBRZ`IVEJDSNX[RE`NM%38%G8(V:5_P`T:,*J)IM(GA5H^9:]
MG'5R(U*W:M5Y1!A"S9.9IKJ5G44]F,V\;1HTOI=:UUPV;>W`[@ZLPMZG?K.`
MN#P!P<0!#MB/!Z2U!T]9O4..DU-T?:-T5I$NL'*UY]4RZAU/U9IV/1!CY<3$
MW$]:+QJFP+48::@L,863&-[<PON@+6N62,ZB+\IK.H^#HV/5N>(A631'D3N]
M.WR]8H,?BYTKT->FLTQ"H2MWR`A.>C+P@+5E8T//4>DOY'&W+TL9AR]O'UVQ
M\,D%1D37R/XG'K!8<#(P\)#>$`M^B'#8D[[G7W1_JO6>2IR8OI4U1H;!PT17
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M<5C#*<;C,?CS-P"8T:5:H91'Q=6)37CCZS@XW\'%OP\3MMN([Y`+RV"`B`B`
MB`B`B`B`B`B`B`B`B`B`B`B`B`B`BUG<MM]^4UZ5SP(9-]E->ITK%?\`S06I
M]MMDQ=.L3]MM6-(+3RLXP4OORP&3?=];LGIEF]5PB8XV+,2OR;)G3-)`:5P6
M1U]..'(.?/I_1;'#Z1S,]?\`[3SC&GMCP&/G`@DX7,^=;U,@A]=VV#8_U$S*
M8YLV$UK_`,MKAU<1[YGCF-]^K8[ELX+9?IIH5IH45IJ667KKH67IKC33333&
M-=----<8UUUUUQC7777&,:XQC&,8Q@<T)))))))W)/,DGM)/K)6<OT*(@(@(
M@(@(@(@(O/\`?M.'U0]V?:'1?XIQP%<B^T;^O]I5T^C;]5CP/_MOKW_'9!1?
M]=WYG?N5LN!10$0$4:P'^O6[]I17X;5T*GL'X?Y*BW[WYBI*%%)`1`1`1`1`
M1`1`1`1`1`1:7^I;U6HMQ-2)ZWJDW61WO^\5?O:E&I;\*8H17V7;#S)=MWG&
M3TBE0^M[.HA6Q*7'R]L,?5;FF,)6-&FV.6Z^Z1(-,Q,IX_:?+NL4Y"QS-ZXI
M"1LUC^9S:XRQL-79OTHS.9`0Z,+[-^11\F27Y1W2!K6AJ?$ZBQ.@M#8._0S&
MHC4?2IR:VSF`JSZ;PV.L22Q2VLEB:N=Q^L;D#875&U*U"K??U.7ACFL507/A
MUY<51,[/XS<=IE)"HO*V.(M[?:<Z@-8HY(N6MVSI(5"5S97&R5C>FBB12R&J
M_E[$6:Z:OJ;1IT4J4+LG0^BPVK/XDQTV0P>+L3LBFBA8V[9K4VRO>SK)=GL=
M;<SJ&NBXN*/Z9D`9NYL@;RC.]%G1YHKI'S/1QK3IQT^W)Z.RN;T]T@G1FBM>
MZAMZ,U)BZN)OT<):IZDPVA*V7FSE#+17*5_!Y._B8Z\8FEO=39J2SV/2*>5C
MI+8,J4--!PZOCXZTJ[&:3'>?SN>(I0>A5[O3)$G5.V06,J&AN<-D!*%_<T/R
MAR3EK3#6)!MNGQC=M=FWSUG&/&053%&ZVPR6K-ELQ:[K(X'AE:$QL?P!LKV[
MO`<3&WZ*\_/#T)4\%J2&*]TGY_5,>6O0:3O,H:7TSIFQA8K,#<?D<Y2EN:ES
M$5^W5%F2SBZ=CJJ<KZ[&9*TULI.+$4KR+?H8\1VP.7;^E?G.1-3HEEU*5'7M
M:+F5B1HW$ARBB%+.<7248D>%*M$N->3S=GQ$<TIRD2PE(I7IU-@8_+2UY(K6
M=E$KY8WMGQ]"K3='$UKP^!K;/S@"V1SFN,A)D:6`-<&EP=NI.D/HGQFH*&6T
MOT$XN;&4\5=I3X+I#UWJK5];(9.Q8J2U,Y9FTV>CU[9Z$,%BLS'Q,&-L1WI9
M+%=\\-:6+*D_&Z,[S.-3M_L*\I8]1B+((PG0/5QS9%#'79+'#XRND<@KN*N4
M;@#O)G]&J4K7M>HC6$QSN=\Y(D"`\A+DB^,3#Z1#9EMY*>2&%L(9)?L-KR;1
M&%TTM2!\-62:5I+I'&'A+SQM8TANVDEZ7,PW3^8TSC-*]&V#Q^9S5K,RVL?H
M#3MC4%$39:/,UL3B]5YJIE]3T</C+$,-?'58LN9F4(_1+-FS')-UN.1[C-P]
MKN.J8@AJBFTS`=)")@L;)6W,<H]-+43>>SI9(J434QZ6FOR1L4JVXAT.4;+D
MZ14K3EG:%J3]3+<6'P56)U=M&@(C,+#F3LCFWG:PQMF<;!D<96L+F!Y/$&N<
M`?I'?'U#\HOI4S679G,STM:BK9:OB9M/Q6J&HG:<=!A)K<=ZQAXX<)-BX(L;
M+=@AM3461-KR6((97QE\,998E0Y16+,FCHJ7Q^.1M(F0%:.*A4W-#(F1YU)2
M-A>BLPQ.@)3>9NG2H-,&:E>;L22GQY-M-<[0NAACXRZ**(!HXB6,C#>36#B.
MS0.8#>>W8`N6Y',0,ADRF6RL3*[WFQ-D<C>8V%S[DH>9Y+EF4,<^U-*'&1TA
M,\L@/$Y[]ST#+;%621W3L$=LN`/[\JU/W2LC+,HZZNZG5,28I4[)VU"XGK#M
M4Z<HT\_)9.V"B2S#3,ZZ:;;8MQW*<KQ%%:K22'<B..>)[SL"3LQKBX[`$G8<
M@">Q:2EJS2V2MQX_':ET_?ORAYBI4LSCK5N01,=)(8ZT%F29XCC:Z1Y:PAC&
MN<[9H)76SF\*6K%Q3L]E6_5]>NZM`6Z)6J<3^*1-R4MAJA2D*<4Z%^=D"H]"
M:J1JTQ:LHK8C=0E4DZF9,(-UUC8OT*C@RU=J5GN:'AEBS#"XM)+0X-D>TEI+
M7`$#8D$;[@K&SNN=%:7LQT]2ZPTMIVW-`VU%5SFH,3B;,M5\DL3+$<%^W7E?
M`Z6&:)LS6&-TD4K`XNC<!W<#LJNK3:%,@K*>0ZPV%&Y',RMZA$E9Y2TIG=,F
M1K5#6>XLBQ<D*<"$;@@5'(]SL'EIUJ4[<O!9Y6VTZUNK<89:EF"U&UQ89*\L
M<S`\!KBPNC<YH<&N:2W?<!P.VQ"SL!J;3FJJ<N0TQGL-J*A#9?2FO8/)TLK4
MCN1Q0S257V:,T\+;$<-B"5\)>)&QS1/+0V1I-?5_/7AFV'')UG)2IM#TYAA)
MQ14J1J]RS2MLZ&%[:I,GY\_3?7.NVO\`OC.,X&M=J/!,)#LK2!!((ZYI(([0
M=M]MESVQT^=#%9[XYNDO2(?&YS'L9E897->TD.:1%QD$$$$>WDIIM2YZOI*'
MZS^U)@VPV';KD+9H^N!2X])NN<RSC4";71N2+5.VZHL@[8O.",Z>33/G;8\N
M/+GW+U2A!Z3<G;!!Q-9UCPXMXG[EH^B''GL=N2]KJO6NEM$88:@U7F:V&PSI
MX*S;]AL\D3I[37NKQAM:&:4NE;&\MV9MLT[D<E4N3=0OCU+:VNU1Q^MF.S:T
M*^I*S[/9&;,?EF$7GPB,JW(I6MV<V9H0J41+CEOT4H]'(I2H)-VU)^C&YA>B
MMZHQKZ&4DQ=V&Q=IXR]>BC,<W#O6@?(TOXV,:YH>&AS0\.(/+;M'),E\H?H\
MR^F];R='VK<=G-4:>T1JC5%&D<?EA#O@\9-99-.;5*G!+`RSZ.)86V6RR,>0
MSEQ.;H\8^M%S`4/3.0X(ZR5H#W1O)6I6J!+S7-2D,5DZ*4[<5^\_^HO.)VW+
M1E_^M1L7K_Y')H>DS4;IHFO;0<UTC&N#*CR\M+@"&#K^;B-PWOV7P[1^6GTP
M27:<=B#2\L#[5=D\57`V7VI872L;)'69\Z?2L/87-A;]Z0M'K7I>K.U7NV:J
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MI*K+0+]ES41L5Z<I/KH49H9N;G0_3TFWEV>2QHR3(HW7+]1D;G.<*-@US,"`
M."5P:XN8-MP!L=]^?-=$Z0.CZ/I!JXZC8U9K72]6C8FGL-T9GG8*7+1S1MC]
M$R<S()S/5C+>L9&`QP>7$/'$5U7'[B52_&A1)W*LFR2XD$U):R)=)95-93+7
MF0ELNZXQKRMR]NBEN),2&.2_?0UO;T1FWRLW4W;?3S-=88W"T,497U&2];.&
M">::Q-/)*(^+@XNL>6CAXG;%K6GF?4L7H^Z(]%=&4F4LZ8JY,9#-LJQY?)97
M-Y3+W,@VDZ=U7KS=M2UV.A=9L%KJ]>%QZYX<7-V`G1NAT19W5R?FB*QQJ?'E
M08K>'EN8VQ"ZNRHW&,&J7)Q3)2EBY0;C77!ARHXTS?&,>=MGR8&P9!!&]\C(
M8F22$E\C(V->\GM+W`!SB?6225[JMAL/3MV;]/%8VK>NR.FN7:U&K!;MRNVX
MI;-B*)LT\CMAQ/E>]QV&Y61BZMD@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@
M(@(@(@(@(@(@(@(HBONZH9QTINQ+ML%0>3%*YC2U_7)T>GIG1Y5Z>8E9(RQI
M?]UTBE3XI;8W'6_3^=P?'5`BT_G/P-Q@,)=U'F<=A,>UIM9&RRNQSSM%"P[O
MGM3N^Y7J0-ELV9.R."*1Y^JK<TK88GRO^JQI<?:?8!WN.P`]9(4#<&Z5FE;U
MM(;.ND@CM*\F)4;==]&%[_*=8X^/2!*BAU1M:LSSCLQBE((D8:Z9D^#CDQBQ
MH>GLC/I7U5MOOM<YNEDLE7Q>%<[^&=,U1A,`".#TB"&1TES+RL&P]*S=]]C(
MS.X0\,FA@=R@;M9JQ.8PR2_;SNZV7GOPD\F1C?[L3`U@'M!/K5UAXE92`B`B
M`B`B`B`B`B\_W[3A]4/=GVAT7^*<<!7(OM&_K_:5=/HV_58\#_[;Z]_QV047
M_7=^9W[E;+@44!$!%&L!_KUN_:45^&U="I[!^'^2HM^]^8J2A120$0$0$0$0
M$0$0$71O\FCT61&N,B>FUF1DI'-=L:X*RD^=TK,W*7AU-(*WVP<J^;VI$K<%
M6B8LTPI&F./VTP67MMBW+-%"TNFD9&T->[=[@W<1L=(\@'F>%C7/=L"0T$]@
M6RQF'RN:L,JXG'V\A/)/3K!E6!\H;-D+<-"DR5[1U</I5VQ!5A=,YC'SS1Q!
MW&]H-&[0YSMC54[5;=51UE50AUF:Z'[6+R`?)!QY@J4M&UHG8B1,+?*8:NL:
MS6Y[(/<"(VGKV%.VSRH87S;56F2M^R@SSMS436TF7J,+'UWV'0&WDY)<76:&
ML:\2QMFKNM7&2`N$(JUY.L,4GTFM;N>A:HTIT:="EK)N^4QTJXCHSJXS$TK\
M>-TL["=(F>R>5O2Y&-FE`_$:A@T_AM1UHL<Z[?QN4S(R->E8KRQ8ZRXRLAC:
MDIU&^:LZO%G>Y=?MJ\?))']T\;2+ZN,I"@/F/26,S@E8XY,6HQ!:TXFI.J%.
M4\N3Q(V1J=X\H>4)L0+;UIR8O%H31YZQD636,E=Q<T?#"QU,X[&B,31O$<4[
M"V[9L#A`D>^:.-\1D::_`\M'->C3Y6FCM2R:;CZ$.BW):4R^B8FYJSTXYW&Y
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M9QS_`+.DL75FKFM*91_.:>,ZH\Y&I0[:JT!E'$,SD7DE49G0LT[8O!OHS=?I
MTQG&_J=!>?H6(K4LV-KOA<7-.3Z0M*-9]4C^9$_.[D`$\G,[=CZEC:8Z#M"Z
M5SV-U'1S?2%D<ABIGSUF9?4^<R=-[WPR0'TBI)$V"PW@E<0UX+0_A=VM"D2_
M+;XL<HG2/.\^XA]26<GQE`L;6;:-\6^4%=MVZ1>H*5'^G^7(8*E6;[&E:9*/
M5F9V*TSMKIMKIMM@961Z'FY-\3\IJ;0<3H6N:UHU]B>0<X$AS,;<G+B"/82/
M4O1:_P"BO0?2;:QUO5N+SMZ3%UYJU1M+(YS$1"*>1LLG6QX^S4;,XN8.%\G$
MYHW:W8$A9#0=O5]QO:']BH'IL=1=&@E+DF=GC1RA,5\Y>X)$OR-,?E3<'(AN
M4H-=4^?,V+(^3%Y_YFE;;Z^7%W'=%6(P[)(Z^O.CZHR5X?*#G<WD"7-&P(-;
M#7CR!VV8=B?%;'0'1YHWHRIY"CHS`Y/'5\I9BMWFV,AD<F^>Q%$88Y.LRV1M
M/BVC^B6PF-CB>)S2>:A-ZI6O9K('R5I.B9R1>GN3/+G('ARF]^4##?EKL]+3
MG%Q6G(5'+IS*2_*5BDX[=.C0ZD$>?DL@@LO74O77OZ).CCK9)KNO=(F661\D
MCJU'75[BD>XO>1PX.)GTG$GEPMY[#8<EXB[\G#H5R60O92YT9QVK^2N6<A>L
M3YK,CK[ER=]BS-U?S\86=9-*]YCBC9&W?A9&UH`%G97+>4UBUMI3[[TJ43G6
MFC='VHN(6!R^IM"V8;XN>WJ6!*HS%4LY5;:M9[6WFE;84*#-MTFF3-SO+MYV
MVFT;T;RU?0K?2%%8JAL;.HK:/SLS"V$M,8'I<U`G@+&D<1!W;S[^GY;2>#SV
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MKY$1*QP7JM$I2@LC"A6H-UQKN;OMM>LX?H7LR-EN.UODY6,ZMLDV`TO`>`%S
M@UIES&0<UO$YS@-CL2>7-;G4'1]I/5EZ+)ZHT3HO4.0@K,I07,YAZ>7LPTXY
M9IV562W:,CFP,FL3RMB:0P22R.`W>XK+(+4/49KUH/CM;&=,:EX^K<#794S0
M'C]>2AN,=%"=*D/<S4#/;5<H%;B:D0HDIJX])A0:G1I2-]O1)R==+]>/H?HL
M,=3#Z[ZLN+S'!D=,8V-SR`"YS(L';'$0UK2[<NV:.?(!;;!::QNEZC\?IG":
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M:NS4[=QV$BM#1'+N`V]6R]+9Q8NPBO==5M5VN8]L$^/JS1->P$,<V.=LK`Y@
M)X#P[MWY'98^X]/JX90QOD9FW4#OIWCLF9G./2*/QNF>($`:GQA>4AJ%V9'$
MR+T`F?<-;FC.-2+=6]];W#*<S?Y(XI%/HU)6KS.9TGDL/EL32Z.-.8EV5QE[
M&C(QY'5%R[1]-K25O2ZHM9QU4V:_6==")ZTT!E8WK89&<3#H,]H?&YW3FH--
MND&.K:APF5P5FQCJ&-KSPULM2FI3/BX:FQ>R.9SFAV[2YK>($+2ZX=)GE_65
MLS9^9H6RVK5U12"-2R-XC\P:HG8%T17YUU7*FN`(7I,[LC=8#`V)337-CF2E
M@9'1U)*:&61'$NB5V)T=;H2Z!Y,-@;,6OM;T-2Y$N9;J7L=C+6(P%ZKP%LN4
MGK4Z]FQB[DW"VO/CA-9C@>Z>S!$^!\#_`,_]+?(PU15Z0[S,SDVQ:-P%JMD,
M5FJ;JYR&HF]=UU2M!3>9&T)ZW5;94VQP-D#8J)LQV&VH?35Q]Y(5/R;A1LUJ
MM]4*L-3D?'II#Y`W*HW8=9S)!_([P:RH2Z:DOD.ES.?C<E8UNB?34_371P:U
M+BTJ4;@ISM0Z;RVF+HI96!K.MB;9I7*\C;..R=*3G#?QEV+>"Y3F;L62Q./"
M=XY6QS-?&W]+X9XYV\49/(EKVN'"]CAR+'M/-K@?4?Q!(YJ=AH5>0$0$0$0$
M0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$6LN??]X7-./5
M`G_Z_C[P>=XS;-RF:_ZC5/>4SH@P[4E5YV^/-+7(J<CRO^,LN2:&J2"9:[U6
ME7IM3T)^FO3<?_W.T58S#OH:@US#:Q.&'9-C]+12=3G,H/7&_,V&?,U1Q:US
MJ<.5?&\MD:3@O_U-IL?_`(-4MDD]C[!YQ1_A$W^:X>\8]QR6S0<R6<@(@(@(
M@(@(@(@(@(O/]^TX?5#W9]H=%_BG'`5R+[1OZ_VE73Z-OU6/`_\`MOKW_'9!
M1?\`7=^9W[E;+@44!$!%&L!_KUN_:45^&U="I[!^'^2HM^]^8J2A120$0$0$
M0$0$5:K;Y<T/2JJ*(9I,=MU4R=E#6UXCC0Z29`AT;79*S2%YD[\SI5,<A[!%
M5:K7,C=Y2[M"9MT)4Z9R:H(W3C4W<YC<>Z!D\Y+K$A8SJ8Y)FM#)&QRR321M
M=%7BA<X==),^,,V/:00O=T>CO/V-.:HUAE[6F]%Z4T=CHLCG=0](&J<!H?&P
MBY0GR.*I4G:ER&.L9;)9NO7=\STL77N2W7/B+0V*02JME/\`)6<\W?X[Q&IY
M]$J205[(XJS,T]@IY%O358SK5\CPZN7FRB'-M5MYLC:FE&9'U#"XV1B.9/.-
M>B]EAJ)-IJ:65M:A^<H*=F#&MK30QQV:Q;?L.C<Z7C?_`#H&TF&5C&F(QNM&
M'?>0<1:U8FA^E3Y+=S+4I]"9R]\HFWIVCUFN\5=Q6>Z/M`T<SEZ;),%C\3G*
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M#XV-C=6:SJ9B:%S'G%:0QWS_`"ND8-FN?F;_`,W8.&7<NWEIOR09N2QK@0%O
M[N(I9NC2H9C#4\[#2EJV8I-1TZ-EIOU(W1Q9+T1U>2-ET<<CVRQP5S&Z5_4B
M,'89>7P_Y+6L7IOR;YOV-HS&Z:Y,J?B%'T/&"OTI>VN-#6A1.B%\XOQ[;M2?
M^FP:EM"*8.+QYWS>G\[<O:]_%VF,0`S2VAL:)&?1;E=73OU/?(;]25F/,=#3
M]>3?GPNQ5H-[`\[`C<-JS.#6RV7-8T`-AJL%:-K0-@P$%TO"!R`#V;#L`6)6
MCT=N"UB0)+"6FK=:Z<B94URA;946<G!SM:0;)CB2WANEEAS13*)3+TSXU84H
M=MY2YO!C8K.*=V[T2Q/M@_T6ENGSI'TOE)LBS+#)P349J?S/?B8S"PES'FM8
MJ8VB*E6G+4G+91Z)'")HPZO+Q1O^CR_I0Z$]$]+&.H4M0U9JUK&W(K-/+XYT
M<64B@ZUCKU`V9HYNLJWX6NCDCE;((9NJM1`2PCBV*5W7<(J6$QNN*XC39$83
M$6PEHCT>:"/0HD"(GR[9^G;;<Y2J4G;FJU[@K-/7N2\]2O7J5*Q2>>9RK,9C
M)Z@REW,YF[/D,GD9W6+ERP[BDEE=L/5LUD;&AL<,4;6Q0Q,9%$QD;&M'2,%@
ML1IG$4,#@:%?%XC%UV5:-&JS@B@B9N?62^221Y=+//*Y\T\SY)II))9'O=F@
MUBVR`B`B`B`B`B`B`B`B`B`B`BI#R#X?;3::E\A^/$SUX_\`+)E;2&]-9#>V
M9<H7:[$W_P`R:M^1$&(/1IK(@Y^NN$J!UR:EG4%,R2ZPN0(3$FS<M]QI[6'H
M-$Z=U%2_B#24\CI'8V27J[N)GD^MDM.WG->[&WFD\<D7"^C?'%%=KO#Q+'BS
M5N)W70NZFP!MQ[;MD`^Y,WEQLY;`_79VL([#R<>N8.D^F:CCY?L,VX_<LV!M
M.<7&K'9SPXQ:S&%%Y=#[)X^3@TE&CL^OU.--CUB=.2EF<).],TS:/-9Z8M8M
MCJ'1YH4FZAT_=_B#25B5L<>5ABZNUC+#]BW&:AH@O?B\@W<-8YSGTKS>&:C9
ME:\LC0V.-W4S-ZFP!N8R=VO`[7PNY=8SUGD',['`$*[0\2LI`1`1`1`1`1`1
M`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`15DY><@\\:Z0?YVSLN)?9
M#VXLM<TE7NF_FJ[(NR?KM(]6T,3:ZF%FY3KGY24O?U).V-FJ*MC\][^0AM-V
MQZ?2&GOXESE>A-/Z'C8(Y\EF\B1]#&X3'QFSDKKCL1Q1P-,==I&TMN6O`/I2
MA6+,W41%X'$\D,B9[\KSPL;^!<=W'U-!/J7[XC<?->-5'QVOW-Z_>^PG5<\V
M%=%A&Z>:MLFZI\O,D=ESA7OL66;DIUD2M0F9$Y^N=VJ,(&)DTSA.V$ZZTU?J
M'^)<Y9R$4/H>.BCAQ^%QP.[,9A,?&*V,HLYD;Q5F-=.YO*6U)/.?I2N)5X>H
MB#">)Y)?*_UR2O/$]Y_$\F^QH:WU*S`\RKZ`B`B`B`B`B`B`B`B\_P!^TX?5
M#W9]H=%_BG'`5R+[1OZ_VE73Z-OU6/`_^V^O?\=D%%_UW?F=^Y6RX%%`1`11
MK`?Z];OVE%?AM70J>P?A_DJ+?O?F*DH44D!$!%TCW)8[&RTILA?F=B+7J,HT
M.SNY(V["Y9@DQ1\D1?*SB<JU?H"3CL)D_I#\E%&;X+SKIMG%N2:*$-,LD<?$
M>%O&]K>)VQ/"WB(XG;`GA&YV!Y+,JXZ_>CN2TJ5NW#CJK[V1FKUY9H<?1C+6
MRW;TL;'1U*<1<T26;#HX(^(<<@W5*VCFFFOJO)=+^&#`P6T7$9OB#O<RM%^>
M*;JYBQI'MWYREICLZ1ERDTB8V/4UL3*T;1'DZA:8Y%'IEQ3;H8XXT5?-R9F%
MYTS5&3E%MM,.L&:G7XW1\?6,W@DL6&M)C;U<,/%(7C@=P_276,?H#0VG\_+C
M^E;I*PF/@QV-L6\MA^BS)Z6Z5=54,S!-3,6C,U'@]2,P&DM17*%MN3X,]F&N
MH4NK?;IF:>*N_29)^<O(SD7<4N9D<Z^>*_=V@N'NG%.AXJIY2R/#&N2M:29$
MN:NB6C5D875W5H730MPN"XJ_.BS4YJ$Z`T@PO=PW]!3Z*NEC.N=D<[7HZ'TS
M:BZG_OE?IX2!\#VQB9T%>8P96\Z8M>8G012O:Q_#"W<A[OF&CTZ=-F1@TW2Z
M+^A_H^Z$)=.:JKZAFZ4M97LATE=+N>;B<K:L8J&CI^O<=T?Z4HNHRP09/%38
MJ:S8LUX[C,TX-C:KWO\`0-\<C8O7L$A?`KC+Q/I^M7%P=8#VDY!M84F:-GXK
M0E>Z$\;^.KPV0!0XK2M=5SDWS^\7`M6Z9*4/+0H7%';9]B_1W0_B8*U?*Y&]
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M=2H./]&\?V/]VZ0J*N:G9-M"]%"*`0]BB^%^2_\`8]U/:4294[J]MOYS5KF>
MK6'F9R:<>89MG;/E<QJ#.Z@G])SF7R66G!):_(7)[75[_=B;,]S86>H,B:QC
M1L&M``"VT<,4(X8HV1CV,:&[_CL.?XE2\-.KB`B`B`B`B`B`B`B`B`B`B`B`
MB`B`B`B`B@7D+QKJ?DY#$\/M!F6&',KD3(H+-XTYJ8S9%7S)%Y-FJ<UG-VS)
M;U$)6U':EF)U[>=\G6%:;-SPC<VA0K;U&^T]J7+:8N.N8N9@;/&:]^C9B;:Q
MN4IOY2T<G1EW@N5)6DAT<C>)A/60OBF:R1MF:".=H;(#N#Q,>T\,D;AV/C>.
M;7#VCD>P@CDJ?QSD?;G#I_9JJYV.R>456[N2-@JGG6VM1#)$710M/T1LT,Y1
MLB#7#94-AG';D(T%BI<)ZFG9II>VQ\-?<'LZCV-G3>(UE!-E="1.JY6&-]C+
M:$EE,]R)K&E\UW2T[_YF8QP`<^3'.XLM0`(#;M<MF;CMFDK.$=H\49Y1VP-F
MGV-L`<HW^H/'\MY]T\ELW*-+.++.),T.).TT-*-*WU,+-+,UQOH87OIG.N^F
M^N<;:;ZYSKMKG&<9SC.,CF)!:2UP(()!!&Q!'(@@\P0>1![%G+]BB("("("(
M"("("("("("("("("("("("("("("("("("("("("+6777_>#S1DMTJ/^NX_
M\)7644]2)>W^HU3ODXYHOFB];63XSYFBY%4S&HQ2L/6[%JDQ<F<;65MZG0U.
M1OCIN1_[G:+K85OT-0:WAJYC.$<IJ&F(G]=@L2[M,;\M.WY[N,!8\U8\2R1I
M#G!8+/\`4V72]L-4NBB]CYR-I9![>K!ZIIYCB,FRV:#F2SD!$!$!$!$!$!$!
M$!$!%Y_OVG#ZH>[/M#HO\4XX"N1?:-_7^TJZ?1M^JQX'_P!M]>_X[(*+_KN_
M,[]RMEP**`B`BC6`_P!>MW[2BOPVKH5/8/P_R5%OWOS%24**2J9R%YM\=^,\
M5*EEAS`]Q1GOKO&2D<$:U4T5%O\`'TK>O?FIW5L_I&*+*V9O=4"Y?K+GE@U+
M3*2LZ;F&;Z%[8CK?%(V"C4R.8MO=,QE'"4+66N%U=K7SAT-*.4Q=2Q[7R&8Q
MM:UP)*Z/I_HLU3G*N7R5U^$T;A,#@8=39/.Z^S=#1^.9A;8OBA;Q[<Q+!D,^
M<E-C;E7'P:=H9:Q:LPNB9%OS6H1PZKG*[E+(WV'<+>*MGNE>K7A(S-=QPYH;
M9!)4[4F?2/G5Y(DT^;V_CE$'YS9"E*-"QRV5R+YG5'&+#CEFZ;S",FGIK7&6
MEWR-?']'>"E?%MF-5VV5<WZ(9&NDMTM+]1:S=ITE?B-<1XBQ5+W,+K;`YKER
MW!=*^@I#T4YO0_1KK_I/?:N5<KTIXWI1Q3^B70F+PUW#6F_P]@+6+U)<U]J?
M4&)S,M2Y8R4./T_IK)5*<E"ID',OC(5>QL[IE\K>;+Y5,GO9]@?'A'6D35Q(
MES>I<[<K>0TN:SW@Y[*/F[RB:J;IB.OA"U:YY3'1-JE;>G3+\(%6KLB;FXDC
MT5O2O0Y4DI37V:MZ1LCCX37$UVU'I/"V0YYDXIFUA>SEG@<7`&*7".>UQ:YK
M0&!F;TI9;572SC<MI*WJ'-='_15J'*V\OJ/H;Z-,YEM*='FI)[%;&5(J^HL?
M0M#+9K'4H,5!Z)C,GG;U%MB2>[-#-<DZ\7*J?H[\/X$T(VVPT4^Y'?)E9+GL
MV79+3%]<;.^F-/2N.E'0I'"Z3./.V+*U^5.\`>'7T!!!!SHH]'MN9NX-?Y+#
MUW4M&XO`:#I.!:6Z4Q<5/(2-VX0;&>M.N9Z:3AY.D.2;Q$D\(Y`>.TQH/26C
ML<W%:;P>/Q-`.$CJU*O%6BFF#0TSV6PM8+5AS6M#K%KKIW!K0Z0@!;+XG#8A
M`6)%%H+%8W"XRV:>B;8Y$V-LCC$WE^3&/1HFAG2HV])IY,8QYA"<O7R8QCR?
M1@>-MW+E^=]J_;LW;4IWDLVYY;,\A]KYIG/D>>]SBO6M:U@#6M:UH[&M``'X
M`;`+)!C*2`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`BZ61QR/3!A>(
MK+&-HD\8D+:K9W^.R!M1O#(]M+@3NF7-CLU.!*A"X(%B<S<A4D5D&D'E;[%F
ME[:[9P+U:S8IV(;52>:K:KR,FKV*\CX9X)HW!T<L4L9:^.1C@'->QP<T@$$%
M4<T.!:X!S7`@M<`00>1!!Y$'U@K62;7MX]/(TQWHAHF/(KA429NH?N-Y:M3)
M;PXX-V-LF*';C@Y.JG=?9E8H"//W4T6_.!DGCY)!>:R>5B;<R)CIPR&#Z1`(
M<]-3T[K9P#:^I"QM;!ZDD[&PZDBA:(\9E'NV#,[7C%6P7$92%C@+:P>"6GSA
M#IJOK@W+I81ZS"2=WQC_`-43Q#[AV^BM@=/W+5]^U^PVE3TT99[!)&3N8V/S
M(?ON7J>1MZ):UN:)060XLCZU*,;HGJ/O*-`],J\HY`Z($BPDPG7GV8PV4T_D
M)\5F:4]"_6($M>=H!X7#=DL3VET<\$K=GPV(7R031D212/80XY<<L<S!)$X/
M8>PCNY$$=H(/(@@$'D0I-&L5Q`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`
M1`1`1`1`14FYS71-*\KF-U32BHG3DKR<E.E+45YQ>5.(NZ.J!2OG%PN:4O.3
MOW;I.!)7RP711Z$U.:Y-K"QG:^E?4VN_MM#86ED<E9RN;83IK3%4YK.\^'TJ
M*&1K*.'B>=F^DYN^Z#'Q-XFN$4EB=IV@<1BVY7,8(XC_`#YW=5#_`,)(W=(?
M^&)F[R>?,-'WE/\`0]+POCM3M=TE7J4Y-$JXC*".MABO?!SDZ'$XV/=I$]JL
M8QE=(9.\J'"12)QWQZ1Q>W1>N-_U%&PT&>S5W468R.;R+@ZYDK+[$H8.&.)I
MV;#7@;]RO5@;'6KQCE'!%'&.30KT,38(F1,^JQH:-^T^UQ[W'=Q/M)4M#4*X
M@(@(@(@(@(@(@(@(@(O/]^TX?5#W9]H=%_BG'`5R+[1OZ_VE6QZ3B][:ND)P
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ME3'/RE4MGN,B8VW4KP5G0OW`=/)2Q\UMK&NYR&O&Z79S6L&^Y'US\H/Y(?2!
M\E/5?R/\MTR=,NJH.B_I)T?4T[TT6=+='&D=79)ORA:-*?4%W1&'E;_"M'#8
M'5^-L6,=IC-S98BD-%9O)6ZEDVXH3L]?4W)/DXJ.5\I[_P"2M/0A<C+;U%$<
M0.%?-!N83F\]`6E=/GJT)E1*"2/JMR,RH-4MSQ&WF/),FZ$(4NY1&YRSZ$S6
M$QEZS3=#F-03TFXRK'D<?_I,54L981D7WQ/JFS=DQ,\AV@K3VF6VQ-)=88]^
MT7A]79RK>P%G2&AL52T=4&K:FH:G26PWK?30*VG=5UM1Z2I4L[)EWZ,TQ%%%
MCZ-+4T>&T5-9U!$Z[4DRD..LR57RM3G%_IATL<UN;3Q/O:=25HVR>AE-N<+>
M75F.*-=M@K7=S9VJ3TBKB,7<S-2",'+HC&F`\_))9AVQANOGCTV)U'F-/83^
M&M-W9].8$RR3R8W"S3TVSS3!HFDN6Q*_(WC)PCB;=N6&-'T8VL8`T:#*7LWJ
M+(SYK5NIM4:VSUM[GVL_K?4V9U=FIBYQ<(AD<_>OSUZ<1<X5,=3=7QM",]10
MJ5H`V(;"R.5]5I2"4R:"<F4R9.460G3D<+>6Y)!!)6N-"B22BZ1U+**+TUUT
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M1,$V/=XCS3M;UE[%\GON8\NOT3!-CW>(\UKXN'#+$+!?N2_"1JY`57>CX=HX
M6C6$AX8<Q2>/W*#1-K])%G,351^YL0LOT6-BH_=\21_O.C,,V1RY!+V,_=$F
MZ%A]74KF/@TSK>O8RN"@:8\7E*Y8=0Z7+NQV+GE(%S&;\[&#MO\`17@!].2G
M.T/=AR57M>9ZKFQRG[2-Q'4S[>^`?HOV^K*T<0^\'#DK!4MU/*4M%0;!9577
M(^JN0L<CC5(;+X[/7&V^Y;8$`2NNVQ*-S4F06M'YN>(FZ':9,89.CW)*7(ST
M67)`R.AYK0FU.I=(W=/MK7XK$&9T[D2[YHU'CN-V/O!HW,$H<.MQ^2A'*WB[
M@CM5WM>`)8@V9]R"=LW$P@Q31_:0R%H>W_B'/9\9^[(W=KA[#N!87M;UE[%\
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M7.VYAF^U)XUTTTUQG;??;.-==<9SG.,8%0"2``220``-R2>0``YDD]@3;\/$
M>:UX\:N1T&O?D)9/.*7Q'D$Z0W=G.I/AF0Q\5^2\R8T]%I5J1TG5R(72,5.\
M,VC[?<X1$[EZZG$OC17L)B#.Z:)E:QU1:=+U<1I;!XW0,!X;X?#G]:/:?I.S
M=BO_`-G85[AVQZ?Q\_#-'Q.8,K=O<@Z%NV#6!L2R7#MP<X:HW&W5-/TY1N?_
M`!GCD=@>K:WM!6Q'M;UE[%\GON8\NOT3',UG;'N\1YIVMZR]B^3WW,>77Z)@
MFQ[O$>:=K>LO8OD]]S'EU^B8)L>[Q'FG:WK+V+Y/?<QY=?HF";'N\1YIVMZR
M]B^3WW,>77Z)@FQ[O$>:=K>LO8OD]]S'EU^B8)L>[Q'FG:WK+V+Y/?<QY=?H
MF";'N\1YIVMZR]B^3WW,>77Z)@FQ[O$>:L>UN)#NV-SLE*7D)G1`D<4Y+HV.
M+*YDD+4Y:DDIQ9GA*A=FE>66;KHK;'1$C<4"C!B5:E3J2C2M"HOO!$!%Y_OV
MG#ZH>[/M#HO\4XX"N1?:-_7^TJXW1_;6YYZ4'!YG>$")U:77C%"&UT:W)*0N
M;G)N7,QB5:@7HE6AJ98B6)C34ZI*H*,(4$&&%&Z;E[[:Y*+_`*[OS._<JXZ?
MC)Q[3-3<R$TY7^&MHL=+<#:EWCB`W"*U6\[4]IL0@TXK<_69,?HR$\>D.3<N
MD>0)43:R*4#>A2)B2IN?;W?HNU4<?Z05;2TP^J(%L=.G-H>I:HUC+64I>WE@
ME3A/&)V5*BD^BC1R9IZ\/,]:ER<PE4WSIZ>9DE-*DKLXNBDJ;_[_`*?LL?N[
MC35U[T*[\;9(WK(Q5;JU19B+9Z^W;HMLR,<-=65U8&:/%E-BIL9VM%E@;VXI
M`F;<)B&K39$E+3Z>CV+U6;P]3/XRSB;SIFU;8C$IKR"*;:*:.9H:\L>!NZ,!
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M!$!$!$!$!$!%5SDGQ.K_`)'IXZ_*G%_K2Z:Z-4.-/<@*Y4$,]HU>[GZYP=JV
M.9A)R201%XQ_TLMKR4)G6&RQM,-2NK5E1A(N1^ITUJS(:;=9@9'7R>%R(;'F
M-/Y)KIL7E(6GZ/6Q`M?7N0_7IY&JZ*[3E`=%+PE\;[$]=D^QW+)6;F.9G*2,
MGV'UM/WF.W:X=HWV(@VK>6-@53/(YQPYV-K!"+*D:[5BI[D/&DQ[9Q_Y,'XU
MV^0M[8I7'*,5-=2L@O.SK3\H<-BG9>6>JK=\DK:I3H4>\RND\?E:%G4FA);%
M[&5HS/F-.V7-EU!IEO\`XDDK8VM^=L(PG^5F*L>\49#,E!6D8Z1]F.P^-XAM
MAK'N.T<S1M#/[-B2>KE]L;CS/U"00%L5'.EFH"("("("("("("("("("("("
M("("("("("("("+77SOE,BLA17/!.KWA:T3_`)4_/&MG29E-SHZ55Q1BVZ+2
M[9SJH*P9LUO4O3.3;3\`4J"R]391.#')&?J9&U6Q71=!U:V-;DM=Y2%DV/TK
MU/S75G;O%E=5V@\X2B6G82P4W129C(-:215HB-[2++0<.VXOX*C"0^QOUCAV
MQUV_:NW]1<"(V?\`$_?[JOK%(K'8-%XW"H@SHH_%(@PM$8C+"VDX3MS+'V%`
MG:V=J0D8\N"D;>WI4Z1,7Y<^825IKY<^3RCP5NU8O6K-VY,^Q;N6)K5JQ(>*
M2>Q8D=+--(?6^21[GN/K<2LMK0UH:T;-:`UH'8`!L`/P')=^,=50$0$0$0$0
M$0$0$0$0$0$7G^_:</JA[L^T.B_Q3C@*Y%]HW]?[2KI]&WZK'@?_`&WU[_CL
M@HO^N[\SOW*V7`HH"("*-8#_`%ZW?M**_#:NA4]@_#_)46_>_,5)0HI("("(
M"("("("("("("("("("("("("("("("("("("("("("("("("("("("+`+1J
MNN;L@<CK"V88PS^`RQ#LWO\`%Y(A+7MJ\C.VIA)N-=O-.1KT2C0I:UNJ$Y*Y
MM+@0F<6Q8D7)B%!>PQ>5R6$OULIB;MC'Y"H_K*]JM(8Y8W;$.'+D^.1I+)8I
M`Z*:-SHY6/C<YIA)&R5A9(T/8X;%KAN/_H1ZB-B#S!!6NO$BO/IT9PEGRZ=\
ME^"R3.,(K-,*7S/D5Q39]/H^2V<E2$J'R\:19"?(8383<G66A!6@H_27-TM9
MT!3ZGZ+Z/@ND;Z6/CH:9UV_[3&`QTM.:KF/W\6Y[FP8/.3G<.Q\CH\7?E+33
MDJ32.@=A[RTN3R^>J/\`Q.;IJX_XP!O+$/?&\C!]8.',;+H=,HE8<689Q`Y*
MQS&'2EL2O,;E$:<T;RPOC4MTP8E<&MT0&GHUJ4[3/ET-(-WU\N-M<YQMKMKC
MF=RE;QUJQ1OUIZ=RK*Z&S5LQ/AG@E8=G1RQ2!KV.:>T.`]O85FM<U[0]C@YK
MANUS2"T@]A!'(A9*,920$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$6-S&7QJOX
ME*)W,WE%'8A"X^\2J4O[D9Z%O98]'V]0ZO+JM-\FV=$J!O2*%1^V-=ML%E;>
M;KMMY,9R:=.SD+=6A2A?8N7;$-6K7C&\D]BQ(V*&)@];I)'M8T>TJCG-8USG
M$!K07.)[`T#<D]P`W5$^!\0DL\Q8O..U69:SV7RP-9G""QAY+\UTJ;B[&?EO
M\"JWV),SOEL>'IK<W"UK!3)\D8.FLZ5H5I&-V!+@KW>O+E:A\VZ&Q4S)L9I-
MLT=ZU"[>++:IM<'S[D@1L)88)8H\5CW.#N&E1:]CMK#]\.HTOX[<@V?9V+6G
MMC@;OU+.XD$R/]KG[>H+8@.=K-0$0$0$0$0$0$0$0$0$0$0$7G^_:</JA[L^
MT.B_Q3C@*Y%]HW]?[2KI]&WZK'@?_;?7O^.R"B_Z[OS._<K9<"B@(@(HU@/]
M>MW[2BOPVKH5/8/P_P`E1;][\Q4E"BD@(@(@(@(@(@(@(@(@(@(@(@(@(@(@
M(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(OYG&,XSC.,9QG&<9QG'EQG&?HSC
M.,_1G&<?[X!%K0F/&"U.+DJ?KJX#I&D]AD#FJD=P\)7UU+CM46:N4;Y4.TOH
M]V.UW;J)N1=CTF5):=-K5\^5938EC2S.9?[T8Z92U/BM4U(,)KY\K;%>)M;#
MZW@B-G+8QC1PPT\Y"TB3/89G+A+G?.F/;Q>B2S1'T58+H)('&6H`03Q252>&
M-Y];HCV0RGU\NK?]YH=])6HXY\GZKY.QAU>H`L=FF2Q%RQ';.JJ;M9L5M>HY
M?H7G93$K(A*[?+BP.I6=#<HU>ORIB?DI67*-N[PU[EK=_*ZCTOE=,6HH<@R&
M6M;C](QF5HRBWB<O3)V;;QMZ,=78B.XXV?0GKN/5V88906#(@GCG:2S<.:>&
M2-XX9(W>Z]IY@^P]CNUI(5B!YU7D!$!$!$!$!$!$!$!$!$!$!$!$!$!$!%K-
MY8[[<J;YKK@8S;[*JY;$T?Y!<T%B?;.R7^%#(_;F511BXXK^719>\_8S%DB;
M-CDRO>K(+*=-M#$DB3>EZ9I+;2N!R.O9APY*1UC3^BV.&SOG:>`#+9V,'M9@
M<?.&5Y>%[!E;]4@A]9VV#8_U$S*@^H.&:S_Y8=_+B/\`YKQNX<CU;'>IP6S#
M330O34LO773337733337&NFFFN,:ZZZZZXQC777&,8UUQC&,8QC&,>0<S)))
M).Y/,D\R2>TDK.7Z!$!$!$!$!$!$!$!$!$!$!$!%Y_OVG#ZH>[/M#HO\4XX"
MN1?:-_7^TJZ?1M^JQX'_`-M]>_X[(*+_`*[OS._<K9<"B@(@(HU@/]>MW[2B
MOPVKH5/8/P_R5%OWOS%24**2`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B
M`B`B`B`B`B`B`B`B`B`B`B`B`B`B`BIGR,X@-=L2=JNZI9BOH#E9#FW+;$+R
MBC>G78?&30S"C^'5S1`XQ,U6W5BY1IIL=&W\PMS85'D=88^1QUP8H/\`9Z<U
MA+B:LN#R]./4&E+DO6W,%;D='U$Y'#\XX:XT.FQ&5C:2!9K@Q6&_RKL%F+9K
M<::L)'"6-QAL-&S96C?<#[DK>R2,GM:>8[6N:5T%#<P'1WGJ?C9RHAR"AN51
M*)6I9V,IP/7U-?K.U:X^73KCE.'`M/\`O0V^ASHX/=>N^$EEP,L[=._LZQ"D
MR_J<C/:/BAQ[M2Z6N29[2KI&,FG,;69;`32_9T=248R[T67?>.#(P\6,OEH=
M7FC>\5VQALDOZBPSJ;'/8;[QS`=KH'GZPVYEA_F,^\-ANKUCPBRT!$!$!$!$
M!$!$!$!$!$!$!$!$!%#]_79#>.5-6)=T^-4:QBNXXK?%2-#IZ9U?7#.Q:)@B
MK"F_W6R.6OZMLC,=0:_S+GMV0)-?)D[&<;C`82[J/,X["8\--K(V60,>\[10
M1[%]BU.[[E:G79+:LR'E'!#(\_55N:5L,3Y7_58W<@=I/8&CVN<XAK1ZR0%!
MG!RDYE659OUC7.4G,Y*<DY4?=E^J"M_E&C%)'U"E1Q6J6E7OG<[,6I:#(V"M
MV%/@\Y+N:R.KT1G!KXJVWWNN<W2RF3KXW"EPTUIJJW":?:1PF>M`]S[>5F8-
MAZ5F[[[&2L.X0\">*%W*!NUFK$Z-A?+]O.[K9O7LX_5C'_#$W9@_`GUJZ8\4
MLI`1`1`1`1`1`1`1`1`1`1`1`1>?[]IP^J'NS[0Z+_%..`KD7VC?U_M*NGT;
M?JL>!_\`;?7O^.R"B_Z[OS._<K9<"B@(@(HU@/\`7K=^THK\-JZ%3V#\/\E1
M;][\Q4E"BD@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(
M@(@(@(@(@(@(@(@(@(H6OGCY4_)6!**ZMZ+E2%E^6I7IC<DJI4S2N%2EMVR:
MRS2!2UJ-2O\`#9DQ*,_*&B1,*Y$X)MLF$;&&HU"I,?NL#J'+::OMR.'M.KS<
M#X9XG-;-4NU91M/2R%24.KW:<[?HS5K$;XW<G`![6.;:EACG9P2-XAV@]CFN
M'8YCA])K@>8<T@A:JKCYQ7'TOVPVN.3F=N4<?>8^]JN,URM;U&(U:,I.8C&\
MC2!<CXGN8EV*=&4EQ3>DNZ`LKJT2M&GQL^1-GERK8IR[;H[HNQ_33=%W2>VD
MW5;%<:NQTU>U:Q&/CL"1WI^FK0!$@LNB>(L!?L13U7N)AN2T8R^+CG2YTQX3
MH:P!OYLC*92ZV6/3F'AF9#=RMB,-XO2=VO-6C6XV&WD>JD:UI;&R*2U+##)L
M"X@\UZ3YF5JVSNMGU,A?,8*1RZN7A>C+F$,?O0ZF*&U<AQOH8X-YG\YK/($)
M.S:\)-<[EY3+D[@W(>==(G1IJ7HUS<N)S=9TE9W%)CLQ7CD./R=0.V;-#(01
M%,W=K;-25W75I"`[CB?#-+O.BSI6TMTM:<CSNG;'5V(NKAS&%L/9\XX6Z]A=
MZ/:8W;K(9>"1U.[&WJ+D3'N9P316((+>#GJZ8@(@(@(@(@(@(@(@(@(@(@(M
M9<Y_[PN:S!5)'_7\>^#+Q'+2MLS7_4:9]RN=FW#K35;&[Z^:4N0TG&5W\7Y4
MET.4$D35]J]*O2ZJ&L_37IM'_N=HFQE7?R]0ZZALXO$`\IL?I.&7JLSD@#N6
M29NU'\SU'EK2ZE!E'QOX96DX+_\`4VA'VPU2V23V/L$;Q,[Q$W^8[M^DZ,'L
M6S0<R6<@(@(@(@(@(@(@(@(@(@(@(@(@(O/]^TX?5#W9]H=%_BG'`5R+[1OZ
M_P!I5T^C;]5CP/\`[;Z]_P`=D%%_UW?F=^Y6RX%%`1`11K`?Z];OVE%?AM70
MJ>P?A_DJ+?O?F*DH44D!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!
M$!$!$!$!$!$!$!$!$!$!$!$!$!$!%3?FUPIJ[F]4BFNYYIJRR5JV4N5=6,B0
ME+'V"2$TK339205L<EV<V%SU*(322.&K$R9X2%$&%J$+L@:79NZ/T8])F=Z,
M-0,S&*/I-*P&09G#2RNCJY6FUQ(8]P:_J+4!<Y]*ZV-[ZTCG`LEKS6*\W*NE
MWHDT[TOZ8DP6:'HE^L9+&"SL,+9;F&O.:`9&-+HS8IV`UD=^@Z6..U$UCFOA
MLPUK,$15[TE.`\/J^*UQ)N.-6VLOCR+.B^QK$A;$\V'('51G4YQ<U4IREU>&
M\D]5YQB%F;%Z=J9R,%ID"?3S-S3=GJ/INZ1]0YZ[FQJ;*XIEE^U?$XR]8@Q5
M&LW<15X:G'U+RUG*6Q+&Z>R_>29QW#6YO1ST6:2Z,M-5=-X"C&\,X9LCD[,<
M;LCE[Y:!+=NS`;[N(X8*["(*L(;#"T`%SNX]5KPV;_\`4A44MBJ5>OTIU=0\
MF^2]9_(\_P#C*5NB-M-C+IYO_HUV:]]-/)_+K@:C_K3UE)RNV\3E6'ZS,OIC
M3.3XQZP^2WB)9SOZ]I03OS*]W\WU1]1LD?LZN>=FWX!L@']$]7\X-7\T(YU]
M06&[E_2GT4WXQVDF+SK_`,-32KQKJSSU16/]MM#E6=]]?HR;C/\`,'_6!'+R
MO:$Z/;@/UBW`3XMQ]O"<'D<6UA]G"S8>[MR5?0R/JV[C?_SA)_\`NLD/]4[,
MO.5D_EBG4JDKL47]"<FWN*M!S3R:8_X:*E-<I:47*O\`VW-RJ+.W^G.3,9\G
MD?Q/H:;_`-+Z-*T1/UG8C5>H*7/UEK<D_-QM[AP%H]A3J+0^K><>7_B00N_J
MP1$\N7]4S'.JI'/])!:_!&U4Y7_`Z2TQ>M0NJK&/_P`]5';CM1K3YVQ_Y(8S
M,:9SGZ#,8Q@/2>BJS]*3$Z\Q3C]VMFL#F(6?E;8PV*E=_P"].-^7,)PWV]DE
M20>UT4L9/X\,D@'@4_BKU-(O_IR'AWQBLS7'ESLMJGF!*HV=MKC_`&]&RVAQ
MQ:2<F;X_^Z,DA1>FV?)\IWUQYV7S5T96N=?6.I\9[(\MH^I9&_?/B]23'8>T
M5B3[H[$ZR\WMK02=\=ES?Z20#^Y.V+R7CO\`-8G3/Y0I",?1LMJJQ.+5ND9\
MG_+<M&1>,2D&Q>/]\>>QEG[X_P""?;;^05_@[3-GECNDS2[W>YE<=JG#N_`O
M=@[=<'\)RT>MP[4])G;]>C/M[8Y*\G].M8[_`)4]9!733_-87''G95R?7_[0
MOD_#:ZI&TI/)_P`O3O%4QZQVKR:_3GRDK#L;8QG;3.VOTBG_`%;Y&7ECM2:$
MRCC]6.KK+"5I7_EARUC&R^+!WIZ:P?7AM1][JTK@/UC:\?U7,1U5>G]Z8M.]
M<D8U`SS=L::D6M&+#I\[7?.?)YAQ=IP^'[I]L9^C;!^I>=<^7SO)Y,BCNBGI
M`X2Z#3=F^T#<NQ-K'9@$=NX.*N7`[_W=]T]/I^N=K?\`S&OC\>-K=OU4[1#F
M1Q$L#T6(+RFXZS'<[R>C)C%UUL^*-MMO)Y-,IVV2J#]3/I\F2MR]3-<_R[:X
MS]`T-S1NK\?N;^E=1TPWM=:PF2@:._BDK-;MW@[=ZO-LUW_4GA=^65A_9RL*
M@<&]T2EKFQ<C<41V/.)5H%)*Q*;CZ,^4M0GW,*,QY,X^G7?./IP//21R1.+)
M8WQO;VLD:YCA^+7`$?J%>!![#O\`@OL$$5)>7O-*`\;XR^Q1@=H_,N3\A8VM
M'2-!DN)6TKG\[G,B0P2O$>[<49JH3,"J7NZ-0^K]]R=T47;9$]%8W3,ZLPKW
MVC]`YC4IART].Y3T=5MR-SNIC`[T#'5*59^0R!Z\@L=8;3A>V!@!:^W+5KN(
M?/&UWFKFKM.U,Y'I5V8QW\4V:#LE4P+K40R,]02B'TAE?BXS'UA)VVXW113R
ML:Z*"9[)%XD<?2N--'QJNUSUM+IZO5O$]N.PC]/(OLNZ)ZX&R2S)VNWV++.V
MP]25:K+:$Y^-MVJ-I&1D+V^3-A&NNFU=J$ZFSEG(QP^AT(V0T,-CFG^7C,+0
MC%;&4(P"6_R*K&&9S>4ME\\Y^E*Y;ZO#U$36$\3R2^1_K?*\\3WG\7'E[&@#
MU*RH\TKZ`B`B`B`B`B`B`B`B`B`B`B`B`B\_W[3A]4/=GVAT7^*<<!7(OM&_
MK_:5=/HV_58\#_[;Z]_QV047_7=^9W[E;+@44!$!%&L!_KUN_:45^&U="I[!
M^'^2HM^]^8J2A120$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0
M$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$7$>00J),3J22E!!VN
M=#2#R]#B3=-OHVT,*,QMIOKG'T9UVUSC/_G`JUSF.#FN+7`[AS20X'V@C8@_
M@B@B7\4^+M@^E_?WC;0DV]/YWILRZGJ]D>3?._Y9,R\1U9G?.?\`?.=LYSY?
MI_W&^IZKU3C]O0-29^CP]GHF8R-;;\.IL,V5EU>!_P!>&%_YHV._=I5>E_2N
MZ>RM48N;^+%<0Q:;GSME=8?O#4JK7/TYQDI16+Y$32,ZYS_)DC<O.GT>9YOD
MP/0Q]*G2$Q@CDU5DKL;>QF4]'R[?U;E(+8=W\0._K5DX^D3N*[&GVQ\49_\`
MEEJ^/U:M.M'\M<W3S7J,G7_X:*#<TN1*QJ*S_P",ZLE@3N=,V^-?_06<@-*U
MQ_+J7C3^43_ZRLS-SR6%T3EW>M]_1>G62D>PSX^A0F&_K+9`?7OOS3T*(?4D
MM1]S+4Y'@][Q_1:6YGT?.7+CU!4<B:[BFKA7:]\36<1RL>I!E;9$=1,ZQ(43
M'5IF#B%:NSVS4M(UL&Z1.EC:YJ*3O.A;8A1N,>;/K'&?*(Z/:_1`^C/IS&Q9
MB"H[!.T%!5X,/=DGBD+KK.)KV-PD^\D]SK7R7H[!?6<Z>66&Y/\`G7F_DO\`
M2A=Z=/G6OJC)/PEW(?Q*.D:6TT9G&Q0SLVQICB,1^?:PZNKCV5XHL:^FV.PQ
ME:O#/0K^JA&08E2)4QJM2O-3IB"#%RS";"M:825J7NK581IT:/"E3MKDX_"1
M(E38-WVP0G(*\TK7X.D<'R2/;&R)KWN<V*/C,<0<XD1QF5\DG`P'A;UDDC^$
M#C>YV[C^CD3'1Q1QNEDG='&QCII>K$LSFM#3+((HXHNLD(XW]5%''Q$\$;&[
M-'TB"N("("("("("("("("("("("("("+S_?M.'U0]V?:'1?XIQP%<B^T;^O
M]I5T^C;]5CP/_MOKW_'9!1?]=WYG?N5^NI#RBN+B;%ZZLV'MR7%+H%S^IY!S
M-H9D,WGE5QQ*X0M.P63K5RI<WN5@4\P9<I"1<Z:%*D<_84;A$GR/KT;>E?MC
M"-&^X]?J]A[M_4?9OR[=UKWC_5+Y*/5UOU2+VR--R&4<E(55$`G39%U:V*O-
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ME`SM6[M'6+5:III?DK+O+)"UQ2.(<8)=3=_3.LB>FMJ3Y\ST>%"TK)NY96-S
M-";'N\1YK(.U,7W>.5'@VJ^,@FQ[O$>:=J8ON\<J/!M5\9!-CW>(\T[4Q?=X
MY4>#:KXR";'N\1YIVIB^[QRH\&U7QD$V/=XCS3M3%]WCE1X-JOC()L>[Q'FG
M:F+[O'*CP;5?&038]WB/-.U,7W>.5'@VJ^,@FQ[O$>:=J8ON\<J/!M5\9!-C
MW>(\T[4Q?=XY4>#:KXR";'N\1YIVIB^[QRH\&U7QD$V/=XCS3M3%]WCE1X-J
MOC()L>[Q'FG:F+[O'*CP;5?&038]WB/-=`DYGQM?)7R'HZ+Y0'R:-M4?>WQH
MTII?\I;FJ5'OR6/+3\[.N"<E.A\8?RD^"S3-\;-A_I="\9*R838]WB/-=_VI
MB^[QRH\&U7QD$V/=XCS3M3%]WCE1X-JOC()L>[Q'FG:F+[O'*CP;5?&038]W
MB/-.U,7W>.5'@VJ^,@FQ[O$>:=J8ON\<J/!M5\9!-CW>(\T[4Q?=XY4>#:KX
MR";'N\1YIVIB^[QRH\&U7QD$V/=XCS3M3%]WCE1X-JOC()L>[Q'FG:F+[O'*
MCP;5?&038]WB/-.U,7W>.5'@VJ^,@FQ[O$>:=J8ON\<J/!M5\9!-CW>(\UTD
MFYE1^'1R02Z343RA9XW%61UD<@=E--+\IFMC8T![F[.*C!+L:=DA$@2J%)N"
MBS#,EE;8TTWV\FN2;'N\1YKMR>5B9024>3QZY3F$GEZ'%;XIM7Y-RS-<;Z;X
M\KQC/DVUVQG'EQC/DS].`3;\/$>:Y.U,7W>.5'@VJ^,@FQ[O$>:=J8ON\<J/
M!M5\9!-CW>(\T[4Q?=XY4>#:KXR";'N\1YIVIB^[QRH\&U7QD$V/=XCS3M3%
M]WCE1X-JOC()L>[Q'FG:F+[O'*CP;5?&038]WB/-.U,7W>.5'@VJ^,@FQ[O$
M>:=J8ON\<J/!M5\9!-CW>(\T[4Q?=XY4>#:KXR";'N\1YIVIB^[QRH\&U7QD
M$V/=XCS3M3%]WCE1X-JOC()L>[Q'FN@.YGQLB4M\*.HOE`7*G5@>)2WLN::7
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MLN;%I92QO691K"?E*)47H>E.\\DW7&^F<`J+,@1`1>?[]IP^J'NS[0Z+_%..
M`KD7VC?U_M*NGT;?JL>!_P#;?7O^.R"B_P"N[\SOW*OK,ZQKBQMV<R?P*'38
MV/*<K&$V51MH?C693LJ;UIAK6:YI%)B')ZMI:U"G5-L7HJ,;D.RC4WY*3YA1
MW759I*F<ER0K-1UCDJ9*R5\O*S`HKDN5+D\D6S-.MDFF6KS7Q61,')QE9*AS
MPJ.*DJ]:^Z;ZNBH]485=S[3R[%(;>WH&E`B:VM$D;6QM2)F]N;F],2C0-Z!&
M3HG1HD2-/H6G2I$J<LLA,F(++)()+T**TUTUUUP5%\#5'6)B52!<SM2)M62M
MZUD4D4I"-237I]U9F>.ZNKAOK]*A;ACC[(U8/W\NWR)K1D_\2=01=T"("("(
M"("("("("("("("+I7^.,4J;M6B1M2%Z;-7)C>=4+@1HH38=8T]M\D8%^"M\
M9U^5-#\TMKLA-_Y$+D*<_3R;EZY!%W0(@(@(@(@(@(@(@(@(@(@(@(NE31UB
M1OSO*4K4B3R)^;F5H>GDHC75P<VR.'/*AA0K%&/YSDS2?(7PU"7MGR$;NBW.
MO_QM@1=T"("("("("("("("("("("+J7]A9I2Q/48D;:C>8](VEQ87UG<"=5
M"!V9G=&<WNC:N3[^70]&N0J#TJDG;&=323=]-OHVR"+LBBBR2BR2M-2RBB]"
MBB]<>370LO7&FFFN/_&NNN,:XQ_XQ@$7("("("("("("("("("("("+I38ZQ
M'2)%+36I$9)FUE=(Z@?-B-<N*1B>ES0YNS40I_YEHG!P8&56J(QGS33VQ&9M
M]).OD(NZ!$!$!$!$!$!$!$!$!$!$!$!%TL<CK%$(^R16,-2)BC<;:D#&PLK:
M1JF;VEH:TQ:-N;D*?3R:$)$:4DI.G*TQC4LHO77'T8!%W0(@(O/]^TX?5#W9
M]H=%_BG'`5R+[1OZ_P!I5T^C;]5CP/\`[;Z]_P`=D%%_UW?F=^Y78]1:*S>3
MXX2'P6-V#)3HKU`.-4OF1<$9I>^$,];,#R\*Y<_S!)%TRI(5%FGR-BI:L?R<
MH4AFI)Q6VANNVV"-]?Y2M:L)HSFH7R7OAMD\<L?]U+G=.8%269+M&Q^PRO,'
MY`<T*O\`X$2YDD&I&K8Z&5%PVWM5=%7-.X*TU:Z(2*]<E#0]R!`VJ2D2W8;=
MOT3^H:=QW;NVW[-UGMFT]R%76OU`2X)"+4*KI\Y]],2;:(%$8G&S58?&FOD'
M'3/)1HK<IR0[$RR(MS@S3_:70^(_+DCXSHI,Q(6AS3/A+<YD!;LWLWX7C]3O
MMOX\EB\)JNS2."3NDY><>[ANYRKJ@_X%UU3Z6`V5+9$^.ER6C);`*T>HI#TA
M[^\0:O*R(XK)'Y=N0IQ")!5<R8T:7>?1E(UZ$^]R('/??<#L[_;V_CR]2Q>J
M^/7*UBY`\53HH@Y"KZZA6W3E:X7/[?C[^PS%KX^U)Q]YK0WDRUV?H:>NT@LN
MFDC?H6OD<">'$E^<7><5N3E"L61PG9A*N[=G=F^[^SLW);MM[1MOM_LK[GFA
M9W8O3<Y"\>)!5-IYNN<<F>>,SX]:V31E^3)"@5-]]3:?TXZ*I`UF,#C5;C-8
M*K9&BH[FD<@:TT3W<SSVQ>I6(EK`N*F^SFG?EPMWV(]T`C;U^O<+T:1W=W,C
M[$9($:=N?MV=LW>V]&M-<TB!WV1$;.2-*Y'ZZGN"=*LR<00M.UU-5E::GF:X
MW,S@%;7<`B`B`B`B`B`BT$2V#*T$"ZOC9;/'*^KFB%I\K&0^G:^)K&ZIH5/V
M^0<<Z3A:*6,S6SH#'.05M"K);)A)'E6U[JVYE5QC=S8$^TCS$-%97!VLV(!X
M>9W:-OI'P.VW?_59`IHQ!8O%=;54ZA]Z.#!KQ@IOA31SUR#XZ6U:LN12K^#[
MA.Y#?5N5?!LJ'Y"V/KHX5<TOKH\.!:"#7!4[>F<G%JDC$42D*F^SM^6^Y<=C
ML.WL']=NWD5^*[9>2-47SQ?LV3TK:"^2UKT7)S#IQ%&`JR+`A&G)1JDG'60,
ME1DS-3L_M*^;/>(7*T!"]0]KWETU2*5+D].AYY*Y:0[$'GVO_`[>W91'??&Z
M2-UP;0KCS6W)5JY/UGT]N0E3LW)Z-P&PF*K[FO2QJ`/3Q`F87&[*&V!(6F)R
MB-F2QH3-QCEJ??5I('5+\QN\=FQ[T_Q_O]54;;;G;AX@2W?F!OSV'>.7JY!8
MW$Z4Y+,U9U/JLKRY4D42=7/B/94`A3=#["3KH7Q_BM4THWV](9)"VYM+51:`
MZ6TP6`^JB)2T(T9KN:ZRY(6:7(R'%85=V[G\CA[?I<P.9[MO_OR6Q"CZP>"^
MI#='(*#P!9':BL?C^KKNP7.0UE:M1R_%XU;=!WS6YNF9RK21^\FRQ(O)9.JB
M=EQQB/1Q&#P&)1=H=26)^2X=G^_]_P"_4H$_1`Y[@[CF"-C[/9S[1Z]]UM*!
M10$0$0$0$0$702MQ2L\6DKLN1/KFB:V!X<5C;%D+JZ29P2HFY2I4(HXVL.,O
MCB^JR2MR&A"S8RZJW`Q.G;L96&$X!%I$X[4S+JW<;@BZRII*W\6GSE/:/-B,
MIH#3]RUXL?JTCW'ZKU#)52&C'LQ;,H+92&]I*R/T4C3$GCCO9$MIZ<RQGAS>
MY+%>NQ3)WVY\]N'F1[3SW'JVY<^P$<RH;/XYV_7U(?NU#:OE6D(-ZT'&GD-4
MZ"IJONF!:E<;GFQJ%LBPG-^H9U.=WVK8S6^Y<^BC\R.K:QLKHKB+I,4L70*Y
M/JJ=W^_]_KYJH()Y]O5D<SO]+F!S\-NW;VJ5N<5:-5D,6K[8-"\G998%G<PD
MC[`)92E46=,9UQXK'C?*H3&&^2LA\>^;VB(NMNIJN<G&O'^2+VPMK:N0,KDY
M9CA'6Z3,3R5&]O(MY-]9`!W]7?MOW]GJ]4*LU$\S4%D<[W:5QVTSVV1T)U.6
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M*D>Z?YM7-"7@GI,(K$)"C/4(H7F?5A6QV[0[*VJ.$%4ENP]HVV[MF`'_`)MO
MQYGL7X?:>?Y'=W(";T'1/*&N(?)N:'`YTO2&R^I;0CD%MZEZ2O=69;-LMB28
MEF.MLRVS53Z;))TBCS0]'.%,5W&%4FU.?I.ZQ[!5[`T$@_1?L0X'8D<@=CR[
MM_62LZXO5?R[KV<=,YRG,$LF13^ONGCRPB\WQ*/WWT@C/8;M)*7=^/->69+R
MT#S&HI*LQ)F>8VM6+-%#XV?-SR2L+4J/DJ94'?VJ)VV=^9OAL[<CV\_\*XO3
M'C7)2.O'/)7R5K^1PQ_FO,C,WCCG()6JEB:5M:OC7QWB[BMAKD>P,"15`T#Q
M$5:2/J&),7'FY1LZPIJ1I"X888K(_;Z.WN\]OQ/Z^/<MIX*"`B`B`B`B`B`B
M\\M!\/\`DQ7]R6+%'UVEDOI*R3:QHZ33U?&97'E5TY:.0_(?E=;MKV?$GC4Y
MQ;#%=,O;?Q/5V&NW*06+)98VIXZM.8D#`FU*X2-A[>9]7+D``/UY^K;\5A,N
MX]7.JM.TK*IVJ),DXKW+RFX+7=8,3Q3ER5Q/WB+1EFNR&W;"I]14\V7R&?R!
MFFZ.E;5GUC,T01;6'K(=E3E^\Q<*/5LY`1ML3S`<!^/T=CO^&XV]6WJW7Y54
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MF8#"96L,2[IF_.[FK:R5!2'U3V;\3=NSV.W_`$[.Y5`X?P9G9X._H&CCMRJJ
M:D5G(SD/S$FU/36E[/BQ<7:(M6T4CL"HBH(1L6=+7-T=I'*XI<K2FBB4E(_W
M!"++20##DG:-=R2J[U#<$[!NX(]9)WW[.X\^S;?UJ/BN.=Q5Q3$/BT6K&4:P
MU)UL:$OZLTE1UE<\'0E<8'RPZDLZ9/4@HIU/>'NI8K6ZY5-X:[QQZ;V5E4;P
ME1,D+`G.E&K@[E4$;G?_`-61ZC]+8@<_7OR_#L]2E+F[6K38L43O5@T)R=EE
MAVMS%UE\)E-)519TRF_'JN./<L@T2994QFL&&]NACW;<8J).K@[O*5S3AD*O
MJ:R3359'VZ5,+T1N_/8@?1Y[D`'?U?IOV>O90NS43S+0V7SM=I7';4/;)%0_
M4Z;7)R94$NV.LJ4V)?C'(^#B2"+&$K5?,G6-4NE>66,$Q=2['URT*3X0[8:5
M+EA#N3=NP[-]V?ILW9WX?2YGV]O/U2E*XAS35Q7HZ1]AI:7K*QJR3\+%=L&$
MRJ01N51YZ9J>F;%:AMSULKA^[F1'X&H3QQ0U.3T[(FQ%*BU:1S1+'1^C3G&2
M#;Z?/F>+;OYCL/\`OS_'[3A]4/=GVAT7^*<<!(OM&_K_`&E73Z-OU6/`_P#M
MOKW_`!V047_7=^9W[E;+@44!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!
M$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!
M$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!%Y_OVG#ZH>[/M#HO\`%..`
MKD7VC?U_M*NGT;?JL>!_]M]>_P".R"B_Z[OS._<K9<"B@(@(@(@(@(@(@(@(
M@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(
M@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(
MO/\`?M.'U0]V?:'1?XIQP%<B^T;^O]I5T^C;]5CP/_MOKW_'9!1?]=WYG?N5
MLN!10$0$0$0$0$74O[^Q15B>I1*'IIC<9C;2XO\`(I$_N*-G8F%B9T9SB[O3
MT[N)R=O:VEK;TZA<XN*Y00C0HR#E*DXHDK??6]7KSVYX:M6&:S9LS1UZ]>O&
M^:>Q/,]L<,,,,;722S2R.;'''&USWO<UK6EQ`5"0T%SB&M:"7.)```&Y))Y`
M`<R3R`54]>H9P#WSC0OG#Q".,VSC4LE/R3II0>;OMGR:%$)R)F8<><9MG&I9
M))>YIN^=="]-M]L8SZQO1ST@O<UC="ZQ+G.#6C^&<T-RX[`;FD`-R?7R6!9R
MN,IU[%RWD:-:K5AELV;$UJ".&"O!&Z6::61SPUD<4;7/D>XAK6M+B0`J%57U
MRN,,_P"1\JJ60^2NZFU,+;JZO>6N9+3&9"Z(?E&'57+T[B4CT@<;=-L%[QAZ
M=E62=$Q.5$JQ'MUNJ9!VC4'R7M;X;15+4=9PRV=:Q]C-Z7HPF>Y1K/#3"VA)
M$Z3YTN5V\7I]>!@/$[AHFVV(R2_+6E/E>:#U+TAW-(20RXO!6)X:.FM57).K
MK96_QNCD;>K2,8_%5;LAC;BIYGN+@!Z>VE).V**_R'J`<#7-:C;6WFSQ&<7%
MQ5)T+>WH>2--JUJY:K-T3I4:-*GF9AZE4I/,+)3IR2]S3C=]"R]-M]M=<\3?
MT?Z]B8^671&KHXXVN?)(_3698QC&`N>][W4@UK6M!<YSB`T`DD`+ZM%RH2`+
M5<D\@!/$22>P`<2C:?<\4%5<P4'%ZPJS5-$=F=63R9U+;+?+"W3^(UBUFQQ:
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M]?3*N,MTM<V-<W31A5QQV(0.FZ9,>5>%VQ.W(;[\QZMO,+&:UZC_`!QE,)AT
MBG$ZC4-?I?\`ONNU98_I9$V9&..16QK<K]MD$HE"FKHCO#4<@4TO."TQD[8H
MFC.DD=DD7CZZ3&,Q;FXD+3SY=GX=W9SY]H[-^U6ZJFV8#=T&9+*K%[-DD(DB
M8I:POIC(_L);L@4$$JDCBB125J9W(YM7I%"=8W..J/Y$XHCR%B$]0F-+-V*/
M8J`0+JJ4AO%[2D]_)#:/*@/)SEEQO84C.GL:ZCYL9P^0/TALV;$$P*J-%[$A
M)A47D4UV9UC>J-2,+,O,T<EQZ8\HHI%IY;<]PT_%V?N`KA0;E305EV#FKX%8
M:65S'#4N>/D[.QRE2Q?)VR,5C-'!'^^?S'K"\OR*)7-5\C4QC$@_>0EGF34N
MW:L$85[IBIL0-_\`?K\CX+&[CY,%UW,Y'6$-B:6>V5%^.]@\CW5B<I1M#69'
M$HDKPPQ=K6OQ4=E:I.Z6'+-7)K93"F%6A;FN+2UX<C]5*!F9I"50-^X;@>/E
MY=^U)(1U:V*P6S@J8P4FN3R+EG;4BI"U8L^V`2UN/%VRH<AM#641B3>9#%AT
MU<D<AIBR&5"00CB7RM&RH'U=LTHWUL)-*O!];GV#B'>.7^"%8WC9S'EW*ZI(
M)R&J6H(^;2EH3A\9X(XR6UC&*PG.NF.<.\#S:*Z%_P`.UC,A(<EK*ID".(D3
M=>]%Q(]O7*%&L@5*(LA*A&QV)YCN]?L[?\*,N.'4:=>0CN[U8=2"&K.2T4D"
MU!*Z0GMIGEZ[0R0UQ*[*I2X(+,FRM%FL[JFUFV.$M2N0IXVTN$">U#FU/#(X
M.34E1/)'-X?7N#V$#U^L'GR(_JN*BNH^\W/2-QW&JX^K(0X\7VJRD'*.J'.Q
M?EMCUA:U4.SFJE54QU%F!-K//5IU;M.;`CLLV=HM&)!^\<+84*O.'21/,1(6
M[$#?MVV.W:#V'MY<^7K]?Z[$BK%A!M=DVUB2MA=<'0PJPM9>>;E.SZPHYDUD
M>DC-/.UTV);OF/?#EN:;IIL6F\NV^NN<9QB$LL<,<DTKVQQ1,=))(\[-9&QI
M<][B>0:UH))]0"P<CD:.(Q][*Y.U#1QV,J6;^0NV7B.O4IU(7SVK,\AY,B@A
MC?)(X\FL:2>Q4WM?J-\7(I64_DT`O*I)E.&"'R%XB,3_`'FT-_>21M[6I5,[
M)Z)(84J,^<UQ9"3S$YFAVWI?(5MKOG&1YO):JQ-7'W;-7(4;%F"K/-!!UX/7
M2QQN<R/9I#CQN`&S2#SY+AFK/E']%F)TQJ#)Z?UUI',YS'X?(7,1B!E&/.2R
M5>K++3H\$+FRN])G:R'AC<UYX]FD'8K4U&NN;;KC)(\VOM3U,T,KB^-*%W=<
MKY9I\VM:M>G(<'#SC7;8K7Y$D,-4^<9KL7CT?EWQG7RX'.ZO2?E;$\4;L90;
M$Z6)LT@=8_EQO>&N?SDV^BW=W/ERYKY+QORZ-76,ECJU_2>DJ=*S>J06[1L9
M9OHU6:Q''8L;OMEHZF)SY-W`M'#NX;+?Y5?(BCKO5/"*HK2AUAJX^0D5/:>+
MNY+F:V)UYAY2(Y9J5])1:DQ,?H5MGZ-MBM\8_P!AUVGD\??+VTKE>T8PTR"&
M1KRP.)#2[;LW(.WMV*_0#2O2)H;7$MR#2&J<-J*7'QPRWH\5<CM.JQV'/9"^
M8,^HV5T<C6$]I8[;L5,Y?U%<UURPF7$^PZ>Q"WQQVC.O&:QGJP=M:ZY(+C4<
M)=;(AB-T(@QRN"6?6K'/&:0FP12DDYLH8"UKJUNR=*1Y^V<O:\/T>+?\1ZQS
MV![>8[_4K!]KJ`%\Q<\,EC:\HIPLI=9;T=DZDO!$7E"N/OC2AFU=LJE1H3\M
MF<.CTNKV;.B),:HQF-35&K\A7S>N\PJ<)X>+U;[=_<?P.Q'Z*@&W62C+EQ0N
M+E!$:MB\C6T@=4S-9%%+K@<XE<]93FRK9::K=*[N&&/U0%/M?26'*GI,X:KR
M6B31"9'-\@01:3*DS1H[+BEP'B`W[=R#V@@#?<'?GV>:M,T\^VC)7..-2:KW
MQ#<?!91&29G6D1>=IL39&+0KY)8-':UG(\1]@5N*ZT25R:*$MCO%VE9'I@6L
M;UNBML*2O"TJ</U?8[L/X'8[_AV_@OF1=1"`SYUX/1JCH\58DBYV5Q+[CK\Q
MXDF8I&895\`A3'*I<]31Y;V"7.1<A1NDHC\,01-O8#U*F2'.Y3HXL25C6*-B
M<)'%O]WD?Q/9^W:N@+ZGE2L_#GDIRWGL1DD9*XE6?;%%W/6[0J2R9V(NBJ)Z
MEK8^'0Q_,(84$E;IE)GB+:P^2+D4>).;I.W*GYO83T[DC1$X3Q!OO;$'N(W_
M`**Q:OD!)ZS0Q9WY*0N&U0SR_:*1MG50RPY);KBJMN:/[4P1ZIFZ-M]4Q:1R
M%]<SW,TUO<(RUO*8].SO*U8F:VU%E;L5-M^SR_RHYSU+.%&[G#VA!<QSZLGS
M343U$,Q:LK?EJ)[17WK*]:=+(=(Q`'9K)<[!6P>5LD?9%BQ.]'R9E4Q4Y`1)
M-T[4<5>%W/EV;[]GJ[?#UKE:>I/PJ?%->IVNZ<*M+1C%/3.'.7\.[7)83HS?
MTU=ZVJ!VD,C404I@A!,VL)B=8,A)F[E'52&6I?W>>"&YU/3)3B<+N?+L)!YC
MM;S/@%V!G45X8%D&'_QR9C\Y<XZT-B5'&9VN<94JETGLF%Q4Z!M2**GN5A-4
MDE5064PL3[!DDA9'5QB3D0A<#\[H\J2<)]G[>K;S"P%NZDM*)[-/K"8[Y97)
M1>-_5*V/;"GF\@CC,R<<ZNBEG6#-K/>7>OHB@K_#6@E[.0Y-Y"B4,#>VKT<F
MUFJUC*?%#&3A/]`?'V<UG%F<YZO8>(7(KEO4&4]RL?':!3:9O\3,4R"N'%:O
MA4`;K./BK@9)8>J?(PYO$+>F%]9SW&)J"5C9(&-T)T,;'(A9D@;](-/+<@>W
MM.WM]JXXEU!N-CM(J[K>73<F$W!.VFJ#E$)41^PG*/1^27'5,KN2%Q9;:>\$
M:J_PL>H1`9ZYLJAQ=V;YWQ$'A(2E*=2?FT$+3S/J'X>W;L_%137_`%4N.4XL
M.X&8QQ-9JG@,)XQS*N[<W:["4G7;KR90W4Z,**$5L=6[=+W!,W,]*/,B;'V-
M:S!GED46'RA"H0,[*O4;$+2`/;NX$>SAV[3OW_HK45IRWX]W%8+M5U9V#K+I
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MBF2O@=DJ`GCA=8?`+<!G;`V'T@R]2)#+U8K_`,[B#-NJ_F#Z/-;B#HCZ5;&*
MJYZ'HUUX[`W<K%@ZN>=I'/1X*?,SYG^'8L6S,R4&8WT]^?\`^Q15-H3#*@X\
ML%IIB%7.,O4KXTW_`$PKN.1V+`:5;D=D2NO#VZT9Y&8=MJK;E:IRBFQ2R2N#
M00K52."F-,A,3)?283+MGML)W4X95*C.@P&M,3FL8[)3S0XD,NV:9AR,\=5P
MX'O=6<#8,7$;%3JYMFC9K^NC!=U3G+M'3#\D+I?Z+^D&#0.)TIJ?I#M3Z1PF
MJH[>B],YC/M,%N"&GFP^#$5;\D$.)U*V]BFRS<)FK#&W)&PG(PQ*VS=>]'N\
MZ(JYIN6J7.S%2$AS35VW6'$5LZ4-JEC*DZ9P(B*9X-D!R%1&SR)"0K+;]B#6
M,XIV+,V0&:*,^C9DL<^R*3,A2?<<T/;49:@=9+'1B8/$`D,I:82)0X-V,9#P
M>$[KA=KHTZ1Z.FI=9WM`:VIZ/AL24YM5VM*YVOIJ*W#DGX::K+G9J#,7'8BR
M\<F*D@?:$K,E&^BYHM-=$*>\D^H"GXL\B(94=G52<W539<,2ZPCD<;-=4\&1
MWL_'3#6"4?9;7^Z1ZFO<V,5!GTB&SW#G(VUR>]$S"8RIU9^=R\U>+#=QN/5Z
MO7MZR/;MOS4H3CF;"*TN;BC24X8W%MD'*A,\HFJ1(5&ZV%0F:IX:X3*(PI^?
MU;<UX.<K+31:PD$#VRF0*GE=!G,G+:0<H3$`J`$@D>KF?PWV_P#NJW*>J+&#
M'/F-&F>$1G-A<-8WR)E4VIR7V8Y02XW2.4<C<7*,S9%#'BLCB5]87*U-Q3U$
MK$A+Q/&AF;)!$]9`00ZO*IK:2KP_5_XM@#ZMSZNWM'L.W@LZX\]1&/VW/&ZM
M+(K[%12J0\*JQY[1A0AF.]@Q=RHB?;Y:WW*]XS$8:Y-,NKZ2X*;'YEV8%B)P
M;7%I>F9X5Y4+FYM(6[#?M'$6_J-OW_PL9;NJ-7<DH7CW:L5KR1G6%R.Y1:<.
MXS2\J="8L^06\VV5S&/SABM=VT:GM3#VZ!-L`D\D>STT;>W92BT94S8R*U#Z
MCVU)PG<CU`<6_=RVV\0K`TMRS*M>P^6E).$*)B]T<09!#FF;Q\F3G/D/D3/:
M%<);.JV4Q^89C#4X%M\E8SU3>]H5T2T<HN^L[LCT)?4);<Z.94(VV/J/CR.Q
MY?\`U[-EKKH_K9LER07$U-I..Q-)O2/&:Z3G+^-+O*X?%]^1M_):*1U?8+_'
MZ2->XQ9;.8HQ*VEN;(?*&)[1*6E#('^"_.>J\A_OQ4BS8[;D\R.SV#??MVV]
MO/EWJ\5B=2OB1`([)WPFP%\V51>21F*',4*A\Q>7)W<Y3?Y_%].KC)NK"6WR
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MRR7I9;`H_(I6WKXNR.Z`MFCDC5K5*76/O&$1.%WL]OLY;=N_LV[U@L;ZGG'=
MQGUN,$A?VAF@$+24BZU99,?<)!87\=&6YJ`E'(\MVBD,B4-5R!*EC%;0R22-
MQ-1YD2;>.M:I^6*6@HO9)@G"?UY[CV;';]RI#=NH[PO:%3FEVNE.]:M#-*W]
M<XPZ"V;/&'5K@U1Q2^9<<FDD)A<@C[@>PU!.8C/%Z!O<U3@6S/[=C1+NL-RE
MU)PGV?L/7M^_)91='+B'UYQ.OOE97S?K:S!1U/2:X/F7*MZA"*9-3!5J&X$B
M%GDSI%733!;]#'5J4('A"RO+<0N78;%N2%Z)T3H2H!N0.S<@?AN=EB,+ZA7&
MY\>ZRKV73(N$7#8K%3:TR"&QZPWAACTAO*L99;,!BRVTOW#:X#A4_P`3K^?*
M654Y.K+AV.B#NA*3$NVFC;L52T\SZAOS_`@?N1XJ+X%U4..<WLFUF#YQ-;*H
MA,"XUS:O;?\`FRP%6]T[\DC[E+8&N#5R;7""6.R9$DIIV?FF11;]\&26Q=<=
M)$"A$T,K@JR0L(`]I+@1RY<.WKW[^[96CK/EUQXN2?KZPK&P]9A-&V&PFQ53
M:VQ::Z(<U_9$<*E<#G"21K(VEC3C$9:RG:F,<C;WA4SKW#4]C)69?$RAN**F
MQ`W(]>WZCU*R(*B`B`B`B\_W[3A]4/=GVAT7^*<<!7(OM&_K_:5=/HV_58\#
M_P"V^O?\=D%%_P!=WYG?N5LN!10$0$0$0$0$7SJTB5>E4H5R9.M0K4YR18C5
MDEJ4JM*I+V)4)E*<[7<D].>3ON4<2;IN6:7OMIOKMKMG&9,>^-[9(W.8]CFO
M8]CBU['M(<US7-(+7-(!:X$$$`@[H1OR/,'D0?6L`_@[47_RLKC_`.AXS\+&
MP&9S`YC+9($<P1>M<O\`YJMNAA<TM=%&YK@6N:YC2US2-B""-B".1!Y$<BJ$
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MK&Q_#_85,O5`<<<0*FJSTL7D%K"Z)?'F30-C,F4)5H")*]<D(URG.D:Q$NK9
M4@_>!+9\8)2I7QL2-;KM!G9]A*U6L8W#4@@J\1W)V'/D>7JVV_J.WOY]H4NL
M/3GIJ-Q.'U\V3>XL5W6O)UJY6U=!54DBJMBK>=M<XD]D?NM&5!\'V?U%=K9E
M+GIV/8I,]R%W1%FDM;)(6EG(T0`G$=R>7,;'EW;;_C_]U\4PZ7W$2PY794BG
MT+=I@U6D;>ZZ00-X>\ZPU"_<EH[5L9N>3L);<D025OD$K0U#%529<9)5>D7=
MCWMVB9#&N<O3$$XB.SEMMS]?+L736)TN>/EOJ).Z6Q*K=L&2R3CQ&N,Y4O>9
M!#F^3QZ`0RRF&WHH[,[C&($P:*IPQV%%HY(4\GDZ>1&JCF<A,Y)ER-4Y)UI`
M\CLV'/?^FWAL3R7:RCIJ4=-+&A5K267VLOFT((X[Z(W!,X5ZR('57QDNB6W[
M7;DZ,,?K=I8DZA59$VD+C)4D>;F%G7MRDEH;6MG0I2"]"!Q`V]7/_F&Q_HOQ
M5733I:DG]KDM8V%=\6=2*TG5228Q)*8@>18,)FMLV-=Z9%+TJR`J",.$&LFU
MYT]0E[BVD8=DJ%\4QQ_62*-&GM!Q"XGM_'\#MM_4#FL]XY\*HAQ7DZ#%/3>>
M,E3I8S9R152IKBR$UFHFUG6BCLM3.66#QR-QN+P9?&]]7V-L[;#VYL8-X_(]
MD9;*W'M9JU\*A<3V]OM]?(;=JAMXZ4/'%]:'IF<97<AJ9_M[EK=SB;I)(<4H
MWG/-2LYM4]V&E;:0#!136HBUA2C:+M^"<ZL#HL(5X-5EHTR8LJ\1_H!^@((_
M8*1:_P"GW7=3(;0::JN#D-7#+;B2N3Y4U1"=1IK*3S6MX?`J]2V='G#]QCGM
MAFLL@U;QJ,S@E"ZZ0M_1E*%NL/1/6R=T3$+B=MP#MO\`UW.W]>2DFQ>,+;-[
MN<+C1R-P8%<VX[2?C-8Q;=H@PZJ84NDFTRB3]&ECHV/C6E?(N[N4S:S4+FS*
MT3HW3HUR^5(UD61H7LJ`[>(*P%RZ>''138,1LQE;Y'#9+%>4;]S%._=1<R(T
M$LO:45[M6<BD<K3N,>=#5:%XC:AS,5M#6H9TN7IY='DKT2X\HP@J\1_Y>']-
M]_W72,G37X\QK6C6AA5SQKK[C3=LGO\`HFK"7**'0JM9[+$TXT<2&%0KAJF;
M&Q%(X6+*GIEASI,7!@9EZIN3($9+&PL3.W$XCS]I&Q/KVY?IZASVW_52_MQ"
MJ?\`>JH[**R^)KDI*I9)2<$N=-B,%6`3`)0UH$"UJ>=L1C,4?=4*QJ;I`RDN
M,5.;VA^)5JD2`M*]R%$[%3B//V$[D>I0;).G37J5SO2951,YK`Y_R)XXH^-5
MIK#%K&KB$S;TS<\Q]#=4VC":,I5$NO2-,LF?#F^6FO328_FY*97LXMI5JS-2
MKQ=GL!W'D/8%>"+UY$(E7,=J=L9DI\#C$+9Z];F!U**=$1L29&--'$30XDK"
MS"7%-LSI2D:LM45N6K+R9J<7MJ9MKF+FM>US'M:]CVEKF.`<US7#8M<T[@M(
MY$$$$<BL>S7KW*\]2Y!#:JVH9:]FM9B9/7L03,='-!/#*UT<L,L;G,DBD:YC
MV.+7-+20H4MCB-2ECUC8$`9JWJV#NTTA\AC#;,FRKHFH<(LN>FM2WIG]$0E3
M,ZDY4U''Z+2"R'5M.W,)UU+6IMLX-UT^1P5"]0N4F5ZE9]JM-7;893A<Z!TL
M;F"5K1U9<6$\0`D821R<WM7--6]$6B=2:7U#I^GIO2V#MYK#Y'%ULS6TMB9+
M&+GNU9:\5^!D4=.5\M5\@F8V.W6>7,`;/&=GC4M&>A(G89+'7Y9R;3O*5D?&
MEW4M"FCM-$[HG;5Z=8<W';FVTK+T)7%D[)3-S$JG370W;.Z<[7&2]N>5NBLU
MYX9OG\O;'+%(Z/YLX1*V-X<8W'YQ<-G`%IW:X`'ZI[%\DXSY"#*&2QU^;I.C
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M!?6[W([.7(C\0=]]_'_96`2O@?3DPL&FK=<'::(+;I&U9_:\:M!BV@K/-WY;
M9C>]L<NADU>4<$TWD->KXR^&18N.9*2&IV%JCR8MQ].PMJI.3?M[QMX?YW_<
M^U1U9?3#H"WXI.(]84EM-_>[#K>G:EE-D[N4"0V4Z02C9^@LR$M;G(VZNTI$
M@6YEK2TK'B02EM?9$M3-Q:$AU1I53D6N*H<1MMZM_P`.?+_/)3!'.%--QZ53
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MS;;N`[!^G]?6I'E'$>-S^*02-61:=P6$X5=/:TLZMYI)'.!%2N'SJJG'=PCD
MC2ZQ^O&*+OSDM+.5MC^IF,8DASJUKEQ&VY)RDQ1DJ;^P`<B/7Z_Q*KK&NDMQ
M9A;C7:^'+K2C958%\6-8PV(9.P*F_!O$&1V#+ZL5.67>(.:]<J<)/:$R>IN=
MNNTS(53EIH3AL2I2$^A5XSS[^+_F`!_H%"T,Z0,,B]S,*-1+7QPXI0/CUQ6K
M&*P51*$*B?2V9<7N3MI<EXOO9I^M:(T2F$)Y1-HT>ETB$FCSRYG18QND!*QH
M<U19Q2+R1_Q;N.^WO-`Y<^XJ77+I!</W2#S&NU3;,SHI,("UU-\VK%\2>2HQ
M5+#.+CLJ.0")EO\`"G8AM0QJ?7A+)='90K)<;$9GYIA3@@F9*B(M6Y91XSR[
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M(VY;<_ZD'_`4;LG1VXSQ]K9T#=.KURMB*?C*CKI^7R.NG9SKE#Q$266RT<AC
MZ1TJU7'7I$P0^WI_!7I+8#%-"9=%WS<J3:N;N02\:$XR?UWW[>?%MOZ^X'DK
M<,7$:`QWD4T<G&Z66+I8;559U)'-^7:.E0][JW0QC<&&(OC&EBB8U8FATE:%
MTMB;B4X)GMJ?)=,RMG-2Q2`]E+*F_+;U=OZ_[_3]59%YCS!(TY220L;.^I23
ML*"4SRVHG1.4HQIN7@\HE<2>66=@LPPO!NNN-\:;[Z^=YNV<9MR112@-ECCE
M`.X$C&O`/9N`X$`[$C=9V/RN3Q,KY\5D;^,FDCZJ2;'W+%.62+B:_JWR5I(W
MNCXVM=P.);Q-:[;<`JL'+WB\?R6I6;U5#9DQTS(+`1H(_(+*3UVCF$@S#"]R
M=7J,(]"I%#U9!,@;DI+`M/W>3B=(^<X-N$&^%99R7S^IL!)GL3;QM6Y'BIKK
M60S7FTFVIO101UL#0+%5S1,QHA>[K2!"7Q\!X@6]EZ".F:/H@Z0].:VS^`R7
M2!BM+V+.4Q>D)=5V,#BQJ!S9'8[,3N?B<]!))B[DS\I6B;CXY#E8ZMPVFF!T
M<U'N!G27<>$\_E$A7<@F>YH'-&`IKDM:OU&IF1`J>&P\Q1&92B=%=FRTE$\,
M&%;PA)WRR*,*&M^=D>=B3#B5)'DM&]',VD[UBP_.LRM2W`(IZ,V)$+721N+J
M]ADKLC9#)(>*5@_E.#HYI6\B0YOT=\IKY<E3Y1.E\-BJW1;D.C_4VGLH^YB-
M7XSI(FR-F&A<B;%F,+8I0:.P<EFADS!0LO:,C"8;N,HV`)&QR0R[?"XQ&B7;
M#^3'F,I]P3JFP]%M*#1VPGT3ZI=",..J?"S!.B731-J5Z;S-4^FI.-<%ZXUQ
MTT0PA_6B*,2;;=8&-#]@.';CVXMN$`;;]G+L7P>_,Y>2B<8_*Y)^-,AE./?>
MM.HF5TIG=(:AE-<R.F<Z8OZOB,KC(3QDE0G=?%VI^145N&`7.V*IY7UW5\P5
MQ+X0[8:=65&TQI=)79G=XZI2-*>0-<H0O,G5/:!]W>U:EG>&YE<F/5L5MQ9N
MUQ:X$C;;D0=P5%=S\!J5O=GPBG+E--9$V6A4UM0>R&7>#M]F5A):5VCYL"15
M[,#(*K6LT?0JV`Q<L:UFCIE<JD<NR8IU)D;@280.([/80>\'MW_WZA[%P6'P
M"IVV%+VX6+([$E;RXP3D36S'(G%7!\2>#P[E`8X:V<R1:2IH&0^;MFC:ZN+)
M$FF4+Y,RQ9J4%%MS;A6W-2M`50XC;;8;$'P_WS]J^2#]/*BX+\D6IG6?2*2H
MJBI?CR1+9:X1)[=]>/5%O*>01>D/FW,+3Q'6`R%V*4JK$*+C.DAGF'%4G?Y`
MI3$-A+>0N)\2?7VGU_[\UCQO3)XXD+;+<8^9,XJHGG(V$\NXPCCZZ--S#2W)
M*",:..MUIU(P)8J2W-#@_M*$I%.V21Z2B-39(H<TK\T*27=RU4DXCR[AP_B/
M8?\`'L]2S/BEQ=D]-,EVO%KR".S2_P"_I9\_W#R`B"=2SNMH&,L9306!..T&
M>FYP8JU3P:"-C/'(]!&9QET90F(UKP:M7N#Z[[*2$[[;=@[`?5SW(W]?/U\E
M7=IZ-7$YKAT6AQC[<[L5`Z;K>@($^N<NC&'R'5+6%Z17D8R15L^;8*W,CCLY
MVE"8PZOS[)65^DBMM;-65$[MS<H5DGE7C=OOR[23WDC;]BLW5]*'BDH12%$G
M)L%LT<E2%3%C6^2MFAM8EH^6:GFT:@@GRF.*B<MKCR$.3R=<DF94QTRT-C9%
MDF4C`FRA,*G&?/O^CP\_T78N'3"H)4DGJ5LEEN1DR7<BDO*^,.,>?86G>*AO
MG$WTL9XFM;.R^`.*\Y-)IELO>'F(60?8D(*P^2!O8HXRMCVXHCR<1_IP_I[/
MT]6R[QYZ<=*2"[C.0;O,;<662=.(C8RE<8_Q'#>JET-X\2[C&@<CV_6"XUSJ
MNK6;R`QT1Z&Z)#9&H(=49*$A,4@U)Q';;U;$>)!_<!1M"ND3Q<@#,R-4=?+=
M+51,F@-(3(%DGBJQ[AJGC=5$]I&`.#+L;!OFM4L65G9LUCDHQ(6I\1NN'?YQ
M2I&UT1(%B8A<3^N^_?N=S_5<B3I#\26CT&8S_$J+&-#!7D7AYS-*&8PZ#,5<
M<;IOQ00-\>,>8L[[*]9!35A29HE)TJ_>12X/:A')T1S:]MR-643C/=Z]_P!2
M'?N%&<8Z>5U4K?$CLFB9'1.]5(V?$2K^B[+A[*X,B6"-O&>NZ(:8R?.6VJ%-
MH1=P<U550'][Y.5-IMO(H9&44>=V-U)PW)64A=OMOV^W<]O$3OMOMZS[.WQN
M2Q\)ZI;.#NW`W0R0,M0.=).]&OF8\]9-?](I*F1:RRM,RODE0/9B;Y8E=71&
MV*%2%0<U(3TY2'5-NC2[$$XCQ<7KWW_7?=1:;TP>/"N=1FP')]M)T=HPZ<;7
M0A`M?HKEE<]^+59VO4M<)'9&GA*<\]"OB%T3LF7%)5:(QW7+42M$<TX;R"L$
MXCMMR^]_S=O[*-F;HY\9&!J:&YMG%Z851%#QN;*W>ELDKUU<JU;N)JJR,4BA
MCB9TJ]8PO:2/1VV9W"7=-8;+-R);%'K=-*"W9U)*=]2%Y/LY[[]_%MO^P[%;
MEEXBP%AY$1[DVWRRQM+$C]5*J0RBP[1LB)/E5;[1]>SP^0,:.)I3%R.)RAC5
MS.*+R5R1Z:9#+)B7\Y'Q]\W8B2IORV]6^_Z^WPY>"M4"H@(@(@(O/]^TX?5#
MW9]H=%_BG'`5R+[1OZ_VE73Z-OU6/`_^V^O?\=D%%_UW?F=^Y6RX%%`1`1`1
M`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1
M`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1
M`1`1`1`1`1>?[]IP^J'NS[0Z+_%..`KD7VC?U_M*NGT;?JL>!_\`;?7O^.R"
MB_Z[OS._<K9<"B@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(
M@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(
M@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(O/]^TX?5#W9]H=%_BG'`5R+[1OZ_VE
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MW>X$X'^Z[X3Y)ZY+I8]_#C?XA-WN!.!_NN^$^2TJ_M`W4?X(\C>F/;5545RK
MIBU+&>)Q3Z]KAD-EZ-W?EZ)EL5B<W92F0D_ZAA3>WISU:G;'T%D%;[Y^C`*Y
..$UP>"6D`;\R"/45__]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>g838054g28a54.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g838054g28a54.jpg
M_]C_X``02D9)1@`!`0$!+`$L``#_X@Q824-#7U!23T9)3$4``0$```Q(3&EN
M;P(0``!M;G1R4D="(%A96B`'S@`"``D`!@`Q``!A8W-P35-&5`````!)14,@
M<U)'0@``````````````````]M8``0````#3+4A0("``````````````````
M`````````````````````````````````````````````!%C<')T```!4```
M`#-D97-C```!A````&QW='!T```!\````!1B:W!T```"!````!1R6%E:```"
M&````!1G6%E:```"+````!1B6%E:```"0````!1D;6YD```"5````'!D;61D
M```"Q````(AV=65D```#3````(9V:65W```#U````"1L=6UI```#^````!1M
M96%S```$#````"1T96-H```$,`````QR5%)#```$/```"`QG5%)#```$/```
M"`QB5%)#```$/```"`QT97AT`````$-O<'ER:6=H="`H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0``9&5S8P`````````2<U)'0B!)14,V,3DV
M-BTR+C$``````````````!)S4D="($E%0S8Q.38V+3(N,0``````````````
M````````````````````````````````````````````````````6%E:(```
M`````/-1``$````!%LQ865H@`````````````````````%A96B````````!O
MH@``./4```.06%E:(````````&*9``"WA0``&-I865H@````````)*````^$
M``"VSV1E<V,`````````%DE%0R!H='1P.B\O=W=W+FEE8RYC:```````````
M````%DE%0R!H='1P.B\O=W=W+FEE8RYC:```````````````````````````
M``````````````````````````````````!D97-C`````````"Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92`M('-21T(`````````
M`````"Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92`M
M('-21T(`````````````````````````````9&5S8P`````````L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0``````````
M````+%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$``````````````````````````````````'9I97<``````!.D_@`47RX`
M$,\4``/MS``$$PL``UR>`````5A96B```````$P)5@!0````5Q_G;65A<P``
M```````!`````````````````````````H\````"<VEG(`````!#4E0@8W5R
M=@````````0`````!0`*``\`%``9`!X`(P`H`"T`,@`W`#L`0`!%`$H`3P!4
M`%D`7@!C`&@`;0!R`'<`?`"!`(8`BP"0`)4`F@"?`*0`J0"N`+(`MP"\`,$`
MQ@#+`-``U0#;`.``Y0#K`/``]@#[`0$!!P$-`1,!&0$?`24!*P$R`3@!/@%%
M`4P!4@%9`6`!9P%N`74!?`&#`8L!D@&:`:$!J0&Q`;D!P0')`=$!V0'A`>D!
M\@'Z`@,"#`(4`AT")@(O`C@"00)+`E0"70)G`G$">@*$`HX"F`*B`JP"M@+!
M`LL"U0+@`NL"]0,``PL#%@,A`RT#.`-#`T\#6@-F`W(#?@.*`Y8#H@.N`[H#
MQP/3`^`#[`/Y!`8$$P0@!"T$.P1(!%4$8P1Q!'X$C`2:!*@$M@3$!-,$X03P
M!/X%#04<!2L%.@5)!5@%9P5W!88%E@6F!;4%Q075!>4%]@8&!A8&)P8W!D@&
M609J!GL&C`:=!J\&P`;1!N,&]0<'!QD'*P<]!T\'80=T!X8'F0>L![\'T@?E
M!_@("P@?"#((1@A:"&X(@@B6"*H(O@C2".<(^PD0"24).@E/"60)>0F/":0)
MN@G/">4)^PH1"B<*/0I4"FH*@0J8"JX*Q0K<"O,+"PLB"SD+40MI"X`+F`NP
M"\@+X0OY#!(,*@Q##%P,=0R.#*<,P`S9#/,-#0TF#4`-6@UT#8X-J0W##=X-
M^`X3#BX.20YD#G\.FPZV#M(.[@\)#R4/00]>#WH/E@^S#\\/[!`)$"800Q!A
M$'X0FQ"Y$-<0]1$3$3$13Q%M$8P1JA')$>@2!Q(F$D429!*$$J,2PQ+C$P,3
M(Q-#$V,3@Q.D$\43Y10&%"<4211J%(L4K13.%/`5$A4T%585>!6;%;T5X!8#
M%B86219L%H\6LA;6%OH7'1=!%V47B1>N%](7]Q@;&$`891B*&*\8U1CZ&2`9
M11EK&9$9MQG=&@0:*AI1&G<:GAK%&NP;%!L[&V,;BANR&]H<`APJ'%(<>QRC
M',P<]1T>'4<=<!V9'<,=[!X6'D`>:AZ4'KX>Z1\3'SX?:1^4'[\?ZB`5($$@
M;""8(,0@\"$<(4@A=2&A(<XA^R(G(E4B@B*O(MTC"B,X(V8CE"/"(_`D'R1-
M)'PDJR3:)0DE."5H)9<EQR7W)B<F5R:')K<FZ"<8)TDG>B>K)]PH#2@_*'$H
MHBC4*08I."EK*9TIT"H"*C4J:"J;*L\K`BLV*VDKG2O1+`4L.2QN+*(LURT,
M+4$M=BVK+>$N%BY,+H(NMR[N+R0O6B^1+\<O_C`U,&PPI##;,1(Q2C&",;HQ
M\C(J,F,RFS+4,PTS1C-_,[@S\30K-&4TGC38-1,U336'-<(U_38W-G(VKC;I
M-R0W8#><-]<X%#A0.(PXR#D%.4(Y?SF\.?DZ-CIT.K(Z[SLM.VL[JCOH/"<\
M93RD/.,](CUA/:$]X#X@/F`^H#[@/R$_83^B/^)`(T!D0*9`YT$I06I!K$'N
M0C!"<D*U0O=#.D-]0\!$`T1'1(I$SD42155%FD7>1B)&9T:K1O!'-4=[1\!(
M!4A+2)%(UTD=26-)J4GP2C=*?4K$2PQ+4TN:2^),*DQR3+I-`DU*39--W$XE
M3FY.MT\`3TE/DT_=4"=0<5"[40914%&;4>92,5)\4L=3$U-?4ZI3]E1"5(]4
MVU4H5755PE8/5EQ6J5;W5T17DE?@6"]8?5C+61I9:5FX6@=:5EJF6O5;15N5
M6^5<-5R&7-9=)UUX7<E>&EYL7KU?#U]A7[-@!6!78*I@_&%/8:)A]6))8IQB
M\&-#8Y=CZV1`9)1DZ64]99)EYV8]9I)FZ&<]9Y-GZ6@_:)9H[&E#:9II\6I(
M:I]J]VM/:Z=K_VQ7;*]M"&U@;;EN$FYK;L1O'F]X;]%P*W"&<.!Q.G&5<?!R
M2W*F<P%S77.X=!1T<'3,=2AUA77A=CYVFW;X=U9WLW@1>&YXS'DJ>8EYYWI&
M>J5[!'MC>\)\(7R!?.%]07VA?@%^8G["?R-_A'_E@$>`J($*@6N!S8(P@I*"
M](-7@[J$'82`A..%1X6KA@Z&<H;7ASN'GX@$B&F(SHDSB9F)_HIDBLJ+,(N6
MB_R,8XS*C3&-F(W_CF:.SH\VCYZ0!I!ND-:1/Y&HDA&2>I+CDTV3MI0@E(J4
M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY`
MGJZ?'9^+G_J@::#8H4>AMJ(FHI:C!J-VH^:D5J3'I3BEJ:8:IHNF_:=NI^"H
M4JC$J3>IJ:H<JH^K`JMUJ^FL7*S0K42MN*XMKJ&O%J^+L`"P=;#JL6"QUK)+
MLL*S.+.NM"6TG+43M8JV`;9YMO"W:+?@N%FXT;E*N<*Z.[JUNRZ[I[PAO)N]
M%;V/O@J^A+[_OWJ_]<!PP.S!9\'CPE_"V\-8P]3$4<3.Q4O%R,9&QL/'0<>_
MR#W(O,DZR;G*.,JWRS;+MLPUS+7--<VUSC;.ML\WS[C0.="ZT3S1OM(_TL'3
M1-/&U$G4R]5.U='65=;8UUS7X-ADV.C9;-GQVG;:^]N`W`7<BMT0W9;>'-ZB
MWRG?K^`VX+WA1.',XE/BV^-CX^OD<^3\Y83F#>:6YQ_GJ>@RZ+SI1NG0ZEOJ
MY>MPZ_OLANT1[9SN*.ZT[T#OS/!8\.7Q<O'_\HSS&?.G]#3TPO50]=[V;?;[
M]XKX&?BH^3CYQ_I7^N?[=_P'_)C]*?VZ_DO^W/]M____VP!#``,"`@,"`@,#
M`@,#`P,#!`<%!`0$!`D&!P4'"@D+"PH)"@H,#1$.#`P0#`H*#A0/$!$2$Q,3
M"PX4%A02%A$2$Q+_VP!#`0,#`P0$!`@%!0@2#`H,$A(2$A(2$A(2$A(2$A(2
M$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A+_P``1"`,^`Q`#
M`2(``A$!`Q$!_\0`'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`
MM1```@$#`P($`P4%!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*Q
MP152T?`D,V)R@@D*%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA9
M6F-D969G:&EJ<W1U=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*S
MM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ
M_\0`'P$``P$!`0$!`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#
M!`<%!`0``0)W``$"`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1
M"A8D-.$E\1<8&1HF)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI
M:G-T=79W>'EZ@H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZ
MPL/$Q<;'R,G*TM/4U=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1
M`Q$`/P#]4Z***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`***
M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH
M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`
MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B
MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`***
M*`"BBB@`HHHH`*3-!.T9-<)>:G=^,O%RZ;H5S+;Z1H<RR:E=1/M\^88*VZD=
MAU;\J`.\HI!TI:`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@#.7Q!8/K;Z0+A1J"0B;R6!!9"<9&>O3G'2M&N:\9
M^$?^$CMX;C3IA8ZUIS&33[T#F-^ZMZHW0BL:#XIP6WAV\DU^W>VUW3G6WN-,
M!R\L[<((_P"\KGD'T^E.P%WQUXCNHYK?P_X88-KNK`[&QD6D/\<S>F.@]36Y
MX9\.VGA;1K?3M-4B.$99V.6E<_>=CW8GDFL;P+X8N--2XU;Q"RRZ]JY$EXXY
M$*_PPI_LJ/S.:ZZ@`HI,TM("*=6"[X@"Z\X]?:BVN$NHA)'T/8]0>X-2UD+-
M]@U_R&XBU",N@["1>OY@Y_"@#7HI,TM`!1110`4444`%%%%`!1110`4444`%
M%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`44
M44`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!111
M0`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`
M!1110`4444`%%%%`!1110`4444`<'\8-=U'0?#D,NA7;6=S+>11>8%!^5B<]
M?I7%1Z[;W/A67Q%KMM'<>+-`E>PBF88<S$[4.WH>N1GISBNS^,6E7FL^'[6#
M2K62ZF34()"J8R%#')_"N3U3X?ZG<?$P+;V\I\/WUU%?W#C[BRHI^4_4_P`Z
M^$S>IF-/,ISP_,XM1A;6R<N;WEZ-*[/H\!#!U,)&-6R:;EY^[;3SNKV7D:/P
MW\8:I'H7B.?QE>-=-HLQ#.0%P`F2./<5J^"OBDOB:'4'U2T.F2:=&LTD;2[L
MPE=P?G'^37&W_AKQ`=.\3Z;::;<(VO:Z!YQ`VK`>2YY^[4DO@7Q'IWB-!=_9
M[^VU?37T^XGM(MB0*%PA8$]B!R.U<F&Q^:X=4H1C*48W4KJ]VW+ENWKI:.UU
M9NYO6PN!JNI.4HJ3U5G9*RBW9;:Z_H=1H'Q!UGQ)-!=6/A^4:+<RE$O&NAOV
MCC?L],UDQ?&B]CM5OKK12-+^W&S,R7H+A\]=A&34WP_O]?T"QL?#^H^&;O-L
M[1M?AU\D)DG?GN?;O7%VOPTU6QTVWUA-,NKC4;76"[Z?(=RR0[LA@N>OO4UL
MQS94*4J$YN33<[Q2LTHZ6Y-4KO1:O^8=+"X#VU2-2,4DTH^\W=7>M^;1[:[+
MJCTC4OB+J-QK5YI7A+1SJLVG*INI9+D0HC'^$9')KDO'GQ<\CX?IXCL+::'5
M]/O_`+)#:2G=MN7!7!/=1R??%:=LFM>"/%NO7</A^_U>QUMEN(GM2"T;8Y5\
MGCJ?RK@?&G@W4+OP9#H-X@M_$/B?5WU"QAW`B&2/YE1S[Y89[$C/>NV&.S6=
M6482DY6J7CRV44OA<797;6N[N9PP^7IP=1+EO#6^KO\`%=7V3\D;L,?BG2+R
MQ;Q#\7M.M==D:*2?1KF"(0D,1F,#(;D<`UNWGQB\03>-M;\.>%?#-IJ)T.2-
M9I[G6%M2X<`@A6'/?H>WO7F?C/0?$7Q%O=#>Y^&>HZ;XEM+RV;4-7)3RI(HS
MR`V>G?\`"K'B7X?W$WQ@\1ZUX@\$>)?$%C/=02Z9/IMP(E5E"Y+?,,C('Y5K
M'$XJ.E'F4>9:OF>EG>_,G9K2]D=/U?#5/>KN+ERR=ERI)\RM;EE&Z>MKNZ1Z
M)=_'U-,^*B>$-5TLV]NTD4!U+[1E5FDCW(I7'0GC.:@U#X_3:?X:U+53HX<V
M'B<Z((OM)&X9_P!9G'Z5S?C#X6ZQXQ\0?$.Z2PN+2:>.PN]#G?`$EQ"I)4'U
MZJ?K7-+X$\7ZE\)[B"_T"]CUF]\9)J,UH%&\1D#=)U^[DFM)X[,XRE%7:]YI
MV\[);?/YF=+!Y9*$)-I/W5+7NKM[_)]K>9ZQK_Q?U@^,[SPS\/\`PVWB&_TJ
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M-]NN_P`SYJ:2DT@HHHK0D****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B
MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`***
M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH
M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`.)^*\L
MD&@V;P2/&QU2T4E&(.#*./I790+B,9ZDDUQ7Q<./#]F?^HK9_P#HT5V\9R@Q
M7E8=O^T*^O2'_MQUU$OJU-^<OT%Q1@>E+17JG()BC%+2%@#R10`'`!S@5Y-X
M6E_X3_XLW^O(-^D^'(C96+X^5Y3G>P_,_F*F\;>-+SQ=J+^$?AV_G7,ORZEJ
M2',5G'_$`W]X]./I7=^$?"]GX/T&VTO3%(BMUY=OO2.?O.?<FFM$!LT444@$
MQ1@>E+10`F,=*,8Z4M%`"8Q2T44`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!1110!C^)=`A\1VD5M=^8(XIXYP4.#N1MP'TK3MP1$-P(/<&I:*S5*"FYI:
MNU_EM^93E)I1;T17NWN8TW6<4<Q'5'D*9^AP:R9?$UQ:G%WH>L;O^F$:3`_B
MK5O45H2<A=^-M38[-&\):[<R'H;CR[9!]2S$_I6-=^%?&'C<;/%>I6^@:8W^
MLL-)8O+*OH\QQ^@KTBBG<#)\.>%M+\)Z<MCH%I':6ZG)"CYG/JQZD_6M:BBD
M!D>)]:G\/Z1<W]MI]QJ7V9"[06[HKE0"2<NP`P!GK5O3M12_L+:Z(\H7,2RJ
MK'D!E!_K5?Q'I5QK>DW=C:WCV/VN(Q-,D2R,JD8;`;CD&J5GX.LY=&T^R\21
MV^MOIJ@0S7=J@*X&`0H&`<`#(]*`*VL^+M1TG6H+5=$,UC<W<-K%=_;45I&<
M98K'C)"`,3DCA&Q267CI;WQ'+I,=FX*O+%'-YBDM)$`7W1_>1>?E8\-QZC.K
M<Z"EUKEAJ$LCE=/67RX,#:7D`'F'OD*&`[?.U9&E_#^WT?Q'-J]K<3L[M*ZH
M8XP<RG+[Y``\@_NAB0N!Z#`!H>&/$TGB"*]:[T^XTN2QNS;20W,B,P8(C@Y1
MB,$.._:IM?UFZTJV673=/.H[=S38N4A6)%&22S<9]!]<D5F:/X*>W_M>+Q!?
MG6[35Y_/EMKFSB1`^U5_A'(PB\'N,T>(?`_]IV-A9Z)?OHME9,6:TM[6-XIQ
M_"KJPQM!YQT)Z@T`%QXV:`:3<#3YCINK>0$N7E1)$:8@(OE?>8C(W>@R><'"
M:3XY&K^*]3T:**T1=+D,<DAOT,S-L1LB#&X+^\`W$]J34_!<^L+81:CJMS)!
M8^4S#[/%YDTJ8/F^9MRC,>NW'&0,9J9O"#W&O1ZE>WADB@F::&U6VCCV.4*9
M,BC<PVLW!/7'H*`-C4KZ:VM9)-.M_MTRCY(%E5-Y_P!YN`._^-<^GCTSZ-:7
M=IITMS>7MZ]C%9QS)AITWE\2$A2@$;G=WQTSQ6DOA:UTVSN8/"\-MHKW1W--
M:VR9#?WBI&">W-9]KX!AM-&BM8+VYBNX+PWL-W''&AAF(*DI&!L"E68;<8^8
MGJ<T`5I/B;9RC2(]-2&:]UF!9X;:XNX[8I&6V_,6)RV[<`J@Y*GMS5U?&Z_\
M)%_9C6-SY!NFLUOMR>6UR(O.,>W.[&S/S8QD$>F:5]\,;&X@A@LI);.)+-;&
M?:BR-/;*68)N8$HVYW.Y<'YC[8TT\&V_]O'4I)IBGG_:EM,CRUN?+\HS`_>S
MY9*XSCDG&:`.@1PPZC/>N=\8>,8_"$FF2WZP+I]Y<217-S)*5-L%ADE#;<'<
M#Y9&,@\C&:T='L;RTEO7U*Z-R;FY>2)1]R"/@)&O?HN3G^)CVQ7FOQM\(^-?
M%;Z)#X*TWPSJ%C87$EU/'K%[+`PGV%(70HC'*[V<'C#*M71@IU%%NR\]!-V5
MSN+SXB^'K"UMY[O41#'=0^=&7@D!$><!G7;E`3P"V,G@55TCXA6EQXFU/0=7
M:&TO[*Z6*W"LS"X1HED4YV@*QW,-N23M.,UX9K7PY^.7B.>SN-;MO`-S=6<"
MP_:#J4R.^&8^8"L`*.0V"5..!QFKLW@[X\2:E-=I:?#V,2ZI!?\`E?VG<-@Q
M1"()N,.2"H&2><C-=WU&FU\<=OYEOTZ?Y$>T79_<>[VGCC1+Z6[BM;[S)+)&
MDE00R`E5.&*#;\X!X^7/)`[BLO\`X7!X/-K'<KK4+V\I`25()65CM9L9"]0$
M8D?P[3G&*\1T'X=?&[P[KJ:KIMA\/%NHK::V4OJ$QWI(5.YV$&YW#(K;B>>X
MY-6+?P-\<4\,6.B7=C\/;F'3GE\F;^U+B-]KPR0E2%@P>)G;/7.*KZE2_G7_
M`($OF'M/)_<>X'XF>&1:0W/]J(8)W95D6&0A2N,EL+\H&0<M@8(.<5GZY\6-
M*T/65LIMTT>_9+<QR)LB.`3P6#/A6#-M!V@Y/>O"]8^$GQEUN"ZAO]-^'LD=
MZI64-J<TA4&-8RT>ZW(C8[`2P&3G'0"H[SX/_&34-5M;Z:P\#QB(1_:K=-9N
M!'>%%*$L/)^4,I8,!QAVQC-'U&CUJ+[T'M/+\#Z#MOBKX5N;@V\>LP&969&!
MCD4;EW`\E<=4<>Y5@,D$5>@\>:#<Z;<7\>H(+:U(68O$Z.I.-HV$!LG(P,<Y
MXS7SW?\`PR^-%_#)$VG>!8EDD1\Q:U<*R[9YIA@^1TS<.I]0![Y72?AI\:-'
M^VM;:5\.UENY[>YC:'4)81;7$(8+(BK;XQM;!5@1^=)X*E9VJ+_P)"]IY/[C
MV>^^+6D07^F?9IDFTZ^>X@EN`DOFPSQ*K>7Y.S<258GU&.F.FT?&=A+K.F6-
MC-!<+J5O)<)(&./+4#E3C#=>1G(ZXKP^[\,_M`75UIUV$\`Q7VG/.XN%U"7$
MKRJ%)9?(Q@*,`#ZD\41>$_CO:7^C3:;9_#RVM]&60);MJ4\HF,IS*SN8<Y8^
MF`.U2\%!VM./7[2\_+T_X`_:+L_N/=+?QQH5WJ+V,&I6[7"%A@Y"L5^\%<C:
MQ'<`DCO56'XE^&9S=!-6@7['$)9?,1TRA;:K+N`W@L,`KG)Z9KQ(>"OC6]M#
M87NC?#N[T2T9C:Z8VL7*K%E64?O!#O8!78`$^F<XJ3_A%/CM+;1QW=EX`N'L
MS$=.F?59@]F8R=AXM\2'D@[N".V>:/J4?YX_^!+^O\O,/:+L_N/9KKXI>%K*
MV@N+O5XHH[EI%3?%("I0`ON7;E,`@G<!QSTK;TC7;#7K)+K2;A;B!RRA@I4@
MJ2&!!`((((((KYTU'P%\;]56=]1L?`$M]=QRQW%XNK7"%U>+RU&SR-H"#D8Z
MG.<YK9TO2/CMI-PDEKIOP^6+[7=74MN=8N=D[3MN(;]QG"L25P1UYS2G@X\O
MNSC?_$@]HNS^X]BNO'F@66LII=UJ44=[)*(E0HVWS,%MF_&T-@$[<YP*KO\`
M$SPS';7-P^K0+#:!6D<H_*E@H9>/G7<0,KD9/6O&W\,?&]IKR,Z/\/&TF^DF
MFN-,.L7!1Y)=WF$2>1O`)9C@'J>"!Q52[\%_'34H(XM4L_`%T+-!'I['5)T-
MJH=&[0?.3Y:C+=L\9-..#C?6:_\``E_7]=0]HNS^X]\\/>,=&\5>?_8%\EV;
M;'F@(R%<D@<,!W5A]5(Z@BMJO(OA!X8\>Z)JVJ3_`!`LO#MK!-;)%:C2KZ2X
M)/VB>9M^^-<8\\@8)R!SS7KM<=:"A4<4[KUO^):=U<****S&%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
$`'__V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>g838054g38b30.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g838054g38b30.jpg
M_]C_X``02D9)1@`!`0$#P`/```#_[2-L4&AO=&]S:&]P(#,N,``X0DE-!`0`
M``````\<`5H``QLE1QP"```"````.$))300E```````0S<_Z?:C'O@D%<':N
MKP7#3CA"24T$.@``````Y0```!`````!```````+<')I;G1/=71P=70````%
M`````%!S=%-B;V]L`0````!);G1E96YU;0````!);G1E`````$-L<FT````/
M<')I;G13:7AT965N0FET8F]O;``````+<')I;G1E<DYA;65415A4`````0``
M````#W!R:6YT4')O;V93971U<$]B:F,````,`%``<@!O`&\`9@`@`%,`90!T
M`'4`<```````"G!R;V]F4V5T=7`````!`````$)L=&YE;G5M````#&)U:6QT
M:6Y0<F]O9@````EP<F]O9D--64L`.$))300[``````(M````$`````$`````
M`!)P<FEN=$]U='!U=$]P=&EO;G,````7`````$-P=&YB;V]L``````!#;&)R
M8F]O;```````4F=S36)O;VP``````$-R;D-B;V]L``````!#;G1#8F]O;```
M````3&)L<V)O;VP``````$YG='9B;V]L``````!%;6Q$8F]O;```````26YT
M<F)O;VP``````$)C:V=/8FIC`````0```````%)'0D,````#`````%)D("!D
M;W5B0&_@````````````1W)N(&1O=6)`;^````````````!";"`@9&]U8D!O
MX````````````$)R9%15;G1&(U)L=````````````````$)L9"!5;G1&(U)L
M=````````````````%)S;'15;G1&(U!X;$!U0BT0````````"G9E8W1O<D1A
M=&%B;V]L`0````!09U!S96YU;0````!09U!S`````%!G4$,`````3&5F=%5N
M=$8C4FQT````````````````5&]P(%5N=$8C4FQT````````````````4V-L
M(%5N=$8C4')C0%D````````````08W)O<%=H96Y0<FEN=&EN9V)O;VP`````
M#F-R;W!296-T0F]T=&]M;&]N9P`````````,8W)O<%)E8W1,969T;&]N9P``
M```````-8W)O<%)E8W12:6=H=&QO;F<`````````"V-R;W!296-T5&]P;&]N
M9P``````.$))30/M```````0`\`````!``$#P`````$``3A"24T$)@``````
M#@`````````````_@```.$))300-```````$````'CA"24T$&0``````!```
M`!XX0DE-`_,```````D```````````$`.$))32<0```````*``$`````````
M`3A"24T#]0``````2``O9F8``0!L9F8`!@```````0`O9F8``0"AF9H`!@``
M`````0`R`````0!:````!@```````0`U`````0`M````!@```````3A"24T#
M^```````<```_____________________________P/H`````/__________
M__________________\#Z`````#_____________________________`^@`
M````_____________________________P/H```X0DE-!`@``````!`````!
M```"0````D``````.$))300>```````$`````#A"24T$&@`````#-0````8`
M`````````````E````'T``````````$``````````````````````````0``
M```````````!]````E```````````````````````0``````````````````
M```````0`````0```````&YU;&P````"````!F)O=6YD<T]B:F,````!````
M````4F-T,0````0`````5&]P(&QO;F<``````````$QE9G1L;VYG````````
M``!"=&]M;&]N9P```E``````4F=H=&QO;F<```'T````!G-L:6-E<U9L3',`
M```!3V)J8P````$```````5S;&EC90```!(````'<VQI8V5)1&QO;F<`````
M````!V=R;W5P241L;VYG``````````9O<FEG:6YE;G5M````#$53;&EC94]R
M:6=I;@````UA=71O1V5N97)A=&5D`````%1Y<&5E;G5M````"D53;&EC951Y
M<&4`````26UG(`````9B;W5N9'-/8FIC`````0```````%)C=#$````$````
M`%1O<"!L;VYG``````````!,969T;&]N9P``````````0G1O;6QO;F<```)0
M`````%)G:'1L;VYG```!]`````-U<FQ415A4`````0```````&YU;&Q415A4
M`````0```````$US9V5415A4`````0``````!F%L=%1A9U1%6%0````!````
M```.8V5L;%1E>'1)<TA434QB;V]L`0````AC96QL5&5X=%1%6%0````!````
M```):&]R>D%L:6=N96YU;0````]%4VQI8V5(;W)Z06QI9VX````'9&5F875L
M=`````EV97)T06QI9VYE;G5M````#T53;&EC959E<G1!;&EG;@````=D969A
M=6QT````"V)G0V]L;W)4>7!E96YU;0```!%%4VQI8V5"1T-O;&]R5'EP90``
M``!.;VYE````"71O<$]U='-E=&QO;F<`````````"FQE9G1/=71S971L;VYG
M``````````QB;W1T;VU/=71S971L;VYG``````````MR:6=H=$]U='-E=&QO
M;F<``````#A"24T$*```````#`````(_\````````#A"24T$%```````!```
M``$X0DE-!`P`````&0,````!````AP```*````&8``#_````&.<`&``!_]C_
M[0`,061O8F5?0TT``O_N``Y!9&]B90!D@`````'_VP"$``P("`@)"`P)"0P1
M"PH+$14/#`P/%1@3$Q43$Q@1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P!#0L+#0X-$`X.$!0.#@X4%`X.#@X4$0P,#`P,$1$,#`P,#`P1
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#/_``!$(`*``AP,!(@`"$0$#
M$0'_W0`$``G_Q`$_```!!0$!`0$!`0`````````#``$"!`4&!P@)"@L!``$%
M`0$!`0$!``````````$``@,$!08'"`D*"Q```00!`P($`@4'!@@%`PPS`0`"
M$0,$(1(Q!4%181,B<8$R!A21H;%"(R054L%B,S1R@M%#!R624_#A\6-S-1:B
MLH,F1)-49$7"HW0V%])5XF7RLX3#TW7C\T8GE*2%M)7$U.3TI;7%U>7U5F9V
MAI:FML;6YO8W1U=G=X>7I[?'U^?W$0`"`@$"!`0#!`4&!P<&!34!``(1`R$Q
M$@1!46%Q(A,%,H&1%*&Q0B/!4M'P,R1BX7*"DD-3%6-S-/$E!A:BLH,')C7"
MTD235*,79$55-G1EXO*SA,/3=>/S1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&
MUN;V)S='5V=WAY>GM\?_V@`,`P$``A$#$0`_`.N^K7U8^K5_U<Z5==TG"LMM
MP\=]EC\>ISG.=4QSWO<ZO<YSG+1_YI_57_RFP/\`V%I_])I_JK_XE^C_`/A'
M&_\`/5:U4E.3_P`T_JK_`.4V!_["T_\`I-+_`)I_57_RFP/_`&%I_P#2:UDD
ME.3_`,T_JK_Y38'_`+"T_P#I-+_FG]5?_*;`_P#86G_TFM9))3C6_5KZG4;/
M6Z5TVKU7BNO?CT-W/=]"MFYGNL=^XJ%F%]1F9+<9O1L*Q_VMN!81BT-#+G5?
M:V[W7MJWM=5_H?5_2?HUM=:Z-A=:P'X.8T['$/KM8=ME5C=:LG'L_P`'=4[Z
M#O\`/_1KFL'ZK=;RJK+.M/I&;7U;$SZ[61ML;B,Q\9^1Z;/;3;F4T6V>G_I+
M/S$E.AB=/_Q>9H!P\3I&0"\5--=6.X&PM-PJ86M]]GI,?9L;^XKE?U7^J5K&
MV5](Z>]CA+7-QJ2"/%KA6L%OU(ZST_I?1<?I.=0<OHQRX==6]E;SEBUK;MM3
M['MNQFV[6?3WI?5WH/7,+K>'5>V^G`Z;ALHEES1C/LK;Z`?114\>LW/]6W)R
MZLS!^T8V3C46UY_^!24[_P#S3^JO_E-@?^PM/_I-+_FG]5?_`"FP/_86G_TF
MM9))3D_\T_JK_P"4V!_["T_^DTO^:?U5_P#*;`_]A:?_`$FM9))3D_\`-/ZJ
M_P#E-@?^PM/_`*32_P":?U5_\IL#_P!A:?\`TFM9))3S76_JQ]6JL.MU72<%
MCCEX;"6XU0.U^5CUV,TK^B^M[F/26GU_^@U?^','_P!O,5))3__0]`^JO_B7
MZ/\`^$<;_P`\UK565]5?_$OT?_PCC?\`GJM:J2E))))*4DDDDIA9=55M-KVL
M#W!C=Q`ESM&,$_G.5?J/4*NGTLOM$UNL96YP_-WG9O\`['YZYWZQ=9Q<EGH5
M@^M2XANX;FGEEONJ>_\`[;N]&ZM__;:Y=N<[J6*^MUEKZ=[]'F#N>/TMK?Z_
MTO\`C/\`A%#++H3$$QC0E,#2'%\K4S<X(6(^HUOTC+^L]*_KMHZP[*=D.MJI
M?;53AL=M8_Z5=!.NQV]_N^T6>STUK8GUIP,GJS.D!MGVBVLVTV!A])[&R#:R
MS]Q[F6>D[Z'_``GYBX/'H%-#:&DO:P0"[F)\E9LZWFX-!L%MC@QOI5$>]U37
M0UWV=KB&5>QFS?\`]M>GZB9BS?K3"(.7B)C#A]!G+Y89/5Q?^%M?'SI$C8L$
M]/TC_A/IJ2SN@WXMW2Z/LIL=4QH;ZEK',<]T;K+/TGTM[W>]W^D6BK`-@%TH
MFP#W'352222*5))))*<WK_\`0:O_``Y@_P#MYBI)=?\`Z#5_X<P?_;S%224_
M_]'T#ZJ_^)?H_P#X1QO_`#U6M597U5_\2_1__".-_P">JUJI*4DDDDI2'D7>
MA0^[8^WTVEWIUC<]T?FL;[=SD10NJ%U3ZG1M>"TR`X0?Y+O:Y([(.QI\XZUU
M!V7UESF8]S6/!%EES:V.8YL[:G-H'^#CT_T_Z?Z"%4UEEFVRSTVP3N/B.RO=
M=Z?1AY%U73F6Y!QV[L@^T,%CM:L:EM5=;&O=_HV;_I^S_"++Q[?5KKML86!T
M%]9YB?<.RHS!L3,(@1/!+U?//U2XI>KC_P`3T.-D!&0F8!]7J_=EW_E%AE8P
MR:35O=7[@X/;SHC3`F>!R4LJQK199CUEP:)95W/_`%2@RS=4VQ[347"2QW(_
MDF$V7'[8!(..,I".L?GE\VG\YPRX?[C'($6+!`)%C;S>N^J_2LBO+=GY#K=*
M176+`X2'PX[=_P#@ZFULV,73KD/JW?G8&/\`:>HU9#,8E[6?9;!F8H8/H.+*
MCDY=3]'>^K]!L_GO36Q_SJZ(;&55W.LL?<['VM8_1S'X]%CK'N:UC*FOSL3]
M(YWZ6N^OT/55^./@C5#SC+W(2_NS=G!$1@`!P]2+XO\`I.NDLRCZR=#O>&5Y
MM,/M&/18;&;+K'-KMV8C]^W(=^FK9^C_`,)[%*SZQ=#9TV[JK<VF[!QSMMOH
M<+VAQ+`*_P!6]7])^EK_`$?\M%E=%)5,7JN!EY=V'CV^I=CLJML`:[;LO#GX
M]E=I;Z5S+&L=[J7V*VDIS>O_`-!J_P##F#_[>8J277_Z#5_X<P?_`&\Q4DE/
M_]+T#ZJ_^)?H_P#X1QO_`#U6M597U5_\2_1__".-_P">JUJI*4DDDDIR/K'U
M3(Z?C458>T9F=:**'O&YM8#+,B_)?7NK=9Z./1;LK_PEWHUK!9E_6"EX?3U>
MRT\N9ET46UN/]7$9T^ZO^QD+2^NXIHZ=1U5[VL=TV\6!CIFUMK7X=N)5M_P]
MK,C=C_F>O57ZOIT^I;7SN/\`6#HF00UN8RIY_P`'D30[X?K`KK?_`-:LL4N.
M,3$DCJLD2"`'1NZSU:VDU9N!5>7->S[5@6AMC=XVO?5A]1%-3+7,]F[[;:]<
MSUG/Q<0NLIJR<*D.:UE654X/(V_I+?M#VNP]OJ?F,R%TVT[0^):[AW(/]5R3
M7.;]%Q$\PC]WQ&0D8B5=):Q8<F.&3YAKWZO),ZW@>F^39D6M+0QV.S=6[7]+
M^EM=37]#]Q_\XIX7UI?AVLN'2J<C:'MM9=<2;&N+75[6^BZG'MJV?3_2[_46
MYE=%Z1EN+[\.HV'FU@-5GSNQC38[^VLW(^I^.0?L67;0[\UF0!=7/:7-%60Q
MO\O?>CCY7E029PD2>Q](\H^EB'+B!!@`2.L]_P#O?^:^B]#S^G]1Z71G=.9Z
M>+D`N;7M#"UTEMU=E;?:VVNYKZ[?^$57)^JG2LG-RLVP6>MFNQW6P[0'&=7;
M6:]/T?K?9L7[3_I?LU"YCZK5Y70_JU7UH.?%>3>.LX6]SV,J;?9C775L_2-K
MR>GM9]IL?0RK[7C^MZOJ/^SWU^@*$@`D#8'1NC8=-'G!]0^A-=41ZP%7I`C>
M(>RAF'531=[?YK=TK"O]FRSU:_YSTK/21F?4WHS<-F"?6?C-LHN<SU"W>[%H
MJP<46.I]-VQC,:B__P`,U;_^#6ZD@ER>D_5S&Z5DB_'R,A[6XM6$VBQS75BJ
M@DX\;:V6;ZO4M]SK/\-8M9)))3F]?_H-7_AS!_\`;S%22Z__`$&K_P`.8/\`
M[>8J22G_T_0/JK_XE^C_`/A'&_\`/5:U5E?57_Q+]'_\(XW_`)ZK6JDI2222
M2GC/\:55AZ+AY`'Z#&S&/O/9H?7=CUVO_D^M=77_`-=7G3RUK2;"`WN70!^*
M]@^L_4CA=.%-=%>5D=0?]DHINUI)>RRRY^4W\_&IQJKK;JF_S_\`,?X5<?B]
M(^PV&_&QNEWVEP?&1A;0T^&-;5?8[$9_(]*].'Q;!R8]K*?5/UQ^;KZ?5PQG
M^ZMER63.>.'Z/I/YZ/)],QLZYQ=T.G+>Z8+\`6-9)_TEU6S%_P"WGKL>E=!_
MQA/@Y1Q:Z@8+<[:^V/%O[+V,_P"W<A;M/UOS*Y&=TFV!$68-C,EL>/I6?8LO
M_MO&M5H?7;ZKEK]V<VNVLAKL:QEC,B3^:W!LK;EV?];I2^_0SZXSC[_JZXO\
M-0Y>6/27'_A[?X+C78?UAQ?Z3TLWL`EUN!<RX?\`L/F#`O\`^V_M"INZM@UO
M%5WKTWNC;BV8U[;W$\-IQWTA][W?\#O9_+72/^LN7=N'3>D95\&&W96W"J/\
MK];/V[_,P'H9ROK:\NL%G3:3/Z/&V7V@C]RSJ&_%]/=_I/V;;L_T::>:C'0R
M!_E_53[-[`N,;<CH_0NI8/7,88[.L59N3196XO:++:K<BWIF4[Z#,RK'9^BL
MK_5LKT[=GZ6O]9['I@N'3<09$^N*:Q;NYW[6[]W]I<CU[J=_UHZ!E8>#0:FX
MU;[.JNN$BF_%F]G3*G?S>1E.S**O7?\`S-6#^D_G,G$78X>0W*Q*,IHVMOK9
M8&GL'M#X_P"DE=ZI3))))*4DDDDIS>O_`-!J_P##F#_[>8J277_Z#5_X<P?_
M`&\Q4DE/_]3T#ZJ_^)?H_P#X1QO_`#U6M597U5_\2_1__".-_P">JUJI*4DD
MDDIYOZZUEM'3LRMOJWX^8QE>."`^[[0RS#?31O+6>LWUOM7O]GIXUOJ>G6LY
MG2>OW_SM^+T]I`]M37Y=H\?TMOV+&;_VQD+9^LY-#^F=1L)&)A91=E.TVULN
MHR,)N59+F_HZ+LBOU7_X*BRV[Z%:CE]1Z?A5-NS<NC&J>)8^VUC`X<S7O=^D
M_P"MJASF''++&4L8E+AX03ZMC+3@^1L89R$2!+A%WHY[?JOT]X/VZ[)ZC,2V
M^XLKT_[J8(P\;_MRNU:>)BXN#7Z6%17BU<[*&-K;_FU!BI,ZVS)C]F86;U$.
M!+;*J3348_[M]2.%2_\`ZSZR!U&[ZWLJ8:<?I^"^V=C,BVV]VG(=955C8U-F
MWZ'])8FQPY*H1X(]ODC_`(J3DAN39_QG9`),#4E5<[JO3.G:9^75C.(D5/</
M5=_Q6,W=D7.=^:RJI<H^[J-T#K`ZG<UPVD8[VNQS/_`=$^S93F_^&,>Q2QLW
MZLX#7G'LQ<)S=+6!HJOT_-?0]K,ZRS^1Z?J/5;)FX+`Q9,E&O2/U?%V]R/N?
M]!DQ@3U&2$?K<O\`%=6G(?9]3LLT!_VWZP9653C8[@X.JMRK;J/2L9MW5NZ?
M0RS(SOW/LV4NPHIKHIKHJ$5U-#&#P:T;6K`^J716T8W[4RZ;&9V79=>RNXDG
M'JO?ZC**Z2YU6+;;4VFS-]+])9D?SW\VNA=96TM#G`&P[620-Q@NVM_>]K5L
M0O@C8HT+'9IG<UKJR24665OW;'!VPEKMI!APY:Z/SDZ<A=),'`D@$$M,'R/*
M=)3F]?\`Z#5_X<P?_;S%22Z__0:O_#F#_P"WF*DDI__5]`^JO_B7Z/\`^$<;
M_P`\UK565]5?_$OT?_PCC?\`GFM:J2E))))*6(!!!$@\A4<3H?0^GV'(PNG8
MV+;&ME%#&/CPW5,:]7U7R,K"K>W'R+&-=:"0Q_!`YW?F_P"<D=BIP^J=0WY[
M;,5[HK86[I]IW?3;L_-_=MW_`/?%F]2ZADC$=>\/RG8]<,J;)<^##9^E[_?[
M[-OT$?*C[0\AS7`F06V&T`?\:[W/5'%R,RW(R&9&,<:NIP%%F[=Z@.[WZ>WL
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M&'9]HM1,_P"J/6L[I!Z._J7Z`Y-MPNM-MUHKV'[%07V6-MN]#+=]JWVW_P"!
MI77)*9+@?5[HO4<#J?4L_/9B-?U#TC.&"P?H]^[U:O2KWVOMNNNLRK+KK;?5
M]/\`1UTL6^DDDIS>O_T&K_PY@_\`MYBI)=?_`*#5_P"','_V\Q4DE/\`_];T
M#ZJ_^)?H_P#X1QO_`#U6M597U5_\2_1__".-_P">:UJI*4DDDDI2R/K-=AX/
M3+NJY%'K.Q6@-#6ASO>YM?T;/T>W<_\`/_FUKI)4#I(7$_,+X>*/Z0XHJ.SQ
MCZWMHQ[C-9R6"T5/:6V,:[Z`N8?H6?R%"9=H>.0NGR>F5N]>]C/5R+6N@O,Z
M[=E;&3[:V+!MP<BBUU9;ZCJPWU#6"X`O^@QVC=SEC<QA.'BK'Z2)1QT(SX>/
M_.3E'BG+VXS_`-DL(IS<GIS<C.Q<TW6,.).VII]KI_>_ZFS_`$E:LG:)>2!'
M))@:H72L+JS*;:<^S[1E->70T$$,<YC&LVEM?Y]F[9M_1UK19]6J.L4>GGM)
MQVVN:^L.+'!U>F]KV?\`";ZGM38PRSS0P'*98H7A]W".*/L2G^LX>+V>./%.
M7SK0#T%$]W1HJZQC8^.[%>W)K?M+J;`&[&D;CMLW^[]U;*#BXE.)7Z5.X,F0
MUSBZ/)N\G:C+7PPX,<8]AKZC/_G290I)))2*4DDDDIS>O_T&K_PY@_\`MYBI
M)=?_`*#5_P"','_V\Q4DE/\`_]?T#ZJ_^)?H_P#X1QO_`#U6M597U5_\2_1_
M_".-_P">JUJI*4DDDDI22222E+E<#Z^=-?4ZW*PLC"-MUC*:PSU[+'5ML?>+
M*,+UKZ,G'91^MX^17^K;Z?\``_I%TV1CTY-%F-D,%E-S'5VUNX<QXV/8[^LT
MK"M^I'1B:GXSK\6R@96Q[+#8XV9M3<6_)MLRO7NMOKJK9Z/Z5)2L_P"LWU;P
M17U:RQ[C9B-RFNK8_P!V-991CMO=N:QOZ.S(I]COT[*_\&GJ^M6+5]8LCH>3
MC.Q:FVLIQLXN!JMR;:J\UV+9H/LV18R_]6]3^F;+O3_3?HE6N^I(.);2,RW(
M#.F.Z5AXUNQE3*S537N>^NE]OJOR,6O(=?[_`$_]%^C1<;ZGTWGJ-G6RS,_:
M[,,Y.*S>&5W8M0I>_'R2_P"TO]2QN]EGZ*U`1B+(`%F_J5/2))@(``[::Z_E
M3HJ4DDDDI22222G-Z_\`T&K_`,.8/_MYBI)=?_H-7_AS!_\`;S%224__T/0/
MJK_XE^C_`/A'&_\`/-:U5S?U:^L'0:?JYTJF[J6)7;7A8[7L=?6'-<*JPYKF
ME_M<U:7_`#E^KG_EKA_^Q%7_`)-)3I)+-_YR_5S_`,M</_V(J_\`)I?\Y?JY
M_P"6N'_[$5?^324SZWU:KH_3;<^VM]_IEC*Z*A+[++'-HIJK'[S[;&+.?]:W
M4]%KS\C!MJSK[ABXW3G'8^V^Q[J,8,?D-H=5CWN8ZSU\FBC]!^D]%'SNK_5'
MJ&+9AYN?@9&-<(LJ??408.YOY_TFN;O8[\QZS,_'^HV7@-P:>HX.'6T5,#JK
M,5Y-=+K+::7-S&Y5>UMMUEOT/4]3_"?SB2G9Z!UNGK73*^H-8*1:Y[167M?]
M"RS%W>I5['LLMI?Z3V?SBY[ZQ?77J?2NH=4PJ,46C%&#]GO],NJK^TOV9'[0
ML]5FW>W^B>FWZ:L48WU$HJZ?4SJ6+LZ9Z1K!R:9L=CBS[+9E.G=9]GLR+[Z]
MGIU^O9]#Z"O7YOU(R3D&_*Z=:<ST_M.ZZD^IZ)WX_J^_W^B[^;24Y&?]=>HX
M'KOM;0YEK.H4]/K#7E[\W$S'8.+C.;O_`$C,BBW&>[T_TGZ+(5SK76.OX>6S
M"Q[\.NRCI=W4,FVZI[JWV4&JMU;=N33]FHL=;O\`4_3^E_PBMOS?J38*P_+Z
M<X4WG+JFZD[;W.=:[);[_P">]2Q[]ZAU&_ZA]5MJNZED=,R[*)%;KK:7P#KM
M]S_<W^2Y)3DX?^,"_,ZWC8;*J*J,K%K+:'V3D-RK<8=59W9ZF'Z;FX7\U79]
ML5"OZ\_62SZNY_5FNQA9T^K#O<RS'>PN^U`[Z/1.8;?1KWTV8_4/YO*_2>G4
MNG.7]1BPUG)Z:6G(^VD&VG^D[O4^U?3_`)_=_A%&R[ZA6U>A;D=-?5Z%>+L=
M;26^A4[U**-I?_-TV>^M)3MXK,IF.QF7:R_(`_26UL-37'Q;2ZR_9_VZC+-_
MYR_5S_RUP_\`V(J_\FE_SE^KG_EKA_\`L15_Y-)3I)+-_P"<OU<_\M</_P!B
M*O\`R:7_`#E^KG_EKA_^Q%7_`)-)2NO_`-!J_P##F#_[>8J2H=;^L'0;<*MM
M?4L1[AEX;B&WUD[696-98[Z?T6,;O<DDI__9`#A"24T$(0``````50````$!
M````#P!!`&0`;P!B`&4`(`!0`&@`;P!T`&\`<P!H`&\`<````!,`00!D`&\`
M8@!E`"``4`!H`&\`=`!O`',`:`!O`'``(`!#`%,`-@````$`.$))300B````
M``%^34T`*@````@`#`$```,````!`?0```$!``,````!`E````$"``,````#
M````G@$&``,````!``(```$2``,````!``$```$5``,````!``,```$:``4`
M```!````I`$;``4````!````K`$H``,````!``(```$Q``(````>````M`$R
M``(````4````TH=I``0````!````Z````2``"``(``@`,^:0```G$``SYI``
M`"<0061O8F4@4&AO=&]S:&]P($-3-B`H5VEN9&]W<RD`,C`Q-3HP,SHP,R`Q
M-CHQ-SHQ-0`````$D```!P````0P,C(QH`$``P````'__P``H`(`!`````$`
M``'TH`,`!`````$```)0``````````8!`P`#`````0`&```!&@`%`````0``
M`6X!&P`%`````0```78!*``#`````0`"```"`0`$`````0```7X"`@`$````
M`0``````````````2`````$```!(`````3A"24T#_0``````"```````````
M_^$!@$U-`"H````(``P!```#`````0'T```!`0`#`````0)0```!`@`#````
M`P```)X!!@`#`````0`"```!$@`#`````0`````!%0`#`````0`#```!&@`%
M`````0```*0!&P`%`````0```*P!*``#`````0`"```!,0`"````'@```+0!
M,@`"````%````-*':0`$`````0```.@```$@``@`"``(```#P`````$```/`
M`````4%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I`#(P,34Z,#,Z,#,@
M,38Z,3<Z,34`````!)````<````$,#(R,:`!``,````!__\``*`"``0````!
M```!]*`#``0````!```"4``````````&`0,``P````$`!@```1H`!0````$`
M``%N`1L`!0````$```%V`2@``P````$``@```@$`!`````$```%^`@(`!```
M``$``````````````\`````!```#P`````'_X4&=:'1T<#HO+VYS+F%D;V)E
M+F-O;2]X87`O,2XP+P`\/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-
M<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O
M8F4Z;G,Z;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N,RUC,#$Q
M(#8V+C$T-38V,2P@,C`Q,B\P,B\P-BTQ-#HU-CHR-R`@("`@("`@(CX*("`@
M/')D9CI21$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S`R
M+S(R+7)D9BUS>6YT87@M;G,C(CX*("`@("`@/')D9CI$97-C<FEP=&EO;B!R
M9&8Z86)O=70](B(*("`@("`@("`@("`@>&UL;G,Z>&UP34T](FAT='`Z+R]N
M<RYA9&]B92YC;VTO>&%P+S$N,"]M;2\B"B`@("`@("`@("`@('AM;&YS.G-T
M179T/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O<U1Y<&4O4F5S;W5R
M8V5%=F5N=",B"B`@("`@("`@("`@('AM;&YS.G-T4F5F/2)H='1P.B\O;G,N
M861O8F4N8V]M+WAA<"\Q+C`O<U1Y<&4O4F5S;W5R8V52968C(CX*("`@("`@
M("`@/'AM<$U-.D1O8W5M96YT240^>&UP+F1I9#I$045%149!-$5!0S%%-#$Q
M.$-#1D8Q0S9"0S%#1#8W-3PO>&UP34TZ1&]C=6UE;G1)1#X*("`@("`@("`@
M/'AM<$U-.DEN<W1A;F-E240^>&UP+FEI9#I$0T5%149!-$5!0S%%-#$Q.$-#
M1D8Q0S9"0S%#1#8W-3PO>&UP34TZ26YS=&%N8V5)1#X*("`@("`@("`@/'AM
M<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#XX148X,44X-T4S148Q,3DU04,Y0CDW
M0C<X04,T0C,U-#PO>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/@H@("`@("`@
M("`\>&UP34TZ2&ES=&]R>3X*("`@("`@("`@("`@/')D9CI397$^"B`@("`@
M("`@("`@("`@(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@
M("`@("`@("`@("`@("`@("`\<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA
M8W1I;VX^"B`@("`@("`@("`@("`@("`@(#QS=$5V=#II;G-T86YC94E$/GAM
M<"YI:60Z-3A%-S!&0S!$0D,Q130Q,3A#0T9&,4,V0D,Q0T0V-S4\+W-T179T
M.FEN<W1A;F-E240^"B`@("`@("`@("`@("`@("`@(#QS=$5V=#IW:&5N/C(P
M,34M,#,M,#-4,38Z,3<Z,#8M,#4Z,#`\+W-T179T.G=H96X^"B`@("`@("`@
M("`@("`@("`@(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O<VAO
M<"!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@("`@("`@
M("`@("`@("`@("`\<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@
M("`@("`@("`@("`@("`\+W)D9CIL:3X*("`@("`@("`@("`@("`@/')D9CIL
M:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B`@("`@("`@("`@("`@("`@
M(#QS=$5V=#IA8W1I;VX^8V]N=F5R=&5D/"]S=$5V=#IA8W1I;VX^"B`@("`@
M("`@("`@("`@("`@(#QS=$5V=#IP87)A;65T97)S/F9R;VT@:6UA9V4O:G!E
M9R!T;R!A<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S:&]P/"]S=$5V=#IP
M87)A;65T97)S/@H@("`@("`@("`@("`@("`\+W)D9CIL:3X*("`@("`@("`@
M("`@("`@/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B`@("`@
M("`@("`@("`@("`@(#QS=$5V=#IA8W1I;VX^9&5R:79E9#PO<W1%=G0Z86-T
M:6]N/@H@("`@("`@("`@("`@("`@("`\<W1%=G0Z<&%R86UE=&5R<SYC;VYV
M97)T960@9G)O;2!I;6%G92]J<&5G('1O(&%P<&QI8V%T:6]N+W9N9"YA9&]B
M92YP:&]T;W-H;W`\+W-T179T.G!A<F%M971E<G,^"B`@("`@("`@("`@("`@
M(#PO<F1F.FQI/@H@("`@("`@("`@("`@("`\<F1F.FQI(')D9CIP87)S951Y
M<&4](E)E<V]U<F-E(CX*("`@("`@("`@("`@("`@("`@/'-T179T.F%C=&EO
M;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@("`@("`@("`@("`@("`@("`\<W1%
M=G0Z:6YS=&%N8V5)1#YX;7`N:6ED.D1!145%1D$T14%#,44T,3$X0T-&1C%#
M-D)#,4-$-C<U/"]S=$5V=#II;G-T86YC94E$/@H@("`@("`@("`@("`@("`@
M("`\<W1%=G0Z=VAE;CXR,#$U+3`S+3`S5#$V.C$W.C`V+3`U.C`P/"]S=$5V
M=#IW:&5N/@H@("`@("`@("`@("`@("`@("`\<W1%=G0Z<V]F='=A<F5!9V5N
M=#Y!9&]B92!0:&]T;W-H;W`@0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A
M<F5!9V5N=#X*("`@("`@("`@("`@("`@("`@/'-T179T.F-H86YG960^+SPO
M<W1%=G0Z8VAA;F=E9#X*("`@("`@("`@("`@("`@/"]R9&8Z;&D^"B`@("`@
M("`@("`@("`@(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@
M("`@("`@("`@("`@("`@("`\<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA
M8W1I;VX^"B`@("`@("`@("`@("`@("`@(#QS=$5V=#II;G-T86YC94E$/GAM
M<"YI:60Z1$)%145&031%04,Q130Q,3A#0T9&,4,V0D,Q0T0V-S4\+W-T179T
M.FEN<W1A;F-E240^"B`@("`@("`@("`@("`@("`@(#QS=$5V=#IW:&5N/C(P
M,34M,#,M,#-4,38Z,3<Z,34M,#4Z,#`\+W-T179T.G=H96X^"B`@("`@("`@
M("`@("`@("`@(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O<VAO
M<"!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@("`@("`@
M("`@("`@("`@("`\<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@
M("`@("`@("`@("`@("`\+W)D9CIL:3X*("`@("`@("`@("`@("`@/')D9CIL
M:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B`@("`@("`@("`@("`@("`@
M(#QS=$5V=#IA8W1I;VX^8V]N=F5R=&5D/"]S=$5V=#IA8W1I;VX^"B`@("`@
M("`@("`@("`@("`@(#QS=$5V=#IP87)A;65T97)S/F9R;VT@87!P;&EC871I
M;VXO=FYD+F%D;V)E+G!H;W1O<VAO<"!T;R!I;6%G92]E<'-F/"]S=$5V=#IP
M87)A;65T97)S/@H@("`@("`@("`@("`@("`\+W)D9CIL:3X*("`@("`@("`@
M("`@("`@/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B`@("`@
M("`@("`@("`@("`@(#QS=$5V=#IA8W1I;VX^9&5R:79E9#PO<W1%=G0Z86-T
M:6]N/@H@("`@("`@("`@("`@("`@("`\<W1%=G0Z<&%R86UE=&5R<SYC;VYV
M97)T960@9G)O;2!A<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S:&]P('1O
M(&EM86=E+V5P<V8\+W-T179T.G!A<F%M971E<G,^"B`@("`@("`@("`@("`@
M(#PO<F1F.FQI/@H@("`@("`@("`@("`@("`\<F1F.FQI(')D9CIP87)S951Y
M<&4](E)E<V]U<F-E(CX*("`@("`@("`@("`@("`@("`@/'-T179T.F%C=&EO
M;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@("`@("`@("`@("`@("`@("`\<W1%
M=G0Z:6YS=&%N8V5)1#YX;7`N:6ED.D1#145%1D$T14%#,44T,3$X0T-&1C%#
M-D)#,4-$-C<U/"]S=$5V=#II;G-T86YC94E$/@H@("`@("`@("`@("`@("`@
M("`\<W1%=G0Z=VAE;CXR,#$U+3`S+3`S5#$V.C$W.C$U+3`U.C`P/"]S=$5V
M=#IW:&5N/@H@("`@("`@("`@("`@("`@("`\<W1%=G0Z<V]F='=A<F5!9V5N
M=#Y!9&]B92!0:&]T;W-H;W`@0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A
M<F5!9V5N=#X*("`@("`@("`@("`@("`@("`@/'-T179T.F-H86YG960^+SPO
M<W1%=G0Z8VAA;F=E9#X*("`@("`@("`@("`@("`@/"]R9&8Z;&D^"B`@("`@
M("`@("`@(#PO<F1F.E-E<3X*("`@("`@("`@/"]X;7!-33I(:7-T;W)Y/@H@
M("`@("`@("`\>&UP34TZ1&5R:79E9$9R;VT@<F1F.G!A<G-E5'EP93TB4F5S
M;W5R8V4B/@H@("`@("`@("`@("`\<W12968Z:6YS=&%N8V5)1#YX;7`N:6ED
M.D1"145%1D$T14%#,44T,3$X0T-&1C%#-D)#,4-$-C<U/"]S=%)E9CII;G-T
M86YC94E$/@H@("`@("`@("`@("`\<W12968Z9&]C=6UE;G1)1#YX;7`N9&ED
M.D1!145%1D$T14%#,44T,3$X0T-&1C%#-D)#,4-$-C<U/"]S=%)E9CID;V-U
M;65N=$E$/@H@("`@("`@("`@("`\<W12968Z;W)I9VEN86Q$;V-U;65N=$E$
M/CA%1C@Q13@W13-%1C$Q.35!0SE".3="-SA!0S1",S4T/"]S=%)E9CIO<FEG
M:6YA;$1O8W5M96YT240^"B`@("`@("`@(#PO>&UP34TZ1&5R:79E9$9R;VT^
M"B`@("`@(#PO<F1F.D1E<V-R:7!T:6]N/@H@("`@("`\<F1F.D1E<V-R:7!T
M:6]N(')D9CIA8F]U=#TB(@H@("`@("`@("`@("!X;6QN<SID8STB:'1T<#HO
M+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B/@H@("`@("`@("`\9&,Z9F]R
M;6%T/FEM86=E+V5P<V8\+V1C.F9O<FUA=#X*("`@("`@/"]R9&8Z1&5S8W)I
M<'1I;VX^"B`@("`@(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B`@
M("`@("`@("`@('AM;&YS.G!H;W1O<VAO<#TB:'1T<#HO+VYS+F%D;V)E+F-O
M;2]P:&]T;W-H;W`O,2XP+R(^"B`@("`@("`@(#QP:&]T;W-H;W`Z0V]L;W)-
M;V1E/C0\+W!H;W1O<VAO<#I#;VQO<DUO9&4^"B`@("`@("`@(#QP:&]T;W-H
M;W`Z24-#4')O9FEL93Y5+E,N(%=E8B!#;V%T960@*%-73U`I('8R/"]P:&]T
M;W-H;W`Z24-#4')O9FEL93X*("`@("`@/"]R9&8Z1&5S8W)I<'1I;VX^"B`@
M("`@(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B`@("`@("`@("`@
M('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+R(^"B`@
M("`@("`@(#QX;7`Z0W)E871E1&%T93XR,#$U+3`S+3`S5#$V.C$U.C4W+3`U
M.C`P/"]X;7`Z0W)E871E1&%T93X*("`@("`@("`@/'AM<#I-;V1I9GE$871E
M/C(P,34M,#,M,#-4,38Z,3<Z,34M,#4Z,#`\+WAM<#I-;V1I9GE$871E/@H@
M("`@("`@("`\>&UP.DUE=&%D871A1&%T93XR,#$U+3`S+3`S5#$V.C$W.C$U
M+3`U.C`P/"]X;7`Z365T861A=&%$871E/@H@("`@("`\+W)D9CI$97-C<FEP
M=&EO;CX*("`@/"]R9&8Z4D1&/@H\+W@Z>&UP;65T83X*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*/#]X<&%C:V5T(&5N9#TB=R(_/O_;`$,`
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`?_;`$,!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`?_`
M`!$(`*<`C0,!$0`"$0$#$0'_Q``?``$``@(#`0$!`0``````````"`D'"@$%
M!@0"`PO_Q`!'$```!@(!`0,$#`T$`04````"`P0%!@<!"``)$1(3%!49(0H6
M%Q@Q.%EXAYBWUB(C)#=!2%%76&&GQ]<G*$=G<30V=X'1_\0`'@$!``$$`P$!
M``````````````8!!0<(`@,$"0K_Q``]$0`!!`$#`P("!P8%`P4````"`0,$
M!0`&$1('$R$4,2)!"!4C46%Q\#)"@9&AP18D,U*Q"='Q8H.2HN'_V@`,`P$`
M`A$#$0`_`-E31CIA]-R6Z3:>2N5:!:8R242;5G7R0R.1ONLE,.SX_OSU4L1<
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MMG/HHNE]\G1HY]52CON/QC*`.N=H-HW4GO7?<JTXU=K?VP>[9Y^]H="U=$_/
M/FKW(_-?G7S%%T/E_F[SDX^0^5>+Y+Y<L\#N>4G=]NB>Z[8S8^Z>_P`0?2#Y
MH.M7V,0OC&2^XQCC&.,8XQCC&?*N1(G-$K;7)(E<&YP2J$2]`M(*5(UJ)64,
MA4D5I3P&$*4JD@P9)Y!P!E'%#&68`0!9QEC-=VI^GOM/K-U#]2H!6\?33GIH
MT'+MD;GIR7NDP8RY;K`W7924X@,DU15,3RO#)YM7:>Q7QAE=+.[.D7&Q&(.3
MY"Y(>:CC#(O&Q^OY_P`?U\L[+5?HW6C2?F=XE\SI-;-J^Z>EU:3TW*FIH?96
MY5B]R39Z\+4J">Q]=(HRPK&Y)%:MG\'CT@3M(FYT]L+&[M:!4X,93>[JV4_E
M^']L@]+-/>I3JIKY.GLN"O#)9$"T2TLT3UH/T`E$[NAR1,.M\DL"T;562\9T
M3J2X(2'9YY:XG6;G.JVA<D?:J+G*%^5NCDWQ%SDO&//]-_'W_=^O?\/9=I;7
M=DED=HNJ&B=.<^=9@G@T?/D9EIOL>E-B-SJO0E."F.3"4Q5ECS%*7R*"5>UA
M9)D;2G-D(FC#PO-6N*U6O4LKF9>,8XQCC&.,8XQCC&:W'LA#L_VB]O\`WY_9
M;^6>/X;_`,O[JF,N)Z>_Q!](/F@ZU?8Q"^,9+[C&.,8XQCC&.,8XQGX+,+.+
M+.),`:4:`)A1I8@C+,+&'`@&%C#G(1@&'.!!$'.0B#G&<9SC/*(J*B*BHJ*B
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M(U3>P"#S:*V5#(K84&>DDDADWCS1*HJ_H<'!2/$??D)#DTN)`%)1"DH"M$I)
M.\%400J(R+)*D@D\!A89//@3*N=,K;!@XLZ!)>ARX[G'FQ)CN$T\T2BI"J@X
M))R`B`MN0$0JBKER)*CSHL>;$=%^++9;D1W@WXNLO`AMFFZ(2<A)%V)$)/8D
M145,]3SR9Z,<8QQC'&,<8QQC-;?V0C^J+]/G]EN,9<5T]_B#Z0?-!UJ^QB%\
M8R7W&,<8QQC'&,<8R+&S-Z5U7<.DL3D4]+@TGD4?<4+$N4JE4;'A8K0&X)-8
M9*XEML84O*$1B=4-I.D[0;Y,,(E*YO`>0<..W>IJFC1!GR6FG5V-MF0910D<
M?C5IJ4\VD,G%1$0FC?!.!?:**$*%"-6ZZTYI1OM6]@Q%D.#S88ENG7M2U%$<
M5B/826VZTGU3CSCNS&OLSW=(`).6KTW=1JZ((\>Y5$+1$PIS(;(XNQP8*W#K
MAG875($`E;.N3E)_(W!C5$*GB'N!1A*QH+/4I4.3V'(D7,+RY75.7IFYZCT.
MFY]1TVA/_P"'CFLDT]45TJ8W'B<(;Z#$<=)N<HDQ+AQ58@2900B=$7`9+0ZV
MZV:]*193],M+IG2Q0Y%+$IHSS4R!5-R(L>,XL"4U'@\76)C;LZMD1V&T@.2S
MBMJ<1196#"!BF15A2:3N<U6.T8?$V!HXLJ\<132["RAP>M2]\X:8GQ\)U0U`
MDQ)`U0U0/*0F"2E&YLVI-?:%NND>C-&0NGL6HU]IRZG3+?7L9V.CNHJV:5DZ
M<>:VW':DNO\`<D5HMK*>DA%"L7TAM!,<8;PQ+LHTJLBQ5A\)S,EY]Z=R15D(
M^IDYS%!1>9DK6ZJI(*-)Q5$)13/L/LM_A;1,8^B;XB^,<]C@XE)V>;0N,3IJ
M71\:O#IA`!LEC8[(4P"GTAMD)0TZ<HS#VRM"T0Q>2=PR#:0UOJ?0MD-QI2U?
MI[46R:9L8J"DR.V:'S&,\2$3*&1(;B-[(ZH"+J&WR`KAIS6-WI7U_P!4N0T^
MLH95\KUM="LA6&1J\K+3<]F0VR/JNS,^S$5*3&CF:D+:B5V73%W+8;LG*V&*
MKDKB"5]2\1CE-U9KRGD3>T/J]W+);VM`]&X7)6I1,C$K<S*FE,G:!#8TKHO\
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M89`WUE-2']^#40)3H:3?2(F::U=+C0=-66G)M]`YM6A0[&?]9&,9TVRA2VHL
M!VEDLPS45$IEDW/BR"<;89%KOH=+A+#&U+N3+R6EN,>SV\M.2^>2%^7B0&@P
M(!85`@8-P$10L![<]@_"SDK.?#SD'-;Y6K-:P=/2>G4G4%TSIB+;.RY.EEGO
M?5(6S#B@ZZ4,7%8)P'VU-4V5I7Q20B*ZB.9IT4J6#!0%?=&,CJF4;N+VD=1=
ME7COQ\*GY;_%[^<R')8LZ1-8G1.ODOCJ4@%I7DJ@*@'@&&&%@R(0<8R$61%"
MSC&<=F0]F0YSCX/!J/3%GI:7'AVGI>])BA,:]+(&0'9<-QL5)105$E5LE1%3
M91V455/:3ZTT->:"L(E9?+!]3-@-63*0)@3`],\ZZTVID(CP(B9-41442#8A
M(D5=L+5XVV&V`D)4^>T+Y@QZ.,CQZ4HHHXMISWLAPJ"0E2E@[^<@R41G!QA'
M=,"(\8,EX#D?K'=]';QS1TCI)I>UTL36F(K.L8L^0^_&>U"/!#."4F?/=<0$
M1T7Y0E&9E(3)C$:=%XCLEJ]5/+$*LC.QMHPI+`R4A5]/=04C-5^>Y?"A>%XH
MO+>3^O89Y`Y;()50Z1AB\\7)@E+)*B98T"1Y,<3#2,B:71T;E`VUW7>(H($\
M(S$3D!.>L3A<B"'!:6JM]!;]4=8L-1H>H[:W;T;5>FIH]Q:NSQHX,CBWZ+3S
M5D<AFL)]N*#/^2&,OIXS4?N@T#;:Y%Z8U?4>\DVLO0C[:V.GZM"[TER(<R)'
MDJ;:1Z0K!M\8DR2#+C2/1EBN(R!,>J;!WMN[H55M,O8*T@#)8#T&1SEIAT<;
MI>_!SD>':1HVE*0\+O%SC`E&5"X!X\JAA`-7G.5(RRQFB`':"I9F1ZNO8L7_
M`%,]F%&;F2/?O209`7W-_P![DXA+S793_:5$5=D^FFG(MI"H*2'=RTGW$6J@
M,6DU-U25/:BM!+?Y+LI]Q\3+N*@JYOW%$5)13WO+AEYQQC'&,<8QQC-;CV0A
M^J+]/GZ,9_<M^WCS\O\`G;^RXRXGI[_$'T@^:#K5]C$+XQDON,8XQCC&.,8X
MQFMSU.=2I0WNLHV!DKW7C5#5SBG:4#&Y.+:JDLH>7$\Y2E0MC+%:?AS<-4$@
MI:L4&2%XD3D%&B4+%\F/\/`<ZX]1M.W%1.?U?&M6:E!=1J,4::4>S>>>4E0(
MWU945W`R!'"-7I,ESM@9.RB1%S0WZ0?3BVA3)^O9%G3U]>3X1H\<Y37UI/ER
M",VV8L>ITO4M=S@+SAE.F3Y",M../V!(.V4@L4TC,@=Y!'F=?@]TBB@M$\(\
MIE"?R4P63"PX*R<466H)"82:3DQ.(PL`R^S.<!&4(<&U7TRUQH_3NC]8ZDJ2
MBT6OX;UEINR]9$F>O9;1ET_4!'?>>B2#9DL21:F`TZXT[N**;;X-:KR:Z9%8
MBRY#2BS.!7([G,#YHFRKR02)0)4(21#1%5%^]"1,M.30@#%VB0>V4E>\+E(T
M:EC$(!BQO3)O*22#3!Y5&'X*"4E3X`$Q.4#`%102LY"7C([78U,$=,5-_P#X
MB:G6\V2<.32D8.2X$:/ZEIEPR62X^+0MQF$`7&&PX26A:7B&Y32YT_5#H;3V
MK5UG'MM16DUVNFZ7-QMZQJ8,/UK$5]TUFO2A8!F%$1H'HC#7:G,`P2@UNYB5
MKG$5>9$\Q-M=R5$@C^,"=&WPE!1I`.TL(QEC.)+)5`)&<24H&E,."0::66;D
M`QAQFZWW2O7VF=&:9Z@W6G9,/1^KR(*&[1^'(CRCV>-MM]N-(>D0'9+4:0]$
M;GLQCEL,.O1Q<;;(DA;U;-CQ(\YY@@BRO##VX$)+Y5$5!)2!20244<05)!51
MW1-\EEJQL>LHZ\8+&V5PAS0]V8YY;BG:TZX3R.KVI(R$C=#7:23<K(I'"DC6
M(&53JYQL`0-"#!+U(CR&I.$\K+W07I1U%U?I_5^M=#6.F09TT_$@65/;FXY9
M6BR01]IJ!'B1WI8]Q50&45V(DV0/8C>J?:-IO-'1"PU146STO3%G2P'9KS=?
M*;OZTY-<^P`>J7U$^*)6$!EM40GCC*`(B`\_S!K[/<?KV2CET(BTD4N4.=53
MRT(U2IQ@,@Q*(6M6C*_*C8Q(,DIA.K0,X!HD2D9!9HB>S!@>^$6<YH2/8Q4&
M/;Q?16;0B$Z+Q?%&)""G<`1DM,/H*%^RCK3;G%4Y#OGTBJI$F56PI$Q8"RW8
MS1REJY)S*Y9"BG=]%)<;9<>C<^7:,V@-0VY#R1<[\Q\92BG)0:[M91#,<%,\
M'&."0!32H&F2K`$.1@C<`0G"1KD2L)2H10Q)EB4_`<E*"1#9<,[3C&<=[';W
M>W'>[.]W>W';V8SC&<]GP]F,YQCM^#MSCC&,9P+&!!S@6,^O&<9QG&<?MQG'
MJSQC.>,9K;^R$<]GO1?I\_1C/[EOV\8RXKI[_$'T@^:#K5]C$+XQDON,8XQC
MC&>=E\NC,`B<GG<U?&V,0Z%Q]XE<KDCPI`C:6".1YO4.SV\N:LS."TR!L;4B
ME:K/'^"4028//JQQC*>"^K/83L[@?HKIL\.E.K1!.97%[NEDB%YNS,;@(TKV
M*G'F">TUBPY$Y"L0L4EO%FD:5(<07)&R.O05K(AEC>C+ER.#^T8",4-([CIB
M^@EY3DG;5L2^\5<11]EV+=$LAZ@KP=5O=TD%5171!%;W151=OBY*FZ>%0=E]
MTW395_4ZW4T0V*<XJ'8!MM.BI)#"G44;%L%5;P.M(PI?\M@'&1N$YB8[#UL5
M/B%,W@)9C9M/W%I:SQ&KE#$XD!-(/A.I=`.V1QG+6L><*`CWI7%:29#8.1VN
MY)[`]V&](`&MF%E@\RT2J1L.)N*QG4VE]*ZY.N?LUCR9%4DKZM&6@O1XCTSL
M"]-2KE?Y.9.:;80816$>9%CN$KA1'TY-G4#LI0D#9'AXO.DGRG)Q%[;L&1,,
M!8:5GC';LPE$=A;-E29,I#)XHK>F18J7(TH7E]"JDRA<E='H>,IR\"$21A:\
MT+U+UK.J-*MW4J115S]H6F]/VU]838&FZ2*+"3K?M.G*CPFY+A1!D-Q$*0[,
MFQH[;*J8@&DW5+I'J:OMT?CBPW#M;>RCZ=TZ%A)LK$*BKB@;]W+<5'F!62@M
M2)HI)<?]7.!M&]S1L(%P.QF2=NR1E3')42M>>`A*H\X$+6TP7>P$\&5R8..Z
M>D!@:E6G\$0R4@0GYSGO=S$<ZB=!=6=/8C=C,20]!1V.S,6953::?`26^W'B
M3)$"7W#^JY3SS4>//!U0=F=R,+>[:.'@V112X[C(%R077FV5)UHV5;5UP6P<
M,%Y+V5(D1'$WW)"%$W3S_5XG>O%=6/(XU8]M5O`9:@'*F>4*6Y,X6%)4SW#$
MKD40R/<;JMIF$Z`%>^H"&!(J-8CB$YBH*WN&I$AW=\NGNG_6/7[4#1D*#K*S
MHZ1^S*M@&W<SJ"IFJCJR%B11%V)#*9*'M./QV1Y*Z;Q<A4U6:U72_6EG.^J;
M1E[3L&,5L`V6H"=@TK,RO;D(3`/O\0594UD8@N1@=7=WO(#@`6;*?2C1Z,6D
MB+MC4C8RQIK*8TTLY=MU8^KE,5-8WQZ8EJ(LZ5U=*X#$9@0U96&O08A*!)\M
MJ\UO7IFE]<2T[PF%G.HZ32^FTUMNP;U126;\1@[&GLG%CQ)2JV2<G(JQ&4E-
M,R.9QGQ,Q%QOX'"3FB[N=)NE.EM*I"U!IS4EY+>>B,C;06KJ!,HWYRQ%!]J1
M'B0Q%PXCSSA1B5_O-?#LX33ABY,G:S2YLL>!KY#KDRUM5.S$6GM?W%5<X<6Y
MQ9H6;9M>3%JD99UB-403"$[H9G'"9)6\JD(&9QEA,,F<A0MBP(51A)F0)5S:
MSHC$&;/DS(T8A*,W*<6049!$@1N.Z]S>98V,MX[3@L$6QJVIB))FUBM@1I#L
MJ-%9COO(J/&P/91Y5(24W6V^+;KNXHG>,"=0=P0^)$BU_M_20O:(1Z<5S!=B
M36RL!1)[25_'"IY9L:1/<_-H+0JFV.>73'(TF)C]AK`NE![03)>CE`)<WIY+
M=,>EJ-"=*2%"Z-6S/=G]U/3OZD;RT3Y*Y[URII<U[C+7V*KH_L+L22!TL$F,
MW`&#V4Z@`E0"KZ,.<REE0JI/J_#,N]&QYGJ$W#81*BIU)V-6QDBKHTAV+G>]
MI.Y,?L"GE\88*T6Z]H:-E*"<-(YU0DAK>?+)G'9-9S*-V*B"J67Y+8M)'=`T
M5I+,J8W5,#<LR4#@B,C'&,E3H+1M@:S:;:[Z]6?F#F3.EZV9*W<55</#V^0Y
M>EB@3&IG<6A;(HM#'8KS@SIT"M8VJ&`@MI7'*&Q*K=$J0ES5L9+[C&:W'LA#
M/9[T7UYQ^?SX/H6_GCE%3?Y(OY_^%QEQ/3W^(/I!\T'6K[&(7RN,E]QC'&,<
M8R%_41ATIGFDNQ\:AK&Y2I^.KM8[`A[*D&X/$W:HPX-TGDD$:F\O\8XN4XCC
M.[1-$W`P(:]2\%(PA%D[`<^B(X#,J,ZZG)IJ0RXX.V_(`<$C3;Y[BBIMG4^)
M&R\`+L9M."*_<1"J(O\`-<H]C<C8I>P,\IC#JB?(](&Y([LKNW'@4H7%N7$A
M/2JDQQ><A&6:4,(L?`(.>T`PA&$0<9^;,'@!UHA<;<%#`Q7<2!4W0D7PFRIY
M3\TS%Q"0$0&*B0JHD*ILJ*GA45/PSNN<]_Q_M^/_`#G',)SK7"B;(4J7&857
M#G!]5EC*-EB%J+CTV`68'`1A2SB.9:9>B[^`@[V43VG%G("\YSVE@R'H].QW
M1D"V+<D/V)3*DQ*#RA?!)94'P\B*KP<'=4%?<45.?<)1X$O<;5%16G41UHA7
MW$FW$("%=O***HOSR`-F=(&CY8GP7![-N6")2%)RU)#7^8.%M58%:J)+3*ER
MJ%SU4L<SEZA,2G3'+TLN;U9R5.40><<645@NYG8SI$YBPLW6]1NQVVF68VK&
M!U)!%MEWO-IZ>P(G$(71%SF,@'5<$34^0B26EZDIW6/3MP&:[[0W1DTPMUDU
MMUQ!0C:D,-J@;H`_#VU#X1^'QMD0Y=TM]EH"6(JOE-1VA'TN!9(3,RM?5<G%
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M6=%EH+E5-J7G5D17">@'*C2XHL<E(`-J2+;SZ`V^VRXXT9F"$`JH[\%#74TW
MK!3).F87B%2>/R%[@EEUO)AH12JL[(BJ@"620Z09;5"I`I$3@Y$]QU];SSF:
M90I[C$XCJA7')*T+%&H6;"YFGC&.,8XQCC&.,9K;^R$?U1?I\_LMQC+BNGO\
M0?2#YH.M7V,0OC&2^XQCC&.,9"CJ/77-M==$]J+HK93A!8,%IR5KH4[B2DK@
M1Z4.*8+&QR@U$I`:E5DQ9Q=$\A.3*BS$IY38,M4`1`C,9N5-`&TN*JL-WLA8
MV4&`;WA>T,N4U')W9?'V:.*7GQX\YXK&44*OGS0#N'$ARI0M^?M"CL&Z@>//
MQ*''QY\Y_FPPJ9616ZTYUKRUK2ACFM7*W=S4LL\D>4CX^.2HU>Z/\DC[@O7Q
M:3OCLXJ%#B[.DA8G-6YKU*A6N,/./,$+Z6/=(=`.1F(K%,5?Z:.W';?K)LN$
MZ2--HT+KX,NI&EOD@\G'I<=\W7%4W%)5WS2QKJ-JX'G7G+-)B//&\;,V/'DM
MHKA<U!HC;[T=I-^(MQG6A`$001$1$R8\#ZD>VL+$`J1NU?W&V`SWAES&*%PZ
M4G]F<?B@2FO3&F.(P9QZL&&5JY&XS^$+)F?5F#6/0PQYG2ZE+;RH1[J`V\1*
MN_PK/KBAHV">WFM?7[]_.\KA=5Q78;.D#?V)ZME&V@IM[^DEI(4R^>WK&AW]
MMD\9+2,=86JD*9,*[JLF=8C-,+*/>HV]1^QHDG$//=[<'C,ATX5B_3A.W5^N
M/%VX"`(Q>K.,=1Z$U-I6.<VWC5_H&]U<G0[>$K#:)Y\MV)UDTR_]#,1U?S]\
MG5+JRBOWAC5[\Q)1[(,61724=+?;SSAI.C"FZ[;N2&\L/C.RM'RDF,C(G[='
M%DT1E.,18K&0/54RJ2H#\!R4M8HC9C9$I.ZI#.^#`%2%I/3BR(.`F9[V.V`1
M;:KF*B1I\5PE]@5T6W%_]IQ0<_\`K^6^2]Z!-C^78SHBG[Z`I!_\QW'^N9SQ
MG&<8SC/;C/KQG'KQG&?@SC/+C[>_Z_C^OZ9X\ZB#69$ZDW.TIF4ED[3"T&;!
MM2.SF4.I@D;<UU+):)L-J6XE+SX0D<?A+A>QVNK6L>'U2W1XN;KJ]0JUY3FX
M,Y*B%:Y[/U9%YHG?]8/97]_M]EWO;?/AOVU+Y<N'SR1::Y^L>VW[?IUY_P"W
MEW`X;_+EMSX_ARR[^"^#%-\=@HTVDEIVFTM?*`N)Q3I^P(#["CTKMZIY-)%0
M<8_&KGR`L%/Q[QLY[?(8$C+SVX"'LQ7DVR:'&,<8QQC'&,<8S6W]D(_JB_3Y
M_9;C&7%=/?X@^D'S0=:OL8A?&,E]QC'&,<8SP%K5E"+IK&PJ@LMF)D5>6?"Y
M+`INQGG')BW6+2MH5LCXB\J3&%*49A[<M4`)6I3B52,[(%*8XH\HLP/(#)LA
M,"(#`D,#%5$A(511(2394(51%147=%3=,H0B0J)(A"2*)"J;H0JFRHJ+X5%3
MPJ+[IG^??(NG!5S?=;K"H5O.RR'7Y*ZK$33L)[T_:*QB0I4Z@9>$JIPK6#BJ
M";`;"P"1N=G1JUV6OW-4E5.!9;#D1K.BRPO_`%#-$4$@=$7VI>G`ZYKP"'+6
MTU?"KW%DBB"`3JXC:%FQ/<2>B#81W3,E(([0$@)C<OHFWEHA:AK:W5B:;E$3
M[(0Z-^3LR2J2K%EHAJ<45Y"T\L1X1%$0GG"%26ZG3;H:=+FSTQKJLW(=]XEZ
M'/=D$>K&W(=7D+:SRQ9P(A7'J6=!W!&590LY*5H7RVSSBS`^&<F),"(.>RT^
MD+U%U.PCL/4L>!72AYLIIMN-'9)LM]BCV(+(GD*HO@@GJB^Z+XSN@=(]&TCG
M!^F=ERV2V-;EQYYQ"3;='8A(S%WW3RA1=_=/;+[J$T)TOU?\F/H;62G*Y>4P
M08]M[7"FI?8*O)>>T!CI8[X2ZSQX.!G&,A/=I$M.QV8[#.8MFV$^R>*38SID
M^06ZD_-DO2GB55W7=U\S-=U\KN63N-#B0FT9AQ8\1I/9J,RVPVFWW`T(BG\L
MDI+(=$9XQJXS.8K&YG&W`/<7QZ6,;9(F-<#NB#W5;2\)5B!2'NC$'NG)QX[H
MA8[.S.>WQYZ,J$OW6+I*5;(1M3I,XGJO9B\HPYH@^OUROM<2=<?G'?RJ8M7(
M0\N<,F[CGN9$`"FD)2<:+(PX(,\8T)GJ'4,JF;[Y6RP&&]MSD2@;C#M[<DD%
MV$\?[D]LZ"JV)Y]OT2272_=::(G5]_96D[GW^47,VZ34CHV)):SQ3LI57].I
M`SIJYNU\NLX;O:*").92I:AK>85?(8O"TU6PZ0IQGN@X>@K"$LLY"66_NR&1
M*$Z=Q+Z3NROQ"=]8M6;2HH-2([S+L?9%^(6EC?8)L7[2`B+O^UY3.85PUG*,
MD4XA)LIMNMN`ZJJGA3[J=Q?'LI>-O;,0=.'#-G:#=..,<J>)C7]*Q^DZ4UM>
MGG"EP$JUX8IGL*X'`:Y<K=7%7-&R"WL=<6N;:^*RREIL9UWB9J]8_+U*J3/?
M7G9ER/&,<8QQC'&,<8S6W]D(_JB_3Y_9;C&7%=/?X@^D'S0=:OL8A?&,E]QC
M'&,<8R#W4J<W=HT.VC6M*]<TE>Y4\(Y.\MBM0@<6.NW)0B;;0?D*](,I4@5L
M=<*Y4[)UR8TE0C-1@4DGDF%!-!'-8R+:)I'54N@;5V]C:<O)%*T(\U<MF:R4
MY6MH/$^2G,%D4'B6ZKMQ+?9;K1-0G[NF9LB0*YZUKVK`U7B@PG);(2B4MTXH
M+"N*J[IMMONF4-26S*@J)$Q,LIFT$@*8U,D:XK'W%[9F10M3IB0)D#7&&#)Y
M2QR\(@H"=$W,J)09@L`2DY'=#@//S94NC]=:ZG2G:'3FI=437'W7Y\F!63[(
MAD.FKCS]A+::=!DS<(G'GI;H;D2D9[KNOU8GW>GM.QV1LK2JJ(XM@W&:DRXT
M05;`4%MN,R9@1H(H@@VR!>$1!39,\>XPW-[.:-3&=,[*ME:F`'S=8,SK)EIY
MLCXA8QE*X-DSO=77$S$F`+(3"GFL6>4K"`_E*`LX0`]NRW3OHKU\TT;4ZNUZ
MWTM3FCJLQ]83W9CH[_$AU>D%MXRN*B?%%N'H(G_IO<-US$^J-?\`3:U$X\K3
MA:P7BH<W*.,+`+^ZHS+ST+G!%]GH`R%']H.2^\I*;U^ZDD-6M1S#N:MUSB*!
M:2<KKE/*IAO2%_:2Q"[K3B3[3,[1[G)(2NZ6%!`V@U&A"$*5`L$G("8HWZT'
MU(Z@Z1BJQJ?7D[J:ZK*-MG:Z:H=+MQ'-DV5'*@ID^Q$?"(Y+E-.N[J1B"KP#
M6O4FE],7;W<I]-L:1'N*1I#MK&W-\=_90G"Q&BJO^QADP#P(JNRD4Q'.@%D\
M*+Q>U];%7P8$SOF()+9ZNLH4J+R(8A-[K5NNJ"EJPE#4'(\!*2S>(RH_PRB<
MJ5BH\)B@VZVO5S6UDI"W8,U;1;IVJR,VTJ)\MI#_`*B4))]X/ANORVV1/%#T
M501.*E&.8:?ORW2/=?Q:;[3*I^!-EF1X!4U6U0A/:ZOK>!URW*1^(J10:(L$
M43*S/A\962Q-Z$M4<(6<B$>?@TT8\Y&(>1"R+./9EC/L7.]83IDYU55>Y+DO
M23W5=U^-XR+\_*?E\LDK$:-%'A&CLQP_VL-`T/\`(!%,P)=U9AFFQFH"!AE<
MXKERN&PK!H.WI'5CT"*3.6Z\#H"Y[L?H$LE"=(H>F)H6V+44`3D2^-*66>0M
M._2$JO)=#7F6K74[,_0F=-#4%G7"XX4!ZJ<F/-;JK8R6)41IE_;]D7%;?<:7
M9$4QX\N7;'C!.H<=@JV)*(122W,%EL]DY*TXR\;C:K[J*$V!IOOQ7EMMS+>:
M=70R,1+=Z?1:NX\S1.#53I/K9!$L?CB%*UL+,E=+7V)/A\9;FY$64E1DQMBB
MJ\XI`67CR)#(4!@0%%KRQ'[39B')W\8QQC'&,<8QQC-;?V0CV?[1>W_OS]/9
M^Y;^6>//R_XW_NF,N*Z>_P`0?2#YH.M7V,0OC&2^XQCC&.,9%K=F:O4`U1O.
M01HAD/DJF#+(E&_;,TI'^,II%8*M'`6)QDK"O"-"^1QJ=9,D<WUF6@$D=&E(
MK0J<9)/'SQV,OT%?.G*"N)"ARI:MI[GZ9@WN"?B7#BGYYWQF?4R8\?EQ[[[+
M/+;?CW7!;Y;?ARWR#.O^K%%ZS1)EBU2U]'V(]K9D32X3$UN1K;`EHDA!"<QT
MF,T/($_R)S6B(`:<:X+322`A)1H$Z-N2HT:?0&=9RIQGW3%I@GG76X,8`BUT
M572-XABP6$"-'#D9*J-MBI$1&:D9&1;(,168XCQ13<0``Y#Q*]*>X"@(3TAQ
M2==+B*)N9KLB((["(HDA/5_]?L_\?H[?_P`]6?Y?H\'G^/W_`)_/;_OY3\?G
MZ<ZI[?62,M2U]D;PU1]D;21*7%Y>W!(U-2!.7CM,/6N*XXA&E(!CUC-/.+`'
M&.W(L<YMMNO."TRVXZX:[`VT*N&2KOL@@**1+X]D1?XYQ,P;%2,A`43=2,D$
M43[U551$3\\AR]]0S5LDI1[G\T=[[6E&F)2D^O41D-O,QZ\HSPS&\VPHJA4U
M4R*0&8$`S,EGC&G),+-+./+&49@/BO+*ETJJIJR_H=+&(HXL:_MH=?9*VH<D
M<;IC=*ZDBHJFWIJ]Y2W'9%4A1?370["Y3>EK+*X%5XH[70GY$7EOQ42GH(P&
MU1?"]V4WMLN_LNV(7[=#8.2F!)K'7B-U^VG=F!2&_;'1*I$@]>?QI=8TV3-6
M5X`+'8()1]V1PW&,YP/`1XR#&&KSZ1_2:F1T($O4&KI0;HV-+5+55;RI_NM=
M0'#L&$W_`'ATY)14\IXVWGE=TIUI/X%):K*1DMN:SIGK9C:?A#K1>BN+^"VK
M7XYBBMK2V+@NZ>M5P/Y[YLU84]7VMKXU4[7;+#:Q@T?B4GIR:6^N=80TSV:J
MB(^]!F%%0L^93Z8V7(GX$&#(6:/IU7CHHHYY?^B!U^LNI/52]TM'TO!H=.AH
MJ=<(@27+6W*P@7--%9>L+=QB$T3'I[-]D(L.N@LHZ0.&#KB\TA/6_IK$TIHV
MNN'+>196A7\>#NK0PX*1I$"<ZX$:"+D@A<1V(#A//RI#BAR`5`405V!-::AE
MM;L,UF%JN;*]WG=\T.LVWW",FN!\2:7C+(S12*U]!S74E(X'0JLH'&XU"VER
M5-[0JEK@V/5@NC(SOLR=V\CZ4YJEDD^,8XQCC&.,8XQFMS[(0[?]HW9WO^?/
M@SV?N6_EGE%V^>W\=L9<1T]_B#Z0?-!UJ^QB%\KC)?<8QQC'&,QU;M712[:M
ML*H)R2M.B%EP^00F18:UIK8[$M<B;5#:H6,[H1^4-3R@"HPM9W1/^4-KDG2K
MB,X.(!G'$P!T#;<$3;<$@,"3<3`T42$D7PHD*JBHONBY42("$A51(50A)%V5
M"1=T5%^2HJ;HN5PHJ?ZA<>3DPH$?U;L7+6(MM27I(;;L>!J9&T$`P23)Y)2;
M%1<L*;)D<'`3'>+,-HBBR]7@]<V2B/)E1+$W:^2N@S#MDZY%OBC59N$;<<H7
M?E,B2[HP+RR6VS$$^$'B#EQVYMF6Y+DMGJ*X$4!>KD=EB*"3HR.VR:HFW<5O
MM$0JONH(6V^ZH2)L*=9:U!W#`X>">7?M1,CFTMS:&M7!-7*LAU3,:\ER6%`7
M$O4OL[-_V"F\%N`LPE>8M+JV4*7+",E.8V&JB0%Q_J-2]/\`HOI`M7W%-<ZL
M[5G505CJ^Z`?YR6`R'36$$>/&;:AC)..LXBCOS$C0C=$I0ED;MNH5X+2N-DU
M%#D(<(K*$6Q+LJJZ_P!Y15!W5"'M_%LB;*N^8_D54=.`N`SMU:Z^%8%DHT;:
M&,S6ZGV7WM:9#F^(DJA*Y1*87M)IW((^A9E2H]*_M,><V1,W!0*D:)`4E&UF
M&62S^DOT7K=&ZK?TH0L6$.!#B5]=!A1JNQLG+Z`P34J$1(G/ZH>E.-V_=Y2(
MDF`]]D^#L1R3#)VHBFMO.2)LJ4XB)P%YXS)5-$5%;0S5!0%)>2#MQXJB)Y3>
ML-UU;HM2Z^?(M!0U$[F`"8M<:.E,UIXYW<>\,9SF^D5](H^A?S%!H_&.0/J1
MS:<C`$/D'A8\/FF_5'Z0@=18C#+^C].RI"1XL=Z1J+3]!>=L8X@CAQ5L(,V4
M,N22.=RP&5'=%IU0;9!P&'F>-5K_`%7I\P<T]?6],0[;C"GOM,ELNZH<<3[+
MJ$NZDCK9BNZ_#[*G9ME>3ME4`9X[L\M<'U6>6I`SWC7D,FC0UL'E2=,,:)55
M1E/SD!:4G"DP3P]8G:M0HP!(8F4'&Y5%XKC:5Z/ZDI&IM[H+4VD7G+EN`_J_
M1EG9-Z3BH\Y'-QJ=`U!'U<3TZ/"67-])4RJXI")&BQX3`<Y19GT[]*_J'5&W
M&MW:C4*^%4)\-J+)1A%0>0N5A134AV7=UUA_DO@D5?BRRKIHZYR999DOV0MZ
M2L<R?8>UK:VJ5!&(VXQ6'PXF2>0N4Z?"&MVD4H<7F;O2!#'VDZ4.+B2!GC1Z
MJ/QEE8P/DS62O>;Z$6C='TD?7MSHZJLW*TYT*D;U7J5Q@M0W!1P*:]#;@P1&
MNHZR(V_"?.$R[92IDJ4#LJQ((D6,Q9M=]8=0]57XY6$>+6U%61>AK8:N$"R7
M11'I<EQTB)Y_M\6VU\-M-D0M`!./D[.O<_<N(:11&%6;9T<7+:L?I!,(W+ID
MWN`2AP1>R5#8UGQ,2MI$WJ,NQ,^>J\#5[-X2]">7.9E#4!1"_P`[""GWVS'V
M12;>JZPD'GQ.;5`\Q2R8S/:OC=J)4;TJD-:U>R6-M6#5?M>)][7&=[>)>CE+
M9,5+6R,T!.9G@4<"-5(V5H6G.R!C.VB'6*UDF3S`X^WP+8-"[3B1Q-G4)72`
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MBDC<E.,+4H3#V]J>VH_\4XM81>"L5Z-]=^O6L.G%_.T]:Z)J;W35U`E1XL?4
M5=-9CR6C[2/JS-B6<VEOH(FK9`KU?5W,-"6-,B,;A+F6.PFO,&31-";1BJ(A
MBJ(J;>?B0B!P?P40(?91_>6OGGS%5>1$2"B>5+8=T$=UWV3RJHB>R>57;Y_/
M(WF!JQI/-:3JVI^HG\LE1UGOHGLQE=S@X9(VF*.4G)4;:EP8>(PU&G/"W$K,
M"3!PV)4B0*,/@X'G9KJ/UMD];]&]!^C]-TQT9I5_IQ5PM'UUS2M[7^K[6T6!
M`.5:SW6XK<=FQGM#8OQ'/4[6LV;.<G$CY`-AIZ`JZRM9OUA,F.7$I'4CO%LQ
M&3D7;;:#<MU!#1H7-QV:$`X?#NOX=]?J[E5TQ?8%49(@S6+-'F9`0E=QI6-0
M45YP`0H7H"R?*3CTY;FK+P44O);U`!@\M1*1`SD4CO>L/6WH9TDUM]$.WC:/
M'2FI[6-J:TD?5S-O<M)/;K)!-55JKXQ6(\LZF$X3DJJ.WB.-.>AF1&W&U3LG
M:4@EJ&->R.^EC#81IL6W]HY#L?`S!!YD0HZ8\>X+9;_&V6VZS8K>Y)!7R]D*
M1HO;,)J7FK(I&%JUY+9B9"XF%%#<Q,K"L;3'QV/[A"--Y>H/+P5W4^2#0A3A
M(B70V7U/-UB9I?3C^I:/24XYC164NWC:0TU8S!1V7=VD*CD0W[><W#914:<*
M>_Z-I&&8,DO2-A*H1R45";;5P&B4AY*:--F2>3)`5%,MD3Q\2[>.*[IM<-#X
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M8J.`,2!O<%4DA$Q4K4*1KCZ5.D5'2VLJVDYAZ<LLP4@KR"O&1><(C'U#<QGV
MS36C7&R6M<QV+K_24^9'-]>Y0Y,\TJJ"2EK<)-)B2T\CD2YO?&%<D5OL@()*
M(>W<\DQP=22BRUZ@\``APQF2XC#XE`(TS0R!Q:.PF'QQ$6VQZ*1%D;(W&F)N
M*R(12!F8F9*B:VM$6(8LEI4*4@@&1"R$O&<Y[6,]%QC-;?V0CCM]Z+]/GZ<8
M_<M^WC?;_P`*O_&,N*Z>_P`0?2#YH.M7V,0OC&2^XQCC&.,8XQF';SEEE0J!
MG/E50TF<R<MT;4XV@X*D[!+6>8,*Q>!$C4)5:X10L$$9)3J"Q$`4C7F=\A&<
M`7(>&_QEQ%$557V]OQ]D^_=?NRBJJ)X3?*AME[146++S#7Z#HXI)&HA,B7&$
M3A3+0$@(*]:0H*18*-MX.\+)BA.@2`."?D0U1HU(CC#/CO\`2,UJ]U`ZA2JQ
M-'!#OH<UNDB.P-43-52)[8/>G@L0X,"2]30W9O)MPJ^OA^K22\HOF[*-PCB5
MB_ZB0H]I!,50$475=54^2((JH"J[HO$4WW7SY7*\K%I1GL.P*RLI5-9<RJ*S
M=2W!*QM#H`,8?<EJP*_#=FX98\9/&86$@U408`PU%WDQ@!8P4,J_]*>H'4_I
MOI3JU]'Z!T9I[Z\ZLT+T2:]>Z6FCK[3<5VL-GUE3*56768(17O6,LS&%CM3%
M;E,NB;AMO12RTTMG:U4TI%@P_5.H\,1DE1A]$(7/MF2'W79!5Q%15!>*[^%3
M(5BSV/UC!I+8$GRKS'XNUF.CCAO3>6K3B0B`460D3=\L!IZD\XH@KQ324X1&
M8,4GD)PF'`P;TRZ::PZE]3M+],-*MLPM9ZAOPI:]+24=2S763!.N/O3I*@3\
M-*X8K[[Z,LO346.3<6,_+5I@_99V#%1!E6,ON"Q";5UU&P4G?A5!00#=/C4U
M04W4415W(A1%5/@K6RHY:-=QRR8J0XEQ^2H1K6].Y(P(7$G!*Q0@4$*TQ9J@
MDLPA8E/*$80H4)C,`P<G/.)&`P60=4]"-?UOT@[GH?K?45+_`(ZA7"P;G4<N
MZD6=5(-:EJY;F-64MMF?..76NL%$C2(\>><AUN')8BO"ZC7.DGLZAB0Y\0G!
M9G"I@LD>#H\2(#$TY&G(2`A^$R$MD43451<D73S5ETL",N":7P^"NK.L1O32
M]3D2@MF`N1*25"<@SNMR]#E1@>/%+`YB0I1>&+`5I:CP0B]W2S4.O-"ZPU#T
MYTSU6TCHVO#4+J3;>Y4'=-7$VCGI$%R%8E43E:;L&HZ?Z\FKBS(2*P]([JM-
ME>HIO-.FPW*991'-^;G^F9`6R*B\5_:1/95!"3PJ[[9L-M:O"UO1J/*T"XPQ
M,G$>I;#<&H#3Q$EC-&D'@PW.4XQ"\0CO&#%X(R\B$+M[V?K_``'BD08;Y/Q)
M1O16'#DP"YPGW#:%3=B'S<4HSAJI,*IFJMJ.Y$NZK+Q7=$7=%W1%W'V7=/=/
MP7Y?AGW\]>5QQC'&,<8QQC-;?V0CCM]Z+]/GZ<8_<M^WC?;_`,*O_&,N*Z>_
MQ!](/F@ZU?8Q"^,9+[C&.,8XQCC&?S-#D91@`^'WAEC"'Q09,*[1!SC'B%X$
M#)A?;G\,&!AR(/:'O![>W'$QY@8_"O(2'8QY@NZ*GQAN/,?/Q#R3DFZ;IOOA
M?UOY_IE#<?UCO>JJZE;'LQ((GL!LA;EAO2JN!U<P+T#=":Z2*TBM><L"@8HD
MD=59YY^$Y9CE&\#8T;CA,![7)4`<(M6OIC4?1ZMU!IBYZ#]++&HZJWS50%*E
M.VZ"PIVF["/8V6KAI*YV36!+W<A5S\V=WAE]U9;PL^FD&_CREJ]05L1\=03H
M]K;29SCL$X31`,6(A"2(2HTPCB\E^'FS]B)<.ZX(H@1\DT8=8LZ#C+LUA3JT
M)I'ER<9Q9N2<*$Y"LDP)Y!HRC0G)E!9H#BS#"S`##D'>"(/;J-0ZQMH>JNJN
MN^I/4ZZT5U:J]--QM.0:R)72(]T<N`<J+4$S]6V=6=2!M4W;B,)$W64-J,Y3
M9>?2ZBX8NR79#YM2A;V!!05Y*0[H*IQ(./['A%3WY(OA5SQSG((28])JZ>':
M.FOTA9ERU-#7%4@-7O#$F_)W`X#*H$(Q:WA"(99W:084,LM3ZA`3J,EZ^1:7
MJ3,K+3J_!K=6NU--J6*W;=184>S&)5ZKLG"GQ/4:BCB(0[>0\HR&S]2V^#ST
M9>0.2HR.V)^5"<DI7R7XQRI;3KJ0WC;)V0RGAT^P2JKC?E>6XJBHA>Z"6WHD
M2%$V(TS>W(TK>@1$EITB)$G*2HTB<H.`E$)DQ`"R2"2PXP$!90`@`'&,!#C'
M(?/L+"VGR;.TG3+*RGR#DS;"?)>F39DEXE)V1*E2#<?D/NDJDXZ\X;CA*JD2
MJJKGH;;;:`6V@!ML!00;;%``!3V$1%$$13Y(B(B9F;ITW!3EQV?;$-F]<2@`
M(X](H`TFS^O\F,SG)1K!#`H:E`TJ]6@$I)*S@DP\;9D")4E/<R0!<&_)7T3Z
M<_1YHNC]MT]>ZO/Z"US`Z\:#@WVAV:-L-8Q*>6[/B;0;F0-4Y]63WV9K+$:Q
M@2CI9#[5M#.8^Y7BZWUZ4NX%S,M8Q0IC2P)*0E*;$X-NN[K\3*KR5-T%?!<#
M$";(Q'N!M=93-&Q6C4$D;(DXR!8ADKX)].2O:Q(I);CLE>`%,V%I$*$)*<).
M"RQ"/PH4FA))P:>/P@]F_,6+%@Q(L"#&CPH4&.U$AQ(K0L1XT9@!;989:!$!
MMIIL1!L`1!$41$1$S(H`((@BFPHB(B)LB(B>$1$3VS-'._.6.,8XQCC&.,9K
M;^R$?U1?7V?G\_;_`-+?LQGC&7%=/?X@^D'S0=:OL8A?&,E]QC'&,<8QQC'&
M,^50C3*@F`/*`/!Q7DYV>Z'`S4V1=X:88^SO"3F>L)A6<]P81#QG'X6>>=^)
M'DB8O-`:.M]EQ>*<G&%+D3!EMR5D_*&WOQ(2)%3XERBHB^_S\?P^[\L@?=FH
M+3-9&%QCASR.63F:&O4DDSHI+&QQ2*IDIV%J5&W)2$P5*DPXYJ2,Z(\XU8J$
M2<9E6F1)EIA>E_5WZ+57J^^&?1.VQ:FUEJQVVO\`4-A(`J?36FX\=Q)<:)`C
MLQQD2''7JV-5Q'W79<@FGG?5QXD>686>75BZ?(%-77GN9N$OP-M(B[H@HB;K
M^R@HOE=E\HB+E:UU=,LR`S5CVG>DZ.22^'(5,>$?''-Z&0T,JHAS1)GEV:ST
MJ1,I\%,ZKD1B@G!A:'*\LQ0$\*=.L1P365'](_HQ]&?572-F^TY=](M1:HCW
MVJ*FIJUEW=:C$NNFM2EM9<&/(8J94ZEJ'K)N-W5BOL-H+X0I5CWHA.T9$"UC
MZD=;5RPB,E'`VG7$;!LA<!#<:V03(1=<!"\HB'N2%P`@FW#-+<M]AP5V>C$L
MB@#ZNE3BX-O@FB`C80-0%450.!^1%C$L<A*S`J32,@PF$B#E.;XPPC!Y])_1
M)]#KO1UK:N1KW15S,U'/FU_9-0B4P5H2--PYKW("*58+)<&0XSP["Q$)ASNF
MAC)FJGB^R1;&R9.$0[+\(<=VQ)=_<MUW5/;;QY]K)XI&6R&QQFBS-@X+4PMZ
M9L;\*3,'*`HTA>"4P#CL!!DX91(`%>*(/?&$`<CR(7:+._\`IK3\#2M!4:;J
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M<F=\!36`[V7$(Y-5L;);W$E`V/Q<7\C/4$C-YHFWA/")X1$^65RU_0[<H[;*
M"S)BL6"+*7VHU\DY%6[5T.Y&&J#*ZLL+<6XHW:+.X\>#+:IL=F$5-*IFJ$U0
MDD$57D@.-`[-[HF3L?I<G9QC'&,<8QQC'&,<8S6W]D(_JB_3Y_9;C&7%=/?X
M@^D'S0=:OL8A?&,E]QC'&,<8QQC'&,<8SS4QAD/L.*R."S^*1N<PF8,KA&Y;
M#Y@QMDEBTHCSLF,1NK#(H^\I5K2],SDD..2KVQR2*42Q,:80H(,+&(.6,C99
M^A.F-U%R@BV-:*AL!)-I-!YE+D$GB#<YMTCD]:0)WJ^OWAX;3@90KE,.K]^=
MHK'@GIQ$MC4L&6F*`86286QGR.^C5"R2<2V82AJ=W]KDTLUFL%OKL:EJ88)#
M+$U,<`N=0SN,%0]FCDJ/D*)2BC9+Q[;97*6E>UPV+L*9K0,2%0VK6,F#@`0Y
M$((0A$/.!#%C&,9'G`<!QD6<8[19P$(0XSGMS@.,8^#&.,9^N,8XQCC&.,8X
MQCC&:V_LA'&<^]%[,=OY_/[+<8W1/==LN*Z>_P`0?2#YH.M7V,0OC&2^XQCC
M&.,9Y^6R$J)1632L]`Y.I,9C[S(3FMG3"6N[D4RMJER,0-2,'X:MR6`393H4
MP/PCU1A10?6/'&,HHZ>_5FLV_*TE]W[,YUV8X=-&E@/UVK&BY`TS2XU-B@J^
MU+PG]'S!%!;FO-L5R6,U9#8^M;'.6D47.%DA#,&Z4TM"LDL*96QG7=-+JZR_
M:"8RD.PECZKD0!TA^K8J]<*3C=CH,L]_;+PBVK=<M8GR7R*?SECG<JI*L*S"
M;/)JT,L&:LR-4]-KDQQ=;'E368RB+^O;S^2_KV]\SSU"=I+.65)TX+>T6EC-
M.DVP&]NOC.PY'-I!7==7-4\XJZZ)`%@ELT:H)/7QFKZ3FM+`ZJ7)/`W\S.43
M<>6V'AR#/&5^[]?)<J1AUZ]2B\W2W:\8[?G<.O9'2/6AGL)B$0F[U*H:ANS5
MOJ':W)*+@#+)'.*PU=+8>V1[,AI6/+W2)QTYWK67O:8^/MI3FH1$,9-V$;=W
MEL9TV.JUU&(7-;"AL4G-'7.Y:3QW'G%K6U<P:_ZP+F=PG$:;U:<A6@EDAV23
MVDM-<O),'KT45B)Y8C$Z=(64QD#7+>.Z6AIL.F]2-E]F]LZVV%KO2FJX7;D:
M<4MRV33.V-J2:PY!M-&:$M16V-F)@]0W4JN)9;:J-NS_`"='6-A((PC,>XV"
M3&-!3*?+POY+[_U7?]>V1\N+>+J'6%3-0D1F?[#PRZ]7-%=P0;5A8YRYUC*8
M5<VJ.S&OM5+MD+%K=-#YDTWD],]12L-PR&C%QS,U3./S1\\U28E:WH$[@RN7
MUZFQ:7K^IYMF4IV;V3LJJ:\HW5>X*TA\BN!_>Z?6O6S(-D/;PJ11,T(FI7%R
M$L1BBV`L83S4D."E2#;QC[0"RRGS]_E[?WRZKC*XXQCC&.,9K;^R$?U1?I\_
MLMQC,P:1=7[IUPC2_42%RC8;S9)HAJ_048D3;[DMY+?-SXP53$VIV0^6-]9J
MV]7Y(O2*"/*4*I2C/\/Q4R@XD0#!,9)[TT_3._B4_HY?W^*^,9SZ:;IG]G;[
MY3U?_#E_?XKXQG'IINF?Z_\`<I\'P_Z.7]_X_=7QC.?33=,_';_N4^#X?]'+
M^_Q7_/C?V_'V_P"<9U#GUB.ET\,KO'UFQ6<-+XA<6QS(0U)L0U'')7<@Y,O\
M%<UUDB7HE)Y2@W.%Z%4F7$'"PH3J2E``&A8R.M<;M=#NJ*\M&KH=9N<1"[@+
MBK@#+(;M[8LGLPAQBB6"GI9M/K$BDIGTB1DPM$DBC<C<Y,H2M$?3E-+44B0A
M\'C&21:>LCTNV)K;6-CV#0L[*S-Z-J:&AKI&]T#8UM;<F+2(&YN0I:G*2HD*
M%(24F2)$Q19"9.46226`L`0X8S[_`$TW3/Q^LI\/K_,Y?W^*^,8]-/TSOXE/
MZ.7]_BOC&/33],[^)3^CE_?XKXQG.>M-TS\?#LI^W_AR_OT?#_Q7QC./33=,
M_P#B4_HY?W\L_NK_`)XXQCTTW3/[>SWRGK^#\SE_?XKXQG/IINF?Z\>^4^#U
MY_T<O[_%?&,X]--TS_XE/Z.7]_//[J_Y9XQCTT_3._B4_HY?W^*^,90QUNNI
M9I1=WO8_<NNKVS>UGW9\OG^G-M,OD7GKW)_-G_N&"-/E/E/FEP_])Y1X/D_Y
01X7BD>(SCR1/G^'S^6?_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>g838054g39l39.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g838054g39l39.jpg
M_]C_X``02D9)1@`!`@$!+`$L``#_X2U517AI9@``34T`*@````@`!P$2``,`
M```!``$```$:``4````!````8@$;``4````!````:@$H``,````!``(```$Q
M``(````;````<@$R``(````4````C8=I``0````!````I````-````$L````
M`0```2P````!061O8F4@4&AO=&]S:&]P($-3(%=I;F1O=W,`,C`Q-3HP,CHR
M."`Q-#HU,CHU,````````Z`!``,````!__\``*`"``0````!```"1*`#``0`
M```!```"A@`````````&`0,``P````$`!@```1H`!0````$```$>`1L`!0``
M``$```$F`2@``P````$``@```@$`!`````$```$N`@(`!`````$``"P?````
M`````$@````!````2`````'_V/_@`!!*1DE&``$"`0!(`$@``/_M``Q!9&]B
M95]#30`!_^X`#D%D;V)E`&2``````?_;`(0`#`@("`D(#`D)#!$+"@L1%0\,
M#`\5&!,3%1,3&!$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`$-"PL-#@T0#@X0%`X.#A04#@X.#A01#`P,#`P1$0P,#`P,#!$,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,_\``$0@`H`"0`P$B``(1`0,1`?_=``0`
M"?_$`3\```$%`0$!`0$!``````````,``0($!08'"`D*"P$``04!`0$!`0$`
M`````````0`"`P0%!@<("0H+$``!!`$#`@0"!0<&"`4###,!``(1`P0A$C$%
M05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U%J*R@R9$DU1D
M1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F
M]C='5V=WAY>GM\?7Y_<1``("`0($!`,$!08'!P8%-0$``A$#(3$2!$%187$B
M$P4R@9$4H;%"(\%2T?`S)&+A<H*20U,58W,T\24&%J*R@P<F-<+21)-4HQ=D
M154V=&7B\K.$P]-UX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8G-T=7
M9W>'EZ>WQ__:``P#`0`"$0,1`#\`]5252_J5&/>*KRVEFGZ6U[6-.X';Z>X_
MI/?^B<WZ:1ZMT[\V]MO,"J;28YVMI%FY)3;256WJ#*PTBFZS<0T!M;AJ0-L^
MKZ>WZ6U,,K,?(;A/88$&U];1J=?YFS(=[6^[Z"2FVDJA/5'.AK:*FZ^XN?8?
MY)V;,?\`ZM+T.H.CU,MK?'T:MIC7CUK,E)3;25'[!E[B[]I9,'\W;C0/_93<
MJC?M[NKOPOM>2*64[_6VU07'V[-<`4^R?4]F38__`$M+*]GJI3LK/Q_4_;N;
M-`97]FQ=N1L<#8[?F;ZC<?T=C:&^E[&?S7K_`/")KNG]1]&ST.I7F[:?2#VX
MX;NCV;RW#+MFY5<3%ZC9GY(R,RVBXTTF*G46`-+LC:-UF!5]!S;/WTE.VDJ;
M,'):"'=0R'S&KFT"(/\`(Q6?23'`RBXG]HY(!GVAN/`_]E=R2FZDJ9P<HLVC
MJ.0#I[@W'G3_`-!=O_166S]I-Z^[IXOR&XQI]5V86U>^PC8RG^@#'_1,;O\`
MZ3ZW_=?T_P!(DIZ!)47].RW.W#J>4P?NM;C1_P!/#<Y.W`R@UP/4LEQ((#BW
M'D$_G-C%V[F_RDE)WYF)79Z3[F-LF-A<`9,&(_M-4ZK:[JVVU.%E;Q+7M,@C
MQ:X+*IZ=EW.RJ7]3RMC;0UY`QV.>TU4N(]2K%K?7]/\`G*=EO^CL6M76RJMM
M5;0RM@#6-:(``$-:T)*?_]#TO/RZ,:L-L+R^[<VJNK6QQ#76.%7]5C/I*F>M
MYQ,5=$S[-)W$XK!_X-FUN_Z"?JH:<["W[BT[VPTD&7OQZN6;7_0?8K^*]K\6
ME[""UU;2TM!`@@1M:_WM_M)*<0]5^LN9A_:<;`Q<6@D.;;DY;MP:UWN=;5BX
MMU6WV_I/US^:41U/JEC8=U3`:XB=F+C79)'T6RVQN5[_`'6U?]IO\)7_`*1!
M%[KNFXG2GPP9%32ZQP82'&WTZG,]7)QOTC+0U]>RO*]_^#_P=V]]AQ6V!]CG
M.<7$MWO/.[[1#1/YKF,_[;24X(?DG]%?U#JF47Q)8S%Q&@'=[FN=7B7;?T-W
M^&>_]&@C%P\AK:GXEN0';FFO.ZAD6`P:6#=4UV;1O?;DUU?]NKHC5TFH['-I
M#G`-VN@D_P"!V^Z7?]J_3_\`0K_ADUO5L&FEUC'&T-8ZV*Q,@-??]+VU^]M;
MOI/_`//B2GF\;I?1KZ*+*.@=.-%X:^GUJ9(;9Z>SU'.Q[&[]MWYKUDCIO1SU
MFV/J_B.!QJW^B&.%(/I69COHT;/7:W]#L]#U?TM5EEG\W0NZIZK78&[J;*WD
M[7-(!VNWMI<PO:YS/YQ_YJYRSJV'D_6>K)L9=MQ*!E4-`F0<:ZSZ(R/399Z.
M5:S^B[]_^'R&?T)*:F5T9F)5DW=+PZ>CYU+'NHS,6VVL!U9R'-^T4FG[-?CO
M_9_Z:J^NVM[+O^NK7JSW5?52KK-C_3R^I447Y.0"/:;6M>ZNAQWLJ94USJ<+
M^<_2^G_2+[+/6UKNL8](LW5VGTP\F&C79]IF'.<UON^PV_Y]*S^B99Z;]2^E
MY%E3K#7A8\U,+=W\VPNVE[F,]C?=]-)2!F.QCO3=TG#>Z2QUEF^VQT&YALMN
MMQGV7.L^S?SEMN_])[U"HX[W,8>C8/BWV:`'[(?^XO\`W?\`_`+/^M[G[5HW
M.:*["6EP/M$>QU['<N_[IV_^!J/[8Q_6;3Z=H>^8EH'#L6O][][/I_\`!4E.
M(!C[=QZ)@!VT&-IF/3MR'#^A_F^AZ:SBRMOUJ8P=.HVG`:3B@G[,)R1B^HUG
MV39]IW.W_P`WO]"K_!KJG=<Q6L:]U=HEN^-HD#T[,GW>[]RES?\`C%E/S:W_
M`%PIL:<CVX6UV.YCO3&[)=B>NQ_J^CZ[;?IL]'U?LOZ3U?\`!)*07>D*"ZCI
M5&+:&FT6XMCJ;6EK;;?T=U6(W<_]"_V6?H;?\-^B6LWJ5UG0&Y;+6"Y\4MR1
M!KWFS[']L:-:W4[_`-98W=L]/_"(XZUC%H=LMAU?JCVCZ.U]O[WTMM3DK,MF
M9T:[(#'U`LM:ZLEK7M=67U6-WLM;5[;*_I,R=G_"I*:>)T;IM@RZ]YNM]0.9
MEEY=D":J6>K]IW>IN]2M^W9LJ_P/I^FM3I]S\C`QK[#+[::WN,1JYK7'0+F_
MJ46/?DNVDVEUC7VOVN>[:YON?=6ZQMOT_P!__MG^970=&<7](P7D078]1(\)
M8U)3_]'T#J=E5F5@[2"YE[0YL$.&X"UOM,;?H;EHX\^@P.#P=H!]2-_]O9[=
MRI=8T=AN$;FY-<3IR=I_Z*/BEF-B5M>YT;M@+FD$ESMK?;[DE//]/]8'IX9Z
MC_T+-Y8#J/M'TG;&/K^C]/WU_H_46A]8<5]KZ+X#JZ:[VNT<7@O:R2S979]/
M'9DTO_FOYU96(QX'30UGJ!M;6@F(`;E,;]/[-E[=C/Y6/ZO^D_PM.SU^P.P[
M*V#U'U@[VAI>0'5V;?:W&S?I?U&?\8DIS6TOR;L9\9EGVJ@Y(;6_&8&N8^A_
MIMVLK?[;+*GO?ZNS]%6IXV%B9%#'T=,OR<6-M9ORMS'M;#&V5U/R+:K,=[*V
M>C9_AJO^"?\`I)8V(S-'2*+=<9V#<;F#7U&AV%^@L=[MV/;_`(:O_#_S5GZ#
MUJK>C24XK\6NQ[GV=!J<^P[GN=]G)+IW;G$GW.W*B.GMKZP+G=+8*[\?TVX(
M&.6349=</<&;]M[:OZE?[BZA4\@-_:>&X_2VW`?,5G_OJ2GGNGTX&/U7+PF]
M(]>XV')>PG&+ZA8&OK]-CGM_5_4]7])O99O_`$55=_I76U'P:+K_`*A]*926
M!_V'$TL?Z;2#56UP=;M?L^E^XJ/6NFN=U?)ZH\59+1E48E5%@NWL-E5'OHL9
MD^@W?;:WU=N+7^A_PZ#@_5WIE?U/Z=G8S749IPZ0;V6V$!SVN=>YM7J.QGO=
M;DY6W=5_.7>HDIU?^:F->76;*;:+02R'V06N=EW5N:YO_AC%_P`S_MR5?U2H
M&15<^NL^EH(LLX+L)Q_M?JE__@:SGYN-578U@S65T`BMC!U$0UKLRNI@KK<W
MZ%>-B[O^OJM?B=`NSJW68>4;++'GU2WJ0(W68]-AW!_L>^K.S/\`KGI?]<2F
M^[ZD[L9U1;7NLKVO_37P7&FRDNW3[?T[V/\`;_@U2R>E4XWURQ,=P<1D8_IU
MU,?<0W=DVY]E[[(^C]EP/1?^L?SWI?H/3]3(KK6-Z&W!>?L^6:Q5ZUS/\J!I
ML;0+)_G/YO=Z?Z3=_-?]N)VY6`/K#BUL9=Z+*'"H^GFG)8RO)?@[&V;OM=='
MV?(J_P`%Z?VFNS]/ZGJ8UZ4[+/J<6X[ZB&;GT[=PNO@6>EZ.[G^;]3_H+8Q<
M?*KZ.^JU@KR;#<_8QQ<&NNLLM8S>S9]'U?=M7-LZM4:S9NS/YK=8#^T1[Q4R
M[V?NU;W_`$V*YTRRFFG,Z=90;,VRJ]UF:X!QR65665C<7MR;K[:/6V6U58V5
M1C^K775^CM]))2;ZJM-5N1COGU:WVA^X%IT]!S?IS9_-OK_.6STIXLZ7AO;`
M#Z*G`-$""QI]H_=6']5PYO4,MI86!UESAN;Z9T&'/Z/[/@[?I?\`<:K_`*Y_
M.K:Z*9Z/@F(G&I,>'L:DI__2]&ZJQECL-CSM'VAIW::%K7VL^E[?<]FQ"S+'
MUXN-Z+V#?F5M)>X6@M-WZ1C;+?\`"?N?GUO_`$5:S-U3,O(!,M/5&!Q:+'PX
MUA^QS_28UNWU:[=WJ6,J]2S]/^B]*K5ZA0<C&H`K?869E5D>QA`9>'>H=_M=
M6QHW?Z6S_!_I4E.*QP+NG%@FLUO@AH<!&53M_1NNQ_\`T?Z/T_\`C%E9>3?3
MU$Y+J;&5VV,K%?I%VUISZ`RUWK8[=_IULKV/M]7^<_1J6/6".G>@3Z)KLUDM
MC]:I?]-M%[?;_P!9]3_2(_4<5F.<UM+2^VT"Q]@:T/(L^W6"IWI8N0WTZ=SF
MT_H/5_TV1;9_.)3'ZOD?M&NI@#:J,=^P!S7$^LSIV7:^QC`UU;WVVO\`I_3_
M`)U=*N<Z+T[$Q>IXN5CEQ=FX=S[2Z8EKL%K17N&YE?T__/BZ-)3E]%Z[7U=K
M2RE]+CBT99#B"`,AV0QM>YOYS/LF[_KE:L930>H83HU'JB?`%O\`L6;]4L2E
MG3Z,RJAM`LQ:J`UIM$-ILRGMI]#,W7,]+[0[]*^WU+_4_FZO3K6AGVBK,Z>2
M'GU;G4@-B-:;K=UDN;[/T'_")*<6UE5OUO=78^"Z&AC'V5V0*F6^J'5%K?3W
M?HOI^K_@_P"93=#R^CY?U,Z9B7YK<<MP<=KX>VNUI977PRT?G;?9^C_2UJZ(
M=UAU8;87MSVW$ACRQH^PMI_27;/09_5]3_JT'!QQ55U/ZNVWVXN-AM]3'O8X
M-+<+*;;Z3&7/W^C]BOJS**/H>C1BXJ2F#<[#L%SQTK+#ZV@WM%M&YC2+;VN?
M^N;&?TS,_P`S_P`*[[G3F]/S&B]V/9BG<U]7JO!%@<<?);;2ZNVVM]?K,I9_
MZL7/7=&Q\T-->)991C`LHLMPJV-:T%[/\GXHQVNK:YV0^[U?T6^RJF_T_2K]
M1%IQ>H5=,HZLT8[!EV59!JK-;M]E]E%S;[<BG']*RQSV4OOMJ:_U-GLOL_G$
ME/1'I'2C0*BX^F*_2'Z0_0]/T/I;O]`L'K5E/2^O.SF4F^K%P+\EWZ5S1ZK'
MY.>VEWTJV^O97D?I7T_H_1_XRNREC>N_&R*Z[FN9B7CISV`#<SW#IK'O=Z#F
M^YF-79['_0L_P%GZ)5?K!TO&Q<\49MC:[KL+):7-+FTFJZRV]]6YE;[/7?D7
M6/8QOL^S^M99_1TE/;U]'Z:*VUMES!6*@WU"06^FRG;,_P"A8Q8_V%F!<_J^
M/<<OI]F*:;+2YE[+2\NL^V9#&_9:644/_GGUV6,L^U?]HL?$65?7=5BEV%;3
MGXS*::6746-+7^M8WIE#*K/2MJ?DNOQ?UBY[V5L_PWL_FNBZ!D5Y/U8^T56"
MRNW[2]EK&EDM-M^Q[6.K>YOM_P"`_P"M)*:7U4N:_-R`WZ.^\M)(=(+<!^YK
MZWW,>QWJ;V/]1;O1P1TC"!Y&/5,&?S&_G+`^J#6-R+/2#A679!:'$D-&SI@9
M76'-J].K9_-5>GLKK^@M[HC=O1\%O[N/4/N8U)3_`/_3[WK5M736TYK*GOWY
ME9N%<N,V,=B>ILG\UKJ]_I_YEB7[6Z,\LPSD;+_5]5E%8>ZQVU]EVE;J_5?O
M]"[U-K/S+E5R>B5_9>NG)QJVTYCQDM>QSW/L-+6V,]=KW.:W9=1[&4>DS9_@
M_P##6G>ZZOI%CFXS+LZBUK+&V5-(<XO9NN#*-GM=19ZU7Y_^F_2>HDIP/VQ@
MT#I1NN./98VYC2^NR'.^U4;F,]2S#]7=_P!?V?Z+_2W^I_6?H>5AVNWFDU7.
MI>ZYCZP7-^T5-:+/7P_YSTK7U;[OYO\`P'^BRL;#K=FVX]N%4^BEMAJ>ZMQW
M;[J#?N]*G(VUM=5]"ME57\[_`,*M*ZNC.MSL.W`Q-F,]NQC:"^W:7YE7J6U4
MLR?8_P"R5>B_]'O_`$O\W^C24EZ/UGI@OP:&6.?=1BY'JUUUVV.;NLQ+/>QM
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MI]_2W^AG58SO5]'&8'G$<VCT\?\`0X^77A9?Z;'H]+%IS/1]EC_62D'2:FTY
M6=C9N1U&RIOIV8Q#LPN%;C<&NL])N_?;Z6ZSU/>^WU%H_8^B[`R>HBINT,J'
MVYK&[(],5L:&[?3V^Q#HRGV_6>@7T_9\L8S1:62ZNRO]:+=F0!Z=M/J-]2BN
MS]/_`#GZ)=&DIYNH='M-E+V=4K92Z3ZK<QM;W;W.]2O3;;^DK]??_+]11RZN
MDV78H-F6_P!2TM>;/M&Z&U7V#T_49]+7\S_!67?\(NF57+!.1A08B]T^?Z'(
M24^?6U=/?5U+;?>^]@MIQZ39CLHHQV7&QEN3B9-E'I[_`%-EMN6W]+5?3;_/
M6^LM+IOUFIQ&7T=2LOH9FT^K0;"+:?5>;;<V^C-Q'MJJPMV30RCU<^K97C^I
M9]GML]6^>51576?U#"8+,K(LLR'TBVRT5YK:/3?5^K_SGK;W/?=?_-_S7J_S
M8<'`I_:.97G8&-;5?CLKP=M+?18`W,S/3QJ]N3MN>QS/7QV?I/T3/Z377ZB2
MFU]3.H=.OS[6XV2RSU3:^MAM+["/2Z:US_TV1F7VM]2JZOU/M%[/T*U/JGU.
MW-QK<=U995@BNFIVQS0X!L;J['N<V]GM;^DV4_\`%^GZ=MN'T'(HZ5U6S'KP
MJZ277-#6-]&!LZ%IL=12[Z69^>UGT/\`A%I?4FMK#U`,I?6S?7MM?78WU/9+
MW577.=7=0RYUE;/0_P`)ZW^E24__U/3LZOU<'(KDC?4]L@21+2/H_G+$MNKR
MF9F+5]F9CVWAQR,E[W-)9Z9=8VJQFS)V.I^C]II_[9].RS:SP#@Y(,0:G\Z#
MZ)Y63CTXN1]7\&ZW;>"<8MM+0):;JG#^O6[]_P#P_P#.?X1)3S;?LE65E9F2
M*Z\:MH+K75BRQ[@X/'Z"^K+LM].EOZ'[-CXW_"6V_P`ZK3<CHV7FYAH],693
M*;[*V!MM9+'YUE[_`%;,;/I=<QF14_+V4;*O6JKKR+/4_2FOQ:'X^+40XBW[
M7O\`TSJR2VZO&;OO^UX=OZ+'>['K_26^E5^CJK6ME?5C&-M%F,;)8]OJ^KDY
M+HK!#G.IW76-;?[?399['^_^=_,24@PFY=.+TIV/4'9&-3?79CZ#?M+&75^K
M]"C(=;7ZF]WZ/?\`H?T?J>M3NXN55ET-OJG:[0M<"US7#1]=C'>YEC'?38N;
MZI]6+'/9EUM?D953)W^HZ7V%CP]OZ1WJ[+'TXM'Z7(]-E=WZ3^869B=2HJR(
MR>G5/>?=;8:C4X06T4F[+JK;@6VZ;/U.S._H]E7J?HDE/:4Y&`TNJH?6W5[W
M-9`$EQ=<_P!OYSK2_P!3_A%7RLS#=D81%U9VVESI<):TU7L:_P"DW\_V+,?7
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M8_*.?>Q]N/D_9J,X9&,_<_[1Z?H_Z3U4E.BVZBWK6`<9I&*['K?CN#=M>QS,
MS8RMGM>QWI[/9Z2WE@UXYP^L8&(TA]5./52UY^F2RO,;+V_0V[6*WTWKV+U'
M.RL.JG(J=BACQ9?4:F6L?N:+<;U/TKZM];F>H^JOU/\``>JDITU3S@/M/3Y,
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MRS=8RBEG_"97_!V*QD'H_56.P\QC;![F[+6D?3&11NJ>?])15DO9Z;M_V?\`
M3?X2M1S.AT9%3F`M<"TAK;V"Y@,-V';9[G;;J,6_Z7O]#_A?46+D=!S<(UMP
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MHJEK5]1LIP&F]IOS6V'&])D!UMK2YK7-;HVOUJV?:_\`@,?])_-UK/Z#U+(W
M68C<=MC'9%]@=5<U^T/OL^U/WD55Y./7DNM].S'_`%AGLQLS%Q\JO]*AFXV/
MU,Y]V\X]GVIU896^TE[3C8A=770VU_T,*US7M;]#(_X1)2\9(^LV,[+>WUGU
M-BJH?HVC;G>W>_\`2VO;N_GOT5;_`/N-2A]9KNZ+UEOUBQ:WVX^6*</J>-2U
MNYSM_IX>:[;6_(NLI;?9C^G7^DL_5&?HZ*[7H_1767]9SK<QDY533738]H#_
M`$!E=0;6UGM9[/2KH^A_.?H?4_2+>24B9C8]=UM]=3&77[?6M:T!S]@VU^J\
M>ZSTV_0W*OG&,KIPB9R7#X?J^453^K_2,_`=E7]0RWY>5DOBQ^X>F]M<UXV0
MW';74S&R7XOHT9?I?H[/LZN9_P#2NG:Q^LN_]M\I)3QF2'#J/4VM?N.]CQ76
M7O>P_;[/\`SZ'K?\!_/?X1;'3MQZEFN<VP7-Z5BGW&TO#O5ZF1M;<+\SU6[O
M^&>JO5Z*G58UCG`>GEY5A@3N(SJZFLL_1W[FU^ONV>D_WJ_TZD!V;<&,JQ3T
M^FLL:VL>YKLU[W.:^C&KV>G:S^=].C^=_1?X1)3F?5-G_9-U"NPEX])CVFP.
MD@5=/JW?IZJ+/IX_^C73=`(/1,$C3]!7I_9"Y[ZLU?\`9$[(J#&TV8US"QAK
M,/8<!QV_9/U=WMM_,71=!!;T7":>12P'MV24_P#_UO1.OXS,CI5P<`37%K`>
M"YA#FLLT=^AM_FK_`&/_`$%EGL62<S-Q-S_L>2+<9[RT4L=<QX>]S[<8>CZM
M;\?>/T-FZK)P?T=?V?TZ[V6[EM5E^596;[*ZA6W]&S8`2[U`7;G5NMW:-^C8
MJM6%U@M?LZBUK2^S8/088ESOIECVM>[\Y_\`-^])3GGJUF)T*VL8F1;U`;S7
M1]ER'5^K8Y]U++;G4"CT6.=^LW^IZ5?^D_FUFT5]3N=6WI'UAJSL@,>YN'U'
M'#&NM98VV_:[%^QYV,SU6;_0M9D_H/\`24KIJL+K(>#;U)KV`&6MH:TS^:=V
M]_M0>K=+ZAGX3\5S\>[=]$OK+2/WIW?:FNWM]G\TQ)3CY/7NO],:']7Z=9AU
M4CTCFXKOMF'`8X_:;J&^EGXM#7[7VVVU/_14^E_AUNX76\7,#7,(?1;'HWL(
M>QTEOMWU&ROVNL]'^<]]U.7_`(/&>N7QLSZQ])SJ<7,;94+"!ZS&NLPS_@*:
MCB669%E+]H]7_)6933CL_39&#Z=5BD:.BY36Y>,Q_0,_-8'LLJI-N)FAS;-[
M!A/K8SJ&]EE_LLQ,/JME?Z6O]7^FE-CZPV86;U:KHF+7]H-S"_J%=9:2ZK9N
M9B8S[7,95EW5.?\`X?'KQ<3*R\C^FYN)<K.+1D]-ZC=GY9I.)CU>FW%QX<:K
M'-PZ\+`Q*O1J]K?UJK'].S],_+_F_P!/Z5$.F]%Z>S*M;E5Y&+9?46XM[K'5
MW6`_I<S-LR<=U?H=3R7_`*3)K;Z7ZK31^93;3CMBC.ZGEV"CW5XX>YW46O#6
MY%KF54U^Q@];!O\`L[?2];'_`.TS[O1]+[9CY*2D'[-ZUU+-MRFNKJ;C.L93
MCUN](TO<-E[^G=0H#VONK]1WVS[5@Y&/=F^KB/\`^ZV:<QK@:\T"_$!OJ&-E
M,;CMJ;76S&RL*ES;'.HJ^RW/M_[JX5'V[-R_M%&939K8UV1TO/JJ#=V.6^E5
M8&@%OI;768)_2^ZG$IWUXS_5JZ9@?I/MU_4>K?SE_(;T2]]74W7C%MNLKWO`
M!9ZM;2^E^0+ZMK'>C9MQLC)95_/8GI_I;<9)35976_,LOZ=B93+!6+:<D-8_
MT[;K;\G-HN]7)8[8ZZW9F].]GI^E^C]%]>+>M6OK.0&,^T=-RZ[H_2L8UEC6
MN_DVUV;;&?N?^">G9^C60[HUU5'K8>62+JVBFVNQC&VV;;O1.S9Z'T:\/VX_
MH4/_`$_ITTTH.:1@WOJR.JMQIU:V[+H8XM+KVU.V6M]F]C</Z'T_4L24[E_7
MVX];K;L',96P`N?Z;2!)V=K-RKY?6ZG9V!2[$R6W;[+ZZW5C<YK*[:+/3_2>
MU[79%?\`.?F+#M=1<+Z[>JU/QA6#;6_,QR``<?W72Q^QG]*=_P!:_P"WJN0R
M[]M=)?\`:Q;C9%5K,?,9=4ZTV.<Z@58U]/O]'?Z-=WH5/I9_A[Z4E-O(S+[F
M.9]COIIQ[;[CFN-8I/K=0JVU,R*,NOT[Z=EOVJBV_$NQ_1_2_P`O4Z9F,>_.
MI87.<,-CW7->'-86^NWTGW,R[K/6VN;;_3OYO_#U*OB_5_/QHKQ[KL;'.YS_
M`$K*F`$NQ2^S96S;ZEK;.H>K9L^G17_(4/JTUQ/4+,EX^WW4'U*'6A^0P!UU
MGZ;$8RU].]N13<W=3E?S_P#UA)2_0LF/K`RIQ)]5N;M)<YQEC.BZ39?F.^CO
M_P"U"Z#HQCH^(6B?T+"`.^GG"YGIECOV_@NL,6/R,JO]('5N.[$P;_T=1Q\+
M_1[O3?1_PGZ1=+T(D]&PR1'Z%FGR24__U_3*W3GWLCBNHSI!DW?^14\5NVIP
MV[/TEIB9YL>[=K^_]-0;</VC906ODTL>';'[(W6-+?M$>AZG_`[O5_/4\9NV
MLC9Z?Z2P[?B][M__`%S^<24K':YK[]SP[=9+0#.T;6>PHR#0&"S(V[I-@W[N
M)].KZ'\G;M1DE,+:JKJS5<QME;M',<`X'XM<L6^DT,=A^G;D]'I`%A!/JTN&
MWTVXCV1D6U8G\]ZM3OMF+=Z7V6[(?ZE.)K7/>]WV>H[7D!SWQ.UD_%OOLVO9
M7_VXB555TUMJK&UC`&M'@`DIY^+7'#Z-U`_;NGY#VNQ<V/4;=354+JZ<^WW-
M^UV7L]7U&_H,_'_Z[2I=-R,GIF<[IN7OL+G2+HGU0\DLRF;?SW._1Y=7Z>WU
M_P!)Z6#TRK%]>'UBZ5=4!GXC[/2J)=9AML-=+C8X/M=:[_M,UUGZQ]OI_3=.
MOJ^V_P"F5BV@YC?V1U4EN4T$X.<(/J@-]Q=[*Z?M&WV9V%Z?V?,H_2>A]FLN
MQL9*;F;TVC,'K5MKL]7:;`\!U=H'\R[(]KG7UXS7/NHHW^GZO_;BP6V9>":J
M]MUP;Z=1M>0^YGTK/6S&/VT7WUX_J]2SK,?]/]H_9]7V>ST/TEQV3U/IU;\7
M)!<;);7<YT5V.<?\#ESNQ+[/]%E_3SLSTL/]4PU8HKKO+:KLL9;+-U>17DL:
M';7`T[<2RH4;&W3C[_Y[UJ+*;/\`M3OM2G/OZUCC'%;\3':USK;[J+ZG,`>*
M6Y?O9:QGZ9^9F8]3[MGO_2?X2[]%$]<^KM3+G^C@LKKWP\-;!VV957[G[N+6
M[_KRWLCI./D6-L-EC2/5G:1[A<WTW^YS7.;LVL]/8FLZ/CO+CZEK=Y+G;7"-
M3<YPU;^=]JM24X)^L'0VVMJ]+!&TDMT!`VNQ&;F^S]W)R/\`ME9/5>KX&1U+
M!LI=C58U+#=DO9O],>E9OR,:YC&_9;/M-=%=%=E_OIM_F=Z[8]+H+BXV6$DE
MT[NY=3;X?]UJUDYW2*&_6#IMOZ5TTWT.MW.]H+7;6NBMU7Z7U[?YVVI_Z+]%
MZWZ1)3G'K?179M6,_`P6UOVF[(M%886N-%7I4>W?9>QV5_A&5T^C_A/YU;/1
M<G'R^@6.K9CAH:\/;C,#*9<WUH:Q[G5?0M_2_I?3]3_,88_5S`.<,\/N;D`L
M+B+#M<*RQ]=;Z_YO9NJ_=WO_`.MT^G#IN);TZG(Z6P%V)CTL=C/%7I_3]9KZ
MIH'I6/K]*O\`F*6/_2_\(DIP.FN:,[%L8?:W,=N+6UEONIZ;C[7OQWW,Q_=;
M_@W_`,[^KO\`YYZZKHT#I6*!QZ8B%S%30,_&+H)&:`WU?4K?)KZ9_-59#*GV
M/V[_`&6_X'U+?YRI=1T@.'3J0\RYNX$_!S@DI__0].;77]LLL@>IZ;&SI(;N
ML,?O;=R?&GTS+2W])9H>?IO]W#?I?23M8T95CQ])U;`1Y`VEO_5J.((J<)<?
MTEI]_.MCS_F?Z/\`D)*6KNK^UV4-K<'GWNL`]I(%;=7?Z3:6(E]OILEHWV'2
MNN0TN=$[1N_D^]4K1E5Y=V8&UNKJ_1ACH:XL+:K'O9;%CMV_<UF/^BKL_P#!
M%:HK+G_:K6%ESF[0QQ#MC9W;!M]K7O\`9Z^QS_?_`(2RNJI)22MA:WW&7NU>
M>)*FDDDI2R<[IS6XUF*_'^V])L$68<2^H`AS3B:MW55/;ZM5+7>OC?\`:'^;
MQ\5:R22G&HNSV,+L>P=8PH?ZE3ME>6PD#91[O0QK?W'UYGV.ZO\`PUU]JJ5L
MZ`+6LHOMZ/D%S0W'N'HM+H98VO'Q\^MV-9Z?V6K_`)._1_H/YQ;>5T_$RG!]
MC"VUHAM];C7:!^ZVZHLLV?R-VQ#^S=18TM9E-O8>1DU!SO-N_'=C,_\``7I*
M<]O1[;J?U?-I=58R&.96X^V*:Y#JLEE;O9BL^BQ2/0<YP>#F,]X(_FGZ;CDN
MEOZS]+]=<W_K2(.E,%F_]D]/W$%KK`8=!.^/Z'^<[W_30_V)C0&CHG38VED$
MB`QQWN9_0OH/=[WL24N[H>?,MS*A#MP_0V3/J5W_`$AE_P#`[%B]1Z%FU]?Z
M1^L.L=93E8YR&MM#:VEE8]_Z6QWJ6.^A^MXOZ3_3+9/1,<N+CT3II)()=(F6
MC:QW]!_,;]%5;NAT_;L*O]FX%&/^F%F.RMKVV`@/:TV?81Z7O]WI[Z_6_P"$
M]-)2?)Z;U)EU;ADM()#B159L;L?1=NN<_.;M;^K_`/GU!Q>FYY^KM^)@6UBB
MVJVNAKJG![Y;Z7KML;?575]LM#\IC_3_`.U'J*P[H>*XN#NA]-<-VX3M,D?1
M>?U+Z:(WHF$QC',Z1@ML#2PM$`-:^3;4UWV;^:<[W>GLV/24Y=MV,7,MQ.G5
M86-CVTW?;1Z5;'4"ZK[8R_VLR,)].UC[,>[T+;,G"R*/YO&_3=!TD6_L^DVL
M=6]^Y_IOT<T/<ZQC;&_FV-8[](S]]9[.B5U/J&-TKI^(UEM=ALKC<T,<PGTZ
MVXC&^IZ=?IL?ZC/36XDI_]G_[3)`4&AO=&]S:&]P(#,N,``X0DE-!"4`````
M`!``````````````````````.$))30/M```````0`2P````!``$!+`````$`
M`3A"24T$)@``````#@`````````````_@```.$))300-```````$````'CA"
M24T$&0``````!````!XX0DE-`_,```````D```````````$`.$))300*````
M```!```X0DE-)Q````````H``0`````````".$))30/U``````!(`"]F9@`!
M`&QF9@`&```````!`"]F9@`!`*&9F@`&```````!`#(````!`%H````&````
M```!`#4````!`"T````&```````!.$))30/X``````!P``#_____________
M________________`^@`````_____________________________P/H````
M`/____________________________\#Z`````#_____________________
M________`^@``#A"24T$"```````$`````$```)````"0``````X0DE-!!X`
M``````0`````.$))300:``````.)````!@`````````````"A@```D0````J
M`%``80!G`&4`<P`@`&8`<@!O`&T`(``U`%\`,0!?`"X`,0`N`#$`+@`Q`#,`
M(`!2`&$`=@!E`&X`(`!'`&$`=`!E`'<`80!Y`"``3`!E`&$`<P!E`````0``
M```````````````````````!``````````````)$```"A@``````````````
M```````!`````````````````````````!`````!````````;G5L;`````(`
M```&8F]U;F1S3V)J8P````$```````!28W0Q````!`````!4;W`@;&]N9P``
M````````3&5F=&QO;F<``````````$)T;VUL;VYG```"A@````!29VAT;&]N
M9P```D0````&<VQI8V5S5FQ,<P````%/8FIC`````0``````!7-L:6-E````
M$@````=S;&EC94E$;&]N9P`````````'9W)O=7!)1&QO;F<`````````!F]R
M:6=I;F5N=6T````,15-L:6-E3W)I9VEN````#6%U=&]'96YE<F%T960`````
M5'EP965N=6T````*15-L:6-E5'EP90````!);6<@````!F)O=6YD<T]B:F,`
M```!````````4F-T,0````0`````5&]P(&QO;F<``````````$QE9G1L;VYG
M``````````!"=&]M;&]N9P```H8`````4F=H=&QO;F<```)$`````W5R;%1%
M6%0````!````````;G5L;%1%6%0````!````````37-G951%6%0````!````
M```&86QT5&%G5$585`````$```````YC96QL5&5X=$ES2%1-3&)O;VP!````
M"&-E;&Q497AT5$585`````$```````EH;W)Z06QI9VYE;G5M````#T53;&EC
M94AO<GI!;&EG;@````=D969A=6QT````"79E<G1!;&EG;F5N=6T````/15-L
M:6-E5F5R=$%L:6=N````!V1E9F%U;'0````+8F=#;VQO<E1Y<&5E;G5M````
M$453;&EC94)'0V]L;W)4>7!E`````$YO;F4````)=&]P3W5T<V5T;&]N9P``
M```````*;&5F=$]U='-E=&QO;F<`````````#&)O='1O;4]U='-E=&QO;F<`
M````````"W)I9VAT3W5T<V5T;&]N9P``````.$))300H```````,`````3_P
M````````.$))3001```````!`0`X0DE-!!0```````0````!.$))300,````
M`"P[`````0```)````"@```!L``!#@```"P?`!@``?_8_^``$$I&248``0(!
M`$@`2```_^T`#$%D;V)E7T--``'_[@`.061O8F4`9(`````!_]L`A``,"`@(
M"0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P,#!$,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,`0T+"PT.#1`.#A`4#@X.%!0.#@X.%!$,#`P,#!$1
M#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`S_P``1"`"@`)`#
M`2(``A$!`Q$!_]T`!``)_\0!/P```04!`0$!`0$``````````P`!`@0%!@<(
M"0H+`0`!!0$!`0$!`0`````````!``(#!`4&!P@)"@L0``$$`0,"!`(%!P8(
M!0,,,P$``A$#!"$2,05!46$3(G&!,@84D:&Q0B,D%5+!8C,T<H+10P<EDE/P
MX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-UX_-&)Y2DA;25Q-3D]*6U
MQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$``@(!`@0$`P0%!@<'!@4U
M`0`"$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D8N%R@I)#4Q5C<S3Q)086
MHK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4I(6TE<34Y/2EM<75Y?56
M9G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H`#`,!``(1`Q$`/P#U5)5+^I48]XJO
M+:6:?I;7M8T[@=OI[C^D]_Z)S?II'JW3OS;VV\P*IM)CG:VD6;DE-M)5;>H,
MK#2*;K-Q#0&UN&I`VSZOI[?I;4PRLQ\AN$]A@0;7UM&IU_F;,AWM;[OH)*;:
M2J$]4<Z&MHJ;K[BY]A_DG9LQ_P#JTO0Z@Z/4RVM\?1JVF->/6LR4E-M)4?L&
M7N+OVEDP?S=N-`_]E-RJ-^WNZN_"^UY(I93O];;5!<?;LUP!3[)]3V9-C_\`
M2TLKV>JE.RL_']3]NYLT!E?V;%VY&QP-CM^9OJ-Q_1V-H;Z7L9_->O\`\(FN
MZ?U'T;/0ZE>;MI](/;CANZ/9O+<,NV;E5Q,7J-F?DC(S+:+C328J=18`TNR-
MHW68%7T'-L_?24[:2ILP<EH(=U#(?,:N;0(@_P`C%9]),<#*+B?VCD@&?:&X
M\#_V5W)*;J2IG!RBS:.HY`.GN#<>=/\`T%V_]%9;/VDWK[NGB_(;C&GU79A;
M5[["-C*?Z`,?]$QN_P#I/K?]U_3_`$B2GH$E1?T[+<[<.IY3!^ZUN-'_`$\-
MSD[<#*#7`]2R7$@@.+<>03^<V,7;N;_*24G?F8E=GI/N8VR8V%P!DP8C^TU3
MJMKNK;;4X65O$M>TR"/%K@LJGIV7<[*I?U/*V-M#7D#'8Y[352XCU*L6M]?T
M_P"<IV6_Z.Q:U=;*JVU5M#*V`-8UH@``0UK0DI__T/2\_+HQJPVPO+[MS:JZ
MM;'$-=8X5?U6,^DJ9ZWG$Q5T3/LTG<3BL'_@V;6[_H)^JAISL+?N+3O;#209
M>_'JY9M?]!]BOXKVOQ:7L(+75M+2T$""!&UK_>W^TDIQ#U7ZRYF']IQL#%Q:
M"0YMN3ENW!K7>YUM6+BW5;?;^D_7/YI1'4^J6-AW5,!KB)V8N-=DD?1;+;&Y
M7O\`=;5_VF_PE?\`I$$7NNZ;B=*?#!D5-+K'!A(<;?3J<SU<G&_2,M#7U[*\
MKW_X/_!W;WV'%;8'V.<YQ<2W>\\[OM$-$_FN8S_MM)3@A^2?T5_4.J91?$EC
M,7$:`=WN:YU>)=M_0W?X9[_T:",7#R&MJ?B6Y`=N::\[J&18#!I8-U379M&]
M]N375_VZNB-72:CL<VD.<`W:Z"3_`(';[I=_VK]/_P!"O^&36]6P::76,<;0
MUCK8K$R`U]_TO;7[VUN^D_\`\^)*>;QNE]&OHHLHZ!TXT7AKZ?6IDAMGI[/4
M<['L;OVW?FO62.F]'/6;8^K^(X'&K?Z(8X4@^E9F.^C1L]=K?T.ST/5_2U66
M6?S="[JGJM=@;NILK>3M<T@':[>VES"]KG,_G'_FKG+.K8>3]9ZLFQEVW$H&
M50T"9!QKK/HC(]-EGHY5K/Z+OW_X?(9_0DIJ971F8E63=TO#IZ/G4L>ZC,Q;
M;:P'5G(<W[12:?LU^._]G_IJKZ[:WLN_ZZM>K/=5]5*NLV/]/+ZE11?DY`(]
MIM:U[JZ''>RIE37.IPOYS]+Z?](OLL];6NZQCTBS=7:?3#R8:-=GVF8<YS6^
M[[#;_GTK/Z)EGIOU+Z7D65.L->%CS4PMW?S;"[:7N8SV-]WTTE(&8[&.]-W2
M<-[I+'66;[;'0;F&RVZW&?9<ZS[-_.6V[_TGO4*CCO<QAZ-@^+?9H`?LA_[B
M_P#=_P#\`L_ZWN?M6C<YHKL):7`^T1['7L=R[_NG;_X&H_MC']9M/IVA[YB6
M@<.Q:_WOWL^G_P`%24X@&/MW'HF`';08VF8].W(</Z'^;Z'IK.+*V_6IC!TZ
MC:<!I.*"?LPG)&+ZC6?9-GVG<[?_`#>_T*O\&NJ=US%:QKW5VB6[XVB0/3LR
M?=[OW*7-_P",64_-K?\`7"FQIR/;A;78[F.],;LEV)Z['^KZ/KMM^FST?5^R
M_I/5_P`$DI!=Z0H+J.E48MH:;1;BV.IM:6MMM_1W58C=S_T+_99^AM_PWZ):
MS>I76=`;ELM8+GQ2W)$&O>;/L?VQHUK=3O\`UEC=VST_\(CCK6,6AVRV'5^J
M/:/H[7V_O?2VU.2LRV9G1KL@,?4"RUKJR6M>UU9?58W>RUM7MLK^DS)V?\*D
MIIXG1NFV#+KWFZWU`YF67EV0)JI9ZOVG=ZF[U*W[=FRK_`^GZ:U.GW/R,#&O
ML,OMIK>XQ&KFM<=`N;^I18]^2[:3:76-?:_:Y[MKF^Y]U;K&V_3_`'_^V?YE
M=!T9Q?TC!>1!=CU$CPEC4E/_T?0.IV5696#M(+F7M#FP0X;@+6^TQM^AN6CC
MSZ#`X/!V@'U(W_V]GMW*EUC1V&X1N;DUQ.G)VG_HH^*68V)6U[G1NV`N:027
M.VM]ON24\_T_U@>GAGJ/_0LWE@.H^T?2=L8^OZ/T_?7^C]1:'UAQ7VOHO@.K
MIKO:[1Q>"]K)+-E=GT\=F32_^:_G5E8C'@=-#6>H&UM:"8@!N4QOT_LV7MV,
M_E8_J_Z3_"T[/7[`[#LK8/4?6#O:&EY`=79M]K<;-^E_49_QB2G-;2_)NQGQ
MF6?:J#DAM;\9@:YCZ'^FW:RM_MLLJ>]_J[/T5:GC86)D4,?1TR_)Q8VUF_*W
M,>UL,;974_(MJLQWLK9Z-G^&J_X)_P"DEC8C,T=(HMUQG8-QN8-?4:'87Z"Q
MWNW8]O\`AJ_\/_-6?H/6JMZ-)3BOQ:['N?9T&IS[#N>YWV<DNG=N<2?<[<J(
MZ>VOK`N=TM@KOQ_3;@@8Y9-1EUP]P9OVWMJ_J5_N+J%3R`W]IX;C]+;<!\Q6
M?^^I*>>Z?3@8_5<O";TCU[C8<E["<8OJ%@:^OTV.>W]7]3U?TF]EF_\`155W
M^E=;4?!HNO\`J'TIE)8'_8<32Q_IM(-5;7!UNU^SZ7[BH]:Z:YW5\GJCQ5DM
M&51B546"[>PV54>^BQF3Z#=]MK?5VXM?Z'_#H.#]7>F5_4_IV=C-=1FG#I!O
M9;80'/:YU[FU>H[&>]UN3E;=U7\Y=ZB2G5_YJ8UY=9LIMHM!+(?9!:YV7=6Y
MKF_^&,7_`#/^W)5_5*@9%5SZZSZ6@BRS@NPG'^U^J7_^!K.?FXU5=C6#-970
M"*V,'41#6NS*ZF"NMS?H5XV+N_Z^JU^)T"[.K=9AY1LLL>?5+>I`C=9CTV'<
M'^Q[ZL[,_P"N>E_UQ*;[OJ3NQG5%M>ZRO:_]-?!<:;*2[=/M_3O8_P!O^#5+
M)Z53C?7+$QW!Q&1C^G74Q]Q#=V3;GV7OLCZ/V7`]%_ZQ_/>E^@]/U,BNM8WH
M;<%Y^SY9K%7K7,_RH&FQM`LG^<_F]WI_I-W\U_VXG;E8`^L.+6QEWHLH<*CZ
M>:<EC*\E^#L;9N^UUT?9\BK_``7I_::[/T_J>IC7I3LL^IQ;COJ(9N?3MW"Z
M^!9Z7H[N?YOU/^@MC%Q\JOH[ZK6"O)L-S]C'%P:ZZRRUC-[-GT?5]VU<VSJU
M1K-F[,_FMU@/[1'O%3+O9^[5O?\`38KG3+*::<SIUE!LS;*KW69K@'')9599
M6-Q>W)NOMH];9;55C95&/ZM==7Z.WTDE)OJJTU6Y&.^?5K?:'[@6G3T'-^G-
MG\V^O\Y;/2GBSI>&]L`/HJ<`T0(+&GVC]U8?U7#F]0RVEA8'67.&YOIG08<_
MH_L^#M^E_P!QJO\`KG\ZMKHIGH^"8B<:DQX>QJ2G_]+T;JK&6.PV/.T?:&G=
MIH6M?:SZ7M]SV;$+,L?7BXWHO8-^96TE[A:"TW?I&-LM_P`)^Y^?6_\`15K,
MW5,R\@$RT]48'%HL?#C6'['/])C6[?5KMW>I8RKU+/T_Z+TJM7J%!R,:@"M]
MA9F561[&$!EX=ZAW^UU;&C=_I;/\'^E24XK'`NZ<6":S6^"&AP$95.W]&Z['
M_P#1_H_3_P",65EY-]/43DNIL97;8RL5^D7;6G/H#+7>MCMW^G6RO8^WU?YS
M]&I8]8(Z=Z!/HFNS62V/UJE_TVT7M]O_`%GU/](C]1Q68YS6TM+[;0+'V!K0
M\BS[=8*G>EBY#?3IW.;3^@]7_39%MG\XE,?J^1^T:ZF`-JHQW[`'-<3ZS.G9
M=K[&,#75O?;:_P"G]/\`G5TJYSHO3L3%ZGBY6.7%V;AW/M+IB6NP6M%>X;F5
M_3_\^+HTE.7T7KM?5VM+*7TN.+1ED.((`R'9#&U[F_G,^R;O^N5JQE-!ZAA.
MC4>J)\`6_P"Q9OU2Q*6=/HS*J&T"S%JH#6FT0VFS*>VGT,S=<STOM#OTK[?4
MO]3^;J].M:&?:*LSIY(>?5N=2`V(UINMW62YOL_0?\(DIQ;656_6]U=CX+H:
M&,?979`J9;ZH=46M]/=^B^GZO^#_`)E-T/+Z/E_4SIF)?FMQRW!QVOA[:[6E
ME=?#+1^=M]GZ/]+6KHAW6'5AMA>W/;<2&/+&C["VG])=L]!G]7U/^K0<''%5
M74_J[;?;BXV&WU,>]C@TMPLIMOI,9<_?Z/V*^K,HH^AZ-&+BI*8-SL.P7/'2
MLL/K:#>T6T;F-(MO:Y_ZYL9_3,S_`#/_``KON=.;T_,:+W8]F*=S7U>J\$6!
MQQ\EMM+J[;:WU^LREG_JQ<]=T;'S0TUXEEE&,"RBRW"K8UK07L_R?BC':ZMK
MG9#[O5_1;[*J;_3]*OU$6G%ZA5TRCJS1CL&795D&JLUNWV7V47-OMR*<?TK+
M'/92^^VIK_4V>R^S^<24]$>D=*-`J+CZ8K](?I#]#T_0^EN_T"P>M64]+Z\[
M.92;ZL7`OR7?I7-'JL?DY[:7?2K;Z]E>1^E?3^C]'_C*[*6-Z[\;(KKN:YF)
M>.G/8`-S/<.FL>]WH.;[F8U=GL?]"S_`6?HE5^L'2\;%SQ1FV-KNNPLEI<TN
M;2:KK+;WU;F5OL]=^1=8]C&^S[/ZUEG]'24]O7T?IHK;6V7,%8J#?4)!;Z;*
M=LS_`*%C%C_868%S^KX]QR^GV8IILM+F7LM+RZS[9D,;]EI910_^>?798RS[
M5_VBQ\195]=U6*785M.?C,III9=18TM?ZUC>F4,JL]*VI^2Z_%_6+GO96S_#
M>S^:Z+H&17D_5C[158+*[?M+V6L:62TVW['M8ZM[F^W_`(#_`*TDII?52YK\
MW(#?H[[RTDAT@MP'[FOK?<Q['>IO8_U%N]'!'2,('D8]4P9_,;^<L#ZH-8W(
ML](.%9=D%H<20T;.F!E=8<VKTZMG\U5Z>RNOZ"WNB-V]'P6_NX]0^YC4E/\`
M_]/O>M6U=-;3FLJ>_?F5FX5RXS8QV)ZFR?S6NKW^G_F6)?M;HSRS#.1LO]7U
M645A[K';7V7:5NK]5^_T+O4VL_,N57)Z)7]EZZ<G&K;3F/&2U['/<^PTM;8S
MUVO<YK=EU'L91Z3-G^#_`,-:=[KJ^D6.;C,NSJ+6LL;94TASB]FZX,HV>UU%
MGK5?G_Z;])ZB2G`_;&#0.E&ZXX]EC;F-+Z[(<[[51N8SU+,/U=W_`%_9_HO]
M+?ZG]9^AY6':[>:35<ZE[KF/K!<W[14UHL]?#_G/2M?5ON_F_P#`?Z+*QL.M
MV;;CVX53Z*6V&I[JW'=ONH-^[TJ<C;6UU7T*V55?SO\`PJTKJZ,ZW.P[<#$V
M8SV[&-H+[=I?F5>I;52S)]C_`+)5Z+_T>_\`2_S?Z-)27H_6>F"_!H98Y]U&
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M*_UHMV9`'IVT^HWU**[/T_\`.?HET:2GFZAT>TV4O9U2ME+I/JMS&UO=O<[U
M*]-MOZ2OU]_\OU%'+JZ39=B@V9;_`%+2UYL^T;H;5?8/3]1GTM?S/\%9=_PB
MZ95<L$Y&%!B+W3Y_H<A)3Y];5T]]74MM][[V"VG'I-F.RBC'9<;&6Y.)DV4>
MGO\`4V6VY;?TM5]-O\];ZRTNF_6:G$9?1U*R^AF;3ZM!L(MI]5YMMS;Z,W$>
MVJK"W9-#*/5SZME>/ZEGV>VSU;YY5%5=9_4,)@LRLBRS(?2+;+17FMH]-]7Z
MO_.>MO<]]U_\W_->K_-AP<"G]HYE>=@8UM5^.RO!VTM]%@#<S,]/&KVY.VY[
M',]?'9^D_1,_I-=?J)*;7U,ZATZ_/M;C9++/5-KZV&TOL(]+IK7/_39&9?:W
MU*KJ_4^T7L_0K4^J?4[<W&MQW5EE6"*Z:G;'-#@&QNKL>YS;V>UOZ393_P`7
MZ?IVVX?0<BCI75;,>O"KI)=<T-8WT8&SH6FQU%+OI9GY[6?0_P"$6E]2:VL/
M4`RE];-]>VU]=C?4]DO=5=<YU=U#+G65L]#_``GK?Z5)3__4].SJ_5P<BN2-
M]3VR!)$M(^C^<L2VZO*9F8M7V9F/;>''(R7O<TEGIEUC:K&;,G8ZGZ/VFG_M
MGT[+-K/`.#D@Q!J?SH/HGE9./3BY'U?P;K=MX)QBVTM`EINJ</Z];OW_`/#_
M`,Y_A$E/-M^R5965F9(KKQJV@NM=6++'N#@\?H+ZLNRWTZ6_H?LV/C?\);;_
M`#JM-R.C9>;F&CTQ9E,IOLK8&VUDL?G67O\`5LQL^EUS&9%3\O91LJ]:JNO(
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MB24]I3D8#2ZJA];=7O<UD`27%US_`&_G.M+_`%/^$5?*S,-V1A$75G;:7.EP
MEK35>QK_`*3?S_8LQ]>,<&J.F8PQ'AOV<[WOW!P%C#1CT8[\FUVW]+Z?IUO_
M`-(HUX(H:_.R^FUNM,,=9>^J@-:3M].BEC\JFECWN_PF3ZUS[/TUB2G.SW-Q
M^FXV5DMNNP:^JT6Y=+7>G%9J;3AO#9H?=2SJ5O3LGTOTG_;:T>I'JIZQE6U!
MC;\'%]?"]`N?9:PN]V)F8SGL];UGTVMJ]GZ/?^KW>MO6;DT=*'VW(MZ2V[(S
MW5'I6'6=EF2YU=;:]N1CVOQ'U8_I,R?M=5W^3J_7ROT7Z.R^S@U9_27_`&2V
MV[J77OLS,7'?;96]KV%C\HY]['VX^3]FHSAD8S]S_M'I^C_I/524Z+;J+>M8
M!QFD8KL>M^.X-VU[',S-C*V>U['>GL]GI+>6#7CG#ZQ@8C2'U4X]5+7GZ9+*
M\QLO;]#;M8K?3>O8O4<[*PZJ<BIV*&/%E]1J9:Q^YHMQO4_2OJWUN9ZCZJ_4
M_P`!ZJ2G35/.`^T]/DP1D.@>)^SY6BI=+PLJGZQ=;R;:BRC*.*:+I!W[*C5:
MW:'N<STG_O5U?31>MLR77=*^S$A[<YA<1M_F_2R/M'\Y^]1ZC?;^D_T:2GF^
MJXV38_%LJR7MI;=G-?CL8TAQ_:%0W^ZC,=^C>6/V^A_@OW/7]9[7Y`^L5&*W
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MZIY_TE%62]GINW_9_P!-_A*U',Z'1D5.8"UP+2&MO8+F`PW8=MGN=MNHQ;_I
M>_T/^%]18N1T'-PC6W!=Z5-0+:\>S==C.:/2955:^RS[512STNG;_2?Z7V?`
MZA9]F_3^]*;76,7!Z:RO-SLR[U6ML;5DQ%K&U569SF8_V?T:*V?9</)?;792
M^K+O^S_:O6KHIQT&WKV.W!>SZPL9;T\,;:[-#"6-V%EM!R\1S=[;?4%5E/HL
ML_G,3UJ,+[7C4*MDYEN0X86779Z](M^RB^9L<^C[#ZF+8VSI[;_Z2RFRC(?5
MDW9^=D>S`^R>M52KSK.L=3P**?T>%TYM'V&_T3;39:/8<RS'L?ZS\1UU7V;`
M>S)M]-]5_4/M%OH_:<5*=CZL]`R+>D4W=9=9]HLQ:L?&H,L?B45MK]-M;OYV
MO/NLJKR\R[^<^T>A1_VBJ6M7U&RG`:;VF_-;8<;TF0'6VM+FM<UNC:_6K9]K
M_P"`Q_TG\W6L_H/4LC=9B-QVV,=D7V!U5S7[0^^S[4_>157DX]>2ZWT[,?\`
M6&>S&S,7'RJ_TJ&;C8_4SGW;SCV?:G5AE;[27M.-B%U==#;7_0PK7->UOT,C
M_A$E+QDCZS8SLM[?6?4V*JA^C:-N=[=[_P!+:]N[^>_15O\`^XU*'UFN[HO6
M6_6+%K?;CY8IP^IXU+6[G.W^GAYKMM;\BZREM]F/Z=?Z2S]49^CHKM>C]%=9
M?UG.MS&3E5--=-CV@/\`0&5U!M;6>UGL]*NCZ'\Y^A]3](MY)2)F-CUW6WUU
M,9=?M]:UK0'/V#;7ZKQ[K/3;]#<J^<8RNG")G)</A^KY15/ZO](S\!V5?U#+
M?EY62^+'[AZ;VUS7C9#<=M=3,;)?B^C1E^E^CL^SJYG_`-*Z=K'ZR[_VWRDE
M/&9(<.H]3:U^X[V/%=9>][#]OL_P#/H>M_P'\]_A%L=.W'J6:YS;!<WI6*?<
M;2\.]7J9&UMPOS/5;N_X9ZJ]7HJ=5C6.<!Z>7E6&!.XC.KJ:RS]'?N;7Z^[9
MZ3_>K_3J0'9MP8RK%/3Z:RQK:Q[FNS7O<YKZ,:O9Z=K/YWTZ/YW]%_A$E.9]
M4V?]DW4*["7CTF/:;`Z2!5T^K=^GJHL^GC_Z-=-T`@]$P2-/T%>G]D+GOJS5
M_P!D3LBH,;39C7,+&&LP]AP'';]D_5W>VW\Q=%T$%O1<)IY%+`>W9)3_`/_6
M]$Z_C,R.E7!P!-<6L!X+F$.:RS1WZ&W^:O\`8_\`066>Q9)S,W$W/^QY(MQG
MO+12QUS'A[W/MQAZ/JUOQ]X_0V;JLG!_1U_9_3KO9;N6U67Y5E9OLKJ%;?T;
M-@!+O4!=N=6ZW=HWZ-BJU876"U^SJ+6M+[-@]!AB7.^F6/:U[OSG_P`W[TE.
M>>K68G0K:QB9%O4!O-='V7(=7ZMCGW4LMN=0*/18YWZS?ZGI5_Z3^;6;17U.
MYU;>D?6&K.R`Q[FX?4<<,:ZUEC;;]KL7['G8S/59O]"UF3^@_P!)2NFJPNLA
MX-O4FO8`9:VAK3/YIW;W^U!ZMTOJ&?A/Q7/Q[MWT2^LM(_>G=]J:[>WV?S3$
ME./D]>Z_TQH?U?IUF'52/2.;BN^V8<!CC]INH;Z6?BT-?M?;;;4_]%3Z7^'6
M[A=;Q<P-<PA]%L>C>PA['26^W?4;*_:ZST?YSWW4Y?\`@\9ZY?&S/K'TG.IQ
M<QME0L('K,:ZS#/^`IJ.)99D64OVCU?\E9E-..S]-D8/IU6*1HZ+E-;EXS']
M`S\U@>RRJDVXF:'-LWL&$^MC.H;V67^RS$P^JV5_I:_U?Z:4V/K#9A9O5JNB
M8M?V@W,+^H5UEI+JMFYF)C/M<QE67=4Y_P#A\>O%Q,K+R/Z;FXERLXM&3TWJ
M-V?EFDXF/5Z;<7'AQJL<W#KPL#$J]&KVM_6JL?T[/TS\O^;_`$_I40Z;T7I[
M,JUN57D8ME]1;BWNL=7=8#^ES,VS)QW5^AU/)?\`I,FMOI?JM-'YE-M..V*,
M[J>78*/=7CA[G=1:\-;D6N9537[&#UL&_P"SM]+UL?\`[3/N]'TOMF/DI*0?
MLWK74LVW*:ZNIN,ZQE./6[TC2]PV7OZ=U"@/:^ZOU'?;/M6#D8]V;ZN(_P#[
MK9IS&N!KS0+\0&^H8V4QN.VIM=;,;*PJ7-L<ZBK[+<^W_NKA4?;LW+^T49E-
MFMC79'2\^JH-W8Y;Z55@:`6^EM=9@G]+[J<2G?7C/]6KIF!^D^W7]1ZM_.7\
MAO1+WU=3=>,6VZRO>\`%GJUM+Z7Y`OJVL=Z-FW&R,EE7\]B>G^EMQDE-5E=;
M\RR_IV)E,L%8MIR0UC_3MNMOR<VB[U<ECMCKK=F;T[V>GZ7Z/T7UXMZU:^LY
M`8S[1TW+KNC]*QC66-:[^3;79ML9^Y_X)Z=GZ-9#NC754>MAY9(NK:*;:[&,
M;;9MN]$[-GH?1KP_;C^A0_\`3^G332@YI&#>^K(ZJW&G5K;LNACBTNO;4[9:
MWV;V-P_H?3]2Q)3N7]?;CUNMNP<QE;`"Y_IM($G9VLW*OE];J=G8%+L3);=O
MLOKK=6-SFLKMHL]/])[7M=D5_P`Y^8L.UU%POKMZK4_&%8-M;\S'(`!Q_==+
M'[&?TIW_`%K_`+>JY#+OVUTE_P!K%N-D56LQ\QEU3K38YSJ!5C7T^_T=_HUW
M>A4^EG^'OI24V\C,ON8YGV.^FG'MON.:XUBD^MU"K;4S(HRZ_3OIV6_:J+;\
M2[']']+_`"]3IF8Q[\ZEA<YPPV/=<UX<UA;Z[?2?<S+NL];:YMO]._F_\/4J
M^+]7\_&BO'NNQL<[G/\`2LJ8`2[%+[-E;-OJ6MLZAZMFSZ=%?\A0^K37$]0L
MR7C[?=0?4H=:'Y#`'76?IL1C+7T[VY%-S=U.5_/_`/6$E+]"R8^L#*G$GU6Y
MNTESG&6,Z+I-E^8[Z.__`+4+H.C&.CXA:)_0L(`[Z><+F>F6._;^"ZPQ8_(R
MJ_T@=6X[L3!O_1U''PO]'N]-]'_"?I%TO0B3T;#)$?H6:?))3__7],K=.?>R
M.*ZC.D&3=_Y%3Q6[:G#;L_26F)GFQ[MVO[_TU!MP_:-E!:^32QX=L?LC=8TM
M^T1Z'J?\#N]7\]3QF[:R-GI_I+#M^+WNW_\`7/YQ)2L=KFOOW/#MUDM`,[1M
M9["C(-`8+,C;NDV#?NXGTZOH?R=NU&24PMJJNK-5S&V5NT<QP#@?BURQ;Z30
MQV'Z=N3T>D`6$$^K2X;?3;B/9&1;5B?SWJU.^V8MWI?9;LA_J4XFM<][W?9Z
MCM>0'/?$[63\6^^S:]E?_;B)55736VJL;6,`:T>`"2GGXM<</HW4#]NZ?D/:
M[%S8]1MU-50NKIS[?<W[79>SU?4;^@S\?_KM*ETW(R>F9SNFY>^PN=(NB?5#
MR2S*9M_/<[]'EU?I[?7_`$GI8/3*L7UX?6+I5U0&?B/L]*HEUF&VPUTN-C@^
MUUKO^TS76?K'V^G]-TZ^K[;_`*96+:#F-_9'526Y303@YP@^J`WW%WLKI^T;
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M/\QAC]7,`YPSP^YN0"PN(L.UPK+'UUOK_F]FZK]W>_\`ZW3Z<.FXEO3J<CI;
M`78F/2QV,\5>G]/UFOJF@>E8^OTJ_P"8I8_]+_PB2G`Z:YHSL6QA]K<QVXM;
M66^ZGIN/M>_'?<S']UO^#?\`SOZN_P#GGKJNC0.E8H''IB(7,5-`S\8N@D9H
M#?5]2M\FOIG\U5D,J?8_;O\`9;_@?4M_G*EU'2`X=.I#S+F[@3\'."2G_]#T
MYM=?VRRR!ZGIL;.DANZPQ^]MW)\:?3,M+?TEFAY^F_W<-^E]).UC1E6/'TG5
ML!'D#:6_]6HX@BIPEQ_26GW\ZV//^9_H_P"0DI:NZO[790VMP>?>ZP#VD@5M
MU=_I-I8B7V^FR6C?8=*ZY#2YT3M&[^3[U2M&57EW9@;6ZNK]&&.AKBPMJL>]
MEL6.W;]S68_Z*NS_`,$5JBLN?]JM867.;M#'$.V-G=L&WVM>_P!GK['/]_\`
MA+*ZJDE)*V%K?<9>[5YXDJ:222E+)SNG-;C68K\?[;TFP19AQ+Z@"'-.)JW=
M54]OJU4M=Z^-_P!H?YO'Q5K))*<:B[/8PNQ[!UC"A_J5.V5Y;"0-E'N]#&M_
M<?7F?8[J_P##77VJI6SH`M:RB^WH^07-#<>X>BTNAEC:\?'SZW8UGI_9:O\`
MD[]'^@_G%MY73\3*<'V,+;6B&WUN-=H'[K;JBRS9_(W;$/[-U%C2UF4V]AY&
M34'.\V[\=V,S_P`!>DISV]'MNI_5\VEU5C(8YE;C[8IKD.JR65N]F*SZ+%(]
M!SG!X.8SW@C^:?IN.2Z6_K/TOUUS?^M(@Z4P6;_V3T_<06NL!AT$[X_H?YSO
M?]-#_8F-`:.B=-C:602(#''>YG]"^@]WO>Q)2[NAY\RW,J$.W#]#9,^I7?\`
M2&7_`,#L6+U'H6;7U_I'ZPZQUE.5CG(:VT-K:65CW_I;'>I8[Z'ZWB_I/],M
MD]$QRXN/1.FDD@ETB9:-K'?T'\QOT55NZ'3]NPJ_V;@48_Z868[*VO;8"`]K
M39]A'I>_W>GOK];_`(3TTE)\GIO4F75N&2T@D.)%5FQNQ]%VZYS\YNUOZO\`
M^?4'%Z;GGZNWXF!;6*+:K:Z&NJ<'OEOI>NVQM]5=7VRT/RF/]/\`[4>HK#NA
MXKBX.Z'TUPW;A.TR1]%Y_4OIHC>B83&,<SI&"VP-+"T0`UKY-M37?9OYISO=
MZ>S8])3EVW8Q<RW$Z=5A8V/;3=]M'I5L=0+JOMC+_:S(PGT[6/LQ[O0MLR<+
M(H_F\;]-T'21;^SZ3:QU;W[G^F_1S0]SK&-L;^;8UCOTC/WUGLZ)74^H8W2N
MGXC66UV&RN-S0QS"?3K;B,;ZGIU^FQ_J,]-;B2G_V0`X0DE-!"$``````%,`
M```!`0````\`00!D`&\`8@!E`"``4`!H`&\`=`!O`',`:`!O`'`````2`$$`
M9`!O`&(`90`@`%``:`!O`'0`;P!S`&@`;P!P`"``0P!3`````0`X0DE-!`8`
M``````<`"`````$!`/_A&`5H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O
M`#P_>'!A8VME="!B96=I;CTG[[N_)R!I9#TG5S5-,$UP0V5H:4AZ<F53>DY4
M8WIK8SED)S\^"CQX.GAM<&UE=&$@>&UL;G,Z>#TG861O8F4Z;G,Z;65T82\G
M('@Z>&UP=&L])UA-4"!T;V]L:VET(#,N,"TR."P@9G)A;65W;W)K(#$N-B<^
M"CQR9&8Z4D1&('AM;&YS.G)D9CTG:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P
M,B\R,BUR9&8M<WEN=&%X+6YS(R<@>&UL;G,Z:5@])VAT='`Z+R]N<RYA9&]B
M92YC;VTO:5@O,2XP+R<^"@H@/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70]
M)W5U:60Z,#DY-3!F.3@M8F8R8BTQ,64T+3DP-#8M83DP9&4W8C@X8C8V)PH@
M('AM;&YS.F5X:68])VAT='`Z+R]N<RYA9&]B92YC;VTO97AI9B\Q+C`O)SX*
M("`\97AI9CI#;VQO<E-P86-E/C0R.30Y-C<R.34\+V5X:68Z0V]L;W)3<&%C
M93X*("`\97AI9CI0:7AE;%A$:6UE;G-I;VX^-3@P/"]E>&EF.E!I>&5L6$1I
M;65N<VEO;CX*("`\97AI9CI0:7AE;%E$:6UE;G-I;VX^-C0V/"]E>&EF.E!I
M>&5L641I;65N<VEO;CX*(#PO<F1F.D1E<V-R:7!T:6]N/@H*(#QR9&8Z1&5S
M8W)I<'1I;VX@<F1F.F%B;W5T/2=U=6ED.C`Y.34P9CDX+6)F,F(M,3%E-"TY
M,#0V+6$Y,&1E-V(X.&(V-B<*("!X;6QN<SIP9&8])VAT='`Z+R]N<RYA9&]B
M92YC;VTO<&1F+S$N,R\G/@H@/"]R9&8Z1&5S8W)I<'1I;VX^"@H@/')D9CI$
M97-C<FEP=&EO;B!R9&8Z86)O=70])W5U:60Z,#DY-3!F.3@M8F8R8BTQ,64T
M+3DP-#8M83DP9&4W8C@X8C8V)PH@('AM;&YS.G!H;W1O<VAO<#TG:'1T<#HO
M+VYS+F%D;V)E+F-O;2]P:&]T;W-H;W`O,2XP+R<^"B`@/'!H;W1O<VAO<#I(
M:7-T;W)Y/CPO<&AO=&]S:&]P.DAI<W1O<GD^"B`\+W)D9CI$97-C<FEP=&EO
M;CX*"B`\<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TG=75I9#HP.3DU,&8Y
M."UB9C)B+3$Q930M.3`T-BUA.3!D93=B.#AB-C8G"B`@>&UL;G,Z=&EF9CTG
M:'1T<#HO+VYS+F%D;V)E+F-O;2]T:69F+S$N,"\G/@H@(#QT:69F.D]R:65N
M=&%T:6]N/C$\+W1I9F8Z3W)I96YT871I;VX^"B`@/'1I9F8Z6%)E<V]L=71I
M;VX^,S`P+S$\+W1I9F8Z6%)E<V]L=71I;VX^"B`@/'1I9F8Z65)E<V]L=71I
M;VX^,S`P+S$\+W1I9F8Z65)E<V]L=71I;VX^"B`@/'1I9F8Z4F5S;VQU=&EO
M;E5N:70^,CPO=&EF9CI297-O;'5T:6]N56YI=#X*(#PO<F1F.D1E<V-R:7!T
M:6]N/@H*(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2=U=6ED.C`Y.34P
M9CDX+6)F,F(M,3%E-"TY,#0V+6$Y,&1E-V(X.&(V-B<*("!X;6QN<SIX87`]
M)VAT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\G/@H@(#QX87`Z0W)E871E
M1&%T93XR,#$U+3`R+3(X5#$T.C4R.C4P*S`U.C,P/"]X87`Z0W)E871E1&%T
M93X*("`\>&%P.DUO9&EF>41A=&4^,C`Q-2TP,BTR.%0Q-#HU,CHU,"LP-3HS
M,#PO>&%P.DUO9&EF>41A=&4^"B`@/'AA<#I-971A9&%T841A=&4^,C`Q-2TP
M,BTR.%0Q-#HU,CHU,"LP-3HS,#PO>&%P.DUE=&%D871A1&%T93X*("`\>&%P
M.D-R96%T;W)4;V]L/D%D;V)E(%!H;W1O<VAO<"!#4R!7:6YD;W=S/"]X87`Z
M0W)E871O<E1O;VP^"B`\+W)D9CI$97-C<FEP=&EO;CX*"B`\<F1F.D1E<V-R
M:7!T:6]N(')D9CIA8F]U=#TG=75I9#HP.3DU,&8Y."UB9C)B+3$Q930M.3`T
M-BUA.3!D93=B.#AB-C8G"B`@>&UL;G,Z>&%P34T])VAT='`Z+R]N<RYA9&]B
M92YC;VTO>&%P+S$N,"]M;2\G/@H@(#QX87!-33I$;V-U;65N=$E$/F%D;V)E
M.F1O8VED.G!H;W1O<VAO<#HP.3DU,&8Y-RUB9C)B+3$Q930M.3`T-BUA.3!D
M93=B.#AB-C8\+WAA<$U-.D1O8W5M96YT240^"B`\+W)D9CI$97-C<FEP=&EO
M;CX*"B`\<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TG=75I9#HP.3DU,&8Y
M."UB9C)B+3$Q930M.3`T-BUA.3!D93=B.#AB-C8G"B`@>&UL;G,Z9&,])VAT
M='`Z+R]P=7)L+F]R9R]D8R]E;&5M96YT<R\Q+C$O)SX*("`\9&,Z9F]R;6%T
M/FEM86=E+VIP96<\+V1C.F9O<FUA=#X*(#PO<F1F.D1E<V-R:7!T:6]N/@H*
M/"]R9&8Z4D1&/@H\+W@Z>&UP;65T83X*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@"CP_>'!A8VME="!E;F0])W<G/S[_
M[@`.061O8F4`9$`````!_]L`A``!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`@("`@("`@("`@(#`P,#`P,#`P,#`0$!`0$!
M`0$!`0$"`@$"`@,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P/_P``1"`*&`D0#`1$``A$!`Q$!_]T`!`!)_\0!H@``
M``8"`P$`````````````!P@&!00)`PH"`0`+`0``!@,!`0$````````````&
M!00#!P((`0D`"@L0``(!`P0!`P,"`P,#`@8)=0$"`P01!1(&(0<3(@`(,11!
M,B,5"5%"%F$D,Q=2<8$88I$E0Z&Q\"8T<@H9P=$U)^%3-H+QDJ)$5'-%1C='
M8RA55E<:LL+2XO)D@W23A&6CL\/3XRDX9O-U*CDZ2$E*6%E:9VAI:G9W>'EZ
MA8:'B(F*E)66EYB9FJ2EIJ>HJ:JTM;:WN+FZQ,7&Q\C)RM35UM?8V=KDY>;G
MZ.GJ]/7V]_CY^A$``@$#`@0$`P4$!`0&!@5M`0(#$00A$@4Q!@`B$T%1!S)A
M%'$(0H$CD152H6(6,PFQ),'10W+P%^&"-"624QAC1/&BLB8U&50V160G"G.#
MDT9TPM+B\E5E=58WA(6CL\/3X_,I&I2DM,34Y/25I;7%U>7U*$=79CAVAI:F
MML;6YO9G=X>7I[?'U^?W2%AH>(B8J+C(V.CX.4E9:7F)F:FYR=GI^2HZ2EIJ
M>HJ:JKK*VNKZ_]H`#`,!``(1`Q$`/P#?X]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
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MH+Y,;9J=G]R[`F[,H]S;:_TC4_9V$PN.R/:F\\QL[&;+SM'F<]1XO8V/V57X
M^#$XF.H;^%4<:4[CR(Y/NO=6H^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z__0W^/?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=$$_F:_(7>7Q6^'/:/?.Q>X>I.CL_U]3TF6I]\=X]3]C]P]92$
MF:&FVSN/;O5>X-N;NPR;IR4E/119B.::'&S2J\E/."(V]U[I+_RC/DI\E/F#
M_+W^/7R5^6>QMJ==]S]N8C=.YLGMG9N"W/M;"IM;^_&Y<=L++Q[;W?79;-8>
M3<.S*&AKPC5E7%/%4)41R!)A&GNO=61^_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z__]'?X]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U0O_P`*0MA9/MW^6+O#IO;G:O5/5N[NTNX>F=O;9_TU
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M]U[W[KW7O?NO=>]^Z]U[W[KW52/\Y3^5PO\`-O\`C7UY\9ZWN2?I#`;<[XVY
MV]N3==%M)-Z92MQNV>O^S-LTN#Q6'GS>WZ/[NIS>]*29I9J@(E/!+96<H/?N
MO="!_*7_`)?%?_+`^&VVOA_4=NTO=N+V3OOL;<>V=\Q;`CZYKY<!OO<E1NJ/
M%9O"1;HW>E9EL;D\E5*U8*RTD#1((T6,#W[KW5EWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z*-\SOE'E/BCU=@-Y[5Z?S_`,@M_P"\NQMI=:;!Z4V;O;K[9.^=_9W<
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M#N#"[JSG7&;R=(E36;3RNXMN_P"X;+5V)=_')+`$4L+%48,H]U[H5??NO=>]
M^Z]U[W[KW7__T]_CW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW1$OYF?VM!\%/DKO/
M)]T_([H+!=5=8;E[DW-V)\3<IL_"]]4^V>I<=/O_`#N"V+E-\8K)X*EK-R8W
M`24<FIZ)GCE*&K@1G;W[KW0E_"[8R]?_`!AZ>P\7</?G>U+E-H8W>5!V3\G-
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M\^$-=3])]&=M46S_`)=;7W)F-P]N9NGQ&[>G:*@ZZ[(J:/L?HV">:@.:[+H<
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MAF0U#-D*JG58`Z$:SZ;@B_'OW7NBC]O?S*_Y?/06Y8MF=S?-'XT=<;OGPL6X
MH=K;H[BV10;AEPD_\1%+D8L,<P^0D@K),34)!:,M/+'HC#.RJ?=>Z*Q_P^]_
M+5S1>DZI[6[/^0V?_A3Y:':WQU^,?R4[DSDL310FAI9O[G]4UV*Q%;E*NK@I
MH5R%52(M141B5HE;6/=>ZGXS^:#W+V-A,G7]&?RF/YD.[LICZHHE#V_LWHKX
MNT%=0&LCHH<G1UW=?>6"RLR5#NSBF&.-;%#&SS0QC1J]U[J;NCY$_P`W7.=0
M=;;KZK_ET]&[8[5W-N/=\&_^L^[_`)A8>%.N-JXV7#OLO)/GNM-B[JQ&YLMN
MJEJJQ:NGI*FV+FI5YJ$D#>_=>ZQ8O9G\\/=^4VM_>_OK^6MTQMN>0U6\(NM?
MCU\A^VMW8VGGA$HPV#K]^]Y[+VYF*O'R_P"3_P`0EHZ*.8DU'VB@"F;W7NF[
M??P3_F0;ZBEH_P#AYOMO9E`V1J<M`VP?B!\8-O9BDF*545!B8\O-A\E]QMFE
MBK7,M/40S5E1)%`YJT\;"7W7NBZ[D_E%?S$LY#G8:?\`GT_,BA&Z,%B(,ZR]
M1=/0"/<>%JGDIZ_:ZX1L')L_`UE)D*V.JH:.02U324[3U,RTD2>_=>ZDXO\`
ME4_S/:JIKZ#?'\^WY,Y;:&Y\/MC#;RH=D_'#HWKO=S08*-/NJKK?>5)-FQU5
MDLA4-(9*JAH:BIJ8BL=0\I577W7NA!E_E>?.B?=%;6_\/:?,ZCVIE>O\/L+*
MX;'==="1YF9<9M_%X.;<^*S%?LS)4.V]ZY&;`TM9/F:&BAR$M3)5L9-=7/(_
MNO=*W`_RP_E5ALAM+)3?SG/Y@N3FVEMG<.TJ>*OQ'Q?KJ+)XS,'<<E!EL[CL
MOT5E<=N+>V'EW#:/-9.&MK?%2P)&8?#"T?NO=!CD_P"6'_,<P.4VI+L+^?#\
MIL;MVAJ=T8W<&,[4^/\`\<>R,GEL+NV&HA\6&ST.$V8U+NG%F4''5V0@RHH9
M@LE)#`J>%_=>Z!+>7\O'^91MGMOHGK?:'_"BCLW`96MQG9V9H>O^U.B^A]S]
MK;XPE'C81N3/[>V]#F=NOV9BMJ5N8H(Y7RE+4P[<6I2:&99)(H3[KW1N\Q_+
M*^55%TKT!U7UA_-S^9>S=U=5=C;I[3[/[IWA0;+[?[$[YW%FXL4N`VYN+^^2
MK@MO=5;*:AG2DVK'2UN(JX:H_>QU,Z+4>_=>Z"C-_P`J7^8CN&FW'19#^?#\
MOH:3=6?&<RB8CHGX]X6>C"949F#'[7K<=B(:W9U'3UO"18R2FIO`%@,)@41^
M_=>ZR9[^55_,)FR.=S&V_P">9\N8,GOO:S;'W\NYNF?CYF,%_=]L9/C3D.N]
MMXK:VW\9UOO&-)B\>7QPCKDJ':;RL]A[]U[K--_*V_F0OBL%BJ?^?'\K**/"
M[7_N1)/#\=/CM-69/;4%&M/15M?D*W'U65JNP1,\K5.Y9JB7)U"^.S1R1F:3
MW7NBO_-;X<?S'_BUT9M;O3;G\]KY'4N4ZP[`ZPZYGK^S.C_C_DMF3;)^07<^
MP.J-Q9/=&W,7M2EB[`WKMJHWE!6X6LS1K9:1*5J2D-(:EZA?=>Z.7-_*/[U?
MJ#JK9,7\WW^8Y3=J=6;_`-Q[LIN[TW]M*HRFY]M;PH::AS_7^[]CUVW:K:F[
M<)0LDU1@JC,+DJK"3SVB:2".*!?=>Z)5\T/Y&V#Q?QH^3.Y-_?S,_P":KV=T
M?L7XS=Z;T;HS>ORDR&Z,=G=[XGK892LSFZ,Y68>.LWMMK(Q[2=FVOD89,2M1
M62?;_;PM+!+[KW0E?%O^4I\K$^/?QWFQ?\[?^8EC-J'I+K2OH-NXZBZ5B_A[
MU>R<=4XRBQM?NC96],O3;;Q<<]-%%CJ^JRLRP0-&U6Y<2)[KW0N;Y_DZ?*+<
M8SU-M[^>%_,XV_C-R4VV:C)T]?N7J?(5\6XMOU4+5%?@<OMG8.Q:G:6`RM`)
M8Y<5BEHXIIW6:JEJQ'XF]U[I*R_R</G3*FX8O^'[?Y@R1[FBIX*\1[?ZLADI
M(J6F^TA_N_-!20R;3G,(!DEQ)H7FE_=<M)ZO?NO=.E;_`">_FWD<;E(ZG^?#
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MM+:7R-DW'O\`[?R>;R=)G:Y^ZINPMN;MPN]<;1YFB5\?C/M*?$8^EDGI(Z0T
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M[,%@,_LG`UN*W1TGAL-3;'S%=2545!E=K5G5&>P6?W;$F/@^XW!41'(SRQ!X
MC3CT#W7NA9D_E*[XEVCU%AD_FL?S1L;N[JC;6X]BS=C8CO'KR//=B[(W)N"3
M-O0]B8C,=19S:^X-W8""5J/%[F:C7.TT`3R5$[0P&+W7NE5U+_*>Q73V^^O-
MUX;Y_?S,=S[9ZUQO8B8;JO?7RCAW#L',;G[,PV=QF?WKO-%V%0[FWMF*/);B
MGS&.I,ID:O$8S,1PRTM'%#&:=_=>Z+%@_P"3'\N=IXY<+MC^>O\`S+8<1@=R
M5FX-B1;HR76&^LIC$J!!2P8W?.?W1MFNR_9F.I\93JAHZR2GQAJBU2E'&[N&
M]U[J/M+^3!\P-K5"Y'_A][^99D,I39V?=-`U9D.M<MAAGYI#QEMO;LP6ZL=G
M-L"`Z3A)K8O7ZUB7]/OW7ND)OS^79\NNF:K;4W:?_"A/Y@X;;79WR5Z[INM<
M)N+K?J^@J]R]P[MK%BV[U55;JV^*3/5.SMZ96CJ(HMKXUL)MF.G;QFB+()6]
MU[H"?FC\:/Y@_P`7^C]\]_=Q?\*'NV.L%RWR3V!E<:N,^*FS<YU=M;,[O[(P
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MVT=&U)_PH`^>\=72T$6):6NVELS(4LF.IJ*6BI6%$-QTM\RJU,C2Y&62:LG;
M0S/Y(TD]^Z]TW[8_D@?/K:F0VU4X_P#X4"_/RHH]L5^1KJ.CR^V]M[C>H.;I
M)Z/+QY-]T[QSM!G8S#62FACR=+7P8QS&]/&LD2./=>Z5R?R;OY@,.%PN%B_G
MY_.(Q8W?5+V/55-3UOU;5UM7N>BRM3G::EBKYZYLFFR#EZDM-MJJGKMOU%*J
MTLE(:=$C7W7NG_,?RG/YD^Y\)N';FX_Y^?RT;%[AS>&W.]7M7X_='[$W/09S
M#)5RQT^+W3M>IHLEA]GUN1J5EJ<)0?9T-5#$L$PD07]^Z]TM\_\`RB/D=G=[
MT>YH_P"<U_,>P&!W#E-J;E[AVIMO=/7N*CWCN?;>"HL;55/764CVH[]([8S^
M0IGGJ<#BX*K%-3N(3$TB?<M[KW0_=P_R^N]^S6^:60P7\R7Y<==Y?Y/TO7]!
MU/1[7R&V*+:'Q+H-AY;!YF6+J7;U'CZ.IDR&]'Q,U#FJYZRFJ:[&5LL;EJ@"
MJ]^Z]U7=G?Y0O\XO,J2O_"A/NNBFDVQ'M"5:'XO;,QE",/'CJ>D6JAHL5V90
MR1;O-4:B:7.^8Y&4R)I:+Q*/?NO=%>[P_EC_`,S/`?+/^7-LC)_SS-][USV$
MK^[MV=+CM3XR;/W#3;:WSU)U+4+#N7+;0IM\-A^Y]P5>VM]Y6AJ,UN9XZK%T
ME1>FD:>98G]U[H_&X/AU_P`*"<KA\O@:7^<%\;*%)X::FQVY\?\``C;6)W.R
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MU/B<=-EZNCCKLG40T\C)!$6E=48A2`;>Z]T6S?\`_,!^"W5>'7/]B_,;XQ[.
MPS[C@V@N0SO>/6]%3G<\]7241P=WW&6&0I9JZ-JF,B]+"3--XXD=U]U[HI^X
MOYZ?\JC"YNNVKA/EWLWM'>-'D8</#L[I#;F_NZ]R9G,2BNE;%;>H>L=J;H3.
MU]+2XNIGGCI9)#3T\#R2:5L3[KW2,[%_G/;<P&[I-A]1_P`O'^:GW_N*7<U/
MMO$9#:OPA[-ZWV#G/(\J3YJE[![TBZQP6.P-/XB159#[.&4$,K&,Z_?NO=&$
MZ6^3_P`Y^[<EVU09?^7/N+XM8;;_`%AE,SU!O+Y(?(7I[+R]B=L3T[?W6V7G
MM@?'_(=N9/9^T6GL^6S$F4DJJ.*R04-3*66/W7N@.APG\^+L>OSSYG?'\M'X
MO[4S%1CJ#$XS9NUN_P#Y*]E[2Q$U12T6?S=%O7=E9TUU_E=T4E!]Q78I*S:T
M^.:J\5-5P-$))F]U[HP7<7Q#^3W:N_\`<^3P7\R?Y(=,=49_8NW-OTG6O5/6
MWQBI,Y@=WXRAEH,]O3%=G[OZ7W=NBF7<SPTU8]$BJ*6M^X\,RTLT=-![KW06
MTO\`*-ZHW)M_=FT_D-\K?YAORPVMO<2IN7:O=/S'[)V[M.NB>6DJ8J2+:WQY
M/16"HZ"CJZ-9(H(X!'=BL@D6P'NO=)[:?\A/^4;M/=";O_V2O8&]LU!`M-1C
MN#<W97>&*H(%1U,5%@.X=[;XP<"L\KRG_)R?/(\HM([LWNO='ZZO^)?Q9Z2C
MDCZ<^-W1'5@GCHXJE^ONIMA[0GJUQ\T%11&MJ<#@:&HK9*6II8Y4>5G<2QJ]
M]0!]^Z]T/L5/3PW,,$,5[`^*)([@<`'2HO8>_=>ZS>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[JBO^>U\2.VOGGT[T%\4=FX/=^.ZPW;VQNSL
MWN#NK8FU]M[NW3T[-TOU!OK=W4;8;&YK<6&RM'5]A]I2T&%:KQ,%771T\LL0
MT).PE]U[HNO1GQ\[#Z+_`)@G\C[J+N'(;`KNS.COY8WS,P6[Z_JZ&KI=D97=
M>)R/QGVSEJG!OEJ?'Y+)4=4FY#.\SP1/457EJ?!"LA5/=>ZV7O?NO=>]^Z]U
M[W[KW7O?NO=%B^9/Q7V?\U?C=V1\:=];O[#Z_P`!V''M:H7?'5.?@VQV%M'/
M['WKMSL/:&X]KYFKQ^6HZ7(X;=NU*&HM+32I(D;)8%@R^Z]U3?U9_+#^7^\]
M_=Q;7[*_F?\`\X#9.VNN=S4>$V?O[(]S_'#%X3O.@W'B,3G,ANO8>'V+L'/Y
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M08O</5ORS^&&^L#+)2-+4SY.E^1^P,''38_)Q34]5MZI,&=D=ZR%UE-.DL`9
M1.6'NO=:GN[_`.5GV_\`%BL[\[SPFX=F=P]$4G\QSX/3=BYOMOI/Y%=1]IMV
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MNG_/_P`[/XU4>.VY4;*^/'\Q3MS,[AS.;QAVAU[\`ODE%N;"X_!PO))NC,0;
M^V7L7%C;>0G58*62EJZJH>9[-"BQS-'[KW2U7^8#\IMS0YFDZX_E*_-"ISIW
M+A<;LP]M[Q^+_3NT<_MJJ=?[P;MW)N*;NW>.:V.F`ABE:/'S8:KKJ]F@6-%,
MDQIO=>Z0U3\D_P"=#O6JJ:38?\LKX[]1X[(5LT>#W%\@?G9B<I78>@I():@5
M>[]G](=0]AQ++EVT04\6-R]<T$NHSZ4LX]U[K+F=G?SW-^5]>M/W1_+0^/&W
MLGBZ'%T\.VNJ_D)\A]W;9JI<`8<WN:DS>Z-U])[=SF4BW)$)<=1SXF&CAI9R
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M!H\A3T])52PB*HBEE18*Z&HI76IA1HFU(2JN2I#`$>Z]U/\`?NO=>]^Z]U[W
M[KW7O?NO=<5='OH=6TVOI8-;4H=;V)MJ5@1_4'W[KW5"/\\+X([V_F09KX$_
M%49'NS:_0N].Z.Z\A\A>P>GY?#3["Q6"^-G8M=UAF=[FHIJ_#SX2L[47&T:4
MU=!X*TSO3)-33RPS+[KW0.=._&W=7P[_`)G'\G3H;(0[G[,BZH_E1_([XY9W
MOJFP6XL9M#<U7UOG.D*ZB>3'MF=STVVJZ+^$^22"MJO';,TL4<\SQPQQ^Z]U
MLI^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NB6?S(XLG/_+R^=<.&R%#BLE)\
M/ODDM/D<EC*G,45*/]#N\?/)-CJ3)X>HJ#]OK"VJ(PCD,P=5*-[KW3+_`"NJ
MS.UW\MGX#5&Y</\`P#,GX=_'*&IQ%Y2U)#2]2[4I<>)?.D<JSSXZ&*212!I=
MR!P/?NO='M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW5)__``H5V;F]Z?RL.XZ?;V.KLQE=O]K_
M`!/W=#B,9B,EFJ_(P;?^573=57P04V*IJNH@$=`999)VC,,,4;-(52[+[KW5
M!?S1_E@_(;^7E\8?F1\A=Q_-'M7OSX^=MY#X.Y'K7ICM;([XIJ[JWN^N_F$=
M"=A-5Y38.1S^:V7A]J[0Q/W5!1&"6:K4Y*HAGI"(UEE]U[K>D]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U4S\R#EX_P"9W_)O
MDHC3IC)-U?.ZBS#-5BGJI8IOB?DZRDIHX?'>NIS6XZ.1X@]M4:2D?M`CW7NK
M9O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=?__7W^/?NO=>]^Z]UAGI
MZ>JB:"J@AJ86*EH9XDFB8HP="T<BLA*NH(XX(O[]U[H&=Q=N;?V9W9U-TB^T
M-Q/E.WMK]I;HQ&[L;B:4;,PIZN&S&R.#SV4$\<U-N#<--O!9L=`D3B:''U3,
MR^,!O=>Z&SW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW0;[([,ZYWUN?
MM?:^RLU1Y/<_4N]L=LCM2AI\=74-1@]Y9'8>S]]8VAK:BLH:2'+R3;'W=B9T
MJ:9ZFG"R>`R"6"6*/W7NA(]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7KV^OOW7NL<
MDT4*2R2RQQ1PQM+-)(ZHD42J6:25F(6.-54DDV``]^Z]T6#M+YO?#KI/!YG<
M7:WRCZ!V)BMOY"HP^8FW'VUL7'2T&9I)I:6HPU12SYU:F/+PU4#Q-3%!,LJE
M"H;CW[KW57W9/_"F+^2UUG6SX^M^8^&WA408K^*ZNM]@=E[[HI@\5>\&/@R>
M"VE48QLK--0B+P&8-"\\33&.)C(ONO=%:R'_``K9_EIUV)_B?5G5OS;[L>/6
ME=3==_'NGECQ%18FFI,K7Y[>^%HH:BM"EHQ$\PT(Q8@@*WNO=!7MG_A1O\Y/
ME!B,H_P._D<?*CM)Z.H>B_OKV?N:79FQ\?6)45(%-73TVQ?X14U+4<&MHESL
M#I-JB]0`=O=>Z0W9?S6_X5P=@555M'K/^6+\=>BY)@:7^^TF\-@[X;&-/$TT
M.1H\AN;Y`5FW:E8839E.)J[3!`T8(:-O=>Z+S1]5?\+3M\99VR'=?4G6JLL9
M5JVL^+$.%+/'9T2/;&P]XU<9@%/R6C4,TG&JYT^Z]T8O:O\`+O\`^%6&^Q15
M?;'\W+I;K..*E$G\/V#M[&YO(FJGFH?)2Y),7T3LK&/%2T\<C++'53$RJ8PN
MB5I%]U[I+]H_R>O^%*U5D,'CMB?SO7W1MO(9"BCW)D\]E-\]6Y[!45'*THK<
M=2[/VSNHYRZS2WIC7T0G?1'*QC_<C]U[H,^Z?^$PG\T[MS9IK]R?SR>X.RM_
MUN!DQV7V=V95]YKU]5F2I4-AX]PT7<>X*B'!S4R>60';LH:<Z3&1>4^Z]U67
MN?\`X2T_SW^L=T568ZE^6G7^[:RKQ-'DJK=FTOD_W/L+.5F39X\#+@YWS>VL
M/735U#A7U^9ZC[5J%&B63R:(']U[HC'S4^!O\]W^5QLC;/R/^1OS!WOU]MRC
MW]A=M;&W3M_YN[[W#F:_?M=!6Y''T&W<%3YW^.U-2F(Q595SNU*M/'1TLOE;
MU*C^Z]T>?H(_\*E^Z=H_'ZNZF_F&8+/X?Y(;/W=NWX[)F_D_T16;L[=VSUW-
MCDW[D-OT.XL=7;YRL^R6RMLO_$(TJ*!H'BJ-$OACD]U[H[VW_AO_`,+/(*E9
MC\P-O8]HZBGD4[@[;Z.S-,Q@$LRLU,.N,[%)3ET"21LEI"ZAE9`Q7W7NE2.A
M/^%KN'D&)I/DIUKF*3[HT"Y<YKX>U<<4#WR#9<SYOJFFS4E*)E^VL\+U*Z[+
M#X@'7W7N@IW%N/\`X6V=)Y65ZRFK.VZ6NA^T@J-N[7^#._L5`ZR^7[F*CP6)
MQ>9HIG2.WDJ(%CT/IX?@>Z]TC,A_/(_X4X_!EZ7<WS7^"<N_NJML5/\`'^P-
MS;H^-^X=I41VI2MD*?)4K=O],53]9[,`\+2I75>-K!#XHY&CDA>TONO=;//\
MI[^?C\+OYL0J-C]=R[AZ>^1V%PQS.X/C_P!E-0'.U^-I*>.3+[@ZYW+BI9<-
MO_;&+G9DFD5:+*4Z!9*F@IXY(V?W7NKPO?NO=4&?.'MWN3^9'VCV=_*Q^#NZ
M6V7UO@J>KV-_,H^9M'0C)8OIK:NY\5XLK\7.F))'BQNZ?D7O_;M;-#FI8Y)J
M;9N/DTU2FLG,=-[KW5X'7&P]O=6=>[#ZQVC2M1;3ZXV9M?8>V*)W\C4FWMH8
M.AV]A:5I"`7:GQN.B0G\D7]^Z]TL_?NO=4/=V?S@]Z]L=U]O?#'^5%\>LG\R
M?DAU=0287LCNS+9S&;.^'/QQWO4YR;;JX[M?L6HJ7RVZ,[@:BAK9I<!A*9ZR
MO:BDBIY2L=7-2>Z]U&P/PW_GJ]IY"'>'=O\`-PZE^.5=-A*.EDZJ^(GPVV%O
M78>-R462JJFIK&W;\B:O/[ORU74XZI6G+A*:",P1E8G/D>;W7NG[_AK_`/F'
MU56B9?\`GK?,2HQ,]3!+DH\-T=\6=NY-H%J?/5T^-K:;K:K3'R3JH6.14*0@
MD&*1/0?=>Z5F9_EF?-FJPTF-Q/\`.W^=E)4&*FABJ:WKGX@3%8Z5)EC,E5C>
M@,5F'F9Y09)!5*\P%I"Q"LONO=!]5?RPOYG,)CCPW\^7Y/I#2U%+5439?XT_
M%[(3)+*V17-QY!QL^-LO3U=/6(**.5A%021Z]$UHA#[KW0D[<^!O\S[%X&HQ
MN6_G7=OY;)00TM/B\D?A_P#$$%T5GFKYLLU5US4U-34U$NA:=HW3[>`,K_<.
MWD7W7ND[E/Y?'\UJIW#!58K^>?VQC=MT\%.L5!6?"?XE9/-M*AH_.*[(T^V<
M1AL@DBI/9QC8'O(A_L'7[KW4#$?R]_YME+E:NMRG\]#LJLI9Z7*00TU+\)OB
MM`L$E9DIJZDJ#3U>WZ^DUT=.8J<:%C.A'TE1)H3W7NN7_#>W\VT&F=/Y[/89
MD6CI*BK:7X(_%IHIMP4]/2TDDD%.D4<<&`G@A9VHR78SL9"Y+-[]U[J$WP&_
MG,"&GT?ST\F]1]P/NV;^7W\9(Z?[0&<L*:(22R_<LHB4%Y"BDLUC8*?=>Z9A
M_+;_`)O5*<MGJ/\`GU=H3;JJ*N>OQV+R7PF^-51L*.5Q^U0U>%"&JBQUY91I
MII(=`,=E)C!;W7NE'EO@M_.;CQF+H]N?SMZ9JJDJ)ZFKK=P?`/H"5ZR31D8Z
M:GJ?L,I')48T#(([1(U/*)*2/]YD9D'NO=,@^$7\]'^,U>4'\[+KM:733F@P
MS_R[NFYL<'5S]Q]X%W935+!XG(&B4`E5-E]1;W7N@=^5O1G\V?HSK2+N3M[^
M>/C=L=3[:[-Z7CWI0[%_E\=+;9R\E'OCN#977]'MF@W0G88RL>(K\MNVEIYI
M"PGEA+:ED!,+^Z]UKO=C_P`W[YX][;M_F'[!V]_-1Z#SW4OQ?[;Z-Q_7&T>T
M/@/U&V<[YVIO;Y,;#ZRSN=QVR=T8#)3XW#_'S=^X*"2>6097*Y&.FAJ8HZ2:
M6.>/W7NMM#<GQ<_G7[AWED,O0?S7/CAL;:[Q(F+VSM'^7+BJNB@>GO`DU1_?
M?Y%;OSKS9"&4RSWRTD<<\:B*-4+>_=>Z0^1^&/\`/(J:*HHZ7^<_U113!;TN
M4IOY</5RU[.<I+4@21U?:%?CHHTH7$#7@E9T4:=#_NGW7ND1A/@I_/KHLC1R
M9+^>%L"MH8E2HJ4E_EY])57GJQ+54WV?V\>8Q;-CA13I4%O.LCU,02P3UGW7
MNE<?BU_/RZ^P"R;+_FG_`!6[XW!3Y2OK#C>^/@K0[!QU?03+.M+CY,_T[V-#
M54T4)J/(B+0^19(8E:I:,R!_=>Z!$_S??F_\",WB\3_.C^&6!ZTZBS9I\=B_
MFU\-<CNSM[X^X_<=5EJR"'&=D;3KJ.LWMUE15E`\7VM16S-+,\$A%.RO>'W7
MNMB+9^\MH]A[8PN]=A;HV_O39VXZ),EM_=.U<QC\_M[-T$C,B5F*S&+J*K'U
M],7C9=<4C*&4CZ@CW[KW2E]^Z]U[W[KW7O?NO=%R^5'RV^.WPHZ<W+WU\G>T
MMN=4=9;7AO59K.SRR5N6R,D<LE%M[:V!H8JK.;KW1E3"RTN.Q]/45<Y4E4TJ
MQ'NO=:O_`'%_,)^:/SL^>/\`*\WY\/?A3%\=MB'<ORDI_C=WO_,IJMR;&VMW
M%N+.=`Y&#L(8GHCJ/-U'8N(K,+USA\O-MO(5=?-2Y^*HG$:TR+)*ONO=6@Y/
MKC_A1?5+,M#\FOY4.-\E#3F.6E^/?R3+T^1+TTM3%&F0[)RL;4L8$L2S/K:5
M;.88V:R>Z]TD,MV[_P`*!?BK0U>\>U>@OA9_,*ZWP>$I:G<&$^+6X=_=!=_H
M\,M*V8RFVMM=GON?9N^ZJEI*B9H<33-05>0:E5(/')*L9]U[JT[X8_,_HSYY
M='XSOOH'+9ZKVM/G]P;,W)MS>6W,CLWL#KOL':%;_#MW]>=A;0RR+7;<W?MJ
MN*I40$RQ.CQS02RP2QRO[KW1K??NO=>]^Z]U[W[KW7O?NO=?_]#?X]^Z]U[W
M[KW7O?NO=!-V#U32[\WITGO<YRNP61Z8W[F]Y4ZX^FII6W-CL_UIOGKW([0R
M53/>6CPM54;MI<I*8@7DJ,1`G"DD>Z]T+/OW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[J/45E)1JK5=53TJN2J-43Q0*[`7*J964,0/P/?NO=5;=;]S_&KX@]M
M_.+</R-^3'Q>Z6K.Z/D_A^R=O8G>'R`ZVVU6C9_^R]]%];X/*9W";AW!BJO;
MN;SNX-AY0O!(@,XC692P?4?=>Z%#+_S7_P"6)@\749FO_F#?#5L?2PBHFDQW
MR.ZGS,X@,DT/F2AP^Z:^OEB$M.ZEDB8`J;_3W[KW1'NVO^%,'\EKJ*LEQM=\
MR,+OS(P5=3234_4^P.S.Q:57I*RFHZB6//8#:,VV:JF7[@RQR0ULB5$,3M"9
M"%#>Z]T27='_``K1^*VZ:N;%?#_X9_.7Y>9"FK:6DJ:S9/4JX7`QM55*T\"+
M+#7;GW**NJY\$4V*@\AL-0:X'NO=-_8?\_S^9KO7;E#7_$;^0?\`,G.35<\*
MS[@[NP6\<1B:97HC6B&AV_M/9KUF86>`AON6R5''`P$;([N`/=>Z)OC.\?\`
MA9#\Q)J[=^P>G>JOA;LBNRQVY3[8W5LGJO8U=B'H)5KWS@Q?=D_9/;U30U9G
MCHS6)`:.94O'$H6:;W[KW2=PG\EC_A2WW]OOK5_EG_,_IML=85VY<+)VA_H\
M[RWJ^_\`:^U)<E_OX)MF8#;?6>V]E9'=<6+IE:F5J^GI%JGB8NXB)]^Z]U9O
MUU_PEH^,='E=R9?Y"_-/^8)\FY]P428X4N\/D'F-J4<-$&J(YHZ^;;$29G-F
MJH)A3NL]9]OHUVB&OT^Z]T).U/\`A*=_)=VSN*@W#6]`]@;U-%5S5LN&WKWI
MVCE,)DY9X)HF7*TU#N'%555$)9?-83J6E12Q9;J?=>Z//T__`"1/Y2W1<=8G
M7OP&^.PDKI999ZW>^S5[7R:F619'CI<KVI5;SR5#3AELL4$L<:*2JJ%)!]U[
MJR#9'7VPNLMOTFT^M]D;1Z^VM0`BAVULC;>&VI@*(,2Q%)AL%14&.I@68FR1
MK]??NO=*_P!^Z]U[W[KW7O?NO=>]^Z]U[W[KW7#RQ6U>2/3J9=6M;:D)5UO>
MVI64@C\$>_=>Z[U+_JE^H7ZC]1L0O^N01Q[]U[K7]_X4!]-U>Y^FNB_D.FT_
MD!V5M[XM[M[;SW9/7?QSZRZ$[CWE/U?VOT?O7K3>.^\EUS\B:/<6P\]@MCT5
M>/,1@LU5TL=<]3&E((6KJ;W7N@Q^/O5&'[A^4W\A3Y7_`!'^.>Z^N?AOLCX'
M?)Z.6IK<9MC#P=8;<[:Z\ZQDZEVINNAP66GH5W)GJ],A42344<T5945$L_E>
M[E?=>ZV4O?NO=>]^Z]U[W[KW4/(8^@R]!78K*T-'D\7DZ.IQ^2QN0IH:V@R%
M!6PO35E#74=2DE/5T=73R-'+%(K)(C%6!!(]^Z]U\^;_`(57?R?^OOC-M;JO
M^8+\".A*?I+$8?.Y[:WRIGZ,>;9NU=KIN%=MXSJO?M'L3;KT>,V30UV2ER.'
MRE9B(:.BEJ:VA%1$9IS*_NO=-O\`)\_G*?S._P"9EU9LO^4[L;>%5MWOIY,E
MD^R/YB>3K*/*[_ZI^&>UX=O8W<=3C]LU5%;=O?\`/E,S#@L3N.HJHI56NIYI
M5-<LF5@]U[K><^(OQ"Z*^$'26VNA/C]M63;^S\`:FORF8RU8V;WQO_=N5G>M
MW)V!V1NVIC3([OWSNG)S25-=73V!9Q%"D-/'##'[KW1F_?NO=4I?S:^]^\=T
M9WH+^63\.MTMLSY-?.:LW+'OGM.A:N.2^-/Q`VA2&+N[O*EEQJM/C-V5HKH<
M!M661Z=)LS5,(YX9XXG'NO=6'_$3X>]!_![I/:O1'QZV/C-I;5V_042YG,BC
MH&WEV/NB*CAI\OV)V;N2EHZ2KWGO_=%3&U3D,C4@O)*Y6-8X5CB3W7NC/>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NJR/YP?0O9'R;^`W9?2O5&T\YO?>&Z^SOBU6_W<VW6X.@S55MC:'RJZ6W
MKOJMH*G<N<V_@5FPFR=NY"N"U51XW^VTZ')`]^Z]UHW9;K3<<&VOYR'QMRGP
M<^2>WN^,7W=\/>X>G^V>\-MS;K[8@^+&`^8O0_6VPNE<!_=WKRD$6W\C,V0S
MN/J<1/'B,KCJ%Q4DRXA9IO=>Z^F1[]U[KWOW7NO>_=>Z][]U[I@W5M7;6^-M
MYW9V\L#B=T;4W/BJW![AV[G:"FR>&S6(R5.]+7XW)8^KCEIJNCJZ>1D='4J0
M??NO=:Y77FP-Q?R,?F;U7U9M3<F9J_Y0OSAW]B>HNM=H[VWX=PU'PJ^9^\VW
M-F]N;7VM4;AQ[[CI^A^YZ/!"AH:9\G71T&=D=YS3W$E=[KW6RI[]U[KWOW7N
MF/=&YL!LK;6XMY;LR]#@-K;2P66W-N7/9.9:?&X3`8&@J,KF<OD*AO3!0XW'
M4LDTKGA8T)_'OW7NM9_^7U\9LE_-L[]I?YS'S8P\N=Z?ASV6I_Y8OQ5W0E14
M[2ZNZLVSGLOA\7\A^P-MSM#A<_VCV-54?\1QRU-'(,?#'3U2RSE<<:/W7NC[
M?/">I;^9C_)%H*2EJ:R1N[/FKE:B*FF%(:?'4'PI['Q]5D9ZDQL'I:.7-Q!Z
M8L@J/(`+LJCW[KW5PWOW7NO$7X/(/!!_/OW7NJ`<?5/\3/\`A073]<[,R,>V
M^H_YF7Q`W7V[OO9-1CYAAL]\J?C5FL9@DWMM6M>=*:@W-ENF9Q'FH*<:*J.E
MAGGB,QBF'NO=7_>_=>Z][]U[KWOW7NO>_=>Z_]'?X]^Z]U[W[KW7O?NO=%V^
M3O>G7OQ_ZIS/8O87=W4G0^!VWF=D5>8WUW'F8<9M"@Q%1N_%?Q7&UB_Q[;M7
M)D=RX&DKZ+&A*BWWKH[1S112Q-[KW0#[L_FN_P`LK8Y"[H^??Q#QDCXV@RT<
M7^S`=95DLV/RD33XZHACH-QU3R_>PKKC5079"K6LRD^Z]T43?G_"CG^2]U['
M329/YR;`SWW63GQ(38FV>Q=^/!4T[3K-+5#:>S\J(,>#3G35$_;2!D*.P="?
M=>Z)OV/_`,*]/Y.^R#/'MG=??W;DL59%3(=A=)Y3&T\\+Q)*^0CG[*RVP"*2
M$L8R"@G,B\1Z/7[]U[HL&7_X5\;0W_7U=+\/?Y8?S+^25/CJ2.HRDM13TVV*
MG%I4R5L=%5U=)UUMOO$I25)@B*>1H0ZR-9]4>EO=>Z+=6_\`"C[^>;W5O3;>
M"^,G\F^':6*[,S^X.O\`K1>W]D=\[AERN_\`;NV<WNK+X?\`O]6UO1>Q9LKB
M\!MZNK7Q\D,$ABHIE$C-&UO=>Z1Z_&W_`(66_)"0[[R_?^(^.-+O:G69MB-V
M=U=L&/:5')6")8UPVR-O;XS&`J1%,TY05DE<D*Z6M(%B]^Z]T7C<_P#PE5_G
M=?*+>NWZKYB_S!^K]YX7'9.-'W5O+OCY&]^;@VYB:YY#F*S:>VMY;'V_1O61
MQQH(Z,9+&0SE@C31*MQ[KW1J_C)_PCM^&>]\[WOM[N#YA_([?NX>DN]8>LLA
M6=>8#KWK''9''2]1=2]H0Q9#&[HPW:^07+34_92J:F#(F`0JBB/6KD^Z]U9Y
MUA_PD*_DZ]?Y5<EN7;'R%[G@2261</V=W;4T>*M(D"1QNO5&W.KLA)'3M$SJ
M&J"2TK:]2A%7W7NK<NJOY2'\L?I/+;5W#UI\$?B_MW<^RZ6*EVYNMNH=GYC=
M=`T5$<>*]]R9S&Y+,UF8DI6825L\TE7(S,S2%F)/NO='LVWLK9NS8ZF+:&TM
ML[5BK&1ZR/;>!Q6#CJGC!$;U*8RDI5G9`QL6N1?W[KW2F]^Z]UT2!:Y`N;"Y
MM<V)L/ZFP]^Z]TFLWO39VVJ.7([CW9MG`8^"9*>>NS>=Q>*HX:B1S''!+55U
M5!!'-(ZE54L&)%@/?NO=5R[V_G6?RE>OCFDW)_,.^*+SX"@FR.0H]M=N[8WO
M7M%3P/424V-H-E5>X*S-Y4I&56BHDJ*QY;1K$9"%/NO=%8P?_"D#^6COW/8_
M:/3%9\J._MZ;AAR]5L;9?37PV^1FZMS=BX_`2QIF\IL?'U6P,0N7QF(IY//5
M3N\$=-""92C64^Z]T@=R?SHOFINOMS:WQV^/G\ECY7-W3O';^Z]XXBD^6/9G
M4WQAV6^R=CY7;>(W3NG&;E:N[%IMTT^%K-UT"5%)1NM:@K(7CCE#$#W7NE3U
M=\S/YV'=_P`B=S_&O)?!SX<_#K+[$V%L3LW=W8W;WR.W-\CL;7['[%W'N+;>
M%R/6^P^H,-UW7[NS&/KMCYF&KI*_,8:EBF@B\M9$):=:GW7ND[L;;_\`.5[W
M^2'RUZ)R7\S_`*"Z-G^-N9Z:EPU7U#\`=J[L?>NU>X^O6W=CLSE,3V[W7NZ?
M:<=#E,3D,='`M?DI:B:DJ)C+'$T$2^Z]TB/BA\'_`)"?+[I/OVD[J_G)?S'=
MT=B[%^2GR;^.V9SW461ZI^,.TL=FNENPLYL'$5M'LW9&R,WO2&ED..ARDBTF
M[:&&OIZI81'%&H=O=>Z)_B_E'V3\MOY8G\FKKGY(=G]ST^^>[OYHVUOA=\M-
MV;(WCNGK3?F]9NF<W\CMOUFU-V[JZ]R6'W-0OV+D>O-NS9.6BK:><,\LYF5X
MRX]U[HV?R7_DA_RV-H=[_!+:>V>CNX*7`]T_(WL'9O:&+Q7RK^5U5C-U;>Q/
MQ@^0G:]')N^ORW=U=F87QV\=D4,\-31U5+52!I()))(I/$?=>Z#OY#?RN_A9
MUA\^_P"7=\,MI83Y88OXZ?*C:/S#SW9G2^#^<GRRI.F:K+=`;%Z_W1MK<&:P
M&0[;RF9J<ADY=VU&/J8*+(4$<T4L3M<1.LONO=-4O\FGX14/\UVD^+/]Q>_\
M;\9\U_+RR?>^U]D8SY=?*J#:]-W7MKY,4.R-X[@6N7MU]R4^5&R][8J!(&R!
MH)(ZF9_M_.3*?=>ZC=%?RF/BA#_-6^97Q1S.2^36X_CKM#XK_$SO;:'660^:
M'RTQ^+PW8N^-]=Q[;S^:JJ_;?;^#S6X9I*3KFD^V_B=;5&AUR?;A=5X_=>ZK
M<^77\O\`VOTIW1_,7WG\;_B)\N?GUV1U'\I/C1\==C=38;Y=?,.3<&S?C_WI
M\*-J]S]J'/[DV%OZJ[(W7LBJ[!FIZ.>#*5M1`L==3QS2&&)8W]U[IC_EZ]!?
MRY/E+MS^6G2Y7X6]K]:[H^6.Q/Y@R8FIV;_,%^7\D/QCJ/A'G*1,;M+8^%R.
M]8ZRDRF[:W=+966AEGHX,2]3'4!:O[IXX_=>Z-5_+Z_EO_&_Y2_R6.N?G]WI
MV;\QJ#Y'4_Q=^0V:F[HG^;GR5DR6TTZOSO:^!QF9Q&,H=[M@,1@,?C=FT\QQ
M,6+DI/#'XY8:AB[2>Z]TKNJ/Y3_Q$[;_`)(&'^8V;W[\VLKW%O#X&3?);=6Y
MZCYJ=]SUN>[?V]U+5;_EDJ=N56>3KVO@IMW89:*B63;\BK10PZ?),/N']U[J
M)EOY,/Q`B_DQX[YWX+(?+&@^5>,_EI8KY7Q=@;3^6/>PS65[M@^+U+VI)FTQ
M&4WEE<'!#7[N5GDIJ>F@1:>1HXO'Z2ONO=+SM[^5U\*NB_Y3M=_,#S&4^<_8
MO<&S/A/LKNZOW37?//Y%;,["W-F:O8.)W:]-4Y*GW%F-J[;9J[/SI]O#@9:.
MF21U2G#$O[]U[H$?YRG\G'X9=#?"3$?(_J[<'RRH=U;_`.U_BWUKO6#>_P`N
MNU-T4V\^NNZ>U>O=J[TPF\Y>R-Q[DPZU-5@ZUV6><B@HZPB9HFCAC1/=>ZH)
M^`'QZWE_+(_X5#]8?%'&;JW-B</M'Y(Y[K6DK<;FJJ@EWMTSV?L#*;EZ_P`9
MN>8045-N&@R^V<_A9J^"2'PRU]/JC5)8XF3W7NOJO>_=>Z][]U[JC'XLQ'L+
M^<7_`#?/D%N'-X1\=\=^J?B3\/.M\O/6UXJ]B[=/5E1\E>VX914R56`@Q&3W
MMOZ@J)W$1=)\60R+:0S>Z]U7=_+=_EH=%_)O^5SM[Y;]K=I_-C?O?7<>T^_N
MSJSL/K?YC?(;K_(5>93??9%%MO)]5[#VOOR@ZWPAK,3AJ1\925N"J8P\BI54
M[J#"ONO=!;TU_+5Z-[1_D>0_.?(=X?S#E[_R?P3WQ\B'W1E_G-WT:^E[*VAT
M_N//?;4^`H]S4NS9=KS;JP`FIH)L6\S4C(CO:Z^_=>Z4GS:_E7].]%_R<HOD
M#M_N/YS;&^2.V-@?';?.XNR\G\X_D#FMQS9[L+=/66V][[4W'BLGNV+K.3!T
MPWC6",T.W<941U$,3K(BAXW]U[H=?YEG\J_XG?''IGXZ;VV;VK\T-BO)\P_A
METMOS-?[/W\H6;>76_;_`'SLGK7L6/<4^\.S-QXG%54^W=R5N0-1B*;&30U"
M,T!A0E1[KW07?S4?Y8OQ'Z&W#_+9VIMC=OS;VQLWY-?S`>F_BOW/%BOFQ\EM
MT8O>/7W8.R>SZEL+N-.S.V\]CL75;FWIAL-%45="U)4KCXZH4RM.8U/NO=//
MR:_E<?%OXO?,[^4Y\:^C,M\J=@=-_*WMWY+[7^1NS]L?-SY4XN#MRGZU^,VZ
M-_;,RNYHE[=CDILIA-P8N)WK,0^,E:E0T[!U=%7W7NE)W=_+PZ%V'_-6^!/Q
M.Z_[+^<>S.HNX.C?ESW%V'MG`?S!_E]%1U^\^IHNK*+K;<6.J\CV_5[GP66P
M<FXLAY)<?DHQ5J\"RPZ(&9_=>Z761_ES]4I_-?VM\7I?DE_,/GZGR'P.WM\G
M%VM/_,7^7DE53]P;=^0&P.JJ'>=-N#_2\=X0U:;-W-4TGC^\2E8,6T.XO'[K
MW0$]=_RYNFNT_P"<_P#+OXO[Q^0W\Q_<'571_P`2OCKVCLO;&>^>_P`D:NDH
M-^=E9S<=#N7+T>]/[^+V354-'C,+BSCJ6IR\T$->V29Q)#]G#3>Z]T_?%W^6
MEM;Y`_-;^9ITKV%\TOYGM7L3X=]W=`;9Z)IJ7^8)\@ERFUX.R/C'L[LS.Y&;
M+U6XZNLR&6HMT[HJ'H*B4F6GIU2%VE0,&]U[I6_RU/@#L?Y-;'^<..[!^9_\
MTG<^8Z/_`)@/RT^*NR]\5'\Q?Y/X+<6%V5U+E,+B=FU5+C-N;NVYM2KS>*H\
MPLSSY+%Y`5E8ADE#T[K2I[KW0>_";^68G?O\MR#Y)=J_.S^;*O<T])\E\QA=
MQ#^8/V]C<C@:3K'LSN#8>RYJ+!X^NJMJ8NJSFT=I8ZHRD$M/6LM6\L?D$9:,
M^Z]T#78'\O#%]3?RDMY_S6NM/Y@'\TRI^2F1^"F`^4V`S&]OF=N:'"8OL3=?
M6&"W[DA7;;Q>W<.<C0561R<E+-BZ^HJXY(@(E(ETS#W7NA[_`)@G\NW:72/P
M,Q'R?J_G5_-.W57T'8?PBW#OC';O^:/8&[MK;DP^^_D+TIL7>+9GK7=-9C-L
M2*NWM]5U33T<<E!%#D$@=B8XFC;W7NM;?NWY#_S.^L>WMGU_RP^0_P#,;H?A
MQ\R?E[MS!=);]V1\U:7;^VI/CGDNW,M0;[ZUWXNQ:/?55LOLROZNR&+KJ"B$
M^&JL92I,TN.K*>I`I_=>ZV,>W/Y;LG3'\RGX'?"OK?YT?S1\-\:ODOTW\L=^
M]E[3Q?S<[BJ<EC-S_'['[+R>SLGBMWC*09;9&`K<AV6\=;'2L\5=5I31N@,K
M.?=>Z4&-^&V\<M_.)WC\!<K_`#"/YL%=\?MK_P`O?KWY4;9@H?FAORER6&[(
MK^\MQ]35E)N#L&EAI]S5N)J,#@XJC'T$K3+-5&K>>1D2&-?=>Z5'Q_\`@GA=
MY_S&_FY\4\K_`#$/YM=5C?BIUO\`%/>O5=-%\]-__;X3"]Z[<[%R&Z\=F,A1
M/49/<F3BS>WEDA&X$EJ(:*JC\.J-8Y??NO=)OXK_``:I?D5\K_YFWQ/W5_,T
M_G%38;X==U='XK:-!!\S=U[,JJ79W<?2&`[(H$GSD&WYMT;FDH]WQYND@K9Z
MJ.&JQ5-1N(2[25-1[KW2<^"G\L_!_+?<_P`WL5V'_,,_F\S4WQ,^?_=?QSZW
MGQ_S9[6VC!4=?;(Q6PMP8^ERD]7!DIL]N"BW;G<@L^6IY::>L@IZ*<K'K4'W
M7N@7^/FUMR?+C^0__.*Z,[:[9[\[_P!T_#CY4_-[%]']J]V;@E[$[>QF2^*,
M&W>WNCJO&[UR4TF5R>5I,QA$6L994D3^(UE)3A*1XH1[KW6T'_+V^062^5OP
M8^)'R/SE_P"\7<OQ\ZKWWNH_;QTJG=^9VCBY-W-%3PJD,-.VY5JC&$&CQVT^
MFWOW7NCB>_=>ZI;_`)^&0W?D_P"7Y5]'[(W!%MK,?+SY$_&+X>5N0GF2F@FV
MK\B>Y]K;"WMBZFJ$<U;2T>7V?6UU-/)2HU2L,CE`1J'OW7NK?]F;/VSU[M#:
MVPMEX:AVYL_9.W<+M/:NW\7`E-C<'MS;N-IL1A<304\8"04>.QU)'#&H%E1`
M/?NO=5O_`#9PGQAG^:O\JW='<_:':&Q^[=O=V=ZX[XL[3V#"_P#=WLG=VZ.C
MLI0]@8CLZN&$R2T6T<?L>DD*@5-#)4551'#K>)Y8S[KW5HOOW7NO>_=>ZJ5^
M</:G977O\Q/^3GMG9\^-.S.WNV_EQL'LS&R8JEJ<UD<;3?%S<6]<#)C\K+%]
MSC,9B<KM0U=9'%*@J7AI]2OXU`]U[JVKW[KW7O?NO=>]^Z]U[W[KW7__TM_C
MW[KW7O?NO=41_P`TO^8/W%L?-Y;XM_$#!YRIW#MG-_'JF^</R:VOD-G-7?"#
MI7Y)]H8'KK;>;V=MW=U4E)O;Y"[MPF2KLG@L<M/71X3'TR96KI*F.2EAE]U[
MKE\E_P"2[_*8P_QK[]W3\E>N<IN/'U>`V]V1\@/E;W'O;M#N_P"1U5A>H*VC
MW?G-QKVINC+[M[`VQ_%\9B:N+)4>U%QE)-35D\<-&JE(U]U[I5;&_P"$_O\`
M)+7#8W<&U/@;TQFL)N&DV[N+%5^7R/86ZX*W'I$,GA:JD?=6\<K+'15]/5J\
M\0TQUL95:E9550/=>Z%S'?R//Y16+I,C0TO\O3XPM2Y.NFR,Z5O7&-R;P550
MGBE.,GR)JJC#0-&`!#2/!$H4646%O=>Z%;K3^51_+5Z>JZ^OZW^"OQ;VQ6Y3
M%T&&R%5!TSLBOGK,;C!!]G33R9?$Y!G\;4R.S_YR20:W9F))]U[H]>*PN'P5
M)'08/$XW#4,,4$$-'BJ&EQ]+%#31+!3Q1T])%#$D<$"!$4"RJ`!8#W[KW6MO
M0;S[NW#WI_+OJ.T]Q[TFGB_GM?S.MIXBBWE59`92?K3;/4_SYP_4^/P_W*@3
M["P.S<='!C8XF-)'2M3K&"%&GW7NMEOW[KW7O?NO=$2[)[%^*?\`+ME[C[^[
MZ[ZJ>N,#\HN[-I9=J#?^>K<SBF[-CZKV7UAC-G].;'P.(K,_4UN?V[UC!D*N
MBH::NJZBK%14.1&`(_=>Z*=D_P">C\2ZO?%+USU1TU\[_D%N[*X_.YG;>-Z@
M^%/>$L6[\#MVAQM9DMQ;1R'8>W^O:#<.WXVRT$(K*:1X-<J.6$,L4LGNO=)N
M/^;5\F.R.S<_TG\>?Y0GS(R?:VV=E8;L7+87Y4[YZ"^)&W&V7G,U/M^CS.$W
M37;[[8&ZM&4I)H9XL725CTLD>F?Q,R@^Z]TP]=?+W^;Y\E.\/D1TGU_T#_+_
M`/BKFOC3+U=CM_4G<O>O:/RAW/-DNUMD/V'MBIQ>$Z<VSTY1P8*LP,T4+S9"
MJH9%J89Q3K6(K-%[KW4#J[!_S,/EAOCN[K_,?S8>F.H-T?&3L/%];=J[-^&W
MP2J*.?$;PSNU=N=CXS%;EW]\PLSVACL[JV5NBBEC_NQ1/1A*E#/5M,KP+[KW
M1>>O_@9\</D=\5M^_)WL?Y__`,V3Y4T?3];WGC]_TF2^4&[.GZ_([V^*FX=\
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MS=OY,G;%.E?7;1[1E^8WQ`W11T]%"U/1UG:G7^P^Q]J5TF2EDB6ED;/]2QR-
M$?(\U/1R>-00Q/NO=##NG>^4Z^_G>=4;8S$#4VT_DI_+?W_@-FUJPT\W\4[#
M^.'R`Q>\L_C'E$_WE`F,V1W0)^8_%4M.`&U0V]^Z]T'74><R.Q_Y_'S)V'F-
ML8J@I>__`.79\5.V]F[EI*V2:OS./Z([9[>ZVW"F2I(8$@IJW^*]H)"?.S2_
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M*^Z]UF^5VP>TLU_-#_E/]C[<ZYWANGJOKS`_/7$=F;WV_10U&W^M<OV#U'UQ
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MJXT.6IJ2NR5/1_Q6&CIIJF`5MT]U[H./Y5O17R#Z0W)_(PZW^0/1>:Z.[/\`
MX7_/<R>0V-F=KUFT<^9-Y8CJ3*X2JR>VJ@N,6^6A:6/'1J*9),924[10F.TT
MONO=6^?RIN@>U>O?^$YNT?C_`-H=)]H;<[6E^+GRWVYFNDMS[7_@G9M?D=[[
MK[PJ\/MZ':6X9\1-2Y/=>-S]*:"FKWI'D6JB\F@-?W[KW0Q=(=-]IXW_`(3P
M;.Z*W/L;?^V>XJ/^5C5]?5O7*;>S-!V;C=[1?'>NQ-+M%-JP_P"YZ'>!R0CI
M10,B51JF\3Q(Y:-?=>ZF=L;`[`J_^$\&:ZIGZV[*RO:N0_E*X/K:3JS:^T,O
M5]FKV)D?BQBMJ?W5&Q::>#-OE\7N:H\5?C`7G5(9HC'*08W]U[I+?,78W=0_
MX3L;YZKVAT9O>K[MJOY<?7W58Z(PU"<AOW"YS(=7[/V/N7;E-AMMT^7>OSFS
M*"HJYGH*-)&F:B:!&4D,ONO=)[^?9MO<X_E!?QLX3=63_P!#W8WPS[3[&IMK
MTE96[LQ&S.M>YNM,MV!GJ&GHZ+(52U6V<3!/6S2^&04\5/)*P*H0?=>ZUTJK
MY9?%+O3_`(5O?%#Y%_'7,;.^6?6W>77O76#QN7VE0UN)DZ]W[D>D]T;)CW)F
MJ7>V"Q=3)NGK;"8:FRU93^."NH*9_MOV\A2O3#W7NOH6^_=>Z:Z]<TU3BCBY
M\7%2+7,<Y'7TM7/4SXTTM0%3%34]93Q4M<*WQ$M,DT9BUC2&L??NO=:DG2WS
MG^,?\M;Y"_SS^I/FUOP]*[V[I^6^_/D!TIMS<77_`&+49/NOK7M/J[;^$VQ7
M=>2;<VON2AWC#59BD-$L5#/-5+.*EY((5BE$7NO=6B?R!-@;TZO_`)*?PJV9
MO?9VXMF;PQ_5._\`)UFT]U86KV[N"D&YNU.R=TX=JW#U])25M)_&,5FJ>JA\
ML0>2"H20ZBUS[KW09=6]-]CO_P`)LLETA/UGV+A.V<K_`"O.WMG_`.BBIP>9
MD[,3?VX.E=[0P[2I-O2PUV=FW#D<]D%AHJ58I)Y&EC1([E4]^Z]TZ?S#MF=G
M=K_R#Z[:NP^L-[Y?M?/_`!U^(W\+ZRS&T,WF-_X_-0;QZ0J<YBL_M22*KW$,
MQM_'0UARD;@U4$<$[2,"K,/=>Z,-_-?ZW[5[)^/OQDP^QL5GL_O3`_/KX$;M
MW%_<;;60W!]EAMM_('9=5O/<4M'%2UDF+VM@Z`SUE565)C@I*6(M,Y6Z/[KW
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MR=Y/_._VSV,-M[@/7M+_`"J=[[*?=\>#RHVK'O*N^7'7V<BVU5;E-.<(V?GP
ME`]5!0K*M6M/%+*5:,@K[KW2$Z6ZFWM@OYYWSE[:;;F^X>NMZ_!+X>XN'=F5
MHS1[%K]YXWL'NG'S;?VS5LL:9RJQF%P"U$YC\KT$]5.LQC6IIQ)[KW7O@)M_
M/X_^99_.VW%58K,T>UMV]W_#ZHVSE<AC<A0XS/U6`^(FRML[EGP5558FEH\M
M28O,8IJ*6>FJ:@+4P21.$:,%_=>Z;_Y-E5NZ*?\`FC[?W;L[.[0;%_S=?FEF
M-O?QO!;@PR;BVON_/;:W!BMQX:;,T\%#F,+D6J)/#54%Z9RK7N^IY/=>Z1G\
MI/;&^L5_*,WULO=V$W-0[HHNPOYBN%I,1-@\]1;AFIZOY*_(&3#C%X:MH(\G
M*:^*M1J".FI_')&\:P(5TK[]U[HM'86U>Q,1_P`)29=BUVQ-\5W9L/\`+#VE
ML[*]?[CV7E\5OK';DJ=D8/!97"R;+Q^-QN:I<AMB>:7[2&2F$Q2EC>H5R9"W
MNO=&=_G5462J?Y,&]H</A,C+24E1\'J_-X6KH<E%N"EVGA_E#\=LEGXQ2"%Z
MJ@R^+Q5&[S-4IXZ58I&FL$)'NO=:0W=.S_G7TO#\6MBYSJ'XO;D_E[]P?S..
MD.\*#N[H2/;&\,=V;W=C=_[IVQ0;$[TWE19VNK<#V+M[;.5R&(W#BJK$8Q(Z
MRDTEY7,K3^Z]UO0_*C"[B_X>\_E-;DI]M;AR^V1\=/YB^`R&>HX,E'M[:62F
MV[T7DZ6JRU?1HM!+/F8Z3[.*DJW9&=TFC3R1!E]U[IYP&V-U8O\`G[=E[SGV
M+O>+8^\?Y4/5FV<;V0^W<W+U]5;NV1\J^R<IEMH1;H@Q?]WJ7<E/A=Y4E6:.
M>K^Z>%M<::=7OW7NH?Q8VV<?_.O_`)LVX30Y:)<Y\=_Y;S+7R4D<.&JFI]O_
M`"'Q\D5/5&..2KKH%Q:![%PB\$CTJ/=>Z1G\M;`[CH/YH/\`/CSV2Q&Y*?;^
MX/D%\/X]NYW.X;-T%)FYL-\6\;39BFPF1R-!!C,M080ST\2&EGF:*%XBZ1QO
M`TONO=*3^4'F=Y5O:/\`.&PVYL96XO$X/^;-WTVT(JO!56"CJ<-E>N>GZI\A
M0QSGQ5])DYH_N15Q>FK>9J@\R\>Z]U3W\6OF%\5_B9\,OYY/Q1[K^3_7O17R
M,3YB?S0,ILOJKNC<>-Z^WU/B^UL!D#TYF-DXC,5^!R&^L7O>/P9"CJ,6UY9J
MO2GC#122>Z]U>K_(UPM1M_\`E"?R\,=58ZJQ4Y^+_7.1DHZR"HIJ@'-X]\TM
M4T-2%E6/(+D!4(;:6CE!7TD>_=>ZM8]^Z]U1]_.T>DH/^&I-R[C#4W7NT/YQ
M?PUSV^\VPI11[>IGH^S<%M#)96:JD5*?$R=AYK$T]1)I;1'.6]-M0]U[JZ_^
M,8CU#^*XVZ_J_P`NI?3R%]7[O'J-O]?W[KW13.^<-W_N+O/X>9[IS!?'_=_3
MNU>R]]S_`"/E[,Q_\0[$VI@,EUSE*'8V[.A\U"98L)O+'[ED>EKU*EZO&5[Q
M@JGD<>Z]T9G;V_=B[NRFZL'M/>FT]SYO8F6BP.]\/M[<>'S64V;G*BDCR$&&
MW5C\;65-7M[+34$R3I3U:0S-"X<*5(/OW7NE9[]U[JE3^816M#_-(_D34<K4
M]/0U/>'S?J&K)ZF=+Y&F^%V]Z7'8V*DB62.:;(KD9BLCJ!&T(76OE.KW7NKJ
M_?NO=>]^Z]U[W[KW7O?NO=?_T]_CW[KW7O?NO=:G?:51FY?Y._\`/&^06:RV
MW\=V5GOG-\SNR:_+UCT5"S1_%'O_`&KU?U%LNJR%+54]3+41[%^/N%Q.,#QT
MM5))4Q$0R32F:H]U[J\/OSYG?$>IZ/\`E3M_<?;6Q\S7]8_&&K[+[KZUQT57
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MW+0SU.W]O[`^5_\`+'P>P:BKVJ7QSSS8FE[IWC63(T,Q@I<ID:IV4L#X_=>Z
MM7^<'9DW6/SA_E'RUM1%3[7[%^0?R$ZBR96DF-6^X=X?%CL?)[+B.1CGC2'&
M3YC;#1RTSQRBHJ7II;+]OK7W7ND_V_OO!;$_G8_"3`Y')3Q9'O3X%_-CK["8
MY+K3U&8V%VK\7>TZ<S#^'U'FD?;V*S#I^_3B,4[7+%T1O=>Z3O5]+LS8G\]_
MY8XJC3)XO=GR!_ER?%[M&JII\5DH<7NFHZ3[L[GZPW'GJ#,-+48NKFP.$WQM
M6AEA'V\D9DNB2?O./=>Z%OXR3[;P?\R;^9]M*CRU$=S;FQ'PF[ERVWVQE92Y
M6&BSG3^Z^IJ3.+DVG;&9?#5HZ:%/&D4:55'54T_G)CFI??NO=,?P1ZSVO1;;
M_F4]!PI45&V/]GU^4$-7B?L)L+1T=%\BMC=<]Y9[%8BJ?&QTU10MD^Y:TB>%
M:F.*:1X[DQF-?=>Z*S@N@=^=_P#_``G`?XU9?K+L';7:51_+@SG5.$ZGJMDU
M.Q.PH^QNI^M\AM_8.T_[GYIZRHAK\ONG9./AC9Q#_$XIUJ(TIA4(D7NO=&6^
M5'Q3[U^8W\JW8_0BSX':7R:K-D_#O?4]7V3E,G08_;G;G36_>FNV-U0YS-[:
MQ.>R='D_XALK(48J*6EF_P`JE!X0LP]U[HP'SU^).=^8'773FUMJ;WP_7FZN
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M!9Q2M5*)2FL!O?NO=/\`2XO&457DJ^BQU!25V9G@JLQ6TM)3T]7E:FEHZ?'4
MM1DJB*-)JZ>FQ])%!&\I9DAC1`0J@#W7NI_OW7NO>_=>Z][]U[KWOW7NO>_=
M>ZH6_P"%`OS/VW_+O^.OQJ^9.4^+W7GR@W)U+\M]JTVQ\3O_`#>6V\>NL[NC
MJGMVBE[`VME<7C\O#3[FI*"DDHZ9JRCJJ>!ZL5*(*F"GEC]U[K7<_GA?/[Y-
M_+/^6_\`R;_G3\?-J=M_'GY+=K[X^2V\]OXWH#>^_:S?.S]J[7VSE\)O083*
M[+I,/F<QM?.[/VTN6KYIZ>,4V*2595-,U0Q]U[K</_E5;][%[2_EL_!KL;MS
M<&Z]V=G;V^,'3VY=][GWPC)NW<&YLKLW%U65S&=>15FJ:W(U,AE-1(/+4JPE
M?UNWOW7NC^^_=>Z][]U[KWOW7NNF575E90RL"K*P!5E(L58&X((/(]^Z]UI*
M?S*TK\)_PK@_E*U341I,56=([)I<2]#14#FH6LSWRDQ->SQ)+"_ABFJ`DDDG
MKAB!>,-I"GW7NMVSW[KW7O?NO=0:K&8VND@EK<?0UDM,XEII:JDIZB2GD4@B
M2!Y8W:)P0+%2#Q[]U[J=[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[J-64=)D*6IH:^EIJZAK(9*:KHZR"
M*II:JGF0QS05-/,KPSPRHQ5D8%6!L1[]U[KYG^[?YS'4/8?\NOY%_P`MCJCX
M8-T7N7H;?G4W:[]M[8[0QVZ*'>_;&U?G]T9#N3L&NVYF]K[:S>%SF]\KF!6/
M.<ODC12R+1K:D1)(_=>Z^F,A$B1R%"I9`P5M#,FM02I:-G0D7L2K$'\$CW[K
MW7/W[KW7050Q8*H9@`S`#4P6^D$_4A=1M_2_OW7NO6`)(`!/U-N386%_ZV'O
MW7NO!57454`L=3$`#4U@NIK?4V4"_P#0>_=>Z!CL7XW_`!X[@S^`W7VST/TU
MV?NC:DZ5.V-Q]A=8[*WGGMNU$<U-41SX/+[CPF2K\5*D]%"X:"2,AHD/U46]
MU[H9D1(T2.-%CCC541$4*B(H"JB*H"JJJ+`#@#W[KW7+W[KW19/F!A/B-N3H
M/>&#^<B])/\`&VOFP?\`?9/D+DMK8CJXU5%F:+);=?-9+>-708.DJH<Y1024
MK/,DGG10AN;'W7NM=7*_&C_A,KF.XLABFZ[_`)2:=%9+8:YC/]RXSYU["V_G
MZ7M&IW#5P8_K/'],8#==+2T6"J-O0R93^-QYRCA6:):9*%WB$L?NO=5L=:?`
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MW7NO>_=>ZU=>F<K'DNS?A/DZF/)MY_\`A0__`#9Z2*H@J<="(ZBGV/\`S%L7
M3PUT1B62HI)H:5K+#&"!&-;@\M[KW6SSF,QB=O8G*9_/Y3'8/!8/'5N8S6:S
M%;38S$X?$XRFEK<CE,ID:V6&CQ^.Q]'"\L\\KI%%$C,S!03[]U[JL>3^=O\`
MRCHY_M_^'#_BK*UZ@"2F[5P%72G[9UCETUM+--1L"SC01(1*`2FH`D>Z]U6K
M_-1^>OQ5^;O5OQT^,?P.^1/3'R;^5V[OFQ\0]_\`66Q>KL_!V-%@(.INY-J]
MD[GWOO\`RVUJN6BZ[VAM?;.&GDKZW(2Q2,'-)%&T\P\?NO=7-?,GX98/Y<9?
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M?:&W<ED0/+48W`9+>63FIT/Z6JWO<!0ONO="!8"]@!<W/^)L!<_U-A[]U[KO
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U27_.L^9W9OP=VE\1.U.ONI^R/D?ALY\A-\;-[-^,766(H,KF.Z]C2
M_%GO_<YAKA/M?>5?2X?KG<FV,?N>JEI\?,L--BI)9B(HR&]U[JF?YP?(>E_F
M&=:?R3>R/AG\5]SY?>W;75OSV[KZ\^.FT?D;G_B=78/`]:]<X/9?9.PX^Q^K
M,9A*O-8O*[HJVITQE",0FYJ>+P2R4M)65)7W7NMLSXI=H;U[L^,O07;_`&1U
M9ENC^P>R^HM@;UWMT[GJ7*T.8ZPW3N+;6.R6=V-D:+.8O"9JCJMM9*HDI6BJ
MZ.FJ(_'IDC5@1[]U[HP'OW7NO>_=>Z][]U[KWOW7NM&7^9AV4-\_\*YOY76Q
MMD1H=P].;'ZFVMN^2M2EJ:8QY_(=V]F9V&G@>.H,4\/7&[D>-V59$GD5T*%5
MD]^Z]UO->_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KY*/6GRC^.O6/4?\`
M,GZWW-U#E.N_DSN#LCX<[BZQ[D&R:"DQ-7TSU!\T^F-R]G4^XQC/L:O(U&X>
MP:)-P093^%Y&OS5-!%35-6WV=/&WNO=?6HIYX:JG@JJ=_)!4PQ3PR`,H>&9%
MDC<*P5AJ1@;$`^_=>ZS>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z!+
MY&=7_'[M_IK?.T/E'L;K?L+HN/$3;FW]@.V<'A\_L6GQ.T1_>1\_F:3.P5%!
M3)MS^&_>K5$*]*8?(K*5O[]U[K2F^9/Q"_X3@_*?M[K.IVO\Y_Y:/Q9^+^R6
MH,UO#8WQNV[M?9_R'[%W#&N5AK\;7=TT^_JC;..V+E(JB@5L?_<RKK:;[6:6
M&KBEJ/)#[KW2N^#./^`$?_"EKHA?Y2,W2/\`LM-!_+>W='W-_H?R\YV[-N''
M93<^WR`,Z*JMS&_))(-DRY3P.M?4Q^6NK))9C5M-[KW5YWPWM_P^?_.C-14I
M'4'I7^62N/H2RO+4XQ>L>YC45Z%8H?%'!D9&B:-C*UV5]8#JB^Z]U>5[]U[J
MGWYV9+&8W^9?_)(?)^>`5?=GS5QU!7_?114:Y2N^$O9=/1XRHQS`RU51E&<^
M"=;"!H3&3>=0?=>ZN"]^Z]U[W[KW7O?NO=>]^Z]U_]7?X]^Z]U[W[KW5+W\O
M3+U5-_,6_GC]45^$DQE-0_(_XL]MT$E=12039C&=O?#WKS;+U\/KEH*W#3Y'
MJ*I\,B'R-+YUF56`4>Z]T87^41OG_2'_`"TOAKGQCGQ0H.F<-L<4;M1,%'6-
M?D^MA41?P]WHTIJX;3\\2*;I%(JL`P('NO=&LZ`Z.P7Q]V=N39&VJM:G"YSM
MON;M:FB%"*+^&U/<W9^Z>TLOBF)JZR6O-#FMV5*?=2.)*@>ME4FP]U[H</?N
MO=>]^Z]U[W[KW6K/UEHH^Z/Y=5)+M_=$E#3_`,^G^<)#YYFRF,PNWL@VW_Y@
M?\,AJ:2NFK1,V36KDJ*"WHE5*EHWC$C(WNO=7X_.;=.\-C?"GY>;UZ^Q6'SF
M^MH_&/OC<VT,/N&GI:O!9/<F"ZNW1D\-19BBKDDHJ[&U%?2HLT$P\,\9*/96
M)]^Z]U4'\8/Y^W\I4_'3H2+(]KR;*W56]2;$K,KUWBOBUW+B9\/DUQ.#QVZ9
M,?M_8_5V7VG28'&;CK9%,^,JZG%A`33SRQ@,?=>Z.-\+/YEG\O;Y0=X=@=5_
M%ON/`[SW[NJ*3LV;9.W_`(X=M=69/$T.,V]MBBW=F=\[LW1UOMC#YK.U&4K*
M=99:^>&LBE9:#2\M.5'NO=6N^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>ZAY#(X_$453DLK7T>,QU'&9JNOR%5!145+$"`9:FJ
MJ7C@@C!(&IF`Y]^Z]T63YH?,+I_X'_';?'R8[Q;=,^QMDR8#')@=B8`[IWWO
M#=&[L_CMK;1V9LK;OW>/CR^YMS;ART%+312U%-`K.7FFBB1Y%]U[JM[9'\\K
M8N2[WZ)Z7[J^!O\`,/\`B)B/DCV%CNI^J.W_`)2]&;<ZTZWRG9&?Q,N3VKL[
M+5D786;RF'S>Z9HUHZ2G-/+-]W*JR+&JS/%[KW5I?<_R<Z7^/VZ.B=F]K[JJ
M-MY_Y)]JT?2?3M)%M_<6<CW1V7D,+E-P4.W9JC`XO)08):C$X6JE^[KVIJ)/
M$0\RDJ#[KW6;L'Y)=1]7]T?'_H#>>XI<9V?\G:KLRBZ<PB8VMJX=QU74>S?[
M_;WAJ*^FBDI<2<?M=6J(VJ#&DY0QH3)I4^Z]TXUO?O6./^06WOB_5YBNA[CW
M5U!NSO3`X$X+-'&5_7&R-X[0V'N?*IN9:$[>2OQFY-]XN)J%JE:QHZH2K&8P
MS#W7ND;MGY7]6[L^6/:GPUQ0W%_I=Z>Z@ZU[JW:]3AWBVNVT^T\[NS`;?@Q>
M;$SBJR]-4[1E>JA>.(+'41&-I2)Q#[KW5!_\V3^9;U7T/_,E_EQ4^ZZ:NH.F
M?AU\M9L'\N>U,G34])MOJS>7RZ^(_9>V?CXC5M1E$BJ,*VSMR[DS^<J6I]6/
MI,.OC8N_CE]U[K-B?G5\9?FM_-0_DX=O_$W?<F4Z3H=H_P`W#J`5M)MNOVKC
MLUFNO-A]%UV0PT&"R4%#)3[=KL=CJ;<.,FCITGJ*6*$M''^]''[KW5XG1_S>
MZ,^1'P\I?G-U=4[JR_1&0V5V5O\`QE76[=DQ>ZLCMSJS,;NPFXIZ?;E75)+'
M4U-9LJL-'%-+$TL9C9_'J(7W7NE%U%\NNF>Y_B-M'YM;9R>8QO16[^EO]/4.
M2W#AY:7<&%V%!MJHW5E6S>#QTN5DCS&$QU'.E33TTE4#-"RQ/*"K-[KW3GM'
MY3=/;S^*F%^9^-S&5I.ALWT7'\C(<_D\!E*?,4G5K;(;L*7+5FVXH*C+BNI]
ML(TS4L4<LSLNF,.2M_=>Z2V\/FQ\?=E?#&H^?64W+F*GXU1=)87Y!P;JQNU=
MPU6;K>L]Q[>QVY\)E*?:)H(]Q)65V*RU.QIIJ>*6`N?,(PCE?=>Z=_D5\O.C
M?BK\8-X?+[NS<==M?I79.SL)O/+Y2'#5V6SDU+N>HQ..VOAL9@,='/6UVX=Q
M9O/45!34XLGW-2ODDCC#R+[KW7SZ.R/DYF/D)_PJ^^$O?,/0GR)^+\^]=W_&
MK#P]>_)79&+Z_P"T:C"9/859L^HSTVUHZG<--0[=W'B*V6&!C4S5+(DAUTTU
MHZ?W7NOI9>_=>Z][]U[JE#Y(_P`Y&LZL^0?=WQW^.WP&^7_S9W!\9*3:Y^0N
M[^C,%M*FV-UWF]X;4H=]X;:-/E=RYVCK=U[I7:%>E744E%3%HF98@78MH]U[
MJQ?X>_*GKKYK?&'I[Y6]5TV=QW7W<NT1NS!X_=-)!CL_BEIZ^OP^6Q>7IX:F
MII8ZO%9G%5,#.DK1.(]:G2P]^Z]U$ZK^8/3'<?Q-H/FILFMW%6]&Y+K;=?:]
M'D)-N5S[EJ-G;.BSD^7JH-L4/WN1JJYH=O5#4]-$'FG]`4:F`]^Z]TG]S_.;
MH3:?P>;^85D\EN*3XY#HC"_(R/)TN!D.ZI^M]P[;Q^ZL3-#MJJJ:2<YNKQF4
MA"T;2*_F?1>_OW7NG+Y)?+W8GQJZ*VCWYN#;VZ]T[9WOV%\?>N,!B=MT]`,W
M)E_D;V=LCJW9E;5PY*NHXH,=C,OONEJ<AH:6H2EBD\,4TNF-O=>Z67R$^2G6
MGQEQ'6.9[-FS4-+V[WGU1\=]EC"XBHRS5'9/<VXX]K;)I<F\)6+$XBIRL@2>
MMF988;J";LH/NO=)_OGY8];_`!X[-^*_5>^,?NNKS_RX[@RO2O7-9M[$)D\7
MB=TXKKG=W8[U>[)ONX:G'X>HQ^T9*5988JADGG1Y%2G2::/W7NF?M/YJ=+]/
M_*OXS_#K=\VXD[=^5V"[9W!U>,?A_N]NI1=.8G$YC<T>X<K]S'+CJFMILNHH
ME2&99##*9&B55+>Z]T(.Y/D9UAM7Y$=6?%W*9*O_`-+G<'7':7:NT</38RLJ
M*'^YG4.4V#AMV9'+96.,T6,9LCV-01TD<C!ZEA+I'[9]^Z]T@L=\S.HLE\V=
MS?`>&'=R]Z;8^/.W_DY5RG;\C;)FZRS^^,CUZC1[FCJ&2'/T6XZ&-9*26)!)
M%51M"\A2=8?=>Z6NP?DKU=V5WW\@OC=M:MRM3V;\9<=T_D^UJ6?&24^(QL'>
M6W\_NC846.RID:/(U=5AMMU$M1&%4TX,=[ZQ[]U[KOI#Y-=.?(C,]Y[>ZKW+
M+F\W\<.Z-Q=`]NXRKQ61Q-5MGLO;&)P6=R&-1,C3TXR>-FQ.XZ2:FKJ8RTE0
M'=4<O%(J^Z]T&'QD^>'Q_P#EAT%O_P"2?6&6W!#UEUCO3N/8V]:G<FW,CC,S
MALMT=E<EC]Z2OB($KJBNIC28\5M*:4U#34T\:V$^N%/=>Z:,Q_,-^-V*^!<G
M\R&#+;KS/QC3J6B[JCR^,VI7Q[NGV/624\/GBVCEVQ5>N1IY*BST[LC>ABI8
M:2WNO=.?R:^;&P/CG\*\_P#-HX7*;VV%1[,ZVWAMO!TU33[>R6XHNW=P;.VS
ML2FFJ<I'*N'6MR>^J`U):*::&(OHAFE"Q/[KW6L/\_9>@-Z_\)\Z;&[]Z4RN
MT/D9NK=72?P!V]N#>N'VO5=\XW=>UOE=09;"1_WB#3[PGZPJ7V1D=U8G;D\M
M-YJ+1#X*9_\`*(O=>ZVKNP?D]U#T=W3\7/C'O;*9JG[)^4H[.PO3<5'@:[(8
MK,5O2.S,9O'>=/F<E0K/%@)%VY7">G><""4QNAD5@H?W7NI]5\I>I:+Y88CX
M7U5?F(>\,[T'E/DCBL>V(F_N]6=:X;?M'UQDI8L]Y/`<Y2[BKXM5'HU"G82%
MN0#[KW3EA?D?UKGODIO_`.*%#/FAVYUOU#UUW?N*EFQ3)@#L/M#=&_-G[8J:
M#-K-)%49/^-]<Y)*BE9(Y(HQ$XU+)<>Z]TS]4_+'I+NCN_Y)_'786YI\EVS\
M3<]L';_=6W)\=4TBX"I[.V1C^P-E5=#7N&H\QC\O@JYT\D+EH:NEGAE5&C&K
MW7NO=$?*7KCY#[U^2FP]B4&\*/,_%;NJ3H7LJ3=."3!4E7O>'8^T.P'J-J:Z
MZHK,MMM\!O>A:&MEAIEJ&9FA5X=$K^Z]U7#WA_/F^'G2/9WR+ZP/5GS/[?F^
M)F97`_(;?W0OQ;WSVCU1U5DX\2N;R<.\NP\1)#@MO18/'+.]7+6O3Q)]I/H9
MQ$Q]^Z]U:QT3W9UU\D>F.KN_NH\U)N'K'N+8VV^Q=B9J:AK,74Y#;.ZL73Y;
M%3U>+R$4%?C*W[:I"S4\Z)-!*K(X#*1[]U[H5_?NO=`=\D^_>O\`XN=&=C]_
M=JT^YZOKSK+!)G-UT^S=JY3>^Y9,7/D:'$L,7M;#0U&2S#K/D4,B1H=$(=VL
MJL1[KW6H!\@_YQOPKWOV\(^C.D/C/@>H(NL\928[/=_?R:OD1W!VA0[_`(*J
MK"[?IXMI[QZRP<FQ::AF0J1'%-2U&M(TJ4<2I[KW0'_%?YC?%/OG_A33\%,U
M\6^J<'UG@JGX4;\Z?[,CQ_169^+='F.X8=C=V[_S^X\9UGDJ/^*5^*JL92T%
M)CC7KYO`P5ZF8TL;GW7NM@'XKY7&T/\`/_\`YKVWJ:*+)5NX?B;\`]RY#)O0
M54%1MNHV[C.Q\(=M05;2O2U=+FJ#.4N0=PJ$N@C`/A<GW7NKW_?NO=4&?S2Z
MW['^:1_("EGJ31T,GR6^65+)4%)S&^0K_C:<=BZ(RT\,LB2Y"6L>%%.F-M1U
MD*"P]U[J_/W[KW7O?NO=>]^Z]U[W[KW7_];?X]^Z]U[W[KW5/?4.8RVU?YY7
MS5V'$,>VW^U_Y??PS[BK/%'$,A#G=@=N?)'JVC:HD2)9"E9C<E*/6S$K3QVL
M``/=>ZC_`,BG;=;L'X%5'5=54/-2]/\`RY^>?5.%@?)KE&QF"V/\R>[,/C,6
M9E2-X5HH8M*QNH?39B%U:1[KW0T_!WN'NSL+Y#?S/.O>W-UR[DP71?S&V_LS
MIFBEP.%P@VMU9NGXR]$]E8S;]/)B::*?+TT.9W?6RBKK)9ZF:25V)12(D]U[
MJR/W[KW7O?NO=>]^Z]UK7;>Z[+;G^!>X?X#MC%OM'_A0#_,6JJZEQ^9W/CH:
M_P#O?C_YBZQ9ZLAW71&LK=S5,D5/4F"%_M'8*M+)X)`H]U[JW#^9OB:W/?RW
MOG]AL;+EX<AD?A;\H*6@?`-,N9-9)TGO84T>-^V9)WJYIM**J$,^K2/K[]U[
MJK'X1_S;]A;$^%?PKVYD/@C_`#1\JF,^+G0VUZ3=>R_@1V?NS9^9CV_UKLW;
M]3F=N9?:K9*.LVGD:N)*C'U21K#6T4D=1`'A.L>Z]T>[X6_S1.L/FMWGW3TA
ML?X\?+WJW,=.TF/R.=W-WQ\;M]].[;*5^-VQ6T^#S%=NZDH:G;V]\DVXFJ*#
M#UL,576XJF>NC!BO;W7NK0??NO=>]^Z]U[W[KW71(`N2`+@7)L+D@`<_DDV]
M^Z]TSY3<>WL)6X#&YG.X?$Y#=>5EP6UZ#)Y*BH:S<>;@Q.3S\V(P5+53139?
M*0X+"UE:T%.LDJTE)-*5\<3LONO=!PW>G72=^P_&>3)9&/MJJZ?J>]*3$283
M*QXFLZZH=Z4FP,CDJ/<C4HP=5D<9N7(TL530QSM5T\57!+(BQS1LWNO=!-U;
M\P=E=I_+OY6?#O&[=SV+WS\4=J_'_>&YL_D)\6V!W7B?D%M_=>>P1V[!!5OE
M4DV__=*6"N,\*)Y)HRC$-[]U[I/_`!)^4F[>_P#L;YN=8[ZV-@-D;@^)/RKR
M?1N,;;VY9=R0;SZ]RO5?6/;_`%QOK)B:BHS@L_G-L=DQQUV.4S)2U%,P$AO8
M>Z]TA?Y>_P`R=Y_+IOFGANQ-K[4V9NWXI_.WOSXJ08G:L^5D_BFQ^N3MG)]>
M;US,.:J:FKAS&[ML[FCGF*+%2O(C&*-5!4>Z]TBOY=O>6]OEW\!]RUFXM^;B
MSO<.`WU\M_CKN_?=&E+M/<G]]NKNX^T.M\-N#$U5#2TV*Q>2?;]#BJZFJ*6)
M*>FED6T<9C:)/=>Z(%A<WVQ\V/\`A+_N^M["KLWOWO+=O\O'M_!;IRN\:N:A
MW'N+M3IW![QVW6Y3.Y?(L&K\W+NOKWS25\DACR%0/.92DWD]^Z]T(/\`-Y[8
MIMW?R'LI\KNNUI\S5[2V'\)?EYUA53XZ/<&/?(;0[CZ%[8V[D,G09/'.]?A?
ML8B:]7AAE>B:4,8KL1[KW3S_`#T*>OW9T?\`RU-P8^+ST%/_`#=_Y<6XLU-%
M2-4108C,]@Y#$P5`H*Q7IY%DS.?HXU6I%E\MCZK`^Z]T('\TVAH\M\O/Y(^.
MJJFJIV'\P_/9F$0()(Y'V]\6>]<O$DRE)"/)5T\4>H#TQR.;C]0]U[IY^=D%
M?5?S3?Y'L=(C5%-1]G?//+9&&&CK)IJ:FI_AENO&IE)ZJ)6HZ/&T]5F(J>0S
M:6>>KA"$^H>_=>ZG=@9BFI/Y\GQCQ8CCJ*O)_P`KCY90R"E&NLQT`^37Q:KZ
M>MRP)418JJ?$S04S"Y-3K4BQN/=>Z`_J":OI/^%)?S%H)%C6BS'\KGXZYB(I
M)(7<8ON[<&+A:1+B-7$U54CD,0H4@C4P/NO=5(_S!F^.>Y?FO_-:V[\P1\2,
MC\=<;\O/Y54W8N(^6G:'?74U+-@8O@QV568->E]S_'C"[AWR>TAN2MGD>GFI
M9,5+@QD%JM"/YD]U[HIO\D6IRVPN]?Y,^P-IU.-W3\=V^7O\\O:O3O:N.P`H
M'[(VGB.G-BKMK.T0RE;#N7'X?-I@ZZJ62HC>IU0I32DFG`7W7NK[_P"5GC)L
M3_PG6I<+1LM?48KH;Y]XFE:!*FL2MFQ_<7R8HH'ACIO/65:U+P@J(]<L@;TZ
MF(O[KW0K_P`JS:T4?_"?7XS[<W2*-\?FO@-FI\BN2DAR&/;`;NV5NG+1I7BJ
M2NIWHOX)ET$D$B/'''>(QV71[]U[IGZ%R=;EO^$TNSLG6U,DE=4?R;\F\]74
MA)G>:+XCY.(SRB,4RR`^/5:X)'U8F['W7N@&^0F%K<1_PE!;"[MDBQN3QO\`
M*/Z9BK4AIE=8LG2])["FH*`P97P&.6:L2&GD:WEB=B\0+J@/NO=*;^?!0?<_
MR-\7@,WDGRN2RVZ/Y?F#8I3S8.GW7E)N_.CEK(*N*AHZ_*8&EKX8IZFU$HJJ
M9XU5-=C')[KW5<WR"Z^J>[_^%D_Q<I:O:V+SV`Z"^*>'W_ES5U](PQU-MWKS
MN++;8W3)33RP3S93#=E[_P`2*:&,33JR15.D1JS)[KW6ZE[]U[KWOW7NJ?OY
M=516S?,W^=<@CI7H$^<G58I<S%DXIJB7(#X.?&.GK<9+@%I%:ACPD=/`%JVJ
M)!6R2NGCB-,S2>Z]T6S_`(3>97*;R_DO=8X>:NDEKL7OCY;[/I:M&R9GC8]_
M]J5$$_[XG*5$DV6\Q%(TL(=_3:37&ONO=8/Y2'W>4_X3D]78B80-6XGXF_*+
M8;_PEO(CU&S=T]W[(UP/ZA)5ROA=3D"QF)(`''OW7ND%V5+5UO\`PD^>?<\4
M\F0F_D[;(GJOXVARE3)7K\>=O2T%9(9M)\TE2L4U/+_RCDHZWT"_NO=&E_FN
MU4+?RS>F\G6XBNSD4/R*_EB9*:?#Y%,/_"W7Y>_'*5,R\M;2SQM1+,PA\<S4
MXO4*3+&5O[]U[IU_G3X"MSFS?Y<DE+2U%?3X;^<+_+QRF4H:>:16J,?_`*5:
MO'HYIA/!%6"CRE?35!5K^-8C(.5Y]U[IW_F.X2?,_-K^2C>,G'X_YM]O9&HE
MCJ$BJ/O<?\+_`)!Y+&T\,<E)5I/')]C++,+*X@A?2R$^1/=>Z*3_`#'=X5&W
M/Y^/\A6@I\ODJ=<Y@_GG@JO'?:1SXUZ;-]3;=`EIG:!WBK*R;%+#52*VJ.!8
MQZ4>0GW7NC?=J0&?^>A\-W>GF5*+^6_\UJJ&IE@O2SSR=\?$JCEAI)^`*NCA
MJ`9A<E8ZB,6LY(]U[I%XO9E'C/\`A17NK>E+45[U6Y?Y-VW:++4U24>AA?%?
M,S(08V3%L2LJ:H(Y/N8@&57*/=3(0?=>Z5OQ&K/N/YPW\XJGF6DIYJ'K'^67
M34D5/DS4S5N.;K+Y`UK9*OQYF<8^K6OK9:8+H6\$$4G^[;GW7N@&_DJSPM\F
MOYZ-*U*R5]-_-3[!::N:LBK#4XY^O=G4^+I6=S/D0](M'*["69HE,^B-(RD@
M;W7NDO\`\)\,#4O_`"^?E3@\;60X*LK_`)Y_/G&T%71TV2J*7`U+]@56*I9Z
M.FR\M!G*FGQTL*R(E8::K8#3)H>[>_=>Z*=UUC<MO[_A'IF::&K@J:^D_EU=
MOY*6HJ:5622AZ[R^]<Q61"&:4`50Q6V'CBD!NLP61!<!??NO=&1_F29._P#P
MG"V'7UDDDLE;TK_+%EFG.DNTM1W=\49Y9I`2A;4;DA06)/"^_=>ZTZODK_*1
M[+^..W,1\H\CN+LC$]AYO^9!TUL7LSXM[NS_`%55=?\`8.3WQV3V-G=J=G[&
MWYT3WMOO.5VS\;)48[`H<Q@\5G,9D<O7^)U96C7W7NM]CYE;8CS'\V?^3%G*
MZ@AK:3;%!_,9J*4R1P2C&[BR/0'7U+C\C&]0FH21XM,A"IBTS`S:AZ`]O=>Z
M06[*W/8O_A1GTY'38ZAAP6Z_Y/G;F,K\O5QU/W&0?;?RZV#EGQ>*E6H%,:S$
MU.3HYI%,9(IZQR228]'NO=")U$(S_/(^;32HL50G\N[X,I2:S$7J:1^Z_E\U
M5/"%@ED6*.I5(V#31'4H/CD&ET]U[HN/\M.BJX_YT'_"@.J^]AIZ`;_^!D7]
MVZ?$UT4-/5U'QFEJQN,Y@)_"9JO/PFT],K?<J].)7`612?=>Z%?^4SF(\Q\F
M/YV4M.\[T]-_,[S-!_E%53U,HJL3\<.AL'6A1&//%3K48DK$KG2D2K&`&1_?
MNO=!1_+?2@R&T_Y_&)JA05YD_F@?-B'(TU?CAD:&6AR'QZZ42&ER&/\`'(F2
MHVIP\4D%F\JJRD78CW[KW0O?\)T:FOJ_Y*GP#ER4[5%0G5VZ::.1IIIRM!1=
ML]A4>*@USDNJTV+@AC"#T1A-"615'OW7NKK??NO=!'WUVR_173O8/;\?67:W
M<K=?[>J-P?Z+^CMK4V]^VMYK32PQOB=B[3JLM@X<_FRDID6G^ZB9XXWT:G"H
MWNO=:ROR<_F[8'?^9[$VKVW\4/\`A0GTML_L3H_&;"J>F>J_B/M+8%1MO*4V
M_(=SUO;.R^Y]K;KG[$I=R;IQ$4&VZY$RDV+CQLLT2T\=1+(_OW7NJC/BQVGU
MUWG_`,*4?Y7.+Z,^//RT^,/5?0/Q'W?U/M':7R_PFY<=W1N;%;0ZN^4&Z,IE
MLK-V)N;=.X<AMN&JWO+CZ:I.5KFT8\QP)!$(Z:'W7NMCWXC0K3?\*$_YO?W-
M57SU.1^+WP!KL9$X=:&DQL&TMT4%=3KH"PR,<A"DL;/>0&68*;:A[]U[J_SW
M[KW5#?\`-0P=1D?YCW\A7(&HI8,?C?EW\@HY_+7QK42Y";XXYO*8V&##RRHE
M;'+'@ZA7J@K/1NT:K8U%C[KW5\GOW7NO>_=>Z][]U[KWOW7NO__7W^/?NO=>
M]^Z]U2O'F*G;G_"AJIV]&D5/C>TOY0-)G*IWI*BHGR6:ZG^7U5CZ5:>M+>''
M14&*[*D\D8NLQD0E0XU'W7NEG_)Q_BN$ZB^8'6.?Q5-BMP=1_P`S'YU[=RZT
MV0ARBUQW_P!Q5G?N'R,M=314\$L]1MKN2A#*L<?B*>-AJ0D^Z]U9MM;,=:UV
M\.S<7M"7:[;XP><V]#VS#AJ2BIL_'GZ_9N"K]L2;OE@@BJZ^NFV/-CQ233M*
M10I'$C!8]"^Z]TO_`'[KW7O?NO=>]^Z]UJS;(RVWH8_@WEZ+?FZ*NHQ__"D;
MYY;?>IIYJ=\A!D-YU7\P=6VCN''/'2O2XRLQ67@62.6*.H@I*I75+,I]^Z]U
M>C_,5HXLA_+\^<]#-2U5=#5_#WY+T\M#0Y/^"U=;%+TQO19*.GR^I/X9+5J3
M&*BX\6K5^/?NO=5;_$3^:;V+COBE\4=O[;_E`?S*)HZCXY]+R;3I-A;*Z>W+
MUDNS(NML*FW:S#]H;O[\PCMC:O%4U.]'#FEI,X::5#64\51JC/NO='>^)WS!
M/<O?/9&R:KX%?S#?C7N3<U/4[MWIV'\E.L\!A^DJG-["QFU=AT^!VAO3;O<7
M8>VGK,ICX8WH8\+3I091*.IK2Y=S)+[KW5F7OW7NO>_=>ZU*/YE?QFIOGC\F
M?YPJ9K?'>^-[&_E[_`[XX;^^'--U]VUOC8V#V+W'N[8?R6[?SF9H-J83(T>V
M=PU?8&3V%M_%9&>LIZB9J.G:&&:"1(Y(?=>Z/?\`.+Y%Q]K_`,@F/YA"E;>$
M.3^.WQ&^5&:I*ND?'U>;I=N;YZ2[CW?3_94-;&,?E:FCQ%8B1"I6&*H(2201
MAF]^Z]T:;Y][FA5?Y:W>&*HJW*;0VY_,)^.];E9Z:J@HYJ+;WR'ZX[;^-VU\
MQ41SUD%+/1TN]N^<&]5'>1Q3F1HPSJ`?=>Z#_P"4FXMM=6?SA/Y7&Z:W(Y"A
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M&NH<CN+'Y7"8NCW/L!Z*..O@@=5I1(IDCE263W7NBY?`;^:3_*]^+=-_,GA[
M`^?OQ@7'Y+^9-\DN[\++M[>=-E:O<^S^Z:+KG>6.KMAX;!4-7F^V(*',Y2MQ
ML]=MRGS%,]503!9F2.X]U[HKW\N'^:G\&NIOC%OSX9?'GJ'^8;\WAN?>WR?W
M_M^DZ_\`@7EZ0;PV9W=V;NW=#4C451O3(X*;:-*-Y"C&6S53C4GI6C%32T3L
M*-/=>Z:(N[_YFW?O\HV#^6YC?Y*ORAK][S_!W"?&3=G9O=G8?572>R\9NW'[
M0DZSP>\MMX+<.5V_G-UX[#G`TV82FC;&U$$B)'+":9HJBI]U[J]3Y&?"7N[O
M/X!_&3HS978.QNN/D=\=\W\+^W-N;G[`V]7]A];2]K_%O.["W;/BMW8C"9/`
MY7-[9S.5VQ/#))25$$SZE92M[CW7NB9=R_"/^=UWIV)\:>SMZ?*C^6A!N/XJ
M=M9CN7K6/"?%_P"05-CZ[=.;ZRWOU164.ZER'>F3KZW`+MK?U;*L-%44$QK8
MX)6E98@A]U[H0-S?&#^>;O;L;J+LW.?*[^67BMQ=+)V1/MN3$?$?O#*4V<J.
MP-KC;]3CLX,YWM)F<5CE6GA_=Q&1H)01KG2L1!3M[KW05;D^`W\['-_,#:/S
M23Y??RXD[5V/T-N/X[X.E'Q,[BCVN^P]X[WVOV)N*:JH:WN7-;E@S\F?VO#3
M15--F88EH&E40(\[D>Z]T^[(_ET_S;\5\M>R/G)E_F_\$,%WQV=TEM+X[YK%
M8'X-]E;DV'0=<[$W!E]U[?K\345WRAVENU=TU.>S\\M8]955M/+'!31%6A@A
MCB]U[HE7S8^-GSB^&^:['^:7R=_F4_RR).NN^]V]4;,[AV-\COY:IBZ-WWN;
M8NS=Q8'J0Y_([3W3VCW+F<YMO$KD9,;]QF8:>D<N$E2-_`WNO=!)_+2^,F_^
MA=A?`[9WQA_F9_RV.]]@=@;\^76XOA%N#L7X"]DY+?V&[$EVWNH?(RFZ*W%C
M^[=JYY,=MRDCKX<@^2J\;Y<<GVS?<1"G@7W7NK5^A/Y?/\U7XV_&6;XJ;!^<
M'PFS^Q&HNX(*3/;O^"._/X_CZCNO?F[M_P"Z*O\`AV,^5R;*K_X7FM^9$XZC
MFPYQOVPBIZB"906/NO=%:[@Z=_FT?R\_Y<6[MFYWYV?RY=D?%[XU?%U.MI>P
M*CX8=N1;^H-I83:5/L^@KH=O8'M3<.R*[>^4JZJ*@IPF!J:*NJIDEDQY>62/
MW[KW587Q1^4G\ZM_BO\`$W^63WG\?_C;\"NC?DU\>8?AO\:_DOWGU=V%V'EM
M^9@]3+A\#LS.[4PO<=7CMF]D=B=>05]5C7W'@(<94UT!A^R<N(E]U[JZ#<GP
M,_G:[U^)DWPQW;\M/Y:.8ZGK>F<9T;D\KD/A]VGEMSY/9N(V]1[<@DKL3D>U
MWZUGR==C<?'%-;`K11ZV>&F1EC"^Z]TT?*+^7-_.;^;/1^*^+W?_`,RO@/@.
MFY]X].;HW5N3ISXS=O[?[3G'4.^=O;WQ8PS;@[8S&R:.HFRVVJ6J98Z"FA::
M(1(L$!96]U[JLC?573[K_P"%K?4>,AK<C2S===`KC\E-3TTJG,5?^R;;^W,D
M>0DQC4<8I)J;>$!>253!Y(EB*6T`>Z]UO">_=>Z][]U[JEW^6UN_%9?Y^?SQ
M=KX:D!I<!\Q.@LO4Y=ZJ4U%7ELU\..F]NYO%'',1'34N%RNQIC%.%#5+5+@E
MEC2WNO=4]?R#OEY\X-C_``%RNQ.DOY9?:GR3V+LCY!_*1\1V]%\F_C[U3MC=
MN2RG;FYMTY'`;/VOV5DL1N>GCQ&3S;TDT@AJ*"6O6H>.H+^6GI_=>Z0_P#^?
M'S/V]_).QFR]K?RDOD%VMU9C>F_E%M7-]Y;7[X^/FUL!DFJ-Y]OGL7<6'V35
MYG']BIC]K9:NR,#_`&N(9IJFAD2E\ATL?=>Z+_F/FU\\]W?\)VJWH^C_`)0G
M9>*^,V$_EQ[1V._RQR/RLZKI,;6;'P?7.(PO^F_%]4S;1HMZ9;!SRXLYJ7$1
M3?<KCWTF5T/E/NO="A_.>^;?\P;_`&3[XC]0]M_$FH_E_='[FW1L+>.YOD;N
MG>N`^76(RW8?QWVQCNZ_CWTY%MGH"EJLKMO)=M=K[#QE-%+E*:%)JI(U4I30
MUT@]U[IS^;O\SW^83W%TA_+>SGR7_DG=H=>Y=_GQ\'^Q-A9VM^0VR-O;>[)[
MWPV6CS^Q]AX+9.;V]/O+K6H[3J*G(4U-'N@F+;ZD+5SSU$;%/=>Z-=\TOG#_
M`#&LC\L?Y;9['_DL]E[;K]@_+/L;<73]'@?F]\;=VU7<N[T^(WR)PE;M+&_P
MJ*BQFUI,7LW/UFX)*K+5D%'*F&GI(S++(A/NO=5-?/G^:3_,$3^:U\:OD!GO
MAKDOB[WQ\3MKX79_QM^"?9F$W5W=VI\V\%\G]ST^T>[EZJ[`ZUV3D.OL-E\7
MLZBAC^ZH:L5&-FIO#KKY35X]?=>ZLYWK_,6^;&7_`)LGQ0[/W/\`R:?F7M7)
M;7^&GRUVIA>N:'L?I[.[OWWAMS;[Z`SVZMTXE)LSA-ATN.Z]KMFXNEJJ:;-I
MDZV;<%(4IQXH%J?=>Z:\[_,L^5N+_G/9/L*@_DV_,[)]AX[^6;#L:?JL;OZF
MEWQ_<:;Y'5^^J+L85>$SNX^O!M:JR=%+B4A@S4F6FRT;4WVKM$H'NO=$2^&7
M\Y#Y;87^9I\L^]*'X6YCY!]H?,9Y-E=K?`KHG;'9>.^5?P\Q'PPJZSKKI[*=
MVY/=VS:'KG5OC"[WK1DJE:VH=JBF0A,?&(*23W7NAV_E;_S,ODKLSO[^;CO?
M97\J#YH]R;H[.^>B[H[$V+M//=9T^7Z)R$VU!MN/K[>5%N&MPN2JMW8\[;JI
M97HH*C'BG-.DD\/[<M1[KW1<?C!_.8^3WPP_EU_.J?K_`/EH_+C(5M5\L?FA
MN:?Y"[I@IY.G^@.Q>U.V,G%78GMK(T&W\I64.7Z4J<M`<O$U-#25F8B:"22D
MCG\R^Z]TT?&;^9-O+;G\CWYR?R]7^*7;ORUZG^-?QH[]Z-P?ST^'^'R^>^,^
M7HNP]I[OW)1[@WU4]EQ]5;SP%!U:V[9),[5XZDRPDHL<9Y*6*GFCEJ/=>Z--
M\Q/Y@'9_</\`)5ZF^-,?\M/^8%L6D;J7X`466^2'8?4>UL;\>-K4G7?8?Q[W
M-4]@1;QPV]=P9>MV?E:7;-\?6'&4Q*UD3U*4JB4)[KW6N-_,DP7Q?VQ_,OJ.
M^?B=\?\`L;X6;9ZJQ4OR,WATQ\X*'?>R]J_(;Y$=*=S25FZ.O_C_`$F-J]V[
M@SF*[1KX*?[2G?*X^G>5:\T_\+18*?W[KW6W=\G_`.;SOR/Y8?RHM_9_^55_
M,SVYO.5?D1GJ?K5.M.N,GF]]/O?X[U5!E=K=:18+L/,S;TK]IS,N7R%+EAM;
M(4>*H?O)*0M>"/W7N@&[$_F:]G0?SMNC?D#EOY5?\RZAW7AOY:G<&R\=T5%M
M'KJ?LC-[?G[8P_8-?V/C-K8K>U?A,GM7#T="V-KHYLQ3Y,9NHH*5*%JKPQS^
MZ]T`W6/\[;MS$_S7]_\`RRK_`(G[\W32?(/;E+\(Q_+HV-A]R;C_`)G'4NVO
MCK%6]J;.[MW_`-*5N&Q6"VUMK>>X>U<O'-0OE(D%/(9$EE%`:BK]U[HSWPT_
MF4]B[-_F6_SBM][,_EC_`,R;LS<':V\?A=G-Y=3XG9_2_P#>?I&?:?Q]Q^Q\
M=3[\I:OM:BQ>-SN^XZN+(4-'15^3F&%I_/4>`4\^GW7NF'X&_P`W7>/67R7_
M`)H>0VU_*>_FE]EY#N+YI8G?^;VWLWH?;.0S/4&;;HKI_9.1Z^[1,>ZJ##;>
MW@<S@9<C2P+4U)GP=;2U4DEVD<^Z]T:W^1SO_+]U]5_SS>RL_P!9;@ZDF[#_
M`)A_RKR]?U?V#24\/;>S,EE>K-LU.4VIV52IE*N@I,S@XZV&C^RC*T]+-#/&
MLLPO)[]U[H\W_"<__MRG\`__`!%^Z_\`W[?8?OW7NKKO?NO=`K\B>YG^/73.
M^NY%ZG[D[Q78F-I\K-U?\?MGTF_^W]T4\N1HJ"HBV7LRLS>WEW%78^*K-5-3
MQU2S&E@E:-9'4(WNO=:ZWR`^<N__`)#]C8G=V"^-7_"H'XZT-#MF@Q,.Q?CS
M\8OC;M/K^JJ*;(U]<V=RE/V#CNPLO7;@R"57CJ&FRIB6GIX8TIHP29/=>Z)5
MU'W]V+\B_P#A3)\!%I?C7\TMJX_H/^7?O/8>[\U\V=EX;KCN2HP0Q7<>.K?D
M3G]O[4C_`+JR4>Z]UYO'X"?(TRTM+E,O5S)#34^B)6]U[J[[HG8G\!_GS_S!
M-VTL^Z:VGWE\"O@]FLHV1JDCV]ALJV__`)!;1I,1A**6K,]52U6+Z]%8DL4/
MBIZR:O60J\R>7W7NKJO?NO=5+_S"NM*W?'S!_DYYZ@R\V)?97S5[-R5<8,>T
M[UF)C^'?R#W%5T,F0BIY):*GKZC:<%-)&SI#,)];@M#&5]U[JVCW[KW7O?NO
M=>]^Z]U[W[KW7__0W^/?NO=>]^Z]U2/V[NL;7_X4#_#3%)@/XS)V7_+7^5NS
M)<DDCP/M"FPG=/3^_P#^-R_Y%41UU/DJC;*8T1"6`QR58D+&RQR>Z]T-/\M%
M<-0=B?S3\%B1IDH_YGG:F9R*K6BOB%;NKX_?&G-U3+,<;BGADDK)IF>G,3_;
ML=`GJ%`G?W7NC'=3=/;SV?\`,7Y@]O9:ED_N1W+LSXNT.S<B^6IZI9<IUGA.
MU,/N_&18?SS5N)2@.;Q\YD98J>J:L/C4R1SN_NO='!]^Z]U[W[KW7O?NO=:>
MG4^Y<I29WJ"A>JJ:6?=G_"M?YA4]4E))3M3U>.PVT?DTXIJ^>C,<48+8^)EB
M(#R%/4#9F/NO=;)G\PF:*G^`OSAJ)ZE:.&#X@?):::K:!ZI:6*+I?>KR5+4L
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MOMW5%2XA!@EGJIB&+%_?NO=$#^-ORCJ.N?Y6F'_E6_)K^63_`#0.T.SMA_'O
ML/XG=L;=Z@^)VZ,[U[NS%XRGW=L>AW/U_P!W[DGPVP:C$[GVVE)D<5D4>;[6
M>HC,<<H@+'W7NC4TGR,_F7;Y^)_7/6?17\C_`'55T?6N#Z/I=@0?._Y,?'K;
M35+]//MC(;8W-GMB8C.'>$6^=L[BVC1U]')6189TK8$K+1.J4Y]U[H/._OB)
M_P`*`_FEO#XE]K[JWO\`RR?AUNWXQ]JU_;VSI]C8KMGO'?N%RVX]I9_K_-XG
M+5V]-F5&VLCCIMD;HK*6OQF.K:6CR55X9C5H]+321>Z]T)FZ/Y,/SB[U^1/7
MOR7^17\Y_NM.PNL>N.P>K]LCXI?';JWXVU&U]N=FO05>ZL5A<Q/N3LZ&2DRU
M3BJ"6HDR6-KLBS4%(\-33RTT,J^Z]TI,G_PF_P#B!O??>Z.U.[/E#_,A^0':
M.Z=CX[KRH[#[3^8.X!NS&[4Q->V4QN&QN4V!MC8DL^&H<G+)4Q8VO^^Q:5,K
MS?;>9VD/NO=#ALO_`(3V?R=]FR8RMF^$VPNP<_CZB&LJ-T]P;E[%[<W#GZ^'
M5:LW/6=@[PW!!N`R!K-#4Q/3:%51$%15'NO=61==?%3XO]055'7=3?'#H;K"
MNQ]##BZ&NZ]ZAZ^V96T>-IT\<&/IJO;FWL=4044*<+$K!%'T'OW7NAXCCCB1
M8XD2.-`%2.-0B(H^@55`50/\/?NO=<_?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW6O3_PI7BR>YO@5U[T[+D]G8+K[OOY4=8=7=LYO?W>6U?C?M"CV=_='LK?
M6+I\_P!S;SV9OW`;%QM;O_9.%66JGQTB2JIIBR?<:U]U[HD7QQ^,?7_Q=[1_
MX2S=4]<]V;,[UV[U_3_S*:)NS>O\]MO<NP]Y[F[#^-NY>P=[OL_.[(:KV]G<
M-MW>3UV-HZXRR3RTT`-1*9BP]^Z]UMY^_=>Z*7\[/B-M+YX?$CO'XC[XW3N'
M9.V^[-I0[=J=W;5BQ]1G=N5^,SF)W/@LO24F4AFH:^*BS^"I7J*9_&:FF$D2
MRPNZS)[KW5#G3W1?\S[YO_+G:?QW_F`=U_%Q.G?Y37R8^/'?51E?C]L;?&$[
M.^6N_,5US/O+H'>>[_X]N2IVWU]A8FK9*S<%!CZ2GC;,I64E-%+21TM6ONO=
M;2_OW7NO>_=>ZT:IMXUE;_PMEHL9DXV9,5TS)L_!'#434S-1M\*JS=S2;DJ)
M*FA-8L=1D:L">,5(*K30E+(S1^Z]UO*^_=>Z][]U[JA/^5Q6-+_,_P#Y_-+)
M(R24_P`G/BG.:&*-OM(89_C-14\%;'*L<,3UF0CH/\H4)K5HUU/)J#>_=>Z8
MO^$VM!F<'_+^[2VG6+%3P[-^=OS5VMMZF:DKZ6&AQV-[?R3/3-1UU745<,<6
M=J*P^,RET!TLQD#NWNO=`;_+(W%NFG_X3F[2P&)V7E]V9?=W3'\RG`9;*XBD
MQ;8':.8HM^?+W.P9'/X_/5D<U1@LYN'&18FFCACK6-7D(%E7P^65/=>Z#N7-
M9<?\(_4K<EBYX:U_Y8E-@HJ2K*TDAQ,N)BVUB,HFA)?)!/@GAK8`!JJ(F0<,
M]Q[KW5@/\V[9=50?RONJ]ORTT&Z)=B]]_P`M(9'<>Y:,K5XN#;_RS^/&*R6\
M*K%T$-'+)D)X&>&IIJ>FU&*LF580/2/=>Z9OY[M%]UM'^5M/XY91C?YU/\OW
M(,D5+65)(AW!OM?5_#,-GLI"I:0#53TSNQ(1K(S$>Z]TLOYH4N1QOS'_`)(V
M:QU3)2R1?S`=Y8":6-7):CW1\3.^,=D:8L9?MPE9BTGA8-$TA1SH=+-K]U[I
M+?S"\;BZ+^;S_(;W9_=?&UV:G[%^>NRFW'68B"HDQ^*RWQ(RV:%%%E4J8:RF
MKEK<)YJ2-DEAL*AQI8>KW7NC3=W5^;Q_\T_^7_&L=/5;>SGQ@_F!X9HT$BUN
M,RL.XOAIG6RDKK!)'+CYZ;$I2Z&=-,TJD7O8^Z]T2S>=9DJ?_A3?TQ3XZ:M:
MEK_Y-O8=-N*G:GJ%H(\='\LH:W%RQU,&B*>IDR],H(GUQQJ/19W%O=>ZY?$2
MLH\7_P`*#/YO>!H<?!3'<OQA^`.Z<G4T^,AA^YR6!VMO'#+/55],D7DJIZ+-
M1I^_Y)ID@`#!(`H]U[I%_P`DB&FB^:O\_9E\\%9)_,KR9FHJA7NE+_=JMFI:
MZ.5H85>/(RU$SHHN4C"7)#!F]U[IB_D"9AM\?$K^9IMO?VWL-4T=)_,]_F!X
M;=&#R\1J3E*;<E?A<ON3#[SQ=?0TH+.^8J*::.9;RTI57C2Q4^Z]T6_X(/M>
MC_X2#[[DP,.'HHY?Y?'SS7,C:,*ZIMS5G^GVFJVR/CITEJ-PU,\L2U[.'8S%
M@'90K>_=>Z.1\TZS!C_A.?MBKAJYJS"3?$;X+C$UT^/JZ*>J6KS_`,>H<#5S
MX^TM3CVGJ98'=9#II[DR,$5F'NO=:-.7_EV_(/J'9.Z?YG&]*SL3;\&P_P"9
M=U%3;3^._='Q_P!^X/`=J9K<O>>[=Q[>WKA=W;UR>$P.^.NJ[`QT9^[Q5/4K
MD),Q44DSTZQI/5>Z]UO_`/\`,:E=?YCW\BR($*LGRD^5$C#3)Y-2?"OMA`!(
MH,*IIG8,K'4UQIN`UO=>Z`+LW,3S_P#"HGXSX6"LK<8F-_E']I5-:K(?L]QT
M^5^068*8F%EBG_X!U6,BK9"3#ZJ5!J/"/[KW3MTM)'0?\*8_FG0)08U6W!_*
M^^/V?EKZ>.%*XOA^WTP@2L>,O)+-4QU"AFD*/X:6!=)55;W[KW7'^6JTU1_.
MQ_X4$55;04V$JH]Q_P`O&B@QU%1RTL&6QM/\>]XI2;HJ&R$)KY\AD$0)+)#(
ME%(R'QHQ'D/NO=&5_EPG,4_S$_G1XO,9F#+O#\[^N<K1?9)60T5'C<W\+/C3
M/C*)8*N:<K7T&-IX:2LD1A'-4TS.BHA51[KW1$_Y,.8P6%WO_P`*&:G>V5JL
MIB<%_-'^4^=W;BJ6JB6M@VG_`'<>>HJJ6E-53BFJ,CB\=44T<S21"5J(#6OC
M)7W7NC@_\)V33G^2[\#S1B441Z[WJ:%:C1]PM">X^R#1+4&,F,U"TI02:21K
M!L2/?NO=74>_=>Z`WY)=L;RZ-Z3WYVKL#HWL3Y);MV?CJ2OQ72_5$^VZ??V]
M#-E*&AK(-OMNO+X7$RS8N@JI:V6(2O4S04SI3PSSM'$_NO=:=O\`,/\`YL?Q
M#[%WM-F_Y@G\H[^<3U3GNO=G9'84U;MC?'8O3FSZ_K'=$]%O*IQ.\ZKK#O#K
MO8V>HLF\5)55<50V0$4D`@DG(@*#W7NA)^&_R.[]^87_``HOZ8[@V?TIO'X-
M=08_^5-BL?/U9\F:3`57:WR!^,LO8&<S&R\ELS"8O)963:V0D[3W%C:M"N1G
MJX,5MFIDJR15FD]^Z]U=CUB)J;^?#\N(1N*MFI\E_+.^'>1DVZ8O\ABFI?D)
M\I<=#4>64E_+01H[QB+]MOXG+K]2#W[KW5Q7OW7NJW_FOW'1]9?)S^5GM>7&
MQ5]9VW\O>P]EP3RS3P'$TO\`LGGR1JJG)0>&JA6HG-8U+3>*6.:%DJ&:RR)$
MP]U[JR#W[KW7O?NO=>]^Z]U[W[KW7__1W]!(ID>(!]<:1NQ,4JQE93(JA)B@
MAD<&(ZE5BR"Q8`,M_=>ZR>_=>ZI.^4F+HJ3^>9_*AW#_`!`??YGXP_S%-M-C
M*:=8:D08C%]$9JFK,E&DRR5F)E-?.L<;JR)51JZ^H$K[KW0W?!G*5V-^8?\`
M-PZS&"QF'V]M[Y9=-]BX:?'8VEH'RU=V]\-?C]D]S5]?)2,PK*Z;-;=>1Y'"
M2N9-;@ER[^Z]T:K"?)"AR_R^[#^)3[9:FRNQOC_UEW]#NY<RD\67Q/8N_.R=
MA-@GP/\`#8I,=4X2OZ[:8U!JI4J8ZU55$,3D^Z]T9GW[KW7O?NO=>]^Z]UJU
M9+-U>Y-S=#T%7A-L[:INLO\`A4/VOM3`8_;..Q6'CR&)KNJ?D-N:3,YMJ2&"
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MQ2U])B?DKUYT#O/JGL#XV;,S_73XG+TG9>-JJ+<>,W=B<Y]Y#-0A_$8PCLC`
MJ?=>Z7F1^>O\Y?'[7DW"?Y%BU$V+PK9'+XF#^9#\>9\Y55=#0--E*+;N%H=B
MUTF2>6KC9:!6G6:JCTZHXY&T#W7ND?\`"#^;/\S_`)%]V?%G;OR(_ERXOXP]
M`?-?:W:6X?CQW#2_*39W;6;R59U[LRN[(Q^#W/L;`;/Q%;BJO<VQ<355M.TL
MM.6CB9U1A'*B>Z]T>+Y<?S)-H_$#M/:O5F=^*'SY[UGW-LJ7>T^^/BQ\3]]]
M[]=[7@_BM;B*/;^Y]R;7E5Z7=61FQ\DJ4=-3U7AI]$E0\(DCU>Z]U2C\&OYM
M/1&T/E'_`#5=QX3X5?S0IY^QOE-UIO&HP&#^%'=6^=P8;*P_&[JG9.7V[O':
MF#@SM=U3NVHW)M.NRXH,X^.:HQ66HY(415>*+W7NK(W_`)XW04;5Q;X?_P`T
MQ::@CR+25[?RZ?D8M'+/055/1)1P2-MD2-4U]1.5A#(JJ8W\K1>G5[KW4;'?
MSQ>H<M]C)C_@=_-UJZ3(/3BGR%)_+=[^K*%HZF18UJ$EH\7/)40H&U'PI(S`
M64,U@?=>Z"NO_P"%`W5^_1FO]DY^!O\`,<^:D>R\YDMI=G9/JKXP;LVE@^LM
M^82N6@SG6NZZSLU=K9%>QL)+(K5N+IJ.H-&C`SR1$A3[KW6:J_G7_(:`02Q?
MR/OYJE73U5#59&FEINN.MJEC34:LTZ5,-'OZJ:AKV*$14LI6IG/^;C8D#W[K
MW74'\\'N)BSU7\DG^;U!31I*\CQ]`[2EJ2(Z>HJ`(*2;?U*]4Q6F:ZHQ8$@`
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MZ`KY$?S1]B?([#]1XOY7?R&?YL>^>D<=V90=D[)H<]\6<%O]:SM#8U#N7#8:
M/>72M'O:I>NPT=/N"9Z6'.#[6KJ")HJ>7[9)1[KW1?<+\K_A-\4^R_Y>6U<?
M_)=_FW?&]>CMW]_[@^%&P]N=,[7SM'O#M'Y"[!W11]K[*?`UO=6YL]F\O5;-
MR^1S*T55DJ.;$BC:22**DI75/=>ZLSS7\];![5R4&)W?_*K_`)S6WJZOI*^O
MQ=/_`+)'3[BDKJ/&A#53,FT>T\^U!X[2M_E'B3Q0M)JT^_=>ZB3?SY=L>3'C
M'?RKOYTF9@R44#T]1B_@;D9D+U/B6..02]APBG6*9S'*\QB1''!9-3K[KW1%
MMK?SQ_Y<OQ3^0G\PSO[N'IK^8K\<_D=VWL?H;LS>WQZ^17QPJ\%N7=^#ZAV9
MF.K^NJSJ:FVUDMQ8O;&(S^!$4^0K-TY/%8B.K>1H:QV6:-/=>Z?*OY\_S8?B
MSU!T+_-2^9/:7Q/W+\!>\*KHW*=D?%;J7K3<$7:W1'5GR/GQ_P#<3<_7&_JJ
MN7-]O]C;*.[,/_',8[U$-?2QUK8^E#HD@]U[HZ-7_P`*1?Y5L-7C</CNP>_\
M_N?+0I)0[/PWP\^4<FZ)YI1*L5'%BZ[JF@,]5+41B$>-W3RNHU6U%?=>ZUZ/
MC-WQ3_,S_A7WM?N#$=)=D?&VEV9T=NRGJMA]^[!;JKN3<E)C?C%GL/1;JW/L
M>:6>NHLON>FWM25="E5*]2=O4\#R:&3PI[KW6_O[]U[KWOW7NM;7=.S_`.9'
M_+N^>'\P?O\`^.7P<A^>O3GSNK^J>TMOU.Q^Z=@=2[TZN[*ZRZUI.M8-B[RV
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MABBE$1"Z??NO=#/\[_AOW9\EOY:=%\2MC[JVVG=2#X?_`'.\]SY?*8S`RY3H
M[NWI/L+>^X)<M08W)9=)ZG&=?U\](4IGEEJFC4Z-19?=>Z</YH'Q;[P^4NWO
MA-1]$3X"CSO0_P#,:^*OR8WKD-P9N/"18_J[J;);KGWO68ORX[*KE\VE%F8U
MIJ'PG[EF()4`L/=>Z<?G#\4NSN_?DK_+'[?V`^+EP7Q/^5.[>S^TJ'-9E,?1
M#8>Y.B.Q]DG+X[&&FGESFZ,?N;)XZ"AC1D,"5L\C'0&9?=>Z??E7\<^TNVOF
M7_++[GV?CMNU_7?Q?[:^1.\^W)LOD:>DRV,Q_8GQC[`ZLV;7[;H98S/E:P;K
MW+%%,D3KXH93*P8)=?=>Z7_;7379&Z?F]\-N\=N4F&EZWZ@ZO^7>S>RZNLR*
M09BDKNX(N@JC8BX7&&TF02IK^M*T54JDBG15!4^4,ONO=%GWQ\0>[\Q_.LZ,
M^<V'@V^W0&S_`("=E?''=U7)G*2+<\&_\[V]#OK"TL&WGI?O*S$5E`R.:J.8
MI%)3LK*FH>7W7NE'\=OB_P!X]<_S2?YCGRAW)!A:+H;Y(]9_#7;G6S)FJ'([
MASF[>EME;TP6\*RHQ4$<M?MW$8=L\D$:3RQ+5S3M+'$PUR>_=>Z3?\NSX;]P
M_&?Y-_S5>U.S:';--MCY<?+S']Q=0U6WLT,E4Y'8D6PJ#%F?.X\6?!Y:#+S3
MPRQ2*'DE1Y`6B:(^_=>Z#[^4Y\-?D3\4^H/YA6Q^Z<#MG#9'O'Y_?+WO#IM,
M7DMOYN/-=7]KG"_W-SF?J,6D4\=5E:ZBJ&-+D6^ZIZ?0C+''H4>Z]T%OQ@_E
MY_([KW_A/7E_Y=6[<'M/:?R8S/Q#^174HPV(W=#D]L4^^.SQV1/MN.;=E!#3
MTL$U>-STOWTT9FIZ:LDETR2PH&;W7NAH[?\`B!W[V!_)'V/\-:?;.#G^1>(^
M)WQ9Z[S&TI=QXE,,N_NIJ;J6JW;AJ?<]54G"2M356S:N.FJFG%+-,B,)0C"0
M>Z]UI>[J_E.U'?'\MCL/^:MU9O/Y1;]W3U=W5OK/]K=`[OWAC7V:N"^/OR5W
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M^6+\HOYQ.(A_EO\`RI^8W77SX[OK.].FNP^@*C96:V$^/[(V]NZDSVT]^/59
M/#;DV3D<)GMP/2SN%JY9*>-72*%?#45GNO=72?R4N@>TOB]_*Q^&'1?=>V*K
M97:>QNK*D;RVA724TF0VQDMR[QW1O"+`Y$TE360)DL70;@AAJ$$KF.=&5CJ!
M]^Z]U:1[]U[H'/D!V'O_`*HZ?WOV%U;TKNCY$[]VU04=7MWIG9>XMI[4W-OB
MHJ,MCZ&IH<5N#?&2Q&U\=)CZ"JEK7-3.ODBIF2,/*R(WNO=4O=S_`,U;^9GU
M)L#LOLG</\BSM'#=>=<[7RN\<]NW?/SO^'F$P^,VCMW&5.7W7G-SP8?.[HDQ
ME#A\;222D4YKS)&I8Z;:3[KW5:?0_P`E.S?D+_PHP^%6]OGG\#=Y?#GMZM^`
MG;VW_B?C\)WAL_O?:.ZJ^IJMZ;NR/8&;W1UW1X[!0X1>J<ANW%143/5R4U?5
M4LT\4?D@DB]U[JY3KG<./E_G]?*/;M'08)ZF/^5M\5:G*Y22HKWW)3UN.^2?
MR*E@Q]#!]NV-CQ%7C=S02UMY4E\L-&460-(8O=>ZN<]^Z]U4%_,8)'S3_DJ6
MDCB/^SR=MC7*\B(0?@Y\FU,0:(JYDF!THI.AF(#`J2/?NO=6^^_=>Z][]U[K
MWOW7NO>_=>Z__]+>'Z>_TQXW![XS?>>:VMDJO+;P.=VCB-EXK+,-D;.DV9LV
MDK=DY*=X6GW/D\+V#1YYH:^G@1:K&S4I*F02,?=>Z*WC/YD&PL#VAA.G?D)T
M-\H/B_O/??>,O073>0[+ZDJ]Y]==W[PG6:NP5;U]V=T3DNVMG8[!9W`1BN2H
MW-4;>\*I41R*'HZH1>Z]T57YPYVEVE_.?_DCY&2E2JGWOMO^9!U8GJ+2T8R7
M276N^X\@L9AF5(H6V"T+R+XV_P`H"EM+,#[KW0U?#G:==M[^8]_-\R]4GV])
MO+?WPPW%BX?XHU<:FGB^*6VMMU64^R>E@.+2?(;<EIU0/*':E9@0+`>Z]T<N
MB^.F%HOEEN3Y9KNS<<FX=Q_'S:'Q[FV.8\1'M*FPVT.Q=Y]BTVZ$EAH(\Y5;
M@JJ[><M+IGJ9*:"GC)AC1Y92WNO=&*]^Z]U[W[KW7O?NO=:QE/68W.;XQARU
M?'D\KB/^%..?H</+5S8:KKL?D,?\>MPM!CJ&7`5!QL+4VT&DB$=4RUD=`6CJ
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M,3XI_$DL;F&,LRV75[KW6U=[]U[JDS^6ANC>N?\`Y@W\\RAW#-DGV]A/EY\?
MZ3;5/55HGHJ66+XF]:XJM7'T@R50M&:C!X;$2R$4T'D#I=Y75D@]U[J[/W[K
MW5&_SN^7/=7R.[IG_E;?RV-\X;%]^YK"5M7\Q_E/BWGSF%^`O4%>D-"LL,N*
MR6,@K/DWV`:N2#;&"2L6OQJ1OD*E*:(15</NO=6=?$SXK]/_``MZ#V!\=.CL
M"^$V+L/'21FJKJB7([BW=N7)S/D=V;]WGFJAGJ\]O3>V?J)\CDZR4WEJ9V"!
M(U2-/=>Z,=[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NJ7OY@7
M8>Z-K_S/?Y&^S\=G:VBVKO;NGYJ3[FP,,LCT6;K\)\0MT8O;E774`EBAD;#'
M=M9X:@ZY*=JDJJE99"ONO=70^_=>Z][]U[K69[H[NP/Q>_FH_P`X+OWMW;G^
MDSKCK;^49\=>Q:KJ[%U6+.8W;USM[>'=M-N?;P7<4U)C8!5Y:/()*EY(&BKH
MR=4KB)O=>Z*;_(3Z>_EG?S*:`?+_`*WZ+^2W5X^&GR%R-#T_\6NX/E;V)WO\
M;^G-Q5.W:;<6S-_=2[#SO\/VU@ZFCI=Q534M`U-)'A*^,M!K5*69?=>ZW%3'
M&7$IC0R`:1(576%/U4/;4`;_`$]^Z]UI$93+Y*D_X6O[:IJ-9*5<E\?:G$9Q
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MM9MKMK(86+%;[H&WINC.XY\>M?F98*O)S"S)1I]O[KW6PS_PEO\`@KWA\->D
M>Y=QYC-YAOC7\A\9T?V+U?M3M/IC/=*?(#"=NT6QIL5WQ5;PVUNC;&/S<W6T
M^;^SIMF5IRN2H\OB*49*G@H_O)&J_=>ZVJ_?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=%^^4V]._P#KSH3L'>7Q<Z;POR`[XPE)AI>O^H=Q;XQG6^&W
ME556Y<+09FGK=ZY@C'8-,7MJJK:Y6D_SSTJQ*"TB@^Z]T5;Y8]Z?S%MB[_V7
MM?XU_P`NSKSY5]2;CZQK:_L_<&ZOEML'I>HP.^\A)D:4=?T>#W3LS<DFXL-2
MT%(AJ:TTAIZX9!8P(!!*7]U[K6^[![J_F&9[_A1K_)SRORT^*?4'QBBK.L_D
M#LOK'K_9G=N/[JCEVOF^L-_P=I9?+;LPE!M?'46X</3?9K04,..%-IC15EJ2
M[&+W7NKG>M,S-#_PHP^4FWQ4XLP9+^5+\<\N]+XJ*;+&7!_(_LZCA>*I64UM
M%2P+N*3[B`K:8S4SM8)#J]U[J\[W[KW5$G\X'=^0V5\J_P"1OD\:9S/7_P`S
M;#[6EB@AIY2U#OGI+LW8F4E=IM;I'#B]SS:]*']LLVI&5"?=>ZO;]^Z]U[W[
MKW7O?NO=>]^Z]U__T]_CW[KW7156MJ4'2=2W`.EK$:A?Z&Q//^/OW7NJ+?YC
M,%#)_-K_`)",SX>IDR4/<'SH6GW`NN.GHZ&7X@;B>KPQE:44SRY*HIX)S&5\
MK)2$H2`X]^Z]T9+XR9@UG\S_`/FEXEJS(LV%V)_+\*XV1)OX13PY+KONVH7(
MT<K3&`Y3(31R0U:)&K)#1TS,S:U">Z]T(G^G3<L'\TK_`&6@[IK'V?E/@%_I
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M+X_Y':^<@JDCI<:NWZOH[LN+/XZNHY/*M5#7PNCH\;P`:)']U[HEN_/DA_.D
MJ-N9E-K_`,K[XO4=1]O7NYSO\PR;/B7%+2S&6BI\;A_C)AYJG+U$8*1GSK%K
M87!''OW7NJN/Y99P&<^,O_"73/5#5^*WUB<_\NMMX7#5V2?*TU3MFD^*/RIQ
M6^JB1Z8&&EFAK=MXEZ"FE(DQL,YI&NR2#W[KW6W![]U[JBK^6=29.G_FB?S[
M99$R:8*J^17P_EQ;50@BQTN2_P!E4PPSLF/IZ>DIX_.#]LDTVN1ID2(/^XCN
M_NO=+W^8Q\W>[U[#PO\`+I_EQRX/<'\POM#`XK=^YMS;DV]-E^MOB%\>LMD3
M@\W\A.S<E5RT^$DSL53/'%MK!(F5K*^L*RS4+4YB6I]U[HXGP/\`@UU?\".E
M&ZKV'F-S[_W?NO<V6[)[Q[Q[$KFS/:G??<6Y_%)NSL[L3.S/-45N6R<D*0TT
M'D>*@HH8H$+:6DD]U[HZGOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[JB+^9'19:;^;;_`"":V@H\E6T=)VU\\(\BM`4,-*E5\6J;179"
M-\?5@T=/%!)=C)#I)&DZRK+[KW5[OOW7NO>_=>ZU,N\OFK\`^H_YP?\`-2QG
MR0[\Z1&,W3_+/Z9Z1J\%OG>.V</-/N*@R/=LW9'QTP6X)J>:6BRV?Q&X\16Y
M/%"22<U-=$TL+M3HD/NO=:RGPC^5?<GQN_E5?&3:O\N?^8'\8OBC\ANP?ES\
MC.P?E?M7N+O/I':F>Q>W,UB=C=:=09&MVKW-M+.4M3L_&[:V//62FF\U>D]3
M%41057F`HO=>ZO*^1G\UOYB9;I7J?KSX^?SO/Y/U/W?LGLSKVHSG;`W'B=G3
M]O\`4^(ZTI<?OK(]OTF^=J]A]5[>W%7=KU$]1-BMK1XR2KQ4,<M$T;%Z3W[K
MW5'7\U7YGQ;H_P"%`.SOE#\*?G[TIL7)GI_K/%;2^6N+J\3NOI78>ZZ?I7/[
M1W+@-RFDV_OFD?;FX<OYZ&M6MQF1:@CS(DDA9(5M[KW5QU%_/B['^*G\JC=_
M=&Z?YI?QS^;_`/,V[;J^K-Z=?]!4?7&W<IM#IO$2;ZP&&WQU:^(Z<HMDM796
MEV34UU;D,AEY\<361%:%9XDBJ:CW7N@OS/\`PKD[ZVK_`"\ML[\JMH_%3L#Y
MH=A)NU*B+9VZ<SM#!]%2P[^R>V=O8W>?Q^W5E\YO_?.>3:V+7-?>4&9I<')#
ME*1=<CTU;'[]U[H_&_NY/Y;/\P'L'^6[D?Y@7\V+X<XWY0_!6C[,[/[,PG0W
M83]9]/[[[)[7V]M&HV!E=@=\9_>&"PVU=R=/U^"PF5^WH*[(U57FZ2:&2GIH
M4E@'NO=`+\/.M_Y"/7_\RO<OS/WO_.PS'RY[5ZGQ&.P?7$/S.[SF2MV=OW:]
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MM*+`7<%2H(=2WNO=:XGP@_X4]=I]N]8_S,-P_(/O7X'==[CZ2V1N+(_`G^^&
M&WWUK4=[[OA_TKY+`IF=EY#?-9N/=&`JZ';F$IOMZ!<9D8*FNCAD#RRL4]U[
MHH,W_"MG^8+UY\6ME=O[JV__`"S.WM[]N5F[J/"[(ZWWAVWANWNBWPL\V'QD
M_=W2F3W#.*FASE;2/7XZ3%9Z03T3J*@TQ>,M[KW1H_Y8O_"J_=/<_9]?A?G#
MV?\`&K96*K/B[VUO7$8:FZ_SGQ[VIA?D?LO>](-@]99+N#>W;/:>/S^'[)ZV
M@EJX<BF.QGV61J#1M2SO"DM1[KW2<Z>_X5=]V;XZ._F,=Y=CK\3^H]T;.ZEZ
M6W#\$>@*[?&-WIN#,]@9_(Y';?8&"W"F.W#M?>W8#P+'%G*BF6BQ;XJ`>"1U
M#(\GNO=+OOW_`(4Y_*W;_8GQ&^(_3_\`PVS-W)W'MCHG/=I_,S)?(>FWM\1]
MJU'8FWJ.IW[CL]M;!;KPE7TY/UUN*6KI\C%FMX9&O\..UPTC"OI=/NO=788/
M^>S\::GY^=;?"X]P_#[>'6&<^+2=P[T^8^VOECU;A>MJ7MR+=$NT6ZBVWLVL
MS&X8),YF*RG%=3XR;<\F7AQM4LYCGA@DFD]U[JECI_\`X5$_*GMO/9+K_$[/
M_EQ4G9.R/E-V9LS<";V^0\G2_5/9/Q[Z[V;G,W15W7':O8W8IHL9OWL7<>)3
M%;<S5119'!5M35T[34=+&S,/=>Z'S^7]_P`*0^Q/F)\^^S]L=[9OX(?!#X6]
M-;%I*3=.VN[/DCM'-=P;P["S%-DZ?$U?4_;]+N';G6'8E-3;@Q^O)14-":/'
MX=T/W$]3-$Q]U[K8QV__`#,?Y<^[-S8'9>U_GG\.MQ[OW3F\1MK;.U\'\D^G
MLKN#<&XMP5=-08+`X7$4.\)Z_)YC,UU9%#2TT,;S3RR*B*68#W[KW7SR.JNW
MOG=TY\*_GKTOC/@[D-]?$3Y-].?S"FH_EY6=E]X28&@VUTMV1VC+E,QA<-E-
M_P"[NC.OJ;:.\VKZ)<+0;7VQE]V5,L$DM54B/RO[KW6U1_*BSW\N/^6_L+)0
M;@_FV==Y.O[7Z<^+TNYOCM\A/F+U?FZ+X\[_`-G]34XWG0;.I-Y;O7=^U(=T
MY'<@DEQ$XIHL=!34].D.B*,1^Z]U<=2?S-/Y<=?3TE71?/CX:55+7BO-#40_
M)GIF2"K_`(5-1T^3^WE7>924T$V1@6;23XS,FJVH7]U[K#+_`#.OY<$)IQ-\
M]?AW%]S`*F+R?)#J)`("T<8DG+;N`I@9)54>30=1M]>/?NO=2:'^9?\`RY\G
M74&,Q_SU^&U;D<I-44V-HJ;Y,],RU-=/24ZU=3#2PIO,O-)!2N)'"@E4-SQ[
M]U[I9?[/9\(#JM\R/BIZ?U?\Y#=1^G_@W^_OX]^Z]TEJ#^9#_+WR>YL[LVA^
M</Q+GW/MK^$_QO##Y"=51U5%_'*5:W%D>7=*150JZ9@P,+2!"0&TL;>_=>ZJ
M3V+_`#"/Y@OR%^5'\Q'??\OV#XW_`#L^)'QNW5U%T!U;TD=[[:Z;SN<[BKNO
M,?GNW-][6^0Y@W)@\_L[8FY<@L553Y"G>FW#$TD>(JJ)L>SY7W7NCX_RHLM_
M-#WITIN?M'^:.G5FR>R^P=T-7]=]!=<[-H\-7=,;)QQJZ):7>&ZL?N[<]+N/
M,;KET5<=(7FFQE.B>6J>:HDI:+W7NCV?(#<O<^S^G-^;D^/'66WNY.Z<7B(Y
MNONM-V;Y@ZUVYNK,RY"CIWI,OO>IQF8BP-)28^::I+FFD,I@$0TF0.ONO=4\
MXOY'?\*',GMNJW!4_P`MCX+;=R&/JZJ;^XN:^:><J=V9_'24].:&@PV0V_L7
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MV7Q"8*2`4.0CQD&8AJHIHYC4PK)4`QF-BZ^Z]U;_`._=>Z][]U[KWOW7NM0"
MM3=/6F46DQ.:G@;??_"OS&#*51R<==!D=J;MVA39RIPU,]?K&,C@C@2CE@A9
M9#44TD:D^0H?=>ZV7_F]B*;/_"[Y>8&MS]!M2CS?Q?[^Q%7NC*Y!\1B]MTV2
MZHW91SY_)9:-)'QE!AXIC435"JQACC+@'3[]U[JDW^79GOY[%7_+X^&M1LW`
M_P`K[<6W<C\6.A:SKW<O9>^?DW0;W.S*GKG;M3M0]B8'8VP*C:]5NQ=J24D-
M=_"\A'2BL1Y%>0'3[]U[H]GQ@V=_-HQ'R=W-V/\`)W:_\M['=-=G8?;&,WI0
M]!9[OV;N3;LFPML[DI]N5='N/>G7^-P?8@RFX<^J2P9#^&)B\=$XIGDD9O)[
MKW5LWOW7NO>_=>Z)=\LMT_S`-NC!+\)NG_BYV<L]%4#<T_R([F[&ZPFQ>2:H
MM1'"8[8O5._H<YCTI8R9_/6X^4/(OC#!6O[KW1*U[%_G]/C+UGQ9_E@^6*@E
MCR$-+\M/D529+(U*)7/++AI3\;*S'XMJJ.6GCIUJ'F$4T3O(Y211%[KW59W\
MK7%T=)\+/^$S^Y)Z09W<6,[I^5>W?N-L-4UF,Q:[R^./SG?=9R[-31VR&)R.
M(ABKS?QQ5D-1H>1%$A]U[K;6]^Z]UJK=C?+;N[H[^:'_`#.OAM\-=CCM#YK_
M`#'W'\3=Y=093*8W(5O6'QGV71?%;;6RNPOD!W_NVMHZ_%4&RNO*K"PU^$VM
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M?MU[CC^+G4NS-W=CX#<RX3L#K7>>YSE,[D<+/L^+=_\`'*&J&8AEECAW)C8J
MAZ66HGDF/NO=9_@IWY_*X^''0'8/5_QI_DE_S5^[=O9#<F,WKO/,=V?#;K+M
M/<&YMSUE+1X#;-'7[GW)OZ:CCH(#BG-'18VA-/1SO4SB!&EF<^Z]T;I/YC7P
MVH:?:E=N[_A.+_,"VGBLZ'_C65J_Y6/6.4I-KJ,Q'BDFJZ?%553E:J`+*)67
M[:&H/Z(HI21?W7NM?I^R/@7\OO\`A5%\,\Q\6NIMF0?'W*T>U=O[TV+D.C)>
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MY9'S7^`^1^=L?\JOXJ[.P^%QGR$QD/55)T9TKNC-5NWN@]Z;XVZ,/25E/UYM
M_%U=7NA=E^2&G:F$<,M0(M;J-1]U[KEL_J#^4GN[^6A%_,\;^4Y\7<?M"7XK
M9CY25G5+?'KX^G>4>U-M;/RV^JW!4F3K-N8K:\]?-BZ"5Z:I=Z=*B-XV8*2(
MQ[KW7'Y)4?\`+3^/?\MK87\Q[?/\J?XXY6&?KKXS[AQ_2)Z0Z7BW[MFF^1.\
M^O=OTVSJ/-5>P)*(;@V;)VK-,T7@@%544SP:J?R^2/W7NC(?,?8O\OCX7=,=
M>]DY#^7K\;]\X;L?Y$_'SI>GP-!TGTKASB,M\A^T-O=>Q[RS%9E=HUZM3;87
M<3U4D$,<LM3(B4X:".1ZF#W7NGWYF;8^!G0NX_A3L_L/X"=#=K+\@/D]LWXP
M]<UG^@OIJIPG3V3WA@]_[OI]SU!S6UJEL;B(JK&5JI2T$:-/5Y&1M2,S>3W7
MNDM\FL7_`"^?C1\G?@_TGE?Y?/QTW9OCYO[^W_T]MG>F*Z,Z5H(]BX_KO9S=
MCY6IS\U;LQZO(XJI7B*D@D1C-=P#I(]^Z]T^]UX7X7]:_,CX7_#"K_E]=`[O
MA^5NU_E!NFCW[3=,]3KM_JVDZ*V=M'.9T93!ML6JEGCWPV[Z3'^=9J2))6C1
MVE>2.,^Z]T7YOC#_`"@.IOYBG6OP2H/Y9?Q7Q'8/;_QFWM\B-O\`9$W2G5)V
MY/3==;YP^U:C8&*Q60V]55M1N=Z2IGRTDE/XDAHZ.[:RWH]U[I2T/P"_D^[_
M`/F;V[\3JS^6+\5:?>/6/1?4GR#RF\*KIGK*AQ6YL=W7OGMK:$&.P6&QV*2M
ME;;]?U1-)754HBB62OABC0\N?=>Z"SXY_"#^3[\A/E%\[/C)3?REOC;LRN^#
M^^>F-EY'>V:ZBV/587L[_3'U12=GTF1P%)%@*9\.^!BG,$U.\U49:>6EJM:?
M<^"+W7NI'P4^)?\`*(^<>%^3U1AOY4OQ/Z_QWQ3^97??PR2'+]0];YNLWG5=
M)U.VSDM]E%V7AY\-3[BKMQN(*"I>MFIHH034'7XX_=>Z9NJ_C?\`R=?DK_+\
MW-\_]K?RHOC&FW]K=?\`R$W/CNL<ITKU'A-SY*?XR9WLO8U9MV;*8/#28*GK
M-PY#K*9(ZB\\:_<+)(TI4NWNO=2>O^FOY.FT?Y>W5/\`-5PO\M'XU;-Q@Z7Z
MH^0&TMOTW3>P)MX[8W+N2KVC7[,P5/N"EV_D%7,8C?590TZ9<0LT0C^X**FN
M/W[KW6O3D?YM?QMV+_PGH^='P>GW'L3`?+?9?9/R1Z(;J6+<229[L/;?<WRE
MRF1W!W-A8,AAGP-4D5#V7E?N<=BJNNE@_A+5D1I:>6(4_NO=;"&3^(O\IGJ;
M#?RU<QVY\$^B>_.ROF=+T3\<<5W+N+J?8NXZO,;CH/C+G-YX7L/?]/F\/%09
MBJW#B.NO#45*4*UE1/51RR^F&R^Z]TM=Z_$K^3-U[\X.B/@#D_Y7WQA?>O?G
M2?:7=&T=\4OQ_P"GGVQ04O5&7Q-/EMMY6:LQD>X'RM?1U\U1%)`DZHD0C<!9
M"R>Z]U`R'\O#^3;OWYX[J^$^2_E?_'B@W3LOXM;*^4!WU@NNMI;2VKD,)O3M
M3<O64.VUQ.T*K$5LN5H\AL+[@2S4WC\;2J"/(WF]U[I-]'_%W^31V%\Y_E=_
M+JQ/\J?XZ87>/Q5V)U+V)F]^[DZ4ZGS.W-[8+N#`T&;H%V_4Y.CJ-Y"3#M71
MP3-(DE/YUEM(IMY/=>Z4/0WP\_DP?)OY1_+[XR8'^5S\9\#N/^7INWIK:.XM
MRY'H_K#'X+>V3[BZZGWY02T&/PE`)\]C<)14/VTW\<6<S3WD2,`ZF]U[JG_N
MCH_X(T7RR^87QP^"O_":[;?S?QGQAS6*;Y/=CGNO"]/4F&WMOG;L?8%/M/I3
M;.^)=P9*HAI\:9(X,=MO[.0R1F"CQPIGII*GW7NKZOY!&R_AM@_Y:W4N_?A+
MTEN+H3KCN?</86_-X[`WQN+(;TW_`(7M7%;SS/76^L!NO>N6H<;E-SG9N4V.
M<+CJB:GIW.*H*<O$DK2W]U[JZ+W[KW07=VS]Q4W4'9=1\>J#8.4[SAV3N*3J
M3'=J5>;H.MZWL!,94':]/O>LVW'+GJ?;,N6$0JVI!Y_#?00>1[KW5(!W1_PJ
M$E6/)GJ[^3-3)CZNI:?;4>]?E@]=N"FDH1'3QTV4DBFHL:M)7$2W=U>9=2'Q
MC2Y]U[JF'>N6_F?;O_X41?R<%_F9;1^*W5F8H:7Y"Y#I8?&3,;PS&W\M@$ZY
MWI6[HPNY:S=FXLSF&W`U=2T5+3DQ4E-)%4<>5O(%]U[J[CKJF6@_X4O_`"/\
MPC2?.?RA^FLO1@2U#22T='\F\SAJJ4QB44J:*JE52&1G`TE&4-(&]U[J_;W[
MKW5,7\X"2NI]Y?RB*I9(:##1?S@/C'!ELU$KOEJ&?(]>=Y8W"8ZB40S1B@W1
ME*M,97,UM,%5P5_6ONO=7.^_=>Z][]U[KWOW7NO>_=>Z_]7?X]^Z]U[W[KW5
M5'SM2HJ?F[_)PHX,?6UP3Y:=_P"6>1%8XVA7'?!;Y)0255=('98:I*7(R_;$
MPN6.M`\6HM[]U[H)?B'155+_`#M?YPT\4]-4XZOZ@_ESU]26RJ-64.4DZQ[,
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M#/OW7NO>_=>Z(?\`,/;W\RK-YO8)^!W9?PWV%MI*#.1]G1_)[K+MW?6>ERGF
MHY=N5FR:CK??FUL=]B85GAK*:MB21"RRQS/8PCW7NB89#K;_`(4'5NR]U"L^
M5?\`+'V_N0X7+QX<;0^*W?\`FZG[SP5BT=1C\EN3OJ"@I:\((GB^YQ-=`M0Q
M62&6-09/=>ZK)_E%_;5'P(_X3AS[7F@%-%\I?EY3;O;=*9Q:^'>S=,_/Z3><
M>'%'GL+`C/G*;)P4B2)64'AEC(IF*C3[KW6WK[]U[K78_D][6K<=_,N_X4#;
MCR[TN;R.2^9'3F*I=V5N1I,GNA\13=79K/8W9U0YE7*4>V-F8K<5'28N)Z>.
MG1`\,4LYIW\?NO=;$_OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>ZJK_F!8#*+\K/Y1'8=)AJ#(8G:GS<WUM3.Y&I9&K,-
M#V7\0/D7A\7-0TKR1^456:Q=.DD@UM"=+:2+LONO=6J>_=>Z][]U[K6<W+\%
M?C!\]OY]_P`T<Q\H^G>ON\=H_&[X'_$+8N`V;V!BZK*XNAW1W#O+N7>`W)'C
M))/X=6Y''X3;%13)4-8TZUH$:>37(ONO=#W\J_Y%O\IW$_&/Y"YO9?\`+OZ4
MEWGM[I+M3<.S*?9N)W%M[=$^[L'L7/Y/;4&`RVVLD,U1Y:;,T\*T[4ZR2>4K
M9'-E/NO=44]=?+KY2?"OX^?RAZ3Y%_SBOEY%FOGAT1L'_1#U]UM\&_BSVUB-
M@T&;I>O:#:V.[#WMVR\?8F\:C`P]CX['OD63)97(24S3E"JJ)O=>Z(7A=Z=U
MR_\`"OKH[9?R/[]H_D-N[I3M_%=+X?ML]?\`7G5\^;VZ.B]TY[;>&RVVNL\=
MCMM+N#%YC?LV.J)=+5$E4A1O&JQP0^Z]U]++W[KW7O?NO=49_`&C8?SB_P">
M]D:W([GGRLV>_EW4R4%7`:7:E+MR'XOY48.3&J\2/6YMJI:X5%0I:+[;P("7
M64#W7ND!_P`)N<E69#X2?(&'*OC#F\;_`#%OFU0YZFQ50LT-#F)NS8\K6T;I
M]S434I#9,21)*PD--)$_*NKM[KW22_D9X*;;W\CW=FV:_'UF.J,'O#^8A@JS
M%.R2Y"AFQG??>>/J,>[*\T<M92O`8R0S!G7ZD>_=>Z3OQ,P^Z.VO^$I]#M3#
MTU)-NG<_\JCOG9&WZ4&GH::JJJ7JCLO:NWX994C6"*6JAHH!)*X]4K%Y#<LW
MOW7NN?\`-=PK[R_X335-=#ELM29#"?%GX2]BXC(U(IL[7U6<V?N7H;=F&ILQ
M)EI$6O?-9.@BIYYY!(WDG\KQR*'1O=>Z,Y_/'&/C^&/QUGR)(-%_,$_ERU%)
M03TOBJ,E4)\G>N(Y\<**-::GBJ#C9*B1HFC$8$3*$4Z2ONO=+/\`FY2QQ;D_
ME-J:W'8R:J_F^_%^EBKLG"LD-O\`1KW]6G&QRFJI7AJLS+0I2TX4OY*J2)=)
MN+>Z]T!7\W?<>;VW_,`_D(U-*U358&L^=/9&'RF(HJ)ZBIGRVXNE,CM;#9AI
MP)5@H<#CL_DI*D&,DP2-)KC$1;W[KW0V?,W"9*#^;K_)BWG2YB*DHWHOYAW7
M5?BIL329#^(P[@^.^W-[AJ:MEC-5A:J&HZWB/W$3#5")(20)2LGNO=)3M'%T
M-;_PH8^)E;58F*MJ,3_*X^4==CJ]YM$F*K#\A.F,4];%&"/*_P##LQ44NDW&
MFM9K>F_OW7NABVGM82_SN.\=Y5^-S&1J,=_+#^..W]N[@GDQU'A=L8O<7R@^
M2%=N+;-%2TM4F0SM3NG);1HJYZFK@?[#^'&**15J61O=>Z*C_*[J*UOYO?\`
MPH5I*B2(00]T?!.I@I*0/#0Q-5?&S<,9JEI;B)<E64E)!]W,`&GECU,386]U
M[I9?R,1C%I_YN0P]2U9CO^'N?G@8*A@0SRM'U2U<A!@IC^QD3-&/0!9/JWZF
M]U[HJ'\I[*SI_P`)S^^<EFJJK2GH]J?S2:EJ6L998L#0P]I_(RJJ<;1Z(8Y?
MLZ><S3$/J?RRR6LNE5]U[J=M&GJMT_\`"5OIV.G,)GIO@7T-.JYBG#QR1[/R
M&QJIX(DJ'15EF@PA2AEO9',4B@V`]^Z]UIB_+&7^5#@_BQ\S>H:'>'3W>7SH
MQG:F._V6CM+JGH3Y<=:]LY7.;C^2^2W'W)MOM[*[]W!'TKO"';>RLE+A\-64
MF$HZR6EIPJ^:3Q-[]U[K>B^=N-W#A\U_PGDJNP\764?8V'^='2FV=V44DL.1
MKL;N7+?$/N*DW715-8D-/]R:7<..'GE01HPA9]'"@>Z]TL?DS6XVD_X4$_RO
MX)UJUKLG\,?G70TDD<%.]+++'4=;9*.*67[L5,0BHZ"K9B8M(=HE4MK?Q>Z]
MT_T-/N&B_P"%&>Y9Z;;>5K=N9O\`D[;-.5W.NX_L\/@JS%_,#>\>.H:G;LGD
M.=J\V9Y13/&8QCA35#$,:MC[]U[HK7QCV-C=L?\`"I'^9#F/[Q5<F1WU\`.@
M-\P;>J*F*M5XTR'5NQ:^IIC'#&^*H\*=J4]J5R[N^4,VK254>Z]T9+^7E48D
M_P`W_P#GST..H:[&U%'NW^7BV4ILC6_=RUE?6_&S=E>V9H1][6BFQ&1IZJ/P
MQ*8A&\;WB1BU_=>Z0'\HFGR5+_,G_P"%`,-73?94C?,?HZII:62;[V<R5O35
M?5O7-D5E,;09.@FI9XJ41JU$KF-F<\)[KW547\H/+U'\O#XA]S_S?>Q_DYNC
M&?#CL;N?Y1GY,?$_&]=UN\MJ8;=U'\IMY=7=/;T^*U-0;FIJGKZ>?<&1@I,U
M1Y*.HBR%!.6EG4TE+)'[KW5T_<W_``H1_E^=%_%?XM?,K>*=_P!9T3\O&WI%
MU=N3;O3&6R<F,K-@[A7;.X\;OP39.BQVV,JN2CJ6HZ;[F>;(T]!4S4JS1Q:C
M[KW5IO>C=Z;RZ$W-/\2=T];;2[LW#A=O9#J_=7=6V-SYSKO%_?9;"UV0J]V;
M5P=3A=T5/EVF]8D%.LD$D=<\7E`577W[KW52<_1?_"BR-8*JE^>?\N>IJ:^,
MOD\55?$WLBEQFWYV:"K-/@*^#>]5D<U3QRH](LE:L+FF<R%?-IT>Z]U29\@=
MC?/C8W_"A;^2?0_/3O[H_OW,5=3W5/UE6]$=69CJE<!A8MK[B3,?WKP]7D\M
M45E1D\E]LR2)4O3I3TLJLMO(7]U[JV7JO*YZ;_A4=\I:,8N67#4O\J7J;'2Y
M*JB:+[.G_P!-&$S%&<9(D=4M31UF3K*F.0O)2_O1.`DAC#GW7NMC3W[KW5#7
M\[C)SXKLG^2M.<AN6BQU1_.6^+^/R$&#JI115\E;M'M2'&4N5Q<=1$N1#Y$Q
M@,4D,%*U2P%VLWNO=7R^_=>Z][]U[KWOW7NO>_=>Z__6W^/?NO=>]^Z]U4_\
M_P"OQ.#^9/\`)WSM9G\Q%DE^8O;FVL9LW%0M*FY4WE\.._\`!5N:KRU33014
M.RVFAGE8EW$-0^A&-[>Z]TQ?$\TL'\WK^;A3%SD*NJZZ_EXY5*L4M'%%@H6Z
MM[5QE1MH5`G:OJ:NH;&PY*4^-8A%5P+J++8>Z]T:/<_3^^:S^8=U!WSB]C;>
MDZ\P/Q-[IZJWAV.:_%T^ZH=R[D[1ZAW5LG:`Q[.,SDL']EMW,U:NB&FIIW?4
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M+G-M?S?>U^OMK[O^(G1N1VKU]@OBG\4=U8CK/:&X.O\`&9S:^U-N[HW=M'<.
MYLS6[/P6:@QHRE?5U$M4**-_'$H$2^Z]U9C\8>A/EAUOWSDI.U/YH-;\IL/M
M+:6.I^Q^E,W\7_C=USNAJG<5%E8.N=T9S?'5N-PN[L3`D6+JYJ>":&6#(3Q5
M)5D2\:>Z]U9O[]U[HD?R6^0W;W4?R,^"'5'7FR=C[NV;\ENW>S-A=LUN>S>7
MQ6\=H[<V=TON[LO';DV+34U)-ALG]G6;8<Y*.K?RM!XXX([RR5-+[KW7+Y9]
M)_-#MO+]>U'Q7^;>$^)&&VY5U%7OG&Y#XQ[-[^J>P3XJO[*BFKMW;VVP=OXJ
M.=X?+%1)'4R*C6J5U`+[KW1%]P_!C^<EE9]US#^>/187%9822T&/P?\`+9^/
MD7\'AJJ)Z;(4./GR/8&2R5/34J(K43O53U*RLSR2NUB/=>ZK9_E1=-#M[^73
M_P`)XL,N]>N9I>E?D_\`(3Y!YG`[LWG0;5WUNW!==X_YJ;-BK^NMH2UASV^J
MS`[][`P]37I`#]M1DSU0$>M#[KW6W1[]U[JB3^5]M9,5_,N_GV[BI(5&/S?R
MI^,.+2IC_P`U+DL5\7-N9[,4X$:K3^6FJMY@R6_<U2?N7-C[]U[J]OW[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=4Q?S5
M<[7;=^2/\EO(18^LK<;-_,VQ6$KG\\U'B*:IW3\8/D7M3'S5U889J`9&+^.2
MS4<$EIJLPR10D%F9?=>ZN=]^Z]U[W[KW5$W2%7E,)_PHA^=>`I_/!@]\_P`N
M3XE;WRL3P&*&OS.TNT>Q]H82NBE$:+4+2T&4KH0Y+G470&R%5]U[JZ'LVIDH
MNMNPJR&CER$U)L?=E3%005L&,FKI(,#7RI1PY*JE@IL?+4LH19Y'1(BVIF`!
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MOY5-!TU4]P?.S);AJNW,#WFN\<?ON/O;M9NV)<7_`':HUZ_CV;5=@)EZG;YG
MI7BI\:T"UD3(&C'NO=/7Q!VW_/6Q'\DOK3,=9]H?RO)OBS%\!MR;@P&V^S.N
M.Y9>U(.JSL#<&0&W-PY3'9"#J^MW7-LN:43U=91MC?O55*Q)E:HJ&]U[HL?\
MR7K7^:YN/^45\-]V_*'MSK#M3^690]2_''>'?>S?@]LINKODBFTLCLG:YZ/E
MW'E>T*W=>Q-Y;3V]NNKP+9*JQ--B((,A,E4V(F@IHYZ3W7NEE\L>M?\`A1?M
M7^6U\<LK\OOD%\28Z"@^0WPNQ>/ZWW7M=L[\D,5ON#Y#=>T?1V3WQV;MK%5F
MT<SNG%;V&*K-Q'"UK5DN(IZ@M73S/5Q2>Z]T:O\`F-=2?SMZ?._`S*?)KYG?
MR_:09'^9]T!0_'C&[#Z#[)CP&U^[LMM#MC_1MF=UUN?KXLGD]NXJ22OH5Q<D
ML\E5++2RO6^0%#[KW5:W\X7I_P#GJ;3^97PCR'?7??\`IG[5W+NNEQO\N7(_
M#?$8K8/46T_EAA-T[?GKAW'LGL>CI*;'5F5Z^K*FHGKZBHKZ6HQT<L6O[*GR
M4'OW7NK&.[-E?\*&<!\_?Y5^)[>[T_ER;T[,S6:^6$_3^X:+KSM&DV1M#+TO
MQSK4[-':.$P\.T]P[EDFV)75/\$7#20TW\6A454L4#J3[KW4?MVC_GRX7^=3
M\7L)%O?^6;F>_MQ_!CY!8':&]H-B_(#&],T?2]%VQLS<N^*W>^T*G=>0W[3=
MCR;JQVWJ3'_PRMFQOVLC:[M]PR^Z]T3_`*O3_A0=C_YMO9`QM?6Y/^8=55>W
M_P#313[TH,!C_P"556_R]*+&5S=,56WY,=)%VW4UR=M3[E@Q[XR&/.4M2*Y)
M9I:^?+W]U[HT'Q&PG\_O$?S"OYQ66ZFC_E6T/R`KM_\`Q0JN^-I;PA[U;8F8
M7(=*5]%TKNKJ'([<J?[U4&WAUU&U7DHMT2&LJ\M'.D4<)\NKW7N@`^,6&_X4
MB]5=1?S8H?BQB?@/FL@GS?\`E3N3NK';5._*CM__`&8;>&RNN]Q=BY+XM4M?
MD<=L]<13X7.8ZNV]2[E9\A_$8IHI8IIM$,GNO=%$_E-9;^="_P#+0^<]+\-\
MQU#N;^71ANN>Z:K%YOYV;3SNT.SLAFZ[8&Y<S\C:/H.EZMW7N1)LBN;?)02U
M&Y,U-@QE9(*A/!4OE::/W7NCR?'[<W\^#(?R9^GLI_=S^6;A_P"7[COAYU_@
M)*#,0]N5?R.S/Q^QN!H-N5&>@ITJZSK./M;(;4IQ6Q^=HJ;^(.KZ!.2@]U[K
M7K_FW?+7O;Y&]_=;=1;_`(OA+DMU=-=P]SXCJ[?'\NGKG;N7[ZR.]J/<W\.Z
MTHNQMT8/*45+6'<G8M70R0TV%GI%-;-6U@HYJZ.FA?W7NMBOYE[A_P"%$F;P
M?\F&;O?K/X#X+MN/Y==<3]5Q5&X^S,GN.N^0\?1._P!=OR_*3!ZH]HX`4NRH
MMSUN9_N?EJX/EN*-8/'#%)[KW0C]UY#_`(4(+_--_E^T&^]K_P`J1?DVWQN^
M9U'TONG!UOR1J>FJG:LDO4=1V]6]@4M1+3;WI-XXN"CP<>"BH('QKQY&I\S%
MBY@]U[HE^`RO\_K$?SH5GS-;0YK^9G/A:';*;)K=JQ4/\K[/_P`MN#%YK+9#
M>$N_,+F*#LR'$;9[UKJ810C'/N'^,5NAIVK]6/D]U[HV/5V5_GRP_P`\3YC5
MVR>K?Y9]3\C)OAU\>(>SY]RY'O/_`$`8SJV3-5=7L"+8F]*3$KW&F\LGG*?)
MTN2I9TAQ=>^/:=H2M)0M%[KW0@_%?+?\*`:3^8]_-2R.PNM/Y43]VUM;\+'^
M0.,W3N?Y#T>PFHXNC]P4?3]5U)E=O0/O+)4,VTUJ7S3;D2"5<C"4HU\6H>_=
M>Z.9_(/K._*GY??SQE^4J]:P_(*+YA=3#LBEZ?EW+)UI'5+U=E:7!3[&&](X
M=W?W5JMNTE*U&V11:ED!UW8'W[KW57&*Z^S?8_\`PD>^2FS,?L;)]O[IRG?O
M=S;#V=U9M^KW!O`[BHOYA<LU!79+#=?4LE;E,EAZZGJ<FP-.T7\'%."@I5CM
M[KW2I^07RRK_`.7S_)U_D8_&;?OPVZ\W?U[\D<OUUU[\C>JOFML/.R5NRHMH
M[CV=N7=^1I]K'(X&?:N[,[N7<U;F,-D:^"H;%TD<4CT32,47W7NMSCN7:W8.
M\.G^R]F]/=B)TYVAN+86Y\#UMVBNV,1O&+KC>>0PM71[7W@VT,VC87<4&W,M
M)#4M0U`\-0D1C:P-_?NO=4#;A^#O\^[-;IGVU%_/KZ_P&:\=3NO$XC#?R\>F
MX)*W;=//C<+))7S35DU+3T\-4R%X(FE;SSEM01QI]U[JL_#?!OYX[(_X43_R
MS?\`9U_YA&/^8N;VUTM\@>[-D[ARG46V^G:;#8+:F)W%M?<'7.T]A[:R=7M^
MHSF8J]VTF2EKHPM2M%2.S!A1Q$>Z]U:FV*R]%_PJ8AK8&EH<9G/Y,U3DLAHK
M)&BST6,^5%+AJ"*:E>.2-3B:Z25P%*&\@:YNRGW7NMB7W[KW6O\`_P`^9LE'
ME/Y/+TM1708]_P"<]\,*;(I3N\=-,T]9N]J1*B6*>*1);0RA/2RLAD4D7`;W
M7NM@#W[KW7O?NO=>]^Z]U[W[KW7_U]_CW[KW7O?NO=4P_P`U8PXCY(_R6MV0
MSUU%EZ3^9KBMG4M;CROE.*W]\8OD1C,[C)UE40_99:"@BBJ#K$@A#!%8GT^Z
M]UW\3C-+_.G_`)N\@R%6::GZ2_EOT)Q,TT!I4J5V+W?6G(T=/%.LB^6&M6*1
MY(F<LEM80(OOW7NC\;K^46#VK\QNF?A]4;8KJC/]R=$]W]Y8[>*Y6AAQN)HN
ME=W=/[4K-N389XVR%=6YX]LBICG1TC@CQ[JRN9+Q^Z]T:7W[KW7O?NO=$9^`
M&V>Y]I=6]QXCNW#?P++S_,[YJ[AV)0M2T=)++U'O#Y,=E;NZTRDJ4$<=++_&
M]MYR.L20:G>*="Y\FH#W7NJ8:\U9W3\K::OV?!DUQG_"FOX9UL$V6^\B?`TF
M6V7\%THMVXM\-*5EJC)5K'$*QQ`8:TJZZ],?OW7NMC;NP2'IGMP1!C*>L=^B
M,)(L+F3^ZN5T!9F5UB8M]&((4\V]^Z]U09_+1_EU=C[U_EO_`,O7<^._F5_S
M%>LX<U\7.B=WY79VR>Q>FZ7;6/P.Y>L=N9G&]<;8Q^Y.BMPU>V=L[.@K(Z&@
MD6::O^S@59IY&LZ^Z]T;WXY_RR.[NDOF)V%\@]V_S(/F5W+U;D\%U+2[,ZBW
M]O38=4F<S&S<1O7&[H_TT5>$ZKV]0[FP/GW!!486GP<6">.1I_OVK-%,4]U[
MJX3W[KW1!_E?T;V[V7\EOY=G:/6N/VK4;;^/'?O9>].VLCF<O4XW<&.V+O7X
M\]F=6^/:M+%CYZ;+2UV7W?`*J"2HIR(T5E$MF"^Z]TH?E-\6.X?D!NC8F>ZQ
M^<?R-^)V-VS15V,W1MKI3&=/9/%[\I*W(4=;]WD6[0ZXWU-B<]20T[T\%73>
MF.&4_M%AJ/NO=%DW5_+1^16?P%#BZ#^<#_,6P]?2PU_W5?"_Q.6/*54U-7K0
M-41T/QCH*R*EIJRIB>6$5#K/#$8_065X_=>ZUD_B#\;:7=O\JS^1=O78/<6/
M^+WSKZ[^?GR<ZB^,W?$_6,G9>UMP[EW1V)\K\QO?8N_L+CZ^B:OZ_P"TJ7K6
M.FFK1/+%`UT53%/(Z^Z]UMY?`?Y=;N^5?7&]:+N'I_/=#_)/H'L#)=*?(_K.
MLI<I6;,QW9F`HJ.NEW%U)OJJI8\;V!U7O;#U]/EL-6P2RSPTE6L-2/*@DE]U
M[HAW\K//+F?YCO\`/IAO.)*'Y>?'N%HY"IC6.D^,VV<#%)&4TI>4X!O[.H($
MU%CS[]U[J]WW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=40_S=,AEJ7YE_P`BRFIJMDQ-3_,5R;U]!)`E315->O1'8%#C
MJR6*H\E(M;0T.3KDIY#$9X34,\+QNMS[KW5[WOW7NO>_=>ZI$6?(I_PHUKZ:
M#.5E!C)_Y-&UILAA(Z-JB@W!4TOS.[`3&R5=5I*4%3A%JJB2`W5I5GE47&JW
MNO=$P_DZ_P`W/Y-_S5MB?S/O]-FPN@,3M3X\)D=I]?;<V'@NP<9DLK2[IVWV
M1!38[>E7NG=>7P67PM;3[*;5)!4T-8)IYA(D<!@*^Z]T77^6M_."_DA[5^#'
M\MC:'R1[#Z^R'R.^,G0NR]K;7RVZ/B5W3O;<74G86VMI8_&[UAZ[[$BZ0W#0
MXS-0+01BNK,!DRDY\;&0AD'OW7NJ,ZSO'J?YW?\`"O#I+MGI/<>]-Y]69/OW
MI/(;5RN\,?V!L/(_\8<Z$PF6S,>-VOO/"[;WKM?`TFY]H5DD6-K:"D6I_<,B
M>"I9V]U[KZ<'OW7NO>_=>ZI8^(%%'1_SK/YR<E/)(D>3Z>_EE9*MIY,J:SR9
M(=<]]8S[R&@:9SC(?X=C((O&%52Z-):\MS[KW04?\)XL5E<3\>?G/1YC.9[)
M9*F_FO\`SQH*RAS7W2'`5E#V!BH:RBHX*]'F@^]JR]=4+Y)5^ZJI+GR>3W[K
MW3W_`"?8:'%?RR>U\#FZ#(2;=/?O\T-\KEJ@43T=-C<7\N^]\764&45<EBZP
M9.NI))I46-8X3'3RZIH6\8;W7N@7_E1YG<M=_P`)BNM\E72/39NB^#ORBH\=
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M-)BYOYE^,V[D:+`U215=14[NZJW=MB&IJ:6>BJJ:?$4F&RF12O?4DJ8^>H6.
MS2^2+W7NA/\`Y@"[ED_FF_R,(\3105V'C[>^<E9ETO)3U=-+#\.]T4L-8*UG
M-(U%38NOKI)*8IYIY(X]#`![>Z]TAN\MQ2X7_A11\#\69#!!NW^7-\L]OIX8
M8ZAZZ6G[+V%NN:DK&>4/0TD*[6CFCF5-3RKX[E6;3[KW0YX2KED_GM]DT:5V
M4C@IOY3/3,M1C%BI6PU7/4?+_O+[6OGF/^6PY''QQRQPJO[<D=3,7Y2/W[KW
M0)_R_A14G\YW^?124M93^:LS/\N;*UE%I:6L>1_BS74R3M.LLT-/2TYC9$B)
M61GD8E%"@O[KW43^1_5US;N_G(X?(U5%/68W^<?\JYZB^/\`M\_(<QMSK"MI
MJW,URQ4U)7TU5CO`M$D=-$M-#$T5Y0!(WNO=$P_DZ;#W#OO_`(3>_(/K[!U$
M%)G-^[9_F:;3VR]765,-+09#/[O[LVY0+/51RXVDHZ>/+2,SO1-!3J"7],AD
M]^Z]T,W2*L__``ESZG5':-F_ET[)59$"ED8X#&@.H8,I93R+@B_OW7NM+#Y6
M=A_RQMU?'_YW=D[.ZWZ1^+OS\ZQ[SQ^V?C_MWHGNGYE9+=W855@OE'MZM[%[
M@W/A^UJ7/]34\=3@,++D,%28S<DM50@5$DM!!+'CYHO=>ZWL?E[N?.]GX'_A
M/UV!D*FMW!/N_P"<7QRW_N3=..IJLXBJK]P_"OY!93^(UE/+0T%3!'GLKE]5
M.98:<Q:B7C4C0/=>ZA?,3,UV%_X4"?R=8,?$K+NKXY?S!]N9N1Z>LJ[8BEV9
MLG<=/X_`WV^-=,MB(?\`*)`$</XC=FCM[KW0EYG.Y)?^%$FP]N05>2BQA_DZ
M]BY2OHJL2S8BJFF^8^P(*2?"ZZQX:+(1-0L*XQPQM-&*82&0)'X_=>Z#7I:F
MRF-_X4C_`#82ORDL]'N7^67\;<[A<<,7&D%-C\5VYF\#+$<JD(9Y:?+1U4P5
MWURBO8<K3KI]U[H8OA5$LO\`-Y_G:5[4ACFBI_Y;.$%8)UD2HIJ+XW;TR\<0
MA\:20R4\F?<L265A(H!])]^Z]T6[^3R*JE_F5?\`"@G%U\5"M;'\R^FLL[+6
MFIR+8S-]7[@J<$*B$K/XJ%L='JA_R@Z7:6,11:-/OW7NJOOC5V3W=\;?^$N7
MS5[7^+.Y<AUQW#L/O7Y3Y?`;OV?2XZGJ]MX>F^6U-M_>V6VNF=;+T6.2@ZT2
MO6":!(ZFCT>2F*U<:3M[KW0`_*W<GQM^=_\`*._D9_)'^9C_`#`LOLS?*]M[
MER%;V?@OCAO3?V0[;JL?NQ\)V)UAF<9L&IQE)L_=FUZ/9.-Q=1NJ>":"NJZ.
M:MCHION&M[KW6\9W+L+*]T=.[UZ^VKVCOWIC*;^VS)BL3VOUG+0XWL38_P#$
M1#(N?VE-G\9D:''Y^"GN(7JJ280NUVC)&GW[KW57)_E3?(UI5F/\Z?\`F?:U
M22,`9OXOK%IE:-V+0+\;Q`S@Q#2Q4L@)"D!F!]U[JI'+_&*I^-__``HW_EIX
M/O'O3YF?//+[D^+OR&S_`%/O;N#<^QJ^+HC?V/AW#CZW<];M_K'9W7V*H^O7
MV5'7T-<]51L:C,Y:@E,T_P!J($]U[JRYJ"&I_P"%+XKEF-%48W^2E"6IYJ&2
MV>@K?FI70M-0Y`!HE_N_)&@GC8J6^]2U])M[KW5\'OW7NJ0?YW&5H\/0?RKJ
MMY*.;+?\/*_!^FP.&R=-156+S55DI>Q\1DDJAD::IHJ:JQ&`R-7D*&=@)(LA
M2P&$B;QD>Z]U=][]U[KWOW7NO>_=>Z][]U[K_]#?X]^Z]U[W[KW52_\`,]H,
M96]N?RBVR4](?MOYI77\])C:XLM/6UL'Q:^6%51U"%8Y;UV*K::*>F!`!F5?
M4!<^_=>Z#?X]8N2D_GR_S(:X9&FK8LG\(?@76-2PP+338ESNCY!8R/'U;"S9
M">089ZKSF^B*JCB^B#W[KW5A&Y_BEM;='S(ZE^9]3N_=]+O+J/HKMCH7$;)I
MZBA.R,IM_MO=G7V[LUG,A324C9*//45=UU1QQM%.L,L1'D1FBB*^Z]T:CW[K
MW04=\;W_`-&71W<W9']X*;:7^C[JCL3>_P#>JMVIDM^4>V?[J;0S&>_O!5[&
MPV4P>7WG38;[#[F3$TE;1U.12,T\4\3R+(ONO=5;_P`A+Y==Q?.+^7EM+Y$=
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M[H!_E)_-%[8^+7S&_D]_$W+8?JK>M=\](\I@^^<MC-K]B0-M[,TN`V51XG=G
M3^X(L\^WXMO9+?6?JQ+C\E39.L@QL<,DTM.LBS/[KW1UOF]\!\=\W9.O%RGR
MP^:?QJIM@TN\:-\?\2.^JSI*EWTF\*7%4\IW^*#"92HW&^`3$ZL</)$M.T\U
MPZR,I]U[HE^W?Y$G6N(Q$N*S?\QC^<+O+70SXJ*IS?\`,)[-QOVN)FI&H1C(
M,?M+';<Q$E-'2R,@\U/*Q#6)*@`>Z]U6E_+>^)/;_9G\LS^35@.I:"JR='\&
MOYL';.^.TSO',T^V\Q_HFZS[K^8_6.X,_BZ?+XW&T6>KZ5MXTCM0T<CR!6G2
M(R3Q/$GNO=7D=B]M_P`SG`_S#^N^L^O?BYT_OC^7=N?9&"EWQ\@JWL>BV]V;
MUUO5:S-S[J:?:]3N>3([CI%Q]+1T^/H:3`Z))JGS29`*KQ1^Z]T3O^5'`*;^
M91_/VB:*&&=OEU\>JAT5ZEZ@T]7\>Z2JI9I?(JTPAJ%F9T"7<,SAO2(R?=>Z
MOU]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW5._\`-LH:27>/\IG*35N.IJO%?S;_`(V+C:6JQGWM9DYLIUQWEC:NDQU:
M0\>-:GQDT]5(SK9Q3@*ZRB/5[KW5Q'OW7NO>_=>ZHQFSN(H?^%)D.`K:*LJ,
MIN'^2W05F#JXJ9:FBQQV[\T]S?Q5ZQ_MI)*"6JI<XD<,_DB0^N)@[2II]U[J
MK?\`X3G[4HNN>N?Y[^U.OMWQ9CH_9_S2[NP'56ZQB<[2AGP.T]W4^3S$F&RD
M5'.#!MU,#JB`2HD:$Z[*82?=>ZO@_DT4CM_*<_ER-DZ:C:L'PYZ%EU1P0V"5
M'7F#EBD)"`?<34[HTS#EY2Q))-_?NO=:IWRIAJD_X6G_`!A:E,L,D^*ZOF+T
MGVCRR4J?%_>\-:)EEJ8`D4M)!)'+J;RB"Y1)#H5_=>ZWY_?NO=>]^Z]U3+\J
M/Y</RNSORKW?\O/Y?WSF3X>=D=Z[/ZNZ\^2V&WKT=L_Y`;*WY@NFZG(CKG<^
MU<-N:IQ=3M7=^WL1G\C0S(M0U%D::HLXA?5(WNO=&9_EJ?!:3^7Q\;ZOI7+=
MR9_Y!;ZW;VWVMWCVEW%N/;E)L^OWWV1V[NFHW-N7,+M6@R^=H<#"SO$ABAJI
M$DE1YK(92B^Z]T+OQE^)NP?BQT[NGI'8V;W9F=I[I[/[Z[1GK-RUF.FSM%D_
MD%VAO+M;=.*I*S%XS&4PQN&S>]ZJGQ[-`9DI8XO,\LH>5_=>Z1'0'P'Z2^._
MP7P_\OC:57O?*]%XKK'?_4TE7G-R,=\5VV.S*O=5;NII-QXNEQQI:Z6;>-8*
M=X(HUIH_&BJ53GW7NL/=7P*ZC[E^!-7_`"\:C,;RVSTN>F^N^CL9E\1D<55[
MVQNS>L(=JTNV3_$\YA,MBJW)M2;0I8ZJ6:A<3!I"%1F!7W7NE/\`,[X8=6?.
M;H4?'GMW*[TQ>SDWWU3V"F4V7EZ'%;B&;ZCWU@-^8**2IR&*RV,J*#)UN`6G
MK(Y:5]4$SM$8IEBEC]U[K/\`+CX:]3?-'"=(;?[=J=UP8[H/Y,=._*C9T6UL
MO#B5R/8/2N4K\EMO%;E6:AK1D]IY%<I/%64R>"9@RO'-&Z!O?NO=1OE#\+NK
MOEAO'XJ[Z[!S.]<+GOB#\A]M_)+K-]H93&8^DRF\-N8G+89,%N^GR>&RYR6U
M<E19=_/%3-1U>I%T5"*75_=>Z>^WOC!A>W?D/\2?D+7[NS>#RWQ*S_<NX,!M
MO&4>/FQN\Y^X^J<IU/D:/<%95K)4TE!AL9EI*R):95DEJDCNZHK*_NO=(7?W
MPCVGOSYX]`_/2HWUN?&;UZ#Z;[2Z5QNPZ>APE3M+<FWNTJF"NR.2R5754CYO
M'Y?&5U'"T+TTR(Z(4=2K-?W7NE71_$[;E%\XL]\XX]W[BDW;N'XL[;^+-7L.
M6*C.U:?;VU^UMQ]K4&ZJ.>,1UZYRHR.Z*BEFCE\L1A1&C,;>02>Z]TS=(?##
M9O1WRK^9_P`L\-O+=V;WA\U*_HVKWIM7*?PN+:.SH^ANNI>N-N)M6"DHTR4E
M5FL?4//D)JJHFUR!%C6-$L?=>Z;_`(??![8WPXW+\N=T;.WKO7>-?\P/E+OS
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MGP^!K=L;KQG=F`3"YBNR&2JJ<9W$97%24M/+#)3RO&\<31%%\KN?=>Z>*SX@
MP5/\PS`_/5-^54%3B/AQN7XE5'6:X2(TN0@SG=&V>WZ/>LFY/XB)8WQLF$GH
MOL/M&$GW"S"=/&T<GNO=)W8OP4P6SOYA_>/\PRL[1WEN7=W;_P`?>N?CKB.M
M<C1XV#:77>T-D;AFW3DIL-6TY^^R3[CSRPU*QRI']G,]6VN?[E1![KW2FZB^
M&6T>I?F/\OOF92;IRV<WI\N,%T!MK+[?K:**FQFQ\)T)LS*;3QU#AJN*KDDR
M<>XY\H]=.9H8S3S`K'<.Y;W7NJV.[_Y6'S<V=\POD=\L_P"6Q\]]J_%>;YG4
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M^''M2X/-8FGS5+/DO),T%$\5#5*9KR%8R#ZB!?W[KW51/R^_E`_'3YK_`".I
M?DKN[Y;?,OK7^(;*H=M[BZRZ#^4^9ZZZLW748NCAH-M[L7$T,>0J,'DJ3%72
M=,7/2TF0=8IY8_+]PU5[KW5#^Q_@WU7_`"NO^%#G\LW8_P`1N]N[.ZJOY*=4
M?)_#?)*E[H[)Q?=.^</L?";,S&X\5-D\CAMK;>EVWMS)[DP<-7$]0'<UN+D8
ML%.E_=>ZN<H*I!_PIJW#2RU$XD?^2)@6I*<+$].RK\W\FU8[/(XF@D4^+2(E
M(D!8N1H6_NO=7R^_=>ZI2_G74E%4X3^6`];5PXU:3^<E\#ZJ+*3&B5:&2/-;
M[#`OD<ABZ-%R$+-1G5,&(J+1I+(4B?W7NKK??NO=>]^Z]U[W[KW7O?NO=?_1
MW^/?NO=>]^Z]U3K_`#7)C1]N_P`G6O6.*9X_YL'5M`L<R$H%S/QL^46+EF#Q
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M`,)?)MR9G^5KMS>^0Z]Z3ZGV=OWNSN7/]9]=]'4.77!8#:E!N<[6K)<_G\[V
M)V-D]T;@R.ZMO9!UJ9:BF9*`4T?B*JLC^Z]TJ_D7+2U^]^_:/"Y!?XCMO^>%
M_*RR>6H,;D7IA7SY7:GP&IFH-R"LHJYHZ>*AJ5JHTIA&LLE+!9A^[K]U[J\S
ML*;(T^P=\3X>?[7+P;0W+-BJGRPP_;Y&/"UKT,_FJ2M/%XJE5;5(0BVNW%_?
MNO=:2'\J7XU_\)JM[?`SXM;@^1/8'Q'I/E%O#K&BK>ZT[&^96;Z\[-C['?(9
M&+=U#E-KS=U;7EVLDU?*ZPTM-14E/4TJQSQ+(`LWOW7NKHOBS\!/^$_>Q?D9
MU#VM\4,M\>,E\B\5+%6=2-L;YO[[[*W'FZK;VV*^**HH=E5/?^Z:3?4F'VI)
M4R:*NAKXX8`\Y0,ID7W7ND/_`,*N%A;^2+\FS)*L;IO;XZM3JW@O-,>_>O$:
M)/*CR:A`[O\`M%7LAN=&L'W7NB5_-'[S-_S"O^$MW5.W-G;MJMA]:;6'9&:I
M,)L7.[BP^T8ZOKCJ?`=>U&6RU)C9J;&08RKV74+/))6:<=!']U.@149_=>ZN
MW_F,_&/^6=\C,[U13?/?L'9FQMS8;";ZI.JX<_\`)O)_'K+9?%YDX.AW1/04
MF+W_`+*.\UPU7+1>)IXZU,?/4^@)]S()/=>ZK0V/\&?^$T_6F;CQ5#\ENFZS
M=N3@>CI?X[_-4[1.<FARD61V[-!!38[Y/8J&05WWD]/I:%OW"56QN/?NO=1/
MY)W7V+[7_E*?!'![+ZOA[?VET=_,'[;W+A<O)W;NSK1]H;2V#\G^_LE@^[5R
M.+I*R'N6KV]1YVE#;7J'.)SQJ6DEE22#2ONO=`)VIOKL'`_\+#/CCUYB^Q]Y
MXWKO?/Q*R><W1U_B.SMS3[/S^1Q/17?[8YMT;%BR,.!H:JDK<!354-%+!*I:
M*&O4B2?T^Z]U99_+0CDI/YJ/\_:@FJ:BMF7Y!?"_)?=SI(%%/F/B9AZNDQ\<
MCR2ZQBH0(`H;TQJA"J&"CW7NKVO?NO=>]^Z]U[W[KW7O?NO=>]^Z]UK2=I_\
M*/-O?'W^8+UK\"OD1\#OD!U#E^V>P]L=?;+WMD^PNGMP9;(1[[W[#UUL7?\`
M+U]M_<%8U+UUN/-/),E;)EUK?LX7>*DFD5X4]U[JQ/\`FI?S8NBOY2/5?5_;
MW?O7W<6_=K]I=F)UEC_]$>!VYEY\'D1M_*;EFK\Y4;IW1M/%T\;8W$3?;4Z5
M#U-6Z/H31%(Z^Z]T9+X+?,7K[Y^?%;J;Y;=5[7[!V;L+M_&9C)X#;W:&"I=O
M;QHH\'N3,[5K6K:+'Y+,XRHHJG(X.:2CJZ6KJ*:KI&CFC>SV'NO=&V]^Z]U[
MW[KW7O?NO=4__P`VJDR%1N7^5)/24\LM)COYN7Q@J\M,D)DCIJ.78/>&-@::
M0(_VXER=?3H&)123IU78*WNO=7`>_=>Z][]U[J@G-N(O^%/.QP*FC!JOY(VZ
MHFIY&D6J;P_->BF3P`JL4C/RUE+D)&Y8+Z2?=>ZK+_D/_"/O'X;;F_GF3_)#
MJ7Y&=<X_=^\=WQ[$[`[`C:DV3VIUU@W[KR<V[]KFDR%5B=V[RGH<_2UDV6IX
M*FE,58(:><M]U$/=>ZNK_D$9C,YW^3A_+ZKLY74^0J8>@,%AZ2:G>-TBPVW,
MIF-NX.AD:**%?N,=B,5#!(""RO&59F8$GW7NM9'Y9[KQ&"_X6D?&"JS%"VX:
M:.@ZAVI#0T-'D$J<1E]V_'#=V(PE=4-!-3??+A\MN.#(S3`O3QTEUD5O$Z^_
M=>ZW[??NO=>]^Z]U[W[KW1%OF'\^>M_AIOKXF]9[LZX[F[1WS\QN[J;H_J[;
M_3FTL7N6?'95:2GR6?W9N^IS>XMM4&(VEM3$5(K:Z2.6>K6BBGG2!XJ:=X_=
M>Z8N[?Y@VT^FOGC\2_@(O47:&^^POE9M'LS?E'O?:\>VX]C]:[2ZTH9JK)9G
M=TV7S5!D:B"2:E>.44L3/#K@"">6=(A[KW4GY^?S`=J?`';W16:W'T9\@>_,
MG\@N^-K?'[9.S_CSL_#;OW0N[]U8S,Y>@EKJ;/;EVM01P2TF"G6&,5!EGE!L
M%C266/W7NGCY5_/[J+XB=N_$+I#?VR^Y-X;^^:O:&5ZJZGH^K=C4^[*#$9C!
M46)R&=S6_,A49W#P8/;F&H<U%45$E-]]5)2Q5%0*<T]-/+'[KW35U%\W<_VU
M\[?E3\,Z;XU]G[<VM\5]N=:Y+._)?,9?:_\`HQW=N?M#:>UMZ;=V1M[$I5)N
M.3+RX/<-1*7C6ICA&-D^Z%,9Z03^Z]TP?&3^870_)GYG_-[X@XCH/MC9L'PG
MS.QMMY_NK<L-`O7V_=Q[RPD&?7!X)(_'6T&1BQ-5%74J,:C[O&.M4_VZRP)+
M[KW5C/OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z^9KG?Y9N[>
MR>]?YN'S)KN^]@=!]I=?[%_FR[GWG\--G;1P>R]P5O7^,V1VML/:^1BAAW/N
MJ.?;'8E/D1E,F:S!T=3)$@JX)W>K@K(_=>ZWQ?B%V;N&K_E7?&;N&F+U^ZW^
M`O3_`&)`TN)%`];N)/CYM_<,9?"@SI3?<Y-!_DZZE`;2.+>_=>ZKK_X3=?.+
MYE?S#OAKV3\DOF%V5UGOS)Y+O3<&S.N<5L#;NV=L9+9>V]K8+!OE,7O'#[9H
M:5*&OKLOE3/11UCS5K8_Q3.VB:,GW7NMAGW[KW7O?NO=>]^Z]U[W[KW14OG8
M.XV^%?RP7X\X[.Y;O5OCQV^O46/VKG<KMK=51V&=B9P;4&U<W@Q_%Z#=$>8,
M3XXTY25ZU8D#IJUK[KW6OCT9_+MVW\^OY)WPWWK_`#>>M/F1W3WQ\;,-WOWI
MD-F[FS.[*3Y-;KFFWUOC(0[`K,%7)!N_<4>]MBX##08S%UQARSPK21I-$2`?
M=>ZMQQOR4_ER?.+^6EO'L7>VZ=JX;X,9WKS(=<=X8#L?<-3U34=1X["2T.U]
MR]0]MIC\[B\]UGO#;.0^WQT]!]Y#4.98&IGFAJ:>2;W7NJ(MU]!?\)5I.K9'
M^-M1_*6S&[Z'*46*IC\C/ESOG:N.H\9([U>8S%7+6;PW#V)NZNH*-B:2FTT\
M-9(!`:^GTCW[KW11<_'_`"K>K/YWO\B(?R_LE\1WEKZ;LO!=_P!7\+]P9+-8
M*LWGNSK==J=8+N>HQ6Y<]CHJ.NW'DZX0PUU7+N#[1ICF/+$8-7NO=7JS)0M_
MPJ-II*G)K1U4?\D:V-H&EI8SF)9/F?6?<P1QS*:B=J&E1IR(2&4`EKJ#[]U[
MK8,]^Z]U0G_/W\;]<?RV:3[^BP]5E?YP/P6QE-G,G)D(,=A8UW'NW-5M=5U6
M,@>KID-'A7AU))#):4^-O)I'OW7NK[/?NO=>]^Z]U[W[KW7O?NO=?__2W^/?
MNO=>]^Z]U3?_`#8@P[<_DY.4C>!?YLO5"R_<35"TZO)\</E`M.6IZ?49Z@36
M,!8%(Y@I8A-1]^Z]T<K;6\^BZ[Y[]N[%Q=)ON/Y)[?\`BOT?G=Z5E=59X=<5
M'3.<[/[M@Z]BV]CZC+OMT[J@WECMP_Q&HIJ"*I:G:FCEGD$:1Q>Z]T/&8[BZ
M[P/;FQ>B\IN".F[0[(V5V!V'L_;/VM7+-E-H]89/8^'WKEC510/1TD6)R/8V
M(CM,Z-*U5Z`VEK>Z]T)WOW7N@-^3V[I^O_C5\A=^4NQ,;VE4[)Z.[8W=!UEF
M*N.@Q/8DNV]AY_,Q[%RE=-19**CQ^[6H_L)I7IYU2.H),;@%3[KW1`?Y&.^.
ML^S?Y8OQP[$Z?ZGZ$Z/Z^WG1;PSV&ZN^.5;O?([!VA5U.]<]'N+#9"M[$P&W
MMU5&^L=N:&L@SC2I54W\0B<4E75T@@G?W7NJ[.WMT;OQ?;G\QW,_<XC*9W`?
MSS/Y.>*P44N*:.B;;]?@OY=]%2XMZ2%Y'J,E0X//SWJGE0O4IYE,8"1I[KW6
MSOD89*C'UU/#,:>6>CJH8J@1+,8))8'1)A"Z2)*8F8-I*L&M8@_3W[KW6FQ_
M*+[0_DH[>_EB?&*3Y0](]$[D[6VAA-[[6[6WSO7^7SN3>U=6;WINRMRX+.5.
M6[`Q/06ZL-N6IJJ?'T<4N0_B4\T\,"?=>*:.6&'W7NCA?%KLW^4O4_S?MQY[
MHSXR[#V?NS>/QNZ7QG2'=6'^%?:/7%#D>UI=\]U83LREV/N"KZSPNU-L9"IV
M1F\!09+</V6)GJT27'39&IB@-/#[KW1]_P">IV+\4NI_Y:O=._\`YJ?'K(_*
M+X]X+<G4*;MZ>PVZLCLC,YJOS/:VT,!MS*XK=.(RF$RF)J]NYO*0UA,-7`T\
M43PLVB1@?=>Z`?YL]U]#]>57\D?%]>;+^0N;V3W!W]U#M+XY;0^.WRCFZ)H\
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MM/Y=PPK?S5OY\<V$$'B;N7X,0Y`TYK0IS-/\0,&,L)HZQ41:H5SOK:$>%N""
M3>WNO=7>^_=>Z][]U[KWOW7NO>_=>Z][]U[K1D_FE=E;TI_Y^'QQZ_\`EA\N
M.DMR?%/9/?OQ"[2ZL^+62WAO'I[/;)>ORM#A\)N#>,F!Z$S]-VC783LBKGW%
M2K-ND41ID%-424<+5"T_NO='7_X5J[#WKWY\7_AA\6NE]@;C[/\`D3W3\P8<
MCU!LK%9*DH</F6ZXZ>[)S&[H,U3;@FH]FYBH.+RL0I*3(5,,KDRM3B33*A]U
M[J\3^5;M[OG:7\N_XD[4^3FR-J]:]X;7ZDQ.W=[]?[*VKMW9.V]FG!UV1QFW
M-N46U=HS3;6PU1B=I4M!#51XXI1&L65X8XXV6-?=>ZL`]^Z]U[W[KW7O?NO=
M4X_S>:Z2CW%_*:5!,XJ_YP'Q9IVBBG,4<FKKSOAU-0@BE-1%%IUA/3:15:_I
ML?=>ZN.]^Z]U[W[KW5`6X%Q$_P#PIXZ\>2CJZC)47\EC>,4,\M"ST=#4/\Q*
M"2&JHJOE4E?'U-3!.W&CRQI<^6WOW7NB(?R4/F%V3\LM\?\`"A#!;\^0?9?;
MXVA\A.RI.H-N[MRM5GMD[`ZCS;]][:V2>LL57>./;V,KZ':$$-1BZ84U'XZ&
MED$0GFJ)&]U[JT;_`(3LYFKSW\ECX!5U;4"JFAZGSV&20.'"TFV^SM^;<Q].
M"I(4TE!BHHB/J"A!YO[]U[K3U_G!8WY+8[_A5GLO<7Q@VK@.S^^L"_QL[6Z<
MZWW%F\;@\3NV;J_I'&[LRFQ*K)Y.OQE)156Z(-D96&G5JB&22>LC$;!W0^_=
M>ZW5?C'_`#I/Y??R0PR463[SVG\<^Z<-6S[>[+^-?R=SF&Z5[NZMWOC72FS.
MT]R[8WI7XR'(RT-<WCBK<;-64%5](Y?('C3W7NCLS?+7XJTSO%4?)CX_0RQA
M3)'+W+UTDD8?1I9T;<89%/E7D@"S#^OOW7NI-!\J/C%E*M:#&?(WHC(5SIY$
MHZ'MWK^JJGC\2S>2.G@W"\KQ^)PVH`C2;W]^Z]UKD='?R.OB'\J^V?EMVSOV
M+^9?UQV3LGY@[QK.H/E#N3Y?[FAW'V5B<OMK;>[(>Y_CIG]N;>Q6W*?KBO\`
M[XU^!QU88LY6K1TDD+Y,5`GI:/W7N@JI?Y2_\GOXX]D=R;C^3'\Q+OOI#Y'X
M/?.\]G;9[Y[3_FL[/V5\C9-N]A;:PNY)=XC(8++[1R&W<KN1,[7T4V.W!CYY
M,C3TAJ:NGJ(JF-V]U[HUGQI_X3\?#?=GQOV54[I[$^65#N/,-F<_M_>?4_\`
M,A[G[,VXN.GS69I-F]B]?;MP=!UWU[F)-\;"F@R+S#:424[9>II5\RHL[^Z]
MTZO_`,)POA?O7I+K:KWGEOF9L+Y%=>8+,Y/$=MXKYS]I[S[4VKNG*8[*09.7
M#;NW/45'66(GR\U8U152XG;6*I7FE8.KPF02>Z]U6?2_R[?Y2/8NQ^E.OOC+
M\TMX[P^16Z>WNG:C>7Q$P/\`.IV-6S[FJ*SL+`3]H29>MVMDM[4F\MU;-VG1
M5.2I5VM2X[*9.HPU.E)/!/=_?NO='3^7W_"=/H/#4776\_C#NCY>3[CW+\N?
MC'EOD7LW-_-/L'^`=R],KV=LS;78=1O?+=B;TAR61W)U]UPDU5M^HH\B,YYJ
M..DI142/!&GNO=;2D]=C\=]C!65U+1M6U,>.QZ5E7'%)75C122QT=*:B025=
M8\-.[A%U2,J,UC8GW[KW6:6JI8)::&>I@AFK)6AHXI9HXY:J9(9*AXJ:-V#3
MRI3PNY502$4M]`3[]U[K/[]U[K%YX!.*8S1?<M$TZT_D3SF!76-IA%?R&)9'
M"EK6!('Y]^Z]UDN+D7%P`2+\@&]B1]0#8_[;W[KW6&&JIJAZF.GJ8)Y*.<4U
M7'#-'*]+4F&&I%/4JC,T$YIZB.30UFT.K6LP)]U[K/[]U[KWOW7NOGH]>?R:
M_CGW7\'OYB'\W"F[9WM2=\;>W-_.3W-AL?LC>6)R>S-Q;?I5[OV'M+%=AX6J
MIJ?*8/,TE+#799*>GR,'\0H<K125*2Q,(6]U[K<)_EBI35'\H_X%0U,N+I:6
MI_E__'**:7,U+TF'A@EZ!VH)9,I5QO#+3XV*&[3R*RLD(9@1:_OW7NJ7?^$=
MLV;I/Y:O=FTJS';:;`[,^;7;^&V]NS:FXJ+.XG=]]D]62Y2LHQ3S3546/HZC
M0M'43:?O:*2*5`5]3>Z]UMC^_=>Z][]U[KJXN5N+@`D7Y`-P"1]0"5-O];W[
MKW28SV^-E[5JJ&AW1N_:^VZW*+*^,H\]N#$X>JR*0/%'.]#3Y"KIY:M89)T5
MS&&"LZ@\D>_=>Z4<$\%5!#54LT5335,4<]/402)-!/!,@DAFAFC+1RQ2QL&5
ME)#`W''OW7NLI%^#R#P0?S[]U[K7L_F:?#7(?%S(]J_S0_AKLBCW'N;&;<@R
M?SG^#TVUY-R]&_/OIW#3D[BK=P=?8W`;AI\1\@]CXJIDRF(W1%CJH3BA:'(Q
M20RSR'W7NB+;V_FT?\)U^_>CJS#];[=?8796_-N08G(TO1'\N_'Y_P"2'2M%
MGSIRV4I:G+?'[?76F(RN/6F6%:^FFR_@FJ(9Z,/*BR1>Z]U49GNSO@)3_P`T
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MW>T=-L?LVEW92TN#S$&<HJF+,6H9\:3*E1[]U[I8_P`V*.2;L3^4/%_":[,4
MS?S;>C))J>@KWQ\E-+2]#_)BLI<K*_\`$,=#/2X:6G-7/"[2>>FADC6*5W6-
M_=>Z=.H,RM;_`#M_G#C*EZ5)\3_+[^"%)C(170U-5+0_Z8_F1E,E4_:JQFQZ
MK69N&.1"!K`BD-PZ^_=>Z.GO+XY0[K^7/0WRGCW#'0573'2_R&Z>J=M-C&GE
MW'2=Y;DZ)W'39%,J*V%<<NV:CIIP8F@G^Y_B'#1>,^3W7NC.^_=>Z!?Y(U*T
M?QW[ZJWWD_724O2_:-2_8,>%H-QR;%6#8^=E;>*;>R@.,SS[9"?>BBJ!X*HP
M>*3TL??NO=:]/_"1'<39G^3UMS$)N7^\%!LKY&]\[8Q-,V*BQ51MO&U&7PN[
MH\-6"*LK?O*FMJ-U2Y8R%[Q+DQ3C4L(D?W7N@B^0\N5H^]?YK573UF2T+_.N
M_D0''4/E^VH8*O3\!DK*FAJ%<RQU>3ADBAJ6*A?%#%:_J`]U[K;5J(XIJ>>&
M<*89898Y@X4H8I$99`X<%"I0F]P1;Z^_=>ZU7OY17\QO*]$?RQOB-L*D_EX?
MS`>Y<'MRD[7V'MWL3XO]";*[#ZTWAMW8G<V[,!1=AT-7#V7M>NH*3=M+/]ZR
MRX^-JJJBK#2FKC6.>;W7NK&^COYOI[Q^76!^)<7\NC^9#U1D,QM&BWED>S.Z
M^A]M;"V3L_"9*JS]%C=P;N5NQ<GDL;M#)9';E104^0B2HDDR:-3_`&P"F3W[
MKW27_GY?"CY&_P`P+X0;:^-7QHV_MG<FZ-Q_)7I+<.]:#?G85=U_UU%UIM3(
M9K+;AKNQ?X/-3;BWALVCR4=`]3B<3(N7:415=$&J:2-3[KW5+O\`.2R^]_C#
M\^_^$T'2^V=F;<Q.TNE^Q=J4#U6U=I;_`.V8\.]!G>E.MMW[1VEEMT5^XNT<
MOM#"[%HJF2@AJ:N;*F*.&KJ7FFI(VC]U[K:(^8'RHR7Q@AZRKL5\.OE=\MZW
M>F?RV*IX?BYUOLG?]5UT]%34"SY;>]1O+L'8<>U\?F<?DYXZ.IC>6&=Z:6&:
M2`,A?W7NB&?\/%5-#79#R?R<OYR--4)-!D*FII/AMU_4/4^1%HXZ]ZFE[R,5
M15*^/,7IDDD2&&-V*QM&??NO=4(_&7M&IVU_)/\`@9W/MKHC>/<O;>Y?YX>2
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MG\TKO*OZ%_X5`_'#;N-V-T)\K9._ZWX(;;.U^]L`.W,_\7DR'8^0V;E\'TE#
MN#)?P+HW<^XJ"2'>'F@I)YC6U\&0C$;5$AF]U[JU'_A7/LVCG_E=[;[JI<=L
MJKWC\>/E!U#OC:\^]<?MW/4CQ[FAW)UYF,/!L_=F)SFW=]19,;HIYJK$UE-)
M`U-1O5,#]H%/NO='C_X3K;)39'\FCX.0G`C;U7NKKC,]@9"D3<V1W1#6U&^-
M\;HW!!GH):\)#@8]PXZL@K?X12)'18IIS31`^,LWNO=77^_=>Z][]U[KWOW7
MNJU?YCW;"]3Y#^7W*>L>I^RY.QOYD7QXZGAE[3VM/N:HZZDWGMCM0'LSK"HI
M\GC3M?M/;L.->''9-EJ4AIZRI1H6$MQ[KW5E7OW7NO>_=>ZU],I-/3?\*@=J
MBKHY*BDR7\F/<%)AZF6O26"@JJ3Y:4=;E)Z.AAF<TL]1`8H9_,B-*K1LGI7G
MW7NCN]1_RV?A7\$-K?,7?WQ?Z5QW6FX_D9@=W;K[:JZ;<.\<U%FZFAPFZ<A1
MXK%T>9S&9CVQMZCK\_7SPT.+B@ABDK)-"6$:)[KW16?^$T@D'\D#X'^1TDOM
M7MPH4C,>F,_(CM[0C7DDUN@X+#3?^@]^Z]U1%_-ZV/G_`(A?\*=/Y8WSCW9O
M/&;.Z9[ZS?6>R)][9%!2XK:E3M5:CJ#LC;VY*ZO%7CJ+'Y3:._Z&;[UOMTA@
MR$S_`+9I7J/?NO=;B7=_PX^'/RR&'S?R%^,_QZ^0<]'A),=MK<G:'56P>Q,I
MC-OY2>/*24VVMR9_"Y/)8O&U]1IJ/\BJ(DD<Z^2;^_=>Z`_'?RC?Y66*HY:"
MC_ES_"7[>>,QR&K^,G3N1J2K0F`Z*W([1JJV)C&Q]2R!K^J^KGW[KW0*]Z_R
MV?Y(W1/5>ZNT.^OA1\#>K>JMM0X]MS;UW+T?UAMG&XS[_*T..Q5.N5I,!35X
MK\KF:JGI*:"F8U%7/,L"*[2:&]U[K7&Z*^$O\P+Y"[*[SZ'_`)5W>^W/B;\9
MOBC_`#N?FRZ95^^^YMK4&8V+LS"=,P=?]0[?P77V.S><KNJ]M9:#,T]7C:NO
M%'55.0CG2$JDDGOW7NKC.B_C#\!=\97^:SWI\GOBATW\@]Q8C^8CWKMS<NZ,
M]\7Z3O;M3`;;QG3?1AH-N4%53[(WCO=<1C<97'(0MBQ'28\5QD/CG6>4^Z]U
M15\&8_YTM9\$/Y(O:'\N/:G:/9WQCZOSW?&X/D'U#1]W=0]5#L[`X'YJ[_.W
M.NL]GNT,O498['R'4V.7$TLD-/7P8Z/SL(/,L6KW7NF#H_Y!_P`\7L;XG]!=
MB]<]/=\T_P`%MG?"#YC;#[SRN8[OZ,HSOG?&4R7R[I*7NIMV;KH=R]OS8?J.
MGQ&`B$*14V3GFQ*+2:8JY:BJ]U[HW&*^+?Q[ZW_D4_R?/DOU-\6.I$^2&V.\
M/Y8N^L%O3';%Z_QG;F[=Z[_^3/4LF[J:/LN08>K6?L[+52Q2OD\G'3K13)#4
M-"L=X_=>Z+]EZ_\`G6[3Z+S63_F28GMY,!EOYP/\L[<?Q?J-Y;ZZJR66&$I/
MDMO^HW%L^APNPY,W7XO&KDJ#:T],<W3&B+BF:F@<*0?=>ZOJ_GE[7V-N7L/^
M2_'NFDK\QEQ_.%^,U%A<#!DIZ?'U^.JL%OW(9VLR.,'BI,C_``:JPV/GCD::
M&:F`<Q^17DBD]U[K/_-DI#_PXE_(0RJ2U,<U)\T.Z<8/%+(D#09?H'*O4K,B
MD*\CIC0JW_L-(/HQ]^Z]U'^8G8^1B_GG?R4<=MW<>[:#`;PV+_,UVCNG;D[9
MW`X3-2;.ZPVJT<U9MS*5F$_B0I-PXAI*6N:DJJ:JCBBGI&FC\<H]U[H9=PUH
MQ'\_[J^CESV8IJ?>G\I[MGQ8%LSDX\%E,MLWY6=82TLT>%CJ%Q4V2Q^*W)6N
M9)(S*8W)!.@:?=>Z9OCSN+<E;_/<_F0;<J]PY:LVUAOAA\&:C$[>FR<DV'Q-
M779ONF6JGHL7S#1555(TCR.-,CB2[:E,>CW7NG/^5D[#Y._SI:7^)9'(PTO\
MR63[;^)U%1/)1)6_%_X^Y&HH*1:A(S3XVER%9,E.B*(Q&`5+`ZV]U[JNSX(?
M-'=O2'\O;^87W?65^^>T,=M[^<3\M>J<SNO?._?X5F^KNN^Q^YMI;1H^P6?*
M29*JVWC>N3O>ERDN&`A*2F=U,$,GG3W7NLGP&^0G:&P_^$P'2':.T,1VKW7V
M7FNH^T=HG+X*6');FVS-GN\>TMM9S?\`NC,2;GQ>2I-I]:XL3U-57Q5%1DUI
MZ6-A322L8A[KW6C)\@>T?DAT5UE\H?C]\3?F;E.V/B_\CMX]E=H?++HC8W6_
M8&WWZGK-H]E4NV:E^QLAOSKR+"8O!Y[,5M!CURNTMQ2TNX/LH:?)1H8:2$^Z
M]UN'?.'Y>=,83^55_+.V7LRDJ]FX+XZ]E?R=,YVK3;JS6YFZVV-UGW3\>MY;
MIQ.#WINZEJ]N9O<F/Q>Q,(3D!D*:BB6KK<=,\99PJ>Z]U2C_`,)A.T=L[=^0
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M87<.^.Q]KT/5/7/9W1&XMU[FP.U<'LG?&W8((,AGTCJ:JK9'=\DTM1&899Y`
M?=>Z/K_PGGSE0WP4W]U<,GO'(8'XX_-3Y@_'C8E/OG/Y+<V=V]USUSV_EEV%
MM$Y;)UV1EDH-I;7RM-CX(HIFIX$I_'%9%`'NO=7J^_=>Z#GN#LF@Z<ZI[([9
MRNV=Z[SQG6NQ]S[YR&T>M]MU&\.P-S46UL-69FIP>R]JTLL-1N+<^3AHS#14
M:.AJ*AU34+W'NO=:0OSL^>6V)ODIUU\V?BU_+_\`YNG0?=7:[;9Z;^1?379O
MQ2R/171/S[Z+Q\&7W'N3:FX]V;:WZNZL=\B-E=>_Q*OVAN3%K796.*A2D,34
MXNONO=1N^/YN7Q&_FD?SEOY#53\7O])BU_37<?;'^DW`=K;!J-E9K:>0[)Q>
MQHL#@ZD/E,M0Y3-4<>S*R6HDHJJKHXBT)6>1F95]U[J^3NK:BS_\*,OA#NL/
MD(GB_EJ?*2!]$,BT%4F&[;V32I3R5$51()C$V^&EDCDAB2-U@(DD=PD?NO=7
MR^_=>ZH)_P"%#^7GP7QB^&^4HJNNQ^2H_P":=\$*C&9*B\Z''5M-V)DZD5E1
M445339&DIXX()`'IBTYD9$4`,77W7NK]O?NO=>]^Z]U[W[KW7O?NO=?_U-RC
M^8/UAOKN'XD=L["ZKVSOW<_;&3H</6=3IUOW`O1&Y=N=GX;/8W+["WTW9C9K
M#_P;`[$W114N6RE/IR/\1QU)-2''9`3FCF]U[HF/\J3X_P#\X+I&BS3?S0OF
MGTG\CZ?*8):;9FS-B]=4B[QVWG/+C&>?)]O4NV.KAG<9C\7C90]"^WZZ:HJJ
MUIVR"K"J2^Z]TX?S7:_<"]Q?R=,'@LK18N/,_P`UGK&HR_WM&*M*W%[?^.OR
M6S-;0Q-$AK*:IK*.FE@ADC9(UGE0S:H@RGW7NEGUEA]O1_SI?ESFJ;;]=C]P
MS?R^/AK39#.30N*#/4\O=_RP"R4<JRS1B6CBQU/3RZA"SF``*XC+^_=>Z-YO
M_LO>&"^6?QLZKQN5H*;8_8O5?R9W1NS$RT=#+D\IG>M\CT%3;/J*.NFU5]'1
M8VFWWE?N$@`29YH?(XT(K^Z]T9_W[KW09=UXK:.=Z:[;PG8%!-E-A9GK+?N*
MWMC*?;U=NVHR.T<AM7*TFY*"#:N,I:[);FFJ\---&N/IX)IZUF$,:.[A3[KW
M5&/_``F4[`[UW3_+>K>ON]L-O+&UOQS^078_Q\ZQR/8O5]=U'V!N+IG9&WMA
MY+KS)[RVCD*6EJ8LW08W<;XPR2&>98*"*&:>HGADFD]U[H&/F1M3>>3W[_,;
M^PR^1KWR7\VK^1]/L^@.+Q\DF)J\9D/@G+6_PV`5&(;-TPDF68IY)*G5#("=
M"W3W7NMG/*XZGS&+R6)JS.M+E*"LQU2U+434E2*>NIY*:8T]73LD]+.(Y3HD
M0AT:Q!!`]^Z]UJD_R0/D)_,4V3_*\^.NT>DOY?'6/?'4?64W>VP=G;__`-G=
MVKUIN_?^/V'W=V;M^&>DV+G>FLQ@:"LEW)CZBD,U1N*&EJ8(15H4658A[KW5
MG?46^?YDFY_EWL#LOL_^6EUATYLS>?6>"ZP[<[/A^?&*[1W#L3:^%KL_O.AI
M</U9B>K<%M_+Y.CWGN6IAEEHJCRUM(5:6K*P4\"^Z]T)'\YSK[Y9=H?RU/D]
ML[X/56[:3Y,UFV]L9'KQNO\`>F>Z_P!_31X#?FUL]NREV/NC;FX]JY*DW74[
M.QU>E%`*P)6S$4S1S>41-[KW2G^+W8&+Z*^'/\NO`_-;)R]?_(7?6S^C^EJ*
MA[GW3_?_`+'R?R@W)U94U6:VI/OFK_B59E^P,_)@,O\`<59G!GD#Q-*S.H?W
M7NA1^7_='R^Z@QFRG^)'PJI_F+FL]79>/=]+DODAUS\=,5L+&T$-"^.JY<EO
MG#[BK=SUN>J*F2.*GHZ01P)3N\TR$Q))[KW1-:+YI_S>W>(9/^2;0TT9>J$[
M8_\`F5?'+(ND2TC-1-"E5L3$K-)/7A8YE9HQ#`3*K2N/"?=>ZIP^*NP^O^Z?
MY/7QCV9WKNWL7X/]T[F_G-=A_P"C/</1^$V_V;7=4_-.7YK=WUG7VWI,=D*+
M.[;BV?MO(22X-JBO1*+5103OY(9E2;W7NCF;+_D0_)G9O\Q';_\`,-R7\TO?
MO:W:D736\.G,[N?M?XT=.YS?F$Q.:VODMN[?J^JJG&RXSKO8$N!DK_N=4&W6
MEG9ZR.=YXLE6QO[KW4O^35U[O/HS^9M_/&Z0[.[DW1\C.RL9NWX']B;F[WWU
MMO:>R-W;^/8/0N[LA2TU9L[8U#CMHX_&[2@A6@I9L?3TT$D:A?"C(2WNO=;)
MGOW7NO>_=>Z][]U[KWOW7NO>_=>ZU_\`YH;;_D+]2?,#:..^:70NP,1\J_D3
MVKU?O#8_:.\OCAWIN"7L7MB7*8;:VPZ+;W?6!V)EMFC(XNMP>/BJ\+%FX:2D
MC,<E;3*DK,WNO='/_FH_RR.NOYK?0>QOCGVOVAV'UEL';/=NR>W=POUQ'@&R
M^\*#:N-W)AJS:$M3N#'Y*FQ/\1H-SS/35ZPSFBK(HI6IZA%:%O=>Z$_^75\(
ML)_+L^*6QOB9M7M;L/N#9_7&7WG/L_<?9DN/EW%B-M;HW7E=RXS9T!QD,-(F
M'VNF4-/3!55;`E4B0I#'[KW1XO?NO=>]^Z]U[W[KW5-7\Y3;D&7PW\MC/9!J
MA<+L?^;9\,<YE_L*^EQF4'\=J.P.O<!)CJVNJZ*D1X-X;UQKSQ-*KU%(LT40
MDF>.*3W7NKE??NO=>]^Z]UKZ[^V@<;_PII^/N])*G<&3BW7_`"H.W<32T$=7
M'/A]L5>S^_<,U3D9*.0Q&@H<W2[K2&5HS*T]:E-=55&8>Z]U?!OK`ONK9&\M
ML1EEDW'M7<.!0I*L+!\QB*S'J5F=)%B8-4<,58*>;'W[KW5.?_"<G%5N"_DN
M?"#"Y'[?[W$[;[=QTYI0@@)H_D/V[3HRF..$.S1Q@LQ4.[$LWJ)/OW7NAH_G
M"?RU>OOYH'PK[/Z+S6$P8[;QN`RNZ/CUOROHZ`9/9';.*I&K=NI#FJF%JK&;
M=W56TL>,S*Q21B;'U#WY12/=>ZKZ_P"$P?S=[,^2?P=W-\</D172CY'?`KL2
MK^-F[L;FJH/N]MB[4Q]+C=AU&Y:=X(IGRFWFQM=MVHG,E4\[X99II3-,P'NO
M=;)&0EK(*"MGQU)'D,A#25,M#02U0H8JVLCA=Z:DDK3#4"CCJ9@J&4QN(PVK
M2UK'W7NJ)]Z]6_.W^8/_`"]?G=\6?DUU_P#'S;GRHH.[<CLKJ;+9#9N_Q\:/
MX)3MU)W#U5OS:&;WQM*3<F_X>M(MPSXV3/TF*\=1N3`SI&@\;GW[KW5=?\O7
MY%?)K^3_`%7S#^+?R[^`O\P[Y/=A]G_.7N;Y+[<^0WPW^-M+W)TUVW@>\(-I
M2_WFARF,SNR\+LC+5N8P<U14XA@#0-4F.5*4Q&/W[KW6?X6_S2^V.@\[\_\`
M<G:/\H;^;I-MCY0_-#LKY`=+4NU/A[N'.9>HV_GNI>J-AR;9[$HJO=&.39>;
MER'7T4JS4T59CC%D"/N97II6/NO=,G\JS^9_6?R^_ACT#\'^Y/Y87\V>D[:V
M7GNRJ+;NT=H_%A]^4)VQV3W)OWL#KS%46\LGN3KZBK*G%[:W=24%2U31XTB>
MG>4QQPLI'NO=`[\6?YILGQ]_E=5_P$[?_EL?S8LAVS4[#^775.)3`_$*>JVU
MDL?V+V9W5!L?''<T.Y\55K-AL'NBCQN6JTQCF&MI*B2,52A))?=>Z!SLGO?M
MVB_E2?!C^6=4_P`I3^;7%VWTAD?A;NS>F<QG1=72[$FRO3O<VPMT]B5.WMU;
M?W1DI=P4FZ8TRB8NDR5)CEQ5?5T3UGVK01U"^Z]U8E_,?^:61^>75FS.E(/Y
M9'\[3KC*]/\`R4^/WR-K\]0?!S9>;\F/Z8WY!N3)XK%5,_?5/A,KD,IB4J$I
M30U-;(E2(F\,J71_=>Z#/^8C_,YI/F4OPVCZK_EL?SEZBO\`BI\_?C)\NL_+
M%\$L]CJ3+;1ZGK]U0;KV]3C);GJY#N"LP^?F-#%/1K%-41://`"9X_=>Z6?R
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M:))%DG`]U[I=?'/Y^[[Q/\U_YL?,C*?RW/YQN.Z;[[^-OQUZYV9@\E\*=S)7
MQ[MZ6FW0,XV5VO#D56AI:F+.Z\+4'(5+B2JR/W"P+-3HGNO=.'Q3_F$S?%;Y
M0_S2ODKV/_+>_F^8CK[Y7]U=.]H=?T4'PCW'FUQV`V3TIL_K7*5.=,6ZS48/
M<FZ-\4V6J%II&?'TN*IJ/5413S?;CW7ND-_+K_F!]5?$7K7Y4=;=D?RWOYN6
M6PWS'^;7S`^1N.PN3^`F[\MA<CM#O#.446V^MJMWW"E+F,S5[$Q44>1ACA^Q
MIY_N(Y9S$J5$WNO="+_+T^<V`^,/P'^.O\N3NG^67_-4@WI6;7[%ZDBVF_Q!
MW35;7SF'W5O_`+%JHS4=AT.7BHZ?%8_`YNC.9R/A#XY:K[ET>%))1[KW6IG\
MJ>M/EME.G.U?C%\4,W_.&SVT8^S>Q9?D;\*=U_&K?U?T1MO=M3W`^[%K-O;K
MV!N&;%9'9.2W#(,E`F2VU0551DXUJ&IT:H+)[KW5W_S:[#Z0^2_\I[HSX-=.
M_"'^:GNK,;,W[\*-T=^[YV?\"^V-IG=-%U!UKLKK?NC==5D<ACVV['NO&]8[
M=J<=CJ)HI*%LQCZ4P^6BC-;[]U[JOWX,[7_EY_'GY2?`SY9?![XR?SFN\NG>
MBNT?D)V9\ANVMQ_&1]V(U/5=53;#ZUVCMBDZBRB;.J_[@[_,G]XI59)#35DD
M<LM2H6F@]U[K8KWA_-EV-VE_,R^)/R&VK\6?YE^(^/\`T[\;/E3U5VWNFH^!
M?>5?1Y+=7>F=Z.S^P]J5>VL-MW.;IJ*#'MTW55M35P43K%4-21H9(I*MH/=>
MZ+UU/\UNNNC_`.;IB?DQLGX5?S&>LO@;M3^63B_A%UQ#4_`WY"/'0=B[1[YJ
M^UL;M3:&V3M7+[IQVUI=J$^*9_"&J8=$Z)'%&Z^Z]T*&W?YH_4O7_P#,C^87
MRQW5\,/YE.YNC?D#\9?BIU9LT2?`KN!ZK,;WZ8W'W'EMX8_^`;IH<9#!AZ?$
M[YQ%33SSF%9IVGTIZ%EE]U[I!_`_YV4/5'\S#^:[\X.YOA3_`#,^I>H_F5BO
MBSD>CTW+\$^^MQ9W)X/HSK+*[4WODMPX_KW:^\J#;R/5U=+64;25CP&AJ`7>
M.0,@]U[JP?\`X3.;MVOV-\(OD=VCLJ',Q;3[1_F._,SL';3YY:FGR<^W=T;R
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MNVHA3RUWVXEDI,H)26%,`/=>ZV4.UZM'_P"%$'Q!H/XAE)7IOY7_`,HJPXJ,
M0C&42UW?/4T*Y&5JB!2QR?\`#VBE$$KS!Z2F+*D>HO[KW5Y'OW7NJ!/^%%ST
MH^(GQ<CGHWJJBH_F9_!:''2)4/%]C6_Z4)I6JC"D<GWPDH8IH!$2H#3B2]T"
MM[KW5_?OW7NO>_=>Z][]U[KWOW7NO__5VO/YIM7D]V=3=1?&G"_&VG^2V4^6
M7>6$ZF@P.XNX^U?CUUQL:GVSL[>O=%=V!V'W1TIA<_V5LS&8JFZP-/0IC*8S
M9#)U4%-JM(4?W7NJ??B?\1M^]7?S`OBKV?VO_)S_`-ENHMO]L][=:;![\ZL_
MF(]V?)>#:-?'TOV+%1]F]C]6;EQD.W\CL'M?`86;$4>=RST>:CJ:FC%73Q.*
M>%O=>ZL@_F[T--)V3_)YRM?]O2T&+_FZ]"12960U`J:>ORW3?R#Q^$QE,*"J
MILBRYW,/!!($$L`%C5(:82D>Z]T8S8E?MR3^:M\F,;#5Y&7=E-\%OB!59&EK
M(V-!2X"I[O\`F&F).%G:BBMYLA#6&L19YE#^)M$9),GNO='IR6:V51;LVOA<
MOE-L4N^,W0;EDV7B\C68N'=.5QN*7$3;O;;%)4R+E:VCQZ5%`^1^U5DC5H&F
ML-!]^Z]TJ??NO=-F:R-'B,/ELMD*ZBQE!C,97Y&NR62M_#L?1T5++4U-=7WE
M@'V5)#$TDOK3]M3ZA]??NO=4V?R$_P"8-V=_,H^!4??O<U1@LAV;@>\.W>J]
MSYG:>V:7:.TLW%M;*T&8VMDMMX6+-9JMAH7V3NC&1S-6-!4O6QS_`+9C$<LO
MNO=(SO7L+.Y[>?\`,*VO/4[YRU)U?_,!_E*4VSZ;$SI@*C:U?N?<OPGR^2FP
M%<L.1R$FW$EKVK,G4/!!35<515T<4RLLLJ>Z]U>E50FHIJBG#F,SP30B0:KQ
MF6-D#C0\;W0M?AE/]"/K[]U[K4I_D^8?^<5UW_+5Z(Q/Q$VC_+HW%TV-Y_)"
M?8>/[_ROR>V)V/%@*[Y&=P9.#(Y@[8Q&>P;X[(Y629<>(4,@QLM+*[SLTKCW
M7NK1OC=E?YUN2^7&#J/EABOY=6U>@Y>N(J7=VRNC>Q_DCNK?='+25V?FAWGM
M.CWIL+;VU*O+9S.5-%03K65*"BQU(Y7RR2K?W7NKE_?NO=4[_P`X:18\=_+,
MUB%D?^<-\"X]+T@FJ?(^Z]U^)J*L-1'_``J6.0`RR^*<S4PEIM*>?S1>Z]T:
M_P"8VZ?Y@FUJ;8E1\%.H_C'VU-4U>4B[(Q_R'[2W[UA/BJ59<2,'4;0J=G;+
MW=2Y45$<E;]X*HT[4_CB:)9RS1CW7NB1Q=K_`/"@N<:O]D]_ED4(IJJBBFCK
M/ECWQ,^2IZB:EBJ9\<U%T9*E''0I,\DIJ+R:(F\4<KZ%D]U[I#?R*L=V+N/X
M`Y#_`$B;/ZH;M2B_F%_,G-]J8A:JJSVRL%O3'?,'L7)[YR/7]:U)E*RHR.VL
ML)UVY4U#JS>"GF>=0;^_=>ZON]^Z]U0?\(W#?SZOYX8ITB$*=4?RS$K6C4HQ
MKQTKOUHC/Y3Y'E-(X`:(>+0H#>L&_NO=7X>_=>Z][]U[KWOW7NO>_=>Z][]U
M[K3^_FPY3*[\_P"%%?\`*'Z,WEW''B^H]NQ=8?(/!]);JW#W*VU-U=P;;[-[
M2Q>VMS;6V]L#J;=&T\?O^A@Q#+'5YC)P4%73PM35U7CJ9E>7W7NMC/YW=A?,
MOK3I"DW'\$NC=F_(7O7_`$B;%H7Z[W_NG&[*VM4]>U&6U;_R-;NC);DVVN'K
M*3`Q.M'-$:^6.JDC;[*J56B/NO=#WTAF^V]R=1]>9[OG8VV>L^Y,MM;%UO8^
MP=F[MEWWM?:FZIH`V3P^%W;-B<(^;HZ:7@2_;J`25#2A1*_NO="G[]U[KWOW
M7NO>_=>ZK$_FV;<V'6_%S:78G:O>NSOCIU=\=OE/\3?DMV#V3O?`;@W)ATV[
MTIWQLK=XVO3X_;4W\27,[PR]+2XZCD^VKHUGG`,!+"6+W7NC>_&CY2=!_,3J
MK'=W_&GL?%]K]49?+YO!8K>^$QV>Q^(R63VW7/C,Y!0#<.)P]75QX[(QO`\T
M<30F6-T5RR,![KW0_>_=>ZH;[RI,AF/^%%?P/BILDF)I-H?RYOEENBNCI&F2
MJW32YCLO8NUCMW+B!PLN*Q]?54N3IQ.#$*FF8K^X%(]U[J^"6188I)G("11O
M(Y9D0!44LQ+R,D:``?5B`/R0/?NO=5#?R%GHY?Y3WQ2GQ]2:RAJ1WC54E0PF
M$CT]5\D>X:B(3?<#RFHC24+(26!=20S`AC[KW5OOOW7NM%7NG>>Q?Y)'_"F_
M$=DU^8W5U1\,_P"9+LC^\_;F3R=:V)ZI@[9WCE-RXO<6X,ME\F*RFKL+LOL^
M2EW#D&\M,<*NZ9#>.D"K)[KW6]-#-%4113P2QSP3QI-#-"ZR1312*'CEBD0L
MDD<B,"K`D$&X]^Z]UD]^Z]U[W[KW5=?S=_FG?#GX#_P/;W<6^\GN[NG>5=C\
M3US\8NDL*W:WR5[(S&7EIXL3CMJ=3X&K3+1_Q22J1::JR<F.H)Y&6-*AI61&
M]U[JOS,?.S^=_P#(3<&R-K?&?^4Q2?%'8'8.?H4_V9CYJ]S==;KJNO\`8M26
MG?<N]/BKUQO;:79F&W#]M"T;8A\K4U5-/)&'B=2Q3W7NE=V+TC_-LV-2[,?N
M3^=C\:NGNL]QUU%M_>W8$7PPZ?ZWWO3;MRL>1BPNS^I\EV?V-NWK^KK-QS"-
M(FR5)-D%:%Y(()#^U[]U[JJ?YJ=Y?S7_`(H_-/I_X!_%O^8)\F?E3\U.Z=FM
MV;UAMGOGX_?`3JWXLYWK_'8[?%5O!\MOJ'$;?WYF]SX2EV-7R1T-#2T!62)=
M,]0=4)]U[JQ_JKX0_P`__?,:UGR6_G*;!ZGCI,3B*?&X3XV?#OI+<^4RU36T
MT%9N"JW=F^PMHXC&8G+XFLDDH:48RFK*2>*-*D^-F:%O=>Z'6H_E[_S2)*N9
MH?YZO=4%!6)"*JG/PB^';UL,D54TQ;$5PVM'!CHY8)&C=7IJ@FRG4`I5O=>Z
MIT^7_P`C_P";?\<MO_S/,OLS^;)C=]Y7^5CMOXZ;VS6W,Y\#>@,14=PQ?)/;
MV-W+!MK=>XL;E*C%X.FVI003&CFQN-6J?[AEJ!Q#+[]U[HTOR@VU_,Y^)GQ+
MR_SB[R_GI]ATG6&V=O\`7F^-\XCJ7^6#\;]WOA:7>V:V[0T-/MS#9/=..RU7
MMFESFYZ:"IDKIHYABPSRE)`Q]^Z]T0??'S.^8G1_P9ZM_F@8S^<A\L]S]$_,
M+?\`0XN*H?\`E"_&C=[]55V*SF7Z[J<SV)@J'N&EP/7FW(:G:4M!3"ARE>^8
MJHZ5*45#.6'NO=7GXOX8?SA\U1X[.TO\\FFCHLUC:7(QPI_+&^.$$<$57$E7
M1BDI,CO1JVF4PU)$BU+-,-*!O4&O[KW55FYOFO\`S5]D[;[:J=Q_S)/CO3+\
M=OYJ/7O\MO/9\_!G&9&NW[BNS\5T^]%V_NK'8CL9J7;V<V]6;^J"N#Q=/2T4
MDU%5K)DG7[=(O=>ZMDK_`(8?SGJNLR$U-_.MV7C*6OKY)XJ6B_EF]&,F%HXY
M*@TU'ASDNS\G4213QN@G-=+6RC1^W(IN6]U[J1MWX??SG\3-"F:_G)=:[JH3
MN#;V2JVK_P"6YU'C,LV%Q.3BJ\OMS'UF$[5H<910;JQZ/25-3-15=33*_DI7
MAD&H^Z]U7+N?M/\`F7;IV1\U=^=4_P`\?HEZ_P"-'8/RGV)F>E=X?`GI+:N[
M\?NWH/!;TS63Z^VWD8>WJC<];C8\?30O09Z>CGJJB*B6M,#QB>*;W7NF[I*K
M_G<;:_E)[%^:U=_,_P"@*S;^&^".'^3T.$[$^%LF]=_#:U!T9!V;'AMW=KQ]
MLTM3N7=]-A(/'49F7`U4];D-4TL4Q<@^Z]T83X.]!_SU-P?%KXT]E5'\SWXM
M21;\ZAZY["DV7NOX'4&Y_%1=BXC%;VE_O%O;:/:W5>0W'N:BH,ZT=14P8_&)
M7U*L\A$DC5/OW7NC&U?QB_GPEEFI/YJ/Q)U+1E#1O_+T6"EDK!4QSAWF/>U?
M5`-%!X2ZD*(YY#XO(L<B^Z]U33D_YGO\S:NWOVGU_P!,?*[N;Y5Y;ICM+>'3
M?86YOB[_`")-T]H=78W?VPLM%A]U8>A[+J?EQMS;N1EQM3Y6"ZHY9HHM<2.D
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M51455)#$S,L3D`>_=>ZH0^5FZOYR^YNH-U4O=7Q]_EH;$ZHH*C'Y'/9:B_F0
M_,+H?)%,+!1Y:.NC[6Z\ZUZ:S.'Q4>0IYG>GERM*)1&$DCE2,22^Z]U69F?D
M/\T>R_YK_P#PGGWKVAB_A5U[L'=FROE'0=2]H]3?(O>OR)VAV[U_NGKO95!V
M%@8MW=I[%VUN6A[(K]L8?$4&`JHJ[-SYS+Y%RV3F$L\'OW7NK6>]/-4?\*0O
M@A"*F-(L?_+>^45>U/)4,C2?=]DX.B<00:BLDLC+&Q%@2D+$DZ`![KW5_7OW
M7NJ+_P"?]A9<G\6/BYD8HZR3^Z_\S;^7]G7^UIC-`BS=[X?;BMDJ@,!CZ)IM
MP*JS$,#4-%';]RX]U[J]#W[KW7O?NO=>]^Z]U[W[KW7_UMU7YE[U[@ZY^/&^
MM[=%C-R]A[>&'K,=2;8Z#R7R:W-74<F7HZ3(TV!Z:Q';O2&1W76"GJ?)((<_
M#+!31RR)#,ZJGOW7NM<#^2_\IOYF_P`B/YC7=.(_F%=C=N;9@VOLKN/*]1?'
M+=W760^+>*I-A#>?76!V_P!@Y;X]OT_E:O<:Y>F+'#9')]H9M\1_E\,0KFD>
MK/NO='*_F:]B?.*L[7^-FU*[^7ST)VIUOM3Y\=/[E^+G:==\YLSUY6Y#MO;V
MW-W9;J_/;]V-2_';,Y;;-&J_QBDR%+3UN4B:5HEU2T[.S>Z]TIO@MV/\JMX_
MS<?EU!\O/C3L3X^]CU/P(^)4V&CZQ[8/=NSLYLW`]Y?*&/'9.+?-7U]UWDJ/
M)Y'-;HR--+C)*5Q#_"/-K*S)[]U[JR/N3I+MG>GS/^%7=NT,Y@\9U9TAM;Y4
MXGN#%URPR9O<;=L[6ZTQ77U!@EEHZEX8Z'<&UYJRKEC>G<1TZ)K*2/%)[KW1
MS_?NO=,NY-O8?=NWL]M3<-##D\!N;"Y3;V<QM0"U/D,/FJ&?&Y.AG4$$PU=%
M4O&PN/2Q]^Z]T23^6O\`$KJ_X1?$[9GQUZ7[=R?=?6&R<UNFFVIO'+TO6*5U
M-##EY<;EML3Y+JO:^UL5N";;F?QM73RUF16MS1F5X:NKF:%0GNO=4V?(#>^4
MVOV[_/4PD5;BGEP?RN_DL=A4D^8K\M4M1XG?<WQ7VC6T^5Q5"*K[+:%*O752
MT<U)%]].SU@*MX:<GW7NMHCW[KW6K;_*[Z`_F_Q_#/:%=T_\X_BGU[U;6=@?
M(*HZMZP[!^'N;[,S6T=K3]\]L"/&YO?NW^Z.L6KJE<QKGAB&-F%)#*(6FJ!"
M`_NO=6_]`;2_F%[<[6PF&^2/R_\`C)VGM^@VW4;CW)L?K/X6=B=7[BR]+DC6
MXRA./[0R_P`G-\;9Q=/B-P6*Q_P6HK*BEIU$D49E,X]U[JQ/W[KW5/W\WRF>
MK@_ECQ))21A/YP/P>J7^\CGD1THLEOVL,<'@#,E6Y@'B9@4$EM6D>H>Z]T;+
MYH=?_.;L3:6UL/\`!WY%=-?&_<T65K9][[L[8Z1KN[*JOQ*)128F@VECEWGM
MK"X6<U,4Z5TE;29$RP3+X/MY(];^Z]T2&/XS_P`]$RTID_FD_$J...MR"U`7
M^7F]3Y<<]+2RX^=D_P!F#HV>LCKTEA:)'A1(&$ADE>T:^Z]U7Q_*X[V^87QV
M_EWXC&[9ZOQ7R=[XE_G7]Q?&_P"4$&RML[E?$];[<W[\K\_#\A.W:?#[=@I:
MZ/%;:FRT^4I:B5$Q^*H\I!-6+]O231GW7NMK3W[KW5%?P_R<TO\`/@_G(XZ3
M#KCXHOC_`/RV3!7B@2A;-1TVQ.WY3DVF0LV8(FRTE%]T^ED6A6``K$I]^Z]U
M>I[]U[KWOW7NO>_=>Z][]U[KWOW7NM/;^;?F_P"?'C?YA-!V;\8:;*[)_EO=
M,[U^/67W/VGLW</Q<P6Y,CM3&S[6?NO`9BORF?QO=6Y=DQ;AR^0BJMK9`34E
M;6TPDCII%%.5]U[K<)]^Z]U[W[KW7O?NO=>]^Z]U[W[KW54?\[3HZH^3_P#+
M=[O^,^.['QW5.?\`D)NKH'I_:V\\WA]R9G;U+NK>OR'ZLQF`QFXX=I[=W/F*
M+!9_(LE%458IXX*59_)//!"'E7W7NDG_`"+/@OWY_+B_E_;5^)OR'SO5^Y-U
M;$[0[:RVV<SU34;GJ\/7;$WCNR?=&'J<W4[KQ6!R#[CJ,GDZZ1XTHJ:.FHWI
MH"KS12S2>Z]U;C182DH,KFLQ#-DGJL\^/>MBJLKD:V@@.-I!14XQ>.JJF:BP
M\<D(U3)2I$DTMY'#2,S'W7NM>_YZ=X=U=)?SL?@YD?CW\>]]?+'>>?\`@5\N
ML)OOIO9N_-D;'J,#UZG9O36Y,=V)3Y;LG)X79&(K)-U;7CQ(DK:VA_B$M3!2
M1S>1EC?W7NAHK_YCG\SN$;FI8/Y$GR):NIL%5Y/::S_+?X?38_+U-.*"(T&?
MKL;O^NIL+(\]4[)'3M7U,T4=TA/K*>Z]T9_^47T/VM\9_P"73\9NF.\=J4>Q
M>VML;?WIE=];,H,OC,]1[7S6^^T=\]A/@J?+8:>JQE7'C*;=4<7[,CJA71<E
M3[]U[JR#W[KW6J?_`,+!/CSB.TOY5#]T)M[&5V[/C3W5UQNJEW!4UE529+"[
M/[!R@ZQW-28Z&"]-E1E,WN;#&6GJ!H6.G,R$21JK^Z]U<+_)V^0]5\I_Y8GP
MJ[JR-+%29?<'1>TL!G8Z=Y):=\]U]!)U[FZB*28+(_W.3VO+(]P`LC,H](!/
MNO=65^_=>ZH&^<'\RWY"=P[J[2^$'\FWKU/D1\J-DU^%VC\A/D(F3V71=#?#
M"GW5E*O;U=597<&\-QX/%]B]U[<$$U5'MO&)D1CQ2S/5I-/324#>Z]T2OX,_
MRR/YS?Q,S/:L6T<I_*XV]O\`W3OC>TN[?GOVWLCY`_(7YI?)+$Y/<F0KL/N/
M?U;6[TP&)P%`^,>C>'"QY..BH9:-8S22-KJ9?=>Z/K3_`,KW^8AVMN&OS?RJ
M_G<?**HP]7'!'2[%^%G4_57P\Q.,6DS4U?`D>Y(T[7W-602X^7P2%W6L<@>6
MIFC7QGW7NBN?S;/Y)G??R`_EK]9?#[XE]X;X[KW;L+Y<X'Y%[KR_S:[5K-^[
MV[2ARL&\,+N"')]JMA:*3"4VW*G?#Y-:&CHZ6*6AIZB&`>=HHIO=>Z3OR?\`
MCG\+<-_/P^"O?G9?\QJ;ISYC[?ZWZPV3U1\+\5UQD]X87=.(EH]_[+FPF,["
MJ%J:'9FV>R:/.9JABARD"9"2H9JB&H$CQ*GNO=;3OOW7NO>_=>ZTN?YG>`V[
MF.JO^%8>3I:2D-,]+_+AQV4>)*^FR<VZ]D=*]2;H\E3,TR0SX^G;,T+4Z1J%
M:43ARZ.%'NO=6]?S]=M;<D_D8_,C!Y/-;[V[M["=%[&FI9ME8&#<&XJNJVYO
M/8-7M7"9>@JI*):7:N6W!0T5/N&L#QOC\*]74`-XO&WNO=:Q.^?YAGS+_E]?
M\)P/Y,^=^)^Y\+BMP]M]E]E;2W5D\AUKM7L!LEA\!VQVCN;:W7]/B=P8_/81
M?XY449IZEDIAE:A:4^&:FF$C>_=>Z^A5MZKR&0P&#K\M2_996MP^,J\G1^"6
MF^TR%31035M+]M422ST_V]2[)H=F=+6))!/OW7NM*[Y8;1SFS^I/G'2[FFQ-
M'B,M_P`*E/C+N;'SXNAQ];4TV+W5AOBQNAJRNI*:&DILC4#&YJG9H)F,KSB4
M2L69G;W7NMVGW[KW7O?NO=?,LV+_`"X^\_DY_-I_FX_-^DVSBU^.'1&^/YK^
M0DW+O[)[?R%%O?L[;6U>V>N\;UK#@,#N&CW?0^+*;T@R;9&7&/14]#0E#]S*
MR)+[KW1ZNR/YS'6V]?\`A.5C?C+T9\<OF;V'EJ?X;]"?!?=/?^)Z-HXOC=M[
MO#([!Z[ZWWCUW6]A9?=,.6RF>D@K)J:E3&86M:>IK*58WC-1%)[]U[K8H^-G
M\X'^7[UE_+SV)W5VUNS>?Q*ZVZ(W'B?A=NW8?R$Z\WIM;M#9?>/3_7^`CSO5
M!V%04F[-V9_-X7"0I*QI$K)$C1Q4&*>.:-/=>ZLQ^*OR\^-WS=ZCQW>OQ7[9
MVYW'U;DLI7X)=R[>3)T<F/S^*2FER6`SV"SU!B=Q;;SU%!6P2R4=?24U0(*B
M*708Y8W;W7NJ;?\`A.1E<O7=)?S#L?6)'_"<+_-K^;M+AY1%4),7J]S[=R62
M@>62JG@FBBFJT=/''!I,C!E8^MO=>Z)G_P`*F<[WO/V#_*$Z?Z?^2W:_QIP_
M?ORYR?66\=V];;_S&RJ7'UF:W%TEB]J[USE+AL_MD[@J^O'S%=7X]*FK2G@E
M+V:-Y%?W[KW0/?.#ICY3_$W^</U'TY\`?ES\D_B?D_YLV_<%N/Y%]S;UZ`Z4
M[%^,LN^.K.KMPFMJ.NLMNO;\DV8[SW-!MVLR.2V]$,52O69RF/W3PR1PT/NO
M=6,_\)@VSJ?`+NV@W+NS,;\S>)_F"?+['9+>NXL;38C<.[LBF[,)493<^?QU
M+-51T>:W#E:F>MJH?-.(9IVC61D1??NO=;&WOW7NDEOZ@WGE-C[PQG76X</M
M+?\`D=L9RAV3NK<&!EW5@ML[JJ\94T^`W!F-L0Y3"2[BQN&RDD51-0K6TAJX
MXS%YHM>M?=>ZU8OG7M;^;7U#LWJ"M^7'\T'X`8#"9WO[KO%]-T2?RU=W=Y[H
MW/WM0S5^:Z\HME]>X[`]PY]MW8^;&35U-D,5BXJW&&G:9*N!59C[KW1=NU.G
M?Y@GQ[_G"?R/\Y_,W^5?7/SEV5N;M#Y%;1Z=H]A]+[6Z3EZK[<RW6=)24^Y,
MI28'$XN/=E+#E\U@ZJFEGG#0C$'12K(`TWNO=6Z=U=7C*_\`"BSX/]DSY*2&
M/#?RV/E4:+'K1S:*BLVYVSL'`5"O6HD\;">C[F\NAA`(FHU_<=I5C/NO=7O^
M_=>ZI7_GK451DOB]\;<;!++`<C_,L_EV4,DRSU<-)$M5\G]C0I)DUIH9(*BA
MCJ'1M%2\,(E".'\J1(_NO=74>_=>Z][]U[KWOW7NO>_=>Z__U]U#YJ]"T7R7
M^-'9O3D^P=M]C9+=%!C'VM@MT]B;TZCQ>.WABLWC<IMG=Z]F]<8W+;_V57;*
MRU+'E8*O#P-7O)2"!"HF9A[KW5;7\KOXC_.OX=;WP_67S0_F_P`OS-R\_3V:
MSF$^,F?V)M!=VXJ#^\NVX,CVDG;>[<_FOD)V%MK:N<KY\/'5U\=-0O\`Q&!'
M6%HHJ<>Z]T)O\W*>@H*_^5SE\G'7U5'C_P";G\0:84-++F8*:HR&Y,=VAM'#
M5.1EQ4D<`I\/F<_!6HE7>GFFIUB(+.`?=>Z-7A,)T7'_`#"NP=S8[J[MBC^2
M%;\2>NMO[G[DJ]J;TI.DLYU!A^U]]9/;'7V%WA5NFPLIV5@]V;@KZ^MI:2-L
MA%CJJ`RR%%")[KW2B[A[VW1U]\HOAWTIBZ?;LFVOD'/W]!NJHR<53)GJ=NK.
MM*;>F!3;3P9"GA@:>MD?[QIJ>HC-.ND&)RA?W7NC9^_=>Z][]U[H@/\`+-W[
MB>P_BN,IB*2FH8\'\AOF+LK(4M*\;1QYK9ORV[KV_F7*QI'XI*G(T4DI5@6.
MO422;^_=>ZIH^=6VMEX_=W\]?="4^Y<?N:2N_DV[RW=FLO333;(GP'6^_=NY
MW;2;=?'P&MGS&.EPF1.5IPTD@CEHRJ6DL_NO=;2OOW7NM7+^3I\:._ODE\`N
MM>Y\#_,D^9G1F,W?WO\`*G<F/ZMZTPWQ8J-@[/HL5\H^[,!_=K;D?9'QIWCN
M],!756/%>])75\M-#--)%%2P0Z(8_=>ZM7V!\`.[MD_(/8O=.5_F>?./LC:F
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M]@R[^VG_`,*+Z?KC??:>4FV_MS>?:>&W;\^>@NM.QANNGVS#58"K;M/!;DJ#
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M#M;<>Z(ZRD2<5U;13U`J-4NOR.[-[KW1[/?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MT4#YT[!^.W;?QTS74'RHH-U9+IOMOL'I/K;)4FS<IOC;^<?>6[.YMAXWJN2'
M<W7E;C-R[7@A[0DP[R9!*JGAIE75-(([@^Z]TV?`OX8XGX&=$3=`[=[A[>[G
MVS3=C]A[VVQF>Z-TU>[]R;2P&]L]+F,9UYB<O7S5-=+MO:D#:(6FEDFJ*J6H
MJ7*M.47W7NCI>_=>ZJ`R<5#+_/QV7-*\9R%#_*([&6ECTP,ZPY'YD=9B=R[W
MG@,AQP"A`!*$>Y_;`]^Z]U;_`._=>Z][]U[KWOW7NJ@/Y^W]R/\`AG+^8&=_
MTF&K<0O0&?\`X3'G(1-2P[W;(8M.O*NENDGBS-'OE\?)0.+%:Q8^1[]U[H$?
M^$Q=.E/_`"0/A)I2N0SX[NNH?[YY7U/)\B>VO72>4G30LJCQA;*!>WOW7NC4
M?S2/D?VSUOUIU[\9?BGD#3?-;YM[S;I+H"OIZ2')S=4X`4JY+NOY-9C'5!2G
M?:_Q]ZY,^49I6$<F9GQM,0YJ`A]U[HMW\O[Y1_`_XU_*KL7^1W\9.J>Y<'V;
M\7.LF[B[)W]F-LXNKVWVCGLQANM\]O/?NY=\UF[)]\[Q[0WG6]D8V:KKJS%I
M2U,Q:"FF2F@IHA[KW0__`,NW^:ILO^8U\;NZ/DYUUT5VIL#9_46Z]];.@VQO
M#,==Y;L'>&:V#BZC+Y;&4^S]E[KW!F-IYIZ<TL4=#FHJ&HFJ*H>`3TX2ID]U
M[H^WQ\[7K.]^C.I.Z*_KG?'4-5VIU]M;?TG6/9E#3XOL'8R[IQ%+F(=N;QQ=
M-/41XS<..@JU2JIF82P2W214D5D7W7NA<DG@AYFFBB^A_<D1.#<`^HCZD>_=
M>ZUROFE_+.^4_=_\^G^7+_,+ZJDZX3X_]!=5Y#:W;V<R68HZ3=N&DPF0[2J6
MP\."^TFKMRG?6+[06EQ4]/Y%H9::L:J>F1:8S^Z]UL;M)&C(C.BO(2L:LP#2
M,JEV"*2"Y"@DV_`]^Z]UT)8F(598V+7"@.I)L+FP!N;#GW[KW6K/\_OCQW'V
M?UG_`,*4MI[%ZBW_`+DSG=.)^&+=38S;&UJZIK>T\EMGXZ=3099MGF:FI*;=
M$V*RN&DI:X4<E3)":9H^9@(A[KW5JO\`-^^''<_SM_EI?(+XH=$[SQ>Q.U^Q
M=K;/AP53GZZ?&[=SW]U-W[8W5E]C9_+4%)D:C&XO>.-P4V/:H2*1$>9/(#"9
M/?NO=5S[W_D+R_+W^6?_`"Y/A]WOOP_$S='PR6'=.7VY\>:F7LW;-7OF"DR6
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M`)?^Y_Y5O6?S'[X^36!ZS^&O7/=DO1NX*/I?-_(,=KX[HO:W3'7F4V[N3?7<
M_?VYDVYLNOW]V7NC=%3D,P<;'382B>)%IC'"\=+3>Z]U5Q_*/_G+]:_&ND^>
M70'4WP[^:_S@S=#_`#!OEEWMNC?WPOZ\V]WAUZNR.U-_5U'UUN/$5-'N_&Y=
M\+N6BV:H@F2C%+4:O/%+)Y`GOW7NE=_-I[LZO_F9TWQ9W7V7_*3_`)\E#F_B
MOVCE=VXC";,^)>R-LT>Y?[QC:U9G-K9_.9RM[+KWPT\^R:*1*FBQQB(22)AJ
MGCEI_=>Z'[XG_P`NGK3^<-\K?G)\U_YDWPU^8VP]IU?:'3V-^'757RGWYW)T
M_N#8.RMM=54F)WR=M[0V'O?:U%BZ&?L"BDR$$E(\B4\E5^W/).U3+)[KW1T/
M^$UFPL/U5\,_E!U=M^DR./P/6W\RWYK;!PM!F)<G-EZ'$;/WIA-OXVCRLN;>
M7-29*FH<?&D[5C-5-("927+'W[KW6PY[]U[I!=I[)J^R>M=^]>X_?.].L:[>
MVT-P[5I.Q>N,C18C?^QJC.XNIQL6Z]EY7)8[+T&-W1@7J!4T,\U+41Q5$:,T
M;`6/NO=:^GR=^%G7?PXZ]R':WR'_`.%`G\T#HG8.8W#+M?%;CW_\D^JLE!-6
M5N/GR=/M'`4$G1=9D<QNLT^$JYHGQ\'\0:-61$%B&]U[JI/Y<_&_(?%K^9O_
M`,)\>R:S^8#\POFIU_W9\FLE5;<I/F#V73Y_);(;/#J"DVUG-I[6EV+LW*[6
M&Z*7>T2Y%<C2BL,E+3PD0,']^Z]U?OVT6_Z"$?AR(\RE2?\`ALGY7_<[=>M@
M)Q$'^G3I8Q9R*@CI35QR;@G44YDEE\4RXXB,*T+^3W7NKO??NO=4<_SX\CE:
M/HWX-4%`<>M!N#^;5_+LP^X7K)((ZF+$)W;39F&3%"HKJ)9:]<YB*/4H\G^2
MF9BJJK2Q^Z]U>-[]U[KWOW7NO>_=>Z][]U[K_]#?1WILS:W8NTMQ;$WO@Z'<
MNT-VXBNP.Y,!DXVEH,OB,E`U/6T-4B,CF*>%R"596'U!!`/OW7NB1_';^65\
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M!;M%)%#41TDXS6)I(X9/-'+I5`4TMS[]U[H0/?NO=>]^Z]U5W_*/ZU[_`.I?
MC/V/LWY%=3Y;I[=4GS$^9&^=H[>S6[MF[PKLKUEVU\@]\=M;+W"U3L;-;@P^
M*CFI=\2T:TCU3S_Y%YR%CGC4>Z]U69\W\)693M7^=_A,G6S#'9CK;^3=G,91
M/524-&]%'W%V+055+)5T=375*PYO([;DI:J,P0&2`Z2C(_D?W7NMG?W[KW6H
M7_)T_E0?'#N/X*[6[H[#[B^7W5G96Z?D#\H\AOK"=-_-+O3I'9V`J-F?*3NS
M8_\`<RFV1L;=VVMK86@J<9MY17S04J5\]29I8JM!(??NO=6"=&_$[XR],_S0
MML;&V-\G_F3DJW8WQ>IN\=E=*[Y^>?=_9_3FY<[N+L_L/KK=6Y,AU]O??FXZ
MS=.6P]+D:19:6IJWQ,<E535'V;U9DG/NO=7X>_=>Z][]U[HFGS3^%?5OS>V+
MMCK[MCL7OOKS;NWMQS9UVZ&[QWITC7[K@JL55XFOVKO*NV?7T3[FVI7TU5KD
MHYP2LL:O&Z'5J]U[JO3:7_"?/X%;;R5558SLKYR5V+J)89TVNOSS^2..P5'5
M14T=/-54[;6WY@LX]35^)'D::ME(9%":$`3W[KW59OPJ^&>:;^7I\@_C)T)`
M^^<?\=O^%$%%D=O9'<?85*F4?JWH7YL?'_.YO<&6W)E*N@Q^]=R8[K["U#U-
M/4.)J^M5VACDKE@B?W7NMPCW[KW5,GQTI\IB?YY'\S&`D38K=7PW_EZ;F9Y8
M5,M)48K.?)W;-#2TM0421*2;[6LE=`75I3>X(TCW7NKF_?NO=51]+?RBOCWU
MK\]^]_YCW8&:W/WO\D>T=T55;U;E.QY9*[;_`,:-D5.$IL-+LWJ/"5-?DH*&
MOJD^Y6;+,4FCI:@TU)#21O5&K]U[HL'\X_JO^1%09#:'R`_FE;%ZAW#VIMX8
M?%["Q5'E-TIWUV=!39*GCP^T,?UYU=N+#[T[<PM-6Y-;4M?2UN/I(I6UM%$[
MZO=>Z-#_`"U/DS\J/E*>PM[[N^%\'PE^$>!QFVMF?$#879F+R6S_`)-[KQ6W
M1/C<GNO>W5E*T6U>J>N#C*:EI\#AUA%8BQLZ2U%(T$S>Z]U:U[]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[HIWS)Q?6V9ZQV%C^T=Z5NQL(WR@^(&0P&
M3Q]*M=59;L/`_)[JC<'6^T#2&6(O1[SWMBJ'&54@U?:TM5)4%6$1'OW7NC8^
M_=>Z][]U[HB><[&^,>/_`)DNP>LLI@1_LW^<^'N^-P;2W0*/-2%>@Z;MG;J;
MGP#5BN-NTX?>^-I*@!U-:=)"$1&0-[KW1[/?NO=>]^Z]U[W[KW6LM_PK@[(Q
M>QOY,W9^V:Z,25G<'='1/7>$_P!R#430Y#';R7M2HG%.I#911B.M*I#!^D>3
MRG_-V/NO=60_R1Z/&4'\HK^7/!B:6DHZ5_B3TY62Q44,<$+Y/([5HLAFZITC
M55:KKLS55$T[D:I)Y'=B68D^Z]T#_P`/Z7,?(_\`FL_S&/E9GJI<SU[\7Z;K
MC^7C\<6CKWK,7A<S@MO87NCY:U]+BZJ*!L/N:N[&W=@<-6U,<*M4TV#CC$\\
M"1B/W7NBL?$#^6O\A^N/^%`?\PCY]]S]>5^:ZJ[-V%M['?'/OJ/MO:E)1?PW
M+[7Z\PF=ZOJND\1CZW<^0DP='ME:1<OD:G&04@PL3QPU\F1:>E]U[K4+^!'Q
MVSV]_B+_`,*`N^NOOF'\JNDT^*=?NW>&P^L>@._MV=8[*WOEZBL[6K*;<O;^
M$Q>.I:+?>-R&VMK28>F1:V*>:"IJUEB1OLW/NO=;77P<_D2?#SM;X9?$;M:G
M^0W\PS&OV+\;^E>Q31[:^;?:VW\'C<COG8&!WEE8<'A,+44F*P=&F<S=3(M/
M2QQQ12.VE0;^_=>Z'#</_"9O^7OO',UF>WOV5\Z=\9"NAITGGW?\QNT<[4/-
M!'#&]8^0K)VRD]34B&[^6=XQJ(1$`4+[KW3]%_PFE_E?8[^$S[9Q/RBV;E\-
M6T-71;@VQ\Q/D/19F."AJZFK_AL4U7ONNI:*BJ&K)%=J:&"I0.S12QR,SGW7
MN@=SW_"6CX-[CJY,CE/DO_,2K<H,S_%Z/,9'Y4UV5R^/61T>MQ]-6Y/:54/M
MLD&G6HF=&K6%5+IG0E"GNO=<U_X2Q_`.*@-%2]Z?/?&5`$3TV9Q?RCS5/E\?
M6)2R4D^2QXJL!782.OKX9-,[244J%!IC2-20?=>Z?5_X2U_RSC0MCZC=/S.K
M(&>DGM4_*S?145U&U,T61^WBIX:,UW^2H-1B(0`:`A5"ONO=,<G_``E<_EYK
MFHLKCN[_`.8%A*!?$:G;6+^5=8F$KV@,S1/63UFRZS<99&FNOCR$>DJ+6NVK
MW7NEC_T#*_!*3&T>'J^^?YAU?BJ*ORE1'C:SYD;U?'MC,HLR/MHT,>)BI(<)
M3(8%0PI%62BDA$]1-^YY/=>ZCU__``F5^$M;N3$9M/DA_,7H\5C5@>IVK%\Q
M-X3XO+5U&E3#0Y"JR-=B*O<=)4TE'5M`GVE;3A8>%TEG+>Z]TM:'_A.G\2L1
M@H\%@/E7_,YVY%#+43PU>#^=?9]#/#4U47VU14Q4*T[X*.>>C5('84=WAC56
MOS?W7NIN6_X3Y?']W@K=E_-_^:OUKN!*MY)]U[3^>O:DNX9<?44;4E=C(:K<
M"YJEIXZ[QTYDD\#N12HGZ;@^Z]UBI/\`A/ET;!7[/R-=\]/YL&XI=K[UQN]Z
MVGW/\Y-X9W&[JKL6DKQ8_.8JMV\V.^PGKG$LSP115CIKB\^B1A[]U[H,-U?\
M)_.JMLT_;'9.\/YEG\W7([:II.Q.T,;LS;'RWKL'@MBY"OI\WGZ^KVC@,'M2
MFEK:W%@Q&A@:91(]'%'+Y8V=&]U[HNOQY_D8]5_,7XV]'?)79O\`-J_G1R;?
M[PZPV=V/M2LWA\M<94;EQVR-Z8"FSM!M'-X^FVKD\919'%M6K'61P5,T4=3"
MZ*S#U>_=>Z4O??\`PG:Z1ZP^.O=79E3_`#)_YLLV[NNNI.P]_+O/-?+:3+4<
M59LK:>5W%35N3VS2[)QSY2AI8<2J2TT=93R30J526)BKK[KW6L+)CNU?YD/P
M0ZFZ5QW\QC^9=\F/E)O'K[:'>>\O@GVWLW=2;`[NV-U+ORHH>P\5\8NP-WT'
M\([*W_USM649^@UUV3I\NV/8L#60+34GNO=&_P#Y/?\`(Z^9M%\S=_=@]';G
M_F+?RO.@<'T='A\CVGW3MWJ_;O=O9'86?S6-D?KS%;%ABJ=K;AV!2TM)-7R5
M]113_9U%!`28:BIB6/W7NK%OYS71O\TC^6#\(\O\K>C_`.<'\V.Z<QM+M':N
M)W'M3>^RNL\AC*#8V[9,Z,CGJG(8#95;4T?\"S/V>J>M,6,CI7:$+&?`GOW7
MNA2ZBZ3^4>Y_Y>F%^<W;W_"@?Y:[73'?%78?RA[XVMM#%]`5,/6LV]NI,1VY
M'M2*EGPK9G#R9#'U\4&'I:A()LEY(S#$?.%/NO=$Z^,'\N7Y1]>?R1MX?.SL
M_P#F8_.SHK?^Z-A=C_S%,1UEUK5XY<+2=TYS.9/L?9N_>QH<5@F[&[7?MC;5
M'AZO+XRKKZ:D2LR;U$RNL)0^Z]U?;_(:_F(?+CY^_'WN&/YO]&R=(?(KXW]K
M87I_>M!+LK=?6]=N9JOK'9F]J3/;DV%NY%K=J;OR$.X?O*RDIQ#1?;5M++3P
M012HGOW7NKE>U.N]L]O=9=A=4[T;++L_LK9.Z-A[I;`YW)[8S2[=W9A:W!9D
MXG<>%JJ++8/(#'UTGAJJ::.:![.K`CW[KW6L[V9_PEU_E"4%)U[3Y7:GR4W%
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M7O?NO=4M_P`[W>FT.M^FOA+V%V#EMM;?V+LG^:C\!-S[OW!O+(#$;3V]M[$=
MN"JR6X=Q99J:LBQ>+P,"&LDJ)(S!#X0\K1Q!Y$]U[K)UMV'UWV#_`#P=T[FZ
MWW]M+L3;^Z?Y3>Q4H\YL?>&(WGM\2[(^8?8L61C6LV]793&4$Q.]Z<#7)$U4
M5D\0D-/.8O=>Z.GWQ!VQ6?*WX)Q;0V'F<]U?C=U_('/]P;[H<F]+B=@+3=$[
MBV_L"GSN-6JB7*Q[OW'N=Z>GU12B">G#>DD$^Z]T<WW[KW7O?NO=>]^Z]UJ4
M_+C/5&U^]?\`A2MG8)ZVEJZ/JO\`E#+C9:&2B@K6R%9@]ST&.@H*C)134=-4
MU61J$BCE928I&U+9U!'NO=;:WOW7NM)+^7+T7_PGTWW\1J+L?YY5_P`#J+Y+
M;I[W^6F2[6/:7>U!U]O2LKL1\LNWJ':=5G-DYGL/;5;2_8;/R.*6A;^'1Q+1
MSQ-#Z)"3[KW5H7Q=^+7_``F@V[W[TMFOBC-\"*_Y&4N6H<_TE%L#Y%XW>?8-
M7G\>*VJQ^0V_@G[2SE9FLZBTDTB&6GGJI`A/J`'OW7NMBOW[KW7O?NO=5\?S
M"OC[_+J[ZV'LBE_F*Q].P['VWN'*2]>YCM[M9NH*7';GS&(,.6CV[N6/>6RY
MILI5X:A+/"E1(PBA\@4:-0]U[JJ39OP0_P"$PNRLA)B,%N_X:U.7K)8J@4F;
M^?.?W+7DY5L5%2K2PYSY$Y!H8ZAWIA"L:J/WK+Q(P;W7NJ]_C%A=D;+_`)6G
M=.U.D:G:\O3>`_X4H]=;;Z^GV?F\KNW:<_5.._F+_&JDV.-H;MAR\YSF$.+@
MQ_VN1K9:Z"LIA<ZY98IE]U[K=J]^Z]U2+\>ZF>?^??\`S'HIJ#*U,='\&_@I
M34F7FDF3&XJF?=/>E8V'IX*@`3KEZNJEJ(Y*?5"DM+4*Q$K,/?NO=7=>_=>Z
M"3OK8>^>T>ENT>N>LNV,WT3V%O78^XMM[,[CVWA<7N+.=:[CRN.GI,7O#&8/
M,E,=E:G#54BRB%WA9P"$EB?3*GNO=?-B_F"=`_R^?BC\M/C3M+XY_P`Q#Y.?
M(W^<CL?YQ=&8+N[NKN_<^.FZXV1F<=G*8[AS^Z=Y=F;7PVU*"MV5N^#&I24I
MW1EX:"`STV1F8PLT?NO=?3S@FAJ88JBGFBJ()HUDBG@=)89HV`*R1R1ED='!
MN""01[]U[K+[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[JIS^<QOJ?K3
MXF=>;VI:]:"KP'S>^`M93%Z6>OBJ9E^7?40%--CJ0&LR"%29/#"5=FC')4,#
M[KW5L?OW7NFW,9K#[>QM7FL_EL;@\/CXC/7Y;,5]+C,;10`A3-5U];+!2TT0
M9@-3NHN??NO=4*=R]B;-P7_"A'^7KF://4>X:#Y$_P`OSY5]5[0K=K9:7,T#
MYGK[>^`[9^^R38O)OA_X#6X"AR44-28IBU=`J!AINONO=7^^_=>Z][]U[KWO
MW7NM';_A4*O97SG_`)A'\KW^4!U_21QXKLS,T7=^\,W1&GERV/CW-N+=>P*W
M-6J<A'204O7'6>R]S9=XY80U3]R@1R1H/NO=;JO6_7^UNI^O-B=6[&QRXC9?
M6VSML[#VCBE;R#';:VCA:+`8.B\EE,AI<9CXD+$78BY^OOW7NJH/Y&V!D7XC
M=N]HY$5TNYOD!\^?GUVWNS)5^5ERTN6RL/RB[$ZLQ=5%/)/4B*EH]H=8XRBB
MC5R@2D!'ZO?NO=7)^_=>Z^>A\.!UMTU\&O\`A5;\>L/M/:&5[7Z17O';>X^U
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M_P"9A[)RK=K];[(_NI1[KZ`Q&P^M]G;AQ.=W/3Y&KRDE7E<?B*RFBC-149"!
MI62.Y4>Z]UN`TG=/3E?7TV+H>V>LZS)ULD,5'CJ3?FUJBOJY:A%DIXZ:CARK
MU$\DZ,"@126!!%_?NO=:SO\`-._FX?R)?F%\?>X_A?W?_,/[1ZYQ<&],?BNQ
MX?CKL7N.FWKFJC86[*BGSFPXLQ5=,[EV;N?;&6KL5+%6QG[BBJ(DCE20@Q,W
MNO=:RN?WI_)(IOFCT?6U/7/RS^.G\I[:WQIV?MSL#.9O9/?.+E_F3]F[*W'7
MY[KVJ[(H-LT\=!G=I4E=CH:]ZXK1-7SXYXX8J&*.$0>Z]UL)?*K_`(4<_P`F
M?Y,?"SN+XT];[LJJW<F]^F,CMKJ[ISM3J'N_KKK7)[OP--2U/6_66Y=T]7T]
M%4[/PV0SN'H:056.RE)1T<)!:MIXU9U]U[JQ_P#D3[U^5-7L_P"7?4'R8^#_
M`%I\)6Z7^024&V<)U=6;^S^`[+SF^=NQ[PWUO([\WWOGL+_226>KQABS6.R#
M4,D%0M*J1M2%%]U[JZCM;:_7V]NL.Q-G]M0XRHZMW/LC=."['AS66FP&'?8V
M4PE;1[J&5SM/78NHPN.&#EG,U6E33O31@R"1"NH>Z]UK'=N?RQ_^$]F,V_MF
M'J#8?\N[L;<M!OO:5-F,=WU_,=[2QF/P/7IJI<=N^LV]DD[2[1R.2S6#Q%5)
M/C]O5$-#B*ZK4&:III$CE'NO=5R_S-/C5_+6^-_SI_D$]I_`3;'4==1;H^>N
MW=G[BJ>J>\Y=];;SV'V;V-T5_!\8:_/=B[GVGBJG`9//2`RQM33.TJPS.UH5
M7W7NKZN\XJ[$_P#"B;X&Y:BI\>8=W_RZ/EMM+,5$E'73UXQNW.RM@;G@6*HI
MZE::C\66K*<))/&T>B6>/F26$Q^Z]U?![]U[JC_^?IGI=K?$GX][DBQ=7FA@
M/YC_`/+[S<F+QX1\A7)B/D?M')+14$$CQ)4UM=-2K!%&70%Y02P`/OW7NJP4
M^)7P)[N^0G\P+-_,+^:5W)MGO'H3YM]O]X]M;+Z]^77>'0VVNNOB96I'ENKN
MCMS[4W@=K85MJ8G9YAER&;V4GW$544I:3+F,(C>Z]U;-_(@VEA]L_`JERNQ_
ME7V%\P^FM_\`>/=F^NA.UNT<#V;M_>=!T]7;M?";=V3E8.VX8-WY.7;^4P%?
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M9MP46V/D/U[_`"Q.@\ONG9N<W1L.F[E_FE9_8#[ABVRQ3<>4BBW!\**&>?`8
M#S4YJ'5$9S4*D#2R"1$]U[K%V7_,T^0GQ\QG5=9\B>O/Y9O6D?:L^/J-MY?<
M7\U^CV-BMQ[8R4N-$>ZMC4W8OQ%VWD=YX^EI\U122BB$BZ*N%Q($<E/=>Z6&
M_/E?_.#P.8HL3LS^4MTKOV@K:R6--Z83^9/M*+;$-#%!42PUE71;H^-FS]TQ
M1Y$H@A,5#4:=8\H2Y*^Z]UK;_P`P#MK^9/O+,?SL<=N#^7/LS:F4WKTQ_+%P
M78U)0?+6BWW-M7;^'[$WX_6^[>N8Z?JW;U-VI%NS<-9EJ2MIE.W_`.`28\R3
M"M]2R^Z]UL693YE_SCZ+8F2W-3?R7=C5NY*"FM#L2E_F8=03[DR=9)+]O%)B
MG?I2EVE/10ZEGE%5FJ&7PAE0/(`&]U[K3@^!OSB^''3OQ<7%_)W^43_+]^0O
M9>P>Z?D$_?'9'9GRW^"FU._ZW>U7VEO7>3>#ICO+&KOW=&VMMT&Y:3;>(JZ?
M,9"'(18YA3:UCT'W7NK!?CY_-.^!/:WRMZ1[<Z2_DF?$C:_<45<W1O1FX)/F
MU\"^J=]T.^CG6KL3C-O]'3SX>"@R]?FJE8=N;KCI6KJ[[\08^=HIU#>Z]TW_
M`,]ND_F5_-SL7XN8#9^RZO\`EJ]TT,^\]D[:Z[[*_FJ_%+KH_(3&;ASFVJ3$
M577>P-I=E[>W3O//T^Z&2CBJ?-*"M5%3I2B:2_OW7NI]#U#\Y>B?BQ%\0_D%
MT;_,SVKC.ZME=7=>;J3(?S@?Y>NWZ;>W=&RMW8/=&_=\?'?<7>N]\EVE@X.W
M<M2IC:G;>+JHZ!,376^R%?,*@>Z]U9#\@_EUNVFZJZ:Z;^:/\@3([JZYV#+M
MC#=/I\P/E[_+[WMM]<YLK`P8&CK?[_=U]GUU#6[W.`C'W5345<V0RE*U7+4,
M\2U#'W7NB?[/^:7\LG?-;D-OTG\D#^5?19[#;GDVQG-G5_R[_DO4F[!6T]10
M+-+M_'MO*/&;AB1JUE9HZZ*(S120E]0(]^Z]T63^7?\`/C$;&^(/R?V=MO\`
MDW_(GMCX7?\`#EO:'?6Q\YU!O_K@]0=+)U]V=UQVWLK:U3O:+.TF)QD73FZM
MCX6:+(4U>=N5U._BCK/MU:.3W7NKN]L?SX.^]ZY/>IV=_)Y^7N[-I]=I!)O3
M=>VNW?C1G:3;5/6[;.[L=D\Q4XSL&IVM1[?R6W!]]!D?XPU%/2%98Y'#+?W7
MNJQ/BQ_-7^17:'\ZWY2]T=1_RW^\=_;;W)\(NB=F]M]/]8]W_';>V_\`#Y':
M&\LSE.M^V5R3]EXKJ_<&'KX]_5&&:BQ^::JHJ1S72+?S0^_=>ZNJW1_-M^5F
M+E7%[>_DC_S)<QN*BS*4.<HLC2=`4.WXL?+C:R2*MPN\L%W#NK$YN0984T3^
M-/MDIWED:<.BQ2>Z]U.Q?\U+YFYG#TM=0?R//Y@<>0JLY68A:',[M^,.W:>.
M&!E-/6S3YON*BR=-%/!4TY:6:ACH0[3*E3)]NY/NO=:_'\[SX8?S`_YG>\/B
MKV#T_P#R8-Q=9X_I7?G;>^N],!VOW#\-]HQ]Z4FZ\GUI_#8MS[SZC^0=#OTF
MOV]L"KARD\E=2U-(*U32U,IC$X]U[JM7^2KVI_-5^->_9/Y@72O4.^8_Y0./
M[%['V7V!T7N?YA=6X[IG8>SZO-PX=\5UU6_*#NS9=#3Y_8>\,UC(<=N*5J09
MFIIWH9ZV3S5('NO=;IA_F3_._)2_;[3_`))7RWSQ=8*VFR51\C?A#C]KY'"S
MP4DT63Q&[Z/OC-;=S)J!5AH$I*B:.>(>1);:@ONO="=B/GI\QZJG7^,_R<OF
MIBJ](':IIZ3N7X#Y6CCJ#YFIZ>GKY/EEC/O%EC6,O(L06(R:3ZE8>_=>ZULO
MD?\`R]/YEO;OS_ZA^3L&UOYR>].@MN]Y]H]U[OZ5W5\G?AGMW(]<>/+Q;EZ:
MV5\=8*'YD5^T,/@ILM,U!E9<A3T\N.PM#%%&M8\FF/W7NC$].=0_S'NLOYDN
M!^9/R"^,_P#."^2?0_6'QZP.S>M]I;N^3GPAK-TT'=4<1V_N?<F=Z(Z4^1.P
M^L=V[)S.W-%5&DTD]<V>#UM<M48Z1H/=>ZNQR?\`,L[V@$L^(_E!_P`R[)T=
M'#%45[U>'^(V+K$C>GFJ9%QN.'RPKZC,3Q(L:^*']PR.R6U)9O=>Z0^7_FC?
M*Q:**IVS_)7_`)BF5F>;3)!GLA\6MLB."5W:ED41]_9RK:62F0F5&A04\A",
MQN&]^Z]UWB_YH_RJ--1R[D_DL?S%<7/'+G(-P08.N^+NY5QTM!,9,.<+*W?>
M%?<M/E<7+#)-+&D"4]2TM/$:HQ>1_=>Z"+O+YP]S]Y;,VQM?L#^3%_,NI<5M
MWMWIOMJE6ERGP^Q@.Z.ENU=D]J]>TTU;D_D1513TF8WCM2FIJNE5(JB6!C#%
M())E*>Z]TN:W^:I\U(C''0?R-_G_`%4TE/42VJ]Y?&2B@62&142-JJG[;R4:
MB1)4-V"O?5H1PC-[]U[JIS^:Y\H>VOFW@OY>GQO^3O\`)]^<&U.M.ROG5MRK
M[)ZLK^S>F<5!W13;/ZF[=R>)ZFVIN79'<6*KZZOR*3G<4YRTVUJ2*GV],L58
M7_>B]U[H+/CAO;XQ?"W^8)#M7X-?\)M?E9M/Y&]?=$YK<>_:S=G9^%Q?9>S]
MD[FW=C^NL3N;JG'[Y[I[/ZLWSL_=#/5T.1W%B\S2U^KS0%I:=:UQ[KW5X^Q?
MYM'R'W509>AR_P#)>_F>;>W]CMQ?PBFVZ^T.C(MI5^+:<0IFT[.WAW-L;;)7
M]F?7'`M3"NB-A.T<R2>_=>Z7N0_F8?(=<,\N%_D[_P`R/([GI6H37X/)4_Q)
MPF(6*K2N,DF-W.?E%D(LL]++2H'1*57"RAF"^D/[KW6JK\Q/DI_,G^-7\S7?
M?\V3N[XR?S$_B;\#<9MG;N*W;U;@>XMCY[:.0[BQW3@Z@ZMR'8^S-F]I+U]F
M.NJWMHXF>M$J5OWE.@4>1JE:;W[KW13_`.5[T%_.TWY\_P#XL?SR?D)\8N^?
MF!LW=R[OR@S^V]\?'K;/8^Z]E[JZGWIU?M*NVMUQO+?G7F+VCL%)=S1U-#"E
M)A\:V.C>HIRD<T,LONO=*O>7\N+_`(4G[RP7R`W;N)_YG^'[/AR@@^+V-VO\
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M)PT51DL#O&GP._\`LBAZW[>W'N!-O]?;LWM/DJAZ2BJHXJ)IY9_%!&P7W7NC
MI?"7^9)_,1V+\*/A]@,W_)5^5G8,.,^+O3&/Q78&P>[_`(Y97%;[Q>%Z\VGA
M-N[Q7!Y/>]%NK:W]]*5(\A+CLM!#DL?%,=<<H1W'NO=&TJOYH/SKH)*2FK?Y
M''S@6IJX-"'']J?%?,T,>4BQ=1D*FFJ*_%=LU45'C1)`(8:R81B9V"B,2E86
M]U[K!A?YIGSDS$-17#^1I\[J7'(:;[9JSL?XNXS*RJ\D$57YL)G>U\16PM`9
M6,87R^4*"WC744]U[K%B/YI'STKJJO;(?R+OF[08E<=4R8FJA[:^+L^3K,Q'
M-(M/09'#Y'LS##%XV:$*S5:5%3(CDJ*=U`<^Z]TK$_F7_-03U<\_\DWYTIA$
MQ\4U'51=D?$2;-39.]3'4T53MX=[B6GHHIDBT5,<\\DB2LW@`C]?NO=);-_S
M5_F>F.D?:7\COY_YO,QU=.C4.X=V?&W:>*^R:HK(*N=,U!VIN2:6LI_M04@2
MD9)-8)E1"CO[KW0-?,/YO?.?Y!_%CN+J'IS^6?\`S6?C9W+O?;:T&PNW^OZW
MXG4.>V/G:')X_,460I\ZGR-GJJ2@R<F.-!D!30+6''U4X@EBF*2+[KW6OA\3
MMD_\*0NL\;\NMW]VXG^;-DOD#V7LW;NV_CIOW;N[OCEW!UKLQJ+/5N>W='O/
MHSNSMM-A;>J]VQ8K#XZES.WHCD<#1RUYITE+B.3W7NK'/Y-7:G\T;X']$]A;
M5^9'\O[^:W\L>_NR^S*G>FX=[;@[EZ;[1V5AMMT^.IL3MK%['':'>^(RNVZR
M18ZF3*P)YON)1`_E$0ABA]U[JU?_`(>#[TAD,59_)6_FOQNK'6:/JKIW(1>-
MHGDB9)H.YUBD=F*!E!]%VN=2Z3[KW3"/YT?=E1'4ICOY*'\VNHKZ3(RXF:FJ
MNE^N<=!_$*8B6J\59/V@RSXU*2>!HZY$:CGE>2))"T+GW[KW4_\`X>=[93<6
MV-O57\F?^;3CVSV3QF/K\I5=![/J,/M^')Y'&XP9;(9+#=B9>B.,H9\B7J#Y
M%FAIX7E,>@7]^Z]TP=W_`,XIZ;:O:NQ]\_RG_P"<91[3EI.P>O=R[TVO\1L'
MN;%0XA]N9"BGW9A9<;VC/49#`UT$KS4U9X1!'2Z9J@Q'7$ONO=%@_EN?S4<'
MTG_+W^&G7/7O\M_^;5W%USL;H+8.U\)V[M?X?8.';^\\5@L)D*.GW=BJ2+NO
M/FJH=S#&4]73RT=35X^6/)(T4XB1]'NO=+WYC?SL$_V3_P"4;Y[^5Q_-IV%B
M)_CAVQ2Y+>?8OQ3PVU=A;4FW)LS,X''5^\-Q/V;75.&VW129%:C)5Z4=0F.I
M4:21#I8#W7NJ*/@MA_Y5^!^&GQ/VYWM_PGJ^?'>W:&0Z$VKN???>6T?AW-NO
M`=JU^X:7#2CL+8V\AW%AZS>^U]RS[@I9:>JC2F_A\%3"3#`C"WNO=&TEQG\D
MU,^VV#_PF2_F=/N/!4RO4X>E^`>YJFI@ITIH<B):XT7>LU)7.:6LC;5*\KMY
M%2Y:R>_=>Z7^.WU_);QFWYNJ6_X34_S!<?M;(11U>6R^6_E65>1SN*H\G`L%
M5E9]X3;RR7:=/#CVIY(O+1SO(LD#M3:KJS>Z]T#N\\C_`"#-DXROSNX_^$[7
M\RFAP>VY\A0[@R&3^"W;&#PVVJB"HJ$$6<DW'W/B,?133TE%]Q&'NT$,A#^*
M3RQK[KW16_F9L'^5?W'\./D)A_AA_(#_`)A_5O>.X^L9)NHNZ]R_#7>VV]C[
M7S\6>PM##E?[PUW;^=CIF-14R4(^UQU7//4N%6*068>Z]T`7RO["_G6]O?-'
M:^]OB_T1_.I^%GP@V]L?H_J_K[IWK38?:]3O'K[:/5G5FW=IUU1B^FZ;>F(V
M=F,A5;C-3.RUN1C:JI)`U74^2)EB]U[HWW6'\P?YOS?+[H#,_P`S?J+^9[VM
MMG'_`,OS?VT>Z/A]MKXJ;*ZPZX[QW9O;,=EX_M7>F[>G<MV]MC:O9G4&P^H:
MJ`U6XI,;3U*9?&@3TN*HV03^Z]T3?O?Y[?\`"5#-U'5=-C/Y77RHV76=:[XI
M>P9J+9>T.K=CMO:'#QEH.ONS#E^\MVG>O7>[:I1'6T[&&J@$%X*F)9)5D]U[
MIN[0^;/\OWL#YU_RHL?\(OY07<&(J_CS\@>\^V]P?%#:])U]MK/=O;FWIBNL
MMT]?[RV97=>9_L&IW+FNMLMU\NX/X/D7I,3'!B8\:'CHY)I(/=>ZVO\`>_8?
M5/;?\_SX0[OV1VKL_.4.QOY;/R[W1GDP>\MI9O'T,$O;77NT)*#*RT&<R%/C
MJZAR$F2-6(M,R28:579HZ><1>Z]UL`83.X3<V*H\[MO,XK<&$R,;RX_,83(4
MF5Q5=$DLD#R4>0H)JBDJ8TFB9"4=@&4CZ@^_=>ZH\_X4*YU=L_"KI?/$SJ<1
M_,(^!V462FHQ7RQ'%?(';&3\BTK054<[!:,Z4>.19'*H5;58^Z]UJX?+OI#N
MG^8]_,T_F*]R9#^5[E_GSUJ?DNW\L;HO<J?(??'28^,/8'1VU\SB<[V=6UO7
MV`K,16;`J\Q')EZK);GIY<5BJ^J@H7J&DJ/#)[KW6UG_`,)Z^Q^U]Y_RNNEM
M@]X;6S>T^UOB[N7LOXA;TH=P9VDW!D9<M\<=Y9+KME>LHXDB@CPD.-3$K!JG
M$?\`#CIFF0I(WNO=7:>_=>Z][]U[K__3W!?YD_R![,^,'Q0W3W'UC7X;:]3M
M[>W5%%OWM#</7&Y^XL%TCT]GNR=LX7MONS+]3;+RV!W7V%CNM-A5M=D9J"BK
M::1(XS4NQAIY$;W7NM?;X??SD/FQ\AOFCU]TALSMG8'R'P66^7E=L;+;-VY_
M+^[LZ;Q6Y_@14['&[(?G+@NYMP]Q;FQ>V\'09.IQ^/H,=74CPUW\7HI1+4K6
MTM_=>ZVF/D3TMMCY']!]T]`;TABFVIW5U9OSJ[/>6DI:[[?';XVSDMN3UT%-
M6I)2O68X9#[B`N+)-&C"Q`/OW7NM%'I?Y5?*K-_S7OY=66W9\K^K_AYWQVY\
M5-]?R\?D32MUAMON5]W_`"E^''<_9/6=;MCO+8V.W+M:"(]L;A;%Y/:&:CSE
M/(DE3'!3^*BE$$ONO=;'78W\M[^:;V/V!UAVAD?YS6+QNZ.E\SG]S];8W"_R
MZ.EJ+:N.W#N786?ZXS51F:&N[7S&6SM%E-L[FK8W@J*R1()IO-3B*6.)D]U[
MH+>^?Y)WR.^6O;_QM[S^6?S<^/'R&WI\8L/V7BMEX#L;^6_M+,=9;A;LZJQ]
M965>_=@_[,A3X?<TVU)\-0_P90*:&#[4//'42RSR2^Z]TF>\/Y`V[>X/E7U]
M\Z,9\COC5UQ\L.NMU9'?:[]VM\!URNV>S-WU6V*/:>+R_;FRNPOE'ON@ST^U
M<70QMAWQDF);'U@%6!)510RQ^Z]T<C'=#_SP*;(QRUG\Q#X.UV/ILAD66&I_
ME^[[?^(XYZ.DBQWW\-!\M,1-3RK4I*[14]4AC8W,\Z,(HO=>ZUSOYG?1_P#-
MKGW%_->WEOCYP]#4VR?C=\>_A?\`*+>FQNG?C''MG&_)C:>RMQ]Q9;8?7V^D
MSN_=Y[ZV!A]JYCK#.UF3HGW!GL9G8YX%E@AI998X?=>ZNJZ1W;_.D^2O5W77
MR4^,GSI_E@]R=+=KXC`;]V7+N7XD]];$AJ,#E<)$]=MC+4>![_WAG=O9'"YD
M/35=)/62Y*EK(Y5FDB,9I1[KW6BO\=-H_'K*;BZ6[;^1'\P/9?QF^3/Q,^3/
M;^YZ#XZX;^5KVQ\A<1B>P,+\@*O?W]VM_=I[-S>$F[II-T;DIBN-QV8K*NKQ
M6*#4`JH"@]^Z]T<[J^JPN5_F9_'OM/XK?*WXI=S_`#>[+P^/ZEZ[VC\D/Y>7
MS^VYM/K;<^>W,E=M;Y`[(R':.2[JW5N+>&RZJ2LIJ+<&?K*#&[=Q<"+#"E/2
MI]K[KW5YGR]_D4_SAOYA'8WQL[K^6/SR^%C]B_%C,U.YNKL1UW\=]WT>V:?.
M'=>W=U*F=S9FV_N3/X[)U>T,<)HI$C@I5C<00EY)9I?=>ZR[Y_D._P`PWL#Y
MQ[*_F`[FJOY8^Y>T>K\ON7=>W^H]_P"4^>';G1>^^P]YY3<&<KNQ-SX;M[L'
M?N4ZZK=E[FS4>8P.%VJ:;!P5M'3J((?"LS>Z]U`_G%=/?S&^\?C&.K?YJ/R\
M_ES?$SXJ[CW%M/"0;W^.GQ=^4GR8WOO+M;%C+[XQV0;%YG;N6S_3&&Q>+VW-
M'4Y2@K(0:5:F.:K6"K-,?=>ZU?LEM'XJ97?O0.0SG\X'^7_F.O?CYC^B:+9O
M4^4^!OSDEZL[#@Z5I<CA<9ENSNFZWX\UVT]XY[L/!5<K;EKVEDGW#4UDYD9&
M43/[KW5IOP!P_P#-+^67\LSY@;;^*\/\H[H[X(_(CYF=PXJHQ_>VW^Q,-3[#
MW3V+NSKC&XK8_5VQ=T;/WWUAC-@U>Z,K@*':5#N'&5^2AKIEA,`D^VT^Z]U8
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M^.7Q.^-?\NG^6O\`%7`XKX#=]U>0ZTW]MOJ;K2MWCF:'MG,=K[=WSL79D]2R
M92386/W7NJ0Y*ER?%1E,E]U%+4HL:QS>Z]T=C^6[A?@%_)P[L[0^*6[OYT\6
M\!2]?=8XBD^(OR7[CV+CMO=`;]IL/0+O2LPFZ\AE:#:V/S&YJZCC^SVS1KC)
M\-C942IBKGE@J_?NO=;144L<T<<T,B30S(DL4L3K)'+'(H=)(W0E71U((()!
M!]^Z]US]^Z]U[W[KW7O?NO=>]^Z]U[W[KW59'\VS>>+Z\^*.T=ZYNLDQV(VW
M\TOY>&5R60CI:JL%%1TOSI^/DD\\L%&T=0T>A2O##U,/]8^Z]U9O[]U[JA#^
M=3EVH.__`.1U1PC74UO\V[IUUB*&-#2KUUV1BZV8UXI*@Q/!%F@RP:D%2>#^
MC7'[KW2JDW'NBF_X4<P[>FH:N;;&2_D[EJ*>22C^UQT]#\O9JNLR%+#'E99Q
M_&*F6*ED=X(YF:A4>/Q(DS^Z]U>+[]U[H*^[N[>JOCCU1OSN_NW>^#Z[ZMZT
MVWDMV;RW;N"J%-0XO#XN`RS&.-0]5D<C5R%(*.BIHY:NNJY8Z>GCDFEC1O=>
MZTCZ?=?;?_"JG^8'M6GH-J]G]>_R2_B#NFJJ-R5-1D8]F97O3L>FPC9+&1YZ
MA-7D(<CN7<>5^U@2CIDJ)-K[2FFE>:CR630/[KW6]G3T,&(Q,&-P..Q]'38O
M'1T.&Q,`7%XNE@HJ9:?'8Z%:2EG3'8^".)(E$4#B&,>E#8+[]U[JGO\`EB_S
M7?\`9R]Y=T?%WY)]7-\5_GG\>=T9O']@_'K.UE:(MT;%BR=5%MOM#JBOW#2X
M;-[VV?D,6D$E55+04Z1-40RHK4M1!*WNO=,_P6EJ^@OYH/\`-5^)N82+'83N
M;<O4/\QGI2`RUM\]A>Y=FT73G?<]'324HH(VV]V[U)3R5;1S:Y'S43%+ZF/N
MO=76^_=>ZJZ_G8XWL[,_RF/Y@.(Z?Q]=EM]97XS=B8ZGQ>+H*C*9/);:K<<M
M-V!08W'TD-155>1J^OY,I'`D2-(9673ZK>_=>ZJE_EW?SQ?BOU-\4/Y?72N3
M^,G\S#9_3&3V=\??C#L;Y<=U?&BCQ_0&8WA4XW%]<;<J<EVWA=Z5>.KL3F]Q
MXYX::KH:&9&B4G0!!4>+W7NMI_W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=(CLS$UF>ZW[!P>.C67(9G9&Z\30Q,ZQK+
M69'`U]'2QM([*B*\\R@DD`7Y/OW7NJ_OY+D%32?RF?Y=U'6/*]51?$CI:BJ!
M+)%,T4M'LW'4STRRP_M/#2-%XHRI8>-!ZF_4?=>Z=OYP.\MU[$_E@_.?.;.Z
M?S_>F3JOC5VKM>OZ]VQEH\/F9ML[VVIDMG[LW3!4-1U\]12[!VWG*K.5=-3Q
M-55-)CY8X/W63W[KW6CYVA_+A_G+?S1OA'_*QW-L3X==&XWJSHSX0[.ZDV)G
M,G\@MITW8G:6P<ZVSLSMSL;+TV=J]L'8J9+9NP,&^-QZ39&HH9<A5U(DO4K!
M1>Z]U8'5_P`KW^8CGNQ>D-T]@?R__FWVWUQT9V)2;]VC\?.U?Y[O4FZ^H-O4
M&&P.+Q^V>N]GT2]'4&[<'L;!Y?;V+G"-EI:Z:DQL5-+/)KGEE]U[H9?YF?;/
M\YO^:?3[M_E8=:?`797PLWTO7G7WR)[2WIO[Y@8G=]=6[$3L6HH]G2=5[UZK
MH=N82KQ]7N;:51C\S#5TF3F5RT;TU)I@JY?=>ZJZ[0_DI_ST:/I/KKX_[>ZG
M^2.<ZJVAN;96:[,V)M;^;1M7<'5O:7\#H:K^_P!D=B]:;]VWLZ3K3.]@Y!IJ
MRGDJ*S(4&+JZH'[&<ZG3W7NKKNV_D1\V.]OY;/SHZS^8?\KW=/PL^$W3_P`6
M]P8FARF'^7>P=T?)>'#]0X_KC(X7:&,PVZMGUE!-E\IM>GJ*N/<>3,<$<=(=
M$-?5&*.J]U[J@O-]6_++_A0O_,/RG\Q[X!],Y/9_0OQUF^/&P<IC^P_DSB.C
M>X]_9+KJD%?7B7<FR)NP9]@;WR^.,T461H:#["DH8J>=!45;3QO[KW1L]T?`
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MZVGG]U[JV?<7_":[J?97\Q;X$_R[\GWCO?9]=VI\`NUNR?D5W)UED8:',;_[
M2VQV!O.7<E'@-O[K>MHH=H3X#.XS!1TB(6J\9BQ55%.LQJG?W7NOH!?%7XP=
M.?#'X^]8?&7H+;$>T>JNI]O_`,"VWBO/-65E1+4UE5E\[GLQ7U#O/D<_N?<&
M1JLC7U#$>6KJI&`52%'NO=4O_P#"F&2.F^#WQWR`,*9'%_S&OACD,+--424B
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MXL?'O^2)\:_F_P!>=/?$JNK8_ECL+#]I4>`ZZZ][W^6G=VRNLJ4;7AI]_4W8
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M#,L,BV]U[JT#X)])]+_`SYQ_++X^]/\`R1^,^W.C_D&VPN]]C_!2F[1V]%W9
MT3\@-U8C)5'8YZYZKHUQ<&!Z1['V;B:'*T-%`E3-'-0L].D%$OK]U[JHO^3G
M_.!^/7Q9^'@Z#WW\<_FYO3=NROD[\M(]S;_Z3^*?8/<O6F6K]S_)'L+=D.4H
M]\;3DR5'7U6+P>X:2GK88(_/#)2D")R4:7W7NK(L;_,9_ER;V^='47R;&!^?
M>#[PR74>3^'NTX\W\(OE3M?K"KVOV;V9M7?DAW,F3Z-@JVS.,W'M2GDBK'KQ
M14%!)4R/#R\L?NO=;"/OW7NFW)9G$89:)\QE<;BDR.1H\/CVR5=2T*U^7R,A
MBQ^+HFJI8A59&NE&F&!-4LK<*I/OW7NBI_,GYP_'#X*=?8GL3Y,9[=^`V?N;
M+3[9Q<^TNH^T^VI*[+BBDK/X97T/6.S=WR86.MIE98I\D*2CFD_:$I<A3[KW
M546._P"%!?\`)RR.8QTXB[:IJJAK:&.ASU1\%OD!(,5.E3-]A44]30]25F2I
MFA:6:6+PQF4#64742#[KW57/3?:.![-_EV_SHOE)U%O&CJ.L.U?YVO4W874E
M=NG:.Y-I4N#@Q7R<^$2C<>X=L;HP^"R&(,]0D+5-/+%'5Q)1WJ5BF9D7W7NM
MV'W[KW5"O2$6&_Z"-?G--CZO)Y'(_P##;?Q97-_>O%)1[>R,G:6[].$Q/C97
M@H*_"P4%<R2*S&JEG8,%*@^Z]U?5[]U[KWOW7NO>_=>Z][]U[KY^/6W_``G!
MV#\LOY@?>FQ?F9G.\^H^Z-B_(GN?Y']@;DQ.W)]W=5_//XQ=J=IS;CZXWCUO
MVBTE-M?IS?.W,EEVP6Z\`8*[()!/%-#!%*LLD/NO=;]^2E.V-K9"?"8.JR[;
M>P%5+B-M8IH8ZW)G$XZ1Z#!XUZN6.G2JK33I3PF5U0.PU,!<^_=>Z(W_`"Z_
MYC_07\R+I@]D]3UTNV-_[4R-5M3O'H'=E1]GVST-V+BIGI,ULO?FWZNEQN13
M[6MB>.FR,=,*"N,;K$_EAGBB]U[JP/W[KW7O?NO=>]^Z]U[W[KW5*'_"@C*4
MN$_EL[CS%?4ST&.Q7R=^"V4R.3@J:FD;%8_&?,SHW(5N3::E*R(E%3TS/JN/
M&P#@AE7W[KW5URD,`PO9@"-2E38B_*L`RG_`@$>_=>ZU[OY^?9_3W1N5_E(]
MW?(&NJML=,]4?S3^H]Z;W["@CJ\C!LJ/#]1=T5F!KLC@<;35>4R.*?<D%)/6
M2TT<LU+1TDQ2*5W5??NO=%CW?_.:_E6;=_F>X7YD5/S&ZAR_4-)_+$W-U]_%
M-MT^X<_OM]\5?R=V-NK$[(.P<=MF;L$[MK<!75%13XIJ,5=-`E;+/#!"LLGO
MW7NCP9'^;/\`)?OJI7%?RZOY7GR@[VQ.2QVW),=WW\G*:/X3=`T<FZH?+!N"
ME'<=!2]K=B;6VW33Q5-:^!P,LE6JR14K,=$K>Z]UJ8?SD^BOF#N[^<)_+7ZV
M_G*=Q[)WQ\7N\<GU;M"FR7QZ@W[U%T#M_&U6_H,!VGMK'TFZ\UN'(X?>*9?+
MXV;/9]IHZR?#9"AD5Z*."&*D]U[KZ(/1'0_4/QDZCV+T3T/L3"=:]3];8*DV
MYL[9V`2?[+%XVD6VN>KK9ZO)Y?*5LQ::LKJV>HK:VID>:HEDE=W/NO="Y[]U
M[JF#^=5\4^BM\_%SL3YIYZ3L'JSY(?!CK#L7O3H[Y)]`5>*V]WUL6IV9M3+Y
MC);:QN6RDM-B-R[.W/0QST=?B<J9J7[>JF>G\-0PD/NO=5CY3Y]Y+YL_"SXS
M?S[_`(Q]']E4W9O\OK?7:6SN^.CYLY@&S?;7QHSVTMN8OY2[=I<]0P8_';BQ
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M8,GC,S-MG)QXS(8Z:NJ:*BAKZ*M9)(6FFBB6107=5NP]U[HB7\F&:MG_`)3G
M\NU\CCUQE6/B)TC%)3+4+5&58-D8J"#(R5"@"2?+P1K5R?4B2=@22+GW7NAZ
M^?\`G)MM?!3YFYZGPF<W)/B_BQW]5PX+;5!'D\]E)(^J]U!*3%X^6KH8ZRKD
M8^F,S1Z@#ZA[]U[H&/Y.^2QN5_E0_P`M^IQ5?29*E@^$GQHQ4E512B:`9#!]
M1[4PN7I"X`*U&.RV/GIYD8!HYHF1@&4CW[KW5B.4RN+P>.K<QFLE08?$XVGE
MK,CE,I64^/QU!20J7FJJVMJY(::EIXD%V=V55')/OW7NJ(,UWCUO0_\`"@+8
M66QW</3M9LS<G\H[?V#W-.G8&RFJ<+F-J_+G:&8VX]365&03P1YJ#<U8M/3T
MU0\E2*6>6:'131R#W7NKDSW_`-#@$GNSJ,`<DGLC9H``^I)_C/OW7NM1WO\`
MW+LO:_\`+:_X4E;-[?[2V7TYD.Y/GS\C-P]3-VYEJ_;^2W]M?<W6?QKK-E9K
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M*,@HP+Q9ZHJX(X95BB^XAD]U[HG?<O\`,J^//SA_F]_R4X/Y6FQL1O/LWKW>
M?R)F[0A[3Z0R_26W,;T9V/L_:^.WMG,=D-[;?VOF<IFMK]>[5W'F\7)AXZHK
M5TT<*&22IDII/=>ZMG^0.$/_`$$D?R^L]54'^3S?R[_E318K(R;B-*KY/$[U
MHFKX(,#/'-#6ST>.W(NH0>&:=*KRN[1T(C/NO=;`_OW7NJ%_^%&.R:?=?P&Z
M_P`[/)4*W6GSG^#^]J>*&2D6"IEK^_\`:O7#P5\=3&\M12?:]@2.$@*R^9(V
M)\2R*?=>ZK9[:_E']VT?\S'YP]Q=/X+^35\S*#Y$;UV;VANK:7\QBG[`[![[
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MK)7W7NMQCW[KW5(_\\#:.U*O87\OCM3,8G$U6YNF?YL?P!SVT\KD<53Y`X^/
M>'=^&Z^W11O/)403TN-R&"W(\TJH)@]51TS&.\:2Q>Z]UV8]A_$S^:SVKNOY
M.4.RX=A_S`]Q]);G^'/=.Z8L`N&Z\^2O1W060Z,WCT/69;,PPS;([1[*ZYKZ
MK);2R$$JC<F/J<QAUD6HIXZ>M]U[J[?W[KW7O?NO=::?R;^/U%N#_A8;\)=S
MYW:-1E=NY3XG5/;\-=786DCQ1W7UAL7O?;^'R])7258;*5&V,YB<+*)0OFI:
MIH0(RB+(?=>ZD?S7-L9[`[V_X4F]@4F%R6WL96?R[_Y>$2YVES,=-)N:ODW+
MVU2',T$%+*TU)-246VI<:DTT3/#)0LRG1+I;W7N@/^0>UJ&@_P"%=7\M/L''
M[>EJ:+MGXJ;1WM7YO>']T:>3=63IND?D'LR'=&,RM77T-/N;<.(QN"Q:.\4:
MY'[BC=:6!T2&_NO="U_(N_FDTW0WQ;W'\<:KX/?S%NZZ39'RG^7\Z]N_';XJ
MKV3T9A\%4=H;H[$K\0-\XG<^)R.;W+ADS$S3XV.AK<N\U1!2TL<^NFA'NO=6
M!;,_G/[K[,_F2?'CJ/"_`7^:MLGJ3M/K;>.P*FM[5^+^5ZXV70;JR_8>QVQ?
M>.=VQE9ZG/TNQ-A4.,EQ^5S574T1Q=+FV=J)_09/=>ZL*_G%;$P_9?\`+.^7
M&S<]\E,-\0<9DNO<95R_(G<5=F<;@^O:C`[VVKN''C*5FW*Z@W#'1[MR&*BP
M3"@,]=(,GH@IJN5DI9O=>ZTN_P"<ATOB=J?RC_Y">R.K_FMM+MXKW]N_$[>^
M2`R^\,/MO=^X^RLZ^XJWN@Y#<^9KMQ8[`=/;G9Z*JJJ^`U]*LP8)17DI#[KW
M6\M\NOEGE/A-TUU_OK*?'SY._+O)9G=&VNO,QA/BEU3!V3O:EK:O;V4R-=V#
MGMKKF\1%A]H-48-TEG69TBJJRGA%S(I]^Z]T2+;7\[W8VXJNJQD/\MW^;]19
M>@K6H\CCG^`>_*HT,T:J[":MQ^;JL>TT*5-/Y(4E:HC:I0%.'T^Z]UKO'OC$
M_(+^5I_PHM[:PF$[$VQUONW^:)UEN["]4]G;?K=D;XVK-E>X_B<=WQ[CVY45
ME55[3W+N.KQX%;0L5FHYX?7^X6"^Z]UOM>_=>ZHLZZGR3?\`"C'Y+4^(Q6T:
M/!1_RK>A)=Y9''"*/<>6W%+\AM^KM:?.BGHXFGR5-AXJJ`-42R.N.BI%#:/&
MD?NO=7I^_=>Z][]U[KWOW7NO>_=>Z26_]VQ[!V)O7?<N"W%NB+96TMQ[MDVS
MM#'+E]V;BCVYAZS,/@MKXEIZ5<IN++K1_;T5.9(Q/4R(FI=5Q[KW5&.U/^%+
MO\J#)?$7:'RMWOWS1]<UV[,;NQO]ENR+8[='R2QFY]F5TN,RFTJ_KG9F0S<N
M,J\I5)$^*KLC-C\77TE3#/\`<1QF0Q^Z]UJ0XO\`FF;@Z&_G@=5_SC\O\-.Z
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M%F*2NJXH%*HT,D+('5[V'OW7NB9=Y?`C9F^O^%2_Q@^055V>V&R&V?A)D^_Z
M;KR'!1"LRF:ZJSV3Z'HL=19*7;]5A'V]/CM_TU94"2<96&2D<0/'&8&B]U[K
M:C`MP.`.`!^/?NO=:QG_``K!^%F*^3?\KS=?=M+7UU!V%\+,Y2]T;56GDG-%
MF-KYNOPNS^R<)701DJCQX"LBRM/4Z2\4V)$8*QSR,/=>ZK'_`).'\TC_`(4)
M_.KXITN(^,G1?P9[!VC\<\?MCH6L[X^2.4[>VUNG>>X\)M*D>AK\B^W-\MC=
MV[GPNWWQTV9GAHJ<33544DBF2=R/=>ZV2/Y,'S0^0'SK^%_^EWY0[9ZYVKWC
MM+N[NOI/?>.ZJI,O0[*ERO4F\ZG:\M9C:3-;@W151R2-"4E9:V6&9X_)&$5P
MB^Z]T.G\T7:V>WQ_+?\`G7LW:O7>9[:W1NGXG][X#;/6NW:/+Y+/;TW%ENN-
MP46#P6(QF`=,UE,C5Y2:(14M+>>I<"-%8MI/NO=5\_\`";OXY=C_`!>_E<[/
M^/G>W3F+Z?[;VAV=VF.S=G/V3L_LS,9>OW?7T6Z<=F=\X[:5=E\=USN*JVAG
M:"@FVQ5SRUU)2T,-14K$]68(O=>Z"K<^T^V?Y"^_=S]E])]?;R[K_E`=E[KK
M]X=P]-[3DK]Q[]_ET[@RU8V1W7VSU!MJ&#(9K=OQSSU5723Y;:U%"S;=:G:M
MBGCB>5)?=>ZORV#VWU=WST]A^W>GM\[:[-ZNW_M&7<&T]Z[.S-)DL#G\-6T,
MK)/1Y*'S1P3(=44T<J":DG1XYHUD1T'NO=:7>VJNNRW_``DB^&1Q<D*Y*D^1
M'1&)PM:^7HH)<)+BOYG4^(PDPR\GVE,*JBIH(86J`:=0C-,="`@>Z]UO.>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[I&
M=C561HNO=^5F'I<;7Y>DV9NBJQ5#F4>3#UF1I\)72T-+E4C9)'QM14HJ3A6#
M&(M8@^_=>ZKP_DI;2RNR/Y3/\OO;V;DHY<C'\8.L\M+_``^9JBDB@W-ATW-0
MTL4C*G-'0Y>*)U`*HZ%5)`!/NO='.^4.(KMP?&?Y$X'%KCGR>;Z+[;Q&.7,3
M0T^):NR6P-P45(N4J*EXZ>#'&HF43O(RHL6HL0`??NO=:KG\H_\`G,=<_&_^
M6=\..HJ/^71_-7W_`(7KWHW%T.2[4ZC^(6=[(Z>W3N=]R9N/<^3V7OJ+=%"V
M=P&2W9)7-'41THIJ>4-2J6,/OW7ND;_,._F+;9_FK=C?R\/Y=>8^)7\QGXO]
M5?(WYU==_P"G:G^1W2#]!8?NCI+8NW:[<N6ZUQN;;=]57Y*/-9C*4%;D(J&J
MCGH:"B6J4RSM31'W7NL/S8_EZ?R"_@5\^NK\G\I]E?#7I/XK9SXC[NJ).EMP
MUWR6SO<^Y>XT[1IXL)V%@=N;&JL[BZC9T>TZ6MQ[35L[54E;"T=-3M9Y8O=>
MZ#S^/_\`")3(?WID?&],4WVU&U5DTDV]\Z<2\L$_V%)IVK`*.EDJ*HK21ND>
M(4S*K22J!Y9G?W7NJ<]R;^_DL8C^6;_,"K:O9/7^[_D')\E^WME_RO=N=SX_
MM.D[PQOQ&W5N3KNFZOS9RM+)C\H=D[*DR&[<EBJG,5KS0)2/1R2^9F@;W7NM
MF3^3SWT_7_\`,F^2'PA^/7P&^&O6?Q;S'4VP_D*WR0^&/9M1OC'OL;+X**A^
M-E5W-DZC)96FGW;V7LSSU=#A9*;`9=4JILP:2IIZN:MF]U[JUCX9_/'N[L?X
MC_+#Y&?*/I_&8_<WQG^1GR\ZK'7OQJQ&XM]YW=VS?C)O'*;07^`;>KLYFLGG
M]^9/*;?R%,8X)X:>L:&.>.*GCE\:>Z]U6?V/_P`*2.F\[%U4O5GQ4_FF[,IF
M[`VSN3<WA_E\8S?$/8FR\4V7;=O46&_C'<>VDV]GL\5A<YV@7)MCTB;QPRL[
MF+W7NJ>?YI?\V'8'S:_F'?R1*7ICHCYB_&?>_37SBVU#E<[\C.EXNC,OG=M=
ME=E]!8"IPVRJ^GW7FL[D\958B"ICR](Z4U.U)D(5D603:1[KW5C?_"@;YOX;
M^55_,M_EI?/[,=<Y[O6.'H'Y>].P=34V^*38./H:J>JZT:+=^/SU3M/>?V]?
M50;]F@K8Q1WGAHZ8"10C!_=>ZMK^2O\`-/W9TW_)MQ_\UC:GQ[_B&8RG2O1?
M=/\`H*WAO?\`AHPF*[AW!L/&U&/K]XT&`:;(KA:'>8E@GAQL3U06-V@B!=%]
MU[HL?\\7LVL["_E2_&_L#=&W5ZUW'VY\GOY=&Y*KKW+9/';BR.W\_N7N'K[>
MN2V33Y_&Z,=E,CMZ.GJ0]93JL=1!1RLJJKV'NO=5F?SH?C-TCUA\H.[ODMWK
MN;^0_L;$;TRO7V<VY3?*CJ_Y9=H_+'=62DP^`V^7WMUUTUVQ65^YJ$QX&4T]
M3AMKST;8^)(ZFGB$<U4WNO=71_\`">_HWJ_I3^7'MNKZJS$F=Q'=/<G=7>69
MKZ?ICL'X_P"V8L]O'>,^)&$Z^ZN[/J*O=V"Z[VQ@-LT&,P\DTTT=924BSH["
M0L?=>ZN^]^Z]U[W[KW7_UM^3-8:@W!C*K#Y2"*JQM<(HZ^BJ*>DK*6OHTGBE
MJ,=6TE=3U5+4T&0BC,,\;H=<,C`%20P]U[H+]B_'3X^]7;HW!O?K/HKISKO>
MF[:MJ_=6[MC=9;*VGN?<M<].M(]9G\_@<)097+U3TJB,R5$LC&,:;VX]^Z]T
M,GOW7NJ=?YW=/D)OBOT9)BJNGH*^B_F)_P`NBMI:VKJZ6BIZ6H@^7?5@@J))
M:N:")Q#.ZL$#!F(%O?NO=#3_`#`/B!MGYF[L^&77O:G3NVNY^@=M]]=@;M[H
MPNYE@%/MS&M\6N_-L;%W913)44N:ILICNR-QXN*DFH'6>EJYX:@,C0I(GNO=
M,/\`+@K.S^M\M\I_A3V/V9N#N_%_"_LS86S.I.X^P,O4YWM_=_3W:G4NU>W-
MG8;N+-30PP;CWSUU)N6JV^,Q&J29?%X^CJ:E!5O.S^Z]U9_[]U[K6(^2GQ=[
MOW%_PIX^$'RGJOCKVUV1\:]B_#K,[-'<>&I)J[K+J3MFL;Y#TE/D,]4U=:F/
MH9DH]ST<,E-$$G,F3@JU27PM[]U[H!OYM?7&7.;_`.%%V1QLV(EAW=_*T^"V
M]*JE&9K:C(1KLS>?R<IZN6IQL\?@QFC#[(J6CC@#1.3'(662>4+[KW7?9/QN
M^1G8/_"E;^6Q\@HOC9VWO_X^=-?![`[:WOWQFL!DST]MC><_6_?]32YS$[HK
MAD,7_>'&[BWSBHC1/75.1>OG\HN(_,?=>Z9OY'/RB^7?2?Q5[.V'U7_+![R^
M2'6-/\S_`)D5F*[FZU[I^+NQ\9FJQNV<I')BUV?W)W%LO=LD^)RD$M!45;+]
ML$IU\+U#I*%]U[JU&N_FG_,&D^1O5/QU?^3;\MJ#,]H8+)[S7.9CNSXG24&V
MMA;4W+M[;V_MX9NNV;VSO;9^,I=K_P!ZJ!X*/(9O'Y'+SU"P4<$C$,?=>Z'K
M^<W\9>T_F1_+'^6?QHZ2VE3;X[6[5V;M7$['VS6[JP^RJ2MS>)[,V1N>.JJ=
MR9^6GP]%!AX,&]:T<\D:U8I_MPZM*&'NO=:^GS^WKUK_`"O_`.3W_*EPOS^_
ME[?"SO/MCJ?=N`Z5R'QOW/N:3.8?`82EP68G["[!ZPR*X#=.$KMY[BQVV,+D
M-SU=7][C*?-9AAJK1)&S>Z]UM`_(KY-[WZ6Z4Z][9Z2^*?<'RZ@WAD=KP_W!
MZ%K^NZ/<VW=EYW;&0W!%O3P;[W3M+%9/#4,='3TBT]',]1)/60Z5$>IU]U[H
MDLO\U'Y05*"3!_R5OYDM:GW5.K?QA/C#MN044LT/FJ1#7]_RS&IBHG=UAT@&
M91$\D8)=/=>ZU^=L[A['^1_P-_X4L;UR?16]^E]W[Q^<?7F3/0^:JZ;=O8&R
M-Z;+J>B:O-19>IVS5+BI<O++A:;)324!FIZ,LVB>LBA5W]U[K>G]^Z]U2#L?
M&1?]!$_?^5QM;'3HG\I/H:GW/C&Q-13ODLK7?*;M3^`Y2')?Q%(*QL;B</-!
M,YI9"RSQ1I)&8)!+[KW5WWOW7NO>_=>Z][]U[KWOW7NO>_=>Z^<IA]G?!S^1
ME_._^<V1_F!?&].UNH>T-LY_Y#?`/<_^A>7L>5=T;JWA_>VCZSZOV[DHJ38\
M6Z*>HW/7;87*31+%C,A@J4_=4$54S/[KW1Q_DI\)OYR/_"C_`&#N_?/?.WMJ
M_P`NKXI==5F5WS\.?C#V=LF;(=O]B]@TNT,O0[7W-V7F*JEP6Z]KXG<5%G7H
M*JOJA1TM(*CR4F#JA`U54>Z]U>/_`,)XLG\T]N?`/%?&SYW],=I=3]R_$C>6
M3Z,P65[&Q5-#1=A=48>AH<CUUD]I;CH*RLQ>\<7M#$US;>%?1//224^+IV6H
MGD>4K[KW5[OOW7NO>_=>Z][]U[JGC^?!LJ/?O\MOL7!UF+@R>#B[L^(&6W6T
MNX*?:[XG:.*^6O2M7N;.TN:JYX*2BJ\1ATEF1I/(H"DZ&(`]^Z]U</[]U[JB
MW^=[288Y;^4%F,K734\N&_G1_"QZ&D"PR45<];!V13U)R$;RK)XJ&`&:)D24
MK4+'<*#Y$]U[I][`IOM/^%#/QOKTJJ>/^._RHOD1C:FEJ(H0\_\`=SY-]0UM
M$:&9YXY6K$_O%4,559"L"R'39F=/=>ZNU]^Z]UH(?\*D_D?_`#`N^/GYTO\`
MRA/B/G-SS;+[UZ"V=G\STUM/*[5VV_=N]MS;T[*K9J/=.Z,\<*U-MK![?ZZI
MY!15&5@QC-#+-,K-HT^Z]U<G_P`)<_C3\X_A_P#!;L#X_?,SX]X_H>GV[W9G
M=T=2_=YK`5>_=X8S=^-HY]X56\<1MNLR]#34N&S..@BQ=?-6&JK:>5X3!%#1
M02U'NO="K_PG/PV^L#\7/E_B=]9S`9&NQO\`,[^;^-I\)@:^AS<>T9Z#L6EI
MMPX>KW+CX*2FW))5[J2MKH*M(($DHZJ$K&@](]U[K8']^Z]UKZ_,78G9W\K3
MY/\`87\U#X]X3-[\^*'<-!25?\T+X\T64JJJKP/]V:7"X+;'S,Z3VX7,9WGL
MW"1M%O6@@#_Q3`TS5"0/4(:BG]U[J]/KSL+8'<G7VT^S.M-T[?[`ZV[#VWC=
MS[0W;MVMI\OMW=&V<[1I5X_)8ZLA+P55'6TDP-CR.58!@0/=>ZU\OF]\`]]_
MRZ\)WW_,9_E7]F8GX_KLK:G8'>7RG^$>](\G7_#OY);7VKMVHW!O2JV_M''5
M]&G0W:?]W\96S4F2V]'!35U=XHI5I8Y*B:3W7NM9OJKO#YH;S_D`?%#%;9Z7
M^+VT/Y>VQ_F9T=UQONOGW]V#N+Y)[NSF)^7&$[`K\_+M[/;;PO6]!M+</:68
MA@J%@RU171P(RA(J;R:/=>Z^E1[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NFC<%//5X'-TE+/'2U-5B,E3T]5,B20TT\
MU%-'%/*D@,;QPR,&8,+$#GCW[KW1%_Y4\V0G_EJ?!1LI0X_'UT?Q9Z7II8,5
MD:7*T$J4FQ\12T]?35M%#!2R+E::%*HJBVB:8QW)4L?=>Z'WY:I))\5?DQ'%
M%!-))\?NY42*I,HIY&?KK<:A)_!)#,8FO9@CHQ'`93R/=>ZK]_D`8J##?R:O
MY?%'3:C'-T+095M3%CY\[N3<><JK$@64561>P_`L/Q[]U[H(_P"<?E,EBODM
M_(^FQZX&,2_S1]H4DU;N+*SXN@09'IOM'%28^*2""K>3*Y.@R%0M`OB99,@D
M$+,BRLWOW7NBN?S!?D_\"?B1_/#Z[[5_F";BZZVUUU-_*FSVV.NJWL7JS,]I
MP/V#E/E/7SU\.W:'";2WE587-U.R*+)4SR_;1&JHZB6#RA6>*7W7ND]TA_PH
M]_D-=O9'>.<WN^P^A*3!Y[$[,V-4=L=!9.MWWO;$8K"5C2[DDQ?7G7&^L+M'
M9%"L7VF(%5FWK98V*ST=`S1PR>Z]T]_S?^^/AA_,$_D,_,CY<?&F@Z_[;PVU
MMDOU]L+M3<72U?2[DVO4[>[FV#AMVXK9D^\]G8W=6%I?#4R?;5V/"T"O(M0)
M=,<A3W7NGCX,_%[^9_\`&C^<KV;ELT^'S_\`+6[H^+6P*O&UFW\-LO;6S>O,
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M14R2OK&N6.2+W7NC:?S/N_:CY/\`_"5OL'Y"?Z,<-U&>W/BO\;MVIU?MA*A=
ML;(HLCV]T\E/B-K0Q8FC:FVK14,*OC8S!%%#0&)=>A?(?=>Z6G\\C`25?\J[
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MO?NO=50?SA\OD\1\=N@I,72/D):O^8C_`"[**?'/)4+CJRG;Y==5U.G,PTEJ
MFMQU+4TL=0(4(,E1#$"'6\;^Z]T<[O/Y-;-Z&W[\8>NMQ8O,9;<'RI[LJ>D=
MCKB7QRPXG+T'5_8?:V2S^=^^K*:;^"46$Z[G@;[=)I355<"Z0&)'NO=$@^&N
M[LQ7_P`T?^<CL;)4,L-%M;*_`7<6%KU>J%%6T.\OC5E*.6*.GDQV/I/OJ.LV
MC)YYXVJWD62.-Z@B%(*?W7NK</?NO=:P?RR^5?R&VQ_PI6^"OQ6IOF#ENE?C
M/O;XMG>V0Z3Q])C\]@^Z>Q_[R=QP-L?-X\X&N&`SF[:7;U`]-DJV>,TU%BI4
MHY8:FI19?=>Z"3^9[N2+?7:'_"B7KI=UX^NQ6R_Y.'QSR>5Q,VV\'3Y;;NZ=
MOR_)_L'%86DRL&!GS6<Q$V.S5-72S5$LPI:C,*B20"&-X?=>Z#3M'Y:_,K_H
M))_EE?%O8W>G:6Q?BQOGXD]?]BY7IC!UM)3]?[JPQZB[OW)N&HW3MM(Y<+GJ
MJLRFRH:+[V0U$^.$"-1R1/$C#W7NE_\`R<.^/GU\?_C?W%U%T_\`RR<E\BNJ
MNN?FK\T]M4G<6!^6_3G6V4W5NBC^1V[J;.4=/UIV3A,/E(L1MV>1Z1LB,A.:
MEZ-M,"D,J^Z]T<3%_(#^:QV/\]?B?W/F?Y1W:'573-%UQV[TCOJ;+_-#XTU]
M1@,5VYOKI[=-;V3O;:F`@SU144VP\%U"T^/Q4-91UF1K,@8#-'(B0S^Z]T=C
M^=?)MJC_`)4GSKS>ZI]_TU#M;H'=F\,74=9;FW+M#=L.[]J?:Y_8DL.?VE)%
MF*+")O3'T!RW(IWQ/W*U!6`R,ONO=:%_\SU!V+_(3_X3_P"2;#;<Q4^Z=^=U
MX/*.<QW'V5G*K*S[A7;5?F:6IR59N?/R4NZJC!/D<YAJ6I^XI\E+#28*G6DB
M:*'W7NOHD]T=F=U?'/X\=8Y#XX?$G='RVW-01;&V;)U-U_V'LCINNV_M.':=
M2)=TQ93O[/X1!B\+/BJ6C&.JZE\Q>L0R`F*=E]U[HAZ_S+OYC\^8R6.IOY$?
MRM:FQN9BQ4E;5?)OXB4(FCJ:R2EIZRC>?L/^%9&'1'KEEI:RHHX`07J!&1(?
M=>ZI9VYW?V9N;X3_`/"C;M[N+H/>?0.\LE\Z^JJ/.]+#>%)E^Q-J9=L+\8MD
M+B,QN/8<+X+,8*MQ<5!D9*S%M/0Y3'5]2%JIZ<K4O[KW6[)[]U[JAB>OKZ/_
M`(4S4..IZM\?CL[_`"4I:G*4B?NQ[BJ,#\TJA<4:A=!^UDP*YBI:)[@N*EU_
MP]^Z]U?/[]U[KWOW7NO>_=>Z][]U[KWOW7NJ(O\`A0'_`"Z-_P#SP^(>V]Y?
M'3&44WS'^'W8^%^1'QMJA#1IF<YEMKRPU>Y^M\=D*N,K')NZEH*6LI*=WBIZ
MG-XC'K,Z1ZG7W7NK.OA-V]V=WU\3NA.VNZNJM[=(]P;PZ[PU1VEU=V'@GVSN
MO:G8&,$N#W?!5X.6*GFH<;D<]C)ZW&ZXH7DQM33NT498QK[KW1H_?NO=>]^Z
M]U[W[KW7O?NO=5.?SPLM7X#^6/\`(?.T&7I,+_!,UT#F<C5U=-%5^?`XCY)=
M0Y+<.,HXIZ')0+DLK@Z2HIJ:1X66&:59"4"ZU]U[JV/W[KW5#?\`/(I'J]P?
MR>DJ<T*+!G^<G\2$RF'2BHFJ,M5G#=FS86L3+5<M,,53X>O@O*/-$M2*@1DL
M_C1O=>Z6?8D<I_X4*?&*215:G7^5/\F_MB6F9DJE^3'1:U+*CWIHF,$L8UQV
MD8$ASI">_=>ZNHK:VCQM'5Y'(U=-08^@IIZVNKJV>*EHZ*CI8GGJJNKJIWC@
MIJ:F@C9Y)'941%))`'OW7NOG0_S!N_.K/F%_PJE_EQ[I^)/<E)W1MK%57Q3V
MAD]\?''?=%,,=)@>R.P]T]@XR/>N,7+XC(4&'V-F9*C/PP%XI\/+4T,C1R&4
MI[KW7T9_?NO=:X=;_P`)E_B.G8'?.[]C_+7^8KTIM7Y$[\WSV%O_`*?Z)^2F
M/ZQZLJ,KOW)U-?E<;_=[%]>U,V6P5/25LM###DYZZ7[(K$\KJH]^Z]T@_P#A
M-IL[<71E=_-<^(K]J=E]H]:?%#^8+O/JGJ6J[0W%+N+.8K;-#BW@G/FT04-'
M49F7'QU5;'1P4M)+6M+.D,;2O?W7NMFW(8^ARU!6XO*45)DL9DJ2IQ^1QU?3
MQ5=#7T-9"]/5T592SI)!4TE53R,DD;JR.C$$$'W[KW5,WP1^)'R2_E^_+#M'
MXT=48E-P_P`I[=6S<OV_T?)O#?:Y;>WQC[HS6X\:V[^@=AX^<3Y>OZ2RYKJG
M+X>GJM!Q<[U*FHGD:1I_=>ZM\WOLO:_9&R]W]=[XP]/N'9>_=KY_9>[\!5O4
M14N<VONG$U>#S^'J9*2:GJHZ?)XFNFA=HI(Y`KDJRFQ'NO=:4??>P^I]L?\`
M"3SI&'J[K/+;6VCANYNC<]4)6U-%/N7%[AI/G/2[5W=V,NY:::6"@J=TU*5(
MI*^9X)(L?DXHIDA?5"GNO=;P:VTK:]K"USJ-K<78DEC_`(W-_?NO==^_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z8=TS55/MC<
M=10^+[Z#`Y>:C\TT%-#]U%CZAZ?RU%535M-!%YE&IY(9D4<LC`%3[KW57/\`
M(JS+[@_E#?`/+2&I,M3T!@(Y6J@H=IJ3)Y>BE:$1Q0Q"B:2G)I@B+&*?1H&F
MWOW7NCO_`"YJ:JC^*/R=JZ&DCKZVE^//=-31T,QM%6U4'6^Y9:>DE/W-%:.I
ME4(W[T7#?K7]0]U[H@O\@BO3(?R;_P"7S-'%)&D/0&%H`9&B;ROCLOFJ&:6/
MQ2/:,ST[`!M+"W(^A/NO=`7_`#G)\&WR?_D:8[)"B.0JOYHVRZS%FIRU-0S)
M_#NM=Z"1XZ&;#5TF1A.0JZ-3HJJ4K4M!'9VF62#W7NB3_P`R;YJ_'CX`?SMI
MNZ/E0F<S^`WQ_*;P77'1FU*#K?(]L8&??L/RC[!W5NFOW5MS#8VNR^'Q^.Q^
M#HI6KH;$4K5"@/($3W[KW0K;4_X4*_R=<AM>FR6XNM^S*3<$<\464Q6,^"/9
MLT4,%7D/L\=EJ>:/961HAB:])(VA+U0J9"P'A61A'[]U[I1?S5_E#T3\K/\`
MA.E\S^[_`(UX[-8;J#*]?U.TMM8S<G6F<ZNJZ*?:??\`M;969IX]CYK'86KQ
MM&V8H)C`WA$=F!==:RQ+[KW6PSUWN/$[@V=L^HH<MCLA45NR]K9HI2LL$S46
M6PU'54E><9(WWE#2UJ2:HUD4$`V^H]^Z]U6)_+[^*O:W\MCXH?+]-QK_`+,7
MO?='R:^87RZVCM3K"NGK=T[\QN_,E+N79G7\51N.EPV/3LO<,.!BIJE(Q]A'
MDZLJDDH!D?W7NBO9#^>+\C*/"C+I_(K_`)LLI5\?'-3OU)M8%'K%@@F$<5)N
M*NRLJP9.H6-6^S4&"\\GB"L@]U[JA7^;E\].\?EQ\R/Y)>U^X?Y>GR=^$5'M
MG^8=UQN3:&9[_;!I2]CTTO;O3>#R-%BZ/#TNO'9K`^*GGG@EG)$%;&Z>2-TE
M/NO=2/\`A<#+DX\K_+?3%3UD$U3@_E]3U0HIY8'J,85^/D^2IIS$Z&6BDI8"
M98VNCJO(/OW7NK[MY?&[O;^9!_PG8ZE^.V&JMD_';N'O?X<?%N@G7=D-=2[(
MVY1[?7K#<=5CZR"BH<ID\+C=S[8VUHAA2*2:A^]2,DF,D^Z]T\?SQ-J9#'_`
M?XI=?UE1%7Y:+YV_RX-F5-?CJ21J&HR-/WGLC%SUL-/41UIAHJBHIV,:S++^
MM48,38^Z]U>3M;8^RMC)GX]E;0VOM"/=>Z<WOC=";7P&*P";DWKN6=*K<>[\
M\N*I*09C=&?J8UDK:^H\E75.H:61B`??NO=/6/Q>,Q,4T&+Q]%C8:FLK,C41
M4%+!21SY#(3O55]=,D"1K+5UM3(TDLC7>1V)8DGW[KW4_P!^Z]U[W[KW7__0
MW^/?NO=>]^Z]U[W[KW5//\[<1P_%?I+*R9"/$KM_^8-_+\W`,G.,A'34C8KY
M3]<5`%178VDK9L6E<!]JE0R%!+.BGEP#[KW1M?E!\4:_Y!=R?![MK'[PHMN-
M\0OD1F^Z:W"5V*GKEWIC-P]*]F]25>%I*ZGK(#B,A1MOY*R*1XYHI!`R,%N&
M]^Z]TB_CQM7H[!_/7^8IG>O,%VQ1=N[PQ_P^R7?^<W+48=^G\SEL;UAO3#==
MT?5%+1S'+TNXL5L:CB?=)K(U662KQ[0LPUZ?=>ZL%]^Z]U1C\H.U.B>MOYQW
MPHV+O+XA?#K/]K]T[+S$VQOESV1VMMG#_)?:S;:I=U86/9_6/7%7U5F]R91H
M9<MXZ1XMP4D%8N1J]'@>DE:3W7NJY?YH4`HODM_/PRF-QM5KD_D*]<09;,12
MAL93UN1W3\DZ*/'Y&B=&AFR&6PU`#3R,08H:*8`'R$CW7NC-=L?$[X'?\/%?
M`3Y8;_\`GG0=/_+G:W1?6>P.AOB)19;8,=-V%L=MN=H[7IJ*D6>GER]1C=X2
M;VR=-3F!*=*AJ1DI;R%6B]U[HHO\IOY"_P`T?J;XV=A[`^+O\O?87S%ZEV]\
MWOFW3T_R+W#\U.ONG:GLC7\B]YR9C*XO9.Y-M;FSJ2G./6VK*RKTUB^-E6Q,
MC^Z]U;CC_FM_-8K^[^D>NLE_*<V5M#9>_*JLK>S]R9/^8'T5G]U=9['QF],3
MM_,;RH]EX;;T&4WA#BL%F*>MD@QZSQ?<5,5(:A)G19/=>ZM[W-MK`;SVWN#9
M^Z\30Y_:^Z\'EMM;DP63A6IQN:P&=H*C%YC$Y"G?T5%#DL=520RH>'C<@_7W
M[KW6GS_PI#^'_1/Q\_EO?RXOB;\9!M?XO;4P?\R3IK9?2V9K,]N$X7J:N[$Q
M7=.5S^^<IO+<%3GMRT^.P6X\\^<KZVIRB2H(M8=O&B+[KW6RQ\G>R?E/\>NA
MMFYGXX?'&M^=';>+R^S=J;HV4_:NR>B<MF\#_!:VFW'V*NY=YPUVW(:]<Q14
MSO0`,6%8Q5@D3-[]U[HAN/\`YAO\UR/>-%B]Q_R&^XJ79;M/#D=S[8^=OPYW
M+G89XZ.IFB;&[7R.X]K8NNHIJJ)(_+49FA8(Y8(SA8G]U[JNO^6YO+Y,]L?]
M!`F]=P?$K#[6^2.?^6.P*^'XN]R9';':FUH=QXGJ'9L6$V)G\_MO(#$;J\.!
MQU)6PY&FF&,!JZ:HI?0KJ/=>ZVT/?NO=:V'R:^0/4WPI_P"%$W0O:_R;R^'Z
M\ZT^7/\`+AJ_BQTMV[G=R08;:.W>U-A?(C)]F;MVUODU<T%%B*+<E%N'`T]'
MDJIEI8:RH@BUJ))WB]U[K9.5E90RD,K`,K*0592+@@C@@CW[KW7?OW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NJP/YQ>!Z!W3\!
M.T-M?)[M/L+IOI+/[VZ)Q.\-\]8;8_O?NNF>M[SZ\BP&&BP8PV>EFQ6Y=QFD
MQ]?+'3/+3TE1)(GJ4`^Z]U9_[]U[J@_^?)A-V9ZD_E,TFSJE*/+I_.5^&4\%
M2$ACJ$\,'9$]>D&0:H$],)-OPUX:**"1ZFP34ALLONO=%2^9^]_E#M'_`(5!
M_P`M+&=68C+;AZSWE\-NPML;_IJ?'RY#$X?K+*[YWI7]KYFMFG:EHL*V*SVU
M-FU,E4LQ=Y?LX-#R3112^Z]U9U_/6DW9#_*!_F$3[+RN3PV9@^->^IJBLP\:
MO6MMQ((#N^BU&:`PT>1VI][!52JVN.EDD90Q`4^Z]UJH?R1_^$ZO7/?'0_\`
M+?\`YI75OR[[>^/G:N*K\AV!OO:^U]L[>W9'G]R]<]Z;^VT4VMN7(9?%/LF@
MW/L?;\&-R5%68_/4LZS3,T30S/3GW7NOH)>_=>Z!K;GR(Z'W?VGV1T=M;N'K
MC/\`<?3U#A\IVGU?BMWX2LWUL#%Y^@ILIALINK;,-8V6P^-R%#6Q21U$T2P_
MN*"P8@>_=>ZU:^HOY>.S?G/WE\X/D7_*W_GJ]]=2['[5^3N>S_R*V!TCM:DK
M:?#=O(\+UU-!G)]P[%RM=@)\?"XPN:A2MH,C2DB*HJA3S&3W7NG_`.)O\U/X
MY_RB-_\`RC^"7\S/^8[\@?D-W-U]WO@JW:/:?<?3'8-7CTZ[[)VA@<MMO$83
M<6#R79-7-0XFI>>?*SY"2AI*>IG<47EI8V>/W7NMM&CJZ;(4E+7T<T=11UM-
M!5TM1$P>*>FJ8EF@FC=25>.6)PP(X(/OW7NI/OW7NM*G<,KY?_A([MC)G!UE
M$N`[1VAD:W;F$DBR,^XQM[^;#219*B6,35*5=9N2HADE,+24R-6R!3X8_2/=
M>ZW5$;4JL59"RABCVU+<`Z6TEAJ7Z&Q(O[]U[KE[]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[IKSD1GPN8@5!(9L7D(A&9WIA(9
M*29`AJ8DDDIPQ-M:JS)]0"1;W[KW517_``G^RE+E?Y.?P,>E^W"T'3T^%G2F
M@>GBCJL+O/=6,J$*.JZYO)3$R2+=9)"S`V/OW7NK%/E%)MF'XS?(J7>HE.SH
MNBNW)-VB&:&GF.V4V!N!L\(IZA)(()3BA+I=U9%/)!`(]^Z]U4S_`"(-Q=LX
M[^13\0\SMSJ+%U_8^`Z(W*_6?7.7[`IMNXKL8T&X]US[$K,KOA-OYR'95)V#
M&8*F:5J#(-C$J3JBD9#%[]U[K4M_GZ?S",!VYO\`^-'RARG2J_'3^9'_`"V_
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MGM7B9X8W8>Z]U0Y_+DI*7=__``JY^=DVR\))M3(8CX^=JS=>ST=3EL=A:#<2
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M_M2,+ZD]U[I1?\*(J_K_`'7_`,)P_B%OKXI02]7_`!QEW+\1=Q8/JC;N\JJ?
M;_\`H?W#UAN9-N]7;BK8,F:[>=/L_<F0Q7FB>HDF_B&,^Z<^6GUI[KW5D7\S
MO=6-[!_E2?R[MR[<HJ"+$=C_`"?_`)2V5P;T>;RF>H\#0;B[7ZGS6.GH-R;D
MR[9O+0T\#)3+75]14U<\<IDG8R,\R>Z]UL:^_=>Z][]U[KWOW7NO>_=>Z__1
MW^/?NO=>]^Z]U[W[KW1$_P"8MM7KG?GQVP6Q>TJ_<V-VON_Y.?"_"PU6SJ*L
MK-QMN,_+?I>OVM0T,M`AJ<52Y7/T-/2UU:KQ&DQ\T\@=2!?W7NAI[U[9?J[/
M?';'C=^RMJP]M_(#"=2S4N\<;6UM1N_^,=>]E;I@VGLRKI,_ADP^\ZNHV<M5
M33S0Y*%Z>DG@-,&F6HI_=>ZJ3V;V/_,LZJ[N^3G;.V/Y,6TLWOONK?&VZ/?.
M]<#_`#,^LX<=V3MSJ7`9;874.[<3LS>6PA'LJ%]FT5,M93F/'U4IJ1*\,LJ.
MD?NO=#%DOFY_-;QU?)1Q_P`E/,Y:%@J4=?B/Y@OQG>F>=HHVO6_Q+#8R6BI%
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MT\ST1K/=>Z,3_)D'\T#;/QL[QVM\0MB_`.OZ&VQ\^/F;MO:&6^0/8_=V,[;R
MT-'WGN.+,Y;==+U-LK=FTVDH*IC3TEIJ>HJJ2GC;Q)$89IO=>ZL*AZP_G3;C
M^6?0GR"WQU5_*OI:7K+&[NZBW-D<!W#\NLANAND.W=S]6;I[3J]F4-7UOA=N
M4^]HY>J,?'C5RD-?3&526,2.Q'NO="9\W/G]VC4=O1_R]_Y<.)VQVO\`/+<&
M/P>:[)W5GX?XQTM\)NH<Y6-193N+O.NH\GCX*G>L5(ROMK9:SC*96:>&ID@>
MD"0UGNO=%5_G=]8?"7;7P_\`@'L?^8IFOE)W=0[2^7_QIZ]V)O/J1]NGM;L7
MN"?`9W#UV>[+%3!08J7:V[\%C<E-FX\8L.7:>6-<85J-+#W7NKJ/DWNCY/[1
MV'A\Q\3NJ.J>YNPEWK@J;<&R^W.T\]T]@Y=@U$&23/9'"[QP/7_9,L6YJ*O%
M%X8:C&M3-3O.Y;6B1R>Z]U7W2=U_ST*G<$M/)\#O@!08.EH*AWFK/G/VPQR%
M?45>%2@6@R5%\4ZR>),;22UCU4<V,5:C2#'-&T2Q5?NO=4?;)W1VM6?'3_A3
M+VAWML+:6R>WL_\`)KJK8>_^M.INS\INW&[<&%ZXZFVI3U.VNS7I]G2YJGJ<
M'N,5=.TV)PTQJXYJ:L5%O#3^Z]UNH>_=>ZH@^6O2_5?R"_G0?&?J7N_8VV^R
M>M-Z_P`K;YQ;=S6T=R8YZRCKJ3<'<?QOVYG0:B-ON*">IV[F*B"&IIGI*JE,
MC/%.)"@'NO=)?;?R-["_DV=G;3^,WRZR>\]^?RW]_;GPFR_B-\Y-Z9_#Y6J^
M-=1DL=*F+^,ORRSU5)2YA]LX6LHOMMI;\R+.9\?)#1Y"662FEJ(?=>ZO^HJV
MCR5'29''5=-7X^OIH*VAKJ*>*JHZVCJHDGI:NDJH'D@J::I@D5XY$9D=&!!(
M/OW7NI/OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[JI?^
M>=04V3_E7_*BBJWJ(J:>EZ>$TU)1O754$8[_`.J6>>F@CAGF6:%0666-1)`1
MY$9&4.ONO=6T>_=>ZU^O^%`M+1UVU/Y5-!D/*U'D?YT/P1H9$ILA/0U;F7,;
MVE44Q2*6$,@@+M*0)8U0K&5\C,/=>Z&C?SRK_P`*`OC6L4<4BO\`RI/E$M2T
MBRL\$/\`LT?QQ=9H#'&Z1RM41HA:0HA1F`.HJK>Z]TD_^%)V;_@/\DKYWU7@
MK:@UNRNM\(%H3.LD?\>[RZPQ!GG>`%UHH5K"T]_0T0*MZ6/OW7NJ@/Y!W\X7
MX)?$G^7'_+P^)':^[.T\7V=VWV#OCK?:F;B^-/9.W>L<KO\`WUWEN"JJ<+1=
MHOAEV1OE]EUV_,10YK)8^MJYZ:2M@^XAB%PGNO=;I'OW7NM-#X*UF5RG_"D7
M^>EW[V)AJ#8V#ZI^.%9L?)[<:/<N0R^7V9A:+IN#;_8=))7X2LVO/0;FVCU>
M:^6D&=Q<RRU\:0TD\25,M-[KW4G_`(1:;YQ6>^"GRKV?1;9QU!6;7^6^0SU5
MNZ&G@ILSNJCWKUMLPXRCS4<:33!MNKMR40!JJH55JV5;:6:3W7NK(/\`A3E@
M=LTW\E_YH[P;;>TI=ST,'04]'GLKMC$9?(QU-'\C^I:>A,=168^KD,T$-5+%
M$9+HB2NI]#L#[KW5['7\C3;"V1*VG5+M';<C:$2--3X:B8Z(XU6-%N>`H"@<
M`6]^Z]TH<E545#CJ^MR-=#C,?1T5555^2J:F*BI\?14\$DM573UD[)#20TD"
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M]T>7Y"[73>_07>.RY*>FJH]W]/\`9>UY*6M8)1U*9_9>:Q+P5;EX@E+,M7ID
M.I;(3R/K[]U[JL__`(3ZMN$_R:_@(NY9J*>MCZ3@CH)*)/$O]W1N;<+;8CJ(
M[*!5P[?:F1VM>0KK/+'W[KW5*_\`/U_ED=;8K^8+_+C_`)@'2M11I\K_`)(_
MS$/BET)GML=PQ0[L^-F6;;NW:^JVMNS=.Q,)C</O>LEH8>M<;2Y&"FSD4-=2
M*55()V\_OW7NA4W?\@/GU\4_YZ^U,CW1TEA/F3NK?7\K/<&WL-UE_+ZVM4;`
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M&[>F7H:'*5U'2_PK"?WXQU7-BL@`]-+3PTZ1/(D\;M[KW1U/^$AN\LIC?Y9O
MS(VYUK4=9;]^0^VN_.P>R*;J&HW!N?`;AHMP[EZYQ.W^M\+W#N/)XJIPN$I-
M[[IZQKHJ6MQ4-6E/CT:6H)G!BC]U[JS7,?+#^>QC]E]=9[/_`,G#XV[F[;GW
M9+MR.NP7SEV_5T.R1FEJ:$;MK\&>M\H^`VV^+,D%9/3;EKIE64&1(T9D'NO=
M4M?S1Z?^9C\G/G-_):ZG^<_5WQ+^&S5/S,DW?TGW-UKW1G>T\:-Q[1J]@[KS
M>Q\[@=P82@AEW=EY<!B*;`))"M#DLQ50TC31K+)I]U[H6_\`A2_NK<G4WR$_
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M;NEP?46\_D%L#;O;>YY\?`LM104>'V#7US2Y&..1L:C&I.A8S+'[KW0=_/WY
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M=V!4U=%+'/D<@\DV'BC@MD9*B'W7NCG]-_`[^<;\2<SW/LKXP_,+X+9#H+LS
MY%]^=_[:QO>7QI[1R_8.Q:CNWL3+=C5NVH:CKSLW9^&S5'_%]Q59EEJ)"\#1
MH(/V7$%/[KW507\S[^;#_/?^$>ZNQNE!NWX#]FYK:O0-?W9WSO+XN=0]J5FY
M?B#UCN'?N'Z\V=O+.3=Q]G0;2DWKN67<-/48'&5M-733R%I)*22D2.IF]U[H
MXO\`+J_FU?\`"?7X&?'S'[`ZD^1W9T&Y-^5\O97=G8W;7QX^3>X^]>X>U]Q*
M:O<F^^X-V8CJ'-8_-[GKZN:0K'15D^-I8W*TQ(=Y)/=>ZK__`.%!?\V7X-?-
M387P8VW\9.Y]X_(+;/2_S8ZV[Z^1/6O5W7'=&U]T'J/9F!J:C);FH]Q[AV!M
MNBQM7AJ7/U&/A>.L6:FR=;R@DI9##[KW5S?:7\]+#?)WM#I#XG_R8L]T!\E/
ME#W)C>P=YYW<7R%7M[K[I/I7KSK;`0Y7(U>]J7';:P_8&<W9NNOK4I,31XR"
M:!#3SRU4B1B/R>Z]T+N#H/\`A2?''BLCG-P_R8:F2GIX&RNV8,)\RX%R4K4]
M.*F&+<4=9(:"1)_)HE6ED358F,KZ/?NO=$-RG2';M%_+Z_G7]M=H=Q_%+>/R
M`^1/R@VY3[_'QDQ^]<5TKU'V)TW'T-U;5[.J\]VG2TNY<WN/"9'"^?,Q$5,"
M922=(I)*F>:GB]U[K;&]^Z]U2'W3NB3&?\*!?@Q@9J9'I\__`"Z/F+C:.H%'
M$9(ZR7MCI+/U9:L.3\NA*79R*JBD7QF9@'E$K?;>Z]U;;W-TMU1\B.L=X=,]
MW;"VUV;U?O[#U."W;LO=F.BR6&R^.JD*D/%):6EK*9[2T]5`\532SHLL,B2(
MK#W7NJ$>M.Q.W?Y)/>>W_C7\A]X=M]R?RI.TGVWMWXN_*CL"&3?6Y/AWV;G]
MP4>T]K_%/NG=6(-3GINFJFG:!=K[LS5/%'125%/BB[1QO)#[KW6Q[[]U[KWO
MW7NO>_=>Z3>Z]Y;/V)B6SV^-U[;V;@DF6G?-;KSN+V]B4G>.69(&R.7JJ.C6
M9XH'8*7U%48VL#[]U[H`*#YP_"O*4LE;B_E]\7<E1Q-)'+5X_O\`ZHK::-X0
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MNJ;_`.=YW9TQVE5?RN>INMNX.F=_=FM_.,^!6;EZ_P!N=K;>R.^Z#"4VX-X3
M3;FAV]MG)9+-T^.I$95EJJB`4B13$W:0Q#W[KW0X=ZYS,X#_`(4)?`2FC?(4
MV&WS_+U^8VTY&2%CC\E)B^Q>JMYUU`\S021ZJ6;`8^>0*R,K""[6<*_NO=6@
M?+OXL=4_-KXW=L?%?NZ#/3]7=R;>@V[NO^ZV6&"W'30T68QFX<9D<)EGI*^&
MCR6+S>&IJF(RT\\#/$%EBDC+(WNO=?,0_FZ_R_.OOY1/\T'X1]!?'GO3M;/]
M029CH_Y";9V[V-NFHW=NCJS?60[B7;>XMS0XO;6SML[8MGSU]1U-+)CZ&7(U
M'V;0SZA#3Z_=>Z^KZK!E5AJ`90P#*R-8BXU(X5U;^H(!'Y]^Z]TGMU[4P6]=
ML;HV?N&B%9@MY;?R^U]PTR2/32UV%SF-J<3D:4U,#1U$1EH:N1`ZL&35=2#[
M]U[K7`_X36[?_ET[!ZW^;W5O\OR7Y3-2=??**LPW<E/\K*;8-+NBAW'28VMP
M6VZ'9Z]>U=1CJG9M#0;>JZ>*HKHZ?+3U$4KU$2`QJ/=>ZM%_FW_#;>O\P#^7
M?\E?B5UMF]K;=[#[5V[M0[(S.]JBOI-ITFY]D=B[/[$Q"YZLQ6&W#D:/'UE5
MM,0/-#15+Q>4-XV`(]^Z]T0;^5G\U/YE.>^<'R._EP_S(,#\5Z_?WQS^.W47
M;>W^T_CA)O#'Q[VH-WSXG!K59#%;D:GH\@*TSR25LE-BMO1X[(PM%#22TM33
MO#[KW5Y/=/6E#W1TYVST[D\G5X3&]L=9[[ZTR&9Q\4,]?B*'?>ULKM:KR=##
M4?L35=!!E6EB5_0SH`>+^_=>ZT.MD]`3]!_\)&^WJ"FWGCFR=5\THMZ[OS]+
M?7@,AUK\_.N^F99,/24N*42Y9$ZBHZV*"NJ)HO\`*#>K$8BA3W7NOH&0L&AB
M82>8-%&PEL%\H*`B32H"KK^M@`!?W[KW67W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=51_R0MQU>Z?Y8/QIR%96/D&H*
MGO':M)6N86^XQ.R/D9V[LW!O&]-''32P?P7`TXC:,R1L@!664?N/[KW5EW8&
MH[#WL%<Q,=I;D"RC[6\3'#U@$G^705-%Z#S^]')%QZE9;@^Z]U2I_P`)I,BF
M3_DH_"N5*[^(+28WN7$I-XX842GP_P`@NU<70Q11QI'**=<?21&/S#S>-EU6
MX`]U[H,?Y\-!4Y+O+^1=2HL34C_S@OCX\_G>`P_<08_.55,&@*/5R.88)M#(
M/$C?YSED(]U[H"OYBF\._-I_SWNEJ?XR?%^B^7/9F]/Y1W<^Q,]UAF.^\5\;
M<;A^OL_\C:#^+;TINS*RBR-=%D:::E./%+1K35MZ^.HIZB-H'(]U[HQ_1OR0
M_FQ=,;+PW3>T/Y*NSI:'8&%Q&(Q^)JOYO/7G8&Y\5MNFA>EP<.>W+V?LW>G8
M>6TI!(D%1DJ^H=E4@,=)]^Z]T(G\P7L#Y)=G_P`C/^85NKY)_'W"_%[N&;XM
M?)&CRO5-%VM@>[L9C]MX_;&8BHLK3[\VE0X7&5]1G<`KR1((4:GF*^5+7C'N
MO=5I?!7^;G\E.S?Y_':/\NS.[TZ_K/BOB?CSBL5UEL3;&P<!@)^O>Q]E=%]3
M[XW!%C-S56*I-Y9>IQ66_O%CZJCJJFLQX6,-3Q)'`CCW7NAS_P"$['R7^:7R
MN^/O\PWLSLZNZ6SN\<)\F-[]8](;K?H?;/1B;GWMLC9$22Y'N2CZEV]MI]P8
M)<EE<(LA:GFW!0H*Z)ZB0&E2+W7NC0Y>'_A2WB\5A<9B:_\`DR;IR>2CJ*#-
M;F.+^8>`&V)'J&-/GXL3496K@SZPT\X!I4$','.K62/=>ZH!_G&8W^;QM+Y`
M_P`H;)?S!=__``:W_P!?#^91TM7=98KXM;2[(VSN:BWMC-Z;/F(W'5=F125I
MVS7X6:5!'25A`J50U(8K`Z^Z]T??_A1%\;^W_E?\Z_Y;7572?RVVM\,=_P"'
M^/GS^[#VQW+F]X9G8-90Y/;^/Z&A&V(=W8'-83*X6GWI45--2S55-*9J#'PU
MU8(:LTZTLONO=#A_-'^!7SO^27\@KISX98O;5)\N?FA3X+XS1=E;RK^VL!12
MIN?8,='N#?W8^,WMOF;;%)V)/4/C9<-&]5+!79"GRK5KF6:-A)[KW0?_`#:V
MM\D^G_Y!7\O["_(;9\F!^0OQX[O_`):>([!V=B,OMC(Y*+*=8]_]>[(V]0X_
M*X2LFVE69[(T5-C&=H:DTBU,SWE(1C[]U[H#?DY_-M^>&,_F"?-3X[Y?^8%_
M+N_EK]4?'#=^.V[UY@?DOU+OS<W;79NR<MM&AW-@.S]L+D8VVIO6ESZ5;W6@
MRD,T#JD7\--TEJ/=>ZNB_D;_`#=^1O\`,!^$<O?_`,E]N;9Q6ZF[J[,V+LK=
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M8SY"4?3^Y=B]B]4[3W)M?:>P/F3B-O[<SE9U'LCMZ?<^`S6.P6ZMF[RFIUP6
M\:4TF3QU%++0U4M3C&^WC]U[JEWN_MC^5!VSO_-]K?*?^51\_-H?)?=&*HH^
MR\3B_A3\LH-RYZLVZM-B,H]?OSX^:>K>U:7"Q(*1L_!E:Z'(XRGB19Y(!#$/
M=>Z)OL#NW^2;W)W3\E>AMR?RV?YE/75%T`>NMM8S^';-_F.9/,[TI.T:.!\9
M'G>E.JMU9'<G44U<^.CJ-O0[HHZ:;-8IVJ*=897J*/W[KW5EO\I7M#^5Y3?'
M'Y)=88O8NROCPO7'R&[IVSW7U9\U,G+C^^:S:!SDJ]9;X[YIODJM+V348S>7
M3T6':DBSCU=/CJ6`XU9;T4D<?NO=52]';E_DI[CVYO7'5/Q+_FH8#;V=[2[V
MGV/O3XZT7\R#(_'#=G5B]M[XP'6>7Z`7X^]@?W`I^ILMMEJ.JPU%0X6GHJ"=
MFIP/&BA_=>ZX_(/JG^7%NOIS=$WQ1[+_`)\GQ'[>PDU!D\%\C,=U)_-P[4Q/
M7AQE1#-N3';HVCO#(46+K<=D]LU4L4IAKL?4TSSP3)4Z%E@F]U[HN?R<V=_(
M(V%\5_D.<PO\X'`=A]@=:UF-WIW/V!LW^8)1Y+LGLK$8RCV]M_>/9N)[/K]A
M]%[TS=-GYZ131;@:DQ"&5:9?`&B`]U[HS.P)?^$XIVIM*@INU/YI$4-)M+:&
M(@J5K_YO-+!'5?P6%('BH=I8NMP%%D%AAU&FQX;%H([4:M`HO[KW3\=\_P`B
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M5%N__A0W_+L[1_G"_$[OWI.C^2/>&W]L_$'Y`]"U^#ZP^.NX,MV%E^Q.T-_]
M5;QVAM_:VT*ZMQ.\]V24V,V+E?O%AI/MZ-I(FIWJ//4F#W7NKKXOY\72-1,]
M/3_!/^;=43QR5$3PP_R[>YWE26D+K51-&$UK)3-&PD!%T*F_T/OW7NF#M'^;
MI\;.W>LM_P#7'<G\MK^:ON/J;>&TJ_!=BX/?'\MSMRMVS7;4W`)</-39O'5E
M/5-+#6SOHC`A>2-],UE1?*ONO=5*_"'^=%L3^7)N'M?H?O'KK^8/)_+2VW#M
M^L^%_??>WQ+[4P^]^K(<G)*F8^.&^LMFC4Y[>NV-NY*M@H=JYR=#5@1M25"K
M"*:1?=>ZMCP?_"C7X`[JIJW([1V)\XMVX6C6)_X[MGX2]]9C#U"3K224S15=
M)MAS$*FGK8Y8_,L6J(AO[2ZO=>Z4=%_PH0^!]?+C8J?8WSD<Y3+282E9/@A\
MG)PV12;(424R+3=?3R553/E\54T"00+-4_>02(T:B-V7W7NJN?G1_-N_E?\`
MS%^:O\MOK*GVOWG\LJ;HGO#OKL+N?XU87X@=Y;FWAMO.XWH3>>V.O\AO/H_>
MW7^$W!NJOVUO3)Q5RT-+CLA)0PQ2552L21^.7W7NCL4/R)_E.]@XZ3#[@_DS
M?)*BQ:RM_!Z+='\DGLRMH\U0ICI`<U@UP?1V?BAHEH*QXU,QI:DI+98R'%_=
M>Z"')_-#^3IT:V$GP/\`)*^1V#CW9E4DQ=9M_P#DQU.SER&Y(ZD8Z6@QS[EZ
M]VG+D\WC()Y7>.C$WC@1UC)D*QM[KW08=[?SM?Y!W4'9^/ZCWC\"-Z9W>M=F
M<708[%UG\M_;6U<E49?,;CAVQ514.U^VL#L3?=9D*-J2.5XZ?$R2U(6."`2U
M(\"^Z]T)VZ_F)_)&GW#6;>W1_)X[?KJVEMEZNLJOY-.;>2',4U<9Y:::&?JB
M'<%/FJ&:A:>9WIUB3PF\I<:??NO=`[VU\W/Y!#=>[DAWG_)Y[8I-F)M/=BUF
M[&_E"P[6I-M8&LPLG\8W)C]V9+9^V:O;'@QP^Y7)4]7234G@6?S0M&D@]U[J
MJ;IK^8%_PFK[!^&>TOC'E/Y8?>&[LCM+K'9>&[F[EZL^&?5%;VOM6HPV2P=7
MG.T\OW30]F;L[3Q&+RFZHW9ZJ?*UM5)12-0R"2)Q`_NO=6_R_+O^0_-1"KP?
M\CWM'=$LOF>+'X+^2GC7JJB@255I,K%)7=:X_'OCLG3R1U$#>;7X94\B(YT#
MW7NG[8OSV_D_=5;RV9O_`&1_(Q^4W4F\<+N'$UNU>Q=N?R<<+M#/;1R$V0BH
MJ'<^&W'MS;L.?H):1ZE9(Y,<7KB'"PQM*PC/NO=5Y?([_A0YUGN7^=U\(=W_
M`!PZ,^0_:.W^L.L>Z/C%WEU'E?CQN&G^1<&6[AW9M3.[AH.J>KLIFL5N>/?^
MV*OJS#-4)4Q4TAHUKJ5HV636GNO=6C=;_P`R/^:/\X>IOEI\V/A5B/B5T]\;
M/C5O[LC8FT?CE\L^ONSYODEV'7=`X?#Y[M.F[7W3M3LK;NU>@\_N&EK:B+'8
MV6@RTN,J(XXZV18RU8WNO=:D7\Z+M;9WS\_G"_`+MG>^[H_C'TY\F/C%\!M_
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M4BCK.R)<JJT[0^.HK::>8J*B242.IC@34$2,#W7NMA/W[KW6FGV`F:W[_P`)
M7ODP-P9:EQ>Z:'O;Y!U6ZWV)MBDHL;/GMO?S5=S9',8BEPT(J1NG&95Z<Q$N
M/N,A%*$DU2%M?NO=;D\`TP0K<M:*,7,7A)L@%S#I3Q$_ZFPT_2WOW7NLOOW7
MNO>_=>Z][]U[KWOW7NO>_=>ZH^_G*?SL-I?R<X.ALIOWXV=E=V[<[TFW[04N
MYME[CPNVL/M3-[(3:]1'@LO5YG&UT,^3W#0[BEJ*6-61C%03M9@IT^Z]U8S\
M(?E!1_-3XF=#_*S';`S_`%?C.]MA4'8&*V-N?)8K,9O"8G*U-6F*:JR>%9L=
M6197'P1UM.ZB-_MZB,21Q2AXU]U[HU'OW7NO>_=>Z][]U[IJSLDT.$S$U/*L
M$\6*R$D,[",K#-'23-'*PE_:*QN`3J]/'/'OW7NJ1/\`A-ADZ_*?R7/AP^1J
M8*VIH3\@,.*RG$0AJH<1\GNZ,=3U"&"26!EFAIPP,;&,@@J2+>_=>ZN@["E$
M.P-\3&:.G$6S]S2FHF77%`(\+6MYI4,D0:.*VIAJ6X'U'U]^Z]U1Y_PF*+O_
M`"4OB/.RJJ5.7^1D\`$<4<GV[?)WN)814)'24K"H"I9_(99+CU2'Z#W7NF7^
M>41'WG_(RF8W5?YPOQ\C*)2RS3,9MO;P5726)V:.-"/6OB8-<,60(=7NO=%_
M^=V\_DOU[_PH3^.FX_AYT3LKY#]SS?RH>V*'.;![)[;_`-"VUAL*#Y#S9&'+
M8W>8VIO`?WD7<U+!11TDE)X9Q6HTDM-&CSK[KW0D_%'+_P`V796`[I[3ZW_D
MJ_#/XQ]A]I;VKMV=B8[LOYZ9+*=Q]U;G%'35$&Z,QNO9W2/9]#EZ.-LC+1T,
M&;W)CS1_;RI%#!3F)Y?=>Z,#\]=X?)S?7\CG^8=N7Y<],[`Z"[@KOB?\FEJ>
MLNN>T'[APN%VY%L'-1X"6NWN-N;9I*[.5L(=ZB.FIWIX@4TR$EE7W7NJ^OY2
MW\G?(?%O^8?V?\\^Y_D#T7-W!W%UL,MU3\6NK:VGSF?AVEOG9.`?+;QW1N/M
M%J_L/$UL]?C:V)Z;``XUI$>0Y&2C`H(O=>Z8_P#A,#T/_,#Z,Z3_`)EFQ_D/
MU5OSX^[BW9\B\EOKI>H[UV)7'%5W:^Z]K;AQV^MY)2"KVWG^QMG4N2PNV7J:
MBDKH<=DD1UH:M)'J)$]U[H^>Y^AO^%!F%H358[^9'\'<A435\-#24M7\'=W4
MT<DE;)2PT0=\)OG=-=`AJ9I%E;[=XX(8UE>32S^/W7NJ(/YU_7W\R/8/?_\`
M)CQOSJ^3G1?R%ZWW!_,(ZOJ\..FOCA7]2U^T]YX_>/6,-7!F<EE-W[@P^XL7
M6X;*5:T,,E1BIIC'-(\4J)>F]U[H>/\`A4Y2?"'`_+7^6IOK^8EL3Y`[Q^+U
M3U?\O]KY9?CI6[=QV]TW[33])Y+92O/N.NPM)5XJFDKZEZBG6OI9KO'*IDCB
MF@F]U[H3_P"??\N=C;]_X3G])_(7XZY+N[I?:W;VZOC%#T51P9C^[&^L5@Q3
M9NJHL#V!D]M;SK9(\:=B[5KG)IJ[)--7QT9=;-)+#[KW2_\`GCVCVKWU_P`)
MU/@[W5V)1;@Q._MT[O\`Y9N[^QLCF)LWB<_2U$_=G5>+_OC52;IRO\;RL^>S
M$]%6QU=3/*U7]\E<"$(D3W7NJ$?^%'S_`!V[-_FG=LXFJVSWI-NOH6DZ(R7R
MKSW8OS`^/VUL+G/C1E=O8?<6Z>K_`(5]+=L0C.P[SR>(W)#DZ<T&8J98LL]9
M-_=_Q57W4GNO=;5'_"9C.=C;M_EET6\]T=A;XW[U3NCY`]VS?$ZF[/[`PG9?
M9>P/BUM[-T&S.M.NM_;DP-34T4&Z=M5VV<FM30?M?9&0(D,$)C@C]U[K80]^
MZ]U[W[KW7__4W^/?NO=>]^Z]U[W[KW517\\NLGH/Y<^^*B*JBQ\"_(?X(?Q'
M*SHCPX?'+\[/CA)59:4RND$<>/$8D9I+Q@+ZA;W[KW0`X_Y+XOX]_P`X_P"8
M&V\AL[/[KG^157_*CZ'I:S$L:6AV4=X;!^?N>HMZ9VKGHYJ.?%PY+88QWVJR
MQ5,LU<C)=48'W7NK\_?NO=>]^Z]U3U\6LG]C_.1_FP[87;;4_P#&>D?Y=6]Y
M-U&G\1R'BVAWMM2'$F955*FGI/X4[Q$WD60SJ25"*ONO=5?_`,Y_XT=!=T?*
M7YV;T[K^.VS^U*OJ/^0AV5V/UCN2HVX<MO#$]FX+M_MJIQV=PD\5=%)19W98
MQ%!)0UL:154%-6UD7EEIY9(5]U[K:$ZDH<7C.J>LL;@\#0[5PN/Z]V90XC;&
M,H:;%XW;F+I-N8V#'X''XRBIZ2CQU#AZ2-*>*"&*.*&.,(J*H`'NO=:W'QK^
M(?R>_F82?)[Y4;V_FK_S!?C_`(?)_-#Y;]3]-=1?&'MW;&P^LMC=0]&=Q;HZ
MBV/2UNVZK9>8JIMRR5.T:JJJYFGA>K@D@+@N6E?W7NE3V+_('[5[N[&QO6?R
M&_FE_P`QGO\`^#65ZOGI^SNINP_D%B(<SV%V#B-Y83*;2V[G8=M]>X?$9+8:
MT5*V0K*JHBDRQKZ&GC28(Y>'W7NC7+_(1^%T6*V-A*3M7Y^4.(ZVQM'B]E8V
MD_F!_*J/'[9IL;028_%C;M`_9,E%MA,7$R&GBQ<=%3Q>%$$?BU1M[KW7'>W\
M@GX.]GXO+;?[3[`^=?:.V-STM+!O;:W8?S]^5V[MO;]GIUQ8FR&\L9F.SZF'
M,5E?)A*1Y0=$`>FB\<<8BC"^Z]T1/,_RY/BI\#_YP/\`)^QG3^WNU<[M'LCK
MGYT]4TNU^Y^W.R>]=B]<Q["ZAP'8VSI.N*7M_*[T&R*V>I?*Q24.*J:2"1)1
M4"%3%(TGNO=/U;_+Z_E__+#^>[\F=M]@_#SI'=.S_CQ\".@L=N7"U>PZ6DVC
MF>Z.V>S-];J@W5DMOXFEQVU*[=6*ZKHL?1)55$4M=]M.+-IC3Q^Z]U)Q/\I_
MX>9KO;Y&_&?^7+\W/Y@7P0[I^*^R^H)=\;2Z8^078V[OC_L-^]:7=&[NN,1-
MUWVKG=RP[@,&W]NUU;+BL?E<9!0IE:>82"5[)[KW0PXOXP?S_P#XZ1^7I?\`
MF*_%'Y];1Q>2-/%L+YH]"U_4NY*K%0+5TN2QDO:W0];G<A6Y^@KC>*6O@8-+
M&JS%41HW]U[JG+Y`0?'/M[LG9OR?_FI_R'/D'UW!L+!=I[7W3\H/Y<G8&"[I
MZ!W-5Q9S'X7*=P=E93XUY;9'8F*INO6V[DWHLI7Y2HKL=%YJ:I@KV\,-'[KW
M0Q_$'#=?;MSSXW^2Q_PI"W'5UN8J?-M3X>_-^#%]Y"NI\901U>X:3#[5[II=
MC=T8G%T..H:^MDJ,'AM:((5EG$<1E?W7NK.L1\[_`.<O\8?LZ3YG_P`L+!_*
M786/JZY,K\@OY:O9]!O'*9#;])CZ"2@SE!\9>T:K$;ZR62K)%GDJ5CRU#"S2
M!:>$+%>7W7NCA_&/^<)_+H^8&1IM@[0[YV]L?M^5,(F5^.WR+Q.1Z'[MQ>=R
M8C=-MIU[VO1[=J=WYG%9`?;SR;>DS-$M2H\=0ZM&[>Z]U:!&D(5#$L82RLAC
M5=-M&E"A46MH-A;\>_=>ZYZ5X]*\&XX'!O>X_H;^_=>Z8HMJ[7@SL^Z8-MX&
M'<U5#]M4[CBP^/CSM13Z(H_!/ETIQD)H?'`BZ&D*Z446L![]U[I^]^Z]U[W[
MKW24S6P]C[DS.$W%N+9FU,]N#;-1%5[;SN:V[B,IF=OU<$IG@JL)DZZCGK<5
M40SDNCP/&RN;@W]^Z]TD^[>].GOC=UGNGN3OGLC:75'5^RL;-E=R[TWIEZ;#
MX?'TT2^F)'G;SY#)5DEHJ6CIDFK*RH=(8(I)71#[KW5*E'N;Y/?SG]P89=O8
M'L;XB?RE\?FGJ]SYG=M+D=C_`"6_F.;?I)*<0[0QNSJW'09KI/X@[R1:B/,3
M5TL.X]Y8:1*98*.DJZJ./W7NKPNO^INJ^I\0NW^K.M.O^M,"E/2TBX3K_9NW
M-FXA:6B1HZ.F7&[<QN-HQ3TD;E8D":8P2%`!]^Z]T('OW7NNB`P(8!@?J"`0
M?]<'CW[KW5&?9NT>J,1_PH6^)VZG3K/"=B[J_EP?*6,(IH,/V)O',8GMSI6F
MQ%74_:8-:O=#8S9G\<CHHZRO9TH:?(24Z*E)/K]U[IX^3G\A'X7_`"9[9["[
M3DWQ\I^BZ3OC<]/NCY3=2_';Y!;LZPZ5^4]<E.:6O/='75(E?BLA59^#T9"K
MQ9Q=75^2:5Y/N9Y*@^Z]T8KY%?R?OY<'RMV-\=>M.]/B]M#=VPOBCA$VKT1M
MFAS>]=GT>RMH1X/&;?39_P!SLO<VW\GF]K"BPE$YHJ^>IA:II(YF!D,A?W7N
MOF'?//X^=`?%W^?INWH/XJ;7ZCR?3G7'RKZ5H=G=:]W;AW-D>D*?<512]>9_
M=75?8^XC497<K=>T785?78:O\DL\M+1JT,K.(G)]U[KZ(G\M?YS?S`_D-V-_
M,=^/WSV^.?4/4.]_A@_5V$P^2^-PWMNW`[NJ>T^M]R]AC#8JEW%N#<=;O'*4
MFT?X'6TOV(HVE_BJTTE,DU@/=>ZK"_X1T]9[GZ]^-GSFGWOUQVCL7=&>^604
M5_96SMW;-ES^`P.TX\52T]-1[C@IJ.3-[>W.N8@R\=.IJ:6JD6&J<E(E3W7N
MMPNMKJ+&TD]?D:REH*&EC,M365M1%2TE-$OZI9ZB=XX88Q?EF('OW7NM>#XN
M9S:FY?\`A2)_,;R.U]R46XTH_@'\5,=DY,7EX,IC\?DGS\-8V/C-'))3(XQ<
ME'4%;LR&J8W'D(]^Z]UL4^_=>ZTV\MA,G2_\)=/E91;EJ,GU#]K\@ODKELGE
M\?@*VARE)AZ/^:+N+*UM:(,Y41U5+'54D,E.*^!FEH:95EA26:`1O[KW6X[2
MO%)34[P3_<PO!$\-3Y!-]Q$T:F.?RKZ9?*A#:APU[^_=>ZS^_=>Z][]U[KWO
MW7NO>_=>Z][]U[K3B_X50]6]Q]Z]P?RR>L?B_P!/57R0^1]%6_*GL/`]%;FP
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MQ=H?:5RODJK(0-`CU:TTPE@/NO=;;G8>*KL[L#?&$Q=;)CLGF-H;EQ>.R$*+
M++0U]?AJVEHZR.)V5)7IJB57"L0K:;'@^_=>ZI'_`.$R<7@_DG?#FG;09Z:J
M^0]-6/$\+TTM;3_*#N>&KFH_MX*>%**6H1FA55"K&0!Q[]U[IB_GNU*X#>_\
MEO>E=!2M@]N_SFOB919*I%3$N7IZC<U#OK#XM,=023P&OIIZES]T5U&%%5[6
MN1[KW15?YL"_S`:C^=1\-:?^6K#TEMOY!0_R_/D)4[HWQ\B:-O\`1;6]1GN+
M91SN&JZS'4.0STV7V[N6#%U$,=-&S0')AC:&2I]^Z]T8GK;<?_"D^3J/`[SP
MF\OY+'R4FW*T&3PN9PE=\E,?B\E@:]Y6BK\7O':-5C=E9O%01H#'-34I>4,!
M=RK.?=>Z6WS3JOF_E?Y"O\P*L^>F,Z"VS\DJCXP?)Z?-XCXXR[LK.ML?LN+`
M9YMMT256]*[+9.JW!/MJ(BJDCD\&J1-(1P]O=>ZK:^._\MCYBT'_``H$^*OS
MXW1U_A.R/BU-\&>MZ*#NV',44T6RMUX3X=XKI^;'5E+79+&[ER^]LUO8RU%/
M5RXF*GJ,3F'E6*&:G?P^Z]UM[[FH\OF-M;DQ6V-Q+M;<=?A,OC<'NA,919YM
MKYVLQTT.*SK82O=*#+/AJR>*J^TG*Q5`0(Y"L3[]U[K6][)^!O\`.UZ^V6=]
M;J_X4256V\7A:.G?>.0D_ER]$Y'&4U97Y2FQM!_"*'"5\V5E@EJ:^*(WA9R[
M`Z54&WNO=43_`,Z_X4_.GXL]C?RP^X/E;_,]['^<\FZ_G7U9B,;L+=/3^W^J
M]@[$W9C\KM[.)NW:^T]O[KS6UTDJ8*6HI)8&Q<),,B@N5UHWNO="3_PMER$V
M1WA_+HV?N?+9G;G7(VQ\L=SG+T6'QV9IJC>M%0=308;&Q4TN1Q-8\]14I24U
M2QGM34E>:B*&H>)XF]U[J_#$?R^OB)WU_(O^'WQB^=?9?6M5T+U#T9\==Z[D
M[IZ@['P>SNKZ?+;!VQ104^\MM=IYFC?$C;.:ILS4TE9EWCI6R4-?43#[5YP(
M_=>Z!?\`GY]2[$^-O\F3JOHOH3`1X+KKK3Y!?"+876F#CS!KY:#!;>[?VLVW
MXH-R;D?+^6LFDH8B]=6FI5S([RAU8@^Z]U2]_P`*<?D]2;.^9W^A[>_Q$^#6
MS.O-YX/K7K_=GS\W5UOTM\M_ESA-DYFAV_N')9G;'2>0W?@]Q]>U/7_WV4HL
M?3;AH7?,P(L^/KJ19873W7NMG;^070?&7;_\KCX[[,^)?R,R_P`HNI-CKO#;
MO^DW<&R:7K7-IO*7=63W#O+;=?UXE!2Y;9J8G-9YWI*+)SY+(?85$$KU]9'+
M%.WNO=7)^_=>Z][]U[K_U=_CW[KW7O?NO=>]^Z]U43_/6:*+^6-W96U$<<U'
MBNT/AWF\A%)DI,.LF-POS4^/.5R*#*01S5-#(U#22!9(8Y)U:WC1Y-*GW7N@
MBA^+6W_D3_-\^6>Y.QLMOG&T?Q[V_P#RK/D!U)#ALY'1T$V]MBO\Y\:CRQ2T
M52TFV*^DW'E<?7T2-&)S4S/J#-?W[KW5Z?OW7NO>_=>ZJMZJFIS_`#F?F=3B
MJKS41_`'X+2_9S9>BDH%$O=7S56::APL3"LIY-,4(EGD!U%@.%*:O=>Z))_,
M=A>'Y3?S':[[SR1R?\)X^VXCB96JC`7HNT>_)EK!"P%$XE6K,4I1A*`%#>DH
M??NO=;!FT6U[4VPVE5U;>PK:4%E6^-ICI4<V47X_P]^Z]UK*_P`N#^7WTSW'
MD?YA/8G:787REZHS<W\V#YTTV(V#T_\`.SOGI78N)PF-[/IJBAD?K[HKN';&
MSJ;-9:2J>IK9*FF;(3"2/6Q@\'OW7NC#9?\`EB;7V3\QOC74;)^0/\R'='2V
M<B[2W%V#FZG^:IWE4;3V1V+LW)=?;JZBVMGNNMT[KR6Z>P-N;]I8L_0>"@RR
MF*.F?[V">-UFA]U[K8%]^Z]U[W[KW56W\QCHCY([BW_\-?E]\3MC[.[H[B^$
MO9?:.Z!\>=[[YAZLQ_<^PN[>H-Q=/[XQ&W>S:O&9G$[/W]MZES$%?BI,E3MB
MY_',D[!O$K^Z]T&_\J7I?Y9T787ST^9OS2Z;H_CEW%\V.[>N<U@^@Z/M7`]P
M/UEU#T;U)@NK>O,=EMV[45]LU6>RC19"KJFHY`DAE5C#3W\8]U[HVWQ4^.V?
MZI[C^=O=F\<5C,7N?Y4_)?%;WQD>-S)S>KK'K#H[JCI'KF:OF>GBEQ^2RD6P
MJ_)RT(>2.C.1$:V(>_NO=*SY9]E[5^)GP^^3G=.-HHMLX[K'J7N7M58-L8^C
MAK*O>,^)W#NIZC%8Y:C&09#=6Z][U_D5!+'-D,G5_J,LMS[KW5262;>_\K+_
M`(3?XS&8*7<V'[YZ\^%>`VQ@!&:O<.[:;Y5?(X4>)HX,0E)'3U];E8>_.W#]
MC&%::/3&K>5U.OW7NHG\R_H'X>=#_P`H*I[`^<'Q)ZL^67<'6GQYZ2ZER->N
M(P>W^[^R>]=S46Q^IH*G8G=;;7R/9F"W=F-^YELD*VC2HR3K'(_V\TA,3>Z]
MU3K0R?##I_\`E];K^3_\F#^8S_,'ZTWWU;W9UW\8=B=!;K[`W9O?J[<OR.[)
MW#MC%;(ZGWKT#WWL@XK%[<KZG)+439C%14HCQE)7(JU4\9H_?NO=&LK?D'\[
M^XMW_(+HWYO_`,F?XV_S@.N/B;V32].[V^3_`$3BNL]O9.NWGDMHX+=6=I-@
M=-]^4V8SFY=Y[*VUOZCQN47;59C8\?6QR@U"L2%]U[H,_BYVS\"-Y;P39?\`
M*Q_FW?)?^6W\@Z:OBQU3\`OG#4[F["Z4P6Z-GP0-E^I:WJ;Y+SR93;V4QKTL
MV-K8]I;Y-7&D$B01R+3*B>Z]U;\/GA_-6^,4%#C/F%_+!RWR7PBY%<<O?'\L
MS?6([,H<W2!ZU8LO6?&_M?*;3[1VK+6T5$M40F4R6/C,XA:J230LGNO=.+_\
M*%?Y<NSJ[+X'Y'Y#Y)_#3>&':&1]D?*WXG]\];;EKL;/#%(N<QT>+V5NO%38
M8R2^,3/5QF1AJ16C*R-[KW6>B_X4>?R5J^.M>#YU[%0T$233Q5>Q.X\?4-')
MKL::GR'7---6%=%V6)79`5+`!@3[KW3/6_\`"B_^61E:REQ72V[._P#Y1YRN
MPL68H<'\;?BOWUV+D*N2IR=-BZ'#0M/L?`T`S-=+4&2.-YUB6.,B21))(4E]
MU[J13_,O^;_\FC!C/C#_`"U]N_$G"3YC.T=5W)_,1[3QB14.)HVIY,)D,?T!
MT5D<UV#F<EDZ-9ED@ERM!0PU4M.L==/$M3)%[KW3WU)_)QV5F.QJKY'_`,R_
MO'/_`,R+O:GGEJ]KTW<NWL5MGXJ=)T=)/52X\=,?%V*NS>Q-M9.@QACCES&8
MJ,YE))(#5+/%435$LONO=&W[Y_FB_P`N3XKU5'A.\_F;\=>M\O*9*:FVO5=C
M;>R6Y($HXE,@EVKMJHR^=H*:!"JAI*:.,%E4&Y4'W7NBRY+_`(4!_P`HW&X;
M<V:/RZQ&1AVI4-2Y*CPG6'=6;R<\S4"9&C&,H<9US529&')4S_Y/+'>%Y%>,
MLLD4JI[KW2,V/_PI!_DR[ZDDCB^:.UMHF/$8O+Z^QMD]F;!BF7)QS2B@HIMR
M[.H(LCD***)6F6G,L866,H[AO?NO=6R=+?(7HCY'[7.]N@.Y.LNZ-IQRP4]3
MN#K'>VW=ZXV@K*FAI<E'CLG4;?R%>N+RJT-;%))25/BJ8A(`Z*>/?NO=:''R
M)E_EQX;:?S<J_F3D/E#A/^%#%+VK\CO]"%=ALK\H*CM^3>V2[*WI%\,J/XMM
MLAHNGZKI#*]>U&WZ>GI(VF`QDU?%K&JF'OW7NM\/XY5/:M;\>^BZOO6G@I.[
M*KI[K6H[>IJ8H8(.S9=FX9]]QQB.BQL<87<[57H2")$/I50`/?NO=%#_`)J?
M\RSIW^5?\2]V_)+M(09[<,DW]T^FNKDKJC'93MKM+(45768;:5'7TV-RIP^,
MIZ.BGKLGD986AHJ"ED(#SM!#+[KW6CG_`,)[/Y;W;_\`-3_F#[W_`)O?RQVC
MMFKZ%Q'?79W;%3BLUA0<-VY\B\UD)=RXS#;7VWD*&:@KNONLL]N6.OJ*QY)8
MA7XRGH;32?=-![KW6UQ_+[RV<J/YVO\`/BQLF=W0NV<=6?R^*B#:\U"])LN'
M/9+XTBEJ-QTK5N0:H.Z<EC\5!2RRT]*E/64=-!JE<PQI'[KW5^,LT--$\T\L
M4$,8+22RND42`GEG=RJ*"3]2?K[]U[JCO_A2/1Y+)?R3_G(</F3B/M]G=;9*
MMJH)9D:LPE%W9UI4Y;'0RTTT)=LECT>-4+>.<MXWLCDCW7NC8_`K^6M\#_@]
MB9-^_$7X\[2ZCW)VGL'9E!O#=.)J=X5V:W)AJ.DCR]#3U)WENK==5BH9JZL-
M1/!!,#+-H,S2M%&R^Z]T=OM6/>4W5_9$772J_8,NPMX1[%1ZQ<<C;R?;V17;
M"OD'BJ$H5;-F`&8QN(AZBIM8^Z]UHR=.9?Y2[\_X2._-#*_++?/=&>W50]P[
MWBQV5[$R+[GW[5=;['^2W4]%O?:U7EMQQY7<'\.3L/#;MQU2^1E^XH'2=5>.
MDAC4>Z]UODXJ:CJ,7C:C'RI/03T%'-0SQ212QS4<M/&]-+'+`3#(DD+*0R$J
M0;CCW[KW4_W[KW09=I=U=.=&X2AW+W5VQUMU#MS)Y2/"8W/=G;XVSL/#9#,S
M4]15PXFAR>Z<GBJ*KR<M+22RK!&[2F.-F"V4D>Z]T(]/44]73P55+/#4TM3#
M%44U33RI-3U%/,BR0SP31LT<L,L;!E92592"#;W[KW6;W[KW7O?NO=:/7_"V
M'8F.H>D/@KW]34=!-NG:';/;?4E/+7U4DZG"]G]>4N>J#%@I'^UJ)J"MZ\2>
M*M`$M%4B*Q.M=/NO=;*7\F?J]>G/Y5GP+V']GN?'STOQKZYW%D*+=^[:#>^9
MILMOO$KOO,11[@Q5568R3!C*;DF.+I:=_%CL8:>D4+X-(]U[JS/W[KW7O?NO
M=>]^Z]U[W[KW6CY_(BA^$/8G\[_YP]E=.[8S?Q][WVAU=W9@-V=.P]HUW:.S
M>U<_F?EENS$=O]EX>KWCC)=W;0GPPVCM&IDPJY&KA+Y]ZBG9*5?"ONO=;OE4
M:<4U0:L1M2B"8U*S()(FIQ&WF$J$,'C,=]0(((]^Z]UIE_R8/AE_,2[N_EP]
M5[I^.O\`-TSGQ5Z/E[(^4N/ZXZ-V-\0>C.Q(-EXNF^2'9V,JX,MV'O#.5.\<
MK+7YS'U64@IVGO04]>M-%.Z*LA]U[IT_F1=/_-[XF]I?RB,E\Q/YG,OS1Z,R
M?\V+XOFIZXW-\1.KNI=XTV\Z#)YRLVSO'';GZKBRU3N/';<@JZR&;%U'VI+5
M5/-$*AX2J>Z]T<'^9-M'Y4]C_P`Z'XB;3^'_`,E-O?$CLK#_`,NOY.[JW/W%
MO#I7;/?&%DZV3NWI^//;6QFQ]RUU+2'-U&4H*&I>KU0/!!%H1Y!-)&/=>Z7F
MS?C?_.GWWU3M#='QZ_G7]&;PP\TX2CFS_P#+3ZRV!MV3"T^J.&@Q])19:JR%
M'3TM.D")$,?3,"T@\MA&%]U[I>?/CK7Y7=4_R+?YBVW/E?\`)_"_*?N:I^-_
M?F7J^S<!TOM/HS"4&U,AM'QQ;'QNS-L92LHJJGQ5'!5A<C/,:VH-59D8QH&]
MU[JU+X3KGT^&?Q(3==3-6;H3XQ]"KN2KJ&B:HJL^O5>U!F*F=H$C@::?(B1F
M**J%B;`#CW[KW5:?\KG^*[I[H_GC;$JLSNW`F3^95OZEQVYL?E2FX\!!NKXU
M]&4%-6;7DS,NX5QE7@XZ-*K'R2124:EXBE.L:&!/=>Z*E\B?Y0&X^E-AYOLC
M+_S:O^%`?9;5^[,9`NT^@^W:OM/L3(Y3/SPXW%04&U]D=6K/BL+3S(@K*^5L
M?A:",^>LDIX5>0>Z]U0A_/:_EWP_`/:7\NCO;-_.+^8O\H%W#\O]C?<]??+[
MN:'M<;`HZ3&8_>63KMJ[>@Q5'!@>PHUQ4=%4:*B=9@1&#9`Q]U[JXG^?%\9.
MD_F[_-8_DW_$7Y$5V\)NJ.[>N/GSA*FAVUG\AA:W;V]8.J=LY/KC?&.@IIJ:
M%,QA]XXZEGM41STU6*-:>IADIS+&WNO=&>_F.?#_`&S\'O\`A-E\BOB'L3=6
MX]V[9Z*^,4>!CW9EH<)B]P;F@@[)PV[-T5U52PT%9BL=_%ZC(5@6%$DDBA<(
M)FE'F/NO=8O^%+V/;._R?8\?@G6CK<KWQ\.Z3;4.07')3M79#M;:=+C:?*96
MJ>DQ^"IX8ZC7+6'3$IC\;!8Y&*^Z]T/^._D'_!3??=?RG[Z^5_5>P/E+OWY#
M_*[$?)3;.?WIMC(T&9ZRV[MW;&T,=MSI89.'<]:-V;#HL_ALC45U+)%28S/4
M5=#29"@FBI(0/=>Z-1_+:_ET[/\`Y;.Q?D'UIUYOZNW9L/NCY4]K_)+:FU&V
MEAMFX'IW$]EP[>IJ3JC:>*PE754<VW]JTNWHXX:A$HXY%("4L`6S>Z]U8W[]
MU[KWOW7NO__6W^/?NO=>]^Z]U[W[KW5;7\W&@J<C\".UXJ+;59O"MIM_?&3+
M4>W*#(XK$5>3J\'\J>E,U3)#E<Y546'QQIYJ!9C/52K!$L99[J"#[KW5;_<_
M>O\`HK_FO=H3;9[4H-ITO9OR`_DT]';G?;V9K<F=SIO##_S$S4=5;H@%-6T^
M&JL[/CZ&H^WIS#"T8II)9%>253[KW6R+[]U[KWOW7NJ9NN,K@8/Y^7RBP4:1
MG<F4_EB_&',3FHQ;K/%B<#\A>]:&)\1F3FI?)35E3N0K7TWV$48>FI'65W\J
MCW7NBD_S)GCQ?RU_F:9>>IJI:=?^$Y/:4TE+/]U58^C2@[5^13S3PT=#&:U4
MJ$E!JS%JE>.%=%BHO[KW6PIU;EX=P=9==9ZGGIJFGS>Q-HY>"IHH:RGHZB')
M;?Q]9%/24^1_W(04TJ3!HTG_`'E0@/Z@??NO=:G7P=^`'\H[Y3Y[^9MV5\W^
ML>@-[]SR?S7OGIM3.9KM+M*?`;RV_M7']D4T6U\-'5X_>>V%Q=)#C:\5-)-1
M`%&JO\\9U?3[KW1]NK_Y-_\`PGFVSOSK3?7573OQM&_-B;FVUN#KC*8'Y/[_
M`,[71;KQ&7;<VULC%0MW?D:7<V6@R<`GIC5PUCND*(-442*ONO=;!7OW7NO>
M_=>Z][]U[KWOW7NO>_=>Z0':/5?77=FQ,[UCVSL[!;_Z_P!S#&C<&T=RT:9#
M"9<8?,8_/XL5U'(0DZT69Q5-4H#P)85/X]^Z]T!GRS^+H^5%#\?,/6=@YC9&
M!Z5^572?R7W#A<;0#(T':=/TCE<CNG`];;EA;(X](\!5[V&*RYE85*QU6'@/
M@<V*^Z]T5W^8%\>NW/E%\DOY;'7V!V[N"GZ`ZL^0F^OE+\@.R\5N"DQ--@JK
MI[JG/;9Z<V`*%<A%ELCFM^=@=IK6TTT5.ZX^+`35*RQ3QPW]U[JBC*?RG/@'
M_+A^:GQUV;UUW3WICNEOCQU]W/\`S:_E#UEVAVI2[EVKD]P?%J'"[&^,7964
MHJ';>#K1E:#>N_\`<TD<5#'4RY./#R0RPL`I/NO=`#\5/Y[.X/Y:O?F`^('S
M3V7LO![3W/\`'WL;YR_)[L^.@W;!VQ3?+SY883<?S5QG5E0'>3;L\M/MO>N)
MV'14=120R_Q+[=VKHX(!3^_=>Z(9_+#^?'PS^9>!_F-]<?S1_@)\?=T8+8>S
M_E+_`#,M_P#;%=09^@[[W)N[/=M;=J7ZVQF;9D["Q;T&)[*Q^W\#)C<O2M28
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M_=>Z$2AQ6'PU+%3XW&XW%4=)$J0PT5'2T--3001Z$6..".**&**(6```5>/I
M[]U[JFWY`_S8<[N/?N1^.'\L'HFL^??R$I:EL-NW?>VL]#A_B%\>LH*NGIZ@
M][?(&&*KVQ%G:"GDEJ$VUAIJS.U0I94\<+*NKW7N@`?^3A\GOFZ<KN7^;[\[
M^RNT<+GJRDRE!\.?AUE\Y\>?BGL4PT$5-_":W(4\]3V7VPM,TM4(ZW*5-'5$
M3%F9N%7W7NK&OC[_`"G?Y;'Q;H*:CZ/^%'QYVE4T>6&<IMR9#KO"[VWQ#E%$
M7BJ(]_[\AW-O9$I6B#00BO$%,S,8D34U_=>Z/=2[:VY0T2XVBV_A*/')"*=:
M"EQ5!3T2TZM.RP+2PP)`(0U3(0H73>1N/4;^Z]T'6\/CUT'V'MZOVCO[H_J'
M>^U,K3M1Y/;.[^M=F;DV_D:1HX86I:[#9G"UF.JZ=HJ>-"DD;*5C46LHM[KW
M537:7_"?K^6#OW=]-O#J38>\_AMVMB)FKJ??/P@[4S7QVW902"@Q5%33+B]J
MM4[8I_L6QL%1$W\+4_=.\KEVFD+^Z]T!&XOC;_.5^$79&Q^T>I=Z]*?S=^F.
ML-LU.+I-I_)[;.R^IOY@^TMNU5;41Y[`]0?)3%X./;>^LSE\+.):NMW/54\N
M1,'VOVK2,LS^Z]T>OH/^<;\*NY=L]T5^_P#=&YOA_P!A?'&AR69[YZ)^96&Q
M_1G<_6>V<<[I'O.NVQD<WE<=N;9>6TK]GD\%792FE>>&%BE1/%"_NO=:FO9N
M*[H_X5B?S%\+3=?4%;U__*3^$.])<3/V9D(]Z;:R';=)GJO%3[JJL%1Y&D%)
M5=K]A8[`)'CZ0TU#-M3;DT4U>XJJB."J]U[K?6ZDZCZSZ&ZVV;T]TYLC;G7'
M677V"H]M[.V5M/&4V(P6"Q%"FF*GI*.E1$,LTA:6>9]4U342/-*[RN[GW7NM
M=G^>?_*>^-N^MB=P?/[9Y[)V!\KJW<'QFV]N:OV=W5OKK;K?NW&0=S=1]9X'
M9W=F(VVN2=ML08BNA!R.(@ILQ12TL%5&\STZ1-[KW1B?^%(=;54/\H_NC;V.
MS6\MLU6^.Q?C5U@N;V3GLOBLKC\7OWOWKG:>Y%JZC'5U%5YG&5VU,C74LM%,
M9H*YYTCGC>-FM[KW0/T?_"6C^6C_``.CVKN+=WS.WMM&FJ,+53;/W7\I=WU>
MTLA+ALK0YD?>[>H,?C<:Z5]=1%I0B(8S,[P&&4121^Z]UL>P00TL$--3QK%!
M3Q1P01)PL<,*"..-1SZ410!_@/?NO=9??NO=:7'8V'@R7_"4_P"=E-29^OCI
M:'N+YK9"EEJJS)U<!I<+_,EW]-3X:&JJ:C(&MH<C#2+H>'Q0O53:Y/7YG?W7
MNMO[IK_F4'5/_B-MC?\`O+XOW[KW57_\WS^<3T]_*DZUV>N3V=N3NKY,=XSY
M'`_'#X^;1IZO^([]W'2U&.QK9#/Y:FI*Z3"[5Q^7S5%3N*6"MRE=5545/1TL
MA:66#W7NM$+Y2/\`*#+?.K.;V_X4:?$/YA=Q/WOTYF:SX:=*?'/>%;0;(VKW
M!GI-FU>SNM^JL;MC=6X=MX:@.,Q38C<F-I:K([DI*N6.NR%%DZQDD?W7NMJW
M_A,]NW>_QVZ1R'\MOY5=R[LW/\R]E468[^D^.&6JLUV++\0?CSE?[E[/Z_ZE
MWMV%B(\[LGK_`'9E*D'<%-LJIRL&2QM!FD(H8&$Z)[KW6TS[]U[KWOW7NJ$_
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M>IJ)$Q<`73<H+FUN1[KW0:?S2NA/D!\B_P"=%\"^O/C9\OMX_"??]7\'_E1D
M\IV_LG9F,[!S-=L[$]C]8?Q?9,.V<]GL%AD&<J:^"H-6[2/!+0Q.(V=(WC]U
M[H1\+_*%_FEG(-)F/^%!WRUJ<2::*:"&C^.O6.'KQ)-(K(LT]=O'+Q%XHHW$
ML1IU*LZ'4;,I]U[HS?R&^(/<'7_\F_YW?&SL_P"0_=WSGW_G_CE\I:C:N^]X
M[6P1[=S?\;V!N#);'Z_H<7M2@K?[SU^*S,$<5+)XI:RI>;QQ)&BP0Q>Z]U5S
M_P`)L/GY_-0^3V^NTNB_GMU/NO8_6/27Q_Z[BZJSFX?C)NKIB2MRV)S-'M*.
MDR.Z:O"87;61RE=MVG,HH4BADG^VEFIHEB@J`/=>Z//_`"J*#&;X^4?\_#!Y
MB"LI$SW\P"IVOEZ^BR.0QF0;!/T'LK`TT=((::*#%55'2K-)'605<E1(\NIX
MX1'$9?=>ZKM^9?\`*)_E(_#'H[+]V?+G^9%_,UJNH,%O/:VT-QXD_+G(]B)E
MMUYBOI9\7MB78^S>LLGN">9P5J)8Z=$GI*13/KC"B0>Z]U2__/I_ER_#3^7Y
M\9OY>?R!^*79OR-W%3]E?(#$;HBRW='<NYMUU2[>J-E8G>\6[*/:&2Q^`@V;
MNUHJ+&_=SPT%'51K'%%,H9%`]U[K9N_F*#%;X_G@?\)[*C'8';&Y*"N@^=V^
M:+<=9+2T\-5CL1T/M;,8JIPF>I9)*[(/BFK%R5)1,AI:F<Q,&OK*^Z]T:'_A
M1!E9,1_)?^?$\;U<1JNI<7BWDHXHY6$.6[!V;CIXI_+',(J6JAJ6A>0*6027
M!6VH>Z]T73_A1E@WR7\GF%<70R346%[G^%N0>GD:AE\&,C[DV!C4%149&JIC
M]:^.+5'Y)9'<*5T.[+[KW6PUA`HPV("(L:#&4`2-#$4112Q!44PL\)51P-!*
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M*S.%RU!+-25U!74DRO'(C$$'^MQ[]U[I8>_=>ZH<VLT__02[VLAJ&:G_`.&8
M>O'%*)96CAD/S%S:K,T4D;*DLX5A^VZ)I07#L28_=>Z+%_-]J4INY?YJ#1":
M/(-_PG-[)2*J$Q-/'13=R]^T]?3O1Q4%3/)/4B9/'+Y$CB"MK%F\D7NO=;#G
MQU`'Q]Z*`X`Z;ZQ`''`_N3A+?0D>_=>ZU!/A?NS^1DNZ?GMN'^9^O\OI_E37
M?S./FKFJNG[[V[L?.;WQNQZ[LAQL_'QU>Z\?75^:VY%%2U,E&WC2G7RE5B5B
M6D]U[HPDW9'_``FFH_FA\1]@].=??RG<_CMWMV5N/(]@[<I]N09W8W:%)D-G
M9?I3#8"#:^UZK8&0R^\-R9')QPTV:R%+58V:BI8:&$/)%"WNO=;;?OW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z(+\M_Y7/P'^=F^NO^S/E?\`
M&[:7;V_>KZ.#&;-W5D,UO7;66H\-2YQ=R4NW\O/LG<^VEW9MNDSNNJBQN6%=
M0Q2SSE8AYYO)[KW0M?*CXL;,^5G5E5U#NNLAP6T=Q[_ZGW5V-24NT=E[DC[*
MVEUEOW;.],AUANJBW?@\UCZG:N_*+;*8?)-XC4#&3RQ1L%9E/NO=4\_SJZ?X
M2_'S97QGV]W%UUUIT5T3\COE%LK;_P`L^^<!TC/#CX>A.JJ2J[QS75N^=X=8
M[&RVXJ>E[[["ZZVQM?[&H_9RE%55:O:.&1X_=>ZJ@[LZ(_G3_,O=O0_\V+H;
MY)Y?8?QGI.]M_?)';'Q?WIW3O?H/9^R?AYU9N/9W^@^3+[.Q-.<=DI.[.G-A
M5N<W-3U\L>B3-E6BC2:18_=>ZMU_D%8+MGOK9OR>_FP=_))0=A_S*.T:3<_6
M.S)Y)ZL]6_%3IBHW+LCHO9=#4US2U5-!6Q5F2R+I"8Z2LAFIJT1)-4S#W[KW
M5[_8786QNIMC[K[,[-W;@-B=?[&P>0W+O#>.Z<G2X?;^W,#BH&J:_*97)5DD
M5/2TM/"A)+&[&RJ"Q`/NO=:H'RZ_FU[4^96^^NNINP(_E;\$OY/W:<V/&Y/Y
MA.9Z6[$V7MCYEQ966GH\9T;M_M.KQN+D^,G1G9M%65,[[VJ`^5S]!1-#2G$4
MTCUDWNO=;1OQ^V+T3UOTSUYL_P",VWNNML]$XK;.-'6F,ZGAPL>P6VS/`D]#
M7[?J-OM)C,I3Y-'\[UJR325DDC32222.SGW7NAC]^Z]U[W[KW7O?NO=:@7SA
M[X^4-!_PJL_EZ]4=#9/LO(;&QGQDVW_IMZ[Q&]:BCV!ENL]Z[P[NH^P-Z;@V
MC6Y:@V[61;1Q<F-R+,T<U;)5XBE:!7FBA7W[KW0>?R),QL*F_GT?SU]B;@Q.
MULSVUB>X^V]P;#[)W#DLMFNXY>NJOO2;$;VV/#G*K.3T5=U_AZNAVNXI&HS4
M8Z=(8UE2,F(>Z]UN>R21PQR332)%%$C22RR,J1QQHI9Y)'8A41%!))(``]^Z
M]U\^G^:]N?>'_"DG^9/L?^7E\%MK=9UW1/P_RV1K.W?G+4[?JLR^`J:\MA^Q
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M<E=MS<G5]=3_`&F)R6-C>.*(Q!#ZD*2!7'NO=;!7OW7NO>_=>Z][]U[K2`V;
MO4[^_P"$F/SXIZVU&NS^P?F%@HJ6L:K2EH!4?,:N[`H\704LU2)<?%!)NY88
M*?SSJDMM1DNT?OW7NMS[J1J9^JNLFHHIH:-NOMF-20U$JSU$5,=N8TP13SI'
M"DTT<1`9@B!F!(`^GOW7NIFZNM>N=]Y+:N9WOL#96\LOL7+KN#9&5W5M7!;A
MR6SL\K0LN;VK79>@K*K;V75J>,BII'AFNB^KTBWNO=:L7\XG^=1\WMD]H]R?
M"7^6+\`_D#W%WYTY6;>H]]?))>B=X=I;.ZY;>6Q(\PM?U;MC:N&RWWFZX<;N
MVC6CS&5ECH8W%0@H*V)ED/NO=*+_`(2A;D^'N3^)?<V#Z<INX9_F1C=\[<SW
M\P_<??6)^T[$S?>>Z8=T-#3463>OR%57[$P63P^;I\?'5F'))5?=U%?#'65<
MI;W7NMK#W[KW7O?NO=4L?SA/F+_,]^'&!ZAWC_+Z^$F`^9FW-P5>Y<1VYCEQ
MN]]S;UV1E(QB)MEU>*VEL'<&-SV0P.7@.12KJDI*J.EF@A$C1>5-?NO=6(_#
MK?'R&[+^,73'8'ROZUVST]\A-X[-IMP]F=8;/K:W(8'966R=765..P<%1D:_
M*5J5U/@'I#6PR5$S4]<TT6M@@/OW7NC+>_=>Z][]U[KWOW7NO>_=>ZJ`_D/4
M4U%_+`Z.$N3DROW78_RTKTGE\A>):SYA=]3-3,\\4-0[12LVKR*'5B5_`/OW
M7NK:,^6&!S91I$<8C)%'A8),K"CFTM$Y90DBGE3<6/Y]^Z]UJ0_R/_FWT#_+
MD_X3];5^4'R?SNY\/UUC_D9W]B):G`X+)[ZWAN'<^X>Z]U8C#XP8S$1O!39?
M)U&,D5YJNIIZ%?'Y)*E/*@/NO=*_^<!\KNCOG=\`?Y4_R]^.U7NK='76Z_YO
M/PYKMBU63VOF=H;JDR.#W;VIL[<.+CPFX*!)AD:;.X>IHXY8EJ:.>6(/#)-$
M0S>Z]U/_`)Q7Q8SWS&_G"?`KI;:'?7<_QLWO7_!;YMY[8?:W1?8V2ZLWAB-Z
MX8[>_NU1Y;=6&QV3R_\`<2ORE5&N=HZ6-:BLQRR1))&S!A[KW3E\2O\`A/M\
MF\=L;*Y#Y^?SF/YCN_\`MW(Y824E'\8OF+VMUSUQM?!4E-%2PT<M;OREW!N+
M=F9JWB,LM4:7#P0H1$M-(ZM4R^Z]U:W_`*`,I\#OY9ORBV)US\MN^>P\WL7I
M+Y'[_P!G_(SY4=CU7<'876^37KG/Y;#U]3NK$;?I,K5[9ZVJL:E70TR4E34P
MK$RJ)/3'[]U[K7__`.$H_P`H_FA\H.T/FX.[/G!NSY?]%]-[3Z5VULVMW_D=
MV5F?_OKOV?=6Y/[PXFEWUA:;=U'CJ2AP>3QE=)75`>IJ883&DL4<<B>Z]U>E
M\#OBIW7TMW+_`#::WY`[7V;C>FOE5\L,EW7U3GL1NNDK,INC86[^I]O[,W?%
MNB&BEAKMJ1X:#;%/#&L\D<HEEJ7C_:$<TGNO=48=U?R]?^$K/Q`V-)O/*;;Z
M\^22[JW_`+9P>)ZQV;\],?N;<&%7>>>P^VFW-0XW/?*?K'#46Q=CK51SYC+5
MV0GGQV,:665Y$6R^Z]U2S_PI/^.?\F?J+XZ?%G<G\L;(_&[^_$G:^[-H=@8W
MH;Y`4O;U?)M%-DTN8CDWAC8.Q]^LLV*S*TJ19%B&)JVC\L@D4#W7NMD+MCL6
MAW7_`#<?^$S.9VQD<!G>M=U?$SY7;EV35T\=`RS?WI^*>W6.7HY8(_O8X*K!
MQ4'VR,P@#H^E0ZO;W7NK=OYR7QX[J^6'\L[Y:?'?X\;5VQO;M_M/86+P.TML
M;NSD.V\3EF@WIMC+Y>"'-5;P4%#FUP6-J6QK5,]-2FO6$2S11ZG'NO=5T?\`
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MNN:*I$;:HQ/2[/PT$P1B`6021FQ_(]^Z]UI]?RY?DQ_*'Z9E^?&T_P"8=!\;
M,I\F-N?S,?F7GZVJW]\?LSW5N.#:>Y-YXVAP5)B=^/U-NB7/TH3'SJ*2*KFJ
M*6(@RPPZM(]U[JV+9_\`,4_X3^5W8>T=M;%IOCZ^^,AGL*VS\GMWX/\`8$$$
M&=?/T..P&2H-Y4?Q]BP^)=,_40?;UYK(8HI-,HE4+K'NO=7^>_=>Z0':G9VT
M>F.N]W]J;]FSL&SMC86IS^X9=L;/W?V!N!,=2E!+_!]E;`P6YMZ;EKF9P$I,
M;CZNJD)]$;>_=>ZUY>T?YUO?/R9[CZ$^'O\`+3^/>\NHOD#WQFNWLOC^W/YF
M'Q][>Z7Z.'5O1VWZO+[JS?7>&H,CB]]]B[ASE8]%%#%3TQ_A,-0#D:>"20>#
MW7NK3OY6'S%W5\[_`(.]/_(WL#;&%VAV1FZKL+8G96'VM)75&S&["ZA['W7U
M5N_+[)K,@7J*K:.?S6SY:ZAO).U/%4?;M+*\+NWNO=6"4]535:/)2U$%2D<]
M12R/3S1S)'4TDSTU53NT;,$GIJB)HY$/J1U*D`@CW[KW6?W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=,NX=M[=W=AZ[;N[,!A=S[?R<7@R6"W#BJ'-8?(07#>&NQF2
M@J:*KBU`'3(C"X]^Z]T`GR^^.]/\IOB=\@_C!#N?*=>T_=W3.^^IZ;=&VWBH
MZS;2[MVU78*EJJ=/MJB,X^`U*I40+'>6D,D2E"P8>Z]U2'T#\O?E9_)ZZ:ZE
M^,7\RCXT5FY/C=TALC9/5NP_GS\+]KYOLKI_%]:[,P#8/%9;Y`]/8NA7M?J>
MOVOAL32)F,O3X>JP=1+*&@=IG$<GNO=8-^UNRO\`A1#V?LO8?6F?R6>_D^_'
M[<6'WSW1V#34.X]G3_-+Y&8J.ERNU.B]MX?<V,V]NFGZ9Z@I*^+);ERTM*D&
M4S<T5!2!FHWJH?=>ZM*^<N]NBL9L3JWX(;OV'NG=(^>51N3XJ[-Z_P"I=N[1
MK<CL3K^;K[+G??<,V&W&HVWM[KKH;:L4%=/6&DJTH:IZ"*&EFDDBB/NO=4W]
MJ?R[ZK^4AN+I63^5/\W=U_'_`'QWGN;!=0=7?`'Y*2[S^0OQ@^3W8VWMNTV[
M-TI24]/2YK?G0&X]X;=V'4UNY-[8[Q8ZBJ*A(9*C$4=3&$]U[JQ+XQ?S9Z/.
M]HX/XI_S".C\S_+Q^9.?:2'8VQNQ]T8[<_2'R!BIIX\>^2^.WR"H*6@V+O3)
MU5>P']VYY8,[$942&.M`>5?=>ZN+!!`(((/((Y!_UC[]U[KOW[KW1<=S_$/X
MS;T^1NPOEUNSI78NX/DKU=M.MV/U]W%D\6:G=^T]K9!LV:G%XBI>7[6$6W+D
M5CF,35$*5TZQR(LK@^Z]UJD_R=NO]U5?_"F7^=[V;CL#CL)L;;-+O/8^XJ?^
M\FS:7+?WGWYVGUYN+;.739]--5;ERF-W91[!RV1DR-.(H*2::..N85=2D0]U
M[J'_`,*-?YT_9=-V+3?R=OY>,<&]?D9WI_#>JN[]X[8J:R7<FQLKV/68;';>
MZ:V#6TTU+C*3?.YL7DW&>R,DSI@J*I6$&*K,\E%[KW5_/\GK^5YUE_*I^(.T
M^C=LP8K-=K;B2GW=W_V=34BQUW8'8U9$[31)4N/N/[K;/II_X9AX#I1::$SL
M@GJ)V;W7NAZ_F`?`WIG^89\>MR]']K4,.*ST<-5GNF>X<90+)V#T!VY1TLAV
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M@[1[DZ9[AW?EJ%Z:+]Y,/E^U<G330AI(S34Z0.P34![KW6_?TU_S*#JG_P`1
MML;_`-Y?%^_=>Z$GW[KW1)_YAFW_`)29[X?]VX[X7=O=9_'SO^KP5-5X7N3M
M/%5V1VKLC;]#6T,V_-Q3+C-O[JJ8,[0;#I:W^'538O(K3U21,83I#)[KW6@E
M_)/_`)W6T/Y:^U_F9O\`[C^.WR?^86V.WOE9/NCY"_S#>NZ;(5V!KVKJ8X_K
M-,[A^P=N;;:DW!O3-9'/Y>FI\_N+$Y";^++&*9)%D1?=>Z^C5T'W3L[Y'](]
M2]_]>P[@I]B]S]=[1[-VA!NO"5.W-R0[=WI@Z+/XF+.82K+RX[)QT=<@EC#R
M1Z@3'))&5=O=>Z%OW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW53?\CW
M$U&`_EE]#8&JIWHJC![U^4F&FQ\DCS28Q\7\N>]Z'^%2S2!9II<6(/MV>0+(
MYC)<!B1[]U[JUZH\Y@G^V,:U/AD^W:8,85GT-XC*%(8QB2VH`WM[]U[KYY5=
MUKNCL/\`X1W=Z38_('*Y+8ORF[#[+R=#ALC&4CQ&W/F3#1[EILRB13"M@HZ+
M(U.86(2?H6"?60ND^Z]T.6X<%LND_P"$^7_">C9NTJK<DB;Z_F4_"Z2FP>=W
M%#-G,SNS<'9W=^3WU08/)9"E@AQ.(BW575KXQ$1(:&B,(8R:6D?W7NCJ?SW^
MJ.BNU/YH7PCI?D7L6E[,V!MSX/\`S!W/A^N:OY*;:^)+]@[\HMR;`P>V=MXG
MNO=W875^%PV2IJS="USP'+:FIJ=Y'IZF)'@D]U[K)L'^4W_PGF[!VWL'L7L3
ML':?4.Y:S`X?*]B=%2_S69-^8##YZLIBN1VUN;>&&[RRPW`(:YRK5>)R=)#5
MN@9;!G0^Z]U;3UK\5?A5\:?Y5_RMZ@^#M;7=@_'S<G4?R@ST[]<=J-W_`)G<
M>Z]P]6YC";QQ^T=SY7=F6H*W<M8V*C@AQHKZ:ECR!LPA:21O?NO=:Q__``C#
MZ`^574':?S&W9V=TWW/UETIV#UGL7'83-[]V#NO9^T-W=A;)WIE(3!AJS<-#
MC:7*YG;N)W!71R>!)3&L\BLRE2I]U[K?<W/DMO87;6X<QNVJQM#M3$X/+9+<
MU;F3",12;>H:"HJLU594U`,`QM/C8I7GU@IX@U^+^_=>ZTB/DM\D?^$J])M7
M%M\;\)_+&HNPX.X-B9/<,O:WQ%^2&Y-E5.P,=N)1V9C,+3=3=45%='E<IM)*
MJ'#:DDV\*Z2&6:)@(V'NO=4_?\*#NY?Y*/??1GQPVW_*4V)TO1=L8?M/L7<O
M9$'37QHWCTKN&3KBFV'4Y/)3[@K,_P!:;%?<&&I<CCUJH(==4*1*>:2-8HS(
M7]U[J_39O8DN6^4'_"/3>5-@UV[)N[X>_(7`5%+)'0U>0&+JOA+U5BZ:!\A2
MTV/#T%0%^Y1%1$C$UQ'JO[]U[K<@]^Z]UK^_\*7DQE7_`"QJC#UV0-%6Y_Y5
M_$##X&",U,E7E<O4=\[0G;'T-!3`ME:M,335=2*9K!UIV8$,JD>Z]U?_`!@+
M&BB]E10+@@V``%P0"#[]U[KG[]U[KWOW7NO>_=>Z_]'?X]^Z]U[W[KW0)_)/
MOC9?Q=^/W=/R-[%EGCV/TAUEO/L_<RTL<TM94XO9N!K<W-CZ&*""IFDK\D:0
M4\"K&Y,TJBWOW7NOF)_ST_COV]\6^NO@3W)OQ*G:/S2_F,UWS*^0OS`J-E,V
M.R,^2[B[$^/V^-G="EZ!WEKMN]08BKH,;#2-)/"<M%531G3(JCW7NMK_`'=\
MNMU_&#^='VQ08W8V/R&6[L3^2Y\.]T93>E=6OD<[CNX\K\OLKN+L&ABPU5'!
M2[MP5/2M2(DJQT3/BI2T#&=)/?NO=+/_`(4M?/;MG^7_`-3_`!`[!ZB^2O=/
M0>2W_P#(7^XN]L?U'LKH7>[[CZJCQE'G>P-Q38ONS9&XXI]V[/H*"&#!0P9'
M%T$U3EI#7F6-(S'[KW6R;MV?[K;^"J?XC-F/N,-C)_XO41T,51E/-102?Q&>
M+&1PXV*:NU>5EIT6!68B,!+#W[KW6M?_`#*/F[\Q/CY_/2_E%]";#W174/Q1
M^0L.7VOV#UU@=Q['DK>R-TYO,[BVWG,WNG;<]+D]\XC;O66-R.$RU+6&.EH\
MA)!5P03F6&H\?NO=(C^<%EZ8=V_S;(:7,/3YO#?\)W*E8J"C:ICF%!GN^?DF
MM?5U-3'3Q)"P%##%'&)G,D<TGI`U7]U[K98Z<ACINH>JZ>&OJ,I%3];['ABR
M=6C1U61CBVQBXTKZE'>1TJ*M5$C@LQ#,;D_7W[KW6LG_`"^/YG/2/Q?SW\Q;
MI3=?37RX[:W5AOYKGS9R,VZ?C7\3NZ.]]A;@I]R;^CR?WD>ZMCXK<N&H,_@*
M:G6GS./DG@J8YU$T,$D$HD]^Z]T=[-?SA^I,AVUT-E$V#_,OZJPDD6XL+O?H
MW<G\L+Y`*=[578`P&.V/N#<V\<AUQ49':E-UGDZ"IF`P%;519(9)EF658D*>
MZ]T#_P#PIO\`F)\LOA/\#>J^VOB5W&.A\]G_`)4]<=>=B=CIMO!;ER>'Z^W)
MLOLG(S+28C<.W-S@Q#/X*AFJOM:-ZXP0M''P[JWNO=#%\A-A_P`QRI^1?\LC
MLKHK^8QU^O1-1/T5MOY4=#[TVCUKU7E_D1@Z.>#-=C]Q]=-GL!F]XU.=['Q-
M2M/+L^FFHGQ(\1I*C6\X7W7NBP_S>>Z,?\>OYJG\OWO+/Y^C@P'2_P`!?YM?
M:%1BI*%:^NHGVGT1M[.R5U`U!3567Q-7G#AX8$J3#4QNE%)!%'KE<GW7NC[?
MRIMH8[X3?R5?B@.T,\=H8WJWX>P]W]E9_,TAJ/[EP[JV[FN^-[U&3H8(XI:D
M;0.YZI98[>604I#%G)8^Z]T:#^71EMZ9CX,?&[?/9G=E?\@-S=A]88WMNO[H
MSG7=+T_6;PPG:$M7V-MFNK>NX@B;0&)VCN.BHS#*3.PI?+.S2N['W7NA3^6/
MR8ZF^'WQV[3^2'=V[O[D=9]8[;?+Y[<<-`,Q74\M=54V'PM+A\('23/9O)YO
M)4U/14,=Y*NIE2)02P]^Z]T'6YNZ*CXL_`G<WR#[3["RO<E9TK\;<]VSN'?V
M[MO;>Z[W!V95;9V/6;JH9,SM?:E!C]N;:W#NJ:*"D:DH*6&%:N8)%$I(3W[K
MW0BX7Y"8#;WQ7VQ\G_D.^`Z%P472>U>W^W8<]N#[_;W5/\3V?C-R[JQ-=N:7
M'8MLI2;5K*R6D%5]I`]48@PA1G$8]U[H9]H;MVYO[:6U]];/RM/GMI;TV[A-
MV[6SE&)5I,SMS<>-ILQA,K2K/'#.*?(XRLBF0.B/I<7`/'OW7NE%[]U[KWOW
M7NO>_=>ZX2Q13QR0S1QS0RHT<L4J+)')&X*O'(C@JZ.IL0001[]U[J+C\;CL
M32QT.*H*+&4,(M#1X^E@HJ6(6`M'3TT<<,8L!]`/?NO=$DV1\3=VS?./L[YH
M=S[_`,-O>JQ_7E)T9\4.O<'@)L9B.C.I<M+@]S]K9G+5U=554NYNUNV]]8>F
M^^R,:4\5#@\51T4`*R51?W7NDATWU]U9\LOD9MK^8E'FM\;DQW5FT^X_CC\<
MMB[^V%_<NBZNSF+[<W9UY\B.X=MT^2(W%ELGW2W76+QF.KJZ"EEI-MXUQ`BI
MEJI/?NO=5]CJ[I;^>G\H^Q=W]N[:INW?Y:?PJR>[.C>F]H95\YAML_(3YDO)
M)B>\.\J>MPV2PF7S6PNC]LR1[1VO4!VHJS,Y#+U]*["""0^Z]T4;IOM;YV_!
MSY#?)CXY_P`M'9>4_F._RX_A$^SMO=C]6=G;WB'?W3':&YSD]S;Y^-?Q-[EE
MJ<G6]V5/5.UJZAR-7@MTP553B:FK7`P5D$T:*?=>ZOX^#7\PKXO_`,POK.H[
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MWOW7NJ(_YQ&$'Q+W'T+_`#C^N\/')OCX<[AP76?R4H:6;+1UG:?P?[FW71[/
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M&W4>>RW97=>*W)\[._-P9#(Y/*]Z?-NHPO>VZL=-EZNJKLC2;`VUN###8'5^
M*K*NLEDD@P6*HFD9[.[1K&B>Z]U2#6[^['[S_P"$H?S2W%V)5XBJW-1'Y9XI
M"=K[?V#0TN`Z\^7FXX\=BX=I['Q&"V[@*O$XK"FEI:2EHX(?-#&L@.IV/NO=
M;<O37_,H.J?_`!&VQO\`WE\7[]U[H2??NO=1JRCH\C1U>/R%)35]!7TT]'74
M-9!%54=91U4305-)5TTZO#44U1"[))&ZE74D$$'W[KW6C+\V_P"41\..M_YV
M'QVV9O'JC<OQ?_E7]P]1U/<7;]/L_+[HVY\0>ROE!UAFM]Y3&[([/*3_`.C7
MI+"K@/X7*R538^@JX&-)0?;25DCK[KW5D_PV_P"%)W57R,^9&?\`BA%\-N[M
MG=,3?('*?%SX]_)7K.AE[:ZIW7O+:\JT%-C=Z4NS]LT&+ZXQ>0Q$,>3I),;6
MY^GH<140SU?V]&DM8GNO=;/GOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NJ8?Y`N>R>>_EG]>'+Y9,Y6XKO3YC8F;*_:UM-45\T7RW[IK*NKKOO99VFK
M*JOK99&9'955UC)+HY/NO=7/'GC^OOW7NOG@9J#>,'_"0'Y-TW7<>4FH8_F)
MO^/>/V%-G/-'U_3?,O`MDI:6HHHIHLIB(YH*(UM1(WV*TWW"R/Y(BI]U[H0(
M-_;MW5_PG9_D.;RW3A\1L3+;#_FF_%7;FP<GA*U:R&NVYU[VQWEM;![VK\-1
M*D4>9JXL-)+54L@J)))XFJ"5><HGNO=6D_SF]N?!C,_S=_Y;Z?S)3U''\5,C
M\4?F%233]W[F7;>P(.P,7F>MJW#//6?Q3&&#+,M;&E+JD3SRN`FIT`'NO=%2
MZWS/_"9.A[#[RW!\CY?Y,5;UW#V'0[<^,E-T%LOMM-W1=:X[&UM:\G?.W<F<
MSM+*[U\WBB;,X&C3%5Q1A+*TTB01^Z]U>ML7N;X/[#_E._*'MS^5-NSIO972
M74?2_P`G=U;)W/TC@\;1;3V5V[LKKW<&Y:S,9+`YS;>11L]09JGHJV893&58
MJJ9H9#%/3R1Z_=>ZKN_X3F5'\XO%U?<%/_,PC[K[&ZZ[9V3LWNOI'N;?/R#Z
M#[CV%C8\\M"\6T]MT&P,EN??>*R&\,1ESDTB_BL>!Q]%0)&F.IZBH,TWNO=;
M260JX<?05U?41SRT]#1U-9/%2TTM94R0TT+S21T])3I)/53NB$)&BL[M90"2
M![]U[K69WG_.@_E*;MWWUQFL5B^^MJU>T=ZY/+;HV]C_`.65OG/9'LM\GM_+
M;63:68RVZN@\[N3;BIE,E%4R3X.;'Y:HEI4IFJ/MY)H9/=>ZI1_X4&_S"?CI
M_,8VE\->IOA?A.YZ7M'#=H][/'D=X?'/>W3D(Q=1T'N'$YG:N&SG:NTL#CJ^
MKRZY2%*NGHQ/+24X%1((I!2L_NO=&-^*V<;?&XO^$;N:$[5<]!U9\T-M?<Y"
MH0SK2[!Z$Q6T7HH:[3+CFBHTV\(J>D^[%6(XT3[<,C!/=>ZWD_?NO=4!_P#"
ME[<TVW/Y66Z8H*S^%ON#Y(?$?#?QM(PU3@&I_D'L3<D.<H9/MYC3UF,J=OI*
MCAX&X*B3U:']U[J_.C7124J&=JDK30*:ER"]1IB4>=R"06EMJ/\`B??NO=2?
M?NO=>]^Z]U[W[KW7_]+?X]^Z]U[W[KW50/\`/;:B?^6?VSC<Q)(=M[A[@^&^
MUMX8R+%U69DW%LC<WS-Z!P>\]L#&T4=14UL.X=L5U52S0K#/]Q!(\/B?R:3[
MKW5"'_"MREV-_?WX:U.]/[OXE<!T-\F:_8&X<G321U^WM_5/?WP7P..R>UJJ
M"6.*//X?;^5R$T0FBK*:GIO/,],^@,GNO=6;=9="=+]^_P`]?^8F>T,,-XGI
M78_\J/Y`=?U4F;W%C'V[W+UW@N_8]B[ECEQV2H**M,%%N!B:*-3B:O[H^6G>
M8R$^Z]T2G_A8-2IF>C?Y<>UZ3/\`5VUMP;A^=FWJ/#[E[+QM'D<9MM9=I9*@
MGW%G(\I3Y'#3]8X6LR5+-N:FK*.K@J8EI=<;(C(WNO=;>FW:>>DV_@J6JKZ/
M*U5-AL93U.3Q])!CZ#(SPT4$<U?0T%*\M-0T=9(IDBAC9DB1@JD@`^_=>ZU@
M/GO\T.H^N?\`A11_+7^-^\/A'TIV?V+N3K+%+LGY5[OW%N*E[1ZSB[6W+VCM
MVBHMFXBCHY]IS4^U*[:==40KDZ>NJ9*C,2?8U&*<RS5'NO=)3^;O2/-\B/YR
M%31XB33!_P`)UL1!D\J'DF\U14]Z_*.?'4T<1AB6F"4=#4L^EIM8C!8QZ0&]
MU[K9^Z?A:FZEZNIW-W@ZZV3"Q"2H"T6VL8C$)/'%,EROT=%8?D`\>_=>ZU4/
MY=7SA^87QQ;^85U-U5_+"^0GR\V'MO\`FL_.I]M=K]0]G=28#:(?,=W9W([P
MVA-ANP,M@L_B,AL^NFBDA*1U=-D6KI"9:8Q6D]U[HR_<O\ZOYD;&^9OPIZAH
M?Y4_S:VUU_W1B.YXNQ-B;DVKT]F^R=VU^WX=EOB=R=7Y;8G:N]-N_P`"ZCIJ
MVHK=R19*KQ3STV4IV#(L2F;W7NC/?SWOA=\9OFI\:>I-J_,WYCTWPV^,76W?
M.&[%["W35Y?9VUUWUE5V3O7:FTMG46[M^5@VUM[+&LW+/4T[ST&5,WC9$IC(
M4DC]U[JAO^9/C^D>O/\`A1/_`,)^*G9VXL5VEURG3'0?7VQ,-_>2IWS'3;:C
MW]V#MKI'M"'-K6C&YBGRE?N:CRE%DX:J>2LGPK54BR)XA-[KW5@O\Z'XO4_S
ML_FD?`/XB4'<6X.H,GV'\&_YD^*W'N3!8+^/5&(VOO[9>Q-F43)C\A68_$Y&
MBW!6)5P9*GCFCJ9L?2/%Y(&FIYXO=>Z!OYP=\_SF_A-TWU9\<?EQU?\`RX?Y
M@_2WS/W[L_X%[5Z\ZUSW<_QU[1WM5=FX'<&UTP>XC6Y"@V[B<;O/;5"(:[)X
MJ6.'`U4X.D0,LJ^Z]T:OO#^8+DNM.BH/C+_,L_DT_+?HWXL9O9^!ZTW7N?XV
M;FP/R2Z&VMLW`TFT*##8FKW1\<]S;7[)V5M`90P8VFA^SI*R6FB2)(I@T\,7
MNO=%N^=W\\3^5+\T\3U/\+/]('RRI>JNPOD+\>\?WEW'UWU%O/JO:W2E3@=_
M;>WYL+8_<F0[:VGM_.46'WKO+;%-0U\>.I?N:.DIJBNBFE6E$-1[KW5G7\XS
M%U/>^2_E\?`.@IY*JA^8'S4V+F>TZ6#,-A96^.OQ/QU7\D>X(X9HZB(3/D6V
M9A\<L;I+&S5PTKYO#?W7NF+^>'59SNS8GQ2_EJ[(S<.)W3_,:^2."ZXWV1D,
MACZZF^+W3N,J>Y_DED::?#,^6@6KVSMJAPK.(GII#F1!,T:S!Q[KW0P?S<_D
M3O3X[?%C8O2'QZR\FTOD9\S>W.M/A)\<,SC(<U4Y#KS-]L5!PVY.U:"GV_0Y
M'*0KTYUI193-Q5(014M724[R%A:*3W7NA5^?GRNJ_P"7+\',AV;M[$R]S]KX
M)>J.D.B]A;HS;Q;@[U[OW[GMO=<;!VQ4Y!JF.OR.9W!D:U\CD)(F:84M-55!
M],;L/=>Z.2>R,?L[JK#=D]YUFU>F!%MO:V0[!7=&\<)#M;8FY,]'BJ*LV]5[
MUK)Z#!UD-%N?)KCH*L/'%62E#&+R*/?NO=";[]U[KWOW7NO>_=>ZIR_GC?-_
MMW^7Q\*Y_DATKVQ\=>MMY;9W_@XXMO?(G:>^]V8[NJFIL3GL_+TQU^FP:^EK
M\+O[>RX,Q4]=5QF@AIEF\M30$K6P^Z]T1ZG_`)N'S&W5_P`)N]P_S4:'8/6.
M"^4D^P=SY&BQ^!QM<O7>"IJ/Y$5O3'^DG';8W)F]QU58^"V?"^=7&5=940U%
M;!H<-`WA/NO=%/\`A%_-;[#@^&/9?5_PZ[6^,7S>^0.?[PZ5^/GQFVY\9?A'
MV5\/^J.D.Q_DQC>Q]UU^]N[\/N:@VYLC(]?[*HMD9K.551B<=2&6OQLM+75+
M_P`0AJ(/=>ZN%[!S77?\CO\`EAT.`Z_QF1[C[<Q_VNRNM,.:"&+L+Y=_-KO'
M-RI293-0XJEGJJ_</9G:&:ER>3F(J)*##PNBM(E-$I]U[JK'NO\`D\_'3X6?
M"+(?.KN#YJ=H?"C^8I@)LAWO\B?YC>S,YN7)9#=?>_=&;QV4WQUWN?J#:E3+
M@NPNH,GOW*Q8K%[4PV.CEF2&*1$F>:JBJ/=>Z&:+^?[N+X*=5=E=9_SA.H9^
MF?F%UCU?DMZ=-9KK;&Y_.=`?S`<;C,)3+@<YT;OFAPE7CMD[IW-N&:&+,87,
M)1C!+61S2+"WFH*/W7NM7;^4Q\5OD]_PHQ_F>YCYS_.>MEW=T%T?G]N9SLS(
MR;9P^*V1N6;;-><WU=\5=G8FGQD6(J=M0Q5"S9Q)(ZFJ_@"RFMJ#79."IE]U
M[KZ@L,,--#%3T\45/3T\4<,$$,:10PPQ($BBBB0*D<4:*`J@``"P]^Z]UE]^
MZ]U[W[KW2-[%V'MOM/K[?76.\L=3Y?:'8VS=S[$W5B:I#)2Y/;>[L)7;?SF/
MJ8P\9D@K<9D)8W`9258BX]^Z]U6'_(^W9NVO_ET=1]1]CUF3J^T/B+N;M3X7
M]@_Q?"Y'!9"*O^,78NXNK]H&HH\EY'DDKNKL-@*LRQRSQ,U20)&8,![KW5MW
MOW7NM>WY$'=_\X[Y3[A^%NRI,GA?Y:7Q)[.IJ'YV=ET52U/3_*WOO8==C,U#
M\(]L0RT=!DDV/U_ES1Y#?66I:B:FJ)HUQ>E'TRO[KW5]^T-G[3Z^VMM_8^P]
MLX#9FS-J8FBP.V-I[6Q%!@-N;>PF-@2FQ^)PF%Q<%+CL9CJ*G0)%##&D:*+`
M#W[KW2C]^Z]UH@]8YO/T?_"3_P#F828J6:<T_??RIPE(,K/44\L&V\U\G-I4
MV>0-5T554-4-19BN?QR(LDE0[*7B8EU]U[K>!ZK=)>K^MY(Z0T$<FPMGO'0L
M;FB1]O8YEI"1%`":93H_0GZ?TCZ>_=>Z7OOW7NO>_=>Z*Y\VOB[M_P":WQ*^
M07Q1W1G9=K8;OCK+<?7TNZJ?%0YVHVK79:F#8;=%-AJBMQT.4J=N9F"GK8X&
MJ(!*\`7R)?4/=>Z^>%T_L7^>'_)V["_F%_R_OY=_9'7G8Z?&7*];_*/>=#@.
ME=M;H[J[MZ_[2VEMC;=-OWJ/KK>>W]]9//X39V.BH(MR8RAGJJC%UT3?:RU2
M/,7]U[K?N_EA]B_*[MGX$_&?L7YP;.J]A_*?=.PYJ[MK;61V[3[0RL&2BW'G
M:+`93-;1I*:BI]J9S<FT*7'Y*MQJ04XH:JKDA,,)0Q)[KW1\O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW5$/_"<^3=,/\N>NP6[$J4R&T_E[\U-MP^99!`T5
M)\CM^U=;_#Y9V>JJ*%,Y75:!Y6:0R*X)-@??NO=7NL-0(N1<$7%KBXM<7!%Q
M[]U[K2NZ![*Z%Z3_`.$P7RKW]W[T'D?D3T;0_(WY+4N2^/N8[,R.R)-SIEOG
M'+@=E8.M[1V3B<!G:.FP.[9:#(5E=1TJSU+4LPCA6.1:=/=>Z0'R;R/1.X/Y
M$O\`)"S_`$1T*GQBZIWS_,W^)&YMJ]15F\=T=L0["DSO8O>5;N>JJ-^;KBBW
M1N2AS^7>KR4<M0JRO35:1*`JJ![KW1SOYTW?OQQ^+W\WS^6?W)\ONJ<OV[T9
M1_&#Y?X.EVOBNGZ#N^I.]:W)=?I'E:/8U?!4I-)A**IBDGJD0R4D$FH<%O?N
MO=%AZ9_FL?RU]N]W]J;K[HZ@_P!)?2&]JO+R=0=7X?\`D?IUOO;HR@BSE368
MO$[L[6QVY]YKV923X95IB\>"@EGJ/#4N:,":G]^Z]U:GV]\I_CGWO_(N_F-=
MQ_"WH'*]6]7T/0'RTVY#L'>W1\G0%/G-P#JZM&]-X4VQ\52XY\G1319UW-:H
M1ZVNHI8974QNP]U[JF/_`(1T=*=.X;<?RQ[TV;W/U[4[LW/U;T)L0?'+;'8>
M2WQO/:6$QF#ILEN[MC?S9;;>U#0_WX[&AJ5Q^-I*>=-OG[FCFF='I)9O=>ZW
MD=Q96?!;?SN<IL/D]PU.&PV3RM/@,)'!+F<Y/CJ*>KBP^)BJ9Z:FER>2DA$-
M.LDD:-*ZAF47(]U[K73;^>1\W\@J5>VO^$__`/,CKL7+61QQ3YZCQ6V,B:`3
M".JJ)<3/MBOFIZR.,$QPL^B1@!Y5!U#W7NJM/YBGSG[E^='S`_E']4]@?RX?
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M[KW51/\`/+Q]1E?Y=.^,=25C8^KK?D!\(::DK11S5RTM7-\UOC_%35$U/"\9
M:GAG=6<LRH%!+$"Y]^Z]UK9?\+1=MU.6SGP1K:3=M/M:6+KOY.T_V>2JZ7'8
MW?&GLSXB"+9BU=7640:N:HK$RWCC^XE-/B9'\)1'DC]U[HS/R=ZYW[FOYV&9
MJMB[)W1N2IQOR6_D&;X[9J=H46:S%#MW9^";Y:XG-[PS`V]:!ME8ROQ>(IJB
MORL4M+32,C:HCX73W7NC/_\`"G?Y:=5_#GK#X;]D]P_`[XR?.;96:[EWIM'*
M8/Y$8V7(9'95)4[8P^<KTZSG.(RU!A,WN^@P4D=3D*F*JAIS04X-'4AR8?=>
MZV7M@Y#%9?8NRLK@<?18C!Y/:6W,AAL3CA&,?C,56X>CJ<=CZ`0T])"**BHY
M4CBT11KH4611P/=>ZH+^:O\`+E^;O<W\[#X#?S#>KY_C!D?C[\6\%B.O]P[5
MWOE-V4?;;X#=];V%3=L[HH:$;.R6V\GD\#@=XK+MM8\I3R0Y",.Z`-(Q]U[H
MJ?\`-BIIXOD#_._DJJ^G2FKOY`G6GV^1,<[R8"E;MSY6T7\&FI(A+45D.<JX
MZB9IXHI!3J`'*$KK]U[K:/ZIIH:/J[K:DIYI:FGI=@[.IH*B>DFH)IX8-NXZ
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M(?'7<;T>$["[-SWQ=KQ'--\;>NZK*8D;JVGOS(T-5CJ:G>.B?"K`9$2L(-/%
M[KW5LGRB@Q$7\_3^555Q5=\]6?$?^8#15]$SL!%BJ.GZCJL+41JT:H9*NJJL
M@#I=VTT_*J`"WNO=(3^9WMMN^_YMO\C?X\T=735-!UUV9\D/FOV!C%R5"E1B
M\;T+LO:,'66:J\<CC+@9'L#,O24;72GGTU5Q+X'">Z]T=_OO>6\-T?S+/@AT
MAL7N'(;-QFR.M?DS\E^].KZ',;LPR=K=>T^!VYTQUQ2UL.)HZC;&YJ';_:._
M%R+T&5D@\9I%J:<M+%I/NO=5F_-3^5A_+_\`YFG\T[?FPNU=T?*O%;NV1\9N
MC>S?DKU=U3DQL3XY]NK!O?L7;G0F0[3W=!]SELIVGA<(,[!24]+3T\RX2-7I
MJ^&2*IB?W7NB`=/_`,MSY$;6_FZ_(^G_`)6_S+W-LK9G\MOHGJSJ[:6ROFE3
M;U^673V*WU\G:',=B=@?'WKK,Y7>U%N3K79./VOMO`9/*U>,FDSU)D*U:9]5
M.]V]U[IXI?Y@WRYV5_,N[+^4/SQ_EZ;S[9P?\L/XY57Q;WMV7_+OJZ?O?KG:
M7<O?"=;=M=D=JX_"]D5G6N]ACZOK9,9CY\53K5U>SJ2HJ_XK+*E0DT'NO=#-
M\4/YG6POYNO\U?X1;CWM\?-\?'CX^=8]!_)GO_X)9;O&JQ-%G?E#WB^>V=TA
MNW<V"QV)RM7MF_4NT%W8F.QM/59>JDE,^28PFFA$7NO=6'?*/;3_`#9_F_\`
MPLZ'P5=!D.K/Y:&'RGSE^2RHM%4T5/W9V9BLGU_\-]@-505HR6.WC20XW<V[
MY8'A$(Q$%,\A)JZ?W[KW6'^8QF*SY@?//X6?RJ\=B*;,=5O#2_/WYK5+0U+R
MTO3O0V^Z$]!;#-7!5+3TE'VE\@\'3ID(I(_N):'%_L.J^:_NO=&\^97R_P"R
MNI_D)\)?BA\=]L;8WOW?\G^UJ[,;WIMUXW.Y/`=8_$KJJDI\AWSVYEI,!E<.
MV+RM)/F\1A]O?=SBGKLSD5B"2Z'4>Z]T>S/]A;$VKN78VS=R[QVS@=W=G9+-
M8?KK;&7S>/H,_OG*;<V]D=V[@H-J8FIJ(Z[/5.#VQB:FOJUIDD-/20M+)I47
M]^Z]TL/?NO=:R?\`PJ=VM2]I_";X[]*TVX.M$W%OGYF]:[@3K_M;N78?1&SN
MQ-C==[&[*SW8E'G^QM]9W;*;=P&$Q51!/55F/KH:ZF>2%D62_C;W7NI&,Z\Z
MK[B_X3)5O4W7W:>"V3UIN#XPY?9-%O7IS(=J?-'";/IZ;LZHIJ_9VWCC=GGM
MKL"CQE5"^WYZ*'$)782+R4\86.A28>Z]T'W_``E\R&T^O^JOD;\5,5W#U/VS
MN3HG)]5'-#K3X/=E?$S<.VJ#/;>S<>(A[BWCV5UGU3N/N7?^6@QYE$^6QDF9
MHHHY'DK:VGJH#![KW5X7:?P@V[W5\T>A/EIV;V+NO<^VOC)LO<,/3'QUJJ+&
M)U?MSO#=-964>3^1>1<7K=P[_P`9LBH&&PJ5*-'A%>HJ:5UFJ7M[KW537R4[
M%Q?R9^:V^^Z?F)25?1?\IO\`E"YRNS^0J>\=O9C;6U?EK\U!0+1X?>V)V[N+
M&01[^ZW^.ZUCT^V7IXZE<UNVOBDH%KDDC\'NO=:SU-UY\W/^%:?\P'&]G[DP
M6[^C?Y8'0>Z<EM?"YQ9YJ/$;7V7'D,;5[CP>R*_)8JOPF]/D]V=C%HY\G4)1
MST&`I?M%JO\`)Z>CAKO=>ZW%?FKVUU-_(9_E0;RW_P#%KX][?J=C?&_&=>[9
MV%U/13U^)PV2RF^NPMJ[&J-R;ZW/24V0S5;75-3N*3(Y3*U1FK<G7<2R^2?6
M/=>ZMNV5N"7=NS=I;JGQ\N)GW-MC`[@FQ4[QRS8V7,XJDR,F/FDA>2&26C>I
M,;,K,I*W!(Y]^Z]TIO?NO=>]^Z]U[W[KW5+7\N[,[IPG\R'^=UTYE):JBVGA
M._\`XK=W;-V[+44DU)12=Z_&/!TNZ=P8U:6MJ?!%NO+]8+43QO'`XJ4D+JSL
MS'W7NAH_FQ?*_?GQH^-6/V=T+%]_\MOEKO[`_%;XG8WP1U,5'V]VA#6TJ[[R
MBR5M$M-@>KML4U?GJF<F6..2BB$D4D;LI]U[HS?PO^)W6_P@^,_5/QEZL6JJ
M-N=;8#[7(;CRK>;<6^]XY:JGS6^.P]U5K,\M?N;>^ZJ^KR-9([-:2H\:$1HB
MCW7NC1>_=>Z26_MX8[KS8N]=_P"8CGFQ&QMI;CWAE8J;1]S+CMLX>LS5='3^
M1DC\[TU$P340NHBY`]^Z]UH4_$?#?S</DG_)KK/@QU!_*DVM6_'WYH?Z6-S;
M7^6^_OE9UKM48O;/R`[MW)V=B>TMS]53P2=@Y*/8U-E:04DEYJS)46-@J889
MDDB@?W7NM]S9.#J=L;-VEMJLJ8JRKV]MC`X.JJX$,4%54XG%4E!/4PQD*8XI
MY:<LJD"P-O?NO=*?W[KW7O?NO=>]^Z]U4]\[/Y5>V/EIWS\=OE_U!W5NSX@_
M,;XY;@I/X%\@>M=L8C<F1WUUBT[RYSI_L[;.2R.%H=Z[/R44T\4,59/+!3Q5
ME5%)!4P5$D/OW7NK81>POR?R0+"_YL+FWOW7NJR?DU_-0^/_`,1/G!\5_A7W
MK1;@V94_+S;69GZM[EKHG/7#=BTF[<3M'!=69.:GI)ZBDS>Y:_+P!*QV2BHY
M*FE2I:-:E)![KW5FWOW7NO>_=>Z][]U[KWOW7NO>_=>ZI0_D`R3?\-[RTE7B
MZW%Y3&?+GYU8_-+5Y*DR$=9FX_EQV]-E:N@AI*:E7$T`K)VA2D<,Z-"SZW5U
M8^Z]U=?[]U[K2.Z+^('<OSF_X3'=\?%'XM8G96^^R=R_+OO6+9E)N/,TVS\#
ME<1LCYQ5&^:RKVYD,S38RAPE=48+$O)11Y!,:@ULKB,E5;W7NDS\N/B=\B_A
M-_(6_E.=6_*Q=KTO:?Q/_F4_&S=V\,]0;N&YMJ=4["S':_;=7MU=W;DFKJ+#
MST6TZ#>^,Q%2U++-C:8+&D$_A42^_=>Z.I\[_P"8K\6NOOYS7\M_O7KG?&7^
M86%VS\7_`)M[(W5U]\)\?0?*'?VT:S)#8-?0Y^OVIUIGLK4Q4.0I<5D/NFTI
M)34N)>>0-"I:/W7NA2Z;_G>=/=<U55LOIW^7C_/A[ZI-\;[RF??=&_>@^S^U
M*@)D*6@J:U-EU_;W;M?D\)M/#K4P"'$PKC*"E24R@*K:V]U[HQGR6^9V[?EQ
M_)*_F7]U+\:_DE\2L_@?CO\`,7KJEZ\^1VQ*?9O8U93[:ZSS^.DW90X1ILE#
M/M[+4N0D@:92Z0UE-5Q122B!:A_=>Z('_P`)<MD?RYM^;1[*^3_PWV1WOU]W
M-@NE?CQ\7_DOA>PMM8#:/5>Y=[[2V1B<UG>U>K\5@:O=*2UW:&Y,9-D<LM1G
MIZFGET.:&BBJX6J/=>ZVR=PU^2Q6W\YD\+A)MRYC&X?)U^)VY3UE)CJC/Y*C
MHIZBAPD&0R#QT%!-E:J-(%FG988FD#.0H/OW7NM:/Y'_`#%_GR]T]15VP=@?
MR>.ZOB[O#*Y#$U'^E;JK^8[\$Z[=F/HZ69YLGA,7'V;UAOO;T29BE)B>?[`U
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MQ_J/L8+'W[KW3S[]U[KWOW7NO>_=>Z__U-_CW[KW7O?NO=5-_P`\J<T?\K#Y
M6Y!<KF,$<5CNI\P,QM^>"FSF-_@_?'5N4^[Q%14U5%2P9"+[2\3RS11*]B[J
MMV'NO=:I_P#PN%JS'O3^6C!YY8%3#_*&K,DDLDE%"5RWQ^3SR4,4;F26,<EU
M)8H"H!]^Z]U>3UM\O^J.C?YOG?.2['GR-56?(3H#^3]\9MB9#9VU:F.'/]I]
MUUORWW!MO(9BDR%;'-0;?>@II9)JR:4RT=+!'3^*:51?W7NEK_PH,_EQ?,'^
M9)UO\2=A_%;+=`X6DZ5^0$_>^^JSOC<NXMNXZ7,;6VV^(Z]QV.&`V/O@Y/&Y
M*;/96+(PRP(+M36UKY-/NO=;`F&?+R8?$ON"''TV>?&T+YNGQ,]158J#+M2Q
M')0XRIJX*:JJ<?%6%UADDCCD>,`LJDD#W7NM,W^:'LGO#%?\*@OY47:M9M#M
MJC^.FX,?U+UGB]\4-+NNIZQS?:6.S'?6XLEMF.IQ#38>#.X_$9&CK*VGF$;?
MP^*2IF4TL4LB^Z]T/'\UFLIZ#Y.?SK\A$V1DS%%_PGJVG'1&EQ446$IZ"M[<
M^4:9:#-YB!HJALX[14LF/CDU&6F:J`(6``^Z]UM1[&KJ3*;)V?DZ"0RT.1VM
MM^NHY6CDB:2DJ\325%/(T4J)+&7AD!*LH87L0#[]U[K6%_EA;D_F;YU_Y@]3
M\1]O?!Q/C?-_,R^=65V%N[O^J[?E[;WGO/,?(>NDWM)N;$]79"GV]B\%@X35
M#&S.$K:Z)*2%X88U-6_NO=&/VKL7^>GOSY[_`!J[4^0_1'\K^@Z6Z3S/9.WZ
MWL3K+??R$RW8N+ZP[9&#I-\-LNEW!E,)#4[JR.#VGC84AR6)?'-60B8K&%5D
M]U[JXWY:_(G:WQ*^,O>OR5WEX9<%TMUENO?;8V:>6G;<.7Q&+F?;6T:.6"GJ
MY_XIO'<KTF*HUCBD=ZNLC559B`?=>ZU%OYDF1W!GOYY__";_`+![UQV(V%\@
M-W=?[&J>Z^N=L5=;E,#L#>-?NH5E#@<7+5TU17RXH]E[HRN(BJII',RT0+&/
M27;W7NMG7YK?`K"?+?/=*=L;1[C[&^,GR<^-N5WAD>C_`)$]3T6T<ON;;6.[
M#V__`'9W_LC<VUM]8/<&U-\]?;RQL5.U;C*N!&%31P303PNKZ_=>Z+?\+/Y7
MW;W2/RRW?\X?F'\W=W?.;Y&Y/IMN@>O\SF^G=A=-;.ZGZPJMT8_=V8H=J;0V
M;692ABSF=RV+B-36P&BUI+4*\<GF++[KW1T-M?%=\/\`.+M7YHY3L+)9NIWS
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M\EY,E'38VKH\[W)AZSN*3:%;*DV311UMU;1X;:L+$L/%AD*PQ`B!/=>ZJ-_E
M]?R2/Y955_+?Q/SD^<OQVH]O[Y[0VEV1\R\_N`=P]N;;7XS]0[KW#NCNSK/:
MG5^5VCO7:4.TJ/K7K2MQ]4:R"G@K:G)-.\[,K+"GNO=9_P"5W\+OYCGQ@^/^
MY/YA_0_R_P!A;IP?S/VKA/D[VCT+_,2V+O[=V^\7UU@\+F:WJ*CW#\M]O=BS
M]@-NK`=%28RCGR.0P=5BX6!<4"QQA3[KW0!?RGOYW_QKV[NKYB_//^:%C>Q/
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M9/<L:ZG\"%?=>Z)C_.@_ES=1_P`YK<O2OPQ_V:?K[J/L'X]5FY?D#V-M3&8O
M'[V[NQ^R-Z[/RFQ=A9;&;6DS6*_A>S<IOG[=LC+5-&E9#2K'"Z3!''NO=2^B
MOY5]?\1?Y*78G\NWNGYOUO6^V=K1]FYZ+Y?]?NG4-=U+L&K[5?N&DS#5N:W`
MD>WXL?)'.N6:7*B/[:LJ(8ZE4T./=>ZE?R,OB=\(^A,=\I.UOAQ_,-[`_F$U
MW?F[M@5W>F_=]=P;0[5KL5V+M+%[E<Y?)/MW'469H-Q;QBW3-+//F)*JKJ:6
MEID6:186D?W7NKY\EDL=AL=D,QF,A18G$8FBJLEE,IDJJ"AQV-QU#!)55V0R
M%=5214U'14=-$TDLLC+''&I9B`"??NO=?.H^=?R5[Z_X5(?-_-?`/X9[MV]T
M[\-_BQ@>P^UJKL7L,[G?:79>Y]DUQV?3]G[UKMF09_&4.W,O-F(Z;:%/4QQO
M34%575LLC3S"CA]U[K80_P"$VW\Q_P"+OR.^).S/AEUUL;`]$]U?$/K_`&SM
M/>/6N-K<(-L]J4L`K*+.=]]15$60;-[QVSO;=%)49',5=12I-39+)CR23I-%
M42>Z]T>'^?+TUFN^OY0OSMZZVWM6KWIN)^F9=YX/;]`Z)D*C(]8;GV[V7'54
M"NDAJ*K&1[3>I6!!Y*GQ>%+/(#[]U[HP_P#+&^16TOE=_+\^(O?&RZNJJ\3O
M3HS8E/7??M1MD*3=6T\/!LW>V,R`H<AE($K,9O#;]=`Z^9WO'=K,2![KW1[/
M?NO=>]^Z]U[W[KW5$GQ.7+'^?G_-QDCJ*B/!#XQ?R]HJRE`/VE5EQMKLI\;4
MNQF4&IH:)ZI%`C>R5!NR7`?W7ND]V#+5?*/_`(4,=([!_BGW?7/\M/X:;K[V
MRNWZN61*$=__`"ERF2ZQV]D*2EHJ\ID,GANJZ1I8Y*V'31"HE\(#S!_?NO=7
M^>_=>Z1_86X<KM'8.^-UX'!-NG.;8V?N;<.&VRM3+1-N+*X7"UN2QV"6L@HL
ME/2-EZRF2G$J4]0\?DU"-R-)]U[JF?\`EP?/7>W\U#^5'V[\HNW]D=7;/??V
M/^3>R(^L>O*G,;GI]M[.VOA\SMNFV_ON3=%1+_%-X9.E62JG1(:2DJ,?64KB
M"+RL@]U[K+_PFX@GI_Y)?P,%17UF1DEV)V'.)ZW)#*20P2]W]G-2T$,XJ*E:
M>CQE)HIX:8,OVL<0B*(R%![KW5X?OW7NO>_=>Z][]U[KWOW7NO>_=>ZUT?Y@
M/\[F3^5Y_,QZ\Z>^86*QFW?@5W7\9I=V]?\`:6T-I;AW;V%@N[=K;KR])NFG
MW)C\-4UM97[7K<;44%*L5)0/-2S2TTQO'+.\?NO=5%?._?ORY_X5&]74NP/Y
M<OQ>V+L+X>]&]K9G/8_YH?*[/0;$WSO;MK95!4TT&VNCL)MN/=6[]H[;S.&S
M4+U=9)05"5<\D,%;-BIJ*2*7W7NKJO\`A/#\UNV/DK\/MS_'GY2U6='S/^`V
M_:GXV?(:@W539([HJZ7#/DJ7K'=^?S60K,B=T97<&WL%44=7D_,9<E78F>K9
M2M1'--[KW5_/OW7NO>_=>Z][]U[KWOW7NJ0/^$^6Y*G>/\OG*;MK*"7#56Z/
MF1\[MQ5&`FJ)JJ3;L^<^6/:V4FP;U,])0-4/035;*SB"'6Q)*(Q91[KW5W_O
MW7NJ&_\`A.O1PXCX*=I;:H*!<=@]I_/7YR[<V[`F1H*Y?X)0=^[F>E"T](6K
M,2M/)/)`*>M_REQ%YQ^Q/![]U[H(O^%0F6Z_PGP*Z!R7;T-?E^G*/^8A\1*O
MN'96(HERN;[%ZNH<[NG(;WV1@\*\]/%F\OD<'22U$%([!9GI;$C]0]U[JFWH
MKY4?`>D_G8?$??/\KS^73W=@?[O?&;Y.X3M_ICK3H'8/QSWSN:KSM5@HML[V
MH=L=J;UZPVGF<+@H:>I2IJ3E(IX890B0EHS'[]U[K8$ZF_F"_P`SO$[A[+Q?
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M)X`N,RF7F::=9"T:%X5]U[H@'RGWW_-CWK_,#_DIP_S`NA/B%TUUI'\[*2NV
M+/T'V)O+L7=E1OV/K;<;UF+W2=R5E/BJ3&?P.67[=Z2"5DKH-1F92BO[KW5?
M7Q\IH,1_PI#ZUZV@RU/)@-I?S@/YJ>]L#MB7-U$&0P59V?\`$_KS=>?R$=+7
MP55'#A\QF<?>GAA=9ZZHAF`TA-?OW7NOH5>_=>ZH`_X4]UF(I/Y,'R?_`(S7
M45#!-N7X_"$UM!7URU<E'W_UME*FAIS04M8])4U.,Q]0%DD5864&)F7R`CW7
MNKZ\'+2SX7#ST)1J*;%X^6D:-&CC:EDI(7IRB.J,B&(BP(!`_'OW7NG3W[KW
M7O?NO=>]^Z]U_]7?X]^Z]U[W[KW51_\`/9S%+@/Y4ORQS&0Q,.>Q=!0=0S9C
M"U%-'70Y7"'O[JF/-4#T,Q6"N^ZQ3S(()"L4Q(1R$8D>Z]U7!_PJ(ZE^&?8O
MQ?Z]RO?W6'=6\?D'MW%]CS?$O<74^R-^[YPFS,_!DNK<KOJ+M'#[;KJ;9E)L
M[<&.Q]!223[A0TT2&9H'CD5B?=>Z6^_OB+BODK_.@[GH-M;HPNT:CX]8'^3?
M\KZZGK=KSU_C7HOL7YH4TG7N$BHLOBH-NU^X]IY.%$JVCJX*6&5H_`Q</'[K
MW11O^%@?QR^1_P`@.AOA-3_'+KGM#L?-8WO7>>ULQB>MERU;(\_8&WMMTNUL
M?DL+BU'\1J<OG<"L=$SM>&1)`JGR,R>Z]UML=88_)8CK3KS$YFGDI,QC-C;2
MQ^5I)999Y:;)46`Q]-74\DTTDTTTD-5$REG=F8BY)//OW7NM33^8?L";L3_A
M5!_*K1:S$;(H>O\`X]1]E5F6[)WW1[6VWV94;<WEW#24NU.HL/D9ZR/=/:./
MFSL+/CJ.GCKJNE#2$K#2-.ONO=&'_FJ[<HI>V?YT=16T<,,FX?Y`NQXZ3<<M
M*M=)C*?#]I_-Q*S&0K3"*O@3*U5132LGE$4KTB.ZL(P![KW6R%U;@XML=9==
M;:@J)JN';VQ-HX.&JJ`@GJ8L3M_'T$=1.([1B:9*<,P7C43;W[KW6KO_`"]-
MK?S7,OL[YYY+X,]T?"#9W6&/_FG_`#PH=I]>_)/I7NG=.ZI\F.^\BF^ZG-]D
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M^(WSK_E$=`[B'\N3YK[G[^[9^<'=.7VUN7X^?*3;&R,]OONSY7]_XG-C?G>7
MQSW_`+5FZR_T8;]Q>#Q51NC(XS+S5FVXJ;`R5DTRO&T-9[KW0K_"_P#F%=9?
M#[X#;'_ET[3Z7W9\<?YG'2?1E-UEUA\-_D!%0["?O_Y)Y*A\%3O3J7N2L&3Z
M=[=VWV/VWG*O.U%50966I(J)A44T`*LWNO=6?=7X#IW^3)_+)R^Z^T<YD<E3
M=,;$W#W1\@M]9;(2YS>/='R+[$R`W!V%G:[,P8YJO/;O[9[AW$,;BRT#LHJJ
M.F`\<2V]U[HJ'QQ_EO=T;_\`CWW!\B_D/\B>Y_AQ\X/G#V1BOD5\C.Q?C[G=
M@8K?74'56#VCF,%U+\-4WCO?;/8&WO\`1ST5L;+HE7D,?2XZKJLW`]2]0X37
M)[KW28^-G0V>_F,_RBOD]\;^VN_]][R^*/;==OGKWX=?+/N&KDW;\AM^?'G9
ME1@*O:_R&[OK<G5[0I-R5-9W%MO+UV#CJ*?`SU>S*3&_>!9)FJ']U[J;_(S_
M`)7WRS_EV;[^:&XOE3V9TEWG5]^0?&RGZ_[AZJ@K\%F<WM;I3:&^-A8S;FZM
MF?W2VO@-NQ;>VO/B#3/1-6M5RU%0TU3.Z^5O=>ZJ\_X5O?S4LQU-L?87\L[H
M;LW;^V-]?(C'SUORGR_FK(:[8?3&6J<11;2VIE<Y1&?^`4'9TTM?/F(XX)ZT
MX#'Z&1:?(*)_=>Z1G47Q.Z*Z%PO6G\DGX?\`8VS]D5V_L'UGG_YS?\R_:F=H
M]K9>OI-XQQY[9?Q&ZD[+S>1Q2GL/OVHR"8G`X"EGG?&;1K9ZIL;65=3ERGNO
M=6C;^_DO9?YG]VYGN#LK<&]?@?#\,<;)\9_Y5]#\6\IMW;F[>KNLM@4F)CQ/
MR*WYN/$U.4J-WU&^<LDU%B=GFJQM!B]HTXAJHUR60K)(O=>Z$?H[^:!W#\5.
MU\'\(/YT6WMF]5;[W.]1@NB/G;MJEDPOPW^5>)HZ"N)I-VYO<+P8SH[N2JHL
M>QK<)DY(L;6U#M]N::.:ACK/=>ZK*^'ORW[&_EUX'?\`\W>@_AW\C][_`,C[
MYA=E[R[5Q?6N.V[BF^0?PEWS_&LOC=T=D]?=+83(OM[*?#ONBKHDRF&-!6I'
MCJ()42/3*(?XU[KW6R7\5OYG'P(^:FR:'?7QR^4O4>^:"I.+AK=OU.ZJ#:F_
MMNY',M+%CL/NGKW=DF%WEM[*5E13R1P1U-$@JFC8P-*EF/NO=&TINT>LZW=D
M&PJ/L38M7OJIQ\F6IMETV[L!/NRHQ42"67)P;<BR#YB7'Q1G4TRPF-5Y)M[]
MU[I=>_=>ZIC_`)<&)W#O'YX_SHOD-F\?BJ;&[C^5737QPVA44BRBMJ,+\7?C
MOL[%Y&645/EE2FFSO84^IDD$4E:E1IB0("_NO=%G_E(8JA[`_FL?S[OD#G,8
MM;O/&_)GJ#XY8+=?\4FJ$I=B]7==2T<FTZ/%R+":(P5./H)ZJ9E=9I%CCB;1
M`Q?W7NMC3W[KW27WQE:3![*W?FZ^HQE)0X?:^X,K6U>;H:S*8:EI,?B:NKJ:
MC+8S'@U^1QD,,+-400#S31!D3U$>_=>ZTW_^$N?:V1J/Y./\Q"?.93$Y;9G5
MO?GR@K]L4^V\578C`46W*[H79.^<K!MNAFI\9N.EP==DLA4U-)!4^.LIXYPA
M\;#2ONO=6\?\)K,C5Y#^2;\&A68J;$O0;1[&QT$<TM#,:VDI^Z>QVI,K$<?)
M)&D.1@E$BI)IG4&TH$FKW[KW5Z'OW7NO>_=>Z][]U[KWOW7NO>_=>ZIW_G7_
M`,IWKO\`FR_$?,]8UT>.P??_`%K3YK=WQF[*KI,D(=G[ZJTQ<F7P&5IJ+)XZ
MFK-J]D8[!Q8K(?<K4)1%H:^.)YZ.)6]U[HEG_"<S^9-@N]^BZC^7;W/M7!=-
M_./X%T6X.I.RNH=O;1;;>$RVP^H<WA>O*?L+'##4\^T:3+P9G(08O.TT53')
M4Y>*6NIX?M*E?%[KW6R52X?$4-=DLG0XO'4>2S+TTF8R%+0TU/7962BA-/1O
MDJN&))ZYZ2G.B(RLYC3TK8<>_=>Z<??NO=>]^Z]U[W[KW7O?NO=4@?\`">F@
MW+2?RW\=6;UEHQO;.?*;YN9C>F,I#4%MO[ME^6';='N/`UC5#SZJW'Y>BF#F
M.:IB(8:9I1ZS[KW5W_OW7NJ$/^$[FVJW"?$/Y-9IED?`;[_F6_.[=>S*Z2JI
MYSE=LT_;TVS4R"T\.F;'!\UM&MC,,Z12EHS*%$<B$^Z]TDO^%(>$WCG/B_\`
M"^':GVD\-+_-'^$LV:Q44L$.[<\E9O/-83!8?8,M125<<>Z)MRY>DE#?ME:6
M&8EB@:.3W7ND1_,]W]W'TI_.0_EO]J?&SXJ[D^9O=E5\1OFQMBGZ8P/:>RND
M%H-MT>?Z7JYM\UW8O86/JMJM1XV'-5U*V/FDADEJ*FG\3>1UBF]U[K'TW\G/
MYBG2NYN^<GTK_(8[NR63[8[0RG8_96/W5_-I^.>_XL;V/FZ.AJJJ&FV]NG?V
M^Z3J.DR=+5BI?#XI*.BBC>%XJ;QNGC]U[JS;`=Z]_=T?R_/D+V=\DOC]G_Y?
M79U)U7WW25&T-R[FZZ^25=L;#X/K_+38OM%$P_\`!-D[UHXM<E8F$KC31U7V
M9@J&6*77[]U[JBS_`(2^]X?"G?E9WSL?K+I?/;'^7='UYU;O[LGLO<_Q"ZH^
M*-3V9TQN3#X1=IY/;NW.I.P-];8_@V8W"[9R62E@PM%E(\M1U$$%0L/E3W7N
MMN;)G)#&Y`X9*&3+BAJSBH\G)/#C7R0@D-"F0EI8IZJ*A:JTB5HT>18[E5)L
M/?NO=:\WR,[M_G\_'W95#O?L'?7\D;K_`&77YS;NSLAOS-T/SI_AVW]T[QW)
MC]N[,HHZ"GI<\U9+N?-96#&1-4M3TZU,D=W5I40>Z]T3KYE;6_FE;B^:'\DC
M/?S!*/X'S=88G^8=@Z?`4OQ.3OA-PP]IR==[TW+M2MW0>XY_&<-'B-FU=1"E
M#&KPUL5IRRM&J^Z]U6#N'K^3;G_"W3;\6+QV<KX,WNZ@[!FO3SM]NF7^`E75
MY;)(ZT"JV$HLA'+>0:D4*4:74IM[KW7T*O?NO=:_'_"H3"Q9C^3!\E9'^Z,F
M(WO\:\E3QT]<**&663Y']6XATR"M3U4==0_;960F%D8&0(]B4`/NO=7[8B/P
MXG%Q:0OBQU%'I4JP7131+I#+%"I`M]0B#_:1]/?NO=./OW7NO>_=>Z][]U[K
M_];?X]^Z]U[W[KW517\^/2/Y2OS*D9(Y/!M#854B3(LL1EI.X^N:F$R1.#'+
M&LT2DJP*L!8@@D>_=>Z0/_"@/>OR8ZY_EE_*#>G0N7ZNP^U,7TKV%1]Q5>[X
M=W+V)2X'/+@,'@\AU!78'[G;\.;HZBNJQ709BF:"HIY4,4].\;,_NO=`)VOW
MENKI[^9_O_<G7N=VGM?-]G;2_D@]2]KQ9K"XRKS&^:'NOY.?,O9>>V_CZ>KJ
M4J,/N:/9-2*B*1&J'IJ.BE*1ZAYD]U[H`O\`A3W6[:W/D?Y/71FX3AUI^R_Y
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M>*R!P,V[LE5U,3(!!$7U"B+RS7]U[I.T_P`,OY_FZ-W;.[+[#^;?\L^'L[8%
M-N'$[)WSC_A+D=Z[LV=@=Y?8Q;SQ&UMVY^JVWF\#C]VP82@&2IZ,TZUOVL2R
M,1$I/NO=`YMG8G\P[^7S_,BZ+^5'RUW'\//EBO\`,-WOT[_+[WUOCJ7JO>?4
MW=O5$&+P?9.]^OLGL7&UNXLWM_*[#R65Q,V0WOY`9GAQ-"\:1)2HR>Z]UL_Y
M;<>WL!-AJ?.Y[#86HW'EXL!MZ#+92AQTV=SU1355;!A,-%63POE,O-1T,\J4
MT`>9HH78*51B/=>Z>??NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW3;/A</597'
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M9"8CYA?(02P--5RS[%JJ&/K'#2:F@5J'/-&4::4/[KW7+>FQOAO_`#J-R?(S
MHWO?XK+VO\??AWVQ'UEU]\B,KNW(8&+>'R#AP69Q7?V%Z<J=F5^!WKA:+I6J
M?&X?(YC[XT&3W`9H8(C)AQ,?=>ZU7OD1\4OYE7Q[^;:T^TML?S4?YDW0?Q(^
M=G2O<?3NWY>Z,AVY\8\W\9^OS)VUN7KG=6*R];4;AWM\HNMM\M'A,8TS"GHW
MQ[)-!*\]-`WNO=7H]T?S!M@?SD=W]:?RTOA'N7>^(Q'9=%5[X_F7YS=FS-Y]
M8[_^.WQAV7GL9ANP_C;G,;G:+$U^#[S[OW/5KL^LIZ26J_A6)DR$K,R2)*GN
MO='<_FL=L]8]9_&;:W\O+8'7>#W=V_\`/S`9KX9_'#H';F-CQ^#V_L[<6U4V
M7OGM?+8C#8;(T^VNF/C5L/,)F\G)'2I##%2T]-&8O)Y8O=>ZH-[$^3OS%_X2
MD](;;^.^_'ZY^>GPWWCAMZX[X@[Y_B5-TQWAUGW/7&IWAG-H]J;*FRF]9=T=
M/QY;)5E92U>->HFID=*9ZNF\E+2)[KW5!?PYRV%W)A>\^X_EW\?>P?EK_-5_
MFN9.OZ8^'&!^6?3N2V;\=,12]LK_``?)?(_&]T]J"AVAGY\$N2IDPD&!$#8*
MBQ=-24%3"E7KH_=>Z/;N/X9]"]=_'+#_`,J_I3JOY$_S8NN>E?E#5]S_`#TW
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M1UYU[A.@/FOL_8U$^_?B/@<E@,2=E4G?6)V!0U5%N?XV;CH*V),3N^`U\V/2
M6G2H=(&AA'NO=6<]L_RH_P"4C\],11=P;I^*WQM[2B[$VR];A.[.JZ#%;=R>
MZ<-GZ8/1;IQ78W5%=A)-Q58B82T.3:IJI8"`89%Y]^Z]T^_$[^37_+9^$':5
M#W9\9?C'MWKKM?';7J-H4F^WW5V#NW.Q8BNQ\&+RACGWINS<,4.0S-%!HK*F
M-$FJ-;ZV.H^_=>Z.A\DN[]J?&CX^=V_(7?%;!C]I=*=6;Z[/SU341U,\?V&R
M]MY'/24XIJ))*ZKFK&H1#%#`K3322*D8+L![]U[HB?\`)4Z*W9T5_+DZ%'9=
M/7P]Q]WP;I^47<[Y;)Y#+99^QOD=N;)]JU])EJS(Y/*RR93;^$W%08JH990L
MLM`TA19'<>_=>Z([_*DRTW4?SK_X4.8'>#48SNU?F!L_O2?;\&5QXRDFP.Q.
MH,GO7:67%,TT='2TV7V[1(L<\DJJ:B.2.8QO$WOW7N@KWW_PHYJU_D_[Q_FJ
M;`^+*8FDI/D\GQ_ZYZOW_P!I4-8^]\/'F*&AJ-YUF<VCMVM&WZX1"O5L8T,P
M5J!G2IEBEB<^Z]U=]TWW1C/FK_+_`-A][8F;;VT:3Y+?%;';XD6HS3UFV=D9
M'LCK+[S,XS([ADHZ.2?&[+R^2GI:JK:GB8K2.YC4^D>Z]UK-_P#"<G=VSLE_
M),^?_54&V.L=G[HZ'W1\GNK>R.Q>H:J'-X_MN7&=%X]\/W!4+C6\&=KIMOLF
M.ILE3!8\W38B*H'[KRD^Z]U9C_PEXSE=GOY(OP[FKTHT?&R=WX.F^SHJ>B5J
M'#]^]F45&]0M.B"IK&@B'EF>\DK<L2??NO=;`7OW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[H,MN=+=0;.[&W]V_M/J_8.V>U>U:7;U#V;V-@=I8/$[V[`I-I0
M5%+MB#>6Y:&B@R^Y$P%+5214GW<LI@C;2ME``]U[H3??NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U3I_(Q@J:7X0;JI:VIIZRLIOF[_`##Z>KK*1@U)5U,/S8[RCGJ:
M5E2)6IYY5+(0J@J1P/I[]U[JXOW[KW5+G\AW,8')?"GL:@P-=35B;;^>/\P?
M"Y"&FD>3^'54WR[[8W!0T<KO<M))M_.T52INUXJA#>Y/OW7N@C_G^;FJ=N[<
M_E2IHQRXC)?SH/@JF<K*ZH>EDHJ7%9?>V<II:6HD>+'0!ZS&HLSU+JBPEK>J
MQ'NO=!#_`#--[?+;9G\ZC^7!D?A=T_M+OOMBF^(7S!CS_7G9O:(ZCZ^H>N\Q
MN[J*CR^ZY-V1QY6K7)4.9IJ$24T>,R,DX2#1"Q0S4_NO=('K#Y]?SS^XAVIN
MSXR_R]/Y:78;X[LW=W779V8Z[^8F#SF4V[VGU\E/MNJVUV;D(,IMN3*;PVUB
M:>ABDCET3K1B%--.+1Q^Z]T<[M/LWYR[K_DK_P`QO=O\Q'HWJWH?OC&_%OYG
M8NFV3T]OB@WAM+);#I^@=PKMK<_\8J-TYZDH,CE,C65L4M,^09ECIDDTHTHB
M'NO='P_EZ=:;%V;\,_AQD\#C,-DMPP_#/XP[*G['?;%#AMX;JVKMCJ3:R8"G
MS-:T+9M,="9Y*B#'SSRI1R3N%&HL3[KW1Q\]292OP>:H,'EC@,U6XG(TF(SH
MHJ;)'"Y2IHYH<?EACJP-29`XZK=)O!*#'+HTMZ2??NO=:Y'87PF_X4&KCJN:
MO_GK=&;,VE0YF"OR.[A\%^G=J5N.P88PS35#Y#^*8R!09@1225BQ/)I'W*"W
MOW7NB<?(3I;Y_P#7WS*_DD;Q^6?\S3:WS?ZWW/\`/7&TW7^SMI?%O8_Q]HJ7
M+_Z'][5,78]9F=D;BSD.\9Z;%Q3T4<=4L)I1DG>`N)9@GNO=#3\D>L]J8?\`
MX5H?R^=_MC9<AF-_?`OMV:1OOWHX\'G]D8?OK$T>XD0UT1R?W>VZY\<U(D;*
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M?N7IC:7\XGNWJ;Y!KU9B*OM/XN_`S<GP_I>SJW;?\9[!WAT/V/\`+;^\*=7Q
M[GKYJS/=C]<9K?%'5VH(SEZ.GK4G%HG,C>Z]U8Y\IL5\9(.I<UVG\L-B=?;R
MZK^/\=1WE59'L'K6F[2@V#6=>T53F1OW;NW#MW=&8&Y=O4L,DM++C*23(AN(
M07(!]U[H6.M^R-@=P[#VEVCU7O+;?877._,'0[EV;O;:&7H\[MK<N!R<0GHL
MIB,MCY9Z2LI9T/U5B58%6`8$#W7NEM[]U[K6&_FX]0OD>S?YN/:L>YJ"@H9?
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MZN.1L3N&DPVX:VECJXM,L<-7(JL`Y]^Z]T7S<_96S-Q?-[JSHNCW=O"'L#KW
MI#?_`']G]J[4[%?$[9DVGN/.XGJ?;2]M=<)2&/=V-S&5J\E5;?J))U;'Y'"R
MR+&0Q<>Z]TM#\C>N*_Y8#XD8W<V4_P!+^WNB4^16Z=K18!WPT?6FX-\3=;;4
MR-=N2IA6&+(Y+=.(R0IJ2DD>7QT$KU`C0P>7W7NA&I>P:RJ[;S/5O^CWL"GH
M,/U]@-]?Z5*K$4,75V5J\]N#/X+^X>&SO\4;)5V^<+#@/O\`(4OV204U#6TC
M^9FFT+[KW0D>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N@#H^L<=T#T(.L?B]
MU3M*BQ^S</44&P.KX=U5_6VW&&5S,N0SB?WSH\-NO*83)5TV5KJ]\@:6KJ9\
MC(9)6UR/*/=>Z`ZD'Q7_`)<W3_QV^+FQZFHZEP?:G9$/Q_Z"PF*2MWSO/.=K
M]CG=.\\KNO(S;ADS>9W9F'R"Y3<>Y,]EVK`\S3560D<RDM[KW1?]U5W4_P#)
M2_EW_9;4BW;W-O\`&XH\!LNCS^5_B?;7S$^;OR)W9**.IS5=E,H'K-Z=T]NY
M^7)95HIO#BL6*F2",4U$D0]U[JMF7^3QUK\7_CUNW^8W\L?F7W1T3_,DVE0[
MT^37RA^?72&[:N?&0YBJP=)59?IM.G\M@ZO9/:/QUVI1X6@Q./VO-A8,AG#2
M*D4M.*I*2+W7NB]_#?YW=B_%7Y`]H_-3^>SU#V1U%V?WUT?@:[XL_)"@ZEER
M70/5WQ3VI"V7GZ2DV[L;</:6X_CEW7V5O;-4N7SF%S5;5U>8R5?C,?+4QRTU
M)!-[KW567Q4Z@[7_`.%4/\T[?7S$[_3<FR?Y=7Q0W1A\1L;K"K\F2Q>8PE%6
MTF3V[TO1I7555AJ7=79-'C8,[V%6TT4X2FJ%HXO&LN.DA]U[K<=_FY;7^`=+
M_+T[ID^?&S=FY#XX;%V5+)A<,]-38G<F-WA24!Q_7&#Z1J,<:/*8+LO(9E:;
M'X./&/"6:3PR@T1J%]^Z]U2%\&DV3_+0^"O\NS:M)\-.K=T?SR.Z.A=W=<=%
M=(83&T>TNS<CL/L3LW-[UEW[\E=R8:EBGV;UGLS:U/09?=V5S02K:OQ]5C:6
M6*I^Y--[KW6P)_+L^&N[OA]U+O$=R]P9/Y!_)[O[L?*=Y?)WNK(PRT=#N[M+
M.8;![=CPVR<1-^YMSK+8&U-MX_![>QP$4=/04*LL-/Y3!'[KW52'_"KCXN]Y
M_*G^6[M':?Q[Z0W5WIOW;'R2Z[W*^W]@;9GW9OG$86HPF[MN5>7PV'Q]#7YB
M>@:LS=/!7&D5'CBE625A!'*#[KW5]/QTZVK-M?%3HKJ3LS:VTTR&WNA.LM@[
M[V70X2C_`+E05^(V#A,#N+;=)@*B;*4#;>IZJFEIDIV>>(P*%NR^_=>ZUO\`
MNCN?KS^09\R]H]9?%>;M+N;XI]V[1[*[^^2?\NGK3;^9[0S?PBZTVY4R9#<O
MS"Z*$5;(.K^GJ[<>0FCS.SJYJ?$U1CJJK&R1&'QP>Z]UL^=.=P]:?('JS87=
M?3F\,/O[J_L[;&+W?LC=^"J/N,;F\%EH!/35$9(2:FJ83JBJ*>98ZBEJ8Y(9
MD26-T7W7NJ4_YHM3#\\/E;\:?Y.VWILA%M/<%3M/YJ?-W<>,`R%!C/C/TYO-
MI]J],Y=<76T^3P&9[X[2QV-I8ZF66C:GQU,\\7W&HPM[KW5^H`````````%@
M`.``!P`![]U[K62^;/9_1?\`+-_FY;G^67R6SL&T?B=_,`_E^[QZA[2S.?I-
MS5FT\GW[\;\WC\AM;:=92[5VQDH*O.;_`.FMSU&-Q4%6[U<QI:U8']0A?W7N
MB=9OO#IG^5S_`,)V>DOE5UK\`NDYMN=Y]V;>[SQGQ;[LW37]T;.VA5=_93=.
M2V%N2FW5N3!5.7R6Y,%UCB\*:=:B&.HQ\3RTK2EHBS^Z]ULE?"WLBD^0O\N[
MH+M&?K/J-J#MOXT[=W-+TWU;+BST\:+=&S34/UEMYLI04&$@V[X*G^%3I44T
M5)"WD1T$:D>_=>Z(1_((^4_1?S=^$'8&Z^M?BCT!\1CMWNWL#I?M'HWH'`87
M%[,ILEMC;^VJ7%5N4J\)MC;6.W)DLIL3*T$3UBQSI)%$J"32NA?=>ZIB_D*_
MS+JCX3].[#^-7R$Z\J-L?R[>QOES\CNCO@[\X:S<6(?!X?=%%V7N/,4?47R5
MQK9!Y.N:_=$];-/@<O5IC::8-)&:<TM/-70>Z]UN^@WY'(/((_/OW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[JC_
M`/X3S`#^6OA6&4QN:+_*3YR,V4Q%%68W&5Y_V;[N9?OJ''UT<=50T5<%$\,+
MW>*&15<APP'NO=7@'_#Z_B_/^\7%_?NO=:\__";&>JG^''RE-;7UF1JT_F9?
M-E:FIJZ6.A5ZA][86>>2DH!//4T$%3-,TS0SD31SRR#E-#-[KW6'_A1_`)_C
M;\(89HYVI:O^:9\)Z"25*,5]-1SU.],M)'5U=/'#-6A5I::>)3#RS2^(AC(H
M]^Z]T@?YF.V?D]N3^=3_`"Y5^&78'2'7G?N/^&_S-KZ7)_(79N\M[=<UNUAN
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MO015]/5T$E;C9I%FB6>*6$N@#HRW!]U[K7XWU_*N_F`[2V;FL_A/YU?\QOLK
M/4$:24.S=I;/^,U/FL]55V2AIQ!C?[ZP[8VU3I2+5F:3[S*4D"00MI=;(GOW
M7NB-_*GX8?)+XO?.'^2UO'NW^9/\A_EYMG<O\P+$;;I^J^[\;LC'XK;>ZZOJ
MC?%50;SP%1L?#X.ER%=BZ>GJ<6S5D3.%R@-/XQ).K>Z]T9O^8%LZ:A_X4??R
M..PDH\N$W1U)\TMDM7T-1304Q.Q^J]V;@--->IHYI88HM^,:F)VF62*9?%$7
M5S[]U[K9F]^Z]U2=_P`**\C!COY-GS1:HP,NXTK-O=88]<;]O434#25/>'68
MCES<U+4T=308-'0"JJ(Y$EBC:Z'7I]^Z]U=!AT,>)Q<9BC@*8ZB0PPLSQ0E:
M:)3%$[^MHXR+*3R0.??NO=./OW7NO>_=>Z][]U[K_]#?X]^Z]U[W[KW2$[2Z
MVVCW+UGV)U#V!C?XSL3M/8V[.N=Z8CRM`<GM3>V!K]M;AH!.GK@:KQ.2FC#K
MZD+7'(]^Z]UI\?R?_C-\)OC]_,7Z:^*.0Z?H-N?S!_@5UQ\T]A=A;OWML[?5
M-N+MWJV;L#KY_C3\IMIY+"U%?U7#7;^Z1[&K,>'KJBJR&/Q<CXM)46GHD/NO
M=6K?S-:/K7M?%?RYOYIO245'W[L/X0?*B+LS>N^^F*6B[+R(^*^\L-N?J[Y`
M[DVG1[9I,IG]Y1=<YNCQN7R&.Q3RU*4^$K&%--/"JI[KW5VW7V_]A]Q]>;.[
M-ZYW)A=]]:]E[3PN\=F;JPL\>0P&Z]H;IQ=/E<+F,?,5T5./RN+K(Y%#*#I>
MS*#<>_=>ZIA[%Z<W5_*!W+G/D9\.^NMZ;^^"N_-[Y7=_S!^&FQ*3'Y67H>HS
ML$F0W7\N_C1C:J3^\$.*PQQVK>'7N/%52Y&GF2NQ4=`:*:*?W7NKD^J>UNN.
M\^M]F=O]0[RP787678>!HMS[*WKMFL6OP>XL%D$+TN0Q]2H4LC6*NCJLD4BL
MCJKJRCW7NJ*OYG\[2[M_FMQX79LK;GQ/\BS(NN?.,FJ*'=N,S^^/EBIP];6Q
MUT=()]CC;M144D,JQS-_%ZAT+HC`>Z]U?MM.W]U=LZ3=?[OX;2;WN/X=36-_
MS<>_=>Z4'OW7N@$WW\C^FNN^^>A/CGO'<+T'<7R.QG;66Z:P"X++9!,_1]+X
M'!;B['>7-45#4XS;YQF$W!3RI][-3K5^J.(O(`A]U[K2=_G!?S^.L>O?YM?Q
M]RWQ'W=U?4[O^!&S_E+TWVGOOOK9_8FX.CMV[T[>K^K\+NCKO:[]2T>7[(AR
M&RJOK:6&HS\%+'1"M26"/[FFN\_NO=3>L_\`A5_\8<%WKUOW%\TOBOB=Q]P;
M>Z9WUUYB/D)\(^Y-S[^VXNT=W;NPF=R.TZOH#MM^KH-L1;@RNR\?5M+ELKE,
MU1>",HL44SI[]U[JP[X4_P`\S^35W]\W?D!\PJ[Y5;DZ+["[!Z)Z'^/F&Z^^
M5^TL%UAA\%M'KK>O9^Z*JMV)OZ@W+N[;U;%NC<?8<4V3H)ZZ@:G:DCJ/',A>
M2G]U[JXWXA;8VCO'YC?.WY<8#N3HGN'"]VI\;NK>GZWI[?\`MGL"JVYT]TAU
MKDZ^LQVZ:_;\]9#C<YF>Z.R-W5#01SRQR4%/1N2&4JGNO='?VAU/LW:O9?;7
M;>&.2EWAV^=CT&\IZG,9:KQ:TW66(R&"VS1XG#5E;48S"M30Y:J:I:DB@^[E
MEURAF4'W[KW2QWGNK%[$V?NO>^<%4<+LW;6=W5F!10BIK3B]O8NJR^0%)3EX
MA/5&DHW\:%EU/87%[^_=>ZJE_EB=K[OV_P#RT:GYN?*3>F?2J[N/?'SPWB-W
MR"*AZKZI[`S&X>R-E[-P%!#D,S_!-I;/Z>H<6T-&)I)8I'EUCRLP]^Z]T=OX
MU_(7+=H_#[J3Y2=[;2PGQWJ-[=*8/NO?^V,WO.CRF!ZNV]EMMC>$\V>WG746
M`HX*+$[8D2KKI:F&F%"/(DUC$S>_=>Z,;M_/X3=>!PFZ-LY;'Y[;FY,3CL]@
M,YB:J&NQ>9PN7HX<AB\KC:VG9X*N@R%#41RPRHQ22-PP)!]^Z]T[^_=>Z][]
MU[KWOW7NDMF]C;+W-G=G[HW%M+;>=W+U]DLEF-B;@R^$QN1S6S,KF<+6[<R^
M1VODZNFEK<#6Y3`9*HHJB2E>)YJ69XW)0D>_=>Z)QO3X@;B[8^=?6GRA[8[`
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MJ6"&*/W7NM4'Y(?S&\K_`##?YTO\I_KS:'46W^R/Y=N.^2W=%#U!D-^9!*;`
M_)/MWI7;=?A=Z?*7:F-A#',=<](Y#)O%L::I6?'9_*T&3-BY44/NO=6(_%OY
MIIO[_A17\Q_BSN+X$=:]1]I[.Z!KZC+?*W*;RRV[^XNRNI]BYCKZ/JN?;L=;
M11[>V9UUOG;^_**MJ<+AR&:NITDR$TU53&.'W7NMF3W[KW7O?NO=:^WST_G^
M=>_#?Y&97X2X+X@_*SL3Y8;MS.W=A?'!<UM+9G7OQV[S['WOC=I3;9@P'<VY
M-_TLTVT,7E=[45)FJZ#%2M05*R0NJG3)[]U[JONGZ"^4F)K<_P#`38O9^T]X
M_P`UO^8F*WNG^;=\U<')1[PPGPZ^)&X:JKV[1=(];U6YZB7(8>IK,9D'VUUO
MMM*=&C@7)91(Z6):6OIO=>Z7G>7Q_P#E9_PG4VKNWO[^67L+<WRN_EX_W-$_
M=WP<[%[$WQN#=O1W85(E'3M\C.EMRQ;?WAG:?9V:2)ZK>^/$3P4Y,E7XEI!'
M/AO=>Z-9_*]SW1WQ$_E^;Y_FV_-'O_K+*]L?.6EI?E?\E/D#'7EL'C,;N3'R
MUW57QLZWBJC49^;&]1;9ECP&,VQ2"HJWSHJJ>GCD_95?=>ZKSZP_FQ?S"OYM
M'9'=O:_\M;O/I/X^8/X;8_.;^V)_+][*Z[K]]?(/YK[1P.6Q9R<_?68>@_A/
M1V$W90^'&[8I=J9.NR*Y;(R1UM1'$:6O7W7NCL_)[?G7_P#/@_DX;G[$Z6ZO
MQFY>].A^QMB=K[F^*?:]-D*?,[+^2GQDW+B=T=M?&/L##56,IL@]=O39+YW;
M-&]11Q15\&<@EDCA+2)#[KW1O>]>A/C%_/\`OY4W7FW-M;ZSW772W?>"ZL[1
MV;G]@18"NS76^>V5DZ:>NV/D,--'_`GR&S\E19#;F4H?VEI*N"0(5:%1[]U[
MH^M%\7MM[0^%W^R;]?5LN*VSA_C95_'C:^9J2,?6QT8ZVGV!1;BR<^`@HVBR
MU4\GWM9/2QQR-4O)(@#GW[KW59?_``GO_EA]P_RI_A5O3H7ORKZLRW9^\?D!
MO/M'(9SJ7<N[MS8#)8#);4V)M7;HR-3NW;FU9*3-4T.U)@\-)1K3BG:$LSS&
M4CW7N@1_DI_%OHWY(?RC>UNAN^^H.OMU=7=P?+3YQ4W8&PJ5:H8NLFIODEOK
M!4E5#64<]/D-OY_;,6WJ6'#UV.J8JNAIZ"BG@GCF4,ONO=+_`..O=7;O\J'N
MS:/P,^9&4W/OGX<=M]@0;%_EV?-7<&;AS<6T_P")TM2NROA;\C\E6RP9/$[S
MVQA<'X=J[EJ$-)GZ:T#R>>&01>Z]UL$^_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[JIS^2QM#96R/A`^!Z^WI2]@;8C^4
MWS@JJ3<M#MO*;1HI:JJ^7W=#Y'%4NWLU%#D<?'MVN$F/.M0LKTK21_MN@]^Z
M]U;"[!$9R&8(K,0BEW(4$V5%!9F-N`.2??NO=:[_`/PFADAJ_A/\D\O38N;#
MTN=_F1_-#+TN/DH*BACIJ>HWEA(HJ:F^[@AJ*J"B6G\!=S(Z21-$S!HBB>Z]
MTMO^%#LE&/B9\6Z6:>K@R&0_F:?`ZCP34%-45M:V6/;L=21244$D2UM4F,IJ
MEXXI&5)'0`$/H/OW7NBZ?S0NLODYW/\`SJ/Y?>S_`(4_(7;GQD[_`-K?"CY;
M;USW:N\.K\%W+A,3UK6;VZTVS#C:78&X/#CJW)Y_/U<E.U1+-']O$/(EW3QR
M>Z]TI>F_B7_PH.WQA\MN3<7\W;KSI^63=F^\,=NYK^6AT5+GLLVU][9K:=#O
M2NHJ7<]'1&AWQ@L!2Y?&U`JIY7QU;"DJHZL%]U[HQ_RDZP^7/3_\D_\`F,[8
M^6OR@/RP[O\`]E>^7FX:3MG8/4>#Z,GI-LUO5&X:G;VUL?L_95954@&W3!.S
MU8?S2T\QC<L(];>Z]T>/^674QUG\N/X$5,-/+213?#7XSO'2SY&3+34R'IK9
MNF"7)S*LM=)$!I,K`%B+V'T]^Z]T='*T+93%Y+&)7U^+;(T%90KD\5-'3Y3'
M-5T\E.*_&SS0U,,%?1F3R0N\<BK(H)5@+'W7NM>Z'_A/E]QFER6X/YPW\Z?,
MXY6RSC#4WS3DP,"MDZBMK4T5.*V-%+&E+7UIE50-)"B,!8[(/=>Z('\BOY7&
M.^&W\P[^2[GH/FG\^?E:F\OG7NM5V+\M_DM4=K;=VQ#M;J3<N]\9N?9M#6X+
M$C%9?;IPGBKI0)9,K22+3DQLP+^Z]T=#^;UN7/;0_F__`/"=_-8N;+I257?W
MRKVA6+38JH.,*;]ZYZVVC6)4YVEU215,V(RE1_D;+XY8%DE<A(V(]U[K9,]^
MZ]U2?_PHGEAC_D[_`"_BF@FF6NI>F,8&@J*6F:G&3^075-!+.[5,BM+&(*AT
M*1+),VOTA>9$]U[JZV*-88XXD!"1(D:`DDA44*H)/)(`]^Z]US]^Z]U[W[KW
M7O?NO=?_T=_CW[KW7O?NO=>]^Z]UKO?S.=Z5OPN_F5?!KYL=)?'7L3Y$=N=@
M]%?*OH[O_JKID;:C[%WY\7NL\=L#MNIWC@,7F9<>^\MY=.[SGI)Z#%I.:O*T
MN1EH8"LKPD>Z]TV_&_Y`]==>=I=8=O\`\N3>6QN^OY>?SS^6]?LSY&=-5$4F
MWMU_#+Y/=G[3R>=R^^-GT=<*3<^V\-V?NS$*N\-@YW%2C'Y^K6NQ5104U960
MM[KW1GJSKSMW^59GLON'XT=1;\^0W\O?>>Y=Y[^[.^-W7#P;B[I^'>Z-P5$N
MX,SO#XH;"K*O&'L/X^;BRLM359CK3&ROFL!D9FK-L4]7#4SXE/=>Z/W\9/F5
M\7_F1LRGWW\:NZ=D]JX5Q4ID*'"9(TN[=LUM`]+#D\/O/8N7CQV\]EYS$5%=
M#%5T64H*2III9%5T4LM_=>ZJI[!Z0[`_E!=K5?R2^&O678_:'P![-S&Z,[\T
M?AWL7+UVZLC\?]RYK*X_-2?+;XI]<5D%?EZFAC5\DN^-D8:H2.LI6IZS'48>
MF<1>Z]T1#^8_NP=D;B_G4]Z]4;FPG871>XOY!_0\E!G]I;B&4H<EENP=Y_*_
M<.P\U31'+!(**?8\-;D&>G6G#TDD;>.29SK]U[K:\V?#]OM+:T%HE\&W,)#:
M",PPCQXRE2T,1>0Q1#3Z5U-I'%S]??NO=*/W[KW6JC_PI:^?.SOY<.=^&'R.
MV]L*+?\`\JX-H?,7K3X^3R=C2;0I>JT[7V)UQMC=W;N7VQ2[7SU5ON';@CHX
M:*C-5B4%9/J^X8*R#W7NGO\`D`?R9>E^KOY;O6N8^<WQ,^._:??_`';NG,=]
MY:L[>Z@V1V7OK;6V-Y4N.;K_`&SN+.;YP.9KX<M3;>@_B%31QLD5+49.2&16
MG25V]U[H[7R@_P"$['\HCY2;4S.!ROQ%V#TKN#)QQ"B[&^-N.QW36\L#4152
M51J\?3;?Q\FQ\A-,`T3KD\-D(C"Y`0%49/=>ZU9?E%_PB7[GP=3N7-_#OY>;
M%W_A88*VOVWL+OK;&5V+NYQ##4S4NWY=][,CW/MC,9.I:.*%*R7%82E:20M(
ML"+<^Z]UK;][?RQOYMG\L/=L/9.^.@OD9T76[-GCJ\7W[TYD,OE=K8*6MGGQ
M=+44/=73>6RN&VY79%@Z1P39&DK7C;F(*PO[KW1W_AY_PJ#_`)J_Q8VK4;1W
M%WM1?(3"8.#!TVU\!\CMC#LK)FCQT\Z97&57:6.W/LWLZ*MK*21`E7E*S/D-
M&!XT`NWNO=;7?PO_`.%C7P,[VRF$V7\K.MM^_$/<.4I\70U&\*N=NVNGWS=9
M*E'5QU6;VSA:'>&W\2TSB03UF%>FIX6/GJ%5#(WNO=6&_P`S7OSJ'YN]7?&#
MX`_%_N/J[M_%_P`POO[;/6?:6=Z;[`VQON#;/Q$ZJH#W-\E<Y2Y'8NY:AL/_
M`!39>V*+;450UH%;<:QZXIY:<M[KW0H_SBUG[<ZR^-_\LC8.=FVYNK^8?W1@
M>H=T-A:B.+.[7^)'4F//;7RGW;CC._H@CZYVK!ME69@7JMSP1JP=P1[KW1\.
MX4QNR^NMA_%KH+NGK_XP]Q;PVW3[4^-%#7;=P.\IZ3;'3])@,ANNAVEUEFJR
M&+/XG;/7-$:&2=EDIL2:RFFE61O%!-[KW2I^0'RIZ3^,,G3=#V[NJHQ6;[^[
MEV/T'U'MO$8;*;EW3O?L??=>M%CJ+%[>P-)69-\3AZ425^7R!B6BQ=!"\T[H
M-`;W7NC%>_=>Z][]U[KWOW7NO>_=>ZU4_P">?_,-D^`.PMD?RV?Y7G5&P?\`
M9UOG#N#?M'3[&Z-Q6V</NKJ<]E2T\V<[/FV)M7'0QQ]H]MYG<E1+B\IDQ3C_
M`"2NR<LC_:HWOW7NG?\`X2I_$SXM=&_"7<G:77V?I]X_,#L3>&6VA\U)\S7U
M+;]ZB[%V!GLW10=!Y_;5;,M1M1-IRSSUTDCTZ3YJIKFJ6GJ:>.C$'NO=&M^=
MG879?\PCY+XW^55\9<_G<+TEMI\5N;^:=\A]AYZMPT^PNJLE3RSXOX:[5W5C
MJ*5*'M_O[&2:\RE-5+68?;!8RH5JY53W7NJUOGGB^O?C_P#\*)OY`'2O6]=@
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M]M^&7$[OD@BC:IJ*B1?=>ZO,V1_PH<^*OPKWU2?`#^81!W7UAW?\8^ONN.N.
MX>]LS2P][]=[IWK_``S%T.VLQG-[]94U=N6;<?:'7[T>\*J2JP5.M,]764<[
M?=TK"7W7NDA\:OY7?\@7?_S*Z_W5TG\C4[NK]S8^?YG],_`VJ^15'OGXWX2;
M/RT53%W!MGHNLI&S/W5#725%4N(R]=4I3+43+-0?:4T<5/[KW1?MJ_'K?^._
MF@_.C$_RA_DWV5V%\G/DAFLVO\P#Y?\`;&#V!N/XK_"7$9'?,>Y]O]>=8X+`
M["HCVY\H<3A93B<+A?XO_#\+1T\TF1&MI6QGNO=)/Y-]`=;?\)U.\?B9\E/B
M-W9W7W5W#WUOS*[:^<_QHWEN#<G;W9WS1ZMR-75;Q[7^3^$Z[VKCP-L;^ZEK
MS6UT>6,<&*CDK8:9W9I:\9#W7NC(=B_(#?7\IK;FV?FS_+UVSUW\J/Y5'\Q3
MO3K7L?,[#S&\<OU_4?%KMCY%YG"XW,]E;$W?FGK,-MOIOM;(3C^)8/,T6/@V
MGNPB%Y*.*>2`>Z]UME*2RJQ5D)4$HVDLI(N58HS)J7Z&Q(_H??NO==,JNK(Z
MJZ.I5E8!E96%F5E-PRL#8@_7W[KW5)/_``G^VQ!M'X%;GPU-#44T-+\U_GK2
M)33U*SI3)B/EEVIM^*GI8D1(Z."*+$*IC6ZF4/(/\Y8>Z]U9Y\G/C#T7\QND
M][_'GY&]>X3LSJCL#'?8YW;N9B(DIZF%O-C,_@<E`8\CM[=&`K0M3C\E1R0U
M='4(LD;J1S[KW5,7Q1^3/<G\M3Y-];_RL?GAN^MWUU#VA3S83^6M\UMS9".2
MI['P&VH\7A<1\7N_\M-C<11Q?(7;M$T"4&10R1;D6H@1=$\T$)]U[K89]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>/`)Y-OP/K_L/\
M??NO=4U_R#8V/\LSK2N?;^Z=KOF>]/FMG'P.^GK'WQC&RWS1[]K&HMY??P4U
M2NY:0R>*KU("TB%F]3,/?NO=7)F]CI(!L;$BX!_!(!4D`_BX]^Z]UKY?\)IZ
M6JC_`)>._P#/UTD"_P![?G#\S-S+%%6FIBHHV[?R6'G@*.%:@5:K#2N(VL61
MQ*?\Y[]U[I%_\*#]\[<WCT-\"7V!V+MW._P_^;I\'L;646T<SA]PS3;@&Z-Q
MST%!73XG^+5F.?'K%).8XA'4-,L7ZEO&_NO=,?\`,HZF^1'?'\Z/X0=<_&CY
M5;D^%O8M%\"/ECN:'NO;74&P.XJC*8=NT>H<?E=A5NV]\U$.-?'54ZTE8]14
M!OM)88_M;33R.GNO="5U#_+\_G$Y;,]JKW!_.B^0VV\7MO>S[>Z@R6&^,GPI
MCEW[M.GP.'JZO?V?P%%M;>E/B<?D]R5,]+0X^HJH,E'34+RSQP&I55]U[H2/
MF-TG\DNCOY'_`/,4V/WY\JMY_,ON2?XH_*#<60[>R/6>SNIZY<;7]2Y/S;6P
M.R>MHACL?MK!Q4-5-&TLM35&.IE$DIC5$3W7NCX_`/)=8;2^)'PZZ0VKNK;8
MSVT?AQ\>*Z@V(V;P2;WIMD476.S\-0;DR&U:.I7(TN+J*G1$U4M.M(:E]"M<
M@>_=>Z-MO3:U#OG9V[-DY.LS..QN\-M9W:V0R&W<K5X+<%!0[@Q=5B:NLP6<
MH'CKL-F:6GJV>EJX666GG59$(90??NO=4,?]`Y/PKPV&=]N=Q_S`*[+8S$5T
M.'@E^=G<&#AKZTB:J-)4Y'&>>+$P9?+$O5204CI')(\@@8C0?=>ZKM[V_EA]
M'_!C^;S_`",]V=3;Z^06\MP]E]U?)'";EIOD!W;N_O\`Q^.QVR>BZC<,!VJ-
MY039#"5<=1FZD?<PM%"L@AG>-&BUCW7NE/\`\*@^^,I\:/D9_([[NQN5EI5Z
MW^9FZ]XY''&&GJJ:MPN(KNE:;<3-2O"TTLTFV\K64JE7&@51(&O2P]U[K;W]
M^Z]U2K_PH<KY*/\`E"_*N""-I*S+5WQ_PV/(QM=E4@KJ_P"3'3J4]7-2T%-4
M,(:-E\K/(8XET>IP;!O=>ZNI75I&H@M8:BH*J6MR0I9BH)_%S;^OOW7NN_?N
MO=>]^Z]U[W[KW7__TM_CW[KW7O?NO=>]^Z]U3M\@%S=5_.W_`)<R35-6^V,3
M\-_GO6T=%'F:&"DI]RY3<7QLHZBKJ,.LYR%7+58>C"(7B6)O$7B<F"9??NO=
M(/YT?R5=B=]=[;7^<'Q%[(/P^^=FQM[;8['C[!H-N#>?2G<VZ-DXW-8K;DG?
MG2TV1QF"W+G*7%9^MQ\&YJ0P9JDHZV82?>!8$B]U[JI/M:?^:)\6^Z]^]Z;P
M^+WR]Z,[][.GVHW9W?\`_*TH,+_,3^%_R1R.W1M[!KN#LSX$=Z9K:'975FYY
M]M8YZ!<S@,OMZL@C*R?Y46G9_=>Z57RP^3O\A[Y*97</8/RS^)OS4^-_RVP,
M-'*N\-N_#+Y7_&'Y5[KKZV/$7W70[HZ?Q4V/W"E!-C0M&-Z9>K-$('%,&.EW
M]U[JO3L?YM=5UV?DFZ!W?_PK@[`V/#4Z*'<.PM]55)LFMQ]#CVH:2DVXN^-F
MY_=CXZHR%,5DGKS'6H\,A*O<H?=>Z'GXH[]_DW?#WXL_.GJ7J?8?\VWY0[@^
M;NPX_P#9C.H=U?&;O&L[HI\A3[<W!M_(=6-OC!]-=<;,VMN6+-=@Y=\CEY*^
MH@^XJB4JI%C@B?W7NC[Q_P#"FVEQM'C**C_D[_S8(XHEH,=%#4_'YHBJJU-3
MK3T;_?5+5M0E(LK1J_C,K1JI*ZRR>Z]TK?EG_P`*G?A#\8M@?&S?>,ZV[>[8
MK.\:#,Y#??6..QZ]>]N]`MA5HJ.?%;\V7V-08)*_,S;D>MQT2T]8E',^-FFB
MJ9(7@>;W7NM9CN'^8G\7O^%`W\[?X#T_:>4F^)GQ'Z<I\=385.YX]JU.4[%W
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M)\#A,-LO.9/*P5&(I7,E1-(A@B8>&4Q5.J!?=>ZL+95=2KJK*P(96`96!^H(
M-P0??NO=5??,_P#DR_RVOGKCY$^07Q?V)4;JMD&H^S.O*5NL.RZ*IRM?C\ED
M:V3=>R3B*C.U%54XY;_Q9,A&JR3!57S2%O=>ZU@?D?\`\(CNN,M5ODOB;\T=
MU;,BFR&5J9-J=[[#Q^]Z.GH*B2"3$X[&[KV16[1R$`QJF5)):G'5DDZ>/]+*
M[/[KW6O_`-V_R+OYX'\H_<^W?DKU5MO>.6K=HRU]13=V_!_>.ZMZYK9M/!1U
M57DQNG!8/#[?['Q^TZW#T4W\1FJL--M^2EU05LMI1$_NO=6-?RP/Y^7R)W1\
MUMO_`"X^8?7^,^;>\<C\?'^.:;9^.]`F(^1_QXV1MO?=-G]S[TV+\>:^DP&V
M.UL]W-E<O05VXEV?.];_``C`^:8T=-C&HY/=>ZVS_@7V]\<?YD_SI[._F+=2
M=Z[4[4V;U#\?MI_%GHCJ*6DW;M7L_HG/[BW#7=@?)_<O:/5^_ML[?RFV=X;S
MRB[4P=%E,<U9056*PLT*U+DNB^Z]T\]&;8Q?SY_F@=S_`"_W1BCF^B?Y<U=N
M'X=?$5<E!3SX/.?)25TJ/F1W7CJ*JD6MCRNQ,G#C-@8NK-.U*[8[(STLS.24
M]U[H;.N/DCVM\F?YF_:76W46X4QOQ%^"77N1ZZ[^RE+#2RGMSYE=KQ;5W%A^
MM*2HJ8JEI-O_`!^ZMI_OLI/2-2RQ[@W!'1R-,L,J1^Z]T?S:?>/4N^^SNUNF
M=G[[P>X>T.CH-BU';6SL;+/-D]AIV7CLMF-C)G7\"T4-3N'%X.JJ(H4E>9(H
MPTBH)(]?NO="M[]U[JI_^<+_`#6>J/Y3/Q5R_=&ZZ?%[S[?W;+/M;X^],5&4
MFQ]=V9OD_:BIGJY:.GJZRAV7LNBK%R&9K`B`1+'21R+5UE*&]U[K3<^".T>Z
MMK=P=6_(WOO?^1PO\ZC^=MO7=.T>C-P=K[2_@]9\,_B?F*;+TO97RWVY@JN&
M9Z7LW=&T-L-@NK,4\6+IXJ.&.&,28]JE']U[K86Z[_E>_%SO"HS_`&%_*7^3
M/?WP$[,Z#W-N[XE=U?)OJG:5/N';_P`RJW:&/P]'V#G]]1[LGQ>R._=Y;7WG
M79:FE[`I(Q64V\UR;"66:C@,/NO=72?!3X-],?R_.AZ#HWIO^\F;^]W!FM_=
MG=G;^S$NY>T.Z>V=V215.]>U>S-SU`$^<W=N>LA4R/9(H(8XX8E6.,#W[KW3
M9V[E/AU%\UOBAM'M'JW8&Y_E[N[9G=VY_CCV#FNM\%G=Y[)VCU5C]N'LPX#L
M.OQLN5VE'/%V-3(E+35"-5&HF8+9';W[KW3GT5_+Z^''QJ[S[U^3'2O16U]F
M]]_)3/Y?<G<G:;5NXMQ;MW17[@S']XL_2T60W5FLX=I8+.[B"U]9C,,N/QU3
M5Q1220,T$'C]U[H*OYG/SVB^!W0V-S&RME5G</R?[QW;CNE?B+T'B14?Q;M[
MO+=;QTN$QLDT,$L..VQM>"=LKEZF=Z>(4=,81,DT\)]^Z]T`?P'_`)0?3'2G
M5&]-W_,;976_RY^:?RLI:;=?S8[J[>V1MC?M/V#NO)5<.>GZ]P.WMP4&3VG@
M.K=C5D=-0T&/Q=#0T5<N+I:J:`/%3I3^Z]U6QUAU#\A/@Y_,E^1W\M;^7]V1
MMW</7G='PKW)\D_CY3]SS[CWUB/Y6>Y<MV+1;!_N_M:;(UF[)ZCJ#?%5-497
M$;06"F^]R=!C5G`HZ>MKJCW7NK]_@E\,]I_!OH2@ZDQ&[MQ]J;[W!N7</9_>
MW>N^&>;L'OSO+?-1%7;^[8WM435N2G.4SE3#%3TM.U34#'XNDI:199!`)&]U
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M/ZR^-OR![$H*^OVC-EJ3%)C<C54M=0Q015A9?=>Z.?\`RVG^?'PB_F8YG^6W
M\R?FQ4=G?&+&_&Z";^7-BM^=5]>T&Y/D3LG8=12?Q^GC[7P+T.Y8^U/COMNH
MAQN<P^4;)5V?QJIE85IZ*G$DWNO='B^4_4'\][<7;FZMP_$7YA?!'8?3M?FW
M39W77:70&^ZS<>W-L4U#1+239O>=)6[R?=&Y,C7_`'#5?CIL;1QH(S"HU,B>
MZ]U2Y_*$V+_//[7^,W9F[NCOGQ\)L%M)_EK\OQEJ;=_QZW#OO,9OMD]X[HR'
M8V;FRN.3:N.Q.U=\[TKJW,8^.CAG:EQU?#Z/(S00>Z]U9[3?'/\`X4@RS86*
MM_F.?`2BI:+'5:92KH?B1N&NK,KD9*ZEJ*8UE)55U'3.D-+')`):23'JL;G5
M!+(5FC]U[H&?E%_+._G:?,7I[/\`2'>_SW^!6Z=F9J6GR5%4K\*<G!N?9FZ<
M='4#`[\Z^W%-NVJK]D]@;7J*EI\7F<>8:^AFYBD`9U;W7NE1A5_X4_\`0N`P
M?4F-Q'\M/YD8W:F*IL1C/D;OG<7;/6?9.]::!VD@RG9&TZ"MPVW8=QPT,?VD
MS8VE=*A_%4R32RFH+>Z]TELMO3_A5SE:;.;6H>H/Y7FU*_.+B'PW9%%N_L3)
MT6SF6HQRUD-/A\A69=\F)(Z2<U9J\=46CJG-,P=(@ONO=3&^0/\`PJCQ<=8D
MOP0_EL;BE2>6:GDI.Y-WTWE@?R^*EIEF[4Q\=HO`/5.8V/F6YX;1[KW2XD[!
M_P"%1>[\=34V)Z(_E%]49#(T-#++D-T;\^1NZ9-OU#BCFK(*NEP57D*&JJXV
M$D)6G>K@4,2DDNE9&]U[J'6YS_A5!'A<":?97\GILO!2U^#SK1Y_Y)U,F3KJ
MBKFK*+>\-(\=%0X6AQF-5*3[%:JLDJ*B\IC56")[KW09[4W!_P`*T7H*6JS.
MR/Y5J566,D9QVY<KV2E7MM<>S0+/D6VADIL?/)FA^\/!/5*!8:(#=/?NO=!A
MW!\G/^%070W:?Q@ZHWEMW^4EG<K\L.S]R=5[`SV`A[^&V]N[OV[U9NKMR3$;
MVFR>X\/F:*FR&U=CY?[2HQ]%DQ)5T1AD\?FIVE]U[I^ZF^9G_"F'MC96*R_7
M?QB_E>=MOU_WCV7U;VKNG97?%?)BMR576FY<EM3<6!I<=%V3/!L>JQ.8B:"2
M1ZNMR@DHR9\93ZPC^Z]T8G:N[/\`A4A7Y+:VX-T=6?RC<%MJLR]'CMS["CW-
M\@:[>N(P?]Y8%R.X$S%%G*G:M3D1MQ9/MX8:Z5&+*[PK)>$>Z]U3'\@/YP/\
M^OXU?S'MV?RS\EF_@AG>Y/DEV739SXY9G=6#W9+MSJK9W;&9RNU^H.M\)N7%
M4VRJ'(U:4^/IZZ.7<.,SU4]9-HJ*F0NU(GNO=67=!=V?\*<Z_H_8U)@=@?RK
M/D[-08C=V.ROR1@[ORN03LK-XS<.;P2FEI>J'VOUWC-S;3RM!+0Y-::@^PFJ
M:1HW6FG6=1[KW2UHNT?^%7-)E<"]=\9?Y5.6QE0!'DZ:#L#M&A6B:FPM1`]1
MF*P[_:J$62RLB3HN.AJ622,1MHA+-[]U[K6/^4/_``F;_F@=7]']R_-'=':F
MT,MNRHWQN7N/LSX<_%#_`$I9K.18/>O9$E7O3']104,$&(SM=A-N9:3(0XWQ
M"U#3-"*B:6)?)[KW0.?RL_AST]\A?YX_Q'J?CK_<7O3X_=3[GRW=_9NWNN.C
M>\NEMN?'O!]>8S-;MZEH>Y*;NVKR60RW9-!V%5XG&U*TV<W)!5UV/$0K\A!K
MG;W7NML;^:/\3]R_+[^<;\'NO]N?*/OWXB/MOX)?+3L*O[4^-6Z6VCV?5X[;
MW9O3F(FVG%EXQ4&'`9&LW3355;%)35"5<=%X50.1+%[KW3MTW_).WOO?J[";
MAVK_`#O?YU@Z]WUM6BR>"Q^Y.X\OU[O&$93')3Y"HS^#[+Z]IM_8`U<B,\>.
MK:/'UU"A".[N/*WNO=&M^0?Q9A^&G\DW^8!TON/Y+_(WY&?8_$'YD[AKNY?D
MSVG5;V[2JI]P].;TEHL#%NIH<;_#]O8]HX::CH8QX]4DE]33L#[KW50'\K+X
MQ?%3`?SPLQV3#V)L?:/?_7W\M'X@RQ=1X3N"FS.7[2[B[7Z1HO\`3CO:+8&8
MDJ,_M;&;(V!B\(HVY33R14L.3@RQ5(JA(X/=>ZW(,GCZ'+8W(8K)PI4XW)T-
M7C\A3N[QI/0UD$E-5PN\;QR(DL$C*2K*0#P0??NO=:[^]_\`A/I_)QQVU=R9
MK!;-W+BZZDILU#AH:WYT_(W:FTO[URR546-Q&2R:=LY*GP=-)GY$II/'33/3
MAB%@D91&?=>Z(1O?^73\#OA#_-+_`)(F_P#X=2SY/?/9G?'R$P&[Z"H^3&\N
MZ(*[9U+\<]XI69G;E)V#N[=U;38':F96L+U5(T'EE?[>?R2M`(?=>Z*K_P`+
MALA64>T_Y;?VD]3320;M^3.0IZFGHJJ*2FK*7&]%_;SP9V,K%2U,3-J6%2)6
M($@X3CW7NMV?XW[GJ][?'?H7>=?E9\]7;NZ7ZMW/6YRI=Y:G,U>?V/@LK4Y6
MHDD59))\C-5M,[,`2SDD7]^Z]U5?_P`*),UD\)_*9^0<V(&/>KK]Z?&["F+(
MS>".>#+_`"4ZFH9X(&X+5<R2Z8P.;FX^GOW7NKMU)958JR$J"4;3J4D7*MI9
MEU+]#8D?X^_=>Z[]^Z]U[W[KW15O]E_[6_TM_P!_/]F\[N_T??Z4?])/^A3^
M`]._W8_AW]Q/[I_Z+/[U?Z-_[_?Z,?X__OX/MOXC_$?XE^W][]K^Q[]U[K__
MT]_CW[KW7O?NO=>]^Z]U7'VKTKLC._S1/B%WF>P,!B.QMC_%WY6[2_T9MD:-
M-T[ZV;GMT]'-'NR#%5.4@J9\!UWF:J2GFGIJ6=TJ=PQK(R(??NO="%\S=[[]
MV1FOA<VQ<_E\-#NOYM=7;(WQ08N:"&#=6PMQ=?\`;4.9P&:,T<C28B&NAI,F
M4C*.U1CH>=.H'W7NCM>_=>Z][]U[KWOW7NO>_=>Z][]U[IGS.WL!N*"*FW!@
M\/G::"HBJX*?,XRBR<$-5!K\%3%%6P3QQU$/D;0X`9=1L>??NO=%[[6^%/PZ
M[UQ])B^Z?BG\<^UZ''092FQ<'872W7.[CB(LU%#!ECAI<YMRMGQ$N0CIHA+)
M3-%(QB0ZKHI'NO=55=K?\)COY*G:S1SS?#VBZ^KXH9H%KNJ>SNU]BJPDB:.*
M23#X_>DNVY9J5V\B.U$2S@"36GI]^Z]U@ZC_`)-OR'^"VSZCK?\`EA?S*^T/
MC[TT-YIO?'_'SY&=)]5_*_J_%5U;*)]U8;;N=R4777:NTMO;KJD\]1!0YP,M
M5)/.K&>9I1[KW12-Q;`_X5-_$G>.U]\8KOOXV_S+>I#OG&YSL?J?&=>]<=*]
MH_W-_O!BZW<^VMAUF9Q.P,325%9@#5TN-FFSM::-PCO!*UE/NO=&G[D_X41=
M!?%_9^4W1\M?A#_,M^--1AMP[>VY5T/8OQAHY]O9";-5"TE=F-N]I[<[`S'4
MN9P."J'4.YS<%76^110TU2^M$]U[JS+X,_S#?B1_,>ZPS/;OQ"[27LS:.V-Q
M1[1W8*G;&Z]G9S:VZ7P^.SO\$S.!WCA<'DDE&.RD3+40)/13,'6*:0QOI]U[
MHZWOW7NO>_=>ZU]OYF__``G1^%W\P#(4?;?6D2_"[Y9X+-P[FP_R$Z(VU189
M\WGH\\=QR9CL39."R&TJ#=.YVRTLM3#N&"JQ^XH:MTEDK:B*%*<^Z]UJU_+_
M`*.^?/\`+YW7%OG^:#\4MV?)#9FSLC#2;<_G`_R^M\UG27S#P]%44%#2X[)]
MK=D;2HXJ?L>KHJBEQ]'?MS;C5=3+3M#3YRHUK*WNO='N_EX?SMM__&OX(9'K
M+H;J[;GSMZ?Z=P.7VITQOKI#);>V;\T=G9/=>7S60P.<^6WP>W#N;<.Z-PY&
MOW;FZBIR6YMCYC<&,R<E-)/52":LDG3W7NKL?C%\G_AA\!/Y247=?0G;5!\R
M<Q4Y3$Y7>^XNMZS!;B[@^3?SV^3.X<!!6T&]MKX_<>5KMJ=K]D]N;UHX*["Y
M&K:KVUC%6GD+14`O[KW1DND]O[._E*_R_P#M#Y`?*W>&%W!W+EUW/\G?F7VC
M0TF+Q]5W)\G^Q_M)<GMG9])A<-CXZV"IW)/CMD['Q5+1"1J*GQ]/'"T\CZ_=
M>Z7_`,9/D-WMUG\&MT?,7^9[N+KWI^NK,?NKY`YS9.$Q4F(Q?QJZ4R]#1YK8
MW36YLM52MD-^]F[6Q++3Y2M$,$E=FJO[&FIV,4;S^Z]UIK[>[;W-_,MW?W[_
M`#PNP]P83>O:>U>S,E\*_P"2I\&Z3;NP.Q]Q8+OC,RSU?4&Z^S^L,G5Y?%UV
M:V')NV/>5=+4/.(ZNDJ\RQ.,QN-I)O=>Z!_L'H+X"[A_F`[Y^'W\\WY-]R;Y
M_F:]A[AZQJNR?G=M[>VT^OOB)T?M^EV3LCL7:/6.R*=EZ]-#F=U=?1';$^5R
M^V(\'B<KEXIZ>B5X9*B;W7NOHO=%]1]3="]/=<=.]%;7P.S.G^O=IXG;O7NV
M]L:7PF/VW30"2B>DJ1+.^2?(>9JF:LDDEFK9YGGEDDDD9V]U[H5_?NO=49?,
M?<6-H?YZ/\F/`5U&DM1F.E/YE28JI1B\U-DUZVZCR"R3QDV@I?X5A:V-7`O)
M)-I/"^_=>ZN/[5[2V!TAUIOWN'M;=&,V3UKUCM+/;YWUNW,2/'C=O[6VSC:C
M+9G*5/B26HE%-14KE8HDDFF>T<:.[*I]U[JF/^7[TCV%\S?D=E_YP/RMV>^W
MJ?>6R,3M;^7%T%NO3DLO\<_C=EH#E*GMS<=,5CQN+[I^2$512Y6LBCA:LP&*
M,6/-5.&*P>Z]T*7S=^>/9F9[>?\`ES?RY9=M;W^?.Y]MP[EW_OS,"@R_4'P=
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MN,?P[=FV6K0L:Y'&U"`WCDIJGQEO!44TWCGC]U[K5]^&];_-WZ7_`)FN]NCO
MEA\QNG]_X;XD]&47861VI@>B<)+\@/YG7QQW:.W'V?OK;]70R8?<F4[4Z@W1
M@TV[%CUR*T^)RH2)H\A#7S5N1]U[IR^2_P`6OYPO\U?XY=]_(O+=M[Z^(.8Q
M>#(^!_P'^-GR&P6RLJNZ\3N>E6JW?\S.\-M5#X[-[^_A$<XCVG2Y&CH\)D(H
MXZAZ.LAG23W7ND?U]O[Y+?+/^7'AOY(]!MK:_P`I/F_C]C[DZ:^>'R*WAVSF
M>X^A?B'MFJWQN0[3[7WEW@E743=N_(Q\",96[;V5@<K59?$9.`R9)J.#%STI
M]U[I;XK$[MVI@NO/Y/W\XSNB#9'>6(H(=R?RN/YL>P]W9/;&^M[[@VOE9<5C
M31]G[PKGSW5_RLVI13T&.K\9/D3'O/!5ST+U57-,LV1]U[HS.#^?W\QW^7YW
MSL#K#^:_M;I&M^#5'USF<`_\R/J'8W<F>7<W8N%JZ&AV1F^]L!M2GW%@N@Z_
M>^)8R9A:W%4^W(,GY9*7+"FM"GNO=7=?'/LOXJ]D[,J,_P#$W??0>^.O\]N'
M<.XZS*_'[<?7^?VIEMV9W(RY3=6<K*GKZKJL75[BS&6J'J<A42%JJHJ)#),S
M.Q)]U[HPOOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZJ._F);<
MW%EOF/\`R8LMA<9!DJ+`_./M!\TTK5I:@I*OX3?)>5J_Q*L^+\--28^H8231
M>=*D0)#)$))6/NO=`O\`R`:?+4'QS^9N+S<&3@R6*_FJ?S`*&J.6@JZ:KGG3
MM[S5$[0URI5(6JIW#AP'$JN&]5_?NO=7L^_=>ZT'?EYU'\3.ZO\`A3'V?B/E
MKV-MCH/<^QN]/Y>>_.CNT,AWUG]K;NW%1[>Z:PF7Q?4FSNM*K8V?V=FX.RNV
M:'%TF1RLNX-NUNVE:.:DBJS5S$>Z]UL>?\)\=0_E5=)AT:-QV_\`-)6C<NSQ
MLOS:^0X*.TI:5G0BQ+$L3]23[]U[K'_/G[I[UZ=^$NV*#H;N^3XMY;O'Y,]&
M?'G?ORK;&U57C?C5UCVIE\KCMQ=JYS*TL$C[/Q*9*CH,*V9\M&^/ES,;PU=+
M.8JB/W7NJH_^$W'97\Q[KKO_`+\^#7R_[-H_D%L#970^U_D!'O2F[_P?REK>
MBNQ]Y=G[@V7BNJL]W-MNMW!10U?;FTMOU>[:+;-1F,I+B\;315*-3R5M93I[
MKW6WI28;#X^MR.2H,5C:+(YAJ9\M7TE#2TU;E&HXFAHVR-5#$D]:U+"Q2,RL
MQC4D+8>_=>ZK>^=O\LO:?S7["Z7[LP/R,^2?Q)[^Z,Q.^-H;5[G^,F]L=M/=
M>1ZY[)CQO]\M@[BIL[A-P8C)X:MK,/35=,_A2:DJXA(&8A0ONO=%-VQ_)0[>
MQ<F.FW'_`#L?YPFXI*)I#+#3_(?9.+H:I7D,B:Z:MZPS\C/$S&S2R3$<:=(4
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M##W7NM8"B_EG_P#"2JN^UK*.3X%50K:DK2NGSWW$8*FI$T@:*.`?)-:8CS0N
MOC"!!I*Z;<>_=>Z+%E?AS_)5Z<_F7?R?,U_+&RGQM?L?<'RS[+J>Q*7IOY)Y
M?O#*OL;`?&OLK=^/DK]LR=P;P?!X:/<.'IE@K4B@ACJ:@*XGC9J=_=>Z7W_"
MFWJG_3[\M_Y372&3PE-NW`=@;1_F58^':=148>%LANR/XW[8J-L5E(,K5X\?
MQ/'96"&:C*5$,QJXXUIW6I,3#W7NKY_Y.><3<7\J+^7+E5R,F5D?X7_'6AJJ
MV:6::9Z_$=7;;Q&2AEEG_=>2CKZ&2%B;B\?!(L??NO=%5_X4=QU#_P`I3O=Z
M2MCI*FE[&^,%=#"]2].V3:A^3/4U6<7%$M31I7RU20D_;R2+%(JG60H+#W7N
MKQ*&8U-%1U!#@STM/,1(4,@,L2.0YC2.,N"W.E56_P!`![]U[J5[]U[KWOW7
MNO>_=>Z__]3?X]^Z]T1?Y9?S$/CS\)=_=-;*^0M/VWMS$]XQ;PI]I=F[6Z:[
M#[+ZVQVY]I08NLBV)NC+=<X+=.:Q&\MV8ZNJ*G#T@QTR5<&-JV:2+QH)/=>Z
M!/`_SB_B1N/^&/C-D_-IZ7+Y2HQ5%D)/Y>OS97'/)3Y"+%M5O6)T7)%%0-5S
MHHD8C3J]04A@/=>Z9.V>Z=K+\I/@E\P*'HCO'<_46>Z<^6/3F6[3Q'QZ^0E1
MV=TYE=_YGH?=FT<7V1T?3;(7M7;.RM^2]0Y*+[_([:\='7T]$9)J:&K1JCW7
MNH.]_P"<Q\`\)NT;+W_A?E)1[IVOD3F\=B]S?R^_F?#6T>3QN*DK*++X2/*]
M!)-'D)Z:O$%)+"%GDDJUC7B7GW7NEUL_^<3\&]X8>ISBY[Y`[6HH,[1;<C7>
M_P`,OF!M:JK\KD*9JJCAQM+D>CEEKDG6-D#1@@2KH-F*@^Z]TQ5W\[_^61B<
ME-A<]\A=P[;SU//4T\^W]S?'7Y/[>W!#+1K#)4"3"9CIBCRB+%#41N28K>.1
M&_2P)]U[J3D/YVO\LS$X4[EROR*R.*VVM//5G<65Z*^1>+P0I:8-YZALMD.I
M::@2*,H029`-7'UX]^Z]UDIOYV/\LROG-+B_D?4YJI.5BPD-/@.E?D#N"HK<
MI4M+'24F,@PG560ERKUM1`\,#4RRI-.C1(S2*RCW7NH]/_.\_E?38K<>9G^3
M\&)H]J9.+$9J'<'47?.W<M%6RPI/:BP&<ZNH,[EJ>!9`)IJ2FFA@?TR,C<>_
M=>Z]@_YY?\HG/)0F#^8#\=,1+D*QZ"&CWCNZ7863@JXZQZ"6+)XK?%!M[)8?
MQ5*$,U7%`JI9R0A#'W7NCN;$^6'Q;[0K(<=UM\D>AM_9*=:AX<9LWMW8&Y,G
M(E((VJG7'XC/U=:5IUF1G.BRJZD\,"?=>Z'Y6#`,I#*P#*RD$,"+@@C@@CW[
MKW7?OW7NO$@`DFP'))X``^I)]^Z]UJU]H_.O^8/O7:>:_FE[*SGQSS'\H#9'
M9NX]K[F^-F[-I8JN[-[<^(G7VZLAL_L3Y6T.],Q75<,W9>0WMM^L_NCLB-:9
M<GBHJ/4K5M44?W7N@\VK#_)D^;U+VSW=D>NNZ/Y&GR.ZCWKUYM8]MY7-8;^6
MG\@JS&=PXW-Y+I[="4V*W#3==[\P';E#M;+4T5+EZ+*5,_\`"ZN)&"!9W]U[
MJ/O+X?\`_"AGX$[YZ2["^+7S-R?\T?XT]:;VWCO;??1/;.>VWU_WOVEM/?,D
M&:W'MO/;_P"P*O=^-WE%`'J5VW54F8IIL+4-"*3&O`[0I[KW1SNL?^%.7\JO
M>6\-K=;]G[^[2^+?9&<RFY]N[CVI\ENI=S]=TW6^YMI_;PY#"[]WC%'F-DX8
MU5>U1305`R#P1S4CI6-2.\"R^Z]U?CM3=FU]^;9P.]-D[BPF[MH;IQ-#GMM;
MHVWE*+-8#/X3)TZ5>.RV'RV.FJ*'(XZNII5DBFB=T="""1[]U[IUR&/H,M05
MN+RE%29+&9*DJ<?D<=7TT-90U]!60O3U=%6TE0DE/54E53R-')&ZLCHQ5@02
M/?NO=4#_`#@_X3;?RX?EI'#O#JK8"?!_Y`8?)T>:VMWA\4Z"FZZGQF1HEB2,
MY+KG`SX;8F21S`CFII:;'99)4U15T>N42>Z]UHH?*/\`E3_S7/Y!G?NS?FIM
MW`;>[&Z[Z$[*CS'7ORDV=M_;F^=D5<N6>KI*2K[<Z]S2Y3=&R:K/TF?EQLU1
MEX&AI:Z<18W+23I1U)]U[K97^)?\[KX,?SCM^?%_<'S<[EP?P:W-\)-ZU_?F
M6^..]-Z8^CZ#^5':&(VTL^P.PZ;?>YEQ-)2TW0&;Q%7E\9MC(/49.JR60IY(
M'J/M&9O=>Z:\IV;VA_PI]^>59T[U]7[IV=_)*^&^]FG[>W;MW,9[;4GS(WW0
MRP97:.$R%#E<=B:V7&Y:LQD%11XR:A#X'`M45]3-'DJ_&0P^Z]U:-_,R_E`?
M$;9/46X/FU\1LGLK^5_\G_A[U9V/OS9'R.Z!V5M38.UQM?";!W*N?VCVGL?"
MX['[9W+A,]B:F6E_B8I&SM(9%$,E1'JHY_=>Z`O^27\$$^4'PXV=W5_,<^%'
MQPS4/:6.PW:NR:7N#`9[O'OSN??^_=D28/M[Y9_)#=';.0SV/J]R]Z4TM//M
MC!QT03:FWQ''2M`)Q&GNO=9_Y@W\J[^:UM?XUUG0W\KK^8/OS;/2E-V1M7.;
M&Z0WG5SX3M[K#;]=V!MVGQW5O6WRLPU91[UP_P`=>J,;6S9.#$5Z565I\+B%
MQ,=76TK+1M[KW1ZNA?YD_2OQ7V1\+_BK\^?FYUIVS\N^^*K<VQ-D=O;0H,16
M;,[_`*W![ZK=H[>WE%4]809C:NQ:'.9:>';%/)F3BI<CN+%UT?C,B2M[]U[H
MRW?7PVWWVQ_,5^`GS)PV[ME8S8OQ)V1\L-K;QVEEL'75N]-RU7R!V5M3;&"G
MVIEBT^*Q=-BZO;WEK9-%-5B)?$DDT53+''[KW5>7S.P&,^;7\YGX^_R^?DIN
M/`4/Q#ZH^+5+\W\+\?\`+5%73+\P^]:#LW=.Q</1;CEH<I00Y[9G0U)AHLX=
MN5/FCR$[335-%64B>:A]U[H6OF#\HOD)\J^^\E_+3_EI;UH=A[EVC''0_/7Y
MCTN!J,GC?AML;.8VGDPNP>HZHY7"X?<'REWC0S/]E2P?>Q[9I1]Q4?;U`\M%
M[KW1/?E?\)>G?Y*VPM@?/CX3=@;SVGWOL_);:ZK[9ZGWSGMS=J;B_FWY_LC=
M=#+!U3OZKKY,_N:;Y1[NW++D<KM;<V!QE344-=-40/CWQ9:.F]U[H1OA'L/#
M_P`[6JH?GK\TLW2[CZMZY[,W+MWHG^6:F1R`V/\`%WL#K7<E9M_*;B^8&"J:
M/;N3[8^2M=)BXJV'#9_'1[>VSCZQ?M:2KDJ151^Z]U8AOS^8EMJM^4>U?A-\
M/]BQ?)KN;:V\-I4WRIJ-IYJBQ'5OPSZ?K,E14.7W+VIO)HGQ-3V1-022KM_8
MV+-1FJV6DG:K7'TT)F;W7NCL=%=<;AZ>ZBV3UWO'MC>W=^Y]L8R>'<7;78\F
M._O?O;,5^2K<MD,OE8L73TF+QT`JJ]H:.CIT$-%0Q0TZ%EC#'W7NA=]^Z]U7
M?\\/Y7GPZ_F%XBFK._>I<1E^U]I[6RN`ZH[KP^2W!M#M#K&JJIVRN*J]O;RV
MAE<)G!1XG<(%9'232S4RN\VF,&>77[KW6NWU#LK:'>O\OGO;X9_R(-G[WZ1R
M/0/?VT<7_,)ZX[FR'<?QY[I^1M%C,%+2]@[6Z9[NS&<[.DZHWWWH.KY,342R
MP4@HZ6K\=0F+BE)G]U[JUWH/^8C_`"V_BG_+AVGOWXR=85/7.W-N;BGZ@VM\
M!]B8"AH_E2ORLR64J:7,?&2KZDJLG+NW+?("JW4E2U<:J2JGK:6-\IYYZ0I,
M_NO=`;W7_,IZ0^2O\T#J3^2I\M/AAUSGMF=X?'#$=E;TD[AW1MW>&3V3W)N7
MJS/=E1]44NW:#"5^%BSF"V[C9J%<S09B&KFK9_)1E8A&\_NO=%N^/71/\R[J
MO=ORD/\`)U[LZ/[4_EW=;]^YGI[K3XJ_.[<&_>Q]L9C<.V<72X_Y$4W0_<.)
MP3;LVSTSL7LO*5.WL3C:G.9BBJ<G@LLTC*ZG[[W7NBM-O[XP9[-;NW9\_P#_
M`(3+?([HOL[KG=V6V+N7O#^7IU[7[CV[5[U;)K)ELE3[_P#C=N/I+<]3%4M7
M";^,4M9G%-1(:?[HR<'W7ND-M[LG^1IN&FRV5V;T/_/OW/1;?W7N';.[8MK9
MK^8/DZ3:>YMKQT^$RFQ-SU5!W28\7F-M^.*22C>H-?1EUCJ646@7W7NG/"?(
MW_A/?NO;E)VKANK_`.<I4]9TK"3<&Z\?O3^9/D.L]MQX_)9"ARHW7N3%]ZY'
M$Q4]"N+J):TTU9/HBBD4'S1R1K[KW6/<%9_(AK<?G>[\IW[_`#SJ7J".ESFX
M<9OQLG_,5GZ8S>SIJPR8?<.U]_5^RZZJ?9=#CZH?PJIKLI`314X-69)3>7W7
MNG7'?('^1#U%U_2[PW3V9_/*V7U_G<+!)@^SMZ]A_P`S+:&U:#%[MG@^PJL%
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M#<FV*+&=](V77#4U(5CF:>&G$89424JBK[KW4'M+?O\`PGTWOOO$5O<7Q@_G
M69/NGK+;.W]QX?9G8-7_`#`,KVKLS8&4QRX7![\QXW)W=D:_:VSJJHHUQ\-=
M#7TD=35.$B$D0)7W7N@LVGVQ_P`)O>M,IOCK79/07\YGK?>U#7PY3L':6UMQ
M?,C:F\=O9W=%#355%D-W;7PW>E)]MF<G2QQS0S9&CD:K15:\L87W[KW0Z===
MJ?R2>U-Q;8QO3G67\^>LW)B.Q,1A*C.;4W'\W-U4^#W?@,YB(:[;^]X-P]M;
MNVM0ICJG)4,V6IY:+734]3&&\>O0?=>Z*WV/N7_A+/V1W?WYVIO;X\?S,NV=
MYX+>^8R'9VY*.?O_`'7@=EYC9^2K*?/Y-=VXCMHYO&82HFQ,LOER61D2CIHP
M*7[2*-43W7NDYT?F?Y&>WNB9,9L\?SY)]B5F]-V[HVCV]TMCOD!LS8]%M[<W
M:^]L]AMDX7&X;L3<O6]9D,/@ZZDP&7RK4'GS-30FMC:GKIZH+[KW3YO_`'G_
M`,)]<+C,=A/D=%_/LW)L/>LN`K:#8_?^9[VI=D=BQ5^1BK=NXRFQE5N';K[@
MIZBJQOW%&\,PDD:+5!*TJ+I]U[I?X_=?_"<;J:HK]N]2;;_G-?!7<N[\WB,=
M)L[IRH^8'6>X>Q=R[:H$GPV+7"3;DWG0YW/PQ54]1`DX6J@9YG0Q(ZZO=>Z4
M>SNU/Y'V:S.`P=;\Z?\`A0CMSM'<>6FR/76P=R=A?+N?L_/Y3ST=,*?KW$[(
MV'GUS5=BX*FH(:&6:J6!ZC7([>(>_=>Z5M7\KOY*&VMRIUIN7^9K_P`*"\9N
M2DRCY-^N=Q]P_-G%[DKI*=&IZB>7$)L2BW>E%)'1RPNJO"R&&0@(RZ_?NO=1
M^O>[_P"1OFMZ9O:.P/G#_/\`.TNV<Q3S9/<6"VMV3\Z\IV76X=(8FFK<UAMI
M;4P^3K<134X@1I9X)"$\=V(Y]^Z]T5O%;M_EPR?!K^:MTWW%NC^:)%T1-_,2
MI-P[+V%L"G[!R_RUH=O47QUZ_P`?-V%\D-K=DU.V\)D>M*3*X&6I\/8-5$L3
MXW'Z42MB4M[KW6PU_)2_E(_R\.H<MU'_`#)OAKVIVUV5M;L[XK]?;3ZYH-\U
M6/VQ5XVJ6ESF#WWO/?\`A=AIMC#[GWQFF1\55T.8H<A!A<C053TE1*QIY*;W
M7NMD/<*X1MOYQ=S4]%6;;;#Y-=P4F2HTR..JL(:*<96GK\?)#41UU%/0>198
M6C<2QDJ58&Q]U[K62@^?G_"4?:%8<=A1_+<Q>2@?(P128_X>XF.GCK,?":.8
M566Q_0\Z()D)C64N_G2_C,GY]U[H@W8'RO\`Y+OR`_F6?R9L-_+)VIT13=B8
M[YD[MSO:5?T9\8I^@,S'M@]3[@H,=3[KW'D.M>MYLU1'<5='4G'?Y8[QT\KD
M0DH)O=>ZM#_G"]>8SM'^:'_(=V1DMS5^UX]R]C_/3%ID<=CGEKJ63_99\35T
MU7CLK30)5T.16OIX8H@*B-%:43$`PAA[KW1B_P#A/%+N/'_REOC=UUO"-EW7
MT5N'Y`?'W<4G\93.P3Y/I;Y$=I[`DEH:^,M&,6L6%1*6)6>.&F1$C9HPA/NO
M=8/^%$./_B'\J'O$"BI:AJ7M+XD5*UU6KE-OW^7/2%*VXE:-',7\*2J+NUN(
MB_YM[]U[J[900JAFU,``6L!J('+6'`N??NO==^_=>Z][]U[KWOW7NO_5W^/?
MNO=$U^0NZNQ\#\D/@CA=I[QI-O['WEVUV[A>UMMSY'!4]3OO"T/QT[-W!M;$
MT..RDT>4RDN'WKB*')O_``U9*B"*D:20"G$KK[KW1RO?NO=>]^Z]U4Y_,0V?
M\P]Y=D_'O;G4WSUIOA!T+O[=E#UCFZSK?H7;_:GR`[#[BW-2[ERFVMOTF[NP
MI,ULC8.POX-MQF^[@Q+5RUH9)9)(94\'NO=!SA/Y;?\`,*V[N*7-8[^>/\LJ
MRC(=H</N7XZ?$7=%(LAJYI8Q41Y;K*6AEITI72,K'3PNSJ6UZ2(U]U[H:\1\
M1OYAV,GI9JO^;5OO<2TR5BR4^<^&?Q.C@K35"(125;;=VIMZJ5\?XR8/!+`I
MUMYA+Z=/NO=!WN[X9_S7LU7>+`?SB\3@]OFO-:U)DOY=?Q^W!EC"9Z@C%25[
M[TQV.EQL=*T2@BB2J:178S:65$]U[I,47P(_FOEI5S'\\G?#P/5O6+_=W^7]
M\2\'/>:17EIVDR,.XT^V15M&-.K4Q9V<\>_=>Z=:CX.?S83ZZ+^=[N:.::"-
M:HU_\O'XDUU.*B-)QY*"F@&.2E@E9HBZ2FHD(C(61==U]U[IEVW\*OYJ^S.Q
M^M=U[S_F+]#?,_8='OK`Q=G=6_(?X,=7]5%.L:NN1=ZUG5V_^G,AE,QAM_1X
MUC)0P5]%48VKJH(%GD@B63R>Z]T</L;^6!_+C[<S%9N/LCX+?$_=NY*^EAHJ
MO<F3Z&ZV&XY:>GEEF@'\>IMNT^722*29],BS"0!B-5N/?NO=`7!_)8^".W-P
M[7W1U/@>]^@,KL_*Y#-X9.AOE;\D^M,.F2R4\514SU&W,/V@VW9HB\;`0?:B
M#1+(I0J[`^Z]TSUOP@_F%=2T=#%\6?YIW8F?I8=VY[-56SOG5TUUI\F-NMMO
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M;JZ]V?D,;(*')YV&HQE'22C[2KJQK>)?=>Z6O6'P6_F8_P`M#9R;;_D_]J_'
M?Y2?!O.5-=V%UI\</E;EZVEWWM6;LO#5^4K*GKKY!;,H<3BLYUQ09A,;DL32
MY$2354%=4QO47TU4GNO=/O\`+E_G]9#O;Y';5_EY?/GXK=F?#7Y]Y.NW%M^+
M!Y/%QITYOG*;2V_N#<F1K=L9W.Y>'+T"Y?&;?+8V.`9F@R4E3%]E7U$<B,?=
M>ZV3??NO=->;PF%W-ALKMW<>(Q>X-OYW'5F(S>"S=!2Y7#YG$Y&GDI,AB\KC
M*Z*>BR&.KJ65XIH9D>.6-BK`@D>_=>ZUCOYE'_"5/^7]\TJ?,;X^/.+I/A)W
MS75-#.,]U7MZGGZ5S*0_94M33[BZ*I:O";=QI_AL#F&7;=1@':K?S50JKE3[
MKW5W_P`#?@WT1_+N^,W7_P`8/C[MNGPVT]GT,55N'/201KN/LC?M9144&ZNR
M=Z5JEI,CN?=-51(\A+&*DIHX:.F6*DIH(8_=>ZJ?R^ZL+_/`^7F].F-J[SHL
MM_*^^!':&WJ3O==KY^._S2^7>U9DS]%TQN#'PU!?+_%CJB*:GK,R*JG;&[OS
ML445*U12TWW,7NO=;$4444$4<$$<<,,,:10PQ(L<444:A(XXXT`1(T0`````
M"P]^Z]UD]^Z]U4_\P?@QV#7=Q]*?,;X;8SI"/O#X_P"V\[LFHZ'[@V'M8]/]
MS=5;@WBO9&X=J[;WA1;8K]U?'_N1]Y0M6X3>.*\U)'75,BY:AK::1C'[KW2`
MZ_\`Y^W\LS<'1&_>Y^TN^<=\<\]TKFZ?9/R`Z%[CQV4QG??3W99SM=M>NV#D
M.L\%19S<6^LE19_%U,7W.V(,Q2&&!Y7>/QS+%[KW51^>[>_E@_SUOD7TWM+I
M?HW.?*WNK>-3NZ'NKY69C:/?7QAR_P`,_BGUKG=SYO9XV%O."K2AJ^W<UF]\
M8^FV]#C)JNGS*U5359M::$1T"^Z]U=!V1F/CQ_)@^)'7_4GQ1^,N_P#L'<V[
M-WS;(^/GQZZCQ^?W#O;O+O7<F.K,A-E^S>Q\B,A#B:/(O2-7[EW;N6K,-+2Q
M>@2R+2TC>Z]U*^+/P%[#SG9.S_FQ_,:WMBN^OF?18F6?8FP,%3R4_P`7?AG!
MGH\?5UNT/CEU_D:G*QU>^<9)`U)D>Q<G-4[FS"7CBEI:/33GW7NJ=/GOUS\_
M/E!\@NZ_DM_)GZV[2^.U#MC;E1TY\Q.U,AGV^.V_/GV^U,I58W(;/^.G5_9W
M7M;1/V)U#@8ZNDPW;F:_NY5SSY!*/!UTU)2O+4>Z]T;'X;?S-_Y%OQ)^+6U=
MD?";L';=1G,_2T53A?C-LS#;OWE\U.W^Y=SY)Z"/9V\-DUV/R7:N].ZLYO3(
MO15,^3:6GI2[2B>+%QI*GNO=&I^/_P`-?DY\E>S=F?,C^9;OC.8+<>%GQ&Z.
MEOY>?56^\M3?&OXZ5%!6XW<.U\IV_4X'*14OR<^0.V,K2++/F\B6VY0URDXN
MACC2%H_=>ZL5V/\`*CX_]E][=L_&KK[L[;N\NZ.B,#M+<'<6SMNR5&5;KJGW
MS4YBGVQB]T9BD@DP6/W/D!@JB9\2:DY*EIO%-/!%%40/+[KW1@??NO=<%C1"
MQ1$0N=3E5"EV^FIB`-1M^3[]U[HLTGPN^*,WR>3YH3=`]93?*>+9Z;$B[PFV
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MGWS8HZK=%/LBMQ6PZB/=?9U7N/`T.%W+401XS=VY\7C,C#-EHHY)IJ5YXEF*
MAXU]^Z]T3_\`E`[EWT/^$Z.9K-TP2G.[3ZK_`)@M!BMTRU=#F!OI,-VC\A*K
M^^<.,CA:/%4]9GI*JG3'3J^A:2]O%(BCW7NDSO\`[&I\Q_PE(W!+A:#<);;G
M\I#K#8M75+CJG%4F2DJ_C7L+%9&MP==ECC8<]@:*DRS)6U-,9(6>&IIXC-+&
M8S[KW2'_`)KGR!Q_R?\`^$O7;'<.$Z[[3ZTI\UU=\6J6':?;FQLIL#=BS83O
MWH:B_B]#A<R@J*S:.>:$5>%R@`ILIC)H:J/]J53[]U[HR'_"A7L;;TG\H+M3
M<E)O+!8W*=1][?"E^P:,92DS%=LG=>*[ZZ$WC5[6W71[8KZ@T&X\3@=QT&6E
MHO-%(U'+%-&VB:"1O=>Z%?\`GK=S;3Z?^-?PM[ZSV?H,-L#8/\SGX!]B[DWE
M5_>2XS`;!QO:`RNYMS3T5%0UM?DJ.FVG]R[0Q()2C:UUL@BD]U[IL_FL=F9K
M9WS7_D397:N[*K!4&\OG-NW;&0,&2JJ"DW#M[?/16Y-LU&+K\<_CI,A%E*/<
M!@B6=3+%-4)X@':X]U[H'^VOE=UAWO\`S</Y(W=G1G:=7N/HKL;XY_S0LM2Y
MC#8?<]#C][;=VQL_84%:U5M[)T>&W!)C:7<6Q):FDDDH)Q4S8V-Z:-UD2;W[
MKW0K;I^4'7W6?\Z6K[%W#F<Y3]-;\_E`]%9ZFW%@MM;QW,,ID-V?.K,;+ZSJ
MZW9VV-N9?=,,-15]KJAK:BEB@Q-/53RU9@IUGEB]U[J?\&<YDX_YSW\^2BDH
M:W-U5-'_`"P6QJ4,F*$$&'D^.F\X/LY*V3^%TT%913UE15203/+4^#E7D)CC
M'NO=-/\`+)[_`,SMOM;Y[]>UNS>R.R'[%_GE?,?J6@S>TL/0Y+;W3>`PGQ[V
M%VS'N7M',55;0-@-FU;[:EQ6/D_RJHGRF1I:6&,IPGNO=:,WQ_ZH^3ORDI>^
M-L]T_)SY>=!?&_8]%_,6WK\6]T[!RFR\-T2=W;>A[3[#^0![9K,AV;L?>53M
M;?V0G;;=754N+S#Y.MS1QSU4$$4D/OW7NMFOX^?(?>B?\)`J[?&*[HS/6G;_
M`%+\1MY8C![PZWS@PG86RJ?9W=VZMG]-TL-1LRKQ><VI5;FVUMJ@Q<&1#0U7
M@D>K:22199&]U[JS7^;CV!V!0_RJ^ANP,+E:=NT'[Z_EB[J@KJ^OE05F[:GY
M,]#959JNOCQ]2PIJ[-@_<2O1R*\!DO"Q/C/NO=")_,6S>[<?\KOY,^(S.1V_
M29?*_P`R7L*LQ<F"QU?4J^QJ'XF?)G'4M!74^3J'#9BLV]GHH*^IC98H*J7S
M0(5C`]^Z]T$/\P#LK;$W\\S^13U-A\[73=BX2F^>^_MU;;P5#+4U^-ZXWA\=
MJO;N`S>X*EJ*HIJ7;.;W+L?(4Y`=7,E`S$IH5F]U[H4NR8<C6_\`"A+XM(RX
MZGQ6&_E8?)[*03LA;)9.JK_D?TCBLE0:HC*5@QZ-131^58D_=F".[%E7W7NB
M==]]C]P[!_X48[^J^A>H<)VWW!2?R0(JGK;JZIWYA^K<5VSG)?F5CXZBFWQV
M#EML;@IMMT>V\?%)4P2%`\B40@61C.L:>Z]T3?\`ED_*_`;3_FF_SG_]FF[D
M^$>P]C]J?(S;/6/=&!WOV')U7FJ+.;9ZWW!L;`MU7GNUVVM4=G[)?*4-5MC+
MTLE)CJN6JGBRU,L=-(U,?=>Z/_\`R#^@OY674>]OG5N/^6_W)M3?D>Y>R=L[
M8W)U]LSOO>'<>W^O.M-EU>\CUADJ.AW[UYL+=&#J=YU^=S4E2S5F[\8TM($Q
M^<J8Q,H]U[K8ZJZF*BI:FLG$S0TE/-4S+34U36U!B@C:6004='%/5U<Q1#HB
MB1Y)&LJJ6('OW7NM;COW^<=_*XW)3[+J^M_DJW1^1PO:N&SO9N9SO\K_`.1G
M<$&^-H8K+9#%[WZNFJZSI;$46T=Q[@S;"G&<@JJVIH:N!E6GJ"Y'OW7NBD_*
M7^:-\,ODS_,1_DL[3^/FV>W:?*;<^=&>K=S9#=OQP[:Z*Q-/4]D=0[BZQQM&
MN2WWMC8=;FLS65VY\775$%,M3`<8B/5ZH_V&]U[H^G\TVHH,/_-T_P"$^.?R
M4L^/IV[Q^:.V5RU-E\G33?>[F^/F"QV(P;8NE'VM12Y[,200S2OR$!B;]J1S
M[]U[I)_\)<>SMT=L?RY.Q]T;PKZ;*YR7YS?+*KK<K!"(9<I7;LWCC.Q,SD:Q
M4;PFIK-P;TJY!XTB00M&H7@LWNO=#5_PI0SG]W?Y,?RZRJ4[3U-)6?'RHHO]
MQ?\`%88*VC^373E?!4U4;1O'2T\34G,S&,*Q"APS+?W7NKNMN2R3[>P4\K5#
MRS8;%RR/5%#5/))0P.[5)C>2,U#,;N59EU7L2.??NO=//OW7NO>_=>Z][]U[
MK__6W^/?NO=$(^4%?%2?+3^6Y3?Q)Z.JR/='?%/#0QX:LK6RT$?Q5[;J*JG;
M,15$-#@H:41).QG28U7C$4:AKNONO='W]^Z]U[W[KW1?^]>I,OVIF/CY7XRM
MQE)2]2?(#;O;>>AR+5239'$8/8O8NVTHL2U-!.G\37,;MI)P)=$3002J6#%?
M?NO=&`]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
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M+L/K_P"<_?777PF[`^0/Q]Z]Q';6V<-U'\B^AMW8KLO(9[I7.QINWH;:O36"
MV''M*F7>6.P>9:N6++BI2E1LG/[KW6QO_+$_FH[U^3?\U'K+X$?$'.9X_P`M
M3XF_`.#$46;[-V+A</O/Y"U/5;[2ZIVMWGMG<.6H5WA-M/)Y&MH:;&FD>EI:
M^FIZJJJ*97DC6#W7N@@[R_F2?';Y@[`[2V;_`#@/B/B\C\:)OEUWOU'\"/E_
M\/8=U[UWQN=?CUO/-8C=O;VP<#CJ_)=Z;)INM8<=C!D-XX2*IP.8R-3)2?P\
M10E)?=>Z@]A3_P`]CX08#HWYH_`3Y5=C?SA?Y=FX=D;4WGC.E>Y>NZ5/D;5]
M6[AQE)786;-RTNRL3W+O/*5&#R9J(<[3!<K2S!3D\)+%3_N>Z]UL+_%#^;Y_
M+X^6?5VT]][1^5?0FV]TY/;%-EMZ]5;R[1VYLWL+K?/TF&ERF\-M;EVGON7:
M.ZZ<[0FH*V.:LDQT---!2-4H?"0WOW7NE3V]_-F_EH]';-J-];_^<7QJ_@T5
M3%0T]%LOM;:G9VZ\MD*B*66FQV`V/UKD-V;RS]?4K"VB*CH9F)L.+B_NO=5V
M[P[_`/G#_.`HO]%GPKVCV]\"O@_F_P"&?Z5?G)WALO-=>]_=T;-JZI:FOVA\
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M>Q=RY6H,F2JL)UWLZIK<J]#C8*G(Y&:GBI:>,R3`CW7NM0WY6_#'`8GL;Y(_
MS&]Y_"WI+%?S`/F5\@<=\:OY47PZWKUWB=RR_P!X<)OG-XO<ORX^075T]=3;
M+W9V7O+:E#D-^Y7)Y6GR>)VKAJ6@DK&J:BH8'W7NKCOB5\'_`.<UM?OSXQ=K
M?+W^9GU=N_JKI[:6]:#L/XY]!_'_`!/6NT>Q:[=F$?'8W`;@K,9!MS;F?QVS
M:V*CFQF5&!QM70QT314M-":NIG?W7NK\/?NO=$*WKTKW_P#(ONG"5O:.\=W]
M!]$_'WNC&[ZZYVIT1V])#6_+/&8_`X2MPW^S%-3;*PFYME;1V=O>EJV&U\1G
M:J@W/23JN6+0I]JWNO=!%\IOYANXL9VMEOAE\#.M,;\K?G!3XK&93>6`J-RM
MM7H7XN[7SE3]G3;Z^4/;E%1Y>+:-4(==5C=H8RGR&[\VB*8J*&FD6K]^Z]UK
MI8+^5=\M?Y,Q^%'SN[D[?Z'^6_QS_ESY;NC>_<NQM@?';%]==X=?[.^35)E\
M1W+V)L_L-\I4;@[^AZNS.[Y<W!%GZS%5,6,IIVIJ1YA%"GNO=6J;;^6_S3_G
M+5<`_EZ9S<GPJ_EVT^4FH=S?/'>>S!3?(_OK(8.2DFK]O_%#J_>%+/C-J[#^
M^9Z#(;MSM*\\DT4\5''!/2SPR^Z]T??YD_+WX_\`\LCKS%UV%ZOJ.SOD;\B=
MW)M[IWX_=283;E!WA\L^YFI\?0U>9R]1C,72))!CEK*>JW3NW(P24V)I)0[B
M2:6FI9_=>ZLAPM3DJW#XFLS.,3"Y>KQE!4Y7#1UR9./$Y*>EBEKL8F2BAIXL
M@E!5.T0G6.-90FL*H-A[KW1<OF?\NNHO@A\9NU/E?WK-GHNK^HL5BLEN*/:V
M+3-;CKYL_N/#;1P.*PF,EJZ""JR&5W%GZ2G3RSPPIY-<DB(K,/=>ZR_#WY<]
M*?.;X[]:_)OH#<9W!UQV;@QEL:E7]K!N#`UL%54X[+[9W5BZ6KK?X-N3`9:B
MGI:NG:1M,L1*LZ%6;W7NC-^_=>Z"WO#J':OR!Z:[5Z*WU49ZEV3W'UYO#K#>
M,VU\O+@=PC:V^<#7[:W!'A\U#'+-BZ^;$Y*5(YU5C&6N![]U[I^ZWZ]VAU'U
MWL+JGK[$)M_8766R]K]?;)P,=15U<>$VCLS!T.W-MXE*NOGJJZJ7'8;&PPB2
M:62:0)J=F8DGW7NB@?`SH'']"8WY<)C>Y<'W'#W+\\/D]WW/-M]L:T/6.2['
MW)C'RG3^07'35"1[@V)D<3*E>LVB?[N=R\:7"CW7N@C^%O\`+DSGQ3_EK;A^
M`V7[HEW[E=Q;?^2V&'9#;9@H,3MX_('='8>X(8L%M2&J@F&'VPV^/(::6L9Z
MBJ$Y26&*2**'W7NL>X/Y=&;S?\G0_P`K\]E8==T)\*</\7(NU?[O2Q;>;<V%
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M11RO%!]RD9D;QAE;W7NN'S4^#&3^6'?G\O7N>@W[B]I4OPE^2.2[TS&`R6`G
MS,F^\=7;)R.W(\)BZN*NI8L+DZ;*/33K42I,BQAR%#JE_=>Z@=O?!+)[U^?/
M\O?Y9[%W%L_8_77PPV)\KMDYOJRDV_)0R;AIOD)LK:NW,$VT%Q$=/A<+!M[)
M;=,]7'(BB6-E$?.H'W7NA"7X<2K_`#)9OY@'^D*5:>7X34_Q";JI,-*L4U1#
MWE4]Q+OZIW$N66&800S''Q4#4+%3(\PG6_C;W7NL72/PGI.EOF_\W?F;2=CU
MFX)OFE@?C3B\IUW5;2PU!%L&M^.NR-Q;%IZS';PIJF3+9ZCW1C\S',U--#3K
M231.2T^M#%[KW7'X2?$/+?%/-?-7.9O=N/W=5_*[YO=N?*VA>AH*BA?;6W^P
M-K]=;8PFS<@9YIA6UV"I]C-JGCTQNDR@*I!'OW7NM%O8W_"9B7Y5_P`S;^:K
M\;>T>X$ZV'5^4V7W_P!1=P]84M%N?`X7%_)K?'8V[=D[`WOU-FC@JRKEKMF8
M^L-7'29F@?$5F)B,<U92UB%O=>Z/K_+I[!^$W8_Q`[+_`.$[NQJJJZL_F(]H
M]%_*WX\][=K8W8M?NWJX]B]#=C]R[<IYMQ[FS&0P63SM=FMF0U6X\=3XNCGH
M<;BZTTG\02OA6'W[KW6SC\VO@5F_E;\2NFOC+@.RZ#9-3U;VU\4.P*W=>2P%
M9E:;/X?XY[]VANO)XG^$T66H'@J]PT>VV^V+S210U)36"/6ONO=*?YB_#_=W
MR4[V_E\=K;;WCM_:F,^'OR9S/>>[Z;*8VIKLQNK`UW46^NOUVSMN:FC`HZJO
MR&Z(34---'`*=6<K+)'$GOW7ND!\E?Y>"]W?S(/Y>O\`,!V_N/"[<S7P]QGR
M`VEV!B:N'(#+=C;([7Z[RNW-GXK&5>/C$<<VR=V9NMK=%7)]L]/7U"A#(5(]
MU[H3<I\/\YD/YDG7GSA.\,>^U]C_``\[;^-_]S:J.OFW+/N3LKNCK7LVGS<-
M=H&,7;&*Q6RZFE6!C]PDT\>G5&/1[KW5)W\P^G^8FP?Y\?2/<7\N?8G5OR#^
M1R?RO.PL3W%T-VOO>'K?`4_2&)^16+@VGN>CW8V0QJ2;@W!V%NTQTE+,Y18L
M)4,Q590R^Z]U@_DI?RZ>M*/'?S'NG_G-TG\;-R]N[Y^5O5W?_:_PRBP<W>/4
M_P`:9-P;+R&\>E<>-W=D0[JQ&[=Z9;#Y_(UT[T61RJ4F.J88IJ@-55%*GNO=
M7F?&[^75\1?B)WAWWWY\<NI-O]1;K^1N%ZQP&_MM;#QV)VEUI0T'5&.R^.V_
M_<_KS;6-Q&V]L5.3&:EGRDL,):NJ@)6TN9"_NO=';FE2"*6:37XX8WE?1')*
M^B-2[:(HE>65[#A54LQX`)]^Z]UK=;[_`.%'W26&WJFQ,/\`!#^:_)EL-N#(
MU%?!C_@P<K_?#;>WZF>@R;X&ARW:6W<U08ZLGJZ*J3)/1NT$,L2R0!YK)[KW
M5;GS,_FE8/\`F"_._P#DB]>]=_$;YP?'V;9G\QW9.^,CNCY8=%)TWM_/8_&4
MV-HLO@=FU3[EW(-Q9F#!Y.HJJN,>`TL"QD:S,-'NO=6C?S;LO6X_^:W_`,)[
M((\2*BAJ/DO\I%ERD^4H<?2T]55=-[5Q,5%IJ;R35<E-DI:B%%'[[T_@0^25
M+>Z]UG_D3;5Z7ZC[C_G'=!?'+<FT\IT;UU_,*_O)L+`;+R,&9V]M)NRND>NL
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MIUM?C7>2"GW'L[.5VVMT8B1G2,_=X7/8RHI9P`0LL3`$VO[]U[I6^_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z1FY\5O?(9K857M7=^*VW@\-N:KR'8
M.&R&U/[PU.^-K2[7W#C:3;F(RO\`',2VS:^EW578[)G("&O\D-`]*8`*@RQ^
MZ]U6E\B_Y1_1W8>_<A\BOBQNS<_P#^8IV]D\)2?(3XTXO;>(QF\(ZUFJ(L=W
M]TCDL=-U-W_MK[TB2:GSF/\`X@X"^*NA:*%H_=>ZJ$[1W_V1\5]Q[ID_F?;.
MP7PZ^0W87Q0W;_+I^.G\X?XPX/+;O^%V-Z[W?FO[T[(@[&Z03-XFI^.O:5#N
MB&*NB&2I(<`TU/.F.R-'0Q,![KW25^'?Q/ZOZH_G!_&OK7*9OY2;4Z>^*WQ'
MZXZK_E6;HZC!R7Q<^5_7AZQW=V5\M^T.YNT]A8_.;6K,YNGLO<7W55A9ZW$T
MU?4Q8YW^[CDH8$]U[K<"CCCACCBBC2**)%CBBC54CCC10J1QHH"HB*```+`>
M_=>ZH3_F:?R0^DOE-V+M+YG="=,_&H?-;J>2LR%'MOOOKJEW3\:?DOCI<7EZ
M!MG?(?8V.@2+(YRD;*FIPFZ%AJ*W'UU/3BLBKJ2*.&'W7NBV?R`\=CM[47>?
M6/S+^'O\O+HOY^?$#M+%;<S>UNDOCGU?U1WMA]O2XA,IMGM?>6(VILC%;-&/
MW;)E6GP&Y=D54F"R--,Y6.DE]$ONO=;00````L!P`.``/H`/?NO=>]^Z]U7G
M\RO@#M?Y'[OZ]^1W5>Z#T'\X>AXG;HOY)87'561,6-:K^]R75'<VTJ#+8&'M
MWHS>"R3TN3P=94Q34T=9//C:FCJG:1_=>Z*D_P#.QZ>Z6^.??.]?F]L^L^-O
MR?\`C!N2IZY['^+O\3CW%NWM;>]73J>L]R?&2*6''9WM#J3OJ:1?[LYMJ*FB
MBD2K@K&3[&:=_=>Z!+JC^3_M+YV];;E^57\X/8%3N/YD]_8],_AMO8/L#>&!
MH_@#U[2)4U/5_4OQ]RF+S\46U=W;$AF3-Y_+LM0:_=D]2TRS4\0$ONO=)_\`
MDE=357?V_.^/G%\@OE5NSYW=P?'GO;Y#_`WXS=VYZ/9^,V)@OCSUUG]NK4;Q
MV)MG8>$PVVZO?W;DDD9W!NAVKZK*4M)##!5/2EI*GW7NMD;W[KW7O?NO=!7W
MAU[N+MCJ#L?K/:7:.\ND]R;ZVCF=L8?MKKP8P[YZ^K<M2/2)N?:C9FDKL=#G
M,:)"]/(\9,4EG0JZJR^Z]U6SE]V?!?\`D:?'K)8AZN+!8'>.>%?UEU'M3'5W
M87RK^4/<]9AJ&GW+5Q1S9&OW[WWW+V5N1(YJ_+50BI:$SQFJGI:50R>Z]T!F
MS/BA\O/YHYR._?YI&.J.B_AKN+[2OZX_E<[*W)5T><S,>(RXK-N[M^:O;VT)
M\-G=ZY2H^VCR"[#Q=7#MZBJ!2-7++5TDL3^Z]T6[L[Y&9S_A.S-0_'W#])]R
M_)#X-=]Y3*T'P"H=L9K&Y_=G1WRBWEEYY*3X3;QW'O7<V,&/Z&W175*9?9V=
MF-=F<6DN4HY8<HM,DT7NO=6-?`WX,=D;&WSNGYT?/;<>T.V/Y@/:V(EQ]1E\
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M`#"NQ^D\$*WJCM>ERW96.PW0FP9-F9K/8G;5'VON"FVGNUI<MC(C#28.)*:J
MI:V*9HH/=>Z-5V7\._D[\;OFC\@/YK&/^0O<7RDQXVIM3:F!^$F(S5-U'L/:
M/Q]P>+CC[-:#&X_#[]Q_=_9VV?!4;CVS0K1;4J,AE3)32UY,J*WNO=&-_E4?
MS'<Y_,MZ$KNY-P_$_O'XH9'%Y#&T(P7;N)JX]O;XHLQ1SY+';LZDW;6X?;D^
M_-F24*1I+7?PZC$5:9(`KB+RO[KW5H/OW7NM3OX6_P`SS?\`T!/\W7P7\H[^
M9?VAL7L_^8?\G>VMD]G]/=$1YG']@87>6[$QM;F\]B=X;TP&8PN<Q&0VLU`L
M%%3ST+T$-,S/#4F:+W[KW1W:K^=[O^G;,M#_`"9?YQ%;!BH\=`DM-\8]L^6J
MS%2)*BNH?LI.RTK!0T-#'K6LA2HCED98BL;.A;W7NB)?S(OYGGR2^9GP2[LZ
MB^)W\O\`_GA_&ON#?F(Q<W5O;F!^)M/MEZJ3%9>BSQV]G,W@.W8]^[*VWOK&
MXN?'5U?C()*VC@G#!*A'--/[KW5=/R-WU_-I[KW1_*PRF)ZC_GT?'/:_4'Q=
MVGU+\W,[TAMFAR&\>T.P\%A<,9M[;'V<.Z(<!GMR[VW+15,.4SV^4QM93T,U
M/,]#,T3T\WNO=$P^4'2_\_KY;?*#;N]-U=:?S5OD9\6MF9C*U4'6>\<=L;^7
M_O+^[5/N3+[CHMF?:=7;SW!L_,;BQ&.GQFC=K4=97U]3&\$$*K31`>Z]T<.K
M[T_GY9'X5?!SXCS])_S9.I][=?5?=VP_G?WUUST9LSM#LKLSJO=F<T]5YGJG
ML_L+LW([SS78^S-KU%3!45<>2VK(\[QO3Y!###(ONO=#+V1NS^8OOOYI=5_(
M+870W\^#JWK;X]?`[K_H'JO<U1U3U'NW=V[OE#@]YYG&Y7M[Y%_&K.]VX[J_
MN78G8FRJTMN2*+)8_)+DEAK$>E6FI*I/=>Z5/Q(S'\PSXJ_,;Y<?+;Y8?%3^
M<Q\G-^=O9_,XOX\_Z*MJ]3T'3F(ZZS.VZ*@RV7W]\;,1\B=Z;"V+OO;V6Q6+
MAP]*E=DJ"6F@DJ`?('!]U[H'?ECW[_.W^3_\JSJ+XY4?QO\`YMVT?YANQ>W<
M?OO?OR"V5TSMKH#978FR*2JW[BH=FUV[^G^WMMYQ6HMO[LQDL@BV]%!D:[$B
M26GB'[R>Z]T!&3Z=_G*=6_#GNGXY]']A?SN-^]C_`"#Q>T<MN#;W=?Q#V-D$
MQ&]<PFUI]TX_!_,.I^8^\]T]:;7FPE#+25M1BZ-YYY?VYZ:EDDJ'A]U[K8R^
M+'SK[!^*G4O2OQAK_P"61_.[[(?;-#38.?MSN/9?4/=N[LQ6;KW%/E#F]]]I
M8OY!U]+/%25.9JGG%2U,,+C*2*GT>F*,^Z]U2?\`S%N@/D[\A?\`A3#M_"_&
MKY#;-ZNI\#C/@36=P=<UOR4Q/3N]>U^N=O[BSO9.Y\=M_J^BWA@=W]Z8S9&U
M]E5N7RM!1TU5-CH*BGE**L\4A]U[IY^"&S.R/CA_,A^=GS!ZXJ-];QZUVO\`
M)+^9#VOVU\<NHNBOB/W!\D._'_V:W>W3VT.J_CSF*S=$_P`IZ"DQ,&WX=T;I
MHZI]N8J,4$4="M6:N:7W[KW5^6+_`)T>3R;>+_AH_P#G-T50],:JG@K?AOMZ
M(3Q^..:-?N5[C>CIII(W)\<TD3J4*L`U@?=>ZQ;@_G>;7V=05.6WE_+._G!;
M8Q%*8A-DZSX-Y;(4B>999!J;`[YRTBA(8'=B5`15-R+'W[KW3;MG^>IL3/TY
MR%9_+9_G#;>PL<!JZG/Y#X";YR6)I*&2=A1ULS;;SV;R#0UE`!5!8Z=Y8X2`
MZ!V16]U[K)B_Y\_0N=Q<67P7PG_FM9VD_@,VXJXX;^7YW!D?X104\<,E0<G+
M3JU/3QP^4@U`=Z,^-B)BMB?=>ZKMVQ_.7^%NYOYF<ORAZS^,/\RK?6[<M\0X
M/C1VWC]J_"??65GZPIMM]NY;LC;-=O3"4^7DW;'D*_(U5;C2F/Q=;&SQQ^29
M5@;1[KW00;#W-\K_`.:'_.UWCW;_`"_.WOES\*_B)U3U-UH/DYN[LSIW=&P]
MK]P?(?IO(=C[?VGU;7=6;PI\(F]:6GAW534.X,7EIZ&LAQV-R)1J6H&+J/?N
MO=6B?&S^7K_--H?YDV<^7GS,_F03=C=%[:VC!0]:?'[X[1;YZ;ZFW3GZS'Y'
M#U-)V3T/G\IOC:='M_;U#DY:B"ICSN7S61R*TTTU7"M*$D]U[J^JMJ6HZ*KJ
MTI:FM:EI:BI6BHDCDK*MH(GE%+2)+)#$]34%=$89T4L1<@<^_=>ZURLY_.TW
M7NO*;$WIC_Y//\\RGR&SMWYN';FW\3\<?[L[1WHN=VED<#*W8>/A[`:DS&&Q
MPS,550K7024--7I'5Q5'EIBH]U[HA_S/^?'9'R_^</\`([VWO+X!?-OX<4>)
M_F*XC=&/W1\CMG;=VACMU-C-NKBIMNX0;>WK693[QTRLDU;%6I2QOC8I&C2N
M0RPK[KW5A?\`./Q5!7_S$OY!%0:/,UV;I_F1W73X^GQL1^WEQLW4&-KLO'4U
MR*DN/G:IQ5&4F66/PTZU$Q#>(%/=>ZJU_P"$B?2W=WQ0[%_F&?';Y!=6[@ZA
MW_F=J?%#O2/:&]:3,X[>M!@=VS]]X/'TV9Q^5:!J7PKB]=FIQ.S3W>65=&GW
M7NKJ_P#A2-5&D_DG_.V5<*,Z[;'Z^A2E,53**-I^ZNM81G0*5'>-]N:_OT=K
M1QO3!F(`)]^Z]U<YLEWDV9M&21F>1]L8!W=R69W;%4C,S,>2S,;D_P!??NO=
M*?W[KW7O?NO=>]^Z]U__T-_CW[KW1-.^\\V-^4GP6Q+C&FESF]N]ED-53T[U
MU/4T/1&Z6HZF@JIZV%J1&>I:FE\4,TDK54:716;7[KW1R_?NO=>]^Z]T0?YZ
M=/=E]P?[)C'UO@I\Y#UE\^/CKW#V*U-7XN@FPO6FQ/[X5.X<[?*55**N"BKJ
MRC2>"G\M5+!*XC1C>WNO='X]^Z]U[W[KW7O?NO=>]^Z]U7;_`"PMZ5>_?CEO
M?<%97TN28?+WYQX2EJZ*>EJ:27&[:^7'<6W\4\<M%!3TPJ)<=C8GJ4`+QU;2
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M6FA75+45,L<$$2DA0TDLK+&BZB!<D<GW[KW5)/>?P9@_F?\`6>(^2T&R^X?Y
M87SMV+N?M#!]"_(#"SX2+O7#;-Q.XLILW`2=P8/;.0H*#?/6?;.T<-2UM7M#
M+5DDM!25(AAJD_<>?W7NJQ?Y&/>?\S[X@_+_`+-_E+?S-AFNQ*0TF^>W?C]\
MH.U>UMP;CS?86-H:O;]!4;;ZHW1OEZVL[EV5E$J#DTH8JJ+.[3GFGAK:=8W6
M&C]U[K;W]^Z]TWY?+8O`8G)YW.9"CQ&%PN.K<ME\KD:B*CQ^,Q>-II:S(9"N
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MW7O?NO=`3F?C'T#N+Y`;9^4^X.JMI9SY![+V!4]7[/[3R]"^1W)M78U;F:G<
M%9A-NFKFFH,,:K*ULSO54\,=:R3/$9O$[(?=>Z))\Q_EUAO@)G-Z[IK=^;Z^
M1??/RMSNP=A_#3X'8>7;B9K+]CXC;%3@WQNPEIZ./+8#9>Y<I3RYC=6Y,Y4+
MA\2L)`DC<QQR^Z]TZ_&CX*[CS&Q^T]Y_S$=P8;Y3]W_*$[0S'<'6VYJ`9_XQ
M=.X?9]=D<[L'I+H3J;<55N#!83:W6F1S$DDF>J&J\]N#,(<C559*TL5/[KW6
ML[\LOYP7R1JOYJ6\_@EW=\EOCE@_AON?YY8CX1=O?%O/=7YG;?8NX?BEW)UO
MBJ//]C;E[D_AG@PNS\D-U38E:[%[@QN7ILE(E1-'!CF1S[KW6S'_`#&?ED?@
M-\8-C[+^/FS<?N+Y&]R[BV=\5/@[TM1PQ_P_,=K;@QW\'VHU?!(YCQW7G5^V
M\?)ELM53?Y-#24*0.WDJ(@WNO=)'JW8?7G\E_P#EK[ZW'N_/2]J;YV?0[X[M
M[IWY+02XW=ORD^6_<&=-=D:G[/$T>9R$^[.X>UL[C]NX2FA@K)XH)*&F1)/$
M`?=>Z,%U7W%V5\>/@5B_D/\`S%]Y;2PO8VP.G,OW'\D<OM;;L>!VWL8BER&\
MLAL3"XBDR&6?+U>P,750[?CFBF>7.5]'YXT5ZI8E]U[HYFVMPXS=NW-O[KPD
MLL^&W/A,5N'$33T\]'/-C,U009*@EFI*E(JFEEDI*E"T<BJZ$Z6`((]^Z]T\
MHB1HL<:+'&@"HB*$15'`554`*!_0>_=>ZY>_=>ZZ`"@!0`!P`!8#_6`X'OW7
MNN_?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=:8
M_P`@OC)_,;[9_G]_,SM[^7QW30=.2=-Q?RQF[XV[NK'X6;$]N=8;YP6>QVX9
ML779[#5U"8=C;3VOEI9\<#'49*-ZI*:J2K2GIY/=>Z*)_*B3XEUO_"A+Y/=2
M[T^%&Y]R?-G9GS>_F%=MP_+2O^2F8P>W^O.OJC<V\I=ET=#T%#5P[?WY7U>*
MW!+CI94EJ:FG7)I6M'+'$[4ONO=;^?OW7NO>_=>Z][]U[KWOW7NL8BB$C3".
M,3,BQM*$42-&C.Z1L]M11'D8@7L"Q/Y/OW7NN8`%[`"YN;"UR?J3_C[]U[KO
MW[KW7O?NO=:_78?\T/\`FFXK<N:P&T?Y!7R)WCC,)NF:@Q>XY/EWTOM2@SU)
MBJZI@AS</\.PN9;^&U\T$<D<,KO#-2R:I2`-#>Z]U6+\ZOE%\Z^^?FQ_)'PW
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ML_\`NI7+\Z;>_=>ZM3V+SLG9Q_KM7;W_`+J:3W[KW2J]^Z]U[W[KW7O?NO=?
M_]'?X]^Z]T13Y#X_`R_,G^7MEJ^LQ]!F\;N7Y+TF#>IGIHJS)Q97H?)IE,#0
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M_P`N;IGYD3[>[%7-[P^/_P`J^M<?54O2GS!Z,R0VCWGUF9_/)_!9\S3!*7L#
MKBMFJ917;8SJ5F*GCJ)FA6FJG6J3W7NJ8NBOYJ>Z_DC_`#!Z?^6+\O=S?'6D
MZUZAK-X;`WAWCA,349WI[^9%W;A(]LOUUUML*?,00[1Z!W]LS*_<YO<&V(,]
MN:LR&Y\%-AJ)TIXI$F]U[K:A]^Z]T4+YH_"OJ7YP]68WKSLJLW=M'<>R=V8[
MLSI;N/K3<%5M+M?HOM[;]'7TFV.S^N-R4A(I,[ADR4R/35453CJ^GE>&J@EC
M:P]U[K7K^'/SE_FF_#S^;5NG^6Q_,3?+_+G9_P`EMPINKXO_`""VIM7:O65-
M!M;%[;C?/;KVYA:B#;>V,KLS;F&Q$;[UVUCJVHR^U\N9*K'P9.FK68^Z]U<%
M_.>W?6X7^7SVQUWA\[D=L[A^3^Z^F_AS@=PXJO&,K<%4?*_MW9?1F6S<=:8Y
M/#'AMK[UKZN0`!GC@*!E+!A[KW5E6S-H[?Z_V?M/86TZ$8O:VR-M8+:.VL8L
MLLRX[;^V\72X;#4*S3O)-**3'44<89V9FTW))]^Z]U3!_,$^)_?_`,<JSY"?
MS(_Y6=/AL5\P=P]=A>_NC]TX7,[YZI^5>T]D[=^RQ6?I>N<7EL+D:3Y*]:87
M')+M.KQ-?CZ?/F.3%92"L^\CF@]U[H-/B5O?X!_$KX@4'\T+_9T*+M2G[[R-
M%NSY-_,[O/;QW%WG\BLI3X'<&&I/CQL/:5#58C,=.5.U>QHHDPG6^`Q-=_"5
MQD^/6@EJ)9,E'[KW1Q/AINSYZ_)CM3/_`"D[P:J^+_Q.K$S6*^-_PSRFQ\$.
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M+'3R(6B6)(T5/=>ZHW^,.^?YCG7VV=W_`#GV/U!_LWW\O?NCLS>7R/Z(^*V]
MLQ6YS^8QT9TQOVFRVY3O3JC<^_WQ6V-VG>^6G.?H.NLEF*K,8G;M;18O%9%J
MJ)L?)[KW0F["^1G4'\Z3YB_&*NZFWYMW)?$3X7T>:^1G;/3>]9Z+:'?F4^;.
M$SV2Z_ZKZ[[9^/F[J/\`OU@-J_'NAFKMSOE?"F*JMS56,2EJJMJ680^Z]T/G
M\SJGS7RK[\^&/\L[:^,I<WM/M'L'$?+/YE?=5&K&8OXA_&/>^ULY%LW/T=-E
M*:HDC[[[HGPFWJ:">FJ::MH:3*<`T[R1>Z]TH?YNNXWWG@/AU\&]J=EYOK/?
MWS<^775NU&JMGU6[</NT]%]$9&G[[[_J\!G-HQPSX2^U=DT6&DEDJJ6/_<Z@
M8F(2E?=>Z7?\S;O#NWJBN_E[]>=`=F4'6&[_`)'?S$NC>GMVY>OV_A=W397I
MJBV?VAV=VCMR+#9VDK6,>YL3U[#C)JZG:"JHA6B1)XF(;W[KW6'^:K\G^W.A
MMD_%KJ?X^=@[=ZJ[Q^:GS#Z@^*6SNS-P]?P]G+UIA-[Q;@S>^>Q</LS)Y'%[
M9SFX=K[=VXWV--E9)*":IJ$62)U)9/=>Z7?\L?O#M[N;H+?F#^0?8VT>V>]O
MCG\FOD=\6>TNP]F;0CV#C=WYCI+L[,X#;FYZ_9E+++B]MY_='7L^&R==2T.F
MACGK#X%6/2/?NO=%E_EO_P`P;O;Y/_RI^Q?F9VMB-C/VSL(_+J'%Q[9P^6Q6
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M4+[.W1D$0*1+$S!XV6158>Z]TT?S7?F+V1\-?CUT]V7U!7['AW+V1\O_`(K=
M&NN]L-E,[!E-H]O]G8S![OI=MTN/JJ*"#<S;5%5/!45D@IH*>&9@&J/`I]U[
MJ;_,#^7N^/B[W#_+6VAM?,[5Q&V?E3\WL!\>>S/[QXV"LK*O:>X>KNQ\YC*7
M;E;45])%A\O5[YPF)IEF"3/(*CQ(NMUO[KW25^5OS`[>Z@_FC?RK_B=M.OP%
M-U%\ML+\T:WMNCK,#!7[AKZWI#J7;V\.OUPF;EF$N"IH<SD9FJA'&QJ4TH2`
M/?NO=*7,?*3M.C_G&['^&5!N':M7TMG?Y=>^_D;N+:L6&CFWIA>R=N_(;9W7
MFWL]6Y]<B\U%MW/[;W!6T]/2M2Q)-44,SB20KIB]U[J7TS\K.U-\?S3/FW\1
M,\F'DZCZ(^/'Q/[,Z_DH<1'39>DW)VW4=HQ[UCS^9-1+-DUR`VY1&AB"1)3Q
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MY\6<Y\!UZTHMB5N`^2'\P/H?XJ]K?WQQ>:RF3HMA]MXW>LU17[)_A.9PT&/W
M/#7[9B2.IK/NJ:&.1B:>4VT^Z]UB^9OS#[`^,OR:^!FQ*'';%/1G>F<^5$OR
M&W+G/XID=^[8VIT3\:MV=U82JZVVOMZKJMQ[@JY*O;-3+D%I</EB8*:.F'@F
MJX&?W7NJOOY;O\Y#YK?+;YG=?_'SNSXB4G4O17:N!^8_9_2OR+RFW^Q-@/\`
M('J;J;L?:&*Z@SVPNN.PZ6@W+MF"CV=O"E.;FR8EDS#UM+54T6/1)H)?=>Z,
MQ_,-[>^;F_\`YY?%K^7I\/\`Y,[%^'T7;G0'=GR(W]WCENIMO]R]A"#JC<.U
M=KXC8^P-H;NS='M.H.>J=W&>O-;3>2.BI9*BFG62F:*3W7NA%_E<=S?+W+]J
M_/;XE?,GMS9G?F_?AGVOU'M7:G<VU^L#U+E.P=A]L]0XOLG`9K=^TJ3*Y/;U
M%N#P5?CE7&Z:42*Y5I49'/NO=7#^_=>ZZ-[&UB;<`FP)_%S8V'^P/OW7NM?#
MN+NS^?YN+<E1MG!_RO?@WN78N%WO35^"SVY/F)5Y&DR%5L;<%!G-G;Z2D.*V
M=E\=#6Y6AIZVBI9:%ZNFE@*U"+9"_NO=5V?-??O\U?=GRC_DU;L^>7QW^(OQ
MZV+MG^9QU+B]L9SJ;O+<G8VX\GNS>F`W=C$P&3V]D<=3T4&+;;N%KJAJJ"IF
M/GFI(_VKS6]U[JUC^:S6K3?.#^1?#"V)FR$_SWWV8L=DZZ2B:;'_`.RU]F4F
M5R5*8IZ9II\1%7(T,9<K+6201,DBR%#[KW1.OA'\4\M_+X_F]?$[XT97?.7[
MBDD_E!?(G;57W%58&OV2N\\GC?Y@V0[OA3);=BW!N/$5>0VQ1]QS4C,U3-4@
MU(J9'O4JB^Z]U9'_`#XY)X_Y._\`,-:F=(Y#\;MXQLTBR,I@EDH(ZI+10SL'
MEI6=5)`4.1J9%NP]U[JT/8O_`!Y&SO\`PU=O?^ZBC]^Z]TJO?NO=>]^Z]U[W
M[KW7_]+?X]^Z]U3]_,+I:Y/G=_)?S<-3F:?'T?RK[ZP^03&UM-0T=8^>^)G:
M@H:3*L\,E740&7'-*(8CIE6%U<`$21^Z]U<#[]U[KWOW7NB"?/K!-FZ+X>21
M4V2JZC!_/OXP9V"'%[<R6X*A5I<_F::NJ9ZC'5$`VUC:#%UL\]7DJA9::.FB
M>%T_?5E]U[H_?OW7NO>_=>Z][]U[KWOW7N@VZOV%UQU]A]PT'6%#CZ#"[@W_
M`+\WGG8\9E*C+4LV_-T;FR&2W[4F:HK:[[2LFW4]4:FE1DCIJC7&(X])4>Z]
MT)/OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>ZJH^:W:O=G?O8%1_+T^&&]J_KSL[-8+;VX?E;\F=NR8>KJ?B-T3O(;A@H
M8=MK6I6Q2?(CMY-OU%%MFAT1UF)QTLN=U0K!33CW7NAYS7\N7X:[B^'N`^".
M;Z0VM7?&G:N$QN+VWLGQU%/68',8F>?(T>_\-N:GGCW'C>SQN"LJ,K)N**J7
M+5&4JIZF6>22>8O[KW5;_5WR(^3'\J/LG:'QL_F*]JU/?GPM[$W)ANO?BE_,
M3W8:.CW_`+.W7FJVI_@O3/SJRE9GDH8*TT;QT>&[#%/#1966F'\4>.JJM--[
MKW5_<<D<L:2Q.DD4B+)')&P>.2-P&1T=25='4W!'!'OW7NB<_.#X/=/?/'I]
M.L.T)-Q;7W'M?.T._>F.YNOLK/MOMCH?MK`$U&T^T.L]T4;Q56+S^`R*1RM`
MY>CKHT\51&Z6T^Z]UJ!_S`?GO_-2^/OR=^$GPL^=>U_C_E>G]B_+WX(Y7'?*
M"NV1OO;<GRQK^LN^-M[KR7>>RJY*Q.K-JUN*PU;C:+?.TY9ZFMP^5A_B5#'%
MCZE/#[KW6^+[]U[KWOW7NM4WYJ?"/X]_RT?YDO6'\W#_`&73:^^/B#O3<&6I
MOF.M?B\YO6#X>=U;OS%%+MCYX]<=<TM+F*:@BJ\QXJ#=M3145148P3?Q&CBB
MJ)&D'NO=&"RG>GR__G.9Q=L?$/.]D?"W^5E%-F%WU\Y8:>GVW\A/F'B<74G%
MUVT?BEMS-TR[@ZGZPR%73U:S[ZK:9*ZLBC7[.*/144L_NO=6/[.W!\#_`.6%
M@OBY\(.N:7'=83=Q[TEV/T3TSLS&;J[![`WAF\O4U&6WAV3NN.BCW+O*HV_1
M5DS5>Y][9^7["CEGC^\K4:2)#[KW5B/OW7NO>_=>Z][]U[I@Q^U=KXG.[AW1
MB]MX'&[FW:N(3=6XJ##X^CSNYDV_2S46!3<&6IZ>.OS*X2CJ9(:05,D@IHI&
M6/2K$'W7NJ>?YC6T.U?F!W[U-\'9J'=/6_P=V[M&+Y1?S`>[\M$FW.NNR>KM
MM9_)46SOB70[NR]`N/J5WKG-NSYS>QIZN..AVOC8X*QO#DC&_NO='"^<OS+V
M7\,/ACO_`.3.#I\-OJJH=J8?%_'W9&#G:NI>Y^V.P128#HKKG:";=6IJ<M#O
M[=>6Q\$1QZR:,>\E0MHHF=?=>Z(-_P`,^=7_`"9Z!ZQ[L^8V$QG4_P#-`K>I
MZ'<';/S2^*^8R?QS[2P'<^2V328^IRU;N3JNKVA0;TQW7ZT=%2)3YJGK,=,N
M*#^%5D<'W7NM=_\`E-TW\U[H7MW`_P`Q?J?X(=\?+_J/O[H[&]7_`"L["[&^
M5W66[.U?DSO+:/8&Y*ZF^3'QMH^QLMMO=^W]@3(\8PN&KUGQV;Q3M-3RQB6"
ML3W7NK1MN?S8_B[V_P#S?-J[W^4V3[D^!&&^&/Q1S?7&$ZP^:'6\'4E##\A_
MEGN;:F=W1F,SV7B=P[OZWPM!3=2=<XFDQ`S63Q;9AJZHGQAG@AJ6/NO='RW7
M\@/B]\U?YIO\O';72?:G4??^.^/O2?R^^5=5NGK#MK:&],%MK-9FGZY^.VPV
M,6U<SDX,MELG3[XW5XHRQ-/'0RS:2%U+[KW4?^:N=I;K^;'\C#K?++/7Y;*?
M/W>O:.&I,94QPUK4W2OQN[0S]3D!.\4D38O$;ERF(EKH]2O+`&C4:C=?=>Z5
MG\FIP]1_-C0-(3%_.@^;<;!RNA"V+Z?FTP!0"L964$WY\A8_0CW[KW1?OY1&
M3PNT?Y&&\Z?>!P_6F.ZWG_F([4WAE=[U6.I,!@EV9WY\@,/D<UNFI^PJ:."C
MH*2C7^(EX*A=<,I".A5/?NO=`QTS#A-T?\)(ZFGQ^2ARF/7^4_V_'4U&SH:;
M)M'EMN]8;W.9Q;4T+TL4F3Q6=QD]'E49@Z5,-0'+.&)]U[H0>_\`,;VVK_PE
M:ILELR:.@W'2_P`H_I2EJ97B\\D.#R70>PL9NO[;T2JE6-M5M7XY"IT-R-)`
M9?=>Z$3_`(4&9K;\7\A[Y&5>>S5%M:7+;)^-#[;;,3QTHFW:O=_3&:V_B9(L
MC#%-4$UE`&J8C$LJTL4SLJ!'*^Z]T[_SPL-A^P?Y?7QLWKA<_B=VX7:7S>_E
MR=@X?=6WJR"NP&X,?F/D'UYLFDS^(K<5438VMQ.6I-]B:GD1Y:=XY59"?0P]
MU[K+_.KKA@>ZOY)>Y:7:E7O/,4W\W'I;;M-AX**IR,46*W?UGVQB<]G6I$K*
M>D%9M.D5,O!/(CM3?8/(&1%E#^Z]TR_S&M^[0V__`#KOY!."R^[,'MS+U.8_
MF&:8\E$KSY"/=/QXVQM7;F$CFJ(12T4VZ-S2)24;>8335:"*-&+>_=>Z%[>M
M-%1?\*"N@:]9#!49[^4_\A\;**6&*!JZGP'REZ-K8J?+U!CGFR$%++F6DI8_
MV!`YD;6VLHWNO=,?QPVQ30_S[OYF6YX\MG/N'^%GP*IYL/)44[8*1\OF.\*=
MJH4YIS5+/CH=F0_;:9516KJPLK%XS'[KW4S^4WNC9V0^2_\`.KVYM[<&$RF3
MQW\SG<&9R5%C\YB\A74RU_QN^/6%K7J:"FGDR-)#2[KVYDZ%GE41"KHYX%/E
M@F5?=>ZT^=B?+CY(=2;-^4O7FW?Y;7S2^9G0G_#E'SD7<.<V9N#*TGQMW-FN
MQ\[O39=-U/F=F[.^.N]JKL##1[BR&,S61Q^>S%=3G.4%"U&:*8*#[KW5V'0$
MN)PG_"-K<XIJ[)8.`?!/Y-4-5+ORGEH:EL_E>QNTZ')XJB@K<G':CR^X:V2B
MP++):6*>E98"S?;GW7NA,_F:TM%V!_PF5^->Y-G93&[GP6U^MOY8&X:C,455
MC,K&]!B=^]!;3RDL.0BJI(X<C09+(F&I^W:2=)$E@9>9+>Z]T*7_``IHH\_V
M'U9_+P^.%/O&+IC:/?\`_,)ZMV_N+Y+7K:'(_'O+X#:V[LAM3?N%W+%G-MT&
MV,A025=95RU,U;32G'T%2L,T)USQ^Z]U29O/XA?-+"_([^1Q_+A_F(]N;(W9
MU1M7Y/=P;X^-WS_Z4^1&=J.V^S]GU&Q\=VKB>M)Y=VSQ[HV]D*[>%!CL%BLX
M0[U5)54=%BG>2F\U3[KW6TI\E*B&G_G7?RMT>L6&2O\`BE_,DI(Z734ZJQXJ
MGXFUHC+11/!I2*FDD_=90#'QZBH/NO=`?\CL'5M_PHP_EMYT3M]H?@=\Q:;P
M2UZTD*OC,[MY)Y*2G?1_%*N9MRP>2!"[+%&)BH6$M[]U[I2?#GLSICK'^<K_
M`#9N@<IO7;6W>V.[L[\2>U^NMC93)/3;BW_C\+\7Z27L*IVO3U0BI<H=L5*M
M65=+2ZZBGIZDU$@,9+)[KW5ZWOW7NO>_=>ZUJ^Y:?_A3+C=Q221]D?R=\1UG
MGNT:7#[7CS6T/DMGZZAHLUNRDQW7=!F:4;7RIJ\E'/)2SO41K$E-7(9)*B.!
M0Z>Z]T2CYE87^<_@/DG_`"ALI_,4W;_+ZWQT<W\W+X_4FW*#XV[=[-PV\<3V
M!D*?>F-V1D\E4]D_91O@8MJ/F*B"*CEDJX<L:=*@U480>_=>ZLX_G)2XRB^6
MG\BK(5DK4]6O\S;"XNDFCEI?+X\UU1O2C>F%++!)4RPUF0^TCDD1E2)3ZAJ>
M-D]U[HEW\OSN[L3N?Y9_R@^Y>W]YU79W979G1W\[_J;.[RKX:6FS"X[J/YF]
M;Q;.P^2@IJ/%1S4^T=I;6I\2M1'3LDCQ@M/.SB1O=>ZM>_GMSBF_D]?S#Y&`
M(;XS[Y@L6*\U24E*INJ2$E6F!`M8G@E0;CW7NK/-B_\`'D;._P##5V]_[J*/
MW[KW2J]^Z]U[W[KW7O?NO=?_T]_CW[KW5?GRPZLJ^P?E9_+6W(V2VI3X;JOO
MKN;>E7B\QB:VOW)D\O+\7.W,#@YMKUD&3I:/&18Y<K5-6M/3SZO)`4:,J4F]
MU[JP/W[KW7O?NO=%`^7W?^\.@:;XU/L[#8#-3]S_`"_Z'Z`W"N>2OD.,V?V7
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M,^Z]UW\;/C-U[\7=F[BVKL:OWCNC*[XW[NGM#LGLCLO<3[P[.[,[`W=51R9'
M<^^-U24M"<I54.*I*/$XZ"*"GH\9A<;1T-+#%3TT:#W7NC#>_=>Z0W9O6>P.
MYNOMX]5=I[3PN^NN]_[>R>U=X[1W#1I78?/8',4LE'7T%9`]F`DAE.B1&26&
M0*\;*ZJP]U[JDS8D^Z?Y(F5VMUGV?V/V)W'_`"P.S.PL9M#K/N?M'/YG>787
MP$WGO.K.,V;U3VGN6ICR55N+XG9W(QP8_";JKI*)]E5\\%%DC4TE6E;3>Z]U
M?3')'+&DL3I)%(BR1R1L'CDC<!D='4E71U-P1P1[]U[HB'\Q;XQ?&7YP_'+<
M/PR^2F[]N;2A[^9\7U76U.;VOC.PL?V=M>/^\.W]V=1T6XI14YC>6SY:<54D
M%%'))+CVG@FM3SRW]U[H!?Y<_P`ONSLOO?L+^75\R:2GP_SD^)NR=JYC);MH
MWHH=I_+/X_Y&LJMK[#^577-%%6U55C3N&?%QTV[<.YD&`W%,8!*RRK%![KW5
MMGOW7NF+=&U]N;VVUN#9N\,%B=T;3W7A<GMS<VV\]04V5PF?P&:HIL=E\-E\
M961S4F0QF3H*F2&>&5&CEC<JP()]^Z]UJ_Y3>GRT_D,3;<^(W6/7.U?D)\)?
MDIW?#L/X+]T=G]@S]>[?^$/:7>6[\A-%T;\E,E]EGGSO1>`S65DRVU:_')C:
MZM1:K$/(M1+32Q>Z]U93UCTMT9_*EZH^0?SC^97R(RO</>>\L+CL_P#)7Y9]
MG4=#CLWGH,,9CM3I;HW85%/6)L'K6GSV1:DVGL3#RU4]5D*J)'DK*MXW7W7N
MAW^#79WS+[ZIM^=]?(_K[:/0G3G9,6V:SXO_`!UGQN4J>^]F;"@&9J9=\_(K
M<M17187%=@=D4.0H*@[1H*%EVM#3K3U%9/6/4*GNO='MQ>6Q6<H*;*X3)X_,
M8NL5WI,EBZRFR%!5)'(\+M35E))-3SJDL;*2K$!E(^H/OW7NG#W[KW7O?NO=
M0LGC,;FL;D,/F,?0Y;$9:AJ\9E<5DZ2"OQN3QM?!)2UV/R%#51RTM90UE+*T
M<L4BM')&Q5@02/?NO=$![N^%%9WS\P?A]VQO+*[43XT_#'![M[`ZXZ6QU!DJ
M2MR/RCR2X[:G7O8.7AII*;;:;4Z>Z\7(?P"E2-IH<QD3-9$@C#>Z]T7S^9UW
M#W/T7\:JSHC:W9DF]?D/_,'^16,^(GQ;RL>T<9M2HZAQ/>=`N-W#F\C48B4X
M[<;]&=<XK<FY(LG4MC)<C4QTU*=#A9&]U[JPWI;:72?QE^/.U>K>O<K@L#TY
M\8^O*'KLS'*PU%)LW;O5.V::EKTW'6>>=Z2NQ>(H!4UIG82C49&_4"?=>ZKE
M_E"8C,?)3X<]F?)CY$8^F[$I_G_\C>Z_DIB-C]CXM-UXK;'1.7W)#L+X_=<K
MC]TT53!6;4PO4W7F)K\?"R24RKDF>+TO[]U[HH777\J?X`=]_P`UO^8#N/=7
MQ#Z,Q6U.B^MOA_L384'6>&RO5LN,[7WKMWL_M?M#?TD76.9VQB*/?63PFZ-L
MTKUT<<.2^UI(BP"R&6I]U[H'MR?R[OBG\6?Y]7\JF+JNJ[QKLAF.JOG9V3%L
M[LWNWL?MC8>R:G;6Q\-CMLUG7=/V!N?-YG:4K'>N1IZFAAJ)<;/34-$Q@6>%
MII/=>Z<O@7_+XJ?DIVS_`#6.TH?FU_,`^-YE_FX_+G`?W(^+7R$Q'6'6N27;
M<.RX(MP9':N1Z_W9*^[JTYN>*NJ5F2*KIX*$LADI(FC]U[HE'Q?_`))^&^3'
M\N;Y(;,V_P#.WYT[-I>J?F!\TMGX7:/:7;=/V;\1^S*OX_?)KL&FHMZ[]Z*Q
M^WL!+N["=BTN!`W-IRS/59MJ^L5)=2P'W7NE%\;?Y:$'97\F3Y"_-R/Y=_*'
MXV57RY^/_P`AOEYN3XQ?#7>AZA^%W7F.W/M'=>Z9>JME?'[-87<-2-M5>WL;
M_#<L$RT'W\<TD5.\=.D#'W7NN'<G\J;%4?\`PGUR?=&"^>/\S^OP&*_EI[1[
MOHOCWO?Y)X<]%+B\1TE@NS5ZXR?4AV"E)0;&Q<5-]K3XJ+(,U)!!%''+*4`D
M]U[I-?S+OY8-7UQ_+6Z;_F3]2?*GY.?+*H^)_0G7G:.T/CA\_LALKY:_'O,=
M5[_ZZV[L3+5*]6T.R-N;8Q>Z-A[&W@V:&;DBR:,<2)9WO&E7'[KW2:^67\C#
M`?$G^51T134W\QG^8'NHT7=GPHIEZ^V_V^=N_&;^^?<_R1ZOVKD-V;"Z=K=N
M/7==+M&CWU/E=NR/D)IJ'-4-/5RQ/-))'[]U[H9/YG7\GC"]+YW^7:K_`,Q_
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MDZ_V%/L8M@\8\")15U=D07=)`H]U[H,?Y5'\D/;FX?ES\G:O=GR3[#Z_B_EP
M]W9;XF[,W)\08!\9NV_DE1U\^S?D9+O[Y;=Q[4R>3W/VKF<GB]^TN!RE`J4A
MD_AZE:P1111>_=>ZHIZ3[)Q/3U=_,/H=J=3_`,Y3Y*Q=/_*_Y%P?(3:_Q2^7
M^YNAOBSLKKW<^^MWX_!=P[ZQ_4NP-S[WF["?$[#R"9&7+Q#;E1%3(]3*J(E.
M?=>ZMDS/\K7HG?7\A7KOY]_'KO#YC56UNA-C;B^:W7OQ!^97<N'^1GQ;EHNL
M\[E<UO[J#=73>,VIUYL?)[?W`=J9$T]=1TN/J9Y*QGJ(C]Q)$GNO=1^^/Y*.
MQ^B?Y#N:^0>ZODC\D,CN3?\`G?C'\J\MT'UEV[E^N/A[LN;O'N+J<Y?8FP^B
MYZC+[?:+9^W.R:M<5EJB:7+29.BHYHBJHM*_NO=#[_.R^#/0'1N[O@!\?JSY
MZ?S9LYV/\K/FIU7B>MMF[C[ZWU\B-D;.Q]#D<7L+L/M+;U#O/"RFF[(P%#V!
M0P8N/^,5%6OW\[0T9IC4GW[KW1>^_?Y/_3O8W\QW;_Q=Z8_F<;+^1_>>XMM[
M7ZE^2&?^;O:%+O/YI?$.LV+08/MW:?8'PICQNY^LYMS[\RFT=N5>,CP^+H<O
M3[+@F^XKS$LJ34ONO=&S[X_E$=I;:_FA_P`M[IS(?S;?YG&Y]V]@=!?,_<%!
MWAF^ZL34=D]<2]94_2@S."ZTR`P"C;NV.RL1NYH<U3U39*6HEQ]([2N(]'OW
M7NB8_P`SO8.Y?Y,W\SO^7W\EZOOGYY_S.>R<-T5\K-R;-V5WUV-D.P,UM3>.
M)VC+M'KZHI9]FX'!5N-Z>K=S[Y6KW10TL4M5-38V1V:42I![]U[JS/\`EF_'
M3O7Y*?S3?G/\S?E3%T7B/F'U-T/\).I-N]A]%1]E4.R=J4W>_P`<:C>O8N^=
MD[/['?)2U.\_[EY+$X&GDR2)2T]13UY%+&'(D]U[K;CIXO!!#!Y9IO##'%YJ
MA_)/+XT5/+-)8>2:2UV:PN23[]U[KFZET=5=HF9659$"%XR00'02))&60FXU
M*RW^H(X]^Z]U2=V7\$?YNNZJK<N9V1_.]S77^1RF>W5-@-NTWP$^-F5V3MS:
M60JF?:>!BAK<@VZJ[.8&D1$JLM/DY#6,69*>G_/NO=5$?S!_AU_,*Z'[D_E(
M[Z^2'\S?L3YT;`;^;M\/-K8OJ#)?'3JSH?%8K<&6KL[7XO?^2W3UX:^ER66P
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MPI<7'BJ?[+=&?V[N?"LL:0T[5M0^!S%*:BJ9`U14F1]4@(E?W7NK*/?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW22W5OG:FS7P%)N+<N
MV\'EMY9K^ZVQL3G]P8O`U6\]WRX[(96DVKMQ<E40OE<Y5T&+J)EIZ=99O!!)
M)H*1L1[KW1-/A9\8MZ==5?8'R4^2DF(W#\T?D/+&_;&;P6;SN;V=UKUY@L[G
MJ_JSXZ]2QY>NFH\7UQU;B<TRRU5+2T4^X\W/5Y6M0S3QQP>Z]T?CW[KW7O?N
MO=>]^Z]TDM_;#V9VGL?=_6G8NV</O/8&_P#;6;V;O3:.X*.+(X/<VUMR8ZHQ
M&=P66H9@8JK'Y3&U<D,J']2.??NO=4Q;3W'WA_*_7)_#H9#!]@=(;]VIG]K?
MRJ.RNULI)28S:O>J;?W3DM@?`+Y![P&3H*LX:6LH:&#K;<$[PU&6PE/4X6KK
M3E:7'FN]U[K4!^6'R8P'3N?^-7<'\T3XK_.2#^8%OCY']*=K=U?*+OG'=?X"
MEZ&ZXZ+[1QF_ZGJ+^6STQC.T\1M%MC9VIVJF+?-92*DIXSE*ZKJYJJ66!(_=
M>ZV4J7>N\?YU_6>^.V>BMC1?`G^:M_+=[@Q^,ZDWM-VWL_NWKR"+?VU\!OR#
MK_<W<G2U/E=I]J]%]Y]:Y&.GW)AX*>J_A&25#HF$9^Z]U[HZO\IO^9UW-\U]
MT_*'XT_+CXS5?Q=^9OPOW%L[!=U[.P]=69SK3<6+W]1YBHVAO/8F7KY*FNIL
M;N$;>JZBGII*G(T\^,DI*NER%9'.X@]U[JZ'W[KW07]U]+]7_(KJ;L#HWNG9
MV*W_`-5]H;9R.T=[[1S*S?99C"9./1*BU%++3U^.R%),J5%'6TLL-90U<451
M3RQ3Q1R+[KW6M31;0J/@/\\^ANK/YHO:G9'R&^$VULYC!_*<^3O=M5BLOL?H
MWO;*T.;Q^6V/\O=X4T>(;-=[8?;LT&*ZXWENF.MH!CA53T\E%DY:MZ?W7NCK
M?(OY"=J?S%>^=P?R_?@MV)6[.Z+V+3XL_/\`^<_6N<2679>%W'C*F8_$_P".
M>Z:7$U^'JOD-O?`9&EK<IN"@KG&Q\5*'8?Q&6&#W[KW1J>QN^?CW_+=Q/PN^
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MF4VCEXZVOQ6Z<=15,U)5.^F`>Z]U:9MW)].=V8S8W:6TLAUIVYAL+D,CGNM>
MQ=N5>U]^XO$Y6HQN6VEELSL?=V,DRM)0Y"?#Y.OQE344%0LC4U1/3NVAY$/N
MO=`[\T_CON'Y._$WY"_&_8.]Z/J+-]^["SG764W[%A#DY,9@M[)38'?E2M#2
M56-EGS.8V--74-/4F753SS1S$.(O&WNO="-MKI#;FR=A]$];;%S.Y=C[/^/]
M/L_%;5P>U<A#BL;F]J[)V#D^N\/LK=E$M+)3Y;:2XC(1U!I`(PM?0TDZ,K0+
M[]U[HE7P`QO86&F^3G8V]/CMF>LMV_(WYY_(7<&8AJ!0TN6H^N>N:?%=/]9=
M@[SR-?+2_P`>AWIM?JZAJL4N*-?3?9Y2'Q2&*.1A[KW0&=WU&WD_GS_"NLW\
M=NXK#;8_ER?,C,=7YS<V0I,2)^R\KW'\?<1NNBVM/D:NGAR6X:#K".KEJ(*=
M7GAQ4]1-(/$-2^Z]U)_DMY%,U0?S2<Y0U\>6VYF/YR/S>K=IY>CJDK\+E,*(
M^K:6>KP&0@DEH:W&#/TU=&TE.[1?=QS*3K5P/=>Z1'\BRMV_O/X/_)W!T6$C
MQ&T(?G]_,6VYC:/6]'23;9S/?^]LU3K`JU-168^DI*#<?V>F2HEFC^V)\C#2
M??NO=`=\6:S=S_R!=B]78KKB4=(YS^3'W3GZSO#;_9M.E1M[L9.M,KC8>MJ+
M:L_DW:4S&%SM=E*#.4];-2TG\+>DECC9J<R>Z]TKWS.<J?\`A-#NG"UVU<AC
M\/C/Y#&V\GBMX2UV(EQ6Y*[-?!C.)FL'1XR"M?/8W(;2;%4[5+5=-%2SQ9&`
MTTLS)4I![KW1>?YC7?-/N#^1C\@/C_N;JS=FWL5@OY0_Q([PQ'<#;3J'Z6W%
MF-]5N'VI1]8X&IP245/A-_;7W'LVAJ4H>:>FHLK2U+H*:*1&]U[H\'\WW,8R
M+^5MM3(U4DJXG%]W?RQLQ_'\CX132T3?,SXUU$M<E0T]1*LU/1QL\[-^D2<,
MUR??NO=9_P";A6Y/3_*H;L;#;9IB_P#.Z^*U)0C&96OR5#!B(/\`3V.M,U)6
MUU+@&H]Q9&AI\6^0I2D]-3UM1/30R52".63W7NEU\],G+A_YD_\`))J:/%0Y
M"NR7>WS'VV]1/,(!C\1EOA;V5596:%O&Q>I!Q,,B)J`D$16Q)#)[KW3;V!*(
MOY_/QG5Z19_NOY5ORFAAJ6DE0T3P_)WXWSRRQJEHIC*@6-E>^D."+'Z^Z]TQ
M]%8_,4G\_+^8!5U=!D8L5E?@+\)JO&UT@*XZHBI^P>]L>!%JK$\KFNI*Q%*T
M\H5H909(B0LWNO=2_P"6-D5D^9O\[G;1BFH,EB_G]U_N*H>EH8H,=48S<7Q+
MZ'CQR13/&T4U?51[?E>MLHD!F635JE##W7NM03XM[0_F?]-;N_F[]T_"3K_X
M7_([;O1_\P7O'L+OOXS]J8OL'=/R,V_N3KC<_;N,VGNO`;*P$NRX=P83,;*W
M/N1,31PY;(#*VKXEHY*A!"?=>ZNR^`(S6?\`^$@O9U'/NG:.Z:R+X(?S`112
MXBJ3*T>`QL<_?>7I=H9R.MI\G'19[;%%-]H],(@*41Q*FC2L@]U[HV?S]AQ=
M5_PFFV\N5E\-*OQ&_E_U5*S$^K+TF\?C76;?A)-1"2T^=@IH^6:Y;]$GZ&]U
M[IO_`.%+^Q,CW!\=_AATED]LY"'KOM[^8S\3.NMT]K;*SV(I>W^O*C>F[\AM
MRF7JC$9C'/##NS)T>0FEI\I]Q+'224HBEHY4F,T'NO=5-UO\FOHW^6W\MMB9
M7.[;[.[,[Z^4G\P*FV_\!?D]7]_8W=7R(ZWQ6T>@U[HR&]=\[.WIM:GZ/["W
M=NCO/:%3M^2HS>*1Z/&9YJ]ZR*HBI@_NO=';^.?RT^=_R=_G'_R\L?\`/;X`
M9+X,[OV#T3_,%K^O*M.PL/V'M[MC![LQG2=/7T%#)04?GP64V#3[>I?OV;(5
M*UKY""5:2E1U/OW7NCR_+"JQ&._X4$_RGIZ^;`TE5D_B=\[\31S9*O\`M<A4
MU9H=@RT-%BH:HK2U.0=9*@11TY-3)"]27&B-+^Z]T8WX=X?'8S^9[_.&K,?E
M,;D9-Q9?X&9O*T]!7RUM1A<K#\:\AMQ\5F(Y%"XW)-C]O4U6*9"RBEJX9;AI
M64>Z]U;+[]U[KWOW7NJ&.Y_^$_WQP[?[#[,[8SWRT_F=4^;[`SF[=V/M/:'S
M1S^(VMMS,[JS]1N.JI]AXC*8*>#`X^BEJ&HZ"BGJI<?2T>F/QW1'7W7NJW/G
M=_*C^-/P?[D_E6=O]=]X?+#?>\<A_-S^%^S:#KSOCY+;N[GVW6[?R^8S$F1_
MNULO=?F9,MMHXB*LCKED,U+2SU2,[1R11K[KW5H/\ZV8KNG^3I344BC.S_SH
M?A])CJ=,+D:^MJ,=3[?[;.YVI<K0>/\`@L-'MZ2>>J\DJ1U-)'(CB2,2(?=>
MZ(_U%\3.T_AIW_\`\)_^D>U,WLW-=E8+Y0_S@MX[EK-KME:G'38ONKKKY!]O
MT@PV0R$!#008+<]"M9%.JU!JV18G*Q2NWNO=6_\`\Y'>M5U]_*E_F&;IH:R*
M@K*;XC]W8NEJ9X6GC%1N;8^6VQ%!XUEA)DJWS`A0ZK*[AB"!8^Z]T:_XJYQM
MS_%[XW[E<UC/N'H3I[..V0I(:#(%LMUYMVO8UU#3L\%%6$U'[L2,4C>Z@D`>
M_=>Z'OW[KW7O?NO=>]^Z]U__U=_CW[KW1&OE=!V!7]Z_R^,?LB>IBQ2?*'=F
M;[)2E3%.\FP<+\8>^VD^X&2JJ*9:#^]U9B%D:E=YPSI:*07`]U[H\OOW7NO>
M_=>Z*Y\GNZ<_TU/\<(<'M3;^YX.WOE'U?TMN"?/U-7"=J8#>..W97S[KPE/2
MT\JU^X*/(;?IJ:GCFDIX8Q5M,7<Q+#+[KW1H_?NO=>]^Z]U[W[KW7O?NO=!;
MU?U'L7J8]C/L:EJ*0=G]I;K[<W>LU<];'/OK=Z8R'<552(WIH*>H;$1,8%X6
M4NQ]3,??NO="E[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NH.2
MR>.PU#49/+5U+C<=2()*JMK9XZ:EIT9UC5I9I66-`TCA1<\L0!R??NO=5Q]+
M?'CMWM/Y<;M^;'RJQ57L[)=<TF].D/A]T#C^P,=O79?7W555GT?<7R%W,F#@
M7!3=Z=^18REU)%+4#;FV:>EQWD>J>K<>Z]U95[]U[KWOW7NO>_=>Z][]U[KW
MOW7N@2^1OQ[ZP^5/2G8'0?<.$;.;"[$PIQ>22FJ9L?F<+D:6H@R>W=V[6S-*
MT=?M[>6S=PT5+E,/DJ9TJ<?DJ2&>)E>,'W[KW5!W:'QNJ>[=N[F^"?S5P>VN
MYOGS@^E\=5[!^0]?L'KGK./^:/\`$[I7LR3M;&?'RB[-R4>ZZCI_.U6^*;#X
M[M7&4`3*8N"M.?QP>BR8FI?=>Z(5TONG9/\`*-^:N'VKV3\B/A3\0MS[GZJQ
MW?OS-Z-ZSBW/MKXL_'SXX85L3C-C]']"=$X'>V(W'\DOF_W!E<145.>[4SN/
MR>:P^U\3'+#C!19"DI:OW7NK8YLETA_,3&'_`)I7\FKOWK;-_*OJVDKNOMUK
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M>ZLF_EI=*[8W1MR7^9;W#O\`V/W3\L?E)LB>NW5VELGM"I[(Z8Z5Z6J,Y/N3
M:/QI^/-9-]E@-I]8]<8^&E&=FAIDKL[NJ&OR.0GE:2*.#W7ND?\`&++[L_F-
M?+:A^?-#O3=N!^$?QLG[)ZJ^$NTMN;BR&-VS\H]XY2*MV+W'\N-ZT%"<=_'^
MOJ2HIZS:^P,=7K6TD\-'4[@B\?W=+?W7N@X^7_S)V_WMW;G>B]K_`,L_M_\`
MF)?''X==K;<S/R=[4Z\W3LZCI.G_`)%['HL9OG:6T^O.D]W;BVIE?E%O'KN@
MR])DLUC\5-4)BYZFGABIZRN!@3W7NA<W;M7XZ?SLMM_$SLS9/9/7';GPAZ9[
MSW/V;W1TSN_JNLKMV[\[SZXVK5[<ZZZN["PN_P"&D?KS&=>97>U=DMT[>RN#
M;(91UQ\&N*CDG%1[KW5G7:_2?4W>75&Z>C.VM@;:WWU#O7`+M;='7N;H$?;6
M6V_&]-)!BI:&G-.(*:EEHX7A\)C:!XD:,J54CW7NJ@_F'\0_EE\-_C%USA_Y
M%NT.F>FJ/IGM2I[AW]\5:/9V"$/RFCR4N$QN3V)_??>6<I*+9R5F+AGFKZMZ
MA,A7?;TD4%;1"F`F]U[JT[XK[\[P[/\`CQU-OWY)]-TWQ][VW+M.FKNS^G*+
M=F/WO1[%W0E14TM5CJ3<V*,E!D*:LAIXZN-$DG^U2H$#33M$TS^Z]T8#W[KW
M7O?NO=%W^0_Q'^+ORVPV`V]\G_CYT]W]AMJ5]7D]K4/;77^VM\Q[:R&0BIX,
MC6;?DS^.K9L+/D8*2)*AJ9HON$B19-050/=>Z7/3G2G4/QYZ]P?4W1/6>Q^H
M>LML_?'`;#Z[VUBMI;5Q+Y.NJ,IDI:+"X:FI*&&?(9*KEGGD":YII&=R6)/O
MW7NA#H\=C\=#+3X^@HZ"":IJJR:"CI8*6&6KKIY*FMJI8X$1)*FLJ96DE<@M
M([%F)))]^Z]UCAQ.*I\8N$I\9CX,,E&<>F(AHJ:+&+0-$86H5H$C6E6C:%BA
MB":"IM:WOW7NH>7VQMK<&V\GLS/;>P>;VAFL)6;:S&U<OB:#);;RVW,A0R8R
MOP&2P=93S8RNPM;C96IYJ66)H)(&,;*5)'OW7NH.Y-B;(WEM#(]?;OV=M7=6
MPLQBEP66V1N3;V)SFT<IA%2.-</D-MY.DJL-6XM8XE44\D+1`*!IX'OW7NIN
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M)_\`Y_78_9G;?4G:E+G?FE\,/CKAZ+<725'A*G!U78.7[Y[*VQO?=?9.RJ[=
MFS,;DJG(839^W9&S"IDLG#_#:@0P,];*S>Z]U;)_*%V;L+']5?S!>E\1M+"4
MW5NSOYGWSKZZQ_7E1CC6;5HMIYC=>(W!D=K+@LM]WCVVU6ONZI(HD3['[:H\
M:QA"5]^Z]U;IDMH;3S&VFV9E]K[=RNSWH:3&-M3)83&UVVFQM`8#0X]L%54T
MN+-#1&EB\,1B\<?C72!I%O=>ZS9W;&VMT)BX]R[>P>XH\'F\9N;"QYW$T&73
M#[DPLQJ,-N#%KD*>H7'YO$U!,E+5Q:)X']2.IY]^Z]U@S6SMH[DR>V<WN+:V
MW,]F=E92HS>S<OFL'C,ID]I9JKQM7AZK+[9KZZEGJL#DZG$5\]+)44KQ2O33
M21EBCLI]U[KCDME[/S.Y=L[SS&U-MY7>&RH<]3;-W7DL'C*[<FTZ?=-/1T>Y
MX-M9RII9<G@H=Q4F/IXJY*66):N."-90X10/=>Z+;\M?@C\2OG1M[:6V_E3T
MMM_M:DV#GSN;8V6FRNZ=G[RV9F9(?MZJHVKV!U_GMJ;[V_!DHE05E-29&*FK
M?#$9XY##$4]U[JHWLC^5UL3^5'U]\ROF[_*[WUO7X^;V3XZUF8W/T-O8[^^2
MGQRWG6]79*GWWDM[Y'K_`"^0SG=5?VE7;1Q.0Q./JZ#<9@I6R$CFD=9)@WNO
M='E_DS_+'OGYN_RZ.@?DI\F=LTVT^Z>P4W\^[<9CMA;DZYPDU+B.QMUXC:65
MP&W]SU%;72XC+;,H\?.E9%/-2U<CO)$VDV'NO=6B>_=>ZUV>[?Y-_P#)[["[
M(WAV/4=M9;KKM_=G<H[*[&W%C_G1W%0Y#+RS[QDS_8VPI<(O?&*BVOA=UO--
M2LM`*2HQ$J0-3:%IQ"_NO=5K_P`QO^7?_)]^)63_`)=O;7Q/Q.Q:+Y(4W\S7
MX1;;VG!0?*?L_LK=._-O5G;^`.\,7/B=T=H;]A--2X^BIZF?()2T_P!D8T7S
M#RK!-[KW5NW\[K*U5'NO^35CX*>O\64_G5?#03Y"GI\?)1THI<;V>XI*VKF#
M92A?)12NL9I=*2A'BF;0X23W7NB.=>?,#LWYE;]_DC?*;M.HVAM;=N._F>_S
M"_CGDL5L3'9#'82IPN/Z>^4_76SX3@LIE=TY^JKZS;6QJ**NKXZB.BAJ:MI)
M4A62+1[KW5QW\Y?&5&7_`)3O\Q:AI8J*:<_#KONJ1,@8Q3_[CNO<WD7D'E!0
MU,24I>`$&\ZH`"??NO=&3^%.:R.Y/AM\2MPY>I-;EL]\9>ALUE*PP4U,:O(Y
M3JS:M=6U)IJ.*"CIS/4SLVB)$C2]E4*`/?NO=&:]^Z]U[W[KW7O?NO=?_];?
MX]^Z]U4A_.%^8VS/Y<W1O5/SOW;T4W>%-TCW?MO:N4AQM554.[]C[&[GQ&;V
M+O;=FR:TG^!1[ACCDHX$BRQBH*U)32F>FFGBJ(_=>Z.-\(?E1A?FY\4.D/E?
MMO9.YNNMO=Y;/&]<%L[>$V.J-QXG$3Y3)4&.?(SXF6?'3?Q.DH$JX6B=E,%0
MGYO[]U[HU/OW7NJ]/YA%%D:R/X2O0154L-#_`#"_C)6Y5:=9="XY*K=L'EJY
M8*:HGAI8J^H@:X,:/(%CD<1/(#[KW5A?OW7NO>_=>Z][]U[KWOW7NB$?`S.9
M/,+\RZ;);DR6YO[O_/;Y&82@GR6ZWW8<1C5FVIE*3;5#,ZP#`X[`#*&"'%+!
M"N/4>*\[!JJ?W7NC[^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[HC$<NX/E-WAT[VMU!W\V,^-'QXWEWQMKM#9&T$SM%E.ZN_-I9#)=/R[%WXF
M:P>/H!UOTSG*/,UCI32U39+<T-'(IBCQX>?W7NCS^_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z*-\S/B)M#Y?\`5M'MBMS-9U[VUUSN&E[/^-_>^WJ2
M"IWKT!WIMREJALOLS;,<[Q4^6IJ"JJ#!E\+5,<;N#$35&/K$:&<E?=>ZUO\`
MY';`[T_F/]W;`^!/<.T,O\;\CEZ6MZS_`)M^\OAWA-@[<[W[*S6/Z_FJOC5W
M=1]A[MVY/N3?_P#+P[O&)J::9UPM3/M_/0_W>S!B%/>7W7NMD/X^_!;XI?%S
M,8C=72'2VRMB;YQO3&Q>@\COS`83'83<^[NN.NH**':]!O.7`TN)Q6X\K2-0
M1NU?-2?=D^@.L5HQ[KW1!OGQ\#.[,#WQ@/YF7\M/';0QGSMV=C$VMV_U=O3=
M.0VEU)\V>CX<7'15'6/9?V<$E)#V5MR''4K;.SDL^/AHJV*):^=Z:&$1>Z]T
M9_\`EV?S%-B_S"-A]C9G&]9=@=!=J]*]DYGJ/NGH#N"3`4W:'7.^<!28VKKX
M\EBL-DJV23;E:F33^'Y"2.G%:JLPB2UC[KW5B'OW7NN$L4<T<D,T:2PRH\4L
M4J+)')'(I5XY$8%71U)!!!!!]^Z]UKD_.+^2!O1>N_D-4_RI^[\A\1Z_Y&4-
M32]^?$.HKQ0_#7OW"9"&*'>6)Q&V,;@Z_*?''?G8>+I5QM=N/:7VOFH))*9H
M8!,]2GNO=/%7_.!VCT_T[M[X98OXYU_PS_F:U=!L+X[_`!M^#_9.SJT]*S]F
M[LIL/L_KS/=8=R=>T0Z7WY\9-GU-:*V>MH,MC<C'B\9)2/04U=+2T\WNO=60
M;$ZIQ7\M3X`;MPW5NV=Q]S;QZ9ZG[)[5W`^#VN<EV+\D>_:K$YG?6^=Z9+;V
M'JZ>JS6^>Y.R9YZF2EBJ0T9JTI8)$AAA"^Z]T5GXSO2?RK/Y7W<_?'RAW'A\
M_P!^8N/M?YC?-.HP=502-G/E?W?%2=C9?KC!40R--1?Q*6NW%M_9^W***6!:
MZ**@$-ON$O[KW1[=F]_9WJ;X:=<?(#YV5^Q>G-[T75?6F=[^3`#+_P!RMG]D
M[RAV]B:[:N!AK),KFJB^^=P0XFC@UU,TU7(D:-(65C[KW1N"RKIU$*6(50Q`
M)8@G2.>6L#P/Z>_=>ZY>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NM5/\`FR]^_P`MSX:?
MS9OCE\B/FS0GM;>6ZOCKUEUKMCKS/?%':O=&S>B-G8_Y`[ZKX?D@W9>YM\[;
MI]AY^7=V?%#YJ?%9S)T-%BY7I83+41(WNO=66_RC6Q;9'^::<9D*^L/_``[U
M\MVKZ:M>!HL77R;8Z9EDI<:L%]&.JH9(ZM-1+,]2S'Z^_=>ZM_\`?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]T`'RO["W!U+\7?D?VEM-<NVZ^N>B>VM\;77;^W1N[-
M_P!Y-K;"SV:P)Q6UWIJR+<%>,K10F*DDB>&=K)(-!;W[KW5;W\@?YG_(3Y^_
MRT^K?DW\F\SMK/=H;OWMVM@ZC)[5VE3[,QT^$V5O?)[4Q1EQ-"1BWKC_``J1
MI9J5(X&N%T!T?W[KW5T'OW7NM=GM#*_\)>MD[]WT_;B_RE5[0R6_MS5/9--N
MS$]!;FWW2]BT65R6/W=!O/&U%%EL[@,_#G)*I:^FK(J9C6"1I$,JEA[KW52G
MS4S/_">?&T'P]'\NG_9(8_DIEOYE_P`%LMA*GHW#460[%H<#2][[4DWBR2XZ
MF;,8+9R82B)J:,24F/DE*!4^XEC+>Z]U>K_.Q#JW\I29#7.8?YUWP0+4U+]P
M(*E)*CLJ+36,'BQZI#(ZR1_<LJF10([RZ`?=>Z`KYO\`QJZ8^-?R5_D:;5^.
MG7&,V+MS$_S+^Z<FE#@\CE<C#39#N;IONK??;]1439O(Y2LJ:C<><IYZJ7R3
MD44=,*>G2.!(XD]U[JUC^99B)<__`"YOGUA(*2:OJ<K\+/E)04M%3^3SU=74
M]'[XBI:>$0D2M+-4,JJ%Y)-O?NO=*SX'BWP=^&8^VK:.WQ2^.X^TR4"TN1I;
M=0[/_P`FKZ99ZI:>M@_3+&)9`D@(U-:Y]U[HUOOW7NO>_=>Z][]U[K__U]_C
MW[KW5>?\T'8?P![+^).Z-G_S+MQ;3VQ\6,GNK9C9W);R[*W-U7B?[WTF86JV
M9#'N;:6?V[F)*XY2+7%2B9XI?&6>-EC)7W7NA+^`>T/C!L'X=="[,^%^[J??
M?Q<VWLZ7%=-;KI-X5V_:7+;7I\[EQ(U/NS(RS5F6AH\P:JG74P$`B\*JJ1JH
M]U[HX/OW7N@>[D[(?K:CZ[J(\5091]Y]P];=;_[D*Q*./&IO7/)BYLK3L\;_
M`'%?20EOMX05,LK*`?P?=>Z&'W[KW7O?NO=>]^Z]U[W[KW1`?@E!L;'9[YWX
M?9F?QN9JL?\`/GM^LWK0T.(7#3;:WENGK_J'>>0PF1B6W\0K'H]Q4];][I'W
M258;U&['W7NC_>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z`[O[96Y.
MY^HNU>GNM>Y,ATOOW=6U)]M+V3L^*DRF]^MXMRT\D'\>P=&V0HI,1N*7&K/_
M``VM=@U-/:HC5VB`]^Z]T(VQ=EX#KG9NV-B;7AK(<!M+!XS;^*_B>3R.<RTU
M'BJ.&BAJ\SGLQ4UN9S^:JUA\M77UL\]965#/--(\KLQ]U[I5^_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[HBOS5^(60[^QFV.V^D]TQ]/_`#.Z
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MN/?NO=9??NO=`5\B_C+T+\M>L,UTY\C.KMJ]K]=YU5>?![GH?+/C,A"0]%G]
ML9NE>ESVT=TXF=1+197%U-)D:*95DAF1P#[]U[JF?<OPL_F/_#SLGI/>GQ][
MQW__`#$?B7T"=Y;IQ'Q*^0O=0ZK^26W\Y5;>RNVL%3;)^1.`VG38CY+8S$[=
MW3DH<9M?M:>GQU//3T;G)&HBIJNB]U[H"^Y_GOTA_,K^6_PC_E^[CQ';OP_S
M^U>^L)\K/DYTW\IMK2]-;^WAE/CGD,1E^AOCYM]5W%-L?M^'M3M7(X[/_<8#
M-9J)<?M6(I"\LP%-[KW1G_GEL^M[P^:WPK_E_P!=N'>W9^S>W?D'EOYAWR.Q
M&9\"[?Z[^/7Q'VYL_']4]44]/C*/!XVJZXWW\G3MZKFIZN3(9"6NBJWF+120
MJGNO="E\]]]]@;K^?7\LGXV;"[-W1UMM#`[R[3^:/R>R.W<]!@L76=*]"8/$
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MG?W9NW<!T`NU=J;T@[*GFFDP=?MS?<N&@V77XT0PO5U[;JJ=Q4,5#%%&TU1+
M51HJEF`]^Z]T\]V_(3IWXYX':.Z.Z=[4&P]O;Y[(V5U'MG,9.DRE10UW878F
M0?$[+V]--C:&M&/DS^444T,]3XJ83NB-(K.@/NO=._8?<_5_4^8ZOP'8F\\3
MM7-=T]@TO5?5N-R)J#5;U[`K,#G=T0;8P\=/!/JKSM[;%?5DR&.)8:5R6!L#
M[KW4_)=L=7X;LC;/3F6[$V3C.VMZ;>SN[MH=95VY\-2[]W/M7:\U'3;DW)@=
MI35B9W*X+`U&0@CJZN"!X*=Y45V!8#W[KW4X=B;";L%^IEWGM=NT(MFQ=B2]
M>#.8T[TCV%/FYMM0;SDVT*G^+IM>?<-/)0I7&$4S5<;1!RZE1[KW3?M?MCK;
M>N].R>N=J;UV_G-^]/5^V\;VCLZAKXWW'L2KWC@8MT;27<F);168Z'<VWIA6
M4$KIXJN`,T3,%:WNO=:_^QOF-\3_`))?\*"?E7\8,S5[0W4W4OP(Z^Z5S>$W
MWBZ?,[0WAV5L/Y`U_;6_<)C:7-4<^V*JJZ_??>"BE6IU5+9:@G^W'^0R.?=>
MZ,1_)NW)@*G%_P`V/LB/,4/]Q,Q_-\^:&X\=NF:GGQF'GP&VMM=1;;SF9&7K
MZ6CILCB\=E]K5\3UD<DU/']LZ>0&)U7W7NK=O]+G5J]6TG>$W8FRZ/IRMV9C
MNQ:?M+([DQ.-V$VPLOBJ?.XS>,FZLA54V&@VY6X:KBJ8ZR298##(KZK'W[KW
M3EO3L38O76!I-T[[W;@-J;=K\_M':U!FLYDJ:@Q];N3?VY<1L[96#HZF9Q'4
MY/=.Z<]14%#"FIZBJJ8T0$L/?NO=2]S;VV;LK^[PWCNS;6U#NW<^*V5M4;DS
MF,P?]Y=Y9WS_`,$VG@/XG54W\8W+F/M9?M:&G\E34>-M"-I-O=>Z8-V=N=9[
M$WGUCUYO+>V`VUO;NC,;AV_U3MO+UJ4>2W[G=J;9K]Y[BP^W(Y`$K\GBMJXJ
MIKY(`PD-+3R.H(1K>Z]T%?RE^97Q=^$^Q:#LGY4=U[*Z7VCF,S3[>P-7NFKJ
MI<IN;.U3Q(F'VIMC#4F4W3NK(Q+,LDT6.HJEZ>"\LH2)6<>Z]TE_A[\^OB'\
M^=L;QW;\2NZL!V]B>O=PP[5WW3T.*W/MG<&T<[54\M51T6X=J;UP>V]SXM:^
M&GF^WFEI%@J'IYDC=G@F5/=>Z-1M[;6W=HXBDV_M3`X7;&!H#.:'";?Q=#AL
M11FJJ9JRJ-+CL=!34=.:FKJ))9-"#7([,;L23[KW3U[]U[K7O^4'RX_X3L=+
M]M;AVQW#NW^6UMOOO&=E'=O8%57?';KSN#=U%O6GS^/FWZV[\GLS8N<J<)V9
MFZ.GEI)JS(5BY2EJ7$\D4QA,3>Z]U6/_`#$/G+_)4^1^S_BAU!\#MR?'+<_R
M/SO\PSX15FSZ?HKHBNV;V9A<9CN_]K93=V=VON>GZKPR82KBPZ3))))(Z2K.
MR^*5F`]^Z]T/O\XC^;O_`"Y=S=J?!/H;$?)7;^0[+^.O\W?XK;][SP@V7V:,
M?U?MKI'=^\L7V)DMS[@FV2FWHI-O9JK@A6*"IGGF+>:)7@CEEC]U[H%.E]K=
MF=<=/_RG5WEL_?W6U5NG_A1I\E=V;>P?8FVMT;+WG_<+L"/YJSX*LJ\'NV>M
MSO\`#MT83(U$RS5$\QJ(*A666H5S._NO=;1WSIK\CBOA)\Q,GAXL]-EL?\6?
MD#6XR+:TRT^YGR%-U/NV:C&WJAIZ809L5"*:5_(A6?20;V]^Z]TU?R^:J2O^
M!/PAKI:FFK9:SXA?&NJDK*.#[:CJY*CIG9<SU-+3:(_MZ:=G+HFE="D"PM[]
MU[HWOOW7NO>_=>Z][]U[K__0W^/?NO=$H^8]1A,EF/B5UONOHG9/>^T>V?E-
M@]I[CQG8.V-I;LV_LBDPO4?</85)O^'&;OE:D@SF"R6RX125$%/4U*^5XXT5
MY5=?=>Z,#T?T=U-\;>K-H])=&;'P_6W5&PZ;(46SMCX#[O\`@VWJ/*9C(Y^N
MI<>M=4UE3'3S9?+5$P0R%4,A50J!5'NO="M[]U[HE7SARV+PVTOC[5Y0RVF^
M:OQ#Q./6*6*)GRF=[MVMA*,,T\4R-$AR!=U`#LBD(R.58>Z]T=7W[KW7O?NO
M=>]^Z]U[W[KW0'].=+;5ZCSO>V<V]38N'*]W]TY/N'>E1C*.IHFK-R9#8^P]
MDP29"*>MK89<C#MC8V.BDFA$$<Y3R&)9&D9O=>Z'#W[KW7O?NO=>]^Z]U[W[
MKW4/(SU=+CZ^IH*$Y.NIZ*JGHL:M3#1MD*N*!Y*:A%74?Y/2FKF58_(_H35J
M;@'W[KW6>!Y)(87FB,$KQ1O+`760PR,@+Q&1/1(8V)&H<&UQ[]U[I%=C;_QW
M6FV1NC)X+>>Y*9MP[.VVF)V#M+-;WW))5[TW;A-GT5<F`P%-5Y%L+AJO.)6Y
M6LT>#&XJGJ*R=EA@D8>Z]TT[&Z7ZOZUW=VOOS8^SL5M[>'>.Z\5O;M?<%()W
MR6]=S8/:N&V5A\EE9ZB:8DXW;&`I:6"*/1#&B$J@9W+>Z]T*'OW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NB._-3X7XSY0X3:^^
M-A;LFZ2^6W2,N0W'\9?DI@:&*JS_`%QNFH6GFJ]L[IQ[!8]^=*[_`&H8:'=F
MUZPM297',6C,%;%2U4'NO=!G\'_GMD^ZLYF/C'\J-@-\:OGIU90RQ;_Z9SU?
M3G;_`'#@L(E-1UGR#^,&=G-.W:'1.YJUS(D\$?WV!G<T.1C22-)9_=>ZLN]^
MZ]U6K_,X_E9?&3^:7T5D^I^\MN4F,WICJ+(R=3]VX;'(W8/4VXJVG\'\4PM9
M#58Z;+X2J`"5^&JYFQV0B`$B"1(I(_=>ZK$P?\V#=?\`)^Z(P'QW_FI?'K?N
MU)/C_P!?]:]<=*_)/XW;1WAVC\>OE!LC:TFU>N:"OI,W44$,_3W:V!VTR9;.
MX#<E1!!+%2SMCZJ:::CHYO=>ZO,^-_S.^)_S`Q69S/Q>^0_4G>M%MRH^VW"O
M6^]<+N/(8&0SRT\+YK$4E2<MBJ:LF@<4\T\$<-3H8Q,X!/OW7NC,^_=>Z][]
MU[HH/S#^!OQ.^>G79ZU^4G3FV>R,51O)5[6W%)'-A.P>OLRQ$D.X>NNPL'+0
M;NV7FJ>I1)/)0U<4<Y0)4)-$6C;W7NJ<,+_*T_F.?!;Y*Y/Y,_!'Y@T?RYV1
M/UG'U,OQ8_F,;S[`SF8VWU;B\^=U8O8?3_R3P5/NK.;<EQV2U+CSDL0*:4>)
M<I)6&..IB]U[H'MM_-#MWXY?S&NXOG+_`#3?Y?WR?^(^UMT_%/J7XP=2;XZG
MGG^<_0FQ]F;6[6[%["[.S?:.\_CQM*LK]DY'>.],[MY<3%5X;[N2&G>T95RR
M^Z]T<'X2_/?X$?,K^85\I?D3U%\L.L=XKM[HSX^?&'J[;^XMS4G7^X9J;'Y[
ML?MSMG-[/Z^W]'MK?&7V[G]P;[VUCI<LE$M/49'`RTRZQ31N_NO=''ZNZQS>
MY?YIORN^1&=PFT_X!L3XK_&?XO\`6&>BR>.RN\5FJMW=O=X]NQR4=/`E;M3!
MY2IW?M:)HIY';(S8I)19($`]U[H'_CI2UV]OYTW\ROL"HV[58O&=.?%[X'?'
M'#YV7RP4^YJ[/#O'O_<E131%Y8JY,93]@8JE,P\1C>)H]+<N?=>Z1/PRV_D9
M?YQ/\\3L>E%1EI*/!?RZ>M<!2392"'#M78'XU;DWMD<)Y1#65.+J4K-Z4LDK
M:#'&M;K$;N6]^Z]TS?!+<^+ZU_F#_P`_'(;@?+'%;=^0?Q,WU6XK!XC=6[]R
MBBW+\-^O9'R&,V/MW%93<>4BR=7C98J5Z"AFDKFI9$36*<:?=>Z"7^0QF<IL
M?;'\U7;60V'GS6X[^>+\P<*^)V]C,>U?B:/?F5ZPJJ3,Y;'G+)!B]L[=Q63B
MK*ETFF:&@!:)9F`1O=>Z6G\HNMW'G_Y"^%EVM@J6MW3/L?Y\4.UMN8TM2TU?
MF:?Y#_)>AV_B*=JQZ[P_>UD<,6J3R*"]R"./?NO=(G^7+NOLG=/\@SXT[3V9
MM3)_W;S_`/*\[MH:ONC'Y[;35G7_`&%L[:-5LS8NV<?L'.A<CNG(9_SY.LBJ
MO1C*(X-8:AF%9$1[KW6;Y597++_PFKSF(./&?QE?_)IPV5R&_P#"RX6FVO#E
M<7\>NM:7'8R'%KDY,HS[LI\Q5UE$])#/1008R99IHGDIEF]U[H//YL6\MS9C
M_A-\E=)M#(;PI=Y?#GXB[CW/OC$)A*.DVAE&W9\::ZBSB;8DKZ#*/53U&4J,
MC2&DIWHL<,8[5;11>-)?=>Z.9_.'R.[*SJ;XL;?QFSMV5&&I/YB7\KO.-OR#
M/;<HMO5-97?,C8V,J]OYK`19&HW;EWQKTU#4SQ1T<5&QR$$J59:DFA/NO=2?
MYJK2#Y%_R6T`8PM_,^PK.?N(P@D3XL_)<17HS::9M+N1*OIAL0W,B^_=>Z#3
MM;#;SR7\[+^6EVCOG95#L3-Y/I;^:;U3114>?AS_`/>3KSKC=/3-7U3N"H(2
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M7LCY`TGR)^?>UL7V=O'<-?5'=M+3Y;'XSL7L6@SF)H,U4YS?>?V7%E,A@Y`A
MBJ\[/2M)(L3.P]U[HSV&VGW-O_\`X3AX2EPV>V5%\=)/Y"66Q\VV,I@LQ0]M
M9#O#"])XO(XO-QYN2IJMN4/6]'L[`5M,D(BEJZRKK(J@-'%&%;W7NC5?S;\Q
MO/=7\O?+?W@ZO;8N&ZH^6W\LFKVOE<INC!5U%V/B9?DA\5,OG<OM2EPTJ9+$
MT.!W+NVLVZL=8M+65<V)J*B&,4\D#2>Z]UC_`)Q^X-QXWNS^3O)F-MX2'"4_
M\Y[XTX3:M>F4.<J,[CMQ])]P8RNRV5Q%5AJ"#;.3PV>RU7%2Q1SY`NE)#5K-
M#(_@C]U[K/\`-;/]A[O^:_\`(+W!OK85=U-N[*_*KY.UFXMAINC:^\*C;#Q?
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MNWN3Y2Y;=6Z]T;2PM?N?=64I_D9V7BJ/+9[.5E'43YZO3!T%+`U07*KXC$+>
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M8S$5<<M+E<@QBM#32(T<\ED8$,1[]U[I`?RQLF<U_+<_E_94UU/DFK_A3\6J
MF2OI5E6GJI9.D-CF66,3S5,Q!DORSL2>2??NO='B]^Z]U[W[KW7O?NO=?__1
MW^/?NO=%6^0^*VU4=E_#G-;C-4)<%\C,DNVS'5M2446Y<U\?N\<3139`14LK
MU:R4=144\$+RPPM45",=<BQ*?=>Z-3[]U[KWOW7NBO\`RJW;TOL_;G3U5W=C
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M+<>T.T.H=QC>W0WR`ZQRE/M;NWHG?"^`/N3KG=L]!E*6*')14R0Y3$9*DR.!
MS5*HAR%%4QA0ONO=$5ZJ^>G<?Q"[9VY\1_YJE;L_!U>[,C!MSXU_S`,+3P[.
MZ+^563K:R"/&;(WSM=()<=\?N^Z.DKH8:K'U=<<#FJF-Y,7.H>.G/NO=74>_
M=>Z3VZ]I;4WYMO,[-WSMG;V\]H;CH)L7N':NZ\+C=Q;;SV,J`!48[,X/+TU9
MC,I03@6>&>)XV'U!]^Z]U19)_*6[*^`^[-R]R_R6]S]8=+2;VW?BMR=O?"[N
MW"Q9/XW]P4SU319U\!VI2[>W-WIT;GJ:@G#XV#%5M;MBF:ECACQ,$;2E_=>Z
M)UD/^%&O>'Q*^1!ZH_FL?RZ>S/B#UIO?MS+;&ZP[CVQE,EV)MBBVUBTQ>,EW
M'DLZ,%0[5[3P=)N#(Q2UF5VW64\]/C:J%H\342*P?W7NMJ['UU+E*"BR=!/#
M54.1I*:NHZFFG@JJ>II:N%*BGG@J:66:FJ(9H9`RO&[QNI!5B"#[]U[J7[]U
M[KWOW7NO$7X/(/!!_/OW7NB8_)C^75\%?F-$!\F_BAT=W#D5*>'<^Z-AX9=\
MTJ(7/@H>P,5!C=[T%*YD)>&'(1Q2&Q920+>Z]T1W8G\AKX?]!;OR6]_AKVI\
MROA#E<Q4X_)9K$?'?Y.;SJ-C;DS6-IYJ2#-;QZ][N@[EV9O:O>CF:%CEZ*L1
M8_\`-+&Q+>_=>Z9-M_RU?YB_2N[>RNR^A_YO.Y]Q[S[5W1BMY]@8GY0_#_HC
MLW:^^LQMC:6V]B;6H*_(=82]+;IV?BJ':&UZ:CE3!U%-"\@-4L"U#SM-[KW2
M6V=\9/Y[?5G8?9_;6VOD?_*M["W5W!EMM9'?.#W5\4NX>L:+(KM/;_\`=G;X
MDWUUQV!6;ZS,V#PD,-)2/FWS$D-/$J+(L:F-O=>Z3^R_CS_/"Z5^17R\^1.Q
M<%_*>W]FOEGF^KLGE,7F=R?*?8=;M.'I_8%+UCLFDDW!0[$W14[IQE-MVB-7
M44LZ0/\`Q*MJ6IYX(76%?=>Z8/BYT7_/K^-5#WG#%LC^4[O+=OR$^0F]ODIO
M[?E7V[\N\+CY-Y[^VQM/;U9AL?L<]89^6CQ&W:#9>.H:(QY>-6HJ10\7G>2=
MO=>ZQ?$WXN_SP/B3\8\;\8MK;;_E(;JVU2Y+N/-/E,GN;Y6X:'^(=V=H[Y[1
MW'35&V<?U_4XRIPF,RO8=53TU)%+3@T%''"S!I"Z>Z]U@Z"^+'\\/XV?"79'
MPBV5@_Y4.?VCU[TC7]+X3>U;O3Y4[>R]=CZG%Y/#19O*[>Q/6CXQL[)!D/N:
MR6*>-*RL,DI$9D('NO=)_>/PK_G:[_\`Y>.2_EQ;CF_E>0=?5WQ<H_BTW:N'
MWA\H:'=[;7PNP\;L/$[ABVJ>LIMNTF>EQ-"GE19/LQ4(TB1I&ZPQ^Z]TI_DE
M\*/YP/R!^!-7_+UQU/\`RQ>MNM,GT'L'HC,[ZCW?\H-[9\XK9V/Q.+_BNS]N
MY3K'%8_:]9%2;<HS1FNJLU+1S$RK,\J1NONO=.'R=^*?\]'Y6;#V/UOOS<_\
MH[#[5V%VYT-W;2TN+Q'S+R-3N/=_Q_[(VQV;MS#;@GJLM10?W.SV?VQ"*^GC
MA-4:<&*.=783Q^Z]TBN]_CG_`,*%ODEOKXS[AWQ1?R==KT?Q=^2^W?D/LNIV
M]F/F!D*S,YW;O7'8_7?ASQR>$>>';V6H>Q:R22AHGIJM)/M]57(D$BU'NO=8
M.W_CW_PH4[4^5WQB^5-#M3^4!M#<7QFVUWKL_;&WZSL#Y:[MQF6Q/R"@V?B-
MVU&XZZ/KS:^3J)L)B]A8V;')0M0C[DU`F:2.98X?=>ZGTGQZ_P"%"$/R2K/F
MG/AOY-)[ODZ>Q?QCEV51U'R]I=KYCIVEWY6=I2[DJM^-2S[EIMVT6Z9VI:2@
MDHZK'Q4U1+,"LI99/=>Z>^D_CA_/MZ[^1W?'R6J:/^3KAMT?*C*].KW-BJ&/
MY@9B;'[:Z(P-1LK9U+M;.QM@Y<KF,AM',5I>7(1""FK%31'XF91[KW6O[_,_
M^/E5\..\>S<9_,.Q/\D_,[,_F%=N]O?(7:&\-Y_'_P":G^EOIW(X"39L.YJ+
M;.^/BWL`]K3;<R>(Q&'FK%J<S%]]N/+Y2J:U.]4M5[KW5@/\LK9_\TS9OQ5[
M6^-/\NG%_P`E?='3VUNU.VL/V#E,C6?S!=B;JHMY]NXFBWS2Q;DV+OS8N)S&
M%KJ#8&\L)'1PB2HIAB::FI1)Y899/?NO='1S/Q2_GR;J^#]1\!LMM3^3]@^J
ML]T!-\7Z_<FS]V_+S;>2VUUM)L>;KJ'-X#;6(VC2XQ,W1X#PS14L,]-2">-E
MTF)]"^Z]TK_E-T5_/C^0_36/Z&R'5O\`*/K-O8'L#X_;ZQ.[Z_M?Y45]14Y7
MH3MCKWMK"U-;M3,=/STZ4N8S&PHZ2M0ULLPH:F;QLTA7W[KW2-^2G4O\_'Y6
M9?X[+O#XM?RKMMR_&;Y.=>_)[:>Y:[OCO/<<>3W/U9#FOX-B<,R]8-F-KQY^
M#.34M16_;23>-R/'$#K'NO=,'<FT/^%#?='>WQ$[VK/A_P#R[-M[@^(&_NUM
MYX3%-\E>Q,K@]^_Z5^I-S=.9"CJ`-IID<%_!\!NBIJH*A7>1JOQ$QB-9(W]U
M[H7MI_$S^:E\MOY@OP.^6GSGZX^%?Q_V'\#J[Y`Y_"X[HCL3L3M#L;LS*=W]
M94_7Z8*27<6UL3A\#MW$5%+%62R-6^1F1@()"RLGNO=0^U<#\YL__.U^46[/
MY>>9^'./K=E_`3XB;"^1;?*?;G9^=H1NW<_;7R1WAUO1;<7J3+[<W-39Y=E4
M$L]9)/524+T4E&CPM*L+Q>Z]T9',[8_X4,U,U\1V[_*'Q\4[OJ7_`$.?+ETH
M8X&A6%H/NNTZ^6KDKXU9Y%<J(&8JK.+,/=>ZE46S/^%!$4:T59WQ_*:J$@G6
M5<X.@/E6,CD(GEJHGI:K$1]TTV-H8X:::.97BFD=Y81&=*L\A]U[H-O^$V2U
MF#_E5[`ZPSU9CZO?/27R!^8/5'9"XUE$%+OK"?)[M+-9B(4Z@?9+40;A@J8H
M3RE//']00??NO=6I=7_+#J3M_P"0_P`GOC%LNHW%4]F_$4]-Q=Q??8"IH-MT
M=7WGLS(;]V10[?SLKF#.U:[:Q_FK5C513--&MV);3[KW3MT%\K/C;\IZ#>.2
M^.G=O7'<M+U[NFKV3OO^X6Y\=G:K9VZZ+5]Q@MRT%-+]_A:^R,46HBC$H1BA
M8*UO=>ZU6ODQM;J'X1_.G^3O_+*V+V=E-W;HW1_-,[;_`)AV<+XZ?;?^C797
M;^7[DAZ_ZXF;'U.4H\E%F<MNW.XNFFEF6KJJ?%2RR14\-4JCW7NMH+YP4F/K
M_AC\LZ/+86GW'BZGXW=VQ9'!558*"FRU"W6^Y!54-16-Q3PSP:@S?T]^Z]T7
M[^3OV31=M?RL?@'OC';2FV-1U?Q9ZBP4.UY)JVIAQHV3M6AV0[XVHR61R^3J
M,%D9-NFJQ[U-3-4O0S0F5O(6`]U[JR3W[KW7O?NO=>]^Z]U__]+?X]^Z]T7;
MOF"E?<OQHJ:[=N%VI28_Y$8NH>+-U5/21[LJJOJKMK#8C:&->HEB27-Y'-Y6
MFJ*6)=4DKTFA`6('OW7NC$^_=>Z][]U[JO3^8[C$RG7WQE4ND<E%_,)^!62@
M=I((V62C^377[OXC4,$:5J=G`4*[,"0%N;CW7NK"_?NO=>]^Z]U[W[KW7O?N
MO=5[[5[!W-U['_-#WSL_K?=>_-U]9]KY;>>TNMZ-9OO^SMQ;?^$GQXW%AMM;
M/:)\@//O3+T"4$*QQK(*N4DPDLID]U[I)_RDOYAF1_F<?#O#?)O.]-570>Z/
M](78766[>KZO<M7NN;;^Y.N\PN)R(;*5^UMG5\3U/E1GI9Z&.:DEU0NSLA8^
MZ]U9I[]U[KWOW7NO>_=>Z][]U[JO_P"073G;_P`G_D#UYUENC'9/97PTZFDV
M5W5O;+T6;VO)D/DKW#MK>%-G=B=.UN&BGR>X<3T_L2IP4.;W&U3#0-N"N:CQ
M\?EH4KO)[KW5@'OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z0O976/77<FR-R=:=L;&VKV/U]O#$
M9#`[HV;O3!X[<>W,[A\I234.0H,EBLI3U-)405-)4.C76X#&Q!]^Z]U1E'UW
M_,8_E'XR.3I$;\_FB?!6BS4:S](;DS%/2?,CXD]7T57F*I<;TEN7*5=>_P`H
MMG8#&9*.GIL)EYHMR4M+BZ.BH7E@>26F]U[JV3XG?-#XT?-[K=>T/C3VG@.P
M\%2UDN&W1AH6FQ.^NN]TTBQG);+[-V%EXZ/=O7^\<4TJBHQV4I*:H"LLBAXI
M(Y&]U[HT?OW7N@W[7Z=ZE[WV7D>N.[.LM@]N[`RY#9/9796T<#O;:U=(L,]/
M'-4X+<=!D<;)40PU,@CD,?DCUDJ0>??NO=4-=[?R4?DMUCUQE=J_RDOYEOR)
M^$V"2FAEP7QVW[N2M[B^/^-R,-5"JTVPL[NREW/V9T=@)*"6<RT&&?)8QIEA
M\5%3JK$^Z]T"/Q9_FB?S`/Y?-5V%UC_/[Z_W%1[-Q^X<72=/_.[HOI^KWQT9
MF,3'!2T^?A[3K^H\9+DMK4:UF6QW\,R-9M?%23225452I>)7/NO='GZU_P"%
M%G\G'M7?%7UYMKYG;1I-RKO"39F%3<NTNQ-N8K=^0\6-^SKMJ9W)[2AP^3Q>
M7K\E]G1LTT4U550R*D10QO)[KW5V@-^1R#R"/S[]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[K1F_X4M[-^-^]/YC?0^(^;_<&S^G.BZWX%[DH^F-W9B?O&EJL1W!7
M?*CK[$]L_<+TIM'L7+5M9DOC]D\K'B(ZS$/A7KDMD1)$B@>Z]U<I_(TV#M?K
M/LC^;#L_8>\ZOL7K_&?-S8K["WSD=T5N[\AN;964^(GQ\SVT\A7;@JHXH\Y5
MG;>7I%DR$8TUC@LI:(1,?=>ZV!??NO=>]^Z]U6U_->^5'>WPI^'&\/DOT%MO
M8&[MP]>;FV12[CP/9&%W3EMM?W7WMN7'["?<&0GV?G\%F</B-GY[<M#E<I51
MBK9,/250CA:4H1[KW2PI-L_-BH^2O4G9"=E1X_I'+Y#N+:G>WQ]RF!V#F=C8
M';.V(,WC>GNQ>K-\TNV-K=PT'8&]<Y18[(9"FR==F\&<76U4"T])/#35#^Z]
MT<C?N^]G=7;'WAV5V%N+&;1V'L#;.<WEO/=.:G^VQ.W=L;;QM3E\YFLC/9C'
M1XW&TDDLA`+:5-@38>_=>ZJ#_DNX/?\`VCL?Y,_S%NUZ`XW=O\Q[O2?N'KG%
M5B.N;VQ\3.O\-'UQ\4]JY317U%+#_P`8^Q\V=2`04U3%+N"4U*^=GCB]U[JZ
MGW[KW7O?NO=:[?QA[,H/Y>W\X+Y7_!'LC.)MWI+^8AN.7YU?#?,[C%#08NL[
M[WL%P_R@Z8QN?>N@I9LSFMS8*'-X7$K3I-XGD4&26H0S>Z]U7C_-"_E[?S%N
MX/YQ.3V7_+A^96[/BM@OEKT=UQ\LODMF:3<^\]E8?![H^+66P?Q]VIDH<_L:
MDK]Q9^NSVWMP8T4>W5DHL=73455+6EHX8GA]U[H/=E?R\?EW_+<[(^*6P<%E
MND-I]U+_`#,J"MP/\SC*]C]4=*1_+_XL=]3Y3=/:OQ=^2?6%?NNL[D[D[DW+
MV'X8MOX*FQV>H:6>2GFQN4QYAJ)Y/=>Z.O\`S2/B1L3XX?)G^6SW5L_<O9FZ
M.QOE%_/Y^,78W9^[]^;H7<&2H\=D.O=Y[/VQU3@*ZEH,748WJ+KK!8ZII-LX
M:?[I<7#F,A$LQ2J9#[KW1Q_Y_P#W'O\`HOA[@?A7T#60U7R<_F0=BX?XF]9;
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MU.%3:.6J=R=;UV,2GS=3%$]0BU/W"4LP,?NO=`__`"I_G;TG_,;^)U'\H.A^
MNMR=8[4W+V1V!A,YM[>.-V1C-U5V]\)DX/[R[FS\77]34X&IRFY9:R.KEJ#H
MJ)S)KD7D$^Z]U9+[]U[KWOW7NO>_=>ZK_P"]^Y^Q>W.T)_B+\1=^8S:W9VU,
MILO</R<[H7#T6ZJ#XY=:5E3B-P)LW&T-?1Y3;U=\B>X-NU"KMW$Y.%Z3&X*6
MKS=8"(<?29'W7NK`/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U6G\I/Y6G
MQ_\`D5VKM#Y)[*SN_P#XI?+?KZ+)C:GR9^-%?@=C[\RRUE,ZTV"[<Q-;@,QM
M/NW8]/7:97Q&XJ*K22(S4Z2PPU-0LGNO=!:GR0_F,?#RDR<'R]^.M/\`-3J_
M'5.Y\W%\EO@CA*+#;XVUL/#TE970MVY\3.Q-Y0;DJ]T*L46AM@YK="U<+2@4
M,,U.BUONO=')^,'SH^*?S$P<>3Z"[FVCNS.T]#CZO='65=7)MON3KNIR%/-4
M1X7LOJ+<'\.[`V%FXUI9KP9+'P>18FDB,D6F1O=>Z-K[]U[K'+#%/&T4\4<T
M3:2T<J+)&VE@ZZD<%3I=01QP1?W[KW52'S%_D7_RP_FW39*M[2^,.S-H=AU<
M#_P[N#I:F3J3LO"Y):6LIZ#,19;:$5#BL]5XR6N:>*',462HS4*DCPNR(1[K
MW19NT_Y37\QW;/5]-UW\./YX7RQV7C,##2UV#QWR8V)U'WQN2NSM)DJC)&FR
M?>-%M+:/9L&V:R6J*-23IE8XH46'1)3JD*>Z]U+^,^<_GW_$'$M@?F!UQTS_
M`#/MK9"NGEH]_?&WLG8?2O>>P\;CZ%%6FS&QNV-I=-=;]BTN4%*TD;4V9I<E
M'52Z'::-@T?NO=!7WW_/<^8O06Y:W,;I_D3_`#[AZ"QBX\Y#LUZ_:&;WG3//
M'34U<M7UYUS0=@[9H*2+-UL<%/5/NMDJ(OW"D9O&ONO=&2HO^%&'\I&'KA-_
M;X^2F0ZKRD&(7(YKJSL3J#N7!]MX*M%0E%48.IV/'L*KR.0R<%8Y6]#]U3R1
M*TZ2&G5I1[KW2,Z#_P"%,_\`)_\`D+VS1=/;?^162Z^SN5IJN;$[D[KV)N+J
M;K^NJ:*,338V;>F[8*/#X*M-.LCH<HU#!)XF59#(41_=>ZM4E^;_`,,8?LM7
MRU^-3#(UJ8ZC:'O'K2H66LDIYJI(2\&YI%B+00,VIRJ_07NR@^Z]T4KY)_SE
MOY77Q3W=LRG[L^<?6V`KMR[?W!48;;NRZS(]KX;)4M/7X>*7+9V;JO;6^9,'
MD<?*#%1)4U=$*B.>H(BG\8>'W7NAYZK_`)E7\O\`[IZVPW;?7GS'^.F4V)G,
M'5;CILGE>U]G[2R%#B*!JM<A4[@VWN_*8+<VUI,<U!-]S#DJ.DFI_$WD1;'W
M[KW1&L-_PI!_DN9[=V`V9COF]LS^);ES>-V_B\A7;*[3Q6VUR65S<VWZ<Y;<
MF4V/1X;;V,AKX@\U?D)J6@AI)$JFF%,3,/=>Z-[\B?YK?\N/XIX0Y[O7YD=%
M[1I_XO!@TQF-WG1;XW1/DYUB=H:79NPAN?=E5%113QO5RQT30T:2*T[1JRD^
MZ]T%?37\\G^4CWUF,A@>NOGMT`V5QE#49*IIM\[EJ^I4DHJ2+SU<]#5=KXW9
M5'E!2PW>1::25D0%B`%8CW7ND9W=_/\`OY1'QY[0BZC[,^:'7\6YY=L4^[/X
MELG#[T[5V5'05E3+34M%+OOJ[;6\-IKG)C!(YHA5FHB1+R*A9`WNO="GMK^=
M%_*CW9U"G>6+^?OQBI^OC2R5,KYWL_`[9WG1RQQ5$YQ.0ZPW%/C.S*#<<D%*
M\D6,EQ"9":/2T<+JZ%O=>Z#SKS^?G_)W[0W'B-J;4^??1T>:SDU?3T";MK-R
M=>8WR8^>K@F^]S^_]O;9P&,28T3O`U351"HB*21ZDD1F]U[I8]Q?SM_Y371#
MX^+L3Y\?'59LI$DU)3['WI'VQ4F&1F19*F#JJFWI+0K=;GSB.RE6-@RD^Z]T
M,G1W\S?^7O\`(_:F'WGTW\R?CQNS#YZ2MAQ]-/V?MC;&YO/CJI*2KIJ_96[J
M_`[QP]5%-+&1%64$$CQRQR*ICDC9O=>ZUT_YCOSQ_DC]W?./:L/>???77RQQ
M.Z.@MT_R]LS\:-B;+S5;E<!O+O#Y#]49+(]R_P"S(9K);/ZPZOQ_65!M6>.L
MK*+.4>:I1Y'II93JA7W7NCF?#/Y/?R^OY=G<'\RC`=D_,7XN=;]8[B^6W55)
MTW1Y#Y!=?[ASG]U]K?"[XZ[*;`UN(HMUY[>5/5[/RFT*O%SRY*)9Y'HQ)*[-
M*&;W7NK&NG/YR?\`*P[Z.XEZR^>7QMR,FU85J<W#N;L/&=<5$%&8%J7KJ.G[
M)_NE/E\?3Q,/-44:SPP-=9&5@1[]U[J%N[^=+_*?V'O+*[!W7_,"^,&*W3A*
MT8[*T/\`I.PM=1T5:::"J,$V<QLE9@;QQ5"AR*DJDFJ-B)$91[KW0H;O_F3_
M`,M[";`SV^=U_-SXB5.P<+1R5N9KD[VZLW+3-#22R%8H,1BMQ93(9>N>IHV$
M%+34\]3/,FF*-WL/?NO=%\WM_/=_E';*V9DMZ?[/7T5O9:&2DIJ/9_5VYU[+
M[+W'D\C54]#CL/M7K?9L.7WEN#)UU951QI'3T;*I)9V1%9A[KW53WRV^2VY/
MFEO;JG$?S)L%OS^73_*JW1N?.[BVQ\;.Q-B]JY7Y>?S!*GJC(X?*4L/=FU.J
M]E;MK_CCT3B<QDL955^TLG44FY<L$O(3!-!447NO=;+'QR^1'27R>ZTI.S/C
M[N@;MZXCRN1VK1Y(;4W7LH4^1VX8*:OQ:[=WGM_;&<HDQ_D1%U4<<96WC)7G
MW[KW5>O9/\^#^61U#V#G>L.Q.YNS=M;NV[V'5=4Y"&J^)_RVFPD^_P"DS<^W
M7V]AMU4O1\^U]PU$^7I9(J>2@K*F"J5#)"\D?K]^Z]U8C\B?D1UC\6>IL_W9
MW!4[OH]@;9GQ$&9JMD];=A]K;AIOXUDZ7%4U1%LKK#;&[MY5E'33U8DJIH:"
M2.DIT>68I&C,/=>ZUMOYF?\`,L_D0?-;8U!T%\A?D7W7TYWSLC+IO+X[[YP_
MQB^9G6GR)Z3[@K<<(=G;VZWI*SIS:^XZC(U59+2D8]V2ERP6)2RNL,\7NO=/
M'PW_`)YN_?CML3JOK7^<%T=\A^CX\AO#+].==?S%NQNC=Q=7=)]^T>/J:V7K
MO>/9^R=R4&&[$Z%WEO\`VK0+65M+6XJ;'++#+6RRT5.94IO=>Z'+H78O\L[>
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M9:6-<A6SXKLG:"44BS_NS**?=<DP6`&4-"&-HUD(]U[JR7W[KW7O?NO=5>?S
M=LMNW;GQ7V'NG:!C:LVS\V/Y?N5R5)XJBJK,EB7^9_2.+FQN-Q\&8P(RE755
MN1@#4SU,<<U.)`?Q[]U[JT/W[KW7O?NO=>]^Z]U[W[KW12]L=^YS&?[.YGNQ
M*"JR&TOC%V)D:?`0;/V7DQNG+[!Q/QKZ@[KR-)1XD9_.3;XW,,OO3)4M)-2)
MCQ6E(:=:59(VEE]U[H-OY9OS!^-WSK^)FU/DA\5MD9OKKJK=^[.P:$[3W/LS
M:&PMS46\,%N[)X[>&0W!MW8F4S6V8LKN',QOD9)X*J5ZH58EETRLZ+[KW1_?
M?NO=>]^Z]T13YD?);<O7M?UW\:^B*-MQ_+'Y+C<F&ZPH*88ZHH>I]GX;&N=[
M?)#L:.OF$%!U]U<M7`T,<D<CYS-S4F+IHY99W\?NO=#%\7?C3L3XI]2X?JW9
M5;N3<U6L]3GM]]E;]RQW+V=VWO\`RY6?<W8_9F[98*>JW-N[<%6+R3NJ1P0)
M%34\<--##"GNO=&)]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U7S\N/Y6WP?^;&X,1O[NWI;'0]Q[=JL35[;^076&6S/4/R$P#X*GJZ7$4V
M/[GZZK=O;^.+Q\%=*(J*>MFHT+7$5P#[]U[HB=1TE_.S^#4&-J?CW\A.N_YH
MG1VW*W`Q3]'?*W'8_JCY93;4_B$]+E<1L?Y,;?K<=L7<V?Q^+:GDCR.]**>2
MH99FD8LJ)+[KW0B];?SSOC)1U^`V3\X^MN]_Y9/:^;>'%TN!^9_7N5V)U5N3
M<<&,R.2SU%UW\C*2"LZ>W7B,/%CQHJZW(8::M%53B&F+R^,>Z]U;YL?L7K_L
MW"Q;DZVWUL[L';LQ`ASVR-S87=>&E8BX6/*8*MKZ)V('T#W]^Z]TL??NO=>]
M^Z]U[W[KW3)D-M;<RZUR9;;^$R:Y2.EAR:Y#%4%:N1AHA4"BBKA4P2BKCI!5
M2^)9-0C\CZ;:C?W7N@USOQR^/>Z*NHK]S=$=-;BKZN::IJJW.]7[(R]74U%3
M(9:B>HJ<A@ZB:::HE)9W9BSMR23[]U[HO^^?Y8_\NCLO(5>6WW\&/B=N;*UV
M-H\14Y/)=!]9/D),?CZJ:LHH!61[:CGC-/-42!75ED$<CQZM#,I]U[IHP'\J
M?^65M=J]]O\`\O[X<XN3)T+XVODIOCIU3Y*B@D-"TE(SR;6=E@D?&PLP4C4Z
M:CZF8GW7NI1_E:_RUON,35+\!OAY'/@VIFQDD?QRZEC-/]GBCA*5#HVF//%3
MXHF!$DU($/TOS[]U[IWRG\M/^7;FL?58O)_!3XA55%6M(U5"_P`<^HP9FFIH
MJ.9FE3:*S:I:.%8F(8$Q#3]"1[]U[J-B?Y8O\M[!54]=B/@)\,\?5U*544]1
M3_&7IE)98JZ*D@K(F8[-/[55%0Q"1?TMHY%R;^Z]TZ5G\M_^7AD51,A\#?AE
M7I'`*5$K?B_TC5(E*LR5"TZK/L>11`)XE?1^G6H-K@>_=>Z:_P#AL7^6Y_#T
MQ0^`'PM7'Q@*M)'\7^E(XM*S&I"D1[*5F0U#>0@D@OZCSS[]U[J+4?RM_P"6
ME55K9*I_E]?"N>N=];54GQ@Z6:4M=+<G9=M*B-0!]`!8"W'OW7NH&<_E3?RR
M=QT#8S,_R_/AO5T;4U+1A!\<NIZ6:*DHI%EI*:GJZ/:M/5TL$#(-*QR*--U_
M22#[KW3!B_Y/W\JS#12PT'\N[X;HDTHFD^Y^/G6=>Q<($&F3(;>JI(TTK^E2
M%OS:_OW7NFW(_P`FO^51DMQ[:W8W\OSXIX[/[1R>.R^#K]O].;/VUX*_$UO\
M1Q\U52[?QN-H\E]M7!9`M3'*&T*K`H-/OW7NBL]M_&K^6S!\J\G\(MR_`;X:
M[&VEOCXG[T^7&Z^_<WTET=!&N0V]\ANO]B9G;&5.X]A^*2LR]5OQJVHRM1DO
M+&]2JQHKL)/?NO=,7PT^$?\`+G[!^0/SXZV/\N#X"8W;GQ7^0'6_5O667P7Q
MNZWRV3SNT]Z_%3HSN:KR6Z\EG\1F:3+Y=\_V=7)%+3Q4\2T0@0K)(C3R>Z]T
M=7/_`,G[^5;N>"&FS/\`+P^'4\5/#!3P&F^/W6V,EB@I]/AA6HQ>WZ*H$:Z!
M<:K,;WO<^_=>Z3R?R5?Y2D35;1?RZ_B1$:T6G\72^SXA;RB8>!8\>JTFF0`K
MX0FFUA8>_=>ZAQ_R1OY1<4E--'_+J^)RR4DJ30M_HBVT;ND;QKY@U*5JETR$
ME90ZEK,06`(]U[I/Y;^1%_)\S"J)_P"7O\<Z!XZF.LBJ=N[3J=J5L%1"#XI*
M>OVODL/6T_C)U!4D50X#6U`$>Z]TC*K_`(3Y_P`I&JRDF77XN9:AJI:4TCQX
MKY%?*+%485C1:YH*.@[IIZ>DJYHZ%4DEA6.2022,Y+NS^_=>ZFTW\@'^4E32
MY:8_$Y:U\RK+5/E.[_D;EIH-<(@9L=59'MVIK,;(L8'C>"1&@L/$4M[]U[I3
MR?R+/Y3E3CX<5D?AEL3-8Z!H7BH]Q;L[3W'")*==$$K+G=^9$R30K?2[$NMS
M8\F_NO="-\9?Y1W\OKX>]MOWI\>NA9=C]I"DW!C:/<M9VKW1O2+$8O=""+,X
MO![>WUV)N7;&&H:F`>-5IJ*-HHO0A5``/=>Z;^^OY.'\LSY0]V[B^1GR!^)&
MP>UNYMUT.'QVX-Z[JS&^ZF7(4NW\;38?"WPE/NVFVU35&.QE'%#'/#11S!(U
M]=P#[]U[I(8S^1;_`"AL7D*G*?[(!\>LS75=-%23S[NVS6;X#0P34\\(2'>6
M3SL$4D1I419$59!#JBOXW9&]U[IQKOY'W\H?(3-/-_+L^*<$K2T<P..ZIV_B
MD22@<R4YCAQD-)!&C.?W4"A*@6$H<"WOW7NH'RPZB^&GQVP/P7V71;1SGQPV
MKD/YAOQGQ?56&^)FVME]7X3.]S4^,W[_`*/MK=LXW"4.&I<KT]N"DI*N@S4$
M:2U,JRPJH*ZR/=>ZM?\`?NO=>]^Z]U[W[KW7O?NO=>]^Z]U__]7?X]^Z]T5_
MY/[0;=T7Q_(I\'.FUOE!T]N^63.$A:1</699$J,5I*DYQIZM(J4:@-<IOJ%U
M;W7NC0>_=>Z][]U[HJWS,Z`V_P#)OHN;J+<O8M=U909#M7X][QI=VX]:"2I_
MCO5G?O6G:.VMM+39*JHZ2K&]]P;.IL-XB^MC7CQI)(%C;W7NC4^_=>Z][]U[
MKWOW7NO>_=>ZJ$QW=_\`,'E^9OSSV9T;\;/C%V)T1U?F.BJ+:V?W_P!R]F]%
M=@;M[8W3T%L;=&](JW-XOJCO7:6Z<9M_"3X:D`CH<!)2+)`C253&9X?=>Z0'
M4OS)RWPXQ>9VKWU_*@^2?Q%V;N7LSM#L'>_9/QHQ.U/F+\<8-Q;@KLSO+?\`
MVYEZGH+(57>6V]O[MR<;ULD^0ZYQKH]27F@@1)67W7NK.?CG\K/C=\NMEU78
M?QE[LZ[[NV=CLF^#RV8Z^W)0YP8+.1PQU,F$W%0PN,GMW,I3S)(:2NAIZ@(P
M)2Q]^Z]U.^1'R&Z\^,G6\O978S9^LHZG<>UMD;5VGLW!U>Z=_=A]@;YS=)MW
M9G7^P-J4'^7;DW=N;,5B14]-&51(UDGGDAIH9IH_=>Z$F'9.T(=YUG8\>VL0
MF_<CMK'[.K-W-10/N*3:>,R-=F:#;/\`%&#U,6#I<ODZBJ%+&X@-3,TA4N=7
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M\=!TZ_Z`_P"89U3\JL!C\))08WK[Y\_'FBI-Q3Y,-DIZ>NJN_P#XS9KK7-:&
MDEIH7>NVMF)4A1W`E>R'W7NF2E^9W\WKK'<.WMN]W?RCL+VW@&I<M)N?MGX;
M?,+K#<N/$E)5TC44V+ZG[\Q?3>ZJ42XVH>].V6K)I9X6$1(95]^Z]TK<G_.D
M^-W7.(S^7^371'SP^)%-M7-T."W%D.[_`(7]VY+:&-ERF0BQF,R0[1Z3V]W!
MU/687(54Z"*HASC@AQ<`D`^Z]TJ=M_SPOY1NZ,'0[AHOY@OQHQ5!D8Y):>#>
M/8%%L'-*L5344DBUFW-[Q[?W!CY5GI7'CJ*6)[6:VEE)]U[H2\;_`#:?Y7.6
M\?V'\Q+X52F5X8XED^3'3]*TLE0VB%8TJMW0-(7?C@&QX/OW7NA9V3\\O@_V
M5D),1UY\QOBWOC+14M172XO:??O5>X,E'0TBXYZFMDH<7NJJJDHX%R]*6E*>
M,?<1\^M;^Z]T)-3\COCS15-=1UG?'3-)5XR.EFR5+4]H;(@J<?#6UAQ]'+70
M2YQ):2.KKP8(FD"B28:%NW'OW7NL&/\`DO\`''+5='C\7W_TID:_(OG$Q]#1
M=I[&JJVN?;$E9#N1:.EASKSU1V_+CJA:W0K?:F"3R:=#6]U[ICJOE]\3*"KG
MH*[Y0_':CKJ9VBJ:*J[LZUIZNGD4!FCGIYMS)-$ZJP)#`$`^_=>Z@1?-/X<S
MR5$,/RQ^-,LM),E-51Q][=7,]/4200U*0S*-TDQRO3U$;A38E74_0CW[KW6&
MF^;?PQK-?VGRZ^,-5XBHD^V[\ZJG\9?5H#^+=C:"^@VO];'^GOW7NHTGSG^$
ML-2M%-\Q/BQ%6.)62DD^0?4J5+K!,*>=E@;=PE80SL$<@>ES8\\>_=>ZZJ?G
M1\)*.NJL75_,7XKTN3H0YK<=4_(3J2"NHQ$P20U5)+NY:BG$;L`VM18FQ]^Z
M]TX+\TOAR^*CSJ?++XSOA)K^',+WOU:V*ETM2*WCR`W4:1]+5\`-G-C-'_JU
MO[KW65_F9\/XHDJ)/E;\;(X)*6.N29^\^KTB>BFA%1#5I(VZ0C4LM.0ZR`Z&
M0Z@;<^_=>Z?\5\HOC/G?M3A/D3T7F17%11'%=N;`R'W9:H%(HI?M-P3?<%JH
MB(:+WD.GZ\>_=>ZUROYW/P[^(?\`,>[CVH_9W>/6T6VNF/BSV;MZ3);3^7_1
MO66Z-A]J;[^1/QN&T<GN':V^]SQXO(8.EV+A-W56C)P+CZ^IHTI#-!7G'S1^
MZ]U8)_*LZ=Z5^)>-^;,.P^XNI-W="CM7I7(;`[-PW=&Q=[H_6/5_PP^-_1PS
M'9F4P>=JL7M//P[LZMRZ535?V8JF0U"1K$Z>_=>ZM&JOD)T%0[?PF[*WO#J"
MCVKN:AR>4VWN:J[+V93[?W!C,+44=)F,C@\S-FDQV6H,35Y"GBJ9J>22."2>
M-7*LZ@^Z]U$J/DG\=*2)YJKOWI6FACTB26H[3V+#%&6=8E#R29U535(X47/+
M$#ZGW[KW3O2]Y])5N/FRU'W%U95XJF$)J,G2]@[2GQ\`J*FFHJ<S5L67>FB$
M]96PPIJ8:I94479E!]U[K@W>_1Z2O`_<O5*S1B$R0MV)M!94%1#'4P%XSF`Z
MB>GF21+CU(P87!!]^Z]U/3N+J.6&GJ(^T^N)(*R6>"DG3>^V7AJIZ5/)4PT\
MBY,I/+3Q^IU4DH.3;W[KW3U2[_V)785MR46]=I5FW5KEQ;9^EW)AJC"KDGJ4
MHEQS96&M>A%<U9(L0A\GD,K!;:B![]U[J=_>O:XSE/M@[DP']Y:NE>NI=O?Q
MC'?QRIHHXUFDK*?$_<_?S4L<+J[2+&4"D$FQ]^Z]TC/].72A=XAW#U:98A,T
MD?\`I!VGKC6G#F=G3^+ZD$(C8N3^D*;VL??NO=9J3NGIROIUJZ'MGK.LI7+A
M*FDWYM:HIW,<CPR!9H<J\;%)8V4V/#*0>1[]U[IGK_D7\?,77U.*R?>W3>.R
M=%B/[P5F.K^S]DTE?28$3/3_`,;J:.HSD=1!B/N(F3[EU$.M2NJX(]^Z]T'N
M1^<OPIQ%304F5^7WQ@QM3E(LI/CH:[OOJNE>MAPE&,CF)J<3;J3R0XN@(FJ&
M'IBB.IB!S[]U[JI[^91\GOBO\A-Z_P`K+9'3WR+Z,[>W1B_YO'Q0W)6;6ZP[
MAV#O#<]'1[6VYVU65.3EPVVL_D,T,9CJVII15,D83QRZ93X6D!]U[K8']^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7_];?X]^Z]T#'<VY]B;;CZNBWUAX<T=R]S[`V
MQLV">FKJA*/?==55E7M_,(:.AKDIYL.N/FJ8Y)_#`KQ@&5'*7]U[H9_?NO=>
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M_#;MH,C'/2`)!-231T]1#[KW08_#GH;YE[_W/LKY.?S+\MU2O?/6.-WILOIG
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M55-36U^TZBIGGJ7`:1W8LY%R3[]U[I@D_EY?`*972;X.?#Z9)(VBD27XT=+R
M))$P8-&ZOLHJ\;!B"IN#<^_=>Z#&?^4;_*TJ*2CHI/Y=OPN%/04>8H*00_&W
MJ:GFAI<]$T.3055/M6*J9Y8W(C=G,E/>\)C//OW7NL6._E#_`,K'$S5510_R
M[?ABDU935=)4//\`'/JNM+P5Q)JU45NV:A8GJ+G4Z!7()YY/OW7NL$W\GW^5
M544"XV7^75\,FI5J:*K&GX[=7)4M-CYVJ*4/71[;6ND@61B'B:0Q2IZ'5D`7
MW[KW6>G_`)0O\JZE:H:'^73\+;U4CRS>7XW=3U`U/1PT!$0J-K2BGC%-3J`D
M>E%>[@!V9C[KW3S'_*E_EAQ/-)'_`"\/A*CU$"TTVGXO=+`20*S-XF3^YF@H
MS/ZA;U6%[V%O=>ZA-_*4_E;OYM7\NOX3_P"43+/+;XR=.K>1#(5*Z=H#QK>9
MO2ME/''`M[KW4:+^43_*PAC6*/\`ET_"H(BZ%#?&KJ-VTC\%WVHSM_KDD^_=
M>Z<4_E/_`,L".:&H7^7C\*O)3TAH8=7QEZ<>-*1HY8F@$+[/:$HZSN3=22SE
MCZB3[]U[J`W\HS^5D^K5_+I^%'K+%K?&?J!;ER2UM.TA:Y/X^GX]^Z]TTT7\
MG/\`E48S)XS,XW^7G\1,=EL-D*'*XK)4'1FPJ.MQ^1QE?%D\?5TE138:*6&6
MDK85=-)``4+;3Z??NO=$R^>G\N+^1]T;L+/][?(/^7KU?N.L[$W?M[JV#"](
M]2U];VSO_?G=>[HMLT%-L'9/762V_E\WONJR^XY*TUF+C_C--!!)/`^J!`/=
M>Z//\:/Y5?P`^).T.Y]C]`?&O9NQMG?(W9>T-A=T[:DDSF:QF_\`:.SMG9#9
M&*P^?H-Q93)1_P"6X7-5SY21%CGRM?75%76--4RM+[]U[I;;[_EO?`3LWJ/K
MKH7?OPY^.FY^F^H6R4G5?7&1ZHV@=K==2YMUESLVR\=!C(4VW/GIU$M?)2&)
MZZ4"2<R/ZO?NO=%WC_D6_P`G^*JJJM/Y=WQ@\M8TCS*_7E%)3(95E5Q2T4DK
MT="EIFLL,<:KQ8#2MO=>ZE)_(Z_E#)`E,O\`+O\`BV(8ZHUF@]9XHF28I"FF
MH=KO4TRB!2L,A:%6U,%#,Q/NO=3J3^27_*.HJ&NQ]/\`R[/B=]MD79ZDS]0;
M8JZD%PJL*6NJZ2>NQ\=EX6GDB4<V')O[KW20'\A+^3D*NKK?^&]/CMYJVNHL
MA,AVWD32)/0"T$=)CSE_L,?0R?[NI8(XZ:I_W=&_OW7NC6_\-X?!->C&^,L/
MQ$^/5+\?7W;0[^DZ@H>J]HT&PY=^8Z&DIZ3?$V!HL9!22[Q2GH(HVRC`UTD:
M:7E8$@^Z]T)<WQ6^-53W?%\E:CHCJBH[_I]CMUK3=P3[&V]-O^EV(\%11R;7
MI=QR4+9"FQ<V/JI*1UC=2]$YIV)@_;]^Z]T5/$_R;OY46%BJ(:+^79\/)155
ME17SR97H3KS/5+5-5%2Q3E:O.8/(U4<++1(1$KB)7+NJAI)"WNO=2\I_)[_E
M49FNILCD/Y=/PQDJJ2F%)3^#X[=7T-,D`DDELU#0[;IJ*677*W[CQM):PU6`
M`]U[K`/Y.7\J,4>0H%_ET?#1*?)TL]'6:/CUUFE0T%14I5RK!6)MY:RCD,\:
ME7ADCD0#2I"\>_=>Z;E_DN_RE5=I%_ER?#D,\$E.P'0O7_C,<LL$S?M?P7Q"
M4/3KIDMY$&I5(#N&]U[H:.F_Y<WP$^/&\<=V'T7\,/C%U-V!AX3!B-];"Z2Z
M]VWO+$Q/C6P\PQFY\;@(,WCVJ\8[0SM#.C5".WE+EF)]U[HYWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z_]??X]^Z]T6[Y+8NNRF)Z?&+W/C-L9''_(WI3*P/EL77
M96ESU+0;MAES>UHDH8)EH<EGMO?=PT55.T5/35GB=G!`#>Z]T9'W[KW7O?NO
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*W[KW7O?NO=?_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>g838054g44a20.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g838054g44a20.jpg
M_]C_X``02D9)1@`!`0$#P`/```#_[2AL4&AO=&]S:&]P(#,N,``X0DE-!`0`
M``````\<`5H``QLE1QP"```"````.$))300E```````0S<_Z?:C'O@D%<':N
MKP7#3CA"24T$.@``````Y0```!`````!```````+<')I;G1/=71P=70````%
M`````%!S=%-B;V]L`0````!);G1E96YU;0````!);G1E`````$-L<FT````/
M<')I;G13:7AT965N0FET8F]O;``````+<')I;G1E<DYA;65415A4`````0``
M````#W!R:6YT4')O;V93971U<$]B:F,````,`%``<@!O`&\`9@`@`%,`90!T
M`'4`<```````"G!R;V]F4V5T=7`````!`````$)L=&YE;G5M````#&)U:6QT
M:6Y0<F]O9@````EP<F]O9D--64L`.$))300[``````(M````$`````$`````
M`!)P<FEN=$]U='!U=$]P=&EO;G,````7`````$-P=&YB;V]L``````!#;&)R
M8F]O;```````4F=S36)O;VP``````$-R;D-B;V]L``````!#;G1#8F]O;```
M````3&)L<V)O;VP``````$YG='9B;V]L``````!%;6Q$8F]O;```````26YT
M<F)O;VP``````$)C:V=/8FIC`````0```````%)'0D,````#`````%)D("!D
M;W5B0&_@````````````1W)N(&1O=6)`;^````````````!";"`@9&]U8D!O
MX````````````$)R9%15;G1&(U)L=````````````````$)L9"!5;G1&(U)L
M=````````````````%)S;'15;G1&(U!X;$!U0BT0````````"G9E8W1O<D1A
M=&%B;V]L`0````!09U!S96YU;0````!09U!S`````%!G4$,`````3&5F=%5N
M=$8C4FQT````````````````5&]P(%5N=$8C4FQT````````````````4V-L
M(%5N=$8C4')C0%D````````````08W)O<%=H96Y0<FEN=&EN9V)O;VP`````
M#F-R;W!296-T0F]T=&]M;&]N9P`````````,8W)O<%)E8W1,969T;&]N9P``
M```````-8W)O<%)E8W12:6=H=&QO;F<`````````"V-R;W!296-T5&]P;&]N
M9P``````.$))30/M```````0`\`````!``$#P`````$``3A"24T$)@``````
M#@`````````````_@```.$))300-```````$````'CA"24T$&0``````!```
M`!XX0DE-`_,```````D```````````$`.$))32<0```````*``$`````````
M`3A"24T#]0``````2``O9F8``0!L9F8`!@```````0`O9F8``0"AF9H`!@``
M`````0`R`````0!:````!@```````0`U`````0`M````!@```````3A"24T#
M^```````<```_____________________________P/H`````/__________
M__________________\#Z`````#_____________________________`^@`
M````_____________________________P/H```X0DE-!`@``````!`````!
M```"0````D``````.$))300>```````$`````#A"24T$&@`````#-0````8`
M`````````````DD```'T``````````$``````````````````````````0``
M```````````!]````DD``````````````````````0``````````````````
M```````0`````0```````&YU;&P````"````!F)O=6YD<T]B:F,````!````
M````4F-T,0````0`````5&]P(&QO;F<``````````$QE9G1L;VYG````````
M``!"=&]M;&]N9P```DD`````4F=H=&QO;F<```'T````!G-L:6-E<U9L3',`
M```!3V)J8P````$```````5S;&EC90```!(````'<VQI8V5)1&QO;F<`````
M````!V=R;W5P241L;VYG``````````9O<FEG:6YE;G5M````#$53;&EC94]R
M:6=I;@````UA=71O1V5N97)A=&5D`````%1Y<&5E;G5M````"D53;&EC951Y
M<&4`````26UG(`````9B;W5N9'-/8FIC`````0```````%)C=#$````$````
M`%1O<"!L;VYG``````````!,969T;&]N9P``````````0G1O;6QO;F<```))
M`````%)G:'1L;VYG```!]`````-U<FQ415A4`````0```````&YU;&Q415A4
M`````0```````$US9V5415A4`````0``````!F%L=%1A9U1%6%0````!````
M```.8V5L;%1E>'1)<TA434QB;V]L`0````AC96QL5&5X=%1%6%0````!````
M```):&]R>D%L:6=N96YU;0````]%4VQI8V5(;W)Z06QI9VX````'9&5F875L
M=`````EV97)T06QI9VYE;G5M````#T53;&EC959E<G1!;&EG;@````=D969A
M=6QT````"V)G0V]L;W)4>7!E96YU;0```!%%4VQI8V5"1T-O;&]R5'EP90``
M``!.;VYE````"71O<$]U='-E=&QO;F<`````````"FQE9G1/=71S971L;VYG
M``````````QB;W1T;VU/=71S971L;VYG``````````MR:6=H=$]U='-E=&QO
M;F<``````#A"24T$*```````#`````(_\````````#A"24T$%```````!```
M``$X0DE-!`P`````'@0````!````B0```*````&<``$!@```'>@`&``!_]C_
M[0`,061O8F5?0TT``O_N``Y!9&]B90!D@`````'_VP"$``P("`@)"`P)"0P1
M"PH+$14/#`P/%1@3$Q43$Q@1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P!#0L+#0X-$`X.$!0.#@X4%`X.#@X4$0P,#`P,$1$,#`P,#`P1
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#/_``!$(`*``B0,!(@`"$0$#
M$0'_W0`$``G_Q`$_```!!0$!`0$!`0`````````#``$"!`4&!P@)"@L!``$%
M`0$!`0$!``````````$``@,$!08'"`D*"Q```00!`P($`@4'!@@%`PPS`0`"
M$0,$(1(Q!4%181,B<8$R!A21H;%"(R054L%B,S1R@M%#!R624_#A\6-S-1:B
MLH,F1)-49$7"HW0V%])5XF7RLX3#TW7C\T8GE*2%M)7$U.3TI;7%U>7U5F9V
MAI:FML;6YO8W1U=G=X>7I[?'U^?W$0`"`@$"!`0#!`4&!P<&!34!``(1`R$Q
M$@1!46%Q(A,%,H&1%*&Q0B/!4M'P,R1BX7*"DD-3%6-S-/$E!A:BLH,')C7"
MTD235*,79$55-G1EXO*SA,/3=>/S1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&
MUN;V)S='5V=WAY>GM\?_V@`,`P$``A$#$0`_`.N^K7U8^K5_U<Z5?=TG"LMM
MPL=]EC\>ISG.=4QSWO<ZOW.<Y:/_`#3^JO\`Y38'_L-3_P"DT_U4_P#$OT?_
M`,(XW_GFM:J2G)_YI?57_P`IL#_V&I_])I?\TOJK_P"4V!_[#4_^DUK))*<G
M_FG]5?\`RFP/_8:G_P!)I?\`-+ZJ_P#E-@?^PU/_`*36LDDIR?\`FG]5?_*;
M`_\`8:G_`-)I?\TOJK_Y38'_`+#4_P#I-8O6_KUCNPKQT2]K;*7U_:,JVISF
MLP['_9;NL8-/M_:5&)D>S]%^A_ZU_.9[<7ZU9G5L3.SL!W57]+W8K0ZS[%3Z
M]=K;<;KU4/L9;3EX-NR]E%-^RZFZKT/\&DIZ)O0_J*XW!N!THG&>*[XIQSZ;
MW&&5W>W]'8[=]!ZD?J_]21BG,/3>F?90W><CT*/3VC\_U=GI[/Y2Y+!_Q?Y5
M_1[\2N_#RJ[:F8U>=7:Z+*J\RO/]^+1CLIJL])MWJ.LR,_(^T_H_M-="W_K;
MTH#%Z771T\Y71,')]7.Z9B,;N<QK'_9MF+^C9?15DN:^_$;_`#W^C2200:.A
M#HT?5KZG9-++\;I73;J;!NKMKQZ',<#^<Q[&%KE/_FG]5?\`RFP/_8:G_P!)
MKF\+K[NG]8.!T7HXQ>G69..,RDLL;=ZV97CO>_T:!=1T[[)1;4^UF4VC'R_1
MROLV1ZM-BZ#I/UJZ?U/(=77%=5EUE'3KG.$9GH-W9EN&SZ3Z,=^YGJ_S:2$G
M_-/ZJ_\`E-@?^PU/_I-+_FE]5?\`RFP/_8:G_P!)K6224Y/_`#2^JO\`Y38'
M_L-3_P"DTO\`FE]5?_*;`_\`8:G_`-)K6224Y/\`S2^JO_E-@?\`L-3_`.DU
MX)Z5/^B9_FC^Y?2*^<$E/__0]`^JG_B7Z/\`^$<;_P`\UK565]5/_$OT?_PC
MC?\`GFM:J2E))))*4N5ZZ,GI_P!:,;KEW3[^J8+,4XU'V5IOMQ;R]S[;VX?[
MN91Z=+\JK])^@]*SV?SO5)CQX)*>1Z!]4L6[,_;W4J75Y-IM?5TRPM<W';>T
M8>RR/TEF_IM./3]DM?\`9<3]-7CT_N=!US.'3^CY>6#M=54[T_ZY&RD?]N.:
MN1'5Z>A].MP\?(I=U>V]_P!LRF'UG.9[]MWK`/8V]OM:VB[?_A?T2YK,ZEU'
MJ!:<[)LR-FK`\B&D_NL9#-R;GE&!(A(3&HX@>W@Z'PWX?EY@B>6$L,8F,I1R
M1G^LC+]''*48PG\OK_<9=/SK^FU^I@WOQ\J1]`G:X`Q^DK(--C=G^D738/\`
MC%N90YO4,3UKFCV64$-:X_\`"LL_FOZ]?J?\4N/CMR>P5G=T[]G%AKM'419/
MJ3["R?HEL^W:S^1O]50<9TJHT.GZ7B?ZSNYN2P3LY83SG)DOB_3P\?Z/%'VY
M1Y:'#\GZQZG!R^F_7'(S,/J.,W"RK:175D8[HO=C;VOR<1V4YFYS'_0M8UGO
MQ[[_`.6MSZN?5UW30[-SS7=U:YC:GV5-VTT4,_F.F]-J/]'P,?\`[<R+?T^1
M_P`'Y@6M<(<`1X%>B_4K'^Q=`ILC??GO=:UD_F_0K]WNVUMJ8VQ_]?\`TBDQ
MS)/"=?%ROBGP_%@C[V.7`)&,(X:O6M^/B_JO3)+A\KZO?65CK\QUN5FMR,^Z
MS]FT9;\<BAO[1^Q6_:WY7Z/W9'3?T6+]GKKHQJO4Q,F^I:+,7ZU4683<XNZA
M7]BNQLI^%9Z#A:YF&69%GVF^KU;_`%:,UM.30RKT_6_FJ5*X[TZ2S?JVSJ-?
M0L&KJC7LSZJ6UY/J/%KB]GZ-UCKF.L;9ZNWU?I_UUI)*4OG!?1Z^<$E/_]'T
M#ZJ?^)?H_P#X1QO_`#S6M597U4_\2_1__".-_P">:UJI*4DDDDI2Q/KA7=;T
M2ZK'R#1=!>&M=M-C&#==07?NOJ_\@MM<3_C"?U2A]%K+7-Z?:QU+V,`$//O<
MVQ_TG>O6/9_Q3TS(:B6UR&.63FL48F,9"7$./Y9<'JX7BA$"-!V5K&_9OV7*
M&5Z@RMH.(YD[=T?1>![?<[_2?F(-M-E)`>`)X@^"CL?L+]IV`P7=I4!C*)(,
M2"-XD;/5>YBRXXSAE'!,QX,F.<?7+C^2,_TN.4?;E#_`4Q[F/#V\M^[B%)V^
M^TEK9<[7:-=``W\Y03ML=6=[3M('.AT^<HQEM&1/M\0E(1_Z0_K*R8O5+-CA
M`\S[9Q8YY+`X;XXXYRAZ_:]Q;@Z@Z'W#@Z'W-_DKO?JITLON9U/$]7"Z6&D4
M8A=K>]T^IE9.K_T?YM.Y^^ST_4_14>RWB+L7(HM8W,K?0;??+Q!()U=_K]!=
MS]0,T/Q,KIX>7LQ'M=5)F&6@ES6Z-]C;F6HXXZV:WK?U7\WR_-PN?\6R7AO&
M3+TF1D!*?+^W.4<4O7_,^]Q?S?\`E/;]YZM)8>9]:\;&ZY^PJ\:[(S37OK##
M6&N<:[\EE/Z6VMS=]>);^D?^BW^E_I%6/U]Z)7TS&ZCD;Z!DR30\U^K6/3R,
MG'?=6+?:S-KPW?8G_P#:CU:58>;>E26/T?ZRXO5LR[#JILJ?311DS8:S->2W
MU*MS:;+7U6_OU6_\9_A%L)*4OG!?1Z^<$E/_TO0/JK_XE^C_`/A'&_\`/-:U
M5E?53_Q+]'_\(XW_`)YK6JDI22222E+ANO\`4LWZPXUN-@LQZNGMM(IR;R][
M[G4NV.OH;C_HZ,;U&74LLL]=]]?Z7T:_T:[E>>=)#<6EO1;7L'4.FC[-=0"`
M\[/YG(KK=%CZ<K']+(K?M_PGI_SB=",9$B7;90R3QRC.!X91(E&7[I#A7=*Z
MW4?TN,<AHTWX]@M`'_%6>EE?YF.JGVD!PQ+7_9G3/HY`]%TSN^C>*['>[\QJ
M[8@M,.$'P*9X;;6:K0+*CS6\!S3\6/W,1/*Q_1,HWH=>G[K>A\;YB@,D,6;A
M/%"4X>J&0?+DCP^CCC_<>/OH=37ZKC^C'+C[?_)*MD9W3RZ,8FT$:AC7.$^&
M_P"A_6_2+I<GZK]`R';SB-HL'T;,<FHB?W:F_JW_`(`J-_U0L$G#SI\*\FL'
M_P`'QO2_]M4Z'*XM1(D1-?*!*0X?]9+U1_Q%3^.<UZ)1$3D@)BS*4<>3W.'Y
M^7Q\&.<\?!^KGQ>ASFY]_4;`W(M>;:F^QN0=?3GW/8YN^MS6?X;W^JNQZ']5
M_K#TK.KOK?4&Y#35?94[=Z=1+7E\7,;OO_T'Z.VO_2^Q</F])ZMBY6-0^K]-
M<]WH68\W,=M8\WLC;7;_`#1_25V5U_H_YM>D?4+JN7E=-LZ=U"I].;TMS:GA
M[7-FMS?4QG^\-=_-?]!1Y,>+%G'`?<CP\7KU]1XOFCZ%QY[FN8Y"0GPXAQ^W
M(8H>W^K'MS]$N.?Z?S_W_P"^Z3_JMT*RU]S\;=;;4:;7E]DO:YMM+GV^_P#2
M9'I9637]K?\`K6R^W],K-O1>E6U4TOQF>GCM+*6-&T-::K,+8-FWV?9;[:=J
MNI($DFRYX%"AHT,'H?2NGY#LG$HV7.J;0'N<]Y;2S^;QJ/5<_P"SX[?I>A1Z
M=6_WJ^DDDI2^<%]'KYP24__3]`^JO_B7Z/\`^$<;_P`\UK565]5/_$OT?_PC
MC?\`GFM:J2E))))*4O!"79F_(S6BS(OL?;D;VB?5<YQN]OYNU_L7O:\RZ_TO
MIG4NL9>3TK&R6L;:YF597=5CU77L);DOPZ\G%S'OL]7]'D7_`*OBV7UV_P`[
M;ZMREQ<UAY<F>8B,".&S6_\`A+,F&>4"./Y@;>;QLWJ.(`,7,OJ8WBLO]2L?
M]9R?6I;_`&6+0POK;U6RT8[<>KJEO>O&98V[_-QFYE?_`++5K<Z;A?47"`=U
M7I>:VRL2;>H,=EU&?_"#LOI[?[=-*U_J?];^E9F+?C.]##.*'W,KJ#6U^@)L
M]K*OHV8S/;:S;_PG^D]-T^>P3UQ0B0=IQEZ/LQ^A=BY'F#&4B2>"N*%?K/5^
M[Q^N3B.^L%&.]M74\/+Z9:YH?MOJWB#^=..;;=O_`%A6\3J73LT[</+IO?\`
MZ-CQZGSH=MN;_P!MK=K^L'U>ZAT7]K=5;1314^UNW*V$MVGVL;ZO^&MI])_I
M5_U%D]/ZQT7J_2JJ[N@OZA^DM]''KPV^C6QSW/KV968W%P&_HW>]]>1_.*$<
MR1\U<)U!^7_&9\O*QC$Z2ADQR&/)"9C+UZ_S?RR_109-UE74>FUU5VVY-.0,
MVRFAI=:W&J9=5DY'I#:[TW?:/L^S^<R?5]+&KR+?T2WL3*HO^M@R,.QMN-G]
M+9:7L@M<*;G?9[)_E-S;D'H&7T+IMS\`=-_8.3;4[((M],MNKJ)]1[<ZBR^N
M[[(U^ZRFZWUJ*K-_I>A^D53ZI68]GUEZIE45OKQ.HTUY/2Q8"/T`LO;F6U,>
M-U-.;G6?;JF?X6K)KR/T7J>FE*?&>(;>#`(T*>Q22202I))))2E\X+Z/7S@D
MI__4]`^JG_B7Z/\`^$<;_P`\UK565]5?_$OT?_PCC?\`GFM:J2E))))*4O-N
ME7/Q<&GIGV7(OS\)HQ\K'QZG6%MC2YCGVWG9BU-R-GVFI]V0SU:K?67H]C2^
MMS6N-;G`@/;$M)_.;O#V;F_RV+E?JJUH^KV$_4W7-=;EN=]-V4Y[_M[K9_PO
MVOU:W_U-BI\_AAEA$3XO3*QPFNGZ3/R\Y0),2+(K5J5X?UBO,LQ\?`;/T\FT
MW61X_9L#]%_\,4]GU.Q,Y[;.LY#\]X.X-KKKQFZ?1;ZE3;>H?_#!=!'M+SHU
MNI<=``/%RRLCZT]`H>:QF-R;0"?1Q`[)?ISN^R-M97_UU]:J8L$(&\6,`_O5
MQR_QI\7"S2G*1J4C+^K_`.@Q38/0.A]/>VS#P**KFZMOV!]L_P#AF_U<C_P5
M7R2=7$D^)7,Y?UR?39Z0P'8!=HR_JSG8M;CXU^A7EUVM_P#0JA(7]8SJ_4=U
M0-H<(CIM;*V_^Q=YZA?_`-M64)9\D<7\](Q/B)2M$(F?R"_J&[]8Z<+*NZ/@
MYC:WB[/;:*[2`PU4U7NRG/:[Z=6U]=#FN_1V/OJJ6G01D_7'*M806=/P:\=Y
M$_SN18[)=7N^CNKHQ\:W_P!":UPGUEP\2C%H<R7YU^0W;?D/??:YC&6>MOMO
ML=>ZAC'_`,TRQE/K6U+1_P`7(OKZK;C5VV?9_1?=:R?:ZPNJK;8]GT/4V_N_
MF5^G_-L5KD\\9XP8@\)D0.+0^?Z3++D)2PY,QE7M7Q?N'2)X8R^;C]7[CZ,D
MJS>I]-=Z>W+I=ZKS75%C3N>WZ55?N]]C?W$9]U+-^^QK?2;OLD@;6>[](_\`
M=9['^[^0KKG,TDP((D<)TE*7S@OH]?."2G__U?0/JI_XE^C_`/A'&_\`/-:U
M5E?57_Q+]'_\(XW_`)YK6JDI22222E+BOK>RKH9?D],R,G!R>IO+WU4BHXYL
M;_/Y3F95&1Z.38QWO^R.H^T/_37?Z1=F][*V.LL<&L:)<X\`!<5]?NKN];%Z
M?6S=4PC(L>1$O@BFICR/:]C'>J__`*VF9*X:/4@:CB;7(8O<YB,>#W`!*1AQ
M<''P1^7B_O/%9(=F$/SK;<YPX.18ZZ)_<9:YS&?];:K=^)F])R*FVL%-H;O8
MT$.&TRPM=L_S'L073D7&&@%^I';0:EQ2N=<ZP^N]UEC?;N>XN,#Z(#G>[8H3
M$T3J8WPQGM%Z;%P"4<48XL,CC]S-RPX3DX9^B/R</ZOW/<QRR<'ZQLY'5<F^
MDT_081M=#G.]O[C=WT&*FYH<*_3K;2^@&+\9OHW$?\/D8WIV6;?^$5K"'2S5
MD'.=:+0W]6%0T+H/TOY6[;_.?H]BKU6VU@AA@O`!@3K_`"?Y2`K](D`C7A]7
M_-]*I8H&,H0P1D<<@8C..'#(S^>4,G!F^7'_`%/YS]6V>GXV%EOL&7=D7=2N
MV483G.-A)<?;7ZE[MC&NL=_-O?57^?\`SB]"^KOU9'1&V.;?OMOV&XEH.C)B
MJMWM]GO?[MBX#'Z+UBS);37B6NMKV6E@+0X-)]C]7MV_S;EW_1,[J6-0*.O-
M?5=8]QHNM+"UPC?Z3GT.>QEC??L]3Z=?T/YM2X,8(.P,*J/6M>+_`!''^+Y1
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MY6+8V['N:'UV,,AS3W",DI2^<%]'KYP24__6]`^JG_B7Z/\`^$<;_P`\UK56
M5]5/_$OT?_PCC?\`GFM:J2E))))*0Y>,W*QWT.):'CD=B#N"YWZW8V'C]"OR
M>H1?DN+64:N8TW']%5:UN[^<KK_2/_P?L74*AE]4Z4S.JZ5E6-=DWUNN%!:7
M@5,]KK\@AKJ\>G?^BKLR/39;;^BJ_2(2%@CNR8,@QY89"">"0E43PGT_UGRX
M8^*WIHS&Y?ZWZFQN,!J!.KR[Z7\W[]_\W_@D"IANM+=T.@N<3J=/+\Y=+]>^
MCX.!D8V7AU"@96]MU;(#-S`TL>RL?0<YI=ZFW_JUS[LIN3AXO3Z,9ANKL,6L
M,V6O>=K&<?G.>W\]5](RJ0N,2"8@D<?U_1XGJ,>2>;E_=PR(EGXQ'+..,_<X
M^OA]'H]['ARQ^3]-A1B9.1><?'K-MHW>UO@W1SO=M34X]][@VIA/O967'VM:
M]YVU-LL/\UN<WVK9ZCT#K?U:;7GU636Y@9;=4`16YT;JK6/W_H?4_FK_`/ST
MC?42UAZS?B7@65YN.\/8\;@YS7!_O#OI;F/N0K4#4$GK^"Z7-'V<F?&89<<(
M@P,>+BXX_P`]QQ_1]/R1<ZZ_K?3>L,L?:Y_4*&MV/;-FZN/H.:T->ZIW^$:]
MO_DUZ'TW/Q^O]+=ZU+Z7/;LR*+&D%KC^<SU6[7M_/IL_]&*A=3]7/JIF.S6L
MM=E]1_18^'2UU]KM@];(^RX[-]WI[6MMR'?S-7IU?S:VNF=4P.K85>?TZYN1
MBV_0L;(XT+7-=M>Q[?W'J:$)1)-UX;_\YP>>YS#GA",<8XH1B/=`]KIZX>SZ
M_1_U1Q.F?4?"P*,7'=DVW4XMCK_3`;6UUIHKZ;3=-+6VUV8^-6]^^JWU/MEU
MF7O]3TTUWU&P'9K^H47V,RW>H&V6Q?+;,>GI_I9'VC?;DU-KQ_4_26^H]]MG
MZ5=,DI'/:71^F5])Z7C=-KMLOKQ*Q4RRTR\AOT9C;]'Z#/Y"NI))*4OG!?1Z
M^<$E/__7]`^JG_B7Z/\`^$<;_P`\UK565]5/_$OT?_PCC?\`GFM:J2E))))*
M6,P=I@]CSJO/NH_5GK=%?4+78QZK70QN7:;"W?U;-`#JSET4N+V]+Z3_`-I.
MBL]*NY]?^&7H222GSK"MZT_I&7G=6Z6[JO3NG7&[%9F765W"MK7/SK:OMF/5
M;G8G_<*K/JKOV>I19=;Z52ZE]_U9KZ=A_66ZFO'QVU4V8^0:X>QF0&58["RD
M.=_VH8S;_@D_6OJT[JUE@/4LO&Q,IC:LW#J<WT[&-W:5FUEEF)ZN_P!/)^S/
M9]II]EBEU?ZO'J%6%AT9/V/IV&^IUF$RMCF6BBRB['I>YWOJJJ;CO9LJ_P!)
M_P`%Z:'"-Z"\9<@`B)R$0"`+-5+YO\9C?];/J\?M>,;77VXTUVXK:;7/L/J?
M8G5XU7I?KOZS^KV?9_5K8_\`G5R(ZE]6NG7V=7Z/3:3BLJS1ZCR)P[;7]/ZA
M9A8T_P`]@6[Z?0S?3_2?O_H]_24?4^VOJEO4G=2M=<&Y#<*PAS[*?M#FOESL
MN[*Q[_L[&>A17]DHK]+^=]6W]*K5'U0Z(RG%;ET_M"[#MMR*\C)ASS=D.-V1
M:YK!73[[';MGI>FS]'_A&)&()!(V3#-DA&483E&,Q4Q$T)C^L\_]4:?K&WKN
M4_/JLS-K'-'4[[)QWM>77TY?3?Y__E"<>N[#P?LF)A8V%1Z_VC*]*M=']6>C
MY72\;*?FOJ=F=1R7YN2W'!;2VRP,8YE&_P![F_HMSK+/TEEBUVM:QH:T!K6B
M&M&@`'8)T6-22222E))))*4OG!?1Z^<$E/\`_]#T#ZJ?^)?H_P#X1QO_`#S6
MM5<Y]6>O]"I^K?2J;NHXM=M>%CM>QU]8<UPJK#FN:Y_M<U:7_.3ZO?\`EIA_
M^Q%7_DTE.BJ/6.L8?1\/[9F$AA>RJM@+0Y]EAV5UL-KJJF[OW[;*ZF?3LLV*
M'_.3ZO?^6F'_`.Q%7_DU3ZIG_5+JN(<7+ZEBE@<VRM[,IC+*[&'?3?1=78U]
M5U3_`*#VI*9#ZW=)?T+&ZY3ZEN-FO93CUM:!8ZU[_L_H.]5]=%>RYKV/MLO^
MS?\`#_06ATGJ5/5NG4=1QV65TY3?4K;:W:_:3[7%LN^FWWL_D+E>MX'U9ZCT
M^K$JZ_CA];J=[\K*^TBUM#KKF5W?K5%S766Y#M^11=5?L_1?S/Z-$Q<?H5->
M`+OK.R^_%?39EWG*:TY'V9MS<>IS&Y'ITT[\C=>W;;]J]&O[2^VW].DIEG_7
MJ[#^LF3T?[+5;5CN97I:1D$OQG=0^U?9S7M^Q4>GZ.5;ZGZ'^<]_\TB](^NO
MJ/IKZ\S&Z:,O!KZEC9(O'H^E8YM?H7NR6X_HY3'6T_0]:JW_`$GZ-6VY/U,%
M_4+_`-H8ALZLUK<T_:F0\,K^S,`;ZOZ/]#[?T:K=+J^HG2Y./GXMKS4S'#\G
M+;>YM-9WTXM/VFZST<>M_N]&G8S_`#$E,LKZV9M70>J=5HP6W/Z9E9..:S;L
M;Z>,Y[/M#W.;N_,_F:UI=;^L.%T.JF[.9::[RYK'UMWC>UCK64<M_2Y.ST\;
M_26K&MPOJ-:S,J=U9K:.H6.MR:&]1<VLNL<ZV_;2S(%;&WN?^E:C9]?U(ZEB
MX^)U#J5&73BM>VMMV:'RY[#1Z]I==^FR:V.?Z&19^DH>_P!2G](DI']:_KGD
M=`R,:NO%98VVA^38+GN8Z&.JJ]!CJ:LFNNS]-_.Y#F8W_"JP/K)F8_7K\#J0
MPZ.G4T'*=G"YX%=;[/L^"W*??35C5Y&5^;5Z_P#@W_\`!^H+J5?U)ZH:G9G5
M*G.JI=C.+,_TS92_;ZM&2ZF^MU]=OIM]3?\`35C%R/J5B79=U.;@A^>:SD3?
M40X5,%./7L+]K:J:V_HJTE-!_P!?ZAU)O3F4!][^J5X#(+]AQ[&,M;G-R/2^
MSNL]_LQO5^A[U=^J7UFR>NV]1IR*J6.Z?:RL64/>6NW@OV^CE58V77Z4;/6L
MHKJR/^T_\VAV-^HUCMS\_%)^W#J?]+:/UIK12VW^=^CL;_-?S:GTBWZH=)??
M;1U:FZ_*+?7R,G-%]CA7N]%GJ76N]E/J/V)*>C26=_SD^KW_`):8?_L15_Y-
M+_G)]7O_`"TP_P#V(J_\FDIT5\X+W[_G']7CI^U,/_V(J_\`)KP#<S]YOWA)
M3__9.$))300A``````!5`````0$````/`$$`9`!O`&(`90`@`%``:`!O`'0`
M;P!S`&@`;P!P````$P!!`&0`;P!B`&4`(`!0`&@`;P!T`&\`<P!H`&\`<``@
M`$,`4P`V`````0`X0DE-!"(``````7Y-30`J````"``,`0```P````$!]```
M`0$``P````$"20```0(``P````,```">`08``P````$``@```1(``P````$`
M`0```14``P````$``P```1H`!0````$```"D`1L`!0````$```"L`2@``P``
M``$``@```3$``@```!X```"T`3(``@```!0```#2AVD`!`````$```#H```!
M(``(``@`"``SYI```"<0`#/FD```)Q!!9&]B92!0:&]T;W-H;W`@0U,V("A7
M:6YD;W=S*0`R,#$U.C`S.C`S(#$V.C$X.C`X``````20```'````!#`R,C&@
M`0`#`````?__``"@`@`$`````0```?2@`P`$`````0```DD`````````!@$#
M``,````!``8```$:``4````!```!;@$;``4````!```!=@$H``,````!``(`
M``(!``0````!```!?@("``0````!``````````````!(`````0```$@````!
M.$))30/]```````(``````````#_X0&`34T`*@````@`#`$```,````!`?0`
M``$!``,````!`DD```$"``,````#````G@$&``,````!``(```$2``,````!
M``````$5``,````!``,```$:``4````!````I`$;``4````!````K`$H``,`
M```!``(```$Q``(````>````M`$R``(````4````TH=I``0````!````Z```
M`2``"``(``@```/``````0```\`````!061O8F4@4&AO=&]S:&]P($-3-B`H
M5VEN9&]W<RD`,C`Q-3HP,SHP,R`Q-CHQ.#HP.``````$D```!P````0P,C(Q
MH`$``P````'__P``H`(`!`````$```'TH`,`!`````$```))``````````8!
M`P`#`````0`&```!&@`%`````0```6X!&P`%`````0```78!*``#`````0`"
M```"`0`$`````0```7X"`@`$`````0`````````````#P`````$```/`````
M`?_A09UH='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O`#P_>'!A8VME="!B
M96=I;CTB[[N_(B!I9#TB5S5-,$UP0V5H:4AZ<F53>DY48WIK8SED(C\^/'@Z
M>&UP;65T82!X;6QN<SIX/2)A9&]B93IN<SIM971A+R(@>#IX;7!T:STB061O
M8F4@6$U0($-O<F4@-2XS+6,P,3$@-C8N,30U-C8Q+"`R,#$R+S`R+S`V+3$T
M.C4V.C(W("`@("`@("`B/@H@("`\<F1F.E)$1B!X;6QN<SIR9&8](FAT='`Z
M+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/@H@("`@
M("`\<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@("`@("`@("`@("!X
M;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+VUM+R(*
M("`@("`@("`@("`@>&UL;G,Z<W1%=G0](FAT='`Z+R]N<RYA9&]B92YC;VTO
M>&%P+S$N,"]S5'EP92]297-O=7)C945V96YT(R(*("`@("`@("`@("`@>&UL
M;G,Z<W12968](FAT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]2
M97-O=7)C95)E9B,B/@H@("`@("`@("`\>&UP34TZ1&]C=6UE;G1)1#YX;7`N
M9&ED.D1%145%1D$T14%#,44T,3$X0T-&1C%#-D)#,4-$-C<U/"]X;7!-33I$
M;V-U;65N=$E$/@H@("`@("`@("`\>&UP34TZ26YS=&%N8V5)1#YX;7`N:6ED
M.D4P145%1D$T14%#,44T,3$X0T-&1C%#-D)#,4-$-C<U/"]X;7!-33I);G-T
M86YC94E$/@H@("`@("`@("`\>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/CDT
M-40P.#A!-S$U-D,X-40X1D$V,C1"1$5%0D(V0T4U/"]X;7!-33I/<FEG:6YA
M;$1O8W5M96YT240^"B`@("`@("`@(#QX;7!-33I(:7-T;W)Y/@H@("`@("`@
M("`@("`\<F1F.E-E<3X*("`@("`@("`@("`@("`@/')D9CIL:2!R9&8Z<&%R
M<V54>7!E/2)297-O=7)C92(^"B`@("`@("`@("`@("`@("`@(#QS=$5V=#IA
M8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*("`@("`@("`@("`@("`@("`@
M/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#I$1$5%149!-$5!0S%%-#$Q.$-#
M1D8Q0S9"0S%#1#8W-3PO<W1%=G0Z:6YS=&%N8V5)1#X*("`@("`@("`@("`@
M("`@("`@/'-T179T.G=H96X^,C`Q-2TP,RTP,U0Q-CHQ-SHU-2TP-3HP,#PO
M<W1%=G0Z=VAE;CX*("`@("`@("`@("`@("`@("`@/'-T179T.G-O9G1W87)E
M06=E;G0^061O8F4@4&AO=&]S:&]P($-3-B`H5VEN9&]W<RD\+W-T179T.G-O
M9G1W87)E06=E;G0^"B`@("`@("`@("`@("`@("`@(#QS=$5V=#IC:&%N9V5D
M/B\\+W-T179T.F-H86YG960^"B`@("`@("`@("`@("`@(#PO<F1F.FQI/@H@
M("`@("`@("`@("`@("`\<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E
M(CX*("`@("`@("`@("`@("`@("`@/'-T179T.F%C=&EO;CYC;VYV97)T960\
M+W-T179T.F%C=&EO;CX*("`@("`@("`@("`@("`@("`@/'-T179T.G!A<F%M
M971E<G,^9G)O;2!I;6%G92]J<&5G('1O(&%P<&QI8V%T:6]N+W9N9"YA9&]B
M92YP:&]T;W-H;W`\+W-T179T.G!A<F%M971E<G,^"B`@("`@("`@("`@("`@
M(#PO<F1F.FQI/@H@("`@("`@("`@("`@("`\<F1F.FQI(')D9CIP87)S951Y
M<&4](E)E<V]U<F-E(CX*("`@("`@("`@("`@("`@("`@/'-T179T.F%C=&EO
M;CYD97)I=F5D/"]S=$5V=#IA8W1I;VX^"B`@("`@("`@("`@("`@("`@(#QS
M=$5V=#IP87)A;65T97)S/F-O;G9E<G1E9"!F<F]M(&EM86=E+VIP96<@=&\@
M87!P;&EC871I;VXO=FYD+F%D;V)E+G!H;W1O<VAO<#PO<W1%=G0Z<&%R86UE
M=&5R<SX*("`@("`@("`@("`@("`@/"]R9&8Z;&D^"B`@("`@("`@("`@("`@
M(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@("`@("`@("`@
M("`@("`@("`\<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B`@
M("`@("`@("`@("`@("`@(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z1$5%
M145&031%04,Q130Q,3A#0T9&,4,V0D,Q0T0V-S4\+W-T179T.FEN<W1A;F-E
M240^"B`@("`@("`@("`@("`@("`@(#QS=$5V=#IW:&5N/C(P,34M,#,M,#-4
M,38Z,3<Z-34M,#4Z,#`\+W-T179T.G=H96X^"B`@("`@("`@("`@("`@("`@
M(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I
M;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@("`@("`@("`@("`@("`@
M("`\<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@("`@("`@("`@
M("`@("`\+W)D9CIL:3X*("`@("`@("`@("`@("`@/')D9CIL:2!R9&8Z<&%R
M<V54>7!E/2)297-O=7)C92(^"B`@("`@("`@("`@("`@("`@(#QS=$5V=#IA
M8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*("`@("`@("`@("`@("`@("`@
M/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#I$1D5%149!-$5!0S%%-#$Q.$-#
M1D8Q0S9"0S%#1#8W-3PO<W1%=G0Z:6YS=&%N8V5)1#X*("`@("`@("`@("`@
M("`@("`@/'-T179T.G=H96X^,C`Q-2TP,RTP,U0Q-CHQ.#HP."TP-3HP,#PO
M<W1%=G0Z=VAE;CX*("`@("`@("`@("`@("`@("`@/'-T179T.G-O9G1W87)E
M06=E;G0^061O8F4@4&AO=&]S:&]P($-3-B`H5VEN9&]W<RD\+W-T179T.G-O
M9G1W87)E06=E;G0^"B`@("`@("`@("`@("`@("`@(#QS=$5V=#IC:&%N9V5D
M/B\\+W-T179T.F-H86YG960^"B`@("`@("`@("`@("`@(#PO<F1F.FQI/@H@
M("`@("`@("`@("`@("`\<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E
M(CX*("`@("`@("`@("`@("`@("`@/'-T179T.F%C=&EO;CYC;VYV97)T960\
M+W-T179T.F%C=&EO;CX*("`@("`@("`@("`@("`@("`@/'-T179T.G!A<F%M
M971E<G,^9G)O;2!A<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S:&]P('1O
M(&EM86=E+V5P<V8\+W-T179T.G!A<F%M971E<G,^"B`@("`@("`@("`@("`@
M(#PO<F1F.FQI/@H@("`@("`@("`@("`@("`\<F1F.FQI(')D9CIP87)S951Y
M<&4](E)E<V]U<F-E(CX*("`@("`@("`@("`@("`@("`@/'-T179T.F%C=&EO
M;CYD97)I=F5D/"]S=$5V=#IA8W1I;VX^"B`@("`@("`@("`@("`@("`@(#QS
M=$5V=#IP87)A;65T97)S/F-O;G9E<G1E9"!F<F]M(&%P<&QI8V%T:6]N+W9N
M9"YA9&]B92YP:&]T;W-H;W`@=&\@:6UA9V4O97!S9CPO<W1%=G0Z<&%R86UE
M=&5R<SX*("`@("`@("`@("`@("`@/"]R9&8Z;&D^"B`@("`@("`@("`@("`@
M(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@("`@("`@("`@
M("`@("`@("`\<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B`@
M("`@("`@("`@("`@("`@(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z13!%
M145&031%04,Q130Q,3A#0T9&,4,V0D,Q0T0V-S4\+W-T179T.FEN<W1A;F-E
M240^"B`@("`@("`@("`@("`@("`@(#QS=$5V=#IW:&5N/C(P,34M,#,M,#-4
M,38Z,3@Z,#@M,#4Z,#`\+W-T179T.G=H96X^"B`@("`@("`@("`@("`@("`@
M(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I
M;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@("`@("`@("`@("`@("`@
M("`\<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@("`@("`@("`@
M("`@("`\+W)D9CIL:3X*("`@("`@("`@("`@/"]R9&8Z4V5Q/@H@("`@("`@
M("`\+WAM<$U-.DAI<W1O<GD^"B`@("`@("`@(#QX;7!-33I$97)I=F5D1G)O
M;2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B`@("`@("`@("`@(#QS=%)E
M9CII;G-T86YC94E$/GAM<"YI:60Z1$9%145&031%04,Q130Q,3A#0T9&,4,V
M0D,Q0T0V-S4\+W-T4F5F.FEN<W1A;F-E240^"B`@("`@("`@("`@(#QS=%)E
M9CID;V-U;65N=$E$/GAM<"YD:60Z1$5%145&031%04,Q130Q,3A#0T9&,4,V
M0D,Q0T0V-S4\+W-T4F5F.F1O8W5M96YT240^"B`@("`@("`@("`@(#QS=%)E
M9CIO<FEG:6YA;$1O8W5M96YT240^.30U1#`X.$$W,34V0S@U1#A&038R-$)$
M145"0C9#134\+W-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#X*("`@("`@("`@
M/"]X;7!-33I$97)I=F5D1G)O;3X*("`@("`@/"]R9&8Z1&5S8W)I<'1I;VX^
M"B`@("`@(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B`@("`@("`@
M("`@('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O9&,O96QE;65N=',O,2XQ
M+R(^"B`@("`@("`@(#QD8SIF;W)M870^:6UA9V4O97!S9CPO9&,Z9F]R;6%T
M/@H@("`@("`\+W)D9CI$97-C<FEP=&EO;CX*("`@("`@/')D9CI$97-C<FEP
M=&EO;B!R9&8Z86)O=70](B(*("`@("`@("`@("`@>&UL;G,Z<&AO=&]S:&]P
M/2)H='1P.B\O;G,N861O8F4N8V]M+W!H;W1O<VAO<"\Q+C`O(CX*("`@("`@
M("`@/'!H;W1O<VAO<#I#;VQO<DUO9&4^-#PO<&AO=&]S:&]P.D-O;&]R36]D
M93X*("`@("`@("`@/'!H;W1O<VAO<#I)0T-0<F]F:6QE/E4N4RX@5V5B($-O
M871E9"`H4U=/4"D@=C(\+W!H;W1O<VAO<#I)0T-0<F]F:6QE/@H@("`@("`\
M+W)D9CI$97-C<FEP=&EO;CX*("`@("`@/')D9CI$97-C<FEP=&EO;B!R9&8Z
M86)O=70](B(*("`@("`@("`@("`@>&UL;G,Z>&UP/2)H='1P.B\O;G,N861O
M8F4N8V]M+WAA<"\Q+C`O(CX*("`@("`@("`@/'AM<#I#<F5A=&5$871E/C(P
M,34M,#,M,#-4,38Z,34Z-#DM,#4Z,#`\+WAM<#I#<F5A=&5$871E/@H@("`@
M("`@("`\>&UP.DUO9&EF>41A=&4^,C`Q-2TP,RTP,U0Q-CHQ.#HP."TP-3HP
M,#PO>&UP.DUO9&EF>41A=&4^"B`@("`@("`@(#QX;7`Z365T861A=&%$871E
M/C(P,34M,#,M,#-4,38Z,3@Z,#@M,#4Z,#`\+WAM<#I-971A9&%T841A=&4^
M"B`@("`@(#PO<F1F.D1E<V-R:7!T:6]N/@H@("`\+W)D9CI21$8^"CPO>#IX
M;7!M971A/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H\/WAP
M86-K970@96YD/2)W(C\^_]L`0P`!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!_]L`0P$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!_\``$0@`I0"-`P$1``(1`0,1`?_$`!\``0`#
M``(#`0$!```````````("0H&!P,$!0(+`?_$`$H0```&`@$"`00,"P<"!P``
M``(#!`4&!P$(``D1$A,4%18*%QD:(2(Q.%%9>+<804AG:(>8J,?6YR,H,C="
M1U<D828S0V2!H;'_Q``>`0$``@("`P$`````````````!@<%"`$)`@,$"O_$
M`#\1``$$`@$"!`,$!P8%!0````,!`@0%``81!Q(($Q0A%3'P(D%1818C<8&1
ML<$))#*AT?$7&"5"4C-#4W+A_]H`#`,!``(1`Q$`/P#2?HUTO.FS+])]/)9*
M]`]-I)*)1JSK[(I)(GW6NGW5[?W]ZJ6(N3P]/#HNB!ZUR=71P4J5S@O6''*E
MBL\Y0H-,-,&/+&2E]R;Z77U=.D/T_-<I;^3.,8]R;Z77U=.D/[+E*_R7QC'N
M372Z^KITA_9<I7^2^,8]R;Z77U=.D/[+E+?R9QC'N3?2Z^KITA_9<I7^2^,8
M]R;Z77U=.D/[+E*_R7QC'N372Z^KITA_9<I7^2^,9\LWI;]*`AW2Q\[0'0TE
M^7)#UZ)D-ULHLMW6(4H@@5+4K:.(X6*$B<8@`/4DDC))$((3!ASG&.,9^6GI
M==)Q_`<8Q:":%O1:818%!C3K=1+B!.,T'E2@G"1Q(X)0C"\^4+"/(<C!GQAQ
MD/P\8_K_`)YZS/TQNDE(E;R@C^AN@3XNCJ[T9(43/KI0KFK8G+&,BRWO*9%%
M#SFQ=C`19\T7`(48P'.?)]L9XQ[?7Y_ZY]_W)OI=?5TZ0_1\UREOY,XQCW)O
MI=?5TZ0_LN4K_)?&,>Y-]+KZNG2']EREOY,XQCW)KI=?5TZ0_LN4K_)?&,>Y
M-=+KZNG2']ERE?Y+XQCW)OI=?5TZ0_LN4M_)G&.,H"ZYV@6C%1?@N^U5IUK#
M6_K#[=GI[U%HNM(KZ9]%>U'Z+]*>A(TB\_\`1WI-Q\R\Z\KYKY\L\CX/.#?&
MQFD/I[_,'T@^R#K5]S$+XQDON,8XQCC&.,8XQE<FR/4IHZH)+:-"U@],%Q[G
MQ"N)K+H'K6%?)8N&RYK#H(797M+MUIEPV0P)NN%[A)Z23,U8F.*B>JV%P;'X
M<<3QU<%Z+8RD%\V3ZA>ZU9U#&)'#'38RK)8_ZO;Y*%NBJJ>ZXXO_`$DFS)-H
M1?NJ)$W?;ACIK;=^N-YO,!>5D0=;?KE[N*#Q\S#D@8EJ22L)3&=I5YT\MB['
MZCZ/;V5P5(AC`;1U=M]DA,AVGJX5TZ@D552+?6"VH;46M&N=W6O8BF1Q3TA,
M002$[40VIIBNLI^S.#WMUPMG;_X-(QSGL:]CGC5$(UKD5S%5$<B/:B\M56JC
MD1R)RBHJ>RIGVR*VQB18$Z5`FQH5H,YJR9(BG#%L11I!(D@L&00;12QQY031
MC/CO(T4@1`D5",<U)@T'H)=>E72"NFD]?HQ6<=Z@4RH&[5[K/ZT.(1'V!L9(
MD,^6P9]46"[-4<<WMZ8!/[6P0I]EA*1-'@(&E!CS%A;@%E>>?%D`*NNK5/I[
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MPM_VSQ[_`'?RY_JF,N*Z>_S!](/L@ZU?<Q"^,9+[C&.,8XQCC&4U]6=]G=?2
M72BY)+$KML+2.I+JDTJW%B.O(YVHL)JR7$@^T-;<CC-8*D4]GU-U#81"V2V9
M#&$U<`WRT<D[G'I(ABQC48PO\O?Z_GD6(YJ76?5KV>QN6T#GM9:>U7.8.*H6
MQ943[4DOV$L:$.;;;+]L]3TI?"JXM^A#WFS5;36MASDF)JYA>D9IN/M;9+(Y
M$$JXB0,X]^5_#^OU^W-"$)@L)K2-((9740C$#A[4:Y'MD6AS"UQF.MQSPZ+7
MQW.1,K,E1-R4UT>G)Q=W$TE.`:YS7K%ZD1JI4>:-G.8*;OVQL)QWAO\`V(K6
MT)373R[6))1Q>0Q-Y/0'+HS'%H8[$&YP`0(:)X;11EF:@'MB\E6W+<`R6:0:
M6+.!1?IS!T79MIW&5O.YS--!$HK.PU^7#,$*V-M%((4&O*IHLMAV/!^L]&U@
MR2U&HQF:OL[NJZY476CI1X7?#7T]Z.^'?5O$$>QVC2=;ZI:[M%7+LF:OKNQ0
MIEOMVSUS8EK3RJB:&]D&CMV!9!!TGJ6R3Q2)PX5I>J?L@29L9K=%MN8,3-&C
M&`D#M&MT2)GEA'^'`5+]"C#D<;>O%G(LGGL"J+B3E`QDII<3LY"**U>^F9VB
MM@(9GR]5'1K"I^9`\H-_YJ-1<)\F.7,;UE_LT*&Q9)N.B>Q$H)J\D;J&UR#S
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MI(D2H$J9"A3)T2)$G)2(T:0DM,E2)4Q824Z9,G)"`DA.02`!1))0`%E%@"``
M0A#C&&<Y['&,<8QQC'&,S;^R$?R1?U^?P6XQEQ73W^8/I!]D'6K[F(7QC)?<
M8QQC'&,<8QQC*2YU;;GJ+>FY^Q.R3_AVD+<WQT&I<1DUE@B\-E\!=<+0.49@
M;+DY:G];6W*%N(E`L1I6Z$'@6.1(1)GY2X*KWLKK0[#4ND^G1M@U[4HEK,DA
MW>?,##2VCW8R!9'G3RR21CEJRN.8D8K9;(8PJQDDHDA(P5'Z-TIZ]W.]]>=^
MH>E_4;JS/UBLCS]&K=9AW=A0.UGT\H\NN@MK8DZ'%O!!BA$>(2$2TF2N]*Z-
M*-9]TC/=L%U:]W+Q9I5`':V4D<@D@.4)5[37D<9HJ<L:3#!YRT#DJ1,9*Q-I
MI0_-%I)3X64ZI@C(784I3SBC-.^H-D2KV78-<I=IC;)1U\\L*+>UL0<*/:A&
MC4>4/:62[R/-4@D>&68$AH_-$8H",<[]*OA'\,'2TO3;I7U@W#H3;=/>J5OK
MD&_LM(WS8[#:IVG6LCN<$<R')C559\4:!L>P8.;KL*QII$GTQH<"RAD&&L3E
M:9V%_7U_/.[:08J/?W>1([OF<CA+<&/*1QAR86H;F2.0>+`2L.8"$3BJR225
MG)I*,M*04N,P,LYV;_)E@5Y>H#4&*=MO+D1&>0Y8Y`B4B*?GV\Q&L([A$]T:
MC6H_W12LX1'4EUNO.M]!4:[+Z(Z;KFZV*[#%9L];?6C*LS->[54JU;CS*Z*A
MBEX$:626<L$?80-58H0KXG2@_"$8L%BR(&!9P`>0^`0@XS\460X$+P"SCMG(
M?$+PY^#Q9[=^8A>.5X]T^Y?ERG[/?C+K;W*QO>U&/5K>YK7=[6NX3EJ.X9W-
M1?9%[6]R>_:G/&:".A6OO2U-G7UWD%PVTMJBGZ^=9`]QM=84N4PQTD4C%B-Q
M=J>F50[C:%!($JB12-*!2G&`"R,D'>#.2L"!/M'6=*LWN?+E.BQ([GO&IRJ)
MY"?JA,<Q7]J^RD(B*G'(TSK-_M%0=.=,Z0P(E?I&DQMRW;9HE?"MPZS1@O85
M54M6WN9T&Q9!;-"JE%659GB,URQ[8C.[AZ\W<;+I=X+0V:U=)U6FZ^L:(01J
MP9==,M>4[$9%I`&*W-K*>U,0&1PKZ:.,J=;%JD^](E#&?,@JY.F3NJ^S"I9E
M9#X^U/EM*G'U_EG2'D)J!G'5J'IO>"]?%[=E5GBTC@QT?==@R8)6URQ+=L%#
MW&MN@-(06)5"L36=!TUJDT@DK]HLK,9;5,B<)SEAEKW$4;4U98R>5*VY>\WW
M4<`.;'L8V:Z235&(NS2TV92Y<"A4/O)JG+FCE*).^*8BT2GU@?(H)N<E+?)7
M]V0Y\62V),W%D&$B8RR7C&.,9FY]D(8[_@C?K\^C\RWTYQSA51/GC+B.GO\`
M,'T@^R#K5]S$+YSC)?<8QQC'&,<8SJ2^LV;BE[.S2[LSLEM8A;[[7#B_HTJY
MJ+F.$)N6%.H3+C2D(C%Z_P`B@2&KL*4298I3JEB!R3$FMZGY9R2EAR4A.:R7
MY)/3N>U'M\U&JK$5JKQ[K[(J\HBJCE:Y$5JS/IV_3A[WJ+NH467,T?\`2"K;
MM4>#))#E.I'RALGO&<#7'1`A<XY!QW!DG$-X(\F*8C)(OYRMFS>Q+%G4EEMK
MR*22FP'-T5>LSO+%:I6^"<4YHR#DBKSO/E$@4`R\HR&THLA*VDD@1)4R<@@L
MD&O$DTB0<A91"%D.<OF/*JJ_N1>%1>?=.U?;M]D;QPB(B<9^IK4M?U?5]=JJ
M73*RKJ-9B0P_"8-*`(:YL4C&D&<'D)P=9+7(<DI[B&ED(Z08I2D<]W(J0A]>
M3J?HHY9TZQ7475('(T4D&%/Y(MQ(3Y&@2''K,>:)"E)GBR(]1D)><EX3A&68
M>68'[:>+!F36@L9GH([AD7U"HWA"-3EC55WV6H[W]W>WMV\HJHN03K=M_4+1
M=!F[%TRT5>HFSQ9]:)NMM?)\TE>>0C)TL`(?][EDC,5O:".U2-0BR%:\0'C=
MUJ]HDK8\N[:A<2'A"WN:]"C=DP1`3.B1(K-(3N*<`OC`)7$E@4E!%G(@@-#C
M.<YQS'F8T92C81"L81[&%;[-(UKE:TC4_!Z(CD_)<LJDG2K*FJ+&?7&IYT^K
M@3IE1)<U\FKE2HHCR*X[V<->:"9[XI7,3M<\2JB(BHF>5T<DR\EO+);R41J1
M/Y$\TG(?^J%V!C`Q!P6#..V0B%\<1@O$:/N+/RYMGJ9U&U_?*G0X53H=3J$_
M5:):FXL*MP$_2$K1PA!D%&&%%(UH?2&D,64>;(\VPD,<=R,\T^H7A4\,/4CP
M\[GXB+W<O$/N76O7>L'4)NYZ5K>VCL7+TUB$D7DN;71),Z_MHQ23$MX-89M/
M`H:UT36ZP[*\3C)$K_C\J+-T.4X]E_%.4]_ERB\K[_)45%Y^2^R^^6L]/F/6
M2^#11G42RIPW;,V*[%LLNC9B)0*I8E6[0ZIE3A/+#0&)U<:?V-M0G@2)ARA+
M(2SG)^41YGAYSRL1.@9MKK.V,WX--DI?RBJ$D=1KZ*-$8]'.EF^RX3T:Q4:Q
MY?-X(11CC>9VF;U^^*B<`NR2/^/.AZH?PWZG3MN:K816(DW[;MTF02AB:50O
M:85O7&EV`W29L2E6H0E=4@L[7:/A7K:0^XJ+H'MKC;`VR1[+DLA0,[:C?)$2
MUIV,E\=TZ0DIQ=B69(8<E:2EZL!JHIN(..*1`-"G`::$O`Q6^-KVC8TC_,(U
MC4>1&HQ'O1$1ST8BJC>Y>5[4543GCG.B.WD5\NULI537.J*N1.E&KJI\PM@^
MN@E,]\6$^>9@RS7Q0*P+I1!C>=S%*YC%=VI]WGGF.QQC'&,<8S-O[(1_)%^'
MM_GY]/YEOHQGC]W/\/ZJF,N*Z>_S!](/L@ZU?<Q"^,9+[C&.,8XQCC&4U]:6
M][PH2A('(:MB4>=8JYST+?.9:\#<EI\56X;3Q11,6Q(C4*<U"^GC=0'/*]<:
MG;W!O:T.&\Q0[)CR8OM%Q94T4,B`$+V/(HSF,CG^4KDY&B#:K4X>J.3S'.X:
MY&M[55Z*FY7@PZ']*NN^[;#J_46]OH,^!3"MM=I:4T2`EVT,GLMGELY`9CT)
M7C?%<E='BL+)CR9,MLL;8!&/Q3NREU=EBR0.OG!ZE[7K7!4X&E""!:N6*#5*
MTW!GAP6(P:@PT8\`S\`LBQVQVY5,RBOX]9"V.=36L:EN3R&5MU(KY0:NR.`I
M621P9[Q-B22!*(S"C`5[AO$5KD11O1.^;6]YZ:2-CM^DVL[MJ$_=.GM33IL.
MA5VRU5AMVJ5,F##?2GOM?%,+<UD:7!DP#1)-C%"R2&5%*PCTDA5_R^87+`_?
M]?ACC./K\/DO\?Z+^_/T$60""/';N$6!8[XP+'<.>^.X18SC..^/AQG&<9^3
M..W/?%DEARHTL/E^=%.&2+S1#.+S0$:4?F!,UX3#[FIWB*QXR-Y8]KFJJ+C[
M>KBW=59TT[U/HK:OFU<ST<N5`E^EGQR13K%G0C1YD*2@BN\B9$.&3&)VF`49
M6,>WZ+JZ*'A3A6I`2`822R,8(+R67V+\6<9SC(A9\8LB%G.>_P`G;&,8#C':
MP.J/4Z\ZL[&#9]@A4\"<"H@T[0TD0D.*X$)\@K3$8:1)*^00LHRN>XJHT?E`
M&U@@L:FN'A*\*'3[P<=,)W2?IM>[ML%!/W*^W8DS?+N-=6XI]Z&MB%AQCPJZ
MJB@K(L6IA,$`4)'EDK+G2B&ES#D6X[HF7BYTEM[%(6I7(3(?LBVK8`\H1&=C
MT+^U)7%_@[R7_9^(2D+NC4QKR/E0$93RI0<8`T],F\G.H/3Z5IFK:1N\G9=>
MF`ZAN/&CZ[$DO?=01QVRB#FR!*Q!N$(L=L63V._NYYH`N[GN7LZ_O%AUFHO$
ME=>(3HU3]*NIE+L'@]=6;/)ZG6]6$.B;$VXDT=9>:U6RV'>9DF75VWZ1UBG#
MYEA"U27*#Z>+SZC89<-U5K0D0!.[4D"B.QHY_8(LD4(H])Y6Y.$CE+B4TQ]E
M:X[#F:02-U<75Q/*3)DS:TJC,B%D8\`*`,8<OG5AG`:XVYU[MN>DUI7L].D,
ML75BBN=E*Q#9ZUQ^4U2X@BPT4^A4U>HNW0J<1D_$VBP<.,1D#T4`QX3DF>`T
MM2`EC.%N6_VH;5#VZP%-R-YT*<H34=E!DS9%9Z]-#;75[>M?M53Z2*V>*KP1
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MI;'KUL"EM:N+,K9I;31"-7RR&+_5-`/&3.XE%AQXI\@&`Y\J8,.?6XP'D\B'
MCXA><@B6R_\`&9NEU/3ZZ;/FZ7KLQT^IKHT&OD@BRU=8/4J3XL7XF5$^)SNP
M4B0036G[6C1HPHSMWZ/=3_[.V;UTW+Q):C85&C=>NIE&#6MSV/<+#:M>D6M.
MUFMC;#-!M+4_3^(Y_P"BFON/+JV"E$)`4QI+GRIQ)'SH[)T8DZM2RJFAX3K2
M1I//4QZ=Q(!C/?`_-U"4XPD6<]_C8\0PBR$.<XS@/;F%Z>]2[OI<FVQJ_7Z.
M=,VJD?0&-?UA),RJ$5#->2O:I!=CBH?D\<["QY)`1'&$1L=&/O'Q#>&?IIXR
MA=%MAL>JFZU^L])][C=2*P?2W<X,/7=RDQO1FC`V&1&#/'(%$=!1(%G7R(EE
M61I]R*#+CDL7G#Y1H%A97EAD""7VR+OW!D6,8_Q9R#`LF8\/^KN''AQG&1=L
M9QS`3>G6ZUU8ZXFT$H,!@5D$(I8CSA"QW:4AX(I#YP$`O"R?.C,6*Q6OD()C
MFN6T:+Q,]"MFVQNDT?46IG[&6<RMCQVQ+@%?,G&&A(D>OOY5:#7[!UBBJVJ=
M"M)#+8S"QZUTLX2B9Y5A+4BCX'E0\)2#0G&`6)E)A1`$Q(,#SD\1IAH?"4$`
M0#$8/`2O[7`?%@0<X%)YNB:@/I%2;Y`WJ)*W"9L!Z:TT-S([9\4#735%,C,:
M=9Q!-C!A2"R'Q/1/]>@&R!R`((]1TWB)ZSN\9N_>'_:.@-M1=#*#IK7[UJWB
M+]38?HS:S2AI&RZ>VER*\6O0Y1+.;>UL:M%<?'`?HZ^Q+6R*N>Z97_?C&W[2
MZU<XZT1J2U6_-K_(</H<-^6IRF9Z]&<E6G)6M>E7C*6#)&A!Y<92)6[HT@CD
M6%A"$6$X(W$J=UD5,:DAZM:RX]O,:D!8]%.D2YLI5:]H(;A!<IR.\OEK1C>;
ML[FM=Y?*)YVMWX4']<"=;K'Q`ZC`W#1M4EU]M7FZNZS"U*NIFQI4:3/MHDB:
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MW5KV^:OSL4A=D`XNPQN/M$$RR\B$5T,-566I!TQ!);8%=1-X@VM,*FZV)QFB
MR93,%VL)=G!B=I^LKA4#@YQ*\Y`=:3PL?K@A)L?F218V,ZB-KF01*GSIC+J<
M8[8QCZ/@^'X<_P#SG\?&,<8S-O[(1_)%_7Y_!;C&7%=/?Y@^D'V0=:ON8A?&
M,E]QC'&,<8QQC,P,M`M2;+;DMTE%C,^*V4D[C)O*YQE8?'7F+0]=3BH0L]A'
M(`4B*O&EO/!C*<KT0I;<#RK;5H"[>TUPEI!H/CO8>0DCCYH57\L5W[0J)$7[
MT3A%]EX@>PH1+!ROY[%$/RN5Y3M1/M<?A^L[_;/-G'?X,_#C/P9QG\?)5F#R
M/-@ZFZW6BK&Z3.FH.K?QBP+,M9VK$1FP<X^3R4WB!C%+2@XS\;P%/(`>+&!9
M#XL8SS'2J>JG/82770SE$]I1'<!B'$0;D>,@SL1IAO8]&N8YCVJQS6N:J*F2
M"EVS:-<4_P``V*[I?5`-&E-J[2;!9*C2!N">/)9',-AP'"]P3!*UPRB<X;VN
M8Y46(EE=,>/OS:I1U1L#;U3Y-'XR$+B3$;39DP,8SW3X63%D]L4PD[X`GB'8
M^3_``.4YR<['ELY`CY3H+:WS@/AMDK(<*96ULTI6O[_/BFG%BMM#1#]_ZR.2
M>X2*,#AM&\`7,^:+?7<.]?L<:]V.):/@`@(2#L=U$B@2(H/1SH=6.:M1`MXB
M!5H;>%`CV2LE6#"RB,L9S9%=$YZ36QT85'NB1)7>PA",61H5QTS?4,X.R$61
M8$ABEL&.,18ODQG`$5H@+",60`*"#'?,PT6PZ;Z8@T;TFU\1!<(EG5JRPL%<
MG_N-!L2O>)_WJ\=RKN%5$1$]L^/JEN/6SJR<LK;NMV[[,I7.=Z#9;:Q6N"B^
M_E!%6F]((*+_`(`!J1"8O*HU%7WB5:%5SR!-Y;-;E86'5(52M,A:G>1QU6W,
MZ)_`/)C1E@L!G$Y0@4B2JDX5;,%FE"A=YRG+.1A%V#G.P$7>M#W.,E$^:2ND
M3$0<6+/C%K9,:8Q%?%-73.UT!+"*9J'A.A32&88;7"Y<B<ZVS-/VBA<6>:"&
MQAL:]LU\<HY\65#,GER03HJKZET*2%S@2FRHK1/&]S7^RYIG]CB=19S523&G
MUU9%'G.WHHDN&HS%JHLUH=)3EG:CIFTQQ4$!("0/;>8D<U3$I3-ZED?T`R"B
MG'$I;W%;U2MVBQN]MV6;<6`K*1=7<Z466..*(C;)2$\P3HP&L`)DH(5+'<%/
M+*H2*J^>XC4[W.NO0NBJ/#YT.M]0TB=I-CT[Z2Z;`GT1+&1?1[SIT>%7K"V:
MONIA'V4R5JUW=1JK9:^T&*SIQW]<WL+0PZ^PD['N2/-`L<8QQC'&,<8S-S[(
M0SV_!&_P_P"_GRXSG_A;Z.,9<1T]_F#Z0?9!UJ^YB%\8R7W&,<8QQC'&,_GP
M]7+;ZXISU,;Z?H!.GZK$]&*$FN,..AI;2@6.C/`@^?R9?.DK@V.33/3U-DO<
MP41HJ8MCXVQF.X0$QU$V*W22K'O<KH;TFU^^T=^PV[YZSKB=*9$+!FEC>BAU
MQ21.$#P2(<I9#3D>Z7'D-:QH$$T:H7OURZH=0;>HV=M17)%2-71@/D"E1F&2
M4>6-LA%4G+#B&,3A,:V.8+G/4JO<Y/+1D>X1U,-KX<!,GD@*SN)"G$'RXI*Q
M*X!*W`&/\01RF$F'Q=&+/R8&55I^,9^-D`NWA%-[/H9)8U74FQC,J>[8UW#[
M7O\`P1UC6^6P?X>U4_\`%?O18U`ZK`<J-M:9P^5]S5DA51J??VPYO<Y_X^\]
MJ>W'W\I,J$=6FIUXDR2T*KLZNU`L8\]>F%.V6?#D@O@[X*.CJA%8:S';N+&2
MJR#W#C./_,R$`H!9]-=XJN5+1/GB:B]TFEDAL!)Q_P",=RQ;5W/"_P"&M7E?
MLIRY4[IA!W?59Z)V6K89%XX#9`)$?[_B9OGP6I\OG,^2\_CDTZRV\UDN%<6S
MUY=U?O4C-P$08>K>RHY.0A'G(0"-@LG"S2\D`Q8R$`S64`!"QG`19SR"&=Z>
M2Z%*82'-9PKX4T184UJ*JHBNB2V!DM151417"1/9?P7)6)//`V3'<R3&=_AD
MQB,D1W?)>&G`X@G*B*G*(]53[\D;SR_)?;_;Z_WSC.`6I!X/9=;3F!64@0.4
M!E<7>666I7+)8$GH-6A."N4C4&_%1FH2L97)7`(@&MRI,2N(-*/3EF`]1AC,
M$H2HBB(-S2<KV\-X55<CN?LJWCE')PK51%145.<]@GO&1CQ\][7(K>/?E47Y
M*GWHOR5/DJ>R^V2OJ;775XO17IT[H5]3E+LUJ1)XT0MARGD)CD;5A/5V2\5[
M4UVDC=$H5V#$:"-VA/7(EK+5B+C\SC["YD@(>XN@.2ZUBJ*R,1Y`0HS7N?WN
M+Y35(]S2(1KU>[N<KD>UI$=SRCT[D7G-I=BZW=7MM@1ZS8NHNV65;%B'A1JP
MEQ*#7`ARH!*N5#%!C.!%9&D5IBP#`0*"+$(^.1JB<K<T$<R&5=CC&.,8XQCC
M&9N/9"&>WX(OP?\`/GT?F6^G&>,9<3T]_F#Z0?9!UJ^YB%\8R7W&,<8QQC'&
M,Q?=='IM`BFQSIM56MN4>P)-C%21PE-,6?9+17<Z/L*.,;+'W^6U.C=$XD4R
MBSHSM[.]3Q"-4VN,3D1C@^A4/2&5811Z^^F'B$J>E%'*JMQ:W]'/5NDP9WK8
M,(D"5*X0D55L3Q8I0R2IYHT]0,HS.+VL.A4:.IMZZ23=[L@6&OO[;?R&@E1E
MCR9#)00\J,Z>D$<XRA:[RWKY+V/$@^5%Y7).B]/>@Y8.TS:FEZS=_4--"P9*
M&Y$:WR,[:61I_%G'E6EV<TB^L8K$7LG&?`;_`&\U3I3_`(HTZG`1`S-[GQ7V
M$MG.JZW7ACD;R&=:3"V*D&]/LE&""Z(`?*<*WB5)8J?^2?.,UG0.$!?^NW,L
MI6K^LC0([(:,>U?=CRRFR"/1/DOZ@+_V+[Y9)K%TC>D:AV4M#5N</US[%WC4
MS<P/3B@MZR1Q2)/I3LTH'EU(B,=I-/5[8^@B@7-N2R)AEN)&H286!\8W(M,Z
MG(Z)M^OF^[/93J>3ML^(\*,>Z)5**H`]A!M<\8WP&AD&:)'-:5AS$7W]^Y$<
MJ;42_"/*T;I/I76@FH0Y>G[A*L84:QD(>REUDB%.D0HA;8$UI!0PW+HDDE3*
M"WR3-"K7*%YHJ2+&K4Z6G2UV(8)+J_'Z1I^M7^ID\7=WXBB8;!85,H<3."EZ
MIEQ)!D1A>TO_`*U(F):J4))BVOZHPKR+QV2K5B)Q,JVTCQ+XY1R)DA;&*HRD
ME`DO;.`LCN<U7%=W]WFH-55I$<O'#OLJK79:O2WJ#U+Z"5<':Z[6J:QT#J#\
M5K64.ZT(;C2]N=K;HX)SFU[B1CH6GD681MFP9$3N,XL1Y)(@R8[8=4!TK])Z
M[ONYM6ZVV%VG*FD*K>$SQ06QVRD;V"K@/+H[)1MS3!#&5QJ=4]'MZB.NKJG?
MJV<DJ)M<F(28)1BU4#'TT-Y95$^551]BM9KH\8!E%-,*0P"/<].Q$</[3E8H
MW/1Z*C6N9QQW+F9ZUT_Z<=--+ZROZ+].^E]7L>U[%KT>3HL&YJ&;$^#"A&28
MZLE6<RMAUXI(K6'#?7BCDD2HEBTW>..%R]L0[0W6FSK*54M+.H$V;#,S`(2J
M::[-3O0[=9TS9T(B_2,9N=177FKPJ@ZS(P$R=GA\#K$UY1#]"O+J>PKW5J=)
MC*VNXEQ7Q"%$UA&JPKQ"092,=[.:JHO:UKD]G>6QBN3V5>.<U2#20`&0[!O5
M6KW,:]ZN8QR?)414[E5/FG<YR(O"\<HBYSK=>*-%$W;KI$ZS<F6+P/>+:BCV
M*[*H+*6$,3;(ZWMJN;2SL/'&IH;5J:-GSD4.8]9K1-&6T1^93J[*->'!S;I6
MA59FL;S+?7U]?M^675<8QQC'&,<8QQC,V_LA'\D7]?G\%N,9<5T]_F#Z0?9!
MUJ^YB%\8R7W&,<8QQC'&,S$6`Y+9QM)M;8\IP8?,2KED%1(`K!#-.BM:5'A/
M'8-%&@)^<F-C"\`RXVL8A)P60ND-DO3YV,`X)Q`Z1?'[MNPVO6TNJS9$AE!J
MM)3?`X'<]D1Q;>`&QL;-!KPPDH\@WH7R$Y5`UX@HJ*Q_/8%X:Z6MA]/V7$<0
MELKFPL/B$E$:ID9!E$B18BO_`,31#$-)+1*O'F2GOX^TG$7[0<=4W27($,\*
MKZ2VPAR#U?;HXU9E=[-I@NX"SXBWP!(Z6VVJ@Y%X2UD:(3J2LB[`.!XOAH_I
M;$\0T563>E:]1*R%WHYTVIE6-1K;W<HO$V9+-$UXC>>%5DPKFK\U;[986X'Z
M8F18^Y?HQ+/V]K8\X,6;:-3Y?W<(6&LV*GW.`Q')]RYU$U:2W?(K>;+QU9B6
MWU266V2(,R:K<NFT&J/P]QE(C/.37"4LVP2:V]E5):_)QH7E&57[4F=$IZMM
M6&F$*%*;._73G:O$95EC3.H>S=-YBL,TAO-KY-KM@T[E5SA2M,-2ZO(*Y.6N
M?.M)KB<JI4?RJK&IW7$D+4I73S79FT7&C2:AU$_5-A!6S-0?6()!@A";LL>;
MM56"+VC?#6D+6$A/$(D,H'B&K9_:C:6[UU#9=JWK:V\+$W6G>"-Q36*;250-
M;DH\Y5OQ#XE<VB4W@JG47-7-7F^&YJPKI0M"V-JA:B0HB4IQ!*2_UZN$KYDJ
M;2UQ2R9C>#R+J0A1D<KFO5Z083`.$K7(J"19Y6L&[R^'<<Y`NI74VYZJ=.M&
MZ9W.LZ/K.NZ`0!*--/KK>//$@(,BO6/ZVWN;,?I9@3,D6+'0G29MC'#-)+1W
M>-W?\>Z;NJB.4RF?SZ)2*^+"GRY<YV!+KYFDAL8F;KG):!Q5FOU?+EB2H0IQ
M+2B3R6QIKMK:$@DR8*-`0!,0$N%SNH&U32R3-LG0'2E<IOA8V0B.[G=[FK*$
MGKGM5W"]A)3T3A$1$1$3(=:W-W?4E%K=[=VMSKVL`C1Z"AGS"$HJID2.Z+')
M"I!^54`DLCO(-TP<%LLJ%*XIB.*1SN^[%UZK6;UH77B!B:J_+CH2W6KY)!FA
MJC;Y3DT:0F'1:?ULI;TJ8N,22*N0@.#>>@`4F4%@4-;HG6LS@XH%6&J-BMJ:
MW!<0YDA9@C,>5SS$)ZIB.121Y7<Y5,(K6]CVO5?GW-5'M:Y(]-K(4^$2"8`T
M`YBM8C6-;Y+N/LD$B(B,>Q?M-5O'WHOV55%Z^9(D\3W2RH=QKFD14_V<VA6=
M.1]+D!;"&,Q>L$DSV2UVF<#J>I8EEQ>5,7@S#-WA!)Y2L7/KS*;`DJ<^12=[
MPU-4-C<+W\:O<UKN%3E$7A?FG*?)?V9K>Y.%<G*+PJIRGR]O;V7^*HOY_++O
M>>6,<8QQC'&,<8S-O[(1QW_!%_7Y^/&/^%OIXQEQ73W^8/I!]D'6K[F(7QC)
M?<8QQC'&,<8S.NV:^UUN%L'L]L/=U7.D>9U]J*Z?0T2KG#PJA3\\4&C2U?*K
M9M&.QA_##9S-Y>[,!D.2I7`EUBR&M(!`P!;3Y"H?7-5IYUE)3R]YBSUUFG%L
ME34QX+[^770)MR(#S'G1HL2>81W0P@;)60,D-PI'FR2L<91M:W-AJ&"VG@S:
MJIVZ5L&N2)(90204LJFJF'+`B)->ZNDJ"21P9*%@/2:-&E]$TS0#\Q$2=D#K
M6NZK8"(K6,"AE<Q=*+.4\=@L898DQDC[=LB+:6%"WH`&9Q_B&%/@0O\`5G.>
M5C)F2II?-F29$LRHG)9!B'>J)\OME<]W'W(G=[?<G'OF5$$(&]@!#"SY]@F-
M&WG_`.K$1/W_`#SFN?\`[^7&<?\`[\/P_+W^CGSI_E\E1?Y>WM\N/QSVYP>?
MV=6U4,1TJM*P816T9(SX3Y%/I6Q0]B)'D.18`8[2%>WH`"R$(A!")1@6<!SG
M&,]LXY]$6'+FD0,.-(EE_P#CC!(<G:GMSV":YW'XKQ[?YYZBG"!O><P@L^7<
M4C1MY_#EZHG/Y9$=\ZAU'B3B%5,=M[8%9D0@I,5773@BC#@'&1!PI;+3M136
ME/NJ+(\=LJ6B?N'<.?&668'..\9O=PTC5G/9L^ZZO2F&BJ6(^S;:V@G(G_IF
MIM?'<7`"+\D9(@"]^.53,Q74.PW"-=4Z_;SAOX[#I$6%$>U?^\<ZS=!A%9^+
MA2'_`+_ED8+VNS:O8BMII6,49XAJS'Y[%GR.K9V7+U=H7.WH'IM4H#4K,T-L
M<C<!@CT9Y?R1TD2R^S!H$0U`F5*C>1H'IJIZR\573W7Y83:Y27FXRXDR.1KK
M2."AH7L&9CRE1J2YUM/;Y2.\F.>)3]QE8X[G`8\!YW!Z.;-8,<VVG5M-'()Z
M.'%(:RGJJL5&B>J"BQ(R*[A"E">8Y!]R"[".:4=5>NW6OV<F9VL@+E@4;L6C
MZ+>(E8[5',,B6I7J4S%F@;M%(2Q(3&%E`RJ8'68I&9+F50IA1);M.([!71H<
M%#4QG&+.TANXSJU7"F.!9O\`4*UK6>6$@XS5<B.,4"."AR_85`H-SA(UZ'5K
MU1B;(B\#?33K754VV]/H&S=':6=IM=;%/:MLKFOL]EMHE?/2-2TFQ20WKM?J
M`NFADW9;0$:X/(@OH62H,:1,D;Y$Y@SB"#3"\DC-)+,&3D7BR4,8`B$7D6,8
MP+(,YR'(L8QW[=^V/DY9Z+RB+\N41>/PSJ#(UK"$8UZ$:Q[FM>B<(]K7*B/1
M.5X1R)SQRO'/SSS<YSPQQC'&,<8S-Q[(0[?W1?D_W\^7O^9;Z./W\?P_JBXR
MXGI[_,'T@^R#K5]S$+XQDON,8XQCC&.,947?$6M/4Z:W?<4=K1UN+7"?N*^Y
MI&BA$GK6,SNCYD5&F]-8YRILMB;UO%)+64R41\,^`Y-,O,F#%.Y#,$JF-ND?
M<FI:R4AU-Z:'V*8FP5<R'%D,C-'8BGO((!!QTX')&80C*TC!?JR#<Q&O8-BL
M<CT5K[0Z>6LZ5-K]2A5DZVL;BR!!I(=:)IYDF?8&8$,(85>/O4TA[58Y'?9<
M]ZO^Q]IM&%E]<ZQ'4HY-1FM3/%@&"%A+([WFV'1R3!QG.`#65K5WG#:I[X["
MR!/<Y&<9[@\7^OE21M#@"=S86QI/''(JR-Y0W?BC9L[@B?DJUJ^WO^6=D>I^
M!/J_=M$?9;35-'CD5O>`TD^S7(6KQW=\"I]-4.<B<\(/97HKO9>$^UD`+'Z@
M^\-L+/*R?8B0Q!E&:$TZ&TBU-U11_MC/QBD\D:<NEQ)RA@SDO(?;7-R''8PO
M(#L!,Q(HE)K\#A04T8[VJB^=9O)8%<B+SVO$]10%Y^]6P6+Q\E3-E-:\`_2V
MO'W[3L>W[9*<)PWC%,C:U5,*Y%1#QXU2%;=CF*J.:*1?RQ*K41['HKD7DJAV
MU97M!5@E-;PS7>F1'A3W8@LBQP7)@"A?A>-FD"PU]-73]2$8SR"E4L4.K($)
M24D\)P""G4V<7T;1MIU=^M[%KE':U+W(;T,N$)!">CO9!QHXP.89K'/&TX"!
M[6?8[^U?,=K-_P`DFXU_4YMI4_&ZR"G;!=&J)/D5DD8XKHS;<>Q2)4Q84-Q!
MQIIJZ9'GV)CN-(\AKGNJ`?,K_<>[(O%Y6>\6VWS1\;E1!\0CEEU4W.)\A;S#
M1X&TGSVLGRM"(XL2@\E@3R[0:7B.)\H;E,J5]BAZB[#X/NA6PBG2((]GT>P1
M5="CZ_8K959%?S[2(VPI9R4[%X=V1[&&-4]F=O\`AR^]K\,/5.JOM2A]/=DJ
M=BUJ9'*/<+/?G1Q6=-+"QCA2*D6N5U0V;"E\$&P)PRY@"JSSC/$KC)S%=N=L
M-L,T%TC5E21^`V18Q*J,BFJ"RSY+B/MZM"HR\.\20+8-%NS\F:BUJE"X/RQ*
MVQE06!V-3R<*#T:M@&A^!^H@;O5SK3;B[73PIHID37TH651;4\9_GBC6\IUQ
M.""M8X:/FMC-*:;&:0#7P5)YPXWN'1W:]*H+O8NI>P:EIV@4D9A]CVNBM+J\
MN6UQY`8:1]?IBZQ`5+NP-)%`@$EG("%-D!.@;1!^07S:;]/^XYYL%6T#?*CF
M"&KX+/HNALQS1LBQ8U,T*CKB4:Y)4BA(6HRO+=6IJ4-C*J;@+B5)AY2@K)J<
MLT8=_:_6K:5;,9+AF:(<QKIQ2HUK%:TO<96N5R(1"</1CA]Z.YY;RF6OU1\5
MW1'2>B<V9HF\T$FTFZ$6+TYH:YTB1,;++4L@TD>1""$A:M:E3Q2SHMFL,T40
M'`/Y9E:U='>^.S74?KZV[NSJ57C8Y5)3.BQE^.RF=5YAWPOL1:P;NDI(]%@-
MS\FFDML<V95#KT./P)A8G5F*BS],#9J>T.,CA`5%V9^>)?W?O^[\_KC]N>XF
MWGVC8J4M>9**WFMA0N"[0TK$*^VH*IG$(BU@:YOMG:M,]MRM_IAVEQ%NC?HV
MW67?43:YK`ZQ5UZZHJFS/R\M2,P"=<SE/?\`/)?ZP;+R2Y-B=LJ]<GYND$%K
M]343_3*YLJZ:P(`X;.(3Z5>T;@^2E0L2S1W:GO*<EP=&T30$@U7YKF/-H2<A
MRQ]_\/ZY//C&.,9FW]D(_DB_#V_S\^G\RWT8SQC+BNGO\P?2#[(.M7W,0OC&
M2^XQCC&.,8XQE2?6SQ`QZ$3XJ;3-ZB2P4FB!L$0LJDT/KK-D[@,U!$7=M`>G
M*=V-0V!=GA>6J,\BTC9DTC**5K&9*A513<T`M$=#'>%?-"H&L5?UYD<O:%[>
M41XU;W/=S[,5B$1%<Q&KNKX`5V1GB1ULFOT$"[`E1>,V(\\3%^`Z^2,UDFZ@
MRW#*Z%8CEK"@QG";WS6SRU3WA!/-(#B!=T"5O/**2.!+@$:<LTP9.,=BC!X^
M$O.0B&#.?]6/"/(@XSX1XQG'<6&ZM:-JVA7E;5ZIOE9OD672PK";,K&C5E=.
M.W];"(>*>7"-W\)("T4E9`!D0$P(R,861VO>#;Q`=7?$1H.T;9U@\/&U^'>U
MI][OM<H:7:B2FFV?7X)46'>QH%M7T]Y"<)7.K9KY=8VML)49\ZEFR8QRQ:_M
MJ4VG#WREX'6+55<>C\HBKPK='RR4IB<U]E)9X7,($:K.&LA<60/"],)04J=E
MY(!M*'",I*3C!)4#DV44U3"KAUH`2(Q7D-/:K5-)1R$3M=^K:_A>]JJCBO1/
M*9V(U/9+-U;I;N%'UGWSJ;:]5-AV#5]JIX=71]-I0Y(J+5B`=6N?,BHMH>`2
M0Q8$AH"Q:F`9S+:<LPLHRJ<W7\"@,LLV5-4*A#0<]R-X,-`B0E&$)P^!.28I
M5*%"I4:2E2)4J8HP\]0H.+*+`#/QLCR`(OAA0I-A)%$B"4IRJJ,8BHU.&HKG
M.<YRHUK6M17.<Y41$3\>$R?[[ONI],]5M-UW>W#2:Y3#$^;/*,QW=YS#CQH\
M>+%$:5*E2I)1@!'CA(1Y'(J-1K7/;Z[_`!9UA4L<HE-FY6SNS`YF-C\WX&F.
M4I#R!8P:`LX@T](>#.,A&4H3G'$'D#"<G,-+&6,4@UJ+KT;;:J)OOQ6+K@K(
M8MA^#H!]H*&BKYBQ?,[Q.7GL5[F(1R@[W`:\OEHL"W[;-[W#H1L>X^&&3INP
M;_>:>:UZ52=T^)1M1L+4S&K$^+L$V)/CKY:'&.-+2(T-HP$>U6-';*</TDKP
MLC[X!XB;L[,RM`H,-:79O6J&UW1^((B_*IUR$TA2F,R4,PO(R3"QY+'D(NWB
M$'/&V/UN-MET_0Y%JFL"L3?H_(LG>5:>A^0W&<)!N:JJKT&KFL,H%'Y[6F4C
M4^GI16=1-EZ)Z56>):BT6?U*L=8KV=3Z&BBBMM(->HY"'CQHEEZV-)$U61BR
M1HZ1"99-.L`A(C(SUU[=%[=NNIS6<%U>6Q1S8[=;6.:RA[EY+>UX8K%6(Y(>
M<:\.KFG7&/JZ;*6!6@&[N3XC'EQ,9U8Q.6!Y1)3-C=;Z<[$+I#3=39#ZYU39
MV,J'Y8I+B6;T9.F06V$MJ#\K]9*B$CO:Z0^4BH(I!-8]?+_.KXU.IFE0O'#U
M'Z%TQKUTW6:+6)42+)@.AZ[KXI&JTETNHZZ-Y6(&L@PK0=C7L@0(U.,4F1$C
MO<:,KI%]_,#E/8XQCC&.,8XQF;GV0AW_`+HW;'?_`#\^G\RWT9QQ^_C^']47
M&7$=/?Y@^D'V0=:ON8A?&,E]QC'&,<8SX\B5.:&/OBUE1A<'E(T.2II0"[Y"
MM<B$9QJ%*+`1`%D*A2$HK.`C!G.!]L"#G/?!/S^6,HCWMUAM7J'5=7R:,N3@
M;+JI99&K,2.CNQQ:-I[`>G+Q.I4Q;%:0I:6G''F1"DC;DCP!,WX5JP&#&9EU
M(Q'-HH6W,/[!2,DQFO?$'WL;'>]_9W>=W,5?=K5:UW>WLYYX5%5%VZ\(7B0_
MY?MX*EA3ULS5-PD0(6W638$V9L\&N@CG>B^`J":,"-9-FM/,B/A2'SVL8Q'C
M(*.0615/%G]6<]>BV=?($D:RH->U[$C5NS6B1I3#0F+U*]"2:2G;3`)S32UY
MPRB!D!R;@>`XSG%+PV.;)8=T-UA&B&&:6!OG>24`B(X@RF!P\0C,8YBE:YCF
MM57,<BHBI^@O8+RK'6AKI&T0=/N-JB&K=:/92:V+:MMIT9!0UK:RU)V6-I!D
M28Y&UWDR$>=K`&"]K^QWJ/2Y$X*@'H$(6\K"<HL1(,@\(C`>+N9C``A#CXF0
M%]^W<6`>,7QA9QBR^L>ZZ=OFTQ+K2=+!HU6*BKJZ351TAL%(L(;I"$FH*"$$
M<?\`=B182.1GF'9";(-VE*YC=9/!%T(ZW^'CI)<:+UZZZS_$!MDOJ%L^SU>X
M63KH\NNURZ%6+'H22]@G6%E(7XK&MKYXW&]+7FO"UD+S8L,4@W[CTCD$2>$4
M@C#RZ1Y];AC,0N[.M4-SBD$:4,@W)"M*84<7@T@TPDT(1X":28849@18Q!S5
MP32(9FF"0L:0/W81CG"*SN;Q[*G#D[FNX7[G-=PO*+FU-[0:YN-++H]CJ:G9
M:"R:T4VKM8L6TK)B`.PC&GC2&FCE<"2!A&*K5<&0)KV*TC$<GHN+BX.Z]:ZN
MRY6YN;BJ.6N#@O4'*UJU8I,$:H5*U1XS#E"@\T0C#3C1B,,&+(A"R+.<\]3W
MO*]Y"/<0A'*][WN5SWO<O+G.<Y55SG*JJJJJJJ^ZYD*ZNKZ>!#JZJ#$K:ROB
MAA5]=`CAB0H42,-!1XL2*!K`1P!$UHQ"$QHV,:C6M1J(F=_1V:Z_L=:Q!.Y5
M&OF-HM5@I'F5G/TB>D$3E$(3B4C51L"B-/;,[M`7`@:-'_T2?"](I)4.A;X8
M`8&S.89)IF5@!K7D+:,F(0Y2&>D<L5.[D2>45CV=R*QO",[D<U2><J*@\I&P
MU/KK8=6-BL@]2ZJDZ1S='-5Z]355'7GV6FW`JQ6CNI'Q>JL8=CZ0K)LGS2SF
M1#QSQZUU(UXB6*Z^=%:)Z;-ZU$TW)K'4;7!WD1&6IU4HI+*#[5J>8EEIU)Z(
M+^Z2%W<VE[;E`$KBS/:0[*1V2`2+B?+I#CDN+QTBZCUH@6&N.4(F)(%)K)!3
M2H+VRV#;/@SX$@I(YP3!C$TZ.'^N8,)&N:\0GCZ)?&/6]<W;1;]/.O\`=DOR
M$)7V5)LT&HI*9;:)42)A-=V&@MJBHKY<8U4>7.].!"^94RI-C",)1R9+)/4=
MB6=U%(MN](:P<9!?CIK,V52O4+YW1VO;`[JRD;=35KR\,[B#E+->IK!G>W,S
MR+U]"U$2*M25*G:52U,TQ?6I=''E;+8!G;0U?(FE/5Q#0(94&1L(Q_4^F*X;
M5D!"=6M(2*T_F>D4_=(;'\ID@IS->8FJ%,"VC5X8]U-CV4X+C#=81XWH_6`8
M5Z1#R(R.<(,U\;REG)&5L1TI"DBAC@>..'EKA8'5<@5/:11]-`@V;<KX_N2W
M8V8RQSA[/'7)OD6K&SEC9A4T5U52DFQ7F:DMENIR#M4W8*S9VRU)TT1R-"`R
MMT^=1!Q^93Z^OW_7W9RC0VVMUYQ?P6:_@W&HKL_2N@Y7*RK!I<VN8[$-IEK)
M#A6A'&5[<-?*5P<K<5#H_*S8W$9]L4P(E#2\&.TDJE6F98*XL9<)QC'&,S;^
MR$<=_P`$7]?GX\8_X6^GCGC_`&5?Y8RXKI[_`#!](/L@ZU?<Q"^,9+[C&.,8
MXQCC&=57E`I#:5.6?6L3EP8#()_"9%#V^9Y:C'H4<'(FP]I4.I+:2YLQJA6F
M2*C\HQ@<THTRKR"K`C/(>1,^6<`DJ')C"-Y!#@(%INU7^7YC58KT:CF*JHBK
MV\.147A>?;)ET\V.KT_>M1VRZI%V2LUK8*N\E4*3&5Z6J5<L<T4,DM\2>P82
MG"-#M=$,TH4(%4:A.]N-_:?2S;KIFP*3`0R>.3BD[B)3Q:0SV+M1X!L+N8!>
M0F;'1`Z>)?&U[TTF+TB5R(-=&E42>:F`L2O)*`0:IG0;S4XDH03B+`LV(`YQ
MC7D;N'M1O#OM">0;GM1R*]BHJHBM(UBIW8=-^IOAU\:>[:?;WFOW%)U*Z42S
M[!KNN6UDUH;.(CXD@DD987]UNH=99@@S7PRLA302(XR$#(K#3!$K@@=.JI?6
MMD6GZU1AF0UIZ+$)C>#Q8<I(I6F>(*-O*#G&`YR`(2R?'@?GBDS"4`0=C#B\
M9KX'Q7MV1/AIVZ_/KYWPVR9YT:R='DCD)$D`Y1#13^7Y)A.7@S'N%[(JN387
MK+U$B!V+6^@[JG>VS.MM!MFO_IKI;_12=&BR:N17/OH]HC7/BV<!TITV-)#V
MNJW1ASW*14$$G!4R]I=92P.LL0+DT4/>FQ,_Y9@X"L.:$BE%E\`VGGAP0-T+
M;#\9)"+X"AFH_*XP`81"E_53J0WJON_Z83M?@ZZR1$JX$N%4D>5#,KV((DIY
MRC$I93PJT;.1M08`Q0?;\OS'U]X4_"[8^#WPYV/1#2>I-KU,O*V5NNR:K=[X
M`40,"TV;U$NHJR5T&5,?$U\5P%TN7V22OESI=U.'Y*R?2@E-&H3K3;NY]9UO
M$U$GC]%65-H7!5*]*><C=V==+<IH^-S:C9&2Y'DI4+^O2+O`[D*0""4J+R`*
M,9000TX:29?@CU_G"JY)HX.55S7L>5&C<\?G=[D:A7([]8B_]R<(SMR1TM[U
M_P!%\-&Q[1U(2AM^L&I4>S;"H4'%D0)\*E*>SBQ+!M$Z%#)*D5$<L975CQ<(
MZ.YSG2VF<ZT'9WI*7@QNE!476]/1)_B*V:-<<<]FX809AT3MCB:8E6.=I13P
M8=F$*='DY^=5Y[K)F`:Q&E;F)Y;#G`#+F4W&N2/)JJN)5QNUAFC+<`Y\U[7<
MM<Z4+A'L3A?-(KB&9W,1HGC1WEYIWT+\6>I_%^LW5W=>K^U>KFT,JUJ.A6RN
M;\*@S(OER8\/2;I3/@6*^:U*>NC1*ZBLO22Y$RZ@6+HOQ1+D=-NE-`M)[$-L
M2L[YNUQ.<VX33*8B['PL$)E[=V,&E)?6A/%O.QGMBHSSUI<43FC<F\_RQ1*S
MS%<Y(ULDI]6!2R/41ITURN:K"A>H4`9OW=[$%SRUWVF.1R.:O*(O:YR+J)UV
M\9>Q]?\`5V:OMG3?I_%9$E)-I[N$._=L%'*Y:TKZZ<6X\AHY86^GFQ9$0\24
M/L>\"2(\4P+5N2G--<<8QQC'&,<8S-O[(1_)%_7Y_!;C&7%=/CY@^D'V0=:O
MN8A?&,E]QC'&,<8QQC,Z^[/5&MTFUB&G6M#*V*CZ*OIIJ:12!LB;>IM??_;M
MK=A)VC0/5-CFC.M2HH84_(CD>SNR"EG.9X3'$#^W0YQ*4-;D^#9Q]_U]?QX^
M[YYV!ME=*/?_`%4E&I$1:FL_<AYKZK+?9(/&'<#O4-D8BLWK9NN)[UZOEU+9
MJ\MB$U=)I,X0N5N:=W:Y#'U@4I\ACC6D=F=2XQ_9X)[&FDQ8H_-D.?'<)G<Q
MO*M.-7?:>YK4X'WJJJY/9,V;\('4C7.E/7K4]PV^S2GUB+!V>)<V"QI<M``F
M:W:#BIZ:!'E3#N)8I"$,<>.5[B/8G:C>52KIT]C_`.X:*OFV2-\LJ)XG)YQ>
M7.MT[^Z)#VY&=D&`9(EBYI(8'!Q39$(3@C\21$666/+<[.AF2RAU^[0K=([2
M-+$>=5^U'0CD5K5X]T*YJ,<Y/?N;[(B)]ESOEG:'#_M+.AA]FE54FEW>!KPQ
MN])M1*V(<<H[.Y7(2EC3264:*7A$C'[3R'O<U)4*(U%>W0?&NF%K43IS%M0Y
MM%DDD:69$<[KYTD((;I@"T'9.'+]8K`\^0-4MKH:K\*9"F486(LQQ$V1MU3.
M;4ERF,GP]9K?A`JDPFD:QJN4Z(C3>I>GVY`W\*K7*OLU%[D\M&C<CFIQG65;
M>+OJP3KI<=;M?N#54V=('"C:Z<A)5$[4(152MU>R@^8P4N(P/)I)1>1(^*2)
MEK#+$F&\UN8.[ND[NGKG>)#;5U<RNY(ZSNB.5P&SX.TB,;3TS6X%+4&9(#SD
M1<2D+<>05A<@<56$Y@B\JVI:O0Y\N&M)FJW5?.1L6,68-CT+'D@9RU48Y%;Y
MB<KY1&JB<M<O"_-BN3WSMUT#QH]`NJ'3LLW<=JI="LID*13[/J6QSD'*$^7%
M>"4M6]1L=<U<D1'K'E11*1C7>1-!&D)V+?WM)U56)J?VW575\LV3;9V>AK*"
MM$[-:V.1TMKM9VQ$(>Y=23O:I`I.VRB<,KRPQV4RXL=3QVPF!F:(NJ<K&=HC
M'1B7CNMBJYC'.:K7.:U7-7YM5415:OYHOLN?GML0!BSYL:+(9+CQYDD$>4/E
M120B,\8I#%X1?+,QK2,7A%[7(O'SSA])/>S>GW4<J'3N8[BS3>VJMG:6M^RI
M`CMYOK<N^-7Y_4!$.7FSI8NJ^,Q!O(H&WQRKU2CL9D$<)%&YKAF1Q=Z4(A.Q
M"SRSX_\`]^OK[LO/XSG'&,<8QQC'&,S<>R$._P#=%^3_`'\^7M^9;Z><+Q^?
M[N?Z8RXGI[_,'T@^R#K5]S$+YSC)?<8QQC'&,<8SH>5:S4I-[T@FR,MA93_<
M%80&;UM7<F<W5[4I85&['4-QTV.C$=,<<QQCD\B3MB9H<IHVM2:6J8]D^/&/
M0F4X:'+&4(.?3=Z772]=_6K95-=]I5!9M3.>O<+]-4J;,J9J"`0QSKZ9$P^<
M)-8ZL:WIWMFTCX;"TB>Y[.:'Z9V6UTXRQ>0S$Y];$_K8Q^628Z=ETN^G_2Z6
MWGMTNL^MZV]MB\I9KY`[F33V8W17NM\ZMV1!U1IB5)#DLGL9YEYD15QIKCC,
MXEN<B0MSU'HRH+3'MP6](SCZ]OK\<KD/ZR>[S(VZ&D&X1R.Z;JJ/06RIW29M
M'4_%HQ:[-MY/"H]+%58RR1;:,%[RJ4PY@4."PYOI;6F>QNJW&.D.-N*,1!_&
M]-+'X?2?7O\`CS^W.W`O74JL.[+79=?;ZMS=]ETYG&N]UD#LVO6C3R+7-/G=
MTNNG=Q-#A*_4*KZSF42.K12R6Q63S+6R?):NF.(>AD%AO:A8%W-8]_K_`'^O
MY=P:I]#:).56U&MV_2.$*L6KDUT5A$(A05L.R4"O1^XIU[:4<TFV*G9$;:E]
MGQJJ7%Y?*_-7P%7$V]]AZ7T0G>%4:D#TT*F<Y?RSUK74?E\BL%A@4,99[+VY
MD9Y9-VF+LC?+Y0TQH@26.-<BDJ1"4]/;>P)A"3LR)R6J4[82(12(L@&<ARQG
M->,8XQCC&.,8XQF;?V0C^2+^OS^"W&,N*Z>_S!](/L@ZU?<Q"^,9+[C&.,8X
MQCC&.,8XQG^9QC..V<8SCZ,_#CC&>F-M;C%"-88@1&*V\!A:!4-*0)0A+.`$
MLXM&>(O)J8!H`A`8$D0`C`$(18SC&,<8SW>,8XQCC&.,8XQCC&.,8XQF;?V0
MC^2+^OS^"W&,N*Z>_P`P?2#[(.M7W,0OC&2^XQCC&1'WTF^PE;:;;&SO5*+&
MS/8B+U=(':JHZE9A21P62,@LO&5+1&@(G,<F?&EM$O>&*-`:G<<A>$")F`SN
MPEN&Y2QE2HM^-K:@Z:VQ-D64\6)*K^10C9F=:_VX]ZW69&6:.L<%15\BKZ.W
M*HL3534>-GVDMF,_/:8&0WZZQMEL]&Q#(C<7FSXQOZ)U8SLC2GJ0G1+5VQ['
MVZL2];:DD'FNQ[U-WHW7=[:%M&L]62"N&F):W6";'M;]9$"V_P!YC]D09WC\
M?%5+.ZV9(9)(RH-ER86=M*)9QS[\?O\`Y)G6_5(TXV4W1WGH:$TZJ=:[AQVC
MFPY!FP#R=<3-':"M%;>.N1D2L""+:U<(^B4;(,,?#)%];QF42-B0N+.GEZAP
M//;&U8A4LYR)M6U;L,U;:#54;4&TJ+;2/=6+9F<6M;=BL=_U5KA8.@RDBR\-
MT8G=I2&/*:4L",SQR-@@*Y:X"P6-+XD]82RZ.L:!(TJ_.F<??]_[?X>W*_C^
M7\\L)2VA<L$ZC<X6[05/=D/:[MT`I^OT*O5J([-[(TE%;(C5Y;6.4E(9KMA5
M&1(F+S,FNWF#/9KK(XA!'E,Z.K6TM`GCS-I<5[.<X%H7.K,@W2@VK00IDW"K
M^VZFG^^#Y41EEZZWI)[S4H)A>5RV)K4X1.&[(PT<DO)<Z0E^@&34;D)_.PH6
M',$U=F)]3.IC<QG`+SE&^6P?1)V6-OVN[*;-SLW2S,4QJ&'TQ+UR>)LL1VOJ
MPX+#4<?K`LN:WS4GM-H2Y:JFD7?WMWGB)UF;>!Y9A(#(Y&F<?/\`E^'/X_/[
MLA_%]1K/V(U(IC76<Z_77F:V?U#[3A4"V!<HCL13Z*D]%E<M2W_:%E0FMK.=
MC)]K+$W*/M#EKO1=975(7^5E21S12>-.CFC5I$2=CW]OKZ_?_/+3-O(UU%IW
MM+H895D?J:ESH5?.T9+;82(5P[25$14I^M<P;(C(MAH<UM&KPH?(Y0O&!CCD
M=!8<C8V>:+FLY!+9*H(PWK6<Y4)758[%H&3HJ)WJI+W>=EJQMBL76Z4N=?-M
M8K8I%:CV%O(,J<%VTCLM=]=ZRJICCK_ZUVY2L]CX;`LV'D1I@',TJ5XA9I+.
M/E]W\/I/X_QS9MQG..,8XQF;?V0CCO\`@B_K\_'C'_"WT\8R,6H_7S]K?5'6
M.O/P4/3/J%KU2\+],>WKZ.]*^JU;QIC])>C_`&G%WF/GWF/G7F?GJSS7ROD/
M.E'@\L-C)"^^)_T/OW@?Z(\8Q[XG_0^_>!_HCQC'OB?]#[]X'^B/&,X[+>OQ
M$Y_&7R%3O1:.S6&R=M4LTEB4MN=MD<9D+0M!DI8U/C"\40L:G9M5E9R6I0KT
MJA*>#.0&E##GMQC.+PGK@4]6D,0UQ7'3FK6OZ\:W0I\;8'";'B\4AC<]$/!$
MA(>$,78M?4#&D="7]*F?"G!.A+5EO"<AS`=A:26>%C.RO?$_Z'W[P/\`1'C&
M/?$WP=_P/OI_*!^CM^9+_OQC[^/V?Y\_Z8]\3_H??O`_T1XQCWQ/^A]^\#_1
M'C&/?$_Z'W[P/]$>,8]\3_H??O`_T1XQCWQ/^A]^\#_1'C&/?$_Z'W[P/]$>
M,8]\3_H??O`_T1XQCWQ/^A]^\#_1'C&/?$_Z'W[P/]$>,93/U<NL/^$C^#[_
H`'=O4SU,]M?_`'<]8O27K%[6OYL6+S/S/T%_[KSCSK_T/(?VS&?_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>g838054g76d20.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g838054g76d20.jpg
M_]C_X``02D9)1@`!`0$!+`$L``#_X@Q824-#7U!23T9)3$4``0$```Q(3&EN
M;P(0``!M;G1R4D="(%A96B`'S@`"``D`!@`Q``!A8W-P35-&5`````!)14,@
M<U)'0@``````````````````]M8``0````#3+4A0("``````````````````
M`````````````````````````````````````````````!%C<')T```!4```
M`#-D97-C```!A````&QW='!T```!\````!1B:W!T```"!````!1R6%E:```"
M&````!1G6%E:```"+````!1B6%E:```"0````!1D;6YD```"5````'!D;61D
M```"Q````(AV=65D```#3````(9V:65W```#U````"1L=6UI```#^````!1M
M96%S```$#````"1T96-H```$,`````QR5%)#```$/```"`QG5%)#```$/```
M"`QB5%)#```$/```"`QT97AT`````$-O<'ER:6=H="`H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0``9&5S8P`````````2<U)'0B!)14,V,3DV
M-BTR+C$``````````````!)S4D="($E%0S8Q.38V+3(N,0``````````````
M````````````````````````````````````````````````````6%E:(```
M`````/-1``$````!%LQ865H@`````````````````````%A96B````````!O
MH@``./4```.06%E:(````````&*9``"WA0``&-I865H@````````)*````^$
M``"VSV1E<V,`````````%DE%0R!H='1P.B\O=W=W+FEE8RYC:```````````
M````%DE%0R!H='1P.B\O=W=W+FEE8RYC:```````````````````````````
M``````````````````````````````````!D97-C`````````"Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92`M('-21T(`````````
M`````"Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92`M
M('-21T(`````````````````````````````9&5S8P`````````L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0``````````
M````+%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$``````````````````````````````````'9I97<``````!.D_@`47RX`
M$,\4``/MS``$$PL``UR>`````5A96B```````$P)5@!0````5Q_G;65A<P``
M```````!`````````````````````````H\````"<VEG(`````!#4E0@8W5R
M=@````````0`````!0`*``\`%``9`!X`(P`H`"T`,@`W`#L`0`!%`$H`3P!4
M`%D`7@!C`&@`;0!R`'<`?`"!`(8`BP"0`)4`F@"?`*0`J0"N`+(`MP"\`,$`
MQ@#+`-``U0#;`.``Y0#K`/``]@#[`0$!!P$-`1,!&0$?`24!*P$R`3@!/@%%
M`4P!4@%9`6`!9P%N`74!?`&#`8L!D@&:`:$!J0&Q`;D!P0')`=$!V0'A`>D!
M\@'Z`@,"#`(4`AT")@(O`C@"00)+`E0"70)G`G$">@*$`HX"F`*B`JP"M@+!
M`LL"U0+@`NL"]0,``PL#%@,A`RT#.`-#`T\#6@-F`W(#?@.*`Y8#H@.N`[H#
MQP/3`^`#[`/Y!`8$$P0@!"T$.P1(!%4$8P1Q!'X$C`2:!*@$M@3$!-,$X03P
M!/X%#04<!2L%.@5)!5@%9P5W!88%E@6F!;4%Q075!>4%]@8&!A8&)P8W!D@&
M609J!GL&C`:=!J\&P`;1!N,&]0<'!QD'*P<]!T\'80=T!X8'F0>L![\'T@?E
M!_@("P@?"#((1@A:"&X(@@B6"*H(O@C2".<(^PD0"24).@E/"60)>0F/":0)
MN@G/">4)^PH1"B<*/0I4"FH*@0J8"JX*Q0K<"O,+"PLB"SD+40MI"X`+F`NP
M"\@+X0OY#!(,*@Q##%P,=0R.#*<,P`S9#/,-#0TF#4`-6@UT#8X-J0W##=X-
M^`X3#BX.20YD#G\.FPZV#M(.[@\)#R4/00]>#WH/E@^S#\\/[!`)$"800Q!A
M$'X0FQ"Y$-<0]1$3$3$13Q%M$8P1JA')$>@2!Q(F$D429!*$$J,2PQ+C$P,3
M(Q-#$V,3@Q.D$\43Y10&%"<4211J%(L4K13.%/`5$A4T%585>!6;%;T5X!8#
M%B86219L%H\6LA;6%OH7'1=!%V47B1>N%](7]Q@;&$`891B*&*\8U1CZ&2`9
M11EK&9$9MQG=&@0:*AI1&G<:GAK%&NP;%!L[&V,;BANR&]H<`APJ'%(<>QRC
M',P<]1T>'4<=<!V9'<,=[!X6'D`>:AZ4'KX>Z1\3'SX?:1^4'[\?ZB`5($$@
M;""8(,0@\"$<(4@A=2&A(<XA^R(G(E4B@B*O(MTC"B,X(V8CE"/"(_`D'R1-
M)'PDJR3:)0DE."5H)9<EQR7W)B<F5R:')K<FZ"<8)TDG>B>K)]PH#2@_*'$H
MHBC4*08I."EK*9TIT"H"*C4J:"J;*L\K`BLV*VDKG2O1+`4L.2QN+*(LURT,
M+4$M=BVK+>$N%BY,+H(NMR[N+R0O6B^1+\<O_C`U,&PPI##;,1(Q2C&",;HQ
M\C(J,F,RFS+4,PTS1C-_,[@S\30K-&4TGC38-1,U336'-<(U_38W-G(VKC;I
M-R0W8#><-]<X%#A0.(PXR#D%.4(Y?SF\.?DZ-CIT.K(Z[SLM.VL[JCOH/"<\
M93RD/.,](CUA/:$]X#X@/F`^H#[@/R$_83^B/^)`(T!D0*9`YT$I06I!K$'N
M0C!"<D*U0O=#.D-]0\!$`T1'1(I$SD42155%FD7>1B)&9T:K1O!'-4=[1\!(
M!4A+2)%(UTD=26-)J4GP2C=*?4K$2PQ+4TN:2^),*DQR3+I-`DU*39--W$XE
M3FY.MT\`3TE/DT_=4"=0<5"[40914%&;4>92,5)\4L=3$U-?4ZI3]E1"5(]4
MVU4H5755PE8/5EQ6J5;W5T17DE?@6"]8?5C+61I9:5FX6@=:5EJF6O5;15N5
M6^5<-5R&7-9=)UUX7<E>&EYL7KU?#U]A7[-@!6!78*I@_&%/8:)A]6))8IQB
M\&-#8Y=CZV1`9)1DZ64]99)EYV8]9I)FZ&<]9Y-GZ6@_:)9H[&E#:9II\6I(
M:I]J]VM/:Z=K_VQ7;*]M"&U@;;EN$FYK;L1O'F]X;]%P*W"&<.!Q.G&5<?!R
M2W*F<P%S77.X=!1T<'3,=2AUA77A=CYVFW;X=U9WLW@1>&YXS'DJ>8EYYWI&
M>J5[!'MC>\)\(7R!?.%]07VA?@%^8G["?R-_A'_E@$>`J($*@6N!S8(P@I*"
M](-7@[J$'82`A..%1X6KA@Z&<H;7ASN'GX@$B&F(SHDSB9F)_HIDBLJ+,(N6
MB_R,8XS*C3&-F(W_CF:.SH\VCYZ0!I!ND-:1/Y&HDA&2>I+CDTV3MI0@E(J4
M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY`
MGJZ?'9^+G_J@::#8H4>AMJ(FHI:C!J-VH^:D5J3'I3BEJ:8:IHNF_:=NI^"H
M4JC$J3>IJ:H<JH^K`JMUJ^FL7*S0K42MN*XMKJ&O%J^+L`"P=;#JL6"QUK)+
MLL*S.+.NM"6TG+43M8JV`;9YMO"W:+?@N%FXT;E*N<*Z.[JUNRZ[I[PAO)N]
M%;V/O@J^A+[_OWJ_]<!PP.S!9\'CPE_"V\-8P]3$4<3.Q4O%R,9&QL/'0<>_
MR#W(O,DZR;G*.,JWRS;+MLPUS+7--<VUSC;.ML\WS[C0.="ZT3S1OM(_TL'3
M1-/&U$G4R]5.U='65=;8UUS7X-ADV.C9;-GQVG;:^]N`W`7<BMT0W9;>'-ZB
MWRG?K^`VX+WA1.',XE/BV^-CX^OD<^3\Y83F#>:6YQ_GJ>@RZ+SI1NG0ZEOJ
MY>MPZ_OLANT1[9SN*.ZT[T#OS/!8\.7Q<O'_\HSS&?.G]#3TPO50]=[V;?;[
M]XKX&?BH^3CYQ_I7^N?[=_P'_)C]*?VZ_DO^W/]M____VP!#``,"`@,"`@,#
M`@,#`P,#!`<%!`0$!`D&!P4'"@D+"PH)"@H,#1$.#`P0#`H*#A0/$!$2$Q,3
M"PX4%A02%A$2$Q+_VP!#`0,#`P0$!`@%!0@2#`H,$A(2$A(2$A(2$A(2$A(2
M$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A+_P``1"`,^`QL#
M`2(``A$!`Q$!_\0`'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`
MM1```@$#`P($`P4%!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*Q
MP152T?`D,V)R@@D*%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA9
M6F-D969G:&EJ<W1U=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*S
MM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ
M_\0`'P$``P$!`0$!`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#
M!`<%!`0``0)W``$"`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1
M"A8D-.$E\1<8&1HF)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI
M:G-T=79W>'EZ@H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZ
MPL/$Q<;'R,G*TM/4U=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1
M`Q$`/P#]4Z***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`***
M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH
M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`
MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B
MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`***
M*`"BBB@`HHHH`****`"BBN0\=>);JT^S:-X9(?7=8REN<9%M&/OSM[*.GJ<4
M`=?1532;.33]-MK:XN)KN2")4>>8Y>4@8+$^IZU;H`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@"G=ZQ96%
MW:VMY<Q0W%\S+;QNV#(0,D#\*N5B^*_"MIXMTI[._P!R,&$D$Z'#V\@^ZZGL
M0:Q/"7B^XAN+C0O&K1V^M:=&7,Y^6.]@'_+9#]/O#L:`-WQ5XEM?">BS:AJ!
M)5,+%$O+S2'A44=R36/X$\-7-K]IUSQ*`VO:QAI^<BVB_@@3V`Z^IS65X?A?
MXB>($\1WJL-$TYBNB6[])GZ-<L/S"^W->B`8I@+1112`:Z;U(Z'L:B@N/,=X
MW&V6/[P]NQ'M4]9.N2_V>(=07(%NX$V/XHSP?R)!H`UJ*0$,`1R#TI:`"BBB
M@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`
M"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*
M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`,?Q?
MJ<VC^'-0O+)D6>VMI)(]PR-P4D<5Y+X>U&/XI6UQ8_$14-SI\27L$]M^X;R&
M7YAD?PG&".X->H^/XVE\':O'&C2.]G*%51DD[3P!7B>N:)JVG>'?"^H:-:W)
MGO\`2&TV[C$1+)NZ$CJ.O?TKXOB#'8S"8^%:BVX0C=Q6SN[?>KW]#W\KPV'Q
M&'E2G92D[)O=:7^YVL=5\.OB'J^M>+QI\T=M!HLMK)+80QP[2L2-M3GZ`UTM
MA\5;#4/%LN@P0W(DC=XX[DLOERN@RRCO7(O8S>"O&44D-I=2Q:7X7,:-'$6#
MR`],CJ<]O2N9'A_Q/HF@Z-K$NF0NEC??;B869KA_-8%E9`.!_*O)IYMF>$@H
M2YI2C)N;M?W?=5O+=M>AVRP&#Q$^96BG%*.MM==?/97]3U+6/BBEKK5SINB:
M7J>L3V(!NC:*N(O8YZGVJOJ'Q7:QU.6QM=(U6]FBM%NI1$J9BC(!.5)!R,\U
MRV@ZT?`/B?Q`VLZ9JDUMK4RW5I-;V[2;P<D*<=#SW]*J>*_#NH^+/'&L3Z8=
M1TW?HJ2Q_(5\T[1^Z8_CR/6MZV=Y@Z+E2FW4<[<BBO=7O6LVNJ2WOY&=/+\(
MJJC4C:'+?F;>K]WMM9M_J=Y+\7-,71-.O[6&\NY-6<I:6<2CS78<$$=!@]ZA
MM/'\7B7^T]%U2SO=&U`6CR>1=@<IC[P(]*X*T6;3++P1KT.D7PLM($MO>VZ0
MLSQ,2?GP1DYSG-:%[JR:YXJOO$PM+ZUT'2-(EAEFG@,;2,P(PJGD_>_E6N'S
MO,*E6FN;WFX+EY?B3BG*5]U9W\E;4FME^$A">FB4GS<VS3:4;>:M^9F^%O&O
MQ!^)%E<:CX3UG0?#7AZUF-K93:C;>;)>%."QR<+G':NIU'XKZIX"T+P^GC*R
M77M>UJYDMHDT%E,<K*?E(W$=01QZYKQ/3CINE?#I_!GQ(\/^(;N*SN)+O0[[
M3;>1XKKS`3&VY?KW]?45!JOAN_@^$WPUMM6L=>MDM]4NGO39VKFYMXF;(<+C
M(..1FKCF6)A&3C)N=M;MZ/F2:Y;67EY'H2R[#5*JC))0YK*R6L>5M/F3N]M=
MM3W7Q)\=_P#A#O"UMK'B?POK^GO=WK6J6,IC\X84MOX;&T@'WXK7M?B_IVH:
MUX7L=.BGN$\56,MY;3J5V1K&N65N^[.1[8KR74-/L]5\*^`;'0$\3:I8V_BL
M+<3:Q:NL^Q@2Q;(^Y\V`>E9?P_\`#6L^%?C3I7A^]LKQM-\.'4397IA;RG@F
M3<@W=,YX^M=KS3'0K1CO%N*O;J[7V2Z7.&.6X.5"<MI1YW:[6BO;1OO;[SU:
M/]H;13X#?Q1=6U_!;_;WL8+0!7GN)E/"H!QSUIES\>_[(T*]U/Q5X7\1Z']D
M\KR8+F-,W9D)"*C`XSQR#TKQ6P\+:XGPDT/4K/2=0N9?#OBZ>]N++R2)'A!7
MYE4\GI_6O3_%WQ&\,_$KP;J-KK.@>,#I&Z$7$\>F.LD+DDAD'4[2O)`/6BEF
M>+J1;G449<J:36C;6KOY;!7R["4YKD@Y1YFFT]8I/1)>:U_(]+\"^,]0\5QW
M)U?P[JOA^6!DVI>[&$JL,AD9201Z^E==7@W[,YUBW37[)I=6N_"]K<)_8UUJ
MENT$SYSN`5N=H`'MFO>:][*\1.OA8U)WOY_\!+3L[:GBYE0C0Q4Z<+67:_ZM
MN_=7T"BBBO0.$****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH
M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`
MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B
MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@#)\5RR6_A
MS4IK=S'+#:R.CKU5@IP157P+<RW_`(4TFYO':6::RB9W;JS%1DFIO&7_`"*V
MK?\`7E-_Z`:K_#PY\$:'_P!>$/\`Z"*\MM_VG:^G)_[<=:2^JM]>;]#H"BGJ
MH./:CRUQC:,?2G45Z=D<@T1J.B@?A1Y:?W5_*G44P&[%'8?E7EOQLOWU0:5X
M0TK!OO$%R@FV]4@4Y8GVR/\`QVNR\;>-].\#Z0]YJLFYV!%O;IS)._95']>U
M<O\`#/PKJ%SJEWXO\:*!K&J)BWMR.+.#LHST)&/\DTXI+4#T*PLXM/L;>UM5
M"0V\2QQKZ*HP/Y5.%`)(`R>II:*0";1Z"FF)",%5(';%/HH`;L4D'`R.^*7:
M,@X&1WI:*`&[%)S@9'?%.HHH`****`"BBB@`HHHH`****`"BBB@`HHHH`***
M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH
M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`
MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B
MBB@`HHHH`H:[9?VEI%W9[MGVJ%XM^,[=P(S^M0>&--_L;1K2P+^9]B@2'?C&
M[:,9Q6M16/L(>U]K;WK6^6Y?/+DY.FY',[1H61&D(_A4@$_G61/XNT^S)74O
MM5DP./W]LX'_`'T`5_6MNBMB#E;OXG>&[13G4?-?M'!;R2L?H%4UC7?CGQ#X
MA!A\#>&;Q-XXU#6%^S0I[A/O-^0KT.BF!P'AKX6K!JRZYXTOGU_71]QY1B&V
M]HTZ#'K7?`8%+12`***\9_;)U*[T?]EOXF7VD75S8WMKX?GD@N+:9HI(F&,%
M64@@^X-`'LU)G'6OSOTSXG>)/!_PW\1?`Z/6-6N/%_B+7=)LO"FI37LDETNF
M:O&LTDWFLQ8^2J7*YSD97TKL/@A\3?$'@/\`9P4:?XLT&*_3XAZMHMI>^,I+
MS4))+>*XD"10Q1$S328487.`-QSQ0!]P9HS7QEX4_:_\=^/?#W@?1O"NE>%!
MXZ\8>*]7T47MW'<)IL5MIWS2W/DEA*&963$9;.<Y]*ZK5_BY\:K7XS>$/AGI
MVF_#B76M0\-_VUX@OY&NA;0+'=F*3R!G<=T>S:K#AB<D@4`?4>1ZBEKXOU?]
MK_QY;>%M0^*-CHWA4_"W3_&8\/+IKK.VL7,(N!;/<!U8QJWF$D1E2<#KR">+
MDM(/CYXW^,7BGXMZ-\0?&=EX"\5+H6A^$_#VIM9#3[6.,N;LQB6'<YY)9CG!
MP`>P!^@>:,U\+G]KUO#OA;X<^&_@C%JLUKJGA677!J7BO2[[7KM+;SWBA@=+
M3,C.65AYK-M"JH.2:["/]I;XJ>,M7^%.B>!O"OAS0->^(7A6_P!4U"U\4K<I
M_9DUJX4@*N'*L>BD`X<'/'(!];//'&Z(\B*\F=BE@"V!DX'?BG9KX?TG]H*7
MXBZK^SSXL\=^'M,BUG^T?%,.H26DLP6REL;=UE:V4/APZIC$@;OC'6NR\&_'
M+XW>*_@Q??%;3?"O@W5]&U+1;B_\/>&]-^TMJ182A8!(V2DF8][LJA6!`4<G
M@`^KZ*\>_9D^*]Y\7?!%UJNM:YX:UF^M[TP2IHMA<V#6)"(3!<V]P3)',K%L
MYX(P17RE^R';W_C?XU>+)_$_AKXA>(8-,\?ZHMOXI'BR9-,TP0L6CMI+3SAO
M^;&/D*_.HZ"@#]#<T9KXG\%?M;_%;5M/\!^*_$FB>!H_!?BSQQ+X4EBLS<&_
M5_.DBCG&YMBC=&05Y.%S_%@8OAS]HCXB_"/3?C]XH^(%_I?BFV\->,O[(TW2
MXX[D^5J$P@6)(268I:`29*`%R<X/(H'8^\L@=2*,U\5C]L3Q]I7PP^*6LZIX
M>L;V^\#:=97^EZJ_A[4-(L=0,TRQR6QANL2;TY^96P=PXXYU_B'^T'\8?AAX
M?\&S>/M.\"^'8O$0N9]4\2C3[_4=*T=<(;:VF$1#H[!FW2GY,KQWH$?7N1ZT
M5\Y?MD_%;7/AU^R[J/B/P3J2P:IJ?V&TBU?3\2);)<R(KSQL<@+M8[6[;E-8
M^H?#GP9^Q/\`"O7OB;X4E\5Z[?:=HP2>&]\0SW$.L7,TD:I-*CL4#F0K\Z@8
M5FH`^HKBXBM(7FNI8X88UW/)(P55'J2>@ID=_;2SK#%<0/,T0E6-9`6*'HV.
MNWWZ5\)_'_XT_$*R\!>.OAS\;;/PI-=^*OA=>Z[IUWX;AN$2T:,8D@F\QF#=
M>)`0,C&/F%:V@:_)X3^/-KK5I=Z+83Z9^SO8SQW.M3M#91,MRI!G=065,XS@
M9]*`/MBYNH;.!Y[N:*"&,9>21PJJ/4D\"I%8.H9"&4C((.<BOSS^+?[0WB+X
MF?!;X[>#?%\WAG5HM)\$V>K6FK:%IUY81R+/<!#&8KGYFQM#!Q@$&O2;/]J'
MQO\`!>YU'3/C/I'AB\LM,^&8\6:>GAUIA)$(G6'[-*\I(<DLOSJ`.IQ0.Q]A
MT9KY-TC]H_XF>&O%WA/1?B[IO@Z7_A87A.^UK1FT".XSILUO!Y_DW!=F$B%6
M"[UVC(]"*K>!?VB?BEX@_9_L/B-XTN/A3X03Q1-9+H`NOMLR['+K)OBCR\LS
ME5,<2'H3D\4"/KO(]::)HS*8A(AE50Q0,-P!S@X].#^5?`WQ+_:.^)/CK]EW
MQAK>A:GHN@ZOX1\=1Z'>ZII<%W:M>0K/`(W@C<AX=QE`=7R2H(X)XZ7QI\;+
MSX'_`!=^)/B#Q=H>BZMXHT#X::0\]WILEQ;QW]S->/%%"$DD98X1(X.<;L%L
MD]*!V/M;(]11D5\D:A^TE\2OAKXAUSPQ\5K#P=>ZVWPZO/%FC7.@V]RMO!+;
M*Q>VN`[-N4D##JR@XQU85>^#O[1'Q*UWXE_#72OBEI/@VVT7XI^%9]9TG^PV
MG>>SDACCD*3-(<$%'S\HX+8[$D$?55)7S+^U1^T-XF^#E]J!\&ZQX`4Z3H$F
MJR:/J5G>WNH7>TGM!A+>(X"B20X+$]`*S_$_[0?Q/UWX@:'X9^$6D>"XWUGX
M;Q>+Y)-?DG;[.[-@PKY9&\$E5&<8R6.<8H`^JLU%:WEO>Q>99SPSQ[BN^)PP
MR#@C([@U\@^%/VK?B'\7)/A;I'PIT?PC:>(O%GA.X\1:Z^MF;[+"L$QM_*@$
M;;OGE1L,=Q52"0>:O?L8R7"?L@>(YIU%I>+JOB9Y%BD+"*3[3.2%;C.#T/'3
M-`'UG+-';QM).Z1QH,LSL``/<T[(KX!\#:Z;;_@D_P#VMK]JOB#R],E,EMJ-
MS-BX7^TBH5I$<28'LPZ8Z<5[/X7^+OQ)^)'Q1\0^'?A39>"[/PS\/9M,L=8D
MUO[0]S>RS1)+.L!C;"!(S\I<'<WXX`/I?-&1ZU\6>"/VV/%OCKXC:4NA>&?M
MOA'6/%;Z(EG!H&H&ZMK4.8OM\E]M^RX#KN:,<J#@G()IEQ^UK\5;2SU/Q7/H
MG@5O`WA[XEOX0OD4W!U"XA-RL(F0;O+5E#H,<[B2<`#%`6/M;(]:*^58?VH_
M$>C_`!C\9:)\1X]"\*Z-X774+FPT6[T^Z74=<L;:W:5;JTNB?L\FXJ28P-R@
M&LW]G7]K;QK\6/B%X9T_7_#<;Z#XOL+F\6:QT#4+4:$47S(4FNIU\FY$B?+N
MCP-V,9S0!]>4M?)G[?/C#2Y-+\$_#;6O%%MX1M/B!K).KZK-?"U%MIULADDR
M^1C=)Y2CU/%<7\./VM]5TC]E#X?7%EJ&@3:\OB,>#M3U[6)FN+.S:`.5NI!&
MP>17ACC((./GW$@"@#[FR*,U\46_[4OQBF^''@;5K+1_`U_KOQ#\;SZ!HJR6
M=Y9VDEHJ2+'=GS&\S:[1^8#CE"!C/-5?&'[:7Q"\/>*]?T;2?#NFZO>^`WL[
M'6K#3_#^I7K:U?%4:Z6UGB4QVR*&^3SLDXSB@#[AR/449'K7Q7\5/VV/%>A_
M$+Q9I'PZ\-+?VG@9K2&YTZ3P_J%_=ZO<2*LDL4<UNIBMMJ.`#+G)!.,<5;^+
MW[5/Q.\)^)?BFO@G1/!Q\/\`POT72M9O#J_VC[7.EU$'>W4(0H<?/\YQC:!@
MYX`/LG(]11D>M?'R_M:>//A_XDUY/C7X<\-QZ4OP]E\::1!H-Q(\\4:2*@M9
MWD^5G^=0750.IY%4_AU^UWX^U^U\1R>(/#UG<0VG@:\\16E_;^'-1TZUL+N"
M,NMG,]R`)]P*D/&0"%..O`%C[.I,C.*^0?AW^T=\7?$7B;X=:?XLTKP!90?%
MSPG=ZGX=:R^TR-8W<,*RJ+G+#=&58,0F"-VW/&3TO[!OB/QQXN^",.J_$O7+
M;7A<:E>QV-PPE-VHCNI4<32.Q##(&P`#"@`Y-`'TS39)HXB@ED1#(VU`S`;C
MC.!ZG`-?$.H?MV^)=!;P]IVLZ-HTFN6GCV_T/QG#%#(L>G:;;W$42W*9?*DB
MY@P6X))X'%6/$'QIU/XF:Y\.M7U'0]`N].D^-%SHWA.X\VX1HX+>*6,7;['`
M=VD608(V[?X<\T`?:EU=P64#S7DT4$,8R\DKA54>Y/`J16#`%2"#R"#7YQ>)
MO$'Q%\2_LG_M-'XF:_I>N6>E^);K3X%C2?S+>>.[MMR1,[$+:@$;$QN!SD\U
M](?`_P"+GQ`D^,<OPX^+FG^%(2W@RU\0:3/H!F.R(R"%X9C(>6!Q@@`'!/&<
M4`?1U%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!1110`5S7Q)^'^E?%7P)KGA'Q5]I_LCQ!9O:7GV:7RI/+;KM;!P?>NEHH`\
MP_X9S\%GXG>%_'SV=R_B/PAHO]CZ;,TV4$`4J&=<?,X5F`;MN-<[<_L>^!)/
M#VG:787/BC2Y='\0WNOZ=J>GZN\%Y:7=V6,Y24#A6WD8QP*Z?]H_XMS_``)^
M"?BKQW9:=%J\_AVV25+*68Q+*7E2/!8`D`;\].U9MU^U-\-O#L&@P^._%FB^
M'M9UO3+2^_L^XG):!;A%9-[`84$M@%L9QF@#`3]BKX?0>#M*\/V-SXLLSH>O
MS:]IVK6^MR)J%M>S#$KK<8W?-W!S75^"OV=_"_@7Q5H_B/2[G7[O6-%T&71(
M;K4=2:Z>:WDN#<.\K-R\AD).XGIQC%'C3]IWX5?#K5[O2O&_COP_H^I6+1"X
MM;FXQ)'YJ!XV*@$[2I!W=.1SS6GK_P`=_A_X7\5Z5X9UWQ5I5KKVM"$V-AO+
MR2B9ML1PH.T.?NEL9[4`<)/^Q?\`#NX\3W.J2-XF&G7NNC7KKPX-:E_LFXU`
M'=Y[VW0MN`;&<9`XJ_X]_9,\&>.O&FI>+(K_`,6^%]=UNS%IJ]SX:UR73QJ4
M07:!.JY5R%XS@'%=?8_'+P%J?Q!F\#Z=XHTRY\5VWF";38G+/&8UW.I8#:&5
M>2,Y%5O"?[0GPX\=:SJ>D^$?&.BZIJ&D1237<$$Q)6.,D2.I(PZJ1R5)`H`Y
M*X_8]\")I7A"T\-W7BSPO<^!].?3=(U+0M=EM+M;5VW/%)(,[U+?-@CKTQ72
MZ'\`?#NA^*O"?B3[;XAU'6O!VEW>G6-YJ6IO<R3QW+AYFG9N9'+#AB1CH!BF
M>#?VF?A9\0_$MEX?\$>.=`UK6=2MC<VEG:7&]YHPNYB.,9`Y*YR.XK(^*/[5
M'@OX2?%7PEX%\57/EWWBA96DN%;Y-.4+^Z,HP2?-;*+C/(R<#F@!_AK]E/P+
MX5F\(2:8FKL?!.I:IJ&F+/>[U,NH`BX$@Q\ZG<<#C%9'AK]C3P9X/M;VS\,Z
M[\0=.T^>">*RLK?Q1.D.D^;,DSM:*/\`5-O1>>>,CN<]EK_[1GPS\+>-X_"'
MB'QIH=AXDDEBB^P33X9))?\`5H[8VHS=@Q!Y'K63^T[\?'_9U^']AXD@T$^(
MYM1URUTF&S%Z+7YY]VUBY5N`5';O0!O?"3X)Z!\&K?6AX;N-:U&]\1W_`-OU
M;4M9OVO+J\FV!`SR'&<*H`XKC?!O[(_ACX?>*KG7/!WB;XA:6+[6WUJ]TR#Q
M$ZV-U<N^]_,A"X93T(]!BD\`_M&:GJ?Q2N?AU\6/!D_@;Q0=+;5=.9=234++
M4+1"!(R3JJX9"?F5E'UKH-*_:A^%.MV6NW>E>.=#N[?PS:M=:I)%(Q%O`K;6
MEZ?,@/5ER!QSS0!0T[]E;P/I?@SPWX7M1K']E^%?%'_"2Z>&OB7%[YSR_.V/
MF3?(WR^F*J:G^R)X#UG4/'4^J2>)+BR^(LAGUO2CK$BV;7),9%Q'&N-DH,28
M8'C'%=Y>?&#P5IU]I=I?>)=)MY];TJ75[`23A1/8Q*'DN`W3RU5@221P:\W\
M=_M6^%Y/@EX_\9_!C7="\4ZCX+TF2\-LS/M#@93S$^5]C<_,.#C@T`7)/V3_
M``U?^"_$7A?Q+XF^(?B/2_$MG#9W`UKQ)+=O;Q12"11"6&$)8#)P20,9K9^*
MG[.V@_%VRM[+Q!KGC+3K"/3FTVYL]'UN2T@O[9L92XC`*OTQG`."15?4?VFO
M`/@?1/#+_%3Q9H?A[5O$&CV^H"TED;(61%+-@`E4W,0"V!QUX-:WC3]HCX:_
M#N<0^-?&FA:5,]E%?1QS7&6EMY&8)*@4'>I*MRN>`3TYH`V-<^%7A?Q'\.G\
M"ZWI-O=^%7TY-/\`[.DR4$"*%C4$\@J%7#9R"H.<UYKX;_8S\!:#HNHZ/J5[
MXR\3:5J&B/H@LM?\13WD5K9NP9DA4D!"2J_,.1M&"*]1N_'VF3?#FZ\9>&KB
M#6M*32)-3LY;:4;+N)8C(NUNVX#&>V:\4^"G[9NF?%+X;>+_`!5XET0^$YO!
MNG1ZK=Z?+?"Y,MC+;>?#,K[%X8!EQCAEH`U]/_8N\!6NEZ[9ZI?>,->?7/#Y
M\/?:]8UR2[GL=.)R;>V9A^[4D+G@GY16QXE_91\`^+Y+P^(;;4[I+_P=%X2F
MB-ZRJ;"*19$(P,B4.JG?GMTKR[P_^WO;WOPJ\0>*/$?@?5-,UW2]>M="T[PW
M;WJW,^IWUS"DL$2MM782'^;(.W!Z]*[;0?C#\7]'T_7M3^,'PLTG0]*T[1+W
M5+:ZTKQ*EYM:"+S%MYU*`JS@$;UW`$'VH`+?]BSP)]A\66^L:GXTUV3QKI$.
MD:M=ZMKKW,[VL4@>-$<CY-I&!CM^=:'A']D'X?\`A.75WE_X2'Q`=7T)O#Y&
MO:Q+??9=,;K:0%CF./Z'/`YKSWP=^V[K.H^'/`OB[Q[\,[KP_P"`_']W'9:?
MKUEK<=_]DGE<I$+B$1HR*S@C<"<5#XG_`&W=8T+Q%J^JV7@6*[^%GAWQ8OA7
M5/$;:LL=R+PNL;31P%<-`KL`26SP>E`ST?P+^R%X'\!ZC'>VUWXKUF>RT:;1
MM*_MO6Y+U=(LI5VR16H;B,%<+GDX`%7+_P#96\%7WPN\(>!8Y?$%EIW@.>&X
M\/W]GJ;0WUC-'NVR+,!][#L,D=ZSI_VB]53]I+P_\,O^$-OK+2=:M=0EC\07
M\RQB[:UC#,;>)<EH\LHWL5SDX'&:74/VB-7M?VD?#?PR_P"$+OK/2]<BOV7Q
M!?SK&MTUK")&^SQ#)9/F4;VV@DD`<&@0^W_9`\"0_"_Q)X$GG\37FD^+-6&K
MZG=76KO+>27@:-O.$Y&=Q:)6.<\DU:E_9/\``VHMKC>)7\0>(I/$GAJ'P[JD
MNKZJ]Q)=6D4C2(S/PWF[F)WY[`<8K._:X_:07]G3P1IMYILFBG7]>U."RL(]
M5,IACC9P)KAUC^9DC4@D`@G(QZ5L77[3/@'P/IWAZV^*OCCPKINO:SIEO>E+
M>2189$D`Q*H8%HXF)^4R8X^E`&=X;_9"\$^'[?75N;[Q;KUUKWAY_#KW^MZW
M)>7%GIK`AK>W=A^[4Y!Z'E173:5\`?"NC:Y\/]6LQJ7VOX::1-I.A[[K*_9Y
M8DB;S1CYVVQK@\<U9\1?'[X=>$_%FG^&/$?C#1;#7]6-M]AT^6?][<_:&982
M@'W@Q4@$<?F*\]_:8_:N;]G3Q#X9L#X5G\16VMVEW?7L\-\(&L;6U:+SI-I1
MM^%E+8R.$-`&S\5/V3/!?Q<\3:IKFO7GBK3+O7],CTO68]&UJ2SBU2UC+%(Y
MT&0X&X^GOFNBT?X">%]#\6Z?XCL?[2&I:9X23PK`7NLI]@5@PRN.9,@?-^E>
M=?M"?MB67P0U/PW;:1H#^+8]9LH]2O)K:^6`65C)<0P13<JV_>\PP./NGFO5
MK_XT^"-*L/%MYJ?B33K>W\"2)'XDD=F`TQG4,HDXX)5E/&>M`'GDG[%_P_70
MO!>FZ9<^+-(D\!VUS::3J.F:W):W?V:X8M-#)*@!9&+'C@\\&NU^&?P)\,?"
M7X:R^!?"`U%-!F:[)6YNS-*/M)8R?.1GJQQG/XUYIKO[6]OX,\<?&"'Q7%IP
M\+?#G0])U'39[<LMQJ,EY`T@BR25RS*JI@#KSZUH^%/VI]-\?ZU\/;GPI>^'
M4\->+-$U"_U%;R[==0M);:)':.*,+M<1EF$C9P,#;GN#,?0/V`/AQX<\+ZKX
M;L-8^(+^']7T\V,^ES^)9)+9(S*DNY(B-JOO0'<!W;UKK];_`&3_``;K/Q`D
M\80WWBS2=2NQ8C4K?2M<EM;;4_LF/)^T1+Q)@*H/3('/4UM^%/VE/AAX[\1V
MOA_P;XWT'5]:O[4W5K:6MQO::,(')4XP2%.2N<CN!7$_";]J_1=3^!6B>/OC
M7J>A>%)-8U*]LHHXS)LD:&XEC41H2SL=D88XSCV%`C=T7]E?POX9\63:SX7U
MWQWHUI<ZR=8N-`L?$<T>ES73.)'9K?IM9P"R@@'TQQ4EQ^ROX(N?!>K>%I1K
M']E:UXM/BJZ`OOWGV\S)-\K8XCWHOR^F1FO1]'\7Z3XF\*P^(?"M]:ZOI5U:
MFYM;JUE#QS)@D8(^F/4'@U\T_#?]MS6/&=_\.)M>^'D6D^'OB=J4NG:5?6OB
M2*\N(I4W\RVPC5E3,;9.>!CU%`'J#?LN^$[OX@P^+=>U'Q;KUQ9SWD^GZ9JV
MMR7-AI[W:LDQ@A;A`5=E`S@`].!A?AE^S)X>^$VJZ=<>%/$7CYM+T<2KIV@7
MOB2:XTVT#AEPD#<84,VT$G&<]<5K?'OXUV7P)\"G7[W3;W6[R[O(=.TC2;(?
MOM0OIB5BA!/"Y(Y8]`._`K$\`?%GQQ9Z-K.I_M'^$-#^'>F:39+>?VK!XBCO
M;8H2=T;_`"JR2*`,]0=V`<T`=;?_``=\-ZM\4$\>ZO;RW^N0Z,=(MTNF$EO;
MP&3S&*1$8#LP&6ZX&.E?._QZ_8V?4=7M-8^$>E1ZA#?^+AK_`(ET.?7'TO[1
M*+9H0UG<(A-N3N)<+][`Z8Q7>_%K]K#1-*^`WB#Q_P#!75-!\5S:'?6=I)%*
MS[(VFN(HR)$!5U.R0L.F<=ZZGX3_`!;U;Q[\5?BSX8U6TL(++P!JEE9V$MN'
M\R=9[82L9,DC(8X&`.*`.&^#G[-VMR>'M"?XZZKJ=[?>$_%C:]X5TY=9:^.C
M0K'Y<5K)=,BM<*`6/(`&0!TKK_%?[+?AGQ-XTU?Q18:[XZ\+:IXA2)=9'ASQ
M%-81:CY:[$:5%X+!/ER,'%<OX-_:_A\3?M#ZS\,-3\-2:3#9:G>Z7IVMO?B1
M+^\M8XI7B\O8"A,4NX?,?NFH_!?[9%AXN^.>O>!)=!.GZ'I%MJ4\/BB74%\F
MX73WCCN6,>T;4#NPW;C]PT`=5XJ_97\+^)/%^H^)=/UWQWX7U36[:&WU9O#O
MB.:Q345B39&9E7(9@GR[A@X[YYJUXC_9@\%^*?\`A/\`^U?[8/\`PLG2[/3-
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M^$_VC/AEX[O-9M?"'C?P_JLWAZS-]J?V>Z!6VMAUF9ON^6.[`D4`0Z5^SUX3
MT;4_AU?V8U/S_A=IDVFZ!ON]P$$L*PMYHQ\YV(,'CFI/@[\!O#_P.L-1L/!=
M]XBETV_N7G2QU+4WNH+-G=G<0(>(PS.2>YXR:K^'/VG?A7XNT[7+_P`.>-]%
MO;7PU9&_U5T=E-M;#.9B"`2G'W@".GJ*N^"/VA?AM\2M=OM&\!^,]"US4M.M
M?M=S!9W._9!D#S,]"H)`)!.*`.4U[]COX<>)/%?C[Q#JEGJ3ZC\2-+_L[6BM
MZ0@B/EY:$8_=N3%&2PZE16KIW[,G@K2?#7P[T*PBU**P^&&I+J.A@7?SFX`<
M;ICC]YGS&)Z9)S7.>-/VN/!MQX"\4ZE\'/%O@K7M;\-)!)-%J-^\-I&DERD)
M=Y%7E<E@"N06VC/-=UXB_:`^'O@[Q38>&?%OB[1=+\0ZBL)BL9I\,/-.(]QQ
MA-QZ;B,T`<C>?L?^"+[3_'^G37WBP:3\2;A[G6=-767^S+.\R2O-#'C".6C4
M%N>!BNZL?A#H&G_$R'QW!]N_MZ#PZN@(6N,Q?9%E$H^3'W]P^]GI4=U\<?`=
MG\0H/`L_BC3/^$MN&")I2.7EW%"X4X!"L5!;!(..>XKN>M`"T444`%%%%`!1
M110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%
M%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110!\\?M
MO^&?&_Q%^"6J^!?AEX2D\27'B]!;7%VNI0VJZ8(YHI%D<2$%PVUAA3D8]Z\6
M_:'^#WQN\2^'?$W@3P[HE]K/ANZ\,Z3IVB2:5J&GV=M(]O&OVAK_`,T>?(V]
M,1JK!0".>37WA10!\>>)OV=_$^LZC^T9<2^&;2[;QKX*TS3?#<DSP.US<0V+
M(\8).4Q,(^6P,J".F:Q[[X0_%#P_XQ\#:K\+_">N:)XJATK0-.\2:X^O6DND
M:G:011K<1W=JY,AEBPZH\8R<`@\\?;=%`'Q=+\%OB.WQ;\567PWT#7?`W@WQ
MC_;7_"2M?:Y:WFGW,\\#QP7MC&O[^"9W968<`#([5B_L_P#[._BWPQJ7A6/Q
MSX*\=0ZOX/\`#VH:9:ZC>>,;.[TBV\VV:(BUMT`EVRG9@$#;G))QS]UT4!<^
M+/AK^SCXP\,>%/V6(IO#-M8ZIX`U&\E\5O%-`'M8Y8)A\SJ?WFYV3(4G/4]*
M]/\`V@O!WB^X^-?P>\:>"/"TWBJR\(W.IKJ=M;WT%M)&+FW2*-\RLH(!!)QD
MX'O7T)10!\%^-?V?_BA/X4^+?PRTWP/!JEM\3/&G]LV7C<ZM;HMM;R3Q2'[2
MC'SMT0C95"*>#Q[^N_MJ?"/Q7\1/@=X8T#X=Z9-XCU;0_$NEWLL+7<<4DL-N
M'WN7D*J6/'?DFOI>B@#XU\6_`_XD?M'^/-?\8>-O#MM\.X;#P/J?AWPQ82:L
MEW>R75T&!N97A^2--K%=H+'#'K69\`OV;M8&LZ1:?%?P/X[M)=-\(7GAZ?4-
M6\86>H:9!!-&L<D5I;QCS-CXRH;&T#O7V[10%S\YO#G[''Q;\6?#?Q[I'Q$M
M[6UUG0?"<'A'P-)]O0K?645VT[.[J3L\Q4CC.X?=/(ZUTB?L]>,->^'WQ0/_
M``@WC^T\8:_\/SH5K<^)_&-EJ27#"162U@$>-B`AB'<J`,#'/'WK10.Y\0:M
M\(/B9X'USX@2Z+\/$\:V_P`2O`6FZ-!=)JUM#+HUS!9?9Y(9!*P_<;F\S*9R
M0>*Y&S\(^+/@W\=_!WA70?"</Q'\0:%\$(]-N81?PQ-`QN'0RQO-@&,.1'C@
M[#WQ@_H;6?\`\(]I?]N_VU_9UC_;'V;[+_:'V=?/\C=N\KS,;MF[G;G&>:!'
MC'P7^$?B'X>_L>:=\/\`7(;>3Q+:>%[RTD@MY@R?:)A*RQA^AP9`N>G'I7SE
M>?L=_$+4M!^#>E6UDNFV6K>%+#PY\3XENHLPVUG<)<H>&Q(Q(>+Y<\'TK]!*
M*`/ASQ?^RKXZUUOB+J^@Z790:UIGQ6M/&'@^UN[Q$M]5A@@C0Q.5),88!@,X
M(*CL<TMK\'?'WB[XI^*/%5I\,M2\`VFL^`=:LM2M+SQ5'?+J6L7:G88T65E5
M<Y&<(!GH*^XJ*`/@3PA\#/BWXY^"'PN^"_C'P#;^%?#OA&_L[WQ%KNH:U!<&
M[2"=Y?(MH869LMN`W,1WZ=:O:Y\!?BM<Z!XX^#]CX4A;PGXO^(IUQ?%W]J0+
M$FF2W$=Q+&\))E$H,80;5ZGKW/W;10%SY5^(^G_$6Y_:F\">*M"^&&L:AX=\
M#6>HZ8]]'K-BOVQ+M8U69%:0,%7:2P8`^@-2?%.S^(UY^U!X"\5:#\,-8U30
M/`D6I6<EY#K-B@OEO(XU66-'D#*$(;<&`/'&:^IJ*`/#_P!K;X=>(/B5X$\-
M6'@G3QJ-[8>-=&U&X3SDCV6T%P'E?+$`X7G`Y/:O'OBA\(_B1I'C;X[Q>%O`
M4?C73OC+I=O;:;K(U6V@?2F6V,#13+*P;R5)\P;`>AXST^T:*`N?+/P:_9RU
MGP-\>]+U7Q7IMMJVD:!\*])T"TUF=TF)U""8F4(&^=1MP0VT<8&:Z3XV?!G4
M_B3\?/AU?R:8+SPA9^'?$.F:[<&9!Y(O;=(XQM)W-N^;D`XQVKZ"HH`_.[2_
MV1OBI)\"_&<?B[3UU3QO<WVA:'HD'VR'_D":7=1LDF\M@%P&<J3GY1QDUU'Q
MI^#?Q9D?]H;PYX(\"Q^(M.^+D]K>V&L_VU;VT=ND<$:/$T3G>9=R8'13G.1C
MG[IHH'<^1Y/@5XUN-?\`C]*-(18?&WP_TK2=#D>ZCQ<W<.GR0R)][*;78#+8
M'<5SVF_#/Q_+-\)-8\3>#;GP[9?#WX>:YHNKFXU&VF*2?88XXI`(W.5D9&P!
MD@#YL5]LU%<VT5Y!)!=1I-#*I22-URKJ1@@CN".U`C\]OV4_`WC;XA^&OV;+
MVW\#6>A>%?AW!>ZE-X@_M"!UU99X6CC\N)/W@=F.6WCJ,Y-)I7[+GQ1\->&_
MA-JO]B^)9+SPF=>M=4TOP[XCMM/O[5;N\>6&X@FD)C;<A`9<@X(&>U?H#HVB
M:=X<TRWTWP_8VFFZ?:)LM[2TA6**%?[JHH`4>P%7J!W/'_V=OAVWP^^!T/AZ
MV\/ZOX<;??2)INKZK%J%TK2RNVZ2:(!"6+;L#.-V,G%?'OP;_9%\::%<_"]=
M-^%TW@;Q?X;UT7OBCQU)XEC87EF)'+V\<$4KEC(C(G*J/EYZFOTBHH$?*7Q[
M_92\1:KX"LKKX<^*/%'BSQ5X5\367B/2K/Q?K/VF*9[;?FWC;:HCWA^_&5&<
M=:H_''P[\7/VEOA#JFCW7PYE\%7.DWNF:E:64_B:WDFUB:&;?/`KQADC0+@H
M[\EPN5&*^NZ*`/@SQ!^SKXN\2_"7XHQZ-X)\=6WBWQ?-H9DF\6^+++49]1^R
MW2LP5HB%18XQU9LMP`..?H;X)?#WQ!X3^-7QOUWQ!8?9=*\7:UIUSHT_G(_V
MF.*S$;MM!)7#C&&`KVVB@#X;\<?LY?$F6P^*WB/P9I*0^-+7XJ1^*O!#-=Q#
M[9#]GB@DR=V$#*9,AL'Y!5[1?V9_'_PNUWP=)\.=/L+Z\\/?"?5]->_OY8C!
M)KUU.L^V5"<LK2%SG!7``-?:U%`'Y_VOP0^,7C&]\>:IXM\-:^E[JWP@N?#5
MJ^LZMITDEQJ32*^R);;:D4));:&SC!R1P*?^T%\./$7@GP9J'B;Q/ID%OH>E
M?L_)X8O+B:59%CU,S1#R-J-N)]''R@X).*^_:K:AIUIJUG-::I;07EI<(8YH
M)XQ)'(IZJRG@@^AH`_.?PA:ZOX_\(?%WP)-::GXA^*WB[X?6_P!CNHM;L+ZQ
M:P@_=6UN)+8(D,FYW)\P`MR<U[1X@^"GCW0_B'H.O_"[P[H]K=:9\&[G0DDG
M,*6_]K90PPRH/OJ,-R04[$X-?3/A3X>^%O`<4\7@CPYH7A^.Y8-,FEZ?%:B4
M@8!;8HS^-=!0!^?L/P,^,7C"[^(6J^*?#6O+?:S\(+CPU:/K.K:?++<ZD9%?
M9&MMM2*$DMM#=,')Z"NZ\2?LS>*M6UWP'#X?TFWT.VM_@WJ7AG5+^VEBA^RW
M\T$2Q(P4[F`?S#D`@<GO7V110!\.:Q\.?BGXS_90NOAE+\(K7PUJVB>'],L8
M+J+6+1UU*:"[B+K$%;*Q[$>4EV'S'`'>LCX@?LQ>,9_B1\34UCPOX\\7^%O'
M^H6U_!_PCWC"TTV"4+&@^SWD4PW8C=/E9<_+T%??5%`'R.?AG\0-`_:7M=:^
M%WA36O#6BZMK4+^,KNYURTNM(UFS2`+]H2W/[Z.[X505`&1SQ7UL@(1<C!Q3
MJ*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBO-M#_:)\!>(_BYK/PST;7$N/&6@P>=>V`A<!0-NX+(1M9E
M#J6`.1F@#TFBBO&/BS\=;OX9?%CP;H5Y86;>&-=B(U75'E=9=/DDF2&W;`^4
MQF5U5B<8W@YX-`'L]%?-OPR_:RN?&+>-;W6?#-S'I&AW-BVB#37$EQ>6ETDK
M12S>:R1ID1;A\P&)%')Z[<_[97@7^Q;O6=)L?%>L:/IF@1ZYJ=_8:5OBT^WD
M21XTE+,")&$+\`$`@9(R*`/=Z*\3OOVL/"NG6=E-J6B>-;0W%@NIWL,NC%9=
M)L&G,*7=TF[,<3,"PQN;:"Q4`&N8TK]I_4M6\8P7-T_@?P_X&N-6O]-L_P"U
M]2G75=2^Q.\=Q/`B(8@H>.3;&S;BJ;LC.*`/I.BO`(?VT_`LVEVUQ:Z;XNNK
MN^N["WLM-M],6:ZNA?)(]K)&JR%2CB%Q]X,I&&"U!8?MA>&;N[U#488]0GT.
M'2-/GM[2+3I/[1DO;J^FLUM=A;87\Z$IC(P026((-`'T-17FO@KX\Z-XY\:7
M_A:QTCQ+I^L:3:Q3ZC%J5BMO]D,BATC<;RV2I^\H*'H&SQ7ET/[6_P#PCVLZ
MNWCU;2UTG3-;\26S?9+.669K;36MUBV8;!D=IP"".2PQC!H`^FZ*\8\1_M6>
M%?![V$7BW2O%.CW5U:F\O+6[L$673+;[0(!/.HD)V&0\&/><`MC`-8EK^V]\
M/I],O]1N;'Q?8V5I9W%W;SW6C%$U".WN5MIC;D,0VR5T!)VJ`V<X!(`/H*BO
M'/$?[5/@WPE>:;;>((-:M9+VPMK^Z_T>-QIEO<3&&%Y]LAX:0$`Q[Q@;CA>:
MNZ)\?M+\<?"[Q5XP\$66H&WT"TO9+<ZE#Y*W,D".>BL64;D((8*X]!D9`/5J
M*^1M1_;5U:T\'^%I+/PYITOBRXU<V7BG3GNI!#I427D%L\B-C<WF&Z@://&&
M.<XKJ],_:0US7?'T$-LG@O1_"=SKU[H=A'K&HSIJNK3VDABGDMT1#$H\Q6"Q
MLVY@N<C.*`/HZBOD72/VRO$^C?#S3O%'Q+\,:$L/B3PIJ6O:!_8NHRGS7M,,
MUK.DBY1BC!MZEE^5AUP#JW7[3?CS1-&U&#7/"_AM]<\.>+-(T;6;BTU*4V?V
M?46MC#)`K*)&DV7(!5B`"A.2"!0!]2T5Y;%\3=<A_:'C\`WFD64.B7/AJ?5K
M74?M3/<3O%-!&04`VHF9B.222F>`:XCQ7^T5KNE>,/%ND^&M*LM5>U\2Z9X3
M\/P7,IMTDU2XMFN9Y+B7DB&.,I@*I)*D#.>`#Z)HKYI\2_&_XM>%?%']@7/A
MCP)?:AH_@VY\2:S%!JMS$MTD5PT2K:R,GREE4-MD'!R-W>M.R_:4U75/%$ZZ
M5X<BNO#UQ\.7\8:,T5R[WNHD%,1;`N$R7*`?,V5ST(%`'T'17S_^SG^TO<_%
M^Q\4KK-CIL^H>'+*TU`#P_)+-'-#<1,XM\2A6^T1O')&PZ$@$8R0-=?VJO"V
MI?"'Q3\1/#5CK.I:)X8MD<EH%@^USLB,8(RS?>1Y%CD)X5@PYVF@#VFBOG;Q
M9\5OB[X-\/>&_P"W/#_@&+Q!XM\5V6DZ>L6I74MI##<12NPE.P/YD9B"[E!5
MMV0!BN1\5?MB^(=!LM+==#\-6^IVWB:;P_KNCSWUS-)+<17$4;FUG2,0HGER
MI+OG91\VW&0:`/K>BO&?BY\3_&OAGXC>$?"GPTTKPYJMQKVEZGJ-Q_;-W-;Y
M6T\G$<;QA@&8S=6!`Q7GR_MI1:GXB^&:Z+IEBF@>*[2TE\1SW=^!<:/)>2O;
MVT<:CB3]_$ZNW0+ANAS0!]3T5\L>'_VG?'/C/XO^*_`'A;1?"%S?:=JFJ66G
M227ERK6"6>S;<WR!<&*5I`@\IMV[MC-9^B_M"_&?7?AEI?B>/POX3F_MS4KB
MUM_[(%U<?9A;S/$PE1^[F-V4@XPN#AF%`'UO17DGA?XJ:T?B+XQ\-^*K&.27
M2/#VG:[IUGI\1:X,<R2I-`Q8[6<3PL%Y&0PSTS7(^%?VTO#NM^`M'\1ZAX6\
M9V<^JV-WJ4NEP:?]JFL["VE$<MXY!`,(+#D98D,`IVF@#Z)HKS#XH_%V3P5_
MPK^YT*W@U.Q\8>(H=.E?#LPMY+::<21!?O.?*4`'KNKG+G]K[P=:64SOI7BN
M748-;L]&.D6VGI<7;7%W$\ML55)"I5UC?^+*D88+0![E17B.D?M>>!=<DMTT
MV#Q')OT*XUJZSIA!LK>!YDE$B[MS.KV\J%8P^"!G`928;[]L;P+IN@:-J]];
M>((K76-.EU4*+6)WMM/C=$-U(%D.8]TB\)N?ALJ-IP`>Z45Y!X4_:A\(^,/B
M$?"&G6?B2"Z?5+W2K;4;G32EC=W=HGF3113;CN(C^<'`!'<'BO7Z`"BBB@`H
MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB
MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****
M`"BBB@`HHHH`****`"BBB@`HHHH`****`"N1T_X3^$M*\<ZCXTTSP]I-KXKU
M:$07NKQ6P6>>,8PK-^`R>IP,]*ZZO"_"'QO\;ZY^TKXK^'^K_#G4M-\'Z)8B
M>R\4R%_+NG^3')&Q@^Y@`I+#8=WL`>YUP'Q0^"'A7XOV6I6?C:WN;B#5]';2
M+E8KEHC]G:9)OE(Z.)(D(8<C%=_VKY4_:E\2WOA?XI^"-2N-?N9M'LW@4>&-
M&UH6.K?;9[CR8[R"$HWVQ-CO&T7&U=QS0!Z5K'[*G@36(I4>#4[4O+I4T;VM
M\T9@?38FAM#&,$#;&S`\$'.>H%9S?L;_``]31YM)L?\`A([#3+S11H]_:6FM
MS11W]LHD$?G@'YV03.%8].,YP*\(\?\`Q+U_P+XP^+:^$_$.L^)=9NO#NLZK
MIEWH_B5]1M-`CBE1%AN+`IMMYEY",K-DJW'6NA\._&/7O`'P=^+^L^!O$#^.
M-,\(:Q80^%-4UV\;4$G%Q%:F>-KA2&E5)9Y!URO3MB@#WKQM^SKX1\?:U;ZG
MKBZM'.FFQ:7>1V>I201ZE91R"1+>Y53B1`^3V/S,,X-4;[]ESP/?^(6U.:/6
M/LCZG)JKZ&-4E&FM>R1R1R3BWSM5F663.W`)8G&:\@NOCS\3(/\`A)['Q,/!
M\UKH=[K>A7LNG075O/-<P:2U_#/$QD.Q<?NR,[LC<".@\LLOB5XEE^(NG7<F
MLZP\;:9971M7U&8QLW_"'2W&"=V3F4E\YSN^;.>:`/KK0OV;_"V@Z?H-A'=Z
M_>67A?5+74M'@O-1,@LI+:-XXD3@'RPDC`J2<X'I65%^R)\/+?3-0L8+;5DC
MU&*%&E74Y!+`T-[+>Q21..4D6XG=@P[8'05X_H7[4?B:R3PKIL']A$V^C>%S
M+IFHF>;4_$']I0`S36LF_D0GEBRMG8^YEXKL/V;?CYXX^).NZ58_$*V\-^7X
MC\&?\))I[:/!-$UL%NS;^5)O9MY8;7R,;3D<]:`/5/#GP-T7PYXPL_$W]I>(
M]6U;3[*2SMI=6U5[KRTDV^81NY)8H"<DC.2`*Q=9_94^'_B`W_\`:]C?W*ZE
M/JL]PC7SJ#)J1B:Y88P1\T,97'W2.*\"O_VV?%,?@NXO;*'PJ^OZ7X)EU?5K
M-TDVV&I)JT5F8)E#[D41NS%3\V0#TZX?C[XS_$+Q?K_AAHO$?@Z^L?"?BC5&
MEFT`72V6LM8Z2+^,L5ERP4EHRFXJ74$Y&5H`^I(_V=/#\>JZ3JR:OXL.M:5;
MFV.J2:P\MQ>0&;SO*G9P=Z!\X&!@$CI4$'[,?@^QM-+@TF77=.;1K&^LK*>U
MU)EDCAO+E;F<9((.9%'4?=)7H:\/U#]J3XC^'/#^@7'B:;X?VNIZKX0B\5PQ
M&UNECU59)(U32[7,F3<[68E@&Y>/Y`,FKFL?M%_$Y_$FMV>FQ^%+/39O%&L^
M&='#V4TEY:W%KIS7D=Q+\^Q\%=A0#G.<\8(![/I7[,_A+0+W0[SP[-K>DW6A
M:?%IR2VE^5-W:Q2M*D<^00X#R2'C'WR.F,:OAWX'>'_#FE>*[&*;5KX>-$9-
M8N;Z^:6:=3$8L!\#&$)&<9[DFO$HOB!XF\4?`/\`9]\1>(/$%O?ZSXC\9:%_
M:MWI)-O%<+(9&:&15.,C"JZ\#<IX'0<]\&OVG/$M]IVGV6HW6B01Z=X8_M6+
M3]0>XN-2\22N]ZQBM)&?)\O[.B\B0_-@XXH`]RNOV5/A_=ZKXBU*33[Q;WQ3
M_9?]I2)>,I?^SWC>WVX^[\T49;'WMHS5FX_9I\'3^+TU]3KD&S6O[<_LJ'59
M5T\ZCM=3=?9\[1(1(Q.W`).2":\&T']IKXJ^*7\&V6@'X>-)XO<,FIG]^MI_
MQ+Y+N:WEMH;AW22-HPH+LN\-RJD&M.T_:Y\32V'AC5[G2]#%GKO@9M;BTFR<
MW5[=:@MO<2M`5$@D@BQ`"C^6X;+*2I`R`>I:!^R'\/-"TF\TV:VU;6;.[T-]
M"BCU;4Y+G[#I[L6>"WY'E!FP21R=J\\"EN_V3O"-[X<ET>XU3QB5NM5@U6]O
M?[=D-U>7,`B%NTLI&6$7DQ%!T!7ZU@_#?XK>-OB+\*_&6I27?A=;VSTD3Z+K
M&FR)+'YSVIE9)[>.>0QO$_'+@L"#M!!%>-_`SXY^/?"WACP7X;1-%UB<:%I6
MK72:E>M'=Z\NHO++,UO-<3[C+$H'R*D@9\J`@*B@#ZE3X':2/B1IOCB36O%4
MNN:78?8(0^JL8'MSM+(\>,,'9$=O5AGBL36_V;]'\4>(_%USXAN99-+\37VF
MZO;1VCM;7.EZK:1^7]J@F4_*S(L7.,_*P.0<5S7[.WQQ\5?%?1]2U/Q#!X;-
MH-$AU&$Z?<(L]A</OW65Q`)I'!4*I$C",D[@5!%>3^"?VT/%.I^%K;4?%^K>
M`D.K:'IVH)+H]C/<MI$]S>"V%O<QM.JAB"'W/(@7#9X`)`/==;_9.\(>(Y8Y
M=?U7QIJ$C:?)IM\\_B&9FU*SDN#.\%PW5XRYQM!`V_+TXK;N?V?]"F\<KXKM
M-5\4:9J,>DG2((=/U5K>WMK,J`(8XU&%4,%<8Y#*#VKYHE_:T\62QZ'XD@M]
M+L[G4_"D2W,EQ+.VG6,CZ^;![V2%7V^6D:&3.<@'&_;S6[X9^('C/1_V0/BQ
MXL\,^(;&X\4:-XAU^ZM=4\A[JV9([DDF!)&)"%,^7G<J@C@B@#Z+\+?!O2?"
M&F^(8-,U'Q!-?>*6WZGJ]YJ33WTI$?EIME/W`B_="@`$D]369X=_9M\">%_!
M_B3PGI6DM_PB_BQ0-3TB:X>2W8^2L3,BD_(SA%9B#EG&[J2:\@LOVF/%2^/=
M)T&:\\'7_D76@V5U:VT4HNO$`U"`/+?6)#D"&)B3R&7$<F74XK.^/'Q?\4_!
MGXS:_P")--N]4U/P]'8V6BMH8=I(([^\@N&LIUCZ!C<Q)$Q])1GH*`/89OV8
M_#MSH%EI5[X@\=72Z7J5KJ.G7=QXBEDN+*:WB>*+RG/W5"R-D8Y/)R145[^R
MAX%O_"MCX8E_X2!/#ENV^]TN/69EAU>0S>>TMX,YFD:7YBQ()Z'C`'S/I7[2
M?C'X'^$/$.F>(?$8\3>(](\2:PVW6K=IWO8[46?FP)-YJ")=]P^U561AD83:
M#7>^-?VH_&UAK7BJS\-7?@6TO]+\667A_2_#^J03M>213RVB"^D99`3"?M+8
MVICY1AB>*`/>/B3\!_#_`,4[W3;O7[S7K"ZTJQNK"&71]2>R9K:Y"":)BG)5
MA&@XP1C@BN9U7]C;X4ZQ;ZDEWX8MA-?PVL$%VAQ/ID5LB)!'9R8S;JH0'Y>I
M))R37":=^T3XY'Q,/A34/^$1N[^PUS^P+K1;:VFCO[IQI_VC^TX@TAVVOFY3
M##&T??+<5Y/X6_:(U/P?IJ^)+K5O%/C+QOJ'A*^U/5M/DU\&RTN_A,8FM9M*
M"!K983*H5@06",<GDT`?6ND?L]>$=%\5V?B6QBOTUJRUF_U=+K[8V7GO8U2Y
M5A_%$VQ&V'@,H/:NG^'OP_TGX9>%[;P_X66>/3+26>2)9Y3*X::9Y7RQY/SN
MWX8%?,NJ_M&?%(G2++P^WP_N'OAKDZZSG[5!>6MA:13JPB@N'$4I9VC9#(>@
M;V.+H'[4_B2\ANM4AFT3P[#XH\5:7:R:CKDT]S8:)%-H4-ZV5+J%W2'RP`R*
M2V<$GD`^GO#OPXFTWXK>+_&>K7EM=/KUE8Z=I\$<!1K.TMQ(S*S9^8M+,[=L
M#:*XUOV0O`7]DZ?IMO)XEMK;3;:[L8_L^M2QM)874@DFLG8<M;EAG:>1DX-9
M/PJ_:(EU/7O&T/Q,UCPC96'APQ207&F2;[86TDIBBE>X\UL.[C!B=$=#@?,#
MFJ7Q]_:0O_A1\1M%T#2)--N)+C^SI;G3;BR827$%U>BU9DN#*H#+G<%6.0_*
M=VT8-`'IWC;X&^&OB!=:`_B'^TS9^&PWV'3;:^>&U#&)X@[1KU98Y'53G@&N
M9\'_`+)/@'P0-/\`['CUEFTS4M/U&W:XU%I");&*6&V!X&46.9UV]\#.2,UX
M1;_MB?$G3/"::MKFG>#YQKNB7.HZ8]M;7")IB0:M%8/+=9<^8@27SFV[<>61
MG!R.S^#7Q1U#P]\%_C'XR\0Z]8ZK+H?C+5IQJ5M!-=V9B2*W(,$6\N8N2557
MQS]['-`'IMC^R]X1TR3238W?B6&+0VNY=.A75G"6L]R9S).G&1)FYDP<X^[P
M=HJ+3_V5_!VE36%YI%WXBL=4LGN6.IV^I;;BZ6XE665)3MVLI=%;`4=_4YX7
M1_C!XC^+'[/OQ"O++Q'H7A76]$U:;2;#Q*["VM'`$#I*Q#RK#N$WEE@[A3\P
M)Z5Y7J&H?\);^S=X<M_!.N_$#P]XIF\22>$_#$5MXOEE@GN6E6-YTGC5?M=I
M"D<DJ.PZ*PSS0!]6:5\`_">C^(;'6K*"^6^T[Q!J&OP$W;%1>7T9CN"5[J58
MX7H*]&KY3^'FN7'AW]J67P[<^)M9\:?VS;WC1267BQ[RWT>*VCAC9+^P*A89
M&D#;9`V2S$8ZU2N_V@_BK>^.[_2-"7P-%87OC+6O"VC-=V5R\D,EE:M<K<3E
M9`&!"&/:H'7=GC!`/KFBO@SQE\9?$WBRZANVO+O29)M4\'W,D5A?3K$&NM)N
MYY452V%7S%7@`9VJ6R1FD^'7[0OB7PMI?A[3O[3LK8ZMH7A"S?7O$5Q/<6>F
MFYTVYGDN)E,BJ&=XDCSN3<S@L20*`/O.EKXLU3]K?XC1Z7#JVG:9X333])\(
M6>OZO#/;W!:_,FI269^RMN&R*1$$J,ZD@,O!S7IGQI^.7BKP3\4M+\+^#;70
M`LVC1ZDHUN=+9-4D>Z$)M89Y)HU214W/D"0Y9!M`.:`/H>BOB7Q-^V1XYTW4
M_$%MI-EX3N+JSF\0BWT/R9GOM/32U^1[D;QN$P(E!`7Y0<;NHO:C^T?X@\>_
M%EM*^'^J:/)9Z?<:K!H^I6;RS03E-"CNE:5%<).!-(P`[;1CG.0#[,HKXR\!
M_M-?$4:-\+M,UV3P]XCU?XHZ/8R:)J=E9ND:7:W`_M!+D!RNZ*V;S,*%&]&&
M.@K[)ASLY.3GK0!)1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%
M%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`444
M4`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`"5RNH)X;UGQSID&HVUO<>
M)]$M)+ZP=[9B]M%)^Y=TDQMYSM(SGOCO75'D5\S_`+1/P&\7_%'Q1KL_ATQI
MIFJ^&-,TP#^TWMG\V+5TN9\;>5_<!L,#DG`H`^C+?1[.SDF>UMK:%[@YF:.!
M5,O^\0.>_7UHCT>RAM1;0VMLEMG(A6%0F<YSM`QUKY`U#]E3Q]IMU<VG@2Z@
MTO1=5UW4])N(/[6D(M?#%VT$H\K.2)4>.;:G;SFY&:TXOV:?%2^(?'<^J1:P
M[:LNL)9:EHOB&*Q:_L[E56VM)-R%T:%``CG(1D[AC0!]2O\`V4=2^P22:?\`
MVA/$UQ]E8IYLD?"-)LZD<A2V.X'>K']D60Y^RVV0,9\E>FW;Z>G'TXKXIU?]
MD7Q??VEO?6_AOP_!KK_#S6?#J7%KJ9M6LKF65C:2,%^4DPEE<IA0SD@8`QT5
MA^R+KN@Z]>7?A/&E-8:EIMQX=N?[:N)#9`Z<T&H2%"QW%YRKD'.\J&ZB@#ZR
M.CV?G0R_9[?S;=-D,GDKNC7T4XR![#UJ.!]*M-56Q@DL(]16U\Q;9619E@W8
MW!!\WE[N,XQGWKX]\/?LD>)KKPYX8TGQ%I]S;6UMXAT:X\2V7_"0*;34(;6W
MG2YN8EB57$DK2)O#'+C&>0<]#\#/V9/$'P]^*WA/Q5XJTFQO)=+\-:AI$M\F
MJO)-9DWTCVF`W^L3[(R0C^[CV!H`]OETOP/\</#7B'2S;P:EI)U.;3=6,4;6
MY:ZMIE,B%P%8[9$7D'!*]Z[&73M.TZT+?9;2&WMP\A"P*`@P=Q``[C.?6ODK
MPW^RGKQ^)^L77B70[6ST?7==\1SZKK%OXBD+WFFW\4B06_V8`!61V63.?E*Y
M!R374?LQZ%XYM/@OXA\0>)[637?&&MG^S[.VN;AK0365BGV2W;=(OR&0)).2
M5&3)SUH`]]\,:EH'COP[I&N^&WLM3T>[A2ZTNZ2`%#&PRKQ[AE<C'85'X*\1
M>'_B!H4.N^%&@O--GN9A!<BWV;Y(Y&BD8;@#G<C#=W`]*^4K#]ESXBV&G>"-
M.N(--NIM#\,:)I]CJ<6MR0?\(O>VEP9+N>*,*/.\V,A>.NP*WRFL.?\`8M\<
M6?A&.P\/1V]C>:SI^H1>)##KTL8NI7UF"YMB,<#9;+,`5`VEB.^:`/N2/2;2
M*..-+>!8HFWI&(E"HV<[@,8!SGD>M(ND6<<D$D=M;));@B%Q"H,8/4*<<9]J
M^3K;]FCQ=X>\6Z<WA_38YM$T3QM=7VB6MQKADLK+3)C;;@T#_/YH*3NC(V49
MCU#FN>\6_LK?$KQ#:>+(+>*TM]6U0:JEUKZ>(90_B&&XOHIK2-X\#R/(B4J#
MU!4!>&-`'V'J%OH7A;3;S5+^/2],LK&*2YNKIXHX4B15)>1FP,`+G)],US_P
MY\?^"/B<D]]\/;W3-2?3-D$[Q6C0S6X=`Z`JZ*ZJRL&7C:P.1FO+],^!GBGP
MK\,OC'X3\&+IMI;>(K^9O!]I?W#7=M!;26D*21NLF[;OE6<D'<,ON.>E97[*
MWP@^(WPB\5:I:^)+.TM?!-S9M]A634H[W4?/#1A/MDRH//V1J8HF&-L:`%<X
MH`]Z\.ZIX;U+4]>TCPR]@;O0KE+?5[>V@$?D3/$LBJ^``28W4]^#4=CK7AK6
M?&&H^'K-;2?6_"UO;37,7V7FR2?>8=KE<#/EL<*>,5\R^*_@!\0_%/B_Q!XA
MUGPSI.IZ+KGB>6\N_"3>(C"+N$:6EI!.TRH!E)4,@3J-P(^914"_LF^-DUQ/
M$%Y<P7_BK2[;PA!I^LC5I8W_`-"E_P")D2.Y:(E`7!+@D'&30!]=C0+!$N5A
MM;>'[:I6=HHE1I00<[B!D]3^=9'A/X;>'?!'A6Q\.>'-,M;?1].M8[6&"2,2
MYBC&$#LV2^!W8FOD71OV/O&.@^%8+)+>[,FJ>&;BV\1QV'B5DDO-0_M1)[=B
M90R,BP!U*D!2I:/HV:Z6Q_9]^(\WC70-2UK3]%CFM!H$EGJMCK,L2>&DM!_I
M]K#;<^8D_P`PQDJ?,PW"B@#ZO_L:RV,IMK;8Z&,KY*X*$Y*XQTSSCIFLSPSK
M6A>++*]?PU<6=[:6E[/8W0@0;$N(7*2Q,,#YE8$&OGW]G_\`9R\3?"KQQX>U
MN^1(5N-,UJ/Q0T>KR7'VNXFOUEL?D8X(2'<!@#;N([UP.O?L=^--<U#QK?30
MV@N;BT\03^&6BUF2$6^I76I?:+.=@F`&6/)W'.TG'-`'VDFC64<L,T5M:K);
MILAD6%=T:_W5..!["I)=+M9MQG@AD+$%B\:G)'0G(ZCMZ5\F7W[+WCEO'6I>
M+-#O$T[Q)J/B^>X75O[7E8PZ5)I!MPOE_=_X^\.4`R=H;/`K%TC]FGXGZ!X?
MCUCP;8:;X<\6Z"NDR6-BWB&2ZM]5U"*.:&_O9G(PGG13#C!+&,%N<4`?9,NB
M6,[*TUI:R%7+@O`K$,1@MR.I[GO6)9Z]X8UG7X[#3[C3K_4;FS:YC>&$3"2&
M&7RV(E`*G9)A=N[((Z5\UV_[-?CK2/B+X)73K32)/#GAIM+6ZUD7["]OH%MY
M8]1BFW$LPEDD#!%PI&2<M7)>#_V0/B%X-\->(])\*6NF:`UQX=U"PMY+?7)"
ME[-)JZ7*G@9A#VB^06ZJ1GOF@#[B33K9;S[7Y$!NMFSS_*7?M]-V,X]JC_LF
MQ^U2W`M;47$Z[99!"NZ0=,,<9(]C7QGJ'[(/B?Q+<SO>Z/9Z/H(LO$$FC>&X
MO$,TD>D7=Q;VR6@#K@,//BEFP/EC+`@9KZ"N_A1XF\3^!/!UC>>/_%OA+6=&
MTJ&'5)M#FMW-[<")%<R--$^[#*Q!&,[B30!V&LZCX8\&-I%OJAT[3#K6H#3]
M-C%N%\^YD5B(U"KP66-LYP"%YKC=<^.OPIT&RMO[?\0Z%:6>J:G=:;#Y]LWE
MRW5FVR>-ODP#&0`6;`&.#6'\1OAKXPOIOA?I^AB3Q/!X-UV+6-1US6-1CAN;
MEH(9D6-D2,*S.9%^8``8.17G6B?!GXF^$IO"'B*P\,Z+JFK:7X@\6:G=Z/+K
M:QQQ+JK$P(92A#[<_/@=.F:`/7/&_P`0?A#:+X?M/&FL^%0GB2ZMM1TE&D#)
M>NK@PW!\OAHPY!#O\F<<YKNO%NK>'_"MK;ZKXOEL+6`W,-I'=W<8.R6:18XD
M#8)&YV51VR17S;\'O@-\0/V>-8N;C3=(\.^.K;Q!H=C:W[/>?8?[*FAFE>2*
M)61R]J%G.Q%&?W8!'.:]%^(FB^*_CM\$].6+P^/#^K7/B'3K\:;J%SM>.TMM
M1CE#R';\LC0Q!_+(R"VTG(S0![)_9%F%V?9[<(59-OE+C:WWEQCH>XZ&I(]/
MMXK=X(X85AD7#1K&`I&,8(Q@\`#Z"OBW1_V1?B!H/A"^L_#MU%I>L:_X-U>P
MUFY&N3N+G4)=06:U)/.%%OYD>Y0-F\C!KZ.^#NE:WX4TZUT.3P+I?@_08K1Y
MHX[373?&&X:8YBVE!P5^?<#@%L8[T`=[)H&G3:5<Z9)96IL+N)HI[80J(Y$8
M;2I4#&".*9IGAS3=&T^PL=+L[>VM-*A6&QB2,8MHU7:JIZ`*,5IT4`4H-'M+
M6>6:UMK:&:?_`%LL<*JTG?YB!D_C3QIEL,$00`ARX(C&0Q&"WU(ZFK5%`%,:
M19YYMK8_=_Y8K_",#MV!P/2F2:)82PO%)9VC12*JO&T"E6"_=!&,$#MZ5?HH
M`IOI-I)G?;V[`H$(,2G*CHO3H.PZ4M]I5GJ1B-_:VUR8&W1F:%7V'U&1P?I5
MNB@#FM3^'>@:OXKT?Q+?6$;ZUH2W"V5R"5*B>,1R[@.'RJ@?-G';%:]MHMC9
ME#:6EK`8_N>7`J;>,<8''%7J*`.<N_A]H5]XET+7;BQ0ZCX:6Y&ELC%$MS<*
M%E8(/E+%1C<1D`GU-='110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!7`:+\=_`OB#XHZM\.M
M)\165QXQT2#S[W3$#;HUXW88C:Q7<NX`Y&X9%=_7%Z5\&/!&A_$35/'>D^&M
M,M?%^M0""^U:.,B69..#S@$[5R0`3@9)H`[2O(/BA\=Y?AI\6/!OAN_TR"30
M/$:%;_5FG*MI\KS+#;DIC!1I'5"21@LIZ9KU^O.?BQ\"_#'QBLM2M/&*Z@T6
MK:,VD3&UN/**0F>.<.AP=L@DB0ANV*`//?AI^UI_PG$GC2YOO"^I1:7H-U9_
MV.=.4W=QJ-K<I(T4SI\JQY$1?EL;649R>=>Y_;!\`1:5<ZI82:_JNEV&A1ZU
MJ%]I^C2S0V%M(DCQB9N-KL(GPOJ,'&14VK_LG>"M6BFC1M;L1++I,J&UO$'D
MOID+0VNU61E(",=P8,"<'`(%9B?L9>"+?0KK1M,OO%VFZ5J6AKHNI6EIJ^U-
M0MT$HB,P*'+H)G`(P.F0<4`:UU^U;X-L;+3;F^M_%-LE_:"^F270)UDTZR:<
MPI=W2$9AA9P2&(R5!;&`2.?T;]I^^USQFA%MX.T;P0^J7VFP76L^(#;ZGJ#6
M;O'<W%O;",JT:O&X"EPQ"%N.!77^.OV=?#/CS6X]2U:Z\06DKZ3%H^H0V%_Y
M,6J6,<GFI!<#:25W;ONE20[`G!K.OOV5_!FHZ_\`;)Y?$"Z8-5FU8>'4U#&G
M+>RQR1RRK%MW)O$TA*HP7+$XS0!1_P"&R_`']EP7:CQ))-=7=C;6NGQZ-))=
MW7VU)'M)(XE)+1RB)\,.A&"!45I^U[X4NIM0OXI9YM`MM'T^[@6*PG-_)=75
MY-:+:^21C?YT)3:#D,#GC!K=\/?LT>&M!T_P[9)?Z_>6GA35;34='2YFA!MV
MMHWCBCW)$K/&%D.0Y))`.>N<F#]CSP+:Z=J%G;/X@C%_';JLZ:B!+;207TU]
M#-$VWY9%GG<Y((P%!!QR`=9X-^.6A>/_`!;>^&M&L_$$.JZ5;13:E'?:6]L+
M%Y%W)%+NY#E3GH5]&SQ7)ZC^V%X&TK6]8TM[;Q?<W>D7M[8-]E\/3S)=75FN
M^X@@91B1UCS)@?P@G/:NL\-?`_2_#WC>T\5W>M>)M:UBRT][&"75+N.8B-]N
M_++&KL24!PS%5).U152W_9X\+V6M6VIV[:M]IM=>U37(LW?R_:M0A:*XR-OW
M-K':.Q[F@"";]IGPE!=6$)A\0LNKZ<]]I4PTEPFHA+;[4T4.>6D\D%@,`'!`
M.>*UO#?QX\)>+--U74]&U%GTK1-&MM7O[YX2D4%O<0M/'EC_`!B)=S+U7(SR
M:YCPQ^R9X+\)^-]-\4Z7)KSWVE212V\%Q>K)#YD=E]B#$;-QS#P5W;<\@`DU
M+\%OV;M*^&GPL\2^#=:2VOK7Q9J&H3ZC';LX3[/<DHENK'YML<&R,=,;>,4`
M8$?[7^@ZSXV\+:3H(:TL;U+ZXU\ZO;M;W%A:PV!NX9E7)!21>=V3PI&`>FS:
M_M=>!;[34GM!X@EU">\M+2VT9-)=KZZ:ZB::W:*('YD>))'W9X"-G!&*GL?V
M6_"<$.DP:K=ZYK$6C6UW:VL=[-"H%O<VOV62)C%$A9?*Z$DD$DYH3]EWPZGA
MK3-'&L^*E.@WT%YHVHQW<$-WIKPQ-$@CD2$!E\MW4B0/G<>]`$OP^_:2T_XB
M+X_;3_"_C&P_X5_/Y5U%>Z6T<MX?($N(D)SYF#_JSA@"I_B%8.A?MG>#M6\#
M:!XCOM-\4Z>-;TQM4ELSI+SRZ;9+*(FN[C9PL&\C$@SD9(&`2/1/!7PBTSP)
MJ/B6[TF\UFY_X2R6*?4H;Z\\]6F2!(#,I(W!WCC3<22"5R`.:X4?L@^#H='T
MK3H=3\7PVNEZ,^AL(M5"M>Z6TWF_8IR$^:(-D`C:^UB"QS0!'\>_VE)O@]XP
M\#:5;Z7/=:9XA%W?:KJ:V$MTEO86L)EE\H1D9E(P<M\JKR<YXOZ]^UKX'\/W
MUK8S)XBOKZ^&G?9;33]'DN)9VOX)9[955>22D+Y_NG&?6NO\9?"'P]X]U31+
MOQ%;32#0K.^L[:U239"\%Y!Y$R.N.1Y?`P1BN+\+?LG>$?"/B+3->34O%>I:
MCH]S93VTVHZFLV/LEM-;0(0$&46*X<8[D*<YSD`YSXJ?MGZ!X=^'2ZU\.(KS
M7]5U#1(]7L8VTJ=K>V@:Y$&^[*X,(WB1!D_>0YXKU/QY\9]$^&MWI\7BR/4X
M+>_>!&U"*R:2UMC-((H_-DSQF1@N`&(R"<`YKA+O]C+P)=Z#9:0ESXHM;*UT
MAM(F2WU7RS?6GVEKE8YSM^;9,[,I&WJ0<CBM[XG_`+-7A7XL>*;+7O$TNM1W
MEE9Q68CM+I4BDCBN%N8]P9&((E122I4D#!R.*`%^('[37A#X;>-G\+^)%U[[
M?;VMK=7=Q::1+<VUG#<S&&*265`0BF0;>?7TR13\0_M9^!/#%WKD>K2ZTEMH
M*WPFU"/2I'M+B:R7==6\,O1YD7)*\9VM@G:<5/&?[-8^(/Q9UWQ+XCUW5+;0
MM8T73+"33-+NC`URUI<2S$3DJ0T9+I@*0W##."13]=_9%\%>(GU]-4N/$CZ?
MK\NH7#:8NIXM;.YODVW-Q`NW*R,"_P!XL%WM@#-`'*ZW^VYI,;Z];:/X6\66
M$ND^'HM;AO=?T::TMIHI+D0J&4`R*&SE6Q\W/'!KM?$7[5?@?POJ>LV>K2ZN
ML6AF\CN=0CTN1[1[FUA\^>UCF^ZTZQY;;WP0"2"*M^./V;?#'Q`OKVZURXUR
M)M2\/P:%>QVMZL:7%M#.)XB05.'5\X88X8Y![9NO_LF>#/$EUK[:G<>(FL/$
M4][=SZ4FI8M(+R[@,$]U$FW*RF-GQDE06)"@F@#I?AQ\=_#7Q0T_6;O0FU.Q
M'AY(IM0AUC3Y+&6&&6'SHIBK\^6\>6!]`>!7E/Q-_;7TW2/`4VI?#;1=<U#6
MKJYTV/38]2T2X2&:VOI?+AO55<-+"<,%"D,SE%X+"O8?#_P?T+PYJ'B:[M8[
MNX;Q;8V=CJ<5Q/N1X;:W-O&%P`03&QW'/)YXKCM+_9-\(:9I=M8R7WBC48[!
MM,6PDOM2$KV5OI]Q]HM;:([`!$)!R""S#`+<#`!H:C\;+O0_BCK/AS4M+EN=
M.TCPG8:QFPMGENYKBYN98?+$>0`H\L')QC)R0!7/6G[9?@V\\46>FPV/B%=,
MN/#]_K5QK<NGE;6R2RD:.XBE.<AD='4GH&VKD[A75?$7]G?PS\3M3UG4/$4F
MKQ76MZ=8V$[6ETJ!([.Z-U"54J1GS6.[<&5AP16)9?LD>";&TAM%;79K5=,U
M72[J&2_&V]M=1E,URDH5!_RU.]2NTJ0.PQ0!TG@K]H'P?XWM[HV^I#2+NSN(
MK:;3]95;2Y$DL0EA549OGWQD,NTG//<$5QR?MA^&;Z?P.?#^@^,-5T[Q[K$F
MF:=J,.DL(@40L92,Y*\'C`8!7)`VFNX\,_!'P_X=TFVL;^-_$HL+E+C3[G6[
M6UFFL)$0(C0LD*;64#AOO`D\US^F_LO>&M,N;&]BU+Q+)J=AXB&OI?M>1)*]
MU]G-NP8)$J%&B)5OEW-DG=GF@`O?VJ/!NG2ZC;ZA'KUKJ5A);+'ID^F,EU>"
MX:186A0GD,8I?O%2-AR!Q45E^UGX$O)=!5I]5MH]?M[*=)I]/*I9+>R-':"Y
M.<Q&5D(7(/49QD5YSXN_80T>+1+>+X:ZE<Q7<-[:R21:[,L\4MO`]Q(D.X1'
M!$ER[;G20M]UO4>@^!OV;8]#FT+6_$^N7=UXNL].L[/5[O3K>W@M-46U9S`&
M@:)@@57*?NRF0,\'&`"M\>OVG+?X67$FA^'+*YU7Q1#/I9N0=/EEL[*"\O%@
M4SS(0(V9?-*9/)09Z\VS^UW\/5NKF&2\U*..&7;%<M8-Y5U$+Q;-[B)@?FB2
M=U5FX(#`XQS6K\0/V;_"_P`1/%,^NZK<^(+6XOH+*+4+>PU(PP7WV.?S[4RI
M@Y,<A.,$9!((/%5=._9@\)Z9X>\1>'K>;6&\/>)+6ZMI--DEA*6:W$AD<P/Y
M7F`AV)&YVQQZ"@""\_:T^']CKL^F7%[J/^AWQL[V\6Q)M[1OM)M5DD?/$;3A
MHPX!&58G`&:PO#/[7.DQ^#;?5/'=G>+J,]SJ\LMIH6GRWOV/3K*^DMFNY@,E
M8QM3<WJ3@8!QT&@_LM>$O"M_H=YX;N-;L+C1=/AT]W$\,W]HP13/,!<^;$VY
MC))*2R;"?,.3TQ4N?V1O!LME;VUG>^*--6.VU&SN7L=5\I[VSO[DW-S:S':<
MQF1CC;M8`X#4`5[O]LWX>6=]K,$[^(5AT22_AEOQHDIM)YK*(S3Q13?==Q$"
MX`/(]^*M^&OVM_!/BC6].TNTM_%5K<ZE?060-]H$]NEO)/#YUN9F88C66,%D
M)ZX.<5S6D?L9:3=1>)[?QKK.LW&FZSKFL7MCI6FWQ@M+.&^B:'[A4GSEA=US
MDJ"<@9R:]%@^`/ANVUN\U13J37&H7FEWDX:ZRGF:?#Y-N`,?=V?>'<\\4`<C
M-^VG\.HU@\N3Q!<3W]Q!%IEM;Z/)--J:3R21Q36Z*29(V>)ESP0<9`!!J]H?
M[5GAWQ3XZ\$^'/#>D>);U/'&GWEY:ZD-.9(;0VLGES13@_,CJX96XPIV@_>%
M3>'_`-EGPIX:BT2VT^[UY]/\,ZK;ZEH]E+<0^7920&0QHK+$)&C_`'K`AV8G
M"\\<Z/AG]G7PWX0U7POJ.@7&MV]UX2;4S:$WBLLR:A-Y]Q%,"OS(9`K#&"-H
M&?4`CUW]I?PCX>U;Q%97RZ[)%X6G2TU&_M](EEM1>/Y>RS20?>N&\Z(!`.2P
M&:BM_P!I_P`(W,NB6T4/B$ZMKNIW6FQ:.VD.MY;W%L%,ZRQDC;M62-N"=RN"
MNX9Q'XE_9>\+>*-1\27%W?\`B>UM_%5W%J%]86>JF*V2_C\KR[V-=I*S*8(B
M.2N5^[3KC]F3PY>:5:6-[JGB:Y6/66UF^FEO(GEU.\+QL)9W,>05\F-5\KR]
MJC`X)H`Q?!W[87A?Q9#8B71/%NEW^J>(;[1+&PN-*)EN)+1L32#!V[5&"PSN
M!RN"0:V/B!^T?I'PO\8ZYIWB]93IVC:7IERQL+.:YNC-?7<EO$@C488%D`&T
MELDY'2FW7[+WAJ\T^73GU/Q+'I,WB"?76T];R)HQ<S3"9PI:(NB^8"PVL&&Y
M@&P<5K^,/@#X;\<^*;KQ!KC:H-0O/[*$GD701!_9UVUU;X&#_P`M6.[GD<<=
M:`$M_P!H7PI<?#:\\;^;J$.EV%^VFW-K/9-%>0WRSB#[*T+8/F^:RKC..1SB
ML=OVL/`RVVFOOUHSZO/<6=I:+ICM,]]!,D,MEL!_X^`\JG9GE<L"0,ULWG[/
M?A74?`^O^%[Q=1:P\1:_+K]P_P!I'FPWSW"W'F1G;@!954JI##C!R*R=?_9?
M\.>*[?1$\2:GXCO;GPY(9])O5NXK>:SN3,LOVE/*B1?.^18]Q7_5Y7'S$D`Y
MGQ?^U]IUEIOA_5/!FBZ]JFDZGXL@T62[?1I]M[$QN%=[''^O826^P#MG)&,&
MNJMOVHO!=UIWAO48GUD:5XFDB@MM0DTQT@@GDE:%8)B>5D\Y&C(`;:PY(!!H
MT3]F3PSH#:5'8ZAXGDL-`UY=;TC39]3WVVGW`:=BD2[<B,FXD)!)/W1G`Q7/
MQ_L5^`8M0TRZCF\2`Z6T31QG4$9':*^DO8RV4R,32N?E*[A@-G`H`N>'/VQO
MAYXFTC4=2MI]<LK73],&I(=0T>6W-[;^?]G+V^?]9^_*Q\?Q,.W-.F_;`\"V
MFCVVI:@NOV4,QO7GBFTLB6R@M)E@N+B9`Q*Q+*VW<,YP2!@$UB^./V.]'U/X
M>G0O!%]=6-]:>'X]"LI-2F\^)[-;Z.\9),+G>SQ[=X!V@_=-6?!?[++V^DZ-
M/XZUV4^)-$%W;6EWH-O;P1Q:?/,LHLV1X-D@5E!\P1HQR:`/?[>>.ZMXIK=U
MEBF0/&Z'(92,@@^A%24V-!'&JJ``J@``8Q3J`"BBB@`HHHH`****`"BBB@`H
MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB
MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`***:K!NE`#J^5OCWJWB[
M0?VC_#NLZ7,-5TOPIX`US7K3P^MO-_I-Y"$CQN1P&=O,0+N5MH#@`E@5^J:Y
M?6?B+X9T'QOHGA76-2M[;Q'XA@FETNS=&W7*18,FUL;01UP2"<'&<&@#Y7T?
M]H_XH^*]8\-Z!X.USP5JC^(]9M+<>)$T*<VENLVFSW4ML8A-\TT+Q*,A\8D4
M,%;-=]\<_P!HG6_AC\3_``_X<T6:VN)9FTM[S3YM*.+J&ZO/LTCI<><"&09?
M:D3X`RY`(KV#PE\3O!GC+4_$&G>$=6T^^N_"=X+;5XX1M%G,P/!8@*>C#*DC
M*D9R*Z>:2T9T:Y6'>%)0R;<X[D9[4`?/WQE^)L7PT^.%O<^*]<NM(\-7'P\U
M,Q!W<0W%_'<1%%0#AKCRRVT#YB#Q7)_%?Q3->_L\^%=(C\<0^'O%6A:7HUWX
MCL-2U>XTN:_C>S9FM)KM`9())2CL&'):/!ZFOJV22TF""40R`OA-VTY8=A[_
M`$KA)/CG\/9O'_\`PA)UNTN?$C2B&2TCM9)D2;&X1/,J&-9,$'8S!N>G-`&?
M\,/B]I7BCX965Q9"]TW6K'PM;:I=Z/J3275Y9120L8C,<!I&;RSSPS8[$U\\
M^%/VK?B/\0];TC0O!5]H'_$]UNRA@UO4-`=1%;7&G75RZM;QW#`21O;;>9,Y
M;:X4U]I">U.9`T.#D%]P[=L^U9D'B'1CKUQH\!5-0L[..]D7[.RHL,C,JN),
M;#DHW`.1WQD4`?#'Q?\`VC_&_P`0OA-IEG?3:5X;&M^$K'59HHK*X,^K71U/
MR98K20./*\M85D88<[9.<`9KV7X[^(+2;XTZ?H/Q5\8>(?!'@.+PNVHZ;=Z7
M?/IL=YJB7&V17N$&7:./RV6'H=Q)#=*^E`UFS(H6!B4WHHVGY3QD#T/J.*22
M2SE!$XMV$9W8?:=I'?VH`^--?_;"\66$OCN'P=<6&M1Z%H.I75C)?:*]N]K=
M65W#;JLB+,SR)(LI?++$3MRJ[34_C+]JGQ[X!TSQ+I/B2_T-O$WA_5KFWM+N
MT\/R?9=3\O38;U82)+A1%S*8@0SN^!M3.17V(QLU>0.MN'*[I`P7)']X^WO2
MM]E=]CQQ._WMI4$Y]?\`Z]`'PQXJ_:"\5>+?B9X5O]9N]/TBT\->)7FC\/VV
MF7,EV+<:')<+=RL''FPN\C*J;5R4&&SG'K/P@_:-\0>._AS\4-9GDLKV3P?8
M"]T>_%B+87*R:?\`:566%99%!1\H0LA/!!P0:]RU7QOX?T7Q+X=T6\F0:IXH
MDN(M,2.+>)3;Q&23+#A0J^IZG`J]JNFZ1K.@W^G:A!;2:7J-M+:W:*P1'C=2
MCH6!&,AB.N>:`/C3PS^U)\5_%B^&])T#7/A]J.J>)KK0U.I6VB7+6^EM?6UU
M)-;RIYWS21&W0@[A]_!`XKI/%G[0/Q!OO%/BCPUH^IZ#8WME>:EHPTL:/,]]
M;10:<;A-9W>8!Y+R`J%(`PZ89F!!^F?"K^&=+TDZ-X9GTPV?A94L9(()UD^P
M"*)0D<AR2K"/;][G!SWK2TW6='UJQM]4TBZL+^SOXQ]FO+>5)$N$.2-C@X8'
M!X!H`_/7P)XV^(W@/X33'PUXHMM'N[$>"9[S4[NRN+N-K?46D>=I%FF8(095
M,KKMW!6^[E2OU!\;_BUKW@SQUX7T.RO]'CT37=/E6Z\J'S[Z2Y8[(MD?F*4@
M(W$RH)"C`;AMR:]SD-HB;94A57^7#``-Z#GK]*>HM9YSB.%I8N#\H+)D=#W'
M%`'PQ\*OV@_''PY^%WAK1_&NKZ<+>Z\'Z#?:9JL>B2W$MD+N=[;R[CS9T1VP
MBNTSNBJ2V0>*ZCP[^TU\5/%MGI^IZ19:`D&G?#ZZ\2ZKI_\`9<\L^HW$%W<6
MZPVY#_N_,\E&P0^,D#.<U]>M]C8M&R0'`PRX4\#U'H.*!+:*04\@;CL!4KR>
MNT>_?%`'DO[-7Q(\2_$C0]3N_%M]X=U:W@:V-E?Z1)&K,9(5>6&>%)9!&\;G
M`^;+*02`<U[+5.&:SMP_D?9XAU?:57OC)_'CFI6O(8SB1U1L$X9@#@=3]!ZT
M`3T5FZ3XCTO7M/M[[1-0LK^RO"1;W-M.LD<V"0=K`X/((X]*BG\5:;;>(+;1
M9YG34+NTDNX4,+;&BC95<^9C8""Z\$Y.>!UH`UZ*HW^MV&EZ=<:AJ=Y;6EA:
M1M)/=3RJD42+G<S,3@`8.3[5C:%\2/#_`(E\2ZOH6AWRW>H:);VEQ=A%)39<
MH[PE'Z/E4)^4G`QZT`=/14*74<I81LKE6VL%(.#Z'T/M7,:5\5?"VMVVF7&D
MZM%<PZQJ5QIEDZHP$EU;^;YT7(X*^1+G.!\AYZ4`=;16/K'BW3-";3QJ4[)_
M:=\EC;&.)I09W!*JQ4$+PIY;`Z<\BI=*\2Z5KME%>:)J-CJ%G/(T<5Q;7"21
MNZL590P."0P((]0:`-.BN;\2?$'1?">L>'=+UF>6.\\4ZB=/TY$A9]\WE22X
M;'W1LB<Y/'&*RT^-G@F3QGJGA5-?MCK6B6[W&I1>6XBLT10SB2;;Y2L%96*E
MMP!!QB@#N**HV>MV.HVMM<V%U;W-M>1":VFBE5TGC(R'0@X9<'.1Q46E>)=*
MUVQAO=$U&QU"SN'9(;BVN$DCD96*LJL#@D,",>H-`&G142W,;2;%(+@`E<C(
M!Z$BI:`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`KPWPC^S
MYXC\-_M*^*OB9>_$/6=2T/7[$6]OX9E#>3:MA,?Q;=J;"5PH/SG)->Y44`%>
M`?M'_!3Q1\1M6BUWX?7.FV?B#0-)23P]<W<K*L6IQ7L,R;P`?W31I(C>SXQ7
MO])B@#X[M?V5_%_A+2=9LO#EKX5UB#4I?#S3PZHX?[6MM;RK?OAXV197EE+*
M65A@DXSBN<E_9&^(C^#-4TG5H/#/B35M3\$0Z+9:S>ZU,LNA7$4=PC"']V2R
M2"6/)!7&#D'`K[GP/04;1Z#\J`/DGX@_LJ:O+?:98_#S3-"70K?PY#I^G"YU
M.>&3PUJ*WGGRZC``&,LCY_O*Q*`$E6(J>T^`_P`4_#FI)H7@O6[32O#X\1ZK
MJDNM6VK/&]Y;WWGR&*YLQ%AIHYI(]LBN!MC[5]7[1Z"C`]!0!\8Z!^Q_K%WX
M>\+Z5XFTVTABL=>T6X\16HUL26>JP6=O/'-<+%'"A661I%W!BQD&-QR.:EC^
MR7\0;3PKJ^F7%WH]TKZ?IEM;V$NJ2^3=P6FLW5VUD[;<I$]K+%%G!'!4C`K[
M9VCT'Y4%0>H%`'SK\)O@IKGA+XQ2>)1X<T'P[H]WI(@N;6#5?MXMY%1%BCM,
MQ(\,8^?>FXHQ`8*#7%7'['%SJOC2]U7Q#9:3=P:UXL\0WNM9OY@UWIEW;LMG
M"0,?<FV.4X"D;@2:^OP`.@%&!Z4`?'_AW]F7QS-X_P##DWC&+PRWAW3K1;+4
MKBTN2+F_LWTG[++!,2F^4^?\XW/LP%(4-S6U^SE\*_&4WP6\=+XCU.ZLO%.N
M6\_A[0]2N8I(WM["RB>TLIMIPP+'?,3@$[\U]3;1Z#FEH`^-?"_[*GB_3;_0
MKW3!;^%KJQL-1MKHQ:PMS!'<3:5]DBO+>*.&/8S289^I.T,23FF67[*WB>U\
M&Z1`NBZ9+-IVLZ9=ZQX;N_$`.F:ZEM:R0NX$<"B)V=UD.]7WF-2QSS7V9@>@
MHVCT'Y4`?.WP4_9TB^']W\5;75?#7ANRTSQ[-%)"+"X>9#";-(I+61&4':DH
MF8-_$)2>*\FL?V/_`!GIO@+PIX>@T?PM(NE>%IM'"'69HTT?4VNQ*-9@VIEI
M&4`[1M8%`-Q!-?<6!Z"C`]!0!X3\9/A%K7C'QUX"UJST_1/%>F^'+6[M;W3=
M8OI+5%GE,)COTVJP:2/RG&,`_O#@BN)^$7[-OCGPQ?WCWVL6GA34VT.YTZ\\
M3Z-=_;;O7KF2]$\=[+%-'Y:,D890&#G]ZP!V@"OJS:/048&<X%`'PJW[.OB_
MQA\2?B!=V6D0"^A\53!/%FJ7\UI<75O_`&,L!C2!4\MXY)I`Q92%!5N,JN-K
M4_V.]<TW0?#6E>%-+\/7$$/A"+3KAKG5IXSHVNF6-YM7A."TLAV8X*-^[4?=
M)%?:&!Z"C:/0?E0!\80_L5WUW>O-X@M])OI-4U'Q3-KLK:A*&OXKSYM-#`8'
M[MPKE1@(WS#)YK9?]F3Q;J?CRQN_$<6AZC:>=HLO]N3:C*UUIUK:V0@O-/2'
M;B2.=A)DE@I$S%E)`KZVP/048'I0!\0:+^QSXFT3P=X2T"?2]*ET[1;#4K&Z
ML],UL6SI<SW<<L>IP2R0/LE\M`F``R[1AL$UZ=^T/\!/%'Q2NKO_`(1F[M?L
M]QX!O-`#7=Z\3M=2W=K*KMM7@;(9,L.02,#FOI':/048'I0!\W6O[,TUM\,_
MC3X%M[;28M`\:22-X6LI)WE@LMUC#&&92"4/VF-I#C.2=W4FN#TS]C_7+34X
M-:L--T+1-9T]O"2:0UKJ<C'3H;!O^)BB,%`_>+D#CY@Q!P*^S=H]!^5&!Z"@
M#YW_`&;?@7KOPNUZ]O/%P+:DUE):W.IVFJ(\&M,UR\HN);<1*RS`-C>SN<,5
MS@"N7M?@)\1;;3#X4>/PW%H>EZIXDU2UU5;]VFOI-1BNEMHO*V#R=C7C;V+,
M#L&.M?6&T`\`48'H*`/C;PC^R%XB\(^(_"(TM-)M_#VG?\([/K=F-0D<75U:
MVUW%?RE6!#M(9HAD_>"\XP*R=,_8X\2:%X-\.Z"NCZ)-IFD2ZY%>:?8:P+8S
MO>3H]OJ,4DD+B*:.)!&`%W+@%6Y-?;^!Z"C`]!0!\FZ=^S)XHL_CMIGBRZBT
M?4;?3O%PU@:_=ZG*^HR6)TXVPLC'LV_NY!OSN`.XD`<U?^(/[.OB3QE\2/%=
MQHEMINA>%_%>EW\&O1-K4MQ;>(9Y+016DLMD8PL,T<FUFE5B2(U'.:^H\#T%
M!`/4"@#XQLOV7O'$4WPWL8-&\&Z5HOA6ST6.\-M=[KA#;S/_`&A'YACW/'/&
M^0BE%.]@X;BL[2?V.O$FA^#O#6@C2-&FTS1VUR&\L-/UD6QEEN[B-[?4H99(
M'$4R11B/`7<N`0W)K[?V@=A05!Z@?E0!X9\)_A'K7@?XR^+-=N+:$:)K<'%U
M>:B+V]N+@&)0RMY:M'$4C):)F8!SE-H+"O=*3`]!2T`%%%%`!1110`4444`%
M%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`44
M44`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!111
M0`4444`%%%%`!1110`4444`)TZT;AZBJ>M2M!H]]+$VQX[:1D;T(4D&ODKX;
M?%SQ;'X&A/B'5=9L#=6GAPSZAXBDMIYK5-0D;S]1BD0;!;L,(@DYC=?F`&`0
M#[!R/6C</4?G7S-=^.=1T#QK)X(3QK?W/AFYU>TLY?%%U<0R7.GR36EU,]E]
MH"A!(S00E6<;E$^.Z8EN?'&L6GQJL_!]OXLOIO",]CICR^(?/AD:.Y\^[*VI
M=5V*UQY2Q&0]?*V##N#0!]*9'J**^5-?^*?BRX\+^(=.M=;NK76_AKH.JOXB
MO(D13/=JYBL6;Y<?-$'N,``9V_2NIU?XF7]EHWC+/B%(;S2OB-IUA"&GC5[>
MQDFT]9$P>B$32@D_WSS0!]!9H)`ZD5X<-:GUS]HJ^M%\2ZM'H^F:;I=Q965E
MK$$-K,TIN=Y>(C?,&\M!\IXQ6E^T=XF\2Z+X5\-S_#'44M]4U#Q!!&@6-)5O
M8D@GG:WY!`$ODA-PY&<B@#U_-+7S!IW[0<^L>.)?%VGZ[%;_``]O?"]VVC07
M,):":X@FM(_M#;`923/=-!M'_//IDYKH="^.7C;Q5;:5IV@:+X=/B.Z.N"X%
MS--'`3IMRD!5%QO#2&1?O'Y,'.>E`'OU%?,M[^TC)JVKZ'XBM[FWT;PM:S7=
MO/+,[NEQ<)IGG2QRJH)*Q3ND?RC.^-Q6C;?M!^,]2T>"WTK0_#K^(EN-<CN!
M<SSP6Y&F&+=M7!=6<2@8;[I&3GI0!]$T5XCIGQ<U7QA\0M/L;9-&LM&M?$,N
MF20C43]ODFCL7F9FBQAH3O4@#D;58\'`].G\2WMO?&VB\.:S/$KA1=1F#RR#
MCYN90V/^`YXZ4`;^1ZTM?-WC'QOJ^@>-_'VH:9XMG6^T/7-'L-+\,W$T3VU[
M'/!:F2)82/,\QFFD(96R"!V!%7;/]I+7Y=`UC7KKPW90:-]S2IY[EH%MYOMR
M68CNV;I@OYC,@P@1E/."0#Z$HKP_3/C-XPG\?1^&I=%T+4?[*N+.WURYTVXD
M*'[2S`30E\!4CVX96RS,KJO(YYMOVF?%1T_4=3&@^'1IMAITVLNIOI?--C;W
MKVLR#Y<><QC9U.=H&%.3S0!]*45\MVO[16O^`&\1_P!OQZ7KVGC5O$"Z7'%>
ML;V#[)=843J1A8`K@9&2H5>N>.\L?BSXTN9/#VDW.A:+::YK6LW5B+B>65+:
M2""W6X,Z1C,@W(60*Q!W+N^Z10![125Y%X_UZ[3XK^%]/\*^*F@U%+A)M:T>
M:YA%K'IA5]\DB$;O.=PBQ_-G(8XVJU+\%O$%UJ^L>*KJ+Q2WB/PBUS`FB7=Y
M<12322D,+AE*!1Y!?:L8(YVL5RI6@#US(]:,CU%>1_$C6KM?B7X3TWPEXGEM
M]9>]ADU'1GN(A;?V:6(FDE0C>7?A(\,#N&0"`]>6:7\3/$MWX0.M6OC*9+OQ
M+X+U36;TR+#+#H-U;21I$L"$8C4EI(MKEOF3/+`T`?6%%?+OQ?\`CO?Z)X4^
M'ZV&LZAIWVN'2-3U+5;33I+I+]'N88GM5EC1D5FS*S@X.T*J\OQ]#:CXBNK&
M94M=!UC48VC#B6U\D*,]CYDBG/X=Z`-O..M`.>E?/WQ:^+VJ?#OXO:%?ZMJ)
MT_P+9:`+CQ%931H1%Y]SY*7+.,D&-Q&I`.TB1L],UR^E?'3Q=X0\,^-;OQ!?
M6-WX@.KM>Z5I.I6[D6]J=,BOGM$\@9!CC;EG.`=Q)/`H`^JJ*\"U#]HK6%TO
MQ)KFFV'AS^R_#:P6\FGW-^Z7UQ=2VUO.&4!=HBQ<;>F3L9N@Q4^O?'/Q)X;U
MRYT_4K'PO.?#UUI-CK<,5[+'/=3ZA(B(UFC`Y1-X/S\L4<#&WD`]UR#T(I:^
M4-/^/-SX;TS3?&&N7OBC6KK6M.O[F32[6\LUT^TNK:&XE?3V@Q]HC:(1$-)@
MY9>3SBNQF^-OCX6MEI\'AWPZNO:A+>&UGN+F6*TN88+6.Y#JO,@W"0Q_-CD;
MQE2!0![]17@,GQOU@^*[W1]%@TJWU+5=5MK:SEUF^?[';`Z1%>R#Y0#D[BH4
M=3EB>,5V/PT^*=_XK\2Z[I7BJ+1])NK'9)96,$[2R26S2211W'F_ZN2.5HV*
M;#D8*L`10!Z;17B7C3XG:YX3^)'B*QTG[/?B2+P[9Z=9WDIC@M[B^NKJ%I6*
M@MCY8R0.H3`Q4_AOXO\`B77?$VG:%=VOA/3KVQM$N=?\^_DQ,&O)[4"R&,M\
MT&[+]Y$3J<T`>S4F1ZBN!^*>KR+8^%X=+U!+>'6/$MA:S3Q7!0R0ER[(C+W;
MRPN.X)'&:^?M'^/GB/POJ>AV_P`0];D33]3\6:Q>6>K21*L4VF6HU%9K.38I
M),#0029`W%'7KM-`'V!17SK8?M&^)'TF6XU73-!M8-+\1-8:OJ["=;:VMA!;
MS)(83^^5G^TJF<%5*@M@,,26GQ[O;Z]EU_4[CP]I>B)I^J&PB%[+/,DD5Y#:
MQB[@1=VXRD8V=-^WKS0!]#45\WVO[3'B*ZTH!=,\+V^JZ;;:M=:D+Z_DM8;B
M.QO&M2EON!(D9@&(?[O`/WLCU_Q7XAO[3P+XMU")K6WN--T^ZFLI()?,*[+?
M>K."`%<-_#SP`<\T`=AD>M&<]*^/8/C7XSU#P;X<T5-;E_X2OPGJ&F3>+KV*
M"(-?VUQ<6R6JLNW"BYCN2QVC_EBX!%=%X4^*M[>OH^JZCK?B2YU#Q=IM_*(8
M+JR&FZ;=P6]Q(UF;?_CXC>$1X+D?,RC<><4`?4'3K1FOCSPG\7_%FH:=IOA_
MQEXKN-&UW3_AY<:S-K3P((K\,;*2SOB@'S<O+`Z+C+!P!\RUVWPJ^(FO>*-=
M\*ZQXJU$Z?JFMWVJV6O>&99V1-$>"W1UMPAZNOEB0NW.+@XRI%`'T=17E?QZ
M^,$_PK\-)>:`VE7>J&UN;^.QO$F;[5:VT8>8HT8PI&Y/F8X&X<&K'C/XF:GI
MGBKP[X?\/IX?M[K5M,N-6N+C6[MX85MH'A5XXRHR9#YP.3PH4D@T`>EYI:^8
M=&^->M>'3XADEWZS/82WOV:.[O2L9W>(9;*)"`IP$0J-W)PH&*UO$GQU\1>$
MKW14\26.D1ZQ<#4+&58-0D33Q.NH6=K#.^Y=PCQ<AVSROS+SG(`/HBBO$-6^
M-^KZ+XM\*Z#<-X6U.ZN]0M;#Q#'IYN&^S/<R2I#)%(1L`_<ME&RV58=LGH_@
M#XLO?$GPWT!M9;4;R]DLVDEOYXB4F_>NH'F=&8`#CVH`],HHHH`****`"BBB
M@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`
M"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@!DR+)&R
MRX*,,,",@CTK(E\*:"Z&WFTO2F26R^Q-"UI&0]JO_+':1S$,_=^Z,]*L^(H9
M[C0M0BL7NH[B2UE6)[4J)E8H0#&6^7>#@C=QG&>*^:O#/PE\2Z=XE\'Z_?>%
M=3O+KPW'J]I;33Z](DD[2+;/;7-S&;EU0/(EP'5"X'RG;@@*`?0R>`O#,>BR
MZ(GA_1%T>=M\NG?V?%]GD;(.YH]NTG(!R1V%30^$-!MK7[-;:/I4-LJQ1B&.
MRC5`L3;XEVA<81CN7^Z>1@U\DZ_X<\7Z#X>-KXNCO]"T[Q)KRS"RFUR1(XB-
M*D,RB4W19<7*[D!F4.4!VX.*[CX;>#?$MQXM\-ZWY_C%M$BMM-;2YYWP38_8
M`DT%Y%)<?(YG!D<^6[%F3#X!P`>Z6B>&]3F\111PZ5/*LJPZZOD(2[B)659\
MCYOW3IC=G@BH!X&\&>(5EU5O#_AS4?[:@1I[Q]-AD-[$=K+O8KEU^5",Y^Z/
M2O&]9^&GBV/XT:UK?A[2=5@.IZU%<?VLNL!+-M/731!+"UOYG,K3*N"8\C"M
MN&VJ&C_#_P"(T6H>'CJEGK[:M9CP^MKJD?B#;:V5K%%%_:<-Q$),2.[1S#.Q
M]_FIAAM.`#V;6_!?@;0DL[[5-$\/:>+3RK*RO?L$43V?F/Y<4<4@7='\\@"[
M2,%N,5T.F^%])TG2]-TS3[&VBL=%2-;"$QAA:A%VH4)Y!"Y&>O)]:^2_"OP]
M\8_$CP8EPEGXD.GZU:60U26^UYC_`&A<QZQ#)Y\"&0F'R[6*49'ED[E`!(S7
M<>,_AKXT@_X1_1/"6FZI-I^AZF;O3]5?7)7GA0ZDKM!(6G7=']E!P764G[F!
MU(![V_A'0Y[/[++I.ER6ODR0^2UG&4\MV#.FW&-K,`2.A(!-/T_PWI&E"W&E
M:?868ME=;?[/;)'Y:N07"X'`8JI..I`S7A][\(_$VIJCW[:VTFI>*=7FU39K
MTL>=/"W9T]%VR#8@9K8[4P?[W0UA7/PX^(>G^'H]/?3=6UN#7]#TAM?:XUZ2
M2>#5%BN/M<T6+B,YWK:J55U3!+`':00#W;0?AGX:T#P['HUOIMI=V4<MS*WV
MV%)VDDN79YW8D<EVD?=Z@XZ5J6?A31=.BCBL-,TVV2!)%B6*TC01K)C>``.-
MV!GUP,YQ7@6D?#_XC)9R)K4.MR^*8_"EI:Z#K:Z[FUTZY&G&.X$\0D`DD-T"
MV\H^X.A##8<+X8\(>./"B:#?:?IGBR^@M]4DFO\`1[K48E:/S=.>(['>YD\Q
M/M!5F+/PQ+*N*`/<KW2?#&CWDNLWMGH]K>H8HI;]K>-9AG$<:E\;OX@H'OBN
M@R!A?RKYCA^$'BG3-5\67^FZ/JT.M^(K7PY(NI)K99"8)+87L3`R\/B-SD+A
MER`?F(+F\#^-3\/IM,OO"VN7VO:M=*GB34)O$;R+<.HG*W-HBW*;5+B$;08P
M%D&5;9B@#W&TTGPEJ'C&]NX=/T.3Q3ID<)N;O['&;N%)%/EYDV[L%58#GHI%
M7AX'\.+/?2_V'H_G:FCI?O\`88\W2N<N)/E^<,>2#G)ZUY!X6\`^/M+\->+W
M^:#Q1JG@G1[*QOIKQ79M2@M)TD9GY.1*Z_.>I.1FN?U[X?>)IM*L8M"\+>-H
M=)33+XQ:;_PEI6[M]9=(3!=22FX^:,,)5'SL`Q+;,-0![XG@/PS'-8SQ:%HR
M3:>%%E*EA$&@`8L`AVY7#$L,=R3UJU_PC&BM!)&-,TWR7A:"1/LD>UHV8LR$
M8P5+$L1TR2>M>#V?P?\`&6K>);:;QK=ZY<V]Q?FVU66UU^6".:P&D1@[4C==
MH:_5FRH#]_N\5RGA_1?B'J?C*QM+F#7[GQ/X93P\UQ>/K?E6=HOD$WR3('Q,
MTRIL)V/EF!RN":`/IU/!?AZ&\O;J/1=(2[U.)HKR=;&,27*-]Y9&VY<'N#G/
M>GZ7X1T/0EA71]*TVQ6WE:6);>U2/8[+L9A@<$J`I(Z@`=*^=_"_PT^(&I0W
MD>OZ?JNC:?KFO:3<ZCIT.N28BB\N;^T%CD^T.^PLT:Y5E+@9"K6E!X4\3Z'\
M0/!7A*VO]8ETO4[9+S6'GU%YI+6'2YF\K+DY/VCSK9&.<L(3GJ:`/6-0TOP+
MJGC]+;5-)T"]\6&U%VLLFF)-<I"OR*S2[#L'4*"P)PV,X.+4/PI\'V:1)IOA
MW1].BAO(;TQ6-FELKS0DF)W$8&_8QW*&R`0#VKR7Q_\`!_6Y?B!XR\3^&-.U
M*5M8MM"@F%IK;VTM]:Q3S?;X(_W@5',7E`'Y>K!6!9LT_#'P_P#&-KXCTQ_%
M&C^*+WPQ;W5S)H>GIXF(FTAOM2&!KEO.!E7R0Q`+2[1E2"6H`]SOO`GAO5-:
MAUC4="T:ZUBW*&'4)["*2XCV<IMD*[AC)(P>*)?`OAJ:WU&"?0=$D@U602:A
M$^GQ,EVV[=F5=N'.XDY.>3GK7BB^$_'FI>"[S0M;L?$UD]JMU$]]9ZA#,]]Y
MFIB5%1?.5O*-O\K$LC!695P0*RK3P!\3;O6[/4+V+5M"OXM-LAI$=AJ/VNTT
MX_962:UG,EQ\R^<`[.8Y6(90K?+0!]`Z=I6AV,)T#3['3K6ULDCG33H;5(XH
ME,C,CK&!M'SQL1CNN:WLC..]>(_"3P;XFT;1]=DDT[6M$U.]T*UAC;6M9742
MVI*L_FRJ=[E8S(ZMUP<DA5Y%<5H7PR\?7-M!:O9>*=(T^Z31(]?ANO$QFDO+
MH7).I7$3B5F1&A.TE60MD;5!%`'TIJ&AZ;JKR'4K&QNVE@\B43VZ2>9%G/EM
MD'*YYQTS6$^G>$?$LZ6]_9:+J$]W-+,L5Q:1R-+)`1#(^&4Y*<(3Z8'2N#\1
M>!/$5A\*M'T'2(M:U.#3];"ZE:)JY2]O=*$\O[M;DNK%MC0GEU)5"N<FN6UG
MX:^,I_#N@6-FGBO3K2&PU:*^CM=3BN+H&;48)8$E;S4$N8%E#,'#!68!@QR0
M#W:?P7X>NKQ[RYT729KIX5@>>2RC9VB7[J%L9*CL.@J:]\+:+J&K6^J7^EZ;
M<:G:`"WO9;5'FAQG&UR-PQN;&#W/K7SE-X&^)5YIFH32:#J]CXB;0[:+P\UC
MXI<6NDC[.5N;9MTI+2LX.)&$G,B'>/+)%N;P-\1='T+6-3^'.GZS826.K*WA
M_P`/ZOKOVAS;2V?D7!=VD<!1.XN%5G/,)Q@L*`/>AX'\.+JLVJ+H>C+J=RK)
M/>BPB$TH8;6#/MW'(&#D\C@U#I7AKPOI-_)I^AZ;HUE=6T?GM;VUI'&T2R`Q
M[\`<!A'M]PN.@KP)OA-\0-$U#Q!'8:AXGN[RWTV[M-"OH[X-#=0'32EO'*7G
M^1EN0&R(MQ?#%MI-;^I_"GQ5:RSV&@MK*Z3=66@13L=<D,C,-0EDU,[VDWAC
M#)R01D$!>@``/:+[P;H.J6\D&I:/I=W#+(DLL<]G&X=T4*C$$<LJ@`'L`!TJ
MD_PW\+>;%-%HFF6S0WT=_FVMUAWW$>XQN^T#>59RPW9`8YZU\S>/=!N?#GC+
M0]`U>_\`$ATG15MYK"&+5YI;LQMK,FQ8E\Y#.6@$<;AO,98R.`1\WJ/BGPUX
MSU;X\:!J=AI<]KH>C7L(?4;?47"7=DUM-YRRQ><%R)WC`7RB2`&W\8`![!+H
M>GSW!GN+*TEG9HV,LD"LY,9+1G.,Y4DE?0DD5F0Z-X>UV[CO#I^EW5UI-Q+'
M!.UJA>VEW?O`C$94[N3CJ>:\(A^%'CG3/"#7*_\`"0WNKZHD/_"0V7_"0L&N
MX8]0+/%`QDVQ2-:$H"A3(`4D'FNIN/!OBBT^#=WIFA:=K,%V^N>>^GR:PIO9
M]--VKR0K=!^)&@W*"7R,[2V>:`/1KGPWH?BG1DTVW5;:VT748GA%B!";2XMY
M`XV8&!@\$`8(9AWK3N/"VB7,<,=QI6F21VTDCPH]I&PB>4,)&4$<%@[[B.NY
MLYR:^==7^%WC5TTV/3X?%NG:)$VHRV]O;:HES>V-RTL;6LSL;A%E(C#(H=I`
MG1@V2:NZM\.OB<T7B^ST^ZU#[%HL)B\,R+J>)=4@NKQ+FY0G>"DD<*&V1F9<
M;LJP!R`#V)_"W@F#5+#03HWAU+R&-]0L[+^SXLJJO&KS(NW`PQB!(Y^[[5JM
MX'\//)?N=$T<OJFX7S&PB)NMV-WF';\^<#.<YP*^=M1^%/C:*32IM"M?$-WI
M]E:7=M=PW%^EK>-92:G92O9PR>>[@&"*4*S2[L`J67(K#\1^%/&[SV_AN*Q\
M7/+>Z;KUUX<TZ+Q(R2Z65N+5-/DN)_-&X1%W;:7DPKX(;&``?2<W@CP?XFTF
M?2TTO1IK6P>:U"0VD6;*5EQ)Y?R_(^&!)'/(K?BT:PAM[B*.W@$-X2;E?+7$
MY*A27X^8E0`<]0,5X/J/PI\9>);Z6Q\33ZP=(N-8U6>=[/6GMV:-K*!;5E*.
M&`^T)(P7@`C)&#SSWA0W4W[1%J_BB\UNXO=/U-[****^>7II41/VB$2A5@#F
M5UD\HY=@"QR*`/HRRTSP_J8N#8VNF7"Q2K;W&RW0X>W/R(W'6,_='\)Z8H'@
MCP[%JT^K)H>C1ZG<JRS7RV$0FD5@`P9]NX@@`')Y`KQ36/A5XQ\47UQ:ZQ+K
M<6DR:AXDND:TUMK=@9'A;33N1PV%Q(57HI'S"KE]\,_&MUK/B'7K&\U2V\0&
MZFAT21]6;[*EL^D!!NAW%,"]^;)7=D9Z4`>RR^%-$E:)I]*TUVM[=;>(O:1G
MRX5966-<CA`R*0HXRH..!63K_P`-/#WB#49K_5[<DS65S:W"(XB259T1)9'*
M@$R>7&(]Y.0N1WKP>V\"?$K1K&]UKP%I7B#3[G2X;&2RT+6O$?VHW]X\,\=\
MY8RNH3,T+C+`,UN2%7(-1:W\&?'&LZQ<Z1-87S:7#X>O=%EOSKDNW5XSIZK;
MRRYGXD-T7R!$NW:"6(;%`'T/=^'_``OJ\EMI&H6&D7S:7;I+;6EQ;I-]FB.4
M1D#`[1\I7CTJ]J?AG2-:%J-9TZQOQ8R"2V%U;)+Y#C@,FX?*<<<5\[+\/O'_
M`(>TG1M2^'VCZK:W'A?PWIRV.AWVL@K=7:2W*74$C&5E.Z.97#,2/E0<8P-3
M2?A=XTT7Q_H#ZIJ/B.^L=)@TH6E_:70D3*@B_2='G48D<EF;RW)5@%(*@4`>
MZGPKHY,A.EZ=F7[_`/HB?-^\\WGCG]Y\_P#O?-UYHO?"VD:DLBZCIEA=+-')
M'()K5'#I(09%.1R&*J2.^!GH*U:*`,*#P+X=MKJTN;?0M'BN-/C$=I,EA$'@
M4$D!&"Y4`DGCN3ZUK65C;Z;:QVVGP0VUO$"$BAC"*HSG@#@<FIZ*`"BBB@`H
MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB
MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****
M`([BXCM())IVVQQ(7=L9P`,DUYYI/[0W@/7+VTM=-UB:62^N(8('.G7"1DS9
M\ARYC"K'(051R0KD84DUW]_;"]LY[=B0)XVC)'4!@1G]:\RL?V?M*L=(33HM
M2U-HDM=!MMS%,E=(D\R`].KD?-^F*`-&3X\>`I)=1AN]96./3(I9Y)KBSF2&
M:.%PDSPR,FV94=E5BA;!/-1M\?O`\&D0ZDVH7ZQ3SSP&#^R+HW$1@*^<TD'E
M^8B('4L[*``RG/(KGY?V9M.N=/;3;[Q#KEQI=K8WMEI-JRPC^SXKJ=)9<,%S
M(1Y:(I;.%'<\UN^*?@R/$.L3:MI>OZKH&IW$%[:S3VB12![>Z2%9$VNI`(:W
MB=6Z@@YR#B@"'Q;^T!X=TC0]>NO#,S:Y=Z)I+ZCB"WE^RRA8EE$?VD(8PYC=
M6VYSA@<5HGX[^"$O;^UN=9%NVG17$LTTMK,D#BW!-QY4Q39*8L'>$)*X.>AK
M"MOV=['3?#FO>&](U[6;3PUK]LT4NFXBD\ES;QP&19&7?]V)6VDXW9/0XJK>
M?LTV%_9SZ=>>(=<DT98=5CT^Q(A`L6U$,)V#[-SX\R38&R%WG.<#`!T;_'?P
M=!X3N_$?VG5/[)L+QK6\D&BW9>U=4#EI8_+WI'L*OO("[6!SS6CX>^(L6K/X
MR-U;2K;^$M1^R[[9'N'N4^RPW&]8U4L3B;&T`D[>.M<Y\1O@%8_$=)8[_6=5
MM(;I9TN8(A&\<J36T=NQ*L"-ZK$"C\E2S8ZUH:C\&;2^\/\`BO2H-6U6R'BN
M]AO)KFW=5D@>**",*O'*%;==P/4,PZ&@".\_:(\"V6B66J7.K745O?\`VC8I
MTNY,L0MY1%<&6/R]T8B<@.7`"YYJE%^T%HVI3ZO;Z5;:A#/HGB`:'<?VG936
MD<LY0L#"Y0B3..!QP020"I*Z)\`-+T"U$<&HW\C?8-7M'(2-%8:C.D\S!%4!
M=K)A5'`!P<]:L7'P1M;V_P!0FFU?4#9ZAXCB\0"T\N/;#=)$(F"MC<48*IP<
MX(X/-`%'P3^TQX1\4^!K+7;R>\L;N:ULY)M,_LZX>=I;F,LB0)Y>Z=24D`>,
M$'RV]#5[5?VA/",5E8OH6IKJ-UJ1B^SQI;3;4WW'D`3,$Q"QD61`LFTED*XR
M*PM*_9FM]*;2;F/Q9K\VK>'(K"WT2^DC@_T*VM$F2.$QA`L@9+F979N3N&""
M!5C2?V<[7P_(\FE>*/$,)OTB.M;A`YU66.[DNA(^8_W9,L\P(3`*O@8P#0!W
MOA_XC^'O%%S9VVA:@+J>]LI+V)%B<$0QR^2Y;(^4B3*X.#E6QT-<QX7^.VBZ
MWXT\0>%]16XLM6T?5+FS@46LSQW:PQ)*=LNS89=CD^4"6PI.*C\#?!JVT;Q+
MX\U3Q##;7MOXKU-)+2RD_>QVMJ@W[0"!@O<23S$<X,G4XK.US]G*UUW4]5GE
M\3^(K2SU&\O+^&SLWBA^QWES:_96GCD"[\K$6VJ3@%B>>,`'1:?\=O!^J"Q6
MRN]1>[U#4);".P.DW*W231A#)YD!CWHJB2,L[`*`ZDGFFGX^>!PVHK_;#DZ;
MZ6,Y^U_O1#_HWR?Z1^](C_=;OF('>N;B_9MLH=,2S@UR\MRVL'59KFVL;>*=
M93Y`(@D"[H`5MPIV'Y@[9SQAD/[-.EZ?9_9-*U:?3X[2\6\TB6#3[;[182I=
M"XC'FE-TL:L-NQ^"O7)`-`&SJ7QZT31/AR_C/4H-2NM(.JFPB&FV$MQ,Q-QY
M"%HMH93N^\"`0?EZX%0Z!\>_#MYXWUKPWK!N-+N]/N52VFN+69(IHS8QW9,D
MA0)%($>3,;,&Q&3BM;4_A2NJ^`+OPS=ZUJ;R7E[]N?5"L7GBX%R+E6VA0F!(
MJ_+MQM&/>F2?"#3[M-<36;F[U!?$E[]KU!7VQAV-@+)U&T<!HQNXZ$\<4`%O
M\?/!-SHMQJD6IW/V>WN(K?RFTVX6>1YE+0>7"4\QQ*%)0JI#8XS5BZ^,WA'3
MM1U:UU>]N],GT6R6^NC?:;<0+]G+*AD1F0"10SHIVYP2`:Q-"^`UGHNGZ7:R
MZD]S_8^HV-]!-'I]O;23-:(RQB9HU'F9#G)/X`9-<UXI_9E>XTSQ7/H.N7MU
MK.NV<]K;/J!3$"37J73;I`I9]A0*F[(555<<9H`[)_VB/`D6F)?3:K=1)Y\T
M,\+Z9<K/:>2$,SSQ&/?#&BR1LSN`H#J<X(J[XE^-/ACPYX6US79+F[O;7P^U
MTEU'8VCS2M);Q^9*B*!SA2#G[N.<X!KE+K]FNQN]0EU:ZUJZO==O)KQ[^^O[
M"VN4NDN4A0QF!D\M51;:#;@?P'=NW$5H2_`*TN'\0Q7&NZPVE>(3?M+IR+#'
M'"]Y;B"9U8)NSMY4$X4D\'C`!9C^/WAM`DU])>6\%SI]I=VELVGW/V^8W#3!
M(Q:B/?G$#D8R<!B0``3TF@?$S0/%&L7>FZ#<75W<6$*2W++8S"*(LJN(FD*!
M1+M=&,>=X##(%<;<_`5;O6M*UO\`X2?5X_$>B6]I#:ZBEO`!_HXN%!:+;M(>
M.[E1AQT!&#6YH/PI.C>/&\4SZU>7=TUDUL\(MH;=;DL(AYMP8U!FD'E?*S?=
M#L!P0``<CX._:BT'6=,U#5/$T=WI%F-4N[:P@_LF\>X^S6S^7+<S+Y7RQAN6
M<?*FX*QW`@=_8_%;PWJU[J=IHUY<:E+H]I]JNVL[*::-$*+(JAU7:SLCJRHI
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MF]^RRV$#/%-<*/-V7!7S%0L&?;GJY&<8``*NC_M&>$=4T[4+R4:]8K8:W)HH
MCNM%N%DNKM-_R0($)DR(W/RC(QR!6M9?&SPGJ<NJ1:7>7U[+I,#SO';Z7<2-
M<QI((Y&MP$S.%D(1C'NP2`:HV7P:@L=72^.K:C-#:^*)O$=K:.D>V&XFBF26
M/>%W-&3.S#/(P!G%8$'[-FGVNGSV.DZQ<V-G]I,UKY5A;B:)?M2W/D22[=\T
M&Y=AC8X93\Q)`-`&KI_[2/@S5-=33[.;5V@;07UQM1;29TM([5"XDWR%?D93
M$X(;&"-O7BK^E?M`>!=8OH;2TUF2.69WCW7-A/;I&RQ&4"1W0*A:(&1`Q&]>
M5R*P++]FW3=.T@:98:YJT5G+X:O/#]XACA/VFWN))9-_W?D='F<C;QC`(K0U
M;]G_`$36X+^WU2ZU">VU+5;74+F(NH#F"R6S$><9"M&N3WR>#0!=A^.?@:[T
MBXU9-1N/)M;F&#8^FW"SN\X)@\N$IYCB4*=A52'QQFD\*_'?PQXQ\8VWASP^
M-9N)[O1HM6@O#I4R6K0.SJ`9&4!7!C8%6QS\OW@0*.@_`6ST;3],M)=3DN!I
M.H6%[!-'I]O;22M9AA&)6C4>9D-R3^&,FMK1OA<F@^,8/$&F:G>HZZ:VGW-H
MZ1M'<1_:)9T;.,JRO._0\C`/2@#&\9_M'>#_``E::^PNKV^O=!MKJ3[-;V$Y
M6\EMT+2P0R[-CNF/G"DE`"3PIQ>TSXQZ?8^`?#NO>-C):7GB",&&QL=-NI97
M?!9@D!C\["H,DE!@#/0BL2__`&<;'4S>VUWX@ULZ/++JL]GIH\K99SZC'(D[
MA]NYP/.G**QPIE.<X7'5>*/AF-<E\-7>DZQJ&C:IX662.SO+=(Y-T<L0BD1T
M<%6R`K`]0R@],@@"ZA\8_"FD:O?Z=J]]<V$VG::^IRR75A/%"]J@0R21RL@2
M0)YB;@I)&[FJ,?Q\\%S:9'>PWVH2>;?262VJ:1=&Z\V-4=_W'E^8%5)(W+[=
MNUU.>17-WO[-FG:AJ.OW>JZ_K5W)K]CJ-D6E$320QWIB,H\S;E@IA78#P@)&
M*Z76OA(-0\1VVOZ1KNIZ-J]M+.5N($BE#1300PRQLCJ00?LT+ANH9>X)!`)8
M/CMX(G.K$:T(X=%MWN;F>6UECB>!)!')+$Y4"5$D(1F0L`2`>M=9HFN6FOZ-
M;ZM8K=);7,?F1BYM9()0O/6-P'4^Q&:\ML_V;-)L-`UG1(-0E72]5M;BVCVV
M%N+FWCEG68K]HV[W567`#=L9R0".ZNM`U;6;?Q/9ZQJTD6FZS$;:P%@/)GL(
MVAV.XEZF0N68'^'"X[T`8T'Q[\'7,2F.[U,73:D=-_L]M'NEN_/$:RD?9S'Y
MFT1NKEMNT*0<UK>)OB3X3\(WDT7B75;6PN(EM#()5.0MU.8(.<<AI05]L9.!
MS7GL/[,5A'X=O--AUZ_BDU&]2[N+V.RMTGCD2WCMU>!PN8)-D0/F*=Q9F)SG
M%='\2O@?HGQ3UG3+[Q!-?1R:79W5IY4#@)<+,F%,F1DF-\2)@C#<T`7)/CGX
M+BU6'3%U=S<27C6;.EG,\4,HG:W`DD"[(PTR-&K,0&92`36?\,/C+)\0-6MK
M*XTM+'[1H7]IEUGW[2+R:V*8P./W(;/^UBJ.F?LZZ7HNHZ7>Z9?-Y]E8VEI=
MM>6,%W]M-O,TRSDNI,<S-))EE_OY`!`(T_"?P9TWP;*9-/U#4I'&BOI&YV52
ML;7,MP7!`&'#3$`^@'>@"PWQ[\'(EV);O4H[NSU!-/:P?1[I;N2=T9T$<!C\
MQP41W#*I&U&.<"MOQ!\2O#OA::ZBU[4!:26FF_VE(KPN2;?S!'N7`^8[V5=H
MYRR\<UYG;?LO6-CX<U+2H_$.HO)JPMA/?RV-N\ZF"W:".6-BN4N,.7,P.\OS
MT)%=KXU^#FE>-KWPE<ZA<ZA'+X4NDF1DD#&^B4HWD3DCYD:2*&0]#NB7MD$`
ML:A\9?"FD:KK.GZS?W.FW&A6GVR[-YI\\*&#>J&6-V0+(H=T4E"<%A60GQ_\
M,6\EV-2FNXO*D@2WM4TVZDO9/,@$Q+VPBWIM0[CP0%P21G%8DG[,NEW5[KUS
M?ZYK-U)KEM<6QDE$1DBBFO$NF!?&7VO&J+N^Z@"@<9K9U_X'QZEXXO/%VB>(
M=6T/7KICBXMXXI4CC:V6!DV.I!!$<;@GD,@[9!`.ETOXI^%M;CEETK5[>Y@B
M6U=ID#>7MN8_,A8-C!#)SGMWQ5SP=XWTGQ[I"ZIX:EN9K"1RL,TUG+;B=<`B
M2/S%&^,@@AURI'0UPF@?L^V?A:]M6\/Z[K%KIUM;V$3:>XAE6=K.(Q0N[LFX
M_*<LH(!8`],@]+\-/AJGPWLK^W@U&>_&H7@N2C0QV\%KB-$V00Q@)&AV;B%X
M+,QXS0!VM%%-W#=CO0`ZBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`*6M:I;Z'I%YJ.H2B"UL;>2>>4@D)&BEF;
M`Y.`">.:\%\'_M'ZIJ5Q:IK_`/PCZV<WBNWTLZC&)+6/[)/ICWL<NV1SM?*H
MOS-R#T!XKZ"NI(HK>1[G;Y*J3)NZ;<<Y]L5SNC67A#6M.6TT.S\/7=@\<-Z+
M>WMXFC*N-T,NT#'S`$JV.W%`'A]Q^T!XJTW4_$FJW5]X3GT"W\.Z+?Z99%'C
M=)+Z=X3.\V\[H$(WN0O"@8(.28M:_:)U[19;N2_AT34KWPRVKPS3:7>RI8Z@
MUO;6DP(4DX(-P48$OL9#@]17T7+X<TF9]\VF:=(_V8VNYK5"?(/6+./N'NO2
MFQ>&='@M([6'2=-CMH@XCA6T0(@?[X"XP-W?U[T`>,Z1\:/%T6OK9>)[/PTU
MJFM7^@RR6#3AVNX+)KQ9E#G"Q%%*%>6SA@<<#*\.?M!>,M1%E>:MIWA=--9M
M`GNTMI)S-]GUAMD*1EOE\R)B"S'AQD`*>3]!G2;$MN-G:EC*TN?)7/F%=I?I
M]XKP3UQQ35T73T3:EC9JN(QM$"@8CYC[?P_P^G:@#PZT_:-OM2\!VNJZ;#H4
M^LSVUH9;,7+%+>:XU%;-1(`2RJ-Q;GDE2*@UGXY>.M'O[#1AHWAZ[UNWMKRZ
MU'RY7BM[Y8+PV_EVS2.OE-M"NS.7";U&#G->YP>&M(MO.^S:5IL7VB3S)=EJ
MB^8^X-N;`Y.X`Y/<9HU'PWI&KB,:MI>G7HB9GC%Q:I)L9OO$;@<$X&3WQ0!Y
M'\<?BGJOAJ\NO#^AW&@V#-X;NM4GNM7NWMS,BMY7E6S#I*"V[)SCY!CYLC(E
M^-^KZ!XTU&QN$L(-"@\4S:?<7MS-)<RL^RU$-O%$KAHR[3$!]K1@C!`R37O&
MH:)IVK/"^JV%E>M;,6A:XMUD,9(P2N0<$CCBHI/#>D37T=[-I>G/>0R&2.X:
MU0R(YQE@V,@\#GV%`'SS8?M,^)+C3;:>.V\)7T^O:7I^HZ<EI=3,--%W?06B
MP7G4[U,Q.5VY,,B[>,U:U'XW^(H]7NI=27P]<Q>%M0U"VGTG3[F2/4+VXL].
MFE9A"Q.89&P57DJ-C$L3@>]0>&]'L!<&TTG38/M4JRS^5:(OFR*VY6;`^9@Q
MR"><G-9VJW_AC0-;LI]632[35]:N%M+25X5\^ZDVD!`0-QPN1Z`'MF@#R3P]
M\:?'&MKX?L18>%X[SQ+JB06.H"1WMC;M8R79;RED9RRB(H"64/N#```BNF^&
MGQ=NO$&@^*;WQQ+I.FW7AHF>]L[/?*-/MS&TBEYE9DFRBEP\>,CC:#Q7HVG>
M&=&TH*=*TC3;+#^8/L]HD>&VE=W`'.TD9]#BJUC#X>T.Y.D:;!H^GW%XKS?8
M8$BA:=5PK/Y8P6`R`3@]10!XAX=^/_B[Q+%]@TF'PQ+JM[XEATFPOI8+B*U,
M,VFF^25XM[/N`7;C<,Y!^7D5+!\:=>\3Z]I.G3'PSI2P76@KJ5J]\ZW=S+=^
M7*QM>S0C+1X(RVU^1MP?7(=1\%Z#IU[/;3>&M/L-"N2M[)&\$45A.%P1(1@1
MN%<<'!PWO51_%WP]-YI%U)JWA#[5?1%-)G:ZM]\T:$$K"V<D`D'"G@D4`<+X
MW^*.OZ#\3KOP]X7BT^2\U`Z19VCZE/*UO`]RE^YD,:D=/LH^Z06SR1@$<!J/
MQ5\;Z=XPO/%.LG198=.\,:.D&EPRW/D65U?W<MO+.Y\P*\:O$6)9<[%0*5)8
MGZ/N-8\-)XF@TRZN-&'B&>+[3!9R/']J=(]P$BH?F(7<X![9;WI9)_#=Q8:C
M)/\`V*]C"K6VHR.8C$BIDM'*>@"[B2K=-Q]:`/)(_C+XPN[[1]$E3P?H&MW%
MI>W=S<ZO,YM;A(+E8%6%4DRKMO#LK.Q0$`@DY'&:;^T-XITGP7X+UOQ7=Z!J
MFJ:OI]^9I;662UL[=Q=V5NC7*!F`$9N&=SP553@#)-?2EMX;T":TL_LNDZ2U
MM;/Y]F$M(]D3-SYB8&`3UR.M,NM+\/:7'Y=UI^D6T5]*T.U[>-%GDGQN3&/F
M9]HR/XL#.:`/&=/_`&B[^TU.XT[Q/)X63^S9-8M[C5+6Z9+2YELK>UF0Q;V^
M7)N61TW,0T1P>M==X+^*6I^(/B/JOAW75TK3XX[/[3I=O#NFGN85\H27!E#%
M%`>4+Y3*KJ<'Y@<UV2:9X7FNHM#73M%:6PC%Y#8_98OW".S*)53'R@L'&X#K
MFK4%AH>F:PS6UII=GJ6HA@SI%''-<A0">0`S8X/?%`'SJGQTUGQ#H,_B-YM#
MBM[G2H;JTT_3-2E2YLUDU*W@,=T,Y$J@L"1@9+ICC)VM8_:&\1Z?J6I:0;30
MH-:DUZ*PL+=D>=+.UE:X6*YGD239+YIMRJHIC97;8PXR?=HO#>D0M<-#I>G1
MM>2>9<%;5`9GR&W/Q\QR`<GN`:C_`.$2T+RKJ(:+I/E7T@DND^Q1[9W!W!G&
M/F())R>_-`'AZ?M$:Z_B3PMIIL]%%S?B.WUW2Q(WF65U):3W$>RZ#F(HRPKQ
MM;`?E@1BLM/VDO%MS8Z=9Z?IWA^Y\22"^EO[<AXX;=[>."3["LAEV-,4N`WG
M!S&%&[;U`^A(O".A021R0:+I,<D,/DQLME&"D?/R`XX7D\=.34;>"_#S6$=B
MV@Z,;*)S)';&PB\M&(P6"[<`D<9H`X/PS\5;^_\`B3K&@>)SHVD6MO;>=ID'
MF^;-<1*85>9YE<QJ!),J>655P=I&X'CFOB-\7O%/P]^(GBY9[OP[<>'-%\*V
M>I6>G31O%<M-+/-"TC2[O]6IC#.0IP@&,')/</+\-_%HU![:X\)W\=M>1+J;
M6T\.5GBF7RUG*'/$JIA6XW`"NTOM+TZZN5N=0L;.>=86A$TT"LPC?ADW$9VG
MN.AH`^?+S]H7Q&NJ7_AB6?P)_:MG-=1R:VUY+%IERD-I!<&*,Y)2<BXVX+,%
M$;-@_=J6'XZ>(!K>A>'/!9T76I[C2#`\-Q',LL>I1Z9]M5&FW;75QY8.U>/,
M!W9^6O=H_"FABPBLTT72EL[>;SHK?[%&(XY.?G5<8#<GGKS4$MIH%EX@MXUM
MM*MM<O;=S;.(42XDBC"JVTXW$*&4<=,B@#S_`,)?'2W\3^`?%/C:=[;3_#&C
M;OL=XZ22%O*@0W#NJ\D).SQX7G]TWX<;IWQ\\<:UI\%CI%EX7;Q"^J:M9>?<
MK/%:NME;Q3AO+#LREA)L(WG:1NY^[7MFC>%M`\`^"QI,,5O;Z%IUO*TYNV#*
M48L\LDK-P=Q9V9FZY)-:6GZ)I%M;6YTO3].A@0%X/L]NBJH<#)7`P-PQG'44
M`>.3?&[Q/_;^I2P:5H\GA[0G@BOH4DE-],\VEB^!B/W,!B(]I&2#GC&#C:-^
MTIK'VG3XM:/A&ZAU(Z%<_;=+NY##:6^I7#Q&*4L<>:BIN#9`;/W1W^A8]-M(
MG+Q6MLCLZN66)02RKM4].H7@'L.*\_;QO\)K*34M$&K^`XI%D=]1TU9K8-NB
M!+M)$.24"$DD<;3Z4`<G>_&_Q%J.LVD/@Z#PU=6$=BFIWL]Q/(WGVIU&2T(@
M9#M#;$WACD9&,<Y&=<?M!^(3H$VKV*>%GCU'7?[(TVRWR/<Z81=26YFO5W@$
M$H,*NSYG1<G.:]P:/1;&2SB,6FP27R^3:IL13,`#)L0=P/F?`]S3I/"^C2F]
M,ND:8YU(@WNZT0_:2#D&3CY\'GG-`'@A^-WB;7K^VTK4H?#.@7-DVEG4[>;4
M3]INVN+YH@UF58KMVPY*$L<R%"05)/8_$3XS7/A?XG^'?#6AR:9=)=WMC;:O
M:S6\HG@6\>1(9$EW!/\`EDYV[6)VG)7BO28O"FB0/:O#H^E1M9*5MF6SC!@!
M;<0G'R@MSQWYJ:YT+3;N^COKG3[*:^@7;%<O;JTL8Y("L1D<D]#0!Y%XA^+7
MB8?&B'P?H%OH?]EP3VT>H-=+*UPT$MO+*\L;AE164QJ@0AB=X;IP.#\$_M!Z
M_8>$/#$;R:)?+IVD^'QJ2:G=/_:&K2:@RH)+?!P=F23E6W%7'RXS7M)^%_AC
MQ1XB@\5_OKQYKFVOD07!-O)/;H4AF"XSN4'C!`.`2#75MX=T?[79S-I6F_:+
M%0EG,;6/=;@9PL9QE1UX%`'S3X#^/^M>']+DT[Q-K/AZ[-RFI-I-R/.NKBTE
M35/LL,5X@89\PS1JFTIC803@;JZ[X5?%#6/'7C#1=0UATA^T>$-2DN[*R9O(
M>>VU,6XE56)()5#C).-^,GK7LP\):$%O%&BZ2!J./M@^Q1_Z3@Y'F<?-@\\Y
MJW::18V'E_8;*TMO)C,<?DPJFQ"<E1@<#/./6@#P/3/CYXDUC1/#%U!>^`;:
MY\<3HVG-+<3-#I$1MY9C%=_."\Q\DH,%!N#C'R\\8OQSU'6/$&B>)=3U!M&T
MFY.C75];07#RVRQ>5K/G,O`9HW%M&_3)"IU(KZ;U+P_X:L-,NO[3TK1H["XF
M66Z62SC\N20M@.XQAFW'J><FD9O#C6+7K0Z2UI:L+=IQ$C)$8RT83('&TLR8
M[9(]:`/G2X^-OBWQ.VAM:ZIX6TB\L/&,E@;R[$UMI]U:OHSW2&:,R%@077`W
MC)53QTK9T#]IW6/$4FD7UO9^'K6PENM%LKO2Y[B07]U)J"QGSK8#@Q()&(!4
MEQ%)RNVO=Y/"/A\::+"30M'-@6W_`&4V,7E;NF=F,9JVWA_2WOK>^?3;`WMH
M@2WN3;(9(5`("JV,J,$\#U-`'S[XK_:-\1Z#X&O/$"'PQ%>/<ZHVE:6]M<2O
M<VNFRR17!>0.JJ[,D9!Z*'QAST(?C#XLM/%>J1^)KW1[VQL/&R6%EI^FK);W
M<=L=*:[Q)\Y$H.0HR,%LGH%`]W72_#VNJ\'V'2+Y=,N6#1F".46TY`9N,':Y
M#ACW^;/>KG]@Z8+XWHTZP%X2N;C[.GF':"%^;&>`2!Z9-`'SSIO[2/B:]MK6
M)(?!U_>ZW::-=Z=)874SPV0U&[%ND-R,DETSNRI7=M8;5QFN_P!0^)FK:-\,
M;74_$$^AZ?XFNM1;28]D$UQ9RW@N7A4*@97PPC+`,PQW;CGT.T\,:-8+(MCI
M.F6RRS+/((;1$WRJ<JYP.6!Y!ZBI[W1M/U*T>UU&QL[JUD;>T$T"NC-G=DJ1
MC.><^O-`'@OAKX^>+O%D'AJ?2M-\.10W.@Z5J^LK/+-O*7=Y+;,EN0<`KY1<
M%\Y^[_M#:^%'Q0U3XB^-;*XO9]`BT^YTW4I;;3[&[=KNU\NZAAVW:'C>-IY&
M,%F7'&X^P1:/80@"&RM(PL:Q@+`HPBDLJ].@))`[$YIEII&G:?>S7%E865M=
M7;L\TT4"(\S'!)8@98G`R3Z4`7Z***`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`IZS"]QI%[%"N^26WD5%]25(`KY
M?TWP-X^TJU\+V&JZ;XI;PM::!H=IJ]CHFIBWN1+#8W".L9216VK.8=^UAGY3
M\P!KZEOKH6-G-<.I98(V=@.X`)/\J\23]J_1IOA'HOCFWT'56?5[Z.T?16DC
M6ZM23ND>3G;M6$K+P>5=,?>%`'+ZIX9^)7]K^+KNSN_%T6I/9ZA'HBQ2^;;3
M0-8_Z)&S-/Y<<J38RXCW-(#EBC9J[XD\#^+O#MA;1^'I/&^NQP:Q'?1Z;)JT
MC+=LUO`'26[$R2Q1K-YK@?.F=X*%=H'K=]\8/"6F:MK.F:GJJV=YH-L;J^2Y
MM9H56$,JET=D"R@,Z+^[+<LHZD55_P"%X^"A'8O)K*0?VA;274*W%G/"Z01[
M]\DJM&&B13&P+2!0"`.I&0#C/A/H/C'3_'VJ7GCB\\0F29[];A)`SZ?<+]I5
MK62)C,PCVPG:%2-,Y??R!GSSQK)X_P!.O_&&N7EOKGAW3;](K-XVUB7[.TIU
M6&.-XW,Q\M7M=Y9HQ"$$A&0PW#V.\_:`\/WNGP?\((&\2:Q>7+V]OI>6L'1D
MC,KO.9U4PQ",;M[*<@C:&R*M+\9_#D-CID/CB2QTB]UDE$LQ<+J$6W?Y8=IH
M0T:Q,Q`#R;!D@'!XH`\2\+>%_&FM>%M9E\%ZSXLN)-*T:^CT::]U24(VK?;K
MI70%I6\X)`8XXW9F0X5A@]-34/!_CF7PYI=E8W?CG^Q#JMT]W;L95O;57M8S
M;[6^U^=+$DXE)S+]]P-I117K5_\`&[P?I,NMZ78:E8OJ7ARPNKJ>RVR0Q1K;
M#]ZGF^64!3*[@NYE#`[<$5-<?'+P7:-J*76L1K)I"I]LV6L\BK(S*@BC98R)
MI=[JOEQEGR0-M`'F5O\`#WQQKOBJUE\0ZIXT_LRXU&.TO)(M5-COT[^R$+N8
MXGQ&[7P.2GS`Y`.WK3\!^'/B9_PEOAZ[^(%WXHCDM(M.56MSYUNT(@*7,-R!
M.(]YD4NTAC=L,FT]0/;=-\<_:H=:U/4+0Z?X<TZWCN+74KC?&;F(P^;+(8V4
M,BID#GG(;@8K)@^/7@6YT:\U:WUZ!K&PNDM)V^S3"03.NZ-5B*;WWKRA52'_
M`(2:`/%=:^#OBW5_AFI\1OXWU75KK^RK[4[!=?D5_/M]1W2^3B50C?92?E5@
MIV(?O#-=O\6/AMK/B+Q7X7U[P5%J\&IZ'X8UB*PF?5)(4MKQXH?LBSKOP^7#
M;B0P.SYLX%=OIOQT\#ZM)J*V.OVI.E6TMW=-+%+"H@B($LJ,Z`2*A(#E"VTG
M!P:CM?CWX%OK!;NTUV.2)[_^STC%G<>>UQM#A!#Y?F$E"'!VX*?,"5!-`'DV
MB^#?&^J7,%E!%X_TGPM>:CI8OX=4UXM>#]Q=&_=95D9TB+O;+\KCYE8H`.:U
MOC-X'\4_\+-TOQS\/-";5]5\(>'PNFHURD7VUVN@)[0R,>-\!+9/&47FN\M/
MC[X0:&R74M4MK>\OED=8;=)KI%"R2(H,B1X5G,3!4;#.P*J&/6+0_P!HOP3K
MGA#0O$T=[J%GI'B*98+*:\TBZBQ(S*H$G[LB,;G4;V(0D\,:`/(-/^#?B7P-
M?SWJZ--KUE!XBBU+48H4@>749Y-)6*2^CB=@DDD=VSL$<C/4?=%+HVC>+H-2
MM+_QY\/]3\6QWND:UIBPQ:;86C$2WL+V[748E$<1>-"69=Q'4C/%>[0?&3PA
M<>(+K1(M:M_[2LC.LZ-%(L:-`"9D\TKY9=`K%E#9`&2,4WQ#\9_!_A31=,U?
MQ!K$=KI^LV_VJPD^S32-/#M5C($5"P55=68D`*#DX&:`/$_!7PJ\6:%-INAZ
MYID]SJ-IXBT75CXG,J2Q"UM;*".>(2%O,WEH98MI&")MV<%JGL_#EY/\'OB]
MH;_#37X8]8U2_N-'TJ2SM1]I^TQJD3HHFVC;(N]MQ!&01DUZE>?'CP[HUYXD
M/B"1K/2=`DLU&I00RW<<Z7%OYXDQ$C%$"YRY^7'.17*>,OVM_"VAZA<:/X>B
MU#4-<@UV#1RL^E7L=J)9(Q)YGG)`^Y`AXV@DG!`V_-0!>\6GQM<_"+PWJ'P]
MTS5;/Q-IBP))H=U-'!)*C1M;R+)\Q3Y-XG'S'_5#N<5QFF?#_P"(U_X:73_%
M5YKMY-9:UIVCF5=1,;7FF6SR>;?EE8$-,LJ[C][]UQBO6X?CQX$G?4T7Q%8I
M_8Z-)=M(DD:!%D$;/&S(%E178(6C+`,0"<U#<_M!^`K.9(KK7?*GD@658'T^
MY$N&0.J%/+W"1D.Y8R-[`$A3@X`/$?AS\$?$%C#X;G>T\::)=^'/"NFVFY];
M8-+?17Q>X1OWK>;"4)VJWR['.`#C'IWQ;A\1W7CK2+[PCX9U#5G\-^']7E67
M[0EM#<SSQQI%;I+O#B0E"<@``8.[/37^)?QTTGP-X`TGQ+I2KJ\/B.ZM;72&
MBCG>*5IR-KN8HG=4`R3\A8XV@9XJ_;_'7P3-<ZA;2>(+".?28))KTR+)'&J1
MD+*R2,@618V(#E"=I^]B@#Q_0_AWX]UC1[72-6N_&6GZ,VIZS(&CUB6&YCMS
M;1&R!D:9Y0!.)"JL[?[7RG%6]9\/>.I]:\01B7QP8]3TVW0ZE$Y!L60VH:V@
MA6X5)5D_?EI5$<J#?ACE:]1\3?%MK/3?"EUX+T6;Q&_B_43:64<LQTXA5AEE
M:1O.3</EA8`$#)(YP<U8\-?&3P[XDLV?SGTZ_MH;F6\T^\C*S6AMI_(N`^T%
M3LE^7*D@Y!&1S0!Y%H&@_$6[\6Z'?>(H?%.A6T-MIK65G9WCW\-O'Y96ZMKE
MFN`"S,-S22)(P5EVL64UZ#\"/"/B'PSI\5QXPO-?N;_5=$L)M3CU343=+#J(
M\T3^6"2$R#'D+\ORC'>K_C3XZ:!X5MO$D5J9;[6?#%HMU<Z:\$MN9(C(D9:.
M1T".`74$H6`)`.,UM?%/XA)\,O"-QK7]F7FM7"R+%:Z;9%1-=R')VINXX57<
M^R&@#YE\-?#;X@V8N!I>@Z[87-E;W%K))="U@'SZY'<J;1HGW2*\'F&0R\@(
MH&"2#8\3?#/X@>,/#&I66JV/CF2Z?399=>237R(=1U!+^%H#8A9?D401SD!?
M+7#Q@@L..^^(G[7VA^"]7N[73[&?4H+31+/4?/%K=D3/>MBU5&C@=-F/F=RW
M0@*'8%1V$/[0_A33-+-SXTU.QTJ5+AH&2`3SY9(H))&*^4'15^T)NW*-H(+%
M<D``\XU/PS\2#XEUNY\,W/BJQF6W:/PRLTC2VOV9M-*QP7)><HDBW0+-(8W<
MMLPQ4MA=1^%.J>+SX8:QM?B)HL.FZ=K#R3WWB!Q?0WDL%MY7[T2LVPRHY"YV
M%D)QM(!]%OOVCO"&B^,Y_#.NW%Q;ZA'+<JKV]E<742I;Q0R.972/$;;9P<9(
M``)(W`5UA^(FC3V6KS:1=1:B^C::FHW$4!/^JDC:2+YL8RZH2!G.""1R,@'.
M^+KNZ\=_"?QYH6DV&H3ZK'HU[I0$T0C6[NVL^D;$X9=\@0MP-P8=LUQ1\#>.
MO[9U35M+O-;L]0L7CMM"MY-2Q8^0='5&WP9*$"]YW$;@5X^7.=SP7^TMHVN>
M'I-3\669\/ND%G,L=O/_`&HLWVI'>*.,P(6>8+&Q:,)N4<XVD$]1XW^)-SHG
MP]?Q=X'TJV\66$=FU^WEZFMJKVBQ-(9$<JP8X487CKU&*`,OX/?:]%T"TM]2
MTCQM!=WS!KY]>OQ>-'<"%6E;<96*HSY4;?E+9P`.:YOXJ?#C4]>UWXAW6B:,
MDPUGX<G3+&6-8U:6],EV3&"<$-B5#D\?-UKL--^+]G::-X;G^(-H/#.H^*71
M+*T5I+Z+,C*L0>XCB$:%]Z`!]O+8!-0:O^T5\/M`MKZ?5=?5(=.FDAN&AL+F
M<(T>?-QLC.X1X(=ER$.`Q!(R`>>ZY\./%_A_2K33O"6I^,ULHK^YE-VMZ-0N
MK6.323'^[\UP7`NB2%+##$D8&,3^(KSQ!H7P&T:&_M/$6CW[^)+*PDM[749)
M;Z>TDU`1$K))(SJTL)SM:0E-X&[C-=UJ_P"T3X$T?3]:NI=7DN!H5A)?745M
M83N[1(`7$?R8D==RAE4DIN&_;26WQZ\(76GW6HWUY';Z7`+-H7FMY_M$CW"/
M)&AMC%Y@<A&VJ`2V.!TR`>7:?X(^)MSI,H@E\3VC6&A:M-X<@O\`6LR1W;7;
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M+!:-@%V_(0,9#"O4=<^/\&@>$]=OKOPWJS^(?#UY'977AZ)T>>6:1!*OE2`[
M)$,.Z4,.R,"`014/B#]H>VTCQ=!I>GZ,-3T^;3]-O%OH=2B65_MTSQ0"*W(W
MRJ"FYF4G:#G!H`?XNT[Q!<?%BPNYK+Q/>Z#!IT#Z4-)U/[-!#?K._G&[0.NY
M#&8L;@ZX608R1GSGPUX5^(VL1WZ:I:^*M"LM;US1YKRS_MF4O:PL)O[12*5I
MG<(-T:ED*@XRBK783?M!^)=/M/%\NN?#]+-_"4L5I((-?CNO.NI8HI8T`$:X
M4I,OS'^+Y<=ZZ_PC\5V\2:KX?L[K3!9?\)#I%S>VY,Q9A);3)'*F-N-A$J,K
M9YYX[T`>77G@CQI'J.GZ?JD7C?5;*PL[&+2;F#5T,:F.\D^T_;E9QYI:#R"&
M*N2%.W:W-49O!WC^ZUN^A\0V7B^ZM'OYI=$;3]4C2W@!U:X>3[7&9`'5K5K?
M8"&PJD+M:O5-,_:/\"ZII^K7HO\`4+:'1M6?29UN-(NEDEN4+`K#'Y9:7A'/
MR`D`$D"M_4/BQX5TWP[INNRZO!-I6LNL>G3VD<ET;MF!.(TB5G;`5B<#Y0I)
MQ@T`?/'C7X?^/?'Y\<-J>B^)[*PO8X)DTRVUV;;+<V^J!@;=C/C+6BE@$$:9
M8+C*Y'=>%?#WB^'XM_;M3G\6VVD172+IT;,T]L^FFQ`6"?=.561)PS,_EM(7
MV_.58X[N]^./A70X[V3Q/J=GIR6NJ3Z>FTR3L[1*C.2JIE=JR*S=0J_,6P#B
M]HGQ>\(^(YH(M&UFVN9;C4?[.A3RI$,EQY+3A5#*,@Q*SJ_W6`X)H`\J\0>`
M/''B3Q;XA@N+OQ-8:%<7VK7-E-IVJFV.X6FGBR(*MG;YR71"GC(.X8/,6M:-
MX^E/C.>.S\92^(I;G%A<VFL+%92Z5O@8PVZ&0(ET8A.H8J&$F3OP178ZM^TM
MX7\/^.(_#VLI?JNH?V>NF7MI9372737<=PZ[EC0F,*+<\GKO'&`Q'2S_`!H\
M'VEWKEM?ZNMI+X;\LZFMS:3P^4LDGEHRED`D5I!L#)N&>,T`>7^$_!?C"\\2
MZ;#J+>,K#P3!K-_/:VU]K3&YCMD@MOLZSNLAD9&N4N&5&9CM(#<';7`^`[7X
MA^)O"VE:QIX\>76B:OI^FR>)!-K.VXU%S.WGO8#S,Q`1;=VTQ[EX`W9-?0O_
M``OKP*-,TN_?7H5M=8:1;9VM9P5\N3RY&E4INA5)/E9I0H4\$BE/QP\"6=WJ
MMB^O64$F@PSRW8,,JQK'!_KO+;9ME\L\,(RQ4\'%`'EOA[PS\0X52^U6V\47
MEII&E:O=:+I-WKIBDFF^UG^S[>ZD1\M)]G8CYBP&1N)8`UA^'_AEXJDUGPGJ
MWB73_&4]KHWBZ[EM8O[8G\VULYK!%1G1[EF:(70?(9V.TGC:V*^@]9^)OAS0
M-0MK'5=0"7M[=BT@MHK>6>1I"B.?E1"0H66,ES\J[UR1FL/PY\<O#^JZ/J%Y
MK-Q#I$VE33K=6\K,[+$E]-9QRC"_,))8&``R<D#Z@'BMIX/^(R>%;\:S?>/I
M=8G$+ZC8VX9H+^YCDFW^7.+L/%%*!&/W/EA5\L[3\XKZ?\-M=/X=TMM5M6L;
MUK*$W-JUQYY@DV#<AD_CP<C=WQGO6BO(R1@^E+0`4444`%%%%`!1110`4444
M`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`
M4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`$%];"]LKBW=BBSQ-&6
M'4!AC/ZUXG:_LGZ':VES!'K>K,EQX?LM)5'6,QPR0+"CW:+CB66.VMT?G&(Q
MCJ:]?\43WMKX=U*?1?LO]H0VLKVOVH,8O,"$KOV\[<@9QS7@>E_M%>([/P9\
M.[K5W\*:GK6O6VEW6MVMBEPOEVU]<1012HV"B-N=\JQY*$#UH`Z75/V9X-:U
M76M0U+Q5K,UUJ*S"SG:-&DLF:^AO8CELAQ%);Q(JD`;%VD'K6]KOP5C\5KK#
M^+-?OKNYUOP[)HEQ-#!'!L1IGE61`,@%2P`!SPO.<FO/O%'[1/C*QTI[OP_H
M?AR62^O]6M=(@GGN)'F.G/)&Z2!%X:5U`0_=3^(Y(I/%WQ[\=QZ?XS/AW0-(
M@;PQ97T,EU=&5A:WEM8_:3*XX#0L<HB`ECE6/RYP`=9>?L]MJ&I7&OZGXKO9
MO%LMS'(FJ&PA$(A6V:W:W:V(*/&Z.Y8$Y+$$$;0*R]#_`&5-)\/O'-8ZI:R3
M2^>+^*?1H6M9]]XUTNR`$)$$9Y%4#(PV2"0#6EXJ\=ZU;>"O``US5=.TB?Q;
MJ4%EJVM:6?W-FLD$L@\EI`0C2,B1*S9PS\9.*XSQEXDOO#?B/Q%_9GQ-O5A\
M)^"HM1TYKNYM98+ZY-Q=`K<*$'FDB*./*E6Y_O'-`'I6H?`[3M0T'7]+?5+I
M$U^XUB9Y1&FZ(ZBI#A?9<Y'KCFJD'P,:U\/:AH%OXB%SH5U?R7MK8ZAI4-R+
M:62<3N=W#-B3>4.0R%^IPN.?'C?Q9>>,?$]EI^K60U27X?6NJZ3H=SY4*:?J
M+^>"CD_,WS(F2YP!V`JU\(O&FHZ;;^/E\=:KJTMCX/\`L\IN==,#RVVZS6>X
M#R6^5958D@8W*#C&,4`=OJ_@:]7X+ZCX0M-1NM8U%_#<VF17^I2YDNI6MVC$
MDK8ZEB"37+^'/@*UNME?^)M?O+_68]1TN^ED6WCCC46,31Q0*JC[N9)"7ZDG
ML`!7-:-^T!XMUVU73],TKPW)K]SXB?2;6:62X@M&3^S1?I*R,OFC*'9C'4@\
M"K5K\:M=\6ZYI-G;VVBZ79PWVBPZI&=4(NS-=PQ7)$*X`DA"OY?JV'/`4@@"
MZ]^SC<Q>"]6TW2?$%SJCVOAC5M&\-V5Y''$EJMZ0S>;(HS(1LB0,0,*N2"23
M73>&/@F-*\3V/B77/$%WJFN6^HF^F<V\4,;_`.@FS2((OW55&+9SDM[<55G\
M12:[\5_$.DZGXKG\+P^%/L+V-E#+#$-02:(LTTOFJ?,C+;H@JXVF)CG)&//_
M`(;>/M96W\'B[\;7.KMXRAU5]7@O)[=Y-(\GS#'<PMM'E(KB.+;)N7,B]^H!
MVWAG]FW3/"FM6]_INJK<!9;>:XBOK".?S)8;B25)$.1Y;@2;,X.-BL,-DU4G
M_9B^U^']!T*[\9:O-I>@6R6L-N;=`K11W$4T3%0=OFKY6PR$'*L>`>:RK#QA
MXMTSX)?%:XAU9Y_$/@]]1&G3:J4GDLTCM5FC$LL0"3.%8N"!QN5&R5:H?"?Q
M?\0>$TTG1M1BT/4+?2K_`$C1M5EEU:XEO[FZU!8I$FA\T$O&HG!(<Y.R3&`E
M`'2_$/X#/K?@2YT#0K^6.?4_%DNKS7SE8WM(+JX=KQ$P/F#02S1`<$[\YXK2
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M6BVNG6LUE;7^FW%M(S)+%.C-Y1#X8O'M`9@`K;N.AKSO2/VH_$&I?V9;R:5X
M6BO/%=II]QHCKJ<C0V7VJ22,)>G;D,#&2`GWB=O!&:`.H3]F.VDTRWTS4/%&
MJ76GZ5ISZ=HT36T2M9P/=PW+!F`S*W^CPQ@G&%4G!))KK[GX16ESXS;Q$VHW
M2S-X@M]:\@(NWS(M/>R$>>NTJY;/7(QTKQFX_:9\7VNK7FH7&G^%9=%T?1+^
M2[L[:>626YN[6_\`L9EAFQCR2VU^5)5=V<D"NRN?C'XZCTW2[&/P[H4?B74]
M0OK6![JXEBLYX[>U%R)E7!D4,N8PK8.Y=WW<9`.RL?A#9V'@?PWX934KMH/#
M>JV^HQ3E%#S-#<&<(PZ`$G!QVKD[K]F2VO=,ETN^\3ZG+I$%EJ5II5M]EB5K
M);Z422EGQF4KC:N<8!YR>:YN;XR^+[B?Q?<:S_85OI&F7?AT6%OI\\D=Y"+Z
M2T+>8Y!5E`F<'`&<8X!S39?COJWBZZFM=.N+".PM_$/AR73M2TSSHQ>V%]J#
MPE'64`G*1-R."'XZ4`>O_$GP!>>.!H$^B:]+X?U/P[J1OK6[2RCN@S&"6%E9
M'X(*S-SU!`KDA^SM':RVLVD^*-5MKE[.[M]6N)+:"634C=72W,TC94!&,BG[
MHP%.`!@&L?Q)\8?%OA#QA\2%N(/#-]HOA>#2CIEHKR0W3O=R*@,C\C;DL20.
M,`#O5S2?C9XE'C*^TWQ#HVEQZ5X>F:RUZ_MWE7[-*MF+IKD;QC[/SL"\N?O=
M`10!+??LUV^J7OB*YU;Q/JUW)KUG=6:O+&K2013W:7.W<2=VPQK&O``0`8)Y
MKM-:^%6D:[K=A>W1GBM[.XGNY+2"5XQ<7,J>6)6=6#95#(``0/WASVKQK0?C
M]XW\6^/_``_H^GIX-ATRXUTVEU<R1W2&[MGTY;V)H@^"C;">OWCMX`)J:']I
MKQ3)I]WJCZ!X>73++3AK4H^W2F;^SUO)+61`-NTS$Q.Z\A0,*>>:`.RT[]G&
MRT_0[_2AK^J2VMU::?96^^--UK;65[+=01@_Q8$OE9/.U`>N36FOP,L%\3ZQ
MK)U.[:365U1983$FU!?16D;@>NT6:D9Z[SGM7'1?M%^(?[%\6^()?"\!T+1+
M/49[-O.>.026=SY#0S%AC=)RXV`A`N&ZC,[?$OXBI\0?"6AZI!X)L4N]9OK+
M5=DL\@GCBMHKB-H&(!5MDI&&!RR^AH`ZFT^",.F>-O\`A);#6KI))-0N[FZM
M);:.2*>&YM[2&2'GD#_0HR&Z_,PQTQ5^$7P>D\&_#S6M&UNY;[=X@N;MI75Q
M(;:W93#:PJV`&$5LD2#@<J?4YSO&WQPU;0_&&IZ=H]EX?ET[1-2TO2[Q+V^>
M.\GN-0,8B>%%!!C3S5)SRVR3&-O/#Z5XB\80?LMW'B+7M<E3Q!K>MVS/J.GW
MS!HXIM2AMW6-I\I#\F]0``B@@XR30!V-I^RIH>C_`-G#PU?G3(M->QN([:*Q
MC\B2ZM[9[62=T4KEIH'"OC'**P.<Y[F#X3Z7!X%OO#L(@MGU'0VTB>[L[98`
M(VB,>4B!V(`#D*..*\\\'?&Z\T'X4^*M7\2Q:EK-YX3O-3C=F5'54MSNBCEN
MHP(W;8R9D5>YX)!)=X@^-OC30+W3M'M]%\-Z]KCV4^I7(TJZE>WGMXWC400L
M0-LQ$H)9SL4;2>&X`.D\3_`J/Q1JF@33>(]3BLM!@T^,6`17C=[.X2=)5&<(
M[E%5S@Y4`#&,UR?Q!^!>KR:;HUAX1;^TH;*3799?M,B19EU"0RJKJ>)(`SNC
MKG)4C@U8\%>,]:OOCS>:3=ZK=RZ<NH:Y&+-Y`458H=+:-<?[+3RX_P!\UFWW
M[1GBV--9N[+0?#9L--L=5U1/-OYA*UIIEX;:X4@)CS9"-R<[5QALT`=)I'[.
M=K9V&K6^HZC:%==M-1CG^SZ<@DM'OT'VD03,25C\PNP4C.&4$D**TM/^!,<6
MK6NJ:IK]W?ZA!J&FWTD@M8XEE>R@EA0;1G`99<G'=1BO.?C!^T'JD3>)-*\+
M3V26B:+?/;:A:^='=6%Y:K;/(CLP\MN)P/DSCN3G%3ZS\??%6F^+M7\/^#-)
MT[4;V'7[B%%U*YED\R)9K:+9&(U_=[1.TGSG;A2`2>@!K7'P8\0:?\3;/4]"
M2SGTRWDTQHYKQE:)4@EN'FW0C!\T+.1&XSM)&<8-=/XY^$^I>+_$'B-8M4ET
MZPURVTB>UO(U29K*\L+IYA^Y8897!CR2?X",=*R(_CIK-O=:_?:[:>'M,\,:
M=)JMI;7KW$TDJW5E<+"IEC5?]7(7&`F6!&.=PQBVO[07C/4]%M8M*T+PZ_B`
M/KOVM;FYG@MRNERQ*X0%2ZM()0`&^Z1SGI0!VNF?`BV_M>/5?%NNZEK^H274
MEY?2L!:"XN#`MO&P$6W8D<(=%4'GS6)).*P[+]EC1+-K:YCU2>;4](CL(M"U
M&6SB>;2H[.ZFFB2-L9(*3&!@3\R*,Y.:J>(OC9K-YH'CK4K&/1K32/#C3V,4
M2ZB\>I/=1&(L^-I58R)#CJ<;6[X%>R^/OC35[+5[S0/!MM=62R31::WFLKV[
MPWBVSBX4X,C;2TNR+)`0KRQ&0#UW0/!%MH6L^*=069[G_A*KZ*[N(9479$4M
MHH-B^H*P@\]R:J7?AN^N_B9HNJ)MAT?1-(NX%59`/-GG>'`V8X")"><_QXQ6
MEX'\4VOC'PKI.K65[87PU&RBN/-LBWE.'7(9`X#A3R1N`.*WJ`/*)/@9/#K#
M:GHWBF]LKNW\176MZ<6LHI5MGNHW2XB8'_6(PD)'0J0.33M0^`T$WPRT;P?I
MFMW%J=&WM%JTEI'+=I,XDW3Q-\ODR[Y68,G3.,$<5ZK10!Y'?_L[Z?J#ZBTF
MLZCNU%]7=V*(Q!U"UCMWYQR5$88>I)S4FH_`1)M?MM;T?Q%?:=J=E)I[V\OV
M2*94^RVMQ;?=88.Y+IS[%5([BO6**`/(_P#AGZ.WU?3=5T[Q'J$&HZ7_`&68
MY7MHY%<V4%U!EUP`?,2\DSC&"`1Z52L_V:;>.?4Y]3\3ZOJ5QJ)M%-Q<1JTH
M2VU'[<@=B3O;=^[SP-H&`"*]IHH`\I\3?`&PU[7SK$-]%'<30W4%S#=Z>EW!
M/%-.)P#&Q`RK[L$Y!W'(/%95Y^S+:ZCI]QI=_P")M5ET:.UU>#2[46\2M8G4
M6)E8R8S+LW.%#8X;G=@&O:Z*`/)]4^!MYK(@FO\`Q7<'5$U$7KZI#ID,5S%\
ML"%+=UP85*6^T_>W!SNS@5EW_P"S_GQ-X(:RNY'TS0M9U+4]5D<JK7BS7)NX
M;9E`^95N620'/'D\YWFO;**`&JNU0!VIU%%`!1110`4444`%%%%`!1110`44
M44`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!111
M0`4444`%%%%`!1110`4444`%%%%`!1110`4444`-=!(I5AD&N?B^'7A6![5X
M?#>A1O8L6M673H@8"6W$IA?E^;YN._/6NBHH`X?QE\'O#_C6*UCO8Y;)+5+N
M/99K$JR)=`"<,K(RY;&=P`8')!Y.=6R^'7AFP:W>WT+2_/MK5+6.X>U1YO*6
M/RE4R,"S#R_DY)R"0>M='10!C2>#=!ET'^PY=&TI]$V;/[,:SC-MMSG'E$;<
M9YQCK5)?ACX/2?3IE\*^'!-I"A-/<:7#NM%!)`B.WY!DD\8Y.:Z:B@#GIOAY
MX6N=7N=6N?#>A2ZI>1-%<WTFG1-/,C+L97D*[F4K\I!."..E7K'PUI.EZ<]A
MINFV-K8R;O,M8;=$C?=][<H&#GOGK6G10!C:;X-T'1X88=(T;2K&*WD,L*6]
MG'&(W*E"RX'#;25R.<''2E;P?H3ZE!J#:-I1O[6)8H+HV<9EB13E55\9`!/`
M!X[5L44`8VJ>#-`US4K/4-;T32=0U#3O^/.[N[*.:6VYS^[=@2O//!JM8_#G
MPKIB:@FF^&M`M$U92NH+!IL,8NP<Y$H"_.#DY#9ZFNBHH`R[+PMH^FZ4^EZ?
MI>GVVF2JZR645LB0N'SO#(!@[LG.1SGFF2>$=#EU:WU271]+?4[1`EO>M:(9
MHE`(`5\;@`&8#!X#'U-:]%`&:WAS2WT@Z4VGV1TMHC";'[.GD&,]4\O&W;[8
MQ19^&]*TX`6&G6-L`4($5NB8**$0\#^%0%'H!@5I44`8VD>#M#\/_:/[`TC3
M=,-V,3FSM4A\SKC=M`S@LQ'^\?6L?PO\(O"/A'PHGAW2]"TV33?)BBN%N+2.
M1KL1?<:8[?WC`\@MSGFNQHH`PF\"^''AM(FT'1C%80O!:1FPBVV\3C#H@V_*
MK#@@<'O4FG>#-!T>*./2=&TNSCAD:2-8+..,([($9A@<$H`I/<#'2MFB@#'?
MP=H4MVUU)H^EM<O%'$TQLXRYCC8-&A;&=JLJLHZ`@$8Q4=CX'\.Z6)!INA:1
M:"69)Y!!91H&D1MR.<#EE;D'L>16Y10!DW7A/1+Z^DO;[2--N;V6)89+F:T1
MY'C5@RH6(R5#`,!T!&:9/X-T*ZU8ZI<Z/IDVIE=OVV2TC:;`4J!O(S]UF7KT
M)'0ULT4`<];?#WPQ9V\-O9^'M$@@M[A;F&*/3XE6.91A9%`7AP.`PY`XJW_P
MB>B>0\/]D:9Y,L!@>/[)'M:(L7*$8Y7<2V.F23UK6HH`P?\`A`_#?VJ\N3H.
MCFYU%76\F-C'ON0Y!82'&6!*KG.<X&>E6[WPQI.I2Q2:CIEA=26]P+F%IK9'
M,<P&!(I(X<``;AS@8K3HH`RKGPIHM[K$&K7NDZ;<:K:@""^EM$:>(#.-LA&X
M8W-C!_B/J:6Z\+Z->Z&^C7NDZ;<:/(NU]/EM4>!ANW8,9&TC=STZ\UJ44`9F
MF^&M)T;21I>D:;86.F!"@LK:V2.$*>J^6`%P<G(QSFL^3X;^%);&WLI/#6@M
M96C,UO;'3HO+B+8W%5VX&<#..N!GI71T4`4+?0=-M;TWEM8645V2Y-PD"B0E
MPH<[L9R0B`^NU<]!49\,:.4D0Z5INR:*6*1?LJ8>.5M\J$8Y5V^9AT)Y.36G
M10!A/X$\.27=U=2Z#H[W5ZFRYF:QC+SK@#:YVY8851@]@/05SGC+X'>%_'&H
MO=ZM!+%]I@,%[#;"-$O$,BR'?E"P8LB_.A5L<9X&/0**`,NX\+Z/=6LUK<Z7
MI\MM<^9YT+VJ,DOF',FY2,'<>6SU[TVS\):)IT,45AI.FVT4"2)$D5JB!%DQ
MY@``X#;5W>N!G.*UJ*`,67P5X?GO;B\FT329+N\B$-S.UE&7FC``".Q&67"K
MP?[H]!5:Y^'/A6\GNIKSPWH4\U\Q:ZDDTZ)FG8L&)<[<L=RJV3W4'M71T4`4
M--T+3M'S_95C:6>8XXC]G@6/Y(QB-?E`X4'`'8=*OT44`%%%%`!1110`4444
M`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`
M4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1
M110`4444`%%%%`!1110!7O[G[%93W!4L((VD(!Y(`)(_2N#TWXT:3=6OA&[O
MX9M/LO%OAR?7DN+B10EE!"EN["4YZXN5Y''RFN]O;5;VTFMW)"3QM&Q'7!&#
MC\Z\7A_9ONKCPN-"\0^+9-1M=.\*W?AK1732D@:SMKA8T9Y<.1-($AB7/RCY
M2<9;@`[&3XZ^!#X>.LP^*-,_L_[:UBLQ<J#<*H8QX(R,*0Q.,!2&SCFK&G?&
M#PK<SZ987NL65KJ^HZ='?"R:7<R(\7FX+`;=VS+`<$@$@8K%\0?!>?4=?M=;
MT'7AI.I6[3JS2:;'=12PS6L%O(C(Q&6_T:)@V>,%2&!K(L_V<;>PU:2ZBU.V
MN8;A;9I$N]/,CQ7$-E]C\Z%A(%0M&$."C;<,`<,<`'4Z[\=?!/A[P//XOO-9
M67P[;WB6;7MK;R3*TK.$`4*I+#+#YAD8[UG^$?V@?"/B?Q%K.B/JEM9:EI4\
MH2&X<IY]O'!'.9P2`%79*"5/("DD8J[JOPG&I?"&T\"QZK);BQTZRM(=06W5
MB&M3&T;F/(!!,2Y7/0D9[UEWGP'MM9T7Q!I_B#5'NO\`A)+Z\O+R6&U$)5KF
MQ6T=4^8D``;QS['(YH`Z2'XN^$KKP?JOBBQUB&ZT71(Y)+ZXAC=C"$7<<IC=
M]T@CCD$$9!S5/2?CIX&UFS\/7%KK]LB^*8UDTN.='B>56;:NY6&4RWR@M@%N
M!DU%X2^%`\/^&==TK4+RQN)]?MQ#=7UG8-;228MQ!O?=))N;`R.0`,*!@5R]
ME^SHUM=Z1=7VLV&JS6.E:?IMVMYI+&.Y2RF,EO*J"8!)`"P.=PSA@`1B@#KK
MGXZ^`;..:2Y\4Z9''!<_9G<LVWS1C<H.,';GYL?=YW8P:F/QJ\#C1KK5E\2:
M?)I]G>BRFFB+/B<J&"!0"S$J0PV@@KEN@S7*W'[/%O<>&]+TC^VIE32[+7+5
M9C:J3(-3W[V(SP4WG']['.*9K_[/AU1;]].UR*RO+JWL([>[?3O,DT^2TMYH
M4GMV61"DO[[<&S@;=I!!-`'=^*OB=X6\$0V4OBS6K/3(]1)^RF=C^\`QEN`<
M(,C+'"C(R17(:'^T-X>UK5_'H2:--%^'Z@7]\ID=Y&$8D<K&(\&,!@`P8EB&
MX`P38\;_``=O_%-Q;W6E>)YM,O?^$<N=`O9[BP2[^U6\^PM)@LH64-'G/(.X
MY4\5H^%OA-;>%=#\2:1:W]S-9^(7!&\`/;(+*&T"@]&.V`-D@<GIQ0!@^&_V
MF_!'B3Q/9:7;ZHD$>M:?97>CSW"/']M-R\R+&%9058-#CYL`EP!FNYT?XB^&
M_$'B#4-#T76+.\U72\_:K:)B63:VUL'&&VM\K;2=IX.#7&^%?@A+H,:'4M=7
M4KA--T:P60:>L(V:;.\L3;=S?,P<*>>",CK@3_#[X*0?#_Q#+?6MU97D"/?&
MS\VR;[5;QW4XG>+SC(04#`]$!;Y<GY>0#9G^-'@JU_MO[3X@LXF\.R)'J2.K
MAX6=BJ`+MR^YE8#:#D@XZ5#:?'/P%?6>G75KXHTU[?5K:2ZM)"S*)($WAY3D
M?*@,3C<V!E<9Z5Y=KW[.VNZ9`VH6GB#4?$VL3WNF":=]L%UY%K=RS^:)'EP9
MOWV.#&NU<`#.#JZ#^SY+K/@J\L?%TUOI=SJOA8:!+:Z=%A+6-+F>:*4'<V9,
M2KO7)4LK8)!H`[U_CEX$CT>TU27Q-IZ65[<-;PR/N4F1<;PR$;E"AE)+``!E
M)."#4FN?&KP-X;U.ZT[7/$NFVE]9Q>;/`SDLHVAL8`.6*L&"C)(Y`P":X6__
M`&:4U"[2^FU'1C?R17<%]G1I#!?17$4*/YL?VC<S[K=#DO@K\A7`%=):_!6&
MU\6PZ['JC*T.OC6!;):JJ!AI@L!&#GA0HW@]?X>G-`'0P_%7PC<ZUIVD6VOZ
M?-J.K6R7-E#')N\Z-UWH0P^7++RH)RPZ`US>L_M+_#;0["[O+GQ/:SPV%U:V
MUQ]DADG9'N'*1'"*<J6#`L,@%&'48K!\$_LT6O@?4]/N+35+;48;5[&>6._T
MYI'^T6T1B$L3"4+&Q38.5;:5)'WC5\?L_+;^!K#P_IVNO;W&FVMG%!?FQ5B7
MMKY;R-F3<,KO7:5W#@D@@T`=QK?Q)\->&Y-'37=5ALCKTB1Z>94<"9G*A!G&
M%R74#=C)8#K5*/XR^")=2U:P7Q+I8N]#MY+C4(VEV_9XXWV2,21CY7(4@$D$
M@'&16#\0_@W??$/5M+N;[Q1=6UE9+:&?3X[<F*6:WNX[D3(/,`5V,80[@^%Z
M8/)J:K^S_!J?AF[TI=9FMY9[W4;V"[6U1F@FNK^.^4[2<,J21("I^^,YQ0!U
M.@_%3P_KGA_5O$,&I6JZ#I<[1O?M)A"%CC<D@@%2"^W:1G(QC)Q5VR^)/AK4
M88)+75H&6YTYM1B#*R,;57"-+M8`@!F"G(SDUB#X87-UX1\0:1K]_IFKW/B.
M[-U=37.CJMODK$-I@5QD8B'._=DYSD5SK?`75F32W;QO>S7EKHUQI-]=76GK
M.]W!+<K.`I9R4V[1&,ESMQSD;J`+VG?M"^&K^7Q99M=6]MK/A&745N=/N+@1
MM)'9MAY0Y&T*1M8\Y4,">*Z>U^+'A&ZU*_T]=?TU;W2;9KF^B:;`@C4`N2Y^
M4[<C=@G;D9QFO*O'?[/>JW&G>)9-+UAM4-^^M76E:0+2.W\J\U*)H7:6X+?-
M'&LDA`V@G/<@"M`?LOV<FEZWILVIP&SUB'4%BF%@6N[%KPJ\OERM(5*^8I;'
ME@L"%)^44`==X;_:"\">+_&4'A?PWK?V[5[FT:ZCC2TF"E%)!^<J`#QG![8/
M<4EE^T+X!O8_$4@UU(4\*ZC_`&=J33VTL>VX[(@*YD)Y`VYSM-2:1\.==M?&
M]GXGUGQ/#J%XFEOIM["FDK!'/%O$B%,2$QL&!)SNSG'&!61>_!"^;7KO5=*\
M3?9)CXH'B*P2335F6WG:U^S31/\`./,C:/.,;64G.3C%`&[XI^-_@SPEX;T7
M7M4UJ)M(\0WD=GIUY:1/<I-*Y(`S&#@`@YSTP1UXJEX7^/?A/7M9\0:->ZE:
MZ9JWARYO$N[:YFV_N+8@//N(`"X96(SD!AGJ*JQ_!.6T^'NB>'=/U^2._P!%
MUI=:&IRV*,)[O[4]S)NA#*`C/*X"AOE&.3CF+5O@!9:WX>U[2;_4Y637[S5+
MJ29;=0\+7H&0O/(0JI_VL8-`&YJ?QQ\%:5\/]1\:RZRDWA[2B1=7$$$DCQMD
M#:8PN\$[EX(Z$'H<U;M_B_X.NM2L-/@UZS-[J=HMU:P,&5GB92ZD@@;25!(5
ML,0#@<5@_P#"E_/^'?BKPS=ZA90W/BM'%SJ.GZ<86#M"D?F.KRN9&_=CJPXP
MO`&:HO\``=[GQ=>:_J&JZ?>3ZI);7-ZLVEL<7<-N;?SH/WV(B4V8!5]I4X/S
M&@#H&^//P^6*VE?Q9I*0W<K102O(520J<%@Q&-@)`W_=R1SR*D_X7'X7N;33
M+[3-7T^XTS4)KN)KQK@1K";:-WERK#)*A#D8X'/2N4U#]G&VU#0-+TM];G1-
M,\)0>'%D%JI,D<4\$OFD9X)^SA=O3YCSQ2^+?V=8/%DNM/-KD]O_`&S?ZC=L
M!:JPB-WI@L&4?-R%`\P>I.#QS0!U!^.?@1?#<VOGQ)9-H]M>FRGNU5V6*8+N
M*MA<J-I#;B,8(.<$&J<7QY\):GJVK:7H6HK=7^@ZK:Z;?QR*T"))<-&J%9'4
M*_,@`"DY(P.QK)^('P%G\;V-W9VOB:ZTFTU*.6*_MX[;='<J]G';!F"NN701
M[U))`+$%3@4[4?@*VI'6+>XU^;^R]8U33-2:W6S`DBFLTMXR!)N^ZZ6RC&WY
M2203P*`.BM?CAX#O;74KFU\4Z2\&D,HO'\W`CW-L5AD?,K-\H9<@G@$FM&/X
MG>%I?!:^+4UNR/AQUW+J&XA#\Y3:!C.[>"NW&[=QC/%><:?^S;,D>D)K7BJ7
M4!X>LM,T_3"NFQPF.ULKR.Y4288[Y'\F)"PV@!20N2:Z_P`1_"HZUX;AT[3]
M5;3;NS\0#7+2[6U614G%TUP%:,D!DR[*>03UR#0!H67Q?\&ZB-&^P>(;"Y/B
M"0QZ:L3%VN&5MK`*!D%6X;<!M/!Q4MW\5/"=CKM[HUWKEE'J>G6SW-U;$DM%
M&B>8^2!C<$^<J#NV\XQS7-^!?@J?!WBI?$-SK3ZEJ,L.IB\_T184FEOKJ&=V
M4`G8J^0JA<G()).:KP_`TZ?XOU;7=)U.RCDU#4+G4K876F&YEL+J>U,#O$YE
M"XR=V"F<%DS@\`'0:O\`&WP+H5C)>:IXGTN&UBD$;2B0NI8Q)+@;0<XCE1SC
M.%;)QS3)/C)X7L]0NH-2U?3[>..[@M;61+@3&[>:".9`BH">5E4^Z_-TKS./
M]G'5?";^%=&^'6MQVFE:1)JCF\O;*.XDLQ=VRHPV;E\TM+YC`\;`0N"J@5TW
MA/\`9ULO!WB#3-2TO6+MH]),?V>!X5W832HM.4%_7;$),XZDC&*`-77?VCOA
M[X=BD?4=?7,.K0Z5,D5I,[Q7$I(0,H3.T[6^;[IVG!.*MW/QP\(:1+*OB;7-
M,TK&HS640EN0VXQ%0SM@?NU!8`E\!21D\UQNF_LW:A8P7,UQXTNK[6I;K2+I
M=2NK$R,\FGR/(C2JTI+F0RMNPR@<;0.E+JG[-5Q=7_BBZTKQ9+8'QE;WUIJR
M/ID<P-O=2!V$66&QUS*`QW`[P2N5%`'I%C\4/"FI>+7\,6&NV,^OQH[M8HY+
M@)C>,XQD!E)&<X(.,'-8WBWX\>"/"+:W#J.OVC7_`(>LY;J[L8B6E(C3>R+Q
MAI`O.P'(!R0!S2^$_A';^$M2>[MKUI\ZU<ZFBO"`4\ZW2#R]W4@!`<]^F*YK
M5/V>)=5N+R&;Q/,NBRZGJFJ6MDNG)YD%U?V\L+EIMV7C3[1.RKM!^8`L0HH`
MZ?PQ\7=+U'X7V'C?Q')!I6FWT`F)B:2Y6-68JHSY:L3TS\G!SU`R;4WQG\$0
M7VD6<GB73?M.NQ12Z=&KEC<)*I:)A@8PX!VYQN/`R>*K>*/AI>ZYX.T/0M+\
M076E'1V@$LJ1%DOXXXC&8Y55T;:Q(?`8<HO49!Q_"7P(MO"4$$4>JRW26^F:
M%8`RVR@[=+DDD1^#U<R8/]W'&:`.YTKQQH.NO"FCZI:WC3Z='J4?DMNW6LA(
M2;/]UBIQZX/I6`/CKX".@SZR?$MBNG6UV;.61E=66<('\O85W[MA#`8Y'(R*
MYKX9?!Z^\,Z;X\6:^GTRY\2WUS!I$ENZ-)I&GKY@M4C(^7*M++*H[;P#R#7/
M?\*`\1>'K_1)_#7B*&YU,^)AJNH:G=V6\6X72GL@PB>4M(S$(3\^<NQ'`Q0!
MZ:_QD\$G4M)TY/$^E&\UY8GTY%FW"X64;HB&'R@./NY(W'@9/%8?ACX_>'M6
M\.R:WK\\.A6<-G;7$HN+@2.IGDE1$V*-Q),+;<`ENPX-<5X>_9PU+2->.F#6
MC#X4L[?0,9M8WN-3ETZ26;EL_N5\TH3A3D$@8ZUKZ5^S0="%A/I'B>>/4=)F
MT^:RGET]'C#VINP0\>X;E=+V1<!@5*JP-`'6:]\<_"FFZ?JS:;J<&H:EIN@S
M:W'8)N1KJVCB$I*,R[3\I7."<;AD"JVG?'CPUK\7AN3PS>0ZE;Z[J,EA-<)+
ML%C(EG)='S`P!QLCZ]#N!&17.W_[.5[KVL:EJ'BGQG?ZK)?Z;J=C&7LPAMTO
MH(HG"CS"H1/++(H4??(8MUIR?LV#4+B2Z\6>(Y]5NKF7%R;>Q6T1[<:;-8+$
MJAF*D)<.Y?)R<#``H`],\'^/O#_CVVN)_"&JVNJ16DGESM"3\C8R."`=I'(;
MHPY!-=!7!_"SX8GX<6UPD]U87]Q<6MK;R7<%@UO+,MNA13*3*^XX8X`VA<G`
MYKO*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H
MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB
MB@"AKU_+I>B7][:VTE[-9VTDT=M&P5IV12P0$\`L1C\:\=\,_M0Z+XMUU=-T
M2PN6\RXM!%<S7"I&UM+:/<37.3T2$QR1M_MC&1SCV]UW#TP<UQ^F_"'P?HOD
M_P!D>'M)LQ;VUW;1+#!M58KJ0R7";>F'<EC]3ZT`>4:C^TMJ-WH]S/HFBPKJ
M.GZXME%#%JB36NH1R:=/>1.9FB!5"L0SM7.<88@FK=I\?];M[3P_<:YX?VZK
MKOA_3;J+2+2_C:#S[V[\B(^<R!@"64G.0JD\,1D^E:9\'O"&CV\5OIV@Z?%#
M#/'.BLK2$2)"T"'+$GY87:,#H%..E.T_X1>$=,AL8K+0[%(],2&.S!W-Y"0S
M>=$JDL2`LGS`=C[4`>>7G[1.KP:CH&F6_@B9]8U)X5U"S?6%!L_,O7M&,>V-
MO/5&C>1CA,)@^N-_XB_&J7X?^(YM.7P_/JEEIMI9WNJWR7R0_9;>YN'MU*(P
MS(X="2N5X[YP#-XF^!&G>(O%,>L0ZC=:8-ENLL5H@63,-T]R&CESNC+O(X?&
M=P8CBM+6_@YX=\4?$#_A*?$<$>IW<-E:VT%K<+NBA,$TDR2;<_,VZ3.&R`44
M@9H`X:S_`&FC?V.H:A:>$]4ET]'C72KA+C"WI>]2S5)&9`L+EY%<+N;*!B<$
M8JU!\:];76[[0;7P\VJ>*&U:6WBTQ]4B@@MTALK6>?%QY?S`&Y4#<N6)/W5'
M'>Q?";PK%+<O'H]L%N[C[3+%OD,9E\]9]XCW;5;SD63(`Y&:76_A/X3\1/.^
MLZ)97,MS=M>2R_,DC3-"(&?>I#`F)0AP<%0`:`/.M&_:`N?'K:1=>#-"U$:'
M)>V$5_?/=0^;%+/`EQ]G\CDL/+D1=ZM]Y@`",D;.E_&^2\^%7B3QIJ6BFQD\
M.033S:-]NW7482,2".=2BF"8J1E"#C((+`@UT\?P<\&6^IVVHVOAW2[>\M(H
MHH)88C&(UB0I%A5(7*H2JMC(7C.*L:;\+O#&E:%JNCV.D6@TW75*ZE#)NF^V
M`Q+$1(SL6;]VJIR>``!0!S7C7XO7OAJ[33M!\.3:YJ]Q>S6MO:_V@EJKF*S2
M[<EV4[?D<J!@Y8#H#D8TGQQN]3U.!M,T2]@T"QOX(=6U(W4;/#*UD+MH?(QN
M*B.1!O4\MP!C)KOM*^%WAC0Q;?V5H]G;FTGEGA8!F9998A#(^XDDLT8"$DDX
M%,C^%'A2'Q!%K<6AZ<FJP",1W*QD%3'&8T;&<%A&2@8C.WC.*`/.=)_:1O\`
M6](M+BS\%WXNM9N[.'1HGOPD-T+J*62,M.T8".HA.]%#[=Z8+9Q71^._B'JW
MA/QWH5A;V]U=V=_X<U2^GMK2V$[B>![81L3D$(/-<''7(KHM)^$_A;0Q;#3-
M(@A2QGCGM(_-D=+:2,2!#&K,0FT2R`!0!\QXZ5M7?AG3K_4H=0O;6">^@M9K
M2*=P2RPRE3(@YZ,43/\`NB@#R#PS^T%<3GP!8:I8V>H7/BC2;:6^NK6_"O:7
M<EB]WL>WV$*K+&<'?GY@0I'-+X.^.GB;Q9XRT&";P?9:5X5UWPU+KR7SZUYU
MTEN&B"L84CQDB4`H"3SG=P0?0+/X/>$-.U*UO['0-/@N[*.*.WD0,!&(H3!&
M0N=NY828PV,[>,XJ[!\-_#MI=:%<6>E6D$_AFU-II+QAE-I`0H\M<'E<(O!R
M,J#UH`\O\9?&'5?!7C4ZOXEN[VP^'GV`2Z=<VNDK/%?2B)VEAN)6(D@FR@$0
MVA&S@DD@#5NOC1XCLX-.MY?`ZG6]1L[G5([`>((MJZ?`(B\OG;,>9F=%$>,9
MS\^WYJ[?5OAAX8UW7!K&M:19WNH<9DG#.I(1HP3&3L)".RY*YP<5ER_`CP+/
MI-MIDWARP>SM`ZPH6DS&KQ")T#[MVPQJJ%,[<*!CB@#R:W_:8\;ZS?1S>%_`
MVCW6AWVOZ786%Q=:^89G@O;.*Y0N@B8+)ME'0D+TPV,UO_'GXPW_`(37PZ_A
M;4]4M+=[^]35FT[0#J4VVWM7FVB)P#LW+\SKVS@CK7HE_P#!SP=J<\\UYH&G
MF2Y^S&0QAHAFW`$#`*P"LBJJAA@X`&<<5OW_`(:T_4[JQN=1MH;BYTWS/L<L
MBY,/F(8WV_5"5/L:`/)X/V@;[3[>SDU70$OK6P@TB/Q)J5EJ*".TNM0$0B$$
M3#,T8,R$MN&`W`8@U2F^.NKZII8UV'2;S1M%OK.SN=)E6Y@N&O(;B_MX$D*D
M?NVVR'<AS@.,'=G;Z%!\$_!-M>:=<Q>'-.$VDQV\=H=K$(MON\C*DX;R]S;"
MP)7/&*?8_!GP5I<=TFG^'-,MX[UU:9%0A3MF$Z@#.%42J'"C`![4`<1#^T3=
M26=S>2^$+N*TN)!;Z'*=3B/]HW)OQ8^6XQ^Y'G,I#$M\ASP?EK;M_C$Q^'_B
MS7=9TLZ3J?A">>SOK`W:W"&Z1$9%250-RN98@"0I^;!`Q7477PQ\,7VB2:/>
M:+I\NF2I(AM6C.S$DOG/CG()EP^1R&`((IVG_#?P[I>D)I=EI5I%IZ7_`/:'
MD89@]T)!()G))+OO`;+$\@>@H`\N\&?&W77\+:9IFHVMCXL\>2:Y=:-(EG<+
M8VER\,37'GAR&V(;?8P&"23CU([#X,?$'Q)\0(O$S^,/#]AH/]C:W/IULMMJ
M?VLRB,_-O^4`,,CD$@YX`QSMZW\*/"OB2^N;W6]%LKF\NYX9Y;G#)*TD*,D;
M[U((8(S)D$94X.1Q45K\)O#NG:G#?:/:OIDD>H+?RQV4S11W,ZQ-$C2*#@@*
MQXX!(!.<"@#S7Q)\>=3\"_&3Q-I?B@VC>$K/2H1I@BB*SMJ1@>?R2V?F\U%9
M44#.Z,]<UG>$/V@O$&DZ/H=G\0+?2]7UZY\1S:3JIL;D6LEFK7_V6%U@VMN0
M,=I8LF?+.,G(KV;5_AIX9UZ\>[UK1--OKB6]M;V22X@$A:XM?^/>3G^*/)VG
MWJG+\'/!\VKKJDF@:?\`;Q<?:3.%8%Y?/,X=@#AB)F:09!PQ)&*`..N/CKJG
MV-]1TSPC)>Z5=ZVVBZ+<'5XXVOKM;E[9O,C*$PIYD;?-ECM!.`<`XGB/]IZZ
M\/Z)>ZG/X6>/3F_M*VTR^.II(LU[8K)YZRQA0T<(:&7#Y)*IDA<BO3[?X2>$
MK;4Y=0AT.P2\FOQJ#2!6P+D.'\T+G:KE@&)`&2,G)I(/A#X0MM;N]6A\/Z8-
M0OOM'VB0P[E;[0%$YV$E`9`H#D`%N^<F@#S(?&6_^'USKMGXOU?5/%&K6JV9
MMK1O#XTRWG>ZN%@C:WN!N#P>8X&XAF`!.6X%:!_:$U1C816_@C4GO#;/=ZG#
M+?K`+6WCN_LSRQ%T!F4G$B?*FY.>#@'L;#X%>!=+M=0MK#PY8QP:I`EO=(6D
M?=%&YDC12S$HJN=P"XP<$=!6M;?#CP_9,[P:;`99+>2V>6:225VB>7S60LS$
MD&3YNO6@#@/#'QHU/7_%6I:!H>B7&LSZ5JEZNISSWL5M]CM([V:VC,:A?WQS
M#(0IP<+\S$D9OZ+\;9=4^'7B+Q5>:#-9R>'=TEQHPO`]Y%$JAR)XV13#*$)8
MQD'@<,P(-=/)\(_"4NIQZBVA6`OHYYI_/161F>6432%B"-P,H#X;(W<@`U<T
M#X>:!X8M-0M=$TVWMX=58-?!BTK7)$8C&]G)+`1J$`)Q@8H`\GE_:<L=<T_Q
M*OABPOFFT.'5YC<)-&?]%LX`\=X@8$,DKNJH",'#$Y`YF^&GQ+\1>)_BG)I&
MI7PDTS=K&R(PHK`0'3C#E@.H%S*/?(]!7HFG?"#P=H]I+::7X>TNTM9M&317
MAABVHU@FX+;X!QL&]OSK1TOP!H&B:I_:6DZ59VE_^^_TB)"&_?>7YO?^+R8L
M_P"X*`/)[O\`:8NX+6WGL?!UW=G49M0.G0C407NH+"3RKF3:L;%7,F%CCYWY
MR2E;>J_'UK&V\3ZLGAJ\?PUX33RM0OGO$CN!>&"*80"W(SC$\:ERPPQ/!`)K
MLKOX6>%[W3K*QFTBV6VTZ>XGM%A9X6@><N9BK(P8;S(^X9P=U17'PC\)75]>
MWEQH5A+<ZE;?9KUF5B+F/RC%AUSAF\L[-Q&[;QF@#S74/VBK_39-+NM:\.:G
MIL:2WJ:G;+*KQ&&$VA:YCE>-6D1$N2WRA>8Y%YP#5C4?VF5CN88=!\,W^L"4
MW5POV>X)>:Q@NC;">%51O,=W5RL>0-J@EAN`KTBV^%GABUC"+I-O*JPSPC[1
M)).1'-&D<J9=B=K)&BD=,+55_A1X1DM-(TV/1K2&WT"R-GIT=O(\)MK9@H\H
M%&!V'8ORDX.WVH`R/B)\84\!>)-!TM+&VU(ZO>6MM=;=0$=Q9K<SK!%+Y.P[
MD+L<DLGW3C)&*H^.O%_B#PY\2-)34Y;O2?!OF6T<6HVUDMW#=W4SF(V]V0PD
M@&7B$;*NTL^6/`4]EK'PT\.>(-=M]9UG2;2ZU2U6$17+[@P$,ADBR`<-L<EE
MR#M))&*@U;X5>&M>\9V'BG5].BN=8TV+9!([L4R&#([)G:SH0=K$9&3[8`/'
MC\5?&?A1?%-KXTO=0M_$$]^J:):7VF6T=I#9RZFMHES!)$Q:;;'<0,RRE26P
M,8)-=9IWQ3U;PIX0\72>*6;Q+?>#?$$.D)<P)':MJ1G^S>6S`?(C*UT$;&!\
MA.!TKL6^#O@]X=5BFT&QGCUN$P7RW&^;S8RYDV?,QVKO);"XP<'J!6C#\/M`
M@T`Z(FEVATHW"W+6S`L'F642B1B3EG\Q0VXDDD4`>5M^T/?2Z;J?]K>&[K1'
MBTW6C;W,6HQ76;W3`PN(E78!M!4E';AL<J.,\N?CGXEMK_Q)-=7\CV&EV&NW
M444<$0E`MK72Y8<$KM+`W<W48.X9'`KW>?X:>&;F(Q7&C6$B.;TE60X)O,_:
MN_\`RTW'=ZYJ%_A/X2D6[5]`TTK?0SPW(,9_>1SI$DJGGHRV\(/M&M`'G5W^
MTLFF6D^IW_AN\_X1^2+5!I>H17\;R7DFG+*UPK0X!BSY$H4Y;.T9"Y%=79_%
M:_A\`>,?$/B?PW+I5WX1AN)Y-/74$N/M,26JW*%)54`;D<*01\K`]1@G0/P6
M\%->ZC=_\(YIAFU6*XBNB8R5=+@*+@!<[5,FU=Q4`MCG-=)+X9TRYT_4;*ZL
MK::TU>(Q7T+IE;A#&(BK#N/+`7Z"@#@_$?Q<O-+N;#3_``]X>?6-8U2]6TL[
M1M02UC9S9&\)>0J=H$:L.A)(''/'FGA_]HCQ%K?B/5/$2:)<2>&/[-T6+1=-
M35(4:6YU)PJ&;]V<-O.W<'VJJGY6+#'IVJ_L]>#]2AT:UBT]+33=)U&2_DLX
M6;%Y(UJ]M^\?=O.$<8(.?D`Z<5T<7PR\,6T(AMM$TZ&(&S(CCBVJ/L9!M<`<
M#RR!M]*`//)?VAKBRF>;5_"\T&E)>7NF?;H=4CE)U&S@FEGA\HJ&\O-O,BR9
MR2H.P`@U0F^/?C"\F\-)IG@2UB;6]=MK)DO->49M+BS>ZBF0I&</B-PRG@%"
M`6W`CTF;X/\`@^XUR[U>X\/Z;)J-_P"<;B5D.'::,12OMSM#O&`K.`&(X)Y-
M6M0^&GAO5;2WMK_2;26&TEMY;=1N4PO`I2%E8$$%5)48/0D'()H`Z:([HU.<
MY%/IJ#:H'7%.H`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@"AKRE]#U`+G)M9<8ZYV&OE3PS\0O$>@67A72FOV\.66H
M^&/#T=YXBN]->[-HYL+F0JX<[-SR1HF6Z9(Y++CZWFD$2%F(`'4GM6!X2\>:
M-XZTJ74O"MXE_I\-S+;/<!&1?-B8K(!N`)`8$9Z'J.*`/!]2^,WCFUU;Q=-;
MW6D&+0K34!:Z1<6WES7`AL?M%M=1I_K7,K8)4X558K]Y>;GB3XA^-_!6FV__
M``D/B*QN(8]71[BXMM(1+VXM7MX)%@M[=B4E(EE96P0^W;C+`UZ=HWQP\*^(
M;?4YM$N-0NVTNW2Y:&/2;@RW,$CE(YK=-FZ:-W5E5DR"0>W-"?''PG+8Z+?)
M>W7V#79Q;V]Z=.G\B"8R^2(IY-FV%S,#'M<@[N*`./\`A-\0_%GBSQ[J5MXE
MN-*ALE?4(WT8A4NM.>WN5CBV@?,ZO$=[.^!EDV<$UY?9:UXX^'[ZU+9ZY:B[
M\3>+->\_6M4TV&%5:R=A:V[NW'ER)NP3]U(BJ<D5]*>-/B=X?\`36T7B*YG2
M6Y0RLMO:27!MX%(#7$VP'RX5)`,C849ZUB/\==!77+C1WTWQ8-0@MI[I(CX<
MN_\`2XH657:`[,2C+IC;G(((S0!Q?P_^)GC'Q+\47L-=N=#M-/2ZGM)M(&%D
M\M;998;JW8_O)!(3G)P@0_W@:RKGXT>(V\7>/%T&6YNM,T7PYJUU:6=YI:(]
MK?64B1HGR$NR2$NP#\NH#*`*]F\#?$C1OB#8W]UHHU&V&EWILKN+4M/ELI89
M@JL4*2J#T=?SQUK=&LZ>;6*Y6^LS;SR".*83KLD<G`4-G!.1C%`'S_K/C[QS
MX:BL-.\0^)K*TCU+4')\0OX>+1VJ&RCN([5HE)&7D,B!\Y*IM'SD&M37O$=Q
M8>!_@W96EQ=+K&J7^E2_9(%E1KF*.WWS*1C(097<'Z9&>:]T-U`&"F:+<=V!
MO&3MZ_EW]*AEU2TC6V)NK4?;&"VVZ51YQ(SA.?FXYXH`^2=1^)7C3QWX7BLX
MM92YN+^/1-2N'M]#D@?PW?/JUM&;-^1YFT>=E7PV(6)^5A7>:OXJ^)%M]ETN
MUUNQ^WZ7IFKW]YJ#:$&&HFROHXHHMF[$?F1.22O.5RN!7L?A;Q]H?B[PW%KN
MD7\']GRQ"5WF<1F$'_GH"?D/'>MC^T[,^1B[MO\`2L>1^]7][D$C;SSP">.P
M-`'SIK/QD\3V/B'7]+DUFU@!UNWMAJ-GIBW=GH5A)/+$LLC\,9RT:JZ2C:A<
M."5IFE?%'XB>)4M3I>HV,-O865S?M>MH+!=:@@U(V\9"L?W0F@'F?+SG!7Y:
M^BQK6G-:1W0O[(VT\@CCF\]=CN3@*&S@G((Q4T]];6LL,=S<0127+[(4>0*9
M&QG"@]3CL*`/G#]K_6+M+GPO8P"[BL;>*^O=0*/(GVJ#RU@>*VVD![U5F:6)
M68#,?`8XQM^)_B-!KOP5\*WFBW&IZ=>:]K&E6=G:R/(UXVR^B$L4N!N$@B1S
M(&QCYP:]`M/C-X;O-+\6:K'<R#1O!<DT>IZCL#0YA#&;9M)9MA5E/RC)'&>M
M2W7QC\)6=MX0N)=7B,'CR>.'P^Z1.PO&D3>AX7**05&6P`64'D@4`>$>._BE
MXLUF#Q?I27J2_;+;Q)97.@1:1(D^D06MM,;>Z$X^9O-(@()X;SP$Y4UU,&K?
M$:QLM#\.GQ);2ZCJNJK:IK9T%2;:W.EFZ`,6[86$R%-Q/W6&<M7NZZSI[PW4
MR7UD8K(E;F03J5@(ZASGY<>]#:SIZ*2]]9JHA,Y)G4`1C&7Z_=Y'/3D4`?-V
MN_&SQGX?>=I[BTO;L^%X;NVL--TPW"P3BW@DN;BZ3_6Q;#*S(BY5U4+D-FI[
M3XD>/->NCH'ACQ'97T3ZM=6EKXL&@?)<)%IRW1_=9\LD3$PEEX(XQN&:]K\4
M_$S1/"5S86]ZU[>W6IQF6VMM+L);^9X01NFV1*Q$8W#+GCD5N66NV-]#9O#<
MQ*=0@\^VBES%))'@'=Y;888!&01D=\4`>3>/M<UA1\,=6B$XO'@OKNZCA1Q$
MTHTB>0*RC^'S`,!N^.]<_8^+_B/)H>AQ7>LV9OO%>H:5Y=XF@A?[+AN[2:65
M/+)VN8Y(@%9O[P#9KW6[\1V-JBLDRW)-W':LMM^],<CD!0X7.T<@DGH.:F?7
M-.B\P37]BC0RK#*&N%&R1NB'GACV'4T`?.&H_&'QSIUUI]M>:C:1:K:6>D"/
M34T)V'B26YG,5R\;9S$(PI;"YVGE_E(JU#\9O%9T[7XO$3W6D3^'9K7P_=7U
MOI*%7U:6X8&Y'FD(MMY`@;<25'VCN5Q7T5<ZC:6<L,=Y<V\$EP^R%990ID;^
MZH)Y/L*H:/XLT7Q!%>2:+JNFW\-A/)!=/;7*2""2,D.CX/RD$'(/H:`/DZ?X
MD^/=3THZGXBUV4C4_`-M>Q:`^CA(;J\%W+'*RD8?>$5)"H/1AQC%==K'QL\8
MV6M:ZVG75O=W%JVO1OX<.BN'TN*QAE>VN6E'+B8K!U^5A.`G*FOI.WU"TO+5
M+FTN;>>V?[LT<H9&YQPPXZU%_;.GFS%VM]9FU;.V<3KL.#CALXZ\?6@#A_AU
MJ7BT:9K4?B6[L]?OX9X9;&3[-_9Z^7+;Q2&)MH;[KLX#8)P!GG)IOQ-\5ZEH
M/PL\8W_B.*TT,PZ/<+9W%G?O<.9WC98P,1J0V\H!C)R>U=GIGB*QU2UL)HY1
M`VI1^9:P7(\J60`9/R-SD=QVJ]:7MO?P":PGAN86)`DAD#J2#@C(XX(Q0!\G
M?$7Q`;^SU2SU6_U-M-TCP[X2@UQ!).BVLCZDK7*R%<$.8""^#G;UJ:3Q/:1:
MF(M8U/6Y/@C=:U-!;W\TESL+?8D986FXF-IYYFVL3MWJBAMN!7T%XN^*6@^#
MK73)[VZ6\.M:@NGZ=#9.DDES<')95RP7Y55F8DC`4]\`RWOQ$TRS\50>'A]J
MN;^0J)VM;626*S+C,:SR*"L9<`[0Q&<9Z8H`R].\1Z)J?@75K'P9?SWBZ9I3
M;2SS/+&KQ,T1W2#><@9!YXQ[5Y9X"\6>.Y(_#\-I>!=*T/1O#PNK"YTTR3:F
M;NT/FYG)W*ZNJG..I;=VKT:#XL^"]'G\0OON=/O=.DBGOX)=)GAN+QIG\F&2
M)"@><.Z^6I0')7%;=M\5?#MWX-D\407K'2(I&@D+6TBS+.LGE&W\DC?YWF_N
M_+QNW<8HT`Y/X(?$2?Q3HMK=>)O$EMJ6K:U''+_9::4;,Z5,8V:6T.>6*%6!
MW_,-N3]X5P?CKXW>/O#/C?6M&L=&6YM=(N)K=KD6#[)GOD!T@JW1@L@>.7!)
MZ$@9%>I77Q]\'V>CVFHSW=\J7+2B:`:9.;BQ$+!)WN8@N^!(V(#LX`&1ZUWD
MFJ6<,<+SW=M&MP5$1>50)"WW0O/.>V.M`'R/\7KWQ!-J7BFWE-Z\VG0:S`MQ
M9PR1_:&&G:2XDPIQDR-)MQC&,#D&O6/CGXQU[PEXGTZ7PI#$TYT&Y*2R6KSK
M'(VH:?",@$`@)-(V.IV]0`:]B_M"U,\T`N;?SK=`\T?F#=&IZ%AU`.#R:C?6
M+!+-KM[VT6U1RC3F=0@;=MP6SC.[C'KQ0!X'K?C_`.(G@^33=(O+F'6[O7-1
MGT*PU--)\I8KT7*&*>5%^4)]E>9C_"6M^/O`'*T7XM_$#5-'\1W4VJ>%]/NQ
M!)Y=CJ!2"71YTOEMS&1@Y'EL2'EX,FS'R$X]]\/^.='\27VL66GW<?VS0[U[
M.\@?".CHB.Q`/5<2)\PXYQ6E'K>FRV@NXK^Q>U<[1.LZE&.=N-V<=3CZF@#P
MSX->,]=\4_$VYEUGQ5JMUHNH^%M.O=+T?4=%BLVE=FN$FE!7."#&I8`D'S5[
M!<\QH&J^'Y]:\>V7C.=O&VFVUG=ZAK&LZ?<7L4T0MYPT5G=6X(59U#%8O*(R
ML;#:,\_4$-[;7;S1VUQ!*]N_ES+'(&,;8SM8#H<=C67K&LZ7X,@%SJ+1VD>I
M:A!;AUB),US.ZQ1@X'4L47)_'B@#Y?\`$'@F3X>^%O`=]J$MI=:AI,%]J;^%
M+V^OGEO)[FXAE2"U9).9(N($#AE^8G:!FO5?CMXX\6>%'M?^$'EBM_)\/ZKK
M%P)=.-UY[V8@:.WZC:)/-8$CYL#Y>>:]<BU6RGEGBCN[5YK4@3HLREHB>@89
MRN?>FIK.GO%;21WUFT=ZVRV=9U(G;GA#GYCP>!Z4`?+GQ/\`%GB^2P\2:!K4
MAU2;3H]42+4K;3GMF:.707N45%0D`I(QC#9)/`^]S56Z\<>)?`WVJ\TBVGN)
M%UOQ`[3W-I-<?9(P;%?."@_,B+)+(5_BV'&.:^K3K>G+#)*;^R$44WDR.;A=
MJ29QL)SPV>,=:E_M"U^UBU^TV_VDJ6$/FC>5'4[<YP,B@#YLC^)'Q`UR9]%\
M,^(;&Y5+_4X+7Q3_`,(_N2^2ULH)E/EY\L_OI)(2R\$(=O/-==\0]?\`$MEX
MM^%5Y8:_<:/IFK>>-5L8K!)(KZ?[.)(X6=@2A9@R+[GCD5[.;J!6"F:(,<X&
M\9..OY=ZXKQ5\9?#G@TR_P!MRW:)%'<2^9':LZND-N+B1D8<,!&P.1U((ZT`
M<%\#OB?XD\;>)H;76]0M]6MKWP^-3U"*/2'LVT&]:=8_L+,?O'`EX;Y\PENC
M"N#T/]H+QE=6%QJ,>J6.IVBVD%U?K!HK*NA$:M#:M&T@R'WVS7$AW<KY)886
MOI35?&^DZ+KVE:1J5REM=:U;S7%HTN%1EB,2N"QX#?ODP._/I5G0K#2/#-I%
MH>@+:6D=G$9(K&*09C1F)+;<YP6)Y]30!X[J_P`3O%.JZC'+X$D\^PCTS7-5
MCC32V9]2^Q3Q)!:J6`*^;YA^8`D@`KUS7*:AK7BOQA-X#O/"?CN*]U-X]4N'
MU*/P_MAM\V$<HMGA)"G#$#+?,,D'YAD>\>&/B7HWB_6M:TW0Y3,V@W8L[JXR
MOE/<;2SQ1G=N9D`^;@#T)P<177Q7\.V7BM?#US=/'?M<109,1\K?+;RW"?/T
MP8X)3GU7'<4`>.:G\:O%,GC[[#X?NH(HH=(NEOK35M/6&VMKN/3UN8Y_-7,O
MD%W52S#:?F502M94?QL\;70T6WTW5+*$16TTDNHZQ9PVUOJ]U#>>3-;HZY7R
ME4J5>(;I`ZD#AA7U*EQ$\K1I)&TB`%E#`D`YQD>^#^5/P/0<4`)&,(!SQZTZ
MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`***
M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH
M`****`(KC=Y3>6H9L<`G`S7D?P[TCQUX1TS4[/Q-H&B7$FO^*;B[_P");JKR
MI;6UR\DLKR%XD/R<*``=Q8=*]:O;D6=G/<."5@C9V`ZX`R?Y5XVW[4V@PPZ5
M-=Z-K]O#J]M#?Q&5(`\=A,X2&[*>;N*NV<(H,F$8E0*`,W1OA/XV\%VNKW_P
M_CTG3M2.AV>C:+IE_K=Q>VUC%'*[R2"1X]PPLFU$VD?(-WI4C_"/Q)=>&/"^
M@V^D:!HL&BW]O?FYBUNXNO)G2Z,T[M$T2I<M(O.YPNUY&(QM!KI)?C_IJKK+
MVVCZU=+I6MIHL2Q"'S+V\>1H@B1F0.@\P8W2!`00P)7FL]?VFM'-C)=C0?$S
MQ:;$9=?"VT6[0E6>6W;SQYGS$2P2C]UO^5"W3%`%7QAX&\8^/=4O]4LK'2M*
M37?#NH^&;FWO[EC+;6\EP?)NUV*0Q,>YC$2,$J-W6NK\,^`=3T37];UJZ>TN
MKB#3(-)\-PM(V(K2&,']Z=O#R3Y+;0?E2/KBL>]_:-TG3GUR2\T3Q$FG:(E[
M_P`3$6R-#=RVDZP311X?<"'=?F8*N-QSA6QC>+_C_JFE7NC+H>C7%S-?OI#R
M:2$AEF:.\GN(BJ3),8F;]R".=H`R6.<``UK_`.$&IW7P)U+P>EU;2>(=;A>;
M4K]V=8I[V:42W$F0-P4L6"\9V[17*>-?V:3J%[''X>T[2?[`635,:-'.+..'
M[4L)6>%O)D$<H>)QE5!42$JP/!T9_P!J"SM-:C:6QN38WVDV[6>G,L<5Y_:3
M7=U!-;NSR")=GV5\DMM&QB"<BM'XB?&S4T^%/A[Q+\,]+O;Z7Q7JEEI]N6AB
M\RR\^<1%S')(BNP.5`W;2Q!)V\T`<EXU_9Q\5ZUXKU#5?#6NVMC9N1)IMM++
M*7AENX5MM3+MC#9BC1XSC.\MDC/';^,_A1>WGBWP3J7@^QTJ&/PLD-JDM]+Y
MD<%HLL9D2.V,;#S?+3"2JZ,I[D9%1O\`M*Z'86MS=:MIGB"VTR&SO+BTU-K:
M-HM2%F=MUY2JY8%3G`<+NP=N:Z36OBHV@Z5H<M[X:\0-K&OO(MKH4*PR78$:
MEY&;]YY8"H-V`Q)W*H!)Q0!YIHG[.NI>$/!$5AX7LO"BZK=V=K:Z[OMU,>IH
MEY)-+G?&RERDC;7=&P>V,8J67[,&J_\`"'G2]0O-)6_MO!#:'IUW&K/]CNC<
M3R%TRHVH8Y5C+*`V-PQCBNNT7]I#2I[W0M'O+/4;K5=0M;(74L$4:)!=W,(E
MB@:-G$@9@1DA2J;EW$4EY^U)X:AM+"33K+5-0N-2M;6>WMD,,)+S)-)Y+/)(
MJ)(B02,P9ACY1R6%`'+7G[/VL)H%HF@:-H=CJMIK#:A;I=:D+FQM9&AAC9_L
MHM5C=<(^$"HP(#APS-6Y\9?@KK7Q#\0:A=:=;^'KN'4]#ATVVNM39UGT*9)V
M=KNV"J<LRR=BAW0Q_-@G%C2?VB%U'4]0^P:7?ZS!J#Z:/#=A90+%=W7VFR:Z
M</YKJB[4C=B6(P!CGBK<G[3.@;;*:UTCQ'<6<T=O+?W*VB*-*CFNI+53.I?<
M2)XG0A`Q&TMTYH`@L_@;+I'PJ^(OAK1+;1+'4/&=WJ\T$]M`(H]MS)(8!*54
M'Y%<`\''.*P;#]G?7K37%GDU/39=,T;Q%9WGANWQ(IL;`77VNZB8<@N9CM0C
M`V1H#CFNDTK]H:UGN;.RDTC6M1GFNMEW=65HB0V,+ZA-91R2!I"<>;"0=NXX
M^;`&0-7X>_'&R^(WBJ_T72M'U>T2RM/M<>H77DB*XB^T/!PJN71M\4GRNJL`
MO(&10!Y=IW[.WC#S;[4=>B\(7MW?:AI5WJ6E1J(K+5FMFN?/\Q4A4*&^T(ZA
MED.Z$!BW4;%[^SS?3IJ%\-(\(F\N?$&G7ZZ84;[++806T,4E@SE,K'YB-(J[
M2A94)7GC('[5NO3?"37]731='B\9V-]/'IVG-)*]M-:*)94N6(^;`@@FW`8`
M=",\BNIO/CO?OJPNA?>'-!\/VVKQ:,PU*TNKB:]NV2%I`)(OD@4&=54N#N/7
M`(H`Y[3?@%XQ\*V5Y)H$FDE]>M+BWO-,LM7N=+72P;V>ZMA:74:%PB>>8V7:
MH8`8P!@V],^`'B*'Q7I>L>)[J'Q%>P66DB35)=0,5Q!<6UN8I\$PL\D3MF3;
MYB;S(^X=*1_VB/%'A3P@/%/C#3=&U+2-3O=:MK"'35DMY[:2R:Z,22[V8.KI
M:/EUVD,P^4BM;7?C%XS\)>'O%T>IV7AO4]>\*KIUV\T'G6]M)9W;,!A"7?S$
M,;KC<`WRG*\B@"IX>_9TNO#?ASP]::9'HUGJ-JWAZ;6+FW#+]LGL)I'FE)VY
M=V$@PS<DCGH*PD_9U\1VOAO0[2TT3P5_;^@2`IK;3,ZZA+N(-U>6[P,)F*'=
M@MO5RQ605[*WC/5XOC';^%;BSL%T6Z\/7&I0W:RLUPTL4\,;*RX"JF)N.221
MVKAKWXZ:QI7Q6\4Z3J&@ZK)I&CFRT[2+:TBMWDU:^N4\U<.TP*?(KG#`*%1B
MS`X!`)_CE\*?$GQ-O](ATAM$72[(12[KR)1<6UREU#+YD<AC=MICC=-J,AW$
M$DCBDT#X1ZWX1\%_$+2?"5AX3T_4/$6KWM]I=U]F#1SI<3-(([F/R\?(KF,?
M?'?&.#E>(OVB[]WO)O"UFMO%:::CS6FIV^V>WO$U>.RGB?:Q&`"XR"1D`@D5
MTD/[26@O-;-=:5K]EINICS-*U.:WC,%_;BXB@>=2KED17GC)WA24.X`B@#DM
M1^$VN>$OV;?&_ARRL8KK4M4O;V\LM/TWY@J3W*NL0V1H.!D'8BCK@5;T#]GR
MZ6]L)=<TWPO:Z4GBR[UF70+-&DL[>%[#[/$D:E`K-YJK.?E4!F)`R,G5?]IG
M0M7TZ"7PRE\\DM\UO(TEGN6`)J$-GEQO4@2&96C/=?FP0,&[<?M%Z7:#69;K
M0O$45AI*W0BU!H(_)OI;>Z6UFBC._*D2N@W.%7!+9PI-`'G]M^S3XBB\/S:5
M=MX<N[BZ\*VNDVNLR-(;G0YH898W-ME"=DAD#9!0\MD'BNV\,_!O4=-^%?C/
MPY9):^&=2\3V\BQ/:7OGP6\SVJ0ET1(HA&NY>BKD_>)W$UIV_P`>K`_#2]\9
M:CHFLZ?;V6I2:<UA,8&F>=+C[/PZ2&((9>/,+A0`6)`K9TGXKV.IZC<6#65]
M;W=H--\]'\MPAOMWE#<CE3MVD,02.F":`/*]%_9KGN/%^F:WKN@>"=,M++6+
M&[_L:PA,\$206-S#)(FZ-1YDDT\1P%'RP(22P&.M\5^`/$.H_&+3]8\-6&GZ
M1;H+:74/$-MJ4R7%[;Q,=UE/:A?+E#9(#LV44Y'(P<7P-^T[]N\&VU[XUT#6
M+/59+2&:WC@MXRNK"2[%H&ME\PD`3/$I#[3B16Z5?O?VE;$Z'?7*:/KNCR16
M-W/;S:A:121R36DZP7<"JDN6:-V`)R%;DJQ`H`KS_"/7M9UG7=8\0Z5I32:F
MNGD65OK]SN:YM;DRK=1W+1[X`F1LB4%2<YQFGQ_"3Q3:?#E=!M[C3;G4H]=7
MQ&+B\O)9%:Z74Q>"U9RF\IM&SS3\V>=M:$W[2>CKI\MW;:/K,\9UTZ-9C?;1
M&ZG7?O)WRCR`/*?'G;"WR[0=PIM]^T/::-?:_:RZ5K&LS:#=7;WL>FVD8-C8
MVZ1%YWWR_/@R8`3YFP<+QD@'.7?P2\8+K>OZW82Z"U]XTL=4LM5@FFD":>MT
M81$\3!,S;(X0&4A-S$D$#BJ_Q>^#.J>+-=T;P_H&CZ?J-A;^![G2XM4UD/Y6
MG3^;;I'<)M4YN%0.Z@;3P<,.:]%M?C=I]_XTB\/Z;I6M743W$-M)JZ0(+6":
M:T%U"CY;?\T1ZA2`2`2,BH/$7QUL]!UR]TZ'0M?U*.ROH],>_MHHOL_]HR1J
M\5IEI`VY@Z#?MV`N`6%`'`V_[.>LVUSXN9I+:YU#6[/6H+36VOS')(+U1Y2W
M$:P[GV-\H)E8(J`J,D@=9\2/@U)JWPYT/0?!FE:*EWHD@N+6.:00V<=R(742
M20^4Z3H7?+(R@G)8,&`-8OAWX\>*+3X,>$_&/B#PGJ>KZEXNU:UMTT^U>VMC
M;17<@$14F4JRC<`I)#-D;@O.+NE_M%'3=7\86_CK1]2L=+\/:CJ"0ZS#;HUL
M8K6&*9H6PY?S=KMSM"DK@'(-`%.'X"ZIIVH>(_$.CQ>&(O&.I:E?7-EJDMH6
M`CFTZ.W2*1<9,8ECW%,D!<=ZI>"OV<;[2[K36\0P:$VGVWB:^UF73HE62.-9
M=/BMX@JB*.,NLT?F\(H&01EAFNLNOCLNI_"CQIXH\-Z=-:ZEX2MIFDLM2V.H
ME6$2IEX79&4JZD[6R.0<$&N4U#]I35]+\7^)M`U+3=,MY;3Q)I^G>'[@ERM_
M"[V*WBN,\31"]5@`<,K`X^5J`-;X)_![6?A9*9)[/3[B^DMH+*\OUU(A;Z-)
MW9KAHE@7]\4?<2[.Q8E=P`!KMOBGX7UGQ@GARQT1+!;*T\06.HZE/<S.DD<5
MM.DVV)54AV8IMY*@9SSTKD/!_P`6_%,^HZ5<>*;;1+C0_$?BK4M!L_L$<D5Q
M8O;RW"Q-)O9EE5EM7W%=I!=>",UVGQ'^*VD_#&WCG\0)=M%-9WEQ$8(M^]K:
M$RM$.>9&0-M7OM;TH`\@O?V>O%NNZMXMO]:F\-I<>(;,6CR6B>2MTJZDMPKR
M*D2D'[.HC.YG8L6Y`-;>J_`2ZT[7M$NO`VEZ!9Q:5J]S<1":3_1[:VN+E)9D
MCMO*8+*0K[9$9"C-P2N11X@_:;$>MZ$W@S0M7\1:3<QSO>K9P1F:0"QCO%\H
MO(HRB2+O![L%&36]_P`+[@/B;4-&TO2=7U^_6>$V=AI]M''*+<V=O<22NTDH
M4A1<Q^ARP4`D9(!YO_PS-X@?3+"QNK70I-%TV[NO(T47:EWBGM(XS++=-;'S
M;A94;;(\>\)(?G+#-=]X/^!@T'Q7_P`)%J%KITNI0:O%<6EVTKSW,-F-+2T:
M`RLH+9E4OZ'.X_,:N_#;XRWWBGQEK/A[7=#U&W%KK.J6EAJJ0H+2=+651Y9.
M\N)`LB\E0I*M@\&EA^.]G'XGCT&2SO;Z^O=?OM-@\F*.W2%+9HP[,TLH#D&5
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MZ1%IRZKH^OVE[<)+)J%E*D`FTR..Y:V9Y%\S]Y^]5L+%O+`%@,4`9,7P)U3P
MUKJZYX/L/"ZZ@GC6^ULQL&MEFMKBSE@17=(R2R-*7Q@CK@@FF0?L^ZK>^(M-
MN/$$NE7&F*EA%J-NC29E2+2KNRF"\=WN5(R?N@D\\5VOA7XN?\)KXQM;#1M+
MU6#1Y;>^>'4KJW407Y@ECB+0L&)`#F08<*2,,!BN/\/_`!]UV;Q9XJL]8\,:
MU</!KLFD:!I%E':^9<BWB$D\QE,P'W75B&V@!D"[B3@`W/V<O".N:#X6O-2\
M<K)_;FLWA5C+&R2"SMD%M:;U;E6:&)9&4]'F>O7:\[\%_&C3OB#JUO9^%=.U
M>XMY=,@U">_EA2&*UCF5C$KAFW%V*2+M4'!7D@$5R7BCXO\`C#PUXVU'P['9
MZ#J"W4FGP:=J$$<HBTRXO+@PQPW0+YE8(/.PA0XX(`*L0#W&BO%K'XQ>)&D\
M-6EW8:-)--XSN/#&N7,;R(OF11RNLMO&<\.(P2&;Y<D?-UK0\%_$K7=2^+7B
M+P[XO:VTNT@N9X]!LY-$N89-0AC6)C.EVS^5*/G;*(H(X/K0!ZS1110`4444
M`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`
M4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`1W,"75O
M+#,,QS(4<9QD$8-<3'\'O#EL=%&DG5-+ET+2H])MI++4)87>SC*E(I"#\X!4
M8)Y&YL'YCGK-<U6+0](O-1N]_D6$#SRA$+,5122`!R3QP!7S+X?U?QMX!T[Q
M/'=27.C:OXQLK?7[6]UMS<V]M>/.L5["C*)%B"Q/;B-'&`P)*D!J`/5?%_P!
MTKQ+>OJ$&H:M!JESJ-C<7%[)>RR2K!:W+7"P0MN'E#<[X(Z9'8`5(?V;_`YM
MXX$LM1CA:%8;Y$U2<#4T%P;C%U\_[XF9G8EN3YC@_*Q%>73?&?QE+!//H][K
M%V]SX-N;K1['^Q(_M*W<=H\OFWT83Y2SA/+\IMC;@I0$UT.M_%#Q/XDMK`>`
M]2N;:WO=0>%]1713(52/2FNFV+*H!#3H(]Q!'S%1R!@`]33X::):VTT.G_;K
M!IKF[NO/M;QXY4ENIA-,RL#D9<#CH!D=#6`G[._@N#3[>UM+34+4VBP>1<0:
ME,DT;PSS7"2!PV=_FW$K$]]V.F!7E@\<^/9W\/)XA/\`:KWS:%K"O_8OE#3W
MN8;OSK=0,\1M#&=S$L-^#U%)<_$+XE:;X1T6;4-=N9K[Q8=*G0VV@1)<:<9[
M6YEG@B1@5;8T"?ZP%@I;N1@`]7C_`&??!=O;V26=E>6TVG1PK:W45_*)XFBG
MDG$GF%B3(99I2S'.[S&#9!Q7377@33-0T73-,U0WM]#I-];WUO)<W3O*9X)1
M+&[/G+8<`X/&!CI7D'B?XD^)=(^"W@;7;7Q39W]W=P1S:W?Z79I//J6V!FD2
MQC,9B+F0`;6"Y4$`AL5%JWQI\66=GXPM]*M+N^\0:+=:N]G8'2)#_HT4*-:D
MX4!B=Q8`-E\$#IP`=W)^SOX)F6^BGLKZ6UO;>\MTM'U&8PVB7;A[D0)NQ%O8
M9.WIR!@'%=-XO^'VD>-WTZ761>Q76DSM-975E>26LT)9"C@/&0=K(2I'0CW`
M(\@MOB%KA\1>'=.3QU?W.B7-O)<QZX?"ZYU6X$T:_8B!&%0!'SE0K'=U^1L\
MQ;_%KXD7&@ZO=ZAX@TC2;HL#<V$]H%N=*=+IDEAMQY)0DQKA6F+AFP00K#`!
M[KIOPF\/^'=3M]1T1]4TQK:VM8)(X-1E6*XCME*Q><I)WD*=I8\L``Q.!C.M
MO@=X*MK>XFT>UFL6O-<;7UO+*]='BNW0HSQN#\L90L-@^3#-QS7A?Q)\;>+?
M'7AKQ5H]OK.NPQ:EH%M=6%M9Z-&)+:+_`$0RQWJM'NCN7,[C8C,A4,!@JV>X
M'BW5-.A\3>!9I)Y9-,N+BRL8H=&\E6TY=%#HX,<8C4&XW`;<<C:!QB@#T.]^
M"_AB]9;RX.JC4$GM;E-474Y5N4F@A:!)!*&SDQ.ZMGA@QSFL&S_9K\,P:_#<
M!KS^PK33K&UMM(2\F$<CVUS-<"2X;?\`O]TDH?#Y^923G<:XKQ;XM\0Z!\./
M`>D6NH7>@VE]X*:2XO#HCZ@T][';0"*R=0"5+AIF/1SY>`0:FTOQE\0-2\;W
MN@V6KV&B1P(;'3["ZM`Q:,Z<)8+N,F,EW\_[P9P@564C=@T`>M:3\(O#&AS7
M$NG64L;W,:I(3<NV56[ENQU/_/::1OQQT`KFOA+\(+SX<:I/-_;:W5HUN\+6
MD$;HD\C3M*+B4.S8E"ML^3:N"3CICRJ\^-'Q*UZPM-2M7/A+3M0GN;59+_3@
MIM;RSMDWQR%XVQ'+<FY&['*6Z[""X)EU3QIXET'Q]XA9]5N/#&FZU-:W%YKM
MMH[WT*S1:1;.D,2NI`21O-Y(R?+V##-0![#'^SUX$B?S$T8B;^PKK0S+]IDW
MFRN)&DEC)W==SOANH#$`@&I-3^!'A/5-2DO)(=3MUN9;6:^M;75)X;>_DMMG
MDO/$K!79?*C&2,D*`<UX]HOQH\?ZMXOT*ROKLV>J&30DO_#46AEA)'=VJR7L
MLDIRT/D_.X!88V[6W;@*=HOQ%^*;Z5#K&H:I+.(-.T/5IM._X1Y8_/-Y=/!/
M9[L;E6-$#Y`W@MDG;A:`/5K']G;P3:O?"ZL]1U.WOEO5%IJ&J3W%O;+>,[7(
MAB9]L6\R-DJ`1G`(J34_@-X6U?PM>^'KZ77FMM3FAEO[A=8G6ZN_)0)&DDP;
M>R*JKA2<9&>N2?*-*^*_Q(E\->*-0N+^Q;5(H%,>DG3B\^E7(OU@=%C5!OB$
M9)R[,S$;E(4\;5O>>-M*^+'@NU\3^-]6DTU9]7LKCR]'BB@U1T>W>V6;:A"N
M4DD4,NT?NB1@EJ`/3(?A!HT/C/2_%!OO$DNJZ38BQ@,NMW#Q-#A=RO&6VON*
M(S$@DLH)Y%3:]\)O#>OW5]>:A;W27M_>V=ZUU;W<D4L5Q:KMADC93\I"D@XX
M8,00037FGBSXJ^)[?XP2Z5X:DU0:=8VUY#>V5QIL9B9TT][F*XB<)YA4R>7'
MN+;2VY0N1FLH^.OB#I.@Z*WB;Q)-;P^(9]/GN]9C\-JS:)'/92RM#Y04AE-Q
M''$&<$J),$YP0`>G6OP&\%Q:?]GAL;B2.2W,,DKWTLDDX-V+MG=RQ+.TXWEB
M<GITXJ.V_9Y\$V]K?VC6%Y<65[IMUIB6D^H3/%9VER^^:*W4M^Z#-@Y7!&U0
M"`H%<G>^*==\/_!_X?FUO[C15U>ZBMM8UR/2&D;3HFBE<2^1(&\O?*L<?[P$
M)YG-8B_%3QFWC:WM+?5KJ=O[7M[&/1V\.-&MYIKV:ROJ9E*Y0[]YQG:NW85W
M'-`'I]C\!_!>FI>)8Z484OETU9E6=QQ8%#;`<Y&#&A/]['.:K^,_@KIFN^"[
MW0M#Q8O=3W%PLDS/*F^>[2ZG#+N!*O(F.""`3C%>6^&OB!\4);*SU35]5EG2
M*+PY?3V'_"/)%YXU*7R[FVW#YE6%?G!`W@_?..*I1_$KXJ+I5_JTNIS$66C_
M`-MK8?\`"/*/-*7TD!L@V-VUHH@Y/+Y?<"%PI`/;/"_PSFTOP;<Z%K&M:E,)
M[Z6YB>SN'@-G&S[EMXGR7\I>F&)SDCI@"OHOP$\'>';S3+G1K34+4:3;V<,$
M$>I3B)_LF[R&D3=AV7>_+9SGGH,>41_%KXBQV'CJ_FN['[=I5CJCVVA-9;IK
M.>WN0EOY:J@,D;Q'<Q9V+%E*8&<+X]\6^+M.A\=:+JGB2]O+O1-%<:9I\GAI
M'77Q):-*;@NB8&V7?&%0@#R@&R7%`'IVE?L^^"-%C9H+6_DCC%N(/M.I32BT
MC@NENDCBW,=B>>JN0.NT`Y``K0O_`()>$=5T];*\L)GME_M`A1=2#_C^F$US
MSG^*10?;H,"O$?B+\0O$_B.]\?Z#I;:R^BKX2UJWET^?3D1K>[MX8!$\3(F_
M;+YDA7<QWA<J!BI=/^)&N:+X^TO2CK.I:1#-XBU26[TZ/01*FI6D)Q&BRF,M
MY\KLBJ0R@JKGJ!D`]<U7X#^%]8775U2;7IW\21+;ZK(VK3;KJV5956W8Y_U0
M$\F!VSUX&&:G^SYX)U>XO)6M=1MI-26>.^-GJ4\'VJ"81B6"3:PW1,(H_E[8
M.,9.?#X/B-XZ\4QV6H/XK\1Z1HEMXLTT_;!HT'F"SN;21WAG"Q;2J2[$(P=K
M-AF)`(LZA\4/&WA^;Q);Z5//H\MA?:G<:'9Q^'C<+XCN?[4GB6W9L94;!`<J
M5)\[?G:IH`^CK'X=Z#IFHW5[8V9AGO+R"\DVR-M\V"W6WC(7.`!$JK@<<9ZU
MDWOP=\+7WBE]?N8+W[3)?Q:C-;B^E%K)>QQ^5'<-#NV&14V@''55/501QGA;
MQWXFM/$FK:[X\UM+3PE:7NMVLEE-IBPI9PV<X$-QYV-S;D#YSPV5VCC)S_VB
M9M9L_&?@+Q!X3&LW`\,VFJ:Q/9Z>9"E_'%]EWPNB\.S0O/L4_P`>".10!Z=<
M_"[P]>^!]+\*+#=0Z1HOV4Z?Y%W)'+;-;,K0NL@.[<I0<YY[T2_";PS<6>IV
MEW8-<6^L7-S<WL<L[L)I+B$0RD\]T`''0\CFOGW2?$_B'PWJ?C+Q#>3^)-,N
M?'D.BW-O*L'FII)N'O/+5EF5HXE2WB@23Y"0[#(R0:T=,^,/CNZT5;O7=1N]
M'U:S\&P:C9Z6/#I<:Y>/;3/+N;:3&4DC5=BE<=P0P``/=$^&>DGPCJGAO4KC
M5]3TK5[<V]RM_J$DS^48Q&55R<J-H[<DDD\DFJ&L?!;PAXA4G5=-:<GQ'!XC
M5_/<,FH0K&B2J0>!MA0%?ND9R.37D&M?$CX@^']4@M)==NKC4([72KG3[%O#
MBLFO/=SD7,>Y%_=K"N`-K!E'S.6!K"\,^(+[3/&^B22>'AJWQ`NKK4(==-[<
M7T5[!<(ET\10!?L[61"0J@W;<2H0-V30![?:?`;P]I%[>ZAHD^L0:C*]Y/82
M3ZE-<PZ7<W6\RSV\#OY:.3(QR!W(&`36YK?PUT3Q9HFAZ9XNAFU==`O+6]M9
MKF9O,:YM\;)792-Q/.X'AMQR.:\.\)?$7XD>)-+T>W;Q';BXU_4K"&>YATE7
MN=($UM=/<(T1C5%59(8U3?N8$MO)RN9=2\=>,]'O!+?3FSEO-*\/6VK>(X-$
M+FT\V6]6XN!&05QN2(8(*Q^=N(Q0![!H7P6\)^&X[!-'T]X%TV>]FM@)V^5K
ML;9N_(VX4`_=``&`!5>\^!?A.ZU7^U(H-1LM3+@F\LM1F@EVBVCMC'N5A\C1
M0Q`KZH&^\,URGPM\?ZYJ_P`2+_2-;U^;7K!M-$]A-:Z4MM"D:"$%[G<BO'<.
MTC$*"8V7)4+M(KDK3XK>+KOP[:76H^);_3;S5=9CM==C'AD'_A$HR9UPN4._
M,D<4>^3>!O\`,^Z10![OHO@'1O#]TUQI=O)'*]]=7Q+3,W[ZY(,K<GOCIV[5
MA:I\'O"NJ[UO!?BTGU<ZM<VJ:A(D%Q=^;'*'D4'!Q)$A`[8(Z$@^7>%_C5XM
M:6SB\3O=#^U-'B?2I%T*2(WTO]J3P><4VDINM%MY65B`H?=@`\<K:^)?$EK)
MJGAZYO;[2-/_`+9O+BQM7T.2Y_MLRZW="5/-QF,1QK"R[2,"0,<J,4`>Y:[\
M%-,\6?$*Z\2>([F[N;2:ST^%-,CN)(H7>TGFF1Y@K`2C?(A"L,`IWSBC3_V?
M/!>EZ[;ZM86-Y%=6]TEV%%]*8Y)XY9Y8Y'7."5>YFQV^?IP,4_B=X@\7VGB_
M3[#P1-(D*Z!J6J/"MDLOVVYMVA$%J9&&(Q(96!(^8[>,<FO+-'^+/CFYTS2D
MUGQ9%::;JUS$UUKMMH@GN=)+6CR?9Y8?*"(&E4*NY68`%6.XJ:`/<D^$?A:V
MT*QT9+*46&GK`MM']H<E1!<K<Q\YR<2HK<]<8/%.O_A9H6I:O%JUN^IZ=J42
MSQM=6%]);O(DTHF='(/S+Y@W#^[DXQDY\,\3_$?QY>/X\M[JZLI+>RL=4@M]
M#N-.(DN(H[/S+:XB41[W:0D%@S[0&*`;EJ]J'Q3^).G6OBJQL[60W/@>Q9[F
MZ;3/DO5N;F,VTT0`P_DV?G.ZIU=0".U`'LWA;X3>'O!NKMJ.@Q7\4@^T>1;R
M:A-);VPGD$LRQ1,Q1`TBAN!QSC`XJ#5?@SX:U69[GR]0LKYM4GU-+VQOY;>>
M*XFA$,I5U;(5HU`*].`<9`-<.?'OBO3/@IJFM/JUKK&IZ7JT<4=_9VOG%[/[
M5")&E18U4NL+2;BB[0`".0:Y?XF?&_Q!;BW_`.$6U^;2(KVTUN[TY_\`A'VN
M9;^6TE@6UMUC9-VR0RL-V`6&"I&<T`>X^#_ASX>\!-(OA2R^Q+)96MD4$K./
M)M@XB'S$\@2/D]23DDUS%I^SOX4M8-2@^T>)9X=3O1J#I/KUS((;P3"9;F++
M_)*'488=AMZ<5R_Q=\0>,-)U7X<ZMI.IZKI0E2Z_M/2;2T6:"\N_L9DAMY6*
M,5#2KY8.1@G@[L&I_@=\0O$GBG6+^'6=4N-?TQ=#L;Y[J3138-9ZA,TGG6(X
M&[8JH<$%EW89CG@`ZS5O@3X9U>UT2!Y=>M%T"_?4;5K+6)[=I+MV9GN)2K`R
M2$N_+9^^PZ&M.?X6:1=:Y-J]U<ZW->M%/';.^J3$6(FQYOV<;OW1(4#(Z#@8
M%>(:!\7/'?B5M9_L:^U2.TO]3T2+3IK[18O/TQ+RYFBN8V14"EHD6-L-N*$_
M,Q!Q7O'PXFUB7PG:+XLOO[2U6"6X@N+O[*+?[1Y<[HCF,<*2BJ3CC)R.#0!T
MX&``.U+110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11
M10`4444`-D947<_05CP^+=!GL7O[?5]*>RCF$+W27L9B63(&PN&P&R0,9SS5
MW6[>[N]'OH-(GBM;^6VD2UGFC\Q(I2I",R_Q`-@D=QQ7SSI'[-OB2P9+V^;P
M=J4[ZTFH7>E7<+-8W/\`Q+1:2,0D2@.'!E4>7@`[<Y^:@#VU?'^C'3M,NO/"
MMJYA:VM7=1.RRRI$&V;L[0SKDC.*H-\7_"JO);OJ<`U:.S:\_L@RH+QH%=DW
MB+=DC*G'MS7FVA_L]ZQI&NZ7<3KX1OH+0:*XN9H9OM.G&QP)(K4\XC<`D;F&
M"[9#9R,>Y_9;U?\`LN6VMY?"\MS>^&;O1Y[V:%Q+`\EY+<1R(0A+#;+L8$C&
M.,CB@#Z%'B#3/MT]D+^R^VVT0FGM1<(98HST=ESE5]SQ6#XFN?!7B;1TF\37
MNB76FV-\`ES)?HB072Y7`D##;)\Q&,@\D5Y+K?[.&NZMJ>JM'<^&81<7NMWD
M.L+#(-0N/MUK+#%;S$#_`%<;3GD,V5AB`4$&I_%?[..IW'A.YT'P8WAC3[#5
MHD35;9[0(L\BV!MUF4^6VUA($<X`+*I&Y3S0!Z;9>-_"GAJQ\06,+Q:-IG@5
M(8KXF+RX+>-X%E39CJ-CKT[\<UF7WQLTS1]'TFYU#0_%WVS6=0EL;72H]&E>
M\,D:-(6,74+Y:;]W3!QUR*R]$^$>I:!H/C.VN!H6N-X@L+&"&SOT<V\QM["*
MV=)AC.UVC)XS@$=^*Y6U^!.N:I\.(=,U[3?#=[<&]DO=-TZ\U6\>+PWNMA'&
MEM/M,C;6WL0=H'F,JG`%`'HE[\:=(TKQ=;^'M5TCQ59SWC2K;7LVD2"UG,4+
M3/MEZ<(K<],C'6M;X??$;3_B-X:CUS1[#6[#3YT1[9M4L&M&GB9%=945N2A5
MA@UA:7\-=737K?4/$FI6FN#1?#,>DZ4;A6#2W#K_`*7<S]>92D0^7.%#>M4_
MA5\);OP#I?B&RCBTG1].U2.*.PT72[B:>TL"L)1W5I`""[$94``!%ZG-`'?P
M>*=%N)HX;?5=-DEDF:!(TO(V9I5&YHP`V2P')'4#FN5'QK\."\%HXU".7SM/
MB*M;=&OI98H.AZ;X7!].#WKSGP]^R]+H.GV@@;P['J5E:^&%AO(;4J\<^G3;
M[R56V[@TZDKNZMGYN*E\/?LXZSHUO:Q3:GI3^1/H<AV(X!%C>7<\@Z?Q+<J!
M[J<]J`/9=*\7Z1JJ6/DW<,%UJ=J+J"RFE1;AX\?>\O.<#N1P*N:=K.FZN]Q#
MI=[97CVC!;B.WN$D,+$9`8*3M)'/-?/7@[]F'7?#?]A6M[<^%KN/3M0T>^?5
M_(D^W6RV4$:/:P$C'E.T*X)9<++*"I.*]$^"WP:3X56%@&32_MRZ#:Z?J-Q9
M0E#>3Q22L96)`+?ZT\GGK0!VFG^,M'OK33;AKN&S;5@OV2"[E2*64G.%"$Y)
M^4\#/0U<O=?T[39X;>^O+6"YN@QMK>2=4DG*C)"*3ECCGBO$_#'[-4VFVNBK
MKTFAZA<:)H&E6%I,8&8V]S:7TER\L9(RNY7101@Y7GBNOU?X9:C<_%:X\3Q0
M>&]2LKVPM+8'4XG:YTMH))69K8@$?.)>>5(90?F'%`&AX2\<^#M6LKOQ1IS6
M^EPZQ;6=Y=7]]MM?M"/"IA+LS=50A>>G2NBD\8:3;2ZC]ON8K*#2UB>>[NI%
MB@`D&5(<G'YUXEX5_9>NM.N=!7Q1/H&KZ=IR6:WEI+;M(EQY.D/9'Y6&#^\9
M7&>@'KBK4_[/&K0:A9W=K)X;U&WL9=()TG4HY&MKM+2PEM'63Y3@@RB1#M;!
M09`Z@`]6\0?$CP[X;TC6=1NM1MKA-`L3?7UO:3)-/%`%W;O+#9P0<CUS71-=
M0);>?*Z1P[02SL%&#TSGZU\[:G^SGXKUZ\\07>L:AX5MYM1\.:GHUH;"V,,<
M<=S]G$"%!&"$B6$KDLY8$'Y>E>D^+?"^M_$WX4Z[X?U"VM-&O-0D>WMA+,95
M:W2<;)'VC@NB9*C.-P&>M`'96GB?1K^XM[?3]4TVZFNH/M%O%!=I(TL6<>8J
M@Y9<_P`0XJ/3_%N@ZM</#I6L:5>SQR&)X[:]CE=7P25(5B0<*QQ_LGT->/ZG
M\`)K#QQK.OZ9::;<V4DXO-,ABN6M9;(K8-:FW1$CPT9."J^8J@R.2,@&N%^$
M?P>\36,ND:CHVB:;IFJ:)+8W4]WJ]M)9KJ#?V9/:/$8EB5@T/FJQ?D2%C\P(
M)H`^BQ\2/#XU+6K*[U""S_L!;5[NYNI5A@VW"EHBLC'!R%-21_$3PM-JNI:9
M'X@T9M0TBW2YO[;[='OMHG&5D<$_*I'.>G(]17DVJ?`;Q3+8WEO8:CX>EBU2
MTTFUO[>X@.V:.TLYHG"LT;[,RO&X(4G:C+E2<UCC]F#6;$VGV$^#[PPZ;X?B
MN3=VSK]MDTT%989,(<PR@JV3DAHTRK`<`'OUQXLT2UMK:YNM7TN&VO-OV::2
M\C5)MWW=C$X;/.,=:N'4[0&<-/"#:@-./,&8@1D%N?E!'//:O#O"_P"S0D5Y
M))XXA\/WVGW5CK,4NFVELQBLGOKM)0MMN'RA(U9=P"G+'``.*M_"_P``^,;?
MX+ZU]MNK2R\?^*5FGDNM0M/,2%P@@MEEC.<X@BBW*<X9FZ]P#U9?&7A\Z9%J
M*ZUI']FR';%>?;HO)8@A<!]VTG)`Z]3BG7OBK3-/U*STZ2XB:^O)%1+:.13(
MH8,0[+G(3Y"-V,9KQ'1/V8)A%#;^)AX?O=._M'6KN33GB,T0%[;Q11J/W:J2
MAC8DA%^]P,UL^&O@=JVA^/(M6N_^$8O;:+5H]134GBD_M&)!8+;&V5L8\L,N
MX9;&&(V@\T`>NOKFF0WXL);ZSCO1"9Q:M<()1$.K["<[1ZXQ4*>+=#?3%U%-
M7TMM.<X6[%[&82<[<!]VW.>.O6O(O%?P(UK7+KX@):R>&"OC"1I[35[JWD>^
ML\VT<7V4D#F`F+G#CY9'&W)S6:W[-FH:KJ5S>ZK#X2L+>[U*>[.C6%N[6<.=
M*>SB90R`%_-82D[!C:,9(S0![C)XGT>*"ZN)-3TY8+%VCNI3=QA8'`W,KG.%
M(')!QQS3T\0Z7(+LQ:A8N+!0UV5N4(MP5W`R<_*"O/...:\2L/V9I+2^T%7;
M0&TFQ30VU*Q%L?+O9[*&ZCGE9=NUVD\^'!;DB/GH*RX_V5]2LO!]GI>FWVB6
MUS%X;L;&^\J-XX]2N[:]2XW3$*2T;*KQDD%@'/!'%`'O-SK.@:G96JW5YI5W
M9ZF4%J'GC>.[/WEV9.'^[D8ST]J@_P"$WT)Y8#;W]I<6L\<\AO8;A'MXA!M\
MS?(&PI&X?D<XKR'_`(9HDN+>^C1M,TOS_#^KV%F5E>]:QNKVY\T7$;,B!<*6
M!"!=NXA>*DUCX(^*;ZTT6?08?`GAR^TNQO+66UL+1FM9Q<?8PYPT>,LMO*N2
MAVAH^&VG(!Z7?_%#P_8ZG8V<4SWK:C8M?6LUD%FBDA$\4#$.#@X>=/PR>U:*
M^/?#!M)+J/Q#H36L4PADG748=BRGHA;=@,<'`Z\5XA;?LR:U#HFFV2ZCHT?V
M,7>8U#E%\[6K;4%12%'"QP-'G:,L0<`=*=[^SIXRU3PAKVCS)\/]/?Q+J5_=
M:H;&!PESYUNT5LXW0'RS"/+&U1\X!.]23D`]Q'Q*\-37NH6&G:K9:CJ&E7D-
MIJ%E9SI+-:R2L@7S$!R!\ZDG^O%:L7B32+A;KR=2TZ5+"3R[HI=(PMW'\+\_
M*?8XKQ>;]GC5/.U^.SD\.VR:UJ>B:@+^*%DNE>R^RB5&PO(;[.SJ=WWGY'4U
MBZ?^R]K+6%G:ZFWA&V2PTS3M.F-C;R#^V!!J,-S+/=`J/G:.#:%^?YII,M@T
M`?1-KJMAJ&G1W]G=VMQ8RINCN8IU>)U/<.#@CWS6=-XTT-;.:ZM=1LKX0V4E
MZ([2YCFDDA3(9T4-\PR,9Z9XS7(:[\(?M/P@\1^"?#W]G:;'JTMXUHD<92"W
M2>X:7;M4<#YCP!CTKB-;_9AFN+75U\/OX?TR?4=2UJ1)8K4QE;.]TZ2VCMR5
M7.U96CD*CY?DR.0*`/6]'^(^@:W]K`NX[1K/56TLK>NL)DN0B/L3)^<E9%QC
MGKZ5)K_Q&\*^%?-/B7Q#HVF&WEABE%W?1QM$\QVQ!@6RNXGC/7KTKQ#5/V7=
M4OM8O;N\N=*U2TO_`+6C6,EU+:B$2I:A)(Y%C=EDS;L&*A3M*X8$&M'Q-^SO
MJ^M:CXDDLX/":V&J:E;:K%:7ZO>&XO(K^.=G>5XM\2/$C(8U+J"Y(`'!`/<8
M/$.E7=U/;6NI6,US;1+-/#'=(SQQL,J[*#D*1T)X-0?\)=H26%U>G5]*6RLY
M3%<W)O8_+AD&!M=]V%;D<$YKQ/3OV=M=BU99KF3PK;_9Y-=F74;2&07EZ=02
M18X9CM&(XO.(SELB*+"K@X==_LQO;Z3H,&B+HD1TV;3I]1LT4PP:C)!9R6TK
MN?+8;_G5U8H>4Y]0`>XZCK>F:39&[U6]L[.S`W&XN+A(HP/7<Q`J.;Q5HMK=
M+;7.K:;%=/;FX2&2\C5VAZF0*3G9Q][I7C_CCX7ZI%X<^%>A:#H.CZM'X>OW
M6YM-3FDNK&*,:?<1KYLC(79=[(`2F2=O`[8WA[]F37+?5/",'BK4M`U;0_"]
MM';`);&.62W-A-;3V^-A9E,DS,K&3A0%VYYH`]\N_$.E::LK:AJ-C:I`@>5I
MKE$$:MG:S$G@':V">N#Z4Q_$NBQ07<TFIZ:D.FG%Y(;J,+:D@']X<X3@@\XK
MP7X>_`G6-:\+Z/<^.UM)KY/%!O;N#4K8LTNG6UG/96,3H<_/L,<Q#9`9W[XJ
M)OV5=1M=-\.0Z9=:)'_9.EZ1#J=JB-%#J]S:22^9),=C;LI,2K,K$,JY&*`/
MH"7Q+H\4UHD^I:=')?`&U#W4:F<;=P*`G+#;SQGCFL+3/%_@;Q1-8>)=*U?P
M_J#H\VF6.I1WD;?.[+YENC;OO,T2';U.T&O/?#W[.$.GZG!=ZA:Z*Z6%KI,>
MG0R.]X]D]I?S7,I25T!PZRJHP!TP1M`K+L/V=M:T;2]#MM%M_!]I?:!K%Y<6
MFH(K[/L]Q=K*QDM3$8WD\H%`<@H50JX&10!]"H%8948SP:<5###`'ZU6TW[7
M]D']JI;1W&]_EMW9TV;CLY8`YV[<\=<XR.:M4`)M%`4`Y`YI:*`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`JZG<?9
M-/N)\9\B)I,9QG:"<?I7SA#^U9JEU\'=$\21^'[!?%=[>I'J&C-=N8K6V"Q3
M23"0#+`V\\#+Q]^=5/0U])WENEW:RP3'$<R%&QZ$8/\`.O,X/V;?`UJMV+>R
MNT:^T*RT.=Q>/EK6U*F+O@/\D89\981H#T%`$^M?'OP_X:\1ZSHFM6>LVUSH
MUF+I9/)CD6^4RQ0JL`20L7,L\2!75"2XQD<TS4?C[H^B&)->T3Q1ILXTR34[
MZ&YL4W:;:HSH9)MLA'+1[5"%RQ9<#&2(9_V;_!ES<:O+<)J;-K`N-^+YE-NT
MUTEVSQ$896%Q''(I))4J`..*V+SX-^'M6@U!-=DU/5FU72)-(O);R^9WEMWE
M:0C(QM8,QP5Q@``=*`.3U?\`:!_M"5-%\,Z3=Z/XJ>6036GBB!K=-/@2`SM<
MRB)F\Q=B_*J-DDX)7!Q#I/[3_ARTT_31KE_9:S/=DM=7OAU6DM+2(SF!991*
MRR+F4%2BAV!#=0,UT#?L_>&Y/,N)KWQ#+K+7D5VFNOJC_;X9(X3"FR4<!?*9
MU*XPV]B02<TFF_L^>&]'NX;S3+W78-17SS<7WVT//>&:X^T.9693D^86((`*
MAV`P#0!7UO\`:"TFT/B6VLM/UJ-]`LM2D.I3Z?OLGGLA^_B4APS,N0<84,,X
M;(.([K]HS0],LY+A]'\375H+U=/M;VWLHUM]0O-YC>"%WE4;E97!+[%.T@,Q
MXKHKOX/>'+S2-6TV=;LVNMS:A-=@7)!9KX$7&#VR"<>E9K?`705T_4].L=3\
M1V.F:M+/)-86^I'R%:?F;:C`@!V)8CLQ)7&30!L^-/B?8^!M/TRXU+3=:O+C
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M>:U;WX0Z+=^(M5UA+C4[677<'4;:WN`L-RWD&`L5VD@F,J#@C.Q">E`'(^%O
MVGO#.IP6$.N?:;.X;2Q<WMZL2_8X[B.S%W<0*=QDRD6YB2NWY2-Q;BKNC_'Y
MM:\>:%X;B\">-[./7;*XNX]1OK:"&**.(Q#>R^:6V'S5R<94E05R3C0TKX!^
M%M'CN[:P.H#3+^V^SWNF-<AK>Y0VHMFWC&[+1@;L,,L-W6K6D?!K2M&U+0]0
MBU;Q+<7N@0R6]I-=ZFTI:W=8E:!\C#)^YC/KE<DDDT`8TG[0=G9>(?%VEZIX
M7\3V_P#PC.I6VG6TR10R#5[B=(VCCMU$F=S"3(W;1M&XE>0*7C_X[RVGPFN?
M%'@71=7O-0&K1Z,UC-9*9K"[:Y6!_.B,BAMC-T5\,2HW8.X=+KOP5\/^(-6U
M34;NXU>&YU:ZM+V0VU\T8AN[4(L-Q&/X9`J*I[$<$')JQ;?"'P_:^$SX>_TV
M:REU1=5N)9KIGGN;L7*W)E>3J2954GH,#&`*`*5C\9-'@\/7M]J@U%?[&:]A
MU)GM0A66SA$EP0@=L#&<`$\\>]9X_:%T>:Q#+X?\8+J$UX]M!I1TP?:YE6%)
MVG5`^#$(I$;.[/.W;N^6M"Y^!7AN[N]=FGEUAHO$`O?M=I_:#B!6NXQ'<.B=
M%9@.O.#G&,FK>M_!_0M;N;&Z>?5K&^TZ0/:W=C?-!+&/($#(&'\+1JH(]0",
M$`T`5-1^+-OX4^%&E^,->T^_OX+C3H+NYBTZ.,/&KPB1GV2NGRJ,\9+=@":T
MO$_Q2TSPOH>BZB+'5]4_X2&5(=+L].MA)/=2/"\RJ%9E`_=QL<L0!CDBJ/BK
MX(^&_&&@:'H^K-J*VGA^V>ULVANR'\IX#;NKL<[MT9QD_-GD$&D\<?"Y/%5E
MX.TW3-3N]'M?"NI)="6UE*7!C2TF@5$?LW[U3DYR%([T`95G^TEX5U(Z?)86
M?B"XTZ\^QK=:BNG_`+C39;IQ'!#<Y;<KL[*I"JP7(+$`@UDS_M,VEWKNDV&A
M^$/%MQ8:PE\8=;>VA2V7[*,2/M,HD9%;(8X'3Y=V:V[']G#P=IC6B::NK6]E
M;&Q>:P34I#!>R6;;K>2=227<-AB<C<57=G`K2D^"GAPV6AVD$FIVJ>'S=_9&
MAO"K,ET2;B-SSN1BW3M@8(H`R='_`&A-$O3HT,UIK,ZZA'IT=UJMMIY^Q6EU
M>QQO!!(2Y=6?SH\##!=Z[F&:U_A_\9M'^(TEW_9&GZY96\%G'>P76HV@AAO+
M=V=?-B8,<@-&P.0#T.""":=G^S]X5L;VRFM&U:.WLI+"8V`U!_LUQ-8QK';2
MRI_$ZJD?<!C$A(.T5T7A;X=:-X.TVSL-&286UCIPTZ%)IC)^X#%L'/4Y)YH`
M\I\=_M1PVWA.:Y\$>'?$T^JWB6LNC&YTU?+O+6XN8K<7D8\U=\8:5,(S(Q+I
MD!6W#L-:^(]]X:\2:987MA->02^%KC5KN.&)([IYX9;>/8JM((USYS9!?`*_
M>ING_LZ^$K"WC@WZS=16MO;6MBESJ3R"QMH+E+F.&'/1/,CCSG)*QJN<`5M^
M//A'X?\`B+?V=[XA^V"[T^,);2V]QY9CQ/%.#C!!/F01GD$8R"#F@#BM._:H
MT+4=1C)T'Q%:Z!_PCDVN3ZW<11"&VCBE>*2-U$A;<'C9<J&!8C&0=U=7X7^-
MOASQ/H^IW[-=:2VCR21WEEJ`1;A"D2S?*L;.'S$RMA"3S@@'(JC!^SSX0M[&
MWLD3439Q:3=:3-`UXQ2[MKB1I9%E'\1$CLX(P03^%=+H'P_LM`T>6PAO=2O`
MZXANKJ5'FM_W8CS&X4;6PH.>I;).:`.,T7]H:#Q#XD\(Z=I7@_Q6]EXOL[J[
MM]2=;810Q0M$-[A9F.TB53D<C(!7)(6.X_:;\/6MCJ4LNB^)S?:9J!L9-,2W
M@>>1A;M<[U(F,>WR4=^7#?+C&>*T[3]GWPQ9RK-'<:T;@W%[-<3&_*M=?:XX
MH[A)`H`V,L$7"@8*9'))/+:U^S)IEI8Z;;^#K@_Z)>I<7"ZI<.PG$=D]I#AD
M`VE%92.#G:<\DF@#HM#_`&CO"^OZ_HVDVMOK$,^M);B.6:W14MYY[<7,5O+A
MRPD,1#'"LHR`6!-1?%#XWKX5TWQ;#X;TC4]2U#POILEQ<WOV8-86TXA\Y()G
MWAMS(5/RJ0-ZY()%:GA+X/6GAV]M-5GUC5+K6V@M1JMRK)%'J<\$/E>=)&%^
M4LH`(4@'8F>E2^(?@GX?\27OB"XOI]9AB\4P"+6+2VU!XX+LB$PB1D'1_+(7
M(P#L0D$J#0!@ZI^T'I?AJ^UBUU*PUO5KC3KVZB%OH^FF1XX+:*WDGD?<_(07
M*$D8R#@*2.;D7QPL8O$^HZ'#I^KZWJ5OJ3P+::18[W@MTBMW>>4O(`4!N4&5
MY.<!20:V%^#OAQ-;OM5"W?VW45O1,WVDX_TN.".;`[96VBQZ8/J:K2?`_P`/
M#Q++K]A<:UINK7$TCSW-EJ#1&9)(X4>)ATV$6T)QU!7((R:`,'QE\?(-.F\0
MZ7H^G7L&M^'KC3BXODC,%U;W-\EJTD;1R,>-SX#A3G!QBMSQC\6[71?$:^'M
M-L=4O;^*XL8[RZALS):V/VF9519G!!5F7>1@$#C<1D9HZ=^SCX-TQ;Y+=-2*
M7WE*RO>$^6D=Z;Q44XSCSR3DY)'RYQBMW5?A)HNK>+)?$,EQJ]M>79M6O(;6
M_>*WO&MGWP-+&.&*GCT(P#G`H`YS2OVF/".L7,Z6T>K+!%+`(KI[=/*N(9;D
M6RW"$.2(A*R@EPIPP8`KS0/VE_",NO0:5`FK2&:]6SDNUMT$4#/<O:PNV7#%
M))HG52JMP-Q"KS6MI_P/\.:=H>J:'%)J4FB:M;3V[Z<]R/*@CE<N?*PH92K-
M\AR=@``Q@4W2?@9X<\/W>DW7A^74].ETG3K73U:"X'^DP6[EXA,64EFRSY88
M)$C`GF@#F/#G[25A'X7TR\\4:;J<ERUH+O6;C2K/S;7287N)88I)B6W!6,+G
M"AB`K$@`9K5N/VD_"UE=ZI'J%IX@M;73(;Z0:A)89M[MK*3R[J.%@Q9FC/8J
M`1G:6P0'R_LY>#_L\<$7]L0V@M8K2\M8M1=8]0@BN&N(XYQ_&`\DG3!*NRG(
M.*SM'_9MT26VU@>+K[4=6?59]6\N(73QP6<-_<M-(L4?\+E=BEN<X.,9-`%I
M/VF/#$)F;7-.\2:%;VANH[NYU*P6.*WN+>(S26S,KMF7R09`%R"`1NSQ4EM^
MT=H%YI#75IH_B:>_&IC3%T>*TCDO'N6MS<HH"R&/YH07SOXZ-M.16QK'P0\*
M:_#=PZQ:SW4%]JMSJ=Q$\YVO/<6K6LO']TQ,0!V//6K&F?";2=.72?-OM6U!
MM#OUOK%[RY#&.5;=K<9VJH(V.Q.>K'<3F@#*\#_&J'X@^,[W0M,\->([.TMM
M(L=4BU:[BCC@E2Z1F1"N_>C?*1@KU5P<8&[)TS]HO2%L]&-]9:SJ-UJ<(GGD
MTS33Y5G`UX]JLLH:0E5$B8."QZMC&<=IH/PTTGPYXB_MC1Y]1BN&TV#3I83=
M%H9HH"YB9T[NOF.-W'!YS6?H_P`%/#.AH%T^.]4#3AIV6NF8^0+E[G'U\V1C
MGTXH`C\9_&_P]X&\26FB:RE_)=3K`]Q);QH\=C'/,887E)8'#R`J`@8\$D`#
M-9</[1WAN^CN4TG3O$>HW]M>+ISZ=;V`^T&_/FE[/#.%\Y$@>1P6"A"K;CN%
M=+KGPQTK7/%47B)KG4+'58[9+5Y;.94$\22^:BN&4YPQ8`C!`=AG!K#C_9]\
M*VJ(VFR:Q87*7L>H+=VVH,LOVQ?,!N2QR&E=)GC<D'<FU2,*,`&=X=^.3W/Q
M)U/PQJ^@:W!;?:[2"QOQ8XB@>:Q6Y\FY8OE),B0<*0/E!()&9X?VC="FMK[9
MHOB<ZA9:PFDC3$M89+BXN9(&GC$>R4H5:-&.2XQCYL5T<7PFT!1J/F_;YSJ\
MD+WCRWCLTS16WV926SG)CZG.2>:RO#'P"\*^$Q9'3?[1DDL+^VOH7GNMQ\VW
MMFMH<X`!`B<C&.3R<GF@#-?]I;PV-4T&RBTOQ+)_;HM-T_V)$CT\W,;R1K<;
MY`RG9%(S;58+L()SQ5WPO\?-$\<Z/KUWX8T_6KB?1M-748[1X8TDO[:17,,D
M.'(PYC8`.588Y49&<:Z^!%Q%\1(M:TC5(+6PS8JP=#)/]G@619;8ALHR2AR"
MQPRAFQVKM/!WPNTKP/I<NEZ/=ZI)IK6HM8K6YN`ZV\0W`*AV@\!MN6).%49X
MH`\X^'_[2\=SX-T74/'>DZ['>W]G;7^IS6NE*MOH\-W(1;>=B9V*MV9=Q*C>
MRH#@>D^&_B;9>*K/6KS2M,UK[%HTTT'VF:!(TO987=)5@R^6VO&R$MM&>A(Y
MK"F_9Z\)R1V4"MJ\-G:Z?8:?/9Q:BZPW\%DVZV6X7^/:>XP6!(.1Q6]=_"S0
M;SP%JGA">.Y_L;6)+I[I1<$2%KB9YI"K]1^\D8CTX%`$GPX^(^G_`!-T2;4M
M'M=0LEMKR:RN+:^1%EAFB(#J=CNAZ@@JQ!S765S?@?P)IG@#3KJST)KAX[V]
MEO9WN)`[R32D%VX``!P.``!V%='D>M`"T444`%%%%`!1110`4444`%%%%`!1
M110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%
M%`!1110`4444`%%%%`!1110`4444`%%%%`%/6)FMM*O)HR`\,#NF1GD*2/Y5
M\P^$_CGXT\0>$KV_L-4TK6I;VP\/7$=W!HS)%I5UJ%T(;BT(#8F\J,K)DD$9
M^;@BOJ6YACN('BG&8Y5*L/4$8(KGM$O-!T6#^P]&>VL].\.V$"HJ.!#;P@O&
MB;R<?+Y)!!Y&!ZT`>`^(_B;XX_M+5-!M?$4*ZHE[?:/)8+H.+BWMX;"29=6#
M@X^=UCP,>7B4*/F%<GI%QXK\$6W@?3]+\3MX?T];3P[)J^H)HB8G6\74'D$P
M;*C#K&">&9I,L<D5]BF>U7!,\7S1[QEQR@_B^G(YZ5RK_$[P^ND>)=1^U.8?
M"378U:,)^\B%LNZ4A,Y88Z$=>E`'%?$OQUJVB_$?2]$&H6T>B:I8/$+&T@6>
M[GN9$G(:4'#1P!8LB1,X;(88(K@?#7C?Q?X%^#^C0>(O$DDEWJ6D:,-'U"/1
M(U:P>6VE9XK@ROL*C[.!O<[BSXP2PKZ8L=1L=05#9W$4CRP),$W#>(W&5)7J
M`?>JVK:[8Z1<VMO<2@SWDPC2)<,V2&8$KG('R'GUXH`^?9?B[\0)O"MUKL)M
MK=M*\):)J5U9G22V^>^#+<2L6;*I;A&DV#D\ACBNHG\6Z]<_!>XO]4O-*UK4
M;?Q!:6D=U8[9%G@-_`N]UB.U9`C'(0E1@'U%>JQ>)]+.GP7DESY)NK?[5!!*
M-EQ(A&>(C\V>V,9SQ2:)XGT/7IYK72]0M)KVUCCDNK(2*)[82*&3S(_O(2I!
MP10!YY\'O%/B[Q1J?VOQA>V<VG:K:W4MM8QZ;Y#63V]ZT`_>9RX=`K<@<YQQ
M7DD%_P"/M8\465M;^/)IM=TKQ+XEA66YT1"ME;QQ2&"-XE(#(ZJA4MG`^[G@
MU]6M?Z>BEWO;55601%C,H`=NB9]3D<=>:DDN+1$+27$*+N*DF10,@'(^HP<^
MF#0!X9X5^*7B[5_BK;Z=?SZ/I^G)/;V\NEW"K')<PRV"S_:H6),C,9MR!0-@
M5'R=PK(^*'BN;3M4^+7A\WU_!KNO+I?_``C-FC2A[G?"D;&VQV\Q7#;2,8);
M`YKV;6_B1X7\.7UA!KVKV-I#J-I<75M>2RJMOY<+Q*^92=H.Z:,`9YR?2M>#
MQ#I\LMTOVE8X[-HPUQ+\D3F10R;'/RMD$=._%`'B7QKUZWLO'OA_6;/5H=7C
MTF06LWA9;ZZMII)VN$3S[4Q?+)<(7"&.0%2IZKDD^D_$?Q];:%X$U+5=.O)4
M,%TM@MU:6Z7!MKAYA!EE<A`J.WS%CM4`D\"NR$]J+K[/]HB^T[-_DF0;]N<;
MMO7&>,T+<V;331)<0M+;@>;&)`3&&Z;AVS[T`?-VB_$_XB^(=%T)[34+&SNH
MM%O=3O[B71O,&H&VU+[.L>`P$8DA._*YYP5XKH?`OCC5_%WQ5A36M3MQ]BO=
M8MVT`:;)%-IB0OY<3O,3AQ+'MD^8#.X;.`:]NBNK.XMS<P74$L`)S*DH91MX
M//3C%,.J::;6.X^WV?V:7`CE\]=C\[1ALX/)Q0!\]6WQ#T#0+_QAJWCR_P!<
MB^(&@7VI>5I\'GRR+8(6-MY%L"(I83#Y<F3P7+98$<5=%^)GQ%\1Z3::;IFL
M6,-_+J6M0KK<FCI,LL-G#%+"=B-Y7SL[(64D$`[>>:^EA<6YV@7$9+L47#C)
M(SD#U(P>/8UA>*O&VB^#K":YU>]B5;5X4EBB(DE3S9$C0^6#G&Z1><<`YH`\
M)\1?'CQ19^,+J/PO#/J26&B7K76B2:8H*WD-A'<H\3*QE:-VD"_,`&PRKR,U
M2U7XM:MHGA77+[2?%JZOJ>I3Q+IFMV>A)'!(8K*2X,4B2ML4D@H"A))PH&_-
M?1'B7Q;I7A30M8U75[E1!H5LUS?+"?,DBC4%LE!STR1Z]JNQZQIK6D5R;^S6
M&9_+CD^T)M=\\*#G!.>W6@#E&\4-K_PKOYC(L>L#PV)[R&#<CVTTMIY@&.JG
MG('6O*?@)IFN+XJ\1^(M:OKK6)K+PEHL%A9W-F%E0/8I,T:3'YCF13N'=FR>
M17N^C^)].UV^UFVL97+Z!?\`V&^,B[0DWE1R@`GJ-DJ<^^.U7O[1T\VT=P+Z
MU-O-((XY?/7:[$X"@YP3GC%`'SE8?&37[OPWX:N;KQOIUD/$<ADU75CX=Q'X
M<D%LTOV%D8X+%U9,R?,-A'5EQ'I?Q=^)/B5]!D#66AF^30X+NW?1'?;)J*S>
M9+\[!E$?E*RH>\F&XQ7T9I^OZ/JU_?V&F:E87=[I<@COK:&X1Y+9RH8"10<J
M<%3SZU(VK:8J>8^H683SO)W&X3'F?W,Y^][=:`/F]OB]\0Y8;=+6YLHI=*BM
MX[V231F<:C,^LS::TFW</*7RXUGVJ3S@9VYRNO\`Q=\>Z;%#I27VE6=[8ZAK
M-K)KM_9QV\&H26;QF")U8[8A)'(Q8KDD1DISQ7OVD>+=(U>[U:W@NA'+H^I_
MV;<B?]W_`*1Y:2!%)^]E9$QCUQ6ND]K//+!'/#)-`1YL0<,T>>1N'4?C0!\^
M:I\3?&0N+R:[URQ\/:3<^*WT%;[^Q_M$6EQ);F9;EG8_.9)"L(+809!Y)KGO
M'OQG\0>$U\5)X=NW75Q/%=Z;=+HX,&J)%IEI(Z,)7^1I'F^5(QOP"`,J37T\
MFI::]O+,E]9M!"66603J50KU#'.!CWZ5!JVO6.E6\$]S<(Z3O&(@C!FDWNJ!
ME&>0"ZY(Z`YH`^8O%'CW4_!'BSQO??VA<Z3;0ZEK-Q%?_8&NVA9+31O+CC1C
MLVN\CKR,9).1AJWO#'Q6\;7OBKP[IUYKOAV]A6TTMKF811P1:\+E6%Q-;MG<
M"DBLB(@P2F7.&&/=6\6Z3%XO?PU+<K%JD=E%=B*3"AXI7D1=A/WFW1/D#GIZ
MUI?VCIQ%R3>VF+(_Z2?.7]P?]O\`N_CB@#PWX1?%*YUW6/[=\<Z_IRHVC`W-
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MBF]Y%POR_NRI.XU]`QS6LUN+B*>)[=D\Q95<%"O7<&Z8]ZA;4=.2UBN&O;1;
M>4#RIC,NU\G`VMG!R2!^-`'S[J_Q-\<:#XTDT.'6K+4]6T_6+/28=&FT/RI-
M7AG@61]0$BGY$0F4?+\@$#!CDBN/\*_$>XT`Q7WAW3+GQ!XRG\)WE_JXNM9O
M6O(=4MX%:6&ZL641(GF,5CVD<#"CG-?4#^,=#:YN+>QU"WOKJQO8["[@LV$\
MEK-(5VK(JY*?>4G.,`\UJK?63K-(EY;E8'*3,)5_=L!RK'L1Z&@#YTL_B/\`
M$#6[#3M.T3Q+H$T^IW-XT.MPZ?'<M'%%8I<QK+"C>6C&0LF,D[",_/T9=?$[
MQ#:>.;K3IM3M/"-AJ4MO+-KLFE/<QB5=-MIOLP5VV@R,\V#UQ$5'S'-?06I^
M(M#T33HM0U;5=-L;&YECBBN9[E(XY'D8!%#$X)8D`>N:NQ75G).;>*Y@>81B
M4Q+("P0]&QUQGO0!Y-\._'6N>)_%?C71[_5+.YO[!&DTU;*T5K.TB,DL4(:7
M.\S$QYDB<`J0<$J17FVC_M"?$?7&E2T\.B.:>W>:PMVL)`\CZ?`_]IP\\_/=
M*D49`(P^03Q7U";FS2Y>W:Z@6=4\UXO,4.$_O$=<>]/AN+:Z@2XMKB*:%URD
MJ2!E8>H(XQ0!\WZ5\;O$<6EZA=#7=/\`$.F6<OA^>?6H=':VCM%O;K;=VS+D
MC]U!M?<?F0/\_(JOXR^)^K6WC#3=>T.\>VLM0TNXL7U5["22#3[8ZRD*W;0D
M`$K&!@M@?-N/RYKZ4_M"P,4TOVVU\J!F69Q,NU&`RP8YX..3FG1WEG+++''=
MP221*K2J)5)16'!8=@1TH`^?_%.I:C+^S?=ZA!K"#4/^$ECE.KV]G(B!5UE2
M;CR2=VS8"Q7.-N>=M<\/C?X[D%E;V>HZ.MK`U_)::]J%FMI:^(Q;W0C`^8_N
ME,;`DQY9CRO&:^H(KRRN9$$-W;RO*&9`DJL7"G:Q&.N#P?2J6H^*=!TJRBNM
M4UC3+6UENEM8IIKM%1IV;:L8).-^>,=:`/*OC7\0_%/A3Q;I.F^%[C2])LYM
M-FOENM45!!>SQRHIM6D8_(NQMQ*@N<C;T-></X]\0>#K_P`2-IBNCF\U58+B
M:W:9HC+K\<`$:LP0D1R,R*<`D#)"YKZL6YM+J22".>"62#:9(U<,R9'RY';/
M:N'\4>+/`FOV5GI>LZC8:E8ZIJQL%:WN@5AO+=7FVO(C`Q.GD,0<@@J/6@#Y
M[U?QGXKUKPIJLNL^(+.>_M8M(F;6K.S&VUV>(9$(E2)BF8X8T,B`\'>"<5/?
M_%?Q='?Z=KUG.VH26^FZGIO]N"P,5M-:C6+&$:CY)(3B-G(YV_*6^[FOJ30]
M)T3PQ;P:;H@M[19FDN(X1-N>=F8M)(2Q+.Q+$LQ))SR:O37ME#(4GN[>-E0N
M5>500J_>;'H`1D^]`'AOC'Q1XPG_`&=Y];LO$MKINO:?J<23ZOI%O'=H]LE^
ML3N5Y0-Y7S2;<J"K@''-5_!7Q9\1:O\`$?3-+EU>RU."\UF^TVZTE-(,4MM9
MV\+O%J7F@_=F(@89&PBX4+RIKWM[VTB6%#<VRM=\6ZF11YO&?E'\7'/%9/A[
MQ=I'B2VDFL+L+Y>H7.FE9L1LT]O*T<JJ#RV&1L8ZCF@#QCQC\2?&]A>:_/8Z
MC;66EP>+H_#T4ATV,C3X&@647C22,%8M(ZPC=A!D$Y-2:3\5/%-]K>EVFJ:O
MHUG<0Z#:WT-E967VB+Q/<R-,CQP3DX0*8XA\F=IER?EQ7O`N[(R2Q+<VYDC8
M1RH)%RK,.%8=B?0UDCQ?H\?B6[T*2Z2*ZL=-CU*4N-L:V\DDD8;?T^]$X([<
M>M`'SGIOQ-\>^+M"T22#4-"O-4U'5;)[/;;J)--GFLKUFAFB1OEC26*-09#N
M.7##A35VY^.OC7Q%H-AJVD+#X:TO7-6EL(+J^LD4V$EM:`RI)YI"CS+M9XPS
M<!8?ER6!KZ<2..11)&RLL@R&7!#`]\]Z4P*P(/(/:@#/\*:A<ZMX7T>^U/[(
M;R\L()KC[&Y>'S&C5F\MCR4R3@GJ,5JTE+0`4444`%%%%`!1110`4444`%%%
M%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444
M`%%%%`!1110`4444`%%%%`!1110`4444`97BG2[C6_#6JZ=IUT]C=7]E-;PW
M29W0.\;*L@QW4D'\*\!L?V>]<M]*L%;P_P"!X(K6ZTJ74=#@FD:SUH6T5Q',
MTVZ/:&8S)*N4;+1#?D\U]"ZYJBZ)HU]J$D<TR6-O).T<";I'"*6*J.[$#`'K
M7FVF?M%^&->U233=!:_O;L75G;Q[(!MD%S:-=)*#GF-8D;<>S+@9)&0#C=.^
M!OC#0M-TJ/2O^$;>;^PM8TNZA>YFCAL%O;Q+E$@^0EXXE4Q`';T4\#@4->_9
MO\0:KXB\6W5C;>%[`Z[-KDZZNCO]LNTOK%K>&TFPG$2.5D/S,,QIA<Y-6(?V
MI-9U/P9K6J:5X3U'?HAT)TO9%B\O4EOI;;<D<(E+HYCG;:&)`P,L.E>AZY\7
M+BV^$.O>,=/TB[L[S1XKH-IFK*L;QS0R&-D?8S`C()!5B"""#S0!QW@+X!ZM
MX6\:7&J:C*K7+RW;1:W9WJ)/Y4R1[8I(V@)D\LJ47=(RJJJ0H)(%M?@KK*_$
M>]UJ[M]!U!)=7-]!KMQ*ZZC';FQ^SFT*JFTH'&_[VW#$A0PS71:]\>]'\,>(
M];TC7+/4(O["T>?5I;J$P3)/!!Y?G!$20R*Z^<GRNJ[N<9Q447Q[M&N]+T^[
M\/>([#5]4U673QI]XEO"\/EI&[2LYE\LJ4FC8*K%VRP"DJ<`'A0^"NJVOBK2
MM(U704UB^TNPTO3[2]6V;RX'32I+>2Z2Y:(@0([DM$'0E@K!2Q^;V3X2?!FZ
M^'7BC5[ZXTWP^W]KZ+IMM)J-HNVY\ZWM4AE1OD!9&9-^[=SQE<\TZ3]I'0AI
M/VVWTO5YA<:I+IVFP>9;127[Q*[R.%>4>4%6-R1-L;I@'<*TK7X_Z3?ZMHMI
MI.D^(=2@U:#3KB2]@M%$5E%?LR6S3!F##<ZE2%4[<9/'-`'!3?LX:EI_A#PC
M86FC>#]<GTK0[RSU6RU'<D%QJ$\<02_#>6Q>13$5W,N[:YP01BLRU^!WBW3M
M>O='T&>RNK31/#<$]I=ZO;,]O>ZY/;I:7,A5PP93;V[,>&`>Z.0U>L>,/C%!
MX.\7W>CSV>H:G.(;!;.QL+93+/<737010[R!<'[*W4*%ZDG/%7Q-\:Y=&\+>
M#M?T?PIKFLKXMU.WL19J\-O/9-*&SYBR.!N4J5P#C(/-`'ENJ?LIZOJG@M='
MD@\,M'$-=DM[*=0T$3WEU:SVZ`+$J@*('5BJ``L"`:UO%W[.VL>)/$LVJ&RT
M0:1<O&&\/1W"I#&HT]+<,A:!T#QR)A"$&%=B"I`%=%H_[1J6,WBH>.M)U2PL
M?#]_JRPZK';(;:YBM)U3REPY;SL2(.556.[!X-;<GQK&J?"CQEXJ\/V$UMJ/
MA.SO6EL-1*,%N(;?SE1GB=D=2K(<HQZD<$$``H>#/A3J_ACXG1:['::;'I\F
ME1VU_-<W9O[N9X[>".(0R-$KQ*#&^\;RKG#;0Q:N$U#]FWQ/?0ZK#"/#EG>S
M6>NPOKL$LBW>LM?/FW^TX0$"('DEGP47;@5[)I7CF^O?B+#X>FBMEMI/"T.K
MF0`B02O.8RO7&T`>F<]ZR/@Q\3M7\=R:Q;^,H].TG6M-D7[1H*VL\-SIH9F"
MB1I#MG4[<K-'A#D@=*`"3X877AKP1XPTCX:V?A_29M9N&GTZVDM@;-&>&*.3
M?%M*X8I(2-I&6!(/(KSW2?V8+F;2+73?$UEH%SI<,GB&5=.(#Q0M?M$UMM58
MT0&/8^2JKM)RHKZ3HH`\-\%?#G4M/^-^KWEQ"P\,Z+:B\TXLC`-JM[&BWC(3
MPRJD`((Z-<R"O,H_A%JGBCX@Z^4\/"+4[O4M0*:M=6S0"TMQJ=K<*))3%NG$
MJ0XC*R/L&5PJ\+]>A0HP,_G0$`Q[=*`/F/6/V9_$>LP:S:LOAFWN+RU\012:
MVKR?:M9_M!F-NET`@(6(/@Y9_P#5KM`R<5O$?[-WB_6_"NN:1IVG^!M&TO7[
MB>9=%MD#Q:7*;.&"&>&1X"`Q=))'V(C'<N'R#GZGHH`\;U;X0ZW?^"/B9H\5
MS9+=>,]06YLI#(X6-1:VL)$A`R#N@?IG@BN9\;_LT'4+A(?#FF:0OA\2ZF?[
M$BF2TCA:[B@VSQ$PR+'*KPN-RJ"HE+*0>#]%44`>5^`OA4_@[QKXZU--)T2.
M#Q6UO/%>VS;+MF6UBBDBE8("09(VDW[B27)P#DUY3JW[-WC.^^']QX2L;7P=
M;:+*UQ]FAF2.>ZMW:VC2*>2Z-MF5UD$Q+A%E*F/Y\@Y^JJ*`/FKQA^S;K?B#
MQ5JVIW9L=5T_4[J\86!O!;M!YMM:1QW"2-#)LF#6SKN4!@K@JV<BNW^'?PQU
MSP;XH\6WL$&D6=EK2-+;222_;+M[QI9&,DD_EHYAVLF(F9]IW!2%P*]>HH`^
M:/"_[-NO`L?&$'AB2'4?$&EZEJ]A;1*+:Y%O;2QW/[I(D0B2216"LIX'S,2*
MTK;]GO5=-\0Z=)!8>&+[3K*'3(M/FN9I5GT-+2Z>1H[8!3E9(W7C<HRN&##%
M?0M%`'DWCCX*P^,_B5+XFU&RTJ[^SZ7IT&F2SIF>SN+>^>X=T;'R94H`0<G!
M!XZ\!)^SSXFU2^\4W_BBT\/W=QK\-NDT6FSI9)=2PWTDZ32*+<JR^6T:E)1+
MO*L&."*^F**`/&_%GPDU/Q5X(^'MMK6E^$M6UOP?J-G>WEO):B&SEV1-',D`
MV-Y:Y8,HVX^0#CC')2_LP7-IX*N[31K?0[77K]9FU&XA'EKJF=5%XD,[;#N5
MH]T9+*V-Q&"O%?2-%`'C%Q\'+\?!>\\*:';V5A<RZH;U+&ZO#/:S1B\6=K9S
M'$@2*10R%$CVH'P`0.?,?$OP(UV75;73+?PQX6N+/67\07$.E.SG2]$\^&SB
MM^1'CS`8Y)0%11N9]I!&:^M:88E.<CKUH`^<[']FW5M)MM9LM*70+:74==T?
M4QKT*F.[F%K%;I,)`$R6WPR2J=YRTIS@Y-4=&_9FUQ;2S@U&Q\*:?!;6FC6>
MHV]B[M'K9M+Q9KFZG!107DC4J`P8G>P9L5].=*6@#QCQ=\"H=4^$EMX2TK1_
M#L\>DZ]'J>GZ?>Q9M!$FH&X\D95M@,3-'PI`W$8Q6;H?P0UNR^)-EK=S9^&X
M$M?$ESJ[ZQ;N_P!NFM9+9HH].(V#]U&SXY;;MAC(4$G'O-%`'S[XB^!>OZH?
M&R06'A6>]U_4WO;37+EW%U-;&2"0:=/A-PA*Q/"<,5V$'9G(K>\(?"W5/"?A
M_P`8N5MM&AUB[N[RS\/:&5:TMXVM4A6+F,'<S1F0B,(-TAZ]3[)2$9&#TH`^
M5_A[^SIK&H:/X?O-?T7P[I%E-'H$FIZ(N]_MWV6*8W$UTI0*T\AG565@<B+Y
MF-7;_P#9K\1W2:G!91^&;"Y>VU]%UNWDD2ZU7[<&%K'<`("JPAQ_$^/*38!V
M^FP`HP.E+0!\XZQ^S#=^5J9\&_V)X=OKG6YYK*_M(C')9V$NE&V:%=H!`-P?
M-*`@'[V=U5)/V:]1OM.NI+GPSX#M-E]H-S;Z!!E[*1K%V:YD9FBPKS"1DR$)
M*HNXG)Q],T4`>(_"#X*ZA\/_`!?=ZKK$%M-<RB_0ZE;WH!NXY[E9HQ+$(59G
M0?(&>1MH7"X#$#(L/V:HOM4-AJGA[P@^@P^.KS7IXD@4B_MIX;I8TDB\L#?&
MUP@`)884D$<"OH6B@#Y\T3]GO4=(\=:1JMW#:7UIID.DK9S1WPAETX6D1BDA
M0F%G:%AAM@D0,7<,.AK3\3_`)O%/Q+G\1:M::)?6<^O6-R4NT\R0V,5A)#+;
MD%<;7F9'*9VMM!/(`KW"B@#Y>O\`]FCQ/-HL6F2)X9U%O[#CTNPOKN23S/#A
MCO9I%FM/D)SY$J*`I0AH$&=O2U-^S;K<GBZ;5-16RU6SN-0N[J");_[-)IS/
MJDEVDD3F%V5FCD"OL*',2KN*DX^EZ*`/GG2O@AXET;PWIUO;:5X2;6]&U^TU
M*;54G>.;7_)N)7+W#^665RC@\E_F+`'&*J^*/V>O%'B/4+#4+R71)?L]K8I>
MZ:LA,%Z8[V\FEC/F1.I3;=(R[T;+Q#(`YKZ0HH`YGX:^&3X-\#:1HK1/`=/@
M,8B:\-T4&XD+YFU,@`X&%``X`P!73444`%%%%`!1110`4444`%%%%`!1110`
M4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1
M110`4444`%%%%`!1110`4444`%%%%`!1110`R5=Z%<`YZ@UYUX4^`7@WP1>V
M-UX:TDVLVFVUW;6[?:7?"7,ADDSN)R068*3]U6*C`->D44`>;V7P#\*:=:/:
M65O?QV<L&G0R6O\`:$GEO]A:-K9RN?OKY,8+=PN#UK9\2_#+2/%?A^ZT35A?
MC3+Z]:[NX;:]>#[0S.7='92"8V)Y3H177T4`>9R_L^^$9KK6YI;2]8:_#>PW
M41OG\M4O71[H1C/R%WC1B>V.,"M;Q1\)M%\81O#K1U%K2>ZCN;FUAO7CAN73
MRMGF*.H'D1^G\7]XUVU%`'FS?`;PY+J,VIS2:U)K,MY#=#57U-VN8VB22-%5
M^R;)9%*X((;G.!C=L_AOI-I?->L+RXNY8+"":XN+MI'E6SD:2`L3U8.[$G^+
M/-=910!R6K_#/0]:\51>(+ZVE?4H9+21)!.R@-;&?R3M'''VF;/KN&>@IVM_
M#?1]>\.66CW:WD4&FWL=[9RVUV\4T$Z.75U<'.<LWM@D5U=%`'$7/P@\-WNE
MZEIM[8O-9ZM+>RW4;W#'>]V09R#G()(!&/ND9&*OV?@&Q@\.:AH>I2W^M:;J
MD3PW4>J71N#)$\8C:/)QA2HZ#N2>IKJ**`.#\,_!_1_"G[S3KG7I[HI;P_;+
MW5YKB<6\#;H[<.Q)$62<K_%D[LU-HWPJTS1-0GOK:[UR:^G2"+[3=:K+-)'!
M%*9%@1F.1&68[E_B'!R`*[:B@`HHHH`****`"BBB@`HHHH`****`"BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB
M@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`
M"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*
M***`"BBB@`HHHH`9+*L$;22D*BC+,3@`=R:Y'2OC!X,UO['_`&9XBTR4:C>+
M966Z;9]JN&B\Y8H]V-[F(A\#/RL#W%=;/"MQ$T<@#(X(96&00>H->'_&;X(M
MXF'AFV\`:=I>E?V+<7=[%-"JP+:WBV?EV<H`Y.)(X5)'(1<=!0!ZG/\`$'PW
M;:CK%A<:WID5[X?M8[O58)+E5:R@D#%)),GY5(5L$^E81^//@`:7;:B?%.EB
MRO+L6<,I=OFG*E@A&,@[59N0!@$]*\9/P6\;WES=>(M0T_27\1:O;:;J>K6,
MEZIM[J]@U)KA['S`O,:P"*-'(()1<]ZU%T7XGQ>)].\0ZAH6LZ[:Z5XE:[L=
M)OM5TY;N&WDTV>&4"2/9&4$TRA0S%MH/-`'M&H_$[PKI,VC1:AKVF1-XA*_V
M6?M`9;L-C:489&TD@`D@$D#.:NCQKH1GU>+^U]-WZ`JMJH^U)_H*LI93-S\F
M5!/..!FOG.V^"/C*RL?$^G+I&G+'X_TMK>1K>_0Q>'I7U&YN&3!"EU2*ZRK1
MCEXL84$-7;VNB^(K#Q[\3;QO`)NM)U[3;6*P87]GC4IK?S5;<A;Y2_G!@7'\
M!S@XH`]97Q9I3Z!'KD5[#+I$T"W$5Y"3(DD38VNNW.0<C&/6M56W#)!'L:\3
ML/"?BRX_9>L_"ITN31/%=CHEMIRV_P#:$9_>0^6I=9HVVA6"DCG.#@\U=^$_
MA7Q%X2N_&/VO3IQ'?S_:K"]U2^62ZOIV,I99O+=D$:YB56`5BN<K\H)`/8:*
M\$^#O@[Q3X0T;QS=^++$:.VM6T-S#96]WYR0W0M6%R8P))"%,I&TYRP`)`/%
M<'\-?A9XK\1^%]"GN=/U73-$UNW\/3ZU:W>OR22ZDZQ3-?W3#?NC\Q984*9#
M-L.5&*`/K>HKJYCL[>2>X;;%"A=VQ]U0,DU\OWOPC^(&_6/[#M;NPUB2VUZ*
M?6E\1'R]4CE5QID21;OD,0>/EE4)Y)P6W5IGX(>)-'O+BY\-K=PRPZ[.ECOU
MN601Z3-I921`KN1\U\=YR-V?F!`H`^@IM>L;?28=3EN`MC.(FCFVM@B0J$XQ
MGDLO;O6A7RYIOPF\?6MO?006=Y)<WUCI(N=3O]74S+-;7-D9((&20@P>7%<-
M\ZJV>,L'J3Q[\.M=\->%_&?B5Y-1AU;4)=7BEGBU65U:RFU")[,%`V%18=P.
MT*55G&1DF@#Z?HKY=LK"70/V8_&L'A*WUF&XCUNX,/DW+_O6:[C)%I*'9C`%
M;RU;/&PYZ5>T#X,>*9+RWCFM;C1="M;W6+O2M,GUQ[D:8[I:BQ+E6.\":.XF
MV994WX]J`/I2JNFZG;ZO:_:+"3S(A+)$6P1\Z.4<<^C*1^%?+5A\(?'<5K;J
M=#U"#23#I:^)-$;Q29'U^X1I?MD\<F_"[MT1Y9#($*D"NFT[P)XXT&2P73M)
MN);:YT.:PDA?Q"LAL9&U)IP[NW,I\AL;E!)(VDC.:`/H2:YBMS&)Y$C\UPB;
MV"[F/11GJ?:I:^5?$'P+U;Q(;>[\5>#YM=UO3?&!U*[U$^(2%U.R%U*8EAC,
M@",D#HNTA-OED`G.:]-\9^$M8U?XHZ3JLNC7&MZ)9Z=$NGHFL&T&EWZSEGGD
M0,-ZM$R`$;S^Z*[?GS0!Z[574]3MM'L9+O4)/*MX<;WP3C)`'3W(KYG\._"/
MQU?G66\0:8-)@\0:KHESJ5A9ZNRQ$1S3G4O+(E9MC1R1KG*LX'W1BKNH_!_Q
M);:A8VD&F7^K:3IMG!!HLO\`PDC1'2&COY7D,@9LRA[9H5&=Y(B*';G-`'T`
M_B;3H]-NK]I_]$LI9(KB78WR.C['&,9X88K0N;J*TA,MS(D42_>>1@JKVY)]
MZ^9;_P"$WC:[\1:K)K>FW>KV-SJ%Y/HLL/B+[.-*,FI32EW3/SK);/$H7#8$
M90A0V:S/''P.\8^/[OQW-K7A^R6+6K%T2SBU0I!?W,6H));2#]ZV&-LARS!`
M&<KC'-`'UB#D4M>`>'?AIX@M/BQ!K=W;ZS;:=;W%N=+^SWT31VE@+(1M8SJ9
M2=J2@L=BMO8JV[@T>*O`OC/7/C-_;EEIL%G86,5U:P7UM?E#=VKZ>Z1B13)G
M>+IQ\HC``16W$T`>_P!5-+U2VUFR2[TZ3S;>4L$?!&=I*GK[@BOG2#X*^(=$
M\/:):QV&H:Q;7#Z;=>*])_X2)T>_N%LYH[AUD9^HG,$C`,H?R\CI@]+K'@'Q
M!<?#'P7HLVG7&HV^G:@K^(]&36-LUY:;9AL^T942E9'B<Y*[]ASUQ0![C2,V
MT$GM7S;X7^#'BR=]+N?&K7S2Z+96LNEQKK\DALKA=4GG,3,&'F%+1X82S9#!
M64$UT/P:^'GB/PGXLU/4/%SZM+=727<=[=&ZC>TU(FZ#P3;?,:0.(LJHVH$4
MLO/!H`]=?Q/I<>K6.FO>0_;=2$YM(@V[S?(($H!'&5+`$?X5HSS);0O+,RI'
M&I9W9@`JCDDD]`*^4=-_9A=Y!IMSX<?3M.M-4\1W;7%MK3)YYNSNLI$*R;U*
M@@$'&&7)!X-:7C/X.^,O'OBC6#JNE6D=C<Z!J&DM<KJ3!-0C>RC6U,V)"2XN
M`^[Y%"A006W&@#Z>C<2HKH0589!!R"*=7AVJ^!?$]G\$O#6G_#*P.@^)?#OD
MM!I=QJ0\MLJT,ZO*"ZL-LKR+G/S*O`/3A%^"/CM=+LK/Q!>7^MV&DW\6E&V%
M_F74=(@BF$%P^Z509?-F5F4LI;RE/8`@'TYJVO6&AR:?'JEREN^JW8L[-6S^
M^F*.X0>^V-S^%:%>'?$3X;ZIXF^&/@'2;G3=3\2R>']2LKG5K.[U.."[NHH[
M>6-]TRLJ&3<ZDX8!N>:Y+P?\)/'MCXB\+WGC.75IUTJ#3_L3Z?J<<O\`9:QS
MR&:UD:21?,4PM$CR!7+A2`00#0!]!:!XST?Q3D^'[V.^4*S%HPV`%EDA;DCM
M)%(OU4UN5\HO\$O'B16]O-$[Z*)P=2TN#4%_TR%M2U29E"^8@R$NK20@LN[8
M4SD8KH9?A-XY%SX<L='U/4X=(OM.MSKMUJ6H*UU9W5B)6M251BK^8\D(?:2-
MMN`<YR`#Z)N)X[6WEFG;9%"A=V]%`R33;*\BU"T@NK1M\%Q&LD3X(W*PR#@\
M]#7AWPD^'7B+POX,\26FK1ZS:ZMJFCQ1O%<WT<D,E^(95EGB=9';<[%"SMMS
MA,*"#2_#/P'XH\.?$'3+_5[&ZN86\/6]IJ5_?Z@LOV66*V@016H23+(\BRL_
MF)D,"RL=V*`/=J*^9M5^!7B;6+W7[J\%\\^IQ>(I$*Z]*@:=KI7T<[5<!1&F
M\C`PI)SS44/PU^(VGZGK^LW,%UK'B.YCNUB>34(TL=0MI84\NWF`E#KY9+JJ
MJJC>F[?AC0!]/55L]3MK^XNX;20226,ODW``(V/M5L<]?E93QZU\TZ3\!_$E
M_H%AHWB&.]BT2VD\0S16J:PT+0><\+:=_JY#@H5D(`9@A[GBNCU/X2^(?%&N
M30>)A<W'AZ^\2/=7D2:N\9DL_P"QXH5'R,&Q]KCW;0>HW8H`]YGF2WB>24A4
MC4LS$X"@=23V%9GA;Q5IWC/1XM5\/2RW&GW!/D3O`\0E4'&Y0X!*GJ&`PP((
M)!!KY/O?!<FN?%*+2?%]OJFK7-DEOIL,:WTDDOS:*48R_O%!M/-+L7"D^;SN
MYQ7=>!/A?XJ^'4/A_2M#T1CIK>&="LKTQZR!'8W=M<O+>-M8DL65^-F0VTC(
M&*`/;-`\?:!XHO9;30-2@O;F"(RRQ1YRJ":2`GD=I894/NAKH:^2=:^'GC/X
M<6.H>+]-L_\`B<:*K/I%M!=@_;IY]8OV%NX7.5>"^C//`?&2-I(^EO`'AU_"
M7@S1]'GN9KV?3K..&>YF<N\\H7]XY)[L^X_C0!T%%%%`!1110`4444`%%%%`
M!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%
M%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110!7O
MKV'3;.:ZO9$AMK:-I)I7;"QHH)9B>P`!->5VOQ]TO4KMY=)AN?L376G6\?VV
MPN;>>4W;S!3'&R98,D2LAP`V[DBO3M<TBU\0:-?:7JJ>99:C;26URFXKNCD4
MJPR.F037!:9\#["SATZ+4O$'B'5WTNYTZ>V>]FB+(MBSF!/DC7C]X=QZMUS0
M!YAX0_:SG\1ZMI#:UHEWH.C7UKJ&JWE]=Z-=JEII]NXC1=^-ID+-EI,;/NH%
MW,*]0M/V@/"5VEFL;ZL+R[O'LQ8/I4RW,,D:QNYEB*YC58Y8Y"S8`1MV:@/[
M/'AF70HM(NIM2GLHM`O-$VO*N3!<S),[YV_?5XU*GH,<@U=T;X+Z7IU]I]W>
M7L]_+IRW:*OV6WMDE6XBCBE$BPQH&)$0.3SECVP``4[?]HWP5=V4US;7.IR[
M)H([>!=*G\Z]$X<V[P1[=TB2^5($8#!*FLV7]IGP]<2:I'H]AK;1V'A=?$*:
ME=Z7-%9&!A)A7?:65@8V!&W.05&2"*O^&_V?=$\-VND6MMJ%]+:Z#>VEU8(8
M+:-U-L)1$LDD<2M(-LI7YB3A1R#DF;5O@1I.J?;T;5=8@M]5\/R:'?01O&5G
MMV>5U;)0E75IY,$$`Y&0<4`5O''[1GAWP%!K@U73O$MQ>:%9)>R6MMI$I-S`
MTB1F2!B`KHKRH&(/&X5K1_'#PLWB"VT6>:^M+ZX"*WVNPEACMYWA\Y;>60KM
MCG,0+^63D`<XKG/^&7_#;G7S/J>NRG7[&ZLF=I8_,@CN+A;AB'V;F*R(H7>6
MVJ`N,5LP_`S2X_$EWK,NH74\^JF-]42:TMF^URK;^0T@?RM\1>/:&\ME'RC&
M.<@$WA7XO:5XXO\`4V\/1:A-8:=IL5\K/ITT,MRCM)L>)'4&1'6/*,OWLUR/
MPZ_:6TOQ!X8L-8\:07FCS:M#<:C!;#2K@"STZ,G,\[,"`J]#)PI+`**[OP!\
M+[;X>P+#!KFMZK%;V$&GVJZC+&PMK:'=Y:+L1<D!L%CDG`R:R(/@!X870TTB
M>;4KFQ_X1>7PV5:X`+VLC[RV0`?,R."./:@!3^T-X16RDFE_MR&ZCN8[;^S)
M=%N4O7DECDEB"P%-[!XXI&4@8PAZ8-;'A#XO^&/')O/^$>O)GCL[.*],MU:2
M6R36LH8I<1&11OB.QQO'`*D>E8MA\"]-@UB'5M9U[7M8UB"\M[HWEW+$&806
MLUM'&51%4*%N9G.!DNY)..*TO#?P:T/PW#;PV\M]<Q0>%X/#>R>0$/:1%R"<
M`'>=Y!(]N!0!23X_^&)=-@OK>W\1S1WTVS3H(]!NC/J"!/,,T$>S=)"$^8N!
MC&.Y`,<O[1G@=)[..UO[W4/[0@@FMI+'3+BX23[0A>W0,J?ZR4*VQ#R2K<#%
M10?`B*SL=#CL_&'BJ*\\,1/;:1?>9;M):VS0^282#%L<;0AW,I;=&ISP<OT+
M]GSPSX>?3O[)N-42+2YM,EMXWN`_-A%)%%N)7)W"5BWJ<8Q0`Z7]HOP5#'I<
MKWE^T6JP0SB1-,G9;.*65H4>Y(7]P/.1HSOQM88/0XS_`!#^T_X.T+1M<O[:
M/6]6&A1><T-CIDC->1"80/+;D@++&DK!6<'`)'/(K,'[-$$GB:YWZWJ</ABX
MLH$GLH94$M[*NHW-ZZRL4R(]\Z@;"K$!@3SFMF#]G+0+7P_K6A6U]?0Z1K%O
M/`L,-O;)+:++,)L),(O,8(P^4.S#'!!QF@"S-\?-!TRWOIM8BU%&AU#[%;6-
MMIEQ->/(+2.Z9&A";A(L;EB!D`*<G((%FV^/7A2^\3:/H>GOJEY<ZXT26MQ!
MIDS6RR26WVI(Y)=NU',&)-IY"D9J73_@YIEAKD.LW&HZI>:E'JTFJO+*\:B:
MX>P%DQ*JH`4QKNP,?-[<5Q^B_!36-#^*4.NZ7=6*:;%<VQ$TQ$TS6D5B+8P>
M6T?R.64-YJR#@L-O)!`.N;XD:MJ6O:S#X6T2SO='\-736>JW=QJ!@E-P(DE9
M8(_+(=461=Q9ER20,XR>>\%?'+6M:TC2)/$7A6&#4?$OAI]>T.'3M3$T5W&B
MQL\#O(B>5(HGASD%3N;!^7!Z*7X/01^+-4UG1_$7B'2+;795GU;2;22'[+>3
MB,1^:=T;.C%%0-L90VP9&<DY7AC]G^W\,:5';0^+?%-[=6&C'1M'O;I[=GTF
MU.S(A00A-Q\M`7=6)"@=J`,'Q%^TN^C^#O"^MVNB:?YNN^&)?$ES;7^L+:K'
M;1+$7@AD*$2SGSE"J=H.TDD5Z'XJ^)VB>%=-T^XU=[O=JG_'M;6=I)=SL`F^
M1O+C#$*B?,S8P![D"N<M_@%:K\/=.\%7_B77M0T&QL6T]X[F*U,EQ;$*HC+B
M$%<("FY<':QR2<$;7B/X1Z3K%]I>H:1=7GAK4=(EE:&[T@11.Z31B.5'W(P;
M<`O)&X%5(/J`8MA\>=(M]-^TZ]D,;72VBM]/MYKF::>]@:6.)4"98ML(7!/O
MBK)_:'\%+<7\4E]>1?8%<AGT^8"[:.589([<[?WTB32)&53)W,!S4MI\#-#M
M+^SO([S57ELY]+F0O,IW-80R10[OEYRLC%O4XQBLN7]F[03%J5O::CJ-G:WU
M[)?0+;PVRRV5RURER'CF\KS,+,F\(S,O)!!&``!7_:3\-6OB&YTS5=+\5Z8M
MIH\>IS7=[H<T,:+)*\2Q$$;O-,B;`N/F8A1DU8U+]HCPI:^'1J5M)J$EQ(MV
M/L7]F3M/:O;8$QN(U4M"B,R!F;`&\>M)XG^`.G^,)9IO$&OZ]<W%YIBV%Y(3
M!^_$=PUS!)CR\*T4KEE``7``8,!3[CX#V4[6DT&OZSIM];PWEJ]SID-K:>=;
M710R0E$BV#YHT8.%W@C[QS0!>U/XM6GA_P`0^#=!O]+UJZO_`!I;/+!/8V+3
M6]N416;S''W1\XY[#DX%<SX"_::\/>(_!4>KZW;ZGIE\EO;/-9?V9<$W$D[O
M'&MKE,SAI(W4%<\J<\<UW6J_#BUU/4_"M_'J&H6=UX3WK;-"4(GBDC6.2.0,
MIR&55Y&",<&N?NOV?_#]SX2TO0?M.HB'18;5+"X8QR/$UO*98W(9"C'+,I!4
M@J2,=Z`+NE?''POKL]E!H9U74;B^LI+T0VNES2/!$C2QOYH"_NV$L$D6T\[U
MVBLZ;]H_P=#H<.J2_P!N;9I+N(V:Z+</=1-:E?M.^$*641A@S$C&/6I9_@-I
M%WIFK6D^I:I&^L:,NDS368AM#'$MQ+.K1K$BHK!IF'3!`&0223S5Y^S8(KS2
M;;P]X@U'2].C_ME]4GMQ#'<ROJ`AW+$HB\M$_=MT`*_+B@#<O/VC?"6D2:@V
MJ7OFV]M/F)M/M9KEOLHMH+A[F0!/EB5+A&+Y*@,O.<@=9X?^).B^*/$&J:/H
M+75Y-HX47=U':O\`94D95;RA-C:9`KHQ7.<,#7%3_LR>&5O_`+=I5S?65TH:
M-&>*"[1(#:V]MY6R:-U*A;6%P2"=RDY()%:=_P#"*:'Q3<>)/#WB&[L-8N($
MM`WV6`11V_F0M)E$1?-?9"41I"VP2-CTH`U-`\3^(H[O7;OQQIEAHNA:<DDM
MM<^<2[1++-\[C)``@2)S_M.P[50N?CSX;M/"%CXGNK;Q#%H6H3"..[?19]J(
M<;9W^7Y86W*0_0@_6N]O;7[;I\T`=K<S1,@=55BF01D!@02,]P1[5XU=?LH^
M'=0M_(O=;UZ2.22=YXE-ND)$K0L1'$(MD&#`F#&JD;I.?F-`&WK?QXT/1;35
MOM\CO>V%]?VT4%E9SW)5;4+YDLP5,I&I=`S_`'1N&":=X\^,<_@NX\&V_P!@
MTR/_`(2I"S7^J:@UE9PN!&1;B41N/.DWGRU;:#L;G/!6]^`6E2ZI<ZEIFN>(
M=(OKZXU![J>RGC!EBO3&TT.&1@%W0QLI`W*1UYK<\:_#.+QGX?AT.76M6T_2
MOL9LKNVMA"RW<)"C#>9&VUL+@,N"-QQSC`!0G^.GA>!-1E_XFTL&GW`M%GAT
MFXDCOKGS#$8+5@F)Y!("A"9P0>P)'/WG[4GAB'47M+#2?%NIF'1;S5)Y+71)
MB(/LK[)K>0,`4E5OE((P#@$\C-^']GS3+/25TO3M?\1VFG6.J_VKH]ND\3#2
M[GSS.3&60EU+LXVR%OE=AZ8?IOP`T?3KF.YBUC79;B>TU*VU266:-CJ2W\@E
MG,GR?*=Z@KLVX``Y%`#/%'[0&E>&?A/HOQ!OK&^L=$U2[LDG348'MYK6"XD5
M3(T>"25!W`#[W&#SFII/CIIGAZULQ\0K2ZT74;B#[9=6]M!+>II=H\C+!+=R
MQIMBW``'/`8,,D*6K3G^$&F:CX%T3PKK][?:OI^AW%K*CW:Q%KE;=@8XY0$"
MLA`"L-HR/K7.W'[-^CS6TEFGB+Q/%97FGQ:9J%N+J-OMMC%.\L-NS%-RJ@D>
M(,I#&-B"2<&@#4D_:%\$P7.JQ3W]U&FDI(\EPUC+Y5R(YE@E,#[<3;)71&V9
MP6'6JT_[0GAR*+3KN3[9;V=ZEZK6]UI\\5Z+BVGA@,"P%,ES+,J!20267;D$
MD1Q_LZ:!%:ZG96][>Q:;J5Q).+>.WME>!GNDN2JS"+S2GF)PK,1AB.<+B#XK
M_`F#QII[3Z5<2'4HYY76&XG\N&5)[FVFG0L$8KD6JJIP<;CD&@#N?`7CS3?B
M-H*ZOX?COXK1KB>W*7UF]K*DD,C12*T;@$8=&'X&O,T_:;BF\+^/+U/#TD>L
M^$M7ETW3M,EO5']KGSGA@E5]N$5Y(9@1@E1$YYKK/A9X)\1>$(XH-<UBSDTZ
MWCN5ATVUM$41F6Y,D9>4*N]DCPNX*N\L[,,XJ@O[./A<>(+363-JQO+0:F`/
MM($<IOI996+IMPQC:>;RR?N^8W6@"76?BOJS>'OAW>>$M%L+N^\?O#LM[^_:
M".V1K-[ILNL;DL%CVCY0"3G@5U/P^\;1^//#YU'[%/IES;W=Q97ME.P9K>Y@
MD:*5-PX=0RG##J"#@=*YG5/@G%>:1X:L-,\5>(M)/A#[/_9$]K]F9[<16KVQ
MSOB8-O1R6R#SC&.E7+;X;W'ACP]'IG@?7[^P)D+3W%VB73RRR7`FN+AR5RTS
M@R+DG:-_W>!0!A_%[XY2_"WQ19V+:=IUUI_]BW.JWLD^H&"X=8IHHEAMH]A$
MLS-,,*2N<8!R:M_#WXWV'BWQ;K'AB[LKZRU33]3OK6V8V4HM[F.V9,XF*[/,
M"R(60'C/UKK[SP-IM_XWL_%-T'DU&PTV73X$8*T:I)+'*7`(R'#1+@@]":S[
M'X86.E&]DTN_U&VN;S4K[41.K(S0SW2E7*@J1A>J@@\]<T`<IJ'QMU/1O%'B
M5=1\/V\GA7PWK=GH]QJ%M?%KI)+B.!EE,!C"F,/<QJ=KE@,M@XQ7K:MG[W!K
MS.Z^!-A?>*=1U6_\0>(9M.U;4K;4[W0_,A6TN+JW2)(W?$?F%?W$;%-^TE>1
MVKJ]*T?5K+7O.N];FO\`2UM#&EM+`@=IVE9S*SJ!P$VQJH'0$G)YH`Z.BDR,
MXSS2T`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!
M1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%
M%%`!1110`4444`4=<D:'1KZ2-BCI;2,K`X((4D&OF?X<>(?B%X4^&_AC5([@
M2V_BV#0;'3G\0:C)JDOVR[5C<WC$$,L9WQ[8=_5#]S-?4<@5EP_0\8]:B-O;
M^5'$8XA'$08TV#"$=,#MCVH`\!TSXX>.;V]\3B"P\+3+I4>IV]O:W=['820W
M=G(J1F4O.24F#>9RB!%,>7.[=6')^T)JL>I:*;/4=&,VKV,5E<:Q>VTUO8V-
MR;^>"222W$Q7:K0^6&$F&9E^?:17TC)H.F2RRS3V-G++<)LED>W1FD4\;6)&
M2.!P?05F37>@V]T=(NK>W4L8;<6_V/<G[P.R)@*0%/EN><`$>I%`'AFD_&WQ
M7!>:+IFB+X:O1*CZA=W$MT%AU))-4FMY%M9I)4V+&H5L[9#EXUQSDUO&'QB^
M(\G@#7M?TG4/"VCPK'<R:=+_`&=+-):"TU1+24R[I-KAT)?(`V8(YZU]"BWT
MG4=0DL[FUM)KG3ECE"R6ZGRA(6VE21@9,9Z>E6UCTVYEGLD-I+)"H\^V&TE%
MDR?F3L&P>HYP:`/)/C?\9-1^&?@33KK1=3T6[\07%A<7T9:Q:6UU!+:$23!#
MYZB,-N7;\[M@\*^#5/4?C-XOM-8\17]M8Z-<^'O#D]Q:/IZ12F]N94TH7Z,D
M@;:!N/E[=I)'.<\5[3)I%A-!#'+:6LD-L0T*-"K+&0."H(P./2H[^>PT>W:Z
MO`(8UE3<Z0ECO<A%R%!/\0&>PZ\4`>/^`?B!KWB#1_&VL0:AX<\3ZI:Z':W6
MG)H3N;>21H)I8XBC,V'W%5.&^8;20I.!P_B/Q=H=Q\%H=6\-_$?4M5U'5;C1
M'UMSXE-NUN);RW2<M@[K'(9D91M"@D;<BOI^VT^SL4"64$-L@SA88@@ZYZ`>
M]0C0=+$5Q&MA9".Z?=<(+9,3-ZN,?,?<T`?.VH>)=`\^[TSQ'X_O?#WA[2/#
M4.I:!>VOBMY&OIC).+B879):[,3K$@C.X#<,H<BNEU3XM>)M%\'_``YM]5N]
M!\.ZYXFT9[O5-3U^!_LUO-!;1RR0E%=,2/N<_>X6-S@XQ7IGB&[\+>'='NKG
M6ETJ&T\/VC7TL;0(QM(!DM*(P,J,JW(')4^E;<UC9ZM:1B^A@O(7`D59HQ(N
M>Q`(QW_6@#P?]G_7?$?Q$^(WB/Q9XLN;6*VFT'239Z4D,RG3Q<VZSL@+/M(W
M9))C#$XY`&#X_9_%CQO>?`Z;P[-XCUL^*(-'/BLZ^'\N=M*,9E11)MP3]J'V
M?`Y\M3GK7VM:7=C=W-]':']]:RB*Z_=%/FV*P&2!N&UAR,CMZBDCBTQYGLX_
ML32QP+OM@$W+$Q(7*]0I*G'&"0:`/G_Q3^TQJ>@>+/$L.D_V9JND:1I=^RI)
M9O!):W=G);12>8XE)>(&=F)\M/EC)4L.:UM8^,/BS12(;*_\)>)?[+\.ZEKN
MH7>EVLI6]6UD11;0J)6V.WFJ"Q9\;>`<\>VKI=C'/+*EM;K-,,3.L*AI!C&&
M.,GCCFLZ2^T71-9TS1HEMK6^O[>>2R@C@";HHBAEVD#``,B$COF@#YWU/XV:
MSK5U;:+XB\1:*-`EN[$ZGXJ\,2/:101W=M<S16K2LSB$F2*!3,&!VS*<(6%5
M=#^/WB*SM8-)\%V,`-D]\\C^(/$$>I)>-;20HUM!?-+&NT+)N,A\PKW4\U]0
MPZ/IL=I);6]G:):RY\R!(5"/GKN4#!SQUIC:!I3V\5O)I]BT$!+11-;(4C)/
M)48P#GTH`\7U_P"*_BY[WQH\4>B)X=T635M,2%5F2\,UOIXNDF\U7``))0J`
M",!@V>!FZ'\;_%.K^&M8O=$NO!\=UIJK8VFA7\QBO%E4P!KF26695=668NJ'
M;N#1CS,L37T&;&V8-NBCPY)<&,?,2,$GCG(XK-UJTT6PM)[O5+.R:-A'#*SV
MJN7!9513QR,E<#H.*`*'PT\;V?CKPAI.I6NI6FHSW=E'<2O#`;8L&+`/Y+,S
M1JQ1\9)^Z<$]:X'XWZ'<>%M'\8^/F\9:GIAT_0+LV%D]PL5M%<BTDC@*Y/+^
M8Y91SEW'7"X]>M+2WM\&WABB8*(SLC"\+T7CL,G`[5C:1XGT7QS)JEK8C[?:
MZ3>&UN))K1O)>>,_,(V8;9-C`J2N0K*1U%`'DUY\<M3TWXAZ!X<TN>QO;4VR
MVNK03V;+/!<_V;)>+(LIE&\$(@($6WYR-^[BLR7XW^/;+X?KX@U9O!]O'J%G
MINJQSI$X_LZQN()I95,,DR&YDC\C@(ZE@S$*2N#]!/IUC]I-R]O;FX*;#,85
MW[?3=C.*2?1]/NXECNK2UFB3&R.2!65<=,`C`QDT`?/NN_M':[I5WKD2-H3.
M\EI_8\:0&5(+.:XB@-]<R>>`N&E&8)!$RG`W$9:KL7QC\?W-U96BP>$X9].T
M]+_5SEIUNXO[1DM2L)BE98G,:>9@M)M;Y#GDCW0Z+IH-PQLK3-YQ<GR%_?\`
ML_'S=>].M]-T^S3R[6UM;=%7&V.%4`&2<<#&,Y/UYH`\N^+/Q3\2>#?$6HVW
MABRL+RTT+PI/X@NX987DGN_+=T$$95@$R<,6(;`4C'.1Q-]\?/&%AI%C%J&H
M^`]/GU&YN_(UVZ8-:-!%9)=*6BCN6V,VYHP#)DKAP.=M>Z^$_%.D^.M,_MC0
M-]Q:2.\,-U):M$+A%/WHRP!>(GD,/E;J,URMBO@'QAXHL;>SAL+C5-!:]DAM
MTM_+6,K)]EN6*8"L0ZA.<XX(H`\VF_:%\8W6@7>M6^GZ-IMK!_8MJT%S!([6
MD^HP6TIFE=I(U$<1F9=IVEB5RRXYU'^.'BK29_"?_"2P>'[>&_\`.@NUL)$O
M9K^[$\L4$,4<<Y,(D$8;?^^5&+(Q&W)]SET^UFCFCD@AE6<8E1XU(D'3Y@1S
MQCK6=HMIHNH6MO?:99V86%I$MY%M51HBKLKA>,K\P;IUZ]Z`/"?#/QW\=^(]
M%TB2./PE'<>*;[3X=.NA^\6S%U#<.Z2P).SL8C``&8Q[R6&U=IIEK\6?B*GB
M+56N=4\&R2IX*L=1M-#DC^RK)>R330RNEQ+*,H&BW;6QD-&N5.6/T-;Z-IMK
M(\EI96<,COO9XX%4LW/S$@=>3S[GUK-N+G0;SQ+_`&%>Q6<VIC3S=K;RVP8_
M9C($)!(QMWXR*`/(_%GQ4\1W_P`+O`GB'P=XGT.Q.J>([6PU74;S1F6WDC:5
MXI!Y;3?NQO3&=[9_A;!!K`T[XH>-O`UMX]UACINOZ'9:MXB:PLG27[7#);2J
MR9DWE3!AI,J`-JJ,$Y./I!M,L9+06C6UNUJBA1;F)?+`'0;<8].U0V$NGZBD
MYL55E@N)(9<P%/W@.'Z@9^HX/J:`/'=1^)/B*3X&>-M9UXZ1/J.B*_V.ZTNY
M\N.ZBV1.KD132-"W[PC'F9(4-QNQ6!K_`,==:CUW6-1A?0KM/#$VNI;^'+=Y
M%U#=91.JO,-V&208D'RKM4I@MG(^A;?2=.L[9H+2TM8+=S\T,<*JC'W4#!Z#
M\J>+"R\^2=8+?SIL"201KO?`P,G&3QQS0!\V>)_VC_%/AKP/<7-Q=>%Y==B:
M:]L#!;K-!JEE%!%*X(2Z(@?,ZJ,N[,,,(^3CM-*\=:AX9\(?&OQ`&-]+X9UN
M\N+*WN96,:+'IMI*(AW5-Q8X']XFO3[S2]"TC3)[F?3["&SLE:Z<):)A-BDE
MP`O7:.HYXIVK>']-\5^'-2TG5K<2:;KEJ\-W$I,9ECD3:P)7!!*G&>M`'SEX
MA_:?\0:)X;\1)%J?A._US2)I9M/N[&PDELM1ACL5NI;?)G4)(GF*A8.Q.1B/
M.0-/XA?%;Q].^IW7AC6O#'A?2M$\4Z-I,\MYIKW3NET+1Y))',JJD:BY*GC)
M"GYE-?0,?A_2H[2&V6PLS;P-OCB-NI56_O`8X;WZU/-IMG-#+%/!!)%/CS8W
MB5EDZ?>!'/0=?04`>`W?QU\::3I'B3Q!)9^'K_1M..KVUE;6\,J3++8WB0>?
M(Y?:T3*S2,`%VA/O')(UM(^*?C?49O#&CN?#":CK6M7EK)J4:>?$]K;VZW`D
M$,4[[)&!9-AD..'[A:]J^PVH4HL,2H=P*!`%.[[V1COWIEII=AIRHMC:6MLD
M;,R+%`J!21R0`."1UH`^=/'GBWQ/X0^-7BK6#JVD-I]E::)IFF)?6\XATG^T
M)Y$>XE*S!&4&/+$J"?W8W(`2>B\`_&'Q7XW\5Z7H4+^&C%#-JAO]4M[>62+4
M(;&YAAW6R[_D\SSNI9PIC;&[M['K$NFV=I+-JZ1F"X:.&7,!D\S>P158`$D9
M;'(P,D],U6U;5=&\(6]C)>FWL8IKF'3[4K#@"29PL<8VC@,V!Z9Q0!\^>,_&
M?CF;6O'&F1^*=$6;2?'6A6NAVL=B\4EI#/):-F;;)NEB(E92,#<0W(!P+'B'
MXM>--#O+1)%\.G6TT6Y^VW/GO':IY.IFW>:."29%D;RT+B,N&))4,1P??4O-
M'N-,;7=D30/;"=K@VI\PQH"P.TKOXP2!C/H,U8DT[3-5M4>XM;:YAF4.OG6Z
MMD-\PX8>IS]?>@#RCQ_\9;[2O#/@>\\-ZOX:L(_&$$LW]LZW;R1VT2)9FY#^
M5YBL-^W;M+9&[N1@\M%^T-XMU#1I=7^S>']$LHX]"MY%O8)G%K<:G%`YGE?>
MH6&'S&^4@%LC+)CGW75_!>B^(+_2;S5K**ZET2222R5^4C:2,QME.A^4D<CC
MM6I+IUM.LRSP0R+<#$RO&")1C&&!'(QQS0!\OZS^T-XBU;2]7T:34?!MA)86
M>I[]7D,T4&N+;RB#%D=_R/ELGF3#``9!)'9ZO^T)-H%MXPC\O3+S5/#6H:G'
M!I<;-]HGMK6Q6='902W+L`6Q@CI7M(T6P$<$?V.U\NUSY">2N(LC!VC'R\>E
M/33+6.>2>.WA6>4`/*(P';`P,MC)P.*`/"=-^(7B^Z^)_@.QD\<>!-0T36;3
M4'O1INFL$O)(_LSQQQR-.VV39/P`3D`DJ<X7WY"64$]ZI1:%I\"0I!96D:6[
M^9"J0*!$YZLHQP>>HYJ\J[0`.U`"T444`%%%%`!1110`4444`%%%%`!1110`
M4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1
M110`4444`%%%%`!1110`4444`%%%%`!1110!E^*;&^U/PUJMIH=T++4;JRFB
ML[DC(@F9&"/^#$'\*^:_%'P4\6ZM\+K3PUX?\&:/I,TT$SW\LFL_:)AJ0MT2
M*\21C\H,GF%FP9.%;`)-?3'B#51H6B7VHFVN[P6-N\YM[2/S)90JD[47NQQ@
M"N`\'_'W2/%VF>%9X-%\3VM]XKT\:A;Z?+IK-+!;<`S2%25$>60!L\[UP.:`
M.1U7X(>(+_5O$VMV,XLO$]Y=W4>C:K_:$G^C6DNDB!5*@X"B[_>8QG/S]:PO
M^%)>+W\-"V\(Z9!X*O);^VG51KKW8@=+&ZB>;./^>\T;[1G=@N?F)%>BC]H_
MPNVBO?+8^)FN4U&;3CI2:0[WAN(H1.ZB-<YQ"PDSG&`>_%9WCK]I?2-"\,>)
M-1\(Z9K7B&Y\/:3%?2"WL',*--&DD,<C<%3LE20C'W<]P10!Q#?!OQ2O@N]T
MO3O!FDV=MK#V2:EIUSK/VXDQP3^9/$7(16,[1'DG(+/C?Q5)?V=/$^GVFN26
M&F61UW6?"NA6MSJT6H[9;F:S*B]MG9OFQ.BA?,Z8ZXKU30/CWI!;3]/\2IJT
M6I2!+6[O/[%EM[1-0,/FFT));9-LYV%CCH6SQ39OVF?!UO86-[<Q>(8K348#
M=P3-H\V#9[D079`&1"6DC`;&3O&!0!:^$NF7G@BV7PL^CZS:V2_:;Y+BZFAD
MAM5>?$=LGE\`8+LJ#.Q5P3R*\!\"?#_4?$>H>(/L.GWI\0:FD1NKR65XD6.'
M6Q*\5PSG<;AH1@8X9(L>F?H#4_CQX=T[P9=^);NQ\1"RTR]EL]2@_LQQ<:>\
M8W.TT9(*J$P^><JRD9S6`O[2NER:??:C/HOB#3+/1_$,NDSOJ&GOFZ\N&65F
MMPA.X[8B<-C`('4@4`<?/\"O',^AZG::E/'?0:;J5CIVEV:WW_(2T&WEDD*R
MEN!(WG*&5N&^S*"<-6IHWP$U)]0T^ZU2&^>/0K'3AHOVW5MTUG<1:C/+-_JB
M$Q]G>)!U^0"/L<][KO[07A'0_/42ZAJ,L,R1)'I]H9C.6MUN6,?0,$A='8YP
M`ZCJ0*T?$'QE\.Z%I.BZA!_:6LQ>(;7[;I\6D6+W4LUJ$1VN-@&1&JR(23_>
M``).*`/-_BO\#KWQ/XV\9:SH?A_3KFZ\4>`Y-%@U-[L126]T!<##`\[726-=
MPZ;#FL[Q5^SM?06MIIOA:QD/A=-1GN+C1H-0&=\EC#&MPGG-MW)/%(0I/64R
M#D5Z3;?M!>#[[6K2PL9]1N(+R*.0:I'82?8HA):_:XQ),1A2T`+C/I@X.,QC
MX_Z"^EVMY%I/BV1]1D8:=9KH<IN+Z%45VN8H\9:$*RDL<=0,9(!`./M?@QK^
MI:U9)XI674-"/B6*^O(+S4S(\ULFC1VZB7;@.WVN,.0/E)&_':F_$CX+:KJO
MCSQOK_A/1;-=3\3>#$TVRUE+WR)K6[C,V0>X#*\0#+T\OM6[8_M'Z1<:UJ,-
MO;WNL6<BV,N@IH]E)<W6H13VHG>3RL`A44Y).,9`ZD`RW7[47@N.>R&FIK^K
M6E_")([ZPTJ26!2;5KL1LQP0_D(S[<9QQUXH`Y'Q!\%?%#_$/3)O!6G:1X?T
MK08WATO4[6<B1()+&X1UE!)=B+N97"@;2%W$EJPC\!_%CQ^#)M%\/6.A'0XY
MSXBL6UMIQK[2):B56D^\HE,4AW9!8JN\88BO:]2^,>C0^'?$^L:+%J&LP^%=
M/CO;F*Q@W-.)+?ST2,G`9O+*L?0.N:X^P_:3MYO$VBVNI:!XALM+U_0['489
M7TQVELGN;J2W47(7*QQDK'AN^_/0'`!J_$GX7ZIXW\4VEW9NEI;V/AJ_@L)S
M.P%EJCM%]FN!&IPQ0"4ACG&>.M>9:1\"?$-E8:/%?^&[C4=(CN!-K/ANXUZ-
M()[@VFP3Q%.NV498R'+E@^-RXKU-?VD?!)EU53<Z@$TQ2RR_87*7JBX6V9K?
M&3(%G=(S@=6&,CFKMS\<]!TW5DT_7K'Q!H\SZ--JRM?Z<T:&&&,23)D$_O$4
MY*^Q`)-`'E5]\%_&T_B#4KJSL(;34Y;G5I&\0+KLC&\LYK.6.SLC'U'ER2QC
M+#:OV?>"6<U9?X$:SINNZ6+30[>_LX+#2C:W7]N20G2;N*=I+]RAR93/N!)Y
MW[,-@8-=H_[27AAO)FDEN])MX;TQ7ZZO836TB0?8YKI)T&.4>.%F5CU`(X;B
MK=O^T;X4NK*WDMX=<>_N=4738M)&GM]L:8Q"8?N\_=\DB3.?N]L\4`<K\8_A
M5XH\8>,[V]T:QBOEN=/L8="U(ZN]HWAVYCN':XF"+RV^-T.5R3Y6P\'-3^'O
M@6/#'PA\7>&].TI["X\0:W?7+)HUXD4LL$EZSQ?/)E?]055E/!7<O?->C>-_
MB=I7@"721K]OJOV?5[N*U6[M[,R0V\DDB1IYK?P@O(HZ'KZ5AG]H/PDE[J\$
MYUB&+1TN"]W)IDH@N7@N%MY8H'Q^\D69T3:.27&,\X`.'\+^`/'NDWVGFYT+
M2+>WN])TFTN8;'4_*@TW[)J$TSA8SN+%H9$X4XW!AD`"LBT^"OB:/PW9VFL>
M&+34KQ-9CG\4R?V^P_X2R%3.H<YP%P9(I=C[1\OE]`*]%O?CI!IGPY\6>,Y]
M&UVXL_#-PZ-ID=BT5Z`D43.KQN1@JSMDYQM&1D55TW]H"W/Q#E\/:YHNNV%M
M<6^FO:7,FFR#[+)=K*1'=D96%MT6!SWY]:`.*N/@GXDD\6:CJ4]GK$*2P*FF
M2Z1KL44EC:G3C`UCYL@+;4E!8$##,RN<%2*@T;X*>)H[CPJFH>&=,:UTJYFM
M'MI[R,VD6GR3-OG:)#D7K1]6C)1MVT@"O0K3]HSPUKSP)X=FGWRZA80H;RTD
MC%U;7<IBCN(<9W(S(X5C@9'.!@UM6WQN\.7/@1_%Y758=%::.&R>:P=)-0:0
MJ(C;H>7#LX53QDY[<T`>2^#_`((>*_AYHWAS3?#.BZ>L/_")Q:9J21:IY,=M
M>"Z262;&#OR@(!7N,'`.0W7_`(2>(]`?Q7XEG2./^S[?5]3TQK:=FD-S_:HO
MK9-J@DAT3:P`/WBN#FO4(/VA/"%Q'HQ$NHK-KTCP6%NUDWF2W,=P+>6W`_YZ
MQNV67/"AFY`)JL?VE/!:2WRW$FKV\=JDK6\\VFRK'J+17"VTB6S8_>NL[I&0
M.[#&1S0!S-Q\-/$FH?"+PG9WU@-7U"75UUCQ;H\VHFW%]]H$LDUOYG0B.6:,
MA20I$`6L&W^!GBB/7?#ESJ-K>O9Z59V@LH['6$>32)XK^264"67!=98I$5W`
M+,L;(?O`UZ)_PT+X9N=.A;1HM6FO;BUO)VMCI[DV(M6*3FYVY\M4?:K<GEAC
M.:=9?M$>%'O[+3[RYN?M5Q:QR2W,5J_V9)VM?M0M]YY\PPY<+CIU(/%`'F6K
M_`3QM=RZI;RSI>:)I&HP6^B6(ON=0TB2Y>XN8I=W`92\485CAEM5!.'($VL_
M`WQ5+'X=^P6DU]I>FZ7#9:EIFHZLBSWUNNH&5K4R(-NWRBI`SM(C$9."37I%
MG^T3X8U#2WO+&R\33RM<Q065BNC2BYU'S86FCDMXR/GC:)'?=P`$.<5I:=\;
M_#&I^,H/#-N^H)?W#^2DDUFT</VD0^>;4L>DPBRY7'&""<C%`'SQK/P@\87M
MW:>&AHLLUS)HVJW.CHVN2BW\-22ZDK6;^</OR6\3\*N2`"%XKN+GX!Z_X@US
M5I/%*"ZLB^L76F%=4D0Q7<MY%+:2@*1M9463G^'<1WKO=7^.VC>%Y-6&L1:C
M>RV>L7&GV]II.GRW,\K06\<\GR8Y*QR%B1Q@<<\5<\7_`!EL_#6J^#;&TT;7
MM6'C8R?8KNQL]\5NJPF4-+D@@;><8R`"3TH`\F^$6B;?CYJ^KZGIVH2ZE-+K
M<1O$5_\`1XOML9C%T7ZDHJB';P$##L*2X^"_C[6-8\9ZC<V&FZ3<>([:*"8:
M=?F%+IDU19?-!4[@3:#!9B&W$J,#%=EX)_::T37/`5IK7B33M;T[4I;:Q8Z>
M--E!O)KI7\L6>[_6H3%*`<C`0DX'-;7C7XTQ6GPLT_QAX".G7L>JW]G9VS:F
M\D$,1FNEMW,NU2P\MBP(`/*D4`>?^*O@'J\,B:=X?T2/4_#4%OJD>E:>=>DM
M!I-S/*DD-RIY)`'F(%&2@.`,,:[?XB^`M6\1>,_"U_<:+#XET/3+":)]/?4S
M:?9+XR0M%=C'#[421>/F7=P.36SX'^,&F>(?AX_BO7IK/3+:W6\DN-MP9%$5
MM+(CS("`^PB/<`RAAG!&:SKO]H_PMIOV1=:M?$>DRW)W2Q7VDR0O9P%Q&EQ,
M#]R)G8!6Y).>/E;`!Y5)\"O'DEOJJVEK'8:Q<:9J=OJ6LQZ\^=?GFNHVM9"@
MYC,<:L<M@INVKQ72:3\!M7\-ZZ+WP];QVBIK.K11[=2D8)I$UDZV\`5B0%%S
MY;[0/E(+9ZYZ_P`$_%W4/$_Q(N_#5U8VD5O:MK`$\;-O;[%=V\*<'CYEN"3[
MJ,=:8O[3?@QY9%1-?,,)5GN?[(E\E8/-,+W)?&!"DH*,YZ$'J!F@#SW0_P!G
M;Q'H\-K=6:I;ZU9R>'Y[:[.JRR^3<(`NK2X8D%I%+`D@^9Q[8K^%_P!GOQ'%
MHMEIVO6]Z6N+[2SXCWZNAMM42&2;[3,`A\QGE5E+%R"RE4Q\O/IWQ%^.]EX.
M3Q5I]E87QU[P_H-QJ]LEY;-':WT<(3?LD!YP9$!X'7C.*J2_M(:#I5[)9ZG#
MJM]=)K$FGR+I6G23+:_Z:;.)IF.-N^8%,C()!QQC(!RMO\&_$EOIVNVT&B6L
M6N7.NQ7"^(5UEO\`3K%-3BN(H3'U01VZF/:<`>7A<AS6;X;^"WC=[W4=0UG2
M])TR?4]<T'4;FUM+L>09K6[EENYD7)ZH\>"QWMMYQ@5ZUI?QPT#6]1U>STFS
M\07,FDVUS.)%TN01WGV>7R9TMW.!(Z284CCD^F367+^TKX1CT33M36'Q#,FH
MI<R&WATF26:UCMI_(N))D7.Q8Y"`QYZC&:`/++?X'>+C+I<=_P"&K1M1TWX?
M7.DPZ_#K8$C:C-;R1_O0?F94^1$8=#*['H*MZ[\'-<\/>'?%OB6[2[/B)(=0
M2SN;/4I6F%DVEI&D2JI[7*LX`&0<MU->O/\`&[P^FKW5F8-;-K9ZC'ILFK#3
M7^P_:FF$)C$W0E965&/0'//!Q;N_BIHZ>#+OQ18VNK:IIME=3VY%E9F260Q3
M-$[HI(R@9&^;/(&:`.*_9>T.RT+0/$T6F:?):+<:T)VGC0K:7!-M`/\`1@3N
M$:[2"#T?S*]JKS&X_:&\'VT2SI)JL]JVDVNJR7,.GR/'#!=#_10[8X>5LJB=
M2P(P*6\_:#\,V7@^#Q--;ZZ=,-^]C?%-/+/IDR-M<7"@_)M)&<9]LT`>FT4S
M>&0L#@>OI7B<'[1IB\4^&-$U;25@GU75M3TW69([C<ND-;2,D#,",L)CLP<8
MP^>G4`]OHKR/P=^T5HNMR:!8Z[%-8ZMKRPL%@C:6WM6N5,EI#)+T$LD)1L`$
M9;J,C-W7?C7;^%_'FL:#JME>7GV:WL6TRVTNU>YN[Z2=;AI%6,=D2W+$\``G
M/;(!Z?17F$7[17@V\EL/[/GU6ZL[P6_G:A#IDK6]@UQ)Y<,=P^W]T[O\N".#
MC.`0:N?!SXK1_%#1I9O)"WMC-<07YMU+6\,D=Q+$(_,/63;&KLO\.\9QD4`>
MAT444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!
M1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%
M%%`$%[;+>6TD$@RDRE'&<94C!_0UYS8_`30[+08]*DO]<N8(?#4WAN%Y+P++
M'82%/E5U53O41J%;J`.<GFNY\427T/AO5)-#EMX-1CLY6M9+E"\:2!#M+J""
M0#C(!%?+7@;XV^*_!GP_T?\`M.X\-ZG<VFA:3K6J_;;NZ^UZPVIR$*+7?(V'
M4CGAE+,%54&*`/;_``Q\"-!\+7%I<64^HRW%GJ<VI*TDD:AYY+06C95$50OD
MJN``/F&>>:K:U^SWH/B"XD?5;W6)8CH\FDQPI/'&L=NZ1(WS+&&<XA4C>6"E
MF(`S7(>)_P!H#Q!X5M-;US4=.T:3PUIWB*[\/P+&\OVG[5&D@MV=B=FV6<0P
MA0,@R`YYP,#6/VI=>A\#:AJ]O9Z)INJ6%LX&GWMO<3?:+RSM6FU*`,KIL6-O
M+17.>I.&Z``]8N_@9HM[K\^IS7FM".XU4ZO)IBW@%J;XP>1Y^W;NSMYV[MNX
M;MN:2^^`?AN_TFQTZ=]3\C3_``_#H416Y`;[+%+%*I)V\ON@3YO3/'-<7KWQ
MR\26=_J7]GP>&K.PAU;3M%M[C47F(BNKRVAN!-,P90(564IM&"S%/F7N>(OB
M%XNTWX*VFO\`AO5_#%OJ\WBI+2ZN[II+VQ$,NJ&!O+<,IV`,,$GA00,'!`!T
M_C#]G+PUXTGU"74Y]7B.J7-W<7:PW*;7-S;Q6\JA60A?W<*;6'S*=Q##)K3M
M?@EHMO>-*USJ<T!UX:XEG+.K0I=&%XGP-F=CJ[$J21G&,5QVC_''6+WQ]9:7
M*OAJ;2[SQ)<>'OLD$\HU".:&W>5KO!8KY#;`0N,A9$;><XK(\:?M/ZCX-\:Z
MKH%QH=O.VB27"7CK*^4$L2OI1X_Y^)/,B/'#(<>X!V6F_LV>%M$T'2=+T=]1
M@&B7]Q>V=W)+'<3`SJ4>-O,1E>,)L15*\"*/GY:W?$?PCLO$::0YU;7-,O\`
M1=/GT^#4-/N$BFDMYHT25'&PISY<;9"C:R@KC&*\[T3X\>(KCQ):V>KQ>&&A
MNK_4]*>QM)I1?6ES80222SR`L5,+M%P,`A9HCN;=6%H_QL\53?$'X?2:Z^FV
ML7Q`\,174*1&;[!IZS31R1>;EB7G*%HE8;5+L!P."`>NZ3\$/#6BZ?=:?8P7
M*V%W]F5[9K@L@2"T%I&@R,X\D`'G)/.:SXO@/9PV.CQ1>)O%\=UX?@DMM,OQ
M?QF>WMI(1$T()CVLI"HV64MNC5MV17!_#_XT^+=>BT==/M-%;2K6WTN35VO;
MJ>2ZD6^FGB7RG)P"AB!.\'<&QQC)W?@K\5_&'Q.MM=OKZT\/+9)IMO<Z/':"
M9)/M$HE)@F+N=P39'^\55#;R0.,4`:]M^S=X;TJZL[OPS?:_H5[IUO%;6EU8
MWHWPPQVOV;9\ZL&!0*26!.]58$$5B^&/V>;GP7X\L]0\+7=G9Z+8RVJ1"1C<
M3M9PV?D&V970\LWS^:'!Y88Y.>6\/?M3ZKXUGDL=)T2VMS>QK]DG>:0<06\C
M:J"1T:"9/)'(^9@2.!GGY_BS\0M7M&AL]=\.VD8'@Z?2;9A.+E6OI8/,\^7S
M-TL1RZOQD@@`CG(![?\`#'X,6W@?X97OA34Y?M8UE[Q]2DBE?D7!9?*1F^;9
M'#LB0GD+&M7=(^#>EZ4L9>^U>]GBTBUT@3W-PI<VUO,TT6=J`;@S$$XY`'UK
MFO&'C_7-*_9]\4Z[KUYINC^)--L-1MQ<V4Q6#[7"\L2-#YISEB@(4Y.3CG%<
M[X@_:,U#0O$^OVFGC2=7TK1M!U6Z&(9H)X[W3XH6EADD+E7!,I&51<8'+4`=
MM;_L_:#:6-WI]M<ZC'I=W=?:19IY*"%_M:78"R"+S"HE085F("L1Z8H^)OV=
M=*U:\\3:OIMY>QZUKMEJ4</VF57@@FO+98';A/,*8C0A=Q"_-M`S6#K7QD\9
M^%-/CE\5Q>$;2&#5@NI:K#Y\D%M8M!!*A\@R"5G+3&,LNX+M#%<-@9VH?M"^
M);6\NM)6TT&#7KC7DL;.U,<MQ'86SBY,,T\B2A)S+]F(4(T9#-M89'(!UUO^
MS1X=N]*$'BNZU;7;N<)]LGN[L'S`ME)9K$`%`$:QSRD`#.YMQ)-7]2^`NG:M
MX2E\-W^LZU)IT[`RE4M8Y7`B$?WE@&&P-WF##AB2&'2N<T#XP^,M<\4:=;-I
M'A^RLK9=(&N0R73S3JU^KC$#HQCPCQYYW;@V,@C)K?%+XP>*OA]\3-<MTOO"
MO_"/6F@Z;/9V=[%)%,+BZO'MC,\H?'E1D!WPO"+V.30!W/C/X(Z)XZU_3]7U
MJ?45FT^&WA6*&=?+=8+A;B/.Y6*L)$7+(5+#Y3D4:C\#M`U/P_=Z/<2:HMM=
M7%[<^9%=[)8IKFZ6Z:1&`X99D1D],8.:YW2_BQXFO_`/C&[M++0-6\0^%=7.
ME126-T8[&^?;`3(GF."-OG%3'YF2\14-D\<A<_M!ZBJM>:)=Z/>G4-/T1(]0
M>.Z%G')<SWL<D@M=_F8!ML8#!CG)8A1D`]>D^%=C>>#=?\-ZQJ&L:I;>)EE&
MHW=W=@W#F2-8VVLJ@)A47``P/2ELOA986M]>7MS=ZCJ%YJ*V"W<UU,I,WV,L
M8B0J@9.]MV``?:O-/`OQC\?>(]3T>#6M-\*VT<*Z5_;\<$TQD5[]'*BW(=E_
M=E5R&+;LG&W'/G/_``L3Q?>ZYKFNW6HP'1]`T8M:6"7]XDRO+K-S:-(9!(%8
MD0#[RG:H55V_,2`>\:-\`-`T33;+3;:ZU-M.TN[M;FQMR85\@VTK20KO6(.Z
MC=M^=F.U0,]SIWGP=T2\^'6F^"V-V-+TB&U2RG\U3/"ULRM#(&*E2P*#JI!Y
MR.:\ZA^/FKWOA"?6QJ/@VRGUF^-KX?TUH;BYN()%EE5HKM%D7YRL+G(,85E(
M.<<KX8^.'B_QC)X?ET;3O#<%I<Z1H.H:LMS),T@_M-WBVP8.`(V3=\V=P..#
MS0!W5U\$-'U"[T6[U&\U6:\\.RM-I<R210?9)6E\QI$2.-4#%<Q$X_U;,O\`
M$2>3T/\`9?TY]#>V\:ZIJ6IWGF7QM##<!8=,6?4#>!K="G$FY8,E]_,>!P<'
M@?"7Q@\?7$>D:SK>HZ)KFH6^BZ]<W6GZ:DEO!)%::C:QMOC+G]\L/G%#QU`(
MY)/H-_\`'34G^%D?B[0[.PF@USQ"-.T&>0.T/V-YS##>388$JY4N`I7(DC&1
MG-`'8P?![2TEGFN[F^N9[C2+S26;]U"HMKJ17D`2.-5#`J,''`ZYJA8_`/0-
M,O+B;3;C4;:*]MXH+J`>2XF\NU^RA][1EU8Q!`VU@"8U..N>07XZ^)K36?!&
MD:OI.B6][XK)BNY!>%DTUHKIHFDDVLP"3QKB)2V1,?+8FL'1?VF]8O=XU67P
MG9#5]-,^C_9UN+M[*X^W):1P7:*X+&5GRN"F-C`YQNH`]8O/@MI$UMHB6%]K
M&G77AQ;5=,O;6Y42PB"!X%^\I5@T4LBL"I!W9X(I^@_!_3O#?BB?6]+O=06>
M[G6YNHI?)D6>80"%I&=HS("RJK-M<`LN<<D'S'P_\?O&/B?3]`GTG3?#2/+I
M$>J:R+B2?#1C4'M)$M\,=IPAD!8MS\O.=PZ#X>?$_5?'OQ!M1<7.APZ4ZZO'
M;Z=:7CF^@-M<QP?Z5&3C)P6!`&W=MP<[J`.S3X0:+'X@;60U]]L;4[O42/M'
MR>=<VJ6TG&/N^6BX'8Y-6]<^&FGZRGAC;=ZE93>$Y-UA-;3*&93"T+H^Y2&5
MHV(/`/<$5X7%\0?B7K4FF0IKWA-M:C^)>H:/;116\\4(MH8;X!+I%D+./W:,
MN"I.T$D]:Z;0/CEXLUWQEI.E1Z+I,=LL&E_VPAG99,WD6]IK>1G4>5&V5`*,
MSE6`P10!V=Q\!_#UQX;T;1=]^D'A^&QCTZ;S4>2$VA<Q-\Z%6)$DBME2&5B,
M5HZW\*[77_!5KX<N]3U:VCL[N"[M[ZR:&"XBFAF$T;KMC\L88#C9C`_&N!\2
M_%O6)/B)<Z392:-%IOA_7K>RFL3=NFIWKFT%SOC3.UHF#>6%QDE6;/RXK*\/
M?M%>(F\'#Q=XOTS1K;PS'_9]Y=WEM*P-G87/F+)N4R,Q>!Q&6D(56!?"@H:`
M/2M/^"/ANS\'ZKX=N8)]0AUP7?\`:5_=RAKNZ:Z):=S*JJ5+%B?EP!Q@52;X
M%64FJ6FJ7.O>(+O5;:T%F]]=M;SR30*RLB,'A*C:5)#*`V9)#DEJ\_T+X\^,
M_$NKQV4^@Z98VWV:W:_B,C1W$,=Y;M/#.CM(!A%*(5VLSNLF-NW%9W@O]H#7
MXM#\*PRRZ+>06MIX;L]2CU"YD&J:G-J,4/\`I$&#M*KYA8Y5M_ER\KMS0![5
MX?\`A3I'AKQ9/XBTYKPZA<&^+"2?='_IDT4TWRX_OP)CG@9ZYK&'[/GAD:/>
M::'U3[-?Z-+I$N;H;OL\ER]PV#M^]OD;!],#%>8V'[3?B6YADE-GX4N6O[**
M?3X+:ZF+V+-JD&G[+PY/WC.9%VA3^[=<-C-3ZC^T?XM\+Z5-?>(=*\.W<;+J
MUG`-/:=2MWIUTMO+/)O;BW8,TFT?,BKRQSP`=Y<_LV>&+R_U^ZN;C6';Q';:
MA;W2FY3]VE\Z/<!&V;OO1IMW%@@&%P.*PM;_`&=;U/'`UKP=J-O9++-]J\^\
M;SI+2X>_:ZG9(S&R.KARH!*E=JG)P,4;SXS_`!`CMH+*WTKPLFM0V6J:A/+<
M2RK!=6UD;<_NXTD9HGD%Q@;V;;LR00P%=!X$^(?B>>X^*5QXQN]$U*U\(ZG<
M)IMAI5N\5TL$=LDP63<YW;@X`.`2V[M@``WM3^!F@:EX8DT)YM5BM'FNIE>.
MY`=7N+Q;Q^JD$>:B_*005RI!!--T3X%:!H-NB6;Z@S)8:C9[GF4;DOK@7%P<
M*@`/F*-N``H.`*\0\5?%_P`;^/=.TK0=+U+PA`=9N=`NYKS2;BZ*"TU"X=!9
MNR2JZR#RP6=74LC'"IUKN?C?\1=9^&GQ(\(:A_;$EKX4T?1[N^\3V@0-'+:^
M?:V[3L<%QY/G^;P>BMG-`'6Z[\$HY/#/C#3/#FJ:C"GB>&]>&RNKLFTLKNY(
M=IT"KO!$H\P#<=K,VW&:M7WP/T?4?`?ACPO-<7\5KX5$1M9H73=*Z0M$6E5E
M9'W"1V.5^\0PP0#7@UC\3O%>H>+=4T_Q5XCU72]$\47T-Y$T5U%:OIT4MC+/
M:Z?%<,-L!F$:$N3G<'`(+5KV'CZ#Q->^#(M5\;>)?!VF1VOB%9I[OQ';,[75
MG<6T2[YES%<(FZ0J#NR#DY(H`];_`.&?/#`T"_T=?[0%I?Z5IFFEC<!GACT_
M<;61"5P)%9MQ)!!*C([&MXD_9TT'Q9;VT6NZAJ\PMXKF`^4;>%7BGDCD9=B1
M!5(:%,.H#@%AN(8UY'X:^*GBKQ,;/6=8UVZM/$NGWV@6MKH-LWDV^HVUZL9G
MFDMCDMN1II`V?D\KC&UL[P^(]^WP&^+%]#\1$DU;PUJ.L"TUE)K4R1+%EH(P
MN/+4-MV+QG'3)YH`^B;&PDM([D2W5Q<FXF:5?.8$1`X^1<`?*,<9R>>M>=:_
M^SKX5\1WWC"ZO?[32;QL+4Z@8KO`@>W*E'MU((B8E5+$#YBH)JQXL^(J:%\.
M]+U32-6TQKW66MK73+BXC>\@N+B4?=Q$Z[LA7YW@`CKVKA/#'QX\6^+U\,W&
MEZ;X=@M;G0]$U76EGDF,A2_N9+=DM\'"E#&7&_.?N^X`/1X?@_I-EXP;Q%I4
MEQI]S-]E^T6\*0M%,;=/+C/SQLZ'RPJ$HRY"+Z5%XC^"VE>(O%P\4?;M8TS7
MXS`8+VPN50P^5'-'@*R,I#)<2!@P.?E(P17+?"'XHZK\2/%]I=7]QH,>GW>C
MWMS::?87CM<VH6ZABV7<;$CS5PWS#&"77'&3[90!Y)8_LU>&M+C@M].O/$$&
MGAK%[VQ&H;HM1DM)/,ADG)4L7WX+;64-M7(P*Z3X=?"31/A?+J#>%6O88]5D
M:>\ADGWI+.TCN9L8X<[]I(QD*N02,UV]%`!1110`4444`%%%%`!1110`4444
M`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`
M4444`%%%%`!1110`4444`%%%%`!1110`4444`(RAU*L`5(P0>]9\GAS299K.
M672].>73E"V;M:H6MP.@C./E`P.F.E3:M%+/I=W':_ZZ2!UCYQ\Q4@?K7S=X
M=^!_B_1;.QO&_M#^V;)?#=U'))KTDH%ZLF-9D*E]K%XC@Y!#``*!B@#Z2.EV
M;1/$UI;&.2;SG0Q+AI-P;>1CEL@'/7(S66VE^'=2O9],GT[2YY[5Q>RV\EFC
M!'E+8EY7&YBKY/7@YKYY?X6_$C4[[Q??6MBGAS5-?6T^RSVNJ$P6M_%?R.+T
M*9',BK`8V*E5\SF/:!S6A!\'O%VI76B6FL07T>A^5I$&LP-KC,TRP_VA]L)9
M6#,'>:W;C!8,!_"0`#WS6H-%M+&1-:M;$VFHS10S1RVZND\C%4C#+@[N=@&>
MF!Z5;DT73YM.;3YK"R>P==K6K0*8B,YP4QCKSTKYPT7X/>/-'T[0P3?RW%S8
MZ-)XC\S6VE:XO+;4(WF(9G_Y]?,7Y<!AA3GBL+3_`(*>+Y_"]E;S^'-<T*"X
MU34KK5=(M=<CN6BFEB06<ULYN`"D/EE`&8'>YD*&@#Z<NH?#^A:K!=7%KIEG
MJ%U&\<5R;=$=DCCW,IDQPH1.Y`POM5^72;"_+27=C9S-(T;,TD*N6,9W1DDC
MG:3D>AZ5XS\=?A5K_P`2_!&C:)IR3WJ)I>H0ZBEW?>299I--EC@,I4@.?M!C
M)QD`\]*B\%>`M9\/_$CP[J-AX=U&QT:'2%L[B+4M225-)1(6PEKLF8LSRD!P
MZL/X@PQB@#VI=!TQ-0FOTTZQ6^N$V370MT$LBX`PSXR1A1P3V'I5&XET&'6K
M'1+B'3UOKFR=[2U:!<M;PM'N"C&-JL\7'8D<5XOJ/P^\?Z?K7BX:=;0:QH]C
M:W3>%K6YU)E%XVH3(]RD@#J5,*K(L>6`(D`!4`XYMO@QX\MO"ME#IUG*MUIM
MMKB6<3:FJRQQ3ZG9W%M`KEVVY@@D7&\A3A2<'-`'TU_8=@D+Q065I$DBJK!(
M57(4DJ.!V))'H3Q7G&E:+X$^!FK6HDN;BWOM4LX=.LY+HO.YMHIE2.%2J\*L
MMT@!;GY^N!QPGCWX?>-_&U];WEY9:U9V#MJ$BV&G:G$USI]RQA-K<J3*D9<*
MD@`RPC+=&!)KW"RTN'5Y([C6M)5+NQD,=M-=".60JK`K(I7.T,0&QP00..!0
M!IIHFG*Z2+I]DLD:R!6$"Y42',@!QT8\GU[TP^'=*:XBG;3-/,\,:112FU3<
MB(044'&0`0"!V(K04;0!G..]+0!2O=%T_4K<6^HV-G=0"43"*>!77S`VX/@C
M&[=SGKGFHSX;TDW-S<'2].-Q>*5N93:IOF4C!#G&6!''-:-%`&?>>'M+U&2)
M]0TW3[IX'$D336R.8V&`&4D<'Y5Y'H/2H1X2T-8+B`:-I(ANY!+<1BRCVS.#
MD,PQAF!YR>:UJ*`*5KHNGV**EC8V=NBA%58H%0`)]P``?PY./3M27VA:;J<P
MFU+3[&[E$3PAY[=9&$;\,F2/NGN.AJ]10!G#P[I2Z6=,73-/&FDY-F+5/)^]
MN^YC;][GIUYK)\1?#G1/$=C96TMO]@&G7$-Q:2V`6!X6AW>6!@8*@.XVD$88
M\5T]%`'/^$O`FB>"-$M=)\.V$%M9VB@(-H9F(8MN9CR3N9C[%CC%:0T/3@KJ
M+"RVRKM=?LZX8;B^#QR-Q+?4D]:O44`94WA/1+@7(GT;2I!>RB6YWV<9\YP2
M0SY'S,"2<GGFK46E64&/)L[6/"H@V0J/E0Y0=.BDDCTSQ5NB@#(N/">E36E]
M##96]FVHQ31SSVD2PRGS1AV#J,AC@'/J`>U)I?A+2=)\,VGAZUL+4Z-8VL=K
M!9/$'C6&-0J+M/!`"C\JV**`,Z#P[I5K`(;33-/@B4*%2.U15&URZ\`8X<EA
MZ$D]:R/#7PS\->%/#_\`8VEZ19&Q?_7+/"LK7&'+@R$C+D,Q(SG%=110!2AT
M73[9%6WL;.)4C$2JD"J%0'(48'W<\XZ9HMM$TZSO9[RTL+*"[N3F:XC@59)3
MZLP&3T'7TJ[10!1CT/38;J2YBT^R2YEE$TDRVZAWD"E0Y;&2VTD9ZX)%,E\.
M:3<7=O=3Z7ITEU:!5MYWM4+PA22H1L97!)(QTS6C10!2?1=/EU%=0DL+)[]5
M"+=-`IE"CH`^,XY/?O4$'A;1;6*[CMM(TN&._4K=I'9QJ+@'.0X`^8?,W7/4
M^M:E%`&=/X<TFZO(;NYTS3YKNW4+#<26J-)&HS@*Q&0!D]/4T?\`".:3]JMK
MH:9IPNK*,1VL_P!E3?`@!`5&QE0`3P/4UHT4`<UX3^'/A[P5HJZ7H.F6L=J&
M#.9(E=Y6#EU+L1EB&8D$].U;$FBZ?*A26QLW1A*"K0*0?,_UG&/XL_-Z]ZNT
M4`9UGX;TG3H_+T_2].M4PXVPVJ(,/C>,`=]JY]<#TJ>#2[.VO)[NVM+:*[N@
MHGG2%5DE"C"AF`R<#IGI5JB@#-L_#6D:<C)I^E:;:H\RSLL-JB`R+]US@?>'
M8]:LW.G6EX6-W;6\Y>)H6,D2MF-L;D.1]TX&1T.*LT4`4+O0=,OX)X+_`$ZQ
MN8;H*)XYK='64+]T,",'';/2JDW@KP]<VUI;7&@Z-+;Z>Q:TA>PB9+<DY)0%
M<*<\\8K:HH`IR:-83:A'?RV-F]]%&8X[EH%,J(<Y4/C(')XSW-9T7@/PU#9W
M%I#X=T*.UNV5KB!=.B"3,IRI9=N&())&>E;M%`&:WAO2&TJ/3&TO3CIL6/+L
MS:IY*8.1A,;1@\]*GBTFQ@`$-G:Q@(D8V0J,(ARB].@))`[$U;HH`I6>BZ?I
M]S/<V%C9VUQ=,7GFA@5'E8G)+$#))(&2:NT44`%%%%`!1110`4444`%%%%`!
M1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%
M%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%-WKG&1D4`.H
MHZT4`%%(2!U.*3S%Q]X4`.HIN]<]11O7U%`"TM-$BL<!@3]:7<,XR,^E`"T4
M44`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!111
M0`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`
M!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%
M%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110!4U
M74[?1=,NM0U&5(+2QA>>XE<X$<:*69B?0`$U^>$/[6?B[5_`'Q&F?Q)JD>I:
MM'IOB'PS]LLWTM;"VDU2.":RBE=%\R(0O;$RKN'[Y^>!7Z)WUC;ZG9S6FHP0
MW5K<(8YH)D#I(A&"K*>""."#65J?@7PYK26Z:SH&BWZ6D/D6Z75A%*(8LJ?+
M0,IVKE$.T<?*OH*`/G<_M6>)_)M]%_LSP-;^*9O$6J:0+R77'.C[;&SCNB_G
M!-P9UE5`I'!#$],55TK]L[5/$-I:KIV@Z-I^I:OKV@Z9IMGJ-\ZL\>I68F,Y
M`&YD23*@J,,H)Z\5]#O\+_!TNB+HTGA/PT^CI.;A-.;28#;K,>L@CV[0_)^;
M&:LW/@'PS>ZK;:I>>'M#N-3LU1;:]ETZ)YX50Y0)(5W*%/(`/':@#YY\/?%O
MQU\0/V-I/%VM:II>B>+-2F6"WU+0^5M@U^EN'VN"%<`ME>1C'KBO,Y?VGOB%
MX@UOP:-)N)+:7PEJ\?AWQ?IRVZXUC6S%>&2`DKD(%M8Y`$QS<+UP*^V;7PAH
M5AITNGV.C:5;6$\YGEM8;.-(I)2P8R,@&TL6`;)&<@&D3P?H,<S31Z+I*S/?
M?V@TBV489KO&W[03C_6XXW_>QQF@#XU\.?&_73X2U;5+GQ]XCUCQ)X@^&>I>
M)($@33SI&G7$$"L\4"1YGAD@DD6,B7.XJQ-9MU\;/&FD7?A_P;:?$F^UG3?$
M</AL:KXJ,%H+KPY)?.XF@,ZH(B[H`Z;U+(`<]5K[1MOAQX3L[S4+NS\,>'H+
MK5HWBOYXM+A5[M'^^LK!<N&[ALY[TEM\-/"-GH5SHEGX6\.0:->2>9<Z=%I4
M*VTS\?,\07:QX')'84`?+OACXQ^,KW2?@?J.L^,X5M]7\:7VAZF@MX8?[:MH
M#>I'=2/Z,L$1_=X4L<YY`KU;X<>,-9N?VD_B3X:U_P`41:O86&E:7>:;IZI%
M$MB9GNA(BJOS,0L<>YF).><#.*])OOA=X-U2*PBU/PEX9O(M*B$5@D^DP2+:
M1@Y"Q`K\BY`.%P*LV7@'PQINORZYIWAW0K76YRYEU*#3HDN9"_WBTH7<<]\G
MF@#>HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`***
M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH
M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`
MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B
MBB@`HJ&[NDLK:2><D1Q(7<CL`,FO*U_:<\&2_"S1_'UO_;$NC:W>I9V\"V)^
MU)(SE3OB)RH4*SL2?N#(SD9`/6J*XBT^*EKJ?B:;2M%T/Q%J5G;7ALKG6;6T
M1K.&X5@KQEBX<[#D,RJ54J03D5S^E_M)>%[FP>^URUUKP]8O'>2V5UJ5JHCU
M!+5F$IA,;-EAL8A#AB!G&*`/5Z*\S3X]Z)#!&NLZ7XBTK43K-II,VFW-D&FM
MI;HJ())#&S(L3;U^?=UR/O`BNFA^(&F3^/IO""1WPU6#3/[2:1K9E@:+S%3"
MR'AF!=<@9QGF@#IJ*QO$WC+0O!=I%=>+=7T[1[:>40Q37URL*/(>B@L0,\'\
MJPO&OQ:\._#_`%S0;+Q=J%OI4&O1W+6]]=W"0P*81&2K,Q'+>:,?[IH`[:BL
MT>)-+-Q-;B_M/M%NT22P^<N]&D&8P1G@L`2/7M6/#\5/!MS=16UOXI\/RW,]
MVMG%"FI1%WN&4,L0&[)8@C`H`ZJBN:B^)?A2=M66+Q'HK'07$>J#[='_`*$Q
M)`$O/R$D$<]P16?=?&3P=9VUI?7'B#2%T6]LGNXM7-_#]E*+*D?WMV3\[@9`
MP",$@X!`.UHKG+'XC>%]3U&QT_3O$&CW5_JEH+NQM8KV-Y+F`C(E10<LI'((
MZCFH?#_Q#T/Q-K&H67A_4K'4TTZ$27,]G=)-'$V]E,;$$X8;23GL:`.IHKS"
M^^/FFVN@3:W:^'O%%]I,DEO'I=W!:1B/56GG2&/R"T@P"\BX,FP%?F&15FY^
M._ARRTDW=Y;ZU#<0ZS!H]YI[:>QN+*ZF9!&)E&51")$8/NVE6!!.:`/1J*X.
M?XQZ-!XX7PT;35W8WZZ8VII:AK..^:#SUMF<'<',6&SMVC(&[)Q73_\`"5:1
M]N%E_:-E]M-Q]F^S^>OF>=Y7F^7MSG=Y?SX_N\T`:M%<#J?QCTS3[G6?L^EZ
M[J.G>'TG&I:I9VRO;030Q^8\))8,6"\$A2H/RE@>*@T'XUV/B"QF^SZ!XD@U
MI-/BU"+0I[:-;NYMY2%22(B0QLN2`3O^4GYL4`>BT5Y]<_&K0(OA;#X]/VN+
M1))X89?/00R6[/=+;-Y@8X`21CN.2,*2">*T1\5_"PMK:\76]+DTBYT^:^75
M5OX3;>5%(D;G=NR?F<#(!`(P2"0"`=A17.+\1_"KZCIM@GB+13?:R@?3[;[=
M'YEVI7<#&N<L"IR,=14)^*G@X:=J6H'Q1H'V'1IA!J%S_:,7EVLAX".V["L3
MT!ZT`=317E?BK]H?PSX=\0:1HD5Q;7>HZY?PVUB@U&WC6>-X5F,P8O\`=",,
M`@%R5"@Y!KK-,^)?AS4GT2W.K:?;:EX@M5NK#3I;R(SS1D9RJJQ##&>5)'!P
M3B@#J**\YM/CEHT_B>\TB\T[6[""VULZ)'JUQ;I]CGO=JD1*ZN64G<JJ750S
M'`)--U+X]>&M-NO'-N\>IRS>`+$7FHA+;`N$VEF%N20)"I&UN@#$`F@#TBBO
M(=8_:-M='L9)V\&>-)YK.^M[#4;2."V$MA<W'D^0D@:<`[_/CPR%AUR1BN\U
M+Q[HWAW0;?5?&=Y;>&;>:)7<:M<1PF%B!E&;<5W#.#@D>]`'145SE[\1O"VF
MS-%?^(M%MY%M#>%9+Z-2+<!29>OW,,IW=/F'K64GQO\``4NMZ3I,'BW0I;_7
M;22[TZ..\1Q<Q1D!V5@=O!/0G/#>AP`=Q17*0?%#PU?V>GWNC:MIVIZ?J%Y)
M:+>6E[$\4;I&\CY;=SA8VR!D]\8R1I^'/&&A^,(KF7PKJ^FZO%93FWN'LKE)
MA%*`"48J3@X(./>@#8HKF+_XD>']&U&\L]?U.QTIK2Z@M1)>7<48FEF3>B*-
MV[<1V(&>V1S5'6?BSX>\+^/+3PIXFU"UTR_U*Q2ZL9+NX2)+DM-Y0B3<03)N
MQP!SD4`=K17*ZA\3?#EDFNI!JNGWM[X<MS/J5C!>1>=;*!GYPS`)Z?,0!W(J
M9?B1X6;4KO3O^$@T8:A86K75Y:_;H_,MH5.'DD7.553P2>E`'245S>C?$7PQ
MXET*YUGP_P"(-(O]'M&=;C4+>\1H(2H!8.X.%(!!.>F:S;+XP^$I=-.H7GB#
M1[33Y+_[%9WDU_&(KURB./*;.&X<#\#0!VU%8L_C/0;6-I+G6-,AC2>6W9Y+
MI%"RQ*7D0DGAE568CL`2:PK?XN^&[W6-(M],U*TO['6=/O;Z'5+:Y1[6..U:
M(2[WS@8\T<]MISB@#MZ*Y$_%SP4N@+KC>*_#PT9G9!?G48O)WC&5W[L9&1Q[
MUH+X]\-MK4&D+KND'5+JV^U068O8S++#C/F*N<E<<Y].:`-ZBN+T_P"+/AG4
M+/7=0LM7T^[T?P_;+<7FI6UTDL"+^\W#<I(!7RSGZBLOP#\=_"WC;0M"U)]6
MTG3)/%`9])L;C58'FN(PV%("M]X\93JIRIY!H`](HKF;OXE>%K/3=<OYM>TL
MVGAN(RZO*ERKBQ7!/[S!.TX!XZ\5S?AG]H+P1XG\1QZ-I>OZ=)->V=I=Z7*U
MTBKJ:7!E"K""=S.I@8,N,@D#K0!Z516+HOC/0O$EY?6OA[5]-U.YTR;R;V*T
MNDE:V?\`NN%)VG@]?0UM4`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!
M1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%
M%%`!1110`4444`%%%%`!1110`4444`%%%%`%;4K0WUA<VZL$,\3QAB,XW*1G
M]:^?+7]DR>UTNXL?^$F1[9M`L[.VMFL/W=MJ"1P17-XOS9)EBM85VD_+ESD[
MC7O/B6]N]-T#4;O2+:*\O;6VDE@MY9_)29U4D*SX.T$C!.#BO&](_:/U:+P;
MX=U;Q3X2AM[G4/";^)]5%GJHDBM+!%4LZ93<\AWIB/`^\07^7)`)+C]GK5#X
MNTFXMM9TQM$T;Q-)KMD9;287]KYUP;B>U2191&T3R$\NA(5F'/!K,/[-&OZY
MX37PSXM\4:4-)TA=1.AG3=*=)EFN_-`EN&>5@_EK,XVH%#;LGH*VY?VB+VW\
M$ZCK%[X6BLM4L[@);Z?=ZL8H]0C,'GDV\Q@S(ZH#N41D`J?FP-U9WAO]HOQ!
MJ>GZ]J=]X,M5L8M8TW3="2#6@TMW)?0V\D0FRFV/'VE"S`G`)&"5RP!:\4?!
M;QGK<%S?6>O>&(O$.JZQIFH7\D^F3O;*FGLCP11(LP89=69F9B<28&,`UM:]
MX.\<P?$MO&&BW?ABZAM?#DVFV^E26DR2S2L5E!,WF[57SD7^'A"1R>:YP_M4
M&UTR&\UCPE=68U.W;^QT74DF-Y<QWL=E-$VU?W:K-+'ASG<A)V@C;6CJ'[06
MJ0:-ITEGX%OKC6;JWU*YN=/DOUMUCAL9$69XI)(P9582!HSL7?WV]:`-3XN_
M#'Q)\5_"]II5OK]KH\=QI]S:ZS;)%(T4[S0A`ZE65OW;;RJL<,&^;H*T_%_P
MGC\7:IX?N;Z:S>#1=)U&P>WGM1*)C=0QQ[AG@8$9R,<AL52\"_%+6M7N/'\W
MBW0K'2M%\'ZA)!;7EIJ)N)+F)+>.<EX]B[6V2`\$]=N/ER?-?'7[07C#5M%T
MW3_"_AC^Q-8\0S://:3_`-N0LQTV^N?)5U8PNL<Y/R[2CJN[<"^,4`>A6_P@
MUBQ\</JMEK.G+I5VVERWEO)8LT[/91M&%1]X55;<&Y4D8QWXYRR_9A-EX=?3
MX]5L?M!\/Z7I:7*V&"CVE[+<M*/FR-_F`=<@KG)[5?C=\4_%G@#Q;&-"NY8]
M-TKPRFJ7\#:?'<Q%C="*22XEX>.)(]S%HQG@G:<;3Z%XL^*_]CWNF:1X.TP^
M(]>U:[E@MK26Y-C$!%&99&:9T(P%`QM#9)'09(`.'A_9SUN_N]6N_%?BBWU6
M[U)M,5IGM'/F1V>IM>@NI<J"RMY>U`%&W.#DBKGC?X!:OJJ7;>"]9TC2);NQ
MU*R*7&G,\8AO;^*YF`".I!*1O'N!!!DW`@BL[6_VBM2UGPGXWG\.:#?:6-(T
M35I]-UAF\]%N;$F.19DV;$S(#L^=]X1CA<<R:K\3_%%I\*/%>N6$JW>KZ5XT
MCTRQB"I&)(#J-O#Y))&T921TW'IG/:@"W8?L]74'B5M1O+C1'MKM[6YDAMX[
MF'^S[B*R-H3:J)=@79M*!PVW+]<C&]\+_A#?^"[1[;Q!>Z)?1IH-MHD;:=II
MM'F@@WA9)F+MN<J_;`!SCK6%??M(7^F/8V-UX(U!]<5+B;5M-MKW[0UM##<F
MW)@9(S]H=F!95PF1U*G`J?6/VA=2MO%&I:+H'@N;5'M+N]LK69]7BMUN9[2%
M)I@05)1/+D7:W.6R,`?-0!5_X4OX[3X?6_@\>*?#4^G^'Y;!M!N)]&F\]EL[
MF.6%;HB8*WR1*A,87/7CI3O$7P4\9:OX=U3[-XA\-_\`"2^)-=L=4U:YFTJ;
M[*BV9A,$,$2S!@,P("S,20S=#C%/Q'^U`R!?^$,T2QUA+[P[<:GITSZOY92X
MBLQ=F"YC$9\K]V1T<MR/E`.:L1_M%ZKIVB6]]K?A!#_9^CV&I^)VM-71AIT=
MVS+#Y`9`9R0A8C*;1P"QZ@&[<_!B;5_B'IOB75/["M&L-1CU*:33;>:.>^N$
MM3`!*6D*;1N8YVEBJQKD8)-F+X.RQ_&F3X@F_LS,]K_9XL_L?`M!'PV[.?M'
MFY_>=/+.S'>N'TG]H[4](TS7I-3T:37X?"M]>RZ]>QW<=LUG9?VC=6]OY<1'
M[YPEN<C*\+U+'%2WG[2&H:F?$'V+PW<Z?IFCM&L6JPZA'-(7_M)+,Q21&/;&
MY/F-C>QV`$<D8`.BE^$?BJT7Q?HFB>(=%C\(^*Y+^X,-WILDEY9RW:'S4219
M50Q^8S.-R%AO(S@#$&C?"'Q=#`EYXCUCPIJ>KV>BQ:'9VRZ1,EC]B#HTWF*9
MB[22;$YW;5V#"G)J5/CMJ#^")_$T/ANPAL+V1?\`A'%O?$"Q/JZ$N3E5B9HY
M-J%P@#DCJ5P<'@GXPW'B2X\4:[.DJZ'9>$-'U^SL&"^9#]I@N99$+#J2(D'I
MD<=:`+<WP7O'^"$/@:/5+)KN"X@N8IIK-GM8C%>I=+`L6_=Y"[!$H+$A`,DF
MN6F_9JU"\?[;JNHZ)?W\TU]<S6YM9[>VBGN+RUN%:`QRB1/+^RC!W$EV+'N*
MT_#W[1UWJ^I646I^#I]-L9]0L;.ZNSJL<QM_MT0DLV"!<ON#H'&1L+<%P"10
MO/V@+WQ!>W&GZ);V=BUCXBT***_M+Y;Z#4+"]OF@+`F-=K%8I.FX#((8T`9E
MK\`_%>M>++N#Q5J]C/IZKX?FO=:>P7[7J4]@KNY@(?$(,FT'*DX)QR<U;T/]
MFG5/#]KH#V.I:"^I^%7LULKJXM;F9;Z&W6XC6.XC:8JOR7#,#'C$@W<C"A/`
MO[3=]XCN?#EA9^&9]1BO;.&34M0GU".*>W+V;W7F&!(BICVH$W[E^=MNWH3M
MV'[0NH7OA&YUF?PI;:;-/;V-WH=K?:\B?VI!=([IADC8I,%B<F,*W3KC)`!:
MLO@9=K\0(?%&H:GISRK>K=26\%@8UW#2OL)"?,=HW?O`.<#`]ZB^&?P0U?X;
M:A9_9]7T?4+$Z9IMI>BXTYO/5[.!H0T#[\(K@JV""5.[!.[A-(_:'G\07FAG
M1O"=U/IE_8Z1>:E>-J$:-I\>HAO)Q'C,I5E(?!&!@C/2J>H?M!W5OX0T7Q=J
M^AW.D>'-5OXY+&:"]BNI;VQ-K<3[Y(]F8CB$':"3\P^;[PH`N0_!?Q')XEU-
M;_7M&/A2\\5KXF2SATZ07CW"&-HX7F,A01B2)&)5`Q"XS@FLO7?V:+[5-!:W
MM_$[C4=3TK5=/UJ6ZA:6&Y%_F25HT#`IBXVN`2WR@KGG-3VW[26H2:7;7-[X
M)NM/,]]%$]W=W[1Z=!;R1>8LKW9APK8^7:5V[_E\SD&O<%?S$)`*YH`\>L_V
M?$T7PYK/AWP[?6UCH=YXCT_6M/MS$\C69AEMY9HMS.2RNUN2O]WS".0!6C\8
M?!_B#Q/X@\#S^$8=*>;2=1O)KB?4[<SV]NLEC-$K/&'5FRSJ!@]3SQ7,GQ_X
MLU/X,^)/B3INNV=M;_V+J4^G:-_9R2"R>`S+&6E)W-*#&/,5@5R"H`QDQ>)/
M'WCGP=H?C?3%U72=7UGP]X-7Q%8ZQ<Z=Y>!B4/#/!&P4M^Y)5@5'S<K\O(!+
MI_[,<NB^%[K3-+URUDND3038W-UIP=2VEA-J3(&&Z.1DY4$8!XSBJU[^S+J6
MI+J,EWKFDQW'B*/6XM6%OIK1I"FHB`9ML/E6C^S)RV=Q=SQFI_%WQ(\:>'_&
MVD96:TT&>]T6RB1]'::#4S>N$N'-R#^Y>,D!5X!/7.X;?5_'/BP^"_#,FH1I
M8W%V9(X+2VO;W[(ES,[86,/L<[CS@!6)QTH`\ON?V>+[4]#%O>7NCV6H/?M=
MW5S:17$@NF.ERV(+>;*Q4CS`0%(`5`O)^:NM\,^!=2^'\VG0>&X-)FM[P6=O
MJ\QC\@I#;69BWHJGYI&=8P,\!<YZ"N=\1?&34]3^$_@/QEX0L)8I_$NJ6.[2
MVD5GF24/NMPY&`20`&P.QP*<O[1B:M8PS>#_``Y/K'VR_L]-LC+?);)+=S63
M7CQNQ4[!&@56."=S$;>.0"/QK\!]5U[QEJGB3PYK&G:;J=_<V\UI?26TK3Z;
ML@CA?R]KA)-ZH<K(I4_+QQ5OXM?!+5/B)XCEOM+U;2K"VU'0_P"Q;[[5I[7$
MT4)N!,9(&#@+)Q@9!`.#VQ678_M.27UA;S)X0NX[G6;;3+K0;9M2CW7L-],8
M(FD8#$)64`,/F^4[N3E1D6W[0/B6]\9VC6/A>2?38],E77-,_M*(-IUS!J;6
M<TL<FW]^!@D`;<JN>#@$`T!^S3<+I?B;3!J&G21:O9ZQ:V&H3)</<VR:A,)F
M5E,OE$!LY(4%@J=,'+/&_P`![F+P)XHBTA;;4]8U&?5KF`16JI*RWLL;;`S-
M]Y1&IZC)5>F!B[J/[3T.D![W4O#-VNA7LE_!HE]%?QO)?3V<IAD1XB!Y(:0$
M*Q9N.6VUIZS\;]7\,-'IWBGP>+/Q'?P0?V181:PDT6H7$ET(#"L_EC;LWQ2,
M2O"N3@[>0#,T+X6:MXC^%7B70+V*'P_=:AK[:A974\33/=LLT4ZRW4)D;&^2
M,HR!^4`QMS@5]<_9VU+6YEOKN\\/2WEQ_::7]C'9W%K930WL<(=0(I0^X-`N
M6+?.';(!.1GZ-^T[KJ>$-!O-<\#QRZ[K-M?:@=/TK4FG4V5K*D;O&?*)>9FD
M`6+&"1RZYKT#QM\9XO#":8VEZ5+?I>7OV>]NKR1[&UTT!0Q:>9HV"DYPH(VL
MP(WKQD`X_P`7_LP#Q1K.OW$>MK9Z?JND[;.P2W)2RU-EA22Y!W99'CMH4*<'
M!D^;Y^&:S^S5=>(+.Y$VI:9I-U=6NHI,UG#/.LL]S]C*ROYTC%@#:!67(#*V
M!CDF?6?VI(O#UUJ$NL>%KV/1X9M2M-/O8[Z.1[R[L9O)DC,.,QHS$;7R>^0.
M"=.S^.>LZL-,TVP\$SGQ-J%S=JUA/J?V>W\BV\HRSQ7#Q`R*1/&%_=C+;AD!
M2U`')ZY\%O%T7C/3];L9?#-SJNJ:W<7M^YTUO[/T]!I1M(OW1DWNS$`D[NK=
M`!3M,_9+&EV$FD)J]O>:7<6EO&+F=)DNK.:/3C8M-"J2"+.W:RAE(7<XYR",
M;6?C7XQN-66XTV&YB\/:3H?B+5+R=+VW2XE>RNY+95:,PLK(N%VJ&4L6#,QV
MD-[/\-_B-?\`C^XNYK?0_LWAZWDFMK;59+]&ENIX)3%,#;A<HN]7PVXYV\A<
MC(!2\#_##5-!TO6XO$%WH$UYK&FVUB6TO2S:1`0PO$'92[%B0P/;``4<`5Q<
MG[-.I)I]OI=KKFE?V;=Z-H>G:FTVF%YXSIK;@]JV_">9SD,&VGYAGI3_`/AJ
M2Y,=Y=)X*NCIME;2:A)<'5H@WV"&Z:UGFV;<[UD1BL>?F49W*<+6AJG[2]MI
M.M^)[-]&BU"UT.Q%Y97>FZHLXOE^U):LC`HJQNLD@!&YP,$$@C%`'7^&OA<F
MA_#K6/"\US!(VL2ZH\EU';!<?;)YI>5S\Q43`<GG;VKEO"GP'N],D6X\1WNC
M7EVEAH5I&UMIY18O[-FE<.I9F8%UD'?@@GFLC3/V@K[0_&WCS2/&MALE\,Z?
M'K-U9P7"R+IUFMC')*L<FQ3<,9FQ@*-N[+%1M#:NE?M`:KJHTRS3P1=1:UK&
MJ_8;2"34=EM(GV8W)E%PT0R%B1PP5#AP%!.=U`&C\'/@M+\+K@?:9]/O_LFG
MC3K6^7[1]IDMUF>1%D#R-&,!AG8HRV3P#BO5Z\M\0?&Z32OB/_PBND>&[W5O
MLTEI%J%U%*0UO)=9\DB,(P:,8!D<LH123AL$5@:+^TM<>*]&M;GPGX.NKN]U
M#66T2TM;G4X[</?16TDURC2;6"QQ^4R"0`[SRHP02`>XT5X3'^U+'=Z*VKZ=
MX6NY-.@TO3[JX>6_1'2>^?RK:!5"MNS*&#/D!5`8;LX&K;?'R^D/AQ-1\(W6
MEOJ]]/:WUQ?W;06EJT4JQ@13M$/-:0N#$K"/S`#@YX(![#17A$G[3L_]GVXA
M\)2'7;Z[N4M]%EU%DN(88(UD=KE?)+0S%77;%M;<2,/CYJU](^,NH>-/$VEP
M:)X>U&PT(:P+"[O[J>-)EN19-.]O+;GYD`W(-V2=RD8`P2`>P44B_='TI:`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@"&[C
M66$I(%96X8,,@CN/RKB?!W@KP.=.0^"[/1I["VMI]+1K27[1&D!<>=;#YB`N
MY0"O;;C`Z5T_BO3WU7PUJEE!+=V\EU9RQI+:2;)D)0@%&P<-GH:^=O"_@WX@
M>%/AWX2TKPO-XHAFT7X>27R6MQ(@$NMJL8BM9V91E1ODQ'D9VC).*`/99/@M
MX,ETR#3Y]%@EM+5P\$<D\S>41"8,(2^57RF9"H."I((JW;?"CPE9W3W%MH=A
M%+)):2-L!"[[78+=MN<;D$<8!QG"`=J\2TN#X@ZK<P:;I6H?$>+PS>ZKIR3Z
MAJENMOJ,*O9W<EX%9HPRQ"06:[BN%8LJ''3JOA(GQ"@DC;Q9/K5Y/J_@^VOI
MAJT2K%9ZON=&@0*J[`5V%DYZ9[G(!Z%=_";PC?6"65WH6GR6L4,\$<10@1I/
M*LTH4YR-TJ*^1SN4$$4LW@KPQH\4<]U:6J)!%<0">[G=RB73+YREW8G$C!,Y
M/4`"O`+#4/B5'X)FCUE_'M[J.LI:B[$-O<03:/=[)VFD200'="SQQH(XE95W
M*Q8*YJWXA\.?$'QAX(U@>)E\2SW%OX9T#[/IBQ*L5Y?2%6OBZ!?G=&C4XR`N
M3QS0!]!:?X'T72]4U34-/L+>"[UI5&HNH.+G:@12ZD[2=JA2<9(`!SBN?\-?
M"[X>V,4A\*:1HCK;7-NS&WD\WR9;5]\"`[CL$;'*H,!2>E<O\--6\3ZI\5_$
MFB:S>WMQI/@<R0&Y?;MU&6\D%Q;[B.I@M]L9'!R^2.A/G'[.GA;Q+X<\52/:
M>&[O3VBT6]M[V74]&DTR%+K^T#)'\ZC-V9$9CYF#L"#!^<T`>\>)?AEX)^).
ML1:AXGTC3=9U'21]EW2R%O*7(D\J10V",E6VL".0<<UK^)_`VB>,[>UB\46,
M&H+8S>=;-(65H'*E2492&7*LRG!Y!P:^>_&DWCCP9XQ\37?A];ZTE\=^)(=#
MM$CC!C6>?3[-4U"/=R5A,%R"?S'&1;U+0_B==W>LO!K?CFWC:#Q!);)"(PJO
M:7"?V6J9C)_>HSD\YD`QP!B@#V5OA3X1MHM2QH]JMOJD,\=]`'<02I,JB;,>
M[8-P1<D`$X]S5ZW\&>&M0T)[:UL-/GTO4[M-3=(_GBGG\Q)5FR#R=Z(P([@5
MX/)XD\<>(/B?+:V4_BDW&G:AID-YI=O:@:9!9SZ;'+>B<E>)`['8"VX$J%!R
M:J>$O"?CSP+\,O"^FI?>/&TZ[M-#36HXHTDO-'C,=PEREH`FY0KK:!E`9D3<
MPYR:`/?]6^&?AO7+F.YU+38GN(C-LFCDDA?]\P:4%D8$AF520>,@<5.GP^\/
M)J#7RZ59B[:XN+@S;#N,L\:QS.>>KHBJ?8"O!="A^(GB.>'3_%NI_$?0H9[&
M5?#FH6=G&KEVN[B-)-1"H0KK;_9'VOMS\Y^]D5F6%UXT^*%IX/\`&M_<>,[&
MW'BI[<Z=HTS"**"&REMS+(D8)>*2]1B6Y'ER`\#D`'O6F_!?P3I%U]HTWPYI
ML$@A:'"H2@1H5@8;"=N3"BQDXR54`DU2;X->`([G3;?_`(1_2WGTRWC6UB=F
M8K#%+YD892WSHDGS*'R%/3%<M\`I/'#VVHS>/+[69[^XTZ"6:PU2QEC6VO\`
M=()O*E9%3RB0F(TW``!L_-7GMG_PL=O#T^I1#QZ==N+#3X]=-]IX1[1VO!]N
M2P*(2RA,E0H<!<,I))P`>[7?P6\#7UY'=7GAS3)9XY6EW%#B1C<&X.\9Q(/.
M)DPP(#$D#FN:T3X%>'O"U_-+KFH/J%G>&2&.TNL0Q2/+>"Y4R@'$LHE"A&(!
M'(YS7(2Q_$VSMO#-CIFH:_JMMXDD;2[W4FLG@DT=8KPR"Z<2*'RUIYD/F$#>
MZQ-@;JP=*TKXAZ_8VG_"7R>(;Z\.OZ1=:AIESITWEVDT.J*998)2BH(!$N0J
M%LJ`Y/6@#V]O@?X':-X_^$>LD1[IKI5C9T$<K&0LT>&'EY\Z7(7`/F-QS6Q8
M?#_P]IEM<VVG:596]O>Z?#IMQ'&F%DM(D9(H2,_=57<`>C&OFG5/%GQ)\.>&
MM5U:_N_&]G=#297U[^T+*,6UEJ!U""*!-/RN&4Q&XP%+*5\LL=QYT+M/BI+H
ME]%H%[X]6RT]-=NM$GO+=%OKLP1VAL8[D%,D-.;L*K!6=%4'CJ`?04?PW\,Q
M#;%H]@H\ZUGP(_\`EI:JJV[=>L:JH'T%4=)^#G@W0HO*TC0;&VC,MM*%7<=K
M6TADM]N2=HC=F95&`"3@5XMXHL_B?I^JW6CVVJ>+V\/&_,BZRD#2W:R26*2(
MF88BQMUN!*"%7@E4)P:V!X<^('B6ZU2?5=<\70(93I\,%K&+*"XMY-'5VG5"
MNZ-_MI.&)RI^3UH`ZZQ_9WT/2O%,6I:1<RV&GP7$,\>F6J"-5\NV^SB$N#DP
M%,$QD')'6NBE^'/@[7M/M]-;3-.N+31##;V\<3D&S,",B(&5@R%4E=<9^ZY!
MX->17_A77+W]FCP9:PW?Q*BU32;W1Y=4,<LJ:KM2XB^U*1MWNJ+YA4`'(12-
MPZRZ?X-\7Z#K?CGQ!H%YXLB;4-5U)K72W13;W*?V5']GN`A7=YAN(U7=GDY7
M%`'M>G?#[P]HZJ-)TJQM%6&T@41QX`CM23;KC/2/)V^F:H:?\(?!NE1".PT#
M3HH4NOM21;2T<<N)!E5)PHQ--\H`'[QN.:\2UF+XE:0+6&SOOB#=:JNDZ==:
M.T4*36USJ$\S?;8[T[-J(@*`*VU40,5R15GQ3XY\;Z3X,\01W$7B:PU"PO=3
MC%_<6OE1.DNJQ1V:12D8)-O(0K*&V@D\L,4`>IW'P@\"?9X-#N-*MI+8Q`QZ
M?)>3,K0QA4`\LOS&HV#;C;T&.:[;3]+MM*AFCL$\I)YGG<;B<NYW,>2>I)..
ME?*NC^$_$_BN>RO-)\4^-YM0\.V/B6%]2C.9X+H7=L]M82O)$/-`1`,!0'VD
MYKTWXYIXYFDMC\/9]?M5L_#VIWH&F1*WGZC$8/LD4@93N#;I?DXW`$=J`.O;
MX(^!WOM8O#X=T\SZ_%-'J7#;+A9@1+E-VT%P3N(`)R<GDU''\!_`4/A>_P##
MD?ARQ&C:LR-?V^^0F[V?=$CEM[`<@`L0`2,8->4^-F^(.AZ'XET+3AX[U19=
M4WZ1KD$A^TP`Z>)MK&*(EXOM(:-0%`!8!F`%9_A6T\=>$H]?U#4'^(E[J-QX
MIT2]O89HWNH3I[PVGVO[.@7'#^>CHG(5!QQD@'NFE_"3PIHT^GS:=I,*/I(0
M6(>6258"BE495=BNX*S`-C(SUJ5?AGH4GA2Q\/:K#-JEEI]P+J&2]N'>83AV
MD\WS`0P?<S$$$8!P,#BO)=<D^)>MI?7WAT^)M.DLO"][?:79S1+$L^HFZN%A
MBF!!W$0&,B/.,A"<XK<\'#Q9:?"SQBZW_B#5-5BMKB70AJ5A-'=PR&T5EB+2
MHAF/G9((7`)V<[:`/2X?`V@6NB:1I%KI=G%IN@S13:;;*GR6KQ9,;(,\%<G%
M8G@WX.^'_!V@V>F06T5W]CU:YU=9I8@I^VW#RM),`N`IQ,Z@#@*<5Y#;Z9\5
MM*FDN;#4O%6IW-EJ]E#9VNI*AM[B&YL$>Y>;"`E([EV`.0(]FT<9R>&+?XCW
MWA&*"YU?QB+O5M5T9;_SK&2*ZTZ.5F74"DLD:KLQ@@("L>,@G<*`/5/$WP+\
M*^)-+TRP6QBL+?2VL4C%J-I-M:3B:.VSG(CW`].1G@UL:5\+?"NAV\<&DZ)I
M]M'%:&S58XR/W)E,I3.<G,A+DGDL<DUX*K?%G2M%TR:>X\;WPUBQQKP6"-KC
M3HX=1BCW6J!!B=K1Y&(PQ;9N`W#G6\.:)\0_%MY;:3?:YXYT70@NLG3]4GC2
M"[=8Y+=+$W1*9R=URP5@K.J*6]P#U2[^#G@*)]5O]0\/:,!J$-RM_).G[HQS
MD-<':QVIO*@L5`R1DU#;_"?POJ.J>$-9TCR)+3PI-=7>F+"_GH\]Q'Y9E\TD
ML<*7XS@E@3]T8\LL]3\5?%C]G/XDZGJMK?75WK>GW6FZ7I,40DW&V@^SRO$J
M_?\`-N5N&')W+Y>*T/A;9^*-"\"_%"?PCH=W9W5U-)=^&4O-(_LDSS?8HT""
MR;"Q*LD84$XWG+'UH`],/P9\&QVB00:);01037$T(@EEB,37`Q-M*N"JOW4'
M:<=*GUWPUX5\>B#2_$$5EJHM=X6T:Z)P%*AU>-6^8`A`58$`XR.:\2U[_A.&
MTW1(O"FK_$FVTV6UO)Y]0U3399+R+4@D#P)+%'$7:W&9QLP%9P5W8VU6/A#Q
MA9>+O$>HZ=#J^BS7*Z^+?6(M)DN-IN+G3"C+&@+?.L<V"`2H5FP=M`'K^B?`
M/P?HSZY<ZAIUOJEUKUQJ$EY<WJ[CY-Y,99H0,X5>0N0`2%&2<5IO\)O!VK6-
MDLFEV]]!;2M<VDSW,LK*9(PC%9"Y;:R``C.T@#@UD?#GQ=/KG@@Z3=V>N6GB
M.QT8375IJNZ:XC$AE2'S)2BAG;RMVT@,%9=P&:XWX32>-++QCX6@\4)XEN+2
M;PO:0W%O]D>SL])G2SB:7S1L\N9WE+`%&#(=RE<+F@#TF+P'X*>QODBTW1S8
MBVO;"\((V+%/*9+J)SG`#299@>_I5O3O!OA7P1>7VNZ78Z?I4MYE[NY63RXS
MNV[F()V*6*)D@#<0"<UX?_P@OC/1;+XCW^C3>)BVM77B<V^C-"DEJ[/AK2:.
M,KG<S!L$DAMY!&`*X?6KKQ1X[L_&FG7NM>)+N[U?1];L=+T.,,\-W);W44:O
M%&(]D;Q("NTN2Y?=CJ*`/IZ?X<^#;:/^SI-(TE/[1L9[+[*PP9[9I3-+&!G)
M7S'+G'=J;;_!GP5;&^:'P]IP_M(,MR-K%7#3_:&`!;"@S?O"%P"W->/^-/!?
MC+2-1TR;3-7\1:B_ABXUJ[LM:U+8[)%]FMI8XI9,*IC=UEBR1T)]*Z33M=\9
M^)OV?[KQ-I']K0^(O$THU+2[58E>?3K2>X00Q*A&,K;88@Y^9GH`]/NOAWX<
MO=6GU2\T?3YM0NF9I[EXLO+NA$+!CW4Q`(5Z$`9'`J'1OAEX:T"2PDTO3(HY
M-+E\RR9Y9)3;-Y)@^3>QVCRF*8'&#7BFJ#Q_X8\6>(#+KOB5--T&&9=.>YMI
M;JWOK%=.9U>241^6LXN58M(S`C:JA<.*S/`\_P`1/%5KIB6VJ^/AX?UR]TE[
MO4[R!(;F/S;*YDOC`Q0%+82?9`K8P&9@I]`#Z$U?X?:!KFM#5]0L$;4O*CB:
MX262-G2-BT:MM8!@K,Q&[.,FN:U[X`^#];&C1#3HK&RTFZCG:TM,Q)<B.UDM
MHD;!!`5)>""#\H!)%>7:4GQ,EMO%)U;7?$>FZC-!>0F$Z)<WD,#K>(L$MJ4C
M"A3;DCY"['<9",QD4N@7OQ'U#Q-X<?4&\7Z!I<-OIYM8+RWFOO/!N)$NUO"L
M0S(R!"K2[/+5E;&0PH`]M_X59X472;S2XM"TV/3]0LH+*YMDAVI);P`B&/`/
M`3<=N,$9SUJ*X^$OA6\2S2\TQ+I;&?[1"MQ<S2@2^8L@8AG(8B1%8;LX*C&*
M\#UCP=\0]5^'$-YX@UOXD/?7HTC4+^SL7$<]G)'J&+A85C3=C[.0QCYR8U;D
MD@W]9NOBK;ZQXKN=$N?$9NK9;N+2=/?3I)H+JT%NKVTD;,@B2X!R69W+-("A
M7!%`'KJ?"CP)`+E5TNSC-I<BZGN/M4@FAE6#RPS3;]ZXA.W&[&TUH:=\*/".
MG:W'KFFZ+8Q:H-C)>(6+;EB\H/\`>P6\O"%OO$<$FO/-%TS6T^%WQ+_LE?%U
M_>7EM<'1I-?L0M]<'[`BH"A4%_W@*C<H)Q@@CK9\-Z3XUG\>'4M6U#Q';:;8
M:I;VD.F;$%E/9MI:-([+MR2MT2-P/!7;C&:`/:@,`4M(O"CZ4M`!1110`444
M4`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110
M`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110!!?7(LK.:X8$
MK!&SL!UP!D_RK@_A3\9++XIP;K?2]2T:X&G6NH_9KTQ2$VUSO,#[HG=06"$E
M"0PR,CFNZU*U-[87%NK;?/B:,G&<;@1G]:\=^$'[/$GP^63^W=8MKP'1['2U
MBT6RDTE)5M2VRXFV2DR3L&VE\CY5`Q0!Z!=?%;P=97NLVEWXGT2&Y\/1";58
MGO4!LT)`!DYXY(&.N2!U(KG-2^/>A6NL:9::8K:Q::O%82VM_93(\3+=WGV5
M3G/\+\GVSW%8FH?`34[KP_?Z%%XAMAIHUY];TEVL&$\%PUXMWMFD613(@?>H
MV[6PRG.4&61?L[G^U+&^74+.Q:TGMIGM[2TD*2/%JC7[-NDD9BSEMK$D\DM[
M4`>DZ_\`$;PMX5U*#3O$OB'1]+OKI"\-O=WB1.Z@$D@$],*>?;%5%^+G@MX]
M!=/%&BE/%+;-&<7:XOFW;<1G/)W';CUXZUS_`(R^#2^+?%=UK,FH)#]I_L7]
MR;028&G7SW6,YZ.7V^V,\US-[^SKJUWJS./%\RZ-+X@.M/IAMG")-_:7VT;0
ML@5B<+$2X8`+N4`DT`=-X=^,OA=[/5+Z]^Q^';6V:>XO[B[GBC):.[ELR[`'
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MEU/:LS3+IUY)<C<&D8!I/,*D+M1<`A>U='I?PDO_``[XS.M^'=6LH(+R`V]_
M9SZ8)`8_MTUVIA(<;&S<2(V00?E;`*\@&QX>^)OA#4;_`$V*+5-&LM;\30_:
M8;$7<+3W*KE0Q*$A^$(!R>%('2N@\->,M#\8Q7<OA75K'5H[&Y:VN'M)A(L<
MJ]5)'?FO(/!O[-!\&ZA9RIJ5GJMK$]C//#?6TQQ<6H95EB5)@@^4K@.K;2K$
M9W8'8?##X=:U\.K5K(:O9SZ4;A3;Z9#:2+!80+`$\FVWRLR`R#S""2H!VJ`*
M`,GQ/\>+SPUXAU[2M2\">(5BT#1[G69K];VS\J2SA$F)%`E+_,T9`7;N&02`
M*V?#OQ=\%7N@Z3=^$M4T6;2+JX:S+VUY"D5BT=NT[(1D`;43.U>@.[&,FCQM
M\*F\9:EXDNSJ)M3XA\'S^'-GV??Y/F-(?.ZC./,^[WQUK%\4_`2#Q)!!%Y^G
MF*&99)K>ZL"\%UC39+';(JNI*E9`W!!PH4'O0!WEM\1?#%WX57Q+!KVEG0&!
MQJ)N%6'AMI^8\?>X^M5]'^*O@[Q`URNA^)]$OVL[`:A<+;WB2&*V/_+5L'A>
M.3V[US2?";4;SX>VOAOQ!K\NHS6VNV^I)=30F0)%!>I<QVP#N6*JJ"(,[,V!
MDY-9$_P#OX=/MT\/>)Y]'U&UCU[R-0M[,!TDU*Z6XW_>_P"697;ZMG.5-`'2
M6GQU\):EJMA#I6K6-YIFH:=<7D>K17*-;@PSQ0-$3G/F%YE`'7/'I6M/\6O!
M=K-K<5QXHT-)?#B[M50WJ9LQG'S\\<\8]>.O%>6:;^S!<6/B;2/$7_"1L-7T
M34K[4;4BV>2)I;J:%W23S)&9TV1,F2=^7#!@5JU;_LV+9V]Q:B;1M0@CN+F7
M39M1MKIY[19KU+O:&2X4*RN@(=`I)5">A!`/1/%/C_PW8:#IM_K-QIUSH&L@
MNEU-)&83$L#W'F88_.`L1.%!/&<8!(CTGXR^"]6^'MOXXM/$-@/"URJLNI2L
M8XQN(`5MW(;)P0>0:SY/AA?W^C>"+77]?N-3O_"4S376H2VX$FHNUG-;,Q&?
ME/[\MW^[COFLM/A-XD@^&'ACPG:>*4MYO#BP6\EU;VLD*:A:11-$L,H24.N1
ML<E7&2@&,$B@"77?VH/ACX>N=5AU/Q?I:/HMC;W]WY>Z0""?_5,A4$/G*GY<
M\,I[UTLOQ?\`!5O&KS^*-%7=I_\`:./M2Y%KA6\XCJ$PZG)ZYKSN']G.]M/"
M^H:!9^(HUL]1\':=X?EDDT\M(LMEYGE7"X<#:WFG<AYX&&%=!?\`PIUVXE\2
MZA8^)1INM>)9M+EN)[.T>-`+0`219$F_RY5W+PP90QP<T`;>K_''P#H>C:=J
MNI^+]`@L-7@:XL)VO%(N8ESN9,<D#!'UXZ\5#X7^./A#QB^A/X?UFPN;+Q):
M&?3+DW"QF=@X3RA&Q#[\D]L9!'7BN2\'?`+5/!3PKI?B*VEAN-*.G:H+C33(
MTB?;)[D/"QDRC?Z3(AW;LX5NHYIS?LY:E>^'=)L[OQ-'#JOA[PS%H^EZE:Z=
MM^SSP7$,UM=[&<Y93`H9<X;<PX!H`]/;XH^$$U#3+%_$NBB\UF62*PA^V)NN
M7C=HW"#/.'5E^H('-<CX@^-?@Z3X@:SX%\1SZ,8M&T87VN2ZC<QI%`CM\D9B
M<'?D#)/1=R=2W&/;?LXPZ9J.F2:;=V<]C:Z5IEC=6E_#,ZRO8SF5)U$<J#<6
M=V(<,-VUNQ!W?&_P<N?%6NZMJUEK"V-W>G1I;0/:":.&;3KB6=#(NX;T<R[2
MH((QD'-`&[HWQ"\!V6EZ,GA_7?#T5CK4OE:3%:7$:I<R%L%8U7J=QY`'!/-5
M;CX[>!K+Q)XAT*_\2:=:ZGX5@BGU>&8L@MHY,;26(P?O+G'3</6L?P1\%9O"
MWC,>)M1U6*^U"=]5FNTAL1#&9;Z6W<^6-Q*JBVJ+R26+%B>U'BGX4>(=2\6Z
MOK'A?Q4-'BUO^S3<VXM'WO\`9"^8O-216$<BR$-MPP(&#C(H`ZN;XL^"X(M/
MEF\4Z$D>JVAO+)S?)B>W",YE4YY3:C'=TX-4+;XZ?#Z]TBWU2T\9>'GL+N^-
MA!<?;D"/<C!:,<_>&Y<^F1G&:\UU+]G2^T'X<ZMIVAW@UG47\'0:#!&85B:0
MQ7,LYE5F;`)\[`!(P4!W9Y$.G_`'5_$-O+=ZREG82F35K1K:^$\O]J6=[Y3-
M)=+%<9$IDB.0'963`(!/`!Z/IW[07P]U.TUV[@\5Z2EKX:OS8:I+-)Y2P3Y(
M"9;&[)#8QG.TXZ5J:E\5O#-GJVEZ5::SI5[JNKF![6SAO$:22&5@%F5<\K@[
MN.H!(KA+SX!ZA+>M/:Z[`BVOBEM?T^/[++'Y32V[03P.T<JL5*L=C*5*G&=U
M+X5^`%WX4U&`Z;J>CP:.+S3K^338]')\JXM(%@"V\C2DQQLB*<'<P.[YL,:`
M/0-:^)&A^&-1O;?Q1J%AI4%C8Q7DMS=7D:*%D>15&TG<.8FP<8/09((K*T[X
M]>`-5\2+H5CXJTB;4'TE-715F_=O9L&83"3[F-J%CSP,$U0\6?!X^*O'UGXF
M?41!]D;2F^RFUWAOL5Q<3#YL\;C/CIQLSSFL+7?V>7UB+5+2VUB*STW6?#DF
MBW,*66UH_P#29[B&6,JX`VO.0RD'<%X*YH`[>3XT>!(M`M];D\6Z"NE7<K10
M71O4V2.I`91SDD%AD=@0>E6=:^*O@[P];&?7/$^B64/E02[Y;Q`"D^[R6'/(
M<(Q'J%)Z"N2\.?!-M.\4Z9KNJW&FRW-F]^]VEO;38O7N;>VA+NTTLC;@MMCK
MC:0N.,GE=,_98;1X;26U\0-=W^GZE.]M)=PRHG]G-;"VALG\J5'/E1!0'#<_
M/D?,:`/4KCXB^"/"EY8Z)-K_`(?TVYN8=]C8BYCC+QA-X*(/X=H+#'49Q63X
M<^/O@KQ;I5CJ_A_7=.N=#O;:[G.HR7"P)"MOY?F;E<AN/-3)`P,C.,C-+0O@
MI!HNIO=I-:!#'H:0VT%GMCMAIJNJB/<Q(5@Y`R25'<URMW^S3J%]X;\.Z7/X
MFA67PG#<Q:9<+IF0P:ZMKF'SD+D-M:U"N`0&#G&W%`'I$_QK\!6OA^VURY\8
M>'HM(NV98+Q[^,1NRE0P!SU!9<CMGG%;=AXTT'5?$-YH6FZO876L:?"LUU90
MSAY(4;&UF`Z`Y'YCUKS.R_9_D?7K[6]>U:UO;[59-6EO8HM-"0$WMO;VX5%+
M$X2.V4'<27+,3C.*UO#WPNUKPQXLU'5]"UBPL;/4(OWFF16<ABN)RT0-S,#*
M1YWEQ,F4"`[\L&VB@#8UGXHZ+H'Q2T7P3?1W::QXCL9KRSG$`^SGRN/+>3/$
MC`,5&.0C>E<U9?M(:/K=SJMAX8T;7=8UC3]8ETNVT^&*.-[]HXDE:XC=W"+;
MA7'[QRO4<?,,R_%;X(S_`!(U:35M.U^?P_JD.E1VVFW<-JLKV-S'<K.EP-QP
M>`R%>X<\U@G]F=-*U2;4?".IVEF^U+6*QOM.^TVDMB;&WM)K:9`ZE@WV:.0,
MI4AAW&<@'4ZQ\:I-&U+3+&3P=XIN+F\TRYU*[@A2W:6Q@@D6-F9/-_>$LZX$
M98D'-9>C?%CP9+XICN/"VC++8ZU<V]I/XJLK2)+<WES&LT$,C9$K%T>,[MI4
M-(BDY/&1H/[/WB/P=;:"O@SQ7I6FSZ;I>H:==/)H;3)Y=W=BY/V=#,/+\L@(
M@<N,`9J]X>_9X'AF>"PT_6'?PM;ZII^JKI\EJ/M!NK.WCAC'GAL>63!#(1MS
ME2,X;%`&OJ?QNT*3P%XG\0W^CZ_-I/AN_GTS4;.32R9I&0*'8Q$\1%7!R^/E
MSD<@5V^MZ_9>$[73FN1##!>WD5G'OFCA6,N#C&X@'`'W1SZ"O*+GX(>,[WP-
MX]\/7/BSP_YGCG49;M[E-!D`M%F4+*@4W'S'")M.1@AL@Y&.S\;?#J^^('A3
M1--\0WVGO>Z9?0WEU(+`FVNVC1U*>47R(VW\C<3C(S0!MV?C_P`*:_X6O-;M
M-;TB\\/VXE2[O3.IMT"\.'8\8YYSZ^]8FF?&;P3'HL%]+KNAZ=I,]]]@TN=K
MR-8KO:J$>7SC`W@8_AQSBL*+X+ZJ_P`,+[PK>>(MTK:E!>Z3*+5I(-,2"2&2
M"V5))&=X5:'D,^<.P!``QE:U^SQ>:W=?VA?:MI=S?W*:I#J$#:?-!9W,-]Y1
M=#'%.K<-"N26.\%@W)R`#T+6_BIX=TF\U"QBU73;K5-*\@WEBMY&DD*S2I&A
M8L0!RZ\$Y.0!R1F"U^-G@.ZGU>"'Q?X?>;01G4U6^3_1`7*`N<\`L"H]2,"N
M,U?X!WVJ:EK;6VMVVDZ1K,D$TNF65G)Y<UQ%<VTHN)0\I'F;+?R\H%R'RV2H
MKD?AW\#?$DEG%I_BBTBTV"T7296NI\32>98Z@URMK$JRLGV;!.T[4(,GW<#`
M`/:D^+G@J2WT.=/%.A-#XE.-(<7J8O>=O[OGGYOE^O'7BG:?\3-!UKQ9-H&@
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M<37H_P`/O!\/P_\``^A>&[2XDNH=#L(K19Y$"-+L4#<5'`SUP.E`'0T444`%
M%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`44
M44`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`$%_<
M_8K*XN""P@B:0@=P`3C]*\2O?VGUL]%T._;PEJ\C^(+!]7M;2.ZB>;^S%\K$
M^U<YE;S0%A&6.#DBO;[I8I+:5+H`PR(5D!.!M(YS^%<HWPO\)ZCIFAQ6UAY5
MKH=B;/2I+&^F@:&U9%4QK)&X9D*HG!)'R@]1F@#S_7/CQ?RVNKZEI&CZG::!
MI>G:S+#JK"&07DMBC+(!$6W(5D1MH?`<*>F*DU#]H_\`L\2I!X:O;H_VL='L
M99+V&!;V\2)IIASGRXUC7=N/4G:!WKM!\%/!*W&J3C08`VLQ745ZOGR[)%NE
M"W`";MJ>8`-Q4`D\GGFKL_PN\+SV?V;^RUBC&J?VJC07$L4B7FW;YRNK!E;;
MQP0""1C!-`'GFO\`[1.HGPWJFI^!?!>I:PVC^'DUC44O[N+3S8^9"\L44B2?
M,S8C8MM'`QC).*M_$'Q=XUD^!,OC/0;FS\(:SI^C2ZK<6$]JFIHX6(NL6X,H
M`/!W#GM773_!_P`'WMU]HN](\^8V"6,SRW<S?:;=0X5)LO\`OL"1P#)N(W'F
MM"W\'^'9?"5QX0CMDN-$%H;2>QEN7E/D."-C,S%\$$@9/3I0!SFJ^--:\!Z'
MX:TZ]C?QKXKU^5X;5+=(M-6Y9(WF=FW,4C58T/<DD#UXPG_:!&H^(-8T/3-$
MU&&2PAO;?^T"4E2"^M[8S/'(@SM0?=$A.UG&T=03Z-XH\#:%XPM;*+Q'8BY7
M2YA<6<B3/#);2!2FY)$967*LRG!Y!(.15"P^&?A:"ZGOM-L6C^W+^_2&^F$$
M^8!!N:(/Y;$Q`+N(SP#G(S0!Y%\/OVBM9NI;*U\2V2ZA-JMS8(EV&CLK:T27
M3+&XDWRM\ID,MRY2/(+#(!^7!]A\:>-XO`]KIUYJL4ALKS4H+&:X4A5M3,VQ
M)9,_P;RBG'3<#63-\&O`J""R_L>%%+02I9B]F2.8VR0+$7CW[9`BV]N!N!`V
M#U.=;_A7&CWO@2Y\)>)4N=?TF_BFBOAJ<[2O="5V=]S#!'S,<8QM``&,"@#S
MFQ_:'^VZ=K6K6NGLT4-CIUUINGWMY#9_:4NFN/+*RMG+/'`)`F,@$`9YQIZU
M\:]5'ASX9ZWX-\,-K%K\0KRWB:*XU".VDLHY;62<'D$,V(S[?*?45T^K_"/P
M7>HL^I:/;QFU6V*3I<20-"+6.2.$JZL"NR.:5<@CAR#D5;?P!X6U7P[H^B+I
M\#:7X=D@DTR&WG>/[&T2;8RCHP8$(Q'7E6(.0:`/)/"/[2>JVW@J34/'OAV]
M\X,4TV\@GA$>K.^H-:1J%!_<D,8R2W\)+>U:M[^T8EC::7JE[I&KVT<^GWTE
MQIGEQES-!>VUK\DC$;E+W`*L!M93GCBO19?A5X4GT$:*^CP?V8L;1I`LLB[`
M9A.2K!MRGS0'#`@@@8(IM]\*/"VJ10IJVF-J'D)+&CW=W-.X62:.=P79RQ!E
MAB;D\;`!@<4`8/B7QCXDGU'PGX;TY;3PQKWBBSNKNXFNE6^%@MNL9>-%5E66
M0M*@Z@!0YYP*XS6_B=XY\+:OXXU.\OM%U+2/`TNF076E+IK0-=K/!"\TD4WF
M$J^9?E1@PXQGG(]9\=^`O#GCNQM8O&EDMS%IT_VBVF6YDMI+9]I4LDL;*Z95
MB#A@"#@UC1?`?P)'KL&L+H*/?0&!T,EY.\3/``(7:(N8W=`HP[*6!`.<\T`9
M\'B_Q'9_&[_A&]1N+:?1-2TR>ZM1+IS6K121-&%2&4N1<95V,G"[,+CKBJ"_
M'BYN--.HZ=X4U&YL-2U3^R_#LWVZ!#JUR))(V&TG,"@PR-N?JJYQG`KN=+^'
M/A[1_$$FMV%@PU-_.VS2W4LPB\U@\OEJ[%8]S`$[`,X'I63+\%O!'E743:)&
MD=U>"]*)=3((;CS?.\V$!_W+&3+9CVY)/J:`.)O_`-IZ#3[>-W\*ZU)/;+.=
M7MUN(-U@8+S['(`=V)3Y[(%VD95MW&,5)J/[1UQ8P301>#M5N==L'U$:CI4=
M_;C[*EDD$LK>:3L?,5U"ZA>I;:<$''7K\)?`5AI1MSHMC%8QP-;.9)WP4:Y%
MPP=RV2QG`<LQW%NIK*\5_`[P;XK\7P7^L1+^]COGO=-CN'C_`+1DN4MHWD?:
MX8@1VJ(5'RD$Y%`&;!^TC97<T-U;:#JK^&[NYDL;76O-B`DO$M7N6B,.=ZKL
MC==_3<,8Q@F)?VCC'X8.JZCX5U.PGO;JRAT6TGO(?^)BMY$98)/,4E8AL20L
M&R5VD<\5UW_"G_`?]N27JZ'9"^<O.84F<(K20_9VE6`-L5S$-F\*#C(SR:TK
MSX=>&+O1(M/N-,C%C;+:+"L<SQM!]E/^CE75@RE".""#US0!PME^T+)J=YI<
M.E>$-<G%S!9S:D998H#IRW-S):QDJ^&D'FQ-RH^YA^X%=+\&/B#K7Q(\(R:S
MXH\/Q^'9?[0NK:&"._6[6589WBW[E`QRA&#W&1P16M;>!O#6EW`E%H/M5Y%!
M!YMS=R2RS+!*\\2EG8LQ5W=QU//H*K:5\,-(T+5K>]T`7NG007-W=FQ@NW^S
MS3W/WW9"2.I<A1A0SEL9H`X6V^/?B"3Q-KNB2>!WFO;;Q')H^AQP:S"/[1,5
MJMS(\A8`18B(;G.=RJ.0:TM4_:`L;7P+X;\0:;I5[=W/BNX>VT_3998[=Q+&
MLC2B20Y50@A<9&<G&.O&_KGPB\$WM_>:OK.EQQ7=W=I>S7:WTUN5N%C$(E5E
M=?+<QX0E<%A@'-:3_#+PRWA[1]$BTJ.VTW0)(Y-+BM99(&LWC!"LCHP8'#,"
M<\[CG.30!Y=/\>KUO%EBR0WEKHVIV6BW$%E/9*EQ$UTM^TB2[B"O%J@[D$<#
MDU<\._M*_P!NS6#3>$M7L=/NYM,\V[EO(&%O!J7%C*55BQ+L0&0#*9!)/;T*
M7X5>%;FX@N+K24N+BVCMXXYI[B623;`)1%EF8EBHN)N223O.<\46OPI\)V5L
MMO:Z+;1PHNGHJ!WP!8$&S'WO^69`QZ]\T`>=Z-^T)=7-S;65MX?U367%T_\`
M:%VDD$`LK=M4N+%'V;LR8>#)"\[1N//%4_%W[3&H:1-X@LO#'A6#7+[1KK3U
M@:/7(?(N[>YO?LA?>`=CB3C8<XR,G@BO5-.^&7A?2)9Y=.TBW@DN5VRLKO\`
M,/M,EUCD_P#/>:23ZL>W%9*?`SP':V&H6RZ#"EKJ$2QW"&ZFPL:SFX54._\`
M=!9F:0;-N&.1B@#(T#XYQZ]\0O\`A%X]#U",1W,EC/?K(LJ07L4(EEB95&1&
M!E!*<!G&`.0:R[SXA>*]7\/^./%?A_4-(LM*\)MJ]G%I4UB9I99;)74S22AQ
ML8R(2$VD;"I)R>/0M*^'GA[3-7;5](MIX;J=EED:/4)_+G<0B(2/'OV.WE@#
M<02<`DD@&L[4?@GX+U77=1UB^T17O=71EO\`;=S)%<[H_+9GA5Q&SE,+O*[L
M`<\4`<CX6\<^-89VT#6+K0]9U>\\(KKVG:D;-[1%?<J/%/"K-QN=2K*1D!@0
M",GDO$/QS\<:?X)\+>)(H+2TM)?"=AK5],VC3W%MJ%U.ZI):B1&_T8*K!PS9
M^\.RMGUG1?@EX+\/Z+J>EZ1I#P6NL6Z6]Z_]H7#SRPIG9'Y[2&547)PJL`,G
M'4U'8?!7P1X>T>QT^VTR6+2=*">19SZI<RVZ+')YB;D>0JP5N1N!`P,<`8`*
M'Q'^.>F^!WL[32[.;7M5NY[B,6<,H@V"W0/,2[#&0&4!0"6+`#N1A7'[36FV
MUSKD,N@ZXC^'=&&MWR2*D<B64D<;P/M/\<A=T\OJK0ONQP3Z9XD\(:-XM%A+
MK5O)/)ITK365Q!<R02P,R%&*21LK`%6((S@_E7*>+/@-X7\1^']9T^RM/[.O
M-;LI[6;4U=Y9PLT<<3EB[9?Y(HQAB<;01@\T`8MO\?[HZE'H]YX0U*U\1+JD
MMC<Z=)?P,D"I;QW1F,P)4KY$H;`&=P*X[UGZ?^U!!JOAC4=:L?"NMR00Q6EQ
MIY#*T=U!=.4CDDE`*P8QN<-G8K*3UKT70OA1X4\,W4%UH^CQ175M<S727#S2
M2RF:6,12.SNQ9B8U5/F)P``,8JG9_#'P?9:-)96$5U;Z7)A!'#K5RD40$C$)
M'B7"+O=AM7`YVXP```<9K_[0;06WB2.VTR:R.B:1%?+>&Z@E^T,ZQ.?L\9($
M\0$H'G*2FX$<<9FN?VBULEURZNO"^K)I.EK>I:WYN8=EW/:7:6LT97.8E$DB
MG>W&T,W&.>K'P+\#>5'$V@QO!!IYTZ"![J9HK>V*Q*8XT+[8P1!$#M`)V<]3
MD\6_![1/$7A&_P!$TV*/2C>2S3K<(AEV2S7*7,S%2PW!Y$!89'?!%`&-I'QM
MFN_AQ/XHU7PY>V-RNL-I%II:7D4S7EQ]I%K$4F&$\MY3PYXV_-56Q^/TDOCB
MU\+ZCX5U2UOTN;>RU8QW,=P-/N9X_,C7"?ZR/849I!@+O&1G(&WI/PJT:R\*
M7?A;Q7<'7;/6+^2Z,%U(R+$Q82+';C>7C6,H&7#$J06!';5L?A;X8T74EU.P
ML[FUNU\LRS)J5P//,;.R-,/,Q*07?E]QYP>`,`'BO@W]I/7X;2.;Q+9KJ_VR
MRTTQM'Y=E!;23/>^;+/.WR1H5MD`W8!;C(S79?$3XG>(/#'Q2T*Q6W>#P?:>
M';_7]9OH)X&DDCM]@*%&!8JOF`_)AF++@X5@=W_A4WPWU*%]$AL+(K>::BRV
M-OJ<J&YL@9%7>B2`O#F:4<Y4[C[5TFJZ-X5O)6U+6(=,D%KIES8233R+Y:63
M%?/C8$[=F8U#9Z;<<4`<1I7Q\>;6+'2/$7A?5-%U34+RPCA@DNH9Q]GO!<&&
M8NA(X-M(&3J#C!(YJ>Z^.3IX@LM,TWPUJ=^DB6DVH74=Q$BV$%S=26L;E6(,
MF)(B2%Z+SVP=/3_@=X`;2%CT_1XY;6Y:TN([E-0GDD(MT*VQ2?S"X5$8A0K!
M<,?[QSL6OP^\*>'4C-IIEK9K]FMK!/WC#]U#,TD$8RW:21B.Y+=Z`.9\!?%>
M^\?^*;46NC7VG>';W3KJYTZ^N'C==16.>&-9`%.Z,_,YV-U5E/7@8.G?M"7#
MWL5E;^']5UITO9OM]S')!`+.U&IS6(?:6R^UH\X')4%N#P?1?#'PN\+>#-3F
MU#PSI,5A=3)*A*32,L:22"5T1"Q6-3(-VU0!GM5?2?`G@VVN[E]'T^R^T7,;
MK/Y4S,65KJ2=LC<>/M#2-]<CMB@##^)?QMC^'6OQZ9_8.I:OLLX+R[FM9HD$
M$4US]FCP'(+L9608'8DDC'.%XB_:1C\->#+K6]1T!X[[2=1N;/5M(?58%GM_
MLX#2/$>DXV/&P"_WP"0:]*UWP!X>\37LMWKNF07=Q/;PVTDCLP+113B>->".
M!*H?ZCTK(UOX*>"O$<]Q-K&A0SRW<MS)<,L\L9F-P(UG#[6&Y7$,65/RG8.*
M`.:U3X\W-AK6M6MEX0UG4K#1)+NVDOH+B'][=6]L+EH4BSN^:$_*W0M\OO78
M>!/B#:>/I-7DT:-VT_3+M;2*\W`I=OY,<CE,<X4R!#G^)6]*T;;P7H^GSW-S
MIMC!!=75[)?22?,VZY>(0M(03R3&`N.F!6?\+OAUIWPK\#:7X:T3+V^G(Y:4
MKM,LCNSR/CMN=F..PP!P*`.LHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH
M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`
MHHHH`****`"BBB@`HHHH`****`"BBB@"CKD;2Z-?HB%V>VD"J.I)4X%?-/A>
MP^(G@#X*:;9V&J>)+MVTGP[YZW-BGVG1XGS'>I`$A))1%C^4H[(,MR:^H9I%
MAB9Y2`B`LQ/0`=ZYNW^)7A*[L=3OK3Q)H,UGHC;=2N$U"(QV;'M(V<*3[T`>
M%7FJ?%)[>T_LS7];N1IMG9^7<VFC_+>/+JSVTGFB:%6=H[,AR0J`LHDQMXJO
MXA\6?$?3)K70[!O&<][H_B-DM-6-JACU6R%]`A2<+`5=A!)*V[,2[4W9+`BO
MH&'XB>&+@Z2+?7]%E;7BPTH)?1M]N*CGRL'Y\>U0CXH>#SI=YJ(\3>'_`.SM
M/N1:W=U_:47E03$X$;MNP&]J`/`M+F\6>&(;O3-3\0?$H:;+XPU<:MJ2V'VN
MZL[<&62Q$!\ALPRC:2RJP!VK\F[%9^E7_P`08M>@U'QA'XJT"/Q#INC+XEU7
M1](#W,,D=K=LJJ@CD"9E,:OM0[2P7Y0:]ZUKXQZ!X;\+:#XAUN3[%I.N7\=F
MES)(BQVYD#[7D8D`)^[Z@]Q6];>.?#U[:K=6>LZ5/;'R`)HKM&4^?CR,$'GS
M-PV_WL\9H`^:/#/CWX@:QXQ\-IX\U_5M#^S3Z;;7UH;1(8;N6XM))!;31K$^
MV>1S"V=Z!1N3`."=+X?>+?&>C^&IKGQ;:^.DU/1?#T/]G>'-*T>.&WOHC8([
MR;O*(6<7`E7;N&TJB["&Y]OU?4/`>E>,[637)?"]IXJN(=]N;IX4O'C0$;AG
MYR`"P!],X[U@Z;^TO\.=8U#2HM.\3Z1+9:S;SR6>HM=I'`\L4L<3098@^83*
MI"XY'/ID`X'X9Q^+=6\8>#[OQ8-;OX-)U37X;?4;^W(?[(T$'D,[>5%D,V\*
MQ12=O3BH=5G^*-]?ZY+:ZYXHLXFB\0S6L-OIL.V-K&X0:=&A:(G$RNY.23(%
M`&,5[Q-XX\/P:Q/I%QK.E1ZM:VINI[%[Q!-%".3(R9R%`YSZ<TQ_'WAI-#.M
M-KFD#1DD>,Z@;R,0!D)#+OSMR"K`C/8T`>#^)?%'CCQ/XLN;.'3_`!1::?<>
M'[VTU33Y+;=:3.VE^;'+"/)RN9W\H9E+%D92HXK@]7\1>./#5G/I,.J:QX.M
M+>P-\U]!8+&;>."QTM#/-^YD:6%&>Y5AM!ROWODQ7UB/B-X7*V)/B'1-NJ0?
M:+$_;XL7,05G,D9W?,@56.X<84^E<]K_`(T^%VL:19>(O$^K^"KW2[>9H;35
M+RZMY(DDX+(DC'`/R@D>P)[4`<,VL^.=-O?$OB66Z\4ZKIUG<:K:V6@VEG$!
M<6L<*R6TT+%-QD+;P&)(;.-O'/.Z-=?$W7M'MM)37?%=C!+J>LJFL?84:Y-O
M%;126FYI($!4S%U!,:E@"OO7N][\3_"&FI,VH>)-"MEMK9;J;S;^-?+@8J%D
M//"$N@!Z'</6GW'Q(\*VIL?M7B+0H?[3A\^R,FH1+]ICVEMZ9;YEV@G(XXH`
M\2\0ZUXRU/2_'JZK-XI_M>#1IHM'T>+1DDT^[B-BCK.28B&E,YE7:7X(";,5
M3CU_XF7$_B0W7B*\T2[W7=L+271;BXAMXDN8A;2VS16Q"[H&.7W2Y9]VW]VP
MKWNU^(GAB^;2%L]?T:=M?5GTD)?1L;\+]XPX/SX]O>L^+XQ^"7U3Q#IG_"2Z
M/%>^$PIUJ&2Z5#8@A2"Y.`!\R@GL3CKQ0`?"SQ/+KOA'21JEKK]GJ)L(I9XM
M9BQ<`,652[A$1G.PL0`"`RY5<XKR+XL6WBOPK\<;WQYX,T/6-;?3_#]AI9L[
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M(XX/W<Y(.`<'%_\`X6MX,&G:A?\`_"4^'OL&E3+#J%S_`&E%Y=K(WW4D;=A6
M/8'K0!X%X=\/:M!XC@F\5:9K!\6:;XBNY_$.MI9RYN=%^P.-D<Z#]XC.T02)
M,L'4X4$9K/,]LW[*^@V3:-XQ%YHWB&W%O8KH]_Y\?EZB)MS1A=SH+<D[F!7/
M'WN*^C-6^)NAZ=X?T[5=-E;7(=:=8]'BTDK</J4A5F"PD$*?E1V+$A0%))%<
MWJ'[0&D:/J<]KK.@>*[&'3]-AU#5KR:P7RM+AEDD13/ARP`\F1BRJRA5W9Q0
M!4^,>@ZAX[N?AL?#EYKFD1OKKW$NI6%N%GLHFTZZ`9A(A"99D0[ER"V.#7#3
M>,/B"WC'PO;6[^)[5[+3XH=9FN=/\VRN]^G2RM=")(<@K<B-"!*&W94)@YKU
MS6/C'X;T/6-9T_4Y+V(Z%H1UN[N/LK&`VH.,QOTD;IPN>H[U:\&?$BP\96VJ
M,+#5=%NM$G$.HV6K0+!+;,T:RJ6PS*5,;JV0QZD'!!%`'C>H-XF\7_LP>-+#
M45\2ZEKR"2WCNY[4M+?,#$S36L1BC?RLEMJ.FX%",L`"<6\\4_$F6$6VF:SX
MIM?#J7NHG2O$&H:.XN[IXX[=[<7,4=LS>3YC72@>7&9!&HW#(S[_`/\`"V/!
M7]@#7CXI\._V-YK1?VA_:47DAUQE=^<;AD9'49J;4/B/H%AJ^GZ4FI6%SJFI
M/%Y-E#=QF8Q2?=FV9R4]QZT`>*6OB?XEMJ_C"YN]1ODO;:RU=;+1QI,K0R>5
M"'L);8^2%!;(+;I6+%BFT%>.TT7_`(3O0/AUXSD@U#4?$7B)+`7FB?VI;1HR
MW#VBN80$50RB;=A2,C.TDXKK[WXE65OXG;0[#2]9U6>T:(:C/I]L)8=.\T9C
M\TE@<D8.$#$`@D`$&L+PC\>M%\76ULT.D>(]/FU.RFO=)MKRS4/JL,9^<VY5
MV5F&5.PD,`P)`%`'FNDW/Q!UZRTO2K3Q9XE2TU*]N6GU-=**7EC&+`3)'(\U
MNB<W(P,)P&,><\C*F\9^,M4\>O#JOB+5;:"WWZ<NGBT06VI7)T43BV\L0MB?
MSV>0DR`%4V;>!GZ&\"^/+#X@:3=7NGVM_8RZ??2V%]9W\0CFMKB+&^-MI93C
M(.58@YZUYOK?Q9\/>&/''B"?4/AOX@@U?0])GU6\UK[!9@/:1+(HE$HFWD,(
M61<C=T!`%`',^%YOBA]A.HVMUJT5SI=M'96&@SZ?%#9W&=#256?Y`P(OODR&
M"C!3%4;3Q%\1'\&V^W7M?N+?4-6L1J5RVF2Q7^EPRV\AF&3:`!?M`A'R1/Y2
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M<GE7UVFI1&*V?.`KMNPISP`>O:@#RWXO6?BK3?$?@35O"5UXH0V>B:E$NG:>
MN^TN+\01-:1W*[#A7<.NYBH`'52<G7^">O>)+N\U\ZG=>*M;T6WTRQN+:;7=
M+6RN3J#K*UU;QC9'E%'D@`KA68J&../0=%\?:-KEBMQ;7MHA:-YA$UPFXPB9
MH1+P?N,R'!Z&LKQ+\</`/@Y[A/$OB[0+&2TO(K.XB>^0O!-*V$1U!)4DYZ],
M$G&*`/#M$\:_$+4(;V6^E\>:;X<U+5]/>:X;3EN-0TF":WN&FBC'V9<[)UMH
MW(C<(&;#$<B:SN/%[MHNDZI)XMM;**VTZ:RA@\/CRM3D>_D-X;L;3Y#(@A8#
M<NP,6`;D5]$W_C30M*N],M=5U?3+.ZUEPFG0SW:(]V3C`B!.6ZCIZU0B^)_A
M&:RU&[@\2:"]KI$QAU"9=0BV6D@!.R0Y^4X!X/H:`/#_`!!J'Q+73[6ZEUOQ
M%I\.KZYJ\-U+'8Y_LV.WDE73PJ);R.(I57<[E3O(0!E#<LOO%/Q`>[\06\FO
M:R+BYLK:2'4K71;B*QLD#VZR0B(VS2+<2!YBLJF55'+(I7%>WZG\4O"^G66G
M7,>LZ3=/K"(^F10WT1>_1F"[H1N^=1NSD9Z&H-0^+?AW3+0/>7UI!=RW5Q;6
MMC)>0B:Z>&4Q/Y:ASNP03CJ.A`.10!YYXNTK6_B)X=^#\MK)XL\.7DFI"XOK
MHQQ-J&G*VF7*YF/EF-7+,J$[`,M@`$UCCQ/X[O\`QUX2T^2/Q4L5O906VO\`
MG6@%GJ"R:=+*]P%6'",+CRXR?-!#94)CD^L>(OC5X#\)0:M-K_BK0;-=#ECA
MU-3>(7M'D?:BR("64EN.1Z^E;%GX]\-ZAJL&E6.N:1<:E<VJW<-E'>HTTD#`
M%9%0')4@@@]P<T`>"_LO_#[Q)X4DU;4KQ-5^V3Z7H=K':ZT1!%'$NG6YE6,B
M(OF.0,FW.`0<_-S7)^,_`GBG6_#W]CV]IXAL;:YU'5YKAK*S7S'#^);=D4LT
M;?(T#22[>C!`QR!7TE8?%KPW=^/-5\'S7]K9^(-,EBC2SN+B-)+P20+/NB3.
MY@%;!XZJ:L)\5_!LFE7&IQ^*?#S:?:78M)[H:E%Y<4YZ1,V<!SZ=:`/,_AQ>
M^-8_B?>V7B+5K^/3;.YO;--,N+!O*DM(@OV.>&1(%C5F0AG8R'<S,H5=N!S/
MCF#Q5XT;7;#4+[QI;:FGB^RBM;&VTI/L=G81:E;-#>0R&(AG\K+EB[#.\%0$
MKZ!UGQIH'AV6P@\0ZMINF2:K*(;%+NZ2(W4AQA(]Q^8\C@>H]:2S\;Z!J.MW
M&BZ?K&EW.L6B&2?3XKM&GB0-M+,@.0-W'3K0!X9XCUWQ]HM[X5T33;KQC?7F
MFZJOFZJUJAAU2T.J"%DG5(""Z6@,A;=$,$,-QX'*VNF^-?"<VO7_`(;TS5[&
M619H9;I+-FDBM9/$=X\KQ#8^YQ;R"1<(QVL&`/%>_:#\7+#7-3\00OI&L:9I
M/ARYN+:ZUV_$$-B\D#[)0K>86`!SRRJ.#S6TWQ"\,)X=@U^77]&30[@J(=2:
M]C%NY)P`LA.TG/&,]J`/%;"3XCZK-8PQ^)];:VTC3OMB7=MI6Q=1E34718)_
M.A5G/V8`,55-QQ(.,9Y"/X@>/[N^\17VF^(]9FN;F"Y-EI8M5=7M8=66">[L
MT6`\Q6O&W=*2S;L'I7TA;_$[PVUIHLFJ:OI>ES^($W:?:WE['')<<X^0$_-^
M'J*S8/$WPV\(ZMJ3V^H^#M'U+S%&HE;FW@E5Y)#@2<@@L^[@]6SWH`\P\.^(
MO&MGXM\(0:MKFN^(--:YEM6@LM+FMVVM/,$N+N66V598TB1%;;Y1R`ZA@X%?
M14>2@W')]:YC5?B5X<TR76+1]4T^XU30[)KV^TR.\B%Q%$H!W,K,-HY'+$#D
M9(J[IWCCP_JFN/HMAK.ESZQ%"9I=/CNT:>-`=I8H#D`'@GUH`W:***`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`IZ
MS"]SI%[%""TDMO(J`'J2I`'YU\Z^"?V</$3>$-#N]<OM#TO7[#2/#\%O81:8
M3`G]G.TQ2ZQ(3*S/*REE(`V@C-?1&N:A+I.C7U[:VLE]-:6TDT=K$P#3LJDA
M%)X!8C`SZUX]HG[3FD>-=5.D^&=-O99YYK5;6<RJJRP36;W$EPHZE83&\;#'
MWP!QDX`*=A^SEJUGJD-]!K6E6%Y?7]U<:S=Z?9RQ/)!<32226D2%R@C^9<.P
M+JP9@1G`KZ'^S5JN@Q:!/9W_`(<?5?#9M$BFN+.YN(M0AA@N+<+/&\Q"D)<%
MEV8P^<Y!`%;PG^T#KS_#/P]JGCW2)])N)$T.:6^MYX;A=0M[PNKR[`O[HYB<
ME!D@,N#GIIZY\8_&MU:>`]2\/^$%1?$VI2?9=,DUF'.HV;:?/<1LTNPB%P44
ME0&Z8!.3@`Z+6/@[J%Q\//"&A:7?:,M_X1U*UOXGGTXFTG:'?\GDJ^47Y^,,
M=N!UKD-!^`&H>'?'7@8-<1W>E:7:SWWB":.V6&&\OHYY)+)(TW$JL37=P5'.
M%C09R!7;^._C4O@WX9V'BN+2X+F>^L/MRZ3<ZDMM,8E@,TJH0K[W10<@#'<D
M#FN`U+X]:CH7CJ]N=2F?_A%[&2:YEM5MT,HMDT.*]"`_WO,9CG/?'2@#K/%O
MP-U#Q'XQU._AU72DTC7-4TC4;Q+C3C+=P/8,C"."3=M57\J/J/EW28SNXS-$
M_9NFM;%++7+[1;ZVL]#U;2;0#3,'9>7,<R2N&8C>OEE3C&>.E3ZC^TJ?"\MY
M:^.O"MWH][8HLDJPZA'=Q;9;:XGME#J`2\AM9(MNWARH!8$&HK;]J"+5+?3K
MK2?#-R;"[>VBN]0O;Y;>UTZ9X1+-#/*%94>/>B?-@,Y(RN!D`=KO[.LVJZ_X
MJNDO=/DM_$4U]<V\UTMPT^GS75@UH^U5D$;`9R,KD*2O7##7^)W@/5;GP?X(
MT?P?:6%Q<Z!KVFS2>?`/L\<4"L&D9`P)4''`.>1UQ6%\3/BSX@\%_%U(I;*1
M_"6C^'?[0E2UO8DEOKF:X%M%&ZO&3M\QD`PZX+%B2!MK8L_CMJ5SKMOX;E\'
MR1>*6U9]/NK+^UHV@AV6T5TTHG"_,ODS`@;`=PVX'WJ`,"Q_9?DC\,:QI\^N
M6?VO5_#IT[[3#IH5+>X:_NKUV1-W^I+W(3R\YV)@GGCE/B/\#/$LNKW6JO:6
M>L7/B%;Y;^UT6P\JV16L8K>*!@THDV2^6V^0-D';QP"/6M1^-9MOB8WA/3?#
MU_J45I<VUIJ%_"Q_T::XC\R/]V$.8PI4NY90N[@-@XXU/VE=:\23Z(G@KP9#
M<0W/BA?#VJMJ&K+";>[6":6>./:K;]GE+B3[K`\#G(`-Y/@_KXTS5KC2=3T[
M1M3\0:Q8ZE>V\<+/&(8K.""2R\Y2)-FZ(L'7!Z#')K(TK]F+^SM(T6QN-5L+
MO^R--\/V7F2Z?GS!IM\]RYP6.!*'"XYQC)W=*LZ5^TXFI>&-1UY/"6K#38H;
M2?2I5ERM_'<W*V\89F4+%+N=6*9;"G)/:C7/CQKC:3=V-CX/NX/$UIIVH7>H
MVJ:G"XTZ*WD,(FC=@!/EL.%POR@YP<`@$NB_`34_#WC>WUO1M6TVS0:S=7ES
M)':R>=+9S74UQ]AVE_*V!I5P^W<I#$8W8K1U[X2>(IO$7BO4/"^O:=IT7B:\
MT^[D5K-_-_T=8XY8&D5@1')'&?F7#J6R#65?_M-V^F7FN"7PWJESI.B2W5F=
M2@?/F7ENRHT;J5"Q(TC;$=GY/8#FNP\*^-]6;1?%^I>,-)ETJXT"=B=.^U)<
M;$2TBE.R50`RL68@D`\X(&*`/+]3_9RU#P]\.-7L[&XM==U+_A"9M#MH%M0C
M/*UU-.70NYQ_K0H!.24!)](=+^`>K^*()KW4+.ST]A>:I$\&I&=#JUO>PP!Y
MIUBFS%*'A"8#$-&.BELBWJW[0_B35I=`@\/>%7L]7N]6TR2/3I]2A9-0TZ^M
MKJ2(M+M(A?=;DL,,5VC!;-=8G[0(.L>"K%]#C0^*O(BO(O[41KC2;B9)&1)(
ME0@K^Z8;]PSU`-`%5/@)>QRWT,>I:7#I\_BJVU^!8K)Q)&4MEA>%B7(*Y0%6
MZC)SD\US?BGX&7WAKPOX.M?#D7VNXT4:1:7]SIE@@F*VEK=Q&<(77<&-PH(W
M9"ENM:MU^T]<VGAK3]<?P7=M9ZEIEWK,2C58O,&G6OD^=*P(QYF9L+&"<XY9
M<\6/$_[2DGA30==N=4\-00ZSX<NW6\T>36D$LEJMNEQY\+*C>8?+D3*X`4G!
M8#!(!<L?A?KUU\-_AX=&&E>$O%/@E8Y+2S='O+)%\A[>2WD&\.RF*0\A\JP'
M+#.:OB#X.>./$>IZU+=>)?#%O:^+_#\&C:]Y.C3&2.)&N-QMMTY"EDN&7+[L
M8W>U:&H?'JZADU";2?"LM]IEOJR:'973:G'"UUJCR1QB$QE3LCW.09"3]P_*
M>,\SJW[1MU9>)O"<4VF36%QJ.JZIH-]H[SQR++J4(@$*K<X"K'F3.\@9#8V[
ML*0#I/$/PD\0ZIXYN[^WN?"=QX8F\+OH":3J.G3RO)$?F_>N)0K`N`"`H^7W
MYJ_X8^$6H>%_#?C.'1M8ATS6_%DC2P7-O"\T.FN+9((2BRNS/M$88Y(!).`!
M7-VO[0.H0ZC=6%GX:O=<N+2_OC?2?;88/LMI!J+6C,HV_O"I`8+P2H.3GK7\
M1?M+:C_8/C#4/"7A":]B\/V6HSZ?=W5VT<%RUE+Y4PF(3]UDAF0;F+A&^Z:`
M+GAO]G6>QO;.Z\1:EI^HE-=O=4NH&M7E23[1IRV>S,C,3C;O)/7)``JWH'P(
MU#0/$MM<PZEHD^EQ:A8ZB5FTHF[BEM[-+4QQ2[\+&5C5A\I(W.O(.:AM?C;K
M4.N7NBOX<:\\43W]M9VFC_VE%';Q.VGB\FQ<[,E57/)4DL<``=.E^(GQ8O\`
MP0FD6^F^&9=9U;5K*[O/L?\`:$=NL$=JD;S!I"""<287`P2.H!R`!O\`PK_Q
M1HGQ`UC5_!VMZ-#HOB>X@NM5LM1TZ2>:&>.)86>W=9%`WQQQ@APV"N1U(KE?
M"'P0\7:'I^APZQX@\-W9\&6%S:^'XHM)F6.1I@$:2[S,2_[O<FU-H^<MV`JP
MG[2#ZH1)X9\+7%];75Q8V.G2SZC';FYO+RUBNHHBNUMB""7<SDG!7:%8FJNI
M?M/2V-A--%X.O9I](MKVZUZ$ZG"OV&*SNC;7)C;!$Q##<H&W<.I4\4`=M\-/
MA_J?@#3WL_M>EM:WNK7-]/:6ULZ0V:2*-L-L"Q(&]?,8MG+2/@#(`K^//A1-
MXRU#Q9<1:C#:KXE\&2>'41H"_D.S3'SCR-P_?#Y>/N]>:Y5OVGX1%KM]%X6U
M:?1-*CNC;7\4F?M#VURMM(C@J%B+.QV9<[@C9"XJI+\;?%\=UXPB\6>%K+0+
M?PWJ&CVL<]CJRWLK->36ZE&#1*N-LQ.X=!P!G!H`W]=^`L.HW%M)9/I,4$-S
M+/-9O9$0W6_27T\HX1E.#N!.,':-HQP1E^)/A1XEM?@1K?A>&ZMM<U&XOH6T
MVV6(^5:VRW,+)!F1]\BHB,27;<P)&>E&D_M*SZQX=U+6-,\$ZW<6<=M;W6E2
M1,\B7<,TWE!I6$9\DKQ(X`D*Q_-V(KHO'?QJ3P;\.+/Q1;6>DZI-=VANX[&+
M6T"SQI$993;RA&\[:HR,*`>I*B@#G](_9WN#JMSJ>NZM8&ZU(:TURNGZ?Y*6
M[WZ6T:M!N8E2B6P))R69V/'2LJW_`&;M?6_TG5[C7/#8U;P];Z7:V,,.BLMG
M=168G!:X3S-Q=OM#D;2`A1<9YKI9?V@Q'KUS%_PC5X=`TT1#4M7^V1YMFDT\
M7R`0XW./+.TD'AB,`C.+_@CXGZCK;:SJGBC1[C0=,M-"M=4MX6NH[KS8)/M#
MF4,G.[8B@H>A7@L.2`8-O\!M;TZ\L9-*UK08(SI*Z;J$:Z0R)Y:WSW8\A%EQ
M&#YC)@[L``C/2C_A1&MP^%9-#@U7P]+'8:ZFK:5=7&DLTTC#4/MGEW3"3YAU
MCRN,\-[5?@^-^NW=CH/V7P03JGBM)+O1;)]<B59[%(DD::2381&X$B#R\-RW
MWL`D5=&_:.E\57NGCPIX1O[W3[NWL9)[J:_BA:V>\@:6W0Q\[OF38Q!PNY2-
MPS@`Z/6/ASK%S\08_$NDZCH\8NM(@TZ^@O-.,YA\F=Y5EMCN&TGS'!#`CY8S
M_#@\7X?_`&<M8AO'OO%WB.SU>_GU+1+NZE-FY%S_`&>\S,S!G(5I#,3A0%3'
M`-+)^U9:7R6*>%O#EUJEUJ$%N8HWN_*5;AK=[B>W=@CD/%&J`X!RTBC`&36Y
MIGQVN]=\00V%CX1U.WT\FWBO;Z[N$AEL9KBQ^UQ(UN1N.!\C<C:Q'!&<`&:_
M[/=Y::SYNC7^@+IEU!9Q7%K=Z096MOLM]+<QFV(<",D3,IR#@JK#IBJ</[-^
MIV.N:O=VFLZ'<VNOW,DMW%?Z09GM@-2GO8S;MY@VM^_*L2#RBL.F*F\'?M'-
MK,WAVPMM!U751>6.FR:I?K@/;2WL(DC)B1-I0`@R/E0H/`;!`S[S]HWQ1J/A
MS3=6\,>`HA_:]YHWV!=0UQ$6YM+^=H5?*(2D@9<;3D`.K9."M`$VJ?LX:_K]
MWXEO->\465_?:K9&ULYYK%V"A=0%W%YB;]H"JB1$)MR`6SDUOZ+\$+K3OB)+
MXDOY]*OH[K5(]6*,+A7L[G[$+:00@2;"O'R[U)568<\$7?BA\4M2\*B?1_#.
MASZGK"Z#<:M<M'=QQ?88$^3S%WC$K"0_=XR%)ST!S;S]H233;R8IX4U34=&7
M4;W2+2]LKA);B\U"TBFDEB6VP&"DV\JJV22P'R@$&@#6OO@TUUXK\0Z]#?VD
M-_J^JV=_9W!L0\MBT%E]FX8GDY+,.@PQ&.37"P_LU^(X]-U&>?Q%I-QXGOKJ
MVNH-8DM[C=97$-DUM]HC`E^9V+%BC9CPQ7;C!K2G_:+DM3IU[/I?G/=Z8\C:
M78ZA',BW!U"WM$1IF1660-<#<K`;?F!&0*DUK]H_5M(_LNR'@6:77[J1TO--
M.LH#%MOA9GR7$9\_YB)"-JXC.?4``V/BK\'M>^(D^EP6_B6&VTBVAMQ=6LMJ
MQWSQ7,4PG&QE!)6(IM;*C=N`R*V/"'PFB\,:[)JK36DUT^JZQ>^:EJ$DV7TZ
MR^66SD[=J@^N!TQ47Q#^,2^!/$NA:3#IUMJAU6\M[:Y":D(Y[3[1,(87,.PY
M0N2-Q9?NG&XC%4/AQ\6]7U_X7ZAXM\<Z/I'A^2TN;V*.)=8#P2+!<20@M*R`
M1DNFWH<GD=0*`,N[_9MLWT?QBVGW5K!XA\4:Z^JC4)+=Y(\"\2ZB@EB+X=,Q
MJC8VD@FM[Q1\--;\0V?A>Z6\\.PZQX<U2:^:W?3'>PN%EAEA9&CWALA)LAL\
MLN2,&J^C_'9=0^&5[XJO=#FM[RRU=M'.F1W8D\V\^U+;(JRLJC8TCI\S*,`G
M(XK/G^/^I+`MC:^"[B?Q6-:N-'DTD:M$L2SPV8O"PN-N"AA(P=H.[@@=:`,?
M6OV;=4O]+;3;/6M#2SU/PU9Z#J1ET<DV\=O,\GFV8#XC++*XVG(4K&V3MP;L
MW[-JW$FIO-?Z?(^H6WB:+?)IX9E?5;A)4<G/)B5-I_O9XP.*L7W[1QMM.U75
M[;PM=SZ%H<-LFHW1OXTFBO+F&&6*W6'!W#_2(5:3<`"Q."`2.K\)?%>'6M#:
M\\3:=/X;NXKF>WDAN=[0GR@&:1)BB@Q;2/G8*.&]*`/.;S]FSQ#K,VK'Q!XM
MM[X7/A[4]%LI7LWW117<<"H&7?MQ%Y&.`&?=ECFNGT_X2W_@H:AK7AQ=*U/Q
M"M_JU]8B>'R0S7FS;$\F<A%*)N(ZA1@<"KGP[^.$/C>/64OM,73KO2M1CLHD
MMKIKR*\,MO'/$R2"-<!DE7D@#/0D<UR]C^UMH>HS206VC:CYZV]C*L;R*-TD
MI)NHAZO:H`TF`>H`[T`>Z6Y<P1^=M\S:-^W.,]\9YQ4E>&67[3CW?AU=1?PA
MJ,$^HW-C#HD<EP?)OOM:221[IO+PC*D3M(JA]N5P6W"H_"GQ\O-<^+5IX?FT
MN\M)-=T"TOK;2[U1`]F5GNTNY&=@"XQ%$40#<P(8!1N(`/=Z*13N4'U%+0`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`-<9'
M)QS7):)\*?"'ANXM)_#VA:;ITMC#<P6QMX]GEI<R^;.``<?/)EB>N2<8S6WX
MH?48_#6JOX<BCGU:.RF:PBD("O<!#Y:G/&"^VOG;1KGXDW6@ZG%I5S\0&CN8
M-!WW.M:>D5W;7L]X%U$6X,8_=);D'HR*0=I.#0![B?`/A*&UTW1WTW35ALXK
M<6%FY^ZEHV8MJDY(C,GN!NYZTS0?A5X1\+BR&AZ-:6@TV<SV05W86SF)HODW
M,=H\N1U"C@!C@"O-/CGHGBO2+_PA>>`;?7=6N=#T74+>>_AC6YNDC>6Q61P2
M,-<&%)V08^9DX!Z5SR:?\2->:72M-UCQ_I^@BZU4:?JMQ:I%J#Q16MNUL92T
M><&Z,X7>H9U4`\&@#W#Q!\,/"OBK3K"P\0:1:WEII<;Q6<;,R^3&\?E.@*D'
M:T9VE3D$<$&DF^%WA*YN9)[C0M-FEE5ED,D>X.IMQ;,"#P08%6/&/NBOG;5O
M%WCNZ\>ZR^D^(=8AU*V&HV&C:4RYL[^]CTR.6.$QB/:LB2&:3<S_`#D*,=JZ
MOPCI_CO5+[PWI]YKOC+^QKG5IIKZYFL9+:ZMX!9I*D,LTT2EE:X!&548R8P>
M,T`>FVGP<\`V]A<:/;Z#I,MN]S:7MQ;S$SLTMOM^S.Q<EOD\M=@)P-O'>K%Y
M\'?!FH6$EG=:):O93WL][-;B618IYIG5Y6D4,`^YE4D-D<=*X3Q[9>,YO'&N
M0^&O[9LM/U&[\.VHO["W0.EL\MRMZR2%3RJ%"2<[,@BO/_$/A_XD^'=8GU#2
M]3^(.J:I%X2-K:R;#+;SRPWTJR.\:IL%P;3$B9`WN1C/2@#Z.U[P'X=\3O>-
MXBTNRU!M0L#I]SYZ;O-MB^\Q'VW?-Z@\YJOH7PS\+>&KBWN=$TFTM[BUN9KJ
M.?<SR^=,@221G8EF9D55RQ/"@=J\GT?1?'&L_P#"-:+<>(O%T>E37NI_;=4B
MLY+6ZBA1(FM8Y99HU9OG+C?M7>!M[&N3UG7/BW>>#-234].\9VNL1G^R+2;2
MP4_TBRM9&-\52-R\=U.P5>`N%7<5&10!]#W'@KPWK'B:;6&@B?6H##'<3073
MHV8P6B$JHP#%1(2-X/#>E9LGPA\#1PVUC_8FFVXB-O);Q1LT3*UL&6)UVL#N
M19&7=U(?!)%<Y\+8]8T?Q3XIN_%&F:HEQXAO-+V3BS8H\BZ5")78CA5$B.A/
M0-A>I%5_C=IWB(:]IFL>"K"]GU#2_"?B,VLUM!YGEWCPVYMEQW9G0[1WVF@#
ML[;X3>$;6VN;:#281:74BR26QGD:$,L_VA2L9;:F)OG^4#FD\2?"KP;XFE%U
MXET:PNWA\\F64E?EEP90Q!&58J"5.1D`XXKF-*MO$W@KP-XQENY/%/BZ[M(_
MM6FPSM&+R8M:QL\,+A`.)?,V_*<$[<'`%>4I+\2#X?&GZW-\1?[*>\U=;:\L
M;#[3>R%8X#9),)(E<P,6NAET4$JH8@8H`]WO_ACX*OY+VYU+3K*8>(-RW2R7
M#>1>F2((Q,6[RV9HT`W;<_+G.1FK-GX'\-Z/X-U/2O#XM],TS78726>*;?YC
M2QB(2;W)W,1L`))S@5X_IUKXONO&5G!K,/C&)=+OH$LK--/5M+^PKIORRF3;
M\LPN"ZM\Q;.%V[3FN6T+PQXXL)X;F^3QS)?W^A>$F%@]OYFGQ.ER@OU\O9Y<
M4B*,XX(#,1T&`#WKP;\$O!_@K2M-M=+TNWDGTY[:87LN6EDG@A,,<I8GJ$9@
M%'RC><`9J^OPF\(IKEMK*:)9KJ5F8FAG!8;6B#B-BN[:6422`,02`Q&<5X+=
MZO\`%E;76;C25\;-KKZ9JSZC;7.GHUG:W4=PJV(L#LP^4WG"LX9>6P:]E\"W
M4_A#4)?"OB/6-;UF\O=1NY-(N-2C\R9[2..%VWR(H7:KR%0S`9Z<XH`UI/AG
MX0N-+ATZ31].>QL-.GTN.#G;#:S;#+#UX5MB$CV%9WB/X8_#[Q)=+>^)--TB
MXN-6)19WG,;7F^)(R@(8;U:.-%*\@A1D'%>)S^`_&-A\2_&\6C:-JW]C?%+Q
M%)I^K7H&$LK>*"W*WG+`['@^UP!E_C$=<AI7@WQ+X/\``36]]X"FU35[;1+2
M/PQ#J'A>36+>""-)%DT\HK`VDAEPWFL0"KKUV84`^FKOX4?#W6]6U5+K2=(N
M;^\*2ZA"LIW;QLVRE`WR2?NH_P!X`&^0<U-;?"SP'=6)TNUT?1[B#37N%>$'
MS6ADN"'F+G);S'(5BS'=D`@\"O$[_P`+WMSXY\4VVD>#]=M/&%]XTT[4-,\2
M1:4T,%O9);V0G)O>%:/9'<Q&++$EL;>215\)>#[JU\*33:OX/\0VWD>!;C3O
M%L*:9+]HUK5&G3RRHC^:Y8%)V,JD@K,.2"0`#Z%M/AYX3L7EN+32["-]066.
M24$GSQ-*9Y!G/.Z3+GU-1GX6>%&FU5FTJ%EUM;A=0@,TAAN/M&/.W1;MF7P,
MD*">O<UXC9SM'9?L_P!Y<>$O&YU'056"_;_A'[HG3XQ82VT@E7&$S,8^2,E1
MNSM%=?\`&+4O&">.?#%GX)LO%$,5K=6,]Q>66Y[.YBDO$2YAE01LN4@#N2[K
MPPVY(X`.VD^#/@J:S^S2Z);.@GBG$AFD\T2Q1>5&XEW;PPB^3.[E>#FJOB[X
M/^&/B'J&B-K:K=V'AJ"ZLQIL<F(G$R1*4?:0PVK&!MSR&.017F-W;?$[3]`U
MG6X;_P`7W5[?M?Q2:8MO&YLK>'5$2*6TC*_ZXV1E902V\@'!.!4^O^%O$6J_
ML]^/[/1+CQU_:L]U<3:9<2QFSU6Z1%BV<``DD(5Z*S`<@$T`>LW'PZ\':M;Z
MAIDVEZ9*DUW;W5W;Q'8T<\2(L$GRD&-E2*,*5Q@*,5S]Q^SKX(N=:TV[GTN!
MM.TK3WM+?2CG[.2]RMPTK\YD8R+DAR0Q.3DUPND>"_$]O\3=5\1^'+_Q?#:G
M^Q8H8=0BVQZK$+65)6NE9`Y=6*;C\I4CIR:N_"*+XB:EX6\0CQ%JNL+KM]H2
M-#!JNGRQ"PU4K,LC1RO&J&+>(\(FX`*&R=]`'HP^&'@K4;G5U73[2X:^F<ZG
M;)=.8VED*.Y>(/L5V,<;$[03C/<YO7_PV\+ZIJU]JE_I=K/?:B+<7DK,W[_[
M/(LD)90=I9'1"&QGY0,XXKQ#3)[BT^'-A#X)\#^,?"_B"#^S[7Q3>Q:$8[[R
M#(BW;PS,#]JESN;S%$AQEASBJ-Y)\6;G0W?2KKQM$FFV>K76DR2V4:W5Z8KV
M".Q2Z4I\S-"\[;"%9PH+8(H`]S@^$GA.UM[BWM=/>W@NGWO#!?3QH#YIE^15
M<!/WC,WRXZ^E&H_"/P=JNA:3HU]HEB^EZ%`T&G6JEHUMH6C\IHUVD'8R$JRD
MD,.N:\*\<ZOXU\-ZY)X7GUKX@/8R7^JMI=YIUJMQJ-_''96L\(4K'AHUN)94
MR%`P-K'&34YUSXKW7B!YFTWQ597EIX8O8+^WV>;97%^FGQR0SP*(_+4M<LZ@
M*[$E&!`&*`/H"#P'X>MFN&ATNR4W<L4L_P`F1*T<(@C+`\'$0">F.*I>$_AU
MX2\'17EIX1TVPLDE2.WNXHV+Y15)2-@Q.%"R'"]`&X&,5XIXIO\`X@?"WPF^
MMIJ_B/7IVO+6%+'4DC+2S7]LD*HN%7*Q7K1O@`E5,@Y`KJ?B/I/B/PAI_AB3
MPY<^)]5NA/')KD&E02?:-9F2."%7:X",D0`!8JX57`;D;:`.Q'P*\!#2H=.7
MP]:+9VTADMT2:56@S&8RL;!]R)L8KL4A<'&*U['P1X6\/W$,>GZ=IFGRSFW2
M"*,"/>;5"(%1<_\`+-,X`'`%>6?&>]\=P>++U/"!\71&VTNT?PVNCV:RV=Y?
M/.Z7"7K%2%14,)^<JH4NP)(KD=-^&/B/4KC2=+N-3^)-O-9?$+6)Y]4N)2TE
MG:/!?"WDMYG0KY3J\0)&1E]ORG@`'NW_``J+P<MO)!!HMI;Q3:M+K#?9G>%O
MMT@(DG#HP978$@X(!!-6X_"'A?PS;SW1MK*QA+PR3W$\Q`+11"&-F=VY(CPF
M2>G7->+V<OQ-;QKIXU?4/$%O!:6.G+&BZ7)+;Z@CVA^T^;Y<>Q)_M`;+,ZA!
MLP#NJ]XH\-:Y>?LTZ:?&%KX@\4ZW?76BZGK>G7-D+N<$7=K)<P);JOW$"R?N
M\'@'K0!Z9;?#/P;IS6&HV=C:6::=9V]O;36]R\,8MX"3`K;7"NJ;CMW9ZT7_
M`,/?!$NF6GAF^L-+2U^S00V>GF;8PBMWWQ>6`P8>6WS`J<@]Z\0N/A]J?CVT
MUKPYI/A?6-+\"^*M8-Y'INH*^G);VT-JH?"8)@\V\9)%C(!/E.VT`\XGC/P=
MXZ\;2Z-KFI^')#>Z-X1M[36A-I+27<TL&HD7']GS`YBG9$:6-@K;@R<#/`!]
M!ZQX5^'OQ%O;2+5TT+7+RQ@DA@47:O(L+8\R,A6RR?*I*MD9`.,U8F^#W@N?
M6+K5I-#LQJ%Z96EG1W0EY8Q'+(H#861D4*74!B._-<Q\._AKI?A_XQ>.M8L?
M"NGZ5;W5MIHT^\BTR.#?^ZE\\(P4'J5W`=\9KSRZL?BL]EK%]'J?C1+J/2-4
MU*TM(X(Q&U[:W[)8VRKY>=DEN`63.9`=V10![1%\(_!.F6V3HFG1Q0%YGEE9
MB<FX2Y=W=FR29HDD+,2<H/2L/QE\#M*\<:W%J]GJMQIB3V@BD:QP'8&X^T&6
M&4',;LQ;+#((;I7G/B&;XAZEXCUFV$/C%YKN_P!1M)M/^PJ=(.C_`&&0P/&^
MW_7-*T(X<ONWJ5P*PM$;XO:-H]TNG'7;74]+T;[+IFC'2Y);6:%=.C,.QB@B
M2=90V2\F2X,>W!%`'T;K'PV\,Z_X@@UO5]+MKG5;;R?+N69@1Y,ADAR`0&V.
MS,NX':22.M5[7X<^#YM"UK1+33K"72=4NY7U2R20O&T[MODRN[Y&W$.0N,$Y
MZG->6W.N^)?#W]G-X>C^)VLZ5=:'JT:-J6EE[L:@3;-;>8-BE``9PK.`.&'/
MRURNN:7\1M*\9^)X]!;7]!TC4-?U#4+:^LM.FN1-=+!8K$TL<<;L\!59@%^5
M796!8$"@#Z#'PS\+CPO>>''TJTDT349'ENK24LZSR.V]I&8DL7+8;=G.1G.:
MCTSX>^$?#T^GVVFZ;86US;75S?V@,A:8SR(8YYLL2SL4DVLQ)X8#TKC?!,OB
M6X^*'BVQU^3Q+=:9=1.]E?&V>SL[%0XC6")'0;I<%G$R,RL!D@'&?)?#GPS\
M7WWA_P`%VXU3XD:=J^AVGB(7>IW66N8;@^3Y$8DD0AX7*AEQD/M(SC(H`^A+
MOX-^"K^>YENM!L)9+VT6TN0=P6>%8S$H90=K$1L4#$;@.`:VK'PAI&FZ'>:1
M!;>9I]^)!=0W,SW`F#KM<,9&8D%1C&<5\[^.U^(WC'7_`!)8Z1;^.M)M)O#F
MIV;I%*R137"6D3VLUNWEA8VDE+I\KLW#!MO%=[)IGB&^\'_#32]"U#QK;6UY
M>>5KU_<(8]1CMUM9G_?-(F8\SI$F[:#@@#KF@#T3PIX"T'P-;SP^$[*/3H[I
MD:?;(SF4HBQIN9B2=J(JCG@*!V%9NF_#CP1IVL076E:5HT&HVU]?7<;0A0XN
M;D#[6Y&>6<%=V0>HZ9KQ'3+_`.*UOH'B"\U"Y\3RZI+&JWNG0Z5(SVNV_1)I
M;!WC$9Q:F0QHI<O\K=1@IJUIX^TW25N/!4/BZZG$&O-!>ZAI2+>LQ>Q6V9P5
M^\567&0"X0EER,``]O@^#OA"VTI],@TE5L&:%TM_M4Q6$PN7B,67_=;6)(V;
M<?2K$'PO\+6]W;W<>DVS7=EY7DW4CO)-'Y32-'B1F+<&:7OR)&!R#BO&=9MO
MBAH/C36+;P_JOB*[728_*T&.]M)+NVU6%K%V'G2K&(UF^U#F1W7:`B[</4>E
MZ'KE]XL^&>L2ZG\7IK*&YNEU=-0A:()/);Q.JS1+&/W'F;U)(VKR`P&#0!]+
M*`%`'3'%+2`8`I:`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*
M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HH
MHH`****`"BBB@`HHHH`****`,R'PQI%OJTNJ6VEZ?#J=P,2WL=JBS2#`&&<#
M<>%4<GL/2M.BB@`HHHH`****`"BBB@`HHHH`****`"F&)3('(&X#`..<4^B@
M`HHHH`****`"BBB@`HHHH`****`"BBB@""2RMYKJ&YF@A>XMPPAE:,%XPV-V
MT]1G`SCKBIZ**`(+JQM[X1"\@AG\B598O,C#>7(O1UST8=B.14P&!BEHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
BBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`__V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>g838054g79a80.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g838054g79a80.jpg
M_]C_X``02D9)1@`!`0$#P`/```#_[2;`4&AO=&]S:&]P(#,N,``X0DE-!`0`
M``````\<`5H``QLE1QP"```"````.$))300E```````0S<_Z?:C'O@D%<':N
MKP7#3CA"24T$.@``````Y0```!`````!```````+<')I;G1/=71P=70````%
M`````%!S=%-B;V]L`0````!);G1E96YU;0````!);G1E`````$-L<FT````/
M<')I;G13:7AT965N0FET8F]O;``````+<')I;G1E<DYA;65415A4`````0``
M````#W!R:6YT4')O;V93971U<$]B:F,````,`%``<@!O`&\`9@`@`%,`90!T
M`'4`<```````"G!R;V]F4V5T=7`````!`````$)L=&YE;G5M````#&)U:6QT
M:6Y0<F]O9@````EP<F]O9D--64L`.$))300[``````(M````$`````$`````
M`!)P<FEN=$]U='!U=$]P=&EO;G,````7`````$-P=&YB;V]L``````!#;&)R
M8F]O;```````4F=S36)O;VP``````$-R;D-B;V]L``````!#;G1#8F]O;```
M````3&)L<V)O;VP``````$YG='9B;V]L``````!%;6Q$8F]O;```````26YT
M<F)O;VP``````$)C:V=/8FIC`````0```````%)'0D,````#`````%)D("!D
M;W5B0&_@````````````1W)N(&1O=6)`;^````````````!";"`@9&]U8D!O
MX````````````$)R9%15;G1&(U)L=````````````````$)L9"!5;G1&(U)L
M=````````````````%)S;'15;G1&(U!X;$!U0BT0````````"G9E8W1O<D1A
M=&%B;V]L`0````!09U!S96YU;0````!09U!S`````%!G4$,`````3&5F=%5N
M=$8C4FQT````````````````5&]P(%5N=$8C4FQT````````````````4V-L
M(%5N=$8C4')C0%D````````````08W)O<%=H96Y0<FEN=&EN9V)O;VP`````
M#F-R;W!296-T0F]T=&]M;&]N9P`````````,8W)O<%)E8W1,969T;&]N9P``
M```````-8W)O<%)E8W12:6=H=&QO;F<`````````"V-R;W!296-T5&]P;&]N
M9P``````.$))30/M```````0`\`````!``$#P`````$``3A"24T$)@``````
M#@`````````````_@```.$))300-```````$````'CA"24T$&0``````!```
M`!XX0DE-`_,```````D```````````$`.$))32<0```````*``$`````````
M`3A"24T#]0``````2``O9F8``0!L9F8`!@```````0`O9F8``0"AF9H`!@``
M`````0`R`````0!:````!@```````0`U`````0`M````!@```````3A"24T#
M^```````<```_____________________________P/H`````/__________
M__________________\#Z`````#_____________________________`^@`
M````_____________________________P/H```X0DE-!`@``````!`````!
M```"0````D``````.$))300>```````$`````#A"24T$&@`````#-0````8`
M`````````````L@```'T``````````$``````````````````````````0``
M```````````!]````L@``````````````````````0``````````````````
M```````0`````0```````&YU;&P````"````!F)O=6YD<T]B:F,````!````
M````4F-T,0````0`````5&]P(&QO;F<``````````$QE9G1L;VYG````````
M``!"=&]M;&]N9P```L@`````4F=H=&QO;F<```'T````!G-L:6-E<U9L3',`
M```!3V)J8P````$```````5S;&EC90```!(````'<VQI8V5)1&QO;F<`````
M````!V=R;W5P241L;VYG``````````9O<FEG:6YE;G5M````#$53;&EC94]R
M:6=I;@````UA=71O1V5N97)A=&5D`````%1Y<&5E;G5M````"D53;&EC951Y
M<&4`````26UG(`````9B;W5N9'-/8FIC`````0```````%)C=#$````$````
M`%1O<"!L;VYG``````````!,969T;&]N9P``````````0G1O;6QO;F<```+(
M`````%)G:'1L;VYG```!]`````-U<FQ415A4`````0```````&YU;&Q415A4
M`````0```````$US9V5415A4`````0``````!F%L=%1A9U1%6%0````!````
M```.8V5L;%1E>'1)<TA434QB;V]L`0````AC96QL5&5X=%1%6%0````!````
M```):&]R>D%L:6=N96YU;0````]%4VQI8V5(;W)Z06QI9VX````'9&5F875L
M=`````EV97)T06QI9VYE;G5M````#T53;&EC959E<G1!;&EG;@````=D969A
M=6QT````"V)G0V]L;W)4>7!E96YU;0```!%%4VQI8V5"1T-O;&]R5'EP90``
M``!.;VYE````"71O<$]U='-E=&QO;F<`````````"FQE9G1/=71S971L;VYG
M``````````QB;W1T;VU/=71S971L;VYG``````````MR:6=H=$]U='-E=&QO
M;F<``````#A"24T$*```````#`````(_\````````#A"24T$%```````!```
M``$X0DE-!`P`````'%<````!````<````*````%0``#2````'#L`&``!_]C_
M[0`,061O8F5?0TT``O_N``Y!9&]B90!D@`````'_VP"$``P("`@)"`P)"0P1
M"PH+$14/#`P/%1@3$Q43$Q@1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P!#0L+#0X-$`X.$!0.#@X4%`X.#@X4$0P,#`P,$1$,#`P,#`P1
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#/_``!$(`*``<`,!(@`"$0$#
M$0'_W0`$``?_Q`$_```!!0$!`0$!`0`````````#``$"!`4&!P@)"@L!``$%
M`0$!`0$!``````````$``@,$!08'"`D*"Q```00!`P($`@4'!@@%`PPS`0`"
M$0,$(1(Q!4%181,B<8$R!A21H;%"(R054L%B,S1R@M%#!R624_#A\6-S-1:B
MLH,F1)-49$7"HW0V%])5XF7RLX3#TW7C\T8GE*2%M)7$U.3TI;7%U>7U5F9V
MAI:FML;6YO8W1U=G=X>7I[?'U^?W$0`"`@$"!`0#!`4&!P<&!34!``(1`R$Q
M$@1!46%Q(A,%,H&1%*&Q0B/!4M'P,R1BX7*"DD-3%6-S-/$E!A:BLH,')C7"
MTD235*,79$55-G1EXO*SA,/3=>/S1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&
MUN;V)S='5V=WAY>GM\?_V@`,`P$``A$#$0`_`.OZ!]5?JS?T'IMUW2<*RVW$
MH?8]V/62YSJV.<YSMGN<YRO_`/-#ZJ?^4^#_`.P]7_D$7ZM?^)SI7_A+'_\`
M/3%I)*<C_FA]5/\`RGP?_8>K_P`@E_S0^JG_`)3X/_L/5_Y!:Z22G(_YH?53
M_P`I\'_V'J_\@E_S0^JG_E/@_P#L/5_Y!:EUK::7W/DLK:7NV@N,-&X[6-]S
MEQO6OK3UY_1NE]2Z4*<:SJ!-M.)M=F6VM`9=CU6,H:Q]%5U>^G,?37>_&R[L
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M`#0^JG_E/@_^P]7_`)!9W6\`]0ZWCY]-&-UO%PJ;L7)Z=8]FZJRUU;GY+&/K
MNKMN=14_'^SW>A_QG\XL_HGULZEB].93DX-(AC!A45.]"NJJG<SJ#<NS(LOM
MQJ.BU,IJR\G*HQOUS]4JHLV>O84$$:$4]#_S0^JG_E/@_P#L/5_Y!+_FA]5/
M_*?!_P#8>K_R"T,'-QNH8=.;B.+\?(:+*GEKF;FGZ+MEK66>[^JCI(<C_FA]
M5/\`RGP?_8>K_P`@J76?JI]6*>CY]M72,)EE>-<YCACU@APK>6N:=GYJZ14.
MO_\`(74?_"M__GMZ2G__T/0_JU_XG.E?^$L?_P`],6DLWZM?^)SI7_A+'_\`
M/3%I)*4DDDDI2X^W,^I_U6ZS8,;"<W+L:?7?1+FU!Y]7TF56V^GC^K_.V5XM
M;/\`!>HM[KO61TC#%XQ[<FRQVRJNII(WGZ/J.'T&KRNJO)S,IM39NRLFR-?I
M.L>9>7_N^[^<WJ/),BQ&K&LG3^&\C#->3/8Q?+#A_2EPRG*4IC^;A",/FFW.
MO=9MZUU!V78PUU!OIT4G4M8"3[_S?4L=[K$;I?UJZWTPQ7?]IIAK13D2]K0W
MV_HG[FOK5=W0>MMR;,5N#<^RDD6%C26B!OEMGT'>HW^;5(U6B@9.QXQR_P!/
MUBT[-\;W4[S[?4VIED2L$0&6]SQ>D2[_`#_-!V!CY6>&.*AS/W;A'!#T\4YX
M_FC&4XPEQX\O'_.3_P##L:0Y+K,YV<\N%MEQNL<PEKO<_P!2QK'^W^RNZS<G
MZF]<SL,9&2'F\-<_&T%5VPFS%QNIG9[O0N=991A6W,J??_.TW?H5Y^-6Z<'N
M/X*5=3[K&45L-MMIVUUM&YSCX!")HR,`==>'YR(1]5\7]5;SG)8\PQC//@]N
M/`,L3'%"62?#",?:GQ_I?ZQ]I26-]5^F]5Z=T\5]3RC>]T>G0?<*0/\`!>N?
MTEO_`)[K_P`$ME3@V+(IYG+",,DH1F,D8FA./RR4J'7_`/D+J/\`X5O_`//;
MU?5#K_\`R%U'_P`*W_\`GMZ*Q__1]#^K7_B<Z5_X2Q__`#TQ:2S?JU_XG.E?
M^$L?_P`],6DDI2HW=:Z?3U*GIEEA&5?(8`"0';76ULL?_@W7U59#\??_`#WV
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MGLLGZ_T'-Z=]G&W%=[NH!PU;N_1>G]'_`+3N_3O=7_._F(&?]>\.W'RL6G`;
M8"_]7-H:ZIPW;S??2=KM_J?I65_^>UQW^O*8B1$QYA,XB2`94#I,_./ZTH\/
MZ+I1^&<O&/&,9F8CBQ0!EBE+_*8XY.,_SO%^KXY\'H9WW/R+WWW0;;3[BUH8
M"?)E>UC5K?5/K%72>K"W(#?LU[?2LM+=SV=ZWUD#>UN_VW-_/_ZTL?X(^!T[
M)ZIEUX.*6-ON!VFQT-&T%Y)<W=NVQ_@VH@DT=SICXIROA_<X(_/PQX?Z[-GQ
MXACR8Y?J\7#+,888<%QA'];[F3U893E.?N8_YF?H_P`I^L?8TE1Z3G.RL<5Y
M$LSL<-9F5.&TBR-;&M_.HN^G18SV/_SU>5@@@T7D0;4J'7_^0NH_^%;_`/SV
M]7U0Z_\`\A=1_P#"M_\`Y[>@I__2]#^K7_B<Z5_X2Q__`#TQ$ZQU.OIN"^\D
M&]\UXM9;8_U+BUSZJO2Q:[\E_P!#?;Z--FREEMO^#0_JU_XG.E?^$L?_`,],
M7/\`UDQ\WJ_UCP^EEE]>)78PO:ZLNQK:-K[\S)]=M5C*,BEU=.#CN]>C,Q[[
M_7Q?0_G;4IE]4NC69>6[ZRYYL<^^PWX;+@PEKK:F579%%M-^4W[&[=;1@TL?
M_0O0^U?;/1P+,;L$R=)3%SFL:7O(:UH)<XF``.22J`RNA==QKL.K)Q\^E[8M
M958RR`>'?HW.V;?I,>L_ZYCU,3!Q[!.+D9M=>2PB6O&RZS'IN_X*[.KQ*]G^
M%_F/\*L7(PL+*C[5CU7%OT7/8TN;'[ED>I7_`&')\<?$#KX(XS"0(L$:@CHX
MGU@^KV1T+(KKLM;?1D;OL]@D/(8&^IZU?T&N:ZQNW8_](J.!B_;,_'PM_IG)
MM;7OY+0_3<UO\C\U=%E=+;DX_P!G.7E,I!#FUNM]=C2T%K2QN<,FROVN^A3=
M4JK,+K_3Z!5TN[!>YAWMONQ]N0'`GWU/L.7BLLVG9O\`333R\K)B1'Y=`/W/
MTG5A\:C[(CEA/)EK)^M,N'^>XOT/\+@X7J,WZC=*OZ;7BXP^SY5#8KS``7/=
M^<[*:W8V_P!1WN_D?X'TUD?5SZGY5'6">KT.]/&`LQK:WQ6ZQKAM?NK+;?Y;
M*W^FN4ZI_P`ZK27]5=GW-!W%S7E]((_/:SI[OL]7_;=:[+ZB?6NS+P:<+J3K
M+;#<_&Q.H.AS+BQC,EN/;>UQ=]M919_AF?K5=7J>K?D?:$[+RW#$2N!]6HA\
MW^%Z?E:6'XGS`$\?%D/'$QO)*7I]7JEC]?SI>K_5?K^9E9EM&4T.R+Q93?\`
M:<BES*11;11C^AC,])G[/S;?VA3Z;_URS^?]'^=4K/J[]8GYIM?<RW';D95S
M0<O(:]U=]->-30[]#90RKUF6Y5E'I65XS_2KP_T7JUW=:DF,#0Z%AYF!T;#P
M\ZX9&514VNZX%S@YP'TM]Q=8_P#KN_[;J_FTNO\`_(74?_"M_P#Y[>KZH=?_
M`.0NH_\`A6__`,]O24__T^WP,TX/U)P\MI:'U=/H->_;MWFJME(=ZMN+6[=:
MYGL^TT;_`/2*A]1+LK-?G9]N3;=6Y^P5FUUM(>YS\FS[.Q]36T-K]9M;&59.
M9^C_`)W)M_0[+=#[&?4?!=7D68COL6*!?50_)>T%E37;<6@.N?O;[/T?\U_.
MJ?U,HKIZ9=MS;>HO?>XV95]%N/:YP;77MMJRO>[8QC/TC&5UO_XWU;'I3OI)
M))*>2_QF95U/U=9CUQZ>=DLQ[S&OI[;;W!O[N]]#*]RX*CK76:-*\Q]C?W+P
M+A_G7!U_^;<O4?K:_`_8[\;-QSEC,>VBC&#BPOM/Z6O].W^C^AZ3LE]_^"KI
M_P`)_-KB,3ZOX.*X.S>FGJ;)U#<U[2!X-QWU85%W_7LGW_Z-/CS_`"G+CV\]
M"<_5&_3Z?EUG^@LERV?*>+'?#'0^?]W])I4_7.QCQ5EXU=KSH/L[RUY_JXUO
MK[_^WENLZDST/7R<7-P:N[\O%MK:/ZUC&VUU_P#77UK:Z7USZK=/KV,PST1I
MT?ZN/Z-?QLS*&V8/^?E*\_ZV="G9BY!ZA9$AF"Q^4?[3L1MU=?\`UU]:)YF$
M_5CX>#^][D?\=0PRCI.^+RX/^:\_C7TY3?4P[69`_>I>+(^=1<@X^5AV?5_K
M]55FVRFV[J>`X`AKG8K:+[,G%MCTLAE76,>[U_2>_P!-_P#.?H[J=^EFU,ZK
M;ZS_`*MXQ)U-W4;*JK7?R/U*KJ5NUW_#.K_J*E]8.I8O4NB##QNGNJR.EM=D
M9N/(K;ATXS7-OQ764?HW?M/%;;@XE-?LR<#*^U_T9B8<\<F@HUKH;7#&8ZGJ
M]P#(!XE.F!!$C4%.@E2H=?\`^0NH_P#A6_\`\]O5]4.O_P#(74?_``K?_P">
MWI*?_]3NNEX-'4/J=@8=[&6,MP*`&VUMM8'"JMU;S3<'56>G9ML]ZS?\7+WC
MI>1CO:[]%:WW_9_LS)-===E6QP999F565?K[]NS[0_\`1K;^K7_B<Z5_X2Q_
M_/3%BX75.IX'ULOZ9U"VZW`R+'-P[;]M;&NL'VFFNFS[/6W)W[K,.BO]HY&9
M^JV_JE=/Z1)3UB2222GG_KBRPXF"['`?F-S:_LM#I`M<]EU%U;[6M?Z+*L.W
M)RG7;/\`M.LZOH74+(.7U`5"-:\*IK3_`.Q.;]K=_F8]"W>O8>9?1CY&"T6Y
M.!>,EF.XAHM'IVXMU#;'>VNU^/DV^@]_Z/U_2]7]$L\9O4[6SC]*O:!].W-L
MJQJVQ]+=Z;\W(_M,QO3_`.$5+FN7&3)&?MB9X>'BD.+K_6]#/BR\,2.(Q%W0
MT1T_5[H];A991]JM'^$RWOR3\FY+K*6?]:JK6FUIV!C!%;1HUHAH']5OM:L.
M^[K=C7`9E..X<-Q*M\_R?MF>;6_]<;TY93NAY60TV9N;9F73/I9X&51\645.
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M_I?3]-6,+JW3L^VZG#O;<^AM;[-LQLN;ZN/:Q\;+:KF?S=M6^M7FNVU0Z_\`
M\A=1_P#"M_\`Y[>KZH=?_P"0NH_^%;__`#V])3__U?0_JU_XG.E?^$L?_P`]
M,6/]<NB`S]8,0/&=16VBU]+'69`I-K-UF`\/_4K\=C\E_JU57>K1;D?:,;(6
MQ]6O_$YTK_PEC_\`GIBL]1P,?J6%;@Y0)IO;M?M<6GG<-KV%KOI!)37Z#U=O
M5^G-R2P57M)KRL>035:T`OIL_<L:US-]-GZ:C^9O].[U*UHKBNE],S?JWFV9
M67<<3HW3Z0S(S+GML^TL_2-QZ:<>H-^Q8V(ZRNRNIM%+Z+_M-+/VC]L?E5=;
M@YN/GXS,K&+C39JQSV/K)'[P9>RNS8[\Q^W])^8DIL+G^O9K\RFW!Q;32TZ.
MR&"7;@9BO^2N@7$XHMJ-E&1DLR+=[GUAH#2*2=M?Z-)2V4_*IQZQ1;6;F[=Y
MNY>T>VQ[&,_PCD[\ZH.(8USF:P9VE`SJ:G95=QK_`$M;"UMNOT7?FM'T?;[E
M6]-_K^KZCM@;M]'\V?WTE-WIK&5XWH-?986$D^J[<Z#_`"OW%IXG6+\>YN#4
MYM]]PBBA[OHD_1ML=].O&;^?_P"`K`8;ADZ[6T`-VO!]^Z??_95[?@MZF[8`
M.H"H/WP9],'V^[Z'_F"2G;N^J>'DO?=DY.2<F[TGWV56&IKKZ2WT<QE-?Z.N
M]C*V4?\`$?3]1_Z16^E=!Z?TFRY^$US?6935M<Z0VO';Z.-2S_BV.=[[/4N_
M?M_FU?K<7UM>1M+@"6GL2.%))2E0Z_\`\A=1_P#"M_\`Y[>KZH=?_P"0NH_^
M%;__`#V])3__UO0_JU_XG.E?^$L?_P`],6DLWZM?^)SI7_A+'_\`/3%I)*:^
M?@XW4,.W"R@74W"'AI+3H=PVO9M<WW-4.G=+P^F5648375T/L=:VDN<YE9=&
MZO'8\G[/1N&_[/5^AKW_`*-6TDE/$_5JS+'UDMPL^^YEV.Q\T/R+;-[CL=%M
M%O4.IX_\Q=7D?H*L7T__``%$&-0W(.1Z8]?;Z?J?G;`?H*75'-Z3]:<?J&9E
MX[:;K):*Z@.H/8^I^-7@[:/TW4L!F7Z5K:Z<?*R_M%F-_@<?[0K_`%C$^S6F
MREI++07`$P/4Y]/?^9ZB2G&ZC158:+7NBRESG5LW1ND#?[/\)LA4[K'5U%[*
MS<X1#&\F5?HJ^TMQ\O-QVTY54EH+B?3W&/ZN[Z/]1,S*KNHONRJ'8[,9SVGU
MARUNOJ,T_._DI*:M>/9DOK#'FIK'!]H`!W-[TE7<J[(&,;<"MN5<2!56'"'>
MZ(#FGW?U-R<Y-#\,Y30;:'5FS:ULES2/<WT_WOS58Z%]FQL1G4:Z_LO3<2M]
MUIL!&Q@:^RSV^][GM_G$E).L_7'/Z7FG'9TA^314QAOR/6;4UMAJR,ZVNLY%
M;*;J\?%P[++;O7_X)=#@9;<W!Q\UC75LR:F7-8^-S18T6!K]I<W>W<O-[OVS
MUKK%F9TIN1AO??4[,LK;9C9532]^)@#.Z?9DY?3.JX]/^'_1T6>GTW,Q<S[&
MO3@`!`X24NJ'7_\`D+J/_A6__P`]O5]4.O\`_(74?_"M_P#Y[>DI_]?T/ZM?
M^)SI7_A+'_\`/3%I+-^K7_B<Z5_X2Q__`#TQ:22E))))*06X>+=D495M37Y&
M+N]"TCW,]0>G:&._=L;]-<S;F]3Z?UW*8_%L'U=#C9FW9,6$ON#6UNP+/4=9
M=7Z[?Z%^ENJ]]557Z7I^*NM5;J'3\+J6)9A9U+<C&MC?6_@P=S3I[FN:[Z+F
MI*<"[H^'UFBP8=U>5AAS'`->X&7,KRZ6[VCW-=3?58W_`(.Q6?V)G/82_P!,
M;M#6XSIX'VN8N>ZYT_J?1ZJ\#I;\D/;199=EU--5-N9GVXW1<1C/2.RO[!CW
M768>'6_]4HQL+_1^HBY?[;KR>J7=<SLWH_00XG[138U]GJF]S,7['953DW4X
M+\1^/ZWZ.G]/LI_[E^HE.Y3@5=/!RNHNJIQ,=CWEI.D,:;''9MV[*JFOL7/]
M9^L]6>YF)4,G`PC<<6GT+G863]LMJ<_!JSJ7TLR,/#R_6^T8N77]IHWT_KM&
MS]&M+&Z=UOZP_5SHC^J>G1F57>MF&^H[GU-%]&QV*Q]=?^4<1[:LRB[]%Z.3
M?^B_P:W.C=`Z9T2NQF"QP-I;ZEEKW6V%K!LQZ?5N<]_H8U7Z+'J_P;/^N)*1
M_5WHE72,(!U=0ZADAMG4;Z1#;;X_36-D-V5>JZQ[*F,II_26>G15ZBU4DDE*
M5#K_`/R%U'_PK?\`^>WJ^J'7_P#D+J/_`(5O_P#/;TE/_]#T/ZM?^)SI7_A+
M'_\`/3%I+G/J_P#6/ZO4]!Z;3=U3#KMKQ*&O8[(J#FN%;`YKFE_M<U7G?6;Z
MKO:6NZM@EKA!'VFK@_\`7$E,:?K;]7+\7-S*LZMV/TZ/M=D.`;NUJ+);^G;?
M_P!IG4>K]I_P'J*]T_J&)U+%;EX;R^AY<T.<US#N8YU-K75W-KL8YEM;V>]B
MY2W&^IS.C'I?3^O8V,UI!H<_,#VUEMF/D5.].K)Q7.?C_8JFXUGK>K3_`*3]
M);ZA>DGZK=+&"*?K)4YF(UWKUG,KV9%K@\>O=6ZU[6>_(RKWUU?S^1;5?D^M
M9C4I*;E_URKJ]]?3LF^BS*^P8=['4!M^0'V4V5U>KD,>RMCZ+/TUK65V(N']
M;L7/=4S"P\JY]^)9F5-+65DFFUN%D83O7MKV9=&0_9=O_0?\.LR_%^H-[K7'
MK-;!9=]JKKKZD6LIO+GVV7XE;<C9CV6V76.LV?O^Q.[$_P`7A:VMG5,>FAF,
M_";15GAE8IMUR&;&W^Y^0_\`27VO_2WVL]2U)3>Z;]=<'J.3TVBK'L9^U&6.
MJ<;*"6NJ-[7[Z*[WY#J/U.[9F5U/Q?YC])^D_1V;OK;T*K$ZAE-R/5;TEI.8
MQC7;V.#[<<418*V^O9=CV,KK<[_16_S%U5JS,9OU&Q[L.P=:JM;T\?JM-O4`
M^ICAO;7<*'7>GZM-5UE%/^CI_P"+K4V'Z@MJSJ7=2P[:NJ`_;669C'"PN-CC
M9K=[+?TNSU*]GLJH_P!!4DI-D?7)N%:*NH]-R<78RJW+>78[VT,ON?A8]EGH
MY+WVL=;5^D^SLM])B7_/7#;TWJ74+<2]@Z5>W&NJ!JL+K'NK8QE=U-]F+O9Z
M]7VEGK_JW^$5$8GU!=959D]:9ENJ#&O^T=2]06BJQ^7C#,8Z_9DMQ[[7/J9:
MW8G;B_XOQB9N+;U:B_\`:1K=EWVYX?<[T"'8OZPZ[U/U;;^B_P"FDIOU?7;I
MK[\;&LQ\FG)OR;,.^I[`?L]M;J*OUFRM[Z_1NMS<)F/?2^VJW[54JN+_`(P<
M7-Q[+\/IV5>VJVFEP:['!#LBQV)BA\Y7Z*Q^2WT[*;?TU++*K[/T*`,#_%J`
M=V=AOM(!&0[-:;A8+#E.RF9)O]=F79>=]F0U_J/].JG^9K]-&QJ_\7N*TMHZ
MCAL:327#[8PR<>]W4,9S]UQW.JR7N]W^B_0?S22GJJW.?6USFFMS@"6&"6DC
MZ+MA<SV_R52Z_P#\A=1_\*W_`/GMZ%_SH^K/_EO@_P#L35_Z45/K7UD^KMO1
ML^JKJN$^RS&N:QC<BHDDL>&M:/424__9`#A"24T$(0``````50````$!````
M#P!!`&0`;P!B`&4`(`!0`&@`;P!T`&\`<P!H`&\`<````!,`00!D`&\`8@!E
M`"``4`!H`&\`=`!O`',`:`!O`'``(`!#`%,`-@````$`.$))300B``````%^
M34T`*@````@`#`$```,````!`?0```$!``,````!`L@```$"``,````#````
MG@$&``,````!``(```$2``,````!``$```$5``,````!``,```$:``4````!
M````I`$;``4````!````K`$H``,````!``(```$Q``(````>````M`$R``(`
M```4````TH=I``0````!````Z````2``"``(``@`,^:0```G$``SYI```"<0
M061O8F4@4&AO=&]S:&]P($-3-B`H5VEN9&]W<RD`,C`Q-3HP,SHP,R`Q-CHQ
M.3HT.``````$D```!P````0P,C(QH`$``P````'__P``H`(`!`````$```'T
MH`,`!`````$```+(``````````8!`P`#`````0`&```!&@`%`````0```6X!
M&P`%`````0```78!*``#`````0`"```"`0`$`````0```7X"`@`$`````0``
M````````````2`````$```!(`````3A"24T#_0``````"```````````_^$!
M@$U-`"H````(``P!```#`````0'T```!`0`#`````0+(```!`@`#`````P``
M`)X!!@`#`````0`"```!$@`#`````0`````!%0`#`````0`#```!&@`%````
M`0```*0!&P`%`````0```*P!*``#`````0`"```!,0`"````'@```+0!,@`"
M````%````-*':0`$`````0```.@```$@``@`"``(```#P`````$```/`````
M`4%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I`#(P,34Z,#,Z,#,@,38Z
M,3DZ-#@`````!)````<````$,#(R,:`!``,````!__\``*`"``0````!```!
M]*`#``0````!```"R``````````&`0,``P````$`!@```1H`!0````$```%N
M`1L`!0````$```%V`2@``P````$``@```@$`!`````$```%^`@(`!`````$`
M`````````````\`````!```#P`````'_X4&=:'1T<#HO+VYS+F%D;V)E+F-O
M;2]X87`O,2XP+P`\/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E
M:&E(>G)E4WI.5&-Z:V,Y9"(_/CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z
M;G,Z;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N,RUC,#$Q(#8V
M+C$T-38V,2P@,C`Q,B\P,B\P-BTQ-#HU-CHR-R`@("`@("`@(CX*("`@/')D
M9CI21$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S`R+S(R
M+7)D9BUS>6YT87@M;G,C(CX*("`@("`@/')D9CI$97-C<FEP=&EO;B!R9&8Z
M86)O=70](B(*("`@("`@("`@("`@>&UL;G,Z>&UP34T](FAT='`Z+R]N<RYA
M9&]B92YC;VTO>&%P+S$N,"]M;2\B"B`@("`@("`@("`@('AM;&YS.G-T179T
M/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O<U1Y<&4O4F5S;W5R8V5%
M=F5N=",B"B`@("`@("`@("`@('AM;&YS.G-T4F5F/2)H='1P.B\O;G,N861O
M8F4N8V]M+WAA<"\Q+C`O<U1Y<&4O4F5S;W5R8V52968C(CX*("`@("`@("`@
M/'AM<$U-.D1O8W5M96YT240^>&UP+F1I9#HS0C!$-C$P,$5"0S%%-#$Q.$-#
M1D8Q0S9"0S%#1#8W-3PO>&UP34TZ1&]C=6UE;G1)1#X*("`@("`@("`@/'AM
M<$U-.DEN<W1A;F-E240^>&UP+FEI9#HS1#!$-C$P,$5"0S%%-#$Q.$-#1D8Q
M0S9"0S%#1#8W-3PO>&UP34TZ26YS=&%N8V5)1#X*("`@("`@("`@/'AM<$U-
M.D]R:6=I;F%L1&]C=6UE;G1)1#XR,S1"04(W-#5!.4(Q-#$W-C0Y-C8W.$5$
M.49!13$Q-3PO>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/@H@("`@("`@("`\
M>&UP34TZ2&ES=&]R>3X*("`@("`@("`@("`@/')D9CI397$^"B`@("`@("`@
M("`@("`@(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@("`@
M("`@("`@("`@("`@("`\<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I
M;VX^"B`@("`@("`@("`@("`@("`@(#QS=$5V=#II;G-T86YC94E$/GAM<"YI
M:60Z,T$P1#8Q,#!%0D,Q130Q,3A#0T9&,4,V0D,Q0T0V-S4\+W-T179T.FEN
M<W1A;F-E240^"B`@("`@("`@("`@("`@("`@(#QS=$5V=#IW:&5N/C(P,34M
M,#,M,#-4,38Z,3DZ,SDM,#4Z,#`\+W-T179T.G=H96X^"B`@("`@("`@("`@
M("`@("`@(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O<VAO<"!#
M4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@("`@("`@("`@
M("`@("`@("`\<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@("`@
M("`@("`@("`@("`\+W)D9CIL:3X*("`@("`@("`@("`@("`@/')D9CIL:2!R
M9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B`@("`@("`@("`@("`@("`@(#QS
M=$5V=#IA8W1I;VX^8V]N=F5R=&5D/"]S=$5V=#IA8W1I;VX^"B`@("`@("`@
M("`@("`@("`@(#QS=$5V=#IP87)A;65T97)S/F9R;VT@:6UA9V4O:G!E9R!T
M;R!A<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S:&]P/"]S=$5V=#IP87)A
M;65T97)S/@H@("`@("`@("`@("`@("`\+W)D9CIL:3X*("`@("`@("`@("`@
M("`@/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B`@("`@("`@
M("`@("`@("`@(#QS=$5V=#IA8W1I;VX^9&5R:79E9#PO<W1%=G0Z86-T:6]N
M/@H@("`@("`@("`@("`@("`@("`\<W1%=G0Z<&%R86UE=&5R<SYC;VYV97)T
M960@9G)O;2!I;6%G92]J<&5G('1O(&%P<&QI8V%T:6]N+W9N9"YA9&]B92YP
M:&]T;W-H;W`\+W-T179T.G!A<F%M971E<G,^"B`@("`@("`@("`@("`@(#PO
M<F1F.FQI/@H@("`@("`@("`@("`@("`\<F1F.FQI(')D9CIP87)S951Y<&4]
M(E)E<V]U<F-E(CX*("`@("`@("`@("`@("`@("`@/'-T179T.F%C=&EO;CYS
M879E9#PO<W1%=G0Z86-T:6]N/@H@("`@("`@("`@("`@("`@("`\<W1%=G0Z
M:6YS=&%N8V5)1#YX;7`N:6ED.C-",$0V,3`P14)#,44T,3$X0T-&1C%#-D)#
M,4-$-C<U/"]S=$5V=#II;G-T86YC94E$/@H@("`@("`@("`@("`@("`@("`\
M<W1%=G0Z=VAE;CXR,#$U+3`S+3`S5#$V.C$Y.C,Y+3`U.C`P/"]S=$5V=#IW
M:&5N/@H@("`@("`@("`@("`@("`@("`\<W1%=G0Z<V]F='=A<F5!9V5N=#Y!
M9&]B92!0:&]T;W-H;W`@0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!
M9V5N=#X*("`@("`@("`@("`@("`@("`@/'-T179T.F-H86YG960^+SPO<W1%
M=G0Z8VAA;F=E9#X*("`@("`@("`@("`@("`@/"]R9&8Z;&D^"B`@("`@("`@
M("`@("`@(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@("`@
M("`@("`@("`@("`@("`\<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I
M;VX^"B`@("`@("`@("`@("`@("`@(#QS=$5V=#II;G-T86YC94E$/GAM<"YI
M:60Z,T,P1#8Q,#!%0D,Q130Q,3A#0T9&,4,V0D,Q0T0V-S4\+W-T179T.FEN
M<W1A;F-E240^"B`@("`@("`@("`@("`@("`@(#QS=$5V=#IW:&5N/C(P,34M
M,#,M,#-4,38Z,3DZ-#@M,#4Z,#`\+W-T179T.G=H96X^"B`@("`@("`@("`@
M("`@("`@(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O<VAO<"!#
M4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@("`@("`@("`@
M("`@("`@("`\<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@("`@
M("`@("`@("`@("`\+W)D9CIL:3X*("`@("`@("`@("`@("`@/')D9CIL:2!R
M9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B`@("`@("`@("`@("`@("`@(#QS
M=$5V=#IA8W1I;VX^8V]N=F5R=&5D/"]S=$5V=#IA8W1I;VX^"B`@("`@("`@
M("`@("`@("`@(#QS=$5V=#IP87)A;65T97)S/F9R;VT@87!P;&EC871I;VXO
M=FYD+F%D;V)E+G!H;W1O<VAO<"!T;R!I;6%G92]E<'-F/"]S=$5V=#IP87)A
M;65T97)S/@H@("`@("`@("`@("`@("`\+W)D9CIL:3X*("`@("`@("`@("`@
M("`@/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B`@("`@("`@
M("`@("`@("`@(#QS=$5V=#IA8W1I;VX^9&5R:79E9#PO<W1%=G0Z86-T:6]N
M/@H@("`@("`@("`@("`@("`@("`\<W1%=G0Z<&%R86UE=&5R<SYC;VYV97)T
M960@9G)O;2!A<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S:&]P('1O(&EM
M86=E+V5P<V8\+W-T179T.G!A<F%M971E<G,^"B`@("`@("`@("`@("`@(#PO
M<F1F.FQI/@H@("`@("`@("`@("`@("`\<F1F.FQI(')D9CIP87)S951Y<&4]
M(E)E<V]U<F-E(CX*("`@("`@("`@("`@("`@("`@/'-T179T.F%C=&EO;CYS
M879E9#PO<W1%=G0Z86-T:6]N/@H@("`@("`@("`@("`@("`@("`\<W1%=G0Z
M:6YS=&%N8V5)1#YX;7`N:6ED.C-$,$0V,3`P14)#,44T,3$X0T-&1C%#-D)#
M,4-$-C<U/"]S=$5V=#II;G-T86YC94E$/@H@("`@("`@("`@("`@("`@("`\
M<W1%=G0Z=VAE;CXR,#$U+3`S+3`S5#$V.C$Y.C0X+3`U.C`P/"]S=$5V=#IW
M:&5N/@H@("`@("`@("`@("`@("`@("`\<W1%=G0Z<V]F='=A<F5!9V5N=#Y!
M9&]B92!0:&]T;W-H;W`@0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!
M9V5N=#X*("`@("`@("`@("`@("`@("`@/'-T179T.F-H86YG960^+SPO<W1%
M=G0Z8VAA;F=E9#X*("`@("`@("`@("`@("`@/"]R9&8Z;&D^"B`@("`@("`@
M("`@(#PO<F1F.E-E<3X*("`@("`@("`@/"]X;7!-33I(:7-T;W)Y/@H@("`@
M("`@("`\>&UP34TZ1&5R:79E9$9R;VT@<F1F.G!A<G-E5'EP93TB4F5S;W5R
M8V4B/@H@("`@("`@("`@("`\<W12968Z:6YS=&%N8V5)1#YX;7`N:6ED.C-#
M,$0V,3`P14)#,44T,3$X0T-&1C%#-D)#,4-$-C<U/"]S=%)E9CII;G-T86YC
M94E$/@H@("`@("`@("`@("`\<W12968Z9&]C=6UE;G1)1#YX;7`N9&ED.C-"
M,$0V,3`P14)#,44T,3$X0T-&1C%#-D)#,4-$-C<U/"]S=%)E9CID;V-U;65N
M=$E$/@H@("`@("`@("`@("`\<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/C(S
M-$)!0C<T-4$Y0C$T,3<V-#DV-C<X140Y1D%%,3$U/"]S=%)E9CIO<FEG:6YA
M;$1O8W5M96YT240^"B`@("`@("`@(#PO>&UP34TZ1&5R:79E9$9R;VT^"B`@
M("`@(#PO<F1F.D1E<V-R:7!T:6]N/@H@("`@("`\<F1F.D1E<V-R:7!T:6]N
M(')D9CIA8F]U=#TB(@H@("`@("`@("`@("!X;6QN<SID8STB:'1T<#HO+W!U
M<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B/@H@("`@("`@("`\9&,Z9F]R;6%T
M/FEM86=E+V5P<V8\+V1C.F9O<FUA=#X*("`@("`@/"]R9&8Z1&5S8W)I<'1I
M;VX^"B`@("`@(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B`@("`@
M("`@("`@('AM;&YS.G!H;W1O<VAO<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]P
M:&]T;W-H;W`O,2XP+R(^"B`@("`@("`@(#QP:&]T;W-H;W`Z0V]L;W)-;V1E
M/C0\+W!H;W1O<VAO<#I#;VQO<DUO9&4^"B`@("`@("`@(#QP:&]T;W-H;W`Z
M24-#4')O9FEL93Y5+E,N(%=E8B!#;V%T960@*%-73U`I('8R/"]P:&]T;W-H
M;W`Z24-#4')O9FEL93X*("`@("`@/"]R9&8Z1&5S8W)I<'1I;VX^"B`@("`@
M(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B`@("`@("`@("`@('AM
M;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+R(^"B`@("`@
M("`@(#QX;7`Z0W)E871E1&%T93XR,#$U+3`S+3`S5#$V.C$U.C,W+3`U.C`P
M/"]X;7`Z0W)E871E1&%T93X*("`@("`@("`@/'AM<#I-;V1I9GE$871E/C(P
M,34M,#,M,#-4,38Z,3DZ-#@M,#4Z,#`\+WAM<#I-;V1I9GE$871E/@H@("`@
M("`@("`\>&UP.DUE=&%D871A1&%T93XR,#$U+3`S+3`S5#$V.C$Y.C0X+3`U
M.C`P/"]X;7`Z365T861A=&%$871E/@H@("`@("`\+W)D9CI$97-C<FEP=&EO
M;CX*("`@/"]R9&8Z4D1&/@H\+W@Z>&UP;65T83X*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`*/#]X<&%C:V5T(&5N9#TB=R(_/O_;`$,``0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`?_;`$,!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`?_``!$(
M`,D`C0,!$0`"$0$#$0'_Q``?```"`@("`P$`````````````"0<(!@H!!0($
M"P/_Q`!-$``!!`(!`@,#!@D("`0'```%`P0&!P$""``)$1(3%!4A%A@Q.'BW
M%QDB-T%169;4)"A786=QA[$*(S)'@K+!QR4V0F)(4G:1DK71_\0`'@$!``$$
M`P$!``````````````$"`P8'!`4("0K_Q`!#$0`!!`$"!`('!08$!00#```#
M`0($!0`&$0<2(3$300@446%Q@?`5(I&QP18C,J'1X0E"4O$7)#-3<D-B@H-S
MDJ+_V@`,`P$``A$#$0`_`'Y\)^R=VGY]PSXCSN9\#./<CF$UXQT)+97(2<24
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M0?9!XU?<Q"^F3EONF,.F,.F,.F,.F,CZ16S5T1/*1646+"`$K3AQZP\Q0M*0
MK*5*0**^GB2S-"-KO=#;F+@-E44RYUNP5&CU5D473E)59/39C$,<F.]<*EL+
M+`>)1,E3<NAEU<:8MR`F').G2@N55+Q+Y4EM(7$.;-85@8D8Q650\)+Y%!,[
MM;'&B?<K(^U>SZ'B6+T3H69&_P`NNWQ_/OD4QD]W'IU?U"SCDUQNY,\DF7&)
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M%1B!U8"X'>PLC?Z_#^N-_1.A')DA'6Y@4XD`EB-*%`2)!HJ9&C#*I!N((D!F
MBVSUFQ*KB"J(UVX03;OE1A!-JHKNR<ZILG.UZ8PZ8PZ8PZ8Q`O?*QX_->^'C
M^>O_`.7^R3]?_3IE*JB=UV_'],9YV]_J#\(/L@\:ON8A?3*LM]TQATQATQAT
MQATQB';&'\L.%?<'Y7<C8+P=EO.F"<SHK3J=9S6HI%5P6SZ!FU45J.K?>CK#
M5M64Q;W)0,U,#=[00FL6?O1T4D<EF2QR,%B#]JMLQDS</>V)5W'1Z7Y/<BC:
MMC<@I7'9Y-+%^51$&4IZDSUTR#>XN2<7JQ3:-!91)JW,6<IEX,,WO(;0F`B(
M0BOP@L^(&QA!NI2][6-<][D:QC5>]SEV1K6HJN<J^2(B*JKY)G(APY5A+BP(
M,<LN=.D`AQ(L<;B'DRI)&!CQP#:BO(4Q7L&,;45SWN:U$553%"2'OOW3\[]K
M,A/IXXFA)2J%VJED$![&I+!==EQB\L<GWS-`WK,G**GRF%C=#(T$S<H#P3I%
M5#!$@]U.37,W[60S-OLIA59ZJC&*\@.K5*KW(U_C*G[UK>=K&KRC7=.9SOMM
M5_X<V@?^!YJ&;S?\:+"G9/369["Q2!4ZB5!3!THJV,<M>ZA$YOV1,EN@RK&0
M(LFR"09%BQH^Q+QA[A/$?E\D^2I.W`Y0^,=(LB$+D:+J'31%RLVT<^5I'9&D
MP>&VR/FW;KDH][W%Z.D54?;ML^3.^]K[3EQIAM(M]$;6OU%5BN:D)9<,II,`
MR-5I%''D&<-Z(]G.(G*]BN1%3??;XJLI[&4;6*54.;=U^@]2SM):FOJJLM9%
M!`NH!3"*!UJ2"".C2^`4D9Y5$IQ-4C6[8G;EIWGR-3<JKVX\2NBZTO7CG'"3
M>!%(^8RHU/E';8$,;S9D57*(R:(G!24ER898!DHCC*B;75%<EKC.==-/V.MC
M5]O+B)%#)A@(T2;/<(Z/:QOB_O/OC<B$YT1JB1>G\>?3_A5_A[4'%+@5H;6[
M]97FD]>:FK)%R1IX42WTX^OE6$Q](GV;M7V02'IT@F)*';$%N97-A.Z<WI(\
M(:(YEU+)^>'%#B_7Q4S/PL5:Q?A_<0>*0*L5K:X^O!E=UE+HS:%9N04QK:M`
M+&-C,6E48YT:K6ZHG"&(!W7@&3O%9"\S*ILAVT$4X0B!857M1A>57(HWJQRH
MK55%:KFKLO153NB9X%XW<([3@?Q%M^'5S<5=Y85`*V42?4-ELBO%:006$9CQ
MS`A**0V,<2F&GBC:KD1ABIUSMNUA4?)V=6R5OV-S&2`JBD<]<S;DWR\MBM6P
M?D3W.;4!BS$4'1BN(#-A:COC5P$J#9ZX%5"!V$BYT<;A&3B,H1YD6D,@+]EF
MI?\`?Z^OUWV4NF3ATQATQATQB!>^7G&/FO>.,?[[/I_PD_JSTRE=_+\D7\U3
M&>=OCZ@_"#[(/&K[F(7TRK+?=,8=,8=,8=,8=,8IGNJ=Q9CPKK-&(5^\8O.1
M5DC7/R+9K(H/D8,`VW69.K%,L7*2[1QELY359Q8602W:ES2*R[IN]%ABC-?%
M-4:A;31D#'<UUC):O@HJ(Y`#ZM60]J[HNR[H)KD5'O155',8]%]I>AOZ+DCC
MYJU]YJ8$@'"W2DL7V^=A"1B:BLFM'(#I:#)$\9A(4+V'N9D9[30:]XQA+'F3
MX9QZM?(;NL<YN1-1HTI-K!`J10J21WFA(!&!L1D<N$))YQ@&>=1_(\:N!W5_
ME+P6-$#\$'";?1[LX9I[-^HT9JK0\^GUE#XGENWR/L)Q=)+0M2.LN[;XPVQ+
M%PF*-`O>6-(:I6ABH*-):9[R/`$ONO6WH9WO#'BCP>U[Z*6G]*QT!K-L3B/'
MXC3Y&H8&FM)&=".34.E`6IWSTMHT>-9UJ/',GVC#VD`M>*.,4V?'7SUI//IG
M]?7TJ>>>NV:MV>RFS5%-ONJKZZF4=<)[;J^/CZN<ZXQG.WC\?-X_#/QQX9Z[
MZ[U3J/4K:QFH+NRN&TT$=95)82BR4KZ\6WAQ(J$<OA!9LFS6[=&M15V:FV#Z
M,X:</N';]2$T)HW3FDGZONY.H]4.H*N+7+>WTO?UFTL_5QL23+,KGJ\C_P#,
M0BHB*1ZKZ[1[('[LHZD.-57+AZJXT>Y<[NEWNSA3=1==RJJJJNJMNIGU%%U\
MZK+;J;[;ZXS\<YGQ(@<*HL?29^&E_?V\B93J_5L6^A/C%K;AG@*GA&6-'`7U
ME224(&(2?'CI'&K9YU.J-T[Z.UQZ3EA-XH5WI$Z"T#H^LIM5"C\)Y^@K8,Z#
M?:0>DYB-/";93YD1M6*-6>K2K.-139RSCC?10F0F.*\G@1WF3/$&@CM$R>M4
M;.:Q/))]3R@PLRCFX9](C#XT:"3=SAJ\</`F2I-Z;'/VC-8SHJJY"J[;,%V#
ML)PZNZN-.4D1]C1V#:Z<TY*&>>*>'#G<A5]90$LH4#,$$KUYWQG%<-Z^$]41
M6\GG;C_Z'>A_2(XPR]2:0XHT=/J6$^KA\7:`$R+J.WK1AK01J.8*GC3VR**S
MEUL(,3U2U]4A20#'9QVN,*2*>[WM_=WNH>6+09`;6<1^GN0"J^S1".+NG#2%
MSO;;?/LRT&,%EU\($U==M$5(B8([F=U_'8.N;1];9IDE#JV):HT$I1PYZKL@
MU54"?KT4#WJNSNR*)[N??JQ7IOMX:])?T(-;\%SS-2Z,%9ZYX:,&AB6@PB-?
MZ<1&_O1ZB@0AC\6(Q4<]MY`BM@-%TG#KW^&AG%=9?GA?#IC#IC#IC$"=\O'C
M\U[X9S^>SZ/\)/ZL],8SWM[_`%!^$'V0>-7W,0OIC+?=,8=,8=,8=,9#M_W`
MWH.GIY;[R&3*?LX(#7..XO`AJ)62/FR&==5ED&R[ELFF/8:;Y?FG^=U,"Q#=
MZ2V07T:;I;<.?,2!#/+4)CH!BO40&HXCD3NJ(JHB-;_$]W^5B.=LNVRYUPTT
M.7B3KG3FAP7U%IH^H[`=>&XU)*?#JHY2(JL80HQ%<^3)<U(\",C6K,G%CQ$(
M-QD>GS_^=O)6S>4G(207?+8,O$W$O1`M@$/75?Y;QN#AQR0L*BQ>%$&2Q#5Y
M[,[)O2B35!B\-/BCEJS:H*IM$<2TE6Z(UK9ZJF\0]7DT0R)I\LG3S!P3S76%
MFQO)#C*C0&5X!\OB'`Q`&EN-M'.#D>J?<,M;Q0]%SA5PBX?>C9PWB<?"EX@K
M7\3+<US64?V;6SY2SK^T>UMB$4*>])`H%8:2>P!20H$9+2+9O(-S^[JO@YR1
MNFA;$Y&5Q`G<CKZM2R`LKHTRKM(36J;-=](",3#80V4D3&'M\#]Y)ABMEZWP
M6;;,&A#5F9R,UM%I+&9`D6,<"DCQGHQ^V_B/V:KB.$S;]XT*<OB;+NG.G*CN
M5_+Z%UCZ0O"K07$C2_"W56HPU6I]5PB3(;C<B5<!72!QJR+=3_$1M8>\(LI*
MI9#$CE]2,DDT5TB`DS$5.&?,(;6TDNB1\=+*C]2`&H\GO,B\=>"D]@I)=9!`
MU@80]`PX#:;):K.B[8=L/8-'#5X\729.4'2FS]7:`TI5\.M$ZLTYJ*9:7]H(
MS=8:?E1D$^ED(BN8:.SU<)APF.;ZNI#ODME*\4N.9@7.$/SKPE],6QU=Z47%
M[@'KFKT9145'.`/@]JZBOFV0M:!8@TDU5C,%83ZPFHI`BI/!!B+5G@NCS:25
M!/8QVD+!\JJ2Q4X+%K&?QJ71^!2,V2%QJ;N`9)O&)$4"Z(Y*C19A1)!B_=,<
M.-/4T0<J8PIHY3QKONU=80L<*>($'AM(N[&[T'6:TK-14DFE$&V08AQS\S2(
M:-(/!GC5CO\`I2AC$PSV*U12!J)S"9IZ3?",GI(OTOH70GI"6O"+7?##5=-K
MNW!I"<LVV+4R!GC"!<U%??4DT"NV]9JY4J06*$G25`D#GQS#Z/QQCPQG./'/
MT?H\?#Z?#_\`G6I$8]Z/>UCG-&B*]S6N5HT5=D5RIORHJ]$5R]5Z;[YZ^<8(
MGA$0PV$.KFA81[&$.YC>9R#8JM5[FMW<]&-7E3KLB9U>K(<+W(%-4?246UV7
M=JZX44VSJGC*F_D3QYO#S9QG?;&FN/-M\<_1CPV275VO^),30G#61;?:$*ID
M1J32M;(?"@QQR)QF0H:2ICT`TK@C(*%&--,Y(L5OA"5O.52>>(W"G@3Z.UIQ
MO](J!I;[!N=55]EK/BAJ*$*WNYTBOI(A;BV6LJ1.FOC#EG!(N+"%3Q1K96C_
M`%F2TG@QDCL/X`=OBX^>LB2?1%%Q"J?$/]4)A;9P<X]U#U$=M-UPD9:9W0S*
M)9E+;534:R=)LQJ:J#DV1&I.66KR;WA1J?2^K+'25YZD&74NC^O2X4IDZ&U)
M,84L30$9R.>=0F8K@%8`H55/&:-',5^F[_\`Q!^!T?@YI_BGI<EO?S-:QK%^
MD=$V,$E'J"3]GV$NID3KP1TD"JZ)DZ$<3+43YPK'PR#J4G%#+2-O=T[6(^F:
MRAM7BI+-)@PA@=`.VDMA2-W*Y>6T1VWW]H,&GF--EU,9WRDV;-T6K`>S3;CQ
M[1LR;((Z;"AQ6PXP8K"&,T+$8A)!%*9^WF]Z]_8B(B-:FS6HB(B9\+-=:NDZ
M\U;>ZOF5-#1R;Z<2<6ITQ5`IJ.$YZ-;X4&O!N@VJC><I2D-)E'<63*,8Y2$=
M)?7)S$\.F,.F,0)WR\^'S7OI_P!]GT9\/Z)/ZL],;(O=-\9[V^/J#\(/L@\:
MON8A?3&6^Z8PZ8PZ8SIMY''DY"A$MSH;25N@SN1MHSN48ZR%S'F#YD,?'4`N
M5\$E@S(D2'#W91-MLQ;/G[)HLOHNZ0348Q7MR]U>LZ@Y@U=Q:9P_\-P^T;"@
ME,/9?Q^DZEER&DK:G!=T+0#<BHHE&!<.JZ-H(>PE47:UKEY^\%:GB>E8:"`#
MDDJQOU]Z=?I<G?G'2O".Q*_:2_F>+A+6+P#90F+EITXZB4@:HM,9>.XX%-`G
MPR3%FYG5/*2D/%+/%2[K9#+$<H5T9+)=)=PZ60!I;EH4$#=S2O>HB(B=5&QX
MW-*]'?\`98JJY=MF\VRYZ&]'K7WI!:7U*>CX"S-0&M]2HV)+I:ZO#=5AB&_Y
M<%K/@6,>740BP%?SMO)@P,A"0GK$IL-3L<OCMS=TSCO8%GG>*D:KF/<?*O'N
M7*/&!OHKEDU-AVNBCLR$ERSEVNU93>0$=BDO'JX7V1(>WO0CQ^_D+5J_DF/Z
M>U17'E$JQQQU\5JJE8W^%'L3=7L+NJHTQ'\YFKOL[F5BN<1$<3TWZ4OH><4-
M-:1KN,MKJFTXFZOE!$3BZ5S$.:OG%5H8-A2#"`93Z?K(J0Z22SPT?%]6CV`(
M\:K,:-52KQX[M%-<@.2_)2F9*\BH&G(=&"1FL9L?50;"YK&H*Q=HVP\.[$5-
MV:S$@VV5DL<:X0TPK"Q9-8BAASJHEURZ_542=96,,JC'#$%213$^ZTX0M7UE
MS^;HK7HJE$FW4#7*Y-]\POB=Z%NN>&W";A1KRG#<6FNKNXC5^K]/U;7GF:>N
M=020OT;&KDAM0PI,0S65-J52.4=_+B#C$\)6.R&+9[LO;.EW%^7QA.NV5@C(
MF^;1J#<:I-7:4>%GE`SERG#387"`\A%XW#$$&&I#VYNJ@=C[#?0:M'T23YF,
M>\.5JK39:PP_5VR&B<@P5I(Z#:3D<O@O9LUPAA1$YE<B\[&_=4?,Y&NS[1?H
M6^EG2<7J2V?J@^F9=U&+:ZBXKU&J'VDNN;/$)U[7S_$DQKBVOB%DK&2.5A*Z
MRDM66.S?%CFE@U2+^L,;>MG;V0A6=9T^W00;LA4&IR,-X;#!S%EC?5MG<:CN
MOL^**Z;8R4,+JZNBB^N55\:ZYU2TX]'Q<U+0:7UEHRI@4`J77(11K(*U2/DQ
MT8-0<]<<9AN8<@E1JK)9*8PB(>.,,ASBN^@DOT,^'=IK/@YQ+U=KGBSJO6_!
M&?-MZ+4&H=<%FI;FEG;.("_CRH1F+5Q9;'FC0ZHM6Y(SE@3Y$^"P8&Q$4*8%
MM?;=FRK[_6IZ^BEC.^5,J9^G;P^.=,^'AMG&?'/FQC&?'/CUP>&/#\O$;5;=
M,I?U6EG,@SK`MG=O4,8+8",<\2)S"53N5Z*C5>SD8PI%78:HN>^DGQWC>CYP
MN)Q&_875'$IAKFFH(VF]&`;*LI3[UQAAEK^YDL;"&T7*I4`;Q3&BQV-7QVN3
MZ!?;'Y"UAR&XBUF:K:(1:LMHD+3ATKJR*:,68R%2,1C";W#`6V65<M!$@WVR
M?%K$?.^<IOU?;7;]^B\>+;$@S0S$E(.7'G$BS9<61+C%(8,PP)!&.GA(9?'(
M"?MZV$I_WI&&12*I.9<^!?I%<-M4<..(D@&HA7OJ^I*VJU-0R-01T!9BJ+:`
M"1&HK%`,;7#MM+-=^SUG#J]J^)(KN2"&/"=&"Q@W7.S0^'3&'3&'3&(%[Y><
M8^:]XYVQ^>SZ/\).F.OE^>WZ+C/.WO\`4'X0?9!XU?<Q"^F,M]TQATQD$WKR
M!AM$!QN"S8U*I_,6LO1JFJ8>&,2";VE)8A$2LP=QT`P##2?NU'9D+PV?RR08
M&0^/."(O$@-C_>+'5RQFO1Q`?\A.>?):(\VJ@VC,$'A["UETB]6>RNQ0%9IO
MV\*A%G5'HO(XU$R+*+\IZ-#,W\]H-NA\M.,G)F@Z>MF=0V&$+4D$.$,CK]?7
MG^N;(+ZF:J($X*7<0&,Z/JTGDBM&#;LAJ(UO'[&EL>F$6DTV;,1V&K%Q)#@*
MP)HS(E7S9T[<*24J^W4]X.<N\,G-`SN43DQ9O,KD61"SLM(0XVY9J,C;\L3?
MEV;(*+,O6.PH%J]6=)M`;9XWW3&-F6J+'V)!#+9/1';37K"-(:ET!3ZVOYO$
M?3,[6VGS0+*OA5T6:^,6+8$EQ/!FB+ZU%5C`1A30#Y"_NU.P@QJK6JS[V0^$
M7'6T]$W@C0>C[K?3G`GB.$.B=3:GNINGH<H5S4)I^Q)+K;2,.IL6R;"?-FTT
MZ>^9%>20Z))C2I"(0K"TYU<IIKI(^T)Z._+ZR>FBF-5OR,X\54M<;>IC77;Z
M-]?]G/Z?AUK3['M"U\N_BU5BZABSAPBVGJABP(LJ0CRQ8<B<T7JS91!-YD$Y
M[7/394;LYN_MK]J]-QKZKT+::HTZW7%K2'N(VF%M(4>]M*N`HHMG;P*,DC[2
M+6!E%1A)(PO"%5Y'%YAD5OH"A2`C5QJV5<*;.EMUU5%U?/OG93&==L>.,:X\
MN=<YQMG.,[;XSGS[;?#PS3B3Q1ON*$NCE74"CK6Z>I045=$H:]T"*R(!ROW<
MQYY#^9SG+RB8\<6.Q$9&CA17\^GO1V]&?1'HU5>M:S1UYK;4A-?:RG:WU#:Z
MZOF7UH:VF-8+D&8,&O%X8QL;SRCA/9S2[FL)\IS`H']"CETT8N'#)M[6X2UQ
MMHA^5GSX\VN-\XQK^5MG73.V^-=?RMO+X:_'KKN&U!IK5&M:*@U=J#]EJ&S.
M:/+O%0"-AD]5.^(A"252-''(F,!&?)D*@8[3*4JHQKG)D/I$:ZXB<,^#FMM=
M<*=!+Q-USIR%#G56BVK-<6V!]IP@VSP1ZYK["<>OJ"3K(5=`:LR<^(D6,UQB
ML8[QRC[V%X2>HJ-O;6NGKH8WSJJCE377;;3S>&,XVUV^&<;:_'&/+OK\=M>K
MX[-W##B06RTC;5NH?V0U%+^P[DD5DFLMA0SF!'FK'\1S'BDA_>-<`Z\CG(:)
M*W:$^<&3IH7I*>CQ'T[Q7TMJ+0*<6.']5^VFD(]F6OU'I65<0HDZ?3ML4CC*
M*772_P!P4<V"WQ6#=$MJQ&DEP<Y'),V*6@MJOC?9FGCQ2W6U4<::*;9VQLIK
MX^;77;.V?+^3KKC&<:ZXQCPQU;UW::NUI:3.)6I*<L46JY[T9:1*B17T,N9!
MCABECUYG-=',4`@,20B23R'%:4DA[S*5V<C@CIKA5P>TU4^CMP]U;'LY/"^C
M`XVFK35<"^UQ4U-S.EV46??Q!O'.B1ILB<58#GU\*`.*^+'@!#$2,/'Q_P"C
M\6V(B_,:=U4^W(^VVC39-03HV9[KL,E8::'']<DG.N^/8M-06L@]G7W3V1W<
M[(M,[Z+.D==]@<.N'6HWZ+MN)F\%FF@V8]/<CY+DL#S=XY%.&,@E8Z*%9#`O
M<\[#<[W.8%XAD(WYJ_XH'&C01]0</^`XVVI^(M>U>(!Y#(0_L2#IVRB6U8V$
M>>Z0TZVLR37BELCAAEC,B`:XTL1RA`_<NZ[S/E3ATQATQATQB!N^5X?S7O'/
MA^>O]/A_1)_7TR%W\MOGOC.^WO\`4'X0?9!XU?<Q"^F3EONF,K7RTY3UQPUI
M&07O:30^3C((K&`"`:+[Q1L<.R"8'V$:CX=@1GLJ@L$$J/B9%#3).936+`&^
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MN!\OT</27U90^EA(TM$T_P`=>%U,6CU%/+?V\-FGH<JHO:[QIL=)T.@N*635
M6=TZMM[*O)(BBYX\@XS5(O!I'E5/"65O-C9+&F5//KGS8SIC7S9VUSKX^;'A
MCQQX>/C^CK60ZZ:^Q'4K&**Q),'`2)(8Z.9DLAF@:`K#(QP7H5R,>A$:K%WY
MMMESW(?4%."@D:H2PC2:"-4R+QUI!*R?%-5QHKYI)D4L13,EA=%&XHGQW$0S
M=O#YN9-^M0-,'(U4JENIEHCA7*FV4ML*:^C_`+?^K^.<_#PSCP^'AGZ<?'PV
M'><(-;:>X@5W#.QB06ZIMB5HH(1649\(RVJ[17+-5S!#;S(]A$(C'M>QR-8[
MF'SZ"T7Z67!K7O`?4'I'Z?M;HG#/2T?4,B[ER-/V(KF&FF/O68TIF#+)D$0:
MB*%8ZD&\1F.>42M.@;@17A/R;FW&W;EE%*N+GJ4P[=HZG!:[!^:58#'KX89D
M"<3:.EI)\G0A0>NQ*%]QNC=MG&SW'J"T';]MU.J^&^L-%65G4Z@JO59M29HI
M8PR(\QO*0;3"DA=&*5"1B!(,B$39S6D3Q&,<TC6=+PX]-OT:>*MCIFKT=Q%B
MR)FK*]9M6VTJ[:C"R5XOA?84R9;0XD./>N*TS!5_CO\`6"!4<<I7FAME4Z;-
M0^Y=X_:J)J$M=,-W>$U_/E+X::?EHXVSC3;.$==<YSCZ=,X^&WF\<FU'J7BK
M%X7:1T3J.#/@</B2C7FE23:5(C;'=\F0KHMH0#22XPGVIY`QM(OW)8B*KP>K
M<M'#[AUZ,%EZ2_%?C-P]O*.^X]1ZR'HSB?&I]9NM2:>:T-=`8.STP":6/4V,
MD.EX5><Q([=C5,D#6@F_:/B[:?;+_`V*[<T]LFWZP/<:4^.6\RN-QRK$1@BP
MD!<.#`%9([M6('GPLL2DKF-QMF_B<EAS8=(8=)`2"$>5"EV<B)QY#ON&-_-J
M:MX&PU=`*\C)\"8T[JN\CF5CG*87B,52-\,:#DQGC/%,$$F(<)V-<SY6?XDV
MG(DSC@&W37L'4II=)$'"K84Z`:\X:R*O<!*<HHC'-BQ)Q3FM(XYS5D3/7;&/
M8QRA&,\MC\%[B,=$/8177("N;=KVSW@VH]YV7<U:Z%0N(*W_`&],Z1H`A+6;
M>42HS$?PRS:&*CF(]JK,`T(-EF@"63!MG34DODU@L!TP[JMLL<!SFNCCG.$^
M4%',:YX2E`C1'\$JO$R0T8%D#8P[H\9Y'`'X,B>MI&$DYP'2FHK3/C(]H"*U
M[FM(QA%<\7BL1KW!5Y/">YPFE,UB%?E[?N-T4Z'TV:0BUX:@+NO*RN.49,/:
MG.",`K?K&6SZ$E8C-@1E4=+(T1+GJRF28EJM'EWK)B)6)RQI&&":ZZ/#SDY/
M'&;DM7/*^LMK6J_4WI&TI?-(*YT.(B,JZ2&`R%[&9"FP+1HU)HC)1:11BNFS
MD$1DT@`/?(HBB2R\:O6K5C+!=,8@7OEXQGYKWCC;/Y[/H_PDZ9"KM[/FNWZ+
MC/.WO]0?A!]D'C5]S$+Z9.6^Z8S6M*E[;[H',&>Q83"ZX@5/5X+MGC!<(.VH
MM&+[DH>IV]N"RB9*<\9[G_`A/.,5J7^-KS225-/F\'Y05#8-?+1969#!QNOQ
MK=XQFQ+`X#!ZMA\>KVM8A&H#!(F.2$QB'0\(.CD:`#$=M]TV(@*);M1[!OA1
M1179-LW3QNLJJLIYE55-]F,RWIC.,YQKC.VV<:ZZXSG;;.<8QC&,>.<YSGX8
MQC'QSG/PQCIC%D/N[1Q82,O=00F\9W7H]Z['+W/7E/2.:5V]<L%U&SI:+,`>
MSJS[!">NBKJQEU=5O+8<;2UU=`)`49JHN%.W#0W!X[908!W@<F['(C>9[5ZH
MY@U<A7M5.J.:Q45.J+MG!?9P!E4#Y(VD3HY%WY6JG='/1.1JIYHKDV\\[276
M=VW.XW"7E*2&SZ?L5\;9DFPN$R$DPA=XPXD68+!\G8Y`[!9!+,ATE;)O/*S>
M+19LIZ_I(N6[E';9NI8A%DT=U47"1!MLJ*SAVU?Z]&5R"FP3CD!>K'HQW+SL
M:CT:YBN:JIS)NBYW\#4-W!J-3T])J&VJJS6>GK'2NIP4]D:**ZH+4#X\VLL!
MA?X,N,09'*@I`RM8_8C&HY-\TQ></'$5PZY*V91(UM*&<.BI-LK!'DR<M"9R
M00XNQ;$11U4B*&C!Q)-YEPXT468#FR+-P@Y&N44'C!TBGKG6Z:SXH\2=1WX:
M@;K:<:'*/]FL975P&QZ^-$AO8>9*\$)I`H37,0DQ3RI:%\)'&51I]Y/1#UIP
MAX3>AWP>J[+6`5I857>5)QV7K-W;.M)&I+2QOZTM570#V!HM7(N$87EKEA0:
M8D$YBMKR!D$[;AA0,CLWD#QM0(57)CU22J\*T#R,EM##2T*(1QQ,PNDE:/R>
M@_43LSW$J.=2*:CG77#=7;"V===_'K%YD+5[M60BZL2]D6KIM<X]A:2)<V24
M(R":`S+,A3K(`T3&I'D!DD$C&(@B(C4VV/K'B-P7H/1[XG`X27_#FEBUG#W7
M9:73.EG:?HUK[DE+:$2.[24<<(U=9$LRJ^3"DU093I)'+(CJ1[N;Z`IJ0511
MT'0=2(W7E/UM&6:0]LX-$HW7\'C[!NCOE%D@J^6$`13-%!)3*39/9NBFBGOG
M33733;PW)(D2)9BR91S29!WN(:1(*\QC$<N[B%*1SGD>Y>KG/<KE7NN?F_"(
M4<;`@&,(A-1HQ!8T8QM3LUC&(UK&IY(U$1/+$8WYVDN%W.UT3O[A;=57Q`F?
M)/=9>8I][&;5IV62'7/KN%MVT.DR3&)R+91?U"^P-[NS<[*X>NHYDFNZ?N^!
MKA^HM:UU!46FH)KH&EHQ8=-72!L?$AA)R(K6L8@2J1K!"`PAGF<*,(4<2,$Q
M&YZY]$STFZKT9K37$]W#:KU4?B+80[/4>I`69Z[5QSQ4-RL)92@VD6;`\23)
MF^HI'@O+8RI,P\XKRIX;JW-*1"7\?=^/%J!1<V@LBJ'6G["`+X=)")3&2,/U
MA\G&[914:OT&1<<H\1U406;/4$E]5$5D'&FBFE<<:AC@"JHJB"(:JG95&QK5
M5/<NW3/,VI[4=[J74-X$9`AN;RVM1!,K7%$.QGR)C!E5JJU2,:9&O5JJU7(J
MHJIE<A_;BXYHS**3T^1O:P))%65;,MG%D\CKLG+.78IFQ)1:]/.+%&'YL['V
M`I5UA3`Q+(0A*VQ1@%.ZC2R;)0D)'.V][.CSH8[VP^-L7/P24##_`"'V.UO/
M+DLR)/WW)"X7Z@V:\@3&#]OGT]7,J4TT)30JN87?D4-42+=&42YBP>-&$H--
M7C&6<X^<<JQXR0XY"ZN9GTV4JG4HLV7&)7*3LRDTKGTS<-W$CDYT](7KUXY?
MD/9&:/I(;-F#9LT;H-&:&FF<;,9.O3&(%[Y>/'YKWT_[[/H\/[)/U],8SSM[
M_4'X0?9!XU?<Q"^F,Q?N%S@;#^/V!DPAEB2>G[)G$<K&_3M8B9M(Y'6])R=J
M85FTU<QFN(;/)Q((^\U&CZ^D#0!'\[,!D[7/EB@4`'+%FC&0_P!HSCFYH'B3
M&'A4U+"Y*S_=\P$L)A'I]"7<)K](,P%P>&AJYL:P+&-U:&=MFI&RGM;#2<=C
M$4F=D2]G'8!`ANR45&,?7RQHW3&'3&4X[AVTBTX'<QMXKL7T-:\:KFREO'LO
M,2/1E\@3OOE2.9'?^(_*),-[PW`^[_Y=[WU9^R?RCT^K@?#\87B_]+Q&>)M_
MV^9.?_\`G?*"<WAOY/X^1W)O_JY5Y?Y[8CH'J&T"A](Y@?K'M18_4%J(PA@5
MJ&U:(X%X&8:_R;`_#+"&&6&W^H]F]/T?]7Y>O0B(U&M1G*K.5O+R;<B,V3E1
MB]N7;;EVZ;;(F^^:K=NKG*[?FW7FWWWWWZ[[]=]^^_7.KET(A=@!EH[/(C&)
MM'W.?%P"EP`5)`Z^?#.OBL,,-'C)7/EVSCQW0V^&<X_3U008BL5A1#*Q4V5A
M6-(Q?_B]%;Y^:+W7VY+'O&Y'#>YCD[.8Y6JGS147*O6UP6HZW&PU)XYLJ&K@
MF'NF.*0JR9.W#Q<1[1L[]TQF!R1W)JS`#<NMU%\M!<*:I^=9?'PT<+ZJ<>+!
MC0#,/!"&,]AO'0?J\63#<5&\J/)6S@2JTJHB-5/$AO5%8-R*CAC5O?P=5ZEK
M02HU??7->*8%P)*UMK8UAR#=MNGKE;)B3&.5-V<XY#'^$\H>;PC%8_%SU7=Q
MJNH4[@7%KGP1@D%="0HTC$',%"PJ6258`S<L6A@K>4982.11TV\;.<X+DZ^A
M$1<%ETFSA_NMEHTT0KE18EK91IFHX0KV)$:]@*L!&:<8T97-<H?7*R(5S8PT
M8UD>..,,49B*T",1SD7I?69@(\IM;/D0)\XJGEVDOQ+XYY"\[GR2CL9+5-*.
M0CRR9)I!#2"+SF>1R(N)NNGBIS54/J3B]:TM&\Y"-]332S\6`1Y-']T]LXWW
MP,?2(R5NC=OMY=<^GO#V>F,:ZXPGCR:XQO+1^K^$]$@O#T,/3,D7*B6#*X5\
M]')MU'9"]9O'HBIOS%AC3SWWW1-4:BTWQ!M%)S:H6\"3?>(Z82J1W?HZ"_P*
MMGL1&2'^S+!]H3DA;7&_N$U4PJ>$S2:E+@='JJM^@63EE`Y7/`*,!F<VCZKD
M)9#Z)`ADV@Q>*:2")E)JX`>B&^5\92/@Q4N,O<8]Z03-&ZHT9&UA23*V7:UM
MO"KS2HO*.:2+-#)_Y*P"]HI37L<(<B,DH:/$P9T$B,(3.UX1_M+0ZD-IVUCS
M8\";7R98P'W=&8>,4/\`S,0K5(!S7-(\)ECOY2/>%2.5S&;_`$*:?MZ%7E`A
M5B0)T15#$')46^&G1!".2F+2:.DW8*4PV8Q@N@U+QF710^P?@Y$!*-D7@\DR
M63SA1'**ROB[/2>2=TQATQATQATQB!>^7X_S7O#/A^>S]/A_1)TRE=O--_EO
MC/.WO]0?A!]D'C5]S$+Z95BD9WSBO;DES`BD"XOW`?K*)#9O'JY(HULMQ=Y3
MU_,7T/N(DD<D$CE-0W!=DTJ&,2B"OE,6;'K/X[0F6!GL&CL0`W-4B,AL"5-V
M/K\OZYL6=,8=,8=,97CEQ>&.-'%KD3R$]RHR5:EJ6LFRV4;<J[-VLC)P^)%3
M8H`Z<::[[MFIHDT:C'+G73?+9!THOY-O3\N;\6.29*C1`[>+*.&.+F79/$.1
MHF;KY)S.3=?),M',R.`T@F_A@$0S]DW7D$Q7NV3S7E:NR9\W:M^7W*JJVZR,
M2MAFJ+<$R9E*"2*"Q@I6@-P8)+E786'@!;:.R.'0D<LY4'Q:$1J9"XY%`*;0
M*"8,V;-MJG]"V\`Z.-6PX<&]N8TR-%"$DB1ZM81#G:-J$,Z(409(V/*BJP,>
MP`(0U0;4Z<V>1%XMVA9L@\NKKCQBG(1@A^-$DB$YRN8))`WD"YS&*B.(6(1[
MW)SJNRJBW5@W=IG8[1NA;%$AY%IIG3#T[4DNR+(+:_'U-V4#GVF!Z?EQX9QH
MYM7;S9SC7SXQX[]8;9<&=7PMW0#5%V-.FP3&JYCE7MRQ9K31.W^NV9UVZ*FZ
MID\+B9IR2J-EBL*MZIW>-DZ,GMYC1W#D=_\`3!7I[%Z+<B#=S'B/+UD&1N<%
MJI)+8U\[>VHP5B(AKMM].CJ=Z)DZT2VT_P#5X37;'AX[ZYVTTWVUU_9Z?U!2
M*OVO1VU>UN_,<T(IH3=NJ\UC#]9K4^[UV=+[;KMLBJF7P;FFLT1:ZVKY:KML
M)DE@I*[]MH<CP9B^2;^!MNJ)W5-[KQ:91"<BDCL)E4;F`1;/@B8BQP9(!:N?
M#Q\$R`ET[:;Y\/CX:K9SUTK",(WG$1A&=N8;VO;\-VJJ?6V=HYCV+L]KF+['
M-5J_@J(N9)U5E.8S`V$.C'.[@+;"X6*YG^+LE=/"3Q=B-]\+QBS*'N5,R"%$
MW6F'+9XBZ%LS[#9HKJ]\@XL(:YPRD9EL^P_6PV.J6%5>4@Y06MV7;Q$<TWW'
M-[.Y$5SV[[\FSN79'OWR#3CW).<Q$YFJ`BKNF_)LX:\R+_EYE1&NV_BW;OOL
MFSQX.BG6_.FXX4,1291CD'2D+Y`ZCT,>1+>V*UD&]-VM)M],>&NJ\C@!+CF+
M6T2QC79>'N'ROF=$G"BFI\SC+K],8=,8=,8=,8@/OF8\?FO?XV?IQC^B3]?3
M&,LX(DTPO;OX:F56A(@D)X7\>":C`,/<EC#U-A1T0=;M!0MGHH[)$G.J646(
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M_O.8L0J@<_PFN.C4([S+/X$7+K$[JZQKVTKC.41Y7K228['+SL`08P/$4K&K
MRM<DAGBHWG5HM^5&RTK_`*,A=<C3%E>0O*NNH`P7326(Q6B888LHLL@KC3?&
M!MF3]6"AF"V4\_%16II$U\^<92V72QC=3"+[TIM2RN8>G:"KIQKOL><4]M*1
M/)S4:D&*QW;[KP'3IW7OF3U7`FC!ROM[6=8D3N.*P4`'P7?UH[D][3"5?9Y8
MW>EO]'Y[;-3*MR$HKF:\ACB&B>NY"_)^6DH1UY?COJ^K2)I0FI"22NW^TD5@
M+_PUQC7S9_*SMIJ]XJ<0M1^(VTU7;N"1%1\2'(^S8;FK_D?%KDB@(WR_>L>O
MM5<V15:$TC3<BP:&O:4>RMD2!>N26N3_`#-D2U.5B_\`@YJ>6VV75.=MG@0:
M&,1K7B31D'W$CM1`0]44#$4G-(^+UVV4T'QR>U`C")M'6>BN^RVC8*?8HZK9
MRMC3"GY76"ADR([_`!`',`G?G$5XW[_^3'(O\\REX1%;R$$,C?\`2]C7-_!R
M*F59G?:HC,<$OBE.<JK?JIH,17>:#+C5CE^UP,:(XV655,$9MK'+G=M4$\9]
M5P\OI'TT-,[J*>?&5<]_%U;=QD1JR6R6)M]V4-I%V3R4C>0J_,BYUAJ.N-NJ
M"4*KYA<K$_\`T7F9^#4S]>.W;6J*2-R-C<A+0@/,M0S'S$3AR44A[.)TA"!Y
M%TSV,2.$@$)]9QG:U]W(MJV;6BO8KD_#&[95G7J$*7)R=U(.);WTZY4:2?#&
M$2JHP!:YHT<O=[N=SW/?MT17.V:BKRHG,[>_!K(T!'>$CG/<B(XA%17;(NZ-
M39K4:F_7HFZKMNJ[)MQPT)3`USNY,5?/K";6:_X,TY7-'0R=/S296?3:)\A)
M`1N!(E9NB;-LGK.HG&:^KFOY,<34<*3@Y&R4W?I"GY]8.RZ7.P3X[XW[IC#I
MC#IC#IC$"]\K&,_->\<>/YZ_^TG]>.F0OUT5?RQB_"O4_MVUN)>L5V=:RC;@
MY0^L;V9;B$WNI_-"17`?9HI(&[L#HZP1]GRWW-M'0C57R;$FZS+"R>S)Q<?!
M7DKR_.\SR])\C[FD)AI%6+B(RBO)/8_#V0N!=EG(E*IU%0C@?Q^XG0<DXDF\
M6KJPB^P]E=6C<8TB<@R6!$5QJZ#=C\L?_P!,8=,8=,95OF_9,NI[AWR>M&`O
M]!$X@M&69(HB=5:H/F\;D;")DU`\H=LG.-FSMC&'^4#[YLXUR@NS'+I*XRGM
MMUUMS.)65%K9"`Z46OK9TX49NZ.D$B12G8!NR.7F,X:#39JKN[HB]LY<".V9
M.A1'D0+)4N/'>9=MA-.9@G$7=439B.5R[JB;)U5,U[8_6<'C,)Q`VX(>_C.Z
M;M0TWD"*1Q64$22V[X_(IB[*Z.591)),36=&I1(#F[TI(#3QZ5+.G+UTLMO^
M9_4.N=7:KU9.UI<WMG*U/8S7S26C)<@4L!7.51!@D&1"0XT5BH"%&C*P46.P
M8`,8-C6I]8ZS3U+34T>A@5T0-1%CM`V&H1."]B-1'OD-<SE.4RHI)!2HYYB.
M<0BJYRKD(`)92-;DMPG'*S++@<G!/,>K7_"*4VH34'$<[_!22T)0/RDA9'.V
MZF<*;S^MB0W&V^RJ_E\,J:^L.%O$7TTX;8S]-6&LI].1K%&;B$*(:B,'NB`N
M]=*#8:(B<K:VU$_E3E1%1=ETSK#2_`,ZE2VC4,6:U5YF:9>8=DQ^^RJ2OT[X
MCG.55VWE0WM]O;=+XU/R/[PR9X*G&(U%;`KE5=JH8-<X([7]3RIX(\^,+[Q4
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M3WH@U^&8$IQ(I$\JB[M('(N0A-%XF21?\EIU-.0:;`HFIA?4C'(_;)V5Q&$K
MZ+8PH@C!8[&6+3;7'L;-MKCR]:XM>(6LKCF27?31B<BIX,)[:\'*O^1S(2`4
MC?\`\RD5?-RYE$/3-%"V\&MCN>WL20U91-_:CI"DY5_\$:GNR/)M!9%1-O4L
M8XB$870$KY'V=I0%I[LH0B5@YD+(8!-9.*M%>K1).,1J1W/6K^!L$X5+C.5,
MI1@E(H_*4S\7]F%--D\%=3VQ+N10RY<B9`D03R@LD%>98DB.\2\PGD<YPQ%&
M\C2#:J,<7PWHB.YN;%M>5$)D`5D$(@2!2!A(X3&C0PBM?T>UJ(CWL<UJM>J*
MY&<[=]MMK<U!3T-HOFI$J[K?)9TS&<,IJ5M(_("2IR8325RCD.$D$6GEA2!;
M71P>F$SDKR^Y"0*NM$M'))^<U%MF+!+V)#TYFIL9/TQATQATQATQB!>^7G./
MFO?'P_/9^K^R3]><=,I<B+MTW_']$7&>=O?Z@_"#[(/&K[F(7TRK*,O.(]J@
M>YTWY`P3C4$9Q\I:`B3&>0Z]\R)S7Z-.K<?)/%)A'MN-)R?&AX;DB_N6935X
M*LRN*SB`=>OY80P;EBY:6VFRF3&.DZ8PZ8PZ8RNW+N516#\5N1\LF\(;6;$0
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MSC7/)!"F26%)'BR#""WG.487O$!B=WF*C5&$;>[GE<UC4ZN5$RR20`3F,(83
M'D78;'/:CR._TC8J\Q'+Y-8BJODF5<-=PBNG&'*5351?=S.D?%--V*KI:K(O
MLIG&<).DI3?S^J&)H/MMY=MBD+1EVJB&WM#%N_UQY=L'O>(O#?3.Z7FOM+A*
MF^\.JG.U1-YD_B$\&EQ7#8AD\QV)87*OW7N8JIF1UVE=56_6OTW;/8O8\V.E
M1'V\GM);OA.,/_WQF'W3JU'97P5RRLH9ROXGW!R)A,5B].1ZP9K$P545HE8-
MZSP/8,XIBSQL8MW1]&(0"D$PG#9LD\J<#5$,K@ZT9C;5FA_20S$TVBN`&=>C
M+QXT3K/BO*T;IFHNC))TM:36:EN1Q:\BG@3*USJ^)3195B@H9P//(?8RK!)1
M2!B@2NAM\9Y<?XL<.+^AT8*]MIU>Q16\,#JF`XTEB#DAE-22:<8,522!D00D
MBAC>"QKS$62=?#1CR>,D0G9>1VUR6MF,O(3.[T=14+$J],98[R.KJ`K)$[I5
M<'EJPQZ0&[S4L>F-D6S,6K%VY1C1JSU*_P#;S"<(0-$/H;GF+Z_IEN^F,.F,
M.F,.F,0+WR_-_->\O]MGC]']DGZ^F4JK4[_+IOC/.WO]0?A!]D'C5]S$+Z95
ME"^[:`GT/,4A=M>3^_82D2+*5?92\!F/([\$*$9!,Y)9T0<V+5_%.(R"]9;(
MY!*1CJN(@YA,FK<4NM.5P\S/R!1Q#XD38QHG&ZX/P^415=NN0S:+'IK#`Q&;
M05$RU.NJTL=%KHQLBJCKYKHCG255=.FL@@$M&O6@\L'DL=*B3(L659/![9C)
MNZ8PZ8R*;VJ<5?%*VS2ALF0!B[7KJ8UZ[/"=4=B\?TEH!^$T/B,.,;(>]@:K
MQ,L,]?79'#YFWRKKG3&V,T%&PPR"(U'C*QXR-7LYCVJUS5]RM547XY4USF.:
M]JJUS'(YKD[HYJ[HJ>]%3?%GB99R>CB#2$3_`(AW%+;6%I>P$"U1.:M?5#.-
MV.V6^\TB$^G-G0@5'`1S5/WHE%;#5BTY"Y65$Y"F,-694OY2L.".IF69@5Q:
M\]8XCG1ILF2H7,"Y=VLD`:,I?%&GW7J)A6/5.9KDYN1NXHVOZET09)3)(Y:-
M1"@$+Q$<]$V51$5[&<CEZISN8YO\*HNW,OX2AKRZ;A7A:8;<;>*P_9NJZ"I2
MD]*.3MIEM-<;8U8+5=$%Z*AX<ENIY$]7HJZK!$-=MME7>NZ">WFRNIX"`3D=
M=7QC+TYX];&:%J+YHDN2XJN1>O7U,2^:=>B=-,XCD^\D&N8SORDEE4BK_P#0
M)&(B_P#WN3MNG?%W7E`K8M*-(#WG(KD:7<N45438Z+63'Z,%(;XRJHFXB6E*
M0RO))E!UG9-N\"V-/IZU3:IJ:HOMUW&J[39E5PMT74<KA4H)A4V7QK-SI[E[
M;+X4A7QFN[;<D=J^>8G,U??S=T?.>%B_^G$Y8Z>].<:(54_\B.W[?"OU<\$X
ME5HER;JZ7S6K;3,N<.))(MB$=MT;)<Z-O)LO)7%LQ62V(Z>$WVRA`IH$LT&Q
M1SA%B)29MM%-U\1XE>CMPPXK@:+5U59.>%K6Q256H+FL9#Y$1K7`K034ID=R
MILJDK"*KNJ_>7=>]TGQ1U?HMZOI9L1$>Y5,R96P);C(Y=U0DHH$L%1%7HUDM
MJ(G1.G;/7`SEA$-$<;B*6NYGKY<O'P(G*:*DNB7C\=!\4/:7%'#3O'Z=WMBP
M]JIG&=]=$/@CCQ?K#_#7IS*8^@^)%A7JB*H*W5=3'LF.<N^S"6]46M(!B=/O
M?8\I^W14[+F^:/TK9P^0>I-*1I*=B2Z::2*Y-MNK84UDII%]WKPDQE'##AY;
MDMN"O.2%Z!(U`X/4NQR24U70J8A9]*9/84EBAJ";V#-S<27>PH$#B</E4S$1
MJ'ASDQ=F3\C2E)HC%GL,$B2FX?1:]$IW`BRMM6:FO8&H-7V->^EB-J0R&5-1
M5ED`E2E$::,$J9-FEBQ4<=T6(V*`1`#:9)!'I@_&'C2WB+$A4M372:VDBRFS
MSNFO$LV;,8(@0H\<=Y`@CQV&,J#0QU,1[".4?A-;CN<YQC&<YSC&,8\<YS\,
M8QCZ<YS^C&.O:V:"RG:/<)X-+I@ET^65"99R<H<$1XEM9493$&G<;=1)D:4'
M&%'^HMT-9/9["6F3*3O8.NZED>;MGRRI9EHLQD[5]=536N5G0*M[#B<U-5D>
MTC%@"8\8:D"$1.K)*+-V!QHEOE=EL[20<[,E]]/97WLCS5HNMLS=:I,9)_3&
M'3&($[Y>,?S7O'/A^>S]'C_1)TQC/>WO]0?A!]D'C5]S$+Z8SO>8W&_YUM!R
MRF]+!L:M'A-R%D@625?."-;R/$HA9-O*8<S=38`R=2P!'MI:+"/#SF&N@TG4
M8,MVP\PUT7<).&,6)VX.1+>K;KL'AA/(I"J-2^6<<@]1<>X&;;V.SKFUVE,R
M2[KMWD-M:1T`_F;F\E@]@VJ!=E#UR2MH<@]J*VY9L?G$C"5X/8Q[G3&'3&'3
M&818=@1VLXN_E<E<^BS:8PFV;)9TV>E'ZFNV6PU@EMMKA5TXSIMG'CG5-%+1
M5RONFW154UE$55V3(543OFO;8<XOJS>2DFG)]Q%$:>*AD4A`5#*JL@&/&K9J
MDT;85V;Z;;>BIHNFKOA;5BX;9]I]D3)+K*9O-1S53V)Y>U4ZKO[.OR3V9:54
MZ^:KY^Q/9_?IY;^:9'QBSCHFW8S7.:\.JQH\,?/7%E;+>2.CG;4<2?:#]L),
MW*/K*JL46/@_(#5\N'R64&SA+">Z]7/LY$Y=DVVW3V]5Z?--^OL_%Y=^OL]N
MVVWY_77,O>6#$F+Q5BX+)^J@GG=3=%)=PAC;'AGT=5FZ:FFZWAGQSIIG;PSC
M.FV<;X\O4>(W==UZ^WJODJ=>BHO1=O+\\(CMNW3Z_HGNZ9$]`M)JSS.,2^S]
MK#;N3F',>;KCE&;H(-4V=;8PJLX336WPZUR@GJR2RLS899[906SEUOII`W=5
M555R(OGO[^O7VKV_/JN')LO;;?Z_W3RZ;9>FKKOGU2O-=HX3V<!MU\+/HR1S
MLX#/?'.OJ[:(YSYV#I377&N7K#=!QGRZ86RLEKE+:IS&K[MNRHO5>B+V5?Z[
M;_/"+MV[=-]T^OSZ_P`L8W&KN_#ZF(BU=AVZXYVRS^&LR15>JBH(+>(N&SF"
M#7HY4>H3LF1(YU<#FR2S9**Q=VVFA]+&2,4`RCCJFRJGLRZB[I[E]N49)=IF
M0R"KJCI:2<N9<2KJI^-UP\+6Z#6GJX%R8UQ/N`;QY"%((L;044%C[":`^.X(
M:K:2$;6RXQ(C+P;$`3]N.<MXR<NCQHXF[\?;,Y+6H_LHE.S_`"3FD;E9<9@'
MF.QR-:1)@8%B]AX]P>D[QS(B8\LDUE!A(F,!$4@0'4)#XSAJ]P18RXG3&'3&
M(%[Y>/JO?'&/SV?3C&?Z)/U],A5V\E7X)OC/.WO]0?A!]D'C5]S$+Z9.6^Z8
MS6+[DE,\GH?W"JNN>E>-P^2@+)6'1?>R*&92N"VFX7?"XS'W"UX<G/P?3!/C
M)!]YF.AD:M8C3*FMSWO1"K:/Q%=%[69\#)V1Y]/BOX;?TQR7"'F9#^6D<G0<
M;)HA,K#I!_"(M:DMJU)1Q3<L-S.``I^&E56E<2*7[MH^<#FTW"T%E$BVLRO7
M6F0T\$,E%PQ0ZR<O%TQATQB0>>=_-!'*Z%T":5D*[@[!D)/%-$!6Z<='ZKX+
M>V:N7:BJ>[U^]4CY'=1^S;.FK1%%D/<+HJZKX2NC5$Z==U\T^O9O\URV]%[^
M2>7UW[]\A7J^O9W1?).O??MUZ>S9?9[.JY;^OKX90;=Q;>TAES2T9$&-)-#[
MO6*M0J"*2`T0IONKHFHH@S9>MMLCNT2QJZT</4-T%L+O%<[XUTXKM^947R[?
M/+S43NB>[X[>?SS"&<V?.Y^1A?R3-(,&`[1YB4K)J:"W"^VB*GH)>+?"6R6^
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M'M5-E5=U[+\>_P#7=?/OYY6Q>JI\_P!/=\NF-/ZMY<PZ8PZ8PZ8Q`O?*QX_-
M>_QK_7_9)^K..F4JNW^KY(B_GC/.WO\`4'X0?9!XU?<Q"^F59;[IC(SN*H(#
M?-<2:JK-#;FXA*FK=)XDU($`ID61'/6Q8!)XO(P[ED=BDRB9YB-DL/ET>?CI
M#%9**%GP1!B5'M'23&*EY:"N3'""O^)/';M9U17@:%EI!9R5D#"$')6'.MX[
M%(EM/RY:%/CT^AD<E%XS55O+3JQ.Z)>AI:<QUT8&YP&-G-S6['U[L:)Q\G[:
MT:1J^=('S,H7.0X/[X/R.OC%3R$G)AC?`>6+GZOD"2)JO#FLF'ED2T*(Z;.(
MR03<!\K.-6>JZC&0HIW`>*J$NS#W<YF(_;![,9Q."=&7V,I78[A_@7@>GR!(
M5BVHQ138EGV#11.Q-FZCO^3Z*[*_D],8OON73.4`)X:DD1K_`.7$OA<=BT?C
M0U)BJZ?K,CKI$D5<M]V2"Q+#1+WNOEVBTSIA7V#&5MM$T]M]+K5V;NB;KOOM
M\]O+Y+[<MNZKLOOZ^[;?\=_AY;[Y!P=P1+QX:Y,#5@!4D(:K$A/M2+M<.^=M
M--W;'#U#'H.%&*RFZ.'*>N$U=DL*8TQC/EQ=3^%>G?=/>FZ;]^R[;?+HJ>S*
M/EM];+^N4'<2T+M9DSK5G@HN2AN=-GQ%RSU;LG&%?9L^1';*^Z^5M/:T\>91
M%-)SY%EFJBR&NJFW&5-E5.^WG[<O(O;Z1$^O+RS(NHR<Q<^+B6J[662)J+37
MC2:J[4T0\B?NQ/?PQOOA??;77&/-G'IXW\WE5VQE'&%=L9RQ[_9ECA&\VF-&
MNT:Q/!0L@(M]DH?*'>=G8S9FL026=/O%%L_SHILW4(M&B^C9UJDYT15RCXI[
M>%YG-R;)\NGO3JNW^VZ)T[+EE>CM^_5?]D^'R_)<9MV](G)%)0T)2XVU(2.(
M0-!`^[&)[-V9PZ2T;C73E-'**&-6.VR;QWG3T&W\IPTV3;(:8RDG#]T:B*G5
M>Z[>S^Z>SVY4SJY5_#YXWSJUES#IC#IC#IC$"]\OP_FO>/\`;9_VD_\`;M_T
MZ9"_!5^"[?JF,\[>_P!0?A!]D'C5]S$+Z9.6^Z8PZ8PZ8PZ8S63E@\AQ-[L]
M-1226=-Y4ZM>5HSZ$0T0^Y4%V9P5<-KOJHVBP]E;7/"Z8W(U:GCLE(6=:AZ-
MT)!JZA$+C+AZ'&QK=T"!#V,8)S::*(7"S<;IXU3?0T,LEOC'AZN$GQAKOG;/
MA\=M=D,Z?'QSC373'T>'5\6VR[^WIOV\EZ_7M^"VG_Q?';^GZ93_`*NN7O\`
M/;;^GEO[>N^^^^V4_2Y4"6R")3:PY0"@[G)B5Q;"#29C&3%WER@Y0SJUT<)9
MRWUU?HMMMM!SU5GNOHR=IZ(N/3V73V5XS^J_=157S1$[;?'*V+LG7Y+]=NR_
M'KD9V,`G[2/O&4<PF`DSA-'<>Y,MM]4=4/7TPYW2\[=SIA;*6-]$M]VSA/17
M.,;Z:YSJII0J*G=%3X],JWWWV^O9F4Q2KY#+A`R-SH;[R3=C6"<J>[,,M1SK
M15-/==TU3<:(:;95WQA9KE!-/;"F-7"*#?73&B52-553HNW??W8<Y-EVV_-/
MK;V]_?EAX?+ZN`2)"B(H1:MS\1C:#SY--&SK;0:)1]DQKZ[W5#V#5[OJ_:.U
MFN[GVW?1YJZW2SKOMOB^FR+R>?3?;KV39$7KMW[]?PRVO???W[]>^_;?;X]<
MNUP>J"S81>%N\GYA:K\906:S>B=8P:71$19FX#[BRA$NY=E7R05H+C#8.8(N
M9%HDPV15*.VS\DFV;$=7-HG\7?Y>S\.GU[,K9V[?/V_7]<776%D=]3>`U3>8
M#F'`.0("?U#0]GE*N&\;N.]O#M+`MGD'&:TL2EX9->,\LC9TK%*&@<L9SN<7
M)A&3Q\4%;;.21!=LB2+MK>5=?C\O[^73^Z]MKWIDX=,8=,8@3OE^/\U[PQX_
MGL_1X_T2?U=,;HG==L9[V]_J#\(/L@\:ON8A?3&6^Z8PZ8PZ8PZ8Q2W<-I>_
M9.%LY2*<C82`I:W(K#1TPIZ9QEH]M9JZJ#>16!*2'$:Q)9<<#K&LK,-P<0\E
M6IV90>6[Q`_7;2?LRHOV#!&-,?7^V6,L):G>7E"9NBEY$(LH8R:R%S`9_#MU
MGXJ4-HP8?##K,(_30PA*`+UV+):!2@O+P646T;%(\1>#7N%WM37;+[E[_P!?
M=_3*'INF_FF)0L.6VD!FM=@H3`6TECDA**-YC(73M5OK&63=9OLXWVU3VTT;
MJ989=KMEG6JR;ITAH/21RY53UWO*KE5$:G39$7X=-_Q55^.4;)YKY=._L\_K
MW]N^8N1<:A#282\-$V>I1TT?R`[\GA+)(]*'0YHN[PDHHBFBL3(N,Z;I-=7*
MNV=W*^<^;&ZV^VT]&IOMLO7MWZ?!>^_EMV_%8_+S[[)Y=?CF%U?;`ZRJO_"/
M(`"T+8(ZG,F&)_;"J+!F%46]J>[.UVK3"[#+5'U]UMVJ.NF^BR.==_1]3>$<
MCD553JOGY=/P\LE4V7;IY>?;?Z]_3JN^9Y"9K%["CC"5PXHB8`$?6T:/$4EV
M_P"6T74:N$%&SI)!RW507243W2613WQX8VQC*>VFVU2;.1-MMM_?[D7\=EZ=
M%\]]LCLO]?Z9'=;3B`67=<UA\/A912TXUJA&B9E2)HH/S;;W@DV2%CRR/JDG
M+?)#TLMF;[1I[<FDF]8I.FC?UDJ>9JJJ(W94\U]GQ^M_9TQMY=_QVZ_S]G^^
M7QY?<FQ?!OA=BNK#F<\@=KSF)V&;CA&IJ$:<JCE:UM%R84C8MFSVJR+AC%B5
M:Q-.6AXM,')HKH/W?SH`&#[D39!FVQ9>J*Y53SRZW=$1%[]??\\35P%X;W3(
M>Y127+>-UI4]?T;/P,?+U;S![<L:DE'\?K[@$*B96P+<:\A.+RLN,BX(KR/-
M3^OZUD"DZ*J2&/VEQI>)QFL\+/\`:>@:<GX_R^7UY;^S-SOIDX=,8=,8@7OE
MX\?FO?XV?K_LD_5C/3*57;Z3]53&>=O?Z@_"#[(/&K[F(7TRK+?=,8=,8=,8
M=,9`O(SC13?*R`C:UO"'C9G$P\^@%EC!Y)D-?I-977$G'R@&XRU+L"8YVP?[
M,G,=DPE^Q=#9+#3DCBI=LY#G"#99C*F\_N2>W"@+`+P:62$:1N+`;*:?-9*R
M:&U^(N-E%JQE4J]XQDMI3EASQ(I7[@+'UB^1Q^&5W#J\<RF92O8H[!`P1AD+
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M)1S-MEV[[+V\^G==^WLZ>7L7=LO].B^7LZ?G_+IG6U'Q]),\AZWKF!%`@E`A
MHWV01%%MF(7!)[ZCLB6=NM5544]=UU73A=ZX\^VFN===L^&FO3=K$Z=O+JGD
MJ]E5/FFWM[XV5?K]/=V7V=-O+&4V=KQFX)5^<Y`'H/.BZL=1&L=T:YA$]N2S
M#KTT1&QQJG&X#$6ATL^>+O"+5LY(-!C=F)9.5MWY!@.V5VS85RKT5>GLRXB(
MGY>:XE<Q&;MYVW9Q;)RKD:%Y%\=N:+JU9J&)\4JLTKPQPUH^HYOK=''ZP8;R
MSTARKZ4CBT^K*E8M<M&\@F#P@2N,VS)`H6.U@VS0/3D[;^:^[R\^O\]OEM[]
M]CFCZ8@7'BI8)2M8#WHV#5X#2!`D2A5^=,NM?67>D"YTZ46<$CD@/%G;\X?,
MOUU7A4R0?/W&^57&W3)R5>F,.F,.F,0'WS/_`(7OAX_GL_7_`&2?JSCICY[?
MA^J+C/NWO]0?A!]D'C5]S$+Z8RWW3&'3&'3&'3&'3&1]9%35=<85C&[9KJ$V
M7'QAMA)!P2=Q@-*A;&0"\+Z#S+1B;9O6S<DU2=.VZ;M)/5;V1X\:;;[-G;A)
M5C$H\P:`YEQ;DA8$PI^^"@H+RD$EJ%HJMJD`D8U(J^.6D!A3"=6Q8;V)``\?
M&Q>@?=5R<DE;IF9V5V*=G\JAM4PHC`DGRT?M9D==_P`OC\?).GUTR?)'W8(?
M%^3D[X\/*C.FP47Y8UKP^"60%EH39J>G9KBA+^6=RR`J*.,P@X+%Z*A@$`&E
M3K23%'#LO*,[N4`B`K?VUD_7Z_6^=9!.\5`[;=3V%4YQ1Y/6K>L%WKU^M1\#
M*\6YD7(0JS6=ANH[96]H0KDI**(`PAB[K*01V4+2.T1<C`RQ[&8]O&W3R3A<
MNV,DK?GD%Y%=N?D+RFX^2UKQRG=>0V^HLZQRA#`XZKQZY!4Y@['S,-O,&X//
M(^+5C<R&-6Q7&IT@/7%$1Y1IN_2=HM%F,2U27&OE#SINZFNX-&Z>`!B%UWCQ
M/Y;0#F))K0,1"W^)]7U_$X9`.5O`4M3!,1M(97"9$4AMJ1N*!`^1U<R96RW=
M@S9\WDHAMN09'7Y?+I]?/S\LV`^&W;_H7@L1Y`D:,WFR?SEK8?W99+&5'F)@
M;BPS&[Y0V6C3-D%$)QYF7W?>9R%:>(=K[(TP+9#\>U>U,G+O=,8=,8=,8=,8
M@7OE8US\U[Q_MK\/CX?T2=,A57R3?Y[8SSM[_4'X0?9!XU?<Q"^F3EONF,.F
M,.F,.F,.F,.F,.F,3K#^TG&X[<503N363K9D2BUF=Q:\K>"2B,>PF+;MOGFF
MSB"))9P,+98!P584L^E52LV::*SPF'="W;=P*PBNRZ8R1ZD[;$>X8PNQ2'!&
M1!XU?,OCE30`1/\`E&PE=Z1</4M.NGR4/J/(&)3&I9`E%0P4_*$QA=K*/E:Z
MD!9&130S-EF"+7+'S_'^VV2SPGX5,N+=*V57]B2\;>D[Y`W9;_(SD-+'L*8Q
MF%3:TKM-)E)<VCM;N24H;1R",&#(1'@D<(G)&YV8"\/"A-Z^?.=L,9>G&,:X
MQKKC&NNN,8UUQC&,8QC'AC&,8^&,8Q\,8Q\,8Z8SGIC#IC#IC#IC#IC$"]\O
MP_FO>/\`;9_VD_\`=K_UZ9"_%4^";_HN,\[>_P!0?A!]D'C5]S$+Z9.6^Z8Q
M?'/'N-U'P'0K`9-(;8EI6+<FMB.ZZJVK6T77E\B#U0!''YT49XE\GB@QTJRV
M/16-`@`U\0E$KF<SBT?!!7?MKY\,8SJ^6?<HK?B5#ZRD,CJ&ZYU)K'J&T>0;
MJKXJ/K\!/:[HZBH,$L"[9_8:-FV!`XV"Q7(N21X$]C2,C?2,U-#8^-@1[]3+
MQVS9"JB=_?\`RR\=8SIG:%;5[9@\09`,+$@\3G3$%(DF;>0!&<N`CS[80=0'
MO2+!$R-1(:,R:3$@_9IO45]&SUTCC1?=DXFR<\^N8)6/]SOD%48_C>&X^]N=
MUR<KC6N[$B5DG[BM:QN//&C2W"$R7F<=L>.1:%0Y>P34;`C(;O!3I640AN;-
M?+6,$78A/5CZ^OY>?]X_DG<GYRUE7W*6/2J#<5+#NZINW7#NXY64OC>ML5Q5
MCNLS/R\0F4&L:!OCMI2UO/8LY@3]>&HA9^R`6:T=:Z/#5=;CR*Z3(\OS]WM_
MED_V[S4Y616\^VM%JV84!.8[S&<UWBS*21C%@N+SC%=/(,7F5Y<C@\Q:SI*(
M1"J:;W6@@)`=)X5(5Y3()@S`Z2ID8>BF;ADYWW!CFMR`N?D?S=X]7B'A3XGQ
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M6`9)VP56:N%V-_;\^B^_\/T_!<EWG#W%N5?'"W>:KVLXYQ[/TAP+XM<>N3MD
M0V?AY^RM"V`UL2:\6,PCT&LP-.T(C!S8(!3WK1)`W5TR0D)XLD,>N1R2B;C1
MDY&^.]HX?\W.6O'`,VHY>`5=3W)+:A=\RI1Y<TDY#\3:AK:UK8CEIP1E*,O(
MY`"6LZF$?A;I,.'(%2%$VEK@JINW13:,C?O]>6_5>R?/*P0SO)<_[&X;\E^2
ML1$<4='7&AKQ%,%G4MH#D?`T)<]Y.Q.'&Y%6R%63B[([8L<<U.O/H@6"74L\
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M64C)Y@FUC7`RAD?GMHDACIPZ>$I2YA%>1."1L<L_UB$-CB!C$=C;(D=>/]6,
MQN?=M_A79UE67;DTI%D2F]S1D]$K97936RH]&K&%R6N2E1&'DR@,;F0B`2"4
MKUJ:)0YO.",87FHT.OHD,D#-5LU508SH17:YX)A*FL^DAE$HMJ_NII&Q=L(_
MA&MQ:7V`"B""C6,1:36<XGRMG$H:#9+NQPZ&*S#Y*H#"!09J']@*$6[EC;;Y
M]<\0/:[X01B?5K:("II(+L"HHI%X)`Y2VO3D'@D.A$+EA&<1F(%L[VINA+XR
M*DY9^13!3%$^,<:+:CGC9P+;MF2+&292?!KC!QX<V82J6NR8`_;X(1%;!EYB
MRK6G<Z,Q6.MC#2-Q9E/;`G$HF4:C,:1/F=HU'XL="AX\X(+NPS-B[SJOJQG8
M5-PGXIT9#K&KNJ:/A4/KVW(]'(K9<":-WS^%3,#%:X&U$+9&XH8?$0+G=>MP
MPJ)2![J/T?RX:/:;2MT:=H:.<,97Y/M%]OI*(1N"IT<:UCD,D&\DAZ.;TY$;
M%HD]WB;^"X&QB3;6QF31^)I0XH3C;:#"2[.%-!))^T;`$4WCC"C&V2,Z[;_"
MAT:I<Q^`D.R:\>4H+I3L*#RF?@JFASFLC!*05\7TI8++&%1G)'#CQ<B:`2B2
MPDS(QQ5SD@@4U=)HJIL9V-N]O3AO?5P)WO<-(!K`LG`R#AGSX](YPK%Y"+K0
MT8D<`93"MF\G;UK-48B=D!DJ"Q+HB:RQ>OUEDLXV\GD8S@AV\.%A2-16)O>/
MD+4%0J;6+8T=<)K'VTB;32W&MBLK,.O9@U,HRXVO-VMLV&C(6QPX28O]9,Z]
M1KXMAV6;&>Z^X!\0",<EL1=4B!VC4\JVDJ6F09$S+FC*2UKQQ?KDJ1CI?1I(
M4-G:M>.'"J8<\IMF2+L/3%DS#\8BBS38RX73&'3&(%[Y>,9^:]XXVS^>SZ/\
M).F.OE^6_P"J9\WZ'?\`D^)?_3`'_P#5M>F4,[?/]$S(^F5YSCZ,_P!W_7'3
M(7NGQ_1<XZ9.<_HS_?C_`"STR/-/@OYIGEM].W]^O^6>F4M[-^#OS3./_5C_
M`(?\L=,J3M\U_-<X_1G^_'^6>F/-/@OYIGECZ/\`@S_GGIE*]_\`YI^29X=,
MKSRQ]&/^/_EQTR%[?-/S3/'IDYS^C']^?\L=,CS7X)^:X?HS_?C_`"STQYI\
M%_-,\]?H_P#Q_P"?/3"=U^/Z)GCM]/\`]_\`FSTR<,?1C_C_`.7'3&0U;?T1
/[^XM_F.Z9"=U^/Z)G__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>g838054g92l36.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g838054g92l36.jpg
M_]C_X``02D9)1@`!`0$#P`/```#_[2WJ4&AO=&]S:&]P(#,N,``X0DE-!`0`
M``````\<`5H``QLE1QP"```"````.$))300E```````0S<_Z?:C'O@D%<':N
MKP7#3CA"24T$.@``````Y0```!`````!```````+<')I;G1/=71P=70````%
M`````%!S=%-B;V]L`0````!);G1E96YU;0````!);G1E`````$-L<FT````/
M<')I;G13:7AT965N0FET8F]O;``````+<')I;G1E<DYA;65415A4`````0``
M````#W!R:6YT4')O;V93971U<$]B:F,````,`%``<@!O`&\`9@`@`%,`90!T
M`'4`<```````"G!R;V]F4V5T=7`````!`````$)L=&YE;G5M````#&)U:6QT
M:6Y0<F]O9@````EP<F]O9D--64L`.$))300[``````(M````$`````$`````
M`!)P<FEN=$]U='!U=$]P=&EO;G,````7`````$-P=&YB;V]L``````!#;&)R
M8F]O;```````4F=S36)O;VP``````$-R;D-B;V]L``````!#;G1#8F]O;```
M````3&)L<V)O;VP``````$YG='9B;V]L``````!%;6Q$8F]O;```````26YT
M<F)O;VP``````$)C:V=/8FIC`````0```````%)'0D,````#`````%)D("!D
M;W5B0&_@````````````1W)N(&1O=6)`;^````````````!";"`@9&]U8D!O
MX````````````$)R9%15;G1&(U)L=````````````````$)L9"!5;G1&(U)L
M=````````````````%)S;'15;G1&(U!X;$!U0BT0````````"G9E8W1O<D1A
M=&%B;V]L`0````!09U!S96YU;0````!09U!S`````%!G4$,`````3&5F=%5N
M=$8C4FQT````````````````5&]P(%5N=$8C4FQT````````````````4V-L
M(%5N=$8C4')C0%D````````````08W)O<%=H96Y0<FEN=&EN9V)O;VP`````
M#F-R;W!296-T0F]T=&]M;&]N9P`````````,8W)O<%)E8W1,969T;&]N9P``
M```````-8W)O<%)E8W12:6=H=&QO;F<`````````"V-R;W!296-T5&]P;&]N
M9P``````.$))30/M```````0`\`````!``$#P`````$``3A"24T$)@``````
M#@`````````````_@```.$))300-```````$````'CA"24T$&0``````!```
M`!XX0DE-`_,```````D```````````$`.$))32<0```````*``$`````````
M`3A"24T#]0``````2``O9F8``0!L9F8`!@```````0`O9F8``0"AF9H`!@``
M`````0`R`````0!:````!@```````0`U`````0`M````!@```````3A"24T#
M^```````<```_____________________________P/H`````/__________
M__________________\#Z`````#_____________________________`^@`
M````_____________________________P/H```X0DE-!`@``````!`````!
M```"0````D``````.$))300>```````$`````#A"24T$&@`````#-0````8`
M`````````````C$```'T``````````$``````````````````````````0``
M```````````!]````C$``````````````````````0``````````````````
M```````0`````0```````&YU;&P````"````!F)O=6YD<T]B:F,````!````
M````4F-T,0````0`````5&]P(&QO;F<``````````$QE9G1L;VYG````````
M``!"=&]M;&]N9P```C$`````4F=H=&QO;F<```'T````!G-L:6-E<U9L3',`
M```!3V)J8P````$```````5S;&EC90```!(````'<VQI8V5)1&QO;F<`````
M````!V=R;W5P241L;VYG``````````9O<FEG:6YE;G5M````#$53;&EC94]R
M:6=I;@````UA=71O1V5N97)A=&5D`````%1Y<&5E;G5M````"D53;&EC951Y
M<&4`````26UG(`````9B;W5N9'-/8FIC`````0```````%)C=#$````$````
M`%1O<"!L;VYG``````````!,969T;&]N9P``````````0G1O;6QO;F<```(Q
M`````%)G:'1L;VYG```!]`````-U<FQ415A4`````0```````&YU;&Q415A4
M`````0```````$US9V5415A4`````0``````!F%L=%1A9U1%6%0````!````
M```.8V5L;%1E>'1)<TA434QB;V]L`0````AC96QL5&5X=%1%6%0````!````
M```):&]R>D%L:6=N96YU;0````]%4VQI8V5(;W)Z06QI9VX````'9&5F875L
M=`````EV97)T06QI9VYE;G5M````#T53;&EC959E<G1!;&EG;@````=D969A
M=6QT````"V)G0V]L;W)4>7!E96YU;0```!%%4VQI8V5"1T-O;&]R5'EP90``
M``!.;VYE````"71O<$]U='-E=&QO;F<`````````"FQE9G1/=71S971L;VYG
M``````````QB;W1T;VU/=71S971L;VYG``````````MR:6=H=$]U='-E=&QO
M;F<``````#A"24T$*```````#`````(_\````````#A"24T$%```````!```
M``$X0DE-!`P`````(X(````!````CP```*````&P``$.````(V8`&``!_]C_
M[0`,061O8F5?0TT``O_N``Y!9&]B90!D@`````'_VP"$``P("`@)"`P)"0P1
M"PH+$14/#`P/%1@3$Q43$Q@1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P!#0L+#0X-$`X.$!0.#@X4%`X.#@X4$0P,#`P,$1$,#`P,#`P1
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#/_``!$(`*``CP,!(@`"$0$#
M$0'_W0`$``G_Q`$_```!!0$!`0$!`0`````````#``$"!`4&!P@)"@L!``$%
M`0$!`0$!``````````$``@,$!08'"`D*"Q```00!`P($`@4'!@@%`PPS`0`"
M$0,$(1(Q!4%181,B<8$R!A21H;%"(R054L%B,S1R@M%#!R624_#A\6-S-1:B
MLH,F1)-49$7"HW0V%])5XF7RLX3#TW7C\T8GE*2%M)7$U.3TI;7%U>7U5F9V
MAI:FML;6YO8W1U=G=X>7I[?'U^?W$0`"`@$"!`0#!`4&!P<&!34!``(1`R$Q
M$@1!46%Q(A,%,H&1%*&Q0B/!4M'P,R1BX7*"DD-3%6-S-/$E!A:BLH,')C7"
MTD235*,79$55-G1EXO*SA,/3=>/S1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&
MUN;V)S='5V=WAY>GM\?_V@`,`P$``A$#$0`_`.M^K'U8^K=_U;Z3==TG"MMM
MPL=]EC\>ISG.=56Y[WO=7N<]SEI?\T_JK_Y38'_L+3_Z32^J?_B5Z-_X0Q?_
M`#S6M9)3D_\`-/ZJ_P#E-@?^PM/_`*32_P":?U5_\IL#_P!A:?\`TFM9))3D
M_P#-/ZJ_^4V!_P"PM/\`Z32_YI_57_RFP/\`V%I_])K6224Y/_-/ZJ_^4V!_
M["T_^DTO^:?U5_\`*;`_]A:?_2:L]2ZSTOI0I/4LFO$;D/-=3[3M87!KK-KK
M3^CK]C/\*Y9W7^L=4Q^I=/Z/TAE'VWJ`ML-V5O-5==`87_HZ36^VRSU/9MM]
MB2FQ_P`T_JK_`.4V!_["T_\`I-+_`)I_57_RFP/_`&%I_P#2:RK_`*]4X76,
M;H672VS.G&IZ@^FQK6LOR@WTOL6-D%F3FT;W?IGU?T:E]?\`.6?HT/ZN_6'J
MG4>H=/Q[+VO%M?4LC*9L:/T=.6,#`:QS`W^;]_\`QG^$24[/_-/ZJ_\`E-@?
M^PM/_I-+_FG]5?\`RFP/_86G_P!)J]AY^+F^O]F?O&-<['M=!`]2N/58USA^
MD]-SO3>YG^%WU_X-6$E.3_S3^JO_`)38'_L+3_Z32_YI_57_`,IL#_V%I_\`
M2:UDDE.3_P`T_JK_`.4V!_["T_\`I-+_`)I_57_RFP/_`&%I_P#2:UDDE.3_
M`,T_JK_Y38'_`+"T_P#I-4.N?5CZM585;JNDX+''+PF$MQJ@=K\K&KL9I7]&
MRM[F/72K,^L']`J_\.X'_MYBI*?_T._^J?\`XE>C?^$,7_SS6M99/U3_`/$K
MT;_PAB_^>:UK)*4DDL;ZT=9S>E=/)Z9A6=0ZE>'C%H8TE@+&FVRV][?S*V-]
ME.[U\NW]7H^G^C2G5R,G'Q:7Y&3:RBBL39;8X,8T>+WOAK5QV9]?;']5P\?!
MK;1TR^IE]N=E-=6XTWML97G4LO\`0IIP\3(95Z]V7;^L>M55B46^K39=E=6Z
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MLMN)<UC6O<SV;W``66>V/YQ_NV*;V#0U'DQ^Z.Q9#H70NFY-&2+\LYE36-N>
M,FXV9/IESJG]2V6-;E>GZC]OK^STOU;^C>G0I]!^K_0<+)9F=,%C7X^._#:Q
M[W$-KLN=GO\`;9+MS\A_\XLRS.PZ<RG!L?MR<D%U->TF0)^D\#:WZ#_I*TW(
MLQ"[(:XU^FTN>8GVM&]_L_/^BG'!IUL[+1F-^#0Q/J7U7IYZ?FF]F3D=,K<6
MU-LLJ#K/6R;['>LVG*L=5GUYF[.I^S[[+L6BOU+*OYNQ]5?K1F]2S,JSJ-]5
M&-8]S<7%>PBQC@^EC:;,EFW%K>VO.Z?39B669&9^T;\BK]!Z/V56NF_6Q_4\
M,9F-6&UN<Y@]1I!EO+AM>]NW7]]:==G3NILQSF5U67X]@MJKL`.VYLMKOI:_
M\]N[]$_Z=:BEBG'<;,D<D9;%*>L],'51T@Y#1GE@M%$'Z)W%H]2/2]5S:K;/
M0W^OZ-=EWI^DQ75R74>A/Z)D9WUHJR/M7H&S-?C9%6]Q$'[0UF34ZNSU:<5O
MV7I-E[+:^FX]V53^EJR/T6CT#K&=EY%N)U*S`?>:J\K&^PW>I--HX?2]SKOT
M/Z+]<_HV4S)J]+TTQ<[B2222E+,^L']`J_\`#N!_[>8JTUF?6#^@5?\`AW`_
M]O,5)3__T>_^J?\`XE>C?^$,7_SS6M99/U3_`/$KT;_PAB_^>:UI7WU8]+[[
MW"NJL%SWG@`<N*2@"30U)2)(=&11DU"['L9=4[Z-E;@YI^#F2U5.I=5_9[\=
MKL>R]N0YS`ZK:2'M;ZH;ML?7NWULM^A_HTV4XQB9R($1J9=*7QQSE+@`]6NA
M]/R_-\R"ZCH?0#G=8%=>);FEARK=Q:VQ[=S:G.:3Z;'?I7[WL9OL_/\`453)
MZCDY-?IO+`PP3L!U[CW;G;F+/ZIE=/ZT?LO4(VEP+,2[?2\$?1+6O]"US_Y=
M:+MJQZFM.VBFMK6-W':UK1#&-EW^:K6$8S`3C(3Z\42)0_P9-?-[D9<,HRA_
M5D#"1_P9,,DY(Q[#B-:[(C]$UYAI,]_[*?'.0<>LY36LR"W]*UAEH=_)6:W+
MZAU%OVG!R68>&7.&,30+GW-:37]IM]9]?I47.8YV/33^E]']+9?[U,9?6ZI]
M3&QLULZ''L=C61_Q&7]HH_\`9ZM/O6]?V+.$U6G[6^_'QWW,R'UM.14"VJX@
M;V!W/IN_M*KAX]71L"PW9#GU5DVV7/!]H,#VL;ZCOI?Y]BKY7UAIQZ'.MQ\G
M$LD-!R:7&H3S8<G$.3BN:W_PPQ4^G_6/!ZC78S,MI?@V35:^XUU-&F]NXM>U
MCJG[?^,3Q$2]5_+XZ\*TV-.[NC+QWX@S&V!V-Z?J"P`QL'<-C=_838V3C9E(
MNQWBRLDB8(((^DUS7?1<LFSZU?5S%J;CXI?E5L;L;5BU$UAO[GJY/V?&<S^K
M;:J_3_K?T[U:\6W"/3L5QVUW;V.K:7'V_:&,;7Z#7N_PS?7V?X7]'^E0H[@'
M@[T?^E\JM-C\W:_^Y>RZ9F7C)KI?834Z1M=KV]L./N6%]9.B4=$O'4L`U8U.
M3:_UK'WLQG5.N:RI_H95OMQL?TV6^I?75G=2H_H?2*L:N_U,:^1!+7#C0@K9
MPOL&51CLN#+[\6'U^J`Y['@%OJ5>I[FN:UVWU*U!FA^D/K_%EQ2Z%#]5\W,S
MNE"[*8\-#W,Q[GL=4;ZA'IY3<:]]N314YV^NC[5;9DWT55Y=O](6NDDH652S
M/K!_0*O_``[@?^WF*M-9GU@_H%7_`(=P/_;S%24__]+O_JG_`.)7HW_A#%_\
M\UK663]4_P#Q*]&_\(8O_GFM:R2G&SOJMT^^TY.&7]-S#J;\4FO<=3^FKK+&
M6[I]_P#A?^%65U2KZPX^(ZG+N%M+2U]66ZOU6L?6X64O<ZCTLK%]S/TGJT=0
MJ_TF4NN67UN][170`0UWO+O';PT?]4HI<K'+Z1(XS+<PVK]+BQR_5S;,.?R8
MP#,#,(?+[GJG'^YD_1>?ZA=6^]S[LW9@Y-+;*X-5E&YCO2R&-]>JYC_IT?\`
M@BKW=&-E?I5Y7IU&":_3:ZLQ[FGT6O92W^O0RI&R^DX&89NJ(<3N+JR6$DZ;
MG!OL>_\`EN9ZBN8[*P:F,`])NUC0#(AOLV[M?HQM1Y+X9CP8Q"<8RG&Q[V/B
MQ3R1_1]S@8LW/ST]DF,"!QX\D,62'%'T_IQR<?I_2<#I>55BEW1<JZBK*Z?M
MH907!CW5@3BW,]2QWKLOQO2L_1_I:OYJ^I:KF.;]($?$+SADY%;K,D"RVY[[
M,C>`2;7.<Z_>#^=ZFY&QK<G$TPLB[%'[M3W!G_;#MV/_`.!+4ARL^")C(2L`
M^K?7Q]7$T9\P#.7$*UKT@".G]7T\+Z"USFF6D@^(T53+Z7TO-)=EX=-SS_A"
MP"S_`+?KV7_^"+F,?ZV]6KL%+G4]0L)@5>F6W'^K]A_]XUT.-U+/LH%V3T;.
MQ@3!VM;<?ZWH33G;/_0)1RCPFI5?F)?]%?$@BQ_WK3R/JC@/DXN1?BN[-)%]
M?^;?^G_]FEC=9Z!U'I^#?D.-69C,:?4-0<RQK2-N]]%FYOI;C^D]+(L]/^<_
MFM[UU575NEW6^BS*K;?,>A:31;/_`(7RQ1=_T$_67"GI>2+6G=D5OQJ*B-;;
MKVNHQ\:IO^$LNL?^;^9^D_FZT1EF`:D?J>**#CB=XC_HIL5V;A9%'3>HW?:G
MW5'T,HM#7&VEK3EX=_IAM;W;/UG%R-K/6IKO];U+JO4L+?9U>KJ&(_!%)Q&R
M<ISS#VD?G5_V/H,9^?\`SWZ)9F3U'&-73,-SGMZAC9F$RRE[8>RQKF8E[;MK
MG,_6,:^]]-C'VTY-/Z2NQ;#LJFO)KH<RRZUWO%-;"XN8"-\.]M7_`((H_=AC
MC*4Y1$(C4S/IU\UT<4\DA&$3*1U](_=_2_NO6U/]2MCX(WM#H/(D2I+G\GZR
M9;;/2JPVUV.$LKM?ZEY'[[<+I[<M[V?]?J2JQ_K7GN#K\IO3:.[:ZF&YP_JO
MLRZZ/Z_VBU__``3%GPYK%D/ZJ\GC`?J__#9?JV_]SF!Q9)PQ`[&4N+B_NC%[
MG$]`LSZP?T"K_P`.X'_MYBJU@8+,*HUMMNO<XR^W(L=8\G^U[*_ZE+*ZU5^L
M']`J_P##N!_[>8JF%UKHUY``D1/$.]<+_]/O_JG_`.)7HW_A#%_\\UK663]4
M_P#Q*]&_\(8O_GFM:R2E+*ZV;BU@#/T+?<ZSGW?1V_R%JJMU`7G$L%`EY$$#
MG;^?L_E;4Z!J06S%Q+SP,$'P5/I?2\;I6.[&Q76.K?8;(L()!(:W:W:UGM]B
MEU#,=A8OKUTNR';FL%;)GW3[O:UZMU.]['$%FK20Z);WA\3]#\Y6^+>-]K:]
M=7C>I]&?F=7S,C";8^DVGUC2ZJMAN$#);2<H.]3(]3?]H>W]5^T?X3UO61Z.
MG?57%!/4L3-:YL39U%K[*?\`/Z9ZG3=O_'-1^D=0PL7IV)@6./VZIAJNPZF/
MNO%M;G5Y._'QF77>^\6/WO9^D6E5^V\B#B],?2UT_I<ZUN,/^V*OMF;_`)^/
M4L'_`$KS_NSB,(EAC*48QGQ8_3&7[\Y>VZ7W/EN")]RID`DQJ7_1]2^#EM=D
MUXW1*,>SIA;-U^&ZO8TP>68IV,V?Z.QGJ6+0+2&EY$,;JYQT`_K./M:LVWZG
M/ZA8+NJY%#+(U.#C-9:#VV]2R_M&1_:JIQUHU_5CH8+7Y&.[/L8(;9GV699^
M3,M]M#/^MTJ[#XB!'UPJ7[L9<48_X7#!KRY0D^F6G<BG+S.N=+R+&8+:_P!M
MM=/JU8U8S6UCB;&5LR*MW\ASJTV+C=-Z?D5Y!Z+9THVGTZ<NUE6QKK#Z;:OT
M&1E.Z;]H=9Z7OKQJK?YK?^8NI:`RMM3`&5M$-8T;6@?R6-]K50^L)QQT#J?V
MB/1^R7!P,:DL<*VC^6ZWT_2_X78F??YF8]`J_.7VKONH$3ZCL\UU7*PG]<Z;
MDUL?>,1[F9CZ@2-P_P"3\7;M_29%&9;]H8S]'^C?Z?Z3U_35UW4Z<NS[+Z!W
MU;;C78+O69$;;FLQ*7/I=[OYS[36JG[.R\+['CV7;AEYF(1C:DMLI(ZGGY%C
MG_3N;]DN]6_WV7>ION728_I/O8S))]$F#K`UXW?R%:EBR9(S!R&`/S"$(?\`
MJ7WD0S8,9B8XC*4=8SGEEZ3W_50PM$WYE-V&"W(_;%A<S&O]%E0O:QINLIR:
M+,AC;:6U[G/_`)G9_P!IO2O^GUF'=D7XS+,G'=B7.'Z2ASFOVGRLJ+F/;^ZL
MJN,KZX/VEIJZ1@MK#0-1;FV>H_M[?3Q^G4?^Q*W%4Y7E8\O$QA.<HDWPRX>&
M/]R,8QX&;/S'N@`PC&CI(?-7[G[G!_@*69]8/Z!5_P"'<#_V\Q5IK,^L']`J
M_P##N!_[>8JL,#__U._^J?\`XE>C?^$,7_SS6M99/U3_`/$KT;_PAB_^>:UK
M)*4H6M>ZI[6':]S2&N/8D:%3224\O959CV&IXVO;H8/;XI5MFQH(D$@1XZJ]
MUJW$.2VBD/R>IN9+,6F)V3I9DO=^CQ:?^'M=_P`3Z]OZ%8>#@]0Q,O,LS<HW
M.O>'-H!<6TD%VYE3K(]GN;6S975OK8KD#Q1LZ&MN[6E'A-=&U]5?=T+%RR_?
MD=0;]KR[1H7VVG<]KH_[C_T6IG^"JH]-:RY^K'ZC@OL'2\FFO&O>;78V52^Y
MM3WEUE[\-U.1BN97?8[U?LMGZ*N[?Z/I>IZ:A;5<^VJGJ/6,BRVTDUX]#FX3
M'1RT,P@,MS?^,SEERY'-*<B2*)^8EN1YF`B*!NM@[F9G86`P/S\FG$8>'7V-
MKG^KZKF[O[*Q[/KOT'U1CXCWYMYX96&TM\OTW47X53]W_`^LFQ^D=)QI-&'2
MQSOI6[=UIG][*LWY7_@R#G48S*C4:SDO<!(N#;FL:\^FS;5:WT77Y-GZ#%]1
MO\Y^D_F*+4LO)PQ8Y3GDV\+]1^6/!\TY2_1]2<6:>;)''".LCWK3]Z4OT68Z
M[UO*MMHIQ\?`-;1NM>YV66N=,5.97]AI];9^D]EMS*U0ZOC77=.R;NIY^1E>
MA1;8R2RFJM[6.>S(KQL1E#'74N]U#LA]_IO^A[U:J^KN%1CL:Q]V+:T#U+\:
M]];2?.M^_$L8W=LK];'^@I?L0V6-&=F79M%;VV-QK&55L<YAWU_:_LU=;LIM
M;_TGH_HZ/49^FJM5>7PWGC.)&6$,9X3,1].2/[_[W_I5FGSG*#B$(2GPW&$I
M?Y3_`%G]7B2X>/F6VLZCU,,&8*?3KHKDLH%FQ^2=SVLWY>2]C/M#_3K9377]
MEJ]F^RS9Z;@C)M)M:[T6B>X#B?S?ZJR,S#R<K*Q+Z,R['?C6;S55KZID/AVH
M]WMV>_UF;/\`!KI.O=1=TWH6;U!L-MHH>^IKM9MVQ17I/T[_`$ZULY#P1%;R
M_!SL<>(Z]&I]58OIS^J`M<.HYUSZG-$?H:"WIF+_`&7T8++O^O+<5/I&`WIG
M2L/IS2'#$HKIW`1N-;6L+_[>W<KBK,ZEF?6#^@5?^'<#_P!O,5::S/K!_0*O
M_#N!_P"WF*DI_]7O_JG_`.)7HW_A#%_\\UI_K+D]1QNFMLZ>+`XWT,R+*6>K
M;7CNL8W*OHQ_3R/6MKIW>ST+O])Z:;ZI_P#B5Z-_X0Q?_/-:UDE/%?M/ZQ-S
M\AK+L^W%:'@&W"],#'^QU6T9S+F8#K/M[NJN]&S&^S9GL];_`"75]G5.SK7U
MT&'1Z?VTYHZ?>^]IP1Z;[PY[<+[.X8_Z/*])GKW?:/T5E7H5_8/M>1Z%/H*K
M=1SJ>G=/R>H7ASJ<2I]]C6`%Q;6TV.#`XM;OVM_>24Y_U3.2_HXNS*33EW77
M.N<ZL5/LBQ]=.1:ST<)[GV8S*?TMN'B6V_SGV:E6>H]-=DO;;26ML^B_=H".
MSM/SFK'M^N69AY-5'4^E'%#:Z;<U[+VW>BW*N=@XFQM;&_:?TS?UC9_-?X+[
M2AU?7F\9%-&9TTT;\MV$^UEWJ5[VOQL3]!9Z-7KVLRLS9;5^B_1XN5979;Z7
MI(B1!L(,011;74,(X%#;K+!9N(8RI@/J/>?HTX[/\+8[^Q_I/YM9K,-K\AN9
MEM:<MFE;03MJ;K^C9]'U;/<[U+W_`.$_F?3K6C]5>K8WUA=;U9]+JLNH5L;3
M8_>*J[JJLMAQVNJQK&_:&7-]6YU7Z>RO]#D7XM5"W[J*;V;+6A[?`_P/YJD&
M7]X6L./]TT\9U#JN-T]U55@<Z_(GT&`$M)!;7^D</<UN^QOT&66)"C!LLQ:K
M#FFY]Y<;FL-`?>6N_2/W[;65TT5V,JK;_,XZZ0_5_`>\.N;ZPK.ZD/#26._?
M8_;NWK%R<'[5UW]ETV%S:J_T[]`6,MAV1_UY]'HXU+V_]S+[O\`J7Q3&,T(F
M&3)')`UBA`\$3FGZ8Y)'Y_U46Y\/N)E'A`!C*6;+=\.(1KAX/W./_'_\+<]_
M3,/J%=KW&W[/80,8FQ[W%C"?UC]8==_27_\`LO\`9UN=)Z>RTM86N^S4L#6D
MDZQ[&-]3Z3O;])7Z>G=)O]^,X/KJ<:W-K>',W5GTWTO^EM]-S=CZUH@`"!H`
MK.(1Q8HXX$R(%2R3/KD>LI2_>DU\LI9<AG/:_3'YN&(],8HZL7&ICTJFL([@
M"?\`.^DLCZR'[1=TGI0<`<W.KLM:1,TX8=U)_P#X/C8M/_7EN+)^S9-WUI^U
MV-(Q<+"]*AQ&CK<FW?D[7?\``U8&+_V^@23NH.LDDDDI2S/K!_0*O_#N!_[>
M8JTUF?6#^@5?^'<#_P!O,5)3_];O_JG_`.)7HW_A#%_\\UK663]4_P#Q*]&_
M\(8O_GFM:R2E*%M55U3Z;F-LJL:665O`<US7#:YCVN]KFN:II)*<C'^J7U:Q
MK,>VGIM#;,,SCOVR6'<ZUKANGW5V/WU;OYG_``2.WH'1F?9`W$K#<!SGXC`/
M:Q[SZC[&U_0]3U/TGJ/_`,)^D6@DDIJ=.Z3TWI=3J>GX[,:MYW.#!$D#:W<[
MZ7L8-C/W&*VDDDI8F!,3Y+,Z#T^W%INR\MH;G]0L-^4)W;9_F<8._=QJOT?]
M?U%J)(&()![;?5?'(8PE`;3KB[U#]'^ZY.;]5^D95S\JNMV#G63NS<)YQ[B3
M!W6OHVMR?H_0RV7U_P`A9O6NG?6>SJ=%G3KGFFC%;CNRBZH6DV/-^=:QCZ_L
M[<FQG3\/%KL^S>C5^T/5KK_0V>GU"YSZTXWUCOR<-_3,AV-A43;DOIDV-<QU
M=N^S'97;=GT_9695->!3_/Y5U/J_\$5CC5=.^OIR0#FWM-UN,S.MK?CVBO9C
M8NZW&QKGUU45?;7YMF?7Z7J7_J?HX]]?K>I:^R?7[TCDV9-ALV57.PZ?LP_2
M6Y#FY>%3;<S;LP.EL;Z+K7?ILR[UO6L_FU'I?1^OXW1ND_8ZW59.1F.ZEU9M
MEGIEWJ..0<?+L:&Y5ENQU=7_`!M/HYE7V9[_`$L[I73?K>SJ#NE5WVXE>+CT
MLLLI:VK'EYPOM3\6FRAE=N3NMZYD?:Z_6]:[T/YOTJZTDIW,_P`8>:[-J+[:
M15C7MEKJJJW76X]E[*,:TL^U/MQLS,Q,?'S&6T8K*NG7_I_7M4\;I?UVP\D/
MQ7664V9'KFRRS'-EE=6W&93U6WT]V0[(Z=BU5XGV7Z&5E679N5^KUV*%OU?^
MO5^._$OR?4J?B64$OR9:6WU9%/H7U"C=D96+D9%5GV[?^DQ\6EFSU;;U*SHG
MUOZ?CVY.#:S#%`OMJQL4>HQQL9U"UKK<6NC=E7UV7=)Q*?;;_0WV[+$E/1?5
MC&^L&/CWCKN0[)N+JS6YPK_T%'VK9]F;4WTOMQRF4L?7O]*M'^L']`J_\.X'
M_MYBJK]3*NILZ*']3?D.NNNM?57EG==73N]/&JM>YM;W/]&MMOZ1GJ?I5:^L
M']`J_P##N!_[>8J2'__7[_ZI_P#B5Z-_X0Q?_/-:UED_5/\`\2O1O_"&+_YY
MK6LDI22222E))))*4DDDDI22222E+/\`K`_-KZ'GNZ>U[\TX]C<4507^JYI9
M2YLQ]"QS7K0224\5B_5GZWUY.)ZW47/Q:[6V/:<V]SF-%M9R:GO%-/[3=E8U
M'Z+U_LM&&_)S?2QOZ.JN+]2/K+CX[#1F-Q<EF)]E#Z\F_6,?-]]I-?Z3U>L]
M0^U,_P"X>/1^K?I%WZ22GB<KZN?7JW'LCJK'76.L#6,OOH8P6-OO;=ZU;+;M
MV-U#)K]*AK-GV#!Q<;U/3LR*T]/1_K9DWO>,O(;B59SJ\>N^^REQQ&VONOR+
M_LY=D9/K;OL^"SU<+9CX^-ZGZMD7U+M4DE*69]8/Z!5_X=P/_;S%6FLSZP?T
M"K_P[@?^WF*DI__0[_ZI_P#B5Z-_X0Q?_/-:+]8.LT]"Z-E=5N8;&8S`16#&
MY[BVJFO=[MGJ6O8S?^8LKZL?6/ZO4?5KI--W5,.JVO"QF65OR*FN:YM5;7,>
MQS]S7-5^_P"L/U3R*7T9'4^GW4V`MLJLOI<US3RU['/VN:DIS3]<KL'ZOYG4
M^M8K,;+Q=[J,-EA#KZP^O&IR&U9%=67CTOR[V8SW7XWZ/^>V?I:ZU:Z+]9V9
M8S&=4?B8=N%=;0XUY&YEAQV5WYMU?VBO%?Z.+Z[67?Z)5LJSZA7X+\*G/Z;A
M,?4<<68UF*Q[:G/]>VAF\65>A=;[KJ75^E:@8^/_`(O:.ECI@ZCA.I+G.ML.
M30VQ_J/9=DL?92:ME.4ZFIF111Z--E-?H[/224W/K%U3+;U;HO3,7.'3\?J7
MVA]N6P5N>12QCZJ:'9++L=OK>MOW>E_@_P!&L6SZP=7QKKLAO6&Y@Q<["PZ<
M+TZ`W,KOIQ/5LH=4P9++[GY5N;4^JZRC]%_,^BNAS.K_`%)SZ1CYV;TS*H:0
MYM5UM%C`X#:UP98YS=VUR'5G_4&G*;FU9'2:\MC0QN0Q^,VP-#?1:QMK3ZFU
MM+?2_P"*_1I*<0_6#.Q<KJF+G=7OJHQ\6C+Q\DU8MMMC/6?1?=@?9*WX==6:
M[T<?%Q\[ULS]+ZO^D65G?6GZY=/.,W,S&UWT=.IR\P5LQW4AYS7XM[LW>&Y+
M_P!4_074=,?ZGVW^975MM_Q<-ILH:_HK:;BUUM0.*&/<R?3=8SZ+W5[W[-R<
M7_XNFFAS;.C`XO\`1B'8LU^XW?H/]%^F>ZW]'_A/>DIGUSZU6=*ZY@=(;CUW
M.ZF&BFPVAA8_U:Z7_::G,]E#ZK?U:QC_`%,C*K^R>C_A$&_J>=D?6K*Z>>HC
MI6+TZK%MKJ<VH_:_7LBU[GY(]3[.S;]A_5O3?]IO_GOYNI6[^K_4G)>Y^1F]
M,N>]K6/=9;0XEM;O7J8XO<=S*KOTU;?S+?TB;)ZM]2,N^G)RLSI=]^,0['MM
MMQWOK((>'4V/<Y]3M[=WL24\O]7OK)U_//1V7=5-C^MT9CLAHJHW89QW6^AF
M5^G2&^B_T_0V9OJ?I/\`P.%_7_K:/J^>K49E]N%8<_(Q\D5XC;Q10VNKI9R:
MLBK&K^SWW-OR+_0QK;]C\:BK^=8NGQ\WZ@8HN&-D=(H&2TLR!6_&9ZC3.YEV
MPCU6^[\]2NZA]0KVX[+\GI-K,,`8C7OQW"D#;`QPX_H?YNO^;_<24X6%]9^M
M?\Y,>K-N?7AWY8Q+<<MI]-C[,.G+JQZV,;^U?M#,VRQMMUWZI75]-_J*?6?K
M!UK#ZMU2S'S@X8&;@XV+TAS*8R&Y5='K45V;/MOVC?>_(JL9;9L]%_Z'T_YO
M;9U+ZBLS7=09E=*;G/G=E"S'%QD;3NOW>K]'^4D>I?40YW[1.5TK[>><OU,?
MUOH^C_/[O5_FOT7T_P";24\PWZ\=3MNZX:\IIILP\O)Z*[TMC:SA.LK_`$-E
M]369_P!JQO3ZA_.9'I?S?L1']7^L;\/,<.J7XMN%U'%Q!7=3B?:=F2<6NTY=
M==-N)Z?Z9]W3K\1_Z:O^>];_``71V=3^HME55-F7TI]6.QU5%;K,<M8Q[/0L
MJJ87;:Z[*/T+V,_P7Z-.[JWU(<^RQV9TLON-;K7&W')>:=<9UCMWO^S_`.`W
M?S/^#24[-%=E=%==ECK[&-#7W.#0YY`AUCFU-96US_\`@V;%0^L']`J_\.X'
M_MYBIO\`G1]6?_+?!_\`8FK_`-*+/ZY]8_J];A5MJZIAO<,O">0W(J)#69>-
M98_1_P!%E;7/>DI__]DX0DE-!"$``````%4````!`0````\`00!D`&\`8@!E
M`"``4`!H`&\`=`!O`',`:`!O`'`````3`$$`9`!O`&(`90`@`%``:`!O`'0`
M;P!S`&@`;P!P`"``0P!3`#8````!`#A"24T$(@`````!?DU-`"H````(``P!
M```#`````0'T```!`0`#`````0(Q```!`@`#`````P```)X!!@`#`````0`"
M```!$@`#`````0`!```!%0`#`````0`#```!&@`%`````0```*0!&P`%````
M`0```*P!*``#`````0`"```!,0`"````'@```+0!,@`"````%````-*':0`$
M`````0```.@```$@``@`"``(`#/FD```)Q``,^:0```G$$%D;V)E(%!H;W1O
M<VAO<"!#4S8@*%=I;F1O=W,I`#(P,34Z,#,Z,#,@,38Z,3DZ,#D`````!)``
M``<````$,#(R,:`!``,````!__\``*`"``0````!```!]*`#``0````!```"
M,0`````````&`0,``P````$`!@```1H`!0````$```%N`1L`!0````$```%V
M`2@``P````$``@```@$`!`````$```%^`@(`!`````$``````````````$@`
M```!````2`````$X0DE-`_T```````@``````````/_A`8!-30`J````"``,
M`0```P````$!]````0$``P````$",0```0(``P````,```">`08``P````$`
M`@```1(``P````$``````14``P````$``P```1H`!0````$```"D`1L`!0``
M``$```"L`2@``P````$``@```3$``@```!X```"T`3(``@```!0```#2AVD`
M!`````$```#H```!(``(``@`"````\`````!```#P`````%!9&]B92!0:&]T
M;W-H;W`@0U,V("A7:6YD;W=S*0`R,#$U.C`S.C`S(#$V.C$Y.C`Y``````20
M```'````!#`R,C&@`0`#`````?__``"@`@`$`````0```?2@`P`$`````0``
M`C$`````````!@$#``,````!``8```$:``4````!```!;@$;``4````!```!
M=@$H``,````!``(```(!``0````!```!?@("``0````!``````````````/`
M`````0```\`````!_^%!G6AT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\`
M/#]X<&%C:V5T(&)E9VEN/2+ON[\B(&ED/2)7-4TP37!#96AI2'IR95-Z3E1C
M>FMC.60B/SX\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X
M.GAM<'1K/2)!9&]B92!835`@0V]R92`U+C,M8S`Q,2`V-BXQ-#4V-C$L(#(P
M,3(O,#(O,#8M,30Z-38Z,C<@("`@("`@("(^"B`@(#QR9&8Z4D1&('AM;&YS
M.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X
M+6YS(R(^"B`@("`@(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B`@
M("`@("`@("`@('AM;&YS.GAM<$U-/2)H='1P.B\O;G,N861O8F4N8V]M+WAA
M<"\Q+C`O;6TO(@H@("`@("`@("`@("!X;6QN<SIS=$5V=#TB:'1T<#HO+VYS
M+F%D;V)E+F-O;2]X87`O,2XP+W-4>7!E+U)E<V]U<F-E179E;G0C(@H@("`@
M("`@("`@("!X;6QN<SIS=%)E9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O
M,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(^"B`@("`@("`@(#QX;7!-33I$;V-U
M;65N=$E$/GAM<"YD:60Z13)%145&031%04,Q130Q,3A#0T9&,4,V0D,Q0T0V
M-S4\+WAM<$U-.D1O8W5M96YT240^"B`@("`@("`@(#QX;7!-33I);G-T86YC
M94E$/GAM<"YI:60Z131%145&031%04,Q130Q,3A#0T9&,4,V0D,Q0T0V-S4\
M+WAM<$U-.DEN<W1A;F-E240^"B`@("`@("`@(#QX;7!-33I/<FEG:6YA;$1O
M8W5M96YT240^,T1#,40T1#1%13DQ.3`U1C,Q-$%#,D(Y,D0W-4(Y144\+WAM
M<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#X*("`@("`@("`@/'AM<$U-.DAI<W1O
M<GD^"B`@("`@("`@("`@(#QR9&8Z4V5Q/@H@("`@("`@("`@("`@("`\<F1F
M.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*("`@("`@("`@("`@("`@
M("`@/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@("`@("`@
M("`@("`@("`@("`\<W1%=G0Z:6YS=&%N8V5)1#YX;7`N:6ED.D4Q145%1D$T
M14%#,44T,3$X0T-&1C%#-D)#,4-$-C<U/"]S=$5V=#II;G-T86YC94E$/@H@
M("`@("`@("`@("`@("`@("`\<W1%=G0Z=VAE;CXR,#$U+3`S+3`S5#$V.C$X
M.C4Y+3`U.C`P/"]S=$5V=#IW:&5N/@H@("`@("`@("`@("`@("`@("`\<W1%
M=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W`@0U,V("A7:6YD;W=S
M*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*("`@("`@("`@("`@("`@("`@/'-T
M179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*("`@("`@("`@("`@("`@
M/"]R9&8Z;&D^"B`@("`@("`@("`@("`@(#QR9&8Z;&D@<F1F.G!A<G-E5'EP
M93TB4F5S;W5R8V4B/@H@("`@("`@("`@("`@("`@("`\<W1%=G0Z86-T:6]N
M/F-O;G9E<G1E9#PO<W1%=G0Z86-T:6]N/@H@("`@("`@("`@("`@("`@("`\
M<W1%=G0Z<&%R86UE=&5R<SYF<F]M(&EM86=E+VIP96<@=&\@87!P;&EC871I
M;VXO=FYD+F%D;V)E+G!H;W1O<VAO<#PO<W1%=G0Z<&%R86UE=&5R<SX*("`@
M("`@("`@("`@("`@/"]R9&8Z;&D^"B`@("`@("`@("`@("`@(#QR9&8Z;&D@
M<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@("`@("`@("`@("`@("`@("`\
M<W1%=G0Z86-T:6]N/F1E<FEV960\+W-T179T.F%C=&EO;CX*("`@("`@("`@
M("`@("`@("`@/'-T179T.G!A<F%M971E<G,^8V]N=F5R=&5D(&9R;VT@:6UA
M9V4O:G!E9R!T;R!A<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S:&]P/"]S
M=$5V=#IP87)A;65T97)S/@H@("`@("`@("`@("`@("`\+W)D9CIL:3X*("`@
M("`@("`@("`@("`@/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^
M"B`@("`@("`@("`@("`@("`@(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T
M.F%C=&EO;CX*("`@("`@("`@("`@("`@("`@/'-T179T.FEN<W1A;F-E240^
M>&UP+FEI9#I%,D5%149!-$5!0S%%-#$Q.$-#1D8Q0S9"0S%#1#8W-3PO<W1%
M=G0Z:6YS=&%N8V5)1#X*("`@("`@("`@("`@("`@("`@/'-T179T.G=H96X^
M,C`Q-2TP,RTP,U0Q-CHQ.#HU.2TP-3HP,#PO<W1%=G0Z=VAE;CX*("`@("`@
M("`@("`@("`@("`@/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@4&AO=&]S
M:&]P($-3-B`H5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B`@("`@
M("`@("`@("`@("`@(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^
M"B`@("`@("`@("`@("`@(#PO<F1F.FQI/@H@("`@("`@("`@("`@("`\<F1F
M.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*("`@("`@("`@("`@("`@
M("`@/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@("`@("`@
M("`@("`@("`@("`\<W1%=G0Z:6YS=&%N8V5)1#YX;7`N:6ED.D4S145%1D$T
M14%#,44T,3$X0T-&1C%#-D)#,4-$-C<U/"]S=$5V=#II;G-T86YC94E$/@H@
M("`@("`@("`@("`@("`@("`\<W1%=G0Z=VAE;CXR,#$U+3`S+3`S5#$V.C$Y
M.C`Y+3`U.C`P/"]S=$5V=#IW:&5N/@H@("`@("`@("`@("`@("`@("`\<W1%
M=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W`@0U,V("A7:6YD;W=S
M*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*("`@("`@("`@("`@("`@("`@/'-T
M179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*("`@("`@("`@("`@("`@
M/"]R9&8Z;&D^"B`@("`@("`@("`@("`@(#QR9&8Z;&D@<F1F.G!A<G-E5'EP
M93TB4F5S;W5R8V4B/@H@("`@("`@("`@("`@("`@("`\<W1%=G0Z86-T:6]N
M/F-O;G9E<G1E9#PO<W1%=G0Z86-T:6]N/@H@("`@("`@("`@("`@("`@("`\
M<W1%=G0Z<&%R86UE=&5R<SYF<F]M(&%P<&QI8V%T:6]N+W9N9"YA9&]B92YP
M:&]T;W-H;W`@=&\@:6UA9V4O97!S9CPO<W1%=G0Z<&%R86UE=&5R<SX*("`@
M("`@("`@("`@("`@/"]R9&8Z;&D^"B`@("`@("`@("`@("`@(#QR9&8Z;&D@
M<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@("`@("`@("`@("`@("`@("`\
M<W1%=G0Z86-T:6]N/F1E<FEV960\+W-T179T.F%C=&EO;CX*("`@("`@("`@
M("`@("`@("`@/'-T179T.G!A<F%M971E<G,^8V]N=F5R=&5D(&9R;VT@87!P
M;&EC871I;VXO=FYD+F%D;V)E+G!H;W1O<VAO<"!T;R!I;6%G92]E<'-F/"]S
M=$5V=#IP87)A;65T97)S/@H@("`@("`@("`@("`@("`\+W)D9CIL:3X*("`@
M("`@("`@("`@("`@/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^
M"B`@("`@("`@("`@("`@("`@(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T
M.F%C=&EO;CX*("`@("`@("`@("`@("`@("`@/'-T179T.FEN<W1A;F-E240^
M>&UP+FEI9#I%-$5%149!-$5!0S%%-#$Q.$-#1D8Q0S9"0S%#1#8W-3PO<W1%
M=G0Z:6YS=&%N8V5)1#X*("`@("`@("`@("`@("`@("`@/'-T179T.G=H96X^
M,C`Q-2TP,RTP,U0Q-CHQ.3HP.2TP-3HP,#PO<W1%=G0Z=VAE;CX*("`@("`@
M("`@("`@("`@("`@/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@4&AO=&]S
M:&]P($-3-B`H5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B`@("`@
M("`@("`@("`@("`@(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^
M"B`@("`@("`@("`@("`@(#PO<F1F.FQI/@H@("`@("`@("`@("`\+W)D9CI3
M97$^"B`@("`@("`@(#PO>&UP34TZ2&ES=&]R>3X*("`@("`@("`@/'AM<$U-
M.D1E<FEV961&<F]M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*("`@("`@
M("`@("`@/'-T4F5F.FEN<W1A;F-E240^>&UP+FEI9#I%,T5%149!-$5!0S%%
M-#$Q.$-#1D8Q0S9"0S%#1#8W-3PO<W12968Z:6YS=&%N8V5)1#X*("`@("`@
M("`@("`@/'-T4F5F.F1O8W5M96YT240^>&UP+F1I9#I%,D5%149!-$5!0S%%
M-#$Q.$-#1D8Q0S9"0S%#1#8W-3PO<W12968Z9&]C=6UE;G1)1#X*("`@("`@
M("`@("`@/'-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#XS1$,Q1#1$-$5%.3$Y
M,#5&,S$T04,R0CDR1#<U0CE%13PO<W12968Z;W)I9VEN86Q$;V-U;65N=$E$
M/@H@("`@("`@("`\+WAM<$U-.D1E<FEV961&<F]M/@H@("`@("`\+W)D9CI$
M97-C<FEP=&EO;CX*("`@("`@/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70]
M(B(*("`@("`@("`@("`@>&UL;G,Z9&,](FAT='`Z+R]P=7)L+F]R9R]D8R]E
M;&5M96YT<R\Q+C$O(CX*("`@("`@("`@/&1C.F9O<FUA=#YI;6%G92]E<'-F
M/"]D8SIF;W)M870^"B`@("`@(#PO<F1F.D1E<V-R:7!T:6]N/@H@("`@("`\
M<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@("`@("`@("`@("!X;6QN
M<SIP:&]T;W-H;W`](FAT='`Z+R]N<RYA9&]B92YC;VTO<&AO=&]S:&]P+S$N
M,"\B/@H@("`@("`@("`\<&AO=&]S:&]P.D-O;&]R36]D93XT/"]P:&]T;W-H
M;W`Z0V]L;W)-;V1E/@H@("`@("`@("`\<&AO=&]S:&]P.DE#0U!R;V9I;&4^
M52Y3+B!796(@0V]A=&5D("A35T]0*2!V,CPO<&AO=&]S:&]P.DE#0U!R;V9I
M;&4^"B`@("`@(#PO<F1F.D1E<V-R:7!T:6]N/@H@("`@("`\<F1F.D1E<V-R
M:7!T:6]N(')D9CIA8F]U=#TB(@H@("`@("`@("`@("!X;6QN<SIX;7`](FAT
M='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\B/@H@("`@("`@("`\>&UP.D-R
M96%T941A=&4^,C`Q-2TP,RTP,U0Q-CHQ-3HT-"TP-3HP,#PO>&UP.D-R96%T
M941A=&4^"B`@("`@("`@(#QX;7`Z36]D:69Y1&%T93XR,#$U+3`S+3`S5#$V
M.C$Y.C`Y+3`U.C`P/"]X;7`Z36]D:69Y1&%T93X*("`@("`@("`@/'AM<#I-
M971A9&%T841A=&4^,C`Q-2TP,RTP,U0Q-CHQ.3HP.2TP-3HP,#PO>&UP.DUE
M=&%D871A1&%T93X*("`@("`@/"]R9&8Z1&5S8W)I<'1I;VX^"B`@(#PO<F1F
M.E)$1CX*/"]X.GAM<&UE=&$^"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@"CP_>'!A8VME="!E;F0](G<B/S[_VP!#``$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0'_VP!#`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_P``1"`">`(T#`1$``A$!
M`Q$!_\0`'@```@(#`0$!`0````````````@'"00&"@4!`@/_Q`!)$``!!`(!
M`@,"!PX%`@0'```%`P0&!P$""``1"1(3%!4*%ADA,3E7&!HB04A167B6F+?'
MUM<7(S=AARAG,D-'=W&!D9>QX?#_Q``>`0$``04``P$`````````````!P$$
M!08(`@,)"O_$`#\1``("`0,#`08!"`D%``,```$"`P0%``81!Q(A$P@4(C%!
M\%$C,E)A<8&1P146)$*AL='A\0DS0V)R8V2"_]H`#`,!``(1`Q$`/P#I6X$>
M&MX=TNX+<+97*N"7#V2RB3<3>.4AD<C/<;:>+G#YXS3T.)%S9DJ_AZ[XF6*D
M'+E\1(/%UG;UXX6<N%5%E=]]FG`_#[/STV7R6OAG_H]^$_[KM)_T5TTT?):^
M&?\`H]^$_P"Z[2?]%=--'R6OAG_H]N$_[KM)_P!%=--'R6OAG_H]^$_[KM)_
MT5TTXT?):^&?^CVX3_NNTG_17331\EKX9_Z/?A/^Z[2?]%=--'R6OAG_`*/?
MA/\`NNTI_1733@?AH^2U\,_]'MPG_==I/^BNFFCY+7PS_P!'OPG_`'7:4_HK
M_?/33@?A]_8&CY+7PS_T>W"?]UVD_P"BNFFCY+7PS_T>W"?]UVD_Z*Z::/DM
M?#/_`$>W"?\`==I/^BNFFCY+7PS_`-'MPG_==I/^BNFFCY+7PS_T>W"?]UVD
M_P"BNFFCY+7PS_T>W"?]UVD_Z*Z::/DM?#/_`$>W"?\`==I/^BNFFN?[QT>"
MG">JON6_\+^(?&:NO?W^-OOSXCT76<5]\>Z_\(O=GO3W%&&7M_N_WB0]B]J]
M7V7VYWZ'D]H6\]">/^1_,C371/X<_P!7OP1_4UXP?P2@_5=-.5TTT=--'331
MTTT=--+)<G,GC-Q[MFC*/NBVXW75E\DR)D-28"1^W-$IV="%(H%7`#C&&FX5
ML>?%9K'F((,1(,R,@6<N_<K9]H+*;,VFE'Y!\I^5AGG<#X(\16W'N*28!Q60
MY;V99/(^-V--PI2,&K9)5+%:Y@,5K><5T0:FG16.G24HFY8Z8'Q=@Y`:H1$X
MZ?>ANTU"4N\:."I<EKHXQ12H)T0_PMDEPU"2N$:Z;%V4?MZJ*)(7.6(2*"(B
M'#H+4NBC/:"M+$*G<;N9_P"QC'$31CQ-G)%FJ<_P_'[_`)<ZP_":YF\D>3\C
M:![MFPV2AX1X9_AHW'.WV8M%X\_(<C.4<)M>R[,D;YU'Q8ADP:+Q4-"]$XZP
M:LP`O.JKH>Q:9<N-EFJ_J^_K_IJX2H;7A=YUK$;<KEZ]*P&>B_?\--O11$+\
M88VNY<)!Y,/9%F[1]N!DK%%$]&B*K=),S'B(LPUQEH^0VV::DCIIHZ::.FFC
MIIHZ::.FFN;?X0C^2+_SY_);IIJWWPYOJ]N"/ZFG&#^",'Z::<OIIHZ::.FF
MHFO2]*FXTU+-[SO*<!*XJJNA.IF7S&0N<-1@IHL\:C&*>VW;91=Z4+/V`@2P
M;Z*.R15^R'M$E7+E)/9IKG4Y>^,';J]U3*AHQ*:YX55!,N-LI?1.[^1PN:5G
M/HV4O?B*8G?&3D8O,9B/&U)&8DQY#J.J.6J<:]F%SN)Q`9G*5Q+.(P^3MQS5
M.?K]-:!P_P##KYC6[7D7L65,)YQAY(TY==,<E:8M+D2;`\@X%'+)$0PI7-Y5
M94<2#<CKFN>0<<+J@Y<@6L>;S#D_#EK3L(@PG,2J:!M_;-=&GSX_CX/C_?5Z
MO(OP^J;Y/S&K[<L&57!7U[5?"R]?-[KXW6U/>/4U.P*4J#B,TKXT1A,@PZ>U
M[(#XMI($8^0>D'L=)H)O`)QB]W>/';5=+T>XR^&Y4\T/G!,*G#T_+@2L7GH&
M"WK?J\&DZ*M6)4L\D,[@"=PCJIE=A.ZV;H14C8Q@`6LYSE%(H_D63B.A/7:\
M;LS.9*,S+`E.(KRCWF>`R\_+LB6.2;@CR':-4((*L>=:[?W3B*#^DTK69.>'
M2H%E$?\`].72/GZ%5=F!^:C4L5EQ'XU;45R+#<41SJJ2?(2CHW090VL=E1Y[
M$6-348M0E,HZL#LA,KCM*^A.1GH8'/4W!W?10V3>OS9!X26P^5Q-W#6S3NHJ
MR=JR(\9+12QM\GB<JI90P*GE5*LI!`XUD\=DJN4K^\U'+)W%&5AVR1NOS5U!
M/:2"&'D\J002-*AGA58_`F:W'SGJ-!?DA,6-/M(PUH<8RF0:2YB@&KZOBOQ&
MA+P,\ES:8"@IJE(9M6<.1@T09P\+*K%*^62RMUID[C-7_P#CJ=_#$Y'W+9=,
MQQOR\L5)>\YV0>%8;%975K^H),Y"#6YT.=$"G[F*P2#VP\2D5=V!.6B55A"G
MQ&J4S7^91(9LB0%VA-VJ#[^_E_#Q^[R7+J_E=0-S6?:5.5O83*16'3I1\)FH
M/46='HY7#/6X:2.(J:*#&0*>#8?*5]H1-B4))'V4+G;5Y#)2N)DC?8=EJNF(
MZ::.FFCIIHZ::YN/A"&._P!R+]/_`*^?1CO]BW^^.G('S/&FK??#F^KWX(_J
M:\8/X)0?IH/O['C3E=--'335<'B9<C>5-"4:NTX8\=+'OF]YFPDBHTO$8D+D
M\<IZ'Q1FR(3:Q#`^02"*A)E.V(9[MI3M,X/-"]MSC5$2WUV""Y"JBTU1]>LT
MY1\Y+RI:Q^&MEV9RUXU\D8N_BDOK:8P^4"^"*E;J+U_55Y<4.6$/!N7N./UP
MQL$XN*[)#<LV`F[64E[B!5)4L+6%#BS%RU3_`"_S_P!OOZ>;*K,\(GC2SJ*D
MG5R6A?%F.^+5)6_QZ'R$I,H^"D]U<=+6.#'#/C?=DK!Q-G+9;`@P@-'J^'.@
M1^)RHI&]Y&B?/$-9C)TB&0Q6/DRF1J4(^[FS,B.RCDI$#W32?(C\G$'?S\^.
M/KJRR-Q,?1LW)".((G958^'D;Q%'_P#W(50?_6H.Y$*WS<L9BT>K_D=/J!TB
M4JC4C'(5RGHR`Y:1%/TP,;]R#GP3*`$7NFT5;#$2&HIQNS0R9&E]T&BC7IG:
M^/VKMZ28VMJ8O-Q2T)Z/;?'=*@L@)+,LLD<P,SIRI?T_4C5B*\D"EU:"\UDL
M_E@GI9Z_C72U%:YJ'MC)A):.,Q(T?Y-6X;L[^QV`,R2D+Q/\ZN:Q+#77W/2-
M[H/7QC3W$-7<#@:>FNF-,:^[T5?37VSGOG=5YERMG;?;_,QKVTQ@\7M[$8A%
M%6I&95Y_M4RK+:8DD\^J5!4?+X8PB^!\//).0R&<R62=C8LR"-O`KQ,T==1Q
MQQZ:MPQ^O<_<W)/GCQI1&M_5T\O$KQZ1=%,V,%B:4S>H;"UM0^HE7#+?&FA7
M.WI[O=$"+)QNEZ6$<)K^75QLNFJBGNKX#(QX*+<3+$,;-::FC>JOK>JO>"3%
MQR(^Z-U[N>>1Y4`@G65R=5LD^*#/[W'`+#+Z9],H>WP'^K<.K<<<<'P205U+
MYCDN<XO0676\"4.%!0`2D6)`(TP2/*21#59-%HCH.4VPV6T]1YC?<AZR'NYE
MNY>Y=HHIJ;=8%-JTMXVZ6)L"L'LR%*]N>4P"N70LSK.OGX@@[8^'65^Q>QB1
MK++GK>W(;-^!I@(5#35XXQ*9@K=H5HFX![2QY8E3&O<W<H!TP-:^(#:MFU]#
MYZC%!<32E09F;T!R*//F9Y@BZ_#T;D&^3:Z26RB>,*I;Z9_S6RJ2VOE\^,:Z
MODNE^"QF0N4#;LVS5F>`SU[4;UW9?!:-O=E8\'P0WR8%3SQK8:F_\Q<JU[(K
MUX/6C63TY:\BRJ&\]KJ9V`Y'D<#R""/GI^X9.J/M<J(E*246;V@K%'L52?.F
MK8;888,:4:O#D7!2C*+0ZF-<$&31\J@`):H+NF+$EG35VU1W1B/+;:RV)>8S
M599*D;L$N1+WPM&#\$CE"QA[AQR)0O#<CSX)D?&Y[&Y)8A%8C2RZCNJR-V2J
M_'Q(O=P)>#SP8RW(X/CY:J%,<0A_@_Q4M<_$LY#"K^V9C6-$2N5\EX!"]HC3
MT&D!:.1:%V'85J5(*J::;0&LGJ1:0608F[Z42R[Y=)PR]BV2`-:[60+U_6:^
M_P#35IG$&_L7?#):..V_QWN*RJNG<H@T[D/&TL[WA:_NL^7&@B;J)E)1."T$
M+/413\6:C2\YG#(=)X_(Q[.5O5Q[\>)::;;IIHZ::.FFN;GX0?C.?N1NV>W^
MOGX\X^Q;JA_9S_#^>G('S/&K>_#F^KVX(]_I^XTXP?P1@_5=-.7TTT=--'33
M2!<@+(XJ^'K&[&N),#6-0S'D580TE+3[(&U"K619BXEL!:RR9[AVNKHR\8B&
M"67I!?7S;XT<OR#E'18N4TW78VRLIO7*M2Q]6>Q#4A:W>,`7O$$?]Q&?A1)*
M?A7GD_H*\A2-]7W7N:EMC'K9LS1136)!7J"7GL,K?WV5?)2,?$W''T[BJ!F5
M6I[>4^M,:R82,PU<AT5]235J,9MF;-=;9'.B#G?=#&=G>-$5-_9\JJJ:::J[
M[IX[[>;J5L7MK%82626G7=+#(8GDFD>215#<L@#^$Y91W]J@GM`/RXU&^1SV
M1RL:16YD,*/ZBI&BQH6(X#'M\MP">WN)XY)'STK5NM[4=0EZA33Z/#IONZ8^
MR/)*GE5BDPPMW?\`H8RU?(>W;IXUU1V=M%VV$]E<9UU5RDII=Y9<HU*1</)7
MCO%H^Q[()C"<\R=OP.O?QP!WHR\$_(\$6V-..6TIR:3/5X;N6`\.6XX4L0RG
ML'U"L&^7T!&MZ":E]0PC$@V8;G\"V&#>XO574=N8PU2]Y[#]7'^?JQV>>MEK
MA;_.PAE/U.V^,]7L/J^C%[P4,_I1^L8P1&9>P>H8PWD(7[NT'SV\<^=6DWI>
MK)Z`<0^H_I>H07$?<>SOXX'?V\=W`XYYUI4UJJ&39G*\.A3$3(9=$WL+(S@.
M-%MIGH`?:=MQZ,AW9JO]F.F^=5,,%U56.VV,>9#/T]>=[U[^+L8>2Y<2A.LH
M]&*=Q'')*AC::.%BT*S=K$%S&25)4\@G5*C1T[\&12M7>U"R$/)$I9EC;O6-
MI`!(8^X`]H8#D`_,#B+R4EJGA52`'68R,]I"HZ]:Q]`L\:.SY=R3.OGS_73V
M06USE)OC?9XHFB@W30:,F^$M<J+8URM<;2VI;M+7P&&#VI*]>:4&S/&C&-7,
MDC%W[$`[Y`L<:@!057Z%M>O<&>A62?+9'M@6:6-"((W8!BH1`%7N8_"A+,W)
M)Y/CPNI.L*UXE6M?KV6?4(.(PBF(6U6$L=GKQ=(XY:-Q^Z+951MC&BFSQ'??
M9=5#">F<_P#F>5/;&9:_#A:T]J\)!'6D6*58D]1P[2B+@#D#PY\DL!P/!)X!
MO,=3EREB*M5,9>96=&D;L0JJ&3DG@GRH\`*3^KY\;7$I2(F<<!2^-NE7(8\/
M:E13O=NNR64;.-<*([[(.=$G""FO;.,Z[:8SC;\+3.VOEVS[:MJ&]5AM0,7K
MV8EDC+*R]R..1RC@$?,\@C\?H?/KL02U)Y:\P"30N4<*P;AE/T920?IP0?X?
M+5C/$RU#9<T:B,SERQ%LJ*;;QYH??IKK;NDW/HN&;%P]VR[<[[ME==L,\+*X
MPFCMNDCKC53/4:;\P5:&M7OX_'K$XF=;CU8BJ"-D[EDE2,>FH#J1ZI5?+`,Q
MY`UOFSLO8EGGIW;K2+Z2&LMB0%BZMPR1,_QL>TCX`QX"DA?!.J8^1/&MCP:Y
M#5Y6_&^QMJYBIV.P8[7%258R(3B^I+FKRDE9UP`&T7%#BIJ_S4%?'38:HI-<
MZ56\0*<8X=VKR84Y(VC@@8$15J1/K_'Q]CGZ_P"6NF:MB<Y,U_#"]F1<;"+!
M)QH._F<.$2-.7CHM(W;%%<J`;2A$4$;G\"76ZC)0JT%,F;U9%19FE[+LCOLU
M76[=--'337-Q\(0QG/W(O;_OY_);ISQ_P3_EIJWWPY_J]^"/ZFO&#^"4'Z:#
M[^SYTTTOE@6"QDU+Y%N13!1YBH2++"09R2OT&*.=?7<(A(V.+&WVK?3;*SC5
M@.=*(MDUG*FFJ"*JFGHLV(JD$MF;O$4*%Y#'%+.X0?,B*!))7X'D]B,0H+'P
M"1EL#@\AN3,8_`XE:CY+*V4J44O9+&XBK)9D!]**3(Y>W1QU8RL/3B-JW"DD
MK)"C&21%;2JMOBE[M';$ZDM&#6$V2QGVM*+R,83(C%-<YUW;F0Z3CWL%>);8
MSJLR+,F3M';\%5'3/S=6N/R^+RJ>IC<A4NJ/SA7GCD=#]1+&#ZD3#Y%9$5@?
M!`UL6].FG4'IU;%/?.S-R;6F<_D'S.)N4ZEQ2.5EQ]]XO<<C7<>8[%&S8@D'
ME)&&H@Y*\E)=Q]D-9,!=+E;3!V2I*0R+\!,(]'2PR8``^9&-CFC"5ZC09%:2
M`&4B(#]UI0)4U^+)%#5%RNLT3WC7J_UCVUT0P-7>&]ZV379WO]7'Y?,XJI+D
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M+^HDK2<E>QD[S(6X9O@[B0&8^`2.>5Q.2]\EQIH6HKU?N6>G/"U>>N8^`RS1
M3B-H2I(4K(%()"\<GC2<14A?]RA`]K/KLF=+M):T1DD/JR"16I2`J/Q$JEJ^
MC#*P"%B5S.)'()JX%+M',PR`.14&.(.%P0%IG`SXRE\2MB]:"V/>YJBR`/%7
MABJLB1-YC$S3P32/,4(,O8\:*Q*(/A]1LV,?1KCT&KK9=/ADGDDG5C(/#^D(
MI8T6,$$1]ZR,0.YSY[1NK*:<M8JMO@@A15TB]<?Y6R&LTH:4((Z9QGLKWWO"
M-R,DIKC.,;)IP$<JMG3'E8(^;;7W)=R49`=:=M>?F/5I.!SX\<W(W;CY\>@O
M/Z(\ZMY,51D\QR6:[?\`L([*<_M`KNH!_'U3^W4777S.L2*0QWLWX_7Q7I]!
M`DY>FM8&*N`1IH.9^LWU#/*>,V5HBB4<9QC0A,`\<T09-G3=^E'W+UL7&[)M
M_(X22X!GUMT80T:J)(I9H).]N'D>?&BV8H84!;F7T6)97[)!&\$N#RV)RT4!
M.*->X_#L3'+''*H5>518;GH=[N?'">J.`5Y4NLB+=4?B4\;+`C[T+RAG==/1
M+O9T49PR:"`TJF;$V#)-,-Q^E=QX87D9=---QN[:OMHK[<P<(Y065QZ^B2.V
MYB3"T+-9MGYR&[D9E$<=?;5VQD+UJ"2-A+(M2BT]Z-D8".>()VCN`=58'NUV
MC7REB&89_%RU:D9+22YJM%4JPRHP[%:S:$51U8%GB<MR>T]K$'A?3M#QC*-T
M;O8]65(V%;C15'*.KZ8-`U95Z01U\OI(*(R74W/]$^^FNWHO*L22UUUT[;9W
M[ZZ6]+I]O+-`J-O&K6E_.GS]B"C`X;@D/5`NY3D\\]LF-7D^">>>/9/NC;V,
M(=LP)9HSR(\3'+:F7CD<K/S6I?J!2Z3P>>./GL/$SQ4AES6='J;M:JAE1%IF
MLH)KD_&9FO,(>3.(-%'32'%_>$4B#Z-EB+)LYTC;I-J2#&7K7(A1P(+O@8TM
MZ]Q[+SVTHJMC))1GH695JI<QLT\D5:TRL8:]N*>M7>%9PC+6G3U(7E40.8)I
M*\<WEB<_BL^UA*$EI+<*-8>M>BB22>`,!)/7DAGG25HNY6GB;LE5"94]:-)G
MBN#TVQHIIOMG?&NN^F<YTSVWU[;8_"TSWQVVQCZ,^;7'?_X]:P?(/U)!^?R_
M?\_'XZRH\$?0`CY?/C]7D:NPKRU8/9K-1>)%L.5VB*.[\6Z2W:%1^JF<ZZ>T
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MDLX3%6JE>24]]JM:4M&U<_(REN8=.01`-,KME=EU.'FD/E`"PM0VEI$X@;B4
M@9&XZ[D$(DC[-WH;N<L=Q)I_#+4MAJ4$D#"3B$"&#E1'7D;K+TO]I.WLW=>S
M<3_1/M!;#S^$OT\AMS,11;>ZCU*\D+AK>)SM2&3#9"]4#*]&.;$T6$B*9KDD
MC<GI?875SV;-P9H9Z/:&W.FVZLABLKMW)X&YETV%B=P5=R8ZSB[]"ANG'U3T
MU:-C96Y0K;CV5L22C=JTIHMSV[$"S!3;:M:I&UERN1&N04J:U[9P6+F8DI&+
M/FV\:9&FZ>\2GD.4@[5\]"CG`IRPC\B+M2\5;.VBDH?>]-$,(*IZ0C_T^.A?
M0_J#L3>'3_VA>C]#$]4>FFXEAAR>7Q%G![KGP>5>66E/)>J)!8MQTKGKU:]L
MFPJ10*T5EH5C[=.ZS[IZO=(=@]-\YMC:.UJK8;,YS:>YDW%T[VED;=V6R/ZU
M[&W'!NJ7&+FK469QDVXL91L8O<3T):^UJ\M1F,HEDTF=<%*]GL>+1_2?SX4`
MD22OO0**2@36,E=7:*B6R[\('A8AH1<;Z+J;ZDG.ZI+1139=%ZFMONKM]:\!
M[,&T]H5WK;-WIU+PE*3@C'6=WV]Q8@%3W1%<?GDOQ!8OE$J.JHGP(%77/]OV
M^]R[G2.OU0Z%]"^I<<4/NT=W<.%WBVY*L/':T>-W)-O.[D<0O;\*QXTUH44*
MHB*HBJIO'[F738%$Q3-R7S706S*RDQ6M'B1E5C$HH0<0QXI'-%H?/'CM*'S5
MD0]B35209/FTF`N\NXU*A#60B2&G4LX''Y_%8L'<>1GRD8EDAJ9>7"#$U9HJ
MS&LP2[`QQM\B:-@7@6O)$P:":$2HQUSKU"W+T^W7FX+G3W8HZ?1M55\GMJ/>
M=W=R);G_`"\<M./+U8LWBX/=W4>[7KF6]7Q/#<6)UC%A8XD.,,6Q,2_9%!KQ
M/"S,@.=(/6+M';OC55L[;**H+IYSC.,*)*;:Y[9[9^;K/#@J&4AE8>&4AE/[
M".1^\:T`@@\$$$?,$$$?QUF]5Y_7_MQJFHMLBD*;N)JFSM6K*_L1%#7.&NTQ
MB0,^Z8;?B5&/2+)=Z,<)Y_"2=#W#9PCOVW25TWQC;'K:.-W21D5I(R&CD('J
M1D?(QR?GQL/HR,I_`C7F'<*R!CV,.'3DE'!^8=/S6!^H8$'233GPK>-DC44=
MPDG9]2/=\;9].)31:1`]U,_^#50!9C.=-&;/3/;&&<>4`:ZZ8QHBHCC&,XVO
M&[WWAB2GN.Y,KZ:`#W>_.N7KE1\D[<JER2)/H!7E@(7X58#CC7[VU]MY$-[U
MA*`=O_+4C./E#?I\T6KH[<^>9HY03Y(.D*L'PZ;=JRU:!;-;,1DU>3#D!4(!
MY9$49OJSGE7N-)X$,LG[GR2(RALL53$+`H[*@!@6^0G!.-"TXYK@HF]0SF>Z
MH9?<.V<AMK-TZ9GRLN-AIY?$K+3-2>+*4[)>S5LV+05Q%!(:UJO,.+8@A-0)
M-ZL>&Q^Q,=A<O5SF+LV#%0BO26L;?*6!8BDHV8`L,\,,'*^I*@FAEA/]F,DG
MO'='V-T&4_)Y=&9W+:`LF1.I@;C`(7.JVGQ1NR:FY]5I9\Y"*I2?48S&B74]
MKV2,M@<M?!QS)B3"'H!(UFS8M(R;)KI=626.:6E8<RM&BS5YV`#SUF)0B3M"
MJ9H)!V2LBA61X)"`\C@92RD;Q1W($$:R.T4\*DE(;"@-^3[BS"&9#W1AB2K)
M,@)5%)G#C:GR;B?-',HVGD<,T-($(^%CM>,@WLTK8/WFP]@905((M6VJ[#;T
MR1=P[*%BJ*RJ[#1L,%ZCL.$LCNY=K7MBRU&H6(,[6%FQ/DI)NZJRQB22!UC+
ML5DY]*!4BBB;M$G,DIE*M;;;?-5-U0SI9CEQL[0P1TTCXG!D*)*I8*`R?]R4
MM([CGLX1/3##H<ZY6UT'HZ::.FFN;?X0C^2+_P`^?R6Z::M^\.;ZO?@C^IKQ
M@_@E!^FFG*Z::.FFJ_>:Y^1Z.(E&<M=F\5627,ZO-=L;:DC;?91ILV4QC'=+
MW4T7U4TTSGLMDGLIGS91U].5^F]6F4OW>\/>5EKF,C@P56"R!Q^/KR*5)_N^
MCQ_>\QSOJQ9#4ZO85J,#.'!!$LZDH5/CQZ2,"!]?5)\D#BJ6P:/I2=/<2RPH
M'%29`0CLZ7D)!+W<YT9LM/6WR6)M%F>[T<V11\^Z!19RR21UWQLEJGG?&=OM
M[-VWELM!E[6"I6,RJ^[QWD@*79HY.U17FE@*26X^50)!8]9`0.Q`>->-/JQU
M&QNR;?3J#>>;78-FY#E9-JVKAMX.KD:KR21Y''4KHGAQ%S\K,)[>,%.>Q'+)
M'8DEB=U/K/)2VG=52(_3,C`R1<E%9,E!CH$DQ)A59`@.(,Q?I/6BJC/.K0TD
MD@OKY^R.Z.Z:N-<Z;8QLV0IW:!L5)Z\U2['$P6"Q$T,B.T?=$6CD"D*>59>0
M`5((\:CZI8K63#.DL=BL\BEI8G$B.@?B3AE)!/A@?J#R#YUQ(1/1/,5!([:+
M8SH(9-W2+W"GMB;I)OHB^0):.,>OJ02=ZKI$4G6N'.KW5QHZUPOA3'77NU&Q
M\NU]OG&B-L:V$QRUE0<IZ(IQ(8F4^.Y>"DRN.Y7[UD'>"-01GQ<CSV7][[UN
M#*7&E9C\7J&Q(W>"/[IY#1LI[2O8R'M(.O4"%]:J5<'8;,#51N'"OJ/"L&F9
MBM?;5]L?-L36C14&W*9SGMG*1/#M)3.NN%$]\8[=8'/;'Z>31RV\SB,-B@YY
MFR$$HV_)W?1Y;E*>B78<<GUG<'@=P8>-9;$;JWE%)'7QF0R5XJ`(Z<D;99`O
MU5*]F*T$4@\?DE4^3VD'SJPR@>2GB9R!-!K4L>FW(\9GR8:.[)IINC&E6F.V
MV$!EPM'E'11=?;3\'#^0S63.\84U663=:XQCJ`=QX+IY4$O]7-Y9:[84DI5B
MQ2;@IMQY[(,G$N#IKY`7OGS-EP""5?C4N8?-[NF,?]-;>QM:$@=T[WSB;(_]
MY*+')V?/S[8L=$OC@=O.KA(5,^8K>,B2]O<046A)WKOJ1#4Y>%?3H\*QIMC&
M'A8/-]ZP"()[I]UMQ\6G,\>(]LH-MR*N=//&W;DU'=)CBREF`]&S7:;L!/;)
M+%+)''&Q7@F**W:[3\(>3CD[E[YC&/:EWM/`),L$PB[B/*I(B-(P!Y4/)7@[
MN.2J?(>_MR6J(:[P.G!HU49'S:)^SW5#I=4+-9SOMC3V47(K`"@(I(U<*YPC
MJI&#QIJLIVU;.%L9USGU&W`A[9C)6;Z"U#+6!/X+),B12?A^3D?S\N=7"1-(
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M#"L+ER?3]X5)`>`.UXVE/'/>@[5<!RRK8C3=_&8U?:L>B=0$Y=)XB->/]497
M+HG7@)^T),7#!N=`NGB\BE1T2UW7V3?%(["2R`MQMHS?*-GZFC;;D'VMO;*Z
M>>SICOZ(WIMW?TEK)R**%C'[<G;#9!8)(YBE?.M)_1??+V@)#8L5Y6[9>$/H
M3B/J_I%[+T>=V?A^KF>ZI[0QVT[LT]#W+;.,W%O7=6*RHB8-B\_CX:&&P.WL
MFT9::I3S.Z:5C(UP;=!+%+^TE@=.4?-B\9#)(A1("NTGD8-J1B8.8=&31H'`
M#Z2:#AR./7I;+Z(1%R_8MG359T,AM&6.=0T<H+N0"""FF=^4-@>T)[0/7FI7
MR_2WI%A=F;+R"B6GO;J'GX[DLE=P"DU/;>#,DEQ^&5VBLY#&CL(:-Y0WP]6M
MT8]G?IQBL1GNI>3W6\&9QRYG`Q9[,8['9'=&+=Y(H;>-Z;;'KY[.PU;,T,T<
M-S/]2=I8V0Q21PY265&`DN)<"K7G;W![E]R[NZV4W"F%5ZEK^9/ZJJG='/?;
M(^29K]G"'\RPGMGMAV,$UXQ<)ZZZ.(_OVVWWZ@P6R=QO7CDWWO2_N2\X5K-7
M$Q-MS!=_:`\45*I/+;:N6!95L7I)!R5:20`'6GYWVFMD;:K_`-&=!^A/3G8S
M1*4CWQNG;]7>V]@XX`M8G^M-C<57;Y8#S!<O;JLQ,6:+*+R%6QB'0Z+U]&`L
M+A0,?&HK'66@X("%(8;L!S-/;;?"+=+&<YQC911153??;=1991197?=3???,
MCUJU>G7BJU8D@KP($BAC':B*//`'[222>222222=<GY[/YG=&8R&X-PY*UE\
MUE;#6LCDKLAEM6[#!5,DKGCY(JHBJ%2.-5C15154<[OPA#./^D7OCO\`Z^?C
M[?8MU[]8C5OOAS?5[\$?U->,'\$8/TTTY7331TTTBO,2-6*:0%%&+#1[`8ZV
M5>.\#U-E7K,BIWPZ)%FF=-5,,D6NNB3=PVPX1:)Y>*O%$,+ZXZD[I]<Q%9IX
M)93%E;<BQQ^JH6.2%>"D,$G)'J-(271^QI#Z8C#]IUH&]:N2G6&6./U,?61G
M?TSW.DAY[Y9DX!"!.`K)W*@[RY7N&JXB(]B7'/Q))MH\'%&3H:_:*]_3<LGJ
M"K5TW4\FVNV$UT%%$MLZ[:[>7;/;;&?GQ+L<CPR1RQL4DB=9(W'S5T8,C#D$
M<JP!'CZ:C1U5T9'`9'4HRGY,K`J5/[0>-1]4M05]1<,1@E;B%`$5:/R);1FX
M*$BFVCLFM[0\6V>EG3MUG7.V-===-E_322TUUUQCY^^0R^8OYRZV0R<PGLM'
M'&TBQQ1#LB7M0=L2J@X'/)XYY)Y_`6M"A5QU<5:<9CA#NX7O=SW.W+?$Y9OG
MX`YX``X&J)E^"T>Y`638?(>+1C#JLK/G1R;Q>/F;9F=1)V8&-DW1'>5X8P:'
M2QS``LJ7<[%P)P4Y^,4L"+LI'((Y'#)9TWU^7_4#_J?[4Z+]0MP].\"F^=VX
M3%YFY6SE_`Y/&XVACL@+$AR-'`QVP]BS)4M&6"U/#<Q$,EJ.3L9V[Y3VIMKV
M.LQU!VMB-TY7^K>"REK&UGQ]?)4;=ZU:J^BHJ6<D\1CAB$T(22&&2OD'2%EY
M[5[4TZ-0Q#CSQ[=($B?``E71L3IJGFUX5'@?)YYOC7.V^N!TM'N3O)@IVSWV
MVW?UDRUQG.N-=L[Y\N))V3_U"_9?Z@3UWRF];VV,U-QXZ@TLA#+#W'CB7<,S
M9'&KY/GG*<#Y_F\L--W'[+'67;$4J4<'6S..CY(7:UBJ(WX^J8J,5+!Y`\=M
M0GZ<<G4^5;R91LN]Y$"&6;4:M<8"-TXY#G1C$:N+0UV8>;8Q7THU#3X6YRY5
M((/&QB.CFFK?`_5CZKK#E5?J?:^\\=O"]/?V[N3:^X-LR5XS2LX3+4LD\DKB
M-@Q:K-*1W'U00X5.P)Z99@Y,+YO;EG`T8JV5P^<Q><69_>8LC0LU(UC4L"H$
ML:(0!Z9!4E^[N[^%*@,5.[NJ"LG"3*>V7"HL6=:]V``I(!J<F*[9UUVU0"Q=
M-?>0FW2N,X]%F(&O72V=M<)(J9VQCK;<AE\7B86GRF1HX^%!RTERU#74>.?G
M*Z<G@<@#DGCP/GK7:F.OY"014:=JW(W@+7@DF/C_`.%8#]9/'[=14C:'(2Q9
MCH*J/A]9D_J9X$V3=3ZQ&J%!CMC3K&^44W$=O32&3E_&=4T_3<DXY7LL3>(N
MDGP_VA%/#=S!FXO:/Z=8*^]9<G#FJR0-W'$+-<EDL>?R2N(EIJB\=KF2<<EN
MY2>THTGXCH]NK)5%F>K)C;+2CA;QC@1(?TV`=IRYY[E"Q^`O:1\089^29CC`
MNQ"7#0M?4?&)HH3<1R7T=(T9Y6YJ8#P1.2O(=)%-:UJ:3@9\2`@C)$!L\A+^
M,2/(IP&8S+>3N0X$G<]/>OFQ][SY#'X^ED<1D*E6S?CQTU2.2QD:]5#).:4=
M`S>\60@!2JH-B4D*B,>.?9G>D&Z,;9Q,<N1Q5F')Y&CBADKN1CQN-QL]^Q'6
MAERN0RCP5L=CHY)`UK(698ZE2$//8DCB1V5!([:,I,\S?NCZKH\[)81<M#J0
MBM</GJD,VG!`25B4DDMLZ*/EW0?TC\=&Q.)NEL!5S92*UK7Q%J>?"=]0T?\`
M.]U#W*,G)D-L=*MW9Q;-%HJBWI<7MQ+DD;1N]B.3(7).T2(L41,\$+F*O`P<
MKPB3_@O9HZ6Q8<1]2_:ZZ*[4-:TMBS1VC%N7J9E8%8.@INF*Q>)QOJHS32(:
M^9MP++-(#Y;N9MXN4O+D0=;`<U-/8@4%R;`>/O6\)B\%E$?E*V<(H%X%:=AW
M((6SVU4T9Z2()73H*435<#G>7H]P['J<Q^T#M[VM.K>T,EM/*]">A%?:&1JM
M9D.[-_KN_(5H0`W?+0PE,0UIP%[GCCNQ6E51^:>&U/71O)^QMT2S,^1VCU]R
MN\LKD(7PF8QVX,5U-QNR-TT)2.,?GMAP=%88LO3$_;8K";?UB*I;C@MT;,-R
M**RE@\(`\NV-^%AU1UK'8G<]:P:I35MFK$N`)F&VO"IT3G@8"!L<56U>OQI&
M:M4:[DI868CS826@F"@%=JJ[B\A>Q@EQ_P"R][+WM%>SWG[DL6^]EV=B9>S/
M9R'3Y(\[-C*<DS,Z/@KUV]>N8^2)B$,DYNM8B!-@2V#[P=IRO4+V<\S@LIM+
M>.[MP9_:\\V0R&W*>U>GE]<AL++V^YX[.SLQN[=U:[!CYI5@CS.%RGOM+-U(
MP]CT<O#2S%.\)AN^58LE";9LS)*-&^Y!FR>*$&;5[NCILZ;-'ZS,<L^;(+Y4
M20=JCV*CE+75;=FVVWRCI]*4+E%,BJCE5+JK%U5R!W*KE4+J#R`Q1"P')5>>
M!P;96NEFPE2::Q46>5:L]B!*L\U=9&$$T]6.Q;2M-)&%>2!+5E(79HUL3!1(
MV7UY:]&N;CX0A^2+\V,_Z^?3GM]BW^^.J']I'[!S_(Z:M]\.;ZO?@C^IKQ@^
MG_V1@_5=-.5TTT=--0=R*CTFDM52%A&7S=FJAIJ2+(+[>CDF%&Z*NWP])WE1
M--KOOE))QG*W=)QHVW:*;)Z.-M\;-M"W2I9VI+=B>0.3!`RCO]&S,1''*T?!
M+@=S)\/Q(7$BAB@&L#N6M:M8BS'5=4*CU9E8]OJP1`O)&K\@*3P&^+X6"E"0
M&)U0G=$CMJ-AXVM4$+'34T_EPQ@<8E'6&C5G&U&[Q1Z[]HV?,<-=]ETV;;+[
M;VQ-DFLHMNP=>7'IS7F;&5K15CB*<=V9[<<<Z2MV(E8JY=PWJ1]OQ!%]0]X0
M,28V\:BC%08V>2<9.U)4B2L[Q-&O<S3`J%4KV/W>"Q[!VEB``X^1W:<1][+H
M),(NV>>YR,GB4@C[<@BHHI[K>&PSL<D]24TU24W]B7<ZKZ;:ZI[Y]+&VNNFW
MS8R,R-+!+&#V-+"Z<@D]C.A7D$<$]I///@^/IJPB<1S1R$=RQR(Y!`'<%8-P
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MEYIG&<;C@O97V'CR'W'N;<NYI``?=\15H;5I*_U4V+1W)<N0\_58<5,1](S\
M\#D>LFX[([<5B,5B5Y_[MZ:SF)V7\1%`,5!`_'T,MQ`?TAK>WWAA4+8#=%OR
M-D]I\EF22J3I.,6')V,5KY%TGGOGO!*>#5L&.L^^<XT9SOXY]M.WJKK*8PIF
M>-F;8VITZF6UL;;.+V_D57M.87WO*YD_@ZW\W9R+U)#]6QJ45!Y[44<@1QGL
MSFMTQM!N'+6\E4)Y]PX@IT!_ZFM0AJB=/U6VLDC\YCIR:PHJE*39.!U.U'6M
M6LGNV-WZ-?PB-Q'WBKCY_7)J`AK%4DZVVSG=1T^W<.%5,[***;;[9VSM60R^
M5RTOKY7)7\E,?/J7K=BTP/ZC/)(5_8.!QP/D!K"U:5.DGITZE:K'^A7@CA7^
M$:J#^_4K?_O_`/'_`/?C^;\WY\=_M_G]_3S^/X76J^O$:>UW(*@K^C)DA'9`
M=O6_Z&!Q&!'41Q+,J:5W;4/N2QG'N8AJLBZ%1NL*^EY@NLX;[LO*FT$JYW>&
MA[1Y,W0+#7<OU2VR:L;&"C:DMY&7MYC2DE:998Y"?A;UPWI",]Q8%V"E8VXC
M_J?D*^/V5FFF<"6>N(*B\\.;+2)Z;)QY'IGARXX"GM'(+*"A535`RK/D7%:Z
M$RF035O!8'9=NRTD:SKC`(Q:QJ(P6M!V--%54LN#X>&6^]=N--L+N'`+VE9!
MNB[:Z=?3##8=<1;]T2U8N!5M7YI)^.8WMM#!70`$CND2"T[MR"[)W$*&`''6
M4RC9.L;+UH:O<U>G$L7RD2LLLTS<D#PC2UU4<<(K=H)X;FZCB>5A;"RDVDG&
M-URQ-+1O$BKK.541IG7;??*.J&V,HZ.R*6<),GVV/6;N$=&R';9[Y];7?4&1
MEPS/2F98(6+Y"!/#35R`.XL/B*0L.Z2,?"Z,7;D1@&XVA-1CR@2W$K32J%IS
M/Y6*8<GM"GX0\@\))^<K`*OF33%\/$]Y2XY,WFLX]ITNGD[8Z4>SWSOHS@]"
MHAN,4=;L=]LY\PDV_IF06`QSIGT5E)TZ>HX\CSS;09J7=.=TTT=--<W'PA#M
M_P!(O?\`[^?R6_WQU0\_3[_P.FK??#F^KWX(_C_Z->,'S_\`",'ZKIIRNFFC
MIIK6IE'<RZ*2&,8?K"_?XA\)V?H)Z+*-M'J&Z"FWHJ9UU5TVTWV353\Z>VZ6
M^^NBJ6^=5-;S'6_<+U2[Z2S^ZV(YQ$Q*AS&P8#N')4@@%3P0&`)5AR#:W:WO
ME.S4]1HO>(9(3(H!*B12I/!\$<'@CD<@D`@^12[/X24KR6F(B7417>"5DL8<
MMO4PW=MG+=)VT<HX5UTWQJLV73VVTVQGTE?.EG;?T_-GHS%Y*'+4*^0KAECG
M5O@?CO1T=HW1N"1\+HP!!\C@\#GC4'9&C+C+DU*8JSPL/B3GM=74.CCD`_$K
M`D'Y'D<GCG4.S-\9VA4V6A&[5[+&,<D>D>1T417TQ*4!+K<0T<Z=]M-%/>?L
MFJJ2V,9QC;\/7&-NKZPLT<,A1&$IA=X0RD!F[6],CD>5+`#GY'5I"8VE0.P*
M"1!+P>>%[AW@^?!"D_@=,UQ&90IAQ:X\(5WE!2%[TS7+L"Y1SYMWS<A%AC]<
MF_5V_P`YR8*O'+DB=>.\[D'AIT^=$5-WZSG;;XM[EER$VXLY+E#*<@^6R!N>
MOW&43BS()%;N\@JP[0IX"J.U1P!KZ+8E*T>,QZ4P@JK2K"N(^.STO13L*]OC
MR/)/U)))).IY*%181@[+&B3`2*8([N'Q(F\;CV#)NGKWW<.GKO=%LV1TQ\^R
MBRFFFN,?A9QCK#(CR,L<:,\CD!412[,2?S0J\EB?U?/Z:OV95!9B%4>2S$``
M?B2?`_?I.9IXA7$Z(^9(99F;4?8<99^R4;&I+<[5!]G&^?83$FKL4?AD6<?@
M;XVQ+I*`13SKOA59/.N<=;]A.EF_]P*DN/VODQ6<@"W=A..J_4@B:\8%8'@D
M&/NYXY'(UK.1WGMC%EDM9FGZRCDUZ\GO4_C_`/%7]1AQR.>[CCGSQI&#?C#.
M3,A+1F'\>I+4;1EMZ2-A<L%I)!8KNGMZ>-30]2L(G:,$(#>ZJ>^C"3W'71A7
M11/=5NRU4USU9]0.GV^>G>).5GV#O3>B)7>U/%L7'X_)PU(XU+.M^6UDJV3K
M=J`,TU3`Y.!$(+.?'-_L[.X3>V6KX;'Y_"XN[=N08^C7S,UN*YD+=F18:\..
MJUJD\%N:>9UAAKMD*T\LA")&6/&M(KJ_>3O)\7+#DEY$J1:#MY(Z``&_':)!
MJMQ(AX_71(HN0?RPA;EC`6RC_7*(MZ$G$7D#A%!=[G`MN\T'Z<==6>OF;V/<
MQ&)P.U<=BLW9Q*7\O%N&6?<AQ,MQO4HUJTT<.$QER[%5XEO>IC;E"*29*T0G
M:%YY.X-R>S[M/9F'Q>T<[E9<WO\`CM)F=WY#$6&Q\&$2S35<?LN.NEF^H>&*
M4Y/+W/6%R2U-3@JV*]:O,EB,;MJR.QYA`<P=55W?LQNNBPE?V-:):;7;/]W,
M<M2-SP_@A(YM,W%AG8?'(+&YK)Y+%FD[!,'$:'G6R+X1EYEWIEO8SWUUCZI>
MU)TV>;<&2OTL%8S68RU2M7@H;=QN).$OTK5J?!X:''XE/6FM5*2S"M'/))-`
MAG':'3G[K[M[8>SNC.\`,74K39&"C1IS2RO8RMR\+]>>"&/(WWM7&,:0S3]A
MD>-$21O2(Y4V"4=3&8FZ+1\44-V7:]A%UIE.Y(^0:;RN9F=&#87H\3"BDDFH
M2*QT,,9`HT"&-DQ4?!C$4UEWI-0J8(_HN"08NK-<MS]L;2![=^R5C1YF"HJE
MN%CC`4)'!`OYJA5`9RS-\G2T^1L15JT/<RH5KU(`7*1@L[$+R78EBSRRM^<W
M)/:H55L?&`\\5^.MY\C9[%DMYE75?3B7QH2ZW;/'N<1V+.R`<4/T14<)(FY4
M<U2"-4].[[;=PV::>G[6JDI$N]-S+DI(Z.,ML^/6,-9,8>-;$Y=O@8LJ,\42
MJA`_[;.Q;XNU")'VK@&HQR7+]8)=9RL`D*NT,(4?&H4L%>1BP/\`?"J!RO<P
M+<\;:DTH7C]2U,8>Y*.:QK*%PPH9W^=>0'@8%BSD,D=[]M<K/Y&<3('"#C?'
MJ.7I!PNIWW4VSF/];IJ;.FFCIIKFY^$(9QC[D;O_`-_/Q=_L6_WQUXD$_+_/
MC^1TU;YX<WU>_!']37C!_!&#]>6FG*Z::.FFCIII`[K&,^1)HY%*1B#4E,`3
MIW')+?I_!$=5\&*BE%FCP&BFUW;OKEE0=XBHP?QJ+Y;@P#QN^$RBPHF;9ZA'
MDF;=N3[5@KV\[>:.A81+57;4'I2Y7(0S!72P2W*8*I.C"6.U;+3V4:.:IC+D
M$GO$>C9JG!N&6:#&55>Y"6@GS4ADCHU)(B5:`=O!REB)@4>O!Q%"RO'8NUI5
M$3U(4YQ*%\2BUGQMN7EA8]+YAM(I9F4N!ZN$C>$E-5UQ28\<PTT8D-W"CY%5
M79WNLV6:^5RJFEJHI.^6W@^\(,5;$52*M5I""F:BR#F#D%1*9)'/J1A!&P`3
MM</RH)X$15,`-OSWZS/.T\MDR6!.R'B7CYIV(OP/SWJ27[E*D$C@G('5&?B/
MOP=4][W13,-D9@E("=>0)>KGT/;&SKM4C(7\93L2KYX?@6)`3<O#)8=7Y^+B
M%SS\G($AR!PJ2(NX$W+T)Z:[LS;;@R^$<Y"9@]HU+D]*"Y(`%]2U#`RK)(0`
M&D!1F`X<D:D_#]4-XX/&KBJ60C-6)2L'O%>.Q+70DGLAD?DJ@//:I#`>>`-0
M[O`N-)*WA]5SP3(;ML]@$^.3(I?9V7WO@)A/?SX7#/+3-2H;$2*B>^7232)#
M@@]%'?&B&C;91-OOF\#M/IYMC))A<'MK$T;XK>\F6/'1/)V`_P#DN2*\ID8$
MMY8@K\R&(75CE,[O#-4&RF1S-V>D9_0],VVC7N/Z->-E7TPW*^1SSR>.`3IN
M7`80[&;!'(L>L'RAHW]UJ,V^S#""6=<I):-,Z>AJFCG1/9'75/&$MM=-D_+M
MICM(3QQR(8I(T>,@`QLH*$#Y#M((X!`(\>.!QP=:>DLB.)4=ED!Y#@D-S]?/
M//GZ\_OYTE=F,!T_?MJG@"+..Q:3&WH,Z:8822>2]6*814F;M%=?"FY&$5DV
M50&DU%-UF)NR"D=ANNJP81-FNW"75#J/-U=ZO5_9@Z6VC#0QD=?/]=]WXQN4
MP.VHI08-I178W'IY;.NOHS*7[Z]%9P35>6E)9^FOL];-QGLZ;"O>T_U0H1Y+
M>=/%5;72O9^15C_1]_<D5A-H6;5=")H=T;S,-G*8B!%6W@^GN,SV\%[,GD=J
MSP^G*:LX,M7@9$L)J*-2O;W;#Q4LB)EM![/3V;-DFK`?M8D`(@9\PSJDBCIE
MPO(&Z?J^EE9;UE$_-T[E]H]'-Q8FMM;/8+8FX<51CK8J'%9*CA\O'51(A#!`
M\4L<[0GTTX#2=A8@DMW'G7%><S/7.MN"_O\`S<G4+"YO>-_*;CGSUROG,-_3
MEJQ9]ZR5RG+/'6BN1I-;0NE3U8X$EBC"I'V+J7:ZXWU;64CS,`S26R&8ZC7@
M5A++)L6?6E(`0-^JT6(!HV3L*221>-#BBK`<H91`Y'[GE1X]<XH179-E4KGI
M_P!'.EO2H7QT[V+MO:+91U?(2X7&P5)[?86,:33HIE>*(NWI0E_2B[B(U4$\
MZ9NKJ#O7>_NW]:]RY7.I34BK'>M/+%#R`&=(O$8D<`=\G;WOP"Q)`TP7'GB*
M.+<R(7RM!`Y9F<1]@F'(EUCA-G#$XUNP5!$O,SVT]F7>K!7KEJV'-UE&:SO?
M4CN,R]T5(I[[NW>7H;'R.TK5FF*=IC+#76"*2\UL2+8A^('O6-9XT=I7`94'
MIB7L*Q'7]M[=DEW/2SU>"QZ]<!99FD=*HKE3%+\QVL[1.RJBDAF(<IR"XL?Y
MCK8D^.-M$Z-_:LWGR<K-N:U[>=-K"J,P7Y0RU4@GG7?3<0>1I)A7C_5339-9
M2=M&>WDR[U53YDU.^G/Z::.FFCIIKFY^$'XQG[D;OCO_`*^?R6_WQU0_MX_A
M_/3GC_@G_+5OGAS?5[<$>_T_<:\8._\`]D8/U736-SR@%W6-2H$+1VLI*/AM
MR5#)K,@T#LYQ3$\M&E8],F!"RJYAMHM3D45B)R0!T]5,;[3"'-I"/8OX>_E0
M-A(G+Y)IJL-#C-SN2L.RS8N)<DX_"G69LX:"#'-N16+B35G(Z(IF'UE3T2AY
M/DO'F6EAU=;H*63N86<;G]1DI*S%'Q"%DS)M:QI5-JGW\_O]_P##S](**\1/
M%)=Q&+C$V_)0'8$*X?T+6!N81SFV0E49O*T1EKT#*K./RF/RGDC$%X+,(G5M
M92F%"',(:A?\1Y39%K*RBZ-@Y$0>D33Z??[_`*_S_CJ^'A3#[IK_`(J4?">1
M!)V8N6+PIL%FY4E*7LU,D73%Z]1%O9#*'Y0\X+2=R`U%*R=76129JA(-B3-A
M*),P;MCQ!JNO=M_CO'K:,B#JY5Q'R#)'=F3<,6*+E4NQQG&[1)3959+1!PSV
MRKJDZV3<YV15]'=+.J2/DVW;^[;>`KV*RP);BE820K+*R+7EXX=@`K=Z2`*6
MC!3XE[@P+-SK>:VW6S$\%AI6KR1J4E9(U=ID'E`>X@*R<L`Y#\J>TC@#A+[R
MX])`B(^#T61?S&UR(OWHK%#?L2HV-QW&RS=2;RPTTV%(AABCQ!1E'@*VNI2:
M%TW(\(LW8C)`9!;'1ZBV'8Q7JE6,R,%CM1&815^Y@.^>#F:26.-27(BD1W[0
M@`+&1<%;V/"BB2I8L2!!W25Y/2,DW:">R&7B-(WD("CU$95+=Q)`["K&*&-U
M+M[TE43*(28SZB9>='A*.AB1.M_3471W,)(>CHQ2P@EJP!,E]!HMDW;-F31-
M!OIGK?,1/A[!>2C<K7[97NM60T;6Y.XCS)P!(D0("QQ`+#$JJB*`HUI^3ARD
M(1+E:>G5![:\'#BM'P#X0\E'DX)+R$F21BSLQ).DRO6\I^+MZ)<>(A6,S>I6
M&#0+.K,`$$QV&(I-T5Q)PP1Z[%[A@QU,4+3;I24F;2V!.3H]XV"D7>K!)WKW
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MRFY-P+NFMNRUG8,;M':>!EO9R27&UJF+Q4N.JP"&&P$3/AO&B"R`>%Q+ZPB!
MF<EY2M-5Q(,`@D/%28SAJDA&8\.%I()+Q^/#&8B,CAFS?=D2:@VI!\S5?+K*
MY_0/T.Z*;?Z.=*-I;*NN<O?P=&*YGL_F+,MR]DL[/&DN3OW;UF5Y)PTX*\22
M&!EC5Q$O/`^8WM$=<LWUBZF7<EB\OGKFU<)2AV;L>+*6[-S)3[<QDTY3+7S8
M>68YO<^2L7]RY1B[RU[F5>A#,:=.LB77<::"5BS$I(;%C`_)UZX:Z`V)5`>2
M6$L6Z>5=WFNG=TDS>NUUL)YUSG1VW39ZXSZ?K;ZYR^\MTK=E@J8B]+[K&CFS
M+`TT*SRN>T1$\1M)'&BD_6-S(?SNT'4?[7VZ:D<MG)U(_>)&001S+'*88U')
M?CXPDCL>/TU"?3N(TYN,8UQC77&-=<8QC&,8QC&,8^C&,8^;&,?BQCJ.];OI
M-<Z.9YSYUVSE/8!QMXP;=M?G53=SOE+8N,>;O\Z2!6&PSC3G';/E<Z"K7[]O
M9W_?=IIR^FFCIIHZ::YM_A".._W(O_/GX\8^Q;\_335OWAS?5[\$?U->,'\$
MH/TTTY7331TTTN7+VXY7Q\XP7K=L'BB,VEM85K)9>!CKM`JZ&NGXECNLF]-M
M0.BAQS'0FOG.R-N%T][K@AI!(9MH]W0WU::J;&>)%?[V_HK3<.O3@YR"92!'
MCX)!EJ=JRP]'UH(WC,[WBTYN^ND&/*VQF6M5<6F-;QZ16T$W<R!D:9-94R6M
MZN"9:.-&K5/O_'C_``_XU`4U\6'Q!ZWBL"F#ZM^-5CA;)JOD;;5>?%6#R"(R
MV<5U74<Y.2.M[8)U05Y92NTJZ@)",4_4=AO7K:+6?')H"N-Q"][`J.9QH;\:
M6JG5J_AB7T<Y.<=S%U3.+P4'/Y):T]%2XY78[5M&)U\7'C9A%I0/(-;-NT&5
M3VANX$2XTBUR6/'8Z4&$HD@7$%`)>)1YIJP<H)%G&*XPR.9%1SK7R.6)%JB\
M:+Z]^^,*MW&BB6_ESC&VN<ZYSKMC&VN<;8QGKVP3SUI5FKS203(>4EA=HY%/
MR^%T(8<CP>#Y'@^->N6**>-HIHXYHG'#1R(KHP_`JP(/[QJ*Q_'ZG1K<HV0@
M@=9,OZF'6S[#D@LBFIG&WI#G+Q==P*TTVQC*61RK533.-<X4[ZZYQG9=V;AF
M>!VREA37X*"/LB5B/',R1HJ3D@GN$P<$'CCC6(CVYA8EE5<?"1-SW&3ND90W
MTB9V9H@/IZ94C\?EJI[B=4L/O[E%?=R-Q62_'JG;'=0V#-"358XTG$UK5D]`
M#-F^%DW.I^/00@5GLX'Z)HN6Y&16+#UDM??4!WVWYDIX?(=2^ON2ZR[B8RU>
MGV).Q>G*KW1Q069GBN[GW#452$26U86K1@F0"6(5+#PRB&XT0[]ZCUL?[/'L
MZ]/^CF-A]TWSU)VS-N[><+2+)8Q.`WO+4R61AN1D=]?);DQN+VGM.6&7B>MA
M=G9N"3U*>Z3S8I2MI<1K4ESM6I"\$3M((-V<'J^?!G=<W+#63S;">7$QI69C
M8M9,'7<^7*6CF3PL,[71W4T25W07W]3HR;,Y:Q5-*QD+<]8LK&*69Y`Q7RH9
MG)=D4^1&6*!@K=O*J1P=%BL;!8%J&E6AG52HDBB6/@-P&(5`$#$#CO"]W!(Y
MX9@65:2>-OY`:B;&0@WLIC;`(4D4::%F#D^!&27<LG'")H.BXW(BV)]0"<T"
M.WS9!N5W#%M6*B^1SS".,U?ZS1Q08705<B2+`HV;OR0M=P.=MWJ"),,0<B3`
MY55LHJFF_%%63P82:;[8<,2#1RS=)I.4%4]6FH(I"II#`ICR0GTP>BWT@O*[
M-INPT%.';I`'`8M6]?517\=RL\9LMTG'N:`JRTPQ1359LY1,9%HT>/4M\.UF
MFIW(%1@A)!<J18#$'3\>*;+$'C=DDX)EGB(X4.04<J):+/R9!RW8CV:>=G#U
MXNBU;)J+JZ:;-->?%Y7&)P`&RN&2()+(P91W<")%&RC(V#*()KJME%QQ4<NY
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MM2TK<=&2.&Y)7F2K+*&,<4[QLL4CA06*QN0Y`!)XXUL6T+>WJ&Z]MW]V4;F3
MVO2SF*N;AQF/,*WLEAJUV&?(X^J]B2*&.:[526LDDCJL9E[SSV\'5Z#I6(\=
MZ?@=-0=)3$?@P-`9H]<8Q[>;**;J/3LD*[^;?U2TC-.7YLFIYMM<O'RVJ?E2
MU3TUM\/BZV%QE/%U!^1J0K'W'\^60\M-/)^,D\K/+(?TG/'CC6:ZG=0L[U5W
MYN;J!N-U.4W)DI+C5XC_`&;'4T5:^-Q-)>%[*.)QT-7'4UX!%>M&7Y<LQS[&
MI.H+>WCZ]H5G!YX]B1)$S$2LGC0HJ:B)A!719$O$SCEMN7C)1/=/7."(-ZP>
M>7NGE;*>VVNV2UH>JO\`D;X89"YKKN*\Y;R7>0^,S0PUE:(,:)D$<Q!Q<2BW
M%Z,`GKF2B+(!H%G4#C]4<CSD:)%AV@V.S#D0RF"#!(A6:"DE::1F$>%FR-4>
MK=T.YMZ@*<*\?+].1>91.GK=K+:/RRU#/)F0R3DR#C&+/#R-\:D$4NH&Z-LG
MPYP.FJ%3P5VT;F`'Q)Q%&GW\OO[_`&Z;*S_"*D9E";N:*Y..::+3RP+"?[%W
ML=G\T5A]/3#BHKQ?CM=PY!6YX_N//P\82EEB-ID_5=9*69,R4Z,@WTA%#W.[
M3['[-+"\\,24!P`:X^8/("LXV4F'*6O9V5J:50Z?6K7RQ$Y:_)LW!Z_,Y6N!
M\@=G8H[R5@L9A4GB0F-0N(1:EPJ#B)O61R0E6+34NU!X/\H1"0IP^YH22<5Q
MB'TB$:D$8Y946L*PJBBI_B7+7$'FTL6N=5PS`/@G&LI'XBV`1Z+D`"E\6Q)S
MWON6FR[HNU3C]X_7_P`_RU<1Q7I9]QTXXTK1A69.+"+5;74:AY><.&;H;\:2
MXH>DD4,M13TL><AACU_EPJ(!J&RWN05EF*T(.TV>JV[5=4:?"$?R1?\`GS^2
MW335OWAS?5[\$?U->,'T?^R,'Z::<KIIHZ::.FFCIIHZ::.FFCIIHZ::.FFC
MIIJD'Q(O#*DG)>06G<X"T:_0D<EK!S6$+%6D$2"(5PZFM1W!QR*/4+?V=2-=
MM4S4'R#E%L&J0'5TT=6I<D5@FIRQ6@%H@';M/O[^_P#765RWX3\5IL2AE@G.
M1U)T!1M-\25:R;QID%B^K5CQ_=FF,AEA1C(2]D(Q*'P$U6T9D,3:&Z]KJ,2+
M8<_,[&K`EL*;J0#9JGW_`#_Q^NJTN-7A5P;D3'>3L6OKD912\O;3\[6);2OP
MJ,N=2"29X_VG'8[=%G%Y:SKYM:-S([<HKDGNEBLV$D%%)<T`D1!N./:WUA,-
M:KIK9IX.M5R&0VF<,<WXM'Y';I6?99R`5`H<(FJ[>91OE6Y'N)7)G5HN2=ES
MF+..7=8R45+'>HM-L`H.D@`>/`HXLST:--:'RC\'M0UN?=<5KDHF17C:4OE#
MN10BX4`HZ!2<8<D/*:U/;IE%AB<Z)6@UI]#D?0[JK(F6$*C*_3HB`6$AH5R;
M<1QZU0_+_7SKHQJ>NPU0U96E31S.V8]5\`AM=@<[ZXTWR&A4='1H7G;3&V^-
M-LL1B'FUQOOC7/?'FV[=\M5US[?"$?R1?^?/Y+=--6_>'-]7OP1_4UXP?P1@
M_333E=--'331TTT=--'331TTT=--'331TTT=--)ASMXTS+EM3,=I>*R^,PH4
M\NJF9Y/RLHC3*:-'<.J*=BK50!MH:8&D8[+=C4VAT-8%HY)_8P!:+JR!J^=]
M]TFCMIJMM'P`*!9"Y*!:W+8+\&0K-*`19I*X14TF?19]FN*"K-^=6.*Q!B8.
M!WH6BE7"%=9=C($#>VI9JT?"BU3+-5@T^_I]^=2%-/`UXV3@G(3;Z;38&:ET
MT>2J4FX<)A\5-G!TEN:ZK(GT3=%109)XD'EE?W`VX_-'#51`I#:JK^*,XF\&
M$TEGO336I1;P*:;KW>IC(JRI5:!2HX7%&KT%:X>OU4+HG]<;68ZAAV:6`W@1
MV6UZ,?9G,7C,F0K@>EES$*=IX6LR+LX*D,*--35PI\)Z*<2IG1ELD;9D5@VS
M6E#OZPL*3+B&@]2X9Q(_=FIR=2UVJY=J.!T;&BV42JP(DQ:EX1#F2`'XSDAC
MDB/=M-6Z=--<V_PA'\D7_GS^2W335OOAS?5[<$?U-.,'\$8/TTTY?331TTT=
M--&<XQ].>WT8^?\`/G/;&/\`YYSC&/SY^;IIHZ::^>;7MG/?';&>V<]\=L9[
M]NV<_G[_`#=OS_-TTU]Z::.FFOG?'?MWQW[=^WX^V.W?/;\V.^/_`*XZ::^]
M--'?'S8[_/GZ,?G[?FZ::.FFCIIHZ::.FFCIIKFW^$(_DB_\^?R6Z::M^\.;
MZO;@C^IKQ@_@C!^FFOSXA-C\AJFX:WK/.*4/?3?D`)C@AC70@9%RLX(#7LDE
ML>BYN;,H6#"R4Q+W%;1<R;L1*+C(S)GL@VBV!+>-GU'>H=ZTU6*4Y2<XZ9\.
MVTBA<M?%N<FB3)A-X'<!SB=(P:=75K9/)*(T4F$4BQFC*`>6U=M01`G+KF`0
ME[QR@QVP8\,C^7$`?CB@K:2M->EP0\2$Z(XSS:X.2TEY/WA#9/?=\#>/-ER.
M@X2$E!ZMH'R`A_$NI:C-,ZEAE9Q(KR'M.S-3LE`P9C%VL@+LG$F=J-Q`B-HL
MF[36Q>)/`$Y'S4XMR7DA0=^\E."(F@.0`5[`:.KJT;B81KEH8EE5+UM-K(K*
MH4G\G>([UHPL..5U-7PAT'@LO)K/O>L;=ODBG33]6J[ZUH^U!_)E0O6W&GF/
M!+M&^*A>EHV?<1:$79$J\D7ALN`TI]Z5L8GI\DQ@US.IJ$7$@*LA48=SB7"9
MQD?)!3J/J,%C*C3[^_\`32^EZ=G([C5XD=?8X+WW:<)O_D-1@7BR[B'$GF'1
MU3UA*I5QU/P">7QOP\([3[D''PG'-=L0EDUG.KZ=)WO=QN,N8PVCAADD:!-4
M^A_U/X_J^^/GK=D>/_)\!XB''V55O`.5]AQ&#R3PIQT6LJ?<=.1L"GL_J2O*
M/=UIR$-V)R+DQ(/7U.BAZ9%*=W_2%F0,O-;;E0IE%VCZ.EM'+E1IYY_Y_P"/
MQ_;X_#S=+.;7YWC_`!5X17$='W$MX?1)&#I3J8,:)CY$:!N96I;H*)5X)G.8
M^J=<<>Y1AO7\FLFV?9B3B!W4-BE5#IP%"3.5B0;5=5YW53TA)6EXM6MS<8^5
MEG<PY^GR`4X$7M"JUNB8UF#X_%>%:<<K2"5]:4.WVKFN73*=ZS\++JU*O!4A
MF5E2<,43!2E^2#N1K5/X_P#'W^O\/EK0*OI,N&K7DI+X1P-Y+RCC7&?#\HMH
MYXFV[6]S1#_'[Q*(L:-;,I/5E+S9TQG8,6/'D1`2W;$!1Z+1.1Z.6Y_;,AS$
MB!A!I]_8^_YZU"5^&E?7'&RO#VJVI3UE6Q:L'$<#V1"7O*9OXW%J$>0#E=+[
MKYC6-`^2@LN/H*!16X8],)]'[&JV<:&IG)(@+KF!!`;\5(PRT?:?7[_`_K^_
MP^1U(W@+TQRJJ?D6=<VO4MU0N(E^+TU"V.0G%-W+0L;&W*'Y4R8_#L2;>USQ
ML/R;M.9UC+%G+2YJT'P^/P>OXD*@I(22(%-2733Z_?W_``_?^J`JIB?+.A1E
M>V?QBXB\Q1W*NKBWB6F.5Q*15G<<1KV^PUCRF]AG#R';H3+5A'+Q-)67*J`G
M(64P`1(LUO5\3F#\K(18A%X*>M5_W_'[^G^FL2,\+?$%C]*0#P^YC1LM?B(3
MX@G&2\(;,K6=6-RAHTG4]B\:[J`74TMF>P0G7#\[&@_)"&E;"F4:^,T;=1'2
M\(+IZCAOD9N]:I^/W]_Q_AII^(7`%Z1L#P<)G<_'.WW,R@=#<L!/+"26RRGC
MQX!NVH#M+BZ-TF!T@XT;.XX!-BYXEQH+%U%\R6L&8M^Q>&T?7=[M5^_O[_VZ
MGNFFN;CX0A^2+\^,?Z^?3CO]BW^V>FFH>X8?"%>%]6\/.)]92"L>3[P]77&J
MBH(;=AX75+@0Z+Q"KHK'R3D4N]NH>\7&KO!ZRK%9VP8NE6VR6[AFV5VW1T:?
MJ^_K_IIE?OE'@Q]E/+']A:?_`+[=--:E.OA"7ANVA%2L%LSCIR$L2$G=&R9R
M'3JHJ'EL5,ILWC<@TT*QX_=)`01T:OVC5\VU=M%L(/&S=REC59%/?5IK^P?X
M0UX<L=!1Z+Q_CWR*!1J(X::Q..AZGHH8"C&!Z2J##$>$LKK08!<,D%ED6F!K
M=MALDJJFCY-%-L9::V?[Y1X,?93RQ_86G_[[=--'WRCP8^RGEC^PM/\`]]NF
MFC[Y1X,?93RQ_86G_P"^W331]\H\&/LIY8_L+3_]]NFFC[Y1X,?93RQ_86G_
M`.^W331]\H\&/LIY8_L+3_\`?;IIH^^4>#'V4\L?V%I_^^W331]\H\&/LIY8
M_L+3_P#?;IIH^^4>#'V4\L?V%I_^^W331]\H\&/LIY8_L+3_`/?;IIH^^4>#
M'V4\L?V%I_\`OMTTT??*/!C[*>6/["T__?;IIH^^4>#'V4\L?V%I_P#OMTTU
M2AXP_C3<6N3?W.WQ#@5_"/B3_BY[U^-T6KMA[1\9/\,?8?=_N:U#_J^E[@>>
1U^T^R>GZC;T?7\ZOHM-?_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>g838054g98e17.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g838054g98e17.jpg
M_]C_X``02D9)1@`!`0$!+`$L``#_X@Q824-#7U!23T9)3$4``0$```Q(3&EN
M;P(0``!M;G1R4D="(%A96B`'S@`"``D`!@`Q``!A8W-P35-&5`````!)14,@
M<U)'0@``````````````````]M8``0````#3+4A0("``````````````````
M`````````````````````````````````````````````!%C<')T```!4```
M`#-D97-C```!A````&QW='!T```!\````!1B:W!T```"!````!1R6%E:```"
M&````!1G6%E:```"+````!1B6%E:```"0````!1D;6YD```"5````'!D;61D
M```"Q````(AV=65D```#3````(9V:65W```#U````"1L=6UI```#^````!1M
M96%S```$#````"1T96-H```$,`````QR5%)#```$/```"`QG5%)#```$/```
M"`QB5%)#```$/```"`QT97AT`````$-O<'ER:6=H="`H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0``9&5S8P`````````2<U)'0B!)14,V,3DV
M-BTR+C$``````````````!)S4D="($E%0S8Q.38V+3(N,0``````````````
M````````````````````````````````````````````````````6%E:(```
M`````/-1``$````!%LQ865H@`````````````````````%A96B````````!O
MH@``./4```.06%E:(````````&*9``"WA0``&-I865H@````````)*````^$
M``"VSV1E<V,`````````%DE%0R!H='1P.B\O=W=W+FEE8RYC:```````````
M````%DE%0R!H='1P.B\O=W=W+FEE8RYC:```````````````````````````
M``````````````````````````````````!D97-C`````````"Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92`M('-21T(`````````
M`````"Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92`M
M('-21T(`````````````````````````````9&5S8P`````````L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0``````````
M````+%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$``````````````````````````````````'9I97<``````!.D_@`47RX`
M$,\4``/MS``$$PL``UR>`````5A96B```````$P)5@!0````5Q_G;65A<P``
M```````!`````````````````````````H\````"<VEG(`````!#4E0@8W5R
M=@````````0`````!0`*``\`%``9`!X`(P`H`"T`,@`W`#L`0`!%`$H`3P!4
M`%D`7@!C`&@`;0!R`'<`?`"!`(8`BP"0`)4`F@"?`*0`J0"N`+(`MP"\`,$`
MQ@#+`-``U0#;`.``Y0#K`/``]@#[`0$!!P$-`1,!&0$?`24!*P$R`3@!/@%%
M`4P!4@%9`6`!9P%N`74!?`&#`8L!D@&:`:$!J0&Q`;D!P0')`=$!V0'A`>D!
M\@'Z`@,"#`(4`AT")@(O`C@"00)+`E0"70)G`G$">@*$`HX"F`*B`JP"M@+!
M`LL"U0+@`NL"]0,``PL#%@,A`RT#.`-#`T\#6@-F`W(#?@.*`Y8#H@.N`[H#
MQP/3`^`#[`/Y!`8$$P0@!"T$.P1(!%4$8P1Q!'X$C`2:!*@$M@3$!-,$X03P
M!/X%#04<!2L%.@5)!5@%9P5W!88%E@6F!;4%Q075!>4%]@8&!A8&)P8W!D@&
M609J!GL&C`:=!J\&P`;1!N,&]0<'!QD'*P<]!T\'80=T!X8'F0>L![\'T@?E
M!_@("P@?"#((1@A:"&X(@@B6"*H(O@C2".<(^PD0"24).@E/"60)>0F/":0)
MN@G/">4)^PH1"B<*/0I4"FH*@0J8"JX*Q0K<"O,+"PLB"SD+40MI"X`+F`NP
M"\@+X0OY#!(,*@Q##%P,=0R.#*<,P`S9#/,-#0TF#4`-6@UT#8X-J0W##=X-
M^`X3#BX.20YD#G\.FPZV#M(.[@\)#R4/00]>#WH/E@^S#\\/[!`)$"800Q!A
M$'X0FQ"Y$-<0]1$3$3$13Q%M$8P1JA')$>@2!Q(F$D429!*$$J,2PQ+C$P,3
M(Q-#$V,3@Q.D$\43Y10&%"<4211J%(L4K13.%/`5$A4T%585>!6;%;T5X!8#
M%B86219L%H\6LA;6%OH7'1=!%V47B1>N%](7]Q@;&$`891B*&*\8U1CZ&2`9
M11EK&9$9MQG=&@0:*AI1&G<:GAK%&NP;%!L[&V,;BANR&]H<`APJ'%(<>QRC
M',P<]1T>'4<=<!V9'<,=[!X6'D`>:AZ4'KX>Z1\3'SX?:1^4'[\?ZB`5($$@
M;""8(,0@\"$<(4@A=2&A(<XA^R(G(E4B@B*O(MTC"B,X(V8CE"/"(_`D'R1-
M)'PDJR3:)0DE."5H)9<EQR7W)B<F5R:')K<FZ"<8)TDG>B>K)]PH#2@_*'$H
MHBC4*08I."EK*9TIT"H"*C4J:"J;*L\K`BLV*VDKG2O1+`4L.2QN+*(LURT,
M+4$M=BVK+>$N%BY,+H(NMR[N+R0O6B^1+\<O_C`U,&PPI##;,1(Q2C&",;HQ
M\C(J,F,RFS+4,PTS1C-_,[@S\30K-&4TGC38-1,U336'-<(U_38W-G(VKC;I
M-R0W8#><-]<X%#A0.(PXR#D%.4(Y?SF\.?DZ-CIT.K(Z[SLM.VL[JCOH/"<\
M93RD/.,](CUA/:$]X#X@/F`^H#[@/R$_83^B/^)`(T!D0*9`YT$I06I!K$'N
M0C!"<D*U0O=#.D-]0\!$`T1'1(I$SD42155%FD7>1B)&9T:K1O!'-4=[1\!(
M!4A+2)%(UTD=26-)J4GP2C=*?4K$2PQ+4TN:2^),*DQR3+I-`DU*39--W$XE
M3FY.MT\`3TE/DT_=4"=0<5"[40914%&;4>92,5)\4L=3$U-?4ZI3]E1"5(]4
MVU4H5755PE8/5EQ6J5;W5T17DE?@6"]8?5C+61I9:5FX6@=:5EJF6O5;15N5
M6^5<-5R&7-9=)UUX7<E>&EYL7KU?#U]A7[-@!6!78*I@_&%/8:)A]6))8IQB
M\&-#8Y=CZV1`9)1DZ64]99)EYV8]9I)FZ&<]9Y-GZ6@_:)9H[&E#:9II\6I(
M:I]J]VM/:Z=K_VQ7;*]M"&U@;;EN$FYK;L1O'F]X;]%P*W"&<.!Q.G&5<?!R
M2W*F<P%S77.X=!1T<'3,=2AUA77A=CYVFW;X=U9WLW@1>&YXS'DJ>8EYYWI&
M>J5[!'MC>\)\(7R!?.%]07VA?@%^8G["?R-_A'_E@$>`J($*@6N!S8(P@I*"
M](-7@[J$'82`A..%1X6KA@Z&<H;7ASN'GX@$B&F(SHDSB9F)_HIDBLJ+,(N6
MB_R,8XS*C3&-F(W_CF:.SH\VCYZ0!I!ND-:1/Y&HDA&2>I+CDTV3MI0@E(J4
M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY`
MGJZ?'9^+G_J@::#8H4>AMJ(FHI:C!J-VH^:D5J3'I3BEJ:8:IHNF_:=NI^"H
M4JC$J3>IJ:H<JH^K`JMUJ^FL7*S0K42MN*XMKJ&O%J^+L`"P=;#JL6"QUK)+
MLL*S.+.NM"6TG+43M8JV`;9YMO"W:+?@N%FXT;E*N<*Z.[JUNRZ[I[PAO)N]
M%;V/O@J^A+[_OWJ_]<!PP.S!9\'CPE_"V\-8P]3$4<3.Q4O%R,9&QL/'0<>_
MR#W(O,DZR;G*.,JWRS;+MLPUS+7--<VUSC;.ML\WS[C0.="ZT3S1OM(_TL'3
M1-/&U$G4R]5.U='65=;8UUS7X-ADV.C9;-GQVG;:^]N`W`7<BMT0W9;>'-ZB
MWRG?K^`VX+WA1.',XE/BV^-CX^OD<^3\Y83F#>:6YQ_GJ>@RZ+SI1NG0ZEOJ
MY>MPZ_OLANT1[9SN*.ZT[T#OS/!8\.7Q<O'_\HSS&?.G]#3TPO50]=[V;?;[
M]XKX&?BH^3CYQ_I7^N?[=_P'_)C]*?VZ_DO^W/]M____VP!#``,"`@,"`@,#
M`@,#`P,#!`<%!`0$!`D&!P4'"@D+"PH)"@H,#1$.#`P0#`H*#A0/$!$2$Q,3
M"PX4%A02%A$2$Q+_VP!#`0,#`P0$!`@%!0@2#`H,$A(2$A(2$A(2$A(2$A(2
M$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A+_P``1"`*C`IX#
M`2(``A$!`Q$!_\0`'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`
MM1```@$#`P($`P4%!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*Q
MP152T?`D,V)R@@D*%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA9
M6F-D969G:&EJ<W1U=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*S
MM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ
M_\0`'P$``P$!`0$!`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#
M!`<%!`0``0)W``$"`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1
M"A8D-.$E\1<8&1HF)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI
M:G-T=79W>'EZ@H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZ
MPL/$Q<;'R,G*TM/4U=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1
M`Q$`/P#]4Z***`"BBB@`HHHH`****`"LSQ'K]OX8T>XU&_#F&W"Y"8R2S!0,
MD@#DCDD`=36G7*?%$7`\"ZJ^G3O;74$0EA=$=CO1E8+A06.2,8`/6D]AK<T_
M"WB>U\6::UY8*RK',\,BEE<!UZX9258<\$'%;%<9\)H;B+PC"VH7\FH7$SEY
M))(RC(=JKL((Z@+SV)R>]<[\3_%WB^R\?>'?#?@"XT>U;5-.N[N:74+)[G)A
M>)0JA9$QGS#U/:M84W.7*OZT"$7)V/5:*\5U2X^,VF:9=WG]I>%)OLD#R^6N
M@2`OM4G`)NN^*33KGXSZA;1S&_\`#$`DC5PLGA^3N,XXNC5^Q7\Z_'_(OD7=
M'M=%>/>5\9O^@OX2_P#"?E_^2:/*^,W_`$%_"7_A/R__`"31[%?SK\?\@Y/-
M'L-%>"ZWK_QDT75=%LGU'PG(=8N&A#_V%*/+PN<X^T\_I6SY7QF_Z"_A+_PG
MY?\`Y*H]BOYU^/\`D+D\T>PT5X]Y7QF_Z"_A+_PGY?\`Y)K#\<>*_BQX`\)Z
MEXAUS5O"YL=*A\V<1>'Y-VW<!QFZ`')').`,FCV*_G7X_P"0_9^:/?:*\,\-
M:U\7?%7AW2]:TW5?"ZVFKV<5W`)?#TJL$D0,N1]JZX(K2\KXS?\`07\)?^$_
M+_\`)-'L5_.OQ_R#D7='L-%>/>5\9O\`H+^$O_"?E_\`DFL;PQKWQD\2P:A)
M'J'A.#[!J5Q8D'0I6W&)]I;_`(^1C/I1[%?SK\?\@Y/-'O5%>/>5\9O^@OX2
M_P#"?E_^2:/*^,W_`$%_"7_A/R__`"31[%?SK\?\@Y/-'L-%?.$?Q*^)\OQ0
MF\!IJGAS^VH=+&I,W_".R>7Y.X+U^U9SEAVQU&>*Z[ROC-_T%_"7_A/R_P#R
M51[%?SK\?\@Y/-'L-%>/>5\9O^@OX2_\)^7_`.2:Q_$NN_&3PY#8R/J/A.;[
M;?1VH']A2KM+Y^;_`(^3G&.E'L5_.OQ_R%R>:/>:*\>\KXS?]!?PE_X3\O\`
M\DT>5\9O^@OX2_\`"?E_^2:/8K^=?C_D/D7='L-%>/>5\9O^@OX2_P#"?E_^
M2J!%\9L_\A?PE_X3\O\`\DT>Q7\Z_'_(.3S1[#17S9KGQ+^*WASP>?$.J7WA
M947<PLVT256E5)UC8!Q<,`<-N&17TBARH)ZD5,Z3BD[W3_K]12A9)CJ***R(
M"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*
M***`"BBB@`HHHH`****`"BBN=\2>/M#\*S_9M9U"WM;MX?,CCF+*K9W;07`(
M4L58*#RQ!P#0!T5%065P;NS@G=/+::)7*9)VDC..0/Y"IZ`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"HI+J&%PDLJ(QZ`MBI:P[_3KJ
M2\+0L_EL^YE7[LHP/E;D8`QZ'@T`;E<?\5U=_`]\L#M'*SPB-TD"%&,R88$D
M#(/."1GIWJ3Q#8WMA8:?Y&LZDCMJ%I$Y7R^5:558?<Z$$BF?$:!8?"US+<.U
MR(EC$=M.\2Q32[U\LN61@/GVGICCI2>P(@^$5A<:?X-MUU'SA>2MON%EG$Q1
M]JKMW@X;`4#/'2N1^(NE'6/C[X%@6^O[#;HNHN9+*;RW8":V^4G^Z>]=7\,4
MEO/"6)M0=[@S'S9+>*WC6,G#@((T"XVLO)!..IS7F_QE\':IXH^*WAC1]"\4
MZKX?U"\T&_\`)U:!5::VVSVI(4+MX8<'G\:Z*'QOT?Y,NEN_1_D>G^(_"")X
M>U1O[8\0';93'!U%O[AJ*3PA=GPPK:'J^KG4#9K]F^TZG(L0?:,%MH)P.O`Y
MJ3QYJMUX3\"A3#<:R[0?8[B4,J2-F)E,V"0"=P!(SW..E3^)W:/P'&T=Q-;,
M([;$D,PB?[R<*QX!/3GCGFL"#)T+P9XC6_?_`(277;A[3R5"+97\P<287<26
M&"I.[`XQQU[=#_PAJ?\`08\0_P#@Q:KWAJ">VT"PBOVD>Y2W42M(VYBV.<GN
M:TZ&!Y+X]\'J/&'@;_B<^(P/[2EX&I-@_N^_%=E>^"Y)+.=;#7-=BN6C80R2
M7[,J/CY21W`..*S/'_\`R-_@;_L)2_\`HNNY?[C<XXZ^E#`\TT;P7XR&HV_]
MN:\'L//;SOLVH3B0Q>5@8RN,F3+'T7C)J?XD^#E_X036L:UXB7-J1E=1;(Y'
MM6K\,[B\N]*N9K^\NKY&GQ#+<,K$@#G:0`"N[(!Z\<XJW\2O^1$UK_KV/\Q0
M!G>$O!R'PIHI_MCQ#SI\'_,1;_GFM9&I>#/&*M?)H^O%U8R&REN=0G4QYQL5
MU53G;R2V><XP*[?PA_R*>B_]@ZW_`/1:UA:N+F7X@Z6MI=7(C6`/-;I<`1[`
MS99DZG)V@$>ASVHZC1HQ>#AY2>;K'B#?@;L:BV,_E7$_"?P>K:?XCSK/B(E?
M$^I#)U%LG]\?:O6:X;X3?\>'B3_L:=2_]'F@1'K?@O7EO8G\/:Y>O:F/;+#=
MZC*K!]X^<,H.0%W#;@9)!R,5:T#P;J8L&_X2;6M3-X9I"/L6HR>6(]QV#Y@#
MD+C/O5GXC-*N@I]FN+BVE-U&$-O.(G<\X4$\<^AZUOZ5')%IMJER2TJ0HLA)
MR2P49_6A#9YE%X03_A<DB_VSXB_Y`!_YB+<?OD]JZ?6_!=^UD/[`UW5XKI9$
M/^DWSLCH"-R\<@D9`/..N#5:/_DM$G_8OG_T<E=R>AH8CSOPSX,\4+<`>,-=
MF>(6JC_B7ZA,"9]QW'YA]W;M`]P>.:S?BGX.467A_&M>(Q_Q/[7.W4F'][VK
MI_AHMR=*N9;NYN;N.2<B&2>X$V0!R5(_AW9P.OK4/Q4_X\O#_P#V'[7^3T`:
MO_"&I_T&/$/_`(,6JMJ/@^=;*8Z7JVM/=[#Y(GU1U3?VW$`G'T%=510!YUX=
M\%^*%ND_X2K79)+?[.H86-].&,V!N;+#&TG/&!C]!TG_``AJ?]!CQ#_X,6KH
M:*`/FCXN>%XX?@P;W^T]:E:W68K%+?%XVS=H/F&.:^E8_N+]!7RQ\9_!VK2>
M#W\2)XHU&/1TTY[9O#P3_1WD%Y_K<[L9.]3]W/R#G&17U.GW%^@K:7\&/J_R
MB:/^&O5_H.HHHK$S"BBB@`K.BU^PGU<:9!<1RWC6[7&Q#NPBLJDDCIRPXJ^Y
MPIKS3X?7U[JGCS6'N=+BT>UL;,1QHEC]G-VSRM\Y(+*VT1]F/^L&0*%N!Z;1
M110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%
M%`!1110`5XU\7-&EU#Q6D]O#K%N]G90W,4]I:WDZ7D\;RF./]P0$9,D[CD_O
M!@<5[+7EWQ'\;^)=!\4VUGX;MWEMC'`9-NG&Z7$AE\QVVN&!18U95'WOFR<`
MX75#1Z'H<TESHUA-/#/;2RVT;O#.VZ2-BH)5CW8'@GUJ]5;3+@7FG6LZR><)
MH4<2;0N\%0<X'3/6K-4]R5L%%%%(84444`%%%%`!1110`4444`%%%%`!1110
M`4444`%%%%`!1110!A>+_P#CST__`+"UG_Z.6CQ=+$^EM92:;#J\EZ"J6D\8
M:)L<EI,@@(.#Z]`.<4>+O^//3_\`L*V?_HY:V+H?Z-+_`+C?RJ9)M:%TVE--
MJYSG@&:WCT:*TATJUT:6.))9+>SA\N!]XR'CP,$'\QC![9Y'Q;_R</X'_P"P
M#J?_`*-MJ]%\.C_B0:8>_P!CB_\`0!7G?BP$_M#^!\`G_B0:G_Z-MJUP=^KO
MH_R9O4Y?;SY59:Z?)G7?$;PY9^)?"E[#J:LT=K&]P@7'WU1L=0?7ZTGB'0G\
M2^!5T^`*9)H8"N6QC:5;/((SQT/![UK>)N?#FJX_Y\9O_0#4^DC&EV8/7[/'
M_P"@BH.431H)[;2K2&^$0N(H5641?=W`<XX''X5<HK-UB^GMQ!;Z<J->7CE(
MS(,K&H&6=AW`';N2!QG-`'+>/_\`D;_`W_82E_\`1==TPW*1ZBOE[]I'6]<\
M+?$7P=;Z=KNI`2Z9=7+'*`+,+RQB#J`N%(2:1?HQKZ(#W>B7D"7%Q)>V%U((
ME>4#S('/W<D`;E)XY&02.3G@`H?#[P_?^&M*GM-5>"3_`$AGA:-%4[3S\VT`
M'G."><8SS3_B5_R(FM?]>Q_F*Z:N;^(XW>!]8&,_Z/\`U%`%WPA_R*>B_P#8
M.M__`$6M9>I>&;J?QWIVM6HA\JWMC!,7(SM)8\`C@Y(P0?7/:N7^`>HZKJWP
M@T+4[J]GOKK_`$I'CFP1(D=S*B*"`,$(J@?09KU"&5;B&.6/.V10RY&.",T`
M/KAOA-_QX>)/^QIU+_T>:[FO$?A!>W]W\1_B!IJW]Q#9V=TUQ!"`I199+V\5
MVP1SD1H#S_#0!Z3X_P##LWB?0A:6@0RI<1S+N(`!4Y[@@_0UO6*21VD2W`42
MJBAPGW=V.<>V:987$D\;K=*J3POLD"_=)P#D>Q!!_&K5`'"Q_P#):)/^Q?/_
M`*.2NY(R"/6O%O&NH7MK^T;X(L[*[N+6#58;F&[$1`\Z-;::15.0>`\:-_P&
MO7+:6>"Z-K=MYH92\,V,%@,9#`<9&1SW_"A@8OP^\-W7A;2)K*\$03[0SQ!"
M"<-R<D`9YS@GG&,U1^*G_'EX?_[#]K_)Z[:N)^*G_'EX?_[#]K_)Z`.VKD/B
M2;HZ99)IMU=6UQ+=;(Q;3B-Y"8W`7GJ,X)'7`XYKKZY;Q_X?O_$%C8+HS6XN
M+.\6?$Z*Z,`K#!#`@C)'N!DCGB@$=):JRV\:N2S*H!).<FL/Q]J,NE>$=2NK
M>X6T>.(9G,HC\I2P#,&.0&`)QD8SBMZ(,L2B3&X#G'3-0ZEIMMJ]E+::C$)K
M:==LD9)`8>G%)@CP+XFMN_9R1EEDG!M21+(X9G_TJ/YB1P2>N1Q7T(GW%^@K
MP+XN1)!\`)8X5"1QQR*JCH`+Q`!7OL?W%^@K>7\&/J_RB:/^&O5_H.HHHK$S
M"BBB@!K_`'3SCBO-_ACX;TW0?$VO2V'B*WU>ZOPDTEJ@&8$9BRD-GYE(([<<
M>HKTA_N&O,?A1;2Q>(M=-S9S6:IA+6&1%(BBWMT8=`Q&=H`48'4T+<'L>H44
M44`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!111
M0`4444`%>3^.M'BU?X@2?Z/XO$MGI]O*)]%,!1BWVF,!A*/O!9).A_C]A7K%
M>-?&+1X/%/BJQTVZ;0O(BMU,\-Y:2F:Y+":14$R'*Q[8)25&"3@9P<%,:/5M
M#LX=+T33[.V66."TM8X8DF(WJJJ``V.,X'/O5X,#T(K@_&6I6DGPD>_6XT.P
MM)=.ADBGU:V:2SA5@I4O&"&(&1A<]<5D?`FUMK#1-733[2.(+?XFNE@DA-Y+
MY:EG*.<J,,N`%5<'@53W=Q+9'JE%<EX,^(5EXI18+E[2TU?,F^QBNA/A58C*
MR`!7XP3MSC-=;2`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBJ>JWD
MNGV;7%O;279B(+Q1'YRG\14=R!SCOC%)NRN.,7)I(P-.\-KJT,MU=:GKBR27
M4X*Q:E+&BA974`*#@``"K7_"%0?]!3Q#_P"#:;_XJJO@KQ!'K,#)I*&XLXY[
MDRW8.$5S,Y"`8Y;!R?[O`//`ZNL*4*<X)VN>CBJ^)HUI0;:L]NW^1XOX_P!+
M-AX]\+Z;'JWB@6U_/$9%_M!WC9A,-N26RK#!(QZ#WKT5O!%NRE6U3Q"01@_\
M3:;_`.*J7Q>!]DT\XY_M:S_]'+6]6GLH6V.?Z[B/YV<K#\.[*")(H-3\2I'&
MH5%76[@!0.`!\U>3?$+X:6&L?&WP;IESJOB=(IM&U"4S1:U,)5*R6X`5R20/
MF.0.N!Z5]!UY3XM_Y.'\#_\`8!U/_P!&VU:X>A2YW[O1_DS6&/Q4FTZCV?7R
M*/B']GK18M!U.0>(?';%+.8A6\1SD'Y&ZC//6I=+_9WT5]*L]WB/Q[DVR9(\
M23C^$^A_VOT'H*ZOXN>*?^$4\%W4X^S>9>G[)&;F0QQ@NK=6`)!P#CCDX'&<
MTS0M2U,^+(+)KIFTX6$;BW^S@;/W2\^9WRQ/'7CTK/V<>QA]:K_S,PF_9VT1
MMV?$?CT;L]/$L_&<].??]!Z"L;P'X43P=\>=0TFSU/7K^Q@\,+<QC4]1DNBL
MDEQAB"WLHKVVO"O%7C:T^'_[0EYJ.L6&M75M=^%H;:-M.T^2Z(<7#,00@X`&
M.?<>M3*,8M,VHU*M92@W?3;YH](\9?"[P]X]U+3;_P`26GGW.E@I`X(&4,L4
MI0\?=+PQGC'W:V_$.A6_B72)M.OI+B*&<H6>WE,;@JX<88=.5%>;O^TMX9C5
MFDTCQJJH,LS>'+@`#USM]_YU?M/V@?#%]]A^S0ZTXU*W-Q:D6!Q)&-N2.?\`
M;7\ZM3BW9,YIT*M-7E%I&E_PJ+3/^@IXB_\`!DW^%-?X/:3*NV;4->E3()22
M_+J<'(R",'\:DM?B[H]W=V]O'::RKW,R0H6LB`&9@HR<\#)Y/:MSQ?XPTSP-
MHK:IXBF,%HLT<((&2SR.%51]2:HR)?"GA?3_``7X?M-&T"'R+"R#")"<G+,6
M8GW+,3^-<Y_PJ'2\L5U/Q$H9BV!J38&3GT]ZZ+PIXIT[QKX?L]:\/3BYT^^5
MC#(.^UBK#ZAE(_"N:/QDT4,RBSUL[6*Y^PD9P<>OM0`__A46F?\`04\1?^#)
MO\*T/!WPVT7P->ZC>:)'.;K51&+J:>3>SA"Y'8=Y')/4EN:Q+#XY^'M2M_/L
M[;6WCWO'G[`1\R,58=>Q!%6/^%R:+_SYZW_X`G_&@#2U_P"'=AXAU5[^ZO=8
MMYI(U1DM;TQIA<X.WUY_E5#_`(5%IG_04\1?^#)O\*9_PN31?^?/6_\`P!/^
M-'_"Y-%_Y\];_P#`$_XT`3Z5\(]"TKQ#8:UNO[S4-,:1K66[G\TQ%XS&Q!QG
M[C$=<<FMGQ1X1M/%:6JWUQJ%M]D=G1K.Y,1)(P0<=17/_P#"Y-%_Y\];_P#`
M$_XT?\+DT7_GSUO_`,`3_C0`_P#X5%IG_04\1?\`@R;_``K)U_X5M8OI=SX<
MDU349[?4H9)HKR^#*L0)W,-V!N''3G!-=SX8\36?BW2EU#2A,+=G9!YJ[3E3
M]3Q6/\4?B#%\,_"LFLSVT-V%E$:QS7T=I'DJS9:63Y5&%/U)`H`Z6VOX[F1H
M]LD4R#+12##`>ON/<59KYTT']JZR\2>)-,M9M(TB'=*P+V7BFVO9MI4Y"PH`
MSYP.!Z9[5Z?_`,+DT7_GSUO_`,`3_C0!WE%<'_PN31?^?/6__`$_XT?\+DT7
M_GSUO_P!/^-`'G_QB_Y()<?[DO\`Z6)7O4?W%^@KY6^)7Q/TK6_@HUI:6NKI
M).TD:F:R**#]L3J<\#BOJF/[B_05M+^#'U?Y1-'_``UZO]!U%%%8F84444`-
MD&4->5_!RVM9-4U6>T49LC)9;FN4D?Y9.0=KMD`!0#[>NZO4Y>8VZ].U>2?!
MS2KRP\07S7\6HHC6A,7GZ:UL$!=1LD8HN^3Y`?E+#YF.>:%N#V/7J***`"BB
MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****
M`"O-_B%X-GUS7);H^&=,\0QS::+:U>4PQR6<^Y\NS2*25PXQC.,-\IW5Z17!
M_$CXB-X-5XHO[+>1[1I5CDO9%N>XW+#'$[%1_>X&:3&C4U?5$\$^!89=9@BO
MC96L,$L%M&$6=SM3;&AXY8X"_0"LGX:V"A]5O]/T2#0M$U=;>XM((9(F69BK
M>9+B,E1N!C'8G;TJSKL5M%\/-.A\<17NHRA+*.5+61DGFN]R!-C!E(8RX.<C
MWI/A8VAS:#N\&VNLVVDG:L(U&29@<#!$?FLQVJ?E./E)'&>M-ZMBZ#?"7A#3
MK;6#J.G13_V9:PJFD1SS3_Z(Q+K,$BD.(U("`8'3('%=Q7&>'(?"D?BJ]MM!
MA9=7L`WVC+RD*"0#]XD'J*?XQ^)5EX4NK:Q2WFO=2N;RVMTM=P@++,ZIO1GP
MKA=W(4D\4=@.PHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*S]?U==!T>
MZU"6*:=+5-[1Q+EB,_TZGT`-:%87CB.*3PGJ@NI%AB6W9VD:81!-OS;BQ(``
MQGDX]:3!"^$]?'B"SN)4L)]/6&X**DJ@>8"`^\8]=W([$$=JW*XKX47+ZCX=
MN-0N'FEGU"\>62:5DS-@*H8*I(4%5&!QZD9-:FK>)FT[4(K81Y,K[(^,[CD`
M]_<=.W-/R"]R3Q?_`,>>G_\`86L__1RUNUQOBOQ-8MI^F/FY^?5;+I:2G'[Y
M>ORUU']I0>=%%F3?,H9/W38Q[G&!^-`%JO*?%O\`R</X'_[`.I_^C;:O2AJU
ML8I9`9=D+;7_`'#Y!]AC)_"O!OC1\4-(^'OQ9\)^)-8M]5NM.L-#U!9Q9V9>
M1=\UL%.UBN1GJ>U;4/B?H_R9I3>K]'^1ZQ\4/#A\2^$;J%;N>S^RAKDM$2"^
MQ&^4X(R#[^@/:J/AK1=3L_&<NH[,Z7?Z;;J27(VND:@$#=@YY&-N>,Y[5DZY
M\8K"]\(:A<6^@^*S'/ILDB9TL@D-$2.-W7FKFC_%JS;2;%AH'BK!MHR/^)9_
MLC_:K$S._NKN.SC#S$_,=J*HRSMZ`=S7+Z?I&HM\1;K6)[58-/ETI;>-FF!<
MR;P<%1T&!US7FWQ$_:0@\':MI[QZ(F)8)-JZWJ2Z6P.1DH&5]XQ@$\8_&NA^
M#7QU3XM7U_:C3M.M&LH_,WV.LI?J1E1AMJ*5/S<>N#Z4`>B^(SCP]JF.OV*;
M_P!`-<'\)F)\+?#7J`?!W3_@-I7=^)/^1=U3_KRF_P#0#7EWP6UX7UGX(TQK
M6XAETWP;&WG,G[N97CM""I^H88]JS?\`$7H_T.F/^[2_Q1_*1Z=%JEAXA2\M
M=-O(II;5_+F,39,,@Y`/N",XKSOX^VNI:O\`#PP16$[W%G?V]S<-"-T:Q1L6
MDDSV`4$X//UJWX&U;3]+U7Q5<RWO^CIJ7E'S.")"QXVA>I)`!R<].*V_C!XB
MM/#?PF\5ZKJ0F^RPZ-<%A''N;YXRHX^K#.<`=20!6B.9[V.:_9[L=4TCX,>'
MM,N+&XL[W;<.SSJ`L:27$KHXY^;*,K`#U&<5ZI!"MO!'$F2L:A1DY.`,5@_#
MJ\CU'X?^&;JW$@BN-'M)$$B%6`,*D9!Z&NBH`P?!)+:`"Q)/VV\Y/_7S+6]6
M!X'_`.1?'_7[>?\`I3+6_0`4444`%%<M'\1M+E^)$O@E8M1_M>'2QJ32FT;[
M/Y1?9@2]-V3T_7@UU-`'#_!WGPB^?^?^X_\`0ZZS56L/LA36S:?9IF$96ZV[
M'8]%PW!)]*Y+X._\BB__`%_W'_H=+\5XTDL?#PD57`\06I&X9P</S0!J6>@Z
M-)J-O/HVDZ;`EJY<W45DB$M@@!&`SWY(],=S5CQ;XG_X1:RAN#9S7HED*%(G
M52H",Y;YCT`4_P`ZW*XGXIW+6VG:6S1136YU%/M*R9XC"L21A@>,9XZ`$]*`
M1V5O+YT$<A&-ZAL9SC-%Q<16L$DUU)'##$I9Y)&"J@'4DG@"B`@PH4P5(XQ6
M#\0;*[U#P?JEOI4,UQ=2PXBBB*AG(8''S?+@]P>",BDP/(_B[<+<?`":6&02
M1S12,KJV0X-VF"#W&*]\C^XOT%?)WQ4^)&EV7P[M_`=Q;ZE'KC:.+O=]E58%
M0W7W2RG`8>4W"C:.!GD5]8Q_<7Z"NB7\&/J_RB:/^&O5_H.HHHK`S"BBN-\9
M^)+_`$K44MM/-NL)LY9KB5[F.%H``=K?/D,/E8X`_A)SB@#LJRK#Q+8ZEKVJ
MZ/:/(U]HJP-=J8R%43*S)ANAX4].E.\,W$EWX;TJ>Y<R33V,+R.>K,4!)/XF
MN-\%C_B\OQ(..L&D=O\`IC+[5,G9HUIP4HR;Z+]4OU/1:***HR"BBB@`HHHH
M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"O+OBK
M#87FH7%MXBT2._@FTO;I]S;QC[0MP6?*LXD5D3[A'(4DMDC%>HUY!\4]-;6?
M%9@:*RN3'IR+9HU]]FDAG;SW+M^Z?S!MB)"DX&QLCFDQHZ;QI:7%]\,=FHPV
M$LXM[>2\6=TD1-I1I&1I#M+J`Q0L<;@I)K*^"MO9V>EZF?#D:KHS3H+02^0+
MC(7YQ((?E`SC;D!L$YXQ6YJ,=AJWPWL9/$E['!;-:VEPUW:)A5E78Z.BE3\N
M\*0I7&."*H_#VYM;_5O$+VU[<ZM(ZVQN-3F@$0G.UP(P@15&P`=,D[^3TIO1
ML2V1>\%>/=&\42;$;3K/6Y/,,UC'=1S2J%8C)9.#D`-CT(KD_&TVIR^-KJ.S
MM[B8VAMY8;:.\F\N9"!F21EG5;<`[ADQG.W/.<4SX=:1HNF>+_+TZ#3KF0>8
M\5Q:RW<7ED($R;>7<@;RP(PRMPH```XKIO&GP\\-WT>JZKK4EY8FYVO=W=K,
M5<*$5&7@$E&5$#+@@[0<`C-&UAZ'=#H*6FQNLL:O&0RL`01W%.H$%%%%`!11
M10`4444`%%%%`!1110`4444`%<_X^MOM?A#4H@MP^8P<6Z!WX8'A3P1QDCN,
MBN@KG/B)#+<>"M6BMEWR20;5&X+C)'/)`..N"0#C'>D]@1A_!FS>T\-76_SG
M1[TB*9T55G1(T174*J]0O.1][=UZUVL^FV]S(7E3);[V#@-]:Y'X1VUY;^&I
MCK<2V^IS73/>VZHJ+#)L4;0J':O`!P`.N>>I[BJ8&%XM&++3P.`-5L^!_P!=
MEK=K"\7_`/'GI_\`V%K/_P!'+6[2`*\J\6''[0_@?'_0`U/_`-&VU>JUY3XM
M_P"3A_`__8!U/_T;;5OA_B?H_P`F:4MWZ/\`([WQ??6]EX=OUNIHX6N+::*$
M.V-[^6QVCWP#^59NB>*7DU>VT9K&0(MI&RW?G*58^4K$;?O9&1^=5_BUX>N/
M$?@ZYALS8!K8FX?[;;F52J*Q(4`C#>AK/\,7B'X@307"`2#2[<6\AMSR/+4L
MHD!P>H.TC/.16!!UNK:?#)=0W<]G#>(B&.5'A$C*I.0RY'8]0.N?:C2]1T;[
M9)8:1+91W2QB>2VA`1PA.`Q7@XSQFM:N(M/^2Q7O_8#'_HU:!'3>)/\`D7=4
M_P"O*;_T`UY9\%_#\5A:>!]4CED:74_!L8DCS\J[([,<"O4_$G_(NZI_UY3?
M^@&O*?A4_B,>&/ASY5MHA4>$?W9:XE!V[;3K\G!Z?K6;_B+T?Z'3'_=I?XH_
ME(W(?A[:ZP=9CLM3EMVN[])Y#';`!2DC,`#G!R3U!ZKT!KJ/'\;)\.O$B1MM
M9=%N@K$9P?);GWKD8_$&H>&]7FL]-T:.>:ZOXX9C#'=-%%)*2=VXQ`!!DEB"
M1S6G\09?%`\`^)/]%T$_\2BZR/M<PX\IL_\`+.M%L<SW)/!>C:Z?!V@D>(S@
MZ9;?\PZ+_GDM;7]BZ[_T,9_\%T=2^!\_\(5X?SC/]EVV<?\`7):F\4ZW_P`(
MWX=U'4_*:<V-N\HC522Q`X'&3C/I0!S'@W1];?0LQ^(2H^VW?']G1?\`/S)4
M_B2#Q9I>FM+H5_)J]Z754MA:01#!8;F+,0``,GW.!5GX6WTFI^!["\G6))+J
M6YE=8B2@+7$A(4L`2.>X!]JZRA@<'X?B\;:C>7J:Y=KI=O$1]E<6\,S3#+9)
MQPO`''/7K6Y_8NN_]#&?_!=%57PMXEFUOQ'XAM)3^[TJY$,06/:,8ZDYR3G/
MM@"NJH![G/\`]BZ[_P!#&?\`P71T?V+KO_0QG_P71UT%%`'`_!**:'P3LNY_
MM,HO[C=+Y8CW?/\`W1P*7XPWL&FZ+H]W?2+#;6NMV\LTC=$15<LQ]@`34GP=
M_P"11?\`Z_[C_P!#J?XG6=U=Z?HS6%G<WIMM:MYI4MTWLD8W9;&>@R*`*_\`
MPO+P'_T,VG?FW^%0W7QF^'EZ@2\\0:3.@.0LBE@#Z\K7:V&J6NIJYLI-[1'$
MB,I1XSZ,I`(_$4W4]9L-%CCDU:Z@M$E?8C2N%#-@G`]\`T`<B/CCX"48'B;3
M@!_O?X4O_"\O`9/'B;3_`/Q[_"NX1E=0R8*L,@^M+@4`?+'Q+^*_A#7?@FUE
MI&OV5U=7&](HDW9=C>)@<CKP>M?4T?W%^@KP3XP@#X"7&T`?+*>!_P!/B5[W
M']Q?H*VE_!CZO\HFC_AKU?Z#J***Q,PKS/XH>!+WQ3K=E/8:7;WD+6S074[7
MSP21K\V`JA@K@[W!W`X#''6O3**!W,[P[:2V'A_3+:[4)/;6<,<B@YPRH`1G
MZBN>\->&K[3/B1XSUFZ2(6.M1:>MHRR`LQACD5\C''+#'K7944FKV*C-Q32Z
MZ?BG^@4444R`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`
MHHHH`****`"BBB@`KQ#XSZ/;WWQ!T$S2ZA#%-:.+R:UTZYD^SHHD"2>;&=I;
M]XZ>7C=AV.0.OM]<!X\\6:]I&O0V'AZ.W;S;(SPJ(%N99Y`Q!5D,T9CC`V_/
MAAR>F.3JAHUM8\.)J'@VQL-*U`:4E@+6:WNC!E8Q`R.NY"1\N$P02,`T_P`$
MVMSIWA^)+_7[?Q'#;QJD5Y#"$+*JX.XAVW-QDG(K$^*-VUS\,TFU&2VLY;F:
MQWDRH]NDC31\2,P*M#N.&)!RN>.:R?@9<Q:UI&J:Q;S6[IJDD6ZW@,"A&1"I
M8QP_*I;W^8J%)`Z4.^HELCK-*\;6^LWMD+*XMY+:_FVP?NY%<J;99U!R,!MK
M;CVP1WS65X@^&VIZ_P"(+N^D\17$5F[*]C;*C@V,O[H-(C!P"<1O@$8!E8G/
M0\OX7L/#^F_$K2K#PUX<L]%O[?SYKL#4(KB181"8QA$D8IR8QD@<#'M743:S
MK.K>*/$&@FWT"[MH)HF@@GU-H;C[.8HB7*(C''F%P"2/3TR+<9WX&*6D'3FE
MH$%%%%`!1110`4444`%%%%`!1110`4444`%87CF,2^$=5!A2?%L["-XI)02H
MR/EC^<X(!^7GCBMVJVI:=;:O83V6I0K<6MU&8YHFZ.I&"#[4GL-;G%_!F*\_
MX12:YU<2M<ZA>R7'VB3)-S&P7RI,GYB-@4?-SQ7>U0T;0['P]9"TT:W6VME.
M1&K$@?3)..G2K]4Q''>-O$5K;:MHVC3B9;J\OK6:!O+)1PLZ[ESV('/-=C7"
M>//#]Y<^(_#VKP:@\-K9WUO#-9X)$^Z9<'K@$'';M]*[ND`5XK\3M0U+3?CS
MX&ET'2&UFY.B:D#;B[2WPOFVWS;GX[#CWKVJO*?%O_)P_@?_`+`.I_\`HVVK
M?#_$_1_DS2GN_1_D6?$_B_QJ?#>K8^'[_P#'C-UU^W_N'VI=(\4>+_LEC.OP
MVQ(UH@,QURU#@;1A2<9__575^/-=L="\,WC:M<QVJ7<,EO$\APID:-B%SVS@
M]:R]#UO4CXHM],>2V.GBPCD6,1$2C]TOS%LX(+''3/'XU@9D7_"7^-/^B?O_
M`.#ZWK-\):CJ6I_%.^E\0:0=%N1H^T6QNTN,KYB8;<G'))&/;WKTRN(M/^2Q
M7O\`V`U_]&K0!V%]:K?65Q;.2JW$31L1U`8$?UKP";]FK4=&MTN4\;P00:7;
MR1P,VCR#R83@[<+<A>B*.`.G2O?-3G>UTV[FAP)(8'=,C(R%)%<KX"6Y\5>%
M=&U?Q+>27UQ-$)3$$6*$."<-L7J1C/).#R*!W=K'+V/PUT&(Z1I^K3:^=6OK
M-995COY50$`>8?O'`W'[N3U[UD^+?A;H^D2:]-:W.LN+71H)8X9M1>2(L990
M<H>""``1W%>A:K!ILWQ(TDS_`&AM3AL9)(@LZB,1[L$LAY)R>H]*X>YU&\O[
M;Q\NI3W$YM+588FGLV@8(+B8@<_?`S@,."`*$)GJ/@\`>$M$`&`-.M\#_MFM
M'BVTO;[PUJ5OHHA:^GMV2`3*"A8CC(/&/K1X0_Y%/1?^P=;_`/HM:UZ`.2^%
M27,?@73TU-$CNTEN1.B8PKBXDW`8XQG-=;6!X'_Y%\?]?MY_Z4RUOT`</X-U
MN\U#QIXHLKZ:1DT^51%&0"-C,VT@CIPI&/;)YKN*Y7PWH&K:=XJUV_U6>WEL
M[YA]C5&8NB@DX;/UX].E=50MD-[A1110(X;X._\`(HO_`-?]Q_Z'6YXQ\70>
M#-+CO+JSU#4&GN$MX+6QB5Y99'SM4!F51T/)(%8?P=_Y%%_^O^X_]#J#XR0W
M<^D:"FF7,=I.?$%KB62#S@H^?/RY&?SH`2T\6:AK7B72WC\$^+-*?S#%<7EX
MMHL0A*DD/LG9CA@I&%//U-7?B:T#6ND6]UO`O-0$*LL*R[2R,#\I([9Y'(/(
MK3_LKQ'_`-#!9?\`@I_^VUD>)O!>N>(-/6*[UZ%Q`_FHD.E*&9@"``6DP#SP
M>,'![4`=I"-L2@=ABL'X@W<MAX0U&YM9[FVE@C5UEMP"Z$,.@)&1Z^V:Y?1)
M/B5<W]G#K,>EV%I)`S7%PL*2F*3G"A1+DC&,GWKJ&T?Q"XP^O6+`]0=(_P#M
ME#`\<^)\S3_LZ++(S.\ELS,S)L+$W49)*]C[=J^@T^XOT%?,_P`9+/7+?X$R
M2/K%I)"'P\?]F!25-]&"`?,X//7%?3"?<7Z"MI/]U%>;_0MOW$O7]!U%%%8D
M!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%
M%%%`!1110`4444`%%%%`!7COQKMV35K(VNBW\MQJD/D+JUJLDYMVC$K(JQQ,
M)%<E]H<?+B5@V0,5[%7!^.OA)I_CW6K6]U:;,,2PK+"8%=L12&13%*?FA8L<
M,R<D`#C&:74:=BQJMG]B^&=I9R&?26AL;>':J2W+P,`@"8B*NYS\ORD9K-^#
MHO7\,R3ZN;TWL^QYK>ZL[JW,+[>4'VAV+?48%=1XD\)P^)-#M]+NKF\CB@N+
M:;S8YB)6\F17`W@@@DH`6!SS5K2_#]OI$4R6LVH2"8@L;F]EN"/H78D?A3?5
MB70\L^'EKI%EXOT@^&=.N])OI+.Z76-*3S4M[#<RN2%D7:295"DH>3R.*RO&
M6L67A_XE:Q>"7Q%9:G&[&W2WSY%V[06@5!F!A^\V[<!NL)Z9-=_X6^%%OX:U
M.POFU"XOKC3PZ1R21(K&/RQ&D9(YVJNYB/XG<N><4OB+X4P>(]9O[V\U*Z$-
MZ4=;;RT802!40R(QYW;$(7^X7=AR:.HSNQTI:0<"EH$%%%%`!1110`4444`%
M%%%`!1110`4444`%%%%`!1144ES%$X661$8]`S`&@#'\7_\`'GI__86L_P#T
M<M;M87B[_CST_P#["MG_`.CEK=H`*\I\6_\`)P_@?_L`ZG_Z-MJ]6KQ7XG?V
MS_POKP+_`,(M_9YNO[$U+=]MW;-OFVV<;><YQ6V'^)^C_)FE/=^C_(]`^)?A
MQ/$OA&\@DNKFT%JC7(:`*2Y16(4A@1M/Y^]9GAFUU"V\;33.MVVGWFFV^TG=
MY<;K&H/^SSZC!R#]:H>)_P#A8Q\-:L`/"@/V&?!)FX/EM5C2#\1O[)L=R^$\
M_9H\X,W7:*Q,SN;V[>)XX+15>XFR5W?=11U9O;D<=\UEV7A8VWBJ;7;B]EGG
MGLA:F'RU6-0&#;AWSP!R:\A^);?%L:M8_P#"/)>E_L[>;_PCK6>S&X8\S[7S
MGKC;QUSVKH?@B?B*;S4/^%FKK*V>S_1_[4-B7W_+C9]F[8WYW>V*`/3M<.-$
MU#/_`#ZR_P#H)KA/AQXQTG1?`VC66J7$UO=6]OMEB:UERIR3V6N[US_D"ZA_
MUZR_^@FO,_AY;^$)_!6COJ(T-M3-L!,7,+2DY/W]W_LU`&CK'B'0;_Q9IFIK
M(DGV)0!.T4RM&/FW`#R\\Y'0C/?H*R_%_C/2-7NO$%EIMQ-<7=SHELD42VDV
M7/G3=/EKHOL_AX?\L/"'E^ZV_F?E]W]:QO&T/@VV\*:I-;?V!%J*6Y,4FZ!)
M%.1]TK_2@#O?"'_(IZ+_`-@ZW_\`1:UKUD>$"#X2T0@@@Z=;X(_ZYK6O0!@>
M!_\`D7Q_U^WG_I3+6_6!X'_Y%\?]?MY_Z4RUOT`%%%%`#78(I9C@*,D^E8+>
M*5TP/-XE$.G64B&6"Z>3$83&=LA/W7QSZ'MR*=IVI7&OPW:AH;26%S%-:2Q%
MGB/;><CJ.01Q@\$U:724U70O[/\`$]I9WD<D?E7$+J)8IE'`)5AW`!P>E`'+
M_!:5;GP/'<1!_)N;N>2%F0KO0N<,,]C2?&&V-YHNCVZ336S3ZW;H)H6`DBRK
MC<I.<,.HXZUW4,*6\210(D<<:A41%P%`X``["N,^*G_'EX?_`.P_:_R>@"+_
M`(5=<?\`0[^./_`^+_XU3)/AI)#CSO'?C5,]-VHPC/\`Y"KOJXCXH6=O?V^D
M070BWRWVR)I%<JC%&&[*@X(SD9X]:+C1'_PJZX/3QQXX_P#`^+_XU1_PJZX_
MZ'?QQ_X'Q?\`QJNXB&(U'H*CO;VWTVSFNM0FCM[:W0O++(VU44=230(^<_CQ
M\+QX8^%]TL'BGQ;>V]J%D%M>WL<D;G[3$V&Q&"1D^M?2,?W%^@KR"ZT.7X_W
M"SZU#-:>!K.3=96[[HY-5D!XD?&"(@0"!U.,]>FWH_B*Y\`:A#HGC*Y+Z9-(
M(M,U29ONL>%@F;^]V5OXNG6MDN:"BMTW^G^15[QL>C44@Y%+6)(4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!7.:II-[-J:2V]Q<)"'W/%$JE9QC&UR>@[=.G3FNCHH`XSQ5I-\
MFG:8IUBY!35++I!$0?WR\?=KJ?LT_G1/]KEV(N'CV+B0^I.,C\*S/%__`!YZ
M?_V%K/\`]'+6[0!2%G<^5*IOYB[ME'\I,QCT`Q@_C7A7QD\'ZOXJ^*_A?1](
M\5:GH&H7F@W_`).K6D2^;;!9[4D*%V_>'!YKZ"KRGQ;_`,G#^!_^P#J?_HVV
MK?#_`!/T?Y,TI[OT?Y'3^-=6/A+P,5OUOM3W6IM)KF*$N^XQ,/-=1V+`9]-U
M4/#RW,GC4>5=7,EM%I\)EA^T@Q1DQ*%'E]0QY.>AX[UL_$/0+7Q#X5O8K\W"
MK:Q/<1F"X>%@ZHV,E2"1R<@\&L_P_P"&KJU\5#64$/V6]TZ&.3+9;*QJ`0,9
M'0]\8QWK`S.JO;225XYK1UCN(<A2PRK*>JM['`^F*R[+Q2UQXJFT*XLGAGAL
MA=><)5=&!8+M'?/(/(K?KB+3_DL5[_V`U_\`1JT`=??VOVZQN+8L4%Q$T>X#
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MB?#3Q3HNC6&GQ?$;5Y4L+:.!7?2K3<P10H)^3VJ[_P`(/XK_`.BA:I_X*K3_
M`.(K<\!^++;QSX1TS7-/97BOHB6VCA9%8I(H]@ZL/PK%F^*]O%/-&GAWQ;*(
MI7C\R/3,J^UB-RG=R#C(/<51)2TKX:>)M(L_LUO\1-89/-EER^EVA.7=G/\`
M!ZL:M_\`"#^*_P#HH6J?^"JT_P#B*BD^,5G$^V7P[XL0GH&TX`G\-]1I\;-,
MD+"'1/$TNQBC[+)6V,.2K8?AAW!Y%*Z%=%G_`(0?Q7_T4+5/_!5:?_$5SOBG
MP=\3A=V4'@_XC6\1D21ISJ>BPODC;M";`/5B<^WO70K\7+=U#)X:\7LK#((T
MS((_[ZK9T/7;?QO93NECJ^F/9SA1]M@\B4-M#!DY.1AL?F*8SSCP!\)/B+IO
MQ/7Q=\1?B0^L6T.GFS31+#3UM[64$D[W[[@>01S[XXKVJN&T;Q^VH?$_4/"4
M,D%TFE:;Y]U-Y1CD68LF$ZX*['!)`Z\5W-`!7!?&.]ATO0](OKYC%:6>MVTE
MQ-M)6)/F!9L=!DCGWKO:AN[2"_M9;:]BCGMYT*2Q2*&5U(P00>HH`?#-'<0I
M+;NDL4JAD=&W*RD9!!'48K!\7^%6\41V`BO);*6PN1/'+$2&#`$#H1ZYP>#C
M!KE?#OA?Q-\/=;.C^%U@U+PC>!WM6O+C#Z*_4IC[TD9_A`Y!ZD#D[?BWQ#/X
M#T.;6-9U>UDAMQS!+;!//;M'&0<ACVSN]3QDT`=/=WMOI5C-=:C-';VULA>:
M:1MJHHZDFO+$L+CX[78N-9BGM?`-M)FVLW!1]8<'B23N(@>@[_R=I\%[\;[J
MWU#6(+C3O!-LX>UT^7Y9-4D'.^7'2,'H.^,_3JKWQQ%X<\2Q:1JMJ+2SG6)+
M&9.CDD@C'0`$*,#H#0!NVTPTEX;&X`6`@1VLH4!<#I&<<!L=.QQZTNO^'[+Q
M)ILMEJMO%<02K@K(FX?YSSZC&1S5/Q?HMYXDT&2VT;4Y=,G<AEFBC20./[I#
M`C!]1R#@]JI^#]:U4V$4/B^S>QN3*\43LVX.5.`"?4CH>C?S:;3N@,70]<O/
M`FHQ:%XKEDFTV=Q'IFIRMDJ3]V&8^O\`=?\`BQ@\UZ&#GI7,>/K.SUGP]J6G
MWCVL2R6DGG7%R,Q6J%3\[\CCN!D'C((QD>>_";XESV\"6&N6U\GAMIQ;:#K=
MV>+E0,!7SR!D$([8W`<\YK5I35UO_6O_``![GM5%(#D<4M8B"BBB@`HHHH`*
M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB
M@`HHHH`PO%__`!YZ?_V%K/\`]'+6[7F?Q"U=K3X@^%K'[9>1I?30YM@`T,I6
M<$$YY##!Y'4#'K7IE`!7BOQ.TW4-4^/7@6+0]7DT6X&B:DQN([:.<D>;;?+M
M<8[CGVKVJO*?%O\`R</X'_[`.I_^C;:MJ'Q/T?Y,TI[OT?Y%KQ-X-\8'PWJV
M?B#=X-C-TT2U_N'_`&:ETGP;XR;3;`_\+#N@/LJ94:':X)VCGI]?SK8^*/B"
M?P[X4FEMK:"Z%T6MI5ENE@*J\;_,I;AF!Q\O<9]*R_#L"R^/-\-QN:#3H3-%
M]I/RYA4+^Z)X[G<!WQ[UB9EG_A#?&/\`T4&[_P#!):__`!-9GA'3-2TKXK:A
M%KVL2:W.VC!EG>UC@*KYB?+M08/.3GWKTVN'M&'_``N2]7(W?V$IQGG_`%JT
M`=1X@_Y`.I?]><O_`*`:\4^$L%PT'B,P0WKK_;<HW0QS%?\`5Q]TF0?I7M?B
M#_D`ZE_UYR_^@&O"?A?]F*^)/M'V/=_;<O\`K5MB?]7'_P`]'!_2N'&OX-.O
MZ,[\"G[^O3]47)X;G_A;T*F&]\S["I"^7/OQMDYQYV['_`L>U3?%**XCM/#S
M7$-ZB#Q#9Y,L<P4<MW>9Q^E9TWV7_A:T7_'EY7V-?X;;9G9)VW[,_CGVJ7XF
M"V^R^'C;FSW?\)!:?ZI;8-U;_GFY;]*\JDU:6GVOU1ZM5.\-?L_HSK?@)IFK
M:)\(="TN[LI+.['VF1I)64K&DMQ+(C#!.XE'4@>_.*]/MX%MH(X8L[(E"KGT
M%9G@_P#Y%+1/^P=;_P#HM:J:KI^MF\GN+76Y(+/(*V\5G$S1@`9^9@=W.3V]
M*^@J3<5=*_I;];'S,Y.*T5PUY8FU5//E>(?9&Y5<\;OF/MQWKB_""P$>*"\T
MBM_;-X``-P*_NSD^G(49]ZV=7T^[2Z#W&O7T[K;>82MK;(!%GGJ!G/H*P?!7
MAV]O9-34ZI/;)>7T\JO';Q/YN=N2P*_*3\IP/E]*X75;<H\NK]/\SD=35KEU
M?I_F>I:;_P`@ZU_ZXI_Z"*BN(IH+K[5:)YH=0DT6X`L!G#+GC(R>#U_"LN'P
M[J\$21IXEN]L:A1_H4'0?\!K;LH9;>UCCNIVN95&&F9`I<^N!P/PKLIRD]'%
MK[OT;.F$F]&K?=_F>/>#--O;3]HWQ1=7UI-:PZCI1EM3+C]Z@:!2P`)XW`CG
MTKV<G`)]*X>7_DMUK_V*TW_I5'7<-]T_2M30\XT?XI:]X@TF#4]&\!ZG<V5T
MA>"3^T[92Z@D9P6R.E=/X*\;6/C?3&N+$26]U;/Y5]8SC;-:2CJCC^1Z'\ZR
M/@C_`,DJ\.?]>I_]#:HO&W@J]35%\4^`6CMO$5LFV>!N(M3B'6*0>OHW4''X
M`'>UXE\5O`VM:Q\1=+U.]L+WQ1X?"".UTJVD2)+:X`^],6/^K8\LXYP`,=-W
MI?@GQM9>-M,:XLUDMKNV?RKZQFXEM)1U1A_(]"/Q`W4N(9)9(DEC:6''F(&!
M*9Z9';-`''Z1X<N?#5S9:CJ%ZUUJNH3K!?",E;<1E3LBACZ*D9`V\9/S$GYN
M.FUO1;;7=/FM+Y`Z2H5S@$K[C(ZUQ_C?Q+>^$?%>F:EKENLOA%8_+>Y@!+V-
MTQ*^;*.\94[01T);/45W<$T=S#'+;R)+%*H9'1MRL#R"#W%`'*:!>7>@7D.B
M7UD5A\N22*XA!,2*&_B;``SG..,=`,#-4CXWEUG4-6M9-/@MM"T^-A<ZC>R%
M%``!W[2`-HPPZYR`>AK8\;VUAJVC75CJTQAM53S;N7SC$D,:\EG(ZC_9/6O-
M].T>3XNB*22&YM?AWI;;K>VD)277Y$Z229Y$((X!^]_(`;X>TO4/C-<%]2,\
M/P[LKC?:"7*7/B!U/^LFZ8B!''][`Z=O6]6\.V&L:2VG7=M";0Q>4(M@"A<8
M"X'0<#ITP,8Q7.^$?%-YKU_"L.GP6>D+;.(_*F5O+D20IY>!@8P`1@8'(S7:
MT[M:@>;^'=7OOA[?1:%XPNI;O3)Y2FF:K-C,>3\L$Q]APK]\8/->C@Y&15#7
M-#M/$&G36>I0QS0S(5977((-</H.MZCX!U4:'XND\[19G6/2-3=B60D?ZF<]
M.O"OW'!YK5KVEVM_S]/\A[GI%%(#GI2UB(****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`,#Q?$AMM.<JI8
M:K9X8CD?OEK?K"\7_P#'GI__`&%K/_T<M;M`!7E/BP$_M#^!\#_F`:G_`.C;
M:O5J\5^)_A^/Q'\>?`MM-=WUFJZ)J3^99R^6Q_>VPP3@\<UOA_B?H_R9I3W?
MH_R/3O&VE6>K^%]2BU2TM[R.*VDEC2>(2!75&VL`>A'8UEZ!X7N+;Q&NMI+$
M(+O3X8I(\L68JB@''0'@\CMCCO6%XG^$EF?#6K!M=\3D&PG!'VX<_NV_V:SM
M%\':7)>VNB_VQXS%S'9Q-YIN!Y3#RPW#[<$\CCK6!F>D:O?PQW4-I<7L-DCH
M9)&:81LR@X"KDYY/4CICWJ33+;23.]SI*6+S[1&\\.UG*YR%+#G&><$UXU\1
M/V<(_&&K:>D.NP*L4$FUM<T6+5F9MPR$9BFP8Y(&<]>U=#\&O@8/A->W]TVI
M:;>O>Q[-MAH46FJ!E3E@C-O/R\9Z9/K0!Z/KXSH6I9_Y])?_`$`US'PETBTL
M?"K3VT(674+VXFN&)SO<2%,\]/E11QZ5U&NC.AZB/6TE_P#0#7F7@ZW\27?A
MJQN]$GDL].ND,T<?VQ'*%F);(-LQ`+9.,MC/6DTGN--K8]`?P=I;^*4\0M#)
M_:4=M]G5O-;9LY_@SMSR><9YK+^)^D6FH>%_,NH@S6-[;7$!!QMD$JJ#QUX8
M\5F_9/%.W)UV$>WVV//Y?9,UE>)[7Q1!H-W<ZE.U[8VRK+)$]\D8DVL&4<6H
M;&X#/3BI5."O9;E.I-VN]M#O_!__`"*6B?\`8.M__1:UCZSX3O;O4[N^EUS6
MHK:0J4MK*Z,(A0*`<#HQR"?QJI\*?&L'B3X>:#J,=K<VUH]O]G$DFT@-"QA8
MG!.`6C.">Q&<5OWGAV:[O)YTU?4X5F((ACE`2/``PHQ[9^I-9XBFIQ2:O\['
M/5AS*UKF;>QI8QPP/=7-XMO;"53)'`2L8XSEQR>*Y7P,[Z;/K<BR3J]Q>S7`
M:,0C]SQUW]#D_=7BNI\4Z==:;X;N)H;[?)91#R#-:12;#D#/(K(T#1;70[[7
M+2\U(Y74/.5I[:-R^^*-V<?+A5W,1Q@#%82IR6M[?UZF4H26NW]>IU'^F3K"
M++4;EVFC$@+PQ@(AZ$_+^E:UE'/#:HE[,)YAG=($V[N?3Z5AWVDN\D<K:OJ!
MDE4*BVP5=X'/10/7K[U=TZ672]+MX=1:>XNR6"J2'DD&XXR>G3&3G`K:G?GL
MT_O-87YM3G)?^2W6O_8K3?\`I5'7<-]T_2O+=#\3QZ_\>]0M%M9[:;1-!>VF
M\QE(<M-"X*D$\8;'/<5ZDPR#]*Z#4XCX(_\`)*O#G_7J?_0VKMS7%?"J"X\.
M^!-#TG7[6:POK>$QNDH!7=N8@!@2,X]Z[4]*`/)+NSOO$FHS^*O`MHVD>)--
MPDT$TJM%JT/)\N3:<=!\K=1QZ<6]+^R^/'_X23P7*=#\2VLBPZM:SH2P*\&.
M9.-V!G:W?VQQL?"J]CO-,OCL5+E;V3SP(&B+$]&()(.1_$O!IGC;P3>C4U\4
M>`WCM?$=JFV6%N(M3B'6*4>OHW8X]B`?4W/#_B'3O&^EW48C$BI)):WEK<1C
M*D9!5U/J.Q]:X*YEU+X(W<<,"RWO@:_GV+,V9'T%F)ZCJ\);``Z@G_OKI/">
MOZ9XJM[G7-%MY+/6;4>5JFGR*?-B=<DQN@[G'#@9.!Z$#G/%5YIGQ`\4>&M$
M\2:I-IL$]O\`;+OPO*OESSL6Q"97!^Z"IS&.<X/;A.2CN[%TZ52I?DBW97=M
M;)=?0AT[3+CXTWBSWB7%IX`M)]\,$F4EUZ53_K).XA!'`[X_+UF:&.#3WB@1
M(HHX2J*HVJ@`P``.@%<;X.\(:QX&\0W%AIMS'=^#;B-I;:&XE)GTZ;(_=)Q\
MT1R3R<KCOGGM[B/SH)(ST=2I_&FS,\0^#MI;VGB/20E]!JTTNB3.NH6^]$F!
MNI-R[74,<$]?]G/I7LEIKEI>ZC=V$3L+JS($D;J5)!`.Y<]1SU%</X9\'7'A
M.YM+R_ABFO8HGM1+",1A&D9E!=F+A1D#D'FF:_;2>(_%-BN@W3/K-AS->VYQ
M!9Q$Y*L/^6C'L">YZ9-,'N>E5GZWHEIK^GS6>IPQSPS(597&00>QI]G?AYVM
M+MHTO8TWE`WWTSC>HZXSQ['BKM";3N@/&O!'Q5T_1O$M[X3N]2.IV&F7/V5-
M3(.+.7)5;>9CC=RKJL@X)1E)##%>R`Y&16-?^#=&O[748'TVQ0:JQ:]*0*IN
M&P!ER!EC@#D\\5Q^D^(+CX;:A;:%XMN))M(NYA!I.I3$LT;'.V"9OH#M<]<8
M/-:M>TU2U_/S'N>E44@((R.:6L1!1110`4444`%%%%`!1110`4444`%%%%`!
M1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%
M%%`!1110`4444`%%%%`!1110`4444`%8.I^*(M.OX[:5@DDS[(5,+-YA&,Y(
MX4<_UK>JO+8Q3.S-O&_[X5R`WU%`'*^*_$UBVGZ:Y-R`^JV7_+I*<9F7_9KJ
M/[1@\Z*+,N^9=R?N6P1[G&!^-9GBT;;+3PO`&JV8P/\`KLM;M`%(:O;&*60&
M;9"VU_\`1WSGV&,G\*\)^,WQ.T7X??%7POXFUP7SZ=IFA7XF$-N1(2\]JJX#
ME1U/)R`*^@Z\+^+\$]U\=/A[!:7DUB9K"[222**.0LAN+4,I$BLN#]*WP_Q/
MT?Y,TI[OT?Y'9?%#Q)(WP]AO=)NI+&'5U0>>?+618GB9P`LGRDMA5(ZX8D<B
MD\,75O+X_FMY?+6Y@TNW>(>:P+*T:[FV$;2>`-P.<<&KOC'PA+J'AC48]2UF
M[NX8;621(Y[*T=594."`8>".Q[5RFE^$?'T5]'>)J6F2C[*%BN=D:2-D@+E?
M*(!$8"D]R."!Q6!!ZU=V<5[$$G!^5@RLIVLC#H01T-<QI^KZ@OQ%NM'GNA/8
M1:6MPBM$H<2;P,EAUX/3%7+/0]9:TA-]XBU!+@QKYRQP6Q4/CG!,/3.:YK0M
M/N;+XRZB;S4[O4-^A+M$\<2!/WJ]-B+U]Z!'>:K"]SI=Y%`-TDMNZ(,XR2I`
M%>;>&4\:^'O#]AI<>C1O#9PA`2Z*Y[\D2GN>U>J44`><7&I>*+:&2XG\,6W[
MI2[R!PTF`,G!$NX_05P.K_&?4M=TJ>PD\.>*DM;Q`KLOA6]D<*2#\N<9/UKZ
M$90RD,,@C!%8UWJ9\+Z7<SZI'-+8:?`\IN(EWL(D4DAE')(`[9S0!SGP2\)W
MGA#X5:+HVOQH+N))WGCQ]T2SR2!2/4+(`1Z@UGS>+_B'IT\MK8_#R*_MK9VC
M@NF\10QF=%+!7VE<C("G!Z;O:O0M/U2VU.PMKRTE5H+N%)HBWRDJP!&0>G!J
MQYT?_/1/^^A2:;ZEPDH[Q3];_HT>3:UXG^)&M:9/8R?#>*!+C"F1?$<#E1NS
MD+M&3@=,CK45[J?CPZWJ-S:_#Z>:"\9?+9O$<%NZIY:*495W`\H3G/0XKU[S
MH_\`GHG_`'T*/.C_`.>B?]]"HE3YMW^7^13G3>]-?^3?_)'C=WXG^+0N(VT;
MX>Z79Q)"L7ESZW%,0`>Q!7`P>G^S7<_#Z\\1ZG:37?C[18=&U3*PI%#=K.KQ
MA02X*_=RQ88R?N@UU?G1_P#/1/\`OH4>='_ST3_OH4H4N65[LAN'2*7SE^K:
M_`\:\,:5=Z-^TYXE:]2+[/JV@B\M)$?)9?,BC8,O8AD_$&O9R<`D]J\V=T;]
MH>WVE6/_``ATG(/_`$^)7I+?=/TJH-N]^YMB(1CR<JW29X;>?M,6=VD\47@K
MQ-<VSEE607%BOF+GA@#/D>HSR*ZRQ^.OA5+738]4OY;:_O(1^X>!F;S`FYUR
MH*DCGH<<<5=^"42?\*J\.?(O_'J>W^VU;&N1I_PDOAOY%XGN/X?^F#59SF)!
M\6O!MKN^RW*P[VW-Y=HR[CZG`ZU-_P`+F\*?\_\`)_X#O_A71:+K^E>(EF;1
M9XKI8'V2E4(V-SP<CKP:TO*3^XOY4`>`_%'4_"OB&0:]X6U.>R\06121A#YT
M"WRQL&$;E,<\8!/T/8B]\%_$-K\7K33?$L-K/<Q6TCBTNM3L&2ZM2&'FKN?!
M!)7:,#D$D'J![AY2?W%_*O#K+Q'XDLO'GB^\T_?J&D^'KJ..XL(U+2K'*&=I
M8QGYMI!R@Y()(Y`JX4/;7\M?Q1O1JU8*2@[75GZ;?\#YGNE<?XY\=7'@6^TV
MYU#36F\-3EH]1U&)RSV+D@1LT8',9Y!;/''%;V@:_9^)--AO=+FCGAF0.K(V
M00>A!]*O7%M%>6\D%W&DT,R%)(Y%#*ZD8((/45+5G9F!Q_B'7#XI\S0?"SQ7
M(NX<7MZK;HK:%QV(ZN0>`#[UE^'-0M/#FJ0^%?`5A%+9Z9&\-ZWW6CG"J5WY
MP=N#DL,]@*VM(T&+X>6*Z7X4TK?87$Y,"QM_J'<DL96)SL')!Y('RXZ5T&FZ
M6ECYDKD2W=P09YRH!<CH/91T`[4@#3]+2S=YY2)KV<#SK@KAFQT4>BC)P/ZD
MFKU%%`!5#6M$M-?T^6SU*&.:&9"K*ZY!![&K]%"=M4!YSH^M7?P\OXM&\532
M3:-*P33M2E.3`3]V&9O_`$%SUZ'FO10<@$=ZSM?\/V/B;2[C3]8MXKFUN4*2
M1RKN5E/8CTKB]'UF[^'FH1:+XGE>;19W$>FZE*V3`3]V&9O3LK]^AYK9I5%=
M;CW/1J*0'(R.E+6(@HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`,+Q?_`,>>G_\`86L__1RUNUQ_C7Q!;6^J:/H\RSK<
MW=]:S0N(B8V"SKN7<.A`YYKL*`"O$_BCX5TOQ=\>?`EGXAMC=6R:+J,JH)GC
MPXEML'*$'N>]>V5Y3XM_Y.'\#_\`8!U/_P!&VU;8?XGZ/\F:4]WZ/\C8F^!/
M@BXADBGTB:2*52CHVIW1#*1@@_O/2EC^!G@J*-4CTFX5$4*H&J77`'3_`):T
MW1M)L[K0KC5=<U/5(5CN+III/[0>-(T25QGK@`*!^57]/\/Z)JR@Z9K.I70*
M*_[K5G;Y6`()`/&00:Q,SSKXJ_#3PSX>L+1--T](Q?B:*02ZO=I)PF5:,^9]
MX'MWR*[G_A1W@K_H$2YR3N_M*YSSCOYF>P_*LVU\#Z3XB\+ZF/$]_JYM!<7,
M<LC:I(OEQHY&=V>,`=:V=(\/Z!J<4:Z/K6I7*&)9$$>KR.=A`(;[V<$$=?6@
M"'_A1_@S_H%7'_@TNO\`XY1_PH_P9_T"KC_P:77_`,<J+P[X:MIX-8EU#4]:
M\NSU*XC#-J4@"1H1COT`J[I>BZ#K:HVDZYJ%V)(Q*OE:L[$H>C8SG'O0!J^%
M_!&C>#!<CPY:R6WVS:9M]U+-NVYQ]]FQ]X]*\<\<SRZ[\8=*T_4Y$N;:*>>V
MVQ32P?N'-N3%,`-KH3D<9SNP2!7<_#F6XA^('CG39+V^N;.P:R^S1W-PTHBW
M+)NQGIG`S]!6C\4?!^C:QX?U/6=3TZWN-4TC2+S[#=.#OMR8RV4/8[D4YZC'
M%'4!/^%(>!!T\,::/^`M_C1_PI#P)_T+.F_]\M_C6;X`\+:/>_#S1-2UE;F2
M633HY;B9KZ89^7)8X>M+2=&\&:XR)I4K7$DD(F6,:A.'\L]&*EP0/J*`#_A2
M'@3_`*%G3?\`OEO\:/\`A2'@3_H6=-_[Y;_&J_A/P9HUSHT\U]%=.8[^\3<U
M_/PB7$BJ/O\`90!^%3Z7H_@S6FA73)6FDN(S)%']ON%=D!(W;2X.,@\XHN`O
M_"D/`G_0LZ;_`-\M_C1_PI#P)_T+.F_]\M_C4'A[P9I%U=:XMU#=.MMJ+1Q`
MWT_RH$0X^_ZDU+I>E>"]9>*/39FFDG#&./\`M"X5G"D@D*7!QD'GIQ0!S6@>
M%-'\'_'Q+7PUI\&G0W'A&262.$'#-]L09.3UQ7KS?=/TKQ[0M,MM&_:0N[73
MU=(1X2#A7F:0@FY3/WF)KV*LZ?7U.K%?8_PK]3A_@C_R2KPY_P!>I_\`0VK)
MNI[63XY6D8NY);V*U/\`H[%PL,9A8\#.SDX.<;NHS@5UB6NDZ#;"#0)['3C:
M`JEJDRI%UR4*9P.<],$9J+4'ANM?\+W<"I_I+S-O`&6!MV(Y[]:T.4H_#!XK
MK3+N[A=V,UTRE6E20)MX"@J>@]\'UKM:R=!\,6'AP7(TN-H_M<OFRY;.6_SW
MZGN36M0`5Y9\*R#\2?B8,]+ZT_\`1;UZG7EOPK_Y*3\2_P#K^M/_`$6];T?@
MJ>G_`+<C2'PR]/U18U_P[?\`@+6)O$7@Y))M)F)DU71X4R58G+7$`]?[T8^]
M]X?-U[?P_P"(+/Q)IL-]I<T<T,Z!E9&R"#W!]/\`/6M(C->-_%?X?ZSINFZC
M=_#J]O--L]3;?JUO8EO-@YR\]NJD'+8PZ*5+`DJ0PY$_:Z/XOS]?T)W]3V6B
ML+P5JEOJGAG3GL]1?50EK&K7DA!>X(4`R-@`98@DX`YSP.E;M8M-.S)"BBBD
M`4444`%4-:T6UU[3YK/488YH9D*,KKD$'L:OT4)VU0'FN@:G=_#2ZM]!\37%
MQ=Z(["+3=4N7+O"3]V&9CU'97/7H>:])!R,BN-^+/B#2O#O@R^GUNT_M)Y8V
MBM-.4`R7TQ'RPH.Y)Q].M9?P@GU_3_!UL?&RR0RR.[QV<J'S;"WW8B5F/S.-
MHR2P#+G!'!K634ES=?S_`*ZC;1Z/12`@@$$$'H12UD(****`"BBB@`HHHH`*
M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**0$'H12T`%%%
M%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`<)X\\.W5UXD\/:S
M#J#PV]E>V\,MGM)$VZ9><YP"#M[=OI7=UA>+_P#CST__`+"UG_Z.6MV@`KRG
MQ9_R</X'_P"P!J?_`*-MJ]6KRGQ9_P`G#^!_^P!J?_HVVK?#_$_1_DS2EN_1
M_D='H44L_@6\2VCN))6FO=B6SJDC'SI,!2WR@_7BJO@/PSJ&E>*=;U/44NHH
MM4M[4)%.Z.8V2/##<O4YZ]JK^'-`MU\/SW][KFMV4"7=V\I34#'%$HG?)Z8`
MK9LO#%KJ$$<UCXCU^>*5`Z/'JA8,I&0>G0BL#/H1^'HWF\*ZJD"SO(UW>A5@
M=5D)WM@*6X!]">*S_!/AC4;#QC?:QJ$=W#%?:7;0^3</&[(Z`9RR]3USQCCW
M%0>%?#$*:+>W%UKNOV\,%[=&1SJ15559&RQ./Q)K9L/#=GJ=O%/I_B77KB&9
M`\;QZH6#*>01QT/%%M0Z$GAM&ET_Q&B"0LVJW841L`Q/'0G@'TSQ6-X)\+ZC
M9>,9M9U".]@BN=&AMC#=21R,CJP/+)P6ZYP,<4WPOX4C\C6Y)M;U^%(-5N0S
M#4"HP",L>/S-:VG^';+5K:*XTSQ-KUU!,F^.2+5-P9?48'2CJ!B^`/\`DJOQ
M$_WK#_T"6NJ^('_(A^)/^P1=?^B6KC/A?8_V=\2_B%`+BZN=K6/[RYE\QS\D
MO>NU\=C/@CQ"#_T"KK_T4U`&1\.(WE^$V@I$KL[:3&%"2;&)V=F_A/OVJIX3
M\):C9>+QK6HQ74`ETB*U>&6^%SL=6!Y;`+'KDXYJ'P7X,T=O!.EW-R+M%%H&
M?;>RHJ@>P;``%:.E>'O#&MPQ2Z5=W%RDR"1-FIRY*GOC=G%'4.A>\'HS>'KM
M5#9;4M0`"MM/_'S+T/;ZUA>&O"&I6_C"PUJ_CN[=8M):TDAFOQ=88R%@2^`6
M;&.<4>$/!.DOHEQ+/]N`34;T$B_E``6YD'][T%7M+\/^%]:AAETNZN+F.=2T
M134YLLH)&0-V<<&CJ!I>%U)N_$8P>=4?V_Y91USOA_P?J:>,=+UF_BO+9+2P
MGMGBGU`76=TC,"S8!)QCZ9QVI_AKP/I4EYK_`)@OL1:FRC%]*./+0\_-[U<T
MO0O"NM1I)I=Y/<I*6"%-3FRVTD'`W9Z@\^U'4#GK8D?M.78['P>#U_Z>4KU8
M\BO'=!TJ#1OVD;RWL3*(?^$2#;9)6D.3<ISEB37L1.`3Z5G3Z^IU8K:'^%?J
M?+EU^R9J\#7,C:UX?EC\R24S3V]T&8%BVY\2XSSS[UW@^$;VUSX)B?Q7XRM6
MA1T:&VU3;%'BV(V(I4D*,<`\@#%=O\/]2NO''@W2-8U]X]][%YKVT";(LAB!
MG))(X!P3BJVI:EJ,WQ1TFREAACTRV21XGVL9)9&A;)W?=V@9&.N>>E:'*-7X
M6AON^,_'+?36`?\`V2G?\*J/_0X^.O\`P;C_`.(H^%EI!#9ZA-9/$T,UT0`C
ML2-N<[@W*DDGY>@[5W5`,X7_`(54?^AQ\=?^#<?_`!%<M\#M(.A^.?B3:?;M
M1U';J%H?/OY_.E.8VX+8'%>QUY;\*_\`DI/Q+_Z_K3_T6];TO@J>GZHN"TEZ
M?JCU*D/-+16!!YKXET.]^']_/XC\&VTUUI\KF75='MUW-DGYIX%_O=W3^+&1
M\PY[?P_XAL_$NF0WNES1S0S(&4HV00>X]O\`/7-:=>;^(?#]YX#U*?Q%X.A>
M73YG,NK:5$N2#_%/`O\`>[LG\6,CYASLFJBL_B_/R?Z,KXM]STBBLGPSXEL/
M%FD6VHZ-<1W%M<QB2-T;(93T(]O_`-74&M:LFFG9DA1112`*Y_QMXVT[P)HS
M7^KL[L["*UM8ANENI3]V.->Y)_*D\;^-].\!Z,U_JS.[NPBM;6$;I;N4_=CC
M7N2?RKF?!'@C4=4UE?&'Q)5'UQU(T[3@=T6D1'^%?64C[S?@*`)/!7@W4=4U
M9?%OQ%1#K<BD6&GAMT6E1'HJ^LA_B;UKN[NU%R@PQCE3F.0=5/\`4>HJQ10!
MC6MTVG.T4Z[(DY=!SY0_O+ZQ_P#H/TZ;`(8`@@@]"*@N[1;I5()26,YCD`Y4
M_P!1ZCO6=:W3:>[13KLB3ET'(B']Y?6,_P#COTH`V:*0$,`000>A%+0`4444
M`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%-?[M.IK#(H
M`\`^&#V5Y\6KR::#2+G4X9;F-9=-TN3RK*/)^3SHI'A60\;C(=['(`7I7K.K
M_$72-%U*[L;YYEGLXVDD`3.0L+3''/\`<4_CQ7F'@'2H%^)-OJ+1F?69I;E;
M^W:.6+^S4(8@B0,(ILD*O"DG=D$8-:?Q!MM,LO&&I7OBB;PDR3QVR6-O?:-_
M:-V<@H<*C!PI=@HR",GK1T0UNSU^VN%NK:*>+.R9`ZY'.",BI:C@7;!&,`80
M#`7:!QZ=OI4E#$@HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*C>>*)@L
MDD:,W0,P!-25B75A<_;Y94>9HY`/W2HC))[,3R/3CZT`-\7?\>>G_P#85L__
M`$<M;M<;XJTJ_73=,4ZQ=!EU2RR1!$?^6R^JUU'V:?SHG^UR[$7#Q[$Q(?4G
M&1^&*`+5>4^+/^3A_`__`&`=3_\`1MM7I(L[D12J;^<N[91_+CS&/0#;@_CF
MO!_C7X1UWQ1\4O#.D^'/%%WH>J7>@W_D:FD>'@"SVI8#RRA^8<<$']:WP_Q/
MT?Y,TI[OT?Y'J6AI-)X#O5M$EDF,M[L6)$=F/G2<`/\`*2?1N/6J'P^\,7^E
M^+-=U748[F)-6MK3;'*$`1DCPP`7@'/7'%:6D?#QM+TZ"V'B'Q"6C7,C)<J`
M\AY=L%3C+$G&>]7/^$,D_P"AB\2?^!:?_$5@MS/H4_#ZR2>$]66W61Y3=WH1
M8E1F)WM@`/\`*3[-QZUD^!?"U_8^-=0UO4([F%+_`$JVA,4JHNR1%7=PAV@\
M<@<<?2L?XBZ7)X-T=+?2=9\4PG5#.%GM[^,-!+MW[\,G()SGT_&NWB\$R1QJ
MK>)?$\A48W/=QY/UQ'1YAY$?AM7;3O$:Q!R[:K=A=@!;/&,`\$_7BL+P+X7U
M"T\;3ZYJ,-W;K=Z+#;-%.D:[9%8'I'\H.!T`QQ]*W;7X?I9";[+KWB./SY6F
MDQ=K\SMU/W*G_P"$,D_Z&+Q)_P"!:?\`Q%'6X=#FO`'_`"57XB?[UA_Z!+76
M^.O^1(\0_P#8*N?_`$4U0^&O!%EX7U/5-0M;G4+N\UCROM4MW,)"?+#!<8`Q
M]X_I7EWQ>\5ZYXFUMO!/AG5G\.+J\-QI]W=/IWG2IN,.)X&W`,=CNNTCOD]C
M0!Z5X*1Y/A[IBP[Q(;'"[&"MG!Q@G@'ZUA>#_!VHVGC9O$&JQ7,4MQH\=K*L
M\\<K;U;/)0`$_08XK2\/?#./1="T^PN==\17<UG;1Q2W"ZE+")G50&?8K;4W
M')VC@9Q7-?$_2VT+3[6VL;SQDW]J.8C>6>NRJ]F05(<Y;[I&X$\XX]:.H=#L
M_!RL_AV[$>[>=2U#;M.#G[3+T/K7.^&O!VI)XXT_Q#JT=W')'H[6<JW%Q%*V
M[S"P+%``3C'08K=L_AS8V$'E6NI>(T3>SD#69^69BS,?FZEB2?<U/_P@UO\`
M]!7Q)_X.9_\`XJCK<`\+@F[\1@9R=4;I_P!<XZYGP_X-U1O'.E:_JT=Y&UII
MT]JXN+B*5CND8J6*`#.,=!W]LUT4/P]L;=I6M]0\01F9]\A75YAO;&,GYN3@
M#\JD_P"$&M_^@KXD_P#!S/\`_%4=;@<9;9'[3=YSQ_PAZ\?]O*5ZLWW3]*\8
MT?PI<:)^TVUU'K.HW5E<^#F(M+MC,4872+GS&RQ]<=J]G;[I^E9T^OJ=6)>D
M/\*_4\I^"^KZ\GPP\/K#X>C>,6[!7_M-!N&]L'&WCZ59U.WU*W\>Z1J\?AO;
M?W9DBD/]L@JZK"V!LQM!]P,UC?"KPCXAU#X>Z)<:=XUU+3;::`M':16%M(L(
MWM\H9D+'\35W7/`GBK_A)?#6/B)K`(N+C(_LRTP1Y#?[%:'*0:;X@\2?#B=]
M-NO"NLZM#?3++;S0WRS1Q%W(9`2,KC&X@\`$8)/%=1X:\>Z[XEMIIHO!]Y9"
M&5H]M[>K$SX/WE&WE3ZTS_A!?%7_`$4/5_\`P66G_P`;H_X03Q5_T4/5_P#P
M66G_`,;H&S:_MGQ#_P!"Y%_X-$_^)KS_`.!]]<ZEXY^)5QJ-D-/N#J5NC0"X
M$VW:LB_>``.<5TK>`_%3*0/B)K`)&`?[+M./_(=</^S;X;U;PIXE^(VG>)_$
ME[XLOH]2MF;4[RUCMY'!B;Y=L?R\$$Y]ZWI?!4]/_;D5':7I^J/=:**X[XB_
M$"W\%6UI$"'OM1D*PH.2J+@O)CH=H*\$CKD\!B,"$=C25QOPTEUF>PN)=;NF
MO;1]AL[J20,;@X.^1<*,1L=I4$<?-@E=IKLZ`/./$/AZ]\#:G-XB\&PR3V,S
MF75=)A7))/WIX5_O=V0?>QD?-U[/P[XBLO$VF0WNESQSQ3(&!1LC!_S_`$.#
M6G7F^O>&;KP%J5QXA\$6[265Q*T^KZ3`N2S'[UQ"O]_C+)_'C(PPYW3516?Q
M?GZ_H7\6AZ36)XT\66O@?PQ?ZWJ<<\MO8Q[C'"A9G)(`'MR1R>!U-5=-^(GA
M[4(])QJUA'-K9(L(7G`:X(&2$!Y/^/'7BNBFACN89(KA$EBE4HZ.H964C!!!
MZ@BL6FG9D'F_P_\`"5WX@U&'QQX\D@N]5NHMVE6<3^9!I<#<@(>C2$8W/^`K
MTNO(Y(KOX%:@9;99[SX?7DN98ES))H<C'[RCJ8"3T_AS^?JUM=P7MM'<6DL<
MT$R!XY48%64C((/I2`FHK.T3Q#IWB2VDN-#NXKR"*5HFDC)(W*<''J/0C@]B
M:T:`"J]W:"Z4$,8Y8SF.0#E3_4>H[U8HH`QK:Z;3I&BF79$G+H.?*']Y?6,_
M^._2M@$,`5((/0BH;NT%RHPQCE0YCD`Y4_U'J.]9MK<MITC13+MC7EXQR(A_
M?7U0^G\/TH`V:*0$,,J00>XI:`"BBB@`HHHH`****`"BBB@`HHHH`****`"B
MBB@`HHHH`****`"D;[M+2'IZT`>$_#[4K63XC+>Z?#I\L.LSLC21:1#`]M*L
M4C",,LC,#L0,YQP713@L<6/BS'9W_P`1K+3KV;3+..XL5EFU!=-F%S:%'+1[
MIT=0Z,PXCY((R1@UU/AKX@S:WKUC!;>'/LEI<S2PSS$,LD,VUW?(V`8`6-7.
M?OR`#=@FL3XKO=1>*K98[+3I;>YA13<7&HM!.AW8/V>`2J+AL'[IV8XY?[M'
M8?<]>A_U*?-O^4?-Z^]/ID(VPH.>%`Y&#3Z!!1110`4444`%%%%`!1110`44
M44`%%%%`!1110`4444`87B__`(\]/_["UG_Z.6MVL+Q?_P`>>G_]A:S_`/1R
MUNT`%>4^+/\`DX?P/_V`=3_]&VU>K5Y3XM_Y.'\#_P#8!U/_`-&VU;X?XGZ/
M\F:4MWZ/\CHM!MM8UVPDO9O$E_;;KF=!%%:VVU%25E`!:,GH!U-:*^'M5D4,
MGBO52I'!%K:\_P#D*LK3(?M'P\U&/RS*'>^!C6`SEQYTG&P$%L^F1GUK/^&N
MDWUAXGUJ:Y@OK>PGM+/[+%,ICCCQ$`RI'D[.1R,U@C/I<@F\%7OQ#T"ZCUGQ
M+J$;QW,\,,\5C:;X=K%=REHC@D#DUU,'AS5O)3'B[5I>/OFUM/F]^(L51T:(
MS^#=:CV&3?<WHV"$REOG;C8""WTR,UC?#K1KVQ\7WER]O?6NG3:/:I#%*AAB
MC<*H8+%D[#QTR>A'/6A#Z&KH%EK>J+J)N?%.I+]CU":W39:6HRJ$8)_==:U$
M\/ZK(H9/%FJ,IZ$6MH0?_(55_#Z>9I?B5`-V[5+P8\OS,_\``>_T[US?PYT:
M\LO%SW)MKZUTU]#ACCBDA-O$D@89`B);:V/<G@]:.HC1\`ZWJUUXV\8:1K&I
M2:C;:.;06K201QLN]9"V=BC.=HZ^E97Q'^&43:O_`,)EI5VEE<Z%:W-Z\)A,
MGVFX559&+;QM&(]I`'(-6_`'_)5?B)_O6'_H$M=;XZ_Y$CQ#_P!@JY_]%-0!
MCZ!=>*M=T6SU!+[1XA=Q"38;-R1G_@=4?%W@7Q!XML%BNK_P\MU`P>TN9-,>
M4V[;E)*@R#KMQUK5\)G'PUL3O6/&GGYV=D"\'DL.0/<<BN9^'UQ>-XPCC@OK
MFYT,Z%"UNBRR2V_F;AEE>3YV)'<T+<.AN>'[CQ;J^GM/)J.B!H[J>`XL7&?*
ME://W^^W/XUI?8_%?_02T7_P"?\`^+IOA'/_``C=[A@I_M'4.6)`'^DR]2.1
M7'^![J];QGI45I?3W&B'1'?;%-)/;M-YK#<))/G8XSU_PHZV`Z+2KKQ7J<^H
MQ_;]%3[!=F#/V)_FPJMG[_\`M5H?8_%?_02T7_P"?_XNE\+_`/'WXDQ_T%'_
M`/125Q/@V[O&\;:/%87\]SHSZ?<M,L$\MQ;M,)6Y\R3YB>OM^E'6P#M(6_\`
M^%_G^VIK:>XA\*O&'MXC&NTW,;=#GG)/?\*]7;[I^E>8PC_C(J?'7_A%S_Z/
MB]OZ_A7IQ&16=/KZG5B=H?X5^IQ'P1_Y)5X<_P"O4_\`H;5#J7B62Z^+&DZ*
MML4AL8I9C<.'4N[0MPOR[64`C)#9SQCO6WH/AX^!M"M=/T>6:ZT[3XRJQ3X,
MNW))(8`9/)X(YK/U#18(_B!HFLPW-Y(]^)(S$TY,"JL#D,J=B<]:T.4M>!_$
M.H:\M]_:_P!DW6LWEK]G5@.^0V[^(<9%=37%_#%[T:9>0:K;W4,L%VX5IGW[
MU)R""5!_`YQZUVE`/<*\M^%?_)2?B7_U_6G_`*+>O4J\6\+7NI:;XJ^*]SX?
ML_M]]%=V;1V^>6&QMVT9&Y@,D+D9.!D9K>E\%3T_]N1I#:7I^J.X\>^.SX:A
MDM-%@-_K7V=KD6RH6*0*0&DVC&[&>%!R<$]`:YCX<>!+R]N?[:\<Z?;O?R6X
MB>>?9))<C<'4L!D#:1PP;DDXPH4"SX%T6\U6_EUKQ)J\MY;3RK+:VUQ:I!AU
M^Y(I"JP9`6CW``.H!(KTX8Q\N,>U8+0A@````,`4M%%`@I.M+10!Y%XT^&-K
MH7BBW\::'I2:F;*;[1<:;LW&%^K7-LO3S.A9.C%0PPX!/I/ASQ%9>)M,AO=*
MFCFBF0,"C9&#_G],'!%:E>;^)/#FH>"M8?Q'X)B:6PE9I=8TB),F0GK/`.S]
MV3^/J,,,G=/VFCW[]_)_HRM_4]%FACN(7BN$26*52KHZAE92,$$'J"*\XM/A
M->6%Y<:59:U)#X'NF\V32`K><K$_-`DN<K`W4@<G[N0"2>V\.>([+Q/ID-]I
M<T<T4R!@4.>/\Y^F"#@@BM2L6FG9DG,2:CI>A>)1;++;VBIIJ(;>,`84.1&`
M@[`!\8'2MZQU*UU*(R6$\4Z`X8HV=I]".Q]C5#5[O2?!^FZMKVH+':PPPM<W
M]PL>7947OCDX`P!6-X+L[K6[QO%>K.D3ZC;!+&RMY0T<%L2&4R,O$DIP"3R%
M^ZO<E`=C112=.M`!TKQKQU<:Y\8M530OAKJKZ1I&EW)&LZ['D>;D$&W@92"2
M,Y)!QQ@]LZVM:W??%35;CP]X-N)+7P]:OY>M:U$>93WMX#W)_B;H!^OH6B:)
M8^'-*M].T6WCM;.U39%$@X`]3ZD]23R333<7=`<%HFJW/PRO(-$\1.\F@.PC
MT^^D8L;3LL4K'DKV5S]#SU]*4A@".0>E4=:T:UUVPEM-0B26*52I#+N&#U&.
MX]JX#0]5O/AA>IH_BBYFNM"GEVV&HSG<;0L?EAD/=.RN?HW/)U:]IJM_S'N>
MG44@8,`5((/0BEK$04444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!
M37Y4TZFM]WTH`\(^'D%Q_P`+$MM:U?2[6&TU>:YAT6\MKN9870!VP(23EV5"
M2\@'0A0O0O\`BGK-G;^.[W3O,AA&L006%\LUQ;(TFZ.5T*F89BC"A@S@GYB,
M*6YJSX%U*RF\>VMYIEL[)J4LT4LWV&VB:*8J\A0[!N&%12Y!&&D16R2<'BNZ
MN%^-T2V5]I*/Y"Q[=3W>7S"[>3M#C@X\S=MZKC/-'8?<]HM8UBM84C^ZD:A?
MFW<`>O?ZU+38\[%SMS@9V]/PIU`@HHHH`****`"BBB@`HHHH`****`"BBB@`
MHHHH`****`/,OB%K<]G\0O"VG+=RI;7\T)>V,89'99U*D'.5;@_4#'T]-K`\
M7QJ;;3G*J6&JV>"1R/WRUOT`%>4^+?\`DX?P/_V`=3_]&VU>K5Y3XM_Y.'\#
M_P#8!U/_`-&VU;X?XGZ/\F:4MWZ/\C8\(:5K,^CO)9:]]DA:]NML7V&-]O[]
M^Y.36V-#U_@CQ-Q_V#8O\:R=-6-_AWJ*SE!$SWV_?"\J[?.DSE$(9N.P(/I6
M?\-+"\M?$^M2R?;!IDUI9_84D1HX4`B`81HW*]!D'FL$9]"QX,T;7)-,N3#X
MB\M1J%R"/[.C.3YAR>M;PT/7\9'B;@^FF1?XUG:,JOX-UH2E0C7-\&+QM(,;
MVSE5(9A[#D]JQ?AQIUU;>+[R>/[8ND2Z/:K:HT;Q0(P5<[(W)*D@=#SP:%JP
MZ%WPCHVN.NL>5XB,>W5[@-_Q+HSN.1D]:WAHFOD9'B;/_<-B_P`:JZ``=*\3
M`D`'5+P$LI8#Z@<GZ#FN:^&^G7-OXO>XMOM8T:30H4MT\J2&W#AADK&Y+*2/
M4YX/6CJ'07X8P7%O\3/B#'?7/VN8-8[I?*$>[Y9>PXKM?'7_`")'B'_L%7/_
M`**:N2\`?\E5^(G^]8?^@2UUOCK_`)$CQ#_V"KG_`-%-3`YKP/#XF;PAI7V.
MXT(0&V78);>4MCW(8"MP6OBM0`MQX=`'3%I+Q_X_5?PF=OPUL2&6/_B7GYVD
M,87@\EAROU'2N;^'^H7\GBZ.VCNQ=:(-#AD@=;][E&EW`,07`9N#U/Z4NH=#
M1\'P^)CI,WV2YT,1_P!HWF1);RD[OM$F[HPXSG'MBMI;;Q6@PEQX<4#H!:2C
M_P!GI/")(\-WA!"D:CJ'+-M`_P!)E[]JY'P1J=^WC#2K6WNUNM$?1GD,D6H/
M<HT_FL,AG`+<9Y]N@HW8&KX:A\3F[UWR+G0@W]IMYFZVE(+>6G3YNF,5M+:^
M*T&$N/#JCVM91_[/3O"__'WXDQC/]J/U_P"N25Q7@[4[\^--(M+.\6[T:2PN
M9)GBU)[I#.)7P-S@%N,_3'H!1U`31$OT_:!G_MI[.2X_X1AL&UC9%QY\7][)
MS^->LGIQ7F4/_)Q4_'/_``BQY_[>(J].K.'7U.K$[0_PK]3PV;X4_%:6:5S\
M3!^\D9\+;%0N23@`<`#.!]*WT\)_$J)M$VZYX0D&BJ4#3:;<,\^8C'EB)1\W
M<X'->IU5U2^&F:?<W3+O%O$TA4?Q8&<5H<IQOV/XE_\`02\$_P#@NN?_`([1
M]D^)?_02\$_^"ZY_^.UU7AW5SKVC6U^8A`;A=QBW[]G.,$X'/X5I4`<']D^)
M?_02\$_^"ZY_^.US7P134T\=?$E?$<UA/>_;[3>]E$\<9'E-T#$GKGOZ5[#7
MEOPK_P"2D_$O_K^M/_1;UO2^"IZ?^W(N&TO3]4;NM>#7NO$E[K5O:VD]T(88
MXX[E0Z7,:[MT;9!VG)X8=#Z@FNET75;;5K(26:M$8F\N6!UVO`XZHP[$?D1@
MC((JY//';0O+<ND442EG=VPJJ!DDGL,5ROA\3>(/$#:_:(UEI9@,,(*[7U(9
M!$S@]$'.S^(AB3@$"N%15.?N]?ZN=KJ3Q%%NH]())/Y:1^=OEZ;==1116YYX
M456GU*TM9/+NKJWA?&=LDJJ<>N":C_MO3O\`G_LO_`A?\:`+M%%%`'F_B?P]
MJ'@G4I?$?@6V>YMYY?,U?28CC<#]^XA7_GH!RR?Q]L-@GL_#GB.R\4:9#>Z5
M,DT,J!@5.1_GK[@@@X(-:AYKSSQ-H%WX*O[CQ)X.@EFMG+3:KI4";C+W::%?
M^>G'S(/O_P"]@UNG[16>_?OY/]&7\6^YZ#-#'<1/%<(DL4BE71U#*P/4$'J*
M\FF@N_@5J#7%BD][\/KR7=/;KEY-#D8\N@ZF`D\C^'^?H_AOQ)9>*-+@OM,E
M62.9`PQVS_DCU!!!Y!K2EB2>)XIT22.12KHZY#`\$$=Q6+33LR!EI>07]K%<
MV4L<]O.@>.6-MRNIY!!]*\TUK6K[XJZI<>'_``=<26GAVU<QZSK41YF/>WMS
MW)_B;L/UYOQUX4U/X?6CVNDZC?6WP^U*Y7^TDMD\R?2XV)WB,]1$V1Z[<G\?
M8O#-CI>FZ#8V_AA+=-+2%?LH@.4*'D$'OGKGJ<T@)=%T2Q\.Z7;Z=HMM':V=
MJFR*)!P!_4GJ2>2:O44R9F2-FC4NRC(4=3["@!]4-9T:UUVPEM-1B2:*52I5
MU#`@C!!'<'TK+\)>,[;Q/]I@`>#4+!_+N[9UP8FYX]QQUZ>E='0G;5`>8:)J
MM_\`#/4QH_B>8S^')75-,OG)9[,G@13,>J$\*W;HW.,^G*P8`J001D$52UC1
M[;7+"6TU"))8I5*D,H(P>H([CVKS_2M:O?AIJ\.B^(1-/X=N#MLM3D?=]B;(
M"PR$\E#D[7[8PW.,[->TU6_Y_P#!'N>G44BL&4%2"#T([TM8B"BBB@`HHHH`
M****`"BBB@`HHHH`****`"BBB@`IK_=YIU(V,<]*&!X?\/K!%\>1:U>C2MM]
M<R06"6&H7FV(31-.I:)T"O(\:;F9C@=%`[[WQ8^&>L>,+X7>E2Z5/;;(5DL9
M8%MYGVR!G_TD*S$,F5V?*.<YKFOA/X8L;7QW?7-Q::M!);:A/_9C3Z,;9)8]
MC+N;Y,+M!95;<"RX.!G%7?B1XK\1:1XVNK+0[M6MKJ(11(3<92XDMI`D2B.)
MP7R/-`S_``\XHZ(KJSVB)0D2*J[`J@!?3VI]06221V4"W#%Y5B4.QZLV.3^=
M3T,E!1110`4444`%%%%`!1110`4444`%%%%`!1110`445@ZMXGCTR\B@?`>>
M7RH4\MF,C#&>1P!R/4]\4`+XO_X\]/\`^PM9_P#HY:W:X[Q9XDLFT_37/VH!
MM5LO^7.4XS,O^S73_P!HP>=%%F7?,NY/W+XQ[G&!]#0!:KRGQ;_R</X'_P"P
M#J?_`*-MJ]*&K6QBED!GVPMM?_1Y,Y]AMR?PKPCXS_$[1_A[\5O"_B76TOY-
M/TW0K]9E@MB)"7GM57`<J.IY.0!^5;X?XGZ/\F:4]WZ/\CUBR\+:SI<3P:;K
MT,5N9I)41].5RN]RQ&=W/+&K']C^(_\`H8;;_P`%:_\`Q=9/AC6O$7C#1(-7
MTN\TJ"SO2SP1S63EPFXA=WS]<`9K5^Q^*_\`H):)_P"`,G_QRL#,XOQ=)X@^
M'NB&/3-<!FOY)W@G.BB:.*8_/AP'!`;YN>V*[./1_$H0>;XBM2_\172E`_+?
M7(:KX;\2?$C1)?,U72K*>UGGA@E2TE(4@["642`,"!T/K77167BY442ZIHCL
M!RPT^09_#S*`*VF^$]=TL70M_$4)^UW3W#[M+7AGZX^?IQ5S^Q_$?_0PV_\`
MX*U_^+K,T2[\6:L+XF^T./['>RVPQ92'=L(Y^_6E]C\5_P#02T3_`,`9/_CE
M`$'A+P3-X<\0:]J][J7V^XUWR/,`MA$(S$'''S'.=_MC%;7B/39-9\/:II]N
MZ1RWUE-`CN#M5G0J"<=LFN<\%^*-2U7Q3XDT?67LY6T06VU[>%H\F3S"<Y)X
MPJ_K6SXU\8:=X`\*:GXB\1M.FF:1`9[IH(&F<(.I"*"3U[4`9&BZ-XIT31[7
M3H9?#TD5K$(P9(YB6'OS5M+;Q3&08QX84@8!6&8<>G6M3PSXBL?%WA[3=;T.
M5IM/U:UCN;9V4J3&ZAAE3R#@\@\@\&M.@#C-%T?Q9H]E);K-X=D#W,\^3'-_
MRTE:0CKVW8JXEKXHC(,8\,*5&`5AF&!Z=:Z>B@#C=-T?Q7ILU_)'-X><W]R9
MV!CF^4E0,#G_`&:MI:^*(R#&OAA648!$,PP#U[UT]%`'E&DQW\7Q_/\`;9LV
MN)O"CR!K0,$"BZC4#YN<\5ZO7D:^)+*;]J0:-']H^W6W@MGDS`PCPUVI&'Z$
MXKURLZ?7U.K$V]RW\J_4*PO'$K0>$M6>)0[+:2$*1D-QTK=K"\<NL7A'5WD1
M9$6SD+(Q`##'3D$?I5O8YH[H/!)@;PQ8M9%C$Z%OF!#`DDD-GG=DG/O6[7,?
M#5UF\&:?+%"MO'.'D2-<84,Y(P`!@<\#TKIZI[B"O*?AE.EK\0_B?-<R)%%%
M>6C.[L%55$3DDD]!7J-S<PV5O+<7<L<,$*%Y))&"JB@9))/0`5X5\*[>W^('
MQ!\>7C2ROH1OK.9+1X]HO3L<QR/SDQX^8(0,G!/``K2#:ISLKZ?JCJPU*,U)
MS=HI:_>M$NK_`.'=EJ>DPPR_$"9+F]22'PU$P>VMI%*MJ3`Y$L@/2+/*H?O?
M>;C`KL``!@<4`8&!2USPARZ]2*]?VEDE:*V7];M]7^B2165X@\0VWA^R>:Y?
MYA]U`-Q)/0`#DD]AW_.D\0^(;;P_9--<N`W`50,DD\``=R3T'?\`,US&FZ=<
M:C=C4]=#B\#$6]N&YM#W_P"VV.O8C@<4ISMHMR:=.^KV.@L]&@U6UBN=6@<W
M$RAV4RGY,]LJ<&I_^$6TP<K;L".A\YSC\SBJ=GJ/]F9\YE^S!2[[>%1>\B?[
M/]Y>JGVK8TW4H-6M%N;)B\,A.QL8W`'K]#UIQDF3*#6O0IVL\FES+:WA+0-Q
M#+_=]C[?R^E:U17-LEW"T<PRK>AP1[BLK0+Z66XO;.;YA8L%5R>6!9Q_[+^M
M60;5)UI:*`//O$7AR]\):G-XA\&1/+#*QDU32XAGS?6:$?\`/3`^9>C@=FP:
MH^%?BR?BCK>L:+X4M=1T^VTZ"-_[?,2O!,6R-L6>"P8$'/3:P(!XKT^O/O$/
MAN\\(:C+K_@J%I()',FIZ3".)<_>FA7IYG]Y>CX[-@ULFIJSWZ?Y/]"_BTZG
M86=U]L22QU6*,7*QXFB(RDR'@LH/53W';H??S6ZBO/@=J+7=DL][X`NY,W-N
MH+R:(['_`%B=S"2>1_#_`#[S3-4L/&NDV][I=P-^/,AGB/S1MTR,]NH(/N#S
M6A:SF[CDM-4BC$^PB6/&Y)4/&X9ZJ?0],X/ODTT[,@L65[;ZE:0W5A-'<6UP
M@>*6-@RNI&00>XJKINOV>K7$\5B[2"%BHDVX24CAMC=&`/!([UYR?`4_@^ZU
M#2]&\2P:3X6U9&:#3I@3+:SD\K"^?EA)(R.V<#&:[71]%CT"ST>SB*M)'(Y8
MJ,`Y1BV`.V<?I4<WO6-?9VI\[?I_F/\`$^FZA_9MQ+X1-E:ZDS"4M+;A_.*C
MH>1SP`":@\'^+SX@C\B_M9;*_B3+QR<[]N`Q!'`(+`%>V1UZUTU01V-O#=2W
M,4$27$X`EE5`&?'3)[U1D3U1UC1[77+&6UU"))8I%*D,H88(P1@]1[5>KEO'
M?CNW\&6<*10OJ&LZ@WE:;IL/,ES)_11W;M0@.+M?'=I\(_$VG^%/%VJP&RU5
MMND&6;=/!UPCCJ8N"!(>GW2<]?7%8,`5(((R"#7EOAOX)V=QJ=WXH\?A-4\6
MZM!Y=Q)N)@MHRI411QYVX"DJ6ZD$C//,^F:Q<_#"^32_$DK2>'96"V=_*V?L
M63@1R,>L?96/3H>Q.UO::K?\_P#@CW/3**:CAU#(0589!!ZBG5B(****`"BB
MB@`HHHH`****`"BBB@`HHHH`*1AD4M(QVJ30P/(?!GA;7--\6Z?J%[X=2SEF
MEG_M29DL!#$K*Y4V_E?O@=VQ?FSD,Q;FH?B_X"UK6==&I:!I-M/#M@\RZLIB
MM^K*VUR`[+'@1,X!7+Y..E7_``M\3T\2^(["TCM]3BN[B]43P'S1'$OV1V<_
M-&!M5U"XS]XYSVKU:CL/89"H6)`-V`H`W=?Q]Z?110(****`"BBB@`HHHH`*
M***`"BBB@`HHHH`****`"JTMA%,[LQD7S/OA7(#_`%JS10!@^+0$LM/"\`:K
M9@`?]=EK>K"\7_\`'GI__86L_P#T<M;M`!7D_C&))OV@_!"3(DB-H&I@JZ@@
M_O;;L:]8KRGQ;_R</X'_`.P#J?\`Z-MJWP_Q/T?Y,TI;OT?Y&]IC+'\.]1+R
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MO5,:I>?,SE`ON6'('N.17-_#B\OI/%C01W?VG1!H<+VY2]DGC,NX;BOF#<>#
MU/7/:MW2="\5:4MX$O=`D%Y>27+;K67@N1Q]_P!JNI:>*HSE+CPZIQCBTE''
MI]^CJ!SG@#_DJOQ$_P!ZP_\`0):](90ZE7`96&"",@BN/\&^#M0T+Q-XCUC6
M+NSN'UW[.1';1,@C,8<'J3UW#\C78T`>1>([#6/@T-0U;P5$M[X;N,S7.E.C
M/]BESR\6""$/.1T'ZBS8^/O&VH6-O>6VC^'#:W:!X)3J(`D4]"#NYKU)T612
MK@,K#!!&017CWBG0M=^$XU#4?AQIZZOI-^&W:08FD:RN&X$D*J"2A)Y3@>X'
M(`"_^*_C'3_$%CHDGA_3)M3U!2\$$$YD(4?Q/AOD7_:/'4]JZ#^W/B1_T+>A
M_P#@=_\`953\`?#B?P=;7'B#7;N6[\27Q$EY*6XVDC,>.F,=!T!`QTKK/&6J
MZCH]O!<Z5:O<I'(#,L8+L02!MV`9.<GD?=.#R,T,#GAKOQ'/W?#>AGZ7_P#]
ME2_VY\2/^A;T/_P._P#LJL^";C6)]9OE>XBFTD%F99F'VB"<M\T;8&"`<X8<
M$8Q[:_B#QM;>'-6L[&^L[YQ>@>5/'&&0L3C8.<EN^`.E`'F-]XEUSP;\3=.\
M5?$_2X-*T*ZTMM(>_M)_-BLY6G61'FY)5&P5W=`<9ZU[>CK(@:-@RL,@@Y!%
M>6?$GXA0:V!X,\!6^G>)O$.OVS*\,N)K.QM6^5KBZ(XV#G"=7(P*[#X<>"T^
M'G@G2?#T-]>:DNEP"/[3=ON=^23]%&<!>P`':L:<DY/EU1W8F#5&#FK2VMW7
M?R[>?Y]+2%0P(8`@]0:I:UK=CX=TNXU'6[F.TLK5-\LLAX4?S)/0`<GM3])U
M:SUW3;>_TBXBNK.Z0/#-&<AE/^>G:MCA+*(L:A8U"J.@`P*=45U=0V-M+<7D
ML<$$"%Y99&"JB@9))/0`5P-I#>_%#4+74Y9K_2O"]A.L^F1PR-!/J4B_=GDQ
M@B'^[&?O_>88P*N,&TWT0TBYXZTJ6^UC3I=>F\SPA$I-]9I']ZX#`QO,V>8`
M,Y7&-VTG(S712Z<EI,U]I$<2R2X,PC0#SAC@DCJ<?_6]YGM+R2(Q/=Q%&&&8
MVX+$>G7'Z?A3[.UMM$TZ*VA*PVUL@5-[]`/<TG)VL%R6TNX[R+?$?9E/535+
M7M>@T2U+RMF1B%C11EF8]`!W)/0=_P`Z=>VDD3M=:80),?,F,A_?'^?\><L]
M,DN;AM4U:2*XF!*QIDE+4'LWJ6&,OV[<5G-M+0J"3>I'8:=-=W8U/7!FZ()@
MA'SBV4\$X_B;'#CL.G`YTI]D:L[-'&$0;][_`";.H#-_<_NOU4U))((D=YV*
M*AR[.P4J0,\GH&`Z-T8=:Y:]NDUU3=7I$.AVQ+H&7;]K/=R.HC/'R?Q'GT!P
MV-UKKT'W-\NNQM=7Q:'1H2)$$HPUVPZ.P[#L`/O\'&,`Z.@272W8U"^,MO:2
M*3%:!B&V?\]7'?K@KU08Z]JUI:2W[QWNIQ"*!,-;6LA^50?NO)CU_A(^X>O.
M:W/]</\`EH'#\]%=7`_(2`?@XH3[#?G_`,,=&CJZAD(96&00<@BN?\._\AO6
MO]]?_0Y:RM)U"]UB\,&BRB/3(V/F3HORRMW\O^ZGK[\+W-=A:6D=G&%B'/\`
M$W=JWC+F5SGG#E=B>BBBJ("D(S2T4`>=^(/"UUX0U>Y\2^"H9)%N7\W5M+CY
M\_C!FA7.!)@?,O`?'][!J]JOBF77?!O]K^"HH;^\B"RQ*7(*KGYRHQDG`8;3
MCG@\C%=J1GK7`^(_"]]X<UF3Q)X-$CHX+:EI$:C%P<\SQ_\`37`P5Z./]H`U
MLG[16;UZ?Y/^O^!=T]"GI<V@_&:TT_4'DN+>\T]]S6Q/ER(P8@DJ>1R".?7D
M=*F\6:QJ_@#Q-_;M[OU+PE<1)!<1I$/,T@CCS!CEHV."V<D8'8"JTUO9:HLG
MC/P<9Y]0CLB%LK:01QRONR788R6'S`@^X(S73^#_`!GIOCC3&$,D$LH0K<V^
M0P]&&#VSD$'Z&L%!1DW:SZE5*U24(PD[J.WE?<Z"SO8-1M(;FQFCGMYT#Q2Q
MME74]"#4]>4W%M=?!2_>[TY)KOP+=R;KFU4%WT=V/+H.IA)ZC^&NF\7_`!)L
M/#VDV<ND@:SJ6L@#2+*U;<UVQZ-D=$'=NWUIF1/X[\>6_@VT@CAA?4=9U%O+
MTW38?]9</Z^R#NW:J/@3P)/I=Y-X@\8SIJ/BG4%Q-,!^[LX^T,([*.Y[_P`Z
MOPU\,1_:;OQ#K]]!K/B>[8Q7-Q&<QV:C_EA#Z*.F1U(/O73>+=/U+4=+\O0K
MLVDRR*S[<!I$'558_=/H<&A@;=9^N:'9^(M-GL=5@BN+>="CI*@=2",$$'@@
M]Q5+PGKW]L6'EW<T$FH6I\N[6(Y"/Z''`..2!TK=IIM.X'FFE:K=?#*_32M?
M=YO#LK!+&]<EC9$G"QR'O&3PK=NA[$^E*P=05(((R".]>9?$77IO%U]+X)\%
MI%<:E*F-3OW3?%I<3#!SV:0CHOYU5\,7-[\'!9:!XEO;O4O#H58K75KIM\ML
MYX"S-W1CT;^$G:>Q.MO:*Z^+\_\`@_F/<]8HI%8.H92"",@CO2UB(****`"B
MBB@`HHHH`****`"BBB@`I&^Z:6FMTXH`\E^'5[%I]QH=NUUXGGL[OS(-.N;J
M^C>&Z9%8G,()>,85BN[I@`X.!7KE>/\`@;PUJT'Q)O-7U#2];TJUD>:-%ECL
M9%N02?WLLD?SKG'RHOJ"Y)X'L%'0.H4444`%%%%`!1110`4444`%%%%`!111
M0`4444`%%%%`!1110!Q_C3Q%96^J:/HT[LE[=WUK/`I0[9%6==P!]1UQZ5V%
M<'X]\-W%UXE\.ZU#?M%!8WMO#+:;"1,'F7G.>,';V[?2N\H`*\I\6_\`)P_@
M?_L`ZG_Z-MJ]6KRGQ;_R</X'_P"P#J?_`*-MJWP_Q/T?Y,TI;OT?Y'H'BG6)
M=!T*YO;6%)YHBBQQNQ52S.JC)'0?-5'S_%O_`#Y^'_\`P+E_^(I?B#_R*=U_
MUUM__1Z55\>7T]B;![.XGMY?WS1[+N.)'<1,5#HW,BYYPOID\5@W8A*YR6MV
M'C#PMKESXJMX=$N+=;:4W=O/J$S;23$%\H>7A1A#G-=L9_%O:S\/_P#@7+_\
M17-1ZKJ>M_!26]\2!5U*XLF-RJJ%`8.1@`=.`*Z+QE=R6L^E^5<7-OFZX\J[
MCA5R$.%<-S(O^RO/'I0]!;E76M:\5Z-I%[?RV.@.EG`\Q47<N2%&?[GM6%H/
MC#X@>(M#T_5+#P_H'V;4;:.XBWW[`[74,,C''!I^D:WJWB'X+:E?>*%1=2EL
MKL2JB!0`NX#@>P%;_P`)O^27^$_^P-:_^BEH8&9_:_Q'_P"A?\._^#!O\*IZ
MKXT\=>&K3^TM<\+Z=<:9:L&O1IUX9)XX?XG5"/FV]<>@->DK(K,RJREEQN`/
M(STS3J`*&AZY8^)-*MM2T2YCN[*[0/%+&<AA_0CH0>0:OUY5K&@:C\*M=?7?
M`MK-?Z!JEPHU;0(!EHY'('GVR^N2-R=#U^GJ@.0#TH`X_P"(WB*_\+P:??1Z
M<;_0XI]VL&$DSP1C&QT7HRAN6]A[UT^G:E::UI\%[I=Q'=6EU&'AFB;*NI[B
MK+*'4JX#*PP01D$5Y9J&G7GP<U&;5O#T,UYX/NY"^I:9$-S:>QZSPC^Y_>7_
M`"`#H+>VT6W.JZ5X0U*+3]8N)B))!^\>.0?-M`;C`&[Y1T!8CO7E7BCXB^(_
M$5]J'PRT?3CJ7BJZB*RZB',4&E1D@-+(P`)4+G&`-Q;:,CFM'XJZZGBW5M+T
MGX-W%K=>+=;B$LU];Y9-/L6ZSRN#B,DX`&-[8*C%>E_#KX=6/P[TF:*":;4-
M4OY/M&JZM='=/?SXY=SV`Z*O11P.Y/G5E4Q%1T5I!;O1\UT[Q7;I=_)'LX94
M<'26(J>]-_#'5<MFK2?=;V5]=WH5_A3\*=(^$_AX:?HX:XO+@B34=1E4>;>R
MXY9O11SM4<*.G?/3:YKECX;TJXU'6KB.UL[5-TDKG@#T'J3T`')-8FI>,QX9
MM9-2\5!+71GC,B72(Q^SC'"2`9Y/8CC)V^F>.\)0_P#"Z=03Q-KTD3>'=.N6
M72='60.#(AP9K@#@MZ+T`/H<MWTZ<:<5""LEL>56K5*U252H[R>K;ZLMZ+H=
M]\5-4M_$/C2V>U\/VS^9HVB3#_6^EQ<#H21T7H`?^^J*VEY\-_'SVWP_A.J:
M+?*USK&B1R!3IQQD2P9X+MVA')`)X`!'5>//'3:(5TS05,^L7.%78GF>1NSM
M^7^*0X.U,@<%F(52:Q]"^'`^RR/?NTFMLQE-X)BQL9#SB-_XI2<;W(Y^[C:`
M@HS)M/1_B_-%J-\CQ>#;>7-G92`J^J2(V/,G4\K$K`[8SR2,L.`*]%````X`
MZ5Q7@W3-6@\07]S>K;V4#H5O(H6RM]<Y&+@1_P#+$[00PYWD@_P@GMJN<^;3
MHAMW"N*^+`7_`(1E&:".Y(N4"PR8PY8,O?N-V?PYXS7:UPWQ?17\+1AO)W?:
MD\LR'`5BK`$'/7TZYZ'`.1`+<['3T$5C;H,$)$JC&.P]JK7MD\4AN;$#?_RT
MC[2#Z?Y_QL:<@CT^V0+M"PJ`N,8P!QCFK-#$CSO6F%[-*VID6NBV@!$,C9,_
M?Y\=8P?NKU)]L`S:?ITNJ7$=[JT31I$P-I9DX*-V=_23NO;MU-=A/HUG<W"S
M3P)(Z/O4-R`W]['3/-5+VR^R_,NWR<8RW1!_=;_8]_X?I6,H6]#>-3[RL<8Y
M/`#$$+_WT0O_`*$GXBL!(9?%5R;73F*:4@V33*Q_T@`_ZM6[Q@]&Z]5'&34G
M[[Q=<M:V1D32U;$\^[YK@CC:"/X1T+C[PX]37:V-C#I]ND-LBHJ`#@`=*48\
MWH.4^31;_E_P0L;&+3[=8;90J*`.!BK%%%;G.%%%%`!1110`4444`<'XE\.7
MWA[5&\0>"X1)YLF_5M/7_ENN.98AT\WID<!P/[P!K+U*`:IIP\2_#I+5=0:1
M9[U8D_>W:+GY%)^[R6R,9)R#@UZA7G_C/0-2\.->>(/`4+2W;JSW>FHH(G<C
M`E1<@;QP67(W@8R&P:U7[RR>_1_HRD[[FKX'\=Z5\0=)D>S>*21"T5S;.O((
M.U@5/./K7G]]\+;7PAXIOI-`UG3M*LM7LS'#;W$3-/;N7^Y%)G"0L6P>,\@`
MU;^$OA*XU2&V\3^(-8MYO$<\<JWCZ8@BAGS(?+=EVCYU&0<!<G(89!SW&I>&
M-/\`$VI6DFNQN+_3F#Q;'*JX'\:_@2#W`8CO6%522:BM3;#>R55>U;LNROZ;
M_B)IUDGAUK73M*1'NA9M^[Z*OSY4MCHH)?'KSBJ7@#6];U"6^M=9TZ-8;2ZF
M1M034A<),^1P@QD`$L,9^3;MY.:XGXJZ;XE\'2ZIJ.C:Y>Q>'?$5S"NJ3K";
MBZTH$A";?N%(.`.=I/`YS6/ILTWPG\4ZA_PKC2=8OO"NG&*/7-.=C(ZMM.^\
MA#<Y4!2R_P`>[*].*225C&4G)N3ZGL.H>!-,O]>MM7*RPW<!RQB?:)""""1V
M.5'(P2,@YKG_`!CXQU#6-8?PE\.W5M6(']I:EC='I49[GUE(Z+VZFJ&O_$N;
MQI-!X?\`A#<Q7=[?P++=ZNOS0Z9`W\1]93V7J#U]NU\'>#M/\$:.EAI*,23O
MN+B0[I+F4_>D=NI)-!(>#?!NG^"-'2PTE&)9B]Q<2'=+<RG[TCMU))K0U?2+
M;6[&6UOXDEBE4J0RA@01@@@]1ZCO5IYHXV19'16D.$!;!8XS@>O`-/HN!Y?H
MNH7OPLU`Z7XBG>Y\-3S!=/NWY.G`X"Q.W5H\_=<\C.T]B?3E=74,A#*>01T-
M5-6TFVUJRDM;^-)8Y%*D,H88(P>#U'M7GNEZI??##55TK7BTWA:7"V=\[EGL
MG)P(WSUBZ8<G()P>Q.S_`'FJW_/_`(/YCW/3Z*:CJZAD(8$9!!SD4ZL1!111
M0`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`
M!1110`4444`%%%1O/%&X621%9NBE@":`,;Q?_P`>>G_]A:S_`/1RUNUA>+_^
M//3_`/L+6?\`Z.6MV@`KP_XL>(9_#?QW\!7-GIESJLDND:A"(8'"D%I;8`Y/
M;.!^->X5XW\1-#T[Q!\??`MMKEG;WUNFBZC*L4Z;E#K-;%6QZBMJ'Q/T?Y,T
MI[OT?Y%C7/'OB#Q+%J&B0^!M9MYX5MIFEDF0I@R;ATY_Y9D?C6I<^,-=O7C>
M[^'UQ.T))C:296*$C!QE..*N:=X&\.MXOUQ3HFF%5M;,@?9EXSYOM7):3\+-
M"\1Z_?-#=:U;M::@;B2"2UACA(YC$<8V\Q_(3[DGO6/4S-+7/$'B/5/#MWI5
MEX'NK-+B(QH5G&U.<_="5+'\1=1UV9Q%X(DOY=.F*OF;<;:49!',?#?3L>O-
M=G_P@/AO_H!Z7_X#+_A7(_#73;31D\<0:7;"U@&LW+>7:+M;//*X_BX&/PH`
MS=?\6^)YO#^HZ;9_#Z>TL[BUDC,RW@41!E.6V"/G')]Z[3X4`#X9>%0K!P-(
MM@&`X8>6O-5/#*R+X(U?S1<!<W!B,[%G*[.I)`[YZ5:^$O\`R2_PG_V!K7_T
M4M-@8OB7PW>^$M4NO$_AJ2>9&?S[ZP&7,QZ,1STV]NW![`5U?A;Q;I_BVS:;
M3)07B(6:(D;HR1GG!Z>_L?0UM=>M9VE>'M/T2:ZETRW2![R3?+M]?0>@]AQR
M:0$E\RI?6#2\1[W`)Z!]IQ^FZO+_`!7\<KG3?%`M/"FCOKNE:4CS:Y-;JSRQ
M1#`W1@<8')YY.W@8Y%[XA^-9=<U63P1X*\B;5;B/.HWTR[H-,B[ECT\W'(7K
MQGM4_P`/#IGATW/A_P`&V,MY]G<B\U:1U(GN,*2S\Y(PPP1QP0*`.ZT+7;#Q
M+I-MJ>AW,5W97B!X98SD,/Z'L1VJ\RAU*N`RL,$$9!%>2:CX8O\`X.:A=>(?
M!$,^H>'[V4SZ]HL?)C8_>N;9>BX_BC'&!Q[>F:#KUAXFTFVU/0[F.[LKM`\4
ML9X(]#Z$="#R*`.4\*?"/3/!6OZU>^')I;33]=D6XN=.10%$XX++)]X)C_EG
M]T')'7%1M>S2>*SHVG3265[%()"\;Y@^SC!P=V=\I'\'&W.[IC/?UXSXR\&2
M>!_&%KXOMQJ6J>';>^>^O=,CN&/V&X==KW4:Y^8<DLI/<XP*K1K4<I.3NW<[
M[6-=MO!.A(FMN^H<F.***$&29,@`;,\X!`)^G'-<+X^L&^'\S>.?!M]%HMO?
M.B:Y9SP%DN8V.//BAX)N%&6"C&[!SW!V9+K1],T^[\7>)]2M-2TR5DFL+B$D
MM,,Y1`G3<#A0HZXRW(X7PSX9U#QEK$'BOX@0&`0'=HNBORMDO:60=Y3P?]GZ
MX`E",[X9"QO0U[YTD^LS[FGEYE-M&YR/+;^,R`!C+CG&,+L"+Z;#=6MM$L<>
MZ)$&`#&PQ^8K@_&O@JYTR^_X2'P;OBN8F:2YMHEW;L\LZ*/O9ZO&/O?>7#CY
MNB\$^-K;Q;8@_+%>1*/.B#;@<CAE/\2GD@]^>A!``-6XD@E=9[2XA2X0<98`
M.O\`=8>G\JX&T\1:Y8^)+Z2ZGGO+KS'<Z.-OEW%FI^5K0_\`/9`?G1B=^>,`
MH1Z'J%VENNT*CRLI(#G"JHZLQ[**\MO;VX\=ZU!9^&"D5KI\Z7DFJ/&!AP#M
MG]DQGRTZR=6_=_?`/4]+U2UUK3X;W3)EGMKA=R.O'U!!Y!!R"#R""#7)?%Z,
M/X44B&*>5;J,01RCY3(V57L><MQTYQS6!!I5_P#"V\N];\/M>:AX2N<SZM8W
M#M+<K*>9+Z(GJ#]YX^_++CH>HU;QCH^L^$GU3P[J.DZI;":W`F21)XU+R(,'
MDX;:_0\\U<H62DM44U97.ILE*6D*L68K&H);J3CJ?>IJQ=1\9^'M%NVL]6UW
M1;"ZC4%K>XOHHG4$9!*E@0"*K'XD^$1U\4^'!SC_`)"L/_Q5'))J]A*,K7L=
M'6;X@L7U+2Y;=`663_6*K%2Z_P!W(['OZC-:$<BRQJ\3*Z.`RLIR&!Z$&G5#
M5Q)VU,[0_LRV*QV*",1@*T>,%2!T^GI[5HUF7]A)'-]LT[Y9U'SIVD'I52;Q
MWH%D?+U;6=*TVX`!>"[O8XG7/3AB#@]CWIQBWHD-)MF]17.?\+'\)?\`0T>'
M?_!I#_\`%4O_``L?PE_T-'AW_P`&D/\`\55^RG_*Q\DNQT5%<Y_PLCPEG'_"
M4>'<_P#84A_^*I?^%C^$O^AH\._^#2'_`.*H]E4_E8<DNQT5%<X/B1X2/3Q3
MX=/_`'%(?_BJ7_A8_A,G`\4>'<_]A2'_`.*H]E4_E8<DNQT5%<ZWQ%\)J<-X
MG\/`CL=4A_\`BJ3_`(6/X2/3Q1X=_P#!I#_\52]E/^5AR2['1T5SO_"Q_"7_
M`$-'AW_P:0__`!5)_P`+'\)?]#1X=_\`!I#_`/%4>RG_`"L.278RO$?AV[T#
M4)?$'A&-F9COU'3X_P#EX]98QT$N.HZ.!ZX-;&@Z[I_CC1K>_P!*G#"11)%*
M@(9#TR`>?4$$>H(IG_"R/"6<?\)1X<_\&D/_`,57%>(?$GAW0]1DU_PAXE\/
M/([;]1TY-5@`N?66,;L"7`Y'1P.>0#6RISFK-._3_)_H_P"E7+)]#MKNQFU+
M5;-[PQO+IX+I:2L5BD?(Q.N`<D=`#G:3ZX-<'XWA\8>%]3O9O",]D;'7BK7V
MR`L^E-]UKD$G+Y48QZ@8'4UU^@ZK9_$:&RU.WYL;.02VY&Y7DD`(W=B$ZC!Y
M/<8ZU]>URU\"ZP'EL[E=/U5VDOK@@&!6QRY8GAN%&W&&R,<YKG::=F9FE\/O
M"6C^#_#EO:^&MLL$P$LEWP7NG/5V/K[=NE=+7GTMJ_A/4(]4\.WDT^BZO)&A
MLT/FK'(QX:)/?/(!!XSVKL?MUQ:\7]L64?\`+6VRX_%?O#]:0&-XR\(G7'@O
M[.::._L5)A4,=K'KP,@!\@8;\#UXD\*^-;3Q`3:2%K;4X<B:TE&'4KU[8)Z$
M@$XS6_;7<%XFZVE25>^TYQ]?2H8])M8]0>^6%!=R*%:7')`[4`4K'7VN_$>H
M:6\,*"RB2176Y5W<-ZH.5'IGK3?&$VE6^@W,GB0QBS"$-N7<6)&-H7^(GICO
M7G>KSQ:5\1/$-])JMNF9M-BDMHK]A-"K!P-\;@H5<XPJX+8))X%:_P#9@\;?
M$O5X->D,VG>&O(-M9X_=NTL>[+COR#GU&!T!#"VN#W.1\'7OQ.M+*=/#EEH:
M:`9=VE+JZ7$TRP$9`W(>5STSSCU&"=_^U_BW_P`^G@G_`,!;W_XJO5N`/3%(
MKJWW2#]#6WMWUBON-%4LMD>5?VO\6_\`GT\$_P#@+>__`!5']K_%O_GT\$_^
M`M[_`/%5ZO13]M_=7W![3R1Y1_:_Q;_Y]/!/_@+>_P#Q5<MXH^,'Q!\(>)O#
M>@ZU!X134/%4SPZ<$LKPJS)MW;B7!'WUZ`^O09KZ`J.2WBEDCDEBC=XCE&90
M2A]CVH]M_=7W![3R1Y9_:_Q;_P"?3P3_`.`M[_\`%4?VO\6_^?3P3_X"WO\`
M\57J]%'MO[J^X/:>2/*/[7^+?_/IX)_\!;W_`.*H_M?XM_\`/IX)_P#`6]_^
M*KU>BCVW]U?<'M/)'E']K_%O_GT\$_\`@+>__%4?VO\`%L?\NG@K_P`!;W_X
MJO5Z*/;?W5]P>T\D?/\`\.?C!\0?BGH$FL>$H/",EE%=/:L9K*\5O,0*3P'/
M&&'?/4$`@BNAO_$GQ7TZSEN+BW\#HD:DY:VO0,]AG/&3Q^->MP6\5LFRVCCB
M0DG:BA1D]3Q6'X]_Y%6^^B_^A"FJUW;E7W#52[V0GP]\13^+_`V@:Y>Q1PSZ
MOIT%U)''G:AD0,0,]AFNAKB?@C_R1[P5_P!@&S_]%+7;5G525227<B:2DT@H
MHHK,D****`"BBB@`HHHH`****`"BBB@`HHHH`*YS5-+OKC4&:&YFC@8@F..%
M6\[IP6/W1C(QTYS71T4`<;XJTN_73=-4ZO<AEU2RS^YB(_UR?[-=!_9M[_T%
MKK_OS%_\353Q?_QYZ?\`]A:S_P#1RUNT`5OL\_VA)/M<GEJN&BV+ACZDXS^1
MKP?XS^&=?\0_%7PSIGA7Q1<:!K%UH.H?9M66V21K;$]J6`48!R`5_&OH&O*?
M%G/[0_@?'_0!U/\`]&VU;X?XGZ/\F:4MWZ/\BI\&=!UW3KWQ%:ZYJNJFX@>$
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MMF::.!AU7Y_ER#MR5&<>]/\`A.=WPP\*$]]'M3_Y"6@"E_PB_CC_`*'FU_\`
M">C_`/CE9OB3P)\0-9T*]LM.^(R:;<W,16*Z@T"-7B/J#YG'IGJ,\<UZ2KJW
MW3FG4`>(_"QK;PYI#_#KQ+IZ?\)?Y1DNY9LM'K(X#WOF'D@YR5SD'@=\::^-
M+3PC?2^'BEW)!&&MGGMD"7!D^4!SN8!5PP"GH3TS7;>./`]KXTL8@TLECJ=B
M_FZ=J,/$MK+V(/=3QE>_Y&N$T.YM/&FOMH7C&2/2O%VDNIU%+%D5=8@4':=V
M,E>A*\$?F`#.S^'@U0:?.NJ7UM?VB2;+*1!B38`!B0=F!X(ZYS7-ZIX8U3X9
MZ^^N_#VSEU#1=2G!UCP_!C*NQ`^T6P/`;GYEZ$?IW&G-;>'Q!IT[1P"5]MJ[
M/C[0QR2.3DOP2?7&?7&S0(04,H=2K`%2,$$=:S]?U^P\+Z3<:GKEREK9VJ[I
M)'_0`=R>@`Y-+H&OV'B?2;;4]#N8[NRNTWQ2H>H]#Z$="#R#0!XEK_PMN?`?
MQ<TGQ1IDL^K^$KF46Z>$U&5L;V5U_P!,@4G!P`21CY1D]AM]?\6V^K/8^=X>
MG59;?+&V<86?CCY@,C!YP.O0TVWL9;76;B_U6*6]G8E+22)04@A/\"KG(8_Q
M-W]<<#0T[4)[^XN=]L;>WA(1&=P7=L9;@<`#('7.<T,#%\#^,T\260BO-T6H
MPC9*KKL\PC(+*#C'W3E>J]ZQ?&/@RYTR].O>$%=)D8R7-K"NXDGEI(U'7/\`
M'&/O?>7#CYNGU;PM#JM_8W*RO;"TG\]EB0#S'X^;/4-@%<\Y#,.]>>_$KXBW
MFHR3^'_`AN7$4JPZKJ=I'O:WW'!CB[&3&222`,'G-`%/4M>U7Q^L=GHELHT\
MJDNK7!F68-'_`'R5X9!U2$[6?!+A5!5_1_#6C64>EPQZ6"=,)\T.[;GO7/)E
MD;J<GU_(``5S_P`,_AO:^%+",0B:*)@S/`LK>7.S-N,C)TSGOU/?/%6[G5;_
M`,*>)KM[V&1]'O7$B-'&!'``HW,6SPY;)(.`1C'.:`-WQUI\>K>"/$-C.\L<
M=YI5S"[Q-M=0T3*2I['GBO'/V=O#^D>#(+O2K>&-;./PSX>95>%2UQ)Y$I+D
M`?,^<9.,\"O:-=NHKWPGJ4]I(DL,NGS,CH<A@8SR*S_ADH_X5WX7.!G^Q[7G
M'_3):`)/^$-T;6)YM0U_0M)N;R[8,6N;*.615`"JI8@G@#UXR:P/B'X$\-6O
M@O5IK;P[H44L4&Y)$TZ)65@PP00O!K3CUG4&^(]QIS.?[.2S#)&".'X)8\9Q
MS@<]0<CH:L_$K_D1-9_Z]C_,52G*UKE<TMKFGX8&/#>D@?\`/C#_`.@"M.LS
MPS_R+>D_]>,/_H`K3J20KYV^.OPQ2X^+GAKQCH%M!=:T=+N=/D@N]$FO[9HM
M\9WMY>"C#<>IY`X&:^B:X_6=:U)_B#IN@6-REI9W6E3W<LBPAY"Z2(H`)X`P
MQ[&B[6SL5"7+).USS'P/HD$U]<P>/-)T:0I;I(L>E>$KF)H6+$`2%U?.5&0`
M!C'?-=E_PBW@C_H"7/\`X3DG_P`8KT'3=,ATJ!H[?>S2.7EED;<\KGJS'N>!
M],8&!5NK]I/^9CE4;;:T/&I+OX4Q&02BT0P^9Y@;1\%?+8*^<P_PL0#Z&M:#
MP]X$N84FM](FEBE4,CIX><A@>A!$'(KL-1\$>';V2XNM0T32[B:6,B626U1B
MPSN.3CN0"?6E\%:U9:[H4<^C6XM+.)C%%",`(%.!@#H/:CVD^[%SON<C_P`(
MMX('31+G_P`)R3_XQ7`_%[PEX,N[?PQ90Z+JO_$P\016TGV30FBDV/#,&*L8
M@`1G/X=*^BJX;XG_`/'WX)_[&JV_]%34>TGW#FEW/+_AI\(_!GP]670--T+Q
M1J%GIFGVD,+ZEIJ3RD;ICN)\L<G/7';VKHM.D^'6K7QLM+T:6ZNP)"T,.D1N
MR^6P5\@)QAB`?K7I5@H;Q=K:L`0;2T!![\S5>M-%TVRN$FLK"R@F2,QI)';J
MC*A.2H(&<9YQ1[2?<.>7<\3^*?ASPO%X#U1HO"FIJ^(@&&AH,9E0==G%>BV7
MPH\,-96Y.E67,2G_`(](?0?[%2_%[_DG6L?[L7_HY*ZFP_X\;;_KDO\`(4>T
MGW#GEW.7_P"%3>%\_P#()L?_``$A_P#B*/\`A4WA?_H%6/\`X!P__$5UY..M
M`()H]I/NPYI=SSK7/A#"_B30O$OA[4M4M-3\,PSQV5D+G;9SK,`'66,#GIP>
MQP:Z?3=2L?%VGR0:G:1&>V<?:K*YC#&*13D'!Z\C(-;]<YXHT4DC5]*F2SU.
MT7B1CA)U_P">;^H/8]C4-W).$T_Q18Z=\2[J^U&\MI]$O\6^F7"3DP6=P%!D
M39C"S/NR3D?*.WS9[K4O%DD$<%_I=NE_HRLRW5S"^\@=-T8'#*#G)_*LGP]I
M^A^,II]1GMYXIYH52\TJ<;$CDSN\QH\#+GCYCV'USVT5O%#"(8HXTB48"*H"
M@>F.E`%1(+'5X8KNV*NLJ[H[B%MK$'ON'\C1Y=]:_P"JD2\0?PR_(_\`WT.#
M^('UKGKFVG\#W3WFFH\^B3ONN[5!DVQ/62,>GJ*TK;7X/%$97PO>0W%L&*7%
M[`X<1$'!1?\`IID<@_=[\X%`'-V%A=ZKXU\12:5<P6!C:T%PLL'G,_R$LK`M
MM'&,$9_.K'A+_DIGCGZV/_HDUKZ!:QV7B;6X;9`D:0V@4?\``7YSW/O63X2X
M^)GCG_MQ_P#1)H`[:61(ES(RH.F6.*\=^'.LZGI%[::7;QVTEG?ZUJ/VAVEW
M21QJ04P,#DD_-Z=.M==\6K:*\T*PBNHI98CJMNS"+=N&ULC[O)!(`(]":Y70
M&M(_$.C-I-U.ROJ]ZMSFY24>:1EHSP".QVC[IZY-"W_KR![?UYGL-%%%`!11
M10`4444`%%%%`!1110`5SWCW_D5+['HO_H0KH:Y[QZ<>%+[Z+_Z$*J/Q(<=T
M97P1_P"2.^"L\_\`$AL__12UVU<3\$>?@]X*_P"P#9_^BEKMJNO_`!9>K*J?
M$PHHHK(@****`"BBB@`HHHH`****`"BBB@`HHHH`****`,+Q=_QYZ?\`]A6S
M_P#1RUNUYE\0M<GL_B'X6TY+J=+>^EA,EN8@T;LLZE2&SE6X/;D#'T]-H`*\
M5^)WA^'Q)\>?`UK=7>I6:#1-2</87;6[Y$ML,%EYQSTKVJO*/%QQ^T-X'_[`
M.I_^C;:MJ'Q/T?Y,TI[OT?Y#=-^$5@?&>NXU[QD/]$L^/[?GY/[[GK6]_P`*
MCL#TU_QE_P"%!/\`XU)X%\21^)_$GB2X2TO+-K806TL5S$4.^-I@2N?O*>""
M..:F\#W5_=ZIK)O;RYN[:*X:.'S`-B$.^50@<@+L&3SV]SC<S/+/$_[,*^)/
M$U_<6NO11@^60-2M);V=AL`W-+YZ[N00..`,5Z7\(OAD/A9X<FTS[=%?-/<M
M.SPVGV=%)[!=S'/J223787=@ETR.&DBFC^Y+&<,!Z>A'L:YOP)KNH:Q=^(H=
M6FBG&FZK);V[)#Y9$:\`-R<GCKQUZ4`;^N_\@34?^O27_P!`-8/PE_Y)?X3_
M`.P-:_\`HI:WM>XT/4?^O27_`-`-<]\(94F^%GA-H75U_L>V&5.1D1@$?@01
M0!GQO-X#UUY=2N;BXT[5)6S/*QD8R<;=WR@(%`(SG!`SU%=Q9WUOJ%ND]C/#
M<0R?=DBD#JWT(XI-0T^VU6SEM-2@CN;:==LD4BY5A[BN%UJUN-+FLO#'A2SG
MM+6X_>RW:OR0",KG.<$#:S9!&1C-`'::M?M9VT@M5\V[>-C#&.Y`ZGT`]:\X
M\<_!BW\4:=:ZSX<G6R\86$(>QU1&,?F,/F".1SL)^I&<\FMO7-=L/A=H=K:V
MJ7.J:Q>8@TZR$C2S7+]ER22$7/4]![UK>`=)UG2=!V^+;U+O4+F9YVCB0".T
M#<B!".JKV)]?3%`$GA?2M2_L^RNO&CVMSK:0@2>0/W4)[[,]SW;N>F!@5?U_
M7[#POI-QJ6N7"6UG;+N=V[^@`[DG@`=:/$'B"P\+Z1<:EKEPEM9VRY=VZGT`
M'<D\`#K7`:)HE[\0=3A\4^/H6M-)LSYFC:+-T0=IYQW<CH.W\P`T71+SXAZE
M#XH\>P-9Z/:-YNC:+-T0=KB<=W/9>W\ZFJZ+J?PPU2Z\4^"K.2?0+R3S=:T"
M(?,H[W,"]%;NR#J/T].BB>]D6:Z4K&IS%$?_`$)O?T';ZU=J$VW?H6TDK=3.
MT#7]/\4:1;:GH5S'=V5VFZ*5#U]B.Q'0@]*HWLVHVTTEAI-NWG7<C2)>.N8K
M=#C<S>K`YPO?CMFN)U_P_?\`PKU>Y\3>!;:2[T*[<RZ[H4(^[ZW-N.S#JR]_
MY>B>'_$%AXHTBVU/0KF.[LKM-T<J'KZ@CL1T(/2K(/+?&?@/Q?H$=V/AWJU_
M=V.NR#^U(KFYWS6Y/^LGA=S\N5!!5?8*.FW>\$^#-,T+1M,DTD;X)70^:RE6
MO0W=@>0@^\%/.1D\UZ+7"^/M5UOPKJUCKT$0U/PW9QE-0L88OW]N2?\`CY0_
MQ87@KZ9/?(`+/C&SU*ROX=;TZ[E:&QC^>W9@L<8R-[D`9;*Y&,\<'G%:I;1_
M'.BM;W*6]_8W4:F6WE'WESD;E/(Y'<"M#2]4L]>TVWO])N([JSND#Q2QG(8?
MYXQVZ5SRZ)I'A;6+F?0;1#J^IY(MT8`<XW.>ZK\H))].*`,#XH>)&\&Z>VF^
M$]/DUG5]=C:"'1+8A2`P*M<>BJHY(_BQQSDUV/@G3SI/@_1+%IHKAK*PA@:6
M(Y1RB!21[9%+H_ABUT[4)]4N(XI]9O8U2YO=N&9020@]%&>!^=4M=U9/">IV
M3QQ2O;ZI,RSHNT)&P4MY@)(^8XQM&=WU'(!FZ??2V_Q/U6U>V8P744;1S`,`
MK+$NX$YVG(V\``C\<UI_$K_D1-9_Z]C_`#%9FGZ9J-U\1KG5E"MHLMHOV:93
M&PD8JH(X^8#COZ5I_$K_`)$36?\`KV/\Q1T`T_#/_(MZ3_UXP_\`H`K3K,\,
M_P#(MZ3_`->,/_H`K3H`*X34/^2U:-_V+UW_`.CHJ[NN$U#_`)+5HW_8O7?_
M`*.BH`[NBBB@"MJ)*V%R5QD1-C(R.A[=ZYWX9_9V\+PR6;[_`#6W2Y4AE?`!
M!!Y&,#'MCM70ZGQIUUG&/)?.>G0UQOP9=9_";316\=O'+<ML6,Y!VJJD_FI_
M_50MV#Z'>5POQ0_X^_!/_8U6W_HJ:NZKAOB@,W?@G/\`T-5M_P"BIJ`*OPOU
MJXUO6_$SWUW%>O;20P+*ENT)VJTN`RGN,XR.#@58^&D*^=J\\`B$+W)C!6\:
M<L59R258_N_O#Y?KSTQL:'96]CXLUU+.&.%7M[5V"*%!8F8DGW-)X/\`#5YX
M;:_2[O?M4%S<-+"AR3%DDD`GG'*\$G&#SS@`%+XO_P#).M8_W8O_`$<E=38?
M\>-M_P!<5_D*Y'XT7*VGPRUR:42,D4<3,(XR[$"5.BCDGV%:-CXQM!86V;+7
M0/)3KH]QZ#_8H`Z0]#7#?#:%?M>N3P"(1/<F,%;QIB6620G*L?W?WA\OUYQC
M%K3_`(K>'=7G$&E37UY,R-((X-.G=MJMM8X"=`W'UKF]!\8Z/X!U>:P\4:M=
MV::T\]W9MJ-E+;11A"#(OF2*!TD3"Y)X8YYP&@\CU2N7L-5_M+QAJEG?1QA-
M*CB>W.]B!NSEB"``>@X)QCMFK-EXZT34_$*:+I=]%?7S6TEPXMCYJ1(C(IWL
M.%)+C`/)Y]*\^O)H;#QYXHNQ?+&RZAIJ21QPS1L,HP"F0`J^2W3&T8^;G!I=
M0Z'H/B'P])=3IJ6B2+;:O;#".?NSK_SS?U'H>U6/#WB&/7()%>-K:]MCLNK5
M_O1-_4>AK7KRCXP:;J+>*/"MUX.E@LO$#M/'!/+NV2`>6=C@'!!`*\@XW4`>
MC:SKVFZ$EM_;=Y;6BWLZVT`F<#S9&!P@]20#^`-<S+\)]*:[N;C3;_6M+2\D
M\V2#3[L0Q%R.6P%ZGU.:PTU>Q^,6@/HFMZ!'_;%E<HNIV-_$S1Z?*IR')&-X
M.,J`?F!YXS7I.FS-+:*)0JR1,8W"C`RIQD#L#C/XU*Y^9WV-I^Q]E'EOS:WV
MMTM;KWO?R^7%Q_!S3H;J:YBUOQ0EQ<!1-*-2PT@7[N3MYQ5;X8Z0FB^*/%5M
M'<7=T0\6Z>[E\R1\/,!N;V``'L!7H]>4:QJGB3X>>)-9U&T\+C7-/U62)898
M-4CA<-O?"E'&<_/V)Z&FVDKLSC&4I*,5=LZ7XHR01Z)9&]\T1G4H`#';>=AB
MWRY&X8YQSGTX-<9X#AOKO5]/>#SA:P:K?R7`4Y4`X"EBGR[BQ)P>Q]:T)=1U
MWXE6EM;:UH-[X4MX+N"[BN5U**=K@+*%,>U/F4,&^\>U;7A;X8?\(U=0R)J3
M-##>75T8(8!"LKS-N)?!Y(Y__4*<>_\`70))JZ>__#G="EHHH)"BBB@`HHHH
M`****`"BBB@`KG_'O_(JWW^ZO_H0KH*Y[Q]G_A%+['HO_H0JH_$AQW1E?!'_
M`)(]X*_[`-G_`.BEKMJXGX(_\D=\%9_Z`-G_`.BEKMJNO_%EZLJI\;"BBBLB
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`P?%Z*;73F*J6&JV>"1R/WR
MUO5A>+_^//3_`/L+6?\`Z.6MV@`KRGQ;_P`G#^!_^P#J?_HVVKU:O%/B?KX\
M/?'KP+<FPU+4=VB:DGE6$'FN/WML<D9Z<5M0^)^C_)FE/=^C_([7P/X;B\,>
M)O$MO;3SSK<"WN"96SM+M,=H]`*M>"_#^H:%?:P=0%N;>\O&GMV1%#@,S$AB
M/O<;>3SDD=@:YFP^),L7BG5[F3PCXR$%Q;6JQ2?V7PQ7S=P^]VW#\ZV/^%JC
M_H5?&'_@L_\`LJQ,SNJ\K\&ZK?V_B#Q?;Z79[UBU>6XN;J?B)4W/F-3U,AV]
M.@!!)[':_P"%JK_T*OC#_P`%G_V5<)8>&/%/CB[URTLWO/"VBW]^]^]W)$\=
MR\A9C'%M..!A68@D'(&>HH`]S&)8_F7*NO(8=CV(KRW4M-O/@[J4^K^&X);S
MPA=R>9JFEQ#+6#'K/`/[O]Y?\C9\!^.+RYO9/#/CI([3Q18IG*C$6H1#I-$>
M^>X['/'4#NF4.I5@"",$$9S0!DIXDM;_`$ZTN="DCU'^T4WV?E/\LB_WB>RC
MN>W3KQ6!XI\5VW@&U1I5;5O$FL-Y=G9Q#]Y=2=E4?PQKGKV]R:Y34O"NM_"'
M7;[6?ACI;:WH^MR?Z=H0D(:UG/"RP'G;'G&Y!P,D^XD\,:5'X)\5PZO\1+V3
M4_%WB8;`X@9HK!`"?)MR!@(,?-SDD@]Z`.F\"^!;C3KR;Q#XRF2_\47Z8DD'
M,=E'VAA'8#N>]=-X@\06'A;2+C4M<N$MK2V7+NW4GLH'=B>`!UJ/Q'XGTSPG
MH5SK&O74=MI]K'YCRDYR.P4#[Q/8#K7GGAK2+OXGZA:^,/'436VBVQ\[0=$D
MZ(.UQ..\A[*?N_6@#*7^UO&OB33M?\;:9>0Z$DI&D::F&-O)U2:X0]21D\\#
M@=^?7K6&:Z6*;4!M*@$1#H&_O'W]NU.2T6ZN%N;B-05XC!'('J??^5&JZM;Z
M-8SW=X7,=O&9'6-"[8]E'-9*+;N]C5R25H[EVBJ&CZY8Z_:"YTBYANH<X+Q.
M&`/7'ZU?K4R"N2\(>"K'P[K>MZGHIN+2VU:8%M/5_P#1TD4D/*J8^5G/7'&`
M*ZVO(?BOX^U#PU,OASPPJW.IZDQ:,0DM)&LC<!@/N_,W![C`%`'K%M=P7B,]
MG-%.BN49HW#`,#@@D=P>"*E(#`A@"#U!KSWX-_#%OAOHUU]KNI9;W59%GN8%
M?$$#\YV*.`26)8]SCT%=QIFJV6M6@NM(N[>]MF9E$UO*)$)4D$9'&0010!Y?
MXITK6OA&-2UOX>01WFBW2O+>Z1)NV6DV/]?$!SMS]Y1Q]!RNUX`TW3-`T&7Q
M3J.JQZSJ.M1)+>ZL.1*/X8HUZA03M"`9SVSP/0"`P(8`@]0:Y/0?AII'AS6K
MN_TXW8AN)O/BTYI<VMK,1AI(X\?*Q]>W;%,#H=+U'^TK?S&@FM90<203`!XR
M1D9P2.A!I^HZ;:ZM9R6NI6\5S;RC#QR+D&J^FW,5_=W=Q9O'+!\L0DC8,KLF
M=W(]"=OU!':M&D!RGAS0]7\-/?->7ZZE9R7&ZW@2'8T,6!P/5@<_4>]4_BOX
MBT[3O`5X;NZC0ZD%M[10"S3R,PPJJ.2?8#C%:_C7QKIW@31FO]79W9F$=M:P
MC=+=2G[L:+W)_2N,\#^";B^\3_\`"6_$5H?^$CNT+Z;H_G!HM)A[[$/60\;W
M`ZT`6=.^)<^CZ':Q7?A'Q<?L-HBRLFGDCY$`)'/M7;>&O$NG>+M%MM5\/W*7
M=E=KN1UZ@]U8=F!X(/0US/@_QU-=VVHR^*)(X%BO3#:N+=HED&6"H,_>?Y3T
M]16GX1\+Z9H$VKZKI</V,Z[<?:;B)7(B4J"`X3.U68?,Q'4GGI0!T]>?:Q>P
M6GQMT!+J:.)KG0KJ.$.V/,?S8SM'J<`G'M6SJOC)+CPV-5\&F#6XII/*2:UF
M61$.=I<X/S!3U`YK-NOAXGC7PYIL'C]GFU"PVRV]S;/Y<MM..LJ/C(8]/0"@
M#NJ*\[L?AY9ZFDC:;XZ\972PR-%(T.O!PCJ<,I(7@@\$58^%1NH&\4V%[J6H
MZHFF:X]O;S7\_G2",0Q-MW?5C^=)-/8<HN+LU9G=D9&#38H8X5VPHD:^BK@4
M^BF(*X;XG_\`'YX)_P"QJM__`$5-7<U@^,/!UIXTLK6WO[F_LS97:W=O/8S^
M5+'(JLH(;![,:`%T[_D;];_Z]+/^<U:M]=?8[9I`AD<D+&@.-[$X`_,UPL7P
M;@AO9[J/Q;XZ$]RB)*W]M'Y@F=O\/^T:NV7PV_LR]@O5\2^+;Y[1_,CM[W5#
M)#(V"`'7:,CF@#C?VBK[4])\+:"J:A(HU/7HK:\BC51&\7DS/LP1G&Y$.<YX
MKURVA2XTR&.90T<D"JRD9#`KR#7GC>#+WXGZ3)8_$N"YM5L+]+JPDMG$4B.J
MLH8'D'Y7;(P0,\$]:TD^$RQHJ)XO\=!5``']LGI_WS4PDIQO8VKT71J.#:=N
MJ=U]YT%MH&C^&YHIM&TBSM[B1?(3[+;I&Y4G<5SQ\N1G\*Y7XC:/<>*=1TZS
MATG3Y[IK"]^SMJ<,<\43;H!OVY.2`34TGP>@FN(9Y?%GCEIK?=Y3G63E=PP?
MX>];'AWP%%X>U3[<VM>(M5E$#0HFIW_GI&&*DE1M&#\HYJC$Y?P;X<N?"OB^
M,7.F::D]Q8714Z9:16JF/S+?@J&Y.[>V<G[U:]GHEQ>^,M<>.ZNM,XLY\0!-
MSY\P,K'Y@0=H]*V/%'@V+Q1/:3-JNMZ5-:(Z*^F7GD%U<J2&.#D948KGHO@S
M:PWL]W#XI\;I=72HLTHU@[G5,[0?E[;C^=`'H5<'X[_Y'CP1_P!?5Q_*.E_X
M52/^AP\=?^#G_P"QJO<?!>TN[F"XNO$_C2:>USY$CZMDQ$D$E3LX/RCD=LB@
M#4\.ZQK&HV&OR)`DE[;7$L=@MQ$;=)2JC8&ZG&>"WZ4WX<>,XO$EC-9WT+Z?
MX@TYBNJ:?*?GCD)R77^]&2>#Z8%5?^%4C_H</'?_`(.3_P#$U'9?!O3[+Q#;
M:Y_;GBBXU.U*A9[B_60L@))C;*<H<D$=_P`!@`[^L.#Q1::EJ=_I]C;W-S=:
M8RB8&'8@+9P0[8!Y5AQGI6Y7DEIH<^K^.?%(2&.[@,:Q-!),8PK-)+\^0/3(
M]1VH`[ZT@FU"[=Y&7RUD4R2)T)0Y6-,]5!Y+=SP/;=JII5NMGIMK;QNL@MH5
MBW+T)4`?TJW0`4444`%%%8_B74KW3H;)-(6U:YO;Q;=3<[MB@JS$G;R?N_K0
M!L45YY%XVUZXM5N;>WAEMY(Q(DJ:-=D.A&0P]B.:Z'PEKUYK)O%U'[$_D^2\
M,MJKJLD<D8<$J_(/-`'14444`%%%%`!7/^/?^15OOHO_`*$*Z"N>\?#/A2^^
MB_\`H0JH_$AQW1E?!'_DCW@K_L`V?_HI:[:N(^"(Q\'?!7_8!L__`$4M=O5U
M_P"++U953XV%%%%9$!1110`4444`%%%%`!1110`4444`%%%%`!6/J.NK8S*K
MO"A>988D;):5R0.,=!D@9YK8JI/IL-PY:3>-Q!8!L!CZ_7W%`'+^+/%6F-8:
M8QN<;]5LN/+8X_?+UXXK?_X2;3/^?I?^^&_PJMXM`6RT\+P!JMF,#_KLE;M`
M%4:E;&YC@\T>=*F]%P>1ZUX5\8?B9H/@#XL>&/$WB"XG&E:7H.HBX>W@:1P6
MGM5`"CD\D5[_`%Y%X]98?CSX)DN8EDA;0]2C42`;9)#);L$R>,X5CCKA2>U;
MX?XGZ/\`)FE/=^C_`"._MO'6AW45FZ:A$IOXO-MXW5E>1=H8X4C/`(SZ5?M=
M<L;V=8;:</(V<+M(SCZBF)I2SIYMTP:Z8966/CR?01^@_GW]*FM+I_,-O>@+
M.HR&'"RK_>']1VK`S+6\9QD9]*=7$^*+&\T/61XBM[J>2VB55N(W)<0Q9&\*
MBJ<AL`YZ@@8X)KJ-*UFSUF#S-/GCEP!O17!://9@#P?8T`8GQ`\&V7BS20]S
M+)8W^G$SV&HP#][:2#G*^H.!E>_UP:T_"G]L#P]8CQ<;0ZL(O])-KG86SP>>
M^,9[9SCBKFJ1/-82K"NYP`RK_>((./QQBO*?'/CK5_&6M+X1^&$MQ;WFY6U#
M4E!C^R(&!()(RO3![GH/6@#V"N6^)VJZ%H7@36-3\<><-$L+<S79@W[]H(^[
ML(;).!P1U]*S?!/CV>?5I/"OC=8K+Q3:1ET`.(]2A''GP^H]1V/X@=Q+$D\;
M1S(LD;C#*PR"/0B@#P[X?:!)\9[BR\;>(GDC\)E1/X8T'<"L8[7,V.KGJ$.=
MIKU.T@E61[J-C=11R$/&JX$I'_+1?5NWH<>O-<)KWARZ^%>H7&K^&H[B?PA?
M/OUG1[;[UKZSP#L/[RC''Z>GZ/J5EK.EVU[HL\-Q97,8:"6(Y5E]O3TQVZ5+
MC=W->9*-D689DN(EDA8.CC(8=ZY+QIX9OKAWU7PS*8]2A@V^622)P&#!<;@O
M]Y<-D8<]*K/JNL>%_%HAU))=1T_692+3[%9$"`@%CYC9P&(Z=CM]:[:&:.YA
M62%@\;C(([U1GL>;>$[/4H/$\9TN"'3[1D)O[&61F$28VH8CT8;D..!C!'3&
M?3:8D,<;N\:(KR$%V`P6P,#/X5P_C[Q_<Z;?0^&_!,*:CXLU%,QQGF*QC[SS
M'LH[#J?Y@C+\;?&2&R\:'X?^"X)M1\;W%FMTL;0M]GLX6./.EDQ@`=<=\CZ5
MT?@OX>VGA;3K@7LAU35=3;S-3U"<9>YDZ_\``5'8#I]:7P#\/[7P19SR/*^H
MZUJ+>9J>J3C,MU)]>R#)PO05U=`%`Z/$PVRRW4L?_/-YV*GV/J/K7G.O^&[_
M`.%NKW'B;P!:O<Z+<MYFN:#",#WN+=>@<#JHX/\`+U6B@#-\.^(M/\5:/;:I
MH5REU972;HY%/Y@CL0>"#TK2KROQ%X=U#X8:Q<^*/`5M)=:1=-YFNZ#"/O>M
MQ;CLXZE1UKT+P[XBT_Q7HUMJF@W*75E=+NCD7]01V(/!!Z4`><>)+6;X(R:A
MXG\/P2W'A#:]UKFDP(6:S`!9[FW4>P)9!U_EOP_&7PU>_#G2_&FEW,EWI>NV
MR3:7&L96:[+CY8U0\AL\$'IWKN64,I5@"",$$=:\;\1>!K;X:^,M/\5>'M+3
M4=-DN/(ETF,9>UEF95\ZU3.-WJH'`ST'*@&1H&GCXC^*]4N?&]Q>:5XVTIP^
MC6$H,::?%U5XQG$A;HQZC\C78V&DZ=XN\0Q-XR@FM_$EA`B*(YFB2XC23>)(
MR,'[V=PSZ@C%;7Q#^'D?C*"WO--G_LWQ#IF7T[4%7.P]XY!_%&W0@^N?7/'Z
M/K+>+6GTOQ%#)I'BG2&#7$"L/,MI.`MS;L?]9"W&1D]5'O3`O:3X.U'7X]3M
MKA[W1H+77%N+3=`H$D:9^YMVX4DDYZY/K4GC&34K_4/^$;T2>&6",>;.%W'R
M@S9`F/H"?E0?>XW84'-L^,M=O(_["L[(KX@Y66\5<P)%T\\9[GIM.,-^5<_K
M6J-X=NHO"W@F)=4\373%]K-O6)S]^[NG[X[*<<Y&",9`,(V5E\+/'5BG@K5H
MKMY('GU_2;V[6.!V/(N(V8[4N&;Y54<$$D[1S7?:%\>?!WB7QO9>$M&OKF;6
M[_3Y+](39R*J1(0&#,0`&!/2MCP!\/[7P/82EI6U#5[]O,U'49A^\N)/Z*.R
M]JSM153\;-&8JNX>';L`XY_UT7>D!N>%?`>B>"9-1;PS9BQ75+C[1<1H[;/,
MQR54G"YY)P!DDD\UP7AKXB^'?!_B3QK:>(]26SN)M?>5$,,CY0PQ`'*J1U4_
ME7KM<-\-?^0OXZ_[&23_`-$0U,(1BK15D:UJU2M-U*LG*3ZMW?8;_P`+Q\$?
M]!V/_P`!9O\`XBC_`(7CX(_Z#L?_`("S?_$5W=%49'(Z-\6?"GB#5+?3M'U>
M.XO;HD0Q>1*N\A2QY*@=`3UK:\3^)M-\&^'M0UOQ)=)9:9I<#3W4[Y(1%]AR
M3V`'))`%6M1@DGMO]'QYT;+)&"<`E3G!]CT_&O*OB]-++X9UN21F%K//I8\F
M249BD6^A!!C/.3GJ.#[TF[-%PBI)W=K+[R[X9_:9^'/BO2+?4=,U_9%<0B;R
MY[.:.2-22`679QRK?E7<^%/&&B^.='CU7PEJ-OJFGR2/&L\!)7<APR\\@@BL
MF_C6*\\6K&JHJZ/"`%&`!MGKQ;]C)Y+'X>2WDTL/V*:]F3`F+2&0;.B<[N#U
M!SZYJ92:DD:TZ494IR;LU:WX_CV/:O%?Q8\*>"-16P\4:NEC=O$)1$;>5R4.
M<'*J1_"?RK&;]HCX>J,MXCC'_;G<>_\`TS]C7=Z=')B:>Y4I)<ON\L_P*!A0
M??`R?<FK>*352^C7W?\`!'&>&LN:$K_XE_\`(L\Z?]H?X>H"6\1Q@#_ISN/?
M_IG[&FC]HOX=,S*GB6!BA*L%M)SM/H?DX->AW5PEI;R32YVQJ20.I]A4&F6G
MV6WS(JB>=C).0/O.>OY<#Z`46J=U]W_!*Y\)_)+_`,"7_P`@>9W?[4GPVL]>
ML-)DUV5KC44D>*1-/N#&NS&0S;."<\5UO@[XI>%O']W=6OA#5X=1N;*-9+B)
M8I$:-6)"DAU'!P:T->\2:;X?O]+CU7Y)=3F>"WE*C"$(7;<Q^Z-JGGVKS[P3
MK^G^(OCWXMFT2]AO8(=$M(6>)]RAP[Y`YP>HY`Q[GL+G35VON_X(/ZO*$N6+
M36J]Y/JNG*OS/7****T.0X>;XV>"K>>6&778?,@D:.0+;RMM920PR$QP0148
M^.?@9L[=?A;'!Q;3'!]_DIWP8_Y$?_N*ZC_Z62UH)X!L["[U.\L=4UFP&IW3
M7ETD5YB/S"JJS`$':,(OMQ0!G_\`"\/!!_YCL?\`X"S?_$5Y!X'^-'AWQ9XQ
MU+Q%HGBF[TG1/M#P2P7&GR*US(DCY!0H2,;AR<'YN*^A?#D#P:=^\N+NZ5Y&
M:*2Z<,Y0GY<D`<8Y'UK1CB2($1(J`DDA1C)/4T`>2?#_`.)G@_PEX;33KWQ!
M;O(EQ-)F."=@`\C.!GREZ;L=*Z/_`(7CX(_Z#L?_`("S?_$5W=%`'"?\+Q\$
M?]!V/_P%F_\`B*VO#'Q`T#QE//#X:U%+V2V4-*JQ.A4'I]Y170UP>B_\EC\1
M_P#8*M?YF@#O*X3X@^-]*T#Q5X'T/4Y9DU#Q!JS"Q5(&=6\N)MVYAPOWUZ^O
MH"1W=8/BA5-SH+%5++JR8)'(_=R=*`.<MO!6M6R6)*:%-<Z=:+:P3M-<+\JH
M4!*`[<D,<_6M?P;8MI=_J=D[B1K2&SA+@8#%8%&<?A755@Z-_P`C/XB_W[?_
M`-%"@#>HHHH`****`*6LZO;Z%IEQ?7Y<06R%WV+N./85YQ\7?BWX?\*Z%H=G
MK<EY%<>,"JZ:L=N9`3NC^^1PO^M0?B>P-='\74MY?AYK4>H72V=O+;[)+AK<
MW`B!8#=Y8(W?2E\2103?#Y'54E5+6(Q.\8R!\N"/0XJH?$5'=$/P1_Y(]X*_
M[`-G_P"BEKMJXGX(_P#)'O!7_8!L_P#T4M=M5U_XLO5CJ?&PHHHK(@****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`,+Q?_`,>>G_\`86L__1RUNUQ_C7Q%
M96VJ:/HT[LE[=WUK/`"IVR*LZ[@#ZCKCTKL*`"L7Q;X2T_QGI#V&KH^W<)()
MXVVRVTHY62-ARK`\@UM44TVG=#3L><>$_%FH>&]93PKX_=3?$$Z=J*KMBU*,
M=QV64#[R?\"7C(&YXZT74=1ALK_P[<)'>Z6[2I')O9)01A@%5AE\<*3D`GI6
MCXM\):?XST=]/UA&V[A)#-$VV6WE7E9(V'*L#R#7'^%O%NI>&-:7PO\`$!PU
MVP)T_40NV/48Q_$.RR`??3_@2\9`UDE-<T=^J_5?JOTVK?5'5^%?$9\1::C7
MUK):3OO4Q3+C>%)4D?ER.U6M&\+Z9X?FN)-(M4MC<G+A.`!DG`'89)./>KMS
M;1WL(#$C'S)(AY4]B#7FOBSXCZA?>(6\">!#%+XK:(27EZ5S!IMN3CS6[&3T
M3J"03QC.)!>\<>.-0O-8_P"$0^'/ES^(9DW7EXPW0Z3"?^6DGJ_]U?S]]OPK
MX6L?A]I"V.F>;>W]TV^XN9FW37LO\4DC>GZ`<=>O+V?AM_!L,'A?PK9WSOJ*
MM<:EKDLNV6XERI)9NK;OF!((V#IUKN/#=A:Z;:FUMKIKR>T`BF>28RNG&0I)
M).`#QF@#(\7_``XM/&-@C7LSVVMVK>;8ZK`,2V<@Y&S_`&.!E>_7K@BKX'\<
M7<^HR>&?',<=GXFLTRK+Q%J,0Z31'O[KVY]P.ZKE?'7A"Q\8IIUM=^?;WD%P
M)K6_M7\N>TVX+%&QWP%QTYSV%`'4D!@0P!!&"#7ENJ:7>_"'4Y]:\+P2WGA2
M[D,FK:3$,M9L>MQ`/3^\O^1Z5-?VMI/;6UU=013W1*V\<DH5YB!DA0>6(`R<
M58(#`A@"#U![T`5-*U>SUS3;?4-)N(KJRNHQ)%-&<JR_T^AZ5'(AMI6N;#]Z
MCG,\*'.[_:7_`&O;O]:Q?#_PYTSPUJ6I3Z=)="RU&59AIC.#:V\O.YXTQP6R
M,@Y'`P!7`_$#XF3_`-NQZ#\(;*/4O$0D*SSVX4Q6R`X=I.Q"]P><C`YH`ZGQ
MQ\19K:ZM_#W@&.+4_%&IINB0\Q6$1ZSSGL!V4\D_KJ^`?`-MX(L9F>:34=8U
M%_-U/4Y^9;J7^BCH%Z`57^&?@+3?!6DRS6,W]HZEJ[_:=3U609DO9FY+$]AG
M.!V^N:[*@`HHHH`****`"O*_$7AS4?ACK-SXI\`VSW6DW3^9KN@Q?Q^MQ`.T
M@')7O7JE%`&9X<\1Z?XLT:VU30;E+JRNEW)(O;U!'8@\$'I5-;&2'79K_5HY
MKME)6P,2;DMXR.?EZ[SSENXP!@5Y[XFT[4/AGXGN/$/PWLI-0TN9_-\3:+"<
M*BXS]H@'_/7N4'4<^E>G>&_$FG>+=%MM5T"YCN[*[3='(I_,$=B.A!Z4`/L-
M2EO[NX06KPV\`4;Y2`SN1DC;V`!'7UZ5SWQ"^'L?C&""\TVX.E^(=,RVG:D@
MY0]XW_O1MT(]^/?2U&YU&SN9;72+5I9[Z3?%<.O[F`;0&9SZC'"_Q9'N1P7C
M+2_%7PWBU'7_``9?7.M07<);4K74&:=H90N!<1`=`,<H.,=L#@`RIOB3KNIQ
M1^'+#2)[3XCPR_9Y'"?Z-`@`)N';&UH]K`A3GJ#Z9]$^'GP\L_`6G2!9'OM5
MOF\S4=1F.9+F3ZGD*.<#^M0?"WP]I6FZ`NIZ5?C6[O6@)[S5W.7NW/ZJH.0$
M[=^<UVE,`KS7Q/J_]D_&C0F^PZE>^9X>N^+.W\W9B:+[W(Q[5Z57"ZA_R6K1
MO^Q>NO\`T=%2`(_C'HDVJ'38K;5WU`3F`VRV9+^8$+E<9_N@GTX/I61\.O$L
M4$GC>]GLM3A5_%3Q"*2V(D!,$/S;<YV^_P"E>A0:#IEM.)K;3K&*82&02);H
MK!R,%L@9R1WKRF71;W7]-\>6FDQ&:<^+5;"D951%"2PR1R.O6@9ZGIFOVFI^
M3'#,GVF2!9V@S\\:L`1N'5>HZU>-Q&)A%O7S2,A,\X]<>GO7,>'?"$VC^(KG
M4OM>;6YLH+>.T\LJ8O+0*,G)ST/TR:DTSP%9Z7XHGUR.XN[BYG1UQ<OYICW.
M6(1CR%YP%Z"@1T]07-E;WB@7D$,ZJ00)(PP!!R#SZ$`U/2,,@T`<!9>(;/Q&
MWC*XTTS!8=.2"5)8RC(ZK.""#^!R.,&J_P"SQ:6\7P7\'RPP0I)+I43NZ(`7
M8CDD\Y/OD_6ETC0IM`;QO#=7DMZUQ9K.&D8DH&$^%R3VJO\`L^3:@OP4\'E[
M>WE7^RX]FR<@E>=N<@C.,9YJ7\2]/\C9?P9>J_)GI]9GB'Q#9^&-.-]JIF$`
M=4_=1-(V3TX%3'4)4'[ZQNE_W-K_`,C61XKCMO$&B3V$V^/[0,?OO-@`]]RC
MMZ=/6FS$K^./$$>GZ1I5Q&)FBOM2M(E,9*MB1Q@G@X'0G(JUH.N3:S:S3Z:W
MVF*"XD@9+E!%)N0X/*Y!_(5SWQ!1[W1?#=O8RQWEQ#K-CYHAG6+<%/)Q@\'T
MX^HK=\!>';SPWI5U!JTD,EQ<ZA<W.Z*:20!'D)09?G(7:".@Q@<4^_\`781-
MJ=IIFJWVGW&O6DT5QI<QFM7ER$1R,$[E.T\''-<3X4@M(/V@/%O]G+`B2Z'9
MROY1&&=G?+'!ZGCG'YUZJ1D8/2O(M)U'2M"_:$\5)=7=A8&;0+)]LLZQ;CO8
M$X)]AVJ7NC:G\,O3]4>O45D?\)?H7_0:TCC_`*?8_P#&C_A+M"SC^VM)R/\`
MI]C_`,:HR/`O#GQLO/!.G6NFV^C?:+6[UK5(X[FX$D.X1RSRRNHVG<JE2N0?
M>O2?A%K<_CJS\17VO&\D:#798([6Y1T2W58HCL56`W*"Q()'.:X?X?R>&O$\
MGANQO+"TU&[.L:G)%<R0+-'-;NU\&57Y&`0,CW&*]`\0_"WP%J&KSW.I:'9W
M.L7F'>.&9TDG(4*&*JP[`#<>PY-`'H=9]MK^FWFISZ=:WMM+?VHS-;K("Z#C
MJ/\`@0_,4GA[1X?#^B66G64:PP6D01(U9F"#T!8DD#W->.Z>!_PTI;,<96PO
MP#Z`N,_R'Y"@#V75];L-`M5N-:NX+*!G$:R3.%!8YP![\'\JR/\`A9'A?_H.
M:?\`]_:N7MM:>(KF*"YM[>]LK1S))YL:R(TF"``#P2`22>W%._X1#0?^@)I'
M_@%'_A0!1/Q)\+@9.NZ<`.YE%<SX0U[3M<^*^M7>D7MO>6M[I4'V:>%MR3;"
M"^QNC8WKG']X5VA\'Z"1@Z)I!!_Z<8_\*^:[6SETSXP^`8_"]KY1CT%9!!:;
M8@0;:/?\O`.0!D<9P.:4G97+IPYYJ-[7/I_5=7LM#LVN]8NH;.V5E4RS.%7)
M.`/J2<5Q_B+Q_P"')YM&,.L63B+4D=RKYVKY;C)]!R/SKHKR*W\0/':SP0W=
MK`XDN%EC$B%P/E3G()!.3Z8%>?\`A?X2:9:G3M1\6V5E#=Z=?7C(LZ(%ECE=
MC&K88J=H;C.>@X%,@[7_`(61X7_Z#FG_`/?VL;2?B#X;B\0Z]++K-@D4K0%'
M:3"D"(9.>F!73)X2T"10R:-H[*PR"+*,@C\J\E_:H\/:5IWP4UV;3]-L+68*
M`)(+9(V`(((R!GD4`>X@@C(Y%<X_Q'\,([*VN:=N1BK`3`X(."/SJAX&U&^M
M?!^GQZK',U\856WCD<.THVC:V0?NX/4XP!S[[%MX,T2*"-9M'TJ60+\[M91D
MNW<GCN<FE%W5RZD.2;C>]BK_`,+(\+_]!S3_`/O[2CXD>&#TUS3_`/O[5W_A
M$-!_Z`FD?^`4?^%9/B_PIHD/A/6I(='TN.1-.G976SC!4B-L$''!ID$'C^X@
M\1_#O4Y=%N;.>.>$B.9YE2/*N`06;@8((^H]:G\2((_A]M1E<+:Q`,""&^[S
MD<?E6+JFGG5OAGK=LLODO+>7964QO)L(N6(.U`6)X["MKQ&HC^'NU59`MK"`
MK\$?=X/O50^(I;HK?!'_`)(]X*S_`-`&S_\`12UVU<3\$?\`DCW@K_L`V?\`
MZ*6NVJZ_\67JQU/C84445D0%%%%`!1110`4444`%%%%`!1110`4444`%%%%`
M'!^/-"O[CQ+X=U6VOUBL+2]MXKBT*D^:6F7!!Z#!V_E7>5A>+_\`CST__L+6
M?_HY:W:`"BBB@`K!\5>&]+\:Z?/I&K*Q:,),DD9*2VSY.R6-_P"%@5)!'I6]
M6?;@_P!NWQP<&V@P?^!2TTVG=`G8\8U?QEXV\+W=GX$:)/[7U9G2R\2R*!;"
MW49:7;_SW`_Y9],C<..!Z%X>\"Z5X)\/Q:;HPFGOIY#.UZSYN+FX/WIG?\><
M\8..<\[?BSPGI_C+1Y-/UF-BA(>&6-MLEO(.5DC8<JP/((KS_P`&:UJ?@CQ5
M+X=\=3FXEOMSV.I2<+=HH'$?96`Y:+URZY!(&K2J+FCOU7ZK]5^FUVOJCOM&
MN0EW+9ZM)$VL%`\F#@2QYP&09R$SQCL>N>IYO4K1?AQ?/JMC%(VDW#M]L5.D
M&X@[W/)8`YQ@9&<=*M>,/"4]SJ,&O^'9IDOK9!YD,14"Z4;MN3C)*[V(4$!N
M`:Z/3+R6Z@6WUB!8+MH\O'U612.2/SP1V^F#6/F02Z-K5IK]BMYIDC20.2`6
MC9"".H(8`BL_QGK<'A?1I=:NI(43359BLLFP2@C&P'^\3C'J1BI]5U32O!&@
MS7E_)!I^FV29.%P!Z*H'4D]`.2:X?0/#]_\`$K5[?Q+XXMWM=)MG\S1-$E[>
MD\X[N>R]A^K`X?PQX%U+XT^*H/%7CI;BTLM,N%DT^.-S%)&R.&VJ1RHRHW<\
M].>37O-QKFGV>J6NFW5[:Q:A?([VUL\H$DRIC<57J<9%/ETR"29I5\V*1_OM
M%*R;OK@\US_C'X<Z9XNTHV\AEM+^&03V>HQ,?/MIA]UPV<GW&?RX(0'5UY/J
MGAV7X/Z[>>)?"5@MSX?U$AM;TZ"(>;!R3Y\..2`6)9?<^V-CP)XXO_[4?PIX
M_1+;Q):)NBG48BU.$=)8SZ^J_7W`[\@$$$9!ZT`8%A?V]U:1:UX8E2^TV^7S
M7CA.0X/5T'9O5>^/7KN6]Q'=P)-;NLD<@RK+T(KS'5M(O?A'J=QKOA2WDN_"
M]W)YFKZ/$,FU)ZW$`_\`0EZ8_3L=/O[>[LXM;\+2I?:;?+YLB0G(<'JZ#LX[
MKWQV/4`Z&BHK>XBNX$FMG62*095EZ$5+0!Q'B'QM=)?W6E:&D4>J6ZB2%+EP
MOVL`@M&@Z@G(`;D=>,XK6\(^*E\16\B7*+;W]N2L\`S@88KE<@'&1R.QX--\
M7^"+#Q=;?Z3&D=[$H^SW0!#1D'(&00<9YX(YK'\&>%YM,DFUGQ?#;6VJ1JT"
MS).2#"#PTAS@N?[W7IGFA;#.[K-O+R6YN&LM+;$JX\^?&1`#_-R.@[=3V!Y_
MP[XVN/&WVE-&T^[L;9'V"]N0HX!(.$ZAN,@'LP)]*ZNSLXK"W6&V4A5Y))R6
M)ZDGN2>IH$%G916%NL-LN%&223DL3U)/<GUKS#Q'X9O_`(8:S<^*?A[;276F
MWLH?7/#\/_+8DX\^W7M+SRH^]7JU4=1P)[$R_P"K^T<YZ;MIV_KC\<4`6H)/
M.ACDV/'YBAMCC#+D="/6GD9'->3>+OCO#I/C'3M$\-6T6J(+M(M5N/G*P*S!
M%"E01G>0,MQVKUJ@#R_6=&O?A3J=QK_A"WDN_#EV_F:SHT0R8#WN(!V/]Y>A
M_P#0?0]&UFR\0Z9;ZCHUQ'=6=TF^*5#P1_0CH0>0:EU"]CTVPN+NY#&*VB:2
M0*,G:H).!]!7D6DZ1IM_XAO%\$>(-?\`"MIJ%LFH/#"L`MG9S@LBR!BK'@D#
M`Y'M0!ZAKVLQZ1#"))8X&N'V+)("0GJ<#J>@`]2*KZ9I&F7^H6^OPO+>7B6\
MEM#=.[#$;,"P"\+@L@YQVX->%?&/X,>+/&DFBIX7^*/B,26TLBNL,WE$,P4@
MDVYCZ!6/S9]L<YZ']G_X*^,OAMJ=WJ7C?X@ZYXFM[RS$,6EWMQ-,ENP;(?,D
MC8.W`PH'4]:F_O6-G"/LE+K?NORW^>Q[C7E_@;4]4MO$7CN.RT1[R`>(WVS+
M>QIN/V>'/RGD8_6O4*X*X^&%XFKZI>Z'XNUW2$U:Z-U-;6\<#()"JJ2-Z$]%
M'>J,3=_MO6_^A;E_\#X?\:SM=\<ZEX=M$N=1\,WQ@:58V:"YCD\O/\38/"#N
MW053_P"%=:]_T4'Q-_WXM?\`XU1_PKK7O^B@^)O^_%K_`/&J`(]%^++:_=6]
MMIN@7_VBYA$RQ32I$R*02-P;!7(!(SUKH?[;UO\`Z%N7_P`#X?\`&L+_`(5U
MKW_10?$O_?BU_P#C5'_"NM>_Z*#XF_[\6O\`\:H`I:EK.L_;/%A_X1V7)TF+
M</[0AX^6?WK*^`&M:V/@MX-_XIR0_P#$IAY&H1'/'UK6?X2:M)/>2R?$#Q0Q
MOX5AG!BML%%W``?NN/OFJ>B?!'4_#FC6FE:'\1_&%I86$0BMH5BLR(T&<*"8
M">_?T%9S;4DTKG31C3E3E&4U'5;W\^R9VO\`;>M_]"W+_P"!\/\`C4%]XIU3
M3;.:ZO?#\D5O;H7D<W\/RJ!SWKGV^%GB`C`^)WC(>XALO_C'^<4'X6>(#C'Q
M.\9#_MC9?_&*.>7\OY?YE>PI?\_5]TO\BGIOQ73QC<"ST?PUJ!O5MDO8C.4B
MV\Y7YFXS\O;L?>NPA\0:S/"DD?AR4K(H93_:$/0_C7-GX6>("1CXF^,ACMY-
MES_Y`J&S^$.N6$*PV_Q-\:^6AR`Z6;GDY/)@S_\`K^E'/+^5_A_F'U>E_P`_
M5]TO\CK?[;UO_H6Y?_`^'_&N`\)37&I?M`^+#J^DBR*>'['9YDT<Q;YWS]WI
MVK8'PL\0!LGXG>,C[&&R_P#C'^<U3L?@G?V&MW6L1^/_`!7)J=[`D$UQ)':$
MM&A)5<"$#@D]N]'-)M>[^0W3I0A)JHF[;6?==T==XD\"6'B2>RFNI[VT%@SN
MB6<PA5F9=N6P,G`)QSCGH:Y_Q"DW@WX5ZQ?>'C'&GA_0KB;3VNXA/+,8869&
ME)ZY*@^I!ZU,_P`-]=D1E/Q"\3`,"#B"U_\`C5=3K7ARVU_PM?:#J+S/::C8
M264[JP5RCQE&((&`<$]NM:'&>2_"G0;/[#X2UM$DCO9=;U&!@DK+%L_TUL"/
M.W.<\XS6]XR^+-A;ZK>Z5I&CZUJ]QI\@AN;JST>ZGCMY\`[?,CC(W*&#'!XR
M!3+#X'7>E6UA;Z9XZ\3VL&FW+W$$:);D"1U<.3F,YSYKGZFK=C\,=1\,27-[
M8^,_$+^==_;KR`Q6Y%TXV[]W[O(RJ!>,=.*35U:Y=.:A*[2?K?\`2QW/A[4C
MJ^B65X\=Q$;B(,5N+=H)!_O1L`RGO@C(KBO"^B6&H_$'Q)=7UG;SW-H56":1
M`6B5WEWA3V!VC/K@5I_%+Q==>$O!UWJ6CR6ZRBVF:*65=RJPA=D8<X^\!P>O
M2L3X/0W,-_JZZE?3ZG=-;VSRW<Z*KRLS3-DA0`.N.`.`*%)-M!*G*,5)[,[K
M7[B32]$N)K"2VM6@CRK2J?+09&20O/3./>L?PWXS;5/[/L[N,_VA=6IN9'4!
M8_+W,H89.<G:#C'?-;VMZ9_;&F3VA<)YP'S%`X&"#T/TK(TGP)8:;?VNH,99
M+^UMC;AP=J%"2?N=!UZ]??DTR>A?\2Z^/#>G+>/9W=ZGGQQNELH9U#,%W8)&
M0,\XYKS'X<Z39:GXSCFO[2">6T\,:>8'D0%HMT8#8/;(X->G>)_#EOXITS[#
M?/)'$94D+1G#94YX/;ZUYY\*E">+'4=%\+:8!G_<%`CU>.)(4"1(J(HP%48`
M_"O,/B5J/_"0VM_I!N+:&.!XC$ZH929A(0%.0`IP.F3CU[5ZC7`ZSX9D\.)J
M^I:1-*EUJ<O#V]NI:,LY8L<AO7&0.@'?F@:.RT=/+TFS0QK%L@1?+5LA,*.`
M>^*XSXUVL-]X3LK:]BCGM[C6[".:*1=RR(TZAE([@@D$5V.AJZZ-8K/O\Q;:
M,/OSNSM&<YYSGUKD_C#_`,B[IG_8?T[_`-*$I]1([&RTVUTY`EC;Q0*%"@(H
M'`Z#Z59HKF_B!)K,/ABZD\),4U&+#)B-')4'YAACCI]?I2`Z2L;QG_R)^N_]
M@VX_]%M5W1YGN=)LIII$FDEMXW:1!@.2H)(]C5+QG_R)^N_]@VX_]%M0!R]Q
MHK>(?AOK6GHZQFXN;T;BY7;BX<YR.>U:_BJT-CX">V?:3;V\49V]/EP./RJ'
MPA;7E]H][%-)%!;-J5XHV+N=T,[]SP.XZ&K_`(]X\*WWT7_T(54/B0UNC*^"
M(Q\'?!0'_0!L_P#T4M=M7$_!'GX.^"NW_$AL_P#T4M=M5U_XLO5CG\3L%%%%
M9$A1110`4444`%%%%`!1110`4444`%%%%`!3'GCC8+)(BLW0%@":?7-ZKIM_
M-?2-;S.L3X/EK;JXFY'#,>5&,C'OF@"?Q?\`\>>G_P#86L__`$<M;M<9XJT[
M5%T[30=64%=4LL_Z(IS^^7WKI(K2^2.42WZR.RXC;[.%V'UQGF@"_15,VUX5
M@`O%!C/[T^0/WOZ_+44UGJ#RNT.HK$A/RH;8-M'IG/-`&C5:/S?M\^Z1##Y:
M;(P?F4Y;)/L?E_(U62QU(.I?4U9002OV11D>G6HX89#K6H;+@B1K>+`,0P@R
M^WG/.#NZ^HH`UJQO%?A/3_&6CR:?K,;&-F#Q2QMMDMY!RLD;#E6!Y!%6GM+X
MV\:)?JLJD[Y/LX.\=N,\5%]AU/\`Z"B?^`B_XTTVG=`G8X?PKXJU'PEK*>%_
M'KAYWR=-U(+MCU",=P.BR@?>3ZLO&0.S\4ZOIFB:'-J6N726MI:CS!.#\RMV
MV>K'H`.N<4GBGPG8>,=%?3M;1I$.&CFC.R2&4<K)&PY5@>017CVEZ7J=I\2[
M;2_C'?1ZA8V"A_#2K#L@O6`^:60=#.O=.F/F48R*U:51<T=^J_5?JOTVMKFU
M1N^$-/U/XFZ]%K?Q*LSI]I9-YN@Z)(V5E3M=2CNY_N'[OT.3ZGJNIP:-I\]Y
M?,5@MT+R,%)P!["B]LXM1@7+%64AX9HS\R-V8'_((K(\->*K;Q`US:2G;>6D
MDD4D;KL,H5BA<*3D*2#P?Y8)Q9!I:'K4&NV"7-L'C)XDBD&'B;`.UAV."#]"
M*T*X+5++5O!.H?:O"U@NHZ9=%5DM%8J\3XP&+89BN.``.._%=U"[20H\B&-F
M4%D)SM/I0!S_`(W\$6?C?34AN7DM+ZT?S;"_@XEM)1T93Z=,CN/P(PO`7Q!F
MN=6N?"GC1[6'Q/IGRLT3CR[Y,`B1/0[2"5[<^X#O&OC6^N-4'A7P`([CQ#.F
MZYN6&8M+B/620_WO1>YJ)O@GHG_",#3XI)TU9)?M2ZYG_2_M7_/4MUQG^'.,
M>_-,#T(@$8/(->6ZOH][\)=4N->\)P2W?AB[?S-8T:(9-J3UN(!^K+Z#\M?P
M3XWO1J;^%_'J1VOB2U3=%*O$6I1#I+$?7U7L<^X'=D`C!&0:0'#S^-]/L+C2
M=0T8M=:1KZNYGB(\K<,8V]Q*<GY<<[6S@BNTMKF.[@2:W=7CD&58=Q7B/B7P
M)KGPX\8ZCXD\/7L]Y\/]1M635O"UM'M>TE;&Z]MVSPP`Y48_P[_P;:6^F>'[
M:_\`"VHW6NZ?=YFD>68RO+GJZ>C#H5XS@]#0!VE<]XGT:W\61)ILN\K#,DTD
MB-@1E3D`]B3Z>ASZ5?.H#4@L>D2*P<`O<#D1@]O][V[=_0W;:VCM(1'",*/4
MY)/<D]S0`VRLH=/MD@M5VQIZG))[DGN?>IZ**`"O._B-XSFGN3X/\&P0:CXB
MU&$^>9>8--@/6:8CIQ]U>I./;+/B9XSU&=YO!WPW=7\7:E;,/M>W=%HT;#`N
M9?<9!5>YQ[9YOX,0-X%L[OP=XX5+GQM+&\]UJ<QX\1D@_OE9OR*?P\^]`":I
MX*T;P-\,8XM`E^WO_;%A)J.HHOF/.ZW"%F.W.%7G`'"C\37J%OXVT*ZGCAM]
M2MWEF<)&HS\S$X`Z5D^'+R'PEH,]QXD6#1K>2]58D8;0N_8B+U))+<#)].V*
MZ$O)J5Q&(XY(K6%P[O(I4RD=``><9Y)/H*&!/J=@NJ:;=6<K,B74+Q,R@$@,
M"">>.]<GI7PS@T_7?M-S+;7FFKI<5DEA+:*5!1LA_3UXQ@=L<YS[Z;Q-X@^(
M.N:3H?B-=$LM)L[25$&FQ7!D:7S,Y+<C&P?G5S_A$?&G_0_G_P`$%O\`XT`=
M/#X:TNUBFCL+"TLQ.RN[6T2Q$LOW6RH'([5C'7K^R^(5CH$DD5Q976E3W9D>
M/$H=)$4#(.,88YXK$UOP[XXT[1K^[@\?9DM;625`V@6^"54D9Y]JX"[\+^.)
MOCOX89OB#*IF\*7DK*NBPA.)H01LS@DF13GMLQW-)M+<N$)3O;IJ>N>!O#.M
M>&CJJ>(/$-QK\-U>M/9-<1@26Z-R8RPX(!.%`````YZUU5>9:#H7CK4HKQKG
MQ\H,%]/`FSP_`/D1R!GGKQ6G_P`(CXT_Z'\_^""W_P`:F$%"/*B\17G7J.I.
MUWV22^Y61W5%<+_PB/C3_H?S_P"""W_QH_X1'QI_T/Y_\$%O_C5F)W5%<+_P
MB/C3_H?S_P"""W_QJKJWA+QP-*O3!\0GBE%O)L<:!;Y1MIP>O8\T`>B45P_P
M0DU:;X2^%I?%>JR:YJ\VG))=ZA)&$:=VR<D#@<$#\*[B@`HKQKQ!IOQI36K\
MZ'K'AS^R_.9K0R1JK"(\@,#&<$<CJ>F<UOZ+X;\?7VDV=QJ?C>.UNYX5>:"+
M18)%C8C)`8XR/?`H`]&HKSR?POX]AD)7QP)(`H.Y=#@WYYR-O3&,=\]:CGT?
MQ=`(=OCZ:=[A2T:0^'8&9E&,GKT&1^=3SI;D\R/1Z*\&%EX_USQIIUQ:?$6^
MM-,TZ&=7LH?#T$G]ILY8*[`XV;`H."3DD_2NM.C>.)Q;MIOCI)TN$9@TFBP1
MXP1QC!Y_PJ55@U=.XE4B]F>F45P%KX3\=O'F\\=)$^3A8]$@<8^O'\JV/#MA
MKFBZBT?B;Q#_`&W%=QXM\Z?';>4ZG)&4/S9!Z'^Z:M.Z*3N=/7&>-O"6OZ]J
MFGW?ACQ)+H8LI(VDA$/FQW(#-O$BY&?E;C!'(!.0,5QG_"5^+/%/QM\4>$](
MUV'1-.T.T@FA9-.CN'<M%"S;B_O,?P45M6.M_$3PY/?V6J>&Y/%T:7):SU2V
MO[2R$D)5<*T3$%6#;L]>W-34IJ:LSHPV)GAZGM(6OYI-?<TT=/XG\(-KOAS5
M-(M;I+>#4K26#;-!YJPEU*[E&01C.<9Q]*\_T)FT#Q=KL-QXML=$B2&WACCN
MH81YQ1I06!=@3VX'3(KTWPMK%_K>F-<:UI$NB723-&UI)<QW!`'?=&2O/IVK
MP/P+X/USPQ<:WI_Q3O-'^(>LF^D<7=WI3MY,)VR(!A2%XG"]LE..*LP/4SXB
M@`/_`!<C0LCMBU_^+KD]/\<>)Y]0A74/%OA&ULFN)!(ZW=H[K%D;#C?C=C.>
MH..U3+9648Q!X3T*+'3;I\A'Y%"*;)M@&X^'/"JQ[E4O<:$Y"[F`!)5!@9(Y
MQ0!U+>(H%3>WQ(T(+S\Q6UQQ_P`#K@/A#'?ZSXHEN-&\7V]W`?#6G`/;V,$B
M#"=,@]15S0_#>LW-VVN1>!/#MS;ZK;1M%;$0+%$NU2'4$\%AU&!T%=/IA\4Z
M(7.C>`="L#(`'-K<PQ;@.@.W&:`.I_L3Q!_T,O\`Y3(_\:Y35H/B;%JEQ'HU
MUI\]BAC$$T\,2N_/[P[0>F,8Y!^O;2_X2'Q[_P!"G8_^#)/\:Y7Q0GQ<U?Q1
MX9O]`@LM'TO29Y7U73A/'+_:B,H"H6+?)MP>Q^]["@#T&+1/$)C4OXDVL1R/
M[-BX/YUQ_P`4])UF#1M)>]U[[3"OB#3M\7]GQIO'VA.-P.16S_PD/CW_`*%.
MQ_\`!DG^-8GBV+QUXKT^VM9/#=E;"VOK>[#"_1]QB<.%QN'4C&>V:`/5ZAN[
M."_A,-[#'/$W5)%#`_A7$_\`"0^/?^A3L?\`P9)_C1_PD/CW_H4['_P9)_C0
M!W4<:0QK'"JI&BA551@*!T`'I61XS_Y$_7?^P;<?^BVKG/\`A(?'O_0IV/\`
MX,D_QJGK&H^/-7TF]L6\+V,0O;>2`O\`VBAVAU*YQNYQF@#J/!'_`"!IO^PC
M>?\`H]Z/'O\`R*M]]%_]"%<SI]YXVT:.>WL/#%M-;O=331M-?QH^))&?#`,1
MD;L<'M7G_P`:++XK^);72KC1G3PQINFS%]4AMKB*9KZ,M'A>6P,!6'((^<GL
M*<=T..YZA\$?^2/>"O\`L`V?_HI:[:N(^"&?^%.^"<]?[!L__12UV]:5OXLO
M5E5/C84445D0%%%%`!1110`4444`%%%%`!1110`4444`%%%%`&%XO_X\]/\`
M^PM9_P#HY:W:PO%W_'GI_P#V%;/_`-'+6[0`4444`%9UO_R'K[_KV@_]"EK1
MJE#Y7]K76P2"801>83]TKE]N/?[V?PH`NT444`%8WBOPII_C+1Y-.UJ,M$Q#
MQR(VV2"0<K(C#E6!Y!%;-%--IW0)V/#M0\:^.O`FH:7X8%EINJ7EQ?(L.H7D
MAABO;3^-EQ@+,HY9>>FY5;)`]%U/P+;76L)JVARIIUW/(K7<T,8S<`#AB1U8
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MW<IZNY_/`[5T-<5XICO]`UI=?%W+)81JJ31NWR6\>1N^4*2V>#GJ".X-=7IV
MIVVJP":RE61"`2`>5R,@$=0<=CS0!A^/?!UAXOT;9J$DEG<V),]EJ$'$MG(.
M0ZG\.1W_`"(N^#UUF/PY9+XP>TDU94(G>V!"/R=IP?XBN,]LYQQ5_4X'N+"9
M(AERN57/WB.0/QQBO'/B?\2=4\1WQ\(_#66\MM1F8+=7T(V26YSRBDCY3Q@G
MKUQCJ0#VPC(P>AKR+Q/HNK?"/4;C7_`D#W?AB^F\S7M'C&Y[,'[UU:KTR.Z=
M._;CTCPG;:M9>&M-@\67<%]K$5NJWMQ!'L223')`_P`YZ\=*U>O6@#F=#O+*
MYTNWUGP;*E_I=\OFND+;O-SUD7_IIG[P/).<\BNBMKF*[@2:V=9(I!E6'>O+
M-9T.]^#^K77B+P9;2W?AB]D,NN:)",FV;^*YMU[>K(.N,_3M],U*VU&QAUWP
MI,E_IM^OFO'"<B0'JZ#LX[KWQZB@#H:X#QWX[O4U1/"OP_2*\\47:;I)7YAT
MN$]9ICZ_W5[\>P-7QE\37NM4A\*?#66UO_%.H0F5I"VZ+3(,X::7W&<!.N<9
M'0%J:5%\)O#WV708KC4=<UB0FYU.X0NT\[<>;*>X#,,1@YQG&<&@#?\`!_A#
M3/AOHDV)I+J\NG\W4-0G^:>]F/<]SDG`4=,U!XI^']O\0;2.77_,L[ZT?S=)
MFA;$NFR8XD!'5SW'3'`]:E\%:/=V\"GQ+J#ZAJD($DD+S>8+9V7DCC/)#$9Z
M`D"NNH`\,\5^,[Y-'@\+^.T2W\16VK6#03H,1:G"+E/WL9]<?>7M^@]SKS_X
MT64$WAW3KF6)&N+36;(P2X^:/=.BM@^A4D$=Z]`H`X;P[_R5SQE_V#M,_P#:
M]=%XM8KX9U,I,UNPM7(E63RRAQU#=OK2GPS9IJ]YJMKY]MJ-]%%'//'*?G6/
M=L!4Y7C<W;O4&JV<^O>'=4TRX6,W,D+P$Y*))N7Y6[X!S[X.10QK<X?Q'XAO
M/"_PTMTN&>2XU=YH/-OF>?:D@D9=S1@_,5P`?NY(Z"H=8U*#1OC%X;OK]BEM
M9^"-1FF8#.U%FM23CZ"MS5_!:S?#M;77B_GZ-;330FVF,0W*CA=VS`/RGD=,
MYK`\06,NH_%WP_:VD@BFN/`VI1QN>BLTMJ`3P>Y]#6=;;YG3A/BE_A?Y'=>`
M[^WU32KR[TZ>.YM;C4KIXIHFW*ZF0X(/<5TE<E\,M/ETGPW)973QR2VM]<1N
M\:!%)$A'````_"NL/2M7N<J,&T\::;=W.HPF9;8Z5+Y5S]H/ED,3@$9ZJ>QS
MS6Y%*L\221G*2*&4^H->:7?@G4M9N?$4$$UQ8_VC<1RB:XC#H3')E0HW9QM"
M]./49S7I-M&T-M%'(Q=T0*S$YR0.326P$M5=4_Y!EW_UP?\`]!-6JS/$.I6F
MG:3=OJ%U;VJ&%@&FE"#)&`.?4D#ZF@#!^#O_`"2SPM_V"X?_`$&NQKAO@UJ5
MI)\-_#=K%=6[W-OIL"RPK*"\9*!@&7J#@@_0@UW-`'#^#M<N/%EKJ9\07ENL
M=MJDUND$*B+?&NTJ&)))ZX.,9Q7;C``QT[5Y!X-LI9M%\1S+%&\::G=?.54E
M2%0G)/.,=,=Z]?'`K.,VY--;$1DW)HYS5H=9?6)'M[V2TTQ;9-IC@60^;N?>
M2"<XV[/UIL]B8+&!=3U'3Y8P28Y)K4[F)Y."''KVK(\3^-M5TSQ`]EHVEWNJ
M6RVL<A>RM_-VNS."&.<=%%<XOQ1EGVQIX4\6M<Z>[QM-;6;?(2?F7A",<`?A
M7.U&[??N_/U,6HZO\W_P2[X6L/M?BC5[<SV1A&#:9MF,;`/)N\O#C`P1GDUW
M;:1>&".%+FRCCBQY82S9=F.F,2<5Y1X3\;R17[366D:A=P.9#%9(&\Z!DED5
MO-!3.>>/J>M=6OQ8NY+M[6'PGK4MS&@=X47+*IX!(QT.#2I.D]&U?R8J;IO1
MM7\F=UI]O<6T)6^N1=2%B0XCV8'IC)I]Y%!-`5O=GE<$EFQ@]CGL?>LOPMXD
M;Q%9O+=:?=Z5<1RM&UK=X$F!@[L>AS4OB6(S:?&BJC,UQ$%#`$$[AC.:Z6U&
M#:UL;MVC='F-W<Z%X`^-=WJ\CW#?VWH0-U,CM<,\RR(B\9)`$<0'`QQSR>>L
M\-_$NU\81ZD=/DL].BLKUK59;JZ3>X"(V\1]5^_T8]JS])M6M?C)$LD:1%O"
M\I"JH!Q]K7&<=\5K>(/"7@O4]7D;5_#/AW5=:N0#FYTN&667C`W.RGCZFJBV
MU=E1;:U.JT^.&*SC%HXEB(R)`V[?GDMGOD\UYL+1+[XI:A%*%(-P"-RA@"+:
M+!P:]#T/2;?0M(M;"PAM[:"UC")%;QB.-!Z*HX`]!7!V/_)6[_\`Z^/_`&UC
MJAG<VMC93(1)8VB2QG;(ODKP?4<=#U%<U\1K&VMM(MVM[>")C=(-R1A3^E=9
M=QM&XN8%+.@PZC_EHOI]1U'_`->N7^)$BS:%:/&0RM<H01WZT`;'@K_D3=!_
M[!EM_P"BEK4NKR&RC#W4J1*3@;F`R<$X'J<`\>U9?@K_`)$W0?\`L&6W_HI:
MY[XO^:V@6,=JL#S3Z@D2K,L94AD=2/GXS@GIS0".XCD65%9""K`$'U%17\S6
M]C<RQ8WQQ,RY]0":Y7PDFJ1^)M7BU&"Z6PMTB2QEE.$90@#;`.,97/XXIL4?
MBS^T-5F\13Z<-*^PR+!;V:9^?+88LWS`[,9'3-`&9<^,(O[1L5T?4[J<3O/$
MZN"=\T6-P&<``<YP"#GBO1Z^?HW2#Q/H4%Y;P6-P+^^VH898WF"F,Y0-G*X(
M);('`(XKZ!HZ(;W"BBB@04444`%<_P"/?^15OOHO_H0KH*Y[QZ,^%+[/HO\`
MZ$*J/Q(<=T97P1.?@[X*Q_T`;/\`]%+7;5Q/P1X^#W@K_L`V?_HI:[:KK_Q9
M>K*J?&PHHHK(@****`"BBB@`HHHH`****`"BBB@`HHHH`****`/-?B!K+VGC
M_P`,:>+Z>..^FA+6GE!HY"LZD-G.5;KVY`Q7I5<]XQMH7ATV9XHVECU6SV2%
M`67]\O0]NI_.NAH`****`"J\?F_;I]Y3R/+3RP/O;LMNS[?=_6K%9UO_`,AZ
M^_Z]H/\`T*6@#1HHHH`****`"L?Q5X5T_P`8Z/+IVM1%XG(>.1&VR0R#E9$8
M<JP/((K8JGK,\EKI%]/`VV6&VD=&QG#!20::;3N@3L>3_#2,?"+4G\)>(T)E
MOYGGM-9D)8ZMR22['_ELHZIW'S+W%>A>,M4GT72QJFE:?<:E/`1\MLZ@^6>I
M.X@%.F>XZCI5GQ1X6T_QEHLFG:W$9(I,.DB';)#(.5D1ARK`\@BN*\,^)M1\
M':S'X6\?/YS39_LS4]NU-00=01T64#[R=_O+W`U:51<T=^J_5?JONTVNR>J.
MV\/>(]/\6Z6+G39HKB)P0X4Y'H?J#SSWIGA_P=I7A>2Y?1;<6_VIMSJO0<DX
M'MEB?QJ>'0[2TA#:''#9ON:1&B7Y6+')!`ZJ?_U5Q7BCXAW>JZP_@_P!Y;>*
M-@.HRL0T>CQ-TD?U8C[H[]_0XD%KQIXTOKO5O^$4^'VR;7YES=W;#=%I41_Y
M:/V+X^ZOT)[`Z'A;X<6/@Z&-]'D9]193]KO;H>:]V['+._.02?0]..:O^"_!
M=AX(TG[)IV^::9O-O+R8[I;J4]7=O7/;M6K8ZI:ZBTZV4T<S6TGERA#G8V`<
M'\"*`,CQ-X9N_%.C7%A<:K=::90#%-IQ,3QNI#*Q;.2`0,KP".#6'X)\;7L>
MJ-X6\?K';>(K9-T$Z\1:G$.DL9]?5>Q_3OJYWQMX)L?&^EK;7K26UU;/YMC?
M0\2VDHZ.A_+(Z'\B`#.O_%.IW7C&'2=!M5,5GN_M#[3$R;PR?NW1NA0'.3WQ
M@5P'CKPEXD^%%AK.L_"FX/\`9^J!Y=5L#"9192G[UU;1YXP.J#('7!QQT7PT
M\9R66LW7A#QY<VS^+K0@O=JZ[=33&5=0/NMM_@XQU'>O4*%H!YM\-?"/A;P_
MX$@N_"MW]N6_;[9+K2?-/>7#$[G/?<6)&P^I!Y)KK-*$U[=>;KJB*\B7,%N#
ME47IO'JQ[_W>@]3Y_KOA>[^$VOS^*?!MO->^&[EC)K.@Q<BV8_>N[9>S8^\O
M<#CVZG7]1O/%?AC3]8^&UW:7C"07$.Z38DZ;2-I;:2N"02,`G:5.*`(-8T5/
M!FIR:]I<%Q/#-(QO(U<'8&`RQ).=@QG'..PY..IT#Q#8>);'[7H\XN(,XW;&
M7G`/1@#@@@CU!%4/"'BVV\5Z>)(\B9,K*K(4!(ZE0><?XBMFRL+;38?*L((K
M>+<6V1(%&3WP*`..^,?_`"*=M_V&=/\`_2F.NYKAOC'_`,BE;?\`89T__P!*
M8Z[F@#POXR_!7Q7X^\8+J>@:C8BQ%HD2P7.MZA9&)@3G"V[;"#G.2,_ABF?#
MWX7>(?!.BZNNM^*ET9+>X\V9K.]N;^/;Y:_,SW)W*0.PXQ@]2:]-M?$-_JGC
M77-#@^S6UOI5K:3+/M+R.9O,R,$[1C8,=>M6_$\4.F^#]4^5G1+61G)<!G)!
MR220,GWQ0QK<X36O">L:QX,U:ZTOX@:A<0/8W`26*W4@D*P./F]0:P(2W@3X
MR>&KOQAXAN+^WE\)WB)-<0X$3&:V./ESUP?^^:Z7Q1K-WX7^&EFFEV[SG5=\
M4SR6S$0K*KNS%8R=N2<`@[1D=J2\M8;OXX^$4NH8ID_X0Z^(61`PSY]ISS6=
M3IZG1A=Y?X7^1;\)?%?PF+?4@=9@!&K76<Q2#_EH?]FMW_A;'A+_`*#5O_W[
M?_XFN@_L33O^?"R_\!U_PH_L33O^?"R_\!U_PK0YCG_^%K^$O^@U;_\`?M__
M`(FC_A;'A+_H-6__`'[?_P")KH/[$T[_`)\++_P'7_"C^Q-._P"?"R_\!U_P
MH`YNX^+?A2*!VCUBV9P/D4HXRW8?=]<5Q7[0NC7\/P[N[BS26YC3R7U%PP+,
M!<P-N*X)(4*QXQ@"O65T73U8%;&S!!R"(%X_2K<D:RHR2JKHPPRL,@CT(I-7
M+ISY'>U]_P`58^>_V=[:=[S7S=VTG]F2-8V[22D*JW$=A`&`!P0P/&5STKU@
M_$?0-&N+G3M:U>%+VPE,4H9')Z!ES@8SM9<T[Q9X!@\21V:6T_\`9R6DA?;!
M&`&SC.0,<''([CK6_P#V-9.!Y]K;SN%`,DL2LS8&.214QYN9IK0VK>S=*$HO
MWMFK;6VUZW/%O#'BW3M/TO6H;K4D@^UWUQ-#$P<%U=5PV,<@C(P>GM7<:W\7
M/#26:_9+\7NZ0"2*$%&*\YY8`>F>>AKL?[$T[_H'V7_@.O\`A2?V'IPZ:?9?
M^`Z_X4G3U;ON<;AJW?<XW2/C-X:N?,CN97TQ8@-GG)E7SG[I3/3'(/J*P[7X
MI^%T:X5]5D@:.\N&RMG.PN$:1B%)"?=((.>OZUZ=_86F_P#0/L?_``'7_"O,
M],CO?#O_``D,4'@.5H/[8GFA>V6)GNA(Y.Y0_08!8]AE0!4NDVE=[$NFW:[,
MCP5XPTZYUK7;BW>ZC@O+B5HYULY2809W96P%R"0<C(P?S%=7IOB[2K3Q/)//
M+<I;C3EB^T/9S`2R>8S$_=SG!!-8BVMK?_&+3+.\\-BQ@BTV4EKB&-DNVQDD
M8Z[22,GUXKTS_A%-$'_,'TK_`,`X_P#"LHX9QDGS:+R_X/Z$1H--:Z'):O\`
M%+3&EDB@L-3N1'@Q7,4&T9QU7=@]>.E6]7\>:1=Z?"D%W(MQYD;$?99OE(()
M.=G:MV[\,:1#:S/;Z-I1D5&*+]B0Y;''`%8'@.TM?$FCR76N^'=&M+B.X,0C
MCL5`P%7GYAGJ3].G7-;>SO>[W-?9O6[W.<T_Q-90_$^+4KJ:Y:Q'A^2V$YM9
MB%D-RKK&3MR3MYK8OOBG;:C/>6>F>$?&.N6UM((GN[.PC6(OM5OD,LJ-P&4Y
MQ]#77_\`"*Z+_P!`?2__``#C_P`*YGX41)!#XECA18XX_$%TJ(HP%`VX`'85
MHE96*2LK'5>'KR?4-$LKB^MKNSGEB!>"[55E0^CA20&]<$BO-[S6[?0/B9J-
MY?+<O"ESAC;V[2D'[-#QA0<?>%>LUGW/A[2[V=I[S3=/GF?&Z26V1V;`P,DC
M)XIC,O1_'EAKZSG2;;4KC[,X24?9"A1B`0"&P>A!KE_'VM1E[+34MKZ.:\G\
MZ*)[<\8(#$8SQEQUZ&O0[+3;33$9--M;:T1VW,L$2QACC&3@=:Y7XKV<EUX1
MNUT[1%UG4IT-M:*/*5H6D&`X:0C`!`)P<\<4`C9\%?\`(FZ#_P!@RV_]%+6K
M<VL-Y&$NX8ID!R%D0,,^N#7SSX+\0_%O4I].T/38M'L+2WB6)[V=8;@6T*#:
M&*))ER=H4`8R3GH*]%_X1SXG_P#0Z^&?_"9?_P"2*R51O:+_``_S.R6%C!VE
M42?I/_Y$]%"A0`!@"HKNW%W:S0,2HFC9"1VR,5Y__P`(Y\3_`/H=O#/_`(3+
M_P#R1698V?Q0OM6O[6/QKX4:&TCA=)5\-.V_?NS_`,O&,#;_`#I\\OY7^'^9
M/U>E_P`_8_=+_P"1.MU/P=/K6KZ=?W\T<<NG(\:&"1E#(VW<"IZYVCO^==97
MG'_"-_%'_H=O#'_A,/\`_)-'_"-_%'_H=O#'_A,/_P#)-'/+^5_A_F/ZO3_Y
M_1^Z?_R)Z/17G'_"-_%'_H=O#'_A,/\`_)-8TA^)L?BR+03XN\-&66R-V+C_
M`(1M\!0Q7;M^T=<C.<_A1SR_E?X?YA]7I?\`/Z/W2_\`D3V"BO./^$;^*/\`
MT.WAC_PF'_\`DFC_`(1OXH_]#MX8_P#"7?\`^2:.>7\K_#_,/J]+_G]'[I__
M`")Z/7/>/?\`D5+['HO_`*$*YS_A'OB=_P!#GX8_\)I__DBN4^*47Q%\-^`]
M7U+4/%7AV\M[2'>\$?A]HV?!X`8SL!SCM3C.7,O=?X?Y@L/3O_&C]TO_`)$[
MGX(_\D=\%9_Z`-G_`.BEKMJ\N^#.FZY+\)/!KVVMV\,3:':%(SIP8H/*7`SO
MY^M=HNF:\/O:Y:M_W#`/_:E:5IOVLO=>[[?YCJ4*?,_WJ_\`)O\`Y$W:*YVZ
M76=,:VEGU2VN(GNHHI(Q8["RNX4X;><'G/2NBJ(RN[6,*E+D2:DFGVO^J044
M451D%%%%`!1110`4444`%%%%`!1110`445B:CXDBL+LPR/%&>B"0-^\.0,`@
M8')P,T`-\7_\>>G_`/86L_\`T<M;M<9XL\4Z8UAIK&X*AM5LNL3\'SE]JZ0:
MY9&U-P)CY*OL+>6W7Z8S0!?HJK_:5O\`:4M_,/G2)O5=AY'UQBJI\2Z<I(-P
M<@X_U3_X4`:E4H;>1-6NYF7$<D$*J<]2IDS_`.A#\Z9;Z[8W<RQ6\Q>1_NCR
MV&?S%5H=7T_[;?3I<N3%'$DRF-L)R^,<<Y)/Y"@#9HJC<:U9VJ1-/*569=R'
MRV.1^`J'_A)M-_Y^#_WY?_"@#4HJG_:]H!;GS3BZ_P!5\C?-^G'XT?VM:[KA
M?-.;49E^1OE_3G\*`+E5-7A^TZ3>P[TC\VWD3>YPJY4C)]JK?\)-IO\`S\'_
M`+]/_A45[K6GWFE:A@O<116LC31JC*63:<@<=3TH`V%&%`]!63XI\+:?XPT>
M73M;A,D,F&1T;:\+CE9$8<JP/((JR-9LQ!!)YI$<YVQG8W)_+C\:;<:]8VDS
MQ3S%9$^\/+8X_(4TVG=`G8\:U?QCXR\$W-IX+N$$M]JLC1Z?XED4"`0@99V7
M_GN!U0#!QN'=:])\(^`-/\(:.D>A2&2^E/G7&I2G?)>R-R6D;^)3Z9X[<\U9
MUS3-$^(.E7&EWX-Q$P#AE5HWA<'Y9$;`*L#R".:X[PUXEU+P#K<?AGQS(9X[
M@G^S=3VX6\4<GCHLH'WD[\LO<#5I5%>._5?JOU7SVVNW-JCTRTNA<HRRH8YH
M^)(VYQ_B#V-<1JEA_P`*\O/[6TJU>32F#+=10H/]&4G<6"JNY^<X],GD#I+=
M^#[^S\4Q:UX1O6\K4)`;^*YG:6/9@D&,$X52220O4D5V-K=+=HZ3)Y<T?$L3
M<X_Q![&L""'1=9M]>T^.\L?,$3DC$B%6!!P<BN-\=>.[YM57PG\/5CNO$MTF
MZXG<9ATJ$_\`+:4_WO[J]3Q[`L\:>-+N/48_!_PUB@E\0SQ@S3;1Y&D0G_EK
M)CC=_=3N<>P/0>!?`MAX$TIK:Q:2YN[I_.O[^<[IKR8]7<_G@=OSI@<['\#]
M#3PJ=-+SMJS3?:VUTG_2S=]?.W]>O\.<8]^:L>"?&U]#JK>%?'ZQV_B&W3=;
MW"C$6J1#I)&?[WJO4'/X=]7/>-O!5CXWTH6M^9+>YMW\VRO8>);24='0_P`Q
MW_*@#H:\IUW0K_X2ZK<^(_!5M+=^&[QS+KFAPC)A/\5S;KV/=DZ$?IK^"O&U
M];ZJ?"OQ`$=OX@MTW6URHQ%JD0Z21G^]ZKVKOZ`.9TS6M$\1:7#>^&)!=PW7
M[^.>QCSM<]68]`W8@\]B*LGQ;8V%I=2:[.E@UA%YMP9@8QY?]\`\D'I@9YX]
M,P^(=4TOX9>"=6U:+3VCTW1+2>]EM=.M<LP4%WVHHY)Y/3U->0^`-,_X:#2R
M^('B(Q77AQU^T:#8.2JSXSM>0=50'^$\DY)]P"?QAJ&N>.;*R\37#3Z3X<MM
M5LTTJP9`)+T/.BF>4'H"I.T=>_N?>J\_O=,OOB1X0N[%K^STV_M[^)X;BWB%
MS%%)"R2*"NX!AG@@-T[@\"2WTSQW8:C8MJ?BW0;RV>Y59;:+PXT+RIU8*_VE
MMIV@\X/TH`SK#6I--^,7C"./2M5OE;3-,)EM8T9%/[_@[G!S5[QE\1-*TW2Y
M+;Q5I6O6=KJ,4L>XVZ?,`A9AD.0#M!Z]>@STK*E\.S>(OBQXI6WU;4=)-O8:
M>6:QE*&7<)>&YY`V\<?Q&M>;X77%S&8[GQ7XBFC/5)+C>#^!H!'+W6H^'M>\
M%WNGZ+I/B&ZB\."5E,!6/R)C$SA3LD`*[9/N],'&.*DL-7?4OCUX7CDT[4;'
MRO!E\0;N-5#_`.D6O3:QK0\2_"V>#PQK1@\5^(H2]C.7,<X7<?+/)]3]:YC1
M+2#PQ^T/X5TZ]UO4M4OK[P7>O$MXS/M436Y^4]!G:WY5%2UEZHZ,/>\K=G^1
M[Q1115G.%%%%`!114%_>PZ;8W%Y>OY=O:Q-+*^"=J*"2<#D\`T`3T5B^#/&.
MD_$'PMIWB+PG=&]TC5H?.M+@Q-'YB9(SM8!AR#U%;5`!1110`4444`<'K'_)
M8_#W_8*N?YUWE>.?$O4-,N/C1X/\/:C?7-E=ZQIMW+;FU!61EAY?$F"%`W`G
M/45J^*?`$.A:+/>V>M>(I)X=I1)K\E&Y&=P`!QC/>@#T74G,=A<NI"E8F(+=
M!@'K7(_!^VGM?!ZK>I&DLEQ)(3$V4?=AMR]QUQSW!QQBHM'\66UIX;MM-UB+
M5A=PVP@N"]LTC!@-IR3G<?<YS2^&O$>F^'=.^RK)K=XN[<'FLCD<`8`4``<9
MQ[T+J!V=U?16C(C[WEDSLCC7<S8Z\>GN>*YCX<Z7>Z9'K[:I:2VGVS6[BX@6
M0J2\;8VM\I.,^_-<'XG^+/B.QUF]3PQX'U[4(6.$OQ);()%V@*%2256`!))R
M.2/0UUVA?%2&708[OQ)I&N:-<1QEIX;J%)&`4<MF)F7!P3C.?:DGK:Q;BE%.
MZ]#O:*XUM-UD>,T\10>(0/"LFFDSZ9+#D;P,I(C<;!@DMG).%'&.<KPO^T%X
M)\:Z;)J'A;4I]0L8KF6U:=+21%\V,@.HW`9()`..*49-WNK%UJ48<O+-2ND]
M+Z/L[I:KRNO,]'J"\M$OK9X9MP5QU4X*D<@CW!YK*T'QEIOB.X>#36G+I'YG
M[R%E#*#@X/0X)''N*W*HQ.6O=87P;)H]K<6,<BZM?QV$4MIM3:Q1BK.AZ`!#
MT)Z]*V-6U<:>8H;:(W5]<9\BV5MN['5F/\*CN?P&20*X[XP:9!K,7A.QOUD:
MVNO$D$<H21HV*F*;HRD$?4$&NE\,>"M'\')<+H%O+$;I@TKS74MP[8&`-TC,
M0/8''4T;#;;=V)'XH1Y8S=6[V]G,WDK=,WRK,#AHV_N\\`]"01QQGG/A?X;N
MO"^J^)+6_P#LH:2:*:,6SR-&J-YA`&_D?0<5K^%;L>*M`U&+5K:W:&2ZF@>)
M(V5)$."3AN>=Q.?4U\X:?%X2L/B=HNBZK//#<>);XZ?'%9ZO>S)=>0I(^;>3
M&W(SR./8T(1[I\(9[ZY^$_AC5)+NZO+R73(Y;D7$QD-P<98Y.2&]_P`ZV/&&
MOWMAJ_@ZVTJ988=<U9[:Y<Q!R8Q9W$P`ST.Z)?PS3-),6@>(+'PIHUI!;:'9
M:3B"*)7_`'07"JI8\8Q[YZYKA-(\.Z!X3^+DUO;Z7K5RNCV0N;#;]IO$MWD4
M1LP+,WS;2PQV#'&,T`>J#4+I[IM/Q&MVB[WFVDIY1X#`>I.1C/8GI7D.E?$$
M6?QHU5?%=R[1V<\NEV4D5J6.P)%*`X0'N[_-CT%;MQ\1M,3XGQ@P:HA2V%FX
M:&3=YSY=(Q%MZD`G.?PINC0:2_QSGFTW2+VSN+_23>74EU9/$))@PC#@OP&V
M*H^7'`H`[OPIXMB\5/JXMX)(5TK4'LR7_P"6A4*=XX'!W?I6_5:TTZVL&G:R
M@B@-S*99BB@>8YZL?4^]6:`"N0^+&CP:_P"`=5L+UI5@N$57,3!6QN'`.#77
MUYM\:_B5H?@?3+#3-?EN4N_$4ODV2PP&0$AXU)8]AND0>OS=.#BH_$AQW-+X
M(#;\'?!(';0;/_T4M=O7$_!'_DCW@K_L`V?_`**6NVJZ_P#%EZL<[<SL<]XB
MU:W$\-C(QCG2ZM9@'7`=/.7)4]#COZ9&>M:VFZE#JUL+BS+-`S$(Y4@.`<;E
M]5/8]ZX[XI:WI&EQZ;%XGTA]4M)IC(C*K$0NA7!.T$XPQ/H0I!SFNQTFY^VZ
M79W!@:V-Q;I(86ZQY4':?IG'X5S1C+G;>QO.=)T8QBGS:^G3^O+SZ6Z***T.
M8****`"BBB@`HHHH`****`"BBB@`JI-IL,[LS;QYGWU5L!OK5NB@#"\6@+9:
M>%X`U6S&!_UV6MVL+Q?_`,>>G_\`86L__1RUNT`%%%%`!5*&8MJUU%M0".")
M@P'S'<7X)]!MX^IJ[6=;_P#(>OO^O:W_`/0I:`-&BBB@`HHHH`*IZS.]KH]]
M-`VR2*VD=&]"%)!JY6?X@!.@ZD`"2;27`'^X:`+ZG*C/<4M-3[B_2G4`%9'B
MGPOI_C#1YM-UN'S8)<%64[7B<<JZ,.58'D$5KT4TVG=`G8\R\,>)=2\%:U'X
M7\<R&?S<_P!EZH%PE\@YP0.%F`^\O\7WE[BJWC[X@7&N:LWA7X07-E=^,`I6
MYO\`(FM]&C/5I\'ECV3KG!],^@>)_#-AXMTB73M9B,D$A#*RG:\3CE71ARK`
M\@BO,OA]8VWPF\3W^CZU900W>OS&:/6(U(&J8W'![)*NYV:,8!+,ZC)85JTJ
MBYEOU7ZK]5^FU/74[/X:^%;#PAI$EC;B1]59_-U6YN&W37<YZRLW=3SM[`<=
M<UU-]>PZ=:2W5ZXB@@0O(YZ*HZFL_P`0;8M-EU.V\QKBQ@::)H%WM(H&2F,_
M,#CIGWX-'AWQ#;>)+`21A%EV#SX-ZOLR/4<,.O(XZ^AK$DDT#Q#9^)+$76FL
M^S.&1UVLO<9'H000>X(-:=<)K,&H^";\7WAVP2\TRX(6>UB.UHF)P&R<X3GL
MI/X8KM;.=KFTAFEB>!Y8U9HGZH2,[3[CI0!E:KHEAKVM6!U6T@N3I#"[M6D3
M)CF)*A@>V`#^8]!567XC^'8/&D/A2;4HDUR>'S8K=E8*_7Y0^-I?"L=F<X4G
M'%8GQ4\4S:)':V/AAY)O%&J`PV5G`H9W0GYG;^XJXSO/3GWQA?";X6VFDRIX
MB\5R0WOB,%F'FD,;`D$,!GD-C()^M,#UP@,"&`(/4&O+?$/AR[^&E]=Z[X.M
M'NO#U[EM<T.$8V`C#3VX'1@.JCJ/TZY/B#I#>+%\/R2317DT(EMI9(BL%UUW
M)%)T=EQR!Z]^<=+2`\YU/Q!:Z/X`LM3^'EU%)!J&HVB+.X,V5DF2-P03PP7C
M!Z$=,UWEM8+#*9I9))YR,>9(1P/0`<`5XY\2?A#=Q3%_!Z--X?UC4[6;6M$5
M20'29&\^$!AMR0-X';)P<8'4:M\'XM1UA[JUU>_T^T*(BV=N25P'#,Q9F)W,
M`5R,<-T.*`+GAW_DKGC+_L':9_[7KM9YX[:)Y;B1(HD&6=V"A1ZDGI7GG@?1
M;/1?BMXTCTV$PK)8:8S@R,^3B?\`O$UUWC((?"NK"=2T9M)`P"!R1C^Z>OTH
M8(/$5U#=^$]8DM98YHS87`#QL&!PC`\CWKAY@#\=?"1P,_\`"'7_`#C_`*;V
ME97C<MHGPSTBWMY5B@N[IA*L2RVH;S%D8*-HRH#$?*W!Q@YS2^*;?6+KXQ>$
M4\*WEI97W_")7I,MU#YJ%/.M<C:.^=O.>QK.IT]3JPOQ2_PO\F>RT5Y=HD'Q
M+U*&[:;Q#X;!@O9X%VZ:_*HY4$_-UP*N7FG?$BTLYYUU[P_*T,;.(QIS`O@9
MQDGC-:'*>BT5X/'K7QWEV?\`$@T.-7(_>-J$!50?XCCJ`.>*]ET?7['6%9+*
M\M[J:``3B(\`],CVR#2;2=BE"33DEHMS3I"`1@\@TM%,D:B+&H6-555Z`#`%
M.HHH`****`"BBB@#@-=B2;XP:`LB@AM(NESCG!/-:?B=VN?#6I^:<FTM_*8^
MKY&3^07\ZS->D$/Q>T&1_NII%RQ^@-:?B>-K7PWJ0E&&N[<RO_UTR,_H1_WS
M0`SP9X=TJZ\/02W.F:?-+)+.7>2U1F8^:_))'-<OXF^$?@J[\3B6Y\*:#))<
MFW>9S8IEV:?:Q/'<<&NX\"_\BQ:_]=)O_1KUYUXH\`ZK/XKN)1XBNR+RX26(
M-+.OD*\Q"HH64#"'D<"N+'?`O<YON_4[L!;G?O\`+]_Z&;%\(/!!TZ)V\)Z"
M7,49+&R7))L7<]O[X#?49KLO`GPO\(:5_:$VG>&-#MI7E$3,EBF2GEQMMY'3
M))_&N#B\!:FUC'(-<N%0QH0@GN<`&T>0#_7=E!3Z&NW^&/A#4=%U.\O;O6KF
M\M]I@-HTDK(7*QL)/G=OF`^7CM7!A$U47[JWGH=V+=Z;_>M^6IH?$.X^R_#3
MQ-8WRLKIHUS'$VTE9E\I@,$=\=1ZUSOPQTVRL]:U`+96D4"6MLAC6!55"WFG
M.,8'(Y^M>MUYQH<9G\4>+H8_]9/)"J?7S)CG\@:]P\,Y6+4KG3/V@]$L[%U@
MM-7;4#=0H@`=196KH#Z8(!_/UKURYU8PZK%&K+]D12EP_9)&QY8)[="/^!+7
M"V.@Z?KWQ:NM0NXG^TZ9$\EG(DK(8O,M[5'Z'G*\<UZ1'9016QMTBC$)!RA&
M0V>N?7\:`/-M7LX/B-XU@TW4[FZM1H0NI$6SGVD2*T`CD(*\,%=\'T8X/-;'
M_"JK?_H8O%?_`(,O_L:ZBVT*TM+];R%'\](6A0M(2%1BI(`)]47\JT*44TK,
MNI*,I7BK(X6/X2VD2E8M>\4(I))"Z@`,^OW:H1_`C18]2DOQJGB%KN0)B1KM
M6,97.&3Y/E)S@D<D``UZ313(.%_X5+:>;YG]O>*/,QMW_P!H#./3.WI3%^#]
M@L[3IK7B-;AQAYA>J)&''!;;DCY1Q7>T4`>:I\!=`BNS=1WNLK<M-YYG%P@<
MR8QOW;,[O?K6_P"'_AW9^']:_M1-0U>^NA`T`-[<"7"D@_W0>WKCDUU=%`!1
M110`5R_Q&T^UO?#,\EY:VUQ);%7@:6)7,39`W*2/E/N*ZBN>\?9_X16]QZ+_
M`.A"JC\2''=&5\$O^2/>"O\`L`V?_HI:[:N)^"/_`"1WP5G_`*`-G_Z*6NVJ
MZ_\`%EZLJI\;/*_CJ9C9Z8&0RZ?'(\MW&)K=`P!0#<LW#H-QX'?;G@UZ-H<D
MLVB:?)=>5Y[VL32>4P9-Q49VD<$9Z8XKSSXWWTMC%HS06,=RLD[1R3.)!Y:L
M44KN0@@$$L0<@K&>"<5Z1IL8ATZU15C0)"BA8TV*N`.`O8>W:LEL0^A9HHHH
M`****`"BBB@`HHHH`****`"BBB@`HHHH`Y#QIXAL[?4](T>=I$O+J^M9H04.
MUPLZ@@'U&,X]*Z^N"\>Z#?W'B;P[JUM?"*QM+VWAGM"#^]+3+AAVX.W\J[V@
M`HHHH`*JQ%_[1G#0JL?E1[90.7.6R#]./^^C5JJ<*I_:MR1*S/Y,6Z(CA!E\
M$?7G_OF@"Y1110`4444`%5]0,HL+G[*Z1S^4WE._W5;!P3[9JQ5/6#$-(O3=
MJ[0"VD\U4."5VG('OB@"V.@SUQ2TB_=&.F*6@`HHHH`*R/%'A?3_`!?H\VFZ
MU%YD,N&5U.UX7'*NC#E6!Y!%:]%--IW0'F?AKQ+J/@W6H_#'CJ0S&?/]F:GL
MVI?H.H/99@/O)_%]Y>XK9N?!]S;Z]:7_`(3N;;3[0[FGA2,;78@G=QU!^4%1
MC&,UL>)_#^E^,;"XT;68S*K(LHVDJ\+9.R1&'W6!4D$<C%<=X:\2ZCX*UJ/P
MSXZD\XSD_P!EZIMPM^HYP>RS`?>3^+[R]Q6K2FN:._5?JOU7S6FU;G?Z??B\
MWQSIY-U!@30DYVYZ$'NI['^N:YWQWX\'A<6^G:-;_P!I^(]3^33]/0\D]Y'_
M`+L:]23Z?4C/^)WC$:)%9VOA>)=0\8:@"NC6D9R&SU>7'2`=6/MQC&1-\-O!
M[:&+G4?$LRW_`(NOP#JMT>0A[1PYZ0CMTSCG&,#$DL^`_`9\-M<:IK]P-4\3
M:IS?W[#A1VBB'\,8].^,^@'52V=O.^Z>"&1A_$\8)K(\7ZQ?Z)I@N-)LUNW,
MBJY9L+"I/+MCDJ.^`35_1M476--@NT0Q^:N6C)R4/<9[X-`&=XQ\%Z?XUT<V
M.I*T;1D/:W,)VRVL@^ZZ'L16%X.\7WUAJ@\*^/2L>M1)FSO0,1ZI$/XU])/[
MR_C7>5A>,/!]CXSTHV>I!XY(V$EK=1';+:RCHZ-V(_6@#=HK@/"OC6[TG4U\
M,?$22*#6$P+*^/RQ:HA("LI[29(!7U/%=MJ&I6FDVK7.IW,-K;H0&EF<(H).
M`,GU)`H`BMM$L;35[S4[>`)?:A'%'<S;B3(L>[8,9P,;FZ#O2ZUI<>MZ3>6$
M[%8[R%HF8`'`88[UG_\`"=^'?^@UIO\`X$+_`(T?\)WX=_Z#6F_^!"_XT`9V
MH^%[;2O`-W83?Z8FGV4[6[S#<4.Q\8SD\`X').!UKG9?^2Z^$O\`L3K_`/\`
M1]I6[XM\>^'$\*ZRSZYIBJ-/G))N5X_=M[URUCK-AK7QQ\+/I-W!>)%X/OE=
MH7#!29[7`)%9U-EZHZ<+O+_"_P`CO_"7_'MJ7_86N_\`T::W"`001D'J*P_"
M7_'MJ7_86N__`$::W:T.8YCQ1JTW@CPQJ.HI`FH66G6[2"W,OEN%'\`;!!'I
MG]:E\*>$M-\/B:[TJ.2-]2(FEWONY(S^?09ZG`]*H_%__DF'B7'_`$#Y*@7Q
MTUKK&CZ79V9N[>\MXF^U1MN0`CU''T]<-TQSG4<%:4CJPT<144J=)Z-7:O:Z
M6IV]%99\4Z*"0VKZ6"#@@WD?!_.D_P"$LT/=M_MG2LXSC[9'_C6ARFK165_P
ME6B?]!C2_P#P,C_QH_X2K1/^@QI?_@9'_C0!JT5QGB'XA?V5J6FP:79G5+:_
M/_'S;OO1?FQU&1U&._)48Y)'4VFJ6=]-+#:75M/-;G$T<4JLT9SC#`'(Z'K4
M1G&3:70VJ8>I3A&<EI+8M453O=9T_39%34;ZSM7<;E6>=4)'J`35;_A*M$_Z
M#&E_^!D?^-68G"?$"_DTCXD:#?+9W=_''921/;VB;YI-Y8@*O?[A)]@:=XD\
M<7.OZ1+90>%/%EO+,5"RRZ:=B<C)."3C&>@-6M3U*TU/XG^'WTVZMKM(UP[0
M2K(%)BN<`X/%>B4`>;:)XOU+1-.2R'AO5+@0R2%95MYU#AI&8'!BR.".*YS6
M/%WC>\UAKJU\)1"&-T$(D-WN*I)O4MB#`)Z'%>V45G4IJHK-FE.HZ;ND>`IK
M?CI+9(1X5@(157=F[_A@:#_GW]&W?ABN@\*^-O%NGS7":SX2?[/*?,!M1=%P
M^U5QAH`,87/U->O45E3PL8.Z;-:F)E-6:1PO_"Q=3_Z%35O^_4W_`,:KF]&U
M_4-%\3:EJEWX:\0W":DH*Q6EC(YA8/(?F+JN<JPZ9ZFO7J*Z3F/./`375_XU
MUC49]+U73K>Z0M&M]:M$5&(5"Y/!.8W.`3QC->CT44`%%%%`!1110`4444`%
M%<]JOB=]-\2:?IGE1&*\4L\K289>N`J_Q=#D_P`..>HK9L=0MM2A,NGS1W$0
M;;YD;;E)P#P>AZ]J`+%%%%`!7/\`CW_D5;[Z+_Z$*Z"N?\>_\BK??[J_^A"J
MC\2''=&3\$?^2/>"O^P#9_\`HI:[:N)^"/'P=\%?]@&S_P#12UVU77_BR]65
M4^-F'XD\)6GB=H&O);F"2W61%>%ER4D`#J0P(P0!SC([$5K6=I%86D%M;+LA
MMXUCC7).%48`R>3P*FHK(@****`"BBB@`HHHH`****`"BBB@`HHHH`***8TJ
M(P5W52W0$XS0!B^+_P#CST__`+"UG_Z.6MVL+Q=_QYZ?_P!A6S_]'+6[0`44
M44`%9UO_`,AZ^_Z]H/\`T*6M&J<,:#5;J190TCPQ!H\?=`+X/XY/Y4`7****
M`"BBB@`K/\0_\@#4O^O.7_T`UH53U@1'2;T79=8#;2>:4^\%VG)'OB@"TGW%
M^E.I%^Z,>E+0`4444`%%%%`&;'_R,5Q_UY1?^AR5'XG\,:?XOT>;3=:A\V"7
M#*RG:\3CE71ARK`\@CI5I"G]K2@0L)/LZ9FSP1N;"_AR?QJY33:=T!XI\/M.
M/PM\9WMAXUDN-2U37)6-CK]T0QO(1R(!@`(Z#J@^]C<,XQ7KM^B26_VN&39)
M`A=)4&[*XR00/O`^GY<U7\3^&-/\7:/-IVMP^;!+@J5;:\3CE71ARK`\@CI7
M$>'/$FH^"=:C\,^.93.)R1I>J;<+?J.=I[+,!]Y?XOO+W%:R2J*\=^WZK]5^
MFU;G;^'?$-MXDTZ.YM0R,Z*S1.,,F1D9'N#FL-/">K:/XB6X\.ZBL>EW4H>[
MM9UWE<$<*3DA=NX`#&"0>:+SPE=6NLV5]X,GM;"U>0O>0A,JZD?PCH%/<#&2
M=V>N>IL[S[0&29?*N(N)(R>GN/4'L:Q)+-<WXY\=6'@72TN+Y9+J\NG\G3["
M`;IKR8]$0?ED]`*/'/CFQ\"Z4MS>K+=7ET_DV%A`-TUY,>B(/RR>@'X"L/P-
MX&OFU5_%?Q!:.Z\372;8($.8=*A/2&+_`&N?F;J3GWR`<)XU\%:A_P`(E<>+
MOB!(D_B6?4M*$$$;$PZ3#_:-N?*B]\?>?OS[D^QWT-MXDV6DUO%>:>D@><RQ
MAXW*G*J`>#\V#GMBM9T61=LBAE/8C(IU`&+_`,(5X?\`^@)I7_@&G^%'_"%>
M'_\`H":5_P"`:?X4OBW6+C0M%DO+".WEE21%VSR%$PS`$EL<8!Z]*N:+>R:C
MI%G=7"+'+<P+(Z+G"DC.!GF@#G?%?@GP\?"^L9T/22/L$_!LT_YYM[5P&M6=
MMX8^*6CS:!%9:4Z>!=2E\Q(`$5EEM=K,JCD"N\^*GBE/#/A>56A\]]262U0&
M41JF8V)8L>.`.!U)P!UKF]0LX;_XU>%[:]C6:"?P5J"21MT93-:@@_A6579>
MIU87XI?X7^1O>`-2;6/`][?3R0*]U<7<CO`Y**2S9*GK@59^&$3IX9622>6X
M2XDWQ/)=?:"4VJH^?)S]TG\>><FG^#M'M[+PYJ>FZ7$EM;I?7D,,:D@1CS&`
M`[XJWX%T*^\-Z!%8:M<174L+$)(B@$KQC<0HR<YYQTQGFMNK.7H4_BT2OPV\
M1%2586+D$'!!KFO@;?QV_P`)M'BM\7%T)[Z.WB#;F`%Y,HR>H4`#D]`*Z+XO
M_P#),/$O_8/DKHM%M(+33+86L,4(:)21&@4$D9)X]R32`PK?X6^%HH45]#TY
MF`^9O*QN/<_B:YR_^&OA:/Q9?,FA:>K+H601'@C]X_O74V7B2\N/&=YI$MO;
M+:P1%TE60F0\(?F7'`^?@]\'T-9%MXBL]?\`%FNI8F42:=I3VUPDB%2CK*_Y
M@CD>Q%`&7\+_``%X>U?X=^';W4](L[J[NM/BDFFE4LTC%>6)/4FNH_X5CX4_
MZ`.G?]^JK?!W_DEGA;_L%P_^@U:\3>)KW1M<TNSL[>UEAOV"R/+(RNO[Q5.T
M`?-PQ./;/3-`%O1K.Q\-(-+M[>&RM4D9[0*NU#O8L0#V;<3QWS7S9^S+J9'Q
M3U1[R[;RVTO568RSDJ<:N^#R?<_G7U:R+*FV10RGJ&&0:\\^'FFVD?C+QF8[
M2V0PWT:QE85&P$,2!QP">?K0!T%WX5TCQ;?MJ&MZ7;702)8;9YX_F*`EB?H2
M>/IGO3/^%8^%/^@#IW_?JM#Q7K%QH>CR7=C'!+,CHH6>0HF&8`DMVP#UZ5:T
M2^DU/1[.[N$6.6Y@61D7.%)&<<\T`<%J'AO3/#?Q(\(IH-E#8I<M=&9805$A
M6%MI(Z9&6Q]37I=<-XK_`.2E^"_K=_\`HDUW-`!1110`4444`%%%%`!1110`
M4444`%%%%`!1110!QGB'3Y[CQII\J6ES*BP;8YXX24@?+_,S;ATR.,&M/P-X
M<N/"OAZ'3KZZ2[DB=B)$4J-I.0,'I_DUT%%"`****`"N>\>G'A6]^B_^A"NA
MKG_'O_(JWWT7_P!"%5'XD..Z,GX(G/P=\%?]@&S_`/12UVU<3\$?^2/>"O\`
ML`V?_HI:[:KK_P`67JRJGQL****R("BBB@`HHHH`****`"BBB@`HHHH`****
M`"L:\M)6N925D8.V<+$KB1<#"[C]W'/\ZV:*`.:U+PWJ>IVEK$^M&-K>Y@G)
M^QHV[RW#;>O?'6M@VEYY4*B^(=&S(_D+^\&>F.WX5=HH`J?9[GSIV^UG9(N(
MD\H?NSZY[_C5;^S]2_Z"I_\``5*U**`*%M9WL4A-QJ!F7:0%\A5Y]<BJL5I>
M&YN(Q<E9PD9-WY"_O%R_R8Z<=<_[5;-48)7;6;R,L3&EO"RKV!)DR?T'Y4`%
MS9WLLNZVU`P)@#9Y"MSZY-0_V?J7_05/_@*E:E%`%;[/<?:4<W7[D+AHO*'S
M'USU%1"TO1;NAOR92^5E\A?E'ICH?K5ZB@#+_L_4O^@J?_`5*2[M-172KM(;
MQ9[ID)A+VZ@9Q]TCH0:U:S_$!(T'4B"01:2X(_W#0!*;:Y+VY6[*K&!YJ^4O
M[W_#\*@DL=0:1VCU,HA)*K]F4[1Z9K03[B_2G4`9T5C?I*K2ZF9$!RR_9E&X
M>F:E^RW6;@_;3B3_`%0\E?W7^/XU<HH`HRV=ZT,2QZ@4D3/F/Y"G?^':H?[/
MU+_H*G_P%2M2B@#)6UOC>A?[47$<2ET\E<N=S<X[`C`X]*M_9[GSIV^UG8ZX
MB3RA^[/KGO\`C4$?_(Q7'_7E%_Z')6E0!E_V?J7_`$%3_P"`J4SQ%X7L?%FB
M2:9K\?VB&0`[Q\CHXZ2(1RK`\@CI6O133:=T!YEX<\2:EX'UJ+PUXXE,XN"?
M[+U0KA;Y1_"W99P/O+T;[R\Y%;OQ$\9Z?X/TB"^)>YU2Y;RM(L[;YI;Z8](U
M`ZJ>-QZ`<]<5M^)_#.G^+M'FTW6X1-;S8((.UHV!RKHPY5@>01TKR'PAHLG@
M'XF3M\2+NYUK4+T>3X>U:X0"-;<#F%`.%GZEN[@Y'.0=6E45UOU7ZK]5^FU;
M['7>"?!.I)=2>+OB*T%SXKN("(H(B6M]*B(SY,.>_P#>;J?SSWNG3M=:?:S2
MXWS0H[8Z9(!-8GCCQ+I6@^"];U+5]1-G86=A-+/<6[YDB0(267&3D=L"N8^'
MEII?B7P'X>U33?$VO36U]IL$L<C:DRE@4')!&0?K6))Z517+?\(Q:?\`0Q:Y
M_P"#4UF:_P"$;JXLT_X1SQ;J=I=1RAB;B_,B2H`<H>ZYX^8<C%`&C\3HKB;P
MA<+8PR3S":(B-'V%@)%SR00!]1CUK?T>7S]*M)!&\(>%3Y<BA63(Z$#@$>@K
MS33_``3XJCGTW^T_'!G@BW?;Q'<.KS?,,;3G`PN[L.2*Z[_A&;3_`*&'7/\`
MP:F@"#XH:#=:YX;E-E?M8BR26>7$0D$RB)ODP>!SCGMUZUSTA_XOKX2_[$V^
M_P#1]I6IXJ\/V5MX7U>67Q'K*I'83$E]6P!\AZYKR^[N]"C_`&D/"&COXHUU
MKRX\(W814U%F4.\D<BJ7`QREO,<$_P``]1F)K1>IT8>5I2]'^1[AX2_X]M2_
M["UW_P"C36[7FFB>'EN-(U<Z3XCU/[4-1O$A:35B4#B1A\V!V/:HO#?@OQ';
M7X;Q3XUFO;,6RKLM;IHG,N!E\^A.>/IP*LYSH/C!_P`DP\2_]@^2NGTW_D'6
MO_7!/_017F/Q=\,6W_"L_$NSQ%KN3I\G35>:Z;3_``Q:?V?;?\5#KO\`J4ZZ
ML3_"*`(M#%Q#\2M>6>UN/)GAC:&X)!3A5R.5RO4=#@X/'%5+'P\-"\8>(I!=
M3S_VCI;W&R0DK%F1^%R3Z^W;BJ=QX.\0/K'F6WC&:/3/ML;&!KUVD^S!?G7=
MTWEN<X('\Z?B:STO1-2UR\U#Q-K<5MI_AM[FXD74RS)&K2$G:`2>%...U"V!
MG4?!W_DEGA;_`+!</_H-0>+OM$7CKPW,EK<7%L%D21H\$1EF4`D%2#USP00`
M3VKD?@-:Z5XA^$7AF[TWQ%XA,2V?D.)=19&26)C'(I!&1AU8?AQQ6MK'@GQ$
M^KF70?'$\6GLP;[/=7#,R@1L"H8$9RY5L]L8YH`]/7H/I7!_#_\`Y''QQ_U_
MQ?R:K.D^%6ATNT36?$^K7%^D*BYEAU(JDDF/F*CL"<\5R/@/PS:GQCXV)\0Z
M[S?1==6./NMT%`'<?$R*XE\)7*V,4D\OF1$1H^PL!(N>2"`,>HQZUNZ-*)])
MLY!')"'@1O+D4*R9'0@``'Z5PWBGP9JUU"A\(>,[^PF6.166[NS*K,P`1\]1
MM.3C^+.#BK'A[PE?00W(\3^++Z[E:<FW:TOFB58MJ@`@DG.0QZ]QZ4("7Q7_
M`,E+\%_6[_\`1)KN:\!U_6].\-?M+^"-*N-<U:Z-]I5P8HKJY::%9&$FTYZ*
MQ$;]?[M>[_;;?_GO#_W\%`$]%0?;;?\`Y[P_]_!1]MM_^>\/_?P4`3T5!]MM
M_P#GO#_W\%'VVW_Y[P_]_!0!/15:;4[2"%Y9;F%4C4LQWC@`9-8'@+XF>'/B
M7X;AUWPAJ"W6FSR/&DDD;0L61MK#:X!'(]*`.HHJ#[;;_P#/>'_OX*/MMO\`
M\]X?^_@H`GHJ#[;;_P#/>'_OX*/MMO\`\]X?^_@H`GHJ#[;;_P#/>'_OX*YO
MQ'\4?#7A/Q%X?T/7-16'4O$\SPZ;&L;.)63;NRR@A?O+RQ'6@#JZ*@^VV_\`
MSWA_[^"C[;;_`//>'_OX*`)Z*@^VV_\`SWA_[^"C[;;_`//>'_OX*`)Z*@^V
MV_\`SWA_[^"C[;;_`//Q#_W\%`$]<]X^_P"14OL>B_\`H0JKX!^*/AKXFZ))
MJW@[45N[&*Y>V:22-H2)$P2-K@'&&!ST.:F\<W,,OA>]6.:)F(7`#@D_,*J/
MQ(<=T9OP1S_PIWP5G_H`V?\`Z*6NWKB?@C_R1[P5_P!@&S_]%+7;5=?^++U9
M53XV%%%%9$!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!6
M?;JPUR]8JP5K>`!L<$AI,C]1^=:%58MW]HW&9E9/*CVPYY0Y?)_'C_OF@"U1
M110`4444`%4]9@>ZT>^A@7=)-;2(BYZDJ0!5RJFK^6=*O/M$C11?9Y/,D09*
M+M.2/<"@"THPH!["EI%^Z,>E+0`4444`%%%%`%)(,:Q--OCPUM&FP'YAAG.<
M>G/Z&KM4D,?]L38C<3?9H\R9^4KN?`^N<_G5V@`HHHH`*RO$OAG3_%VD3:;K
MD'G6TV#P=K1L.5=&'*L#R".AK5HIIM.Z!.QY?<?`#06@D\[4_%$P*G<KZJS;
M_KD<YIEC\`]`>RMVCO\`Q1;JT2D0C5&41Y'W<8XQTKU";/DOAMIVG#'M[U'8
M[OL5OYDHG;REW2@\.<#YOQZUK]8J_P`QI[6?<\Z_X4%H7_06\4_^#9_\*/\`
MA06A?]!;Q3_X-G_PKTRBG]9J_P`P>UGW/,_^%!:%_P!!7Q3_`.#9_P#"C_A0
M6A?]!7Q3_P"#9_\`"O3**/K-7^8/:S[GE]Q^SSX=NX)(;K4?$LT,JE9(Y-49
ME=3U!!'(K&_X9]\-VWBVS@M[S7HU_LV9PR:@0R[9(@`#C(&&/%>TUAS_`/([
MV7_8*N/_`$;#6=3$U;+WNJ_,Z,-5GS2UZ/\`)G$VW[._ARS5UM=0\2PK+(TC
MB/5&7<['+,<#J3U-3?\`"@M"_P"@KXI_\&S_`.%>F45I]9J_S'/[6?<\MO?V
M=?#>HVLMM?ZAXEGMYEVR12:JQ5QZ$8J5?V?]!1`JZKXH"J,`#5GX'Y5Z;12^
ML5?Y@]K/N>9_\*"T+_H+>*?_``;/_A4#?LZ>&GN&G>_\1M,T7E-(=38LR9SM
M)Q]W/.*]3I#T-'UFK_,'M9]SR30/@)H#Z+8O'J/B.$/`C;(M39%7(R<`#BM#
M_A06A?\`06\4_P#@V?\`PKT33_.^P6_VQ42?RE\Q4^Z&QSCVS5BCZQ5_F#VL
M^YYG_P`*!T(_\Q7Q3_X-G_PJO;?LX^&+.>XFM;[Q)%+=,&G==48&1AT)XYKU
M2BCZQ5_F#VL^YYG_`,*"T+_H*^*?_!L_^%'_``H+0O\`H*^*?_!L_P#A7IE%
M/ZS5_F#VL^YY%=?`+P__`&W8!M0\1,[0S$2-J1+KC9T;&0.36C_PH+0O^@KX
MI_\`!L_^%>ARB;[=;^6J&#8_F,?O`_+MQ^OZ59I?6*O\P>UGW/,_^%!:%_T%
M?%/_`(-G_P`*/^%!:%_T%O%/_@V?_"O3**?UFK_,'M9]SS/_`(4%H7_06\4_
M^#9_\*/^%!:%_P!!7Q3_`.#9_P#"O3**/K-7^8/:S[GF?_"@="/75?%./^PL
M_P#A6=H'P#T!](MGCU'Q'"&4G9#J3(H.3T`%>NU6T[SOL47VQ42;'SJG0'/:
ME]8J_P`P>UGW///^%!:%_P!!7Q3_`.#9_P#"C_A06A?]!;Q3_P"#9_\`"O3*
M*?UFK_,'M9]SS/\`X4%H7_05\4_^#9_\*/\`A06A?]!;Q3_X-G_PKTRBCZS5
M_F#VL^YYG_PH+0O^@KXI_P#!L_\`A6?J7P"T`7FF;M1\1NSW+*&?4F9D_=.<
MJ<<'Y1TKURJUUYWG6GD*A3SCYI;J%V-R/?=M_`FE]8J_S![6?<\\_P"%!:%_
MT%O%/_@V?_"C_A06A?\`05\4_P#@V?\`PKTRBG]9J_S![6?<\S_X4%H7_05\
M4_\`@V?_``H_X4%H7_06\4_^#9_\*],HH^LU?Y@]K/N>9_\`"@M"_P"@KXI_
M\&S_`.%(?@#H1_YBOBG_`,&S_P"%>FT4?6:O\P>UGW/(]$^`>@&VF\K4?$<*
MK=SKMBU)D!Q(PS@#KQR:O2?L_P"A2(RG5O%0#*5)&KN#@C![5Z+8^<(Y/M2H
MK>=)M"8Y7<=I^N,9JS2^LU?Y@]K/N9OAS0+7PMH&GZ/I0D%GIELEO`)&W,$0
M87)^@K2HHK)MMW9F%%%%(`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*
M***`"BBB@`K&DUS2K'6[J"[N[.VNE@A9S+<JI927VC:3QCG\ZV>E<\MG87>N
M7%U=V%O(EU%#'%<2VZMYC*7R,D9[C&?PH`O?\)-H_P#T%M-_\"T_QH_X2;1_
M^@MIO_@6G^-2?V#IG_0.L?\`P'3_``H_L'3/^@=8_P#@.G^%`#!XET@]-5TT
M_P#;TG^-!\2Z0#@ZKIH/_7VG^-<MXA^$.E^(KZZN9;W4;);F%(?(L_*BCC56
MW<#9G)/4DY[=*Z/3?">E:9I]M:1V-I*MM$L:O)`A9@HQDG')]Z`)?^$FT?\`
MZ"VF_P#@6G^-5=6\5Z1!I5Y*NI:5*8[=V$;W2%7PI.",]#5[^P=,_P"@=8_^
M`Z?X5F>(]&TI='NX3IU@9;B"1(E-N@RQ4XY(P.<<F@"\GB?1R@(U;3.1VNX_
M\:7_`(2;1_\`H+:;_P"!:?XTVTTK2;J$/%I]B0."/LR<'\JF_L'3/^@=8_\`
M@.G^%`#/^$FT<_\`,5TW_P`"T_QH/B32`,G5-.QZ_:D_QJ#5?">G:GIUQ:I;
MP69N$*>?!;Q[T!ZE<J0#[XK`\/?"+2/#VL?V@+B^U!Q:+;+%?,DB*J@#<!M'
MS<=:`.E_X2;1_P#H+:;_`.!:?XT?\)-H_P#T%M-_\"T_QJ3^P=,_Z!UC_P"`
MZ?X4?V#IG_0.L?\`P'3_``H`ST\7:7_:\L#:MI?DBV1U'VJ/.XLP/?T`JY_P
MDVC_`/06TW_P+3_&LI+#1QKLCM86`BD@CB5_L\?+AGSVSCD<]*V?[!TS_H'6
M/_@.G^%`$?\`PDVC_P#06TW_`,"T_P`:4>)=(/35=-/_`&])_C3_`.P=,_Z!
MUC_X#I_A7,>)/A1IGB6]DN)+N^L%>U-N(;(11(H)!+?<)+''4GCMB@#I#XET
M@'!U730?^OM/\:3_`(2;1_\`H+:;_P"!:?XU6T7P;I6B:5;6,=I!<+:QA!+/
M"C2/[L<<FKO]@Z9_T#K'_P`!T_PH`KW7B71S;3#^UM,YC;_E[3T^M5]%\3:/
M_8]C_P`3;3/^/:/_`)>T_NCWJ?4=&TI+21'TRQ<RJ45!:H=Q(Z8Q4.AZ+I;:
M7:QG3K%9((421?LZ?*0H]!C'N.*`+?\`PDVC_P#06TW_`,"T_P`:/^$FT?\`
MZ"VF_P#@6G^-2?V#IG_0.L?_``'3_"H;[PSIUW9S01VMK;-*A4316T>Y,]QE
M2,_44`2?\))I(&3JFG8'_3TG^-)_PDNCCKJNF_\`@6G^-<5;_![2O#[G4HKS
M6+R6RTV2WBCE\N;^$_.%V#=(#TS]*B^&.EZ;<S7S"3^ULVUJTDLUFHC60A\J
M.N'`VAE[84\DDT`=S_PDVC_]!;3?_`M/\:Q)_$ND?\)K9M_:NFX_LNX&?M:=
M?-A]ZW_[!TS_`*!UC_X#I_A7-3V.D#QQ:_\`$MM"BZ;<*T@M%V@^;#WQ6=39
M>J_,Z<-\4O27Y,Z'_A)M'_Z"VF_^!:?XT?\`"3:/_P!!;3?_``+3_&I/[!TS
M_H'6/_@.G^%']@Z9_P!`ZQ_\!T_PK0YA@\2Z0>FJZ:?^WI/\:#XET@'!U730
M?^OM/\:Y_P`2_"_3/$MY'.]Q=Z>L=M)`L5BL4:'?U8Y0DG`XYXK2\/>!]*\/
M:1!816\5VL`(\ZZB1Y'R2<LV.3S0!=_X2;1_^@MIO_@6G^-!\3:/_P!!;3/_
M``+3_&I/[!TS_H'6/_@.G^%1W&D:3!'F73K$ACM"BU4EB>V,4`5-(\2Z$NE6
M8MM7L&A$";&>[CW$8XSSUJW_`,)-H_\`T%M-_P#`M/\`&J/A_0]-32K6VETR
MRBGM8(TEC-LF5(7'88QQU%:7]@Z9_P!`ZQ_\!T_PH`C_`.$FT?\`Z"VF_P#@
M6G^-._X2320#G5-.XZ_Z4G^-)-X>TZ6%T2RLXF=2`ZVR$J3W&01D>]<CH_P7
MTC2-5T^^-[J=ZVGQNB0W;1O&^XDDLH09/S''I0!UO_"3:/\`]!;3?_`M/\:/
M^$FT?_H+:;_X%I_C4G]@Z9_T#K'_`,!D_P`*/[!TS_H'6/\`X#I_A0!GW'B7
M0CJMF7UBP$HCE$:B[CVD?+G//7I^M7/^$FT?_H+:;_X%I_C69>Z3I2ZU:S#2
M[)H[>*9)9!:H=I8H<=,_P\XZ=ZUQH6F$9&G6'/\`T[I_A0!'_P`)-H__`$%M
M-_\``M/\:4>)=(/35=-/_;VG^-/_`+!TS_H'6/\`X#I_A6!XD^&NF^([JTF,
M]SIPM$D`CL4BC5RZ[2S90DX'0=*`-P^)=(4X;5=-!][I/\:3_A)M'_Z"VF_^
M!:?XUF^%_A_I'A;2([""!;U8V9O/O(TDD8DYY;'-:W]@Z9_T#K'_`,!T_P`*
M`(_^$FT?_H+:;_X%I_C5/1_$FA)IL"VVKV#1!2%+W<>[J>O-7)](TJWCWR:?
M8XR``+9223T`&*H>'M$TV/38;:;2[**>!,/&;9..>.@Q0!?_`.$FT?\`Z"VF
M_P#@6G^-'_"3:/\`]!;3?_`M/\:D_L'3/^@=8_\`@.G^%-D\/Z:Z$+86*DCA
MA;(<?F*`#_A)-)P3_:FG<=?]*3_&F_\`"3:/_P!!;3?_``+3_&N0LO@KI-IJ
MMA?2W^J7;6$TDPAN&C,4C.<G<H0<>@Z"NS_L'3/^@=8_^`Z?X4`1_P#"3:/_
M`-!;3?\`P+3_`!JI?>)="-S8&75]/#"X)C"W<>"WEOUYZ8S^.*O_`-@Z9_T#
MK'_P'3_"LG5-'TIKZQ=-*LY/L5P6F=;1#Y:F)QZ>K+P*`-+_`(2;1_\`H+:;
M_P"!:?XT?\)-H_\`T%M-_P#`M/\`&GKH>ENH9=/L"",@BW3G]*7^P=,_Z!UC
M_P"`Z?X4`,'B72#TU73>/^GM/\:#XETA3AM5TT?6Z3_&L?Q%\.M-\0RV3>9-
MIRV<IEVV,<4?FMC`W$H20,GCISSFE\)?#G2/"6EFQA0Z@#*9#-?(DDA)`&,[
M1QQ0!K?\)-H__06TW_P+3_&C_A)M'_Z"VF_^!:?XU)_8.F?]`ZQ_\!T_PIDV
MCZ5!&SRZ?8A5_P"G93^'2@`T&[L[RSEETJY2ZA-U-F17#C?O.X9'8']*TJQ?
M#,,%A;SVEO;QV9%S-*(414&UY&8'`XZ$>];5`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`(RAE(/0C!K#M?#0M]1:Z\UB6
M"AOG)!"XP`O1>@R1UQ6[10`4444`%%%%`!56[M3.R.@C8H"I2095@<?X"K5%
M`%+2M-73+;RDV@9R%7.%'H,\_P#ZZNT44`%%%%`!1110!A#PT!J7VHR#/EB(
MMW,8.0N,=??/X5NT44`%%%%`!1110!0U?3!JEN(V.,'IDC/(/4=.0#^%-T71
MX]&MC%"`%/10<A1DG^9)_'I6C10`4444`4]9NDL=(OKF<$QV]M)(X&<E54D]
M.>U>:?`B[MI[;5!;W=M>32,D\AMKAY8HU+2($7<`5P8V/)).0>X%>F:KN.EW
MFS[1N\A\?9P#)G:?N`\;O3WKR?P#9ZKJ>B:^NDZ@8[V[6WD25-S0=#N0;CE)
M2!M?;\JDJ1SFDW9-V-*<%.2BW:[W?0]@BFCG4M"ZR*"5)4Y&0<$?G7'3Z$R^
M/X7BG=5N-+G#@,<%?,BXV],\]:O:!8ZA_9-NMG<QV$2+M%M)INQHL'!4C?Z]
M^<]><TEO!>0^-[7[?=QW(.E7&W9;^7M_>P^YS6$IN25UV[?YG93I1A.:4T[*
M7?L_*WXG3T445T'GA1110`51U?35U6R>W9B@;N"1QT/(Z?6KU%`&5H6AKHL3
MJCN^_&-[ER`/<]:U:**`"BBB@`HHHH`P+[PNMYJ'VGS""&!4[ONX8MTQZL>X
MST.:W44(BJO11@4ZB@`HHHH`****`*FI6*ZC:-"QQN]<X/&"./8FJ^DZ1_9S
MRNSL[R'DLY8DX`R2?95'3M6G10`4444`%%%%`!7/:MX1BU34HKMW8/`^^+]X
M5V'.2<#KS]*Z&B@!D,0AA2-<X10HS[4^BB@`HHHH`*AN[?[3`4!VG(*G'0BI
MJ*`,;0O#L6B/*;91&DCE_+#E\,0`3D\]%'%;-%%`!1110`4444`%%%%`!111
M0`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`
M!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`4M;@-UHU_"B2R--:R
M($B<([$J1A6/0^A[5P/P;BL;$:M8Z2;ITMS"]PUTJ*\<[AB\)`13A.,=OFX[
MUZ+>)YMI.F-V^-AC:&SD>AX->??!CPU<^'-+O1J%C=Z;/=RJ\EL\4<<2;1L4
MQJCL!\BID9P#TSUH74?0]'K#G_Y'>R_[!5Q_Z-AK<K#G_P"1WLO^P5<?^C8:
MSJ;+U7YG1A?BEZ2_)FY117GWQ!\;ZUX5UFRM]+L8+BUU!5CCEDS\L[%@%XZC
M/E].VXUIUL<QZ#1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!24M%`!7+ZYJD&B^++"
MZOUN1;OI\\0DAM9)@',D1`.Q3C@'KZ5U%%1.+DK(VH5(TYWDKJS7;=6[/\CC
MM<^(EE86GVNQ-U(MMF2>*33;A/,C`YVL4PK#J,\'&.,Y'!_%#5VGU_1-5TR&
MVF0V$<L$D_G13VJS,P\P(!R,^667K\N,?-7L.H:7;ZH(5O5:2.&02>5N(5V'
M3</X@#S@\9`JIJWAFWUB]M;FXEN8WLR6B$;@`-GKTZ\5,%-3O)Z&E:>'=)*G
M%J75MI_HC7HHHK4Y0HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
..BBB@`HHHH`****`/_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>g838054gra14.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g838054gra14.jpg
M_]C_X``02D9)1@`!`0$`6@!B``#_X@Q824-#7U!23T9)3$4``0$```Q(3&EN
M;P(0``!M;G1R4D="(%A96B`'S@`"``D`!@`Q``!A8W-P35-&5`````!)14,@
M<U)'0@``````````````````]M8``0````#3+4A0("``````````````````
M`````````````````````````````````````````````!%C<')T```!4```
M`#-D97-C```!A````&QW='!T```!\````!1B:W!T```"!````!1R6%E:```"
M&````!1G6%E:```"+````!1B6%E:```"0````!1D;6YD```"5````'!D;61D
M```"Q````(AV=65D```#3````(9V:65W```#U````"1L=6UI```#^````!1M
M96%S```$#````"1T96-H```$,`````QR5%)#```$/```"`QG5%)#```$/```
M"`QB5%)#```$/```"`QT97AT`````$-O<'ER:6=H="`H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0``9&5S8P`````````2<U)'0B!)14,V,3DV
M-BTR+C$``````````````!)S4D="($E%0S8Q.38V+3(N,0``````````````
M````````````````````````````````````````````````````6%E:(```
M`````/-1``$````!%LQ865H@`````````````````````%A96B````````!O
MH@``./4```.06%E:(````````&*9``"WA0``&-I865H@````````)*````^$
M``"VSV1E<V,`````````%DE%0R!H='1P.B\O=W=W+FEE8RYC:```````````
M````%DE%0R!H='1P.B\O=W=W+FEE8RYC:```````````````````````````
M``````````````````````````````````!D97-C`````````"Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92`M('-21T(`````````
M`````"Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92`M
M('-21T(`````````````````````````````9&5S8P`````````L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0``````````
M````+%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$``````````````````````````````````'9I97<``````!.D_@`47RX`
M$,\4``/MS``$$PL``UR>`````5A96B```````$P)5@!0````5Q_G;65A<P``
M```````!`````````````````````````H\````"<VEG(`````!#4E0@8W5R
M=@````````0`````!0`*``\`%``9`!X`(P`H`"T`,@`W`#L`0`!%`$H`3P!4
M`%D`7@!C`&@`;0!R`'<`?`"!`(8`BP"0`)4`F@"?`*0`J0"N`+(`MP"\`,$`
MQ@#+`-``U0#;`.``Y0#K`/``]@#[`0$!!P$-`1,!&0$?`24!*P$R`3@!/@%%
M`4P!4@%9`6`!9P%N`74!?`&#`8L!D@&:`:$!J0&Q`;D!P0')`=$!V0'A`>D!
M\@'Z`@,"#`(4`AT")@(O`C@"00)+`E0"70)G`G$">@*$`HX"F`*B`JP"M@+!
M`LL"U0+@`NL"]0,``PL#%@,A`RT#.`-#`T\#6@-F`W(#?@.*`Y8#H@.N`[H#
MQP/3`^`#[`/Y!`8$$P0@!"T$.P1(!%4$8P1Q!'X$C`2:!*@$M@3$!-,$X03P
M!/X%#04<!2L%.@5)!5@%9P5W!88%E@6F!;4%Q075!>4%]@8&!A8&)P8W!D@&
M609J!GL&C`:=!J\&P`;1!N,&]0<'!QD'*P<]!T\'80=T!X8'F0>L![\'T@?E
M!_@("P@?"#((1@A:"&X(@@B6"*H(O@C2".<(^PD0"24).@E/"60)>0F/":0)
MN@G/">4)^PH1"B<*/0I4"FH*@0J8"JX*Q0K<"O,+"PLB"SD+40MI"X`+F`NP
M"\@+X0OY#!(,*@Q##%P,=0R.#*<,P`S9#/,-#0TF#4`-6@UT#8X-J0W##=X-
M^`X3#BX.20YD#G\.FPZV#M(.[@\)#R4/00]>#WH/E@^S#\\/[!`)$"800Q!A
M$'X0FQ"Y$-<0]1$3$3$13Q%M$8P1JA')$>@2!Q(F$D429!*$$J,2PQ+C$P,3
M(Q-#$V,3@Q.D$\43Y10&%"<4211J%(L4K13.%/`5$A4T%585>!6;%;T5X!8#
M%B86219L%H\6LA;6%OH7'1=!%V47B1>N%](7]Q@;&$`891B*&*\8U1CZ&2`9
M11EK&9$9MQG=&@0:*AI1&G<:GAK%&NP;%!L[&V,;BANR&]H<`APJ'%(<>QRC
M',P<]1T>'4<=<!V9'<,=[!X6'D`>:AZ4'KX>Z1\3'SX?:1^4'[\?ZB`5($$@
M;""8(,0@\"$<(4@A=2&A(<XA^R(G(E4B@B*O(MTC"B,X(V8CE"/"(_`D'R1-
M)'PDJR3:)0DE."5H)9<EQR7W)B<F5R:')K<FZ"<8)TDG>B>K)]PH#2@_*'$H
MHBC4*08I."EK*9TIT"H"*C4J:"J;*L\K`BLV*VDKG2O1+`4L.2QN+*(LURT,
M+4$M=BVK+>$N%BY,+H(NMR[N+R0O6B^1+\<O_C`U,&PPI##;,1(Q2C&",;HQ
M\C(J,F,RFS+4,PTS1C-_,[@S\30K-&4TGC38-1,U336'-<(U_38W-G(VKC;I
M-R0W8#><-]<X%#A0.(PXR#D%.4(Y?SF\.?DZ-CIT.K(Z[SLM.VL[JCOH/"<\
M93RD/.,](CUA/:$]X#X@/F`^H#[@/R$_83^B/^)`(T!D0*9`YT$I06I!K$'N
M0C!"<D*U0O=#.D-]0\!$`T1'1(I$SD42155%FD7>1B)&9T:K1O!'-4=[1\!(
M!4A+2)%(UTD=26-)J4GP2C=*?4K$2PQ+4TN:2^),*DQR3+I-`DU*39--W$XE
M3FY.MT\`3TE/DT_=4"=0<5"[40914%&;4>92,5)\4L=3$U-?4ZI3]E1"5(]4
MVU4H5755PE8/5EQ6J5;W5T17DE?@6"]8?5C+61I9:5FX6@=:5EJF6O5;15N5
M6^5<-5R&7-9=)UUX7<E>&EYL7KU?#U]A7[-@!6!78*I@_&%/8:)A]6))8IQB
M\&-#8Y=CZV1`9)1DZ64]99)EYV8]9I)FZ&<]9Y-GZ6@_:)9H[&E#:9II\6I(
M:I]J]VM/:Z=K_VQ7;*]M"&U@;;EN$FYK;L1O'F]X;]%P*W"&<.!Q.G&5<?!R
M2W*F<P%S77.X=!1T<'3,=2AUA77A=CYVFW;X=U9WLW@1>&YXS'DJ>8EYYWI&
M>J5[!'MC>\)\(7R!?.%]07VA?@%^8G["?R-_A'_E@$>`J($*@6N!S8(P@I*"
M](-7@[J$'82`A..%1X6KA@Z&<H;7ASN'GX@$B&F(SHDSB9F)_HIDBLJ+,(N6
MB_R,8XS*C3&-F(W_CF:.SH\VCYZ0!I!ND-:1/Y&HDA&2>I+CDTV3MI0@E(J4
M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY`
MGJZ?'9^+G_J@::#8H4>AMJ(FHI:C!J-VH^:D5J3'I3BEJ:8:IHNF_:=NI^"H
M4JC$J3>IJ:H<JH^K`JMUJ^FL7*S0K42MN*XMKJ&O%J^+L`"P=;#JL6"QUK)+
MLL*S.+.NM"6TG+43M8JV`;9YMO"W:+?@N%FXT;E*N<*Z.[JUNRZ[I[PAO)N]
M%;V/O@J^A+[_OWJ_]<!PP.S!9\'CPE_"V\-8P]3$4<3.Q4O%R,9&QL/'0<>_
MR#W(O,DZR;G*.,JWRS;+MLPUS+7--<VUSC;.ML\WS[C0.="ZT3S1OM(_TL'3
M1-/&U$G4R]5.U='65=;8UUS7X-ADV.C9;-GQVG;:^]N`W`7<BMT0W9;>'-ZB
MWRG?K^`VX+WA1.',XE/BV^-CX^OD<^3\Y83F#>:6YQ_GJ>@RZ+SI1NG0ZEOJ
MY>MPZ_OLANT1[9SN*.ZT[T#OS/!8\.7Q<O'_\HSS&?.G]#3TPO50]=[V;?;[
M]XKX&?BH^3CYQ_I7^N?[=_P'_)C]*?VZ_DO^W/]M____VP!#``@%!@<&!0@'
M!@<)"`@)#!,,#`L+#!@1$@X3'!@='1L8&QH?(RPE'R$J(1H;)C0G*BXO,3(Q
M'B4V.C8P.BPP,3#_VP!#`0@)"0P*#!<,#!<P(!L@,#`P,#`P,#`P,#`P,#`P
M,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,##_P``1"`*"`<D#
M`2(``A$!`Q$!_\0`'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`
MM1```@$#`P($`P4%!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*Q
MP152T?`D,V)R@@D*%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA9
M6F-D969G:&EJ<W1U=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*S
MM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ
M_\0`'P$``P$!`0$!`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#
M!`<%!`0``0)W``$"`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1
M"A8D-.$E\1<8&1HF)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI
M:G-T=79W>'EZ@H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZ
MPL/$Q<;'R,G*TM/4U=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1
M`Q$`/P#W^BBD)Q0`M%94NOVL;W2$-OM9A`P)`RQ0/QD\\$54B\6V5Q;B>VAG
ME0VS79P`-J*Q4]3UR#TJN5BNCH**Q5\2VCR2HD<Q\N'SAP`77;N^52<GCT'6
MFCQ19F*W8*Q>X+!$#*2-H!.3G`ZCCK1RL+HVS50ZG9+*T+74:2*<%6;:1^=9
MDOBNT6(R"WN&"VQNG&T`H@)!ZGKD&K\MII^KVD4L]M'/'*@==Z9X(R*%&WQ$
MR<G\!:BN8)3B*:-R.RL":E%>)>'HM8D^(-[I.CWL%G]G,F9Q`&.P'&/UKV/2
MH+FVLDBO;LWDXSNF*!-WX"M:U)4G:Y%&I[2-[%NBBBL#8****`"BBB@`HI,T
MN:+@%%&:*`"BBB@`HHS10`4444`%%%&:`"BBB@`HHI,T`+129I:`"BBB@`HH
MHS1<`HHS29H`6BBDS0`M%%%`!1110`4444`%%%%`!1110`4444`%%%%`!111
M0`4AZ4M(*0&'_8EM%+-=78\^XEN3<!P_EE&V!!@Y'\(Q5:VAT:!6MX;:-%\E
M[=E,P^X6)9>3ZL:Z1D5AAE!^HJ%;.V7=^XCRQ)/RCDFJNQI1ZF+)%I2R0221
MJ/)7RXC]IR$&W''S<<=Z9%9:.S+Y5LA<RF576Y^<N0!G.[/(`K>:SMFQF&,X
M.1\HIPMK<$$0Q@CD?**5V.T+&?\`V5:W)D^T69_>0?9V+R%BT?7!YS^/6GWT
MDFGZ>(=.M6FD5?+AC'08'&2>@K2HP/2FGW,W&ZT.3\"^$O[":[O[Z1;C4[YB
M\T@Z`$YVC\376"BBG.;F^:0H04(\J"BBBI+"BBB@`IKG:I//'I3J;*P5"Q&0
M!G@9H`XV;Q=JUE);7.IZ.EKIUU<BV0-(?/4DX#,N,8_'--O?&]S#/=W4&GQR
M:18W(M9YC+B3<2`65<8(&1WK!L]1DU_Q6E_XBM-2BMK64+8V8LY"F<\2.<8]
M*+ZPOH=/UKPXMA=27&H:CY\$JQDQF-F4EBW08VGK7N+#4E)1G%)Z7[6;_1;F
M=WT.F\7>.+?0I8+6VC%S=S/&"O.V-&.,D^_85I>+O$47AS1)+^51))]V*+N[
MGH/YFL7XC::[>'[)+2V:65;NWWF--S$+W.!G`J#QQHFN7EW/?VJV5Q:Q6;QQ
M0RERZ,1\S*`,;L<"N>G2P\E3;TU=]=]ON'=W.L\/ZB^JZ%9:A)&(WN85E*J>
M`2,XK-\.^(Y=6T34+^2!(VM9IHPJG(8)T-+X!BOHO">GQ:E$D4B0J%1=P(7`
MQN!'#>M<A9ZCJ'ABUU;1)=!U"ZEN9YGMI8(]T;A^F6[5,,/"<JD(VNFK:]+N
MX)NR9UNA>++2[T'3[_5)H+*6]5F6-GP.,YQGV%3WOB.U?19;_2;VPF6-U0O+
M*1&"6`P2`2#SQ7'6WA^ZMF\$V=Y:-(+8R&<;-RH=I(W=ASBJ^NZ7<K#XLCMK
M&;9+>VSQ*D1P_P!TDJ`.>_2M?JE"4_=E_E;FM^6I/,TKGI-OJ=I/+/#'<QO+
M;`><H/,>1GFJDOB?18;2&ZEU.V2"?_5NS@!_I7'^.].U.TU%;C1+>1VUBV%C
M<;%)V'(PYQ[9%4O$&@W&D:[`RF_73UL%MH7M+99B&'52"#C=US[U$,'2FD^;
M=;>F_P".Q7,[GH5YK^E62Q-=ZA;Q+,I>,LXPRCJ144_BC1+:2&.?5+6-YE#(
MK2`%@>AKA](T&X@U/PC%=65P8H5N'=9AO\K()4,0`!VP*;XOTY[;7-0FTZ+4
M(I[@+F%[`7-M=87``Z[1VYQ1'"47-0YM[_G;S%S.QZ!J>O:5I:QMJ-_;VPD&
M4\QP-WTJCJGB/[-JNB6UFL5Q!JCNOFAL[0%R",=:X[6(]3FO[2/4]/GM4?35
M13IUJ"S2XYC+@911Z<"F>'K&\6#P2'M+A3;33^:&B8>7P>O'`JHX.G&'/)WW
M_)V_%!S,[SQ1KT6@::+IXGGDD<10PI]Z1ST`K)T;Q'X@?5H;/7/#S6D=SDQS
M0R"0)C^_CI4OQ!TZ\N[&RO--A^T7&G7270A!P9`#R![U6TSQ??ZIJ,4-OX=O
M[>W4,;B:[79LP/X1SNK*E2BZ'-&*;UO=VMVZ_P##E-ZC?$OCEM'\11:?':+-
M;($-W/D_N=[86M?7==ETW5-'M(XDD749VB9B<%`%SD5P$/ASQ7KUOJ][$;*W
M@U>5BT5XCB954D*!\O&!4]UJ&H_V7X5U"]TN_EGTZ=TN(XX&9SM7;G'OQS78
M\'1?+&+3:NGKUM=?CI]Q#D]3N?&6MS:!X?GU&WA2>2,H%1S@'<P']:R]'UCQ
MA=7T`U#P_:V]FY^>5+I6*KZ@9K%\6Z_)XH\(ZE;6NB:M`\?EMMFM]I<;QD+C
M.36=X131K37;%[70O$L5SNV"2X3]TI(P2W/3FHIX6,<.W./OW?GT7FOR8W+5
M6.F\,^.O[8FU2VGMU@N;+S&C7)Q*JY!(]P<9^M5I?'&JR:-H5SIVF03W>K-(
MHA:0J!M]"?ZUAV_A_4)/"U]>V<$T&IV=_<2Q`H0TL;<,N.X(_E381>:5H7@V
M[DTR^F^Q2S/+##"6=<\=#TZ]ZW>&PSDW!)ZVM?M%_@W8+L[#0/%&HS:R-'\0
MZ6-.O9(S+#LD#I(HZ\CO5>[\<-!XS72/LJM8"5;>2ZR?EE920N/R_6LY;Z]U
MWQ#%KZZ1?6=EI-K,0+B/;),Y'0*,FL%?"OC"[\.7$^^R5+N7^T&BD5OM`D'(
M'3@\8QFLX8:@Y7JVC=)6OLW]^RU%S/H=KXK\3:OIVO6>DZ)IL-]-<Q-+B279
MC!YY/%2>%O$VH:AJ]SI&MZ:MA?01"8".02*RDXZC\*YC4-+?QAKOA^34K2]@
MADL'\\A60QR#/!...1^-:/P^TM_#6NZCI%S9.S/B2&_V,?-C_NLW0$>E9SI4
M(X>UESI?/?>][?*P^9WN>@#I12#I2UXQH%%%%`!1110`4444`%%%%`!1110`
M4444`%%%%`$=PYC@=UQE5)Y^E>>:!XD\=Z]ID>HZ?IND-;RE@I=W4\$@\;O4
M5Z%=_P#'K-_N-_*N2^#G_(@V/^_+_P"C&KMH<L*,ZCBF[I:^:?\`D2]R+[9\
M1_\`H%Z+_P!_6_\`BJ/MGQ'_`.@7HO\`W];_`.*KMZ*7UF/_`#[C]S_S#E\S
MB/MGQ'_Z!>B_]_6_^*H^V?$?_H%Z+_W];_XJNWHH^LQ_Y]Q^Y_YAR^9Y[JVO
M>/M)LS=7>F:.(@Z)\KN3EF"C^+U(JW]M^(V/^07HO_?UO_BJT_B-_P`BPW_7
MS;?^CTKH9&9869%W,%R!ZFK=>/(G[..K??R\PMYG%_;?B-_T"]%_[^M_\51]
ML^(W_0+T7_OZW_Q57_!?B2?6I+F"^58+N`*7MC"T;QYSUR2&''4?E73TJE;V
M4N25.-_1_P"8)7ZG$?;?B-_T"]%_[^M_\51]M^(W_0+T7_OZW_Q5:WC+7+C0
MX["2W2)DFN-DWF`G$84LQ&#UP*;X.UZYUQ]0>=(EABFQ;F,'+1$94G)ZD8]*
MTYI>S]K[*-OG_F2]':YF?;?B-_T"]%_[^M_\51]M^(P_YA>B_P#?UO\`XJNV
M%8OBB]U"P6TDL);=!-<Q6["6$O\`?;&00PZ>E9PKJ<N54X_C_F5;S,/[;\1O
M^@7HO_?UO_BJ/MOQ&_Z!>B_]_6_^*KM(@XC42,&?')"X!/TYQ2R9V';C/;-3
M]97_`#[C^/\`F%O,XG[;\1?^@7HO_?UO_BJ7[9\1O^@7HO\`W];_`.*JHWCJ
M^526MX/EB,+?*?\`C\R<)UZ<=.O/6O0(MWEKYF-^!NQTS6U64J-G.E'7U_S$
MM>IQ7VSXC?\`0*T7_OZW_P`52?;?B-_T"]%_[^M_\57;2!BC!"%;'!(R`:Q/
M#MYJ-Y=Z@E]-;.EI.8%$4#(6P%.<ESZ]*S5=-.7LXZ>O^8[>9B"]^(Q_YA>B
M_P#?UO\`XJC[;\1O^@7HG_?UO_BJ[<5D>+M2GTC0I[VU"&6,H`'0L.6`Z`@G
MKTI0Q"E)15..OK_F'+YG/_;?B-G_`)!>B_\`?UO_`(JC[9\1O^@5HG_?UO\`
MXJNJT>::XM!)/)YC$G!^S/!Q_NN2?QJ[2>)2T]G'\?\`,+>9Q'VWXB_]`O1?
M^_K?_%4OVWXC?]`O1?\`OZW_`,56GXUUZ[T*&WEMX,P.Y6:<Q-*(ACC*J0<$
M]^U;=C<K>6,,\;HZRQAPR?=.1GC-6ZMH*;IQL_)_YA;I<\X@\:^+Y8%F-KHD
M2NYC4.[@DB3R_7^]Q4Q\7>+54-)_PC,>55\2794[6.%)!;(R>!ZU;\.Z-I^I
M>&4GU*:2)(9[V/<KA1AY74DY'49X]ZOIH_A][JUF75B3$RK#'YT>TNGRYZ9)
M/ED$9Q\IX'-.KB(QFXJG'1^?^8E'3<YX^-O%YFTQ(;31)QJC%;=HI&920`3G
MYN.HZUM?;/B-_P!`O1?^_K?_`!59FJZ):^'=?\$Z;8R3/;Q7,Y3S6!(R$)Z`
M=\G\:]*K2K6A"$)*G'5/OW:[^0DGW.(^V?$;_H%Z)_W];_XJC[9\1O\`H%:+
M_P!_6_\`BJ[>BN;ZS'_GW'[G_F5R^9Q'VSXC?]`O1?\`OZW_`,51]L^(W_0+
MT7_OZW_Q5=O13^LQ_P"?<?N?^86\SSR;7O'T6JP:<^F:/]HN(WE0;WQM7`/.
M[_:%6_MOQ&_Z!>B_]_6_^*K3U+_DH6C_`/7E<_\`H4=7?%6HW>E:/)=V-N;B
M1&7*A"Y5<C<VT$9P.V16KJIN,8TXW?KW]02\SG_MOQ&_Z!>B_P#?UO\`XJE^
MV?$;_H%Z+_W];_XJNB\,ZHNL:1#>++'+O)!:-2HR#C&#R#[5J5G*OR-Q=*-U
MY/\`S!*ZW.(^V_$;_H%Z+_W];_XJC[;\1?\`H%Z)_P!_6_\`BJE\2>+;S2==
MN[)(H6C6T5X"RG+3L2%4G/3BNA\-WLNHZ%97MR$$T\2NX0$*"?3.:UG*4(*I
M*G&S]?\`,76USF?MOQ&'_,*T7_OZW_Q5'VWXC?\`0+T3_OZW_P`57;GD5A-=
MZD/%::?Y]L;5K<W'^H;?@,%VYWX[]<?A6<:ZE>U./W/_`#&UYF-]M^(W_0+T
M7_OZW_Q5'VWXC?\`0+T7_OZW_P`57;]JS/$E_-I>DR7L"HWDLA<,,C9N`8]>
MP)-*-=2:BJ<=?7_,+>9S7V[XC?\`0+T7_OZW_P`52B]^(Q_YA>B_]_6_^*J3
M0_%=YJ>JPV9BA7SY6E0A3DVNTE6Z]2=OY]*[(=*NK4=)VG2C^/\`F):]3B/M
MOQ&_Z!>B_P#?UO\`XJC[;\1O^@7HO_?UO_BJZK6I+F#3)Y[.2))8D:3]Y&7!
MP"<8!'\Z9X?GNKO2+:YO7B>6=%D_=1E`,@'&"Q_.H]NN7F]G'\?\QV\SF?MO
MQ&_Z!>B_]_6_^*H^V_$;_H%Z+_W];_XJNVKGM?UB\L]=L[&V9$CGADD9OLDE
MPV5*@<(1@<]33A7YW94X_C_F%O,ROMOQ&_Z!>B_]_6_^*H^V_$;_`*!>B_\`
M?UO_`(JNU0$*-Q!;')`QDTK'%1]97_/N/W/_`##E\SB?MOQ&_P"@7HO_`'];
M_P"*JGJFO^/M+MTGN],T<))*D(VNY^9V"C^+U-;$OB6X@\8#2;Q$MK>1@L#2
M1-^_RN?E<'`.<C!';K4WQ`_Y`UI_V$+7_P!&K73":]I&,Z<;/U_S$UYG-R>+
M/&4=S]G>WT(3;BNW?)G(95QU]64?C4<OC/Q3$(B\GA<><Q1,7F=Q!P<8?L>#
MZ=ZZ;5="T2.^?4-0NW@D>9;D[Y0J_(I&.1]WG)]^]45\(Z!?I)9C4IKF52C/
MMFCWKL("<!>,>6!T_A]<FN?ZS'_GW'[G_F-KLR3P;XBUG4]=U/2M<MK.&:Q2
M-O\`1B2#O&>I)SQBNPKA_"PV_$_Q2,EL16HR>I_=BNXJ<7&*J+E5KJ+^])A'
M8BO"1:3=_D;^5>5?#SQ/JNF>%;6UL_#5[J$*,Y$\1^5LN2<<=NE>JW8_T67V
M1OY5R?P<_P"1`L?]^7_T8U0HR>'DU*VJ_)G11JTZ;]^"EZMJWW$'_";Z[_T)
M>I?G_P#6H_X3?7?^A+U+\_\`ZU=S17'R3_F_(ZOK-#_GROOE_F<-_P`)OKO_
M`$)>I?G_`/6H_P"$WUW_`*$O4OS_`/K5W-%')/\`F_(/K-#_`)\K[Y?YGEOC
M'Q9J]YH;Q7/A:^LX_.A<RR'@%9%('3N1C\:O/\1-0="C^$[TJPP1O'(_*MOX
MG_\`(H3_`/7>W_\`1R5D5JZ<_9)\_5]%Y`L3A_\`GROOE_F9VG>+Y--E>6T\
M'Z@LCJ$+/<-(=HZ*"V<`9Z#BKW_"Q]1_Z%2]_P"^Q_A3Z*S:J2=W-A]9P_\`
MSX7WR_S*.I>,Y=36-;[P=>S",DJ#+C!*E3T'H2*33/&,FEJRV'@V]A#A00)2
M>%4*O4>@%7Z*?[VW+SNP?6</_P`^%][_`,QG_"Q]1_Z%2]_[['^%07GCJZO5
MC6Y\(7KB*19D_>XPZG(/`]:M45*C-:J?Y!]9P_\`SX7WR_S&_P#"Q]2_Z%2]
M_P"^Q_A2'XCZC_T*E[_WV/\`"GT4N2?\WX(/K.'_`.?"^^7^9CMXCA965O`]
MV0US]L/[T_Z[.=W_`-;I6K_PL?4O^A4O?^^Q_A45Q?6MO*(IIT20C=M)YQZX
M_"H_[5L?^?E*J7M9?%-L/K&'_P"?"^^7^9:_X6/J7_0J7O\`WV/\*KVOCJZM
M'G>W\(7J-<2>;(?-SN;`&>1QP!4\,L<\2RPNLD;#(93D$4DMQ#"0)IHX]W3<
MP&:7+-:<_P"0?6</_P`^%]\O\Q?^%CZE_P!"I>_]]C_"J^H>.;G4;5K:\\(7
MLD+$$KYN,D$$<@9Z@5;ZC(HH49IW4_R#ZSA_^?"^^7^8P?$;41T\*7O_`'V/
M\*/^%CZE_P!"I>_]]C_"GT4N2?\`-^"#ZSA_^?"^^7^90U+QE-J047?A'46V
MY`*7#1G!ZC*XR#Z58@^(%[;P)#!X1O(XXU"JJL,`#H.E3T=*KEJ.T>?0/K.'
M_P"?"^^7^9A:'K^IS>%)].A\,W]S#<//^_BQP6D8G''4$X^HJI/;ZC-&BCPQ
MK"A+B*Y3I\K1J1Z="26/N37??##_`)%&+_KXN/\`T<]=56E:G.-62YNOD)8J
MA_SY7WR_S/(?$WB75+OQ'X=N;CPW>VTMK-(T<+GYIR0N0O';%=+_`,)OKO\`
MT)>I?G_]C3O'?_(Z^#?^OB;_`-!2NWK6M3FJ5)\[V?;^9B^LX>_\%??+_,X;
M_A-]=_Z$O4OS_P#K4?\`";Z[_P!"7J7Y_P#UJ[FBN7DG_-^17UFA_P`^5]\O
M\SAO^$WUW_H2]2_/_P"M1_PF^N_]"7J7Y_\`UJ[FBCDG_-^0?6:'_/E??+_,
M\JU+QCJ:>*M/O9_#-[#)%;31K"Q^:0,4R1QVP/SJW?>.KJ^@\FY\)7[)D,-L
MQ0@CH05P16AXX_Y&_2/^O2X_]"2H:VJ0G&,&I]/+NP6)P_\`SX7WR_S*EAXY
MN=/MQ;V?A"]CC!+8\W)))R221DDGN:L?\+'U'_H5+W_OL?X4^BL7&;=W/\@^
MLX?_`)\+[Y?YF7>^*1?7GVNZ\%7DD^4;<9B.4SMXZ<;C5NR\>7=C:16MKX1O
M8X8E"HOF9P/J1FK-%4_:M6<W8/K.'_Y\+[Y?YC/^%CZE_P!"I>_]]C_"H#XZ
MNC?B^/A"]^T",PA_-_@SG&,8ZU:HJ5&:VG^0?6</_P`^%]\O\QO_``L?4O\`
MH5+W_OL?X5!>^/;N^M);6Z\(WLD,RE'4R8R#U'`JS10HS6JG^0?6</\`\^%]
M\O\`,S;7Q9]DO(KNW\%7B3Q0"V1Q*>(QC"]/;KUJ_P#\+'U+_H5+W_OL?X4^
MBG)5):RFV'UG#K_EPOOE_F0S_$*^GA>&7PG>M'(I5AYF,@\'M26WC^]M;>."
M#PE>I%$H1%\S.`.G45/49N(1+Y1FC$A_@+#=^5+EG:W/^0?6</\`\^%]\O\`
M,7_A8^H_]"I>_P#?8_PJO)XYN9+Z*]?PA>FXB1HT?S>BMC(QC'85;J*>X@MP
M//FCBW=-[!<_G0HU%M/\@^LX?_GPOOE_F/\`^%CZE_T*E[_WV/\`"D/Q'U$]
M?"E[_P!]C_"H?[1L?^?VW_[^K_C4\<B2H'B=70]&4Y!I<D_YOP0?6</_`,^5
M]\O\S/?Q8TE^+U_!U^TZN)!F=BH;&-VS[N<=\9J'Q/XVO]2LK>!_#EW;[;N"
M0%FSN*R`A>G4XQ6Q6=KG^KLO^O\`MO\`T:M=.'C4G5BG-B>*PZU]@OO?^9)K
MNMZMK/V87'@_5%6WD+E5Q\XQC:>.F<'\*S]$FU;2-6CU&/PQK$THM%M'\S!W
M@,S;CQURQKUREKFY)_S?D'UFA_SY7WR_S/.OA]>SZAX]\1W5U92V,TL5ON@E
M^\F%QS]<9_&O1.?2N)\-_P#)4O%?_7.V_P#18KMOQKNQ"E&24G?W8_DCBG*,
MY.4%RKM_PY'=_P#'K-_N-_*N2^#G_(@V/^_+_P"C&KK;O_CUF_W&_E7)?!W_
M`)$"Q_WY?_1C5I#_`'6?^*/Y2,WN=E136<("S$``9)-5)-6L(]/^WO>0+9D9
M$[2`)Z?>Z5R)-[%%VBJLFHV<:V[274*K<D+"2X`D)&0%]:?%=P33RP1S1O-!
MCS$5LE,C(R.V:.5]@.=^)_\`R*,__7>W_P#1R5D5K_$__D4)_P#KO;_^CDK(
MK9_P(^K_`"0NH4445@,1B0I(&2.@]:YNX\4S6R2I+8*+J*5D,7G'!41F0G.W
MT&.F">A[UTC*&4J>A&#64_AS37A:-XI&W-N+F5B_0KC=G.,$C'I1U`TX)5N(
M(YD^[(H8?0C-1WTL\%K)):P">51PC/M!_'!Z?0U,BA%"J,*H``]!45Y;1W<#
M0REPIP<HY5@0<@@CD4,$9&G^(S>WFGVXLI(Q>0-*9"WRH5_A'')_+%;M4H-)
MLK=K5H8MIM`XB^8\;OO?4GWJ[3=@,F'_`)&V[_Z\8/\`T9-4FF:M_:%_?VQM
M9+?[(RJ#(<%]P)SCL./QIEU:7\>KR7UB+9Q);I"RS,RD;6<Y&`?[_P"E1Q6V
MK0W4]Q';Z>);C;YA\^3G:,#C;2`32)FM_"D4RX+)"S#/KS5F*PBM[-I/(2ZN
M63+O)C,AQT+'H/;H*?IEB;?2(K*Y*R;8RDFW.#G.<56GL[TV,NGRJEU;.OEA
M_-,;[>F"1[<9!I=`*7AC44DNS!!"L,$BRE4C??&AC=%8H<#Y3O';JIKI*R?#
MVC#2H_FD+,%$<:;V98HQ_"">?J:UJ;`I:U>SZ?827-M;"Y,8W,I<KA0,D\`G
M/MBK-M,+BVBG`P)$#8R#U'J*BO[&&_A$4_F!0<_(Y0],=1VJ:"*."%(84"1Q
MJ%51T`'2A`/K)U'7([/6;'35C\V2Z;#,&P(A@D$_7!X^M:U4KK2-/N[N"ZN+
M2)[BW</'(5&X$#`Y[]:<=T'0Z/X8$?\`")1_]?%Q_P"CGKH4OX7U"2R7?YT<
M:R,"I`VDD#![]*Y_X8<^$HCW^T7'_HUJZ(6D(O&N@I\YD$9;/\(.1Q^-:XC^
M++U8EL<?X[_Y'3P;_P!?$W_H*5V]<1XZ_P"1T\&_]?$W_H*5VYK;$?PJ7H__
M`$IB6["BH+J[@M%1KF:.)7<1J7;&6/0#W-1MJ=DL$\YNX1#;L5F<N-L9'4,>
MV*Y.5O9%%NBH(KRWEN&@BGC>95#LBL"0IZ''H:GI/0#A?''_`"-^D?\`7I<?
MS2H:F\<?\C?I'_7I<?S2H:Z*OPP]/U8ENPHHHKG&5M1GGMK22:V@$\B#.PL5
M&/J`3Z]`3618>)UO+VUA6V"1W&U2_F9*.T9?;C'(PO7/7M6S>VL=Y#Y4I<+D
M'*.4(_$55MM"TZUN8IX(-CPKM0!C@<$9QT)P2,]>:%YB9HT444#,W1]6.I7%
M_$;62W^R2B(>9U?*@YQV'-:5006D,%Q<3Q*1)<L'D.3R0`!].!4]`$=R[QP.
M\2"215)56;:#]3VJGH.I?VMIXN1&J?.R?*VY6VG&5.!D>^*LZA9PZA936ER&
M,,R['"L5)'U'-)IUE%I]I':VY?RHQM4.Y8@=AD]J%U`@UB1_*AMXW:,W4HA,
MBG!52"21[X!'XU3UN.WTK26,.E0W%NO,JGC`]>A)/O\`B36G?VHN[<Q[FC<$
M,CKU1@<@_P#UJS=0LKV_MUAN8(7=>-Z3NB-QSE1S@^G-`%O269?/MRY=(F!C
M8G)VL`0">^/7TQ45TJMXFL`RAA]CN3@C/\<%6=,LA8P%=V^1VWN^,9.`.!V`
M```]!45[;W/]JVMY;QI((H)865GVGYVC(/3_`&#^=`%:[U:VM]>L]*2V622X
MSO<8`BX)`/')..GM5S1P!:N%&!YTN,=/OM5*XT_[1?PWLVCVS7,#;DE\P;LX
MQR<<\5H:9#+#:E9PJNTCN0ISC+$]?QH`M5R2:M=7UQ%#J""WE2_@:.`V[1MY
M?G@!MQ8[@0!V%=;6#?:3:6+VTT"OYDE];*6>1G(7S0=HR3@9)XKIPG\>),OA
M/5=1O$L+1[B2*654_AB3<U5M-UF'49Y(H8+A-B+('D3"LK=".?YXJ?5M-@U6
MR>TNC*(G()\J1HR<'U!!Q3K.Q@M/,\H-F0@NS,6)(4*.3[**Y2CD?#7_`"5+
MQ7_USMO_`$6*[:N)\-?\E2\5_P#7.V_]%BNVKLQ?QQ_PQ_\`243$CN_^/6;_
M`'&_E7(_!W_D0+'_`'Y?_1C5UUW_`,>LW^XW\JY'X.G'@"Q_WY?_`$8U.'^Z
MS_Q1_*0/<V/$NO66CHD5^S1+<HX24CY`0.A/8GM7$R"[F\/>&M$@T]KZ0QF\
MN+;>L>8Q]T$MP,EA^5>DRO;.K"5HB$(#!B.#VS44M]809EEN;>/;E2[.HQ@X
M()]CQ11K^R2M&[_X#_S[@U<\O,4VK:/HNA7N^VO+'4'MC\^6C(C9HVR.N./R
MKH_AS=75YKGB"34(C'=(T$4H[%E0@D>QQG\:ZD:CI)E3_3+/S)/G3]XN6&.H
MYYJ9KNQMV)DN+>)G8(2SJ"6(X'UQVK6IBW.$H<F_X:W8N4P/B=_R*$__`%WM
M_P#T<E9-:WQ.Y\(3_P#7>W_]')637,_X$?5_DBEN4M;FFM]'NY;4JLZ1,8RQ
M``;'!)/'7UJ#PU>/>Z8'EEDFD21HVD<J=Q!ZJ5501Z'`JU<:A90R2Q37$2O%
M'YLBD\JG3)'I3[&XM[FV62S96AZ#:,`8[8[5S]QD]8/C#4+S3[:V-FQB$DA$
MDH*_(`C,/O`CD@#I[5O5GW.KZ4L#O/=0F-93"Q/(#CDC\._I0!;LY?/M(9?F
M^>-6^9=IY&>G:I:12"H*G((R,=*;-*D$+RS.$C0;F9C@`>M`&5=27+>)K6WM
M[V:.(1&::':A0KT`R5W`DG/7M6Q547UD9+;$\9>[!,'/,@`W''X<U:HL`5S7
MAC5;V]U>]ANI_,B4%HUVCY,.RX.`"O`'!)SUSVKH+BZ@MC&+B58S*XCC!."S
M'L/6HK2\L[B>>.U96DB;;+M0@9';/0T+>X/8M53UF6>#2KF6T9$F2,E&?[H-
M69I$AB>20X1%+$^PK(-W/<.RS7\-BQB,_P!GV!F6/CYG)_7^O6DP)/"][<7V
MGR/=[R5E9$=]FYU'0G9\N?IQ6L>^.M96B:HEWNMP\;L@RCQC:KKG!^4]""1D
M>X]:U>IIL#C;C6-7BANTN+I(6COVA,L:+MB00[POS`]6P,GUXQQCJM.EDGT^
MWFG7;+)&K..F"1S5>?5-,C@GDDFC:**3RY2JE@K@`X.`>@Q5V"5)H4EB8-&X
M#*1W!Z4=`*^K/=1Z=.]B8UG"$JT@)`]\=ZQ;+4]2DF\/&2:,P7MN&FPOS._E
M[CVP!]*Z*:1(8GDF=4C12S,Q``'?/M5-=4TTS6T2W$9>90\(]0<XQZ9YQZU4
M?B`Z7X8_\BC%_P!?%Q_Z->M"WUAY_$ESI@>V9(8PY$<F9$)QC</?)^F/>L_X
M9?\`(I1?]?%Q_P"CGKI!%$LIE6-!(W5PHR?QK3$?QI>K)6QQWCK_`)'3P;_U
M\3?^@I7;-7$^.O\`D=/!O_7Q-_Z"E=I+(D<9>1PB*,LS'``^M;5_X5+T?_I3
M!;LXGQ=K-KJ-W:Z/`)1?P:G;DQ.N"R@Y+CU7'>LG4KZVMM(\4:-<2>7J%W>2
M&"`@[I`^W:5'>O19)+2.7=*\*R<`%B`>3@?F:AEOM+6X02W5FLQ&5#2+N(]N
M_8U5/$*"247IK\[^@-'*P:MI^B>-+S^U;R*T#6%NJF5@N2-V:[:WFCN(4FA<
M21R*&5AT(/0U26[TF\!E6XL[@*#EPZM@#KD_B/SJS;W-M)(\$$T321`!HT8$
MIZ9':N>K+GL[.XSC?''_`"-^D?\`7I<?S2H:F\;_`/(WZ1_UZW'_`*$E0FG5
M^"'I^K!;LY[QEJ=WID-N;5VBC8N9)!MR-JY"C<",G]<8R,UO0OYD*/S\R@\C
M!Z>E49]7TL0"2:Z@:,RF,'.1O'4?AW-:(]1T-8+885C2R73^*8X(;Z=8(X?.
MFAV1E#GY5&=NX<Y/7M6K<3Q6T#SW$BQ11J6=V.`H'<U$M[:&>",31^;<J7B'
M=U`R2/;!_6A;@6:**AN+N"VDA2>9(WG?9&K'!=O04!U.?\(:M>ZA?7L=Y-YJ
MH`Z`*!L^=P0<`8X4<')[YYXZ:JMG=VES+,EHZLT;8DPA`ST/.,&K5-C*.O37
M%OI%S-9ND<R)E6<@`>IYX_/BH?#%Y<7NF>;=[BPD=%9MN74'`)V_+GZ<>E6Y
M;ZS666WFGC$D<?FR(Q^ZG3)IUC<VUU;K)9NKQ=`5&,8[8[4D(F;.T[<9[5Q<
MVM:Q%;S">Y1)([J=-\:*%^104C&1W)/N?45U>H7+VT:B&/S9Y6V1(3@$]<D]
M@!DFL:[OA!;27$FK6SK'(5<?9]T2N,9!(Y&/7-"W#H=!`S/"C.NUF4$CT.*I
MZ_+=V^CW4VGM&D\<;,K2#(&!GIWJ;3KL7MJLVPHV2KJ?X6'7_P"M[8J6YFAM
M[>26Y=(X4!9V8X`'?-)C1@P:AJ+:KHR/+']EN[8LZA/F=P@))/8<]JZ*J0U/
M3S=0VZSQ>=(@:->^",C'ID`_E5VJ9*,+7IKR#6]%\N[,=M-<&.2%1C?^[<Y)
M].!Q6'INH'4=0D>TNY+C3X]0M8T,TN]GD$WSN!_"O0`8`XZ5UEWJ=C:WMK9W
M,J"YN&/E)U)P"2?;@'FLJ?4-/OA:BP"AA>VK'$>W<IE&&'J#@\UTX3^-'U":
MT/4/$>HG2M)ENQ);Q%"`&N&*IR>G')/H*SO#?B"YU74+NVGMHXEA564I('SZ
M]#Z^H&>V1S7031I*FR5%=3V89%,BBC0DQHJEN#@8KE0V<=X:_P"2I>*_^N=M
M_P"BQ7;5Q/AK_DJ7BO\`ZYVW_HL5VU=>+^./^&/_`*2B8D=W_P`>LW^XW\JY
M#X0#/P_L0#CYY?\`T8U=?=_\>LW^XW\JY'X._P#(@6/^_+_Z,:G#_=9_XH_E
M(/M&C;^'I+>UU.'[69C>-O1Y``0V.IP/7'X5G_\`"*7<22&*>.1V,3J"Y0[A
MS(=V#C<>>AK3UTZA'<7+6YN'A^S@JD2_Q;^<$#.2*IRW>M01:4Z12%G202HT
M3R#[R[`Q&-IVYY;WS3A*HU=26O\`D%E>PKZ)J,DLS9C"SP^4W^E,=IVE<D>7
M\W7VJ1M!NX[2."%X)2C-B61BKX8#).`0W3H1R,<BL^SO/$*2S.;><DHIC66-
MRH;YO?GMW]*N66NZDVMV^G720AF)#A8'!(`8[P2Q"@X'!R><YJI1JK9IV!V3
ML)\2E*^#)58@D36X)`Q_RV2LK&:UOB;_`,B?/G_GO;_^CDK)-82_@Q]7^2&M
MS$NM)N(]3N]0TO[-%<3VOE`R`@>9NR&;`Y&*L^'+"73=*2WN`IFW,\C"4R;V
M)R6)*KR3VQQ6;JNI:K;:E?PQ-;I%'9B:`-@$'?@LQ/&<9P.GK6AX9O;B_P!,
M,MTKAUE>,%PH9E#8!.WC/TXKG0V:9`8$-T/!KG&\/W$6EW]C9K:B&[G=@AW*
M$C90!C`Z@C.,8/3CK712':C'<%P"<GH/>N(?Q%J+64DUK>^9;-,ZQ73(@+!8
MV;`7&`I9<#/)'?H:%J!VMNC101QLV]D4*7QC=@=:BU.RBU"PFM9D1Q(I`#C(
MSV)_'%2VLC2VL4CKL9T#,OH2*I^(+Q+#2+BYEN_LB(!F4*&(YZ`'C<>@X/4<
M&FP3,F#PO/%J6D7OVTEK&,1/'M!7`C*X7C/).3DUTU<SIFIZO)J&D17ODI%=
M6\CR8`+LPY&<<#C&<=\UTU#N%C,UK25U&:QF58A-:SK('<<A<\@>F<"H=&TF
MXL=1N9GF`@D+$1K(S!V+;MY#?=/.,#(-1>*-2FLKBP@L[H)<W$FU+?8I\P`C
M<6)Z*`3TP<D<T:#J<]]K-_$ET+JT@^3?M5=LF3E5`Y(`QDG/.>>U-`]38OH#
M<V<T(."Z%0?0URU];V5S=W,EW<P:9/-9-;S"5@C[LK\P)P&48Z@]ZZ^N;N]4
ME_X266S@OXQ%#"7G\R-=EM\HV<]2Q.21G&.PJ>H">%K*Y%TUU<LS1Q+)'#DL
MP(<H2`6`)`\L8)]3Z5TI`((/(K*\-7DUW9R_:9?.DAF>+S,`;@#P<@`'CT%:
MC'`)SC'<T,$<^/#\D-G?VMJ888;R[27:H(`BP@93[D*1^-="````,`<"N(G\
M3:A%I6I7%E(]]&C%+>Y^S[@I`)=BJ#[@Q@$]\\XKL-/F-Q8V\S9S)&K'*[3R
M/3M3$QNHVD5]9RV\T:2*XZ.,C/;/XUS\'A>ZBO=+F,\16SAAC<@G(,8;.!C#
M!MW4\CMUK:U^\CL-+GN9;O[(D8R90H9A[`'@D]!UK!M-8U(WFFC4)&1)(TWI
M$T19W=F`W+@G&`,[<#)/I3AN-GH?PQ&?"47_`%\7'_HUZOP:5*GBF?4S';I&
M\'E;D_UDG((W<=L'!R>O08YS_AC_`,BE'CI]HN/_`$<]:,&O07'B2YT>,H9+
M:%9'/F#=DGIMZXP1S[UKB/XTO5B7PF%XZ_Y'3P;_`-?$W_H*5T/B;27UC2I;
M1+EH"P/0`ACC@'(/&:Y[QU_R.G@W_KXF_P#04KM)@QB8(VUB#@@9Q6U63C3H
MM=G_`.E,2W9S^MZ!/J)A,=PJF.!D)8<EP/D;CT/-5&\.7T1987B,<ELL#'SV
M3#`$$[=AW<GU%.M9=874=-21;IU*#S78$*.7W;L#&3\N.GM5>:^UXK-"L$S!
M9Y-KB%U95W/MYSAA@+@@8Y'>J7M+**D@VU+$7AZ^D:VDGEC5K5&"KYYE$ARA
M`;*+\OR'CZ5I:7IMS!JDMQ(($B(;`0DEBQ!Z$?+[X)S[8K'CU/Q!:6P;[*'6
M&"-Y/.C?<[%1N^;.!@\GBMGPMJ<VJV<LT^P[9"BLD31AA@?PL2?6LZBJ*+;:
ML/L<]XW_`.1OTC_KUN/_`$)*@=0Z,C#*L,$>HJ?QQ_R.&D?]>EQ_Z$E5IVV0
MR,75-JDEFZ+[FHJ_!#T_5@CGY/#]S'H]UIUF;5([B:5P#N7RT8Y7&.X],8/K
M70Q@JBJ6W$`#/K7#MXDU$Z<9[>Z,D!DE:"X9$#3!$R!MQ@!FSCC./SKN(F+Q
M(S#:Q`)'I7.D-E76+!-2TV>UD1&\Q#LWC(#8X/X&LBW\-3PZUIVH_;6;[-#Y
M3QD#`&S;A3C."02<UH^([U-/TF:Y>[-H%Q\ZH&8G/10>,GH.#]*S=,U'5WU7
M38+_`,A8I[-Y'5.6+C;R3T'7M[^U-('L=)69J^D+?WEA=*(Q+:3!R[#G;SD#
MZ\?E6G6#XCU*>TU#3[:SNPMQ<2#%OM4AD##<S$\@`'M@DD?2DA$N@Z3<Z==W
M#22J().%B61W#'<6+_-]TG.,#(XK9K!\.ZE-J&HZ@%NOM=G"P192JK^\!.Y5
M`ZJ.!DY.<\UO4WL-'/ZGX;6\O;V>%D@6\MA"S*"&+AL@G\`!6AH5G<65D8KN
M7S',C.!O+A`3PH8\GZFLJ;5IF\17=I#J4:P0PDSO(B[+9CMV@'JS=2<G'3BM
M+PU=SWFG%KI_,ECEDC+8`W!6(!X`!XQR!BDM@>X_5T<>1=)$TWV9B6C7J4(P
M<#N>>E<_!'806;6UO>6H@>_^T-;1YW^6`"(]@&<Y"Y&.E==(=L;$D+@$Y/05
MPMQXIU"+1[NZLGDNX_-"PWGV;=A!C<<(.`3D+G]:%N'0Z_2H7CCFFEC\N2ZE
M,S)_=X"@?7:HS[YIVL6":EIL]K(B-YB$+OY`;'!_`U9B?S(D?GYE!Y&#^59_
MB.^33])EN9+LVBH1\Z('8DG[J@\%CP!P?I4M=!I]3,B\.W*ZQ97GGQ;+>.)&
M()!&Q6&`.ASNSD\C'O72UREGJ^H_VGIZ:C(462*-6CA:-MTC;B=PP6Q@#D$#
M-=75ON2C-U73&O;[3;B,QK]EG,DFX<LNQEP/Q:L*+09-,N8+B5H^;JU@CCC9
MBJH)\C&>G7ISCU-6?$M_)%KEA9Z?=2_;9&5S%O"Q)$&^9F'<GH*R=*U*[O+F
M!+YI3*UU;2LOF!DC/VC:5QC*GCIG&!ZUTX/^-&P3T1[/XHL9]2T:6UMH+6>1
MR/DNB1&1GG.%;GTR",]JH>&=`GTK4KJY<QI%,BJJ+)YC$C&2S;%)QT&<\>G2
MM77;V33]+FN8%B>6,91)7V!SZ9]3VK-\->(GUBYDC,,4:!-Z;9"7&#@[@0,>
MU<HWMJ9/AK_DJ7BO_KG;?^BQ7;5Q/AK_`)*EXK_ZYVW_`*+%=M77B_CC_AC_
M`.DHF.Q'=_\`'K-_N-_*N2^#G_(@V/\`OR_^C&KK;O\`X]9O]QOY5R7P<_Y$
M&Q_WY?\`T8U.'^ZS_P`4?RD#W.Q(KC=0\4WUK)>NMJ'\D[8X0K9)!?.3ZD*#
MZ=*[.FE<^E<\)1C\2N-HY7_A)[T7XA^P`0K.+>1\DMD]U'&1@KD_6NG$,1E\
MXQIYN-N_:-V/3-$-M%`"(8DC#,6(1<9)ZGZU(!14G&7PJP(YGXE.8_"<S*%)
M\^`?,H8?ZU.QK&R.YQ6O\3_^10G_`.N]O_Z.2N3UB=GG2RVRK"Z[II%0G<N?
MN`CN>_M^ER2]C%^;_)`MS,O-3M-3NYL736B6RL8G,;!9BO+9;&&49QM!YSGT
M-;.A:A!J-@KP1&`QGRWA9"AC8=MI`(]O:N>O-*%]?7DEW<,\$L/D6\:VSJ;9
M>/N\XY(&3CL!4]E"=)A$]N9IIU9C)&D#(C1DYV*.<8[9]_6L%L,Z@@$$$`@\
M$&H4L;1$*):P*A()41@`D=#4RMN4,`1D9YI:`"F30Q3H4GC21#U5U!'Y&GT4
M`1QP0QA!'$B!!A0J@;?IZ5)110!%-:V\[*T\$4K+]TN@)'TS1#:V\#L\,$4;
MO]YD0`GZXJ6B@`J'[);><9OL\7FMU?8-Q_&IJ*`&Q1I$@2)%1%Z*HP!^%.(!
M&",@T44`0Q6EM"K+#;Q1J_W@J`!OKZU,````,`=!110`R:&*>,QSQI*A_A=0
M1^1IJ6MNC(4@B4QC"$(!M'MZ5+136Z`V?AK(TOA6)F"@^?./E4*.)6'05TVU
M=V[:-V,9QSBN7^&'_(I1?]?%Q_Z.>NIK7$?Q9>K$MCB/'?\`R.O@W_KXF_\`
M04KMS7$>._\`D=?!O_7Q-_Z"E=O6V(_A4O1_^E,2W9FZ_?2Z?8F:",,VX+E@
M2$SW..<5SR>*[V'S/,LS.L$"RR,%*MG*AACU^;(Z5V1&:BGMHKA-D\:2+D':
MPR,CD5C3G"*M*-QO4R?#VK76HS74%_:+!)"0/D.Y2"/7U]N*V88HX4"0QI&@
MZ*B@`?A3@,4M9RDI.Z5@2.'\;N1XLTI,+AK6<Y*C/WD[]16;J5W#964DUP-R
M`8"8R7)Z`"M#QQ_R.&D?]>EQ_P"A)7.O-//>2W$EK<JT6Z.V7RMRKVWG!Y)_
ME]36M5>[#T_5@MS&%S86%F=42-GE$H^TP)9OM5>H7;M^4@$$,>O/K786L\=U
M;I/`X>.10RFN5T[3;B&R2&\^T3RM=+<W$HMF!GQV.6..0/8`5KV<DD6IE8+6
MX6UN,EPZ;1$_]X>Q[^_U-8#ZFI-#%<)LGB25,YVNH8?D:5(8HP@CC1`@PNU0
M-H]!Z4^B@`J*6UMYI%DF@BD=/NLR`D?0U+10!%!:V]NS-!!%$6^\40+GZXJ6
MBB@"'[':^:TOV:'S'!#-L&6'N>]21QI$@2-%1%X"J,`4ZB@!"`P((!!X(-11
M6=M%&T<5O"B/]Y50`'ZBIJ*`"HYX(KA-D\22IUVNH8?D:DHH`B2VMT9&2")6
MC&U"$`*CT'I4M%%`$,MI;2RB66WB>1>CL@)'XU3U94@^R/%%$K27]ON)0'=^
M\7D^_O6E6=KG^KL?^O\`MO\`T:M=&%5ZT5YBEL>G2Q1SQF.:-9$;JK@$'\#3
M8K:"*1Y(H8T=\;F5`"V.F3WJ6BN<9Q'AK_DJ?BO_`*YVW_HL5VU<3X:_Y*GX
MK_ZYVW_HL5VU=>,^./\`AC_Z2B8D=W_QZS?[C?RKDO@Y_P`B#8_[\O\`Z,:N
MLO"?LDV.?D;^5>5?#S6O$]GX5M8-)\-_;[56?9/]I5-V7.>#Z'BH511P\HN^
MZZ/LSHHX>==MQ:5N[2_,];HKAO\`A)/&W_0FC_P,2C_A)/&W_0FC_P`#$KB]
MK'S^YG3_`&?5_FC_`.!Q_P`SN:*X;_A)/&W_`$)H_P#`Q*/^$D\;?]":/_`Q
M*/:Q\_N8?V?5_FC_`.!Q_P`S0^)__(HS_P#7>W_]')61W-9?C77/%5UX?EBU
M+PP+.W,L1,OVI6P1(I48'J<#\:H_VOXB_P"A>_\`)I*UE7C[)*SW?1^14<NJ
MO[4?_`H_YG14=ZYW^U_$7_0O?^324?VOXB_Z%[_R:2L?;1[/[F5_9M7^:/\`
MX%'_`#.BHKG?[7\1?]"]_P"324?VOXB_Z%[_`,FDH]M'L_N8?V;5_FC_`.!1
M_P`SHJ*YW^U_$7_0O?\`DTE']K^(O^A>_P#)I*/;1[/[F']FU?YH_P#@4?\`
M,Z*BN=_M?Q%_T+W_`)-)1_:_B+_H7O\`R:2CVT>S^YA_9M7^:/\`X%'_`#.B
MHKG?[7\1?]"]_P"324?VOXB_Z%[_`,FDH]M'L_N8?V;5_FC_`.!1_P`SHJ*Y
MW^U_$7_0O?\`DTE']K^(O^A>_P#)I*/;1[/[F']FU?YH_P#@4?\`,Z*BN=_M
M?Q%_T+W_`)-)1_:_B+_H7O\`R:2CVT>S^YA_9M7^:/\`X%'_`#.BHKG?[7\1
M?]"]_P"324?VOXB_Z%[_`,FDH]M'L_N8?V;5_FC_`.!1_P`SHJ.]<[_:_B+_
M`*%[_P`FDH_M?Q%_T+W_`)-+35>-]G]S%_9M7^:/_@4?\SN?AA_R*47_`%\7
M'_HYZZFO*O!6N>*K70$BTWPP+RW$LI$OVI5R3(Q(Q['(_"MS_A)/&W_0FC_P
M,2M:]>+J2=GOV9']GU?YH_\`@<?\QWCO_D=?!O\`U\3?^@I7;UY#XGUGQ+<>
M)/#LU[X<%M<P32&WA^TJWGDA<C/;''YUTO\`PDGC;_H3!_X&)6M:O%TJ2L]$
M^C_F8EE]6_Q1_P#`H_YG<T5PW_"2>-O^A-'_`(&)1_PDGC;_`*$T?^!B5R^U
MCY_<Q_V?5_FC_P"!Q_S.YHKAO^$D\;?]":/_``,2C_A)/&W_`$)H_P#`Q*/:
MQ\_N8?V?5_FC_P"!Q_S$\<?\C?I'_7I<?S2H36!XEUCQ+/XAT^6]\."WN$@E
M6.+[2IWJ2N3GMC`_.F?VOXB_Z%X?^!2UK5KQY8:/;L^[*CEM5Z\T?_`H_P"9
MT5%<[_:_B+_H7O\`R:2C^U_$7_0O?^325C[:/9_<RO[-J_S1_P#`H_YG145S
MO]K^(O\`H7O_`":2C^U_$7_0O?\`DTE'MH]G]S#^S:O\T?\`P*/^9T5%<[_:
M_B+_`*%[_P`FDH_M?Q%_T+W_`)-)1[:/9_<P_LVK_-'_`,"C_F=%17._VOXB
M_P"A>_\`)I*/[7\1?]"]_P"324>VCV?W,/[-J_S1_P#`H_YG145SO]K^(O\`
MH7O_`":2C^U_$7_0O?\`DTE'MH]G]S#^S:O\T?\`P*/^9T5%<[_:_B+_`*%[
M_P`FDH_M?Q%_T+W_`)-)1[:/9_<P_LVK_-'_`,"C_F=%17._VOXB_P"A>_\`
M)I*/[7\1?]"]_P"324>VCV?W,/[-J_S1_P#`H_YG145SO]K^(O\`H7O_`":2
MC^U_$7_0O?\`DTE'MH]G]S#^S:O\T?\`P*/^9T59VN?ZNR_Z_K;_`-&K6=_:
M_B+_`*%[_P`FDJEJFIZ[(EJ)M"\H+=0LI^T*=S!P57\3@9]ZZ,-B(QK1=G]S
M)EEM6S]Z/_@4?\SV^BN&_P"$D\;?]":/_`Q*/^$D\;?]":/_``,2N=5H^?W,
MG^SZO\T?_`X_YCO#7_)4_%?_`%SMO_18KMJ\[^']S?7?C[Q)/J=E]ANWCM_,
M@WA]F%P.1UR,'\:]$Y]J[\1-3DFOY8^71'%.FZ4G"5GZ-/\`%$5V/]%E]D;^
M5<G\'?\`D0+'_?E_]&-76W?_`!ZS?[C?RKDO@[_R(-C_`+\O_HQJJ'^ZS_Q1
M_*1GU.RHK)\0Z]'H:6V^SNKR2YD\J..V568G!/<CL*H7?B]+2WM))M&U037<
MC1QV_E)YF5&<XW8Q^-81HU))-+<=TCI<T5SESXL6UT^&YGT;5(Y)Y_(CMC&G
MFL<9R!OQC\:N:#KT.LM<1+;7-G<6Q42P7*!77(R#P2,'ZT.C44>9K0+HS?B?
M_P`BA/\`]=[?_P!')616O\3O^10G_P"N]O\`^CDK(JW_``8^K_)`MPHHHK`8
M4444`%%%'\J`"BBB@`HHHH`*.E([*B%W("J,DGL*SDN-1O$66TC@A@)RIGW%
MW7UP,;<]NOTH`TJ*J65X\TKV]S$(;F,`LH;<K`]&4XY'!JW0`4444`%`HI<8
M--;@:WPO_P"11B_Z^+C_`-'/74URWPP_Y%&+_KXN/_1SUU&:UQ'\67JQ+8XG
MQW_R.O@W_KXF_P#04KMZXCQW_P`CKX-_Z^)O_04KMC6V(_A4O1_^E,2W8N:*
MP[?Q/8W'B*;1$287$0.9"H\MB`"5!SG(##M1)XGLTTB]U(Q3^39S-`ZA1N+*
MVTXYQC/O6'L:ETK;V_'8=T;E%8.I^*;:QN1;0V5[?W(C$CQ6D88QJ>A;)`'\
MZT]*U"#5+&*\MMXBE&0'4JP^H-3*G.*YFM`N<AXX_P"1OTC_`*]+C_T)*AJ;
MQO\`\C?I'_7I<?S2H:TJ_!#T_5@MV%%%%8#"BBB@`HHHH`**#10`44=Z*`"B
MJU]=BU5`J&6:5MD<8.-Q]SV`[FJ[R:K$IE>&VF0<F*-FW^^&/!/Y4`:-%16M
MQ'=6\<\))209!(P?QJ6@`HHHH`*SM<_U=E_U_P!M_P"C5K1K)U:Y@G6U6":.
M4QZA;*X1@=I\U>#CI73A/X\?44MCU:B@T@.:Y1G$^&^?BGXK_P"N=M_Z+%=M
M^)KB?#7_`"5/Q7_USMO_`$6*[:NS&+WX_P"&/_I*)B1W?_'K-_N-_*N1^#O_
M`"(%C_OR_P#HQJZZ[_X]9O\`<;^5<C\'B!X`L<G'SR_^C&IP_P!UG_BC^4@>
MY>\9:1+J]QI$<8G6*.Z+S202%&1=C#.1R.<5D^,-#GCBT6.RAU2^AM)I&D,-
MR?/`(X^=B#U]ZZ@:S9LEU(C,Z6CB.1@O&3CIZXS51O%-AARBS2;7\O"J.N[:
M.I`P>H/I54JM>'+RK2/Z_P##@TF<QJFGWEWH-BD&F:V!;WPD=);D-<E<'E7W
M<=?6M7P+87=I>:C-):7=K:S["HOI1).S@$$E@3QC&.:UF\0VXD9#!<#9'YCG
MY/D&">?FYX';-.;7K4)&Z)-*LC%5,:YW8`R1SR!G''X4Y5JLJ;I\NC_X<5EN
M9OQ._P"10G_Z[V__`*.2LFM;XFG=X/F/K/;_`/HY*R:P?\&/J_R12W"BH[B1
MHH'>.)I649"+C+>W/%5M'U*/5+/[1&A3#M&R[@V&4X."."/>N<9;EXC;Y2W!
MX'4UQ-MH\M[I=PEQI(A^U7:8MGC4BW3H6!/5B,Y(QR:[BJ.M:E_9-B;HV[SH
MGW]C!=H]>?Y>M`%R.-8D5$7:JC:!Z`=*SO$P<Z+<"*P.HN0-MOG`<YXS[#J1
M6C&P=%<#`8`X-.H`X;2M%U"#6]+F:&9TA1`9'`4`;7W#U7EAA1P>,]*[FLZ[
MUB"WUBSTPJ[SW6[E1Q&`I;D^^,5HT[W`YSQ=;3W=UIT-O8R2?O-SW:+N-NH(
M/RC/WCTSV&?6F^&=-O+/5;V20.MNX(^=`K2/O)#$ACNX.,\<<8XKI>!69I&L
MQ:G<W<,*H!;N8R1*K,2#CE1R.G>@"WJ,3SV$\4?WW0@?7%<G=PS:G>2W&DV\
MD,QMY()G=@`25&!USD$8VG`&2>]=I]:H:M%I\%O/?WMO&PB0EVVC)`J0,7PG
M;N=0DD1##;6XFC6,@`+O9"%X.,KL/'^U74/T/&?:J.AWD5[IPD@A2&)24"(Z
MLHQZ%>*OTV!QD^C74VGZQ'9VUS:1R['BA#!6=P#D'!Y&<'.<DUV,0Q$@/4`5
M4UB^?3;![I8/.6/EEWA?Y]_:K4#M+!'(\9B9E!*'JO'2@!]8VHV,\OB+3+R-
MI6CBWJZAOD0%3@X]2>/PK9K)O-=AM-<M]+:%FDG`(8$#KNZ#J<;3GTR*<=T!
MUGPQ./",7_7Q<?\`HUZNVG]I#Q5>-.\QL#$/+5DPBD8Z'<=Q//88QWS5+X8_
M\BE'_P!?%Q_Z.>MV+4K6?4)K&*1FN(`&D`1MJYZ#=C&>G&<\UKB/XTO5DK8Y
M7QU_R.G@W_KXF_\`04KL[AF2!W12[*I(4=2?2N,\=?\`(Z>#?^OB;_T%*ZS5
M;^WTVQDN[I]L<8R<#)/L!WK>LFZ=%+L__2F"W9Y_;>&_$5I%8ZQYZS7$=V;N
M2Q6$+(/,.'!DW<X4],=JL7=AK`L]2T%-*DE2]NVF2[#J(E1F#?-SG(P>U==?
MZU9V#JMP7!<*1A>Q./TQD^E5_P#A);/S"$BN&`C\UF`4`+SV)R>AZ"M?K-:5
MI.*^ZWY"Y4S'U2UU72M0U":QM+FYAU".-1):,GFP.HQT?@C'_P"JMSPA#J<&
MBQIK<IDN]S$EB"0N?E!QQG'I38?$=JXCW131M*I:-6"DO@J,#:3S\PXJW8ZG
M%=W<L$<<H,1(WLORG!P><^OKC/:N>I.<H6E'Y^F@TD<KXX_Y&_2/^O2X_FE0
MU-XW_P"1OTC_`*];C^:5#4U?@AZ?JQK=A15#6]3_`+*M?M#6[S1@_.58#:/Q
MZ_05?'*@^M<XS*\5"0Z+,L.G_P!H2-@+`?NDYZL.X'7'>N?TC1M0MO$&GSM%
M,\<4:HTL@"_+Y;`YYR#N(^7IW]Z[6LZ;6+>'7+;2MK//.C/D#A`!GGW-"=F!
MHUS?BFVFN]4TV.&RD8+('>\09,(#`[5YX+=SV&:Z2BCS`YOPGIUY8WMXTP=;
M=PJKO0(SOO<ECACDX(&[C..G%=)6;HVL1:M)<B!4"P.8\B56)P2.0.5Z=ZTJ
M8CD]9TV[GU:[FTZSEB:2W>.61B`)#E",'//`(P>G/K6QX:MY;73F26,PJ97:
M*(@#RT+<+@=/I5S4;V+3[&:[G.(XER?\*9I5\NH62W"H$4DC`D60<>C*<&DM
MAD&JNMM<V]W,I,(5XW;H$)Q@D]NF,^]<Q>:=)'I-]+''-9VHN89XH?,"EL%0
MP('4<9Z_,>N:[@@$$,`0>"#WK'U9+72($NH-*BG*.-H3:I5B<#:#W)..*`+>
MAHR:>&="GFR23!",;0[LP!'K@C/OFKU(A+("PP2.1Z4M`&+>V$[^*-/OD:5X
MD21'!;Y$XXX]2>_M6U65<:]#!KT6DF)C+(H8-N'<-T'4CY3D]LBM4T=@`]"<
M9P*X?3X+M]0:^O+&33P]]:Q06_EA52)9N#D=6.2?:NW8@*3@G`S@5R<?B!=8
M>UB:%8F%S:3J`VX[&F``88&&XY'O75A/X\29?">N>(_M!T>X%F9UG(PC0`%E
M/8XR,CU&>E0Z(-2%Q-_:#.8S#"5#8PKX;>./?'YU?U"[AL+.2YN2XBC&6*1M
M(0/7:H)_2H+#5[&_GD@M)C(\:AC\C*"#W4D88=N,X-<I3.7\-?\`)4O%?_7.
MV_\`18KMJXGPS_R5+Q7_`-<[;_T6*[:NO%_''_#'_P!)1,2.[_X]9O\`<;^5
M<A\'P#X`L<]-\O\`Z,:NON_^/6;_`'&_E7(_!W_D0+'_`'Y?_1C41_W6?^*/
MY2![FJVG:/817]NCI;+<)OF4,!L7ID>G^-0+X?TF6,)!<.#<I$R$,K96(``@
M,"#U&<@U=U;1FO)YIH9EAD>$1AMN2&#;@:I7/AEYH=.07*E[0.6D=<DLS*Q9
M<$8.0?SHC-/>;5]QVU&PZ1IES<LL>I-)(T?EN@2')&".R97C/W<=*NR>'K8V
MPMXIIX8`V1&A4KVR`"#CIGCD'H169%X0E3SMU\&\U`A^4C(&[/?_`&J++0[R
MS\16[HBM9Q982Y^Z,,`@&<XY!Z?C5/E?PSV![[#OB4H3P9*@Z+-;@?\`?Y*R
MJUOB;C_A#Y\?\][?_P!')6364OX,?5_D@ZE?4;47UC-:M++"LRE"\1`<`^A(
M--TJP33+"*SBD>2.(;5+A0<>GR@#]*CUZ&2XT>ZBB:579#CRAECWQC(S],U7
M\+075OI(2\`5C([(@4KL0M\HP>1QVKG0S6JIJM@NHVWDO<3PJ<AO*8#<I&"I
MR",$'Z^F*M,,J1G';-<3=Z3J26-Q%BZN5^W2O\QW.X,1"-QV#D'T&/:@#M(8
MUAB2*,;4C4*H]`.*?45HLB6T0F.Z0(H<^IQS4&LV\EUI=S#!++%(R$!HCAOH
M/KTH!*Y#<Z%87&JP:F\.+N!MP=>-WRE>?4`&M*N9T_3[Z/4=#GE:X*1VC1RQ
ML?E1MHY/J2<\GTKIJ-M`ZA[5GV>DP6M\]V)99)&4HOF$812V2!@#C/KDU5\1
MV=S<3Z;+;23XAND+Q1G"LN>2WKC^M5?#D<K:YJ-PUI/90D[$CD1OWN&.9"QX
M).>`.@IK4);'1DA02QP`,D^E95S++JMG+%#8K-:3(5W22[/-!'88)Q[_`*5=
MU.-Y=/N(XAEVC8`>IQ6%'"9]6:]C%U<V4M@T?E(V`AW+\@&1AN#WJ0-'P]%%
M:I/`!,+K?YD_G%2Q)X!^4`$$#C`[>M:M<MX4AE&HR*(WCAMUF7##'#NA1<=L
M!6&.VX>M=2>A`--@M2MJ%E%?P+#,SA%D23Y3C)5@P!]L@59^M<7?:7K8TC6K
M6S>25I[IG\R:4K))'Y:_<(4]2",<<5UFG"1;"W$ZA91&N\`YP<#O0M@>Y8K-
MNM$M;K5([^1Y1(NPE`1L<H24)XSP6/0CK4^KV\EUIT\,4LL+.APT1PWT![9K
MF;2ROX[S19)+5Y7BM88F66+*Q]?,._/RMT[<TXZL3/1OAC_R*<>?^?BX_P#1
MSUK6^AVMMK=QJL1<3W*X=<+MS@#/3/15ZD@8X`R:R?ACSX2BS_S\7'_HYZUK
M>"[&O7,CW5R;01J$B<)Y>X]2I"[N,=R>M;8C^-+U8E\)SOCK_D=/!O\`U\3?
M^@I73:[I]EJ&GRQ:DJ^0%8ESQLX(+`]CBN9\=?\`(Z>#?^OB;_T%*["]222T
ME2!D65E(0NNY0>Q([UM5;5.BUV?_`*4PCNS#N;?0]4EMHVNU9V@>&)$D`W(1
M@G'J,']:9/HNE@"X-\T<7EBV)Q$00N01N920>N<$<TZU\/W,5Y!/+/`=I5Y0
MD9!9@7((R>,[SFJS^$I7DF*W<:"29I3MC(+;BY^;GDC?C\*7-';GT`M67A_3
MGCBECN7N1&I$4@6-=FX*=PV*.?E&#SU/6M&RTN."_DO//FED8$`.5PH)YY`!
M/3N3CMBL*7PE-Y64N\S1PI'$P!4J5&"0<\9K4\(V=S9:?(MW"L$DDI<1+C"#
MCT)';/!J*EN6ZG<:,#QO_P`C?I'_`%Z7'\TJ&IO''_(WZ1_UZ7'\TJ"0%D90
MQ4D$`CM4U?@AZ?JP6[*FJZ='J=OY,L\\49!5Q$P'F*1@@Y!_QJVB"-0BC`48
M'TKB+O2M3736@5;FX(NKDH7^9BQ'[IS[`\^@S7;1[A$@<Y8*`3G/-8=!CJS9
M="T^36(M4\G;=Q$G>O&XE<<^O'2G>(+:6[T:[@MY98Y&C;'E'#'C[N>V:S+"
MPO8]9TNYE:X,2V)CD1C\D;83MZGGK0MQ,Z.BBL;7[*YGU#2IX))RD%R#)'&<
M+C!RS>N/ZT#+5AI4%E=27*RRRR2+L'F$'8N2=HP!D9)ZY-7ZYSPK%*=1U*X>
MTGL8G8*D$BM\V"<R%CU8Y[9P`*Z.AB(;ZTAOK22VN%W1RKM85%IFGQ:=`T43
MR2%W,CO(1N9CU)P`/R%9-S93IK]]<3I=W=I+9@>6C8`.[E%P1SCGK_A5SPM!
M-;Z7Y4\;(!(YC#C!V%B5^7^'CMVH0V:%S<Q6L)EF.%7`Z9))Z`#N:S+YI;I;
M>:XTZZ$4$JS!5="V1G!*YY`SG`.>/PJ?5L+<V$DC!85E()(Z,5(4^W-<QJ6E
MZ\-"O[:T9Y=UX\C-+,5ED3Y2NTA2,9'3C@8HZ@=I;S1W,*30.'C<94BI*S?#
M^YK>>7@12SL\07D`8`.#W!8,<]\T_P`06TMWHUU#;RRQR-$VWRCAB<=`?>AZ
M;`M1D^BVLVJIJ#M*)%*L4!&QF4$*3QG(#'H1[UI5RL5G>1ZUILYMFE*6\43>
M;"-L0`;>P?/#9(XP,UU6:;5M`O<0LJD!F"EC@`GJ?:N;FTRRLIXY;>8SW#W]
MLLC.REE'F@A3@#U/7)/KQ5C7M.DGUO1KR%)',-P0Y#':BF-^<=.N.:P=*L-0
MLKF%;V,[?M5LLDKQA2TGVC/RL!EE((/.>3^%=&$_CQ]13V/<=4LQ?V4ELTLD
M0<8W1[<_DP(/T((JEI&B)IEQ-)%>7,ZR*JB.;81&H&`%(4-CZDU+XC:X71K@
MV;W"3[<(\"!V4]CM/4>M9_AZ75)-2G^W?:1#Y,?RS(JA)/XMI`^8'K[5S#9E
M>&?^2I>*_P#KG;?^BQ7;5Q/AG_DJ7BO_`*YVW_HL5VU=>+^./^&/_I*)CL1W
M?_'K-_N-_*N2^#G_`"(-C_OR_P#HQJZV[_X]9O\`<;^5<E\'/^1!L?\`?E_]
M&-3A_NL_\4?RD#W.Q(KC;^S\2B6]DM"_G2';')YBX`#.5P..,%1SS]<5V=%<
M].IR;(;5SD(H_$4M^94N)#!%=>6(RH4/&#DL2<'O@8S]T>M=8N><T^BBI/GZ
M6"QRWQ.X\(3_`/7>W_\`1R5D&MGXEA#X4G\TL$\^#E1D_P"M3'>L:K?\&/J_
MR0=3#O\`Q&EE>WL$MK(J6=N)_,8X#_-C`'IGO5_1KXZC8B=HUC;<RLJN6`(.
M.I`/Y@5D7]FFM7=Q-;2JBQ0F`[CD3\Y(([*#W'.?I6EX=6U73L6:LN78RAWW
M,)#][)[GW],5@O,8[6$24V<<R;XVN/F4C.1L8_TK!-[;2:7<WEOH%N6M[@V_
MD3OY;.>,8PC8))''ZUT6IK)FUDBB:4Q3;V5<9QM8=_J*H-:PG=G3+OY[@71^
M9<&08Y^][=*`+&D1+!<WB)"D(S&3&G125YQTJSJEY]@L)KKR9)_+7/EQC);V
M_P#KU'IPE:YNYI8'A$A7:'(R<+@]#5R6-9HGB<91U*L,]010","V\4"?4[&S
M%F56[B20OYGW"RLP'W<'[OJ#Z`\UT-9D7A_3HKF"X6)M\"JJ`N2/E!"DCN0"
M<&M.@#.U?5O[.GLH?LTDWVN81;P<+'GN3Z^@JOHGB&/5;ZXM?*6*2(%MOF;F
MP&*X88&T\=.>"*TKRSAO!$)U+>3()5P<88=*CM=.@M;B6>/>TDO5I'+$#.<#
M/09).*`9;KEM=N[.SU-TNK$C,3S![>Z:-WV@<NJXXR<`DGGM74UEG0+%M0NK
MUQ*TEVGES`R':ZXP!CM0'0=X?N8KBSD6.VCM6@D:*2.,[E##G(.!G.?2M(YP
M>YJOI]E#80&*#=@DLQ9BQ)/<D]:G894C/4=J&".=N/%+6T%^TNGL\MDRJRP2
M;UY!.&;`VD`9(YQD5T,;;T5O49K+L_#MA::=<6$0F:VN,ET>5FZ\D@^]:JC:
MH`Z`8H`AOII8+5Y88TD91G#R;%'N6P<#\*QK?Q,TPTQ_L86+4#L4^=\V[GE5
MV_,N!G/'!%:NK:;;ZM8R65X',,GW@CE2?Q%5H_#]FFI07X>X-Q!'Y2,9F/R9
MSC'^>E5'<&=3\,?^11B_Z^+C_P!'-6Q#K5G/K-QI4;,;NWC621<<!3T_G67\
M-1&/"L7DL[+Y\_+*`<^:V>Y[UL1:5;Q:I+J"*_GRC#?.=O0`D#U(5?RK2O\`
MQ9>K$MCE_'7/C3P;_P!?$W_H*5VQKB?'7_(Z>#?^OB;_`-!2NWK;$?PJ7H__
M`$IB6[,W7TO)=/*V&[S"PW!6"L5[@$\9KFY8_$ME&[Q,RI%"BQQY$@>3*^G(
M!&<\<=:[:BL:=9P5K)C:N87AR#58+BZ35)FN(\CRG?:&/KP#T_(^U;E+16<Y
M<SN-'"^-_P#D;](_Z]+C^:5`[;%9B"=HS@#)-6O&X3_A+-))+;_LL^!CC&Y,
M\YJG-*D$32S.$1!EF/0"M:OPP]/U8ENS!/B.YDTE[RVTU"R7#6WD3W!C8G=M
M&,(W)].,>M=`I8J"XPQ'(SFN8BMUB"ZE./\`0&N3<F'.3"Q)Q(3^)RO;CT.>
MG!!&0<@\BL!E36+_`/LW3IKL6\EP8E)$<?5OQ[#WK,MO$WGZQ:V'V3:+B)9/
M,\S.TLA?&,8Z#'7/MCFMRXA2XMY(91E)%*,`<9!ZU0BT*PBO8KI(F$D0`7YR
M5R%*AL>NTD9]Z`-*LW5=7_L^]L;86TDOVN7RRXX6/CJ?4\=*TJ@NK.&[:!IU
MW&"02ISC#`$?U-`&9H/B"/6+FX@$(BDA4/@2;S@LRX;@;6RO3GJ.:VJJ66G0
M6<LLL6]I)>&>1RQ`!)`!/09)X]ZMTQ&#J?B,Z;J$MM/:J0L+3(5ERQ`*CYEQ
M\H);`.3T/%:6D7YU&V:1HQ%)'(T3H&W`,IP<'`R/PJN/#]C]LO+EA,TEZ,3`
MR$JPQ@<=L=JNV-G#8P>3`&VY+$L<DDG)))ZTADDZ++"Z2()%8$%",AO:N/EU
M*"*VN(Y;&YE6WN(X'BCNVDB!8K]YB!TR,KR.U=C(H=&0D@,".#BLRS\.V%II
MC:=$)3;,X?:\A)!#;L@_49H`U$544*@"J!@`=`*@U&XDM+1YXHXY"HR?,D\M
M0.Y+8.`/H:L"J>L:7;:Q9-:7H<PL06"N5S@Y'3^5'H'J9MMXD:>33/\`0PL6
MI`;,R_/T))VXY48'.1U'%;U9D6A6D6I)J`DN&N$C$09I2<KZ$5IF@$8NOZM<
M:7=V:H+=TN95B6'YC+(2><=@%'.>?PJC<:C>3:FMA?I`CP7EI*ACSRK2X[]<
M8Z\<GI6M=:':7.KQ:FYF6ZB3RU992`%SDC'3FJMSI5E926TR^:7DO+92[.9&
MP)0549/`R373A/XT?4F2T/4M5OHM-T^:\N`QBA7<^T9('<_A45AJEK>W$D%N
MY:2-$D;@@`.#CGUP.G;BI[^T2^M6@D:15;^*-RC#Z$53TKP_IVDSRS6$!B>5
M51OG8@@$D<$X'4]*YBCG/#7_`"5+Q7_USMO_`$6*[:N)\,_\E2\5_P#7.V_]
M%BNVKKQ?QQ_PQ_\`243'8CN_^/6;_<;^5<E\'/\`D0;'_?E_]&-76W?_`!ZS
M?[C?RKDO@Y_R(-C_`+\O_HQJ</\`=9_XH_E('N=E1117&4%%%%`'+?$__D4)
M_P#KO;_^CDKDM;O`)4L?-:W$@W2S`'Y4Z8!_O'].?:NM^)__`"*,_P#UWM__
M`$<E9%;R_@Q]7^2$MSA_,A.NW,G]F!+*&%HHE0Q@7.0,[SG(X&`,8J?194TJ
MS%RGR/YC^;;@99XBQ(/R_+O`/;CM78T5@,16#*&'0C(I:**`"BBB@`HHHH`*
M***`"BBB@`HHHH`****`"BBCO36X&O\`##_D4HO^OBX_]'/74URWPP_Y%*+_
M`*^+C_T<]=36V(_BR]6);'$>._\`D=?!O_7Q-_Z"E=O7$>._^1U\&_\`7Q-_
MZ"E=O6N(_A4O1_\`I3$MV%%%%<904444`<+XX_Y'#2/^O2X_]"2N9OM0L]0F
MFCEEA>UMB1Y)D"F>0=N2.`?7O]*Z;QQ_R-^D?]>EQ_-*JFWA)),49)_V16];
MX(>GZL2W9YU-;7=YX?GC1K6SEFF\V2S,T87`QM12C$8&,DG!)KKM)OH+:Y33
MA<1RQN"T!5]VWN4/T[>W':M;[-!_SQC_`.^!3EAB5MRQHI]0H%8#'T444`%%
M%%`!1110`4444`%%%%`!1110`4444`%9VN?ZNR_Z_P"V_P#1JUHUG:Y_J[+_
M`*_K;_T:M=.$_C1]12V/4:***YAG$>&O^2I^*_\`KG;?^BQ7;5Q/AK_DJ?BO
M_KG;?^BQ7;5V8SXX_P"&/_I*)B17A(M)N,G8W\J\J^'GB/7-.\*6MMI_A>;4
M+=6D*W"W`0-ER3QM/0Y'X5ZK=C_19?\`<;^5<G\'/^1!L?\`?E_]&-67)*6'
MDU*VJ_)G11JTZ;]^"EZMK\FB#_A,?$__`$)%Q_X%C_XFC_A,?$__`$)%Q_X%
MC_XFNYHKBY)?S/\``Z?K5#_GQ'[Y?_)'#?\`"8^)_P#H2+C_`,"Q_P#$T?\`
M"8^)_P#H2+C_`,"Q_P#$UW-%')+^9_@'UJA_SXC]\O\`Y(\J\;>)=>OO#\L-
MYX4GLHC+$QF:X#`$2*0,;1U/'XU2_MW6O^A:F_\``@?X5W/Q/_Y%"?\`Z[V_
M_HY*R*VE3G[)/G>[[>7D5'%X=;T(_?+_`#.=_MW6O^A:F_\``@?X4?V[K7_0
MM3?^!`_PKHJ*Q]G/^;\BOK>'_P"?$?OE_F<[_;NM?]"U-_X$#_"C^W=:_P"A
M:F_\"!_A7149%'LY_P`WY!];P_\`SXC]\O\`,YW^W=:_Z%J;_P`"!_A1_;NM
M?]"U-_X$#_"NBHH]G/\`F_(/K>'_`.?$?OE_F<[_`&[K7_0M3?\`@0/\*/[=
MUK_H6IO_``('^%=%11[.?\WY!];P_P#SXC]\O\SG?[=UK_H6IO\`P('^%']N
MZU_T+4W_`($#_"NBH'/2CV<_YOR#ZWA_^?$?OE_F<[_;NM?]"U-_X$#_``H_
MMW6O^A:F_P#`@?X5T54#JBNS_9;>>Z1"09(E&TD=0"2,_AQ1[.?\WY!];P__
M`#XC]\O\S,_MW6O^A:F_\"!_A1_;NM?]"U-_X$#_``K;L[N*[5C'N5T.UXW7
M#(?0CM_7M4]'LY_S?D'UO#_\^(_?+_,YW^W=:_Z%J;_P('^%']NZU_T+4W_@
M0/\`"NBHH]G/^;\@^MX?_GQ'[Y?YG._V[K7_`$+4W_@0/\*/[>UK_H6IO_`@
M?X5T5'>A4YW^-_@'UO#_`//A??+_`#,KP3XEUZQT!(++PK/>Q"65A*MP%!)D
M8D8VGH<C\*W/^$Q\3_\`0D7'_@6/_B:T/AA_R*,7_7Q<?^CGKJ,UM7IS562<
MWOY?Y&?UJA_SXC]\O\SR+Q1XAUNZ\2>';BY\,36L]M-(T$)N`3<$A<@';QC`
M_.NF_P"$Q\3_`/0D7'_@6/\`XFE\=_\`(Z^#?^OB;_T%*[>M:U.:I4O?>S[?
MS/R$L50_Y\1^^7_R1PW_``F/B?\`Z$BX_P#`L?\`Q-'_``F/B?\`Z$BX_P#`
ML?\`Q-=S17)R2_F?X#^M4/\`GQ'[Y?\`R1PW_"8^)_\`H2+C_P`"Q_\`$T?\
M)CXG_P"A(N/_``+'_P`37<T4<DOYG^`?6J'_`#XC]\O_`)(\@\2^(-;NO$.G
MSW/AF:VEC@E5(3."7!*Y;.WM@?G3/[=UK_H6IO\`P('^%=1XX_Y&_2/^O6X_
M]"2H:VJTY\L/?>W9=V5'%X?_`)\1^^7^9SO]NZU_T+4W_@0/\*/[=UK_`*%J
M;_P('^%=%16/LY_S?D5];P__`#XC]\O\SG?[=UK_`*%J;_P('^%']NZU_P!"
MU-_X$#_"NBHH]G/^;\@^MX?_`)\1^^7^9SO]NZU_T+4W_@0/\*/[=UK_`*%J
M;_P('^%=%1WH]G/^?\@^MX?_`)\1^^7^9SO]NZU_T+4W_@0/\*/[=UK_`*%J
M;_P('^%=%U&:*/9S_G_(/K>'_P"?$?OE_F<[_;NM?]"U-_X$#_"C^W=:_P"A
M:F_\"!_A7144>SG_`#?D'UO#_P#/B/WR_P`SG?[=UK_H6IO_``('^%']NZU_
MT+4W_@0/\*WKB:*WB:6=U1%ZDU4;5[=`'FCN(8C_`,M9(651]3_"/KBCV<_Y
MOR#ZWA_^?$?OE_F9G]NZU_T+4W_@0/\`"C^W=:_Z%J;_`,"!_A70@@@$'(/0
MBEH]G/\`F_(/K>'_`.?$?OE_F<[_`&[K7_0M3?\`@0/\*/[=UK_H6IO_``('
M^%=%11[.?\WY!]<P_P#SXC]\O\SG?[=UK_H6IO\`P('^%4]4UG5I$MA+H$L6
MVZA=29@=S!P0O3N>*ZZL_7/]79?]?]M_Z-6M\-2FZT5SO?R)EB\/;^!'[Y?Y
MFO\`\)CXG_Z$BX_\"Q_\31_PF/B?_H2+C_P+'_Q-=Q1D5AR2_F?X?Y$_6J'_
M`#XC]\O_`)(\[^']Y=7_`(^\275]8M87$D5OOMV?<4PN!S@9R`#^->B5Q/AK
M_DJ7BO\`ZYVW_HL5VU=V(3C)*3O[L?R1Q3G&<G*$>5=E_P`$CN_^/6;_`'&_
ME7)?!S_D0;'_`'Y?_1C5UMW_`,>LW^XW\JY'X._\B#8_[\O_`*,:M(?[K/\`
MQ1_*1F]SLZ*Q9O$ME#XF3076474D7G*^T>7CGC.<YX/:H]%\5Z?K%E>WEL)H
MX+)V61I5`S@9R,$\8K'V%2W-RNVGX[#NC>HKG++QC87?AZZUE(KI8+7/F1.@
M$HX!Z9QR",<U)I7BJ#4+Z*SDL-0L99D,D7VJ(*)`.N"&--X>JDVX[;A=%7XG
M_P#(HS_]=[?_`-')616O\3O^10G_`.N]O_Z.2LBF_P"#'U?Y(.H4445SC&RL
M%B=F8J`I)8=1[UP,NJZM+X?U"?1VNIHVD/EL9%::%`.6(8C&X]`.@[=J]`HI
M#&0,7@C9U96902#U!Q[5G^)KN.RT6XN)I+A$0#_CW.)&.>%![9Z9K3HJGJ2M
M#C=*O+_^TM,%U<&ZWQ*OEQ3/P3NRY_A<`8!.379444#.<\77S6]UI]O;W,T-
MS/(-IW[8E4$;F?UXX"]\].*;X:N[Z75[R.^$I8!B1ORD>'(48(X)&",'&/>N
MEHH3L#=T5M4W_P!G7/E9W^6V,=>E<S!?0S:_]DLKJ<6D%KF5?-*@C8-JQ`8.
M1U+#GMGTZ^L]M(1&/V.ZN;-68LR0LNTD]>&!QGVQ2`RO#*3)=6SO++))/:--
M<+*Y=H]S*8D)//`\P?Y%=(Y`4DG``ZU%:6D-HK"%3ESN=F)+,?4D]:FH8'GL
MVJ7MQ97,UA>W(M6N0B&60[P`C99B.4#,%``QT'K7=::\DFGVSSAQ*T2EP^,Y
MQSG%6**`"L?4I+Y/$6F".<BSD+J\2J>2%)RQ_+%;%`ZTX[H#6^&/_(HQ?]?%
MQ_Z->KEKJMY)XKNM.DC0VL<0D1U`R/N]3NSDDMP5'3J>U/X8#_BDHO\`KXN/
M_1SUU.`:UQ'\:7JQ+8XGQU_R.G@W_KXF_P#04KMZXCQW_P`CIX-_Z^)O_04K
MMC6U?^%2]'_Z4Q+=BT5S=YXSTZTU&6TEBNV2"189KE(@88G;HK'.>X[47GB^
M.#5;K3[?2=4OI+4J)'MH591N4,.2P[&LEAJK^STN.YTE%<WJ'C&&ROI+3^R]
M3N)(HDFE\B%6$:MG&[Y@>Q[5N:?>0W]G#=VS;X9D#H<8R#42I3@E*2T871QO
MCC_D;](_Z]+C^:5#4WC?_D;](_Z]+C^:5#6E7X(>GZL%NPHHHKG&97BJ\CL=
M%FFE>X4`@*+=MK,V>!GL/4]A6)I-Y?C6-/6ZN#>>9"B[8I7PORL3(1]UAT&>
M><=ZZ*[O;A-0BL[:".1GB:4M)(5``*C'`/\`>I?,U+_GVM?^_P"W_P`333L!
M=KG/%-\\&IZ;:VUS-%<3.#]_;$J!ADM_>)^Z`?7/:MG3+LWMJ9601LLDD3*&
MW<H[(>?JM6J0'-^%+N^N+V[34/.,@&Y@7W(AWL-N".#C!P#C&/7)Z2BBD!RD
MM_YGB6_A2YNOL]M;N;A#*R[FPI"Q`8(P`<D<\XK:\.PS0Z/;_:999)9%\QO-
M<L5W<[<GGCI^%:-%-`9VI%/MUH)V*QJ)'7_?`X_(9KBIM4OKBQ>6SN[@VKS.
M(UED)?`3C?CD%FY"=.Q]*[^\M(KR'RYE.`=RLIPRMV(/8U6?3IIHS%<:A/)$
M>"H"HS#T+``_EBCJ`SPRS-HT.[=M#.J;ASL#D+^F*;XIO(K#1IIYGG`!`5;=
MMKN2>%SV![GC%:<<:11K'&H5%&%4=`/2G4/4$<9IUUJ_]JZ;')=BZ\Q(_,\M
MFVJFUMQQC#<X^;.:[.BBF(YKQ45%_9-:-,;]9HR(E+C?'N^;!^[[GJ<#M6/H
M[7AN(/M)D)\^S^T;\\7'V@[AS[8Z<8Q7>UE:Q/#+]E2*5'>._M@ZJP)0^:O7
MTKIPC_?1]0GJCT/Q'=RV.C7%Q;RQ13(N4:5"R9[!L$8!Z9[5F^&-8OM2O[J.
M\$*I&J,B(C!DR!D.2>OH,=.]=)28%<@SB?#/_)4O%?\`USMO_18KMJXGPT,?
M%+Q7_P!<[;_T6*[:NS%_''_#'_TE$Q([O_CUF_W&_E7(_!W_`)$&Q_WY?_1C
M5UUW_P`>LW^XW\JY'X.\>`+'_?E_]&-3A_NL_P#%'\I!U*/C/0]6NM;O-0TJ
MW8S100?9WX^9LNKC_OEZA'AW5+;0]5TBSMWC%[<PPK+@8$7EJ&?KTX/YUUMM
MXABGMKJ<6\JI;OMY'+C.-P]JJ3>,[*.&24Q,%C?:6DD5%`+85BQ.`".0?2MX
MU\0XJ"CM;\+6_KS$TF[G-7WA[7[./6K0D:C'J=F"'@A$065,`#;N/5>_M6IH
MF@7>C>)K:607>H6LMOM2:>9I&M'Q\R\G[I^E:3>,+-9Q$1#GR?.&+J,EAM)^
M09^;IU%3OXF@^S0W,4#26\S[4EWJJMTYR3CDG`]:4J^(E'E<='_E_D@Y8E+X
MG?\`(H3_`/7>W_\`1R5DUK?$TAO!TQ'>:W/_`)&2LFN5_P`"/J_R174IZR<:
M5<D6LEX?+.((S@R'^[^-4_"-O+;:)&EPC1R%F<QE-@CR<[5']T=!5W6+W^SM
M-GO/*,ODKNV@X_$GL!U)]*BT'58]8L/M4?E\.T9,;[U)4XRK=Q[USH;-"L7Q
M?:?;-):$6LMQ(V?+,?.Q\'#$9'?OSC.?>MECM4G!.!G`KFI/%CK:22KIY25;
MB2$12OM.U$+DG`."0.GTHL!T5L'%O%YPQ)L&X`Y`..>>]24RWF6X@CF3[LBA
MQ]",U!JEVUCI\URD$EP8UR(XQDL?Z?6A@8^J6>K2>+=,ND1&L(68$"8@KE&!
M9EVX/)&.?YUT58MIK[7-]IMM]B=1?6YG\TGY5(`.T>IY]L<5M46LK!U"N=\.
MV=S::Q?.]M^[F9G>:2)4<MOX`()W+CU/%:&L:J=.GLHA:O,+J81%P<+'GN3_
M`$^M-L-6DN-8N]/FA17MT$A9)-^`20`W`VDXSCGBA;W!K2QJ53UJ&XGTF[BL
MFV7#Q,(SG'./6IKR?[-:2SXW>6A;'K7/(SSZM+8W=K/<W/V8S^:TICC9L@;$
M`/`&[&?;O2>N@="_X3MIK;3GBFM_LZB4^6NW82O'.WH._2MBN?\`#6I2S3-:
MS@C=YA1&<NR&-@K@D@''SJ1D`\FN@)QSSQZ4V!D^*;+^T-)-O]DCN6DD1!O0
M-Y8+`,XSZ*2:TX(4MX8X8EVI&H51Z`"N?E\5"/3-0NGL9$EM9S!'`Q^>4A`V
M?;@D_05OVTGG6\<N-N]0V/3(H\P)*Y?5["]F\86=W%`[0QB,!P>``7WY/5>"
MO`^]WZ5OZE=-8V4MREO)<-&I(CC'+&LBU\2&XO-.@$$<8N[:.=V=GPA?.U`0
MN,\'J13CN@V1VOPR'_%)18_Y^+C_`-'/1,-=75(`7NVB^TM@HB["F\??]!MS
MC'>E^&)`\)1G_IXN/_1SUKIKMF\L4:B;=-.]LN8F'SJ"3G/3A3UZUMB/XTO5
MB6QS?CO_`)'7P;_U\3?^@I7;."1Q7$^._P#D=/!O_7Q-_P"@I74:UJ:Z5:"=
MH9)BSA%2,9))K:LG*E12[/\`]*8ENSA]>TK5SK=W+I^F74%[+,K175K,!;RJ
M,<S*3UQGM3-0TR_B\4ZI<SV&O2QSF$I)IMP(D;$:@Y&X9YKL=0\0V]@8O-C=
MA*BNI4C&TGD_0#DU3D\8VB7"Q&-59H1,%>=%=@<_=4G)Z=O6MXXBMRVY-+6_
M+S\@LKF<_AE]8\3WMU>_VA:6LEI`J^7.8_,/S;E;:><9'YUU]E:Q65K%;6Z"
M.&%0B*.@`Z5A6GC"RN?)"*CO<;A$L4Z2;F&WY<@\'YLX]C6C8:NMYJ%Q:"%H
MV@ZY=<]<9*YR`>Q/6N2LZLDN9:+_`(8%8YCQQ_R-^D?]>EQ_-*KS<PN-I;@_
M*IP3[`U8\;_\C?I'_7I<?S2H:FK\$/3]6-;LXM]&NY-*N$M8;FWB%Y'+#`&V
MDKE<J5!Z#![\]37:5G:]?W.GVBRVD$5PY<($DE*9).`!A3W^E:";MH+``D9(
M!SBL.@WN9LG_`",\'_7G)_Z''4,]C/\`\);:WRO,\'V>1&&[Y$.5QQZGGFM"
MYL(+F=)Y`XE12BLC%3@X)''T%8<EW$GB9-(,<Y5@/WWVA^#M+>F.B],Y[XQS
M0!I>'/\`D'R_]?EW_P"E$E:9_2HK2VBM(!#`NU-S-C.<EB6)_$DG\:EY[4/8
M.ISGA6";^TM1N9+*6P21@L<#+]X`G]XS?Q,<_@`!71UB>'O$*:Q<W%OY:QR0
M@-M5]Q4%F&&X^5OER1Z$5MTV!7U%5>QF62%YT*D&-#@N/3J*I>%K:6TTKRIH
MVB`D<QJPP0A8E>.B\=NU07OB/['?WMO)9R!+6W$PD8[1(2VW`]LGK]:OZ/?G
M4+9G>,1R1R-%(JMN`93@X.!Q^%+S#R+M<_XXL]5OM(,.EJCKG=(OF%'?!&`"
M%/&>HXK2U6:1#!;0-LDN&(+@9(4#+$#U]/K7-OJ$/]F2W8TZ^2:*[^S[OM#!
MTY4;W.<#[W3FCJ!V$6X1)O`5MHR`<@'ZTZJ>E7$DT4L5P0TUM(878#&[`!!^
MI5E)]Z-8OFTW39KM+>2X,2EA''U/^`]Z&!DW]E=-XNM[R.W\Y0J1[I(5*1)\
MVYE?.0W(XQ^==%6*VN2)=Z9&UM'LU!05(ERX)7<?EQ]T<9.>XK:H:Z`F!Z'L
M3WKA=+T[4+&X@6\C.U;JV1I710SR?:,_*1R5P0>>YKI-5U2YL]7TRTCME:"[
ME,;S,W(.QFP!_P`!ZUF7&HWDNJ+I^H+`KPW=I+'Y0(RK3>Y.<8Z\?2NG!Z5X
MDS?NGK'B+[1_8]P+(SK.5^1H%#,I['!ZCU%9?A4ZZ;V[_ML/M(4I\H"I[`Y^
M;/4GC!XK;U6_BTO3IKV=6:*!2[[<9"CJ>2!@=>M0:=K$=_<RP1VUQ'Y:+)OD
M4!65NA&#[=\5S%/8YGPSQ\4O%?\`USMO_18KMJXGPU_R5+Q7_P!<[;_T6*[:
MNO%_''_#'_TE$Q([O_CUF_W&_E7(?!X9\`6/^_+_`.C&KK[O_CUF_P!QOY5R
M/P>_Y$&Q_P!^7_T8U$?]UG_BC^4@ZFW_`&=910W=O+=NWG1X;>Z!HTYZ<#@9
MZG-5#X8TR6%EBFD`F6+!!1^(Q\I`92#UYX-)J^CW-_?7+-:6WDO'M1EF9'D)
MQG=A<CI@8/%,O-%OV73/L\JH]JKJQ$[+M#,I'('SX"XYZT1;LDIVN%M1Z^'+
M":<L+R1F:/RF"I!R,$=DRO!/W<5;D\.6K6PMHIYX8%;(C0KM'3@`J<=,\<@]
M,5C6WAK5H9)W%W&CRHJETD8-GYLG./\`:%2V=MJ]OXBMX9'NI;9,L9#,[)LP
MV%.>&.<<DY_#FK:>O+4O8'Z#OB6H3P;*BYPLUN!G_KLE95:WQ-_Y$^;_`*[V
M_P#Z.2LDUC+^#'U?Y(?4BO+<75K)`[.JR*5)0C(^E1:7I\&F6@M[;.W)8D@`
MLQ.2>`!^0`K"UG3]3.I:E)92SOYUCMCR<(C;ONKCH<=^M:/A:.6+2]DL!@`D
M?RU(8$IG@[2<K]*YUU&:U9%UX<L[E)4:2=&EG><LK+D%EVL!D$8(R/Q^E:Q!
M((!P?7TKD&T>YDTR\LKF&:[:74<+--RP0[=SCTXSC'2@#KHHUBC6-!A4`"CV
M'2DGB6:%XF)"R*5./<8I8T6.-4C&%4``>@JKK-O)=:7<0PRRQ.R$!HL;OH#V
MSTS[T,:Z#(-(MX7L'1Y";"-HHLD<J0!\W')X%7ZXJQL=377=)FD@N`L4$2N6
MS@#8X?+=L$K\O?@]J[6FQ%:_L8KY81,S#R95F7:<?,.F?:JND:-'I=S=SQW=
MQ.UW(9'\[8>?8A0<`<`$D8J'Q':7-Q/ILMM).%AND+QQ_=9<\EN^!^7-5/#-
MI?6^K7C2^9]G((+2H5:1]Y(/4Y^4XR.,8';@0V;]U"MS;20L<"12I/I6(Y5+
ME9M2AOXKL0-;"2UB>5&4D'<"BDJ>!UQWZUT%<?J\-]=:_>?8+6YMC';NHFVO
MBX<J,`-]T*!],M^JZAT-70]+-O=R7<@E!(8(9BID8L5+LVW`&=B8`'&/>MNL
MGPO#-#82B5'BB,S-!&X(*Q\8&#R.<\5JOPK'!.!T'4T,2,F[\-Z=>Q7D=RC2
M"ZE,Q)(RC%`F5XXX'OWK3MH$M;:*WB!$<2A%SZ`<5Q:6-]=Z-J[V\5[8-(P,
M5H%968#.,LW4L>3@]@,UVT0(C0-UVC--;`$T2S0O&V=KJ5.*RU\/6R_8QYTY
MCM$C58R5VOY?W">,Y&>Q`J3Q*Y31IV%E+?M@!8(\Y<]@<<X]?85SEE;7*W^B
MP&"[W0H'FO&AD`ZG]TH/W1SR3C@#K3AN)['I?PQ&?"41/7[1<?\`HYZVO[&M
M_-CDWR[H[EKL<C[[*RD=.F&-8GPQ)_X1*/'_`#\7'_HYJ66YUE-3M87EO`K7
M;@M':AHC$",!R`2..AR/4GM6F(TK2]6"V*7CO_D=/!O_`%\3?^@I76:E:+=6
MX1II(-AW!TVY'_?0(_2N3\=?\CIX-_Z^)O\`T%*Z_48WEL9XXHHIG9"%CE.$
M8XZ$X/'X5O6TIT?1_P#I3$MV9EUHNFZA'`&=C&D#V\?ER#E6&#SW(`XJO-X:
MT]I%D%S(BB(6_P#RR.0H(^\RD@\G."*BL-`O([^PO)98H1`7+VZ_,H+;LE3@
M=<CC'&*K2>'=5?SHUN(Q"\[R;3,[!@S.1\N,+]X<#TS23Z*8/N:%KX8L%$3+
M<22F)6$;A8E*$[>1L0<_*.3[UH6FD16VH27OGSRR."H#E<*"<]0`3^)..V*Y
M\:%K5O;_`.CWS1O#`BQK'*V-P7#?+P&Z<9_2M;PB+S^SY&ODGC+2$HDTC.RK
M@=VYZYZU-1/E;4[@M+&!XW&/%^D?]>EQ_P"A)4-3>./^1OTC_KTN/YI4#@LC
M!6*D@@,.WO45?@AZ?JQK<KWMC%>_9_-+@02K,H4XRPSC/MS5G.:X?4--UT>'
MKFULO-E/VR5V:24K+(FX;<?*<@]>W`KMTSL7<`K8Y`.<'ZU@,7^=9LFAVKZP
MNI%YO-4A_+W#87"E0W3.=I(ZX]J?X@MIKO1KJ&WEEBD:-L&$@,>.@/;/2L*Q
MM;Z+7K"9[=Y/]'CC<R0\1*$.XA\]=Q`(QGGVH6X'64'\J*Q?$%G=3W^E36TD
M^R&Y!>-#\N,'YF]<?UH`M:;I%MI]S<7$32/-.?F:3&0,DXX`[L>3D^]:%<WX
M4MM0M[V[^W0G+#+S'<-[;FXP3@_+CYACT[5TE#!&?>:-:WMS+-.7+2P>05!X
M"[MV>G7-3Z=8QZ?;>5$SOEB[.^-S,3DDX`'Z5CW5E.NO:A/*DUY;26/RQ.,I
MN#?<4?A]>:T/#MC_`&=H]O"5V2%=\@]';DC'89.,4=`>Y+J4$KB*XME#3V[;
MU1N-X(PPSVR/Y5D21V<MM=V:VNIF6YF%R\?D,N'RIP)"-F/E'<]ZZ)@2I`."
M1UKA=0TK519R0K]JG(O9G$C`LS90!#@=!G.#T6CJ#V.PTRVDMX7:X"B>>0RR
M[>@)P`!]``/PJ:ZMTNK:6WDR$E1HVV]<$8IUN&$$?F##[1N&<X./6J?B"WFN
M]&NH;:66*1HVVF(X9CC[H/O[4GUN->17B\/PQ:K;WZ7=T6MX1`D3;"@4#'=<
M@GN01FM>N2AL=176].D02X6.+S3(APBA"&4-G')QD$9S76FJ9**.H6EM=7=D
MT\Q26VE,T2AP-QVE?J>&/2LJ[TVVMKF"Z2ZENKAKVUB+2N&**)@0G`'J>N3[
MU#XGAGO-=L;:&SDCC#++-?)`7/RME8U(!QSR2>U9NDV%Y9SVYN8I(PLUG%*S
M#'FRBX)9AZ\$<^]=&#5ZT?44]$>XZG9+J%E):O+)$L@P6CVDX^C`@_0@TS3M
M,@L%<0F1M^WEVR0%4*`/;C/U)J/Q$]RFCW!LGN(Y]OR/!&)&4]CM(.1Z\$UE
M>%Y]=DU"[_MCS1%M4HC1!5C..0&`&[/7J<=.*YBF9WAK_DJ7BO\`ZYVW_HL5
MVU<3X9_Y*EXK_P"N=M_Z+%=M77B_CC_AC_Z2B8D=W_QZS?[C?RKDO@Y_R(-C
M_OR_^C&KK;O_`(]9O]QOY5R7P<_Y$&Q_WY?_`$8U.'^ZS_Q1_*0/<[(UQFH7
MGB2*2]>VMIGDSMA78-@P7QZYR-O/OVKLZ3%<\)J&ZN-JYR$&J:]-??N(TDM8
MKD0,(U&7'4MGD#`(&..AYKKUHVB@#%%2:GLK`E8Y?XG_`/(H3_\`7>W_`/1R
M5D&M?XG_`/(HS_\`7>W_`/1R5D5;_@1]7^2!;F1<:Q/%J[:>MD))6B:6$+,-
MS;<<L,?*"3@')Z=*M:-J']IV"W!B\IMS(4#;@"I(X.!QQW`K"FTD7.JZA<Z5
M<2Q,V/.)E.)V'`0=U`]1W(]#6UH(M!IX-ENVL[&3><MYF?FW'US6"&7V)"D@
M9('2N;NO%JVEE?2W-GF>T<1^3%+O#L5W8W8&"!UZX]372.NY&4DC(QD'!%8L
M?A/2%TQM.EM_M%N22HG.\H3U*D\@GUH`VD;<@;U`-0WTTEO:22PQ+*RC.UY-
MB@=R6YP`.?PJ6*-(HUCC4(B`*J@8`%5M6TZWU:PDLKO?Y,N-P1BI.#G&10Q+
MS,G3/%*:A>VD$<$<:W$0D+/*PQG<`%^3#9VD\D?2NAK.71;436\CM/*;?&Q7
MD)7(S@XZ9&:T:8S,UW57TI(9?LXEA>18V;S-K`D@`*N#N)STXZ'FH]%UV/5;
MNXBBB54B)VMYF6;!*G*X'<=L_ATJ?4M&M=1O;6[G:99K0L8BDA4`GJ<?A3K3
M2;2SO)+J!"LC@KR<A03D@#MD\T('L3:C<&TLI9E7>RCY5]23@?J:P)RZ:LMA
M=+)/<SQLZ2"_>,94`D[5'R+DXSR?:NAO;<7=K)`6*[Q@,.H/8_G6!'9&#4I[
MR>QOWN[E!'*\$@:)P!@8R00.^*0%CPIJ-W>12I?(!CYX9!)YF^,DC.[:O]T\
MXZ$5N]NGX5FZ+8-:KO=/*_=)!'$&W>7&F=HSW/))K1(RI'3(QQ0P.9O/%SV8
MN$>P!FMY5C*I/N7YE+8)"YW8'(`/4<XR1T5I,+BVBF"[1(@;'ID9K)A\*Z=#
M9_94-P8Q(95)E)*L<[B#UYW'-:]O#';P1PPJ$CC4*JCL!T%-`,OI98+9Y8(E
MD=1G#R;%QZEL'`'7H:P+/QC%<75E";81"["89I.26+`;!CYE^7D\=5XK:U?3
M;?5K"2RN]_DRXWA'*D^V14::-;+-;R.\TIMP`@>0E>,X..F1D\TX[B9TWPPP
M/"4?_7Q<?^CGK5/B"P$L$>Z7]_<-:H?+('F#J#GZ'\JROA@/^*1B_P"OBX_]
M'/6O+H5I),LA,HQ,9RH<[6;(/([X(!K3$?QI>K!;'-^._P#D=?!O_7Q-_P"@
MI7;FN(\=?\CIX-_Z^)O_`$%*[>ML1_"I>C_]*8ENS-U^6\BL2VGJQDW`'8NY
M@.Y`[FN;?5=?L4D=X&\N&%,>>`#))E05!]2">YYKM2,TFP&L:=505G%,;5S%
M\.S:N\]S%JZ`A"OERJNU6]1C';UR:W*3'O2UG*7,[VL"5CAO''_(X:1_UZ7'
M_H257<L$8JI8@$@`XS5CQQ_R.&D?]>EQ_P"A)5*_>*.SF:X<I&$.Y@<''M[U
MM6^"'I^K!&%)XK\JVE>2P9Y8KE;9Q#)O12<9)?`Z9P>.O'-='QVKE=-TZ&QL
M([*YW?V9<2+Y2%\F!@055CWSC)]^*ZJL+C>Y6U*YDM+.2>*))&0;L22>6H'<
MEL'`'T-9=EXB:YN--0V?EQZBFZ,^;EQA2Q.W'W>,;L]2.*T-8TRWU>Q:SO/,
M\EF#$(Y4G'/;M4%MH-K;ZF-022X:X\L1$M*2"H'`(_7ZT+0#4K,UK5GTN2V)
MMUDBFD6(MYNULLP`"K@[CW[<#K6G6??:/;7NHVU]*TPGM01'LD(`SUXZ<T@&
MZ=J<MU?WEG<6OV>2VVL/WF[<K9P>@YX[9'(YZUI53LM,M[.XEGC\QY9`%+R.
M7(4$G:">V2:N4`9%SKJVFKM9W<*QQ^2TRR+)N;:N.2N.`2<#GDCI5C0=3_MC
M34O/(-OO9U\MFR1M8KS^51+H%A]ON[N1&F:\P)HY6WH^.@VGC`Q5K2]-M-*M
M?LUA"L,.YGVJ,#).3_.A;:@,U2>5!#;VS;9KABH;NH`R2/?'2N5EU6.(M#LF
M2\CN/):4ZA(R(=FXDD*1QP"-N`3UKJ]4M9+B%7@8":(EDR<!LC!7/;([]JP;
M;28K>Q_L^#3]3"Y)VM<`(2>H+`Y(.?0T=0-W2+M[JW=9RK302&*0H<@G`((^
MJLI_&I-1N);6T>:&-)&09/F2>6H'<EL'``]C3-)LS8V8C?:9&)=R@P,^@]@`
M`/I1K&F6VL6+6=YO,+D$A'*YP<BA@C)T_P`517UY:P16X43HC,7DVE2P)``Q
MSPOJ.O0]NB-9O]AV;74%S()))8=N"SGYMN=I;U(R<?6M*F!BZ_J\^EW-FJB!
MTN95A6(Y,LA)YVCH`!R3S^'6J,E[?75V8[EK=X+;4;6-9(XRA+^8I8<L<XR/
MSK6N=$M;G5XM4=IUNHD\M"LA`"YR1CWJ"_LH;*&V%N"/-U.&9LG.6:8$UT83
M^-'U%+8]/U.^ATRPEO+D/Y,*EG*#)`'4U!IFM6>IS/':LY*#=ED*AAT)&>N#
MQ5F_M$OK5H'DDC#?Q1N58?B*IZ9X?T_2[J:YLXMDLRJC'V48`_05S#.<\-?\
ME2\5_P#7.V_]%BNVKB?#7_)4O%?_`%SMO_18KMJZ\7\<?\,?_243$CN_^/6;
M_<;^5<E\'/\`D0;'_?E_]&-767?_`!ZR_P"XW\JY+X.G'@&QS_?E_P#1C40?
M^RS_`,4?RD'4[.BDR*,BN0H6BDR*,B@#E_B?_P`BC/\`]=[?_P!')7)ZSJ"I
M,E@LZ022C=)(6QY<?J/<]!^-=9\3C_Q2,_\`UWM__1R5CD`]0#]:WE_!CZO\
MD"W.&U.W@DNYQI:P6R_9GA+^:FV;.W&,'=DXP=W`SQU-6M'GAT>W>Z6:*..2
M5VEM5=3LC)^4@*<94>G;Z"NNV+_='Y4;%_NC\JP6@^5BHP=0RG((R#ZTM%%`
M684444!9A1110%F%%%%`684444!9A1110%F%%%%`68444"FMPLS7^&'_`"*4
M7_7Q<?\`HYZZFN5^&!`\)1?]?%Q_Z.>NIR*UQ'\67JQ+8XGQW_R.O@W_`*^)
MO_04KMZX?QT1_P`)KX._Z^9O_04KM\UK7_A4O1_^E,E;L6BDR*,BN0H6BDR*
M,B@#AO''_(X:1_UZ7'\TKFYKZTU*261YHI+2WW".+S54SR`$9Y/0'('OSV!K
MI/''/B_2/^O6X_\`0DJ@=.L2239VY)_Z9+_A6]7X8>GZL$>>7.GSWFD#=#%;
MRR3O(;99H`D64VH!\Q!'JWWNXKM=&OU$@TV>YBEG1-T;+(&,B#C\QW_`U=_L
MVP_Y\K;_`+]+_A3X;.UA??#;0QMTW(@!K`=F3T444!9A1110%F%%%%`68444
M4!9A1110%F%%%%`684444!9A6=KG^KLO^OZV_P#1JUHUG:Y_J[+_`*_[;_T:
MM=.%?[Z(I)V/4:*3-&17*!Q/AK_DJ?BO_KG;?^BQ7;5Q/AO_`)*EXK/_`$SM
MO_18KMJ[<9\<?\,?_243$BNP?LDW^X?Y5X[X&\':WK'AJWO;#Q1=:?`[.%MX
MR^U<.0>C@<GGIWKV.[_X]9O]QOY5R7P<_P"1!L?]^7_T8U8^QA4P\I2Z-?BG
M_D=>'QE7#-JG;7ND_P`S&_X5WXF_Z'>^_.3_`..4?\*[\3?]#O??G)_\<KTN
MBN+ZO#S^]G7_`&MB>Z_\!C_D>:?\*[\3?]#O??G)_P#'*/\`A7?B;_H=[[\Y
M/_CE>ET4?5X?TV']K8GNO_`8_P"1XYXM\%:[IFB275[XKN[V%9(E,+E\$M(H
M!Y<]"<_A57_A%=9_Z&>[_-__`(NO1/B?_P`BC/\`]=[?_P!')616TL-3=*+U
MW?5^14<XQ2TT_P#`5_D<E_PBNL?]#-=_F_\`\71_PBNL?]#-=_F__P`776T5
MS_5J?G][*_MG%>7_`("O\CDO^$5UC_H9KO\`-_\`XNC_`(176/\`H9KO\W_^
M+KK2<#)Z57CO[*2%IH[RW>)&V-(LBE5;.,$YX-'U:GY_>P_MG%>7_@*_R.:_
MX176/^AFN_S?_P"+H_X176/^AFN_S?\`^+KK:*/JU/S^]A_;.*\O_`5_D<E_
MPBNL?]#-=_F__P`71_PBNL?]#-=_F_\`\775-+$DJ1-(BR/DJA89;'7`I]'U
M:GY_>P_MG%>7_@*_R.2_X176/^AFN_S?_P"+H_X176/^AFN_S?\`^+KK:A@O
M+:XEDCM[B*62(XD5'#%#Z'!XH^K4_/[V']LXKR_\!7^1S'_"*ZQ_T,UW^;__
M`!='_"*ZQ_T,UW^;_P#Q==;2.ZQJ7=@JJ,EB<`#UH^K4_/[V']LXKR_\!7^1
MR?\`PBNL?]#-=_F__P`71_PBNL?]#-=_F_\`\7746UQ!=PK-:S1S1-T>-@RG
MZ$5+1]6I^?WL/[9Q7E_X"O\`(Y+_`(176/\`H9KO\W_^+H_X176/^AFN_P`W
M_P#BZZN62.&-I)G6-%&69C@`>I-*K!E#*00>01WH^K4_/[V']LXKR_\``5_D
M<G_PBNL?]#/=_F__`,71_P`(IK/_`$,]W^;_`/Q==;4$M[:07$5O-=0QSRY\
MN)G`9_H,Y-4L-3OU^]A_;6*\O_`5_D8?A+P5KNIZ*MU9^*[NRB:651$A?`(=
M@3PX')!/XUL?\*[\3?\`0[WWYR?_`!RNA^&!_P"*2BQ_S\7'_HYZZG-:U\-3
M522UW[LS6;XIZW7_`(#'_(\5\1>$-;L-?T*TN?$UU=37LLBPSL7S;D!<D9<]
M<]L=*Z#_`(5WXF_Z'>^_[ZD_^.5J>._^1T\&_P#7Q-_Z"E=O6M;"TU3IM7U3
MZONQ?VOBNZ_\!C_D>:?\*[\3?]#O??G)_P#'*/\`A7?B;_H=[[\Y/_CE>ET5
MR_5X?TV/^UL3W7_@,?\`(\T_X5WXF_Z'>^_.3_XY1_PKOQ-_T.]]^<G_`,<K
MTNBCZO#S^]A_:V)[K_P&/^1XIK_A'6K'7+&UN?$]W<2S0R.DQ+YC"E<J,OWR
M/RIO_"*ZS_T,]W^;_P#Q==GXX_Y&_2/^O2X_FE0UM5PM/E@]=N[[LN.<XI::
M?^`K_(Y+_A%=8_Z&:[_-_P#XNC_A%=8_Z&:[_-__`(NNMHKG^K4_/[V/^V<5
MY?\`@*_R.2_X176/^AFN_P`W_P#BZ/\`A%=8_P"AFN_S?_XNNHN;B&UA::YF
MCAB7J\C!5'XFFQWMI+,L,5U`\K)O5%D!9E]0/3WH^K4_/[V']LXKR_\``5_D
M<S_PBNL?]#-=_F__`,71_P`(KK'_`$,UW^;_`/Q==;4,UW;02Q137$44LQQ&
MCN%+GT`/6CZM3\_O8?VSBO+_`,!7^1S'_"*ZQ_T,UW^;_P#Q='_"*ZQ_T,UW
M^;__`!==/!=6]PTBV\\4K1-MD"."5/H0.AJ:CZM3\_O8?VSBO+_P%?Y')?\`
M"*ZQ_P!#-=_F_P#\71_PBNL?]#-=_F__`,776_4XID4L<T8DAD21&Z,C`@_B
M*/JU/S^]A_;6*\O_``%?Y'*_\(KK'_0S7?YO_P#%T?\`"*ZQ_P!#-=_F_P#\
M776U#=W=M9JK75Q%`K':ID<*"?09[T?5J?G][#^V<5Y?^`K_`".8_P"$5UC_
M`*&:[_-__BZ/^$5UC_H9KO\`-_\`XNNM^E%'U:GY_>P_MG%>7_@*_P`CDO\`
MA%=8_P"AFN_S?_XNC_A%=8_Z&:[_`#?_`.+KIVN[9;I+5KB(7#KN6(N-Y'J!
MUQ4U'U:GY_>P_MG%>7_@*_R.2_X176/^AFN_S?\`^+JIJ7AK585MS+XAN9@]
MS%&NXO\`*S.`&^]V)S^%=Q6-J][;33P6L,RO-;WUIYJ#JFZ0$9_*NC#86G*K
M%._WL4LZQ5GM_P"`K_(O?\*[\3?]#O??]]2?_'*/^%=^)O\`H=[[\Y/_`(Y7
MI9I`>:Q^KP_ILC^UL3W7_@,?\CS?X;:=<Z5XX\165]?27\\,4&^XDSN?*Y&<
MDG@$#KVKTBN)\-?\E2\5_P#7.V_]%BNVKOKTXTY1C'M'\4F>?5KSKS=2>_W$
M=W_QZS?[C?RKDO@Y_P`B#8_[\O\`Z,:NMN_^/6;_`'&_E7)?!W_D0+'_`'Y?
M_1C5<?\`=9_XH_E(Q>YV5)GFN<\<ZI<:=I]O#8W26EY>SK#%*X4B,=68AN.@
M_6N>O_%5[)X5T:YCU%[6XDNA:WDT,"S-E58,0FT@Y*@\"E3PE2I%26S=AMI.
MQZ)2YKS6Y\1:U!X9GN/[0N`@OHH8;Y[,)(\;8W'RRO..>W-;'@?5KW4=0NT_
MM&75=/C0;;F:U$#++DY3:`,\8/3O53P52$'-[+U\O+S%S(L_$_\`Y%"?_KO;
M_P#HY*R*U_B=_P`BA/\`]=[?_P!')616;_@Q]7^2&MPHJ&^NXK&TENKAML42
MEF(&33--O5U"T6X2.2,,2-LF,C!QU!(/U!-<XRPX)1@`"<=#T-<I<^&[B]LK
MU98(8WFFCEAB$A*HR@`G..F.@QQ7652U?4?[+LVNGM9[A%^\(2F0/7YF&>>.
M,F@"Z!@"BFQMOC5BK(6`)5NH]C3J`,FZTHR>)++5(U7,4<D<A+'."!C`_.M:
MLR?7+6'6X=*=)?/E&0P`V]"1WST4\@$#N:TZ`"L+0[&_CU>]O=1ABC+_`+JW
M6%P46(-D<8'S$DDG\.U;OK6=IFM6VI3R10*ZE`6&_`WJ&*Y&"3C((YQ0!HU%
M=*SVTBQQQRL5.$D.%8^A]J+N<6UK+.1GRU+8]<5@&]L$NYX-3FGGNX8/M,Q!
M81Q#(^50"!GD>_J:0&CX?LY[&TF6Y55,LSRJ@;=M#'."W<UIUAZ!J*R7)M`T
MY0J[1K.<R1E"H96;)SC>A!R>I]*W.G-,#&\6Z3<ZSI$EI:SQQ;LY61"RR<<`
MX(P,X/X=ZTK"*2"Q@BF96DCC56*C`)`YP*S&\5Z6MA=7F^4PVTQMS\AR[8!^
M4=Q@]?;-;*MN4,.A&:`%K$O].O9/$$%[:.8UVHDC&7C8&)9=F.2<CG/%:>H7
MD&GVDEU=,5BC&3@$D^P'>J*Z_;'[`WD7"Q7RH8Y64!07&54\YSQV!QWIQW#9
M'5_#+_D4X_\`KXN/_1KT^32]92^MC!.C6L=Z\[J\S;V0]!TY`!/&<4WX8D?\
M(E%_U\7'_HYZW#K&G^;%$+N(O*[1H`<[F'4<>F:UQ'\:7J);'+>.O^1T\&_]
M?$W_`*"E=N:XCQU_R.G@W_KXF_\`04KM7.%)]*VQ'\*EZ/\`]*8ENQ<TM<(N
MH:_=Z3=^(;?48H((#*T=B8%*LB$CYG^]DX/3VJV^HZIKVI"TTN]&F)%:QW+R
M>4LC.SYPN&X`XZ]:AX62W:TW\OZ\AW1U^:6N*\3_`/"16.B6]X-:%M<QE(ID
MAMT9)"S@;OF!(X/2NHTBWNK6S2*^O7OIADF9HU0G\%`%9SI<L5.Z>MNH)G)>
M./\`D;](_P"O2X_FE0U-XX_Y&_2/^O2X_P#0DJ&KJ_!#T_5@NH450UC5H=+6
M#S8WD>XD\J-49%RV">K,HZ#UJ^.F<8]O2N<9G>(8[Z72Y$TJ.%[IB`IFZ+SR
MPX/([>]8NE^&I[34[*:/?!!;[9)`9@_F.(RG/RY[CD'''2NKK/.L6_\`;`TQ
M5D>;&690-J<9`/.>@ZXQTYYH`T*Q_$%A=7\ELMK%"-DB.9F;!7:P.,8Y'7OU
MK8HY[4`8/AO1[G3KJ>2Y9=OEB%-K9+@.[;CZ??Q^%;U4+#5/MMY<VQL[FW:V
MVAFD*%23TP58]N<'U%7Z`([F".Y@>&9=T;C##.,BJ7ARQDTS1+6SE"!X5*D(
M<@<DU:O[N.QLY;J;<8XE+,%&3BH])U"'5+);JW5E0DKAL9!!P>02#]030'8M
MUB>*[/4+^UBM["*(I(VVXD+A76/N$)!P3TSV%:&IW+P0HL&//GD$4>[H&.>3
M]`"?PK*U5K?2VB>[N]1DN9%8[XYB`%499BA(3`';!/UH`W85V1(@7:%4`#KC
MBGU2TJYDFCDCG(:6%@"X&`ZD9#8[9!Z>H-2:G?V^F6,EW=L5BC&3M7)/L!W-
M`%'4+"ZN-:LYXHH4B@D\QI=WS,-I!4KCKSP<\<UKUEQZ_:/=V]L%ES.J,'*@
M*A<$JIYSD@'L>G6M2@!#T.#@XZUQEMH5[I.J/<W-S#<1W=[9DNL11W<2\D_,
M?7Z=.F,5T5_K$=EJEC8F&9GO'*"0+\B?*QY/K\IXK-EUB/5)!%%!+$+34[6/
M,@QORZG('I]:Z<)_&BR9;6/4O$EO?W>CSV^ER1QW$@VAG8KQWP0"0?>LSPSI
M>HV6H7,M^%^=<%UF+^8<Y!P>F!Q[UT,\T=O`\T[K'%&I9G8X"@=2:9;WEO<R
M/'!,DCQA2P4Y*@],_6N8HX_PS_R5+Q7_`-<[;_T6*[:N)\-?\E2\5_\`7.V_
M]%BNVKKQGQQ_PQ_])1,2.[_X]9O]QOY5R/P=_P"1`L?]^7_T8U===_\`'K-_
MN-_*N0^$!(\`6.!GYYO_`$8U.'^ZS_Q1_*0/<W-5\.V6KZG;W>HQI=1V\;(M
MO+&KQY;'S8(Z\51@\%V-M>++:R-!"EXMXEO&H"(P0J0!V!SFEM]8U*:UU:6:
M!K=K5@T2,F<)@$^N3U_.LN7Q'JOD3/(ZP*C1-NVJN%E.5&6XR%XR:J,:_+RJ
M6B\_Z[@['3:WH\6KV\,,TC1B&XCN`5`Y*-D"F6>A0V>N7.I6TSQBZ4"6`8V,
MPZ/]:P'\0W2W#JFH(VVW\R-1+`?,.TGH.6Y'\/%3S:[>BTCFFN4M)"YWQ,JY
M'`VJ,\-G.>#DYXJ%"JH\J>G^>H:;D_Q*V#PE-YH9E\Z#A3@_ZY,5C5J?$IM_
M@R5N>9K<\C'_`"V3M676<E^Y7J_T&MROJ-E%J-C-9W`S%,I5JBTC3ETVU:%9
M6E+R-*S-@98GG`'`%9ES<WD6NWL5S>F*R%GYD9B3)B^;&XG!R?T%6O"US+=:
M2'GD:8B1U64G(=0QP0>XQCGO6"&:U5=2LEOHXHY)&18YEE.W^+:<X/MFK+9V
MG;C=VSZUQ&I:MKEKH&J%&DN+J*ZD0SQ1@"%`H/"YZ=AUZT`=Q13(&+P1L0RE
ME!(;J/K[U6UDW(TNY-E*D,X0E7==V,>@[GKBAZ`M2K/H4,^MIJ;3.'0JVP8P
M2H8#GKC#'CO6M7(6&J7C:II2SRM*LUM%F)9<.6926<IMY4<9.>*Z^F`'H:S-
M,T6"PO[F]4AII\@D1JF!G/.T#)SW-0^(YKZ"?36M)Q'"]TD<R[,LX)Z9[#KG
M\*I^&M1O+G5[N&]+[@&)0.&6/#D`$8!4D8/4Y'-"0/1'0W,*W%O)"^0LBE21
MVS6!<:>\LC#4;>>1S:M:EX`&6120=WJ#P.O'UKHQUK"N)KQ/$DT$]R5L38O*
MJ1KM*D,OS$^O)J;:V#H.\/:3):32W=SGS9-VT-C<-Q!8G'`)VKP/[HK;K+\,
M"=M&@GN9I97N!YP\TY9%;E5_`$5J'/;KVIL$94NAP2VNI6YD<#4)#(Y`&4^5
M5X_[YK41=J!1T`Q7$:CJ6KV]E>B6]Q)'J!B\P#RD5/)#!=W.!N(`ZY/'&:[#
M39))M.MI)@PD>)6;<-IS@=1VHZ`2SQB:%XCP'4J3CI6+#X:$5]IMP+V1X]/@
M6&*%T!7@8+>S$=ZTM7^T_P!G3FRE2&<(2'9=VWW`]:Y>TU/5#?:*//,OVFW@
M9X\@$@@^8S#'/8Y'3OC/+A\6@/;4],^&PC/A6+R0ZKY\_#$$Y\UL]AWJW)X9
M@>^ANA+AH9WG'[I2P+$$@-C*CCG'450^&)(\(Q?]?%Q_Z.>B3Q+?QZO:VDL$
M,<<MS)"S#YBP4@`+EE.><G`.`#QWK2OI6DO,2V*?CO\`Y'7P;_U\3?\`H*5V
MQ&>M<3XZ_P"1T\&_]?$W_H*5T'BG4+S3M'GGT^W::=5)!`!"`#.XC(S715BY
M4Z,5V?\`Z4Q+=F=-X+A=YHHM2O(=.G<R2V*,/+8DY(!QD`]P#BK.I^&4N;E+
MG3[Z?2[A8Q"9+<+\\8Z*001QV/:H->UB_LWA-LIVR0>>04R0$^9Q]2"![5G2
M>(+])P);Q(F-JLR1YB7<Q#'[K?,>@Z4+V[2ES!IL;DWAR"708])-S.8XV1O,
M=M[DJP;DGW%;(&*XRT\0W[BW$=RMRLJ.99%,4GD@&/YODXXW'@^N3TK7TG4Y
MKC6;BV>Z695#$(JC]W@C&>A'XCGMTK*=.=KR?=C,7QOL_P"$KTG(;?\`99\'
M/&-R9JO4WC?_`)&_2/\`KTN/YI4#[MC;,;L'&>F?>E55HP]/U8+=F?KFDIJ]
MNL,DAB`W#.Q6)5@00">AP>HJ_%&(HU1<E5`4$\GCWKB;_6;NTT5Q=ZFRW[WT
MT$+`K$C$'@MD<(.OO7;1DF-22"2!DCH:P6PQU94VA6\NMIJ?F.KA@[(N/F8*
M5!)Z]#TJ;Q`UVFC73V$JP3)&6$C+NQ@9.!Z^E8UK?SMJ^DJ+R60SQ#[1;X^[
MF,L'QCIGJV>N!0!U%**2N;UN>Z@\2V/V68QQR-%'.FWF129,`'MT.?PH`VM/
MLEL1/MD:1IYFF8MUR>WZ`?A5JN=\-:CJ%YK6JQZA%-"D?EM%&Z@!%.X=0>2<
M9KHJ`*VI62:C8RVDK,J2KM)4\TS2-/73;4PI(TA9VD9B,9).3@#H/:L75;O4
MX-5U.-;I!$+#S(%"X$;;L;BW//X8K1\,W3W6EAW+N5=D\QI/,$F/XE;`ROIQ
M0@?8LZI:M<PHT(7SX'$L6XX!89&#[$$C\<UE:VD.L6T<=U:W*M&W,1MEDSG@
MX8Y`]B#70'.T[<9[5Q%WJFL6]K+]HN"X2\F1YD;R@-J@HBD@]3D`=SQ1U#H=
M7I5K)!')).`LDI!V`Y$:@85<]^!^9-3WMNMW9S6SG"RHR$CJ,C%.MG,EO&Y#
M*60'##!''>JGB![N/1KJ2PE6&=(V8.5W;<#/`]:3MJ-%9/#L$=[;7`E<B!8\
MI@89D4JK'\":V,YKG;9[BYU72@+NX4_9!<SJ&^1N``,8ZDDG\*Z*J9*\BI?Z
M<E[<64[NRM9S&9`,?,=K+@_]]50O+"&TNA=,TCF\U"U<J"!M(=5&/;BH]?\`
MM4>N:*\5S*L,ER8WA485OW;G)]>@XKG-!NKN:\VW,TL@^V6K$.Y;:WV@\,#]
MQ\8RHX`QZUT817K1%/8]RUS2TUC3I+*6>6!9,9:(C/Z@@_E1IVEQV$\DJ2.[
M2111,6QSL!`/'<Y_2F>(]3?2-'GO(H'GD081$C9^>V0H)QZG%9_ASQ`^K:C=
MP"XLI4A1#LAR)(F(^ZX)R?R&.G/6N8IF5X:_Y*EXK_ZYVW_HL5VU<3X9.?BE
MXK/_`$SMO_18KMJZ\9\<?\,?_243$CN_^/6;_<;^5<C\'O\`D0+'_?E_]&-7
M77?_`!ZS?[C?RKD?@]_R(%C_`+\O_HQJ<?\`=9_XH_E('N;6HZR]G<M`;-V!
M7,;!U^<Y`Q[#+8R?>FG7[6,6?VE'B^U!_P"$L$9&"D'`]3UZ<58N-#L;BXFG
ME68R3J%?%Q(!QTP`V`1CJ*RY_P#A'=RV\LN$TX;=QF?"[CR&.?F.4YW9J(*F
MTM'YV_KN/J2VWBJRDDE$BF)(E#M(<L"#GH`,G[M7;;7-/N;B*"&5C)+PJF)Q
MS@G!)'!X/!YK/CM?#*7"P(T0FFPJH)FRV"PZ9]=U68O#L,>M)J$4KHJ9/D@G
M!<@@L>?0^G^%.2I:[KL)WZ%'XF_\B?/C_GO;_P#HY*R:UOB;QX/G_P"N]O\`
M^CDK)J'_``(^K_)%+<R[S7K2SN9(KI)HMJ,ZNR863:`2%YR>H[?G5O3KV._M
MO.B5DPQ1D<`,K`X(.*YC5]+EEUB^E$C7P>+;*/+YMH^"%C.>6)&[&.<<GD5T
M.AVT5M8#R9A.)G:9I`,!V8Y)QVK#H#W+S':I//`SQ6/)XHTZW@DDNA-;M%(L
M9BD3#DMRN`#Z<^W?%;#@E&"MM8C@XS@U@6OACR])N;*XN_/>XD\U[@QX=FSG
M)R3D]NW%`'09R!BHKNX^S6[2^5++C&$B7<Q.?\\FI>U4]9LI=1TV:TANGM&E
M&TRH,D#N.O<<4,$5K?Q!9SR6BHEP$N_ECE*83?\`,=N<]?E/3(]^:U:P+/PV
M]OJ5G=&[1X[.+RHH!!A$ZY9?FX)&!DYK?IW$4=4U2'3?+:XCF,;G!D1,K'R!
MEC]2.!D^U+8ZI#>7D]JL<T<L`#$2)MRI)`(]N#UQ^55M;T:35+NRE^U^7%:O
MYA@:/<LC=B>1T[=N:FLM,:#49;Z:Y::5T\L?(%`7)(SCJ><9]*0RY<3+;P23
M/G;&I8XZ\5AI>RRWPAOKF[LFE4M&$15C&!N.&()8@=3C;VK;O(/M-K+!G'F(
M5SZ<5RSV4,FJ37&O7$@:6+[-Y#1L`JXY\N13T8C)[]CB@#4\.ZR-1W1^;YRG
M>8)BNPRJC;6R/4$CD<?,*VB<`FN>\,Z0EE.\L:S^0AE$/GLQ=A(P9C@DD#Y5
M`SSP3WKH#G!P<'U]*`,=_$EI&)`\-RLL;I&(655=M^=I&3C!P3R1TZ5L(VY%
M;:5R,[3C(]N*YR#PJR6DT4]ZEQ-+,9FGEME9F)!'.3V!P,8QBMZSMUM+2&W1
MF98D"`L<DX'>G>Z![A=S_9H&E\J68C&$B7<Q^E9]KXBLKJ6"*W$TCSC)VIGR
M\DCYN?53TSTJSK5E-J.FRVD%V]FTHVF5!E@.X'UK-A\*V\=S:3K(J-;K&I$4
M>T,$)*XY.W[QSUS1'="9VOPPX\)1Y_Y^;C_T<];DFL:9%-%#)?VRRS.8XT,J
MY=AU4#N?:L/X8C/A*/\`Z^+C_P!&M6M!HT<,RNLGR+/)<",+@;V&/TY_.M<1
M_&EZL%L<YX[_`.1U\&_]?$W\DKLKEVC@=T0R,H)"#`+'TYKC?'7_`".G@W_K
MXF_]!2NRNX$NK:2"7.R12K;6*G!Z\CD?A6U?^%1]'_Z4Q+=F+;>(/.NH;=K1
MT+D*[;P0A)8#Z@[#S39?$]DJ2'8_F1RM$8V4@G:6&0<8(^4]/YU-)I>DZ6(;
MR?>@MAA'DN)&QUQG+'.-QQG.,\52C@\-3MEBN^4^:4DF?(+DG@9XR7/`XYJ8
MJFW=)V!W+5OXGTQDB,\IA:1%DP48A00"-S`8'7N:T].O[;4(FDM69E5MK!D9
M"#Z88`UCVFFZ!J=O,FGE)5V+$61V8#:/EZG!Q^O>M'0=*&DVC0^>\[,Y=G?.
M2?Q)/;UJ*BI).UT_,$<OXW_Y&_2/^O6X_P#0DJ!F"*68@!1DD]JG\<?\C?I'
M_7I<?S2H6QCYL8[YHJ_!#T_5C6YB?\)3IIMEGC:62,O(@(3LGWFYQ\HZ_P!*
MVE(8!AR",BN.N-,CO5:&?"Z;=74C),T88L7ZC'55/16'7'N*[!%"(J+]U1@5
M@MAD5Y<BTMVE\J6;!`V1+EC_`$'U.!5"R\16%Y<P0P&1C.!M<K\NXJ6"GWV@
MGTXJ?7=/EU339+.*[>T\W`9U7)*]U[=>E4[/PW%;7UO<B5<0[6\M(]JEU0H&
M')P-I/'TIH1MUF7][!IFH">X28K<K'"75,I'AV`).>Y?H,GBM.LG5]'DU'4;
M*X-UMAM&W_9VCW*[?WCR.1V],YI#+6FZM::E+=1V;^8;63RI&`XW8!X/?K5R
MJEE8):7E[<(Y)NY%D9<`!2%"_P!*MT`^IG3ZS!#?/:O!=>8$9TQ'_K=N,A.Y
M^\.V.O-3Z;?1:A;F:(,NUV1D8#*L#@@X)'Y5F7&@7,NHWUZFIM'+<Q>3&WD@
MM;KZ(<X]^G)J_HFG#2M-BLU97$8^\J[<^YR3S[YH6P#M2N)HC%!:@&:;.&89
M"*!RV!U[<5A2ZP;>"69;G43/;L!*D\"%0",@N`!M&/0@^QZ5LZLDZ/%=VJL[
M1!E=5&6VMW`[D$`X[XQ7-V]A&FF3V,>HRW<UPY><"T_>3%O[Q/0CL<@#'2@#
MJ]-NUO;*.=5VDY5E_NL#AA^!!IU[<_98#+Y,LY'`2)<D_P`A^)J+1K1[+3HX
M96W2Y9W.<_,Q+'GZFFZYI\FJ:;+9Q7;VGFX#.@R2O<=1UZ=:`(8?$%A--8QQ
MR%GOU9HE`[`9)/IT(_"M2L*+PM9QWMC>*SI/:8&(F=$<!2H&S=@`9K=H`S=6
MU<:9-#Y]NY@E=(_.W+@,QP`%ZFLH:Y'K/E>2B(L.I0)Q*&8XG"Y*CIG&15[4
MM#>^URTU%KL;+4?N[=XMRACU<<CYL<<YQ52[TEK6[MKR>Z-Q*UW;0J?+5-J>
M<&P0."<GK73A$O;1]12>A[#++'#$\LSK'&@+,S'`4#J2:AM[^SNIY(;>YAEE
MAP9$1P2F>F1VS4&O:6-9TN2R:YEMA)C+Q!2?H0P((]L5!I6BO8WTES)=M<,8
M5A7<@4[5]2."?3@?C7,,Y_PU_P`E2\5_]<[;_P!%BNVKB?#/_)4O%?\`USMO
M_18KMJZ\7\<?\,?_`$E$QV([O_CUF_W&_E7)?!S_`)$&Q_WY?_1C5UMW_P`>
MLW^XW\JY+X.?\B#8_P"_+_Z,:G#_`'6?^*/Y2![G8D9%8%YX0T^[69)I;DQS
M$EDWC;@ECC&.F7)_*N@HKEC.4/A=BCGH?"EI]H>:9B9&N/M`*``C&,#)R1[X
MQR370*N!UH%+1*I*>LG<5CEOB?\`\BC/_P!=[?\`]')7.ZE=/`%AM@KW4W$:
ML>!ZL?8?_6KHOB?_`,BC/_UWM_\`T<E<U?:/8W]P)[F)S*%V!DF=.,YQ\I%:
MR_@1]7^2!;G-VX\K7+VWA:_\B"%VN&>20&YD(!^3&`,8/(P23CM5_P`/PRZ'
M8VWVAY6M[G#2"5RQMY&YQDDG;SCKP>>]7O\`A'--_N7'_@7-_P#%4C^&M+D0
MI)%.Z,,%6NI2"/INK`9K44B*$4*O`48%+0`4444`%%%%`!1110`4=J**`#\*
M***`"BBB@`HHH[TUN!K_``P_Y%&+_KXN/_1SUU.*Y;X8?\BE%_U\7'_HYZZF
MM<1_%EZL2V.(\=_\CKX-_P"OB;_T%*[>N(\=_P#(Z^#O^OB;_P!!2NWK;$?P
MJ7H__2F);LJZE81ZA;B&5Y$PP=6C.&!%8=YX.LI8YA'++OEC$.Z1MVU,J3C&
M#GY>.>*Z:BN>%6</A=AVN9VEZ+:Z9<7$UMN#7!&X<`#'3``'KU.3[UHXHHJ'
M)R=V-:'"^./^1PTC_KTN/YI6'JLGVTSV:M(EM$N;J2/[W3.Q<=SW]OK6[XX_
MY'#2/^O2X_\`0DK#;PYIA=V$,JEW+MLN95!8G).`V.2:WK?!#T_5B1QTLE_=
M:'NB6\^PR2OBW=Y3,BA/D5CU!)'3H,CMQ7::3<3(5LKXMYZH&1W_`.6B_P#Q
M0Z'\^],_X1S3?[EQ_P"!<O\`\53[;0M/MKF.XBBE\V(DH7GD?'&.A8CI7.,T
MJ***`"BBB@`HHHH`****`"BBB@`HHHH`****`"L[7/\`5V7_`%_VW_HU:T:S
MM<_U=E_U_6W_`*-6NG"?QX^HI;,]1HHHKF&<1X:_Y*GXK_ZYVW_HL5VU<3X:
M_P"2I^*_^N=M_P"BQ7;5UXSXX_X8_P#I*)B0W9_T2;/]QOY5Y9\._'6FZ'X4
MM;"[M[UY8VD),4.Y>7)X/XUZI=C_`$6;_<;^5<E\'5!\`V)(S\\O_HQJCEF\
M/)Q=E==/)G11G1B_WL'+YV_1D7_"TM%_Y]-2_P#`?_Z]'_"TM%_Y]-1_\!__
M`*]=MM7^Z*-J_P!T5PVG_-^'_!.KVN#_`.?3_P#`O_M3B?\`A:6B_P#/IJ7_
M`(#_`/UZ/^%I:+_SZ:C_`.`__P!>NVVK_=%&U?046J?S?A_P0]K@_P#GT_\`
MP+_[4\M\:^/]+U?0);2WM[Y':2)P9(,+A9%8\Y]!5#_A,]-_YX7G_?D_XUW/
MQ/4?\(C/@#_7V_\`Z.2LFMI0J^R3YNKZ>GF.-;!=:3_\"_X!SG_"9Z;_`,\+
MS_OR?\:/^$STW_GA>?\`?D_XUT=%8\M7^;\"O;X+_GR__`O^`<Y_PF>F_P#/
M"\_[\G_&C_A,]-_YX7G_`'Y/^-='11RU?YOP#V^"_P"?+_\``O\`@'.?\)GI
MO_/"\_[\G_&C_A,]-_YX7G_?D_XUT=%'+5_F_`/;X+_GR_\`P+_@'.?\)GIO
M_/"\_P"_)_QH_P"$STW_`)X7G_?D_P"-='11RU?YOP#V^"_Y\O\`\"_X!SG_
M``F>F_\`/"\_[\G_`!H_X3/3?^>%Y_WY/^-='11RU?YOP#V^"_Y\O_P+_@'.
M?\)GIO\`SPO/^_)_QH_X3/3?^>%Y_P!^3_C71T4<M7^;\`]O@O\`GR__``+_
M`(!SG_"9Z;_SPO/^_)_QH_X3/3?^>%Y_WY/^-='11RU/YOP#V^"_Y\O_`,"_
MX!SG_"9Z;_SPO/\`OR?\:/\`A,]-_P">%Y_WY/\`C71T4<M7^;\`]O@O^?+_
M`/`O^`<Y_P`)GIO_`#PO/^_)_P`:/^$STW_GA>?]^#_C71T4*-6_Q?A_P0]O
M@O\`GR__``+_`(!E>"/'VEZ1H*6EQ;WSR":9R4AR,-(S#G/H:W?^%I:+_P`^
MFI?^`_\`]>KWPP4'PE$2`?\`2+C_`-'/74[5]!6U>-3VDKRZ]O\`@F:K8/\`
MY]/_`,"_^U/(O%'CC3=1\2^';V&"]6.PFD>0/#AFR%^Z._2NF_X6CHO_`#Z:
ME_X#_P#UZ/'2@>-/!W'6XF_DE=MM7T%:UHU53I7ET?3^\_,%6P=_X3_\"_\`
MM3B?^%I:+_SZ:C_X#_\`UZ/^%I:+_P`^FH_^`_\`]>NVVK_=%&%_NBN2U3^;
M\/\`@C]K@_\`GT__``+_`.U.)_X6EHO_`#Z:E_X#_P#UZ/\`A:6B_P#/IJ/_
M`(#_`/UZ[;"_W11M7^Z*.6I_-^'_``0]K@_^?3_\"_\`M3R+Q-XWTW4/$.GW
M<4%XD<$$L;!X<'+%<8&?:H_^$STW_GA>?]^#_C74^-P!XOTC`_Y=+C^:5#6U
M6%7EA[W3MYOS'&O@NM%_^!?\`YS_`(3/3?\`GA>?]^3_`(T?\)GIO_/"\_[\
MG_&NCHK'EJ_S?@5[?!?\^7_X%_P#G/\`A,]-_P">%Y_WY/\`C1_PF>F_\\+S
M_OR?\:Z.BCEJ_P`WX![?!?\`/E_^!?\``.<_X3/3?^>%Y_WY/^-'_"9Z;_SP
MO/\`OR?\:Z.BCEJ_S?@'M\%_SY?_`(%_P#G/^$STW_GA>?\`?D_XT?\`"9Z;
M_P`\+S_OR?\`&NCHHY:O\WX![?!?\^7_`.!?\`YS_A,]-_YX7G_?D_XT?\)G
MIO\`SPO/^_)_QKHZ*.6K_-^`>WP7_/E_^!?\`YS_`(3/3?\`GA>?]^3_`(T?
M\)GIO_/"\_[\G_&NCHHY:O\`-^`>WP7_`#Y?_@7_``#G/^$STW_GA>?]^3_C
M1_PF>F_\\+S_`+\G_&NCHHY:O\WX![?!?\^7_P"!?\`YS_A,]-_YX7G_`'Y/
M^-'_``F>F_\`/"\_[\G_`!KHZ*.6K_-^`>WP7_/E_P#@7_`.<_X3/3?^>%Y_
MWY/^-4]5\66%PEL(XKH>7=0RG=%CA7!/X\5U]9VNC,=E_P!?]M_Z-6M\-"JZ
MT4I=>W_!%*O@K?P7_P"!?\`V?^%HZ+_SZ:E_X#__`%Z/^%I:+_SZ:C_X#_\`
MUZ[;:OH*7:OH*PY:G\WX?\$GVN#_`.?3_P#`O_M3SOP!JL&L^/O$FH6J2I%/
M%;[5E7:PPN#D?A7HF#7$^&O^2I>*@.T=M_Z+%=MFN[$*2DN=W?+'RZ(X9RA*
M3=.-EVO?_(CN_P#CUF_W&_E7)?!W_D0;'_?E_P#1C5UMW_QZS?[C?RKD?@[_
M`,B!8_[\O_HQJTA_NL_\4?RD9O<N:UXGGTWQ;I^E?9T:UN4S)+D[D))"_AG`
MJ#P]XP;4DUFXNH$AM=/8M$RGF2/YL$^Y`I?%OA:YUN\GFM[B*$O9^3$6SE9!
M(&#<#IQ5-_!5R-/NK".YB6WNUMHG/(;RXQA^W4UM!85TUS:2T_/5_=^0GS7T
M+F@>)=4U;2+]C8P1ZI:JKI;[CM=67<O/7D9'UJ?0O%3:]J,46G0J;:.`27;O
MD&.0](P/48.:9I7A5M&\0K?:?=326\L!BN$N9FD<D8V$$YZ<\>]7_#&COI(U
M'S6C8W=X]RNSLI``!]^*SJO#KF<%O:WZ_P#`'J9_Q._Y%"?_`*[V_P#Z.2LF
MM?XG_P#(H3_]=[?_`-')616#_@1]7^2'U"BBBL!B,0H))P!R2:SVU[2EMS.;
MV+RPVS//7&>GT!.>F*T'W;&V8+8XSTS7&S^%M3O;*07LELUY).TLCB9]K@HR
M`#Y05"@CCD'&">:`.R4A@&4@@C((J.[NH;.!I[F18XEQEC[]*6VC,5O'&S[V
M1`I;&,D#KBJVMQ7TVF31Z4\,=VXPCRYVKZG@'G'3B@`@U:PGGCAANHWDE7>B
MCN,?_6/%7:Y:P\+RV]]83`1P1V^UY`D[N7=0PYRH!^]UX],'J.IH`K7>H6=G
M+%%=7"1/,<(K'[QZ?S(_.EM[ZVN9I88)T>2$X=1VJEX@L+O48X8;=H5C#J[,
MY(9"K!@1V;IC!]<YXJ'0]%ET^^DFDD1D"-'&%))(+E\MGH><=^GX4`]#;H)`
M&2<`=3Z453U2ZTZ"`Q:I<VT,4H*D3R*H8>G)YI>@$UI=07D"SVLJ31,2`Z'(
M.#@_J*FK,\-V8L-'BMQ)%(H9V5HCE<,Y88_`UITV!7OKZVL(A+=RK$A.T%NY
M^E31NLB*\;!E8`@@Y!%9GB6TU"^TXVVF/#&SL!*TCE/W?\04A3@GIG'>M"SA
M%O:0PA`@C0*%5MP&!TS@9H`EJM+J%I%>QV<DZ+<2#*QGJ>O^!JS65J>GW5[J
M5E*C0K!;R++NYW@C(*XZ$$'KQCWIK=`=7\,/^12B_P"OBX_]'/74Y/:N5^&7
M_(I1_P#7Q<?^CFI+CPQ.VJ6ERCQLD%T\X+.Q9`Q!XR#DD#'5<9[]*UQ'\:7J
MQ+8J>.O^1T\&_P#7Q-_Z"E=JYVJ3Z5Q7CK_D=/!O_7Q-_P"@I7:R?=(K:O\`
MPJ7H_P#TIB6[.&L_'TMQI5Q*UK''>07:0^42=K1M)M#C]?Q%:,_B#6+J[O?[
M$T^UGM+"0Q2M/*R/*P&6"``CCIS67>>`YY]/TX)<11WEI<%Y&!.V2(R%]IX[
M5HS:%K5G=WXT.^LX[34)#+()XV+PL0`Q3!P<XS@XKHFL+>].W7>_=?H2K]2Q
M8>*/M>HZ<OEK'9:C:-/"[?>#J1N0]N`3^57O"VJS:SIGVZ6)8HY)'\D+GF,'
M"D^YQFL77?!TMQX:L--TF[$-S8D>7/)GD%2'SCUR:Z?3+..PL+>SA`"01K&N
M/0#%<U;V')^[W_3_`(.@US7U./\`''_(WZ1_UZ7'\TJ&IO''_(WZ1_UZ7'\T
MJ&HJ_!#T_5E+=A1117.,AO+J"R@,US((XQ@9/J:KIK.GR7,-NERK2SC,8`.'
MXSP<8Z>])KT-_<:9)#I,D45R^`'E)`4=\$`\XZ<55TG2)+2YM9'$:16UKY,<
M2N7VL3\QW$#.>.<#Z4`;-5KK4+2TFBAN;A(Y)3A%8]><?A^-6:Q=?TZ_U"]L
M1"8#81.))HVE9&=@05Z*<@8SCC)Q0!H6>HVE[)+':W"2M"<.%SQU_P`#^56J
MP?#6A3Z3=W4TTL;"8!0$).[YF;<<CY?O8VCCJ>];U`%)]7T^.>:&2[C62!=T
MBD_=''^(_.K%M<0W4*S6\@DC;H17/ZAH5_J.JW<UV+66W,1BM%\UU\O."25"
M]20.<\`=#6IH&GR:;8&.:3S)))'E<[BV"QSC)Z_7`^E`&@2`"2<`<DU077-,
M:'SA>Q&/?LS[]?Y<U?8$J=N,XXR.,UQ5]IO^G2M=:IIUO=W!93;F?`PR!"XS
M\V>`0N,#IGO0!VP((R*AN[N"S@,UU((XP0,GU/0#U-/@01P1HIW!5`SZU#J*
M7$EHR6HB9SQME9E!'?YAR#[XH`$U&S>2"-+F-GN5+Q*&Y=1U(]JLU@:?X=-I
M<Z7/NB:2SB:*5PN&88PH'L*WZ`"L.]U2SU`Q1V4PF:VU*VCEQT5O,4XSWK<K
MG+C3&L;MYQY8CNM2M&14XV@,@_I73A/X\29;'L6:`:SO$=C=ZEH\]I8W26LL
MHVEWC+C'<8#*1GU!JCX?TC4K#4;FYU"_ANEFACC58X60IMSQRY&.>P%<Q1D>
M&O\`DJ?BO_KG;?\`HL5VU<3X9_Y*EXK_`.N=M_Z+%=M77C/CC_AC_P"DHF.Q
M'=_\>LW^XW\JY#X/L%\`6)/]^7_T8U=?=_\`'K-_N-_*N1^#W_(@6/\`OR_^
MC&IP_P!UG_BC^4@^T:=MXEBN[?49[9%=+)PO^L&67N2.W?K5$^+I720Q6(8J
MZ@#<S95V^0X52>5YP!6EJ.H6=M//;SV,["9?F(1<3G@;1D\GY@,GCWJ!YM!=
M+=+FVCA%Z,`2*!@QD*%//4$X&,T14+7Y'J'48_B*Z261&LAMBA\USLFZ[2V,
M[,+T_BP?:G_\)!,]G%=6]HK0NQ!+,V548Y8!21SZ\`<G%5[:Z\.2SN#;)'Y4
M?S/)MVA<-WSR.#ZUH`Z!?31Q@VDTLOSHH();CK^0_2DXQ6\&/R,_XE,'\&2L
M""&FMSQ_UV2LJM?XD1[_``C-&FT?OH,;F"CB5.YK(K.7\&/J_P!`ZE;4[V+3
MK":[G.(XEW'W]JI>%=6?6M&CO)?)$C.ZL(6W*,,1U^F*T3<P>>UN94\Y4WE,
M\A?7'I3-/^R&U5M/\LV[$LIB^Z<GDC\:P0RQ65XDU&[TZUADL8]S/)AV,1D$
M:!69F(W+Z>M:M9FI7.BW%O\`\3":UDACEV?.P(60#D>QH`OV\JSV\4R.'610
MP8#`(/.0.U24U-NP!,!0.,=,422)%&TDK!$0%F8G``'>@2U,2YUR6+Q(FG!$
M2`>6K.Z$[F<-M`.>/N^A^HK=K.,VD7&HV[&2VDO&3?"<@L5(/(_#-:-&PPK*
MTJZOKG4KZ.:6VDM;=A&C1Q,C;\9(R7(.`1S@<YK1FN8;<QB>5(S(P1-QQN8]
MA45L;..XN+>V:)9@1+*BD9RW1C]<?I0!)=2F"UEE5=QC1F"^N!G%9>Y=,T";
M4@J27)@\]WD'+MC.#CMVP*V3C'/(K%DC-EOL(Y[22W$32>1<'YHX^_U4>_YT
M@6A4\-7<LMPLKQQPR2R213PQKL&Y0"'VY.UL<'!.<BNEK'\.VEJ(EN;=X)`0
M400+B-`2"0OKD@<^PK8[U3W!&3XEU&[TRUCFLX0^7(=C&TFP!2<[5()R0!GM
MG/:K^GW!O+&"Y*[#-&KE?3(SBJM_/I-Q;R&^EMI(;>3:^\@A'QG'UP:OQ%&B
M0Q%3&5&W:<C&.*70.I7U2XGM;"::UA$\R+E49MH/U/I6#:^)+N:?3E,,02>*
MW:4!6R6E#?=.>`-O?/7M72SF-87,Y41@'<6/`&.<UE"708[BP`:T678JVG3.
MTCY=OX=*J.^H/8Z[X9?\BE'_`-?%Q_Z.>K,OBF".\@@EMWC\ZX:WS(ZJ=P('
M`[\D<#H.:K_#=&B\*QJQ4GSYS\K!AS*W<5N/IME)*DSVT9DC<R*V/NL>I^M:
M8C^-+U8EL<KXZ_Y'3P;_`-?$W_H*5T?B768M$TN2[E`9@#L0L%W'&>IZ5SGC
MK_D=/!O_`%\3?^@I77WPC^QRB:(S1E"&C"[BXQTQWS715:5.C=75G_Z4Q+=F
M/J_B$:<T6V`2K)&)@P?C9_&?P'/XU5_X2>Y,AVV(V+`)R?WC<$,0,A"HX'<C
MK5A=4TV^NX(9K"4R,&B)D12(MVX;"<GKL/3(XZU#/=>'6#3-;QO)`QMV0`;E
M"EAC&>GRG'M4<L;6<'<!(?$\Q:V2>SV/=*WE\2(`04QDN@P/GZ]./>M/3]3F
MGU*:UG@2(*"4.XDL`<$],'J.A..^*H65QX<5(U1;>W,\>5CD(W%&`)XR<=!^
M5:6D)I<KR7>FK"S.2KR1^O<5$U%+X6AG,>-_^1OTC_KUN/\`T)*AJQXWC)\5
MZ4X*X%K.,%@#RR=NM5Z57X(6[?JP6[,CQ/J=QI=@L]J8/,+;5BD1G:9CT10"
M.3Z]JU4)**6&&(&1Z&L_6X-)E$#:RMNVU_W1FXPW?%:0```7H.E8#"LF[U"Y
MMM=L[9OL_P!CN2T8X.\.%+<G..<=,>^>U:<TL<$3RS.L<:`LS,<!1ZFJ*'29
M-421#;M?21AT88WLF.OY9HZ@:-!P.2:*BGN(8&B6:5(VE;9&&(!=O0>IH`QO
M#WB%=:U34K>/R1%;;/*VMEV!W`EAGCD=*WJK6YLVNKAK<Q-.I5)BA!8$#(#?
M@:LT/H!4U:XEM--N)[>+S9HXR43&=S=A^=1:%?/?6/F3LK3HYCE58_+V,.HQ
MN;I]34UW<6)$UO>2PX6/?+&Y'"=,D>E&E_8OL:?V;Y7V?)V^5TSWH!C-9EDB
ML3Y3^6TLD<(?NN]PN1[C=Q[XK+UZ\70K>WM;&VCQ-O9R\>\8498D9&2?7/KP
M>E;ES;QW-N\,PRCC!QQ6#>3(UKY-[=Z;=0I)Y2R3G!WCJ"!QD4`7]'VQSS00
M$&V9$FC`Z)NSD#VXR!VS6I573K06J,S2>=+*0SR8P#V``[`#@?XYJ>:5((GE
MF=4C0;F9C@`#O38&;=W=ZFOVMG;RVQAD1I)8VA8NJ#`R&WXY)`^[V-:M5/,L
M1=0S;X?/N$V1-D;G7[V!ZCO5NEL&@=.>E</IFLWNIW$:7D@9/M=K+$-H'!N"
MN4Q_!A1][G-==<ZE:6MW;VDTZI<7)*Q1]2V`2?Y=:QE_LNXDC.DPB-AJ,`ED
M,+1*Y68`@,P`;D'IFNC"NU:+)DM#U;6=1ATK3IKRYR4C&0HQESV`SW-4]'UQ
M=3OKBW6VEA$*JRO("!*".J\8(!XR":TKVV@O+=H;N".>)NJ2*&4_@:ALM-LK
M*622TM8H'D`#%%QG'05SH9ROAG_DJ7BO_KG;?^BQ7;5Q/AG_`)*EXK_ZYVW_
M`*+%=M77B_CC_AC_`.DH42.[_P"/6;_<;^5<C\'O^1`L?]^7_P!&-777?_'K
M-_N-_*N2^#G_`"(-C_OR_P#HQJ(_[K/_`!1_*0/<W+O1([FYFGDN[D>:H`4%
M<)@@@KE<CD9ZU%)HEC,;>V,\N^T4D@,,NKD$EN.Y7MCO6T17(:AX+FNA=JE]
M"GVERQ8VNYARQ!SNY8;N#QP*SI3O\4K#9I1^%=.CW;?-^8!3ENPS[>YIL/AT
MP:XE]#<[;="7,&WDN01G/T;]*HQ>$II+XW;SB)X[G?$'3S-L8.<#G`R2QS@D
M9KK%4]ZN=64=(RO<5KG+_$TY\'S?]=[?_P!')636O\3_`/D4)_\`KO;_`/HY
M*R#42_@1]7^2*6YCR:#"^M7-VT41@NK;R95/WG;=GGVQ[U8\/6#Z9H]O9RE"
MT0(^3IU)&*R=:UG4+"^U*,^1'##9>=;\;B6W;<GICV%:7AF]N+[3#)=G,R2O
M&W`'W6QVX/X<5@O(#390P*GH>#7*W7AS4(=,N;'2A9QPW-VTC`R,A6$J`54A
M3ACTZ=":ZIB0I(&3C@>M<;=:_K,.GW,KK"LL%W+$RQ@,0JQ[E4;L;N>IZ]\4
M`=A!&(H(XPH4(H7:#D#`Z9J#5;*/4=.FM941UD7`#],]B?QJ6UD::VBE=2K2
M(&(/8D9JMKMT++2I[AKI;41@$R%-^.>@'<GH/?%'0$9EOHU\DVD!C;".P5=T
MBNQ8D(5*[<8(.>#D$<\<UT-<GI^NZK)J%E!>1B,R>6CQ%1N;>KMNSV(V#(Z=
M:ZRFP,O7-)&HS6,Z+'YMK<+(&;.0H/S`>YXJKHF@W.F:YJ%]+>"XCNT0<KAR
MP9CS[`,`/I3_`!)J-Q93V,5E.#<3R;5MO+#&09&23GY5`R2?I4ND7UY<:MJ=
MO>K$BV[1^4J<X5@>I]>*0&M7+:O;V!UJZF6>!'N+1[67!;<7)7&2!P`!CKQZ
M5NZU*T.ESNC^6<`;P<;02`3^&<UBM>O9ZQ)I]E<PI:V\!>;,0V6PV_*2V<LQ
M.3CT]*0&CX:@GM]/Q-.LR.V^(),TP1,<*)&Y8>YK5(R,'I7,^#+B>>6[:3B"
M4":+,>PD%F&_:.!N"@X]O>NE)P">!]:;!'*S>%9ECG%FT4(^VFZAC21HP08@
MA!91D'.3QG]:Z6QBD@LH(IY!+*D:J[@8W$#!-<PFL:A/97\MM?1/'$Y%O,T2
MK]H902R("<8!`YYZ-]:Z;3YS=6%O.>LL:OT(ZC/0T=`8W4[.*_L9;::-)%D7
M&UNF>V?QK.T[1[F`Z0EP\316%KY;*K$YEPHW#CI@-^?2KNMW2V6F37#W2VBQ
MC)E*;R![#N3VKGH_$>HI?:+:75L\3W)_TAFA;G(;:H(&`>`3SQ50WT$ST+X:
M9/A"/'4W%Q[?\M7JG9^&-32]M[B2VTZ+9/YF([F1_*&Y3N3,8^9@"&R>Y.3T
MJY\-./"$9]+BX/\`Y%>KEIK\\TMLLMBJBXNFMA)%<!TP$9]V<#/W2#@8![FM
M<1_&EZL%L8_CG_D=/!O_`%\3?^@I797D/VBVDA\QX_,4KOC.&7/<'UKC?'7_
M`".G@W_KXF_]!2NW-:U]*5+T?_I3$MV8\.@6]O-!.;FX<P`?>*X?&[&[`'3<
M?_KU`/#FG7(,OFS2+(YE3Y^!N+$XXZ$L:OZ[IS:I8FW5T3Y@W[Q-ZMCL5R,C
M\:YVY\(7:"66WNU:9HDBC\N(1%2"N'+9.[&#VZ<5-.7-JYV8,TY/"M@]O)$/
M,^:)8LLV1A1@5<\.Z;-IEF\=S<&YFD<R/)C&3T_I5?PYH']B3W1CE5HIR"J"
M/;MQZMDEC^0]JW*SJ5).\>:Z&MCA?''_`"-^D?\`7I<?S2H:F\<?\C?I'_7I
M<?S2H'+!&**&;!P"<9-.K\$/3]6"W,3Q5HLVL01I;.D4@#QF0N5*HRX..#GM
MQQ]16U&FR-4SG:`,GO7'7/B/4X;',YCCF^TW"N\2!PB1C.,,1GZ]3CCK780O
MYD*.#G<H.<8ZC/2L%L,JZU81ZGIEQ:2(CF1"%#_=#8X)_'%9%GX?NX=4M)WE
MB,,.QVPQW;UA,>T#'W><YS^'>M;7;B[M=)N9[!(FGC0LOFGY1@9)]\>E9ME>
MWMSJE@HNSY;VHN)X_+7'(P`#U&3D]>U"W$SH*RM9TD7][I]TBQ^;:3AR[]0F
M#D#ZY'Y5JUCZ[?7MI?:8ENL0MIYQ',S<L<@\`?AUH'N2:+I/]F7NI21K&D-U
M,LJ*G4?(`<^Y()K4KG/"NLWFI7MW%>%615#Q%5`XWNO;M\HZ\]:Z.@'J85YH
M]S%JE]J.EI:">XM1&/-)PTN[@M@'C&*M^'+"?3M+2"[*M<EF>5UD,@=R<ELE
M5ZGMCBLW5-6U2WU._@B2!8XK4309;ECNP22<#UP*T?#E]-J&G&2Y5@Z2O'EE
M"E@IP"0.`:%L#W-)]I4[\;<<Y]*XMK:WBL+S3+.:Q6.ZN'=2SNJQHP7&&"X)
MR.1G!Z9KH]9'G26MM)Q#*Y+YZ':"<'U!(Z=\5S3:_?/:R*CI-9DR&*X:%0LP
M1,E0O3:3P#Z"A;@=I"I2%%9MS``%@,9JMK5@FIZ7<6CHC>8A"A\[=V."?QJ#
MP[(S6LT1#!(9=D98Y^7:K8_`L5_X#3]?O!8:7)<M="U"8R_E[V//0#N3T%)Z
M[C1E_P#".78U?2KXWBD6<:QO&5R%4(0=A]SUS[>@KI*YVSU/5VU'2(;V&**.
MZA=I1G+EP,_0`<>O/TKHJIDJQEZMI;7FHZ9=Q")6M)S)(Q^\5V,N!QZL#BL5
M=&FTZ\AG,=M;0R7ELOE6S,1(WG@F1L@8;G'?ZU;\17T\6M6%GIUS*UW,P9H%
MQY:1`_.[\9Z<#GK6?9W]Q?7[F*XEN=.BO[6-)I0/GE$WS[,`?*.!^%=&$_C1
M%/8]A\26=Y?Z//:Z=<);S2KMWN&Q@]1E2",^HZ5F>%M$U#2]0O)[Z:&9;@*=
MR\L2/^`@@#H`6;\.E:GB+6+;0M)FO[MD"1C`#.$#,>BY/`S4&C:I<ZE<S@V]
MNMM&J,DL5P9"Q8;L$%``<$'@GJ*YD4]C`\,_\E2\5_\`7.V_]%BNVKB?#/\`
MR5+Q7_USMO\`T6*[:NO%_''_``Q_])1,2.[_`./6;_<;^5<E\'/^1!L?]^7_
M`-&-76W?_'K-_N-_*N2^#G_(@V/^_+_Z,:G#_=9_XH_E('N=E1117&4%%%%`
M'+?$_P#Y%&?_`*[V_P#Z.2L<D`$G@#UK8^)__(HS_P#7>W_]')7+:S'=3^7!
M#`9+9LF<JX5B!T7GL>_L,=ZZ'_!CZO\`)"ZF5/>:1J]W<F^9?L\$3!0T3?.H
MY9PV/FQV`Z=<<BM'P[=Q-;BT6,PF,9C!A:$21]F"D#'OQ[]"*Q[O2=6O=1O)
MKRTAF@D@-O;1F3`A4CD8!&<XY.>@%6;.PU*WTU8Q;,+F.1I8661=L>3G8,G)
M7M^-<Z&=+4,EG:RC;+;0N"_F$,@/S?WOK[T^!I&A1ID$<A4%E!S@]QFGT`%1
M75M!=PF*ZACGC)SLD0,OY&I:*`((;&T@:,P6L$1B4HFR,#8#U`]!4]%%`%>Z
ML+.[=)+JT@G>/[C21ABOT)'%3+&BNSJBAFQN8`9..F:=10`V6-)8VCD`9'!4
M@]Q6-_8&R1S$+&3>-OF7-H)),=,%@1N&..?UK;HH`HZ1I5MI4+I;(JF1MSE4
M"@GZ#@"KK`,""`0>QI:*`*::1IL<;QII]HJ.0S*(5`8CH2,<U<``&!THHH`B
MN;>"ZB,5U#'/$>J2*&!_`TD5I;11Q1Q01(D7,:J@`3Z#M4U'>G'<3-;X8J#X
M1CSR/M%QP?\`KJ];]KIEA:($M+*V@4.9`(HE4;L8W<#KCO6#\,/^11B_Z^+C
M_P!'/74UMB/XLO5@MCB/'7'C3P;_`-?$W_H*5V]<1X[_`.1U\&_]?$W_`*"E
M=O6N(_A4O1_^E,2W84445QE!1110!POCC_D;](_Z]+C^:52U"\BL+5[B<X5>
M@[D]@*N^./\`D;](_P"O2X_FE8-TNHO?32BT#K$"MJ/,7:"1R[#KG/&/3ZUT
M5?AAZ?JQ+=F3-)I,MG]NN&A%X9M^'MVVJ?O;64KD+CDL1C/S5T]C=1W=N)(_
ME(^5D/5".H-<E#H^N?V/<6EQ!#)/>.7N)RX)<GHPY^7'&!TP*W(TOH[^&>&T
M90^$N-TJX8#H^/[P]NH^@KG&:[JKJ4<!E(P01D$4Q(8XVW)&BMM"9"@'`Z#Z
M5)10`4V2*.3;YB*VT[ER,X/K3J*`(H;:"!I&@@CB:4[G**`7/J<=:EHHH`CD
M@AD+&2)'++L8LH.5]#[>U+#%'!$L4*+'&@PJJ,`#V%/HH`KWUG%>VYBF!QG(
M(ZJ?45FQ:&\</V>/^SXH2VXF*Q"N<=#UV[AZX_`=MJB@"*TMHK2W6&$81<]>
MI).23ZDDD_C1=6MO=Q>5=P1SQYSLD0,OY&I:*`(H[6WB6,101((AB,*H&P>@
M]*EHHH`K7&G6-S.L]Q9V\LRXVR/$K,/H2*SM1T^RLA:/9VD%NSWUMN,4:H6_
M>CK@5M5G:Y_J[+_K_MO_`$:M=.$_C1]12V9Z>ZAU*L`0>H-)%$D6[RT5=QR=
MHQGC'\@*?17,,XCPU_R5/Q7_`-<[;_T6*[:N)\-?\E3\5_\`7.V_]%BNVKLQ
MGQQ_PQ_])1,2.[_X]9O]QOY5R7P<_P"1!L?]^7_T8U=7>?\`'K*`<?(W\J\K
M^'GA[Q!J'A6UN=-\3OIULS.%MQ;!PN'(/.>YYK)3E'#R2C?5=NS.BC2A4?OS
M4?6^OW)GK=%<-_PB/BW_`*'>3_P#7_XJC_A$?%O_`$.\G_@&O_Q5<?/+^5_A
M_F=/U6C_`,_X_=+_`.1.YHKAO^$1\6_]#O)_X!K_`/%4?\(CXM_Z'>3_`,`U
M_P#BJ/:2_E?X?YA]5H_\_P"/W2_^1-#XG_\`(HS_`/7>W_\`1R5D5E^-?#GB
M.R\/RS7WBN2]A$L2F$VH7),B@'.>Q(/X50_L/7/^AD?_`,!5_P`:UE5G[)+D
M>[[>12PE#K7C]TO\CHZ*YS^P]<_Z&1__``%7_&C^P]<_Z&1__`5?\:Q]I+^1
M_@/ZIA_^?\?NE_D='17.?V'KG_0R/_X"K_C1_8>N?]#(_P#X"K_C1[27\C_`
M/JF'_P"?\?NE_D='17.?V'KG_0R/_P"`J_XT?V'KG_0R/_X"K_C1[27\C_`/
MJF'_`.?\?NE_D='17.?V'KG_`$,C_P#@*O\`C1_8>N?]#(__`("K_C1[27\C
M_`/JF'_Y_P`?NE_D='17.?V'KG_0R/\`^`J_XT?V'KG_`$,C_P#@*O\`C1[2
M7\C_``#ZIA_^?\?NE_D='17.?V'KG_0R/_X"K_C1_8>N?]#(_P#X"K_C1[27
M\C_`/JF'_P"?\?NE_D='17.?V'KG_0R/_P"`J_XT?V'KG_0R/_X"K_C1[27\
MC_`/JF'_`.?\?NE_D='17.?V'KG_`$,C_P#@*O\`C1_8>N?]#(__`("K_C1[
M27\C_`/JF'_Y_P`?NE_D='17.?V'KG_0R/\`^`J_XTO]AZY_T,C_`/@*O^--
M5)7^!_@'U3#_`//^/W2_R.Y^&'_(I1?]?%Q_Z.>NIKRKP5X<\17N@)/8^*GL
MH3+*HA%JK8(D8$YSW.3^-;G_``B/BW_H=Y/_``#7_P"*K6O4FZLFX/?R_P`R
M/JM'_G_'[I?_`"([QW_R.O@[_KXF_P#04KMZ\A\3Z!K]KXD\.P7?B9[J>XFD
M$$QM@/(("Y.,\YX_*NE_X1+Q;_T.\G_@&O\`\56M:I-TJ5X/9]OYGYB^JT?^
M?\?NE_\`(G<T5PW_``B/BW_H=Y/_``#7_P"*H_X1'Q;_`-#O)_X!K_\`%5R^
MTE_*_P`/\Q_5:/\`S_C]TO\`Y$[FBN&_X1'Q;_T.\G_@&O\`\51_PB/BW_H=
MY/\`P#7_`.*HYY?RO\/\P^JT?^?\?NE_\B)XX_Y&_2/^O2X_FE0U@>)=!UZV
M\0Z?#=>)GN9I()628VP'EJ"N1C/.<C\J9_8>N?\`0R/_`.`J_P"-:U:L^6'N
M/;R[LJ.$P_6O'[I?Y'18HKG/[#US_H9'_P#`5?\`&C^P]<_Z&1__``%7_&L?
M:2_D?X#^J8?_`)_Q^Z7^1T=%<Y_8>N?]#(__`("K_C1_8>N?]#(__@*O^-'M
M)?R/\`^J8?\`Y_Q^Z7^1T=%<Y_8>N?\`0R/_`.`J_P"-']AZY_T,C_\`@*O^
M-'M)?R/\`^J8?_G_`!^Z7^1T=%<Y_8>N?]#(_P#X"K_C1_8>N?\`0R/_`.`J
M_P"-'M)?R/\``/JF'_Y_Q^Z7^1T=%<Y_8>N?]#(__@*O^-']AZY_T,C_`/@*
MO^-'M)?R/\`^J8?_`)_Q^Z7^1T=%<Y_8>N?]#(__`("K_C1_8>N?]#(__@*O
M^-'M)?R/\`^J8?\`Y_Q^Z7^1T=%<Y_8>N?\`0R/_`.`J_P"-']AZY_T,C_\`
M@*O^-'M)?R/\`^J8?_G_`!^Z7^1T=%<Y_8>N?]#(_P#X"K_C1_8>N?\`0R/_
M`.`J_P"-'M)?R/\``/JF'_Y_Q^Z7^1T=9VN?ZNQ_Z_K;_P!&K6;_`&'KG_0R
M/_X"K_C535-'UB-+;S=?:4-=0HH^S@;6+@!NO8\X]JZ,-5FJT6H/\!2PF'M_
M'C]TO\CVZBN&_P"$2\6_]#O+_P"`:_\`Q5'_``B/BW_H=Y/_``#7_P"*KGYY
M?RO\/\R?JM'_`)_Q^Z7_`,B.\-?\E3\5_P#7.V_]%BNVKSOP!:7=CX^\26VH
M7QO[B.*WWW!387RN1QVP"!^%>B?C7=B).4DY*WNQ_)'%."A)QA+F7=7_`%([
MO_CUF_W&_E7)?!W_`)$"Q_WY?_1C5UMW_P`>LW^XW\JY'X._\B#8_P"_+_Z,
M:M(?[K/_`!1_*1GU.PFD$43N1D*"V*Q-(\46^IS6,45O*AO;9[E"Q'RA6"D'
MWYI_B6;68?*_LBQCOHG5TFC+A'&1\I!)`QGJ*P+71M8T./1+JTLEU"6TM'MI
MX$E5#EB&R"V`<$8I4J4)0O)J[VU\G^MAM]C1O/'%C9V7VNXMYEA%\UDS<':0
M<%C[<5K6.LPWFKWFGQ(VZU2-S)D%6#C(Q7+1>&K^73K&.\M4+2ZG)=W40<$1
MH^[()[XR!Q5KP/H.HZ+K.K&]^>V<1QVLI8$NB@X!YSD`@<UO4I8=0DXO5>>^
MJ_X)-W<L_$[_`)%"?_KO;_\`HY*R*UOB=_R*$_\`UWM__1R5DUR/^#'U?Y(I
M;A1116`RC?W-Y'<PP6,,$CR*SDS2E``,>BGUJ#[5J^TMY&F;0<$_:WP/_'*F
MN_\`D*0?+O\`W$ORY^]RO%<B=#U:>Q>5K![61KDR-9KY)39Y;*H&6*GD@DG!
M/.*!G9Z;<2W-L7N(TCE5V1E1BPR#C@D#^5668(I9B`HZDFL_P^KIIP695617
M8,$^Z#GD#VI/$BSOH\ZVE@NH3D#9`[*%8YZG<0,#KC-#$B^)HMP3S4W'HNX9
M-/KF=&T1XKK3'NK0`6=NQ\V01[_-)(Q\I/`&<8.!FNFIL!K.JD!F`+<`$]:%
M=6+!6!*]0#TKG_%EG=WUS816VG-/$)-TURICWPJ"#A0S#DXZCH*9X8TJ]L=8
MO;BYA\N.8'YBRD$[V(VXYQ@\[N?PH2!Z+0Z6F^8FXKN7<!G&><>M.KDM6TJ]
MU#7KL_V=+!;+`R1SQ/&#<.5`RQW;@`!@#'N:0'6(RNH92"#W'-+61X6LKJQT
M^1;P!&DE9UC`4>6I[8!('X$UK-R#QGVH8(3S8]I;S$P#@G<.OI3JXFYT._D:
M=X--\NV>8.;4O'ECY;KD<[<!F5N>>"?05UVFQ2P:?;Q3MNECC57/J0.:`)V9
M5!9F``ZD]J`RG;AA\W3GK575XA-82(;4W8.,Q`J">>HW?+^!K!TS1+R"?0YI
MD<O:K)'(/-!5%(;!QG!8Y&2/PXIK<#O_`(8''A&+_KXN/_1KUU.?:N5^&>1X
M0C(&3]HN.G_79ZJV46N?;+4RV>LQQ_:F9C)=PNL:<?>`DRP;GC^')PHXK7$?
MQI>K$MAOCK_D=/!O_7Q-_P"@I7;$XYKB?'7_`".G@W_KXF_]!2NV;I6U?^%2
M]'_Z4Q+=G*0>-U<F:;2;R'3Q.;<WA*%`P;;R`<@9[XJ>Z\5W"ZO>:?8:)=W[
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MI^K!=0HHHKG&([JBEG8*HZDG`H#+\OS#YNG/6LSQ.ER^CRI96"7\[8VQ.5VC
MG[QW$`XZXS6)INB:K;ZUI%PWS6EK"T161@'BRO.0"026]"<#'X@'7TUG1656
M906X`)Y/TIU<]XFL[N]U/3DM]/:2!)!)-=H8]\8#`A1N8$9QR1GCCO0!OK(C
M$A75BO4`YQ]:=6!X9L+VQO+SSXBD,A+[Y!%O9RS$X*<E<$?>YS6_3$-\Q-Y4
M,NX#)&>12JRNH9&#`]"#7(:GI.I7^LZC)!9&S3R&CAG5HR+ACMR7.[=VP`1Z
MFMOPU;7-KIIBNH1"?-8HN$#!2>-P3Y<_2D-EF>\F6[-O;V_FE8Q(Q+A0,D@?
MR-1&_N`N3;0@9QG[0O6G'_D+7)";S]E3Y1QN^9^*YFQT2[N[&1+_`$A;?[5=
MH9(3Y12"$#^'#').`">IS1U`ZZQN!=V<5P%V>8N[;G.*IS7FHFXG6U@L_*A8
M+OFG9">`>@0COZU+H2A='M54`!4``'I6;K*7+V&I+9:>NH3F9=D3E0H.!\QW
M$`XZX[T,$6)KW5X8V=K?33M0O@73Y(`SQ\E:T3;XD?&-P!Q7"MH-_!=6TX@D
M,4%LJL\K1\81]V[!)!RPP%^7'7H*[BUQ]FBQ_<'\J;2L"&37UI!<1V\US#'-
M+]R-Y`&;Z#J:S]5N[:Y2U6VGBF,>H6RN(W#;3YJ\''2J/B2TO]0UBSMDL9#I
MJE9;BXB:,.[*V53YF!"@\D@'VK-L-(O+"Z@DN%:*!+BTMHD<J6(6?.[*DYX(
MY."?05TX1+VT?44MCW;.*`:S?$@U)M'G7155KQAM3+A,>I!((SZ9K-\,P:U'
MJ5Y)JOFB)U78'E#J"/[N&/X_*O/KUKD0S-\-<_%/Q7_USMO_`$6*[:N)\-?\
ME2\5_P#7.V_]%BNVKLQ?QQ_PQ_\`243$CN_^/6;_`'&_E7(_!W_D0+'_`'Y?
M_1C5UUW_`,>LW^XW\JY#X/C/@"Q'^W+_`.C&IP_W6?\`BC^4@ZG6)>6LA?9<
M1-Y;;7PX.T^A]#22W]G$A>6Z@102"6D``(.#^O%8]OH<\5C?6[-&K3Y,>)&<
M;LD[CG[O..!D5G'PI>QQRF*>)Y&,+KERGS`YD.=K8W-ST-9JG3=[R'=G3#5-
M/+JJWUL6<;E'FKEAZCGD5))>VL9`DN84RP4;G`R3SCZ\US;:'J<LTS%H0L\'
MEM_I.<':1R/*^;KZCZ5(_A^]CM(X(FMYF1C^^E8AR&QDGY2&Y'3N,<BE[.'\
MPKL3XG?\BA/_`-=[?_T<E9%:OQ*4IX,E5B"1-;@D#'_+9*RJ)?P(^K_)#6XC
M$*I9B``,DGM4=K<0W<"3VTJRQ.,JZG(-+<P17-O)!.BR1R#:RMT(]*J:!8/I
MFD06<A0M""#LZ=2>*PZ#+%S96UTR&YA20IG:3VSUJC?6^C6$:R7B0Q*QV@MG
MDUJUD>*;+4-1L%M=.>%5D?$YDD,9:/'*JP5L$],XZ9I`:5K##!`J6RJL?4!>
MG-2TR",101QA0H10H53D#`Z"GTV!6?4+1+Y+)[A!<N,K$3R1S_@?RJS65?V%
MW=:Q93@PI;VLGF;LMO)VLI7;]TYSUSD?C6K0`5$EU!)=2VR2JT\0#2(#RH.<
M9^N#4M8>BZ#/I>MWU[)>&XCNT4'>H#%@S$YP/0@#_P"M37F!MLP52S'``R3[
M5F1R7=U`UVUPMG:[=Z#9N;;_`'F)X''.*T+F(3VTL+'`D0H2/<8K$N+VU71I
M-.U.>&QE$1@/VA_+1^,95N,@CTYI/8"UI.I-<,L4LJ7"R*6BGC0J'QC<"#T(
MR/8_A6K7-^&H;EI$WR&2W@+,C>8\@&X`!%=L%@!DY/J`*Z2A@0W=W;V<)FNI
M5BC!QN;UJ2-UDC5XV#(PR&!R"*R_$>E2ZG#;_9Y-DMO(9%'F-&&RC+]Y>1][
M/X5H6,,L%G#%/)YLJ(%=\8W$#DT`_(FJI<:G9VUW%:SSJDTI`12#\Q/0?I5O
M/-4;BSEGUBUNBZF"WC?"<Y\PX`/X#/YTX[H#I?A@<>$HL_\`/Q<?^CGKJ-P]
M:Y3X9J6\(1@?\_%QW_Z:O45EX7OEDM7EM=-MWBO#<EX96<H,8.W*`Y8?>&1D
M\DGI6N(_C2]6);$/CO\`Y'7P;_U\3?\`H*5V=Q<0VT1DN)4BC'5G8*!^)KC/
M'?\`R.G@W_KXF_\`04KI?$%@^H62Q1JK,L@<!I6CSC_:7D5O52=.BGV?_I3$
MMV76N(%QNFC&<8RP[\#\ZA?4K%)%C>\MU=AD*9`"1],^U8VL>'[F_6WVW*;H
M[<HS,"-T@'R-QZ')JHWAS4(W*P20F-[986)F*X8*P)V[#GEO45DJ=-QOS#ZG
M2PZC93*S0WEO(J@DE9`0,=?YBI8[F"65XHIHWDC^^BL"5^H[5R\7AS46:V:X
MEB4VR,%7SC()"2A`;Y%P/D/KVZUIZ9IEU;:I+<2BW6%@V-C%F8D@]Q\OOR<\
M=,5$H02TD!S_`(W_`.1OTC_KTN/_`$)*@=@BEF("@9)/:I_&_P#R-^D?]>EQ
M_-*@D#&-@FW=@XW#(S[U=7X(>GZL%N41K>FFW6X%Y%Y3/Y8;/&[T_*K]<G=^
M&;^Z29VEMTEG>3=&'8JH=`C,&(R3QD`C';.*ZJ)=D:H"3M`&37.MA];#JB:Z
M@6Z2U:5!.ZEUCS\Q4<$X].14M9<NDJ?$<&JQK&I6%XI#CYF)V[?P`!H`U***
M/I0'4K6FH6EX\B6LZ2M$<,%/2K-8N@:=?P7][>:J8'GN"%1X968+&"=J!2HQ
MU)/)R2:VJ-@W&3S1V\+S3NL<:#+,QP`*;:7,-Y"LUM(LL;=&6EN1,UN_V81F
M7'R>9G:3[XYJGH-A+IUB89RNYI'DVJ2P3<<XW'!;ZD4`1ZW:6S`7#K<&X;;#
M&(+J2'>23@':P]2>^!FLNZT3[):O=7FLW5N%()+7D_ECG&.9,^U;>KPR21PS
M0IYDEM*)@G=Q@A@/?!./<#UKG_%KV&O6*V\6L16MPN66W?&YF[90C=D<XP/>
MCJ!OZ*Z"R%LL9B:U/E,A<OVR"&/)!!!R>>>>:?-IMG-*TLMNC.W5L=:AT5)6
MCEN9T:-IF&U'&&"@8!/N>3CW%:-`&3+;:*EXEE)%%Y\B[A'@Y(_R#6JJA5`4
M8`X`Q6-=:3=2>(8[^WF$2`()&$K@LJ[OD*?=.2V<GD5M4=`"L*_U.UOC;1VS
M.QCO[;+%&"M^]`^4D8/(/2MT\C!Z'BN-M?#TVC36[&5/)^U6T2*A),F)\[WR
M.&P0._3\!TX3^/$4OAN>XFC(K.\1V-WJ6CSVEA<I;2RKMWNA88[C@@C/J#6=
MX<T*\TS4[JYN9(2DR*O[LDEV`&6;Y0>.@!+8'<=*YAF7X:_Y*GXK_P"N=M_Z
M+%=M7$^&O^2I>*_^N=M_Z+%=M77B_CC_`(8_^DHF)'=_\>LW^XW\JY'X/?\`
M(@6/^_+_`.C&KKKO_CUF_P!QOY5R7P<_Y$&Q_P!^7_T8U.'^ZS_Q1_*0/<N:
MG<WXU6Z33/M;RK%@++&PAR<8V-MVY')Z\GBHGOM9@M-$D$,K2R6Y%RC0L^7^
M3[VW[I^]R>!S75$#TKC;_P`5W=I+>R"U600';'#@@D@OD$XX)"@CM4TKST44
M[?\`##T6HRSOO$"33.;:=B44QK+$Y4-\WXGMWJ]9:_J+:W!I]U'"I8D.%A<%
M@`QW`Y(`X'!R>]1_\)1>"_6`Z>!$+@6\CE^=Q_NC^(8*GCID\<5TP@B,_GF%
M/-`VB3:-V/3/7%75DH_'!:]A;['-_$XY\'S?]=[?_P!')636O\3_`/D4)_\`
MKO;_`/HY*R#6+_@1]7^2'U*&OW<ECHMW=0$"6*,LI*Y&>W%1>&;R>]TS?=MN
MECE>(G`'W6QVX/U'%37&JZ>DUQ;S3H7MX3--'@MM3GDX'MTZ^U3:?);R6B-9
MQM'#_"K0M%@?[K`$?E6"ZC+%87B_4+W3K.*6R=5Y;=RNXX0D`!NO(YQSBMT]
M.:R9=8T>:U::2:.XACF,65B,G[Q>>``2<#N*`-*VD::VBD=2CN@9E/\`"2,X
MJ#6);F'3+B6Q$9G1"5\PG:/<XZ_3VJTC!T5E.58`@CO4=W/!:VLD]W(L<*#+
ML_0"AC70YBQUV_FU'3HW8%)DA#QA!\^^-V+CN,%1TXZUUE92:GI7VJR1%8R7
M"`6TBVK[2I&<!]N!P.F:U:IDW,CQ!>WMG/IPM1$()KE8YB_+8/8#I^-+I%[?
M3ZOJMO>^4%MVC$2Q\X5@3R>YXJW?WEE;/;QWDD:O-(%A5ADL_L*98:C87EW/
M':.K3)_K/W;+NP2,@D?,,@C(STI#9>K"O-2O(->N+>:>WM;);)YTD(W%2"`6
M;IZGBMJ:1887ED.$12Q/L*P9K^*XFE2]N[:VD%N96@:'S&2+(^^3]1Q_.I8%
MOPM>7-_IGVBY8NKNWDNZ@,\?\+,!P"1]*UCT.*Q_#M[#(&M42%"HW@Q1&(.,
MX;Y#RI!QD'U'K6P3@9--@CE3JFJ-8ZH9KNWM;FVNF2)5"D.!&KA`6ZGGDX/&
M>G4='I\YN;"WG;[TD:L?E*]1Z'I6;+K&AO#*9BK*'&]'MV+,V"0VW;DC"D[@
M,84\\5KQNDD2/$P9&`*D=Q1T`KZM)=1:=/)8B,SJA*^:3M'N?6N;C\1WK77A
MZ$QR;+Q(VN)?L[LKLR$X4@8'(R?P]ZZB\N(K6W:6XSY8X("%R<]MH!)^E5(=
M3TJ9[*&*:(M,"UO&$P?E'/&/EQR.<>E5#<&=+\,V*^$8SC_EXN/_`$:U.A\9
M1FZM;6XCMDENKDPQE+D,KKC[RD@;CGC`]^:/AB`?",8(!'VBX_\`1KUMVRZ5
M;JL=J+*(/(<+'M7<XZ\#J?UK3$?QI>HEL<MXZ_Y'3P;_`-?$W_H*5U^I/Y=A
M.V91A"<PKN<<?PC!R?PKD?'7_(Z>#?\`KXF_]!2NV-;5W:E1?D__`$IB6[.>
MTI[UVT]S)=-"_F^8LT3*P'\.[<`<CI[UG2ZAKV)H4@G;;<2;76!U95W/M&3P
MPP%Y`QR!UYKHM=OGTZQ\Z)%)W!<MD*N>YP.E<Z/%MU$KB2S,RP0K+(Z@ANJA
MA@]_FR/44Z2E/WE%,'H+'J^OVMN':S\Q8H$>3SHW#.Q7GYLX7!SGBMKPQJDV
MJV<LLYC8I(45DB:,,,#G:Q)'6HO#NJW.I3W4%]:)!)`0"$;>I![$^OM6S!!%
M;QB.")(D'144`#\!6=:2UBXI/R!=#B?''_(WZ1_UZ7'\TJ&IO''_`"-^D?\`
M7I<?S2H&(`))P!WI5?@AZ?JQK=F5XFFN8;2$65V]M/+,L4>U$8%F]0P/09/&
M*U5!4`%MQ`Y/K6<^M:4U@U^]S&UM#*4\W:2`X.,#CGD]JTA7.MAA7.3:O>)X
MQCL0_P#HA(C*[!U,;/\`7/'7ICBMV]N[>QM9+F[E6&&)=SNQX`JK%?Z=/J,:
MQ*9+EX@ZNMNQPC=,OMPN<="1]*%N!H4'/:BJMWJ%I9SV\-S.L<MRVR).I<XS
MQC^=`&1X8U6^O+VZM[W#JB+('7:5!+,NT%3R,*.O/6NAJEIUW83RSQV&T,K;
MI-L14,<XR#@!N1U&>E7:&".;U75]2L]4U"(+%Y,5H)8549;);!9OUX]JT_#]
MU-=V3FX?S&CF>(28`\P*<!N./RITU_IPO)[<E9+F*+?)&D9=PA/3`!)^GZ5)
MI-W9WMDLFG`B!24`,318P<$;6`(_*A;`]RT<@$J`3V!/>N4DUG6DTF[N&^S+
M+!?B!R,X2/<@P/4_-U-;^ISRIY-O`XCEN&*A^#L4#)8#UQTK%EF\/BU=UO9.
M9F0SQEW)D7DDX!!QU)QB@.AT_MZ51UZ>ZM='N9[!8C/'&S@R?=&!UQW^E.TF
MY:XMW65U>:!S%(R]"<`@_BI4_C4U]<VUI9RSWLB1VZ*2[/TQ_6D^HUT,"/5K
MJ35M*MH;I97G@66X@"*!&A7[Q;KDG&`,=^*Z6LJ.[T:34(5C6%KIE5HW\GD`
MC*C=C@XZ`G.*U:IDHP]<N+ZWUO1UBN%2TGG,<D87E_W;GEO3@<5E+=2-K'V8
M7S7UN+FSFCDWJX&9L'D``=.@KH-3U.VL9X1=V\A3>H$^P;(V8[1R3U)..,XS
MSBLIM3TZ]:!+"+RC]NMI20@7S5,P`<8Z@D'K@UT83^-'U%/;4]5\0ZC-I>ER
M75M;K<S*RJL32",-DXZGVJCX>\0R:O=RQ/!%&BJ61DE+$X;:=P(&.>G7(K8O
M5M6M7%\(3;_QB;&S\<\4EM!9QR/);10+)(`7:-0"P[9(Z^U<Q1R'AK_DJ7BO
M_KG;?^BQ7;5Q/AK_`)*GXK_ZYVW_`*+%=M77B_CC_AC_`.DHF)'=_P#'K-_N
M-_*N2^#G_(@V/^_+_P"C&KK;O_CUF_W&_E7)?!S_`)$&Q_WY?_1C4X?[K/\`
MQ1_*0/<[*@T45QE$4%O%;AA#$D89BS;1C)/4U+110!RWQ/\`^11G_P"N]O\`
M^CDK(-:_Q/\`^11G_P"N]O\`^CDK([UT/^#'U?Y(2W,:_P!!2ZN[N<>4%NK4
MV[(4/S'=G)P1GTJUH>GOIMB8))`Y+LX"C"H"?NJ.P%95Y?R)KES%'J,RVT$#
MO=R$+LMN!M`./O=3WXJ_X7GNKG25FO#(2[N8C*`',>?E+`=\5SK89J$`@@C(
M/45S=WX3$L$B1RQH?M3W$8V?*H9-F,`]NOUQ72/PI^;;QU]*XYM0O9-)U&XM
M=2G,43%K.5PBM<;4);&1RH//'84(9UUK$T%O%$\C2M&@4NW5L#J:CO[5+VTE
MMY`I#J1\PR`>QQ3[63SK6*0'(=%;.,9R/2J^N3QVVESS37;VD:#+2H`6'/09
M!Y/3\:&)%;3M(>UGLGDG$BVEH+=5VX^;C+?B!BM:N+L]=U3^VM"L;OSHEE#_
M`&@/"<R$HQ0$XQP`I..AKM*;$MS/U?2UU%[23*I);3K*&*Y)`Y*^V>*JZ'H+
M:9J5U=-.K^>""%3!;+%LL>Y&<?2F>*;N>W>SCLKF5;R:0+%;HH(DY&XMD?=`
MS2:!?R3:G=P73W!D8O)&K,AC\L.5&W;T/UH0Y,U[^`W-E-"I`,B%03V-<]+!
M:W5W--=O#:W#VC6TT,R8RQ*G=GC</E[=JZCZUR>OZE<VNIW*V$TEP;>W>6XC
M**8X1M^0#C.XGG&>F:E@6/"NF^1<M<H79%5PKMNQ(TA0L1NR<#RUY)[FNC;)
M!VGYNQK+\-W7VFTE5I9Y'BD,;^>%W`X!QE>".:U#T/:FP1RT?A>]9));N\AF
MOGF,OG^6V&!1DVD9X`5N`.]=)8VPL[.&V4Y$**@)[X&*Y1[ZZFLM2FM]0N7M
MUD2&UN,*#),3M(''*[BH_`UUMNCQP1I(YD=5`9VQECCD\4T!6UJWO+K39H-.
MNEM+B0;1,R;MH[\>M4;3P^EM)I<B"&-[$,K;%/S@@CJ3GN3SWS5[6YXK73)I
M[BZ:TB09:5,%@/09SR:Y6UU?5QJNFPWDLR!EB\U&"\;VD`WCJ6(5>G3!S3CN
M!Z7\-`3X0C`QG[1<#G_KJ]-L_"ES%>6UU-+:++#.TI,"/&-IQP%W;>@`Y!]>
MO-/^&9QX1CX_Y>+CC_ML]5[7Q/J[:E:6MU:V@26X=998P[)Y60%VG^]N(!SQ
MP<5IB/XTO5B6Q'XZ_P"1T\&_]?$W_H*5V]</XZ_Y'3P;_P!?$W_H*5W%;8C^
M%2]'_P"E,2W8E0W%M'<*4GC21,@[6&1D<C]:GHKC*$`Q2T44`<+XX_Y&_2/^
MO2X_FE0.H92K`%2,$'N*L>./^1PTC_KTN/\`T)*K2X$3DN(P%)W'M[UT5O@A
MZ?JQ(YK4/"(N].EM5O'M\W$D\?EHNQ=QZ%2#G`X&,=:Z5!M0*26(&,GJ?>N+
MFU36#I;76GW+26?VQ%6XG4!Y(L@$K@8P6)P<=*[85A8;*VIVB7]A-;.%_>(5
M!9<[3C@X]JR;;PZT&J6EVLL:^1&B.ZH0\@5"NTG.-O.<8Z@5?\07,=II4TTU
MU):HF#OBP6)[*`>YZ?C6+IU[J+ZGI=O+<3-=-%OO8"JA8DVG!.!]XMM_6A*X
M'55GZII:W]S93@JLEK,)-Q7)(P?ES6A6%XDNYX+NQALKB474T@"VZ*"K(&&]
MFR.`!^II+<!^@:"='N)F2?="Z[5C`QGYB=S>IYQGT%;1K$T:ZF;6[ZUDO&NH
M1''-"QVGJS`D%>V1C'7@UMT,#*ETAO[3N;ZUECADGM3#PG1\Y#'U[?E5W3;5
M;'3[>U0Y$,:IGUP.OXU@WVJSVFNW0MIKB[AMX&:>(1[DB<[?+48&23R3UX-6
M_!5]<:CH$<][*9;CS)%=BA7HY'0@4+5`3Z[(J>08\FY0EXTV,P<8PP.`<`@]
M:Y&_LC<631P6%VCM<22K`]KA$WJ%!R#CY>H(S]*[2X/_`!-X.=O[B3GTY6N6
M.KWK(98KJ[GTU9R1.AC221%C.\KG&5W8QCG@T+<.ATWA]`NG!C)YLKLQE<J5
MRX.",'TP!^%,UB6UO+6YL721V*%,B%G",1P>!C(J309%FLGE0DJ\TK`GJ07-
M5-0N8K2TU&>>ZDM4249>(`N?E7"J"#R>E#!&:+"V2_L[N0S*EHB%B()5+LBE
M<G^$C![C(]:ZP,&4,IR",@UQ*ZOJ`=8-6:YA;R$4JJIM9G5S\_?/RCIT(-=E
M:_\`'M%G^XO\JIZH5K&/K.B7>I:S9W+W$36-K\PMG4\R?WR0>2!T!XJA'H']
MD26<C3"15N;2WB`7&$6;<,\\GYOTJ?Q/._\`:UA::=-<G4)75O+25A''"&^=
MG`..1QSGVJK;Q!KR>XCFN'A75;:WC22XDD`V2+N(#$X^8GIZ5O@_XT?4);'K
MOB/3#J^DR68*#>RM\Y<#@@]4((Z=C3=(TK[!=SSF17,T4,;87&60,-Q^N1^5
M-\57U[IVBS7&EPQ37@*K$DN=I)('.WGIGIS57PYJVHW]Y<I>1VOV=8XVBDMV
M8\D<AL]#W`ZX(SBN5#9D>&O^2I>*_P#KG;?^BQ7;5Q/AGGXI>*_^N=M_Z+%=
MM7;C/CC_`(8_^DHF)'=_\>LW^XW\JY+X.?\`(@V/^_+_`.C&KK;O_CUF_P!Q
MOY5R7P<_Y$&Q_P!^7_T8U$/]UG_BC^4@>YV5%%%<904444`<M\3_`/D49_\`
MKO;_`/HY*R"0.3TK7^)__(H3_P#7>W_]')7)ZS*\DZ6C17'V9AOEDBB9MX_N
M#'KW]OK6\OX$?5_DA=3!NTT'5KRZN)1;6WE*Q20V^/.(QEV)&''3Y>>#GN*W
M_#5U97.G!;&"*V\MBLD$:>6$;O\`+@$>O(K#O+*>]U*ZFNXVF@,1AM8S;3`0
MKQV`')('.<C`J73[<Z5;)-:Q7<MV'9Y08),2JS9*Y(SQG@GW]:P]1LZIE#*5
M8!E(P0>015./1],CB,4>G6B1E@Y18%`+#H<8Z^]7%;<H;!&1G!ZBEH`*BNK:
MWNX3#=P13Q-U25`RG\#4M%`$,5I;0I$D5O#&D/\`JU5``GT].O:IJ**`*UUI
M]E>21R7=G;W#Q?<:6)6*?0D<5)#;6\$DDD$$4;RG<[(@!<^I(ZU+10`56&G6
M(NS=BSMQ<MP9O*7>>W+8STJS10!';6\-K$(K:&.&->B1J%4?@*>0""",@\$&
MEHH`J6^E:=;`BVL+6$,P<B.%5RPZ'@=15NBB@"*ZM;>[A,-W!%/$>J2H&4_@
M:CATZRA:$Q6=O&8`1$5B4>6#U"\<?A5FBFMP-;X9*&\(Q@C(-Q<<?]MGK;M]
M$TJU*&VTRSA,;F1/+@5=KD8+#`X..]8OPP_Y%*+_`*^+C_T<]=36N(_C2]6)
M;'$>._\`D=?!O_7Q-_Z"E=O7$>._^1U\&_\`7Q-_Z"E=O6U?^%2]'_Z4Q+=A
M1117&4%%%%`'#>./^1PTC_KTN/\`T)*SM4NH;2S=YT$@;Y1&>=Y/;\N?I6AX
MX./%^D'L+2X_FE<[%=22S37<UO<I.`R6\;6[E8QZG`Y)Z\=L#Z]%7X8>GZL2
M,FUGT;1K47,1A,4\N+J!8"J[L9#JFW@*,'.,;><UV*,KHKH0RL`05Z$>HK@I
M=$N+G3A'=M+)=O*\LLWV:4[V9=N[&WC;V'2NFTAVM[G[''%<&U*[D=X63RSW
M7D#@]1^(]*YQ]32N[6WO(?)NX(KB(G.R5`RY^AJ&'2--@G2>#3K2*6,821(%
M#*,8P"!QQ5RB@`JM<Z?974T<UU9V\\L7W'DB5F3OP2.*LT4`106T%N9#;P1Q
M&5M[E$"[F]3CJ:EHHH`K1Z?91W;7<=G;I<OG=,L2AVSURV,FIXHXX5VQ(L:Y
M)PHP,GDG\Z=10!2OK:>2YBF@6%P(WC9)<@$-CT!]*I1Z3Y4?EQ:3I")N#[53
M`W#H<;>OO6U10!6TZWDM[<K,4+M(\AV9P-S$X_6JEUI\L[W"/;6=U;S.'V7`
M+`$`#I@BM2B@#'DTZ=HE1+'38RD;1QLH.8P>H7Y>![5JPKLB1"<[0!^E/HH`
MJSZ;87-PMQ<65M-.F-LLD2LRXZ8)&1576(8XHK,11H@;4+=CM4#),JY/UK4K
M.US_`%=E_P!?UM_Z-6NG"?QH^HI;,]+N[6WO;=X+N&.>%^&CD4,I^H-16NEZ
M?9SRSVEC;033?ZR2*)59_P#>(&3^-6Z*Y4,XCPU_R5+Q7_USMO\`T6*[:N)\
M-?\`)4_%?_7.V_\`18KMJ[<9\<?\,?\`TE$Q(KO_`(])O]P_RKB/A'JNGP>!
M;*.:^MHW#RY5I5!_UC>]=U+&)(VC;.&!4XKS/_A0G@K^[J/X71_PK*%5*E*D
MUNT_NO\`YCMK<]!_MK2_^@E:?]_U_P`:/[:TO_H)6G_?]?\`&O/O^%">"O[N
MI?\`@6?\*3_A0G@K^[J7_@6?\*S]SS`]"_MK2_\`H)6G_?\`7_&C^VM+_P"@
ME:?]_P!?\:\^_P"%">"O[NI?^!9_PI/^%">"O[NH_P#@6?\`"CW/,#<^).J6
M$_A29(+VVD<SP':DJD\2IGO67_:%E_S]P?\`?Q?\:@_X4+X*'\.H_P#@4?\`
M"D_X4)X*_NZE_P"!9_PK3GAR*#3W%9W+']H67_/W!_W\7_&C^T++_G[@_P"_
MB_XU!_PH3P5_=U+_`,"S_A2?\*$\%?W=2_\``L_X5-Z?9_?_`,`>I/\`VA9?
M\_<'_?Q?\:7^T++_`)^X/^_B_P"-5Q\!/!7]W4O_``+/^%+_`,*$\%?W=2_\
M"S_A1>GV?W_\`>I/_:%E_P`_<'_?Q?\`&C^T++_G[@_[^+_C5<_`3P5_=U'_
M`,"S_A1_PH3P5_=U'_P+/^%%Z?9_?_P!:EC^T++_`)^X/^_B_P"-']H67_/W
M!_W\7_&H/^%">"O[NI?^!9_PH_X4)X*_NZE_X%G_``HO3[/[_P#@#U)_[0LO
M^?N#_OXO^-']H67_`#]P?]_%_P`:@_X4)X*_NZE_X%G_``I/^%">"O[NH_\`
M@6?\*+T^S^__`(`M2?\`M"R_Y^X/^_B_XTO]H67_`#]P?]_%_P`:K_\`"A?!
M7]W4?_`L_P"%'_"A/!7]W4?_``+/^%%Z?9_?_P``-2Q_:%E_S]P?]_%_QI/[
M0LO^?N#_`+^+_C4'_"A/!7]W4?\`P+/^%'_"A/!7]W4?_`L_X47I]G]__`#4
ML?VA9?\`/W!_W\7_`!H_M"R_Y^X/^_B_XU!_PH3P5_=U+_P+/^%)_P`*$\%?
MW=2_\"S_`(47I]G]_P#P`U)_[0LO^?N#_OXO^-+_`&A9?\_=O_W\7_&J_P#P
MH3P5_=U+_P`"S_A1_P`*%\%?W=2_\"S_`(4<U-:V?W_\`-3<^&VJ:?!X6CCG
MOK:-Q<3G:\J@X,K8XS73?VUI?_02M/\`O^O^->?'X">"O[NH_P#@6?\`"C_A
M0G@K^[J7_@6?\*=2<)S<M=02LB]XVU.PE\9>$7CO;=TCN)BY652%&U>O/%=D
M-9TO_H)6G_?]?\:\^_X4+X*_NZC_`.!9_P`*/^%">"L_=U+_`,"S_A55*L)P
MA"WPJWXM_J"5CT+^VM+_`.@E:?\`?]?\:/[:TO\`Z"5I_P!_U_QKSW_A0G@K
M^[J/_@6?\*7_`(4)X*_NZE_X%G_"LO<\P/0?[:TO_H)6G_?]?\:/[:TO_H)6
MG_?]?\:\]_X4)X*_NZC_`.!9_P`*/^%">"O[NH_^!9_PH]SS`N^,]1L9?%FE
M217D#HMK."RR`@$E,#.:B_M"R_Y^X/\`OXO^-0?\*$\%?W=2_P#`L_X4G_"A
M/!7]W4?_``+/^%:RG"2BK/3S%9EC^T++_G[@_P"_B_XT?VA9?\_<'_?Q?\:K
M_P#"A/!7]W4O_`L_X4O_``H3P5_=U+_P+/\`A47I]G]__`'J3_VA9?\`/W!_
MW\7_`!H_M"R_Y^X/^_B_XU!_PH3P5_=U+_P+/^%'_"A/!7]W4O\`P+/^%%Z?
M9_?_`,`-2?\`M"R_Y^X/^_B_XT?VA9?\_<'_`'\7_&J__"A/!7]W4O\`P+/^
M%`^`G@K^[J/_`(%G_"B]/L_O_P"`/4L?VA9?\_<'_?Q?\:3^T++_`)^X/^_B
M_P"-0?\`"A/!7]W4?_`L_P"%`^`O@K^[J/\`X%G_``HO3[/[_P#@"U+']H67
M_/W!_P!_%_QH_M"R_P"?N#_OXO\`C4'_``H3P5_=U'_P+/\`A2?\*$\%?W=2
M_P#`L_X47I]G]_\`P`U)_P"T++_G[@_[^+_C2_VA9?\`/W!_W\7_`!JN/@)X
M*_NZC_X%G_"C_A0G@K^[J7_@6?\`"B]/L_O_`.`&I8_M"R_Y^X/^_B_XTG]H
M67_/W!_W\7_&H?\`A0G@K^[J7_@6?\*/^%">"O[NI?\`@6?\*+T^S^__`(`]
M2?\`M"R_Y^X/^_B_XT?VA9?\_<'_`'\7_&H/^%">"O[NI?\`@6?\*/\`A0G@
MK^[J7_@6?\*+T^S^_P#X`M2?^T++_G[@_P"_B_XUGZW?6C1V6VZA.+ZW8XD!
MP!(,FK'_``H3P5_=U'_P+/\`A2CX"^"O[NH_^!1_PK2E4ITYJ:3T\_\`@"=V
MK'H/]M:7_P!!&T_[_K_C1_;6E_\`02M/^_Z_XUY]_P`*$\%?W=2_\"S_`(4?
M\*$\%?W=2_\``L_X5A[OF,U/"D\4_P`3?%,L$B2QM';8=&!!_=CO7=YKE_!/
M@#0_!8N1HB7`-UM\QII2YXZ`?G73X%:5ZJJR32Z)?<K`E86BBL/Q>VM+I\?_
M``CT<CW1D'*M&`!_M;QT/M@UB,W*Q->MM5W+/I-TXD\Q"8FQY>U<DCIGYN`3
M]*Q5?QEO.Z.?HQ`VV^W=W[YV_P!WOG[U%N?&,SK;S">"-F_X^2+<NL?&,@9&
M_&2<#;Z>P*X:3'XBN/)743?P321GS2'7RU4KP!CGS`W?I3;"UUZVUBQ^T76H
MR6RVJF4%1(&E._=EMX`Q\O!5NW-,AM_&(8N9YT8J)&!\DJ6VYV`=E+<>O7!J
M72=0UV_TO4VAEFEFCN5C1D6$D#C>(_X3CMNY]:+Z7!O6Q=U&'7CK,EW:/*+2
M*!2$$P#2-M;($97;G)7DGC'0UE6&H>+[F1;.5A%,JK)*P6-G0&0J`>,<H-V<
M#Z4^X_X35+=U@28R;&(_U!&=YQ@L3\^,8S\N/>D$OCGS&9[=@GGQ?NT>`GR\
M'=\Q'TSQGKC%'D.^A=T:3Q++?0-?B98-K!RZHIW;3U"\?>Z>P%4H+SQNT1:X
MM_+<28142,[N,C=D\+G`)'-:FKWNL2:EIZZ7%<^4\+R2Q%8UZ%0`Q;D<$XQW
MZ\5C077C+BUF:03F)I67$)F51+@<@"/<4)ZX&4]S0MPZ&AH+>*EU*]75&=X)
M+97MW94`2;'*X';ICZ&JD%]XZ<VQDLHD#3G>IVC:AP0#@'@`E21@Y7.:K_:_
M&5I+;AQ*J'R8<3F%_,=L!B-HW#&2QR2/D]*TP_BH>%[D/#<'5?.*Q,KP`[<\
M'&-H7V.6Q[T7`@T*X\8RZM8MJL&RT9)5N`I4[6R-G8<=>G;'/6I9KGQ;;IM5
M&N6DD&&$<8\M2RY!YZ!=WO4$D?C-K1`\DY>5U9A$(`8QN;*Y_NX"Y/+<\5;U
M2+Q-'?7DEA)</;22#9''Y)9%"IRF_N3NR#QP>/4\@6C*EP_C&)(CYTTQ+@GR
MX8@1\AX]"-Q`/L*1[CQO(ET2@@9)',8C"/N`'R@;EZ'CU.>]-GC\9K$3MG9F
MDW%87B_ODXRQX7;Z<YQVS4,=WXT(>U&\7!BDF56$!E50P"@D#9D[C_WP:?D#
M-+6+CQ7_`&?:S:;&ZS"W4RPDQDF0D9YVGD#T`')JB3XV@NI$C=I4FCDDWML(
MCDP0%4;>@PI&3W.<]NMM5N;S2$2^CFMIVB"R`2`,&QR0R>^>1BN8:P\5V,,1
MTZ:XE=;-0R7$RR`S'S"3ELG(/E]#CGOV2=F!<U4^(K?5P+!KB>W9(QG9&5+#
M.<YP0#U)'MBH-8;Q4NKW*Z:CM:ETEB?*X`"@&/!YP22W_`?>H+0>./-M7G+E
M&F02H1!\L>U<DX&3DE\X.>!C`JUJ8\62ZU=)IXE@LAM\IV,!4D#/'&X`G`.<
MGKC%%]@(O.\7&W,JF;;]T(88O,*\G>>V_@8'3G\J1U3Q?91+)+%)MC101<>6
M/.D+@!1M&02"1U/(%7Y8?%4WAFU,BR_VH)R64.B';S@L5(!`.#@=0.15O6HM
M;&H3R64=XY"'[,T4T:Q*-G(9&/S-NZ<8Z<CG(*Q7U-?$L>LN]A/.\*1HVW9'
MY;M\H(YY_O'^53:1/XC^TRV]^DKQB!G6<I&N7*IM48[@^9V]*JA?%NT3M<2Q
MJ@!\ID@)8`K][`ZD;L[3C(XJM]H\9RVUJULEP2Q)9Y?LXRI`^\H'9ONX(X^]
MD]1=4'9CVF\4I;VT%G%?DM*PDEF,6=F!R002.22`#V_"FQW/C%TCB2*>(0PL
M6D>.(M(VTX&,_3TYK3TF775UDV-[<>?#'`96=E0/NW,J@[0!R.>/[M9YA\:0
M)'F;[1(8XAF)$10VT[@X=V.,_>9<$\8I(-M2M+J?BZR@\YXY?*BA+L]R(@)'
MWC:N%&0S#Y>O<8%:VN?\))*T<%C+-$LD`#RQ)'A6(.X@GD,#MQVZUFHGC&-D
MW"]=5C<XBD@Y8[@"2^26'!`QMQ38;SQG(%C_`-9-"8#<+'Y08%E^==Q&W@@'
MCG#?D_(IZ&AJ">)(=<W:?+/):H@.UU0H_P#JQ@GK_?.:2SF\53Z#$]W&8M0\
MYMRIM^[^0&,_I4>KS>)YM0ODTH2F.+`C#"()G"D!2?F/5L[N.F*L:=+XGN-4
MG^VP3P6<D#^7\T/[MLG;G&26QCOM^M&Z$M!EC-XNCU+3XKI1-:LQ-Q*512`5
M4XPH[$L!@CISFH7F\8/J<[(CI##(YC!\O9,I9=JXQD#;NYR3Q^%06EMXTBMH
MT%Q<9;<S>=Y#%2`VU<X/#';GK[8JWX??Q<=3LO[80"T\EO.)\K.[+8W;>=WW
M?N\8SD9HM=!W(5O/&GG6B)`7A=QYKRI&KJO`.0#CJV1CLG/6K$UWXBM=#C-Q
M)*][+/&H,<,9?!3+*!]WALC)IBR:SYJ77^DJ#;D2YDRAFWC@+NXP=R_=''?M
M3-9N/%;7E^-%61HT<*NX0@`?+_J]W)/+9W<8QCFCR&MR.ZO?&<5J8X[1VGV;
MRZ!"H.>5!/?KC@\8Z]*MZH/$DE[9RV+W$*^2K2QXC9`P5\J<CJ3M''X8JG*?
M&J3@@SS)(DA81_9P(CNXVAADG:.,G&3R<<5++_PF*V=Q(#.\KH%BCC^SJ4.(
M_FR003DOD'CCCM3?8GI<GMIO$MQI&H_VC'+#.)P(1:[2_EYYV_=[>Y/7FF)<
M>*I&BMECFMU(!:=EC<JN%]>K9W=O3K4UP/$_]D6WEK*+MF<S",QDC/0'<<!>
MO3GICO5+RO&<:"`--+B,A9"81N.#G>1@Y!VA=N!UW9XI!T*]U>>-@[/%!<&4
MQ@*BK$L2MP>^201G/OT(K2AU'7[G09IX?GG6Z:)&@5&+1J2N\`\<L.?;.*;8
MMXN_M2Q%Q&_V3S'^T%_)SC`Q]WG;G.TCGINS4;Q^+X)BD+32QLY=2?).TEFP
MK$\[-N#QELD8/:GLAK74==V_B5=)B:*[NVO9+R1I-HC(2,A@H'&-HX/KSWJ3
M3+CQ8;ZXBOHE\A+=O*DPOSN"0IP!P3U/./851D3QA%-%\MX\:\E8I(,']T0<
MEB3G?C`^[ZU%%>^-7C>`9DN+=8FE5/)#DL3E2Q&T<+DD#^/H*+:6"^ERU-<>
M-(K@1H@FB6"0B4J@+R?-MRN,?W>X'7-3Q?\`"2MI$[2-/]N>X1@-J*%3RUW!
M<=@V>O-/U6W\21ZS+<Z=+=/#*R!8BT1B0`+G(;D`Y?)'.0O:FWX\60KI8M?,
MN1Y)-XP,*L7QT.1CUQM[XSD9I,KJ1K<>,(;FQ#H)X'<-<,512H(&4P`<@<]P
M<XYK1\16FISSBXTVXO(R+2;$:2`+YNT>7E?7)/M6/:IXTN($BO6N+=SQYB?9
M^%\P_,2/X]N.@VXSQFK5^WC%CIXM$5<V?^D$",XGVG.0??&-IQUS39*[C],G
M\5IK<4%Y&)+%8W!F;:"Y!.,A1P?N]P.O%59KOQ<3;)%!<G+OYS.L2*%QQC&3
MPW0Y''7-+.WBNVNH;=;B>X\V0E6V0#@9&&.!A<`$X^;)X]*9=7'BRS4MN()D
MBBC241LDA8A?E(RW`)8[NZ\<9J>MA+4?I\_C652UTJ0LCL=@",'Y4!<X&%P6
M/'/'4U5ANO&WF;$BNR&9LR3)"``5XPH!Y!'KC!Z&K-BWC?S+(72#;]I87!_=
M$[.,=/X?O8Q\W3-:UI%KRZ](\TK_`-G^<RK&=A&S:2&S][[P`QGN>/1]1[E7
MQ%)XH@NQ_8[&:)4B7#*@W-EM['Y2>R9`QP3C'6LV'_A-+*\CCC:2[AEE=W>X
M9/ER.%`"_=';ISU-2VEOXA>^MW:'58H?M1)$MS$=B[DRS8<[E*[\#'!(X[UH
M6">(X;^P^U1236D4,@G83)O=R3C*\=L8P>YH0,H6T_BQ=4M6>.ZFMI'42B1(
MH]J\\G&<>^.O'(IUW_PEL&K:G+8F::#<!;Q2B/805;D'&>#MZ_K6[KVGW-Y)
M9-;2W47ES9E$%P8P4VMU`(S\VVN;*^.K>"VBA+3[8#ND?R=Q?RQPWJ`V0"/Q
MR*3=PV.L\/R7\FE6[:L`MV5_>`>N>_`&<>@%:-<KIW_"3PC5EOA+<+''BS8&
M%7D;!Y!``!Z?>&,^U9L(\=;+61R^XR(LJ-Y'"\Y8X'.>^"/;%/J&QWE%(.@I
M:`"BBB@`HHHH`0CB@#%+10`4&BB@!`.:",TM%`#=O.<TZBB@`I,4$XJA_;FF
M?\_D1^AH`OXI`N#FJD6KV$TR11W4;.YPJYY)J[0`4444`%%%%`!5;4C,FFW3
M6I83B)S'M4,=V#C`/4Y[59II.`<\`4`<CX>O-:FODAO)KYBMLQ8W%GY<;OGY
M6!"#![E21U`QG)JHFM>,7$9.D1P@W(3YXWXC/^Z&/L3T'K7:P313`F&1)!W*
ML#4N*`//HM8\:O=P-+IRB$K<"5(X6.U@%\O[P7/.X9!P16A<ZOXA71])E@L'
M>\FE5;E#;MM"[@&/8KP21D#I78XHP*`.-M;_`,3_`&[3X;N/$;2CSGCM3AE*
M@D$Y.S&<9[D5'->ZZ^JE;:;41;K=[2CV(`9?0-LX0_WN>G+#(%=K@"EP*`.8
MU.YUNVT>22'S'N5O&4;;;S"8MQQ\@[8QSGWK-:^\7"9RL,B_ZTJIA#*#M7:,
M@`D;MW?FNYP*3:!0(XZTUS61X@72[P1-(('DV+"07P/E?.2%R>-OXYYJDFN^
M*8@&>W8KO=G>>T:)%01@CG/&'R.3SU'MW@AC\PR;!O(QNQSBG,BLI5AD'L:$
M,X_2M7\17B7AN+-H0UDL]L5A^Z[#.S)R&/../0Y`XJ>6\UN/1KZ2[%PLP<>0
M;.UW2!22,;2&!Z#)P>#TKJL`#CC%16\T-PK-#(D@5BK%6!P1U'US1<#DK*Y\
M1,+D--=/(H0CS+143[X^Y\H)RN2<DX/ITK7T*\U*>_ODU2TGMD\[%N&5"NP+
MV9&/U^;'7&.*V\"C`H`6BBB@`HHHH`0C-(%IU%`"8I:**`#%%%%`";:",TM%
M`"`8I<444`)BEHHH`*,444`)BC%+10`4444`%%%%`!1110`4444`%%%%`!11
M10`4444`(_W3]*HZ`!_8UI_US%7B,@BLNVTR]M8$@AU,B-!A08%.!0!)K./]
M"Q_S])_6LO7?$=SIMW<0164LXC2)A(JY52S8.XY'Z"M(Z;=2S0-<Z@TJ0R"0
M((E7)&<<_C5Y[>*0MOB1M_#94'(]Z`.0OO%=_:V#WP-E)'()A';@-YD1CW<N
M=WS?=Y&%QGJ:T-=UR\@U&ULM/EM(S<X_?3(9%3DYX#+GIZ]ZV6TRQ:2:1K*W
M+SKME8Q+F0>C''(^M1'1-+^S"V_LVS\C_GEY";>N>F,=:0=3G)/&<UNUC'+`
MLI:5TNI(8I&145S&)`1D*"?F^8XP#R>M;FEW][=ZA<V\T4:):?)(X_Y:,>5*
M\\#;R<YY..V3?2RMD0HEO$J%0A4(`-HZ#'I[5+'&J%BJJI;J0,9I@.'2L::W
MCU76;B&]426UFJ;8&Y5V8$EF'<=`,]P:VJS=0TV6:Z%Y8W`M;Q4\O>R;UD7)
M(5UR"0"21@@C)YY-`%;6]+M(K2:_M(4MKNVB9XYH5"MP,[3CJI]#Q4&O:QJ%
MMI>FS:?&OGWLJH5,!F*@QLYPH=,GY<=:M3:7?7Y$>J7D;6P(+0V\93S,'.&8
ML3MZ<#'OD5J&%#L)124.5)'0],B@#EH/%-Y_;5KIMW;"%I(@DT@B<HD[#*C=
M]T#`Y4MG+"K(UR__`+%U;4'MHXFL8I`B'+;Y44ECU^[G`'0]:WC;1'.8H\,P
M<C:.6]?K[TIMXC&\?EIL?.Y=HPV>N:`6YQ<GB'Q'%]EBD@BC><N0YL225`'_
M`"S\\8Y/7<<^@J23Q/JT.LSVYC@:W1VC4FW9`Q$(<_O/,(SD_=V],\\5U5[I
MMEJ"*M_9V]TJ<J)HE<+],CBG?8;?R_+^SP[`00NP8R!@<?08H%J<W#XCO9)!
M/NM!`LT<#6Q5O.<L%.]6W8`^;IM.0#S5CPMK=_?RVJW[6DWVNT^U`VT;)Y/*
M_(P+-G[W!XZ'BMO^S[4W*7)M8//1=BR^6-RKZ`]<46.G6=AN%E:06P<Y80QA
M-Q]\4(9:HHHH`R-8N9Y)4TRP?;<SC+N#S#%T+_7L/4_0U7FM$\/.EU9H4L2H
M2Z0?P@#B7ZC^(]QSVJQ#I%U!=74\.I,&N9-[;H58@=E'L!_7UJ5['4'&UM3R
M#P0;=:`(?%6I7.F>';J_TY(Y[B,+Y2/G:Y+`=C[UAP>+;R^N?+LTM889WBC@
MN)@S*I*.7+`$9PR%``1SWKH]*TL6.G+9S3&Z1&)7S$'`SD*!Z#M4[:=:/"T#
MVD#0N-K(8E*L,YY&/6@#D+KQG?6@NFF@MY(;2!R]Q'NV&0,54@9/R'&#SP>Y
MJ]<ZQK-E+>R3O:74%O)`JQ06KK(PD8?Q&4@D`^@R?3I71"QMEB\M;:$1[/+V
M[!C;_=QZ>U/-O$V=T2$D@D[1R1T/X4P9@:5XCFO-4^S30?94+2J!,-KC9LQG
MG'\1_2KFG:I=3WEY'=Q1PQ6'R3/G[S8#`KSPNP@G/<X[5<N=*L;IE:ZLK:<H
MV]3)$K$'U&1UXJP;>,AP8D(D^_\`*/FXQSZ\<5(')6/C&XU"W*QPI9W$ERL<
M37,,BHD3!BCLK;2WW<<$`DCFK"Z]?/.T8N]+06J*\SMN*SY=E(3YOEQM[[N3
MCWKH9[&UN(V2>VAE5E"%70,"OISVIITRR;R`]G;D6W^IS$O[O_=XX_"F!S-Q
MXGU"*W:[46DB2"<16RJWFQ&-6(+G=\P.WD87&1R:GO\`Q/<6^K)#;PQ7-JNP
MRLA)8*49F([$C`./3/M70I86J7$EPEM"LTHP\@C`9QZ$XR:2VT^TM8Q';6L$
M*@DA8XPH!/4X'K0(YNRUS5[YM-GAN+!;6\LGNRGV9V?Y=G`;S`,'?UQQCO4%
MCXQNY7A2ZM8T^T2HD+)DB0>6&<>S`G\1^-=<MI"@4)#&H12J@*!M!Z@>W`_*
MA;2!0H6"(!6W*`HX.,9^M`V<_HGB"ZNKWR;LP2>=:_:XA!&0%'&4+%CN(SUP
MOTJ"/Q)>+%:SSSZ<Z7DL(6*/<'A5Y`I#'<0Q&>N%YXQ72V]C;6SR/;VT,+RG
M=(T:!2Y]21UJ%]&TUTF5]/M&6=@TH,*D2$<@MQSSZT`8]_K]W#>W+0/:&VM)
M(XVA8$RS[PO*-N``^;CY3G!Z51NO%&IPQ7`S:-,2&MQ%$9!L\P*3D28DZCNG
M/;O74+I5BKPNMC;*]N-L3")08QZ*<<?A2-H^G,)E;3[0K.<R@PJ?,/JW'/XT
M@&Z'<7-UI\<MZ5,QSNVQ>4.O]W>^/^^C6A4%G9V]E"(;."*WB7HD2!5'X#BI
MZ8!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444
M`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`
J4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`?_9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>g838054gra15.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g838054gra15.jpg
M_]C_X``02D9)1@`!`0$`5P!?``#_X@Q824-#7U!23T9)3$4``0$```Q(3&EN
M;P(0``!M;G1R4D="(%A96B`'S@`"``D`!@`Q``!A8W-P35-&5`````!)14,@
M<U)'0@``````````````````]M8``0````#3+4A0("``````````````````
M`````````````````````````````````````````````!%C<')T```!4```
M`#-D97-C```!A````&QW='!T```!\````!1B:W!T```"!````!1R6%E:```"
M&````!1G6%E:```"+````!1B6%E:```"0````!1D;6YD```"5````'!D;61D
M```"Q````(AV=65D```#3````(9V:65W```#U````"1L=6UI```#^````!1M
M96%S```$#````"1T96-H```$,`````QR5%)#```$/```"`QG5%)#```$/```
M"`QB5%)#```$/```"`QT97AT`````$-O<'ER:6=H="`H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0``9&5S8P`````````2<U)'0B!)14,V,3DV
M-BTR+C$``````````````!)S4D="($E%0S8Q.38V+3(N,0``````````````
M````````````````````````````````````````````````````6%E:(```
M`````/-1``$````!%LQ865H@`````````````````````%A96B````````!O
MH@``./4```.06%E:(````````&*9``"WA0``&-I865H@````````)*````^$
M``"VSV1E<V,`````````%DE%0R!H='1P.B\O=W=W+FEE8RYC:```````````
M````%DE%0R!H='1P.B\O=W=W+FEE8RYC:```````````````````````````
M``````````````````````````````````!D97-C`````````"Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92`M('-21T(`````````
M`````"Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92`M
M('-21T(`````````````````````````````9&5S8P`````````L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0``````````
M````+%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$``````````````````````````````````'9I97<``````!.D_@`47RX`
M$,\4``/MS``$$PL``UR>`````5A96B```````$P)5@!0````5Q_G;65A<P``
M```````!`````````````````````````H\````"<VEG(`````!#4E0@8W5R
M=@````````0`````!0`*``\`%``9`!X`(P`H`"T`,@`W`#L`0`!%`$H`3P!4
M`%D`7@!C`&@`;0!R`'<`?`"!`(8`BP"0`)4`F@"?`*0`J0"N`+(`MP"\`,$`
MQ@#+`-``U0#;`.``Y0#K`/``]@#[`0$!!P$-`1,!&0$?`24!*P$R`3@!/@%%
M`4P!4@%9`6`!9P%N`74!?`&#`8L!D@&:`:$!J0&Q`;D!P0')`=$!V0'A`>D!
M\@'Z`@,"#`(4`AT")@(O`C@"00)+`E0"70)G`G$">@*$`HX"F`*B`JP"M@+!
M`LL"U0+@`NL"]0,``PL#%@,A`RT#.`-#`T\#6@-F`W(#?@.*`Y8#H@.N`[H#
MQP/3`^`#[`/Y!`8$$P0@!"T$.P1(!%4$8P1Q!'X$C`2:!*@$M@3$!-,$X03P
M!/X%#04<!2L%.@5)!5@%9P5W!88%E@6F!;4%Q075!>4%]@8&!A8&)P8W!D@&
M609J!GL&C`:=!J\&P`;1!N,&]0<'!QD'*P<]!T\'80=T!X8'F0>L![\'T@?E
M!_@("P@?"#((1@A:"&X(@@B6"*H(O@C2".<(^PD0"24).@E/"60)>0F/":0)
MN@G/">4)^PH1"B<*/0I4"FH*@0J8"JX*Q0K<"O,+"PLB"SD+40MI"X`+F`NP
M"\@+X0OY#!(,*@Q##%P,=0R.#*<,P`S9#/,-#0TF#4`-6@UT#8X-J0W##=X-
M^`X3#BX.20YD#G\.FPZV#M(.[@\)#R4/00]>#WH/E@^S#\\/[!`)$"800Q!A
M$'X0FQ"Y$-<0]1$3$3$13Q%M$8P1JA')$>@2!Q(F$D429!*$$J,2PQ+C$P,3
M(Q-#$V,3@Q.D$\43Y10&%"<4211J%(L4K13.%/`5$A4T%585>!6;%;T5X!8#
M%B86219L%H\6LA;6%OH7'1=!%V47B1>N%](7]Q@;&$`891B*&*\8U1CZ&2`9
M11EK&9$9MQG=&@0:*AI1&G<:GAK%&NP;%!L[&V,;BANR&]H<`APJ'%(<>QRC
M',P<]1T>'4<=<!V9'<,=[!X6'D`>:AZ4'KX>Z1\3'SX?:1^4'[\?ZB`5($$@
M;""8(,0@\"$<(4@A=2&A(<XA^R(G(E4B@B*O(MTC"B,X(V8CE"/"(_`D'R1-
M)'PDJR3:)0DE."5H)9<EQR7W)B<F5R:')K<FZ"<8)TDG>B>K)]PH#2@_*'$H
MHBC4*08I."EK*9TIT"H"*C4J:"J;*L\K`BLV*VDKG2O1+`4L.2QN+*(LURT,
M+4$M=BVK+>$N%BY,+H(NMR[N+R0O6B^1+\<O_C`U,&PPI##;,1(Q2C&",;HQ
M\C(J,F,RFS+4,PTS1C-_,[@S\30K-&4TGC38-1,U336'-<(U_38W-G(VKC;I
M-R0W8#><-]<X%#A0.(PXR#D%.4(Y?SF\.?DZ-CIT.K(Z[SLM.VL[JCOH/"<\
M93RD/.,](CUA/:$]X#X@/F`^H#[@/R$_83^B/^)`(T!D0*9`YT$I06I!K$'N
M0C!"<D*U0O=#.D-]0\!$`T1'1(I$SD42155%FD7>1B)&9T:K1O!'-4=[1\!(
M!4A+2)%(UTD=26-)J4GP2C=*?4K$2PQ+4TN:2^),*DQR3+I-`DU*39--W$XE
M3FY.MT\`3TE/DT_=4"=0<5"[40914%&;4>92,5)\4L=3$U-?4ZI3]E1"5(]4
MVU4H5755PE8/5EQ6J5;W5T17DE?@6"]8?5C+61I9:5FX6@=:5EJF6O5;15N5
M6^5<-5R&7-9=)UUX7<E>&EYL7KU?#U]A7[-@!6!78*I@_&%/8:)A]6))8IQB
M\&-#8Y=CZV1`9)1DZ64]99)EYV8]9I)FZ&<]9Y-GZ6@_:)9H[&E#:9II\6I(
M:I]J]VM/:Z=K_VQ7;*]M"&U@;;EN$FYK;L1O'F]X;]%P*W"&<.!Q.G&5<?!R
M2W*F<P%S77.X=!1T<'3,=2AUA77A=CYVFW;X=U9WLW@1>&YXS'DJ>8EYYWI&
M>J5[!'MC>\)\(7R!?.%]07VA?@%^8G["?R-_A'_E@$>`J($*@6N!S8(P@I*"
M](-7@[J$'82`A..%1X6KA@Z&<H;7ASN'GX@$B&F(SHDSB9F)_HIDBLJ+,(N6
MB_R,8XS*C3&-F(W_CF:.SH\VCYZ0!I!ND-:1/Y&HDA&2>I+CDTV3MI0@E(J4
M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY`
MGJZ?'9^+G_J@::#8H4>AMJ(FHI:C!J-VH^:D5J3'I3BEJ:8:IHNF_:=NI^"H
M4JC$J3>IJ:H<JH^K`JMUJ^FL7*S0K42MN*XMKJ&O%J^+L`"P=;#JL6"QUK)+
MLL*S.+.NM"6TG+43M8JV`;9YMO"W:+?@N%FXT;E*N<*Z.[JUNRZ[I[PAO)N]
M%;V/O@J^A+[_OWJ_]<!PP.S!9\'CPE_"V\-8P]3$4<3.Q4O%R,9&QL/'0<>_
MR#W(O,DZR;G*.,JWRS;+MLPUS+7--<VUSC;.ML\WS[C0.="ZT3S1OM(_TL'3
M1-/&U$G4R]5.U='65=;8UUS7X-ADV.C9;-GQVG;:^]N`W`7<BMT0W9;>'-ZB
MWRG?K^`VX+WA1.',XE/BV^-CX^OD<^3\Y83F#>:6YQ_GJ>@RZ+SI1NG0ZEOJ
MY>MPZ_OLANT1[9SN*.ZT[T#OS/!8\.7Q<O'_\HSS&?.G]#3TPO50]=[V;?;[
M]XKX&?BH^3CYQ_I7^N?[=_P'_)C]*?VZ_DO^W/]M____VP!#``@%!@<&!0@'
M!@<)"`@)#!,,#`L+#!@1$@X3'!@='1L8&QH?(RPE'R$J(1H;)C0G*BXO,3(Q
M'B4V.C8P.BPP,3#_VP!#`0@)"0P*#!<,#!<P(!L@,#`P,#`P,#`P,#`P,#`P
M,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,##_P``1"`*"`<L#
M`2(``A$!`Q$!_\0`'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`
MM1```@$#`P($`P4%!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*Q
MP152T?`D,V)R@@D*%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA9
M6F-D969G:&EJ<W1U=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*S
MM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ
M_\0`'P$``P$!`0$!`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#
M!`<%!`0``0)W``$"`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1
M"A8D-.$E\1<8&1HF)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI
M:G-T=79W>'EZ@H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZ
MPL/$Q<;'R,G*TM/4U=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1
M`Q$`/P#W^BBH+Z\@L;<SW3B.-2`6/J3@?J:`)Z*SY=;L(;Y;.:4QS/D(&4@-
M@$G!Z'@&H%\3:486E-R4C$1GW.C*&0=6&1R/I3LQ71KT5G-K=DK6Z,T@>Y!,
M:>6VX@=3C'`Y%`US3S<B`3_.SF-3M.TL.J@]"?:BS"Z+TLL<2AI75`3C+'%.
M#`]"*RK76-+U?RX8G\U;B,RQAXR!*@QDC(Y'(_.N:^(-A'H?A^;4]+$\1A9=
M\<=U)&I4G'`4^XJX0YGR]69SFX+F2T.ZS1WKS[X<:GXGU;2K>Y6.Q&G,[#S+
MB>66<@-@]>.QZFO0:F<'"7*RH2YX\R%HHHJ2PHHHH`***,TK@%%%)GVI@+11
MFB@`HHHH`****`"BC-%`!11FB@`HHHH`***3-`"T444`%%%%`!129I:`"BC-
M%`!11FC-`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%9GB33Y=
M4TPVD+*N^1"S-V4,"<>IXK3HHN&YS$VB627HDD>Z;9</<`>7NR[JRGYL9(`8
MX%.@TJQ2.U\D77^C6S6J;HL@J<9R",'H*VKK3[:Y!$L>0S!CR>2.E1KHVGJ/
MEME'T)I\TAJ,>IB_V'8O8QVGF702*4R#]W\P);=\IQE<>U2V6EV5K<O-!'<;
M9':0J;?)#-UPV,]S6HNBZ>"3]G!))/)/>K-K9V]H"+>,(#UP:.9@XQZ&;INA
M6MD-,>%YO^)?;M;Q!NZMMSGW^05A>/H;WQ+$/#^DH0KNK75RP^2-0<[<]SG'
M`]*[7`H"J.@Q51FXRYNJ,IT^>/+?0SO#ND0:%HUKIMK_`*JW3;D]2>I/XDDU
MI48%%2VV[LM))604444AA1110`&L_7=5CT;39;R:*68)@".)=S,2<`#\:T#6
M5XGUJW\/Z-/J-URL0^5>[L>@%73BYS44KWZ`9MAXP1Y[NWU>QETNYMK?[4T<
MCJ^8N?F!7Z=*70O%RZG?PVMSI\]B;J(SVK2LI$\8QD\=#R.#7&Z?'_PD&D:[
MJESJ-K=:S>V;+':03*Q@B`R%P#UJ_H]S!K&O^%EL)1,=/L'^T[/^69*JH5O0
MY!XZUZ\\)22EIJKW\FE?\7H9<S:NCJ+'Q=8:AXHDT2R_?M%"97F5OE!!`V^_
M6J__``E5]<:S>6.F:'+>QV<HBEG%PB`$@$\-SQFLVPL+33/B9';6$"6\*Z4V
M$08'^L%8&M?V-;F^N="N+V'Q'_:'RPR2D.SEQNQ&."A&><5G##492M%/5+SU
M?5VMH4V[,])U[5%T?1;K4GB,JVT9D*`X)QVS5'6O$Z:5H-KJC6S2+<-&HC#8
M(W^_M3?&5O/>>"M2A1"T[VK?*.I.,XKAM9\2Z=K_`(:TC1=-:674?.@5H/*8
M%-IYR<8K+"X554FU=<VODK`W8]2:\MT+"2>)"F-V7`VY]:@N;^2&]M(4MQ)%
M<!B\OFJOEX`Q\I.6SGMTKA)M*LM3\9^*A?P+,(K2,HK9P#LZ_7WJIX?=YSX#
M,S&0F*Y!W<Y&%I_4H\O-S=/SBW^@.5CTXW<`A$QFC\H\;]PP?QI3<PB41&6,
M2,,A-PR?PKRNWL[A]>C\%,C_`&2VOC>EL<&`#<J_]]''X5F7$$D^I:H+_4K"
MQOUOV$3312-<@;OE\O:?NXQT'2K67KK/I?;H]A.9[,UY;K)Y;3QA\@%2X!R>
M@H2Z@:4Q+-&9!U0,,_E7`Z/I=M??$#7Y-0C6>2WCMV1F4G:_EK\P'K7.Z:;?
M3->LF@;3]8,EZ`KQL\5ZA+=77()`]&&*A8&,FTI:V3V[JX^8]@>Z@241/-&L
MAZ(6`)_"L^TUQ;CQ'>Z.("K6D22F3=D,&[8KRGQO>VEV=6G@M;2TO+>Z"[Y9
M':Z;!'S*#]U?IQ7<^'3N^(>KMG=FQMCGUX-.6!5.DYR[?Y?YCYM;(U?$_BFW
MT$PP+;3WU[<9\FV@7+,!U/L*9X7\5)KLD]O+87.GWEN`9()U((!Z$'O6+XFN
MH_#_`(]LM;U%6&GR6C6QF"%A$^X'G'M_,U:3QUI=U8ZK>:?%,\%G#O\`M)C*
MI(QZ*,X.<TOJR=*+A!N]O>\[[=OU"^I9L/&MI>^+)]"2!U,994N"WRR.H!90
M/49/Y5HQZ\C^*9=$$!#QVRW'F[N""2,8_"O)U7Q'IFCZ?J4VA&&.RN3?O>^<
MI9PY^;*YSC!`_"NGN?$NDZ9\16U&_NA#;7&F1;'VLV<L2.%!-=57+X7?LE?1
M[.^J]/+H0YG4^,?$I\-V]JZ6,M])=3>2D4388G&>.*H:=XQO[A;M[WPU?6$5
MM;O/YDW`;;_#TZFN>^(VN:9K>D:/>Z?J31VJZ@%:ZC1@8B%.2`0#QFH])U"P
M>QU>&#Q==ZW+)82X@GC=0N!G<,_E40P<5AXRE'WM;_%W^Y?,;EKHSIK7QW:7
M/@Z?Q#%;L1!GS+?>-RG/3/XYHUWQK+IM]:6=GHMSJ,US;BX"P-RJ_3!]:X#5
M+:72OA[:WMM&6M=3M%@N0/X9`<H_Y`C\JZ34-9L-#\:Z1>:I<""`Z24WE6;D
ME<=`3VK9X*BI-PCS*\K+T2T^\2D[(ZKPMXHAU_SX3:S6-Y;$":VG&&7/0^XJ
MKIGC:TU#Q3<:(D#H8BRI.3\LK+C<!],USEOKT$NM>(/%-D&.G0620I*5*^=(
M.F,^Y`KG%7Q%I6E:9J,^@^1%87!O)+SSE+2!S\V5SG!!`_"HA@*<W*ZM>R2;
MV;5_GTT\P<M#T#7_`!K/IFNOI-EH5UJ<L<2RL;=LD`^V#6CX4\31^(8[D?9)
MK*ZM7"36\P^9">E<7JMA=^(/']TVCZM-I[G38Y4DBR/,!(P#@].:U_A284MM
M0@N/.&LI-B^\]]SLPX4@^E9U\/1AAN9+WDE?>^O?I;T'=W.[HI!TI:\<T"BB
MB@`HHHH`****`"BBB@`HHHH`****`"BDI:`,#QAXFC\,6-O<S6DUUY\X@2.'
M&XL02/Y5B?\`"PKS_H3M>_\``9O\*=\6O^/70/\`L+P_R:NW'05W)4:=&$I0
MNW?JUL3JV<-_PL*\_P"A.U[_`,!F_P`*/^%A7G_0G:]_X#-_A7=45/MJ'_/K
M\6%GW.%_X6%>?]"=KW_@,W^%+_PL*\_Z$_7O_`8_X5W-)1[:A_SZ_%A9]S@D
M^)4KSR0)X4UIIH@"\8@)9`>A(ZC.#4G_``L.\_Z$_7O_``&/^%:FC?\`(_\`
MB'_KWM/Y25H^(=;M]$MX9;D;C/*(47<%!8@GDG@#`/6MINBIJ$:5[I=7U28E
M?N<W_P`+"O/^A.U[_P`!F_PI/^%AWG_0GZ]_X#-_A79V-S]JM8I_+:+S%!V/
MC(_*IS6+K4%HZ7XL=GW.%_X6'=_]"?KW_@,?\*/^%AWG_0GZ]_X#-_A6KJ'C
M"RL;W4[::"8OIT2R-@#][NQA5YZ\C\ZV]+O$U#3K>\B5E2XC610W4`C-:2=.
M$5*5'1^;#6]KG(?\+#O/^A.U[_P&;_"D_P"%AW?_`$)^O?\`@,?\*[JL>+69
MI-=?2SI\JLB>89/,3;L)(#=<]NE2JE&5[4OQ86?<YW_A85Y_T)^O?^`S?X5'
M/X[EN(]ESX*UN9.NU[0L/R(KO:I:MJ,6F1P23(2DLR0Y&/E+'`)]LXHC5HMV
M5+7U86?<XNW\9BV??;>!-7A8C&Z.RVG'X"GQ>.9(&9H?!&M1LYRQ2T(+'WXK
M=TSQ;9ZG.D5O#+O>Y>W`;'\*[M_7[I%=".E5.I3@[3I:_P")@EYG!_\`">3^
M=YW_``A6M^;C;O\`LAW8],XII\<.9Q.?!&M&8#`D^Q_-^>,UVFI7+V5E)<1V
M[7'E@L45@#@=3S3-$OVU/3H;TV[VZ3HLB*[*25(R#P?>I56ER\WLM/\`$Q6?
M<Y/_`(6%=XY\'Z]_X#'_``J"+QJ8IC-%X%UA)3U=;/#'\<5Z#63JFL_8=2MK
M&*TEN9KE'=0K*H`7&<DD>M.-6D](TO\`R9C:?<Y<>.Y1)(X\$ZUOD&';[(<L
M/0\<TU/&[)Y>SP/K*^5GR\6>-F>N..*[R%F=%9TV,1RI.<>W%/-3]8H+_EW^
M+"S[G!?\)W,)C,/!6MB4C:7^R'<1Z9QTJ*Y\>K%F]N_!FK)Y*Y,\EKC8/7<1
MP*ZAO$=N=>;28HGDFCV^80RC;GH=I.2/<5'X^_Y$K6?^O63^5;0E2YXQE2M>
MW5[,5GKJ<]'X_<2--'X-UD/(`6=;7EACC)QSQ2#QP4G,X\#ZPLQZR"SPQ_'&
M:L7/A.YO[A;R&ZABCF6$A&4DE2BI,#]45<>XYJKJ7@75=1@N8WU)8MV/**SR
M':X<-YIST8@8V\@8%9.O03:]G^+'9WW(O^%@6MQ?36__``AVI2W80&6/[,#)
MM[;AC..G6K4?CN6.0R1^"=;1R`I9;0@D#H.E,\*Q20?%#58IRIE33H%<J3@D
M*@)YYKT&MJ\Z%-I*GND_B?57)C=]3@IO'L\\92;P7KDB'JK6A(/X8J,>-6%N
M;<>!M8\D_P#+/[%\OY8Q7H-%8>WHK3V?XLJS[G!/X]N)(C&_@O7&C(P5-H2"
M/3&*@D\7QR[3)X!U5RH"C=8YP/0<5Z)10L116U/\6%GW/-T\<6TIDLT\$:DY
MA(9X19@^62."5QQD5)%XOCA),7@+5D)!4E;'&0>HZ5NZ#_R//B;_`';3_P!`
M:M#7]>M]$%L)U+O<N8XUW!02!GJQ`K9U*?,H1IWNOYGVN))]SEF\;NUN+=O`
M^LF`=(S9_+^6,4V?QF+@J;CP)J\I484O9;L#TY%=Y:S>?;QR[&3>H;:W4>QJ
M4UC]8I+_`)=_^3,+/N<`?&[&`0'P/K/DCI']C^7\L8I\GCV>2(Q2>"]<>,C!
M5K0D$?3%:FH>-;*Q?55EMYRVF,BL!C,F['W>>V:Z2TF6YMHIU!"RH'`/49&:
MTG*$$I2I?B_4$GW.%C\<R1.'B\$:TCA=FY;,@[>PZ=*5/'4B3-,G@G6EE?[S
MBT(9OJ<<UWIZ5CV>LS7.LW&G'3Y8VMU5GD:1"H#9VG@Y_A-0JM&5[4MO[S"S
M74Y[_A85Y_T)^O?^`S?X4?\`"P[O_H3]>_\``8_X5W(Z50U34XM,:V-PK;+B
M80AQT4D$C/Y8_&E&K1D[*E^+'9]SE?\`A8=W_P!"?KW_`(#'_"E_X6'>?]"?
MKW_@,W^%;&B>*K75Y+=((95:=I1M?&4"8Y//0Y&/K7054YTJ;M*E9^K$KOJ<
M-_PL.\_Z$_7O_`8_X4?\+#N_^A/U[_P&/^%=7K>H-I>GRW@MGN$A4NZHP!"@
M9)Y-2:9<O>V4=P\#6XD`949@3@C@\&I]I1MS>RT]6.S[G(?\+#O/^A/U[_P&
M;_"C_A8=W_T)^O?^`Q_PKNCTK'U#63;:M%IL%E+<S20F;*NJ@*"!U)'K3C4H
MR=E2_%A9]SG?^%AWG_0GZ]_X#'_"E_X6'>?]"=KW_@,W^%=O$2R`LNTD<CTI
MU3[:A_SZ_%A9]SA?^%AWG_0GZ]_X#'_"H[CXERVL8DN?"FM0H6"AI("HR3@#
M)[DUT<'B.WN=<FTRWB=Y('V2,&7Y3C/W<YQ[XJI\1O\`D`P?]?UK_P"C5K:#
MHNI&$J5K^;$[]S*_X6+<_P#0HZ[_`.`Y_P`*4_$2['7P?KP[<VQ_PJQ?^$+J
M?69;V.[BCCDN%8*5)/E'!D7ZEU4_A67J'@75KZW=6U)89`8C#MN)6",LBLS\
MCJP4]N,\>M8JM0_Y]?BQV?<WO"GC%?$.IW5@VFW=A/:HKNERNUL'IQU'K745
MP7A563XI>(EDQN6UM@<'(SL3I7>TL7"$*BY%9-)_>KA%MK4X3XORI#I^B2RL
M%CCU6)F8]``&R:UAX^\+X_Y#%O\`F?\`"LKXM`&TT$'G.K0_R:NS%I;_`//"
M/_OD5-;F]A3U[_F;4W1^VG?U_P"`87_"?>%_^@Q;_F:/^$^\+_\`08M_S-;W
MV2V_YX1_]\BC[);?\\(_^^17':?<TYJ'\K^]?Y&#_P`)]X7_`.@Q;_F:0^/O
M"_\`T&+?\S6_]DMO^>$?_?(I#:6W_/"/_OD46D'-0_E?WK_(X/2O&.@1>,M:
MO)-3@6WN(;98W).&*A]P_#(JWXC\3^&-9L/LIUJPV%@66>(R*P],9!'U!K/U
M**-?'6KJL:A1!;8&/9ZF\M/[B_E736=6$XR35[1_)#3PS6TOO7^1=\.^)_"N
MB:-;:='KL,JP`@,2><DG\N>/:M'_`(3WPO\`]!BW_,U@^6G]Q?RH\M/[B_E7
M/)U)-R;5V-?5EHE+[U_D4M5N?"VHZQ)?MXE@3?,)=@0G@1[=I.>>0&_"N@T?
MQAX8TW2K6R.N6\GV>)8]_(W8&,XK,\M/[B_E1Y:?W%_*M)UJ\XJ$GH@MA;WM
M+[U_D;W_``GWA?\`Z#%O^9K/C\5>&$UZ34_[=MCOMU@\O!XPQ.<_C5'RT_N+
M^5'EI_<7\JS3J+9H?^S=I?>O\C=_X3WPOG_D,6_YFJ'B'Q5X7UG1[FP_MVWA
M:91MD&3L8$$-CV(%4?+3^XOY4>6G]Q?RHBZD6I)JZ"^&[2^]?Y$6EZCX2T[6
MX=1C\06Y6.T6W\K:0"XX,F?4C`Q71_\`">^%_P#H,6_YFL'RT_N+^5'EI_<7
M\JJI4K5'>;N)?55LI?>O\C9O/&_A>XM)H/[:MU\U&3/)QD8J'2/&/AC3M*M+
M(ZY;R&VA2+?R-VT`9QVZ5F>6G]Q?RH\M/[B_E4WJ<O+=6'?#=I?>O\C>_P"$
M^\+_`/08M_S-8^J:[X/U/6;.^N]7LIHK9'7R)8]X8MCGGIC'I4/EI_<7\J/+
M3^XOY41E4B[IA_LW:7WK_(W%\=^%E`"ZO;`#@`=J4^/?"Y'_`"&;?\S6%Y:?
MW%_*CRT_N+^53:?D%\-VE^'^1!J^I>%M4UNWU";7[)3;R+(C+$1*,?P[P>A]
MP:N>,O&?AZ\\*ZG:6FJ02S2VSHB*3EB1P!47EQ_W%_*LWQ/&@\.Z@0B@^0W0
M>U=5*=:I4A%M:-6^\EO"KI+[U_D7];\0^'M5T>QMX]<M(9(B@DW%O]64*2`8
M[[6./?%9>@7^EZ9X@MM0E\26,D21R1S(C.N_YOD.,<E5"CGWKTO3K2W.GVQ,
M,9/E)_"/05/]CMO^>$?_`'R*PESJ3U%>@_LO[U_D>:Z9XJT2'XEZMJ,FHPK:
M36D:1RD\,1MR!^1KK?\`A/O"_P#T&+?\S6-I$$1^+>MQF--@LHB%VC`X2NV%
MI;?\\(_^^173BN?FC=KX8_D@3P_2+^]?Y&%_PGWA?_H,6_YFC_A/O"__`$&+
M?\S6]]DMO^>$?_?(H^R6W_/"/_OD5R6GW#FH?RO[U_D8/_"?>%_^@Q;_`)FC
M_A/O"_\`T&+?\S6]]DMO^>$?_?(H^R6W_/"/_OD46GW#FH?RO[U_D<%H_C#0
M(/%VOW4NIP+!<K;")R3A]J,&Q],U/XG\1>%]<LUMFUK3_+!)99XC(#QVP001
MZ@U1O88QXXUU0BA=MMQCC[AJQY<?]Q?RKIJ.I"<91:O9?D4GAK;2^]?Y&CHG
MBSPKI.E6M@FNPRK;QB,.Q.6Q5S_A//"__08M_P`S6%Y:?W%_*CRT_N+^5<\G
M4D[MH%]6727WK_(S=4;PKJ&IW%ZWB:W0SO(^W82/FB"#//.",UU5EXV\+VMG
M!;_VU;MY4:INY&<#&:Q_+3^XOY4>6G]Q?RK2=:O4BHR>B!?55TE]Z_R-[_A/
M?"__`$&+?\S6?;>*_#$&MWNH_P!NVS"ZCB39@C;LW<Y[YW?I5'RT_N+^5'EI
M_<7\JS3J)-)K4=\-VE]Z_P`C>_X3WPO_`-!BW_,UE>*/$GA;7M'EL/[?@MV=
ME990"2I5@<X_"JWEI_<7\J/+3^XOY4X2J0DI1:N@OANTOO7^0FD:MX2TS79]
M1BU^W*20)$L."`A``+9]PJ_E6_\`\)[X7_Z#%O\`F:P?+3^XOY4>6G]Q?RIS
MG5J.\G<2^K+I+[U_D:>K^,?#&HZ9=68URWC^T1-%OY.W((SBI;+QMX7M;.&W
M_MJW;RD5-W(S@8K'\M/[B_E1Y:?W%_*IO4MRW5@_V;M+[U_D;Q\>^%S_`,QB
MW_,UCWVN^#[[7H=2N]6L9TB@,0AECW<E@0V3Z8]*A\M/[B_E1Y:?W%_*G&56
M'PL']6?27WK_`"-U?'GA=1@:Q;8^II?^$^\+_P#08M_S-8/EI_<7\J/+3^XO
MY5'O^0[X;M+\/\B&\U/PM>>(X-7EU^R#P2;T*1%9",8VE@<$?49]ZF\;^,-`
MO]'BBM-3AED6[MY"JD_=6123^`%'EI_<7\JS/$,:?9K7"+_Q^6_;_IHM=="=
M:I5@FUIL2_JRN[2^]?Y&GXJ\0^&]<BM8X]=M(PCD3%BV6A92&`QWSM_*LGPO
MJ6F:5K_]H7?B2QE66W,<\:.XS(79MP&,'@@<]A7J/V.VQ_J(_P#OD4AL[;_G
MA'_WR*Y5S(.;#_RO[U_D<)X,O[74OB9XBO+"99[>6W@VNO0X50?U%>AUPGAQ
M%3XK^)510JBWM\`#'\"UW==N*OS1YOY8_DCGDX-^YL</\6O^/70/^PO#_)J[
M<=*XCXM?\>N@?]A>'^35VXZ55;_=Z?S_`#(6[%HI"0*-P]:XRA:2C</6B@#S
MO5/^1]UC_KWMOY/4M1:I_P`C[K'_`%[VW\GJ6NG$_%'_``Q_)"04445S#*NI
M7HL+<S&WGG`ZK"`2!U)))``Q[U3LO$=A?7<<%MYA$N`DI4!2Q4/MYYSM(/3'
MO3O$>E2ZQ8BU2[^SQEPTHV;A*H_A."#@]^:BB\/1#5HK^62,M"HV+'"$(.W;
MU].>`<X]>U"`V1TJA?ZM#875O!/%,1.P02A?D5B<`$YR3]`<=\#FK]9NJZ4^
MHS0E[IDMXV5S$$&=RG(*MU'H>O'I2ZC':9K%MJ4LB6ZR+L&Y2X&'3)`88)XR
M#UP?:M#_`#BLK1=#CTJ5W20R#8(HQMQL0$D#W.2>>*U:8C,FUZTM[R:VN4F@
M\F,R>8Z_*Z@@$CG/4XY`SVS5K3+Z+4K"&\MPXBF7<FX8./<=JJ_V0SZK]MN+
MHRA%9(D\L`J&[$C[P&.`1^=6-(LETW38+-7,@A7;N/4T`5?%DLL/AZ\>W,@E
M"C;Y;E&.6`P&'(^M9%]866C6(N-7U/5B\S!52*_GX8]E&[MW)]*V/%4<LGA^
M[6W5VEV@J$0N<A@?NCD_2LN[U6WU?2GM+VVU.UE;`+#3IVR00<K\G3COB@"7
M1+6?3?$4UG)=7-Q`;42(T]S)(3\^.0Q(!'J,9JYK47VG5-.MGEN$B<2EEAF>
M(L0!C)0@]_6J6B7D^I>(YKIK.YM[=+41Q^?;O$WW\G.X`<^@SQ5S6I?LVJ:;
M<O%</$@E5C#`\I4E1C(0$T`5+RWTZSOH+:;^U\3,$68:A/Y88]%SYF2>#T!Q
MWJ[H<?D7FJ6ZRSR1Q3H$\Z9Y2`8D)`+DGJ2>O>LJ]EANM?MM2::_,5LN$MWT
MBY*JW=@=H^;'&<'%:F@R>?>:I<+%/'%+.A0S0O$6Q$@.`X!ZB@#7[_TKGM>U
M6&XT_5K`13QRQ6S-F1,!UZ9'.>OJ!GMFNA[US>OZ8\=GJ=_/=-,QM9(XU\L+
MM4\X;'WL8XX&/>NC#?QX>J_,4MF>MZ;_`,@VV_ZXK_(4^WN(K@.894D",4;:
M<X8=0?>F:;_R#K;_`*Y)_(4S3;!;'[0$.1/,TV`,8)QQ^E82^)AT.2T?_DK^
MN?\`7E%_)*[FN&T?_DK^N?\`7E%_)*[FNO&?%'_#'\D*(44FX>M&X>M<90M%
M&0:*`/.;[_D>M>_W;;_T6:FJ&^_Y'G7O]VV_]%FIJZ,1O'T7Y"04445SC*>J
MZBFF0>=)!-*@!+F-1A%'5B20`/\`(JOIVOV6HW7D6_F'[VR1E`63;C=CG/&1
MU`]J3Q%H\NLPP0K=B"&.0/)$8]ZS8Z*PR..^.],L=!CMM7?47='E((3;"$P#
MC.2.O3C^M"!FQ6?>ZQ;V-[%;W$4ZK+P)MOR`X)QUST!Z`@=\9K0K*U;13JEQ
M&9[IOLR'=Y(09S@]'Z@'//7\*`)M)U:#58W:!)4*8)60`'!&5/!/!!SZU?K,
MT/2%TE9<S&9Y`B[]NW"JNU1CZ=36G3TZ!ZE?4;ZWTZSDNKM]D48RQ`S^`'KV
MIUE=1WMG#<PAA',@==PP<$9IUU"MQ;R1-QO4KG&<9'6H].M18V%O:*^\01K&
M&QC(`QFDM@$U&Y-I:-*B;WR%1,XW,3@`^@K)U1O[-MQ/J%SJ,['+/+;D(D(&
M.<9`QST.2?2M;4K=[JT:.)_+E!#QL>@8'(S[<5@:^C:J;1+C[5:_9W\R2V-D
M\\<S?P_,N`0.3U],XH`V=-FF\V6VNG$CQ!663&-Z'H2/7MQ4.OH9KC2K<RS1
MQSW963R9FB+`02MC<I!QE0?PJ;3(YWEFO+J/RGE"JD1()11TSCC/)XJ'7W,-
MQI5P8IY(X+LM)Y,+RLH,$JYVJ"<98#IWH`I2VVG1:K%I[G6`\P.R3^T+C83C
M./\`69Z#KC%7-`C,%QJUN)9Y(X;L+'YTSRE08(FQN8DXRQ/7O5"YNK:YU2WN
MY)-2\JW;?'$-*G!#;2/O!,D<]/85?T!_/N-6N%BGCCFO`T?G0O$6`@B7(#`'
M&01^%`&M7/:KJUK>7+6-NS-+9WEKYIQ\H)D'`/<\<UT)Z5RMUX=M=)N?M=J\
MP%Q=6JF-Y7<+B;)/S$]=WX?C73A/X\?44]CV*^N[>QM7N+R=((4^\[M@#\:@
ML=7T^_GDM[*]AN)8U#.J,"0#T/THUNRN-0TV2VM+E;65R,2M'YFT9YXR/SSQ
M3=*TS[`&+.)'*(@VIM5550,`9.!G)Z]ZYAG+>'?^2L^)O^O>W_\`0%KNJX7P
M[_R5GQ-_U[V__H"UW5=F,^./^&/_`*2B8G#_`!:_X]=`_P"PO#_)J[?.%KB/
MBU_QZZ!_V%X?Y-7;'[HHK?[O3^?Y@MV<MXGO4GU'P^;&Y613J.Q_*?(.%;*G
M'H>U<EJ?BBWB\;OJ)U!U6UO$L_LWS;6AP0[^G#'.?:NZ@\*Z3;ZLVHQP.)RS
M.!YC%%9NK!>@)R>:G7P_IRZ))HXA/V.0,&4L<_,22<]<Y-;4L10II)IO2W;=
MZ]Q--G`ZAJU[IFI^);B29VTZX9[8<G]S)Y648'L"3C\J[_PD[2>&=-=V9F:V
M0EF.23M%1#PQI9T^]L6A9X+X@S!G))(4*"#VX`K3L+2*QLX;6W!$4*!$!.>`
M.*SQ%>G4IJ,5JOR2L-)IZG!:K_R/FL?]>]M_)ZEJ+5?^1\UC_KA;?R>I:RQ/
MQ+_#'\D-&1XBUR/1E@`C\Z::14"9QM4L%+'V&?UK7JCJNCZ?JR*M_:13[2&5
MF4;A@@\'KU%70`````!T'I7-T&+6.-:W>(9--V(B(%'F/O!9R,X7Y=N<8[Y]
MJV*I2:7;/J"WD@D>5#N52YVAL8W!>@..,T^H="[03@9/044G4>M)@C'\/:\-
M9DEVQI'&H#1_,=Q4DC)!`].V1VZULU1L-(M+"XDFMXRKN-O))"KG.T#L,DG'
MO5Z@1#>22Q6LDD(C+JN?WC%5_$@&J^AWMQ?Z9#=74"0/*"RJC%AM[')`ZCFK
M-Y;QW=I-;39,<R-&V#@X(P?YTZ.-88DCC&$10JCV'2@8^L?Q/K;:);PO';B=
MI7*XR1@!2QZ`GMZ8'<BM*]NHK.`RS$X!``49+$]`!W)K(U2%M3A1KS2Y_+C+
M$&.8"0`C!X!Z$=LT`;4$GFPI(.CJ#C.>HI]06#P26<36N/)V@(`,8`XQCM4_
M>A[@MC#U#Q"MEK\6FR0J$D,8#,V&8OD?*,<@;>>>,BMRJD^FV\]]'=R^8TD>
M-J;SLR,X.WIGD\U;I]`ZF9KVK-I,=NZVKS^=*L9(.%0$@9)_'IWK&U77?MUA
MJMH80B""?RW#9+>6VQLC''/2NEO;.&^A$5PI9`ZN,'!R""/U%8VO:5:6NDZK
M=P(1)+!)G+$@9Y;`[9/)K;"?QX>J_04MCU?3CC3;8G_GBO\`(5%I>J1:D)Q'
M%/$T#['69-IZ`@_0@BI=.&=,MAZPI_Z"*ATC28-)ADBMI)W61S(3-(7.3UY-
M8R^)C.5T?_DK^N?]>47\DKMV8#D]N37$:/\`\E?US_KRB_DE=LP!X-=>,^*/
M^&/Y(F)R.N7JW/BK0&LKD2P2Q71)B?<K808/'!YK+%U,_P`.]%D6X<RO=PJ6
MWG<?WIR,]ZZG2O"VDZ7?O>6<#K*P8*&D9EC!.2%!.%!]JBM_!VC0:@+R.&0,
MKF58C*QB1SSN"9P#FM8UZ,5%);>6^_\`F2XMW(_!<KO<ZZ)9&?;J4JKN.<#"
M\#VKI`<BN<D\&:7)?S7@DO8Y9I/.<173HI;UV@XKHEZ<=*Y*\H3GS0+/.[[_
M`)'G7O\`=MO_`$6:FJ"^_P"1YU[_`';;_P!`-3U6(W7HOR!&/J^M&PU2ULU2
M/9,I>264L%0;@`,A2`3D]2!Q6Q5+4-*MK^1&N=[!.-@<A6P<\KT."*NXQTZ5
MS]!]0K&T_7EO=8GLHXT6.)G0,6(9F4@'@C!'/8Y]JV<U1CT>TBU(WRQD3')Z
MG:"?O$#L3QDT+5@]B]2/G:=H!;'`/2EHZ_C1N!F:'J%UJ"W#7,$$:Q3&)'AD
M+K)CACR!T/%:=06%G#8VJV]LI$:DD`G)R22<_B34_;B@'H4->U%M+TQ[I(A*
MRLB!"2,EF"]@2>O0`GTIVBW_`/:6F079C\LRKDKG.#G'^<\U+J%E!J-L;>Y!
M*EE<%6P00<@@]L$4MC9PV%JEM;IMC3L3DY//)]>:%L'D3UB>)=?&B/`'A4QR
M*[L[OM'RX^4<<L<Y`]C6I>74=I$'DW,S':B*,LY]`*RM2#WB1R7VG7`AC.66
M*<$X/]Y0?F''3F@#;4[E##H1FJ6MZ@VEZ9-=I;R7+1J2(TZGW)[#U-6X)(YH
M$DA8-&ZAE8=P:;=01W5M);S#,<JE&`..".:`,6'Q)YNIV]L;=5CF\M&?>25D
M>,N!C'(P.N:WQ6>FBV4=Y#=+&XEB4*HW''"D`D=R!D9K0H`R]9UAM-N+&);5
MY1=3"(R`X6/)[GU]!]:S;K5VU&6:V-J]N+/4+51O/+@R`YQVK>O+.&\6(3*6
M\J02I@XPPZ&LW6K.&`K<QJ1+<WMJ9#G(.)%`KIP?\>-^Y,MCU#4;Q;"S>X:&
M:8+CY(4W,<G'2J.C^)+#6+N>VLS(9+=49PP`X89'&<CKWQ5S5M-AU6Q>SN'F
M2)\;C%(4;@],BH=-T2TTV=YK<RL[KM)DD+>YQ]3R:YD4<OX=_P"2M>)O^O>W
M_P#0%KNJX;P]_P`E:\3?]>]O_P"@+7<UV8SXX_X8_DB8G#_%K_CUT'_L+P?R
M:M_Q7'J<VDLFD%1*6&[+E&V^BD`\YQ^&:P/BU_QZZ!_V%X?Y-7:R%A$2B[FQ
MP,XR:J<N6C2?K^8=6<OK]OJ\DT1LA-CR!*P1SCS$R0G_``(D?7'-41::I'=@
MS+=.S6Z[?EE;#E6S\P<*.2.H-:=EXBN+F\TZ)X$1;F,-)@$["58C#=/X>AY.
M>*8_BMA`W^C,DRNP7<!M<!BN1@Y'3N/P[U4?:VY5%?U_PPFE<S[*VUC[-;K"
MLX(R9PRRHS#:,@%W;YC@X/`^G6M?1X[A=;E;RKP1,&R9]P"^@')4_@`1WS4<
M/BR$*HN;>?IEY(U&Q!QURV3U["M;2-334TE=()H#&^QEEVYS@'^$D="*SJNI
M%/FC8%;H<5JO_(^:Q_UPMOY/2W,)GMWB61XBX*[TX(^E)JO_`"/NL?\`7"V_
MD]+<S"W@>9@[*@+$(I+'Z#O6>*^)?X8_DBHG)1Z+>#P_H\9%SYMI>([1;^J^
M=DLWKA>?QS78US+^,$2QL+G[$P^U[CL>3#*%?;CIRW.<<#WKIAR*PZ"5C%\9
MZ?-J7AV[@MS,9?+)5(C@R''"GVJE]GDF\:12"QEMXK=,M=>63]H)7&W=_"JC
MMW-:OB'5TT33)+UX)+C8/N1CK]3T`]S5>/Q#$VN#36BV$MY8<O\`,6V[ONX^
M[COGJ.E"*-JL37=/FGUC1[J(S2+!<?.@/R*OEO\`,1ZY(%;8Z>E9>L:NVESV
MXDM@\$TBQE_,`;<QP`JX^;U/3BIZC*?AVS:WU:^EALI;2UF5?ED&T[P3GIG=
MG.=V3Z5T%9.BZXFJS.BP^6-@FB.[=OC)(!/`P<CIS]:UNU/H+J<U>Z;J:ZY?
MW&G.S/<6:HDD[D(AWG*K@'&%Z<=35KP3:75CX>M[:]A\F5&<;=Y8XW'!)('-
M.NM>^R:D]I<6C_ZMI(_*;S'<`@9*`<`D\<_E5W1KX:II=O?"(Q"=-P1CDK]:
M$!#JY"36,LAQ$LI4L#]TLI"G\SC\<UR]UH=S'830O%<7"QZC).@DB6?SOW>%
M+!OX<GKCCVZUVUS$DT#QRQ"5&!RA`(;VYKD9=0"6=Z);>9H[%@L\3:@2BKMS
MM+XW%NVWD9XSB@.AN>%R\FGO<,BQI/(9(XT&%48`./8L&/XU:UBV:]TRXMTD
MEC+H1F(X8^P/OTJ>T9&M8FB3RT*`JF,;1C@8IM]-+!:O)!")G7D*7"#ZDGH!
MU)Y^AH>X(X^STO4XKW29)+8R+%!;HH=>(2-WF$MU4X*_7&*[?K6!:^)#<'3W
M%B1;WIV"7S0<-ST&.1QUXZC&:WZ?0+ZF+XLL)KZTMS`9F,4\;F.,X##<,EO4
M``UEZII4,2^(=0^PQ6[F$Q1NL84R#&YFXZDD]3Z5NZ]JKZ1:"Z^SK+$IS(6D
M";1Z#@Y)SP/U%9&LZ[!>VVLZ=!&Y-O9F1I3T).05^H[UMA/X\/5?H*>QZ_IW
M_(,MC_TQ7_T$5G>&6OF-]]M-P8C.3!]H7:P7`^7W`.><\YK1TW_D&VW_`%Q7
M^0IMC?6]Z]P+:3S/L\AAD('`8`$CWX(K&7Q,9R.C_P#)7]<_Z\HOY)6YKT6K
M2:IIS6.PV<<JF8"0JQ^HVD%0/<<UAZ/_`,E?US_KRB_DE=7K5U+8Z;<74$:R
MO#&7"LVT'`SR:[L0VJD+?RQ_)$)73.=UJTU@ZA.UG]H:)'#)MD(#>8-K?]\C
MG\:HWEGJ:M>*JWC,;@;6"3']WYB]Q(`1MSP`#^M;:^(9/[0O+<QQDP0R2J!G
M(V!?O'ISN_2JESXO9886CM665L;XY0.,H6!!!(["JBZK22BM![ZD=I;ZF+A&
M*W)L@B`HN]'+Y?D!V)P.,@GT[5J>%8[B);A9X[@)E=K3E@S'OPQ/MR#@YX`J
MO'XNMAE9;6Z8@A0RJNUW.W"C+9S\Z]<#WK;TN]34+*.YC1T63/RR`!A@XP<$
MCM6%5S4?>C8#@[W_`)'G7O\`=MO_`$`T7T!N;26%99(BXQNC.&'T-+??\CSK
MW^[;?^@&B^N4M+5YWCDD"#.V-<L?8"IQ&Z]%^0XG%VUA=!?#MK)IT\4EO#&T
MUX8R[1[?^68_ND]SZ#O7=?YS7-0^+X9?L+/;&)+N**0EI`&7S#@!1CYL'KTQ
M[UTO>L!]3%\86$VH:5LMS,7CD1Q'&<;\..OJ`,FH+2S9?%;W5O920(8W2=W&
M`YR-K`C[V?0]/:M'7=2?2K)KM8%DCC!:5FE"!5_(DD]`,56TSQ!'?WXMU@9(
MWWB-RW+,F-P*XXQGU/X4D#-FL#6=/NY/$&FWUIYDGEB52C,1$G[LX)QZG`S6
M^:RM4UAM.OK:&6VS#<.$$@D&XM@GA`"2!CD\?C0MP*7@RRU&R.I#54422W'F
M>:)"_F$J,D948&:Z*L[0M676()IDMY+<13-#ME&&.,<D=OI6C0'4Y#5-&N7N
MM9!-U+#=)`=^P2D@.2RJI(&`N!C^=;_AY)H](@2XMX[9E!`CC0(`N3CY1P#C
MJ*J2Z[.E_<60L%,T<?FH/M``*;L;G./D'4]S@=,\5?T;4%U338;Q$*+*"<9S
MWQP>X]Z$#(-4PM_9F1BB2"2%7'5'8#!_(&N3O='U&#38OW,DT4$UR_ERKO+,
M6!C<GMP#\W49KN+Z&.XM)(Y;<7(QD1G'S$<C!/0Y[URCZDILWDGMKBXBMI_)
MG0WI>-3\N,'&7/S8P>.#D^HMPW1T/A[)TM)-GEI*[RHH/168D?@<Y_&F^)K.
M2_T*[MX7F5WC.!$VUGX^[GWK27&T8&!C@57U*YEM+-YH85F9>2'D$:@=R6.<
M`?0T,$8EGI"2:U87%QI\:M:6:GSC&-QD(V[<]>!G\ZZ2L*S\46]W>:;;16\F
M^^B,I.>(AC(!]<X_*MVFP1B>);":[GTR:$S-Y%TC-&A^7;GEB.^/ZUSEAIMY
M97\TMQ`\:37EON+#`+_:"1@_Q_*1\QY[5U6NZN^D+%*;82PLZJ[>8%()(`"C
M!+$YZ<=.M9<^M+JN8XTA1+?4($7;+EVQ,!DKM``X]371@OX\?4F>QZGXHEGB
MT:9[5;MI<@`6@!D/(Z<'CU/I69X7?6_[2NEU%II;<1(4EE!7<Q'92HQ[X)Y]
M.E;^HWD5A92W5QO\J(;FV(7('T'-5-,UVPU2>2&S>1VC4,2T3*I'^R2,''0X
MZ&N9%',^'?\`DK/B;_KWM_\`T!:[JN%\._\`)6O$W_7O;_\`H"UW5=F,^./^
M&/Y(F)P_Q:_X]=`_["\/\FKMR,KBN(^+7_'KH'_87A_DU=N.@HK?[O3^?Y@M
MV9E]'IFF+'>36T2-$/+B9(=SC/\`"H`SZ]*S(K_PV'"36\4$LX65@]L0&W=]
MVW!ZX_&MW4+"#4(/)NE8ID,-KE"".X(((K(N_!^ES12K'&T;3*(V9G9\)D9`
M!.`3@<_C6=.5.WOMW&[]"73)M#UB.9=/C1PN%9O)9/I@D#/X5;T/1X-&M3;V
MI8JS%F+8R3^``[>E.LM(L[*YEN+>(K+*`&)=FX'0`$\#Z5>J)SO=1;MY@O,\
M[U7_`)'W6/\`KA;?R>EN)X[:!YIW"1QJ69CV%)JG_(^ZQV_<6W\GK$U24ZI!
M</';+>VML#Y5ON`%S*/4DXV@_@3SV%:8GXH_X8_D@B9<5A:,EFFH.8+&?>EN
M5E&2&;<8Y#TYQGC&,8STSV8```'`'`K@6T2_GTJWW02B[+2NT1$'EH[D<8).
M$`&,KSP:ZW2KF1'-A>2*UQ&NY7!_UJ>OU'0__7KG&6M2LHM1L)[.X+"*="C;
M3@X-0'2+<ZDM\[2O(@^1&;*H<8R.,]/?'M5^BD`5EWNB17FKV^I/<W"36ZE$
M1=A3!//!4\GU'-:E%`%#3-(MM-ED>WWG>-H#$'8N2=HXZ9)ZYJ_110!F66AP
MVFJW=^ES<N]V?WBN5(Z8`!V[@!Z9Q5O3K.+3[**T@W>7$NU=QY_&K%%`#94\
MR-DW,NX$;E."/<5SR^#K1;*&T%]>^5#-YZC,9R_JWR?-SSSGFNCHH`1%VHJY
M+8&,GJ?RJGK.FQZMITMC/++%%+@,8F`8C/3)!XJ[10!E+H,&ZV,ES<RI;;2L
M;,H0E?NG:``",]L>^:U:**`,S6=%BU:6UDFN+B(VK^8@C*[2W8D,I!QV],UF
MZYH&FV=AJ>HVMLD5S):/&Q10`<G)/`ZDUTM9GBC_`)%W4/\`K@W\JZ,+_'AZ
MK\Q2V9Z5IXW:9;#UA4?^.BJVB:+::*EPEEYVR>3S6$LSRX.T#@L20,`<5:TW
M_D'6O_7)/Y"K%8R^)C1PVC_\E?US_KRB_DE=K-$DT;1RHKHPVLK#((]*XK1_
M^2OZY_UY1?R2NYKJQGQ1_P`,?R1,3%U6?2])+2RVR&:Z4J0D66D`P#N('3D<
MGCFJ/V_PM$9(6AAB\@L61K5EP<<X^7G@GIUR<5M:EI-GJ1C-W&S&,G:5=EZX
MR#@C(X'!XXK.;PCI@EA:*,JJ2B9PS,Y<J"%&2>`,]JBG*E;WV[C]!8;31]?T
MI_LD86&0X\Q(O+8$8Z;A[#M@@5JZ;8PZ=8Q6EN"(XEVC--TW3;;34D2T1E$K
M[VW.6);UR2?2K=93G?1-V!'G-]_R/.O?[MM_Z`:2_N8+.SDGNG"0H/F;_#U-
M+?D#QSKY)P`EL<G_`'#6#JLCZG9S7D-HM_#"#]EM"RA9W_YZ')Q@=OQ/I6F(
MW7HOR")5TS3X89-.@U&3;"%7[&@E!1MO(5O5QUR,`_A775Y^N@:BRVV5<[PI
M8.(@(7\PLY`R=HY&W:<\#/%=CI=VSL]G=,INX1EBO21>SCZ]_0USC&:WHT.L
M?9O/GGB^S2"5!$5P6'0D,"#CM3K31K:UOFNXVD:1LG:Q&T%L;F``ZG'/Z8K0
MHH`*S)M$BEUN/53<W"SQIY83Y"FWO@%21GO@@UIT4`5K&QBLC.8=V9Y6F?<<
M_,>O\JLT44`<_-X2M98[]'OK[;J#[YL,F3ST!VYQQC&<8K:LK<6EK';B1I!&
M-H9@H)'_``$`?D*FHH`CN(O/MY(?,>/S%*[XSAESW!]:QX/"UK#IL>GB[O&M
MDR"A=0'4XRK849^O7KSS6Y10`B@*H4<`=JI:YI46LV!L[B6:*)F5F,1`)P<X
M.001[8J]10!DKX<TT7UK?-"KWEMTGV(K.=NT%L`9P.E:U%%`&9JNB1:E?V=Y
M)<W$<EF28UC*[<GN0RGGW[=JH:II,%F\-T))II7NX$4RL#Y:F96*CC.,^N:Z
M*LSQ#_Q[6O\`U^V__HU:Z<)_'CZDRV/2=2L_MUH]N9I8-_\`'$0&'Y@@_0@B
MJ.B^';71Y7>UFG92FQ(I&!2,9R=N`#R>3DFM>EKF*.%\.<?%GQ-_U[V__H"U
MW5<+X=_Y*UXG_P"O>W_]`6NZKLQGQQ_PQ_\`243$X;XLG_1=!_["\/\`)J[@
M=*X/XORB'3]$E8,1'JL3$*,DX#'@=S6H/'%@.MAJ^?\`KPD_PK.M4BJ-.-^_
MYF]/#5JGO0C='4T5R_\`PG-A_P!`_5__```D_P`*/^$YL/\`H'ZO_P"`$G^%
M<?M(=S;ZEB/Y&=125S'_``G-A_T#]7_\`)/\*#XYL/\`H'ZO_P"`$G^%'M(]
MP^I8C^1F%JO_`"/FL?\`7O;?R>H5TNP10JVD2@<`!<8K-O?$5K+XNU.Z%M?A
M)88%"FU<.,!NHQD=:F_X2.U_Y]=0_P#`1_\`"NC$5J;DK/HOR0XX#$V^!EW^
MS;+_`)]H_P`J=#86D,HEBMXUD4$!@.15#_A([7_GUU#_`,!'_P`*/^$CM?\`
MGUU#_P`!'_PKG]K#N/ZAB?Y&:]%9'_"1VO\`SZZA_P"`C_X4?\)':_\`/KJ'
M_@(_^%'M8=P^H8G^1FO161_PD=K_`,^NH?\`@(_^%'_"1VO_`#ZZA_X"/_A1
M[6'</J&)_D9KT5D?\)':_P#/KJ'_`("/_A1_PD=K_P`^NH?^`C_X4>UAW#ZA
MB?Y&:]%9'_"1VO\`SZZA_P"`C_X4?\)':_\`/KJ'_@(_^%'M8=P^H8G^1FO1
M61_PD=K_`,^NH?\`@(_^%'_"1VO_`#ZZA_X"/_A1[6'</J&)_D9KT5D?\)':
M_P#/KJ'_`("/_A1_PD=K_P`^NH?^`C_X4>UAW#ZAB?Y&:]%9'_"1VO\`SZZA
M_P"`C_X4?\)':_\`/KJ'_@(_^%'M8=P^H8G^1FO6;XH_Y%W4/^N#?RJ+_A([
M7_GUU#_P$?\`PK/\0:[;W&B7L26UZK/"R@O;.H''<XXK?#UJ:K0;?5?F)X#$
MV^!GK^F_\@ZV_P"N2?R%6*Y&Q\;6,=E`AL-6)6-02+&0CI]*F/CFP_Z!^K_^
M`$G^%92J0YGJ+ZEB/Y&9VC_\E?US_KRB_DE=S7E>F>)K6+XDZMJ!M-0,4UI&
M@06CF08"]5QD#CK76?\`"<V'_0/U?_P`D_PKIQ56#E&S^S'\D2L%B/Y&=117
M+_\`"<V'_0/U?_P`D_PH_P"$YL/^@?J__@!)_A7)[2'<KZEB/Y&=117+_P#"
M<V'_`$#]7_\``"3_``H_X3FP_P"@?J__`(`2?X4>TAW#ZEB/Y&<_J"AO'&OJ
MPR&2V!![CRS4:Z58*H5;2(`#``7@5FW7B*V?Q;K%T+6_"3+!M4VK[AA"#D8R
M/ZU/_P`)':_\^NH?^`C_`.%=%>M!M:]%^0XX#$_R,N_V;9?\^T?Y4Z"QM8)?
M-A@C23&W<!SCTJA_PD=K_P`^NH?^`C_X4?\`"1VO_/KJ'_@(_P#A7/[6'<?U
M#$_R,UZ*R/\`A([7_GUU#_P$?_"C_A([7_GUU#_P$?\`PH]K#N'U#$_R,UZ*
MR/\`A([7_GUU#_P$?_"C_A([7_GUU#_P$?\`PH]K#N'U#$_R,UZ*R/\`A([7
M_GUU#_P$?_"C_A([7_GUU#_P$?\`PH]K#N'U#$_R,UZ*R/\`A([7_GUU#_P$
M?_"C_A([7_GUU#_P$?\`PH]K#N'U#$_R,UZ*R/\`A([7_GUU#_P$?_"C_A([
M7_GUU#_P$?\`PH]K#N'U#$_R,UZ*R/\`A([7_GUU#_P$?_"C_A([7_GUU#_P
M$?\`PH]K#N'U#$_R,UZ*R/\`A([7_GUU#_P$?_"C_A([7_GUU#_P$?\`PH]K
M#N'U#$_R,UZS/$/_`![6O_7[;_\`HU:C_P"$CM?^?74/_`1_\*S];UVVFM[<
M+;WJ[;J%SNMG'`D!].M=&%K4U6BV^HI8#$V^!GLU%<N/'-A_T#]7_P#`"3_"
ME/CFP_Z!^K_^`$G^%<_M(]Q?4L1_(S-\/?\`)6O$W_7O;_\`H"UW5>=^#+Y-
M2^)?B&ZACFC22WAPLT91QA5'*GD=*]$KNQ4E*47%_9C^2.:5.5-N,U9G#_%K
M_CUT#_L+P_R:NW'05Q'Q:_X]=`_["\/\FKM\X`JJW^[T_G^9FMV+17/W'C/1
MK?49;&22X:>)Q&X2VD8*WID+CO3)O'&B17DMJ9;EY89#$_EVLK`,.V0N*R^K
MUG]E_<.Z.CI*Y^^\:Z)8WLMI<33B6''F;;:1E3(R,D+@<&MRVGCN8$G@8/'(
MH96'0@]#43I3@DY1:3"Z//\`5/\`D?=8_P"O>V_D]2U%JO\`R/NL?]>]M_)Z
MEK7$_%'_``Q_)"B%%%%<Q0444'B@`HHHH`****`"B@<T4`%%17-Q%:PM+.X1
M%ZG^E4O[7<$L^EWZ0`9\XJA&/7:'W_\`CM`&E13(98YXEEA</&XRK#H13\4!
MN%%&**`"LSQ1_P`B[J'_`%P;^5:=9GBC_D7-0/\`TP;^5=&%_CP]5^8GLSTO
M3?\`D'6O_7)/Y"K%5]-_Y!UK_P!<D_D*L5C+XF,X;1_^2OZY_P!>47\DKN:X
M;1_^2OZY_P!>47\DKN"<5U8SXH_X8_DB8BT5DZ7XETO5A=FPN/-%F2LWRD8Q
MGID<C@\BGMX@TY=/L[XS$6]ZZ)"VP_,6^[QCBN=TIIV:8[HTZ*PM1\8:)IUX
M]K=W962,XD*1LZQ_[S`87\:VH94FB66)@Z.,JP/!%*5.<4G)63"Z//+[_D>M
M>_W;;_T6:FJ&^_Y'G7O]VV_]`-35KB-X^B_($%%%%<XPHH-%`!111]:`"B@\
M44`%%%%`!14%Y=PVB*TQ.6.U5499SZ`=ZJ?VN8\M>:?=VD6<>;)L9?J=C,0/
M<@4`:5%`((!!R#THH`****`"LSQ#_P`>UK_U^V__`*-6M.LSQ%_Q[6O_`%^V
M_P#Z,6NG"?QX^HI;'J5+24M<PSA?#O\`R5KQ/_U[V_\`Z`M=U7#>'?\`DK7B
M?_KWM_\`T!:[FNS&?''_``Q_])1,=CA_BU_QZZ!_V%X?Y-7;'[HKB?BU_P`>
MN@?]A>'^35V%[=P65JUQ=2+%$G5FZ"G53="DEY_F"W9Q^AZ9J4WB/6;B#5)K
M.W6_RUN($99AM7^(C//M6%8W_P#9^O:PDVOWFEA]1=Q!'IYF60<<[MAZXQUK
MT6YU6QM6VSSB,DJ!D'G<<+4(U[3VDV(\KX7>72WD95'/)8+@=#WJXUY.[E"Z
M:2^[Y,&NAY_K5V(?$&OQMK=YIJ76S;'%8F83@Q@?>VG;Z=17?^$EE7PWIZW%
MO]ED6!0T/]SCI3XM<T^2/S/,DC4@D>;!)'N`&<C<HSU[=:FM-4M;JY>WAD8R
M)G.8V4''7!(P<=\=.]37K2J04>6UK?@K=E^HDK,XC5?^1\UC_KWMOY/4M1:K
M_P`CYK'_`%PMOY/4M98GXEZ1_)%(**HZGJ]GILEM'=2$27,JQ1(HR6)(&<=A
MDCFKU<PS!\:WJ66DAFDG661PD0AE,67(XW..0HZGGM6;IUWJ2Z_;QW<TEP"$
M16BD(61/+!,FW[I&[//7.*[#M5&3588]3CLI(ID:0[4D9,([8S@'J>.^,>]'
M4"]7,^);W9KVG6=M=30W,C!V)E*0K&&YX'#,>@!SZ\=:Z:BD!B>'8&-WJ%R)
M;HQ>>88XYIWD`"\%@&)QEL]..*V_6J.GZK#?SSP)%-%)!C<LJ;20>AQ[X/7!
MJ]3Z!U.%UC4;B75-3CTRZNE^SQ[9=TQ)9R1_JT_A51G+`9Y/6ND\)RS2Z,C7
M+O(P=P'=BVY=QP03R1CN>:U)9%AC:21@J("S$G@`56TG48-5L([VT+&&7.PL
M,$X./Z4("OKC1QRV4EPY6!)&+-V#;#M)_']<5QIU&]N+*2ZL=0G^SM*PAMY;
MA_-+;#M+,,XR1G8<`]/:O0;B&.XA:*9`Z-U!K&U6.#3H8(YKG4;B*=A#';+(
MN6."?O'#$8!SEJ`)_"YD:PE9PH1IB4"]!P-__C^^K.MM$FFRFXN)K>/@-)%N
M#+SW*\@>IXX[CK5J!$CA18D\M```G]T>E/H>X)V.%TV\U5[W3UFENB2(A&"Q
MQ*NZ3S&(_BX"8+<]/6NZ-49]5@AU&.Q*RR3,`6\M=PC!R`6[C.#V^M7J?0%N
M8/C&9HK.,PW5Q#<@EH4B+*)&&."1P3Z`G!ST.*SM2:^'_"0+=SR21&S5XD(P
ML>=W`]3TR:Z\=:YW7]46:PU73_LES%)%:NY=PNPCH.0QZ\]:VPO\:'JA2U1Z
MSIYQIEL?^F*_R%9?A+4KS48+IKYX7>.8JIA!"A>PYP<COD5J:=_R#;;_`*XI
M_(465Y:WH=K.XAG6-BC&)PVUAU!QWK&7Q,9Q^C_\E?US_KRB_DE=!XOOI=/\
M/WDULK/<%/+B"]=[<#^=<_H__)7]<_Z\HOY)77W=Y;6TL*7$JH\[[(U/5F]!
M7=B':K!VO[L?R1,3SO1M.UG0-5M(+VTMHH+ZS-B3;N7!D4$JS9`P3DC\:6VN
MOM^D^']`BM[H:A8W41N8VA91$J9RQ;&TCIT-=W/K6GV\PCGN%1LNNTJW55W-
MV]*A?Q#IZF0EIR(VV%A:2E2V0,`A<$Y(X&:T>)G/WG#7R[Z_YBY;:'&S:A<:
M%8:CI31>7J,MW)*AELWG2[1CD8V\9Y`Y/&*[GP^UU)HEF]]"L%R8E,D:K@*<
M=`.U-76;!L`RLC-CY)(G1^<_PD`C[I/3@#/2IM/U&VU!&:UD9@IYW(R'GH<,
M!Q[]*YZU1U(_!9[M@E9G"WW_`"/.O?[MM_Z`:GJ"]_Y'G7O]VV_]`-3U&(W7
MHOR*0450U'58=/EC6>*?8Y`,JIE$R<#)SW)Z#)J_7.,YSQQ>BTLH%2:>.YFD
MV0>7*8D#8^\[#G:O7'?I@U)H\#R:]<S"XN62WB1&S/(8Y9&&YF"DE0`".@[U
MOU1AU6&74WL/+G255+*73:K@8R5[XY'/0]J$#+U<IX@OV'B.VM;*YGCN%3S)
M!YA";`#\BKT9V]\XQGCOU=%""QS/@.:\EM+@7DLLQ!0[G=F`8H"P&[D'.<CH
M#TQ7352TS5;75#<&S<N+>4PLQ'!8#MZU=IO42T.#O-1FN+_4S8ZC/%;V[JLH
MFF<&0[QNVX&8U`^7<`/7WKJ?#,EU+HEL]]N\XJ<[B22,G!)/)XQ5K4KV+3K*
M2ZG#%(\<*!DDD``9]R*EMI?/MTE\MX]W.Q\;A]<$C]:2&S.U`Q)JR-.TB?Z+
M)Y;H"2#D;L#!RV,8XSUQWKDKJ\O$M9%2[N7LD:8PS-*Q$C838I)Y(Y?(/&<^
ME=W>6D-Y&(YU)P<J02"I]01R#63J?V6R:&._GOK[S3F.W^4\#&20H&X#(ZY-
M'4"]X?##1;7<"!L!4'J%_AZ^V*;XA:-=,?S;F6V!(`DC9EP>P++R!ZG(^M:`
MZ#'`I:'KH!RNDS:J^IZ,]S<3>3+9OOA88^<`?,Q[DGI7550GU1;?58+!K2Y+
MSYV2@*4X&23\V>/I5^F]0"N1D-Z-0O8[VX:=%U"T,65PJJ77A1775S5[K=KJ
M92WMQ*'@O+?)=<!AYP7(Y]0>N#Q71@_X\?4F6QZIXBO'L='N+B*=+>15^621
M"R*>V['0>_:JOA_4[V^FD%Y&J*+>"5`$(.64[@?Q%:E[=6]E;-<7D\=O`G+2
M2L%51[DU%:ZC8WDLD-I>03R1`%UCD#%01D9`Z9KF*.2\._\`)6?$W_7O;_\`
MH"UW-<-X=_Y*UXF_Z][?_P!`6NYKLQGQQ_PQ_P#243$X?XM?\>N@_P#87A_D
MU=+KVD0ZS9"WG>2/#;E9'(PV#SP1GKTKFOBU_P`>N@?]A>'^35VLJ"2(H<X(
MP<5523C0I->?YAU9B:IX>AU&2,M<LFRW:$`#))(P'^HR?SJK_P`(R4N0\=S;
M[3"L)\R%BW`(R"'`&<]P:@TW0K^WU#36*1K'!$HDD/S,"`PV@YR`=PSP<X[5
M$^BZP\4L'/E>8S!7D5ARQ(*^@P1QZTXM_#[16!I7+EMX4`B@6>YBS;DM$UO$
MR8;``8[G;)&![>U:-AI4]OJ+7<URCA@?E2+86)_O<D'';@>Y-8T>EZY;1;H9
MFB$2@JB.-I.!G([\5H^#9[NXL9I+P7(S)^[^T?>QM']<U%7F46^=-"5NQS.J
M_P#(^:Q_UPMOY/4M1:I_R/FL?]<+;^3U+48GXH_X8_DBD4=7TY=1C@5G\LQ3
MQS9"Y)V,&Q^.*O5ROC;4;NRN[1;6=H059B`VW>P9<`<?,V,_+QGUKJ@<J,CG
MWKFZ#ZA6/_8UP?$AU::[CEC5-D4#PG]R.^UMV`3W)!Z8K8KES?7R^,A:B;S8
MF?F-7&(X]F>5ZYW#KT[9H#H=1_GFBBL37;B^@U?2?(G5+6:X,4D87YG^1SR>
MPX'XTNMAV+.G:7):W]Q>7%UY\LRA>(Q'E03@L`>6[9XZ=*TJYKPC?W=Y<SK<
M2M+B,-*I.?)E+,"GMP!Q72BF+JRMJ5E#J-F]K<[S$_4(Y4G'/45#H.E+HVFI
M9I-).%9FWN3GYB3[^M9LLVJ_\)%?6R7D2J;-9(%\L[8_G(R1G)/'\JN^%[B:
MY\/6,]S*99GCR[GJ3FA"ZV-&:6.")I9G6.-1EF8X`'J:Y_Q"UIJMG'YC-#$K
M'][-9,Z`$%<\X*]>&Z#K6CK`#W%@DA`B,Q//W68(2H/MGGZ@5RM]K-Q::7=)
MJ&JD7IOWM[?8ZPHS;1@'.<(N<]?SSB@9VUG&D5I#'&YD1$55<G)88ZDU-63X
M8W"PD0,CPI*5B9#E2,#=CVW[P/85;UC[5_9DYLI4AG"$J[+NV^IQZ_UH>X)7
M10O_``_'=ZS'J(E\MAY>\;,LVPDC#9^4?,0>N:VJX^#4YRV@O_:,KW$R1>=;
MY&75E.6"XYYQDYXQ[UV'<T!LP%8&N6'V;2-<N&D,C74989&-@"8`]^Y_&I?%
M<U[;VMO+97"PJ)XQ+\N68%@,`]AUS6!J.IZA<W^O6UU%-!;+8L88V7"\,1OS
MZMU^E=&%UKP]4*6S/;[`;M+MP>\*C_QT51\,Z)_8=O+`)_-5W+*`I4*/Q)Y]
M3P#Z"K^G?\@RVP>?)7K_`+HJIH%Q?7,5P]_+;RA9F2%H86BRJ\<@LW<'G/(K
M&7Q,#FM'_P"2OZY_UY1?R2NBU;1;>_O[:]EDDCEMF!4AR`1G)&,XY]:YW1_^
M2OZY_P!>47\DKI?$4$EQI[1Q6:7K%A^[<@`>_/!QZ5VXAM5(6=O=C^2$E=.Y
M1U/PW#J%W//]K:,R&-@H4'9M/S?]]#@_2JUWX6>5[C;=6JQSR^<"UNQ;[X?!
M/F`$<=@#[U%I^@W4,MQBU\H-:21"1W4M(6"!`V/[NUNOKQ56?0=:N;>%)%++
M&>!+*K,!L9>OID\#TIJ3V]IHAI7U->V\-^5.+O[3&MR$$0,41";<MD;69NH;
MUZ@=N*OZ+IDNGB8RSK+YA&%CCV(,=\9/)SSC`X'`KG;NUUZPM9+CSYMBX4Q1
M,#A,)G:`.#G?S71^&GN9-%MGO/,\YE);S/O=3C/OBL:JER7YDUL)'%WO_(\Z
M[_NVW_H!J>H;[_D>=>_W;;_T`U-4XC=>B_(<3&UC1KC4=3LKG[9$MO:MO^S2
M0%U9\\,2''('3.<5LXQQ7,>)KZ^M-;M$MILAPHCA#A2S;\,2#]X;3T'2NG^E
M<ZV'U"LV/2Y/[9_M">Z\S:K)&HC"D*<<,P/S`8XXXR>M5_%\U];Z3YUA<+!L
MD3S#MRQ!<#`].O6J>DZA>3>)9H))6(W2B2'=Q&BD>6V.V1GGO0M=0>ATU,GB
M6:%XI-P5U*G:2#SZ$=*>*P]5GOX?$>EQQ7"):S>8IB"?>8(3ECZ9QP*0$^@:
M#!H?VI;>61XYY`X1V)\L!0,<D^E:O:L7PG->307JZA<">6*[>/<%V@`8X`]!
M6U3`J:M8C4;%K<F,9*L/-C$B95@1E3U''J/J*-(L!IFGQVHD,FS/.,#DD\#L
M.>!Z5S>JZM-IUSK;:MJ+16T,44D7D`*5W,P"@G/)P,GW[5N^&IIKC0[6:YE2
M:5UR71PX]AN'!([FA;!Y%^::.")I9G6.->K,<`5S?B*WL-96WFE>6TVJT2S2
MVS;0KXSR<;3P,$]#6KJ:F34+.+*YQ(\8?E3*`-N1W[G\*YFXU"Z&@E[G5&:\
M6YF15`"B<*^"H&#GC.%SSG\:%N!VT:A4502P4``FG9Q6=X>(.FA4+&))'2,G
M^Z&(`_#I^%)XF>\BT.[DT^=8)DC+>8R[MH`R<#UHV$3_`&#_`(F_]H-*21#Y
M*QXX7G).??BK=<C'J^I-XAT:!DG2SDA^9]H(F8Q[BV?0']:ZZ@?4*Y*7P^ND
MS"Y6X,OG7D"@;-IP9PV6.?F;G&>.*TO$MQ?6]QIKVLZQ0-=)',NWYG!/3/8=
M<_A6'#J$UQ>R07$AF<7T+`I.72-?/`"%<#8V,''.:Z<'_'CZDR^$]JUBUEO=
M/EM[>987D&W<\>]<=P5R,@^Q!]ZS/#^A7.DW$CSWD-S'Y:QQ`6Y1XU`Z%MY#
M<\_=!S5_Q%?-IVD7%U'/!`Z+E7G7<@/;/S+Q[Y%9?AK7Y]5U"2&5K=XQ;QS`
M1(5:-F'S*V6/U'"\>O6N9%&5X=_Y*SXF_P"O>W_]`6NZKA?#O_)6O$W_`%[V
M_P#Z`M=U79C/CC_AC^2)B</\6O\`CUT#_L+P_P`FKM\9`KB/BU_QZZ!_V%X?
MY-7;CI16_P!WI_/\P6[,WQ!>S6%AYMLH+E@I9D+!`>Y`Y/\`]>N<_P"$JU*U
MSOM#/%#"LDK&%D8=-V"3SUST'3O7:D`]>:CFMX9T"3Q)(H(8*Z@C(.0>:QIU
M(15I1N-HQO#NJW]_<W,&I6RPR1;2/+0[>>VXGD_@/QK<P`:7:,]**SG)2=TK
M`>=ZI_R/FL?]<+;^3TMS/';0/-,VV.-=S'&<"DU3_D?=8_Z][;^3TZ>6*"%Y
M9F"(HR6/85OBOB5OY8_D@B8J^*;.6#3Y8X96-^6\I69$8;3@YW,/R'-;N?PK
MC8M(D:WMK6^?R+*;>D3;%W@,V[8Q_A)[$'KQ[UV*J%4`=!QS7/I8#EM5OTM'
MU>\U"_OTAM;A8XXK8C./)C?`&/5B<DU(AADU;^SX]1U1Y%'S,LR84X!QC&>A
M'.,=/6FWLE@[>(-.U&Y^S?:IUP2ISM-O$,CCU!_*F%M"_M87ZZB%.\2L@4_,
MX7:"3C/3MTH&;GAV>6Y\/Z;<7#F266UB=W/\3%`2?SI+[6+6RU*TL9-[7%TQ
M5`J\+P3DGH/NGWIOA=63PSI2N"K+9P@AA@@[!4]]IZ7=Q93,Y0VDWG+CN=K+
M@^V&_2I6XR'3=4-[>7-LUE/;M;8W-(4*DGD`;6/..>U:(JKIUBMBL^UVD:>9
MYV9NN6/3\!@?A5JF(QKOQ)8VUQ>PE9G:RB$LA5>.6Q@$D<Y[]!ZU>TG48M3L
MDNH$=8V)&&(XP<'D$@CW!JIJFA0ZC<3RR321F:!8"%QQA]P/OSVJUI.GKIMH
M8%<RDNTC,>,L3DX';Z4(.I/=P0W%N\=RH:,C)SVQSGVKE3K=E+;';<ZE-!YC
MQ[<*K,J`,S%C@XP1[FNOK#O/#%O=0W$4D@,<]RUPRO$CCYAC`R..G!'-`&M9
M+`MG"+156`(/+"C`"XXHO)S;6[2I!+.1@".,#+?F0/SI\,20PI%&,(BA0/85
M5UNP?4],FLH[J2T,PVF6/[V.X'U''XT/<$4+7Q387-Q;QQQ3?O=NYB%Q$6+!
M5//<HW3(X]Q6YC%85OX8@BGMI!+A8%0%$C"JVPML..V-Q^M;QIAU,_6=332[
M<33032Q#)=DVXC`[G)'KVYK+UC6;6_TS6;2U\QGMK<EW*X4Y!X![XQS5W7]%
M;6&M0UX\,5O)YIB"!DE(Z;@>N.H]ZK>(K!(=.U:]#DM-:>65Q@#;G!_6ML)_
M&AZH4MCU;3CC3;8_],5_D*9INH6NH)(]G,LJ1L48KV-.L!G2[<9QF%?_`$$5
M3\.Z+%HL=PD+[A/)YAP@3G'4XZGU/4UC+XF!SFC_`/)7]<_Z\HOY)7<8KA]'
M_P"2OZY_UY1?R2NYKKQGQ1_PQ_)"B8/B?4;RR6&.S3'FDYDV,_(*X4`="<GD
M\<5D_P#"4ZH)75+`2(T@AB9HFCRS#C(R>!@Y_E79X![4QX(9)(Y'B1GB)*,5
M!*D\'![5E"K!*THW&S-\-:A<:E92/>Q".5)"AVH54].1DG(]^/H*U0,4``=*
M6LI--W2&><WW_(]:]_NVW_H!I+RZBL[:2XN&*QQC)P"2?H*6^_Y'K7O]VV_]
M`-+=RQ06TDMRP2)5)8GL*VQ&Z]%^0HF3;^)[*Y-B(8I6:\C655^4%%;@9&>>
MAX&>E;?OUS7&Z;HB^;9V]Z)+8K$B0MQNFCC.Y58_PN.I`[$^AKLC]<USC*&M
M:M;:/;I-=AV\QPBHBY))./P%-BU0OK+:>;*X1E0R><2A7;G`Z-D9]Q4VJV":
MG9/:R,45RIW`9(PP/]*6UL5M[Z[N][.]T4R#_"%7``]LY/XT(.I:K-O-:M;7
M5(-.<2M<3*SC8F0H`)Y/O@\5I51U+2X[^XMII'=?L^_A?XMRE3S^-"`BT#6K
M?6X'FMHY(PA`._:<Y&1T)'X=1WQ6G69H&B1Z/'*J3-,9-BY(``51A1@<=._>
MM.F_(2,2?Q/8QSW<*1S326[QQD*HQ([L555)('4<D\5I:;>1:A91W-N"(W'`
M/48."#CW%4K[0HKN>\E,FUKN.-&5HU=<(2>C#!SGFKFEV$6F6$5I;_<C!`.,
M9[FDAL748(Y[5O,60E!O4Q_?!']WWKF)-;5D,-W<WOR.RS0A(E=%4`L2P/0!
MEZ<\UUEQ&TMO)''*T+NI42*,E">X]Q7/6_@Z"*PBMGNGD*;U:0QKND5\%PWJ
M25'-"W`Z&WBBAMXX[=%2)%"HJC`4#IBF7UR;6W,JV\MP0<;(\9^N20!^)J90
M%4*.@XJAK^F-J^FO9+=26JR$;V09+*.J_0]#[4/8"M8^)+"^O;2UM_->2YA,
MZDK@*!C@GUY[5LUFP:3''<V,_F?/9Q-$H1`JL"!V'3IVK2H8&?K&JII0CDGM
MYGB9@&E0#;'D@#.2.Y'3)K,U/5H[J=+$V\T$T-W;R8D"_,OG`9&"2.1WP:N:
MUHC:I>V=P;MHTM&WB#RPR.W9B#W';ZUF3:*VF%KB2[:ZDN]0MW9I$`;_`%HP
M,^@!P!73@_XT;]R9['L5]<PV=L]Q=/LB099L$X'T%,MKVUN93';SI(X19"%/
M(5ONG\:35[,W]A):B41>8,%B@<8[@J>"#TK-\/>&XM$N9IH;RZG\V-4*S%2!
MMZ8(&>G').!7,48?AW_DK/B;_KWM_P#T!:[JN%\._P#)6?$W_7O;_P#H"UW5
M=F,^./\`AC^2)B</\6O^/70/^PO#_)J[<=!7#_%H_P"BZ#_V%X?Y-7<"BM_N
M]/Y_F"W8M%%%<904E+24`>=ZK_R/FL?]<+;^3UA:O>6UY;W-S<SLFF688YB/
MSRN.I'L#T]_I6[JHSX\UC/\`S[VW\GJ$:99``"UA`]D`KJQ7Q1_PQ_)"B<'<
MZE'=Z%:6\FHN)[Z9O)!NR5MX]P/[Q\_.P'8D\G':NVTN[82-874JO/&-R./^
M6R?WOJ.A_/O5@:=9X_X]8O\`OFG165K#*)(K>-'`P&"C(KF&3T444@"BBB@`
MHHHH`****`"BBB@`HHHH`****`"LSQ1_R+NH?]<&_E6G6;XH_P"1=U#_`*X-
M_*NC#?QX>J_,3V9Z5IO_`"#K7_KDG\A5BJ^F_P#(.MO^N2?R%6*QE\3&<-H_
M_)7]<_Z\HOY)7<UPVC_\E?US_KRB_DE=S75B_BC_`(8_DB8A1117&4%%%%`'
MG-__`,CUKW^[;?\`H!K!UVZ@NK"XO+J2==-M>5\C(>=P>H/H#P/?GM6YJ*B3
MQOX@1QE62V!'_;,U!'HNG1QK'':JBJ```2`!71B-X^B_(43D'\V\L-*#W]P]
MX9U=(HY6<*A<]&Z.R@@$DG`';.:[+3;MY@\%R`MW#@2`=&]&'L?TZ4W^R+'_
M`)X#C_:/^-/MM,L[6<SP0*DI79OR<XK`9;HH^E%(`HHHH`****`"BBB@`HHH
MH`****`"BBB@`K,\0_\`'M:_]?MO_P"C5K3K,\0_\>UK_P!?MO\`^C5KJPG\
M>/J*6QZE2TE%<@SAO#O_`"5KQ/\`]>]O_P"@+7=5POAW_DK7B?\`Z][?_P!`
M6NZKMQGQQ_PQ_P#243'8X+XORB+3]$D*NP35(F(1<DX#<`=S6J/&UJ/^81KG
M_@OD_P`*SOBR,6N@?]A>'^35W``K.M&7L:>NFO3S-Z<Z4=)PN_6WZ',_\)O:
M_P#0'US_`,%\G^%'_";VO_0'US_P7R?X5T]%<?++O^!M[2A_S[?_`(%_P#F/
M^$WM?^@/KG_@OD_PI/\`A-[7_H#ZY_X+Y/\`"NHI*.67</:4/^?;_P#`O^`>
M27WB&&7Q?J=U]AU)5EA@4(;5@ZX#=1VZ\5)_PD4'_/AJ?_@(]:>J?\C[K'_7
M"V_D]2UT8B,^97ETCT\D$:N&M_#_`/)O^`8__"10?\^&I_\`@(]'_"10?\^&
MI_\`@(];%%<_+/O^!7M<-_SZ_P#)O^`8_P#PD4'_`#X:G_X"/1_PD4'_`#X:
MG_X"/6Q11RS[_@'M<-_SZ_\`)O\`@&/_`,)%!_SX:G_X"/1_PD4'_/AJ?_@(
M];%%'+/O^`>UPW_/K_R;_@&/_P`)%!_SX:G_`.`CT?\`"10?\^&I_P#@(];%
M%'+/O^`>UPW_`#Z_\F_X!C_\)%!_SX:G_P"`CT?\)%!_SX:G_P"`CUL44<L^
M_P"`>UPW_/K_`,F_X!C_`/"10?\`/AJ?_@(]'_"10?\`/AJ?_@(];&<<GI5-
M=6T]G"+>0$D[0=XP6],],T<L^_X![7#?\^O_`";_`(!3_P"$B@_Y\-3_`/`1
MZ/\`A(H/^?#4_P#P$>MBBCEGW_`/:X;_`)]?^3?\`Q_^$B@_Y\-3_P#`1Z/^
M$B@_Y\-3_P#`1ZV**.6??\`]KAO^?7_DW_`,?_A(H/\`GPU/_P`!'JCX@UV*
M?1+V%;+4%+PLH9[9E4<=SV%=-69XH_Y%S4?^N#_RK?#QFZL4I=5T\Q.KAK?P
MO_)O^`=+8^-+:.R@0Z3K1*QJ,BPD(/'TJ;_A-[7_`*`^N?\`@OD_PKH--_Y!
MUK_UR3^0JP:RE&7,]?P)]I0_Y]O_`,"_X!Y7IGB6&+XDZMJ!T_4V2:TC01+:
M.95P%Y*]0.*ZW_A-[7_H$:W_`."^3_"LW1P/^%OZY_UY1?R2NY`KIQ49\T;R
M^S'IY(2JX?\`Y]O_`,"_X!S'_";VO_0'US_P7R?X4?\`";VO_0'US_P7R?X5
MT]%<G++O^!7M*'_/M_\`@7_`.8_X3>U_Z`^N?^"^3_"C_A-[7_H#ZY_X+Y/\
M*Z>BCEEW_`/:4/\`GV__``+_`(!Y#=>((9/%NL7/V'40LRP80VK;UPA'S+U'
MM4W_``D4'_/AJ?\`X"/6C??\CSKW^[;?^@&IZWKQFFO>Z+IY#C5P]OX?_DW_
M``#'_P"$B@_Y\-3_`/`1Z/\`A(H/^?#4_P#P$>MBBL.67?\``?M<-_SZ_P#)
MO^`8_P#PD4'_`#X:G_X"/1_PD4'_`#X:G_X"/6Q11RS[_@'M<-_SZ_\`)O\`
M@&/_`,)%!_SX:G_X"/1_PD4'_/AJ?_@(];%%'+/O^`>UPW_/K_R;_@&/_P`)
M%!_SX:G_`.`CT?\`"10?\^&I_P#@(];%%'++O^`>UPW_`#Z_\F_X!C_\)%!_
MSX:G_P"`CT?\)%!_SX:G_P"`CUL44<L^_P"`>UPW_/K_`,F_X!C_`/"10?\`
M/AJ?_@(]'_"10?\`/AJ?_@(];!.!DG`%06]_9W,C1VUW!,Z?>5)%8K]0.E'+
M+O\`@'M<-_SZ_P#)O^`9W_"10?\`/AJ?_@(]'_"10?\`/AJ?_@(];%%'++O^
M`>UPW_/K_P`F_P"`8_\`PD4'_/AJ?_@(]'_"10?\^&I_^`CUL44<LN_X![7#
M?\^O_)O^`8__``D4'_/AJ?\`X"-5#6M<AF@MP+/4%VW4+_/;,`<2`X^OM73U
MF>(?^/:U_P"OVW_]&K71A8S]M&TNO84JN&M_"_\`)O\`@'5CQO:_]`?7/_!?
M)_A0?&]J?^81KG_@OD_PKI\4&N>TNXO:4/\`GV__``+_`(!YYX+OEU#XE^(;
MN.&>%9+>'"3QF-QA5'*GD=*]$KA?#PS\6?$W_7O;_P#H"UW5=V*34H\SO[L?
MR1RR<6VX*R^\X?XM?\>N@?\`87A_DU=N.@KB/BU_QZZ!_P!A>'^35VLLBQ0M
M(YPJ*6)]A55?X%/Y_F0MQ]%8/_"8Z$=#?61>_P"@QR>4TGEMG=G&-N,]_2I]
M2\2Z5ID=I)>W7EK>D"$[&.[.,9P..HZUA[&K>W*_N'=&O25CZUXFTO1+B&WU
M"6599E+HL<#R$@=3\H-6]'U6SUBT^TZ?+YL6XJ25*D$=00>0:ETJBCSN+MW"
MZO8XC5/^1]UC_KWMOY/4M1:I_P`CYK'_`%PMOY/4M;8GXH_X8_D@04445S#,
MKQ-?/I^FF>.Y\A]VU0(P[2,>B*#W)JG%J.HQZKIT=W+"%NEV30JH/DR!`V,Y
MSGK[8_78OM/LM0C5-0M(+I$.Y5FC5P#Z@$=:6/3[*&83Q6=O'*J;!(L2A@OI
MGT]J`+%86NZC<VNIV-O9S!Y9F&;41Y)0'YG9L\`#]:W:J3Z7I]S=)=7%C;2W
M,?W)7A5G7Z,1D4!T,CPUK\NKZOJ<#KLB@V&%"A#!3D$MD=21G':NBIBP1)*\
MJ1(LK@!W"C+8Z9/>GT`<MJFLZA#J%_;Z?*MUY,3$@1A5@D.`B[B>6YR1GIZ5
MLZ#>&]L-[R2-+&[1R>:JJP8'!!"\?E3ET;2Q/+,--LQ+-GS7$"AI,]<G'.?>
MK5O!#;0+#;Q)#$G"I&H51]`*`*.MKY\EI:NP6&:1O,!Z,`I(4^V1S]*Y>;7;
MUK-H4Q<6<DCQI<K;KM=40LP5"0-N1QSG`/4UV6HV4.H6S03@[2<@CJI]163'
MX:B2T-FD5A';L06"62#)'0X^[GWQ1U`L^&9O-L&57,D44FR)R,;EVJP]^-Q7
MGTJQKES]DTN>X-TEH(QN,K)OVCV'<^GOZU/96L5E:QV]NNV-!@9.3]2>Y]Z+
MRTMKZ`V][;Q7,+')CE0.I[C@\4`<]97VK7-QI223F"6X1IIH7B7_`%:GKZ@G
M*\=N:Z?O4%O8V=L4^S6D$'EJ479&J[5SG`P.F>U3T`8OBG49]/@@-I,!/*^R
M*`1[VG;L/8#DDU@W.M7M['K-K<E1"()_+PH`RC;3@@YX[YQSTXKKK[3+#4"C
M7UC;71C^X9HE<K]"1Q6?XBLK2WT35)H+6"*9X&#R)$%9N.Y'6NC"Z5X>J_-"
ME\)ZCIQQIEL?2%?_`$$51\.ZTVKBY$D`@DMY-C*&+=>1G*CGU'(]S5[3O^0;
M;?\`7%?Y"ELK.VLT9+2WAMU=B[+$@0,QZGCN?6L9?$QG':/_`,E?US_KRB_D
ME=S7#:/_`,E?US_KRB_DE=P2`,DUU8SXH_X8_DB8BT5AV'BW1=0U#[#:W@><
MDA<HP5R.NUB,-^!J"'QOH<]U]GAFN7?S#%E;24KN!QC=MQUK'ZO6_D?W#NCH
MZ*YV3QMH45[):274BR12F%V-O)L5^F"^W;^M="I#`$'(-1.G.G;GBU<9YS??
M\CUKW^[;?^BS4]07W_(\Z]_NVW_H!J>M<1NO1?D)!1117.,QO%.H3:?9));7
M`CF9MD<0CWM.Y'"CT]2?2J6E^(KB\\4G394$426Y)4H=S2*1N.2/N\X'KCZ5
MN7VFV.H;/M]E;77EG*>=$'VGVR.*E6V@6595A175=BL%`(7TSZ>U"T=V#V):
MP=8U*ZMM;M;:TE$Q<;Y+<1CY(QG<[-V[`5O54FTO3I;P7DMA:R72@`3-"I<?
M1B,T(#.\*:C<WUM(FH-(+M%1Y$9$`4,,C:5)R/KS6Y4%K9VUDK)9VT-NC'<R
MQ($!/KP*GH`Y'4/$%_;7E[':2?;(HI(X6D2(`0R/(%"C)^8A3DY/7TK?T*\:
M^TR*9W+ORK$H$.0<'(!([=CBG1Z-I<;S/'IMHC3Y$I6!09,]=W'/XU:AACMX
MEA@C2*-!A410H4>@`Z4('J9NJQBZO%MY9$2&.%IBKC*LP(`+#C*CJ1[BN:EE
MNM6TF`Q7&SS;H0V4_P!G13(N/]8/[H&&QCJ*ZS5=-2_1<L%=05^9`RLI^\K`
M\$'TJC!H3QQI#'#IUG"K%B;2WV-G&,K_`'3C(SUYH`T=(FDGTV%YV#R8*LX&
M-Y!(W?CC/XU#XAO/L&E2W'VH6NPCY_+WDY.-JCU/05>MX8K:WC@@01QQJ$55
M'``Z`5'>V-IJ$/D7UK#=19#;)HPZY'0X(ZT`<M8:_JKZY96M\JQ(ZQK,FP?*
M[1LV#SD-P.G&,]Z["JL6FV$$D<L-E;1R1)LC=8E!1?0''`^E6J`,/Q-J-S92
MV:6,P-Q.^U+81[C+R,DG/"@9R?I6,FK7UY="TOE^Y<V\@PH"K_I&W:"/O#`'
M/UKJKS2]/O9HYKVQMKB6+_5R2PJ[)]">15#6;2VMH8FMK:*%I;^W:0QH%+GS
M!R<=373@_P"-&_<F6J/3M7NI;+3Y;B"-)I4&4C>0H'/ID`G/X&LOP]XADUFY
MF0V@MX517B?S&8R`@9P-H&`21P3TZ"MF\M;>]MVM[N".>%_O1RH&5A[@\5':
MZ=96<DDMI9V\$DF`[QQJK,!P,D#G`Z5S%'(>'/\`DK/B;_KWM_\`T!:[JN%\
M._\`)6?$W_7O;_\`H"UW5=F,^./^&/Y(F)P_Q:_X]=`_["\/\FKK]1R=.N`.
MOE-_*N0^+7_'KH'_`&%X?Y-74ZSJEOI-FMQ=9*LXC`!49)]V('ZU4TW1I6\_
MS!;GD0TV\.E+8?9I/L<EB=18;3_K%B*8^N2#6U?V&KZ_<20V%G!+!::<EKFY
M=H\.RABRX!R1@?E7>7NN6EDRK/O4MLQ@9SN.,]>@P2?0"H4\1VTDA6&WN'4)
MYC284``@GNV>W8>E=;QM65I*!/*D<7%_:VN:AH<MG=2Z??1V$\<DWE!P)%8`
M@[ACDBNF^'7&EW*3I*E^+AS>>;U:7U&`!@@#&*OQ^(K5HXY)89X?-'[M6"EG
M.`<`*QY.1Q5FQU2*[O);>."=3'D;V4;21U'!X_''MFN:O7G.'+R67_!?^8U%
M7N<9JO\`R/FL?]<+;^3U+46J?\CYK'_7O;?R>I:PQ/Q1_P`,?R12,/Q2;Y/L
M$EG</%&+R%941>9`7`P3V7&<UN5D:[KT.CS6T4L)D,Y.,,%[@8&>IY''UK7K
MF6UAA7,O?>9XV2TM;J9?*7-PLLI","ORHB=">Y...F>:Z;CO60NOP'6_[.,9
M4[_*$A8<OMW8QUQCOZT^H=#7HHK.U#6(;+4K.Q>.1I+MBH8+\J<,>3T_A/%)
MC*'AV=GU:_2*YN+JUPK*TI8['R=RD-C:?8`#&.*Z"LO1];BU25T2-DPHEC)(
M/F(20&]NG2M04"*FKRW<.GROI]N;BY"_)&"HY]?F(''7K5#P5+=S^'H6U#SS
M.&=6:<@LV&(R<$T^3Q#;1W]W:&&X/V2(2LPC/SY.-JCJ3GO5S2+Y-3TV"]C1
MHUG7>%?J/8T+J!;KG_&<LT=I;&&8Q()2S@221F0!6P@9.02<=2,^]:>JWDEM
M'$ENJF:=MB;LD+@%BQQV`!^IP*YW^V;EM+N-2M[B](MIG603K%&F`,Y*E0P!
MR,#.[U-`'56;F2UA=D:-F124<Y*\=#[U+5+1[XZA8K,Z>7(#M=/0]?U!!_&I
M-2O8]/LI;J5)'6,9VQH68GL`!1LP6Q@ZO=7T7BN"+]]]FQ%Y21.1O)+!R1T;
M&%SGH.E=/^%8T?B!7DTW_0Y%BU!5*2%UX)!.,=3C')]Q6P*=M`8HKD=3MRR^
M(9TENO)BA,0CDGD="Q&YF"L2!U`XK>UG6(=)6`RQ2RM/*L:B-<XR0,D]`.16
M5KVLV]U#K.EPHS/;6A=Y!]W)R-H]Q6^%_CP]4*7PGJJR2Q:`DEN%,J6P9`PR
M"0O&<5BZ#KM]>Z[]ENGB"F%7,"Q$,N8T;?G/0LS#&.U;MM/%;:-#/.ZQQ1P*
M[LW`4!>2:2TU*RNKE8+>=7E:$3A1G.P]#^-8R^)CV1RFC_\`)7]<_P"O*+^2
M5VDY/E/M3>=IPN<9KB]'_P"2OZY_UY1?R2NHU#5[:QO[2SE!,UUG9@J!@8!Z
MD>HZ9KLQ2;G"W\L?R1*/-]"9K?5M-M=-CN9!'<,9-.O+7<;%3G+K-M^G?O3_
M``IJ*V4_D7'B"[M,7LA^PC3RZG+GCS-AZ_6N]N_$-C9W'DS"4/EU.%SC:N[]
M1T]34,GB:W02N+2Y*1N(MPV?,VX+@9;/4]\"NB6(E.+O#1^GGW7_``?,7*<Y
MH_AV[UB;6XY]4N+:PDU.7S+18EQ(`0<[R-PS[>E=_&@C0(O``P*RH]?MC((F
MBF2<J&,1`+!3GGY21@8/?T[G%6M+U)-2C9XHI8P,8\Q<9!Z$$$C^OK7%7J5*
MKO)612.'OO\`D>M>_P!VV_\`0#46KO$FGRF>>6"/&&DASN'X@9'U[5)>_P#(
M\Z]_NVW_`*`:GI8C=>B_($<%97FJF:S5Y[EF#*MN2[%9QYK!R?[PV8P6R<<]
M:[WZ'-9>I:W#8ZC!8[0\TN"09%3`)P,9(R>O`]#6H*PZ#>YA^,)?*T[]W=3V
M]QR8?++*'<#@$K^@)`)]:9I4E^?$<PNYY&A>SCD2(K@1G<1CW;U-27]E;7_B
M-(KR%9HUM"P5N@.\#-58M/TY]:?3VT2%52/S#*)-V!G`R.Q//Y&DMP>QTM(P
M8J=I`;'!(SS69X6&-"MU!.%+J,G/`=@*TI6V1,^"=H)P.IHZ!U,?PH;SR+Y-
M0N'N)8[MU#N,9''0=AZ5M5E>'=<AUVWDFAB,80@??#`Y&>H[C/([&M6G81E>
M*;N&PT2XN+AYU1`.+=BKL<C"@CD9Z9XP.]/\,O,^AVK7,RSRLN2ZOO'TW=\=
M,U-K.HKIEG]H:,R%G6)5R`-S-@9)Z#GK3M*OH]2L8KJ$81P>.N"#@C]*2ZC9
M:K`\8S&&TB,%U<0W(.Z%(BP$IR/E)`P3C.`3SD\&M#5[R6V6..W"B23<Q=E+
M"-%&6;`Y/;@>M<X?$$J6,=U;W5VTK-*3'<I&`$C(#$@*".HX!SZT+5V#;4[%
M"2@)!!(Z&EJOIUW]LLTFV%&)*NO]U@<$?F#4>LZE%I&G37LR22+&,[(U+,Q]
M/_KG@4`8NH7FK#QII\0M[A-.PZ[D9-DAV9+-\V1CTQ735DPZ_#-JEK8+#+ON
M(//W$?(HP#C/<\]JUJ&`5P\-Q.][)%.[SDWT+^8)9"L?[\`1E&X4XP?E'],]
M/JNL0Z9<V<$D<LCW<@C7:O"^Y/05EZEJWVFZ73Y;=H)H+JVDP6#94S``G'3.
M,X]*Z<'_`!X>I,OA/5/$5V]CH]Q<13QV\B+\LDB%E4]MV.@]^U8WA#7=1U6\
MNH]1A2$(JLD:K\R^[>F>H'I70ZA=165H]S<>9Y40W-Y<;2-C_=4$G\JJZ?K-
MGJ%P\%JTY>-`Y+V\B*5/0JS*`WX$URHIG,>'?^2L^)O^O>W_`/0%KNJX7PY_
MR5GQ-_U[V_\`Z`M=U7;C/CC_`(8_DB8G#_%K_CUT'_L+P_R:NKU:UCN;0"6X
M>V6,[_,0J,<$'.X$8P37*?%K_CUT'_L+P_R:NOOTFDLI$MTB>4K\JS?<)]_:
MJJ?P:7S_`#!;LQ+NRT34Y+9/MT;/);/#"D4RY=",$@=R,'D>]-DT'3%D6Z^W
MF)#$L&3Y)#!05X9E)!Y/0BET_1+R&^@N9E@B<9:5HYW8DY8D8V@$$MG.!CWJ
MI_PC.H;9H_M,:1N[-M$CL&RQ.2".",@8''&:(M;<]D*WD7+'PSIIAC"7+7*0
MY\LJ(EV$@#(**.>!SUJ_9Z0D%_\`;&N9YI-I4"3;QGKR%!/XDCTK'/AO4$7>
MMX0\2CRQ'(V!Z\=#^-7O!T%[#82F_A>!GERL;R,Y`V@=6YZ@G\:BI\+:G<2]
M#F=4_P"1\UC_`*][;^3U+46J_P#(^:Q_U[VW\GI;F.26WD2&4PR,,*X7<5/K
MBHQ3M)?X8_DBXZE#6-#MM6DC>>25"JF,B,@!D)!*G(/!P.F#[UI````=JX=U
MU*/2-*:0SSO#YI:&1)2T[;\*"RD8XZ%LCVKN%)*@D8..0:PMH%Q16<VC6[ZP
MNI2/(\J_<4[<*<8XXST[9Q[56\9Q7<OAV[^P3S0RI&6'DC+/@?='<?A5!3J"
M^+5,J2/$7`C`W@+'L&6)SM^]G@C/(H0=#J:JWUA%>S6DDK,IM9O.0*1@G:RX
M/MAJM5B:[#>'6-'EAFF\@7!62%!\I'EO\S$=LX]J74:+6E:-;:9+(\#2-N`1
M0Y&(T!)"C`Z<GKFM&L3PY:!+O4+H+-&KSF*..1W(VKP6`8]SDY';%;@_"@"I
M]@B_M-K_`'/YKPB`C/R[02<_7FETRRCTVPAM(&9HX5VJ7/./?IZUS6OPZG'J
M&IM%-=RI)9H8PBD+'^\((`'7`Y.#D^U:_A+SQHR+<^86#N`S@C<NXX.#R!CH
M":%L'4M:G#,WDW%JH>6!\[,XWJ001]<'(]Q7/ZAIUG>J\2'5DE>Y-XT*P#:S
MG``)9"A`QG&?SKK&!*D*<$C@XSBN$NH-6BL[@?:;JXD2]F";PX\S*#:PVC@`
MYP/NGU%`'7Z1:R6UN[W&W[1</YLNWIG``'X*JC\*M31B:%XV)"NI4X[9IMGY
MOV2'S_\`6[%W_7'-4?$UPEMHEQ+)#<SA0,16VX.YSP,KS@]_:A[A$C3P]`JV
M:&YNF@LP@2$LNUBGW6/&<\]B*U^IKA=-751?:<99)Y6*Q%&`D"!=S^:ISZ#8
M/FYKNJ;V#=E74K&+4+<03,ZJ'63*$`Y4Y'7Z5A:YX?T^QM-5U*UC,<\MJZ,H
M/RG)+$X]233O'$[)#:0P)<_:)G*I+%OV0CC+OMZX[`]3574H+V$>(/M%Q/<1
M/9JT9==JK][@#\JWPO\`'AZH4M$>Q6L:SZ/#$Q.'MU4XZ\K4=EI<%K/#+&\A
M:&V%LNXC!4$')XZ\4*95T!6MB!,+8%"5W#=MXXR,UDZ'J=]<ZXMO<32X%JCR
M1-:E%5RJGA\<G).><#@8R,UB_B8=#-T?_DK^N?\`7E%_)*Z76;>U+QW5[>&V
MABP'W,JHW((!+#CD#H17-:-_R5_7/^O*+^25U.M0WD]H4L$@>7(P9F*A?4@@
M'!].*[,2[5(?X8_DA+9F??Z+IE_<W$TURP>58IF"R#"JAR&'H#W/>JM[X>TM
MGF>;43"+J3S<%8.N[?P2F2/EZ$D8IUEX8EMI[R1;DXN;,6XB)#",C(`#;02H
M'`_&J;>%=2DMHHGNHD5#D1^8[J/D9<@D9YSGVZ4XR6WM-AV-6T\/6:%;F*XD
M>7:JK.FQ3M!/`VJ!@[B.GZ\U>TG2H]/,KK-+,\Q&YI`HZ?[H`_'J?6N=O=`U
M6"WEN(KF2XE!7,23.-Z`)E1Z9VMR.>?PKH?#<5Q#HULEXC)-M)968L5R>F36
M52_+?FN!Q5]_R/.O?[MM_P"@&IZAOO\`D>=>_P!VV_\`0#3;^*6:SEC@G:WD
M9<"11DK]!4XC=>B_((E75-#M=2N4GF>1&"A&V$?.H8,%.0>,@'C%:5<5;BZ^
MP:"S?;S?JL/F*0^&7/S`G[H/<[NPKM:P!F/?/-:Z['<K97%S$UL8\P@'#;P>
M<D=JBMKK[/>7=TFEZHTET5W[D0X"K@`?-TZG\:?XOANY=)+6,\T31R(66$?,
MXWCC/4"J=FVK-XVD:\@G2S-NRQ8<&,`,,'@_>//^126HWH:OAR*6'1H$GB:*
M3YV*-U7+$C./K5^:-9HGB<$JZE3@XX-.'6L+68KX>(--G@GG,&)%:)5^0'8<
M%L=<G%`%S1=&@TA9!#++*9`H+2E<A5&%'``X'XUHUSG@G[2EI-#<!Y-FW_2&
M61?-8CYOE<DY![\`^E=']*8(K:C9K?V;VSO)&KX^9,$C!S_$"#^(-+IUC#IU
ME%:VX(CC&!GOZFN7U6'5X[[51#<7$J.+=@2IVJAD.\*%ZX4<XY-;WAMI6T:`
MSQO&X!&'W9(!.#\Q)Y]#R*70'HR348YUF@N[9/-:+<KQC@NC8SCWR`:PKG3[
M">/R8(M2>8/(Q7R2FX2$%D+,NW:<#H<C%=3*KO$ZQOY;E2%;&=I['%<?'8W%
MQIEM:737DD[ZA)&9RSJRQ[B2W!'!"X';GBA:L&=1I5J]I9K',P:5BSN1T!))
MP/8<#\*DO+9+RTFMI"0DJ%"5Z@$8XJ8#`P.@K-\317,VAW:6<\D$OEDAHAES
M@=!Z9]>M`$B:7`EQ93AWW6<30QC(PP(`YXZ\5>KC+4:D/%-@6%SY?EQ!E(?!
M'E'<Q.=N-V`01G.#GM79T/8%N5=0L(KX0"9F7R9EF7:0,LO3/M6#/H<>D*9D
MO+FX:[U"WD?S]A.?-'0A0?8`DX%7?$L5XT^F2VT\ZQI=()(HAPX/=CUP/3WK
MG[1-02]D6X>22W6[MP7?>"TGVCKA@,?+CIQT]:Z<'_'CZDS^$]PU6S%_926Q
MFDA$@P7C"DC\&!!^A!%1Z7I<&FQE(6D<%43,A!("J%`_3/U)IGB.>6VT>XEM
MY)(I0OR/&F\J?IM;CUX-8WA/4M8OK^Z75$=(EC1D5H]I4XYS\H'/7JW_``'I
M7,BBCX=_Y*UXF_Z][?\`]`6NYKA?#O\`R5KQ-_U[V_\`Z`M=U79C/CC_`(8_
MDB8G#_%K_CUT#_L+P_R:NW'2N(^+7_'KH'_87A_DU=N.E%;_`'>G\_S!;LS?
M$,EW%9;K%7,FX!BB;V5>Y`[]JYF;5M?L$+^0YAAB7<)U`+MD?*#CDG)[GD8X
MKN",TAC!&"`1[BLJ=505I13&]3"\-SZP]Q<1:N-P7:4D5-JGU`!'ZY/X5O4;
M1164Y<SO:P)6/.]4_P"1]UC_`*][;^3TMP[QPN\,?FR*"53<%W'TR>E)JG_(
M^ZQ_U[VW\GJMKPMCI%RMY,\$#H49XVVL,^A]:WQ7Q1_PQ_)!$RF\4LNF_;OL
M4;1QS-!*5N,@L&`Q&=N7))]!T/-=&IR`:X>#2H;;^RI;[476T1]MHJ/'M@8\
M`'"X;CC('!)KN!T]:YP*.LWTFG6+W4<4<@C!9S)+Y:JH&2<X/\JJ6VNR37ME
M"]DT<-]%OC=I/FSMW$%<<=<=<Y[8YJSKFCP:S;QPW,LR)'()`(R,$CID$$$>
MQ%(NCP_;(KJ6>XF>'E%DDRH;&-P&.#C/`XYZ4D,T:R]8U=]-GME:V5X9I%B\
MSS<,6)P`JX^;'4\C@5J5F7NAP7FK0:E)/.LT"E$4%2F">>"#R>F1SCBD`W2-
M<BU34+ZV@B81VA4"4GB3.>0/08(SWK5K.TW0M-TR]GNM/M(K>2X55<1H%&!G
MH`/?FM&J8'/ZMXE_LNZN(I[-<QP/-&%FRSA<`;@!\H)(`.3WXK6TJ[-]8I.1
M""V<B&0NH_$JI_0513P[;I>7MTMU=B2](,A$@R,=-IQD`=AG'7CDU?TZQBT^
M`Q0EFW,7=W.6=B<DGWH0F0:G-,TT-E;,4DF5Y'?'*HN`0,\9)8#GW/:N7NM<
M^SB2$"6'4(Y?+YO"\>0NX[B5QD="`.O?'-=3JMG-,8[BS(%Q$K)R<;D;&Y<]
MN0I!]16!'H")IBV-O9WX=69DDN)(AY98$,2RY+`@G/!)SV[+J,Z+1KQK_3HI
MY$"2?,CJ#D!E)!P>XR./:I;Z66WM7EMX5FD49"M)L7'J6P<`?0U'I%A'I>FP
MV<1!6(')`QDDDD_F32:SIL.KZ=+8W#RQQ3`!S$VTD>GTH8(S+3Q#<W;:<UO8
MQ-%>YY^T$.H&=S`;,%>.#D9STK?]B<U0M-)@MI[>8/)));PF!"Q``4D'H`!G
M@#\*OT`9NOZJ^D6@NA;I+$IS(S2[,>@`P=S'/`X^HK$U'Q`-2L]9L1;>4(()
M"&WY)P<'(Q@?@3QUQ6WK&BP:M+:R3S3QFU<R1B,KC=ZD$$$CMZ5FZUHEI9:7
MJ=Y%O,C02X#-D+O.Y\?4\UT87^/#U7YH4MM#U:WGCM]&BGF.V..W5V.,X`7F
MHK/6;.YOTM(FD,DD`N$)C(5D/<'\14]G$LVD0Q/G:\"J<>A6H+/0[>TO([E)
M;AS%$(HTD?<J#`&1QGD`=\=\9)K&7Q,?0YG1O^2OZY_UY1?R2NYKAM'_`.2O
MZY_UY1?R2NYKJQGQ1_PQ_)$Q,+Q1)J*I#'IRR;'SO:)-S9R,#V!^;GV'K6(^
MK^(DN2@A*+<2B*!9D`89!);MD+CMG.>M=OMYI"@)!(R1TK*%51C9Q3&U<R_#
M,^H363_VJC"99"`Q7:'''(!`('U_,UK4@&*6LI.[O8:/.;[_`)'K7O\`=MO_
M`$`T7<DD5L[P1":0#Y4+A`?J3T%%]_R/6O?[MM_Z`:H>*!:R:+<17LDT<4P"
M8A?:[D_P@GU]^/6ML1NO1?D*)G6OB]+AH<6@V$JLKB7(7<Y12GR_."03GCBN
MFKD-,L[.&ZM+;5+N)I@BO`R2*J3(IRJD`#.PGC`&?S%=?6#&9VO:F^DV37:P
M)+''EI"\NP*/;@Y)[#'XBH].UM;[59;)+6:(1PK+YD@V[LG&`/;UI^M:+!K'
MV;[1+-']FD\U!&1@MV)!!!QVJS'8Q)?F]R[3F$0DD]5!)_/FD@99Z5E:IK$F
MGZA:P&T#QW3B-&$H#LQ!.`F.0,<DD8SWK5K*NM"AN=6&I&YN8YQ'Y0V,NU5[
MXR#@GU%`#M%U9M2DNHI8%AEM9!&X27S%R1G&[`Y'0CMZFM.L_0M'@T6T-K:R
MS219+#S2"03UY`!.>Y.:T*;!&'-KERE_<V2Z>CSQ1^;&HN!RN[&7X^7U&-Q(
M'3/%:.DWPU+3H+Q8S$)EW;2<X_&J,'ARWMY;R6&\O4>\?S)&$@!#9XP<9P,8
MP21CC%:.GV<-A:);6ZD(F>IY))R2?<DTD#*^K37/[NVLRRR2AG+*1D*HY"YX
MR20*YJ?6X[:PDD7[2M['<"WVQ7)E4GC+9(`(&1GCKQ72ZS93748>UD,<RJR<
M-MW*PY&<'!Z$'U%<^WART?2(],&B2SF/B)[SR?W'(/WEY(..<`D]Z%HQG3Z9
M</<V:O.H292R.!TW`X)'L>H^M)J=S+9V;SP1)*R<D22>6H'<EL'`'T-+IMK]
MBLTA+;VY9VQC<Q.20/3GCVJ+6]*AUFQ-G=22I$S*S>4P!;!S@Y!!'M0(S=,\
M4)J.HVUM'!'$LT"2DRRD-E@3M4;<,>,\D<5T'>LQ=$@^TV\\L]Q,;?#(CN-N
MX`@-@`8.">F![5ITP1EZ]J[Z2D,GV9986<([&7:020`%7!+'GVZ&LF77DU<*
MD42K'%>P;6\S+-B8*<K@8Y';(_&M?5-$@U*^M;R6>>.2TR8PA7;D]200>>V:
MS]2T:TL'AN8`V][R!0">$!F#$+]2<UT8/^-'U)GMH>LZE>16%E+=SA_*B7<V
MQ2QQ]!5;3=;LM3E>.T=R44-EHRH8>Q/7'0U:U"T%]:/;M-+"&_CB;##^8_`@
MBJ&C^&]/TB[EN;1"))8TC)(7A5&`,@`GIU.37*BCG?#O/Q9\3?\`7O;_`/H"
MUW5<+X=_Y*UXF_Z][?\`]`6NZKMQGQQ_PQ_])1,3A_BU_P`>N@?]A>'^35VX
MZ"N'^+/_`!Z:!_V%X?Y-7;@T5OX%/Y_F"W8ZBDXHXKC*%I*,BC-`'G>J?\CY
MK&>/W%M_)ZYR]U&WU""XNV$%W'$I%I9NZKYK=-S;C@>V>@Y[UT>J'_BO-8_Z
M][;^3T_8O]T?E73B?BC_`(8_DA11YO)I[7.EQH[B.YN/,$X=X?+B+,#PH<[0
M,8!&3[<UV.CW\<=S_9C7*7&%W02!LED'56]Q^HQ6OL7^Z/RI0JCH`/PKG*L+
M1112"P4444!8****`L%%%%`6"BBB@+!1110%@HHHH"P5F>*/^1=U#_K@W\JT
MZS?%'_(NZA_UP?\`E71AOX\/5?F2]CTK3?\`D'6O_7)/Y"K%5M-_Y!UM_P!<
MD_D*L9K&6[&</H__`"5_7/\`KRB_DE=S7#:.?^+OZY_UY1?R2NXS75B_BC_A
MC^2)B+12<49%<90M%)Q1Q0!YMJLT<'C7Q%+,X2...V9F)P`!&>:Y^^NEO+&?
M4?*M[Z;9BSLI944`'^)MQ`R>"<\@#'K71:BBR>-]?1U#*R6P(89!'EFF?V7I
M_P#SX6O_`'Y7_"NC$;Q]%^0D<G9Z='<0:;;W<D<:Q>;<RRM)$'6?.4`"L<+E
MF(`/89KI]&U%;P202/&;JW(63RVRK`]''L1^72I?[+T__GPM?^_*_P"%2V]I
M;6V?L]O%#NZ[$"Y_*N<JQ-1110%@HHHH"P4444!8****`L%%%%`6"BBB@+!1
M110%@K,\0_\`'M:_]?MO_P"C5K3K,\0_\>UK_P!?MO\`^C5KIPG\>/J3):'J
M5+2`T&N89PWAW_DK7B?_`*][?_T!:[JN%\/?\E9\3?\`7O;_`/H"UW5=F,^.
M/^&/_I*)B<'\8(S+I^B1AVC+ZK$N]#AER&Y'O6D/!UQ_T-&N?]_D_P#B*H_%
MK_CUT#_L+P_R:NW'05%:$?84WZ_F;0KSA[L7I\CEO^$-N/\`H:-<_P"_R?\`
MQ%'_``AMQ_T-&N?]_D_^(KJJ*X^2)I]9J]_P1RO_``AMQ_T-&N?]_D_^(I#X
M-N,?\C1KG_?Y/_B*ZNDHY$'UJKW_``1Y'>Z%+%XNU.V.LZD[1PP,93(N]\AN
M"=O0=JE_L*3_`*#.I_\`?U?_`(FM/5/^1]UC_KWMOY/4M;XBC!26G2/Y(N..
MKI6O^",?^PI/^@SJ?_?U?_B:/["D_P"@SJ?_`']7_P")K8HKG]E$KZ]7[_@C
M'_L*3_H,ZG_W]7_XFC^PI/\`H,ZG_P!_5_\`B:OW]_:Z?");R41(3@$@G)^@
MIJ:E927:VJ7"-,R[PH.<C&1STZ<X]*/91#Z]7[_@BE_84G_09U/_`+^K_P#$
MT?V%)_T&=3_[^K_\36Q56XU*SMKN*UGN$2:7&Q#WST]AGWH]E$/KU?O^"*/]
MA2?]!G4_^_J__$T?V%)_T&=3_P"_J_\`Q-:5O=V]Q+-%!,DCV[!)0ISL)&0#
M^%34>RB+Z]7[_@C'_L*3_H,ZG_W]7_XFC^PI/^@SJ?\`W]7_`.)K7=E1"[D*
MH&22<`5':W,-W;QW%M(LL,@W(ZGAA[4>RB/Z]7[_`((S/["D_P"@SJ?_`']7
M_P")H_L*3_H,ZG_W]7_XFMBJU_?VNGHKWDPB5C@9!.?RH]E$/KU?O^"*']A2
M?]!G4_\`OZO_`,31_84G_09U/_OZO_Q-:ZL'164@JPR".XI:/91#Z]7[_@C'
M_L*3_H,ZG_W]7_XFC^PI/^@SJ?\`W]7_`.)J[-J5G#>I9RW"+<2#*H>O.<<]
M!T/Y5;H]E$/KU?O^",?^PI/^@SJ?_?U?_B:H>(-&DAT2]E.K:C*$A8['D4JW
M'0_+73UC>)KRV;2=3LTF4W*6K2-&#R%/`/Z5OAZ,'6@O-?F)XZO9Z_@CJ;'P
MA</90./$VMKNC4[1,F!QT^Y4Q\&W&/\`D:-<_P"_R?\`Q%=#IIQIUMG_`)Y)
M_(58#9K.4(\S,_K57O\`@CRO3/#LTGQ(U:P&MZHCQ6L;FX65?,?.WACMQ@9]
M.U=7_P`(;<?]#1KG_?Y/_B*H:/\`\E?US_KRB_DE=S73BJ45*-OY8_DA+%57
MU_!'*_\`"&W'_0T:Y_W^3_XBC_A#;C_H:-<_[_)_\17545R<D1_6:O?\$<K_
M`,(;<?\`0T:Y_P!_D_\`B*/^$-N/^AHUS_O\G_Q%=511R1#ZS5[_`((\ANM"
ME3Q;J]N=9U(F)8,R^8N^3*$_,=O;M4W]A2?]!G4_^_J__$UI7W_(]:]_NVW_
M`*+-35O7I1YEZ+\BXXVLE:_X(Q_["D_Z#.I_]_5_^)H_L*3_`*#.I_\`?U?_
M`(FMBBN?V42OKU?O^",?^PI/^@SJ?_?U?_B:/["D_P"@SJ?_`']7_P")J_?:
MA:V"H;N41ASA<@G/KT]/6F6VJV-U=M:P7*23(,E1G]#T/4=*/91#Z]7[_@BG
M_84G_09U/_OZO_Q-']A2?]!G4_\`OZO_`,36Q52XU2RMKD6\]RB2D9P>@^IZ
M#H?RI>RB'UZOW_!%+^PI/^@SJ?\`W]7_`.)H_L*3_H,ZG_W]7_XFM"ROK:^B
M,EI*)%!P<`C'YU8H=**#Z]7[_@C'_L*3_H,ZG_W]7_XFC^PI/^@SJ?\`W]7_
M`.)JR=;TT-<+]K3-M_K!SQSCCUYXX[\5;MKB*Z@2:W<21N,JP[BG[*(?7J_?
M\$9?]A2?]!G4_P#OZO\`\31_84G_`$&=3_[^K_\`$UL5#=WEO9HC74R1*[B-
M2QQN8]`/>CV40^O5^_X(S?["D_Z#6I_]_5_^)H_L*3_H,ZG_`-_5_P#B:V**
M/91%]>K]_P`$8_\`84G_`$&=3_[^K_\`$T?V%)_T&=3_`._J_P#Q-7FU&S6_
M6R:=1<-T3GGC/7IG`Z>U6J/91']>K]_P1C_V%)_T&=3_`._J_P#Q-4-;T>2*
MWMR=5U"3==0IAY%.,R`9'R]1U%=/6%JFI6=\D45I<)+)!?6XD4?P_O0/Y@_D
M:Z,+1@ZT4^Y,L=7MO^".R7P;<X_Y&C7/^_R?_$4O_"'7'_0T:Y_W^3_XBNI)
MQ2%O:L.1$?6JO?\`!'GO@JS:P^)7B&U>ZGNVCMX<S3L"[953R0!ZXKT2N%\.
M\_%GQ-_U[V__`*`M=U7;BHJ,HI?RQ_)&$IRJ/FD</\6O^/70/^PO#_)J[<=*
MXCXM?\>N@?\`87A_DU=N>@JJW^[T_G^9"W849K@-5\4W<'B_='>HNEVMS'9S
MV_RY9G4Y?UX)451UWQ!J*:]K$%MK-['-;2(+2TALQ*DA*`X+;>,D]R.M5#`5
M96]+]?ZZ@Y)'IH-%>9ZYXBO8->F@U#6[O2%2T@D$4%J)09&'S`G:<<^]=OX4
MGOKG0;6;55*W3KELKM)YX)'8X[5G5PLZ,%.3T?ZA?6QR&J_\C[K'_7O;?R>I
M:BU7_D?-8_ZX6W\GJ6EB?BC_`(8_D@0450U/5X=/N;6W:*2:6Z)"*C(O3J26
M8#O]:OUS%%#6[>YNK"2WM4A?S04=99&3Y2,'#*"0?PK)T[P[=VFHV\DMS%+#
M&RS,XR&9Q$(\;<8QWZ_A72UGC5[=M6;3D25Y5X=P`50XS@\YZ'KC'/7I0!H=
MN:R-;T^\O[BU2(P+!%*DQ=BV]2ISPO1LCCG&.O-:]'X4`9>CZ2--O=0DC6)(
M+F17C1.V%`.??.:U*S].U3[;>7-L;*YMWML;C+Y94YZ8*L?KVZUH4`17=M%=
MVTD$\:21N,%7'!^OM570+*33='MK.8H7A3:Q3H?I4VI7L>G6,MW.&:.(9(7D
M_KQ^?%)I=_%J5DEU`K*K$C:^,@@X/0D'D=0:`+58WBFRU+4+)+73C`L<CXN/
M,E:-C'W52%;!/3.*N:H\Q:WM;9S&]PY#2+U1`"21[]!^-9FKII6DQ0K)%<&5
MU8K+$Y\T!1EF+E@3@=>23Z&@#<MXQ%;QQA50(H7:IR!@=,U)6?H=T]S:,LL@
MEE@?RVD`QOX#*WXJRD^Y-6=0O8-/LY;JZ8K%&N6(&3]`.YH`H:KI]Y>:G9O&
M8$M[>19=Y9O,!&<C;C!!SUR,>]:W]:QXO$EE+-:QHDW^DI&X8JN(]^=@;G.3
MM/3/O6Q0`<UQNJ>'[BQDUK4VO?/BN;1U*NHW[LDCMT`X%='JVKVNDB$W1?,\
M@C147)))`S[`9ZUFZYJ]K>:;K5C;LS2VD!\P[<+D@C`/X5T87^/"W="GL>HI
M;_:M`2`''FVP0')&,KCJ.167HNB:E9ZS%=75Y!+;Q68MEC56#(0%SR3@Y()S
M@'D5L6<J0Z1!)*X1$@5F9C@`!>M);:G97%R+:&YCDG\L2[%.3L/0UC+XF/H<
MGHW_`"5_7/\`KRB_DE=S7#:/_P`E?US_`*\HOY)74>(=1.DZ->7P3>;>(N%]
M2!77BHN4X)=8Q_)$Q-#-%</+<:]HME9ZO>:L+R.>2))[4PJJ*'('R$<\$CKF
MIHY==U^YU&XTW5?L$=G<O;0PF)660IP2Y/."?3%9_5FES<RMW_I`G<[+-+7$
M>)(=<AU?3$B\07%NNH3>2T<<496/$>25R,G)'?UKL+&*2"UCBGG:XD10&E8`
M%SZD#BLYTN2,97O<=SS^^_Y'G7O]VV_]`-3U#??\CSKW^[;?^@&IJO$;Q]%^
M0(**H:KJ]KIDEK'<%B]W*L,:H,G)[GT`]:OUSC,;Q58ZEJ-I':Z<8%AD?_2=
M\K1LT?=5(5L9[GTJMI&@7-CK;WCO$L)WX5&8D[MN%VD87&.HY/<5T59]IJ\5
MWJ=S910RDVQVO*63;G`.`-V[OUQCK0MP>QH?CBN>UO2=0U36(#,MK)I<2Y\I
MI65C(01N8!2&`'0;A70TV1UCC9Y"%1068GL*`,?PQH\VE+</<R`R3%!M60NJ
MA5P`"0#^GYUM=ZHZ1JL.K0-+!%+&H(P9``&!&01@G]<'U%7J'Y@<SJ6@ZA?W
M[W1>U1HS&8E5VQ+LD#J&X^3ICC.<Y]JV=$LGT_3(K:5P[C+,5)(R23Q[<U->
MW#6MJ\RP23[.2D94'ZY8@?K3=,O1J%A#=)#+`LJ[@DH&X#WP2/UH6P%FLOQ!
MI(U2*WV+&)X)DD1W_A`8%L>Y`J?5+B1#;VUNP2:Y?8KD9V@`DGZX%9.M/8:,
M+?SYM2,TS';*EPQ(QU)#,%/7[H!]A0!T=%4M*N)9X'2XP9H',3L!@-P"&`]P
M0:NF@##N-.U&Y\3V]W.+=].MAF)1,RNLA!!<KMP>N`-PK<Z5FMKEJNK_`-G%
M9!(&$9D(&S>5W!>N<[1GICWK2HZ!U`=:Y6_L+V+4/MUV;=5EN+6-5A9FW;9@
M0QR/EX.,`D=ZW-3U>TTZXM(+@OYMW)Y<:JN>?4^@K)O]9MM2,<$"RJT5[;L&
M<#$B^<%W+@GC*D<X-=.#_CQ]12V/4?$MC=ZCHUQ::?<1VT\J[1)(I8`=QP01
MD<9SQ63X6T"\TG4+B>Z2S_>(%,L!;?,>N7!`QM'RCEN!VKI+B6."%Y9G6.-`
M69F.``.IJ.WO+:Y=DMYXY60*S*K9(##()^HKF&<=X<_Y*SXF_P"O>W_]`6NZ
MKA?#O_)6O$W_`%[V_P#Z`M=U79C/CC_AC^2)B</\6O\`CUT'_L+P?R:NU?[G
M7!KB?BU_QZZ#_P!A>#^35T/BIM2&DL-(3=,3\Q#88+@YV^_0?C53CS4:4?7\
MPV;,H^`=(DTNXM[F*.:\N&=VOFB'FAF8G<#VQ_2M70M%&DS7DWVEKA[ID9BR
MXP50+_3-9NO-K"RQ_85N<&`3,$R1N3G9]6)`]\&J`;5$NQ]H-\6-NK+Q<8WE
M6)&$&S.<<$TW[6I"TIW3Z"=K[&]/X=M;G4M1NKEO-CU"!8)(F'`"YYS^-6M!
MTY])TV&Q>Z>Z$(VK(XPVWL#ZXKF+*35VM[<6XO"2#]H+F?=MVC.WS0/FZXQQ
MFM71GN/[:D#?;GB96.9E=54<;1AAM_[Y.>N16513Y;.5U_EH--=CG=5_Y'S6
M/^N%M_)ZEJ+5/^1\UC_KA;?R>EN4>:VDCCE:%V&`Z`$K[@4L4[27^&/Y(<49
M^MZ*NK[%>41C!1OW09BI()VMU4\=ORK31=JA1G`&!DUPLT=VFB:3926M^UV\
MC@W1BE?[.HD)W-M!^8C&,^OI7=*/E'-<^R"XM9#:!#_;8U)9"A,@E9`.6<+M
MZ^F.WTIGC2VNKKP[=I8RW"3",L%@'S2''"^OY57EA?\`X2BSDMX+H,`5G9E<
M(4*<$,3MP#_#P<G/U%N,Z*BBL/7;:[;5](N())VACN")(D'R8\M_F8_7`]*7
M4#1TVQ%B+@^896N)GF9F&#DG@?0#`_"K=<SX7CU=-<U635X'03"-D;?NC'7Y
M4XZ`8_R:Z:CH'4J:M8+J>GR6CNR+)CYEYY!!Z=QQR*;H]@NFV7D+(9,NSEL8
M&2<G`[#T%8.LV-^VHZKLFNY(KBQ"H5C++&=YRJJN.<<\<UK^&1(-+42VRVX5
MV"`(R;ESPVUCE<^AH6P=2SJ5M).D4ELRK/!)OCW=#P00?8@G]*Q]?MKK6K5+
M5],=&4G<9/*>(@C!PV=PZG!`S[5T3`E2`VTD<'&<5P=Y8ZM#9SQL+JYC6^E9
MS+&[M(-@V$!,'&[H1P.#VH`['2+$:?8I"6WOU=L8R?\````#V`JQ<1">!XFZ
M.I&?3WIMD7-G`94,;E%W(23M..F3UJ'6();C3+B*WFE@=D.'BQN^@SZ],^]#
M!;&;!X7@AGM'6=BMND2,I4?O#'G8<]OO&MX=*Y33]->XGT+[5:S+)!:B6:9U
M8'<N`J,?J2<'GBNK[YIL.I3U6P34;987<QXD1PP&?NL#C]*S/$5@L-CK%\'.
MZ>TV%,<#;DY^O-2^*[:ZN+6W:UEN!Y4\;-%"/OC>O7'.`,USD\%]'-X@DGBN
M%A>&<Y=&`'S_`"?,>'R.F/NCBML)_&AZK]"9['M\$"W.B1P/TDMPAXSU7%9^
MD^'DL-5%ZDZMB!8<"(*S;5`^9ARPXX!Z9Z]JNJ9AX?4VQQ,+8%#MW?-MXX[U
MB^'KW6Y=?>+4EF%L;9"H\G:@.Q2S$[.NXL,;N,?='6LG\3*Z%'1O^2OZY_UY
M1?R2NQO;:&]MI;6X4/%*A1U/<&N.T;_DK^N?]>47\DK<UY]5&J:>+&,FT$H\
M\HWS'/&",?=`YKMQ*;J0L[>['\D0M$RE;>$"LL$=]J]W?6%JRO!:2!0%*_=W
M,!EL>]/O_"CSW=S)I^KW>GPWC;[F&$*1(W<@D94GVJMKC:VE_.+3[688G4KL
MR0XD&TX_W/O>U4+QM2C:]4'4#(+@!2INN8_,7IM7;C;GE<G%4O:NTN=:_P!;
M#ZV.HN]%CN9M,?SY!_9LF]<_,7^4KR3]>M:J\5R%H^IFY0C[9]@$:9($I??E
MQ_RT`8C.,Y]OX:T_"KW!2=9OM;*",/<!QN..<!P"/PRO/%<U2$N765[#.6OO
M^1YU[_=MO_0#4]07W_(\Z]_NVW_H!I+^&2XLY8HIGMW<8$D>"P^F>]&(W7HO
MR'$H:SX>L]6NH+F5YHYX'1@Z3.,A6S@@$#KWQ6O7(:=9ZB+7PM+*]YF(JD\)
M!PO[M\L_?K@<\5UXZ5@T`5E0:*D6L&_,P/+,J+&J<MC.XC[W3C/ZU#XPM;JY
MTD_8Y)P\<B,8X1S)\Z\''.._%5--,DWC"Z=+:[M8(E*EI8I<7+G&2&(VA1T'
M/<XI+5@SIJ9-&L\,D4@W(ZE6'J",4^L'6;:Z/B#3+E'N9+8"57BCX1?D/)([
MDX`R?I0!9T'1(]'$@29I=X51\NT!5&%X]<=3WK5[5@^%(GB:^"PW,=JTH,/G
MJZ$?*,C#<]>IZ&MZGJ(JZI:?;].N+3S6B\]"F]1DC/I5B-!'&J*``H"CV`KE
MKNUUF+4-9^QO-.T\47EO(VU4!+;@AQC('ZUJ^$5N8_#=BE]')%.L>&64Y;CU
M]Z2&RUJ5M+-Y,]MM^T6S[T#'`.001GMD&L7Q!:?VTL/^BWL4\:LGE&,8PV,_
M,3M!&!R#GD\5T<J,\3K&^QF4@.!G:<=:X>>SU&+3;96BN;IX+JX=4FMWD\XY
MPF[:1M!R2"?E%"WL#T1U^DVDEI;'SF#3RN9)",D`GL,]@`!5RD3)1=PVG`)'
MI6;XGMY[K0KN*UFFBE,9(,'WVP/NCZ]..:;`;/H<-QKL6IRNK-#@HOE*&#`$
M?>')&#T-:M<=:Q:FGB&Q>:VEDC*1*K%9!Y:^6=Y+9P#N_A;KD>E=C1T`I:GI
MRZ@+?<Y0P3+,"`#G:>E8EUH46F-'.DC.&N[>.-2,;%\_=CWY8U=\2VUW+/ID
MMM+/LBND,D<0X89^\Q]!^7-9CV"QW5Q>?9FMM^HV\4:D$`J)%)8`]<DGGVKH
MP?\`'CZDR^$]=U_3%UC2Y;%[F:V$HP7BVEOIA@01^%,TO2DTZ=Y1,TC2111,
M64`G8",G'<YH\37-[::-/+IEM)<W87$:1@$@GO@D`XZXS69X7O[^\U&Y6\:]
M55C0F.YLC"JOCG8VW##U^9N>F!7,BC,\._\`)6?$W_7O;_\`H"UW5<+X=_Y*
MSXF_Z][?_P!`6NZKLQGQQ_PQ_)$QV.&^+7_'KH/_`&%X?Y-79W3O';.\*!W`
MRJLVT$^Y[5QOQ:_X]=`_["\/\FKLKJWAN[9[>X3?%(-K+DC(_"G5M["E?S_,
M%NS"LO$%Q<7<,,EG&B%_+=Q*3R=^"HP,J=G7CK37\51K;LQMF6968;&R`X#$
M94XYZ5<N+'2-($5Y)$(_L_RQL69B#@@`#)R>3^M4H7\-LRAHHXWN,/MD##);
MG@].I[=S2BJ<M>5V!W)(/%5H0OVB.6,D99E&Y4'N:T]*U*+4D=X4D3RVVLLB
M[2#@'^1%4+"/0]3AF^P*DJ<*S*IQGM@G@XQ5O0=(BT:U:WAEDEWMO9Y""2<8
M[?2LZBI6:2:?9@K]3C=5_P"1\UC_`*][;^3TMS.EM`\TI(CC7<<`D_E2:K_R
M/FL?]>]M_)Z=/-';PO+,P1$!9F/848G22_PQ_)#CJ80\76GV2VN#!,J3(TK;
ML`H@?;DC/J>E=`""`<YSWKCHM)22.RMM2#)8N[?9U95+98D[7)'!.>",>E=B
M.!@5@%RIJEZUA:M.MNTP7);:P4*`,DDD^U4++Q+:WEW##!')Y<H4+(<8#E-X
M7'7[M3^(-'76[-+:2YF@C5P[",*1)C^%@001[4R'08(]16]:61W4A]I"A2^S
M9OX'!V\8'%(9K5FZIJPTV:`2V\AAE=8_.!&`S'`&,Y)^G:M*LF_T-;W6+746
MNYE-J"$AVH4R>K8(//;/I2`FTG6(-4FNTMTD`M9!&6==N[C.1[5H55M;".VO
M+NZ1F9[ME9P<8&U0HQ^`JU3`R;C6V@U`V1LIFE*,\(#+F4#&<#/`YZFK6D:C
M'JEG]IC4J`S(P+`X*D@\C@\BLN?POYUSJ-S_`&I>))?IY;,H3=&G]U&VY`Z\
M>]:NDV*Z9I\-G'(72(;5)55X]/E`%`#-7N)XDB@LQ^_N'VJV,[``26Q]!Q[D
M5STNI+#;W+XU&.XM'`F)N%.S*Y!(SM_X#Z^E=#J]M/-%%-:L1/`Q8`$#<"""
M/UR/<"N>M=)6VTI[&.;5)&E9C(#$@:0L#N#-MP?KVH`Z+1[Q[RU)G"K/$YCE
M"],@`@^V5*G'O4U[.]O;-+%`\[#&$4@$_B>!4&BV)L+())CS7.]\<@'``&>^
M%"C/M2ZWI_\`:NFS61N)K83#:TD)`;'<9(/4<?C0]010@\4V<\FG1HDADU!F
M50,'9C.23TQD$`BMRL-?"FGB>RG._P`^T*E70[-P4$*"JX&!GL*W*`,_6M4&
ME6_GO;O+$,F1U8`1@=SGK]!61JFMQ:EINMVL"+_HT3HS>:I.<?W`<CKW]*TM
M>T1=8:U,EW-"MM)YHC1597;L6#`YQVK/U[1H[?3]2OFGEED^SRJB,%`3=RW0
M#/([YKHPO\:'JOS0I;'K%M/%;:-#/<2+'%'`K.['`4!>2:CM-8L;F]6T@D=I
MFC$J_N7"LI`.0Y&T]1T-2VL2S:/#$Q(#VZJ2.O*U'INF163JZ.[E8$@7=CA5
MSS]3GGZ"L9?$QG+:-_R5_7/^O*+^25UFJW$MK:O-!'&[*,GS7V*!W).#_*N3
MT?\`Y*_KG_7E%_)*["_L;;4(!#=Q^9&&#8W$<CH>*Z\5;GA?;EC^2)B8MKXC
MGE:0S60B58))5!DRVY`NY6&./O\`J>E0W/B^..")X[1M[XW1R$H5^0MGH>./
MUJW?1Z-HNZ:6':\ZF+&68NO`/],GZ<U6SX7B#Q.L*>1N9@X8$8&">>O!_P`*
M453>O([#6FY-'XKLLE7CF##`&U,J[';A0>Y^<?G6OIUW%?V:7$(94?/#K@C!
MP0164-+TC6=+860\N.0Y6:,$$'Y>1N_W5Y]JU-*L8].T^*TA+,D0P"QR3[UC
M4]G;W;I@<'??\CSKW^[;?^@&B\NH[.UDN)MVQ!G"J6)^@%+??\CUKW^[;?\`
MH!HO9XK:UDFG;;&HY..?H/6JQ&Z]%^0XF)'XNM7DTU1;R@ZA&DD>2H(#'`XS
MEO?'2NAKC=-T(17%C#J#RPIY:)`JD8<1G<J.<<..ORX!Y':NQ'2L6!0UO5X-
M'MTFN$DD+N$58UR>3C)/0`9J*PUZWO-2>S2-D*LZ(S$?.4(##'48S^-6]3L8
M]2LGM969$<J25Z\,"/Y56MM%MX-8EU(L7G<$#<JC:#C/(`)Z=R:E:`]33_2L
MO5=:CTRXB2Z@D6&5@HF##`)!.,=3TYK4K(OM`CO-9CU":[F.R,Q"`JI0`_>(
MR,@GN0<T`3:-J\6JI(RQO"\>TE7(SM8`J>/45HUGZ/I,.E(ZQR22L^T%GQD*
MHPHX`Z#\ZT*/01B77B6&SN+B&\MIXC#&95``9I%W;<A1DC)Z9K4L+I;VR@NH
MU95F17`;J`1G%9MCX?2UN]0N&O9YVU#._P`P+E1C`"D#.!V%:5A:I96,%K&2
MR0((P3U(`[T#*^K3SJ8[:T!\V8,Q<`$JJCG`/!/(`SZUS\NJ+%937,9OX9;6
M0K.SW"R",X!^8$X;[PX'/;BM[6;6XE19K1F$J*R$)@,58<[2>,C`(SZ5S0T%
M%L+*UMYM4E-K(94B>&-0[GO(2N"0<G)]>]`'6:5=O>6*22H(Y02DB`\!@<''
MMW'MBG:A<O:6S31P-.5_@4A>/4DG``I--MWMK-8YG$DI)>1@,`LQR<>V3BH-
M?TL:SIKV3W,ULCL"[18RP!SM.0>#WH8%:R\1Q7=Q91I;2B.^CWQ2$C'3)XSG
MC'7IT]:V364FB*+FTEENYY5M,-'$0JJ&"E<X`'8GCI6J*`,[6=5&DK'++;.\
M+$!Y%(`3)`'!.2>>@K,U+6;>_NWLH%8M9WEKO?'RL6E'`]<;35[6-#75+VSN
MGNYHA9L76)0I1F_O$$'D=OK6=?>'['2IUO+)71I[JU1DW$J,2@\`^I-=.#_C
MQOW)GL>PW<\5K`]Q<2+%#$I=W;HH'4U6L]4L[RX>"WD9I(U#D%&4%3T()&&'
MN,T:WID6L:;)8W$DT<<F,M"^UN/>JNDZ%%IMT]PMS-.[1+"!+MR%7ID@`M^.
M<5S(HY[P[_R5KQ-_U[V__H"UW5<+X<Y^+/B;_KWM_P#T!:[JNS&?''_#'\D3
M$X?XM?\`'KH'_87A_DU=N.E<1\6O^/70/^PO#_)J[<=!16_W>G\_S!;LJZG8
M1:C`(IBZ@,'#(V&4CT-8=[X+LITD$;N'E01EI#NVKD'CH<_+D<\'M73T5SPJ
MSA\+L-J^YF:;HEIIUU-<6RE7F"JW0#`Z#@?SK2I:2HE)R=Y`E;8\[U7_`)'W
M6./^6%M_)JQ=6;^T[:Y<VTMW8VP.((^MU(.P_P!D?J?I6UJH!\>:R#_S[VW\
MGKGC\/O"Y)/]F=>?^/B7_P"*KHQ2]Z/^&/Y((F`^C:A+I5MFT9E)D86GD%4A
ME9@550<%5`R-PQSZ9KM=+N94<V%Z<W,2[@_:5/[P]^Q]_K61_P`*]\+_`/0,
M/_@1+_\`%5<TGPCH>CWHO-.LO)G"E0_FNW!Z\%B*YAFW1110`4444`%%%%`!
M1110`4444`%%%%`!1110`5F^*/\`D7=0_P"N#_RK2K,\4?\`(NZA_P!<&_E7
M1AOX\/5?F)['I>F_\@ZV_P"N2?R%6*KZ;_R#K7_KDG\A5BL9?$QG#:/_`,E?
MUS_KRB_DE=S7#:/_`,E?US_KRB_DE=S75C/BC_AC^2)B9VJ:3!J;1F<RJT>0
M#&^W*DC(/L<#\JRF\&V(FB>,N0)EFD+_`#,Y4$*,\>O).<XKIJ*YXU9P5HLK
M<H:/I5OI44D=L&Q(YD;..OT&!5^BBH;<G=@><7Q_XKG7B?[MM_Z`:P]8?^T[
M">[:Q?4+2`'[/:IG-P_3<?\`9]/Q/I6UJ<:2^-?$,4@RCQVZL,XR#&:P1\/?
M"X&!I?'_`%\2_P#Q5;XC=>B_(2,>/1+ITTXM;RRR*F%1K7:D):3<VTGE-HQC
M@9P/H.RTVZD<O:W>!=P8W8Z2+V<?7OZ'/UK%_P"%>^%_^@8?_`F7_P"*J_HW
MA71=$NFN=+L_(F9-A;S7;*Y!QAB?2L!FQ1112`****`"BBB@`HHHH`****`"
MBBB@`HHHH`*S/$/_`![6O_7[;_\`HU:TZS/$/_'M:_\`7[;_`/HU:Z<)_'CZ
MDRV/4J4TE+7,4<-X=_Y*UXF_Z][?_P!`6NYKA?#O_)6O$_\`U[V__H"UW5=F
M,^./^&/_`*2B8G!_&"7RM/T238[[-4B;:@R3@-P!ZUJ#QF,#_BGM?_\``(_X
MUF_%C_CUT'_L+P?R:NX6LZT9>QIM/O\`F;TZE*.DH7?JSFO^$S'_`$+NO_\`
M@$?\:/\`A,Q_T+NO_P#@$?\`&NGHQ7'RS[_@:^UH?\^_Q9S'_"9C_H7=?_\`
M`(_XTG_"9C_H7=?_`/`(_P"-=124<LNX>UH?\^_Q9Y)?:^)?%^IW7]E:HOFP
MP#RFMOG7`;J,\9SQ4G_"0#_H$ZK_`.`W_P!>M/5!_P`5YK'_`%PMOY/4M=.(
MA/F7O=%T\D.-;#V_A?BS'_X2`?\`0)U7_P`!O_KT?\)`/^@3JO\`X#?_`%ZV
M**YN2?\`-^!7ML/_`,^O_)F8_P#PD`_Z!.J_^`W_`->C_A(!_P!`G5?_``&_
M^O6Q11R3_F_`/;8?_GU_Y,S'_P"$@'_0)U7_`,!O_KT?\)`/^@3JO_@-_P#7
MK8HHY)_S?@'ML/\`\^OQ9C_\)`/^@3JO_@-_]>C_`(2`?]`G5?\`P&_^O6Q1
M1R3_`)OP#VV'_P"?7_DS,?\`X2`?]`G5?_`;_P"O1_PD`_Z!.J_^`W_UZV**
M.2?\WX![;#_\^O\`R9F/_P`)`/\`H$ZK_P"`W_UZ/^$@'_0)U7_P&_\`KUL4
M4<D_YOP#VV'_`.?7XLQ_^$@'_0)U7_P&_P#KT?\`"0#_`*!.J_\`@-_]>MBB
MCDG_`#?@'ML/_P`^O_)F8_\`PD`_Z!.J_P#@-_\`7H_X2`?]`G5?_`;_`.O6
MQ11R3_F_`/;8?_GU_P"3,Q_^$@'_`$"M5_\``;_Z]4/$&MB?1+V+^S=2CWPL
M-TEOA5XZDYZ5T]9GBC_D7-0_ZX/_`"K?#PG[:%I=5T$ZV'M_"_\`)F=-8^,0
MEE`G_"/ZZVV-1E;,D'CMS4Q\9C_H7=?_`/`(_P"-;^F_\@ZV_P"N2?R%3XK*
M49W>OX$^UH?\^_Q9Y9IGB/R_B3JU_P#V1JK^;:QIY"VV94P%Y9<\#BNM_P"$
MS'_0O:__`.`1_P`:S-'_`.2OZY_UY1?R2NY`KIQ49\T;R^S'IY(2JT/^??XL
MYG_A,Q_T+NO_`/@$?\:/^$S'_0NZ_P#^`1_QKI\45R<LNX_:T/\`GW^+.8_X
M3,?]"[K_`/X!'_&C_A,Q_P!"[K__`(!'_&NGQ1BCEGW_``#VM#_GW^+/(;K7
MP_BW6+G^R]37S5@_=FV^=,(1\PSQGM4W_"0#_H%:K_X#?_7K1OO^1ZU[_=MO
M_0#4]=%>,^9>]T73R*C6P_\`SZ_%F/\`\)`/^@3JO_@-_P#7H_X2`?\`0)U7
M_P`!O_KUL45S\D_YOP'[;#_\^OQ9C_\`"0#_`*!.J_\`@-_]>C_A(!_T"=5_
M\!O_`*];%%')/^;\`]MA_P#GU_Y,S'_X2`?]`G5?_`;_`.O1_P`)`/\`H$ZK
M_P"`W_UZV**.2?\`-^`>VP__`#Z_\F9C_P#"0#_H$ZK_`.`W_P!>C_A(!_T"
M=5_\!O\`Z];%%')/^;\`]MA_^?7XLQ_^$@'_`$"=5_\``;_Z]'_"0#_H$ZK_
M`.`W_P!>MBBCDG_-^`>VP_\`SZ_\F9C_`/"0#_H$ZK_X#?\`UZ/^$@'_`$"=
M5_\``;_Z];%%')/^;\`]MA_^?7_DS,?_`(2`?]`G5?\`P&_^O1_PD`_Z!.J_
M^`W_`->MBBCDG_-^`>VP_P#SZ_%F/_PD`_Z!.J_^`W_UZ/\`A(!_T"=5_P#`
M;_Z];%%')/\`F_`/;8?_`)]?^3,Q_P#A(!_T"=5_\!O_`*]4-;UH36]N/[-U
M)-MU"^7M\`XD!P.>I[5T]9GB'_CVM?\`K]M__1JUTX6$_;1M+KV%*MA[?PO_
M`"9G5CQF/^A=U_\`\`C_`(T?\)F/^A>U_/\`UY'_`!KIP*"*YK2[B]K0_P"?
M?XL\\\%WOV_XE^(KK[-<6WF6\/[JX38ZX51R/PKT2N%\/#/Q9\3?]>]O_P"@
M+7=5W8I-2CS._NQ_)'+*49-N"LOO.'^+7_'KH/\`V%X?Y-79SL4@9EZJI(KC
M/BU_QZZ!_P!A>'^35VLJ[XF7.-P(S5U?X%+Y_F0MSR^#QKK;>%;IGGC.JF=1
M;OL7'EG))VXQP$:M77?$FL+INFC2YHQ>-9F^N"8P=R*H)4#L2<U/#\/XHVM7
M:^+/;VDMMGRL!BV[#XW=@Q%3P^`=.EN3-K)34MD,<$*LA3RE1<''S'.3S7;.
MM@^;FBNK>WRMZ=2$I6L.UCQ%/I]OI^N(_F:/-&!<(J@E"P^5P>O7@BM7PK+J
M5SI@NM6;;+<,9$BV@>4A^ZI]3BLX>$#_`,(?/X>%]B-V/E2^5_JTW[@N,\XZ
M=:Z6)-D:KUV@#-<%:5+DY8+6^_ET*2?4\_U3_D?-8_ZX6W\GJ6HM4_Y'S6/^
MO>V_D]2U.)^*/^&/Y(I!1117,,K:A>I80>=)%-*/2)-Q]<^U58M<MYKRUMXX
M9V%VGF12!/D9<`DYSGN.W>D\2:9<ZO8"TM[U;1&8&7,1?S$[IPRD`_6G6>EF
MWU#[6\B$"V2WCB2/:L8!))')QGCCV'-`&E5&_P!5@L9XXITE"R,!YH0[%).`
M"WN:O5C:OHUSJ.KV=T;V(6MJ=WV62$L"^>'W!AR.V01WI=0+.EZQ:ZG+*EMY
MF8^?G7`89(R/;(-:'8YK%\/^'QHUQ/+]H$IF&,"/86Y)W-R=S<XSQQBMJGT#
MJ95YXALK*=X;I9XV7A"T9`E.0,+ZG)'YU>L;R*^MQ/#D+DJ588*D'!!]QBL*
MY\-7%UJ-]=75]!,+A/+A5[4G[.N00H^?!Y&3P#[C`K6T334TFP%M&V\[F=F`
MP"S')P,G'YFF@9=9@JECG`&>!FL<^)K%86=UN$97V&-HR''R[LX]`O/^<5L.
M"48!MIQPWI[UQ,]A932RR2:S']HD9BTJ6K"':4*-T.W<1U;<.1T[5(=#M8W6
M1%=""K#(([BG5%:1I#:PQ1-NC1`JG.<@#C]*EJGN!2GU6S@U*WTZ24?:IP66
M,<G`&<GT'%7:HWFFBZU&RO`X0VK,2-N2^5(QGMC.:O4N@!VYKG_$&J03Z;J=
MD$FCE6WD(\Q-H<#@E?4`UT%<GJNBW-I!KNHW=[%=&X@=4'D%6B3L@.\C'KP,
MGFM\-_'AZK\Q2^%GL5@RIIENSD*HA4DDXP-HI8;^SFN3;17<$DX02>4L@+A#
MT;&<X/K4,5NMUH:6T@!66W"$$9'*XZ5F:-X<.G:N+S[4LBK`L6SRR#D*JYSN
M(Q\N>F>>I&`,G\3#H9&C_P#)7]<_Z\HOY)71^*[V?3O#M_>6C[)X869&(S@]
MN*YS1O\`DK^N?]>47\DKJ=?T_P#M;2+K3_-\G[1&8]^W.W/?%=N(:56FY;6C
M^2%$Y'3/%][=7&AP3,(KAWEBOXMHR2J;@1Z`]>*?'JWB.YT23Q+!>6RVBAI4
ML#!G=&"1S)G.[`SZ5I3>#H'\2:?K"3[)+2+RI(PG$WR[0>O!_.H#X-N!#)IT
M6MRQZ-(Q+6GDJ6"DY*"3.0OMBMY5,-=.%EWNK]7=+\+/\169'_PE5Q:2ZN]X
MX:-;..]LUV@':RX*^YW_`,Q72:`;Q]'M'U%]]TT8:0[0O)YZ"L;Q!X-MM8O-
M-F6X-NEEA'C5,^=&""$//'*@]ZZ9>!CM7'7G2<%[/=[^7_#[@D[ZGG=]_P`C
MSKW^[;?^@&IZ@OCGQSKW^[;?^@&IZG$;Q]%^12"BBBN<93U/48M.B$DT<SKR
M28TW;0!DD^@%,L]6MKRZ,-L)7`!_>A#Y9/&1N]1G_P#75?Q+I%SK-O#;PWJ6
M\`D#S1O"7$X'\)PRG'\ZATWPW'8:NU]%,@#%V*)%M)+8R"V3E>,@=LGFA`S=
MJC>ZK!9W*6\T<V9"%5PAV;CG"Y]3BKU8U[HUS=:_:Z@]Y$UM;#]W:O`3M;NX
M8./FQP,@XI`6],U.+4C.L<,\30/L<2KCG&>,'WJ]5/1[#^SK(0-+YSL[R/)M
MVEV9BQ./QJY3`R+GQ'96KRQSI<(\9&T-$09?F"_+GK\Q`R<=?2K^GW<5_:1W
M5N6,<@R-PP?Q%8$_A6YNI[^6\U&*=[MU*9MC^[16!$9&_#)QR,#.3S6WHUA_
M9FFQ6?F&7RAC=MVCDYP!DX`Z`4+8&6I7$4;2$,0@+849)Q[=ZQ_^$HT\$(XG
M23)WQLF&C`QEF'8?,OYUK7"2202)!((I64A'*[@I[''&?SKB&T6P6UCL+S58
M9Y1(YGG2T<M+NQNRP<@-QW./;@4+<#NP<C(Z57O[M+&V,\D<LB@XVQ)N//M4
ML#1O`CPNKQL/E93D$?6H=2MYKJT:&WE2)FX)DB\Q6'<%<C(/U%#V`JV^OV%Q
M=001.Y,ZAE;;\N2"P!/J0":TZYVQ\*K9WEM*+PR1P%'*NG+.J%`=V>!@],>G
M-=$*&!2U+58-->$7*2D2MMWI&2JY(`W'ZD5F:CJMGJ`\BSF$K6E_;1RD=`QD
M7@'O5W7-+FU011K=+#"K!F'E;FR"""K9&T\=>>M4=3TY;2=[I)`5N[VT.P)@
M+M=1U[UTX/\`C1]12V/7W=8T+NP55&22<`"FI/#(VV.5';:&PK`G!Z'Z51\1
M:6=9TB:P%S):B88,B*K''H0P((-4?#OAM]'O;BYDU&2\:>-(R'B1=NWI@J!Q
MZ`]*YAF-X=_Y*UXF_P"O>W_]`6NYKA?#O_)6?$W_`%[V_P#Z`M=U79C/CC_A
MC_Z2B8G#_%K_`(]=!_["\'\FKH/%.I7.F:29K.!Y92<9"%@@ZEB!]/S(KG_B
MU_QZZ#_V%X?Y-7973,ENS1Q><X'"9`W'ZGI53:5&DVK[_F'5G.:YK=]8RQB`
M`AX1<X9.B+DR#Z]![9JDFOWYNMLLX3_1UF51Y0!+*QY#,&/0=`:U+3Q`US=Q
M026`0%_)D?S-P5CNQCCYE.SKQU'%,D\1V'E&0VX,T;%"CH03AB,JQ7!'%-1=
MN7V>H.]]S.M?$=^;:W8/YYFR9&/E-Y0V@[L1L>!D\'FM;2-3FGUF2WDNHYT(
M8H(U4@`8QR#D'ZC'H:2V\1:6NQ9%^SL_.%C9@HQ_$P&!^-:6E7EG?H\MD#\A
MV,6B*'.,]P#T(K.HFD[PL):]3B=5_P"1\UC_`*X6W\GJ6HM5_P"1\UC_`*X6
MW\GI;B:.V@>:9@D:`LS'L*G$_%'_``Q_)%(Q?%MY)9PQ26]Z89E(80C&91N`
M.`1\QP3\O'UK=!R`?7G!K$;Q/ISV=K=^5,\4X:0$HN8U5MI=@3P,^F3[5N=>
M17-T'U#@=:YNYU:]'C.SLO+FBLF613F(XE8*#NW>@SC\\UK:WJ]KHM@]Y>LP
MC7LB[F8^@%-&KV;ZRFF*6>Z,32_=X4#'!/K\PZ4=1/8T*#0.E4+W5[2SU"TL
M92QN+MBJ*JYQP3D^@^4TBC+\*ZA<7%W=0WDIFDR9`4F$D:*7.%X4;6`QQS71
MUG:=J<%U>3VJV\MO-&`Y650I=22`V`3Z'K@^U:-,74S?$EU<V>C7$]DI,RA0
M".P+`$_@"33/#%T]WI@DD=I661H][,'W8/4,`-P]\"EDUVT^VW5E$DUQ/;1B
M21(H]V<G&T9X)_3WJSI5Y#J%BEQ;(R1MD;2`"I!P1QQU'8XH0,BUI1)#;P2,
M1#-,J2X[KSQ^)`'XU5\4^9%IT,=K<36TTLR01>5@#+''.0>`,G'M6I>00W%M
M)%<J#$1\W.,>^>U<P=<@&DSWJZI<-9VTWD9:W7S7('12>O7.<=LT`;>B1BV>
MZM(W+PP.H7/\)*@D?3)S^-:7UJ"PMXK:T2.`$)C=ECDL3R23W)-)J%[!I]G)
M=73%(HQDD#)/L/>AAN<[K&IWD/C"UM8K@K;D1!HAC+;BX)`Q\PX&3D;??-=5
M6/!KUI=7EE#!;2227,`G5OW8\M&Z9RP/;L#TK8'M3'U"N&NM0U"8:W:7$GG1
M)!.2592B8;Y``.0=IY![BNKU;5[725A-TS;IY!&BHN222!GZ#(YK*UG5;:\T
MW6+:VB<F*&0-+@;69>",@YX/'(&>V:VPO\>'JOS)ELSU-9I(-`6:%%>2.V#*
MK'`)"]SS63HWB.XO=<2QFBC59+99P$!)&5!R6SC!)(`QGC.>:UX;F&UT6&:Z
ME6*%(%+.QP`,"H[#5-+N[OR+.Y@DN/+#[4(+;#T/TY%9/XF/H<SH_P#R5_7/
M^O*+^25N:[JMU9ZGI]M!;N8II`)9=A90#P%&.A[\UAZ-_P`E?US_`*\HOY)7
M6ZG/);6[2Q0+,RX.&DV`#U)Y_0&NW$-*I"ZO[L?R1"U3.<UK7K^QOYH8MFR!
MP&)3)Q(,1X_X%G-4[OQ%?PF\!NL-%.(@O[@`#S%4D`ONS@GE@!6S;>(1<-*9
M+`QH('F7<XW,4"EE(QQC<.YJO=>)=/$<4L=IYK2?>5T*,IVEN05Y'RTXIZ)4
M]BMR*VUV]>Z2$R+Y/EJYN'"$;B7^4E"1SM`R,_F:T_#.HS7R3I<3K.\>WYD5
M=O.>A4G(XZ'!'<5'%XCTA5,;'8R@$JL+E23@@`[<$_,.!SS6KILUM=VB7%H/
MW4G(^0K^AYK"II'6%A'!WW_(\Z]_NVW_`*`:GJ"^_P"1YU[_`';;_P!%FIQU
MI8C>/HOR&C%U^XOK?4-*^SSHEK+<K%*NW+/D,<9[#BMJLS4];M=/O;>TN(Y6
MDFP5*@87)"@\G)Y(Z`FM,=*YQA7-Z?JC77BZYL[6],\%NI$ZNRX5^,*@ZG`Z
MGWKI*RK'5K&ZU*2VAB=9`SJ)&4`2%#AP.<\$CJ!0MP>QJTV4A8G8ML`4G=C.
M/>G"LZ\UJSL]2AT^9V\^96?`7A%`)RQ[<`TM]`*?A6\DN&OHWNS>1Q2+Y4_!
M#*5!^\`.<]NW2MVL_1M4MM2C<VT3P[-I*.JJ<,,JW!/4<^OTK0JA(S]?O)[+
M2II;.%YI\;4"(6VD_P`1`Z@=:B\)W<U]X=LKFY9WF>,;V==I)]<?K39/$NFH
M]^C2,5L%4RMMR"22`J^IR,<5H6%S'>64-S""(Y4#J",$`C/3M20R#6V(T]@)
M&B5W1&=3RJE@#CT.#C/;-9/BNYETJ*Q2T98+:/>TD<<HB9U51A4!4Y//3CIU
MK?O!"UK*MT%:`H?,#C(*XYS[8KE_[54:8MW:W5Y+8J[+ODMU=H@IP6+,0<>G
M5CZ4`;6F[$U&ZB@!6(JDI7^X[9SQV[?G]:TZKV%I':P?NV:1G.YY7.6<^I-,
MU;4K;2;"2\O&811CG:,DGT`[F@#"N=4NX_&*6DCNEN62..-6'S@H26*D9(!&
M"01CCUKJ*RTUBV?4+2#[-.&NDW12E!M/R[L9SGI[8[9K4H8!7(L9IKFXE-[<
M3V\6HV\")*P(#"12Q&`/7`^E=!J6K6NGW%I;W!8RW<@CC55SD^I]![UEZGJM
MG>7+65KN:2TO+4R-MPN6D&,>_P`O-=.$_CQ]29?">G^)-5&BZ-<7Q3>8U^5<
M$@MVS@'`SWK,\,>()]7U"ZBE6$11HCQ",`D@@9).XD<D\%5/UKH;F2.&%Y)F
M5(T!+,QP`.Y-5K*\L;F:5+2:*25`"_E]<$<9_"N8HY3P[_R5KQ-_U[V__H"U
MW-<+X=_Y*UXF_P"O>W_]`6NZKLQGQQ_PQ_)$Q.'^+7_'KH'_`&%X?Y-78W=O
M'=VKV\P8QR+M;:Y4X^H((_"N.^+7_'KH'_87A_DU=N.E%72A2^?Y@MV8KZ7I
M&E>5>2L\0M<!'FN78#@@9W-@GYB!GIGBJD,/AF9]OF1^9+A_+>X;<-QR,`MQ
MDG.!QS6SJVGKJ-NL3R21%6#J\9&Y2/J"/7M6%?>#(9HI/*N9VD9!&AE<8C&5
M.5P`<_+D<_I4TIQ?QR:8VBW:6.@W\4R6#12XPK&.4OM/;N?2K7A[2!H]L\/G
MO.SMO9VSR<`=R>P'>C2=#M]+N)I;=Y,2@#RSM"J!Z``?F<FM2LZE1N\4VT)(
M\[U3_D?-8_ZX6W\GJ0@$$-T-1ZI_R/NL?]<+;^3TMS&\UO)'%*T+LI`=1DK[
MC-5BOB7^&/Y(J)AOX4A:T@M_M+!8U>-SM'[Q&?>5]OK70`84`=N*XFTM1>6.
MDZ5<K))=I,S7#.3YL,89F!;N-V%&3Z\5VH&.!@#%8/82*NL6":IIEQ92.8UG
M0IO`R5SZ4U].1M5M[_>5>")XMH`PVXJ<_P#CHJEXSMKJZ\.W:V4MPDJH6"P#
MYI./N^OY5F)#J`\;"4PW'D[@,E&V[/+Z[_NXW?P]<\T(?0ZVJ6H:>MY<6<V\
MHUI-YPP`=WR,N/\`QZKM8FO6UU)J^D302W!B2X*R11CY`/+?YFP/7`YXI=1D
MF@Z+)I<UW+-=B[ENGWO(T>']@3D\`<`"M>N8\'07\-U="X$OD!0NZ5'1I)`Q
MRQ#>V.1Q[UT^*?0GJS.N=+9[^:]M[IK>9[<0@J@;;ABV<'KG.*ETG3QIEH(!
M(9"69V.,#).3@=AZ"N3U,7ESK.H?8+6]MTB7:Y>&7_2LLN_:Q&W`7(`!R23B
MND\,I,FF!9ED13(YB5P598\G;D'D<>M"6@R_=7$-M"TMPZH@X)/^>:Y2_P!(
MTN\M;E;T7T$=Q,\T<Y62-8BP`Y"D<8'\0%;>JE!JEF;D,81'*R``Y,N%V@=\
M[=^!_P#6KE%M;V]\/W\T*7]DAG5DLC!(K%00/F+C)SR3M_QI;@=[;HL<$:(Q
M954`,3DD?6DN8EG@DB;^-2*I>'2#I,>S_5!Y!$?6/>=F/;;C'M3?$\JPZ)<.
MUG<7N`-L%NK%G.>`=O.,]?:AZ@M-$5$\,QJ]EFXREI'$F/*4.VS)7YQR!R<C
MD5O=_>N%LEN/[0T6`Q7HE11)-=FVG"`9.(E!&!UY+8X`KNC38=2GJNGIJ-LL
M+OLVR(X8#/W6!Q^E8.L>'X+&SU6]BD.'@F(C`Q@N=S9.>>1QZ9-2^.&<Q6D$
M%K=2SRR$+-%%+(EN.[L$'7TS_C6?J44BOK#Q0W:P-9R"5IT=09`>""W#9&<8
MZ`8K;"?QX>J_-"FM#V![:>[\/I!:W/V69X$"2^6'V<#G!JIH?AU]-OEN&O%D
M0+_JEAVC?L5"V<DX(0<>N>:FOKB2U\+B:%KA9%MT(-M!YTHX'W4P<G\#]*BT
M"XU.6YMOM;N\$ED'8O;-$WF[L?-D#!QVP/I63^)V'T,71O\`DK^N?]>47\DK
MKM2L+?48/(NA(4R&^21HSD=.5(-<CH__`"5_7/\`KRB_DE=S75BVU.#7\L?R
M1,3!N[71M'#W%R65KA#!^\G=BX.`0`S=3@9(Y.*JK:>%RK)YL)\K);=<L67`
MP<DMG@''M6KJ^C1:HT;32S1&,%<QE?F4D$J<@\$J.G/'6LJ3P9;M<1R&>:;,
MJR2M,P+$*"`HP!GJ,YSG%33G"WO2:8]MB7^Q=)U337_LR1`&;*SQR%PK#:/7
MT4#@^X(/-:^CV"Z;IT-HCLXB&-S=2?6H]%TJ+28)(H9))`[E\OM&/8!0`!QZ
M5H5E.HW[J=T%CSF^_P"1YU[_`';;_P!`-35#??\`(]:]_NVW_H!IM_#)/:2Q
M13/`[#`=,;A],U>(W7HOR")0U;0(]2OH;EIV38JJR@9R`VX;3_"<]3W%:X]*
MX+3VNF?1U*/=7-K;1));R0NS(Q.69G!PC`#/S#GD"N]KG\A]0K)M="A@UJ74
MRZM(V=@$2H5SC.2/O=._2H_&%M=7.DG['+<*\<B,8X!S)\XX..<`<U1TJ/4(
M_%-PUU`[JS2?O=KA5CXV#=G:W?C&1@^M"!G450U+2HK^YMII6*B#?\H'WPRE
M3D_0U?K"U6SN9/$FES+)</;'S$DB4?NU&P\MCN3@<_A0@+>B:.NE)*/.,KN%
M7<5V_*J[5'X`5I5B^$[+[-9S3M`UNUS,[^4P(V*"0HP>G`!_&MJAL%H9S:3&
MU[>W.\_Z7"L)4*,+C=R/^^JLZ=:BQL+>U5BZP1K&&/?`Q7*:U9:DMSJVQ[NX
MCF^S,K!"RJOF'<JJOW@%ZJ.3^-;_`(72XCT*U6[619`I!$@(;&3C@\CCMVH6
MP=30N)88('EN'6.)1EV8\`5R-[IL<T$/[^[BLH[E[I_,LV,<A)R-PR#@>XQW
MK>UQ&DEL4+B.)I2&8@':VT[#SU^;%<K<V.JII\"QF[EF6>X5/-1VR2X*2$CI
MP#@GY<$T+<'L=Y$ZR1(Z,'5@"&7H1ZU%J%JM]936KMM$R%-V,[<C&:I^'\>1
M<B,YA%PPCZ8[;L8[;MWY&HO%THBT20_8[B]<LJI#"CL2QZ%@G.T=30P0X:(?
MM=E))=NT5D%\N/8`0P7;]X<X.<D>M:U<7I5KJ4>L:?O-S+M$?[YXG1?*\MMX
M.<8._'!YZ5VE#T`I:GIZ7_V?<Q0P3+,"`#G':L*Z\/6FDW(N[1IQ]HNK53&\
MSNJXF!)&XGJ3^'XT_P`9&1[S3[>WM[HRN^?M4<4LB6Z@C)(0$;CT&?>H'M;J
MWO[TW,MQ-&^H6;1O*,#&\<+QC`Z<>E=.#_C1]29:Q/7M?TL:SI<UBUS-;"4`
M&2(*6^F&!!'KQ5#P]X:31+J>:.X,OG`!LQA68]V8CJ?3@8'%7/$MU>V>C7$V
MEVTES=A<1I&`QR>^"0#CKBJGAX:E)<3SWUS=F-HX\07$4:!'*@MMVJ#CG')/
M(-<Q1A^'?^2L^)O^O>W_`/0%KNJX7P[_`,E9\3?]>]O_`.@+7=5V8SXX_P"&
M/Y(F)P_Q:_X]=`_["\/\FKMQT%<1\6O^/70/^PO#_)J[<=!16_W>G\_S!;L6
MBBBN,H*2EI*0'G>J?\C[K'_7"V_D]5-:OI+2#99Q&>]D!\J)>^.K'V&?U%6]
M4./'FL<?\N]M_)ZQ[C2M2FCO@+J%)KO*"=`0\:<[57KC'\\UUXKXH_X8_DB8
MF5-JMG;:5#<PK(NHI=&#/#-)*6"ON(X*\C/IQCD"NIT^\6]M]X5D=&*21MU1
MAU4_S^A!KFO^$.9M,@LIG@?[/M"2@LC8#!L':`#DCDD9YK:BLKU=42[+V\:E
M=DRH&)D`^[U[@]_K7-H4:GTH^E%%(`HHHH`****`"CZT44`0W=K#=PF*X3>A
M(/7!!'0@CI55M(CDC$<]Q<S1#_EF\O##W[G\ZT**`$5510J@``8`%+[=J**`
M"BBB@`K-\4?\B[J&/^>#_P`JTJS/%'_(NZA_UP;^5=&%_C0]5^8I;,])TU<Z
M=;9_YY)_(58`QZ5#IO\`R#K7_KDG\A5BL9?$QG#:/_R5_7/^O*+^25W-<-H_
M_)7]<_Z\HOY)7<UU8SXH_P"&/Y(F(4445Q6*"BBBF!YS??\`(]:]_NVW_H!J
MEK=]/;Q_9]/A:>\E7*HN/D7H6.>/IG_&KM__`,CUKW^[;?\`H!K$N=$U*XT^
M\MFO(TFO"?,N8LJX'8#.<`#@?C71B-UZ+\A1,\ZE#;VEG=Z=:2JXE,)E:12)
M'+D%&.?FR1G(Z=:ZJQNH[RV6:/(SPRG[R,."I'J#7-0^%K^*ZT^87T16P39%
M$8UV?7&WKCC/6MFULKR/56NF>W2*5<31H&.]OX6YZ'U]16`S3HHHI`%%%%`!
M1110`#BBBB@".X@BN(6BGC62-A@JPX-4_P"R4*>6]W>/'_=:8\CT)Z_K6A10
M`R&)(8UCB4(B#:J@8`'I3Z**`#ZT444`%9GB'_CVM?\`K]M__1JUIUF>(?\`
MCVM?^OVW_P#1JUTX3^/'U)EL>I$9%`&**6N8HX7P[_R5KQ/_`->]O_Z`M=U7
M"^'?^2M>)_\`KWM__0%KNJ[,9\<?\,?_`$E$QV.&^+/_`!ZZ!_V%X?Y-7<`\
M=:X3XP1^=IVB1EG3?JD2[D.&7(;D'L:T1X)C/_,>UX?]O[UG6<O84]--?S-J
M<*;UE*S]#JLCU%&1ZBN6_P"$)C_Z#^N_^![T?\(3'_T']=_\#WKDO+L:^SI?
MS_@=3D>HHR/45RW_``A,?_0?UW_P/>D/@F/_`*#VO?\`@>]%Y=@]G1_G_`Q=
M4_Y'S6/^N%M_)ZEK"O/#Z0^+M3M?[2U,B.&!O,-TV]LAN"W4@8X]*F_X1]/^
M@IJO_@6U=&(E/F7N]%U\D5&EA[?Q/P->BLC_`(1]/^@IJO\`X%M1_P`(^G_0
M4U7_`,"VKFYI_P`I7LL/_P`_/P9KT5D?\(^G_04U7_P+:C_A'T_Z"FJ_^!;4
M<T_Y0]EA_P#GY^#->BLC_A'T_P"@IJO_`(%M1_PCZ?\`04U7_P`"VHYI_P`H
M>RP__/S\&:]%9'_"/I_T%-5_\"VH_P"$?3_H*:K_`.!;4<T_Y0]EA_\`GY^#
M->BLC_A'T_Z"FJ_^!;4?\(^G_04U7_P+:CFG_*'LL/\`\_/P9KT5D?\`"/I_
MT%-5_P#`MJ/^$?3_`*"FJ_\`@6U'-/\`E#V6'_Y^?@S7HK(_X1]/^@IJO_@6
MU'_"/I_T%-5_\"VHYI_RA[+#_P#/S\&:]%9'_"/I_P!!35?_``+:C_A'T_Z"
MFJ_^!;4<T_Y0]EA_^?GX,UZS?%'_`"+NH?\`7!OY5%_PCZ?]!35?_`MJS_$&
MB+!HE[,-0U*39"QVR7+%3QW'>M\/*:K0:CU7YB=+#V_B?@SU[32/[.MN?^62
M?R%6,CU%<A9>"XY+*!_[=UQ=T:G"WS@#CM4Q\$1X_P"0]KW_`('O6<G*[T,_
M9T?Y_P`"AHY_XN_KG_7E%_)*[C(]:\JTSPTLGQ(U;3_[4U11#:QOYRW;"5LA
M>&;J1ST^E=8/!,8_YCVO?^![UTXJ4N:-U]F/Y(%3H])_@=3D>HHR/6N6_P"$
M)C_Z#^N_^![T?\(3'_T']=_\#WKDO+L/V=+^?\#J<CU%&1ZBN6_X0F/_`*#^
MN_\`@>]'_"$Q_P#0?UW_`,#WHO+L'LZ7\_X&%??\CUKW^[;?^@&IZP;K0%C\
M6ZO;?VEJ9$*P?O/M3;WRA^\>^.U3_P#"/I_T%-5_\"VK>O*?,O=Z+\BHTL/;
M^)^#->BLC_A'T_Z"FJ_^!;4?\(^G_04U7_P+:N?FG_*5[+#_`//S\&:]%9'_
M``CZ?]!35?\`P+:C_A'T_P"@IJO_`(%M1S3_`)0]EA_^?GX,UZ*R/^$?3_H*
M:K_X%M1_PCZ?]!35?_`MJ.:?\H>RP_\`S\_!FO161_PCZ?\`04U7_P`"VH_X
M1]/^@IJO_@6U'-/^4/98?_GY^#->BLC_`(1]/^@IJO\`X%M1_P`(^G_04U7_
M`,"VHYI_RA[+#_\`/S\&:]%9'_"/K_T$]5_\"VH_X1]/^@IJO_@6U'-/^4/9
M8?\`Y^?@S7HK(_X1]/\`H*:K_P"!;4?\(^G_`$%-5_\``MJ.:?\`*'LL/_S\
M_!FO161_PCZ?]!35?_`MJ/\`A'T_Z"FJ_P#@6U'-/^4/98?_`)^?@S7K,\0_
M\>UK_P!?MO\`^C5J/_A'T_Z"FJ_^!;5GZWHBQ6\!&H:B^ZZA3#W)8#,@&1[C
ML:Z<+*?MHVCU[BE2P]OXGX,]FR/6C/N*Y4>"(_\`H/:]_P"![TO_``A,?_0>
MUW_P/>N>[[$>SH_S_@9_AW_DK7B;_KWM_P#T!:[JO._!5B-.^)7B&T6>XN!'
M;P_O+B0N[953RQZ]:]$KMQ3;E&Z^S'\D<[48NT'='#_%K_CUT#_L+P_R:NW[
M"N(^+7_'KH'_`&%X?Y-7;'[M56_W>G\_S(6[,G7M7?3+K3(4B607MR("2<;1
MM)R/RK*D\63+X-;7/LJ&19C%Y6\XXF\O.?UICZ/K]]KEI_:DEM)8V-TUS',I
MQ(XP0J%0,#&>M43X:US[`V@;;0Z8UUY_VHR'S-GF;]NS'7/?-:PI4.5*35]&
M]>FOX[:;@VS17QB!XAU+29K<1M:Q>9`Y/$I";BOL:V_#NHMJVB6=^\8C:XC$
MA0'(&:YG6/"-UJ#:Y*C)%<3RI-92AN598]N#Z`]*Z/PM8S:9X?L;*ZV^=!$$
M?:<C(]*C$*A[-.GOI?[M?Q)3=]3C]5_Y'S6/^N%M_)ZEJ+5?^1]UC_KA;?R>
MI:RQ/Q1_PQ_)%K8****YAG/?;[UH[BYFU:SL;=+F2%!+;Y^ZQ4?,7')Q4=_J
M=W8LBG6K&:8M$?LXM]K,C.!G[_H3@U6NQ>S:/=6^F>1YLE_<+([R!6B0R-N*
MY_BQT^M4]3TR:T,<EFXAA$EJKJ;K>&1610FSU!YW4`=U5>>^M(+B.WGN8HYI
M?N(S@,WT'>K%<_KUAJ%_JMDB0(=.C823,KA9'8'*@\?=!Y^M"O<?0V;>]M;F
M66*WN(I9(3B148$H?>IZY_POH][I4TB7$H:!4V+E]Q<[B=P_NC!''KS704"*
M<NK:?%)+'+>VZ/",R*9!E![^E2V5Y;7T`GLIXYXB2`\;!AD=>16"UCJ\FM7M
MZT$2".%X[$)(`H)'+.,9W$X]@/K6WI=F+'3X+8=8T`8^K=S^)S0!9)`!).`.
MYJE_;6E^29O[0M?+#^7N\T8W>GUJY+N\I]BAVP<*3@$^E</)X;U>\MVENH8U
MO))69UCFVJ%*%%"$=%4'D'[W-+J!W((8`@Y!Z'UIES<0VL+37,J11)RSNP`'
MU-):1M#:Q1R%2Z(%8J,`D#M577UOFTJ9=*BADNSCRQ-PJG/WOPZTWN&Y+'J=
MC++%%'>0/),NZ-0XRX]15JN/LO#%S%=V+H)(5C\M[AC.K;W0L>1MZG=V('/3
MBNP)H`@NKVUL_+^UW$4'F-M3S'"[CZ#-9OB.\MIM$U2"*>-YHH&WQJP++QW%
M.\365S?V?V>VAB?>"#([E3&<@@].1QR,\UAWFC7=C9ZG/<.IC6WN-K`_ZPR/
MOZ=L=*Z,+_&A?NOS0I;'M6G,/[.MO^N2?R%6,BL:]AFN/#'DVUNMS*]NH6)I
M#&&X'!8=!6;X:TJ^M=72:ZM##&ELL?F_:O,+M@9!7L!CC'UK!_$PZ%+1O^2O
MZY_UY1?R2NNU6Y:RTVZNU4,8(FD"GO@9Q^E<CHW_`"5_7/\`KRB_DE=9K,#W
M>DWEM%CS)H7C7)P,E2!7;B;>TA?;EC^2%$YS3/%&JE=-N-8TVW@L]2V+#+!,
M7*LRY4,"!C/M4>C>)M;U:3?#9Z6MMY[1?/=D285L$[=O7BF:;HNO75OI%AJM
MO:6MII9C?=%,9'F9%P.,#'K5#1?"VHZ;>>9+X=TJYD%RTHO'N")`"V0<;>H'
MO70XT+2VOTUTZ^9.IMS^(M5GN+MM$TI+VSLI##*YFVR2,/O"-<<XSCDUT]N[
M21*[HT9(!*MU7VKD_P"SO$6DS7MOH2V;VUY.TZS3N0UNS8W?+C##.2.E=9;B
M184$S!Y,#<P&`3["N+$*"2Y+6_'YE*_4\]OO^1YU[_=MO_0#4U0WW_(\Z]_N
MVW_H!J:EB-X^B_(:"BBBN<9!=WMK9*K7EQ'`KG:ID8*"?3FDBOK2:Y>WAN89
M)X^6C5P67ZBLSQ9:ZC?6L=KIT4;+*VV=RP5UC/4(3W/3/I3;'3;F/6XKDV\-
MM!#"T0VN6WJ<$<8&#QR>]`&[5>2^M([I+62YB6XD^Y&6`9OH*L5SVM:?J=_K
MEMY<<<=C"!()5<;S+SM+#NJYZ9YH`W89X9VD6&5)&B;8X4Y*MZ'T-25@^$=%
MN]&%]'=313+--YB.BE2WR@%CDGDFMZAAW*;:MIR^?NO;<?9AF;,@_=C_`&O2
MK%O/%<PI-;R++&XRKJ<@_C7*7.B:E?WFH37UL`K;4MHX+CRQY8<,<D#.YB,D
M_A[UT>C0W4&G11W\OFSC.3G)`SP">Y`P,]Z%MJ#\B#4[Z[AU&"ULUMAO@EG>
M2<L`H0H.W^_G\*HC6+O[.D_V[1?*9MBOYK8+>F?6I]5=DUV`HL;N;"Y")(VU
M6.^'@GTKG%T+49+>.YDGB746,OFA;@!"SA<$`?PKM`V]Q0MP.NT:\GNTN1=)
M$LL$YB)B)*M\JG//^]5&XU6]6>^97L+>UM)A#ON'89.Q&SZ#[V/PJ?PZ<MJ1
MW!S]L(+#H?W:5F7C7AAUN+3/LYNFOE`,S@>6/)BRPSW';WH8!J'B.YL89&:[
MT>218C*L*S,'D`7=\OKD5U-<7J=A]GT28,T8M[32Y(XT,H=_,(())[\=_>NT
MH:`KW5]:6DD4=U<Q0O*<(KN%+'VS69K%]:74<45M<Q2R0WUN)%1P2A\T<''3
MI4?BBQU#4)[."V@C>RW;KEMX60@$$(..F1D_2L>#1+S3;DSW.P)+=P*-K;MQ
M^T%@0/X1ANG3.373@]:T?44]CW4D#K1N%9WB6VOKO1;BWTN2..YD7:K2,5`!
MZX(Y!QWK)\+Z-J.GZG>7.H/D7$:#Y9=R[@/X>`>W.<\],#BN8?0S_#O_`"5K
MQ-_U[V__`*`M=S7"^'/^2L^)O^O>W_\`0%KNJ[,9\<?\,?\`TE$Q.'^+7_'K
MH'_87A_DU=??WL%A;B:Y9E4L%&U"Q)/8``FN0^+7_'KH/_87A_DU=/KNF_VI
M9I#F$;9`_P"^B\Q>A'3(YYX.>#532=&ES;:_F'5CKC5+.W8"><1DE!A@1RQP
MOZU$-=T\R!$F=SMWY2%V4#GJP&!T-4M4\.KJ#QDW+)Y=NT()7)+$85^O49;\
MZA_X1>6.</%>QA#`L)4QODD*02,2`<Y[@UBH4;7<M0=^AJ0ZW82Q^8)F2/!;
M=)$Z9``.1N`SUJ:UU.TN;EK>&7=*HY!0CZX)&#COCI6';^%'6.W6>]#&V.Z-
MHT<8;``)W.V>@XZ5HZ?I=Q;ZDUU)=(RL#F..(IN)[M\Q!_``^I-*4:27NL$V
M<EJO_(^:Q_UPMOY/2W$RP0O*RNP09(12S'Z`4FJ?\CYK'_7"V_D]+<I))`Z0
MR^5(1\KE=VT_3O58GXH_X8_D@B9O_"1Z:(;:225D:YF^SI&R_/OW;2,>QZFM
M:L%/#8%C'`UPGF+>)=EEAVJ,.&**N?E!(]3UK>KF**<VD:;/(TDVGVCR,<L[
MP*23[G%44C\/QZRFGPV5D+Y4,VU+=<H`1R3C@\C%;72J$NF*^M6^HJX7R89(
MB@7[VXKSGVV_K0!?H_E10<X..M`%&PU6"]N)8$66.6,!BLB%2RY(#`'MP:O5
MC:!H]QIMQ>7%[>17L]T^YI1"48#LOWB,`<``"MF@"*ZN%MK=Y621P@R5C4LQ
M^@%1Z?>Q:A:+<6Y;8Q(Y&""#@C\Q4EW'-+;NEO*(93]URF\#\._Z56T73_[,
ML1;>8)#N9LJNU1DYPJ\X'H,T`2ZC<200J+=0TTKB.,-T!/<^P`)K,U2*#2]/
M>]U#5+U"F/W@?J3P,)]WJ>F*T-4@EF@1[?'G02"5`>C8ZK^()%8OB.WMM>L!
M#.+ZVN$!V*D9.&(P<]CQGO0!LZ7<RS1R1W(7SX6VLRC`<$95L=L@CCU!J[6=
MHEK-;PO+=9$TI!VDYV*!M`SW/&3[DUHT`MBG-J,<6HQV2Q2R2NGF$HN51<XR
M3GCG-7*QM2T!;W68-1\R*,Q;,GR09/E)(`?/"G/(P<UL]Z`>@5S^O:G!=:1J
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M=>$YI6N`E]$B33><`8I"5^<-@XE`[8R`#62A0LKRU*N[FW'K%BX'[XJ3C"NC
M*W.<?*0#V/X#-2V&HVU^K&TD+A>N5*GV.".GO6/;>&Y(;I;LWB_:5C6+*QML
MVY;(PS,>0WKP1Z<5?T339M/$IFN1,'QM5$**N/0%CR?;`XZ"LY1II>ZPU9QM
M[_R/.O?[MM_Z`:6ZN%MH'E9))`O\,:[F/L!27O\`R/.O?[MM_P"@&H]7MKF\
MTZ>WL;L6<\B[5FV;]GJ<9%5B-UZ+\@12A\2Z=--'$C2[F(5LQ_ZMBQ4!O0Y!
M%;%<S#X1119+)/!LMMN[RX&4N5;<#DN>_7.>O&*Z:N<93U348-,A$UPDK)SN
M,:%@H[ECV%,M=8M+J]:TA+EUSABORL1C<`?49&:37-/FU.S-M'/'%&X*R!X?
M,W#VY&".H/MT-5-+\.KI]^)Q<M+&F]HU9?F#/C<2V>>GH.O>A`]C;I&8`$L0
M`.23VI:#@C!&0>*%L!3TK5+35H9)K"7S8HY&B+XX8CKCU'O5RJ.DZ<-.^U;9
M-XN+AI@`N-N0/E_#%7J!(@O+E;2W:5HY9,$86-=S'\*+&\AO[1+FV),;YQD8
M((Z@^]0:[9W5_IDUI97@LI90%\[R]Y49YP,CMWS3](LO[/TZ"T_=_N5V_NT*
MK^1)/ZFA#9!KT=N\$9FLK>ZF9_+A$\8<*S=3SVXR?I6)J>AZ+IR))>02M(YY
MEB@4JG09*@;0.1Q@_C71:G;R3PH;<@30N)4!.`Q'8_49K(UQSJMFMOF>VSQ)
M$UH9&)XP58'`8=CDB@#0T/9%'/9B*&-[9\-Y*!%8$9#;1T)_I4\^E:=<2M+<
M6%K+(WWG>%68]NI%1Z3;RIYUS<KLEN"#LSDHJC"@GN?7'T]S?%`&+/!X?M]3
MMM/?3[(75PK-&JVZ]%&2>G%;58USX=BE\0P:PES,DL1)>/.5;Y=H'MZUL_2A
M[`&,\>M8&I:C%?1QK#',%AOX$\QEPK$2@$#GFM_KQ7)W.@C3;A;M98L37D`V
M10^6#F8-N?D[FYZ\<5TX/^/'U)EL>TRNL<9=V"JHR6)P`/6J]O>VES+)#;7,
M$TL6/,2.0,4R,C('3(YJ#Q%IAUC2)[`73VOG#!D158X],'@@U0T'P[)I-[+<
M->F=7B6-(Q'LVX^\3R1DD9X`'M7*BF8WAS_DK/B;_KWM_P#T!:[JN&\._P#)
M6?$W_7O;_P#H"UW-=N,^./\`AC^2)B</\6O^/70/^PO#_)JZ[4T,FG3*MN;H
ME#B$,%W^V3TKD?BU_P`>N@?]A>'^35VXZ"G5=J%+Y_F"W.3TO1M2BU#3[AMM
MO:Q>9NM6`'E;LD[=K$8SC'H*@;2=;:"6WV,8O,8JLCH1RQ(*8Y`P1UYS70^(
M9KN"QWV"LTA8`E8]Y5>Y"CK7,S:WKUDNXVTC101*S^=$5+ME00&/!)!)'.<C
M%72G4J>\K?/^O,'9;EB+3]=M8\PRM$(E!5`5*L<#.>YK2\&W-U=V4LMV9R/,
MQ'YX&[&T>GOFCP[=:O-<7,.K1CY-I1TB9%YZKR.?J"16Z!@UA6J/6,DK]T**
M70\\U3_D?-8_Z][;^3U+46J_\CYK'_7O;?R>EN9EM[=YG#,J`L0BEB?H!UHQ
M/Q+_``Q_)%11D>)+9KJXTZWC:YC::?#20RN@1%!9L[2`<[0.?6MH#&!DG'%8
M#>++=-(L[XVTH>[D$:PY^91OVEF/3`_J!WKH*Y^@PKD_,OAXXQNN/(WA1'EM
MNSR_O?W=N[VSGOCBMOQ!JZ:+IDMY)!+/L'"1KDGZGH![FHHM;677FTV-8041
M69VFPQ)&<*N.>W<4('HC6_2@@D$`X/K16;J.L1V6I65BT,KM=N5W@81/E8\G
M_@)XJ;`C*\'G4/M=TMU*TT*J`9&:0[I,G)PX&WC'`XKIZR="UR/6))O)C58T
MY1O,#,1DCYEZJ>/?Z]JUJ8=6<GK0U2+5=1\FXGDB>UC954%5C'FX;;C^+;GG
MK6QX9,S:9F8NR^8_E&0DL8]QVY)YZ>M-;6R^IW=A;6K-);0B7?,QC1^<$`X)
MXQUQ5G1;Z74=.BNYK<6YER50/ORN>#G`Z]>E"V`N,&*G8=K8X..E<7/'K"Z%
MJ(^WW1FAO_OA3ND3Y>%]%Y)XKJ-5N98(XX[;`FG8JK,,A``26([\#IW.*Y6X
M\0R1:<;N.:^$@N7@_P!(*("57=RNWC/8=?4B@#MEZ"JNL)/+ILZ6D[02["0Z
MC)'KCW]Z;H]ZU[:;Y4\N9&V2)Z'`/Z@@_C4FIWJZ?92W3QR2",9"1KN9CZ`4
MGH".2M[R=[[0;;S;Q+KR(Y+B65WV;<'*XZ,Y/7/0#M7;'K7.P>+();NSB-N8
MQ<I$VYG`(,F=H`_B'&"?I7153V#J8OBM;S[+;R65Q+$$N(_,2(<N"P&">PZY
MK&U5W\[6EADNY(&M)/,64L%CD#=,-QR.F/3OUKH=>U5M(M1<FW$D*\R,9`NT
M>PY))SP,?B*Q]5UV+4-,U2U6$H!;S>6Y;._8=KY';!K;"?QH>J_04MCU"]NC
M9>%_M`F,)CMU.]8C*5X'1>YJAX=UN_OM5AMKB%Q#]D\PS>0RI(_!R&Z8P<8]
M<UL0W,=GHL%Q/N\N.%"=B%VZ#HH!)/TJ+3?$&G:E>_9;.5Y)?*$Q_=.`%/3)
M(P#[=?:L9?$QG.:/_P`E?US_`*\HOY)72^(X'N--:..P^WLQ`\HE0/J0Q`./
M0US6C?\`)7]<_P"O*+^25W-=F*?+.#_NQ_)$HX_3]#OK>>\8Q2_OK1H@\LB%
MF^50B\'.1ALYXY&.IJK/HNNW5K!'(C,L9X$LB%@/+9>H[9/%;GBF;48DA33U
MEVR$[WCC+D'(PO'W01N^;V]ZQGUOQ`L[*MMM6:40PB:(JP)!.2.^W!SC.?6K
MISJ27,K?,=^46[AU_3K26Y,TJQ+@-%%LX3"`E0!PV=_M71^&I+B;1;:2\,AE
M9229,;L9XSCVJ/PU<WUU9.=2C*S)(5W>6R!QZ@,`?S%:P&.*YJM2ZY&E?R!'
MG-]_R/.O?[MM_P"@&IZ@OO\`D>=>_P!VV_\`0#1>W26=K)<.LCJ@SMC7<Q]@
M*>(W7HOR")S_`(FEOXM9M3%YS6P52J1,REY-XR../N\_-D<'CN.G'O6%#XC:
M6VTRZ%@RP:@$&XRC*,W08[X[GC\:W36%N@^H5B6-J7\37LX:Y2*!%0*TTA21
MV&YB%)QP,`8'K5K7M7CT>U69X99B[J@5!P,D#)/8#-,AUN&;7Y-)BC9FBB\Q
MI<_*#D`J/4\C-)>0,U*CNBPM92@8L$.`O7..U25F7NM16NL6VG-!*S3JS&7&
M$0!2>O<\'I1Y`9G@-[QK6X%Y)/*04P\I;&[8-P^8DY!Z]L]`*Z:LOPYK(UNR
M-RJ1(#C"I+O(&,_-P,'VYK4J@2,KQ3YW]COY$S1%9$+;2Z[EW#*ED!89'&0.
M*=X9-TVB6QO\^>0<[B2<9XY//3'6J=SXJM[>:^C:"5?LAC0-)\@E9V*C&>@R
M.M:VFW?VZRBN-@3S!G:KAA^!'7_/2I6P>I-,KM$XC;8Y4A6(S@_3O7"S/JL=
MC'&US=RNLMR%DW,&>4./+SC^'&[CI75ZP[-)#;^8\43*\DS1Y#E%QD`CGG(Z
M<]:P7N;:;2$O-.T6.$F=H$'F>1,K[L#&U3R>3C/US0M]`>UCKTSY:[OO=_K6
M=XF2ZDT*[%C</;S",D/&,MP.@]SZU-H\TTUB!=$&>-FB=@.&*G&?QZ_C2:UJ
M2:3ILU[)%+,(QD1QKDL?Z?7M0!D6R7XUS2))+B9K=[-@T6/E5@%Y8]SG/6ND
MK!A\31RZQ;:>+8@SQJ^[>,C<I;[N.G'7U[5O4VM!7U,3Q*M[]HTR2UN)8XA=
M(LL<8^^">Y'8>E8-O=&\U.YDBDN5M4O;=%CN&8LS"8;G`/"KV`'7%=/J^L1Z
M;<64#02RM=RB,%5^5/<G\:Q9?$$6K-';K%Y31W=NZ@N&)7S]N2/X3E>GH171
M@_X\?44_A/5O%5U=6>B3S6#QQSC`5Y`VU<D<G"L?T-9?A/5K_4+Z>.]=\(@/
MEM!L\HYX^;'.1S[5O:MJ%MI=B]Y>N8X(L;B%+'DX&``2>M-LM2M+Z22*VD+2
M1*C.I4J5##*YR/TKF11R?AW_`)*SXF_Z][?_`-`6NZKA?#O_`"5GQ-_U[V__
M`*`M=U79C/CC_AC^2)CL</\`%K_CUT#_`+"\/\FKMQTKB/BU_P`>N@?]A>'^
M35VXZ"BM_N]/Y_F"W8$9IKQ(^-ZA@.<$4^BN,H3`HI:2@#SO5/\`D?-8_P"O
M>V_D]2U%JG_(^ZQ_U[VW\GJ#6)%BTNY>2&>=1&28X`Q=_9=O.3[5TXKXH_X8
M_DA1*,_A729[*&UF@\P0MN21L%U^?>1G'0G]*V0```!@#H/2N$L!<W>F6A@N
M;@2P:C&\UC'&ZF!6<':X8;L*O/I7>5S]`*VIV46HZ?/93EA%.A1MIP<'TJ!]
M(@DU&.\>69O+(=8F8;`X&`W3.<=LX]JH^-93'I(6.SN+N61PD:Q)(X0G^-P@
M)VCK6=8+*WB6RB6.^"V\"^?=S03!;DE,!02-J@=3G'/XTAG7]*JWEC#>36LD
MQ8-:R^<F#QNVE>?P8U:KF/$C/)K^GP6]O=J^X.]VD4K1QJ&^X-H*[F]3VS2O
MJ!K:9HEIIMP\UN7)9=B*Q&V-,D[5P.F23SDUI"N>\.QNFK7[1074=JX4C[0K
MJ0^3N'S$[B>NX''05T%4]KB6Y0O-)@NIKB:1I5>>V^RMM8#"Y)R..O-7+>)+
M>%(HP0D:A%]@!Q7(3OJ$OB&_.DVEQ`\<;1AYTE"W#G&2&(VA5'3U-:_@J.[B
M\/01ZA',DZLX(F)+D;C@FBPR_J,,TGDSVN#-;ON"DX#@C!7/;K^@K"N].M+J
M*0+::HES+*\Y4(%PSKM9=Q!3:1[G'8]*Z:<A89&8,0%)(0')^F.<UY^L=Y<:
M>T\5M=P0_:O,6RFLYW.`C!0W0Y8D$D$@'&:2[!T.UT6Q^P6>U@HDD;>^WH#@
M`#WPJJ,^U6YHUEB>-S\KJ5..N",4VS+FTA,L?E.4&Y,YVG'2J/B>58=$N':S
MN+S"C;!;ABTASP/EYQZ_C0]P0R/P]9QR6;;YG6S14CC9@5^7[K'C.>>V/>M:
MN%TZ#58;[3FFCFN8@D83,,R>62S^9R<;0`5^\.0*[K-`+<S-:T6+5I;626YN
M(?LK^8BQ["I;U(96!QVK/UO1K6RTK5+J)I"[P2?*Q&U"QRV,#NW)I/&[OY5I
M#!;74D\LA"S112.EN.,NP0'GT_\`UU4O]/5(=?O/(DB"VYA0L&`DRNYGP>N2
M<9]JWPG\:#\U^8I;'KIL_M_A]+47$]MYL"KYL!`=>!T)!'Z5#IOA^"PO4NA=
M7$\B1"("01@=`,_*HZ@#CIW`!)-)>W$MKX7$T+7"NENA!MH/.DZ#[J8.3^!^
ME9?AB_URXUIH]3^T-:FW4H6MS$I.T$LV8Q\Q)88W=ONCK63^)AT*>C?\E?US
M_KRB_DE=S7#:-_R5_7/^O*+^25W-=6,^*/\`AC^2%$3:*:T2,RL5!*]#CI3Z
M*XRA`,=*6BB@#SF^_P"1ZU[_`';;_P!`-2L,J0>A'-17W_(]:]_NVW_H!JKX
MAE6#1[F22VN+L*O^IMPQ=_8;>:Z,1NO1?D*)`OAVU2"TMQ<7)M[14`A+C:^T
MY4D8Z@^F,]\UK_6N"L+;5`U@S+<LW[MHOW,JK!^\)D0[@"`%P`6Z@<5WM8M#
M*VI6<6HV;VL^X1N5)*G!X((_E5:'0=.M]7_M."W6*Y*,A*``-DY)/OQ6=XX=
MQ8PQ06ES//*^U)(HY'2#UD8(">.WO4NE6MW!XCFDFGNKB&2SCVM(I5`P8\`8
MX..3WJ8^0,WAUJK>:?#=W-M/,7#VQ?9M;`^9=IS^%6JY77G9_$MHD5O>HL:B
M2:Z2&5U*@']VI4;03GD\=J$!MZ7I<6G-*Z2RS2R[5:29AG"C"C@`<?GZDU?K
MG/!`E>"[F>"XM$EES';3Q2(T:@8Y+CDGJ<9KHZ;T!&;=Z):7=Q<32F023K&"
M01\AC8LC#CJ"<\U9TVQBTZS2V@+%5))+=22<DG\37)KBYU356DLM1ALU_=E/
M(G+7#;@3)VRHZ`*>1GC'%='X96X30K5+M9%E5<'S,[L9X)!Y''8]*%J#)]0M
MI)6BFMF5;B$DKNZ,#U4_6LE=+N=D*0VAB>*Y:Y#/,&3>V<G`&6')P.*V[YU2
MSG9TE=1&V5B!+D8_AQSGZ<UP$BZW/H`-A:7,,<ER)7ML21RQ*"NU,.,MGDL1
M_C22U`[ZQM5M+9(02Y&69FZNQ))8_4G-9U_J'VL7MA'IE]<HA\B1X3$!DH&(
M&YP>C#M6NF=@R,$]:Y35)?)L=<865Q>N;]52&!78EC#%@L$YVCJ:&"%%K';W
MD5\=&U<?9U5MGF6^TE%*AS\^<A21P<>U=-:SI<VL4\>0DJ*ZYZX(S7%0P7T%
MY;.ZR7@^RK&7DMI4\M=C;GW$X!R0-I&<8KK="_Y`EA_U[1_^@BFP'W]C%?"$
M3%OW,JS+M./F'3-8^HZ1!8E+I'EEEGO;<%I"#M7S@=H(`XR3UR?R%1>,6=[S
M3X(+>[,KOG[5'%*Z0*""2=@(W'&!GW[5EVJ:A%=LM_`^YKR$O,5=03]H^4#)
MVM\N#E1QTKHP?\>/J3/8]PU2P34K)[6262(/@[X]N00<]&!!^A!%,T_2K?3W
M+0&0EHHX3N;/RH"!^/-0>*9KR#1)WTYY$N.`K11&1E&1DA0K9X_V3]*S?"^H
M:A=W]REZ]_L2-/DNK,Q!6QSM?8H8>O)YS@`<5S(HS?#O_)6O$W_7O;_^@+7<
MUPOAW_DK7B;_`*][?_T!:[JNS&?''_#'\D3$X?XM?\>N@?\`87A_DU=N.@KB
M/BU_QZZ!_P!A>'^35VXZ45?]WI_/\P6[%HHHKC*"DI:2@#SO5/\`D?=8_P"N
M%M_)ZHZU>SQI]ETY1)?2J60$X"*.KD]NO'J3]:O:K_R/FL8Z_9[;^3U@/I^L
M36EW!=6=E*UYD2R+J$B$J>BC]R<`#BNG%?%'_#'\D3$Q9=?%G;6=Q8V:^=%)
M)&[+(66958!_FV\Y+9W'`!'7L>XL[J*\MDGA.5;C!Z@C@@^X/'X5S'_"/7AM
M8+=]-M'C@7RU!U.3E./D/[GE>!Q6KIUOJ<6IO--;VEO;2K^\2*Y:3+C&&`,:
M@<#!YYP*YQFQ1112&%%%%`!1110`4444`%%%%`!1110`4444`%9GBC_D7=0_
MZX-_*M.LWQ1_R+NH?]<&_E71AOX\/5?F)[,]*TW_`)!UK_UR3^0JQ5?3?^0=
M;?\`7)/Y"K%8R^)C.&T?_DK^N?\`7E%_)*[FN&T?_DK^N?\`7E%_)*[FNK&?
M%'_#'\D3$****XR@HHHH`\YOO^1ZU[_=MO\`T`T7DDL-L\D$:R2*,A6?8OXG
MG`HOO^1ZU[_=MO\`T`U%J]A!J>GS6=VSB"9<.4?:<?7M71B-UZ+\A(Q[7Q%=
MW::>]M96[I=RM%S.V<*3N=?DY7`SDXSD5T=<O9P-;2VVJ1+))8VD;6\8<Y?R
MB1F0>WR@8].:Z=&#*&4AE(R".AK`9G>(-2DTFP:[2*-XX^9#)+LP/0<$DGH!
M532?$1O]8DL#:&(*&(9F.>`N<C&._8G&.0*NZOH]MJS6S733`VLGFQ^6^W#=
MC[XI+31;.UOFNXU<RG<<,V0"WWF`]3@9I(&:)K&US7)-)NK=&M!+%,=J!)/W
MK'!)VKCD#'))[UL_2LR?0[6;6!JC23K<B/RLK(0NWTQV_"A!T(O#>O1ZU%,5
M1%>$KN$<F\?,,CG`Y'0CL:V*J:=I\.GHPA,C,Y!9Y&+,V.!DFK=,%YG/WWB.
M>QO9K::Q02906_[TX?<X09.WCDYXS@=>:U=(OAJ6GQ703RR^05SG!!P1GOR*
MJS>'K&>62282N[_=9I"3'\P;Y2>G(!_"K]E:Q65JEO;KMC08&3DGW-)"94U9
MYGEAM("R^8KN^UMK%5Q\H/;)(&:YZ2_@2S3=IDD-PMT+8O!,W[LY`W%B`?XA
MC(Y^E=)JUE)=(CP,!-&&"@L5#`C!7(Y'U'3`K*737:T:WCTV99))5F>6XN%8
M;E(VLQ!);ITX_"@'L;&ES2S6H^T$&:-FB<@8!*G&?QZX]ZYU=`FU+6-7GBUW
M5;`"Z5?*M9$5.(8N<%3S_A72:=:"RM4AWM(PRSNW5V))8_B2>*R;#5-.LM2U
MB.\O[6"3[8#LEF53CR8N<$T#.?U#2KJ'5O[,_P"$@\1,LEO)*9GFB"$J/N@;
M.>OM79:'_P`@2P_Z]H__`$$5G:CJ6@SDW1U6R,T44B)BZ3HPYXSSTK1T+_D"
M6'_7M'_Z"*&!=KE]0U:2ZOCI\T"(]O=6K[HY-_!F``;@`-QG'/%=17-W6BVV
MDQ(]J\Y^T:A!)())-P+&5<FNG!_QX^I,OA/5=<U2UT;39;^^?9!%C<>.Y`'4
M@=3ZU'IVM6U_>2VD2R)+%&DI#@<JW0C!-6M0M%OK5H'DEB#8.Z)RC`CG@BJN
MFZ):Z=,9;8RD[!&HDD+!%'9<]/6N8HYGP[_R5KQ-_P!>]O\`^@+7<UPOAW_D
MK/B;_KWM_P#T!:[JNS&?''_#'\D3$X;XL_\`'KH.?^@O#_)J[=3D5S/Q`\'I
MXSTNVLI+^:P-O<"X62%0Q)"LN.?][]*X[_A23?\`0X:I_P!^HZ.>E.E"$VTU
M?I??YH+-/0]8XHXKR?\`X4FW_0X:I_WZCH_X4FW_`$.&J?\`?J.HY,/_`#O_
M`,!7_P`D/4]8XI":\H_X4FW_`$.&J?\`?J.C_A2C?]#AJG_?J.CDP_\`._\`
MP%?_`"0:FIJ?/CS6/^N%M_)ZFQ6&?@AR6/BW4B3W\F/-'_"D/^IMU+_OS'6U
M1X>HT^9[);+HK=Q+F1N8HQ6)_P`*0_ZFW4O^_,='_"D/^IMU+_OS'67)AOYY
M?<O\QWD;>*,5A_\`"D/^IMU+_OS'2_\`"D/^IMU+_OS'1R8;^>7W+_,+R-O%
M&*Q/^%(?]3;J7_?F.C_A2'_4VZE_WYCHY,-_/+[E_F%Y&WBC%8G_``I#_J;=
M2_[\QT?\*0_ZFW4O^_,=')AOYY?<O\PO(V\48K$_X4A_U-NI?]^8Z/\`A2'_
M`%-NI?\`?F.CEPW\\ON7^87D;>*,5B?\*0'_`$-NI?\`?F.C_A2`_P"ANU+_
M`+\QT<F&_GE]R_S"\C;Q1BL3_A2'_4W:E_WYCH_X4@/^ANU+_OS'1R8;^>7W
M+_,+R-O%&*Q/^%(#_H;M2_[\QT?\*0'_`$-VI?\`?F.CDPW\\ON7^87D;>*S
M/%'_`"+NH?\`7!_Y57_X4A_U-VI?]^8Z1O@<",'Q;J)'3F&.M*3P].:GS/1W
M^%?YB=VCU+3<?V=;?]<D_D*L9KR<?!-NWC#4_P#OU'1_PI-O^APU3_OU'6;C
MAV[\[_\``5_\D&IOZ0?^+O:Y_P!>47\DKN01BO)1\#E$ID'BW4M[``MY,>2!
M3O\`A2;?]#AJG_?I*UK2P]5I\ST27PKHK?S"5T>L<4<5Y/\`\*3;_H<-4_[]
M1T?\*3;_`*'#5/\`OU'6/)A_YW_X"O\`Y(=V>L<4<5Y/_P`*3;_H<-4_[]1T
M?\*3;_H<-4_[]1T<F'_G?_@*_P#D@NS2OC_Q76O<_P`-M_Z`:S[VXCU*Z:P$
MJ"UB_P"/DE\;CVC']?P'>H_^%'@L6/BW4B3U/DQYIA^!$)8L?%-^2>2?L\63
M^E:5/J\VFI/1);+_`#!71!XFCAGN;+[-;F2YB=#'*"-@4-\RY!^3CG..>F:N
MVDT6F7:6?F1_9)VQ`0P_=M_SS^GI^7I4'_"AX/\`H:+_`/\``>+_``H_X41`
M,'_A*+_(Y'^CQ?X5FHT/YG]R_P`PUN;]+BL3_A2'_4VZE_WYCH_X4A_U-NI?
M]^8Z?+AOYW]R_P`QW9MXHQ6)_P`*0'_0W:E_WYCH_P"%(?\`4VZE_P!^8Z.7
M#?SR^Y?YA>1MXHQ6)_PI`?\`0W:E_P!^8Z/^%(?]3;J7_?F.CEPW\\ON7^87
MD;>*,5B?\*0_ZFW4O^_,='_"D/\`J;=2_P"_,=')AOYY?<O\PO(V\?6C\/TK
M$_X4A_U-VI?]^8Z/^%(?]3;J7_?F.CDPW\\ON7^87D;>/K33&A.2@)]Q6-_P
MI#_J;=2_[\QT?\*0_P"IMU+_`+\QT<F&_GE]R_S"\C8\J/\`N+C_`'13L5B_
M\*0'_0VZE_WYCH_X4A_U-VI?]^8Z.3#?SR^Y?YA>1MXK+\1?\>MK_P!?MO\`
M^C%J#_A2`_Z&[4O^_,=(?@>#U\6ZB>_^HCK6B\-3FI\TM/)?YB;DT>L@YI<U
MY/\`\*3;_H<-4_[]1TO_``I-O^APU3_OU'6')A_YW_X#_P#;#U-[P]_R5GQ,
M?^G>#_T!:[JN,\!^`X_!]Q=S_P!JW.I2W(52TZJNT#Z5V=/$U(U)IPV22^Y6
M%%6044'I7%:IXBU^'79[6TT]VLHV4+,UA*^#@YP0V'!X&1@#//0US%'93`M&
MRHVQB,!@,X]ZXO4;OQ79WTD$/FW=N9-J3K;J&51"I/&,'+$D>XQ[5"WB7Q.-
MA72RSD9,?]GS#G^)=V<#:.=W1N@HGUWQ1<P2S6UG]GA^8+OL)3+@,^&"DC^%
M%XQ_$*+6U"VA;M_[<NG@ECU/5$MUF<`R6D4;S1A`09%:+*_-N7@+D`<=ZD\'
M7>KRZ3(VIWEY<7A5CB>Q:$J=HX&8HQUSV.>QXJC-X@\2VEFT]Q;QK$=WSM8R
MEH@".64,,YSV`QUYYJU?ZYKP2U:SLB_FVT4Q5+9VWLW+#?G:H'`P>><]J;3$
MV5(K_P`76$%E'.)+F6YD!9I(!+Y:87.YHT15P23@CH,9IEKX@\57%LMV;54A
M<JJ(EH\I)PV?F5NA9?O8P`1FF2>*?%(+!-':X3R6*O\`V=,F]O4@MD`?W>K=
MJU/"FO:G<7AM=8L/L47EQBWV6DD:EBN2,M]#QCC'-*^@]F0'5O%$'AJ.Y6QD
MN=0:4(T;P\J"@.<+C@-D5#<:QXMED6&"T\EGQN8V3L(AY>[.[.&);C';'/44
MVX\4^(<RBTL//Q=-&NVPE*[5D*E2V[!.T9WCCJ.M12^*/$SO%(ED5A$LB,(+
M&2??L#JQR#@#>H('4@C!ZT/4$6EUOQ3'X1TZ\.F/+JCG;=0_9VRI').T'N`0
M#ZD?2J\GB#QDD=T?[)0/&\80&WF8`$'/W5.X=.5SCO4;>*_%20QK_92&8QI-
M)MM)2P4NRD>7NW`G&1VP?:M37M;U^+6;6STFQ+0RHOF22V4CK$3WWJP!QSE>
M#[T[Z^H=+#-(U+Q1<Z)<F[@\G4%O6BC,ELQ7R=YPV!C/R_2HVUSQ3+-'!!8&
M)\;I))+.0H!Y>X8.0"=W'7C-.AUCQ'->31R6S1B.PFD"I9R`><`FP[VR#DEL
M*.>.<U`^N>*T+V[6>Z1`5\R.QD`<;<[P22HP<+MY)SD8Q0F%MA&UOQ;"]TOV
M(SO'&VU19NJ<,PWAAG.0!\@R><CBI=.UKQ5)?V0O;,"VGG$;K'9R`JNQ26+-
MC`RQ^\!]W')JC+XD\612-BQF=A&JK'_9DK+NS_$X(!R.XX7H15^P\3:_+K,,
M-QIN+(320RR0VTDARO.[(.%&".""<@BC9Z@0ZGJWC$7UU;6MNB0O'.8)EM'9
MD(W!>>5)X4\X!W<9Q5OP]J/BFYU0VNHPI';PNRM,]LX:0*..<!>>#E<CJ,<5
ML^(8[Z:.S;3;VZM2TRK)Y$4;$H>I(=&QC\*YMM=\6VHAC;3Q=%Y\&4VD@PA)
MP"%[\?>QCIQ23!ES1-3\0RK+!>1RLZ6C-O:S>,^8`,$$_*Q))&T#C`/>J,.L
M^+D`\^SF`0)"2UH7\QU#9<!.0'(7GHN<U?\`#^M^(YKN6+5M/58TLA.'BM9$
MS(0#M&XD$\D;<@\>_&6/$WC%K5YAI2$),L2@Z?.K,IR0^W<2!@`$8."<GIB@
M"Q<:QXMBLX3):LLLFQR(+%W(SC,?4@$#=\QX[<5/X<U_Q!>:JEKJ%FL44AD9
M7:!HG"*!@E6.1G=C_@)K2-YJW_"310".4VC6V]AY>(T;!_C*\MG`QNZ=N]9#
M:MK=N!-;PW5U<.=L@N--8!&Z^4C*%.TG^,[E'4D]`Q#=.U#Q>3)')F17N#$K
MRV#+Y:C9\V,C(Y;GVZU<CU76KOP_+--'=Z?/')&A>*R9I,;5+E496)&[(R%;
M\>M5KO7O$]J@>X@MTC>01C;83.4R`0<!LMU(P*9+XB\5RW4D-MI@C40>86EL
M9<*X7)0$-AL]B,8]Z70=];$5SKWBLW:);V=PD*1*[%[!R6?`^3(X(.<Y&,8(
M.*?=Z]XJE2XFM[26W@\S9#G3I&D(PQ!VYSR0!DCC/-:EKJVN7FFW3QVT*W4%
MX+=!@['4,,L>I`P?PYK(?7/%P#P/8MYHF928[1SA!*0&#D;2-N!C&['S55KL
M5M"QIGB'Q'+J4%O<V6R&YN1"C2V[1.%V[F)4GG`5AD<9*GO5NWO/$5UXB2$E
M[:QAE<R_Z&0&`R%3>V0P/#;E^E9%UX@\3QW3M'IK2RHP2-6TR4A1N(8>9D<E
M0&W#Y>V,UHZ/XBUV[U*U2YT\1VDR2[G2W=@&4D9,F[:`2I([D,/>IWU#K8H1
MZOXQMK6[D:![K$KI'OL75D`V?-A>6'+=!SC@UK7M]XE:ZLA:Q^4)H(C+FW+Q
MQNV_>>@;C"\$CM6=%XH\0M''<FP>:#]X"8K&4!N%*_+RW4D;AP>3]+5CK7B&
M]T2[EN+62SNX;A%0"QDY3(SA2<MQW'%,!VE:UXEN)KU;W3A"(K-98AY$@+2[
M0<9(P>2?E!R,>]48M;\6F$7+VLJQNJJR&P<E#_%($!#$?[)YZ?2D.O>,X+%F
M:PCG>*"%F8V,N79\9X5NJ]P!W[=*T=+U[7IK?57U+3ULS;8$($3COC.6&'XY
MXZ9P>E);7&]RK:ZYXOGN&@?2U@PBD3-;L5W$@],^CK^*M4^IZUK\*Z?!!#NN
MYH&>5%M7)+!@,YSA``2><YP!WJS8ZCJ2ZI+'+)<26[W.R/SX0A`\MB0"%7<`
M5&",C!ZD],BW\3>)IKFU:+2HYH9696G^Q3*,?W>IZ==WW6Z#%-]@+!\0^)/[
M5MK==,G-N'1)Y/L<G.6<'!Z8VA#GIR>>U+>:CXJM=:U+[+&UU:Q;?)A:T8!L
M[_NR=\87.,]>QJ!/$GBN/S8Y]/#2(D;*\>F3;"2N=N-YSDX&1PO4^E27&O\`
MBF$0!].WR2S=(K&4A(\X(+!CAAG.2,'TI`6IM3UV7PW974@N;:Z:1O,%K9NS
M,!G:I1T+*"<9)7\1UJ$ZYXIEN'CM]/9!`)&?S+1_WA63"JK9`Y4@Y&1_2;5=
M6\0QP6<5E`XEEMHV=C9O(=Y^\21A5Q_=(R<\8Q5:+Q!XI>Y$;:<?D!W!;.10
M<+P=Q)!#'/`Y&.3S3$G<K'Q!XK4G;;2R;[C`:73Y(XTCV)DY[;6+<G@X..*U
M'UK7I=,TNXM[7;+>#<Z+;M*%R1A20<+A23N/''O4>EZWK][?RVMWIP6U^RNR
MRM9RQF1NQPV0,]-AYJDNM^+(H5MC89D5``\=A(-^4!R#DJNW.,$?,>@&*3'M
MJ6+J?Q5;Q::L%U)/,]MOG+V.07R20VW`7L`.#]>:L:3K'B:^L]2:YL4M+A)$
M6W5H).`3@DY`#`#!R#]:RKSQ%XKMYG$5E,Y6-PB?V9*X+;EV%F!`.03TQCOF
MKMKXE\0S:Q!;OIH%KYYAF>.W=R.`W4-A,!L$MW4T-=!+:Y%<:_XOBED1-+5R
MD*%<6TOSL2-QS]T#[QQG(QWS5J>_\2QZ=:M`)IK@S3B3-H5!`E`3*D9`VD]#
MR*@N-5\5VFH7L21_:D:9S;AM/DVHG.#O5@#@@?*>6SD$`8JWJVN:_9ZK-;16
M/F6\=KY@G2SEDW2>P4X(S_#G=CG)H0V)8:OXC76[6VU&S!M-DGFS);2C<0S`
M$8!`X"G!/.[BI?$":_'JI?2M0NUA98L1?9XI(E)D56YV;R-N2?F]>E9-OX@\
M77<=N38?99L;I(VL)2,",G[Q/=N`!RIQG.<5HZKK?B--;%I8:<@MGCC(FDMY
M7`9B-QRI`XR?ER#QFF]Q/J&EZQXEGN+U+K30@AM"\*^4Z^9(!Q@D;>3GC=D5
M0N/$7BK[3#'9:?/<)L)=FL'AWGJI&XG`.,$'D?B*+[Q'XGA58!:QFZ>"20+%
M8RDG"H1CDA<%CUR"1BI+KQ)XE@G=8M,CE#2F*-'MWB.[#D#+'YQA!\R\?./0
MT6900:WXNDL$N7LT!"_-&+*7<V=W.&P1C`XQSZ\BHH-=\6/-:01VLK>8Q66:
M73I%"`S8#=N-G8\C@FK>A>(?$MWJ&GPWVE"&"<-YLGV:9,8S_>^YT'#=<\&K
MFE:EKLD]T-1A*6ZQOY;+:/Y@("D'KAL[C@`?PT$KJ5M6U/Q3!JYAM+9'M7N!
M$CFVD.U=BDG*YZDMR<#Y<9K-L]8\:6:6]M<P/>-Y;M)<R6;!B=[=%C7:-J[2
M`2"V>#5K3M4UR>ZLAY^HLD@?`GTTQ@CY^9<QKM883`!4'/?K5W2+_5VUI%U$
MW7D&W0%!:E4#G&6)\ON21@/P!R!UHW'<JZ5K'B,ZQ;0W4$TMM/*P=S821[%V
MKMY)(`ZDYY[=>*JRZMXQLQ<R10/>*)7C57LG!0#)WC;RPXQP#G/'I70^)$U0
M7EF^FWMW#'B3S8X88W5BJ$KDLC$9.!P1^=<\WB'QC'.EL=+1SLQYYLY=KDXY
MP#@8ST)&><8Q0%CMM(EN)M,MIKU%CN)(E:50"`K$<@!@".?4`U<R/6N.M==U
M\Z;J\EY8>7/:R;+?9:2MOYQG;GYQT.5/?VJG:^(O%DCV+3Z4B)<21I(IM)04
M!1"V3DXY9N2,#;@T@Z7.]HI%Z4M`!3=HSFG44`-VTNWBEHH`@N;.WNXO*NH8
MYX\@[)$##/K@U+L&,#@4ZB@!NS\Z"M.HH`8L2(,(JJ.N`,#UI(((X$"0HJ(.
MBJH`'T`J2B@"-8(UE>5442.`&8#E@.F3[9/YT\+BEHH`:5%&SWH9L4Z@!NSW
MID,$<*%(46-22V%4`9/7]>:D!YQ2T`-"X[TNVEHH`3;[TFSWIU%`#=HK"\7Z
MO<:19PRVK6Z,\P1FG7<-N#PHW+ECV&<GL":WZ3`H`Y)?$S+I>JWMREO>Q6$X
M"M`I7Y>.H);#`GGH?85DR_$J9%^;12I,)D(-P%P0<'J/N@Y!8=*]""`'-+M%
M`'G,/Q#-KYZ-I5M!$C0NG[[:K"098@@$-@^G4L/6M?7?&,FGZY%IEI9P7,LJ
M*5#7!C*LQ`&X;#@8)YYZ5U^T4;10"..TKQ?)J5W>1R16=K%;VAF;?,69&_Z:
M#`PO<>HYK*B\9WB6R_9)]&:#[*SQM$/D8[V4,1YHV(`!G.0#P66O1=@SFC:,
M8H=@Z'&WGBR:P33$6*UD^UVK2X&8R6!`^1,ME><D9Z<YJM;^-M2>*=S86TQB
MR=H=H^`&)Y^;LOI7>;1FD*CTH$<C:>,FN+/4;C[-;H;)E7:USPNYB/WAV_(1
MC)Z\&LN#XB221PK+IT-SNM8YIO(E)*EMH(VE>F77G)XR>U=U::?:V<DSV\95
MIVWNS.S$G\2<#VZ4^YM(+I56=-ZJZN`2<9!R#[T=1G(V_B^2Y\/RZFFGP">W
MG:$PB0L!A2<;]HP>`#P<=ZGO?$LMG8:<Q;3K&>>X:W-O,Y(?:VTA&^7'<Y(/
MT-=80`.!0J@T`<78>++Z>S:?-C<!9GC9X0RA<1;]F,M\P/!.>W05M^%-5;5M
M+BEN)K>6XZO]GP$QD@$8=^.#SDYP:V0HH"@'-`!MXQ1L]Z=10`W;[T;!3J*`
M&[/<TR*WCB#")%0,Q8A5`R3U/UJ6B@!NSW[4!13J*`&A<4I6EHH`88E+!\#>
M!@-CD#T_2D>"-W1W12\?W6*@E<]<>E244`(1S1M]:6B@!"OO2!,'-.HH`3%)
MLYSFG44`-VTNVEHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`,#QK;P
M7=A96]U#'/#)J%LKQR*&5AY@X(/!%2_\(?X8_P"A<TC_`,`HO_B:?XFL[V\L
MX/[.CADF@NH9PDLAC5@K`D;@#CCVIGVSQ'_T!=/_`/!DW_QF@"KX>L++2_$F
MLP:=9V]G!Y5LWEP1K&N2),G``&>!2_\`"::04A,<K2RR@XAC96D#;@H4J#P2
M2`/Z58T2UU+^U=1OM3MK>V-RD*(D,YE^YNR22J_WJ1_"FFO!#"8F7R00CJ0&
MR2&#9QU!`(^E`"V7B.&YU!-/EM+JUO&!+0S!,H`,@DJQ!!'3!/(-5[CQ;!%<
M7$::??31VJ&2XF01[8E#,N2"X8_<8\`\4YO"D9GCNEU+4%O4)+76Z,R.,8VG
M*%0,=@!W]:)_"=M+<2R"[O$2X79<1*Z[9EW,V&^7.,LW0CK0)>9.WB.S%Y=V
MRI.[6B+([*HPP/7;SSMR,^F1UJ]I6H1:E`TUMN:$,560XVR8_B7U&>_M6?:>
M%=+M+P7EO;+'>;G+W"A0\H;JKG'(Z8';:*U-/M(["R@M(`1%;QK$F3DX`P*`
M)V..2:P;2U?7+?[9?W%RD,V3%;P3-#L3/&60@ECU/.*WF&:Q;6UU'26,%G#%
M=6&28TW^7)$#SMZ889Z=,>]`Q&$NC7=HJ7$TUG<R>08YG,C1L02I#'DC@YR3
MUJ/5O%=IIFKKITUO.\A5&+H\0`#L5'RLX=N5/W5-6(K.^OK^"YU%(K>"V)>*
MWC?>6?D;F;`Z`\`=\\FK9TRW.H2WQ3,\D:1[C@[0I8C'I]XT`44\26<AO-JS
M!;*01ROM`7!X+CG[H(()]CZ4E_XFMK+2(]2:WGD@EE$4?S1H7R<!@7=5"G'&
M2*;:>$=)LA)]CMQ`TT#V\[Q@!IPW5G./F;.3GW/K6A/I=O/;VT$J;H[9E=`<
M8RHP,TN@&%:^.;.[NX[>&SNBS@,2TMNNW)8=#+EONGE0P/;-+9>.;"[W?Z-<
MQ`>6`2T+_?<("=CMMY8<'!QG@U?N?#4,NJ&^BNKBW9E56CB$>Q@N<#YD)'7L
M12?\(OIXV".-XU41!@C`"3RW#J6XY((_(FF"\RM+XOMX(1-)I]^(Y<&V8B/_
M`$GD#"?/QU!^;;Q6KI.J+J0F4V\]I-`X26&?;N4D`CE68'@CH:S9/"-K)$8I
M+J]:-,?9U,BD6W(/R?+[#[V>.*T]*TQ--23$LMQ+,V^6:8@NYQ@9P`.`,<`4
M`7Z#THID_F>2_D[?,P=N[IGMF@#)U:>6\N%TBS9D:1=US,IYBC]!_M-T'IR>
MPRW3'?3+H:3.[-&P+6<KL264=8R3U9?U'T-1Z3;:Q8P,'M;.6XF8R3S&X8&1
MC_P#H!@`=@!2ZM:ZMJ-J8FM+6.12'BE6Y8-&XY##Y/TZ$9!X)H`L:_KUKH4=
MK)>K*4N;A+93&`=K,<`G)'R^IJFGBRWFN9K:RLKV\N(I7B\N-4!8)MW."S`;
M?G`Z@GL*MZAHRZWID%OK*AG49D$+84L5*G&>W)Q5=/"=I"J&TN;NUG3(%Q$Z
M[R"%#`Y!!SM!/'49XH%K<B@\8Z?<&=(4N7DB5&V;`I?<<8&2.03@YQBB'Q=`
M#_I]C=:;&+C[+YEU)"%\S:6ZK(<#"_J*E/A'2_*2,1.!'+',C!SN#)[]>>^>
MN:N2:):2.ID1G"W)N\,<@N4*]/3!-'4-2OI/B2TU8W0L4FE^S+NR-I$@W.OR
MG/.3&?3J/PL6&M6M]'/-`7,,"@O(1A0<9*_4=_2JMCX8M]/U(WEC=W4`;_60
M(4\N3YF;!!7(Y<]"*M2:):R:;<:>P8VUR[M*N1\P9MS+]#DCZ&A^0RE'XI@N
M;2WFL[*]N9;C>4MD5%D`7&XG<P4=1W[U,/$,;S;([&^>--OG3"-0L!(!PP+!
MNAYP#COBH1X0TZ`L=+,NE'>77[%M0)D`,`I4C!P,\=1GK4H\,VRR`QW-VD1"
M^;#YV4F(&`7R"2<=<$9[YH`BC\56Y,1FLKVW2=0UN\JH!,I*C(PQ(^\#A@#C
MM3[CQ58V^J"PF6=9"[Q[RHV;E56P3GC.\`>_%-7PI:>7LDN+N54C\J!7E!^S
M+D'Y#C.?E'+9/'I2KX5L621;II[IYD=9996!:3>%!)P``0$7&`.E`$+>+`MP
M4.D:AY(MS=?:,P[/+QG./,W>V,=?;FGQ>+]-DCF<^?'Y$DD<@=0"H0$ENO*G
M:<$>E6QH%H(!%F4J+3['DOD[/KZ^]0/X2TN1XFDCD8Q^:.7^\),[E..HY./2
M@&/L?$4%R+L3P363VB>9(L[1DA.N[",V.G0X/M3(O$:NT(GTZ_M1/(D<1E5,
M/NSAN&.!QR#@CCBI++P[;6TMQ)+)/>/<1>2S7#*3Y?\`<X`R/<Y/O4#^%(GB
M56U/4B\;HT,AE4M$%S@`%<'KU()/K0(EN/$<$-W)&;6[:"&012W2JOE1N<8!
M^;<>HY"D<]:I-XUM([.2Y>RNPJ2(@#/"I8L>#DR`+]'*GVJY_P`(Q;F7=)=W
M<B,P>:(NH29QC#L`H.>!TP..E02^#[:;>\M[>M,2I25F1FC"G(`RA!Z]6!/O
M0AFSI5Z-0L8KM8VB$HR%9T<C\49E/X$U:JMIMI]BLTMS-)/L_P"6D@4,>?\`
M9`'Y"K-`D%%%%`PHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB
MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****
M`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`
"_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EVYBI">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock- based Compensation - Additional Information (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
        <th class="th" colspan="1">60 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2010</div>
        </th>
        <th class="th">
          <div>Feb. 28, 2003</div>
        </th>
        <th class="th">
          <div>Oct. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based compensation arrangement by share-based payment award, options, outstanding, number</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" onclick="toggleNextSibling(this);">3,572,116</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" onclick="toggleNextSibling(this);">3,200,958</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" onclick="toggleNextSibling(this);">$ 11.40</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" onclick="toggleNextSibling(this);">$ 4.90</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of option term</a></td>
        <td class="text">6 years 3 months<span></span></td>
        <td class="text">7 years<span></span></td>
        <td class="text">7 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Common stock, shares issued</a></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" onclick="toggleNextSibling(this);">568,906</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" onclick="toggleNextSibling(this);">1,268,049</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" onclick="toggleNextSibling(this);">863,176</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Cash proceeds from exercise of stock options</a></td>
        <td class="nump"><a title="us-gaap_ProceedsFromStockOptionsExercised" onclick="toggleNextSibling(this);">$ 744,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromStockOptionsExercised</span><span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromStockOptionsExercised" onclick="toggleNextSibling(this);">$ 1,100,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromStockOptionsExercised</span><span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromStockOptionsExercised" onclick="toggleNextSibling(this);">$ 47,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromStockOptionsExercised</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value of options granted</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" onclick="toggleNextSibling(this);">$ 17.41</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" onclick="toggleNextSibling(this);">$ 6.91</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" onclick="toggleNextSibling(this);">$ 0.94</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" onclick="toggleNextSibling(this);">14,500,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" onclick="toggleNextSibling(this);">5,400,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" onclick="toggleNextSibling(this);">271,929</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of shares vested</a></td>
        <td class="nump"><a title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" onclick="toggleNextSibling(this);">3,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</span><span></span></td>
        <td class="nump"><a title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" onclick="toggleNextSibling(this);">487,603</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</span><span></span></td>
        <td class="nump"><a title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" onclick="toggleNextSibling(this);">879,024</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost related to non-vested stock-based compensation arrangements</a></td>
        <td class="nump"><a title="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" onclick="toggleNextSibling(this);">$ 19,600,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense recognition period</a></td>
        <td class="text">4 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Options granted, maximum term</a></td>
        <td class="text">10 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mgnx_StockOptionPlan2000Member', window );">Stock Option Plan 2000 [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based compensation, number of shares authorized</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized[us-gaap_PlanNameAxis=mgnx_StockOptionPlan2000Member]" onclick="toggleNextSibling(this);">130,725</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized<br>/ us-gaap_PlanNameAxis<br>= mgnx_StockOptionPlan2000Member</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease', window );">Increased number of shares authorized</a></td>
        <td class="nump"><a title="mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease[us-gaap_PlanNameAxis=mgnx_StockOptionPlan2000Member]" onclick="toggleNextSibling(this);">150,297</a><span style="display:none;white-space:normal;text-align:left;">mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease<br>/ us-gaap_PlanNameAxis<br>= mgnx_StockOptionPlan2000Member</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based compensation arrangement by share-based payment award, options, outstanding, number</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber[us-gaap_PlanNameAxis=mgnx_StockOptionPlan2000Member]" onclick="toggleNextSibling(this);">19,705</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber<br>/ us-gaap_PlanNameAxis<br>= mgnx_StockOptionPlan2000Member</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice[us-gaap_PlanNameAxis=mgnx_StockOptionPlan2000Member]" onclick="toggleNextSibling(this);">$ 0.81</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice<br>/ us-gaap_PlanNameAxis<br>= mgnx_StockOptionPlan2000Member</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mgnx_EquityIncentivePlan2003Member', window );">Equity Incentive Plan 2003 [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based compensation, number of shares authorized</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized[us-gaap_PlanNameAxis=mgnx_EquityIncentivePlan2003Member]" onclick="toggleNextSibling(this);">2,051,644</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized<br>/ us-gaap_PlanNameAxis<br>= mgnx_EquityIncentivePlan2003Member</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease', window );">Increased number of shares authorized</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease[us-gaap_PlanNameAxis=mgnx_EquityIncentivePlan2003Member]" onclick="toggleNextSibling(this);">4,336,730</a><span style="display:none;white-space:normal;text-align:left;">mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease<br>/ us-gaap_PlanNameAxis<br>= mgnx_EquityIncentivePlan2003Member</span><span></span></td>
        <td class="nump"><a title="mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease[us-gaap_PlanNameAxis=mgnx_EquityIncentivePlan2003Member]" onclick="toggleNextSibling(this);">3,790,760</a><span style="display:none;white-space:normal;text-align:left;">mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease<br>/ us-gaap_PlanNameAxis<br>= mgnx_EquityIncentivePlan2003Member</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based compensation arrangement by share-based payment award, options, outstanding, number</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber[us-gaap_PlanNameAxis=mgnx_EquityIncentivePlan2003Member]" onclick="toggleNextSibling(this);">2,008,474</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber<br>/ us-gaap_PlanNameAxis<br>= mgnx_EquityIncentivePlan2003Member</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice[us-gaap_PlanNameAxis=mgnx_EquityIncentivePlan2003Member]" onclick="toggleNextSibling(this);">$ 1.64</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice<br>/ us-gaap_PlanNameAxis<br>= mgnx_EquityIncentivePlan2003Member</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Increase in aggregate number of shares authorized</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized[us-gaap_PlanNameAxis=mgnx_EquityIncentivePlan2003Member]" onclick="toggleNextSibling(this);">545,970</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized<br>/ us-gaap_PlanNameAxis<br>= mgnx_EquityIncentivePlan2003Member</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized[us-gaap_PlanNameAxis=mgnx_EquityIncentivePlan2003Member]" onclick="toggleNextSibling(this);">1,739,116</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized<br>/ us-gaap_PlanNameAxis<br>= mgnx_EquityIncentivePlan2003Member</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mgnx_StockIncentivePlan2013Member', window );">Stock Incentive Plan 2013 [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based compensation, number of shares authorized</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized[us-gaap_PlanNameAxis=mgnx_StockIncentivePlan2013Member]" onclick="toggleNextSibling(this);">1,960,168</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized<br>/ us-gaap_PlanNameAxis<br>= mgnx_StockIncentivePlan2013Member</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease', window );">Increased number of shares authorized</a></td>
        <td class="nump"><a title="mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease[us-gaap_PlanNameAxis=mgnx_StockIncentivePlan2013Member]" onclick="toggleNextSibling(this);">2,967,272</a><span style="display:none;white-space:normal;text-align:left;">mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease<br>/ us-gaap_PlanNameAxis<br>= mgnx_StockIncentivePlan2013Member</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based compensation arrangement by share-based payment award, options, outstanding, number</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber[us-gaap_PlanNameAxis=mgnx_StockIncentivePlan2013Member]" onclick="toggleNextSibling(this);">1,543,937</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber<br>/ us-gaap_PlanNameAxis<br>= mgnx_StockIncentivePlan2013Member</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice[us-gaap_PlanNameAxis=mgnx_StockIncentivePlan2013Member]" onclick="toggleNextSibling(this);">$ 24.22</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice<br>/ us-gaap_PlanNameAxis<br>= mgnx_StockIncentivePlan2013Member</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance', window );">Stock reserved for future issuance</a></td>
        <td class="nump"><a title="mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance[us-gaap_PlanNameAxis=mgnx_StockIncentivePlan2013Member]" onclick="toggleNextSibling(this);">1,960,168</a><span style="display:none;white-space:normal;text-align:left;">mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance<br>/ us-gaap_PlanNameAxis<br>= mgnx_StockIncentivePlan2013Member</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan', window );">Percentage of common stock share outstanding</a></td>
        <td class="nump"><a title="mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan[us-gaap_PlanNameAxis=mgnx_StockIncentivePlan2013Member]" onclick="toggleNextSibling(this);">4.00%</a><span style="display:none;white-space:normal;text-align:left;">mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan<br>/ us-gaap_PlanNameAxis<br>= mgnx_StockIncentivePlan2013Member</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Common Stock Capital Shares Minimum Increase In Shares Reserved For Future Issuance</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of shares of company's common stock outstanding for increase in shares reserved for issuance under stock plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Share based compensation arrangement by share based payment award number of shares authorized after increase.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Unrecognized cost of unvested share-based compensation awards.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (j)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.D.2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section D<br><br> -Subsection 2<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of additional shares authorized for issuance under an established share-based compensation plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (d)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (d)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of options outstanding, including both vested and non-vested options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)-(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of share options (or share units) exercised during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mgnx_EquityIncentivePlan2003Member">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PlanNameAxis=mgnx_EquityIncentivePlan2003Member</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mgnx_StockIncentivePlan2013Member">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PlanNameAxis=mgnx_StockIncentivePlan2013Member</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mgnx_StockOptionPlan2000Member">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PlanNameAxis=mgnx_StockOptionPlan2000Member</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EPIAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Collaboration and License Agreements - Additional Information 5 (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Oct. 31, 2010

</div>
          <div>Molecule</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014

</div>
          <div>Program</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DeferredRevenueCurrent" onclick="toggleNextSibling(this);">$ 14,248,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredRevenueCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredRevenueCurrent" onclick="toggleNextSibling(this);">$ 20,267,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredRevenueCurrent</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=mgnx_PfizerIncMember', window );">Pfizer [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CollaborationAndLicenseAgreementEnteredDate', window );">Collaboration agreement date</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">October 2010<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CollaborativeAgreementPeriodOfContract', window );">Period of agreement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">3 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedAsPerCollaborations', window );">Commercialization of molecules</a></td>
        <td class="nump"><a title="mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedAsPerCollaborations[us-gaap_CounterpartyNameAxis=mgnx_PfizerIncMember]" onclick="toggleNextSibling(this);">2</a><span style="display:none;white-space:normal;text-align:left;">mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedAsPerCollaborations<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_PfizerIncMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NonRefundableUpFrontPayment', window );">Nonrefundable upfront payment</a></td>
        <td class="nump"><a title="mgnx_NonRefundableUpFrontPayment[us-gaap_CounterpartyNameAxis=mgnx_PfizerIncMember]" onclick="toggleNextSibling(this);">5,000,000</a><span style="display:none;white-space:normal;text-align:left;">mgnx_NonRefundableUpFrontPayment<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_PfizerIncMember</span><span></span></td>
        <td class="nump"><a title="mgnx_NonRefundableUpFrontPayment[us-gaap_CounterpartyNameAxis=mgnx_PfizerIncMember]" onclick="toggleNextSibling(this);">5,000,000</a><span style="display:none;white-space:normal;text-align:left;">mgnx_NonRefundableUpFrontPayment<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_PfizerIncMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_AdditionalPotentialClinicalMilestonePaymentsUnderAgreement', window );">Clinical milestone payments</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="mgnx_AdditionalPotentialClinicalMilestonePaymentsUnderAgreement[us-gaap_CounterpartyNameAxis=mgnx_PfizerIncMember]" onclick="toggleNextSibling(this);">17,000,000</a><span style="display:none;white-space:normal;text-align:left;">mgnx_AdditionalPotentialClinicalMilestonePaymentsUnderAgreement<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_PfizerIncMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_AdditionalPotentialCommercializationAndSalesMilestonePaymentsUnderAgreement', window );">Commercialization and sales milestones</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="mgnx_AdditionalPotentialCommercializationAndSalesMilestonePaymentsUnderAgreement[us-gaap_CounterpartyNameAxis=mgnx_PfizerIncMember]" onclick="toggleNextSibling(this);">195,000,000</a><span style="display:none;white-space:normal;text-align:left;">mgnx_AdditionalPotentialCommercializationAndSalesMilestonePaymentsUnderAgreement<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_PfizerIncMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NumberOfPrograms', window );">DART program</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="mgnx_NumberOfPrograms[us-gaap_CounterpartyNameAxis=mgnx_PfizerIncMember]" onclick="toggleNextSibling(this);">1</a><span style="display:none;white-space:normal;text-align:left;">mgnx_NumberOfPrograms<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_PfizerIncMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ResearchObligationCompletionDate', window );">Research obligation completion date</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">2014-01<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_UpfrontFeeAndParticipationRecognitionEndDate', window );">Term of the agreement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">2014-01<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicensesRevenue', window );">Recognized revenue under agreement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_LicensesRevenue[us-gaap_CounterpartyNameAxis=mgnx_PfizerIncMember]" onclick="toggleNextSibling(this);">100,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LicensesRevenue<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_PfizerIncMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_LicensesRevenue[us-gaap_CounterpartyNameAxis=mgnx_PfizerIncMember]" onclick="toggleNextSibling(this);">3,500,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LicensesRevenue<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_PfizerIncMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_LicensesRevenue[us-gaap_CounterpartyNameAxis=mgnx_PfizerIncMember]" onclick="toggleNextSibling(this);">5,500,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LicensesRevenue<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_PfizerIncMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized', window );">Milestones achieved</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized[us-gaap_CounterpartyNameAxis=mgnx_PfizerIncMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_PfizerIncMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized[us-gaap_CounterpartyNameAxis=mgnx_PfizerIncMember]" onclick="toggleNextSibling(this);">500,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_PfizerIncMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DeferredRevenueCurrent[us-gaap_CounterpartyNameAxis=mgnx_PfizerIncMember]" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredRevenueCurrent<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_PfizerIncMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredRevenueCurrent[us-gaap_CounterpartyNameAxis=mgnx_PfizerIncMember]" onclick="toggleNextSibling(this);">$ 7,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredRevenueCurrent<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_PfizerIncMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_AdditionalPotentialClinicalMilestonePaymentsUnderAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate potential clinical milestone payments available to be earned under collaboration agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_AdditionalPotentialClinicalMilestonePaymentsUnderAgreement</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_AdditionalPotentialCommercializationAndSalesMilestonePaymentsUnderAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate potential remaining commercialization and sales milestone payments available to be earned under collaboration agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_AdditionalPotentialCommercializationAndSalesMilestonePaymentsUnderAgreement</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborationAndLicenseAgreementEnteredDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Collaboration and license agreement entered date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_CollaborationAndLicenseAgreementEnteredDate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>us-types:dateStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborativeAgreementPeriodOfContract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Collaborative agreement period of contract.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_CollaborativeAgreementPeriodOfContract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_LicenseAndCollaborationAgreementsLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_LicenseAndCollaborationAgreementsLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonRefundableUpFrontPayment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Non-refundable up front payment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_NonRefundableUpFrontPayment</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedAsPerCollaborations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of molecules to be developed and commercialized as per collaborations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedAsPerCollaborations</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NumberOfPrograms">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of programs being pursued under collaboration agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_NumberOfPrograms</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ResearchObligationCompletionDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Research obligation completion date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_ResearchObligationCompletionDate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearMonthItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_UpfrontFeeAndParticipationRecognitionEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Upfront fee and participation recognition end date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_UpfrontFeeAndParticipationRecognitionEndDate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearMonthItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 8<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 13<br><br> -Section A<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LicensesRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LicensesRevenue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of consideration recognized during the period for the milestone or milestones.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 28<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=19771982&amp;loc=SL6892177-166501<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=mgnx_PfizerIncMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=mgnx_PfizerIncMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EIJAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Lease Exit Liability - Changes in Lease Exit Liability (Detail) (Contract Termination [Member], USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top">
          <div class="a">Contract Termination [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Accrual Beginning Balance</a></td>
        <td class="nump"><a title="us-gaap_RestructuringReserve[us-gaap_RestructuringCostAndReserveAxis=us-gaap_ContractTerminationMember]" onclick="toggleNextSibling(this);">$ 9,445</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RestructuringReserve<br>/ us-gaap_RestructuringCostAndReserveAxis<br>= us-gaap_ContractTerminationMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_RestructuringReserve[us-gaap_RestructuringCostAndReserveAxis=us-gaap_ContractTerminationMember]" onclick="toggleNextSibling(this);">$ 10,074</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RestructuringReserve<br>/ us-gaap_RestructuringCostAndReserveAxis<br>= us-gaap_ContractTerminationMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Principal payments</a></td>
        <td class="num"><a title="us-gaap_PaymentsForRestructuring[us-gaap_RestructuringCostAndReserveAxis=us-gaap_ContractTerminationMember]" onclick="toggleNextSibling(this);">(1,439)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsForRestructuring<br>/ us-gaap_RestructuringCostAndReserveAxis<br>= us-gaap_ContractTerminationMember</span><span></span></td>
        <td class="num"><a title="us-gaap_PaymentsForRestructuring[us-gaap_RestructuringCostAndReserveAxis=us-gaap_ContractTerminationMember]" onclick="toggleNextSibling(this);">(629)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsForRestructuring<br>/ us-gaap_RestructuringCostAndReserveAxis<br>= us-gaap_ContractTerminationMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Accrual Ending Balance</a></td>
        <td class="nump"><a title="us-gaap_RestructuringReserve[us-gaap_RestructuringCostAndReserveAxis=us-gaap_ContractTerminationMember]" onclick="toggleNextSibling(this);">$ 8,006</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RestructuringReserve<br>/ us-gaap_RestructuringCostAndReserveAxis<br>= us-gaap_ContractTerminationMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_RestructuringReserve[us-gaap_RestructuringCostAndReserveAxis=us-gaap_ContractTerminationMember]" onclick="toggleNextSibling(this);">$ 9,445</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RestructuringReserve<br>/ us-gaap_RestructuringCostAndReserveAxis<br>= us-gaap_ContractTerminationMember</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 420<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 5.P.4(b))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 5<br><br> -Section P<br><br> -Subsection 3, 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>40
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0`!@`(````(0#9PY]K0P(``*TE```3``@"6T-O;G1E;G1?5'EP97-=
M+GAM;""B!`(HH``"````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````````````#,VLUNVD`4!>!]I;Z#Y6V%
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M.9+2K59-294K'[MT`D7H/9DJU$2Q:XOQO>A,8U]RG]@_WAS8^,:O'&3X?>/@
M"W,(D!P2)(<"R:%!<LQ`<KP'R7$#DN,#2`X^10F"(BI'(96CF,I14.4HJG(4
M5CF*JQP%5HXBJT"15:#(*E!D%2BR"A19!8JL`D56@2*K0)%5H,@J4625*+)*
M%%DEBJP215:)(JM$D56BR"I19)4HLBH4616*K`I%5H4BJT*15:'(JE!D52BR
M*A19%8JL&D56C2*K1I%5H\BJ4635*+)J%%DUBJP:15:-(NL,1=89BJRS_R5K
M3&448N/KOY_%..9,&R+$74OARO]@[H>>VUP;3]7WZ%-MY^H!_IQ])D=IVO*N
M3OV5*Q_"8>ZI_:E4<^]='U*]R-/E`5[Z0\/3DSX-(A\;.C2(CC5Q#AM3->GR
MA:^J0#24GRJJCNQF8]EJ^1L``/__`P!02P,$%``&``@````A`+55,"/U````
M3`(```L`"`)?<F5L<R\N<F5L<R"B!`(HH``"````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````````````````````````````````",
MDL].PS`,QN](O$/D^^IN2`BAI;M,2+LA5![`).X?M8VC)$#W]H0#@DICV]'V
MY\\_6][NYFE4'QQB+T[#NBA!L3-B>]=J>*V?5@^@8B)G:13'&HX<85?=WFQ?
M>*24FV+7^ZBRBXL:NI3\(V(T'4\4"_'L<J61,%'*86C1DQFH9=R4Y3V&OQY0
M+3S5P6H(!WL'JC[Z//FRMS1-;W@OYGUBETZ,0)X3.\MVY4-F"ZG/VZB:0LM)
M@Q7SG-,1R?LB8P.>)MI<3_3_MCAQ(DN)T$C@\SS?BG-`Z^N!+I]HJ?B]SCSB
MIX3A363X8<'%#U1?````__\#`%!+`P04``8`"````"$`O=(5+(\"``!&)0``
M&@`(`7AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS(*($`2B@``$`````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````O)I-:]M`&(3OA?X'L?=:?O<K28F<
M0TLAUS;]`8N\MDQLR6BW'_[W7=Q6<:"9YB#F8I"$5X-W9IY71K=W/P_[ZGL<
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MQ(`GQTRG_F+A!IE7V%@0:&/-QH*&6#!L)QMH9<-.N8$QMVPL6(@%R\:"A5AP
MLV)A2O7+07<&!=V5>9C+\&LDQ\_:RFW8MQ^ZL.N??IWI%%+!=@PTC&=7L8=5
M+&Q0"085FPP"R:#99-"0#)I-!@W)8-AD,)`,AIUS`X-NV62PD`R6308+R>!F
M)<-KN`GG=3]K[Z1\VI<_HJ;'N]_'"%'LS<%[PT:4@XABYPC&2-A$$$@$81-!
M(!$TNX(UK&!#MP[TCF&GW,"86W8%6UC!CCV).CB):O9PH^%P8]F=;&$GNUEY
M^1I\PSG=LUO9XU8F/X3#K6*G'(9<V(`0"`C-!H2&@-!L0&@(",.VCH'>L6Q`
M6`@(QQZ]'!R]A,TK@;PR;%X96(*6S2L+>>78O'*05Y[M'0^]XV>%1.K"&-=?
M\EC>&;E\)K\\C1[-Z<Y!8M@5"!M0V/042$]ATU,P/=E[9:;-JI^]_;3Z!0``
M__\#`%!+`P04``8`"````"$`9;=4;=P$```$$P``#P```'AL+W=O<FMB;V]K
M+GAM;)287W/B-A3%WSO3[\#XO0OX'Y`)V4E2,LU,NDM+NONH$;8`36R)M>4E
M]-/WVB3FV'(\Y8E<B`[W'OWNE<SUY]<T&?P462ZUFCOC3R-G(%2D8ZFV<^>?
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MJ!,9<[*(W?&$JTBP5;DT!XG0`PWW`@VVY""#*I79'V:R,I10N=\YTQOV=2]`
MQ8=<_-Y<FBHK@ZZ$*!-<('//&\Y`,A456-+7;,N5_+="M=JF+]P4F;!+"@F#
M>H\F[61619KR[%@N6\FMDM0/7!EV&T6Z4`:<"4.0F;9EEAEU:$:45,#\*.2^
M-!B73V#YK+V<[(M>=CJ)J<_8@I:;(ZZEH5%7,!YU+E[SG""[URD-BKPR!05F
M*&!Q^D@3*A7LF;_2-#JS/:$..W^M1>:3H*]DBU=IV)/D:YDTDYXT6J.#R"3A
M:YV=]^^))I$BQ=MMAD1.7,RB@\DTE>9$<^D]]9RA84M#5S:+P?X86TS2_L5%
M9-B?-.QR0Z.9FNM8JZ(IB/;8HG*1[A-]%(+="24V9,V2NAZ7(XQCB\:_"IX9
MD25']B`5C0O)D^ZY,T$:QQ:.JV*=BQ\%(<@6/YL@3A#$L4UB;S_0GE8]6(Z^
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M+7^J?+IT*H=`Q\=12,%%.MBO/D)-P45"..-]A)J"EE!CJ)XM?CO[L#)DVK>8
M;NB4ER$ZR=_NN68G0&>*3OL6T@V=OT6DZ2A.Y.FNHC>@XR/1%/359>DTG,:!
MYEM(=QX<M5&8$"+M6TAWZMSO.-V8<B91!Y'V+:0[=1Z*Z@:^S$!GUD#10OI>
M]UT#T:``A2AH.=TOA"C.D.G`8KI?",^@`)FFX**,\`R:-80LJ/LSPC-HAMT1
M6%3W"^$9%"#6%%Q4&IY!`6)-@274=Y5I;#]R'5A<]]^)&MN/AUE@@=W_(-#(
M"$=(8)'=^210'Q_0(2&"34'+HOY;&E86(M@4M(3:SP1U+M4S!B:$.(85U\/J
MZ*4?22*>1/3K3?E2_?SA!^'IQCY\_P'KYC\```#__P,`4$L#!!0`!@`(````
M(0"!%OBY.00``/(-```8````>&PO=V]R:W-H965T<R]S:&5E=#0N>&ULE%==
MCZ,V%'VOU/^`>$_`?!B(DJP6T+0KM5)5==MG0IP$#>`(D\G,O^^U+P'L[,QF
M7F:"[_'AW`_[7M9?7IO:>F&=J'B[L<G2M2W6EGQ?M<>-_?V?IT5L6Z(OVGU1
M\Y9M[#<F["_;7W]97WGW+$Z,]18PM&)CG_K^O'(<49Y84X@E/[,6+`?>-44/
MC]W1$>>.%7NUJ:D=SW6ITQ15:R/#JGN$@Q\.5<ER7EX:UO9(TK&ZZ$&_.%5G
M<6-KRD?HFJ)[OIP7)6_.0+&KZJI_4Z2VU92K;\>6=\6N!K]?25"4-V[U<$??
M5&7'!3_T2Z!S4.B]SXF3.,"T7>\K\$"&W>K886-_):N<A+:S7:L`_5NQJYC]
MML2)7W_KJOT?5<L@VI`GF8$=Y\\2^FTOEV"S<[?[267@K\[:LT-QJ?N_^?5W
M5AU//:0[!(^D8ZO]6\Y$"1$%FJ6G9)2\!@'PUVHJ61H0D>)5_;]6^_ZTL7VZ
M#"/7)P"W=DST3Y6DM*WR(GK>_(<@(D6-)-Y`$H#ZP>XMO3@D(?TYBX.*E(-Y
MT1?;=<>O%E0-O%.<"UF#9`7,-\]0Q^CK>ZZ"/$GR5;(H+O!"0'Y>MC18.R\0
MTG*`I`B!$S%"B([(;@CIM&3-9PL.R!TU0R1,S3[D],?9N$F4FPR)H2X@O8=X
M.B*[1_BN#LGO(92.$,T-7W?C8_D2#&4S"Q^-1EH5KA0A@2H:&;_,7,AG"YH2
M2/P\H!\KD>"-#6Z.B:2QH00AD2J$(/+,6LCF]I!&H:_OSS5[0H-W`@AGYW'9
M$FS(3O37I@@)E.S0-T1E:*7*2KS8*(U\;@Y(/)6%%FGZ&<D2K$N.)EK,.4)0
M5!!%B5$3V=P>QJYOE'P^MU,_]MZ)=/09V1*LEVID'/44(;-2-1?RV8(60-E2
M9_?5QZ4JP48`C;2E",$`1BZ)IP"H`&=S>T##N[1K]C"858TF._F,;`DV9!O%
MF")D*,8PF>4-96MVXL9&7>2:'=R>3K`FF\"U^GBX%=H0?M<&)./&1N4Q)<1(
M2#:0("",*#5.::X#H/E-Q:5KE^WCX5(AV&SFUUID')9TP*"TA1_[Q$!D`P*O
M$']V\:NLY!I![+G3=EVY["&/*\>.HRDWJC@EB$%==Q&?&Q?4,VM%VTS"R:R+
MELWE<='8BC31$S'>;00QV$94N(U3D.D(CTZ5,,1[SA#[=/)<ER[[S4RZ'()^
M/E`0[%*:"],Q&EQ`3**:QH(LC=.0#1R#W5VZ!B`?`!B#Z?+7Y<O6\WGYV+`T
M^<912^6,.QY6+_+C($DF$<K%3,/0.(BHV83D:#[1P&7D>]%4H.@*CMXXF3:L
M.[*,U;6P2GZ18S6!^(VK./*G<N170_MH@(G[7!S9GT5WK%IAU>P`6]UE!&_O
M<&;'AYZ?U2"XXSW,VNKG";ZM&(Q,[A+`!\[[VX/\*AB_UK;_`P``__\#`%!+
M`P04``8`"````"$`3[<[H10#``#@"```&0```'AL+W=O<FMS:&5E=',O<VAE
M970T-BYX;6R<5MMNHS`0?5]I_P'Q7NZ0BY)4#:B[E7:EU6HOSPZ88!4PLIVF
M_?L=VX%@TDVKOB3@.3Z<,S-F6-T^-[7UA!DGM%W;ON/9%FYS6I!VO[9__[J_
MF=L6%Z@M4$U;O+9?,+=O-Y\_K8Z4/?(*8V$!0\O7=B5$MW1=GE>X0=RA'6XA
M4E+6(`&W;._RCF%4J$U-[0:>E[@-(JVM&9;L/1RT+$F.,YH?&MP*3<)PC03H
MYQ7I>,_6Y.^A:Q![/'0W.6TZH-B1FH@716I;3;Y\V+>4H5T-OI_]".4]M[JY
MH&](SBBGI7"`SM5"+STOW(4+3)M50<"!3+O%<+FV[_QE-K?=S4KEYP_!1SZZ
MMGA%CU\8*;Z1%D.RH4RR`#M*'R7TH9!+L-F]V'VO"O"#604NT:$6/^GQ*R;[
M2D"U8S`D?2V+EPSS'!(*-$X02Z:<UB``?JV&R,Z`A*!G]7\DA:C6=I@X\<P+
M?8!;.\S%/9&4MI4?N*#-7PWR3U2:)#B11*#^%`^<8![[<?(VBZL5*8,9$FBS
M8O1H0=/`,WF'9`OZ2V#NG6D=@]?_606/DN1.LB@N<,&A/$^;6>*OW"?(:7["
M;#4&3L2`F2#2'B$3*&FST8(+>@?1D(JIZ!"*^GHY>HURDZDQ6$PDO@(Q$>DE
M(O1,2'8)29(!8M@(31O7Y4LP],TH?6$\U:\QD6H;F<!TNI"-%@PI4/IQ1J]+
MD>"U#3Z'2D9^-%A4I=MJS$SU@C_SYF8X-<+Q(C##F1D.S^2&:#@[8]&R=]]N
M`[EI*CXV'[_5F$B)#Z*)N'0<]?US;77/CJ/QV;8A//F(<+EI*GSR\*W&:.&+
MF>DJ[8/#\1HM&/)F'Y$G-TWE311L-4;+FQR;]$HL>SUF:):3=O0>N][`$CS5
M>BZ5;F"-T0T<>-'$2CH.7_8W#"/YA%/[C_M;B]:31K^(&\SV.,5US:V<'N04
M\:'QAE4]X+8PX-0X<(<`#)@.[?%WQ/:DY5:-2]CJ.3-H0*9'E+X1M%.OO1T5
M,%K4905?$AC>#YX#X))2T=_((3A\FVS^`0``__\#`%!+`P04``8`"````"$`
MO;KAF#X$``"6#P``&0```'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6R<5UV/
MXC84?:_4_Q#E?4D<(`$$K"8D:5?:2E75;9]#,!!-$J,X##/_OM<VR=C7LPR4
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M]M_A1W;YK2UWW\N&0K0A3R(#6\:>!?7;3D`PV;-F9S(#?[;.CN[S<]7]Q2Z_
MT_)P["#=4_!(.+;8O264%Q!1,#,*I(R"52``OIVZ%*4!$<E?Y>^EW'7'E3L.
M1]/('Q.@.UO*NZP4)EVG./..U?\J$A&B!B/!U<@$U%_'@U$PFY)I^(`5>)^4
M`K^]E>EH$DRCV2-:PJL5^.VMD'L=\E1P9*R3O,O7RY9='"A@<)^?<K$<R`(,
M]T%6(1G"_K.H0Z2$D2=A9>7"RH.`<BB5EW44!DOO!=);7#FQS2$F8],S1`*$
MV00#J0+@>WA/&,Q-*UG/$;4%3@Z>0BIU3S\NH]XA018.]5)B!>AO1OYM;,;8
M-Z4E-B4,34IJ4Z)P;'*RCSB3@6,X/3:=%ND=PTJ\[;R8!#PMRE$X'>S+U,2*
M,QD"M,%`@H$4`YD&&*)AL=V?*4%>N1"2H20B'-18<2:R,`.?S$Q?-OUPG^P$
M`RD&,@TPI,,*UZ7?%V\Q";L0F1ICQ='BC8$$`RD&,@5$,@Q37WZ&MQA>P$:@
M>W&[6@09JT<1CA5')0`MBLV-L>3&6-J/]5G+-,#P)GK$&T%&WO@X%XJCY0(#
M"092#&0:8(@5IQ>T'W^^8,6DSQ:LXFBB,9!@(,5`I@&&Z/G_$2TFH4B':"^/
M%4<3C8$$`RD&,@6$LNIGMZJ>P,:HQ_YVV4NVJ3^<H]J.KR3-`0M)+"2UD$Q'
MC,@3T>T>KA<YZ[."N9)T[:JUOB.)Q4DM)-,14[OH8X]K5]W/W/!QW1!%>E>Z
ML9#$0E(+R:Z(VC()7`#$Y^,]DXAN]K@WJ@?JWH2X/\72],K5O=%:Y_6HA)'4
MFI7IB)D)T<X>UZZ:(+Q8:[WXG$"T3BF5;BPDL9#40C(=,;6+KO:X=M4+];A'
MT7MFU1E'W#9@B]+CCI'$XJ171&TX))B$H3]&]2GN38-EY8VZ!JFC>4W;`]W0
MJN).P<[BBA/`[C6@P_7K*1#'+X3'9`'G9L"]80!N1:?\0/_(VT/9<*>B>S#I
MCR(0T:I[E7KHV$E>"+:L@_N0_'N$^R^%H[@_`O*>L:Y_$"\8;M3K_P```/__
M`P!02P,$%``&``@````A`'L!LOS0`@``:P<``!D```!X;"]W;W)K<VAE971S
M+W-H965T-#@N>&ULE%5=;YLP%'V?M/]@^;U\!YHHI&I2=9NT2=.TCV?'&+`*
M&-E.T_[[7=L)`M*M[4N"[7./S[GW<EG?/+4->F12<='E./0"C%A'1<&[*L>_
M?MY?76.D-.D*THB.Y?B9*7RS^?AA?13R0=6,:00,G<IQK76_\GU%:]82Y8F>
M=7!2"MD2#4M9^:J7C!0VJ&W\*`A2OR6\PXYA)=_"(<J24W8GZ*%EG78DDC5$
M@WY5\UZ=V5KZ%KJ6R(=#?T5%VP/%GC=</UM2C%JZ^E)U0I)]`[Z?PH30,[==
M7-"WG$JA1*D]H/.=T$O/2W_I`]-F77!P8-*.)"MS?!NN=AGV-VN;G]^<'=7H
M&:E:'#])7GSE'8-D0YE,`?9"/!CHE\)L0;!_$7UO"_!=HH*5Y-#H'^+XF?&J
MUE#M!1@ROE;%\QU3%!(*-%ZT,$Q4-"``?E'+36=`0LB3_3_R0M<YCE-OD05Q
M"'"T9TK?<T.)$3TH+=H_#A2>J!Q)="*)0?WI//*BZT6X2%]G\9TB:_".:+)9
M2W%$T#1PI^J):<%P!<QG9T['X/5?5L&C(;DU+)8+7"@HS^,FR\*U_P@YI2?,
MUF'@C1@P,\3NC#"E`'F#1G`^UQA##5_._EF2"9I*BI8S12]`IHC=)2(.!LA$
M(^1NK/'_V@PXQT`^I"++HH'7IG3K,(EM`9/CW6AC<G,RO=E4\/7LF"#`C16D
MBYD"AQDI&&U,%$`/O]V[`<^]Q[.;'2:SC;1,DIFPW?@X#((L&<(GLM+WR#+@
MJ:PDGO7GUF%2*^LJ3.)9/^W<>>+.TU&[361E[Y%EP%-9V<BNZQ2'<=FZAN_"
MD`U[#'/14+R03*?*#3TW$UHF*[9C3:,0%0<ST$(P,^RZ6;N%66LGDS\<P*SK
M2<6^$5GQ3J&&E1`:>!D42KIIZ19:]/:5W`L-4\X^UO!18]#>@0?@4@A]7I@A
M,'PF-W\!``#__P,`4$L#!!0`!@`(````(0#$B`,B/@,``"`*```9````>&PO
M=V]R:W-H965T<R]S:&5E=#0Y+GAM;)166V^;,!1^G[3_@'@OQ$"X1"%5LZI;
MI4V:IEV>'3#!*F!D.TW[[W=L$P*D29N7$#B?O^_<?.SE[4M=6<^$"\J:U$;.
MS+9(D[&<-MO4_O/[X2:V+2%QD^.*-22U7XFP;U>?/RWWC#^)DA!I`4,C4KN4
MLEVXKLA*4F/AL)8T8"D8K[&$5[YU1<L)SO6BNG*]V2QT:TP;VS`L^$<X6%'0
MC-RS;%>31AH23BHLP7]1TE8<V.KL(W0UYD^[]B9C=0L4&UI1^:I);:O.%H_;
MAG&\J2#N%Q3@[,"M7T[H:YIQ)E@A':!SC:.G,2=NX@+3:IE3B$"EW>*D2.T[
MM%BCN>VNECI!?RG9B\%_2Y1L_Y73_#MM"&0;ZJ0JL&'L24$?<_4)%KLGJQ]T
M!7YR*R<%WE7R%]M_(W1;2BCW'")2@2WRUWLB,L@HT#B>=B-C%3@`OU9-56M`
M1O"+?NYI+LO4]D-G'LU\!'!K0X1\H(K2MK*=D*S^9T!(.=63>!T)/#L2Y#E>
M/$?S\'T6UWBD`[S'$J^6G.TMZ!K0%"U6/8@6P*PB"\Y&!MZH-7=JD5X*:`'E
M>%Y%T7SI/D,*LPZS-AC8`3W&ZQ$NB/<>@.K4`Q\J]'9N#QZH16,/O*2GUTZN
M#236A1WJ^6.]RSH*#-4:1!%%X43(8((3H>`:(05.;4\GTYNA:3:-.=)F/PF.
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MM^0+J2IA96RG#F$$,ZO_:BX(:[@@>'I`]P8XGUN\)3\PW])&6!4I8.G,B<`]
M;DYX\R)9JP^:#9-P,NN_)=S$")R#,P?`!6/R\*+N$/W=;O4?``#__P,`4$L#
M!!0`!@`(````(0#^Y=%-:P8``!<<```9````>&PO=V]R:W-H965T<R]S:&5E
M=#4P+GAM;)Q9VX[B1A!]CY1_0'Y?C&VP#1IF-<:]R4J)%$6Y/'N,`6LQ1K9G
M9_?O4^UJ<%4URR4OPW`X59RNKN[3II\^?JOVHZ]%TY;U8>EXXXDS*@YYO2X/
MVZ7S]U^?/L3.J.VRPSK;UX=BZ7PO6N?C\\\_/;W7S9=V5Q3="#(<VJ6SZ[KC
MPG7;?%=463NNC\4!/MG4395U\+;9NNVQ*;)U'U3M77\R"=TJ*P\.9E@T]^2H
M-YLR+](Z?ZN*0X=)FF*?=:"_W97']I2MRN])5V7-E[?CA[RNCI#BM=R7W?<^
MJ3.J\L7G[:%NLM<]C/N;-\WR4^[^C96^*O.F;NM--X9T+@JUQSQWYRYD>GY:
MES`"7?914VR6SHNW4,'4<9^?^@+]4Q;O+?E_U.[J]U^:<OU;>2B@VC!/>@9>
MZ_J+IGY>:PB"72OZ4S\#?S2C=;')WO;=G_7[KT6YW74PW3,8D1[88OT]+=H<
M*@IIQOY,9\KK/0B`OZ.JU*T!%<F^]:_OY;K;+9T@',^B2>`!??1:M-VG4J=T
M1OE;V]75OTCR3"I,XILD\&J2>+/QU)]%\2-9`I-E.F3QQWX\\V;A`UI`=3\@
M>'U<BXO5Z8N=9EWV_-34[R/H8!A_>\ST>O`6D/E49:S)N>X_*CO46R=YT5F6
M#BP]J&@+O?+U.8KB)_<KS&]N.`ERX.^9$P83SEG9>3S.2$\,/>'ZJ]7UM"X,
M\SQ6F$4ZULN==!J2)NLAG;XH08#K#[BZE<WQ.2.U&;(("BE1U-=QZD7SH4IL
M.-!6=#AZZ@)89M>'I8.`1V8ABN9<8X*<?FWW-5Y)()6`(@#3""W_N$8=M'2@
M#.=.B>*A!KVD!#E$(P)8M"B,O'`R$3$II<1!Z`<619&T;!RP-!X?APZ2XQ#]
MG"`G[.?:BT&05+U"QC#25`**`$QTR$5?;PQ-EF)%\R;(&:2L$##JI_Y4#X`W
M4THI_L0/(XNB2%JF/WI$OR9+_6)Y)L@A^A$P^L-I!!XO]5-*Y`5V6RF2E<G7
M)Q&RM5XOOR9+^5->R@0Y1+X$4@DH`C!M<Z[MOKU#!]W:.Y!#-$H@E8`B`-/H
MP69V?P%[MJS@3%30D(@\@T2QV6WGD:AZ:L4HBG#%VHS(E-]75@\M[/I^9TA4
M.89A\T8SZ%R[>:TH11&N7=O.X]K1K+AVN<=Y2*+:$3$+;PX[<13QJ4JM($41
M+EV[#Y%^?:5YZ%5<<LB_/3$D*AG#T&`"89FIQ5<4X6JUQQ"U=S8).A-7+6J6
M>,2^T+D-@H4V/2)W."M*481KUU8CM$\!NU%Q-"BNW3H>$A<SVA$QVG_4X3),
MZ8<$V*;ZJ>/BM<\0\3=$HRMQT6+:$X]8EQ%]0O0AV*KTZ</3H5+1!%RL=I7[
MQ:('4;%3L8\E'O$IH_6$7-1Z^G#02A"N5;O,_5K1DZC6V5PZM4>,RXB52&IQ
M%$6X0NTQ1.&=:PZ="1;^<!"U#LL>L2^C5"*IQ5$484K]ATRO9]\R/4,B>YE!
MSJ87A;)3K1A%$:Y8F-[U9>5?,CNYK`R)*J9FI\_MMM=908HB7#(T'VV'&Y(U
MFQ?96EP^<JAB1(P]>Q<5RR!%TW#%#UF<?\'BR%-DWZ:)(5')&#8@J<51!C'.
M+4\=7//_,CK_@M'-Y8G"D`:E*X,87?@@936UM$=%\W#MVD0>WC#TKSFB4Z*Y
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M/^2`P04'C.4QPY"H8@R[MM:L($41+ED8X/6U!I<I5I&M?=B0J&0,P^?2R]N#
M%:0O;O1W]6E0,M[#X-5`533;8E7L]^THK]_T'8L/OXZ<T?/]SXNO?QT7^,I;
MP(_T@+OG#^!:YIAMB]^S9EL>VM&^V$#*R3@"VVOP8@??=/6QOY!XK3NXD.G_
MW<$%7`$_\T_&0-[4=7=ZH[_@?*7W_!\```#__P,`4$L#!!0`!@`(````(0!J
MN/38$P4``!84```9````>&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;)Q8VX[B
M1A!]CY1_L/R^^,+%!@&KP:U)5DJD*,KEV6,:L`:[D>T99O\^5:[&5+=GP>1E
M&(I3Q>DZW:=P+[]^%$?G759UKLJ5&XQ\UY%EIK9YN5^Y?__U_"5VG;I)RVUZ
M5*5<N=]E[7Y=__S3\JRJU_H@9>-`A;)>N8>F.2T\K\X.LDCKD3K)$C[9J:I(
M&WA;[;WZ5,ETVR851R_T_9E7I'GI4H5%-:2&VNWR3`J5O16R;*A()8]I`_SK
M0WZJ+]6*;$BY(JU>WTY?,E6<H,1+?LR;[VU1URFRQ;=]J:KTY0CK_@@F:7:I
MW;[IE2_RK%*UVC4C*.<1T?Z:Y][<@TKKY3:'%6#;G4KN5NY3L!#AS/76R[9!
M_^3R7+/_G?J@SK]4^?:WO)30;=`)%7A1ZA6AW[88@F2OE_W<*O!'Y6SE+GT[
M-G^J\Z\RWQ\:D'L**\*%+;;?A:PSZ"B4&853K)2I(Q"`OTZ1X]:`CJ0?[>LY
MWS:'E3N>C::1/PX`[KS(NGG.L:3K9&]UHXI_"13H4E0DU$7@51<)IJ-).(WB
M1ZJ,=97)M4HX"N-I,)W=Y^+1NMHVB;1)U\M*G1W8>\"\/J6XDX,%5+[TAU;3
M=>Q'#8-.89$GK+)RX=!`+VI0^7T=S:.E]P[*9!JS(0S\[3"SL6]BDGZ=P$2(
M"P)%AR5TZX#>\G5\KN^%+H*1+NJ-_#<4X-RB>6Q^<W))NO(/383H(]@"#;:@
MY7"V"#;84L!D.S>Y)':28`&#"HC.J>`&&,,QN]U`3`(<TS**+`8;PDRZ)B=V
M0+"`00E.%J=TFPJ"5RZTOMM6L6]MJPUA&!4*1.U.#2;A!%*L',$AH1_.(@XQ
MZ,X>H8M@D^YT/C&UVQ"&T;4#@@4,*I%)99B8F'1/3,(P2G9`L(!!"2<I,YC;
M8B+8[$X43ZWN$(91H4`4MVI.@C"R,@3+,*C-'Z&&8)-:[%OFM"',A(B8M)/+
M9Q?/$2Q@L`K@]`WO6(NV>5G&M-$@UC,=F9%73V%O]PX`3S()H@</EC0@Q^8'
M-.KM>`WB!"D-+(*=Z['94\'33(IHQ<,IDG$;%&/;S@("<8H4H1Y./^\AAZ#)
M\#:;C-&?AS,F-^>,8]^VD8!`G/$E@A/:-KP.;GYHLD3+'LZ2#-YD:7WM)F!3
MH!W&21<QB;0?"OTA-7T\N]51='#&=9@9XH_#WCFW#&6C0;RSE':-"(XQ>XCF
M_3@OLGP0L#L/_9$;L+F@>VE'!,>8O-#!&:_;3AV0WYO:SLSSN=&@:U<2'2'Y
MPDDK7]]Y?C1+`G1R1G&@I.3_)M7>KU,V)'3K[(AHOW[EMLLQ6X=>_C@OF@!W
M)&5C0O.R(R)@$8-7^-`H:='V*+$EU2`FJ8YH2<D&>Y+R-).B-4Q0T@D<IMN[
M+^P/E=BW?K!O-(A3O0R5;@ASC,D+MLOCDH:8=>^WE`9Q7I1VC0B.,7FAA;.M
M=J=/9/CFUK<G6TB@Z[<G.J(E_?R0\BR3H34C!BKZR:P([%D1]F9%+R)XQ.3U
MO^8!/EK?5]1V_T2G77LJ>,3D9<V#.XJ2H=]1U';]!.Y8<!GTQ!/J0VJZ-=[#
M(*;E3`SI6H7N"PI9[64BC\?:R=0;7IG@[]PNVEWG/(WQB<^*)W#-T]Z)V/%P
M`4^J?;P(%_#`"G&O2X!;F5.ZE[^GU3XO:^<H=T#!'T70^HKN=>A-HT[MK<:+
M:N`^IOWW`/=O$A[S_1&`=THUES?X!=V-WOH_````__\#`%!+`P04``8`"```
M`"$`@8+V@W4$``"&#P``&0```'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6R<
M5]MNXS80?2_0?Q#T;DO4S;)A>[&6D':!%BB*[O99EFE;B"0:DA(G?]\9#261
M=#9Q^I+8G,/C,Q?.D.LO+U5I/?.F+42]L=G<M2U>Y^)0U*>-_?V?AUEL6VV7
MU8>L%#7?V*^\M;]L?_UE?17-8WOFO+.`H6XW]KGK+BO':?,SK[)V+BZ\!LM1
M-%76P=?FY+27AF>'?E-5.I[K1DZ5%;5-#*OF'@YQ/!8Y3T7^5/&Z(Y*&EUD'
M^MMS<6D'MBJ_AZ[*FL>GRRP7U04H]D59=*\]J6U5^>K;J19-MB_![Q<69/G`
MW7^YH:^*O!&M.'9SH'-(Z*W/2V?I`--V?2C``PR[U?#CQO[*5BF+;6>[[@/T
MH^#75OELM6=Q_:TI#G\4-8=H0YXP`WLA'A'Z[8!+L-FYV?W09^"OQCKP8_94
M=G^+Z^^\.)T[2'<('J%CJ\-KRML<(@HT<R]$IER4(`#^6E6!I0$1R5[Z_]?B
MT)TWMA_-PX7K,X!;>]YV#P52VE;^U':B^I=`3%(1B2=)`E`O[=[<BT,61A^S
M.*2H=S#-NFR[;L35@JJ!WVPO&=8@6P'SX!GI&'W]F:O@(Y)\19:>"[QH(3_/
MVT48KYUGB&DN,3O"P)$8,4Q')`,"`XBTJ;+@@-Y1-(3"%.U#4M].QZ`1-^D:
MO:4N8/<&1$<DMPC?U2'I+22*1HCFAO]_W,!-4#]*&!>AZ0=A@KY\,)")N9`J
M"YHD*('/1Q8W;6SP>\RL'T\N]ZG<$6;1U\:,^0$SPI9H@*51&JEJ]9;>XNV`
MPF%2U;]?#P@V59N!)$PD54>N4=,)V8/>'KG&[E3=S8)H\E@+>?09T0@V1)NQ
MVA%&R?ZP@.=R%H?A&#PZ99HY9-YHUF0N=)G8*#X^<[C)E!N,_%09A*$8^ZYO
MF!,R4XAG?F"8T\&,[5MM$3AZE;[V?BD@V)1I%C!A9"EXGF>6`MFE3L\SMJ>#
MV=2Y_(Q.!)LZC:+;$6:(U\(P)X-Y[+'*@A9`!@WU_@CV:$-:-)U2RK0$26W,
M-[7I]CCP]4I)I5WF((B74Y!UZ3@W[DX^HRFCMJ_`G9BE=`(-88VG0]+;$TE"
M]AO=ZN:I;G3-.#;NUTQ#1M<\,4O-!")-B]!P*6&JV0O,CJN;E3K29>,@463?
MUQ88C1]=OE$-.PE2^MBX@HW,8\:&5#//PBD+NF(<)8KB]SL#H\&C*65&J'82
M1'7)@J4W=7I9'<0B`5YL'(Q4$LA,*69=.<Z3^Y73]-&5&V6[PTLL=!3ZX1O5
M[QC3G^S4!>-DN5\PS2%5\$*9F;*FAV$U]*^$F2NINJ+KP6&AZ+FS6&G$0,F.
MUYO;&Q=3YI#,N;F2JAA=%PX'1=<')4FC1(V3OS3.P@Y>0YA8>=\*(V-L)M(^
M'2Y\/U$IC!.*GD/T6JAX<^()+\O6RL43/G487'K&57J&[?`9UC^D1@.\@B[9
MB?^9-:>B;JV2'V&K.U]`:37TCJ(OG;CT=_.]Z.#]TW\\PWN7P^75G0/X*$0W
M?$&!XPMZ^Q\```#__P,`4$L#!!0`!@`(````(0!AAAN?'00```$.```9````
M>&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;)1746^C.!!^/^G^`^(]`6/`$"59
M;:AZM]*M=#K=[3X3XB2H@"-,F_;?W]A#`3O9-GEI@^>;S]_,V,.P_/):5\X+
M;V4IFI5+YK[K\*80N[(YK-S__GV<):XCN[S9Y95H^,I]X]+]LO[]M^59M$_R
MR'GG`$,C5^ZQZTX+SY/%D=>YG(L3;\"R%VV==_#8'CQY:GF^TTYUY06^'WMU
M7C8N,BS:6SC$?E\6_$$4SS5O.B1I>95WH%\>RY-\9ZN+6^CJO'UZ/LT*49^`
M8EM69?>F25VG+A;?#HUH\VT%<;^2,"_>N?7#!7U=%JV08M_-@<Y#H9<QIU[J
M`=-ZN2LA`I5VI^7[E?N5+#*2N-YZJ1/TH^1G.?GMR*,X_]&6N[_*AD.VH4ZJ
M`ELAGA3TVTXM@;-WX?VH*_!WZ^SX/G^NNG_$^4]>'HX=E#N"B%1@B]W;`Y<%
M9!1HYD&DF`I1@0#XZ]2E.AJ0D?Q5_S^7N^ZX<FD\CYA/"<"=+9?=8ZDH7:=X
MEIVH?R*(]%1($O0D%-3W]F`>)!&)XL]9/%2D`WS(NWR];,79@5,#>\I3KLX@
M60"SBBS\9600DO+YJIRT*Z`EE.-ES2*V]%X@A46/V2`&;L"`"4Q$=HF@_@#Q
M0-\@$D*W15(HXO7TOXM43J;((!WH=1P;A.B#HQ>RR8(A`#(S%?#QQ@H,%9Y$
M3F-J[8R84!=8I32;+!@[A^;.JCZ?AZZ<5BX$,^2>QJ&E`#%,5R^*:)28]FQJ
MIW$4D\%NZ(.S<GMF%-C6%0V\6!/$Q%H798&5N,PP4Q(/WH:J^!Y5"FRK&GE1
M%6)0%2/,.NS9U$Q9,GH;JM@]JA385F5MNT$,JB)ID%CVS+0GR9A,0Y=Z34UZ
MP,>G6X%-7838]PHQJ"OT8\N<3<T1H6-?,%2E]ZA28%-5:!]XA/0'*TUL45-S
M$I`QE88H`FWG]EQIM"F+QM9%V_2@OHJ4CCMC3S+M(1W]3656)_^XB@2;K]DB
MK)1L>E"H[V(:CW7JA2%'+SRDH[LI3#75FX\7P19L"&/C:P%O8P_"G=,H]2^D
M(0L"6,K8"#"UJ;9[NS9LTJ:VL2_VVA"$6\_2,$@O"FH@6$HG[<149S7_3TIZ
MI>LS^Q(0!/4UBWVK^V:]'4M.T]%L"KNKZZM)"2XG1#V^CMC(W*<-09,W8N^F
M5\S=[^KNY$I[9V.#[G>?-O`9N9(7!&!>9K].S%TMGESI\6R\1;VT:1._*@T!
MGTJSNOQMDP1,U79CI<G%=400SA*64<WEBL$V8D5QXL:!M.;M@6>\JJ13B&<U
M30?0>(95G/0W9`%3&TS8UGH&7P!ZW1L,,("?\@/_GK>'LI%.Q?=`Z<\9'+06
M1WA\Z,1)CXE;T<'HK7\>X5.+PU3FSP&\%Z)[?U`?"</'V_I_````__\#`%!+
M`P04``8`"````"$`#I=A[`<&``"R&@``&0```'AL+W=O<FMS:&5E=',O<VAE
M970T,RYX;6R<F=MNHT@0AN]7VG=`W(\Q8(P3Q1D%6MD=:4=:K?9P37#;1C'&
M`G)Z^ZVF&JAJB(V3BQRJ?\H?5<U?!.Z^O^<'ZU66558<U[8[F]N6/*;%)CON
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MS`M4IK0X``!\M_),;0VH2/+>_'S+-O5^;?O+61#.?1?DUI.LZL=,I;2M]*6J
MB_P_%+DZ%2;Q=!+XJ9.XWM5)?)UD09-XJ\`-EI=1'#RMIDHBJ9/[N[)XLV#K
M`7AU2M1&=F\A<UL>/)FN8)_5"PJEDCRH+&L;KADH105-?KT/??_.>87&I%H3
M#34N5\2M0G5!I14DX`!O!PUUI-#CO6S9E%BQM5DC#$#N#M8S0(8*?\XE8BA9
M+CL)@X6^38=58MABA"WT%UW>IBH1:A;="<5F0)``0X$&4Q35;!^NJ//U4P>M
M;3C?KERA'QA(J`F;SAN5BL^LB?$UQ@Q7&64^SZK$)FO?%BP?:A8-JS?W3-QV
MN=TN@@08V)*#32NF.L@$#(UBHJ8%--L?M\L=(`DPP)`#GJ^<$IM@*P,,-4N\
MOMVY^N**&!7]UA0DP-C4>#5LY_).5`>9C#><($)-6SS7V*AQN]P5CP08X,U7
M`-5!!N#"*%&$FA;0,YH?M\L=(`DP0!<NW.M+V!QE(AH^'&D1-MH-W-58J[6(
M])I&.*KR<:/;"[BLSN](%]V?&<_"<.I(B_2>#$=!,0\%)1$.JER=@%X`Q!G`
M`0=3#T6ZELM10)100!+A@,K9IP/B'."`YC1Q4706D,P3/9A)A`,J1R>`TUS1
MQ3E`0?V5>>%H$5XYQF)\;E%TBW!1<5KE[83V0K]Q$E#*<&$83*3N+<$#=#G'
M-R23^"-;0N@LS9;@Q,KLIQ/C:.#$YCQTV_FA;ML&=3VS*#XYD@.K"4"`)VX(
MG!L<W+#*R&V'BP*'?ZL,&XN[]<Y+:813JC%P/24.#TYI#DVWG3!(Z1K77]RM
M]Y3M$8/MJF8!H;RP77%R,+KYH(9DO#27=NR:$4$CK&J>,8+.\S3J2_>V6M1[
M83R("!KA/"-SYO)=A3<V9\S;"BW"RQKV&GSQ&X]8*WIR02.<$WHRO8^>4O.1
MO;PQ/CW2HO[3XT%$T`CG46X^>5]YZ/WPG?Q#8.SJ2(LH#QD9.$2HAO-\:8AX
MPR$2+@9]1)&VY\5H(U'2HPN=N8EPT*OFA_HOW6AD&`P:B:+^TV-]6!\1-,)Y
MKIH.'GK[A4:V`Z"UIU@?1GF(AO,8YG_!($9,/S!,/?)0I!L8K&Y&6]A.AA9:
MZ,-&6F@X_P7$$<</S'M2#T7:*Y9C`S[6&EK$SUS?N\KU&S5WBS`P;TJUJ/_T
M>!`1-,*:JAQUNELTZDNNKT6$9Q`1-,)Y#-<_WT%_Q.T'FTR+\'F&._='?4*+
M>FA!(QSQ*L/WAX8?!J;!:E'_Z?$@(FB$\R@OGFSX/CKW>9_0(LJ#A_41036<
MYTN&[X\8?F#>CVM1]_^VX;=QM]Y9!8UPRJO<WA]S>_/>6XOZ&L6#B*`1SG.5
MV_M3W%Z+*`_Q=AS;5,-Y#+>?=JL/#_^'4W'0Q=;0\29Z\$Q,)^FYU3L%E;:)
M("6^(L"'W[DL=S*6AT-EI<6+>OSOP5.M+MJ]FGCPU%-6(Q[!*XOF^;[3+<`;
M@U.RDS^3<I<=*^L@MY!R/@MA#Y3XS@'_J(M3\\C]J:CA74'SZQ[>#4EXV#V?
M@7A;%'7[!WRPT[UMNO\?``#__P,`4$L#!!0`!@`(````(0#\^$`IF1$``-UP
M```9````>&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;)S=76_;.+>&X?,-[/\0
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M_/+C^T-`_W>W^_D<_?WL^=O^IWJZ^US?/>Y<VNYY:I^!3_O]'VVI^=R2V_@2
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MRNQB=K6<+D\(Y]+O`8<=*KMYN?GX_FG_\\P=I=S=>_Y^TQ[SIN^F;NCCKN0G
M?K=S_=.^Y7:J=I3?VV$^G+MGS>TVS^Z`\.?'U>SJ_>6?;B>^#34;7^.^1C77
M:<UVH&8^26LRUDS3BIP5JYGX2<5`S5R,HWQ-\JCDO=''FO8HTT9A))02*@_N
MZS\'40_4R!]MCS7'']U$<.F>W^Y)=E,O>9*'CY/'Y[*M;I_+X[`;#\G]G<_2
MR+=#-?.T)F.-&"5GQ6J^2$<IAFJ6:8T:JEFE-=K7K->'V3J_NEJ)^6J&!EFG
M@Y1#-6*<*OE!"W>2$8^H'AI$3%?+&CD=&I:L^L><S`=W+!DQ']IJ=X:,I^M"
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MA%)"):&68"4T$21YNJ52DN?K.;;5,D>QKVY\31_25D)VA/A`VY_W#FNR_%AS
M7-(4$I0$+<%(*"54$FH)5D(301*DZUU&!-E6BR#EJ<:71#E*R#R$<\]L>=CA
MQ=DGEQL5$I0$+<%(*"54$FH)UL.K][6):UQ;+AY/DG;;["5QGW8<.&PF<E^(
M%>(F%$7)!_'W?G&X8^($A6UR2`%1$`TQD!)206J(A32QI.&V74G<8KY^4&@;
M9CF9%V))O0E%<:A^LUXRU.20`J(@&F(@):2"U!`+:6))0VP7]R-"]+V`6\E&
MJT^Q,V^FOJB/;`O)(#FD@"B(AAA(":D@-<1"FEC2$-N5_8@0?2/P^A*^O2[C
MIJO?F>5!YG#RV8:2/N<,DD,*B()HB(&4D`I20RRDB25-M5WHCTC5]P5IJG)%
MWUZ)<JGZU>=4G,VWX=8XT*C9\&=\U!00!=$0`RDA%:2&6$@32QIHN^H?$:AO
M$M)`Q>6#37MUW`7:1[:%9)`<4D`41$,,I(14D!IB(4TL:8CMDG]$B+Y#>..`
M&;418=>6DDVEY)`"HB`:8B`EI(+4$`MI8DE#;-?Y(T+T;4$Z$^5"=.J+_`%S
M/;#ZV8:*?JYFD!Q20!1$0PRDA%20&F(A32QIJ.V:?T2HOD5(0\7QTA?]T_$R
MZC(.\S:;2LDA!41!-,1`2D@%J2$6TL22!MJN].-`3UR]^P8A#O8*ZTQ?TT_%
M[51*!LDA!41!-,1`2D@%J2$6TL229#F3G=#KB_5#^5O7AD-1%"(D@^20`J(@
M&F(@):2"U!`+:6))0QS7\<R&.AYYV`Q%<8CH>%"3!PF-\M5BMG8O=*3-9H&M
M%$1##*2$5)`:8B%-+&FL;E=-]O,WYF9;+KMS>=ESYHOB6*5DJ,F#A%C=FS_:
M/S)6.8[".!IB("6D@M00"VEB26,=UQ7-!KJBI7CPFU`4Q^HWZR5#30XI(`JB
M(0920BI(#;&0)I8TQ'%-T,SW*Z\O-T-1']D6DD%R2`%1$`TQD!)206J(A32Q
MI"&.:WS:MX1@!\=Q$XU/V*R/-8/DD"*(W^7GB]G\>KX6U_P5MM(0`RDA%:2&
M6$@32QIKVY*,7Q_-?"?C#F/]-:0EXI7MSC9L%L<K:W+4%$&.\0X=416VTA`#
M*2$5I(982!-+&N^X)FDVU"3)]7PHZD/<0C)(#BF"A+X@/4,IE&N(@920"E)#
M+*2))<VS[4U^8;KZEB:=KLA5]CW;F92LD_9=3).+B5@OY=WMW8M)$`71$`,I
M(16DAEA($TL:K>R4WEA!L4-:+;&"D@W1=B8E@^20`J(@&F(@):2"U!`+:6))
M0FQ?'T[FY^LA'LK?:I%"4;2_0S)(#BD@"J(A!E)"*D@-L9`FEC3$<2W2?*!%
M6HK3[R84Q2&B1>IJVIU[>K&<B&O+>5?0[=T0!=$0`RDA%:2&6$@32YIIVW'$
M!\XW)J9O4-(#IGSY?>Z+XDRE9%W-(=/9Q5Q<?,Z[@CY3.8A"C8882`FI(#7$
M0II8TDS'-4?SH>9(3+%-*(HS17.$FAQ20!1$0PRDA%20&F(A32QIB..:H_DI
MS5$HBD/TF_62H2:'%!`%T1`#*2$5I(982!-+&N*XYF@^T!SQB(GF*&P6AWBL
M.>S=Z1(R1WD!41`-,9`24D%JB(4TL:1YRJ[HC:/E4#>$HZ7L=+9S*5DGASRO
M+M;B#2-Y5]`?+>4@"C4:8B`EI(+4$`MI8DDS'=<*S0=:H:6(8Q.*^AFYA620
M'%)`%$1##*2$5)`:8B%-+&F(LO]Y8V+Z!N;U2TESV>5L(1DDAQ00!=$0`RDA
M%:2&6$@32QKBN$YG/M#IX-W:H2B>B>AT4)-#"H@*XJ]^K-U_=YK.YF(_T-C*
M0$I(!:DA%M+$DL2ZD+W/:2^U'383E^)Q*2D41?%",D@.*2`J2+BX-)D/7*[7
MV,I`2D@%J2$6TL22QCNN*UH,=47B<L4F%,6QHBM"30XI("J(CW5V>(]SNCS0
MV,9`2D@%J2$6TL22AMKV&J>W10O?FKBOT65/T=%L0E$<JNQH,M3DD`*B(#J(
MCWGJYN[<3>`T:(.M2D@%J2$6TL22QBH[HQ,/!4,=DKQ,MY#]T!:2==*NH^87
MB\EU_.<J_TT,FG<;=.LJB()HB(&4D`I20RRDB27->EP#M?"=4#J%Y=624!1/
M83107<UAK7HQG<<17XN=(N^J^X#EB`HU&F(@):2"U!`+:6))`Q[77"V&FBO9
M#(2B..!C*W4,*.MJVH!7%]=BC+R[_;A%`5$0#3&0$E)!:HB%-+&DD;9-RXC#
MKN]QDCF[$H>YS4(V0EM(!LDA!41!-,1`2D@%J2$6TL22ACBNH5KXANKU7B`4
MQ?/2;]9+AIH<4D`41$,,I(14D!IB(4TL:8CC&JJ%[Y62F8A>(!3UD6TA&22'
M%!`%T4'"`F`ZN5[.9E/1'AAL5D(J2`VQD":6-%?98YVX`ACHM=@,R,YJNY"2
M07)(`5$0'<3GNUA<#[0'!EN5D`I20RRDB26)=RE[K=>O`QS*98\EFX%0%$U;
M2`;)(05$0720X[IU.EN("^$&VY20"E)#+*2))0U5=EBGS=GE4*<E%IB;4!2'
MBTZKJ_&K5O<VDOC/P*JUVZ!;`4`41$,,I(14D!IB(4TL:=9M2W3Z"F#9ELL)
M+%>MH2C.V&_62];5'%:M::>4=S?V><H!%&HTQ$!*2`6I(1;2Q)+F*3NN-PX(
M0YV66&!NENBT(%DG;9[K"W'FR;N;^T3EH`HU&F(@):2"U!`+:6))$QW75RT'
M^JJ5?$=4*.KGXQ:207)(`5$0#3&0$E)!:HB%-+&D(8[KG9:^"7)3I+^^@E\G
M$HKB$-$[H2:'%!`%T1`#*2$5I(982!-+&J+LEDX\+PUT34N<E]`U+:5DG;3[
M^/)B%M[3[-^'-YGS:DJW0;_7RT$5:C3$0$I(!:DA%M+$DF8]KJE:^N[(G27Z
M"8M74D-1/&'15'4U@^<E65YTY<>$%41##*2$5)`:8B%-+&F>X_JKY4!_M<1Y
MR1?%>4K)PD`+_]MRW.]"DZ=ZN471;=%'*FLT:@RDA%20&F(A32QII+_66BT'
M6JN5B&43BN)HT5JA)H<4$`71$`,I(16DAEA($TL2YFI<(W4H?^L->Z$H"A&2
M07)(`5$0#3&0$E)!:HB%-+&D(<K&Z?7%YVJ@85K)MXZ&HCA$-$RHR2$%1$$T
MQ`0)_>EBL5C-9F)M6Z8UKH-=3>2[VRJ,7$,LI(DE#;IM1T[OFE:^>TG.3BO9
M-86B.&B_62\9:G)(`5$0#3&0$E)!:HB%-+&D(;8=R(@0?</R^IITY8OZR+:0
M#))#"HB":(B!E)`*4D,LI(DE#7%<=[0:Z(YPW304Q2'ZS7K)4)-#"HB":(B!
ME)`JB#\LK*ZGJ^E4O`Q1)R7SJ_G<_7XT<:7-8N`FEC1GV4"=MO9?^8XHV?-Q
M'344]>EN(1DDAQ00!=$0`RDA%:0.XI^!V6+H=Z=9;-7$DL;;]B4CC@6^C4EC
M%<_N9B5[G2TD@^20`J(@&F(@):2"U$'"_P5:NBDK'I7%-DTL::CC>JC50`^U
MDFO^4!3/5=D49:C)(05$033$0$I(%<3/S.7T:BW_<U"=5,RNULNY7%-8#-O$
MDJ;<=B<CIJYO9I*I&_T*V,.O?MBL9,>SA62=M)WJY$(^4WEW^[&/*B`*HB$&
M4D(J2`VQD":6--)?ZZQ6`YT5+K2$HG@"H[/J:DZ]T-)MT&<M!U6HT1`#*2$5
MI(982!-+DO5Z7.-U*'_K!8!0%&4,R3H9NM#2W=CE"5$0#3&0$E)!:HB%-+&D
M>8[KP=8#/1@NM(2B.$_T8%W-(4]>:.EN[R.58RC4:(B!E)`*4D,LI(DEC;3M
M@^(C[&EKKW6[F9BJ*]$\;D)1'*W?K)<,-3FD@"B(AAA(":D@-<1"FEC2,,=U
M7>M3NJY0U$>VA620'%)`%$1##*2$5)`:8B%-+&F(LNLZ<48.=%_R-]IOUK+7
MVD*R(&&-XU\`$!=6L5$!41`-,9`24D%JB(4TL:3I_EJOM1[HM5;B_8^;4!1/
M5;]9+UE7XU=6$_'J8=[=WA]*Y1@*-1IB("6D@M00"VEB2:.5?=:)$W>@WUJ+
MCGNS1K\%R3HY1"NGK!R@Z,J/22N(AAA(":D@-<1V,G!GF^Y&=]?2B&77=6+$
M`]W76LR\C?L@C/:4UL_5+23K9.!>Y]V-QT`+B()HB(&4D`I20VPG`W>VZ6Y$
MQ.-:KO5`RX5?D1"*XFAE$Y:A)H<4$`71$`,I(16DAEA($TLZ3V63]?J+!6O?
MT+Q^^344Q2'*/BA#30XI(`JB(0920BI(#;&0)I8D1/<!:NG2]/40#^5B2;J4
MIZA0%(4(R2`YI("H('[9,)VO)NX_L8GW^VEL92`EI(+4$`MI/WZN.YSY6/VG
MR?D/OWK8/7W=;7?W]\]GM_L?[2?%S=RKR)UVGV+W^ZS]1!OA:OK.?:93>^#H
M;G`?+O?]YNO.WCQ]O7M\/KO??7%#3B[:<^63_W@Z_X^7_??#1VY]VK^XCY4[
M_/6;^QC!G?O<J,F%*_ZRW[\<_]'^@.Z#"3_^6P````#__P,`4$L#!!0`!@`(
M````(0!J.U!Y_`<``-`D```9````>&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM
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M]'B_;Y0"/>RKKGY^6']C=S),UYO'^W&`_M/4[SWX>]6_MN^R:_9_-J=:C;;*
MD\[`4]M^U]0_]AI2)V_(V6+,P#^ZU;Y^KMX.PS_;][_5S<OKH-(=*T5:V-W^
M5UGW.S6B*HP7Q#K2KCVH&U#_KXZ-+@TU(M7/\?.]V0^O#^LP\>+4#YFBKY[J
M?A"-#KE>[=[ZH3W^UY"8#66"!#:(^K1!6.QMXSA*MNGM44(;)9JC!%ZPC5F<
M?.)>U/5&0>ISNI?$BX(XW7Y&46*CJ,\IRA?N);51U.<ERK5!W9@$C?DNJZ%Z
MO._:]Y6:1"H%_;G24Y+=J8!3HDU:+JG_?YE7*==!ONDH#VLU^U52>U6N/QZ3
M-+C?_%`EMK.<G'*8RR@FAJXG';;$`#>`^A]<)W2CB(DS19$`V"C5%^FJKJ#T
MY=J>%&JR5CA%S0T`;P4)+B@C]-U[+2DE25P*7Z"DD<L12YS8Y<@ESGPM9V#4
ME($#HVLB4H7_\0#ID]0T=U*3NO>0&TYT&<0"`R4&.`8$!B0`'!5JPG]>A3[I
M8:W&"A38%JDPG&0L\S!.`\;F<1SKMG`8:NG*8A2C-(QY)#@&!`8D`!R=*C-0
MY\=9TF2L+T/Z#"<;]3'FH6(KX.'(RWSG'R*7A@QT8D!@0`+`T:F:YNTZ-1GI
MW*+)EQN.&M8YUUO<DB@G#%!5ES=P^,29VH?`@`2`(ULUY=ME:S*6C=I2;CBF
M?.-DF_FX>B&!!<G6CU"%E)"Q34*6HA#<$.:T"PQ(`#ARM8-$ZU&H[,O'5:U/
MPK+1LI`;3CI6=1I%JFK=LB\@@;&QJEU&"1E12B)P<QRHQH`$@*,Z^XIJ?1)6
MC>9?;CAV+J=>A.L;'D^\#!TNX6'?RU!T;@X#P1B0`'`$,Y53G.?D:I['L[!D
MM-#EEF0*G$7Q0B8+AQ/K8L#E4#J4(&59@&8!MPP@GR`2(NX`:%<""OWC`F?&
MPSCKTA9-NMR2[,(T:L(U[E"B;9KX:)J4#F.;9GZ`DVX94+:YNQF1D./*UC8$
MR+[-6S!C7ESYJ`WGEF1F.,N2A:06EC/?:4D03A!!$`D15Y]V(TC?]?[%C(=Q
M]2'+D%N2NUZAFBPNI&FA*0G""2(((B'B"M0V!`B\4K?&M#C",E24.3.D.2D%
M04J"<(((@DB(N"JTR0`J;BQ#8TU4LF;'D)(R!/[%N$']X*P:]:RO)`@GB""(
MA(BK1GL'H.9*3HS3<'."&G_.)CLR2PT82EQQ(<W%-ITV(9QP!$$D1%QAVB7<
M+LQX"E<8=C\,&`^;'HR4A,,)(@@B(>*JT*L^4'%CL1FO<*78@*&P:C!2,HQP
M@@B"2(BX:O22CM3<T.&,$7!S@]:>G!F27;E#/PW0VEY8!IQ*P&&,(\`)1Q!$
M0L11%R!?\O%4&MG(CV"3E%N2517[089:1F$90!5!.$$$021$7%7(;-Q6@<&"
MZ4CQJF1)5EV6^CAEE@#%8;O`"4<01$+$%:>*"A;DE91I-DI9BE;1/#`D8YM]
MCSP5VN-0DSEC1CCA"()(B+B:D(VXHFG!/F0H#WE@2/,=%@0I"<()(@@B(>*J
M0%[AQK(S=N#CQA<0ST"0DB"<(((@$B*NF@7/<+WQZ7?,N-XRW/@L">:&>`;"
MX001%C&3,?!CED3(O4MXDBOO4R8B6#(1Z%JY)4%9V!^4EF-N.0K#),4O2;E#
M"=4CB7IL<9_,!;F2A(BK$WF*&XMRP5O07FA(T_#[VPB_J2T"8C8(P@DB""(A
MXLK3JSU8GJ]T#N,-5/,"CI9T0T.R+Q&\!*6Y"+#!*`G""2(((B'B:OJ2Y0B6
M+`=^9K8D6*+84)268](:1[%:Y-SRXPZ#I6%&7@D+<B$)$4>N;BJWIW!DHP4-
M.XS<DH!,@I0$X001!)$0<55\R7.$QAM\W/PM":K!EJ(D'$X001`)$5>-7M_!
MM-)=0TO_>'J%QA4XTXLT?TN":LQI,U(2#B>(((BTB"E<_4:$);-]<^5I<P#D
M79%EK(0K"W6%/#0DVPPS]7L@_D6PL!2HTYPT(YQP!$$D1%Q97S(@H?$6CCS2
MZRW)CFT<A5F(;;VES&)*@G"""()(B+CRD".YDK4%)T*<;VA(IM<'D1>@Y^?"
M$J`H;%4XX0B"2(BXHC[E0\(E'S(7^?A$F%O2\CPPC\V6`F5AJ\()1Q!$0L25
MM6`[;F@@"[8CP^NSV@BB+69J]/F>CZ9B80E0'+8AG'`$0?2.D\N++"/.;"`Q
M&PJ.=?=2%_7AT*]V[9O>'!*H'ULNZ&7CRK=`__Z+\)S=J5_[%;ZY'%#[2<[5
M2_WWJGMI3OWJ4#^KD+ZGMWYT9D>*^3*TYW$;PU,[J)TDXY^O:N=0K380^)XB
M/[?M,'W1%[CL17K\'P```/__`P!02P,$%``&``@````A`-T6N>@Y`P``S0D`
M`!D```!X;"]W;W)K<VAE971S+W-H965T-#`N>&ULE%;;;N(P$'U?:?\ARGMS
M(3=`0%6(NEMI5UJM]O)L$H=83>+(-J7]^QW;D,:F+>Q+2V;.',Z<<3PL;I_;
MQGG"C!/:+=W0"UP'=P4M2;=;NK]_W=],78<+U)6HH1U>NB^8N[>KSY\6!\H>
M>8VQ<("AXTNW%J*?^SXO:MPB[M$>=Y"I*&N1@$>V\WG/,"I54=OXDR!(_1:1
MSM4,<W8-!ZTJ4N"<%OL6=T*3,-P@`?IY37I^8FN+:^A:Q![W_4U!VQXHMJ0A
MXD61NDY;S!]V'65HVT#?SV&,BA.W>CBC;TG!**>5\(#.UT+/>Y[Y,Q^85HN2
M0`?2=H?A:NG>A?,\#%Q_M5`&_2'XP$>?'5[3PQ=&RF^DP^`VS$E.8$OIHX0^
ME#($Q?Y9];V:P`_FE+A"^T;\I(>OF.QJ`>-.H"/9V+Q\R3$OP%&@\2:)9"IH
M`P+@K],2>33`$?2L_A](*>JE&Z5>D@51"'!GB[FX)Y+2=8H]%[3]JT'AD4J3
M3(XD,:@_YB?>9)J$27J9Q=>*5(,Y$FBU8/3@P*F![^0]DF<PG`/SJ3.M8^CU
MO5:A1TER)UD4%W3!83Y/JRP(%OX3>%H<,6N-@5=BP(0F8G-"2`,E;3X*^*!W
M$`U6V*(C&.K;XSAIE$6FQLG,%+!^`V(B-N>(R.HS/X>DZ<!BM!&=MQ&_>ZI.
M;<@B.#\C&[/`,G*M,;$Z/M+(C1W(1P%#$AR!L;,?.RK!2Q?Z'2::!9.A537"
MM<9DZDQ$DS@VTYMQ>II:Q;F1C:9#K2$9'+M>L@3;DJ.!5TO6F)%[=B`?!0PI
MJ2E%ODR7!RJ++@U48T:2[$`^"AB2,E/2QP.58-L=:R9KC4G50.758YJWT>E8
MI9,@,[/Y.!MGK[6&9+DU1U?2QY(EV)9L';*UQHS<LP/Y*&!(F9E2KANH++HT
M4(T92;(#^2A@2((]]Q_V*+3MSZOO^L`?0?HE#=.IE=\8^2A)K*&:Z;/+3F]5
MO71:S'9X@YN&.P7=RXT9PDD9HGJ;K^4V5_MX2,`R[=$.?T=L1SKN-+B"TL#+
MX$5D>AWK!T%[=<5OJ8`UJC[6\+,)PQT8>`"N*!6G![GPAQ]BJW\```#__P,`
M4$L#!!0`!@`(````(0#64)ANZP,``'4-```9````>&PO=V]R:W-H965T<R]S
M:&5E=#0Q+GAM;)176X^K-A!^K]3_@'A?P!#(14F.-J';'JF5JJJ79P).@A8P
MPLYF]]]W!G.QS9X<3AZ2,/[\Y9N+QY/ME_>RL-YHPW-6[6SB>+9%JY1E>779
MV?_\_?*TLBTNDBI+"E;1G?U!N?UE__-/VSMK7OF54F$!0\5W]E6(>N.Z/+W2
M,N$.JVD%*V?6E(F`Q^;B\KJA2=9N*@O7][S(+9.\LB7#IIG#P<[G/*4Q2V\E
MK80D:6B1"-#/KWG->[8RG4-7)LWKK7Y*65D#Q2DO<O'1DMI6F6Z^7BK6)*<"
M_'XGBR3MN=N'"7V9IPWC["P<H'.ET*G/:W?M`M-^F^7@`8;=:NAY9S^334Q"
MV]UOVP#]F],[5[Y;_,KNOS9Y]GM>48@VY`DS<&+L%:%?,S3!9G>R^Z7-P)^-
ME=%S<BO$7^S^&\TO5P'I#L$C=&R3?<24IQ!1H''\5D;*"A``[U:98VE`1)+W
M]O.>9^*ZLX/("9=>0`!NG2@7+SE2VE9ZXX*5_TD005$#B=^1P&='0D)G%8:+
M:+6<SQ)T+(N1Q7?\54C"Z/M:7.E7&Z8X$<E^V["[!;4'RGF=8"63#3!C?!:@
M27HS1.Q;`0,GD>09678V'!K8SB'+;_NE%V[=-\A,VF$.4PS1$<<>@;%#VE@Q
MN*!W$`V!5$5_GLQ>&X)16\]ZD`;@'L3ZAI`I(O!T2#R%1-$`T<1"WE2Q?80?
MB\9-4&N*QFBY'/C;Z!PD9C$X=C0-L6+0)$&B54F/I2!X9X._0[@"LC:D2,PR
M:E-OA.KX:#'^QJ(F%^IQOEP$&W)]0]%!8GJY3F1$]BC7Q\C&QH9PK%Q-:/0C
M0A%L"C4*\2`QHY"C:8BEH7.%./XO3R.'IFWY(]H0K&M;>F-YR_*3&,C?4!?1
M:HQ+BSE.,8%O!#M^C-%\P%M9:5:/ZQ;!I@_&;Q\D1HFO:8@5@R9EK4N9=ZIQ
MT_=.M<0HDDQ#K!@T201NQ_GA:=%Z?(+)0>E`BIK.,IR=,-!;0:QNT>5A-Y^=
M/2)[O]9V_+&T90EVH*'ZEVO]I1X&69#F#NV\M)"X@[0^ZPY@SY_O@+PA5`>B
MM=F(B`2I\34ML8K1]6![5_3,JT$B+P5X'\_MY&KI0*HNY2[IXJ18=%W8TQ5=
MCX\ID3>`&J=/ZE""5#W2,M2AV</CCO>3-&(SGR]/MGY=WJ0.M?O!=X)/"L^`
M$+U2UY,=.!9CMU`<D%.N'-]*VESHD18%MU)VPPG6A\MWL`[3];./\X%A/^#4
MC79W6("AMTXN](^DN>05MPIZ!DK/P?FTD6.S?!"L;H?&$Q,P[K9?K_#WAL*X
MYCD`/C,F^@?\@7O_AVG_/P```/__`P!02P,$%``&``@````A`/"#C4?^!```
M)Q,``!D```!X;"]W;W)K<VAE971S+W-H965T-#(N>&ULG)A=;ZLX$(;O5]K_
M@+@O8$C(AY(<'4#=/=(>:;7:CVM"G`0UX`AHT_[['7L<8@]-F[0736->3Q_/
MC&>P%]]>JX/SPINV%/7295[@.KPNQ*:L=TOWG[\?'Z:NTW9YO<D/HN9+]XVW
M[K?5K[\L3J)Y:O><=PY8J-NEN^^ZX]SWVV+/J[SUQ)'7\&0KFBKOX&NS\]MC
MP_.-FE0=_#`(8K_*R]I%"_/F%AMBNRT+GHGBN>)UAT8:?L@[X&_WY;$]6ZN*
M6\Q5>?/T?'PH1'4$$^OR4'9ORJCK5,7\QZX63;X^P+I?V2@OSK;5EX'YJBP:
MT8IMYX$Y'T&':Y[Y,Q\LK1:;$E8@W>XT?+MTO[-Y%D:NOUHH!_U;\E-K_.VT
M>W'ZK2DW?Y0U!V]#G&0$UD(\2>F/C1R"R?Y@]J.*P)^-L^';_/G0_25.O_-R
MM^\@W&-8D5S8?/.6\;8`CX(9+QQ+2X4X``#\=JI2I@9X)']5GZ=RT^V7;A1[
MXTD0,9`[:]YVCZ4TZ3K%<]N)ZC\4,6T*C83:"'QJ([#D6R>#4A'`YWGRZ.;)
MH%23X5-/9J$73L=L''_.[Z,OE&NSO,M7BT:<',A76&U[S&7VLSE8/OL4/=![
M^9J3P;O2R'=I1=D"_[60&2^K23!=^"\0S4)K$M3`9NPUS%:D9X4,G32;&0,^
M\/;0X'P*'4$ZO9\(9T8YR6:,QS9`,I2$MB(=*J+`EF1#21SW$FL9D`9T&:.K
M^7Q>AIP$F6NX,0IFO7WEMP0U(Y6XTI$I'<B,`0L)4H`B?>Y9.6GIPKK[R$X&
M2*B)56Y$4#AG8Y(?*2HNT)DQ8#&"BTS&CZ,NQ82-D8@EJ$&VV22>QL2?*0H,
M-&/`0HOO09-BBD:V1((:1'L8Q]-9<,DE%>O44K`PG@8C@I]9DFD<L<G%B(4_
MN0=?BBD^V2X):C1^!&QDQZ4H,#QK#%AHLHD;=>KCH$LQ18O('D&-3LCQ)&3L
MXA3TK*5X+V4S5"AZ"W9V#ZP44]@1@44-PK(8TB`FGDY183C2&+#8&!3*VSVI
MU)2.!#'1(NW+:,38C.)IB<%GCMB`LNH;H98MZ?,:Q+!76$6(1C31HIFJ0B-O
M%E@_Q.FI5IO,^$^&`6>RZ-_/C*W"9IZ0T"O32Q>9PXDW*`!:8&*BW7<P9=F_
M'Q.;A8U)JG?"4(28S(M((4OU<Y/R6@]BLO#?3XGMPJ8DE3!1IL_.G'E&'<0M
MKY^;E->ZD'SS_`(E=@Z+,J3]2)D^4S+F#1(3C=R6QIFV]DXVR+YPOY^QF]@K
M(-%.&(J0,/+"P0KPN>EG8\0N![(CW$^)?<2F)$4I82C2.0LG1](C4BTP,:_U
M)R9[P?V8V$%L3$*1*--+%Q+Q\GXU].BY%YDB4JBSWI(\9IDOU$QVB_OIL<?8
M]*2+)LHTI2=%+NU%EU?_:_TK)/U+MH?/WYK5+-+'0EK#M,AV-"DA:2_J4<T1
MRZOAESJ9FD50Z2$CT:*)ZF33$1P"[;:1:H&1NN:(C0D!-(/_\;M5*-44C^Y_
M+<(W@C$<L,G62[7`Q$.[:L3&^U+3DJ?R`2:A2+1(>S&(0K+U4BTP,0=="^\K
M\%!=\6;'4WXXM$XAGN5=!(,(]:-X3Y+`/8FZ5/#[!W!-<<QW_&?>[,JZ=0Y\
M"U,#;P*%OL&+#OS2B:,ZPJY%!Q<4ZL\]7$AQ..,%'HBW0G3G+W*/]U=<J_\!
M``#__P,`4$L#!!0`!@`(````(0`W@-B#P0@``-DJ```9````>&PO=V]R:W-H
M965T<R]S:&5E=#4R+GAM;)Q:76_CNA%]+]#_8/C]VM:';3E(<K$6R?8"+5`4
M_7A6;"41UK8,2]GL_ON2&DJ:#\66>Q^2S?'A>`YGR$/I\O'WG\?#Y$=^J8KR
M]#0-9HOI)#_MRGUQ>GN:_OM?YK=D.JGJ[+3/#N4I?YK^RJOI[\]__M/C9WGY
M7KWG>3VQ$4[5T_2]KL\/\WFU>\^/634KS_G)?O):7HY9;?^\O,VK\R7/]LV@
MXV$>+A:K^3$K3E.(\'`9$Z-\?2UVN2IW'\?\5$.02W[(:IM_]5Z<JS;:<3<F
MW#&[?/\X_[8KCV<;XJ4X%/6O)NAT<MP]_/%V*B_9R\'J_AG$V:Z-W?PAPA^+
MW:6LRM=Z9L/-(5&I>3/?S&VDY\=]816X:9]<\M>GZ;?@P<2;Z?SYL9F@_Q3Y
M9X7^/:G>R\^_7(K]WXI3;F?;ULE5X*4LOSOJ'WL'V<%S,=HT%?C'9;+/7[./
M0_W/\O.O>?'V7MMR+ZTB)^QA_TOEU<[.J`TS"Y<NTJX\V`3LS\FQ<*UA9R3[
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M1+1M;BS:M4!D%_UU\6Z0Y2&MZ_6FB]],_!8X<3=!*0<4!S0'#`)(TG9-X:2O
M)^O(3U,[)5UAD@5KK"UPUDWS!G$86P:CI$#I]2@\)ER$J[48H_D8@P`BR&X.
M6-"X*KA!3%@0LRH`9]4(BUR&0A<PD"X.:`X8!!`5=@O!*JZ7Q9%Y]DN6/7`@
M^V`5KZV7\[(`!:6/QZR#:"6&:#[$((#H6=^CQY&IGN6&);L%3I]LR@'%`<T!
M@P"2K#M`L;W\]D)V@VXM9."@I#F@.*`Y8!!`DM[0I*]WC"/3&5XGO&.`LTZ:
MAH\729S0EDJ!T*M1'-`<,`@@R0=VG\13?CW[ALW2%PWB27UZJ4=@#;C^=_]1
M34J,T@(Q&*$JG$.BQKFA`OP4[Z;K#=]T`B#9S:[?<@/F46E':AU4"40+Q&"$
MRG">-UX&."21D7`'"X`$4S^X=WI&7RY%QH1!-%`N33B;8(!B<&`JTUGB>)E@
MH%AF$JQI]VP#Y+*-=:<"41[Q.W&3,>]"+489C%`5S@?'JP#7)"KXMV\#(.$,
MJ<[4,W"Q\)C-0!VT&&,P0C4Y5T2:QGFX>S1BFUH2L#UKZTE]YJE`E$"T0`Q&
M:.[.`>_/'7S3MD^WS.4Q,$#FZKN+(TIPM$`,1FCNSA!1[C?V+[!/W$O21`(@
MM2X2!,O^\.PU(!=N$.7']#72`C$8H1J</X[7`&Y*-$@G09;K<^:("CBB!6(\
M\H7_4!7.*,>K`%NE*H23M-[;MU@2L'TZ#5I2[R0<T8)C,$)DA'?9>L-FMBZ<
MQ)/\YM0\*?`-+/6<OH$4&96X@RP?I`G%GP[HMF=P7*KS+N,/I?%+*_$DT+EL
M$F9GE=13L,SVM.#>'#"Z[N@#'YKN0UMX*LUVU?A.#!V;EE`^(7H22(N&?#WU
M%"P-(L.@+RH(E'Z0P6&HJKN\/QSP_I!-[]:3?&-^43%^/E!^5)^S%HC!"%7!
MO'^<3X8#9X"0O?S9>I)7,]Q^$*=/7?E!<?/$P.9'7_O0=!^*]F-'@>N6Y-X"
M\O8+V7NAK2?9[#NO34+N2AVIVP@%H@5B,$(K]7^="D*P=]O6*%.^KWN27QA-
MI>BVE7H&+A0_-VC!,1BA6NXZ)83RE)"$_%'3DZ!Q6+W2[L.^%/S(H`7'8(2F
M[YQZM+6&X.NT!.SY:^M)M*/8LT':D7H9XLP@.`8C5(;SY?$RP,6QC%@T$G#\
MDE\//J6%_#2@/`*C-O%`_VDQR&"$J'*O6<:K:MC,;0+>6Y[D9<5#&::>@U8(
M&>5>88KS@AAC,$)5L>/!N'TZ&C@FA/QYQI/ZS%.!*(%H@1B,T-R=J:(^&YF[
M&W7K;5@$))P[1Y3@:($8C-#<[W+Y2+J\?!_C272I\U-T1^J6ND"T0`Q&J`QG
MM*P$L76ZZUX8N5%L<?#_`;+U)%P"&-8C2G"T0`Q&:.[,OT>V#_BX+4AG?/)Q
M.`)2GVDJ$"40+1"#$9H[,^T;\RW->J!]6N/MA241.WNE44OJVX<C6G`,1J@,
MYM<C2S#@VQ&SYFW$C3@5B!*(%HC!",V=F?7(W,%8;[0/=]\TXH@2B!:(P0C-
M_2Z'CJ1#)Q$[E6X]";P,'IRX+Z6>TR\+)1`M$(,1HB*^RY$;-MMT%FQ[W'H2
MJ(CAG,&>%E+/02H$H@5B,$)5,`>^OI3C`>>-^'')D]IS17-$$,7P)"P#8O>(
M%AR#$2J#F?$-&>"F]F>WBR81/Q[%0`(9X0*..J(:0.J35GY8CVB!&(Q0&<R7
MW:J^;6BQ].<DXD=Q3^KS2@6B!*(%8C!"<Q\P8W?PNU$*<-7K.U+,K3<5B!*(
M%HC!",V=F?&-G,%?:?OP'<F5S9XRH'U6PV\]/*>OB1*(%HC!"%7AS!`=AVZH
M`.LD*N2.!"10L?EB#7`/5C%'M$`,1J@*YLHW5`RYL=B1@`0J6G<02YE;MHHY
MH@5B,$)E,(.^(0,<EA1#[DA`\BW5ZF#O-&+AU0+1`C$8H3*85X\[9]C+?_*(
MS9[[MYX$%V*^6"`0!R\0CF@?IN>XJX?NVQL$Q,!-0KB6=LPO;WF:'P[59%=^
MN%N"H7TMUZ'=#<9OH;M6Q'`5/-CK7Q:?=Q_8BX7G["W_>W9Y*T[5Y)"_VI"+
MV=JN_PM<380_ZO+<7(9[*6M[I;#YY[N]0IK;"V2+F26_EF7=_N&^H+N4^OP_
M````__\#`%!+`P04``8`"````"$`\AJ;!`4%```9$P``&0```'AL+W=O<FMS
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M$(%,NU7SP]I^8,O48[:S674)^J?@UX9\MIJ3N/Y2%_O?BHI#MF&>Y`P\"?$L
MJ3_V$H+!CC'ZL9N!/VIKSP_9R[G]4UQ_Y<7QU,)TAQ"1#&RY?T]XDT-&06;F
MA5(I%V<P`*]66<C2@(QD;]W[M=BWI[7MSV=AY/H,Z-83;]K'0DK:5O[2M*+\
M%TE=1*.(UXO`>R_"PEG@A5'\%16_5X'_'52\F1>'+)S?]^)@7%V:DJS--JM:
M7"VH/7#>7#)9R6P)RD-^,)HQ8_^7,,B4%'F0*FL;%@WDHH%9?MW$?KQR7F%F
M\IZS10Z\CIRY[ZJ<G:G#5$8R,.14R;].">!`3&-@D&P:V.T)'_Q+LO0_J&X1
MH&9C?Z%:V9D<3V4D@^Q'R'K$J4F9ST<5)2"8_^D!2;(2$`(TH&BA!V1RXD";
MH4073@F@V`U4N[*P?%B^G\^#'`0\4B-1I+G<(B<8YVJG`XD.I`10/$+!3T^I
M)*]MF*^Q?F-7R\X6.<0;`E&W)%C@!3!$&Y-0BN=Z\\B@I$16\3__BG])UORS
M<"RU;C%MD4/\(S!'__,@@O:E^Z>4B/ES@Y$25<5^]!7[DJS:#Q?:>MLBA]C7
M@40'4@(HWN0!0-L7[Y>O''2O?)%#/.I`H@,I`12/"]7CYTM+DM7\1;$^_<@A
MWA"(XF[^`S<(M8PG^HB4`(I7!FN?)O1SLQU;=1N[6BO8]J0`BU,KR]WXZ["G
M)P:24D1U*[L*F?X[;K$'T:TA6FA^M@Q)_5(*8948"V77<SXF(#&0E"*J9]E*
MB.=I.R[#!D2]QX&1:21]^-KUPS#WOKJ+)../0^I3BJBF9?L@IN\D&IN-8M;5
M^P-#$C6+"*8^8+=2GQBC4HJHGF4[F>X9FX_BV0_4C&T9Z5#=3KSK$?0<+VY[
MUD>E5$?U+%O(=,_8<%3/^F8AC]&PH]`\(])[]F][UD>E5$?U+/O&=,_8913/
M@;9=;1EI17V>!X2T]<`HZ('T4=`$44W+AC+=-+8?:CJ*C8(F/:HWC4B_E_CR
MQ&"T9:9P@N`&)U4Y3--1XY)-:'I<V+)H7(%1\Z2M]6'I2,(0Z0/UY.E)#S3M
M.5T=JI9E+YIN&3L7M6R>[QAI;[UG1-!A>,M@T@]""N98:PXIU55B\+[4-CNV
MUC:-,UY/(NO60)(>^22JE`Y2+7^I=WIF[XQ9I&V//8E:QF%XL):'4J,NDGX0
M4F[V6WGS(+>PVRH8%-XLX"-SR>LCW_'SN;%R\2)O#63_&]'Q1N/!EP\G&KZ#
MFX[N6D##$V\)#U4F/_66\&P%N#,.@(N)2W;DOV?UL:@:Z\P/8,&=1;"EUGBU
M@5]:<>D>[)]$"U<2W<<37$%Q>%QV9T`^"-$.7^0?C)=:F_\```#__P,`4$L#
M!!0`!@`(````(0"*$08)N00``(T1```9````>&PO=V]R:W-H965T<R]S:&5E
M=#4T+GAM;)18VVZK1A1]K]1_0+P?<S$8;-D^"H:T1VJEJNKE&>.QC0*,!3A.
M_KY[,X#WS+@)>4GBY36+M2\SF\GZ^UM9&*^L;G)>;4QG9IL&JS)^R*O3QOS[
MK^=OH6DT;5H=TH)7;&.^L\;\OOWYI_6-UR_-F;'6`(6JV9CGMKVL+*O)SJQ,
MFQF_L`J^.?*Z3%OX6)^LYE*S]-`M*@O+M>V%5:9Y90J%53U%@Q^/><9BGEU+
M5K5"I&9%VH+_YIQ?FD&MS*;(E6G]<KU\RWAY`8E]7N3M>R=J&F6V^G&J>)WN
M"XC[S?'2;-#N/FCR99[5O.''=@9REC"JQ[RTEA8H;=>''"+`M!LU.V[,)V>5
M.$O3VJZ[!/V3LUM#_C::,[_]4N>'W_**0;:A3EB!/><O2/UQ0`@66]KJYZX"
M?]3&@1W3:]'^R6^_LOQT;J'</D2$@:T.[S%K,L@HR,Q<'Y4R7H`!^&F4.;8&
M9"1]ZW[?\D-[WICSQ<P/[+D#=&//FO8Y1TG3R*Y-R\M_!<GII82(VXO`[U[$
M\6>>ZP?A5U3FO0H\=U!Q9V[H._[B<R^6B*M+4YRVZ79=\YL!O0?.FTN*G>RL
M0'G(CXAFS-C_)0PRA2)/J+(Q8=-`+AJH\NLV]+RU]0J5R7I.)#CP<^0LYK;,
MV>DZCLR(!P:6"A^=$,""F,;`(-DTL,<%'_PC&?T/JI$`J-EPOI2M['2.*S/B
M0?8>LAIQHE,6BU%%"@CJ/ST@)$L!"8`&%"S5@'1.Z/FCF2[=L2J<$$"RZ\EV
ML;'FL'T_K@,N`A[ID2!07$:"XXVUVJE`K`()`22/T/#34XKDC0GU&OM7:W%!
M(=8$$'0[PO%<+[1MI>5C2G%M=Q%HE(3(2O877[&/9-F^KS9`)#C$OPK$*I`0
M0/(6R-ZFE1\7?59^P2$>52!6@80`DD<<\N3L^[@UD2SG+PB5S1$)#O$F@"#L
M&L"S/5\](=05"0$DK\NO>$6R[#7T[J=*MY$CP2%>!^#>WZX=*+M_X`SG9$(`
MR:X#6WUZ;CNV8MA63OZH)WE=+I4\[L8O!V>QAB04D<WB#)G<"(Z8./0@");*
MKHYZTJ(SZ\.6UG;U[G-*W%/N14HH(L>`@V1Z#&+LT!A"6SUH'4&Z/WW7(R(J
M!T\J+:Q86Y501/:,LX-XGG9(.&+B2-X]I5&CGD2]BV6]]^7#FL3:LH0BLGD<
M*L3\QZ>'(T:0;#J4=U?4DZCI87+A*Y6R(6*-GE!$-HLC9+I9,7!DL\J.B_`M
M&@X9:G9`[B=(Z"E-%6O+$HK(IG&V3#<M)I%DVM>V)1E7W3&X<P;D0],#:3A=
MDG$9(+)I'#;338O11$T'H9*RR"'SJS<MD+Z7'^Y"RIB+9I>[+>EE^R-*H<@Q
MX5":'I,8830FN*3(#X\<,N?ZF`8$6UVI6ZS1DQ[IW<LID,WCB)IN7@PT:EY[
MRX/[JMKY`A'O>9IW^N6#MSLJ)YR+VZRXII6L/K$=*XK&R/@5;ZHX`$=TO$4_
MS?&%6,%W>+M^@,?N"E[D=7[BKN!]'EMZ%(++\"4]L=_3^I17C5&P(UBP9P'L
M]5I<I\6'EE^ZR^2>MW`-[OX\P[\]&%S1[!F0CYRWPP=\P/B/E.U_````__\#
M`%!+`P04``8`"````"$`^V*E;90&``"G&P``$P```'AL+W1H96UE+W1H96UE
M,2YX;6SL64]OVS84OP_8=R!T;VTGMAL'=8K8L9NM31O$;H<>:9F66%.B0-))
M?1O:XX`!P[IAEP&[[3!L*]`"NW2?)EN'K0/Z%?9(2K(8RTO2!AO6U8=$(G]\
M_]_C(W7UVH.(H4,B).5QVZM=KGJ(Q#X?TSAH>W>&_4L;'I(*QV/,>$S:WIQ(
M[]K6^^]=Q9LJ)!%!L#Z6F[CMA4HEFY6*]&$8R\L\(3',3;B(L()7$53&`A\!
MW8A5UJK59B7"-/90C",@>WLRH3Y!0TW2V\J(]QB\QDKJ`9^)@29-G!4&.Y[6
M-$+.99<)=(A9VP,^8WXT)`^4AQB6"B;:7M7\O,K6U0K>3!<QM6)M85W?_-)U
MZ8+Q=,WP%,$H9UKKUUM7=G+Z!L#4,J[7ZW5[M9R>`6#?!TVM+$6:]?Y&K9/1
M+(#LXS+M;K51K;OX`OWU)9E;G4ZGT4IEL40-R#[6E_`;U69]>\W!&Y#%-Y;P
M]<YVM]MT\`9D\<TE?/]*JUEW\084,AI/E]#:H?U^2CV'3#C;+85O`'RCFL(7
M*(B&/+HTBPF/U:I8B_!]+OH`T$"&%8V1FB=D@GV(XBZ.1H)BS0!O$ER8L4.^
M7!K2O)#T!4U4V_LPP9`1"WJOGG__ZOE3].KYD^.'SXX?_G3\Z-'QPQ\M+6?A
M+HZ#XL*7WW[VY]<?HS^>?O/R\1?E>%G$__K#)[_\_'DY$#)H(=&++Y_\]NS)
MBZ\^_?V[QR7P;8%'1?B01D2B6^0('?`(=#.&<24G(W&^%<,04V<%#H%V">F>
M"AW@K3EF9;@.<8UW5T#Q*`->G]UW9!V$8J9H"><;8>0`]SAG'2Y*#7!#\RI8
M>#B+@W+F8E;$'6!\6,:[BV/'M;U9`E4S"TK']MV0.&+N,QPK')"8**3G^)20
M$NWN4>K8=8_Z@DL^4>@>11U,2TTRI",GD!:+=FD$?IF7Z0RN=FRS=Q=U."O3
M>H<<NDA(",Q*A!\2YICQ.IXI')61'.*(%0U^$ZNP3,C!7/A%7$\J\'1`&$>]
M,9&R;,UM`?H6G'X#0[TJ=?L>FT<N4B@Z+:-Y$W->1.[P:3?$45*&'=`X+&(_
MD%,(48SVN2J#[W$W0_0[^`''*]U]EQ+'W:<7@CLT<$1:!(B>F8D27UXGW(G?
MP9Q-,#%5!DJZ4ZDC&O]=V684ZK;E\*YLM[UMV,3*DF?W1+%>A?L/EN@=/(OW
M"63%\A;UKD*_J]#>6U^A5^7RQ=?E12F&*JT;$MMKF\X[6MEX3RAC`S5GY*8T
MO;>$#6C<AT&]SAPZ27X02T)XU)D,#!Q<(+!9@P17'U$5#D*<0-]>\S210*:D
M`XD2+N&\:(9+:6L\]/[*GC8;^AQB*X?$:H^/[?"Z'LZ.&SD9(U5@SK09HW5-
MX*S,UJ^D1$&WUV%6TT*=F5O-B&:*HL,M5UF;V)S+P>2Y:C"86Q,Z&P3]$%BY
M"<=^S1K..YB1L;:[]5'F%N.%BW21#/&8I#[2>B_[J&:<E,7*DB):#QL,^NQX
MBM4*W%J:[!MP.XN3BNSJ*]AEWGL3+V41O/`24#N9CBPN)B>+T5';:S76&A[R
M<=+V)G!4AL<H`:]+W4QB%L!]DZ^$#?M3D]ED^<*;K4PQ-PEJ</MA[;ZDL%,'
M$B'5#I:A#0TSE88`BS4G*_]:`\QZ40J45*.S2;&^`<'PKTD!=G1=2R83XJNB
MLPLCVG;V-2VE?*:(&(3C(S1B,W&`P?TZ5$&?,95PXV$J@GZ!ZSEM;3/E%N<T
MZ8J78@9GQS%+0IR66YVB629;N"E(N0SFK2`>Z%8JNU'N_*J8E+\@58IA_#]3
M1>\G<`6Q/M8>\.%V6&"D,Z7M<:%"#E4H":G?%]`XF-H!T0)7O#`-005WU.:_
M((?ZO\TY2\.D-9PDU0$-D*"P'ZE0$+(/9<E$WRG$:NG>94FRE)")J(*X,K%B
MC\@A84-=`YMZ;_=0"*%NJDE:!@SN9/RY[VD&C0+=Y!3SS:ED^=YK<^"?[GQL
M,H-2;ATV#4UF_US$O#U8[*IVO5F>[;U%1?3$HLVJ9UD!S`I;02M-^]<4X9Q;
MK:U82QJO-3+AP(O+&L-@WA`E<)&$]!_8_ZCPF?W@H3?4(3^`VHK@^X4F!F$#
M47W)-AY(%T@[.(+&R0[:8-*DK&G3UDE;+=NL+[C3S?F>,+:6["S^/J>Q\^;,
M9>?DXD4:.[6P8VL[MM+4X-F3*0I#D^P@8QQCOI05/V;QT7UP]`Y\-I@Q)4TP
MP:<J@:&''I@\@.2W',W2K;\```#__P,`4$L#!!0`!@`(````(0!HYLB3>`P`
M`+QT```-````>&PO<W1Y;&5S+GAM;-1=>V_CQA'_OT"_`\%KBP2H+8FB+,FQ
M')QT9G/`]1KD7+1`4Q2T1-FL^5`IZLY.T>_>F>5K5N)C*2VUEP@Y2Y1VYC?/
MG1TNR9OO7WQ/^^Q$6S<,9OK@LJ]K3K`,5V[P.-/_>F]=3'1M&]O!RO;"P)GI
MK\Y6__[VM[^YV<:OGO/IR7%B#4@$VYG^%,>;ZUYONWQR?'M[&6Z<`+Y9AY%O
MQ_`Q>NQM-Y%CK[8XR/=Z1K]_U?-M-]`3"M?^4H2(;T?/N\W%,O0W=NP^N)X;
MOS):NN8OK]\_!F%D/W@`]65@VLN,-OMP0-YWEU&X#=?Q)9#KA>NUNW0.44Y[
MTQY0NKT)=K[EQUMM&>Z">*8;^2$M^>;]:J9?Z5HB\B)<`8@__&<7QM_]+OGS
MYH]OWO3_]>UW__C)6?WSYV\.O_OY6[V7L2$TP0;U-"_[M63AZX1R+Y7@]F8=
M!H4@0P#-%'3]'(1?`@N_`V<`\?!GMS?;7[3/M@='!@AO&7IAI,5@99"/'0EL
MWTE^L;`]]R%R\6=KVW>]U^2P@0>88Z2_\UTP$Q[L)1S.R^<!T60R31`&)],0
MCU"9?!#)QH/U,MG_+I&)XS5JYG6*_CA>3(IZN:3Q.O2+`QV>PBNW%>$3/3[,
M=,N"'#+H]U&MU&`=,9LN^L#O;,RN1F>3;&@-K;%4R3A?/+0;,AQ:,E79P-!Z
M.WYW-G7*9U8E79J&SQ4!&'!RM>A"Z-;$]]C"USG\Y,P36C<68U2YI,]"K\B-
M]Z[O;+6/SA?MI]"W`U0LG=38K[DYF7.\;LAS+B"?1<?D,^=EV;-.]9)JH\-Z
M9<_$DOBPFJU[>1K%.<ECY5//S$VFM/+,T1IW3IF$0%[ER$Z[56'=&<-<.N)7
MW3/#_-:=#U=EEL[D0JN=G6EN.1),G4J8,9Q>#@\73'O)KD64L6EM"_.=ZWGY
M&GYHXBH7CMS>0#LA=J+`@@]:^O[^=0-KW``Z'^A(O>1W#;]^C.S7@<&`BPW8
MAIZ[0A2/"[:R3G6[N+JS%G>,+T$FBJ*"J&4MQAT0O9M/%_*1+J93V40-"UZ2
MB;X=X4LR40O^6TC3:3I#F;)`YO2TV,5.6/]R/)U.)X.KR60R-8<#TV1*?D@]
MV@U6SHN#S3%I:CI$,`($T^%D>F4`D+XY8:S.BF`(`,:CT60TF!HF_,]25?<(
M9.MTI*NV*D&@R*H$@2*KLN5$3T+F3R,%6KR*8Y4@4&15@D"15<>2,_!8N54)
M`D56)0@46945QA)C%<[W*(Y5@D"150D"15:55GRF&7BJW*H$@2*K$@3GMFJV
MK%K<W5FLH7Q8F577QVPE!VO'AS!:P<GR[`SP`%>/R;';&\]9Q[!*C-S')_P;
MAQOX]R&,8SBU?'NS<NW',+`]>-O+1F1_:T;"R7<XSS[3XR=W^0S,N&9&@C=A
MT16'/!.96.&;8[,_-D?&5;*(DL3:=U;NSC^4+N==ZBN@1M1ML^!$AT'.)'6'
MXOQ"#ZV0FD]P!#,UL[3@`/")S"4$1\B0L3C7)BHC&2$F(QD@*",9(2HCA$Y9
M<&6:7(4[V/>Q;V#+FO3[;"76VE_*"1+@)1[3..90GXU#2C3:.$94IYGR(+\<
MQ,;<P!>K6$LD;1AQ*&?#@!(I&T:(RLC[3:G$>3L!TW,)DCU]<S\_#@8P2@9F
M>/:28)J?L.^?G'`5=M]R<1O)$ZF!0KOI*I-A3TV',LA@TD:2#%CCF#HCIO,U
M3/]+Q_,^X83\]W5>`T"KZ_;F94VV:\$>.MS/A+O!\"WTD].WR7R??``=5PTR
M*@=I]F;CO7[<^0].9+&-=8P%.XI]Z^+3G!4JQ>>WGOL8^`YKUND)F1^C,':6
M,=OXQTXY5>$95N`9I(1$\)S"WZS@#WH2UL<I_*$95&I$T(M2_N!<POQE^@.T
M43)]@`FH4]?AD8D`EOP9`C"""@2X)3,-;'!/%0A@*94A``<M$`"<&J\X)0X&
M))N!#Q0L@7]7+"''9%)R+#N4LBK]`O\:*2TN_9ZD9I)OP=$+-<.'&@`GL:Q*
ML:I2##$[1%JA`OA0HP(+9ETY4]Z@*N<K4PA)NH"AT`BD@3J-R/-*DG.!9P&@
M7B-SB74(<0I,1:HA`!PE$(@A!HKFWP'%H&@&IMZ@:`JF$+@Y^(PQ02W!S9"*
M,``>)5%1U`D#;L8XHQH(!%49DGB#H2I%4@RJ<F1A"D-5BB005&5(:@E5*9)B
M4)4CB2E4I4@"`32B)$-22ZA*D12#JAQ9F&*H*D42"*HR)+'$L.,4V:-MTZ2)
M2OJGX^E1_5/M9=W82!U4+9K`[MGP9/64K!S!%FPM19;2>!&LG?5.M:<P<G^!
M129>#+N$9JH3Z7CQ=.PNZ9$OD;VY=UY@*9J<=WI95_=Z`4G6W]AW1AYA)::"
M/S37=:T-<^GZ.0'+Z8IHE)PMZAL;\WN>P3>W&SVD$00V=U1CP+!0C0'MG6*0
M[H:2PA0FR0RBL'?*=A>J)I@PQ7*%!8K%Y-.0S1I]E3)'9:0-;SC,%3!\HNJ`
MN;#VNTB2N(Y2)CFN9=LQKSFOV)Y8@P/1.,,=`G0R;#\9M1:U`=T)DY%1TP_O
MW-OAVJ&6-F]01)LX%W;VRE"C3I'52&T04"\=[J^<ZY1OL5YW8]:C^!J=5L-+
M5Y)D"H'5$ZSDFF"+`?V:E'8L%BE3Q7$68W<@.;38&>HOBI=M@Q*HR@DL&@#U
M^BLO-@0GX&-08G;(BC;9Z?H03U/$444UA1Q7$76:*5KY70/L"@.+Y8]#A38O
M#BO<\#B8I^I<-':(5^+;M$IMP)SY@&"]U$2M5-8N:3?,^8?&;XHFHCIX6U/@
M"\W\1]B.AG,]@O-D.(.TR*3@:3.)5C*'>[#M=2AX;<S3$^Z-=9`<--`ZK*O)
MND%3U=;#70%2T-#H.::&55K"5S)7XSI5QFJPE5"6.<HV58"DJ>=D[ZE$"-/S
MU^'?*E,C.$[+.;[U7-E<*"&(DDKXJ#+A?/``=<W$SD\D0@'8T0*Z'F<ELC93
MVD!E-_57UE-L<-`V:L?M&%GTUEM9T!M;,<?E3;H\.#]SI3U%*`>525YY?N>K
MJ=?`&3+M-&5PL;7W";WGH4I353*75ARUB==J-"J6'5^_&U<C5%HXXDR;UDKB
M@2:M]26\1BB'63]/E*.L+%!.71F(J\\2RU-'`6+7`?T*#(K:RFKTJB45_*9N
M1=69)0VEY:?LWGVKI$Z<&-Z>OAYIQ5QE^4D;G$UE!OAML8-#,)A/*3I45L9P
M#\Z\_#J[1]!U8!=&H1GVY-5R1>:M5UK+.:HQG.@VNLJ*`R#Q>;4<A>`BCRHQ
MF\\+;\^.-"/'MM7AQ-6Y^M@&6-CR2FX@P-\^(-\@J^&=VN'),OW?:Q?:VR5*
MEO?[T5,?=JX'MP;#G:^X>7FYV\(=<.;)P72[:1VMO&PV(-XI+8C`MK3RDA)/
M55!:,+FTI07L$V_!BI_0@GLKM*8%NV=26GBY0:$O$TJ`MKA@2$J+U_U(4/=F
MF1W9A3D%+A19!!>E5=@1-$=DA/LEMZ95V!$,1VF!R&UQ%78$A(26"4S:TBKL
M"%:@M,#=VM+*[6ABK!>Z'PGJ_JK4CKROXBYZ$5R45F%'WE?Q@4QM:15VY'T5
M16Y+J[`C4"7Z,N&+MK0*._)YPA3,$U1?A1UYW8\$=;^?47F/QYI<1+J$2F$[
M>$=TA$6$.)7":KR7#P6]/,%2V(OW;U/0OQ,JA:6`'I'(A"_$)<IM-.2U:PIJ
M=VZOLJS+.PS.,R(PX/D7RYT'SX8+\<ER["H1[%X1@;`)+43IR5D^:PNXZ4].
MB(\'G$9%"-V];#P[L.,P>M7PRI"<'&_TD2"Y/X5AKB.>@@$?10#]`,_A@T?\
M::"71$.\#V-9UX9,'@N\>O`R\39D8'2"AO<_7#>U(0.C$S)\4L7Z283,^V"S
MRRW$YU*<ND5(?'"#9V?%>PZO8=QA+$+IH[.+(SOW/SZD#$'%?,1;1>4T^!21
M/&PDNZ]56G]^A#M#94K$<I_$#BY!1(#_91<3->(H0L00S$OW;@QW],N"F".!
ML$1PW(=PM59.8B^C"-+XFQT%&"U<Z.[Y:(5$Q;5O4/VO7HK;AC&]Q_BD2G9#
ML7P]`(I:.6M[Y\7W^9<SO7C_9W:O3'"F]%<_NI_#F)&8Z<7[#W@34HABV/0%
MZ>;#%FYL"7^U7>3.]/_>S<?3=W>6<3'ISR<7YM`974Q'\W<7(W,Q?_?.FO:-
M_N)_H#)\K.<U/!?RA,=FLL=[PM5O`_-ZZ\'#-:-4V!3\I^+83"<?$OCLSH,`
M&S9>9T+TMOEC1V__#P``__\#`%!+`P04``8`"````"$`BT^-`ZB:``#R'@(`
M%````'AL+W-H87)E9%-T<FEN9W,N>&UL[)W;;AQ9EI[O#?@=`D*/30$D14IU
M[*[2@**DLJ9+$BVRNMT8^"*8&22S*S,C.R-3*O55O8-],X`-"'X4/4H]B;]_
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M?3L[KZ?]7Y]_]^*_]/\66/VJNIR(9`C`BW(V6/_SH^-7+[][\N+9\6GQ[,7Q
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M^\/X2C;_%D5W.BG/)]/):E(-J9:(L2C?;J($OR_7;&$;);Y'K2I^G:R*.,U`
M=A]7%Q6J.X;@KZOY>D!MWU]\G55NWF0D]S4/;EJ-D;2H+Q*[3(_K>7^2;)48
MF3C)C9NY[?#.J#CLADV:RE[5TS$FXC^:1*S>#H7<U;MQ]?[-P?[!8;'`&R#J
MZVKO\/[GNP<'!_IOT;CJE^O55;V<_+4:XPR_W/WZZ\]WOWCPE0D=#Q]^^>7N
MYU]_&1^N6SM1E*L"_UO-SA&]Z(/]M8/#![NP4DJ\FKRNI@,2G8$EFC7V+BR3
MH49UL_I=\=47G]L0AY_M/OCJ,,[Z"3,=C<>(=3U'&:6O>Y,YNK:8H)Q][B+'
MZ]EZ:C9L7%U,1I.!FCF';,T]-O0'&_#2=G6;-Z^UI2<8:]!0M9K@Y>]NLZVG
MN)_*,`4R_70RQQQ/V/])W1@IBNWP)?B&P)4D-OW==1\;R-&M'L\DJ?]\7SI\
M@OY3'4*E+>-$+HJ7V,U27&^,["QWL:RNL-,((^AA5,^J8N?[NFFVDK#KGJJ?
M1M5BA4>#_`5>KOQ8CW6_OXE7;N^&5C?\4%PLZQFZ,9V6Y[7VQ`90+.#=:.`O
MOC-XM<6"ND"&'P?F\QCE<UI%*SZP*S@KF]4H.F;9T]K\47]'WU5SB#^UQ\KQ
M;#(WW*>%]Y_T)4GONU/WGXL,FQK#C"!RC,[@_L/N*2:!QV$W=_M/O:AD<'*I
MB&_8)/W''Y4-T$=N>#R9KN6O\<%%YY6"%6E(02N3UYO'>%--+J\T6$GP5EY6
MQ7QMME2.*!MH`[,RM-45_%-9_62:GH`9@`\[^"U9LX\5]OY.C&_]/YX2H(`C
MC_8."Q23#:TFH*;B9!D]NRVM^.?GYB\&<5-Z_?ZGO/[H4UX^_I27'W_:OA_O
M?=R^CS,LOY6VR9Q>SX+,4Y[(4V("C]U3;ATY=YE!R+8^^X@(<#Y7=!0#!/?J
M*7X_[(O4X(T4K=STIAGJO7-P)\@:-<?RF[7HS^`$J1=R%2#4:CDB]ACHV^:G
MXF+Z8\JT="Q#_P$"TFNH,/`0W<?CK`%\)>(-7E,,:V%89DT<$LIT\<?Z`LBM
MA9@![B_R`U^/R^H/XZ9`B2E-B1,.,+_14HI5G0R=_OV37MZV@B[Y^F1[T)^S
M^W@<],;77$06!+YX9X>09(<FKS&_NXZ\M7_',<5$Z85Q?^9KA[CVS5?`P67"
M>ZL.M.[/<MVS<;?]=[HTZ=/BL^L?CX/>^-HU<.Y8X3J)AS=;LPD!\"'-@>P;
MHJ>C\9_7S4JPN)'D$=K7X&)\U-"7\[/^:&F"M8P(44.`')TI!B#I<86,`[:#
M0;'40)\^3\M)B,:*,BU)XO&F7!J"BQ'@(&HZOBKGESC9[FHLUV'@)+[(YC>L
M+*B>`HC^DF2S;MQL_R7CRH5QQ3#9!*_?6/IK.P].UN!6S+*A],7&_$9_FL':
M;C-/?VT7'@1UF->?B'3+J*K&C4-N*>DGV,_N8&[N;O(SD3B2A>NU.-$$$KZ>
MC!'0\[?%;?9H+YH428B,Y4*U]@_7Y,.,G)L>E%:?)\<N$V]YZCYIKWV_8@%;
MWWR!CDK[-VUN(./7>IO^FEXN+\OYY*^NJMK;"W*VA'<LI0T?^R^%7)C<Y@D)
MSY$@[_9H^G"_^*A9GI>C94T<-1DUNPI7]XL=8O[BEY__!WAO4<[?_O+S_[R+
MN9`E&-5+LE66M("CCW$^F!%V,2^.UI?8N_?O2*50'CDXV"?A6H%Q;02<4%$6
MHRGA&9F$/7*_Q!_GDWI!B#LK1]7:,@P&GIBON%`I`3%CV#$5AAI\+QI81.2A
MH/X5?%>_AJ#$J(1!]8ARDP6"A`+U^&W`8\I4E@N;`%6KEX6V)G$WTRSRCZ1W
MRUW2F<4;LO/ZW]<EY8\U2UZOZLELMIX3AD^:>JE,F*UB,K]0KDG/\(,RCDUW
MOY<6EJ[@UP3[OY@L*O9NW$:'QNN1#"#`3"GL:`'T'":*N,92\PW!E+TPKWY:
M[87QA&PH:M@&BU4UNIK7T_KR;0$46*FXQ1:N)J,K)D5/IA-HQ0*(.Z&@;1Q]
ML1J8$N9L?4@V29C('"?98\L0>,RCTVJT)FUN^R3#.MS';IA<%(Y\Q_H66`R6
MK.PZ:UC6ZTNMKR$)+W*J4"AFLII`2<F%;4KK<.KOS:HQ7D[+8,_H43-#5&<E
MN>KQF/Q$XL)>2.2/"AZ;DFR7_W*22$SG-73W'/GT+132Q#.<$>:,A+%[$Q<8
MZ+#?U\;3]6RFH@E+/9U<SMD1/%P5&Y2T_^;]_>+C7U8VP!S8B3(QU&W,VXLX
M)VC%:+*`*5I3BVB0DOX*SN`)`*0MFP0+A\+``D_?F7Y/UV,7E3(6)1AZ:"&,
M-S#Q#=$_I*2>!7.:]7DS@5$*S7?SEXH??E]\/YDAT)*L<>>G/^+%@]EY0HP@
M&%NE1._[=_?O>\VT.U[VDNS2K%I>,O2;R<H++I,YD&JXZ".TFY^(NX)52GO4
MHE0N;(0EE,>[(DF"@%3$:5,6/H\6KZ4ACW55OA4LQVY2/7"<M-[31PA;4UT*
M$6*H^W]"[93L(W4B2K(GK9&7!1_A`$B??ZR6F`=TC^3<>A7DNJ$P)(-LEG)9
M\0\8)RNDRUC([KXN)Z3S0)[1_(VN)A4165K"&`QI0=.L_%&6$"N9_TE:<HG>
M+G:U(?UB&GM5OQ&P1<WJD>9'.FOP5C0@X,2FT:N9S>D2[/6D`F++%(2EQ`3J
MK)SC'_RG\S6#2,,#+0,%HZUA?R$Y:+I\>S>0K'YKXDVF-QCVOB[]``=@R1/L
M!>T*PP!>N@8N-[:(!SPKD[A%XP@A<*IC`W\FP&[JI57\0AY8XN"Z:-1L=7[G
MNZ.CD[O0G;P;Q+=)HMV%,6)F(8ALBS2]^_-Z;/)GU,3IK4JH.IHLJ43($(MW
MJRLP5FF*:`.R#ZK,6L/,:Y021HL!=E-)RM0]YGIMHIC6Q:NB63%&E2\GX1E@
M#ZHD^(Y8AP'MV2RHV`>,!$)JY]`0PK<*R)HVD51^0>)C!0FYGUF)19.4G4.,
MK01A6Y$@<:<85UE#"\>V,7"WN"3L9G7CM:\-9^>I8NF&*+^D%D)<CLK+=6,/
M+FL]3[9H@I'4N)%GE6IF$BA;;>*<M$X+<1K4T"#2DQD"U?G?48U+DO':+2Y2
MR.>V([#+PH(-::I=$;F3*1F$AK8&E3%6Y4^R[;RP%]$<#F0]]JIQ^A-U9CP+
M8KM<EU-'%%9L%_N<Z<*R^]CHQ"JESWH[%_Z[PBU3+E27B80*UV+89:G?(DSS
MH9'*]<QR:T&*<Q`$J<Y%.+5<F"TT]&'D[\C_/NY\Q9IYM%E/$1HJ\U/EX96^
M\E#-Y3"Q9P`3$%I026`%]EJ8L\X9_<O/_](4STY>RJ2]'*UJ%31I*'K0E08@
M\515TI[$YKOD_3$&?ZFJARM(QGJ9'4D]?L2*!$IY=>WOI<)_)LC#17B%CH34
M)&R>R";,@4W6,(%QF-M.6@G;-(W<5UP8XX.N).:/ZG)IH==CK!7;7C88<7GL
MR7R!-[.@OE7=CFQ8,"#1J?")K+H2\'9M0>#-F@5^?`@=SN."QG%!^:JUY,AD
M+$U2J6C.<[I*F]DH(EEF597Z_,\!SL@(`H[BOUZ`,FS[K6*#\:NEPA<0YH]*
MC["M9$I@BB.CP&0`<H;])_/QFL8.UT"M.JI,9!\<=0BL'Z.Q`0FR)B_)!TGI
M68&!8*>PVOY!U9XM_2QGV3QQ(^S!T)>2-IX40WJOJ$CAYZ8T\=';TEKSR9P-
M6?\>"--!':!D0D;?*$3@K$(3RR:>J"SZ4\L>BF92RGZU4\56>F81DD#20FR`
MQ?=9\F&?L@,1OUC4_\FY@--@%#D'0_RRS_S[&+](?=O>\Q11VA7J5KV-C+S`
MT(1-2&+`GK*,Y^7\1S>+W4U/5J@]K`^+RI9I\-"@.JZ8:6?J_9)Y4#X=@SQ%
M(\S>\B?#N-`Y@J1R0;#V4\`!K20/&'P4(?^KK7U(Z1%4.+0J06P6U&HNV-FQ
MB)8AYPYEO=T'.Z`4/'$9\:_@;@(7R()8)F%)C5WGH;'+>D#9'&S(NT$<C@!"
M!`XQ2\*A;PQ%">:.Z_7YZF)M/LAP2]?TO4&`C(\7A*%A159`;+>EV`;XKV5-
M)S\2!5S5=$1*$GP#0G:@3S+A*..`E+D*M'[=]VC[CQ1A0-C6;_]R4[*L+FD0
M63I6\`VD7>*1%160[V<1;G[6B\PG!AO3P0XY!H74[J.,/_1:.5XR;VNJ109F
MA<>7E8:Z2L%(@<$;H/8N&9J.9^99MDEW6-R5^*_D=SVCJ!V7!8O4BH!_DE>W
MGC1D(^#.B[6EQEI"YS/L%R\\Z'!F*_R#:<K-(&:FFH]#E]#[=ZE-B.G<PP;1
MC%90HEH&@^F[#LS%TLJ:L^..T(4]#=C]"FT+K76R)OV((9<&DQE#[(2<@HBH
MB<'P+0;&M*NIEL2C+%8T$:C$ADC,$P)*L=S4DE'&U)2K*T;TNF&K1G+`D2\@
MG8#H1U-`A>=GF`'@$[=B]A`RN-A>HYJH\F\>A#8OL?LWGQU8WY>4=@,W](BS
M@\E2T]:`J$_E<_^@/C+)V]/46/2L]0Y=0B_I_%:'^6^;!3G%;^\L&%Z$N_-0
M####%]RKL(/;<>VM:X.CX[D=_`_Y-@\5AAY$6^WX@TA^M*JURJ(P>X4_R[="
M,&%Y-U%/,0<BY"\W=-6M]H0&D2GSD(:PM?,H[7%N$QV4ADR89M,:Y_5\K_U+
MZR-(K:ASSJ(IPUD:(X]61;^6-4>N(!KUU(X`+'%^#OQVGAZ=/KJ;9\O:)XXY
M/:!LFF6V=HY.C^\67]VG6=[9"UOUGQ/^W^0>G?I_%7TX>7!PAW]#(=`#5C&#
MX8?ZR_(I0-$?.9O,X/(+#-:K&@>E7R_*V03(X2/H#_=LX-7#3-J>YWL6=1ZG
MP#54Z[,E_3K+V2S&A6@CTMQ%>_V?`"*(+[ML>;8KW$J0,\%SRKRUOV#I,!W4
MQ)1BCPV\QO\L[(XLQU2`RA/NE1M0*!^2#9AM_AV;VP;US&5YJ?:=.)1!(W=@
M<=GM2L#S8"')T5\(O`*P(\0-/<)FEBU$P!/YHF.81UM<J);J[1AQN!1A,;)U
M=);NZ8O!MJ5]RE%W=AU!8V8BH4+8LT$M_(39)RWA`NM<O_$81,!4>3%ZYU'$
M4#Q";K+3)K_\_+^Z!FSU\'N5-XK#7W[^[T\3Y>7AX^:8DG!*.;%+D(L7=/G;
M7]:`D'$$_)[#P2BWJ3\`EI5)`<L68'@MQ#/SBJTWTV1@DGUY]V^U/.=90`,6
M.8;-;5NMAV'*)B^!+>V_G<N(*VA70HA0$2\((@GFN3>8Q+HA82O8M'E/O-@G
M!>]T":A1;J*-QL$E>;XZ$'6_>!7:,<+FM5`2('5:+;W/)'"BV,K.!W$EH8$$
M+8V%8NZL'E=3)+Y94\[!+4=,7RC7*\`[+MY.*F(XK+BJ/,9S3:<0IUXN:^O?
M='&I$P4#]ZVI=`MS']S`W+"S)&/K>3:\EC57D:6W@N!V"<G*_>('SY^R7?XA
M#$<(54^UCR:KK&BT+&QNLY<X/;9IB3VTH<0J+<)1&"`E%N3]NU]^_F]%M7^Y
MOYLT1T05-^1UR6LH.,SZ(00^3:V%Q+$<"M#-1DZF'IW*+B%0M;HMH*I'I4K^
M$2,T<J4\,*#H&38A.M\V"FCAQA8)#7N6[<EL6,<3"YRR[>C"+9NHYY.=,(.:
M;W9JE@7C%G(!1&)NU"P[,RNJ$D%K":E46SV6S<ZLC\MJ\@$R>7%[S&T)YXW\
M0G[Y78^W[!V9U0SLCPH1ER]F95N7(!"-8=%,'<)+U#>-#R%X''B6`3M:G/+Q
MA'^C5;`?-_5T"-GLX631W4&/P/MW[]_U;;Q9]C\8KNTBC4U@N?_R?S9+__[=
MB:7FWK^;S/M/'+E)>NYVOO\KIJW_IV=6GY47.+),<?_WK-CY_MU+N#@8X64R
M,/UWGYG![O\U&['_TP^9.>G_%OS'YC\/6A+]Z4'+G>]QP*C?]$?%#&YBWO-!
M<J?_HO>9;R;EA[!^L')GO:J^2LH.&9]1M=C()NTG_M^6[<6?X_]N>2PS;);-
MCIX]6$(`CQP95E]8VU*`GD7K!9>[MPB8+('FV#':FF@ES.UMR=*:"P<J;%B9
MHZ?@\7=:%'4WXJ>-[A]_$"&IMC=`$0-K<TPO$>XH5(/`H\<>A;^:-(/>TU,J
MY\1+*W*#$,S2#EXT#%LV(ELX+E,XR%,JEQ83"=$YS<H_RX6EJ%DYU9A>U.IE
MC7^@8L3S!&)@BGU"=<MI4OT6L#`7YXE*=5KH4`K/ZC4OD"DH9]`U^!U;KAX3
M(),EP<U(AP0IPW[G1S2FY*IX&Y\??V+-ZL+`ZXPKXK=Q81FL,4?"V23_M><I
M3=7+:I?G@'2J=,PP5%3!?QP0O#7O>?[8@,H">!RIF[QKUWLAI2V[+(\4LB::
M*\DP4JV6"V,3^]_*$H^64L"-IP[94I=D2_A1S2])XB),XE],Y<2LC=+`E/(V
M\T\$NE1.;FYI.\J=K(J!6))RZC'A(YE2W7!(*D1#G'P+44FN62`W3-18Y\4#
MPYJD:VC$T"L=B50VR@\*`4C:6N34,"HNO[PD#/+$N(G3&37I<5F<=-N^HE['
M%I$=?^SN+MJ+!OL,M=6X3PD%B&%M3<H#2:*1)W#W"+_$?YLB/K(3\X<Z$4A?
ML+_)H-_1A5LB]5`,ED/D9];SYG_F]T=U=:7$"-,\X_]/R<W,BN]FY_^IV&E_
MXKF3"Q+PM$OXZ_YO_/G)=$*S"WK\_MU_*&>+WT$Q.NK27^_:VK^#+AQX6'+&
MB-^7"Y[(_D1XWSE=Y8EF4=5RAH@J9F6$=9,<*,FEF)X>#2Q(/$3,DU91^V'_
M='^3J+@<FI$((;>8FR<[6YEU`56VR8;<+@44M6Q)6R<=^$KFS()FJ\R&P$XA
MC6(ERWB:C&ETTV90JC8-4*<*HFXE</WAP3](^E=V#CI*(G11-TVP=@YI9;K'
MRC55XP$(T#T&[]\]D3J\?]?1A_["HW]$+SZ+_WS-,P]N\<S];<\$R>T/_P]#
M9-F*9_]AUZC^7UWD^W]-HMK_X>QOS:T-]E'I%PF85>^V<^I:YF2:U-^":^G@
MKWEKN`J;"]FL:Y]2'LR>ZA7F5(XCQ%4IAF8L;)89:,QMP]E_MZ!Z1+(:@A"2
M2;A=Q%1_0I^U^]CA`8&R0\)(?6SVE\=0Z4FMF4DI$SDUC/IHT1*:&!1,798H
M@2",#`X1G?LV34K:&6NL]CGL==N(I50&)YB#0ANXJ'2R5PII)RA90.CR82XI
ME6+1BH@1%-&N4U/1R&:'&!UW:7M4&$H=1MRSIE@Z,*]46L.=V>9;@T`>TZJ6
M((.F4C5O2KP=<VGMK2WR'\Q`22DRI<^Z!^[I^G\^K2]6ZE_N__WI>@DR(NW=
M_^'P8/-`T4>%*CR'G<#HVY?S^9915+O1<<K8LVN>L[^&4R7Z*^Q4??'^G95[
MWK]3VI\_\$<G%#],+@:K?T8O]F3I`GE1?$\KTM[WUMR[*5@A57E-,26Z;,FP
M_A.DUEJUL]*F&E!HR[Z$T9+4(/&&G<$Y8Y,G`P:2"H.0ZD,T'$,X3P'OBW_E
M*L!)L`1X=TY7K4PA>P;A5\_]/_3D/GM'@4.ZW?S>D)+GL@*JR,H,H,KT>D<.
MJWI-RB?565W1K2$:^G>:GI)'A(O!_*925(OU<;+&/T/M<Y)\-GG@N)*S8#`K
M$]O5'I:V%U?[BY;U":DLRV5S+$#=N*!L3*8\..]LF%U_]NDQ4Z%`3&N%3@>L
MK8MIKJX9.[MA9X3RLC(+]:9*X2<2ANU8$,4'M?Y6\LN"]'D1+H0]+M_TEVF%
MG6G;*3OP6'.TW5E!/[*,5M@H0U7+J=7\.NLXPGAGO&3+@=CT^*GIHT=#VY!5
M<[6]MMDG[:7E8KMWVW)G?ZVY':ZTNSS+$\EAL*R._UI*()6,E;:[)X<=2.$V
MSA*BID)':.9P!\/@#<<QT(5M17UY.2\C:U/1(J7D@#RI+X%%6=IN3A[>%$2+
M\RUHC"N"`7X*?U'LNX<N[<EAA\"I6[8![ZL5\DRMD'WCS+%DOUF&1LDXHN;(
M4P?RW=DJ4^^8-QE:3`)=5V\4(6AG;0S8IF<UIJ;PQ"_$S?;3F8OG-%_2N-8)
MX\Z][X)AVJ("!WH"RM9K/2W"<%3>&IQZ8_)%]]\0#%\V6(8S=A%>1,FI6-Y(
M(^U(P`1[9?`]K1')!UVHUU5ZX,!#W&!IHI5C?.>\I2%$).TN#.:A3-AZB(':
M:J^DE#+`8'T>?W%L1Y?6T'<S)YQO&LZ"D)90_:&MXY`8"%U(/$;+A115,8JU
M$,GR8$5E.TTT&RU<RJ)>(IDBM9NX!=RPAC?$E/;NN72,2BD$V,]J[P3[X1J6
M0"`?5CL2$2RUHXE6Q.`V78^Y_G?Y9GL>]`H*T@8VR6IIV\*MTQGU=D_;VO-M
M`3D-P=@^4+\TK9^V:=8L4T<<S-:*8YVUS>P.KY5J#FKMLZ'<KI[CS2X@Z+6F
M$''0D!3_.#ZPBGDJH_561@33ZO3T#)0PLUJW,4"KU=00O(M*L#&6C5OH0!Y6
MFBG]="^]-:E()_7D-&[)0-C^B.9YD&ZST':?[QNIY#_F".W(AZ0`0"WQT&,!
M9P^R.*_0+VZO&ABA\/="#CDTA7?MU.VP'2&0SKNQ*>_::S,];M%(EQ&?]U,\
MW7A=H$0LR6YPT>9HB;G->3TFMJ-Z.&71S="8ETFAS6+*K7PX'X'FQODC&&S>
M@BF[2U/*1"$0-RZM=&**!0F2+I5Q4*>?#LTI&QF2#Y1U[@I#VQ;)$+$+/TYK
MW*[/;:SV9ZV33>;BL8J'\ZQU/9W/RPJZ0..G(PX"(6OYN=#'-$'L'1%`$(&\
MA85[9Y)F"^)V'A^].KO;GOM#MG99J99*<^P5`[*0@(VZ\^/V=`;0X@E[Q=Z!
M1I8X$CMS!N$7=)>`1)<!,3=851BI#"WVX[SB:)TN=+`]Y^PV&T;FGZSF\&=,
MCR=%=R:O6;#H19YWK5(K@9:>7^2'"J!X.DT0CU%XTX+>S&?=+TZ\>]%6F_%!
M0`VAX2]=6<CY3-\3"68>M-13X&AQ48FRX0"U_TOJB?=_#0V3OB(EHVX@)!VZ
M<9%1)3YX]SIPXSJ7A^-QW&R&K!U4Y*"PJY.@,>Z+!H@F"8PD]L9S=LOZ;3!7
M\!AIL4.JPD#HEE638+R9X`&971*Z-(YZI/E--B5)PG-Q:&LT#,F)E,!HV8IN
M"C'@&Z,^FUA))-'B=,KSLJK)>BY07[2"]AT=%8G&(&ACJM1J*=T04W]Y2E>:
M]5*=U0M&^>+@\SVNH?M7[3S;8*XINST/EFKOB7N@XDC7-?BYIF#Q?_5(=',7
MFJNQRNT9S;[Z/X)F4:2+YY93<J_WJY/IH8Y'H686BBK;%E2\HQ)VFDUMRE@D
M@@U_>..3W4!R!F**1Z@]=.VXKJ!H7JYC%:;PL>IB#C,VG@0OUWF[S:2G8Z1<
MJ>PZE^TGA2@V^F9S,E)+/7TUHD4\KD:4P!L1`9C#Q8=P;:S9(C5?6X5JSVZ*
M-A0=&UI[%OX,3<6%MT=B%`1046,T`)A`MR7TA?@@OU9YW7Y<@&TOBP4VU6R_
M@A7`E`:.H(DLJ>_)0BB::>@X(>RJO5<F.,#N1!L#QJ<!!,4"!(Y.U0L%$UI$
M-%2*0_7O;?YS]09@P<W.9@-;H/7;XO"N`G?.?,A.=EPWKAQL%,Z91%P1D8K6
MOD8JLUD-RR:P0#`S']^3[PTHU=&6<*V=6M#).&PH&P&;,%B86E,NR,.,X84R
MS4AL,-&BE^$7.F72(4->5#./=$:=_7$?<95W?V=R>_^N@:-Z?J_UKU&PS0=9
MLP'(@:`4,?)^5Z83!E3;5[HRT$:[GB@0)-X2$1V4,&>\H($%MZY)J0%$.,3.
MPF;I##*[#>FER-,QC6%()%%?0!,A0-U"#'.5>ZN::Q=L^1FZOCN`_V<BHHDF
MV8L`T823U57!_^B@@($N480R<HPR'>_DKE",(.$4!)K\5_(S2`HQ7`+/Q$1V
ML+/-2$@IR5%ZT@(R99(U6.^3Q.GO`[#N1B6KA^P(QF7`W!$<U!M(24N9D-M3
MXT2..H9O=)=G@B]`W>)I4F<Z;(:XZ5""F>E,CM6>01HQR+/;$$')3G]G9_59
MW/=!^+R5=X61.2KN2/5'HG1S1(UB2W*7@OB9"=)^[.J#5F"AF@`]E\\L%!('
M%S-*(AIA982,N=I(>-@,2,:+5-[,FI1X("%9I\B0?:W]2P+91>^F^>91(R:6
MYLL4$(JK#4*F0KOU!Z.XQ^4`H+V'Q84^)XNE7BPD](1BQQJ8("E1CQ5JQ[@=
M#QLU)9!+4JYT3JLX#4#*G-)EHC]Z6*JLFJ>O)>+F!1L[6&?"^D8T=BM-VH0<
MA#%++]O!9:_MQ2A1]?`V$+%N&VWSQ@`AA8PV@$<*7#H3(IH\K$,\,M&RCH2.
M@-TD5QT!W^C+8%L0-8GN#0+&N0]%-51"H:NN`M#)CR6FCM#?UA7W(I$8"DJP
MXL;AS3XPZ+4BZ!SL1/,?HT:%6.)=M.NF-'J)/XT&[MH'[:2<;.E)/I5;L+P"
M65].[%D93:/9>5Z;*O/H>>SO!LZ/A<?6';55!#<5E2.Z@M;I*7'8*N!`<<\R
M&S*NH;22@:F#7_YC64]%(?<T[;A`#5.N(((T>*6@E)_.P6+8*26TP_4ED5]1
M]@8K^:/FL,R5%-YR5YS)Y@10.Z?MI75RREK$#`,*1N/]Y,(K,G([X5:@S"EV
M0=O?X?G2!57!O4@>;!=JVO&%R9-GE#2A)KTT!E4(RL?:!&9L3V:,ID/U%()E
MBIVSDR?T5L&J$JD`7_)?S]$R46=JFK2>G)[P+`EX$/V85U*ZH#V1WP[\A].7
M3^XJBI#(I@,SOJ?V>6;1L"'=FS+B9D-LQ[+@;>$MZK\;X7BS$&M70D4KDZ;%
M.$AV/+C5`(%;5;-KUQJU!$@!/5SR:,DJ/_NZA<:AKVCO2XQ'*4@PA7M0S(#%
MXQ-RBNY&H#LV,69$P]'</'X+QS;07XZ/HC8R8Q9?+#!G[5U;&][TWJWP@V;3
MU0T`4KC,5J.KTYK-`44?#'`G)(C7L,GDZE($M#+X!5[W@S&\!L$CWL,,QC-A
MX`V?!MP2EE\O%N21%-=2K\DJQGGI-HI3-Q%JE4CSZ>=94P,H!N_LM#"+R2E#
MMD03*]&'(H4V_,*W1F_5QA.ZD4"W/1K"U`"!ZP;,*"7I5KA(&7&T<Z.-^7]C
M7/0W7B6SO-B/W#N0TX)8SY;4E5>3$K.Z#O6R0QGHE=?W`E(*D;4L)AI@K,H,
M9UR+AQ9YR3()56X#U!HTP/;],85VNB&U9LYR$2B/(3&]&$:74"%?=O&`2G%M
M$F'M9]@W*X\)LZ?/@T;FMBG(%FR.Z"LD,EE.J(V9J"D"#Y%%=SD"GK9=.]"6
MQ6>1E#*),2=BZ\<(19*R);P]4H>Y,,_>:1#/+$:P-*;A4C/\K-NN?"]Q5&=4
MK(==3'YB&NQC%`^?#;&$M&R?NZ>V,+Z3<PF;OY9I>0*)@\Z)<!W+W82%+]@Y
M-E71QJ:DC!D`2_OT$C+1GHI>\46ME%3;4O`?,Q*2.Z%T;$>>XEL\F=C1N7RF
MQ7#MX:55D:PIYBS23TH;M5)EY"3LMMJN6'>E>@!CGG5'%4>N(W`7D\2,GR*(
M-@$WC*A2`NZ&_%NX7P(CT!6D8!+@)C.&8W/!173N%%,ZU&B=R225:RH_PIYQ
M3&FQXC-C!(8_Y2RBE1<1.F%5'BSPE14WT2H1A(6UD$^X`:G0",'%Z_-#EO)(
MJT]#J]Q*P$N>S-:C.I7NY,%]C>P(:G:]DP:,OC[NHZ4ZLPI4)'/560_)8KQZ
MS,9%QR]2"9[+]:D-6;Y"W:$&W'7IGQ.!W"<?"$GT5SU(PI>)')[439M><*,8
M'H]3Z>8,#XV!RS$T[MLD9R<CJ6"HH3I[8+$>>CK0$B^UJ12G\/Q@P%3XS^BF
M?#%L,\.D2>(2DX!V,L2!DWXPQ,,'0&1P$9!,-&1OH*5X-:)\?U?AN@K#G*V^
MV4)`9ZGWM&ND(M7C&K4::]Q@D"7;O29[/H!35(/C6>76K>H\!N)OZH!MM81B
M%MA[M,TCR.\`@J7CPJ*B="CI0NXG%EA'N[NV9:;%1!D*4WH=J>#)]IXW[335
M9`FG#:2@-0#(.,VU250AMBCO^7*R6#6KDVL'^5-"V9+QA4X^>,Z$]<2_)J2.
MW.O-[,H>EZI..;X7$E.51(!TG/B#7[8SR(:E&,'@5C<!'/QR'FM'0T1&-A2^
MM>!D?5)*2+S?6GH?AO`:-@B8)SND!E&\XJ!X6#L@D1GB9'\='&!]60ZQ1JJI
ML`XSWL%\;)+P&+AI&Z!O()%2Y`H']\0@M9^IQ=M47S'!)B?!F0PU,+5&8.BO
M4F;!<*OR'N/<,!CS/,-GRY#UC$5WP<K44R5290`A`P7A?N)H:$.RGIUG\&W@
MJY^G.(M1U8>7&J(WON_)IV&LF)8ALQPZY-8+:N/H830V:CXP3Z:SUOQ3NM"?
M?^8_BQ8Y!=<55L"_A61BWE2'V+56;O-:$0>_".&"TI<%*!)6E<H(EKO.`!0@
MSB(N%F-AH%1.RWTT=,0HDUO792^H;N\B[-"OP2,(#KC7"T=Q[[3:X?Y`WJHO
MF8^T-)GFN\&H:$6QG"+!QBZJ&@)N'RZ!9[7!AH^&QOGE3>(_<W80L\>9LV`I
MH@\+R5:U(L6KV5R=M&4[B!%=M$+1#%5'!L-8ML^5CYH>687N-I>*#J5J;KD=
MQO[I4Q\6U0`PY'>&.Y&0RTIP2B2@@Y;#^=#AY@7+2)*[E\U)0M%CN%G2+>SQ
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MR"5Y^P`VMV679&',5B05:;LQ@D0.="5G)9T1*H)@!@(]K:<L=.*YC50P>"M6
MYEE/%V5#MWJ7CPC0L$R*VL!GSV<A_^A@VQ(IBQO6SM19685EL=`0F1O:[DM8
M1-3@&EU^#L/'R[5BNK:100KH\>'0/@SYIKO7_."'"!/:980*DY0GE0G^`\0D
MT!B+DDE,<TMMUB`+''"C<;SKN&5`.-J99`O#1?NIZM,"-K<JOEIS#**^Q\+L
M"CTI+PE7+D-&V=QV[\8MC[MS\J5IX%IHF[4;-DE#4/=)E2?7FQ#S6@=D]J.2
MF"U#VI=L39E$^L>+E8!1WG[HGM7>JQ07C`9?C,F?J.)K]:IXI&+5VC:_3WN!
M?59WXZM-J]ZR`/,1^*H97QB2V(FB'B9(G@TQDAWPNJ#4V8YN/]55IY+]QY+`
MH^RSFHRP\_3QT5VMVI&'-;VIZQ(.(PFZL=3H&;[S:UW$>MC\=$Q;J.F768<+
MR5M\O:5(,VG1\4YM7@O'@MD.Q#A5BVK&H"UT<$;,YYK6>0I6I^E[%!J=2&%Q
MW]9`@H\V9$,]E16#9<QV6XG(%I)$V0UU-*C#W)P-EP2I@_S0+7&!\>T2"J$K
MB,[(8$A)C@<[5@F*-I0LE"R7\'DWP$PSR%!@[S-3U*:ZD56+7V)31\P?9BFL
MO`F/84:J=M@M(,1NUI%04<["2NV4(6/$4@"KIO_!H%B]FLW$HJ_D+BW/BGP[
MY^EECI;PT6?M)P"I3C(KI6RM`K##%W9QI+H9RYI.Y#3;@(.HCM6:N5+-"_%/
MR.:#U]CFUF+:S_&^^U;`.Y_+P=ZSR45)M3+?N#C:2:CU**H8,EQ2;Z.%`H/E
MF!Q*YFD^=V\>YH:,3U8=R/!"US^T8AAK=-Z;8RBD:'0UQDI1FKZK'56:OK)4
MVK)IW0!(-/4:4FK%<#"JVBN,U#TFPY9PW6O.;['?U$\<]J9O&[Z]5IM%V#E8
M,KA=J=DTH+T;!;<C6L-4QS6TOH'(`>9G!%:VF+!<<F5)[%:3!E:%SXQQVVHZ
M=I#[*$E'2_*63('"\GR]<UM!BS`37<G7UH]UM%8?\/H7%#ZTTV>@!+'DDC>1
M?5LTH_FBA(,.TF/1,O%S0M2V@AC0;6LNZC!$\)?*K7DBDG!!GK#$US;BDDRB
M0)/<M8N>%JID^Y;%GE>CLI<F(#K#AH9W<+"D%Z"M$4EBIH4&TD;K8RJ2#)7#
MD#;N:?EP00!L[]^"OC+OUQ.QMX@!`343(S@!.OGV&*/!HI@#D'C1+0J5E)X1
MX7/35--$"Z228_UXUGQS;_4PO^7TE=WT0$]K`$[%472=@X-K9SV1M=AB<SNL
M()6:0]A*GEPU#T06H\7'H>\6CO:.;8G)0?/,9+3&C9.54N:0J4+L-Q\S&:(Z
M9>X,'/).-P\<<UO:>@C<(VJVR1?;8LV('/E?NNEF`!X1*?XU:[9TEY>\FJ&*
M\)+)AOR'=V2Q`)G1N+]12FY9!J]=>DY9KC39>)B*&ZJ4DE1CW3E9E+;T'BR/
M@W!<@\3VVIIRIR,:4\;G!T-RC,\/^BR@P)@CH;^G=<'DFML(-^7J##2*4J);
MZF!,=BF6=67]$)A63,J1^1H(U+?+N82XNX\!37_Q:7"C3K9N4NFZDNBN0]IV
M=3SBY^(::\RM9^>I8YOER3::ZR>]J!$'#D4RD?5(6-@4U2[)>%([8<Q!Y:^+
M%IT<C=\IY0(C#G9%XF7XVLXU3F)R@2'9P'T@VM;U=0$S:XWX5SF2NE/3SM?C
ME<`1GVF`2CR7>*"%Q_WP]W!LX-;,1>5BJ=I`3F^W&(H(I;&F$7?$^?1P[C1C
M<LS6I/.G8FWZ,(PS&77M97G2X><>"X`''/N,ABVAV11>&R!7,2/0PK%)HH83
MVJXCVD:O'(%JS7Z_5LQ:1V=KRN!ALQ[*0K7\I,",#P#*E1+F$MK9C4<>P'2X
MV$,QFU<^4("G*-!VB;*2/)SX5$EPNQF-;VY=(R50E8S=74G.\8:=9++UW%X.
M-3M&MMM9LDFYC`=1VQ-;0KW<4N#H%`GWR,9H5`7E_%"5H]!PS8*@)UH8D5WJ
MG0[H)N#)MJ#58:=W!)B![BAE5!"9JMN3P+P?ZNU3.P)+!27),&`I,U*69XN$
ML.ICKV;EGH-QH@],3L..OR;G(6IE?(W>(F1?4U6A0S9P=>PRUV5,P8*'5[$I
M-TALGE9HFS3SJ*0G79677?#&XO^P:2%_-<`1$Y36V%!(DX6@U=:24M9.:GVT
MZI&5TQ!8_K=ND=VNY7_OE?W_H%=V._NM6$ERZ._MLWG;DQ42,FCX]_99/^47
M\C<A3+$$B8+BO[?/6C@:?;W`]_^5[;-*_'9P2(P&A'RB^Y:[#M&>(,"M8<A&
M&-CUQN4J9)3<&\?9%;WI;3G>6T_7S=S&9N--?KZ+,6(ADL_DJ%$@KD$+]:^P
M]PZ(G%.53;T?`0MHH:`@.^]@V"A/K<3H%\A.^R:'Y<^!O]P2]#K>F]9>T?E#
MOH*_1<C=);=WEMA)W$1Y@[AMYBN!-$>>XH2*OBE8B6R)2#[F\[.ZJ8@1]]PA
M:9?N+.V3.,PT+,N:VUUZXFF*O9#02U`\I%ZMN)_N*OC0R4WA/?6:0T0#?N!>
MVTT2.I/<O,\L6HI\*;';S^I,J5W?")N=7!4U<_.;.:EPMY8$;A"CF"3WKPPH
M=M1SMJ9V%020&[2?>7"I;#*H]9KH\/_1UJ6.V3`'MQT[Y1^\3[RV-*&<(OUC
M&Z*?81;JII"&Y,C?*`COA>!8;P;>GO[O&HNHX:Y<MS;#//XQ\;>IUR=I<V+(
M;92OP_6VQ/$A9W&CH[#VP8^,TP=%@"J[(NNQ)\FMK'*LVZ2O?3IGD-V$QUG$
M-=ENXWFX&@^M5_-$O(+Z53Y;_KY?+;K8]&D2G4^LW^*>8WM4&)I*B"?M%!K3
M.<!-M9H;Z!#OP^)[>YP8X1Z,=@EYNM]37E:8D#*I?9TY`CGJY67)59:QYN(E
M3ZO!4&'C^\)A*HDL-6NZ026TY'SX@V4H^D8T=<-9QPAKUP.6X5.:VS+;VH>6
MWS;6Z2_=%_F1;`*=I[Y3]P[D*L,U.W&_[8UDRDI[3ELCQ]I<2M<GHJ)"DSG7
M1MH]9FJQLWXJGR6=`X#`G(S0!\LW?*T^$MOS6LY0JHB=#W/I:Y9I0SHN$&ZS
M\_Q,K&>G[I>A)9-?6E;X86O">^97,>Y\S^7I=_NRVGT445$"?T?WK-NI8OX5
M<;-DIQ?O=4]Q]RFMRBF<'>54P9L6WY1QMH*6#@19EG<P"!^,[BRY.P.#B96#
MMXQCDI`/^@[((/EZFK%*RX!L)M!=4FV_=#)_/^4B9=$#)-"N@0(":Q:,6/^(
M*936C@R]GG2O#?_R\%_Y.K)\U]S=9ALRCG1)\>O?1.;FO[U26<@TUZ1$7B*[
MU(1)RXUCI=@%;?=VZ.N:L@RB\2/.OOVX=TIQQ9JM]&U"GPE#%GMITC7.RA0&
M.*B#EIQ&X6`I_<DQ&VK-'+)ML=,PI'-C*S&OMU5US:YOQFLE;3E=?W7/%(01
MRF8?UA00466%*P*JO?AVR4W_=$3:WM1Y&XR85DN7)!U56FR[Y>XW"F)4H8QR
MA+<VBP\:;;)!)=K]O+_7Y%26V@[/WS@CP@W`U^$=W%F('_/Y7F4WD_78*BL3
M12W?6'[NMGL*<-&>0\CE(Q#)D\]-(=[*%:AU-?M.MTB:-[<Z8P9VX0PN23.L
MUL#9!BCLF&N#.)F&!XD4K[LBK+9:6V;@>F(C=U/Z*65UA7G(YA<$Y%Y[BP2K
MM\E+O7K`/BHH==$'E-@OZ?X_JZJL3I?V>H'@=>QB:KE[TX[L=P0([ND<1?2@
M#!4^:ZY93/KV3,^Z.^0-H[VIE4Z1M'/*7>B`I,VE;JN]"[6Z2E"T7KLE`<JY
M?-FU9&,<'O=FA$^$9C^\KJ<0R8Z^RNMH18FO>9'"E]*UWZN'+W!=SW)?6)S0
MZ'+*YT,&GYIX1/OZ2`O/O"%2`A29<45?N*@&S4O8UAHF;-WB?O?%J`QV/AT$
M$0>1V]%ET[K&(K1;O*E4$:TX%Z;B*I>'S]>S<^:%3O$M+9>L*-^1U0$RS3;H
MB,(2T<2HPJF`%Z2$UM+$;!3-;1_X0/!4TZ0O>#*E@TB'F/N;]FMYV"T_^*=0
M6&W:JS&!K@!6PB5Y#AS^]CO.U]K9O#RKEA!TV-I+=.DR'W9#"6R;;O!D*$VZ
MX4!BF[TZULZE*/'R"$<ZQZ[Z%GKFRAL^5,6]&O&K;,63"+Y/;<*3-=^STEFJ
M$S["X7KA$!%K2VD<8Q"E=W+!_4ES>"W*_PW6">J[\,OI;<4#DR:;+VH),'$R
M8,RLCRF:2L;X6LFA?3&-#Z4-D9:$W^7`3B65TY$:I7G=>_HU)K<]@EI1_+@1
M_RD<W,.=J7?$I81L1\@OXBI09)YL_T(/K+!30NOPR^NB-G9?AO7Z(EWP)G7(
M/N*8^P^[MR'U;UHNP4)B7+V*QB[0D`15Z*1>S)=H?_X=>.9_S&>11G;V?URQ
M81UU)OL:;180Q10=XVHWM$!Q1\<`/:CHY]Z,7N#SO5R/C;Y6\(BZ+FGR&"C:
M":;7NZ=$-U7S_MW1'CP[VH-ECW:+X]WBL1OXQWOWI?J2JXFNX.B)1;A<[1R)
M5W/SE`U`Y$@(C=]^<"/NRX[U!!%@$?T1C4J>QF382(.`R^*%]JTQ>R,DYJ,-
M-BR/H#89W6ENC'>YVS"I%^=9;_AL=%`D\T'>+N#$<VI!IQZQ3/9$*PG<-B'B
M"QZI?ZEC>5IV?2(W6@O`OG/6>^);_)`=7\_PR<&,ZV^Y?7IV\A*R%2\12[D+
M?59DH/ONTZ0O9O!@^M#4Q]GE9&0P^7>W^.0G_%[7WB>#\;^Z:"4(ABECLA3`
MA'+X26%]I*YX,C0]?6^]\^"KW0>'#_I_IK&^_Z>=^U\<]O_V/:>8?]NU*ZW]
MZ=B6;7SOC[C#<KX8?*57F*)+1A]<6I=QTYQV?T1G2'3Y=":XR\]YT''TF]_O
MSMX'*?UW=@[W/SL8_/%@_^"S_A\_G8*F7B'W,AZ3"QFIT;X>>I?^U$_")4X<
M(8NNN37J_8<C;OEX.L81/HR29ZA@>]5Q9%H?5WEROIO],(4.'C3H<]3(ZQSO
M>=L#CB\+6"697)VTWHOD&GP9LK6`?'\Y0@0#*WURIB?OW_+)1[=\[OB6SSV^
M[7/8[1OVTLK1<0)9-[SRQXC0D%/.ZXT,Q@6:R%/<\+J1-,1T&]+"NI2$@.H9
MP1'F]\@O41=F.1665WS?9<?VG!,0Y3E-R_I^I_NXI_H0`(?D;.#3'XH7]?[[
M=_IY[^#K?YN[[2W3!^'#MUXMX76\;E:$5,NPSU\]H;3Y"P#%SA$4"L2AU);]
MFW?A<O657=^$#0>O-TK!DI(U>\;A/?:PS.ZNV51"O%S3QJ.+'QT#6V*?,MYW
M1T<G-@J'KG4=$R4*"]7`CV19]67F:15RQE:D5#O@1=W><"91V3#=AAVTJ0'+
MMBN)H;P_&,^_/96&R2%REF+1MD,D<<EI2OQ0=K`6,(`-(R7&YSTMKVD6+7#:
MT)>1U.K9=KE,7$W66:N")\$BE1"5W`E5-88W<8-A[6-P"+;8X.G^].6A>.V5
MG[(1XF@O0@3(D4KE#9,]"JHF;$)/+H1Y5F73;6@>F*'T\3N#\9HT_X'81K>E
M)R*&;+8G\6'?6E\0E8<+1S6@&5_]O-"'K]3.X8OH,@N,Y99<(8A87?H9S_93
M:1[8DB&H.,=MUV25=D"GC=L./[>X[0MNT[13VN4X]`@P^)R61T:@=9E@C0>$
M]R4(2O&8;%MN3VL6_2VE@!DJPB%(KBOA$\_AS!N&2^N#%,7(O^J:Q<SM52YZ
M(D0I,1\;%]2YET[H4@0SBRC*<L`7SMF%T,&Y:4GQ78TYT%.[2"<$&<=9N`ZM
M&[YOI?GA4?H&.=OS3XP%=F)_+;NG>2%4.IC0S<9B:O]IS>8%JJ^WM0_V#HDP
M0L!+W4SA=?N=D2\_TP<Q+R&OYENHAD9M.B)Z^+'F6SY!/9$B/IP5^^8I/)-&
M,-P4OG#+`,JT%#LO7GY_%V;RS4>$1\E<E"==FZ0Q]!@)<AAG0X:/PN=O`.$)
MO@E[S_XW>V>V7-=QK.E7V:&`NZ$($,+>F-NV(BA2M.FV+`4%N^-$1U]@(@D;
M)!`81--7_2!]H6?1H_23]/?G4,-::V.PK&.?TSKA0P$;:Z^JRLKQSZPLD5O3
M]I0?\80(GH9$BV/^<;B$.AJQDA\1]:7`NLN78&R#=-R:*M5FJF`I-(SF:;(5
M$C!C58-%L8!L!I6KTJ+T\\22@$8/81YA'4S*QLY;!76_)-1<G<<)W:)7[%WE
MNK?L]<*$';C4E!@P$ET-P4/%BU=M9H<?DOTM:^ZW<_SY%L6D%E'R]Z2S5A?E
MA+"1T1OFF7L,2&7"N(0\%FE'*X&J:TMQ?NZ0>D;#3DB8N*UJ6]MG9*]LM)4=
M5QT$2M$(O#32:S3UX7GDV.[50HB(UL?5$Z9[HD5KHLEV@24)Y`F9G1+340PK
M%@U!MW:I>0X8!$9!NNTY3`NT[9Y0EHII=TP;Z8=I[:"^O1;TF@NE-1SA!I#J
ME[&+8PJM,N)-;)29-RG9AR]T>GCIWE!.HU5_<]>MOK/_^92F3DK+_Z_>>;SY
M?).[Q1)TTH*^1'@O)=S#![NG).+VE!%*JB$9NH8[JR@'(<S7O/9Z'..7"ZB-
M%^Z[3IK;IY??-3T]M>$"%*PJNSIYV_CPX=7Y[MKF]O;XX^VU[<U1A-_=!YY)
M-\F%6.E1B6>3M)7Y^IXJ#,[1!&LS?EOD;T8K/MC(#Y3@J;(XX@J+-0(7_*^V
MMS<?AVO2CJ.DE[/(%ATH%+/&>P"[E[SI.1H,1;+8V``N@Y?X(:QARF.('';&
M>O2AXC>WUA:;^VN;NUL-U%<"S+F]I_QZ-V*YFL\-D4<_BBBR;<C1"2`*PD5>
M%T954'VI(M!3^;%8GDM^^VLF!E<VMRK)1T3&^%=0;2-BK5PQDH3*$(Z&_X39
M-5#6A*5&#;B+A^Z3KFQNK&_6O=6LF$R6ZR`D?!T*NS<YGN8"/&QC@_O$RSDY
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M9]_2:Q%3BHXXIPB9B7QE=VP21:#XT!5Y-:]9!6OF`SL6$</``)/$2#:ME(XC
M:0DI"M'156W(XVC]Z04Q^!3[^#*LJHYR%GFFJ#'PI"W8>[%()IZ2J6^!_"-I
MB&0-]C0E:['56KI[U=W*?'MG;7=O;RQ82@1L[J[M[.XMX8XG#[,=SWENH+'8
MIX.&'0VQ")X</,DV1>XV;7^!!U'!B[6]W>VUS4(TJ>7<E?&H/NC2`4PS1A6K
MI1+Q/E6#HG(@%G`FW^."US=[H((Q]1?%/R$Y&1T:"'W("[D_KN:3<)U\3*+[
MO]+?!O6GEQ'>,->5C?6=;;.?L4P*4PQA_.'[.;H.IL7PM(*;K]!;R1#)U]>K
MF->7YV>SW^/?Z#JSR8*WY72IB&LY`FX^4#7EFH+VQ[`UYKVSML_\T+P-9]SQ
M?DGV8>ZD)EOV<!L*[F[LE>,44@91:7'W3D*FWW$/,+<R02I/H/-O2ZJ0AS<$
M5FB1Q@]9F2^JYS%F>V:TM<!3123J5%JE.,%80__ON7>T.,;XJPJ>T;/6D-\T
MR898K<I;PINU"Z@M4?%/2H4Q;02?AH$=$6@I8T\;)EBNC\$[("C"++Z48=9Q
MUW[?7VJNT>'UVU9SP@!:@U7[>/3&>1F4LLM7L[1ERVE``28H],4;L=ZT]5MB
M&G46M6:MCG.Q()BGJ8"*^!#L1-)D6>LA@M?4YGG-UY-OHB7X5]9=VHMVHK^Q
MU69YI[`Z*VLJ\C4K%N:*#:=.-^*13]5C)'94-:8%U6)/*Q!6(TQ-,I`D'C`_
M7%^J)</Y?BOG41092J?A:ZN+F<@[HV\PLGIP"=4CT&XT"%33Z?2TEKZ5P8Z0
MVMSK*@+,M'J1+'K*M#&OD=UZ'A4:,3Y%U@V,:9KA^/A*Z1,9PBH:3]=22"BQ
M")YZ5GYZW@0Q/WP_86'4_8/3.^C=T+,REZC;C<TM](3]L-BRE^CG[04FBOT5
M"DS3ES;^<SUN8I;E%8X+2J>I$BU*4:*2;%RMHA(OKZO3<9F4T?*]:T'`P<>Q
MS++T'[YOUMZL>#9V.6*"P#]LC=K8/Z&E&#/D_VNF'2*SV?")X8=^V5((LP\]
M)*6^WN[[.K`D&%.['!//LIIB)K63SDK6/S)&&;(FTMR^7G-_*%L=,,"S!GM.
MVJG8I/Q,@4[\W!"R?/:\(^E8K0<R92TW1;,0#2OM,>&8KV\KOE$0K'^5$\R?
M<?Q%/(N/78:&;`5)NK4'#T0.(0CFWJ<KUH:<5E@HQCX."W-=8N`AB54W%D6I
M4I['[I2'TO)3;@([W%QD(KO-OQ&[*]^$>Y,8.UI*A:6R'/T>2/SEV('G&3_2
M,JR/%S&$^.[R>6O'SKI9(\TE"NH=I5^]5J!!RW?FH^\T5'(W2P3@:]A%NW6!
MD^Q*"K6Z+!T;/6EJP[]880UZ@:!(`M;6^*-!8KMB7J/(D#Y8.LG*UQY;3N1J
M?;I<;;C5]$Z]4*T2L''E5FT3W8N*4S7<LXX4P8,-@MZLU)C.4I#O):B.78]8
MLQ)=?A8P%&#;WOKN+O_=6=\G9;:RN[Z+N.BO"Q>2^%$.?E]X5K<YJNWB@P<)
ML\]\$GSI17%DL?`M`WPJ;O@`<X-HI(SET\LQ-&\?BG@&:MO@(B"CAQ+=1`5W
M`6U]([>^!`?SG0Y=(X-Y<F(!H_;7G5W+<W^P^\8+7/RLT8IR%*K%U]Z3&3UO
MZ@SYB*H6';+@3HSS"^NTE`?=.S1/WTWDBPBG22GO;@OL>/!R[UOD`0/%$C#$
M<8ZZ\]_W-FN$6_UWVX4(=PM9Y+XJ"<,MXVQ4FC-"&5-!^MV3%XF@*9+C1(3:
M)2^56!L(8BVI2GR$5/Y8V1N&'2_'YI/98/]%!HE7<*O$M\*KF5YM^6;LQACQ
M.D3$\%Q=P'DXFS_A[4],SL&25"IQ19#BL,[U)0<'9*O$0>T8[>I=C4Q]\8CR
M*USNFBE#C[8QN(?)FP@'.V)JSF9:E7?V,F?-FH%T\/TY:L>>>)Y4/-?.`SQY
M'&*9>3L:J,,M)2H1;<41C$IG5(6;EF5VW?NFR=>;_2(-.+'2MD@"OO<8+F^4
MC<)@\][2"-:T+DMCDVL924M9/=T(Z^7AV<D3G@_HS;#F_+/!986V0A]ZM6>A
MQ^,X`T61F>U)%A`Z3K_@<-,5_G!OF1D:H6(8/T(.+N#61K![L/$U[83=A=%F
MDJNUCNCP!`RFU+;*2PQLN;RE*^DQ'P>^#QD4I;*1^F)E#U>W$4$K2>>L:-,6
M;Z,BV$P'<([OFJZ!6#XW]XRBE;G.A]4*[&J(NTTR5'MK46T'TYW77ST(:5Y8
M'ZPOE-*KRQ^D"`SAQ+BT;*+(!P<*TMI+AJ[;`]\<N!T2T'HIN%+LR//A(8<M
M)?/%6".C^_+][,7IT940'3TP2/E`K#"XAR@R#-6')^PYXJ`T6^ZQ\:\;8>WQ
M,[>#:JHM1WSOA^\C_]<89BG$;B,&UFES!Q>_)='#3'#.Z">WO5MN>W_XOFY6
MLW03V$<M[Z"AV[3QW=U9WZV4C&P,&BV7[*=8V/M_@`T>VK?GM7B-`;2_Y?3B
MJ[B_]YD:`Q#AR=^-DKYO\C:OY>G8;?(&RH[%-]HW#^?04,C("Q"_X5_.,X52
M&2\I0B13AK:QLTBK]I1^Y)2-N!>=()NAO;*S?1*6.$2)<@[\P3Y$@^:5%?I]
MOKFQMKO8#A;.B$R1"\I3YZ_<YLSAB\5^YA(H1+K;_,HAT%R8TSL]R[MB^F[#
M/2B%KCHB+P3!P\7!'_U7N07$DUYAY>=]S-_FY)&=,HRG0J]V'_HE<=4K0S5I
M1H8Z.W4P\TL4"^>.T7].TD)M<Y(S&HU%R"`6_%F>;$?>?>#HI*XHT4E/I^#D
MJX^*W]/7;KSXC?6]H9)%P<$TQAE"."-[X$J>>/?U[16;@4>APK+2)3GT;%TE
MI:SOH8=Z3);HKIMN$_;'J^J7ZPP,??(I0*ZXPXHF1W)I()W9W@_*6EQ;V2`T
M%A)`(:..'?,3._2:ND7XCF_@;4;UMB?55&&*]R3_TX`B11\Z%.R)$+YMWVF*
M!I1PZ19Q=*HO^^*%U>)EX1(*A2TM)4V4]$13^BMNEIT)T1S+(W]R>;R]-!<I
M^UI/6.N1K?K2#DI(NM-D69*U]Y94<W5N5U!()&TZ&YM1Y3&E'V(^S@4J4(8S
M6B^DN-N!-#YKPCR3J<Q4(LOL+BKM(`<U3KM`%BG)%/U_G`I:K&ULS]=VMMKJ
M$JVOG5"[A>NS+TYO/NC*-::U8QX5.[-A-'EW2$'([;O[':3&]T%^`7-"''IB
M]#K`*6J$K,J1+\S7=L$EYK5&@C=NKNWNHUEW-H!K;RU>TI+N.:^I1_XI*]C>
MVE[;WRTA-_/?(E=+'I=:E^#XU';1N&"2,M%_/:J.ERA]1[GQLV'CH/9+%>#`
M2K-7`A#)=3VCM<-L]>6K9Y^:1-]A)4:R]$!][GOY:'T.KP+\;^UNM1Y2RYR]
MT_I0G3Y?W]EJO4+#"L0-O%I^JI+Z87(-+="?8/Z&(8NB10?*X/W[J?V8Q']R
MM2^5IPZ&C];MQ"%+H9$)E1YF))5M_(KYMVLF*LI=O+S.9[*M]^C6/L]#*&;X
M80SES#!X_%>'+>*O4U[1`0Q6'9E[PTV_1LQ,P7>'9^=6[2!_M!A1K+C,Z8V1
MS]V0UG?(9>+WS]?V=S;6YCN9+7=*W#L#`217`H^Z8<V\]S!V:FZE!VO&7])E
M6+%I:(M"ZA^M<&(+^^+]*B5>O(64A3R)_K$%-CN4&BUJF))>;'=0#=?%51"Z
M78JBQ5^D:'L5T+U+;;U&%M'&Q/DF><RG-CVP^U,=23/38\IT]9AAI4#N':BT
M5RB*>@S6/-B\;3G`_%.:M^2B4?2R@*=VUQ:["^`IXJ+2>=6]5`(`W/QT5+-_
MV$=\3]V`9;5<][J=R@)UCK,PGBX6D>];7%O;B/B.N=+-^-8GA>H?FQ8"X25F
MU?W%V3)?>GA1[1*G_5A8?#6U/EKO!-N%0O%U3;-WA,4J1=LDM(>M]A!@??9;
MHD^&D-DID8,9`[U*,-';4_"256@<?3UU[XAB)LX]VI^!4R1(G+KP-<??-&XZ
M]C7\J9NGUP.K/G*V#W,/@I,>[1[,U[:W-M?VNPK>'^\=4($7]02V22.71\JZ
MUO2WBE_N0X$T$KBV_!`*PD\05N``.V!@<]QK",_<<SS@P`K$EXX7J8\AX#%H
MLO*U-4X:')B]^=S65'MYI7IV+S1*A1`.I,P*P`D6'7&PTR$\[1Q;^VCUO9[\
M-78KO%C/F\/6AREWNGWG\ZI(AF`6YU.:`HQ.9G^9?:FRFF'V\0R^'RT^'_NN
MM$`:/K*]^8L?OG_RP_<[N[\8_NE5Z;I$N0!23?LK5:0,'P.;]%>0+QV]@Y,*
M^<?%Z(]E%5*'(S[;60<HLJ,2PQ%WEWS\P_<3C^LT].=EI"QFF?U;I=<]YXFO
MWAS]^I,7+\`\^+]//OO\5U<O.)2I=,6O/WD&ED1IK3Y]?0@^^]$_7NB#Z^.W
MQ,_^`0=2+Z[TX6=7W]B$Z)<GGGOF4;!5BKV77JL5.6@P93N:>A5Y`@)<<+8%
MGEA=P`G)<767M'`4A8]?<NK^T*WZA091VZ.)/3W^-&",?Q(MZC1PXD"FHC(_
M'8S('^'JQ#')YGCF=^0';<5YER,%JP*40HF+8*_/.4!(HS3I&"YUH0F/B@QF
M52@^E8F3?*>\8!3*E[Q>SL"_]AO1/XNDA"DR@_9D1')+R]FZCQS9L!3<]>UK
MDD6Z9))V:YJ%L']+:NK&]/IN=UWR/5J`^IHIT\0"KL4E3#X21/K<KT6EY2'G
MGFF:PW__!@`F97S.(4TR#&(<<D`T!F.\MC.L_I`Z[;J9P:P_WUUX)/8#-$UO
MM\/ARSC,E,<+M6RS<%O*XU51'O\D+K/6W&RSMLFN_#V0TZ667])KYLOK3X`]
M.I3B'GJ8`%?PL>=Z2)IF+<%!3B^AP7@O^9=W0/C4L'+5$]I`\O@.!>YC%O9J
MN\[Y`,O(6!37`0.X'OP7()ZSO'&#JLMMW2**KZ7T*30$MBP:F?+&](`YZ6EQ
MN/SKL'Q&81B\'(ET:,T(RV;<`,"9=O<(+:6C<J_&+V.-"1P[9.!;M2S]RV[5
MS1CU(>C3I2V:JS%U%(8W+S/NR:X[9<#&@K$_35=.`O+T8N6&:I:MO;>+`WJ!
M[Y<43CRZW)FT2N;MU7OK+HH/`I2/YUN0=Q4)U/Y]2N`K'6UC6V(^Q'B6W9_-
MDM!<2QQ<-]$<M]@5I]-P+B%*.6%J-0'&T4BA:8;<8&PRT+)'39@B)9S`O!PL
M93>\KP&+YGM'IS)PCI_+-7(T7FTY:5(P]!$.6,EK2[46+XH4`,VPKJPAI[F1
M62DD-2CWIHN@E,WA7,ZW?R3G1<T?S90_FH90=G?DCWUK*8SA'/Y']F4<_N&I
M=/B;D2?U9206?OC^&Z8R^G-YW9*OO\H+3X?#/8LF$KH&O.J1>D_%ZK^AS,9-
MGI]F:FGX/C0Z&#.]+H=_^!/]2$?3QJT7`I#'?H??^;KVI*03W3#COCE\_#=J
MA7@ZX>E&3F;X_.KVSM[:_L;.\/,7;=X',=8!F.$SJV#2>QO;PX_OGO'6\/'1
MFL;L$QLO-V;X[3\9>YL)K\KFPKH##Q\-Y-_+#RQ[),;FAX7)=:K,2#T$7:CY
M75M`HHVM?1MD;V=S;;Z[8\=?(TA'^V+N2_5\7WYH50LHG#_3$J&>]^S$*Y6]
M5[`A4;/SPTLK4I.0YK2$(:&IJ-C6>8U2,5<.3.9;I+S:UUM"U;)+]7#NQOIN
M/9W)*=]Y_F9+7-G:M8J_L.83].J7.*E;,G=:>JZ:IIQJ<CM4@\N'M5S/RGQW
MG2+_'[Y7P:F?=J;29;\![`>SLT29@WG$:2Z8M9@J1T_R$5!X@FABV9ZTNX3V
ME93SK?7MI!YEK]OK6_F;TW+!.>+]!76R*-#2\L7-A<^I.>\RVCGWYEV#WS>O
ME<UZ[(F);.UQMH^4A%A\96]W?VUC`>;73V(Y^B([Y]/KVJ?`YA7`D+A12\D[
MSRUTP((J,Q2S[5E0LX"QKTOY2'ZI,9EI)GE(D.'*?']])VF9E1":5PJ$B[O9
MY@*?>#_QFKDOW%<]LEX47E_<.A@[;O?_TD\#'=`,I:E,65YE0J>@^I73$82"
M0C4U8T[:#!0841ZK/@.W?==2,6'210^B6JO3)SJR](,=O(!\W%ET8A$//UHA
MF]!P)=`=P6MN7^8#"P1U_`A'SID+CN`@('/AZ_AWTA[GM-,Y_CAJ%S.FD-13
MV_!)[''Q'@?'=$ZS5U9*4SJOU/G)U5/OI]4\,L:)WT_]<`$K=O=DT!ISW!;C
M>3:\&;UWY(:\"%)9<&/%Q/`%I2PX2R(*JK6V_!E:CV]5)#C5+>BN+[TBOK$#
MRA*`-K+T]CHF#L.!OKZZ5'^=DZM;VA9@=<]N)A]K.VB,7@'MKX8?_L:.2B[?
MA>'S<E:\S,<*"E1],7QD=9]>%/N[HX]1-YN[HX__0*#_\.&GMK5AD]'>?J-2
M:/`@4TL0C8A@)(.K%#:,_975S?V1#[.<6,T<ANN^<X&?%2;_.+HN1(*4:JWH
M,@"'\0Z$NK,&2H66"'9*4H90UNH-?4/`363`30:ZI.PO"KGYC.8=(/4\2G1!
MA*\6_`2:BL1*PS`)KWWAC*NS40YJJ:$'C2'6*(MXCW^N>EI<'P^F)*>DLEX;
MKL;3N/#7NE^$KUHK+`\S7`-QS/V2.F"`A9,S5?">PEO7OXS+V^,-J:U"JJW9
MIUV\8G/1V^V-$V\RF]=*I;]:LQN\%%R0`F$TGSVM5JH>0\](!M6/("!JPIN]
M1:$%1H3R8].F(O[YX8=?VJA^7;L^$@)I?>741>B&+G,Z=-#LLZE$J:"RBT/U
MI8W3/MVQ>318M\W#-Y"]-ONB2SG,!ZQHVC5&#@+KTVGB2CLUQS:/+B[^8@JQ
M6`D#':JI@/K5EOFRM!16(,"(ZAW'6R?X5W^29Z7%-9-^30AI;TPI\+L^9)<8
M=5J%:M+4DP]TI3O1PU9G:>URAB<V6$=^;9J9(U]//IEK<4V\].WP,.1]C37+
MA//):25&V6.)A2IJ-/="3DCB;>C2OLM%J,2,?9T@YLCQ[AVZ6;2>CUQODE:G
M5,T`IN,P)A:,TKM)M)'86R\=76SZPP<V-AO75WZ).R.F@BSQCV(FB!0]!4D3
M[H:LU>9GQAN<&LO4_H+CO(,C#-)+=2'7_4*TA;E/+&%EL5-;`X6[\V-F,E3W
MDN9PF9IIF6"/Z*L-K]/K'`T[E1YRZ<ZAT'FX(_&6D)-C.QAA3P^'`Q]''[X]
MN[2=,4ZN5XW&9:9B>:^8&'Z[Z56"CNIYJ-Q?`!-QM*\&BM!W^)X_?DO!I/NB
ML!2BPC+4\E52+(8P6G6J0ZI@^\EB@PX?['WF+D`P'(KWC(69,M7QWY*X/H+D
MJ?0F(##M^D;3_`O9(;PM(9F+MJ.LLAZP==,X3/K1)AZ*-^=NVA&CR=@AXH=O
M#L%W;J:U*23L#O(-!(7SD1G5E`&C[I5-+VE@_-]#1GS/$1AIQJAU*2]^$B=]
MGF23'3NU7HTYO>+8'A!X#HW0A4<8]*EY]+88\RI[)NPQ5I4.!M!<+0:;>7CD
M]\0$2T*40X('B@6M&)XLGI5[B@&K`N"7YOR-\:_OM-1OWWD3>W.B*/+&78:1
M?HM5R2+V\Q7AK,D$NUV"1I$W56K1P)I;78>H,?R*M3"P%JK5-IM(*5;!1+`O
MKKKU?I&U69V,L+QE._*DTR<36IM*+N<>[UW2S<SC(1-"8WZ]_HCK!?&/R-J=
M,KY"0?LB0D7]F]K30$=S"_]V>J5+6/"G5&$R=">NJP.J*&M$VP-;"=[<,5OL
M?G]9'\Z:A#@C].[EA4<#O&\\SVSWJ0A39E%>DQUYT[(Z%2E;P?%F'$)1VK)-
M8?;"KU!`BUBR^`=&A7\$GF;*%K7QI=!+MH\W9II\.`TUU.NK'(S;FH_[^>^/
M[D/PF)"7PKBKQLYX6#%4T&7DZUL,LC<<\_G4MI6#\>-`9F^BT^+V?*+-8G"#
M&V/P4\,=C,#UW/WX]9M;(YCV5?IA;F$G8])5^K0M1FM;72Q&\/)![>6'9D>5
MGF07VR%E5C=W]X>?+?\V=0/NT9L/59<X?`.P]VB%[/MHI-6]K<W1=[?6]O9'
M*_H:IJ8D@4#A4!`(>>O3=Q.$W1OMT9=VS"VJ/X\;A&TX[HM:@%,7)B5T.3P-
MZ.V#JIX;OFEU>[2H9^9=N'=V;]S_LB!,'FY?GWZVNHS?GZ(?I[1*=?NDA.%+
M&>0H9&!-KAP[]%'"&Z-@11ZC#+XH7;Y#F0X)PH(L<D%)IM\.$"6G)0V(\9-F
MD,V,1WN[_!T-1][Y!N!`G\70RICK7'2R*TN'ZN1>V1]&T_G2*;IDP4\M&ASC
MC^9`XI5M4A/IULUAX'NV@W+#`2S>>#EA9$N7SK@HZ?7A=V``N@22?/(@_C,G
MNAX*;VR95-<(QSY7^NS-6[R=&@='E!#0(TX*WHF3T$(2F:"EMC)F^'Y9](TG
MF*X6*Y\T\N4*D71-S&%!4,UW,5-MILV7WEE*Y:IQAS7#=A%+R3'&%6K[[89R
MR;A5+>#B10.NG*3\EPFJ8-[X0SB_FI?8.*^CH]BE@4U#A,=@\0N$25_U$.>!
M^'?OY7EQ%U5VC9M,E6NIOF,$4A)XI#@X/'0.JQ#UN%]R)TG&6(1Y7X5B*)OV
M=4L7GS"#N<[B'M4VV<FX#%JZO:HW<7LNPVJ=.I4WM7TLJ`'=$9_46%;D$(Q#
M!0EA`\<+.,5&9O+F[7A##@;\90Y9!G"26?<9FBG0'H&B"KRI*THA./`R%W$-
MS8G"E>9(XNE?J?<+@</U*TQSBZC2T&02#O-71JS#>S>"6>+MQ`KO32<W[Z8\
MVZHW3/YME&GM:*SN",1)IR;,:^NR`/".5I]`@IA;A64(KDY*V`04R4)H\C"9
MT_.9CISJWQL<]B559K/?9_`TM#TX5C=7*L"S<VD:^E6P[E.OJQ`W+T\[[:[/
M[A^%FIN;Z5M;OO9[&+(5SK#M:`$/'M"=5:H04_<=8C?[EAK]M[-O"1!?X.G1
M%O/XHO%P5)O^^H*;1*!K5@JSC^<7WB$=RP//7E`DIE-HZC%U='%B/'1U>'F*
M*!TK#$"=H(0M>6-5,5?KT=A5(5*BT@R@OA'EW4]@#\`%'+33*^;*/O(P&L_.
MO[&E7"SQP_?[NOO#MZDI)CM3S>K?I.Q__<G<"EV/:5)K2NW=*1\-2E\/J/RZ
MGOV!"P->T;;I_;`$UA[/:M?G=8**6)C@EU&W.)K%3S0#@]D@VJ@K=0,.]<HX
MRB1^7)-A*/Y3=1(.6>RKS1J=YTC^C:!NP]JJ!%:I:Y4^VK*AA;PC$PE3Z+#1
MTG>@/[V=&D$Y8UAG(I8-'U+MJL2C]MY5CI2DC)G%:"I-U2CG4B&HG4/%Y:XW
MGW+FQ.M<P06>Y"0YP:&$C`Z5`;PID(@>5NY*F`,[;78W]D>*Z^6XUQ"SNV.=
M"#]I$JX,3;_1HCKFWQ"M9R#4'M[?&;"&9+2G7X/0))!IEAQ]4I))#70D$KEE
ME9]7LL^#)_BJ:(N5<#0-"[,W6KC'005E->IKS)O&;1*PR6H?B$1P(1E]3SC7
M'C@.*;F1W[T8S0.%3-^MW5&0^@U6@ANM>%_N]]">K.XL1F'L0^8P"@E!*K;&
M$?%#7C6:]0O/"J)Q!Y.7!X$W;;W[;DN'!Z=Z:5<L8L-)(ZIM&<3\\)V0]&<#
M`U`XBJ\M@VGE%."D9E,H;RW]$CWT861U!@*SDU61O5%X3RDY#$RU`ZZQLJSB
MB5I[:LKBK>XYL1&:5S"8U(`U6Y/EP5Y*NN512?P']O8F6Z%_!!,\OU;+)`SF
MJ?>L=GD792@[*O=;X`6B'I*FX?VZ];::G.PC<$NIA@WIIT7S4/,E%E7K.[FP
M_"J+UK1>GUV!T7R#`\Y)9ZJW^8Y.")"AX%\F((.>*QNMR0?_O__[_SP3CGF%
MA3M]-WNFDZ_?7%U0%O9N78UV_V!GT(Q<U-4U2R`7JRGDX#XFN@-50VGOJ7EV
M[_&ULX^E/`K,<E3#>H_\N,QKCW)JWD54WU4`AXI&"0\J=#-=1T?@/&#:?U->
M")IK>8+2>QA]RD-1O1>^<`1VQG)DDJV02G3\$504$>4]CCE$"169&N.RE;V&
M5V"/OE_VR2E.MDY3^"VYK328H=)FD]:'Z_DA=GR"C1^TY4/%=<`N-Q+64SJY
M6HV8;U7AZM+*GI6<2)5M],PQL@0Q2F"+EF";B218&SQ[]I[C9EQ>0M'/TOU3
M4*8"-TNM8`"(`D^D,JCCOKHX\N1_]O8M\^;\"A8X1)`0&;6AX@JXNYEHGOVS
M.-'BPS+/J#X4QS\J4AX9D&<4=U,]#UZB=@6BQ>^#SYZFYAMA1@>*&K\@??&7
M.P(.A.CO>3<GLTF@E`L>UF8ON=AAR`*X':GE+;`<>`SRVB$_/A+DA%>&*TQ)
MJKK=ZOXGAYZMQL>.\XG@39Q@!,.'XKH(FAUEX8N8_JO?/.>R"8]U7)43?7`Q
MEU2160+8+-K<F6WH01PX!^8\17M]G#U_^NJ`8Q=QV07QC0+[=^1*`)!)CZM6
MY_#J#0C"L^=S+SY^]GS3V%Z3O:37+M;(M#!A4-J9+Y[0N.<<@WJN5GE8VT'=
MB4F8%\WD*+RF):M7;D[82?'0&5?>\`#-@Y*)B,!UH:83^N(M[1<I9_\OA^\N
M?SG[G?_*3G,2P_@0>/YWOWO^S#>?'>!G>HHHC8@SK+23H9JQ,=GSR;.%>M9'
M-4^PS$_EM9MX2KODP3XTO9)$HQ8^TV8B"+XZ&6RD6%J"+5W9W.]:L0I?O)1:
M,&LO:2^W'*WL-J;67<Z"R^$+I.N)UB@$0AV@?!IH1#/#8FA_&U02FO8PKVRJ
M,F919_3A$.\?)0Y68>>"W5OZ+6;PR;?'%S<W3UY=`*%?T#&*$V]7MYCKE_2>
MYP2,...::W'-,Y_O[])2TRE:#"9&'I+?1F^^[=DJAR316&S&?'-PEP<ZD/O;
MWEB3;/@US!K$7-FFW6!);-]>8FLP(N&CNN5),?2;-D6%ATCP$6"?(NE"YG5-
MUE1)JED_Z,*&X=)<V]1DET.:13.7640G3PVS&^\(8-M&+L;89V^,31$J!>[/
M58+YU+?`M.CJRS\\AU^=?)#"BKS"%!%-T)3IJ<XJ:T@`1%D7II83,0F5#(W4
M2J_EO-`A*1L]3I"0:N=6MELN1":+1R;.?7-[?FBIU,FQJN.:FW/M;!RR@N:@
M@]?Y*>S"_KZ&RR0IY'^#5KS[-$"4X@:V>I/)]!&]Q$<U##AUN,C\61MO6*/F
MATMX>'((^N!G*%+;JO-8(\"!Q^/43C'?R07-0$^YIOL-PUQ=?`P`V*S>Q]F;
M<VSUN9_7,,=%PPI)UON]^E\K!9]BHKKGPO[P[@(2W'(36&=`FMD/+1<&/KU%
MB;OL^9OW*JS,NGT-=T<,/M\J/9Q@K*(\I!RM?5!&^06='X[F=VPL"92F#"U7
M>-UO8XM%919!K#(WI\W!X5].3]2VT^']EA>F&3!M*%W"J[O[T]G0T_=O!*AA
M.A=?&#&?/=_=I\6X"[%X\N;#Q2S,YO7M%4"+SD;#")3X<*6*S/V&?+_(!"I?
M)>CW],DD_R<=#)M,HZR>-V?OWG&N4^VJA5;P9NLJQ;&38P!-A2P>YA3JKLV"
MLA8;4R#(V0K21PBD>9ZI666^4#Q5]<++C>0@V[X_XGCL;&7XN$V9SVII[8>+
MJ_.3#QR-!.SPF$3+"1)4[:GWH\2$+\7,M9%(8."H'JK-"1YN;D^(7`]X/M6+
MZ6SB>]0*;@ITMFBXXYJ*O]UBRX@RS<D&3C4U$>O)\SJX]5@W7Q9GK2B0D>]-
M'<TM%2/%)'C5DA83Y4S=@/`VY&S)!F<F!8)BKS&)F@A,"RS-C<HZ4"KBF2%O
M7U>0`7A,<W$406WRRR;]G7:BN)^#:Z.6&.5)T[&ULU</+(F3FZF/K(='>F5!
MC<5XD+Y.&_:/5M#!D+8%P0ZIF=NJG_79"^^(V-N2>PR<,^]F,:DM@42O@77[
M`Z;Q[>PI<0)^FJ6$BK$;*=U6#NH=NY*F9#9IS#O5;!JOIAF4!QT6G@I&C0)C
M7:L6%?I&)\459T@LRSD'<E+B_?3:&A_A4"(8WH;U`D#67:#K3FPMBX[3!.R"
M2))37/*E8L/N65(@+D7U<'C8DOK30(IZB:&/9+)K!6NO9$RSQ]*L;006R3''
M)*V$GPV*WFA2#3Z8%!F(`C%ZNSW$\^46%((%[5%P76P/,M?20_OB>JK93>D,
M%(OI:X/;4FFELJ_O>@^`I415V1O=%J%1H117TK4&HME9]V+D5M6,EX\FH$W8
M`X>RR[1BM%*9D+,9+%V68LA>%N+5B'.)$FU\SZHS>D()QO1BC8"1RH.8)Q8B
M.B3P@^_4D-B$F(B(AZZQ"N?L8'&QC+A$H2W@*N*5E]/T+1USF1WOR9>R$B\R
M(A_;91MGAWB(<+E!,_0X^)2?C@]OB>IX*Q/PF1JSVX8Q4UQF#[2,W$[C2]ZL
MW$^1RG8DVU_]8X;M@-FFB1P2GS$9>9G$E5`5_A%DBXC;T7P<@\#*^)`V>'4!
MK=2AYFQ=I1N+K5MB?L*-(4#-5MS"NB_2D9`V40,VT3=F;-K!@`Q#A86;$2\H
M!D8J&OO"=ZK\0IQE#L/0MW[ZFD`YF[R4`M)&6`S;\RR;IA?&P*K@7`?V%J`A
ML)R'(Q"-4MLJT:0U"0@WH;8`@EXOP#U6W*NRX3;@#:\K72DU0PC*\A<-TN`\
MKBO,.[E'W^G)#ML?#%.UK+2;=N1AZFVB*(IEWTV'XN$7S3G<W:*FB554,6%2
MZ:*6K7<X"_7^FEHO]%EO8!"1^AU?"(H9#KK$112^M'JZ_F:==M2NU.T,_&M:
M@%&E!TW*AAH-5'-MN([>D^J?]>G7&\H0Q'<IMJG]6Z^NGW*^H)VZ>W]^=DV,
M$CW:M"JKR,[E(D=^DJ$1`N>G)J+6M&XOGSA@(I-1>2RV>V1YO&%@:!/%F-;H
MI+%NBZTG5O43:%%&.T57>/0K0;6^3<@KF))8OYEH)ZVBTV/<_4>M+TE\+Q,;
MDE8BX(P.&DE:#BB-O2K,G$=?T"]%,F=2&.1.'Z[9@+0ED'!0"=D<RV^\H]C2
M$NT]&"7`@$[DCR=.Y^2,A$8T)#M!DZ(A.XBA4S&LP$-C*Z.QIO"X)E)$B_[X
M3WU*H6E$QR-ZO6SN\YF`&_3B&M$1"FLS4`;%.5L&\0_W,UG<7%D_%-F*_[VL
M13Q>TL^"91/);:&8F*@"B.@X]E%G,$Q*22:W$%WJ%5SLH%.DA/!H_AS@VK7N
M;A+D798[U*C"%P=ZLJBZ\#>)>`M@Z(B3Z3E!US@JR<^F5CBC,(]FLX7QE;>Z
M4O&MG"Z`8]L`U`'M@>VP[:E=!@DB(L8&A*S.)QUS%_&VD!;SNUNB%X`YQ>L9
M6D2PMHX@`E5G;74-RY<X.8RU&6-Y-)TNHB>W<G-SM>+<UV=_#;G^RWNUCPMW
MVC+GK$4FV8D@USKF!\&L=L:<<:;I]2*\)L&68`QROF=OW@IVT+%HU40Z3+>Z
M%9,T\Q0PH#5M,:6?Q;\B45*B42&=%.+"I``/,H+4KG%6HJ3)Z@&]HEU:X>Z]
M%_V%*@*5OYW=<+V#6)<9:(K\]^S=T2T7>[D;*YHNY<MBZ3'.8A![44B'19M\
M4Z;%1>,.KV1ME!=I\3`<VI&(2"2FE$R3P-CLO3T6VZ2WV.S,7+D5_PV%'+"C
MUAL_0I0`Q]*=@R\*,A9;GSR7--))NU)E:`R%"AAG#UU=6-<12_\ESHR4OV`&
M%F?E9SF?8X[@@QB*F#%&OT!V=6I#*X1EK7<XF.3)KMT&_Q'C\_6\D@2W:)3:
MF421%@/?=V710I`P[V6+CY8P3!"D'5MC*2N+K?%+VD]X2Y/S2+#U/HP*0BX!
M5EO5%3L=6ES.JD*=0OA*:>,+U^"MV!I%^5:\IY*:27<`4:^HT!<<HMW.--F(
MCP\:S3!4]-*;]>1JJ#H/FAF$AA<H,O(<;524ML=BY@:\<=LI'Q"M6#1>KLD$
M&-'++^BE<<=BKTT>#A34S1L*R<^0@6)#VP<[WXS</!0R2-Z30@\]+$GV8S^I
MGL+.6,!GYR2\HAJ\@EI(N^0C%1@>`'=K%2."-Y-Z$I>SY!YU,VD,7'"D``W=
M"@R!]+=8RL0E/$.'<!&X46"FK!VL]6:8M<ND@*'/=\I(#Z(V*^F\QEQ'I^^E
MB*88F,G(2B)J_QI`*I-9LJ[$4*OR@;(34$/YNI;<RE]:\5ZJ429#Y+/5*7E`
MN^)$%CHG3J0Q4)3IZI2`$XIB#X^LS'XI2J7;"PQJDJHM?4R$1;505+)V>GL:
M\MXUNL4L4Q@C9+-5#3JL6XCE("T1*2\=J'>?:&*%#]HX=_CY`+-XR.I_0+:L
M!-P+6BK8^9Q4UH5DDB>F5(9NM\Z_?Z=L:.HAJ;97YOB93)NW!N;%A*B^9C9_
MOD`U5!K*<3F[N<%=@*&B[MRKF[AZ0`M071'Z@0'T&X>1WM[(%=9LB6A4HXZ^
M`7VTKJ"JAT,I6=C9*!7L]%?C)D*LF6H[7J3FWKQ)E<X.?GO=@,^T3E"AV!%O
M;<V>36QH/9489$=&,#L7)N#\D?P`J+%L;1IL9O*@&?#2;G3/09HNUV!&>H4[
M].R&AE8O&\<=B3M$L0K2%H2MB;+NW.*6OUQ=64@R`""VJ\-AI.D*0'-GI/.*
MGDP)N[L`T5Y&U0ON-E(A^2",."?=2RE$X_$9!0Q(#X`>!S#8H1UTM-`IF(.A
M:'/8-7A(/:W=O0?F,.1_`MU0-E;\FY6'-:0RK:&HT%B'9;XCI2+`KXR4PS]H
M22_?0QL*LHY@;PA'$:$8X%D$Q7V<XB'F$_#*D'OTYQU6[5NER'AM;EVK+"2H
M$IDLK@F)4BGC4]I3@EX*<N216[7'1%P=`,4KB6*=-JFZ%B4[:[.O.!5Q3$7Z
M[PXO#PF`O[437_^=XZV'QADO<40.1[NZQ#=/UN,UL9!:];"DZ&$8@C2D[`T:
M7+8\KEGA2K62EA<ETJJ4F.E:S31W^X?2GZU\GA"!GIYW@0WOG'1R`U-`[MB>
ME<5&4QZ@>2Q+O:LU6=(H$WB.YKI73TKW2(D_69]:"284'5C<V$/CU>HT;%++
M&^R^<T5/PPFG(`D50!S1)4M!5J3U.H<AD)>[$IG]8%-NV70",O=A''PWBR^Z
M2(Y=B6J^(['S<RK2HD;'QK1-7F/C4B^#<C/!:O(P8\]Q#V`,JE+QVEJ%@RYU
M)FK$606IB@VJMUH9IV*OK46H7WY8I&&G&T:1!7-\QYWH>#/(85L;V$49DCAW
MG3GL2_&DJJ9_]=G-YVVG^H-65RO'A#UW%ZTXA0]2T9*_*1;_B2,/;=70L8\M
MZ.7"%)*%I%*I*>8FWVY=>+Q^<>11)=)ZE[SK0!<O1UOPKO2X_H["A9@J3E0)
M4`WF8M/Q"JT=J"4A4U&FEQK3+ZZV%Y'A$L?M15T"F+:4ZR@+\.JB/-"D"8F8
M;V!7"/25TA9QER\\H&(&2BSAHQ+HU5*]N_++>!4Z4Z!4//"JW:?"90W'1BM!
M`.<J[M6!1"2`.(),]?7MI?)UB=:6:0AKM:^-/&$^#_2<E55W7*S=9&_T:ZL7
MRH.]OA_ZZG#&CZ]W(,@D1FDY^`$E#FE8!8$]IL:A+*R/&<RQ5"<)=_0R-S\,
M,CO75333!Z,4;Q=!:EWYNL7NW;G>81Q98\]V;S2NWOK,O5%CW]&VZX'"'7?L
M[O-;ZV6`CTMBLGDKW$`,1'V\S2D<@W86,;</2I:='V(R5&MIH2,<UUQQ7$35
M$R]P<@U`4`9_QMHPA#1Z76U$2QY.>K0ZW`GTQN%L:]'1<V0'8G%:UMT!TD0O
M[R0O5"S%2QE""!RF,?\/W^.PG`/FXDDNYDT#2]%[9;_F8/NP*P_+]+E=6B($
MCM4,B*W+R2]+)FW"76$L.-K15;JT.JVZ5IDA8QB_I<#T;APBU6A^@E31O-P*
MIG`8)SKG.FIJ,`>Y3B7CCB_H$((RRK.EX8\.S?%4?+AEVLIC4FA9NU4:[;@E
M0`Z[:.N9.T?X/*J#74I0-Q7,#:F]-)@<SO/E(`&^Z"5B$/5=PQ?LLR69'AW\
M:96)XN--N)7#TI9\%O57H#HEJ5;36V'E[=F01R.E%%N&C:=V8"VZ>&2JA'C'
M[#>FD[#80"#M)J>I=?Q,0C@X\(IJ4^U#W!1N/^XBQ.I:@,SS7^Z*>GM&GY4N
M/6:W:/QG"U+AC/1;>IXP]8<#<T?8NC/(MZ6;UH6M^X.8,L.ER;#5!5Z[V"6B
M38XY]B2<BD)40_[D!EI`9HZ^-A,T0)NZ:TRS9`<)M0>Q]F20UL?%.\/X_'%Q
M<4BI%%!*@X2D"W^#W^'D>R)GMS6=2(A=,Y!PK6%TB=WH>A>'=X5P%*W)D)I9
MF%RC7?5`D`8_,O4-P8).W6OB_O/FP*LB;]-[5%/AQ<\1M$+`?Y=BWC].X)N/
MC6:/3NG>Q825/WL2&1//E8D/ID-:];)*;G0YP<[^?Q;6NE[RBOE'Q;7M%_]>
M',MDM"34HT/20_/I_VDBQJ9@R;T^._9HOD&3`#):C2*,GSJP7%I&;[M$;-.6
M+5VV12QMF%*``]3_TFPFP?>_?@R:?D/Z[Z-8-*),8.(F@NABT</98K^+F/Z>
M3":9WR4AH]1=6L6L4R(E$#%D$X\:6I''9/%Y95K=X94KB:7F1?B7-1YO=S0#
M3Q[(JK_UV1<87E4&R2,5.O,=9QIZ1,._UIOQ?V@PNKO=D=;-?"80%<0*0"NM
M>YM<8D;(3%N7Q2A%[N%.4VQ24W/-WF(R%+?+;R?75GK5WQ<&+XLD`0!R]Q*%
M\\"\!A^!QK%ERT,/CQD,4#&`21W%0Z/D:_M=*(&HXM?664Y.-[@XIR:/5H8R
MQ>$!<YF"C$OI&4U#\-EB@KZ^?GJU<B5`"F8P.H+G!2L#I913U)23*@?5B_QI
MK4C%@Z&0>Q;9OH3U_8>''1]E'4HTU>J1_[B6H9>2PF7@!6.;<!\\V1:X["V6
M%;AXVO*.^A9+5R:/*UJF]]/5B86@9JZEX4O50B]?K=6P<-IC*:]QPRSK7`.`
M9U4Y.<RKM@S:8:(E[;TT<=I#69F/8UZH3L"000M-*>B:N3>X_/KFB::C6+M,
M7YD0:>%LXR`M%_TB-<VEJ&O,0J53]D+1Y.XV$WHB0\XZHC+$S:V63;Y;F(P`
M,[O<Z*ZI]`6$_;HQHFU5BVI$9(CSM6*Q,A>W0)O@O;)$B^7E&6;B<RF*>55D
MQL:J#PR]<+@^KQ*>";A)4)HI/13F6'!.1@WSF3MJ"2FS_M:7[/KBW+H\`6FU
M-W(`&QAPNY?8XGV64M7:*IF?*C<1=&F.BA;>+4_4B88B:<DU[GRG1XSW:G6,
MPQ6<VBGU#4,,<PKGK(AQX\;?S5!!0L291AH=>%20CE(>X9V`TNP:N&12W)_=
M+:JUO$![<NX)5_?L#)*JK7FH?"WVT`AH\KS+(4R.6(H5-,KF!O?/RI&E5.9#
M9@8"G_3NU\^?#LN7+)IKB#]%L^'AK:4[7'EZB!)/HMFJ)1E<%Y1[W^GDJ3GQ
MW<TF>0"OU/-:>>Y&2I)JE7H_DEBY/J;<"XGSJW=(X,29LTV&V.^_^YC9-9S:
M#]O-;F.]R%7_5)W<D)08BJ^/;RZBR$JWB55]-T#;>_T@<J3=JWK9+,T7%Z=O
MQ49*16$S5`Y/Y6,I.S&.ZX#!/!<&@J/H8XB:!Y6O+]&LI3,#$\W^UBA+NL34
MN@@BF25GTMK5)?;?S-;B:3(Y.LR%ULM3+&@"JX7XR&E8DX^ULG)G)OEVT\GB
MQ@*4];NJX>[XOX!`>;15+_!+[FQL-7MB!\$SQVKS&NG-/Z+&,\W,3_"F%EMV
MIC?XKMQ1JZQXF-8S1=G$`#U8JH06;3IA#0]RW99[Y,@=CLJ4J^R/;GOF>20^
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M?9&^<"FZ6Q"MT`<':OO1&%J/0PMKDC$[Q)Y18R%"H$P!+:/@01_<.\E/;0=Y
MU(_P4)Q!A"L:=\A&'LL=GZ.Y<U5'31.:$[O?G`5XZURI8@U3;LP),Y2=(),8
MK!):4XSG=&`[&ZF2KY8^!;'YK;/6DOB]86'<HP@1S%@8D,7='F\X[.;N,*-"
M2OK!>.=>1A4Q0Y5P`0M7:W\`\5MK)^/'\K4FE1.V\BT?\I`_Y#&7C[/5=N:I
MH<SJV<3*`3][R](];%:D:$A3;`;Q^L0\F:4_II^4M+4N`<COT@%28ES"K<6A
M/"X/O.-TUY@EC*.:$*KZ07FJ:BRFM&NZH/&R"D@*U'/_M,*M!'&^I,=\1`#<
MY>*;6#@X@*=2[CGMA?WJCOI?:;F&[WX^8`48'*=D;E!,3?T_!ZPN/I!Z(%B2
M^OO7/6DE-I905&;HDY/F>:('Y&WZZ3@.=!WK\A*3L](X+U^0$G@OU]YI?AJQ
MB>#:]-_`R9\WB1J!!FU(+U9=F<]K)N?!:`6IFPZ/>AQ\U,P\G/;'54L6FSX=
MYO2X5H<ZV8KO@+UR9P8-XTH`5`8D6I@"/M1L9[O')1X!?"PM')P<2R`+$&@'
M@CQB,+H-U.@-NUG!G0YE&:RF/O5@E*4/Q@<PB\?2!B+62,[4^C>O:9'\6$P%
ME%%F>HBI])Y'8B$Q@O?/K3G'Y4A(`4+$1C"QPP%+4(4&5#`K)R^F?*?P48W/
M]<Z?Y(C^7<8*I35523@Q/3ADJ%E:!FIB^<N'P`=&DI7Y?DNEYAW2I%E<ZD&!
MR+,<)<A`7O#`)#K0<\##@_N2N+0)-_A'`[%`Q*;R&<7P<QM+B^,.%6CH'SL[
M%M(&L3![P'>U&[_4WL.8QM-(J:0##NI**==F[3B/"/'QNSD@=M]AL`J[FKEO
M3MV2ZZ%-3,>'>L2;I($>^J$-KJ:XOI5?##?+-TA_'G[/*]E`5XM?4)W?BA7P
MUEBX$*^FM]'6G=Z"6+Y6%FCL,LH`ZB[P0ZN&->$IJ?F)3Z;]$TL6"GFT]%;P
M2Z2C/_R=D,GTUSQV^LGQDB6#9V5C\:["-_L'(B9#0`SNZ8&/1/*7X"@=VR[;
MER:LZ$5L!%QE<%N`#`O6_N51E!<$\PI(4*T&I]DIBY-H9%;`N=&Y6Q&CWJ4`
MQN#`!F\Y^BFPE]##+7KQS\%=8B(_8RYJXJ`]E^`T(=A/C[FT1NH?B+ATD5T"
M5EG#5USM'OD6]-]?E_%+&>(&^O*3QZ"(=M#*T5L0<;]>6C(46J/W*!MZ9@PV
MQJE&8P.S17/?5$7"V1*JTF!W*-_Q^QN;ODPY)OE/K<[D,0Z$WABB]#.FM133
M*KHT':,&*5(RPQHBB93H7P21<T5YJT*:OG`)&ROVKPV.W>EUCL5B"J-JCF."
M:6P.FQ*U78H&E4=+RVGN!J@4,H2A#"?'BJH*C"97:"(&M@:STJ`<(*V=&E6P
MEH?U5!"0J?=K?!MJ^N[O;U0$?ESV-2+NT^EJFW(^-97/9(9<E4&#('YW;8.C
M=_^.78Y^QTU'/WP/N0<7U0QPH3MCDM]P5/7][!DGN[U00(JR]=#!*O112)+%
M$+J;Y,EOOWRELW)Q9SPU*=R@>*O*QB,I<[1S4X?HIV6O9^U8R&N%B5)C$SCB
M@-E513HA0C\%XKMOB)6X(L],K?\\O!J7P=`"Q'T%YU"]2)V1@KNF;Y(%N5\=
M7E$7">W@[F:!]J9VGCTM20?2ONS$6IA%=BJ/R]?J"<[J<MF#>X2#BJ+QPTI2
M<08UNY81W;[C@D$M?,2O2PIU<D+].H[P0VGL/X5(=3WTK*!O4*\K4"`I;:;*
M=F"SUJ[8H7'":&O*C>M0!%CH?IXP+D!ORT[]1E4!K]@=#!?O7=3W]@["5/!L
M!2ZU>.=Q@\.N'>IT4#E>3L[R9LYMIQL="W14C27<R7[MZT60EM],S[$!NO\V
M6P;298$")G2E6+RT##R^H(J9FY?H;*Z7R/74A9)-=I)J+L>8Q>!\]_+PO?J.
M57V@.TP(=DP`"F0\X+NKSW]U,_OKN_/_1A7=\>FO/P%=4M1^^LGG[3*T)3TD
M4D=17KR\/;J#-EI'DY_:T;3ZJ89;A6)P2BD]:O)@F$1Z&BZ[:NDI>RFLICG6
MDH(78G?L"&G(=CLD.F29SE`1(17J.K4D2J,RU!1^\.6IJOHWMV3EU4#%"@A4
MK8R'_?3;9[.=C>TG"S*JCC>S!?K?-_QS]MGGO[K^F[+RO_YDOO$)OT%G3T*_
M8W/F^N3JA>X$M4<.@`NO[9+-5Q=`%?KKZT.LZL=X@S[XS%Y\\_E7>775_Z/N
MS';C.+(T_"IY84]3`,GFHHUMP``E41X9DL4FI6X,C+DHDB6)[5(5IQ;9'LS#
M^+9?P_UB\_TGUHS(S"I2MC$#3$^K61G[B;/^Y\2)>V.G.4ZEG,$\G/G$IC.'
MD)97\EXUO=]G:MWD%R*)'3S5A'/K!6LP!=HE:1?R"7&7CL_?PO[WCG;V#ZME
M_(Z[[&]7=J1_Z)YE=_8N_L!TC;UG"];3+<=;64MP'8MJ#K_#XY!4F9(/W^#6
M]7/!ME3H@!`%O4(L1C>S)?F<OK/>-7DU,P-CK3_+#Q(!/=8J@B%81BP(4F,W
M$E7\>7'-#><_2^.OH?K0%SF^=%/[W,!?OH!40O9VW)?*F/Y*ERNF<-[*C,_,
M_U[D2_N,F9H.QQ6=[9!UYIB[%0HF5/;(3*;HF1'".]B'B9R#GT`J-6R!JI?-
M\Q5/#AKZ?(46YZ!(0O1Y2NJ!.R6/-KLFP]2_94\'1D'5FU^Z&"YEU,5B5-<E
M=K(`9S5!*HAT8V)*7(H7--TKHM"R>P4L+@ED4B$`@^`*NNH:D95+)IV8-PH,
MD3('VQTPH)HKI65@#:Y&E*G+_I3M`7=O5/3*7FC(/8UL=[8[H=:)<42F3'K-
M1KM!E36,,GOB2G_RD]+X9BNG!;@$&7T#(RM>_GN/<J(FK>UJ:]=NA5+1M,;X
M*@"W]%`Z;5G[R%O:LC8*[<K=\K"1V2%[HN@R\7.0B9@.A:/V9'I&94XJ:UC$
MYC`4UG(E@P@L!'O;6VC8;N-@C>$[#%GM2I=M[BPUKI6)=\`A:$ANV1=L.8?!
M]@$CL'RRD#L6]-M\2X+?CK_E\1F'X9,F)V+Q`'ABJ]WY:!!'M_O@BX</W&E`
MY.%F;Y)&%`Z19@D8TH:/I([3%VL>A?(I.O(2[%$`*K^U4+B/<T@MZA+C(H@^
M-7YK.</B-_ZH3H\#O?%2G"GG)Y-K\)H3-$UZ-];./[TE:)0F6R;`$F0E<VO_
M>X7[`"V@^<`_W*O>YFMX^HQ;-9O.+L')X!4*7@>[GQ(E@9VG26PW:?S19>!,
M8A(_^2P=YSXD].,8>RBT51%BM]'=/=+:8LJM+!$_LK_[WBGQLYW4XWS^5E\S
M/SAJG`>_6#";M0-?/,CK/NGLS&2Q'N4A8D=^_<4=B7799EVI2^LJX9FJ'7D=
M$[^8*S-U_B?7,0+/.6WR^=*AM,$K'#J&D=;"$<+.=-6'B5F-[`E*KHTR!VDG
M'(`!FOAW,NDI\I_X]REOB/_KG^__]4]?RHY%O_GY1@XC"F-3W@?[QY?#X[`1
M>`GK&DENMSE7DBRBB7Y'["T"18FSOEPG,\1\P*+GJ:IWE/@<7?(/MO?&ZODS
MGM;@W^!^,6V>CR_F*WW,QA2UQP7$SX@Q78$>:G2KC*2\<?8QQ>^RTUY@TR[,
ME:9CR+SD&4A(2Y`72)O.5;/BO!A)<><"'QTW:;]%8B=31#W75U4$%RU]W,R+
M-)C<#@AH:AA+6CO-I(4?9LZ.JT65V;ZDI"'9Q3QD@E/(8T:E)XVG<_[,%W&&
MFDU&=38\Y4O@%W1(I4/I."Q.G]AL[0.G1+B)LPS3@W.!'FG.E4GTOA6>HXMN
MDW@X&0N4\HSWPFVOL1A+P@Z;%)&ZJ6W8&_LX6BGY>LQ/UW4RT)]N24+'V"3]
M(JO+^ZR=OE[Z_$6SM;L_VU;)V*X$Z;V4H4K8(4\GU;E\<;B_2WT"IQBUU8N^
M@IH$`B)+DD^1T]E8Z8"^<(0-XV"KG8$/XUMSJJ+F_-3(E?Q*2OLNG(<@F6:#
M'S?/2%R=S!8KYOS]\<7"7O[[S[*+HUWISYL/^1KJYR)#Q2]Q-]53>@-AT^&-
M'K`B&UL5$R@FP,NZ)FTGHXL9S6>P)?/C&3F)'7S@5;;_@EW!D:4.-6>SRQ\^
M29VBUB!,C-+$5[N__@);<Y1A2`GKWFEA[)?<5K!+5\_'.+T9)%;XQ7G,#F&#
M-'^LST+\VOT-.\LZ#SJT%:`,(Q7K0=E.FK9?FEL+5@:N2>7BN&HI^9I0)Y3S
M%EA.Q_#YQLD/B5QTL"%_R\VS[)9,_^&FVMU,>K+;<MO5=WKFSQ%?8A,+.>.U
M+\,%S_W!Z163/'T,L_-Z(N,F/R`_/2J]Z[29#^B38-NC:Q'M-GL,3;8C%A;J
M6-1['>K\N/)!#W9,_,['T_&/L%*_,5X[[IYD2PI$WWFF:C;TQ4ZMYJYO-WTQ
M]>Q\W<&R7/&>[G$DC-UK*,TQ\GGRZR^.S.YK`G!RUZ^=?OM8RU-,$_B<H[.!
MK*OAB\>:7"SJ'$)[SD/-:$67LZ[#="=HMDC0*:+&];CB7\<@/[U\\[,0J9(U
M#<OF:HP7EY33<'FH$[U%+D)'O7?OUP>.T6HRND!9,H;H7DV4-&6V+8D*"/-&
MKR:*J6L45ZQ%@I1R643@C#6H_KD-;6M10MU\I.#]#L]_$]2UG+KHU##FD2_$
MU'S^4%.QK0`*/FP;-G(()`,=O?/=V,K0V`PG*(7N+M$EV0VQ\I9UQA^.LLK0
MZ7[KP9VS?(7.61,NNN."]0R+U`[CF4JIR,;HFD.<5%M65F?^W#W3C2I]_7'U
MT5-\R)SW)(6!"%+MDK(>>@?.'P52Q!,)#*]G;R5QY2.5]H7_W^[B;+6`:A;W
M_E)*,Y@HRJVT]_*703GZ?#[[:)AFL6YAF]LGZ=^=RG)</U%&@4D`'%I>OW?D
M+#(.FBP>):8`:<\Q-5BD9R`N4(;L`[A&D$PKOE"$EIA-FUM%].+%&"<2?-P%
MH9)RE4U%@C9YL/S`/*O%OL&T^/]<`EBR]GEI8:?1`O-5A\"-`;'MJ-#8=O9J
M%7K#@F[MO2V\$U9`J3IW='`+DK^*=N#IZ.>DNIRYHA.91EH>"J7&I<A_7B<O
MZCI,L+1C.5":TQ7A=8FE:"D[M\";V01>H)"7*&9T,U[Q^AC<X\7T<K?9BK_>
MDS<OB0SO/_.>S#T"8Q(+0=OQNY5[(*TF:!.[RR4++&[!@Z2.(644_A=(_-ZO
MO^!,VS[RCA;>``K\,=-%#=`R7DI5$>XE^$Z=I]X8+.3EPN>'WC`RWO*.`W<V
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M@S#0Q\58Y)H*S%RT"CM4/.F$K(O9S]A=3]`5W\$W3[$=2KZC*PMR.3'NL[%B
MY6)=FUE-9%@V&XV$ERJZ%]":8!EX0/$Q9"2)3N0?9]0><=RO1I?SV3=CWG19
M-/?W]K=^N&>+<&]6:CGWHMDT]JL-N23GTD1GTU]_\>VX6>KQQ=G35IJ+.I%%
M,FE2!U%&\$:E,QMHS#N)"+$V?B=%S12UL/Y=?RS#^S?<7UTY8-7@HB<S7V`3
MRP]IYYR$X0;BDKC@+7J/N,$%;3R!F5_/A67!`&P]'>Z>I;33^C@"[+7J,&?"
MZ4@(XX53EY_8:+;8S9F>X\#LF'D\M%5:2DL8FX,F_]1T!/^ED7"6`N&)\\EL
M1.")53^#JJA.-4>T0,JJ)#6'TI"_<Q2Y-W3BA4<U2&L^C+@<R<N$`^/Q]N$1
M7E2>X#[8/CK<\^HBA$7BG9&%%C'L<RBTP37*W5^=58XI]SPJWB^FZ)TH':RD
MO%IK/M_P>E$&<%U'6ZOI"+''B7K\1W"+@&E8?KWOYI7A&R[`F`2,P]'NX0-A
M3GXST,IB.3C>X]]TL%]_\7L3QXS1>EO[0?R[EB^XSN^Z]NG5X'A_[-IK$,WO
MNO;Y_Z6UWQ\\A]^<YI<?!L?[P\Y]^77+*-Q6<(U0NMST_DT-150*)K'\^LQI
M'6X-@7<LO_X.JT'&3_GWK</M_;W'U5_W#[8/'AQ5?S[</CKH^/AH&_=C^7$8
M,4UXVYP1E\;;KZXG2$9/9FF:6P#L_3UO_?&^)X+6'_>[_OBPF@A+/'SXL)S>
MUL%1W?QP^V#O0?FE%H(^.\/%N*4MO%>MJ&RQA9_#W]C6A`^J$0?[[MFC@3::
M)T83WB>)2^?!,UO&SQ_5:`8&,RBM\6UJ-%'>;")XH6>O*]WS/-86;$Y0:9?E
M<LO?%P-^>8I\$`X,M0J[^\/R#8YDW$_>''T^EE4Y:=[,1U>F7WS$"D50Q[>B
ML(L4#O>A3_WBM<0?1RR+%?KX5O(:_SMZW<[YY6RYW#D#%8[*?BR0RWR%1^'%
M1S1V7CEFN8OF&%@2G>T?/7KH[&SON0HJ4Q'%QS"*AF8(W+MV+`M;"U`+G^B$
MS+9L\/(Y:SZ:*/;!]52:G1RW12??/GO:;&%C<,X4O;MPNM]W,Q3-QP(A@<P4
M<OG]!.U2@WA=#$W-$KKWN<.'VWN/'O68NEK4MQK">7Y\Z8@O'N7U#\QNM8_2
M;@ZN!74Q5*0<%Z'T$F[G^O8;E;K?8(\["/>CQ94YNW->\M(#DJ`;;(=6BI:^
M;TZ!GR@"U6R%?U4,]7RU>2=OY(!:#'7Q7)73_L:[J]A#N*Y6WCI+.J@SQK7W
M+[TOM2-`=A*K/KU=C"D?R;?02GDOSRAP=BUW'9WE!3Y=/H+9/\ZA3.S'P#K.
M'88K^(;S\B7NT.]A?3=BUDU*NVC[F'F/Z(,*@(;2H,ZKJ?V%@/UKI/C$-5&5
MG%M4_DV1Z&KI[%8.BR<K_%.?SYR8D`/+^.]+X[^GB$":R#MSCA]\7"[\7!6-
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M?U0NMPCZ&TN">SN%M02(`QL0_%D5\WII8=>3G]C&L"(J#/;ME3T>8Q'VKG;E
M_'U@YY2LG\OK&Y0*3QZ+YJTA3UP?QT'LELW%>GJQ#+USS)G2*Q]2\A-QXX5)
ME,.M]1CT;0H$1!0%<H&%+"+.,G4'T9*48OJAAS_P73GZZ_E[@04=P>A@OQLM
MD5HZT=2HV<F<KC#KZ$9IMIY1;/)Z4E%BWNUV-D'I;1KE%!5+S%`W5&,E`7G.
M'[U>U@__R'V-'/*,,"H,%#+'9JK%13?KEB(%[;;4A+7K;+;>GC]KOJC6>SY^
M+[Y:[JY)^VK/O=`01N0?Z']1%'S_4A'=%RQ_40F2DQBNUQ*U90B/]W7`\+N5
ME93D]Q2L7+C)5?-X31*X8;SPB4ENFL<SQ:FOIS"]E:G(Y;H,4;K\4/5(&'WV
MHP6HQ`;T3$C9TC$,E([)"/W><'4H)U!#X*]4S?Y0-DJ+TJM2!LR@-4CC_@_=
M[P!T)E<[D.N.'//EU^&:!MG9_$]SSF<2J^;:WR;W:]DKVMOR7%YI/2<;E-"Y
MCPZX<,X&(WMRS&5Z[]##:D%!T=G'=]-.XR7O(_Z_KC!.=*?!2QF3-L&HB(!J
M[;M,H1=77`\]]QX$V4LV:`+.-&Q^N479M#M4G_XU/HW/J>"_QD`B0(`0=.RF
M>26XY1ND":[U+W6)WLA%'<Z[.7&QM\#4FJT!<NA@`51J1J'K6U!+T6O.KA<_
M-$,7/JO<VM?CF]$/XZM1[X#?$-\&S-'7.N$G^[[X8XZ@B_#3"73]&N9;'T%V
M`3L:EB3V399'&_HLO_&%1OI^OM46)1TL-^OB]2J'EH:(73;/U/:^:015G:)S
M!((`3+24_2$R.Y^]6Z(T@[7LL6!(Y$+7E4K0]\7+A([4N*\=;C+9&KWMI`)^
MF)&AU?+&]'U^KA?7V0UN+70MS)[EHLTQ6[WI^:[B\+<Z'K??426YK94:S[&/
M31["?@@D+H!]=PA&XJV[//YC4:[*CP@GY4>/T"OI)&]Y6/X(ZB-V6_V8=UO]
M>*N]R[5?>=E^#Y,\;G"YQLT&+(Y7O!XILFCD;3!;<I`=M\9(SE1Y[3,_PZ5=
MV4A"$OXVQ@UC+.3*(""L_ZH4E_,Q9=LQ_*0JXV:A,`CN#91D;P<ZH[/O9CC=
M4!?C+JW_;GF+_7I.RYCN90*!`Q6L9Z?)*:/GH\3MNY7KQ()NQU]&%[=@G=7$
MCQ->NLOBZ;OE>+<!EBF'$<_#:HHZB06&_3Q7[7W@X[XP2TG#+:><ECGZJ+0+
M;YAY\$W9R(Y&'!34WI]LK>CP=[9A]@;YT_[@KP?W!W\FD6ZWV7_H0OCE*H#G
M[C8^%ZKB?+C4:>DXGX^.IY@+D-'`%O<J_F5C.IZY5W6;<[ZJVV]7/.SA6U;A
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M-$?>`%!45EFT+%<6YW6P\;Q\DR<;-SCS+R]&^K4H2#43$[Z:,I(ZHC\%*7-Q
MT^I[)Y:?;CP-/^]GOUT#G!)G5&^;-D^NL;+]0\;2%?#C[O:3L%NHCPER<3PF
M5<C@#H]UF/;.YB<4,,I0<Z=&<_*3\I/A$$8EY<;*$2MWB3GM3N/%\&RSQQ1I
M-2IH+BA6S6A%L&I.Q?Z*A0XW!Q_HGNL9G&K?J&ZC[]24MX"LK`5,MVQOV[$C
M6`5\0?IK#*[<6<@_');RF43=WRNGDPGJ07$;:@(E07TN$ND*$F55DE2]*?^N
M%=,9U,WS5M+`XR[E%3GHW0C5S^+&0?Z;D8L8.0F#QI:=QG8S-6=JN0U_'RO]
MAA/A6LX5S@M)7]VDKE"618XFU^^,6P9IAOE:=OW08R#[_*O00.1:D>*[:>\I
M?E0FE*L%<9[P/R>W_;++:805[H05VD,5O$N+Y_E=?!M,;-1W$%`:94>_Y<F$
MV9N'$8.*-RF518#?F)2$R^Z[:PY/:GD1CM>:'5-T@-IRJJW(58N*++,[P[:K
M:(3KP^VBIZA6FXSR*M6I?R2O;#4^AF;!$;?2<K;W':&4?W[E<,6]8N&UBWV&
MX]H&-V!`9/.EE)TY9NR:."@W(/"]WK[[SCI<H^P$^GDT0DUE=:0&Q4"&/[;^
M1G(U8?C05M(-I4E.,"'6#WLG&\81K'KTGD@@Z5!4'-I\3+<YU9#[_4.Z%G)$
M4_\/7`**_CN7@:8++(6Q/``\$QEB`/J*=]^1<LZLRK8V6H_HR$UR]UU_!#XZ
M7?KLW8!8;]`A/DD?S.D`?A6Y\3;/D9B:Y4-^BC+[Q\)9J%Z8?4H)!<!E`T:3
MFZV3AZW[UF,@G[';5JI4%O4S11QF#O_0YTHA?\%@:/K^^$JI@8+"&%'U-=ET
MI[/@B[]3AE;((O-H^`JT/_,!OF](]5HV;V,MU">3$4@+#H\LL(6W879D%\I<
M>S6CCF,\K)(:H@R2S[3\L0R#E;]OND#[+MA6VD!V/T3UW&\MU$2<;!]E&2$A
MDE\G!8FW"R,*X8E[X+Z:K3'Y;?`([%ZM!(9.@WI::8GA@^>S^;NQ</JDA<L*
M5M2Q;ZS6#$\<,F+-]/SX`I3U]?HWMD]:!CLI\C8=`DU>HJ=L$@7VL5=)PO*P
M0[B3M]W#M=WU;.[:=F%:U4ZN;;G)<:SMY!;GM+:O@0-<V_9S3O9L+*R?KCR6
M.+R)1W*)8+[A7K=.N:201X5FV5!0@ARG2CD)&N@^3[*Y:`6NO:X/JT4.36Q@
MLQYL.+%;C7>+#0X;0X45M][]@\[U'D<MX474.0WHV=IV2@<-7O^!7@;V:*#5
M+5:*LB*0I8.EW=F`3+VTDJ(&A#;>,?^^K^D\'N@M/^=2DN[:36LIM%Q)M1$5
M#I(,Q9"\*<>*783%,O>,?&[7;NR.2.EF94,!/A)PIBNCHOX"83RY!C'FE3HK
M^2'-@02_]=UW-G9*>=DX73!A^KP696Y:;`1V!):@"=>[V#5EI<]%_0L$SHB,
M59=Y&HJ]I/3='244[UQ/=RY'-]?@)<J)^4S:5"N"LV1+?*F(\NOOY-_$#8IN
M$XM+J($A=LJ/':IPE:,*]:V?:T4O+=,*VY`D>%7E4E%K:EDI^Z$<P).S.AW_
M1'%G/%+:63O$K%Q!]MLV_K@I5K]1WV_7'7RC[*SKW%JD1N2[H00`M?^DI@A9
MQ_]-)0]0D:^KM;[=/:<6B;]_W\C)/C4P<)]F6X]/;?[Y_&>NL;PF=?_GL?<W
M[*>[L$"]U$;VCAJ5:SPW'B`=YR4NV$GS[8KB$U=`;74*?1.C$74+_X/[V_O)
MNKGG?&2`'WAN/CA4XHA<YAWSTZT%]FI_C@W"UD;TKE6*B\%D1-T!\;MVF`0W
M3`-"][#K8L0A:PW=DZMG>W=\]8_5P@5?^@XU#63;6(R#^^;S0<AKE^V0N@4J
M^<ZBTN*(/NIYOR3\[,<ZCFB6TPK5SD)QLHO-#)`YB_-@T$3VJ%V$@2VF'/;U
ME$QNM("8E!0<H2N#1L<_QZ2DLH,L<#<R\+?0F]U8SSB6][5F=2E"`A7'BH]2
ME53*<9P=%J*BN&D@]"E&D/B"U4BUB,:"W*\ZF[OG&)\.P\@SZ@BJM>G5028$
MPMUNNF$*@XW*Y0%/H\[E9+T]&S[TG*C'K.Q9\2V1\-D.="^Q("Y\)(Z'#7&!
M.T2O$H93IVW"`2MVBK2+H'UQVHP4<X3&_MIEO`R](7;:8V7]#ZW)N3-\=.W*
MW5+GJ'5^:'R>5&FSWRLIV=56K,VWEXX<&Y=4$Q-#`KS8:U)KOY//NN?;D+3H
MXXO#<<7V;D4FT8F[Q_F7')86!>S'+Z`4$@2$!UF)IS)G$`;C2U.7"WTZ0=%&
M;Y`Z^UXQ<]5H%,%@ZL0"R4ZEBT6(8L&:LC.)'.^1#/OKN&)<9]EB<-KEQX'J
M7,RDT0-[YMNQQ-:\U$Z<:=E#YL&L%BS,!Y5)8DTKS]<K\CMV&3LQY*U\T-[U
M1;^A)T[8=3;1<GIX"IP-7?Y0`)45T@Z.V39!'4L/])<S.$E#FDZOJM?NXK;<
MXF`MMS`(D@=?'I9+>X4SEK3"RHE7WE228)S14W:@6Z)(^0@MWA$JFQP*:E>G
M%S;'`G(BH>H+ZN!T'P*H-(PA-%.P`!]4GJW2Q0O`.,>TSC5\UKYT!0V62^WH
M?TV\JFYQ2APY7'H![=R2B!IXS,`&DX[-UU^6NXV_9E&?1Z^':^GUN]FG"/FM
ML&T9?*VNQ.`4)(N)I>0H=MAR?'F8S9OM9APK$Z?6VFJR?SF;ON<Q\SD%%OL3
MG@^HV6C>MY)DX@D'IEU^8%$GT+79^9,%S#-X9%@0I1=W\URSD/2A0=GAP5'/
M5#P_&@=<"Y>O;`OT7>7[&!._0PH\92P3N:08EQ,KES%5Q=2<]&!4U:^%;3%9
M/:1&HD-*-\+*]&''G<M6CX-+L_RA38!)N(:B?#@3%!9U)&#J?8_T31C&>)7P
M)/5P%Q"#JDO?/5=*0G4YF;M.%T5092P))ZZW*>_W;<%M.X:M?!Y9/>*5OTX*
M[YC)NBA^IO=.O+#LEP<9BXZ'%"Y3)3S.-U0B-ICT9^_8`)OV]Z=7;6D3^&TU
M@OMK.6P&+:Y14J>^F&AYZ])E\3ZZO&9#T-9TK:V21MDZ*DSI40#IN#<3*\S6
MJ7^KN,K.7H6\_;S->;!V<W#W0XV5Z_O4Q?A1;@:.K52%='2%4E'1[+/CLS=R
M(G0-J@+=.WN5$%2T3'`4F5V]LXFBIY^E?=Y6/ER[E7GR3H7&TSM;.WM5X:.,
M*YH<RHI4(A8M8`CJ!X&L4M3NM53W;&-)<6^G%-GM?ABH_+0KD4Z*V!I%*(6U
MTM.C'A+C,5?7'R]4<K@KM3JR!]%(LO8VL(`^[]0>9:=6IU#V^X:&:@KTNC+6
M9<8XMT\D85\RR+2%\HR>.2^%;D2[;E#0*O[?E:QO_O"*]6<*6@F+@2NJW%^?
M]FC")B5$GJ,DI\Q)[D3'"Q%1=RV[=*=KV!-G&0J`67YTS.6X0F.;6$[DFH\W
MG&17B?T^??E5ZZV%]GK+N;[4,Z]CFZJBE3E($N0MFB'+5!132UG(P^'>39#U
M4':5Z4"WF4'@_*.4W.4>2[`QRT%\@033L;7W!MJKFJ(K=[^Q4'8G4[^_L$@[
M52Y8WITE1#(6U.VG10;?KCIYOS=U'0LZ?#B8^96)L+KT7E5J?3"RD1TYDBPK
M0RZ=0G[H%-2('+'K"'`IXP>A0-"B,W$AZ&^0'_Y$;A9BU!2%1#*MX2N%1*E1
MO-3D4K%\=,-I,>5L@H"L*HYS%3SRLVP2X99/LD+1=S\]<P>$^L[E6!CS%"21
MBUR(%TH=RTP]A?D%K_QK]F5.D35@?JBAOM:9P+=DLF[RB@_R\WTHY<\ACD,1
M[%2KV4:DPW)JH=IS^7>TS`PR&SLTS2>L@/-$IZ26\8:-!;AC%_(^RI9AI_)O
MFAOF35E/MZAYNXQRJS?E>J[JXC&IDD^JCI/'.5RH^?8E@-9RCQ=3:F3XQRIB
M75)VUJ=)PPE'MTEM52C^VA=XZRZP:7YP2QFOG9)E-<F[TWKNQWU0GF`US&#X
MIZAP&24X`O[;V0>J,4V;?QM]O/DJ_J\7T^GLDQ/BJJMH3S9LQV;K)Y.\FQN&
M:_Z\6"R__E\!````__\#`%!+`P04``8`"````"$`'B/`<9<"``"S!@``&```
M`'AL+W=O<FMS:&5E=',O<VAE970S+GAM;)1576^;,!1]G[3_8/F]F(]`0A12
M-:FZ5=JD:=K'LV-,L`H8V4[3_OM=VRDM9.O:/!",SST^Y_AB5I</;8/NN=)"
M=@6.@A`CWC%9BFY?X)\_;BX6&&E#NY(VLN,%?N0:7ZX_?E@=I;K3-><&`4.G
M"UP;TR\)T:SF+=6!['D',Y54+34P5'NB>\5IZ8K:AL1AF)&6B@Y[AJ5Z"X>L
M*L'XM62'EG?&DRC>4`/Z=2UZ_<36LK?0M53='?H+)ML>*':B$>;1D6+4LN7M
MOI.*[AKP_1#-*'OB=H,S^E8P);6L3`!TQ`L]]YR3G`#3>E4*<&!C1XI7!;Z*
MEML,D_7*Y?-+\*-^<8]T+8^?E"B_B(Y#V+!-=@-V4MY9Z&UI'T$Q.:N^<1OP
M3:&25_30F._R^)F+?6U@MU,P9'TMR\=KKAD$"C1!G%HF)AL0`%?4"ML9$`A]
M</]'49JZP$D6I/,PB0".=ER;&V$I,6(';63[VX.B$Y4GB4\D":@_S<=!O$BC
M-/L_"_&*G,%K:NAZI>010=/`FKJGM@6C)3!;9PGD\W=G8,G67-DB5PIH#;MQ
MOTX7*W(/";(39',.B<>([3DB"0<(`7F#1G#^?HVV"+Q@]*PQ'^B=C8V'S%S*
MUM?VQ8.1`&!Y*>#U<"RXP$`U+)P]^_(+>TCND@N#,!KKVOYS>B1J]AY1%CP1
M-5EUXR&9$P5]&;K?1-GKF)$\:.RW9V;!$WF3=MEXB)<7S_,\S9))SVU'D#2:
MS]-\/A@8B<O>(\Z")^*2@=9OJ(?,7':++!W/PLED"4[)SI+%<_)>E#]W_&O9
MTSW_2M5>=!HUO((>"H,Y&%/^U/$#(WOW^NVD@=/"W=;P<>#0PV$`X$I*\S2P
MY]KPN5G_`0``__\#`%!+`P04``8`"````"$`0P14*3X%``"/%```&````'AL
M+W=O<FMS:&5E=',O<VAE970R+GAM;)Q8VXZC.!!]7VG_`?'>`1MSBY*,!EJ]
M.]*NM%KMY9DF3H(ZQ!'0E_G[+5-.?*&[)^Q+NJ$.Y>-3Y6/PZLM;>_1>>-<W
MXK3VR2+T/7ZJQ;8Y[=?^WW\]W&6^UP_5:5L=Q8FO_>^\][]L?OYI]2JZI_[`
M^>!!AE._]@_#<%X&05\?>%OU"W'F)XCL1-=6`UQV^Z`_=[S:C@^UQX"&81*T
M57/R,<.RNR6'V.V:FM^+^KGEIP&3=/Q8#<"_/S3G_I*MK6])UU;=T_/YKA;M
M&5(\-L=F^#XF];VV7G[;GT17/1YAWF^$5?4E]W@Q2=\V=2=ZL1L6D"Y`HM,Y
MYT$>0*;-:MO`#*3L7L=W:_\K698T]X/-:A3HGX:_]L;_7G\0K[]TS?:WYL1!
M;:B3K,"C$$\2^FTK;\'#P>3IA[$"?W3>EN^JY^/PIWC]E3?[PP#ECF%&<F++
M[?=[WM>@**19T%AFJL41","OUS:R-4"1ZFW\^]ILA\/:CY)%G(81`;CWR/OA
MH9$I?:]^[@?1_HL@HE)A$JJ21,!>Q>F"9C&)DQ]G"9#1.,'[:J@VJTZ\>M`U
M,&9_KF0/DB5D?G]&,!6)_2K!XR-`MH<RO&QHM@I>0+E:00J$0.-KB(THIX@H
MO$("H'7E!C,VN4G5(ZC=YQSE0P['_)I^G$:!D&Q45\ZK-&Y8!$`0D\#G`TLP
M$#1F'A%G8(0P/;!QPQJ8S1E8@M<^S.$J>42=@1&2CB4C<1KG#K/2`I"$91I@
M$8-VO5T1"7:(10XQA"382WD4V^'2"H<ANX8M4LD<4A+LD-)IL3\0@J08)5J*
M,5QBF(V<\U1+;7%*YW"28(>3HT2!$.0$]4FC]*H%LK(`)&>Q!EC$Y)YT\X*7
M8(=88H];(`35B$*]DI&5&66AGI1%*9]#28(=2GJF6#^$H%9)FNE1D9,9CD.C
MYRQ2!)SF=J%&M$-K8HTRX]I7S1XF3MN5*@=*F1FT;5[S'!O=UC('UPX)8E1O
MI5&6.34N;02-T^R#KB?226_NKA%M6R9S&JA0&,,SS3NV,M)-;Q\<O==4ACDK
MO2"(N:RZQ%&NM.(1,>(VL5EV3J9^SK3<V.$*@\32W-A`L<6M>!1GNM5L8K/L
M7+[Q.$N/N7ZN,!?%7.*E'6>15M0F-LO2R=33F9ZQ4LPT=<(H<U9GJ9(@<QK2
M1+N*36V6LY.IM3/'CPJ%N6AFN*0J)N90%IMHR6U>LXR=3)V=.:N^4!BE2!KF
MCJ:E#<@RJMO4IN88_&TO<F3J]$S71%75]/(DFEJJ&<_@H^FZ>5D$Z2RO']&V
MU[O=5"B,TBY)'5LK[7C^T9L-=<S^-N7&IQR">J&A<@IS:3IFO,=@UUF`E$0?
M23?+\:E$V\QB1YI"89!93)/).X4%8$F6Z*5L5W76?D#1Z^'W^AH=N_N!PAB;
MD7G''MSQ?%FY%`ST\V\(.O7^6"\J53G$H!W0S)&O5"E4V'C:IN<XOZ3'?DQO
MN@/$VHX4/<3@^'?$Z;M2?JI"!ZAP_%'I9OD_G?I_['A5H3#855$4AZE3W-)"
MT)@Q8VJV=K-V`#K=`6)W!U`8)'='"0M=,RYM"$GC--+*V_1F;01TNA'$>JFK
MDB)&>04E=/*"J+(@(LURHN6WN?VOG0".=B:NX>X$"J,^<=][B;41[[W$XOD/
M'H^TO-OSDA^/O5>+9WFV0^&#[WH7SYT*LBRH_)IW[I?R/$K>#ZX!.`XZ5WO^
M>]7MFU/O'?D.4H8+:0D='BCAQ2#.X^G%HQC@(&C\]P`'?QR.*<(%@'="#)<+
M.<#U*''S'P```/__`P!02P,$%``&``@````A`)[ARWM4!```"1```!D```!X
M;"]W;W)K<VAE971S+W-H965T-C(N>&ULG%?;CN(X$'T?:?\AROL0'"`7!(P:
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M6BWR`B*0:7<:MENZ3V2>D-#U5HLN0?\6["R4[XXX\//7ILA_+VH&V89YDC.P
MY?Q%4K_G$H+!GC7ZN9N!/QLG9[OT5+9_\?,W5NP/+4SW#"*2@<WS=\I$!AD%
MF9$_DTH9+\$`O#M5(4L#,I*^=9_G(F\/2W<2C&;A>$*`[FR9:)\+*>DZV4FT
MO/H/2:270A&_%X'/7H3,1E-_%D:/J$QZE>E5Q1_YT8S,@@>\@.LN(/A\W(N'
MV>F23=,V72T:?G:@@B%^<4SE>B!S4+YD&7,RY/U7:8=\2Y$GJ;)T8>E!1@74
MRNLJBF<+[Q7F-^LY:^3`^\`))F.=L[%UB,Z@%X:<</G7R<>R'H0YQ`JSJ,;Z
M\TJZA"3),J3+'ZT1T/U/='<;F^/K#&HSS"0D-B6*@T%&BP@JZ_Z()!E6@3(!
M41P.NETVU\B9#E%O3(":0*(`FC>H=M6;K*P)[`(?9UT.6KJ0@:%(8*D9'I$3
M=&5&HK%\Z8P-,JY14!-(%$`S#4O@<=-RD&G:L+1&SM72!H&PBR(,0A)885"5
M$DT"?V)1$D56BR/0X_@XZ9)L^I_J*5TC1_%O`M0$$@70O(6/>)/D6T6+',6;
M"5`32!1`\R9/#\9V>+MHY2`S?V;1(D?QB$!?Q3',;6BL16H.211`,QW_']-R
MD&G:+%KD**810-/A3*X\<^U1<TRB`)IK`IO!X[GN1IF^C<RM>Y)BO$?0>6_<
MB)9:HQ(5T;W+KF/4R136XL?KC&"O4G>W*(Z,A=:35.\X[(I0BY.HB.Y4=A/%
MZ0V'V'M@2Q_V7[M'$"1=_6PLA%I(HB*Z0]E`%(?W-0J";4?-I=TI>I+J5.E6
M7<>C%B?ID9\O3=VZ;"./6\?FHULWBG%-E`[5&=U8"+60I$=^L4!U[[)U/.X=
M&X[J/8ICLX25KM1[-Q$JC_*P_URG)E$1W:EL)(K3&R6,;>=&"2N]J7=H(I28
M2*(BND/93A2'=Y8P-B$UEV%D;65*I^J=F@B%:YB92T3P=&%M=^@=;UYX&:A8
MLV<;5I;"R?A)WJI\.)@,Z'#C>_+ER=#`-V0.QW+`O>$'N(@=TSW[(VWV12V<
MDNU`<CP*8=(;O,KA0\N/W15DRUNX@G5?#W#E9G"P'X^`O..\O3S(/Q@N\:L?
M````__\#`%!+`P04``8`"````"$`65`GR:T$``!V$0``&0```'AL+W=O<FMS
M:&5E=',O<VAE970V,2YX;6R<6%MSLD@0?=^J_0\4[P$&!,%2O_H4\;I56UM[
M>48<E0HP%F!,_OWV,(HSC9O$S4.(YYQI^C;M3(8_WO-,>Z-EE;)BI!/#TC5:
M)&R7%H>1_M>?T8NO:U4=%[LX8P4=Z1^TTG^,?_UE>&'E:W6DM-;`0E&-]&-=
MGP:F625'FL>5P4ZT`&;/RCRNX6-Y,*M32>-=LRC/3-NR/#./TT(7%@;E=VRP
M_3Y-:,B2<TZ+6A@I:1;7X']U3$_5S5J>?,=<'I>OY]-+PO(3F-BF65I_-$9U
M+4\&RT/!RGB;0=SOI!<G-]O-AX[Y/$U*5K%];8`Y4SC:C3DP`Q,LC8>[%"+@
M:==*NA_I/\E@X^OF>-CDY^^47BKI;ZTZLLN\3'>;M*"0;"@3+\"6L5<N7>XX
M!(O-SNJH*<#OI;:C^_B<U7^PRX*FAV,-U78A(![78/<1TBJ!A((9PW:YI81E
MX`#\UO*4=P8D)'YOGI=T5Q]'NN,9;M]R",BU+:WJ*.4F=2TY5S7+_Q$B<C4E
MC-A7(PYX?^5MP_9=XGI/6.E=K<"SM?)M%\#9)@YXMHN?CL.[&NG+1IZ.`W96
MXPH\6U>^'4=P70S/=O'3<1!H(U%5J,S=S'<C,46/-"T7QG4\'I;LHL$VABZH
M3C$?"F1`P/2MV41KM.WW7]T';<>M_.1F&F/06!7LF+>Q']A#\PW:/+EJ)D(#
M*6PUGA6HFNE-P[N:&PXQ,,-`A($Y!A886&)@=0/NKA'5L?5-<7-L(P$FY+)-
M*.2PDU`'BO=X]][RQU?A_#FJ"Y.N!F5XVE5XQ%*MA%U-3U7,N@J/H'1$78V#
M7C3O2CR"'%X\TJ"PEX\TR.555X/>M.XJL,.;KL3SVM0H-8:A^#]JS%?!+);Z
MW\4)F0A-KQG%O/^G&`@Q,,-`A($Y!A886&)@A8$U!C82H.0&1KV2F\_[GJM'
M.F2^G0DN03-A(C3]9JJXO?Z])LV$F,HT\1T?53Z4^<"V49O.9)KT^OCMD<H'
M%GK]7.9MRW;0ZQ<R3VP[0-$M%=YR`[]MN2:\E<SW^OV@K_)KF7=]RW%5?B/S
M'F3G[K]2-OB2?:)L7*V6#?L]$1)1M1<26`0%-E4$3F`C/E1XR)R+,C=3!`ZQ
MD(%(Y6T+968N\YYGH9FRD.D7.T#T4J$=1QH5HFXJ[SL$S;6U(K`]-&$W,NT[
MWKVME++!\>:)LG&U6C;706Y-A$::0!@(,3##0"2`H-FQ+Y9!>I;R@T*=R_(O
MU0M9#<9M7!B%MXT`!;A2>&*@Y6N%M@S<%AO!B[Z^SQ*E*'#65(K"SU1?'P'X
M*K4X/FZZB="TB?50RT\1_T7B0R3OH5S,$(^_K2+!WWMECH$%!I886`G@&E*W
M'`K]H!R"_[0<_%HL'W$__T;B:K4,KG.?F<W>G@C-/>XI!D(,S#`0":`MY1>E
MFLMR2`/:0@N9?K0I%/[!IE#X;A44^D$5!/^X"N*>*RX=.2T/=$JSK-(2=N9W
M6!N&1(N*Z_6$#."$#@=MA*_@VMW@9DO`M?<4'^AO<7E(BTK+Z!Y,6D8?AF<I
M+L[B0\U.S>EZRVJX\#9_'N'_&Q1.6)8!XCUC]>T#O-AL_V,R_A<``/__`P!0
M2P,$%``&``@````A`!H-L^@D`P``^@@``!D```!X;"]W;W)K<VAE971S+W-H
M965T-C`N>&ULG%9=;YLP%'V?M/^`_%X()'PD"JD:2+=*G31-^WAVP`2K@)'M
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MV1`Y.WWA-+VG%0&SH4RJ`'O&'A3T+E4AF&Q-9M\V!?C.C91D^%C('^STE=!#
M+J':+B2D\EJESS$1"1@*-*;C*J:$%2``KD9)56>`(?BIN9]H*O,0S3W3]6=S
M&^#&G@AY2Q4E,I*CD*S\HT'VF4J3.&<2N)]);-=<.*X?_`_+_,P"Z[8LCND$
MKNUZ;VNQ=%Z-33&6>+/F[&1`ZX%R46/5R/8*F%M_=#:=8Z\9!DXIDAO%$B+8
M,^"%@"(_;H)@L;8>H3+)&;/5&+AV&,]9#C'1E,<>(N(6H4JEEM[U`A;DU"4&
M9O<3>[G@K7X%5OI;UJT.],4&@3N4$DTQSA`13Q'SV1"RFT(\KX,,$H+Z]Q-2
ME5J\VLEM8FH2]&S/]""X\#<.;C5FT24?C0/Q.+#K!08:%U.-<]BS_S9?30H1
M&-$U1A#XG0=:H\;`M8<)AIBHQ;1%C,>!72\PD`TVCJU]6[::-)8]ZN>MQOA>
MLR5&K1SIEQ??XW%@UPL,]'H?T:LFC?0N1]VXU9B+I$@'7DX@'J-WO<!`K_\1
MO6K26._(PJW&]/3J@-_X/;>#^3C#N`]P7&<YV9`#@./:R\NVUSGILT9_1$O"
M#R0B12&,A!W5.>+`TEVT.^)N'+6[1O$(CK[FH+"Z%W#TU/A`OF%^H)4P"I(!
MY<STH1&X/KST0+*Z^73OF81#IWG,X1^#P`=Q9@(X8TRV`UC8ZOY:-G\!``#_
M_P,`4$L#!!0`!@`(````(0"2U\",G`0``"$1```9````>&PO=V]R:W-H965T
M<R]S:&5E=#4U+GAM;)R8WX_B-A#'WROU?XCR?@2'_`(!IP5KVY-Z4E6UU^<0
M#$2;Q"C)+KO_?6=LDQV;.R[;%R##=X:/9^RQS?+S:UUY+Z+M2MFL?#:9^IYH
M"KDOF^/*_^?OQT^9[W5]WNSS2C9BY;^)SO^\_O67Y46V3]U)B-Z#"$VW\D]]
M?UX$05><1)UW$WD6#7QSD&V=]_#8'H/NW(I\KYSJ*@BGTR2H\[+Q=81%.R:&
M/!S*0G!9/->BZ7605E1Y#_S=J3QWUVAU,29<G;=/S^=/A:S/$&)75F7_IH+Z
M7ETLOAP;V>:["L;]RJ*\N,96#S?AZ[)H92</_03"!1KT=LSS8!Y`I/5R7\((
M,.U>*PXK_X$M>,C\8+U4"?I6BDM'/GO=25Y^:\O]'V4C(-M0)ZS`3LHGE'[9
MHPF<@QOO1U6!/UMO+P[Y<]7_)2^_B_)XZJ'<,8P(![;8OW'1%9!1"#,)8XQ4
MR`H`X-6K2YP:D)'\5;U?RGU_6OFS9!*GTQD#N;<37?]88DC?*YZ[7M;_:I$:
MT1`D-$'@W01A\20*XS3[2)29B1*]1PDG81:S./DY2Z#'I=+$\SY?+UMY\6#N
M`7EWSG$FLP5$ON9'CV;(V(\2!IG"(`\89>7#HH%<=%#EEW46A\O@!2I3&,U&
M:^!UT"2SJ:W9WL9AMH)?%5AT&,(P#L@M'<?WZWO%13'B8KV1?Z,-E"V+9_8O
M;V\US@CYK8(,T**%6E):S/H,YO9]:G0"'4E@FLYMR(W61,/(MJZ!$X.%!,6G
M2/=14+SR8;Q#+;.I4\N-UA`4;4C5]&!1&(&+X\.I))R&24HE%BZLOO&X*'9P
M6>QD3FL(KC8D&C>)4NC<+BZ5I&R64(5%FWR$%L4V;3S/'%JM(;2N@1.#A9+:
M*..F'CK];.II#4%R#9P8+"3<;$D/NC_U4&QG)\W<6FH-0=&&-%/%C*8SLBY5
M`^#$PT*;?P0-Q39:%CM39J,U!.UJ($LICNQJ\ZO&;7H,>L;XS"FUS9?.73XC
M,M,>)C2=TRI76R-Y'P.G%BM]#-LU*>VXV::\;-`L=FML1.\46V,QZ+/OH'/J
M9(-B[R:@]^<@TYV>]K\T<UNQ$5%`[68`L;?==!3C1-,_S`4;&/OX>&#=]2DP
M'!R&R'H39&1K,)6^6G!'=V8*'^3VES8E-O3QE+K]4\K(60H;IC4TJZZ%&XU.
M8A);:;;QL(&/Q]/MGN)E<>(F48LH']TEXA!Q;!^.!U)H',K'YL,F/IY/MWR+
MS_VM#2/[@BFR:^%&,V(28D<?SZ?[O\5WLPTSLDD8/M?"C4;SQ??JBVV=\(UL
M/WHSL#CCU*[9AI$=PW"Z%DXU=EVQH7^<2V\#L":'4]?M`9"1O<)PN19.-197
MZ.PGX_*EO-QV[1Y8C(BL"V.A5707!G6R0?_7OA+JRX-=6+=M&Q$%U6[ZX*K6
MK[NJ\`KKK&!](]57K5JT1[$55=5YA7S&VV8(!Y'!.MR$'T(\MSOV+=R0U74R
M&+Z`"^HY/XJO>7LLF\ZKQ`%"3B<IM)%67W'U0R_/ZH*WDSU<3=7'$_P5(>#&
M,YV`^"!E?WW`H\7PY\;Z/P```/__`P!02P,$%``&``@````A``-.%F9M`P``
M2@H``!D```!X;"]W;W)K<VAE971S+W-H965T-38N>&ULE%;;;NHX%'T?Z?Q#
ME/>2A)`+"#@JA,Q4FI%&HW-Y-HD!JTD<V::T?S_;-DEMTU-Q>`"RLKRR]L79
M7GY];1OO!3-.:+?RHTGH>[BK:$VZX\K__JU\R'V/"]35J*$=7OEOF/M?UU_^
M6%XH>^8GC(4'"AU?^2<A^D40\.J$6\0GM,<=W#E0UB(!E^P8\)YA5*M%;1-,
MPS`-6D0Z7RLLV#T:]'`@%2YH=6YQ)[0(PPT2X)^?2,\'M;:Z1ZY%[/G</U2T
M[4%B3QHBWI2H[[75XNG848;V#<3]&LU0-6BKBQOYEE2,<GH0$Y`+M-';F.?!
M/`"E];(F$(%,N\?P8>4_1HLR]X/U4N7G!\$7;OSW^(E>_F2D_IMT&)(-99(%
MV%/Z+*E/M81@<7"SNE0%^)=Y-3Z@<R/^HY>_,#F>!%0[@8!D7(OZK<"\@H2"
MS&2:2*6*-F``OKV6R,Z`A*!7]7LAM3BM_#B=)%D81T#W]IB+DDA)WZO.7-#V
MIR9%5RDM,KV*Q.#^>A\>ER=1DOZ&RNRJDKZK3.]6"71<*DT%$FB]9/3B0>N!
M<]XCV<C1`I1E?F+(LHYFS-BO$@:9DB*/4F7EPYZ!Y1R*_++.TW`9O$!EJBMG
M<\M)8X>S'3BR$%*X&(!WX<B6W0V,84EI``$$.48*53`C_;@#AH`D608TJ&XT
MD&4JN%D83^>VCZU%B.?)W"$4F@#NQAQ-;8G=+<--4'E+2=-1Q0H7FNW^<"5Y
MY8/XZ"V9)Z.N*L5&<V9C2K8N4+C`S@5*`[#,0F^;9H<N_+Q&<A%TJV$ZRYRD
M;S3',.T"A0OL7*`T`,LTO`!,TY^;E60[PUGN9EAS#+,N4&@@RU47QO,X>2^^
M*M+.75$:@&4>]OK]YB79,3]WMNY&<PSS+E!HX+J#HE!][![;N6M*`[#L9[]C
M7Y)M^WF4V4_>:$ZJ$IM\Y&W[`</)0:$I,R7BW-L-]X8W2FD`5FCRY&&\D3]O
M*TFV0\MR=P]HCE$9%R@T,+S;9/1V=G8F(?^@<##"I0^M`+/1INCP](S6PZ?%
M[(BWN&FX5]&SG+\Q)&U$QZ/!XU2^;AQ\$RU@4-SB!1PE%!Z,"V"4]^B(_T'L
M2#KN-?@`CPHG&>P*I@\#^D+07HW"/14PQ-7?$YS9,(R@<`+D`Z5BN(`'!^,I
M</T_````__\#`%!+`P04``8`"````"$`RS5T2V0$``!9$```&0```'AL+W=O
M<FMS:&5E=',O<VAE970U-RYX;6R<F%V/JS80AN\K]3\@[D^(20))E.3H`-KV
M2*U45?VX)L1)T`*.,-GL_ON./4#&YFR6[<TJC%^&QS/V"][-U]>R<%YX+7-1
M;5TVF;H.KS)QR*O3UOW[KZ<O2]>135H=TD)4?.N^<>E^W?W\T^8FZF=YYKQQ
M($,EM^ZY:2YKSY/9F9>IG(@+KV#D*.HR;>"R/GGR4O/TH&\J"\^?3@.O3//*
MQ0SK>DP.<3SF&4]$=BUYU6"2FA=I`_SRG%]DEZW,QJ0KT_KY>OF2B?("*?9Y
MD3=O.JGKE-GZ^ZD2=;HO8-ZO;)YF76Y],4A?YEDMI#@V$TCG(>APSBMOY4&F
MW>:0PPQ4V9V:'[?N-[9.?.9ZNXTNT#\YOTGRVY%G<?NES@^_Y16':D.?5`?V
M0CPKZ?>#"L'-WN#N)]V!/VKGP(_IM6C^%+=?>7XZ-]#N!<Q(36Q]>$NXS*"B
MD&;B+U2F3!0``'^=,E=+`RJ2OFY='QZ<'YKSUIT%DT4XG3&0.WLNFZ=<I72=
M["H;4?Z+(CVC/LFL33+ODS!_XB\7;!%\G,5#(CW!)&W2W:86-P=6#3Q37E*U
M!MD:,G<S0XY^KN]-%>:HDGQ3670NF(6$_KSLE@';>"]0TZS51*B!+=%K+$7<
M*50!5=J$!#S@[:&ACA3ZQVWHV)389`O\P&(;:GQ3$0\5LZDI28:2X/X<@Q]:
M.9Y?B6'!D+J%X3VO+E2$FKE>>JIRL1U(2,!`@9Y3%-W_V;M+NZNINDLOY[Z7
MR\"J6(0:^$LT,[-D<:?I.TX"!B804<S''5=BDVZ^-!\<H62EEZH_"<W1V!Q=
MF:,)CNIB&XS!9QB5V&1<!G/S01%J0H0TQV(<>V<"R7NC!F]H\JK6S\`:']=6
MW61S+TRV"#5D-=J!A`0,)/7")&[T&$6)/]H8J"$H=B`A`0-E]1D4);:K8N]1
MU"QT-^<SMK+L(\;Q.VI"`@89@R:-KY)6VVS6@H]:40<W,.^X%1`Z&C'QE&N3
M)HY;5PR]'CR4V(6]:UO1G2(>1!(:,;F4/Q.NQXN+H9L_MMU61'GPMGLDH1J3
M1UGR>!XT<+,^]A)C*.K:R!:6=<6M@.+A+3IBXBDK'H^'QFWB64^/&'%W_=Z*
M!Y&$1DP>9;OC>="D87+]<AJ^-=4G'&S;>S7B022A$9-'>>QX'G1DLSZ#]J&H
M;1]\XULOA)BAX`Z<T(B)IRR6X(W<A6C,!F9H&57$.O>^U]9GUML_[D7]JYU&
M3%1EP9]'1>,V4:TORH@1=V]7G!U)J,;D4@9,N#XP#+3K#U8<\?26QXXDC$0,
M'O]3OJ_5EN^'5I>B5@3[LM\FP=+:MG$OZEM)(R;B__)^_P?>'UJ?BE$K:C<'
M"^W/[[@5D,U!(XB))SP\`)6\/O&8%X5T,G%5IS<&[^8^BB?+"$Z6^ACF]0-P
ML+ND)_Y[6I_R2CH%/\*MTTD(9E+CT1`O&G'1QXZ]:.!(IW^>X0C/X?-\.@'Q
M48BFNX#*>OT_!7;_`0``__\#`%!+`P04``8`"````"$`__?H)N,"``#Q!P``
M&0```'AL+W=O<FMS:&5E=',O<VAE970U."YX;6R<55UOFS`4?9^T_X!X+V"^
M`E%(U:SJ5FF5IFD?SPX8L`H8V4[3_OM=VPD!LG;-7I*0>^XY]]QK7U;7SVUC
M/1$N*.LR&SF>;9$N9P7MJLS^^>/N*K$M(7%7X(9U)+-?B+"OUQ\_K/:,/XJ:
M$&D!0R<RNY:R7[JNR&O28N&PGG00*1EOL81'7KFBYP07.JEM7-_S8K?%M+,-
MPY*_AX.5)<W)+<MW+>FD(>&DP1+J%S7MQ9&MS=]#UV+^N.NO<M;V0+&E#94O
MFM2VVGQY7W6,XVT#OI]1B/,CMWXXHV]ISIE@I72`SC6%GGM.W=0%IO6JH.!`
MM=WBI,SL&[3<(,]VURO=H%^4[,7HMR5JMO_,:?&5=@2Z#7-2$]@R]JB@]X7Z
M"Y+=L^P[/8%OW"I(B7>-_,[V7PBM:@GCCL"1,K8L7FZ)R*&C0./XD6+*60,%
MP*?54G4TH"/X67_O:2'KS`YB)UIX`0*XM25"WE%%:5OY3DC6_C8@=*`R)/Z!
M!+X/),AW_"1"4?QO%M=4I`W>8HG7*\[V%IP:T!0]5F<0+8%9.0M?=0:65,Z-
M2M*I@!8PCJ=UL@A7[A.T,#]@-@8#-V#`^`/"!?&A`E"=5Q#`A/[>VV,%*FE:
M@9\.]+K(C8$D>K!CO>!_]%023&WD)DQ/?HR@P81G@N%4\&UC"IS9OFZJ[Z%H
M9LJ$%SH<I.$I/&DI#'#<TK<5%7BD&,\433C6BF$0G\8\48PO453@D>)BIFC"
M!\4P?<7CXA)%!1XI)C-%$SYZ3$\MF'A4VWQT5=[NJ@*/%.>'TX2-(DH6P5#0
M1#&]1%&!E>+IPD6>-_":(VHPH1XF0J_XA$UZ@5&-GNHF\YMQP)ACBU*4G-IA
M_)K-:Q932WA%/I&F$5;.=FJK(JAW^-=L_`UL?%_?M"$`"[?'%7G`O**=L!I2
M0JKG+.``<[.RS8-DO=X<6R9AU>J?-;Q:"2PVSP%PR9@\/JB7PO"R7O\!``#_
M_P,`4$L#!!0`!@`(````(0`M-<GKK`,``,4+```9````>&PO=V]R:W-H965T
M<R]S:&5E=#4Y+GAM;)1678^B2!1]WV3_`^&]^1`%-.JDE>W=26:3S69G][F$
M4BL-%*'*MOO?[[U<A`)G',8'E<NIP[F?W/6G]R*WWGBMA"PWMN]XML7+5&:B
M/&WLK_^\/,6VI30K,Y;+DF_L#Z[L3]M??UE?9?VJSIQK"QA*M;'/6E<KUU7I
MF1=,.;+B)=PYRKI@&B[KDZNJFK.L.53D[LSS0K=@HK2)855/X9#'HTAY(M-+
MP4M-)#7/F0;]ZBPJ=6,KTBET!:M?+]53*HL**`XB%_JC(;6M(EU]/I6R9H<<
M_'[WYRR]<3<7=_2%2&NIY%$[0.>2T'N?E^[2!:;M.A/@`8;=JOEQ8S_[J\0/
M;'>[;@+TK^!79?RWU%E>?Z]%]D64'*(-><(,'*1\1>CG#$UPV+T[_=)DX*_:
MROB177+]M[S^P<7IK"'="_`('5ME'PE7*404:)S9`IE2F8,`^+8*@:4!$6'O
MS>]59/J\L8/0641>X`/<.G"E7P12VE9Z45H6_Q'(;ZF(9-:2!*"^O1\Z\]DB
MBG^&9=ZRP.^-93&9Q26_FC`E3+/MNI97"VH/E*N*827[*V#&^`009?*FB]CW
M`@:10I)G9-G8T#1P7$&6W[9QM%B[;Y"9M,7L"`/?'<8?(O;WB#@*AYCD'A,&
M7H=QP:O.-0B[Z=JW4W[S`,'H`98`NK0C@REWUCVF0>Q_B$CN$7$4=2P#L5`;
MT\4B&/)DA#*.XHZ7]!-FWCFT'QL2PS"0`F5@2KF5Q./XX:&-#0YWV8VCY4@2
M80Q)8T-"AK"I(-];+CSX="0#D=!]ILC'XA`\$A?WO!0OPACBQH:$#"0N"/V@
M+_"!LG"H;%KX\-!8X:@]=H0Q%-X,V&\C=Y+;/1R.9E-$0W6/XX;@L:I1%^P(
M$S4I&XG8T[U><6(8!JKP=6M,H<>J$#Q4%7E]5U$V"=,_>3\V)(9A(&7Y,U(0
M_*-&)(PA96Q(#,-`B@^#V`S+M%)J3@WC$\=!UT44GQ9DJ+JS)*TE:MO1B9IV
MQ)9L/K/?GOI:&.K&(3TYG3Z-='-TA,M1)>U:D*F7CO66Q,0,]>`<GJZ'IO;C
MZ>H3J'_Z_LZ2F):A'IR\AIZ)>:5Y;<;I&WDUAGJ3Z3UL5UBCO5+<M]#2YM5S
MO'E7'"23MBE:$PI>G_B>Y[FR4GG!3<F'5N^LW1;W/,,WC=O=@"6J8B?^)ZM/
MHE16SH]PU(,:LJV:UC"ZT+)JEI"#U+`^-7_/L"YS>`5[#H"/4NK;!3Z@6\"W
M_P,``/__`P!02P,$%``&``@````A`.'Q*"-<!```8`\``!@```!X;"]W;W)K
M<VAE971S+W-H965T,2YX;6R4EUV/JS80AN\K]3\@[A-B\ATE.5I`VQZIE:JV
MY_2:$).@!9QB[V;WWW<&8V.;TQ6YR<?P>OQX9CS&^R_O5>F]T887K#[X9#KS
M/5IG[%S4EX/_[>_GR<;WN$CK<UJRFA[\#\K]+\>??]K?6?/"KY0*#SS4_.!?
MA;CM@H!G5UJE?,INM(8G.6NJ5,#?YA+P6T/3<SNH*H-P-EL%55K4OO2P:\;X
M8'E>9#1AV6M%:R&=-+1,!?#S:W'CREN5C7%7I<W+ZVV2L>H&+DY%68B/UJGO
M5=GNZZ5F37HJ8=WO9)%FRG?[9^"^*K*&<9:+*;@+).APS=M@&X"GX_Y<P`HP
M[%Y#\X/_1'8)V?C!<=\&Z'M![]SX[?$KN__2%.??BII"M"%/(CW]14N:"7J&
MS/D>9N3$V`L._0JF&4S"6P%.PO]5TSR%.$N@IS%_JRF?V[3]T7AGFJ>OI?B3
MW7^EQ>4J8*8EA`&CL3M_))1GD`:8:QHNT6O&2G`!GUY58#U!&--W25><Q?7@
MSU?3Y7HV)R#W3I2+YP)=^E[VR@6K_I$BTKF23L+."7S?N^=0E",'S[O!\*T&
MA]-PLR3+U0,(B\X+?/=>1JXCD#%IPYVD(CWN&W;WH-AAU?R6XM8A.W"L8BLC
MH:/]?\&&**.3)_1R\"$@$$<.&7\[SO;!&^0TZQ215,"G5A!;$2L%)A"=)H8A
M`%J-#"DPD7]<!HH,Q4BFO$;28(*$#LA0,;<5R5"QT`H+%1)NHF)TY[!I/D?&
M0:`S0K74WMO(1%*QT(N*74-B&"P@2+$)]#D(B@\^+%;G;.6`2`5\:L7:5L1*
MH>*?&`:+#+;B>#(4VV0;>]Y(*B39Z4<5&2N%)C,,%MGJ$3(4VV1;ATPJEBW3
M`LZ?OG3:Y,;R>9_<Q#!87.M'N%!L<Q%WBTK)H@4+9\3E4H]UO`R#Q86'M=%2
M/J\Q%#M<3F.(I,0L,N)N6271;(;!8ML^PH9BA\WI!)&46&QNW)1$LQD&BXU`
M9Q@?N%;MT+E]HM-8>,X6CK5&\YD6&Q`[\NC,$MF_S?9!G.X0=1I9<P3.X_G"
M64.L)3V?=-SN$)L/^_)X/MG%+3ZWBQ"I0;[\.)F0<#*'ZLSQ@)L09V/'6MR3
MJN%@L4FQ/X\GE=W<(G4FCXCJ^'TK#IT-'FM-#ZA&#0"A9AX`1+5=BZ&[BXG4
MF+48NMM8:WI`-6H`B-UZ?`1E;S<C&+I;&5\I81$6X"""2M,#&A8[Q=BVQP/*
M)F\!.HTD(NH@,%(\V"U*TP,:%AL0^[<!..[EA,BN;X$Z+27J-/T1%G>6E3Q;
MMMO59K%V1B7F*!L4F[D!^OF!`M>702T.VHYQ/,A#MQO5(^,U"/VLY3D]7X=D
M3C9]N"6AO+_(%^J*-A<:T[+D7L9>\3Y"8*RVZ@M6=_/1#^"J<DLO]/>TN10U
M]TJ:P]#9=`V%U<C+COPCV*U]73\Q`9>4]N<5;K(47I5G4Q#GC`GU!W>+OAL?
M_P,``/__`P!02P,$%``&``@````A`.)#<K:-`@``(P8``!D```!X;"]W;W)K
M<VAE971S+W-H965T,S<N>&ULC%3;CML@$'VOU']`O*^QG<U5<5:;6-NNU$I5
MU<LSP=A&:XP%Y+)_WP$2-TYZV9?$P)G#F3,S+!^.LD%[KHU0;8:3*,:(MTP5
MHJTR_/W;T]T,(V-I6]!&M3S#K]S@A]7[=\N#TB^FYMPB8&A-AFMKNP4AAM5<
M4A.ICK=P4BHMJ86EKHCI-*>%#Y(-2>-X0B05+0X,"_T6#E66@O%<L9WDK0TD
MFC?4@GY3B\Z<V21["YVD^F77W3$E.Z#8BD;85T^*D62+YZI5FFX;R/N8W%-V
MYO:+&WHIF%9&E38".A*$WN8\)W,"3*ME(2`#9SO2O,SP8[+([S%9+;T_/P0_
MF(MO9&IU^*!%\4FT',R&,KD";)5Z<=#GPFU!,+F)?O(%^*)1P4NZ:^Q7=?C(
M155;J/88$G)Y+8K7G!L&A@)-E(X=$U,-"(!?)(7K##"$'OW_012VSO!H$HVG
M\2@!.-IR8Y^$H\2([8Q5\F<`)2>J0)*>2.Y!_>D\C=+9.!E/_L]"@B*?8$XM
M72VU.B!H&KC3=-2U8+(`YG-F04>?Z]]2A1P=R:-C\5R0A8'R[%>@:4GVX"D[
M8=8!`Q/18Y(A8G-&.`,=;7ZQ04!O+QJLN!3]YS*<M3GPM;;)\.;U+28=(C:W
MB%$\A.2WD,GO>P;Z1T/]SO01-.6_\W!!@+OP#XH_E+`.&#\)WL'-]49^L3&0
M!+6_M/1MDEQ0AB'OOJ23='HE*6#FOBF2:#8\W0Q/KTR'D7;\TQ#;1P;=85A#
M+TNN*[[A36,04SLWB`G$]+OAC5C#&^$GBO0',*,=K?AGJBO1&M3P$D+C:`I#
MJ<.4AX55G>^@K;(PG?ZSAL>80X_&$8!+I>QYX=Z1_GE?_0(``/__`P!02P,$
M%``&``@````A`+@_3O\R!0``9Q4``!D```!X;"]W;W)K<VAE971S+W-H965T
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M2E6ESR>8]P>;IMDE=_MAD+[(LTK5:M],(%V`H,,Y)T$20*;-:I?##'39O4KN
MU_X#6PJ>^,%FU1;HGUR^U^1OKSZJ]U^J?/=;7DJH-O1)=^!9J1<=^FVG)1@<
M#$8_M1WXH_)V<I^^GIH_U?NO,C\<&VCW#&:D)[;<?1>RSJ"BD&;"9SI3IDX`
M`#^](M>O!E0D_6A_O^>[YKCVHW@RFX<1@W#O6=;-4ZY3^E[V6C>J^!>#F$F%
M2;A),@5Z\SV?\,6,S>+Q+`$2M1,4:9-N5I5Z]^"M@6?6YU2_@VP)F?7,8J@/
M<G1S_=%488XZR8/.LO;A=8?A-?3G;1.SV2IX@YIF)N9Q&,/LB.TE0A=0IQ5$
M"("W@X924.CK;;BPZ6#-=LGZB`+D[F"Y`S*,B$([1`Q#XK@+L6`C&U97.((*
M?PZM!ZU]>$C'N(BZ]&UQ'C%DVLUKZPJ""!81])F63Q--?_@V7\JH!P$Y(8I9
M/V-$PAB"Y`J""!82//Y^)#W(+E+,YDZ5,(8@N8)`(6[?6@Z+B;%IE\-BC(>,
MXXW4@VS&19\>JX8A!-$5!!$LHOF0:+R1>M!8(S&&(+F"((*%I+<\QT_&D?0@
MNTC#1F(,07(%@0(V,DHXG_>%MA"3(>)X'_4@&W'A&AR&$$)7$$2PB!CXP?U5
M:T>-==($$:J!(JAB<VD#OKN;#&V;FM>PG2:(<N&P7A$F!CLZC:(XC/KE;8-J
M.W9`QWO*T,0IZ,*U-!/34VT'BJ"*C:4=V,$:7PT,??MSJS5!E`N']8J@,3:7
MMN'[N="\:;FN])4X?&MO6^8JPBC8UUD2)DG8E]T&U>;L@-[05[1T&W31F3JZ
MKO[_#59T7Z[M0!%4L;FT(SM<-S06?7RDL<3L30%=13"BV%S:EN_G0C.WZ]6O
M-%,OXOB&RU4$0P4;.X^3:=Q7W>;47NUPWM!7='C*N>@?8##=;6'+7$50Q<;2
M!NU@W=!6M/61MA+O-^5S%<&(8G'Q_[4_M*/L/6NX7DT0608#11C%[*Q1PI*D
M_]?=!KVR88SWE5_;,!)GO9H@"CK8,&B,S07OS/V-Y7K4V`9K@B@7#NL506-L
M+NW9=[]P')V>KH,KC<6@GF)KAF$;6<062<('QQHRRB9UMHS/CR_\RE;A/NO1
M!%'"P59!8VR>*SO#^%+5!^7QC@YV!C.L)Q54L;FT-=_?433TD8X2UT<+X:XB
MC&)ZO`CGY+1A<VJK)IPC_41CM_AX[P%HO=S=#[8#15#%YKFR(]S03_1V>&F[
M<_+P5,K=#6`[4`15;"[MR:1.MQV6X3+*/2Y<6:$8A+WB83)-PO[$8AILA40L
M2N:#%4M#(CZ%B/XZ`Z>"]UIX[5/(ZB"W\G2JO4R]ZCLK#B??3NWNTQZXOEAP
M]$>X9VLOI8+N"[CF.J<'^7M:'?*R]DYR#RG#R1S64(479?BA4>?VLNE9-7#!
MU?YYA`M-"=<\X02"]THUEP_PX*"[(MW\!P``__\#`%!+`P04``8`"````"$`
MKU*T'SD'``"Q'@``&0```'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6RL6=N.
MXD80?8^4?T!^7\`7K@)6`W8G*VVD*-HDSQYCP!K`R/;,[/Y]JMRWZFX/XQWE
M9=DY5)7K=%UIKSY_OYP'+WE5%^5U[?G#L3?(KUFY+Z['M??W-_9I[@WJ)KWN
MTW-YS=?>C[SV/F]^_67U6E9/]2G/FP%8N-9K[]0TM^5H5&>G_)+6P_*67^&;
M0UE=T@;^K(ZC^E;EZ;Y5NIQ'P7@\'5W2XNIQ"\NJCXWR<"BR/"ZSYTM^;;B1
M*C^G#?A?GXI;+:U=LC[F+FGU]'S[E)67&YAX+,Y%\Z,UZ@TNV?++\5I6Z>,9
M>'_WHS23MML_'/.7(JO*NCPT0S`WXHZZG!>CQ0@L;5;[`AC@L0^J_+#V'OPE
M"WUOM%FU!_1/D;_6Y/^#^E2^_E85^Z_%-8?3ACAA!![+\@E%O^P1`N61H\W:
M"/Q9#?;Y(7T^-W^5K[_GQ?'40+@GP`B)+?<_XKS.X$3!S#"8H*6L/(,#\._@
M4F!JP(FDW]O/UV+?G-9>.!U.9N/0!_'!8UXWK$"3WB![KIOR\B\7:ADI(X$P
M`I\=1NXHAD(1/J7B,`HFLWG[]#N*D5"$3Z&XZ*<(I%J^\"F?Z`_GDTDTG<\`
MN_/(J="$3Z'ICX=^-)[B0;EZ(W[0;=SBM$DWJZI\'4`QP%'6MQ1+RU^"+1DP
M;D&%\*T(0NC0R`-:67M0Q1"<&M+N91,%P6KT`JF2"9FM*^.;$CLI@7F!9F,;
M2&R`$6`$C!0MB/W_0`NM("WIT%8"FJ?%<B<EI$IL`XD-,`(8'"`-;0XA5&1W
M+<E(H!)4C1&)T#SG+9>)-*^=@\0.DC@(HXCA.=0!]?R^QR@,V0>G<"=YN%"T
M,(0BD]=.":G#=Y#$01A%#!902)0%EL8T'.JZ[%T=:*AE*/W:<F0"V4LX3RPZ
M2DBJQ0Z2.`BCB$$'JMNF$\ZQ#8MVT9L.&C+I<,2B,[7H*"%%QT$2!V$4,>C,
M7#K!9/CS;-".R88C%IN9Q48)*38.DC@(HXC!!A<@TH;O5PP*FRYSQ')Y;KFL
MA)3+#I(X"*.(X3+4(G693XZV/.Y[CWJF]QR91*K/[APD=I#$01A%#%=]:)O4
MU_L.MM*FAQ+BBP;.IIT+Q2Z4N!`S(---G&:]L\#GLP\:IXSG5D`!T"5]96'E
M@932BK&&M*(_LQI2(J0BJ$EM/AR;YIF0@C532_E3+652QN%'*),L:DY%]K0M
MX4E@J2-B(>P98OO@$]0X"0Y%4'#$56?A$(HZK#'.(4Q/#24""F%0$%O6X&=2
MD4H%$UV#)FT<G81V!SUHS(H?'[0&/PZ%?(GF":D@[28]=[%2":FIRIK$=R`F
MH=:\Z3F.R_Z>\^%J>,XA,T=#:T79^4**YJ@#)5)JT:Z<BRBR,I8)@9ZYB*.3
M4/M8+O+Y:S#FT'NY*!1UXL7XR\G.10Y9N6@M0DPJPHFIC'T[%W'$$MKOY"(?
MR`8_#AFYJ"#M0$<N"BF:BP[$?&4+^IR9BSA.B><?"QB?R08A#EDI:N76SA=2
M-$451&B[;51(\:R=PPV%W4&Y0,^LQ0%]YQ"^E;>W.BAM,7S,&Z?`(2.L"B+\
M2&L7+49(S4B+<2#F*UM.6'&.$T;O)"2?^H;G8A&@$R@*K5/>^4I*SL_8A1(7
M8@9D)"1F#/6<).1]$JVBN7((B&Y%+A2[4.)"S(!,CW&)Z'W6`4I;;@I(MZV=
ME-)0[$*)"S$#,MW$J=S?33'#=65N`P[!0>#E1##V[6J6`EHGUA#)=J>:I12O
M9G\:V8N!$.A7S0'.XOY$^>2FN=\:6'LP;`11.^V%`%EP8A=*!-1VB)>-/Y]:
M9IC4H2.&=G@S?#BZ^[/B@]Y@Q2$=/OOG6"`$:/@<*)%2/%:![UMK!Q,"/6.%
MLYBP(M7>?W?%W]]V27%(AU`OD6V#W4D=6F#"C(82(25"&(1S*^69-`/GI+:$
MMT.(4YB0?:>?\9EMA)".<<%#0=T.\'$2""FR);@0DY"[L08X38GG'PL3'\D&
M(0[-=,KMVD>M/:AX-5(T1#BZ383;"MY<"829GHF)H_4.XWXK0<`'M$&9SFP1
M0P41?LY*(&R%9"5P(2:ACAA:*T$;PS'T])^\IX8#=JI-K0&:0!0Z_45)Z<@Z
M4"+,PSV,E&(&9#1%O,M](TKWBZM5-*>P@.BRX$*Q"R4NQ`S(]-A:%C`*'[M"
MQ#RVNIZ`S#NLT&Y]6DJ><.Q"B0OA6R]\(@\-9\7?8O&W(9>\.N:[_'RN!UGY
MC&^HX&?'9J5@_OILNUC")1,\V<9]^`+6PHYO@O$2UZ^N;T`'LJ/CFQ!T(`I=
MWZCW=Y8'\&+OH>TZ%KX%A38;;3R`AW<^`1[=@3]$RP<XP@Z7HB7<H'?@DR5<
M17?@TR7<Z7;@LR7<CG;@\R5<00(^4@S@A>$M/>9_I-6QN-:#<WZ`<(W;F\>*
MOW+D?S3BE\]CV<"K0H@HO-Z"5\,YW-Z-\:+X4):-_`,?H%XV;_X#``#__P,`
M4$L#!!0`!@`(````(0">W)V82@8``*\?```9````>&PO=V]R:W-H965T<R]S
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MCD%]KRZWGX^7IBV>SY#W-Q$7Y1@;WRS"UU79-EUSZ%<0+A@FNLPY#_(`(CT^
M["O(0)7=:^5AYS^)[8=4^,'C`Q;HWTJ^=K/_O>[4O/[:5OO?JXN$:L,ZJ15X
M;IHO:NCGO3*!<[#P_H0K\&?K[>6A>#GW?S6OO\GJ>.IAN1/(2"6VW7__*+L2
M*@IA5F&B(I7-&28`?[VZ4JT!%2F^X>MKM>]/.S]*5ILDB=--!F&>9==_JE1,
MWRM?NKZI_QM&84I3E%!'@=<Q2KI*LG4D0/1.D&"8$2;XL>B+QX>V>?6@:T"R
MNQ:J!\46`M,902IJ[),:O/.AJV&N'2S#U\<XRA^"KU"Z4H_Y,(R!O],8,8T(
M0'12!C5W9358*:O:JJE\&`QSF9"6B7Y$1@V&Q9E-/H[74]Q!>1@38\/,\XE_
M1$@-AI)#%E.9EJ74@Z!=WP;%3#6A`]RKJ0:C^E1.;3$S9RJ:FE)J,\3K?`7F
MV]VC_$Q5;9FO8AQ'4[V-=LF6JHE8J>US6U7YF:K:8JK&M*HBN//V4(--*6V9
MEU7D&2V5FU+.955^IJJVF`DFM*J`[IIGZ"R+CJ;N:#*%4T881MG"47QW.85R
MLV2UR91EJJRVG"TKUJ%#(Z&GI:PI9"IOF(05.&:]I"KMDO#`&U"?-JO0)E/V
M#<3&OA$_Q"4<;26I,60V,9>D`HF59+B.7<JK$33/4YN,/),W'IMY$E@*8YCT
M;3R()95&DRG+<%<07'*176()(T'I35F&P<("DVHFD40N=5Y2"H,ME!D."X)3
M6:;./?<JO005QEH(,R@."5*E\>JN+OJ!R*RQ1I-9:H:0(8R:M_3M?L+1EIH*
M`"9S`W%9$GQR*F^H631/D\)3PO`X5%"Q=FZ4K1WJJQRMC+7)K"]#Y-`"E/,W
M$#I:PII5IC##*M6R=L9")`X9:R[-2ZU-IC"#Y)!`E=-9!AVMC*DS5,HP,B1@
M)6*8\YV>7L(*(\%,C'Q3AI$A`:MH$SDP`SVMA#6_3&4&DR$!*Z>S*CI:PM2Q
M*F4H&1&P<A)&1U-X-)D9,_R(8-2BJ5-X3KRWR.AH":M88#*%&4Q&!+C<#E;H
M:2E3Y$H9<D46N6XW,XZVU#2NX&5ZT!(YIT;@RF$/19I,,V:,)K.\#"4C`E91
MDCE\X:.GE3!%JY3!9$30RNVH@9Z6,HDKAI,1@:LH"AVX@9Z6LH:84>V,`65$
M$$ODT)1W>FMYML)(,!-3E@%E1.#*[?2,GE;"%*\R!I2QQ:O;>>)H4VTTS?=0
MN&;HJ+YR%I`*-PX+BYZ6L@JVJ#"G3%`J6J<.VRC62)IMX-%DKBT#9O4HLLCY
M?DNAFY6PQI4IRV`Y)G#E\-2);I8L=;;*&$JJ!_E%MBYG*W2TA"E:90PG8XI6
M6>[26AI-\P6F:)4QG(P)6CD=)]'12IF$%8/)F("5RX,1^EFZU.%JPT`RMFAU
MAQD:1_/R:I/)#(90B44H]R=>]#3S'$W&%MHP5$X48*PG(X<O`W2S9%4D,)FR
M7,($JL*-<.CD9(FJT60J,Y!,"%2%.6S_VRN,;E;"%*HV#"$3`E4YK/H=58VE
M65]AH$69&4`F%*F<?A!$3RM?"E4;AI&)A:H[>2[QA`%@`O/](W*&$@F%)[<\
M-8SF%:;XM&&0G!!\<OI)`QVM`I.`8HB<6(`:D.'P78^.EK!F5;:X]TD),+GM
M4_0T94:3N4^9)84KSP68[F\8]+)452`P&:JYC?WA>G2X/:QE>Y2_R/.Y\\KF
M15U]AG`?.%FG:]DG;!K;'F^?ANO:8/H$KDNOQ5'^4;3'ZM)Y9WF`F&M<JW:X
M<!W>],T5)@K7G4T/]Z3X[PDNQB7<">)O58>FZ<<W\(-Y,%VU/_X/``#__P,`
M4$L#!!0`!@`(````(0#\+FM[.P<``/@?```9````>&PO=V]R:W-H965T<R]S
M:&5E=#$U+GAM;*R9W6_;-A#`WP?L?S#\7MN4_!$;B8O8(K<"'3`,W?:LR'(L
MQ+8,24G:_WYW)"7Q>*HK%WNIFQ^/I_LBCQ+O/WX]'0=O:5%F^?EA*$:3X2`]
M)_DN.S\_#/_^HC[<#0=E%9]W\3$_IP_#;VDY_+C^]9?[][QX*0]I6@U`P[E\
M&!ZJZK(:C\ODD)[B<I1?TC.,[//B%%?P9_$\+B]%&N_TI--Q'$PF\_$ISLY#
MHV%5]-&1[_=9DD9Y\GI*SY514J3'N`+[RT-V*6MMIZ2/NE-<O+Q>/B3YZ0(J
MGK)C5GW32H>#4[+Z]'S.B_CI"'Y_%=,XJ77K/YCZ4Y84>9GOJQ&H&QM#N<_+
M\7(,FM;WNPP\P+`/BG3_,'P4*Q5.A^/UO0[0/UGZ7CK_'Y2'_/VW(MM]SLXI
M1!ORA!EXRO,7%/VT0P23QVRVTAGXLQCLTGW\>JS^RM]_3[/G0P7IGH%'Z-AJ
M]RU*RP0B"FI&P0PU)?D1#(!_!Z<,2P,B$G_5O^_9KCH\#,/Y:+:8A`+$!T]I
M6:D,50X'R6M9Y:=_C9"PJHR2P"J!WPXE5R:&=B+\VHG3]N%7YDWM//BU\T0X
M6HC),ER`U5<FPJAV%WYOLW1N)\)O\\2N)XU-?'6ZHKB*U_=%_CZ`-0`1+"\Q
MKBBQ`B5UGHRM3>:^ESC(&"IY1"T/0UB\D),2JNUM/5V*^_$;5$AB939<QI/8
MUA)8#J@V\H'T@7+`&#QJW(*4_P]NH19TJS9H4X/6SX!ZN:TEZBF1#Z0/E`.(
M#U!]O@\A+,3N)51G`B?!8B&9\&S<&)EIZ]>6D8@1R8AR";$<ZM^U_+K%*`S5
M!U&X4CQ&:$XK+/1BWP@UP6=$,J)<0KR`Q=C?"Q367M3/WACB1IF1B!')B'()
ML0^6:W_[4)C:9\@"DNC$?>J%M!&JW8H8D8PHEQ"3%[>8C,+49$/<D#(2,2(9
M42XA]N'QP]L-9[#%W+@;HA9JN"'S)8GUS(MU(]3$FA')B'()\04>YOIR?1&B
M,#79$#?6C$2,2$:42XA]`O8RUT!L/3\1;*V&FFZ1%^ZY%^Y6JHDW1Y(C11!U
M"=N14S_78RY,\X*=KS9@8Y$;=8XBCB1'BB!J)G:<_F::_D3,-,@+\,(/<"-5
M^Q?A+@]U!A-K)#E2!%'+L>7TM]PT*&*YV[/T(6,K&(HXDAPI@JB9V%,<,W^V
MM$UK(O;;;@6KRMFU[_S(-U)UF"/!D.1($41=PC;DN/2#TC9-BUCN]C$;>88B
M?$>``G$6@.1($43-Q-;3WTS3J(B9!GFEO?0#W$BU`69("H840=1R;$K]+3<M
MC%CN=C4;8(8BP9#D2!%$S<1^XYAI7AA&^'[S@Y(PC8I8;-!"OTI:BQF*!$.2
M(T40M1@[D&/Q#\PT_8J8:5M8LV=MA4\B1B0CRB7$PL#KA-<MU-*TX5DT6^A7
MKV`B_*.%%0C,^[%^MVI1NY.(A3=1UE)W6G.XG'H"R@K@BTFS(8GYI%DOU-&;
M^B-8ZQ]*+`IJ/_V>;L?UAPU=4!$CLM8Q->^IX=P[\RH4Z.$+MK+>9168QN>6
ME45MTOS^:07`G&:3X4C6R&1H.EVR#)E']\S030TVX`W6HB9#?FNRXVZ&;/]M
MO)2UCCI#2R_-"@5Z9`A;7O\,F09),F10FR&_#01&@&2((5E+F0R)NX7WWJJL
M0,\,88=TO'(VX.J0)2^;'"(#%=RQB810\7I5/.)'-.^\;Q$42Q/9V:1=QV9[
MMD)N]FS#=K)G2(A/>UL+P9('X\TCOK]58.]TW.QP!XQI_#&=EB3/H)GSE2-H
M4+<!=L>P4LX9M9[8(E4CK9YN<MAA'<M_+D&F31.'#()JK+>#;6`0J;\&.3[R
M;=U*V9)<BCNOM)55W;,FL45?<?E+?OE>3;I)-(V>^&P026*#'`>=AF.3:*3F
M[=%"!@PIBXQZFL2;#@T!/S18Y!QDMQQ%'$F.%$'$3$R/'_@@Q$_JG>N_73!Z
M(CU$6+1H%_>6HX@CR9$BB%I\TQ$@Y$<`B]S`<A1Q)#E2!%$S;^KN(>_N%I'/
M:[.)_\6[E:K7=,21Y$@11"V_J8/#+NTW`HM(@&V+;O?2B$M)CA1!U$SLD]Z6
M$=[IRKWQ:QM<8S$7#"(O<;.)]QE\:R<Z'R,BCB1'>'&&3S03C5?F(LS<K)S2
MXCG=IL=C.4CR5[SD@F:QOF^PN8';A'@%I\]V;"2`$?U5B(V$,!)B`V`CT_I"
MSQ\1LQ6^,'?,$7,8F7>.+&!$-QJF[0Y&=!WX(\%RA3M5QW/""=BF=V)_#DSI
MG"%@!GQFZ]`E(&KP9:MK!*)F>H?_%`%1@X\U77,@:O#-@X_`_>AC9P;P\1WR
M&WAXISPFK$/^<;IZA#+B#]Z`19T<LMB91,AA9PHA@YT)A/R9,TL3);AWO<3/
MZ1]Q\9R=R\$QW4/)3O0K?6%N;LT?E>WB3WD%-ZZZH1_@ACV%F[K)"#K./L^K
M^@]P;-S<V:__`P``__\#`%!+`P04``8`"````"$`\/I3?W$"``"7!0``&0``
M`'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6R45%U/W#`0?*_4_V#YG3C)Y:!$
MET-'$2U2D:JJ'\\^9Y-8Q'%D^SCX]UW;7!0X4.E+%&_&L[.SNUE=/*B>W(.Q
M4@\5S9*4$AB$KN705O37S^N33Y18QX>:]WJ`BCZ"I1?KCQ]6>VWN;`?@"#(,
MMJ*=<V/)F!4=*&X3/<*`7QIM%'=X-"VSHP%>ATNJ9WF:GC+%Y4`C0VG>PZ&;
M1@JXTF*G8'"1Q$#/'>JWG1SM@4V)]]`I;NYVXXG0:D2*K>RE>PRDE"A1WK2#
M-GS;8]T/6<'%@3L<CNB5%$9;W;@$Z5@4>ESS.3MGR+1>U1(K\+83`TU%-UEY
MN:1LO0K^_):PM[-W8CN]_V)D_4T.@&9CFWP#MEK?>>A-[4-XF1W=O@X-^&Y(
M#0W?]>Z'WG\%V78.N[W$@GQ=9?UX!5:@H4B3Y$&&T#T*P"=1TD\&&L(?*IIC
M8EF[KJ*+TV1YEBXRA),M6'<M/24E8F>=5G\B*`NB(E>0=L4=7Z^,WA-L-Z+M
MR/WP9"42'S1%ADGE6R)1G2?9>):*XIQB?HO&WJ^7Z6+%[M$-\82YC!A\3IAL
M0C!4,TE"&7-)K]MSR.S!/C,:'Z1<QL`\3?YZFL7_I/%@]'LFOBC2B3=FCI@B
MV#VOIWB>R%N<G_H6O]'Y0VG^'K8%"YH<.W;U"83#.`,5D[)GQF+&N;%>R"([
M3_XIQ-\+0B:3GR)SEY?I\D76N`AQVA28%CY#WULB],X/>8YC,D6G_=ODWKZ7
M\:+<A(5@TP?<BY&W<,M-*P=+>FB0,DW.4)B)FQ4/3H]AQK?:X4:$UPY_@(!#
MF_K"&ZW=X>!W=_JEKO\"``#__P,`4$L#!!0`!@`(````(0":_."@?`(``/(%
M```9````>&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;(Q476^;,!1]G[3_8/F]
M&$A(&P2ITE7=*FW2-.WCV3$&K&*,;*=I__VN[021)NOR@O#E^)Q[S[V7XO9%
M=NB9:R-47^(DBC'B/5.5Z)L2__KY<'6#D;&TKVBG>E[B5V[P[>KCAV*G])-I
M.;<(&'I3XM;:(2?$L)9+:B(U\!Z^U$I+:N&H&V(&S6GE+\F.I'&\()**'@>&
M7%_"H>I:,'ZOV%;RW@82S3MJ(7_3BL$<V"2[A$Y2_;0=KIB2`U!L1"?LJR?%
M2++\L>F5IIL.ZGY)YI0=N/WAA%X*II51M8V`CH1$3VM>DB4!IE51":C`V8XT
MKTN\3O*[!2:KPOOS6_"=F;PCTZK=9RVJKZ+G8#:TR35@H]23@SY6+@27R<GM
M!]^`[QI5O*;;SOY0NR]<-*V%;F=0D*LKKU[ON6%@*-!$:>:8F.H@`7@B*=QD
M@"'TI<0I"(O*MB6>+:+L.IXE`$<;;NR#<)08L:VQ2OX)H,0G%;A\:O?4TE6A
MU0Y!NP%M!NJ&)\F!^'PND(3#KAVXQ#".(&/`O^=5%B\*\@Q%LSWF+F#@.6*2
M$4%`=%0&M<N5'=@I.U=<*G<A,)5)S\O,CF6<Z3-HW?N%NDN`FQ21Q=<C?\@@
M8.;>W6E=\V/!]X4<&*R':D:[3BW=@R#K">AF3.?(59B$J:M^QI(L^N>8'5KK
M[OE$1H?WD:G%6;P\K[HXHQJGT?5_9=W%8]E]Y$@VB=_(AAT+@RRY;O@GWG4&
M,;5U^Y/":([1<;77J6O5V_@\7_N5)^,'6+F!-OP;U8WH#>IX#92QKT6'I0T'
MJP;('!9/65@V_]K"OY7#=,;.[UHI>SB`,!G_UJN_````__\#`%!+`P04``8`
M"````"$`9:\7DB`$``#]#@``&0```'AL+W=O<FMS:&5E=',O<VAE970S-BYX
M;6R45UV/HS84?:_4_X!XGX#Y#%&2U8;1M"NU4E5UM\\$G`0-X`B3R<R_[[4O
M`[;9AN1E)EP?7\[].MCK+^]U9;W1EI>LV=ADX=H6;7)6E,UQ8W__Y^5I:5N\
MRYHBJUA#-_8'Y?:7[:^_K*^L?>4G2CL+/#1\8Y^Z[KQR')Z?:)WQ!3O3!E8.
MK*VS#A[;H\//+<T*N:FN',]U(Z?.RL9&#ZOV'A_L<"AS^LSR2TV;#IVTM,HZ
MX,]/Y9E_>JOS>]S56?MZ.3_EK#Z#BWU9E=V'=&I;=;[Z=FQ8F^TKB/N=!%G^
MZ5L^3-S79=XRS@[=`MPY2'0:<^(D#GC:KHL2(A!IMUIZV-A?R2KUB.ULUS)!
M/TIZY<IOBY_8];>V+/XH&PK9ACJ)"NP9>Q70;X4PP69GLOM%5N"OUBKH(;M4
MW=_L^CLMCZ<.RAU"1"*P5?'Q3'D.&04W"R\4GG)6`0'X:]6E:`W(2/8N_U_+
MHCMM;#]:A+'K$X!;>\J[EU*XM*W\PCM6_XL@&='@Q.N=^,"^7_<6WC(D833O
MQ4%&,L#GK,NVZY9=+>@:>"<_9Z('R0H\B\B"_XT,0A)[OHI-<BN@.93C;1MY
MWMIY@Q3F/6:'&)B``6,@TBG"=P<G#O`;2$+H)DD?BOCS]'^2%)MTDEXRN)=Q
M[!"RE!43@:6*02,`F7F<@-@$E58R$+E&#G:("48&BD%C$.@,;H<NP!L;@AES
MGXRIQ=@1$\OJ>0$)C/546W?#*!YRI_&"7E$S<YN7`)N\R.`7>2$FDKR>2.R'
MH0Y(=4`8^F-.-6;1(\P$6&?FCP$C,80@L2A>FK34Y=#UQV6-5/P(*0'6246N
MF2[$*`VD&+0WBV^1,>CS,R0VS;4P8A0&BD%CD.@,;K>*`.NQ>Y,61@Q6Q`N3
MR&@4;=F/Q^'76!$0$C4QMVE)M,XK<GW]Q;L>I*1$M>AO_XG^SI>%H'3>EI8>
MI++`;=*BLQ"ZIS3'3`Y0)6_+"T$0%H=$2R-'J;X>Q..TZ<R$'BK,Q/?ICOR@
MBJH,(\]@L".*U,H)3U6+SL)0WSM9H(3.5`E!:I44B\[B(:T5YY/9">I!@53;
M.#3$)=66(V59Y_60TI*IU$9>8$X0@M2L*!;][8:DWED;E,F9VBA:VG>(8M%9
M&/(Z,T$HD6I_3M6-(*B?(#\AXXCT9#0`(=$H@#JWAX273)4W<D?/^"WL06I]
M<-M46SQ#7^^KC]PU]^7I00H+U:+EP#-T]G9])%I7^6E]>A">H$*2&/HB+B1B
M`'$]6"9CCR,SO&W@8;RF[9&FM*JXE;.+N$EX,)*#%6\Y.[*"$RO<+@Q[*FX_
MPNX,"W#Y.&='^F?6'LN&6Q4]@$MW$8,FM'A]P8>.G>41><\ZN';(GR>X9E(X
M"[L+`!\8ZSX?Q`N&B^OV/P```/__`P!02P,$%``&``@````A`)IUAJQ7%0``
M$78``!D```!X;"]W;W)K<VAE971S+W-H965T,3(N>&ULK)U=;QNYDH;O%]C_
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MYI\>[E]VK[LO;^_(W(5U%*_Y^N+Z@BQ]?/_Y@:[`A/WL9?OEP_EOLYM^/3^_
M^/A^'Z!_/VQ_OGK_?_;Z;?>S>'GXW#X\;RG:-$YF!#[M=K\;:?79(&I\`:WS
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M_K]^OS/%:'8S(VN<XW:`AJP_E/24[<;*;\;,AW,:,DKG5YJI/S[.9^OW%S]H
M=MT[S2UJ9J%BPPHSE8S95(-,@UR#0H-2@TJ#6H-&@U:#3H/>`Q<4VB&^E!9_
M1WR-&1-?CLPM`R_@*IBLX":I!ID&N0:%!J4&E0:U!HT&K0:=!KT'@F#21`F"
M.5Z(.2>-FDJNEY/)\CH,TJW5+"2P&R`ID`Q(#J0`4@*I@-1`&B`MD`Y([Y,@
MA#3%3PBA45-EH/&(S&LK6E#9'43)ZC(,]&80#>D()`.2`RF`E$`J(#60!D@+
MI`/2^R0(*]T>3PBK4>_#RL&XM61)5<2+H2Z/@XB;I4`R(#F0`D@)I`)2`VF`
MM$`Z(+U/@AC22B&(H;T5O3,+E/A$-PW#<%JR7`SU<@,D!9(!R8$40$H@%9`:
M2`.D!=(!Z7T2Q(X634'LX@$SZC!@EJC\FZLY/(B&_`.2`<F!%$!*(!60&D@#
MI`72`>E]$L30;-MP*71$_IF&83@M\?,/2`HD`Y(#*8"40"H@-9`&2`ND`]+[
M)(@=%?\@=O'\,^HP8([8G8]9^FV`I$`R(#F0`D@)I`)2^R2X4+-7"*[4JU)O
MWQ[N?[_=406G.CX2@806QFZY;*R$$=@;)N0M103)76&F[ZRI4R4T-L.]8WZI
M[AV9J'CRYH@*1"6B"E'MD/4^#)A9&1^85B<$S*ZO:27"[M^:K9>)H1^P`4DH
M1@)F50LS'+1/N9PMPCJ7.<LDX,YR[*P0%.FL%%NNLR3LK!(!=U:+94)A,,W*
MV`_F2);1T<*09G8A'43-HCDEX)`MR4HYM3$K/HKMG/X,JI%`#BIV/9.&C')$
MA:"(^5)4;*M"5`<H#)99!/O!,E-UOGPWN9XP&W(].RV:TY\A(,E*)<Z&&U*"
M#:J1L#GS@6J]#/,B<[;VH_GCXW*9+*]"1<Z]T:+T<&\%JX+>=!$I1U7:IRKT
M*5DM5ZK,U&SGD$_A`)GEM#]`$]EL5]\TX)P/M^;$PN0IW=.'$)!;8:`VK)K(
M9F=+S&?<\'I?*9+U7,V3W`F2:'`+-A/MOQ057U[%R/6?S%;AE=53_8?A-BOO
M$\)M%^I!N"U2LT`YM3%'I&;Z1(.2BHHO-W/(I?QZME8G2#FWH9$:AAOF5\&J
M:/^EJ+C_*NP_65^I*ZNYS:'^PW";Q?H)X;9K^R#<%JGL5D'9S)PJFEVIJ/AR
M,T8VNV;7\RME.G>*J?0^QH&2>Y/I53%B!ZZNU/RJIQP(`VY6]B<$W&X$@H!;
M%.3W;*;.C#8SUS":7ZFH).#.O+E!__BXN%PIRSFW.91?^\5CP:IH_Z6HN/_*
M(;ZES!*UP:NYS:'^PW";S<`)X;9[AR#<%@7YO8![JA--I/>@XJO-:&&XOS>X
MXGE]!=&V@JGL'BQ':D[)G?G9'?1_!>?AM6MSL/\PVF9'<D*TW09&_+F=610D
M=[)2BXJ-4TT5;W]_M,_*C,W;Y)XE"103U^90<KGD'BQ'PSVH>+@KU?\B45=6
M\Y4=ZC\(MUD?!^'^I6W>WDJXS7,HR/E$%X(-J^))+RJ.0N;08K4O,=<K-<-S
M]_K!G+.#((9C@R`J[KYBY"KZ(E%SKI[J/QP$JG#!(,37AW,C5]&V*+'OSN[/
M%9R*4.3:4E:MAK5FABAG).8+01'S):O$?(6H9K0W'T:&$N.4R!BYBHQ%8358
MZU-[LP&T2SD>XA11YI"[KUPOKR\A[9R=0W//I1WT5F)O5=C;^GJ]5KW5W.A0
M;V$HS6[,+ZR_-M/=GLZKMR:T%+MPIJ_5AFG#*FF8(LH<HFDM647;D7`WD#M5
M,+GG>MM8H/D2437>HUZ?3?481IK&(XCTQ'0V<I6T%@73>4`2&=@2I'.GDOF6
M(<H9^=/Y&/,E-Q3S%:*:T<AT-CLF/P<G(N,V6)(SMS3W3+`6M,(<=D;)6J^E
MG(IN[C*=G2U!F5.YZ4S!5/OIG,U0;(;.(.8%J\1RB:AR*%G8+?:UZJOF)H?Z
M"C/,[$1.B*/=N/A+TKG;RP3'8_H<9,,J&8`4488H1U0@*A%5B.H`A6$P^PP_
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MW7<*].A;@71;XS=I3+JI=8Y#?E$0Y`71\VR_@DY9M1YN\!FBG)%7%`1%S)>L
M$O,5HIH1%H7$+/#]HF`B9AXZ./%IP[T=E<-V[Q`^P7"E5]NN(:F&!1"B#%&.
MJ$!4(JH0U8@:1"VB#E$?H#`[Q_8U]MVO4Z.->YO$(A5MM1_9B$JB/31DE*$J
M1U0@*A%5B&I$#:(648>H#U`8;:H^D-G)E7DN_.3D-J94<ENDPJTV8QNSE**&
M07(#RE"5(RH0E8@J1#6B!E&+J$/4!R@,M]FUZ$(R6Q[QK(XY]]'1M<A_6L>I
M/)0BRA#EB`I$):(*48VH0=0BZA#U`0I#>=J>*<$]DT,J._7>4U0\\U-$&:(<
M48&H1%0AJA$UB%I$':(^0&%(S7;$S\[XKB!QNQ=9PMXZI$*J]L8;44E(K2VO
M!F2HRA$5B$I$%:(:48.H1=0AZ@,4AM1L6OR0>FNMB>C:[8Z_YS*/2IE"Z3T>
MBBA%E"'*$16(2D05HAI1@ZA%U"'J`Q2&TNPY_%!.Q,]N48+X.22KJ$T"*$64
M(<H1%8A*1!6B&E&#J$74(>H#%,1O\;=LP_96PKL\(^^!-D&197GJ5&;(APW6
M?*F.93)1<;7($16(2D05HAI1@ZA%U"'J';*/]H7!G]IS'?7XY0*W7(S\X#N5
M'U8\AW$-#S]-*`*)^V"942']RQA"9Z78.O`TH0C8<BV6&36"(IVU8LMUIM;W
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M\J%DM\\YL"J:'J6H..:50ZK@J&UAS0U])T8&?KB\Z,`[E6R5.F<^?IS?CSGA
MS[!PX$\[@S")KZ>]16K:JR7PQC6<FO;.EBP],M=0S3AU=\N=:FHA,)B/!+X4
M5V7T;4/E!-SUK2KN1"/F(TZT<D'L1,<H6@![5AW*\'#T3SLN,9-;C[Y%:MJK
M.^&&&QYRRKZ%(BJ^YLRA8-HM+N$^[_R*3KM"S$<"7[)*IEWE4'S:U=(P8KYA
M5302+:O$B>XH)WII..Y$./KF,,8_CC`G.\=\2H<^M`]Y8%%0!1;ZHW`;UW"J
M"CA;?A6PR"3WL&I8P+-NSGQ\`A9'.5&*+4[&BE%T`M:LBHYP<Y03K=AB)SI&
M42=Z5AUR(LR#TXZES-<-Z"I@D<F^87B2E2K2&VYXR"E7!>`\*W,-5150"YZ<
MS4]4@<&\N.K?'=UJ?U!QX*MQ)]0RI#[*B895T4BTHF(GNG$GU#*DYX:'(A&,
M_E(?JL67?GMYN/!W2,U]O0)@59"X>L^2BHJO.7-(S7V57+E33<Q],1\;?5&Q
M$Y4X8?9Z*O7JL<XAJ1HQ&^F\%15WWH6=JV5'/]5Y.-J4<D'-GQAM(U>C;5$P
MUQ>7RJF->?_$-*0_0T6`B*2BXFO-'**Y;@*]UF>I.3?Q<QL,%ZR*=E^*BKNO
MPN[G"[5]K;E)M/N&5='N6U%Q]YWJ?JT64CTW.=1].-8TU8*Q/O;^OC0-U:A;
MI.:X<F_C&D[<WYV*IBI?=\8H*`ZPN6=5-*S%44Z4HF(G*H>HT.Q/7?6GS^JC
MNF_$<"3S6U%Q]YUT+PT7,[76[<><\+>880;H<SSOO;OCOP%@B<=[#H5%8*8F
MRX8;1L<K%16'(G-H.-JZGJLPY-SHT$2PVWU611TH1<4.5,H!^'QFS6VB_3>L
MBO;?BHK[[QSB*J@/OGMN<JC[,`M(%=2!B9IOY&KV6T2/,K"'&WH+UZC,TPVQ
M`N]4\BQKQ@T%Y8S$?"$H8KYDE=BJ$-6,Q'PC*&*^9968[Q#UC/"ANZ4YPM$;
M+/>LS`G3SQT$R7;H=F^8]FK^^S&+F3J&W+!*&J8.!:LD?&R451/5V/H5VM(+
MN@*=*-E\,"OT.QH5JZ).U*P*;&DG&G2B'6VHG>A8%76B9]4A)\+9:$Z)8DEQ
MW+.K2WO8Y#\<X%`P2]V1U,0L=2IYN#1C6X)R1C*-"D&1:52R2FQ5B&I&8KX1
M%#'?LDK,=XAZ1B.SU)P>^0,R41[=89/,JMNE169Q-M3"Q4QM$C:BXB*:(LH0
MY8@*1"6B"E&-J$'4(NH0]0$*<]P<U_@A]=8=$]&U!SU!6EM$99;CMED"2A%E
MB')$!:(2486H1M0@:A%UB/H`A:$T)Q%^*"?BYPXN_.R$LXS-$E"**$.4(RH0
ME8@J1#6B!E&+J$/4!RB(WTH?;WBI>/P]>&\E7!,Q\AY;$21U`/:FJ5--/#,D
M*L[Z'%&!J$14(:H1-8A:1!VBWJ&19X965!&#Y/VUX!LK*O@.^<$?4#3X5D5O
MC>_W>/@-9'N7Z<$%[QO('++79S<6@B*=E6++=:9N"94(>)!KL<RH$13IK!5;
MKC.U'.Q$P)9[L4PHG#:TX@E&+EYV5D:NAL@BM495YZ4;UW#BQ&!4I1=K&:O<
M5R"L]:%4[@03*U8V$ZSY])*R'%5IERI6.9>6\*C`42XU;";J4CNJTBYUK&*7
M]#OI_91+89Z,G3`<\Q[2"@\5'`H^X[J8J</M#3>DB3PLMD:*K#/OG3&YAFY/
M/5^H^9&S8=JR'C9<L"K:?2DJGFM5V/T,OE",FT2[;U@5[;X5%7??A=WKKR;H
MN<6AWL-!-[MZ?TUBROI1@VX:JC)A4?!9TX4.SF;E5-$)D(J*+SMSR)WI7>MW
M#=S+4Q7AF-Y+L<6]5XP"M_6Q9LVJZ)@V3A6OE*W88B<Z1E$G>E8=<B),@+&#
MC?EJ_YFK$Q95>+"QLDB5`#5J&Z>:>'.!5;)OR-@\[7=EBNOQR*6AI](W@()5
MAP)FWTADE3A1'>5$+0TC3C2LBCK1LDJ<Z(YRHI>&XTZ$26%.$?RJ,+%DL(<.
M_DYOY<XAY`A@(VC<@WV44U;)05V&*&<DY@M!$?,EJ\1\A:AF).8;01'S+:O$
M?(>H9X0'&"M]@/%KJVP\U]@;AF-&_58?JV3+F0KRKENO1#)6N6>6+Q=JGN=.
M,%6=K>-4&+GDE6PY+'EJ)5&QZM!ZL3ZJ_X;-2/^MH,CU=ZSBE9A>'/93_8?3
M+W+FLJ_)QYTKKO``QB'_7%&0=X&Z1*:LDI.Y#%'.2.9-(2ABOF25F*\0U8S$
M?",H8KYEE9CO$/6,1J:E/KF15=*)'P-?X:&.0^K(4;\?*RJ>&BFB#%&.J$!4
M(JH0U8@:1"VB#E$?H"#]UV/G/+_TH?N]I7"1ZE`8;?V>Y$940[0198AR1`6B
M$E&%J$;4(&H1=8CZ`(71I@5'<*_W;CGQV_[:M%31M<@_X'4J#Z6(,D0YH@)1
MB:A"5"-J$+6(.D1]@,)0TDTJ".5$_(Q<Q<\BE9WZS7CZN3[3D%22G8`R5.6(
M"D0EH@I1C:A!U"+J$)G?'Y0+LB&UOR=H?V7M:?OR=;O9/CZ^GMWO_C"_%;C?
M^0_8_I#A[=K\DN$^)O#*G'_C4+^2K&_,!Z8ICO#*%;VR/Y34KRRI#;UA,M)F
M26WH_'_DE=7UC:EX(Z^L+\FW_4\H0C]D;*S%BDR-<7)KU"MR:M2GA*)"7WTR
MXE.2T"O[8U/E$YUXWYAS8VR3KF8W&1U"XBMT=GICCD?Q%3KH)&MCK]"/4OXV
MZAD-\9C^EBYE5&\N9*3GWQ8WOU'2H4NWBQOZ?2KD]`,A-^8G.\9>H0NG_2N^
M0C];06W&7J$/&]^8C^QBFW1!UNCSG_@*?6SUIAI]A3YC2M;&VMPF=#DT5]#:
M;;*D5T;3*Z'\HJ]EH#87P^C3#W)^O_NZ[>Y>OCX\OYX];K_0)+S<?U/(B_U)
M3_N/-_=E39]V;_1+G%3;Z+<0Z:=7M_1;-)?F)R.^['9O_`_3P?!CKA__7P``
M``#__P,`4$L#!!0`!@`(````(0#:A\;]$Q8``#>#```9````>&PO=V]R:W-H
M965T<R]S:&5E=#$Q+GAM;*S=6W/;.);`\?>MVN_@\OO8UM672K+5$>]WLF9W
MG]V.DK@ZCE*V>WKFV^^!"!`$_HPL978?-M,_'AZ2.`1)0)3\[K_^^?3M[!_;
MYY?'W??WY[.+J_.S[?>'W:?'[U_>G__WWZ._W9R?O;S>?_]T_VWW??O^_%_;
ME_/_^O"?__'NK]WS'R]?M]O7,\GP_>7]^=?7UQ]WEY<O#U^W3_<O%[L?V^^R
MY//N^>G^5?[S^<OERX_G[?VG_4I/WR[G5U?KRZ?[Q^_G?8:[YV-R[#Y_?GS8
M!KN'/Y^VWU_[),_;;_>OLO\O7Q]_O)AL3P_'I'NZ?_[CSQ]_>]@]_9`4OS]^
M>WS]US[I^=G3PUWZY?ON^?[W;W+<_YPM[Q],[OU_(/W3X\/S[F7W^?5"TEWV
M.\ICOKV\O91,']Y]>I0C4,U^]KS]_/[\M]E==ST_O_SP;M]`__.X_>ME]+_/
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MC4SK?C0P*II7$!-A5@E\"'V(?(A]2'Q(?<A\R'TH?"A]J'RH?6A\:'WH1N`4
M1*XO*,A2>NST#<CT$;66W&I&?61Q=>LV^,<^9FF+M($$D!`206)(`DDA&22'
M%)`24D%J2`-I(=U8G)+(]=LIR>%2J&BYXDE]#URO^J#U^**VF%VY!=L,04,7
M@820"!)#$D@*R2`YI("4D`I20QI("^G&XI1'.L<)Y5'1^_*81OW8R[A?0`)(
M"(D@,22!I)`,DD,*2`FI(#6D@;20;BQ.P\M#B=/PZOZ^N%'/Q?KYXNA;O,KD
M%J67M3P>#KUH,?/OZ4.0J64`"2$1)(8DD!2207)(`2DA%:2&-)`6THW%J9,\
M`3IU.GS]4M%N+7H9=Q!(``DA$22&))`4DD%R2`$I(16DAC20%M*-Q6EXN;P[
M#:\ZR'QU<7K_4(G<FO3B]8^Y=P,9@H;^`0DA$22&))`4DD%R2`$I(16DAC20
M%M*-Q2F37&2<,AWN'RK:K44OX_X!"2`A)(+$D`220C)(#BD@):2"U)`&TD*Z
ML3@-KX;R3LO_<@?99W*KHLGK(@NOB]BHH8^00E)$BDD)*25EI)Q4D$I21:I)
M#:DE=0ZYE5/CR?'8_G"?45,U7J?1-.XUI(`4DB)23$I(*2DCY:2"5)(J4DUJ
M2"VI<\BMA1I*CFNA>M%*6OS4>99^2"HC%],5/JI1C-3-ZT-+OP\-46;%P*YH
M*"1%I)B4D%)21LI)!:DD5:2:U)!:4N>06S<UX!S7[8T^U(]/)9]ITH]J,E+*
MX_0A4,"HD!218E)"2DD9*2<5I))4D6I20VI)G4-N+=3H\H1:](-1IQ9Z?"HW
MN]&(9>5WE2'*%#%0T\-]'S,4DB)23$I(*2DCY:2"5)(J4DUJ2"VI<\@MCQJ#
MGE">?LCJE*<GIZN``C5#[W:HD!218E)"2DD9*2<5I))4D6I20VI)G4-N+=0X
M<UP+=;N9K2[4!SYO7,'Z$:I3EIZN]Q_*[>?E-S-00`I)$2DF):24E)%R4D$J
M216I)C6DEM0YY)9%C4+'97FC%OV@U:F%'L<.]Y>-^NQ(=8=!`D@(B2`Q)(&D
MD`R20PI(":G&XC:9&A&.FVQT)K]^?7SXX^-.G=J3I_5"/HC2'T_UXTJG)7NR
M[;91'W_M6]+>'&9K;[XWT$%KV>)P"YFOUNXM)+11YGX1D6)20DI)&2DG%:22
M5&G:MX/;\FI(^.^W?#^P=%I>CS6',W8S,V+;=*+E^Z#UO/]X\6KF/>*&.HL$
MV$8WB8W$QVPJL9GVGV1>S;P1:6H#3.)L2&PD'^3`414VD]Z4-S]4V@"3N!H2
MBS@EF_MC]</7EWVX.R#7M)*+RG!Z7WN[M-%!\W$?8+TFHZZ]AZW01-WLJSI;
MK;V-13I@(8<V[!$V%ILT!W<IF8SR=RG54?*!GBK)ZNK:[=S947N43V[+OYP4
MDU'^'I7N'BW]@E1O[9%[DD@;_?O]6A5?+I;C?JU)!II#H:Z]CK/1,?(X/<2@
MF,$09,[XT*1>]F?)^@9GR<'"QT/&`YM-AB"SV53+0MU(_O%AL?).WDPM__EQ
MY$/"`T'%$&2V6GI;77LWE^JG6W7+K`;\X\OW&]>"?G[`J6=/J]&'T?.!#AQ2
M8*)NAPMQ2(H,V?2QI0/I$Q-ETZ>DS)!-GULZD+XP439]2:H,[=.[#>]/&:@G
MEL75_MG[^">6.6<2-#G7YL7,.SLV.DI.$G-"!99&Q^U?9$(3U5^)%_.E=W^-
M=,!;5^)^QT?;3TQFI[?XVT]UE+[LWO@W@NRHS>=V6^;P"TL'#K_T-K_PWEZJ
MWMJ\>PZH^8)QY_.?6O^^^_&SIU;Y:-8\ML[[:0>G4_;D=,J!1L?GWVD"G6MM
M1W$A*=(T2A];.I`^8:Z4E-E<ICJYI0/I"^8J297-)>G=@JA)@W%!WK@:]G,,
M3L-CVF&C/D1W9R("4DB*2#$I(:6DC)23"E))JD@UJ2&UI,XAMQ;^Y,0;M>",
MQ%Q//XPO*(N9]YRVL5'F9`M((2DBQ:2$E)(R4DXJ2"6I(M6DAM22.H?<\J@)
MA1.Z2C__X'05/25A;[V;.2@@A:2(%),24DK*2#FI()6DBE23&E)+ZAQR:^'/
M?KS153C-,>_)^W3(N[EM;)3M*L.*AD)&1:28E)!24D;*206I)%6DFM206E+G
MD%L>-;UP0E?I9R.<KJ(G*,9=!13,02$I(L6DA)22,E).*D@EJ2+5I(;4DCJ'
MG%JHQU*G%J-'KL.]9K^F.Y35-)[R)@6DD!218E)"2DD9*2<5I))4D6I20VI)
MG4-N6>0>[93EC5JH<*\6/8TF:A>^!)`0$D%B2#(6]S#\T?3H[#I^4+?@(%O3
M^.CZ('FH__G40J!7>V,:VD:9:WA$BDF)0VY#3(UN]2=+)S0$1[<RR=+/OIM=
MW0QRL"'ZU5;K_13-G+/"QV2)=)#-XLU;Q<=D29#%SE*Y;:@&;,??-A;]^&Y\
MV]#D305X7R;8Z*B?SA?UW['14>M^DLO[O",\*D=T,$=\5([D9SG<ICMM'+?@
M.$Z3=+*A>RWFWE%O=-`;?;!/ONXG):\NUMX`)#PF2V1V46[QHQWRWJ*.CTF5
MZ*!AAU8VB]N(IPW`%AR`:7+/O[D]W?M/B7746^=?GWXMK3EJ`*\#AD?EBG24
ME\N;R(J/RI687/V5978Q#_]F#]!MS]-&3`N.F#2Y)Z4WV[S106^<E#JY>SIY
MDX3A,:DBLY]N*N\DCX])E4RGLJ,0MSE/&_0L..C1-'Z1A!200E)$BDD)*25E
MI)Q4D$I21:I)#:DE=0ZYM5`CCQ-N52K<>WSKR?T:U1RWJB'*W/Z#!2@D1:28
ME)!24D;*206I)%6DFM206E+GD%.>I3_H.?QTO0]WRZ-IW%5(`2DD1:28E)!2
M4D;*206I)%6DFM206E+GD%L+?Z2CA@B_]$V2)0=!FMQ>M/`?6VS4T(M((2DB
MQ:2$E)(R4DXJ2"6I(M6DAM22.H?<RJD1U_$7N64_0!L_CVMR>E$?-:*`42$I
M(L6DA)22,E).*D@EJ2+5I(;4DCJ'W%H<&%^^<7'CF'+9TW@:AQ200E)$BDD)
M*25EI)Q4D$I21:I)#:DE=0ZY93EMR+KDD%73J#]L2`$I)$6DF)204E)&RDD%
MJ215I)K4D%I2YY!;B]/&P.J'";QG,DW>W<2.%OOAFXVR=Q,]Y+73U2&C(E),
M2D@I*2/EI()4DBI236I(+:ESR"W/::/K)4?7FIRNTD>-*&!42(I(,2DAI:2,
ME),*4DFJ2#6I(;6DSB&W%J>-S)<<F6ORNHJ="-!=I5]1HFQ7`84VEXF*2#$I
M(:6DC)23"E))JD@UJ2&UI,XAMSRGC?3E[,>5K*=1O]CHJ!$%I)`4D6)20DI)
M&2DG%:225)%J4D-J29U#;BW4</N$A^!^=.X\!.L!N_QC)_(6WD3>9CE$F4X0
MD$)21(I)"2DE9:2<5)!*4D6J20VI)74..>59G3;2WX>[(WU-<@:8AM^0`E)(
MBD@Q*2&EI(R4DPI22:I(-:DAM:3.(;<6_DC_\,!$?<W7>P#3Y+Z5L?#FJ3<V
MRE0L((6DB!23$E)*RD@YJ2"5I(I4DQI22^H<<LMSVG!^Q>&\)J>K<#C/J)`4
MD6)20DI)&2DG%:225)%J4D-J29U#;BU^>3B_XG!>TW@X3PI((2DBQ:2$E)(R
M4DXJ2"6I(M6DAM22.H?<LIPVG%]Q.*]I]-X")("$D`@20Q)("LD@.:2`E)`*
M4D,:2`OIQN(VO3]Z[]\D.?F7(%8<UFMR+EM]E'KL&Y[)^(4;O>):ABQ#U&+A
M??X8VBAS.XJXQ=B2S84M)C:7C5HLO(\I4QMEMIC9](9R2S87MEC87#9JL?`^
MARIME$E?V?2&:DLV%[;8V%PV:K'TGH=;&V72=S:]D'OR^',+OWKR<-)!WGU1
M3RG.R0,*=)2<*69O0U+$7#$IL2N.VF?A?;Z<VBBSQ8RY<E)A5QRE7WH?F90V
MRJ2OF*LF-7;%<7KO$:ZU429]Y^1RJZNF#,9#L%^M;C_U,!Z;J3<U_.J"`AWE
M5+>/&E'$7#$IL;E&[>-_JR:U4:9],N;*285=<91^Z4UAEC;*I*^8JR8U=L5Q
M>N^*V-HHD[YS<KG5]2<[^NJ>^+TP^68.!A.<`]%1H\X<:)(W!LV^AJ2(*\:D
MA"NFI(PKYJ3"KCAN:6^"K;119N\KYJI)C5UQG-Z[T;0VRJ3OG%QN(=4,QKB;
MOC'\ZR<\G-[8DSI7[/UVZ5WY-JL^ZHW7IVR4V?70D/DFW]75[<J^:[.?L8QT
MC'IQ=]@%W,)BDTE&L#^/2B:C\/T^'243Y^K+M,N+VROG_[PK9W;4#N:3F_:_
M^U;8*--&I;LWZPOO0:`Z:O.U37R@?1H;93;?DCJ'G!-.OK-WR@FW#W?G?C3)
M&'8HX\+_??:-#I)G_2$(9T0P!)E#"4WN_C7(V^OUS=IKS$B%_#QG/.0\$)0,
M06;#J19YZW;_TPG7%U=>M\X.;S<?4A[8;C$$F>V6D`I2#W(@=3,$F=0MI!N+
M>U*<-@FEWA3W)J$T>5<AKW8;'?7&5<A&F6,)-:D/RH;:+U;>\U>DHYSKT-R_
M6L4VO<V%<S.Q468G4KL3ZAR972R\)X1L:OO(G-O,![9?V"BS_9)4D6I+!](W
M-LJD;TF=0^X9X\^+_=(#B/R\"DZDGIRKR^C=X_XC,KW>&U>7/I.=50CU:NK5
M^M%9Y#T>1"IJ6#QQ^IBT-@@U3H8=-*V;VFVKD^?VXAK7E_%FD3$?,A[8;#$$
MF<V6D`I2#W(@=3,$F=0MI!N+>[;X,W>'GW+DZP,X+7J2!RFS_8V.4L]60[G0
M;H&)LK_`$)(B0S9];.E`^L1&F?U*21DIMW0@?6&C3/J25)%J2P?2-S;*I&])
MG4-N7?VIOU^["G!&4+YVH,X`]W:R\J8[-CI*;B=F]P-2:$@_P:ZNYS/_ARXB
M'>/<.7`NQ2:3W5Y"2C7I9]/9[,)_&CUJ8SDS%Z32W=CUA==$U5';JIFXL30Z
M@?SG\-9$]6U[LUS-O&%M]]8.N.?3]'RF'=8>]U,7ZBL;_O-)3\[U8Z#1$?J/
M^X'.)8].YAP+29&F4?K8TH'TB8TRZ5-21LHM'4A?V"B3OB15I-K2@?2-C3+I
M6U+GD%MO?PKRC?L"9QK7/8WOG8N5U^$V.L@^"020$!)!8D@"22$9)(<4D!)2
M06I(`VDAW5C<:JCIN>/G(M0,O]_+>O(NV]XE8:-7="[;_8HC"DU4?VF9K=<W
MM_[/^$0ZYJW+-I(G)KF]DJ>:]&5[<3'WSJ+LJ(WES%R02G=C*UZV^UT^?&`U
M$S>DUE#?D"OYPX3>$V^G(WZZ-?<L\:<>W^BSG&-4[[_)B>/V6>]Q>*.#QGVV
M7\U*:!+ULP6+Q7(VN_6.+5(Q/W\\C+&9!))JT7,#<D._\NZRV>&-Y$A90$IW
M(]<7WG%4AS=1(V$#:;7(#QNI(<C-U6+N'4?WTXVX9\!I<Y;JQ13_.M'3:$IY
MHZ-&%)!"4D2*20DI)66DG%202E)%JDD-J25U#CFUD/<73KEF[\/=Z3Q-:A-#
M/UFL_/EC&V7N]`$I)$6DF)204E)&RDD%J215I)K4D%I2YY!;GM,FUJXYL:9I
MU"\VI(`4DB)23$I(*2DCY:2"5)(J4DUJ2"VI<\BMA9JX&3_>J,'J+WVG3OX>
ML7]%T^3U(N^#DHV-LKVHSR4K&@H9%9%B4D)*21DI)Q6DDE21:E)#:DGJKSRK
M5NU;HJ]<_U>;^[\Q^[1]_K+=;+]]>SE[V/VI_B*SE/K#NX'[/Q?]\?I*_E[T
M?K"&)>HO2>\?^+!D;O[&M+]D>7NGWJ.5TOA+5K(=>:MS:HEL1UXHG%HBVY'7
MVZ:6+&3)8FK)6O:@;Q)_#Y:RCGS):B+;<BE+]L])6&<E2_9_QAI+UK)D/9GM
M6I;LW]'`.C>R9#]EYB]92.O(X^3$OBUD'?F*^-02.5+Y=O+$DJ5DD^_*3BV1
MMI;O8DXMD;:6;P9.+)G)D<K/ZD\LF4OKR$\-3BV1=>17[J:62.O(;ZY-+9$C
ME9_[FEHB1RH_/C6Q9"9'*G^$:6J)'*G\2:"I)7*D_0?"?A5F<H;(GT"96D?.
M$/GK&U-+I`WD;T%,+%$GU93+"I/QTF23+28--ME>TER3K26--=56\DK4G7KA
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M@OPE]^W]IZW\$?4K];<L/^]VK^8_U`;^VCW_L?]C\!_^3P````#__P,`4$L#
M!!0`!@`(````(0#U'SAG20,``&H*```9````>&PO=V]R:W-H965T<R]S:&5E
M=#$P+GAM;)16;6^;,!#^/FG_`?&]@$D(292D2E=UJ[1)T[27SPZ88!4PLIVF
M_?>[,X1BDC3I%P*7N^>Y-]]Y<?M2%LXSDXJ+:ND2+W`=5B4BY=5VZ?[Y_7`S
M=1VE:9720E1LZ;XRY=ZN/G]:[(5\4CECV@&$2BW=7.MZ[OLJR5E)E2=J5L$_
MF9`EU?`IM[ZJ):.I,2H+/PR"B5]27KD-PEQ>@R&RC"?L7B2[DE6Z`9&LH!K\
M5SFOU0&M3*Z!*ZE\VM4WB2AK@-CP@NM7`^HZ93)_W%9"TDT!<;^0,4T.V.;C
M"+[DB11*9-H#.+]Q]#CFF3_S`6FU2#E$@&EW),N6[IK,[TCD^JN%2=!?SO:J
M]^ZH7.R_2IY^YQ6#;$.=L`(;(9Y0]3%%$1C[1]8/I@(_I9.RC.X*_4OLOS&^
MS364.X*(,+!Y^GK/5`(9!1@O-&XDH@`'X.F4'%L#,D)?S.^>ISJ'MYD73B,2
M34#?V3"E'SABNDZR4UJ4_UHM]*I#"5L4^&U11A,OBH,1N0SB-QZ9`.^IIJN%
M%'L'N@8H54VQ!\D<@$]'!$Z@[AJ5ERYT-?BJH`S/JW`6+?QG2%W2ZMPU.O#L
M=$BGX0-IQPQLUS.C,C)C/M"5NT;0IPE/TXP^0H/*2Q>>G?/A;-+A-LR-SM@T
M3#^>\4>(4!E2#E'TF(:I;)6@77M*<>>.E4UHHWXVL4/C&+OQ0DG1SCC29;:5
M6*F=34^S3HY923B]@A8-;=I68M/.3M/&)VA)Y%T,%NULUE;29QT%P6E6G.:]
MHV*&P!@LWS\S:&5SMA*;\\PAF1USAE-R18+1T*9M)3;MF4-#H.>&L89CZ/SW
M8S5F-NM!9-..3F>8@-:0EL0P*B]6UE@.F!$,1#;S^`SS8!IA<4>C\!KF=A*%
M;[,)C_4Q\]OIM@XNP7DR:*N0Q)>;V1@.0FYFTR#DMP%F$P\&E@DYBKWX<K*[
MZ=4-#=**[&2?F56X.H<ADPGLLHO]A8:#D%N133P<5\UF;Q9?R>26?6%%H9Q$
M['!KA[#*.FEWHUB;B@[EX_FZN6GXW3^PZ6NZ93^HW/)*.07+`#,P>93-7:'Y
MT*(&WV'="PTKWKSF<*=CL,X"C#T30A\^(+%^=TM<_0<``/__`P!02P,$%``&
M``@````A`'K[`Y;7"0``0B\``!@```!X;"]W;W)K<VAE971S+W-H965T-2YX
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M/K._])>\I\?[YQU_`N'VV:E^>9C_R=:5Q>;+Q_O.0?_=U9^M]GG6OC6?Z6GW
M7.V.-?<VCY.(P%/3_!#2_%D@WGA)6B==!/Y]FCW7+YN/_?D_S6=6[U[?SCS<
M#G\B\6#KY]]1W6ZY1WDW=Z8C>MHV>SX`_O_LL!-3@WMD\ZO[^;E[/K\]S"WW
MSO$,BW'Y[*ENS\E.=#F?;3_:<W/XGQ1U3S1T8JE.^*3Z?B>^ZH3_5)V8]AVS
M#?>&@3#N/_DXPI%RJ*9UYS'#M[SKGX<-7N$?^B>RKW8',_M1\`_]*/AC?>W-
MI8Q,%^AH<]X\WI^:SQE?/7P,[?M&K$6V%EWW(98!&8)^*>8\V**7/T4W76<\
MG"V?J#\?5\;]\B>?6ULE":2$1W&4F%`23D@L*(DF)#:4Q!,2!TJ2"8D+)>F$
MQ(.2;$*R@I)\0N)#24$E/G)=.2%AL)=J0C)Z=\F#/42<!QE$?'HQ]X$5:A18
M]-6!E*RZ]2\F0XA!A$&,08)!BD&&08Y!@4&)0:4!X!*^Q=S@$J%^F/.^AHGL
MHUD:2(G7+80%\^P5FJ.A+C!=-"4BW>JAIC$P,F1-="MC#,VD%)AMU#C3K:Z%
MIGNN6W''A6Y<.&@9E+J5N9;MH'%5NF#!5M;*&L<&0L4W2A`JL5]9?#_^>A:+
M5BAD8__=#A9(B3W.8@G<+H:FN_)LSQ]75-<FTB6>Y=K."BEBH.#G#3.Q6Q-=
MP@/F.Z;)D.M3H+%MVS5-),ETB6NY*\8\M*7ENH09MF]8*`P%4-C6"BWU4MI'
M)U4:`&'BQR$(T]?A$6H4'K1C!U)BRZ/%0O,K[*TB!1%;4(1!C$&"08I!AD&.
M08%!V8/N`,2CK'JK2+GT'=F]R5E"C9R%`AU(B726C8QA;QQ\A4&,08)!BD&&
M08Y!@4'9`^$K/,BJ-V)7>3>Y2JB1J]"R":1$KO*5:Y%%$TK!..4C#&(,$@Q2
M##(,<@GD,&Q_A<^+`C<H,:@T`":7J,7T!._KE2C4R&-HK052HCQFN6C'"Z59
M\Q<&,08)!BD&&08Y!@4&)0:5!!/C!N[BF?0-[A)JY"YTE@=2(K]VL3+QIA!*
MNURK-!/0K203`$:2">A?/)$)Z(T9R01T*\T$="O)!'0CS02D5;J#N;:EG?/=
MSEWI`IXZ.;8WSC`0*5&.W1"J3@YCQ0QT_@5*-,[>4!$YX`MI`-!,YP%0,IT(
M`,VE3`"*IE,!H+F0"P`-SSI6/IY`!91,9`-*,'JKT@D,EJA/KM^&1(V,%Q;.
M")1&I01D'QK,PSE'2$Q(0DA*2$9(3DA!2#F0+C?`PZT&,S[Q1%$./'==QMLU
MP],=I7.!$HU[(JIC0B48(QP1$A.2$)(2DA&2#T0X"%<0Q6#MPUDJT@_><=$$
MJ?0F<#**:D.?C%>Z5!8I>N''C'%SDF4$DZ+18R$A$2$Q(0DA*2$9(;DBTB>.
MYQC\'WQ14)!&)2&53J#G1+[_#<_),@%Z#LVU@$F1'#M;N6C@H;++];Z@1R6T
MD\,2F?%NEX"O7TP<F+`#>F1".STT@9UY:"T6@WF<X+I#;-)AI;>`41*%QC>B
M).L3&"5<)HO7OWQGUN>W)#)N/"Z3E;)JID07SDC0D7?AD`2BBZ<D5%TX)H'H
MTCFIBYAGN`9_?8&7E-2,/BF)ERJ=P&")4D</UM<).I.5D1XD'U5X@=*HE62X
M*(,/E7T<;T1(3$A"2$I(1D@^$+&K,[3FB\$Z3GKY?/W8';*I7ZH,F2B`;O"C
MK)>`'W%MV'7Y,%=CX3.;OS.!H0^51'>E5HAU1T),-`DA*2$9(;DB7PRG((U*
M0BJ=P)DH*J0;/"@+*N!!--,"UE=A(OI\;T";7CC8^_A'A,2$)(2DA&2$Y(04
MA)2$5`,A3P!])\J6&WPGJQS==\Q`4SU@>BGDT00]5`)]\LDF(XF))B$D)20C
M)!^(\(/IH+2G`&9:]2FSG+JF8]L.V@DJH!!UGV>-$N!J\[:ZKY/C1!COF$HT
M^BTD)"(D)B0A)"4D(R17I/<.\SS'1WM1`31LHA@CW58Z@1Z\K1@SKRC&E$8^
M@F7B]PFALH\.C@B)"4D(20G)",D)*0@I%;DTWDIO`7W'URQ8Z-?5#J9HAF<A
MV@T#)9*#\ER/H6D:*H'N1=GO2&*B20A)"<D(R0?2+7B\W@=KOW&7BO2#=WV4
M)55Z$^C2[Y5CYC7EF!*-_@D)B0B)"4D(20G)",D5D3XQS:ERC#0J":ET`CWW
MO7+,G"K'T(83*)$LMSP3'4[A8.XG0$1(3$A"2$I(1D@^$#$5T9HH@''!4()6
M`K.'W[Y6@YD_!G2MR.GU`_W*=2Y+`7BPXZQ(W#F!-10A$2$Q(0DA*2$9(;DB
M<E(Z(JE%^U`QM!'^7N'W*N5@[D-?Z01Z\;;BQJ3%#7\U"5/N0(GT):W5!/+/
M?T03$Y(0DA*2$9(34@Q$>`N_MRJ!E21&U6`F\^^V<L:\HIQ1FB'POH'64J@4
MHVLC0F)"$D)20C)"<D(*0DI"*IW`F79;\6+2XH5<E@B4:'1'2$A$2$Q(0DA*
M2$9(3DBAB`S@8C()[.NM<6EJ!#KLMHK%I!6+3_8UO6!9\#L<N-X/52^C1R-"
M8D(20E)",D)R0@I"2D(J192/X3,`_XE+)^"`^/J]32='"2!#&V^@1/+>$#.9
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MH.4OY^:]NQGYU)SYW>7NXQN_JU[S^T?&'1>_-,VY_T5\P7#[_?'_````__\#
M`%!+`P04``8`"````"$`CF2BVG@&```-&@``&````'AL+W=O<FMS:&5E=',O
M<VAE970V+GAM;)Q9VV[C-A!]+]!_$/1NRZ2N#N(L5A*V7:`%BJ*79T66;2&6
M94C*9O?O.]10$F>4.$I?=F/R<')FYI"'9NX_?:_.UK>B:<OZLK/%>F-;Q26O
M]^7EN+/__NO+*K*MMLLN^^Q<7XJ=_:-H[4\//_]T_U(W3^VI*#H+(ES:G7WJ
MNNN=X[3YJ:BR=EU?BPO,'.JFRCKXV!R=]MH4V;Y?5)T=N=D$3I65%QLCW#5+
M8M2'0YD7:9T_5\6EPR!-<<XZX-^>RFL[1*OR)>&JK'EZOJ[RNKI"B,?R7'8_
M^J"V5>5W7X^7NLD>SY#W=^%E^1"[_S`+7Y5Y4[?UH5M#.`>)SG/>.EL'(CW<
M[TO(0)7=:HK#SOXL[E+7M9V'^[Y`_Y3%2VO\;+6G^N67IMS_5EX*J#;T277@
ML:Z?%/3K7@W!8F>V^DO?@3\::U\<LN=S]V?]\FM1'D\=M-N'C%1B=_L?:='F
M4%$(LY:^BI379R``_UI5J:0!%<F^]_^_E/ONM+/=8.V'&U<`W'HLVNY+J4+:
M5O[<=G7U+X*$#H5!I`[B`7L]+]<R\H4?O!_%049]@FG690_W3?UB@6K@=[;7
M3&E0W$'D(3/D,>;Z5JJ0HPKR647I8T$6+?3GVX,0[KWS#6J::TR,&-@2$X8B
MD@&A"JC"IL:``WQ'TE`*3MJ%IK[>CH&C6D0YRBTE$+\"H8ADCG`W%)+.(4$P
M0D@:+DWC-GT%!MV8Y1/>&+>O5XP8KY>-*F#"!U)C@%"!UIL5O4U%@7<VY#EV
M<ALQ)@@)>RFLW,CE:D@(0`:"KD_-Z<@-Y#A-6,/F,5DK\7IO;LM!!VH1+Z0_
MQL="(L8H)!](C0%"*:"4;A=2@6DAA9BT@E00$^"FBN14B7XZ(=-BRS9=BM->
MOWH;3%(EG,./<%9@RGG+JX<0I.Q*CZDTP6GD%!FM[1-*R:P[Z8HP5L;*3JWW
M#P"UB#(7(F2-1XS1^&%`G6F!9,U)S=F5\"<5$[;;_\-6+>(RG:J!VD",P98/
MI,8`H23@N#0K>%NG/9J6SF5*BS4&V[K:NE,M4*ADWF,R3O6LEKGK3_.4MG($
MH_'OT$;_,`\JEXDQ%HC!7[QRI<L\(=$`G5?$`Z1T?CNE38DK5UA.'#V$$&?2
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MF_-BP]J6DN6>L9$H;V5%RWFC<9F\O4F'6N:(P:(+R3TE$8;Y:6$;(X2<_)`=
M]FAJAT).[4)V&H3LP%A"GY4]H0CAB9!MY)0B`C^:`)3^AVQ1HN7!J3O>WX7D
MQY\&&7>+V4AJCE`^T+?EO98*S<LY9:K+B:"AG#ZO5:*C:(#<SKY2:(`^K[?>
MU##*7;G18IU*]"Y3IT*R#1)KT`WN&.4&=P2\R_U#+BC1P""TH0.V]V,-,G4P
M^-YXLS`QM);*2(Q:JB]H[]_3U6O&3`]\\VL0EBP,0OZ]*2&`R`M#IO!4`_K,
M*&OE(@;KVY=,B9Y#%<!.]UB#L'_A[!N1GL9DA.!7C90L-^R:TOZ0J\FYJPG)
M+@*Q!FG9<=](QNE)"1CUE9HRUUJHA%?<2_+[I4205@(4ES4Z(8#(C^9*,/WM
MS?(J[S!4L3`#=!RJ#F8$L4009N`)$``S8`((HM#X6HS&1@"KT#/NT$0C:O-]
M/(E^%3N@^;-7K$&#A@,OXGT@"-B0'CLG4P+P?2FF5M,LF-TM:X6+MD=:P;^E
MQAJDL_#!M&=98)BW\TQ)#)HG30.HF,VX?<ZX"LT>!%SNDAIDG-:SD=0<H7R4
MR1@*?X</6A(M)^MH#(_RBK3)!T?P95!NC=V&2C97(#M\E<='ZZIHCD52G,^M
ME=?/ZL5=P-/6.(I_#8CAKP']T[DS3L!C_#4[%K]GS;&\M-:Y.,#2S3H$IVGP
M.1\_=/6U?R)^K#MXAN]_/,&?70IX2]VL`7RHZV[X`(>>,_XAY^$_````__\#
M`%!+`P04``8`"````"$`Q>_M`VP"``"Q!0``&````'AL+W=O<FMS:&5E=',O
M<VAE970W+GAM;)14RV[;,!"\%^@_$+Q'M&0[:03+@=/`;8`6*(H^SC2UD@B+
MHD#2=O+W79*VHL8IFEPDD=R=V1W.:G'SH%JR!V.E[@J:)A-*H!.ZE%U=T)\_
MUA<?*+&.=R5O=0<%?01+;Y;OWRT.VFQM`^`((G2VH(US?<Z8%0TH;A/=0X<G
ME3:*.UR:FMG>`"]#DFI9-IE<,L5E1R-";EZ#H:M*"KC38J>@<Q'$0,L=UF\;
MV=L3FA*O@5/<;'?]A="J1XB-;*5[#*"4*)'?UYTV?--BWP_IC(L3=EB<P2LI
MC+:Z<@G"L5CH><_7[)HATG)12NS`RTX,5`5=I?GMG++E(NCS2\+!CKZ);?3A
MDY'E%]D!BHW7Y"]@H_76A]Z7?@N3V5GV.ES`-T-*J/BN==_UX3/(NG%XVW-L
MR/>5EX]W8`4*BC!)%LH0NL4"\$F4],Y`0?A#>!]DZ9J"3B\IV8!U:^FA*!$[
MZ[3Z'0]37\R0G!V3\3TD)_.KR31%KO^`L%A(Z.N..[Y<&'T@Z!6DM#WWSDMS
M!'ZY$2S"QZY\<$'1RUBK1?'WRW0Z6[`]*B:.,;<Q!I]/,4,$0]*!&=E>S^R#
M/;/7PY=R&S?&--G+--.WT/A@O)-Q\=/Y@!N98\PL^&3<S^PM1#X8)<<NGF0Z
MD_(8A"X=!5T.Y?RE)CI@K*8W9C:?)U?_-.?I3GUBJ&20]K@SUC:=7CVCC2,2
MK:3`U/`1VM82H7?>_AF:8]@=)G.5>=&>[\_R51@5-AS@Q/2\AJ_<U+*SI(4*
M(2>A%Q-G+BZ<[H.!-]KAS(3/!G^-@/Z8)-A%I;4[+9"8#3_;Y1\```#__P,`
M4$L#!!0`!@`(````(0!\PH1-S30``!)``0`8````>&PO=V]R:W-H965T<R]S
M:&5E=#@N>&ULK)U;DQLWMF;?)V+^@T+O1RH6Z^JP?:+%6_)^B3,SSVJYW%:T
M93DDM;O[W\\'`CL![)65)*M]'H[<JS8VP%P`,K')8GW_W__Z].NK/YZ^?/WX
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MY[^'T/E/`:GQ6[2>'A7LOKSZZ>GG]__X]=OA\S^;IX]_^^6;?-_J)857]MU/
M_QX_??V@2ZHT;ZYO0Z8/GW_5`/3_7WWZ&.:&+LG[?_WP^EH=?_SIVR\_O![>
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M9AXT'LP]6'BP]&#EP=J#C0=;#W8>[#TX%*`2HOVD$M)]1[*U$:)U[ZG6QFU]
MH=_%F)LL9P0R!IF`3$%F(`W('&0!L@19@:Q!-B!;D!W('N10DDJ%]N<+5(1H
M[73RVK-/Q:`;W=N*H,=:V*@-:I<&R`1D"C(#:4#F(`N0)<@*9`VR`=F"[$#V
M((>25'IT-[Q`3X@^ZK&+^BZ26STL9!<W5\Y%&V3-QB`3D"G(#*0!F8,L0)8@
M*Y`UR`9D"[(#V8,<2E*YT`-)Y2+<ZH</X=DY/1J>?;</F6I/D=SJ#E9X&CA/
M;5#K"60",@69@30@<Y`%R!)D!;(&V8!L078@>Y!#22I/>@RL//7?74)T[2(2
MMV;\G;T-:EV`3$"F(#.0!F0.L@!9@JQ`UB`;D"W(#F0/<BA)Y4)/M)6+EZ^9
MD*GV%(E;,T.W9MJ@UA/(!&0*,@-I0.8@"Y`ER`ID#;(!V8+L0/8@AY)4GG2S
MAJ?KVS>7;VTA4:TI$J?IQFEJ@UI-(!.0*<@,I`&9@RQ`EB`KD#7(!F0+L@/9
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MUD0;HBW1CFA/=*A0;2Z<=DMS)_:]>#BN]$14[WNWOL00WG>*NV/6`S1AU)1H
M1M00S8D61$NB%=&::$.T)=H1[8D.%:KUA$/N!7KBF;C2TQZ3B\K"K:\LA#=;
M_.H!FC!J2C0C:HCF1`NB)=&*:$VT(=H2[8CV1(<*U7K"N?<"/?&87.EI3\ZE
M'E]L".]L^=4#-&'4E&A&U!#-B19$2Z(5T9IH0[0EVA'MB?0>>G%Q:CWAN%OJ
M>7GU(;RU)P.5NO8P7:KS]8?4L'CX'A--B*9$,Z*&:$ZT(%H2K8C61!NB+=&.
M:$]TJ%"M+AR!2W4G[DOQQ%SI28?H_`PX&@"-B29$4Z(944,T)UH0+8E61&NB
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M0S0G6A`MB59$:Z(-T99H1[0G.E2HUA(>_DLM)U9-/"M4+M+QH2H,WOKRTG4;
MU=8OB"9$4Z(944,T)UH0+8E61&NB#=&6:$>T)SI4J-;3=0(;W+X)'Q\]88H'
MKNMTX#I^9/JXMD9$8Z()T91H1M00S8D61$NB%=&::$.T)=H1[8D.%:JU7':Z
MNN;IRE!YFTQ1&8T9-2&:$LV(&J(YT8)H2;0B6A-MB+9$.Z(]T:%"E8MAU^DJ
M+9%OOWS\\/=WG\/S<>=Z&;8WF6.6^G'`4/F9R-"7HK20\F'KSM5JQZGAL(YR
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MH'F.LJNS,)1O+DNBE:'\T+`FVAC*N;9$.T,YUY[H8.B8J[86*A7_N;58[RB/
M?#J<I\<@NSJCC,I)YW:.<8JJGHP>W'UPDH,L^S1G-S3+J*?#)D7=:%?)V_&]
M>Q2;YRA+O\CI#2TS*G+YA[]5SE5$W;O7N,Y1EGZ3TQO:9E3D\CWN<JXBZM[=
M<O8YRM(?<GJA>N;X8DW_67/("DU"X4V&XL*[+71D4;I?Y2C_`L<YRH8^(9H2
MS3+J2=_D*$L_)UH0+3/J2;_*499^3;0AVF;4DWZ7HRS]GNA0H5KU906@(0M`
M"87J<BMQZ";\R-K5ST78'U+V*NK>;<X3ZS"4",/O>0YN;US(U+K3O:0=T\!/
MK)E%5=WYJ*8SR@]J?GI0"TO4.ZBE1?4.:F5152X_J+4-2NLS7X9[=PS8=.;R
MEV%K4;WCVEE4[[CV9XWKT)FK&%<]CT-QJ[S9G=BR0K@[+$04BG'%Q7+/UJ-P
M[U+#\+99CBH&=7Q^&.<H6Y430X_'67M]=W7C/$Q31#@0/9]Z9GEZ!]#D*!O`
MW-"S`UB<-8"EY>D=P"KGL@&L#54-.1OC!>Z_"MNS!K&S'O-!:&^H=Q`'BWI.
M13WU?#7P94_'+!+JL?@XUZJ=U<V:40H*'\U^?M:,<Y3IF"2DY\>PC0ZOW&8\
MM2;54O8S?691O=TW.<JZGY_H?F%->KM?6E1O]RN+RI7O=4+AG9%\V3@9DY3>
M06PM?>\@=A:5![$_:Q"'W+`8:B&BFHPJ6%VR#Q[#ZWTP(3T=FJM11MTCB)N>
M117OX!)-#>7TLXQZTC<6E=//B1:&<OIE1CWI5Q:5TZ^)-H9R^FU&/>EW%I73
M[XD.AH[I:Z^:7-7][46;3"AIN-M>0NY)W54C1A:5S^[CC(K7[1]!)A85[SH#
M?:?(HSM^35-(_XX_LT1Y!$U&/2.86]3S(UB<-8*E)<HC6'4V]-=@;5&]]YR-
M1?7N(EL.8M?9T`]B;U&]@SA8U'.#J.>D<O7.R?_Y_+OVELZW7O1)`7N#_R:D
M<7M01-4>U*)"=K$+ICTH1=VWF]<DI=?3I.UG4T-Y%<\RZDG?6%3.-2=:&,KI
MEQGUI%]95$Z_)MH8RNFW&?6DWUE43K\G.ACJV(-"<?;\9^Q0=?%>(ZJ\1G23
M;XOCU+!`$Z(IT8RH(9H3+8B61"NB-=&&:$NT(]H3'2I4KST]DE0N7G8_"%G<
MTDLH5QU'$G&,TI-Y?E;BTHM1X=$Y1]V[=X`F*9>B\FIL&QJ:,:HAFA,MB)9$
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M07;MISF[H5E&/1TV*2H\/6;;>-LS1UGZ14YO:)E1D8MWWGBY7(_N7:`U>]SD
M]-;C-J.>'G<Y5Q&%MSUSE*4_Y/1"U7H/OX-=S9S^1[%C>/THEI`KIK@M=&11
M]4.#GS4YRH8^(9H2S3(JKHPWUN0H2S\G6A`M,^I)O\I1EGY-M"':9M23?I>C
M+/V>Z%"A6K6>5"Y1'<*=ZHCZW_8,OTL2VNF?O!"]BG%GE"_@3%+4L7#RQX^/
M5S=#-Z^FED?GJ>=[FUE4[YB:SB@_IOG),2TL3^^8EA;5.Z:5156Y_)C6-J;^
MRGYG+F]F:U&]X]I95.^X]F>-Z]"9JQA7/8NU@UPRBT.XF\41G7C34[]B%QJ>
M>-,S1]F:G!C*[SFZA_9IBCA1_+4\&L?S,[O)43:`N:%G![`X:P!+R],[@%7.
M90-8&ZH:XGTFB^J=9]NS!K'+N6P0>T.]@SA8U'.#J*=>*-O]Q\_&^G4MS,B(
MZGW5O^EI[9X;:BP&YRB[$I.$TIN>-U?N"7AJ3:JE7"R_8^*91?5VW^0HZWY^
MHON%->GM?FE1O=VO+"H75M<)G7C3,S?L66Q;B^H=Q,ZB\B#V9PWBD!MV#Z*>
MC+I>U60\\>`6PMT^&%%9F+YM4?<(TAQ+4?E]O8DUS&AJ*)?L9QGUI&\L*N>:
M$RT,Y?3+C'K2KRPJIU\3;0SE]-N,>M+O+"JGWQ,=#/$-AUM?&WW1`?R8Q>F.
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M%W?<A9;.5$0Z)]GJ&:6H`HV))D13HAE10S0G6A`MB59$:Z(-T99H1[0G.E2H
MUN*K5OVWHSN6IQ)RJ\9]X&.4H\S8F&A"-"6:$35$<Z(%T9)H1;0FVA!MB79$
M>Z)#A6H]H9A2/LP59ZL3IF(9IGRNNXNH6"(CHC'1A&A*-"-JB.9$"Z(ET8IH
M3;0AVA+MB/9$APK56GP9YH2+6+2H7"243S*C.Z`QT81H2C0C:HCF1`NB)=&*
M:$VTJ5!]_4Z5#,[ZBIH[5@P,%9](R*@XS?@"]CA%59](&#RZ=Z`G.<IVL2G1
MC*@AFA,MB)9$*Z(UT2:ACL]7WOGS>[&GG/_=!<<L[JZ<3OKEQ6]1[\6/4?5G
M)?QO14Q2CXK*%[]-;VAFX\J#:'+#8A"/[J,8\QQEN1;,M21:Y89E>E=26^<H
M2[^I<M7KX[(S_!W/\`G5]=Q'7V*QJ*H:R+41TQ=5WTEJJ(_['7]5[NZ-RSQ-
M`74U]]'5$&:Y?[LH#=&\[NQV\,:==1=G=;9DYA71NNYL</_&B=R<ZJP6>=EI
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MGU)1N&=%P5`^3XXRZMWT8ZZJHG!]Y7[U;I)RE;_]230C:HCF1(N$.JH`]^'H
M7#[O%&OW_"K`,8M;QSB3CRQ*Y\B^NV1L>*(*D'*558"<WG;O&5&3&Q:#0!4@
M1UFN196KGG27'=/O>4Q/R#UEN">[D46=>,K@,3TUM&.Z_KA`=01RQXUI"C_U
MT(%^FCQ`NVKSNFL4"!:G^JHO]&7'Z'L>HQ-R#^?^&&T-3SR<X[`[20WM&#UX
MXZI+4\NL.UI>`JB'6%3>9!NB>=W9X-IWMK`VSW567=N'R\ZRQ_!ZQ2=43>+K
M*W<%1A;5/XESE,VD24+V^'K_YJ&:Q/[).86?F,3LI\D-K>NYH6K,.-E:U'.S
MIK[<X918[KO]#TH/(=Q=[HC<5/;G3&OXW*#BR<2B\FELDE#_:6R:&Q;SV1]\
M9A95S&>B>4)I\=P.<4"Q-N?-YW`FNN`"AW!W@2-R\]G5`4</*4K_Y!7MK\`X
M16DVVJ2:&*H:^DDUM:A>?[,\"$O?$,T3LA5T[6N:B\[.BMVIGL&7'<H>>"A+
MJ/J`V?65O^OE*'MM8Z()T91H1M00S8D61$NB%=&::$.T)=H1[8D.%:KUA$/3
M!?,_A+OY'Y$[,[N2[^BAC<IZ@":,FA+-B!JB.=&":$FT(EH3;8BV1#NB/=&A
M0K4>?S@KGKM/W`IX3GN(J#PS$XV))D13HAE10S0G6A`MB59$:Z(-T99H1[0G
M.E2HUN+/CR=<\*#XD%#>Z4=$XPK5(_`'LA,C2,>L_&L([QXB<O<M_XQK4=7M
MA_>ME*N,NK[*!X9ZZ)>=@QYX#DJH>J:YOL(S36K8>T\<6_HRZOFA7W:R>.#)
M(B%WU=U3Z<BBRNN)[U\>=T5=#_*G$*JK_GC9@_LQO-[H$ZJO^L"5*$;6L+R>
M''I7U/4@'P+JH2O7!?>HQQ#NAAY1?=4'_ADM-3SQ:[I=4=>#_#A2#UT&+QEZ
M"'=#CZA^^AGXV^MC&]7>7HDF1%.B&5%#-"=:$"V)5D1KH@W1EFA'M"<Z5*C6
MXQ].P^UU^'#\JXH?_O'UV^=/S=/'OQWON:>^A?&1#ZX)U4]&`[_#YJBL+N92
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MCD9ME$D9YX:&)D13HAE10S0G6A`MB59$:Z(-T99H1[0G.E2H4C>X\D?7XZ/>
M[1LME`O5Q53U`<N8DY?/HG'=%6&F:MS!)AULVL%F':SI8/,.MNA@RPZVZF#K
M#K;I8-L.MNM@^PYVJ)F3>=EA?G#%T[PQ9\P?YXNPPEA,IZ;&9`Q,QL!D#$S&
MP&0,3,;`9`Q,QL!D#$S&P&0,3,;`9`Q,QDKFC%U6PQA<L8AAS-W;<M'$UE@J
M8Q0WMZ)I80QQ,@8F8V`R!B9C8#(&)F-@,@8F8V`R!B9C8#(&)F-@,E8R9ZRK
MK/&BWWL>7+&L8<PM/U^2*L),G#9,5C8ZF&0B3C+!)!-,,L$D$TPRP2033#+!
M)!-,,L$D$TPRP22S9$YF5Z'C936JP15+'\:<35^E*L(*FS%=O9F"R2:8;(+)
M)IAL@LDFF&R"R2:8;(+))IAL@LDFF&R"R6;)G,W+ZB.#*Q9(C#ECOD)2A!7&
M8KK:&)B,@<D8F(R!R1B8C(')&)B,@<D8F(R!R1B8C(')&)B,E<P9ZRJ9W-^]
MZ.F3)9/!55OZ*$]]OF92A!4RVZ;&]"P#)IE@D@DFF6"2"2:98)())IE@D@DF
MF6"2"2:98)())IDE<S)]$>7EQ\#!%2LLQMS2]"66(LS,Z=88T]5+$TPVP603
M3#;!9!-,-L%D$TPVP6033#;!9!-,-L%D$TPV2^9L^IK+RZN9@RL69(S5-H>^
M(E.$%3933:8Z9X#))IAL@LDFF&R"R2:8;(+))IAL@LDFF&R"R2:8;(+)9LF<
M35^BZ7_K8'#%.HPQ9\P78HJPPABJ,]I-P60,3,;`9`Q,QL!D#$S&P&0,3,;`
M9`Q,QL!D#$S&P&2L9+6QP9]7F#FF<H69Q)Q,%&9R6)9)-AF033O8K(,U'6S>
MP18=;-G!5AULW<$V'6S;P78=;-_!#C5S,D,%`&^HOJC*%KZOWWV,89"8DXF:
M30XK9):UB6.E0#+!)!-,,L$D$TPRP2033#+!)!-,,L$D$TPRP203;-_!)+.,
M<S)#<>!/DAGK#.7;Y0/]CR#8R40Y)X<5,MNFQB033#+!)!-,,L$D$TPRP203
M3#+!)!-,,L$D$TPRP2033#)+YF2&XH"7^<(*P"`6&M2;7?YW@\2<3=1S<I@U
M'1=-C<EF6<LX+E?9!)--,-D$DTTPV02333#9!)--,-D$DTTPV02333#9+)FS
M&8H#WN;+BG.#6&>H9;:UA^(\.40Y)S65<Q,GF6U38Y())IE@D@DFF6"2"2:9
M8)())IE@D@DFF6"2"2:98)())IDE<S)#W:"4>>*9=1#K#+6Q5'O0/_E]WR'*
M.:EI^<;O@$S&VG1F4<;`9`Q,QL!D#$S&P&0,3,;`9`Q,QL!D#$S&P&0,3,9*
MYHR%XD!I[.5O)@YBG:&6V=8>2IDHYZ2F]?)KFYHXR0233##)!)-,,,D$DTPP
MR0233##)!)-,,,D$DTPPR023S)(YF:$V\"?)C&6&6F9;>BAEHIHS:,-,G/92
M,,D$DTPPR0233##)!)-,,,D$DTPPR0233##)!)-,,,D$D\R2.9FA-.!E/CR^
MY,.X`_T*.T\@;>FAL'F#:DYJ6B_-MJD9EDTPV02333#9!)--,-D$DTTPV023
M33#9!)--,-D$DTTPV2R9LQG*!J7-4W?&6&:HUU];>BB-H9HS:,/,CM8?F(R!
MR1B8C(')&)B,@<D8F(R!R1B8C(')&)B,@<D8F(R!R5C):F/AMR,J8_]!-?68
MRY5S$JN/&3<HY^2P;)-L,B";=K!9!VLZV+R#+3K8LH.M.MBZ@VTZV+:#[3K8
MOH,=:N9LAN)`N?Y>_IQS'>L,U=),S,E$.2>'%3++LD4JYS!.,A$GF6"2"2:9
M8)())IE@D@DFF6"2"2:98)())IE@DEDR)S,4!TJ9)S;3\"M,O@"76/WIWQO4
M;')882S5)O*?=]?R`Y,Q,!D#DS$P&0.3,3`9`Y,Q,!D#DS$P&0.3,3`9`Y.Q
MDCECH0!0&OL/EE^L)=3+KZTOE'=&E&S"7P&,=;I")IAD@DDFF&2"22:89())
M)IAD@DDFF&2"22:89()))IAD@DEFR9S,4``H99Y:?K%@4!M+103=9/,I_P9U
MF>LVK#`&)F-@,@8F8V`R!B9C8#(&)F-@,@8F8V`R!B9C8#(&)F-@,E8R9RP4
M`"XQ%@L&M;%41-"V7!A#749_4)AK#$S&P&0,3,;`9`Q,QL!D#$S&P&0,3,;`
M9`Q,QL!D#$S&P&2L9,Y8..5?8BQ6!6ICJ5)0KS$47\*7U81=,=_.Q@,R&4.<
MC(')&)B,@<D8F(R!R1B8C(')&)B,@<D8F(R!R1B8C)7,&0M'^4N,Q:-_;:PM
M!Y1K#!66\/>5<1\#DS$P&0.3,3`9`Y,Q,!D#DS$P&0.3,3`9`Y,Q,!D#DS$P
M&2N9,Q:.ZY<8B\?[VEA[Y"^,W:**<MV&%?<Q,!D#DS$P&0.3,3`9`Y,Q,!D#
MDS$P&0.3,3`9`Y,Q,!D#D[&2.6/AN%X:^P\>(^/)OY;95@-*F2BP7+=AA4PP
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M#,=U;_.LOQ`X&,:3?BTOG?[S5UN.+*[XOK1Q!Y,IM)4I,)D"DRDPF0*3*3"9
M`I,I,)D"DRDPF0*3*3"9`I.IDCE3X9A>FCIUVXO'^EI/.NIK=>>S^"WJ7?I2
M4)P3R&0,<3(&)F-@,@8F8V`R!B9C8#(&)F-@,@8F8V`R!B9C8#)6,F<L'--+
M8^&I\\RU%4_XM;QTZJ_6%IC6%IA,@<D4F$R!R1283(')%)A,@<D4F$R!R128
M3(')%)A,@<E4R9RI<#PO39U:6_$X7^M)+-]\M/6!20^8](!)#YCT@$D/F/2`
M20^8](!)#YCT@$E/R=SE#&?G\G(6$__\K[D?#.,1O+[*B15_&:"-T_FOW=7X
M77D65O]M@%M7.I:+V$/YQP$ZF%P@3B[`Y`),+L#D`DPNP.0"3"XBT^<(]##D
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M87D@<V/]`UE86/]`EFU8[T!619CM%&MCX?&S?:G7=Z[FN+&P:B#ELG)S1`.Y
M9(^Y"?%^,D2FIRT;K,RW+`^VRWP*NVN;RCS8M&6Y"SD]IPLY13HY!9/`-IV]
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M-TV)JW`7_O'[XR7\R^`FEA3J91N9N\6ZAU@MV]0T'T*U;,%D)+)CKWK^OA\^
MW#SZ/[PN1ZFE_LGSUBN7-G0@1V!R%%GJ].[AYO[NT3T'2EIJJ'^>[U,>D5_2
MP"0MLM2G?F]^>.T?&V0Q-=0_G7TZL:&.4(H]I3/6'6J=D;E=V!V"I#.%5;MP
MRXK!^CU'AF-8O0O?N:=S*8YAU0Y6/A\<IZ04MYW:4I+BEO4,1-8[!^*.W?)^
MSD#DO>W4!B+O+>L9B*9".Y!P(G-OM6L2=`R@?$9QDR!4/RZ9!*E:DDV^&P0W
MVGFK-<W36(K2;RG;*]:23MFTN^<)VS$'8EC]C,BCEV4KIW_7'&@[M8%H#K2L
M9R":`YT#X9TX9>L=B.9`VZD-1'.@93T#T1R(86D[Z#I46:)R##W3(!1>RFD0
M'M3"N>R2$U4JWE13(S*W/[C-4OM#"LM--3<BTXJVJZ/-(+'>!Q!M!FW3XB)V
M[/?H51.A;6J]ROHYO6KEMTU[>I5U]"KK8%(<6?#8KHVN@U%'K^6D=\L]U&5*
MSZ?V_%3'R6*TW".K'ZI:E@=;SC9[J$IAU<$(3`+;=&9!6W?+>KJ00*230##9
M:M-9%U+3LIXN9`OI9`M,.W&;3ETX#Z'D47IXX<$H5D[J6W)D8?H4\\857;3D
M4M.\O+3D6I:;XAB@51C#3F['*5NY`Y4STV[);:<F0A);UC,0>>T<"+?C<P8B
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MLIXN)!!=2""8;+7IK`NI:5E/%[*%=+(%)C5M.G7A/&AJ5AY>]CRDSV9Q8XW,
M;:SN(4'&4EC>X[2Q@FG))79B8XU1)S=6="!A8!)6=?K<QGI.GY**_#(()H-5
MG\]MK"?Z=)9#::)<;<%RN;&>6>H-WQN/^V<J>^1G`3EM6<_\E>84EI\%I!E,
MJ[!-9TM$J[!E/5U(*M))*IA689O.NI"PEO5T(8=()X=@6H5M.J["4%4H_9S:
M#5.Q(J^9=X/;R.H[W+VK4DE-:IKO-?+0LN*%LAJ4PNKC!RN"EDTS-)^#^$:\
MA>6!R-8Y`Y'`&.8&@HJ@9>L=B#2WG9IZ.6U9?@T=QX\\D,Z*H&4I!U#>_MTB
M#06%2R9!+$#4M\3(PF-7OO;W[DU=38(VS%ZR)@&8%B.8%B.8%B.87())')A6
M'IB4@$D)F)89F)89V+:#[3K8OH,=:N:,A3I#::S85D^MX%BBJ.5%IOW?K,@4
MF$R!R1283(')%)A,@<D4F$R!R1283(')%)A,@<D4F$R!R1283)7,F0H%@-+4
M*3VI8%!ML(GE#4MZP*0'3'K`I`=,>L"D!TQZP*0'3'K`I`=,>L"DIV3UY;P[
M52$Y[Z!V3.,*),;*SP1FEG>U<A]-#_4I+'P$+F]^_'QF#K-E-E4RS8_P)V?;
MI3?K8$T'FW>P10=;=K!5!UMWL(VQKL]GWH5S>#FUBTWH@C<1CFF\BWC$C[VF
M`Y;%E1=9P_O^[1\Z6GQ(9_#Q((7I[>WTZ47WUN2DB"@TH$-I:%FVB@YE)H;E
M#ET%1Y[:".M0GMKDQN2I93T=2EV;[KG/9^8(2RZ1;7(QMZC"`;H4>6*/NDL'
M[G*/2JP^<]VC!FUARM"N%%Q328P]5.\$&:N:^G?$M:#:ICT]2&X,"U_@\OQ`
M)+?-9E=2.A.KFOJ!R'#;M*<'28]A_0.1]#;,!J+UFE@ZF.K94=]46J\'>3\Q
M##<5PH']DJD0#_C5T\1=9.X\X%;%:)#"PG=8/V]`4R'UD)]-M((C.U4$RTU[
M>M!42#WT#D13`0/15#AG()H*;=.>@6@JG#,0384VK)@*:2#ALSA__#A\O+Z^
MYTPX,0HW$\(Y_Y*9$.+]-AZ9VQ3<P#034IAF:N],B&'UII!8U=2O16T*;=.>
M'C03SAF(9D*;S01H)IPS$,V$MFG/0#03SAF(9D(;9@/1II!8W!1NAL.[*_]5
MPMH43@S#3850/[AD*L1Z0[TI1.8V!?>A'DV%U+1W+6I32&'5IA#9R4VA;=IC
M0%/AG(%H*K39S("FPCD#T51HF_8,1%/AG(%H*K1A-A!-A320N"G</E[I@W*N
M5J&I<&(8;BJ$\L0E4R&5,ZI'A<C<KN`&IJF0PJJEW?&\%\/J72&QJFG'KM`V
M[3&@J7#.0#05VFQF0%/AG(%H*K1->P:BJ7#.0#05VC`;B*9"8G%7T*<7;^[<
M6U":"2=&X69"J'9<,A-B=:3>%")SFP(^*W27FI[:%%)8M2E$=G)3:)OV"-!,
M.&<@F@EM-A.@F7#.0#03VJ8]`]%,.&<@F@EMF`U$,R$-)#TI#!\'CX^N3*>I
M<&(8;BJ$\L<E4R&62^JI$)G;%-P<U::0PJJ5W;$IQ+!Z4TBL:MJQ*;1->PQH
M*IPS$$V%-LP,:"HD%M>BOK#BX?'1_Y5WS81SQJ&9T';0,US-A#:;C4,S(;'>
M"Z*YT#;M[L'-A5"[*>?"\6V]<SXB<9>J/M6M(C*W0>"=/&MZ:H-(/50;1&0G
M-XBV:?=%.-8H-"M26.]`-"O:;&9#L^*<@6A:M$U[!J)I<<Y`-"W:,!N(ID4:
M2-P@!@]7]P_NB5USXL0HZCEQ[XMV)^H+QWAWE$BLWA\>7/5G-+"P:DYS?\AA
M]KHG;=-TFKYZO'F\<B]\:D':6'HN_\S"^@_U31%FPYBW+`UCJ-^5].^E+2RH
M?QA+"^L?QJH(LV&L6Q:',;R^T2A<-6=C0<\.PTT#7;1J:S@U#4*\GP:1A4^5
MM4?%ZP=W_](T:,/L%8T[F)PC3HK!Y!-,\L`D#TRNP"0&3!;`9`%,%QULV\%V
M'6S?P0XU<\:TC"IC83-_X1<FW8=<WF9D]9N&#VZ:R68;5M@$DTTPV02333#9
M!)--,-D$DTTPV02333#9!)--,-D$DTTPV2R9LQGJ/_[6_%*;J994WJSO(W,V
M4??+887-MJDQV02333#9!)--,-D$DTTPV02333#9!)--,-D$DTTPV023S9(Y
MFZ&$4]H\M9O&DD_UT'T?F3/F;GI:?VV8V=%N"B9C8#(&)F-@,@8F8V`R!B9C
M8#(&)F-@,@8F8V`R!B9C8#)6LFCL[==?GIZ^C=]_>__C]Y^>OOSM:?3TZZ]?
M7WWX_(_P"Y3A';:"O_KR]/,/K]]I5_Y.R8[O^+9MVI]=AY\=EQY_-@P_&X9W
M$_FSF_"SX],O?C8,.?5M:UWMAB&GOM^K\V<AISX/T_FSV_"SX\>ST-_MO7ZF
M3TQTM;M]"#\[OB.*=M=W^IF>UKO:78><^O;;SI^%G/J>U<Z?/8:?/7;^;'BE
MG^E+,KO:#8.C>,;D.$,[/:UVM;L.[?3''CI_%CSH@:WS9\&#OJ6^\V?!@[X/
MO?-GP8,^T]KULT%HI^]8Z/Q9:*>_I-;YL^!!?YBK\V?!@_[.T_^GZVQWU`2#
M,'HK32^@"[M4A#2;J*B@H.@=;%-WN^F'C6O2V^\9;?N'XT]S'&9XGG'""PC*
MPH?K==V!9FGXP/MI+"Z).-X=K2SB>$NQL31\X,6_RL*'Z[\3A[6$#]=A.63A
M`R]XM&TF$9>X?TG$)3?BPH?$?4C"A\1]2,('WG>OM80/O#U=6$%8H5$%087'
M8$&A#A084+C^2>B?N/Y)Z)_H[V",'&-58XP88]6B0/I"E2\0OE#="_(4FJ<@
M3Z%Y1N3AJJJH.B(/5^>,D(>++D)R8GQ>Y\3XM!X3,]8\]Q"?$/?LC\^`&*D^
M46.@^CR]IQ=\FL9@OS77L5L53:.)M1O3:&'MQC0&@G;C98QH-\;@];D;#6SN
M7,:'=^]E>&A,C`#MCQ1W;LP-O-8I/$G+B6^+`,M.<OT^J:UC)EDYN7%,0$G:
ML322NHB)ZB$6JH,8:/[QG,&\O#PL;OAK@8W+RQ/6ABR>E%9>'H8V9/%0L]BF
MYQLE,`[#AG%Q.Q'YN'=FR#B-EY)/&6?6TMBFQ56CO)QS@EVV"&F4M)!.296/
MRB8WW:N</+GF@31*]AGF\B?686U55I1S_LTX)#6D4=)".B4]9*>D&HW84]N?
M:1P6^E'A1WZ^W#0XK&V*M7MU=HI!>_5G@P8;U6`+V2KI(3L>PS"LH,]&$-N?
M/LLAYD^?C2'FPHH\*R5KR%I)"^FTMI;:.JVMI;9.:VNIK=,\5991M4X,*IAJ
MS`PR4U)!YDH6D(62)62II(8TJD&-!HUJ4*-!HQK4:-!HGGTL"70U5#VP/[H6
MJB&-DA;2*>DA.R6SC$'/O8C#3MQ0VT9KVT*V2GK(3E<X/0O&G:X7>Y:+.UTM
M]@]TB.99D6>E9`U9*VDAG=;64ENGM;74UFEM+;5UFJ=B";CS%2`53#5F!IDI
MJ2!S)0O(0LD2LE120QK5H$:#1C6HT:!1#6HT:*YY[OXO>MX>/_UZ>CET3Z>7
MUY]O[[X?GCEID7S(N6WD]/H2)X2O'\Y_G]GU^7@^'W]P7N/]NZ^'IR^'4WR!
M+S\?C^=_'VC.N]_'T[?+B9''/P```/__`P!02P,$%``&``@````A`-A4DA)7
M!P``2Q\``!@```!X;"]W;W)K<VAE971S+W-H965T.2YX;6RL6=MNXS80?2_0
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M"?1W6;PWO?]'S:%ZC^IR]UMY+D!M&"<R`D]5]4),DQV!P'F"O,-N!/ZH1[MB
MG[T>VS^K][@HGP\M#+<+/2(=6^Y^^$63@Z)`,[9<PI171V@`_!V=2I(:H$CV
MO7N^E[OVL#+LV=B=3VT3S$=/1=.&):$T1OEKTU:G?ZA1UR-!8C$2>%XA&7"T
MF:,C'<=S<^K9<P@^X`=ONU;#DP4TK?'"=9W9XH[GC'G"DWE"[(%(<V8/]<*[
M]J$6>LP/GI]LH0DY0(>$)`.5^VH;)W0HN\SPLS9;/]35^PC*#0:KN62D>,TE
M8>,Y0;LILN16DD!V$)9'0K,RH.,P_@UD]MO:FCH/DS?(QIS9;+"-J5ILN05)
M/4+KZT"@`Z$.1#H0ZT"B`VD/F(`L0AM(T?]#&T)#M.&]VG"@)Y8F!+?@+KX.
M!#H0ZD"D`[$.)#J0]@!%""@])(0-R7)]XN`Y0;Q@BNCGQ,)5.[JA-HX49XL0
M'R$!0D*$1`B)$9(@).TCB@1058H$PUTGUE!1H.=`/5`C!ZI>&BUFJD!;8212
M`2$!0D*$1`B)$9(@).TCBAPPF7Y"#F+=R<$[L:&("Y77Z_M<Z[LPXFX^0@*$
MA`B)$!(C)$%(VD>4OL-RH/2=3IECLI@,9P5Q5&6@B.N(N6&+$!\A`4)"A$0(
MB1&2("3M(TJ?86E3^CS<46*M=I0A="M`IO8M0GR$!`@)$1(A)$9(@I"TCR@=
M)7M=O!YV@]L>ROQE4T'"0MI>$<"&=8^NAH1$[3]#>O.<0&0%F+.I6@$^-;+A
M(<MDJJV:@3#B91(B)$)(C)`$(2E%S*[5BDHP9_UWE0B)JA)#>BH)1`J`5:)&
M#M&?[#M,;>,1B/="($'+D4@@`X%B0<0"V>IP)>(]ITT%+2"*@F2OI4AX):%@
M5\TSJC-7Q6*0!42]Y-#7#V[57XJP@E>MYMIB'7`KCPKM>EJPD!G8_6D=!8LX
MS6"3XJM6>I,2;L6:9,\]=4C2>TU2!X7L!/O5?V=0B+DV*!1R8'[I#<I";=36
M9([P$%9()U]:\70*&-0EQMO:G"VT#`RY#RS<MYDC;C48/Y96/'ZBQ7?FVI*=
M<I];\56YR7[S$W(3<TUN"JDUL$!R,RMXW!;%)[LUH+<LL1@'#')F7<+/76WF
M#=G[>_DNB`?"QSA\HH:?Z>'3>^%5L<G6]A-BTYTPA."#OS'9YEC)[856<%MF
M11)A2&Q&+S<$`7/DN6U[II9<(:>^E5S=XAMQJ\$&Q-**]R_1&F":,VU^2[G3
MK0:H@H.5(GAOG_CQK81)6+2DIY":]*8V$VR9(Z3SX#@P+CG,`7>D4ZIK>AIS
MR`SN9;U@'H@?\V`R?L(A&M]9>-IRGMZ+KXX"V<9_(NWIKE])>PK9]$2LV[N2
M0S,8%(`&^N9SJYDHH0!#(8<D?22A`?J86TGZ!$,IASIZ51FRV?^$,O3;0%&&
M0A;4LBAUR]/VL%N3.<I2]S$4,(A5O^68CL83<B?(*Q$-+9H1MY+18@PE6K2I
M.]/FFI0[W8JF2DD^)_I2_ERILX\260L;DT)JJ7O:,K3E5M+1QU#`(%C,I'Z6
M9ZE;DY!9*<5MN=J*&F'Z&$/)]8C:=)+>BZ@J33Y)^DK?V:&Q+QBIS`:^9ECM
M\HE_*R&I#,HLGUO)>@LP%'*H7\XBX@!]S!TE?8*AE$-7RIE\:O25^;D<9!\L
M?<$HI%2YK97+UF1^LNQ\"?6ZK6_@`V;%ZGXVUT\(0TYSJQ#9HH_BQ]Q1V0?H
M\1,UOCNUM8^>E-/<BJ^D)RG4P4'X5EU@,;]Z?-!)0,\/.AIUT6=0?Q624$]@
M=(3`K>9R%<)0R*%>VDIH@#[F5I(^P5#*(9RV%HB!%+/<,2RMG[R"Z)@TT0CY
MRE"/&?7]Q)8Y@A6?$7P,!1@*,11A*,90@B%R[\>:"HV@.47O\>AMS:FHGXMM
M<3PVH[QZ)7=TL!"O'P1,+Q`WLR4<X0&!CEOB9E%[XR^6<.Z#/7QO"<<F&(^]
M)9QR8!RN+A^[.4/CWT#@3E<=M^"J\PK/QE["&?P5?@?XKQ(Y2SBEQ@X;=PDG
MN(!/1&2XRKQDS\7O6?U<GIO1L=B#C-/N:*^FEZ'T1\MJ]*EJX1*S*]<#7%H7
M<&HY)7FYKZJ6_R`!Q#7X^E\```#__P,`4$L#!!0`!@`(````(0#*`ZU%;`(`
M`+8%```9````>&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;)14RV[;,!"\%^@_
M$+Q'E&0[B07+@=T@;8`&*(H^SC2UD@B+HD#2<?+W79*.ZCI!X5PHD1K.SL[N
M:G'SI#KR",9*W9<T2U)*H!>ZDGU3TI\_[BZN*;&.]Q7O=`\E?09+;Y8?/RSV
MVFQM"^`(,O2VI*US0\&8%2TH;A,]0(]?:FT4=[@U#;.#`5Z%2ZIC>9I>,L5E
M3R-#8<[AT'4M!=QJL5/0NTABH.,.]=M6#O:%38ESZ!0WV]UP(;0:D&(C.^F>
M`RDE2A3W3:\-WW28]U,VY>*%.VQ>T2LIC+:Z=@G2L2CT=<YS-F?(M%Q4$C/P
MMA,#=4E76;&>4;9<!']^2=C;HW=B6[W_;&3U5?:`9F.9?`$V6F\]]+[R1WB9
MO;I]%PKPS9`*:K[KW'>]_P*R:1U6>X8)^;R*ZOD6K$!#D2;)@PRA.Q2`*U'2
M=P8:PI_"<R\KUY8TOTIF5^DD0SC9@'5WTE-2(G;6:?4[@C(O:B3)#R3X/)!,
M+L\E85%0R.^6.[Y<&+TGV#,8T@[<=V!6(/';":$(CUUY<$FQIU&KQ2(\+F>3
MZP5[1.?$`;..&%Q'3#8B&`8=(V.T\R-[L(_L_?!2UO'@.$S^=IC)>\)X<$EQ
M'<7/)O.1-T:.F&GHE^-\IN\)Y,%H.69Q%.G4R@,(N_4O:)J.<OYQ$]OHV,W0
MH'.D_W]!_:T@8_3U<')L[&QZ6L$X)[&/%)@&/D'762+TSL]`CITQGH[CN<J]
M8Z?GTV(5YH6-'W!L!M[``S>-["WIH$;*-+E"828.7MPX/83NW6B'`Q->6_P_
M`C9'FB"XUMJ];#`P&_^XRS\```#__P,`4$L#!!0`!@`(````(0!Z*4VA90D`
M`,\M```9````>&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;*R:VW+B2!*&[S=B
MWX'@?@!)R!S"]H0Y"`D$2(H]7--8MHD&Y`"ZW?WVDZ52EE2991EF=RX&_'76
MK[\JLPX2NO_SUV'?^)F>SKOL^-"T6IUF(SUNL^?=\?6A^>]_>7_TFXWS97-\
MWNRS8_K0_)V>FW\^_O,?]Q_9Z?OY+4TO#5`XGA^:;Y?+^[#=/F_?TL/FW,K>
MTR/\RTMV.FPN\.?IM7U^/Z6;Y[S18=^V.YV[]F&S.S:EPO!TC4;V\K+;II-L
M^^.0'B]2Y)3N-Q?P?W[;O9]1[;"]1NZP.7W_\?['-CN\@\2WW7YW^9V+-AN'
M[3!X/6:GS;<]]/N7U=UL43O_@\D?=MM3=LY>+BV0:TNCO,^#]J`-2H_WSSOH
M@1CVQBE]>6@^6</$ZC?;C_?Y`/UGEWZ<*]\;Y[?L8W;:/8>[8PJC#7D2&?B6
M9=]%:/`L$#1NL]9>GH'HU'A.7S8_]I<D^_#3W>O;!=+M0H]$QX;/OR?I>0LC
M"C(MVQ5*VVP/!N#_C<-.E`:,R.97_OFQ>[Z\/32=NY;;ZS@6A#>^I>>+MQ.2
MS<;VQ_F2'?XK@ZQ"2HK8A0A\HHC3LKJ=NQLTG$(#/@L-J]5WW>Y=OW>]D6XA
M`I^%B-VR^Z[EYDYJ>@"7R(<!/HN&/=6!FF9W13/XQ.M=/6B]HBU\_OT.PS3.
M?<,G&KBNPX.B(7RJ#O>LSL`1HUW38PLJ5!:,*%59#)#V*PO%4N4&7_Y^KRTL
M./$%35S7;POK3'Q1/>_:;J^?5WQ=U[&ZK$IY7=]U+#$Q._^'KF/)696:NZ94
M+:PW\45U7,WTNGYCD<$ZABV_3'E;KC/YLC797#:/]Z?LHP%[`23^_+X1.XLU
M%(*X8$D#:@G[;`6#I4NH/`F9AR:TA\7I#,ONST?7LN[;/V&IW!8Q(QY#(L88
M(=9%(3NA8$J!1\&,`I^"@((Y!0L*0@J6%*PH6%,041!3D%1`&]*C<@39_7_D
M2,B('.'HCA"42;/UE(TQ`IM,*)A2X%$PH\"G(*!@3L&"@I"")04K"M841!3$
M%"05H"4$UBJ6$`<68/,NCW-$M(+]7)LC9,!',J9;)FG,R(21*2,>(S-&?$8"
M1N:,+!@)&5DRLF)DS4C$2,Q(4B5:2F`/T%)2GPH1#2L>Y+=FO9)!7=B2*T$.
MF2$J2$T11J:,>(S,&/$9"1B9,[)@)&1DR<B*D34C$2,Q(TF5:.F!359+C]QF
M6N)T4Y\IT3#/%([O2!*WJ]:Q,2,31J:,>(S,&/$9"1B9,[)@)&1DR<B*D34C
M$2,Q(TF5:#F`$XJ6@_J!%]'ZP!=$WFN([7G,R(21*2,>(S-&?$8"1N:,+!@)
M&5DRLF)DS4C$2,Q(4B7:P,,)3QOX2O%?WG;;[Z-,WM(9$N+`64J>L(2(GH^"
M5/8*1<H5R[KKZ"O61`8Y^EFMJP=-51!..T]I(YDI4G,U7PF507#_IU\M4$&H
M/5?:2!:*E$*L;Z$2*H-<ZTZ_VE(%H?9*:2-9*U(*L:M%2J@,<JV>?K58!:%V
MHK2!:'4"*='JQ%`/<`>/!2&B]8(H2*4@%"D=LFY,9%`73I^5?:ZO=V.J@K`;
M'B,S1GQ&`D;FC"P8"1E9,K)B9,U(Q$C,2"*)?$BDI0<.`C>D1T3KZ9$$MCQQ
M>V1W+#+GQO+?[>JAA"=+!6$>IHQXC,P4*5/,I'T5A-(!(W-&%HK42(<J"*67
MC*P862M2(QVI()2.&4FJ1$NI>'QR0T[S<#VI!;+A8%J9/0-]]HRQ876.L01,
MC%$]LEA.\8JRCJQNSR)7\U`'3F/*$[O:#*-J/?G&*.HIT#T-;)ML.G.4J;6T
MP*A:2Z$QBEI:ZI:LOM,G]UHKU*GUM,:H6D^1,8IZBG5/;K='MJ8$93ZSI!<O
M6+JE>$4X*5Z);-B15*&X-'=C\900&GZQ,)51.!&G!>K"P:@B3Q[Z>$64`U=1
M4;9+]I]9*5]&L9KVRR@T$9A-D%J87V5B4<K7F`C+*#2Q-)L@]Y*KJTRL2_D:
M$U$9A29BLPFR"R5?F=!+4#PAJ3X^K#^RB!MN6H(2Z>NG3=:\,3:LU@C+_L08
M12?AM(ARJG/,M<E,]%"K&F6HRJ)#M;Y\U-*BJ*_`[(L<)^>H5>MK@5':%>F=
M0&B,HKZ69E]D?JY0J];7&J-J?47&*.HK-OLB>V&"6I_YTLM9/%ZZH9SETRBX
M!,ZQD?@9`RJ\/.21.3XN`KY:3*4,1*'RM&R(R.-H5J*:Q<$OHU`KX&C.T:)$
M-?)A&87R2XY6'*U+5",?E5$H'W.4:$C/,M3"+5D6X63?E$A?M.@Q;"Q^EQ(-
M:XM]8HRBQ3XMHO+;OY^/5L<=D`GHH0Y<5&VC;(F<852M)]\813T%Q)-M#\CD
MFZ-.K:<%1M5Z"HU1U--2]V1W;(?L]"O4J?6TQJA:3Y$QBGJ*=4]6=]`AFTV"
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ML7A;""H9HG##F7`TY<CC:,:1SU'`T9RC!4<A1TN.5ARM.8HXBCD2[YB6@R,7
M&OG.J'SYZI">7M-QNM^?&]OLAW@?%&Y7'N\5EB^KCKI#^$4=1I=R=PB_\AJX
MU<>W6TF+26\(/^GQ%GYO"#^^<1[VAO`S&>=1;QB;^*0_C/.?G<AUX77;I[RP
M"!^)UW`-^B-[F!CCG6'B&.*?NL,G&&HPVE97@-=IWS>OZ7)S>MT=SXU]^@+#
MV\E?-3C)%W+E'Y?L'88=7AC,+O`B;?[U#5Z<3N&'[4X+SITO67;!/\0%U*O8
MCW\!``#__P,`4$L#!!0`!@`(````(0"RH[$:UB```+:Z```9````>&PO=V]R
M:W-H965T<R]S:&5E=#(Q+GAM;*R=R7(<.9*&[V,V[T#CO4GFOIBD-C%CWW*Q
MGIDSBZ(D6DFBC&15=;]]`P%X.N`_$I'4=!^:JB]^.#S@6!W)Y+N___/[MXL_
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M5\K<M7$4WWEUO;I6ECZ\^_2HWD`W^\7SP^?WEQ]'Z\-J=7G]X5W?0/_[^/#7
MB_/OBY>O3W_ESX^?FL<?#ZJU59QT!'Y[>OI=2\M/&JG"UU`ZZR.P>[[X]/#Y
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MHM1)1MQ+XM'3_=^XR?WCS`XYHIZB_V']')\5!^HR(^XSR_/>C_K,B#M-W-MK
M,X;[*2&Y>[W[\.[YZ:\+-<^J@+[\O-.S]FBMK=%D8`)SG!Y.S0YJ6M!6/FHS
M[R]5>37P7]24]N>'V73R[OI/-0W=6\TM:D:^8D,*/>=HLXD$J029!+D$A02E
M!)4$M02-!*T$G01;"782["4X..!:A><8(S5R_A,QTF9TC*AU;PEPT,8B(*2@
M(HD$J029!+D$A02E!)4$M02-!*T$G01;"782["4X.,`+B)I+O("$5TX:&UJM
MAI<RY@R.J=_2MT8T4UW@*!K-5KYH<Q0=XP$D!9(!R8$40$H@%9`:2`.D!=(!
MV0+9`=D#.;C$"X^:]+WPF#GM2F\LXI'2!?M(4?O>&C*;'@?-!D@")`62`<F!
M%$!*(!60&D@#I`72`=D"V0'9`SFXQ(N!:FLO!O&&UVJ_X2TQFT:]%FR`)$!2
M(!F0'$@!I`12`:F!-$!:(!V0+9`=D#V0@TN\AE>;$*_AG<[_^O7Q_O?;)[,W
M#P1DHA9NLYQK(WX\+.'58W,DSHPUO_%GK,2()N[&8#07RWYZ%-&PRX#D0`H@
M)9`*2`VD`=("Z8!L@>R`[($<#%'[+/6F7M34#M"+6B`ZZGQ#X=%J/SR&3/I3
M8Q_"S9'$PF-$T_Z\V!=+@61`\B.)F"ZLR%WU1G.QORB/(HI\=;1-I#Z22&W-
MT9`KFON=L3V*R'9WM$UD>R2N(=&K=T=#KD@LUONCB&P?##%!\J*OAL<;HJ_5
M?O0-<:,/)`&2`LF`Y$`*0Z;>1F4NMOKE443O7H&A&DAS+.4VZT($\2@BTQT8
MV@+9'4LYIA<BK/NCB$P?7$->Q-29^PT1TVH_8H:X$0.2`$F!9$!R((4A(F)B
M_UD>1?3N%1BJ@33'4DZSSI<B8D<1F>[`T!;([E@J8GI_%)'I@VO(BYA.=G@A
M^Z6%L;?BA](B-Y:($D0IH@Q1CJ@@I'HG'Q;F,[_92U91XU2$>)FH$36$>*UO
M$76$V-86T8X0V]HC.A#J;?E1TV=BS$_T>_GSMS,Z;24&("%V;,/(;58Q2216
MY6UIEF)=2UE$;9^Q=4(YHTB%A55-U7&'H[T0>ZB2562^8O.$:D:.+;EI:]B6
MHUJ(=VQ91>8[-D]HR\BQ)6O<L2U'M1"KRIY59/[`YA7R>XX^O+L])[ZETL=S
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M'<]OIB(.F55,HBV<DYVH`P6KR(&2T$D'JK,<J,E.U(&&;9$#+2&O(/9&TW3Q
M5MB>Y<2.:N1,V)Y0U(D#J4Z%PN]Z.I_D3J&_MCNV62EW9C7(GUE%K]GHVS?=
MDT^Y:B^#CBH*1VH+3J9]AYS<B&4W(\,J'CP>G.'7&\Y)%:V^8!557PY47U&1
M:/4UJ:+5-Z3B5'1KT7A@:K3-%G5B2^:C3NQ(Q4[LSW+BP`7#@?`[HTZ3N9UQ
M8.MFLVINKS-H8CZ^T*>/]>VLZF,*A3VP?<RJYL>]04H%&66$V'S.*&*^(!7;
M*A%5A-A\S2ABOB$5FV\1=838_)91Q/R.5&Q^C^A`J#?OQU4GP-RX_MHD8])H
MWO;-(+%3%WF(C;YF-\L>#>"$D?/><@N2DLJL.J/98KD2QZ_,2N(S?DZ&N*<6
MC"(>E*0Z[4%UE@<U&6(/FF!!V08MJ:)K3D>JZ"RR12=VP8+2B3VIHDX<2'7*
M";]/ZA1?K$_^X^FG6IF&;@[U1R?T"L;M>FN1-P?9?.+`'&15"V<.`I2A^9R1
MTY?D:E>0BLV7B"I"/$G4C"+F&U*Q^1911XC-;QE%S.](Q>;WB`Z$`G.03A"Z
M\1Y86TP^T8NK33&RZYN105->%A-$*:(,48ZH0%0BJA#5B!I$+:(.T1;1#M$>
MT<%#WMC3\[47BU]:#WHK_M`CY"3W&$5Z5V)57G)OM!`W.RFK:"')$.6("D0E
MH@I1C:A!U"+J$&T1[1#M$1TL4F-+O;8?2#4_>H&,#ZJQEHN(&>0FT:U*H6C$
M3$'W"M,6=%"&*&<4,5^0REMQEN*84;**.D1%B*]6:T:1&AM2^36*_4;+*JJQ
M(\0U;AE%:MR1RJMQ+CK]GE54X\$B$S2_0RA;;^D06BXZA$%>AP"4Z!2&*NBH
M4D09HAQ189&X)Q,YZ))5U`P5VJH1-5S0C85(S;2L(O,=VMHBVG%!QSS<<+**
MS!\\6WX0WY96U4=\&42#G/!LK,I!":(4488H1U18)((H<O8EJZ@9*K15(VJX
MH-/*<.')*C+?H:TMHAT7C)C?LXK,'SQ;?A!U*LK=[_S:&JNMB`%JD!/(S1A0
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MS)OI>R(=ZNBUIQ4-).>#*IG`2:E"<^VYNIE.1+_*R(Y:2D[WJYQ4:O-_6E4$
M5=*G<M"GBNQ$?:I)%?6I(95G2_K4DD]J*/+[P353T)8<@UM21?W:D2KJU_XL
MOPY!6XY??B_6J:TW3%@F$^9-6`;I6IW&$COKS=BJ!B:LHXK&9$H%^<Y1F,ZL
M8B#Y2W:B#A2L(@=*0B<=J,YRH"8[40<:MD4.M(2\@M@;3=/%6V%[EA,[JM&Y
M]"04=>)`JE.=W>]Z.FWG=KU?VQN;Y)_7(PWRYU5YZ3FVY4ZY:BZD6$7A2"VR
MEY[3&[$#SJB(-Y2=X6<N/4D5K;Y@%55?#E1?49%H]36IHM4WI.+$:FN17A:=
MT2X:M^."CDJVP99442=VI&(G]F<Y<>""82>\SCB1R=#X:M[+_1.91>Z%`Z.P
M!Z:/D8KO]5)$&2'.>^>,(N8+4K'Y$E%%B,W7C"+F&U*Q^1911XC-;QE%S.](
MQ>;WB`Z$>O-^7%7G^O]/,GI6%0=PB\0^75YZDHK/@`DCY[WE%B0EE;UR',V7
M2S'(,BO1/W@HRD&6DR'VH&#D%)0>E*0Z[4%E)?K':0]J,L0>-,&"TH.65-Z:
M(T^]':FB3FS1B5VPH'1B3RK?"9&7/)#JE!-^GU2VHGWRO$O/B38CYB"#O#GH
MB"(Q2JRM"=_KI8@R0CR*<T81\P6IV'R)J"+$YFM&$?,-J=A\BZ@CQ.:WC"+F
M=Z1B\WM$!T*!.>AMF=S),9/+3L'G4V^MRON59?7]'?YO(6Q811N(!%&**$.4
M(RH0E8@J1#6B!E&+J$.T1;1#M$=T\)`_0M7NZ=0('=@8Z))B4!KD_A:SVCQJ
ME8,21"FB#%&.J$!4(JH0U8@:1"VB#M$6T0[1'M'!0WY89%YV(!:8@-6?/]/A
MX9/-!E'B(=\#G9USSRP#'IADGGLXF1CD[1O&-S!NK4I-WJ=7UH1LN:KQ#9^/
M?=??EJ]22P%T9(.F[DE_?`-;'EOPU%)H-[T!U6G7]=GV#:UNCL)>J]O$@IM5
M'=^(2]:-3J^KWJ'OY&*M'E"-1YRQ]UM='G('.@R>9M45CW;*;_61N)'>6-5`
MFC"D&H_X-RT\U]4-_EM:O9?[,Y]%?E\?B;W3AE3Q5@^IQB/.7_JNJ\[WA@ZC
M[ROUK.!Z,)OR..J[[*U5>2ON>":._QM6'5=<1"FB#%&.J$!4(JH0U8@:1"VB
M#M$6T0[1'M'!0W[$5-M[$7.20?$A,]4E1;\SR%E>-U;EH`11BBA#E",J$)6(
M*D0UH@91BZA#M$6T0[1'=/"0'Y:W;5WU=:&,A47.BDLJ1@FB%%&&*$=4("H1
M58AJ1`VB%E'G(;_](AO)\W^!5GVR$9K5(N<FF51J>8JL7E;EW22/9V+_D;**
M9K$,48ZH0%0BJA#5B!I$+:+.HL#GXJ9RN^C,*6]H?-Q%]H;5E.,VOE4--+Y1
MJ?ZB?^]P?..L7_T:DUK+2L#M?K1,*.?Z(Y$NV):M3"R\)0O(<L66"=6,(I4U
M;,M6QIN*_LU:%I#ECBTKY`^;MVVSI[C-MLC;>JSD5I5$[KH_DAFT)*B2>:+4
MJO2/X^@;S\0>(K,JG2YR5,*O/%BC]*L(JJ1?I57I'TZ-8N=;657<KSI8H_2K
M":JD7RVI3'IQ.9%?3M.%7'*#XW<8?9QP3PAZJ(_G^AM4+]XPU.VAA#.5MWK;
M#;MO^<H;JQK8?9.*;S)2B^+7*1D7Y!BZ3=&/L)Q4;M\"54$J=J(\RXF*"T:<
MJ$D5=:)A%4T&K47Z\,_]5'Y754<%/=6,QX_?*?1!S>T4`QM)<ZYSCXU3@]Q\
M*B/V$UHY(15?6Z2(,D*<D<P91<P7I&+S):**$)NO&47,-Z1B\RVBCA`F/*?R
MT/MKHQ'/PKUA\>&HL9PY-J3B89PP<MY;SDFI5>F9A_L@SN'&K_A<F7.-U,4+
M1FQ^))THPT[`A'V.$S772$XT%GG>@Q,MJ;R5$3YS0*I3@]T;C3.93I"[L?-N
M/7HS_G'/(G>4,G*:6D[;":DXL9\BR@CQ,,H91<P7I&+S):**$)NO&47,-Z1B
M\RVBCA".4IW(\*;'?I3.KM22&9\H^X(B!-J63%+)[R7;4$'GX(<HM4@MW?U6
M<C%93E<K3J_UBUU&Y=R%`*;AG%1<88&H]"N<+Z>+^4ILW"HJ%JVO)A77UR!J
M_?I&-\O)&(86%3M5GS^T=+[C_(5N9M(C[D)GD;=='L\YN]8W^H94SL3*R.FJ
M<DY+K<J?6.579F56Y4U-8V=Q-]L<KI'FM()1Q(DR[(0X^59G.5%SC>1$PRCB
M1,M.Z,XM>G47JMSMU7[4WY:;F6%NQB*]J3JN=W!(HG+<IQ-&7`[6D-2J_!T=
MK*9DR^WH@:!#%JF@@M[B(WM>&79"KJ9D*^I$32INB891I"5:J[(S6N"L0V;<
M^D_'7:F\T:[G;9W9/_^@H]*@,J%DD9@!Q#2X(94[`QA;:M324$BM2M^('_O5
M2$YQ&:F\`,HU.L<:"RY(-9:$HC56I(K66&.-#:+6(C&EB6N9+E2CV[O]`:TS
M/6^8QFUBB&-Q.S/(VPD=D1,+V<H)%>0=?XHH(\1;E9Q1Q'Q!*C9?(JH(L?F:
M4<1\0RHVWR+J"`5V0CI_Y#;\+YU79MJ*V!89Y$VP>%ZA@CR"$D;.>\O)+;6J
MH1G6^N5.+FX?M,NJ5;$3Q5E.E&$G8(8]QXF::Z21W1!RO8>UIK6J>!ZE"]IR
MQH(_&D,II=&,O_ORS/,*YI1F!GFC](B<>#N>]3%*J"#O^%-$&2$>1CFCB/F"
M5&R^1%018O,UHXCYAE1LOD74$0J,4IG..?N\@HF=F4%BM1,)\@VI>(9-$*6$
M["\(G#BOV$Q2=.G)R1176"`J"9D*3YQ7SJFO)DM<7X.H)60_"1H^KPS4YP\M
MG;R0\ZT[M,[ZEOR928%XQQB#Q'S+Z4%[C+$%>:I+R!9G15.+XE-*Q@4C73\G
M%==8$.(:R[-JK+A@I,::5%QC0XAK;,^JL>."X1J]V,YEFB>>2^CE_J)ID3L]
M,@I[8*9'4O$V($64$>+Y*V<4,5^0BLV7B"I";+YF%#'?D(K-MX@Z0C@]SM74
M`H/JS5<@O141#VT8DJYB@=_8@NJS4[1T)XA20M&YTHJ\/(![&C(;%C+%%1:(
M2D*QN?*L^FJRQ/4UB%I"L;ERJ#Y_/,G<CE[UW+GRO&W('',^%GGCS*@4BO34
MA`KR0IXBR@CQ0,@91<P7I&+S):**$)NO&47,-Z1B\RVBCE!@G+TM[3+'M(M%
M_BHEORQD0P5Y!D\8.2\(IP*K\D\%D&PC6^Z^&D\%I&(G"D81)\JP$S+91K:B
M3M2D8B<:1A$G6G8BE&PC&V[E[C3C#T.E\F;7@65-R_MIE/V;3<5&Y'9N5#K7
M>\R3C.5WRV]8Q3/KL2"A%%49HAQ1@:A$5"&J$36(6D0=HBVB':(]HH.'_(CI
MQ,>)3>9`\$S*Q-U8S@U2Z1QJ\`VB!%&**$.4(RH0E8@J1#6B!E&+J$.T1;1#
MM$=T\)`?%IT(<,,R$`N;-^!5]W8.F8H-H@11BBA#E",J$)6(*D0UH@91BZCS
MD-]^0VF)L\Y.<\Q*$'(^U,:(YR=WAK3;;IN[4"=`GL7@$X76EOK<(8V@#%&.
MJ$!4(JH0U8@:1"VBSJ+`)PKG^I3K=EZY&3NO\<U9V9M?+.+6V?1UJ27$;=9`
MXYN"IS]1:,VXGRADRQ2*G!''$"HKV);]D)](F)0L(,L56R94,XI4UK`M6YG\
M1"$+R'+'EA7RAXU,.0Q,.YA;F!ODIXSD]Q-M2.5=1$`BSZK<.Q-"7D&X,R&5
MNV.`..5G.5&P+6J_DE#4B8I442?JLYQH6$5.M(3L&5'])>Z1_)QL-^2"%_O%
MVU(2O=P_`ELD=NRB]V^H8+1=$E+Q5B*U:"#5Q`4CPR8G5=2)@E3L1'F6$Q47
MC#A1DRKJ1,.J8^S)"?/9C\EJ/)9??=51*;4%/BXW[A#P0Z\\\";L^+!?:+D(
MO4%BV,M/1MB"`[\Y9E7NL"<4'7$9J:+MF9_E1,&VJ-5+0E$G*E)%G:C/<J)A
M%3G1$C+#?CJ9S&\FXOJY&W+!C[UZG;?$7LM%[`T2PU[^QM?"%HRV2T(J'G&I
M14/#WIH_U=]--HS,1YTH2,5.E&<Y47'!\*#KG:A)%76B817'WKRC_8#$;'6C
M/O`E<@4=%3O5#G[LWY:D66"2QB(Q[H53&U(I_X.3D=DA6Y4W[DV-`Q^1X((1
M\_E93A1LBYJ]).1Y+_<<%:FB4:W/<J)A%3G1$C+C7GWT;BJ_T;4;\L`/O<Z-
MN'OT@2E?R\6P-T@,>S$7;1:V8+19$E+QB$LM&AKVUKSZ<;IGY60^ZD1!*G:B
M/,N)B@M&G*A)%76B816'WKRC'?:3R6JTDG_:HZ-BI]K!C[W,^0S$'A,]^J_4
MJ^X@AKU(W&U(Y0T<V.5;E3?LC?FA86]5T0;-SW*B8!4U>TG(WE%,1LO5:BP^
MBEBQ\]'0V^:*-D3#MLB'EI!74$X]':E.-80??)E9.O?S`0O,,5DDI@!YYT4%
M3[EG9W]KGD=?:@L.30''@I$0Y&<Y49"*G2C/<J+B@A$G:E)%6Z)A%?<#\XYV
M"A@M;Q9+L;?NJ-1Y,X!,CPW,`)@'6QCDSP#R;PYL2.7U7YP!K"W.7J94T)YN
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MB`X>\L.BE@9ONAN(A9:+6%C$E^J;):`$48HH0Y0C*A"5B"I$-:(&48NH\Y#?
M?FK&]]K/Z=;G_QK%4EL1S6J1LU:02JTBIT]RB55YW\LQDK_VEK**9K$,48ZH
M0%0BJA#5B!I$+:+.HL`MVE(F9WZM\3%GTQM6\7`;WZH&&M^HU"69$R)Y%$VM
M>?<J#6O,$15<T#4O]CLEJRBV%=JJ$35<T#4O;B=:5I'YSK/ECP]],G>W4P/S
MBSG(NS>:2X.\;?1H)7:Z&U*Y&S`WF6].4*PBUU.+U*_?Z-O!R?Q*6,ZLP-]#
MKT3N-D?+!:+2KVPVNA)IP.JLRFJTW"!J_<I&BRL1R&ZH,C^0^H#^AD":\[P7
M2(.\H_!H)5I@L[0%U1(2F^2.*@ZD0>K3:OTU[U*V;4:6O>,?!A(L%U205[C2
M(JIL>B42.Q65B596DXHM-XA:O[+1\FJR\O[G;U`[LG"J:C^L^MC\AK#:3`*?
M0V^7]N"M]G<<,/EKSQM2#8Q/:XO-I[:@'9^CN6SIS`J&QB=8+K@@]:&2D.>E
M3"95I(IVT=JJG,\Q-UR0:FP)16OL2'6J1C^D;\M<+#%S89$8J:*+;ZC@*:?L
ME&O-<Q=/;4$[>$8CG')MF5,]N+><<_W4F@6B4E0VD?VGHC+1RFI2\6LTA#@3
MUEH43\=U7-`9,4[*QX^FSAF\88":%(,W[QHD%E!YK%U:E=<1':=L-(\J:O/4
M%K0#].9*&,[L\Z'Q"88+]HCJ*OVZH.-49]55H^$&4>O7-5W*%^N&*O/#*!,6
MYZ65EO:S0L[<.IN)WPV^M2+U-3K44!M$":(4488H1U0@*A%5B&I$#:(648=H
MBVB':(_HX"$O2BN9I(CO5GMY?VSC@8QI):ORTDKC&Y%\VK"*@I@@2A%EB')$
M!:(2486H1M0@:A%UB+:(=HCVB`X>\B.F5A]O>G2.@`/!TR7],_?*(#>MA"A!
ME"+*$.6("D0EH@I1C:A!U"+J$&T1[1#M$1T\Y(=%+2->6`9BH>4B%A;Q@KM9
M`4H0I8@R1#FB`E&)J/*0_\[Z[.^NU$Y7/#\5M+)Y!MX"WQ)RYG=&///@<=>J
MO%20^JY0_[R0LHIFG@Q1CJA`5"*J+`JD;U9JR_4?:#!M1?0=B]P&.Z)H@QG5
M0/JF]UM]1Y7SW:H6.0FC'%'!!1TG5C)]PRJ*1^79\CN=/JZZG6Y@H-G3K=N[
M#!+;0Y$%V:RL2@U!/N7!]I!5Y'IJ$>57)E=C[^PJ/@R36?G`;A'K*1"5?M60
MV:F&ZO(;6A\@W]#0YKSI[L-7!HE3E<Q_6-7`-X"RBAO:F*>4Q.A*]*N,RJ@^
MSB&$_`>I>-XM$)46T1%N+"NKJ,RIRORV]4ZL@W>M*SRQ6N1UXK&\"-Z0:J`3
M&_/.P3VU!2D)L;A2'W1Q_^?/J)F5#W5BJ*?@@A36DI#G,Z0D2'7J+.XWMSYK
M';OR<'.;HYG7E0T275DF"%:VX"FGS)&25'R,3BV*'Z,S+NCT9SDEY:1R^_/1
M+VYE@VQ_GDUD2J(B,^?U9^^P-]S`Q]MI\N=V9<]]JNQQK(YO1`)W0RJO;\@6
M2*Q*]48RGQ+R"LI.E9$J&K^<G2#S!:+2(AI!8YF,KH*5.;.3Z<'7+U\?'EZ3
MN]>[#^^^/SQ_>=@\?/OV<G'_],</U4YJJ^'@B^>'S^\O/ZYNUA^5<>7<L8!Y
M<JN>Z)-%Z,E(/>G;2Y3Y.)^N/ZK/DP3*J"?ZETA#3V;J2?_[W\*:^D#(6G_(
M`<M\7*S6'U6"`9^H3RFH,L'W6:KW43>]6.;C9++^J/[N"3Y1?_UKK?]\5>B)
M>A\U'O#)Q^EH_5']SC,^47_99*W_-$?HR5@]Z7<=H@T^*F,A?JM,!2TI0R']
M1_6*ZM.0@:KU&X:X>K_0ZZD+U+6^AD1+R7*RUG=W^$1=S*WUM1L^47=JREKH
M2;)2952/Q3+):KI.U98/GZ@=I"H3>J*20"KXH6Z13&=K_><``M;4$_W=_?A$
M?0O_6G_1/CY)YHNU_E7'T)/E.E6_-X=/U*_[K?5O].$3];MYREKHR6&LXC\.
MO6DR5N^C/N:'U@KUI`P^:=23-OADIY[L@T^2Z52U0<B#3OG6!7W;JB?;X).=
M>K(?ASKT;CQ63T+];3>>J">A'K(;3]63D&^5JJ<*/JG5DSKXI%%/VJ!OC?*M
M#?K6*-_:H&^-\JT-UI.,;Y37P6E(>7`;++-13S;!)XEZD@:?9.I)%GR2JR=Y
M\$FAGI3!-BA4&Y3!-BA4&Y3!-BA4&Y3!>@X+-:V%FB`9J=<Q?TY.S)"%>E(&
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M#_\6````__\#`%!+`P04``8`"````"$`2&@#UV<#``#B"@``&0```'AL+W=O
M<FMS:&5E=',O<VAE970S,"YX;6R45EMOVC`4?I^T_Q#EO23.'42H"E6W29LT
M3;L\F\2`U22.;%/:?[]CFT*<<"DO+;&_\_D[-_M,[U_KRGDA7%#6Y"X:^:Y#
MFH*5M%GG[I_?3W>9ZPB)FQ)7K"&Y^T:$>S_[_&FZ8_Q9;`B1#C`T(G<W4K83
MSQ/%AM18C%A+&MA9,5YC"9]\[8F6$UQJH[KR`M]/O!K3QC4,$_X1#K9:T8(\
MLF);DT8:$DXJ+$&_V-!6O+/5Q4?H:LR?M^U=P>H6*):THO)-D[I.74R^K1O&
M\;("OU]1A(MW;OTQH*]IP9E@*SD".L\('?H\]L8>,,VF)04/5-@=3E:Y^X`F
M"Q2ZWFRJ`_27DIWH_';$ANV^<%I^IPV!:$.>5`:6C#TKZ+=2+8&Q-[!^TAGX
MR9V2K/"VDK_8[BNAZXV$=,?@D7)L4KX]$E%`1(%F%,2*J6`5"("_3DU5:4!$
M\*O^OZ.EW.1NF(SBU`\1P)TE$?*)*DK7*;9"LOJ?`:$]E2$)]B0AJ-_O!Z,@
MBU&<7&?QC"+MX".6>#;E;.=`U<"9HL6J!M$$F)5G"<3GM&?@DK)Y4$;:%-`"
MTO$RB[-TZKU`"(L]9FXPT`$'3&`C%D-$Z!\@'N@[B`37^R+#JR*5D2TR&!_H
MM1]S`\ETF)5CB\Z")0`BTQ5P.3H*#!GN>([2J'>RP43'DSL+ULG1+2<K<.Z"
M$X>8A[V@SPTDU4E#(8JCV%:VZ`+&?A0>E5NZH&X_'A$%MG6AM%\O!I-H84'B
M1TE/5W__:&_I2F[1I<"VKK!W[-Q`(BTK](_UJ0MHT=V-_&,H+4GI+9(4V):$
MTLP.Q=Q@3*A0G&9C9`,6%@`E67;TRE*FWJ=>\U_O*V5D*XRSOD*#Z91W9\%2
M,+857&XL!;[66`;3.;FS8)V,X`+I.G_Y:(VVO1ZTUAZSS\NIWK(0%YH+]6[E
M*]K,1=IM^V%[:4JXV\_VUP!PIL&0NB,[17-%F[E1N]H&+:89<_=<CUG;9YL,
MGO];9)GKMBMKV&::,G?W=^6I/K,1IQK-C!3FQ:T)7Y,%J2KA%&RKQH4`LG%8
M-:/,'$W@68(1HK>^@!%'KWN'#9@P6KPF/S!?TT8X%5D!I3]*X:;D9D8Q'Y*U
M^AU<,@FSA?ZY@5F2P(/GCP"\8DR^?Z@IZ#"=SOX#``#__P,`4$L#!!0`!@`(
M````(0"8K?+Y&`0``(8.```9````>&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM
M;)1778^C-A1]K]3_@'@?P)`0B)*L)GBG76DK556W?2;@)&@`(TPF,_^^]V)"
M;+--,GF8"2?'AW,_N#:K+^]5:;VQ5A2\7MO$\6R+U1G/B_JPMG_\_?(4V9;H
MTCI/2UZSM?W!A/UE\^LOJS-O7\61L<X"A5JL[6/7-4O7%=F15:EP>,-J^&7/
MVRKMX+(]N*)I69KWBZK2]3TO=*NTJ&VIL&P?T>#[?9$QRK-3Q>I.BK2L3#OP
M+XY%(RYJ5?:(7)6VKZ?F*>-5`Q*[HBRZCU[4MJIL^>U0\S;=E1#W.YFEV46[
MOYC(5T76<L'WG0-RKC0ZC3EV8Q>4-JN\@`@P[5;+]FO[F2PI6=CN9M4GZ)^"
MG87RW1)'?OZM+?+O1<T@VU`GK,".\U>D?LL1@L7N9/5+7X$_6RMG^_14=G_Q
M\^^L.!P[*/<<(L+`EOD'92*#C(*,X\]1*>,E&("_5E5@:T!&TO?^_[G(N^/:
M#D)GOO`"`G1KQT3W4J"D;64GT?'J7TDB@Y04\0>1&;@??O<=/YJ3>7A?Q96.
M^@!IVJ6;5<O/%G0-W%,T*?8@68(R1A9"?J2/,=;_"Q5B1)%G5%G;T.ZP7$!]
MWC;S*%ZY;Y#3;.!LIQRB,Y(+`Q.(LE0!7/`[FH94J*9_7H:+-R2CMXOJ5@*@
M/9KU#2-31N#I%#JEA.%(T<P&GS&+Y+4-XJ.W>6S<>BLYLS&@Q`2H`FA6H,"/
MYPW)T*B:%:-B6\E1K)@`50#-"O2]:@7[+H"^NUU*7&1D)YJ/6>][9BLYB[#O
M0L\)PB#6/CH],>AS$GKJQPB8&G2R\#7Q:\]KP89ZL+>#1+(19&PTZ%9RE+R;
M`%4`S<KB,U:0?*\%)$>Q8@)4`30KN#L:H^=^"^`B(SN3%I"<L05@1FI%BHP6
M,.DS@T`-`HEFHX(64*P'=+O,2#8"B8-15_:RY"BY-0&J`)H5`L^2FMS;7GKV
MO4(/),7-!*$JHOO!4?[I8A.Y`6CC<%+M@326FX21^@1[QB.<#/QK'%1%=-<X
MY177=[(H]P3-;7QM%5E2(DG7NR<3A*J([@<'^^-^Y#9P>X(325+]F`A5.;H?
MG.Z*G\>F.)%[@I:G:54EZ5I58F0R&62NC.!FW>G`[R/5H\"AKD1QI\IR"]#<
MQ^8FA(=#>+K5K)H(53FZ'YS=C_N1D_Y.E97MH._#A)@(51'=#PYPQ<^#599C
M7\O3M,J2--0P<K0Y'<?!UR=C)"9PS,?,#BN(,_OZ9&R.^":@4#QG%D6Z[CAE
M99CRV"]/Q15K#RQA92FLC)_P2._#06)$Q]>-9Q^/7P:^Q=<0Q-WQ!W@+:-(#
M^R-M#T4MK)+M0=)S%M`-K7R/D!<=;_JS^(YW</[OOQ[A?8_!*=AS@+SGO+M<
MX`W&-\C-?P```/__`P!02P,$%``&``@````A`%BT0?Z?`P``J`P``!D```!X
M;"]W;W)K<VAE971S+W-H965T,S(N>&ULE%==;YLP%'V?M/^`>"]@R+>25$VZ
M;I,V:9KV\>R`DU@%C&RG:?_][L6$V-"U21[:<#D^]]Q[S,69WSX7N??$I.*B
M7/@DB'R/E:G(>+E;^+]_/=Q,?$]I6F8T%R5;^"],^;?+CQ_F1R$?U9XQ[0%#
MJ1;^7NMJ%H8JW;."JD!4K(0[6R$+JN%2[D)524:S>E&1AW$4C<*"\M(W##-Y
M"8?8;GG*[D5Z*%BI#8ED.=6@7^UYI4YL17H)74'EXZ&Z2451`<6&YUR_U*2^
M5Z2SK[M22+K)H>YG,J#IB;N^Z-$7/)5"B:T.@"XT0OLU3\-I"$S+><:A`FR[
M)]EVX=^1V9J,_7`YKQOTA[.CLKY[:B^.GR7/OO&20;?!)W1@(\0C0K]F&(+%
M86_U0^W`#^EE;$L/N?XICE\8W^TUV#V$BK"P6?9RSU0*'06:(!XB4RIR$`!_
MO8+CUH".T.?Z_Y%G>K_PDU$P'$<)`;BW84H_<*3TO?2@M"C^&A!IJ`Q)W)`D
MH+ZY'P?Q9$B&H_=90J.H+O">:KJ<2W'T8-=`3E51W(-D!LQ8V0CZ8W2TM?ZO
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MRF"L#ED!)S.!X79YBVKT>^XT("NY'7&SXXB[V"!B!J([0;H.-:#6(C*>.`Y-
MW4ZM&WRMUM6&8_!R;69HNMH&;JX5,2"[,U;$S8Z#[_+L9DR^/>&(`=G9K8B;
M_:KQ2LRH=&OO^6+-TWI^K)MEK5/#Q)UE2=L]5]M5`QB/);VGI;,'5@W([HQ9
M]LJNN&J,$C,2W_'%FIM-9ZR(6_M5HQ2.@/W:>[Y8L[/);B*M+R3N.F$.AN;<
M5#"Y8VN6Y\I+Q0$/?3&\R-IH>R"]B_&EWHFO\*"*\;"]`>?$BN[8=RIWO%1>
MSK9`&05C,$2:DZ:YT**J3VL;H>&$6'_=PR\"!D><*`#P5@A]NL`$[6^,Y3\`
M``#__P,`4$L#!!0`!@`(````(0!6:)GD20,``"H+```9````>&PO=V]R:W-H
M965T<R]S:&5E=#,S+GAM;)1676^;,!1]G[3_@/Q>P"0A:Q12M:NZ3=JD:=K'
MLP,F6`6,;*=I__WNQ0F!0!/RD@1R?,X]QY>+EW>O1>Z\<*6%+"-"79\XO(QE
M(LI-1/[\?KKY1!QM6)FP7)8\(F]<D[O5QP_+G53/.N/<.,!0ZHADQE0+S]-Q
MQ@NF75GQ$OY)I2J8@4NU\72E.$OJ147N!;X?>@43);$,"S6&0Z:IB/FCC+<%
M+XTE43QG!NK7F:CT@:V(Q]`53#UOJYM8%A50K$4NS%M-2IPB7GS;E%*Q=0Z^
M7^F4Q0?N^J)'7XA822U3XP*=9POM>[[U;CU@6BT3`0XP=D?Q-"+W=/%`Y\1;
M+>N`_@J^TZW?CL[D[HL2R7=1<D@;]@EW8"WE,T*_)7@+%GN]U4_U#OQ43L)3
MMLW-+[G[RL4F,[#=,W"$QA;)VR/7,20*-&XP0Z98YE``?#J%P-:`1-AK_;T3
MB<DB,@G=V=R?4(`[:Z[-DT!*XL1;;63QSX+HGLJ2!'L2^#Z0!"Z=^N%E#L_6
M4]M[9(:MEDKN'.@94-05PPZD"^`]^+)5-$[?,PH.D>0>62("S0X>-.S.RRKT
M_:7W`HG&>\R#Q<!G@Z$-PH-JFI*@C'9)PQ$?E!&,RA@YEO)@;[1E@F&9R34R
M"(X(<#?%A_ZQ?*ML,=.ZC]I^IETAC'@"#7C>%RX"7$?P:,0*6DQ?$#IJ?(`(
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MOCN'35#VK&,OC*SJ$\-:&CBCU#\S.)-R>._Z+H!3*<WA`D]3S2EW]1\``/__
M`P!02P,$%``&``@````A`.TF,?7^!0``)!H``!D```!X;"]W;W)K<VAE971S
M+W-H965T,S0N>&ULG)G;<N(X$(;OMVK?P>5[\`D,ID*FAO@,6[6UM8=KQQAP
M#<:4[4PF;[\MRQBIVR$D<S$.7_]JI%9++9F';[^*H_(SJ^J\/"U58ZRK2G9*
MRVU^VB_5?_[V1W-5J9ODM$V.Y2E;JF]9K7Y[_/VWA]>R^E$?LJQ1P,.I7JJ'
MICDO-*U.#UF1U./RG)W`LBNK(FG@8[77ZG.5)=NV47'43%VWM2+)3RKWL*CN
M\5'N=GF:N67Z4F2GACNILF/20/_K0WZN+]Z*]!YW15+]>#F/TK(X@XOG_)@W
M;ZU352G21;0_E57R?(1Q_S(F27KQW7X@[HL\K<JZW#5C<*?QCM(Q.YJC@:?'
MAVT.(V!A5ZILMU2_&XN-,56UQX<V0/_FV6LM_*W4A_(UJ/+M)C]E$&V8)S8#
MSV7Y@TFC+4/06".M_78&_JR4;;9+7H[-7^5KF.7[0P/3/841L8$MMF]N5J<0
M47`S-MMNI.41.@#_*T7.4@,BDOQJGZ_YMCDL5<L>3V>Z98!<><[JQL^92U5)
M7^JF+/[C(H-UJG=B=DXLZ'UG-\?F?&I,[4]XF71>X-E[N;L+T-EV'/#L&W]Z
M'';G9"8Z^?0X8&FU78%GWY6[Q^%TC>'9-_[T.`Q((SZK,#-7-_>.1.,YTJ:<
MFS3)XT-5OBJPCB$+ZG/"=@5C88#K2[+QU.C3[[WL@XQA7KXS-ZTS2*P:ELS/
M1UN?/V@_(<W33K/B&@BAH'%DS=-%PU*1.78Q\##P,0@P"#&(,(@OX-HU0^[8
M^J*X=&PC``UBV0<48D@":L'D#:_>2_Q8*Q2_J=R#%968LN*)*FQ#ES4NU4QD
MA4<5MH&BX5.-A;XHH!+;0!T.AS26W)UH2(.Z'%,-^J8U5>`.;ZC$MON^2%,,
M>Z(TQ;>GEJEA"Q;2WK#PW'+-I-V!6=H_8>!BX&'@8Q!@$&(081!CL,9@(P`I
M)K##?R(F3+U4(>+]5N#@W8)+9NU>,C(<W4"")TE@.2:RNY+=,,TIVFL\26`9
M>+_R9;NIHTD+1+MMZR@I0]$\,AUDCB2S90FYUFY\L6R?6P9:&&M)8-IHB6Y$
M\]RRKPM"FC:HK=*TL>W_X]V*M9*GS[31^E]QC9#2&+@8>!CX&`08A!A$&,08
MK#'8<&#S3'L_5'"2^$*H6"L<JNM<M%.]XAHA5!BX&'@8^!@$&(081!C$''2!
ML`92[M*"U?<13;F+F1UNQ9((9Z\O1(ZUPI%#:V#%-4+D,'`Q\##P,0@P"#&(
M,(@YX)$S9]9\XCAH/:Q%B3V?S&QGUE>7-@TVH@)V(\N<O5-_V$5//+/=KC],
MC>.(-J,5UPAQQ,#%P,/`Y\#ART@?&Q-=^H?VIT"4?Z@.1?4([CUH`)%D-\<.
M2I18LAMCU'PMF?4QWLLWW,Z+T75BI22'T_TG)H6IY4DA!9!+NM4X5``EP4`!
ME.Q#!5`2#!1`V4X+H&@?*(#</.$)00N@V'HT4`!E^\!N)/LG!5!L__ZNSNY5
MTKRQ"CB!DG![4;7-Y`DT;;2@5YU(6%:$N(1XA/B$!(2$A$2$Q(2L"=ETY,-J
M:+#[C[@)W7=R:)OAN.%ZV(G$N/';UI6X1.,1XA,2$!(2$A$2=Z0[BPX51EE!
M*Z/H4]HUV)7[*V'DEQ7Q`&W::,];M;XAF:^W"D)<0CQ"?$("0D)"(D+BCMRL
MDI)FN$Q*DIMUTF"7%3%'/UC3_&XC!Q7=*E:M3SFHPI6H>V>!B4=:^80$A(2$
M1(3$/6%GLFMI:CNROF7<O&.4TY/=(L0(WKG*^>5#CB2Z?JT,+A+3$Q.7:#Q"
M?$("0D)"(D+BCMQ.3]Y#KGDG/47)[?1D%X\O!)??5Z3@SM#,K]C[8CA@B,'%
MQ"4:CQ"_(W>?ZB0]'*30J2^4[$,'.5DP<)*3!?0H)]L'SG*=8/@PQU_*\S>D
M15;MLZ?L>*R5M'QA+]Q-.,OTE/\8L#(6\#H1;CR(Q^Q'`L:UW@#OZ,_)/OLC
MJ?;YJ5:.V0Y<ZN,93$S%W_+S#TUY;E\%/I<-O)UO_SS`KS$9O!?2QR#>E65S
M^<"^H/]]Y_%_````__\#`%!+`P04``8`"````"$`]>K(-1\U``!`/P$`&0``
M`'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6RLG5ES'$>R9M_';/X#C>^71%5A
ME4FZUJA]7^S.S#.;@EJT%@49R=[^_7Q1&1Z+GT16%:1Y&/4]\/",RA,1&>%9
M`+__[W]__O7-/Y^^?/WT_-L/;WOOKMZ^>?KMX_-/GW[[VP]O_\__3/[K_NV;
MK]\^_/;3AU^??WOZX>U_GKZ^_>\?__?_^OY?SU_^_O67IZ=O;Y3AMZ\_O/WE
MV[??OWO__NO'7YX^?_CZ[OGWI]_TDY^?OWS^\$W_YY>_O?_Z^Y>G#S\=&WW^
M]7W_ZNKV_></GWY[VV3X[LLY.9Y__OG3QZ?1\\=_?'[Z[5N3Y,O3KQ^^J?]?
M?_GT^U?+]OGC.>D^?_CR]W_\_E\?GS__KA1__?3KIV__.29]^^;SQ^_F?_OM
M^<N'O_ZJS_WOWO6'CY;[^'\@_>=/'[\\?WW^^=L[I7O?=)2?^>']PWME^O'[
MGS[I$X3;_N;+T\\_O/U+[[M#[Z[_]OV/WQ_OT/_]]/2OK\7_?O/UE^=_3;]\
M^FGUZ;<GW6Z)"@K^^OS\]Q`Z_RD@-7Z/UI.C@MV7-S\]_?SA'[]^.SS_:_;T
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ML0<3#Z8>S#R8>[#P8.G!RH.U!QL/MA[L/-A[<"C`>^E)CC3@_PQ'(4UP9'?W
MT4"6YI0-+<*:C#P8>S#Q8.K!S(.Y!PL/EAZL/%A[L/%@Z\'.@[T'AP)40K2>
M5$+:GT@V-T*TGCW%W.@-;NJ1_]C$7&<Y0Y`1R!AD`C(%F8',018@2Y`5R!ID
M`[(%V8'L00XEJ51H?:Y4O'+]"FFT!$IX6L#TV'22FJ`;/;E>#AJFH#1G0,8@
M$Y`IR`QD#K(`68*L0-8@&Y`MR`YD#W(H2>5-CTEX&]R'C5S<IYS]Z`F9CNKL
MAC\VY$;+:>')/VM2D#4;@8Q!)B!3D!G('&0!L@19@:Q!-B!;D!W('N10DLJ3
M=C&5I^ZE+D1C&KF'RF,3Y*:1"QJFH*0'9`PR`9F"S$#F(`N0)<@*9`VR`=F"
M[$#V((>25'JT9:STA.7O==,H9*JG44/<-!K4:^(P!25/(&.0"<@49`8R!UF`
M+$%6(&N0#<@69`>R!SF4I/*DG3$\]6_>:=I=N-$.B6I-#7&:KIVF%)0T@8Q!
M)B!3D!G('&0!L@19@:Q!-B!;D!W('N10DDJ3SK.5IN[5+D1CM?,[NR;(K78N
M:)B"DAZ0,<@$9`HR`YF#+$"6("N0-<@&9`NR`]F#'$I2Z0E%@\I/6.Y>-8V.
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MT9[H4*':6#@=7V"L.4Q7$RJ=KTN)OB017FXUTR[K`1HS:D(T)9H1S8D61$NB
M%=&::$.T)=H1[8D.%:KUA-/Q!7J:P[2;4*[^\!A>WW!"N:AACLK&4D-#8T9-
MB*9$,Z(YT8)H2;0B6A-MB+9$.Z(]T:%"M;%P3BZ-O;YL$5Z:R5,UV=(IO)QL
MOG`1&VIW8IY&1&.B"=&4:$8T)UH0+8E61&NB#=&6:$>T)])[_6;T'V].K2Z<
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MAV!_\-*B-;C1MY.:[RR%=\UNZQC1S2`]SH9$(Z(QT81H2C0CFA,MB)9$*Z(U
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MB*89=:2?693VT\6`<$7*>8ZR`;$PE/NUS*C,Y3[0RJ+J*^:3V'%GM<Y1=L6-
MH7S%;48=5]Q95'U%MPW8YRB[XB&B1EH](,+1M*R;=#_Q!B'<#8@&50,":!0;
M%E%CH@G1E&@6T;6N4JAV1<UYCK+;L&"N)=$J-RS3YQ-1]-I\1G7"TF^8:TNT
M:TU_YP;7/D=9^D.5JY:H`7&)Q!#N)#:HT#,<`(V(QD03HBG1+"(GT1U8YSG*
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M^E6.LO1KH@W1-J..]+L<9>GW1(<*U:HO*P`-6`"**!1^D\2!&_!#:U?OB[`^
MQ.Q5U)U;G,=VP5`B_.>/O4'OYMJ%3.QR6JA2GWI^8$TMJKJ<CYJU1OE.S4]W
M:F&).CNUM*C.3JTLJLKE.[6V3NFVYMMPYXX!F]9<_C9L+:JS7SN+ZNS7_JQ^
M'5IS%?VJQ[&OE)U8LE@>&S0H5'V*F^7VUD.+.K%DQ5QYJS.VA@_'4=N_O;IV
M'B8Q(NRE<P>*SWO<FDPM3V<'9CG*EH6YH1<[L#BK`TO+T]F!5<YE'5@;JAIR
M-#:WKOLN;,_JQ,ZNF`]">T.=G3A8U$LJZJ$7"G=_?'<<RW]YR#R&?5)XB%8K
MJQLUPQ@4OB'\\J@9Y2C3,8Y(NX"PC`ZNW&(\L2;55.9PC-WNO/S,<F41\Q.7
M7UB3SLLO+:KS\BN+RI7O=42A])YO&P=C_'2=G=A:^LY.["PJ=V)_5B<.N6'1
MU4)$/1A].?3$.LBZITY>8=1IRV!#99A1>P^.*]/(HHHWN$030SG]-*..]#.+
MRNGG1`M#.?TRHX[T*XO*Z==$&T,Y_3:CCO0[B\KI]T0'0\?TE5?5)O^$1>:8
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M#=+>P6[I\)A4>SAMY;(+&FL::LVWAN/8L$`3HFE&'>EG%J4)GCMQ[XX9\QQE
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M:R&+>\Y&E#LVU%^".T;I/\6ZYQYQHQA5[8SPVC,'V;V?Y.R&IAEU7'`6H\*F
M(W<+KSUSE*5?Y/2&EAD5N?CD;6Z$NZ)["[3F%3<YO5UQFU''%7<Y5Q&%UYXY
MRM(?<GJA>N1<5CN[9NTL(E=,<4OHT*+J30-&39->O[5A71_GAH8F1-.,BCOC
MC<URE.6:$RV(EAEUI%_E*$N_)MH0;3/J2+_+499^3W2H4*4Z_`9^M4AT/Y^/
MX?5J$%%=G'<#?FCMZGV1-]T:Y0LX8[M@\]KSX>IZX,;5Q/)H6Y^GO1<_M:C.
M/LU:HWR?YB?[M+`\G7U:6E1GGU865>7R?5I;G[HK^ZVY_+W:6E1GOW86U=FO
M_5G].K3F*OI5CV+UZY)1',+=*&[0B9>>X9=5U3#\`MG+`VN4HVQ.C@WE=XYN
MTSZ)$2>*OY:GLP.S'&4=F!MZL0.+LSJPM#R='5CE7-:!M:&J(=XS693N\\LW
M>'M6)W8YEW5B;ZBS$P>+>JD3]=!3KFKHO6IOK-_=Q(AL4+VN^I>>UNZEKC;%
MX!QE=V(<47SI>7WE=L`3:U)-Y6+Z->_@+:KS\K,<99>?G[C\PIIT7GYI49V7
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M+GFPJ)<Z4:\UOCSKQ^1Y+SUO6+:-J%J#8ME6_\FR_>-H9`WS>[TQT<10GL73
MC#K2SRPJIY\3+0SE],N,.M*O+"JG7Q-M#.7TVXPZTN\L*J??$QT,M:Q!EU5R
M;UC)C2ALK[+$>W=X&^:HO-@TN=30T)A1$Z(IT8QH3K0@6A*MB-9$&Z(MT8YH
M3W2H4#T=?8WVQ*,_%6-+%VX7^'C31(6S6&',10USE.D9$8V))D13HAG1G&A!
MM"1:$:V)-D1;HAW1GNA0H=I8*!5>L%F+)=;\`'J\:9";4.X).\Q164]J:&C,
MJ`G1E&A&-"=:$"V)5D1KH@W1EFA'M"<Z5*C6<UD1](9%T(B<'G?P'^8H<S$B
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M=JR_3<=ZR_T845WB??!5%XNJ"H2<&TWZ\JL8L:&^/';\[;G;=R[S)`;4!=X'
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M,I2/[NN(3KR7SPV+A:A8XFJ;NKT7'&OO0KBSV2`W0?VQ-C8\\=6@')5M-NGC
M!+UZYQ)/8I,3\Y.)9T3SB&PQ\`-G<=:UEDR\(EK7U[J^]Q]L<^IBM49-\$LT
MAG"GL4%5=:+O?]E_>)>B3-"(:$PT(9H2S8CF1`NB)=&*:$VT(=H2[8CV1(<*
MU7I>79VX8W4BHK(Z030B&A--B*9$,Z(YT8)H2;0B6A-MB+9$.Z(]T:%"M18M
MRI?,FA#N9DU$>=T>W@&-B,9$$Z(IT8QH3K2H4/V9_Y2*0OC#TOY61)3/DT.+
MTIXW;XF+)U%\A#<-JXI"_\K]-MXXYBI_(91H2C0CFA,M(FJI`MR%HW-9^'U5
M%>"8Q8T=G,F'%G7BAIU5!8BYRBI`3F^K]Y1HEAL6UE`%R%&6:U'EJ@?=9<?T
M.Q[3(W*[#+>S&UJ4GE)=`X[']-C0CNGZ]P:J(Y`[;DQB^*E-!ZXSRQVTNS:O
M+XT"P>+4M>H;'8Z7Y6`]L3F/I]'BI?E=@]SFW!^C8]2)OR:4H^S3CB.R8W3O
MG:LN3:R-5M&L$/40B\KK[HQH7E^LU_<76UB;ERY6W]MPQKO@WC9'PO+W^>[B
M*;'\ODC_RMV!H46=&,0X<8YC0]N^WKV[KP8Q=LY-AE.#&->9Q>NHH6F=&ZKZ
MC).M16E+G]T6SX/J=M]?=LX\AM<+;$1N*/MSIC5\J5/-0\JB\FEL'%'W:6R2
M&[9_YN:P:5'YELZ(YA'%R7,SP`'%VIPUGN_#R>K\\7P,=S>X.9M5BW+_RM4!
MA['AB:-?C"H&U=A0YZ":6%2GOVGNA(W9&=$\(IM!?5_37+1>K%B=ZA&LCE]R
M@T/X\0;GD=*_<H^XQ_LFJOK.&:*&.<H^[HAH3#0AFA+-B.9$"Z(ET8IH3;0A
MVA+MB/9$APK5QOPYK?OQ><_#643N&.VJP,,<E?4TN8KW_F-&38BF1#.B.=&"
M:$FT(EH3;8BV1#NB/=&A0K6><+0J5ZQB*W["5&CI%J\&E<?H>Z`1T9AH0C0E
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MT91H1C0G6A`MB59$:Z(-T99H1[0G.E2H5N>/A4'=JW[U[($GQHB<N7Q4BI.N
M:5AM&8'&.9?YG1!-B69$<Z(%T9)H1;0FVA!MB79$>Z)#A6ISEYV*'W@JCLCI
MP=&R:5CI`1KG7%D/HJ:,FA'-B19$2Z(5T9IH0[0EVA'MB0X5JO3TKBX[^C?Q
M]9'+F'MJY0-[,X&*,+OYHQ8V;F&3%C9M8;,6-F]ABQ:V;&&K%K9N89L6MFUA
MNQ:V;V&'FCECON+QZK6P=Y6J(6;DT9B;;JY",BS"K*ED-NF*.2B98)())IE@
MD@DFF6"2"2:98)())IE@D@DFF6"2"2:98))9,B?SSRN&]*Y8#3'F;/IR2!%6
MV$R5%&.R"2:;8+())IM@L@DFFV"R"2:;8+())IM@L@DFFV"R"2:;)7,V+ZN/
M]*Y2@<1NL>9?K&IHS!1'`%\.*<*LJ>9?:FI,QL!D#$S&P&0,3,;`9`Q,QL!D
M#$S&P&0,3,;`9`Q,QL!DK&3.6%M]Y.[VG0Y@%QX)>E>LCQAST\\72(HP$R>9
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MU\+V+>Q0,R<S%`?\S'SE-B=\)\A]'Z(7F;.)>DX.*VR6=8MC$4\VP6033#;!
M9!-,-L%D$TPVP6033#;!9!-,-L%D$VS?PF2SC',V0W'`VWS5BXJ>%EC*3+6'
M<IU%.2<VE?-"9FIJ3#+!)!-,,L$D$TPRP2033#+!)!-,,L$D$TPRP2033#+!
M)+-D3F:H&Y0R3^Q9>TV=01GM%C_V(JMKXP.4<W*8-=5B&LL6Q3O=%B9CB),Q
M,!D#DS$P&0.3,3`9`Y,Q,!D#DS$P&0.3,3`9*YDS%HH#I;$_\&1LZ@RUS%1[
M**<?RCF]%%;(!-/T`Y-,,,D$DTPPR0233##)!)-,,,D$DTPPR0233##)!)/,
MDCF9H3;P)\ELR@RUS%1Z*&6BFM-+885,,,D$DTPPR0233##)!)-,,,D$DTPP
MR0233##)!)-,,,D$D\R2.9FA-.!EWC^\YEN?O5Y39JAMIM)#8?,:U9S8M'XR
MIJ9F6#;!9!-,-L%D$TPVP6033#;!9!-,-L%D$TPVP6033#;!9+-DSF8H&Y0V
M3ST9FS)#;2R5'DICJ.;T4IC9T9,13,;`9`Q,QL!D#$S&P&0,3,;`9`Q,QL!D
M#$S&P&0,3,;`9*QDSEBH#93&_D`U57_1@#O35'LH;:*<$YO6\R\U-<.R"2:;
M8+())IM@L@DFFV"R"2:;8+())IM@L@DFFV"R"2:;)7,V0W'`VWSE,:.I,]13
M,]4>2IDHY_12F(G3U`233##)!)-,,,D$DTPPR0233##)!)-,,,D$DTPPR023
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M&C14"F.HWH1_,5)UUVI70R9CB),Q,!D#DS$P&0.3,3`9`Y,Q,!D#DS$P&0.3
M,3`9`Y.QDCECH19PB;&F=N"FG2O':-K%$D,][5R8IET**Z8=F"2"22*8)())
M(I@D@DDBF"2"22*8)())(I@D@DDBF"2"26+)G,10`[A$8E,SJ*==JB.4TPZE
MF7X**XR!R1B8C(')&)B,@<D8F(R!R1B8C(')&)B,@<D8F(R!R1B8C)7,&0OG
M_$N,-76!VEBJ%13&;E!^"7_8"`LEF(R!R1B8C(')&)B,@<D8F(R!R1B8C(')
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M#C5S-L,YWT_-WLWQUWY/++7A[UCZAV-DY=_XZI&-6IA,Q9)#_HN/,@4F4V`R
M!2938#(%)E-@,@4F4V`R!2938#(%)E-@,E4R9RH<YDM3I_0TA_]JI1S$@H"N
MDD_L-RB4Y;!B;J6FQF0,3,;`9`Q,QL!D#$S&P&0,3,;`9`Q,QL!D#$S&P&0,
M3,9*YHR%PWQI+*R49\ZMI@Y0RXNU@3P_M`J":6Z!R1283(')%)A,@<D4F$R!
MR1283(')%)A,@<D4F$R!R1283)7,F0HG]M+4J;G5G/!K/9'EKY5)#YCT@$D/
MF/2`20^8](!)#YCT@$D/F/2`20^8])3,W<YPG"YO9S'PS_]WW'J#YE1>W^7(
MBC]ZG^*T`4VK&O]<G875?_;^QA68Y:*Y0OEW[UN87"!.+L#D`DPNP.0"3"[`
MY`),+AJF=Z):G)V+<%#^$UPTY^W:1625B\2Z731A^EOYX5]ITS\^X/9WTI`B
M['FC*9&2&Y.&Q#HN*#,I7;R@.Q[(4XJPY/*4DAN3I\0Z+BAU*5V\H#N#2F2*
ML.02F9*+.9'AD%R*/+5&-8?JVEC#PAO,-%,>4.L=Q"@]V5)4VWQJ"[MSFPF)
M;,+T)YYSMOZ->TL@MTU8V`"EB_9O7-^DN^VB_@^"2G=;F.^;G+?VS952-0S.
MZ9M&1MM%?=\T,MK"?-\T/&+8PW&*W`]NW0#28&GI5NG)C9]P/B_'S_$0?GO\
MCMDEBW)SS*^'5</J/\WI/[B>AK%IJ;CL[[$BI@=D#,O['`VBAH6J7QH=/?_G
M[C6(4M,BS'=$@^B<CF@0I6PV035BSNF(1DQJVM$1C9AS.J(1D\*L(QH>#0M/
MX71'^K>N#*DQTM*1<EJY,1*._>48.;7&-&6">C`T3(\DZZS,)Y8[VV8^AMVF
MIC(/)LTIG5U"3A/KN(2<(IV<@DE@2F>7D*W$.BXA6T@G6V!2D]+I$K6'Z[8:
M2__BN7I,X\HKD56/@+Y?6X8]"\O?UA\5K/C\?N$:6]BI!3]>X=2"SX[,[`KA
M]78:^SW?D;F%N8Y@=3^K(TO+IHO:B%@9JSX#.K).875_W<YSD\)>6A_=&%%8
M-5?])OM_GG^7^U-_);9W'?+X0=*P:@['N+#5S#?=KZT:)+'I7;I-&A%@D\3R
M,C$M6,<EI!_IY!ILD5B^A"S&N,Y/(;%()XM@4I;2<0Z'PD"YEAZ?MS?ACV><
M6%6O0TMOI&'N$>LVL9JVL6D^A,H(F(PT3.\]C[O3N\']]8/_-\7E*+8LGS%8
MMJ4-%Y`C,#FJ+GI[?WUW^^#V@9)VSC7E$?DE#4S2JFOJEX`'?;]MD,43UW03
M+]012K&G=#9UA^HA&?Y!<2EVJ[`[!$EG#,MKCG0F5DP2O_C)<!-6+WZW;G<N
MQ4U8M8*5^X/CGDR*TT5M\9/BQ#HZ(NNM'7&+G[R?TQ%Y3Q>UCLA[8AT=T5!(
M'0ECWKU]UR!HZ4`YV-T@"-6/2P9!K)9DDX^]ZX95<YJGL1BE7ZNT3ZPQ$+-I
M]<EK<<L8:,+J/2*/7I9-T2E;VQA(%[6.:`PDEIOB`:@QT-H1/HEC-OWGY8YH
M#*2+6D<T!A++3=$1C8$F+*Y[;8<J2U3VH6,8A,)+.0S"(A\V=A><J*Y##K_<
M-\RM#VZQU/H0P_*HTMAHF&:TW1TM!I%IG4LWMN7X9&'5L/*/>"T&N*H&`JXJ
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M.=RB]+C)-J<AWCMM6+4?"M_Z4MRI(I.%E?LA,@E,Z<S"M&`=MU<"8]-\"0D$
MDRU<0FH2Z[B$;"&=;(%)34J'M?0F5"Y*#Z_;#QW3>#VQ<E*^*^S?NDV"IEP,
M*Q=6LG&*ZUY88\M3"RLO(&'HB(1%UESTA87UK&M**O++()@,5M=\86$]=4TW
MVT)IPELN%]8S=S0W38FC>GY&5L_"6`K12>KE%6C4LZ9Y]R+-L6EFFH4I73$+
M$^NXA*0BG:2":1:F='8)"4NLXQ)RB'1R"*99F-)Q%FJIKOR<6@U#O)]N#:N?
M<'>N2J7I%IOF55\>$BL^*(\?,:P^?K`B:-F4-,EO.7Y86.Z(;)W3$0ELPEQ'
M4!&T;)T=D>9T45,OIXGES]!R_,@=::T(6I:R`^6#V$W24'<H)^FI0=#4*>K)
MV+"PX.=[?^=J%QH$*<P^L@8!F"8CF"8CF!Z)8'())G%@FGE@4@(F)6":9F":
M9F#;%K9K8?L6=JB9,Q;J#*6Q\/`\[_N9-TV)HI;7,(T:LR)38#(%)E-@,@4F
M4V`R!2938#(%)E-@,@4F4V`R!2938#(%)E-@,E4R9RH4`$I3I^96+!CD3<EC
M[R:RO&!)#YCT@$D/F/2`20^8](!)#YCT@$D/F/2`20^8])3,W<YP."]O9S'P
M+RA<WS1G_'H21%9^)]#B]*.TJI7K:"R0Q+#PC944UN?W,W.833.Y:*ZJIL;D
M`DPNP.0"3"[`Y`),+L#D`DPN&M;V_<R;<,3^$UPT)_7:163YKFC$)Y9O<IN+
M)DSOQ.*W%]VK24V)%&&W7!I2<F/2D%C'!64FI8L7=!4<>4H1EER>4G)C\I18
MQP6E+J6+%W1?KY/(%&'))3(E%ZLGU:VO?IQ8HX[Q;A,865W,NG,]&\J7QHS>
M'NNDD69*B\085KT),E8U]6_$)W:%4^>PLSHR*[+9G9PGUMF110HK=T2"W[__
MI^[_QU@S6EI8]QU9%6'6D75B\6"JQY#^[&*=?V-!+]X/-Q3"@;V<TZ>&0G/`
MKR;O;</<><#-"@V%V%3_Z1P*,2SO3<;6M+LPI*&0FG9<89K".CNBH9"RF0$-
MA89U=T1#(37MZ(B&0@S3?UZ^(QH**<PZHJ'0L/AV>/#0[]]Q),1VYQT*;D,Q
MX)*1$.+]HM`PMRBXCFDDQ##]Y^7//;*P>E%HFH9?9<I-6Q:%&-9Y9S42FK#N
MN:B1D+*9`(V$R/2?ESNBD9":%F$MBT(3UMT1C8049AW12(BL612N!X/;*_]G
MB;4HG.B&6Q1"_>"2H=#4&^I%H6%N47!?ZM%0B$T[16DHQ+!J46A8]US4HI":
M=AC04#BG(QH**9L9T%`XIR,:"JEI1T>T*)S3$0V%%&8=T5"('6F^*G?S<*4O
MRKE:A8;"B6ZXH1#*$Y<,A5C.*(\SMPUSJX+KF(9"#--0S3/*3Q4-A2:L7A4B
MJYJVK`JI:<<5-!3.Z8B&0LIF!C04SNF(AD)JVM$1#85S.J*AD,*L(QH*D36K
M@KZ]>.U?06DDG.B%&PFAVG')2&BJ(_6BT#"W*."[0K>QZ:E%(895BT+#3BX*
MJ6F'`(V$<SJBD9"RF0"-A',ZHI&0FG9T1"/AG(YH)*0PZXA&0NQ(LR@,!@^]
MAP=7IM-0.-$--Q1"^>.2H="42^JAT#"W*.`UZ6T,JV9VRZ+0A-6+0F15TY9%
M(37M,*"A<$Y'-!12F!G04(BLF8OZQ?G[AP?_;\%K))S3#XV$=(&.[FHDI&S6
M#XV$R#IOB,9":MI^!3<60NVF'`O'UWKG?'?\-E9]JD=%P]P"@3=YUO34`A&O
M4"T0#3NY0*2F[3<A?FWBK(YH5*1L9D.CXIR.:%BDIAT=T;"(89UW1,,BA5E'
M-"QB1YH%HG=_=7?O=NP:$R=ZX<9$J"&58^+4H3+6G*J1T+!Z?;AWIVEM&F)8
M-:9;UH<49I];A\K(XFGZZN'ZX<I]<.T>FZ`73],V#E+^#DL:!RG,NJ%Q4'=C
MH%^V\N_2-`K.Z89&0<K?T0V-@A1FW=`HJ+HQZ%^K%ZZ:HV%PHAMN&(0*U"7#
M(%:L2I?]>_>L>NS=-F'AJRQIGX@PC8P49A]2>T<P#0,P60?3`P!,/L'D$TSZ
MP.0*3&+`)`9,'L"V+6S7PO8M[%"S6N*=KQ6&]?V5_ZS5,9<K&416OT>\=R-O
MV,MAV2;9N"5NTL*F+6S6PN8M;-'"EBULU<+6+6S3PK8M;-?"]BWL4#-G4\^'
M:DK^$9LAE[?9,&<3I<"[%%;8!)--,-D$DTTPV02333#9!)--,-D$DTTPV023
M33#9!)--,-DLF;.IE;*R>>(Y>Q?BO;&&.6/N.:CYE\(*8V`R!B9C8#(&)F-@
M,@8F8V`R!B9C8#(&)F-@,@8F8V`R!B9C)6N,O?_ZR]/3M]&';Q]^_/[STY>_
M/0V??OWUZYN/S__X3<MI[RZ\O$K\S9>GGW]X^ZB_U_3=\8\VZ8[S9X/PLT%X
MB8B?W=SH9_IR0NO/;L//CM\4=.W^HJ?`=W\)G6]KIY\='Q-M/[N[TL^T&+?^
MK!=^=GR1[:[WJ$N%G[5=[R_ZP\3JB_[89EM._4Q_]N^XJ4?.?OCLJHJWM@N?
M71O_UI_=A9^U74_=N%=?M/5I;7<?VKWPLW#/].<)V]H-PCW3'P%L_5FX9\U1
M%I^O%W+JWZ!@._7S*MRS]GNMGZDO[=?KA^NUME.Z?LC9/L[T,[5K\_>H)N%G
M[>UZX6?ZQ]_X&1[U/BO\K-UM+[C5/TW5VBZXU3]TU/JSX%;_I$[KSX*__T_7
MN>:V"811="M1-U`<OQA410*3!&RPL7>0JDX:]>$JB=3M]WQVVS^<_'2.A[G<
M.\P$9CQ<)KM'7F=1CA<K6[DLRO&>7F61$:]]-3:)''B[JK+(X?+CR9&627A]
M>8`R8EF4RSSW+,IEGE$6.62>0Q8Y9)Y#%CGPPG<[ARQRX/7A8U:F:5$F/2+D
MD%1'0H:6*=.<AJD70@4Z))674)=,7)7(.FG4B:23!IW(.7G,6<2<6<QESA65
MC%200ZY1Y1B4JT$Y!N5F:IDFU*-'@QR2-I>$`BU3SI=%F6L9R($%/./`JSG.
ML9S$",ZQ/D'(`N.8JC>":F8]C:":"2XC^,9\AY`8>W3HJ9:483P>EV$,*$H=
M.KDG)6YM5Y/H0]2=2?0@ZD[TU=Y51X_K'6Z,B3XDQHCH`^(UJGTXO$;U.X,A
MK>J]KIOST7S.?9?F<QX)W.L8__4:/H\0UN)9-X<"*U,2G#J-`9H:IZ^9$9D=
MIXQ_G+311@\A3:DZ#P-6HL1?MXISLR-%B["_TXK56'PUBRK:CYJ*I_9]]KZ:
M%VP6]`Y;%.=M\<8746QO5YQWL!NSV(DNCFF1L-@QAVEW`DO4IQU*+->B/F6Q
MLBJ.:0G5"TZ!)^%CE0VD5=)!>B7U<EZT2_5J23U+K0?2*CG,(BQKH/4L+V[Y
M/:.HAK1*.DBO9(#LE=0+PF?.:%Q/->>:TDYRB^JMJMY!=DH&R)YM#L;U#+,Y
MQ!0,LP7$'!UF2XCYMJ:>M9(-9*.D@_2JK4-;K]HZM/6JK4-;K_74LRFJ[5JN
M4%!IF15DI:2&W"JY@]PIN8?<*VD@K7K0X$&K'C1XT*H'#1ZT6L\A;I?T;K>>
M<C[\/&/<0AI(JZ2#]$H&R%[):D9'R^8[XWJV:-NJMAUDIV2`[/7N;YA.(-;3
M#SP.V+/N::Q@F-)"M)XU]:R5;"`;)1VD5VT=VGK5UJ&M5VT=VGJMI[Y.Q=[O
MCE%0:9D59*6DAMPJN8/<*;F'W"MI(*UZT.!!JQXT>-"J!PT>M)=Z/OZ_>7N]
M^?3KX>G8/[P\/?]\O?I^?.1!4';>S/[E^2D>RUX^O/W=&NWSZ>WM](-G11^N
MOAX?OAQ?X@O,VC^>3F__/M`T/OX^O7P[/VRZ^0,``/__`P!02P,$%``&``@`
M```A`,1$Z5S+`P``9PT``!D```!X;"]W;W)K<VAE971S+W-H965T,CDN>&UL
ME)?;CN(X$(;O5]IWB'(_.0`A@`BC)JW>'6E'6JUV9ZY#8L#J)(YLTW2__5;9
M)&.;8_<%3>P_Y:\.J13+K^]-[;T1+BAK,S\.(M\C;<DJVNXR_[]_7[[,?$_(
MHJV*FK4D\S^(\+^N?O]M>63\5>P)D1Y8:$7F[Z7L%F$HRCUI"A&PCK2PLV6\
M*21<\ETH.DZ*2MW4U.$HBJ9A4]#6UQ86_!$;;+NE)7EFY:$AK=1&.*D+"?QB
M3SO16VO*1\PU!7\]=%]*UG1@8D-K*C^44=]KRL6W7<MXL:G![_=X4I2];75Q
M9KZA)6>";64`YD(->N[S/)R'8&FUK"AX@&'W.-EF_E.\R..9'ZZ6*D`_*#D*
MX[LG]NSX!Z?57[0E$&W($V9@P]@K2K]5N`0WAV=WOZ@,_,V]BFR+0RW_8<<_
M"=WM):0[`8_0L47U\4Q$"1$%,\$H04LEJP$`/KV&8FE`1(IW]?](*[G/_/$T
M2-)H'(/<VQ`A7RB:]+WR("1K?FI1?#*EC8Q.1L9`?]H?!:-9$B?3^U9"3:0<
M?"YDL5IR=O2@:N!,T158@_$"+/>>:8[!UVNN@H]HY`FM9#Z4.W@A(#]OJR0=
M+<,WB&EYTJS/-;&MR'L%I@+P!D;PW&2\'/4>!<6(@EE`MK5>`-L#FT.6GRO&
MT8!FD4"$'B=!L46B%TR2)!T/!RG:_))F,F@LF,EG8%!LP>@%&^;701JFU[@)
M@:)]/`PHAH(WXI^DR>"1SI'63(:DY<:"Y?/T,R>C./,ANT/FDW3JG*PUB:K9
M23R?.V2YWE=D%DCZ&1`4NR"I`Z(U$P7B/AC]GIL'?+\X#^\8FMOM!P1O<F%F
M#HS60/J-R,UM37Y;8P5K;G/>YD.QPS?[]3CJ>M&:5`7+V<LO[UD\,03)#-QM
M(*5VB9P4K4\BC32.\,^)EZ681(FIL.FP#QIIO4.':I?.Z7#K6(MT=9V!7=ZT
MF;!'/LZD.ZKUY,V<3K>.M>@*T^5-FPE[I<&$[Z[[Y1_K#FNS.8UO?1(9#<E<
ML2FP21H4=[*E6^KM;AAKD7FZL6*?[K3B!V.@VZL=`Z?SK7'`@<)*I_HI"YR*
MST_[YZTQ=IKT@TP7NO7,[=;*=.:;D;G6H.-/=6BEOO>6.HG,TZ]U9IA&K:IX
M,`87>O/L+"]:=#TO?6,>WA9ZKM5C7T/XCN2DKH57L@/.K"/([[`ZS--/RDMG
M?8US-KZDPV$#QMRNV)'O!=_15G@UV8+)*$BA>+@>E/6%9)T:-C=,PH"KON[A
M!PV!"2T*0+QE3/87>,#P$VGU/P```/__`P!02P,$%``&``@````A`-_!L)F'
M"```L"@``!D```!X;"]W;W)K<VAE971S+W-H965T,C<N>&ULK%K;DJ)($'W?
MB/T'P_=5`='6Z.Z-]GX7B;T\,TJWQ*@80D_/_/UF`5E0F34T[NX\#'KZU*E3
ME5E9)?#X^_?SJ?;-OT5!>'FJ&XU6O>9?]N$AN+P]U?_\8_+;0[T6Q=[EX)W"
MB_]4_^%']=^??_WE\2.\?8V.OA_70.$2/=6/<7SM-YO1_NB?O:@17OT+_.4U
MO)V]&+[>WIK1]>9[AZ31^=0T6ZU.\^P%EWJJT+]5T0A?7X.]/PKW[V?_$J<B
M-__DQ>`_.@;7"-7.^RIR9^_V]?WZVSX\7T'B2W`*XA^):+UVWO?G;Y?PYGTY
MP;B_&VUOC]K)%R9_#O:W,`I?XP;(-5.C?,R]9J\)2L^/AP!&(*:]=O-?G^HO
M1M\U['KS^3&9H+\"_R,J?*Y%Q_!C>@L.J^#BPVQ#G$0$OH3A5T&='P0$C9NL
M]22)@'.K'?Q7[_T4N^''S`_>CC&$VX81B8'U#S]&?K2'&069AIG8V(<G,`#_
MU\Z!2`V8$>][<OT(#O'QJ6YU&G:W91E`KWWQHW@2",EZ;?\>Q>'Y[Y1D"%-2
MQ,Q$X(HB5L-HMSIW:%B9!EPS#:/Q8-OMSD.WNI%V)@+73,1LF`^V82=.2D8`
M7233`->L85<.H*19)VL&5^RO\J1UL[9P_?<#AF6<^(8K&J@VX%[6$*YRP%VC
MU;/$;)>,V(`,31-&I&J:#!#VBHEBR'2##_]^U`8FG/B`)JJ-V\`\$Q_DR-NF
MW7U(,KYLZ)A=1B&]J@\=4TRLSO\P=$PYHY!S55+5P'P3'^3`Y4HO&S<FF5'(
MLL_&W4SK3%*V1E[L/3_>PH\:[`40^.CJB9W%Z`M!+%BI`5G"?E;!H.H(E1<A
M\U2']E"<(BB[WY[M3O>Q^0U*Y3[C##C'4!E#9(AB)F1'%!A38$*!*05F%)A3
M8$&!)056%%A38$.!+04<"NPHX!:`)H1'Q@A6U?\1(R$C8H2S.T`@#YI)`H(,
M;#*BP)@"$PI,*3"CP)P""PHL*;"BP)H"&PIL*>!08$<!MP`H`8%:Q0)B00'6
M[_*X1D0KV,^+:\0@$SY(.>T\2$.&C!@R9LB$(5.&S!@R9\B"(4N&K!BR9LB&
M(5N&.`S9,<0M(DI(8`]00E(>"L&&B@?Q+=2K!S7Y!QDI/5N)<C1DR(@A8X9,
M&#)ER(PA<X8L&+)DR(HA:X9L&+)EB,.0'4/<(J+$`G94)1;IGM(01YGX&.R_
M#L+T"*N)D05[1[JC")$D1%A[!AE26!L2R<-H=%IJ&$<IR5+V)J.MDL:2A+U-
MI#8B4XF4]#:30CD)SKMJ;W-)0NV%U$9D*9%<B(UM)85RDFUTU-[6DH3:&ZF-
MR%8BN1#KS9%".<DVR"Z_DR34=J4V($J>P)%)R1--/L`O%DP(P583(D,*"2&1
MW"$;QB@EM6&WS1>_01;_6))P&!.&3!DR8\B<(0N&+!FR8LB:(1N&;!GB,&3'
M$#=%X.Q'PP,'TSO"(]AJ>%($5KTX#IHMNN:&Z=_-8A'FP9(DC,.8(1.&3"62
MAYA)SR0)I><,63!D*9$2Z94DH?2:(1N&;"52(NU($DKO&.(6$67%01&\(Z2"
MK88T14S8A0M+IZ?6FV'6K+B^V.2/=*0NJ9/CK+LT@XQVUR!=33(5V(FD'];5
M5-<5W25F.A+U,U?\]$R3;#6+*G:6NIZHG96.1.VL%3O&@_5`3I.;*GZVNJZH
M'T='HGYVBA^[W24;D?N)'253X4;('9DJV&JFIH@)*T%FADWC-<Q(Y15(DG#!
MC5.D#86SH$U^RTY2DE5<!:9-=IFIU,Z56/[.)`D-S+4&2/`750PLI7:)@94D
MH8&UUH"EUH%-%0-;J5UBP)$D-+#3&B"'.O<3`TJ^B1MI=R1<0E<S+H/4XFB2
MDC;$AL6\8"$?:5ETO8TSEE4L?[9)5MT$M8HLGHG(*O4UT[*HK[G>%SDH+E"K
MU-<26:6^5EH6];76^R)K<H-:I;ZVR"KUY6A9U-=.[XOL=2YJ_<R7FL[@ZYYT
M%G22SBF4']_(\AZ*F\?0YI/S6\["M3OFT(1#TQPJJ0RSG(7R<PXM.+3,H1+Y
M5<Y"^36'-AS:YE")O).S4'['(5>!U"B+&U3%N[?EOZ#$_0X:Y112BQ8]9@VQ
M(41<[GB:HI7)*RR:[.-,*_EA]^W9:-D]L@`GV%LQT5EO4V0IO=%SRTS+HI[F
MQ)-I]LCB6Z!.J:<ELDH]K;0LZFFM>C);ID4V^`WJE'K:(JO4DZ-E44\[U9/1
M[K7(9N.BSL\\J>DK[N;=D;[IS3_H`E?+0#PU$C6H>,RC^31$$J1G6?9F4KGZ
M.&NH'O0L<NB?9*Q/3GJ53,QR%@YQKC=!3IN+2B:6N7S)3*QR%II8(]1+?LMW
M.BURU-KH^F=K=HLRI9%P<A;VO\L@$@FR(%R=B>))1TT^2-%[DD_0R0Z90FKM
MM-@VF34L77\C\0Q3R"LLNO[&&4L]\%DD%A/4`DF9[\5I2.ZO3I&E],CK9Q5?
M<[TO<O1=8(^EOI;(*O6UTK+H?*US7^(65$L\EU7^D56T0=6B0TT6Z^:$SIR#
M6LHXJ,-=[C"/E6V2'=%%K:*O8D35Q!;W6^^HJMGMV;SN#<0C<5I5;8N4^B&R
M2A?S2,NBTS#.6&1]L\1.?7U6:3/WI;YFE7S-];Y88E?QM=3V2--FI671^5KG
MOM+$;K%,UEC29'*5J7(J6=KEEDHS6>.+9W+Z>E7ZGL+9O[WY0_]TBFK[\%V\
M.@4_A)X?)9R^US6R^_`,!_8+@L_L/CQMX?C*[L-S$8X[=G^GPT>=/MPZYWQX
MG^PE63FDWX%XSTS#'YA]>*K,=096W[4T^$N[_P(S"PV:L@=X7^SJO?EK[_86
M7*+:R7^%26DEC]=NZ1MGZ9<XO,)DP9LA80QOBB4?C_!FH`]/,EL-B,-K&,;X
M170@WS5\_@<``/__`P!02P,$%``&``@````A`&I:$0G]!@``\1P``!D```!X
M;"]W;W)K<VAE971S+W-H965T,C(N>&ULK%G;CN)&$'V/E']`O"_&5RX"HL$7
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MV@G0&;2AN,\+8V$`TV:U+Z$'1/9171S6XR=SF9J+L;%9=0+]4Q8?3>__H^98
M?>SJ<O][>2E`;1@G,@+/5?5*3),]@<#90-Y1-P)_UJ-]<<C>3NU?U4=<E"_'
M%H;;A1Z1CBWWWX.BR4%1H)E8+F'*JQ,T`/X=G4N2&J!(]JW[_2CW[7$]MKV)
M.YO:)IB/GHNFC4I".1[E;TU;G?^E1B:CHB06(X%?1F+-)H[ESN8=RX"GS3P=
MX6E.YJ[K>/,9A!]PA*]=N^&7A?0FUMPU78^T>\#18X[PR]LZ:#]C]E`PS/Z3
M+5PP1_C]L1::D`1T3$@V4+U!6=PG@XYEEQI!UF:;55U]C*#>8+2::T:JUUP2
M-IX4E$*DR;TL@?0@+$^$9CV&CD,"-)#:[QO7M5;&.Z1CSFRVV,94+7QN07*/
MT`8Z$.I`I`,['8AU(-&!M`<8((O0!I3\/[0A-$0;WJLM!Z18FE0^M^`N@0Z$
M.A#IP$X'8AU(="#M`8H04'I("!N2Y?;,P7.">,$<T<L)J#IUQ+?4QI'B^`@)
M$!(B)$+(#B$Q0A*$I'U$D0!F'46"X:X3:Z@HT+-7#[;6=VKD0O8)(VL^4XU\
M8212`2$A0B*$[!`2(R1!2-I'%#E@XE3DH-/&A,S$P\H0QTX9WI\M15Q'U(>/
MD``A(4(BA.P0$B,D04C:1Y0^PS*@]'FXH\1:[2A#Z'I(IC<?(0%"0H1$"-DA
M)$9(@I"TCR@=A75,Z6AO<-MCF;]N*[K,WQ#`AKF?K@B$1.T_0WJU+A!9`:8W
M52L@H$9V?VVQIMK*$0HCGE810G8(B1&2("2EB-FU6E&);(OQRMF5P.=5(B2J
M2@SIJ220(96HD4/T?]^`/HZJ8BB^"X$$+4=V`AD(%`LB%DB;U1+QG=.F@A80
M14'8[B@*WL@GV*'QA"+6JE04L6`ADA/HU%,[[C.C_E2,<^R6T4Q;JT)FM*`2
MNPLM4D2_V_WY'$7:W8JDIWQ\RTAO3J(VQYXMU(ZG#YJCC`39^?W`4'3FZE@P
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M.6(&C[)>,`_D0<R#R?@)AVA\9[[0UO#T47QU%&"LE%%XD/;$7)MC*&33NZ!N
MPVH*:*!O`;?RQ-"%&(HX).EW$AJ@C[F5I$\PE'*HHU>5(3O\?GX^4(8>")1$
MI)`%(RU*W5IH&U>?W*T12>6&/\!0R"!6_99C.AI/Q)U`>Q'MQM*&HL7<438@
MT:)-74^;:U+N="^:*B4Y0_2E_+E29R<160M;DT)JJ2^T9<CG5M(QP%#((%C,
MI'[60KMRB9B54MR6JZVH.TP?8RBY'5&;3M)'$56ER3FDK_2#I&7'%JG,UJ20
M4LX"DLJ@S`JXHZRW$$,1A_KE_!GZF#M*^@1#*8=NE#,Y7_25^;D<9*>4OF`4
M4JK<ULK%AX,A*G(!]535M^\A<V1U[\WTJ[&(,]\K1+;HBV!\F8RYH[(/T.,G
M:GQW:FO'G933W(NOIB<Y;0P-PM?J"E/AH]LA>/Y`JQ`[Q\B\\ID59')/8/T0
M%7"K66\58EP2BKB5I-]):(`^YE:2*\$0><\A':)%1Q6C[S/T$OY<U"^%7YQ.
MS2BOWLC;"YPC-BL!TX>A8+:$BPD87QV?+^%<C_%XOH1C.,;A@>FIRV^-9TL>
MGF[8;ZTE7`ECGJV]A(M2C#\YRR?H,/ZP=99PE7@#=Y=PW0:X(5H$#T[7[*7X
M(ZM?RDLS.A4'$&7:W:K4],F*_M&R?'JN6GAJZE+K"$^+!5RK32>0&(>J:OD?
M)(!XK-S\!P``__\#`%!+`P04``8`"````"$`^`FA>U@/```[3@``&0```'AL
M+W=O<FMS:&5E=',O<VAE970R,RYX;6RLG-MR&DD2AN\W8M]!H?M!-`U((FQM
M6/21/G"(V=UK+&&;L"04@.V9M]^LKLK.KOI;#9K9N1BLK[/^.F2=LJKAP[_^
M>'ZZ^+G9'[:[EX^77J]_>;%Y>=@];E^^?KS\]^_1;S>7%X?C^N5Q_;1[V7R\
M_'-SN/S7W3__\>'7;O_]\&VS.5Z0PLOAX^6WX_%U<G5U>/BV>5X?>KO7S0L]
M^;+;/Z^/].?^Z]7A=;]9/U:)GI^N!OW^^.IYO7VYU`J3_3D:NR]?M@^;8/?P
MXWGS<M0B^\W3^DCE/WS;OAY8[?GA'+GG]?[[C]??'G;/KR3Q>?NT/?Y9B5Y>
M/#],TJ\ON_WZ\Q/5^P]ON'Y@[>H/D'_>/NQWA]V78X_DKG1!L<ZW5[=7I'3W
MX7%+-5#-?K'??/EX^<F;K(;]RZN[#U4#_6>[^75H_/OB\&WW*]YO'_/MRX9:
MF_RD//!YM_NN3--'A2CQ%:2.*@\L]A>/FR_K'T_'U>Y7LME^_78D=X^H1JIB
MD\<_@\WA@5J49'J#D5)ZV#U1`>C_%\];U36H1=9_5)^_MH_';Q\O_7%O=-WW
M/3*_^+PY'*.MDKR\>/AQ..Z>_ZN-/".E109&A#Y;1#H2^B8A?9J$@][@9N2-
MQBKWCH1#DY`^34+/[UU[_5O_NCLA/:WJ2Y\FX6WO9C0:CF].)!R;A/3YOARO
M34+Z?%\=:8A61:5/+FIGF]P:>_HT]@U/=K2E1YU.]P'R\ON*Z+'GU3],TN[V
M]]CEZA]<K;,\Y['/5?=^9S'9>9YX;W!>INP]3]QW<UY*=I\G_NONW%=Z:%8C
M/5@?UW<?]KM?%S1]DEL.KVLU&7L3I<9C7/NT'O5O#7H:[4KEDY+Y>$GI:3P?
M:*;Z>4?]_L/53YI='HS-/=IXML64+=14HF0#%X0NB%P0NR!Q0>J"F0LR%^0N
M*%Q0NF#N@H4+EBY8-<`5N:?V$?7__X>/E(SR$;?N/0-QVL!Q"%MPDL`%H0LB
M%\0N2%R0NF#F@LP%N0L*%Y0NF+M@X8*E"U8-8#F$IA=PR)!FCO:%D<>(2D5+
M8&.,^/U;N\'OM<U0G#0%$@`)@41`8B`)D!3(#$@&)`=2`"F!S($L@"R!K)K$
M<@E-X)9+NEVAK&G&(_\VYJN1XPMM-*)161OYGF,TK8WJ(0(D!!(!B8$D0%(@
M,R`9D!Q(`:0$,@>R`+($LFH2RSTT."SWZ&6FI_9%W9Y2"2M/<?O>:S(:UO/8
M%$@`)`02`8F!)$!2(#,@&9`<2`&D!#('L@"R!+)J$LL'M#^Q?-#=\,K:;GA#
M]/9<+<]3(`&0$$@$)`:2`$F!S(!D0'(@!9"R2:P&HVV9U6"-3GO\MGWX?K_3
MT4M+0_JT!]([(R5BMZ,AC3F^)C+3>..^/1T%VLAO[K$&H[%M%-9&/%PB(#&0
M!$@*9`8D`Y(#*8"4FM!6DTIHM395[.^WMA*Q6]N01FO7I*NUM=%0^?'GW:#O
M.9O9L'Y>-W0MRR2N24=&22UD,O)MCZ;U<Y:=U;),LIIT9)370B8C9Z]7U,]9
MMJQEB5BNHBC0<E7+`*`8FT>`LK9]HLF`8L-Z9;UVBC,U-LTE&L=$F]&ULT2'
MQNBV<J4*_^T6CO1SO[G.0TYQ6T[N$$W:C-SBI-IH.*Z*,^I?VZ69G5.:K"TC
MMS1YFY%;FL(JS=#U0GFB-%:O4+&^U2W^TGQ9J=C=Q:`A31W27YQQ,N5TG6X,
MQ(I[>6A0U6%_WGGC&[=_<!K:W-398P=AJ\[\$['B_%.#_&'5(?R1TWUGG*0S
M^XRM.K//Q8JS+YSLQ\Z*4G*2M[*WNP!E;W6![IG!4^:.KS7R]7EBM<LP5H0Z
MVC]@JW&]+PP118Q$/A;4(9^PE<BGB&:,1#X3U"&?LY7(%XA*1I6\W?`J5,5S
MG&J#??Y>105$KC\TLN9JWW,ZR=0D'`SJQ@\$->KM3C\A6^G)V1\,G74V,@8G
M9F>6D?P301WYI\;*S,8W[MHP.RO[3/+B894+ZLB^<++W;^S%H#R5O=T'5'#<
MU0=^W[W28#L5<:G#4[<3:&0-RAHUZN<N08'1\J_K?A$BBAC)J(D%=<@G;"7R
M*:(9(Y'/!'7(YVPE\@6BDE'+H%3A<-,A)V9#95[-AE*HD;O#OU='U60UII6Y
M7HU\S^DX4['B'AD@"A%%B&)$":(4T0Q1ABA'5"`J$<T1+1`M$:TL9`\A%3R_
MPV,ZUJ91RJU\KRX0R#W-$SQ$`:(0480H1I0@2A'-$&6(<D0%HA+1'-$"T1+1
MRD*V+U1<WO1%8SMY8B"9B+[I%HVNJPO/*C"?JOL:\E0#!8A"1!&B&%&"*$4T
M0Y0ARA$5B$I$<T0+1$M$*PO9;E$!?-,M)WQAXOVF+S1J'."I"S`U:.IA%``)
M@41`8B!)D]C54,%MLQJ-WO6.#9,)D9NU,W%T79>INE:K:B<3-H0/@3$:T_)<
M3^MXO"-6/.%$B&)$B87LAE`AWM]O"!TH6C.A1N+4J<=$JMC2$-IHI./CEI.7
M<U0B8R0J3K@8GZ.2@(J$AE8;JMVQU8;=8Z(RM\,>@T8T$&KW^YYS.S0U5H-F
M)\$6-%9C?7;E'".&9VE$G1KQ61K)6QIVTZEXK]G]3C2=,G>:3J/F09$_<&H]
M54UV<@P:H[&.Q/N]L7,V$YZC$ADCU7?$E0/GJCL^1RIQ"S02%;L1W>CO1"-B
MF$>1FVH?N_\-I+OK)=-8J6+556OI?UIKW(S7_8$S`,.SM")CY6@Y06)\EE;"
M6GIF\7J#\#>IH-V>;B1UHCTQ8AIH1"U1-Y0_<$YVIL;HK9,5_0J$,7*ZDQ.`
MA^=(1>U23B>/SY%*VJ4D"K&;\WUQT*`U#G**>6^L[.M9W^D94['B!3-`%"**
M$,6($D0IHAFB#%&.J$!4(IHC6B!:(EI9R/:8&P<U=D<GQ@*&1'2R6LTMC9T`
MH@!1B"A"%"-*$*6(9H@R1#FB`E&):(YH@6B):&4AVRUN2'3"%Q@'#0QJ7.(B
M"A"%B")$,:($48IHABA#E",J$)6(YH@6B):(5A:R?:%BEG=L7'2(T]P@#S3R
M;R54$"3K1LL"JQ,.F\NP[SNK2VBTR(JGODCD&<6".G),1$NL?-]9A%*Q8OF9
MR#/*!(D6U#$7+;'R?6=#7(@5RY<BSV@N2+0@QX5HB94_=+8M2[%B^97($[+[
MB!MDGABO&$T.-++Z"*#`6#5<'2**4"M&E$C"1C/XSNJ;BA4WPPRU,D2Y)&S(
M#YWM>B%6+%^BUAS10A(VY9U=P5*L6'YE:=E.5`'I.P:ZCE^M@:Z1Y41`P4`C
MRXF`(F/5T(H1):+5:`;W=B$5*VZ&&6IEB'))V)`?2G!2[5P+L6+Y$K7FB!:2
ML"GOS&]+L6+YE:5E.=%W(_3&AN;\XYY*Q8X^#6KX8XHH8"1OH82((D:R(,2(
M$D:BE2*:,1*M#%'.B*84B5.&$A5I1XH5MW3)2.3GB!:,;'EGV5B*%<NO&%7R
MMB-5('_^:%3WALYY@4'J=*)19V>"F[)5,X*#-2,0*RYZR(AO-/O]VY'$156#
M1L9&?=1%`/&8E3J+D+1:N?>LJ;$R]YS#WFW?^L^9(&?&7'V\7<"L-6OW#C`7
M*VZCPB!3FG'/6=9+\UQ]O)W]7(0[K!9BQ=DO$:TL9'<X=9KQC@ZGS)TI0B,5
M,M>U\8=.GYCZ)F%GG0.QXMJ$!E'4H%[LNKT>WXR=]HPX5>=)0\Q6G25(Q(I+
MD!IDWF`97/?ZSA"?<:+.`F1LU5F`7*RX``6B$M%<D/@!1MU"K%A^B6AE(;N_
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M:)F`K>3]M1!1Q$C>Q(D%=<@G8L4MDR*:(<H$=<CG8L7R!:(2T5Q0A_Q"K%A^
MB6AE(=NO[K'?7YL@\#30U\C>"H^<(X\I6\DE=X`H9&3VO:/K@>>^)A@9&VM1
M@;X4LY+DER!*#3)[2,_KP1Y65ZX[LPR5<T2%G=EUSVFBTCSOSFN.P@M!C0[D
M[MZ7;*7;]F9(7V*W7Q1<G2J`W9_4^6%S2^OVI_->%*2W^F#^T(BZ,O?TJ;%2
MO;MK_C`)Y56[D!,*BAB)?"RH0SX1*RY7BFB&*!/4(9^+%<L7B$I$<T$=\@NQ
M8ODEHI6%;'^K$\.FOT^L"_J`L7F"I;YU1$N%]0:^[W[!>VJL:"?!Y0P0A8@B
M1#&B!%&*:(8H0Y0C*A"5B.:(%HB6B%86LMVC3OG>X1Y]*&BY1R,[8G"_2#"E
M,ZIJ.RCS:H`H9*3G&F\\OKEUWXJ.C$WW=!>SDN27($H-,O.XWQO`/*Z+W9U9
MALHYHL+.;(3S^#EYS5%X@6C)2#?DB'[TQ-D:KXS%FS6S>@G]T,M[>DEE;I]#
M&.2$`\Y^><H)&X,84<A:^M#!]X>>=^M4+^)DG3OOF*TDOP11:A#M?:MXD7YT
MR%F"9YRH,[>,K22W'%%AYW;=<VI6<I+.O.9L)7DM$"T-,L<W-WUX4T;]Q$^U
MSKZ5F^XF^E=\]&][/&_V7S?3S=/3X>)A]T/]0@_=*MQ]J+'Y^:#!</*)Q&FR
M=I[0RQ43]79`VY,1/:G67S<-)6E-00G:[#]YE#OUQ98\Z(EZ1[OM"8G1&\-M
M3\;TI(H^G'+1O=Y$W=IA&KHLHB?5,3JDN:4GU>&S^\3O3]2!-:K1->!$G5OC
M$_J9ID_5'.AHW=//-U5]P^4#:N(6G7N?,FCAGZ@AZ4L(F#%=HD[4%6G;DQMZ
MTE9UNMNA)VU5I\N"2=%:0;ISG:@;`<R'KEXGZF(`G]"5\D1=&+<]N:$G;66C
M:RUZTE8VNA29J%L05*,;Z(FZ#,$G=!$]47<B^"2@9FLK67`SH>_]HGU"!6[C
M.35R&Z>7?2?JC5Q4NJ<RW;>6:4I/U,T2I@GHB;I-PB=TWS]1ETKXA*[])^IN
MB9Y<U;V/?KKK=?UU4ZSW7[<OAXNGS1>:./K55\CV^L>_]!]'\S6BS[LC_6@7
MK3'TJT'T(VT;^D6`?H^V^5]VNR/_H3*H?_;M[G\```#__P,`4$L#!!0`!@`(
M````(0`IJFRJ8P(``$8%```9````>&PO=V]R:W-H965T<R]S:&5E=#(X+GAM
M;(R4VX[:,!"&[ROU'2S?;TR`P(((*RBB7:DK554/U\:9)!9Q'-GFL&_?<0PI
ME-V*FR1.?G\S_\PXLZ>CJL@>C)6Z3FD<]2B!6NA,UD5*?_Y8/SQ28AVO,U[I
M&E+Z"I8^S3]^F!VTV=H2P!$DU#:EI7/-E#$K2E#<1KJ!&K_DVBCN<&D*9AL#
M/&LWJ8KU>[T14US6-!"FYAZ&SG,I8*7%3D'M`L1`Q1WF;TO9V#--B7MPBIOM
MKGD06C6(V,A*NM<62HD2T^>BUH9O*O1]C(=<G-GMX@:OI##:ZMQ%B&,AT5O/
M$S9A2)K/,HD.?-F)@3REBWBZ'%(VG[7U^27A8"^>B2WUX;.1V5=9`Q8;V^0;
ML-%ZZZ7/F7^%F]G-[G7;@&^&9)#S7>6^Z\,7D$7IL-L)&O*^IMGK"JS`@B(F
MZB>>)'2%">"5*.DG`PO"C^W](#-7IG0PBI)Q;Q"CG&S`NK7T2$K$SCJM?@=1
M?$(%2/\$P?L)$H^B83\9/]Y!82&CUN"*.SZ?&7T@.#08TS;<CV`\1?+96<BC
M\_J>5?3H(0M/22E..[JPV)[]/!E-9FR/-14GS3)H\-IIXD[!,)LN)4SC,J6W
MBWR.[,4^LB^Z3V497ER&Z;\=9G`=QCL?OMO3<SB_";MW80+;V/%#!D'3CN.5
MK^%UP/_[\N*4HIFN6LGX;[U"H*!)VGH/1N/D7Z-AGD.[%9@"/D%562+TSL]J
MC/NZM]TQ6O3;D]!]P#%N>`$OW!2RMJ2"'+?VHC%6RH2#$!9.-^TP;;3#`6X?
M2_Q?`;:D%Z$XU]J=%_ZH=7_`^1\```#__P,`4$L#!!0`!@`(````(0!O8H?7
MS00``-<0```9````>&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;*Q8VXZC1A!]
MCY1_0+RO,3<S(-NK,9=DI8T419ODF<%M&PW0%C#CF;]/]96F>\8B45Z6]:'J
M4*=/]6VV7]_:QGI%_5#C;F>[J[5MH:["Q[H[[^P_?Q1?'FQK&,ON6#:X0SO[
M'0WVU_W//VUON'\>+@B-%C!TP\Z^C.,U<9RANJ"V'%;XBCIX<\)]6X[PLS\[
MP[5'Y9$FM8WCK=<;IRWKSF8,2;^$`Y].=84R7+VTJ!L928^:<H3ZATM]'01;
M6RVA:\O^^>7ZI<+M%2B>ZJ8>WRFI;;55\NW<X;Y\:D#WFQN4E>"F/PSZMJYZ
M/.#3N`(ZAQ5J:HZ=V`&F_?98@P(R[%:/3CO[T4T*-[2=_98.T%\UN@W*_ZWA
M@F^_]/7Q>]TA&&WPB3CPA/$S"?UV)!`D.T9V01WXO;>.Z%2^-.,?^/8KJL^7
M$>P.01$1EAS?,S14,*)`L_)H&15NH`#XUVIKTAHP(N4;?=[JXWC9V?YF%49K
MWX5PZPD-8U$32MNJ7H81MW^S()<4)4D\3@+/#TCN)/H\$9XB<15X8?1`OWXG
M,>")\.2)\=T*00N5"4\>[T6KR%W'?@30G0]M>"(\[WW(8<-*7<K*L=QO>WRS
MH/5AX(9K22:2FP"'L(=]41KVF5\PQH3DD;#L;)BS8,4`3?:Z#S?AUGF%QJAX
MS,&,<><1J8@@UA':3`=R'2@4P`%%4A8X_3_((BQ$EBCH((!)IZ=I$!$B)=.!
M7`<*!9AI@*;3-?@P_SZ>.<()D@1S1'$BB+4:#RPFF'2E!I(92&X@A8K,*H>N
MUROWPI5LY,5M17B@,6&`E+[:S$?\P()"Z`09%,3Q/"B50=(7`\D-I%"1F4"0
MH@MTPQ69JO?=(7E4D"CCP)`PD#V6&DAF(+F!%"HR*Q4FM5KJ_?I(\+P^CK#U
ME$S*U$`R`\D-I%"167W1OZF/!,_K8X@7T47'6[O:JI/R]YX<WTPB4[^XD9:6
M\Z"8TOIQH+TOV'M?;3IWLY9--U-(CC+*$GO?`1(\5\@0SQ<*M?Y/><;D4&8@
M.><(*4?@;P)9*5UH"YX!_2[GT*=R8"-;+H<$S^4P9#(LFI>2\O>*80:2<X2Y
M$P2Q[@Y[O\P=%Y;4Y7IH]%P0AR:#'C1%(D=QR(1R02,\BC6?"Y&SR"27;(R+
MFXY&:ZK8SCKYI*^H/,=3C#*A7$#,*O<A\N>#4_"`A5Z1K5)1Q4XK=-T=+W7U
M?,#0OE#X!U.,3!]^5F'[+>PJ<A$F.PRT:0"S6O9_N)ZF,TU,>114+!(S$\HY
MY`=TKKFN82/__#(;R1:K"/Y`&!R#I3*V(4,%HL"#RR"?':WI^CU!DUAULO.C
M%T_<2*Y<)$Y0(2!*/UOT7+)W*I7_-ZL(B=:7#(HFC2G]U,Z>=2*+`DC1:"SR
M(I$W9^P^:$U>\(B%W4GVX#N2?^#K9]VIFLAV\IF)#)J9*"%%H+(!<1-Y5*28
M:$#D^D=&F=$S$]EUCET46M2?48J:9K`J_$*N:F2SE:B\1CY22S3\0*Z7Y.LZ
M[B5P[OT`]Q,X5IKX8Y`\LFNJ3A0D<$PS$PYA`F<BP!V9`-?*:WE&OY7]N>X&
MJT$GT+*FJT?/+J;LQ\A]>L(C7"BI91?X`P*"P\^:'&)/&(_B!_F`_)/$_A\`
M``#__P,`4$L#!!0`!@`(````(0#X$68FVQ(``+UD```9````>&PO=V]R:W-H
M965T<R]S:&5E=#(T+GAM;*Q=66_;2!)^7V#_@^'WL4V1LBPA\2+B?6*QF-U]
M=FPE$<:V#$M)9O[]5K.[6-U55(L*]B7'QZ\.5E=5'R*E#__X\^7YXL?F?;_=
MO7Z\#*YN+B\VKX^[I^WKUX^7__X]^^WN\F)_>'A]>GC>O6X^7OZUV5_^X_[O
M?_OP<_?^Q_[;9G.X``VO^X^7WPZ'M]7U]?[QV^;E87^U>]N\PI4ON_>7AP/\
M]_WK]?[M??/PU`N]/%_/;FYNKU\>MJ^76L/J?8J.W9<OV\=-LGO\_K)Y/6@E
M[YOGAP/XO_^V?=NCMI?'*>I>'M[_^/[VV^/NY0U4?-X^;P]_]4HO+UX>5^77
MU]W[P^=GN.\_@^CA$77W_Q'J7[:/[[O][LOA"M1=:T?E/2^OE]>@Z?[#TQ;N
M0(7]XGWSY>/EIV#5W=Y<7M]_Z`/TG^WFY][Z]\7^V^YG_KY]:K:O&X@VC),:
M@<^[W1^*6CXI"(2OA736C\`_WR^>-E\>OC\?_K7[66RV7[\=8+CG<$?JQE9/
M?R6;_2-$%-1<S>9*T^/N&1R`/R]>MBHU("(/?WZ\G('A[=/AV\?+\/9JOK@)
M`Z!??-[L#]E6J;R\>/R^/^Q>_JM)@5&EE81&230HB:Z"Z.96J?"(P=7>-OQM
M;`<1V?8(WAI!^-L(1E?1;+ZXZYWV""Z,(&3_(#C!T:41@[_/<S2`\>QO4?UC
ML#C)U0!')J"AF135`$=#_0/=G4V+3P`CJ/VUA]+G[[7.ISX]DX?#P_V']]W/
M"ZAY<'__]J`Z2+!2:C$Q]>@,J7HL4R%%E99/2LW'2Q@O2,(]E->/^_G\[L/U
M#RB)1\-92T[@,F)DJ/Q7:A,.I!S(.)!SH.!`R8&*`S4'&@ZT'.@LX!I".\07
MLN+_$5^E1L47([-&@`(^8\%$!HHD'$@YD'$@YT#!@9(#%0=J#C0<:#G068`3
M3*@4)YCCW1-S4K&A3UHY&<Z7;I#6FA-18&.!)`))!9())!=((9!2()5`:H$T
M`FD%TMF($T(H\3-"J-C0&6`\K+KF,=2D.53`0`IO>38.I"$=!9(*)!-(+I!"
M(*5`*H'4`FD$T@JDLQ$GK#`W.F'5;?1J`;@_295@'V&,RUHC\VBH]5@@B4!2
M@60"R052"*042"606B"-0%J!=#;BQ`Z6!T[L_`%3;#=@!M%K'35MQ`))!)(*
M)!-(+I!"(*5`*AMQ;A26-<Z-6DER^+9]_&.]TTNXD0"$,*?JF58I<>_?(%8/
M&Q"JR.#VQFU]B2:%]IP]NV$S<CJ0,#TS@>0"*012"J322-![[41);7GDBJ0O
MI>E14DK<*!G$BM*`^**D29&*_X][B$_D1C$=K@\!&M0BD@^(QU`Q*#*&0M=0
M.5Q'M=6@%A`G@K#^=2(XDD^PY,>$4FPW5!J9P5K8:NC,G]B0[*E!YMA`0J=3
M@60"R0>$[`O5Q4!"U:5`*AMQ(J36^4Z(5"G.YE?0H_S!Z@7=:!EH!E.N%2Z6
M)S$*VK.DN*EDE+68NZF0HD4UAFJA'?*E=H9Z8+X:?!+6<F1Y?2I&6=RGTO4I
MO)W?LE92H9YC/KD#I-;3=A<X,2R*SH9%0S/H,T,(P"TWE+':OH'@S)_&Q,)D
M2Q%:]F,0+F:L/C)#",'`8']D"*;8+]#8;%@3E`@9^V%PZ]Y9=<J^&VZUXCXC
MW(K.PJTA5@7,J5BM))6@-R@)L2C<1KU.^46P6+BWFZ',L>SJ)\\<65[[!;'0
M?FF@OFW^N`\7=^S.*I0Y9M\-MUJ>GQ%NO9H'$^C/6AT:J+QULYL%)486!.]X
M#B;$0O4I0CJ[@N7LCJG.#.-4>ALWO0X4:(WNKT0(';B[8_55G7+`#3@,RSD!
M5W26WQIR\CL(V%8H5B<H$_)[8%'`C7J=WW`FQS1GJ!EXQX<R1]:)_!;V2R-H
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M(=2?MO3'!@1Y[BU!UNTP&Z<2RA`B]3E!'O4%LDA]*:$*H5Z]&QFUZ3DC,GJ/
MY/1>LVV"N7N8:L(%.SZ(`R-(QRZ)A%(#F7EE.5_>L(DE0Z$3M2^L%2A(#I2N
MM<5RL6#6*A0Z9LT)I=H!.Z'\I4KOM;B+"0.YE;Y@&Z88692TB812`T%9VZ/%
M[CLS+*>X9WS;F$OUA83*<8M\?7;*HAMIM0V:GK0S16<AU9!=SH8%$$5&[,`2
M9%&]I1+*$++*F2"/^@)9I+Z44(60+&?5Y\^)C**SR&@H@OYKE3-?2_5V0)"J
M*9%0:B!3SA!,MI_.4.98?>E)!%EDK)!0::`PTEOL);-5H<@Q6VZ&J9W(&1FF
M-RYV6U2K([6.=([%^#E(C"R[:(T@0:ED91+*)51(J)10Y4!N&"!83AA^K:4I
M+2S+-*0L6UG&=LGQS`C2P"<22@T$`V_KXHM&%+19(RU-6"Q0D)PHQRWR92(*
M'K/H1EIM#LY(.+V7<!).0TY+&R"*S$A+,RSJ.2E4K!JQD*`,(;NE35%?H"#I
M*B54(332TM0*_8S(F`4]E<]ZIB$V?[(%98PL$DPDE!J(S9\BV;3%4_.G\8LL
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MA!H)M1+J',@-Y7F[&36IL-440M3+8@DE$DHEE$DHEU`AH5)"E81J"342:B74
M.9`;/[[GX=USTH,2H=P*(60]!$"0KWD:EONPQ)S-4RFQL%MD$LHE5$BHE%`E
MH5I"C81:"74&@F,D<-4-OMJM\$8<S,]\_B+4>QY[*8&0'7S#@AF&IG_>JA,C
M>/P9#")0W`?-".5DWV.L(%U'GL,@`FJN2#-"-4$>8PWI,L;8L4U+!-3<D6:`
MW)%36QU[Y$ZT;45G;5M#[A:7?]09JWT9"*KMMV_4QEAB`6ATN:MO\6&C8:F.
M,5B46[U)?A6C+.Y7.>X77Z-/\JL>M<BSO!EE<;]:9.E3]-ERQC8JW9A+]@[1
MS1BUWSLC8_3VT"EJ#;']`=^)J2,XO3^@\;.=TBM48F&RIP92-S4,?+ADVX\,
M!6W62'I,<:)`733SEN2$JM+;&W9W%8K8YL7=U<BR<UBP&F)A#%H#P7Y:F0\B
MGCD=RARS[PZYVE:>,>1Z%^H,N8;<)K'DA]=PTC"E26@6%#;>;FH$U00U#+G<
M$B++&\U\DA,%L=")TD!N6UJR[ER-.2'RKB;UU@WQ06R(A4ZTXTZP<_;NE!/N
MZ/-S@A-3A#P0",<.!);\--FP3GQ43"R\Y]1`)MG#FY!ISE#F6++K`V9D>=.C
M(!;:+PW$&@[;%E8H:#LQ,O##J8AWX`V+GO=NC7K_J4@WYH3=4-R!5YOX,\I>
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MYH2;!\`Z8PZ(%)V-OH;<+G#+FG2,@L><TJM]8N$]IP9B78`M>#(4]'<!9'F=
M*(B%3I3C3K!E2(6"7B=J9'F=:(B%3K3C3K!E2(>"QYQP1Q\RZ9S15W0V^AIB
MM<]7`)%AP5^T?I>U/[#PGE,CR&J?)5=F6*=J?U#O<:(@5]&)DIQ0FRV6>M68
M<7O)U6=V36H]QAMBH?'6-<Z6'=TIX^YH\U,\_XP/9VMBM#7DU'ITPYR*4=";
MX0FQ\%Y3`T&MJT`O^%EJAB)V;HM0Y\CRFB^(A>9+U_PL8MO7"D6\YFMD><TW
MQ$+S+3._8`NI#D6.F7?'&EA.9:OC\DGSNQ)D-:XA5N/,O3@RK!,UKEE0JGC?
MJ1$\L;E'EC>L^20G"F*A$Z6!H-&HU)OQA_BK2>9K4NRM\B%2:+XE\R08!6RM
MVXTY86\QW0Q01UOV[NZ7/C")S`$9/;VP-I#;!`)6+#$*>L<K(1:&(C70<+2U
MG+$P9"@$83P^F^3(\CI0$`L=*)D#XC67"F6\]FMD>>TWQ$+[K8&P"_*#[PY%
MCIEWLT`=IME9<*+GZ[,W>X^OYEYH"'"@B![&!'D&($$6/1*42BA#B-3G!'G4
M%\@B]:6$*H1(?4V01WV#+%+?2JA#2#Z[H,K#"?ROE9\Y"+++3T-N-P[8,63<
MFW=><$D,Y*R2Y-,WR'+:.-_H9,CR)G<NG2A&!?DG&B6RO$Y4R/(Z44LGFE%!
M[D2++*\3';*..>%6HSHELJN1)\6T1X#@JTG$'&W.GRC/8\-2GP0<;Y,)LN@9
MG51"&4*D/B?(H[Y`%JDO)50A1.IK@CSJ&V21^E9"'4(C5:I.C^P!.=$>S6&3
MG1+BI>9UI%G.8T11P/8-,;&PKR822B6422B74"&A4D*5A&H)-1)J)=0YD)/V
M\['#)O/X@#_@O:2[&C60_1B1A!()I1+*))1+J)!0*:%*0K6$&@FU$NH<R`TE
M])DS$E;E(%O-(T0K\%A"B812"642RB542*B44"6A6D*-A%H)=0[DQ@]*UXD?
M[\"3'B.:*RTL+0UD/<F"+&C-G@9L6.KL?F#-^-8W)19VBTQ"N80*"942JB14
M2ZB14"NASD`CCQ'-^0'$KP5?GDOTBF$\[.`;EAU6<5:0&$'86O?;/OE5+D2@
MN`^:$<K)/HVA,%:0+F.,30DE$5!S19H1J@GR&&M(ES'&5H@M$5!S1YH!<LM&
M;5FGSY/0G$5]:(@M6]D1:FP$3SQ&-,KBZ[<46>;ET@4_I\H,P5T0\U/)'-78
M<_[(V)K;<UC<I1)U&9?FXNF!22[5J,8QQAUO1EG<I199Z!+_<+T[Y9*;)V.'
M#E..G>;RG,%`SMM#4<#.NV,4/+;^UA\L$`N3/360V6;/(E8?&8K`P`Y]68Q[
MCBRO^8)8:+YTS0?BJUI0Q&N^1I;7?$,L--^ZYOE+GQU*'+/N#CH_8U!M?=*@
MR].&N8;4BQ5#U",>G!A9W@)(B(6WG1H(MNVJ*R[Y!PGF\JF.8'ST6B](%UHO
M$7($^=ZZ0I9W3&O#\G?*AG2A$RU"7B<Z9!USPDV`L;..V:WZUN*+Z5_/-I=G
M'09B+8"-6HR"QWPU+<"HI\_54U0/XSDDFWRL#-4?JX5>?8XLKQ,%LLB)<I(3
M%0E:KO*67R/+ZT2#+'*BG>1$1X+C3KA)H4XDSE@R*#I;4FO(/GF<#]"X!V:H
M#8O.[E(4)"A#B`X=<H(\Z@MDD:Y20A5"I+XFR*.^01:I;R74(23/-.;\3./7
M5MG#40=VCG6O&#J[_;)S%/!/_Y!%1Y8)0=9]\Y5(BBSS&/--Q.H\,X13W5D[
M#HT1'2]0L]ORV$JB1-:Q]6(UR7Z-:LA^0Y#G_EMDX4J,+PZ[4_:=\H,OKG?+
MCV?!M*/&7HU;E@:RRY(@ZP9Y=TJ018=UJ80RA*AN<H(\Z@MDD?I20A5"I+XF
MR*.^01:I;R6D?B]`M3$='#T@^OO_]1>LOVS>OV[BS?/S_N)Q]UU]MS^\/W[_
M88#U#P^LYROX9EQ(7X9_FBU7G^`P4UZ!5Q=7ZCV^D2OAS4J]EB:O?(I`&_@K
MK\`)YDH=YXU<F8,V.)V25Y+Y;*5.`\:NA*L4MI;R"NR(5VK3*Z_`]A6TC5V!
M'V7X-&9E#3_6T!]IL9BM9Q"8$0OK$,(R@G^*0/]HB".(R8A`LEC!-]G*6TCN
M5NF8GN)N!=_;.L(/(8#P(?C8%0@@O.(CK\";2:MR]`J\1@3:>IGK(2+PXQ%O
M#U\W[</[U^WK_N)Y\P42\*9_B^M=__R$_L_!O(C\>7>`GXV`ZH>?`("?"=G`
MURC?J*]#_;+;'?`_X-3U\,,C]_\3````__\#`%!+`P04``8`"````"$`SQ:R
M124&``"K&```&0```'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6RL65F/XD80
M?H^4_V#Y?3'M@TO`:O"1K)1(4;1)GCVF`6LPC6S/L?\^U9?[8AF/=E^6Y:.J
M7-7UU>&>]>>WYNR]X+:KR67CH\G4]_"E(OOZ<MSX_WPM/BU\K^O+R[X\DPO>
M^-]PYW_>_OK+^I6T3]T)X]X#"Y=NXY_Z_KH*@JXZX:;L)N2*+_#+@;1-V</7
M]AATUQ:7>Z;4G(-P.IT%35E??&YAU8ZQ00Z'NL(9J9X;?.FYD1:?RQ[\[T[U
MM9/6FFJ,N:9LGYZOGRK27,'$8WVN^V_,J.\UU>K+\4+:\O$,<;^AN*RD;?;%
M,=_454LZ<N@G8"[@CKHQ+X-E`):VZWT-$=!C]UI\V/@/:%6$L1]LU^R`_JWQ
M:Z?]W^M.Y/6WMM[_45\PG#;DB6;@D9`G*OIE3R%0#ASM@F7@K];;XT/Y?.[_
M)J^_X_IXZB'="41$`UOMOV6XJ^!$P<PD3*BEBIS!`?C7:VI*#3B1\HU]OM;[
M_K3QH]DDF4\C!.+>(^[ZHJ8F?:]Z[GK2_,>%D##%C83""'S>,')',1**\"D4
MT21<)"B9T:??48R%(GP*1?C?'7FPQL*$3_F@:#)'TV4TO_^@F5"$3_F@NQX&
M_'Q9NK*R+[?KEKQZ4`-P@MVUI!6%5F!,YHG[/&3N>XF#C%$C#]3*QH?BA9QT
MP+:7+1S5.G@!AE1"9N?*(%,BE1*4#M1L9@.Y#10:$$!$0UB0\I\0%K5"PY(.
M[22@XK2B3*6$5,EL(+>!0@.,&(!]=@P1%.+M$I*9H$I0+%HFXC`RSWG'96(5
M5^H@F8/D#E+HB.$YD%[W_+['5!C8!Z>@D<=VF0LED.Y!*`X79ESI(#0<OH/D
M#E+HB!$%5*`>!2^-"2W,^P%1/1:0=&/'D83U6\;LU$$R!\D=I-`1PU6H7-W5
M^_Y18=,_@?#N22LO=9#,07('*73$\&_^$?^HL.D?1T(@OY;]I95](10.U9H-
MB%)#\\14R[E0#*XKV]'4%"JX4*33#\V4D!$K76&<CLIHTY_JZFE'X#E@Z$:.
M(NB<O)]2&^81<"0&1S0W[08JU%0>,P?).1(!ZS5#5A<KA)HN%":JW(QXEV:\
M-^*"H2D#H\)F8!R)^!+`N#<@RD/]L/EH$$*S(=NY@Q2#(2A$PV4$3-)S=-]G
M)FTZ+2"3D9'5M%(II5'2A7()+=G<7,:QQ=!""(QC'Z(3\4?IQXQ8$5.[&_\=
M`DI%C8$NE`O(XF!LU9Q4'$5".C[TL-_)*!^YH#2T:&8`!J?&0P7=(Z*4TICH
M0H6$F'F3BW2*_G#"^"B&IZB`.&11U.)6BH244LP4I(7MM$TIQ5F[@+<K.WW<
M\DC6TB%\YQ"^DBO0\6;3U)H+HE8LVG+(2.L`:?%IS5RLGD)J/IQH+LQ'"BHD
M=".M=%9;$87)!-"/KM9\Z%,"#0T[F5G%LJ/O5A"ZN2!%5DY2)25IDKE0[D*%
M`9GTI3/?BA,E([8D))8%Q;R=@/0]R84R%\I=J#`@TV,ZS#6/WVD5?/0;E24@
MU>12Y$"9"^4N5!B0Z2:=P>/=%!-;/TT.00.@[V/A%#FU+P243H8&2)'-79FD
M%*]]-(OM]4$(C*Q].J;'!\J'NI$/#L%H$H$ZM!<Z*F$9<J!<0*R?O&S18F:9
M*:0.=(:A$O7%Q$@?[;OCHV+29N<2D$K?W&RPJ130TN="N81XKD*$K"6E$`+C
M<A7^C.V"&;&"';8+D4*U:_+W):FCI="%<@&)%(;1PJ)\(77&I?!#.T7H[A0"
MTH>/@FYSB`\?*:7M%"Y42,@=/B&=O5I)::^NX]]!F!$K37RFSQ7E4B$%O@PC
M14%:C,X"(:6^NT`(@9'$I./Z3L3C%@BX$;47"`$9.>12`&GQ.0N$5%3;0NY"
M]`Z6/I&;YPV$WZGR2[H&MT><XO.Y\RKR3.]+X65@NQY@>9F;K![`$F3`^@7V
M@A4=WK=^F<$OC&"6#EP-/[!L6O@.KHQ9^=EX"%?)MYX0K>"&R'WR0[QZ@+W)
M_6$7K^`RY@8.,7".#T^&J^)K><1_ENVQOG3>&1_@:*9LZVCY93/_THN]\9'T
M<$D,IP<WG/!'`0Q7'%.ZBQT(Z>47>'`P_)EA^S\```#__P,`4$L#!!0`!@`(
M````(0!D4<_'E@```*H````0````>&PO8V%L8T-H86EN+GAM;#R.P0H"(11%
M]T'_(&_?.#.+B%`'"OJ"^@!Q7J.@3_%)U-]GFS87#A?.O6IYIRA>6#EDTC`-
M(P@DE]=`FX;'_78X@>!F:;4Q$VKX(,-B]COE;'17;P.);B#6X%LK9RG9>4R6
MAUR0>O/,-=G6L6Z22T6[LD=L*<IY'(\R=0$8Y435<)EF$*&?`!%_*8V2_Q7S
M!0``__\#`%!+`P04``8`"````"$`CXV-^+4#``#X#@``$``(`61O8U!R;W!S
M+V%P<"YX;6P@H@0!**```0``````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``"<5TUOVS@0O1?8_V#HWLA)LVDWD%6DKH,62!MOY;9'@I;&-A&*5$G*L/KK
M.Y(<V6I&3.";1,[C?+V9(:/WNUR.MF"LT&H2G)^-@Q&H5&="K2?!]\7MZW?!
MR#JN,BZU@DE0@0W>Q_^\BN9&%V"<`#O"(Y2=!!OGBNLPM.D&<F[/<%OASDJ;
MG#O\->M0KU8BA8\Z+7-0+KP8CZ]"V#E0&62OB^[`H#WQ>NM./333:6V?_;&H
M"C0XCFZ*0HJ4._0R_B)2HZU>N=%LEX*,PN/-"*U+("V-<%4\CL+CWRA)N80I
M'ARON+00A8>%Z!/P.FAS+HR-HZV[WD+JM!E9\1O#=A&,EMQ";<XDV'(CN')H
M5BW6_C3?LK#.Q#^U>;`;`&>C$`7:Q>;S6/;X6US&5Q>-!'[U)>L36DMPHV_C
M0C@)]GXUY\81)E_U;&ZL:"UN#7K,(D-NL)ER&"_V6;79%OK8\LZ'J5962Y%Q
M!QG[P"57*;#DB:<OD6=S_KR*Q*&FFFF6Z16[+S!AW=EUZ%M'>E;U(8E[@2-]
MR)3WLM9IN3=KKL3OAH%-R+YR5QKP&9:4><Y-58LD8JT$U@ZRAMVDJ2Z5(WW9
M%V75)N57*8K:?5(4?4L?-EIF6/MLAJ*N&I:KN9NQJ<ZQIFWC`RG[&3M'#FS!
M=T!'X0[P(#;;"<?N!%\*.:1UJJ7D2VT.\;K#SJ$0?+,V0WG,<^':=-><Q+PZ
M+$CL9MBC2',Q6EF9.O9%8!TX;&_(JJH[@(3,\D+J"H!]``4K=&..+"8E_R^Q
MK,#(BMT*A4P77#Y7'TFYM/"KQ(RQV78P;UY6G).V^)G4=HY]F^D(2U,)<[O$
M8-%::D8]98H/<DP8GQS%&Y\\,G68"XRTWI\O.J[^HJ8Q_ER\(6WS8RY/P/Q[
M`N;J!,S;$S#O3L#\1V(&.)S@#24K<?!W9#],@P'(398)O#R0$**3LKV\XK26
M!L*(6FEPPUHH2./-"9`!>M9%/*B&;A6]*CYXOF]WI&D]2#U7L/ONY[3;T/V]
M!_D&J<:>*D4[(/3J>2U/('0`R%;3.46J(2'3#<?A8YEX.>2V;*X$<T-"_".1
M=L:/H;/IQ]`-RH^A&Y0?0S<H/X9N4'X,W:#\\V,HUKZ90\?:?P.A]9!7D*[A
MD-3QSS;:M+\O(YV&YAYSK*;WQ/CK47$GU(/]7BST1[R*/[Z:^HM1LN$&,GQ/
M/.X?%J)/^&`RLCZDK:?L4>;I1OW&^]$^9./SR[/QFS$^WX[6HG#?V_$Z&/\!
M``#__P,`4$L#!!0`!@`(````(0#Z!9,6,P$``$`"```1``@!9&]C4')O<',O
M8V]R92YX;6P@H@0!**```0``````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``"<D5%+PS`4A=\%_T/)>YMV<T-"FX'*GAP(3A3?8G+7!9LTY$:[_7NSKJL3
M?1+R$LZY7\X]*1<[TR2?X%&WMB)%EI,$K&R5MG5%GM;+])HD&(15HFDM5&0/
M2!;\\J*4CLG6PX-O'?B@`9-(LLBDJ\@V!,<H1;D%(S"+#AO%3>N-"/'J:^J$
M?!<UT$F>SZF!()0(@AZ`J1N)9$`J.2+=AV]Z@)(4&C!@`](B*^BW-X`W^.=`
MKYPYC0Y[%W<:XIZSE3R*HWN'>C1V79=UTSY&S%_0E]7]8[]JJNVA*PF$'_II
M!(95K'*C0=WL^>[--PGBMJ2_M5+)/AV3'D0`E<3WV#'=27F>WMZMEX1/\F*6
MYM-XUI."S:Y8/G\MZ<DUS/,1:(8`_R:>`+S/_?//^1<```#__P,`4$L!`BT`
M%``&``@````A`-G#GVM#`@``K24``!,``````````````````````%M#;VYT
M96YT7U1Y<&5S72YX;6Q02P$"+0`4``8`"````"$`M54P(_4```!,`@``"P``
M``````````````!\!```7W)E;',O+G)E;'-02P$"+0`4``8`"````"$`O=(5
M+(\"``!&)0``&@````````````````"B!P``>&PO7W)E;',O=V]R:V)O;VLN
M>&UL+G)E;'-02P$"+0`4``8`"````"$`9;=4;=P$```$$P``#P``````````
M``````!Q"P``>&PO=V]R:V)O;VLN>&UL4$L!`BT`%``&``@````A`($6^+DY
M!```\@T``!@`````````````````>A```'AL+W=O<FMS:&5E=',O<VAE970T
M+GAM;%!+`0(M`!0`!@`(````(0!/MSNA%`,``.`(```9````````````````
M`.D4``!X;"]W;W)K<VAE971S+W-H965T-#8N>&UL4$L!`BT`%``&``@````A
M`+VZX9@^!```E@\``!D`````````````````-!@``'AL+W=O<FMS:&5E=',O
M<VAE970T-RYX;6Q02P$"+0`4``8`"````"$`>P&R_-`"``!K!P``&0``````
M``````````"I'```>&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+`0(M`!0`
M!@`(````(0#$B`,B/@,``"`*```9`````````````````+`?``!X;"]W;W)K
M<VAE971S+W-H965T-#DN>&UL4$L!`BT`%``&``@````A`/[ET4UK!@``%QP`
M`!D`````````````````)2,``'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q0
M2P$"+0`4``8`"````"$`:KCTV!,%```6%```&0````````````````#'*0``
M>&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+`0(M`!0`!@`(````(0"!@O:#
M=00``(8/```9`````````````````!$O``!X;"]W;W)K<VAE971S+W-H965T
M-#4N>&UL4$L!`BT`%``&``@````A`&&&&Y\=!````0X``!D`````````````
M````O3,``'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q02P$"+0`4``8`"```
M`"$`#I=A[`<&``"R&@``&0`````````````````1.```>&PO=V]R:W-H965T
M<R]S:&5E=#0S+GAM;%!+`0(M`!0`!@`(````(0#\^$`IF1$``-UP```9````
M`````````````$\^``!X;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L!`BT`
M%``&``@````A`&H[4'G\!P``T"0``!D`````````````````'U```'AL+W=O
M<FMS:&5E=',O<VAE970S.2YX;6Q02P$"+0`4``8`"````"$`W1:YZ#D#``#-
M"0``&0````````````````!26```>&PO=V]R:W-H965T<R]S:&5E=#0P+GAM
M;%!+`0(M`!0`!@`(````(0#64)ANZP,``'4-```9`````````````````,);
M``!X;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L!`BT`%``&``@````A`/"#
MC4?^!```)Q,``!D`````````````````Y%\``'AL+W=O<FMS:&5E=',O<VAE
M970T,BYX;6Q02P$"+0`4``8`"````"$`-X#8@\$(``#9*@``&0``````````
M```````990``>&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+`0(M`!0`!@`(
M````(0#R&IL$!04``!D3```9`````````````````!%N``!X;"]W;W)K<VAE
M971S+W-H965T-3,N>&UL4$L!`BT`%``&``@````A`(H1!@FY!```C1$``!D`
M````````````````37,``'AL+W=O<FMS:&5E=',O<VAE970U-"YX;6Q02P$"
M+0`4``8`"````"$`^V*E;90&``"G&P``$P`````````````````]>```>&PO
M=&AE;64O=&AE;64Q+GAM;%!+`0(M`!0`!@`(````(0!HYLB3>`P``+QT```-
M``````````````````)_``!X;"]S='EL97,N>&UL4$L!`BT`%``&``@````A
M`(M/C0.HF@``\AX"`!0`````````````````I8L``'AL+W-H87)E9%-T<FEN
M9W,N>&UL4$L!`BT`%``&``@````A`!XCP'&7`@``LP8``!@`````````````
M````?R8!`'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+`0(M`!0`!@`(````
M(0!#!%0I/@4``(\4```8`````````````````$PI`0!X;"]W;W)K<VAE971S
M+W-H965T,BYX;6Q02P$"+0`4``8`"````"$`GN'+>U0$```)$```&0``````
M``````````#`+@$`>&PO=V]R:W-H965T<R]S:&5E=#8R+GAM;%!+`0(M`!0`
M!@`(````(0!94"?)K00``'81```9`````````````````$LS`0!X;"]W;W)K
M<VAE971S+W-H965T-C$N>&UL4$L!`BT`%``&``@````A`!H-L^@D`P``^@@`
M`!D`````````````````+S@!`'AL+W=O<FMS:&5E=',O<VAE970V,"YX;6Q0
M2P$"+0`4``8`"````"$`DM?`C)P$```A$0``&0````````````````"*.P$`
M>&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+`0(M`!0`!@`(````(0`#3A9F
M;0,``$H*```9`````````````````%U``0!X;"]W;W)K<VAE971S+W-H965T
M-38N>&UL4$L!`BT`%``&``@````A`,LU=$MD!```61```!D`````````````
M`````40!`'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6Q02P$"+0`4``8`"```
M`"$`__?H)N,"``#Q!P``&0````````````````"<2`$`>&PO=V]R:W-H965T
M<R]S:&5E=#4X+GAM;%!+`0(M`!0`!@`(````(0`M-<GKK`,``,4+```9````
M`````````````+9+`0!X;"]W;W)K<VAE971S+W-H965T-3DN>&UL4$L!`BT`
M%``&``@````A`.'Q*"-<!```8`\``!@`````````````````F4\!`'AL+W=O
M<FMS:&5E=',O<VAE970Q+GAM;%!+`0(M`!0`!@`(````(0#B0W*VC0(``",&
M```9`````````````````"M4`0!X;"]W;W)K<VAE971S+W-H965T,S<N>&UL
M4$L!`BT`%``&``@````A`+@_3O\R!0``9Q4``!D`````````````````[U8!
M`'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"+0`4``8`"````"$`KU*T
M'SD'``"Q'@``&0````````````````!87`$`>&PO=V]R:W-H965T<R]S:&5E
M=#$S+GAM;%!+`0(M`!0`!@`(````(0">W)V82@8``*\?```9````````````
M`````,AC`0!X;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L!`BT`%``&``@`
M```A`/PN:WL[!P``^!\``!D`````````````````26H!`'AL+W=O<FMS:&5E
M=',O<VAE970Q-2YX;6Q02P$"+0`4``8`"````"$`\/I3?W$"``"7!0``&0``
M``````````````"[<0$`>&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+`0(M
M`!0`!@`(````(0":_."@?`(``/(%```9`````````````````&-T`0!X;"]W
M;W)K<VAE971S+W-H965T,3<N>&UL4$L!`BT`%``&``@````A`&6O%Y(@!```
M_0X``!D`````````````````%G<!`'AL+W=O<FMS:&5E=',O<VAE970S-BYX
M;6Q02P$"+0`4``8`"````"$`FG6&K%<5```1=@``&0````````````````!M
M>P$`>&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+`0(M`!0`!@`(````(0#:
MA\;]$Q8``#>#```9`````````````````/N0`0!X;"]W;W)K<VAE971S+W-H
M965T,3$N>&UL4$L!`BT`%``&``@````A`/4?.&=)`P``:@H``!D`````````
M````````1:<!`'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"+0`4``8`
M"````"$`>OL#EM<)``!"+P``&`````````````````#%J@$`>&PO=V]R:W-H
M965T<R]S:&5E=#4N>&UL4$L!`BT`%``&``@````A`(YDHMIX!@``#1H``!@`
M````````````````TK0!`'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+`0(M
M`!0`!@`(````(0#%[^T#;`(``+$%```8`````````````````("[`0!X;"]W
M;W)K<VAE971S+W-H965T-RYX;6Q02P$"+0`4``8`"````"$`?,*$3<TT```2
M0`$`&``````````````````BO@$`>&PO=V]R:W-H965T<R]S:&5E=#@N>&UL
M4$L!`BT`%``&``@````A`-A4DA)7!P``2Q\``!@`````````````````)?,!
M`'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+`0(M`!0`!@`(````(0#*`ZU%
M;`(``+8%```9`````````````````++Z`0!X;"]W;W)K<VAE971S+W-H965T
M,3DN>&UL4$L!`BT`%``&``@````A`'HI3:%E"0``SRT``!D`````````````
M````5?T!`'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"+0`4``8`"```
M`"$`LJ.Q&M8@``"VN@``&0````````````````#Q!@(`>&PO=V]R:W-H965T
M<R]S:&5E=#(Q+GAM;%!+`0(M`!0`!@`(````(0!(:`/79P,``.(*```9````
M`````````````/XG`@!X;"]W;W)K<VAE971S+W-H965T,S`N>&UL4$L!`BT`
M%``&``@````A`)BM\OD8!```A@X``!D`````````````````G"L"`'AL+W=O
M<FMS:&5E=',O<VAE970S,2YX;6Q02P$"+0`4``8`"````"$`6+1!_I\#``"H
M#```&0````````````````#K+P(`>&PO=V]R:W-H965T<R]S:&5E=#,R+GAM
M;%!+`0(M`!0`!@`(````(0!6:)GD20,``"H+```9`````````````````,$S
M`@!X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L!`BT`%``&``@````A`.TF
M,?7^!0``)!H``!D`````````````````03<"`'AL+W=O<FMS:&5E=',O<VAE
M970S-"YX;6Q02P$"+0`4``8`"````"$`]>K(-1\U``!`/P$`&0``````````
M``````!V/0(`>&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+`0(M`!0`!@`(
M````(0#$1.E<RP,``&<-```9`````````````````,QR`@!X;"]W;W)K<VAE
M971S+W-H965T,CDN>&UL4$L!`BT`%``&``@````A`-_!L)F'"```L"@``!D`
M````````````````SG8"`'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"
M+0`4``8`"````"$`:EH1"?T&``#Q'```&0````````````````",?P(`>&PO
M=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+`0(M`!0`!@`(````(0#X":%[6`\`
M`#M.```9`````````````````,"&`@!X;"]W;W)K<VAE971S+W-H965T,C,N
M>&UL4$L!`BT`%``&``@````A`"FJ;*IC`@``1@4``!D`````````````````
M3Y8"`'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"+0`4``8`"````"$`
M;V*'U\T$``#7$```&0````````````````#IF`(`>&PO=V]R:W-H965T<R]S
M:&5E=#(V+GAM;%!+`0(M`!0`!@`(````(0#X$68FVQ(``+UD```9````````
M`````````.V=`@!X;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L!`BT`%``&
M``@````A`,\6LD4E!@``JQ@``!D`````````````````_[`"`'AL+W=O<FMS
M:&5E=',O<VAE970R-2YX;6Q02P$"+0`4``8`"````"$`9%'/QY8```"J````
M$`````````````````!;MP(`>&PO8V%L8T-H86EN+GAM;%!+`0(M`!0`!@`(
M````(0"/C8WXM0,``/@.```0`````````````````!^X`@!D;V-0<F]P<R]A
M<'`N>&UL4$L!`BT`%``&``@````A`/H%DQ8S`0``0`(``!$`````````````
M````"KT"`&1O8U!R;W!S+V-O<F4N>&UL4$L%!@````!(`$@`H1,``'2_`@``
!````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EXEAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Collaboration and License Agreements - Additional Information 6 (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2010</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue, Current</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DeferredRevenueCurrent" onclick="toggleNextSibling(this);">$ 14,248,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredRevenueCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredRevenueCurrent" onclick="toggleNextSibling(this);">$ 20,267,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredRevenueCurrent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue, Long-term liabilities</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DeferredRevenueNoncurrent" onclick="toggleNextSibling(this);">16,472,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredRevenueNoncurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredRevenueNoncurrent" onclick="toggleNextSibling(this);">7,136,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredRevenueNoncurrent</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=mgnx_GreenCrossCorporationMember', window );">Green Cross [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CollaborationAndLicenseAgreementEnteredDate', window );">Collaboration agreement date</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">June 2010<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_UpfrontFeeAndParticipationRecognitionEndDate', window );">Term of the agreement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">2020-06<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NonRefundableUpFrontPayment', window );">Nonrefundable upfront payment</a></td>
        <td class="nump"><a title="mgnx_NonRefundableUpFrontPayment[us-gaap_CounterpartyNameAxis=mgnx_GreenCrossCorporationMember]" onclick="toggleNextSibling(this);">1,000,000</a><span style="display:none;white-space:normal;text-align:left;">mgnx_NonRefundableUpFrontPayment<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_GreenCrossCorporationMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_AdjustmentToRevenueUnderAccountingStandardsCodification', window );">Adjustment to revenue from contract material modification</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="mgnx_AdjustmentToRevenueUnderAccountingStandardsCodification[us-gaap_CounterpartyNameAxis=mgnx_GreenCrossCorporationMember]" onclick="toggleNextSibling(this);">1,300,000</a><span style="display:none;white-space:normal;text-align:left;">mgnx_AdjustmentToRevenueUnderAccountingStandardsCodification<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_GreenCrossCorporationMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicensesRevenue', window );">Recognized revenue under agreement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_LicensesRevenue[us-gaap_CounterpartyNameAxis=mgnx_GreenCrossCorporationMember]" onclick="toggleNextSibling(this);">1,700,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LicensesRevenue<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_GreenCrossCorporationMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_LicensesRevenue[us-gaap_CounterpartyNameAxis=mgnx_GreenCrossCorporationMember]" onclick="toggleNextSibling(this);">100,000.0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LicensesRevenue<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_GreenCrossCorporationMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized', window );">Milestones achieved</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized[us-gaap_CounterpartyNameAxis=mgnx_GreenCrossCorporationMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_GreenCrossCorporationMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized[us-gaap_CounterpartyNameAxis=mgnx_GreenCrossCorporationMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_GreenCrossCorporationMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DeferredRevenue[us-gaap_CounterpartyNameAxis=mgnx_GreenCrossCorporationMember]" onclick="toggleNextSibling(this);">650,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredRevenue<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_GreenCrossCorporationMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnbilledContractsReceivable', window );">Unbilled receivable balance</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_UnbilledContractsReceivable[us-gaap_CounterpartyNameAxis=mgnx_GreenCrossCorporationMember]" onclick="toggleNextSibling(this);">525,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_UnbilledContractsReceivable<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_GreenCrossCorporationMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue, Current</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DeferredRevenueCurrent[us-gaap_CounterpartyNameAxis=mgnx_GreenCrossCorporationMember]" onclick="toggleNextSibling(this);">100,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredRevenueCurrent<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_GreenCrossCorporationMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue, Long-term liabilities</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DeferredRevenueNoncurrent[us-gaap_CounterpartyNameAxis=mgnx_GreenCrossCorporationMember]" onclick="toggleNextSibling(this);">550,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredRevenueNoncurrent<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_GreenCrossCorporationMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=mgnx_GreenCrossCorporationMember', window );">Green Cross [Member] | Maximum [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_AggregatePotentialFutureCostReimbursement', window );">Aggregate potential future cost reimbursement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="mgnx_AggregatePotentialFutureCostReimbursement[us-gaap_CounterpartyNameAxis=mgnx_GreenCrossCorporationMember;us-gaap_RangeAxis=us-gaap_MaximumMember]" onclick="toggleNextSibling(this);">5,500,000</a><span style="display:none;white-space:normal;text-align:left;">mgnx_AggregatePotentialFutureCostReimbursement<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_GreenCrossCorporationMember<br>/ us-gaap_RangeAxis<br>= us-gaap_MaximumMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_AdditionalPotentialClinicalAndCommercialMilestonePaymentsUnderAgreement', window );">Clinical and commercial milestone payments</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="mgnx_AdditionalPotentialClinicalAndCommercialMilestonePaymentsUnderAgreement[us-gaap_CounterpartyNameAxis=mgnx_GreenCrossCorporationMember;us-gaap_RangeAxis=us-gaap_MaximumMember]" onclick="toggleNextSibling(this);">$ 2,500,000</a><span style="display:none;white-space:normal;text-align:left;">mgnx_AdditionalPotentialClinicalAndCommercialMilestonePaymentsUnderAgreement<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_GreenCrossCorporationMember<br>/ us-gaap_RangeAxis<br>= us-gaap_MaximumMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_AdditionalPotentialClinicalAndCommercialMilestonePaymentsUnderAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate potential clinical and commercial milestone payments available to be earned under collaboration agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_AdditionalPotentialClinicalAndCommercialMilestonePaymentsUnderAgreement</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_AdjustmentToRevenueUnderAccountingStandardsCodification">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Adjustment To Revenue Under Accounting Standards Codification</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_AdjustmentToRevenueUnderAccountingStandardsCodification</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_AggregatePotentialFutureCostReimbursement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate Potential Future Cost Reimbursement</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_AggregatePotentialFutureCostReimbursement</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborationAndLicenseAgreementEnteredDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Collaboration and license agreement entered date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_CollaborationAndLicenseAgreementEnteredDate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>us-types:dateStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_LicenseAndCollaborationAgreementsLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_LicenseAndCollaborationAgreementsLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonRefundableUpFrontPayment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Non-refundable up front payment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_NonRefundableUpFrontPayment</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_UpfrontFeeAndParticipationRecognitionEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Upfront fee and participation recognition end date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_UpfrontFeeAndParticipationRecognitionEndDate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearMonthItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 13<br><br> -Section A<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 8<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 13<br><br> -Section A<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 8<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 13<br><br> -Section A<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LicensesRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LicensesRevenue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of consideration recognized during the period for the milestone or milestones.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 28<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=19771982&amp;loc=SL6892177-166501<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnbilledContractsReceivable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Unbilled amounts due for services rendered or to be rendered, actions taken or to be taken, or a promise to refrain from taking certain actions in accordance with the terms of a legally binding agreement between the entity and, at a minimum, one other party. An example would be amounts associated with contracts or programs where the recognized revenue for performance thereunder exceeds the amounts billed under the terms thereof as of the date of the balance sheet.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.3(c)(3))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 3<br><br> -Subparagraph c(3)<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 912<br><br> -SubTopic 310<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6471842&amp;loc=d3e55302-109406<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_UnbilledContractsReceivable</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=mgnx_GreenCrossCorporationMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=mgnx_GreenCrossCorporationMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E2LAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Income Taxes - Reconciliation of the Beginning and Ending Amount of Gross Unrecognized Tax Benefits (Detail) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Beginning balance</a></td>
        <td class="nump"><a title="us-gaap_UnrecognizedTaxBenefits" onclick="toggleNextSibling(this);">$ 1,708</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_UnrecognizedTaxBenefits</span><span></span></td>
        <td class="nump"><a title="us-gaap_UnrecognizedTaxBenefits" onclick="toggleNextSibling(this);">$ 1,592</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_UnrecognizedTaxBenefits</span><span></span></td>
        <td class="nump"><a title="us-gaap_UnrecognizedTaxBenefits" onclick="toggleNextSibling(this);">$ 1,534</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_UnrecognizedTaxBenefits</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increases/(decreases) for current year tax positions</a></td>
        <td class="nump"><a title="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" onclick="toggleNextSibling(this);">242</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</span><span></span></td>
        <td class="nump"><a title="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" onclick="toggleNextSibling(this);">116</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</span><span></span></td>
        <td class="nump"><a title="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" onclick="toggleNextSibling(this);">58</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Increases/(decreases) for prior year tax positions</a></td>
        <td class="nump"><a title="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" onclick="toggleNextSibling(this);">97</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations', window );">Decreases as a result of expiration of statute of limitations</a></td>
        <td class="nump"><a title="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations</span><span></span></td>
        <td class="nump"><a title="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations</span><span></span></td>
        <td class="nump"><a title="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Ending balance</a></td>
        <td class="nump"><a title="us-gaap_UnrecognizedTaxBenefits" onclick="toggleNextSibling(this);">$ 2,047</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_UnrecognizedTaxBenefits</span><span></span></td>
        <td class="nump"><a title="us-gaap_UnrecognizedTaxBenefits" onclick="toggleNextSibling(this);">$ 1,708</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_UnrecognizedTaxBenefits</span><span></span></td>
        <td class="nump"><a title="us-gaap_UnrecognizedTaxBenefits" onclick="toggleNextSibling(this);">$ 1,592</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_UnrecognizedTaxBenefits</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of unrecognized tax benefits pertaining to uncertain tax positions taken in tax returns.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Unrecognized Tax Benefit<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6527854<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15A<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=SL6600010-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15A<br><br> -Subparagraph (a)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=SL6600010-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15A<br><br> -Subparagraph (a)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=SL6600010-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15A<br><br> -Subparagraph (a)(4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=SL6600010-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EVGAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Estimated Useful Lives (Detail)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Lives</a></td>
        <td class="text">3 years<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Software [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Lives</a></td>
        <td class="text">3 years<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Lives</a></td>
        <td class="text">10 years<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mgnx_LaboratoryAndOfficeEquipmentMember', window );">Laboratory and Office Equipment [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Lives</a></td>
        <td class="text">5 years<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Leasehold improvements</a></td>
        <td class="text">Shorter of lease term or useful life<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 35<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6539997&amp;loc=d3e1205-110223<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mgnx_LaboratoryAndOfficeEquipmentMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=mgnx_LaboratoryAndOfficeEquipmentMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	word-wrap: break-word;
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E3FAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Detail) (USD $)<br>In Millions, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DescriptionOfLesseeLeasingArrangementsOperatingLeases', window );">Lease agreement description</a></td>
        <td class="text">During 2014, the Company exercised its 5-year renewal option on the manufacturing facility. The Company also entered into a new four-year lease for additional space in the manufacturing facility effective April 1, 2014. This lease also has an option to continue the lease for five years under the same terms.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCredit', window );">Deferred rent liability</a></td>
        <td class="nump"><a title="us-gaap_DeferredRentCredit" onclick="toggleNextSibling(this);">$ 2.7</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredRentCredit</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredRentCredit" onclick="toggleNextSibling(this);">$ 2.9</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredRentCredit</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseNet', window );">Rent expense</a></td>
        <td class="nump"><a title="us-gaap_OperatingLeasesRentExpenseNet" onclick="toggleNextSibling(this);">$ 2.0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingLeasesRentExpenseNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_OperatingLeasesRentExpenseNet" onclick="toggleNextSibling(this);">$ 2.7</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingLeasesRentExpenseNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_OperatingLeasesRentExpenseNet" onclick="toggleNextSibling(this);">$ 2.7</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingLeasesRentExpenseNet</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=mgnx_OfficeAndLaboratorySpaceMember', window );">Office and Laboratory Space [Member] | Rockville, Maryland [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiration date</a></td>
        <td class="text">Mar. 31,  2018<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_AmendedLeaseExpirationDate', window );">Amended lease expiration date</a></td>
        <td class="text">Jan. 31,  2020<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=mgnx_OfficeAndLaboratorySpaceMember', window );">Office and Laboratory Space [Member] | South San Francisco [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiration date</a></td>
        <td class="text">Feb. 28,  2018<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=mgnx_ManufacturingSpaceMember', window );">Manufacturing Space [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiration date</a></td>
        <td class="text">Dec. 31,  2014<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm', window );">Lessee leasing arrangements, operating leases, renewal term</a></td>
        <td class="text">5 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=mgnx_AdditionalManufacturingSpaceMember', window );">Additional Manufacturing Space [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract', window );">Term of additional space lease</a></td>
        <td class="text">4 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_LeaseAgreementInitiationDate', window );">Origination date for additional space in manufacturing facility</a></td>
        <td class="text">Apr.  01,  2014<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_AmendedLeaseExpirationDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amended Lease Expiration Date</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_AmendedLeaseExpirationDate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_LeaseAgreementInitiationDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Lease Agreement Initiation Date</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_LeaseAgreementInitiationDate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCredit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cumulative difference between the rental payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense over the term of the leased property by the lessor or lessee, respectively.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 25<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7501430&amp;loc=d3e39896-112707<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredRentCredit</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DescriptionOfLesseeLeasingArrangementsOperatingLeases">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A general description of the nature of the existing leasing arrangements of a lessee for all operating leases including, but not limited to: (1) rental escalation clauses; (2) renewal or purchase options; (3) guarantees or indemnities, if any, (4)  restrictions imposed by lease arrangements; (5) unusual provisions or conditions; (6) contingent rentals, if any; and (7) lease expiration dates.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6452660&amp;loc=d3e36991-112694<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DescriptionOfLesseeLeasingArrangementsOperatingLeases</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Date which lease or group of leases is set to expire, in CCYY-MM-DD format.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Term of the lessee's leasing arrangement renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Term of the lessee's leasing arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasedAssetsLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingLeasedAssetsLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41499-112717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=mgnx_AdditionalManufacturingSpaceMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=mgnx_AdditionalManufacturingSpaceMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=mgnx_ManufacturingSpaceMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=mgnx_ManufacturingSpaceMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=mgnx_OfficeAndLaboratorySpaceMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=mgnx_OfficeAndLaboratorySpaceMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E2F">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Lease Exit Liability (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock', window );">Changes in Lease Exit Liability</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Changes in the lease exit liability are as follows (in
 thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0">
 <tr>
 <td width="84%"></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Accrual balance at December&#xA0;31, 2012.</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">&#xA0;10,074</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Principal payments</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(629</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Accrual balance at December&#xA0;31, 2013</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">9,445</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Principal payments</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(1,439</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Accrual balance at December&#xA0;31, 2014</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">8,006</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Future Principal Payments Under Lease Agreement</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Future principal payments to be made under the lease agreement as
 of December&#xA0;31, 2014 are as follows (in thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0">
 <tr>
 <td width="86%"></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 2015</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,642</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 2016</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,866</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 2017</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,113</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 2018</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,385</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top"></td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">8,006</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 420<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 420<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ER4BG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Collaboration and License Agreements - Additional Information 1 (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="2">12 Months Ended</th>
        <th class="th" colspan="1">1 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Feb. 28, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>May 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock issued during period value, new issues</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueNewIssues" onclick="toggleNextSibling(this);">$ 76,716,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueNewIssues</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueNewIssues" onclick="toggleNextSibling(this);">$ 83,623,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueNewIssues</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during the period for new issue</a></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesNewIssues" onclick="toggleNextSibling(this);">1,800,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue current</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DeferredRevenueCurrent" onclick="toggleNextSibling(this);">14,248,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredRevenueCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredRevenueCurrent" onclick="toggleNextSibling(this);">20,267,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredRevenueCurrent</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue non-current</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DeferredRevenueNoncurrent" onclick="toggleNextSibling(this);">16,472,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredRevenueNoncurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredRevenueNoncurrent" onclick="toggleNextSibling(this);">7,136,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredRevenueNoncurrent</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=mgnx_JanssenBiotechIncMember', window );">Janssen Biotech Inc. [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CollaborationAndLicenseAgreementEnteredDate', window );">Collaboration agreement date</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">December 2014<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock issued during period value, new issues</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueNewIssues[us-gaap_CounterpartyNameAxis=mgnx_JanssenBiotechIncMember]" onclick="toggleNextSibling(this);">75,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueNewIssues<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_JanssenBiotechIncMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during the period for new issue</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesNewIssues[us-gaap_CounterpartyNameAxis=mgnx_JanssenBiotechIncMember]" onclick="toggleNextSibling(this);">1,923,077</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesNewIssues<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_JanssenBiotechIncMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Common stock price per share</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_SaleOfStockPricePerShare[us-gaap_CounterpartyNameAxis=mgnx_JanssenBiotechIncMember]" onclick="toggleNextSibling(this);">$ 39.00</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SaleOfStockPricePerShare<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_JanssenBiotechIncMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NonRefundableUpfrontPaymentReceivable', window );">Nonrefundable upfront payment receivable</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="mgnx_NonRefundableUpfrontPaymentReceivable[us-gaap_CounterpartyNameAxis=mgnx_JanssenBiotechIncMember]" onclick="toggleNextSibling(this);">50,000,000</a><span style="display:none;white-space:normal;text-align:left;">mgnx_NonRefundableUpfrontPaymentReceivable<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_JanssenBiotechIncMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_AdditionalPotentialClinicalRegulatoryCommercializationPaymentsUnderAgreement', window );">Clinical, regulatory and commercialization milestone payments</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="mgnx_AdditionalPotentialClinicalRegulatoryCommercializationPaymentsUnderAgreement[us-gaap_CounterpartyNameAxis=mgnx_JanssenBiotechIncMember]" onclick="toggleNextSibling(this);">575,000,000</a><span style="display:none;white-space:normal;text-align:left;">mgnx_AdditionalPotentialClinicalRegulatoryCommercializationPaymentsUnderAgreement<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_JanssenBiotechIncMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicensesRevenue', window );">Recognized revenue under agreement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_LicensesRevenue[us-gaap_CounterpartyNameAxis=mgnx_JanssenBiotechIncMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LicensesRevenue<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_JanssenBiotechIncMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DeferredRevenue[us-gaap_CounterpartyNameAxis=mgnx_JanssenBiotechIncMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredRevenue<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_JanssenBiotechIncMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=mgnx_TakedaMember', window );">Takeda [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CollaborationAndLicenseAgreementEnteredDate', window );">Collaboration agreement date</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">May 2014<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicensesRevenue', window );">Recognized revenue under agreement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_LicensesRevenue[us-gaap_CounterpartyNameAxis=mgnx_TakedaMember]" onclick="toggleNextSibling(this);">3,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LicensesRevenue<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_TakedaMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DeferredRevenue[us-gaap_CounterpartyNameAxis=mgnx_TakedaMember]" onclick="toggleNextSibling(this);">7,100,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredRevenue<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_TakedaMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NonRefundableUpFrontPayment', window );">Nonrefundable upfront payment</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="mgnx_NonRefundableUpFrontPayment[us-gaap_CounterpartyNameAxis=mgnx_TakedaMember]" onclick="toggleNextSibling(this);">15,000,000</a><span style="display:none;white-space:normal;text-align:left;">mgnx_NonRefundableUpFrontPayment<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_TakedaMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialLicenseOptionFeeAndEarlyDevelopmentMilestoneFee', window );">License option fee and early development milestone</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="mgnx_PotentialLicenseOptionFeeAndEarlyDevelopmentMilestoneFee[us-gaap_CounterpartyNameAxis=mgnx_TakedaMember]" onclick="toggleNextSibling(this);">18,000,000</a><span style="display:none;white-space:normal;text-align:left;">mgnx_PotentialLicenseOptionFeeAndEarlyDevelopmentMilestoneFee<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_TakedaMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_AdditionalPotentialDevelopmentRegulatoryAndSalesMilestoneUnderAgreement', window );">Development, regulatory and sales milestone payments</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="mgnx_AdditionalPotentialDevelopmentRegulatoryAndSalesMilestoneUnderAgreement[us-gaap_CounterpartyNameAxis=mgnx_TakedaMember]" onclick="toggleNextSibling(this);">468,500,000</a><span style="display:none;white-space:normal;text-align:left;">mgnx_AdditionalPotentialDevelopmentRegulatoryAndSalesMilestoneUnderAgreement<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_TakedaMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_UpfrontFeeAllocatedToAgreement', window );">Amount allocated to agreement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="mgnx_UpfrontFeeAllocatedToAgreement[us-gaap_CounterpartyNameAxis=mgnx_TakedaMember]" onclick="toggleNextSibling(this);">10,000,000</a><span style="display:none;white-space:normal;text-align:left;">mgnx_UpfrontFeeAllocatedToAgreement<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_TakedaMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_UpfrontPaymentRecognitionPeriod', window );">Expected period of development</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">24 months<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue current</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DeferredRevenueCurrent[us-gaap_CounterpartyNameAxis=mgnx_TakedaMember]" onclick="toggleNextSibling(this);">5,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredRevenueCurrent<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_TakedaMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue non-current</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DeferredRevenueNoncurrent[us-gaap_CounterpartyNameAxis=mgnx_TakedaMember]" onclick="toggleNextSibling(this);">2,100,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredRevenueNoncurrent<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_TakedaMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=mgnx_TakedaMember', window );">Takeda [Member] | Research Collaboration And License Option Agreement [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CollaborationAndLicenseAgreementEnteredDate', window );">Collaboration agreement date</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">September 2014<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicensesRevenue', window );">Recognized revenue under agreement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_LicensesRevenue[us-gaap_CounterpartyNameAxis=mgnx_TakedaMember;us-gaap_TypeOfArrangementAxis=mgnx_ResearchCollaborationAndLicenseOptionAgreementMember]" onclick="toggleNextSibling(this);">5,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LicensesRevenue<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_TakedaMember<br>/ us-gaap_TypeOfArrangementAxis<br>= mgnx_ResearchCollaborationAndLicenseOptionAgreementMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_UpfrontFeeAllocatedToAgreement', window );">Amount allocated to agreement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="mgnx_UpfrontFeeAllocatedToAgreement[us-gaap_CounterpartyNameAxis=mgnx_TakedaMember;us-gaap_TypeOfArrangementAxis=mgnx_ResearchCollaborationAndLicenseOptionAgreementMember]" onclick="toggleNextSibling(this);">$ 5,000,000</a><span style="display:none;white-space:normal;text-align:left;">mgnx_UpfrontFeeAllocatedToAgreement<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_TakedaMember<br>/ us-gaap_TypeOfArrangementAxis<br>= mgnx_ResearchCollaborationAndLicenseOptionAgreementMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_AdditionalPotentialClinicalRegulatoryCommercializationPaymentsUnderAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Additional potential clinical regulatory commercialization payments under agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_AdditionalPotentialClinicalRegulatoryCommercializationPaymentsUnderAgreement</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_AdditionalPotentialDevelopmentRegulatoryAndSalesMilestoneUnderAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate potential development regulatory and sales milestone payments available to be earned under agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_AdditionalPotentialDevelopmentRegulatoryAndSalesMilestoneUnderAgreement</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborationAndLicenseAgreementEnteredDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Collaboration and license agreement entered date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_CollaborationAndLicenseAgreementEnteredDate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>us-types:dateStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_LicenseAndCollaborationAgreementsLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_LicenseAndCollaborationAgreementsLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonRefundableUpFrontPayment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Non-refundable up front payment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_NonRefundableUpFrontPayment</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonRefundableUpfrontPaymentReceivable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Initial fee receivable from collaboration or license agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_NonRefundableUpfrontPaymentReceivable</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialLicenseOptionFeeAndEarlyDevelopmentMilestoneFee">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Potential license option fee and early development milestone fee.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_PotentialLicenseOptionFeeAndEarlyDevelopmentMilestoneFee</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_UpfrontFeeAllocatedToAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Portion of upfront fee allocated to agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_UpfrontFeeAllocatedToAgreement</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_UpfrontPaymentRecognitionPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Period over which upfront payment is to be recognized.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_UpfrontPaymentRecognitionPeriod</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 13<br><br> -Section A<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 8<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 13<br><br> -Section A<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 8<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 13<br><br> -Section A<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LicensesRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LicensesRevenue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of new stock issued during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=mgnx_JanssenBiotechIncMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=mgnx_JanssenBiotechIncMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=mgnx_TakedaMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=mgnx_TakedaMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EGDAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock- based Compensation - Schedule of Stock Option and Restricted Stock Unit Activity (Detail) (USD $)<br>In Thousands, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares, Outstanding, Beginning Balance</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" onclick="toggleNextSibling(this);">3,200,958</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Shares, Granted</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" onclick="toggleNextSibling(this);">976,869</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares, Exercised</a></td>
        <td class="num"><a title="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" onclick="toggleNextSibling(this);">(568,906)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</span><span></span></td>
        <td class="num"><a title="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" onclick="toggleNextSibling(this);">(1,268,049)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</span><span></span></td>
        <td class="num"><a title="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" onclick="toggleNextSibling(this);">(863,176)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Shares, Forfeited or expired</a></td>
        <td class="num"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" onclick="toggleNextSibling(this);">(36,805)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares, Outstanding, Ending Balance</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" onclick="toggleNextSibling(this);">3,572,116</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" onclick="toggleNextSibling(this);">3,200,958</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Shares, Exercisable</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" onclick="toggleNextSibling(this);">1,668,962</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Shares, Vested and expected to vest</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" onclick="toggleNextSibling(this);">3,341,192</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Outstanding, Beginning Balance</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" onclick="toggleNextSibling(this);">$ 4.90</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Granted</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" onclick="toggleNextSibling(this);">$ 27.06</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Exercised</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" onclick="toggleNextSibling(this);">$ 1.31</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Forfeited or expired</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" onclick="toggleNextSibling(this);">$ 9.76</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Outstanding, Ending Balance</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" onclick="toggleNextSibling(this);">$ 11.40</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" onclick="toggleNextSibling(this);">$ 4.90</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Exercisable</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" onclick="toggleNextSibling(this);">$ 3.24</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Vested and expected to vest</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" onclick="toggleNextSibling(this);">$ 11.03</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-Average Remaining Contractual Term, Outstanding</a></td>
        <td class="text">7 years 3 months 18 days<span></span></td>
        <td class="text">6 years 10 months 24 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-Average Remaining Contractual Term, Exercisable</a></td>
        <td class="text">5 years 3 months 18 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted-Average Remaining Contractual Term, Vested and expected to vest</a></td>
        <td class="text">7 years 2 months 12 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding, Ending Balance</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" onclick="toggleNextSibling(this);">$ 84,515</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable</a></td>
        <td class="nump"><a title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" onclick="toggleNextSibling(this);">53,122</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Vested and expected to vest</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" onclick="toggleNextSibling(this);">$ 80,323</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Net number of share options (or share units) granted during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of options outstanding, including both vested and non-vested options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)-(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount by which the current fair value of the underlying stock exceeds the exercise price of fully vested and expected to vest options outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>As of the balance sheet date, the number of shares into which fully vested and expected to vest stock options outstanding can be converted under the option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>As of the balance sheet date, the weighted-average exercise price for outstanding stock options that are fully vested or expected to vest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of share options (or share units) exercised during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EXBAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Property and Equipment - Additional Information (Detail) (USD $)<br>In Millions, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
        <td class="nump"><a title="us-gaap_DepreciationDepletionAndAmortization" onclick="toggleNextSibling(this);">$ 1.8</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DepreciationDepletionAndAmortization</span><span></span></td>
        <td class="nump"><a title="us-gaap_DepreciationDepletionAndAmortization" onclick="toggleNextSibling(this);">$ 1.2</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DepreciationDepletionAndAmortization</span><span></span></td>
        <td class="nump"><a title="us-gaap_DepreciationDepletionAndAmortization" onclick="toggleNextSibling(this);">$ 1.0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DepreciationDepletionAndAmortization</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EANCI">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Collaboration and License Agreements - Additional Information 3 (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="2">12 Months Ended</th>
        <th class="th" colspan="1">1 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Nov. 30, 2011</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue, Current</a></td>
        <td class="nump"><a title="us-gaap_DeferredRevenueCurrent" onclick="toggleNextSibling(this);">$ 14,248,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredRevenueCurrent</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DeferredRevenueCurrent" onclick="toggleNextSibling(this);">$ 20,267,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredRevenueCurrent</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ChangeInAccountingEstimateCurrentYearImpact', window );">Change in accounting estimate, current year impact</a></td>
        <td class="nump"><a title="mgnx_ChangeInAccountingEstimateCurrentYearImpact" onclick="toggleNextSibling(this);">3,700,000</a><span style="display:none;white-space:normal;text-align:left;">mgnx_ChangeInAccountingEstimateCurrentYearImpact</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue, Long-term liabilities</a></td>
        <td class="nump"><a title="us-gaap_DeferredRevenueNoncurrent" onclick="toggleNextSibling(this);">16,472,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredRevenueNoncurrent</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DeferredRevenueNoncurrent" onclick="toggleNextSibling(this);">7,136,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredRevenueNoncurrent</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=mgnx_ServierMember', window );">Servier [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CollaborationAndLicenseAgreementEnteredDate', window );">Collaboration agreement date</a></td>
        <td class="text">November 2011<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NonRefundableUpFrontPayment', window );">Nonrefundable upfront payment</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="mgnx_NonRefundableUpFrontPayment[us-gaap_CounterpartyNameAxis=mgnx_ServierMember]" onclick="toggleNextSibling(this);">20,000,000</a><span style="display:none;white-space:normal;text-align:left;">mgnx_NonRefundableUpFrontPayment<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_ServierMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_UpfrontPaymentRecognitionPeriod', window );">Expected period of development</a></td>
        <td class="text">27 months<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicensesRevenue', window );">Recognized revenue under agreement</a></td>
        <td class="nump"><a title="us-gaap_LicensesRevenue[us-gaap_CounterpartyNameAxis=mgnx_ServierMember]" onclick="toggleNextSibling(this);">700,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LicensesRevenue<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_ServierMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_LicensesRevenue[us-gaap_CounterpartyNameAxis=mgnx_ServierMember]" onclick="toggleNextSibling(this);">21,300,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LicensesRevenue<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_ServierMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_LicensesRevenue[us-gaap_CounterpartyNameAxis=mgnx_ServierMember]" onclick="toggleNextSibling(this);">9,100,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LicensesRevenue<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_ServierMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized', window );">Milestone payment</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized[us-gaap_CounterpartyNameAxis=mgnx_ServierMember]" onclick="toggleNextSibling(this);">10,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_ServierMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue, Current</a></td>
        <td class="nump"><a title="us-gaap_DeferredRevenueCurrent[us-gaap_CounterpartyNameAxis=mgnx_ServierMember]" onclick="toggleNextSibling(this);">100,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredRevenueCurrent<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_ServierMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DeferredRevenueCurrent[us-gaap_CounterpartyNameAxis=mgnx_ServierMember]" onclick="toggleNextSibling(this);">900,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredRevenueCurrent<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_ServierMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=mgnx_ServierMember', window );">Servier [Member] | Second Right to Develop Collaboration [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CollaborationAndLicenseAgreementEnteredDate', window );">Collaboration agreement date</a></td>
        <td class="text">September 2012<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NonRefundableUpFrontPayment', window );">Nonrefundable upfront payment</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="mgnx_NonRefundableUpFrontPayment[us-gaap_CounterpartyNameAxis=mgnx_ServierMember;us-gaap_TypeOfArrangementAxis=mgnx_SecondRightToDevelopCollaborationMember]" onclick="toggleNextSibling(this);">20,000,000</a><span style="display:none;white-space:normal;text-align:left;">mgnx_NonRefundableUpFrontPayment<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_ServierMember<br>/ us-gaap_TypeOfArrangementAxis<br>= mgnx_SecondRightToDevelopCollaborationMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_UpfrontPaymentRecognitionPeriod', window );">Expected period of development</a></td>
        <td class="text">29 months<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicensesRevenue', window );">Recognized revenue under agreement</a></td>
        <td class="nump"><a title="us-gaap_LicensesRevenue[us-gaap_CounterpartyNameAxis=mgnx_ServierMember;us-gaap_TypeOfArrangementAxis=mgnx_SecondRightToDevelopCollaborationMember]" onclick="toggleNextSibling(this);">16,700,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LicensesRevenue<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_ServierMember<br>/ us-gaap_TypeOfArrangementAxis<br>= mgnx_SecondRightToDevelopCollaborationMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_LicensesRevenue[us-gaap_CounterpartyNameAxis=mgnx_ServierMember;us-gaap_TypeOfArrangementAxis=mgnx_SecondRightToDevelopCollaborationMember]" onclick="toggleNextSibling(this);">8,600,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LicensesRevenue<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_ServierMember<br>/ us-gaap_TypeOfArrangementAxis<br>= mgnx_SecondRightToDevelopCollaborationMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_LicensesRevenue[us-gaap_CounterpartyNameAxis=mgnx_ServierMember;us-gaap_TypeOfArrangementAxis=mgnx_SecondRightToDevelopCollaborationMember]" onclick="toggleNextSibling(this);">2,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LicensesRevenue<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_ServierMember<br>/ us-gaap_TypeOfArrangementAxis<br>= mgnx_SecondRightToDevelopCollaborationMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized', window );">Milestone payment</a></td>
        <td class="nump"><a title="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized[us-gaap_CounterpartyNameAxis=mgnx_ServierMember;us-gaap_TypeOfArrangementAxis=mgnx_SecondRightToDevelopCollaborationMember]" onclick="toggleNextSibling(this);">5,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_ServierMember<br>/ us-gaap_TypeOfArrangementAxis<br>= mgnx_SecondRightToDevelopCollaborationMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized[us-gaap_CounterpartyNameAxis=mgnx_ServierMember;us-gaap_TypeOfArrangementAxis=mgnx_SecondRightToDevelopCollaborationMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_ServierMember<br>/ us-gaap_TypeOfArrangementAxis<br>= mgnx_SecondRightToDevelopCollaborationMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized[us-gaap_CounterpartyNameAxis=mgnx_ServierMember;us-gaap_TypeOfArrangementAxis=mgnx_SecondRightToDevelopCollaborationMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_ServierMember<br>/ us-gaap_TypeOfArrangementAxis<br>= mgnx_SecondRightToDevelopCollaborationMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue, Current</a></td>
        <td class="nump"><a title="us-gaap_DeferredRevenueCurrent[us-gaap_CounterpartyNameAxis=mgnx_ServierMember;us-gaap_TypeOfArrangementAxis=mgnx_SecondRightToDevelopCollaborationMember]" onclick="toggleNextSibling(this);">3,300,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredRevenueCurrent<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_ServierMember<br>/ us-gaap_TypeOfArrangementAxis<br>= mgnx_SecondRightToDevelopCollaborationMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DeferredRevenueCurrent[us-gaap_CounterpartyNameAxis=mgnx_ServierMember;us-gaap_TypeOfArrangementAxis=mgnx_SecondRightToDevelopCollaborationMember]" onclick="toggleNextSibling(this);">8,600,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredRevenueCurrent<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_ServierMember<br>/ us-gaap_TypeOfArrangementAxis<br>= mgnx_SecondRightToDevelopCollaborationMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_OptionExerciseFee', window );">Option exercise fee</a></td>
        <td class="nump"><a title="mgnx_OptionExerciseFee[us-gaap_CounterpartyNameAxis=mgnx_ServierMember;us-gaap_TypeOfArrangementAxis=mgnx_SecondRightToDevelopCollaborationMember]" onclick="toggleNextSibling(this);">15,000,000</a><span style="display:none;white-space:normal;text-align:left;">mgnx_OptionExerciseFee<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_ServierMember<br>/ us-gaap_TypeOfArrangementAxis<br>= mgnx_SecondRightToDevelopCollaborationMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts', window );">Offset to research and development costs under collaboration arrangement</a></td>
        <td class="nump"><a title="mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts[us-gaap_CounterpartyNameAxis=mgnx_ServierMember;us-gaap_TypeOfArrangementAxis=mgnx_SecondRightToDevelopCollaborationMember]" onclick="toggleNextSibling(this);">1,000,000</a><span style="display:none;white-space:normal;text-align:left;">mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_ServierMember<br>/ us-gaap_TypeOfArrangementAxis<br>= mgnx_SecondRightToDevelopCollaborationMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts[us-gaap_CounterpartyNameAxis=mgnx_ServierMember;us-gaap_TypeOfArrangementAxis=mgnx_SecondRightToDevelopCollaborationMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_ServierMember<br>/ us-gaap_TypeOfArrangementAxis<br>= mgnx_SecondRightToDevelopCollaborationMember</span><span></span></td>
        <td class="nump"><a title="mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts[us-gaap_CounterpartyNameAxis=mgnx_ServierMember;us-gaap_TypeOfArrangementAxis=mgnx_SecondRightToDevelopCollaborationMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_ServierMember<br>/ us-gaap_TypeOfArrangementAxis<br>= mgnx_SecondRightToDevelopCollaborationMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_OptionExerciseFeeRecognitionPeriod', window );">Option exercise fee recognition period</a></td>
        <td class="text">82 months<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CollaborationAgreementConsiderationReceivable', window );">Collaboration receivable, included in accounts receivable</a></td>
        <td class="nump"><a title="mgnx_CollaborationAgreementConsiderationReceivable[us-gaap_CounterpartyNameAxis=mgnx_ServierMember;us-gaap_TypeOfArrangementAxis=mgnx_SecondRightToDevelopCollaborationMember]" onclick="toggleNextSibling(this);">800,000</a><span style="display:none;white-space:normal;text-align:left;">mgnx_CollaborationAgreementConsiderationReceivable<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_ServierMember<br>/ us-gaap_TypeOfArrangementAxis<br>= mgnx_SecondRightToDevelopCollaborationMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NumberOfMilestonesAchieved', window );">Number of milestones achieved</a></td>
        <td class="nump"><a title="mgnx_NumberOfMilestonesAchieved[us-gaap_CounterpartyNameAxis=mgnx_ServierMember;us-gaap_TypeOfArrangementAxis=mgnx_SecondRightToDevelopCollaborationMember]" onclick="toggleNextSibling(this);">2</a><span style="display:none;white-space:normal;text-align:left;">mgnx_NumberOfMilestonesAchieved<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_ServierMember<br>/ us-gaap_TypeOfArrangementAxis<br>= mgnx_SecondRightToDevelopCollaborationMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ReviewPeriodByRegulatoryAuthority', window );">Review period</a></td>
        <td class="text">30 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
        <td class="nump"><a title="us-gaap_DeferredRevenue[us-gaap_CounterpartyNameAxis=mgnx_ServierMember;us-gaap_TypeOfArrangementAxis=mgnx_SecondRightToDevelopCollaborationMember]" onclick="toggleNextSibling(this);">17,700,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredRevenue<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_ServierMember<br>/ us-gaap_TypeOfArrangementAxis<br>= mgnx_SecondRightToDevelopCollaborationMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DeferredRevenue[us-gaap_CounterpartyNameAxis=mgnx_ServierMember;us-gaap_TypeOfArrangementAxis=mgnx_SecondRightToDevelopCollaborationMember]" onclick="toggleNextSibling(this);">9,400,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredRevenue<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_ServierMember<br>/ us-gaap_TypeOfArrangementAxis<br>= mgnx_SecondRightToDevelopCollaborationMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue, Long-term liabilities</a></td>
        <td class="nump"><a title="us-gaap_DeferredRevenueNoncurrent[us-gaap_CounterpartyNameAxis=mgnx_ServierMember;us-gaap_TypeOfArrangementAxis=mgnx_SecondRightToDevelopCollaborationMember]" onclick="toggleNextSibling(this);">14,400,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredRevenueNoncurrent<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_ServierMember<br>/ us-gaap_TypeOfArrangementAxis<br>= mgnx_SecondRightToDevelopCollaborationMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DeferredRevenueNoncurrent[us-gaap_CounterpartyNameAxis=mgnx_ServierMember;us-gaap_TypeOfArrangementAxis=mgnx_SecondRightToDevelopCollaborationMember]" onclick="toggleNextSibling(this);">800,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredRevenueNoncurrent<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_ServierMember<br>/ us-gaap_TypeOfArrangementAxis<br>= mgnx_SecondRightToDevelopCollaborationMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=mgnx_ServierMember', window );">Servier [Member] | Scenario, Adjustment [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_UpfrontPaymentRecognitionPeriod', window );">Expected period of development</a></td>
        <td class="text">42 months<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=mgnx_ServierMember', window );">Servier [Member] | Scenario, Adjustment [Member] | Second Right to Develop Collaboration [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_UpfrontPaymentRecognitionPeriod', window );">Expected period of development</a></td>
        <td class="text">75 months<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=mgnx_ServierMember', window );">Servier [Member] | Maximum [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_AdditionalPotentialLicenseGrantFeesUnderAgreement', window );">Additional license grant fees</a></td>
        <td class="nump"><a title="mgnx_AdditionalPotentialLicenseGrantFeesUnderAgreement[us-gaap_CounterpartyNameAxis=mgnx_ServierMember;us-gaap_RangeAxis=us-gaap_MaximumMember]" onclick="toggleNextSibling(this);">30,000,000</a><span style="display:none;white-space:normal;text-align:left;">mgnx_AdditionalPotentialLicenseGrantFeesUnderAgreement<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_ServierMember<br>/ us-gaap_RangeAxis<br>= us-gaap_MaximumMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_AdditionalClinicalMilestonePotentialPaymentsUnderAgreement', window );">Clinical milestone payments</a></td>
        <td class="nump"><a title="mgnx_AdditionalClinicalMilestonePotentialPaymentsUnderAgreement[us-gaap_CounterpartyNameAxis=mgnx_ServierMember;us-gaap_RangeAxis=us-gaap_MaximumMember]" onclick="toggleNextSibling(this);">47,000,000</a><span style="display:none;white-space:normal;text-align:left;">mgnx_AdditionalClinicalMilestonePotentialPaymentsUnderAgreement<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_ServierMember<br>/ us-gaap_RangeAxis<br>= us-gaap_MaximumMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_AdditionalPotentialRegulatoryMilestonePaymentsUnderAgreement', window );">Regulatory milestone payments</a></td>
        <td class="nump"><a title="mgnx_AdditionalPotentialRegulatoryMilestonePaymentsUnderAgreement[us-gaap_CounterpartyNameAxis=mgnx_ServierMember;us-gaap_RangeAxis=us-gaap_MaximumMember]" onclick="toggleNextSibling(this);">140,000,000</a><span style="display:none;white-space:normal;text-align:left;">mgnx_AdditionalPotentialRegulatoryMilestonePaymentsUnderAgreement<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_ServierMember<br>/ us-gaap_RangeAxis<br>= us-gaap_MaximumMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_AdditionalPotentialSalesMilestonePaymentsUnderAgreement', window );">Sales milestone payments</a></td>
        <td class="nump"><a title="mgnx_AdditionalPotentialSalesMilestonePaymentsUnderAgreement[us-gaap_CounterpartyNameAxis=mgnx_ServierMember;us-gaap_RangeAxis=us-gaap_MaximumMember]" onclick="toggleNextSibling(this);">208,000,000</a><span style="display:none;white-space:normal;text-align:left;">mgnx_AdditionalPotentialSalesMilestonePaymentsUnderAgreement<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_ServierMember<br>/ us-gaap_RangeAxis<br>= us-gaap_MaximumMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=mgnx_ServierMember', window );">Servier [Member] | Maximum [Member] | Second Right to Develop Collaboration [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_AdditionalPotentialLicenseGrantFeesUnderAgreement', window );">Additional license grant fees</a></td>
        <td class="nump"><a title="mgnx_AdditionalPotentialLicenseGrantFeesUnderAgreement[us-gaap_CounterpartyNameAxis=mgnx_ServierMember;us-gaap_RangeAxis=us-gaap_MaximumMember;us-gaap_TypeOfArrangementAxis=mgnx_SecondRightToDevelopCollaborationMember]" onclick="toggleNextSibling(this);">65,000,000</a><span style="display:none;white-space:normal;text-align:left;">mgnx_AdditionalPotentialLicenseGrantFeesUnderAgreement<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_ServierMember<br>/ us-gaap_RangeAxis<br>= us-gaap_MaximumMember<br>/ us-gaap_TypeOfArrangementAxis<br>= mgnx_SecondRightToDevelopCollaborationMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_AdditionalClinicalMilestonePotentialPaymentsUnderAgreement', window );">Clinical milestone payments</a></td>
        <td class="nump"><a title="mgnx_AdditionalClinicalMilestonePotentialPaymentsUnderAgreement[us-gaap_CounterpartyNameAxis=mgnx_ServierMember;us-gaap_RangeAxis=us-gaap_MaximumMember;us-gaap_TypeOfArrangementAxis=mgnx_SecondRightToDevelopCollaborationMember]" onclick="toggleNextSibling(this);">98,000,000</a><span style="display:none;white-space:normal;text-align:left;">mgnx_AdditionalClinicalMilestonePotentialPaymentsUnderAgreement<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_ServierMember<br>/ us-gaap_RangeAxis<br>= us-gaap_MaximumMember<br>/ us-gaap_TypeOfArrangementAxis<br>= mgnx_SecondRightToDevelopCollaborationMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_AdditionalPotentialRegulatoryMilestonePaymentsUnderAgreement', window );">Regulatory milestone payments</a></td>
        <td class="nump"><a title="mgnx_AdditionalPotentialRegulatoryMilestonePaymentsUnderAgreement[us-gaap_CounterpartyNameAxis=mgnx_ServierMember;us-gaap_RangeAxis=us-gaap_MaximumMember;us-gaap_TypeOfArrangementAxis=mgnx_SecondRightToDevelopCollaborationMember]" onclick="toggleNextSibling(this);">300,000,000</a><span style="display:none;white-space:normal;text-align:left;">mgnx_AdditionalPotentialRegulatoryMilestonePaymentsUnderAgreement<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_ServierMember<br>/ us-gaap_RangeAxis<br>= us-gaap_MaximumMember<br>/ us-gaap_TypeOfArrangementAxis<br>= mgnx_SecondRightToDevelopCollaborationMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_AdditionalPotentialSalesMilestonePaymentsUnderAgreement', window );">Sales milestone payments</a></td>
        <td class="nump"><a title="mgnx_AdditionalPotentialSalesMilestonePaymentsUnderAgreement[us-gaap_CounterpartyNameAxis=mgnx_ServierMember;us-gaap_RangeAxis=us-gaap_MaximumMember;us-gaap_TypeOfArrangementAxis=mgnx_SecondRightToDevelopCollaborationMember]" onclick="toggleNextSibling(this);">630,000,000</a><span style="display:none;white-space:normal;text-align:left;">mgnx_AdditionalPotentialSalesMilestonePaymentsUnderAgreement<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_ServierMember<br>/ us-gaap_RangeAxis<br>= us-gaap_MaximumMember<br>/ us-gaap_TypeOfArrangementAxis<br>= mgnx_SecondRightToDevelopCollaborationMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_AdditionalPotentialMilestonePaymentsReceivableUponNewDrugApplicationAcceptance', window );">Clinical milestone payments under agreement</a></td>
        <td class="nump"><a title="mgnx_AdditionalPotentialMilestonePaymentsReceivableUponNewDrugApplicationAcceptance[us-gaap_CounterpartyNameAxis=mgnx_ServierMember;us-gaap_RangeAxis=us-gaap_MaximumMember;us-gaap_TypeOfArrangementAxis=mgnx_SecondRightToDevelopCollaborationMember]" onclick="toggleNextSibling(this);">$ 5,000,000</a><span style="display:none;white-space:normal;text-align:left;">mgnx_AdditionalPotentialMilestonePaymentsReceivableUponNewDrugApplicationAcceptance<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_ServierMember<br>/ us-gaap_RangeAxis<br>= us-gaap_MaximumMember<br>/ us-gaap_TypeOfArrangementAxis<br>= mgnx_SecondRightToDevelopCollaborationMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_AdditionalClinicalMilestonePotentialPaymentsUnderAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Additional Clinical Milestone Potential Payments Under Agreement</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_AdditionalClinicalMilestonePotentialPaymentsUnderAgreement</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_AdditionalPotentialLicenseGrantFeesUnderAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate potential license grant fees available to be earned under collaboration agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_AdditionalPotentialLicenseGrantFeesUnderAgreement</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_AdditionalPotentialMilestonePaymentsReceivableUponNewDrugApplicationAcceptance">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Additional potential milestone payments receivable upon new drug application acceptance.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_AdditionalPotentialMilestonePaymentsReceivableUponNewDrugApplicationAcceptance</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_AdditionalPotentialRegulatoryMilestonePaymentsUnderAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate potential remaining regulatory milestone payments available to be earned under a collaboration arrangement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_AdditionalPotentialRegulatoryMilestonePaymentsUnderAgreement</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_AdditionalPotentialSalesMilestonePaymentsUnderAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate potential remaining sales milestone payments available to be earned under collaboration agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_AdditionalPotentialSalesMilestonePaymentsUnderAgreement</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ChangeInAccountingEstimateCurrentYearImpact">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of the effect of a change in accounting estimate on current year operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_ChangeInAccountingEstimateCurrentYearImpact</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborationAgreementConsiderationReceivable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Collaboration Agreement Consideration Receivable</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_CollaborationAgreementConsiderationReceivable</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborationAndLicenseAgreementEnteredDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Collaboration and license agreement entered date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_CollaborationAndLicenseAgreementEnteredDate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>us-types:dateStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Collaboration arrangement offset to research and development costs.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_LicenseAndCollaborationAgreementsLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_LicenseAndCollaborationAgreementsLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonRefundableUpFrontPayment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Non-refundable up front payment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_NonRefundableUpFrontPayment</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NumberOfMilestonesAchieved">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of clinical milestones achieved during period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_NumberOfMilestonesAchieved</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_OptionExerciseFee">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Payment from collaborator upon exercise of option to develop and commercialize product.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_OptionExerciseFee</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_OptionExerciseFeeRecognitionPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Option exercise fee recognition period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_OptionExerciseFeeRecognitionPeriod</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ReviewPeriodByRegulatoryAuthority">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Review period by regulatory authority.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_ReviewPeriodByRegulatoryAuthority</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_UpfrontPaymentRecognitionPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Period over which upfront payment is to be recognized.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_UpfrontPaymentRecognitionPeriod</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 13<br><br> -Section A<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 8<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 13<br><br> -Section A<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 8<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 13<br><br> -Section A<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LicensesRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LicensesRevenue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of consideration recognized during the period for the milestone or milestones.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 28<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=19771982&amp;loc=SL6892177-166501<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=mgnx_ServierMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=mgnx_ServierMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ENGAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Quarterly Financial Information - Company's Consolidated Quarterly Results of Operations (Detail) (USD $)<br>In Thousands, except Per Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="8">3 Months Ended</th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2013</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
        <td class="nump"><a title="us-gaap_Revenues" onclick="toggleNextSibling(this);">$ 5,476</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Revenues</span><span></span></td>
        <td class="nump"><a title="us-gaap_Revenues" onclick="toggleNextSibling(this);">$ 18,382</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Revenues</span><span></span></td>
        <td class="nump"><a title="us-gaap_Revenues" onclick="toggleNextSibling(this);">$ 9,220</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Revenues</span><span></span></td>
        <td class="nump"><a title="us-gaap_Revenues" onclick="toggleNextSibling(this);">$ 14,719</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Revenues</span><span></span></td>
        <td class="nump"><a title="us-gaap_Revenues" onclick="toggleNextSibling(this);">$ 14,906</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Revenues</span><span></span></td>
        <td class="nump"><a title="us-gaap_Revenues" onclick="toggleNextSibling(this);">$ 20,232</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Revenues</span><span></span></td>
        <td class="nump"><a title="us-gaap_Revenues" onclick="toggleNextSibling(this);">$ 12,299</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Revenues</span><span></span></td>
        <td class="nump"><a title="us-gaap_Revenues" onclick="toggleNextSibling(this);">$ 10,598</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Revenues</span><span></span></td>
        <td class="nump"><a title="us-gaap_Revenues" onclick="toggleNextSibling(this);">$ 47,797</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Revenues</span><span></span></td>
        <td class="nump"><a title="us-gaap_Revenues" onclick="toggleNextSibling(this);">$ 58,035</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Revenues</span><span></span></td>
        <td class="nump"><a title="us-gaap_Revenues" onclick="toggleNextSibling(this);">$ 63,826</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Revenues</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (19,018)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (3,928)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (12,259)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (3,108)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (3,205)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="nump"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ 6,604</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (294)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (3,366)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (38,313)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (261)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="nump"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ 8,362</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income (loss) per share, basic</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num"><a title="us-gaap_EarningsPerShareBasic" onclick="toggleNextSibling(this);">$ (0.14)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareBasic</span><span></span></td>
        <td class="nump"><a title="us-gaap_EarningsPerShareBasic" onclick="toggleNextSibling(this);">$ 0.14</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareBasic</span><span></span></td>
        <td class="num"><a title="us-gaap_EarningsPerShareBasic" onclick="toggleNextSibling(this);">$ (0.24)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareBasic</span><span></span></td>
        <td class="num"><a title="us-gaap_EarningsPerShareBasic" onclick="toggleNextSibling(this);">$ (2.93)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareBasic</span><span></span></td>
        <td class="num"><a title="us-gaap_EarningsPerShareBasic" onclick="toggleNextSibling(this);">$ (1.40)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareBasic</span><span></span></td>
        <td class="num"><a title="us-gaap_EarningsPerShareBasic" onclick="toggleNextSibling(this);">$ (0.04)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareBasic</span><span></span></td>
        <td class="nump"><a title="us-gaap_EarningsPerShareBasic" onclick="toggleNextSibling(this);">$ 0.00</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareBasic</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare', window );">Net income (loss) per share, basic and diluted</a></td>
        <td class="num"><a title="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" onclick="toggleNextSibling(this);">$ (0.68)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare</span><span></span></td>
        <td class="num"><a title="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" onclick="toggleNextSibling(this);">$ (0.14)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare</span><span></span></td>
        <td class="num"><a title="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" onclick="toggleNextSibling(this);">$ (0.44)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare</span><span></span></td>
        <td class="num"><a title="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" onclick="toggleNextSibling(this);">$ (0.12)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num"><a title="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" onclick="toggleNextSibling(this);">$ (1.40)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare</span><span></span></td>
        <td class="num"><a title="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" onclick="toggleNextSibling(this);">$ (0.04)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare</span><span></span></td>
        <td class="nump"><a title="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" onclick="toggleNextSibling(this);">$ 0.00</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income (loss) per share, diluted</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num"><a title="us-gaap_EarningsPerShareDiluted" onclick="toggleNextSibling(this);">$ (0.14)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareDiluted</span><span></span></td>
        <td class="nump"><a title="us-gaap_EarningsPerShareDiluted" onclick="toggleNextSibling(this);">$ 0.01</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareDiluted</span><span></span></td>
        <td class="num"><a title="us-gaap_EarningsPerShareDiluted" onclick="toggleNextSibling(this);">$ (0.24)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareDiluted</span><span></span></td>
        <td class="num"><a title="us-gaap_EarningsPerShareDiluted" onclick="toggleNextSibling(this);">$ (2.93)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareDiluted</span><span></span></td>
        <td class="num"><a title="us-gaap_EarningsPerShareDiluted" onclick="toggleNextSibling(this);">$ (1.40)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareDiluted</span><span></span></td>
        <td class="num"><a title="us-gaap_EarningsPerShareDiluted" onclick="toggleNextSibling(this);">$ (0.04)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareDiluted</span><span></span></td>
        <td class="nump"><a title="us-gaap_EarningsPerShareDiluted" onclick="toggleNextSibling(this);">$ 0.00</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareDiluted</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1252-109256<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 52<br><br> -URI http://asc.fasb.org/extlink&amp;oid=32703322&amp;loc=d3e4984-109258<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.21)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-04.23)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 18<br><br> -Article 7<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 21<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1252-109256<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.21)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 18<br><br> -Article 7<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 21<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income (loss) from continuing operations per each basic and diluted share of common stock or unit when the per share amount is the same for both basic and diluted shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_Revenues</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EUJAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Lease Exit Liability - Additional Information (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Jul. 16, 2014</div>
        </th>
        <th class="th">
          <div>Jul. 16, 2008</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_LeaseExpirationYear', window );">Operating Lease</a></td>
        <td class="text">2018<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_OnetimeMilestonePaymentToBePaidUnderAgreement', window );">Onetime purchase payment under purchase agreement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="mgnx_OnetimeMilestonePaymentToBePaidUnderAgreement" onclick="toggleNextSibling(this);">$ 5,000,000</a><span style="display:none;white-space:normal;text-align:left;">mgnx_OnetimeMilestonePaymentToBePaidUnderAgreement</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ContingentConsiderationRecordedAsIncrementalInProcessResearchAndDevelopmentExpense', window );">Additional amounts recorded</a></td>
        <td class="nump"><a title="mgnx_ContingentConsiderationRecordedAsIncrementalInProcessResearchAndDevelopmentExpense" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">mgnx_ContingentConsiderationRecordedAsIncrementalInProcessResearchAndDevelopmentExpense</span><span></span></td>
        <td class="nump"><a title="mgnx_ContingentConsiderationRecordedAsIncrementalInProcessResearchAndDevelopmentExpense" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">mgnx_ContingentConsiderationRecordedAsIncrementalInProcessResearchAndDevelopmentExpense</span><span></span></td>
        <td class="nump"><a title="mgnx_ContingentConsiderationRecordedAsIncrementalInProcessResearchAndDevelopmentExpense" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">mgnx_ContingentConsiderationRecordedAsIncrementalInProcessResearchAndDevelopmentExpense</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_OnetimeMilestonePaymentToBePaidUnderAgreementUponSpecifiedLevelOfSalesOfProducts', window );">Onetime payment paid under license of product</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="mgnx_OnetimeMilestonePaymentToBePaidUnderAgreementUponSpecifiedLevelOfSalesOfProducts[us-gaap_RangeAxis=us-gaap_MinimumMember]" onclick="toggleNextSibling(this);">8,000,000</a><span style="display:none;white-space:normal;text-align:left;">mgnx_OnetimeMilestonePaymentToBePaidUnderAgreementUponSpecifiedLevelOfSalesOfProducts<br>/ us-gaap_RangeAxis<br>= us-gaap_MinimumMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_OnetimeMilestonePaymentToBePaidUnderAgreementUponSpecifiedLevelOfSalesOfProducts', window );">Onetime payment paid under license of product</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="mgnx_OnetimeMilestonePaymentToBePaidUnderAgreementUponSpecifiedLevelOfSalesOfProducts[us-gaap_RangeAxis=us-gaap_MaximumMember]" onclick="toggleNextSibling(this);">$ 12,000,000</a><span style="display:none;white-space:normal;text-align:left;">mgnx_OnetimeMilestonePaymentToBePaidUnderAgreementUponSpecifiedLevelOfSalesOfProducts<br>/ us-gaap_RangeAxis<br>= us-gaap_MaximumMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=mgnx_ConvertiblePreferredStockSeriesDMember', window );">Series D Convertible Preferred Stock [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Shares issued in connection with acquisition</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesAcquisitions[us-gaap_StatementClassOfStockAxis=mgnx_ConvertiblePreferredStockSeriesDMember]" onclick="toggleNextSibling(this);">12,466,039</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions<br>/ us-gaap_StatementClassOfStockAxis<br>= mgnx_ConvertiblePreferredStockSeriesDMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ContingentConsiderationRecordedAsIncrementalInProcessResearchAndDevelopmentExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Contingent consideration recorded as incremental in process research and development expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_ContingentConsiderationRecordedAsIncrementalInProcessResearchAndDevelopmentExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_LeaseExpirationYear">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Lease expiration year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_LeaseExpirationYear</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_OnetimeMilestonePaymentToBePaidUnderAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>One-time milestone payment to be paid under agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_OnetimeMilestonePaymentToBePaidUnderAgreement</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_OnetimeMilestonePaymentToBePaidUnderAgreementUponSpecifiedLevelOfSalesOfProducts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>One-time milestone payment to be paid under agreement upon specified level of sales of products.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_OnetimeMilestonePaymentToBePaidUnderAgreementUponSpecifiedLevelOfSalesOfProducts</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of stock issued during the period pursuant to acquisitions.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=mgnx_ConvertiblePreferredStockSeriesDMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=mgnx_ConvertiblePreferredStockSeriesDMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Property and Equipment<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>3. Property and Equipment</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Property and equipment consists of the following (in
 thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="71%"></td>
 <td valign="bottom" width="9%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Computer equipment</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,596</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,379</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Software</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,683</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,477</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Furniture and office equipment</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">751</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">651</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Lab equipment</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">13,917</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">11,166</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Leasehold improvements</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,193</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,894</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Property and equipment</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">24,140</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">20,567</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Less accumulated depreciation</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(17,355</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(15,532</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Property and equipment, net</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">6,785</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">5,035</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Depreciation expense for the years ended December&#xA0;31, 2014,
 2013 and 2012 was $1.8 million, $1.2 million and $1.0 million,
 respectively.</p>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391110&amp;loc=d3e2921-110230<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1361-107760<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13-14)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EDLAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Subsequent Event - Additional Information (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="2">12 Months Ended</th>
        <th class="th" colspan="1">1 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Feb. 28, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Jan. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during the period for new issue</a></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesNewIssues" onclick="toggleNextSibling(this);">1,800,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock issued during period value, new issues</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueNewIssues" onclick="toggleNextSibling(this);">$ 76,716,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueNewIssues</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueNewIssues" onclick="toggleNextSibling(this);">$ 83,623,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueNewIssues</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=mgnx_JanssenBiotechIncMember', window );">Janssen Biotech Inc. [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during the period for new issue</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesNewIssues[us-gaap_CounterpartyNameAxis=mgnx_JanssenBiotechIncMember]" onclick="toggleNextSibling(this);">1,923,077</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesNewIssues<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_JanssenBiotechIncMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock issued during period value, new issues</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueNewIssues[us-gaap_CounterpartyNameAxis=mgnx_JanssenBiotechIncMember]" onclick="toggleNextSibling(this);">75,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueNewIssues<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_JanssenBiotechIncMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NonRefundableUpfrontPaymentReceivable', window );">Nonrefundable upfront payment receivable</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="mgnx_NonRefundableUpfrontPaymentReceivable[us-gaap_CounterpartyNameAxis=mgnx_JanssenBiotechIncMember]" onclick="toggleNextSibling(this);">50,000,000</a><span style="display:none;white-space:normal;text-align:left;">mgnx_NonRefundableUpfrontPaymentReceivable<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_JanssenBiotechIncMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Johnson &amp; Johnson Innovation JJDC, Inc, [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during the period for new issue</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesNewIssues[us-gaap_CounterpartyNameAxis=mgnx_JohnsonAndJohnsonDevelopmentCorporationMember;us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember]" onclick="toggleNextSibling(this);">1,923,077</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesNewIssues<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_JohnsonAndJohnsonDevelopmentCorporationMember<br>/ us-gaap_SubsequentEventTypeAxis<br>= us-gaap_SubsequentEventMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock issued during period value, new issues</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueNewIssues[us-gaap_CounterpartyNameAxis=mgnx_JohnsonAndJohnsonDevelopmentCorporationMember;us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember]" onclick="toggleNextSibling(this);">75,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueNewIssues<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_JohnsonAndJohnsonDevelopmentCorporationMember<br>/ us-gaap_SubsequentEventTypeAxis<br>= us-gaap_SubsequentEventMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Janssen Biotech Inc. [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NonRefundableUpfrontPaymentReceivable', window );">Nonrefundable upfront payment receivable</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="mgnx_NonRefundableUpfrontPaymentReceivable[us-gaap_CounterpartyNameAxis=mgnx_JanssenBiotechIncMember;us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember]" onclick="toggleNextSibling(this);">$ 50,000,000</a><span style="display:none;white-space:normal;text-align:left;">mgnx_NonRefundableUpfrontPaymentReceivable<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_JanssenBiotechIncMember<br>/ us-gaap_SubsequentEventTypeAxis<br>= us-gaap_SubsequentEventMember</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonRefundableUpfrontPaymentReceivable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Initial fee receivable from collaboration or license agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_NonRefundableUpfrontPaymentReceivable</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of new stock issued during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=mgnx_JanssenBiotechIncMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=mgnx_JanssenBiotechIncMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>55
<FILENAME>Financial_Report.xls
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xls
M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O
M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y
M/2(M+2TM/5].97AT4&%R=%\X9&(U,S=C-%]E.#<X7S1A,V5?.#(X85]B-3`P
M9C-E9&8Q,68B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7
M96(@4&%G92P@86QS;R!K;F]W;B!A<R!A(%=E8B!!<F-H:79E(&9I;&4N("!)
M9B!Y;W4@87)E('-E96EN9R!T:&ES(&UE<W-A9V4L('EO=7(@8G)O=W-E<B!O
M<B!E9&ET;W(@9&]E<VXG="!S=7!P;W)T(%=E8B!!<F-H:79E(&9I;&5S+B`@
M4&QE87-E(&1O=VYL;V%D(&$@8G)O=W-E<B!T:&%T('-U<'!O<G1S(%=E8B!!
M<F-H:79E+"!S=6-H(&%S($UI8W)O<V]F="!);G1E<FYE="!%>'!L;W)E<BX-
M"@T*+2TM+2TM/5].97AT4&%R=%\X9&(U,S=C-%]E.#<X7S1A,V5?.#(X85]B
M-3`P9C-E9&8Q,68-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.&1B
M-3,W8S1?93@W.%\T83-E7S@R.&%?8C4P,&8S961F,3%F+U=O<FMB;V]K+FAT
M;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B
M;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I
M:2(-"@T*/&AT;6P@>&UL;G,Z=CTS1")U<FXZ<V-H96UA<RUM:6-R;W-O9G0M
M8V]M.G9M;"(@>&UL;G,Z;STS1")U<FXZ<V-H96UA<RUM:6-R;W-O9G0M8V]M
M.F]F9FEC93IO9F9I8V4B('AM;&YS.G@],T0B=7)N.G-C:&5M87,M;6EC<F]S
M;V9T+6-O;3IO9F9I8V4Z97AC96PB('AM;&YS/3-$(FAT='`Z+R]W=W<N=S,N
M;W)G+U12+U)%0RUH=&UL-#`B/@T*/&AE860^#0H\;65T82!N86UE/3-$(D5X
M8V5L(%=O<FMB;V]K($9R86UE<V5T(CX-"@T*/&UE=&$@;F%M93TS1%!R;V=)
M9"!C;VYT96YT/3-$17AC96PN4VAE970^#0H\;&EN:R!R96P],T1&:6QE+4QI
M<W0@:')E9CTS1")7;W)K<VAE971S+V9I;&5L:7-T+GAM;"(^#0H-"CPA+2U;
M:68@9W1E(&US;R`Y73X\>&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX
M.D5X8V5L5V]R:W-H965T<SX-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^1&]C=6UE;G1?86YD7T5N=&ET>5]);F9O<FUA=&EO/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]N<V]L:61A=&5D
M7T)A;&%N8V5?4VAE971S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U
M<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`R+FAT;6PB+SX-"B`@(#PO
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^0V]N<V]L:61A=&5D7T)A;&%N8V5?4VAE971S7U!A/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`S+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]N<V]L:61A=&5D
M7U-T871E;65N='-?;V9?3W!E/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`T+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^0V]N<V]L:61A=&5D7U-T871E;65N='-?;V9?4W1O/"]X
M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H
M965T<R]3:&5E=#`U+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]N<V]L:61A
M=&5D7U-T871E;65N='-?;V9?0V%S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H
M965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`V+FAT;6PB+SX-
M"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T
M/@T*("`@(#QX.DYA;64^3W)G86YI>F%T:6]N7V%N9%].871U<F5?;V9?3W!E
M/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R
M:W-H965T<R]3:&5E=#`W+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4W5M;6%R
M>5]O9E]3:6=N:69I8V%N=%]!8V-O=6YT/"]X.DYA;64^#0H@("`@/'@Z5V]R
M:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`X+FAT;6PB
M+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H
M965T/@T*("`@(#QX.DYA;64^4')O<&5R='E?86YD7T5Q=6EP;65N=#PO>#I.
M86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E
M=',O4VAE970P.2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@
M("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-T;V-K:&]L9&5R
M<U]%<75I='D\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E
M9CTS1")7;W)K<VAE971S+U-H965T,3`N:'1M;"(O/@T*("`@/"]X.D5X8V5L
M5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M
M93Y3=&]C:V)A<V5D7T-O;7!E;G-A=&EO;CPO>#I.86UE/@T*("`@(#QX.E=O
M<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q,2YH=&UL
M(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@("`\>#I.86UE/DEN8V]M95]487AE<SPO>#I.86UE/@T*("`@
M(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q
M,BYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E
M;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/DQE87-E7T5X:71?3&EA8FEL:71Y
M/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R
M:W-H965T<R]3:&5E=#$S+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]L;&%B
M;W)A=&EO;E]A;F1?3&EC96YS95]!9W)E/"]X.DYA;64^#0H@("`@/'@Z5V]R
M:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#$T+FAT;6PB
M+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H
M965T/@T*("`@(#QX.DYA;64^0V]M;6ET;65N='-?86YD7T-O;G1I;F=E;F-I
M97,\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7
M;W)K<VAE971S+U-H965T,34N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H
M965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y0<F]D
M=6-T7TUI;&5S=&]N95]087EM96YT<U]A;F0\+W@Z3F%M93X-"B`@("`\>#I7
M;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,38N:'1M
M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K
M<VAE970^#0H@("`@/'@Z3F%M93Y%;7!L;WEE95]"96YE9FET7U!L86X\+W@Z
M3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE
M971S+U-H965T,3<N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*
M("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y1=6%R=&5R;'E?
M1FEN86YC:6%L7TEN9F]R;6%T:6\\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE
M9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,3@N:'1M;"(O/@T*
M("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^
M#0H@("`@/'@Z3F%M93Y3=6)S97%U96YT7T5V96YT/"]X.DYA;64^#0H@("`@
M/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#$Y
M+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L
M5V]R:W-H965T/@T*("`@(#QX.DYA;64^4W5M;6%R>5]O9E]3:6=N:69I8V%N
M=%]!8V-O=6YT,3PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(
M4F5F/3-$(E=O<FMS:&5E=',O4VAE970R,"YH=&UL(B\^#0H@("`\+W@Z17AC
M96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.
M86UE/E-U;6UA<GE?;V9?4VEG;FEF:6-A;G1?06-C;W5N=#(\+W@Z3F%M93X-
M"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H
M965T,C$N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z
M17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y0<F]P97)T>5]A;F1?17%U
M:7!M96YT7U1A8FQE<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C
M92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970R,BYH=&UL(B\^#0H@("`\+W@Z
M17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\
M>#I.86UE/E-T;V-K8F%S961?0V]M<&5N<V%T:6]N7U1A8FQE<SPO>#I.86UE
M/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O
M4VAE970R,RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/DEN8V]M95]487AE<U]4
M86)L97,\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS
M1")7;W)K<VAE971S+U-H965T,C0N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R
M:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y,
M96%S95]%>&ET7TQI86)I;&ET>5]486)L97,\+W@Z3F%M93X-"B`@("`\>#I7
M;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,C4N:'1M
M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K
M<VAE970^#0H@("`@/'@Z3F%M93Y#;VUM:71M96YT<U]A;F1?0V]N=&EN9V5N
M8VEE<U\\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS
M1")7;W)K<VAE971S+U-H965T,C8N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R
M:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y1
M=6%R=&5R;'E?1FEN86YC:6%L7TEN9F]R;6%T:6\Q/"]X.DYA;64^#0H@("`@
M/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#(W
M+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L
M5V]R:W-H965T/@T*("`@(#QX.DYA;64^3W)G86YI>F%T:6]N7V%N9%].871U
M<F5?;V9?3W!E,3PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(
M4F5F/3-$(E=O<FMS:&5E=',O4VAE970R."YH=&UL(B\^#0H@("`\+W@Z17AC
M96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.
M86UE/E-U;6UA<GE?;V9?4VEG;FEF:6-A;G1?06-C;W5N=#,\+W@Z3F%M93X-
M"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H
M965T,CDN:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z
M17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y3=6UM87)Y7V]F7U-I9VYI
M9FEC86YT7T%C8V]U;G0T/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U
M<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#,P+FAT;6PB+SX-"B`@(#PO
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^4W5M;6%R>5]O9E]3:6=N:69I8V%N=%]!8V-O=6YT-3PO>#I.
M86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E
M=',O4VAE970S,2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@
M("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-U;6UA<GE?;V9?
M4VEG;FEF:6-A;G1?06-C;W5N=#8\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE
M9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,S(N:'1M;"(O/@T*
M("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^
M#0H@("`@/'@Z3F%M93Y3=6UM87)Y7V]F7U-I9VYI9FEC86YT7T%C8V]U;G0W
M/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R
M:W-H965T<R]3:&5E=#,S+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4W5M;6%R
M>5]O9E]3:6=N:69I8V%N=%]!8V-O=6YT.#PO>#I.86UE/@T*("`@(#QX.E=O
M<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970S-"YH=&UL
M(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@("`\>#I.86UE/E-U;6UA<GE?;V9?4VEG;FEF:6-A;G1?06-C
M;W5N=#D\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS
M1")7;W)K<VAE971S+U-H965T,S4N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R
M:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y0
M<F]P97)T>5]A;F1?17%U:7!M96YT7U-C:&5D=6P\+W@Z3F%M93X-"B`@("`\
M>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,S8N
M:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7
M;W)K<VAE970^#0H@("`@/'@Z3F%M93Y0<F]P97)T>5]A;F1?17%U:7!M96YT
M7T%D9&ET:6\\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E
M9CTS1")7;W)K<VAE971S+U-H965T,S<N:'1M;"(O/@T*("`@/"]X.D5X8V5L
M5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M
M93Y3=&]C:VAO;&1E<G-?17%U:71Y7T%D9&ET:6]N86P\+W@Z3F%M93X-"B`@
M("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T
M,S@N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC
M96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y3=&]C:U]B87-E9%]#;VUP96YS
M871I;VY?061D:70\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@
M2%)E9CTS1")7;W)K<VAE971S+U-H965T,SDN:'1M;"(O/@T*("`@/"]X.D5X
M8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z
M3F%M93Y3=&]C:U]B87-E9%]#;VUP96YS871I;VY?4V-H960\+W@Z3F%M93X-
M"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H
M965T-#`N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z
M17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y3=&]C:U]B87-E9%]#;VUP
M96YS871I;VY?4V-H960Q/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U
M<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#0Q+FAT;6PB+SX-"B`@(#PO
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^4W1O8VM?8F%S961?0V]M<&5N<V%T:6]N7U-C:&5D,CPO>#I.
M86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E
M=',O4VAE970T,BYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@
M("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/DEN8V]M95]487AE
M<U]!9&1I=&EO;F%L7TEN9F]R;3PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E
M=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970T,RYH=&UL(B\^#0H@
M("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@("`\>#I.86UE/DEN8V]M95]487AE<U]#;VUP;VYE;G1S7V]F7W1H93PO
M>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS
M:&5E=',O4VAE970T-"YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^
M#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/DEN8V]M95]4
M87AE<U]296-O;F-I;&EA=&EO;E]O9CPO>#I.86UE/@T*("`@(#QX.E=O<FMS
M:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970T-2YH=&UL(B\^
M#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@("`\>#I.86UE/DEN8V]M95]487AE<U]296-O;F-I;&EA=&EO;E]O
M9C$\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7
M;W)K<VAE971S+U-H965T-#8N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H
M965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y,96%S
M95]%>&ET7TQI86)I;&ET>5]!9&1I=&EO;F$\+W@Z3F%M93X-"B`@("`\>#I7
M;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T-#<N:'1M
M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K
M<VAE970^#0H@("`@/'@Z3F%M93Y,96%S95]%>&ET7TQI86)I;&ET>5]#:&%N
M9V5S7VD\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS
M1")7;W)K<VAE971S+U-H965T-#@N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R
M:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y,
M96%S95]%>&ET7TQI86)I;&ET>5]&=71U<F5?4'(\+W@Z3F%M93X-"B`@("`\
M>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T-#DN
M:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7
M;W)K<VAE970^#0H@("`@/'@Z3F%M93Y#;VQL86)O<F%T:6]N7V%N9%],:6-E
M;G-E7T%G<F4Q/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2
M968],T0B5V]R:W-H965T<R]3:&5E=#4P+FAT;6PB+SX-"B`@(#PO>#I%>&-E
M;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA
M;64^0V]L;&%B;W)A=&EO;E]A;F1?3&EC96YS95]!9W)E,CPO>#I.86UE/@T*
M("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE
M970U,2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D-O;&QA8F]R871I;VY?86YD
M7TQI8V5N<V5?06=R93,\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R
M8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T-3(N:'1M;"(O/@T*("`@/"]X
M.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@
M/'@Z3F%M93Y#;VQL86)O<F%T:6]N7V%N9%],:6-E;G-E7T%G<F4T/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#4S+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]L;&%B;W)A=&EO
M;E]A;F1?3&EC96YS95]!9W)E-3PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E
M=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970U-"YH=&UL(B\^#0H@
M("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@("`\>#I.86UE/D-O;&QA8F]R871I;VY?86YD7TQI8V5N<V5?06=R938\
M+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K
M<VAE971S+U-H965T-34N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T
M/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y#;VQL86)O
M<F%T:6]N7V%N9%],:6-E;G-E7T%G<F4W/"]X.DYA;64^#0H@("`@/'@Z5V]R
M:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#4V+FAT;6PB
M+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H
M965T/@T*("`@(#QX.DYA;64^0V]M;6ET;65N='-?86YD7T-O;G1I;F=E;F-I
M97-?,3PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$
M(E=O<FMS:&5E=',O4VAE970U-RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K
M<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D-O
M;6UI=&UE;G1S7V%N9%]#;VYT:6YG96YC:65S7S(\+W@Z3F%M93X-"B`@("`\
M>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T-3@N
M:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7
M;W)K<VAE970^#0H@("`@/'@Z3F%M93Y0<F]D=6-T7TUI;&5S=&]N95]087EM
M96YT<U]A;F0Q/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2
M968],T0B5V]R:W-H965T<R]3:&5E=#4Y+FAT;6PB+SX-"B`@(#PO>#I%>&-E
M;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA
M;64^16UP;&]Y965?0F5N969I=%]0;&%N7T%D9&ET:6]N/"]X.DYA;64^#0H@
M("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E
M=#8P+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X
M8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^475A<G1E<FQY7T9I;F%N8VEA
M;%]);F9O<FUA=&EO,CPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C
M92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970V,2YH=&UL(B\^#0H@("`\+W@Z
M17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\
M>#I.86UE/E-U8G-E<75E;G1?179E;G1?061D:71I;VYA;%]);CPO>#I.86UE
M/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O
M4VAE970V,BYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@(#PO
M>#I%>&-E;%=O<FMS:&5E=',^#0H@(#QX.E-T>6QE<VAE970@2%)E9CTS1")7
M;W)K<VAE971S+W)E<&]R="YC<W,B+SX-"B`@/'@Z06-T:79E4VAE970^,#PO
M>#I!8W1I=F53:&5E=#X-"B`@/'@Z4')O=&5C=%-T<G5C='5R93Y&86QS93PO
M>#I0<F]T96-T4W1R=6-T=7)E/@T*("`\>#I0<F]T96-T5VEN9&]W<SY&86QS
M93PO>#I0<F]T96-T5VEN9&]W<SX-"B`\+W@Z17AC96Q7;W)K8F]O:SX-"CPO
M>&UL/CPA6V5N9&EF72TM/@T*/"]H96%D/@T*("`\8F]D>3X-"B`@(#QP/E1H
M:7,@<&%G92!S:&]U;&0@8F4@;W!E;F5D('=I=&@@36EC<F]S;V9T($5X8V5L
M(%A0(&]R(&YE=V5R+CPO<#X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM
M+2T]7TYE>'1087)T7SAD8C4S-V,T7V4X-SA?-&$S95\X,CAA7V(U,#!F,V5D
M9C$Q9@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\X9&(U,S=C-%]E
M.#<X7S1A,V5?.#(X85]B-3`P9C-E9&8Q,68O5V]R:W-H965T<R]3:&5E=#`Q
M+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN
M=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA
M<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U
M:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S
M970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,]
M,T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S
M8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R
M97!O<G0@:60],T1)1#!%555!13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY$
M;V-U;65N="!A;F0@16YT:71Y($EN9F]R;6%T:6]N("A54T0@)"D\8G(^/"]S
M=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS
M1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@@8V]L<W!A;CTS1#$^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@
M8V]L<W!A;CTS1#$^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1F5B+B`R-RP@,C`Q-3QB<CX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN(#,P+"`R,#$T/&)R/CPO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D1O8W5M
M96YT($%N9"!%;G1I='D@26YF;W)M871I;VX@6T%B<W1R86-T73PO<W1R;VYG
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$;V-U;65N="!4
M>7!E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XQ,"U+/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!;65N
M9&UE;G0@1FQA9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^9F%L
M<V4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D1O8W5M96YT(%!E<FEO9"!%;F0@1&%T93PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^1&5C(#,Q+`T*"0DR,#$T/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$;V-U;65N="!&:7-C
M86P@665A<B!&;V-U<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M,C`Q-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^1&]C=6UE;G0@1FES8V%L(%!E<FEO9"!&;V-U<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^1ED\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1R861I;F<@4WEM8F]L/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#Y-1TY8/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;G1I='D@4F5G:7-T
M<F%N="!.86UE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#Y-04-2
M3T=%3DE#4R!)3D,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D5N=&ET>2!#96YT<F%L($EN9&5X($ME>3PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^,#`P,3$R-3,T-3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0W5R<F5N="!&
M:7-C86P@665A<B!%;F0@1&%T93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^+2TQ,BTS,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^16YT:71Y(%=E;&PM:VYO=VX@4V5A<V]N960@27-S
M=65R/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#Y.;SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YT:71Y
M($-U<G)E;G0@4F5P;W)T:6YG(%-T871U<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^665S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y%;G1I='D@5F]L=6YT87)Y($9I;&5R<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^3F\\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N=&ET>2!&:6QE<B!#
M871E9V]R>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^06-C96QE
M<F%T960@1FEL97(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D5N=&ET>2!#;VUM;VX@4W1O8VLL(%-H87)E<R!/=71S
M=&%N9&EN9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,CDL.38X
M+#0W-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^16YT:71Y(%!U8FQI8R!&;&]A=#PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`T,S<L,C$S+#$X-3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^
M#0H-"BTM+2TM+3U?3F5X=%!A<G1?.&1B-3,W8S1?93@W.%\T83-E7S@R.&%?
M8C4P,&8S961F,3%F#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+SAD
M8C4S-V,T7V4X-SA?-&$S95\X,CAA7V(U,#!F,V5D9C$Q9B]7;W)K<VAE971S
M+U-H965T,#(N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O
M=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S
M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@
M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M
M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R
M:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE
M;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C
M;&%S<STS1')E<&]R="!I9#TS1$E$,$510T%'/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,3X\
M<W1R;VYG/D-O;G-O;&ED871E9"!"86QA;F-E(%-H965T<R`H55-$("0I/&)R
M/DEN(%1H;W5S86YD<RP@=6YL97-S(&]T:&5R=VES92!S<&5C:69I960\+W-T
M<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R
M,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L
M(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^0W5R<F5N="!A<W-E=',Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D-A<V@@86YD(&-A<V@@97%U:79A;&5N=',\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,34W+#4Y,3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3$V
M+#0X,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^06-C;W5N=',@<F5C96EV86)L93PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,BPY,S4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XR+#`P-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')E<&%I9"!E>'!E;G-E<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"PR,3$\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY-S(\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R974^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!C
M=7)R96YT(&%S<V5T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,38T+#<S-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$Q.2PT-3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E)E<W1R:6-T960@8V%S:#PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,S`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-#`U/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]P97)T>2!A;F0@97%U:7!M
M96YT+"!N970\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8L-S@U
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-2PP,S4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D]T:&5R(&%S<V5T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,BPP-C0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XX.#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!A<W-E=',\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$W,RPX.#8\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,C4L-S@R/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-U<G)E
M;G0@;&EA8FEL:71I97,Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D%C8V]U;G1S('!A>6%B;&4\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$L-C8Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,RPQ-CD\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8W)U960@97AP96YS97,\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<L.3,P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPU.#0\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQE
M87-E(&5X:70@;&EA8FEL:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ+#8T,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$L-#,Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y$969E<G)E9"!R979E;G5E/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ-"PR-#@\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,"PR-C<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]T:&5R(&QI86)I
M;&ET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#8P-3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,V
M,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E1O=&%L(&-U<G)E;G0@;&EA8FEL:71I97,\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C(W+#`Y-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C(X+#@R,CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&5A<V4@97AI="!L:6%B
M:6QI='DL(&YE="!O9B!C=7)R96YT('!O<G1I;VX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C8L,S8T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^."PP,#8\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E9F5R<F5D(')E;G0@;&EA
M8FEL:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#8W,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L
M.3`T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y$969E<G)E9"!R979E;G5E+"!N970@;V8@8W5R<F5N="!P;W)T:6]N
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-BPT-S(\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW+#$S-CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E1O=&%L(&QI86)I;&ET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XU,BPV,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XT-BPX-C@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4W1O8VMH;VQD97)S)R!E<75I
M='DZ/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D-O;6UO;B!S=&]C:RP@)#`N,#$@<&%R('9A;'5E+3$R-2PP,#`L,#`P('-H
M87)E<R!A=71H;W)I>F5D+"`R-RPY.34L-C,X(&%N9"`R-2PQ-S<L-3DW('-H
M87)E<R!O=71S=&%N9&EN9R!A="!$96-E;6)E<B`S,2P@,C`Q-"!A;F0@,C`Q
M,RP@<F5S<&5C=&EV96QY/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XR.#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XR-3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E1R96%S=7)Y('-T;V-K+"!A="!C;W-T.R`X-C4@86YD(#$T
M+#,X,2!S:&%R97,@870@1&5C96UB97(@,S$L(#(P,30@86YD(#(P,3,L(')E
M<W!E8W1I=F5L>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3DI
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH
M-3@I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y!9&1I=&EO;F%L('!A:60M:6X@8V%P:71A;#PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,S,U+#`W,3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(U-"PT-3,\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8W5M=6QA=&5D
M(&1E9FEC:70\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(Q-"PP
M-#8I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XH,3<U+#<S,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y4;W1A;"!S=&]C:VAO;&1E<G,G(&5Q=6ET>3PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3(Q+#(X-CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<X+#DQ-#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O
M=&%L(&QI86)I;&ET:65S(&%N9"!S=&]C:VAO;&1E<G,G(&5Q=6ET>3PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q-S,L.#@V/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q,C4L-S@R
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^
M#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\X9&(U
M,S=C-%]E.#<X7S1A,V5?.#(X85]B-3`P9C-E9&8Q,68-"D-O;G1E;G0M3&]C
M871I;VXZ(&9I;&4Z+R\O0SHO.&1B-3,W8S1?93@W.%\T83-E7S@R.&%?8C4P
M,&8S961F,3%F+U=O<FMS:&5E=',O4VAE970P,RYH=&UL#0I#;VYT96YT+51R
M86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y
M<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*
M("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E
M(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T
M('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.
M;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@
M/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P15E)
M04,^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P
M86X],T0Q(')O=W-P86X],T0Q/CQS=')O;F<^0V]N<V]L:61A=&5D($)A;&%N
M8V4@4VAE971S("A087)E;G1H971I8V%L*2`H55-$("0I/&)R/CPO<W1R;VYG
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,30\
M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q
M,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N
M9SY3=&%T96UE;G0@;V8@1FEN86YC:6%L(%!O<VET:6]N(%M!8G-T<F%C=%T\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M
M;6]N('-T;V-K+"!P87(@=F%L=64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@,"XP,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@,"XP,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K+"!S:&%R97,@875T
M:&]R:7IE9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3(U+#`P
M,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ,C4L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K+"!S:&%R97,@;W5T<W1A
M;F1I;F<\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(W+#DY-2PV
M,S@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XR-2PQ-S<L-3DW/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y4<F5A<W5R>2!S=&]C:RP@<VAA<F5S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XX-C4\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-"PS.#$\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*
M/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7SAD8C4S-V,T7V4X-SA?-&$S
M95\X,CAA7V(U,#!F,V5D9C$Q9@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO
M+R]#.B\X9&(U,S=C-%]E.#<X7S1A,V5?.#(X85]B-3`P9C-E9&8Q,68O5V]R
M:W-H965T<R]3:&5E=#`T+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I
M;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL
M.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@
M(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T
M97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O
M:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI
M<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\
M=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%4%=!13X-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A
M;CTS1#(^/'-T<F]N9SY#;VYS;VQI9&%T960@4W1A=&5M96YT<R!O9B!/<&5R
M871I;VYS(&%N9"!#;VUP<F5H96YS:79E($EN8V]M92`H3&]S<RD@*%531"`D
M*3QB<CY);B!4:&]U<V%N9',L(&5X8V5P="!3:&%R92!D871A+"!U;FQE<W,@
M;W1H97)W:7-E('-P96-I9FEE9#PO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H(&-O;'-P86X],T0S/C$R($UO;G1H<R!%;F1E9#PO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^/'-T<F]N9SY2979E;G5E<SH\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5V96YU92!F<F]M(&-O
M;&QA8F]R871I=F4@<F5S96%R8V@\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@-#<L,C8T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`U-BPW-3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#4Y+#8T-CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1W)A;G0@<F5V96YU
M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3,S/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PR.#(\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+#$X
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E1O=&%L(')E=F5N=65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XT-RPW.3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XU."PP,S4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XV,RPX,C8\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0V]S=',@86YD(&5X
M<&5N<V5S.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y297-E87)C:"!A;F0@9&5V96QO<&UE;G0\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C<P+#$X-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C0V+#4X,CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0U+#0S,SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1V5N97)A;"!A
M;F0@861M:6YI<W1R871I=F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$U+#DR-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$Q+#`X-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$P+#$X.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&-O<W1S(&%N9"!E>'!E
M;G-E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#8L,3$R/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3<L
M-C8Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-34L-C(Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^26YC;VUE("AL;W-S*2!F<F]M(&]P97)A=&EO;G,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#,X+#,Q-2D\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS-C8\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX+#(P-3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M3W1H97(@:6YC;VUE("AE>'!E;G-E*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#8R-RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ-3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y.970@8V]M<')E:&5N<VEV92!I;F-O;64@
M*&QO<W,I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#,X+#,Q
M,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B0@*#(V,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#@L,S8R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y"87-I8R!A;F0@9&EL=71E9"!N970@:6YC;VUE
M("AL;W-S*2!P97(@8V]M;6]N('-H87)E/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B0@*#$N-"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B0@*#`N,#0I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y"87-I8R!A;F0@9&EL=71E
M9"!W96EG:'1E9"!A=F5R86=E(&YU;6)E<B!O9B!C;VUM;VX@<VAA<F5S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-RPS.#0L.3DP/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-BPX-#<L
M-CDW/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,2PP.#,L,C<V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].
M97AT4&%R=%\X9&(U,S=C-%]E.#<X7S1A,V5?.#(X85]B-3`P9C-E9&8Q,68-
M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.&1B-3,W8S1?93@W.%\T
M83-E7S@R.&%?8C4P,&8S961F,3%F+U=O<FMS:&5E=',O4VAE970P-2YH=&UL
M#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE
M#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB
M#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$
M0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T
M9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO
M=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T
M/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T
M(&ED/3-$240P150S04L^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0Q/CQS=')O;F<^0V]N<V]L
M:61A=&5D(%-T871E;65N=',@;V8@4W1O8VMH;VQD97)S)R!%<75I='D@*$1E
M9FEC:70I("A54T0@)"D\8G(^26X@5&AO=7-A;F1S+"!E>&-E<'0@4VAA<F4@
M9&%T83PO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E1O
M=&%L/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<FEE<R!!
M+3$@0V]N=F5R=&EB;&4@4')E9F5R<F5D(%-T;V-K(%M-96UB97)=/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<FEE<R!!+3(@0V]N=F5R
M=&EB;&4@4')E9F5R<F5D(%-T;V-K(%M-96UB97)=/&)R/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/E-E<FEE<R!"($-O;G9E<G1I8FQE(%!R969E
M<G)E9"!3=&]C:R!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y397)I97,@0R!#;VYV97)T:6)L92!0<F5F97)R960@4W1O8VL@
M6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5R
M:65S($0M,2!#;VYV97)T:6)L92!0<F5F97)R960@4W1O8VL@6TUE;6)E<ET\
M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5R:65S($0M,B!#
M;VYV97)T:6)L92!0<F5F97)R960@4W1O8VL@6TUE;6)E<ET\8G(^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^0V]M;6]N(%-T;V-K(%M-96UB97)=
M/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E1R96%S=7)Y(%-T
M;V-K(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/D%D9&ET:6]N86P@4&%I9"U);B!#87!I=&%L(%M-96UB97)=/&)R/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D%C8W5M=6QA=&5D($1E9FEC:70@
M6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R8SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D)E9VEN;FEN9R!"86QA;F-E(&%T($1E8RX@,S$L(#(P,3$\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,3<L-#@T*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,C8Y/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`W-#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-S$T
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`Q+#$Q,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@,30T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`V,S<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#$P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XD("@U."D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$V,RPT-3`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#$X,RPX,S0I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F,^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y"96=I;FYI;F<@0F%L86YC92P@4VAA<F5S(&%T($1E8RX@,S$L(#(P,3$\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(V+#@W-"PW.3(\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW+#,V
M-"PU.#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XW,2PT,#$L,C,W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,3$P+#DU,BPR,3<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-"PT-#8L,C(W/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C,L-C@Q+#$W
M-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$L,#0Y+#`S,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$T+#,X,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4VAA<F4M8F%S960@8V]M<&5N<V%T:6]N/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX,S@\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX,S@\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K(&]P
M=&EO;B!E>&5R8VES97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C0V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-#8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E-T;V-K(&]P=&EO;B!E>&5R8VES97,L(%-H87)E<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#8S+#$W-CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0Y+#@X-#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&EN
M8V]M92`H;&]S<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@L
M,S8R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^."PS-C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R8SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D5N9&EN9R!"86QA;F-E(&%T($1E8RX@,S$L(#(P,3(\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#@L,C,X*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(V.3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<T/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S$T/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PQ
M,3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ-#0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XV,S<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#4X*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$V-"PS,S0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@Q-S4L-#<R*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')C/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YD:6YG($)A;&%N8V4L
M(%-H87)E<R!A="!$96,N(#,Q+"`R,#$R/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XR-BPX-S0L-SDR/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-RPS-C0L-3@R/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S$L-#`Q+#(S-SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$Q,"PY
M-3(L,C$W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,30L-#0V+#(R-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C8S+#8X,2PQ-S8\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#`Y."PY,30\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-"PS.#$\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H
M87)E+6)A<V5D(&-O;7!E;G-A=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^.#8R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^.#8R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y)<W-U86YC92!O9B!C;VUM;VX@<W1O8VLL(&YE
M="!O9B!O9F9E<FEN9R!C;W-T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^.#,L-C(S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XX,RPU-C4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/DES<W5A;F-E(&]F(&-O;6UO;B!S=&]C
M:RP@;F5T(&]F(&]F9F5R:6YG(&-O<W1S+"!3:&%R97,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C4L-S4P+#`P,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]N=F5R<VEO;B!O9B!P
M<F5F97)R960@<W1O8VL@=&\@8V]M;6]N('-T;V-K/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ+#@V,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^*#(V.2D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@W-"D\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@W,30I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,2PQ,3`I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,30T*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#8S
M-RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ-S$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XT+#8S-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^0V]N=F5R<VEO;B!O9B!P<F5F97)R960@<W1O8VL@=&\@
M8V]M;6]N('-T;V-K+"!3:&%R97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^*#(V+#@W-"PW.3(I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XH-RPS-C0L-3@R*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#<Q+#0P,2PR,S<I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3$P+#DU
M,BPR,3<I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XH,30L-#0V+#(R-RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B@V,RPV.#$L,3<V*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$W+#`V,"PV,S0\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K
M(&]P=&EO;B!E>&5R8VES97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$L,#8X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ+#`U-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4W1O8VL@;W!T:6]N(&5X97)C:7-E<RP@4VAA
M<F5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#(V."PP-#D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M+#(V."PP-#D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/DYE="!I;F-O;64@*&QO<W,I/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B@R-C$I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XH,C8Q*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')C/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YD:6YG($)A;&%N8V4@870@1&5C
M+B`S,2P@,C`Q,SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S@L
M.3$T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,C4R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XH-3@I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,C4T+#0U,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^*#$W-2PW,S,I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F,^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;F1I;F<@0F%L86YC92P@4VAA
M<F5S(&%T($1E8RX@,S$L(#(P,3,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C(U+#$W-RPU.3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ-"PS.#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H87)E+6)A<V5D(&-O;7!E;G-A
M=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPR-#0\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#(T
M-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^27-S=6%N8V4@;V8@8V]M;6]N('-T;V-K+"!N970@;V8@;V9F97)I;F<@
M8V]S=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<V+#<Q-CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(R
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-S8L-CDT/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y)<W-U86YC92!O9B!C;VUM;VX@<W1O8VLL(&YE="!O9B!O9F9E
M<FEN9R!C;W-T<RP@4VAA<F5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XR+#(U,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E-T;V-K('!L86X@<F5L871E9"!A8W1I=FET>2P@
M=F%L=64@;V8@<VAA<F5S(&ES<W5E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-S(U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^*#$Y*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C<S.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4W1O8VL@<&QA;B!R96QA=&5D(&%C=&EV
M:71Y+"!S:&%R97,@:7-S=65D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XU-C@L,#0Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^.#8U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y2971I<F5M96YT(&]F('1R96%S=7)Y('-T;V-K
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU.#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#4X*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1O8VL@
M;W!T:6]N(&5X97)C:7-E<RP@4VAA<F5S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XU-C@L.3`V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y2971I<F5M96YT(&]F('1R96%S=7)Y('-T
M;V-K+"!3:&%R97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$T
M+#,X,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/DYE="!I;F-O;64@*&QO<W,I/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B@S."PS,3,I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XH,S@L,S$S*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')C/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YD:6YG($)A;&%N8V4@870@
M1&5C+B`S,2P@,C`Q-#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`Q,C$L,C@V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`R.#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B0@*#$Y*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@,S,U+#`W,3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,C$T+#`T-BD\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M8SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N9&EN
M9R!"86QA;F-E+"!3:&%R97,@870@1&5C+B`S,2P@,C`Q-#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,C<L.3DU+#8S.#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@V-3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^
M#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?.&1B-3,W8S1?93@W.%\T
M83-E7S@R.&%?8C4P,&8S961F,3%F#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE
M.B\O+T,Z+SAD8C4S-V,T7V4X-SA?-&$S95\X,CAA7V(U,#!F,V5D9C$Q9B]7
M;W)K<VAE971S+U-H965T,#8N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O
M9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT
M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@
M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$
M)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X
M="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4
M:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@
M(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$4T,4%'/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S
M<&%N/3-$,CX\<W1R;VYG/D-O;G-O;&ED871E9"!3=&%T96UE;G1S(&]F($-A
M<V@@1FQO=W,@*%531"`D*3QB<CY);B!4:&]U<V%N9',L('5N;&5S<R!O=&AE
M<G=I<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@@8V]L<W!A;CTS1#,^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/D]P97)A=&EN9R!A8W1I=FET:65S/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!I;F-O
M;64@*&QO<W,I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#,X
M+#,Q,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B0@*#(V,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#@L,S8R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D%D:G5S=&UE;G1S('1O(')E
M8V]N8VEL92!N970@:6YC;VUE("AL;W-S*2!T;R!N970@8V%S:"!U<V5D(&EN
M(&]P97)A=&EN9R!A8W1I=FET:65S.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y$97!R96-I871I;VX@97AP96YS93PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PX,C(\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#$Y,SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDV,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAA
M<F4M8F%S960@8V]M<&5N<V%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XS+#(T-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C@V,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C@S.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^1F%I<B!V86QU92!A9&IU<W1M96YT(&]F
M('=A<G)A;G0@;&EA8FEL:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XV,C8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B@Q-3$I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-H86YG97,@:6X@;W!E<F%T:6YG(&%S
M<V5T<R!A;F0@;&EA8FEL:71I97,Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D%C8V]U;G1S(')E8V5I=F%B;&4\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#DS,2D\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT,CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,S4R/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F5P86ED
M(&5X<&5N<V5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S+#(S
M.2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@X,S0I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XH.3$I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y297-T<FEC=&5D(&-A<V@\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$P-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$W-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^3W1H97(@87-S971S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@Q+#$W.2D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S-S4I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C;W5N=',@<&%Y
M86)L93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,2PU,#`I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-3<P
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M*#<L,S$R*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^06-C<G5E9"!E>'!E;G-E<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-"PS-#8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XR+#,T-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$X-3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&5A<V4@97AI="!L:6%B:6QI
M='D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$L-#,Y*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#8R.2D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@U
M,S0I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y$969E<G)E9"!R979E;G5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XS+#,Q-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^*#$V+#8W-BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@Q,"PX,3`I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$969E<G)E9"!R96YT/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R,S0I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`S/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#0Q/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/=&AE
M<B!L:6%B:6QI=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,2PR-#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y.970@8V%S:"!U<V5D(&EN(&]P97)A=&EN9R!A8W1I=FET:65S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S,BPW-3DI/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,30L,3<R
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M*#8L-3@R*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY#87-H(&9L;W=S(&9R;VT@:6YV97-T:6YG(&%C
M=&EV:71I97,\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4'5R8VAA<V5S(&]F('!R;W!E<G1Y(&%N9"!E<75I<&UE;G0\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#,L-3<R*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(L.38Q*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#DT,"D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/DYE="!C87-H('5S960@:6X@:6YV97-T:6YG(&%C=&EV:71I97,\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#,L-3<R*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(L.38Q*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#DT,"D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^0V%S:"!F;&]W<R!F<F]M(&9I;F%N8VEN9R!A8W1I=FET:65S/"]S
M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R;V-E
M961S(&9R;VT@:7-S=6%N8V4@;V8@8V]M;6]N('-T;V-K+"!N970@;V8@;V9F
M97)I;F<@8V]S=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<V
M+#<Q-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C@T+#<W,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^4')O8V5E9',@9G)O;2!S=&]C:R!O<'1I;VX@97AE<F-I
M<V5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW-#0\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#$P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0W
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y0=7)C:&%S92!O9B!T<F5A<W5R>2!S=&]C:SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH,3DI/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&-A<V@@<')O=FED960@8GD@9FEN
M86YC:6YG(&%C=&EV:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C<W+#0T,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C@U+#@W,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C0W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&-H86YG92!I;B!C87-H(&%N9"!C
M87-H(&5Q=6EV86QE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XT,2PQ,3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XV."PW,S@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B@W+#0W-2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A<V@@86YD(&-A<V@@97%U:79A;&5N
M=',@870@8F5G:6YN:6YG(&]F('!E<FEO9#PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,3$V+#0X,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C0W+#<T,SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4U+#(Q.#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V%S:"!A;F0@8V%S
M:"!E<75I=F%L96YT<R!A="!E;F0@;V8@<&5R:6]D/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ-3<L-3DQ/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3$V+#0X,3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0W+#<T,SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N
M9SY.;VYC87-H(&9I;F%N8VEN9R!A8W1I=FET:65S.CPO<W1R;VYG/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VYV97)S:6]N(&]F('!R
M969E<G)E9"!S=&]C:SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`R+#DT-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\
M+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A
M<G1?.&1B-3,W8S1?93@W.%\T83-E7S@R.&%?8C4P,&8S961F,3%F#0I#;VYT
M96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+SAD8C4S-V,T7V4X-SA?-&$S95\X
M,CAA7V(U,#!F,V5D9C$Q9B]7;W)K<VAE971S+U-H965T,#<N:'1M;`T*0V]N
M=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N
M=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\
M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E
M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^
M/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^
M+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE
M860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS
M1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@
M8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY/<F=A;FEZ871I;VX@
M86YD($YA='5R92!O9B!/<&5R871I;VYS/&)R/CPO<W1R;VYG/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%
M;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D%C8V]U;G1I;F<@4&]L:6-I
M97,@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y/<F=A;FEZ871I;VX@86YD($YA='5R92!O9B!/<&5R871I
M;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV/@T*(#QP
M('-T>6QE/3-$)VUA<F=I;BUT;W`Z,3)P=#L@;6%R9VEN+6)O='1O;3HP<'0[
M(&9O;G0M<VEZ93HQ,'!T.R!F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86XG
M/@T*(#QB/C$N($]R9V%N:7IA=&EO;B!A;F0@3F%T=7)E(&]F($]P97)A=&EO
M;G,\+V(^/"]P/@T*(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z-G!T.R!M87)G
M:6XM8F]T=&]M.C!P=#L@=&5X="UI;F1E;G0Z-"4[(&9O;G0M<VEZ93HQ,'!T
M.R!F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86XG/@T*($UA8W)O1V5N:6-S
M+"!);F,N("AT:&4@)B-X,C`Q0SM#;VUP86YY)B-X,C`Q1#LI('=A<R!I;F-O
M<G!O<F%T960@:6X-"B!$96QA=V%R92!O;B!!=6=U<W0F(WA!,#LQ-"P@,C`P
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M<')O9'5C=`T*(&-A;F1I9&%T97,L('=H:6-H('1H92!#;VUP86YY(&AA<R!I
M9&5N=&EF:65D('1H<F]U9V@@:71S#0H@=6YD97)S=&%N9&EN9R!O9B!D:7-E
M87-E(&)I;VQO9WD@86YD(&EM;75N92UM961I871E9"!M96-H86YI<VUS+`T*
M(&UA>2!A9&1R97-S(&1I<V5A<V4M<W!E8VEF:6,@8VAA;&QE;F=E<R!W:&EC
M:"!A<F4@;F]T(&-U<G)E;G1L>0T*(&)E:6YG(&UE="!B>2!E>&ES=&EN9R!T
M:&5R87!I97,N/"]P/@T*(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-
M"BTM+2TM+3U?3F5X=%!A<G1?.&1B-3,W8S1?93@W.%\T83-E7S@R.&%?8C4P
M,&8S961F,3%F#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+SAD8C4S
M-V,T7V4X-SA?-&$S95\X,CAA7V(U,#!F,V5D9C$Q9B]7;W)K<VAE971S+U-H
M965T,#@N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D
M+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970]
M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T
M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@
M8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T
M('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@
M*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S
M<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N
M9SY3=6UM87)Y(&]F(%-I9VYI9FEC86YT($%C8V]U;G1I;F<@4&]L:6-I97,\
M8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L
M<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P
M,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^06-C;W5N=&EN9R!0;VQI8VEE<R!;06)S=')A8W1=/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-U;6UA<GD@;V8@4VEG
M;FEF:6-A;G0@06-C;W5N=&EN9R!0;VQI8VEE<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/&1I=CX-"B`\<"!S='EL93TS1"=-05)'24XM0D]4
M5$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@34%21TE.+51/4#H@,3AP="<^#0H@/&(^,BX@4W5M;6%R
M>2!O9B!3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S/"]B/CPO<#X-
M"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/
M4#H@-G!T)SX-"B`\8CX\:3Y"87-I<R!O9B!0<F5S96YT871I;VX@86YD(%!R
M:6YC:7!L97,@;V8-"B!#;VYS;VQI9&%T:6]N/"]I/CPO8CX\+W`^#0H@/'`@
M<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#9P
M=#L@5$585"U)3D1%3E0Z(#0E)SX-"B!4:&4@8V]N<V]L:61A=&5D(&9I;F%N
M8VEA;"!S=&%T96UE;G1S(&EN8VQU9&4@=&AE(&%C8V]U;G1S(&]F#0H@36%C
M<F]'96YI8W,L($EN8RX@86YD(&ET<R!W:&]L;'D@;W=N960@<W5B<VED:6%R
M:65S+"!-86-R;T=E;FEC<R!52PT*($QI;6ET960@86YD($UA8W)O1V5N:6-S
M(%=E<W0L($EN8RX@169F96-T:79E($1E8V5M8F5R)B-X03`[,C(L#0H@,C`Q
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M96-I<VEO;B!M86ME<BP@;W(@9&5C:7-I;VX-"B!M86MI;F<@9W)O=7`L(&EN
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M86YD(&EN9F5C=&EO=7,-"B!D:7-E87-E<RX\+W`^#0H@/'`@<W1Y;&4],T0G
M34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#$X<'0G/@T*(#QB
M/CQI/E5S92!O9B!%<W1I;6%T97,\+VD^/"]B/CPO<#X-"B`\<"!S='EL93TS
M1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@-G!T.R!415A4
M+4E.1$5.5#H@-"4G/@T*(%1H92!P<F5P87)A=&EO;B!O9B!T:&4@9FEN86YC
M:6%L('-T871E;65N=',@:6X@86-C;W)D86YC92!W:71H#0H@9V5N97)A;&QY
M(&%C8V5P=&5D(&%C8V]U;G1I;F<@<')I;F-I<&QE<R`H1T%!4"D@<F5Q=6ER
M97,@=&AE#0H@0V]M<&%N>2!T;R!M86ME(&5S=&EM871E<R!A;F0@:G5D9VUE
M;G1S(&EN(&-E<G1A:6X@8VER8W5M<W1A;F-E<PT*('1H870@869F96-T('1H
M92!R97!O<G1E9"!A;6]U;G1S(&]F(&%S<V5T<RP@;&EA8FEL:71I97,L(')E
M=F5N=65S#0H@86YD(&5X<&5N<V5S+"!A;F0@<F5L871E9"!D:7-C;&]S=7)E
M(&]F(&-O;G1I;F=E;G0@87-S971S(&%N9`T*(&QI86)I;&ET:65S+B!);B!P
M<F5P87)I;F<@=&AE<V4@8V]N<V]L:61A=&5D(&9I;F%N8VEA;"!S=&%T96UE
M;G1S+`T*(&UA;F%G96UE;G0@:&%S(&UA9&4@:71S(&)E<W0@97-T:6UA=&5S
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M;2!T:&5S90T*(&5S=&EM871E<RX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.
M+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$14Y4
M.B`T)2<^#0H@26X@861D:71I;VXL('!R:6]R('1O('1H92!#;VUP86YY)B-X
M,C`Q.3MS($E03R!I;B!/8W1O8F5R(#(P,3,L('1H90T*($-O;7!A;GD@=71I
M;&EZ960@97-T:6UA=&5S(&%N9"!A<W-U;7!T:6]N<R!I;B!D971E<FUI;FEN
M9R!T:&4@9F%I<@T*('9A;'5E(&]F(&ET<R!C;VUM;VX@<W1O8VLN(%1H92!#
M;VUP86YY(&=R86YT960@<W1O8VL@;W!T:6]N<R!A=`T*(&5X97)C:7-E('!R
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M:6YC;'5D:6YG(&5X=&5R;F%L(&UA<FME=`T*(&-O;G-I9&5R871I;VYS(&%F
M9F5C=&EN9R!T:&4@8FEO=&5C:&YO;&]G>2!I;F1U<W1R>2!A;F0@=&AE#0H@
M:&ES=&]R:6,@<')I8V5S(&%T('=H:6-H('1H92!#;VUP86YY('-O;&0@<VAA
M<F5S(&]F(&ET<R!P<F5F97)R960-"B!S=&]C:RX\+W`^#0H@/'`@<W1Y;&4]
M,T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#$X<'0G/@T*
M(#QB/CQI/D-A<V@@86YD($-A<V@@17%U:79A;&5N=',\+VD^/"]B/CPO<#X-
M"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@
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M<V4@=&\@8F4@8V%S:"!E<75I=F%L96YT<RX@0V%S:"!A;F0@8V%S:`T*(&5Q
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M97,@9F%I<B!V86QU92X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/
M33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($U!4D=)3BU43U`Z(#$X<'0G/@T*(#QB/CQI/D%C8V]U;G1S
M(%)E8V5I=F%B;&4\+VD^/"]B/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM
M0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@-G!T.R!415A4+4E.1$5.5#H@
M-"4G/@T*($%C8V]U;G1S(')E8V5I=F%B;&4@=&AA="!M86YA9V5M96YT(&AA
M<R!T:&4@:6YT96YT(&%N9"!A8FEL:71Y('1O#0H@8V]L;&5C="!A<F4@<F5P
M;W)T960@:6X@=&AE(&-O;G-O;&ED871E9"!B86QA;F-E('-H965T<R!A=`T*
M(&]U='-T86YD:6YG(&%M;W5N=',L(&QE<W,@86X@86QL;W=A;F-E(&9O<B!D
M;W5B=&9U;"!A8V-O=6YT<RX@5&AE#0H@0V]M<&%N>2!W<FET97,@;V9F('5N
M8V]L;&5C=&EB;&4@<F5C96EV86)L97,@=VAE;B!T:&4@;&EK96QI:&]O9"!O
M9@T*(&-O;&QE8W1I;VX@:7,@<F5M;W1E+CPO<#X-"B`\<"!S='EL93TS1"=-
M05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@,3)P=#L@5$585"U)
M3D1%3E0Z(#0E)SX-"B!4:&4@0V]M<&%N>2!E=F%L=6%T97,@=&AE(&-O;&QE
M8W1A8FEL:71Y(&]F(&%C8V]U;G1S(')E8V5I=F%B;&4@;VX-"B!A(')E9W5L
M87(@8F%S:7,N(%1H92!A;&QO=V%N8V4L(&EF(&%N>2P@:7,@8F%S960@=7!O
M;B!V87)I;W5S#0H@9F%C=&]R<R!I;F-L=61I;F<@=&AE(&9I;F%N8VEA;"!C
M;VYD:71I;VX@86YD('!A>6UE;G0@:&ES=&]R>2!O9@T*(&-U<W1O;65R<RP@
M86X@;W9E<F%L;"!R979I97<@;V8@8V]L;&5C=&EO;G,@97AP97)I96YC92!O
M;B!O=&AE<@T*(&%C8V]U;G1S(&%N9"!E8V]N;VUI8R!F86-T;W)S(&]R(&5V
M96YT<R!E>'!E8W1E9"!T;R!A9F9E8W0@9G5T=7)E#0H@8V]L;&5C=&EO;G,@
M97AP97)I96YC92X@3F\@86QL;W=A;F-E('=A<R!R96-O<F1E9"!A<R!O9@T*
M($1E8V5M8F5R)B-X03`[,S$L(#(P,30@;W(@,C`Q,RP@87,@=&AE($-O;7!A
M;GD@:&%S(&$@:&ES=&]R>2!O9@T*(&-O;&QE8W1I;F<@;VX@86QL(&]U='-T
M86YD:6YG(&%C8V]U;G1S+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]4
M5$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@34%21TE.+51/4#H@,3AP="<^#0H@/&(^/&D^4F5S=')I
M8W1E9"!#87-H/"]I/CPO8CX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/
M5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#9P=#L@5$585"U)3D1%3E0Z(#0E
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M92!S:&5E=',@87)E("0S,#`L,#`P(&%N9"`D-#`U+#`P,"!A=`T*($1E8V5M
M8F5R)B-X03`[,S$L(#(P,30@86YD(#(P,3,L(')E<W!E8W1I=F5L>2X\+W`^
M#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU4
M3U`Z(#$X<'0G/@T*(#QB/CQI/D9A:7(@5F%L=64@;V8@1FEN86YC:6%L($EN
M<W1R=6UE;G1S/"]I/CPO8CX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/
M5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#9P=#L@5$585"U)3D1%3E0Z(#0E
M)SX-"B!4:&4@9F%I<B!M87)K970@=F%L=65S(&]F('1H92!F:6YA;F-I86P@
M:6YS=')U;65N=',@:6YC;'5D960@:6X@=&AE#0H@9FEN86YC:6%L('-T871E
M;65N=',L('=H:6-H(&EN8VQU9&4@8V%S:"!E<75I=F%L96YT<R!A;F0@;6]N
M97D-"B!M87)K970@86-C;W5N=',L(&%P<')O>&EM871E('1H96ER(&-A<G)Y
M:6YG('9A;'5E<R!A=`T*($1E8V5M8F5R)B-X03`[,S$L(#(P,30@86YD(#(P
M,3,L(&1U92!T;R!T:&5I<B!S:&]R="UT97)M#0H@;6%T=7)I=&EE<RX@5&AE
M($-O;7!A;GD@86-C;W5N=',@9F]R(')E8W5R<FEN9R!A;F0@;F]N+7)E8W5R
M<FEN9PT*(&9A:7(@=F%L=64@;65A<W5R96UE;G1S(&EN(&%C8V]R9&%N8V4@
M=VET:"!T:&4@1FEN86YC:6%L($%C8V]U;G1I;F<-"B!3=&%N9&%R9',@0F]A
M<F0@*$9!4T(I($%C8V]U;G1I;F<@4W1A;F1A<F1S($-O9&EF:6-A=&EO;B`H
M05-#*2`X,C`L#0H@/&D^1F%I<B!686QU92!-96%S=7)E;65N=',@86YD($1I
M<V-L;W-U<F5S/"]I/B`H05-#(#@R,"DN($%30R`X,C`-"B!D969I;F5S(&9A
M:7(@=F%L=64L(&5S=&%B;&ES:&5S(&$@9F%I<B!V86QU92!H:65R87)C:'D@
M9F]R(&%S<V5T<PT*(&%N9"!L:6%B:6QI=&EE<R!M96%S=7)E9"!A="!F86ER
M('9A;'5E+"!A;F0@<F5Q=6ER97,@97AP86YD960-"B!D:7-C;&]S=7)E<R!A
M8F]U="!F86ER('9A;'5E(&UE87-U<F5M96YT<RX@5&AE($%30R`X,C`@:&EE
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M;F<@=&AR964@8V%T96=O<FEE<SH\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.
M+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#9P=#L@34%21TE.+51/4#H@,'!T
M)SX-"B`F(WA!,#L\+W`^#0H@/'1A8FQE('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D]21$52+4-/
M3$Q!4%-%.B!C;VQL87!S92<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG
M/3-$,"!W:61T:#TS1#$P,"4@8F]R9&5R/3-$,#X-"B`\='(^#0H@/'1D('=I
M9'1H/3-$-24^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$=&]P('=I9'1H
M/3-$,B4@86QI9VX],T1L969T/B8C>#(P,C([/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$=&]P('=I9'1H/3-$,24^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M=&]P(&%L:6=N/3-$;&5F=#Y,979E;"`Q)B-X,C`Q-#M&86ER('9A;'5E(&ES
M#0H@9&5T97)M:6YE9"!B>2!U<VEN9R!U;F%D:G5S=&5D('%U;W1E9"!P<FEC
M97,@=&AA="!A<F4@879A:6QA8FQE(&EN#0H@86-T:79E(&UA<FME=',@9F]R
M(&ED96YT:6-A;"!A<W-E=',@86YD(&QI86)I;&ET:65S+CPO=&0^#0H@/"]T
M<CX-"B`\+W1A8FQE/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P
M=#L@1D].5"U325I%.B`V<'0[($U!4D=)3BU43U`Z(#!P="<^#0H@)B-X03`[
M/"]P/@T*(#QT86)L92!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)/4D1%4BU#3TQ,05!313H@8V]L
M;&%P<V4G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@]
M,T0Q,#`E(&)O<F1E<CTS1#`^#0H@/'1R/@T*(#QT9"!W:61T:#TS1#4E/B8C
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M<F]B;W)A=&5D(&)Y(&]B<V5R=F%B;&4@;6%R:V5T(&1A=&$N/"]T9#X-"B`\
M+W1R/@T*(#PO=&%B;&4^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@
M,'!T.R!&3TY4+5-)6D4Z(#9P=#L@34%21TE.+51/4#H@,'!T)SX-"B`F(WA!
M,#L\+W`^#0H@/'1A8FQE('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D]21$52+4-/3$Q!4%-%.B!C
M;VQL87!S92<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T
M:#TS1#$P,"4@8F]R9&5R/3-$,#X-"B`\='(^#0H@/'1D('=I9'1H/3-$-24^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,B4@86QI
M9VX],T1L969T/B8C>#(P,C([/"]T9#X-"B`\=&0@=F%L:6=N/3-$=&]P('=I
M9'1H/3-$,24^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$=&]P(&%L:6=N
M/3-$;&5F=#Y,979E;"`S)B-X,C`Q-#M&86ER('9A;'5E(&ES#0H@9&5T97)M
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M"B`\+W1R/@T*(#PO=&%B;&4^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/
M33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($U!4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$14Y4.B`T)2<^
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M('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q.'!T
M.R!-05)'24XM5$]0.B`P<'0G/@T*("8C>$$P.SPO<#X-"B`\<"!S='EL93TS
M1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@,'!T.R!415A4
M+4E.1$5.5#H@-"4G/@T*($9I;F%N8VEA;"!A<W-E=',@86YD(&QI86)I;&ET
M:65S('-U8FIE8W0@=&\@9F%I<B!V86QU92!M96%S=7)E;65N=',-"B!W97)E
M(&%S(&9O;&QO=W,@*&EN('1H;W5S86YD<RDZ/"]P/@T*(#QP('-T>6QE/3-$
M)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,G!T.R!-05)'24XM
M5$]0.B`P<'0G/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"
M3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E)R!C96QL<W!A8VEN9STS1#`@8V5L
M;'!A9&1I;F<],T0P('=I9'1H/3-$.3(E(&%L:6=N/3-$8V5N=&5R(&)O<F1E
M<CTS1#`^#0H@/'1R/@T*(#QT9"!W:61T:#TS1#0S)3X\+W1D/@T*(#QT9"!V
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M)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$
M8F]T=&]M(&-O;'-P86X],T0Q-"!A;&EG;CTS1&-E;G1E<CX\8CY&86ER(%9A
M;'5E($UE87-U<F5M96YT<R!A=`T*($1E8V5M8F5R)B-X03`[,S$L(#(P,30\
M+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`X<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,CXF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI
M9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&(^475O
M=&5D)B-X03`[4')I8V5S)B-X03`[:6X\+V(^/&)R("\^#0H@/&(^06-T:79E
M($UA<FME=',\8G(@+SX-"B!F;W(\+V(^/&)R("\^#0H@/&(^261E;G1I8V%L
M($%S<V5T<SPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O
M;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT
M97(^/&(^4VEG;FEF:6-A;G0F(WA!,#M/=&AE<CPO8CX\8G(@+SX-"B`\8CY/
M8G-E<G9A8FQE/&)R("\^#0H@26YP=71S/"]B/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N
M/3-$,B!A;&EG;CTS1&-E;G1E<CX\8CY3:6=N:69I8V%N=#PO8CX\8G(@+SX-
M"B`\8CY5;F]B<V5R=F%B;&4\+V(^/&)R("\^#0H@/&(^26YP=71S/"]B/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#PO='(^
M#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S
M;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N
M=&5R/CQB/E1O=&%L/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q
M<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS
M1&-E;G1E<CX\8CY,979E;"`Q/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P
M,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A
M;&EG;CTS1&-E;G1E<CX\8CY,979E;"`R/"]B/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N
M/3-$,B!A;&EG;CTS1&-E;G1E<CX\8CY,979E;"`S/"]B/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O
M<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$
M14Y4.B`M,65M)SX-"B!!<W-E=',Z/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@
M/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($U!4D=)3BU,1494.B`S96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-
M"B!#87-H(&%N9"!C87-H(&5Q=6EV86QE;G1S/"]P/@T*(#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG
M;CTS1')I9VAT/C$S,2PU-#4\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I
M9VAT/C$S,2PU-#4\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P
M/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M;F]W<F%P/3-$;F]W<F%P/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^#0H@)B-X,C`Q-#LF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^#0H@)B-X,C`Q-#LF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E;3L@5$585"U)3D1%3E0Z("TQ
M96TG/@T*($UO;F5Y(&UA<FME="!F=6YD<SPO<#X-"B`\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A
M;&EG;CTS1')I9VAT/C(V+#`T-CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
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M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X-"B`F
M(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*
M("8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^
M#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($U!4D=)3BU,1494.B`S96T[(%1%6%0M24Y$14Y4.B`M,65M
M)SX-"B!297-T<FEC=&5D(&-A<V@\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1R:6=H=#XS,#`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P
M/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^,S`P/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^#0H@)B-X,C`Q-#LF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL
M93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4
M3U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z
M(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="
M3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$
M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^
M#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y
M;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO
M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4]
M,T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-
M"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*
M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF
M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP
M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!
M,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT
M<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX]
M,T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
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M)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^#0H@)B-X,C`Q-#LF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G
M1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C
M,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P
M,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$
M15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52
M+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-
M"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL
M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO
M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4]
M,T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^
M#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-
M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G
M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@
M/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF
M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*
M(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P="<^#0H@/'1D/CPO=&0^#0H@
M/'1D(&-O;'-P86X],T0Q-CX\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$
M)T9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$
M8F]T=&]M(&-O;'-P86X],T0Q-"!A;&EG;CTS1&-E;G1E<CX\8CY&86ER(%9A
M;'5E($UE87-U<F5M96YT<R!A=`T*($1E8V5M8F5R)B-X03`[,S$L(#(P,3,\
M+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`X<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,CXF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI
M9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&(^475O
M=&5D(%!R:6-E<R!I;CPO8CX\8G(@+SX-"B`\8CY!8W1I=F4@36%R:V5T<SQB
M<B`O/@T*(&9O<CPO8CX\8G(@+SX-"B`\8CY)9&5N=&EC86P@07-S971S/"]B
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG
M;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\8CY3:6=N
M:69I8V%N="!/=&AE<CPO8CX\8G(@+SX-"B`\8CY/8G-E<G9A8FQE/&)R("\^
M#0H@26YP=71S/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@
M<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E
M;G1E<CX\8CY3:6=N:69I8V%N=#PO8CX\8G(@+SX-"B`\8CY5;F]B<V5R=F%B
M;&4\+V(^/&)R("\^#0H@/&(^26YP=71S/"]B/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$
M)T9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$
M8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/E1O=&%L/"]B
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG
M;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\8CY,979E
M;"`Q/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G
M('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\
M8CY,979E;"`R/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@
M<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E
M;G1E<CX\8CY,979E;"`S/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO
M<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!!
M<W-E=',Z/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^
M#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,
M1494.B`S96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!#87-H(&%N9"!C87-H
M(&5Q=6EV86QE;G1S/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CDP+#0S
M-#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^.3`L-#,T/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XD
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A
M;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XD/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG
M;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO<CTS1"-#0T5%
M1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)
M3BU,1494.B`S96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!-;VYE>2!M87)K
M970@9G5N9',\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR-BPP
M-#<\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,C8L,#0W
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P
M/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^#0H@)B-X,C`Q-#LF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG
M/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM
M3$5&5#H@,V5M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@4F5S=')I8W1E9"!C
M87-H/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-#`U/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C0P-3PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A
M;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M(&%L:6=N/3-$<FEG:'0^#0H@)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q
M<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S
M;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI
M9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P
M,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q
M<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z
M(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P
M,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$
M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M
M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@
M/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O
M;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*
M(%1O=&%L($%S<V5T<SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ,38L.#@V/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1R:6=H=#XQ,38L.#@V/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C>$$P.R8C>$$P.R8C>$$P
M.R8C>$$P.R8C>$$P.R8C>$$P.R8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XD/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT
M/@T*("8C>$$P.R8C>$$P.R8C>$$P.R8C>$$P.R8C>$$P.R8C>$$P.R8C>$$P
M.R8C>$$P.R8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@
M<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!
M,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T
M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[
M/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U
M8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L
M92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P
M,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@
M,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/
M4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z
M(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D
M/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\+W1A8FQE/@T*(#QP('-T>6QE/3-$
M)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T.R!415A4
M+4E.1$5.5#H@-"4G/@T*(%1H92!#;VUP86YY)B-X,C`Q.3MS($QE=F5L(#$@
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M;W(-"B!L:6%B:6QI=&EE<R!I;B!A8W1I=F4@;6%R:V5T<RX\+W`^#0H@/'`@
M<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#$X
M<'0G/@T*(#QB/CQI/D-O;F-E;G1R871I;VX@;V8@0W)E9&ET(%)I<VL\+VD^
M/"]B/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M34%21TE.+51/4#H@-G!T.R!415A4+4E.1$5.5#H@-"4G/@T*(%-U8G-T86YT
M:6%L;'D@86QL(&]F('1H92!#;VUP86YY)B-X,C`Q.3MS(&-A<V@@86YD(&-A
M<V@@97%U:79A;&5N=',-"B!A<F4@;6%I;G1A:6YE9"!W:71H(&UA:F]R(&9I
M;F%N8VEA;"!I;G-T:71U=&EO;G,@:6X@=&AE(%5N:71E9`T*(%-T871E<RX@
M1&5P;W-I=',@:&5L9"!W:71H(&)A;FMS(&UA>2!E>&-E960@=&AE(&%M;W5N
M="!O9B!I;G-U<F%N8V4-"B!P<F]V:61E9"!O;B!S=6-H(&1E<&]S:71S+B!'
M96YE<F%L;'DL('1H97-E(&1E<&]S:71S(&UA>2!B90T*(')E9&5E;65D('5P
M;VX@9&5M86YD(&%N9"P@=&AE<F5F;W)E+"!B96%R(&UI;FEM86P@<FES:RX\
M+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)
M3BU43U`Z(#$R<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@1FEN86YC:6%L(&EN
M<W1R=6UE;G1S('1H870@<&]T96YT:6%L;'D@<W5B:F5C="!T:&4@0V]M<&%N
M>2!T;PT*(&-O;F-E;G1R871I;VYS(&]F(&-R961I="!R:7-K(&-O;G-I<W0@
M<')I;F-I<&%L;'D@;V8@8V%S:"!A;F0@8V%S:`T*(&5Q=6EV86QE;G1S+"!A
M;F0@86-C;W5N=',@<F5C96EV86)L92X@5&AE(&-O=6YT97)P87)T:65S(&%R
M90T*('9A<FEO=7,@8V]R<&]R871I;VYS+"!F:6YA;F-I86P@:6YS=&ET=71I
M;VYS(&%N9"!G;W9E<FYM96YT#0H@86=E;F-I97,@;V8@:&EG:"!C<F5D:70@
M<W1A;F1I;F<N/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P
M=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4G/@T*($9O
M<B!T:&4@>65A<G,@96YD960@1&5C96UB97(F(WA!,#LS,2P@,C`Q-"P@,C`Q
M,R!A;F0@,C`Q,BP@=&AE#0H@0V]M<&%N>28C>#(P,3D[<R!C;VQL86)O<F%T
M:6]N(')E=F5N=64@<F5L871E<R!T;R!A9W)E96UE;G1S('=I=&@-"B!486ME
M9&$@4&AA<FUA8V5U=&EC86P@0V]M<&%N>2!,:6UI=&5D("A486ME9&$I+"!,
M97,@3&%B;W)A=&]I<F5S#0H@4V5R=FEE<B!A;F0@26YS=&ET=70@9&4@4F5C
M:&5R8VAE<R!397)V:65R("AC;VQL96-T:79E;'DL(%-E<G9I97(I+`T*($=I
M;&5A9"!38VEE;F-E<RP@26YC+B`H1VEL96%D*2P@0F]E:')I;F=E<B!);F=E
M;&AE:6T@1VUB2`T*("A";V5H<FEN9V5R*2P@4&9I>F5R+"!);F,N("A09FEZ
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M<F%T;W)S(&%N9"!5+E,N(&=O=F5R;FUE;G0-"B!A9V5N8VEE<RX\+W`^#0H@
M/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$R
M<'0[($U!4D=)3BU43U`Z(#!P="<^#0H@)B-X03`[/"]P/@T*(#QP('-T>6QE
M/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`P<'0[(%1%
M6%0M24Y$14Y4.B`T)2<^#0H@5&AE(&9O;&QO=VEN9R!T86)L92!I;F-L=61E
M<R!T:&]S92!C;VQL86)O<F%T;W)S('1H870@<F5P<F5S96YT#0H@;6]R92!T
M:&%N(#$P)2!O9B!T;W1A;"!R979E;G5E(&5A<FYE9"!I;B!T:&4@<&5R:6]D
M<R!I;F1I8V%T960Z/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ
M(#!P=#L@1D].5"U325I%.B`Q,G!T.R!-05)'24XM5$]0.B`P<'0G/@T*("8C
M>$$P.SPO<#X-"B`\=&%B;&4@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"3U)$15(M0T],3$%04T4Z
M(&-O;&QA<'-E)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I
M9'1H/3-$.#0E(&%L:6=N/3-$8V5N=&5R(&)O<F1E<CTS1#`^#0H@/'1R/@T*
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M)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$
M8F]T=&]M(&-O;'-P86X],T0Q,"!A;&EG;CTS1&-E;G1E<CX-"B`\8CY996%R
M)B-X03`[16YD960F(WA!,#M$96-E;6)E<B8C>$$P.S,Q+#PO8CX\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT
M<B!S='EL93TS1"=&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G
M('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX-
M"B`\8CXF(WA!,#LF(WA!,#LF(WA!,#LF(WA!,#LR,#$T)B-X03`[)B-X03`[
M)B-X03`[)B-X03`[/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L
M:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E
M<CX-"B`\8CXF(WA!,#LF(WA!,#LF(WA!,#LF(WA!,#LR,#$S)B-X03`[)B-X
M03`[)B-X03`[)B-X03`[/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@
M<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E
M;G1E<CX-"B`\8CXF(WA!,#LF(WA!,#LF(WA!,#LF(WA!,#LR,#$R)B-X03`[
M)B-X03`[)B-X03`[)B-X03`[/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C
M;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-
M"B!397)V:65R/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,S8N
M-#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M)28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-3$N-CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)28C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^,3<N,SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^)28C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($)O96AR
M:6YG97(\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR."XV/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XE)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XR-"XX/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XE)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1R:6=H=#XQ."XT/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XE)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XG(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@
M/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@
M+3%E;2<^#0H@5&%K961A/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^,38N.#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`^)28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A
M;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[
M(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!':6QE860\+W`^#0H@/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@86QI9VX],T1R:6=H=#XQ,2XT/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#XE)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H
M=#XQ,RXX/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#XE)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO
M<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!%
M;&D@3&EL;'D\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XP+CD\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B4F
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$N-#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)28C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^-#@N.3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^)28C>$$P.SPO=&0^#0H@/"]T<CX-"B`\+W1A8FQE/@T*
M(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0
M.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4G/@T*(%1H92!F;VQL;W=I;F<@=&%B
M;&4@:6YC;'5D97,@=&AO<V4@8V]L;&%B;W)A=&]R<R!T:&%T(')E<')E<V5N
M=`T*(&UO<F4@=&AA;B`Q,"4@;V8@86-C;W5N=',@<F5C96EV86)L92!A="!T
M:&4@9&%T92!I;F1I8V%T960Z/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"
M3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,G!T.R!-05)'24XM5$]0.B`P<'0G
M/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"3U)$15(M0T],
M3$%04T4Z(&-O;&QA<'-E)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<]
M,T0P('=I9'1H/3-$-S8E(&%L:6=N/3-$8V5N=&5R(&)O<F1E<CTS1#`^#0H@
M/'1R/@T*(#QT9"!W:61T:#TS1#<U)3X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q,"4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T
M9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M.24^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-
M"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#AP=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P
M,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$-B!A;&EG
M;CTS1&-E;G1E<CX\8CY$96-E;6)E<B8C>$$P.S,Q+#PO8CX\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S
M='EL93TS1"=&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A
M;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX-"B`\
M8CXF(WA!,#LF(WA!,#LF(WA!,#LF(WA!,#LR,#$T)B-X03`[)B-X03`[)B-X
M03`[)B-X03`[/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G
M('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX-
M"B`\8CXF(WA!,#LF(WA!,#LF(WA!,#LF(WA!,#LR,#$S)B-X03`[)B-X03`[
M)B-X03`[)B-X03`[/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO<CTS
M1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!397)V
M:65R/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,S,N,SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)28C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^-BXT/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XE)B-X03`[/"]T9#X-"B`\+W1R/@T*
M(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^
M#0H@0F]E:')I;F=E<CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M/C(Q+C(\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P/B4F(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$R+C(\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B4F(WA!,#L\+W1D
M/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO<CTS1"-#0T5%1D8^
M#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,
M1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!'<F5E;B!#<F]S<SPO
M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$W+CD\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B4F(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG
M:'0^#0H@)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*
M(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z
M("TQ96TG/@T*($=I;&5A9#PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^#0H@)B-X,C`Q
M-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M-3,N-#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^)28C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O
M;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*
M(%!F:7IE<CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^#0H@)B-X,C`Q-#LF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,3(N,SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)28C>$$P
M.SPO=&0^#0H@/"]T<CX-"B`\+W1A8FQE/@T*(#QP('-T>6QE/3-$)TU!4D=)
M3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q.'!T)SX-"B`\8CX\:3Y0
M<F]P97)T>2!A;F0@17%U:7!M96YT/"]I/CPO8CX\+W`^#0H@/'`@<W1Y;&4]
M,T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#9P=#L@5$58
M5"U)3D1%3E0Z(#0E)SX-"B!0<F]P97)T>2!A;F0@97%U:7!M96YT(&%R92!S
M=&%T960@870@8V]S="X@57!O;B!R971I<F5M96YT(&]R('-A;&4L#0H@=&AE
M(&-O<W0@;V8@87-S971S(&1I<W!O<V5D(&]F(&%N9"!T:&4@<F5L871E9"!A
M8V-U;75L871E9`T*(&1E<')E8VEA=&EO;B!A<F4@<F5M;W9E9"!F<F]M('1H
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M=&5D('5S969U;"!L:79E<SH\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/
M5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$R<'0[($U!4D=)3BU43U`Z(#!P="<^
M#0H@)B-X03`[/"]P/@T*(#QT86)L92!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)/4D1%4BU#3TQ,
M05!313H@8V]L;&%P<V4G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS
M1#`@=VED=&@],T0W-B4@86QI9VX],T1C96YT97(@8F]R9&5R/3-$,#X-"B`\
M='(^#0H@/'1D('=I9'1H/3-$-34E/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#4E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/"]T<CX-"B`\
M='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N
M/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$58
M5"U)3D1%3E0Z("TQ96TG/@T*($-O;7!U=&5R(&5Q=6EP;65N=#PO<#X-"B`\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/C,@>65A<G,\+W1D/@T*(#PO='(^#0H@
M/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-
M"B!3;V9T=V%R93PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/C,@>65A
M<G,\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO<CTS1"-#
M0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!
M4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!&=7)N:71U
M<F4\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XQ,"!Y96%R<SPO=&0^
M#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$=&]P
M/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%
M3E0Z("TQ96TG/@T*($QA8F]R871O<GD@86YD(&]F9FEC92!E<75I<&UE;G0\
M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XU('EE87)S/"]T9#X-"B`\
M+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L;W(],T0C0T-%149&/@T*(#QT
M9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@
M,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@3&5A<V5H;VQD(&EM<')O=F5M
M96YT<SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(%-H;W)T97(F
M(WA!,#MO9B8C>$$P.VQE87-E)B-X03`[=&5R;28C>$$P.V]R)B-X03`[=7-E
M9G5L)B-X03`[;&EF93PO=&0^#0H@/"]T<CX-"B`\+W1A8FQE/@T*(#QP('-T
M>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q.'!T
M)SX-"B`\8CX\:3Y);7!A:7)M96YT(&]F($QO;F<M3&EV960@07-S971S/"]I
M/CPO8CX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($U!4D=)3BU43U`Z(#9P=#L@5$585"U)3D1%3E0Z(#0E)SX-"B!4:&4@0V]M
M<&%N>2!A<W-E<W-E<R!T:&4@<F5C;W9E<F%B:6QI='D@;V8@:71S(&QO;F<M
M;&EV960@87-S971S(&EN#0H@86-C;W)D86YC92!W:71H('1H92!P<F]V:7-I
M;VYS(&]F($%30R8C>$$P.S,V,"P@/&D^4')O<&5R='DL(%!L86YT#0H@86YD
M($5Q=6EP;65N=#PO:3XN($%30R`S-C`@<F5Q=6ER97,@=&AA="!L;VYG+6QI
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M8F4@9V5N97)A=&5D(&)Y('1H92!A<W-E=`T*(&]R(&%S<V5T(&=R;W5P+B!)
M9B!C87)R>6EN9R!V86QU92!E>&-E961S('1H92!S=6T@;V8@=6YD:7-C;W5N
M=&5D#0H@8V%S:"!F;&]W<RP@=&AE($-O;7!A;GD@=&AE;B!D971E<FUI;F5S
M('1H92!F86ER('9A;'5E(&]F('1H90T*('5N9&5R;'EI;F<@87-S970@9W)O
M=7`N($%N>2!I;7!A:7)M96YT('1O(&)E(')E8V]G;FEZ960@:7,@;65A<W5R
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M('1O('-E;&PN($%S(&]F($1E8V5M8F5R)B-X03`[,S$L(#(P,30@86YD#0H@
M,C`Q,RP@=&AE($-O;7!A;GD@9&5T97)M:6YE9"!T:&%T('1H97)E('=E<F4@
M;F\@:6UP86ER960@87-S971S(&%N9`T*(&AA9"!N;R!A<W-E=',@:&5L9"UF
M;W(M<V%L92X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T
M.R!&3TY4+5-)6D4Z(#$X<'0[($U!4D=)3BU43U`Z(#!P="<^#0H@)B-X03`[
M/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'
M24XM5$]0.B`P<'0G/@T*(#QB/CQI/DEN8V]M92!487AE<SPO:3X\+V(^/"]P
M/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM
M5$]0.B`V<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@1&5F97)R960@=&%X(&%S
M<V5T<R!A;F0@;&EA8FEL:71I97,@87)E(&1E=&5R;6EN960@8F%S960@;VX-
M"B!D:69F97)E;F-E<R!B971W965N('1H92!F:6YA;F-I86P@<F5P;W)T:6YG
M(&%N9"!T87@@8F%S:7,@;V8@87-S971S#0H@86YD(&QI86)I;&ET:65S(&%N
M9"!A<F4@;65A<W5R960@=7-I;F<@=&AE(&5N86-T960@=&%X(')A=&5S(&%N
M9`T*(&QA=W,@=&AA="!A<F4@97AP96-T960@=&\@8F4@:6X@969F96-T('=H
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M=7)E9"!A<R!T:&4@;&%R9V5S=`T*(&%M;W5N="!T:&%T(&ES(&UO<F4@;&EK
M96QY('1H86X@;F]T('1O(&)E(')E86QI>F5D('5P;VX@=6QT:6UA=&4-"B!S
M971T;&5M96YT+B!4:&4@0V]M<&%N>28C>#(P,3D[<R!P;VQI8WD@:7,@=&\@
M<F5C;W)D(&EN=&5R97-T(&%N9`T*('!E;F%L=&EE<R!R96QA=&5D('1O('5N
M8V5R=&%I;B!T87@@<&]S:71I;VYS(&%S(&$@8V]M<&]N96YT(&]F#0H@:6YC
M;VUE('1A>"!E>'!E;G-E+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]4
M5$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@34%21TE.+51/4#H@,3AP="<^#0H@/&(^/&D^4F5V96YU
M97,\+VD^/"]B/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P
M<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@34%21TE.+4Q%1E0Z(#(E.R!-05)'24XM5$]0.B`V<'0G/@T*(#QI
M/E)E=F5N=64@4F5C;V=N:71I;VX\+VD^/"]P/@T*(#QP('-T>6QE/3-$)TU!
M4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`V<'0[(%1%6%0M24Y$
M14Y4.B`T)2<^#0H@5&AE($-O;7!A;GD@96YT97)S(&EN=&\@8V]L;&%B;W)A
M=&EO;B!A;F0@;&EC96YS92!A9W)E96UE;G1S('=I=&@-"B!C;VQL86)O<F%T
M;W)S(&9O<B!T:&4@9&5V96QO<&UE;G0@;V8@;6]N;V-L;VYA;"!A;G1I8F]D
M>2UB87-E9`T*('1H97)A<&5U=&EC<R!T;R!T<F5A="!C86YC97(@86YD(&]T
M:&5R(&-O;7!L97@@9&ES96%S97,N(%1H92!T97)M<PT*(&]F('1H97-E(&%G
M<F5E;65N=',@8V]N=&%I;B!M=6QT:7!L92!D96QI=F5R86)L97,@=VAI8V@@
M;6%Y(&EN8VQU9&4-"B`H:2DF(WA!,#ML:6-E;G-E<RP@;W(@;W!T:6]N<R!T
M;R!O8G1A:6X@;&EC96YS97,L('1O('1H90T*($-O;7!A;GDF(W@R,#$Y.W,@
M=&5C:&YO;&]G:6-A;"!P;&%T9F]R;7,L('-U8V@@87,@:71S($9C#0H@3W!T
M:6UI>F%T:6]N(&%N9"!$=6%L+4%F9FEN:71Y(%)E+51A<F=E=&EN9R`H1$%2
M5"D@=&5C:&YO;&]G:65S+`T*("AI:2DF(WA!,#MR:6=H=',@=&\@9G5T=7)E
M('1E8VAN;VQO9VEC86P@:6UP<F]V96UE;G1S+`T*("AI:6DI)B-X03`[<F5S
M96%R8V@@86YD(&1E=F5L;W!M96YT(&%C=&EV:71I97,@=&\@8F4@<&5R9F]R
M;65D(&]N#0H@8F5H86QF(&]F('1H92!C;VQL86)O<F%T;W(@;W(@87,@<&%R
M="!O9B!T:&4@8V]L;&%B;W)A=&EO;BP@86YD#0H@*&EV*28C>$$P.W1H92!M
M86YU9F%C='5R92!O9B!P<F4M8VQI;FEC86P@;W(@8VQI;FEC86P@;6%T97)I
M86QS(&9O<@T*('1H92!C;VQL86)O<F%T;W(N(%!A>6UE;G1S('1O('1H92!#
M;VUP86YY('5N9&5R('1H97-E(&%G<F5E;65N=',-"B!M87D@:6YC;'5D92!N
M;VYR969U;F1A8FQE(&QI8V5N<V4@9F5E<RP@;W!T:6]N(&9E97,L(&5X97)C
M:7-E(&9E97,L#0H@<&%Y;65N=',@9F]R(')E<V5A<F-H(&%N9"!D979E;&]P
M;65N="!A8W1I=FET:65S+"!P87EM96YT<R!F;W(@=&AE#0H@;6%N=69A8W1U
M<F4@;V8@<')E+6-L:6YI8V%L(&]R(&-L:6YI8V%L(&UA=&5R:6%L<RP@;&EC
M96YS90T*(&UA:6YT96YA;F-E('!A>6UE;G1S+"!P87EM96YT<R!B87-E9"!U
M<&]N('1H92!A8VAI979E;65N="!O9@T*(&-E<G1A:6X@;6EL97-T;VYE<R!A
M;F0@<F]Y86QT:65S(&]N('!R;V1U8W0@<V%L97,N($]T:&5R(&)E;F5F:71S
M#0H@=&\@=&AE($-O;7!A;GD@;V8@=&AE<V4@86=R965M96YT<R!I;F-L=61E
M('1H92!R:6=H="!T;R!S96QL#0H@<')O9'5C=',@<F5S=6QT:6YG(&9R;VT@
M=&AE(&-O;&QA8F]R871I=F4@969F;W)T<R!O9B!T:&4@<&%R=&EE<R!I;@T*
M('-P96-I9FEC(&=E;V=R87!H:6,@=&5R<FET;W)I97,N(%1H92!#;VUP86YY
M(&9O;&QO=W,@=&AE('!R;W9I<VEO;G,-"B!O9B!T:&4@1D%30B!!4T,@5&]P
M:6,@-C`U+3(U+"`\:3Y2979E;G5E#0H@4F5C;V=N:71I;VXF(W@R,#$T.TUU
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M979A;'5A=&4@=VAI8V@@9&5L:79E<F%B;&5S(')E<')E<V5N=`T*('-E<&%R
M871E('5N:71S(&]F(&%C8V]U;G1I;F<@8F%S960@;VX@=&AE(&%C:&EE=F5M
M96YT(&]F(&-E<G1A:6X-"B!C<FET97)I82P@:6YC;'5D:6YG('=H971H97(@
M=&AE(&1E;&EV97)E9"!E;&5M96YT(&AA<R!S=&%N9"UA;&]N90T*('9A;'5E
M('1O('1H92!C;VQL86)O<F%T;W(N(%1H92!C;VYS:61E<F%T:6]N(')E8V5I
M=F5D(&ES(&%L;&]C871E9`T*(&%M;VYG('1H92!S97!A<F%T92!U;FET<R!O
M9B!A8V-O=6YT:6YG+"!A;F0@=&AE(&%P<&QI8V%B;&4@<F5V96YU90T*(')E
M8V]G;FET:6]N(&-R:71E<FEA(&%R92!A<'!L:65D('1O(&5A8V@@;V8@=&AE
M('-E<&%R871E('5N:71S+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]4
M5$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@34%21TE.+51/4#H@,3)P=#L@5$585"U)3D1%3E0Z(#0E
M)SX-"B!&;W(@=&AE('!E<FEO9',@<')E<V5N=&5D+"!T:&4@0V]M<&%N>2!H
M860@=&AE(&9O;&QO=VEN9R!T=V\@='EP97,-"B!O9B!A9W)E96UE;G1S.B`Q
M*2!E>&-L=7-I=F4@9&5V96QO<&UE;G0@86YD(&-O;6UE<F-I86QI>F%T:6]N
M#0H@;&EC96YS97,@=&\@=7-E('1H92!#;VUP86YY)B-X,C`Q.3MS('1E8VAN
M;VQO9WD@86YD+V]R(&-E<G1A:6X@;W1H97(-"B!I;G1E;&QE8W1U86P@<')O
M<&5R='D@=&\@9&5V96QO<"!C;VUP;W5N9',@86=A:6YS="!S<&5C:69I960-
M"B!T87)G971S("AR969E<G)E9"!T;R!H97)E:6X@87,@97AC;'5S:79E(&QI
M8V5N<V5S*3L@86YD(#(I#0H@3W!T:6]N+W)E<V5A<F-H(&%G<F5E;65N=',@
M=&\@<V5C=7)E(&]N(&5S=&%B;&ES:&5D('1E<FUS+`T*(&1E=F5L;W!M96YT
M(&%N9"!C;VUM97)C:6%L:7IA=&EO;B!L:6-E;G-E<R!T;R!T:&5R87!E=71I
M8R!P<F]D=6-T#0H@8V%N9&ED871E<R!T;R!C;VQL86)O<F%T;W(M<V5L96-T
M960@=&%R9V5T<R!D979E;&]P960@8GD@=&AE#0H@0V]M<&%N>2!D=7)I;F<@
M86X@;W!T:6]N('!E<FEO9"`H<F5F97)R960@=&\@:&5R96EN(&%S#0H@<FEG
M:'0M=&\M9&5V96QO<"!A9W)E96UE;G1S*2X\+W`^#0H@/'`@<W1Y;&4],T0G
M34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#$R<'0[(%1%6%0M
M24Y$14Y4.B`T)2<^#0H@5&AE<F4@87)E(&YO('!E<F9O<FUA;F-E+"!C86YC
M96QL871I;VXL('1E<FUI;F%T:6]N(&]R(')E9G5N9`T*('!R;W9I<VEO;G,@
M:6X@86YY(&]F('1H92!A<G)A;F=E;65N=',@=&AA="!C;VYT86EN(&UA=&5R
M:6%L#0H@9FEN86YC:6%L(&-O;G-E<75E;F-E<R!T;R!T:&4@0V]M<&%N>2X\
M+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)
M3BU,1494.B`R)3L@34%21TE.+51/4#H@,3AP="<^#0H@/&D^17AC;'5S:79E
M($QI8V5N<V5S/"]I/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-
M.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@34%21TE.+51/4#H@-G!T.R!415A4+4E.1$5.5#H@-"4G/@T*
M(%1H92!D96QI=F5R86)L97,@=6YD97(@86X@97AC;'5S:79E(&QI8V5N<V4@
M86=R965M96YT(&=E;F5R86QL>0T*(&EN8VQU9&4@=&AE(&5X8VQU<VEV92!L
M:6-E;G-E('1O('1H92!#;VUP86YY)B-X,C`Q.3MS($1!4E0-"B!T96-H;F]L
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M3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.
M5#H@-"4G/@T*($=E;F5R86QL>2P@97AC;'5S:79E(&QI8V5N<V4@86=R965M
M96YT<R!C;VYT86EN(&YO;G)E9G5N9&%B;&4@=&5R;7,-"B!F;W(@<&%Y;65N
M=',@86YD+"!D97!E;F1I;F<@;VX@=&AE('1E<FUS(&]F('1H92!A9W)E96UE
M;G0L('!R;W9I9&4-"B!T:&%T('1H92!#;VUP86YY('=I;&P@*&DI)B-X03`[
M870@=&AE(&-O;&QA8F]R871O<B8C>#(P,3D[<R!R97%U97-T+`T*('!R;W9I
M9&4@<F5S96%R8V@@86YD('!R92UC;&EN:6-A;"!D979E;&]P;65N="!S97)V
M:6-E<R!A=`T*(&YE9V]T:6%T960@<')I8V5S('=H:6-H(&%R92!G96YE<F%L
M;'D@8V]N<VES=&5N="!W:71H('=H870@;W1H97(-"B!T:&ER9"!P87)T:65S
M('=O=6QD(&-H87)G92P@*&EI*28C>$$P.V5A<FX@<&%Y;65N=',@=7!O;B!T
M:&4-"B!A8VAI979E;65N="!O9B!C97)T86EN(&UI;&5S=&]N97,L("AI:6DI
M)B-X03`[96%R;B!R;WEA;'1Y#0H@<&%Y;65N=',L(&%N9"`H:78I)B-X03`[
M:6X@<V]M92!C87-E<R!G<F%N="!T:&4@0V]M<&%N>2!A;B!O<'1I;VX-"B!T
M;R!P87)T:6-I<&%T92!I;B!T:&4@9&5V96QO<&UE;G0@86YD(&-O;6UE<F-I
M86QI>F%T:6]N(&]F('!R;V1U8W1S#0H@=&AA="!R97-U;'0@9G)O;2!S=6-H
M(&%G<F5E;65N=',N(%)O>6%L='D@<F%T97,@;6%Y('9A<GD@;W9E<B!T:&4-
M"B!R;WEA;'1Y('1E<FT@9&5P96YD:6YG(&]N('1H92!#;VUP86YY)B-X,C`Q
M.3MS(&EN=&5L;&5C='5A;"!P<F]P97)T>0T*(')I9VAT<R!A;F0@=VAE=&AE
M<B!T:&4@0V]M<&%N>2!E>&5R8VES97,@86YY(&-O+61E=F5L;W!M96YT(&%N
M9`T*(&-O+6-O;6UE<F-I86QI>F%T:6]N(')I9VAT<RX@5&AE($-O;7!A;GD@
M;6%Y('!R;W9I9&4@=&5C:&YI8V%L#0H@87-S:7-T86YC92!A;F0@<VAA<F4@
M86YY('1E8VAN;VQO9WD@:6UP<F]V96UE;G1S('=I=&@@:71S#0H@8V]L;&%B
M;W)A=&]R<R!D=7)I;F<@=&AE('1E<FT@;V8@=&AE(&-O;&QA8F]R871I;VX@
M86=R965M96YT<RX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@
M,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($U!4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@
M5&AE($-O;7!A;GD@9&]E<R!N;W0@9&ER96-T;'D@8V]N=')O;"!W:&5N(&%N
M>2!C;VQL86)O<F%T;W(@=VEL;`T*(&%C:&EE=F4@;6EL97-T;VYE<R!O<B!B
M96-O;64@;&EA8FQE(&9O<B!R;WEA;'1Y('!A>6UE;G1S+CPO<#X-"B`\<"!S
M='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@
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M97)I82P@:6YC;'5D:6YG('=H971H97(@=&AE(&1E;&EV97)E9`T*(&5L96UE
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M=&EV92!E=FED96YC92`H5E-/12D@:7,@;F]T#0H@879A:6QA8FQE+B!4:&4@
M;V)J96-T:79E(&]F($)%4U`@:7,@=&\@9&5T97)M:6YE('1H92!P<FEC92!A
M="!W:&EC:`T*('1H92!#;VUP86YY('=O=6QD('1R86YS86-T(&$@<V%L92!I
M9B!T:&4@96QE;65N="!W:71H:6X@=&AE(&QI8V5N<V4-"B!A9W)E96UE;G0@
M=V%S('-O;&0@;VX@82!S=&%N9&%L;VYE(&)A<VES+B!%<W1A8FQI<VAI;F<@
M0D534`T*(&EN=F]L=F5S(&UA;F%G96UE;G0F(W@R,#$Y.W,@:G5D9VUE;G0@
M86YD(&-O;G-I9&5R<R!M=6QT:7!L90T*(&9A8W1O<G,L(&EN8VQU9&EN9R!M
M87)K970@8V]N9&ET:6]N<R!A;F0@8V]M<&%N>2US<&5C:69I8R!F86-T;W)S
M+`T*(&EN8VQU9&EN9R!T:&]S92!F86-T;W)S(&-O;G1E;7!L871E9"!I;B!N
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M('1O('1H92!L:6-E;G-E+B!);@T*('9A;&ED871I;F<@=&AE($)%4U`L(&UA
M;F%G96UE;G0@8V]N<VED97)S('=H971H97(@8VAA;F=E<R!I;B!K97D-"B!A
M<W-U;7!T:6]N<R!U<V5D('1O(&1E=&5R;6EN92!T:&4@0D534"!W:6QL(&AA
M=F4@82!S:6=N:69I8V%N=`T*(&5F9F5C="!O;B!T:&4@86QL;V-A=&EO;B!O
M9B!T:&4@87)R86YG96UE;G0@8V]N<VED97)A=&EO;B!B971W965N#0H@=&AE
M(&UU;'1I<&QE(&1E;&EV97)A8FQE<RX@1&5L:79E<F%B;&5S('5N9&5R('1H
M92!A<G)A;F=E;65N="!A<F4-"B!S97!A<F%T92!U;FET<R!O9B!A8V-O=6YT
M:6YG(&EF("AI*28C>$$P.W1H92!D96QI=F5R960@:71E;2!H87,-"B!V86QU
M92!T;R!T:&4@8W5S=&]M97(@;VX@82!S=&%N9&%L;VYE(&)A<VES(&%N9"`H
M:6DI)B-X03`[:68@=&AE#0H@87)R86YG96UE;G0@:6YC;'5D97,@82!G96YE
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M;65N=`T*(&ES(&1E;&EV97)E9"X@36%N86=E;65N="!E>&5R8VES97,@<VEG
M;FEF:6-A;G0@:G5D9VUE;G0@:6X-"B!D971E<FUI;FEN9R!W:&5T:&5R(&$@
M9&5L:79E<F%B;&4@:7,@82!S97!A<F%T92!U;FET(&]F#0H@86-C;W5N=&EN
M9RX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!
M4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@26X@9&5T97)M
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M=VAE=&AE<B!O<B!N;W0@*&DI)B-X03`[=&AE(&-O;&QA8F]R871O<B!C;W5L
M9"!U<V4@=&AE(&QI8V5N<V4@9F]R#0H@:71S(&EN=&5N9&5D('!U<G!O<V4@
M=VET:&]U="!T:&4@<F5C96EP="!O9B!T:&4@<F5M86EN:6YG#0H@9&5L:79E
M<F%B;&5S+"`H:6DI)B-X03`[=&AE('9A;'5E(&]F('1H92!L:6-E;G-E('=A
M<R!D97!E;F1E;G0@;VX-"B!T:&4@=6YD96QI=F5R960@:71E;7,@86YD("AI
M:6DI)B-X03`[=&AE(&-O;&QA8F]R871O<B!O<B!O=&AE<@T*('9E;F1O<G,@
M8V]U;&0@<')O=FED92!T:&4@=6YD96QI=F5R960@:71E;7,N($EF('1H92!#
M;VUP86YY#0H@8V]N8VQU9&5S('1H870@=&AE(&QI8V5N<V4@:&%S('-T86YD
M+6%L;VYE('9A;'5E(&%N9"!T:&5R969O<F4@=VEL;`T*(&)E(&%C8V]U;G1E
M9"!F;W(@87,@82!S97!A<F%T92!U;FET(&]F(&%C8V]U;G1I;F<L('1H92!#
M;VUP86YY('1H96X-"B!D971E<FUI;F5S('1H92!E<W1I;6%T960@<V5L;&EN
M9R!P<FEC97,@;V8@=&AE(&QI8V5N<V4@86YD(&%L;`T*(&]T:&5R('5N:71S
M(&]F(&%C8V]U;G1I;F<@8F%S960@;VX@;6%R:V5T(&-O;F1I=&EO;G,L('-I
M;6EL87(-"B!A<G)A;F=E;65N=',@96YT97)E9"!I;G1O(&)Y('1H:7)D('!A
M<G1I97,L(&%N9"!E;G1I='DM<W!E8VEF:6,-"B!F86-T;W)S('-U8V@@87,@
M=&AE('1E<FUS(&]F('1H92!#;VUP86YY)B-X,C`Q.3MS('!R979I;W5S#0H@
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M871I=F4M<V5L;&EN9RUP<FEC92!M971H;V0N($EF(&9A8W1S(&%N9`T*(&-I
M<F-U;7-T86YC97,@9&EC=&%T92!T:&%T('1H92!E>&-L=7-I=F4@;&EC96YS
M92!D;V5S(&YO="!H879E#0H@<W1A;F0M86QO;F4@=F%L=64L('1H96X@=&AE
M(')E;&%T960@<&%Y;65N=',@87)E(&1E9F5R<F5D(&%N9`T*(')E=F5N=64@
M:7,@<F5C;V=N:7IE9"!T:')O=6=H;W5T('1H92!P97)I;V0@;V8@<&5R9F]R
M;6%N8V4N/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4G/@T*($UA;F%G
M96UE;G0@<F5A<W-E<W-E<R!T:&4@<&5R:6]D(&]F('!E<F9O<FUA;F-E(&]V
M97(@=VAI8V@@=&AE#0H@0V]M<&%N>2!R96-O9VYI>F5S(&1E9F5R<F5D('5P
M9G)O;G0@;&EC96YS92!F965S(&%N9"!M86ME<PT*(&%D:G5S=&UE;G1S(&%S
M(&%P<')O<')I871E(&EN('1H92!P97)I;V0@:6X@=VAI8V@@82!C:&%N9V4@
M:6X@=&AE#0H@97-T:6UA=&5D('!E<FEO9"!O9B!P97)F;W)M86YC92!I<R!I
M9&5N=&EF:65D+B!);B!T:&4@979E;G0@80T*(&-O;&QA8F]R871O<B!E;&5C
M=',@=&\@9&ES8V]N=&EN=64@9&5V96QO<&UE;G0@;V8@82!S<&5C:69I8PT*
M('!R;V1U8W0@8V%N9&ED871E('5N9&5R(&$@<VEN9VQE('1A<F=E="!L:6-E
M;G-E+"!B=70@<F5T86EN<R!I=',-"B!R:6=H="!T;R!U<V4@=&AE($-O;7!A
M;GDF(W@R,#$Y.W,@=&5C:&YO;&]G>2!T;R!D979E;&]P(&%N#0H@86QT97)N
M871I=F4@<')O9'5C="!C86YD:61A=&4@=&\@=&AE('-A;64@=&%R9V5T(&]R
M(&$@=&%R9V5T#0H@<W5B<W1I='5T92P@=&AE($-O;7!A;GD@=V]U;&0@8V5A
M<V4@86UO<G1I>F%T:6]N(&]F(&%N>2!R96UA:6YI;F<-"B!P;W)T:6]N(&]F
M('1H92!U<&9R;VYT(&9E92!U;G1I;"!T:&5R92!I<R!S=6)S=&%N=&EA;"!P
M<F4M8VQI;FEC86P-"B!A8W1I=FET>2!O;B!A;F]T:&5R('!R;V1U8W0@8V%N
M9&ED871E(&%N9"!I=',@<F5M86EN:6YG('!E<FEO9"!O9@T*('-U8G-T86YT
M:6%L(&EN=F]L=F5M96YT(&-A;B!B92!E<W1I;6%T960N($EN('1H92!E=F5N
M="!T:&%T(&$-"B!S:6YG;&4@=&%R9V5T(&QI8V5N<V4@=V5R92!T;R!B92!T
M97)M:6YA=&5D+"!T:&4@0V]M<&%N>2!W;W5L9`T*(')E8V]G;FEZ92!A<R!R
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M4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.
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M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'
M24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4G/@T*(%1H92!#;VUP86YY
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M(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0
M.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4G/@T*(%1H92!#;VUP86YY('1Y<&EC
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M<F-H+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M34%21TE.+51/4#H@,3)P=#L@5$585"U)3D1%3E0Z(#0E)SX-"B!4:&4@0V]M
M<&%N>28C>#(P,3D[<R!L:6-E;G-E(&%G<F5E;65N=',@:&%V92!M:6QE<W1O
M;F4@<&%Y;65N=',-"B!W:&EC:"!F;W(@<F5P;W)T:6YG('!U<G!O<V5S(&%R
M92!A9V=R96=A=&5D(&EN=&\@=&AR964@8V%T96=O<FEE<SH-"B`H:2DF(WA!
M,#MD979E;&]P;65N="!M:6QE<W1O;F5S+"`H:6DI)B-X03`[<F5G=6QA=&]R
M>2!M:6QE<W1O;F5S+`T*(&%N9"`H:6EI*28C>$$P.W-A;&5S(&UI;&5S=&]N
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M=F5L<RX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($U!4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@070@=&AE
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M)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T.R!415A4
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M=&EA;`T*(&EN=F]L=F5M96YT(&%N9"!A<F4@<F5C;V=N:7IE9"!A<R!R979E
M;G5E('5P;VX@86-H:65V96UE;G0@;V8@=&AE#0H@;6EL97-T;VYE+"!A<R!T
M:&5R92!A<F4@;F\@=6YD96QI=F5R960@96QE;65N=',@<F5M86EN:6YG(&%N
M9"!N;PT*(&-O;G1I;G5I;F<@<&5R9F]R;6%N8V4@;V)L:6=A=&EO;G,L(&%S
M<W5M:6YG(&%L;"!O=&AE<B!R979E;G5E#0H@<F5C;V=N:71I;VX@8W)I=&5R
M:6$@87)E(&UE="X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@
M,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($U!4D=)3BU,1494.B`R)3L@34%21TE.+51/4#H@,3AP="<^#0H@
M/&D^4FEG:'0M=&\M1&5V96QO<"!!9W)E96UE;G1S/"]I/CPO<#X-"B`\<"!S
M='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@-G!T
M.R!415A4+4E.1$5.5#H@-"4G/@T*(%1H92!#;VUP86YY)B-X,C`Q.3MS(')I
M9VAT+71O+61E=F5L;W`@86=R965M96YT<R!P<F]V:61E#0H@8V]L;&%B;W)A
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M>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T
M.R!415A4+4E.1$5.5#H@-"4G/@T*(%1H92!A8V-O=6YT:6YG(&9O<B!R:6=H
M="UT;RUD979E;&]P(&%G<F5E;65N=',@:7,@9&5P96YD96YT(&]N('1H90T*
M(&YA='5R92!O9B!T:&4@;W!T:6]N<R!G<F%N=&5D('1O('1H92!C;VQL86)O
M<F%T;W(N($]P=&EO;G,@87)E#0H@8V]N<VED97)E9"!S=6)S=&%N=&EV92!I
M9BP@870@=&AE(&EN8V5P=&EO;B!O9B!A(')I9VAT+71O+61E=F5L;W`-"B!A
M9W)E96UE;G0L('1H92!#;VUP86YY(&ES(&%T(')I<VL@87,@=&\@=VAE=&AE
M<B!T:&4@8V]L;&%B;W)A=&]R#0H@=VEL;"!C:&]O<V4@=&\@97AE<F-I<V4@
M=&AE(&]P=&EO;G,@=&\@<V5C=7)E(&1E=F5L;W!M96YT(&%N9`T*(&-O;6UE
M<F-I86QI>F%T:6]N(&QI8V5N<V5S+B!&86-T;W)S('1H870@87)E(&-O;G-I
M9&5R960@:6X-"B!E=F%L=6%T:6YG('=H971H97(@;W!T:6]N<R!A<F4@<W5B
M<W1A;G1I=F4@:6YC;'5D92!T:&4@;W9E<F%L;`T*(&]B:F5C=&EV92!O9B!T
M:&4@87)R86YG96UE;G0L('1H92!B96YE9FET('1H92!C;VQL86)O<F%T;W(@
M;6EG:'0-"B!O8G1A:6X@9G)O;2!T:&4@86=R965M96YT('=I=&AO=70@97AE
M<F-I<VEN9R!T:&4@;W!T:6]N<RP@=&AE(&-O<W0-"B!T;R!E>&5R8VES92!T
M:&4@;W!T:6]N<R!R96QA=&EV92!T;R!T:&4@=&]T86P@=7!F<F]N=`T*(&-O
M;G-I9&5R871I;VXL(&%N9"!T:&4@861D:71I;VYA;"!F:6YA;F-I86P@8V]M
M;6ET;65N=',@:6UP;W-E9"!O;@T*('1H92!C;VQL86)O<F%T;W(@87,@82!R
M97-U;'0@;V8@97AE<F-I<VEN9R!T:&4@;W!T:6]N<RX\+W`^#0H@/'`@<W1Y
M;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#$R<'0[
M(%1%6%0M24Y$14Y4.B`T)2<^#0H@1F]R(')I9VAT+71O+61E=F5L;W`@86=R
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M<FEO9`T*(&1U<FEN9R!W:&EC:"!T:&4@8V]L;&%B;W)A=&]R(&-O=6QD(&5L
M96-T('1O(&5X97)C:7-E(&]P=&EO;G,@9F]R#0H@9&5V96QO<&UE;G0@86YD
M(&-O;6UE<F-I86QI>F%T:6]N(&QI8V5N<V5S+B!4:&5S92!P97)I;V1S(&%R
M90T*('-P96-I9FEC('1O(&5A8V@@8V]L;&%B;W)A=&EO;B!A9W)E96UE;G0N
M($EF(&$@8V]L;&%B;W)A=&]R('-E;&5C=',-"B!A('1A<F=E="!F;W(@82!P
M<F]D=6-T('!R;V=R86TL(&%N>2!S=6)S=&%N=&EV92!O<'1I;VX@9F5E(&ES
M#0H@9&5F97)R960@86YD(')E8V]G;FEZ960@;W9E<B!T:&4@;&EF92!O9B!T
M:&4@;W!T:6]N+B!&;W(-"B!R:6=H="UT;RUD979E;&]P(&%G<F5E;65N=',@
M=&AA="!I;F-L=61E(&UU;'1I<&QE(&1E;&EV97)A8FQE<RP@=&AE#0H@0V]M
M<&%N>2!D971E<FUI;F5S('1H92!S96QL:6YG('!R:6-E<R!O9B!D96QI=F5R
M86)L97,@=6YD97(@=&AE#0H@87)R86YG96UE;G0@=7-I;F<@5%!%(&]R(&$@
M0D534"P@:68@5E-/12!I<R!N;W0@879A:6QA8FQE+B!4:&4-"B!O8FIE8W1I
M=F4@;V8@0D534"!I<R!T;R!D971E<FUI;F4@=&AE('!R:6-E(&%T('=H:6-H
M('1H92!#;VUP86YY#0H@=V]U;&0@=')A;G-A8W0@82!S86QE(&EF('1H92!E
M;&5M96YT('=I=&AI;B!T:&4@<FEG:'0M=&\M9&5V96QO<`T*(&%G<F5E;65N
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M(&YE9V]T:6%T:6YG('1H92!A9W)E96UE;G1S+`T*(&%S('=E;&P@87,@:6YT
M97)N86QL>2!D979E;&]P960@;6]D96QS('1H870@:6YC;'5D92!A<W-U;7!T
M:6]N<PT*(')E;&%T960@=&\@;6%R:V5T(&]P<&]R='5N:71Y+"!D:7-C;W5N
M=&5D(&-A<V@@9FQO=W,L(&5S=&EM871E9`T*(&1E=F5L;W!M96YT(&-O<W1S
M+"!P<F]B86)I;&ET>2!O9B!S=6-C97-S(&%N9"!T:&4@=&EM92!N965D960@
M=&\-"B!C;VUM97)C:6%L:7IE(&$@<')O9'5C="!C86YD:61A=&4@<'5R<W5A
M;G0@=&\@=&AE(')I9VAT+71O+61E=F5L;W`-"B!A9W)E96UE;G0N($EN('9A
M;&ED871I;F<@=&AE($)%4U`L(&UA;F%G96UE;G0@8V]N<VED97)S('=H971H
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M=&%N9&%L;VYE(&)A<VES(&%N9`T*("AI:2DF(WA!,#MI9B!T:&4@87)R86YG
M96UE;G0@:6YC;'5D97,@82!G96YE<F%L(')I9VAT(&]F(')E='5R;@T*(')E
M;&%T:79E('1O('1H92!D96QI=F5R960@:71E;2P@9&5L:79E<GD@;W(@<&5R
M9F]R;6%N8V4@;V8@=&AE#0H@=6YD96QI=F5R960@:71E;2!I<R!C;VYS:61E
M<F5D('!R;V)A8FQE(&%N9"!S=6)S=&%N=&EA;&QY('=I=&AI;@T*('1H92!#
M;VUP86YY)B-X,C`Q.3MS(&-O;G1R;VPN(%1H92!A<G)A;F=E;65N="!C;VYS
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M92!U;FET(&]F#0H@86-C;W5N=&EN9RX\+W`^#0H@/'`@<W1Y;&4],T0G34%2
M1TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$
M14Y4.B`T)2<^#0H@268@82!C;VQL86)O<F%T;W(@97AE<F-I<V5S(&%N(&]P
M=&EO;B!A;F0@86-Q=6ER97,@82!D979E;&]P;65N=`T*(&%N9"!C;VUM97)C
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M86YA9V5M96YT)B-X,C`Q.3MS#0H@8F5S="!E<W1I;6%T92!U<VEN9R!T:&4@
M<')O8V5S<R!F;W(@86X@97AC;'5S:79E(&QI8V5N<V4@87,-"B!D97-C<FEB
M960@86)O=F4N/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P
M=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4G/@T*(%5P
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M;&EZ871I;VX@;&EC96YS92!A;F0@;W1H97(@9&5L:79E<F%B;&5S+`T*(&EF
M(&%N>2P@=&\@9&5T97)M:6YE('1H92!A<'!R;W!R:6%T92!R979E;G5E(')E
M8V]G;FET:6]N(&UE=&AO9"X-"B!4:&ES(&UO9&5L(&ES(&-O;G-I<W1E;G0@
M=VET:"!T:&4@0V]M<&%N>28C>#(P,3D[<R!A8V-O=6YT:6YG('!O;&EC>0T*
M(&9O<B!U<&9R;VYT('!A>6UE;G1S(&]N(&5X8VQU<VEV92!L:6-E;G-E<R`H
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M('1E<FUI;F%T:6]N+@T*(%1H92!#;VUP86YY)B-X,C`Q.3MS(')I9VAT+71O
M+61E=F5L;W`@86=R965M96YT<R!H879E(&)E96X-"B!D971E<FUI;F5D('1O
M(&-O;G1A:6X@<W5B<W1A;G1I=F4@;W!T:6]N<RX\+W`^#0H@/'`@<W1Y;&4]
M,T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#$R<'0[(%1%
M6%0M24Y$14Y4.B`T)2<^#0H@1F]R(')I9VAT+71O+61E=F5L;W`@86=R965M
M96YT<R!W:&5R92!T:&4@;W!T:6]N<R!T;R!S96-U<F4-"B!D979E;&]P;65N
M="!A;F0@8V]M;65R8VEA;&EZ871I;VX@;&EC96YS97,@=&\@<')O9'5C="!P
M<F]G<F%M<R!A<F4-"B!N;W0@8V]N<VED97)E9"!S=6)S=&%N=&EV92P@=&AE
M($-O;7!A;GD@8V]N<VED97)S('1H92!D979E;&]P;65N=`T*(&%N9"!C;VUM
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M:7IA=&EO;B!L:6-E;G-E<RX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/
M5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#$X<'0G/@T*(#QB/CQI/E)E<V5A
M<F-H(&%N9"!$979E;&]P;65N="!#;W-T<SPO:3X\+V(^/"]P/@T*(#QP('-T
M>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`V<'0[
M(%1%6%0M24Y$14Y4.B`T)2<^#0H@4F5S96%R8V@@86YD(&1E=F5L;W!M96YT
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M86P@86-T:79I=&EE<R!A;F0-"B!R96=U;&%T;W)Y(&%P<')O=F%L<RX\+W`^
M#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU4
M3U`Z(#$X<'0G/@T*(#QB/CQI/D-O;7!R96AE;G-I=F4@26YC;VUE("A,;W-S
M*3PO:3X\+V(^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P
M=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!-05)'24XM5$]0.B`V<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@0V]M
M<')E:&5N<VEV92!I;F-O;64@*&QO<W,I(&ES(&-O;7!R:7-E9"!O9B!T:&4@
M;F5T(&EN8V]M92`H;&]S<RD-"B!A;F0@;W1H97(@8VAA;F=E<R!I;B!E<75I
M='D@=&AA="!A<F4@97AC;'5D960@9G)O;2!N970@:6YC;VUE#0H@*&QO<W,I
M+B!#;VUP<F5H96YS:79E(&EN8V]M92`H;&]S<RD@97%U86QS(&YE="!I;F-O
M;64@*&QO<W,I(&9O<@T*('1H92!Y96%R<R!E;F1E9"!$96-E;6)E<B8C>$$P
M.S,Q+"`R,#$T+"`R,#$S(&%N9"`R,#$R+CPO<#X-"B`\<"!S='EL93TS1"=-
M05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@,3AP="<^#0H@/&(^
M/&D^4W1O8VLM8F%S960@0V]M<&5N<V%T:6]N/"]I/CPO8CX\+W`^#0H@/'`@
M<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#9P
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M;W!T:6]N+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[
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M92!A8V-E;&5R871E9`T*(&%T=')I8G5T:6]N(&UE=&AO9"X@4F5C;V=N:71I
M;VX@;V8@<W1O8VLM8F%S960@8V]M<&5N<V%T:6]N(&5X<&5N<V4-"B!I<R!B
M87-E9"!O;B!T:&4@=F%L=64@;V8@=&AE('!O<G1I;VX@;V8@<W1O8VLM8F%S
M960@87=A<F1S('1H870@:7,-"B!U;'1I;6%T96QY(&5X<&5C=&5D('1O('9E
M<W0@9'5R:6YG('1H92!P97)I;V0N/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)
M3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.
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M9"!L:69E(&]F('1H90T*(&%W87)D+CPO<#X-"B`\<"!S='EL93TS1"=-05)'
M24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@,3AP="<^#0H@/&(^/&D^
M3F5T($EN8V]M92`H3&]S<RD@4&5R(%-H87)E/"]I/CPO8CX\+W`^#0H@/'`@
M<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#9P
M=#L@5$585"U)3D1%3E0Z(#0E)SX-"B!"87-I8R!I;F-O;64@*&QO<W,I('!E
M<B!C;VUM;VX@<VAA<F4@:7,@9&5T97)M:6YE9"!B>2!D:79I9&EN9PT*(&EN
M8V]M92`H;&]S<RD@871T<FEB=71A8FQE('1O(&-O;6UO;B!S=&]C:VAO;&1E
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M:RX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!
M4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@1F]R('1H92!Y
M96%R(&5N9&5D($1E8V5M8F5R)B-X03`[,S$L(#(P,3(L(&YE="!I;F-O;64@
M*&QO<W,I('!E<@T*('-H87)E('=A<R!C86QC=6QA=&5D('5N9&5R('1H92!T
M=V\M8VQA<W,@;65T:&]D('5N9&5R('=H:6-H(&%L;`T*(&5A<FYI;F=S("AD
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M;&1E<G,@;V8@=&AE#0H@4V5R:65S)B-X03`[02TQ+"!!+3(L($(L($,L($0L
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M('!R969E<G)E9`T*('-T;V-K(&-O=6QD('1H96X@8F4@8V]N=F5R=&5D+B!4
M:&5R969O<F4L('1H92!397)I97,@02TQ+"!!+3(L($(L#0H@0RP@1"!A;F0@
M1"TR(&%R92!P87)T:6-I<&%T:6YG('-E8W5R:71I97,N($%L;"!O9B!T:&4@
M;W5T<W1A;F1I;F<-"B!S:&%R97,@;V8@4V5R:65S)B-X03`[02TQ+"!!+3(L
M($(L($,L($0L(&%N9"!$+3(@8V]N=F5R=&EB;&4-"B!P<F5F97)R960@<W1O
M8VL@8V]N=F5R=&5D('1O(&-O;6UO;B!S=&]C:R!U<&]N('1H92!C;VYS=6UM
M871I;VX@;V8-"B!T:&4@0V]M<&%N>28C>#(P,3D[<R!)4$\@:6X@3V-T;V)E
M<B`R,#$S+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[
M($9/3E0M4TE:13H@,3)P=#L@34%21TE.+51/4#H@,'!T)SX-"B`F(WA!,#L\
M+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)
M3BU43U`Z(#!P=#L@5$585"U)3D1%3E0Z(#0E)SX-"B!"87-I8R!A;F0@9&EL
M=71E9"!I;F-O;64@*&QO<W,I('!E<B!C;VUM;VX@<VAA<F4@:7,@8V]M<'5T
M960@87,-"B!F;VQL;W=S("AI;B!T:&]U<V%N9',@97AC97!T('-H87)E(&%N
M9"!P97(@<VAA<F4@9&%T82DZ/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"
M3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,G!T.R!-05)'24XM5$]0.B`P<'0G
M/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"3U)$15(M0T],
M3$%04T4Z(&-O;&QA<'-E)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<]
M,T0P('=I9'1H/3-$.3(E(&%L:6=N/3-$8V5N=&5R(&)O<F1E<CTS1#`^#0H@
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M(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L
M:6=N/3-$8F]T=&]M(&-O;'-P86X],T0Q,"!A;&EG;CTS1&-E;G1E<CX\8CY9
M96%R($5N9&5D#0H@1&5C96UB97(F(WA!,#LS,2P\+V(^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y
M;&4],T0G1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI
M9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&(^,C`Q
M-#PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V
M86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&(^
M,C`Q,SPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED
M)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^
M/&(^,C`Q,CPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L;W(],T0C0T-%
M149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'
M24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@3F5T(&EN8V]M
M92`H;&]S<RD\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#,X+#,Q,SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@R-C$\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/BDF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1R:6=H=#XX+#,V,CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT
M<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@
M3&5S<SH@=6YD:7-T<FEB=71E9"!E87)N:6YG<R!A;&QO8V%T960@=&\@<&%R
M=&EC:7!A=&EN9PT*('-E8W5R:71I97,\+W`^#0H@/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*
M("8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^
M#0H@)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^*#@L,S8R/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT
M<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/
M4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%
M4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-
M"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL
M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P
M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS
M1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*
M(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@
M/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C
M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@
M<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P
M.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS
M1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M
M24Y$14Y4.B`M,65M)SX-"B!.970@:6YC;VUE("AL;W-S*2!A;&QO8V%B;&4@
M=&\@8V]M;6]N('-H87)E<SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH,S@L,S$S/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^*#(V,3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M(&%L:6=N/3-$<FEG:'0^#0H@)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q
M<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D
M;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U
M8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P
M,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P
M,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M
M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/
M4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\
M=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT
M9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@
M,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@0F%S:6,@=V5I9VAT960@879E
M<F%G92!C;VUM;VX@<VAA<F5S(&]U='-T86YD:6YG/"]P/@T*(#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^,C<L,S@T+#DY,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XV+#@T
M-RPV.3<\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,2PP.#,L,C<V/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO<CTS
M1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!"87-I
M8R!I;F-O;64@*&QO<W,I('!E<B!C;VUM;VX@<VAA<F4\+W`^#0H@/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^*#$N-#`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P/BDF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XH,"XP-#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C`N
M,#`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-
M"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@
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M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH,C8Q
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^."PS-C(\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-
M"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L
M:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@
M5$585"U)3D1%3E0Z("TQ96TG/@T*($QE<W,Z('5N9&ES=')I8G5T960@96%R
M;FEN9W,@86QL;V-A=&5D('1O('!A<G1I8VEP871I;F<@<V5C=7)I=&EE<PT*
M(&%N9"!O=&AE<B!A9&0M8F%C:W,@=&\@;F5T(&EN8V]M92`H;&]S<RD\+W`^
M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I
M9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^#0H@)B-X
M,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#@L
M,S8R/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XI)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)
M6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@
M,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X
M('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C
M,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P
M,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52
M+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/
M4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT
M9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D
M('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q
M96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!.970@:6YC;VUE("AL;W-S*2!A
M;&QO8V%B;&4@=&\@8V]M;6]N('-H87)E<SPO<#X-"B`\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH,S@L
M,S$S/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XI)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^*#(V,3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P
M/3-$;F]W<F%P/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P
M/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^#0H@)B-X,C`Q-#LF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].
M5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P
M,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P
M,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M
M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/
M4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\
M=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS
M1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-
M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G
M0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@
M/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XG(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@
M/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@
M+3%E;2<^#0H@0F%S:6,@=V5I9VAT960@879E<F%G92!C;VUM;VX@<VAA<F5S
M(&]U='-T86YD:6YG/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,C<L,S@T+#DY,#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XV+#@T-RPV.3<\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^,2PP.#,L,C<V/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^
M#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M
M)SX-"B!%9F9E8W0@;V8@9&EL=71I=F4@<V5C=7)I=&EE<SPO<#X-"B`\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^#0H@
M)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M
M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P
M,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q
M<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z
M(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P
M,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$
M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M
M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@
M/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O
M;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*
M($1I;'5T960@=V5I9VAT960@879E<F%G92!C;VUM;VX@<VAA<F5S(&]U='-T
M86YD:6YG/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,C<L,S@T+#DY,#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@86QI9VX],T1R:6=H=#XV+#@T-RPV.3<\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^,2PP.#,L,C<V/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO
M=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R
M('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]2
M1$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%
M4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^
M#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y
M;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\
M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE
M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P
M/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE
M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*
M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^
M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-
M"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T
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M;&EG;CTS1')I9VAT/B@Q+C0P/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#`N,#0\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/BDF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1R:6=H=#XP+C`P/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/"]T86)L
M93X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:
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M;G1I+61I;'5T:79E.CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-
M.B`P<'0[($9/3E0M4TE:13H@,3)P=#L@34%21TE.+51/4#H@,'!T)SX-"B`F
M(WA!,#L\+W`^#0H@/'1A8FQE('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D]21$52+4-/3$Q!4%-%
M.B!C;VQL87!S92<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W
M:61T:#TS1#DR)2!A;&EG;CTS1&-E;G1E<B!B;W)D97(],T0P/@T*(#QT<CX-
M"B`\=&0@=VED=&@],T0V,R4^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,R4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\
M=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^/"]T
M9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^/"]T9#X-"B`\=&0^/"]T9#X-
M"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS
M1"=&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS
M1&)O='1O;2!C;VQS<&%N/3-$,3`@86QI9VX],T1C96YT97(^/&(^665A<B!%
M;F1E9`T*($1E8V5M8F5R)B-X03`[,S$L/"]B/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$
M)T9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$
M8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/C(P,30\+V(^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N
M/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/C(P,3,\
M+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L
M:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/C(P
M,3(\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^
M#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#145&1CX-
M"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@
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M;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I
M9VAT/C(L,34V+#$Q-#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@4V5R
M:65S($$M,B!0<F5F97)R960@4W1O8VL\+W`^#0H@/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*
M("8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^
M#0H@)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^,SDR+#(W-#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R
M/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V
M86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M
M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@4V5R:65S($(@4')E9F5R<F5D(%-T
M;V-K/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C0L,S,V
M+#`S-SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG
M/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM
M3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@4V5R:65S($,@4')E
M9F5R<F5D(%-T;V-K/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I
M9VAT/C4L.3`Y+#DP-CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T
M;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.
M1$5.5#H@+3%E;2<^#0H@4V5R:65S($0@4')E9F5R<F5D(%-T;V-K/"]P/@T*
M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@
M86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C<V.2PT-C@\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L
M:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@
M5$585"U)3D1%3E0Z("TQ96TG/@T*(%-E<FEE<R!$+3(@4')E9F5R<F5D(%-T
M;V-K/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C,L,SDQ
M+#DY,3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG
M(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E
M;2<^#0H@169F96-T(&]F($-O;G9E<G1E9"!0<F5F97)R960@4W1O8VL\+W`^
M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$S+#$X.2PY,C`\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X
M03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT
M9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@
M,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@5V%R<F%N=',@=&\@<'5R8VAA
M<V4@4V5R:65S($0M,B!0<F5F97)R960@4W1O8VL\+W`^#0H@/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I
M9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$
M<FEG:'0^#0H@)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^,3@P+#<X-#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-
M"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L;W(],T0C0T-%149&/@T*
M(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&
M5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@4W1O8VL@3W!T:6]N<SPO
M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(L,#DT+#DP-#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR+#,Q,RPY-S`\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,RPR-#DL-S`R/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\<"!S='EL93TS
M1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@,3AP="<^#0H@
M/&(^/&D^4F5C96YT;'D@27-S=65D($%C8V]U;G1I;F<@4W1A;F1A<F1S/"]I
M/CPO8CX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($U!4D=)3BU43U`Z(#9P=#L@5$585"U)3D1%3E0Z(#0E)SX-"B!);B!-87D@
M,C`Q-"P@=&AE($9!4T(@:7-S=65D($%352!.;RXF(WA!,#LR,#$T+3`Y+"`\
M:3Y2979E;G5E(&9R;VT-"B!#;VYT<F%C=',@=VET:"!#=7-T;VUE<G,\+VD^
M("A!4U4@,C`Q-"TP.2DN($%352`R,#$T+3`Y('=I;&P-"B!E;&EM:6YA=&4@
M=')A;G-A8W1I;VXM(&%N9"!I;F1U<W1R>2US<&5C:69I8R!R979E;G5E(')E
M8V]G;FET:6]N#0H@9W5I9&%N8V4@=6YD97(@8W5R<F5N="!'04%0(&%N9"!R
M97!L86-E(&ET('=I=&@@82!P<FEN8VEP;&4M8F%S960-"B!A<'!R;V%C:"!F
M;W(@9&5T97)M:6YI;F<@<F5V96YU92!R96-O9VYI=&EO;BX@05-5(#(P,30M
M,#D@=VEL;`T*(')E<75I<F4@=&AA="!C;VUP86YI97,@<F5C;V=N:7IE(')E
M=F5N=64@8F%S960@;VX@=&AE('9A;'5E(&]F#0H@=')A;G-F97)R960@9V]O
M9',@;W(@<V5R=FEC97,@87,@=&AE>2!O8V-U<B!I;B!T:&4@8V]N=')A8W0N
M(%1H90T*($%352!A;'-O('=I;&P@<F5Q=6ER92!A9&1I=&EO;F%L(&1I<V-L
M;W-U<F4@86)O=70@=&AE(&YA='5R92P-"B!A;6]U;G0L('1I;6EN9R!A;F0@
M=6YC97)T86EN='D@;V8@<F5V96YU92!A;F0@8V%S:"!F;&]W<R!A<FES:6YG
M#0H@9G)O;2!C=7-T;VUE<B!C;VYT<F%C=',L(&EN8VQU9&EN9R!S:6=N:69I
M8V%N="!J=61G;65N=',@86YD#0H@8VAA;F=E<R!I;B!J=61G;65N=',@86YD
M(&%S<V5T<R!R96-O9VYI>F5D(&9R;VT@8V]S=',@:6YC=7)R960@=&\-"B!O
M8G1A:6X@;W(@9G5L9FEL;"!A(&-O;G1R86-T+B!!4U4@,C`Q-"TP.2!I<R!E
M9F9E8W1I=F4@9F]R(&%N;G5A;`T*(')E<&]R=&EN9R!P97)I;V1S(&)E9VEN
M;FEN9R!A9G1E<B!$96-E;6)E<B8C>$$P.S$U+"`R,#$V+B!%87)L>0T*(&%D
M;W!T:6]N(&ES(&YO="!P97)M:71T960N($5N=&ET:65S(&-A;B!T<F%N<VET
M:6]N('1O('1H92!S=&%N9&%R9`T*(&5I=&AE<B!R971R;W-P96-T:79E;'D@
M;W(@87,@82!C=6UU;&%T:79E(&5F9F5C="!A9&IU<W1M96YT(&%S(&]F#0H@
M=&AE(&1A=&4@;V8@861O<'1I;VXN($UA;F%G96UE;G0@:7,@8W5R<F5N=&QY
M(&%S<V5S<VEN9R!W:&%T(&5F9F5C=`T*('1H92!A9&]P=&EO;B!O9B!!4U4@
M,C`Q-"TP.2!W:6QL(&AA=F4@;VX@=&AE($-O;7!A;GDF(W@R,#$Y.W,-"B!C
M;VYS;VQI9&%T960@9FEN86YC:6%L('-T871E;65N=',@86YD(&%C8V]M<&%N
M>6EN9R!N;W1E<RX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@
M,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($U!4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@
M26X@2G5L>2`R,#$S+"!T:&4@1D%30B!I<W-U960@05-5($YO+B8C>$$P.S(P
M,3,M,3$L('=H:6-H(&%M96YD960-"B!!4T,@5&]P:6,@-S0P(')E9V%R9&EN
M9R!P<F5S96YT871I;VX@;V8@86X@=6YR96-O9VYI>F5D('1A>"!B96YE9FET
M#0H@=VAE;B!A(&YE="!O<&5R871I;F<@;&]S<R`H3D],*2!C87)R>69O<G=A
M<F0L(&$@<VEM:6QA<B!T87@@;&]S<RP-"B!O<B!A('1A>"!C<F5D:70@8V%R
M<GEF;W)W87)D(&5X:7-T<RX@5&AE(&%M96YD;65N=',@:6X@05-5#0H@3F\N
M)B-X03`[,C`Q,RTQ,2!R97%U:7)E(&%N(&5N=&ET>2!T;R!P<F5S96YT(&%N
M('5N<F5C;V=N:7IE9"!T87@-"B!B96YE9FET(&%S(&$@<F5D=6-T:6]N(&]F
M(&$@9&5F97)R960@=&%X(&%S<V5T(&9O<B!A;B!.3TP-"B!C87)R>69O<G=A
M<F0L(&]R('-I;6EL87(@=&%X(&QO<W,@;W(@=&%X(&-R961I="!C87)R>69O
M<G=A<F0L#0H@<F%T:&5R('1H86X@87,@82!L:6%B:6QI='D@=VAE;B`H,2DF
M(WA!,#MT:&4@=6YC97)T86EN('1A>"!P;W-I=&EO;@T*('=O=6QD(')E9'5C
M92!T:&4@3D],(&]R(&]T:&5R(&-A<G)Y9F]R=V%R9"!U;F1E<B!T:&4@=&%X
M(&QA=R!O9B!T:&4-"B!A<'!L:6-A8FQE(&IU<FES9&EC=&EO;B!A;F0@*#(I
M)B-X03`[=&AE(&5N=&ET>2!I;G1E;F1S('1O('5S92!T:&4-"B!D969E<G)E
M9"!T87@@87-S970@9F]R('1H870@<'5R<&]S92X@5&AE($%352!D;V5S(&YO
M="!R97%U:7)E(&YE=PT*(')E8W5R<FEN9R!D:7-C;&]S=7)E<RX@5&AI<R!A
M;65N9&UE;G0@=V%S(&5F9F5C=&EV92!P<F]S<&5C=&EV96QY#0H@9F]R(&9I
M<V-A;"!Y96%R<R!B96=I;FYI;F<@869T97(@1&5C96UB97(F(WA!,#LQ-2P@
M,C`Q,RP@86YD(&1I9`T*(&YO="!H879E(&$@;6%T97)I86P@:6UP86-T(&]N
M('1H92!#;VUP86YY)B-X,C`Q.3MS(&9I;F%N8VEA;`T*('-T871E;65N=',N
M/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'
M24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4G/@T*(%1H92!#;VUP86YY
M(&AA<R!E=F%L=6%T960@86QL(&]T:&5R($%357,@:7-S=65D('1H<F]U9V@@
M=&AE(&1A=&4-"B!T:&4@8V]N<V]L:61A=&5D(&9I;F%N8VEA;',@=V5R92!I
M<W-U960@86YD(&)E;&EE=F5S('1H870@=&AE#0H@861O<'1I;VX@;V8@=&AE
M<V4@=VEL;"!N;W0@:&%V92!A(&UA=&5R:6%L(&EM<&%C="!O;B!T:&4-"B!#
M;VUP86YY)B-X,C`Q.3MS(&-O;G-O;&ED871E9"!F:6YA;F-I86P@<W1A=&5M
M96YT<RX\+W`^#0H@/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM
M+2TM/5].97AT4&%R=%\X9&(U,S=C-%]E.#<X7S1A,V5?.#(X85]B-3`P9C-E
M9&8Q,68-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.&1B-3,W8S1?
M93@W.%\T83-E7S@R.&%?8C4P,&8S961F,3%F+U=O<FMS:&5E=',O4VAE970P
M.2YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I
M;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M
M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q
M=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R
M<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C
M/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO
M<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$
M<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E!R
M;W!E<G1Y(&%N9"!%<75I<&UE;G0\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4')O<&5R='DL(%!L86YT(&%N9"!%
M<75I<&UE;G0@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y0<F]P97)T>2!A;F0@17%U:7!M96YT/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV/@T*(#QP('-T>6QE/3-$
M)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q.'!T)SX-"B`\
M8CXS+B!0<F]P97)T>2!A;F0@17%U:7!M96YT/"]B/CPO<#X-"B`\<"!S='EL
M93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@-G!T.R!4
M15A4+4E.1$5.5#H@-"4G/@T*(%!R;W!E<G1Y(&%N9"!E<75I<&UE;G0@8V]N
M<VES=',@;V8@=&AE(&9O;&QO=VEN9R`H:6X-"B!T:&]U<V%N9',I.CPO<#X-
M"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@
M,3)P=#L@34%21TE.+51/4#H@,'!T)SX-"B`F(WA!,#L\+W`^#0H@/'1A8FQE
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S92<@8V5L;'-P
M86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#<V)2!A;&EG;CTS
M1&-E;G1E<B!B;W)D97(],T0P/@T*(#QT<CX-"B`\=&0@=VED=&@],T0W,24^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24^/"]T9#X-
M"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$."4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\
M=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&
M3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O
M='1O;2!C;VQS<&%N/3-$-B!A;&EG;CTS1&-E;G1E<CX\8CY$96-E;6)E<B8C
M>$$P.S,Q+#PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#AP=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$
M,B!A;&EG;CTS1&-E;G1E<CX\8CXR,#$T/"]B/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N
M/3-$,B!A;&EG;CTS1&-E;G1E<CX\8CXR,#$S/"]B/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-
M"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4
M.B`M,65M)SX-"B!#;VUP=71E<B!E<75I<&UE;G0\+W`^#0H@/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^,BPU.38\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I
M9VAT/C(L,S<Y/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!
M4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!3;V9T=V%R
M93PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$L-C@S/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$L-#<W/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO<CTS1"-#
M0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!
M4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!&=7)N:71U
M<F4@86YD(&]F9FEC92!E<75I<&UE;G0\+W`^#0H@/"]T9#X-"B`\=&0@=F%L
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M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^-C4Q/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!
M4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!,86(@97%U
M:7!M96YT/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,3,L.3$W
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$Q+#$V-CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X
M03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L
M;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@
M3&5A<V5H;VQD(&EM<')O=F5M96YT<SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG
M;CTS1')I9VAT/C4L,3DS/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO
M=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT/C0L.#DT/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T
M>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52
M+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/
M4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT
M9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$
M)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/
M4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T
M9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG
M/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM
M3$5&5#H@,V5M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@4')O<&5R='D@86YD
M(&5Q=6EP;65N=#PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(T+#$T,#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@86QI9VX],T1R:6=H=#XR,"PU-C<\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T
M<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@
M=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E
M;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($QE<W,@86-C=6UU;&%T960@9&5P
M<F5C:6%T:6]N/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#$W+#,U-3PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^*#$U+#4S,CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@
M<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$
M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M
M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@
M/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4]
M,T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-
M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G
M0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\
M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)
M3BU,1494.B`S96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!0<F]P97)T>2!A
M;F0@97%U:7!M96YT+"!N970\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-BPW.#4\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A
M;&EG;CTS1')I9VAT/C4L,#,U/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@
M/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G
M0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/
M4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO
M=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@
M<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!
M,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T
M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[
M/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\+W1A
M8FQE/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'
M24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4G/@T*($1E<')E8VEA=&EO
M;B!E>'!E;G-E(&9O<B!T:&4@>65A<G,@96YD960@1&5C96UB97(F(WA!,#LS
M,2P@,C`Q-"P-"B`R,#$S(&%N9"`R,#$R('=A<R`D,2XX(&UI;&QI;VXL("0Q
M+C(@;6EL;&EO;B!A;F0@)#$N,"!M:6QL:6]N+`T*(')E<W!E8W1I=F5L>2X\
M+W`^#0H@/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].
M97AT4&%R=%\X9&(U,S=C-%]E.#<X7S1A,V5?.#(X85]B-3`P9C-E9&8Q,68-
M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.&1B-3,W8S1?93@W.%\T
M83-E7S@R.&%?8C4P,&8S961F,3%F+U=O<FMS:&5E=',O4VAE970Q,"YH=&UL
M#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE
M#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB
M#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$
M0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T
M9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO
M=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T
M/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T
M(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E-T;V-K:&]L
M9&5R<R<@17%U:71Y/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/D5Q=6ET>2!;06)S=')A8W1=/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K:&]L9&5R<R<@
M17%U:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV/@T*
M(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0
M.B`Q.'!T)SX-"B`\8CXT+B!3=&]C:VAO;&1E<G,F(W@R,#$Y.R!%<75I='D\
M+V(^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-
M05)'24XM5$]0.B`V<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@1'5R:6YG(#(P
M,#(@86YD(#(P,#,L('1H92!#;VUP86YY(&ES<W5E9"!A('1O=&%L(&]F(#,T
M+#(S.2PS-S0-"B!S:&%R97,@;V8@4V5R:65S($$M,2!A;F0@4V5R:65S($$M
M,B!C;VYV97)T:6)L92!P<F5F97)R960@<W1O8VL-"B`H4V5R:65S($$@<')E
M9F5R<F5D('-T;V-K*2!F;W(@)#$N,#`@<&5R('-H87)E(')E<W5L=&EN9R!I
M;B!N970-"B!P<F]C965D<R!O9B!A<'!R;WAI;6%T96QY("0S-"XP(&UI;&QI
M;VXN/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-
M05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4G/@T*($EN($]C=&]B
M97(@,C`P-"P@=&AE($-O;7!A;GD@96YT97)E9"!I;G1O(&$@<V5R:65S(&]F
M('1R86YS86-T:6]N<PT*(')A:7-I;F<@)#,P+C,@;6EL;&EO;BP@;F5T(&]F
M(')E;&%T960@;V9F97)I;F<@8V]S=',@;V8-"B!A<'!R;WAI;6%T96QY("0R
M,S@L,#`P+"!F<F]M('1H92!S86QE(&]F(#<Q+#0P,2PR,S<@<VAA<F5S(&]F
M(&ET<PT*(%-E<FEE<R!"(&-O;G9E<G1I8FQE('!R969E<G)E9"!S=&]C:R`H
M4V5R:65S($(@<')E9F5R<F5D('-T;V-K*2X@26X-"B!C;VYN96-T:6]N('=I
M=&@@=&AE(%-E<FEE<R!"('!R969E<G)E9"!S=&]C:R!O9F9E<FEN9RP@,3,L
M-C`T+#`Q-@T*('-H87)E<R!O9B!C;VUM;VX@<W1O8VL@=V5R92!A;&QO8V%T
M960@=&\@:&]L9&5R<R!O9B!397)I97,F(WA!,#M!+3$-"B!P<F5F97)R960@
M<W1O8VL@87,@86X@86YT:2UD:6QU=&EO;B!M96%S=7)E+CPO<#X-"B`\<"!S
M='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@,3)P
M=#L@5$585"U)3D1%3E0Z(#0E)SX-"B!);B!-87DF(WA!,#LR,#`V+"!T:&4@
M0V]M<&%N>2!R86ES960@)#0T+CD@;6EL;&EO;BP@;F5T(&]F(')E;&%T960-
M"B!O9F9E<FEN9R!C;W-T<R!O9B`D,3`Q+#(T-BP@9G)O;2!T:&4@<V%L92!O
M9B`Q,3`L.34R+#(Q-R!S:&%R97,@;V8-"B!I=',@4V5R:65S($,@8V]N=F5R
M=&EB;&4@<')E9F5R<F5D('-T;V-K("A397)I97,@0R!P<F5F97)R960-"B!S
M=&]C:RDN($EN(&-O;FYE8W1I;VX@=VET:"!T:&4@4V5R:65S($,@<')E9F5R
M<F5D('-T;V-K(&]F9F5R:6YG+`T*(#$P+#`P,RPS,#`@<VAA<F5S(&]F(&-O
M;6UO;B!S=&]C:R!W97)E(&%L;&]C871E9"!T;R!H;VQD97)S(&]F#0H@4V5R
M:65S($(@<')E9F5R<F5D('-T;V-K(&%S(&%N(&%N=&DM9&EL=71I;VX@;65A
M<W5R92X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($U!4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@26X@2G5L
M>28C>$$P.S(P,#@L('1H92!#;VUP86YY(&ES<W5E9"`Q,BPT-C8L,#,Y('-H
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M87)C:"`R,#$Q(&$@<V5T=&QE;65N="!W87,@<F5A8VAE9"!W:71H('1H92!F
M;W)M97(@4F%V96X-"B!S=&]C:VAO;&1E<G,@8G)I;F=I;F<@=&AE('1O=&%L
M(%-E<FEE<R!$('!R969E<G)E9"!S=&]C:R!I<W-U960@:6X-"B!C;VYN96-T
M:6]N('=I=&@@=&AE(%)A=F5N(&%C<75I<VET:6]N('1O(#$T+#0T-BPR,C<@
M<VAA<F5S+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[
M($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@34%21TE.+51/4#H@,3)P=#L@5$585"U)3D1%3E0Z(#0E)SX-"B!);B!3
M97!T96UB97(F(WA!,#LR,#`X+"!T:&4@0V]M<&%N>2!R86ES960@)#(T+C@@
M;6EL;&EO;BP@;F5T(&]F#0H@<F5L871E9"!O9F9E<FEN9R!C;W-T<R!O9B`D
M,34V+#<X."!F<F]M('1H92!S86QE(&]F(#,X+#,S-RPV-S@-"B!S:&%R97,@
M;V8@:71S(%-E<FEE<R!$+3(@8V]N=F5R=&EB;&4@<')E9F5R<F5D('-T;V-K
M("A397)I97,@1"TR#0H@<')E9F5R<F5D('-T;V-K*2X@5&AE($-O;7!A;GD@
M86QS;R!I<W-U960@<')E9F5R<F5D('-T;V-K('=A<G)A;G1S#0H@9F]R('1H
M92!P=7)C:&%S92!O9B`R+#@W-2PS,C<@<VAA<F5S(&]F(%-E<FEE<R!$+3(@
M<')E9F5R<F5D('-T;V-K+@T*(%1H92!P<F5F97)R960@<W1O8VL@=V%R<F%N
M=',@=V5R92!E>&5R8VES86)L92!A="!A;GD@=&EM92!P<FEO<B!T;PT*(%-E
M<'1E;6)E<B8C>$$P.S(P,3@L(&)U="!E>'!I<F5D('5P;VX@86X@25!/+"!A
M;F0@:&%D(&$@<W1A=&5D#0H@97AE<F-I<V4@<')I8V4@;V8@)#`N-C4@<&5R
M('=A<G)A;G0N($]N($UA>28C>$$P.S$V+"`R,#$P+"!T:&4-"B!#;VUP86YY
M(&5X97)C:7-E9"!A('!U="!N;W1I8V4@=&\@16QI($QI;&QY(&EN(&%C8V]R
M9&%N8V4@=VET:"!T:&4-"B!397)I97,@1"TR('!R969E<G)E9"!S=&]C:R!P
M=7)C:&%S92!A9W)E96UE;G0L(')E<W5L=&EN9R!I;B!T:&4-"B!I<W-U86YC
M92!O9B`V+#DQ-BPQ,3`@<VAA<F5S(&]F(%-E<FEE<R!$+3(@<')E9F5R<F5D
M('-T;V-K(&%N9"!A#0H@=V%R<F%N="!T;R!P=7)C:&%S92`U,3@L-S`X(&%D
M9&ET:6]N86P@<VAA<F5S(&]F(%-E<FEE<R!$+3(-"B!P<F5F97)R960@<W1O
M8VLN($]N($IA;G5A<GDF(WA!,#LQ,2P@,C`Q,2P@=&AE($-O;7!A;GD@<F%I
M<V5D(&=R;W-S#0H@<')O8V5E9',@;V8@)#$R+C`@;6EL;&EO;B!F<F]M('1H
M92!S86QE(&]F(#$X+#0R-RPS.#@@<VAA<F5S(&]F(&ET<PT*(%-E<FEE<R!$
M+3(@<')E9F5R<F5D('-T;V-K+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM
M0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@,3)P=#L@5$585"U)3D1%3E0Z
M(#0E)SX-"B!$=64@=&\@8V5R=&%I;B!P<F]V:7-I;VYS(&EN('1H92!397)I
M97,@1"TR(&-O;G9E<G1I8FQE('!R969E<G)E9`T*('-T;V-K('=A<G)A;G0@
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M<R!R96-O<F1E9"!A=`T*(&9A:7(@=F%L=64@86YD(&AA<R!B965N(&%D:G5S
M=&5D('1O(&9A:7(@=F%L=64@870@=&AE(&5N9"!O9B!E86-H#0H@<F5P;W)T
M:6YG('!E<FEO9"!U<VEN9R!T:&4@3W!T:6]N+5!R:6-I;F<@365T:&]D+"!W
M:71H(&-H86YG97,@:6X-"B!V86QU92!R96-O<F1E9"!A<R`F(W@R,#%#.T]T
M:&5R(&EN8V]M92`H97AP96YS92DF(W@R,#%$.R!I;B!T:&4-"B!A8V-O;7!A
M;GEI;F<@8V]N<V]L:61A=&5D('-T871E;65N=',@;V8@;W!E<F%T:6]N<R!A
M;F0-"B!C;VUP<F5H96YS:79E(&EN8V]M92`H;&]S<RDN(%!R:6]R('1O('1H
M92!#;VUP86YY)B-X,C`Q.3MS($E03R!I;@T*($]C=&]B97(@,C`Q,RP@86QL
M('1H92!P<F5F97)R960@<W1O8VL@=V%R<F%N=',@=V5R92!E>&5R8VES960@
M86YD#0H@<W5B<V5Q=65N=&QY('=E<F4@8V]N=F5R=&5D(&EN=&\@<VAA<F5S
M(&]F(&-O;6UO;B!S=&]C:R!I;@T*(&-O;FYE8W1I;VX@=VET:"!T:&4@25!/
M+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%2
M1TE.+51/4#H@,3)P=#L@5$585"U)3D1%3E0Z(#0E)SX-"B!$:79I9&5N9',@
M=V5R92!N;VYC=6UU;&%T:79E(&%N9"!A8V-R=65D(&]N('1H92!397)I97,@
M02P@4V5R:65S($(L#0H@4V5R:65S($,L(%-E<FEE<R!$(&%N9"!397)I97,F
M(WA!,#M$+3(@<')E9F5R<F5D('-T;V-K(&%T(&$@<F%T92!O9@T*("0P+C`X
M+"`D,"XP,S0Q+"`D,"XP,S(T(&%N9"`D,"XP-3(R('!E<B!A;FYU;2P@<F5S
M<&5C=&EV96QY+"!A;F0-"B!W97)E('!A>6%B;&4@=VAE;B!A;F0@87,@9&5C
M;&%R960@8GD@=&AE($)O87)D(&]F($1I<F5C=&]R<RX-"B!$:79I9&5N9',@
M:&%D('1O(&)E(&1E8VQA<F5D('-O('1H870@=&AE(%-E<FEE<R!!+"!397)I
M97,F(WA!,#M"+`T*(%-E<FEE<R!#(&%N9"!397)I97,@1"!P<F5F97)R960@
M<W1O8VL@=V5R92!P86ED(&EN(&QI:V4M:VEN9"!A;F0-"B!P87)T:6-I<&%T
M960@97%U86QL>2!T;R!T:&]S92!O9B!T:&4@4V5R:65S)B-X03`[1"TR('!R
M969E<G)E9"!A;F0-"B!C;VUM;VX@<W1O8VLN($YO(&1I=FED96YD<R!H860@
M8F5E;B!D96-L87)E9"!P<FEO<B!T;R!T:&4-"B!C;VYV97)S:6]N(&]F('1H
M92!P<F5F97)R960@<W1O8VL@=&\@8V]M;6]N('-T;V-K(&EN(&-O;FYE8W1I
M;VX-"B!W:71H('1H92!)4$\N/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"
M3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@
M-"4G/@T*(%1H92!#;VUP86YY)B-X,C`Q.3MS(%-E<FEE<R!!+3$L(%-E<FEE
M<R!!+3(L(%-E<FEE<R!"+"!397)I97,@0RP-"B!397)I97,@1"!A;F0@4V5R
M:65S($0M,B!P<F5F97)R960@<W1O8VL@=V5R92!I;FET:6%L;'D@8V]N=F5R
M=&EB;&4-"B!I;G1O(#$N-3`V+"`Q+C`P+"`Q+C$T+"`Q+C`P+"`Q+C`P(&%N
M9"`Q+C`P('-H87)E<RP@<F5S<&5C=&EV96QY+`T*(&]F(&-O;6UO;B!S=&]C
M:R!A="!T:&4@;W!T:6]N(&]F('1H92!H;VQD97(N(%1H92!C;VYV97)S:6]N
M(')A=&EO#0H@;V8@8V5R=&%I;B!S97)I97,@;V8@<')E9F5R<F5D('-T;V-K
M('=A<R!S=6)J96-T('1O(&-H86YG92!I;B!T:&4-"B!E=F5N="!S<&5C:69I
M960@9&EL=71I=F4@=')A;G-A8W1I;VYS(&]C8W5R<F5D+"!W:&EC:"!I;F-L
M=61E9"!T:&4-"B!#;VUP86YY)B-X,C`Q.3MS($E03RX@5&AE<F4@=V5R92!N
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M.W,@25!/(&EN($]C=&]B97(@,C`Q,RP@86QL(&]U='-T86YD:6YG('-H87)E
M<R!O9@T*('!R969E<G)E9"!S=&]C:R!A=71O;6%T:6-A;&QY(&-O;G9E<G1E
M9"!T;R!S:&%R97,@;V8@=&AE#0H@0V]M<&%N>28C>#(P,3D[<R!C;VUM;VX@
M<W1O8VL@870@=&AE(&%P<&QI8V%B;&4@8V]N=F5R<VEO;B!R871I;W,-"B!T
M:&5N(&EN(&5F9F5C="X@5&AE(&-O;G9E<G-I;VX@<')I8V4@=V%S("0Q,BXS
M.2P@)#$X+C<W+"`D-BXY-2P-"B`D-RXW,"P@)#$R+C(P(&%N9"`D,3(N,C`@
M9F]R(&5A8V@@<VAA<F4@;V8@4V5R:65S($$M,2P@02TR+"!397)I97,-"B!"
M+"!397)I97,@0RP@4V5R:65S($0@86YD(%-E<FEE<R!$+3(@8V]N=F5R=&EB
M;&4@<')E9F5R<F5D('-T;V-K+`T*(')E<W!E8W1I=F5L>2X\+W`^#0H@/'`@
M<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#$R
M<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@3VX@3V-T;V)E<B8C>$$P.S$V+"`R
M,#$S+"!T:&4@0V]M<&%N>2!C;VUP;&5T960@:71S($E03RP@:6X@=VAI8V@-
M"B`U+#`P,"PP,#`@<VAA<F5S(&]F('1H92!#;VUP86YY)B-X,C`Q.3MS(&-O
M;6UO;B!S=&]C:R!W97)E('-O;&0@870@80T*('!R:6-E(&]F("0Q-BXP,"!P
M97(@<VAA<F4N($%D9&ET:6]N86QL>2P@=&AE('5N9&5R=W)I=&5R<R!O9B!T
M:&4-"B!#;VUP86YY)B-X,C`Q.3MS($E03R!E>&5R8VES960@=&AE(&9U;&P@
M86UO=6YT(&]F('1H96ER#0H@;W9E<BUA;&QO=&UE;G0@;W!T:6]N(')E<W5L
M=&EN9R!I;B!T:&4@<V%L92!O9B!A;B!A9&1I=&EO;F%L#0H@-S4P+#`P,"!S
M:&%R97,@;V8@=&AE($-O;7!A;GDF(W@R,#$Y.W,@8V]M;6]N('-T;V-K(&%T
M(&$@<')I8V4@;V8-"B`D,38N,#`@<&5R('-H87)E+B!4:&4@0V]M<&%N>2!R
M96-E:79E9"!P<F]C965D<R!O9B`D.#,N."!M:6QL:6]N#0H@9G)O;2!T:&4@
M25!/+"!N970@;V8@=6YD97)W<FET:6YG(&1I<V-O=6YT<R!A;F0@8V]M;6ES
M<VEO;G,@86YD#0H@;W1H97(@;V9F97)I;F<@97AP96YS97,N(%5P;VX@8V]N
M<W5M;6%T:6]N(&]F('1H92!)4$\L(&%L;`T*(&]U='-T86YD:6YG('-H87)E
M<R!O9B!P<F5F97)R960@<W1O8VL@875T;VUA=&EC86QL>2!C;VYV97)T960@
M=&\-"B!C;VUM;VX@<W1O8VL@870@=&AE(&%P<&QI8V%B;&4@8V]N=F5R<VEO
M;B!R871I;W,@=&AE;B!I;@T*(&5F9F5C="X\+W`^#0H@/'`@<W1Y;&4],T0G
M34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#$R<'0[(%1%6%0M
M24Y$14Y4.B`T)2<^#0H@26X@8V]N;F5C=&EO;B!W:71H('!R97!A<FEN9R!F
M;W(@:71S($E03R!I;B!/8W1O8F5R(#(P,3,L('1H90T*($-O;7!A;GDF(W@R
M,#$Y.W,@0F]A<F0@;V8@1&ER96-T;W)S(&%N9"!S=&]C:VAO;&1E<G,@87!P
M<F]V960@80T*(#$M9F]R+3$X+C<W,SD@<F5V97)S92!S=&]C:R!S<&QI="!O
M9B!T:&4@0V]M<&%N>28C>#(P,3D[<R!C;VUM;VX-"B!S=&]C:RX@5&AE(')E
M=F5R<V4@<W1O8VL@<W!L:70@8F5C86UE(&5F9F5C=&EV92!O;@T*(%-E<'1E
M;6)E<B8C>$$P.S(V+"`R,#$S+B!!;&P@<VAA<F4@86YD('!E<B!S:&%R92!A
M;6]U;G1S(&EN('1H90T*(&-O;G-O;&ED871E9"!F:6YA;F-I86P@<W1A=&5M
M96YT<R!A;F0@;F]T97,@=&AE<F5T;R!H879E(&)E96X-"B!R971R;V%C=&EV
M96QY(&%D:G5S=&5D(&9O<B!A;&P@<&5R:6]D<R!P<F5S96YT960@=&\@9VEV
M92!E9F9E8W0@=&\-"B!T:&ES(')E=F5R<V4@<W1O8VL@<W!L:70L(&EN8VQU
M9&EN9R!R96-L87-S:69Y:6YG(&%N(&%M;W5N="!E<75A;`T*('1O('1H92!R
M961U8W1I;VX@:6X@<&%R('9A;'5E(&]F(&-O;6UO;B!S=&]C:R!T;R!A9&1I
M=&EO;F%L('!A:60M:6X-"B!C87!I=&%L+B!);B!A9&1I=&EO;BP@:6X@4V5P
M=&5M8F5R(#(P,3,L('1H92!#;VUP86YY)B-X,C`Q.3MS($)O87)D#0H@;V8@
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M;G0N(%1H92!A;65N9&5D(&%N9"!R97-T871E9`T*(&-E<G1I9FEC871E(&]F
M(&EN8V]R<&]R871I;VX@86QS;R!C:&%N9V5D('1H92!A=71H;W)I>F5D(&YU
M;6)E<B!O9@T*('-H87)E<R!O9B!C;VUM;VX@<W1O8VL@9G)O;2`T,C4L,#`P
M+#`P,"!T;R`Q,C4L,#`P+#`P,"P@86YD#0H@875T:&]R:7IE9"`U+#`P,"PP
M,#`@<VAA<F5S(&]F('5N9&5S:6=N871E9"!P<F5F97)R960@<W1O8VL@=VET
M:"!A#0H@<&%R('9A;'5E(&]F("0P+C`Q('!E<B!S:&%R92X@5&AE<F4@=V5R
M92!N;R!S:&%R97,@;V8@=6YD97-I9VYA=&5D#0H@<')E9F5R<F5D('-T;V-K
M(&ES<W5E9"!O<B!O=71S=&%N9&EN9R!A<R!O9B!$96-E;6)E<B8C>$$P.S,Q
M+"`R,#$T#0H@;W(@,C`Q,RX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/
M5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$14Y4.B`T
M)2<^#0H@26X@1F5B<G5A<GD@,C`Q-"P@=&AE($-O;7!A;GD@8V]M<&QE=&5D
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M;B!A9&1I=&EO;F%L#0H@-#4P+#`P,"8C>$$P.W-H87)E<R!O9B!T:&4@0V]M
M<&%N>28C>#(P,3D[<R!C;VUM;VX@<W1O8VL@870@82!P<FEC90T*(&]F("0S
M-BXU,"!P97(@<VAA<F4N(%1H92!#;VUP86YY(')E8V5I=F5D('!R;V-E961S
M(&]F#0H@)#<V+C<F(WA!,#MM:6QL:6]N(&9R;VT@=&AI<R!O9F9E<FEN9RP@
M;F5T(&]F('5N9&5R=W)I=&EN9PT*(&1I<V-O=6YT<R!A;F0@8V]M;6ES<VEO
M;G,@86YD(&]T:&5R(&]F9F5R:6YG(&5X<&5N<V5S+CPO<#X-"B`\+V1I=CX\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-
M"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7SAD8C4S
M-V,T7V4X-SA?-&$S95\X,CAA7V(U,#!F,V5D9C$Q9@T*0V]N=&5N="U,;V-A
M=&EO;CH@9FEL93HO+R]#.B\X9&(U,S=C-%]E.#<X7S1A,V5?.#(X85]B-3`P
M9C-E9&8Q,68O5V]R:W-H965T<R]3:&5E=#$Q+FAT;6P-"D-O;G1E;G0M5')A
M;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP
M93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@
M(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@
M8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@
M='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO
M="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\
M8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X]
M,T0Q(')O=W-P86X],T0R/CQS=')O;F<^4W1O8VLM8F%S960@0V]M<&5N<V%T
M:6]N/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q
M+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/D1I<V-L;W-U<F4@;V8@0V]M<&5N<V%T:6]N(%)E;&%T960@0V]S
M=',L(%-H87)E+6)A<V5D(%!A>6UE;G1S(%M!8G-T<F%C=%T\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1O8VLM8F%S960@
M0V]M<&5N<V%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M9&EV/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@5TA)5$4M
M4U!!0T4Z(&YO<FUA;#L@5$585"U44D%.4T9/4DTZ(&YO;F4[(%=/4D0M4U!!
M0TE.1SH@,'!X.R!#3TQ/4CH@<F=B*#`L,"PP*3L@1D].5#H@,3!P="`G5&EM
M97,@3F5W(%)O;6%N)SL@34%21TE.+51/4#H@,3AP=#L@3$545$52+5-004-)
M3D<Z(&YO<FUA;#L@5$585"U)3D1%3E0Z(#!P>#L@+7=E8FMI="UT97AT+7-T
M<F]K92UW:61T:#H@,'!X)SX-"B`\8CXU+B!3=&]C:RUB87-E9"!#;VUP96YS
M871I;VX\+V(^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P
M=#L@5TA)5$4M4U!!0T4Z(&YO<FUA;#L@5$585"U44D%.4T9/4DTZ(&YO;F4[
M(%=/4D0M4U!!0TE.1SH@,'!X.R!#3TQ/4CH@<F=B*#`L,"PP*3L@1D].5#H@
M,3!P="`G5&EM97,@3F5W(%)O;6%N)SL@34%21TE.+51/4#H@-G!T.R!,1514
M15(M4U!!0TE.1SH@;F]R;6%L.R!415A4+4E.1$5.5#H@-"4[("UW96)K:70M
M=&5X="US=')O:V4M=VED=&@Z(#!P>"<^#0H@5&AE($-O;7!A;GDF(W@R,#$Y
M.W,@,C`P,"!3=&]C:R!/<'1I;VX@86YD($EN8V5N=&EV92!0;&%N("@R,#`P
M#0H@4&QA;BD@86QL;W=E9"!F;W(@=&AE(&=R86YT(&]F(&%W87)D<R!I;B!R
M97-P96-T(&]F(&%N(&%G9W)E9V%T92!O9@T*(#$S,"PW,C4@<VAA<F5S+"!W
M:&EC:"!W87,@:6YC<F5A<V5D('1O(#$U,"PR.3<@<VAA<F5S+"!O9B!T:&4-
M"B!#;VUP86YY)B-X,C`Q.3MS(&-O;6UO;B!S=&]C:R!I;B!T:&4@9F]R;2!O
M9B!I;F-E;G1I=F4@<W1O8VL-"B!O<'1I;VYS+"!N;VXM<75A;&EF:65D('-T
M;V-K(&]P=&EO;G,L('-T;V-K(&%P<')E8VEA=&EO;B!R:6=H=',L#0H@<F5S
M=')I8W1E9"!S=&]C:R!A;F0@<F5S=')I8W1E9"!S=&]C:R!U;FET<R!A;F0@
M;W1H97(@<&5R9F]R;6%N8V4-"B!A=V%R9',N($%S(&]F($1E8V5M8F5R)B-X
M03`[,S$L(#(P,30L('5N9&5R('1H92`R,#`P(%!L86XL('1H97)E#0H@=V5R
M92!O<'1I;VYS('1O('!U<F-H87-E(&%N(&%G9W)E9V%T92!O9B`Q.2PW,#4@
M<VAA<F5S(&]F(&-O;6UO;@T*('-T;V-K(&]U='-T86YD:6YG(&%T(&$@=V5I
M9VAT960@879E<F%G92!E>&5R8VES92!P<FEC92!O9B`D,"XX,2!P97(-"B!S
M:&%R92X@5&AE(#(P,#`@4&QA;B!H87,@97AP:7)E9"P@86YD(&YO(&9U<G1H
M97(@87=A<F1S(&UA>2!B90T*(&ES<W5E9"!U;F1E<B!T:&4@<&QA;BX@06YY
M('-H87)E<R!O9B!C;VUM;VX@<W1O8VL@<W5B:F5C="!T;R!A=V%R9',-"B!U
M;F1E<B!T:&4@,C`P,"!0;&%N('1H870@97AP:7)E+"!T97)M:6YA=&4L(&]R
M(&%R92!O=&AE<G=I<V4-"B!S=7)R96YD97)E9"P@8V%N8V5L960L(&9O<F9E
M:71E9"!O<B!R97!U<F-H87-E9"!W:71H;W5T(&AA=FEN9R!B965N#0H@9G5L
M;'D@97AE<F-I<V5D+"!O<B!R97-U;'1I;F<@:6X@86YY(&-O;6UO;B!S=&]C
M:R!B96EN9R!I<W-U960L#0H@=VEL;"!B96-O;64@879A:6QA8FQE(&9O<B!I
M<W-U86YC92!U;F1E<B!T:&4@,C`Q,R!3=&]C:R!);F-E;G1I=F4-"B!0;&%N
M("@R,#$S(%!L86XI('5P('1O(&$@<W!E8VEF:65D(&YU;6)E<B!O9B!S:&%R
M97,N/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@5TA)
M5$4M4U!!0T4Z(&YO<FUA;#L@5$585"U44D%.4T9/4DTZ(&YO;F4[(%=/4D0M
M4U!!0TE.1SH@,'!X.R!#3TQ/4CH@<F=B*#`L,"PP*3L@1D].5#H@,3!P="`G
M5&EM97,@3F5W(%)O;6%N)SL@34%21TE.+51/4#H@,3)P=#L@3$545$52+5-0
M04-)3D<Z(&YO<FUA;#L@5$585"U)3D1%3E0Z(#0E.R`M=V5B:VET+71E>'0M
M<W1R;VME+7=I9'1H.B`P<'@G/@T*($5F9F5C=&EV92!&96)R=6%R>28C>$$P
M.S(P,#,L('1H92!#;VUP86YY(&EM<&QE;65N=&5D('1H92`R,#`S#0H@17%U
M:71Y($EN8V5N=&EV92!0;&%N("@R,#`S(%!L86XI+"!A;F0@:70@=V%S(&%M
M96YD960@86YD(&%P<')O=F5D#0H@8GD@=&AE($-O;7!A;GDF(W@R,#$Y.W,@
M<W1O8VMH;VQD97)S(&EN(#(P,#4N(%1H92`R,#`S(%!L86X-"B!O<FEG:6YA
M;&QY(&%L;&]W960@9F]R('1H92!G<F%N="!O9B!A=V%R9',@:6X@<F5S<&5C
M="!O9B!A;@T*(&%G9W)E9V%T92!O9B`R+#`U,2PV-#0@<VAA<F5S(&]F('1H
M92!#;VUP86YY)B-X,C`Q.3MS(&-O;6UO;B!S=&]C:RX-"B!"971W965N(#(P
M,#8@86YD(#(P,3`@=&AE(&UA>&EM=6T@;G5M8F5R(&]F('-H87)E<R!O9B!C
M;VUM;VX@<W1O8VL-"B!A=71H;W)I>F5D('1O(&)E(&ES<W5E9"!B>2!T:&4@
M0V]M<&%N>2!U;F1E<B!T:&4@,C`P,R!0;&%N('=A<PT*(&EN8W)E87-E9"!B
M>2`Q+#<S.2PQ,38@<VAA<F5S('1O(#,L-SDP+#<V,"X@1'5R:6YG('1H92!Y
M96%R(&5N9&5D#0H@1&5C96UB97(F(WA!,#LS,2P@,C`Q,BP@=&AE(&UA>&EM
M=6T@;G5M8F5R(&]F('-H87)E<R!O9B!C;VUM;VX-"B!S=&]C:R!A=71H;W)I
M>F5D('1O(&)E(&ES<W5E9"!B>2!T:&4@0V]M<&%N>2!U;F1E<B!T:&4@,C`P
M,R!0;&%N#0H@=V%S(&EN8W)E87-E9"!B>2`U-#4L.3<P('-H87)E<R!T;R`T
M+#,S-BPW,S`N(%-T;V-K(&]P=&EO;G,@9W)A;G1E9`T*('5N9&5R('1H92`R
M,#`S(%!L86X@;6%Y(&)E(&5I=&AE<B!I;F-E;G1I=F4@<W1O8VL@;W!T:6]N
M<R!A<PT*(&1E9FEN960@8GD@=&AE($EN=&5R;F%L(%)E=F5N=64@0V]D92`H
M25)#*2P@;W(@;F]N+7%U86QI9FEE9"!S=&]C:PT*(&]P=&EO;G,N/"]P/@T*
M(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@5TA)5$4M4U!!0T4Z
M(&YO<FUA;#L@5$585"U44D%.4T9/4DTZ(&YO;F4[(%=/4D0M4U!!0TE.1SH@
M,'!X.R!#3TQ/4CH@<F=B*#`L,"PP*3L@1D].5#H@,3!P="`G5&EM97,@3F5W
M(%)O;6%N)SL@34%21TE.+51/4#H@,3)P=#L@3$545$52+5-004-)3D<Z(&YO
M<FUA;#L@5$585"U)3D1%3E0Z(#0E.R`M=V5B:VET+71E>'0M<W1R;VME+7=I
M9'1H.B`P<'@G/@T*($%S(&]F($1E8V5M8F5R)B-X03`[,S$L(#(P,30L('5N
M9&5R('1H92`R,#`S(%!L86XL('1H97)E('=E<F4-"B!O<'1I;VYS('1O('!U
M<F-H87-E(&%N(&%G9W)E9V%T92!O9B`R+#`P."PT-S0F(WA!,#MS:&%R97,@
M;V8@8V]M;6]N#0H@<W1O8VL@;W5T<W1A;F1I;F<@870@82!W96EG:'1E9"!A
M=F5R86=E(&5X97)C:7-E('!R:6-E(&]F("0Q+C8T('!E<@T*('-H87)E+B!5
M<&]N('1H92!C;VUP;&5T:6]N(&]F('1H92!)4$\L('1H92`R,#`S(%!L86X@
M=V%S#0H@=&5R;6EN871E9"P@86YD(&YO(&9U<G1H97(@87=A<F1S(&UA>2!B
M92!I<W-U960@=6YD97(@=&AE('!L86XN($%N>0T*('-H87)E<R!O9B!C;VUM
M;VX@<W1O8VL@<W5B:F5C="!T;R!A=V%R9',@=6YD97(@=&AE(#(P,#,@4&QA
M;B!T:&%T#0H@97AP:7)E+"!T97)M:6YA=&4L(&]R(&%R92!O=&AE<G=I<V4@
M<W5R<F5N9&5R960L(&-A;F-E;&5D+`T*(&9O<F9E:71E9"!O<B!R97!U<F-H
M87-E9"!W:71H;W5T(&AA=FEN9R!B965N(&9U;&QY(&5X97)C:7-E9"P@;W(-
M"B!R97-U;'1I;F<@:6X@86YY(&-O;6UO;B!S=&]C:R!B96EN9R!I<W-U960L
M('=I;&P@8F5C;VUE(&%V86EL86)L90T*(&9O<B!I<W-U86YC92!U;F1E<B!T
M:&4@,C`Q,R!0;&%N+"!U<"!T;R!A('-P96-I9FEE9"!N=6UB97(@;V8-"B!S
M:&%R97,N/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@
M5TA)5$4M4U!!0T4Z(&YO<FUA;#L@5$585"U44D%.4T9/4DTZ(&YO;F4[(%=/
M4D0M4U!!0TE.1SH@,'!X.R!#3TQ/4CH@<F=B*#`L,"PP*3L@1D].5#H@,3!P
M="`G5&EM97,@3F5W(%)O;6%N)SL@34%21TE.+51/4#H@,3)P=#L@3$545$52
M+5-004-)3D<Z(&YO<FUA;#L@5$585"U)3D1%3E0Z(#0E.R`M=V5B:VET+71E
M>'0M<W1R;VME+7=I9'1H.B`P<'@G/@T*($EN($]C=&]B97(@,C`Q,RP@=&AE
M($-O;7!A;GD@:6UP;&5M96YT960@=&AE(#(P,3,@4&QA;BX@5&AE(#(P,3,-
M"B!0;&%N('!R;W9I9&5S(&9O<B!T:&4@9W)A;G0@;V8@<W1O8VL@;W!T:6]N
M<R!A;F0@;W1H97(@<W1O8VLM8F%S960-"B!A=V%R9',L(&%S('=E;&P@87,@
M8V%S:"UB87-E9"!P97)F;W)M86YC92!A=V%R9',N(%1H92!A9V=R96=A=&4-
M"B!N=6UB97(@;V8@<VAA<F5S(&]F(&-O;6UO;B!S=&]C:R!I;FET:6%L;'D@
M879A:6QA8FQE(&9O<B!I<W-U86YC90T*('!U<G-U86YT('1O(&%W87)D<R!U
M;F1E<B!T:&4@,C`Q,R!0;&%N(&ES(#$L.38P+#$V."!S:&%R97,N(%1H90T*
M(&YU;6)E<B!O9B!S:&%R97,@;V8@8V]M;6]N('-T;V-K(')E<V5R=F5D(&9O
M<B!I<W-U86YC92!W:6QL#0H@875T;VUA=&EC86QL>2!I;F-R96%S92!O;B!*
M86YU87)Y)B-X03`[,2!O9B!E86-H('EE87(@9G)O;0T*($IA;G5A<GDF(WA!
M,#LQ+"`R,#$T('1H<F]U9V@@86YD(&EN8VQU9&EN9R!*86YU87)Y)B-X03`[
M,2P@,C`R,RP@8GD-"B!T:&4@;&5S<V5R(&]F("AA*28C>$$P.S$L.38P+#$V
M."!S:&%R97,L("AB*28C>$$P.S0N,"4@;V8@=&AE('1O=&%L#0H@;G5M8F5R
M(&]F('-H87)E<R!O9B!C;VUM;VX@<W1O8VL@;W5T<W1A;F1I;F<@;VX@1&5C
M96UB97(F(WA!,#LS,2!O9@T*('1H92!P<F5C961I;F<@8V%L96YD87(@>65A
M<BP@;W(@*&,I)B-X03`[=&AE(&YU;6)E<B!O9B!S:&%R97,@;V8-"B!C;VUM
M;VX@<W1O8VL@9&5T97)M:6YE9"!B>2!T:&4@0F]A<F0@;V8@1&ER96-T;W)S
M+B!$=7)I;F<@=&AE('EE87(-"B!E;F1E9"!$96-E;6)E<B8C>$$P.S,Q+"`R
M,#$T+"!T:&4@;6%X:6UU;2!N=6UB97(@;V8@<VAA<F5S(&]F#0H@8V]M;6]N
M('-T;V-K(&%U=&AO<FEZ960@=&\@8F4@:7-S=65D(&)Y('1H92!#;VUP86YY
M('5N9&5R('1H92`R,#$S#0H@4&QA;B!W87,@:6YC<F5A<V5D('1O(#(L.38W
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M1&5C96UB97(F(WA!,#LS,2P@,C`Q-"P@=6YD97(@=&AE(#(P,3,-"B!0;&%N
M+"!T:&5R92!W97)E(&]P=&EO;G,@=&\@<'5R8VAA<V4@86X@86=G<F5G871E
M(&]F(#$L-30S+#DS-PT*('-H87)E<R!O9B!C;VUM;VX@<W1O8VL@;W5T<W1A
M;F1I;F<@870@82!W96EG:'1E9"!A=F5R86=E(&5X97)C:7-E#0H@<')I8V4@
M;V8@)#(T+C(R('!E<B!S:&%R92X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.
M+4)/5%1/33H@,'!T.R!72$E412U34$%#13H@;F]R;6%L.R!415A4+51204Y3
M1D]233H@;F]N93L@5T]21"U34$%#24Y'.B`P<'@[($-/3$]2.B!R9V(H,"PP
M+#`I.R!&3TY4.B`Q,'!T("=4:6UE<R!.97<@4F]M86XG.R!-05)'24XM5$]0
M.B`Q,G!T.R!,151415(M4U!!0TE.1SH@;F]R;6%L.R!415A4+4E.1$5.5#H@
M-"4[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>"<^#0H@5&AE(&9O
M;&QO=VEN9R!S=&]C:RUB87-E9"!C;VUP96YS871I;VX@86UO=6YT<R!W97)E
M(')E8V]G;FEZ960@9F]R#0H@=&AE('!E<FEO9',@:6YD:6-A=&5D("AI;B!T
M:&]U<V%N9',I.CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P
M<'0[(%=(251%+5-004-%.B!N;W)M86P[(%1%6%0M5%)!3E-&3U)-.B!N;VYE
M.R!73U)$+5-004-)3D<Z(#!P>#L@0T],3U(Z(')G8B@P+#`L,"D[($9/3E0Z
M(#$R<'0@)U1I;65S($YE=R!2;VUA;B<[($U!4D=)3BU43U`Z(#!P=#L@3$54
M5$52+5-004-)3D<Z(&YO<FUA;#L@5$585"U)3D1%3E0Z(#!P>#L@+7=E8FMI
M="UT97AT+7-T<F]K92UW:61T:#H@,'!X)SX-"B`F(WA!,#L\+W`^#0H@/'1A
M8FQE('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ("=4
M:6UE<R!.97<@4F]M86XG.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E.R!4
M15A4+51204Y31D]233H@;F]N93L@5T]21"U34$%#24Y'.B`P<'@[($Q%5%1%
M4BU34$%#24Y'.B!N;W)M86P[(%1%6%0M24Y$14Y4.B`P<'@[("UW96)K:70M
M=&5X="US=')O:V4M=VED=&@Z(#!P>"<@8V5L;'-P86-I;F<],T0P(&-E;&QP
M861D:6YG/3-$,"!W:61T:#TS1#@T)2!A;&EG;CTS1&-E;G1E<B!B;W)D97(]
M,T0P/@T*(#QT<CX-"B`\=&0@=VED=&@],T0W-"4^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$-24^/"]T9#X-"B`\=&0^/"]T9#X-"B`\
M=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$-24^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-24^/"]T9#X-
M"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\+W1R/@T*
M(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ("=4
M:6UE<R!.97<@4F]M86XG)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P
M="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0Q,"!A;&EG;CTS
M1&-E;G1E<CX\8CY996%R($5N9&5D#0H@1&5C96UB97(F(WA!,#LS,2P\+V(^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T
M<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9
M.B`G5&EM97,@3F5W(%)O;6%N)R<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@<F=B*#`L,"PP
M*2`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG
M;CTS1&-E;G1E<CX\8CXR,#$T/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@<F=B
M*#`L,"PP*2`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$
M,B!A;&EG;CTS1&-E;G1E<CX\8CXR,#$S/"]B/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@<F=B*#`L,"PP*2`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS
M<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\8CXR,#$R/"]B/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ("=4:6UE<R!.
M97<@4F]M86XG)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$
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M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$L-38R/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
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M1')I9VAT/C0W,CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B`G5&EM97,@3F5W
M(%)O;6%N)R<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N
M)SL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($=E
M;F5R86P@86YD(&%D;6EN:7-T<F%T:79E/"]P/@T*(#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^,2PV.#(\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^,S4U/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I
M9VAT/C,V-CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS
M1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z
M(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z
M(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\
M=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS
M1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P
M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS
M1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P
M/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`Q<'@@<V]L
M:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`Q<'@@<V]L
M:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO
M='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ("=4:6UE<R!.97<@4F]M86XG)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\
M=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M86XG.R!-05)'24XM3$5&
M5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@5&]T86P@<W1O8VLM8F%S
M960@8V]M<&5N<V%T:6]N(&5X<&5N<V4\+W`^#0H@/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,RPR-#0\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!A;&EG;CTS1')I9VAT/C@V,CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^.#,X
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M
M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L
M,"PP*2`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P
M+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]2
M1$52+51/4#H@<F=B*#`L,"PP*2`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/
M4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*
M(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@
M/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`S<'@@9&]U8FQE
M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*
M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L
M92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T
M<CX-"B`\+W1A8FQE/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P
M=#L@5TA)5$4M4U!!0T4Z(&YO<FUA;#L@5$585"U44D%.4T9/4DTZ(&YO;F4[
M(%=/4D0M4U!!0TE.1SH@,'!X.R!#3TQ/4CH@<F=B*#`L,"PP*3L@1D].5#H@
M,3!P="`G5&EM97,@3F5W(%)O;6%N)SL@34%21TE.+51/4#H@,3AP=#L@3$54
M5$52+5-004-)3D<Z(&YO<FUA;#L@5$585"U)3D1%3E0Z(#!P>#L@+7=E8FMI
M="UT97AT+7-T<F]K92UW:61T:#H@,'!X)SX-"B`\:3Y%;7!L;WEE92!3=&]C
M:R!/<'1I;VYS/"]I/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-
M.B`P<'0[(%=(251%+5-004-%.B!N;W)M86P[(%1%6%0M5%)!3E-&3U)-.B!N
M;VYE.R!73U)$+5-004-)3D<Z(#!P>#L@0T],3U(Z(')G8B@P+#`L,"D[($9/
M3E0Z(#$P<'0@)U1I;65S($YE=R!2;VUA;B<[($U!4D=)3BU43U`Z(#9P=#L@
M3$545$52+5-004-)3D<Z(&YO<FUA;#L@5$585"U)3D1%3E0Z(#0E.R`M=V5B
M:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@G/@T*(%1H92!F86ER('9A;'5E
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M(&YO;F4[(%=/4D0M4U!!0TE.1SH@,'!X.R!#3TQ/4CH@<F=B*#`L,"PP*3L@
M1D].5#H@,3)P="`G5&EM97,@3F5W(%)O;6%N)SL@34%21TE.+51/4#H@,'!T
M.R!,151415(M4U!!0TE.1SH@;F]R;6%L.R!415A4+4E.1$5.5#H@,'!X.R`M
M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@G/@T*("8C>$$P.SPO<#X-
M"B`\=&%B;&4@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@)U1I;65S($YE=R!2;VUA;B<[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P
M<V4[(%1%6%0M5%)!3E-&3U)-.B!N;VYE.R!73U)$+5-004-)3D<Z(#!P>#L@
M3$545$52+5-004-)3D<Z(&YO<FUA;#L@5$585"U)3D1%3E0Z(#!P>#L@+7=E
M8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X)R!C96QL<W!A8VEN9STS1#`@
M8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$.#0E(&%L:6=N/3-$8V5N=&5R(&)O
M<F1E<CTS1#`^#0H@/'1R/@T*(#QT9"!W:61T:#TS1#4X)3X\+W1D/@T*(#QT
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M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ(')G8B@P+#`L,"D@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T
M;VT@8V]L<W!A;CTS1#4@86QI9VX],T1C96YT97(^/&(^665A<B!%;F1E9"!$
M96-E;6)E<B8C>$$P.S,Q+#PO8CX\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE
M/3-$)T9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@)U1I;65S($YE=R!2
M;VUA;B<G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P+#`L,"D@,7!T('-O;&ED)R!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1C96YT97(^/&(^,C`Q-#PO8CX\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@<F=B*#`L,"PP*2`Q<'0@<V]L
M:60G('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1&-E;G1E<CX\8CXR,#$S/"]B
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P
M="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$8V5N=&5R/CQB/C(P
M,3(\+V(^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@8F=C;VQO
M<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O
M;6%N)SL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*
M($5X<&5C=&5D(&1I=FED96YD('EI96QD/"]P/@T*(#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@86QI9VX],T1C96YT97(^,"4\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$8V5N=&5R/C`E/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A
M;&EG;CTS1&-E;G1E<CXP)3PO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA
M;B<G/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<[($U!
M4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!%>'!E8W1E
M9"!V;VQA=&EL:71Y/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1C96YT97(^-C<E/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1&-E;G1E<CX\9F]N="!S='EL93TS1"=72$E412U34$%#13H@;F]W<F%P)SXU
M,R4F(WA!,#LM)B-X03`[-C<E/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@86QI9VX],T1C96YT97(^-3$E/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B`G5&EM97,@3F5W
M(%)O;6%N)R<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O
M<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B`G5&EM97,@3F5W(%)O;6%N)SL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)
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M;VT@86QI9VX],T1C96YT97(^,2XR)3PO=&0^#0H@/"]T<CX-"B`\='(@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@)U1I;65S($YE
M=R!2;VUA;B<G/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA
M;B<[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!%
M>'!E8W1E9"!T97)M+CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$8V5N=&5R/C8N,C4@>65A<G,\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$8V5N=&5R/C<@>65A<G,\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$8V5N=&5R/C<F(WA!,#MY96%R<SPO=&0^#0H@/"]T<CX-"B`\
M+W1A8FQE/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@5TA)
M5$4M4U!!0T4Z(&YO<FUA;#L@5$585"U44D%.4T9/4DTZ(&YO;F4[(%=/4D0M
M4U!!0TE.1SH@,'!X.R!#3TQ/4CH@<F=B*#`L,"PP*3L@1D].5#H@,3!P="`G
M5&EM97,@3F5W(%)O;6%N)SL@34%21TE.+51/4#H@,3)P=#L@3$545$52+5-0
M04-)3D<Z(&YO<FUA;#L@5$585"U)3D1%3E0Z(#0E.R`M=V5B:VET+71E>'0M
M<W1R;VME+7=I9'1H.B`P<'@G/@T*(#QB/D5X<&5C=&5D($1I=FED96YD(%EI
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M4CH@<F=B*#`L,"PP*3L@1D].5#H@,3!P="`G5&EM97,@3F5W(%)O;6%N)SL@
M34%21TE.+51/4#H@,3)P=#L@3$545$52+5-004-)3D<Z(&YO<FUA;#L@5$58
M5"U)3D1%3E0Z(#0E.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@G
M/@T*(#QB/D5X<&5C=&5D(%9O;&%T:6QI='D\+V(^)B-X,C`Q-#M6;VQA=&EL
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M0TE.1SH@,'!X.R!#3TQ/4CH@<F=B*#`L,"PP*3L@1D].5#H@,3)P="`G5&EM
M97,@3F5W(%)O;6%N)SL@34%21TE.+51/4#H@,'!T.R!,151415(M4U!!0TE.
M1SH@;F]R;6%L.R!415A4+4E.1$5.5#H@,'!X.R`M=V5B:VET+71E>'0M<W1R
M;VME+7=I9'1H.B`P<'@G/@T*("8C>$$P.SPO<#X-"B`\<"!S='EL93TS1"=-
M05)'24XM0D]45$]-.B`P<'0[(%=(251%+5-004-%.B!N;W)M86P[(%1%6%0M
M5%)!3E-&3U)-.B!N;VYE.R!73U)$+5-004-)3D<Z(#!P>#L@0T],3U(Z(')G
M8B@P+#`L,"D[($9/3E0Z(#$P<'0@)U1I;65S($YE=R!2;VUA;B<[($U!4D=)
M3BU43U`Z(#!P=#L@3$545$52+5-004-)3D<Z(&YO<FUA;#L@5$585"U)3D1%
M3E0Z(#0E.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@G/@T*(#QB
M/E)I<VLM1G)E92!);G1E<F5S="!2871E/"]B/B8C>#(P,30[5&AI<R!I<R!T
M:&4@52Y3+B!4<F5A<W5R>2!R871E#0H@9F]R('1H92!W965K(&]F(&5A8V@@
M;W!T:6]N(&=R86YT(&1U<FEN9R!T:&4@>65A<BP@:&%V:6YG(&$@=&5R;0T*
M('1H870@;6]S="!C;&]S96QY(')E<V5M8FQE<R!T:&4@97AP96-T960@;&EF
M92!O9B!T:&4@;W!T:6]N+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]4
M5$]-.B`P<'0[(%=(251%+5-004-%.B!N;W)M86P[(%1%6%0M5%)!3E-&3U)-
M.B!N;VYE.R!73U)$+5-004-)3D<Z(#!P>#L@0T],3U(Z(')G8B@P+#`L,"D[
M($9/3E0Z(#$P<'0@)U1I;65S($YE=R!2;VUA;B<[($U!4D=)3BU43U`Z(#$R
M<'0[($Q%5%1%4BU34$%#24Y'.B!N;W)M86P[(%1%6%0M24Y$14Y4.B`T)3L@
M+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X)SX-"B`\8CY%>'!E8W1E
M9"!497)M/"]B/B8C>#(P,30[5&AI<R!I<R!T:&4@<&5R:6]D(&]F('1I;64@
M=&AA="!T:&4-"B!O<'1I;VYS(&=R86YT960@87)E(&5X<&5C=&5D('1O(')E
M;6%I;B!U;F5X97)C:7-E9"X@3W!T:6]N<R!G<F%N=&5D#0H@:&%V92!A(&UA
M>&EM=6T@=&5R;2!O9B!T96X@>65A<G,N(%1H92!#;VUP86YY(&5S=&EM871E
M<R!T:&4-"B!E>'!E8W1E9"!L:69E(&]F('1H92!O<'1I;VX@=&5R;2!T;R!B
M92`V+C(U('EE87)S+B!4:&4@0V]M<&%N>2!U<V5S#0H@82!S:6UP;&EF:65D
M(&UE=&AO9"!T;R!C86QC=6QA=&4@=&AE(&%V97)A9V4@97AP96-T960@=&5R
M;2X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!72$E4
M12U34$%#13H@;F]R;6%L.R!415A4+51204Y31D]233H@;F]N93L@5T]21"U3
M4$%#24Y'.B`P<'@[($-/3$]2.B!R9V(H,"PP+#`I.R!&3TY4.B`Q,'!T("=4
M:6UE<R!.97<@4F]M86XG.R!-05)'24XM5$]0.B`Q,G!T.R!,151415(M4U!!
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M<R!B969O<F4@8F5C;VUI;F<@9G5L;'D@=F5S=&5D+CPO<#X-"B`\<"!S='EL
M93TS1"=-05)'24XM0D]45$]-.B`P<'0[(%=(251%+5-004-%.B!N;W)M86P[
M(%1%6%0M5%)!3E-&3U)-.B!N;VYE.R!73U)$+5-004-)3D<Z(#!P>#L@0T],
M3U(Z(')G8B@P+#`L,"D[($9/3E0Z(#$P<'0@)U1I;65S($YE=R!2;VUA;B<[
M($U!4D=)3BU43U`Z(#$R<'0[($Q%5%1%4BU34$%#24Y'.B!N;W)M86P[(%1%
M6%0M24Y$14Y4.B`T)3L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X
M)SX-"B!4:&4@9F]L;&]W:6YG('1A8FQE('-U;6UA<FEZ97,@<W1O8VL@;W!T
M:6]N(&%N9"!R97-T<FEC=&5D('-T;V-K#0H@=6YI="`H4E-5*2!A8W1I=FET
M>2!F;W(@,C`Q-#H\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@
M,'!T.R!72$E412U34$%#13H@;F]R;6%L.R!415A4+51204Y31D]233H@;F]N
M93L@5T]21"U34$%#24Y'.B`P<'@[($-/3$]2.B!R9V(H,"PP+#`I.R!&3TY4
M.B`Q,G!T("=4:6UE<R!.97<@4F]M86XG.R!-05)'24XM5$]0.B`P<'0[($Q%
M5%1%4BU34$%#24Y'.B!N;W)M86P[(%1%6%0M24Y$14Y4.B`P<'@[("UW96)K
M:70M=&5X="US=')O:V4M=VED=&@Z(#!P>"<^#0H@)B-X03`[/"]P/@T*(#QT
M86)L92!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B`G
M5&EM97,@3F5W(%)O;6%N)SL@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S93L@
M5$585"U44D%.4T9/4DTZ(&YO;F4[(%=/4D0M4U!!0TE.1SH@,'!X.R!,1514
M15(M4U!!0TE.1SH@;F]R;6%L.R!415A4+4E.1$5.5#H@,'!X.R`M=V5B:VET
M+71E>'0M<W1R;VME+7=I9'1H.B`P<'@G(&-E;&QS<&%C:6YG/3-$,"!C96QL
M<&%D9&EN9STS1#`@=VED=&@],T0Y,B4@86QI9VX],T1C96YT97(@8F]R9&5R
M/3-$,#X-"B`\='(^#0H@/'1D('=I9'1H/3-$-#,E/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE/CPO=&0^#0H@/'1D/CPO=&0^#0H@
M/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#@E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE/CPO=&0^
M#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE/CPO=&0^#0H@/'1D/CPO=&0^#0H@
M/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G
M1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N
M)R<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@<F=B*#`L,"PP*2`Q<'0@<V]L:60G('9A;&EG
M;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\8CY3:&%R
M97,\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P="!S;VQI
M9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R
M/CQB/E=E:6=H=&5D+3QB<B`O/@T*($%V97)A9V4\+V(^/&)R("\^#0H@/&(^
M17AE<F-I<V4F(WA!,#M0<FEC93PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(')G
M8B@P+#`L,"D@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS
M1#(@86QI9VX],T1C96YT97(^/&(^/&9O;G0@<W1Y;&4],T0G5TA)5$4M4U!!
M0T4Z(&YO=W)A<"<^5V5I9VAT960M079E<F%G93PO9F]N=#X\+V(^/&)R("\^
M#0H@/&(^4F5M86EN:6YG/"]B/CQB<B`O/@T*(#QB/D-O;G1R86-T=6%L(%1E
M<FT\+V(^/&)R("\^#0H@/&(^*%EE87)S*3PO8CX\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(')G8B@P+#`L,"D@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L
M<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&(^06=G<F5G871E/&)R("\^#0H@
M26YT<FEN<VEC/&)R("\^#0H@5F%L=64\+V(^/&)R("\^#0H@/&(^*&EN)B-X
M03`[=&AO=7-A;F1S*3PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@8F=C;VQO
M<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O
M;6%N)SL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*
M($]U='-T86YD:6YG+"!$96-E;6)E<B8C>$$P.S,Q+"`R,#$S/"]P/@T*(#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,RPR,#`L.34X/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@86QI9VX],T1R:6=H=#XT+CDP/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/C8N.3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@)U1I;65S($YE=R!2
M;VUA;B<G/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<[
M($U!4D=)3BU,1494.B`S96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!'<F%N
M=&5D/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^.3<V+#@V.3PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR-RXP-CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@
M/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ("=4
M:6UE<R!.97<@4F]M86XG)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L
M:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M86XG.R!-05)'24XM3$5&5#H@,V5M
M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@17AE<F-I<V5D/"]P/@T*(#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#4V."PY,#8\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/BDF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/C$N,S$\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<^#0H@
M/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)SL@34%21TE.+4Q%
M1E0Z(#-E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($9O<F9E:71E9"!O<B!E
M>'!I<F5D/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#,V+#@P
M-3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M*28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^.2XW-CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R
M('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]2
M1$52+51/4#H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]2
M1$52+51/4#H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\
M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@
M/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ("=4
M:6UE<R!.97<@4F]M86XG)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L
M:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M86XG.R!-05)'24XM3$5&5#H@,65M
M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@3W5T<W1A;F1I;F<L($1E8V5M8F5R
M)B-X03`[,S$L(#(P,30\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XS+#4W,BPQ,38\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,3$N-#`\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^-RXS/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XX-"PU,34\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q
M<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P
M>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`S
M<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<^#0H@
M/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)SL@34%21TE.+4Q%
M1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($1E8V5M8F5R)B-X03`[
M,S$L(#(P,30Z/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M86XG
M)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ("=4:6UE
M<R!.97<@4F]M86XG.R!-05)'24XM3$5&5#H@,V5M.R!415A4+4E.1$5.5#H@
M+3%E;2<^#0H@17AE<F-I<V%B;&4\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ+#8V
M."PY-C(\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,RXR-#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#XU+C,\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-3,L
M,3(R/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M86XG
M)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M86XG.R!-05)'
M24XM3$5&5#H@,V5M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@5F5S=&5D(&%N
M9"!E>'!E8W1E9"!T;R!V97-T/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,RPS-#$L
M,3DR/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$Q+C`S/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A
M;&EG;CTS1')I9VAT/C<N,CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XX,"PS
M,C,\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\+W1A8FQE/@T*(#QP('-T
M>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@5TA)5$4M4U!!0T4Z(&YO<FUA
M;#L@5$585"U44D%.4T9/4DTZ(&YO;F4[(%=/4D0M4U!!0TE.1SH@,'!X.R!#
M3TQ/4CH@<F=B*#`L,"PP*3L@1D].5#H@,3!P="`G5&EM97,@3F5W(%)O;6%N
M)SL@34%21TE.+51/4#H@,3)P=#L@3$545$52+5-004-)3D<Z(&YO<FUA;#L@
M5$585"U)3D1%3E0Z(#0E.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P
M<'@G/@T*($1U<FEN9R`R,#$T+"`R,#$S(&%N9"`R,#$R('1H92!#;VUP86YY
M(&ES<W5E9"`U-C@L.3`V+"`Q+#(V."PP-#D-"B!A;F0@.#8S+#$W-B!N970@
M<VAA<F5S(&]F(&-O;6UO;B!S=&]C:RP@<F5S<&5C=&EV96QY+"!I;@T*(&-O
M;FIU;F-T:6]N('=I=&@@<W1O8VL@;W!T:6]N(&5X97)C:7-E<R!A;F0@4E-5
M(&QA<'-E<RX@5&AE($-O;7!A;GD-"B!R96-E:79E9"!C87-H('!R;V-E961S
M(&9R;VT@=&AE(&5X97)C:7-E(&]F('-T;V-K(&]P=&EO;G,@;V8-"B!A<'!R
M;WAI;6%T96QY("0P+C<@;6EL;&EO;BP@)#$N,2!M:6QL:6]N(&%N9"`D-#<L
M,#`P(&1U<FEN9R`R,#$T+`T*(#(P,3,@86YD(#(P,3(L(')E<W!E8W1I=F5L
M>2X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!72$E4
M12U34$%#13H@;F]R;6%L.R!415A4+51204Y31D]233H@;F]N93L@5T]21"U3
M4$%#24Y'.B`P<'@[($-/3$]2.B!R9V(H,"PP+#`I.R!&3TY4.B`Q,'!T("=4
M:6UE<R!.97<@4F]M86XG.R!-05)'24XM5$]0.B`Q,G!T.R!,151415(M4U!!
M0TE.1SH@;F]R;6%L.R!415A4+4E.1$5.5#H@-"4[("UW96)K:70M=&5X="US
M=')O:V4M=VED=&@Z(#!P>"<^#0H@5&AE('=E:6=H=&5D+6%V97)A9V4@9W)A
M;G0M9&%T92!F86ER('9A;'5E(&]F(&]P=&EO;G,@9W)A;G1E9`T*(&1U<FEN
M9R`R,#$T+"`R,#$S(&%N9"`R,#$R('=A<R`D,3<N-#$L)B-X03`[)#8N.3$@
M86YD("0P+CDT('!E<@T*('-H87)E+"!R97-P96-T:79E;'DN(%1H92!T;W1A
M;"!I;G1R:6YS:6,@=F%L=64@;V8@;W!T:6]N<R!E>&5R8VES960-"B!D=7)I
M;F<@,C`Q-"P@,C`Q,R!A;F0@,C`Q,B!W87,@87!P<F]X:6UA=&5L>2`D,30N
M-2!M:6QL:6]N+"`D-2XT#0H@;6EL;&EO;B!A;F0@)#(W,2PY,CDL(')E<W!E
M8W1I=F5L>2X@5&AE('1O=&%L(&9A:7(@=F%L=64@;V8@<W1O8VL-"B!O<'1I
M;VYS('=H:6-H('9E<W1E9"!D=7)I;F<@,C`Q-"P@,C`Q,R!A;F0@,C`Q,B!W
M87,@)#,N,"!M:6QL:6]N+`T*("0T.#<L-C`S(&%N9"`D.#<Y+#`R-"P@<F5S
M<&5C=&EV96QY+B!!<R!O9B!$96-E;6)E<B8C>$$P.S,Q+"`R,#$T+`T*('1H
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M<')O>&EM871E;'D@9F]U<B!Y96%R<RX\+W`^#0H@/"]D:78^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D
M>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\X9&(U,S=C-%]E.#<X
M7S1A,V5?.#(X85]B-3`P9C-E9&8Q,68-"D-O;G1E;G0M3&]C871I;VXZ(&9I
M;&4Z+R\O0SHO.&1B-3,W8S1?93@W.%\T83-E7S@R.&%?8C4P,&8S961F,3%F
M+U=O<FMS:&5E=',O4VAE970Q,BYH=&UL#0I#;VYT96YT+51R86YS9F5R+45N
M8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O
M:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-
M"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0]
M,T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T
M97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E
M(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@
M("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S
M<&%N/3-$,CX\<W1R;VYG/DEN8V]M92!487AE<SQB<CX\+W-T<F]N9SX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT
M:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY);F-O;64@5&%X($1I
M<V-L;W-U<F4@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y);F-O;64@5&%X97,\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQD:78^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/
M5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#$X<'0G/@T*(#QB/C8N($EN8V]M
M92!487AE<SPO8CX\+W`^#0H@/"$M+2!X8G)L+&)O9'D@+2T^#0H@/'`@<W1Y
M;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#9P=#L@
M5$585"U)3D1%3E0Z(#0E)SX-"B!&;W(@=&AE('EE87)S(&5N9&5D($1E8V5M
M8F5R)B-X03`[,S$L(#(P,30L(#(P,3,@86YD(#(P,3(@=&AE<F4@=V%S#0H@
M;F\@8W5R<F5N="!P<F]V:7-I;VX@9F]R(&9E9&5R86P@;W(@<W1A=&4@:6YC
M;VUE('1A>&5S(&1U92!T;R!T:&4-"B!T87AA8FQE(&QO<W-E<R!W:&EC:"!R
M97-U;'1E9"!O<B!U<V4@;V8@;&5G86-Y($Y/3`T*(&-A<G)Y9F]R=V%R9',N
M/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U3
M25I%.B`Q,G!T.R!-05)'24XM5$]0.B`P<'0G/@T*("8C>$$P.SPO<#X-"B`\
M<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@
M,'!T.R!415A4+4E.1$5.5#H@-"4G/@T*(%1H92!S:6=N:69I8V%N="!C;VUP
M;VYE;G1S(&]F('1H92!#;VUP86YY)B-X,C`Q.3MS(&1E9F5R<F5D(&EN8V]M
M90T*('1A>"!A<W-E=',@*&QI86)I;&ET:65S*2!W97)E(&%S(&9O;&QO=W,@
M*&EN('1H;W5S86YD<RDZ/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U14
M3TTZ(#!P=#L@1D].5"U325I%.B`Q,G!T.R!-05)'24XM5$]0.B`P<'0G/@T*
M("8C>$$P.SPO<#X-"B`\=&%B;&4@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"3U)$15(M0T],3$%0
M4T4Z(&-O;&QA<'-E)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P
M('=I9'1H/3-$-S8E(&%L:6=N/3-$8V5N=&5R(&)O<F1E<CTS1#`^/"$M+2!"
M96=I;B!486)L92!(96%D("TM/@T*(#QT<CX-"B`\=&0@=VED=&@],T0W,24^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$."4^/"]T9#X-
M"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$-R4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\
M=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&
M3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@<F=B*#`L,"PP*2`Q<'0@<V]L:60G('9A;&EG;CTS
M1&)O='1O;2!C;VQS<&%N/3-$-B!A;&EG;CTS1&-E;G1E<CX\8CY$96-E;6)E
M<B8C>$$P.S,Q+#PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#AP
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@<F=B*#`L,"PP*2`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS
M<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\8CXR,#$T/"]B/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@<F=B*#`L,"PP*2`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O
M;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\8CXR,#$S/"]B/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#PO='(^#0H@
M/"$M+2!%;F0@5&%B;&4@2&5A9"`M+3X\(2TM($)E9VEN(%1A8FQE($)O9'D@
M+2T^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D
M('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q
M96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!$969E<G)E9"!I;F-O;64@=&%X
M(&%S<V5T<SH\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*
M(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-
M"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`S96T[(%1%6%0M24Y$14Y4
M.B`M,65M)SX-"B!&961E<F%L(%4N4RX@;F5T(&]P97)A=&EN9R!L;W-S(&-A
M<G)Y9F]R=V%R9#PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D
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M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X
M03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L;W(],T0C
M0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-
M05)'24XM3$5&5#H@,V5M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@4W1A=&4@
M;F5T(&]P97)A=&EN9R!L;W-S(&-A<G)Y9F]R=V%R9#PO<#X-"B`\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!A;&EG;CTS1')I9VAT/C,L-S(S/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/C,L,S$V/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^
M#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($U!4D=)3BU,1494.B`S96T[(%1%6%0M24Y$14Y4.B`M,65M
M)SX-"B!297-E87)C:"!A;F0@9&5V96QO<&UE;G0@8W)E9&ET+"!N970\+W`^
M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XW+#$W-SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XS+#<X-CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T
M9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L;W(],T0C0T-%149&
M/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM
M3$5&5#H@,V5M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@3W)P:&%N(&1R=6<@
M8W)E9&ET+"!N970\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ
M.2PR.#<\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,3DL
M.#@S/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^
M#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,
M1494.B`S96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!$969E<G)E9"!R96YT
M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-"PP-CD\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-2PQ,S(\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#
M145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%2
M1TE.+4Q%1E0Z(#-E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($1E9F5R<F5D
M(')E=F5N=64\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XS+#DX
M.3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XX+#(Q-SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X
M03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT
M9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@
M,V5M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@1&5P<F5C:6%T:6]N/"]P/@T*
M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,2PS,S<\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,2PT,S@\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#145&1CX-
M"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%
M1E0Z(#-E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($]T:&5R/"]P/@T*(#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^.38R/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!A;&EG;CTS1')I9VAT/C$L-#,Y/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO
M='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y
M;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G/B8C>$$P
M.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y
M;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G/B8C>$$P
M.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X
M('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X
M('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-
M"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1T;W`^
M#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,V5M.R!415A4+4E.1$5.
M5#H@+3%E;2<^#0H@1W)O<W,@9&5F97)R960@:6YC;VUE('1A>"!A<W-E=',\
M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@86QI9VX],T1R:6=H=#XY-2PY,#(\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^-SDL-S<R/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O
M<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`S96T[(%1%6%0M24Y$
M14Y4.B`M,65M)SX-"B!686QU871I;VX@86QL;W=A;F-E/"]P/@T*(#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^*#DT+#(Y-SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#<Y+#,W-SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C
M>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q
M<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P
M>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P
M>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@
M<F=B*#`L,"PP*2`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@
M<F=B*#`L,"PP*2`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT
M9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D
M('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q
M96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!.970@9&5F97)R960@:6YC;VUE
M('1A>"!A<W-E=',\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ+#8P-3PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@86QI9VX],T1R:6=H=#XS.34\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-
M"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L
M:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@
M5$585"U)3D1%3E0Z("TQ96TG/@T*($1E9F5R<F5D(&EN8V]M92!T87@@;&EA
M8FEL:71I97,Z/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG
M/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM
M3$5&5#H@,V5M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@4')E<&%I9"!E>'!E
M;F1I='5R97,\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH,2PV,#4\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/BDF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG
M;CTS1')I9VAT/B@S.34\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P/BDF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE
M/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/
M4#H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/
M4#H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*
M(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE
M/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\
M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE
M/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\
M+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T
M;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,V5M.R!415A4+4E.
M1$5.5#H@+3%E;2<^#0H@1W)O<W,@9&5F97)R960@:6YC;VUE('1A>"!L:6%B
M:6QI=&EE<SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@Q+#8P-3PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^*#,Y-3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M
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M;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^#0H@)B-X,C`Q
M-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P(&%L:6=N/3-$<FEG:'0^#0H@)B-X,C`Q-#LF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP
M+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L
M,"PP*2`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$
M15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]2
M1$52+51/4#H@<F=B*#`L,"PP*2`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@
M/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#PA+2T@16YD(%1A
M8FQE($)O9'D@+2T^/"]T86)L93X-"B`\<"!S='EL93TS1"=-05)'24XM0D]4
M5$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@34%21TE.+51/4#H@,3)P=#L@5$585"U)3D1%3E0Z(#0E
M)SX-"B!4:&4@0V]M<&%N>2!R96-O9VYI>F5S('9A;'5A=&EO;B!A;&QO=V%N
M8V5S('1O(')E9'5C92!D969E<G)E9"!T87@-"B!A<W-E=',@=&\@=&AE(&%M
M;W5N="!T:&%T(&ES(&UO<F4@;&EK96QY('1H86X@;F]T('1O(&)E(')E86QI
M>F5D+@T*($EN(&%S<V5S<VEN9R!T:&4@;&EK96QI:&]O9"!O9B!R96%L:7IA
M=&EO;BP@;6%N86=E;65N="!C;VYS:61E<G,-"B`H:2DF(WA!,#MF=71U<F4@
M<F5V97)S86QS(&]F(&5X:7-T:6YG('1A>&%B;&4@=&5M<&]R87)Y#0H@9&EF
M9F5R96YC97,[("AI:2DF(WA!,#MF=71U<F4@=&%X86)L92!I;F-O;64@97AC
M;'5S:79E(&]F(')E=F5R<VEN9PT*('1E;7!O<F%R>2!D:69F97)E;F-E(&%N
M9"!C87)R>69O<G=A<F1S.R`H:6EI*28C>$$P.W1A>&%B;&4@:6YC;VUE#0H@
M:6X@<')I;W(@8V%R<GEB86-K('EE87)S(&EF(&-A<G)Y8F%C:R!I<R!P97)M
M:71T960@=6YD97(@87!P;&EC86)L90T*('1A>"!L87<[(&%N9"`H:78I)B-X
M03`[=&%X('!L86YN:6YG('-T<F%T96=I97,N(%1H92!#;VUP86YY)B-X,C`Q
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M<V4@:6X@=&AE('9A;'5A=&EO;B!A;&QO=V%N8V4@:6X@,C`Q-"!I<R!D=64-
M"B!T;R!T:&4@9F%C="!T:&4@0V]M<&%N>2!G96YE<F%T960@<F5S96%R8V@@
M86YD(&1E=F5L;W!M96YT(&%N9`T*(&]R<&AA;B!D<G5G(&-R961I=',@86YD
M($Y/3"!C87)R>69O<G=A<F1S('=H:6-H(&EN8W)E87-E9"!T:&4@;F5T#0H@
M9&5F97)R960@=&%X(&%S<V5T+B!4:&4@:6YC<F5A<V4@:6X@=&AE(&-R961I
M=',@86YD($Y/3`T*(&-A<G)Y9F]R=V%R9',@=V5R92!O9F9S970@8GD@=&AE
M(&1E8W)E87-E(&EN(&1E9F5R<F5D(')E=F5N=64@86YD#0H@<F5S=6QT960@
M:6X@82!N970@8W5R<F5N="!Y96%R(&EN8W)E87-E('1O('1H92!V86QU871I
M;VX-"B!A;&QO=V%N8V4N/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U14
M3TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4G
M/@T*($%S(&]F($1E8V5M8F5R(#,Q+"`R,#$T+"!T:&4@0V]M<&%N>2!H860@
M52Y3+B!F961E<F%L($Y/3`T*(&-A<G)Y9F]R=V%R9',@;V8@87!P<F]X:6UA
M=&5L>2`D,34X+CD@;6EL;&EO;B!A;F0@87!P<F]X:6UA=&5L>0T*("0Q,#,N
M-"!M:6QL:6]N(&9O<B!S=&%T92!T:&%T('=I;&P@97AP:7)E(&EN('9A<FEO
M=7,@>65A<G,-"B!B96=I;FYI;F<@:6X@,C`R,"!T:')O=6=H(#(P,S0N($EN
M(&%D9&ET:6]N+"!T:&4@0V]M<&%N>2!H87,@52Y3+@T*(&9E9&5R86P@=&%X
M(&-R961I=',@;V8@)#(V+C,@;6EL;&EO;B!W:&EC:"!W:6QL(&5X<&ER92!I
M;B!V87)I;W5S#0H@>65A<G,@8F5G:6YN:6YG(&EN(#(P,C`@=&AR;W5G:"`R
M,#,T+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M34%21TE.+51/4#H@,3)P=#L@5$585"U)3D1%3E0Z(#0E)SX-"B!4:&4@=7-E
M(&]F('1H92!#;VUP86YY)B-X,C`Q.3MS(%4N4RX@9F5D97)A;"!.3TP@86YD
M('1A>"!C<F5D:70-"B!C87)R>69O<G=A<F1S(&EN(&9U='5R92!Y96%R<R!A
M<F4@<F5S=')I8W1E9"!D=64@=&\@8VAA;F=E<R!I;B!T:&4-"B!#;VUP86YY
M)B-X,C`Q.3MS(&]W;F5R<VAI<"!A;F0@=&%X(&%T=')I8G5T97,@86-Q=6ER
M960@=&AR;W5G:"!T:&4-"B!#;VUP86YY)B-X,C`Q.3MS(&%C<75I<VET:6]N
M<RX@07,@;V8@1&5C96UB97(F(WA!,#LS,2P@,C`Q-"P@)#<N,0T*(&UI;&QI
M;VX@;V8@=&AE($-O;7!A;GDF(W@R,#$Y.W,@55,@1F5D97)A;"!.3TQS(&%R
M92!L:6UI=&5D(&9O<B!U<V4-"B!O=F5R('1H92!Y96%R<R`R,#$U+3(P,C<@
M:6X@=VAI8V@@82!R86YG92!O9B!S=6-H(&%M;W5N=',@8V]U;&0@8F4-"B!U
M=&EL:7IE9"!O;B!A;B!A;FYU86P@8F%S:7,@;V8@)#`N,B!M:6QL:6]N('1O
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M(&%N(&%L=&5R;F%T:79E(&UI;FEM=6T@=&%X(&]R('-T871E('1A>`T*(')E
M<75I<F5M96YT<R!I;B!W:&EC:"!N970@;W!E<F%T:6YG(&QO<W-E<R!D;R!N
M;W0@97AI<W0N/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P
M=#L@1D].5"U325I%.B`Q,G!T.R!-05)'24XM5$]0.B`P<'0G/@T*("8C>$$P
M.SPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%2
M1TE.+51/4#H@,'!T.R!415A4+4E.1$5.5#H@-"4G/@T*($9U<G1H97)M;W)E
M+"!T:&4@0V]M<&%N>2!R96-O<F1E9"`D,2XV(&UI;&QI;VX@;V8@8W5R<F5N
M="!D969E<G)E9`T*('1A>"!L:6%B:6QI='D@86YD("0Q+C8@;6EL;&EO;B!O
M9B!N;VYC=7)R96YT(&1E9F5R<F5D('1A>"!A<W-E="!A<PT*(&$@<F5S=6QT
M(&]F('1H92!R97%U:7)E;65N="!T;R!A;&QO8V%T92!I=',@=F%L=6%T:6]N
M(&%L;&]W86YC90T*(&%G86EN<W0@9W)O<W,@9&5F97)R960@=&%X(&%S<V5T
M<RX@07,@<W5C:"!T:&4@8F%L86YC92!S:&5E="!W87,-"B!G<F]S<V5D('5P
M(&)U="!N971S('1O('IE<F\@9&5F97)R960@:6YC;VUE('1A>`T*(&%S<V5T
M<R\H;&EA8FEL:71I97,I+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]4
M5$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
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M;&]W<R`H:6X@=&AO=7-A;F1S*3H\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.
M+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$R<'0[($U!4D=)3BU43U`Z(#!P
M="<^#0H@)B-X03`[/"]P/@T*(#QT86)L92!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)/4D1%4BU#
M3TQ,05!313H@8V]L;&%P<V4G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN
M9STS1#`@=VED=&@],T0X-"4@86QI9VX],T1C96YT97(@8F]R9&5R/3-$,#X\
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M.'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B!R9V(H,"PP+#`I(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O
M;'-P86X],T0Q,"!A;&EG;CTS1&-E;G1E<CX\8CY996%R($5N9&5D#0H@1&5C
M96UB97(F(WA!,#LS,2P\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%
M.B`X<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ(')G8B@P+#`L,"D@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@
M8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&(^,C`Q-#PO8CX\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(')G8B@P+#`L,"D@,7!T('-O;&ED)R!V86QI9VX],T1B
M;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&(^,C`Q,SPO8CX\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P+#`L,"D@,7!T('-O;&ED)R!V86QI
M9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&(^,C`Q
M,CPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\+W1R/@T*(#PA+2T@16YD(%1A8FQE($AE860@+2T^/"$M+2!"96=I;B!4
M86)L92!";V1Y("TM/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L;W(],T0C0T-%
M149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'
M24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@56YI=&5D(%-T
M871E<R!F961E<F%L('1A>"!A="!S=&%T=71O<GD@<F%T93PO<#X-"B`\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@86QI9VX],T1R:6=H=#XH,3,L-#$P/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^*#DQ/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,BPY,C<\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@
M=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E
M;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(%-T871E('1A>&5S("AN970@;V8@
M9F5D97)A;"!B96YE9FET*3PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I
M9VAT/B@Q+#8P.#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-C`Y
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$L-#8P/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO
M<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!$
M969E<G)E9"!I;F-O;64@=&%X(&%D:G5S=&UE;G1S/"]P/@T*(#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R
M:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@86QI9VX],T1R:6=H=#XH.#4U/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1R:6=H=#XH-3$R/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO
M=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-
M05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@1&5F97)R
M960@<W1A=&4@8FQE;F1E9"!R871E(&%D:G5S=&UE;G1S/"]P/@T*(#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^,RPP,S0\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^*#,T-#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X-"B`F
M(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*
M(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XG(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI
M9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!4
M15A4+4E.1$5.5#H@+3%E;2<^#0H@4F5S96%R8V@@8W)E9&ET+"!N970\+W`^
M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH,BPR,C@\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/BDF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!A;&EG;CTS1')I9VAT/B@R,C8\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/BDF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^
M#0H@)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T
M<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ
M96TG/@T*(%1R86YS86-T:6]N(&-O<W0@9&5D=6-T:6]N/"]P/@T*(#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#,W.3PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X-
M"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT
M/@T*("8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO
M='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D
M('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q
M96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!4<F%N<V%C=&EO;B!C;W-T(&1E
M9'5C=&EO;B8C>#(P,30[<')I;W(@>65A<B!A9&IU<W1M96YT/"]P/@T*(#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#4V-#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H
M=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I
M9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-
M"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4
M.B`M,65M)SX-"B!/<G!H86X@9')U9R!C<F5D:70L(&YE=#PO<#X-"B`\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!A;&EG;CTS1')I9VAT/B@Q,SD\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/BDF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A
M;&EG;CTS1')I9VAT/B@X-#,\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M;F]W<F%P/3-$;F]W<F%P/BDF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I
M9VAT/B@T+#@Y-CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ
M96TG/@T*($]T:&5R('!E<FUA;F5N="!I=&5M<SPO<#X-"B`\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/B@S.#(\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P/BDF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT/C,\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M.#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*
M(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&
M5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@17%U:71Y+6)A<V5D(&-O
M;7!E;G-A=&EO;CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C<U
M-CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR-#$\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,C<Y/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO<CTS1"-#
M0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!
M4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!&86ER('9A
M;'5E(&%D:G5S=&UE;G0@;V8@<')E9F5R<F5D('-T;V-K('=A<G)A;G0@;&EA
M8FEL:71Y/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR,3D\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#4S/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[
M/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX]
M,T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4
M+4E.1$5.5#H@+3%E;2<^#0H@0VAA;F=E(&EN('9A;'5A=&EO;B!A;&QO=V%N
M8V4\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ-"PY,C`\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,2PR.#<\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-S@W/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`Q<'@@<V]L
M:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`Q<'@@<V]L
M:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P
M+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P
M+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$
M15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$
M15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO
M=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ
M96TG/@T*($EN8V]M92!T87@@97AP96YS92\H8F5N969I="D\+W`^#0H@/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)#PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X-"B`F(W@R
M,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX]
M,T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T
M9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*
M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L
M92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-
M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B
M;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P
M+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H
M,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/
M4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*
M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="
M3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-
M"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/"$M+2!%;F0@
M5&%B;&4@0F]D>2`M+3X\+W1A8FQE/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"
M3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@
M-"4G/@T*($$@<F5C;VYC:6QI871I;VX@;V8@=&AE(&)E9VEN;FEN9R!A;F0@
M96YD:6YG(&%M;W5N="!O9B!G<F]S<PT*('5N<F5C;V=N:7IE9"!T87@@8F5N
M969I=',@:7,@87,@9F]L;&]W<R`H:6X@=&AO=7-A;F1S*3H\+W`^#0H@/'`@
M<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$R<'0[
M($U!4D=)3BU43U`Z(#!P="<^#0H@)B-X03`[/"]P/@T*(#QT86)L92!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4G(&-E;&QS<&%C:6YG
M/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0X-"4@86QI9VX],T1C96YT
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M;6%N)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P="!S;VQI9"<@=F%L
M:6=N/3-$8F]T=&]M(&-O;'-P86X],T0Q,"!A;&EG;CTS1&-E;G1E<CX\8CY9
M96%R($5N9&5D#0H@1&5C96UB97(F(WA!,#LS,2P\+V(^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y
M;&4],T0G1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P+#`L,"D@,7!T('-O;&ED)R!V
M86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&(^
M,C`Q-#PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P+#`L,"D@,7!T('-O
M;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT
M97(^/&(^,C`Q,SPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P+#`L,"D@
M,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX]
M,T1C96YT97(^/&(^,C`Q,CPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#PA+2T@16YD(%1A8FQE($AE860@
M+2T^/"$M+2!"96=I;B!486)L92!";V1Y("TM/@T*(#QT<B!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG
M(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E
M;2<^#0H@0F5G:6YN:6YG(&)A;&%N8V4\+W`^#0H@/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^,2PW,#@\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P
M/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$L
M-3DR/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ+#4S-#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[
M)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V
M86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,V5M
M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@26YC<F5A<V5S+RAD96-R96%S97,I
M(&9O<B!C=7)R96YT('EE87(@=&%X('!O<VET:6]N<SPO<#X-"B`\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!A;&EG;CTS1')I9VAT/C(T,CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#XQ,38\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^-3@\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P
M/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P
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M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^.3<\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($U!4D=)3BU,1494.B`S96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!$96-R
M96%S97,@87,@82!R97-U;'0@;V8@97AP:7)A=&EO;B!O9B!S=&%T=71E(&]F
M(&QI;6ET871I;VYS/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^#0H@)B-X,C`Q
M-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@
M<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$
M15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$
M15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO
M=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@
M<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G/B8C
M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@
M<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G/B8C
M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@
M,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@
M,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T
M9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L;W(],T0C0T-%149&
M/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM
M3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@16YD:6YG(&)A;&%N
M8V4\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^,BPP-#<\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$L
M-S`X/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ+#4Y,CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-
M"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP
M('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^
M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\
M<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G
M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L
M,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP
M+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%
M4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$
M15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\
M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/"$M+2!%;F0@5&%B
M;&4@0F]D>2`M+3X\+W1A8FQE/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U14
M3TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4G
M/@T*($%S(&]F($1E8V5M8F5R)B-X03`[,S$L(#(P,30@86YD(#(P,3,L(&]F
M('1H92!T;W1A;"!G<F]S<PT*('5N<F5C;V=N:7IE9"!T87@@8F5N969I=',L
M(&%P<')O>&EM871E;'D@)#$N-R!M:6QL:6]N(&%N9"`D,2XS#0H@;6EL;&EO
M;B!W;W5L9"!F879O<F%B;'D@:6UP86-T('1H92!#;VUP86YY)B-X,C`Q.3MS
M(&5F9F5C=&EV92!I;F-O;64-"B!T87@@<F%T92P@<F5S<&5C=&EV96QY+B!!
M;'1H;W5G:"P@9'5E('1O('1H92!#;VUP86YY)B-X,C`Q.3MS#0H@9&5T97)M
M:6YA=&EO;B!T:&%T('1H92!D969E<G)E9"!I;F-O;64@=&%X(&%S<V5T('=O
M=6QD(&YO="!M;W)E#0H@;&EK96QY('1H86X@;F]T(&)E(')E86QI>F5D+"!A
M('9A;'5A=&EO;B!A;&QO=V%N8V4@=V]U;&0@8F4-"B!R96-O<F1E9"P@=&AE
M<F5F;W)E+"!Z97)O(&YE="!I;7!A8W0@=V]U;&0@<F5S=6QT('=I=&AI;B!T
M:&4-"B!#;VUP86YY)B-X,C`Q.3MS(&5F9F5C=&EV92!I;F-O;64@=&%X(')A
M=&4N(%1H92!#;VUP86YY)B-X,C`Q.3MS#0H@=6YC97)T86EN(&EN8V]M92!T
M87@@<&]S:71I;VX@;&EA8FEL:71Y(&AA<R!B965N(')E8V]R9&5D('1O#0H@
M9&5F97)R960@:6YC;VUE('1A>&5S('1O(&]F9G-E="!T:&4@=&%X(&%T=')I
M8G5T92!C87)R>69O<G=A<F0-"B!A;6]U;G1S+CPO<#X-"B`\<"!S='EL93TS
M1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@,3)P=#L@5$58
M5"U)3D1%3E0Z(#0E)SX-"B!&;W(@=&AE('EE87)S(&5N9&5D($1E8V5M8F5R
M)B-X03`[,S$L(#(P,30L(#(P,3,@86YD(#(P,3(L('1H90T*($-O;7!A;GD@
M:&%S(&YO="!R96-O9VYI>F5D(&%N>2!I;G1E<F5S="!O<B!P96YA;'1I97,@
M<F5L871E9"!T;R!T:&4-"B!U;F-E<G1A:6X@:6YC;VUE('1A>"!P;W-I=&EO
M;G,@9'5E('1O('1H92!F86-T('-U8V@@<&]S:71I;VX@:7,-"B!R96QA=&5D
M('1O('1A>"!A='1R:6)U=&4@8V%R<GEF;W)W87)D<R!W:&EC:"!H879E(&YO
M="!Y970@8F5E;@T*('5T:6QI>F5D+B!4:&4@0V]M<&%N>2!D;V5S(&YO="!E
M>'!E8W0@:71S('5N<F5C;V=N:7IE9"!I;F-O;64@=&%X#0H@<&]S:71I;VX@
M=&\@<VEG;FEF:6-A;G1L>2!D96-R96%S92!W:71H:6X@=&AE(&YE>'0@='=E
M;'9E#0H@;6]N=&AS+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-
M.B`P<'0[($9/3E0M4TE:13H@,3)P=#L@34%21TE.+51/4#H@,'!T)SX-"B`F
M(WA!,#L\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($U!4D=)3BU43U`Z(#!P=#L@5$585"U)3D1%3E0Z(#0E)SX-"B!4:&4@0V]M
M<&%N>28C>#(P,3D[<R!5+E,N($9E9&5R86P@86YD('-T871E(&EN8V]M92!T
M87@@<F5T=7)N<R!F<F]M#0H@,C`P,2!T;R`R,#$T(')E;6%I;B!S=6)J96-T
M('1O(&5X86UI;F%T:6]N(&)Y('1H92!T87@@875T:&]R:71I97,N#0H@5&AE
M($-O;7!A;GDF(W@R,#$Y.W,@,C`P,2!T:')O=6=H(#(P,3`@>65A<G,@<F5M
M86EN(&]P96X@9F]R#0H@97AA;6EN871I;VXL(&5V96X@=&AO=6=H('1H92!S
M=&%T=71E(&]F(&QI;6ET871I;VYS(&AA<R!E>'!I<F5D+`T*(&1U92!T;R!T
M:&4@;F5T(&]P97)A=&EN9R!L;W-S97,@86YD(&-R961I=',@8V%R<FEE9"!F
M;W)W87)D(&9O<B!U<V4-"B!I;B!P<F]S<&5C=&EV92!Y96%R<RX\+W`^#0H@
M/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO
M=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R
M=%\X9&(U,S=C-%]E.#<X7S1A,V5?.#(X85]B-3`P9C-E9&8Q,68-"D-O;G1E
M;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.&1B-3,W8S1?93@W.%\T83-E7S@R
M.&%?8C4P,&8S961F,3%F+U=O<FMS:&5E=',O4VAE970Q,RYH=&UL#0I#;VYT
M96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT
M96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH
M=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N
M="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\
M<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO
M*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A
M9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$
M240P14U%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C
M;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/DQE87-E($5X:70@3&EA
M8FEL:71Y/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N
M(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#X\<W1R;VYG/E)E<W1R=6-T=7)I;F<@86YD(%)E;&%T960@06-T:79I=&EE
M<R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/DQE87-E($5X:70@3&EA8FEL:71Y/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\9&EV/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"
M3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q.'!T)SX-"B`\8CXW+B!,96%S
M92!%>&ET($QI86)I;&ET>3PO8CX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.
M+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#9P=#L@5$585"U)3D1%3E0Z
M(#0E)SX-"B!/;B!*=6QY)B-X03`[,38L(#(P,#@L('1H92!#;VUP86YY(&%C
M<75I<F5D(%)A=F5N($)I;W1E8VAN;VQO9VEE<RP-"B!);F,N("A2879E;BDL
M(&$@<')I=F%T92!3;W5T:"!386X@1G)A;F-I<V-O+6)A<V5D(&-O;7!A;GD@
M9F]C=7-E9`T*(&]N('1H92!D979E;&]P;65N="!O9B!M;VYO8VQO;F%L(&%N
M=&EB;V1Y('1H97)A<&5U=&EC<R!F;W(@=')E871I;F<-"B!C86YC97(N(%)A
M=F5N('=A<R!C;VYS:61E<F5D(&$@9&5V96QO<&UE;G0M<W1A9V4@96YT97)P
M<FES92!A<PT*(&1E9FEN960@:6X@05-#)B-X03`[.3$U+"`\:3Y$979E;&]P
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M>6%B;&4-"B!O9B!2879E;BX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/
M5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$14Y4.B`T
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M96YD960@1&5C96UB97(F(WA!,#LS,2P@,C`P.2X\+W`^#0H@/'`@<W1Y;&4]
M,T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#$R<'0[(%1%
M6%0M24Y$14Y4.B`T)2<^#0H@26X@8V]N;F5C=&EO;B!W:71H('1H97-E(')E
M<W1R=6-T=7)I;F<@86-T:79I=&EE<RP@87,@<&%R="!O9B!T:&4-"B!C;W-T
M(&]F(&%C<75I<VET:6]N+"!T:&4@0V]M<&%N>2!E<W1A8FQI<VAE9"!A(')E
M<W1R=6-T=7)I;F<-"B!L:6%B:6QI='D@871T<FEB=71E9"!T;R!A;B!E>&ES
M=&EN9R!O<&5R871I;F<@;&5A<V4N(%1H92!T97)M<R!O9@T*('1H92!O<&5R
M871I;F<@;&5A<V4@97AT96YD('1H<F]U9V@@,C`Q."X\+W`^#0H@/'`@<W1Y
M;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#$R<'0[
M(%1%6%0M24Y$14Y4.B`T)2<^#0H@0VAA;F=E<R!I;B!T:&4@;&5A<V4@97AI
M="!L:6%B:6QI='D@87)E(&%S(&9O;&QO=W,@*&EN#0H@=&AO=7-A;F1S*3H\
M+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)
M6D4Z(#$R<'0[($U!4D=)3BU43U`Z(#!P="<^#0H@)B-X03`[/"]P/@T*(#QT
M86)L92!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4G(&-E
M;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0V."4@86QI
M9VX],T1C96YT97(@8F]R9&5R/3-$,#X-"B`\='(^#0H@/'1D('=I9'1H/3-$
M.#0E/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#<E/CPO
M=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/"]T
M<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@
M=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E
M;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($%C8W)U86P@8F%L86YC92!A="!$
M96-E;6)E<B8C>$$P.S,Q+"`R,#$R+CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XF(WA!,#LQ
M,"PP-S0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.
M+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(%!R:6YC:7!A;"!P
M87EM96YT<SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@V,CD\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/BDF(WA!,#L\+W1D/@T*
M(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@
M<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P
M.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y
M;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO
M<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O
M<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$
M14Y4.B`M,65M)SX-"B!!8V-R=6%L(&)A;&%N8V4@870@1&5C96UB97(F(WA!
M,#LS,2P@,C`Q,SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CDL-#0U/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG
M;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%
M6%0M24Y$14Y4.B`M,65M)SX-"B!0<FEN8VEP86P@<&%Y;65N=',\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#XH,2PT,SD\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P/BDF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R
M('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]2
M1$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52
M+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*
M(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C
M;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-
M"B!!8V-R=6%L(&)A;&%N8V4@870@1&5C96UB97(F(WA!,#LS,2P@,C`Q-#PO
M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#XX+#`P-CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*
M(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$
M)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*
M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="
M3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\
M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\
M<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@
M,3)P=#L@5$585"U)3D1%3E0Z(#0E)SX-"B!&=71U<F4@<')I;F-I<&%L('!A
M>6UE;G1S('1O(&)E(&UA9&4@=6YD97(@=&AE(&QE87-E(&%G<F5E;65N="!A
M<PT*(&]F($1E8V5M8F5R)B-X03`[,S$L(#(P,30@87)E(&%S(&9O;&QO=W,@
M*&EN('1H;W5S86YD<RDZ/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U14
M3TTZ(#!P=#L@1D].5"U325I%.B`Q,G!T.R!-05)'24XM5$]0.B`P<'0G/@T*
M("8C>$$P.SPO<#X-"B`\=&%B;&4@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"3U)$15(M0T],3$%0
M4T4Z(&-O;&QA<'-E)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P
M('=I9'1H/3-$-C@E(&%L:6=N/3-$8V5N=&5R(&)O<F1E<CTS1#`^#0H@/'1R
M/@T*(#QT9"!W:61T:#TS1#@V)3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0X)3X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*
M(#QT9#X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO<CTS
M1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B`R,#$U
M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/C$L-C0R/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^
M#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M
M)SX-"B`R,#$V/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,2PX-C8\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#
M145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%2
M1TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(#(P,3<\+W`^
M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@86QI9VX],T1R:6=H=#XR+#$Q,SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R
M/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E
M;2<^#0H@,C`Q.#PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(L,S@U/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X
M)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L
M:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G
M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^
M#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A
M;&EG;CTS1'1O<#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@86QI9VX],T1R:6=H=#XX+#`P-CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\
M+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T
M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[
M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL
M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO
M<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/"]T86)L
M93X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:
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M"B!0:&%S92`R(&-L:6YI8V%L('1R:6%L(&]F(&%N>2!P<F]D=6-T(&1E<FEV
M960@9G)O;2!T:&4@4F%V96X-"B`F(W@R,#%#.T-A;F-E<B!3=&5M($-E;&P@
M4')O9W)A;2XF(W@R,#%$.R!.;R!P87EM96YT('-H86QL(&)E(&UA9&4@:68-
M"B!T:&4@4&AA<V4@,B!T<FEA;"!S=&%R="!D871E(&AA<R!N;W0@;V-C=7)R
M960@;VX@;W(@8F5F;W)E#0H@2G5L>28C>$$P.S$U+"`R,#$X+B!/=&AE<B!C
M;VYS:61E<F%T:6]N(&EN8VQU9&5S(&$@<&5R8V5N=&%G92!O9@T*(')E=F5N
M=64@*&5X8VQU9&EN9R!C;VYS:61E<F%T:6]N(&9O<B!R97-E87)C:"!A;F0@
M9&5V96QO<&UE;G0@86YD#0H@97%U:71Y*2!R96-E:79E9"!B>2!T:&4@0V]M
M<&%N>2!F;W(@;&EC96YS92!O9B!A('!R;V1U8W0@9&5R:79E9`T*(&9R;VT@
M=&AE(%)A=F5N("8C>#(P,4,[0V%N8V5R(%-T96T@0V5L;"!0<F]G<F%M)B-X
M,C`Q1#L@86YD(&$@;VYE=&EM90T*('!A>6UE;G0@<F%N9VEN9R!F<F]M("0X
M+C`@;6EL;&EO;B!T;R`D,3(N,"!M:6QL:6]N(&1E<&5N9&5N="!U<&]N(&$-
M"B!S<&5C:69I960@;&5V96P@;V8@<V%L97,@;V8@<')O9'5C=',@9&5R:79E
M9"!F<F]M('1H92!2879E;@T*("8C>#(P,4,[0V%N8V5R(%-T96T@0V5L;"!0
M<F]G<F%M+B8C>#(P,40[/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U14
M3TTZ(#!P=#L@1D].5"U325I%.B`Q,G!T.R!-05)'24XM5$]0.B`P<'0G/@T*
M("8C>$$P.SPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[
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M('1H92!Y96%R<R!E;F1E9"!$96-E;6)E<B8C>$$P.S,Q+"`R,#$T+"`R,#$S
M(&%N9`T*(#(P,3(N/"]P/@T*(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^
M#0H-"BTM+2TM+3U?3F5X=%!A<G1?.&1B-3,W8S1?93@W.%\T83-E7S@R.&%?
M8C4P,&8S961F,3%F#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+SAD
M8C4S-V,T7V4X-SA?-&$S95\X,CAA7V(U,#!F,V5D9C$Q9B]7;W)K<VAE971S
M+U-H965T,30N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O
M=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S
M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@
M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M
M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R
M:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE
M;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C
M;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T
M<F]N9SY#;VQL86)O<F%T:6]N(&%N9"!,:6-E;G-E($%G<F5E;65N=',\8G(^
M/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A
M;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,30\
M8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^
M5&5X="!";&]C:R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D-O;&QA8F]R871I;VX@86YD($QI8V5N<V4@
M06=R965M96YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I
M=CX-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.
M+51/4#H@,3AP="<^#0H@/&(^."X@0V]L;&%B;W)A=&EO;B!A;F0@3&EC96YS
M92!!9W)E96UE;G1S/"]B/CPO<#X-"B`\(2TM('AB<FPL8F]D>2`M+3X-"B`\
M<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@
M-G!T)SX-"B`\8CX\:3Y*86YS<V5N($)I;W1E8V@L($EN8RX\+VD^/"]B/CPO
M<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:
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M"B!*;VAN<V]N)B-X03`[)F%M<#L@2F]H;G-O;B!);FYO=F%T:6]N)B-X,C`Q
M-#M*2D1#+"!);F,N("A*2D1#*2P@86X-"B!A9F9I;&EA=&4@;V8@2F%N<W-E
M;BP@=6YD97(@=VAI8V@@2DI$0R!A9W)E960@=&\@<'5R8VAA<V4@,2PY,C,L
M,#<W#0H@;F5W('-H87)E<R!O9B!T:&4@0V]M<&%N>28C>#(P,3D[<R!C;VUM
M;VX@<W1O8VL@870@82!P<FEC92!O9B`D,SDN,#`-"B!P97(@<VAA<F4L(')E
M<')E<V5N=&EN9R!P<F]C965D<R!O9B`D-S4N,"!M:6QL:6]N+B!4:&4-"B!E
M9F9E8W1I=F5N97-S(&]F('1H97-E(&%G<F5E;65N=',@=V%S('-U8FIE8W0@
M=&\@=&AE(&5A<FQY#0H@=&5R;6EN871I;VX@;W(@97AP:7)A=&EO;B!O9B!A
M;GD@87!P;&EC86)L92!W86ET:6YG('!E<FEO9',@=6YD97(-"B!(87)T+5-C
M;W1T+5)O9&EN;R!!;G1I=')U<W0@26UP<F]V96UE;G1S($%C="!O9B`Q.3<V
M+"!W:&EC:`T*(&]C8W5R<F5D(&EN($IA;G5A<GD@,C`Q-2`H<V5E($YO=&4@
M,3,I+B!4:&4@0V]M<&%N>2!I<R!E;&EG:6)L92!T;PT*(')E8V5I=F4@82`D
M-3`N,"!M:6QL:6]N('5P9G)O;G0@<&%Y;65N="!F<F]M($IA;G-S96X@869T
M97(@=&AE#0H@8V]L;&%B;W)A=&EO;B!A;F0@;&EC96YS92!A9W)E96UE;G0@
M8F5C;VUE<R!E9F9E8W1I=F4N($IA;G-S96X@=VEL;`T*(&)E(&9U;&QY(')E
M<W!O;G-I8FQE(&9O<B!D979E;&]P:6YG($U'1#`Q,2!F;VQL;W=I;F<@<W5B
M;6ES<VEO;B!O9@T*('1H92!);G9E<W1I9V%T:6]N86P@3F5W($1R=6<@07!P
M;&EC871I;VX@*$E.1"DL('=H:6-H(&ES('!L86YN960-"B!F;W(@,C`Q-2X@
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M;VX@;V8@;&%T92US=&%G92!C;&EN:6-A;`T*(&1E=F5L;W!M96YT(&EN(&5X
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M=&AE(%4N4RX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T
M.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($U!4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@3F\@
M<F5V96YU92!W87,@<F5C;V=N:7IE9"!D=7)I;F<@=&AE('EE87(@96YD960@
M1&5C96UB97(F(WA!,#LS,2P-"B`R,#$T('5N9&5R('1H:7,@86=R965M96YT
M+"!A;F0@;F\@<F5L871E9"!D969E<G)E9"!R979E;G5E('=A<PT*(')E8V]R
M9&5D(&%S(&]F($1E8V5M8F5R)B-X03`[,S$L(#(P,30N/"]P/@T*(#QP('-T
M>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q.'!T
M)SX-"B`\8CX\:3Y486ME9&$\+VD^/"]B/CPO<#X-"B`\<"!S='EL93TS1"=-
M05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@-G!T.R!415A4+4E.
M1$5.5#H@-"4G/@T*($EN($UA>2`R,#$T+"!T:&4@0V]M<&%N>2!E;G1E<F5D
M(&EN=&\@82!L:6-E;G-E(&%N9"!O<'1I;VX-"B!A9W)E96UE;G0@=VET:"!4
M86ME9&$@9F]R('1H92!D979E;&]P;65N="!A;F0@8V]M;65R8VEA;&EZ871I
M;VX@;V8-"B!-1T0P,3`L(&$@<')O9'5C="!C86YD:61A=&4@=&AA="!I;F-O
M<G!O<F%T97,@=&AE($-O;7!A;GDF(W@R,#$Y.W,-"B!P<F]P<FEE=&%R>2!$
M05)4('1E8VAN;VQO9WD@=&\@<VEM=6QT86YE;W5S;'D@96YG86=E($-$,S)"
M(&%N9`T*($-$-SE"+"!W:&EC:"!A<F4@='=O($(M8V5L;"!S=7)F86-E('!R
M;W1E:6YS+B!-1T0P,3`@:7,@8W5R<F5N=&QY#0H@:6X@<')E+6-L:6YI8V%L
M(&1E=F5L;W!M96YT(&9O<B!T:&4@=')E871M96YT(&]F(&%U=&]I;6UU;F4-
M"B!D:7-E87-E<RX@57!O;B!E>&5C=71I;VX@;V8@=&AE(&%G<F5E;65N="P@
M5&%K961A(&UA9&4@80T*(&YO;BUR969U;F1A8FQE('!A>6UE;G0@;V8@)#$U
M+C`@;6EL;&EO;B!T;R!T:&4@0V]M<&%N>2X@5&%K961A(&AA<PT*(&%N(&]P
M=&EO;B!T;R!O8G1A:6X@86X@97AC;'5S:79E('=O<FQD=VED92!L:6-E;G-E
M(&9O<B!-1T0P,3`-"B!F;VQL;W=I;F<@=&AE(&-O;7!L971I;VX@;V8@82!P
M<F4M9&5F:6YE9"!0:&%S92`Q82!S='5D>2X@5&AE#0H@0V]M<&%N>2!W:6QL
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M871I;VX@;V8-"B!-1T0P,3`L('1H92!#;VUP86YY(&ES(&5L:6=I8FQE('1O
M(')E8V5I=F4@=7`@=&\@86X@861D:71I;VYA;`T*("0T-C@N-2!M:6QL:6]N
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M(&$@<&]R=&EO;B!O9B!0:&%S92`S(&-L:6YI8V%L(&1E=F5L;W!M96YT(&EN
M(&5X8VAA;F=E#0H@9F]R(&$@3F]R=&@@06UE<FEC86X@<')O9FET('-H87)E
M+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M
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M)B-X,C`Q.3MS#0H@<W5B<W1A;G1I=F4@<&5R9F]R;6%N8V4@;V)L:6=A=&EO
M;G,@=6YD97(@=&AE(&QI8V5N<V4@86YD(&]P=&EO;@T*(&%G<F5E;65N="!I
M;F-L=61E(&5X8VQU<VEV:71Y+"!R97-E87)C:"!A;F0@9&5V96QO<&UE;G0@
M<V5R=FEC97,-"B!T:')O=6=H('1H92!0:&%S92`Q82!S='5D>2!A;F0@9&5L
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M=&5N=&EA;`T*(&9U='5R92!D979E;&]P;65N="!A;F0@<F5G=6QA=&]R>2!M
M:6QE<W1O;F4@:7,@<W5B<W1A;G1I=F4N#0H@06QT:&]U9V@@<V%L97,@;6EL
M97-T;VYE<R!A<F4@;F]T(&-O;G-I9&5R960@<W5B<W1A;G1I=F4L('1H97D@
M87)E#0H@<W1I;&P@<F5C;V=N:7IE9"!U<&]N(&%C:&EE=F5M96YT(&]F('1H
M92!M:6QE<W1O;F4@*&%S<W5M:6YG(&%L;`T*(&]T:&5R(')E=F5N=64@<F5C
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M9"!D979E;&]P;65N=`T*('1H<F]U9V@@=&AE('!R92UD969I;F5D(%!H87-E
M(#%A('-T=61Y+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P
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M;VUP86YY(&%L;&]C871E9"`D,3`N,"!M:6QL:6]N('1O('1H92!E>&-L=7-I
M=FET>2!C;&%U<V4@=&\@:71S#0H@=&5C:&YO;&]G>2!A;F0@=&AE(')E<V5A
M<F-H(&%N9"!D979E;&]P;65N="!S97)V:6-E<R!A;F0@)#4N,`T*(&UI;&QI
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M<"UF<F]N="!F964@86QL;V-A=&5D('1O('1H90T*($U'1#`Q,"!O<'1I;VX@
M:7,@8F5I;F<@<F5C;V=N:7IE9"!O=F5R(&%N(&EN:71I86P@,C0M;6]N=&@@
M<&5R:6]D+`T*('=H:6-H(')E<')E<V5N=',@=&AE(&5X<&5C=&5D('!E<FEO
M9"!O9B!D979E;&]P;65N="!T:')O=6=H('1H90T*(&-O;7!L971I;VX@;V8@
M82!P<F4M9&5F:6YE9"!0:&%S92`Q82!S='5D>2X@5&AE('!O<G1I;VX@;V8@
M=&AE#0H@=7`M9G)O;G0@9F5E(&%L;&]C871E9"!T;R!T:&4@;&EC96YS92!F
M;W(@=&AE(&EN:71I86P@<F5S96%R8V@-"B!C;VUP;W5N9"!W87,@9&5F97)R
M960@=6YT:6P@=&AE(')E<V5A<F-H(&-O;&QA8F]R871I;VX@86YD(&QI8V5N
M<V4-"B!O<'1I;VX@86=R965M96YT('=A<R!E>&5C=71E9"!A;F0@=&AE(&QI
M8V5N<V4@9&5L:79E<F5D+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]4
M5$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@34%21TE.+51/4#H@,3)P=#L@5$585"U)3D1%3E0Z(#0E
M)SX-"B!4:&4@0V]M<&%N>2!R96-O9VYI>F5D(')E=F5N=64@;V8@87!P<F]X
M:6UA=&5L>2`D,RXP(&UI;&QI;VX@=6YD97(-"B!T:&4@34=$,#$P(&%G<F5E
M;65N="!D=7)I;F<@=&AE('EE87(@96YD960@1&5C96UB97(F(WA!,#LS,2P@
M,C`Q-"X-"B!!="!$96-E;6)E<B8C>$$P.S,Q+"`R,#$T+"`D-RXQ(&UI;&QI
M;VX@;V8@<F5V96YU92!W87,@9&5F97)R960-"B!U;F1E<B!T:&ES(&%G<F5E
M;65N="P@)#4N,"!M:6QL:6]N(&]F('=H:6-H('=A<R!C=7)R96YT(&%N9"`D
M,BXQ#0H@;6EL;&EO;B!O9B!W:&EC:"!W87,@;F]N+6-U<G)E;G0N/"]P/@T*
M(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0
M.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4G/@T*($EN(%-E<'1E;6)E<B`R,#$T
M+"!T:&4@0V]M<&%N>2!A;F0@5&%K961A(&5X96-U=&5D(&$@<F5S96%R8V@-
M"B!C;VQL86)O<F%T:6]N(&%N9"!L:6-E;G-E(&]P=&EO;B!A9W)E96UE;G0L
M('=H:6-H(&9O<FUA;&EZ960@=&AE#0H@;&EC96YS92!F;W(@=&AE(&EN:71I
M86P@<F5S96%R8V@@8V]M<&]U;F0N(%5N9&5R('1H92!T97)M<R!O9B!T:&4-
M"B!A9W)E96UE;G0L(%1A:V5D82!M87D@:61E;G1I9GD@=7`@=&\@=&AR964@
M861D:71I;VYA;"!C;VUP;W5N9',L#0H@=VAI8V@@=VEL;"!B92!S=6)J96-T
M('1O('-E<&%R871E(')E<V5A<F-H(&%N9"!D979E;&]P;65N="!P;&%N<RX-
M"B!4:&4@0V]M<&%N>2!D971E<FUI;F5D('1H870@:70@8V]U;&0@<F5C;V=N
M:7IE('1H92!E;G1I<F4@;&EC96YS90T*(&9E92!A<R`H,2DF(WA!,#MT:&4@
M97AE8W5T960@8V]N=')A8W0@8V]N<W1I='5T960@<&5R<W5A<VEV90T*(&5V
M:61E;F-E(&]F(&%N(&%R<F%N9V5M96YT+"`H,BDF(WA!,#MT:&4@9&5L:79E
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M*#0I)B-X03`[=&AE(&-A<V@-"B!W87,@<F5C96EV960N(%1H97)E9F]R92P@
M=&AE($-O;7!A;GD@<F5C;V=N:7IE9"`D-2XP(&UI;&QI;VX@:6X-"B!R979E
M;G5E(&1U<FEN9R!T:&4@>65A<B!E;F1E9"!$96-E;6)E<B8C>$$P.S,Q+"`R
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M3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q.'!T)SX-"B`\8CX\:3Y'
M:6QE860\+VD^/"]B/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-
M.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@34%21TE.+51/4#H@-G!T.R!415A4+4E.1$5.5#H@-"4G/@T*
M($EN($IA;G5A<GD@,C`Q,RP@=&AE($-O;7!A;GD@96YT97)E9"!I;G1O(&%N
M(&%G<F5E;65N="!W:71H($=I;&5A9`T*(&9O<B!':6QE860@=&\@;V)T86EN
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M<"!T;R!A;B!A9&1I=&EO;F%L("0R,"XP(&UI;&QI;VX@=&\@)#(U+C`@;6EL
M;&EO;B!I;@T*('!R92UC;&EN:6-A;"!M:6QE<W1O;F5S(&%N9"!U<"!T;R`D
M,C0P+C`@;6EL;&EO;B!T;R`D,C4P+C`@;6EL;&EO;@T*(&EN(&%D9&ET:6]N
M86P@8VQI;FEC86PL(')E9W5L871O<GD@86YD('-A;&5S(&UI;&5S=&]N97,N
M(%5P;VX-"B!E>&5C=71I;VX@;V8@=&AE(&%R<F%N9V5M96YT+"!':6QE860@
M:61E;G1I9FEE9"!O;F4@;6]L96-U;&4@=&\-"B!D979E;&]P(&9O<B!W:&EC
M:"!T:&4@0V]M<&%N>2!G<F%N=&5D($=I;&5A9"!A(&QI8V5N<V4@:6X@97AC
M:&%N9V4-"B!F;W(@8V]N<VED97)A=&EO;B!O9B`D-RXU(&UI;&QI;VXN/"]P
M/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM
M5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4G/@T*(%1H92!#;VUP86YY(&1E
M=&5R;6EN960@=&AA="!A;GD@<F5M86EN:6YG(&QI8V5N<V5S(&%R92!C;VYD
M:71I;VYA;`T*(&1E;&EV97)A8FQE<RP@=VAI8V@@87)E('-U8G-T86YT:79E
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M<&]N(&%C:&EE=F5M96YT(&]F('1H90T*(&UI;&5S=&]N92`H87-S=6UI;F<@
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M;&4@9&EG:70@<F]Y86QT:65S#0H@;VX@<')O9'5C="!S86QE<RX\+W`^#0H@
M/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z
M(#$R<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@5&AE($-O;7!A;GD@979A;'5A
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M('5N:70@;V8@86-C;W5N=&EN9R`H=&AE('5P9G)O;G0@<&%Y;65N="!A;F0@
M=&AE(&5X<&5C=&5D#0H@<F5S96%R8V@@86YD(&1E=F5L;W!M96YT(')E:6UB
M=7)S96UE;G1S*2!W87,@<F5C;V=N:7IE9"!R871A8FQY#0H@;W9E<B!A('!E
M<FEO9"!O9B`R,2!M;VYT:',L('=H:6-H(')E<')E<V5N=&5D('1H92!E>'!E
M8W1E9`T*(&1E=F5L;W!M96YT('!E<FEO9"X\+W`^#0H@/'`@<W1Y;&4],T0G
M34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#$R<'0[(%1%6%0M
M24Y$14Y4.B`T)2<^#0H@5&AE($-O;7!A;GD@86YD($=I;&5A9"!H879E(&%L
M<V\@86=R965D('1O(&5S=&%B;&ES:"!A(&IO:6YT#0H@<F5S96%R8V@@8V]M
M;6ET=&5E('1O(&9A8VEL:71A=&4@=&AE(&=O=F5R;F%N8V4@86YD(&]V97)S
M:6=H="!O9@T*('1H92!P87)T:65S)B-X,C`Q.3L@86-T:79I=&EE<R!U;F1E
M<B!T:&4@86=R965M96YT<RX@36%N86=E;65N=`T*(&-O;G-I9&5R960@=VAE
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M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4G/@T*(%1H92!#
M;VUP86YY(')E8V]G;FEZ960@<F5V96YU97,@;V8@87!P<F]X:6UA=&5L>2`D
M-2XU(&UI;&QI;VX@86YD#0H@)#@N,"!M:6QL:6]N('5N9&5R('1H:7,@86=R
M965M96YT(&9O<B!T:&4@>65A<G,@96YD960-"B!$96-E;6)E<B8C>$$P.S,Q
M+"`R,#$T(&%N9"`R,#$S+"!R97-P96-T:79E;'DN($YO(&UI;&5S=&]N97,@
M:&%V90T*(&)E96X@86-H:65V960@=6YD97(@=&AI<R!A9W)E96UE;G0N/"]P
M/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM
M5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4G/@T*($%T($1E8V5M8F5R)B-X
M03`[,S$L(#(P,3,L("0S+C8@;6EL;&EO;B!O9B!R979E;G5E('=A<R!D969E
M<G)E9`T*('5N9&5R('1H:7,@86=R965M96YT+"!A;&P@;V8@=VAI8V@@=V%S
M(&-U<G)E;G0N($%S(&]F#0H@1&5C96UB97(F(WA!,#LS,2P@,C`Q-"P@=&AE
M<F4@=V%S(&YO(')E;6%I;FEN9R!D969E<G)E9"!R979E;G5E#0H@=6YD97(@
M=&AI<R!A9W)E96UE;G0N/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U14
M3TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q.'!T)SX-"B`\8CX\:3Y397)V:65R
M/"]I/CPO8CX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T
M.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($U!4D=)3BU43U`Z(#9P=#L@5$585"U)3D1%3E0Z(#0E)SX-"B!);B!.
M;W9E;6)E<B`R,#$Q+"!T:&4@0V]M<&%N>2!E;G1E<F5D(&EN=&\@82!R:6=H
M="UT;RUD979E;&]P#0H@8V]L;&%B;W)A=&EO;B!A9W)E96UE;G0@=VET:"!3
M97)V:65R(&9O<B!T:&4@9&5V96QO<&UE;G0@86YD#0H@8V]M;65R8VEA;&EZ
M871I;VX@;V8@34=!,C<Q(&EN(&%L;"!C;W5N=')I97,@;W1H97(@=&AA;B!T
M:&4@56YI=&5D#0H@4W1A=&5S+"!#86YA9&$L($UE>&EC;RP@2F%P86XL(%-O
M=71H($MO<F5A(&%N9"!);F1I82X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.
M+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$14Y4
M.B`T)2<^#0H@57!O;B!E>&5C=71I;VX@;V8@=&AE(&%G<F5E;65N="P@4V5R
M=FEE<B!M861E(&$@;F]N<F5F=6YD86)L90T*('!A>6UE;G0@;V8@)#(P+C`@
M;6EL;&EO;B!T;R!T:&4@0V]M<&%N>2X@5&AE($-O;7!A;GD@:7,@96QI9VEB
M;&4@=&\-"B!R96-E:79E('5P('1O("0S,"XP(&UI;&QI;VX@:6X@;&EC96YS
M92!G<F%N="!F965S+"`D-#<N,"!M:6QL:6]N(&EN#0H@8VQI;FEC86P@;6EL
M97-T;VYE('!A>6UE;G1S+"`D,30P+C`@;6EL;&EO;B!I;B!R96=U;&%T;W)Y
M(&UI;&5S=&]N90T*('!A>6UE;G1S(&%N9"`D,C`X+C`@;6EL;&EO;B!I;B!S
M86QE<R!M:6QE<W1O;F4@<&%Y;65N=',@:68@4V5R=FEE<@T*(&5X97)C:7-E
M<R!T:&4@;W!T:6]N+"!O8G1A:6YS(')E9W5L871O<GD@87!P<F]V86P@9F]R
M(&%N9`T*('-U8V-E<W-F=6QL>2!C;VUM97)C:6%L:7IE<R!-1T$R-S$N(%1H
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M;&5S(&EN(&ET<PT*('1E<G)I=&]R:65S+CPO<#X-"B`\<"!S='EL93TS1"=-
M05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
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M97!R97-E;G1S(&ET<R!E<W1I;6%T960@<V5L;&EN9R!P<FEC92`H:2YE+B!N
M;PT*('-U8G-T86YT:6%L(&1I<V-O=6YT('=A<R!G:79E;BDN(%1H92!#;VUP
M86YY)B-X,C`Q.3MS('-U8G-T86YT:79E#0H@<&5R9F]R;6%N8V4@;V)L:6=A
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M:6]N<R!R97!R97-E;G0@82!S:6YG;&4@=6YI="!O9B!A8V-O=6YT:6YG+`T*
M('-I;F-E('1H92!L:6-E;G-E(&1O97,@;F]T(&AA=F4@<W1A;F0M86QO;F4@
M=F%L=64@=&\@4V5R=FEE<@T*('=I=&AO=70@=&AE($-O;7!A;GDF(W@R,#$Y
M.W,@=&5C:&YI8V%L(&5X<&5R=&ES92!A;F0@8V]M;6ET=&5E#0H@<&%R=&EC
M:7!A=&EO;BX@07,@<W5C:"P@=&AE(&EN:71I86P@=7!F<F]N="!P87EM96YT
M('=A<R!D969E<G)E9`T*(&%N9"!W87,@8F5I;F<@<F5C;V=N:7IE9"!R871A
M8FQY(&]V97(@=&AE(&EN:71I86P@,C<M;6]N=&@@<&5R:6]D+`T*('=H:6-H
M(')E<')E<V5N=&5D('1H92!E>'!E8W1E9"!P97)I;V0@;V8@9&5V96QO<&UE
M;G0@86YD('1H90T*($-O;7!A;GDF(W@R,#$Y.W,@<&%R=&EC:7!A=&EO;B!O
M;B!T:&4@<F5S96%R8V@@86YD(&1E=F5L;W!M96YT#0H@8V]M;6ET=&5E+B!$
M=7)I;F<@,C`Q-"P@=&AE($-O;7!A;GD@9&5T97)M:6YE9"!T:&%T('1H92!D
M979E;&]P;65N=`T*('!E<FEO9"!W:6QL(&QA<W0@;&]N9V5R('1H86X@;W)I
M9VEN86QL>2!E<W1I;6%T960L(&%N9`T*('!R;W-P96-T:79E;'D@861J=7-T
M960@:71S('!E<FEO9"!O9B!R96-O9VYI=&EO;B!O9B!T:&4@=7!F<F]N=`T*
M('!A>6UE;G0@=&\@82`T,BUM;VYT:"!P97)I;V0N/"]P/@T*(#QP('-T>6QE
M/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T.R!4
M15A4+4E.1$5.5#H@-"4G/@T*($1U<FEN9R!T:&4@>65A<G,@96YD960@1&5C
M96UB97(F(WA!,#LS,2P@,C`Q-"P@,C`Q,R!A;F0@,C`Q,B!T:&4-"B!#;VUP
M86YY(')E8V]G;FEZ960@<F5V96YU92!O9B`D,"XW)B-X03`[;6EL;&EO;BP@
M)#(Q+C,@;6EL;&EO;B!A;F0-"B`D.2XQ(&UI;&QI;VXL(')E<W!E8W1I=F5L
M>2P@=6YD97(@=&AI<R!A9W)E96UE;G0N(%)E=F5N=64-"B!R96-O9VYI>F5D
M(&EN('1H92!Y96%R(&5N9&5D($1E8V5M8F5R)B-X03`[,S$L(#(P,3,@:6YC
M;'5D960@80T*("0Q,"XP(&UI;&QI;VX@<W5B<W1A;G1I=F4@;6EL97-T;VYE
M('!A>6UE;G0@<F5C96EV960@=7!O;B!D;W-I;F<-"B!T:&4@9FER<W0@<&%T
M:65N="!I;B!A(%!H87-E(#$@9&]S92!E>'!A;G-I;VX@8V]H;W)T('1R:6%L
M(&]F#0H@34=!,C<Q+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-
M.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@34%21TE.+51/4#H@,3)P=#L@5$585"U)3D1%3E0Z(#0E)SX-
M"B!!="!$96-E;6)E<B8C>$$P.S,Q+"`R,#$T(&%N9"`R,#$S+"`D,"XQ(&UI
M;&QI;VX@86YD("0P+CD@;6EL;&EO;@T*(&]F(')E=F5N=64@<F5M86EN960@
M9&5F97)R960@=6YD97(@=&AI<R!A9W)E96UE;G0L(')E<W!E8W1I=F5L>2P-
M"B!A;&P@;V8@=VAI8V@@=V%S(&-U<G)E;G0N/"]P/@T*(#QP('-T>6QE/3-$
M)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T.R!415A4
M+4E.1$5.5#H@-"4G/@T*($EN(%-E<'1E;6)E<B`R,#$R+"!T:&4@0V]M<&%N
M>2!E;G1E<F5D(&EN=&\@82!S96-O;F0-"B!R:6=H="UT;RUD979E;&]P(&-O
M;&QA8F]R871I;VX@86=R965M96YT('=I=&@@4V5R=FEE<B!A;F0@9W)A;G1E
M9`T*(&ET(&]P=&EO;G,@=&\@;V)T86EN('1H<F5E('-E<&%R871E(&5X8VQU
M<VEV92!L:6-E;G-E<R!T;R!D979E;&]P#0H@86YD(&-O;6UE<F-I86QI>F4@
M1$%25"UB87-E9"!M;VQE8W5L97,L(&-O;G-I<W1I;F<@;V8@=&AO<V4-"B!D
M97-I9VYA=&5D(&)Y('1H92!#;VUP86YY(&%S($U'1#`P-B!A;F0@34=$,#`W
M+"!A<R!W96QL(&%S(&$@=&AI<F0-"B!$05)4(&UO;&5C=6QE+"!I;B!A;&P@
M8V]U;G1R:65S(&]T:&5R('1H86X@=&AE(%5N:71E9"!3=&%T97,L#0H@0V%N
M861A+"!-97AI8V\L($IA<&%N+"!3;W5T:"!+;W)E82!A;F0@26YD:6$N/"]P
M/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM
M5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4G/@T*(%5P;VX@97AE8W5T:6]N
M(&]F('1H92!A9W)E96UE;G0L(%-E<G9I97(@;6%D92!A(&YO;G)E9G5N9&%B
M;&4-"B!P87EM96YT(&]F("0R,"XP(&UI;&QI;VX@=&\@=&AE($-O;7!A;GDN
M($EN(&%D9&ET:6]N+"!T:&4@0V]M<&%N>0T*('=I;&P@8F4@96QI9VEB;&4@
M=&\@<F5C96EV92!U<"!T;R`D-C4N,"!M:6QL:6]N(&EN(&QI8V5N<V4@9W)A
M;G0-"B!F965S+"`D.3@N,"!M:6QL:6]N(&EN(&-L:6YI8V%L(&UI;&5S=&]N
M92!P87EM96YT<RP@:6YC;'5D:6YG("0U+C`-"B!M:6QL:6]N('5P;VX@24Y$
M(&%C8V5P=&%N8V4@9F]R(&5A8V@@;V8@34=$,#`V+"!-1T0P,#<@86YD(&$@
M=&AI<F0-"B!$05)4(&UO;&5C=6QE+"`D,S`P+C`@;6EL;&EO;B!I;B!R96=U
M;&%T;W)Y(&UI;&5S=&]N92!P87EM96YT<R!A;F0-"B`D-C,P+C`@;6EL;&EO
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M<W1A;G1I=F4N($%L=&AO=6=H('-A;&5S(&UI;&5S=&]N97,@87)E(&YO=`T*
M(&-O;G-I9&5R960@<W5B<W1A;G1I=F4L('1H97D@87)E('-T:6QL(')E8V]G
M;FEZ960@=7!O;B!A8VAI979E;65N=`T*(&]F('1H92!M:6QE<W1O;F4@*&%S
M<W5M:6YG(&%L;"!O=&AE<B!R979E;G5E(')E8V]G;FET:6]N(&-R:71E<FEA
M#0H@:&%V92!B965N(&UE="D@8F5C875S92!T:&5R92!A<F4@;F\@=6YD96QI
M=F5R960@96QE;65N=',@=&AA="!W;W5L9`T*('!R96-L=61E(')E=F5N=64@
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M=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4G/@T*(%1H
M92!#;VUP86YY(&5V86QU871E9"!T:&4@<F5S96%R8V@@8V]L;&%B;W)A=&EO
M;B!A9W)E96UE;G0@=VET:`T*(%-E<G9I97(@86YD(&AA<R!D971E<FUI;F5D
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M;B!A;B!E>&5C=71I=F4@8V]M;6ET=&5E(&%N9"!A(')E<V5A<F-H(&%N9`T*
M(&1E=F5L;W!M96YT(&-O;6UI='1E92X@5&AE($-O;7!A;GD@9&5T97)M:6YE
M9"!T:&%T('1H92!P97)F;W)M86YC90T*(&]B;&EG871I;VYS('=I=&@@<F5S
M<&5C="!T;R!T:&4@<')E+6-L:6YI8V%L(&1E=F5L;W!M96YT(')E<')E<V5N
M=`T*(&$@<VEN9VQE('5N:70@;V8@86-C;W5N=&EN9RP@<VEN8V4@=&AE(&QI
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M=F5R#0H@82`\9F]N="!S='EL93TS1"=72$E412U34$%#13H@;F]W<F%P)SXR
M.2UM;VYT:#PO9F]N=#X@<&5R:6]D+"!W:&EC:`T*(')E<')E<V5N=&5D('1H
M92!E>'!E8W1E9"!D979E;&]P;65N="!P97)I;V0N($1U<FEN9R`R,#$T+"!T
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M(&$-"B`W-2UM;VYT:"!P97)I;V0N(%1H92!I;7!A8W0@;V8@=&AI<R!C:&%N
M9V4@:6X@86-C;W5N=&EN9R!E<W1I;6%T90T*(')E9'5C960@<F5V96YU92!T
M:&%T('=O=6QD(&AA=F4@8F5E;B!R96-O9VYI>F5D(&EN(#(P,30@8GD@)#,N
M-PT*(&UI;&QI;VXN/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ
M(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4G/@T*
M($1U<FEN9R!T:&4@>65A<B!E;F1E9"!$96-E;6)E<B8C>$$P.S,Q+"`R,#$T
M+"!397)V:65R(&5X97)C:7-E9"!I=',-"B!E>&-L=7-I=F4@;W!T:6]N('1O
M(&1E=F5L;W`@86YD(&-O;6UE<F-I86QI>F4@34=$,#`V+B!!<R!A(')E<W5L
M=`T*(&]F('1H92!E>&5R8VES92P@=&AE($-O;7!A;GD@<F5C96EV960@82`D
M,34N,"!M:6QL:6]N('!A>6UE;G0@9G)O;0T*(%-E<G9I97(@9F]R(&ET<R!L
M:6-E;G-E('1O(&1E=F5L;W`@86YD(&-O;6UE<F-I86QI>F4@34=$,#`V(&EN
M(&ET<PT*('1E<G)I=&]R:65S+B!5<&]N(&5X97)C:7-E(&]F('1H92!O<'1I
M;VXL('1H92!#;VUP86YY(&5V86QU871E9"!I=',-"B!P97)F;W)M86YC92!O
M8FQI9V%T:6]N<R!W:71H(')E<W!E8W0@=&\@=&AE(&QI8V5N<V4@9F]R($U'
M1#`P-BX@5&AE#0H@0V]M<&%N>28C>#(P,3D[<R!S=6)S=&%N=&EV92!P97)F
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M92X@5&AE($-O;7!A;GD@9&5T97)M:6YE9`T*('1H870@=&AE('!E<F9O<FUA
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M;V0@9F]R($U'1#`P-BX@26X@86-C;W)D86YC92!W:71H('1H90T*(&%G<F5E
M;65N="P@=&AE($-O;7!A;GD@86YD(%-E<G9I97(@=VEL;"!S:&%R92!C;W-T
M<R!I;F-U<G)E9"!T;PT*(&1E=F5L;W`@34=$,#`V+B!296EM8G5R<V5M96YT
M(&]F(')E<V5A<F-H(&%N9"!D979E;&]P;65N="!E>'!E;G-E<PT*(')E8V5I
M=F5D(&EN(&-O;FYE8W1I;VX@=VET:"!T:&ES(&-O;&QA8F]R871I=F4@8V]S
M="US:&%R:6YG#0H@86=R965M96YT(&ES(')E8V]R9&5D(&%S(&$@<F5D=6-T
M:6]N('1O(')E<V5A<F-H(&%N9"!D979E;&]P;65N=`T*(&5X<&5N<V4N($1U
M<FEN9R!T:&4@>65A<B!E;F1E9"!$96-E;6)E<B8C>$$P.S,Q+"`R,#$T('1H
M92!#;VUP86YY#0H@<F5C;W)D960@87!P<F]X:6UA=&5L>2`D,2XP(&UI;&QI
M;VX@87,@86X@;V9F<V5T('1O(')E<V5A<F-H(&%N9`T*(&1E=F5L;W!M96YT
M(&-O<W1S('5N9&5R('1H:7,@8V]L;&%B;W)A=&EO;B!A<G)A;F=E;65N="X@
M3F\@<W5C:`T*(&]F9G-E="!W87,@<F5C;W)D960@:6X@,C`Q,R!O<B`R,#$R
M+B!!<R!O9B!$96-E;6)E<B8C>$$P.S,Q+"`R,#$T#0H@=&AE($-O;7!A;GD@
M:&%S(&$@8V]R<F5S<&]N9&EN9R!C;VQL86)O<F%T:6]N(')E8V5I=F%B;&4L
M('=H:6-H(&ES#0H@:6YC;'5D960@:6X@86-C;W5N=',@<F5C96EV86)L92!O
M;B!T:&4@8V]N<V]L:61A=&5D(&)A;&%N8V4@<VAE970L#0H@;V8@)#`N."!M
M:6QL:6]N+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[
M($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@34%21TE.+51/4#H@,3)P=#L@5$585"U)3D1%3E0Z(#0E)SX-"B!$=7)I
M;F<@=&AE('EE87)S(&5N9&5D($1E8V5M8F5R)B-X03`[,S$L(#(P,30L(#(P
M,3,@86YD(#(P,3(@=&AE#0H@0V]M<&%N>2!R96-O9VYI>F5D(')E=F5N=64@
M;V8@)#$V+C<F(WA!,#MM:6QL:6]N+"`D."XV(&UI;&QI;VXL(&%N9`T*("0R
M+C`@;6EL;&EO;BP@<F5S<&5C=&EV96QY+"!U;F1E<B!T:&ES(&%G<F5E;65N
M="X@4F5V96YU92!D=7)I;F<-"B!T:&4@>65A<B!E;F1E9"!$96-E;6)E<B8C
M>$$P.S,Q+"`R,#$T(&EN8VQU9&5S('1W;R`D-2XP(&UI;&QI;VX-"B!M:6QE
M<W1O;F4@<&%Y;65N=',@9G)O;2!397)V:65R('5P;VX@=&AE(&%C:&EE=F5M
M96YT(&]F(&-L:6YI8V%L#0H@;6EL97-T;VYE<R!R96QA=&5D('1O('1H92!)
M3D0@87!P;&EC871I;VYS(&9O<B!-1T0P,#8@86YD($U'1#`P-PT*(&-L96%R
M:6YG('1H92`S,"UD87D@<F5V:65W('!E<FEO9"!B>2!T:&4@52Y3+B!&1$$N
M($YO(&UI;&5S=&]N97,-"B!W97)E(')E8V]G;FEZ960@=6YD97(@=&AI<R!A
M9W)E96UE;G0@9'5R:6YG('1H92!Y96%R<R!E;F1E9`T*($1E8V5M8F5R)B-X
M03`[,S$L(#(P,3,@;W(@,C`Q,BX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.
M+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$14Y4
M.B`T)2<^#0H@070@1&5C96UB97(F(WA!,#LS,2P@,C`Q-"P@)#$W+C<@;6EL
M;&EO;B!O9B!R979E;G5E('=A<R!D969E<G)E9`T*('5N9&5R('1H:7,@86=R
M965M96YT+"`D,RXS(&UI;&QI;VX@;V8@=VAI8V@@=V%S(&-U<G)E;G0@86YD
M("0Q-"XT#0H@;6EL;&EO;B!O9B!W:&EC:"!W87,@;&]N9RUT97)M+B!!="!$
M96-E;6)E<B8C>$$P.S,Q+"`R,#$S+"`D.2XT#0H@;6EL;&EO;B!O9B!R979E
M;G5E('=A<R!D969E<G)E9"!U;F1E<B!T:&ES(&%G<F5E;65N="P@)#@N-B!M
M:6QL:6]N#0H@;V8@=VAI8V@@=V%S(&-U<G)E;G0@86YD("0P+C@@;6EL;&EO
M;B!O9B!W:&EC:"!W87,@;&]N9RUT97)M+CPO<#X-"B`\<"!S='EL93TS1"=-
M05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@,3AP="<^#0H@/&(^
M/&D^0F]E:')I;F=E<CPO:3X\+V(^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)
M3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`V<'0[(%1%6%0M24Y$14Y4
M.B`T)2<^#0H@26X@3V-T;V)E<B`R,#$P('1H92!#;VUP86YY(&5N=&5R960@
M:6YT;R!A(&-O;&QA8F]R871I;VX@86YD#0H@;&EC96YS92!A9W)E96UE;G0@
M=VET:"!";V5H<FEN9V5R('1O(&1I<V-O=F5R+"!D979E;&]P(&%N9`T*(&-O
M;6UE<F-I86QI>F4@=7`@=&\@=&5N($1!4E0M8F%S960@;6]L96-U;&5S('=H
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M="!T:&4-"B!W;W)L9"X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/
M33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($U!4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$14Y4.B`T)2<^
M#0H@57!O;B!E>&5C=71I;VX@;V8@=&AE(&%G<F5E;65N="P@=&AE($-O;7!A
M;GD@<F5C96EV960@86X@=7!F<F]N=`T*('!A>6UE;G0@;V8@)#$U+C`@;6EL
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M=',@;V8@87!P<F]X:6UA=&5L>2`D-#$N,`T*(&UI;&QI;VX@<F5L871E9"!T
M;R!P<F4M8VQI;FEC86P@86YD(&-L:6YI8V%L(&1E=F5L;W!M96YT+"`D.#DN
M,`T*(&UI;&QI;VX@<F5L871E9"!T;R!R96=U;&%T;W)Y(&UI;&5S=&]N97,@
M86YD("0X,RXP(&UI;&QI;VX@<F5L871E9`T*('1O('-A;&5S(&UI;&5S=&]N
M97,@9F]R(&5A8V@@;V8@=&AE($1!4E0@<')O9W)A;7,@=6YD97(@=&AI<PT*
M(&%G<F5E;65N="!I;B!T:&4@8V%S92!O9B!F=6QL(&-O;6UE<F-I86P@<W5C
M8V5S<R!O9B!M=6QT:7!L92!$05)4#0H@<')O9'5C=',N(%1H92!#;VUP86YY
M(&AA<R!D971E<FUI;F5D('1H870@96%C:"!P;W1E;G1I86P@9G5T=7)E#0H@
M8VQI;FEC86PL(&1E=F5L;W!M96YT(&%N9"!R96=U;&%T;W)Y(&UI;&5S=&]N
M92!I<R!S=6)S=&%N=&EV92X-"B!!;'1H;W5G:"!S86QE<R!M:6QE<W1O;F5S
M(&%R92!N;W0@8V]N<VED97)E9"!S=6)S=&%N=&EV92P@=&AE>2!A<F4-"B!S
M=&EL;"!R96-O9VYI>F5D('5P;VX@86-H:65V96UE;G0@;V8@=&AE(&UI;&5S
M=&]N92`H87-S=6UI;F<@86QL#0H@;W1H97(@<F5V96YU92!R96-O9VYI=&EO
M;B!C<FET97)I82!H879E(&)E96X@;65T*2!B96-A=7-E('1H97)E(&%R90T*
M(&YO('5N9&5L:79E<F5D(&5L96UE;G1S('1H870@=V]U;&0@<')E8VQU9&4@
M<F5V96YU92!R96-O9VYI=&EO;B!A=`T*('1H870@=&EM92X@0F]E:')I;F=E
M<B!A;'-O('!R;W9I9&5S(&9U;F1I;F<@9F]R('1H92!#;VUP86YY)B-X,C`Q
M.3MS#0H@:6YT97)N86P@86YD(&5X=&5R;F%L(')E<V5A<F-H(&-O<W1S(&%N
M9"!I<R!R97%U:7)E9"!T;R!P87D@=&AE#0H@0V]M<&%N>2!M:60M<VEN9VQE
M(&1I9VET(')O>6%L=&EE<R!O;B!P<F]D=6-T('-A;&5S+CPO<#X-"B`\<"!S
M='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@
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M:6-E<RX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($U!4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@5&AE($-O
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M:7,@<')O<')I971A<GD@=&\@=&AE($-O;7!A;GDN($QI:V5W:7-E+`T*($)O
M96AR:6YG97(@8V]U;&0@;F]T('-E;&P@=&AE(&QI8V5N<V4@=&\@86YO=&AE
M<B!P87)T>2`H=VET:&]U="!T:&4-"B!#;VUP86YY(&%G<F5E:6YG('1O('!R
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M87)C:"!A;F0@9&5V96QO<&UE;G0@<V5R=FEC97,@=&AR;W5G:`T*(%-E<'1E
M;6)E<B`R,#$U+"!W:&EC:"!R97!R97-E;G1S('1H92!E<W1I;6%T960@<&5R
M:6]D(&]F#0H@9&5V96QO<&UE;G0N/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)
M3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.
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M(&YO="!A(&1E;&EV97)A8FQE+B!(;W=E=F5R+`T*(&AA9"!M86YA9V5M96YT
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M<FEO9"!F;W(@=&AE(')E<V5A<F-H(&%N9`T*(&1E=F5L;W!M96YT('-E<G9I
M8V5S+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M34%21TE.+51/4#H@,3)P=#L@5$585"U)3D1%3E0Z(#0E)SX-"B!4:&4@0V]M
M<&%N>2!R96-O9VYI>F5D(')E=F5N=65S(&]F(&%P<')O>&EM871E;'D@)#$S
M+C<@;6EL;&EO;BP-"B`D,30N-"!M:6QL:6]N(&%N9"`D,3$N-R!M:6QL:6]N
M(&1U<FEN9R!T:&4@>65A<G,@96YD960-"B!$96-E;6)E<B8C>$$P.S,Q+"`R
M,#$T+"`R,#$S(&%N9"`R,#$R+"!R97-P96-T:79E;'DL('5N9&5R('1H:7,-
M"B!A9W)E96UE;G0N(%)E=F5N=64@<F5C;V=N:7IE9"!I;B!T:&4@>65A<G,@
M96YD960@1&5C96UB97(F(WA!,#LS,2P-"B`R,#$T+"`R,#$S(&%N9"`R,#$R
M(&EN8VQU9&5D(&UI;&5S=&]N92!P87EM96YT<R!O9B`D,BXP(&UI;&QI;VXL
M#0H@)#4N,"!M:6QL:6]N(&%N9"`D,BXP(&UI;&QI;VXL(')E<W!E8W1I=F5L
M>2P@9F]R('1H92!A8VAI979E;65N="!O9@T*(&-L:6YI8V%L(&UI;&5S=&]N
M97,N($%T($1E8V5M8F5R)B-X03`[,S$L(#(P,30L("0U+C@@;6EL;&EO;B!O
M9@T*(')E=F5N=64@=V%S(&1E9F5R<F5D('5N9&5R('1H:7,@86=R965M96YT
M+"!A;&P@;V8@=VAI8V@@=V%S#0H@8W5R<F5N="X@070@1&5C96UB97(F(WA!
M,#LS,2P@,C`Q,RP@)#$R+C@@;6EL;&EO;B!O9B!R979E;G5E('=A<PT*(&1E
M9F5R<F5D('5N9&5R('1H:7,@86=R965M96YT+"`D-RXP(&UI;&QI;VX@;V8@
M=VAI8V@@=V%S(&-U<G)E;G0-"B!A;F0@)#4N."!M:6QL:6]N(&]F('=H:6-H
M('=A<R!L;VYG+71E<FTN/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U14
M3TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q.'!T)SX-"B`\8CX\:3Y09FEZ97(\
M+VD^/"]B/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[
M($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@34%21TE.+51/4#H@-G!T.R!415A4+4E.1$5.5#H@-"4G/@T*($EN($]C
M=&]B97(@,C`Q,"P@=&AE($-O;7!A;GD@96YT97)E9"!I;G1O(&$@=&AR964@
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M9"!F=6YD:6YG(&9O<@T*('1H92!#;VUP86YY)B-X,C`Q.3MS(&EN=&5R;F%L
M(&%N9"!E>'1E<FYA;"!R97-E87)C:"!C;W-T<R!U;F1E<B!T:&4-"B!A9W)E
M96UE;G0N/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4G/@T*(%1H92!#
M;VUP86YY(&ES(&5L:6=I8FQE('1O(')E8V5I=F4@;6EL97-T;VYE('!A>6UE
M;G1S(&]F#0H@87!P<F]X:6UA=&5L>2`D,3<N,"!M:6QL:6]N(')E;&%T960@
M=&\@<')E+6-L:6YI8V%L(&%N9"!C;&EN:6-A;`T*(&1E=F5L;W!M96YT(&%N
M9"`D,3DU+C`@;6EL;&EO;B!R96QA=&5D('1O(&-O;6UE<F-I86QI>F%T:6]N
M(&%N9`T*('-A;&5S(&UI;&5S=&]N97,@9F]R(&5A8V@@1$%25"!P<F]G<F%M
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M=&5D(&ET<R!R97-E87)C:`T*(&]B;&EG871I;VYS('5N9&5R('1H:7,@<')O
M9W)A;2!I;B!*86YU87)Y(#(P,30N/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)
M3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.
M5#H@-"4G/@T*(%1H92!#;VUP86YY(&AA<R!E=F%L=6%T960@=&AE(')E<V5A
M<F-H(&-O;&QA8F]R871I;VX@86=R965M96YT('=I=&@-"B!09FEZ97(@86YD
M(&AA<R!D971E<FUI;F5D('1H870@:70@:7,@82!R979E;G5E(&%R<F%N9V5M
M96YT('=I=&@-"B!M=6QT:7!L92!D96QI=F5R86)L97,L(&]R('!E<F9O<FUA
M;F-E(&]B;&EG871I;VYS+B!4:&4-"B!#;VUP86YY)B-X,C`Q.3MS('-U8G-T
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M=&EO;B!P97)I;V0@=&\@<&5R9F]R;2!S97)V:6-E<RX\+W`^#0H@/'`@<W1Y
M;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#$R<'0[
M(%1%6%0M24Y$14Y4.B`T)2<^#0H@5&AE($-O;7!A;GD@9&5T97)M:6YE9"!T
M:&%T(&ET(&AA9"!F86ER('9A;'5E(&]F('1H92!U;F1E;&EV97)E9`T*(&5L
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M:7-E+`T*(%!F:7IE<B!C;W5L9"!N;W0@<V5L;"!T:&4@;&EC96YS92!T;R!A
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M=`T*(&]F(&%C8V]U;G1I;F<@86YD(')E8V]G;FEZ960@;W9E<B!T:&4@97AP
M96-T960@;V)L:6=A=&EO;B!P97)I;V0-"B!A<W-O8VEA=&5D('=I=&@@=&AE
M(')E<V5A<F-H(&%N9"!D979E;&]P;65N="!S97)V:6-E<R!T:')O=6=H#0H@
M2F%N=6%R>2`R,#$T+"!W:&EC:"!R97!R97-E;G1S('1H92!E<W1I;6%T960@
M<&5R:6]D(&]F#0H@9&5V96QO<&UE;G0N/"]P/@T*(#QP('-T>6QE/3-$)TU!
M4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.
M1$5.5#H@-"4G/@T*(%1H92`D-2XP(&UI;&QI;VX@=7!F<F]N="!P87EM96YT
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M=F5L;W!M96YT('-E<G9I8V5S+"!W:&EC:`T*(&5N9&5D(&EN($IA;G5A<GD@
M,C`Q-"X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($U!4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@5&AE($-O
M;7!A;GD@86YD(%!F:7IE<B!H879E(&%L<V\@86=R965D('1O(&5S=&%B;&ES
M:"!A(&IO:6YT#0H@<F5S96%R8V@@8V]M;6ET=&5E('1O(&9A8VEL:71A=&4@
M=&AE(&=O=F5R;F%N8V4@86YD(&]V97)S:6=H="!O9@T*('1H92!P87)T:65S
M)B-X,C`Q.3L@86-T:79I=&EE<R!U;F1E<B!T:&4@86=R965M96YT<RX@36%N
M86=E;65N=`T*(&-O;G-I9&5R960@=VAE=&AE<B!P87)T:6-I<&%T:6]N(&]N
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M="!H879E(&AA9"!A(&UA=&5R:6%L(&EM<&%C=`T*(&]N('1H92!A8V-O=6YT
M:6YG(&9O<B!T:&4@87)R86YG96UE;G0N/"]P/@T*(#QP('-T>6QE/3-$)TU!
M4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.
M1$5.5#H@-"4G/@T*(%1H92!#;VUP86YY(')E8V]G;FEZ960@<F5V96YU97,@
M;V8@87!P<F]X:6UA=&5L>2`D,"XQ(&UI;&QI;VXL("0S+C4-"B!M:6QL:6]N
M(&%N9"`D-2XU(&UI;&QI;VX@9'5R:6YG('1H92!Y96%R<R!E;F1E9"!$96-E
M;6)E<B8C>$$P.S,Q+`T*(#(P,30L(#(P,3,@86YD(#(P,3(L(')E<W!E8W1I
M=F5L>2X@26YC;'5D960@:6X@=&AE(#(P,3(@<F5V96YU97,-"B!A<F4@;6EL
M97-T;VYE('!A>6UE;G1S('1O=&%L:6YG("0P+C4@;6EL;&EO;BX@3F\@861D
M:71I;VYA;`T*(&UI;&5S=&]N97,@:&%V92!B965N(&%C:&EE=F5D('5N9&5R
M('1H:7,@86=R965M96YT('1H<F]U9V@-"B!$96-E;6)E<B8C>$$P.S,Q+"`R
M,#$T+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M34%21TE.+51/4#H@,3)P=#L@5$585"U)3D1%3E0Z(#0E)SX-"B!!="!$96-E
M;6)E<B8C>$$P.S,Q+"`R,#$S+"!D969E<G)E9"!R979E;G5E('5N9&5R('1H
M:7,@86=R965M96YT#0H@=V%S(&%P<')O>&EM871E;'D@)#<L,#`P+B!!<R!O
M9B!$96-E;6)E<B8C>$$P.S,Q+"`R,#$T+"!T:&5R92!W87,-"B!N;R!R96UA
M:6YI;F<@9&5F97)R960@<F5V96YU92!U;F1E<B!T:&ES(&%G<F5E;65N="X\
M+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)
M3BU43U`Z(#$X<'0G/@T*(#QB/CQI/D=R965N($-R;W-S/"]I/CPO8CX\+W`^
M#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU4
M3U`Z(#9P=#L@5$585"U)3D1%3E0Z(#0E)SX-"B!);B!*=6YE)B-X03`[,C`Q
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M(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0
M.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4G/@T*(%5P;VX@97AE8W5T:6]N(&]F
M('1H92!A;65N9&UE;G0L('1H92!#;VUP86YY(&)E8V%M92!E;&EG:6)L92!T
M;PT*(')E8V5I=F4@<F5I;6)U<G-E;65N="!F;W(@8V]S=',@:6YC=7)R960@
M9F]R(%!H87-E(#(@86YD(%!H87-E(#,-"B!C;&EN:6-A;"!T<FEA;',@=7`@
M=&\@)#4N-2!M:6QL:6]N(&%S('=E;&P@87,@8VQI;FEC86P@9&5V96QO<&UE
M;G0-"B!A;F0@8V]M;65R8VEA;"!M:6QE<W1O;F4@<&%Y;65N=',@;V8@=7`@
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M8V]L;&%B;W)A=&4@=6YD97(@=&AE(&%G<F5E;65N="X\+W`^#0H@/'`@<W1Y
M;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#$R<'0[
M(%1%6%0M24Y$14Y4.B`T)2<^#0H@5&AE($-O;7!A;GD@:&%S(&5V86QU871E
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M92!P<F]V:61E9"!B>2!!4T,@-C`U+3(U+"`\:3Y-=6QT:7!L92!%;&5M96YT
M($%R<F%N9V5M96YT<PT*("A2979E;G5E(%)E8V]G;FET:6]N*3PO:3X@87,@
M=&AE(&]R:6=I;F%L(&%G<F5E;65N="!W87,@86-C;W5N=&5D#0H@9F]R('!R
M:6]R('1O(&%D;W!T:6YG($%352`R,#`Y+3$S/&D^+CPO:3X@5&AE($-O;7!A
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M"B!A8V-O=6YT:6YG+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-
M.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@34%21TE.+51/4#H@,3)P=#L@5$585"U)3D1%3E0Z(#0E)SX-
M"B!4:&4@:6YI=&EA;"`D,2XP(&UI;&QI;VX@=7!F<F]N="!P87EM96YT(')E
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M9B!T:&4@86=R965M96YT('1H<F]U9V@@2G5N92`R,#(P+@T*($9U<G1H97(L
M(&1U92!T;R!T:&4@9F%C="!T:&4@<F5S96%R8V@@86YD(&1E=F5L;W!M96YT
M('-E<G9I8V5S(&%R90T*(&YO="!D965M960@=&\@:&%V92!S=&%N9"UA;&]N
M92!V86QU92P@<F5V96YU92!F;W(@=&AO<V4@<V5R=FEC97,-"B!S:&]U;&0@
M8F4@<F5C;V=N:7IE9"!O=F5R('1H92!E;G1I<F4@=&5R;2!O9B!T:&4@86=R
M965M96YT("AT:')O=6=H#0H@2G5N92`R,#(P*2X@07,@82!R97-U;'0@;V8@
M<F5A<W-E<W-I;F<@=&AE(&%R<F%N9V5M96YT(&EN#0H@86-C;W)D86YC92!W
M:71H($%30R`V,#4M,C4L('1H92!#;VUP86YY('=A<R!R97%U:7)E9"!T;R!R
M96-O<F0@86X-"B!A9&IU<W1M96YT(&]N('1H92!D871E(&]F('1H92!M871E
M<FEA;"!M;V1I9FEC871I;VX@=&\@<F5F;&5C="!T:&4-"B!R979E;G5E('1H
M870@=V]U;&0@:&%V92!R97-U;'1E9"!H860@=&AE(&5N=&ET>2!A<'!L:65D
M('1H90T*(')E<75I<F5M96YT<R!O9B!!4T,@-C`U+3(U(&9R;VT@=&AE(&EN
M8V5P=&EO;B!O9B!T:&4@86=R965M96YT+B!!<PT*(&$@<F5S=6QT+"!T:&4@
M0V]M<&%N>2!R96-O<F1E9"!A;B!A9&1I=&EO;F%L("0Q+C,@;6EL;&EO;B!O
M9@T*(')E=F5N=64@9'5R:6YG(#(P,30N/"]P/@T*(#QP('-T>6QE/3-$)TU!
M4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.
M1$5.5#H@-"4G/@T*(%1H92!#;VUP86YY(')E8V]G;FEZ960@<F5V96YU97,@
M;V8@87!P<F]X:6UA=&5L>2`D,2XW(&UI;&QI;VX@86YD#0H@)#$P,"PP,#`@
M=6YD97(@=&AI<R!A9W)E96UE;G0@9'5R:6YG('1H92!Y96%R<R!E;F1E9`T*
M($1E8V5M8F5R)B-X03`[,S$L(#(P,30@86YD(#(P,3,L(')E<W!E8W1I=F5L
M>2X@3F\@;6EL97-T;VYE<R!W97)E#0H@86-H:65V960@=6YD97(@=&AI<R!A
M9W)E96UE;G0@9'5R:6YG('1H92!Y96%R<R!E;F1E9`T*($1E8V5M8F5R)B-X
M03`[,S$L(#(P,30@86YD(#(P,3,N/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)
M3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.
M5#H@-"4G/@T*($%T($1E8V5M8F5R)B-X03`[,S$L(#(P,30L('1H97)E('=A
M<R!A("0U,C4L,#`P('5N8FEL;&5D(')E8V5I=F%B;&4-"B!B86QA;F-E('5N
M9&5R('1H:7,@86=R965M96YT+"!W:&EC:"!I<R!I;F-L=61E9"!I;B!O=&AE
M<B!A<W-E=',@;VX-"B!T:&4@8V]N<V]L:61A=&5D(&)A;&%N8V4@<VAE970N
M($%T($1E8V5M8F5R)B-X03`[,S$L(#(P,3,L("0V-3`L,#`P#0H@;V8@<F5V
M96YU92!W87,@9&5F97)R960@=6YD97(@=&AI<R!A9W)E96UE;G0L("0Q,#`L
M,#`P(&]F('=H:6-H('=A<PT*(&-U<G)E;G0@86YD("0U-3`L,#`P(&]F('=H
M:6-H('=A<R!N;VXM8W5R<F5N="X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.
M+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#$X<'0G/@T*(#QB/CQI/D5L
M:2!,:6QL>3PO:3X\+V(^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U14
M3TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!-05)'24XM5$]0.B`V<'0[(%1%6%0M24Y$14Y4.B`T)2<^
M#0H@26X@3V-T;V)E<B8C>$$P.S(P,#<L('1H92!#;VUP86YY(&5N=&5R960@
M:6YT;R!A;B!E>&-L=7-I=F4@;&EC96YS90T*(&%N9"!C;VQL86)O<F%T:6]N
M(&%G<F5E;65N="`H=&]G971H97(L('1H92!!9W)E96UE;G1S*2!W:71H($5L
M:0T*($QI;&QY('1O(&IO:6YT;'D@9&5V96QO<"!A;F0@8V]M;65R8VEA;&EZ
M92!T97!L:7IU;6%B+"!A(&AU;6%N:7IE9`T*(&%N=&DM0T0S(&UO;F]C;&]N
M86P@86YT:6)O9'DN($%S('!A<G0@;V8@=&AE($%G<F5E;65N=',L($5L:2!,
M:6QL>0T*(&%C<75I<F5D('1H92!E>&-L=7-I=F4@<FEG:'1S('1O('1H92!M
M;VQE8W5L92X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T
M.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($U!4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@57!O
M;B!E>&5C=71I;VX@;V8@=&AE($%G<F5E;65N=',L($5L:2!,:6QL>2!M861E
M(&$@;F]N<F5F=6YD86)L90T*('!A>6UE;G0@;V8@)#0Q+C`@;6EL;&EO;B!T
M;R!T:&4@0V]M<&%N>2X@26X@36%Y)B-X03`[,C`P."P@16QI#0H@3&EL;'D@
M<&%I9"!T:&4@0V]M<&%N>2!A(&UI;&5S=&]N92!P87EM96YT(&]F("0U,"XP
M(&UI;&QI;VX@86YD(&EN#0H@36%Y)B-X03`[,C`Q,"P@16QI)B-X03`[3&EL
M;'D@<&%I9"!A;B!A9&1I=&EO;F%L(&UI;&5S=&]N92!O9B`D-2XP#0H@;6EL
M;&EO;BX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&
M3TY4+5-)6D4Z(#$R<'0[($U!4D=)3BU43U`Z(#!P="<^#0H@)B-X03`[/"]P
M/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM
M5$]0.B`P<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@3VX@3V-T;V)E<B8C>$$P
M.S(X+"`R,#$P+"!,:6QL>2!N;W1I9FEE9"!T:&4@0V]M<&%N>2!O9B!I=',-
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M<&]I;G0@:6X@=&AE('-T=61Y+B!);B!&96)R=6%R>2`R,#$Q+"!T:&4-"B!#
M;VUP86YY(')E86-Q=6ER960@=&AE(&-O;6UE<F-I86P@<FEG:'1S('1O('1H
M92!M;VQE8W5L92!F<F]M($5L:0T*($QI;&QY+B!$=7)I;F<@=&AE('EE87(@
M96YD960@1&5C96UB97(F(WA!,#LS,2P@,C`Q,BP@16QI)B-X03`[3&EL;'D-
M"B!S871I<V9I960@:71S(&]B;&EG871I;VX@<F5L871E9"!T;R!T:&4@8V]S
M="!O9B!M;VYI=&]R:6YG('!A=&EE;G1S#0H@=6YD97(@=&AE(%!R;W0F(WA%
M.3MG)B-X13D[(&%N9"!%;F-O<F4@=')I86QS+B!4:&4@0V]M<&%N>28C>#(P
M,3D[<PT*(&]B;&EG871I;VYS(&-O;G1I;G5E9"!T:')O=6=H(%-E<'1E;6)E
M<B`R,#$R+"!W:&EC:"!R97!R97-E;G1E9"!T:&4-"B!F;VQL;W<@=7`@<&5R
M:6]D(&9O<B!E;G)O;&QE9"!P871I96YT<R!A;F0@=&AE($-O;7!A;GDF(W@R
M,#$Y.W,-"B!F:6YA;"!R97!O<G1I;F<@;V8@=&AE('1R:6%L)B-X,C`Q.3MS
M(')E<W5L=',N(%1H97)E(&ES(&YO#0H@861D:71I;VYA;"!C;&EN:6-A;"!T
M<FEA;"!A8W1I=FET>2!U;F1E<B!T:&4@16QI($QI;&QY($%G<F5E;65N=',-
M"B!A<R!I="!R96QA=&5S('1O('-U8V@@=')I86QS+B!(;W=E=F5R+"!%;&D@
M3&EL;'D@8V]N=&EN=65S('1O#0H@<F5I;6)U<G-E('1H92!#;VUP86YY(&9O
M<B!M;VYI=&]R:6YG('!A=&EE;G1S(&EN(&]N92!C=7)R96YT;'D-"B!A8W1I
M=F4@=')I86PN/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P
M=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4G/@T*($1U
M<FEN9R!T:&4@>65A<G,@96YD960@1&5C96UB97(@,C`Q-"P@,C`Q,R!A;F0@
M,C`Q,BP@=&AE($-O;7!A;GD-"B!R96-O9VYI>F5D(')E=F5N=64@;V8@)#`N
M-"!M:6QL:6]N+"`D,"XX(&UI;&QI;VX@86YD("0S,2XR(&UI;&QI;VXL#0H@
M<F5S<&5C=&EV96QY+"!U;F1E<B!T:&ES(&%G<F5E;65N="X@3F\@;6EL97-T
M;VYE<R!W97)E(&%C:&EE=F5D#0H@=6YD97(@=&AI<R!A9W)E96UE;G0@9'5R
M:6YG('1H92!T:')E92!Y96%R<R!E;F1E9"!$96-E;6)E<B8C>$$P.S,Q+`T*
M(#(P,30N/"]P/@T*(`T*(`T*(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^
M#0H-"BTM+2TM+3U?3F5X=%!A<G1?.&1B-3,W8S1?93@W.%\T83-E7S@R.&%?
M8C4P,&8S961F,3%F#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+SAD
M8C4S-V,T7V4X-SA?-&$S95\X,CAA7V(U,#!F,V5D9C$Q9B]7;W)K<VAE971S
M+U-H965T,34N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O
M=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S
M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@
M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M
M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R
M:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE
M;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C
M;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T
M<F]N9SY#;VUM:71M96YT<R!A;F0@0V]N=&EN9V5N8VEE<SQB<CX\+W-T<F]N
M9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ
M,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#;VUM:71M
M96YT<R!A;F0@0V]N=&EN9V5N8VEE<R!$:7-C;&]S=7)E(%M!8G-T<F%C=%T\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M
M;6ET;65N=',@86YD($-O;G1I;F=E;F-I97,\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQD:78^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/
M33H@,'!T.R!72$E412U34$%#13H@;F]R;6%L.R!415A4+51204Y31D]233H@
M;F]N93L@5T]21"U34$%#24Y'.B`P<'@[($-/3$]2.B!R9V(H,"PP+#`I.R!&
M3TY4.B`Q,'!T("=4:6UE<R!.97<@4F]M86XG.R!-05)'24XM5$]0.B`Q.'!T
M.R!,151415(M4U!!0TE.1SH@;F]R;6%L.R!415A4+4E.1$5.5#H@,'!X.R`M
M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@G/@T*(#QB/CDN($-O;6UI
M=&UE;G1S(&%N9"!#;VYT:6YG96YC:65S/"]B/CPO<#X-"B`\<"!S='EL93TS
M1"=-05)'24XM0D]45$]-.B`P<'0[(%=(251%+5-004-%.B!N;W)M86P[(%1%
M6%0M5%)!3E-&3U)-.B!N;VYE.R!73U)$+5-004-)3D<Z(#!P>#L@0T],3U(Z
M(')G8B@P+#`L,"D[($9/3E0Z(#$P<'0@)U1I;65S($YE=R!2;VUA;B<[($U!
M4D=)3BU43U`Z(#9P=#L@3$545$52+5-004-)3D<Z(&YO<FUA;#L@5$585"U)
M3D1%3E0Z(#!P>#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X)SX-
M"B`\8CX\:3Y/<&5R871I;F<@3&5A<V5S/"]I/CPO8CX\+W`^#0H@/'`@<W1Y
M;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!72$E412U34$%#13H@;F]R;6%L
M.R!415A4+51204Y31D]233H@;F]N93L@5T]21"U34$%#24Y'.B`P<'@[($-/
M3$]2.B!R9V(H,"PP+#`I.R!&3TY4.B`Q,'!T("=4:6UE<R!.97<@4F]M86XG
M.R!-05)'24XM5$]0.B`V<'0[($Q%5%1%4BU34$%#24Y'.B!N;W)M86P[(%1%
M6%0M24Y$14Y4.B`T)3L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X
M)SX-"B!4:&4@0V]M<&%N>2!L96%S97,@;V9F:6-E(&%N9"!L86)O<F%T;W)Y
M('-P86-E(&9O<B!I=',@:&5A9'%U87)T97)S#0H@:6X@4F]C:W9I;&QE+"!-
M87)Y;&%N9"XF(WA!,#M);B`R,#$T+"!T:&%T(&QE87-E('=A<R!A;65N9&5D
M('1O#0H@97AT96YD(&ET<R!T97)M(&9R;VT@36%R8V@@,S$L(#(P,3@@=&\@
M2F%N=6%R>2`S,2P@,C`R,"XF(WA!,#M);@T*(&%D9&ET:6]N+"!I;B`R,#$T
M+"!T:&4@0V]M<&%N>2!L96%S960@861D:71I;VYA;"!O9F9I8V4@<W!A8V4-
M"B!A9&IA8V5N="!T;R!I=',@:&5A9'%U87)T97)S+"!A;'-O('1H<F]U9V@@
M2F%N=6%R>2`S,2P-"B`R,#(P+B8C>$$P.U1H92!#;VUP86YY(&AA<R!A;B!O
M<'1I;VX@=6YD97(@96%C:"!L96%S92!T;R!C;VYT:6YU90T*('1H92!R97-P
M96-T:79E(&QE87-E(&9O<B!F:79E('EE87)S('5N9&5R('1H92!S86UE('1E
M<FUS+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[(%=(
M251%+5-004-%.B!N;W)M86P[(%1%6%0M5%)!3E-&3U)-.B!N;VYE.R!73U)$
M+5-004-)3D<Z(#!P>#L@0T],3U(Z(')G8B@P+#`L,"D[($9/3E0Z(#$P<'0@
M)U1I;65S($YE=R!2;VUA;B<[($U!4D=)3BU43U`Z(#$R<'0[($Q%5%1%4BU3
M4$%#24Y'.B!N;W)M86P[(%1%6%0M24Y$14Y4.B`T)3L@+7=E8FMI="UT97AT
M+7-T<F]K92UW:61T:#H@,'!X)SX-"B!4:&4@0V]M<&%N>2!L96%S97,@82!M
M86YU9F%C='5R:6YG(&9A8VEL:71Y(&EN(%)O8VMV:6QL92!U;F1E<B!A#0H@
M;&5A<V4@=&AA="!O<FEG:6YA;&QY(&5X<&ER960@;VX@1&5C96UB97(F(WA!
M,#LS,2P@,C`Q-"X@1'5R:6YG#0H@,C`Q-"P@=&AE($-O;7!A;GD@97AE<F-I
M<V5D(&ET<R`U+7EE87(@<F5N97=A;"!O<'1I;VX@;VX@=&AE#0H@;6%N=69A
M8W1U<FEN9R!F86-I;&ET>2X@5&AE($-O;7!A;GD@86QS;R!E;G1E<F5D(&EN
M=&\@82!N97<-"B!F;W5R+7EE87(@;&5A<V4@9F]R(&%D9&ET:6]N86P@<W!A
M8V4@:6X@=&AE(&UA;G5F86-T=7)I;F<@9F%C:6QI='D-"B!E9F9E8W1I=F4@
M07!R:6PF(WA!,#LQ+"`R,#$T+B!4:&ES(&QE87-E(&%L<V\@:&%S(&%N(&]P
M=&EO;B!T;PT*(&-O;G1I;G5E('1H92!L96%S92!F;W(@9FEV92!Y96%R<R!U
M;F1E<B!T:&4@<V%M92!T97)M<RX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.
M+4)/5%1/33H@,'!T.R!72$E412U34$%#13H@;F]R;6%L.R!415A4+51204Y3
M1D]233H@;F]N93L@5T]21"U34$%#24Y'.B`P<'@[($-/3$]2.B!R9V(H,"PP
M+#`I.R!&3TY4.B`Q,'!T("=4:6UE<R!.97<@4F]M86XG.R!-05)'24XM5$]0
M.B`Q,G!T.R!,151415(M4U!!0TE.1SH@;F]R;6%L.R!415A4+4E.1$5.5#H@
M-"4[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>"<^#0H@5&AE($-O
M;7!A;GD@86QS;R!L96%S97,@;V9F:6-E(&%N9"!L86)O<F%T;W)Y('-P86-E
M(&EN(%-O=71H(%-A;@T*($9R86YC:7-C;R!U;F1E<B!A(&QE87-E('1H870@
M97AP:7)E<R!O;B!&96)R=6%R>28C>$$P.S(X+"`R,#$X+CPO<#X-"B`\<"!S
M='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[(%=(251%+5-004-%.B!N;W)M
M86P[(%1%6%0M5%)!3E-&3U)-.B!N;VYE.R!73U)$+5-004-)3D<Z(#!P>#L@
M0T],3U(Z(')G8B@P+#`L,"D[($9/3E0Z(#$P<'0@)U1I;65S($YE=R!2;VUA
M;B<[($U!4D=)3BU43U`Z(#$R<'0[($Q%5%1%4BU34$%#24Y'.B!N;W)M86P[
M(%1%6%0M24Y$14Y4.B`T)3L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@
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M(&QE87-E+B!!<R!O9B!$96-E;6)E<B8C>$$P.S,Q+"`R,#$T(&%N9"`R,#$S
M+"!T:&4-"B!#;VUP86YY(&AA9"!R96-O<F1E9"!A(&1E9F5R<F5D(')E;G0@
M;&EA8FEL:71Y(&]F("0R+C<@;6EL;&EO;B!A;F0-"B`D,BXY)B-X03`[;6EL
M;&EO;BP@<F5S<&5C=&EV96QY+B!296YT(&5X<&5N<V4@9F]R('1H92!Y96%R
M<R!E;F1E9`T*($1E8V5M8F5R)B-X03`[,S$L(#(P,30L(#(P,3,@86YD(#(P
M,3(@=V%S("0R+C`F(WA!,#MM:6QL:6]N+"`D,BXW#0H@;6EL;&EO;B!A;F0@
M)#(N-R!M:6QL:6]N+"!R97-P96-T:79E;'DN/"]P/@T*(#QP('-T>6QE/3-$
M)TU!4D=)3BU"3U143TTZ(#!P=#L@5TA)5$4M4U!!0T4Z(&YO<FUA;#L@5$58
M5"U44D%.4T9/4DTZ(&YO;F4[(%=/4D0M4U!!0TE.1SH@,'!X.R!#3TQ/4CH@
M<F=B*#`L,"PP*3L@1D].5#H@,3!P="`G5&EM97,@3F5W(%)O;6%N)SL@34%2
M1TE.+51/4#H@,3)P=#L@3$545$52+5-004-)3D<Z(&YO<FUA;#L@5$585"U)
M3D1%3E0Z(#0E.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@G/@T*
M($9U='5R92!M:6YI;75M(&QE87-E('!A>6UE;G1S('5N9&5R(&YO;F-A;F-E
M;&%B;&4@;W!E<F%T:6YG(&QE87-E<PT*(&%S(&]F($1E8V5M8F5R)B-X03`[
M,S$L(#(P,30@87)E(&%S(&9O;&QO=W,@*&EN('1H;W5S86YD<RDZ/"]P/@T*
M(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@5TA)5$4M4U!!0T4Z
M(&YO<FUA;#L@5$585"U44D%.4T9/4DTZ(&YO;F4[(%=/4D0M4U!!0TE.1SH@
M,'!X.R!#3TQ/4CH@<F=B*#`L,"PP*3L@1D].5#H@,3)P="`G5&EM97,@3F5W
M(%)O;6%N)SL@34%21TE.+51/4#H@,'!T.R!,151415(M4U!!0TE.1SH@;F]R
M;6%L.R!415A4+4E.1$5.5#H@,'!X.R`M=V5B:VET+71E>'0M<W1R;VME+7=I
M9'1H.B`P<'@G/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<[
M($)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4[(%1%6%0M5%)!3E-&3U)-.B!N
M;VYE.R!73U)$+5-004-)3D<Z(#!P>#L@3$545$52+5-004-)3D<Z(&YO<FUA
M;#L@5$585"U)3D1%3E0Z(#!P>#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T
M:#H@,'!X)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H
M/3-$-C@E(&%L:6=N/3-$8V5N=&5R(&)O<F1E<CTS1#`^#0H@/'1R/@T*(#QT
M9"!W:61T:#TS1#@T)3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0X)3X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\
M+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M1D].5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M86XG)R!B9V-O;&]R/3-$(T-#
M145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M86XG.R!-
M05)'24XM3$5&5#H@,V5M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@,C`Q-3PO
M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#XS+#DT-3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*
M(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B`G
M5&EM97,@3F5W(%)O;6%N)R<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B`G5&EM97,@
M3F5W(%)O;6%N)SL@34%21TE.+4Q%1E0Z(#-E;3L@5$585"U)3D1%3E0Z("TQ
M96TG/@T*(#(P,38\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XT+#,V-#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X
M03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@8F=C;VQO<CTS
M1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N
M)SL@34%21TE.+4Q%1E0Z(#-E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(#(P
M,3<\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XT+#0Y-3PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-
M"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<^#0H@/'1D('9A;&EG;CTS1'1O
M<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B`G5&EM97,@3F5W(%)O;6%N)SL@34%21TE.+4Q%1E0Z(#-E;3L@5$585"U)
M3D1%3E0Z("TQ96TG/@T*(#(P,3@\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XT+#,Y
M-CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@
M8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B`G5&EM97,@
M3F5W(%)O;6%N)SL@34%21TE.+4Q%1E0Z(#-E;3L@5$585"U)3D1%3E0Z("TQ
M96TG/@T*(#(P,3D\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ+#@W,SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X
M03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<^#0H@/'1D('9A
M;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)SL@34%21TE.+4Q%1E0Z(#%E
M;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(%1H97)E869T97(\+W`^#0H@/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1R:6=H=#XQ,38\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@
M<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$
M15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$
M15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO
M=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA
M;B<G(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^,3DL,3@Y/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T
M>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52
M+51/4#H@<F=B*#`L,"PP*2`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%
M4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO
M=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\+W1A8FQE/@T*(#QP
M('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@5TA)5$4M4U!!0T4Z(&YO
M<FUA;#L@5$585"U44D%.4T9/4DTZ(&YO;F4[(%=/4D0M4U!!0TE.1SH@,'!X
M.R!#3TQ/4CH@<F=B*#`L,"PP*3L@1D].5#H@,3AP="`G5&EM97,@3F5W(%)O
M;6%N)SL@34%21TE.+51/4#H@,'!T.R!,151415(M4U!!0TE.1SH@;F]R;6%L
M.R!415A4+4E.1$5.5#H@,'!X.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H
M.B`P<'@G/@T*("8C>$$P.SPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]4
M5$]-.B`P<'0[(%=(251%+5-004-%.B!N;W)M86P[(%1%6%0M5%)!3E-&3U)-
M.B!N;VYE.R!73U)$+5-004-)3D<Z(#!P>#L@0T],3U(Z(')G8B@P+#`L,"D[
M($9/3E0Z(#$P<'0@)U1I;65S($YE=R!2;VUA;B<[($U!4D=)3BU43U`Z(#!P
M=#L@3$545$52+5-004-)3D<Z(&YO<FUA;#L@5$585"U)3D1%3E0Z(#!P>#L@
M+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X)SX-"B`\8CX\:3Y#;VYT
M:6YG96YC:65S/"]I/CPO8CX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/
M5%1/33H@,'!T.R!72$E412U34$%#13H@;F]R;6%L.R!415A4+51204Y31D]2
M33H@;F]N93L@5T]21"U34$%#24Y'.B`P<'@[($-/3$]2.B!R9V(H,"PP+#`I
M.R!&3TY4.B`Q,'!T("=4:6UE<R!.97<@4F]M86XG.R!-05)'24XM5$]0.B`V
M<'0[($Q%5%1%4BU34$%#24Y'.B!N;W)M86P[(%1%6%0M24Y$14Y4.B`T)3L@
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M;"!L;W-S(&UA>2!B92!I;F-U<G)E9"X\+W`^#0H@#0H@#0H@/"]D:78^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@
M(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\X9&(U,S=C
M-%]E.#<X7S1A,V5?.#(X85]B-3`P9C-E9&8Q,68-"D-O;G1E;G0M3&]C871I
M;VXZ(&9I;&4Z+R\O0SHO.&1B-3,W8S1?93@W.%\T83-E7S@R.&%?8C4P,&8S
M961F,3%F+U=O<FMS:&5E=',O4VAE970Q-BYH=&UL#0I#;VYT96YT+51R86YS
M9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z
M('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\
M:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O
M;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y
M<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@
M4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O
M9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$
M,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E!R;V1U8W0@36EL97-T;VYE(%!A>6UE
M;G1S(&%N9"!2;WEA;'1Y($%G<F5E;65N=',\8G(^/"]S=')O;F<^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS
M($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^5&5X="!";&]C:R!;06)S
M=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E!R;V1U8W0@36EL97-T;VYE(%!A>6UE;G1S(&%N9"!2;WEA;'1Y($%G
M<F5E;65N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78^
M#0H@/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HQ.'!T.R!M87)G:6XM8F]T=&]M
M.C!P=#L@9F]N="US:7IE.C$P<'0[(&9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;B<^#0H@/&(^,3`N(%!R;V1U8W0@36EL97-T;VYE(%!A>6UE;G1S(&%N
M9"!2;WEA;'1Y($%G<F5E;65N=',\+V(^/"]P/@T*(#QP('-T>6QE/3-$)VUA
M<F=I;BUT;W`Z-G!T.R!M87)G:6XM8F]T=&]M.C!P=#L@=&5X="UI;F1E;G0Z
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M92!A9&1I=&EO;F%L(&-O;G-I9&5R871I;VX-"B!A<R!F;VQL;W=S.B`H:2DF
M(WA!,#LD,3`L.34P+#`P,"!I9B!C97)T86EN(&UI;&5S=&]N97,@87)E(&UE
M="P-"B!I;F-L=61I;F<@=&AE(&EN:71I871I;VX@;V8@4&AA<V4@,R!T<FEA
M;',@86YD(&9I;&EN9R!O9B!V87)I;W5S#0H@<F5G=6QA=&]R>2!P<F]D=6-T
M(&QI8V5N<V4@87!P;&EC871I;VYS.R`H:6DI)B-X03`[,S8L,3,U('-H87)E
M<R!O9@T*(&-O;6UO;B!S=&]C:SL@86YD("AI:6DI)B-X03`[<F]Y86QT>2!P
M87EM96YT<R!B971W965N(#$N-S4E(&%N9`T*(#0N,"4@;V8@;F5T('-A;&5S
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M;6)E<B8C>$$P.S,Q+"`R,#$T+B!!9&1I=&EO;F%L;'DL(&-E<G1A:6X@86=R
M965M96YT<R!R97%U:7)E#0H@=&AE($-O;7!A;GD@=&\@<&%Y(')O>6%L=&EE
M<RX@0W5R<F5N=&QY+"!T:&4@0V]M<&%N>2!I<R!N;W0-"B!O8FQI9V%T960@
M=&\@<&%Y(')O>6%L=&EE<RP@87,@;F\@<F5V96YU92!F<F]M('!R;V1U8W0@
M<V%L97,@:7,-"B!B96EN9R!G96YE<F%T960@8GD@=&AE($-O;7!A;GDN/"]P
M/@T*(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X
M=%!A<G1?.&1B-3,W8S1?93@W.%\T83-E7S@R.&%?8C4P,&8S961F,3%F#0I#
M;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+SAD8C4S-V,T7V4X-SA?-&$S
M95\X,CAA7V(U,#!F,V5D9C$Q9B]7;W)K<VAE971S+U-H965T,3<N:'1M;`T*
M0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*
M0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*
M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O
M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M
M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N
M:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\
M+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I
M9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY%;7!L;WEE92!"
M96YE9FET(%!L86X\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^0V]M<&5N<V%T:6]N(&%N9"!2971I<F5M96YT($1I
M<V-L;W-U<F4@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y%;7!L;WEE92!"96YE9FET(%!L86X\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78^#0H@/'`@<W1Y;&4],T0G
M;6%R9VEN+71O<#HQ.'!T.R!M87)G:6XM8F]T=&]M.C!P=#L@9F]N="US:7IE
M.C$P<'0[(&9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<^#0H@/&(^,3$N
M($5M<&QO>65E($)E;F5F:70@4&QA;CPO8CX\+W`^#0H@/'`@<W1Y;&4],T0G
M;6%R9VEN+71O<#HV<'0[(&UA<F=I;BUB;W1T;VTZ,'!T.R!T97AT+6EN9&5N
M=#HT)3L@9F]N="US:7IE.C$P<'0[(&9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;B<^#0H@3VX@4V5P=&5M8F5R)B-X03`[,C4L(#(P,#(L('1H92!#;VUP
M86YY(&5S=&%B;&ES:&5D('1H92!-86-R;T=E;FEC<PT*(#0P,2AK*2!0;&%N
M("AT:&4@4&QA;BD@9F]R(&ET<R!E;7!L;WEE97,@=6YD97(@4V5C=&EO;B8C
M>$$P.S0P,2AK*0T*(&]F('1H92!)4D,N(%5N9&5R('1H:7,@4&QA;BP@86QL
M(&5M<&QO>65E<R!A="!L96%S="`R,2!Y96%R<R!O9B!A9V4-"B!A<F4@96QI
M9VEB;&4@=&\@<&%R=&EC:7!A=&4@:6X@=&AE(%!L86XL('-T87)T:6YG(&]N
M('1H92!F:7)S="!D87D-"B!O9B!E86-H(&UO;G1H+B!%;7!L;WEE97,@;6%Y
M(&-O;G1R:6)U=&4@=7`@=&\@,3`P)2!O9B!T:&5I<B!S86QA<GDL#0H@<W5B
M:F5C="!T;R!G;W9E<FYM96YT(&UA>&EM=6US+CPO<#X-"B`\<"!S='EL93TS
M1"=M87)G:6XM=&]P.C$R<'0[(&UA<F=I;BUB;W1T;VTZ,'!T.R!T97AT+6EN
M9&5N=#HT)3L@9F]N="US:7IE.C$P<'0[(&9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;B<^#0H@16UP;&]Y965S(&%R92`Q,#`E('9E<W1E9"!I;B!T:&5I
M<B!C;VYT<FEB=71I;VYS('1O('1H92!0;&%N+B!4:&4-"B!#;VUP86YY)B-X
M,C`Q.3MS(&-O;G1R:6)U=&EO;B!T;R!T:&4@4&QA;BP@87,@9&5T97)M:6YE
M9"!B>2!T:&4-"B!";V%R9"!O9B!$:7)E8W1O<G,L(&ES(&1I<V-R971I;VYA
M<GDN(%1H92!#;VUP86YY)B-X,C`Q.3MS#0H@8V]N=')I8G5T:6]N<R!T;R!T
M:&4@4&QA;B!T;W1A;&5D("0S,3@L,SDP+"`D,C4R+#DS,"!A;F0@)#(R-2PQ
M.34-"B!F;W(@=&AE('EE87)S(&5N9&5D($1E8V5M8F5R)B-X03`[,S$L(#(P
M,30L(#(P,3,@86YD(#(P,3(L#0H@<F5S<&5C=&EV96QY+CPO<#X-"B`\+V1I
M=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L
M93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7SAD
M8C4S-V,T7V4X-SA?-&$S95\X,CAA7V(U,#!F,V5D9C$Q9@T*0V]N=&5N="U,
M;V-A=&EO;CH@9FEL93HO+R]#.B\X9&(U,S=C-%]E.#<X7S1A,V5?.#(X85]B
M-3`P9C-E9&8Q,68O5V]R:W-H965T<R]3:&5E=#$X+FAT;6P-"D-O;G1E;G0M
M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M
M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^
M#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y
M<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I
M<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O
M($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*
M("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%
M344^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P
M86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^475A<G1E<FQY($9I;F%N8VEA
M;"!);F9O<FUA=&EO;CQB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY1=6%R=&5R;'D@1FEN86YC:6%L($EN9F]R;6%T
M:6]N($1I<V-L;W-U<F4@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y1=6%R=&5R;'D@1FEN86YC:6%L($EN
M9F]R;6%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV
M/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM
M5$]0.B`Q.'!T)SX-"B`\8CXQ,BX@475A<G1E<FQY($9I;F%N8VEA;"!);F9O
M<FUA=&EO;B`H=6YA=61I=&5D*3PO8CX\+W`^#0H@/"$M+2!X8G)L+&)O9'D@
M+2T^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)
M6D4Z(#$R<'0[($U!4D=)3BU43U`Z(#!P="<^#0H@)B-X03`[/"]P/@T*(#QT
M86)L92!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4G(&-E
M;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Y,B4@86QI
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M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P="!S;VQI9"<@=F%L:6=N/3-$
M8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/C$\<W5P('-T
M>6QE/3-$)T9/3E0M4TE:13H@.#4E.R!615)424-!3"U!3$E'3CH@=&]P)SYS
M=#PO<W5P/B8C>$$P.U%U87)T97(\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!R
M9V(H,"PP+#`I(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X]
M,T0R(&%L:6=N/3-$8V5N=&5R/CQB/C(\<W5P('-T>6QE/3-$)T9/3E0M4TE:
M13H@.#4E.R!615)424-!3"U!3$E'3CH@=&]P)SYN9#PO<W5P/B8C>$$P.U%U
M87)T97(\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P="!S
M;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N
M=&5R/CQB/C,\<W5P('-T>6QE/3-$)T9/3E0M4TE:13H@.#4E.R!615)424-!
M3"U!3$E'3CH@=&]P)SYR9#PO<W5P/B8C>$$P.U%U87)T97(\+V(^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P="!S;VQI9"<@=F%L:6=N/3-$
M8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/C0\<W5P('-T
M>6QE/3-$)T9/3E0M4TE:13H@.#4E.R!615)424-!3"U!3$E'3CH@=&]P)SYT
M:#PO<W5P/B8C>$$P.U%U87)T97(\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].
M5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!C;VQS<&%N/3-$,30@86QI9VX],T1C96YT97(^/&(^*&EN('1H;W5S
M86YD<RP-"B!E>&-E<'0@<&5R('-H87)E(&1A=&$I/"]B/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/"$M+2!%
M;F0@5&%B;&4@2&5A9"`M+3X\(2TM($)E9VEN(%1A8FQE($)O9'D@+2T^#0H@
M/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG
M;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%
M6%0M24Y$14Y4.B`M,65M)SX-"B`\8CXR,#$T/"]B/CPO<#X-"B`\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-
M"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1T;W`^
M#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,V5M.R!415A4+4E.1$5.
M5#H@+3%E;2<^#0H@4F5V96YU93PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H
M=#XQ-"PW,3D\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CDL,C(P
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ."PS.#(\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C4L-#<V/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO<CTS1"-#0T5%1D8^
M#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,
M1494.B`S96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!.970@;&]S<SPO<#X-
M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@S+#$P.#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#$R+#(U.3PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^*#,L.3(X/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1R:6=H=#XH,3DL,#$X/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO
M=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-
M05)'24XM3$5&5#H@,V5M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@3F5T(&QO
M<W,@<&5R('-H87)E+"!B87-I8R!A;F0@9&EL=71E9#PO<#X-"B`\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#XH,"XQ,CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M/B@P+C0T/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#XI)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#`N,30\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/BDF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@86QI9VX],T1R:6=H=#XH,"XV.#PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/"]T<CX-
M"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L
M:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@
M5$585"U)3D1%3E0Z("TQ96TG/@T*(#QB/C(P,3,\+V(^/"]P/@T*(#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D
M/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O
M<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`S96T[(%1%6%0M24Y$
M14Y4.B`M,65M)SX-"B!2979E;G5E/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I
M9VAT/C$P+#4Y.#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,3(L
M,CDY/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*
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M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[
M/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L;W(],T0C0T-%
M149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'
M24XM3$5&5#H@,V5M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@3F5T(&EN8V]M
M92`H;&]S<RD\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH,RPS
M-C8\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M/BDF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@R.30\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/BDF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C8L-C`T/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!A;&EG;CTS1')I9VAT/B@S+#(P-3PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/"]T
M<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E;3L@5$585"U)3D1%3E0Z("TQ
M96TG/@T*($YE="!I;F-O;64@*&QO<W,I('!E<B!S:&%R92P@8F%S:6,\+W`^
M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#(N.3,\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/BDF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1R:6=H=#XH,"XR-#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C`N
M,30\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@P+C$T/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[
M/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L;W(],T0C0T-%
M149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'
M24XM3$5&5#H@,V5M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@3F5T(&EN8V]M
M92`H;&]S<RD@<&5R('-H87)E+"!D:6QU=&5D/"]P/@T*(#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG
M;CTS1')I9VAT/B@R+CDS/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO
M=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#`N
M,C0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M/BDF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XP+C`Q/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@86QI9VX],T1R:6=H=#XH,"XQ-#PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/"]T<CX-
M"B`\(2TM($5N9"!486)L92!";V1Y("TM/CPO=&%B;&4^#0H@/'`@<W1Y;&4]
M,T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#$R<'0[(%1%
M6%0M24Y$14Y4.B`T)2<^#0H@3F5T(&EN8V]M92`H;&]S<RD@<&5R('-H87)E
M(&EN8VQU9&5S('1H92!E9F9E8W1S(&]F(&EN8V]M90T*(&%L;&]C871E9"!T
M;R!P87)T:6-I<&%T:6YG('-E8W5R:71I97,N/"]P/@T*(`T*(`T*(#PO9&EV
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE
M/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?.&1B
M-3,W8S1?93@W.%\T83-E7S@R.&%?8C4P,&8S961F,3%F#0I#;VYT96YT+4QO
M8V%T:6]N.B!F:6QE.B\O+T,Z+SAD8C4S-V,T7V4X-SA?-&$S95\X,CAA7V(U
M,#!F,V5D9C$Q9B]7;W)K<VAE971S+U-H965T,3DN:'1M;`T*0V]N=&5N="U4
M<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4
M>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-
M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP
M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP
M="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@
M3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@
M(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-
M13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A
M;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY3=6)S97%U96YT($5V96YT/&)R
M/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P
M86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T
M/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG
M/E-U8G-E<75E;G0@179E;G1S(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W5B<V5Q=65N="!%=F5N=#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=CX-"B`\<"!S='EL
M93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@,'!T)SX-
M"B`\8CXQ,RX@4W5B<V5Q=65N="!%=F5N=#PO8CX\+W`^#0H@/'`@<W1Y;&4]
M,T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#9P=#L@5$58
M5"U)3D1%3E0Z(#0E)SX-"B!);B!*86YU87)Y(#(P,34L('1H92!&961E<F%L
M(%1R861E($-O;6UI<W-I;VX@9W)A;G1E9"!E87)L>0T*('1E<FUI;F%T:6]N
M(&]F('1H92!W86ET:6YG('!E<FEO9"!U;F1E<B!T:&4@2&%R="U38V]T="U2
M;V1I;F\-"B!!;G1I=')U<W0@26UP<F]V96UE;G1S($%C="!O9B`Q.3<V('=I
M=&@@<F5S<&5C="!T;R!T:&4-"B!C;VQL86)O<F%T:6]N(&%N9"!L:6-E;G-E
M(&%G<F5E;65N="!W:71H($IA;G-S96X@86YD('1H92!S=&]C:PT*('!U<F-H
M87-E(&%G<F5E;65N="!A;F0@:6YV97-T;W(@86=R965M96YT('=I=&@@2DI$
M0R`H87,@9&5S8W)I8F5D#0H@:6X@3F]T92`X*2X@06-C;W)D:6YG;'DL('1H
M92!#;VUP86YY(&ES<W5E9"`Q+#DR,RPP-S<@<VAA<F5S(&]F#0H@8V]M;6]N
M('-T;V-K('1O($I*1$,@86YD(')E8V5I=F5D("0W-2XP(&UI;&QI;VX@9G)O
M;2!*2D1#('5N9&5R('1H90T*('-T;V-K('!U<F-H87-E(&%G<F5E;65N="!A
M;F0@<F5C96EV960@=&AE("0U,"XP(&UI;&QI;VX@=7!F<F]N=`T*('!A>6UE
M;G0@9G)O;2!*86YS<V5N('5N9&5R('1H92!C;VQL86)O<F%T:6]N(&%N9"!L
M:6-E;G-E#0H@86=R965M96YT+CPO<#X-"B`\+V1I=CX\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*
M/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7SAD8C4S-V,T7V4X-SA?-&$S
M95\X,CAA7V(U,#!F,V5D9C$Q9@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO
M+R]#.B\X9&(U,S=C-%]E.#<X7S1A,V5?.#(X85]B-3`P9C-E9&8Q,68O5V]R
M:W-H965T<R]3:&5E=#(P+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I
M;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL
M.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@
M(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T
M97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O
M:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI
M<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\
M=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%4$-!13X-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A
M;CTS1#(^/'-T<F]N9SY3=6UM87)Y(&]F(%-I9VYI9FEC86YT($%C8V]U;G1I
M;F<@4&]L:6-I97,@*%!O;&EC:65S*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD
M960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY!8V-O=6YT:6YG(%!O;&EC:65S
M(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^0F%S:7,@;V8@4')E<V5N=&%T:6]N(&%N9"!0<FEN8VEP;&5S
M(&]F($-O;G-O;&ED871I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQD:78^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($U!4D=)3BU43U`Z(#9P="<^#0H@/&(^/&D^0F%S:7,@;V8@4')E<V5N=&%T
M:6]N(&%N9"!0<FEN8VEP;&5S(&]F#0H@0V]N<V]L:61A=&EO;CPO:3X\+V(^
M/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'
M24XM5$]0.B`V<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@5&AE(&-O;G-O;&ED
M871E9"!F:6YA;F-I86P@<W1A=&5M96YT<R!I;F-L=61E('1H92!A8V-O=6YT
M<R!O9@T*($UA8W)O1V5N:6-S+"!);F,N(&%N9"!I=',@=VAO;&QY(&]W;F5D
M('-U8G-I9&EA<FEE<RP@36%C<F]'96YI8W,@54L-"B!,:6UI=&5D(&%N9"!-
M86-R;T=E;FEC<R!797-T+"!);F,N($5F9F5C=&EV92!$96-E;6)E<B8C>$$P
M.S(R+`T*(#(P,30L($UA8W)O1V5N:6-S(%=E<W0L($EN8RX@=V%S(&UE<F=E
M9"!W:71H(&%N9"!I;G1O($UA8W)O1V5N:6-S+`T*($EN8RX@06QL(&EN=&5R
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M;`T*(&%N=&EB;V1Y+6)A<V5D('1H97)A<&5U=&EC<R!F;W(@8V%N8V5R+"!A
M=71O:6UM=6YE(&%N9"!I;F9E8W1I;W5S#0H@9&ES96%S97,N/"]P/@T*(#PO
M9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^57-E(&]F($5S=&EM871E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/&1I=CX-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P
M<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@34%21TE.+51/4#H@,3AP="<^#0H@/&(^/&D^57-E(&]F($5S=&EM
M871E<SPO:3X\+V(^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ
M(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!-05)'24XM5$]0.B`V<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@
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M(&%S<V5T<RP@<W1O8VLM8F%S960@8V]M<&5N<V%T:6]N+`T*('!R969E<G)E
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M=&5S+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M34%21TE.+51/4#H@,3)P=#L@5$585"U)3D1%3E0Z(#0E)SX-"B!);B!A9&1I
M=&EO;BP@<')I;W(@=&\@=&AE($-O;7!A;GDF(W@R,#$Y.W,@25!/(&EN($]C
M=&]B97(@,C`Q,RP@=&AE#0H@0V]M<&%N>2!U=&EL:7IE9"!E<W1I;6%T97,@
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M<G)E9`T*('-T;V-K+CPO<#X-"B`\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A<V@@86YD($-A<V@@17%U
M:79A;&5N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78^
M#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU4
M3U`Z(#$X<'0G/@T*(#QB/CQI/D-A<V@@86YD($-A<V@@17%U:79A;&5N=',\
M+VD^/"]B/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[
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M;F0@8V%S:`T*(&5Q=6EV86QE;G1S(&-O;G-I<W0@;V8@8V5R=&EF:6-A=&5S
M(&]F(&1E<&]S:70@86YD(&EN=F5S=&UE;G1S(&EN#0H@;6]N97D@;6%R:V5T
M(&9U;F1S('=I=&@@8V]M;65R8VEA;"!B86YK<R!A;F0@9FEN86YC:6%L#0H@
M:6YS=&ET=71I;VYS+B!#87-H(&5Q=6EV86QE;G1S(&%R92!S=&%T960@870@
M86UO<G1I>F5D(&-O<W0L('!L=7,-"B!A8V-R=65D(&EN=&5R97-T+"!W:&EC
M:"!A<'!R;WAI;6%T97,@9F%I<B!V86QU92X\+W`^#0H@/"]D:78^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-O
M=6YT<R!296-E:79A8FQE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\9&EV/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-
M05)'24XM5$]0.B`Q.'!T)SX-"B`\8CX\:3Y!8V-O=6YT<R!296-E:79A8FQE
M/"]I/CPO8CX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T
M.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($U!4D=)3BU43U`Z(#9P=#L@5$585"U)3D1%3E0Z(#0E)SX-"B!!8V-O
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M:6]N(&ES(')E;6]T92X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/
M33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($U!4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$14Y4.B`T)2<^
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M>$$P.S,Q+"`R,#$T(&]R(#(P,3,L(&%S('1H92!#;VUP86YY(&AA<R!A(&AI
M<W1O<GD@;V8-"B!C;VQL96-T:6YG(&]N(&%L;"!O=71S=&%N9&EN9R!A8V-O
M=6YT<RX\+W`^#0H@/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y297-T<FEC=&5D($-A<V@\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78^#0H@/'`@<W1Y;&4],T0G34%2
M1TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#$X<'0G/@T*(#QB/CQI
M/E)E<W1R:6-T960@0V%S:#PO:3X\+V(^/"]P/@T*(#QP('-T>6QE/3-$)TU!
M4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`V<'0[(%1%6%0M24Y$
M14Y4.B`T)2<^#0H@5&AE($-O;7!A;GD@:7,@<F5Q=6ER960@=&\@;6%I;G1A
M:6X@8V5R=&EF:6-A=&5S(&]F(&1E<&]S:70@=&AA=`T*('-E<G9E(&%S(&-O
M;&QA=&5R86P@9F]R('9A<FEO=7,@;W!E<F%T:6YG(&QE87-E<R!A;F0@8V]R
M<&]R871E#0H@8W)E9&ET(&-A<F0@86-C;W5N=',N($%M;W5N=',@8VQA<W-I
M9FEE9"!A<R!R97-T<FEC=&5D(&-A<V@@;VX@=&AE#0H@8V]N<V]L:61A=&5D
M(&)A;&%N8V4@<VAE971S(&%R92`D,S`P+#`P,"!A;F0@)#0P-2PP,#`@870-
M"B!$96-E;6)E<B8C>$$P.S,Q+"`R,#$T(&%N9"`R,#$S+"!R97-P96-T:79E
M;'DN/"]P/@T*(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^1F%I<B!686QU92!O9B!&:6YA;F-I86P@26YS
M=')U;65N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78^
M#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU4
M3U`Z(#$X<'0G/@T*(#QB/CQI/D9A:7(@5F%L=64@;V8@1FEN86YC:6%L($EN
M<W1R=6UE;G1S/"]I/CPO8CX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/
M5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#9P=#L@5$585"U)3D1%3E0Z(#0E
M)SX-"B!4:&4@9F%I<B!M87)K970@=F%L=65S(&]F('1H92!F:6YA;F-I86P@
M:6YS=')U;65N=',@:6YC;'5D960@:6X@=&AE#0H@9FEN86YC:6%L('-T871E
M;65N=',L('=H:6-H(&EN8VQU9&4@8V%S:"!E<75I=F%L96YT<R!A;F0@;6]N
M97D-"B!M87)K970@86-C;W5N=',L(&%P<')O>&EM871E('1H96ER(&-A<G)Y
M:6YG('9A;'5E<R!A=`T*($1E8V5M8F5R)B-X03`[,S$L(#(P,30@86YD(#(P
M,3,L(&1U92!T;R!T:&5I<B!S:&]R="UT97)M#0H@;6%T=7)I=&EE<RX@5&AE
M($-O;7!A;GD@86-C;W5N=',@9F]R(')E8W5R<FEN9R!A;F0@;F]N+7)E8W5R
M<FEN9PT*(&9A:7(@=F%L=64@;65A<W5R96UE;G1S(&EN(&%C8V]R9&%N8V4@
M=VET:"!T:&4@1FEN86YC:6%L($%C8V]U;G1I;F<-"B!3=&%N9&%R9',@0F]A
M<F0@*$9!4T(I($%C8V]U;G1I;F<@4W1A;F1A<F1S($-O9&EF:6-A=&EO;B`H
M05-#*2`X,C`L#0H@/&D^1F%I<B!686QU92!-96%S=7)E;65N=',@86YD($1I
M<V-L;W-U<F5S/"]I/B`H05-#(#@R,"DN($%30R`X,C`-"B!D969I;F5S(&9A
M:7(@=F%L=64L(&5S=&%B;&ES:&5S(&$@9F%I<B!V86QU92!H:65R87)C:'D@
M9F]R(&%S<V5T<PT*(&%N9"!L:6%B:6QI=&EE<R!M96%S=7)E9"!A="!F86ER
M('9A;'5E+"!A;F0@<F5Q=6ER97,@97AP86YD960-"B!D:7-C;&]S=7)E<R!A
M8F]U="!F86ER('9A;'5E(&UE87-U<F5M96YT<RX@5&AE($%30R`X,C`@:&EE
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M;F<@=&AR964@8V%T96=O<FEE<SH\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.
M+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#9P=#L@34%21TE.+51/4#H@,'!T
M)SX-"B`F(WA!,#L\+W`^#0H@/'1A8FQE('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D]21$52+4-/
M3$Q!4%-%.B!C;VQL87!S92<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG
M/3-$,"!W:61T:#TS1#$P,"4@8F]R9&5R/3-$,#X-"B`\='(^#0H@/'1D('=I
M9'1H/3-$-24^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$=&]P('=I9'1H
M/3-$,B4@86QI9VX],T1L969T/B8C>#(P,C([/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$=&]P('=I9'1H/3-$,24^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M=&]P(&%L:6=N/3-$;&5F=#Y,979E;"`Q)B-X,C`Q-#M&86ER('9A;'5E(&ES
M#0H@9&5T97)M:6YE9"!B>2!U<VEN9R!U;F%D:G5S=&5D('%U;W1E9"!P<FEC
M97,@=&AA="!A<F4@879A:6QA8FQE(&EN#0H@86-T:79E(&UA<FME=',@9F]R
M(&ED96YT:6-A;"!A<W-E=',@86YD(&QI86)I;&ET:65S+CPO=&0^#0H@/"]T
M<CX-"B`\+W1A8FQE/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P
M=#L@1D].5"U325I%.B`V<'0[($U!4D=)3BU43U`Z(#!P="<^#0H@)B-X03`[
M/"]P/@T*(#QT86)L92!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)/4D1%4BU#3TQ,05!313H@8V]L
M;&%P<V4G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@]
M,T0Q,#`E(&)O<F1E<CTS1#`^#0H@/'1R/@T*(#QT9"!W:61T:#TS1#4E/B8C
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M<F]B;W)A=&5D(&)Y(&]B<V5R=F%B;&4@;6%R:V5T(&1A=&$N/"]T9#X-"B`\
M+W1R/@T*(#PO=&%B;&4^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@
M,'!T.R!&3TY4+5-)6D4Z(#9P=#L@34%21TE.+51/4#H@,'!T)SX-"B`F(WA!
M,#L\+W`^#0H@/'1A8FQE('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D]21$52+4-/3$Q!4%-%.B!C
M;VQL87!S92<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T
M:#TS1#$P,"4@8F]R9&5R/3-$,#X-"B`\='(^#0H@/'1D('=I9'1H/3-$-24^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,B4@86QI
M9VX],T1L969T/B8C>#(P,C([/"]T9#X-"B`\=&0@=F%L:6=N/3-$=&]P('=I
M9'1H/3-$,24^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$=&]P(&%L:6=N
M/3-$;&5F=#Y,979E;"`S)B-X,C`Q-#M&86ER('9A;'5E(&ES#0H@9&5T97)M
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M"B`\+W1R/@T*(#PO=&%B;&4^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/
M33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($U!4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$14Y4.B`T)2<^
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M('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q.'!T
M.R!-05)'24XM5$]0.B`P<'0G/@T*("8C>$$P.SPO<#X-"B`\<"!S='EL93TS
M1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@,'!T.R!415A4
M+4E.1$5.5#H@-"4G/@T*($9I;F%N8VEA;"!A<W-E=',@86YD(&QI86)I;&ET
M:65S('-U8FIE8W0@=&\@9F%I<B!V86QU92!M96%S=7)E;65N=',-"B!W97)E
M(&%S(&9O;&QO=W,@*&EN('1H;W5S86YD<RDZ/"]P/@T*(#QP('-T>6QE/3-$
M)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,G!T.R!-05)'24XM
M5$]0.B`P<'0G/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"
M3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E)R!C96QL<W!A8VEN9STS1#`@8V5L
M;'!A9&1I;F<],T0P('=I9'1H/3-$.3(E(&%L:6=N/3-$8V5N=&5R(&)O<F1E
M<CTS1#`^#0H@/'1R/@T*(#QT9"!W:61T:#TS1#0S)3X\+W1D/@T*(#QT9"!V
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M)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$
M8F]T=&]M(&-O;'-P86X],T0Q-"!A;&EG;CTS1&-E;G1E<CX\8CY&86ER(%9A
M;'5E($UE87-U<F5M96YT<R!A=`T*($1E8V5M8F5R)B-X03`[,S$L(#(P,30\
M+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`X<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,CXF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI
M9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&(^475O
M=&5D)B-X03`[4')I8V5S)B-X03`[:6X\+V(^/&)R("\^#0H@/&(^06-T:79E
M($UA<FME=',\8G(@+SX-"B!F;W(\+V(^/&)R("\^#0H@/&(^261E;G1I8V%L
M($%S<V5T<SPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O
M;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT
M97(^/&(^4VEG;FEF:6-A;G0F(WA!,#M/=&AE<CPO8CX\8G(@+SX-"B`\8CY/
M8G-E<G9A8FQE/&)R("\^#0H@26YP=71S/"]B/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N
M/3-$,B!A;&EG;CTS1&-E;G1E<CX\8CY3:6=N:69I8V%N=#PO8CX\8G(@+SX-
M"B`\8CY5;F]B<V5R=F%B;&4\+V(^/&)R("\^#0H@/&(^26YP=71S/"]B/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#PO='(^
M#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S
M;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N
M=&5R/CQB/E1O=&%L/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q
M<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS
M1&-E;G1E<CX\8CY,979E;"`Q/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P
M,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A
M;&EG;CTS1&-E;G1E<CX\8CY,979E;"`R/"]B/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N
M/3-$,B!A;&EG;CTS1&-E;G1E<CX\8CY,979E;"`S/"]B/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O
M<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$
M14Y4.B`M,65M)SX-"B!!<W-E=',Z/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@
M/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($U!4D=)3BU,1494.B`S96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-
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M;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^#0H@)B-X,C`Q-#LF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^#0H@)B-X,C`Q-#LF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E;3L@5$585"U)3D1%3E0Z("TQ
M96TG/@T*($UO;F5Y(&UA<FME="!F=6YD<SPO<#X-"B`\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A
M;&EG;CTS1')I9VAT/C(V+#`T-CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
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M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X-"B`F
M(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*
M("8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^
M#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($U!4D=)3BU,1494.B`S96T[(%1%6%0M24Y$14Y4.B`M,65M
M)SX-"B!297-T<FEC=&5D(&-A<V@\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1R:6=H=#XS,#`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P
M/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^,S`P/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^#0H@)B-X,C`Q-#LF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL
M93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4
M3U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z
M(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="
M3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$
M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^
M#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y
M;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO
M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4]
M,T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-
M"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*
M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF
M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP
M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!
M,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT
M<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX]
M,T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4
M+4E.1$5.5#H@+3%E;2<^#0H@5&]T86P@07-S971S/"]P/@T*(#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M/C$U-RPX.3$\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$U-RPX.3$\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B0\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^#0H@
M)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^#0H@)B-X,C`Q-#LF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G
M1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C
M,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P
M,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$
M15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52
M+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-
M"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL
M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO
M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4]
M,T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^
M#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-
M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G
M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@
M/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF
M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*
M(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P="<^#0H@/'1D/CPO=&0^#0H@
M/'1D(&-O;'-P86X],T0Q-CX\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$
M)T9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$
M8F]T=&]M(&-O;'-P86X],T0Q-"!A;&EG;CTS1&-E;G1E<CX\8CY&86ER(%9A
M;'5E($UE87-U<F5M96YT<R!A=`T*($1E8V5M8F5R)B-X03`[,S$L(#(P,3,\
M+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`X<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,CXF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI
M9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&(^475O
M=&5D(%!R:6-E<R!I;CPO8CX\8G(@+SX-"B`\8CY!8W1I=F4@36%R:V5T<SQB
M<B`O/@T*(&9O<CPO8CX\8G(@+SX-"B`\8CY)9&5N=&EC86P@07-S971S/"]B
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG
M;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\8CY3:6=N
M:69I8V%N="!/=&AE<CPO8CX\8G(@+SX-"B`\8CY/8G-E<G9A8FQE/&)R("\^
M#0H@26YP=71S/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@
M<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E
M;G1E<CX\8CY3:6=N:69I8V%N=#PO8CX\8G(@+SX-"B`\8CY5;F]B<V5R=F%B
M;&4\+V(^/&)R("\^#0H@/&(^26YP=71S/"]B/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$
M)T9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$
M8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/E1O=&%L/"]B
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG
M;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\8CY,979E
M;"`Q/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G
M('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\
M8CY,979E;"`R/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@
M<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E
M;G1E<CX\8CY,979E;"`S/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO
M<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!!
M<W-E=',Z/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^
M#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,
M1494.B`S96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!#87-H(&%N9"!C87-H
M(&5Q=6EV86QE;G1S/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CDP+#0S
M-#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^.3`L-#,T/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XD
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A
M;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XD/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG
M;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO<CTS1"-#0T5%
M1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)
M3BU,1494.B`S96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!-;VYE>2!M87)K
M970@9G5N9',\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR-BPP
M-#<\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,C8L,#0W
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P
M/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^#0H@)B-X,C`Q-#LF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG
M/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM
M3$5&5#H@,V5M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@4F5S=')I8W1E9"!C
M87-H/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-#`U/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C0P-3PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A
M;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M(&%L:6=N/3-$<FEG:'0^#0H@)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q
M<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S
M;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI
M9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P
M,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q
M<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z
M(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P
M,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$
M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M
M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@
M/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O
M;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*
M(%1O=&%L($%S<V5T<SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ,38L.#@V/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1R:6=H=#XQ,38L.#@V/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C>$$P.R8C>$$P.R8C>$$P
M.R8C>$$P.R8C>$$P.R8C>$$P.R8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XD/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT
M/@T*("8C>$$P.R8C>$$P.R8C>$$P.R8C>$$P.R8C>$$P.R8C>$$P.R8C>$$P
M.R8C>$$P.R8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@
M<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!
M,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T
M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[
M/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U
M8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L
M92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P
M,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@
M,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/
M4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z
M(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D
M/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\+W1A8FQE/@T*(#QP('-T>6QE/3-$
M)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T.R!415A4
M+4E.1$5.5#H@-"4G/@T*(%1H92!#;VUP86YY)B-X,C`Q.3MS($QE=F5L(#$@
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M;W(-"B!L:6%B:6QI=&EE<R!I;B!A8W1I=F4@;6%R:V5T<RX\+W`^#0H@/"]D
M:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y#;VYC96YT<F%T:6]N(&]F($-R961I="!2:7-K/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV/@T*(#QP('-T>6QE/3-$)TU!4D=)
M3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q.'!T)SX-"B`\8CX\:3Y#
M;VYC96YT<F%T:6]N(&]F($-R961I="!2:7-K/"]I/CPO8CX\+W`^#0H@/'`@
M<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#9P
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M/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T.R!4
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M;65N=`T*(&%G96YC:65S(&]F(&AI9V@@8W)E9&ET('-T86YD:6YG+CPO<#X-
M"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/
M4#H@,3)P=#L@5$585"U)3D1%3E0Z(#0E)SX-"B!&;W(@=&AE('EE87)S(&5N
M9&5D($1E8V5M8F5R)B-X03`[,S$L(#(P,30L(#(P,3,@86YD(#(P,3(L('1H
M90T*($-O;7!A;GDF(W@R,#$Y.W,@8V]L;&%B;W)A=&EO;B!R979E;G5E(')E
M;&%T97,@=&\@86=R965M96YT<R!W:71H#0H@5&%K961A(%!H87)M86-E=71I
M8V%L($-O;7!A;GD@3&EM:71E9"`H5&%K961A*2P@3&5S($QA8F]R871O:7)E
M<PT*(%-E<G9I97(@86YD($EN<W1I='5T(&1E(%)E8VAE<F-H97,@4V5R=FEE
M<B`H8V]L;&5C=&EV96QY+"!397)V:65R*2P-"B!':6QE860@4V-I96YC97,L
M($EN8RX@*$=I;&5A9"DL($)O96AR:6YG97(@26YG96QH96EM($=M8D@-"B`H
M0F]E:')I;F=E<BDL(%!F:7IE<BP@26YC+B`H4&9I>F5R*2P@16QI($QI;&QY
M)B-X03`[)F%M<#L@0V\N("A%;&D-"B!,:6QL>2D@86YD($=R965N($-R;W-S
M($-O<G`N("A'<F5E;B!#<F]S<RDN($=R86YT(')E=F5N=64@:7,-"B!R96QA
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M4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,G!T.R!-05)'24XM5$]0
M.B`P<'0G/@T*("8C>$$P.SPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]4
M5$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@34%21TE.+51/4#H@,'!T.R!415A4+4E.1$5.5#H@-"4G
M/@T*(%1H92!F;VQL;W=I;F<@=&%B;&4@:6YC;'5D97,@=&AO<V4@8V]L;&%B
M;W)A=&]R<R!T:&%T(')E<')E<V5N=`T*(&UO<F4@=&AA;B`Q,"4@;V8@=&]T
M86P@<F5V96YU92!E87)N960@:6X@=&AE('!E<FEO9',@:6YD:6-A=&5D.CPO
M<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:
M13H@,3)P=#L@34%21TE.+51/4#H@,'!T)SX-"B`F(WA!,#L\+W`^#0H@/'1A
M8FQE('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S92<@8V5L
M;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#@T)2!A;&EG
M;CTS1&-E;G1E<B!B;W)D97(],T0P/@T*(#QT<CX-"B`\=&0@=VED=&@],T0V
M-B4^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24^/"]T
M9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$."4^/"]T9#X-"B`\=&0^/"]T9#X-
M"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$."4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\
M=&0^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#AP
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N
M/3-$,3`@86QI9VX],T1C96YT97(^#0H@/&(^665A<B8C>$$P.T5N9&5D)B-X
M03`[1&5C96UB97(F(WA!,#LS,2P\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].
M5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T
M;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^#0H@/&(^)B-X03`[)B-X
M03`[)B-X03`[)B-X03`[,C`Q-"8C>$$P.R8C>$$P.R8C>$$P.R8C>$$P.SPO
M8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B
M;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^#0H@/&(^)B-X03`[
M)B-X03`[)B-X03`[)B-X03`[,C`Q,R8C>$$P.R8C>$$P.R8C>$$P.R8C>$$P
M.SPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX]
M,T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^#0H@/&(^)B-X
M03`[)B-X03`[)B-X03`[)B-X03`[,C`Q,B8C>$$P.R8C>$$P.R8C>$$P.R8C
M>$$P.SPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L;W(],T0C0T-%149&
M/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM
M3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@4V5R=FEE<CPO<#X-
M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C,V+C0\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B4F(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A
M;&EG;CTS1')I9VAT/C4Q+C8\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M;F]W<F%P/3-$;F]W<F%P/B4F(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$W
M+C,\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M/B4F(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D
M('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q
M96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!";V5H<FEN9V5R/"]P/@T*(#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,C@N-CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)28C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^,C0N.#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^)28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,3@N-#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)28C
M>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$
M(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(%1A:V5D
M83PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$V+C@\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B4F(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$
M<FEG:'0^#0H@)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H
M=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\
M+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@
M/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@
M+3%E;2<^#0H@1VEL96%D/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^,3$N-#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`^)28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,3,N.#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)28C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R
M:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-
M"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L;W(],T0C0T-%149&/@T*
M(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&
M5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@16QI($QI;&QY/"]P/@T*
M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,"XY/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XE)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1R:6=H=#XQ+C0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P/B4F(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C0X+CD\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B4F
M(WA!,#L\+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\<"!S='EL93TS1"=-
M05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@,3)P=#L@5$585"U)
M3D1%3E0Z(#0E)SX-"B!4:&4@9F]L;&]W:6YG('1A8FQE(&EN8VQU9&5S('1H
M;W-E(&-O;&QA8F]R871O<G,@=&AA="!R97!R97-E;G0-"B!M;W)E('1H86X@
M,3`E(&]F(&%C8V]U;G1S(')E8V5I=F%B;&4@870@=&AE(&1A=&4@:6YD:6-A
M=&5D.CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/
M3E0M4TE:13H@,3)P=#L@34%21TE.+51/4#H@,'!T)SX-"B`F(WA!,#L\+W`^
M#0H@/'1A8FQE('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S
M92<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#<V
M)2!A;&EG;CTS1&-E;G1E<B!B;W)D97(],T0P/@T*(#QT<CX-"B`\=&0@=VED
M=&@],T0W-24^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,3`E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE/CPO=&0^#0H@/'1D
M/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/"]T<CX-"B`\='(@
M<W1Y;&4],T0G1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V
M86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#8@86QI9VX],T1C96YT97(^/&(^
M1&5C96UB97(F(WA!,#LS,2P\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U3
M25I%.B`X<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@
M8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^#0H@/&(^)B-X03`[)B-X03`[
M)B-X03`[)B-X03`[,C`Q-"8C>$$P.R8C>$$P.R8C>$$P.R8C>$$P.SPO8CX\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T
M;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^#0H@/&(^)B-X03`[)B-X
M03`[)B-X03`[)B-X03`[,C`Q,R8C>$$P.R8C>$$P.R8C>$$P.R8C>$$P.SPO
M8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L;W(],T0C0T-%149&/@T*(#QT
M9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@
M,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@4V5R=FEE<CPO<#X-"B`\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!A;&EG;CTS1')I9VAT/C,S+C,\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B4F(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT/C8N-#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^)28C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.
M+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($)O96AR:6YG97(\
M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR,2XR/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XE)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@86QI9VX],T1R:6=H=#XQ,BXR/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#XE)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT
M<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX]
M,T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4
M+4E.1$5.5#H@+3%E;2<^#0H@1W)E96X@0W)O<W,\+W`^#0H@/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@86QI9VX],T1R:6=H=#XQ-RXY/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#XE)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!':6QE
M860\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C4S+C0\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B4F(WA!,#L\+W1D
M/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO<CTS1"-#0T5%1D8^
M#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,
M1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!09FEZ97(\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A
M;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!A;&EG;CTS1')I9VAT/C$R+C,\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B4F(WA!,#L\+W1D/@T*(#PO='(^
M#0H@/"]T86)L93X-"B`\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R;W!E<G1Y(&%N9"!%<75I<&UE;G0\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78^#0H@/'`@<W1Y
M;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#$X<'0G
M/@T*(#QB/CQI/E!R;W!E<G1Y(&%N9"!%<75I<&UE;G0\+VD^/"]B/CPO<#X-
M"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@
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M;F<-"B!E<W1I;6%T960@=7-E9G5L(&QI=F5S.CPO<#X-"B`\<"!S='EL93TS
M1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3)P=#L@34%21TE.
M+51/4#H@,'!T)SX-"B`F(WA!,#L\+W`^#0H@/'1A8FQE('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S92<@8V5L;'-P86-I;F<],T0P(&-E
M;&QP861D:6YG/3-$,"!W:61T:#TS1#<V)2!A;&EG;CTS1&-E;G1E<B!B;W)D
M97(],T0P/@T*(#QT<CX-"B`\=&0@=VED=&@],T0U-24^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-24^/"]T9#X-"B`\=&0^/"]T9#X-
M"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L;W(],T0C0T-%149&/@T*
M(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&
M5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@0V]M<'5T97(@97%U:7!M
M96YT/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^,R!Y96%R<SPO=&0^
M#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$=&]P
M/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%
M3E0Z("TQ96TG/@T*(%-O9G1W87)E/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^,R!Y96%R<SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B
M9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG
M/@T*($9U<FYI='5R93PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/C$P
M('EE87)S/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V
M86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M
M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@3&%B;W)A=&]R>2!A;F0@;V9F:6-E
M(&5Q=6EP;65N=#PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/C4@>65A
M<G,\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO<CTS1"-#
M0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!
M4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!,96%S96AO
M;&0@:6UP<F]V96UE;G1S/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M#0H@4VAO<G1E<B8C>$$P.V]F)B-X03`[;&5A<V4F(WA!,#MT97)M)B-X03`[
M;W(F(WA!,#MU<V5F=6PF(WA!,#ML:69E/"]T9#X-"B`\+W1R/@T*(#PO=&%B
M;&4^#0H@/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y);7!A:7)M96YT(&]F($QO;F<M3&EV960@07-S971S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV/@T*(#QP('-T
M>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q.'!T
M)SX-"B`\8CX\:3Y);7!A:7)M96YT(&]F($QO;F<M3&EV960@07-S971S/"]I
M/CPO8CX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($U!4D=)3BU43U`Z(#9P=#L@5$585"U)3D1%3E0Z(#0E)SX-"B!4:&4@0V]M
M<&%N>2!A<W-E<W-E<R!T:&4@<F5C;W9E<F%B:6QI='D@;V8@:71S(&QO;F<M
M;&EV960@87-S971S(&EN#0H@86-C;W)D86YC92!W:71H('1H92!P<F]V:7-I
M;VYS(&]F($%30R8C>$$P.S,V,"P@/&D^4')O<&5R='DL(%!L86YT#0H@86YD
M($5Q=6EP;65N=#PO:3XN($%30R`S-C`@<F5Q=6ER97,@=&AA="!L;VYG+6QI
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M8F4@9V5N97)A=&5D(&)Y('1H92!A<W-E=`T*(&]R(&%S<V5T(&=R;W5P+B!)
M9B!C87)R>6EN9R!V86QU92!E>&-E961S('1H92!S=6T@;V8@=6YD:7-C;W5N
M=&5D#0H@8V%S:"!F;&]W<RP@=&AE($-O;7!A;GD@=&AE;B!D971E<FUI;F5S
M('1H92!F86ER('9A;'5E(&]F('1H90T*('5N9&5R;'EI;F<@87-S970@9W)O
M=7`N($%N>2!I;7!A:7)M96YT('1O(&)E(')E8V]G;FEZ960@:7,@;65A<W5R
M960-"B!B>2!T:&4@86UO=6YT(&)Y('=H:6-H('1H92!C87)R>6EN9R!A;6]U
M;G0@;V8@=&AE(&%S<V5T(&=R;W5P#0H@97AC965D<R!T:&4@97-T:6UA=&5D
M(&9A:7(@=F%L=64@;V8@=&AE(&%S<V5T(&=R;W5P+B!!<W-E=',@=&\@8F4-
M"B!D:7-P;W-E9"!O9B!A<F4@<F5P;W)T960@870@=&AE(&QO=V5R(&]F('1H
M92!C87)R>6EN9R!A;6]U;G0@;W(-"B!F86ER('9A;'5E+"!L97-S(&-O<W1S
M('1O('-E;&PN($%S(&]F($1E8V5M8F5R)B-X03`[,S$L(#(P,30@86YD#0H@
M,C`Q,RP@=&AE($-O;7!A;GD@9&5T97)M:6YE9"!T:&%T('1H97)E('=E<F4@
M;F\@:6UP86ER960@87-S971S(&%N9`T*(&AA9"!N;R!A<W-E=',@:&5L9"UF
M;W(M<V%L92X\+W`^#0H@/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);F-O;64@5&%X97,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78^#0H@/'`@<W1Y;&4],T0G34%2
M1TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#!P="<^#0H@/&(^/&D^
M26YC;VUE(%1A>&5S/"]I/CPO8CX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.
M+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#9P=#L@5$585"U)3D1%3E0Z
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M9"!T87@@87-S971S(&%N9`T*(&QI86)I;&ET:65S(&]F(&$@8VAA;F=E(&EN
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M:6QL(&YO="!B92!R96%L:7IE9"X@1FEN86YC:6%L('-T871E;65N=`T*(')E
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M)B-X,C`Q.3MS('!O;&EC>2!I<R!T;R!R96-O<F0@:6YT97)E<W0@86YD#0H@
M<&5N86QT:65S(')E;&%T960@=&\@=6YC97)T86EN('1A>"!P;W-I=&EO;G,@
M87,@82!C;VUP;VYE;G0@;V8-"B!I;F-O;64@=&%X(&5X<&5N<V4N/"]P/@T*
M(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4F5V96YU97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQD:78^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($U!4D=)3BU43U`Z(#$X<'0G/@T*(#QB/CQI/E)E=F5N=65S/"]I/CPO8CX\
M+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)
M3BU,1494.B`R)3L@34%21TE.+51/4#H@-G!T)SX-"B`\:3Y2979E;G5E(%)E
M8V]G;FET:6]N/"]I/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-
M.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@34%21TE.+51/4#H@-G!T.R!415A4+4E.1$5.5#H@-"4G/@T*
M(%1H92!#;VUP86YY(&5N=&5R<R!I;G1O(&-O;&QA8F]R871I;VX@86YD(&QI
M8V5N<V4@86=R965M96YT<R!W:71H#0H@8V]L;&%B;W)A=&]R<R!F;W(@=&AE
M(&1E=F5L;W!M96YT(&]F(&UO;F]C;&]N86P@86YT:6)O9'DM8F%S960-"B!T
M:&5R87!E=71I8W,@=&\@=')E870@8V%N8V5R(&%N9"!O=&AE<B!C;VUP;&5X
M(&1I<V5A<V5S+B!4:&4@=&5R;7,-"B!O9B!T:&5S92!A9W)E96UE;G1S(&-O
M;G1A:6X@;75L=&EP;&4@9&5L:79E<F%B;&5S('=H:6-H(&UA>2!I;F-L=61E
M#0H@*&DI)B-X03`[;&EC96YS97,L(&]R(&]P=&EO;G,@=&\@;V)T86EN(&QI
M8V5N<V5S+"!T;R!T:&4-"B!#;VUP86YY)B-X,C`Q.3MS('1E8VAN;VQO9VEC
M86P@<&QA=&9O<FUS+"!S=6-H(&%S(&ET<R!&8PT*($]P=&EM:7IA=&EO;B!A
M;F0@1'5A;"U!9F9I;FET>2!292U487)G971I;F<@*$1!4E0I('1E8VAN;VQO
M9VEE<RP-"B`H:6DI)B-X03`[<FEG:'1S('1O(&9U='5R92!T96-H;F]L;V=I
M8V%L(&EM<')O=F5M96YT<RP-"B`H:6EI*28C>$$P.W)E<V5A<F-H(&%N9"!D
M979E;&]P;65N="!A8W1I=FET:65S('1O(&)E('!E<F9O<FUE9"!O;@T*(&)E
M:&%L9B!O9B!T:&4@8V]L;&%B;W)A=&]R(&]R(&%S('!A<G0@;V8@=&AE(&-O
M;&QA8F]R871I;VXL(&%N9`T*("AI=BDF(WA!,#MT:&4@;6%N=69A8W1U<F4@
M;V8@<')E+6-L:6YI8V%L(&]R(&-L:6YI8V%L(&UA=&5R:6%L<R!F;W(-"B!T
M:&4@8V]L;&%B;W)A=&]R+B!087EM96YT<R!T;R!T:&4@0V]M<&%N>2!U;F1E
M<B!T:&5S92!A9W)E96UE;G1S#0H@;6%Y(&EN8VQU9&4@;F]N<F5F=6YD86)L
M92!L:6-E;G-E(&9E97,L(&]P=&EO;B!F965S+"!E>&5R8VES92!F965S+`T*
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M=&\@<V5L;`T*('!R;V1U8W1S(')E<W5L=&EN9R!F<F]M('1H92!C;VQL86)O
M<F%T:79E(&5F9F]R=',@;V8@=&AE('!A<G1I97,@:6X-"B!S<&5C:69I8R!G
M96]G<F%P:&EC('1E<G)I=&]R:65S+B!4:&4@0V]M<&%N>2!F;VQL;W=S('1H
M92!P<F]V:7-I;VYS#0H@;V8@=&AE($9!4T(@05-#(%1O<&EC(#8P-2TR-2P@
M/&D^4F5V96YU90T*(%)E8V]G;FET:6]N)B-X,C`Q-#M-=6QT:7!L92U%;&5M
M96YT($%R<F%N9V5M96YT<SPO:3XL(&%N9"!!4T,@5&]P:6,-"B`V,#4M,C@L
M(#QI/E)E=F5N=64@4F5C;V=N:71I;VXF(W@R,#$T.TUI;&5S=&]N92!-971H
M;V0\+VD^+"!I;@T*(&%C8V]U;G1I;F<@9F]R('1H97-E(&%G<F5E;65N=',N
M($EN(&]R9&5R('1O(&%C8V]U;G0@9F]R('1H97-E#0H@86=R965M96YT<RP@
M=&AE($-O;7!A;GD@;75S="!I9&5N=&EF>2!T:&4@9&5L:79E<F%B;&5S(&EN
M8VQU9&5D#0H@=VET:&EN('1H92!A9W)E96UE;G0@86YD(&5V86QU871E('=H
M:6-H(&1E;&EV97)A8FQE<R!R97!R97-E;G0-"B!S97!A<F%T92!U;FET<R!O
M9B!A8V-O=6YT:6YG(&)A<V5D(&]N('1H92!A8VAI979E;65N="!O9B!C97)T
M86EN#0H@8W)I=&5R:6$L(&EN8VQU9&EN9R!W:&5T:&5R('1H92!D96QI=F5R
M960@96QE;65N="!H87,@<W1A;F0M86QO;F4-"B!V86QU92!T;R!T:&4@8V]L
M;&%B;W)A=&]R+B!4:&4@8V]N<VED97)A=&EO;B!R96-E:79E9"!I<R!A;&QO
M8V%T960-"B!A;6]N9R!T:&4@<V5P87)A=&4@=6YI=',@;V8@86-C;W5N=&EN
M9RP@86YD('1H92!A<'!L:6-A8FQE(')E=F5N=64-"B!R96-O9VYI=&EO;B!C
M<FET97)I82!A<F4@87!P;&EE9"!T;R!E86-H(&]F('1H92!S97!A<F%T92!U
M;FET<RX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($U!4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@1F]R('1H
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M=F5L;W`@8V]M<&]U;F1S(&%G86EN<W0@<W!E8VEF:65D#0H@=&%R9V5T<R`H
M<F5F97)R960@=&\@:&5R96EN(&%S(&5X8VQU<VEV92!L:6-E;G-E<RD[(&%N
M9"`R*0T*($]P=&EO;B]R97-E87)C:"!A9W)E96UE;G1S('1O('-E8W5R92!O
M;B!E<W1A8FQI<VAE9"!T97)M<RP-"B!D979E;&]P;65N="!A;F0@8V]M;65R
M8VEA;&EZ871I;VX@;&EC96YS97,@=&\@=&AE<F%P975T:6,@<')O9'5C=`T*
M(&-A;F1I9&%T97,@=&\@8V]L;&%B;W)A=&]R+7-E;&5C=&5D('1A<F=E=',@
M9&5V96QO<&5D(&)Y('1H90T*($-O;7!A;GD@9'5R:6YG(&%N(&]P=&EO;B!P
M97)I;V0@*')E9F5R<F5D('1O(&AE<F5I;B!A<PT*(')I9VAT+71O+61E=F5L
M;W`@86=R965M96YT<RDN/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U14
M3TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4G
M/@T*(%1H97)E(&%R92!N;R!P97)F;W)M86YC92P@8V%N8V5L;&%T:6]N+"!T
M97)M:6YA=&EO;B!O<B!R969U;F0-"B!P<F]V:7-I;VYS(&EN(&%N>2!O9B!T
M:&4@87)R86YG96UE;G1S('1H870@8V]N=&%I;B!M871E<FEA;`T*(&9I;F%N
M8VEA;"!C;VYS97%U96YC97,@=&\@=&AE($-O;7!A;GDN/"]P/@T*(#QP('-T
M>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,B4[
M($U!4D=)3BU43U`Z(#$X<'0G/@T*(#QI/D5X8VQU<VEV92!,:6-E;G-E<SPO
M:3X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!
M4D=)3BU43U`Z(#9P=#L@5$585"U)3D1%3E0Z(#0E)SX-"B!4:&4@9&5L:79E
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M9W)E96UE;G1S+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P
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M96UE;G0@;V8@8V5R=&%I;B!M:6QE<W1O;F5S+"`H:6EI*28C>$$P.V5A<FX@
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M('1E8VAN:6-A;`T*(&%S<VES=&%N8V4@86YD('-H87)E(&%N>2!T96-H;F]L
M;V=Y(&EM<')O=F5M96YT<R!W:71H(&ET<PT*(&-O;&QA8F]R871O<G,@9'5R
M:6YG('1H92!T97)M(&]F('1H92!C;VQL86)O<F%T:6]N(&%G<F5E;65N=',N
M/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'
M24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4G/@T*(%1H92!#;VUP86YY
M(&1O97,@;F]T(&1I<F5C=&QY(&-O;G1R;VP@=VAE;B!A;GD@8V]L;&%B;W)A
M=&]R('=I;&P-"B!A8VAI979E(&UI;&5S=&]N97,@;W(@8F5C;VUE(&QI86)L
M92!F;W(@<F]Y86QT>2!P87EM96YT<RX\+W`^#0H@/'`@<W1Y;&4],T0G34%2
M1TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$
M14Y4.B`T)2<^#0H@5VAE;B!E;G1E<FEN9R!I;G1O(&$@;F5W(&-O;&QA8F]R
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M92`H5%!%*2P@;W(@82!B97-T(&5S=&EM871E(&]F('-E;&QI;F<@<')I8V4-
M"B`H0D534"DL(&EF('9E;F1O<B!S<&5C:69I8R!O8FIE8W1I=F4@979I9&5N
M8V4@*%933T4I(&ES(&YO=`T*(&%V86EL86)L92X@5&AE(&]B:F5C=&EV92!O
M9B!"15-0(&ES('1O(&1E=&5R;6EN92!T:&4@<')I8V4@870@=VAI8V@-"B!T
M:&4@0V]M<&%N>2!W;W5L9"!T<F%N<V%C="!A('-A;&4@:68@=&AE(&5L96UE
M;G0@=VET:&EN('1H92!L:6-E;G-E#0H@86=R965M96YT('=A<R!S;VQD(&]N
M(&$@<W1A;F1A;&]N92!B87-I<RX@17-T86)L:7-H:6YG($)%4U`-"B!I;G9O
M;'9E<R!M86YA9V5M96YT)B-X,C`Q.3MS(&IU9&=M96YT(&%N9"!C;VYS:61E
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M=7-E9"!T;R!D971E<FUI;F4@=&AE($)%4U`@=VEL;"!H879E(&$@<VEG;FEF
M:6-A;G0-"B!E9F9E8W0@;VX@=&AE(&%L;&]C871I;VX@;V8@=&AE(&%R<F%N
M9V5M96YT(&-O;G-I9&5R871I;VX@8F5T=V5E;@T*('1H92!M=6QT:7!L92!D
M96QI=F5R86)L97,N($1E;&EV97)A8FQE<R!U;F1E<B!T:&4@87)R86YG96UE
M;G0@87)E#0H@<V5P87)A=&4@=6YI=',@;V8@86-C;W5N=&EN9R!I9B`H:2DF
M(WA!,#MT:&4@9&5L:79E<F5D(&ET96T@:&%S#0H@=F%L=64@=&\@=&AE(&-U
M<W1O;65R(&]N(&$@<W1A;F1A;&]N92!B87-I<R!A;F0@*&EI*28C>$$P.VEF
M('1H90T*(&%R<F%N9V5M96YT(&EN8VQU9&5S(&$@9V5N97)A;"!R:6=H="!O
M9B!R971U<FX@<F5L871I=F4@=&\@=&AE#0H@9&5L:79E<F5D(&ET96TL(&1E
M;&EV97)Y(&]R('!E<F9O<FUA;F-E(&]F('1H92!U;F1E;&EV97)E9"!I=&5M
M(&ES#0H@8V]N<VED97)E9"!P<F]B86)L92!A;F0@<W5B<W1A;G1I86QL>2!W
M:71H:6X@=&AE($-O;7!A;GDF(W@R,#$Y.W,-"B!C;VYT<F]L+B!4:&4@87)R
M86YG96UE;G0@8V]N<VED97)A=&EO;B!T:&%T(&ES(&9I>&5D(&]R#0H@9&5T
M97)M:6YA8FQE(&%T('1H92!I;F-E<'1I;VX@;V8@=&AE(&%R<F%N9V5M96YT
M(&ES(&%L;&]C871E9"!T;PT*('1H92!S97!A<F%T92!U;FET<R!O9B!A8V-O
M=6YT:6YG(&)A<V5D(&]N('1H96ER(')E;&%T:79E('-E;&QI;F<-"B!P<FEC
M97,N(%1H92!A<'!R;W!R:6%T92!R979E;G5E(')E8V]G;FET:6]N(&UO9&5L
M(&ES(&%P<&QI960@=&\-"B!E86-H(&5L96UE;G0@86YD(')E=F5N=64@:7,@
M86-C;W)D:6YG;'D@<F5C;V=N:7IE9"!A<R!E86-H(&5L96UE;G0-"B!I<R!D
M96QI=F5R960N($UA;F%G96UE;G0@97AE<F-I<V5S('-I9VYI9FEC86YT(&IU
M9&=M96YT(&EN#0H@9&5T97)M:6YI;F<@=VAE=&AE<B!A(&1E;&EV97)A8FQE
M(&ES(&$@<V5P87)A=&4@=6YI="!O9@T*(&%C8V]U;G1I;F<N/"]P/@T*(#QP
M('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q
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M(&]N#0H@=&AE('5N9&5L:79E<F5D(&ET96US(&%N9"`H:6EI*28C>$$P.W1H
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M:&YO;&]G>2!P;&%T9F]R;7,L('1H92!#;VUP86YY)B-X,C`Q.3MS('!R:6-I
M;F<-"B!P<F%C=&EC97,@86YD('!R:6-I;F<@;V)J96-T:79E<RP@=&AE(&QI
M:V5L:6AO;V0@=&AA="!T96-H;F]L;V=I8V%L#0H@:6UP<F]V96UE;G1S('=I
M;&P@8F4@;6%D92P@=&AE(&QI:V5L:6AO;V0@=&AA="!T96-H;F]L;V=I8V%L
M#0H@:6UP<F]V96UE;G1S(&UA9&4@=VEL;"!B92!U<V5D(&)Y('1H92!#;VUP
M86YY)B-X,C`Q.3MS(&-O;&QA8F]R871O<G,-"B!A;F0@=&AE(&YA='5R92!O
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M"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@
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M=&%I;G,@:71S#0H@<FEG:'0@=&\@=7-E('1H92!#;VUP86YY)B-X,C`Q.3MS
M('1E8VAN;VQO9WD@=&\@9&5V96QO<"!A;@T*(&%L=&5R;F%T:79E('!R;V1U
M8W0@8V%N9&ED871E('1O('1H92!S86UE('1A<F=E="!O<B!A('1A<F=E=`T*
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M<W-I9FEE9"!A<R!D969E<G)E9`T*(')E=F5N=64L(&%T('1H92!D871E(&]F
M('-U8V@@=&5R;6EN871I;VX@;W(@=&AR;W5G:"!T:&4@<F5M86EN:6YG#0H@
M<W5B<W1A;G1I86P@:6YV;VQV96UE;G0@:6X@=&AE('=I;F0@9&]W;B!O9B!T
M:&4@86=R965M96YT+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-
M.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
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M:79E<F5D(&5L96UE;G1S+"!W:&EC:`T*(&=E;F5R86QL>2!I;F-L=61E(')I
M9VAT<R!T;R!F=71U<F4@=&5C:&YO;&]G:6-A;"!I;7!R;W9E;65N=',L#0H@
M<F5S96%R8V@@<V5R=FEC97,@86YD('1H92!M86YU9F%C='5R92!O9B!P<F4M
M8VQI;FEC86P@86YD(&-L:6YI8V%L#0H@;6%T97)I86QS+CPO<#X-"B`\<"!S
M='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@,3)P
M=#L@5$585"U)3D1%3E0Z(#0E)SX-"B!4:&4@0V]M<&%N>2!R96-O9VYI>F5S
M(')E=F5N=64@<F5L871E9"!T;R!R97-E87)C:"!A;F0@<')E+6-L:6YI8V%L
M#0H@9&5V96QO<&UE;G0@<V5R=FEC97,@=&AA="!R97!R97-E;G0@<V5P87)A
M=&4@=6YI=',@;V8@86-C;W5N=&EN9R!A<PT*('1H97D@87)E('!E<F9O<FUE
M9"P@87,@;&]N9R!A<R!T:&5R92!I<R!P97)S=6%S:79E(&5V:61E;F-E(&]F
M(&%N#0H@87)R86YG96UE;G0L('1H92!F964@:7,@9FEX960@;W(@9&5T97)M
M:6YA8FQE+"!A;F0@8V]L;&5C=&EO;B!O9@T*('1H92!R96QA=&5D(')E8V5I
M=F%B;&4@:7,@<')O8F%B;&4N(%1H92!#;VUP86YY(')E8V]G;FEZ97,@<F5V
M96YU90T*(')E;&%T960@=&\@=&AE(')I9VAT<R!T;R!F=71U<F4@=&5C:&YO
M;&]G:6-A;"!I;7!R;W9E;65N=',@;W9E<B!T:&4-"B!E<W1I;6%T960@=&5R
M;2!O9B!T:&4@87!P;&EC86)L92!L:6-E;G-E+CPO<#X-"B`\<"!S='EL93TS
M1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&
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M<F5V96YU92!F<F]M#0H@8V]L;&%B;W)A=&EV92!R97-E87)C:"X\+W`^#0H@
M/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z
M(#$R<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@5&AE($-O;7!A;GDF(W@R,#$Y
M.W,@;&EC96YS92!A9W)E96UE;G1S(&AA=F4@;6EL97-T;VYE('!A>6UE;G1S
M#0H@=VAI8V@@9F]R(')E<&]R=&EN9R!P=7)P;W-E<R!A<F4@86=G<F5G871E
M9"!I;G1O('1H<F5E(&-A=&5G;W)I97,Z#0H@*&DI)B-X03`[9&5V96QO<&UE
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M4RX@1F]O9"!A;F0@1')U9R!!9&UI;FES=')A=&EO;B`H1D1!*2!O<B!O=&AE
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M(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0
M.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4G/@T*($%T('1H92!I;F-E<'1I;VX@
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M<R!A;@T*(&%S<V5S<VUE;G0@;V8@=VAE=&AE<B`H:2DF(WA!,#MT:&4@8V]N
M<VED97)A=&EO;B!I<R!C;VUM96YS=7)A=&4-"B!W:71H(&5I=&AE<B`H82DF
M(WA!,#MT:&4@96YT:71Y)B-X,C`Q.3MS('!E<F9O<FUA;F-E('1O(&%C:&EE
M=F4@=&AE#0H@;6EL97-T;VYE+"!O<B`H8BDF(WA!,#MT:&4@96YH86YC96UE
M;G0@;V8@=&AE('9A;'5E(&]F('1H90T*(&1E;&EV97)E9"!I=&5M*',I(&%S
M(&$@<F5S=6QT(&]F(&$@<W!E8VEF:6,@;W5T8V]M92!R97-U;'1I;F<@9G)O
M;0T*('1H92!E;G1I='DF(W@R,#$Y.W,@<&5R9F]R;6%N8V4@=&\@86-H:65V
M92!T:&4@;6EL97-T;VYE+`T*("AI:2DF(WA!,#MT:&4@8V]N<VED97)A=&EO
M;B!R96QA=&5S('-O;&5L>2!T;R!P87-T('!E<F9O<FUA;F-E(&%N9`T*("AI
M:6DI)B-X03`[=&AE(&-O;G-I9&5R871I;VX@:7,@<F5A<V]N86)L92!R96QA
M=&EV92!T;R!A;&P@;V8@=&AE#0H@9&5L:79E<F%B;&5S(&%N9"!P87EM96YT
M('1E<FUS('=I=&AI;B!T:&4@87)R86YG96UE;G0N(%1H92!#;VUP86YY#0H@
M979A;'5A=&5S(&9A8W1O<G,@<W5C:"!A<R!T:&4@<V-I96YT:69I8RP@<F5G
M=6QA=&]R>2P@8V]M;65R8VEA;`T*(&%N9"!O=&AE<B!R:7-K<R!T:&%T(&UU
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M=&AI<R!A<W-E<W-M96YT+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]4
M5$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
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M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'
M24XM3$5&5#H@,B4[($U!4D=)3BU43U`Z(#$X<'0G/@T*(#QI/E)I9VAT+71O
M+41E=F5L;W`@06=R965M96YT<SPO:3X\+W`^#0H@/'`@<W1Y;&4],T0G34%2
M1TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#9P=#L@5$585"U)3D1%
M3E0Z(#0E)SX-"B!4:&4@0V]M<&%N>28C>#(P,3D[<R!R:6=H="UT;RUD979E
M;&]P(&%G<F5E;65N=',@<')O=FED90T*(&-O;&QA8F]R871O<G,@=VET:"!A
M;B!E>&-L=7-I=F4@;W!T:6]N('1O(&]B=&%I;B!L:6-E;G-E<R!T;PT*(&1E
M=F5L;W`@86YD(&-O;6UE<F-I86QI>F4@:6X@<W!E8VEF:65D(&=E;V=R87!H
M:6,@=&5R<FET;W)I97,-"B!P<F]D=6-T(&-A;F1I9&%T97,@9&5V96QO<&5D
M(&)Y('1H92!#;VUP86YY('5N9&5R(&%G<F5E9"!U<&]N#0H@<F5S96%R8V@@
M86YD('!R92UC;&EN:6-A;"!D979E;&]P;65N="!P<F]D=6-T('!R;V=R86US
M+B!4:&4@<')O9'5C=`T*(&-A;F1I9&%T97,@<F5S=6QT:6YG(&9R;VT@96%C
M:"!P<F]G<F%M(&%R92!A;&P@9&ER96-T960@=&\@80T*('-P96-I9FEC('1A
M<F=E="!S96QE8W1E9"!B>2!T:&4@8V]L;&%B;W)A=&]R+B!5;F1E<B!T:&5S
M90T*(&%G<F5E;65N=',L(&9E97,@;6%Y(&)E(&1U92!T;R!T:&4@0V]M<&%N
M>2`H:2DF(WA!,#MA="!T:&4-"B!I;F-E<'1I;VX@;V8@=&AE(&%R<F%N9V5M
M96YT("AR969E<G)E9"!T;R!A<R`F(W@R,#%#.W5P9G)O;G0F(W@R,#%$.PT*
M(&9E97,@;W(@<&%Y;65N=',I+"`H:6DI)B-X03`[=&AE('-E;&5C=&EO;B!O
M9B!A('1A<F=E="!F;W(@80T*('!R;V=R86TL("AI:6DI)B-X03`[=7!O;B!T
M:&4@97AE<F-I<V4@;V8@86X@;W!T:6]N('1O(&%C<75I<F4@80T*(&1E=F5L
M;W!M96YT(&%N9"!C;VUM97)C:6%L:7IA=&EO;B!L:6-E;G-E("AR969E<G)E
M9"!T;R!A<R!E>&5R8VES90T*(&9E97,@;W(@<&%Y;65N=',@96%R;F5D*2!F
M;W(@82!P<F]G<F%M+"!O<B`H:78I)B-X03`[<V]M90T*(&-O;6)I;F%T:6]N
M(&]F(&%L;"!O9B!T:&5S92!F965S+CPO<#X-"B`\<"!S='EL93TS1"=-05)'
M24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
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M3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.
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M(&1E9F5R<R!A;GD@=7!F<F]N=`T*('!A>6UE;G1S(')E8V5I=F5D(&%N9"!R
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M('1H90T*(&%R<F%N9V5M96YT('5S:6YG(%1012!O<B!A($)%4U`L(&EF(%93
M3T4@:7,@;F]T(&%V86EL86)L92X@5&AE#0H@;V)J96-T:79E(&]F($)%4U`@
M:7,@=&\@9&5T97)M:6YE('1H92!P<FEC92!A="!W:&EC:"!T:&4@0V]M<&%N
M>0T*('=O=6QD('1R86YS86-T(&$@<V%L92!I9B!T:&4@96QE;65N="!W:71H
M:6X@=&AE(')I9VAT+71O+61E=F5L;W`-"B!A9W)E96UE;G0@=V%S('-O;&0@
M;VX@82!S=&%N9&%L;VYE(&)A<VES+B!%<W1A8FQI<VAI;F<@0D534`T*(&EN
M=F]L=F5S(&UA;F%G96UE;G0F(W@R,#$Y.W,@:G5D9VUE;G0@86YD(&-O;G-I
M9&5R<R!M=6QT:7!L90T*(&9A8W1O<G,L(&EN8VQU9&EN9R!M87)K970@8V]N
M9&ET:6]N<R!A;F0@8V]M<&%N>2US<&5C:69I8R!F86-T;W)S+`T*(&EN8VQU
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M4U`@=VEL;"!H879E(&$-"B!S:6=N:69I8V%N="!E9F9E8W0@;VX@=&AE(&%L
M;&]C871I;VX@;V8@=&AE(&%R<F%N9V5M96YT#0H@8V]N<VED97)A=&EO;B!B
M971W965N('1H92!M=6QT:7!L92!D96QI=F5R86)L97,N($1E;&EV97)A8FQE
M<R!U;F1E<@T*('1H92!A<G)A;F=E;65N="!A<F4@<V5P87)A=&4@=6YI=',@
M;V8@86-C;W5N=&EN9R!I9B`H:2DF(WA!,#MT:&4-"B!D96QI=F5R960@:71E
M;2!H87,@=F%L=64@=&\@=&AE(&-U<W1O;65R(&]N(&$@<W1A;F1A;&]N92!B
M87-I<R!A;F0-"B`H:6DI)B-X03`[:68@=&AE(&%R<F%N9V5M96YT(&EN8VQU
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M(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4G/@T*
M($EF(&$@8V]L;&%B;W)A=&]R(&5X97)C:7-E<R!A;B!O<'1I;VX@86YD(&%C
M<75I<F5S(&$@9&5V96QO<&UE;G0-"B!A;F0@8V]M;65R8VEA;&EZ871I;VX@
M;&EC96YS92!T;R!A('!R;V1U8W0@<')O9W)A;2P@=&AE($-O;7!A;GD-"B!A
M='1R:6)U=&5S('1H92!E>&5R8VES92!F964@=&\@=&AE(&1E=F5L;W!M96YT
M(&%N9`T*(&-O;6UE<F-I86QI>F%T:6]N(&QI8V5N<V4N(%1H92!#;VUP86YY
M(&1E=&5R;6EN97,@=&AE('-E;&QI;F<@<')I8V4-"B!O9B!T:&4@;W!T:6]N
M(&QI8V5N<V4L('5P;VX@97AE<F-I<V4L('1H<F]U9V@@;6%N86=E;65N="8C
M>#(P,3D[<PT*(&)E<W0@97-T:6UA=&4@=7-I;F<@=&AE('!R;V-E<W,@9F]R
M(&%N(&5X8VQU<VEV92!L:6-E;G-E(&%S#0H@9&5S8W)I8F5D(&%B;W9E+CPO
M<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:
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M3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@
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M96YS97,N/"]P/@T*(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4F5S96%R8V@@86YD($1E=F5L;W!M96YT
M($-O<W1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV/@T*
M(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0
M.B`Q.'!T)SX-"B`\8CX\:3Y297-E87)C:"!A;F0@1&5V96QO<&UE;G0@0V]S
M=',\+VD^/"]B/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P
M<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@34%21TE.+51/4#H@-G!T.R!415A4+4E.1$5.5#H@-"4G/@T*(%)E
M<V5A<F-H(&%N9"!D979E;&]P;65N="!E>'!E;F1I='5R97,@87)E(&5X<&5N
M<V5D(&%S(&EN8W5R<F5D+@T*(%)E<V5A<F-H(&%N9"!D979E;&]P;65N="!C
M;W-T<R!P<FEM87)I;'D@8V]N<VES="!O9B!E;7!L;WEE90T*(')E;&%T960@
M97AP96YS97,L(&EN8VQU9&EN9R!S86QA<FEE<R!A;F0@8F5N969I=',L(&5X
M<&5N<V5S#0H@:6YC=7)R960@=6YD97(@86=R965M96YT<R!W:71H(&-O;G1R
M86-T(')E<V5A<F-H(&]R9V%N:7IA=&EO;G,L#0H@:6YV97-T:6=A=&EV92!S
M:71E<R!A;F0@8V]N<W5L=&%N=',@=&AA="!C;VYD=6-T('1H90T*($-O;7!A
M;GDF(W@R,#$Y.W,@8VQI;FEC86P@=')I86QS+"!T:&4@8V]S="!O9B!A8W%U
M:7)I;F<@86YD#0H@;6%N=69A8W1U<FEN9R!C;&EN:6-A;"!T<FEA;"!M871E
M<FEA;',@86YD(&]T:&5R(&%L;&]C871E9`T*(&5X<&5N<V5S+"!L:6-E;G-E
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M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M<')E:&5N<VEV
M92!);F-O;64@*$QO<W,I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\9&EV/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-
M05)'24XM5$]0.B`Q.'!T)SX-"B`\8CX\:3Y#;VUP<F5H96YS:79E($EN8V]M
M92`H3&]S<RD\+VD^/"]B/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]4
M5$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
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M97(F(WA!,#LS,2P@,C`Q-"P@,C`Q,R!A;F0@,C`Q,BX\+W`^#0H@/"]D:78^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y3=&]C:RUB87-E9"!#;VUP96YS871I;VX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQD:78^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/
M33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($U!4D=)3BU43U`Z(#$X<'0G/@T*(#QB/CQI/E-T;V-K+6)A
M<V5D($-O;7!E;G-A=&EO;CPO:3X\+V(^/"]P/@T*(#QP('-T>6QE/3-$)TU!
M4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`V<'0[(%1%6%0M24Y$
M14Y4.B`T)2<^#0H@4W1O8VLM8F%S960@<&%Y;65N=',@87)E(&%C8V]U;G1E
M9"!F;W(@:6X@86-C;W)D86YC92!W:71H('1H90T*('!R;W9I<VEO;G,@;V8@
M05-#)B-X03`[-S$X+"`\:3Y#;VUP96YS871I;VXF(W@R,#$T.U-T;V-K#0H@
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M<F%L;'D@=&AE('9E<W1I;F<@<&5R:6]D(&]F('1H90T*(&]P=&EO;BX\+W`^
M#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU4
M3U`Z(#$R<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@1F]R(&%L;"!T:6UE+79E
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M:&4@<&5R:6]D+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P
M<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@34%21TE.+51/4#H@,3)P=#L@5$585"U)3D1%3E0Z(#0E)SX-"B!4
M:&4@0V]M<&%N>2!U=&EL:7IE<R!T:&4@0FQA8VLM4V-H;VQE<R!M;V1E;"!F
M;W(@97-T:6UA=&EN9R!F86ER#0H@=F%L=64@;V8@:71S('-T;V-K(&]P=&EO
M;G,@9W)A;G1E9"X@3W!T:6]N('9A;'5A=&EO;B!M;V1E;',L#0H@:6YC;'5D
M:6YG('1H92!";&%C:RU38VAO;&5S(&UO9&5L+"!R97%U:7)E('1H92!I;G!U
M="!O9B!H:6=H;'D-"B!S=6)J96-T:79E(&%S<W5M<'1I;VYS+"!A;F0@8VAA
M;F=E<R!I;B!T:&4@87-S=6UP=&EO;G,@=7-E9"!C86X-"B!M871E<FEA;&QY
M(&%F9F5C="!T:&4@9W)A;G0M9&%T92!F86ER('9A;'5E(&]F(&%N(&%W87)D
M+B!4:&5S90T*(&%S<W5M<'1I;VYS(&EN8VQU9&4@=&AE(')I<VLM9G)E92!R
M871E(&]F(&EN=&5R97-T+"!E>'!E8W1E9`T*(&1I=FED96YD('EI96QD+"!E
M>'!E8W1E9"!V;VQA=&EL:71Y(&%N9"!T:&4@97AP96-T960@;&EF92!O9B!T
M:&4-"B!A=V%R9"X\+W`^#0H@/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@26YC;VUE("A,;W-S*2!0
M97(@4VAA<F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78^
M#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU4
M3U`Z(#$X<'0G/@T*(#QB/CQI/DYE="!);F-O;64@*$QO<W,I(%!E<B!3:&%R
M93PO:3X\+V(^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P
M=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!-05)'24XM5$]0.B`V<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@0F%S
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M;B!S=&]C:R!E<75I=F%L96YT<RX@1&EL=71E9`T*(&EN8V]M92`H;&]S<RD@
M<&5R('-H87)E(&ES(&-O;7!U=&5D(&)Y(&1I=FED:6YG('1H92!E87)N:6YG
M<R`H;&]S<RD-"B!A='1R:6)U=&%B;&4@=&\@8V]M;6]N('-T;V-K:&]L9&5R
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M3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.
M5#H@-"4G/@T*($9O<B!T:&4@>65A<B!E;F1E9"!$96-E;6)E<B8C>$$P.S,Q
M+"`R,#$R+"!N970@:6YC;VUE("AL;W-S*2!P97(-"B!S:&%R92!W87,@8V%L
M8W5L871E9"!U;F1E<B!T:&4@='=O+6-L87-S(&UE=&AO9"!U;F1E<B!W:&EC
M:"!A;&P-"B!E87)N:6YG<R`H9&ES=')I8G5T960@86YD('5N9&ES=')I8G5T
M960I(&%R92!A;&QO8V%T960@=&\@96%C:`T*(&-L87-S(&]F(&-O;6UO;B!S
M=&]C:R!A;F0@<&%R=&EC:7!A=&EN9R!S96-U<FET:65S(&)A<V5D(&]N('1H
M96ER#0H@<F5S<&5C=&EV92!R:6=H=',@=&\@<F5C96EV92!D:79I9&5N9',N
M($EN('1H92!E=F5N="!T:&%T('1H92!";V%R9`T*(&]F($1I<F5C=&]R<R!D
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M02TR+"!"+`T*($,L($0@86YD($0M,B!A<F4@<&%R=&EC:7!A=&EN9R!S96-U
M<FET:65S+B!!;&P@;V8@=&AE(&]U='-T86YD:6YG#0H@<VAA<F5S(&]F(%-E
M<FEE<R8C>$$P.T$M,2P@02TR+"!"+"!#+"!$+"!A;F0@1"TR(&-O;G9E<G1I
M8FQE#0H@<')E9F5R<F5D('-T;V-K(&-O;G9E<G1E9"!T;R!C;VUM;VX@<W1O
M8VL@=7!O;B!T:&4@8V]N<W5M;6%T:6]N(&]F#0H@=&AE($-O;7!A;GDF(W@R
M,#$Y.W,@25!/(&EN($]C=&]B97(@,C`Q,RX\+W`^#0H@/'`@<W1Y;&4],T0G
M34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$R<'0[($U!4D=)3BU4
M3U`Z(#!P="<^#0H@)B-X03`[/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"
M3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`P<'0[(%1%6%0M24Y$14Y4.B`T
M)2<^#0H@0F%S:6,@86YD(&1I;'5T960@:6YC;VUE("AL;W-S*2!P97(@8V]M
M;6]N('-H87)E(&ES(&-O;7!U=&5D(&%S#0H@9F]L;&]W<R`H:6X@=&AO=7-A
M;F1S(&5X8V5P="!S:&%R92!A;F0@<&5R('-H87)E(&1A=&$I.CPO<#X-"B`\
M<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3)P
M=#L@34%21TE.+51/4#H@,'!T)SX-"B`F(WA!,#L\+W`^#0H@/'1A8FQE('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S92<@8V5L;'-P86-I
M;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#DR)2!A;&EG;CTS1&-E
M;G1E<B!B;W)D97(],T0P/@T*(#QT<CX-"B`\=&0@=VED=&@],T0U."4^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24^/"]T9#X-"B`\
M=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$."4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^
M/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$."4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T
M9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#AP=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P
M,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,3`@
M86QI9VX],T1C96YT97(^/&(^665A<B!%;F1E9`T*($1E8V5M8F5R)B-X03`[
M,S$L/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D
M/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P
M,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L
M:6=N/3-$8V5N=&5R/CQB/C(P,30\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C
M,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R
M(&%L:6=N/3-$8V5N=&5R/CQB/C(P,3,\+V(^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X]
M,T0R(&%L:6=N/3-$8V5N=&5R/CQB/C(P,3(\+V(^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*
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M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH
M,C8Q/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XI)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^."PS-C(\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N
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M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@X+#,V,CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P
M.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI
M9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-
M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^
M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q
M<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@
M<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P
M,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P
M,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[
M/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L;W(],T0C0T-%
M149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'
M24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@3F5T(&EN8V]M
M92`H;&]S<RD@86QL;V-A8FQE('1O(&-O;6UO;B!S:&%R97,\+W`^#0H@/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^*#,X+#,Q,SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@R-C$\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/BDF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T
M>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52
M+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4
M3U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@
M/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4]
M,T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^
M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$
M)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*
M(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@
M/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF
M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP
M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X
M03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\
M='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*
M($)A<VEC('=E:6=H=&5D(&%V97)A9V4@8V]M;6]N('-H87)E<R!O=71S=&%N
M9&EN9SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(W+#,X-"PY.3`\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^-BPX-#<L-CDW/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I
M9VAT/C$L,#@S+#(W-CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T
M;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.
M1$5.5#H@+3%E;2<^#0H@0F%S:6,@:6YC;VUE("AL;W-S*2!P97(@8V]M;6]N
M('-H87)E/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!A;&EG;CTS1')I9VAT/B@Q+C0P/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#`N
M,#0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M/BDF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@86QI9VX],T1R:6=H=#XP+C`P/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^
M#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M
M)SX-"B!.970@:6YC;VUE("AL;W-S*3PO<#X-"B`\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH,S@L,S$S
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^*#(V,3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C@L,S8R/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO<CTS
M1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!,97-S
M.B!U;F1I<W1R:6)U=&5D(&5A<FYI;F=S(&%L;&]C871E9"!T;R!P87)T:6-I
M<&%T:6YG('-E8W5R:71I97,-"B!A;F0@;W1H97(@861D+6)A8VMS('1O(&YE
M="!I;F-O;64@*&QO<W,I/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A
M;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/B@X+#,V,CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/"]T<CX-"B`\
M='(@<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="
M3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$
M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^
M#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y
M;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO
M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4]
M,T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-
M"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*
M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF
M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP
M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!
M,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT
M<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@
M3F5T(&EN8V]M92`H;&]S<RD@86QL;V-A8FQE('1O(&-O;6UO;B!S:&%R97,\
M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^*#,X+#,Q,SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@R-C$\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/BDF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XD/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*
M("8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^
M#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4]
M,T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^
M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$
M)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*
M(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@
M/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF
M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP
M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X
M03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@
M9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O
M=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@
M/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\
M=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z
M(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($)A<VEC('=E:6=H=&5D(&%V
M97)A9V4@8V]M;6]N('-H87)E<R!O=71S=&%N9&EN9SPO<#X-"B`\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT/C(W+#,X-"PY.3`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-BPX
M-#<L-CDW/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$L,#@S+#(W-CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[
M)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V
M86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M
M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@169F96-T(&]F(&1I;'5T:79E('-E
M8W5R:71I97,\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$
M<FEG:'0^#0H@)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X-"B`F
M(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*
M(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$
M)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/
M4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T
M9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S
M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[
M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL
M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P
M/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G
M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@
M/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C
M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@
M/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG
M;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%
M6%0M24Y$14Y4.B`M,65M)SX-"B!$:6QU=&5D('=E:6=H=&5D(&%V97)A9V4@
M8V]M;6]N('-H87)E<R!O=71S=&%N9&EN9SPO<#X-"B`\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M/C(W+#,X-"PY.3`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P
M/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-BPX-#<L-CDW
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$L,#@S+#(W-CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[
M/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L
M92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-
M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G
M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@
M,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P
M>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z
M(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C
M,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF
M(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A
M;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[
M(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!$:6QU=&5D(&EN8V]M92`H;&]S<RD@
M<&5R(&-O;6UO;B!S:&%R93PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH,2XT,#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT/B@P+C`T/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,"XP,#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T
M9#X-"B`\+W1R/@T*(#PO=&%B;&4^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/
M5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$14Y4.B`T
M)2<^#0H@5&AE(&9O;&QO=VEN9R!C;VUM;VX@<W1O8VL@97%U:79A;&5N=',@
M=V5R92!E>&-L=61E9"!F<F]M('1H90T*(&-A;&-U;&%T:6]N(&]F(&1I;'5T
M960@;F5T(&EN8V]M92`H;&]S<RD@<&5R('-H87)E(&)E8V%U<V4@=&AE:7(-
M"B!E9F9E8W0@=V]U;&0@8F4@86YT:2UD:6QU=&EV93H\+W`^#0H@/'`@<W1Y
M;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$R<'0[($U!
M4D=)3BU43U`Z(#!P="<^#0H@)B-X03`[/"]P/@T*(#QT86)L92!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4G(&-E;&QS<&%C:6YG/3-$
M,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Y,B4@86QI9VX],T1C96YT97(@
M8F]R9&5R/3-$,#X-"B`\='(^#0H@/'1D('=I9'1H/3-$-C,E/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/CPO=&0^#0H@/'1D/CPO
M=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#,E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^
M#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E
M/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@
M/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`X<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@
M,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#$P(&%L:6=N
M/3-$8V5N=&5R/CQB/EEE87(@16YD960-"B!$96-E;6)E<B8C>$$P.S,Q+#PO
M8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q
M<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS
M1&-E;G1E<CX\8CXR,#$T/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P
M,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG
M;CTS1&-E;G1E<CX\8CXR,#$S/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P
M,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A
M;&EG;CTS1&-E;G1E<CX\8CXR,#$R/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@
M8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M
M)SX-"B!397)I97,@02TQ(%!R969E<G)E9"!3=&]C:SPO<#X-"B`\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$
M<FEG:'0^#0H@)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX]
M,T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XR+#$U-BPQ,30\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$
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M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C,Y,BPR-S0\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R
M/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(%-E
M<FEE<R!"(%!R969E<G)E9"!3=&]C:SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^#0H@
M)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X-
M"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#XT+#,S-BPP,S<\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T
M<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ
M96TG/@T*(%-E<FEE<R!#(%!R969E<G)E9"!3=&]C:SPO<#X-"B`\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$
M<FEG:'0^#0H@)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX]
M,T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XU+#DP.2PY,#8\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#145&
M1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.
M+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(%-E<FEE<R!$(%!R
M969E<G)E9"!3=&]C:SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO
M=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^#0H@)B-X,C`Q-#LF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P
M/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M;F]W<F%P/3-$;F]W<F%P/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T
M.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R
M:6=H=#XW-CDL-#8X/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!397)I
M97,@1"TR(%!R969E<G)E9"!3=&]C:SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^#0H@
M)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X-
M"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#XS+#,Y,2PY.3$\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T
M<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@
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M='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T
M.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R
M:6=H=#XQ,RPQ.#DL.3(P/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO
M=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^#0H@)B-X
M,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\
M='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE
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M<F%P/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$X,"PW
M.#0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B
M9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG
M/@T*(%-T;V-K($]P=&EO;G,\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R
M:6=H=#XR+#`Y-"PY,#0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^,BPS,3,L.3<P/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO
M=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT/C,L,C0Y+#<P,CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#PO
M=&%B;&4^#0H@/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y296-E;G1L>2!)<W-U960@06-C;W5N=&EN9R!3
M=&%N9&%R9',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78^
M#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU4
M3U`Z(#$X<'0G/@T*(#QB/CQI/E)E8V5N=&QY($ES<W5E9"!!8V-O=6YT:6YG
M(%-T86YD87)D<SPO:3X\+V(^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"
M3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`V<'0[(%1%6%0M24Y$14Y4.B`T
M)2<^#0H@26X@36%Y(#(P,30L('1H92!&05-"(&ES<W5E9"!!4U4@3F\N)B-X
M03`[,C`Q-"TP.2P@/&D^4F5V96YU92!F<F]M#0H@0V]N=')A8W1S('=I=&@@
M0W5S=&]M97)S/"]I/B`H05-5(#(P,30M,#DI+B!!4U4@,C`Q-"TP.2!W:6QL
M#0H@96QI;6EN871E('1R86YS86-T:6]N+2!A;F0@:6YD=7-T<GDM<W!E8VEF
M:6,@<F5V96YU92!R96-O9VYI=&EO;@T*(&=U:61A;F-E('5N9&5R(&-U<G)E
M;G0@1T%!4"!A;F0@<F5P;&%C92!I="!W:71H(&$@<')I;F-I<&QE+6)A<V5D
M#0H@87!P<F]A8V@@9F]R(&1E=&5R;6EN:6YG(')E=F5N=64@<F5C;V=N:71I
M;VXN($%352`R,#$T+3`Y('=I;&P-"B!R97%U:7)E('1H870@8V]M<&%N:65S
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M=61I;F<@<VEG;FEF:6-A;G0@:G5D9VUE;G1S(&%N9`T*(&-H86YG97,@:6X@
M:G5D9VUE;G1S(&%N9"!A<W-E=',@<F5C;V=N:7IE9"!F<F]M(&-O<W1S(&EN
M8W5R<F5D('1O#0H@;V)T86EN(&]R(&9U;&9I;&P@82!C;VYT<F%C="X@05-5
M(#(P,30M,#D@:7,@969F96-T:79E(&9O<B!A;FYU86P-"B!R97!O<G1I;F<@
M<&5R:6]D<R!B96=I;FYI;F<@869T97(@1&5C96UB97(F(WA!,#LQ-2P@,C`Q
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M)B-X,C`Q.3MS#0H@8V]N<V]L:61A=&5D(&9I;F%N8VEA;"!S=&%T96UE;G1S
M(&%N9"!A8V-O;7!A;GEI;F<@;F]T97,N/"]P/@T*(#QP('-T>6QE/3-$)TU!
M4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.
M1$5.5#H@-"4G/@T*($EN($IU;'D@,C`Q,RP@=&AE($9!4T(@:7-S=65D($%3
M52!.;RXF(WA!,#LR,#$S+3$Q+"!W:&EC:"!A;65N9&5D#0H@05-#(%1O<&EC
M(#<T,"!R96=A<F1I;F<@<')E<V5N=&%T:6]N(&]F(&%N('5N<F5C;V=N:7IE
M9"!T87@@8F5N969I=`T*('=H96X@82!N970@;W!E<F%T:6YG(&QO<W,@*$Y/
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M<F5D:70@8V%R<GEF;W)W87)D+`T*(')A=&AE<B!T:&%N(&%S(&$@;&EA8FEL
M:71Y('=H96X@*#$I)B-X03`[=&AE('5N8V5R=&%I;B!T87@@<&]S:71I;VX-
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M8F5R)B-X03`[,34L(#(P,3,L(&%N9"!D:60-"B!N;W0@:&%V92!A(&UA=&5R
M:6%L(&EM<&%C="!O;B!T:&4@0V]M<&%N>28C>#(P,3D[<R!F:6YA;F-I86P-
M"B!S=&%T96UE;G1S+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-
M.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
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M+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\
M+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?.&1B-3,W8S1?93@W.%\T83-E
M7S@R.&%?8C4P,&8S961F,3%F#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O
M+T,Z+SAD8C4S-V,T7V4X-SA?-&$S95\X,CAA7V(U,#!F,V5D9C$Q9B]7;W)K
M<VAE971S+U-H965T,C$N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN
M9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[
M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@
M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E
M>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J
M879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES
M($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT
M86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5)24%#/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N
M/3-$,CX\<W1R;VYG/E-U;6UA<GD@;V8@4VEG;FEF:6-A;G0@06-C;W5N=&EN
M9R!0;VQI8VEE<R`H5&%B;&5S*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4W5M;6%R>2!O9B!&86ER(%9A;'5E($UE87-U<F5M
M96YT($9I;F%N8VEA;"!!<W-E="!A;F0@3&EA8FEL:71I97,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78^#0H@/'`@<W1Y;&4],T0G34%2
M1TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#!P=#L@5$585"U)3D1%
M3E0Z(#0E)SX-"B!&:6YA;F-I86P@87-S971S(&%N9"!L:6%B:6QI=&EE<R!S
M=6)J96-T('1O(&9A:7(@=F%L=64@;65A<W5R96UE;G1S#0H@=V5R92!A<R!F
M;VQL;W=S("AI;B!T:&]U<V%N9',I.CPO<#X-"B`\<"!S='EL93TS1"=-05)'
M24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3)P=#L@34%21TE.+51/4#H@
M,'!T)SX-"B`F(WA!,#L\+W`^#0H@/'1A8FQE('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D]21$52
M+4-/3$Q!4%-%.B!C;VQL87!S92<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D
M:6YG/3-$,"!W:61T:#TS1#DR)2!A;&EG;CTS1&-E;G1E<B!B;W)D97(],T0P
M/@T*(#QT<CX-"B`\=&0@=VED=&@],T0T,R4^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$-R4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^
M/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$-R4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-R4^/"]T9#X-"B`\
M=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$-R4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^
M/"]T9#X-"B`\=&0^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4
M+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O
M;2!C;VQS<&%N/3-$,30@86QI9VX],T1C96YT97(^/&(^1F%I<B!686QU92!-
M96%S=7)E;65N=',@870-"B!$96-E;6)E<B8C>$$P.S,Q+"`R,#$T/"]B/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#PO='(^
M#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$
M8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/E%U;W1E9"8C
M>$$P.U!R:6-E<R8C>$$P.VEN/"]B/CQB<B`O/@T*(#QB/D%C=&EV92!-87)K
M971S/&)R("\^#0H@9F]R/"]B/CQB<B`O/@T*(#QB/DED96YT:6-A;"!!<W-E
M=',\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@
M=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB
M/E-I9VYI9FEC86YT)B-X03`[3W1H97(\+V(^/&)R("\^#0H@/&(^3V)S97)V
M86)L93QB<B`O/@T*($EN<'5T<SPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P
M,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@
M86QI9VX],T1C96YT97(^/&(^4VEG;FEF:6-A;G0\+V(^/&)R("\^#0H@/&(^
M56YO8G-E<G9A8FQE/"]B/CQB<B`O/@T*(#QB/DEN<'5T<SPO8CX\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT
M<B!S='EL93TS1"=&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G
M('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\
M8CY4;W1A;#PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O
M;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT
M97(^/&(^3&5V96P@,3PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@
M,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX]
M,T1C96YT97(^/&(^3&5V96P@,CPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P
M,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@
M86QI9VX],T1C96YT97(^/&(^3&5V96P@,SPO8CX\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XG(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@
M/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@
M+3%E;2<^#0H@07-S971S.CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#QT<B!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!-05)'24XM3$5&5#H@,V5M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@0V%S
M:"!A;F0@8V%S:"!E<75I=F%L96YT<SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R
M:6=H=#XQ,S$L-30U/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ
M,S$L-30U/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C
M;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($U!4D=)3BU,1494.B`S96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-
M"B!-;VYE>2!M87)K970@9G5N9',\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N
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M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^,C8L,#0V/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^#0H@)B-X,C`Q
M-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X-"B`F(W@R
M,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT
M<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!-05)'24XM3$5&5#H@,V5M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@
M4F5S=')I8W1E9"!C87-H/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^,S`P/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C,P
M,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^#0H@)B-X,C`Q-#LF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G
M1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C
M,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P
M,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52
M+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/
M4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT
M9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$
M)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/
M4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T
M9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S
M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[
M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL
M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P
M/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P
M/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%
M3E0Z("TQ96TG/@T*(%1O=&%L($%S<V5T<SPO<#X-"B`\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ-3<L
M.#DQ/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ-3<L.#DQ/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P
M,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO
M=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M
M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P
M,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@
M,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/
M4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z
M(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G
M0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/
M4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO
M=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@
M<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!
M,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T
M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[
M/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@
M<W1Y;&4],T0G1D].5"U325I%.B`Q<'0G/@T*(#QT9#X\+W1D/@T*(#QT9"!C
M;VQS<&%N/3-$,38^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4
M+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O
M;2!C;VQS<&%N/3-$,30@86QI9VX],T1C96YT97(^/&(^1F%I<B!686QU92!-
M96%S=7)E;65N=',@870-"B!$96-E;6)E<B8C>$$P.S,Q+"`R,#$S/"]B/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#PO='(^
M#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$
M8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/E%U;W1E9"!0
M<FEC97,@:6X\+V(^/&)R("\^#0H@/&(^06-T:79E($UA<FME=',\8G(@+SX-
M"B!F;W(\+V(^/&)R("\^#0H@/&(^261E;G1I8V%L($%S<V5T<SPO8CX\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B
M;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&(^4VEG;FEF:6-A
M;G0@3W1H97(\+V(^/&)R("\^#0H@/&(^3V)S97)V86)L93QB<B`O/@T*($EN
M<'5T<SPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED
M)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^
M/&(^4VEG;FEF:6-A;G0\+V(^/&)R("\^#0H@/&(^56YO8G-E<G9A8FQE/"]B
M/CQB<B`O/@T*(#QB/DEN<'5T<SPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4
M+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O
M;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\8CY4;W1A;#PO8CX\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B
M;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&(^3&5V96P@,3PO
M8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI
M9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&(^3&5V
M96P@,CPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED
M)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^
M/&(^3&5V96P@,SPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L;W(],T0C
M0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-
M05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@07-S971S
M.CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT
M9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@
M,V5M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@0V%S:"!A;F0@8V%S:"!E<75I
M=F%L96YT<SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*
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M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX]
M,T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R
M:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-
M"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L;W(],T0C0T-%149&/@T*
M(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&
M5#H@,V5M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@36]N97D@;6%R:V5T(&9U
M;F1S/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,C8L,#0W/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(V+#`T-SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P(&%L:6=N/3-$<FEG:'0^#0H@)B-X,C`Q-#LF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\
M=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z
M(#-E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(%)E<W1R:6-T960@8V%S:#PO
M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C0P-3PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^
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M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX]
M,T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG
M;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G
M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@
M/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C
M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X
M('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O
M;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P
M,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P
M(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/
M4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@
M(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF
M(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO<CTS
M1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!4;W1A
M;"!!<W-E=',\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,3$V+#@X-CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^,3$V+#@X-CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`@86QI9VX],T1R:6=H=#X-"B`F(WA!,#LF(WA!,#LF(WA!,#LF(WA!
M,#LF(WA!,#LF(WA!,#LF(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X-"B`F
M(WA!,#LF(WA!,#LF(WA!,#LF(WA!,#LF(WA!,#LF(WA!,#LF(WA!,#LF(WA!
M,#LF(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R
M/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE
M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P
M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS
M1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-
M"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*
M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^
M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\
M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C
M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X
M(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D
M;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P
M,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P
M,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!
M,#L\+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\+V1I=CX\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5S=&EM871E
M9"!5<V5F=6P@3&EV97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQD:78^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!
M4D=)3BU43U`Z(#9P=#L@5$585"U)3D1%3E0Z(#0E)SX-"B!297!A:7)S(&%N
M9"!M86EN=&5N86YC92!C;W-T<R!A<F4@97AP96YS960@87,@:6YC=7)R960N
M#0H@1&5P<F5C:6%T:6]N(&ES(&-O;7!U=&5D('5S:6YG('1H92!S=')A:6=H
M="UL:6YE(&UE=&AO9"!O=F5R('1H90T*(&9O;&QO=VEN9R!E<W1I;6%T960@
M=7-E9G5L(&QI=F5S.CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-
M.B`P<'0[($9/3E0M4TE:13H@,3)P=#L@34%21TE.+51/4#H@,'!T)SX-"B`F
M(WA!,#L\+W`^#0H@/'1A8FQE('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D]21$52+4-/3$Q!4%-%
M.B!C;VQL87!S92<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W
M:61T:#TS1#<V)2!A;&EG;CTS1&-E;G1E<B!B;W)D97(],T0P/@T*(#QT<CX-
M"B`\=&0@=VED=&@],T0U-24^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$-24^/"]T9#X-"B`\=&0^/"]T9#X-"B`\+W1R/@T*(#QT<B!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T
M;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.
M1$5.5#H@+3%E;2<^#0H@0V]M<'5T97(@97%U:7!M96YT/"]P/@T*(#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^,R!Y96%R<SPO=&0^#0H@/"]T<CX-"B`\='(@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(%-O
M9G1W87)E/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^,R!Y96%R<SPO
M=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#145&
M1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.
M+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($9U<FYI='5R93PO
M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/C$P('EE87)S/"]T9#X-"B`\
M+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@
M/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@
M+3%E;2<^#0H@3&%B;W)A=&]R>2!A;F0@;V9F:6-E(&5Q=6EP;65N=#PO<#X-
M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/C4@>65A<G,\+W1D/@T*(#PO='(^
M#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A
M;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[
M(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!,96%S96AO;&0@:6UP<F]V96UE;G1S
M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@4VAO<G1E<B8C>$$P
M.V]F)B-X03`[;&5A<V4F(WA!,#MT97)M)B-X03`[;W(F(WA!,#MU<V5F=6PF
M(WA!,#ML:69E/"]T9#X-"B`\+W1R/@T*(#PO=&%B;&4^#0H@/"]D:78^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#
M;VUP=71A=&EO;B!O9B!"87-I8R!A;F0@1&EL=71E9"!);F-O;64@*$QO<W,I
M(%!E<B!#;VUM;VX@4VAA<F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQD:78^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($U!4D=)3BU43U`Z(#!P=#L@5$585"U)3D1%3E0Z(#0E)SX-"B!"87-I8R!A
M;F0@9&EL=71E9"!I;F-O;64@*&QO<W,I('!E<B!C;VUM;VX@<VAA<F4@:7,@
M8V]M<'5T960@87,-"B!F;VQL;W=S("AI;B!T:&]U<V%N9',@97AC97!T('-H
M87)E(&%N9"!P97(@<VAA<F4@9&%T82DZ/"]P/@T*(#QP('-T>6QE/3-$)TU!
M4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,G!T.R!-05)'24XM5$]0
M.B`P<'0G/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"3U)$
M15(M0T],3$%04T4Z(&-O;&QA<'-E)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A
M9&1I;F<],T0P('=I9'1H/3-$.3(E(&%L:6=N/3-$8V5N=&5R(&)O<F1E<CTS
M1#`^#0H@/'1R/@T*(#QT9"!W:61T:#TS1#4X)3X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Y)3X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT
M9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0X)3X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0X)3X\+W1D/@T*
M(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#PO='(^#0H@
M/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI
M9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0Q,"!A;&EG;CTS1&-E;G1E
M<CX\8CY996%R($5N9&5D#0H@1&5C96UB97(F(WA!,#LS,2P\+V(^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\
M='(@<W1Y;&4],T0G1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED
M)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^
M/&(^,C`Q-#PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O
M;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT
M97(^/&(^,C`Q,SPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T
M('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C
M96YT97(^/&(^,C`Q,CPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L;W(]
M,T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@3F5T
M(&EN8V]M92`H;&]S<RD\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#,X
M+#,Q,SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^*28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@R-C$\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/BDF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@86QI9VX],T1R:6=H=#XX+#,V,CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R
M/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E
M;2<^#0H@3&5S<SH@=6YD:7-T<FEB=71E9"!E87)N:6YG<R!A;&QO8V%T960@
M=&\@<&%R=&EC:7!A=&EN9PT*('-E8W5R:71I97,\+W`^#0H@/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I
M9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$
M<FEG:'0^#0H@)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#@L,S8R/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\+W1R
M/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE
M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^
M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$
M)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@
M/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\
M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X
M03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S
M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[
M/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L
M:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G
M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^
M#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A
M;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[
M(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!.970@:6YC;VUE("AL;W-S*2!A;&QO
M8V%B;&4@=&\@8V]M;6]N('-H87)E<SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH,S@L,S$S
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^*#(V,3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P(&%L:6=N/3-$<FEG:'0^#0H@)B-X,C`Q-#LF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P
M(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S
M<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0
M.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@
M(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="
M3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]2
M1$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T
M9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG
M/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM
M3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@0F%S:6,@=V5I9VAT
M960@879E<F%G92!C;VUM;VX@<VAA<F5S(&]U='-T86YD:6YG/"]P/@T*(#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^,C<L,S@T+#DY,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H
M=#XV+#@T-RPV.3<\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P
M/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,2PP.#,L,C<V
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C
M;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-
M"B!"87-I8R!I;F-O;64@*&QO<W,I('!E<B!C;VUM;VX@<VAA<F4\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^*#$N-#`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P/BDF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH,"XP-#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I
M9VAT/C`N,#`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M
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M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H
M=#XH,C8Q/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#XI)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^."PS-C(\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\
M=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z
M(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($QE<W,Z('5N9&ES=')I8G5T
M960@96%R;FEN9W,@86QL;V-A=&5D('1O('!A<G1I8VEP871I;F<@<V5C=7)I
M=&EE<PT*(&%N9"!O=&AE<B!A9&0M8F%C:W,@=&\@;F5T(&EN8V]M92`H;&]S
M<RD\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG
M;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^
M#0H@)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^*#@L,S8R/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&
M3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P
M,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P
M,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M
M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0
M.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G
M0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]2
M1$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D
M/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^
M#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,
M1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!.970@:6YC;VUE("AL
M;W-S*2!A;&QO8V%B;&4@=&\@8V]M;6]N('-H87)E<SPO<#X-"B`\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H
M=#XH,S@L,S$S/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#(V,3PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M;F]W<F%P/3-$;F]W<F%P/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^#0H@)B-X,C`Q-#LF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0
M.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@
M(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="
M3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]2
M1$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T
M9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S
M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P
M.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y
M;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\
M+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T
M;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.
M1$5.5#H@+3%E;2<^#0H@0F%S:6,@=V5I9VAT960@879E<F%G92!C;VUM;VX@
M<VAA<F5S(&]U='-T86YD:6YG/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,C<L,S@T
M+#DY,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XV+#@T-RPV.3<\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^,2PP.#,L,C<V/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-
M"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4
M.B`M,65M)SX-"B!%9F9E8W0@;V8@9&EL=71I=F4@<V5C=7)I=&EE<SPO<#X-
M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG
M:'0^#0H@)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X-"B`F(W@R
M,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO
M=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$
M)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@
M(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P
M,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%
M4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4
M3U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\
M=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS
M1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*
M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="
M3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO
M=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ
M96TG/@T*($1I;'5T960@=V5I9VAT960@879E<F%G92!C;VUM;VX@<VAA<F5S
M(&]U='-T86YD:6YG/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,C<L,S@T+#DY,#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XV+#@T-RPV.3<\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^,2PP.#,L,C<V/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^
M#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4]
M,T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^
M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$
M)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*
M(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@
M/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF
M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP
M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X
M03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@
M9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O
M=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@
M/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*
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M='1O;2!A;&EG;CTS1')I9VAT/B@Q+C0P/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#`N,#0\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/BDF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#XP+C`P/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@
M/"]T86)L93X-"B`\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E-C:&5D=6QE(&]F($%N=&ED:6QU=&EV92!3
M96-U<FET:65S($5X8VQU9&5D(&9R;VT@=&AE($-A;&-U;&%T:6]N(&]F($1I
M;'5T960@26YC;VUE("A,;W-S*2!097(@4VAA<F4\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQD:78^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/
M5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$14Y4.B`T
M)2<^#0H@5&AE(&9O;&QO=VEN9R!C;VUM;VX@<W1O8VL@97%U:79A;&5N=',@
M=V5R92!E>&-L=61E9"!F<F]M('1H90T*(&-A;&-U;&%T:6]N(&]F(&1I;'5T
M960@;F5T(&EN8V]M92`H;&]S<RD@<&5R('-H87)E(&)E8V%U<V4@=&AE:7(-
M"B!E9F9E8W0@=V]U;&0@8F4@86YT:2UD:6QU=&EV93H\+W`^#0H@/'`@<W1Y
M;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$R<'0[($U!
M4D=)3BU43U`Z(#!P="<^#0H@)B-X03`[/"]P/@T*(#QT86)L92!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4G(&-E;&QS<&%C:6YG/3-$
M,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Y,B4@86QI9VX],T1C96YT97(@
M8F]R9&5R/3-$,#X-"B`\='(^#0H@/'1D('=I9'1H/3-$-C,E/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/CPO=&0^#0H@/'1D/CPO
M=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#,E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^
M#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E
M/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@
M/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`X<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@
M,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#$P(&%L:6=N
M/3-$8V5N=&5R/CQB/EEE87(@16YD960-"B!$96-E;6)E<B8C>$$P.S,Q+#PO
M8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q
M<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS
M1&-E;G1E<CX\8CXR,#$T/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P
M,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG
M;CTS1&-E;G1E<CX\8CXR,#$S/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P
M,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A
M;&EG;CTS1&-E;G1E<CX\8CXR,#$R/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@
M8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M
M)SX-"B!397)I97,@02TQ(%!R969E<G)E9"!3=&]C:SPO<#X-"B`\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$
M<FEG:'0^#0H@)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX]
M,T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XR+#$U-BPQ,30\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$
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M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C,Y,BPR-S0\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R
M/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(%-E
M<FEE<R!"(%!R969E<G)E9"!3=&]C:SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^#0H@
M)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X-
M"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#XT+#,S-BPP,S<\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T
M<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ
M96TG/@T*(%-E<FEE<R!#(%!R969E<G)E9"!3=&]C:SPO<#X-"B`\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$
M<FEG:'0^#0H@)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX]
M,T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XU+#DP.2PY,#8\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#145&
M1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.
M+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(%-E<FEE<R!$(%!R
M969E<G)E9"!3=&]C:SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO
M=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^#0H@)B-X,C`Q-#LF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P
M/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M;F]W<F%P/3-$;F]W<F%P/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T
M.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R
M:6=H=#XW-CDL-#8X/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!397)I
M97,@1"TR(%!R969E<G)E9"!3=&]C:SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^#0H@
M)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X-
M"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#XS+#,Y,2PY.3$\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T
M<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@
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M='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T
M.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R
M:6=H=#XQ,RPQ.#DL.3(P/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO
M=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^#0H@)B-X
M,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\
M='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE
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M<F%P/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$X,"PW
M.#0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B
M9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG
M/@T*(%-T;V-K($]P=&EO;G,\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R
M:6=H=#XR+#`Y-"PY,#0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^,BPS,3,L.3<P/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO
M=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT/C,L,C0Y+#<P,CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#PO
M=&%B;&4^#0H@/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y3=6UM87)Y(&]F(%-I9VYI9FEC86YT(%)E=F5N
M=64@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4W5M;6%R>2!O9B!097)C96YT86=E(&]F($-U<W1O;65R($-O;F-E;G1R871I
M;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78^#0H@/'`@
M<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#!P
M=#L@5$585"U)3D1%3E0Z(#0E)SX-"B!4:&4@9F]L;&]W:6YG('1A8FQE(&EN
M8VQU9&5S('1H;W-E(&-O;&QA8F]R871O<G,@=&AA="!R97!R97-E;G0-"B!M
M;W)E('1H86X@,3`E(&]F('1O=&%L(')E=F5N=64@96%R;F5D(&EN('1H92!P
M97)I;V1S(&EN9&EC871E9#H\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/
M5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$R<'0[($U!4D=)3BU43U`Z(#!P="<^
M#0H@)B-X03`[/"]P/@T*(#QT86)L92!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)/4D1%4BU#3TQ,
M05!313H@8V]L;&%P<V4G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS
M1#`@=VED=&@],T0X-"4@86QI9VX],T1C96YT97(@8F]R9&5R/3-$,#X-"B`\
M='(^#0H@/'1D('=I9'1H/3-$-C8E/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#DE/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^
M#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#@E
M/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#@E/CPO=&0^#0H@/'1D/CPO
M=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y
M;&4],T0G1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI
M9VX],T1B;W1T;VT@8V]L<W!A;CTS1#$P(&%L:6=N/3-$8V5N=&5R/@T*(#QB
M/EEE87(F(WA!,#M%;F1E9"8C>$$P.T1E8V5M8F5R)B-X03`[,S$L/"]B/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#PO='(^
M#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S
M;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N
M=&5R/@T*(#QB/B8C>$$P.R8C>$$P.R8C>$$P.R8C>$$P.S(P,30F(WA!,#LF
M(WA!,#LF(WA!,#LF(WA!,#L\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\
M+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P
M="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$
M8V5N=&5R/@T*(#QB/B8C>$$P.R8C>$$P.R8C>$$P.R8C>$$P.S(P,3,F(WA!
M,#LF(WA!,#LF(WA!,#LF(WA!,#L\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P
M(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N
M/3-$8V5N=&5R/@T*(#QB/B8C>$$P.R8C>$$P.R8C>$$P.R8C>$$P.S(P,3(F
M(WA!,#LF(WA!,#LF(WA!,#LF(WA!,#L\+V(^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ
M96TG/@T*(%-E<G9I97(\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H
M=#XS-BXT/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#XE)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XU,2XV/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XE)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@86QI9VX],T1R:6=H=#XQ-RXS/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#XE)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT
M<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@
M0F]E:')I;F=E<CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(X
M+C8\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M/B4F(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(T+C@\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B4F(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
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M<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$
M14Y4.B`M,65M)SX-"B!486ME9&$\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1R:6=H=#XQ-BXX/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XE)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P(&%L:6=N/3-$<FEG:'0^#0H@)B-X,C`Q-#LF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\
M=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z
M(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($=I;&5A9#PO<#X-"B`\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!A;&EG;CTS1')I9VAT/C$Q+C0\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B4F(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT/C$S+C@\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P
M/3-$;F]W<F%P/B4F(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P
M/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^#0H@)B-X,C`Q-#LF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B
M9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG
M/@T*($5L:2!,:6QL>3PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M/C`N.3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^)28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,2XT/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XE)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#XT."XY/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<#XE)B-X03`[/"]T9#X-"B`\+W1R/@T*(#PO=&%B
M;&4^#0H@/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y3=6UM87)Y(&]F(%-I9VYI9FEC86YT($%C8V]U;G1S
M(%)E8V5I=F%B;&5;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y3=6UM87)Y(&]F(%!E<F-E;G1A9V4@;V8@0W5S=&]M97(@0V]N
M8V5N=')A=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I
M=CX-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.
M+51/4#H@,3)P=#L@5$585"U)3D1%3E0Z(#0E)SX-"B!4:&4@9F]L;&]W:6YG
M('1A8FQE(&EN8VQU9&5S('1H;W-E(&-O;&QA8F]R871O<G,@=&AA="!R97!R
M97-E;G0-"B!M;W)E('1H86X@,3`E(&]F(&%C8V]U;G1S(')E8V5I=F%B;&4@
M870@=&AE(&1A=&4@:6YD:6-A=&5D.CPO<#X-"B`\<"!S='EL93TS1"=-05)'
M24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3)P=#L@34%21TE.+51/4#H@
M,'!T)SX-"B`F(WA!,#L\+W`^#0H@/'1A8FQE('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D]21$52
M+4-/3$Q!4%-%.B!C;VQL87!S92<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D
M:6YG/3-$,"!W:61T:#TS1#<V)2!A;&EG;CTS1&-E;G1E<B!B;W)D97(],T0P
M/@T*(#QT<CX-"B`\=&0@=VED=&@],T0W-24^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,3`E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D
M/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#DE/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO
M=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`X<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P
M,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#8@
M86QI9VX],T1C96YT97(^/&(^1&5C96UB97(F(WA!,#LS,2P\+V(^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\
M='(@<W1Y;&4],T0G1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED
M)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^
M#0H@/&(^)B-X03`[)B-X03`[)B-X03`[)B-X03`[,C`Q-"8C>$$P.R8C>$$P
M.R8C>$$P.R8C>$$P.SPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^
M#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O
M;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT
M97(^#0H@/&(^)B-X03`[)B-X03`[)B-X03`[)B-X03`[,C`Q,R8C>$$P.R8C
M>$$P.R8C>$$P.R8C>$$P.SPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L
M;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@
M4V5R=FEE<CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C,S+C,\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B4F
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C8N-#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)28C>$$P.SPO=&0^#0H@/"]T
M<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ
M96TG/@T*($)O96AR:6YG97(\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R
M:6=H=#XR,2XR/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#XE)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ,BXR/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XE)B-X03`[
M/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L;W(],T0C0T-%
M149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'
M24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@1W)E96X@0W)O
M<W,\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ-RXY/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XE)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS
M1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O
M<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$
M14Y4.B`M,65M)SX-"B!':6QE860\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C
M>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I
M9VAT/C4S+C0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P/B4F(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@
M8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M
M)SX-"B!09FEZ97(\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$R+C,\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B4F
M(WA!,#L\+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\+V1I=CX\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B
M;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7SAD8C4S-V,T7V4X
M-SA?-&$S95\X,CAA7V(U,#!F,V5D9C$Q9@T*0V]N=&5N="U,;V-A=&EO;CH@
M9FEL93HO+R]#.B\X9&(U,S=C-%]E.#<X7S1A,V5?.#(X85]B-3`P9C-E9&8Q
M,68O5V]R:W-H965T<R]3:&5E=#(R+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M
M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X
M="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D
M/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N
M=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS
M1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO
M=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-
M"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O
M=W-P86X],T0R/CQS=')O;F<^4')O<&5R='D@86YD($5Q=6EP;65N="`H5&%B
M;&5S*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S
M,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M/'-T<F]N9SY0<F]P97)T>2P@4&QA;G0@86YD($5Q=6EP;65N="!;06)S=')A
M8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E-C:&5D=6QE(&]F(%!R;W!E<G1Y(&%N9"!%<75I<&UE;G0\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78^#0H@/'`@<W1Y;&4],T0G34%2
M1TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#9P=#L@5$585"U)3D1%
M3E0Z(#0E)SX-"B!0<F]P97)T>2!A;F0@97%U:7!M96YT(&-O;G-I<W1S(&]F
M('1H92!F;VQL;W=I;F<@*&EN#0H@=&AO=7-A;F1S*3H\+W`^#0H@/'`@<W1Y
M;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$R<'0[($U!
M4D=)3BU43U`Z(#!P="<^#0H@)B-X03`[/"]P/@T*(#QT86)L92!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4G(&-E;&QS<&%C:6YG/3-$
M,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0W-B4@86QI9VX],T1C96YT97(@
M8F]R9&5R/3-$,#X-"B`\='(^#0H@/'1D('=I9'1H/3-$-S$E/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE/CPO=&0^#0H@/'1D/CPO
M=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#@E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^
M#0H@/'1D/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%
M.B`X<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L
M<W!A;CTS1#8@86QI9VX],T1C96YT97(^/&(^1&5C96UB97(F(WA!,#LS,2P\
M+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`X<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@
M,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX]
M,T1C96YT97(^/&(^,C`Q-#PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P
M,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI
M9VX],T1C96YT97(^/&(^,C`Q,SPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G
M8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^
M#0H@0V]M<'5T97(@97%U:7!M96YT/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I
M9VAT/C(L-3DV/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR+#,W
M.3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*
M(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&
M5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@4V]F='=A<F4\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ+#8X,SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ+#0W-SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-
M"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L;W(],T0C0T-%149&/@T*
M(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&
M5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@1G5R;FET=7)E(&%N9"!O
M9F9I8V4@97%U:7!M96YT/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^-S4Q/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C8U
M,3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*
M(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&
M5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@3&%B(&5Q=6EP;65N=#PO
M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$S+#DQ-SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ,2PQ-C8\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#
M145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%2
M1TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($QE87-E:&]L
M9"!I;7!R;W9E;65N=',\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H
M=#XU+#$Y,SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XT
M+#@Y-#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&
M3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P
M,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P
M,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M
M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0
M.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D
M/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@
M=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E
M;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(%!R;W!E<G1Y(&%N9"!E<75I<&UE
M;G0\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XR-"PQ-#`\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^,C`L-38W/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO
M=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS
M1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M
M24Y$14Y4.B`M,65M)SX-"B!,97-S(&%C8W5M=6QA=&5D(&1E<')E8VEA=&EO
M;CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!A;&EG;CTS1')I9VAT/B@Q-RPS-34\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/BDF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I
M9VAT/B@Q-2PU,S(\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P
M/3-$;F]W<F%P/BDF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$
M)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@
M(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P
M,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%
M4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4
M3U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\
M=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT
M9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@
M,V5M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@4')O<&5R='D@86YD(&5Q=6EP
M;65N="P@;F5T/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C8L-S@U/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R
M:6=H=#XU+#`S-3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL
M93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4
M3U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0
M.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT
M9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$
M)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*
M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="
M3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\
M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\
M+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T
M86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T
M7SAD8C4S-V,T7V4X-SA?-&$S95\X,CAA7V(U,#!F,V5D9C$Q9@T*0V]N=&5N
M="U,;V-A=&EO;CH@9FEL93HO+R]#.B\X9&(U,S=C-%]E.#<X7S1A,V5?.#(X
M85]B-3`P9C-E9&8Q,68O5V]R:W-H965T<R]3:&5E=#(S+FAT;6P-"D-O;G1E
M;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E
M;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT
M;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT
M+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS
M8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J
M($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D
M/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)
M1#!%2T@^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O
M;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^4W1O8VLM8F%S960@0V]M
M<&5N<V%T:6]N("A486)L97,I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/D1I<V-L;W-U<F4@;V8@0V]M<&5N<V%T
M:6]N(%)E;&%T960@0V]S=',L(%-H87)E+6)A<V5D(%!A>6UE;G1S(%M!8G-T
M<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4V-H961U;&4@;V8@4W1O8VLM0F%S960@0V]M<&5N<V%T:6]N($5X<&5N
M<V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78^#0H@/'`@
M<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#$R
M<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@5&AE(&9O;&QO=VEN9R!S=&]C:RUB
M87-E9"!C;VUP96YS871I;VX@86UO=6YT<R!W97)E(')E8V]G;FEZ960@9F]R
M#0H@=&AE('!E<FEO9',@:6YD:6-A=&5D("AI;B!T:&]U<V%N9',I.CPO<#X-
M"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@
M,3)P=#L@34%21TE.+51/4#H@,'!T)SX-"B`F(WA!,#L\+W`^#0H@/'1A8FQE
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S92<@8V5L;'-P
M86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#@T)2!A;&EG;CTS
M1&-E;G1E<B!B;W)D97(],T0P/@T*(#QT<CX-"B`\=&0@=VED=&@],T0W-"4^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-24^/"]T9#X-
M"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$-24^/"]T9#X-"B`\=&0^/"]T9#X-"B`\
M=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$-24^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^
M/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#AP=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$
M,3`@86QI9VX],T1C96YT97(^/&(^665A<B!%;F1E9`T*($1E8V5M8F5R)B-X
M03`[,S$L/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\
M+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C
M,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R
M(&%L:6=N/3-$8V5N=&5R/CQB/C(P,30\+V(^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X]
M,T0R(&%L:6=N/3-$8V5N=&5R/CQB/C(P,3,\+V(^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P
M86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/C(P,3(\+V(^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P
M/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%
M3E0Z("TQ96TG/@T*(%)E<V5A<F-H(&%N9"!D979E;&]P;65N=#PO<#X-"B`\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@86QI9VX],T1R:6=H=#XQ+#4V,CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^-3`W/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO
M=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H
M=#XT-S(\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.
M+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($=E;F5R86P@86YD
M(&%D;6EN:7-T<F%T:79E/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^,2PV.#(\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M,S4U/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C,V-CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X
M03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)
M6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@
M,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X
M('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C
M,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P
M,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52
M+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/
M4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT
M9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO
M<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!4
M;W1A;"!S=&]C:RUB87-E9"!C;VUP96YS871I;VX@97AP96YS93PO<#X-"B`\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1R:6=H=#XS+#(T-#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^.#8R/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1R:6=H=#XX,S@\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@
M<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$
M15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52
M+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-
M"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL
M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO
M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4]
M,T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^
M#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-
M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G
M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@
M/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF
M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*
M(#PO=&%B;&4^#0H@/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y38VAE9'5L92!O9B!3:&%R92UB87-E9"!0
M87EM96YT($%W87)D+"!3=&]C:R!/<'1I;VYS+"!686QU871I;VX@07-S=6UP
M=&EO;G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78^#0H@
M/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!72$E412U34$%#13H@
M;F]R;6%L.R!415A4+51204Y31D]233H@;F]N93L@5T]21"U34$%#24Y'.B`P
M<'@[($-/3$]2.B!R9V(H,"PP+#`I.R!&3TY4.B`Q,'!T("=4:6UE<R!.97<@
M4F]M86XG.R!-05)'24XM5$]0.B`V<'0[($Q%5%1%4BU34$%#24Y'.B!N;W)M
M86P[(%1%6%0M24Y$14Y4.B`T)3L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T
M:#H@,'!X)SX-"B!4:&4@9F%I<B!V86QU92!O9B!E86-H(&]P=&EO;B!A=V%R
M9"!I<R!E<W1I;6%T960@;VX@=&AE(&1A=&4@;V8-"B!G<F%N="!U<VEN9R!T
M:&4@0FQA8VLM4V-H;VQE<R!O<'1I;VXM<')I8VEN9R!M;V1E;"!U<VEN9R!T
M:&4-"B!A<W-U;7!T:6]N<R!I;B!T:&4@9F]L;&]W:6YG('1A8FQE.CPO<#X-
M"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[(%=(251%+5-004-%
M.B!N;W)M86P[(%1%6%0M5%)!3E-&3U)-.B!N;VYE.R!73U)$+5-004-)3D<Z
M(#!P>#L@0T],3U(Z(')G8B@P+#`L,"D[($9/3E0Z(#$R<'0@)U1I;65S($YE
M=R!2;VUA;B<[($U!4D=)3BU43U`Z(#!P=#L@3$545$52+5-004-)3D<Z(&YO
M<FUA;#L@5$585"U)3D1%3E0Z(#!P>#L@+7=E8FMI="UT97AT+7-T<F]K92UW
M:61T:#H@,'!X)SX-"B`F(WA!,#L\+W`^#0H@/'1A8FQE('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M86XG
M.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E.R!415A4+51204Y31D]233H@
M;F]N93L@5T]21"U34$%#24Y'.B`P<'@[($Q%5%1%4BU34$%#24Y'.B!N;W)M
M86P[(%1%6%0M24Y$14Y4.B`P<'@[("UW96)K:70M=&5X="US=')O:V4M=VED
M=&@Z(#!P>"<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T
M:#TS1#@T)2!A;&EG;CTS1&-E;G1E<B!B;W)D97(],T0P/@T*(#QT<CX-"B`\
M=&0@=VED=&@],T0U."4^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,R4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,R4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,R4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\+W1R
M/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ
M("=4:6UE<R!.97<@4F]M86XG)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I
M(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0U(&%L:6=N
M/3-$8V5N=&5R/CQB/EEE87(@16YD960@1&5C96UB97(F(WA!,#LS,2P\+V(^
M/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#AP=#L@
M1D].5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M86XG)SX-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B!R9V(H,"PP+#`I(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$8V5N=&5R/CQB/C(P,30\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ(')G8B@P+#`L,"D@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1C96YT97(^/&(^,C`Q,SPO8CX\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@<F=B*#`L,"PP*2`Q<'0@<V]L:60G('9A;&EG;CTS1&)O
M='1O;2!A;&EG;CTS1&-E;G1E<CX\8CXR,#$R/"]B/CPO=&0^#0H@/"]T<CX-
M"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M)U1I;65S($YE=R!2;VUA;B<G(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V
M86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<[($U!4D=)3BU,1494.B`Q
M96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!%>'!E8W1E9"!D:79I9&5N9"!Y
M:65L9#PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$8V5N
M=&5R/C`E/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1&-E;G1E<CXP
M)3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1C96YT97(^,"4\+W1D
M/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M86XG)SX-"B`\=&0@=F%L:6=N/3-$
M=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ("=4:6UE<R!.97<@4F]M86XG.R!-05)'24XM3$5&5#H@,65M.R!415A4
M+4E.1$5.5#H@+3%E;2<^#0H@17AP96-T960@=F]L871I;&ET>3PO<#X-"B`\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$8V5N=&5R/C8W)3PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4]
M,T0G5TA)5$4M4U!!0T4Z(&YO=W)A<"<^-3,E)B-X03`[+28C>$$P.S8W)3PO
M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$8V5N=&5R/C4Q
M)3PO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<G(&)G8V]L;W(],T0C
M0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<[
M($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!2:7-K
M+69R964@:6YT97)E<W0@<F%T93PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)U=(251%+5-004-%
M.B!N;W=R87`G/C$N."4F(WA!,#LM)B-X03`[,BXS)3PO9F]N=#X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$
M)U=(251%+5-004-%.B!N;W=R87`G/C$N,B4F(WA!,#LM)B-X03`[,BXR)3PO
M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$8V5N=&5R/C$N
M,B4\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M86XG)SX-"B`\=&0@=F%L
M:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M86XG.R!-05)'24XM3$5&5#H@,65M
M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@17AP96-T960@=&5R;2X\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1&-E;G1E<CXV+C(U('EE
M87)S/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1&-E;G1E<CXW('EE
M87)S/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1&-E;G1E<CXW)B-X
M03`[>65A<G,\+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`-"B`-"B`\+V1I
M=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E-C:&5D=6QE(&]F(%-T;V-K($]P=&EO;B!A;F0@4F5S=')I8W1E9"!3
M=&]C:R!5;FET($%C=&EV:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\9&EV/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4G/@T*(%1H92!F
M;VQL;W=I;F<@=&%B;&4@<W5M;6%R:7IE<R!S=&]C:R!O<'1I;VX@86YD(')E
M<W1R:6-T960@<W1O8VL-"B!U;FET("A24U4I(&%C=&EV:71Y(&9O<B`R,#$T
M.CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M
M4TE:13H@,3)P=#L@34%21TE.+51/4#H@,'!T)SX-"B`F(WA!,#L\+W`^#0H@
M/'1A8FQE('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S92<@
M8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#DR)2!A
M;&EG;CTS1&-E;G1E<B!B;W)D97(],T0P/@T*(#QT<CX-"B`\=&0@=VED=&@]
M,T0T,R4^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24^
M/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$."4^/"]T9#X-"B`\=&0^/"]T
M9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$.24^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-
M"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24^
M/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\
M+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q
M<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS
M1&-E;G1E<CX\8CY3:&%R97,\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P
M,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L
M:6=N/3-$8V5N=&5R/CQB/E=E:6=H=&5D+3QB<B`O/@T*($%V97)A9V4\+V(^
M/&)R("\^#0H@/&(^17AE<F-I<V4F(WA!,#M0<FEC93PO8CX\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@
M8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&(^/&9O;G0@<W1Y;&4],T0G
M5TA)5$4M4U!!0T4Z(&YO=W)A<"<^5V5I9VAT960M079E<F%G93PO9F]N=#X\
M+V(^/&)R("\^#0H@/&(^4F5M86EN:6YG/"]B/CQB<B`O/@T*(#QB/D-O;G1R
M86-T=6%L(%1E<FT\+V(^/&)R("\^#0H@/&(^*%EE87)S*3PO8CX\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T
M;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&(^06=G<F5G871E/&)R
M("\^#0H@26YT<FEN<VEC/&)R("\^#0H@5F%L=64\+V(^/&)R("\^#0H@/&(^
M*&EN)B-X03`[=&AO=7-A;F1S*3PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G
M8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^
M#0H@3W5T<W1A;F1I;F<L($1E8V5M8F5R)B-X03`[,S$L(#(P,3,\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^
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M1&)O='1O;2!A;&EG;CTS1')I9VAT/C0N.3`\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^-BXY/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-
M05)'24XM3$5&5#H@,V5M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@1W)A;G1E
M9#PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CDW-BPX-CD\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,C<N,#8\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#QT
M<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX]
M,T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,V5M.R!415A4
M+4E.1$5.5#H@+3%E;2<^#0H@17AE<F-I<V5D/"]P/@T*(#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^*#4V."PY,#8\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/BDF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG
M;CTS1')I9VAT/C$N,S$\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI
M9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,V5M.R!4
M15A4+4E.1$5.5#H@+3%E;2<^#0H@1F]R9F5I=&5D(&]R(&5X<&ER960\+W`^
M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH,S8L.#`U/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XY+C<V/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G
M1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C
M,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P
M,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B
M9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG
M/@T*($]U='-T86YD:6YG+"!$96-E;6)E<B8C>$$P.S,Q+"`R,#$T/"]P/@T*
M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^,RPU-S(L,3$V/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I
M9VAT/C$Q+C0P/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C<N,SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^.#0L-3$U/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@
M/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G
M0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/
M4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO
M=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/"]T<CX-"B`\
M='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*
M($1E8V5M8F5R)B-X03`[,S$L(#(P,30Z/"]P/@T*(#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@
M/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG
M;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`S96T[(%1%
M6%0M24Y$14Y4.B`M,65M)SX-"B!%>&5R8VES86)L93PO<#X-"B`\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT/C$L-C8X+#DV,CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XS+C(T
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C4N,SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1R:6=H=#XU,RPQ,C(\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@34%21TE.+4Q%1E0Z(#-E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(%9E
M<W1E9"!A;F0@97AP96-T960@=&\@=F5S=#PO<#X-"B`\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M/C,L,S0Q+#$Y,CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ,2XP,SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@86QI9VX],T1R:6=H=#XW+C(\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^.#`L,S(S/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/"]T86)L93X-
M"B`\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'10
M87)T7SAD8C4S-V,T7V4X-SA?-&$S95\X,CAA7V(U,#!F,V5D9C$Q9@T*0V]N
M=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\X9&(U,S=C-%]E.#<X7S1A,V5?
M.#(X85]B-3`P9C-E9&8Q,68O5V]R:W-H965T<R]3:&5E=#(T+FAT;6P-"D-O
M;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O
M;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*
M/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT
M96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G
M/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS
M/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H
M96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60]
M,T1)1#!%2T@^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L
M(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^26YC;VUE(%1A>&5S
M("A486)L97,I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$
M96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#X\<W1R;VYG/DEN8V]M92!487@@1&ES8VQO<W5R92!;06)S=')A8W1=
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O
M;7!O;F5N=',@;V8@=&AE($-O;7!A;GDG<R!$969E<G)E9"!);F-O;64@5&%X
M($%S<V5T<R`H3&EA8FEL:71I97,I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\9&EV/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P
M=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!-05)'24XM5$]0.B`P<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@5&AE
M('-I9VYI9FEC86YT(&-O;7!O;F5N=',@;V8@=&AE($-O;7!A;GDF(W@R,#$Y
M.W,@9&5F97)R960@:6YC;VUE#0H@=&%X(&%S<V5T<R`H;&EA8FEL:71I97,I
M('=E<F4@87,@9F]L;&]W<R`H:6X@=&AO=7-A;F1S*3H\+W`^#0H@/'`@<W1Y
M;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$R<'0[($U!
M4D=)3BU43U`Z(#!P="<^#0H@)B-X03`[/"]P/@T*(#QT86)L92!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4G(&-E;&QS<&%C:6YG/3-$
M,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0W-B4@86QI9VX],T1C96YT97(@
M8F]R9&5R/3-$,#X-"B`\='(^#0H@/'1D('=I9'1H/3-$-S$E/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#@E/CPO=&0^#0H@/'1D/CPO
M=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#<E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^
M#0H@/'1D/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%
M.B`X<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L
M<W!A;CTS1#8@86QI9VX],T1C96YT97(^/&(^1&5C96UB97(F(WA!,#LS,2P\
M+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`X<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@
M,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX]
M,T1C96YT97(^/&(^,C`Q-#PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P
M,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI
M9VX],T1C96YT97(^/&(^,C`Q,SPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G
M8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^
M#0H@1&5F97)R960@:6YC;VUE('1A>"!A<W-E=',Z/"]P/@T*(#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG
M/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM
M3$5&5#H@,V5M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@1F5D97)A;"!5+E,N
M(&YE="!O<&5R871I;F<@;&]S<R!C87)R>69O<G=A<F0\+W`^#0H@/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^-34L,S4X/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1R:6=H=#XS-BPU-C$\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$
M=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E;3L@5$585"U)
M3D1%3E0Z("TQ96TG/@T*(%-T871E(&YE="!O<&5R871I;F<@;&]S<R!C87)R
M>69O<G=A<F0\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XS+#<R
M,SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XS+#,Q-CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X
M03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT
M9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@
M,V5M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@4F5S96%R8V@@86YD(&1E=F5L
M;W!M96YT(&-R961I="P@;F5T/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^-RPQ-S<\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P
M/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^,RPW.#8\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*
M(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E;3L@5$585"U)3D1%3E0Z
M("TQ96TG/@T*($]R<&AA;B!D<G5G(&-R961I="P@;F5T/"]P/@T*(#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^,3DL,C@W/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!A;&EG;CTS1')I9VAT/C$Y+#@X,SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\
M+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@
M/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,V5M.R!415A4+4E.1$5.5#H@
M+3%E;2<^#0H@1&5F97)R960@<F5N=#PO<#X-"B`\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG
M;CTS1')I9VAT/C0L,#8Y/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO
M=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT/C4L,3,R/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O
M<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`S96T[(%1%6%0M24Y$
M14Y4.B`M,65M)SX-"B!$969E<G)E9"!R979E;G5E/"]P/@T*(#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^,RPY.#D\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^."PR,3<\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-
M"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E;3L@5$585"U)3D1%3E0Z("TQ96TG
M/@T*($1E<')E8VEA=&EO;CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I
M9VAT/C$L,S,W/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M/C$L-#,X/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\
M<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`S96T[(%1%6%0M24Y$14Y4.B`M
M,65M)SX-"B!/=&AE<CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M/CDV,CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ+#0S
M.3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4
M+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P
M,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@
M,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0
M.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C
M,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C
M>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L
M:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E;3L@
M5$585"U)3D1%3E0Z("TQ96TG/@T*($=R;W-S(&1E9F5R<F5D(&EN8V]M92!T
M87@@87-S971S/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^.34L.3`R/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/C<Y+#<W,CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R
M/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V
M86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,V5M
M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@5F%L=6%T:6]N(&%L;&]W86YC93PO
M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!A;&EG;CTS1')I9VAT/B@Y-"PR.3<\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/BDF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M/B@W.2PS-S<\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P/BDF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/
M3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P
M,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P
M,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4
M3U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z
M(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^
M)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V
M86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M
M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@3F5T(&1E9F5R<F5D(&EN8V]M92!T
M87@@87-S971S/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,2PV,#4\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^,SDU/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@
M/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG
M;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%
M6%0M24Y$14Y4.B`M,65M)SX-"B!$969E<G)E9"!I;F-O;64@=&%X(&QI86)I
M;&ET:65S.CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-
M"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%
M1E0Z(#-E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(%!R97!A:60@97AP96YD
M:71U<F5S/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#$L-C`U/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1R:6=H=#XH,SDU/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS
M1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z
M(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P
M,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$
M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M
M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@
M/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O
M;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@34%21TE.+4Q%1E0Z(#-E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*
M($=R;W-S(&1E9F5R<F5D(&EN8V]M92!T87@@;&EA8FEL:71I97,\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#XH,2PV,#4\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P/BDF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@S.34\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/BDF
M(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A
M;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[
M(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!.970@9&5F97)R960@:6YC;VUE('1A
M>"!A<W-E="\H;&EA8FEL:71Y*3PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XD/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS
M1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@
M/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF
M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP
M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X
M03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@
M9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O
M=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@
M/"]T<CX-"B`\+W1A8FQE/@T*(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5C;VYC:6QI871I;VX@;V8@
M4F5P;W)T960@17-T:6UA=&5D($EN8V]M92!487@@0F5N969I=#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=CX-"B`\<"!S='EL93TS1"=-
M05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
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M:7,@87,@9F]L;&]W<R`H:6X@=&AO=7-A;F1S*3H\+W`^#0H@/'`@<W1Y;&4]
M,T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$R<'0[($U!4D=)
M3BU43U`Z(#!P="<^#0H@)B-X03`[/"]P/@T*(#QT86)L92!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4G(&-E;&QS<&%C:6YG/3-$,"!C
M96QL<&%D9&EN9STS1#`@=VED=&@],T0X-"4@86QI9VX],T1C96YT97(@8F]R
M9&5R/3-$,#X-"B`\='(^#0H@/'1D('=I9'1H/3-$-C8E/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#<E/CPO=&0^#0H@/'1D/CPO=&0^
M#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#8E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@
M/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#8E/CPO
M=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/"]T
M<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T
M('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#$P(&%L:6=N/3-$
M8V5N=&5R/CQB/EEE87(@16YD960-"B!$96-E;6)E<B8C>$$P.S,Q+#PO8CX\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\+W1R
M/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@
M<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E
M;G1E<CX\8CXR,#$T/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q
M<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS
M1&-E;G1E<CX\8CXR,#$S/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P
M,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG
M;CTS1&-E;G1E<CX\8CXR,#$R/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C
M;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-
M"B!5;FET960@4W1A=&5S(&9E9&5R86P@=&%X(&%T('-T871U=&]R>2!R871E
M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@Q,RPT,3`\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/BDF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@86QI9VX],T1R:6=H=#XH.3$\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P/BDF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H
M=#XR+#DR-SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XG/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'
M24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@4W1A=&4@=&%X
M97,@*&YE="!O9B!F961E<F%L(&)E;F5F:70I/"]P/@T*(#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^*#$L-C`X/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
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M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^,2PT-C`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*
M(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z
M("TQ96TG/@T*($1E9F5R<F5D(&EN8V]M92!T87@@861J=7-T;65N=',\+W`^
M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@X-34\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/BDF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!A;&EG;CTS1')I9VAT/B@U,3(\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/BDF(WA!,#L\+W1D/@T*(#PO='(^
M#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M
M)SX-"B!$969E<G)E9"!S=&%T92!B;&5N9&5D(')A=&4@861J=7-T;65N=',\
M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XS+#`S-#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH,S0T/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS
M1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO<CTS1"-#0T5%1D8^
M#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,
M1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!297-E87)C:"!C<F5D
M:70L(&YE=#PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@R+#(R
M.#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M*28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#(R-CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI
M9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[
M/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX]
M,T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4
M+4E.1$5.5#H@+3%E;2<^#0H@5')A;G-A8W1I;VX@8V]S="!D961U8W1I;VX\
M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH,S<Y/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG
M;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L
M:6=N/3-$<FEG:'0^#0H@)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#
M145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%2
M1TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(%1R86YS86-T
M:6]N(&-O<W0@9&5D=6-T:6]N)B-X,C`Q-#MP<FEO<B!Y96%R(&%D:G5S=&UE
M;G0\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH-38T/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A
M;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M(&%L:6=N/3-$<FEG:'0^#0H@)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L
M:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@
M5$585"U)3D1%3E0Z("TQ96TG/@T*($]R<&AA;B!D<G5G(&-R961I="P@;F5T
M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#$S.3PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#@T,SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^*#0L.#DV/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT
M<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX]
M,T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4
M+4E.1$5.5#H@+3%E;2<^#0H@3W1H97(@<&5R;6%N96YT(&ET96US/"]P/@T*
M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#,X,CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^,SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1R:6=H=#XX/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!%<75I
M='DM8F%S960@8V]M<&5N<V%T:6]N/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^-S4V/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I
M9VAT/C(T,3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR
M-SD\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B
M9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG
M/@T*($9A:7(@=F%L=64@861J=7-T;65N="!O9B!P<F5F97)R960@<W1O8VL@
M=V%R<F%N="!L:6%B:6QI='D\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P
M,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO
M=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT/C(Q.3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
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M/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494
M.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!#:&%N9V4@:6X@=F%L=6%T
M:6]N(&%L;&]W86YC93PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M/C$T+#DR,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ
M+#(X-SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XW.#<\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P
M(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P
M>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@
M(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P
M,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%
M4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4
M3U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\
M=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L
M;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@
M26YC;VUE('1A>"!E>'!E;G-E+RAB96YE9FET*3PO<#X-"B`\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<#XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XD/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT
M/@T*("8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO
M='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y
M;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\
M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE
M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P
M/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE
M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*
M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^
M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S
M<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X
M(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^
M#0H@/"]T<CX-"B`\+W1A8FQE/@T*(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5C;VYC:6QI871I;VX@
M;V8@=&AE($)E9VEN;FEN9R!A;F0@16YD:6YG($%M;W5N="!O9B!'<F]S<R!5
M;G)E8V]G;FEZ960@5&%X($)E;F5F:71S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\9&EV/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ
M(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4G/@T*
M($$@<F5C;VYC:6QI871I;VX@;V8@=&AE(&)E9VEN;FEN9R!A;F0@96YD:6YG
M(&%M;W5N="!O9B!G<F]S<PT*('5N<F5C;V=N:7IE9"!T87@@8F5N969I=',@
M:7,@87,@9F]L;&]W<R`H:6X@=&AO=7-A;F1S*3H\+W`^#0H@/'`@<W1Y;&4]
M,T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$R<'0[($U!4D=)
M3BU43U`Z(#!P="<^#0H@)B-X03`[/"]P/@T*(#QT86)L92!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4G(&-E;&QS<&%C:6YG/3-$,"!C
M96QL<&%D9&EN9STS1#`@=VED=&@],T0X-"4@86QI9VX],T1C96YT97(@8F]R
M9&5R/3-$,#X-"B`\='(^#0H@/'1D('=I9'1H/3-$-S`E/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#4E/CPO=&0^#0H@/'1D/CPO=&0^
M#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#4E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@
M/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#4E/CPO
M=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/"]T
M<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T
M('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#$P(&%L:6=N/3-$
M8V5N=&5R/CQB/EEE87(@16YD960-"B!$96-E;6)E<B8C>$$P.S,Q+#PO8CX\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\+W1R
M/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@
M<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E
M;G1E<CX\8CXR,#$T/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q
M<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS
M1&-E;G1E<CX\8CXR,#$S/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P
M,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG
M;CTS1&-E;G1E<CX\8CXR,#$R/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C
M;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-
M"B!"96=I;FYI;F<@8F%L86YC93PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H
M=#XQ+#<P.#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,2PU.3(\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$L-3,T/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG
M;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`S96T[(%1%
M6%0M24Y$14Y4.B`M,65M)SX-"B!);F-R96%S97,O*&1E8W)E87-E<RD@9F]R
M(&-U<G)E;G0@>65A<B!T87@@<&]S:71I;VYS/"]P/@T*(#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^,C0R/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG
M;CTS1')I9VAT/C$Q-CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R
M:6=H=#XU.#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XG(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@
M/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,V5M.R!415A4+4E.1$5.5#H@
M+3%E;2<^#0H@26YC<F5A<V5S+RAD96-R96%S97,I(&9O<B!P<FEO<B!Y96%R
M('1A>"!P;W-I=&EO;G,\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H
M=#XY-SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO
M=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^#0H@)B-X,C`Q-#LF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%2
M1TE.+4Q%1E0Z(#-E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($1E8W)E87-E
M<R!A<R!A(')E<W5L="!O9B!E>'!I<F%T:6]N(&]F('-T871U=&4@;V8@;&EM
M:71A=&EO;G,\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO
M=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^#0H@)B-X,C`Q-#LF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL
M93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4
M3U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z
M(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="
M3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$
M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^
M#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y
M;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO
M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4]
M,T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-
M"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-
M"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4
M.B`M,65M)SX-"B!%;F1I;F<@8F%L86YC93PO<#X-"B`\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR+#`T
M-SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^,2PW,#@\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M/C$L-3DR/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$
M)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@
M(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P
M,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]2
M1$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%
M4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^
M#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y
M;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\
M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE
M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P
M/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\+W1A8FQE
M/@T*(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X
M=%!A<G1?.&1B-3,W8S1?93@W.%\T83-E7S@R.&%?8C4P,&8S961F,3%F#0I#
M;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+SAD8C4S-V,T7V4X-SA?-&$S
M95\X,CAA7V(U,#!F,V5D9C$Q9B]7;W)K<VAE971S+U-H965T,C4N:'1M;`T*
M0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*
M0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*
M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O
M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M
M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N
M:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\
M+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I
M9#TS1$E$,$4R1CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY,96%S92!%>&ET
M($QI86)I;&ET>2`H5&%B;&5S*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^/'-T<F]N9SY297-T<G5C='5R:6YG(&%N9"!296QA
M=&5D($%C=&EV:71I97,@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#:&%N9V5S(&EN($QE87-E($5X:70@
M3&EA8FEL:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV
M/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM
M5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4G/@T*($-H86YG97,@:6X@=&AE
M(&QE87-E(&5X:70@;&EA8FEL:71Y(&%R92!A<R!F;VQL;W=S("AI;@T*('1H
M;W5S86YD<RDZ/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P
M=#L@1D].5"U325I%.B`Q,G!T.R!-05)'24XM5$]0.B`P<'0G/@T*("8C>$$P
M.SPO<#X-"B`\=&%B;&4@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"3U)$15(M0T],3$%04T4Z(&-O
M;&QA<'-E)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H
M/3-$-C@E(&%L:6=N/3-$8V5N=&5R(&)O<F1E<CTS1#`^#0H@/'1R/@T*(#QT
M9"!W:61T:#TS1#@T)3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0W)3X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\
M+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO<CTS1"-#0T5%
M1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)
M3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!!8V-R=6%L(&)A
M;&%N8V4@870@1&5C96UB97(F(WA!,#LS,2P@,C`Q,BX\+W`^#0H@/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^)B-X03`[,3`L,#<T/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO
M=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!0
M<FEN8VEP86P@<&%Y;65N=',\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH-C(Y/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X
M03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P
M>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O
M;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED
M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R
M/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V
M86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M
M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@06-C<G5A;"!B86QA;F-E(&%T($1E
M8V5M8F5R)B-X03`[,S$L(#(P,3,\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XY+#0T
M-3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*
M(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&
M5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@4')I;F-I<&%L('!A>6UE
M;G1S/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#$L-#,Y/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\
M+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T
M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\
M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE
M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^
M#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^
M#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.
M5#H@+3%E;2<^#0H@06-C<G5A;"!B86QA;F-E(&%T($1E8V5M8F5R)B-X03`[
M,S$L(#(P,30\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^."PP,#8\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\
M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C
M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@
M<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!
M,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#PO
M=&%B;&4^#0H@/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y&=71U<F4@4')I;F-I<&%L(%!A>6UE;G1S(%5N
M9&5R($QE87-E($%G<F5E;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/&1I=CX-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[
M($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@34%21TE.+51/4#H@,3)P=#L@5$585"U)3D1%3E0Z(#0E)SX-"B!&=71U
M<F4@<')I;F-I<&%L('!A>6UE;G1S('1O(&)E(&UA9&4@=6YD97(@=&AE(&QE
M87-E(&%G<F5E;65N="!A<PT*(&]F($1E8V5M8F5R)B-X03`[,S$L(#(P,30@
M87)E(&%S(&9O;&QO=W,@*&EN('1H;W5S86YD<RDZ/"]P/@T*(#QP('-T>6QE
M/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,G!T.R!-05)'
M24XM5$]0.B`P<'0G/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E)R!C96QL<W!A8VEN9STS1#`@
M8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$-C@E(&%L:6=N/3-$8V5N=&5R(&)O
M<F1E<CTS1#`^#0H@/'1R/@T*(#QT9"!W:61T:#TS1#@V)3X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0X)3X\+W1D/@T*(#QT9#X\+W1D
M/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-
M"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4
M.B`M,65M)SX-"B`R,#$U/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$L-C0R/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG
M;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%
M6%0M24Y$14Y4.B`M,65M)SX-"B`R,#$V/"]P/@T*(#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M,2PX-C8\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ
M96TG/@T*(#(P,3<\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR+#$Q,SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X
M03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI
M9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!4
M15A4+4E.1$5.5#H@+3%E;2<^#0H@,C`Q.#PO<#X-"B`\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M/C(L,S@U/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$
M)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@
M(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P
M,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!
M,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO<CTS1"-#
M0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XX+#`P-CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[
M)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z
M(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X
M(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D
M;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*
M(#PO='(^#0H@/"]T86)L93X-"B`\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL
M/@T*#0HM+2TM+2T]7TYE>'1087)T7SAD8C4S-V,T7V4X-SA?-&$S95\X,CAA
M7V(U,#!F,V5D9C$Q9@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\X
M9&(U,S=C-%]E.#<X7S1A,V5?.#(X85]B-3`P9C-E9&8Q,68O5V]R:W-H965T
M<R]3:&5E=#(V+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U
M;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R
M<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!
M(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT
M;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C
M<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM
M96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@
M8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS
M=')O;F<^0V]M;6ET;65N=',@86YD($-O;G1I;F=E;F-I97,@*%1A8FQE<RD\
M8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L
M<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P
M,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^0V]M;6ET;65N=',@86YD($-O;G1I;F=E;F-I97,@1&ES8VQO<W5R92!;
M06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E-C:&5D=6QE(&]F($UI;FEM=6T@1G5T=7)E($QE87-E(%!A>6UE
M;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV/@T*(#QP
M('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q
M,G!T.R!415A4+4E.1$5.5#H@-"4G/@T*($9U='5R92!M:6YI;75M(&QE87-E
M('!A>6UE;G1S('5N9&5R(&YO;F-A;F-E;&%B;&4@;W!E<F%T:6YG(&QE87-E
M<PT*(&%S(&]F($1E8V5M8F5R)B-X03`[,S$L(#(P,30@87)E(&%S(&9O;&QO
M=W,@*&EN('1H;W5S86YD<RDZ/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"
M3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,G!T.R!-05)'24XM5$]0.B`P<'0G
M/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"3U)$15(M0T],
M3$%04T4Z(&-O;&QA<'-E)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<]
M,T0P('=I9'1H/3-$-C@E(&%L:6=N/3-$8V5N=&5R(&)O<F1E<CTS1#`^#0H@
M/'1R/@T*(#QT9"!W:61T:#TS1#@T)3X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0X)3X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D
M/@T*(#QT9#X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO
M<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($U!4D=)3BU,1494.B`S96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B`R
M,#$U/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!A;&EG;CTS1')I9VAT/C,L.30U/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO
M='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\
M<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`S96T[(%1%6%0M24Y$14Y4.B`M
M,65M)SX-"B`R,#$V/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-"PS-C0\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$
M(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M34%21TE.+4Q%1E0Z(#-E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(#(P,3<\
M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@86QI9VX],T1R:6=H=#XT+#0Y-3PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\
M+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@
M/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,V5M.R!415A4+4E.1$5.5#H@
M+3%E;2<^#0H@,C`Q.#PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C0L,SDV/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO<CTS
M1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($U!4D=)3BU,1494.B`S96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B`R,#$Y
M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^,2PX-S,\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*
M(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z
M("TQ96TG/@T*(%1H97)E869T97(\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ,38\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P
M(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P
M>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^
M#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#145&1CX-
M"B`\=&0@=F%L:6=N/3-$=&]P/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$Y+#$X.3PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[
M/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L
M92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-
M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G
M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^
M#0H@/"]T86)L93X-"B`\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM
M+2TM+2T]7TYE>'1087)T7SAD8C4S-V,T7V4X-SA?-&$S95\X,CAA7V(U,#!F
M,V5D9C$Q9@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\X9&(U,S=C
M-%]E.#<X7S1A,V5?.#(X85]B-3`P9C-E9&8Q,68O5V]R:W-H965T<R]3:&5E
M=#(W+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP
M<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U
M<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M
M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H
M87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S
M<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO
M/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,]
M,T1R97!O<G0@:60],T1)1#!%344^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^
M475A<G1E<FQY($9I;F%N8VEA;"!);F9O<FUA=&EO;B`H5&%B;&5S*3QB<CX\
M+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N
M/3-$,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q-#QB
M<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY1
M=6%R=&5R;'D@1FEN86YC:6%L($EN9F]R;6%T:6]N($1I<V-L;W-U<F4@6T%B
M<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y#;VUP86YY)W,@0V]N<V]L:61A=&5D(%%U87)T97)L>2!297-U;'1S
M(&]F($]P97)A=&EO;G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQD:78^#0H@/'1A8FQE('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D]21$52+4-/3$Q!4%-%.B!C
M;VQL87!S92<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T
M:#TS1#DR)2!A;&EG;CTS1&-E;G1E<B!B;W)D97(],T0P/@T*(#QT<CX-"B`\
M=&0@=VED=&@],T0U-24^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$-B4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-24^/"]T9#X-
M"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$-24^/"]T9#X-"B`\=&0^/"]T9#X-"B`\
M=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$-24^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^
M/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#AP=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$
M,B!A;&EG;CTS1&-E;G1E<CX\8CXQ/'-U<"!S='EL93TS1"=&3TY4+5-)6D4Z
M(#@U)3L@5D525$E#04PM04Q)1TXZ('1O<"<^<W0\+W-U<#XF(WA!,#M1=6%R
M=&5R/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G
M('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\
M8CXR/'-U<"!S='EL93TS1"=&3TY4+5-)6D4Z(#@U)3L@5D525$E#04PM04Q)
M1TXZ('1O<"<^;F0\+W-U<#XF(WA!,#M1=6%R=&5R/"]B/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C
M;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\8CXS/'-U<"!S='EL93TS1"=&
M3TY4+5-)6D4Z(#@U)3L@5D525$E#04PM04Q)1TXZ('1O<"<^<F0\+W-U<#XF
M(WA!,#M1=6%R=&5R/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q
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M5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#$T(&%L:6=N/3-$
M8V5N=&5R/CQB/BAI;B!T:&]U<V%N9',L#0H@97AC97!T('!E<B!S:&%R92!D
M871A*3PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L;W(],T0C0T-%149&
M/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM
M3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@/&(^,C`Q-#PO8CX\
M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@
M=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E
M;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(%)E=F5N=64\+W`^#0H@/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^,30L-S$Y/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1R:6=H=#XY+#(R,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M,3@L,S@R/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XU+#0W-CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X
M03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L
M;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!-05)'24XM3$5&5#H@,V5M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@
M3F5T(&QO<W,\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH,RPQ
M,#@\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M/BDF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@Q,BPR-3D\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/BDF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@S+#DR.#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#$Y+#`Q.#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/"]T
M<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E;3L@5$585"U)3D1%3E0Z("TQ
M96TG/@T*($YE="!L;W-S('!E<B!S:&%R92P@8F%S:6,@86YD(&1I;'5T960\
M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#`N,3(\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/BDF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#XH,"XT-#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M/B@P+C$T/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#XI)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#`N-C@\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/BDF(WA!,#L\
M+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO<CTS1"-#0T5%
M1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)
M3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B`\8CXR,#$S/"]B
M/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT
M9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@
M,V5M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@4F5V96YU93PO<#X-"B`\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
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M;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^,C`L,C,R/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ-"PY
M,#8\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B
M9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E;3L@5$585"U)3D1%3E0Z("TQ96TG
M/@T*($YE="!I;F-O;64@*&QO<W,I/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^*#,L,S8V/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO
M=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H
M=#XH,CDT/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#XI)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XV+#8P-#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C
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M;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`S96T[(%1%
M6%0M24Y$14Y4.B`M,65M)SX-"B!.970@:6YC;VUE("AL;W-S*2!P97(@<VAA
M<F4L(&)A<VEC/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@R+CDS/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#`N,C0\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/BDF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1R:6=H=#XP+C$T/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO
M=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H
M=#XH,"XQ-#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`^*28C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B
M9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E;3L@5$585"U)3D1%3E0Z("TQ96TG
M/@T*($YE="!I;F-O;64@*&QO<W,I('!E<B!S:&%R92P@9&EL=71E9#PO<#X-
M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XH,BXY,SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG
M;CTS1')I9VAT/B@P+C(T/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO
M=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,"XP
M,3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#`N,30\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/BDF(WA!,#L\
M+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\+V1I=CX\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*
M/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7SAD8C4S-V,T7V4X-SA?-&$S
M95\X,CAA7V(U,#!F,V5D9C$Q9@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO
M+R]#.B\X9&(U,S=C-%]E.#<X7S1A,V5?.#(X85]B-3`P9C-E9&8Q,68O5V]R
M:W-H965T<R]3:&5E=#(X+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I
M;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL
M.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@
M(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T
M97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O
M:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI
M<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\
M=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@("`@("`\='(^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X]
M,T0R/CQS=')O;F<^3W)G86YI>F%T:6]N(&%N9"!.871U<F4@;V8@3W!E<F%T
M:6]N<R`M($%D9&ET:6]N86P@26YF;W)M871I;VX@*$1E=&%I;"D\8G(^/"]S
M=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS
M1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^3W)G
M86YI>F%T:6]N+"!#;VYS;VQI9&%T:6]N(&%N9"!0<F5S96YT871I;VX@;V8@
M1FEN86YC:6%L(%-T871E;65N=',@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y-86-R;T=E;FEC<R!I;F-O
M<G!O<F%T960@9&%T93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M075G(#$T+`T*"0DR,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM
M/5].97AT4&%R=%\X9&(U,S=C-%]E.#<X7S1A,V5?.#(X85]B-3`P9C-E9&8Q
M,68-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.&1B-3,W8S1?93@W
M.%\T83-E7S@R.&%?8C4P,&8S961F,3%F+U=O<FMS:&5E=',O4VAE970R.2YH
M=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A
M8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C
M:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV
M/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T
M/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$
M4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R
M:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P
M;W)T(&ED/3-$240P15-3044^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^4W5M
M;6%R>2!O9B!3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S("T@061D
M:71I;VYA;"!);F9O<FUA=&EO;B`H1&5T86EL*2`H55-$("0I/&)R/CPO<W1R
M;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R
M/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T/&)R/E-E
M9VUE;G0\8G(^07-S971S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/D1E8RX@,S$L(#(P,3,\8G(^07-S971S/&)R/CPO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E)E=F5N=64L($UA:F]R($-U
M<W1O;65R(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y%9F9E8W1I=F4@9&%T92!O9B!M97)G97(\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/D1E8R`R,BP-"@D),C`Q-#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M3G5M8F5R(&]F(&]P97)A=&EN9R!S96=M96YT<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^3W)I9VEN86P@;6%T=7)I='D@;V8@9FEN86YC
M:6%L(&EN<W1R=6UE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XS(&UO;G1H<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/C,@;6]N=&AS/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y!;&QO=V%N8V4@<F5C;W)D960\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06UO=6YT<R!C;&%S
M<VEF:65D(&%S(')E<W1R:6-T960@8V%S:#PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`S,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`T,#4L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.=6UB97(@;V8@:6UP
M86ER960@87-S971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^3G5M8F5R(&]F(&%S<V5T<R!H96QD+69O<BUS86QE/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^36EN:6UU;2!;365M8F5R72!\(%-A
M;&5S(%)E=F5N=64L($YE="!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/E)E=F5N=64L($UA:F]R($-U<W1O;65R
M(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y097)C96YT86=E(&]F(&%L;"!S:6=N:69I8V%N="!R979E
M;G5E(&5A<FYE9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`N
M,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y-:6YI;75M(%M-96UB97)=('P@06-C;W5N=',@4F5C96EV86)L92!;
M365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R
M;VYG/E)E=F5N=64L($UA:F]R($-U<W1O;65R(%M,:6YE($ET96US73PO<W1R
M;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y097)C96YT
M86=E(&]F(&%L;"!S:6=N:69I8V%N="!R979E;G5E(&5A<FYE9#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`N,#`E/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO
M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\X9&(U,S=C-%]E.#<X7S1A,V5?
M.#(X85]B-3`P9C-E9&8Q,68-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O
M0SHO.&1B-3,W8S1?93@W.%\T83-E7S@R.&%?8C4P,&8S961F,3%F+U=O<FMS
M:&5E=',O4VAE970S,"YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG
M.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@
M8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\
M345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X
M="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA
M=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@
M0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A
M8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P141&044^#0H@("`@("`\='(^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X]
M,T0Q/CQS=')O;F<^4W5M;6%R>2!O9B!3:6=N:69I8V%N="!!8V-O=6YT:6YG
M(%!O;&EC:65S("T@4W5M;6%R>2!O9B!&86ER(%9A;'5E($UE87-U<F5M96YT
M($9I;F%N8VEA;"!!<W-E="!A;F0@3&EA8FEL:71I97,@*$1E=&%I;"D@*%53
M1"`D*3QB<CY);B!4:&]U<V%N9',L('5N;&5S<R!O=&AE<G=I<V4@<W!E8VEF
M:65D/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C
M+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$
M96,N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#X\<W1R;VYG/D%S<V5T<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^0V%S:"!A;F0@8V%S:"!E<75I=F%L96YT<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q,S$L-30U/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Y,"PT
M,S0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/DUO;F5Y(&UA<FME="!F=6YD<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,C8L,#0V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,C8L,#0W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y297-T<FEC=&5D(&-A<V@\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,P,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0P-3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L($%S<V5T
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,34W+#@Y,3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$Q-BPX
M.#8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E%U;W1E9"!0<FEC97,@:6X@06-T:79E($UA<FME=',@9F]R($ED96YT
M:6-A;"!!<W-E=',@3&5V96P@,2!;365M8F5R73PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D%S<V5T<SH\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V%S:"!A;F0@8V%S:"!E
M<75I=F%L96YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3,Q
M+#4T-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/CDP+#0S-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^36]N97D@;6%R:V5T(&9U;F1S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XR-BPP-#8\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-BPP-#<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E<W1R:6-T960@8V%S
M:#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#`U/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T
M86P@07-S971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$U
M-RPX.3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#$Q-BPX.#8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]
M7TYE>'1087)T7SAD8C4S-V,T7V4X-SA?-&$S95\X,CAA7V(U,#!F,V5D9C$Q
M9@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\X9&(U,S=C-%]E.#<X
M7S1A,V5?.#(X85]B-3`P9C-E9&8Q,68O5V]R:W-H965T<R]3:&5E=#,Q+FAT
M;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B
M;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I
M:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78]
M,T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]
M=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13
M:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I
M<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O
M<G0@:60],T1)1#!%5D1!1SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY3=6UM
M87)Y(&]F(%-I9VYI9FEC86YT($%C8V]U;G1I;F<@4&]L:6-I97,@+2!3=6UM
M87)Y(&]F($-O;&QA8F]R871O<G,@=&AA="!297!R97-E;G0@36]R92!4:&%N
M(#$P)2!O9B!4;W1A;"!2979E;G5E($5A<FYE9"`H1&5T86EL*2`H4V%L97,@
M4F5V96YU92P@3F5T(%M-96UB97)=*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,SXQ,B!-;VYT:',@16YD
M960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-E<G9I97(@6TUE;6)E<ET\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#;VYC96YT<F%T
M:6]N(%)I<VL@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E!E<F-E;G1A9V4@;V8@86QL('-I9VYI9FEC
M86YT(')E=F5N=64@96%R;F5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XS-BXT,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XU,2XV,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ-RXS,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D)O96AR:6YG97(@6TUE;6)E<ET\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#;VYC
M96YT<F%T:6]N(%)I<VL@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!E<F-E;G1A9V4@;V8@86QL('-I
M9VYI9FEC86YT(')E=F5N=64@96%R;F5D/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XR."XV,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XR-"XX,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ."XT,"4\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1A:V5D82!;365M8F5R
M73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-O
M;F-E;G1R871I;VX@4FES:R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4&5R8V5N=&%G92!O9B!A;&P@
M<VEG;FEF:6-A;G0@<F5V96YU92!E87)N960\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$V+C@P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^1VEL96%D(%M-96UB97)=/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0V]N8V5N=')A=&EO
M;B!2:7-K(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y097)C96YT86=E(&]F(&%L;"!S:6=N:69I8V%N
M="!R979E;G5E(&5A<FYE9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,3$N-#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,3,N.#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y%;&D@3&EL;'D@6TUE;6)E<ET\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#;VYC96YT<F%T:6]N
M(%)I<VL@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E!E<F-E;G1A9V4@;V8@86QL('-I9VYI9FEC86YT
M(')E=F5N=64@96%R;F5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XP+CDP)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$N-#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-#@N.3`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM
M+2TM/5].97AT4&%R=%\X9&(U,S=C-%]E.#<X7S1A,V5?.#(X85]B-3`P9C-E
M9&8Q,68-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.&1B-3,W8S1?
M93@W.%\T83-E7S@R.&%?8C4P,&8S961F,3%F+U=O<FMS:&5E=',O4VAE970S
M,BYH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I
M;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M
M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q
M=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R
M<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C
M/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO
M<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$
M<F5P;W)T(&ED/3-$240P14]:044^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^
M4W5M;6%R>2!O9B!3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S("T@
M4W5M;6%R>2!O9B!#;VQL86)O<F%T;W)S('1H870@4F5P<F5S96YT($UO<F4@
M5&AA;B`Q,"4@;V8@06-C;W5N=',@4F5C96EV86)L92`H1&5T86EL*2`H06-C
M;W5N=',@4F5C96EV86)L92!;365M8F5R72D\8G(^/"]S=')O;F<^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^,3(@36]N=&AS
M($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4V5R=FEE<B!;365M8F5R73PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-O;F-E;G1R
M871I;VX@4FES:R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4VEG;FEF:6-A;G0@06-C;W5N=',@4F5C
M96EV86)L93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S,N,S`E
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-BXT,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D)O96AR:6YG97(@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#;VYC96YT<F%T:6]N(%)I<VL@6TQI
M;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E-I9VYI9FEC86YT($%C8V]U;G1S(%)E8V5I=F%B;&4\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(Q+C(P)3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$R+C(P)3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1W)E96X@
M0W)O<W,@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY#;VYC96YT<F%T:6]N(%)I<VL@6TQI;F4@271E;7-=/"]S
M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-I9VYI
M9FEC86YT($%C8V]U;G1S(%)E8V5I=F%B;&4\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$W+CDP)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^1VEL96%D(%M-96UB97)=/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0V]N8V5N=')A=&EO
M;B!2:7-K(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y3:6=N:69I8V%N="!!8V-O=6YT<R!296-E:79A
M8FQE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU,RXT,"4\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!F
M:7IE<B!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#X\<W1R;VYG/D-O;F-E;G1R871I;VX@4FES:R!;3&EN92!)=&5M<UT\+W-T
M<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VEG;FEF
M:6-A;G0@06-C;W5N=',@4F5C96EV86)L93PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,3(N,S`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM
M+2TM/5].97AT4&%R=%\X9&(U,S=C-%]E.#<X7S1A,V5?.#(X85]B-3`P9C-E
M9&8Q,68-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.&1B-3,W8S1?
M93@W.%\T83-E7S@R.&%?8C4P,&8S961F,3%F+U=O<FMS:&5E=',O4VAE970S
M,RYH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I
M;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M
M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q
M=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R
M<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C
M/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO
M<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$
M<F5P;W)T(&ED/3-$240P159'044^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^
M4W5M;6%R>2!O9B!3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S("T@
M17-T:6UA=&5D(%5S969U;"!,:79E<R`H1&5T86EL*3QB<CX\+W-T<F]N9SX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-
M;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M<'5T97(@17%U:7!M96YT
M(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^4')O<&5R='DL(%!L86YT(&%N9"!%<75I<&UE;G0@6TQI;F4@271E
M;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D5S=&EM871E9"!5<V5F=6P@3&EV97,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/C,@>65A<G,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E-O9G1W87)E(%M-96UB97)=/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4')O<&5R='DL(%!L
M86YT(&%N9"!%<75I<&UE;G0@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5S=&EM871E9"!5<V5F=6P@
M3&EV97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/C,@>65A<G,\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D9U<FYI='5R92!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/E!R;W!E<G1Y+"!0;&%N="!A;F0@17%U:7!M96YT
M(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y%<W1I;6%T960@57-E9G5L($QI=F5S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XQ,"!Y96%R<SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&%B;W)A=&]R>2!A;F0@
M3V9F:6-E($5Q=6EP;65N="!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/E!R;W!E<G1Y+"!0;&%N="!A;F0@17%U
M:7!M96YT(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y%<W1I;6%T960@57-E9G5L($QI=F5S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XU('EE87)S/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,96%S96AO;&0@
M26UP<F]V96UE;G1S(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/CQS=')O;F<^4')O<&5R='DL(%!L86YT(&%N9"!%<75I<&UE
M;G0@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/DQE87-E:&]L9"!I;7!R;W9E;65N=',\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/E-H;W)T97(@;V8@;&5A<V4@=&5R;2!O
M<B!U<V5F=6P@;&EF93QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?
M3F5X=%!A<G1?.&1B-3,W8S1?93@W.%\T83-E7S@R.&%?8C4P,&8S961F,3%F
M#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+SAD8C4S-V,T7V4X-SA?
M-&$S95\X,CAA7V(U,#!F,V5D9C$Q9B]7;W)K<VAE971S+U-H965T,S0N:'1M
M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L
M90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI
M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS
M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU
M=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H
M;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP
M=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R
M="!I9#TS1$E$,$4Q54)'/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E-U;6UA
M<GD@;V8@4VEG;FEF:6-A;G0@06-C;W5N=&EN9R!0;VQI8VEE<R`M($-O;7!U
M=&%T:6]N(&]F($)A<VEC(&%N9"!$:6QU=&5D($EN8V]M92`H3&]S<RD@4&5R
M($-O;6UO;B!3:&%R92`H1&5T86EL*2`H55-$("0I/&)R/DEN(%1H;W5S86YD
M<RP@97AC97!T(%-H87)E(&1A=&$L('5N;&5S<R!O=&AE<G=I<V4@<W!E8VEF
M:65D/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L
M<W!A;CTS1#@^,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:"!C;VQS<&%N/3-$,SXQ,B!-;VYT:',@16YD960\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y397`N(#,P+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/DIU;BX@,S`L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^36%R+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D%C8V]U;G1I;F<@
M4&]L:6-I97,@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y.970@:6YC;VUE("AL;W-S*3PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XD("@Q.2PP,3@I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@S+#DR."D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#$R+#(U
M.2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B0@*#,L,3`X*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^)"`H,RPR,#4I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`V+#8P-#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,CDT*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,RPS-C8I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@S."PS
M,3,I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XD("@R-C$I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`X+#,V,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^3&5S<SH@=6YD:7-T<FEB=71E9"!E87)N:6YG
M<R!A;&QO8V%T960@=&\@<&%R=&EC:7!A=&EN9R!S96-U<FET:65S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@X+#,V,BD\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@:6YC;VUE
M("AL;W-S*2!A;&QO8V%B;&4@=&\@8V]M;6]N('-H87)E<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH,S@L,S$S*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(V,2D\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D)A<VEC('=E:6=H
M=&5D(&%V97)A9V4@8V]M;6]N('-H87)E<R!O=71S=&%N9&EN9SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C<L,S@T+#DY,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8L.#0W+#8Y-SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L
M,#@S+#(W-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^0F%S:6,@:6YC;VUE("AL;W-S*2!P97(@8V]M;6]N('-H87)E
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#`N,30I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P+C$T
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD
M("@P+C(T*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^)"`H,BXY,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B0@*#$N-"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B0@*#`N,#0I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@:6YC;VUE("AL
M;W-S*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3DL,#$X*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#,L
M.3(X*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#$R+#(U.2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B@S+#$P."D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B@S+#(P-2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XV+#8P-#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(Y-"D\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S+#,V-BD\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S."PS,3,I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH
M,C8Q*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C@L,S8R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y,97-S.B!U;F1I<W1R:6)U=&5D(&5A<FYI;F=S(&%L;&]C
M871E9"!T;R!P87)T:6-I<&%T:6YG('-E8W5R:71I97,@86YD(&]T:&5R(&%D
M9"UB86-K<R!T;R!N970@:6YC;VUE("AL;W-S*3PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH."PS-C(I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&EN8V]M92`H;&]S<RD@86QL
M;V-A8FQE('1O(&-O;6UO;B!S:&%R97,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^)"`H,S@L,S$S*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^)"`H,C8Q*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0F%S:6,@=V5I9VAT960@879E
M<F%G92!C;VUM;VX@<VAA<F5S(&]U='-T86YD:6YG/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XR-RPS.#0L.3DP/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-BPX-#<L-CDW/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PP.#,L,C<V
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y%9F9E8W0@;V8@9&EL=71I=F4@<V5C=7)I=&EE<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&EL=71E9"!W96EG:'1E9"!A=F5R
M86=E(&-O;6UO;B!S:&%R97,@;W5T<W1A;F1I;F<\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C(W+#,X-"PY.3`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV+#@T-RPV.3<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#`X,RPR-S8\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D1I;'5T960@:6YC;VUE("AL;W-S*2!P97(@8V]M;6]N('-H87)E/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#`N,30I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P+C`Q/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@P+C(T
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M)"`H,BXY,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B0@*#$N-"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B0@*#`N,#0I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-
M"@T*+2TM+2TM/5].97AT4&%R=%\X9&(U,S=C-%]E.#<X7S1A,V5?.#(X85]B
M-3`P9C-E9&8Q,68-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.&1B
M-3,W8S1?93@W.%\T83-E7S@R.&%?8C4P,&8S961F,3%F+U=O<FMS:&5E=',O
M4VAE970S-2YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T
M960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E
M=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H
M='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL
M.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I
M<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N
M="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L
M87-S/3-$<F5P;W)T(&ED/3-$240P14%+0D<^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS
M=')O;F<^4W5M;6%R>2!O9B!3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC
M:65S("T@4V-H961U;&4@;V8@06YT:61I;'5T:79E(%-E8W5R:71I97,@17AC
M;'5D960@9G)O;2!T:&4@0V%L8W5L871I;VX@;V8@1&EL=71E9"!);F-O;64@
M*$QO<W,I(%!E<B!3:&%R92`H1&5T86EL*3QB<CX\+W-T<F]N9SX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,SXQ,B!-;VYT:',@
M16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-E<FEE<R!!+3$@0V]N=F5R=&EB
M;&4@4')E9F5R<F5D(%-T;V-K(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^06YT:61I;'5T:79E(%-E8W5R:71I
M97,@17AC;'5D960@9G)O;2!#;VUP=71A=&EO;B!O9B!%87)N:6YG<R!097(@
M4VAA<F4@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D%N=&ED:6QU=&EV92!S96-U<FET:65S(&5X8VQU
M9&5D(&9R;VT@8V]M<'5T871I;VX@;V8@96%R;FEN9W,@<&5R('-H87)E+"!S
M:&%R97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L,34V+#$Q
M-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4V5R:65S($$M,B!#;VYV97)T:6)L92!0<F5F97)R960@4W1O8VL@6TUE
M;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N
M9SY!;G1I9&EL=71I=F4@4V5C=7)I=&EE<R!%>&-L=61E9"!F<F]M($-O;7!U
M=&%T:6]N(&]F($5A<FYI;F=S(%!E<B!3:&%R92!;3&EN92!)=&5M<UT\+W-T
M<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06YT:61I
M;'5T:79E('-E8W5R:71I97,@97AC;'5D960@9G)O;2!C;VUP=71A=&EO;B!O
M9B!E87)N:6YG<R!P97(@<VAA<F4L('-H87)E<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,SDR+#(W-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4V5R:65S($(@0V]N=F5R=&EB;&4@
M4')E9F5R<F5D(%-T;V-K(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^06YT:61I;'5T:79E(%-E8W5R:71I97,@
M17AC;'5D960@9G)O;2!#;VUP=71A=&EO;B!O9B!%87)N:6YG<R!097(@4VAA
M<F4@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D%N=&ED:6QU=&EV92!S96-U<FET:65S(&5X8VQU9&5D
M(&9R;VT@8V]M<'5T871I;VX@;V8@96%R;FEN9W,@<&5R('-H87)E+"!S:&%R
M97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0L,S,V+#`S-SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4V5R:65S($,@0V]N=F5R=&EB;&4@4')E9F5R<F5D(%-T;V-K(%M-96UB97)=
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^06YT
M:61I;'5T:79E(%-E8W5R:71I97,@17AC;'5D960@9G)O;2!#;VUP=71A=&EO
M;B!O9B!%87)N:6YG<R!097(@4VAA<F4@6TQI;F4@271E;7-=/"]S=')O;F<^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%N=&ED:6QU=&EV
M92!S96-U<FET:65S(&5X8VQU9&5D(&9R;VT@8V]M<'5T871I;VX@;V8@96%R
M;FEN9W,@<&5R('-H87)E+"!S:&%R97,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C4L.3`Y+#DP-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4V5R:65S($0@0V]N=F5R=&EB;&4@4')E
M9F5R<F5D(%-T;V-K(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/CQS=')O;F<^06YT:61I;'5T:79E(%-E8W5R:71I97,@17AC
M;'5D960@9G)O;2!#;VUP=71A=&EO;B!O9B!%87)N:6YG<R!097(@4VAA<F4@
M6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D%N=&ED:6QU=&EV92!S96-U<FET:65S(&5X8VQU9&5D(&9R
M;VT@8V]M<'5T871I;VX@;V8@96%R;FEN9W,@<&5R('-H87)E+"!S:&%R97,\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<V.2PT-C@\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-E<FEE
M<R!$+3(@0V]N=F5R=&EB;&4@4')E9F5R<F5D(%-T;V-K(%M-96UB97)=/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^06YT:61I
M;'5T:79E(%-E8W5R:71I97,@17AC;'5D960@9G)O;2!#;VUP=71A=&EO;B!O
M9B!%87)N:6YG<R!097(@4VAA<F4@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%N=&ED:6QU=&EV92!S
M96-U<FET:65S(&5X8VQU9&5D(&9R;VT@8V]M<'5T871I;VX@;V8@96%R;FEN
M9W,@<&5R('-H87)E+"!S:&%R97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C,L,SDQ+#DY,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^169F96-T(&]F($-O;G9E<G1I8FQE(%!R969E
M<G)E9"!3=&]C:R!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/D%N=&ED:6QU=&EV92!396-U<FET:65S($5X8VQU
M9&5D(&9R;VT@0V]M<'5T871I;VX@;V8@16%R;FEN9W,@4&5R(%-H87)E(%M,
M:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y!;G1I9&EL=71I=F4@<V5C=7)I=&EE<R!E>&-L=61E9"!F<F]M
M(&-O;7!U=&%T:6]N(&]F(&5A<FYI;F=S('!E<B!S:&%R92P@<VAA<F5S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,RPQ.#DL.3(P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y787)R
M86YT(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^06YT:61I;'5T:79E(%-E8W5R:71I97,@17AC;'5D960@9G)O
M;2!#;VUP=71A=&EO;B!O9B!%87)N:6YG<R!097(@4VAA<F4@6TQI;F4@271E
M;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D%N=&ED:6QU=&EV92!S96-U<FET:65S(&5X8VQU9&5D(&9R;VT@8V]M<'5T
M871I;VX@;V8@96%R;FEN9W,@<&5R('-H87)E+"!S:&%R97,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$X,"PW.#0\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K($]P=&EO;G,@
M6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY!;G1I9&EL=71I=F4@4V5C=7)I=&EE<R!%>&-L=61E9"!F<F]M($-O
M;7!U=&%T:6]N(&]F($5A<FYI;F=S(%!E<B!3:&%R92!;3&EN92!)=&5M<UT\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06YT
M:61I;'5T:79E('-E8W5R:71I97,@97AC;'5D960@9G)O;2!C;VUP=71A=&EO
M;B!O9B!E87)N:6YG<R!P97(@<VAA<F4L('-H87)E<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,BPP.30L.3`T/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPS,3,L.3<P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPR-#DL-S`R
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^
M#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\X9&(U
M,S=C-%]E.#<X7S1A,V5?.#(X85]B-3`P9C-E9&8Q,68-"D-O;G1E;G0M3&]C
M871I;VXZ(&9I;&4Z+R\O0SHO.&1B-3,W8S1?93@W.%\T83-E7S@R.&%?8C4P
M,&8S961F,3%F+U=O<FMS:&5E=',O4VAE970S-BYH=&UL#0I#;VYT96YT+51R
M86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y
M<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*
M("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E
M(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T
M('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.
M;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@
M/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P140V
M044^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P
M86X],T0Q(')O=W-P86X],T0Q/CQS=')O;F<^4')O<&5R='D@86YD($5Q=6EP
M;65N="`M(%-C:&5D=6QE(&]F(%!R;W!E<G1Y(&%N9"!%<75I<&UE;G0@*$1E
M=&%I;"D@*%531"`D*3QB<CY);B!4:&]U<V%N9',L('5N;&5S<R!O=&AE<G=I
M<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/E!R;W!E<G1Y+"!0;&%N="!A;F0@17%U
M:7!M96YT(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y0<F]P97)T>2!A;F0@97%U:7!M96YT/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(T+#$T,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,C`L-38W/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,
M97-S(&%C8W5M=6QA=&5D(&1E<')E8VEA=&EO;CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH,3<L,S4U*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^*#$U+#4S,BD\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]P97)T>2!A;F0@
M97%U:7!M96YT+"!N970\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C8L-S@U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-2PP,S4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D-O;7!U=&5R($5Q=6EP;65N="!;365M8F5R73PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E!R;W!E<G1Y
M+"!0;&%N="!A;F0@17%U:7!M96YT(%M,:6YE($ET96US73PO<W1R;VYG/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]P97)T>2!A;F0@
M97%U:7!M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#4Y
M-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C(L,S<Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y3;V9T=V%R92!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/E!R;W!E<G1Y+"!0;&%N="!A;F0@17%U
M:7!M96YT(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y0<F]P97)T>2!A;F0@97%U:7!M96YT/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#8X,SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-#<W/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&=7)N:71U
M<F4@86YD($]F9FEC92!%<75I<&UE;G0@6TUE;6)E<ET\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY0<F]P97)T>2P@4&QA;G0@
M86YD($5Q=6EP;65N="!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O<&5R='D@86YD(&5Q=6EP;65N
M=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S4Q/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C4Q/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,86(@
M17%U:7!M96YT(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^4')O<&5R='DL(%!L86YT(&%N9"!%<75I<&UE;G0@
M6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E!R;W!E<G1Y(&%N9"!E<75I<&UE;G0\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$S+#DQ-SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$Q+#$V-CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&5A<V5H;VQD($EM
M<')O=F5M96YT<R!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/E!R;W!E<G1Y+"!0;&%N="!A;F0@17%U:7!M96YT
M(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y0<F]P97)T>2!A;F0@97%U:7!M96YT/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#4L,3DS/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`T+#@Y-#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^
M#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?.&1B-3,W8S1?93@W.%\T
M83-E7S@R.&%?8C4P,&8S961F,3%F#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE
M.B\O+T,Z+SAD8C4S-V,T7V4X-SA?-&$S95\X,CAA7V(U,#!F,V5D9C$Q9B]7
M;W)K<VAE971S+U-H965T,S<N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O
M9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT
M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@
M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$
M)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X
M="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4
M:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@
M(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$580D%#/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S
M<&%N/3-$,CX\<W1R;VYG/E!R;W!E<G1Y(&%N9"!%<75I<&UE;G0@+2!!9&1I
M=&EO;F%L($EN9F]R;6%T:6]N("A$971A:6PI("A54T0@)"D\8G(^26X@36EL
M;&EO;G,L('5N;&5S<R!O=&AE<G=I<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#,^,3(@36]N
M=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E!R;W!E<G1Y
M+"!0;&%N="!A;F0@17%U:7!M96YT(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5P<F5C:6%T:6]N(&%N
M9"!A;6]R=&EZ871I;VX@97AP96YS93PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`Q+C@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#$N,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-
M"BTM+2TM+3U?3F5X=%!A<G1?.&1B-3,W8S1?93@W.%\T83-E7S@R.&%?8C4P
M,&8S961F,3%F#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+SAD8C4S
M-V,T7V4X-SA?-&$S95\X,CAA7V(U,#!F,V5D9C$Q9B]7;W)K<VAE971S+U-H
M965T,S@N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D
M+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970]
M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T
M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@
M8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T
M('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@
M*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S
M<STS1')E<&]R="!I9#TS1$E$,$53,T9-/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R
M;VYG/E-T;V-K:&]L9&5R<R<@17%U:71Y("T@061D:71I;VYA;"!);F9O<FUA
M=&EO;B`H1&5T86EL*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C`@36]N=&AS($5N9&5D
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,2!-
M;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS
M<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:"!C;VQS<&%N/3-$,3XP($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C(T($UO;G1H<R!%;F1E
M9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0T/C$@
M36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L
M<W!A;CTS1#$^,"!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:"!C;VQS<&%N/3-$,3XQ($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CPO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y/8W0N(#$V
M+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D9E8BX@
M,C@L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C
M+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*
M86XN(#$Q+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/D1E8RX@,S$L(#(P,#,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^3V-T+B`S,2P@,C`P-#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y-87D@,S$L(#(P,#8\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^36%R+B`S,2P@,C`Q,3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y*=6PN(#,Q+"`R,#`X/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/DUA>2`Q-BP@,C`Q,#QB<CX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y397`N(#,P+"`R,#`X/&)R/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#;&%S<R!O9B!3=&]C:R!;
M3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^3G5M8F5R(&]F('-H87)E<R!I<W-U960@;W(@<V]L9#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PX,#`L,#`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<FEC92!P
M97(@<VAA<F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,S8N
M-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4')O8V5E9',@9G)O;2!S86QE(&]F('-H87)E<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`W-BPW,#`L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]C965D<R!F<F]M
M(&EN:71I86P@<'5B;&EC(&]F9F5R:6YG(&YE="!O9B!E>'!E;G-E<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#,L.#`P+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5V97)S
M92!S=&]C:R!S<&QI=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M,2UF;W(M,3@N-S<S.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K+"!S:&%R97,@875T:&]R:7IE
M9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3(U+#`P,"PP,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M,C4L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C0R-2PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!9&1I=&EO;F%L('-H87)E<R!S;VQD
M('5N9&5R(&]V97(M86QL;W1M96YT<R!O<'1I;VX@=&\@=6YD97)W<FET97(\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0U,"PP,#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DE03R!;
M365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R
M;VYG/D-L87-S(&]F(%-T;V-K(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.=6UB97(@;V8@<VAA<F5S
M(&ES<W5E9"!O<B!S;VQD/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XU+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E!R:6-E('!E<B!S:&%R93PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`Q-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^3W9E<BU!;&QO=&UE;G0@3W!T:6]N(%M-
M96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^0VQA<W,@;V8@4W1O8VL@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYU;6)E<B!O9B!S:&%R97,@
M:7-S=65D(&]R('-O;&0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C<U,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E!R:6-E('!E<B!S:&%R93PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`Q-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4V5R:65S($0M,B!#;VYV97)T:6)L92!0<F5F
M97)R960@4W1O8VL@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY#;&%S<R!O9B!3=&]C:R!;3&EN92!)=&5M<UT\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3G5M
M8F5R(&]F('-H87)E<R!I<W-U960@;W(@<V]L9#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,3@L-#(W+#,X.#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O8V5E9',@9G)O;2!S86QE
M(&]F('-H87)E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3(L
M,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4V5R:65S($$@4')E9F5R<F5D(%-T;V-K(%M-96UB97)=/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0VQA<W,@
M;V8@4W1O8VL@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/DYU;6)E<B!O9B!S:&%R97,@:7-S=65D(&]R
M('-O;&0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,T+#(S.2PS
M-S0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E!R;V-E961S(&9R;VT@:7-S=6%N8V4@;V8@8V]N=F5R=&EB;&4@<')E
M9F5R<F5D('-T;V-K/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS
M-"PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y0<FEC92!P97(@<VAA<F4\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^06-C<G5E9"!N;VYC=6UU;&%T:79E(&1I=FED
M96YD<R!O;B!P<F5F97)R960@<W1O8VL\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B`P+C`X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y397)I97,@02TQ(%!R969E<G)E9"!3=&]C:R!;
M365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R
M;VYG/D-L87-S(&]F(%-T;V-K(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VYV97)T:6)L92!P<F5F
M97)R960@<W1O8VL@<V5R:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ+C4P-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^0V]N=F5R<VEO;B!P<FEC92!O9B!P<F5F97)R960@<W1O
M8VL\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B`Q,BXS.3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4V5R
M:65S($$M,B!0<F5F97)R960@4W1O8VL@6TUE;6)E<ET\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#;&%S<R!O9B!3=&]C:R!;
M3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^0V]N=F5R=&EB;&4@<')E9F5R<F5D('-T;V-K('-E<FEE<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]N=F5R<VEO;B!P
M<FEC92!O9B!P<F5F97)R960@<W1O8VL\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B`Q."XW-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4V5R:65S($(@4')E9F5R<F5D(%-T;V-K(%M-
M96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^0VQA<W,@;V8@4W1O8VL@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYU;6)E<B!O9B!S:&%R97,@
M:7-S=65D(&]R('-O;&0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C<Q+#0P,2PR,S<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E!R;V-E961S(&9R;VT@:7-S=6%N8V4@;V8@8V]N=F5R
M=&EB;&4@<')E9F5R<F5D('-T;V-K/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XS,"PS,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y296QA=&5D(&]F9F5R:6YG(&-O<W1S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,S@L,#`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R97,@
M;V8@8V]M;6]N('-T;V-K(&%L;&]C871E9#PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,3`L,#`S+#,P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C<G5E9"!N;VYC=6UU;&%T:79E
M(&1I=FED96YD<R!O;B!P<F5F97)R960@<W1O8VL\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B`P+C`S-#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;G9E<G1I8FQE('!R969E<G)E
M9"!S=&]C:R!S97)I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$N,30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D-O;G9E<G-I;VX@<')I8V4@;V8@<')E9F5R<F5D('-T;V-K/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#X@-BXY-3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4V5R:65S($,@
M4')E9F5R<F5D(%-T;V-K(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^0VQA<W,@;V8@4W1O8VL@6TQI;F4@271E
M;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/DYU;6)E<B!O9B!S:&%R97,@:7-S=65D(&]R('-O;&0\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$Q,"PY-3(L,C$W/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]C965D<R!F<F]M
M(&ES<W5A;F-E(&]F(&-O;G9E<G1I8FQE('!R969E<G)E9"!S=&]C:SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#0L.3`P+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5L871E
M9"!O9F9E<FEN9R!C;W-T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,3`Q+#(T-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^06-C<G5E9"!N;VYC=6UU;&%T:79E(&1I=FED96YD<R!O
M;B!P<F5F97)R960@<W1O8VL\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B`P+C`S,C0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D-O;G9E<G1I8FQE('!R969E<G)E9"!S=&]C:R!S97)I
M97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;G9E<G-I
M;VX@<')I8V4@;V8@<')E9F5R<F5D('-T;V-K/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#X@-RXW/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y397)I97,@1"!0<F5F97)R960@4W1O8VL@
M6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY#;&%S<R!O9B!3=&]C:R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C<G5E9"!N;VYC=6UU
M;&%T:79E(&1I=FED96YD<R!O;B!P<F5F97)R960@<W1O8VL\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B`P+C`U,C(\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;G9E<G1I8FQE('!R
M969E<G)E9"!S=&]C:R!S97)I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D-O;G9E<G-I;VX@<')I8V4@;V8@<')E9F5R<F5D('-T;V-K
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#X@,3(N,CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4V5R:65S
M($0@4')E9F5R<F5D(%-T;V-K(%M-96UB97)=('P@4F%V96X@0FEO=&5C:&YO
M;&]G:65S($EN8RX@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY#;&%S<R!O9B!3=&]C:R!;3&EN92!)=&5M<UT\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAA
M<F5S(&ES<W5E9"!T;R!A8W%U:7)E(&5N=&ET>3PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,30L-#0V+#(R-SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$R+#0V-BPP,SD\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-E<FEE<R!$
M+3(@4')E9F5R<F5D(%-T;V-K(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0VQA<W,@;V8@4W1O8VL@6TQI;F4@
M271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/DYU;6)E<B!O9B!S:&%R97,@:7-S=65D(&]R('-O;&0\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C8L.3$V+#$Q,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,X+#,S-RPV-S@\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R
M;V-E961S(&9R;VT@:7-S=6%N8V4@;V8@8V]N=F5R=&EB;&4@<')E9F5R<F5D
M('-T;V-K/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-"PX,#`L
M,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y296QA=&5D(&]F9F5R:6YG(&-O<W1S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#$U-BPW.#@\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!U<F-H87-E9"!S:&%R97,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4Q."PW,#@\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#@W-2PS,C<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D5X97)C:7-E('!R:6-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#X@,"XV-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^06-C<G5E9"!N;VYC=6UU;&%T:79E(&1I=FED96YD<R!O;B!P
M<F5F97)R960@<W1O8VL\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B`P+C`U,C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D-O;G9E<G1I8FQE('!R969E<G)E9"!S=&]C:R!S97)I97,\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;G9E<G-I;VX@
M<')I8V4@;V8@<')E9F5R<F5D('-T;V-K/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#X@,3(N,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^56YD97-I9VYA=&5D(%!R969E<G)E9"!3=&]C
M:R!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/D-L87-S(&]F(%-T;V-K(%M,:6YE($ET96US73PO<W1R;VYG/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y5;F1E<VEG;F%T960@
M<')E9F5R<F5D('-T;V-K+"!S:&%R97,@875T:&]R:7IE9#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-2PP,#`L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y5;F1E<VEG;F%T960@
M<')E9F5R<F5D('-T;V-K+"!P87(@=F%L=64\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B`P+C`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y5;F1E<VEG;F%T960@<')E9F5R<F5D('-T
M;V-K+"!S:&%R97,@:7-S=65D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^56YD97-I9VYA=&5D('!R969E<G)E9"!S=&]C:RP@<VAA<F5S
M(&]U='-T86YD:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4V5R:65S($$M,2!0<F5F97)R960@4W1O8VL@6TUE;6)E<ET\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#;&%S<R!O9B!3
M=&]C:R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4VAA<F5S(&]F(&-O;6UO;B!S=&]C:R!A;&QO8V%T
M960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$S+#8P-"PP,38\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-
M"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7SAD8C4S
M-V,T7V4X-SA?-&$S95\X,CAA7V(U,#!F,V5D9C$Q9@T*0V]N=&5N="U,;V-A
M=&EO;CH@9FEL93HO+R]#.B\X9&(U,S=C-%]E.#<X7S1A,V5?.#(X85]B-3`P
M9C-E9&8Q,68O5V]R:W-H965T<R]3:&5E=#,Y+FAT;6P-"D-O;G1E;G0M5')A
M;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP
M93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@
M(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@
M8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@
M='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO
M="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\
M8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%5EE"
M23X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A
M;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY3=&]C:RT@8F%S960@0V]M<&5N
M<V%T:6]N("T@061D:71I;VYA;"!);F9O<FUA=&EO;B`H1&5T86EL*2`H55-$
M("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M(&-O;'-P86X],T0S/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C8P($UO;G1H<R!%;F1E9#PO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CPO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$
M96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^1&5C+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y$96,N(#,Q+"`R,#$P/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/D9E8BX@,C@L(#(P,#,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^3V-T+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3:&%R92UB87-E9"!#;VUP96YS871I
M;VX@07)R86YG96UE;G0@8GD@4VAA<F4M8F%S960@4&%Y;65N="!!=V%R9"!;
M3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4VAA<F4M8F%S960@8V]M<&5N<V%T:6]N(&%R<F%N9V5M96YT
M(&)Y('-H87)E+6)A<V5D('!A>6UE;G0@87=A<F0L(&]P=&EO;G,L(&]U='-T
M86YD:6YG+"!N=6UB97(\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C,L-3<R+#$Q-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C,L,C`P+#DU.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^5V5I9VAT960@879E<F%G92!E>&5R8VES
M92!P<FEC93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q,2XT
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`T+CD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D5X<&5C=&5D(&QI9F4@;V8@;W!T:6]N('1E<FT\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/C8@>65A<G,@,R!M;VYT:',\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XW('EE87)S
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M-R!Y96%R<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^0V]M;6]N('-T;V-K+"!S:&%R97,@:7-S=65D/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XU-C@L.3`V/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PR-C@L,#0Y/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#8S+#$W
M-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^0V%S:"!P<F]C965D<R!F<F]M(&5X97)C:7-E(&]F('-T;V-K(&]P=&EO
M;G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-S0T+#`P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M,2PQ,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`T-RPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E=E:6=H=&5D+6%V97)A9V4@9W)A;G0M9&%T
M92!F86ER('9A;'5E(&]F(&]P=&EO;G,@9W)A;G1E9#PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`Q-RXT,3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-BXY,3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XY-#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F4M
M8F%S960@8V]M<&5N<V%T:6]N(&%R<F%N9V5M96YT(&)Y('-H87)E+6)A<V5D
M('!A>6UE;G0@87=A<F0L(&]P=&EO;G,L(&5X97)C:7-E<R!I;B!P97)I;V0L
M(&EN=')I;G-I8R!V86QU93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,30L-3`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C4L-#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C(W,2PY,CD\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9A:7(@=F%L=64@;V8@
M<VAA<F5S('9E<W1E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,RPP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-#@W+#8P,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C@W.2PP,C0\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E5N<F5C;V=N:7IE9"!C;VUP96YS
M871I;VX@8V]S="!R96QA=&5D('1O(&YO;BUV97-T960@<W1O8VLM8F%S960@
M8V]M<&5N<V%T:6]N(&%R<F%N9V5M96YT<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`Q.2PV,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y5;G)E8V]G;FEZ960@8V]M<&5N
M<V%T:6]N(&5X<&5N<V4@<F5C;V=N:71I;VX@<&5R:6]D/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XT('EE87)S/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y-87AI;75M(%M-96UB97)=
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4VAA
M<F4M8F%S960@0V]M<&5N<V%T:6]N($%R<F%N9V5M96YT(&)Y(%-H87)E+6)A
M<V5D(%!A>6UE;G0@07=A<F0@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]P=&EO;G,@9W)A;G1E9"P@
M;6%X:6UU;2!T97)M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XQ
M,"!Y96%R<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4W1O8VL@3W!T:6]N(%!L86X@,C`P,"!;365M8F5R73PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-H87)E+6)A
M<V5D($-O;7!E;G-A=&EO;B!!<G)A;F=E;65N="!B>2!3:&%R92UB87-E9"!0
M87EM96YT($%W87)D(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R92UB87-E9"!C;VUP96YS871I
M;VXL(&YU;6)E<B!O9B!S:&%R97,@875T:&]R:7IE9#PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,3,P+#<R-3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YC<F5A<V5D(&YU;6)E<B!O
M9B!S:&%R97,@875T:&]R:7IE9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,34P+#(Y-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4VAA<F4M8F%S960@8V]M<&5N<V%T:6]N(&%R<F%N
M9V5M96YT(&)Y('-H87)E+6)A<V5D('!A>6UE;G0@87=A<F0L(&]P=&EO;G,L
M(&]U='-T86YD:6YG+"!N=6UB97(\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$Y+#<P-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^5V5I9VAT960@879E<F%G92!E>&5R8VES92!P<FEC
M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P+C@Q/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%<75I
M='D@26YC96YT:79E(%!L86X@,C`P,R!;365M8F5R73PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-H87)E+6)A<V5D($-O;7!E
M;G-A=&EO;B!!<G)A;F=E;65N="!B>2!3:&%R92UB87-E9"!087EM96YT($%W
M87)D(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y3:&%R92UB87-E9"!C;VUP96YS871I;VXL(&YU;6)E
M<B!O9B!S:&%R97,@875T:&]R:7IE9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,BPP-3$L-C0T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y);F-R96%S960@;G5M8F5R(&]F('-H87)E
M<R!A=71H;W)I>F5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT
M+#,S-BPW,S`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XS+#<Y,"PW-C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E-H87)E+6)A<V5D(&-O;7!E;G-A=&EO;B!A
M<G)A;F=E;65N="!B>2!S:&%R92UB87-E9"!P87EM96YT(&%W87)D+"!O<'1I
M;VYS+"!O=71S=&%N9&EN9RP@;G5M8F5R/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XR+#`P."PT-S0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=E:6=H=&5D(&%V97)A9V4@97AE<F-I
M<V4@<')I8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,2XV
M-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^26YC<F5A<V4@:6X@86=G<F5G871E(&YU;6)E<B!O9B!S:&%R97,@875T
M:&]R:7IE9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-30U+#DW
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$L-S,Y+#$Q-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^4W1O8VL@26YC96YT:79E(%!L86X@,C`Q,R!;365M8F5R
M73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-H
M87)E+6)A<V5D($-O;7!E;G-A=&EO;B!!<G)A;F=E;65N="!B>2!3:&%R92UB
M87-E9"!087EM96YT($%W87)D(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R92UB87-E9"!C;VUP
M96YS871I;VXL(&YU;6)E<B!O9B!S:&%R97,@875T:&]R:7IE9#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PY-C`L,38X/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);F-R96%S960@
M;G5M8F5R(&]F('-H87)E<R!A=71H;W)I>F5D/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XR+#DV-RPR-S(\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H87)E+6)A<V5D(&-O;7!E;G-A
M=&EO;B!A<G)A;F=E;65N="!B>2!S:&%R92UB87-E9"!P87EM96YT(&%W87)D
M+"!O<'1I;VYS+"!O=71S=&%N9&EN9RP@;G5M8F5R/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ+#4T,RPY,S<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=E:6=H=&5D(&%V97)A9V4@
M97AE<F-I<V4@<')I8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@,C0N,C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E-T;V-K(')E<V5R=F5D(&9O<B!F=71U<F4@:7-S=6%N8V4\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L.38P+#$V.#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4&5R
M8V5N=&%G92!O9B!C;VUM;VX@<W1O8VL@<VAA<F4@;W5T<W1A;F1I;F<\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0N,#`E/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-
M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\X9&(U,S=C-%]E.#<X7S1A
M,V5?.#(X85]B-3`P9C-E9&8Q,68-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z
M+R\O0SHO.&1B-3,W8S1?93@W.%\T83-E7S@R.&%?8C4P,&8S961F,3%F+U=O
M<FMS:&5E=',O4VAE970T,"YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D
M:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M
M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@
M("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G
M=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT
M+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H
M:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@
M/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14M)044^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P
M86X],T0R/CQS=')O;F<^4W1O8VLM(&)A<V5D($-O;7!E;G-A=&EO;B`M(%-C
M:&5D=6QE(&]F(%-T;V-K+4)A<V5D($-O;7!E;G-A=&EO;B!%>'!E;G-E("A$
M971A:6PI("A54T0@)"D\8G(^26X@5&AO=7-A;F1S+"!U;FQE<W,@;W1H97)W
M:7-E('-P96-I9FEE9#PO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H(&-O;'-P86X],T0S/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$
M96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^1&5C+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY%;7!L;WEE92!397)V:6-E(%-H87)E+6)A<V5D
M($-O;7!E;G-A=&EO;BP@06QL;V-A=&EO;B!O9B!296-O9VYI>F5D(%!E<FEO
M9"!#;W-T<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4W1O8VLM8F%S960@8V]M<&5N<V%T:6]N(&5X
M<&5N<V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,RPR-#0\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#@V,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@.#,X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y297-E87)C:"!A;F0@1&5V96QO<&UE;G0@6TUE;6)E<ET\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY%;7!L
M;WEE92!397)V:6-E(%-H87)E+6)A<V5D($-O;7!E;G-A=&EO;BP@06QL;V-A
M=&EO;B!O9B!296-O9VYI>F5D(%!E<FEO9"!#;W-T<R!;3&EN92!)=&5M<UT\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1O
M8VLM8F%S960@8V]M<&5N<V%T:6]N(&5X<&5N<V4\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$L-38R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-3`W/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#<R/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y'96YE<F%L(&%N9"!!9&UI
M;FES=')A=&EV92!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/D5M<&QO>65E(%-E<G9I8V4@4VAA<F4M8F%S960@
M0V]M<&5N<V%T:6]N+"!!;&QO8V%T:6]N(&]F(%)E8V]G;FEZ960@4&5R:6]D
M($-O<W1S(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y3=&]C:RUB87-E9"!C;VUP96YS871I;VX@97AP
M96YS93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q+#8X,CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M,S4U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`S-C8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'10
M87)T7SAD8C4S-V,T7V4X-SA?-&$S95\X,CAA7V(U,#!F,V5D9C$Q9@T*0V]N
M=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\X9&(U,S=C-%]E.#<X7S1A,V5?
M.#(X85]B-3`P9C-E9&8Q,68O5V]R:W-H965T<R]3:&5E=#0Q+FAT;6P-"D-O
M;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O
M;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*
M/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT
M96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G
M/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS
M/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H
M96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60]
M,T1)1#!%-E5!13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY3=&]C:RT@8F%S
M960@0V]M<&5N<V%T:6]N("T@4V-H961U;&4@;V8@1F%I<B!686QU92!/<'1I
M;VX@07=A<F0@17-T:6UA=&5D(&]N('1H92!$871E(&]F($=R86YT(%5S:6YG
M('1H92!";&%C:RU38VAO;&5S($]P=&EO;BU0<FEC:6YG($UO9&5L("A$971A
M:6PI/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M(&-O;'-P86X],T0S/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q
M+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@
M,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C
M+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY3:&%R92UB87-E9"!#;VUP96YS871I;VX@07)R86YG96UE
M;G0@8GD@4VAA<F4M8F%S960@4&%Y;65N="!!=V%R9"!;3&EN92!)=&5M<UT\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17AP
M96-T960@9&EV:61E;F0@>6EE;&0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C`N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,"XP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XP+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17AP96-T960@=F]L871I;&ET>3PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C<N,#`E/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3$N,#`E/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y2
M:7-K+69R964@:6YT97)E<W0@<F%T93PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,2XR,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D5X<&5C=&5D('1E<FT\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/C8@>65A<G,@,R!M;VYT:',\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XW('EE87)S/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^-R!Y96%R
M<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^36EN:6UU;2!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/E-H87)E+6)A<V5D($-O;7!E;G-A=&EO;B!!<G)A
M;F=E;65N="!B>2!3:&%R92UB87-E9"!087EM96YT($%W87)D(%M,:6YE($ET
M96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y%>'!E8W1E9"!V;VQA=&EL:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XU,RXP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E)I<VLM9G)E92!I;G1E<F5S="!R871E/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+C@P)3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$N,C`E/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y-87AI;75M
M(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^4VAA<F4M8F%S960@0V]M<&5N<V%T:6]N($%R<F%N9V5M96YT(&)Y
M(%-H87)E+6)A<V5D(%!A>6UE;G0@07=A<F0@6TQI;F4@271E;7-=/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X<&5C=&5D
M('9O;&%T:6QI='D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8W
M+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4FES:RUF<F5E(&EN=&5R97-T(')A=&4\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C(N,S`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,BXR,"4\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL
M/@T*#0HM+2TM+2T]7TYE>'1087)T7SAD8C4S-V,T7V4X-SA?-&$S95\X,CAA
M7V(U,#!F,V5D9C$Q9@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\X
M9&(U,S=C-%]E.#<X7S1A,V5?.#(X85]B-3`P9C-E9&8Q,68O5V]R:W-H965T
M<R]3:&5E=#0R+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U
M;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R
M<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!
M(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT
M;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C
M<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM
M96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@
M8VQA<W,],T1R97!O<G0@:60],T1)1#!%1T1!1SX-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^
M/'-T<F]N9SY3=&]C:RT@8F%S960@0V]M<&5N<V%T:6]N("T@4V-H961U;&4@
M;V8@4W1O8VL@3W!T:6]N(&%N9"!297-T<FEC=&5D(%-T;V-K(%5N:70@06-T
M:79I='D@*$1E=&%I;"D@*%531"`D*3QB<CY);B!4:&]U<V%N9',L(&5X8V5P
M="!3:&%R92!D871A+"!U;FQE<W,@;W1H97)W:7-E('-P96-I9FEE9#PO<W1R
M;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0S
M/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB
M<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY$
M:7-C;&]S=7)E(&]F($-O;7!E;G-A=&EO;B!296QA=&5D($-O<W1S+"!3:&%R
M92UB87-E9"!087EM96YT<R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H87)E<RP@3W5T<W1A;F1I;F<L
M($)E9VEN;FEN9R!"86QA;F-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XS+#(P,"PY-3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E-H87)E<RP@1W)A;G1E9#PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^.3<V+#@V.3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F5S+"!%>&5R8VES960\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#4V."PY,#8I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,2PR-C@L
M,#0Y*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#@V,RPQ-S8I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y3:&%R97,L($9O<F9E:71E9"!O<B!E>'!I<F5D/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S-BPX,#4I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R97,L
M($]U='-T86YD:6YG+"!%;F1I;F<@0F%L86YC93PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,RPU-S(L,3$V/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPR,#`L.34X/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R97,L($5X
M97)C:7-A8FQE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#8V
M."PY-C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E-H87)E<RP@5F5S=&5D(&%N9"!E>'!E8W1E9"!T;R!V97-T/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#,T,2PQ.3(\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=E:6=H
M=&5D+4%V97)A9V4@17AE<F-I<V4@4')I8V4L($]U='-T86YD:6YG+"!"96=I
M;FYI;F<@0F%L86YC93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`T+CD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E=E:6=H=&5D+4%V97)A9V4@17AE<F-I<V4@4')I8V4L($=R86YT
M960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,C<N,#8\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=E
M:6=H=&5D+4%V97)A9V4@17AE<F-I<V4@4')I8V4L($5X97)C:7-E9#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q+C,Q/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y796EG:'1E9"U!
M=F5R86=E($5X97)C:7-E(%!R:6-E+"!&;W)F96ET960@;W(@97AP:7)E9#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Y+C<V/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y796EG:'1E
M9"U!=F5R86=E($5X97)C:7-E(%!R:6-E+"!/=71S=&%N9&EN9RP@16YD:6YG
M($)A;&%N8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3$N
M-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@-"XY/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y796EG:'1E9"U!=F5R86=E($5X97)C:7-E(%!R:6-E+"!%>&5R
M8VES86)L93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S+C(T
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y796EG:'1E9"U!=F5R86=E($5X97)C:7-E(%!R:6-E+"!697-T960@86YD
M(&5X<&5C=&5D('1O('9E<W0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,3$N,#,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E=E:6=H=&5D+4%V97)A9V4@4F5M86EN:6YG($-O;G1R
M86-T=6%L(%1E<FTL($]U='-T86YD:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XW('EE87)S(#,@;6]N=&AS(#$X(&1A>7,\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XV('EE87)S(#$P
M(&UO;G1H<R`R-"!D87ES/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y796EG:'1E9"U!=F5R86=E(%)E;6%I;FEN9R!#
M;VYT<F%C='5A;"!497)M+"!%>&5R8VES86)L93PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^-2!Y96%R<R`S(&UO;G1H<R`Q."!D87ES/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y796EG
M:'1E9"U!=F5R86=E(%)E;6%I;FEN9R!#;VYT<F%C='5A;"!497)M+"!697-T
M960@86YD(&5X<&5C=&5D('1O('9E<W0\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/C<@>65A<G,@,B!M;VYT:',@,3(@9&%Y<SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06=G<F5G871E
M($EN=')I;G-I8R!686QU92P@3W5T<W1A;F1I;F<L($5N9&EN9R!"86QA;F-E
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#@T+#4Q-3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06=G
M<F5G871E($EN=')I;G-I8R!686QU92P@17AE<F-I<V%B;&4\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C4S+#$R,CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06=G<F5G871E($EN=')I
M;G-I8R!686QU92P@5F5S=&5D(&%N9"!E>'!E8W1E9"!T;R!V97-T/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#@P+#,R,SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^
M#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?.&1B-3,W8S1?93@W.%\T
M83-E7S@R.&%?8C4P,&8S961F,3%F#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE
M.B\O+T,Z+SAD8C4S-V,T7V4X-SA?-&$S95\X,CAA7V(U,#!F,V5D9C$Q9B]7
M;W)K<VAE971S+U-H965T-#,N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O
M9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT
M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@
M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$
M)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X
M="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4
M:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@
M(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5154)'/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S
M<&%N/3-$,CX\<W1R;VYG/DEN8V]M92!487AE<R`M($%D9&ET:6]N86P@26YF
M;W)M871I;VX@*$1E=&%I;"D@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,SXQ,B!-;VYT:',@
M16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^26YC;VUE(%1A>"!$
M:7-C;&]S=7)E(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]V:7-I;VX@9F]R(&9E9&5R86P@;W(@
M<W1A=&4@:6YC;VUE('1A>&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D9E9&5R86P@5&%X(&-R961I="!E>'!I<F%T:6]N
M('-T87)T('EE87(\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/C(P
M,C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D9E9&5R86P@5&%X(&-R961I="!E>'!I<F%T:6]N(&5N9&EN9R!Y96%R
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XR,#,T/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@;W!E
M<F%T:6YG(&QO<W,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<L
M,3`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^3F5T(&]P97)A=&EN9R!L;W-S97,@;&EM:71E9"!F;W(@>65A
M<B!M:6YI;75M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XR,#$U
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y.970@;W!E<F%T:6YG(&QO<W-E<R!L:6UI=&5D(&9O<B!Y96%R(&UA>&EM
M=6T\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/C(P,C<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E;6%I
M;FEN9R!P;W)T:6]N(&]F(&YE="!O<&5R871I;F<@;&]S<V5S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-3$L.#`P+#`P,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&]P97)A
M=&EN9R!L;W-S97,L(')E8V]G;FEZ960@87,@82!B96YE9FET('1H<F]U9V@@
M861D:71I;VYA;"UP86ED+6EN+6-A<&ET86P\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C<L-S`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0W5R<F5N="!D969E<G)E9"!T87@@
M;&EA8FEL:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#8P
M,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/DYO;F-U<G)E;G0@9&5F97)R960@=&%X(&%S<V5T/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#8P,"PP,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!D969E<G)E
M9"!I;F-O;64@=&%X(&%S<V5T+RAL:6%B:6QI='DI/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^1W)O<W,@=6YR96-O9VYI>F5D('1A>"!B
M96YE9FET<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PW,#`L
M,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,2PS,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y5;G)E8V]G;FEZ960@:6YT97)E<W0@;W(@<&5N86QT
M:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN8V]M
M92!T87@@97AA;6EN871I;VX@>65A<B!S=6)J96-T('1O(&5X86UI;F%T:6]N
M+"!286YG92!S=&%R=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M,C`P,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^26YC;VUE('1A>"!E>&%M:6YA=&EO;B!Y96%R('-U8FIE8W0@=&\@
M97AA;6EN871I;VXL(%)A;F=E($5N9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^,C`Q-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^36EN:6UU;2!;365M8F5R73PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DEN8V]M92!487@@1&ES8VQO
M<W5R92!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^3F5T(&]P97)A=&EN9R!L;W-S97,@;&EM:71E9"!F
M;W(@=7-E('5T:6QI>F5D(&]N(&%N(&%N;G5A;"!B87-I<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,C`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^36%X:6UU;2!;365M8F5R
M73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DEN
M8V]M92!487@@1&ES8VQO<W5R92!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&]P97)A=&EN9R!L
M;W-S97,@;&EM:71E9"!F;W(@=7-E('5T:6QI>F5D(&]N(&%N(&%N;G5A;"!B
M87-I<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PT,#`L,#`P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y5+E,N($9E9&5R86P@1V]V97)N;65N="!;365M8F5R73PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DEN8V]M92!487@@1&ES
M8VQO<W5R92!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^3F5T(&]P97)A=&EN9R!L;W-S(&-A<G)Y9F]R
M=V%R9',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$U."PY,#`L
M,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y54R!&961E<F%L(%1A>"!C<F5D:71S(&-A<G)Y(&9O<G=A<F0\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(V+#,P,"PP,#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T871E
M(&%N9"!,;V-A;"!*=7)I<V1I8W1I;VX@6TUE;6)E<ET\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY);F-O;64@5&%X($1I<V-L
M;W-U<F4@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/DYE="!O<&5R871I;F<@;&]S<R!C87)R>69O<G=A
M<F1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$P,RPT,#`L
M,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y3=&%R="!996%R(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^26YC;VUE(%1A>"!$:7-C;&]S=7)E(%M,
M:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y.970@;W!E<F%T:6YG(&QO<W,@8V%R<GEF;W)W87)D<R!E>'!I
M<F%T:6]N(&5N9&EN9R!Y96%R/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XR,#(P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y%;F1I;F<@665A<B!;365M8F5R73PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DEN8V]M92!487@@1&ES8VQO
M<W5R92!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^3F5T(&]P97)A=&EN9R!L;W-S(&-A<G)Y9F]R=V%R
M9',@97AP:7)A=&EO;B!E;F1I;F<@>65A<CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^,C`S-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM
M+3U?3F5X=%!A<G1?.&1B-3,W8S1?93@W.%\T83-E7S@R.&%?8C4P,&8S961F
M,3%F#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+SAD8C4S-V,T7V4X
M-SA?-&$S95\X,CAA7V(U,#!F,V5D9C$Q9B]7;W)K<VAE971S+U-H965T-#0N
M:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT
M86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S
M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I
M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E
M=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS
M1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C
M<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E
M<&]R="!I9#TS1$E$,$4V2T%%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,3X\<W1R;VYG/DEN
M8V]M92!487AE<R`M($-O;7!O;F5N=',@;V8@=&AE($-O;7!A;GDG<R!$969E
M<G)E9"!487@@07-S971S("A,:6%B:6QI=&EE<RD@*$1E=&%I;"D@*%531"`D
M*3QB<CY);B!4:&]U<V%N9',L('5N;&5S<R!O=&AE<G=I<V4@<W!E8VEF:65D
M/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S
M,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N
M(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#X\<W1R;VYG/D1E9F5R<F5D(&EN8V]M92!T87@@87-S971S.CPO<W1R;VYG
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&961E<F%L(%4N
M4RX@;F5T(&]P97)A=&EN9R!L;W-S(&-A<G)Y9F]R=V%R9#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`U-2PS-3@\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#,V+#4V,3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1A=&4@
M;F5T(&]P97)A=&EN9R!L;W-S(&-A<G)Y9F]R=V%R9#PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,RPW,C,\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#,Q-CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5S96%R8V@@86YD(&1E
M=F5L;W!M96YT(&-R961I="P@;F5T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XW+#$W-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C,L-S@V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y/<G!H86X@9')U9R!C<F5D:70L(&YE=#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3DL,C@W/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3DL.#@S/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$
M969E<G)E9"!R96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT
M+#`V.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C4L,3,R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y$969E<G)E9"!R979E;G5E/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XS+#DX.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C@L,C$W/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$97!R96-I871I;VX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,S,W/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PT,S@\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]T:&5R/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY-C(\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#0S.3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D=R;W-S
M(&1E9F5R<F5D(&EN8V]M92!T87@@87-S971S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XY-2PY,#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XW.2PW-S(\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E9A;'5A=&EO;B!A;&QO=V%N
M8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#DT+#(Y-RD\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@W.2PS
M-S<I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^3F5T(&1E9F5R<F5D(&EN8V]M92!T87@@87-S971S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#8P-3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,Y-3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY$969E
M<G)E9"!I;F-O;64@=&%X(&QI86)I;&ET:65S.CPO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F5P86ED(&5X<&5N9&ET=7)E
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,2PV,#4I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,SDU*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M1W)O<W,@9&5F97)R960@:6YC;VUE('1A>"!L:6%B:6QI=&EE<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,2PV,#4I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,SDU*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!D969E
M<G)E9"!I;F-O;64@=&%X(&%S<V5T+RAL:6%B:6QI='DI/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL
M/@T*#0HM+2TM+2T]7TYE>'1087)T7SAD8C4S-V,T7V4X-SA?-&$S95\X,CAA
M7V(U,#!F,V5D9C$Q9@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\X
M9&(U,S=C-%]E.#<X7S1A,V5?.#(X85]B-3`P9C-E9&8Q,68O5V]R:W-H965T
M<R]3:&5E=#0U+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U
M;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R
M<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!
M(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT
M;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C
M<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM
M96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@
M8VQA<W,],T1R97!O<G0@:60],T1)1#!%0S%!13X-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^
M/'-T<F]N9SY);F-O;64@5&%X97,@+2!296-O;F-I;&EA=&EO;B!O9B!297!O
M<G1E9"!%<W1I;6%T960@26YC;VUE(%1A>"!"96YE9FET("A$971A:6PI("A5
M4T0@)"D\8G(^26X@5&AO=7-A;F1S+"!U;FQE<W,@;W1H97)W:7-E('-P96-I
M9FEE9#PO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O
M;'-P86X],T0S/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R
M,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L
M(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S
M,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M/'-T<F]N9SY%9F9E8W1I=F4@26YC;VUE(%1A>"!2871E(%)E8V]N8VEL:6%T
M:6]N(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y5;FET960@4W1A=&5S(&9E9&5R86P@=&%X(&%T('-T
M871U=&]R>2!R871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@
M*#$S+#0Q,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B0@*#DQ*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@,BPY,C<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T871E('1A>&5S("AN970@;V8@9F5D
M97)A;"!B96YE9FET*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH
M,2PV,#@I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-C`Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,2PT-C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D1E9F5R<F5D(&EN8V]M92!T87@@861J=7-T;65N
M=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#@U-2D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@U,3(I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$
M969E<G)E9"!S=&%T92!B;&5N9&5D(')A=&4@861J=7-T;65N=',\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L,#,T/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,S0T*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5S96%R8V@@
M8W)E9&ET+"!N970\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(L
M,C(X*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#(R-BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E1R86YS86-T:6]N(&-O<W0@9&5D=6-T:6]N/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B@S-SDI/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/<G!H86X@9')U9R!C<F5D
M:70L(&YE=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3,Y*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#@T
M,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@T+#@Y-BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D]T:&5R('!E<FUA;F5N="!I=&5M<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XH,S@R*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C,\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XX/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%<75I='DM8F%S960@8V]M<&5N
M<V%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW-38\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-#$\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR
M-SD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D9A:7(@=F%L=64@861J=7-T;65N="!O9B!P<F5F97)R960@<W1O8VL@
M=V%R<F%N="!L:6%B:6QI='D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C(Q.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^*#4S*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^0VAA;F=E(&EN('9A;'5A=&EO;B!A;&QO=V%N8V4\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$T+#DR,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,C@W/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S@W/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M26YC;VUE('1A>"!E>'!E;G-E+RAB96YE9FET*3PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y0<FEO<B!996%R($%D:G5S=&UE;G0@6TUE
M;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N
M9SY%9F9E8W1I=F4@26YC;VUE(%1A>"!2871E(%)E8V]N8VEL:6%T:6]N(%M,
M:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y4<F%N<V%C=&EO;B!C;W-T(&1E9'5C=&EO;CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XD("@U-C0I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M
M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\X9&(U,S=C-%]E.#<X7S1A,V5?.#(X
M85]B-3`P9C-E9&8Q,68-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO
M.&1B-3,W8S1?93@W.%\T83-E7S@R.&%?8C4P,&8S961F,3%F+U=O<FMS:&5E
M=',O4VAE970T-BYH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q
M=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA
M<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\3454
M02!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H
M=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S
M8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M
M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE
M(&-L87-S/3-$<F5P;W)T(&ED/3-$240P13),04,^#0H@("`@("`\='(^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R
M/CQS=')O;F<^26YC;VUE(%1A>&5S("T@4F5C;VYC:6QI871I;VX@;V8@=&AE
M($)E9VEN;FEN9R!A;F0@16YD:6YG($%M;W5N="!O9B!'<F]S<R!5;G)E8V]G
M;FEZ960@5&%X($)E;F5F:71S("A$971A:6PI("A54T0@)"D\8G(^26X@5&AO
M=7-A;F1S+"!U;FQE<W,@;W1H97)W:7-E('-P96-I9FEE9#PO<W1R;VYG/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0S/C$R($UO
M;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CX\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY);F-O;64@
M5&%X($1I<V-L;W-U<F4@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y"96=I;FYI;F<@8F%L86YC93PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q+#<P.#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,2PU.3(\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$L
M-3,T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y);F-R96%S97,O*&1E8W)E87-E<RD@9F]R(&-U<G)E;G0@>65A<B!T
M87@@<&]S:71I;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR
M-#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ,38\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XU.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^26YC<F5A<V5S+RAD96-R96%S97,I(&9O<B!P<FEO<B!Y96%R
M('1A>"!P;W-I=&EO;G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/CDW/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y$96-R96%S97,@87,@82!R97-U;'0@;V8@97AP:7)A=&EO;B!O9B!S
M=&%T=71E(&]F(&QI;6ET871I;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D5N9&EN9R!B86QA;F-E/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#(L,#0W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q+#<P.#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,2PU.3(\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y
M/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7SAD8C4S-V,T7V4X-SA?
M-&$S95\X,CAA7V(U,#!F,V5D9C$Q9@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL
M93HO+R]#.B\X9&(U,S=C-%]E.#<X7S1A,V5?.#(X85]B-3`P9C-E9&8Q,68O
M5V]R:W-H965T<R]3:&5E=#0W+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC
M;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H
M=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*
M("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS
M1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E
M>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@
M5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@
M("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%54I!1SX-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W
M<W!A;CTS1#(^/'-T<F]N9SY,96%S92!%>&ET($QI86)I;&ET>2`M($%D9&ET
M:6]N86P@26YF;W)M871I;VX@*$1E=&%I;"D@*%531"`D*3QB<CX\+W-T<F]N
M9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,SXQ
M,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C
M;VQS<&%N/3-$,3XP($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H(&-O;'-P86X],T0Q/CPO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T
M/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P
M,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@
M,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6PN(#$V
M+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;"X@
M,38L(#(P,#@\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^4F5S=')U8W1U<FEN9R!#;W-T(&%N9"!297-E<G9E(%M,:6YE
M($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y/<&5R871I;F<@3&5A<V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/C(P,3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D]N971I;64@<'5R8VAA<V4@<&%Y;65N="!U;F1E<B!P
M=7)C:&%S92!A9W)E96UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@-2PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y!9&1I=&EO;F%L(&%M;W5N=',@<F5C;W)D960\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^36EN:6UU;2!;
M365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R
M;VYG/E)E<W1R=6-T=7)I;F<@0V]S="!A;F0@4F5S97)V92!;3&EN92!)=&5M
M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M3VYE=&EM92!P87EM96YT('!A:60@=6YD97(@;&EC96YS92!O9B!P<F]D=6-T
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX+#`P,"PP,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DUA
M>&EM=6T@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY297-T<G5C='5R:6YG($-O<W0@86YD(%)E<V5R=F4@6TQI
M;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D]N971I;64@<&%Y;65N="!P86ED('5N9&5R(&QI8V5N<V4@;V8@
M<')O9'5C=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q,BPP
M,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y397)I97,@1"!#;VYV97)T:6)L92!0<F5F97)R960@4W1O8VL@
M6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY297-T<G5C='5R:6YG($-O<W0@86YD(%)E<V5R=F4@6TQI;F4@271E
M;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E-H87)E<R!I<W-U960@:6X@8V]N;F5C=&EO;B!W:71H(&%C<75I<VET:6]N
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,BPT-C8L,#,Y/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@
M(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\X9&(U,S=C
M-%]E.#<X7S1A,V5?.#(X85]B-3`P9C-E9&8Q,68-"D-O;G1E;G0M3&]C871I
M;VXZ(&9I;&4Z+R\O0SHO.&1B-3,W8S1?93@W.%\T83-E7S@R.&%?8C4P,&8S
M961F,3%F+U=O<FMS:&5E=',O4VAE970T."YH=&UL#0I#;VYT96YT+51R86YS
M9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z
M('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\
M:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O
M;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y
M<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@
M4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O
M9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14E*04,^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X]
M,T0Q(')O=W-P86X],T0R/CQS=')O;F<^3&5A<V4@17AI="!,:6%B:6QI='D@
M+2!#:&%N9V5S(&EN($QE87-E($5X:70@3&EA8FEL:71Y("A$971A:6PI("A#
M;VYT<F%C="!497)M:6YA=&EO;B!;365M8F5R72P@55-$("0I/&)R/DEN(%1H
M;W5S86YD<RP@=6YL97-S(&]T:&5R=VES92!S<&5C:69I960\+W-T<F]N9SX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXQ,B!-
M;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VYT<F%C="!497)M:6YA
M=&EO;B!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#X\<W1R;VYG/E)E<W1R=6-T=7)I;F<@0V]S="!A;F0@4F5S97)V92!;3&EN
M92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^06-C<G5A;"!"96=I;FYI;F<@0F%L86YC93PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`Y+#0T-3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3`L,#<T/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<FEN8VEP86P@
M<&%Y;65N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$L-#,Y
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M*#8R.2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D%C8W)U86P@16YD:6YG($)A;&%N8V4\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@."PP,#8\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#DL-#0U/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO
M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\X9&(U,S=C-%]E.#<X7S1A,V5?
M.#(X85]B-3`P9C-E9&8Q,68-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O
M0SHO.&1B-3,W8S1?93@W.%\T83-E7S@R.&%?8C4P,&8S961F,3%F+U=O<FMS
M:&5E=',O4VAE970T.2YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG
M.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@
M8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\
M345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X
M="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA
M=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@
M0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A
M8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P141!044^#0H@("`@("`\='(^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X]
M,T0Q/CQS=')O;F<^3&5A<V4@17AI="!,:6%B:6QI='D@+2!&=71U<F4@4')I
M;F-I<&%L(%!A>6UE;G1S(%5N9&5R($QE87-E($%G<F5E;65N="`H1&5T86EL
M*2`H55-$("0I/&)R/DEN(%1H;W5S86YD<RP@=6YL97-S(&]T:&5R=VES92!S
M<&5C:69I960\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/D]P97)A=&EN9R!,96%S960@07-S971S(%M,:6YE
M($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#XR,#$U/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#,L
M.30U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#XR,#$V/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+#,V
M-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^,C`Q-SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"PT.34\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/C(P,3@\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0L,SDV/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M5&]T86P\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$Y+#$X.3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4F%V96X@0FEO=&5C:&YO;&]G:65S($EN8RX@6TUE;6)E<ET\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY/<&5R871I;F<@3&5A
M<V5D($%S<V5T<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^,C`Q-3PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,2PV-#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/C(P,38\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$L.#8V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#XR,#$W/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XR+#$Q,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^,C`Q.#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,BPS.#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y4;W1A;#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`X+#`P-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?
M3F5X=%!A<G1?.&1B-3,W8S1?93@W.%\T83-E7S@R.&%?8C4P,&8S961F,3%F
M#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+SAD8C4S-V,T7V4X-SA?
M-&$S95\X,CAA7V(U,#!F,V5D9C$Q9B]7;W)K<VAE971S+U-H965T-3`N:'1M
M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L
M90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI
M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS
M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU
M=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H
M;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP
M=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R
M="!I9#TS1$E$,$52-$)'/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D-O;&QA
M8F]R871I;VX@86YD($QI8V5N<V4@06=R965M96YT<R`M($%D9&ET:6]N86P@
M26YF;W)M871I;VX@,2`H1&5T86EL*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$@36]N
M=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A
M;CTS1#(^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@@8V]L<W!A;CTS1#$^,2!-;VYT:',@16YD960\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1F5B
M+B`R."P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$
M96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^36%Y(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/DQI8V5N<V4@06YD($-O;&QA8F]R871I;VX@06=R
M965M96YT<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4W1O8VL@:7-S=65D(&1U<FEN9R!P97)I;V0@
M=F%L=64L(&YE=R!I<W-U97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@-S8L-S$V+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@.#,L-C(S+#`P,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1O8VL@:7-S=65D(&1U
M<FEN9R!T:&4@<&5R:6]D(&9O<B!N97<@:7-S=64\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$L.#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5F97)R960@<F5V96YU92!C
M=7)R96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-"PR-#@L
M,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,C`L,C8W+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^1&5F97)R960@<F5V96YU92!N;VXM8W5R<F5N=#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,38L-#<R+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<L,3,V
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^2F%N<W-E;B!":6]T96-H($EN8RX@6TUE;6)E<ET\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY,:6-E;G-E($%N9"!#
M;VQL86)O<F%T:6]N($%G<F5E;65N=',@6TQI;F4@271E;7-=/"]S=')O;F<^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;&QA8F]R871I
M;VX@86=R965M96YT(&1A=&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/D1E8V5M8F5R(#(P,30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K(&ES<W5E9"!D=7)I;F<@<&5R:6]D
M('9A;'5E+"!N97<@:7-S=65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XW-2PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y3=&]C:R!I<W-U960@9'5R:6YG('1H92!P97)I
M;V0@9F]R(&YE=R!I<W-U93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,2PY,C,L,#<W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VL@<')I8V4@<&5R('-H87)E/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#,Y/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.;VYR969U;F1A
M8FQE('5P9G)O;G0@<&%Y;65N="!R96-E:79A8FQE/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XU,"PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;&EN:6-A;"P@<F5G=6QA
M=&]R>2!A;F0@8V]M;65R8VEA;&EZ871I;VX@;6EL97-T;VYE('!A>6UE;G1S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU-S4L,#`P+#`P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4F5C;V=N:7IE9"!R979E;G5E('5N9&5R(&%G<F5E;65N=#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5F97)R960@<F5V96YU93PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&%K961A(%M-96UB97)=
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^3&EC
M96YS92!!;F0@0V]L;&%B;W)A=&EO;B!!9W)E96UE;G1S(%M,:6YE($ET96US
M73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#
M;VQL86)O<F%T:6]N(&%G<F5E;65N="!D871E/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#Y-87D@,C`Q-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5C;V=N:7IE9"!R979E;G5E('5N
M9&5R(&%G<F5E;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,RPP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y$969E<G)E9"!R979E;G5E/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XW+#$P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYO;G)E9G5N9&%B;&4@=7!F<F]N
M="!P87EM96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-2PP
M,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y,:6-E;G-E(&]P=&EO;B!F964@86YD(&5A<FQY(&1E=F5L;W!M
M96YT(&UI;&5S=&]N93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,3@L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^1&5V96QO<&UE;G0L(')E9W5L871O<GD@86YD('-A;&5S
M(&UI;&5S=&]N92!P87EM96YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-#8X+#4P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D%M;W5N="!A;&QO8V%T960@=&\@86=R965M
M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,"PP,#`L,#`P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y%>'!E8W1E9"!P97)I;V0@;V8@9&5V96QO<&UE;G0\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/C(T(&UO;G1H<SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5F97)R960@<F5V96YU
M92!C=7)R96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+#`P
M,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D1E9F5R<F5D(')E=F5N=64@;F]N+6-U<G)E;G0\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C(L,3`P+#`P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&%K961A(%M-96UB
M97)=('P@4F5S96%R8V@@0V]L;&%B;W)A=&EO;B!!;F0@3&EC96YS92!/<'1I
M;VX@06=R965M96YT(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/CQS=')O;F<^3&EC96YS92!!;F0@0V]L;&%B;W)A=&EO;B!!
M9W)E96UE;G1S(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y#;VQL86)O<F%T:6]N(&%G<F5E;65N="!D
M871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#Y397!T96UB97(@
M,C`Q-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4F5C;V=N:7IE9"!R979E;G5E('5N9&5R(&%G<F5E;65N=#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-2PP,#`L,#`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!;6]U;G0@
M86QL;V-A=&5D('1O(&%G<F5E;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`U+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM
M+2TM+2T]7TYE>'1087)T7SAD8C4S-V,T7V4X-SA?-&$S95\X,CAA7V(U,#!F
M,V5D9C$Q9@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\X9&(U,S=C
M-%]E.#<X7S1A,V5?.#(X85]B-3`P9C-E9&8Q,68O5V]R:W-H965T<R]3:&5E
M=#4Q+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP
M<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U
M<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M
M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H
M87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S
M<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO
M/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,]
M,T1R97!O<G0@:60],T1)1#!%25I!1SX-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N
M9SY#;VQL86)O<F%T:6]N(&%N9"!,:6-E;G-E($%G<F5E;65N=',@+2!!9&1I
M=&EO;F%L($EN9F]R;6%T:6]N(#(@*$1E=&%I;"D@*%531"`D*3QB<CX\+W-T
M<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,3XQ($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M(&-O;'-P86X],T0R/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*86XN(#,Q
M+"`R,#$S/&)R/DUO;&5C=6QE/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^/'-T<F]N9SY,:6-E;G-E($%N9"!#;VQL86)O<F%T
M:6]N($%G<F5E;65N=',@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E9F5R<F5D(')E=F5N=64L($-U
M<G)E;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,30L,C0X
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,C`L,C8W+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^1VEL96%D(%M-96UB97)=/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^3&EC96YS92!!;F0@0V]L
M;&%B;W)A=&EO;B!!9W)E96UE;G1S(%M,:6YE($ET96US73PO<W1R;VYG/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VQL86)O<F%T:6]N
M(&%G<F5E;65N="!D871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#Y*86YU87)Y(#(P,3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D-O;6UE<F-I86QI>F%T:6]N(&]F(&UO;&5C=6QE
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&EC96YS92!G
M<F%N="!F965S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW+#4P
M,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D5X<&5C=&5D('!E<FEO9"!O9B!D979E;&]P;65N=#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^,C$@;6]N=&AS/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y296-O9VYI>F5D
M(')E=F5N=64@=6YD97(@86=R965M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XU+#4P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XX+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DUI;&5S=&]N92!A8VAI
M979E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E9F5R
M<F5D(')E=F5N=64L($-U<G)E;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XS+#8P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D=I;&5A9"!;365M8F5R72!\($UI;FEM=6T@
M6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY,:6-E;G-E($%N9"!#;VQL86)O<F%T:6]N($%G<F5E;65N=',@6TQI
M;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E)E9W5L871O<GD@86YD('-A;&5S(&UI;&5S=&]N93PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C0P+#`P,"PP,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D=I;&5A9"!;
M365M8F5R72!\($UA>&EM=6T@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^/'-T<F]N9SY,:6-E;G-E($%N9"!#;VQL86)O<F%T
M:6]N($%G<F5E;65N=',@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E9W5L871O<GD@86YD('-A;&5S
M(&UI;&5S=&]N93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C4P
M+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D=I;&5A9"!;365M8F5R72!\(%!R92U#;&EN:6-A;"!-:6QE
M<W1O;F5S(%M-96UB97)=('P@36EN:6UU;2!;365M8F5R73PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DQI8V5N<V4@06YD($-O
M;&QA8F]R871I;VX@06=R965M96YT<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0VQI;FEC86P@;6EL
M97-T;VYE('!A>6UE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XR,"PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y':6QE860@6TUE;6)E<ET@?"!0<F4M0VQI;FEC86P@
M36EL97-T;VYE<R!;365M8F5R72!\($UA>&EM=6T@6TUE;6)E<ET\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY,:6-E;G-E($%N
M9"!#;VQL86)O<F%T:6]N($%G<F5E;65N=',@6TQI;F4@271E;7-=/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-L:6YI8V%L
M(&UI;&5S=&]N92!P87EM96YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`R-2PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM
M+2TM/5].97AT4&%R=%\X9&(U,S=C-%]E.#<X7S1A,V5?.#(X85]B-3`P9C-E
M9&8Q,68-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.&1B-3,W8S1?
M93@W.%\T83-E7S@R.&%?8C4P,&8S961F,3%F+U=O<FMS:&5E=',O4VAE970U
M,BYH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I
M;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M
M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q
M=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R
M<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C
M/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO
M<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$
M<F5P;W)T(&ED/3-$240P14%.0TD^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^
M0V]L;&%B;W)A=&EO;B!A;F0@3&EC96YS92!!9W)E96UE;G1S("T@061D:71I
M;VYA;"!);F9O<FUA=&EO;B`S("A$971A:6PI("A54T0@)"D\8G(^/"]S=')O
M;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^
M,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@
M8V]L<W!A;CTS1#$^,2!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXQ,B!-;VYT:',@16YD960\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ($UO;G1H<R!%
M;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/DYO=BX@,S`L(#(P,3$\8G(^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3(\8G(^/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^3&EC96YS92!!
M;F0@0V]L;&%B;W)A=&EO;B!!9W)E96UE;G1S(%M,:6YE($ET96US73PO<W1R
M;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$969E<G)E
M9"!R979E;G5E+"!#=7)R96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#$T+#(T."PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#(P+#(V-RPP,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-H86YG92!I;B!A8V-O
M=6YT:6YG(&5S=&EM871E+"!C=7)R96YT('EE87(@:6UP86-T/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#<P,"PP,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E9F5R<F5D(')E
M=F5N=64L($QO;F<M=&5R;2!L:6%B:6QI=&EE<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,38L-#<R+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<L,3,V+#`P,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4V5R=FEE<B!;
M365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R
M;VYG/DQI8V5N<V4@06YD($-O;&QA8F]R871I;VX@06=R965M96YT<R!;3&EN
M92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^0V]L;&%B;W)A=&EO;B!A9W)E96UE;G0@9&%T93PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^3F]V96UB97(@,C`Q,3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F]N<F5F=6YD
M86)L92!U<&9R;VYT('!A>6UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C(P+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D5X<&5C=&5D('!E<FEO9"!O9B!D979E;&]P
M;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^,C<@;6]N=&AS
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y296-O9VYI>F5D(')E=F5N=64@=6YD97(@86=R965M96YT/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XW,#`L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C$L,S`P+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDL,3`P
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^36EL97-T;VYE('!A>6UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$P+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E9F5R<F5D(')E=F5N=64L($-U<G)E
M;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P,"PP,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY,#`L
M,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y397)V:65R(%M-96UB97)=('P@4V5C;VYD(%)I9VAT('1O($1E=F5L
M;W`@0V]L;&%B;W)A=&EO;B!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/DQI8V5N<V4@06YD($-O;&QA8F]R871I
M;VX@06=R965M96YT<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]L;&%B;W)A=&EO;B!A9W)E96UE
M;G0@9&%T93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^4V5P=&5M
M8F5R(#(P,3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/DYO;G)E9G5N9&%B;&4@=7!F<F]N="!P87EM96YT/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,"PP,#`L,#`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%>'!E8W1E
M9"!P97)I;V0@;V8@9&5V96QO<&UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/C(Y(&UO;G1H<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4F5C;V=N:7IE9"!R979E;G5E('5N9&5R
M(&%G<F5E;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,38L
M-S`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C@L-C`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C(L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^36EL97-T;VYE('!A>6UE;G0\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4L,#`P+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$
M969E<G)E9"!R979E;G5E+"!#=7)R96YT/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XS+#,P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XX+#8P,"PP,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]P=&EO;B!E>&5R8VES
M92!F964\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$U+#`P,"PP
M,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D]F9G-E="!T;R!R97-E87)C:"!A;F0@9&5V96QO<&UE;G0@8V]S=',@
M=6YD97(@8V]L;&%B;W)A=&EO;B!A<G)A;F=E;65N=#PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,2PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]P=&EO;B!E>&5R8VES
M92!F964@<F5C;V=N:71I;VX@<&5R:6]D/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XX,B!M;VYT:',\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;&QA8F]R871I;VX@<F5C96EV86)L
M92P@:6YC;'5D960@:6X@86-C;W5N=',@<F5C96EV86)L93PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^.#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3G5M8F5R(&]F(&UI;&5S
M=&]N97,@86-H:65V960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E)E=FEE=R!P97)I;V0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/C,P(&1A>7,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D1E9F5R<F5D(')E=F5N=64\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$W+#<P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY+#0P,"PP,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E9F5R<F5D
M(')E=F5N=64L($QO;F<M=&5R;2!L:6%B:6QI=&EE<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,30L-#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@P,"PP,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-E<G9I97(@
M6TUE;6)E<ET@?"!38V5N87)I;RP@061J=7-T;65N="!;365M8F5R73PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DQI8V5N<V4@
M06YD($-O;&QA8F]R871I;VX@06=R965M96YT<R!;3&EN92!)=&5M<UT\+W-T
M<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17AP96-T
M960@<&5R:6]D(&]F(&1E=F5L;W!M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XT,B!M;VYT:',\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-E<G9I97(@6TUE;6)E<ET@?"!38V5N
M87)I;RP@061J=7-T;65N="!;365M8F5R72!\(%-E8V]N9"!2:6=H="!T;R!$
M979E;&]P($-O;&QA8F]R871I;VX@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY,:6-E;G-E($%N9"!#;VQL86)O
M<F%T:6]N($%G<F5E;65N=',@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X<&5C=&5D('!E<FEO9"!O
M9B!D979E;&]P;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M-S4@;6]N=&AS/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y397)V:65R(%M-96UB97)=('P@36%X:6UU;2!;365M8F5R
M73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DQI
M8V5N<V4@06YD($-O;&QA8F]R871I;VX@06=R965M96YT<R!;3&EN92!)=&5M
M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M061D:71I;VYA;"!L:6-E;G-E(&=R86YT(&9E97,\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C,P+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-L:6YI8V%L(&UI;&5S=&]N
M92!P87EM96YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#<L
M,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4F5G=6QA=&]R>2!M:6QE<W1O;F4@<&%Y;65N=',\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$T,"PP,#`L,#`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y386QE<R!M
M:6QE<W1O;F4@<&%Y;65N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C(P."PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y397)V:65R(%M-96UB97)=('P@36%X:6UU;2!;
M365M8F5R72!\(%-E8V]N9"!2:6=H="!T;R!$979E;&]P($-O;&QA8F]R871I
M;VX@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M/'-T<F]N9SY,:6-E;G-E($%N9"!#;VQL86)O<F%T:6]N($%G<F5E;65N=',@
M6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D%D9&ET:6]N86P@;&EC96YS92!G<F%N="!F965S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV-2PP,#`L,#`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;&EN:6-A
M;"!M:6QE<W1O;F4@<&%Y;65N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/CDX+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E)E9W5L871O<GD@;6EL97-T;VYE('!A>6UE
M;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,#`L,#`P+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4V%L97,@;6EL97-T;VYE('!A>6UE;G1S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XV,S`L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0VQI;FEC86P@;6EL97-T;VYE
M('!A>6UE;G1S('5N9&5R(&%G<F5E;65N=#PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`U+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*
M#0HM+2TM+2T]7TYE>'1087)T7SAD8C4S-V,T7V4X-SA?-&$S95\X,CAA7V(U
M,#!F,V5D9C$Q9@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\X9&(U
M,S=C-%]E.#<X7S1A,V5?.#(X85]B-3`P9C-E9&8Q,68O5V]R:W-H965T<R]3
M:&5E=#4S+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E
M9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T
M/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT
M='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[
M(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP
M="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT
M("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA
M<W,],T1R97!O<G0@:60],T1)1#!%5$]!1SX-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T
M<F]N9SY#;VQL86)O<F%T:6]N(&%N9"!,:6-E;G-E($%G<F5E;65N=',@+2!!
M9&1I=&EO;F%L($EN9F]R;6%T:6]N(#0@*$1E=&%I;"D@*%531"`D*3QB<CX\
M+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N
M/3-$,3XQ($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H(&-O;'-P86X],T0S/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y/8W0N
M(#,Q+"`R,#$P/&)R/DUO;&5C=6QE/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^4&%Y;65N=',\8G(^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DQI8V5N
M<V4@06YD($-O;&QA8F]R871I;VX@06=R965M96YT<R!;3&EN92!)=&5M<UT\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5F
M97)R960@<F5V96YU92P@0W5R<F5N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`Q-"PR-#@L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R,"PR-C<L,#`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$969E<G)E9"!R
M979E;G5E+"!,;VYG+71E<FT@;&EA8FEL:71I97,\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$V+#0W,BPP,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW+#$S-BPP,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D)O96AR:6YG
M97(@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M/'-T<F]N9SY,:6-E;G-E($%N9"!#;VQL86)O<F%T:6]N($%G<F5E;65N=',@
M6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D-O;&QA8F]R871I;VX@86=R965M96YT(&1A=&4\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/D]C=&]B97(@,C`Q,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;65R
M8VEA;&EZ871I;VX@;V8@;6]L96-U;&5S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^3F]N<F5F=6YD86)L92!U<&9R;VYT('!A>6UE;G0\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$U+#`P,"PP,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYU
M;6)E<B!O9B!A;FYU86P@;6%I;G1E;F%N8V4@<&%Y;65N=',@<F5C96EV960\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-L:6YI8V%L(&UI
M;&5S=&]N92!P87EM96YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-#$L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4F5G=6QA=&]R>2!M:6QE<W1O;F4@<&%Y;65N=',\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@Y+#`P,"PP,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-A
M;&5S(&UI;&5S=&]N92!P87EM96YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^.#,L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4F5S96%R8V@@;V)L:6=A=&EO;B!C;VUP
M;&5T:6]N(&1A=&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/C(P
M,34M,#D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E)E8V]G;FEZ960@<F5V96YU92!U;F1E<B!A9W)E96UE;G0\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$S+#<P,"PP,#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-"PT,#`L
M,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,3$L-S`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^1&5F97)R960@<F5V96YU93PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,3(L.#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5F97)R960@<F5V96YU
M92P@0W5R<F5N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-2PX
M,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-RPP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y$969E<G)E9"!R979E;G5E+"!,;VYG+71E<FT@
M;&EA8FEL:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4L
M.#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^36EL97-T;VYE('!A>6UE;G0\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@,BPP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`U+#`P,"PP,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(L,#`P+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE
M/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?.&1B
M-3,W8S1?93@W.%\T83-E7S@R.&%?8C4P,&8S961F,3%F#0I#;VYT96YT+4QO
M8V%T:6]N.B!F:6QE.B\O+T,Z+SAD8C4S-V,T7V4X-SA?-&$S95\X,CAA7V(U
M,#!F,V5D9C$Q9B]7;W)K<VAE971S+U-H965T-30N:'1M;`T*0V]N=&5N="U4
M<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4
M>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-
M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP
M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP
M="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@
M3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@
M(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$50
M24%'/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS
M<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D-O;&QA8F]R871I;VX@86YD
M($QI8V5N<V4@06=R965M96YT<R`M($%D9&ET:6]N86P@26YF;W)M871I;VX@
M-2`H1&5T86EL*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$@36]N=&AS($5N9&5D/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#,^,3(@36]N
M=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/D]C="X@,S$L(#(P,3`\8G(^36]L96-U;&4\
M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q
M-#QB<CY0<F]G<F%M/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^1&5C+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY,:6-E;G-E($%N9"!#;VQL86)O<F%T:6]N($%G
M<F5E;65N=',@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D1E9F5R<F5D(')E=F5N=64\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,30L,C0X+#`P,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,C`L,C8W+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4&9I>F5R(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^3&EC96YS92!!;F0@0V]L;&%B;W)A=&EO;B!!9W)E
M96UE;G1S(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y#;VQL86)O<F%T:6]N(&%G<F5E;65N="!D871E
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#Y/8W1O8F5R(#(P,3`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E!E<FEO9"!O9B!A9W)E96UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/C,@>65A<G,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D-O;6UE<F-I86QI>F%T:6]N(&]F(&UO;&5C=6QE
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F]N<F5F=6YD
M86)L92!U<&9R;VYT('!A>6UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C4L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C4L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0VQI;FEC86P@;6EL97-T;VYE
M('!A>6UE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-RPP
M,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y#;VUM97)C:6%L:7IA=&EO;B!A;F0@<V%L97,@;6EL97-T;VYE
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3DU+#`P,"PP,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D1!4E0@<')O9W)A;3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4F5S96%R8V@@;V)L:6=A=&EO;B!C;VUP;&5T:6]N(&1A=&4\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/C(P,30M,#$\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1E<FT@;V8@=&AE
M(&%G<F5E;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^,C`Q
M-"TP,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4F5C;V=N:7IE9"!R979E;G5E('5N9&5R(&%G<F5E;65N=#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`P+#`P,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L-3`P+#`P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4L
M-3`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^36EL97-T;VYE<R!A8VAI979E9#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C4P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E9F5R<F5D(')E=F5N=64\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-RPP,#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B
M;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7SAD8C4S-V,T7V4X
M-SA?-&$S95\X,CAA7V(U,#!F,V5D9C$Q9@T*0V]N=&5N="U,;V-A=&EO;CH@
M9FEL93HO+R]#.B\X9&(U,S=C-%]E.#<X7S1A,V5?.#(X85]B-3`P9C-E9&8Q
M,68O5V]R:W-H965T<R]3:&5E=#4U+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M
M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X
M="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D
M/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N
M=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS
M1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO
M=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-
M"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%6$5!1SX-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@
M<F]W<W!A;CTS1#(^/'-T<F]N9SY#;VQL86)O<F%T:6]N(&%N9"!,:6-E;G-E
M($%G<F5E;65N=',@+2!!9&1I=&EO;F%L($EN9F]R;6%T:6]N(#8@*$1E=&%I
M;"D@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:"!C;VQS<&%N/3-$,3XQ($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/C$R($UO;G1H<R!%;F1E
M9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y*=6XN(#,P+"`R,#$P/&)R/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY,:6-E;G-E($%N9"!#;VQL
M86)O<F%T:6]N($%G<F5E;65N=',@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E9F5R<F5D(')E=F5N
M=64L($-U<G)E;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M,30L,C0X+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@,C`L,C8W+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5F97)R960@<F5V96YU92P@3&]N
M9RUT97)M(&QI86)I;&ET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ-BPT-S(L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-RPQ,S8L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y'<F5E;B!#<F]S<R!;365M8F5R
M73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DQI
M8V5N<V4@06YD($-O;&QA8F]R871I;VX@06=R965M96YT<R!;3&EN92!)=&5M
M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M0V]L;&%B;W)A=&EO;B!A9W)E96UE;G0@9&%T93PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^2G5N92`R,#$P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y497)M(&]F('1H92!A9W)E96UE
M;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/C(P,C`M,#8\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYO
M;G)E9G5N9&%B;&4@=7!F<F]N="!P87EM96YT/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%D:G5S=&UE;G0@=&\@<F5V96YU
M92!F<F]M(&-O;G1R86-T(&UA=&5R:6%L(&UO9&EF:6-A=&EO;CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PS,#`L,#`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y296-O9VYI>F5D
M(')E=F5N=64@=6YD97(@86=R965M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ+#<P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y-:6QE<W1O;F5S(&%C:&EE
M=F5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5F97)R
M960@<F5V96YU93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C4P
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^56YB:6QL960@<F5C96EV86)L92!B86QA;F-E/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XU,C4L,#`P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$969E<G)E9"!R979E;G5E
M+"!#=7)R96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,#`L
M,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y$969E<G)E9"!R979E;G5E+"!,;VYG+71E<FT@;&EA8FEL:71I97,\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4U,"PP,#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D=R965N
M($-R;W-S(%M-96UB97)=('P@36%X:6UU;2!;365M8F5R73PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DQI8V5N<V4@06YD($-O
M;&QA8F]R871I;VX@06=R965M96YT<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06=G<F5G871E('!O
M=&5N=&EA;"!F=71U<F4@8V]S="!R96EM8G5R<V5M96YT/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XU+#4P,"PP,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-L:6YI8V%L(&%N9"!C
M;VUM97)C:6%L(&UI;&5S=&]N92!P87EM96YT<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`R+#4P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL
M/@T*#0HM+2TM+2T]7TYE>'1087)T7SAD8C4S-V,T7V4X-SA?-&$S95\X,CAA
M7V(U,#!F,V5D9C$Q9@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\X
M9&(U,S=C-%]E.#<X7S1A,V5?.#(X85]B-3`P9C-E9&8Q,68O5V]R:W-H965T
M<R]3:&5E=#4V+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U
M;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R
M<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!
M(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT
M;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C
M<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM
M96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@
M8VQA<W,],T1R97!O<G0@:60],T1)1#!%44Q!13X-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^
M/'-T<F]N9SY#;VQL86)O<F%T:6]N(&%N9"!,:6-E;G-E($%G<F5E;65N=',@
M+2!!9&1I=&EO;F%L($EN9F]R;6%T:6]N(#<@*$1E=&%I;"D@*$5L:2!,:6QL
M>2!;365M8F5R72P@55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/C$@36]N=&AS($5N9&5D/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#,^,3(@36]N
M=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/DUA>2`S,2P@,C`Q,#QB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y-87D@,S$L(#(P,#@\8G(^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5L:2!,:6QL>2!;365M
M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG
M/DQI8V5N<V4@06YD($-O;&QA8F]R871I;VX@06=R965M96YT<R!;3&EN92!)
M=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^0V]L;&%B;W)A=&EO;B!A9W)E96UE;G0@9&%T93PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^3V-T;V)E<B`R,#`W/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.;VYR969U;F1A8FQE
M('5P9G)O;G0@<&%Y;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`T,2PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y-:6QE<W1O;F4@<&%Y;65N=#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-2PP,#`L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3`L,#`P+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E
M8V]G;FEZ960@<F5V96YU92!U;F1E<B!A9W)E96UE;G0\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@-#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@.#`P+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,S$L,C`P
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A
M8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?
M.&1B-3,W8S1?93@W.%\T83-E7S@R.&%?8C4P,&8S961F,3%F#0I#;VYT96YT
M+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+SAD8C4S-V,T7V4X-SA?-&$S95\X,CAA
M7V(U,#!F,V5D9C$Q9B]7;W)K<VAE971S+U-H965T-3<N:'1M;`T*0V]N=&5N
M="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N
M="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M
M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M
M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C
M<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@
M1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^
M#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$
M,$4S1D%'/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C
M;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D-O;6UI=&UE;G1S(&%N
M9"!#;VYT:6YG96YC:65S("T@061D:71I;VYA;"!);F9O<FUA=&EO;B`H1&5T
M86EL*2`H55-$("0I/&)R/DEN($UI;&QI;VYS+"!U;FQE<W,@;W1H97)W:7-E
M('-P96-I9FEE9#PO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H(&-O;'-P86X],T0S/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N
M(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E
M8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M1&5C+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY/<&5R871I;F<@3&5A<V5D($%S<V5T<R!;3&EN92!)
M=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^3&5A<V4@86=R965M96YT(&1E<V-R:7!T:6]N/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#Y$=7)I;F<@,C`Q-"P@=&AE($-O;7!A;GD@97AE
M<F-I<V5D(&ET<R`U+7EE87(@<F5N97=A;"!O<'1I;VX@;VX@=&AE(&UA;G5F
M86-T=7)I;F<@9F%C:6QI='DN(%1H92!#;VUP86YY(&%L<V\@96YT97)E9"!I
M;G1O(&$@;F5W(&9O=7(M>65A<B!L96%S92!F;W(@861D:71I;VYA;"!S<&%C
M92!I;B!T:&4@;6%N=69A8W1U<FEN9R!F86-I;&ET>2!E9F9E8W1I=F4@07!R
M:6P@,2P@,C`Q-"X@5&AI<R!L96%S92!A;'-O(&AA<R!A;B!O<'1I;VX@=&\@
M8V]N=&EN=64@=&AE(&QE87-E(&9O<B!F:79E('EE87)S('5N9&5R('1H92!S
M86UE('1E<FUS+CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^1&5F97)R960@<F5N="!L:6%B:6QI='D\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,BXW/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R+CD\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E;G0@97AP96YS
M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R+C<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(N
M-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^3V9F:6-E(&%N9"!,86)O<F%T;W)Y(%-P86-E(%M-96UB97)=('P@4F]C
M:W9I;&QE+"!-87)Y;&%N9"!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/D]P97)A=&EN9R!,96%S960@07-S971S
M(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y,96%S92!E>'!I<F%T:6]N(&1A=&4\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/DUA<B`S,2P-"@D),C`Q.#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06UE;F1E9"!L
M96%S92!E>'!I<F%T:6]N(&1A=&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/DIA;B`S,2P-"@D),C`R,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3V9F:6-E(&%N9"!,86)O<F%T;W)Y
M(%-P86-E(%M-96UB97)=('P@4V]U=&@@4V%N($9R86YC:7-C;R!;365M8F5R
M73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D]P
M97)A=&EN9R!,96%S960@07-S971S(%M,:6YE($ET96US73PO<W1R;VYG/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,96%S92!E>'!I<F%T
M:6]N(&1A=&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/D9E8B`R
M."P-"@D),C`Q.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^36%N=69A8W1U<FEN9R!3<&%C92!;365M8F5R73PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D]P97)A=&EN
M9R!,96%S960@07-S971S(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,96%S92!E>'!I<F%T:6]N(&1A
M=&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/D1E8R`S,2P-"@D)
M,C`Q-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^3&5S<V5E(&QE87-I;F<@87)R86YG96UE;G1S+"!O<&5R871I;F<@
M;&5A<V5S+"!R96YE=V%L('1E<FT\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/C4@>65A<G,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D%D9&ET:6]N86P@36%N=69A8W1U<FEN9R!3<&%C
M92!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/D]P97)A=&EN9R!,96%S960@07-S971S(%M,:6YE($ET96US73PO
M<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y497)M
M(&]F(&%D9&ET:6]N86P@<W!A8V4@;&5A<V4\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/C0@>65A<G,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]R:6=I;F%T:6]N(&1A=&4@9F]R(&%D
M9&ET:6]N86P@<W!A8V4@:6X@;6%N=69A8W1U<FEN9R!F86-I;&ET>3PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^07!R(#$L#0H)"3(P,30\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@
M/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7SAD8C4S-V,T
M7V4X-SA?-&$S95\X,CAA7V(U,#!F,V5D9C$Q9@T*0V]N=&5N="U,;V-A=&EO
M;CH@9FEL93HO+R]#.B\X9&(U,S=C-%]E.#<X7S1A,V5?.#(X85]B-3`P9C-E
M9&8Q,68O5V]R:W-H965T<R]3:&5E=#4X+FAT;6P-"D-O;G1E;G0M5')A;G-F
M97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@
M=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH
M96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N
M=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP
M93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!2
M96UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D
M>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%3D9!0SX-
M"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS
M1#$@<F]W<W!A;CTS1#$^/'-T<F]N9SY#;VUM:71M96YT<R!A;F0@0V]N=&EN
M9V5N8VEE<R`M(%-C:&5D=6QE(&]F($UI;FEM=6T@1G5T=7)E($QE87-E(%!A
M>6UE;G1S("A$971A:6PI("A54T0@)"D\8G(^26X@5&AO=7-A;F1S+"!U;FQE
M<W,@;W1H97)W:7-E('-P96-I9FEE9#PO<W1R;VYG/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0V]M;6ET;65N=',@86YD
M($-O;G1I;F=E;F-I97,@1&ES8VQO<W5R92!;06)S=')A8W1=/"]S=')O;F<^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/C(P,34\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,RPY-#4\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/C(P,38\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0L,S8T/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#XR,#$W/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+#0Y-3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^,C`Q.#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-"PS.38\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/C(P,3D\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$L.#<S/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4:&5R96%F=&5R/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,38\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q.2PQ.#D\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H
M=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7SAD8C4S-V,T7V4X-SA?-&$S95\X
M,CAA7V(U,#!F,V5D9C$Q9@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#
M.B\X9&(U,S=C-%]E.#<X7S1A,V5?.#(X85]B-3`P9C-E9&8Q,68O5V]R:W-H
M965T<R]3:&5E=#4Y+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z
M('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C
M:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-
M151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT
M+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V
M87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#
M;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B
M;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%-%!!13X-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS
M1#(^/'-T<F]N9SY0<F]D=6-T($UI;&5S=&]N92!087EM96YT<R!A;F0@4F]Y
M86QT>2!!9W)E96UE;G1S("T@061D:71I;VYA;"!);F9O<FUA=&EO;B`H1&5T
M86EL*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C,V($UO;G1H<R!%
M;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q
M/C$@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN(#,P+"`R,#`U/&)R
M/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E)O
M>6%L='D@06=R965M96YT(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!9&1I=&EO;F%L(&-O;G-I9&5R
M871I;VX@;V8@87-S970@<'5R8VAA<V4@86=R965M96YT/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#X@,3`L.34P+#`P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K
M('-H87)E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S8L,3,U
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y087EM96YT<R!R96QA=&5D('1O('1H92!A9&1I=&EO;F%L(&-O;G-I9&5R
M871I;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y2979E
M;G5E(&9R;VT@<')O9'5C="!S86QE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y-:6YI;75M(%M-96UB97)=/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4F]Y86QT>2!!9W)E96UE;G0@
M6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/DUA>&EM=6T@<F]Y86QT>2!P87EM96YT<R!P97)C96YT86=E
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+C<U)3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^36%X:6UU
M;2!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/E)O>6%L='D@06=R965M96YT(%M,:6YE($ET96US73PO<W1R;VYG
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y-87AI;75M(')O
M>6%L='D@<&%Y;65N=',@<&5R8V5N=&%G93PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-"XP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM
M+2T]7TYE>'1087)T7SAD8C4S-V,T7V4X-SA?-&$S95\X,CAA7V(U,#!F,V5D
M9C$Q9@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\X9&(U,S=C-%]E
M.#<X7S1A,V5?.#(X85]B-3`P9C-E9&8Q,68O5V]R:W-H965T<R]3:&5E=#8P
M+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN
M=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA
M<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U
M:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S
M970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,]
M,T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S
M8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R
M97!O<G0@:60],T1)1#!%6$Y!0SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY%
M;7!L;WEE92!"96YE9FET(%!L86X@+2!!9&1I=&EO;F%L($EN9F]R;6%T:6]N
M("A$971A:6PI("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,"!-;VYT:',@16YD960\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,SXQ,B!-;VYT
M:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^4V5P+B`R-2P@,C`P,CQB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CX\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY$969I;F5D
M($-O;G1R:6)U=&EO;B!096YS:6]N(&%N9"!/=&AE<B!0;W-T<F5T:7)E;65N
M="!0;&%N<R!$:7-C;&]S=7)E(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16QI9VEB:6QI='D@;V8@96UP
M;&]Y964@<&%R=&EC:7!A=&EO;B!0;&%N/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XR,2!Y96%R<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4&5R8V5N=&%G92!O9B!E;7!L;WEE92!C
M;VYT<FEB=71I;VX@=&\@<V%L87)Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ,#`N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y097)C96YT86=E(&]F(&5M<&QO>65E('9E<W1E
M9"!C;VYT<FEB=71I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$P,"XP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D1E9FEN960@8V]N=')I8G5T:6]N('!L86XL(&5M<&QO>65R
M(&1I<V-R971I;VYA<GD@8V]N=')I8G5T:6]N(&%M;W5N=#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S,3@L,SDP/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R-3(L.3,P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R,C4L
M,3DU/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B
M;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\X
M9&(U,S=C-%]E.#<X7S1A,V5?.#(X85]B-3`P9C-E9&8Q,68-"D-O;G1E;G0M
M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.&1B-3,W8S1?93@W.%\T83-E7S@R.&%?
M8C4P,&8S961F,3%F+U=O<FMS:&5E=',O4VAE970V,2YH=&UL#0I#;VYT96YT
M+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT
M+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL
M/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4
M>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R
M:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$
M;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-
M"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P
M14Y'04<^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O
M;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^475A<G1E<FQY($9I;F%N
M8VEA;"!);F9O<FUA=&EO;B`M($-O;7!A;GDG<R!#;VYS;VQI9&%T960@475A
M<G1E<FQY(%)E<W5L=',@;V8@3W!E<F%T:6]N<R`H1&5T86EL*2`H55-$("0I
M/&)R/DEN(%1H;W5S86YD<RP@97AC97!T(%!E<B!3:&%R92!D871A+"!U;FQE
M<W,@;W1H97)W:7-E('-P96-I9FEE9#PO<W1R;VYG/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0X/C,@36]N=&AS($5N9&5D/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#,^,3(@36]N
M=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q-#QB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN(#,P+"`R,#$T/&)R/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,30\8G(^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,3,\
M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q
M,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R
M,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L
M(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S
M,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M/'-T<F]N9SY1=6%R=&5R;'D@1FEN86YC:6%L($EN9F]R;6%T:6]N($1I<V-L
M;W-U<F4@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y2979E;G5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#4L-#<V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`Q."PS.#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#DL,C(P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q-"PW,3D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$T+#DP
M-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@,C`L,C,R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`Q,BPR.3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#$P+#4Y.#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-#<L-SDW/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`U."PP,S4\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#8S
M+#@R-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^3F5T(&EN8V]M92`H;&]S<RD\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^)"`H,3DL,#$X*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^)"`H,RPY,C@I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@Q,BPR-3DI/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@S+#$P."D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@
M*#,L,C`U*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@-BPV,#0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B0@*#(Y-"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B0@*#,L,S8V*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,S@L,S$S*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,C8Q*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M."PS-C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/DYE="!I;F-O;64@*&QO<W,I('!E<B!S:&%R92P@8F%S:6,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,"XQ-"D\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N,30\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#`N
M,C0I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XD("@R+CDS*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^)"`H,2XT*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^)"`H,"XP-"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!I;F-O;64@*&QO<W,I
M('!E<B!S:&%R92P@8F%S:6,@86YD(&1I;'5T960\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^)"`H,"XV."D\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#`N,30I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@P+C0T*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,"XQ,BD\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@
M*#$N-"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B0@*#`N,#0I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y.970@:6YC;VUE("AL;W-S*2!P97(@<VAA<F4L
M(&1I;'5T960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,"XQ
M-"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#`N,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B0@*#`N,C0I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XD("@R+CDS*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,2XT*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,"XP-"D\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B
M;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7SAD8C4S-V,T7V4X
M-SA?-&$S95\X,CAA7V(U,#!F,V5D9C$Q9@T*0V]N=&5N="U,;V-A=&EO;CH@
M9FEL93HO+R]#.B\X9&(U,S=C-%]E.#<X7S1A,V5?.#(X85]B-3`P9C-E9&8Q
M,68O5V]R:W-H965T<R]3:&5E=#8R+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M
M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X
M="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D
M/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N
M=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS
M1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO
M=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-
M"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%1$Q!1SX-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@
M<F]W<W!A;CTS1#(^/'-T<F]N9SY3=6)S97%U96YT($5V96YT("T@061D:71I
M;VYA;"!);F9O<FUA=&EO;B`H1&5T86EL*2`H55-$("0I/&)R/CPO<W1R;VYG
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$@
M36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L
M<W!A;CTS1#(^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@@8V]L<W!A;CTS1#$^,2!-;VYT:',@16YD960\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M1F5B+B`R."P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^2F%N+B`S,2P@,C`Q-3QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^/'-T<F]N9SY3=6)S97%U96YT($5V96YT(%M,:6YE($ET
M96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y3=&]C:R!I<W-U960@9'5R:6YG('1H92!P97)I;V0@9F]R(&YE=R!I<W-U
M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PX,#`L,#`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3
M=&]C:R!I<W-U960@9'5R:6YG('!E<FEO9"!V86QU92P@;F5W(&ES<W5E<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`W-BPW,38L,#`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`X
M,RPV,C,L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y*86YS<V5N($)I;W1E8V@@26YC+B!;365M8F5R73PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-U8G-E<75E
M;G0@179E;G0@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K(&ES<W5E9"!D=7)I;F<@=&AE('!E
M<FEO9"!F;W(@;F5W(&ES<W5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ+#DR,RPP-S<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E-T;V-K(&ES<W5E9"!D=7)I;F<@<&5R:6]D('9A
M;'5E+"!N97<@:7-S=65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XW-2PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y.;VYR969U;F1A8FQE('5P9G)O;G0@<&%Y;65N="!R
M96-E:79A8FQE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU,"PP
M,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y3=6)S97%U96YT($5V96YT(%M-96UB97)=('P@2F]H;G-O;B`F
M86UP.R!*;VAN<V]N($EN;F]V871I;VX@2DI$0RP@26YC+"!;365M8F5R73PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-U8G-E
M<75E;G0@179E;G0@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K(&ES<W5E9"!D=7)I;F<@=&AE
M('!E<FEO9"!F;W(@;F5W(&ES<W5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ+#DR,RPP-S<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K(&ES<W5E9"!D=7)I;F<@<&5R:6]D
M('9A;'5E+"!N97<@:7-S=65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XW-2PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y3=6)S97%U96YT($5V96YT(%M-96UB97)=('P@
M2F%N<W-E;B!":6]T96-H($EN8RX@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3=6)S97%U96YT($5V96YT(%M,
M:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y.;VYR969U;F1A8FQE('5P9G)O;G0@<&%Y;65N="!R96-E:79A
M8FQE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#4P+#`P,"PP
M,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L
M93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7SAD
M8C4S-V,T7V4X-SA?-&$S95\X,CAA7V(U,#!F,V5D9C$Q9@T*0V]N=&5N="U,
M;V-A=&EO;CH@9FEL93HO+R]#.B\X9&(U,S=C-%]E.#<X7S1A,V5?.#(X85]B
M-3`P9C-E9&8Q,68O5V]R:W-H965T<R]F:6QE;&ES="YX;6P-"D-O;G1E;G0M
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M;&4@2%)E9CTS1")3:&5E=#`R+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B
M4VAE970P,RYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#0N:'1M
M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`U+FAT;6PB+SX-"B`\;SI&
M:6QE($A2968],T0B4VAE970P-BYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$
M(E-H965T,#<N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`X+FAT
M;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P.2YH=&UL(B\^#0H@/&\Z
M1FEL92!(4F5F/3-$(E-H965T,3`N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS
M1")3:&5E=#$Q+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q,BYH
M=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,3,N:'1M;"(O/@T*(#QO
M.D9I;&4@2%)E9CTS1")3:&5E=#$T+FAT;6PB+SX-"B`\;SI&:6QE($A2968]
M,T0B4VAE970Q-2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,38N
M:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$W+FAT;6PB+SX-"B`\
M;SI&:6QE($A2968],T0B4VAE970Q."YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F
M/3-$(E-H965T,3DN:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#(P
M+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970R,2YH=&UL(B\^#0H@
M/&\Z1FEL92!(4F5F/3-$(E-H965T,C(N:'1M;"(O/@T*(#QO.D9I;&4@2%)E
M9CTS1")3:&5E=#(S+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970R
M-"YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,C4N:'1M;"(O/@T*
M(#QO.D9I;&4@2%)E9CTS1")3:&5E=#(V+FAT;6PB+SX-"B`\;SI&:6QE($A2
M968],T0B4VAE970R-RYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T
M,C@N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#(Y+FAT;6PB+SX-
M"B`\;SI&:6QE($A2968],T0B4VAE970S,"YH=&UL(B\^#0H@/&\Z1FEL92!(
M4F5F/3-$(E-H965T,S$N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E
M=#,R+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970S,RYH=&UL(B\^
M#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,S0N:'1M;"(O/@T*(#QO.D9I;&4@
M2%)E9CTS1")3:&5E=#,U+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE
M970S-BYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,S<N:'1M;"(O
M/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#,X+FAT;6PB+SX-"B`\;SI&:6QE
M($A2968],T0B4VAE970S.2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H
M965T-#`N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#0Q+FAT;6PB
M+SX-"B`\;SI&:6QE($A2968],T0B4VAE970T,BYH=&UL(B\^#0H@/&\Z1FEL
M92!(4F5F/3-$(E-H965T-#,N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3
M:&5E=#0T+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970T-2YH=&UL
M(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T-#8N:'1M;"(O/@T*(#QO.D9I
M;&4@2%)E9CTS1")3:&5E=#0W+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B
M4VAE970T."YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T-#DN:'1M
M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#4P+FAT;6PB+SX-"B`\;SI&
M:6QE($A2968],T0B4VAE970U,2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$
M(E-H965T-3(N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#4S+FAT
M;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970U-"YH=&UL(B\^#0H@/&\Z
M1FEL92!(4F5F/3-$(E-H965T-34N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS
M1")3:&5E=#4V+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970U-RYH
M=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T-3@N:'1M;"(O/@T*(#QO
M.D9I;&4@2%)E9CTS1")3:&5E=#4Y+FAT;6PB+SX-"B`\;SI&:6QE($A2968]
M,T0B4VAE970V,"YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T-C$N
M:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#8R+FAT;6PB+SX-"CPO
M>&UL/@T*+2TM+2TM/5].97AT4&%R=%\X9&(U,S=C-%]E.#<X7S1A,V5?.#(X
285]B-3`P9C-E9&8Q,68M+0T*
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EQUBG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Income Taxes - Additional Information (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Provision for federal or state income taxes</a></td>
        <td class="nump"><a title="us-gaap_CurrentIncomeTaxExpenseBenefit" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CurrentIncomeTaxExpenseBenefit</span><span></span></td>
        <td class="nump"><a title="us-gaap_CurrentIncomeTaxExpenseBenefit" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CurrentIncomeTaxExpenseBenefit</span><span></span></td>
        <td class="nump"><a title="us-gaap_CurrentIncomeTaxExpenseBenefit" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CurrentIncomeTaxExpenseBenefit</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_TaxCreditCarryforwardExpirationYearRangeStart', window );">Federal Tax credit expiration start year</a></td>
        <td class="text">2020<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_TaxCreditCarryforwardExpirationYearRangeEnd', window );">Federal Tax credit expiration ending year</a></td>
        <td class="text">2034<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount', window );">Net operating loss</a></td>
        <td class="nump"><a title="mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount" onclick="toggleNextSibling(this);">7,100,000</a><span style="display:none;white-space:normal;text-align:left;">mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_OperatingLossCarryforwardsLimitationsOnUseYearStart', window );">Net operating losses limited for year minimum</a></td>
        <td class="text">2015<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_OperatingLossCarryforwardsLimitationsOnUseYearEnd', window );">Net operating losses limited for year maximum</a></td>
        <td class="text">2027<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_OperatingLossCarryforwardsNotSubjectToLimitation', window );">Remaining portion of net operating losses</a></td>
        <td class="nump"><a title="mgnx_OperatingLossCarryforwardsNotSubjectToLimitation" onclick="toggleNextSibling(this);">151,800,000</a><span style="display:none;white-space:normal;text-align:left;">mgnx_OperatingLossCarryforwardsNotSubjectToLimitation</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_UnrecognizedTaxBenefitsResultingInNetOperatingLossesCarryforward', window );">Net operating losses, recognized as a benefit through additional-paid-in-capital</a></td>
        <td class="nump"><a title="mgnx_UnrecognizedTaxBenefitsResultingInNetOperatingLossesCarryforward" onclick="toggleNextSibling(this);">7,700,000</a><span style="display:none;white-space:normal;text-align:left;">mgnx_UnrecognizedTaxBenefitsResultingInNetOperatingLossesCarryforward</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGrossCurrent', window );">Current deferred tax liability</a></td>
        <td class="nump"><a title="us-gaap_DeferredTaxLiabilitiesGrossCurrent" onclick="toggleNextSibling(this);">1,600,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxLiabilitiesGrossCurrent</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossNoncurrent', window );">Noncurrent deferred tax asset</a></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsGrossNoncurrent" onclick="toggleNextSibling(this);">1,600,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsGrossNoncurrent</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred income tax asset/(liability)</a></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsLiabilitiesNet" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsLiabilitiesNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsLiabilitiesNet" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsLiabilitiesNet</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Gross unrecognized tax benefits</a></td>
        <td class="nump"><a title="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" onclick="toggleNextSibling(this);">1,700,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</span><span></span></td>
        <td class="nump"><a title="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" onclick="toggleNextSibling(this);">1,300,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Unrecognized interest or penalties</a></td>
        <td class="nump"><a title="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_IncomeTaxExaminationYearUnderExaminationRangeStart', window );">Income tax examination year subject to examination, Range start</a></td>
        <td class="text">2001<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_IncomeTaxExaminationYearUnderExaminationRangeEnd', window );">Income tax examination year subject to examination, Range End</a></td>
        <td class="text">2014<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_OperatingLossCarryforwardsAnnualLimitationAmount', window );">Net operating losses limited for use utilized on an annual basis</a></td>
        <td class="nump"><a title="mgnx_OperatingLossCarryforwardsAnnualLimitationAmount[us-gaap_RangeAxis=us-gaap_MinimumMember]" onclick="toggleNextSibling(this);">200,000</a><span style="display:none;white-space:normal;text-align:left;">mgnx_OperatingLossCarryforwardsAnnualLimitationAmount<br>/ us-gaap_RangeAxis<br>= us-gaap_MinimumMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_OperatingLossCarryforwardsAnnualLimitationAmount', window );">Net operating losses limited for use utilized on an annual basis</a></td>
        <td class="nump"><a title="mgnx_OperatingLossCarryforwardsAnnualLimitationAmount[us-gaap_RangeAxis=us-gaap_MaximumMember]" onclick="toggleNextSibling(this);">1,400,000</a><span style="display:none;white-space:normal;text-align:left;">mgnx_OperatingLossCarryforwardsAnnualLimitationAmount<br>/ us-gaap_RangeAxis<br>= us-gaap_MaximumMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">U.S. Federal Government [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Net operating loss carryforwards</a></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration[us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember]" onclick="toggleNextSibling(this);">158,900,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration<br>/ us-gaap_IncomeTaxAuthorityAxis<br>= us-gaap_DomesticCountryMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">US Federal Tax credits carry forward</a></td>
        <td class="nump"><a title="us-gaap_TaxCreditCarryforwardAmount[us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember]" onclick="toggleNextSibling(this);">26,300,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_TaxCreditCarryforwardAmount<br>/ us-gaap_IncomeTaxAuthorityAxis<br>= us-gaap_DomesticCountryMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Net operating loss carryforwards</a></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration[us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember]" onclick="toggleNextSibling(this);">$ 103,400,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration<br>/ us-gaap_IncomeTaxAuthorityAxis<br>= us-gaap_StateAndLocalJurisdictionMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=mgnx_StartYearMember', window );">Start Year [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_OperatingLossCarryforwardsExpirationYear', window );">Net operating loss carryforwards expiration ending year</a></td>
        <td class="text">2020<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=mgnx_EndingYearMember', window );">Ending Year [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_OperatingLossCarryforwardsExpirationYear', window );">Net operating loss carryforwards expiration ending year</a></td>
        <td class="text">2034<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_IncomeTaxDisclosureLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_IncomeTaxDisclosureLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_IncomeTaxExaminationYearUnderExaminationRangeEnd">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Income tax years subject to examination by taxing authorities, range end.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_IncomeTaxExaminationYearUnderExaminationRangeEnd</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_IncomeTaxExaminationYearUnderExaminationRangeStart">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Income tax years subject to examination by taxing authorities, range start.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_IncomeTaxExaminationYearUnderExaminationRangeStart</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_OperatingLossCarryforwardsAnnualLimitationAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Operating loss carryforwards annual limitation amount.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_OperatingLossCarryforwardsAnnualLimitationAmount</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_OperatingLossCarryforwardsExpirationYear">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Operating Loss Carryforwards Expiration Year</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_OperatingLossCarryforwardsExpirationYear</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Operating loss carryforwards limitations on use amount.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_OperatingLossCarryforwardsLimitationsOnUseYearEnd">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Operating loss carryforwards limitations on use year end.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_OperatingLossCarryforwardsLimitationsOnUseYearEnd</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_OperatingLossCarryforwardsLimitationsOnUseYearStart">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Operating loss carryforwards limitations on use year start.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_OperatingLossCarryforwardsLimitationsOnUseYearStart</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_OperatingLossCarryforwardsNotSubjectToLimitation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Operating loss carryforwards not subject to limitation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_OperatingLossCarryforwardsNotSubjectToLimitation</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_TaxCreditCarryforwardExpirationYearRangeEnd">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tax credit carryforward expiration year range end.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_TaxCreditCarryforwardExpirationYearRangeEnd</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_TaxCreditCarryforwardExpirationYearRangeStart">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tax credit carryforward expiration year range start.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_TaxCreditCarryforwardExpirationYearRangeStart</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_UnrecognizedTaxBenefitsResultingInNetOperatingLossesCarryforward">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Unrecognized tax benefits resulting in net operating losses carryforward.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_UnrecognizedTaxBenefitsResultingInNetOperatingLossesCarryforward</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 6.I.7)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Current Tax Expense (or Benefit)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509736<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 6<br><br> -Section I<br><br> -Subsection 7<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards expected to be realized or consumed after one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31917-109318<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31931-109318<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Deferred Tax Asset<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510090<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossNoncurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards, net of deferred tax liability attributable to taxable temporary differences.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGrossCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of deferred tax liability attributable to taxable temporary differences expected to be realized or consumed within one year or operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31917-109318<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGrossCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Carryforwards<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506874<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32718-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15A<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=SL6600010-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=mgnx_EndingYearMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=mgnx_EndingYearMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=mgnx_StartYearMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=mgnx_StartYearMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ESSAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014

</div>
          <div>Segment

</div>
          <div>Assets</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>Assets</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_BusinessMergerEffectiveDate', window );">Effective date of merger</a></td>
        <td class="text">Dec. 22,  2014<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
        <td class="nump"><a title="us-gaap_NumberOfOperatingSegments" onclick="toggleNextSibling(this);">1</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NumberOfOperatingSegments</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_LiquidInvestmentMaturityPeriodToBeClassifiedAsCashEquivalentMaximum', window );">Original maturity of financial instruments</a></td>
        <td class="text">3 months<span></span></td>
        <td class="text">3 months<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Allowance recorded</a></td>
        <td class="nump"><a title="us-gaap_AllowanceForDoubtfulAccountsReceivable" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AllowanceForDoubtfulAccountsReceivable</span><span></span></td>
        <td class="nump"><a title="us-gaap_AllowanceForDoubtfulAccountsReceivable" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AllowanceForDoubtfulAccountsReceivable</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Amounts classified as restricted cash</a></td>
        <td class="nump"><a title="us-gaap_RestrictedCashAndCashEquivalents" onclick="toggleNextSibling(this);">$ 300,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RestrictedCashAndCashEquivalents</span><span></span></td>
        <td class="nump"><a title="us-gaap_RestrictedCashAndCashEquivalents" onclick="toggleNextSibling(this);">$ 405,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RestrictedCashAndCashEquivalents</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NumberOfImpairedAssets', window );">Number of impaired assets</a></td>
        <td class="nump"><a title="mgnx_NumberOfImpairedAssets" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">mgnx_NumberOfImpairedAssets</span><span></span></td>
        <td class="nump"><a title="mgnx_NumberOfImpairedAssets" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">mgnx_NumberOfImpairedAssets</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NumberOfAssetsHeldForSale', window );">Number of assets held-for-sale</a></td>
        <td class="nump"><a title="mgnx_NumberOfAssetsHeldForSale" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">mgnx_NumberOfAssetsHeldForSale</span><span></span></td>
        <td class="nump"><a title="mgnx_NumberOfAssetsHeldForSale" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">mgnx_NumberOfAssetsHeldForSale</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum [Member] | Sales Revenue, Net [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of all significant revenue earned</a></td>
        <td class="nump"><a title="us-gaap_ConcentrationRiskPercentage1[us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember;us-gaap_RangeAxis=us-gaap_MinimumMember]" onclick="toggleNextSibling(this);">10.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ConcentrationRiskPercentage1<br>/ us-gaap_ConcentrationRiskByBenchmarkAxis<br>= us-gaap_SalesRevenueNetMember<br>/ us-gaap_RangeAxis<br>= us-gaap_MinimumMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum [Member] | Accounts Receivable [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of all significant revenue earned</a></td>
        <td class="nump"><a title="us-gaap_ConcentrationRiskPercentage1[us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember;us-gaap_RangeAxis=us-gaap_MinimumMember]" onclick="toggleNextSibling(this);">10.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ConcentrationRiskPercentage1<br>/ us-gaap_ConcentrationRiskByBenchmarkAxis<br>= us-gaap_AccountsReceivableMember<br>/ us-gaap_RangeAxis<br>= us-gaap_MinimumMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_BusinessMergerEffectiveDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Effective date of merger of subsidiary into parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_BusinessMergerEffectiveDate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_LiquidInvestmentMaturityPeriodToBeClassifiedAsCashEquivalentMaximum">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Liquid investment maturity period to be classified as cash equivalent maximum.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_LiquidInvestmentMaturityPeriodToBeClassifiedAsCashEquivalentMaximum</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NumberOfAssetsHeldForSale">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of assets held for sale.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_NumberOfAssetsHeldForSale</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NumberOfImpairedAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of impaired assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_NumberOfImpairedAssets</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>For an unclassified balance sheet, a valuation allowance for receivables due a company that are expected to be uncollectible.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 4<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35738203&amp;loc=d3e5074-111524<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 21<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13537-108611<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6404-108592<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13531-108611<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 18<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6351-108592<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideRevenueMajorCustomerLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EntityWideRevenueMajorCustomerLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The carrying amounts of cash and cash equivalent items which are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. This element is for unclassified presentations; for classified presentations there is a separate and distinct element.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Organization and Nature of Operations - Additional Information (Detail)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationDateOfIncorporation', window );">MacroGenics incorporated date</a></td>
        <td class="text">Aug. 14,  2000<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationDateOfIncorporation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Date when an entity was incorporated</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityIncorporationDateOfIncorporation</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EQLAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Collaboration and License Agreements - Additional Information 7 (Detail) (Eli Lilly [Member], USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">1 Months Ended</th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>May 31, 2010</div>
        </th>
        <th class="th">
          <div>May 31, 2008</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top">
          <div class="a">Eli Lilly [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CollaborationAndLicenseAgreementEnteredDate', window );">Collaboration agreement date</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">October 2007<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NonRefundableUpFrontPayment', window );">Nonrefundable upfront payment</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="mgnx_NonRefundableUpFrontPayment[us-gaap_CounterpartyNameAxis=mgnx_EliLillyMember]" onclick="toggleNextSibling(this);">$ 41,000,000</a><span style="display:none;white-space:normal;text-align:left;">mgnx_NonRefundableUpFrontPayment<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_EliLillyMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized', window );">Milestone payment</a></td>
        <td class="nump"><a title="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized[us-gaap_CounterpartyNameAxis=mgnx_EliLillyMember]" onclick="toggleNextSibling(this);">5,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_EliLillyMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized[us-gaap_CounterpartyNameAxis=mgnx_EliLillyMember]" onclick="toggleNextSibling(this);">50,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_EliLillyMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized[us-gaap_CounterpartyNameAxis=mgnx_EliLillyMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_EliLillyMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicensesRevenue', window );">Recognized revenue under agreement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_LicensesRevenue[us-gaap_CounterpartyNameAxis=mgnx_EliLillyMember]" onclick="toggleNextSibling(this);">$ 400,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LicensesRevenue<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_EliLillyMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_LicensesRevenue[us-gaap_CounterpartyNameAxis=mgnx_EliLillyMember]" onclick="toggleNextSibling(this);">$ 800,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LicensesRevenue<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_EliLillyMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_LicensesRevenue[us-gaap_CounterpartyNameAxis=mgnx_EliLillyMember]" onclick="toggleNextSibling(this);">$ 31,200,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LicensesRevenue<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_EliLillyMember</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborationAndLicenseAgreementEnteredDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Collaboration and license agreement entered date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_CollaborationAndLicenseAgreementEnteredDate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>us-types:dateStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_LicenseAndCollaborationAgreementsLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_LicenseAndCollaborationAgreementsLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonRefundableUpFrontPayment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Non-refundable up front payment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_NonRefundableUpFrontPayment</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LicensesRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LicensesRevenue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of consideration recognized during the period for the milestone or milestones.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 28<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=19771982&amp;loc=SL6892177-166501<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E6KAE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Income Taxes - Components of the Company's Deferred Tax Assets (Liabilities) (Detail) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred income tax assets:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic', window );">Federal U.S. net operating loss carryforward</a></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" onclick="toggleNextSibling(this);">$ 55,358</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" onclick="toggleNextSibling(this);">$ 36,561</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">State net operating loss carryforward</a></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" onclick="toggleNextSibling(this);">3,723</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" onclick="toggleNextSibling(this);">3,316</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credit, net</a></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" onclick="toggleNextSibling(this);">7,177</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" onclick="toggleNextSibling(this);">3,786</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther', window );">Orphan drug credit, net</a></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" onclick="toggleNextSibling(this);">19,287</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" onclick="toggleNextSibling(this);">19,883</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent', window );">Deferred rent</a></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" onclick="toggleNextSibling(this);">4,069</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" onclick="toggleNextSibling(this);">5,132</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsDeferredIncome" onclick="toggleNextSibling(this);">3,989</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsDeferredIncome</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsDeferredIncome" onclick="toggleNextSibling(this);">8,217</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsDeferredIncome</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Depreciation</a></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" onclick="toggleNextSibling(this);">1,337</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" onclick="toggleNextSibling(this);">1,438</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsOther" onclick="toggleNextSibling(this);">962</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsOther</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsOther" onclick="toggleNextSibling(this);">1,439</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsOther</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred income tax assets</a></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsGross" onclick="toggleNextSibling(this);">95,902</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsGross</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsGross" onclick="toggleNextSibling(this);">79,772</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsGross</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
        <td class="num"><a title="us-gaap_DeferredTaxAssetsValuationAllowance" onclick="toggleNextSibling(this);">(94,297)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsValuationAllowance</span><span></span></td>
        <td class="num"><a title="us-gaap_DeferredTaxAssetsValuationAllowance" onclick="toggleNextSibling(this);">(79,377)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsValuationAllowance</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred income tax assets</a></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsNet" onclick="toggleNextSibling(this);">1,605</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsNet" onclick="toggleNextSibling(this);">395</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsNet</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract', window );"><strong>Deferred income tax liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses', window );">Prepaid expenditures</a></td>
        <td class="num"><a title="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" onclick="toggleNextSibling(this);">(1,605)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxLiabilitiesPrepaidExpenses</span><span></span></td>
        <td class="num"><a title="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" onclick="toggleNextSibling(this);">(395)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxLiabilitiesPrepaidExpenses</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Gross deferred income tax liabilities</a></td>
        <td class="num"><a title="us-gaap_DeferredIncomeTaxLiabilities" onclick="toggleNextSibling(this);">(1,605)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredIncomeTaxLiabilities</span><span></span></td>
        <td class="num"><a title="us-gaap_DeferredIncomeTaxLiabilities" onclick="toggleNextSibling(this);">(395)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredIncomeTaxLiabilities</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred income tax asset/(liability)</a></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsLiabilitiesNet" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsLiabilitiesNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsLiabilitiesNet" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsLiabilitiesNet</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of deferred tax liability attributable to taxable temporary differences.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Deferred Tax Liability<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510232<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 15<br><br> -Subparagraph b(2)<br><br> -Article 7<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=29652012&amp;loc=d3e28680-109314<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Deferred Tax Asset<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510090<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards, net of deferred tax liability attributable to taxable temporary differences.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (b),(c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 20<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=29652012&amp;loc=d3e28680-109314<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 20<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=29652012&amp;loc=d3e28680-109314<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences not separately disclosed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=29652012&amp;loc=d3e28680-109314<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to other deductible tax credit carryforwards not separately disclosed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred rent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 20<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=29652012&amp;loc=d3e28680-109314<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPrepaidExpenses</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EDFAE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Summary of Fair Value Measurement Financial Asset and Liabilities (Detail) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsFairValueDisclosure" onclick="toggleNextSibling(this);">$ 131,545</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</span><span></span></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsFairValueDisclosure" onclick="toggleNextSibling(this);">$ 90,434</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_MoneyMarketFundsFairValueDisclosure', window );">Money market funds</a></td>
        <td class="nump"><a title="mgnx_MoneyMarketFundsFairValueDisclosure" onclick="toggleNextSibling(this);">26,046</a><span style="display:none;white-space:normal;text-align:left;">mgnx_MoneyMarketFundsFairValueDisclosure</span><span></span></td>
        <td class="nump"><a title="mgnx_MoneyMarketFundsFairValueDisclosure" onclick="toggleNextSibling(this);">26,047</a><span style="display:none;white-space:normal;text-align:left;">mgnx_MoneyMarketFundsFairValueDisclosure</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash</a></td>
        <td class="nump"><a title="us-gaap_RestrictedCashAndCashEquivalents" onclick="toggleNextSibling(this);">300</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RestrictedCashAndCashEquivalents</span><span></span></td>
        <td class="nump"><a title="us-gaap_RestrictedCashAndCashEquivalents" onclick="toggleNextSibling(this);">405</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RestrictedCashAndCashEquivalents</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total Assets</a></td>
        <td class="nump"><a title="us-gaap_AssetsFairValueDisclosure" onclick="toggleNextSibling(this);">157,891</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsFairValueDisclosure</span><span></span></td>
        <td class="nump"><a title="us-gaap_AssetsFairValueDisclosure" onclick="toggleNextSibling(this);">116,886</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsFairValueDisclosure</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets Level 1 [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsFairValueDisclosure[us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member]" onclick="toggleNextSibling(this);">131,545</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsFairValueDisclosure<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel1Member</span><span></span></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsFairValueDisclosure[us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member]" onclick="toggleNextSibling(this);">90,434</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsFairValueDisclosure<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel1Member</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_MoneyMarketFundsFairValueDisclosure', window );">Money market funds</a></td>
        <td class="nump"><a title="mgnx_MoneyMarketFundsFairValueDisclosure[us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member]" onclick="toggleNextSibling(this);">26,046</a><span style="display:none;white-space:normal;text-align:left;">mgnx_MoneyMarketFundsFairValueDisclosure<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel1Member</span><span></span></td>
        <td class="nump"><a title="mgnx_MoneyMarketFundsFairValueDisclosure[us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member]" onclick="toggleNextSibling(this);">26,047</a><span style="display:none;white-space:normal;text-align:left;">mgnx_MoneyMarketFundsFairValueDisclosure<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel1Member</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash</a></td>
        <td class="nump"><a title="us-gaap_RestrictedCashAndCashEquivalents[us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member]" onclick="toggleNextSibling(this);">300</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RestrictedCashAndCashEquivalents<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel1Member</span><span></span></td>
        <td class="nump"><a title="us-gaap_RestrictedCashAndCashEquivalents[us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member]" onclick="toggleNextSibling(this);">405</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RestrictedCashAndCashEquivalents<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel1Member</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total Assets</a></td>
        <td class="nump"><a title="us-gaap_AssetsFairValueDisclosure[us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member]" onclick="toggleNextSibling(this);">$ 157,891</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsFairValueDisclosure<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel1Member</span><span></span></td>
        <td class="nump"><a title="us-gaap_AssetsFairValueDisclosure[us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member]" onclick="toggleNextSibling(this);">$ 116,886</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsFairValueDisclosure<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel1Member</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_MoneyMarketFundsFairValueDisclosure">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Money market funds fair value disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_MoneyMarketFundsFairValueDisclosure</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The carrying amounts of cash and cash equivalent items which are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. This element is for unclassified presentations; for classified presentations there is a separate and distinct element.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EVDAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Summary of Collaborators that Represent More Than 10% of Total Revenue Earned (Detail) (Sales Revenue, Net [Member])<br></strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top">
          <div class="a">Servier [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of all significant revenue earned</a></td>
        <td class="nump"><a title="us-gaap_ConcentrationRiskPercentage1[us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember;us-gaap_ConcentrationRiskByTypeAxis=mgnx_ServierMember]" onclick="toggleNextSibling(this);">36.40%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ConcentrationRiskPercentage1<br>/ us-gaap_ConcentrationRiskByBenchmarkAxis<br>= us-gaap_SalesRevenueNetMember<br>/ us-gaap_ConcentrationRiskByTypeAxis<br>= mgnx_ServierMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ConcentrationRiskPercentage1[us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember;us-gaap_ConcentrationRiskByTypeAxis=mgnx_ServierMember]" onclick="toggleNextSibling(this);">51.60%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ConcentrationRiskPercentage1<br>/ us-gaap_ConcentrationRiskByBenchmarkAxis<br>= us-gaap_SalesRevenueNetMember<br>/ us-gaap_ConcentrationRiskByTypeAxis<br>= mgnx_ServierMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ConcentrationRiskPercentage1[us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember;us-gaap_ConcentrationRiskByTypeAxis=mgnx_ServierMember]" onclick="toggleNextSibling(this);">17.30%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ConcentrationRiskPercentage1<br>/ us-gaap_ConcentrationRiskByBenchmarkAxis<br>= us-gaap_SalesRevenueNetMember<br>/ us-gaap_ConcentrationRiskByTypeAxis<br>= mgnx_ServierMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top">
          <div class="a">Boehringer [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of all significant revenue earned</a></td>
        <td class="nump"><a title="us-gaap_ConcentrationRiskPercentage1[us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember;us-gaap_ConcentrationRiskByTypeAxis=mgnx_BoehringerIngelheimMember]" onclick="toggleNextSibling(this);">28.60%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ConcentrationRiskPercentage1<br>/ us-gaap_ConcentrationRiskByBenchmarkAxis<br>= us-gaap_SalesRevenueNetMember<br>/ us-gaap_ConcentrationRiskByTypeAxis<br>= mgnx_BoehringerIngelheimMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ConcentrationRiskPercentage1[us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember;us-gaap_ConcentrationRiskByTypeAxis=mgnx_BoehringerIngelheimMember]" onclick="toggleNextSibling(this);">24.80%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ConcentrationRiskPercentage1<br>/ us-gaap_ConcentrationRiskByBenchmarkAxis<br>= us-gaap_SalesRevenueNetMember<br>/ us-gaap_ConcentrationRiskByTypeAxis<br>= mgnx_BoehringerIngelheimMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ConcentrationRiskPercentage1[us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember;us-gaap_ConcentrationRiskByTypeAxis=mgnx_BoehringerIngelheimMember]" onclick="toggleNextSibling(this);">18.40%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ConcentrationRiskPercentage1<br>/ us-gaap_ConcentrationRiskByBenchmarkAxis<br>= us-gaap_SalesRevenueNetMember<br>/ us-gaap_ConcentrationRiskByTypeAxis<br>= mgnx_BoehringerIngelheimMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top">
          <div class="a">Takeda [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of all significant revenue earned</a></td>
        <td class="nump"><a title="us-gaap_ConcentrationRiskPercentage1[us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember;us-gaap_ConcentrationRiskByTypeAxis=mgnx_TakedaMember]" onclick="toggleNextSibling(this);">16.80%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ConcentrationRiskPercentage1<br>/ us-gaap_ConcentrationRiskByBenchmarkAxis<br>= us-gaap_SalesRevenueNetMember<br>/ us-gaap_ConcentrationRiskByTypeAxis<br>= mgnx_TakedaMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top">
          <div class="a">Gilead [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of all significant revenue earned</a></td>
        <td class="nump"><a title="us-gaap_ConcentrationRiskPercentage1[us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember;us-gaap_ConcentrationRiskByTypeAxis=mgnx_GileadSciencesIncMember]" onclick="toggleNextSibling(this);">11.40%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ConcentrationRiskPercentage1<br>/ us-gaap_ConcentrationRiskByBenchmarkAxis<br>= us-gaap_SalesRevenueNetMember<br>/ us-gaap_ConcentrationRiskByTypeAxis<br>= mgnx_GileadSciencesIncMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ConcentrationRiskPercentage1[us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember;us-gaap_ConcentrationRiskByTypeAxis=mgnx_GileadSciencesIncMember]" onclick="toggleNextSibling(this);">13.80%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ConcentrationRiskPercentage1<br>/ us-gaap_ConcentrationRiskByBenchmarkAxis<br>= us-gaap_SalesRevenueNetMember<br>/ us-gaap_ConcentrationRiskByTypeAxis<br>= mgnx_GileadSciencesIncMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top">
          <div class="a">Eli Lilly [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of all significant revenue earned</a></td>
        <td class="nump"><a title="us-gaap_ConcentrationRiskPercentage1[us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember;us-gaap_ConcentrationRiskByTypeAxis=mgnx_EliLillyMember]" onclick="toggleNextSibling(this);">0.90%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ConcentrationRiskPercentage1<br>/ us-gaap_ConcentrationRiskByBenchmarkAxis<br>= us-gaap_SalesRevenueNetMember<br>/ us-gaap_ConcentrationRiskByTypeAxis<br>= mgnx_EliLillyMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ConcentrationRiskPercentage1[us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember;us-gaap_ConcentrationRiskByTypeAxis=mgnx_EliLillyMember]" onclick="toggleNextSibling(this);">1.40%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ConcentrationRiskPercentage1<br>/ us-gaap_ConcentrationRiskByBenchmarkAxis<br>= us-gaap_SalesRevenueNetMember<br>/ us-gaap_ConcentrationRiskByTypeAxis<br>= mgnx_EliLillyMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ConcentrationRiskPercentage1[us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember;us-gaap_ConcentrationRiskByTypeAxis=mgnx_EliLillyMember]" onclick="toggleNextSibling(this);">48.90%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ConcentrationRiskPercentage1<br>/ us-gaap_ConcentrationRiskByBenchmarkAxis<br>= us-gaap_SalesRevenueNetMember<br>/ us-gaap_ConcentrationRiskByTypeAxis<br>= mgnx_EliLillyMember</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 21<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13537-108611<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6404-108592<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13531-108611<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 18<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6351-108592<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>2. Summary of Significant Accounting Policies</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 <b><i>Basis of Presentation and Principles of
 Consolidation</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The consolidated financial statements include the accounts of
 MacroGenics, Inc. and its wholly owned subsidiaries, MacroGenics UK
 Limited and MacroGenics West, Inc. Effective December&#xA0;22,
 2014, MacroGenics West, Inc. was merged with and into MacroGenics,
 Inc. All intercompany accounts and transactions have been
 eliminated in consolidation. The Company currently operates in one
 operating segment. Operating segments are defined as components of
 an enterprise about which separate discrete information is
 available for the chief operating decision maker, or decision
 making group, in deciding how to allocate resources and assessing
 performance. The Company views its operations and manages its
 business in one segment, which is developing monoclonal
 antibody-based therapeutics for cancer, autoimmune and infectious
 diseases.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Use of Estimates</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The preparation of the financial statements in accordance with
 generally accepted accounting principles (GAAP) requires the
 Company to make estimates and judgments in certain circumstances
 that affect the reported amounts of assets, liabilities, revenues
 and expenses, and related disclosure of contingent assets and
 liabilities. In preparing these consolidated financial statements,
 management has made its best estimates and judgments of certain
 amounts included in the financial statements, giving due
 consideration to materiality. On an ongoing basis, the Company
 evaluates its estimates, including those related to revenue
 recognition, fair values of assets, stock-based compensation,
 preferred stock warrant liability, income taxes, pre-clinical study
 and clinical trial accruals and other contingencies. Management
 bases its estimates on historical experience or on various other
 assumptions that it believes to be reasonable under the
 circumstances. Actual results could differ from these
 estimates.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 In addition, prior to the Company&#x2019;s IPO in October 2013, the
 Company utilized estimates and assumptions in determining the fair
 value of its common stock. The Company granted stock options at
 exercise prices not less than the fair value of its common stock as
 determined by the Board of Directors, with input from management.
 Management used contemporaneous valuations in estimating the fair
 value of its common stock. The board of directors determined the
 estimated fair value of the common stock based on a number of
 objective and subjective factors, including external market
 considerations affecting the biotechnology industry and the
 historic prices at which the Company sold shares of its preferred
 stock.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Cash and Cash Equivalents</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The Company considers all investments in highly liquid financial
 instruments with an original maturity of three months or less at
 the date of purchase to be cash equivalents. Cash and cash
 equivalents consist of certificates of deposit and investments in
 money market funds with commercial banks and financial
 institutions. Cash equivalents are stated at amortized cost, plus
 accrued interest, which approximates fair value.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Accounts Receivable</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Accounts receivable that management has the intent and ability to
 collect are reported in the consolidated balance sheets at
 outstanding amounts, less an allowance for doubtful accounts. The
 Company writes off uncollectible receivables when the likelihood of
 collection is remote.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The Company evaluates the collectability of accounts receivable on
 a regular basis. The allowance, if any, is based upon various
 factors including the financial condition and payment history of
 customers, an overall review of collections experience on other
 accounts and economic factors or events expected to affect future
 collections experience. No allowance was recorded as of
 December&#xA0;31, 2014 or 2013, as the Company has a history of
 collecting on all outstanding accounts.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Restricted Cash</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The Company is required to maintain certificates of deposit that
 serve as collateral for various operating leases and corporate
 credit card accounts. Amounts classified as restricted cash on the
 consolidated balance sheets are $300,000 and $405,000 at
 December&#xA0;31, 2014 and 2013, respectively.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Fair Value of Financial Instruments</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The fair market values of the financial instruments included in the
 financial statements, which include cash equivalents and money
 market accounts, approximate their carrying values at
 December&#xA0;31, 2014 and 2013, due to their short-term
 maturities. The Company accounts for recurring and non-recurring
 fair value measurements in accordance with the Financial Accounting
 Standards Board (FASB) Accounting Standards Codification (ASC) 820,
 <i>Fair Value Measurements and Disclosures</i> (ASC 820). ASC 820
 defines fair value, establishes a fair value hierarchy for assets
 and liabilities measured at fair value, and requires expanded
 disclosures about fair value measurements. The ASC 820 hierarchy
 ranks the quality of reliability of inputs, or assumptions, used in
 the determination of fair value and requires assets and liabilities
 carried at fair value to be classified and disclosed in one of the
 following three categories:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr>
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">Level 1&#x2014;Fair value is
 determined by using unadjusted quoted prices that are available in
 active markets for identical assets and liabilities.</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr>
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">Level 2&#x2014;Fair value is
 determined by using inputs other than Level 1 quoted prices that
 are directly or indirectly observable. Inputs can include quoted
 prices for similar assets and liabilities in active markets or
 quoted prices for identical assets and liabilities in inactive
 markets. Related inputs can also include those used in valuation or
 other pricing models, such as interest rates and yield curves that
 can be corroborated by observable market data.</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr>
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">Level 3&#x2014;Fair value is
 determined by inputs that are unobservable and not corroborated by
 market data. Use of these inputs involves significant and
 subjective judgments to be made by a reporting entity&#xA0;&#x2013;
 e.g., determining an appropriate adjustment to a discount factor
 for illiquidity associated with a given security.</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The Company evaluates financial assets and liabilities subject to
 fair value measurements on a recurring basis to determine the
 appropriate level at which to classify them each reporting period.
 This determination requires the Company to make subjective
 judgments as to the significance of inputs used in determining fair
 value and where such inputs lie within the ASC 820 hierarchy.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 18pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%">
 Financial assets and liabilities subject to fair value measurements
 were as follows (in thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0">
 <tr>
 <td width="43%"></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"><b>Fair Value Measurements at
 December&#xA0;31, 2014</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Quoted&#xA0;Prices&#xA0;in</b><br />
 <b>Active Markets<br />
 for</b><br />
 <b>Identical Assets</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Significant&#xA0;Other</b><br />
 <b>Observable<br />
 Inputs</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Significant</b><br />
 <b>Unobservable</b><br />
 <b>Inputs</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Total</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Level 1</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Level 2</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Level 3</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Assets:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Cash and cash equivalents</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">131,545</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">131,545</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Money market funds</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">26,046</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">26,046</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Restricted cash</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">300</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">300</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Total Assets</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">157,891</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">157,891</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1pt">
 <td height="16"></td>
 <td height="16" colspan="16"></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"><b>Fair Value Measurements at
 December&#xA0;31, 2013</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Quoted Prices in</b><br />
 <b>Active Markets<br />
 for</b><br />
 <b>Identical Assets</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Significant Other</b><br />
 <b>Observable<br />
 Inputs</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Significant</b><br />
 <b>Unobservable</b><br />
 <b>Inputs</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Total</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Level 1</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Level 2</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Level 3</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Assets:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Cash and cash equivalents</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">90,434</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">90,434</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Money market funds</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">26,047</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">26,047</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Restricted cash</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">405</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">405</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Total Assets</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">116,886</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">116,886</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The Company&#x2019;s Level 1 securities primarily consist of
 restricted cash, cash equivalents and money market funds. The
 Company determines the estimated fair value for its Level 1
 securities using quoted (unadjusted) prices for identical assets or
 liabilities in active markets.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Concentration of Credit Risk</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Substantially all of the Company&#x2019;s cash and cash equivalents
 are maintained with major financial institutions in the United
 States. Deposits held with banks may exceed the amount of insurance
 provided on such deposits. Generally, these deposits may be
 redeemed upon demand and, therefore, bear minimal risk.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Financial instruments that potentially subject the Company to
 concentrations of credit risk consist principally of cash and cash
 equivalents, and accounts receivable. The counterparties are
 various corporations, financial institutions and government
 agencies of high credit standing.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 For the years ended December&#xA0;31, 2014, 2013 and 2012, the
 Company&#x2019;s collaboration revenue relates to agreements with
 Takeda Pharmaceutical Company Limited (Takeda), Les Laboratoires
 Servier and Institut de Recherches Servier (collectively, Servier),
 Gilead Sciences, Inc. (Gilead), Boehringer Ingelheim GmbH
 (Boehringer), Pfizer, Inc. (Pfizer), Eli Lilly&#xA0;&amp; Co. (Eli
 Lilly) and Green Cross Corp. (Green Cross). Grant revenue is
 related to contracts and research grants received from U.S.
 government agencies. The majority of the outstanding receivables
 are due from the Company&#x2019;s collaborators and U.S. government
 agencies.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%">
 The following table includes those collaborators that represent
 more than 10% of total revenue earned in the periods indicated:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <tr>
 <td width="66%"></td>
 <td valign="bottom" width="9%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center">
 <b>Year&#xA0;Ended&#xA0;December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">
 <b>&#xA0;&#xA0;&#xA0;&#xA0;2014&#xA0;&#xA0;&#xA0;&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">
 <b>&#xA0;&#xA0;&#xA0;&#xA0;2013&#xA0;&#xA0;&#xA0;&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">
 <b>&#xA0;&#xA0;&#xA0;&#xA0;2012&#xA0;&#xA0;&#xA0;&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Servier</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">36.4</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">51.6</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">17.3</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Boehringer</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">28.6</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">24.8</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">18.4</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Takeda</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">16.8</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Gilead</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">11.4</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">13.8</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Eli Lilly</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.9</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1.4</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">48.9</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The following table includes those collaborators that represent
 more than 10% of accounts receivable at the date indicated:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="75%"></td>
 <td valign="bottom" width="10%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="9%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">
 <b>&#xA0;&#xA0;&#xA0;&#xA0;2014&#xA0;&#xA0;&#xA0;&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">
 <b>&#xA0;&#xA0;&#xA0;&#xA0;2013&#xA0;&#xA0;&#xA0;&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Servier</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">33.3</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6.4</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Boehringer</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">21.2</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">12.2</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Green Cross</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">17.9</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Gilead</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">53.4</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Pfizer</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">12.3</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Property and Equipment</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Property and equipment are stated at cost. Upon retirement or sale,
 the cost of assets disposed of and the related accumulated
 depreciation are removed from the accounts and any resulting gain
 or loss is credited or charged to operations. Repairs and
 maintenance costs are expensed as incurred. Depreciation is
 computed using the straight-line method over the following
 estimated useful lives:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="55%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Computer equipment</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">3 years</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Software</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">3 years</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Furniture</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">10 years</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Laboratory and office equipment</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">5 years</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Leasehold improvements</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 Shorter&#xA0;of&#xA0;lease&#xA0;term&#xA0;or&#xA0;useful&#xA0;life</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Impairment of Long-Lived Assets</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The Company assesses the recoverability of its long-lived assets in
 accordance with the provisions of ASC&#xA0;360, <i>Property, Plant
 and Equipment</i>. ASC 360 requires that long-lived assets be
 reviewed for impairment whenever events or changes in circumstances
 indicate that the carrying amount of an asset may not be
 recoverable. Recoverability of the long-lived asset is measured by
 a comparison of the carrying amount of the asset to future
 undiscounted net cash flows expected to be generated by the asset
 or asset group. If carrying value exceeds the sum of undiscounted
 cash flows, the Company then determines the fair value of the
 underlying asset group. Any impairment to be recognized is measured
 by the amount by which the carrying amount of the asset group
 exceeds the estimated fair value of the asset group. Assets to be
 disposed of are reported at the lower of the carrying amount or
 fair value, less costs to sell. As of December&#xA0;31, 2014 and
 2013, the Company determined that there were no impaired assets and
 had no assets held-for-sale.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 18pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 <b><i>Income Taxes</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Deferred tax assets and liabilities are determined based on
 differences between the financial reporting and tax basis of assets
 and liabilities and are measured using the enacted tax rates and
 laws that are expected to be in effect when the differences are
 expected to reverse. The effect on deferred tax assets and
 liabilities of a change in tax rates is recognized as income in the
 period that such tax rate changes are enacted. The measurement of a
 deferred tax asset is reduced, if necessary, by a valuation
 allowance if it is more likely than not that some portion or all of
 the deferred tax asset will not be realized. Financial statement
 recognition of a tax position taken or expected to be taken in a
 tax return is determined based on a more-likely-than-not threshold
 of that position being sustained. If the tax position meets this
 threshold, the benefit to be recognized is measured as the largest
 amount that is more likely than not to be realized upon ultimate
 settlement. The Company&#x2019;s policy is to record interest and
 penalties related to uncertain tax positions as a component of
 income tax expense.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Revenues</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 2%; MARGIN-TOP: 6pt">
 <i>Revenue Recognition</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The Company enters into collaboration and license agreements with
 collaborators for the development of monoclonal antibody-based
 therapeutics to treat cancer and other complex diseases. The terms
 of these agreements contain multiple deliverables which may include
 (i)&#xA0;licenses, or options to obtain licenses, to the
 Company&#x2019;s technological platforms, such as its Fc
 Optimization and Dual-Affinity Re-Targeting (DART) technologies,
 (ii)&#xA0;rights to future technological improvements,
 (iii)&#xA0;research and development activities to be performed on
 behalf of the collaborator or as part of the collaboration, and
 (iv)&#xA0;the manufacture of pre-clinical or clinical materials for
 the collaborator. Payments to the Company under these agreements
 may include nonrefundable license fees, option fees, exercise fees,
 payments for research and development activities, payments for the
 manufacture of pre-clinical or clinical materials, license
 maintenance payments, payments based upon the achievement of
 certain milestones and royalties on product sales. Other benefits
 to the Company of these agreements include the right to sell
 products resulting from the collaborative efforts of the parties in
 specific geographic territories. The Company follows the provisions
 of the FASB ASC Topic 605-25, <i>Revenue
 Recognition&#x2014;Multiple-Element Arrangements</i>, and ASC Topic
 605-28, <i>Revenue Recognition&#x2014;Milestone Method</i>, in
 accounting for these agreements. In order to account for these
 agreements, the Company must identify the deliverables included
 within the agreement and evaluate which deliverables represent
 separate units of accounting based on the achievement of certain
 criteria, including whether the delivered element has stand-alone
 value to the collaborator. The consideration received is allocated
 among the separate units of accounting, and the applicable revenue
 recognition criteria are applied to each of the separate units.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 For the periods presented, the Company had the following two types
 of agreements: 1) exclusive development and commercialization
 licenses to use the Company&#x2019;s technology and/or certain other
 intellectual property to develop compounds against specified
 targets (referred to herein as exclusive licenses); and 2)
 Option/research agreements to secure on established terms,
 development and commercialization licenses to therapeutic product
 candidates to collaborator-selected targets developed by the
 Company during an option period (referred to herein as
 right-to-develop agreements).</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 There are no performance, cancellation, termination or refund
 provisions in any of the arrangements that contain material
 financial consequences to the Company.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 2%; MARGIN-TOP: 18pt">
 <i>Exclusive Licenses</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The deliverables under an exclusive license agreement generally
 include the exclusive license to the Company&#x2019;s DART
 technology with respect to a specified antigen target, and may also
 include deliverables related to rights to future technological
 improvements, research and pre-clinical development activities to
 be performed on behalf of the collaborator. In some cases the
 Company may have an option to participate in the co-development of
 product candidates that result from such agreements.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Generally, exclusive license agreements contain nonrefundable terms
 for payments and, depending on the terms of the agreement, provide
 that the Company will (i)&#xA0;at the collaborator&#x2019;s request,
 provide research and pre-clinical development services at
 negotiated prices which are generally consistent with what other
 third parties would charge, (ii)&#xA0;earn payments upon the
 achievement of certain milestones, (iii)&#xA0;earn royalty
 payments, and (iv)&#xA0;in some cases grant the Company an option
 to participate in the development and commercialization of products
 that result from such agreements. Royalty rates may vary over the
 royalty term depending on the Company&#x2019;s intellectual property
 rights and whether the Company exercises any co-development and
 co-commercialization rights. The Company may provide technical
 assistance and share any technology improvements with its
 collaborators during the term of the collaboration agreements.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The Company does not directly control when any collaborator will
 achieve milestones or become liable for royalty payments.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 When entering into a new collaboration arrangement or materially
 modifying an existing arrangement, the Company must identify the
 deliverables included within the agreement and evaluate which
 deliverables represent separate units of accounting based on the
 achievement of certain criteria, including whether the delivered
 element has stand-alone value to the collaborator. The selling
 prices of deliverables under an arrangement may be derived using
 third-party evidence (TPE), or a best estimate of selling price
 (BESP), if vendor specific objective evidence (VSOE) is not
 available. The objective of BESP is to determine the price at which
 the Company would transact a sale if the element within the license
 agreement was sold on a standalone basis. Establishing BESP
 involves management&#x2019;s judgment and considers multiple
 factors, including market conditions and company-specific factors,
 including those factors contemplated in negotiating the agreements,
 as well as internally developed models that include assumptions
 related to market opportunity, discounted cash flows, estimated
 development costs, probability of success and the time needed to
 commercialize a product candidate pursuant to the license. In
 validating the BESP, management considers whether changes in key
 assumptions used to determine the BESP will have a significant
 effect on the allocation of the arrangement consideration between
 the multiple deliverables. Deliverables under the arrangement are
 separate units of accounting if (i)&#xA0;the delivered item has
 value to the customer on a standalone basis and (ii)&#xA0;if the
 arrangement includes a general right of return relative to the
 delivered item, delivery or performance of the undelivered item is
 considered probable and substantially within the Company&#x2019;s
 control. The arrangement consideration that is fixed or
 determinable at the inception of the arrangement is allocated to
 the separate units of accounting based on their relative selling
 prices. The appropriate revenue recognition model is applied to
 each element and revenue is accordingly recognized as each element
 is delivered. Management exercises significant judgment in
 determining whether a deliverable is a separate unit of
 accounting.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 In determining the separate units of accounting, the Company
 evaluates whether the exclusive license has standalone value to the
 collaborator based on consideration of the relevant facts and
 circumstances for each arrangement. Factors considered in this
 determination include the research and development capabilities of
 the collaborator and the availability of relevant research
 expertise in the marketplace. In addition, the Company considers
 whether or not (i)&#xA0;the collaborator could use the license for
 its intended purpose without the receipt of the remaining
 deliverables, (ii)&#xA0;the value of the license was dependent on
 the undelivered items and (iii)&#xA0;the collaborator or other
 vendors could provide the undelivered items. If the Company
 concludes that the license has stand-alone value and therefore will
 be accounted for as a separate unit of accounting, the Company then
 determines the estimated selling prices of the license and all
 other units of accounting based on market conditions, similar
 arrangements entered into by third parties, and entity-specific
 factors such as the terms of the Company&#x2019;s previous
 collaboration agreements, recent pre-clinical and clinical testing
 results of therapeutic product candidates that use the
 Company&#x2019;s technology platforms, the Company&#x2019;s pricing
 practices and pricing objectives, the likelihood that technological
 improvements will be made, the likelihood that technological
 improvements made will be used by the Company&#x2019;s collaborators
 and the nature of the research services to be performed on behalf
 of its collaborators and market rates for similar services. Total
 arrangement consideration is then allocated to each of the units of
 accounting using the relative-selling-price method. If facts and
 circumstances dictate that the exclusive license does not have
 stand-alone value, then the related payments are deferred and
 revenue is recognized throughout the period of performance.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Management reassesses the period of performance over which the
 Company recognizes deferred upfront license fees and makes
 adjustments as appropriate in the period in which a change in the
 estimated period of performance is identified. In the event a
 collaborator elects to discontinue development of a specific
 product candidate under a single target license, but retains its
 right to use the Company&#x2019;s technology to develop an
 alternative product candidate to the same target or a target
 substitute, the Company would cease amortization of any remaining
 portion of the upfront fee until there is substantial pre-clinical
 activity on another product candidate and its remaining period of
 substantial involvement can be estimated. In the event that a
 single target license were to be terminated, the Company would
 recognize as revenue any portion of the upfront fee that had not
 previously been recorded as revenue, but was classified as deferred
 revenue, at the date of such termination or through the remaining
 substantial involvement in the wind down of the agreement.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Upfront payments on exclusive licenses may be recognized upon
 delivery of the license if facts and circumstances dictate that the
 license has stand-alone value from the undelivered elements, which
 generally include rights to future technological improvements,
 research services and the manufacture of pre-clinical and clinical
 materials.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The Company recognizes revenue related to research and pre-clinical
 development services that represent separate units of accounting as
 they are performed, as long as there is persuasive evidence of an
 arrangement, the fee is fixed or determinable, and collection of
 the related receivable is probable. The Company recognizes revenue
 related to the rights to future technological improvements over the
 estimated term of the applicable license.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The Company typically performs research activities and pre-clinical
 development services, including generating and engineering product
 candidates, on behalf of its licensees during the early evaluation
 and pre-clinical testing stages of drug development under its
 exclusive licenses. The Company records amounts received for
 research materials produced or services performed as revenue from
 collaborative research.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The Company&#x2019;s license agreements have milestone payments
 which for reporting purposes are aggregated into three categories:
 (i)&#xA0;development milestones, (ii)&#xA0;regulatory milestones,
 and (iii)&#xA0;sales milestones. Development milestones are
 typically payable when a product candidate initiates or advances
 into different clinical trial phases. Regulatory milestones are
 typically payable upon submission for marketing approval with the
 U.S. Food and Drug Administration (FDA) or other countries&#x2019;
 regulatory authorities or on receipt of actual marketing approvals
 for the compound or for additional indications. Sales milestones
 are typically payable when annual sales reach certain levels.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 At the inception of each agreement that includes milestone
 payments, the Company evaluates whether each milestone is
 substantive and at risk to both parties on the basis of the
 contingent nature of the milestone. This evaluation includes an
 assessment of whether (i)&#xA0;the consideration is commensurate
 with either (a)&#xA0;the entity&#x2019;s performance to achieve the
 milestone, or (b)&#xA0;the enhancement of the value of the
 delivered item(s) as a result of a specific outcome resulting from
 the entity&#x2019;s performance to achieve the milestone,
 (ii)&#xA0;the consideration relates solely to past performance and
 (iii)&#xA0;the consideration is reasonable relative to all of the
 deliverables and payment terms within the arrangement. The Company
 evaluates factors such as the scientific, regulatory, commercial
 and other risks that must be overcome to achieve the respective
 milestone, the level of effort and investment required to achieve
 the respective milestone and whether the milestone consideration is
 reasonable relative to all deliverables and payment terms in the
 arrangement in making this assessment.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Non-refundable development and regulatory milestones that are
 expected to be achieved as a result of the Company&#x2019;s efforts
 during the period of substantial involvement are considered
 substantive and are recognized as revenue upon the achievement of
 the milestone, assuming all other revenue recognition criteria are
 met. Milestones that are not considered substantive because the
 Company does not contribute effort to the achievement of such
 milestones are generally achieved after the period of substantial
 involvement and are recognized as revenue upon achievement of the
 milestone, as there are no undelivered elements remaining and no
 continuing performance obligations, assuming all other revenue
 recognition criteria are met.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 2%; MARGIN-TOP: 18pt">
 <i>Right-to-Develop Agreements</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The Company&#x2019;s right-to-develop agreements provide
 collaborators with an exclusive option to obtain licenses to
 develop and commercialize in specified geographic territories
 product candidates developed by the Company under agreed upon
 research and pre-clinical development product programs. The product
 candidates resulting from each program are all directed to a
 specific target selected by the collaborator. Under these
 agreements, fees may be due to the Company (i)&#xA0;at the
 inception of the arrangement (referred to as &#x201C;upfront&#x201D;
 fees or payments), (ii)&#xA0;the selection of a target for a
 program, (iii)&#xA0;upon the exercise of an option to acquire a
 development and commercialization license (referred to as exercise
 fees or payments earned) for a program, or (iv)&#xA0;some
 combination of all of these fees.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The accounting for right-to-develop agreements is dependent on the
 nature of the options granted to the collaborator. Options are
 considered substantive if, at the inception of a right-to-develop
 agreement, the Company is at risk as to whether the collaborator
 will choose to exercise the options to secure development and
 commercialization licenses. Factors that are considered in
 evaluating whether options are substantive include the overall
 objective of the arrangement, the benefit the collaborator might
 obtain from the agreement without exercising the options, the cost
 to exercise the options relative to the total upfront
 consideration, and the additional financial commitments imposed on
 the collaborator as a result of exercising the options.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 For right-to-develop agreements where the options to secure
 development and commercialization licenses to a product program are
 considered substantive, the Company does not consider the
 development and commercialization licenses to be a deliverable at
 the inception of the agreement, and therefore defers any upfront
 payments received and recognizes this revenue over the period
 during which the collaborator could elect to exercise options for
 development and commercialization licenses. These periods are
 specific to each collaboration agreement. If a collaborator selects
 a target for a product program, any substantive option fee is
 deferred and recognized over the life of the option. For
 right-to-develop agreements that include multiple deliverables, the
 Company determines the selling prices of deliverables under the
 arrangement using TPE or a BESP, if VSOE is not available. The
 objective of BESP is to determine the price at which the Company
 would transact a sale if the element within the right-to-develop
 agreement was sold on a standalone basis. Establishing BESP
 involves management&#x2019;s judgment and considers multiple
 factors, including market conditions and company-specific factors,
 including those factors contemplated in negotiating the agreements,
 as well as internally developed models that include assumptions
 related to market opportunity, discounted cash flows, estimated
 development costs, probability of success and the time needed to
 commercialize a product candidate pursuant to the right-to-develop
 agreement. In validating the BESP, management considers whether
 changes in key assumptions used to determine the BESP will have a
 significant effect on the allocation of the arrangement
 consideration between the multiple deliverables. Deliverables under
 the arrangement are separate units of accounting if (i)&#xA0;the
 delivered item has value to the customer on a standalone basis and
 (ii)&#xA0;if the arrangement includes a general right of return
 relative to the delivered item, delivery or performance of the
 undelivered item is considered probable and substantially within
 the Company&#x2019;s control. The arrangement consideration that is
 fixed or determinable at the inception of the arrangement is
 allocated to the separate units of accounting based on their
 relative selling prices. The appropriate revenue recognition model
 is applied to each element and revenue is accordingly recognized as
 each element is delivered. Management exercises significant
 judgment in determining whether a deliverable is a separate unit of
 accounting.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 If a collaborator exercises an option and acquires a development
 and commercialization license to a product program, the Company
 attributes the exercise fee to the development and
 commercialization license. The Company determines the selling price
 of the option license, upon exercise, through management&#x2019;s
 best estimate using the process for an exclusive license as
 described above.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Upon exercise of an option to acquire a development and
 commercialization license, the Company would also attribute any
 remaining deferred option fee, in addition to the consideration
 received for the license upon exercise of the option, to the
 development and commercialization license. The Company then applies
 the multiple-element revenue recognition criteria to the
 development and commercialization license and other deliverables,
 if any, to determine the appropriate revenue recognition method.
 This model is consistent with the Company&#x2019;s accounting policy
 for upfront payments on exclusive licenses (discussed above). In
 the event a right-to-develop agreement were to be terminated, the
 Company would recognize as revenue any portion of the upfront fee
 that had not previously been recorded as revenue, but was
 classified as deferred revenue, at the date of such termination.
 The Company&#x2019;s right-to-develop agreements have been
 determined to contain substantive options.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 For right-to-develop agreements where the options to secure
 development and commercialization licenses to product programs are
 not considered substantive, the Company considers the development
 and commercialization licenses to be a deliverable at the inception
 of the agreement and applies the multiple-element revenue
 recognition criteria to determine the appropriate revenue
 recognition. The Company does not directly control when any
 collaborator will exercise its options for development and
 commercialization licenses.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Research and Development Costs</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Research and development expenditures are expensed as incurred.
 Research and development costs primarily consist of employee
 related expenses, including salaries and benefits, expenses
 incurred under agreements with contract research organizations,
 investigative sites and consultants that conduct the
 Company&#x2019;s clinical trials, the cost of acquiring and
 manufacturing clinical trial materials and other allocated
 expenses, license fees for and milestone payments related to
 in-licensed products and technologies, stock-based compensation
 expense, and costs associated with non-clinical activities and
 regulatory approvals.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Comprehensive Income (Loss)</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Comprehensive income (loss) is comprised of the net income (loss)
 and other changes in equity that are excluded from net income
 (loss). Comprehensive income (loss) equals net income (loss) for
 the years ended December&#xA0;31, 2014, 2013 and 2012.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Stock-based Compensation</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Stock-based payments are accounted for in accordance with the
 provisions of ASC&#xA0;718, <i>Compensation&#x2014;Stock
 Compensation</i>. The fair value of stock-based payments is
 estimated, on the date of grant, using the Black-Scholes model. The
 resulting fair value is recognized ratably over the requisite
 service period, which is generally the vesting period of the
 option.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 For all time-vesting awards granted, expense is amortized using the
 straight-line attribution method. For awards that contain a
 performance condition, expense is amortized using the accelerated
 attribution method. Recognition of stock-based compensation expense
 is based on the value of the portion of stock-based awards that is
 ultimately expected to vest during the period.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The Company utilizes the Black-Scholes model for estimating fair
 value of its stock options granted. Option valuation models,
 including the Black-Scholes model, require the input of highly
 subjective assumptions, and changes in the assumptions used can
 materially affect the grant-date fair value of an award. These
 assumptions include the risk-free rate of interest, expected
 dividend yield, expected volatility and the expected life of the
 award.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Net Income (Loss) Per Share</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Basic income (loss) per common share is determined by dividing
 income (loss) attributable to common stockholders by the
 weighted-average number of common shares outstanding during the
 period, without consideration of common stock equivalents. Diluted
 income (loss) per share is computed by dividing the earnings (loss)
 attributable to common stockholders by the weighted-average number
 of common share equivalents outstanding for the period. The
 treasury stock method is used to determine the dilutive effect of
 the Company&#x2019;s stock option grants, potential Employee Stock
 Purchase Plan awards and warrants and the if-converted method is
 used to determine the dilutive effect of the Company&#x2019;s
 preferred stock.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 For the year ended December&#xA0;31, 2012, net income (loss) per
 share was calculated under the two-class method under which all
 earnings (distributed and undistributed) are allocated to each
 class of common stock and participating securities based on their
 respective rights to receive dividends. In the event that the Board
 of Directors declared a dividend payable in cash or other property
 on the then-outstanding shares of common stock, the holders of the
 Series&#xA0;A-1, A-2, B, C, D, and D-2 convertible preferred stock
 would be entitled to receive the amount of dividends per share of
 preferred stock that would be payable on the largest number of
 whole shares of common stock into which each share of preferred
 stock could then be converted. Therefore, the Series A-1, A-2, B,
 C, D and D-2 are participating securities. All of the outstanding
 shares of Series&#xA0;A-1, A-2, B, C, D, and D-2 convertible
 preferred stock converted to common stock upon the consummation of
 the Company&#x2019;s IPO in October 2013.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%">
 Basic and diluted income (loss) per common share is computed as
 follows (in thousands except share and per share data):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0">
 <tr>
 <td width="58%"></td>
 <td valign="bottom" width="9%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"><b>Year Ended
 December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Net income (loss)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(38,313</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(261</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">8,362</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Less: undistributed earnings allocated to participating
 securities</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(8,362</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Net income (loss) allocable to common shares</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(38,313</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(261</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Basic weighted average common shares outstanding</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">27,384,990</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,847,697</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,083,276</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Basic income (loss) per common share</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(1.40</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.04</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">0.00</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Net income (loss)</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(38,313</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(261</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">8,362</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Less: undistributed earnings allocated to participating securities
 and other add-backs to net income (loss)</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(8,362</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Net income (loss) allocable to common shares</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(38,313</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(261</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Basic weighted average common shares outstanding</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">27,384,990</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,847,697</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,083,276</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Effect of dilutive securities</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Diluted weighted average common shares outstanding</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">27,384,990</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,847,697</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,083,276</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Diluted income (loss) per common share</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(1.40</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.04</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">0.00</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The following common stock equivalents were excluded from the
 calculation of diluted net income (loss) per share because their
 effect would be anti-dilutive:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0">
 <tr>
 <td width="63%"></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"><b>Year Ended
 December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Series A-1 Preferred Stock</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,156,114</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Series A-2 Preferred Stock</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">392,274</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Series B Preferred Stock</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,336,037</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Series C Preferred Stock</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,909,906</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Series D Preferred Stock</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">769,468</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Series D-2 Preferred Stock</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,391,991</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Effect of Converted Preferred Stock</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">13,189,920</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Warrants to purchase Series D-2 Preferred Stock</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">180,784</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Stock Options</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,094,904</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,313,970</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,249,702</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Recently Issued Accounting Standards</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 In May 2014, the FASB issued ASU No.&#xA0;2014-09, <i>Revenue from
 Contracts with Customers</i> (ASU 2014-09). ASU 2014-09 will
 eliminate transaction- and industry-specific revenue recognition
 guidance under current GAAP and replace it with a principle-based
 approach for determining revenue recognition. ASU 2014-09 will
 require that companies recognize revenue based on the value of
 transferred goods or services as they occur in the contract. The
 ASU also will require additional disclosure about the nature,
 amount, timing and uncertainty of revenue and cash flows arising
 from customer contracts, including significant judgments and
 changes in judgments and assets recognized from costs incurred to
 obtain or fulfill a contract. ASU 2014-09 is effective for annual
 reporting periods beginning after December&#xA0;15, 2016. Early
 adoption is not permitted. Entities can transition to the standard
 either retrospectively or as a cumulative effect adjustment as of
 the date of adoption. Management is currently assessing what effect
 the adoption of ASU 2014-09 will have on the Company&#x2019;s
 consolidated financial statements and accompanying notes.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 In July 2013, the FASB issued ASU No.&#xA0;2013-11, which amended
 ASC Topic 740 regarding presentation of an unrecognized tax benefit
 when a net operating loss (NOL) carryforward, a similar tax loss,
 or a tax credit carryforward exists. The amendments in ASU
 No.&#xA0;2013-11 require an entity to present an unrecognized tax
 benefit as a reduction of a deferred tax asset for an NOL
 carryforward, or similar tax loss or tax credit carryforward,
 rather than as a liability when (1)&#xA0;the uncertain tax position
 would reduce the NOL or other carryforward under the tax law of the
 applicable jurisdiction and (2)&#xA0;the entity intends to use the
 deferred tax asset for that purpose. The ASU does not require new
 recurring disclosures. This amendment was effective prospectively
 for fiscal years beginning after December&#xA0;15, 2013, and did
 not have a material impact on the Company&#x2019;s financial
 statements.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The Company has evaluated all other ASUs issued through the date
 the consolidated financials were issued and believes that the
 adoption of these will not have a material impact on the
 Company&#x2019;s consolidated financial statements.</p>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for all significant accounting policies of the reporting entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18726-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18861-107790<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18743-107790<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18854-107790<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EOZAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Summary of Collaborators that Represent More Than 10% of Accounts Receivable (Detail) (Accounts Receivable [Member])<br></strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=mgnx_ServierMember', window );">Servier [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Significant Accounts Receivable</a></td>
        <td class="nump"><a title="us-gaap_ConcentrationRiskPercentage1[us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember;us-gaap_ConcentrationRiskByTypeAxis=mgnx_ServierMember]" onclick="toggleNextSibling(this);">33.30%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ConcentrationRiskPercentage1<br>/ us-gaap_ConcentrationRiskByBenchmarkAxis<br>= us-gaap_AccountsReceivableMember<br>/ us-gaap_ConcentrationRiskByTypeAxis<br>= mgnx_ServierMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ConcentrationRiskPercentage1[us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember;us-gaap_ConcentrationRiskByTypeAxis=mgnx_ServierMember]" onclick="toggleNextSibling(this);">6.40%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ConcentrationRiskPercentage1<br>/ us-gaap_ConcentrationRiskByBenchmarkAxis<br>= us-gaap_AccountsReceivableMember<br>/ us-gaap_ConcentrationRiskByTypeAxis<br>= mgnx_ServierMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=mgnx_BoehringerIngelheimMember', window );">Boehringer [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Significant Accounts Receivable</a></td>
        <td class="nump"><a title="us-gaap_ConcentrationRiskPercentage1[us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember;us-gaap_ConcentrationRiskByTypeAxis=mgnx_BoehringerIngelheimMember]" onclick="toggleNextSibling(this);">21.20%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ConcentrationRiskPercentage1<br>/ us-gaap_ConcentrationRiskByBenchmarkAxis<br>= us-gaap_AccountsReceivableMember<br>/ us-gaap_ConcentrationRiskByTypeAxis<br>= mgnx_BoehringerIngelheimMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ConcentrationRiskPercentage1[us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember;us-gaap_ConcentrationRiskByTypeAxis=mgnx_BoehringerIngelheimMember]" onclick="toggleNextSibling(this);">12.20%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ConcentrationRiskPercentage1<br>/ us-gaap_ConcentrationRiskByBenchmarkAxis<br>= us-gaap_AccountsReceivableMember<br>/ us-gaap_ConcentrationRiskByTypeAxis<br>= mgnx_BoehringerIngelheimMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=mgnx_GreenCrossCorporationMember', window );">Green Cross [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Significant Accounts Receivable</a></td>
        <td class="nump"><a title="us-gaap_ConcentrationRiskPercentage1[us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember;us-gaap_ConcentrationRiskByTypeAxis=mgnx_GreenCrossCorporationMember]" onclick="toggleNextSibling(this);">17.90%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ConcentrationRiskPercentage1<br>/ us-gaap_ConcentrationRiskByBenchmarkAxis<br>= us-gaap_AccountsReceivableMember<br>/ us-gaap_ConcentrationRiskByTypeAxis<br>= mgnx_GreenCrossCorporationMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=mgnx_GileadSciencesIncMember', window );">Gilead [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Significant Accounts Receivable</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ConcentrationRiskPercentage1[us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember;us-gaap_ConcentrationRiskByTypeAxis=mgnx_GileadSciencesIncMember]" onclick="toggleNextSibling(this);">53.40%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ConcentrationRiskPercentage1<br>/ us-gaap_ConcentrationRiskByBenchmarkAxis<br>= us-gaap_AccountsReceivableMember<br>/ us-gaap_ConcentrationRiskByTypeAxis<br>= mgnx_GileadSciencesIncMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=mgnx_PfizerIncMember', window );">Pfizer [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Significant Accounts Receivable</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ConcentrationRiskPercentage1[us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember;us-gaap_ConcentrationRiskByTypeAxis=mgnx_PfizerIncMember]" onclick="toggleNextSibling(this);">12.30%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ConcentrationRiskPercentage1<br>/ us-gaap_ConcentrationRiskByBenchmarkAxis<br>= us-gaap_AccountsReceivableMember<br>/ us-gaap_ConcentrationRiskByTypeAxis<br>= mgnx_PfizerIncMember</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 21<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13537-108611<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6404-108592<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13531-108611<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 18<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6351-108592<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=mgnx_BoehringerIngelheimMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=mgnx_BoehringerIngelheimMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=mgnx_GileadSciencesIncMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=mgnx_GileadSciencesIncMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=mgnx_GreenCrossCorporationMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=mgnx_GreenCrossCorporationMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=mgnx_PfizerIncMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=mgnx_PfizerIncMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=mgnx_ServierMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=mgnx_ServierMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EKIAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock- based Compensation - Schedule of Stock-Based Compensation Expense (Detail) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensation" onclick="toggleNextSibling(this);">$ 3,244</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensation</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensation" onclick="toggleNextSibling(this);">$ 862</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensation</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensation" onclick="toggleNextSibling(this);">$ 838</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensation</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
        <td class="nump"><a title="us-gaap_AllocatedShareBasedCompensationExpense[us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember]" onclick="toggleNextSibling(this);">1,562</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AllocatedShareBasedCompensationExpense<br>/ us-gaap_IncomeStatementLocationAxis<br>= us-gaap_ResearchAndDevelopmentExpenseMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AllocatedShareBasedCompensationExpense[us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember]" onclick="toggleNextSibling(this);">507</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AllocatedShareBasedCompensationExpense<br>/ us-gaap_IncomeStatementLocationAxis<br>= us-gaap_ResearchAndDevelopmentExpenseMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AllocatedShareBasedCompensationExpense[us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember]" onclick="toggleNextSibling(this);">472</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AllocatedShareBasedCompensationExpense<br>/ us-gaap_IncomeStatementLocationAxis<br>= us-gaap_ResearchAndDevelopmentExpenseMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
        <td class="nump"><a title="us-gaap_AllocatedShareBasedCompensationExpense[us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember]" onclick="toggleNextSibling(this);">$ 1,682</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AllocatedShareBasedCompensationExpense<br>/ us-gaap_IncomeStatementLocationAxis<br>= us-gaap_GeneralAndAdministrativeExpenseMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AllocatedShareBasedCompensationExpense[us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember]" onclick="toggleNextSibling(this);">$ 355</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AllocatedShareBasedCompensationExpense<br>/ us-gaap_IncomeStatementLocationAxis<br>= us-gaap_GeneralAndAdministrativeExpenseMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AllocatedShareBasedCompensationExpense[us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember]" onclick="toggleNextSibling(this);">$ 366</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AllocatedShareBasedCompensationExpense<br>/ us-gaap_IncomeStatementLocationAxis<br>= us-gaap_GeneralAndAdministrativeExpenseMember</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.F)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (h)(1)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section F<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ETOAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Collaboration and License Agreements - Additional Information 4 (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Oct. 31, 2010

</div>
          <div>Molecule</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014

</div>
          <div>Payments</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue, Current</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DeferredRevenueCurrent" onclick="toggleNextSibling(this);">$ 14,248,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredRevenueCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredRevenueCurrent" onclick="toggleNextSibling(this);">$ 20,267,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredRevenueCurrent</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue, Long-term liabilities</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DeferredRevenueNoncurrent" onclick="toggleNextSibling(this);">16,472,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredRevenueNoncurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredRevenueNoncurrent" onclick="toggleNextSibling(this);">7,136,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredRevenueNoncurrent</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=mgnx_BoehringerIngelheimMember', window );">Boehringer [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CollaborationAndLicenseAgreementEnteredDate', window );">Collaboration agreement date</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">October 2010<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedAsPerCollaborations', window );">Commercialization of molecules</a></td>
        <td class="nump"><a title="mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedAsPerCollaborations[us-gaap_CounterpartyNameAxis=mgnx_BoehringerIngelheimMember]" onclick="toggleNextSibling(this);">10</a><span style="display:none;white-space:normal;text-align:left;">mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedAsPerCollaborations<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_BoehringerIngelheimMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NonRefundableUpFrontPayment', window );">Nonrefundable upfront payment</a></td>
        <td class="nump"><a title="mgnx_NonRefundableUpFrontPayment[us-gaap_CounterpartyNameAxis=mgnx_BoehringerIngelheimMember]" onclick="toggleNextSibling(this);">15,000,000</a><span style="display:none;white-space:normal;text-align:left;">mgnx_NonRefundableUpFrontPayment<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_BoehringerIngelheimMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NumberOfAnnualMaintenancePaymentReceived', window );">Number of annual maintenance payments received</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="mgnx_NumberOfAnnualMaintenancePaymentReceived[us-gaap_CounterpartyNameAxis=mgnx_BoehringerIngelheimMember]" onclick="toggleNextSibling(this);">3</a><span style="display:none;white-space:normal;text-align:left;">mgnx_NumberOfAnnualMaintenancePaymentReceived<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_BoehringerIngelheimMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_AdditionalPotentialClinicalMilestonePaymentsUnderAgreement', window );">Clinical milestone payments</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="mgnx_AdditionalPotentialClinicalMilestonePaymentsUnderAgreement[us-gaap_CounterpartyNameAxis=mgnx_BoehringerIngelheimMember]" onclick="toggleNextSibling(this);">41,000,000</a><span style="display:none;white-space:normal;text-align:left;">mgnx_AdditionalPotentialClinicalMilestonePaymentsUnderAgreement<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_BoehringerIngelheimMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_AdditionalPotentialRegulatoryMilestonePaymentsUnderAgreement', window );">Regulatory milestone payments</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="mgnx_AdditionalPotentialRegulatoryMilestonePaymentsUnderAgreement[us-gaap_CounterpartyNameAxis=mgnx_BoehringerIngelheimMember]" onclick="toggleNextSibling(this);">89,000,000</a><span style="display:none;white-space:normal;text-align:left;">mgnx_AdditionalPotentialRegulatoryMilestonePaymentsUnderAgreement<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_BoehringerIngelheimMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_AdditionalPotentialSalesMilestonePaymentsUnderAgreement', window );">Sales milestone payments</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="mgnx_AdditionalPotentialSalesMilestonePaymentsUnderAgreement[us-gaap_CounterpartyNameAxis=mgnx_BoehringerIngelheimMember]" onclick="toggleNextSibling(this);">83,000,000</a><span style="display:none;white-space:normal;text-align:left;">mgnx_AdditionalPotentialSalesMilestonePaymentsUnderAgreement<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_BoehringerIngelheimMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ResearchObligationCompletionDate', window );">Research obligation completion date</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">2015-09<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicensesRevenue', window );">Recognized revenue under agreement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_LicensesRevenue[us-gaap_CounterpartyNameAxis=mgnx_BoehringerIngelheimMember]" onclick="toggleNextSibling(this);">13,700,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LicensesRevenue<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_BoehringerIngelheimMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_LicensesRevenue[us-gaap_CounterpartyNameAxis=mgnx_BoehringerIngelheimMember]" onclick="toggleNextSibling(this);">14,400,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LicensesRevenue<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_BoehringerIngelheimMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_LicensesRevenue[us-gaap_CounterpartyNameAxis=mgnx_BoehringerIngelheimMember]" onclick="toggleNextSibling(this);">11,700,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LicensesRevenue<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_BoehringerIngelheimMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DeferredRevenue[us-gaap_CounterpartyNameAxis=mgnx_BoehringerIngelheimMember]" onclick="toggleNextSibling(this);">12,800,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredRevenue<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_BoehringerIngelheimMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue, Current</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DeferredRevenueCurrent[us-gaap_CounterpartyNameAxis=mgnx_BoehringerIngelheimMember]" onclick="toggleNextSibling(this);">5,800,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredRevenueCurrent<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_BoehringerIngelheimMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredRevenueCurrent[us-gaap_CounterpartyNameAxis=mgnx_BoehringerIngelheimMember]" onclick="toggleNextSibling(this);">7,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredRevenueCurrent<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_BoehringerIngelheimMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue, Long-term liabilities</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DeferredRevenueNoncurrent[us-gaap_CounterpartyNameAxis=mgnx_BoehringerIngelheimMember]" onclick="toggleNextSibling(this);">5,800,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredRevenueNoncurrent<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_BoehringerIngelheimMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized', window );">Milestone payment</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized[us-gaap_CounterpartyNameAxis=mgnx_BoehringerIngelheimMember]" onclick="toggleNextSibling(this);">$ 2,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_BoehringerIngelheimMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized[us-gaap_CounterpartyNameAxis=mgnx_BoehringerIngelheimMember]" onclick="toggleNextSibling(this);">$ 5,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_BoehringerIngelheimMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized[us-gaap_CounterpartyNameAxis=mgnx_BoehringerIngelheimMember]" onclick="toggleNextSibling(this);">$ 2,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_BoehringerIngelheimMember</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_AdditionalPotentialClinicalMilestonePaymentsUnderAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate potential clinical milestone payments available to be earned under collaboration agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_AdditionalPotentialClinicalMilestonePaymentsUnderAgreement</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_AdditionalPotentialRegulatoryMilestonePaymentsUnderAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate potential remaining regulatory milestone payments available to be earned under a collaboration arrangement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_AdditionalPotentialRegulatoryMilestonePaymentsUnderAgreement</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_AdditionalPotentialSalesMilestonePaymentsUnderAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate potential remaining sales milestone payments available to be earned under collaboration agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_AdditionalPotentialSalesMilestonePaymentsUnderAgreement</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborationAndLicenseAgreementEnteredDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Collaboration and license agreement entered date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_CollaborationAndLicenseAgreementEnteredDate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>us-types:dateStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_LicenseAndCollaborationAgreementsLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_LicenseAndCollaborationAgreementsLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonRefundableUpFrontPayment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Non-refundable up front payment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_NonRefundableUpFrontPayment</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NumberOfAnnualMaintenancePaymentReceived">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of annual maintenance payment received.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_NumberOfAnnualMaintenancePaymentReceived</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedAsPerCollaborations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of molecules to be developed and commercialized as per collaborations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedAsPerCollaborations</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ResearchObligationCompletionDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Research obligation completion date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_ResearchObligationCompletionDate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearMonthItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 13<br><br> -Section A<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 8<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 13<br><br> -Section A<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 8<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 13<br><br> -Section A<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LicensesRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LicensesRevenue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of consideration recognized during the period for the milestone or milestones.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 28<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=19771982&amp;loc=SL6892177-166501<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=mgnx_BoehringerIngelheimMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=mgnx_BoehringerIngelheimMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EQCAG">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Consolidated Balance Sheets (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">$ 157,591</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">$ 116,481</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
        <td class="nump"><a title="us-gaap_AccountsReceivableNetCurrent" onclick="toggleNextSibling(this);">2,935</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsReceivableNetCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_AccountsReceivableNetCurrent" onclick="toggleNextSibling(this);">2,004</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsReceivableNetCurrent</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
        <td class="nump"><a title="us-gaap_PrepaidExpenseCurrent" onclick="toggleNextSibling(this);">4,211</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PrepaidExpenseCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_PrepaidExpenseCurrent" onclick="toggleNextSibling(this);">972</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PrepaidExpenseCurrent</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
        <td class="nump"><a title="us-gaap_AssetsCurrent" onclick="toggleNextSibling(this);">164,737</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_AssetsCurrent" onclick="toggleNextSibling(this);">119,457</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsCurrent</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash</a></td>
        <td class="nump"><a title="us-gaap_RestrictedCashAndCashEquivalents" onclick="toggleNextSibling(this);">300</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RestrictedCashAndCashEquivalents</span><span></span></td>
        <td class="nump"><a title="us-gaap_RestrictedCashAndCashEquivalents" onclick="toggleNextSibling(this);">405</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RestrictedCashAndCashEquivalents</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentNet" onclick="toggleNextSibling(this);">6,785</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentNet" onclick="toggleNextSibling(this);">5,035</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentNet</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
        <td class="nump"><a title="us-gaap_OtherAssetsNoncurrent" onclick="toggleNextSibling(this);">2,064</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherAssetsNoncurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_OtherAssetsNoncurrent" onclick="toggleNextSibling(this);">885</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherAssetsNoncurrent</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
        <td class="nump"><a title="us-gaap_Assets" onclick="toggleNextSibling(this);">173,886</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Assets</span><span></span></td>
        <td class="nump"><a title="us-gaap_Assets" onclick="toggleNextSibling(this);">125,782</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Assets</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
        <td class="nump"><a title="us-gaap_AccountsPayableCurrent" onclick="toggleNextSibling(this);">1,669</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsPayableCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_AccountsPayableCurrent" onclick="toggleNextSibling(this);">3,169</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsPayableCurrent</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
        <td class="nump"><a title="us-gaap_AccruedLiabilitiesCurrent" onclick="toggleNextSibling(this);">7,930</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccruedLiabilitiesCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_AccruedLiabilitiesCurrent" onclick="toggleNextSibling(this);">3,584</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccruedLiabilitiesCurrent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveCurrent', window );">Lease exit liability</a></td>
        <td class="nump"><a title="us-gaap_RestructuringReserveCurrent" onclick="toggleNextSibling(this);">1,642</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RestructuringReserveCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_RestructuringReserveCurrent" onclick="toggleNextSibling(this);">1,439</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RestructuringReserveCurrent</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue</a></td>
        <td class="nump"><a title="us-gaap_DeferredRevenueCurrent" onclick="toggleNextSibling(this);">14,248</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredRevenueCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredRevenueCurrent" onclick="toggleNextSibling(this);">20,267</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredRevenueCurrent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other liabilities</a></td>
        <td class="nump"><a title="us-gaap_OtherLiabilitiesCurrent" onclick="toggleNextSibling(this);">1,605</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherLiabilitiesCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_OtherLiabilitiesCurrent" onclick="toggleNextSibling(this);">363</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherLiabilitiesCurrent</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
        <td class="nump"><a title="us-gaap_LiabilitiesCurrent" onclick="toggleNextSibling(this);">27,094</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LiabilitiesCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_LiabilitiesCurrent" onclick="toggleNextSibling(this);">28,822</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LiabilitiesCurrent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveNoncurrent', window );">Lease exit liability, net of current portion</a></td>
        <td class="nump"><a title="us-gaap_RestructuringReserveNoncurrent" onclick="toggleNextSibling(this);">6,364</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RestructuringReserveNoncurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_RestructuringReserveNoncurrent" onclick="toggleNextSibling(this);">8,006</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RestructuringReserveNoncurrent</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditNoncurrent', window );">Deferred rent liability</a></td>
        <td class="nump"><a title="us-gaap_DeferredRentCreditNoncurrent" onclick="toggleNextSibling(this);">2,670</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredRentCreditNoncurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredRentCreditNoncurrent" onclick="toggleNextSibling(this);">2,904</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredRentCreditNoncurrent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue, net of current portion</a></td>
        <td class="nump"><a title="us-gaap_DeferredRevenueNoncurrent" onclick="toggleNextSibling(this);">16,472</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredRevenueNoncurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredRevenueNoncurrent" onclick="toggleNextSibling(this);">7,136</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredRevenueNoncurrent</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
        <td class="nump"><a title="us-gaap_Liabilities" onclick="toggleNextSibling(this);">52,600</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Liabilities</span><span></span></td>
        <td class="nump"><a title="us-gaap_Liabilities" onclick="toggleNextSibling(this);">46,868</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Liabilities</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.01 par value-125,000,000 shares authorized, 27,995,638 and 25,177,597 shares outstanding at December 31, 2014 and 2013, respectively</a></td>
        <td class="nump"><a title="us-gaap_CommonStockValue" onclick="toggleNextSibling(this);">280</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockValue" onclick="toggleNextSibling(this);">252</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockValue</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, at cost; 865 and 14,381 shares at December 31, 2014 and 2013, respectively</a></td>
        <td class="num"><a title="us-gaap_TreasuryStockValue" onclick="toggleNextSibling(this);">(19)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_TreasuryStockValue</span><span></span></td>
        <td class="num"><a title="us-gaap_TreasuryStockValue" onclick="toggleNextSibling(this);">(58)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_TreasuryStockValue</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
        <td class="nump"><a title="us-gaap_AdditionalPaidInCapital" onclick="toggleNextSibling(this);">335,071</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdditionalPaidInCapital</span><span></span></td>
        <td class="nump"><a title="us-gaap_AdditionalPaidInCapital" onclick="toggleNextSibling(this);">254,453</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdditionalPaidInCapital</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
        <td class="num"><a title="us-gaap_RetainedEarningsAccumulatedDeficit" onclick="toggleNextSibling(this);">(214,046)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RetainedEarningsAccumulatedDeficit</span><span></span></td>
        <td class="num"><a title="us-gaap_RetainedEarningsAccumulatedDeficit" onclick="toggleNextSibling(this);">(175,733)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RetainedEarningsAccumulatedDeficit</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity" onclick="toggleNextSibling(this);">121,286</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity" onclick="toggleNextSibling(this);">78,914</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
        <td class="nump"><a title="us-gaap_LiabilitiesAndStockholdersEquity" onclick="toggleNextSibling(this);">$ 173,886</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LiabilitiesAndStockholdersEquity</span><span></span></td>
        <td class="nump"><a title="us-gaap_LiabilitiesAndStockholdersEquity" onclick="toggleNextSibling(this);">$ 125,782</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LiabilitiesAndStockholdersEquity</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.3-4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph a(1)<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 4<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.30(a)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 12<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 18<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_Assets</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 9<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3044-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 25<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=7501430&amp;loc=d3e39927-112707<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.26(c))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredRentCreditNoncurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 605<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 13<br><br><br><br> -Section A<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 605<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 13<br><br><br><br> -Section A<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19-26)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_Liabilities</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.32)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 32<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.21)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 21<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate carrying amount of current liabilities (due within one year or within the normal operating cycle if longer) not separately disclosed in the balance sheet. Includes costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered and of liabilities not separately disclosed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6904-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Current Assets<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509628<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (g)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6787-107765<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 340<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 05<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=47804770&amp;loc=d3e5879-108316<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The carrying amounts of cash and cash equivalent items which are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. This element is for unclassified presentations; for classified presentations there is a separate and distinct element.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount as of the balance sheet date of known and estimated obligations associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid in the next twelve months or in the normal operating cycle if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 5<br><br><br><br> -Section P<br><br><br><br> -Subsection 4<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 420<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RestructuringReserveCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount as of the balance sheet date of known and estimated costs associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid after one year or beyond the next operating cycle, if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 420<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 5<br><br><br><br> -Section P<br><br><br><br> -Paragraph Question 4<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RestructuringReserveNoncurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.31(a)(3))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 4.E)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section E<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30, 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EC1AE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Income Taxes - Reconciliation of Reported Estimated Income Tax Benefit (Detail) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">United States federal tax at statutory rate</a></td>
        <td class="num"><a title="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" onclick="toggleNextSibling(this);">$ (13,410)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</span><span></span></td>
        <td class="num"><a title="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" onclick="toggleNextSibling(this);">$ (91)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</span><span></span></td>
        <td class="nump"><a title="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" onclick="toggleNextSibling(this);">$ 2,927</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State taxes (net of federal benefit)</a></td>
        <td class="num"><a title="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" onclick="toggleNextSibling(this);">(1,608)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</span><span></span></td>
        <td class="nump"><a title="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" onclick="toggleNextSibling(this);">609</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</span><span></span></td>
        <td class="nump"><a title="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" onclick="toggleNextSibling(this);">1,460</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_IncomeTaxReconciliationDeferredTaxAdjustments', window );">Deferred income tax adjustments</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num"><a title="mgnx_IncomeTaxReconciliationDeferredTaxAdjustments" onclick="toggleNextSibling(this);">(855)</a><span style="display:none;white-space:normal;text-align:left;">mgnx_IncomeTaxReconciliationDeferredTaxAdjustments</span><span></span></td>
        <td class="num"><a title="mgnx_IncomeTaxReconciliationDeferredTaxAdjustments" onclick="toggleNextSibling(this);">(512)</a><span style="display:none;white-space:normal;text-align:left;">mgnx_IncomeTaxReconciliationDeferredTaxAdjustments</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_IncomeTaxReconciliationStateDeferredTaxesAdjustments', window );">Deferred state blended rate adjustments</a></td>
        <td class="nump"><a title="mgnx_IncomeTaxReconciliationStateDeferredTaxesAdjustments" onclick="toggleNextSibling(this);">3,034</a><span style="display:none;white-space:normal;text-align:left;">mgnx_IncomeTaxReconciliationStateDeferredTaxesAdjustments</span><span></span></td>
        <td class="num"><a title="mgnx_IncomeTaxReconciliationStateDeferredTaxesAdjustments" onclick="toggleNextSibling(this);">(344)</a><span style="display:none;white-space:normal;text-align:left;">mgnx_IncomeTaxReconciliationStateDeferredTaxesAdjustments</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Research credit, net</a></td>
        <td class="num"><a title="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" onclick="toggleNextSibling(this);">(2,228)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</span><span></span></td>
        <td class="num"><a title="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" onclick="toggleNextSibling(this);">(226)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationDeductions', window );">Transaction cost deduction</a></td>
        <td class="num"><a title="us-gaap_IncomeTaxReconciliationDeductions" onclick="toggleNextSibling(this);">(379)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeTaxReconciliationDeductions</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsOther', window );">Orphan drug credit, net</a></td>
        <td class="num"><a title="us-gaap_IncomeTaxReconciliationTaxCreditsOther" onclick="toggleNextSibling(this);">(139)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeTaxReconciliationTaxCreditsOther</span><span></span></td>
        <td class="num"><a title="us-gaap_IncomeTaxReconciliationTaxCreditsOther" onclick="toggleNextSibling(this);">(843)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeTaxReconciliationTaxCreditsOther</span><span></span></td>
        <td class="num"><a title="us-gaap_IncomeTaxReconciliationTaxCreditsOther" onclick="toggleNextSibling(this);">(4,896)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeTaxReconciliationTaxCreditsOther</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherReconcilingItems', window );">Other permanent items</a></td>
        <td class="num"><a title="us-gaap_IncomeTaxReconciliationOtherReconcilingItems" onclick="toggleNextSibling(this);">(382)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeTaxReconciliationOtherReconcilingItems</span><span></span></td>
        <td class="nump"><a title="us-gaap_IncomeTaxReconciliationOtherReconcilingItems" onclick="toggleNextSibling(this);">3</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeTaxReconciliationOtherReconcilingItems</span><span></span></td>
        <td class="nump"><a title="us-gaap_IncomeTaxReconciliationOtherReconcilingItems" onclick="toggleNextSibling(this);">8</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeTaxReconciliationOtherReconcilingItems</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Equity-based compensation</a></td>
        <td class="nump"><a title="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" onclick="toggleNextSibling(this);">756</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</span><span></span></td>
        <td class="nump"><a title="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" onclick="toggleNextSibling(this);">241</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</span><span></span></td>
        <td class="nump"><a title="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" onclick="toggleNextSibling(this);">279</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_IncomeTaxReconciliationFairValueAdjustmentOfPreferredStockWarrantLiability', window );">Fair value adjustment of preferred stock warrant liability</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="mgnx_IncomeTaxReconciliationFairValueAdjustmentOfPreferredStockWarrantLiability" onclick="toggleNextSibling(this);">219</a><span style="display:none;white-space:normal;text-align:left;">mgnx_IncomeTaxReconciliationFairValueAdjustmentOfPreferredStockWarrantLiability</span><span></span></td>
        <td class="num"><a title="mgnx_IncomeTaxReconciliationFairValueAdjustmentOfPreferredStockWarrantLiability" onclick="toggleNextSibling(this);">(53)</a><span style="display:none;white-space:normal;text-align:left;">mgnx_IncomeTaxReconciliationFairValueAdjustmentOfPreferredStockWarrantLiability</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
        <td class="nump"><a title="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" onclick="toggleNextSibling(this);">14,920</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</span><span></span></td>
        <td class="nump"><a title="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" onclick="toggleNextSibling(this);">1,287</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</span><span></span></td>
        <td class="nump"><a title="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" onclick="toggleNextSibling(this);">787</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense/(benefit)</a></td>
        <td class="nump"><a title="us-gaap_IncomeTaxExpenseBenefit" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeTaxExpenseBenefit</span><span></span></td>
        <td class="nump"><a title="us-gaap_IncomeTaxExpenseBenefit" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeTaxExpenseBenefit</span><span></span></td>
        <td class="nump"><a title="us-gaap_IncomeTaxExpenseBenefit" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeTaxExpenseBenefit</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioPreviouslyReportedMember', window );">Prior Year Adjustment [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationDeductions', window );">Transaction cost deduction</a></td>
        <td class="num"><a title="us-gaap_IncomeTaxReconciliationDeductions[us-gaap_StatementScenarioAxis=us-gaap_ScenarioPreviouslyReportedMember]" onclick="toggleNextSibling(this);">$ (564)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeTaxReconciliationDeductions<br>/ us-gaap_StatementScenarioAxis<br>= us-gaap_ScenarioPreviouslyReportedMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_EffectiveIncomeTaxRateReconciliationLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_EffectiveIncomeTaxRateReconciliationLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_IncomeTaxReconciliationDeferredTaxAdjustments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Income tax reconciliation deferred tax adjustments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_IncomeTaxReconciliationDeferredTaxAdjustments</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_IncomeTaxReconciliationFairValueAdjustmentOfPreferredStockWarrantLiability">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Income tax reconciliation fair value adjustment of preferred stock warrant liability.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_IncomeTaxReconciliationFairValueAdjustmentOfPreferredStockWarrantLiability</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_IncomeTaxReconciliationStateDeferredTaxesAdjustments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Income tax reconciliation state deferred taxes adjustments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_IncomeTaxReconciliationStateDeferredTaxesAdjustments</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Income Tax Expense (or Benefit)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -Subparagraph (a),(b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e32123-109318<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationDeductions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to deductions. Including, but not limited to, extraterritorial income exclusion deduction, qualified production activity deduction, dividend deduction, deduction for dividend paid to employee stock ownership plan, Medicare prescription drug benefit subsidy deduction, and other deductions.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationDeductions</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Subparagraph 2<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible equity-based compensation costs.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherReconcilingItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority noncontrolling interest income (loss), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, increase (decrease) in enacted tax rate, prior year income taxes, increase (decrease) in deferred tax asset valuation allowance, and other adjustments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherReconcilingItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Subparagraph 1<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsOther">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other tax credits.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsOther</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioPreviouslyReportedMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=us-gaap_ScenarioPreviouslyReportedMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E41AG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Operating activities</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (38,313)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (261)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="nump"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ 8,362</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income (loss) to net cash used in operating activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
        <td class="nump"><a title="us-gaap_Depreciation" onclick="toggleNextSibling(this);">1,822</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Depreciation</span><span></span></td>
        <td class="nump"><a title="us-gaap_Depreciation" onclick="toggleNextSibling(this);">1,193</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Depreciation</span><span></span></td>
        <td class="nump"><a title="us-gaap_Depreciation" onclick="toggleNextSibling(this);">960</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Depreciation</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensation" onclick="toggleNextSibling(this);">3,244</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensation</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensation" onclick="toggleNextSibling(this);">862</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensation</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensation" onclick="toggleNextSibling(this);">838</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensation</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value adjustment of warrant liability</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_FairValueAdjustmentOfWarrants" onclick="toggleNextSibling(this);">626</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FairValueAdjustmentOfWarrants</span><span></span></td>
        <td class="num"><a title="us-gaap_FairValueAdjustmentOfWarrants" onclick="toggleNextSibling(this);">(151)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FairValueAdjustmentOfWarrants</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInAccountsReceivable" onclick="toggleNextSibling(this);">(931)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInAccountsReceivable</span><span></span></td>
        <td class="nump"><a title="us-gaap_IncreaseDecreaseInAccountsReceivable" onclick="toggleNextSibling(this);">42</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInAccountsReceivable</span><span></span></td>
        <td class="nump"><a title="us-gaap_IncreaseDecreaseInAccountsReceivable" onclick="toggleNextSibling(this);">1,352</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInAccountsReceivable</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInPrepaidExpense" onclick="toggleNextSibling(this);">(3,239)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInPrepaidExpense</span><span></span></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInPrepaidExpense" onclick="toggleNextSibling(this);">(834)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInPrepaidExpense</span><span></span></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInPrepaidExpense" onclick="toggleNextSibling(this);">(91)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInPrepaidExpense</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities', window );">Restricted cash</a></td>
        <td class="nump"><a title="us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities" onclick="toggleNextSibling(this);">105</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities" onclick="toggleNextSibling(this);">177</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInOtherOperatingAssets" onclick="toggleNextSibling(this);">(1,179)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</span><span></span></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInOtherOperatingAssets" onclick="toggleNextSibling(this);">(375)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</span><span></span></td>
        <td class="nump"><a title="us-gaap_IncreaseDecreaseInOtherOperatingAssets" onclick="toggleNextSibling(this);">1</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInAccountsPayable" onclick="toggleNextSibling(this);">(1,500)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInAccountsPayable</span><span></span></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInAccountsPayable" onclick="toggleNextSibling(this);">(570)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInAccountsPayable</span><span></span></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInAccountsPayable" onclick="toggleNextSibling(this);">(7,312)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInAccountsPayable</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
        <td class="nump"><a title="us-gaap_IncreaseDecreaseInAccruedLiabilities" onclick="toggleNextSibling(this);">4,346</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInAccruedLiabilities</span><span></span></td>
        <td class="nump"><a title="us-gaap_IncreaseDecreaseInAccruedLiabilities" onclick="toggleNextSibling(this);">2,347</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInAccruedLiabilities</span><span></span></td>
        <td class="nump"><a title="us-gaap_IncreaseDecreaseInAccruedLiabilities" onclick="toggleNextSibling(this);">185</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInAccruedLiabilities</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInRestructuringReserve', window );">Lease exit liability</a></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInRestructuringReserve" onclick="toggleNextSibling(this);">(1,439)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInRestructuringReserve</span><span></span></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInRestructuringReserve" onclick="toggleNextSibling(this);">(629)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInRestructuringReserve</span><span></span></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInRestructuringReserve" onclick="toggleNextSibling(this);">(534)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInRestructuringReserve</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
        <td class="nump"><a title="us-gaap_IncreaseDecreaseInDeferredRevenue" onclick="toggleNextSibling(this);">3,317</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInDeferredRevenue</span><span></span></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInDeferredRevenue" onclick="toggleNextSibling(this);">(16,676)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInDeferredRevenue</span><span></span></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInDeferredRevenue" onclick="toggleNextSibling(this);">(10,810)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInDeferredRevenue</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_IncreaseDecreaseInDeferredRent', window );">Deferred rent</a></td>
        <td class="num"><a title="mgnx_IncreaseDecreaseInDeferredRent" onclick="toggleNextSibling(this);">(234)</a><span style="display:none;white-space:normal;text-align:left;">mgnx_IncreaseDecreaseInDeferredRent</span><span></span></td>
        <td class="nump"><a title="mgnx_IncreaseDecreaseInDeferredRent" onclick="toggleNextSibling(this);">103</a><span style="display:none;white-space:normal;text-align:left;">mgnx_IncreaseDecreaseInDeferredRent</span><span></span></td>
        <td class="nump"><a title="mgnx_IncreaseDecreaseInDeferredRent" onclick="toggleNextSibling(this);">441</a><span style="display:none;white-space:normal;text-align:left;">mgnx_IncreaseDecreaseInDeferredRent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities', window );">Other liabilities</a></td>
        <td class="nump"><a title="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" onclick="toggleNextSibling(this);">1,242</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInOtherCurrentLiabilities</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash used in operating activities</a></td>
        <td class="num"><a title="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" onclick="toggleNextSibling(this);">(32,759)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</span><span></span></td>
        <td class="num"><a title="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" onclick="toggleNextSibling(this);">(14,172)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</span><span></span></td>
        <td class="num"><a title="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" onclick="toggleNextSibling(this);">(6,582)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
        <td class="num"><a title="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" onclick="toggleNextSibling(this);">(3,572)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</span><span></span></td>
        <td class="num"><a title="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" onclick="toggleNextSibling(this);">(2,961)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</span><span></span></td>
        <td class="num"><a title="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" onclick="toggleNextSibling(this);">(940)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations', window );">Net cash used in investing activities</a></td>
        <td class="num"><a title="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" onclick="toggleNextSibling(this);">(3,572)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</span><span></span></td>
        <td class="num"><a title="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" onclick="toggleNextSibling(this);">(2,961)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</span><span></span></td>
        <td class="num"><a title="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" onclick="toggleNextSibling(this);">(940)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of offering costs</a></td>
        <td class="nump"><a title="us-gaap_ProceedsFromIssuanceOfCommonStock" onclick="toggleNextSibling(this);">76,716</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromIssuanceOfCommonStock</span><span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromIssuanceOfCommonStock" onclick="toggleNextSibling(this);">84,771</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromIssuanceOfCommonStock</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from stock option exercises</a></td>
        <td class="nump"><a title="us-gaap_ProceedsFromStockOptionsExercised" onclick="toggleNextSibling(this);">744</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromStockOptionsExercised</span><span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromStockOptionsExercised" onclick="toggleNextSibling(this);">1,100</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromStockOptionsExercised</span><span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromStockOptionsExercised" onclick="toggleNextSibling(this);">47</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromStockOptionsExercised</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Purchase of treasury stock</a></td>
        <td class="num"><a title="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" onclick="toggleNextSibling(this);">(19)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations', window );">Net cash provided by financing activities</a></td>
        <td class="nump"><a title="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" onclick="toggleNextSibling(this);">77,441</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</span><span></span></td>
        <td class="nump"><a title="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" onclick="toggleNextSibling(this);">85,871</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</span><span></span></td>
        <td class="nump"><a title="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" onclick="toggleNextSibling(this);">47</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net change in cash and cash equivalents</a></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" onclick="toggleNextSibling(this);">41,110</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</span><span></span></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" onclick="toggleNextSibling(this);">68,738</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</span><span></span></td>
        <td class="num"><a title="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" onclick="toggleNextSibling(this);">(7,475)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at beginning of period</a></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">116,481</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">47,743</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">55,218</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at end of period</a></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">157,591</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">116,481</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">47,743</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Noncash financing activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion of preferred stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ConversionOfStockAmountConverted1" onclick="toggleNextSibling(this);">$ 2,947</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ConversionOfStockAmountConverted1</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_IncreaseDecreaseInDeferredRent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Increase decrease in deferred rent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_IncreaseDecreaseInDeferredRent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3044-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 230<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450594&amp;loc=d3e33268-110906<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountConverted1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_Depreciation</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 480<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6939902&amp;loc=d3e20148-110875<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in other current operating liabilities not separately disclosed in the statement of cash flows.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentLiabilities</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in other assets used in operating activities not separately disclosed in the statement of cash flows. May include changes in other current assets, other noncurrent assets, or a combination of other current and noncurrent assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash inflow or outflow for the increase (decrease) associated with funds that are not available for withdrawal or use (such as funds held in escrow) and are associated with underlying transactions that are classified as operating activities. This may include cash restricted for regulatory purposes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInRestructuringReserve">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the period in the carrying amount (including both current and noncurrent portions of the accrual) of the liability pertaining to the exit from or disposal of business activities or restructuring pursuant to a duly authorized plan, excluding costs or losses pertaining to an entity newly acquired in a business combination and to asset retirement obligations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInRestructuringReserve</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash outflow to satisfy an employee's income tax withholding obligation as part of a net-share settlement of a share-based award.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 15<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3291-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3213-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the additional capital contribution to the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (j)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E4PAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Product Milestone Payments and Royalty Agreements - Additional Information (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="1">36 Months Ended</th>
        <th class="th" colspan="1">1 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2005</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_RoyaltyAgreementLineItems', window );"><strong>Royalty Agreement [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_AdditionalPaymentUponAchievementOfMilestone', window );">Additional consideration of asset purchase agreement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="mgnx_AdditionalPaymentUponAchievementOfMilestone" onclick="toggleNextSibling(this);"> 10,950,000</a><span style="display:none;white-space:normal;text-align:left;">mgnx_AdditionalPaymentUponAchievementOfMilestone</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NumberOfPotentialSharesToBeIssuedAsAdditionalConsiderationUnderAssetPurchaseAgreement', window );">Common stock shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="mgnx_NumberOfPotentialSharesToBeIssuedAsAdditionalConsiderationUnderAssetPurchaseAgreement" onclick="toggleNextSibling(this);">36,135</a><span style="display:none;white-space:normal;text-align:left;">mgnx_NumberOfPotentialSharesToBeIssuedAsAdditionalConsiderationUnderAssetPurchaseAgreement</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_AmountOfAdditionalConsiderationPaidUnderAgreement', window );">Payments related to the additional considerations</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="mgnx_AmountOfAdditionalConsiderationPaidUnderAgreement" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">mgnx_AmountOfAdditionalConsiderationPaidUnderAgreement</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenue from product sales</a></td>
        <td class="nump"><a title="us-gaap_SalesRevenueGoodsNet" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SalesRevenueGoodsNet</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_RoyaltyAgreementLineItems', window );"><strong>Royalty Agreement [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_RoyaltyPaymentAsPercentageOfNetSalesUnderLicensingAgreement', window );">Maximum royalty payments percentage</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="mgnx_RoyaltyPaymentAsPercentageOfNetSalesUnderLicensingAgreement[us-gaap_RangeAxis=us-gaap_MinimumMember]" onclick="toggleNextSibling(this);">1.75%</a><span style="display:none;white-space:normal;text-align:left;">mgnx_RoyaltyPaymentAsPercentageOfNetSalesUnderLicensingAgreement<br>/ us-gaap_RangeAxis<br>= us-gaap_MinimumMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_RoyaltyAgreementLineItems', window );"><strong>Royalty Agreement [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_RoyaltyPaymentAsPercentageOfNetSalesUnderLicensingAgreement', window );">Maximum royalty payments percentage</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="mgnx_RoyaltyPaymentAsPercentageOfNetSalesUnderLicensingAgreement[us-gaap_RangeAxis=us-gaap_MaximumMember]" onclick="toggleNextSibling(this);">4.00%</a><span style="display:none;white-space:normal;text-align:left;">mgnx_RoyaltyPaymentAsPercentageOfNetSalesUnderLicensingAgreement<br>/ us-gaap_RangeAxis<br>= us-gaap_MaximumMember</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_AdditionalPaymentUponAchievementOfMilestone">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Additional payment upon achievement of milestone.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_AdditionalPaymentUponAchievementOfMilestone</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_AmountOfAdditionalConsiderationPaidUnderAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of additional consideration paid under agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_AmountOfAdditionalConsiderationPaidUnderAgreement</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NumberOfPotentialSharesToBeIssuedAsAdditionalConsiderationUnderAssetPurchaseAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of potential shares to be issued as additional consideration under asset purchase agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_NumberOfPotentialSharesToBeIssuedAsAdditionalConsiderationUnderAssetPurchaseAgreement</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_RoyaltyAgreementLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_RoyaltyAgreementLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_RoyaltyPaymentAsPercentageOfNetSalesUnderLicensingAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Royalty payment as percentage of net sales under licensing agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_RoyaltyPaymentAsPercentageOfNetSalesUnderLicensingAgreement</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SalesRevenueGoodsNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EAKBG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from the Calculation of Diluted Income (Loss) Per Share (Detail)<br></strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=mgnx_SeriesA1ConvertiblePreferredStockMember', window );">Series A-1 Convertible Preferred Stock [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount[us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=mgnx_SeriesA1ConvertiblePreferredStockMember]" onclick="toggleNextSibling(this);">2,156,114</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount<br>/ us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis<br>= mgnx_SeriesA1ConvertiblePreferredStockMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=mgnx_SeriesA2ConvertiblePreferredStockMember', window );">Series A-2 Convertible Preferred Stock [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount[us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=mgnx_SeriesA2ConvertiblePreferredStockMember]" onclick="toggleNextSibling(this);">392,274</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount<br>/ us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis<br>= mgnx_SeriesA2ConvertiblePreferredStockMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=mgnx_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount[us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=mgnx_SeriesBConvertiblePreferredStockMember]" onclick="toggleNextSibling(this);">4,336,037</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount<br>/ us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis<br>= mgnx_SeriesBConvertiblePreferredStockMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=mgnx_SeriesCConvertiblePreferredStockMember', window );">Series C Convertible Preferred Stock [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount[us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=mgnx_SeriesCConvertiblePreferredStockMember]" onclick="toggleNextSibling(this);">5,909,906</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount<br>/ us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis<br>= mgnx_SeriesCConvertiblePreferredStockMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=mgnx_SeriesDConvertiblePreferredStockMember', window );">Series D Convertible Preferred Stock [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount[us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=mgnx_SeriesDConvertiblePreferredStockMember]" onclick="toggleNextSibling(this);">769,468</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount<br>/ us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis<br>= mgnx_SeriesDConvertiblePreferredStockMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=mgnx_SeriesD2ConvertiblePreferredStockMember', window );">Series D-2 Convertible Preferred Stock [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount[us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=mgnx_SeriesD2ConvertiblePreferredStockMember]" onclick="toggleNextSibling(this);">3,391,991</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount<br>/ us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis<br>= mgnx_SeriesD2ConvertiblePreferredStockMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember', window );">Effect of Convertible Preferred Stock [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount[us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember]" onclick="toggleNextSibling(this);">13,189,920</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount<br>/ us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis<br>= us-gaap_ConvertiblePreferredStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount[us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember]" onclick="toggleNextSibling(this);">180,784</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount<br>/ us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis<br>= us-gaap_WarrantMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember', window );">Stock Options [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, shares</a></td>
        <td class="nump"><a title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount[us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember]" onclick="toggleNextSibling(this);">2,094,904</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount<br>/ us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis<br>= us-gaap_StockOptionMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount[us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember]" onclick="toggleNextSibling(this);">2,313,970</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount<br>/ us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis<br>= us-gaap_StockOptionMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount[us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember]" onclick="toggleNextSibling(this);">3,249,702</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount<br>/ us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis<br>= us-gaap_StockOptionMember</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Antidilution<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6505113<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Diluted Earnings Per Share<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510752<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Contingent Stock Agreement<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6508534<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=mgnx_SeriesA1ConvertiblePreferredStockMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=mgnx_SeriesA1ConvertiblePreferredStockMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=mgnx_SeriesA2ConvertiblePreferredStockMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=mgnx_SeriesA2ConvertiblePreferredStockMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=mgnx_SeriesBConvertiblePreferredStockMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=mgnx_SeriesBConvertiblePreferredStockMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=mgnx_SeriesCConvertiblePreferredStockMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=mgnx_SeriesCConvertiblePreferredStockMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=mgnx_SeriesD2ConvertiblePreferredStockMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=mgnx_SeriesD2ConvertiblePreferredStockMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=mgnx_SeriesDConvertiblePreferredStockMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=mgnx_SeriesDConvertiblePreferredStockMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Property and equipment consists of the following (in
 thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="71%"></td>
 <td valign="bottom" width="9%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Computer equipment</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,596</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,379</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Software</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,683</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,477</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Furniture and office equipment</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">751</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">651</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Lab equipment</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">13,917</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">11,166</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Leasehold improvements</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,193</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,894</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Property and equipment</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">24,140</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">20,567</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Less accumulated depreciation</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(17,355</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(15,532</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Property and equipment, net</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">6,785</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">5,035</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 13<br><br> -Subparagraph b<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ED6AE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Property and Equipment - Schedule of Property and Equipment (Detail) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentGross" onclick="toggleNextSibling(this);">$ 24,140</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentGross</span><span></span></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentGross" onclick="toggleNextSibling(this);">$ 20,567</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentGross</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation</a></td>
        <td class="num"><a title="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" onclick="toggleNextSibling(this);">(17,355)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</span><span></span></td>
        <td class="num"><a title="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" onclick="toggleNextSibling(this);">(15,532)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentNet" onclick="toggleNextSibling(this);">6,785</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentNet" onclick="toggleNextSibling(this);">5,035</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentNet</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentGross[us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember]" onclick="toggleNextSibling(this);">2,596</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentGross<br>/ us-gaap_PropertyPlantAndEquipmentByTypeAxis<br>= us-gaap_ComputerEquipmentMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentGross[us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember]" onclick="toggleNextSibling(this);">2,379</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentGross<br>/ us-gaap_PropertyPlantAndEquipmentByTypeAxis<br>= us-gaap_ComputerEquipmentMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Software [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentGross[us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember]" onclick="toggleNextSibling(this);">1,683</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentGross<br>/ us-gaap_PropertyPlantAndEquipmentByTypeAxis<br>= us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentGross[us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember]" onclick="toggleNextSibling(this);">1,477</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentGross<br>/ us-gaap_PropertyPlantAndEquipmentByTypeAxis<br>= us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mgnx_FurnitureAndOfficeEquipmentMember', window );">Furniture and Office Equipment [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentGross[us-gaap_PropertyPlantAndEquipmentByTypeAxis=mgnx_FurnitureAndOfficeEquipmentMember]" onclick="toggleNextSibling(this);">751</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentGross<br>/ us-gaap_PropertyPlantAndEquipmentByTypeAxis<br>= mgnx_FurnitureAndOfficeEquipmentMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentGross[us-gaap_PropertyPlantAndEquipmentByTypeAxis=mgnx_FurnitureAndOfficeEquipmentMember]" onclick="toggleNextSibling(this);">651</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentGross<br>/ us-gaap_PropertyPlantAndEquipmentByTypeAxis<br>= mgnx_FurnitureAndOfficeEquipmentMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Lab Equipment [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentGross[us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember]" onclick="toggleNextSibling(this);">13,917</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentGross<br>/ us-gaap_PropertyPlantAndEquipmentByTypeAxis<br>= us-gaap_EquipmentMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentGross[us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember]" onclick="toggleNextSibling(this);">11,166</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentGross<br>/ us-gaap_PropertyPlantAndEquipmentByTypeAxis<br>= us-gaap_EquipmentMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentGross[us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember]" onclick="toggleNextSibling(this);">$ 5,193</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentGross<br>/ us-gaap_PropertyPlantAndEquipmentByTypeAxis<br>= us-gaap_LeaseholdImprovementsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentGross[us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember]" onclick="toggleNextSibling(this);">$ 4,894</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentGross<br>/ us-gaap_PropertyPlantAndEquipmentByTypeAxis<br>= us-gaap_LeaseholdImprovementsMember</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.14)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 14<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 13<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 8<br><br> -Article 7<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mgnx_FurnitureAndOfficeEquipmentMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=mgnx_FurnitureAndOfficeEquipmentMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EKH">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Components of the Company's Deferred Income Tax Assets (Liabilities)</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%">
 The significant components of the Company&#x2019;s deferred income
 tax assets (liabilities) were as follows (in thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="71%"></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Deferred income tax assets:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Federal U.S. net operating loss carryforward</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">55,358</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">36,561</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 State net operating loss carryforward</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,723</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,316</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Research and development credit, net</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7,177</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,786</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Orphan drug credit, net</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">19,287</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">19,883</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Deferred rent</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,069</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,132</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Deferred revenue</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,989</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8,217</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Depreciation</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,337</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,438</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Other</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">962</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,439</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Gross deferred income tax assets</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">95,902</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">79,772</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Valuation allowance</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(94,297</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(79,377</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Net deferred income tax assets</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,605</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">395</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Deferred income tax liabilities:</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Prepaid expenditures</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(1,605</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(395</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Gross deferred income tax liabilities</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(1,605</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(395</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Net deferred income tax asset/(liability)</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation of Reported Estimated Income Tax Benefit</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The reconciliation of the reported estimated income tax benefit to
 the amount that would result by applying the U.S. federal statutory
 tax rate to the net income is as follows (in thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <tr>
 <td width="66%"></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"><b>Year Ended
 December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 United States federal tax at statutory rate</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(13,410</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(91</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,927</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 State taxes (net of federal benefit)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(1,608</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">609</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,460</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Deferred income tax adjustments</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(855</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(512</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Deferred state blended rate adjustments</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,034</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(344</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Research credit, net</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(2,228</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(226</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Transaction cost deduction</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(379</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Transaction cost deduction&#x2014;prior year adjustment</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(564</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Orphan drug credit, net</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(139</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(843</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(4,896</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Other permanent items</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(382</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Equity-based compensation</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">756</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">241</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">279</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Fair value adjustment of preferred stock warrant liability</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">219</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(53</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Change in valuation allowance</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">14,920</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,287</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">787</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Income tax expense/(benefit)</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Reconciliation of the Beginning and Ending Amount of Gross Unrecognized Tax Benefits</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 A reconciliation of the beginning and ending amount of gross
 unrecognized tax benefits is as follows (in thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <tr>
 <td width="70%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"><b>Year Ended
 December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Beginning balance</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,708</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,592</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,534</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Increases/(decreases) for current year tax positions</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">242</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">116</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">58</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Increases/(decreases) for prior year tax positions</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">97</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Decreases as a result of expiration of statute of limitations</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Ending balance</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,047</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,708</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,592</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the change in unrecognized tax benefits.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 217<br><br> -URI http://asc.fasb.org/extlink&amp;oid=32707879&amp;loc=d3e36027-109320<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15A<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=SL6600010-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Organization and Nature of Operations<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and Nature of Operations</a></td>
        <td class="text"><div>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <b>1. Organization and Nature of Operations</b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 MacroGenics, Inc. (the &#x201C;Company&#x201D;) was incorporated in
 Delaware on August&#xA0;14, 2000. The Company is a clinical-stage
 biopharmaceutical company focused on discovering and developing
 innovative monoclonal antibody-based therapeutics for the treatment
 of cancer, as well as various autoimmune disorders and infectious
 diseases. The Company generates its pipeline of product candidates
 from its proprietary suite of next-generation antibody technology
 platforms which it believes improve the performance of monoclonal
 antibodies and antibody-derived molecules. These product
 candidates, which the Company has identified through its
 understanding of disease biology and immune-mediated mechanisms,
 may address disease-specific challenges which are not currently
 being met by existing therapies.</p>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35735333&amp;loc=d3e288-107754<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=d3e5614-111684<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 915<br><br> -SubTopic 235<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6472506&amp;loc=d3e38932-110933<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 272<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6373374&amp;loc=d3e70478-108055<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EYIAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
        <td class="nump"><a title="us-gaap_CommonStockParOrStatedValuePerShare" onclick="toggleNextSibling(this);">$ 0.01</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockParOrStatedValuePerShare</span><span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockParOrStatedValuePerShare" onclick="toggleNextSibling(this);">$ 0.01</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockParOrStatedValuePerShare</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesAuthorized" onclick="toggleNextSibling(this);">125,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesAuthorized</span><span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesAuthorized" onclick="toggleNextSibling(this);">125,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesAuthorized</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesOutstanding" onclick="toggleNextSibling(this);">27,995,638</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesOutstanding</span><span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesOutstanding" onclick="toggleNextSibling(this);">25,177,597</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesOutstanding</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockNumberOfSharesHeld', window );">Treasury stock, shares</a></td>
        <td class="nump"><a title="us-gaap_TreasuryStockNumberOfSharesHeld" onclick="toggleNextSibling(this);">865</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_TreasuryStockNumberOfSharesHeld</span><span></span></td>
        <td class="nump"><a title="us-gaap_TreasuryStockNumberOfSharesHeld" onclick="toggleNextSibling(this);">14,381</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_TreasuryStockNumberOfSharesHeld</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockNumberOfSharesHeld">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares held for each class of treasury stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_TreasuryStockNumberOfSharesHeld</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Employee Benefit Plan<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Compensation and Retirement Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Employee Benefit Plan</a></td>
        <td class="text"><div>
 <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <b>11. Employee Benefit Plan</b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 On September&#xA0;25, 2002, the Company established the MacroGenics
 401(k) Plan (the Plan) for its employees under Section&#xA0;401(k)
 of the IRC. Under this Plan, all employees at least 21 years of age
 are eligible to participate in the Plan, starting on the first day
 of each month. Employees may contribute up to 100% of their salary,
 subject to government maximums.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 Employees are 100% vested in their contributions to the Plan. The
 Company&#x2019;s contribution to the Plan, as determined by the
 Board of Directors, is discretionary. The Company&#x2019;s
 contributions to the Plan totaled $318,390, $252,930 and $225,195
 for the years ended December&#xA0;31, 2014, 2013 and 2012,
 respectively.</p>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for pension and other postretirement benefits.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 715<br><br> -SubTopic 70<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6414718&amp;loc=d3e28014-114942<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 715<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35743120&amp;loc=d3e2410-114920<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 715<br><br> -SubTopic 80<br><br> -Section 50<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35742057&amp;loc=SL14450702-114947<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 715<br><br> -SubTopic 60<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6414199&amp;loc=d3e39622-114963<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 715<br><br> -SubTopic 60<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39675-114964<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>79
<FILENAME>0001193125-15-075224-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-15-075224-xbrl.zip
M4$L#!!0````(`&F&8T:%/R,'DW`!`'BG#@`1`!P`;6=N>"TR,#$T,3(S,2YX
M;6Q55`D``]8L]E36+/94=7@+``$$)0X```0Y`0``W%UK;]M(=_Y>H/]!]8>B
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M+N`GV$6ZHLY9.?*=?3I[9?PLS?ZRY'L>;S_8&/^-N='$&'/AGCX-38LYIT2]
M-IERQ/-W%VG5-\-0<O'G+S]_FMPF=V.TC0`DY68\OG]^\WI<?''OK1[`^X0C
M3!`C3Z],DY<?<C,JDLGYS?SK!3RH&'YWDSUL3.QN/,GG-TF63@HG,?850E]>
M@%]>/-XG1>6<W).*7[$3F2XVY[6"+R[*AQM#T\JALAR:/@TM%O=Y-5;[Q$Z#
M;$YC`G*]R!^KWUD]M*^QK=>6>0[:N^^]U=,*V,G#Y+;Z)?NDXH5L#&2O?L,]
MJL"49E^38E']3OFL`E&13O80+IU4_$:6W(#63_=*N[G(Y[/D8C7L^:WE7?4;
MTT5^827E`D8D>3IY?@$,0_T[\PQMO;=<Y*],#9Z>@0D9C9P1F;TKG*I=)M<C
MI]'O[+?^>%:D=_<SJW?NLW$^L8B:V0[WQFV>7/]X9K4)/6G,^4,Q;6%:FENM
MBQ+6RA:\^W0[SA/?N@-K4).L<`;;R_-Q=I-89^$_O@SY.'ZT'WG?QOGTU^7=
MER3_<.V>%MYR<3O/TW^`5YG,LT7RL+BTT)+Y[.IC1)2AAB,$"#'Z;S!>_.K3
MY_`*7]FI84HU_)50C8WD#T02S+@\&RVSM/R.POW`V6B:3-*[\0PD_?VO\=DH
M!<E*IU=2<TVEO`JICI00"H6AIQ#W98B,Q/!/&7C*A(QP%5\1^.TK?/83Q8)(
MSG^XZ(P*%40NWA?%\F#ZP$>,./HHR3%^()PJ(^C!]`E"7U(6&A2QR$><!B'R
MA0A1@(%*$9<XBB/[>^2*G?U$F,0<$[E%H!6"36S!;%P4'Z[_&%MB+3[DSA<_
MDR4!0Y<NTJ0(QN"\I_[C:ERQ&E@<1@Y@('!NG1Q.7-C!Y%"<RC@P!OFA,HB'
MF"+?US&*2>@3!>B5%SCQO))G/PFB%=8OQ#@2\J`4D+!G`5LI(&.48W,P10WA
M@1]1BB(N*.)&1\@CE"./AAP#@;GOTV<%)*";1.I^%?`C6/_D0.KPTCRM46,5
MHEW]]BF\ND_RJV;4D4(1"71%Q`/-XT00Y"LJ$0Y\3KCD-":ZI`ZH'Y/G`F_1
MQDV^!&7]Q;M?YQE,!R+N\9=9\MO]=0ZP5G2Y3"9)^M5^?B!88:6A5"["E'Z`
M/QD3[M\4*PK*AH4PNIH8ZQ1`8H<`3/O4^%(A'4<"<64"9+`FB((O4U)CGT>T
MM#\4%`Z7__UPT1QK21N(5]]%V2)=/((<W<VS3XOYY*]2-CXL%RYS@FSJ8+I0
MJC:$H!G3<21CQB`N"HEF8',Q1B:2!L5QZ(,5IEX$7PM,IU<:?)(Q\)X"F]L,
MPYHL>--I:M5E/%M1Y;=[T)W);9I\=;KSX?J7=`8Q'62,!WH?@27#^\2_#K[P
M`NRQ4"###%B$R,3("_T824R)$!X-#`ZOV)-%P$:LL?P`2.M*L3(&'^<+&)..
M9R75/L_]I'1=7O'RQ0%DD>G4ILCPS]\R^)M7%,GBXS*?W(*5\6[RQ/W4T21K
M)BS-J46LA2!,/&E'%Z!/%K^`R=B,7Z@F1*C#XSOC!]P'HIC8CQ#G++;Q"T:1
M3T04^5Q$X*N?XQ<0),;PM@W=B%\<[3YDR2*]2YYE:25LEG8?Q^FT)%!+0=!8
MV5"EE;4,`T%Q$%`41I%&7&N%#-$8HA4OY*$05%!^Y?1&;%C*@_"TI8-5Q4_W
M,/WK-)G^#`HY`_<[AC=!!O/Y=#DY-*I[(A4(B838EEG'(PQOYVB:D6[E:`AM
M3[X&9!@TA8'$LCL*TY6ETCT0^$U2$2"IL8:^MU3$63:JE6!4=9F+M`F3(8EX
M2LL(T]2*%Q5LCP(?$#8'L?;C4(&MAQ`9PF;"D"9>9-,+&E'-6!3X900%HD;D
M^8[)7PN;.P`)(L!I/R"I!<EJ0;[$CA^77V;I))[-QP<Z+LAY&@9]N%W$RZ[,
MV4^<*0H4U6(]WEV;\VEX!JDMW0H_I)%JC]T[@&=1(`W(>(!"%D`ZP[P0:>`4
MDJ"S8>`3'47L.9TAS>32AOFW\QF8P"+Z^Q+(<2#?2(FU@4UG.WC\V&<FT"$*
MO9@@CB%[UXKZB&DF5<2]R$:?(/_&*AHBBFN.-T#M3'X3W&]9GDSF-YE-S3^/
M'_PD2Z[3@ZL_QR`,K`10`0&D@:_G@031A/`484'B6$@<$K,RLS8;$6P3WY[Y
M;_F?<7'K95/[AZ7!5_!58&J]10!&]Q%2MM_'L^6A1N<8R)S)(`"-!/ED$G$?
MP.L8*R1BA:6/?;DR+""D"B))08G>`-T(3S="O%)8XA16Z":A8'NAUJ50:_C\
M,*ENGQ=5X%28T\/KNDTQ,F>(,#>8O9H6=<C(;8"G9R1S80!^0QZR-J73IO"$
MXR%GFKP5![?@G9Z#PJFBT(>QL`ND$`-UBE25(2OCX@WEU1`I15?RBDTIKYQ+
MNIZR]"JRVPA/SDCL0B)`^89<E!(?7G!LBL^%L%1JQ6%2;\7%+82GYZ(K5D"L
M\69<A.P2MUCW;HK/^7^P:ESH-V+B#L#3,]'Y?_5VF@APP(5UYO^=)DHF-2&J
MT=K\Z9FX@_#TCM%IHF3J[;AHF"&=1>+817&*P$]1]D9><0?AZ571!7(6Y5MQ
M40B#*>^,B\K%-G;5D@+AWH:-.Q!/S\8R2B4'YE0[Z]:M=Z?0G?)'PYJJ\5AH
MO`!IC@/$(\60!Z$:(BJ*I&9*X9!<,5OJX?1Y":W!]$_,TEUX)V8ALR4[!2F5
MINRPI.HT%;MC`#:JV#FO[RIVA@ZC8G<,Y$85NS*:`Z9RI3A[\XH=[;MBQVS%
M3KDRM."*]N5A=G%V6+%CMIBEW;88;<CV3M5N_$L]P-,SDEE&]E>QJX#87<6.
MV7*6[K-B5P_O]!P43A7[KMA5(>VT8L=LQ<[*J@33W%M4NPNSPXH=L[4LW7/%
MKA[AR1F)74348\6N`F-W%3NW15#W7+&K1WAZ+A++Q1XK=CL8NZS8,1OCZ7XK
M=O4`3\]$Y__[J]CM0.RR8L=L+4OW7+&K1WAZQ^@TL<>*W2[&#BMVS-:R=,\5
MNWJ$IU=%%\CU6+';P=AEQ8[94I;NNV)7#_'T;"RCU$,K=I=)L<B7D\4R3[.;
MU3GZ]F"59KA,'S?VPS8'BT/./4$$\C'V$&?VW!`7#"G"*(6_*;N][FG5SI8I
M-Z6V"DU-A;+]Z2#6LD3I*RQ"HS%BPJ>(:T/MV09@*/>,"@-C#/6NZ!65$.4(
M8K=KJU=*E#LG@TY?B^T:J+#[\8\HQK8]0OCAW@Y<I^`?B=T<G4R]KTD^ODFB
MAR2?I$7+3<.O5`/W;#BE.R0D'HD5B#VRJ1F04'#D*1(C1F440>X-2;YXU@=^
M;K:W>'5/EDU>?,Z3<;','QW;-H]H_E<R&YK@[=9H:N:_5\,^CO,/^:>%;6C@
M2JT?D]R]U8/0'$,`?O83/L>D4NGV0>I,^4IR]R0BRL<>IK&'M`A]<#1!C/P`
MVP8;L><Q(3T5O"@6LZTAQ"E.+>]#O4G4#XO;)/\Y'7])9^4A#M<TY-#M_*\*
M4UW0T4R`B+1'$C>7(O9,?A-AF%PG\+%=H%D;^C%/[L?I-'JP)$T.77(Z!B]1
MGA]YOD*4LA@!2'O>D'N(8>G'G"E?V^/0[KR)/:?MCJR^0&Z$9B\!W$',PNI8
M*46SV?R;:]LT2/@8<@5CUU'W$&`?FFKXE\G7)%LFO\ZSR5!EG%K$MC%&%>"=
M^6_"]":3Y=UR9FUHF-SG,!M'%/C[+''4R:;>W3Q?I/]PGW_,YV#C%X\?9V.P
M%]G4!NSWAY]`/8HJ$@>&$<51%..XI(H7Q!+14'DT"#P6Q7$I"M(NO@JVN0YW
M*L2;=/PN;*&M2FI--^E19PB?]2.>Y^%\^65QO9P!#6UWJ:)U/X?&:'</<C%?
M*!YH4/U`0[;I>=H>3[3F(!(>XSCT/5`)N_"^SO1&(!IM,_A\.U[\,5_.IN_O
M[L>3171]G4P6Z=<$AES:GG9=L;WJM*OO23\$9@-/$0<J($/#",$/!HH%/H[A
MJYTBV%T(;"M[:0>O/C<?KOAS%TR;VGR\4@W6XLXV6R_Z<`/V$*Z@^U+4B@T6
M3QH`\9\5_^%RCD)$0[;64ZHGORV?BW&:)=-HG&?`WV+#]E^GDW2`8!DN]X\H
MQK8DM0[+#G/S93+]+AR3C5C%UKG-O?,_<26T#Y;:#:=VL\Q!A<\UY!!W?!<X
M7=\*H?3>"*,22'7@_3Z;S.^2S81EF`D'WY]O58'84M.U=D(IC`_&]^EB/!L>
M<ZFQ[H5SL6F6]LS_U61JN(9(V`Z,5%;GCINS[V)/ZC$0F^Y)+:-!A763:+`^
MW!MR8DRTZ_(B:R.^?=GQVYB>I@II"^I22[W/V.[3P6P1P)\=QCZ[J8HFBI&8
M>,CVU(-4):+(EV&`2.Q[2L<\"!E_%DYJME*5W:G701NT5!H'D==`W">376P,
M[T-:[=*OY)H<NRM\;T'FUV2`S+;=*S#;#`Y>0[`5'+A293Q.<T>(,"TFLWFQ
M/.VJ35T@Q+4.F0?(@A"`*H\A3_,(42(T84$0>&%0KD,(QV*M-^WM7@PUY>;_
MS.?%,`,^8PO,:FM[?_7\*_QG.H&,K5KNAR>^$EP,%KO^\Q40-6QUBR^#9*NN
M*`]53[\&XF;P/TBLP%<-W_DZUDT<=7R]=ZT[LYN?0>R=^;Z>YW9!L0CAY6*1
M3@9)"->Q5$A2P_5:<#74@;^47GWC91M]CO/)[2`I8VLR2E<O*C7$U=!Q]VWI
MFR\@N710;*6#K^.H$80A+*`UEP%5;C]Y708:KI!5R<[39ZL5Z%4V9JM$KOH'
M`-;CXD&22-@F_*PF%C@8:E48.+SHP%26^\K9-DE:OI?`%G(7R->VSE8UAE2C
M!FL)>[\9S`%.4FPLIM9`J,$[6)#DU6TSSY-OY>F'&_7:15&C-6OCYRN"X=U%
M=2#98.N]=L44XYUUI[T(*C;!K>1BP/4F6P35FW)=.?-7]LD.M:9DJRN;T<GN
MM*M<Z6`%TI50#!>JPJ/6;5.L2U7<3EGP6#_/)[VN+S6W17:9GY&:E*,AP.W<
M8WVGXV#9#\;8;-65*F>^UKW_EWF6//XRSO]*%O$RFWXW,94UO;:#_$L'_@9(
M*BY4L=N4TMQ>)7*2&+G\FMH[DU3H!Q&(=&QT`"(M0^3)""-@9JPP47'@B^?E
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M[<`8<N3Q0*`(G`X0(@IE8$H-WK]UZBT4V"&V_S8&0R3"F=&J'06H!M32(R@0
M(5``1P'2V+BK:HF"$4&(_6?1'I8^OP41[/5V)[#EWR5VJP5\`.K.A:2M3KB%
M,19^%(2(,&HW2S*##`\%4M(/2019AQ"\U/;#]REWL0COFL@0)EVK0R/;I1J-
M%N6?KYJ#;'PS%S]D4;YK&@A@47<T8$^[9)DR@R6!`D#=D8`_522TX<,E@5'M
M>ILU(H%XBFRX:K\[I5L2<`JCVC5;;D0"N?+V4I`C*+"RF:?LM_1RI2.S/4,/
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M2]]CR-+T1'89IBLF-G6AFY:^+P=-(+A*BGBY6.;)+VF6WBWO5A:V")?)9[`]
MR?AZ<0)'TIQ@QF<>5X0C$W*"N.WXY?NA0#&7,>>Q#\/8>E.637-Y*+`3MSKN
MPTW8PJ7"6\O#;]+JN#':EJV.R??2ZK@YV]NW.B:KYG9#;G7<A_ASYS]H;2&[
MBU;'??A'>]Q`[RTL=M7JN`_.45>'&D"KXQ[`NE;'E'#,MULT'M;JN*%#>Y_%
M\V7^/\DX[S/.;^ZJ0:@Y,ZU\]1JT;KI`]R'ZS%W<@;=%OY<NT'U(N]N(3NC6
M*<*ZQ=2&$C!(B;;1NB':M!'IMBH.#GRX*F[]LE:LI8H_06M)FL^W>3)@VH#G
MXWRK`4L+;)TV4>_#3%"7XFX?-F[71'VS.N0V0'9M_W>#]PA'TC=4(!-)>ZY<
MQ$@38E`<^U'$?2,XB5^"]WW'%O9#Z:Q_?$_E+?Y*>:^O!O)]!.W&;J(06&UN
MU^VO@7P?,8PMMW#*JUOF==]`_AB(31O(.R]&G\YZU\R_PP;R?;"SO".]_@K?
M?;78YO[KVWRXGMDVFM^FPL'(3M59OP]+!8`%W79$W776/\:Y-NVL[YPKW:Z,
M]=A9OP]UM9WU7;?65IWU&XIT_\ZGN:;:,_R&MXJAJTN!'5PVT(<"VXL?E3!#
MNFR@!]@*O)72;2\;..$6@_?9`IQCD4[ZE@_(K66@`XZ8LAM]8B"9IKY&A"BI
M?1D1(5]\FN:";!*K,Q)TTPSK&$I%$*4&$*<BGTJ#>*@B2,HD`W*%7AA[(3;<
M?UE!%/;ZLC>[UJ&?/.S_N+NRYK:-9?U?SONX9E]>4H5M;KDJL5V.<T[ER45+
ML,)3%.E+4DY\?_WM!L`-7#```9#R2R)+I*C^T-/;=/<'SL,I1V].ZS""H<">
MRUHDT&Z;U_!-<='3TS)_FJSS5V!+!*Z<$%ST:DLZ0Q1R`$>(XJZI`['+=:"3
M@@S`.S*.W8$<T^D&JS,X[<@XHJ+=<;:!8N6VM",CU?QP7YQ0#<P*]T4[,@XR
M>`G(3$.KW\UH1\9I<D/:$5FPQ79<:U`XEB_-ON=+\PC%H6]A=^E_(=U3@M5X
M[8?#8"2*EW'.&PX\"-%PWNZ5XF4<B!3NOM4-7NL6%"\C9`KNY&7DF!0OXR2Y
M6#$2N+/K_CA>K@(@..3F-Z5X&2GJ8I<'*<;G>!E'[H+CA=M.0=6)S"-[_C9;
M_,CSW\&\31_RTXDN)&;?RPRV^#6?%NO);/_GR6*U?K=8_YF#V)M[PQ%S4>V]
MT<;'Q$8)!<L@%;$N8\18;JEBB9/[K*:NGHP.!L%@;#IC=*X@K[$X&LT8D4UG
M!"%Q41&MWX6.0*<SQJT)QH*'8<Z0=#HC2*3*,2IQ;W0ZXYA]I-,QO('9ZV9T
M.B,\?EP1R5E].^#8?#KC!+`5`8/NRJ=S7@_`1?W^\N6_^</ZT^+7Z?-T73BO
M,8=_(I]Z8T#^C`DL!"0D1CX*1HWBJ4G@\9N]JRJV6?_<2:Z^*8:.!>^7C&<S
M_C4NQ=#P4H53#!6O.=-^!CGXRVQ=7,="W'&@"_F!-MRE.NM__6+,OC)?*^6@
MU]"],,Z$&CQ^W;7T,%>V(R,@K[W%';AD,S(<O91PAHT!1D9DN)@@FL]?)K.=
MUXR>,<N[`A3%1;$ZW<F.#!DA1I5OBB$R+$(X+>4>0'N]ZXLUZ-44$OS9=#Z%
M@!EU;O'\C'<(D]EOTQD<3,!^TV_WQ_P1,L:G99YWOQBHX]:>%.GD';U-7.(,
MH5&&8'*+M"H9J%FJ8OB3E*.JQ)'A:M!]''L"XS*\'_,G'`1=+'_@%`P<YM7(
MV%[!PQ1S"GK(%-$)UT0*K@!;*4B<V@0R&IYHFI84!WJ+[25T6V,1IKDW`73'
M$:(TY=P,!["H7.=N->65@%Q&]18Z>@W34"Q$)B`B3V.:0F:=&1)K&1/-8DL=
MC81.^=X0B&W"\'JUW&GYSXBBV'JCL)-^%92_3A^PZ/$_R\E\[?/\9\"/;6+@
M2_!=EOLD9L=G?_/+?B+EPXE;<P:\M@!<UKPCM=W=!_SQ;0%9Z]_I\N4I^O9M
M!I]9A%H/#_FW=?>59$W(]L-)Y6.E+(=@R44QD4QG));&$^M$G,6*)@R)FJIC
MWNANKL#H7EW0R"@KG-9KM`:OWB6-C*K<F=B?TT6-C"?;\,G^E"YK9#"1B/M<
M$'J%"QN_\@%@=LLJ@RH?&W8+/ESAXP:9.6(V7F8NJZHS;Q.OOZ[,_!2@XV7F
M:E.S;,2W56:^VU#P93J;88O.?+V</%R_TK%]P>UXQ6,0!WDY+\`/"]L7Q!EN
M=T;[TW::>#V`D+R^U_+2$HV:G@P41(QD9[8$W6>JJR&AP;#/?@3:[K*IOX'(
M^9(.C&8\K\<DM9&F\`M(G%'PX%I#H)-Z2S*I?*0SJ3G?=?1(]OK+EF-"!MF+
M%3]#2C@F:#C0ZGK.^`8V25?4RU)+=>938FWLP2BGDD0R4213BH*YRE*=N-(;
ML1;F:*"M\S?E5B_')&0#N7K32.X0#WYD&+#J7&^]Z*`,KU+V8L'V^3U"A6`'
MF32:C0VG#<0K=R0TE<JQ.$J(MK@[R>@8;$`&86F2I3**9"QD5I894.C#FLV1
M7'LR)XO9;/)EL2QSYXT9A$!]-7W,R^_VEWO<!(]BX\$>&JTD'L4L2*5Y0'_>
MJ?0D]53%69(2)CBNU!*..)DJ`GBD+)-"*B6O24]&#TT#L3B5L"2IT(YQDN*L
MC#0J`[-@(H@@LHBZ3*?2B#VS,$IHNNLDJ?@\AJXWC0DC3JBYYLZ$CA",%9IH
MI03KA)1PF8A2F4)"Z,$/99$@4>P5`)<)H1ES+C:[AO>&@&SD2&0,J?G>1>(M
M(X\Q9&6X"B(XT*A?G90.&APSSJM/EK,?*;QEMBC&UK?'I(]XI#L4*DXYTT82
MKG&41RE-(L\=D1$SJ9!.VW17#F*'UQQ=Q;UL6_?>=*&&W;-='0-`Y%;0MJE?
ML8OXM<T;\,KW7TLZ0^1OO(Z6<0>2IDJY,U%="YI&E2HFDPC;0E)!)$3\`!B$
M^2[R5G`/AY'M2@#"O3E8J'%&M$$-S26YFX2UVFI)(T<R`_^1(K,0SFI+6`*Q
MLJ=&IX?#)LTVYAV&L5]?YH]E4\;7)0A7>=K^`OI0D4^=A^#'*[=^9#ME$R+;
M\*MU$`?-A,;K*.%TMQ;YH%4[FT2&"<<.!T3;K-H9&@,%^<9P&(@J=.>JQCMS
M3Q`8$&@X".3F.#`G[A<"9T+Z^3M"H+8[]^R]0B`YO"K$*':$0%?!M5'U<>%P
M!!+<][!<3\%.?EA6/J1PER43]]O5ZB5_Q%:^\H6KSE.T!2R@MZ@93NG]V"DL
M#$BE2U.L[&29YCCE$1&GN2"93BBVC`@1^UU_\D$4T$'(VZ-D&5-F&)0V74CL
M#9,_`4IV&)3$9O*J7UTZ]:Z]!:G7(B(8=TRV1B1QD4A=E!`K:0*(&,AP*76$
M&8#("F-HRK91V.%J@DO2-(L>O:S_6BR[;](947)VHHYQ6:1+XI]CCN\=AFY9
M5S@LN(7K#67G,#DG9[-JE&?I[M5"-!Z(4I";&TLLYVH]C+&4FW#LU3M>:9F@
M`SE>M;EU>*.H[A.FV62U>O_U/Q/<%+I^O_PX??IKO;GG*PH?VQ^NJI^N.JY%
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M(GW&B4NI)RF+J79>)3[;%62XL!U9<L^0A`]*,3TR/K+H3.I$HGXC6N61`>+8
M-\$Z4E"?HUD>B>=R9*@P![.ZDRZ=X[T<@V-P9)0*TF;)NZ!TLE7E%+]J=R",
M%;0,J\[E5PU`T%3*2#%%8DH!"/!.Q$HEB&&"<_C*9)G8Y@I'IN>4,-U7SF[6
M56;_?)LNKUC#"<!8JE7AP;7H>-GL+21*3B4DD;B'C%-%(IY8$F?*9D;$"J`O
M"[]XCB!/.]/*TTWPNP+14JD&!%%N6Y"KJ8QA0#RY`/[*^>8Q$<*-1+K>EG]!
MJ,'H+_^38WDD?XR^P[-XR@^J*%<@Z;1$D\[/9A=G*D7\N$]$F33AJ2.<ZXQ(
M%TL2V2PCQE//4B&3--M-.G#YAO-!.#(OX338PRFWR?;^&`+[KX*!+XZ[%$Z8
M0:`O43B867A^7LR+I"J9?)NN)[,R9ZZ<]MOY`ZZ"A[BF_';ERG`3;^G<,;>^
M:EW/=<`Z)I,XXQR'V3@`"^EDQ#B@RU-)94IE'/.R\LE*/@>F[79VH1_)7Z<Y
MT4KK,S/]P>8D%HDW8.<)SU0*X"<IB764$L=L@@//$7SLKM'NC66OU9IL-E'W
M=MUZ[BF$*7TDI$BPR<]&0F&[GR#.)`DQ2L$CB96.M=C-+PEJ>+TDUB<(]VZQ
MNV$<KMN(L3.T#X@OV^M79F**.YHS$\O!)B9B'G3:IL0+=)P*4C%([!R)$I&:
M-/(6#/TN:7^CY6LU,4.I_]%3"#0QP;C38G&+E688Z$\>`/3995$_+1+L#_ER
MNG@L#=.[_._B1RU*30R1HU0QW<,=8]!=+'R:*-;6.?@85J]N-XK6`H[HX7]?
MIJMBX*$M(I*:0T2D8TS3]FT@QE@;*44LQ,!$&IJ1.,E2$L4JBQ*?NEAD.U/*
MI=94N$!(]L4[*@U,Y]6:G.F7%WP%-G/^-OD'H[MRT]7^#U?P:S?T7O#E0ZLR
M'"MB3.JX.B"'^`9A8A,Z(M72N,P2GUA5-LG$#G#RUCFO4@]>AWX^T1?2@WQ[
M:<#F)ZML-GW"2^[H*?^T^#!9KJ</TV\%UWC%.H$?TA68;J*#5GS@[,\J;&_W
MEQ[U*C_D^>/*+Q?/F_#]+3PL7`WW\F4V?7C_]6N^;-5!6)P4P2B>E$YUCL3;
MV*?&X[)6.!V,"6(9;EYWEF?<"I$E\>=JGTE]+TZP/"/8SPH#M!9,6%Y0'2C1
MOJ\T#(_*6ASU$O9N/_N#`QRR;-_$$`3'IAFY7!UUAV@`&*S:.6>U-=C7#]]2
MK='(T@SK)AG1^%$RAO3'T9@3%W,N9>8R,!T[5V(E1P[;Z_`X=<;>+\NAN+:W
MZ8%8M*!M",8#_0<_[KQMDFU_;+0HGK[_NK=H<W_/PX?)]+'K@"B#6+45O=+I
M[7()C40*"`B'S5W.DRB-/=&4,Z4BGF!G`:]ZK[M)U',Y8?>YW0L+#&0OPM>>
M`O^4V\PH94B:1K@$0T/*JRG\4R>1<:E@TOARM)85%-$8$O987#@/R9XF]E["
MB+ZN\^6FX/<:L"\H'AV%=*)2Y6$A&=9#<%MF&QR^:)]=:`59"I>4L"A)P4&J
M8GF1)C2))9/@-#VSU1JO>OAT:W=P3O`6=,9APH/-,[J^NZF5\;\(U:=%82;_
M7DY!9U9^L=P42-Y_??\=S.=LMEBCPI79_5TI1G&4I-J;A^Y1TO,3Y'YORCH<
M#U&4>!AV\?2U`R^$,X)7-9X+4^/[\NQ)_7'Q8S);_]C8FU65=TZ>`*]W^;I8
MKU``6BZS`+`[!`\%*E117:%RCE0L)!D/BB&V$RMOJ-S@<86D=X-7;15Y;WAM
MLA.<<#*J5\!Z/%9T"\CU;&II`G$Y@S@\A=@`MY)X8C.6$1&GGDLA+7.FJNFT
M.U5#N>!2)^#(;R`8I01:4E5##@O.:8@L[>O9H8W^D0E7CG!TT.S*D)K/!4E/
M^7!\2[)8M:$[O1*&X]I?.`IX2A0HB*T[Z*T8PQ@$OA/V-D071:3?P?4.9B2*
M8BY\KY<I^R2--1>I(Q!_``0<+UB52DE"(>7)I*:9S[9&PD`4"$F6N5<C$8A,
MBZIP,#H4:7KJW6\W,A+7P7!L),)18,5XQ(DHOF8D-@#%+Q!2Y*O]^Z,RYWD+
MLH(&K:NAH??+XI<`8H>)<MN!J!(:2\VIW0L7&K<#RZ(^59HF!BP)17."94".
MFZ!HDEK%M<H\NW##U@\8O5OA\EIVITWC+$+G)Y;^AF4[&U!^6\SRAY<99HMQ
M7JV6RQ\/N'"+"@O&O`<+=-L>M0!P-G]+<X.BI%G$+=$^RR!BA6PPHI'&0G(D
M087`5[G/9<UO"\K5XHZE,=T7N-K$.Q;'AD#$KHGTDL%7H$#PP8+:1*<J!E".
M:?Y>C\+4L0E5F$!D<.IH$'T9'3J!=WK[T!WQP81"%\8&@V=-]@S=H)$A//TM
M0I`\%V3W.+^YEU&#JNCVWDW8F+L8YV]\IH@T+B$0?S/"F7-&6QK+;+\5CPMJ
MK@P4S[RGV+TR(CPMENL&0\2V!$/-A?!#>>\@@&)@OFX:0)4>$$X^A`IFF`!J
MV.Q-4]7/)CD7)S)VGC@?0[P@A<?(G)(L9BK+8JD@PMI1AS#J%`=-ONOTK1F:
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M-4DH!+Z21B26`C(IC:;"RHP(I6)O#,>1R]-JTEG2?L<]"C+/U=MY&?W4GF'Q
MPW2RSOUDNBQB\1O!K+TW&A721@DE,I60L+J,$6,YN$F6.%DH)%@?_<;U..37
M$IW#1_,N7R>3U5\02GV?/N:/\8\_X$/>SK=S\M'#>OH=W$.^.O7T^T6Z8=4$
M*&^29!I)"%&-8_!]UE-#E#=4QS3618_O9U;L?I+,'.[<N$[0GO1Y^Q`B"-J>
MR\>7_?,M?X`'ED[Q#YL_?H2'U0.N];Z$$V/NU-@,Q_:HPVR8:4LB*B21&>37
M(N9Q)MUG71!Y'3)=#"W]";"_-'_<ES8?]RE?/K=82UE'N1N2XE^_?#!_UH`<
M1+(`/UXEU7ONKF;'1W+CH<X)$F1XB]'.-'CS1L%Z4J_&^<>/^?-DBE%6,5\T
M>5B_3&;X='AO>L>,D=IS`0%NQ,$BQH*XR#KBDXPQ:R+OD+"^RAP_Z#\9_8W+
MM`<%["Y[D&:>"\CN*[)D-%PESTET.;LH%/>^<PO9F%H40K0HVA4_?+\Q:F7?
MZ##&Z%3%CK)$>+RF4;%$+D++220@B),J\@E$<9!V1]7E)]>6RM`)S)-2A9OI
M5=V<W==1$"V-\Y$XPUXL7!][!NWCU)2YPBK`-[FX]NK@6N/\[WRUQ@BW_*1M
MR'!%U-.^IA>8$H$1P4M"*OIS3>>D/UGRP^2VS*)&5:K`T`>O!KCEIZIWNS_\
M**O;I>[1]\ETAH6M3XN]93[5;MA!"EA-.P/#C$JQ4ENS>A;73K!#7"HV2.0L
MS)??X1^KUD1\XSUWK-IJHPX-R5D)CDI4Q4A2FF_6,[U?_P7F=YOM%MOP[C)]
MQTX]<[C!-TR:<!\R5(@QB#]!7B"J;;`["8@TML#MSM(]'@`+FG!NO^SN+S]5
MF_TT^0?O+>8/T]FT<!S;/8?%@K+)\N&O40767F6*99XDUB=$^E3B6@]'$LF%
MSUQDF(I*/\BYKJM^F#R',/PQ7V[O;>"UU:J'U>8@X;M>9HAC4=<M]\R6.@2O
M_K!HO0FE#Z7`FU0.5L$Y'-).-"6.4DT@3O!>:9HREU2]=>P0HWZ$K1T1-##O
M%O/%H<)AE67>9OAUO-/BP%UJ?DC5>5F*<(.Y8^LXN%__/7^`5V+-]%Z-9\$,
MK</;>!H%/1D_WJ7UQ&Y+2X4Z%3?66T:JG=.?%D5KSC(_R^MXEQ$#:#YWM4`Q
M7*2ND?,`Q9E^XF9^5=Q\(AT_>/,]JCK&C)=%;HJ.HX<'7'*QZL)3/9ZF8T94
M6R4?(DK+"*EP&O<8'H'X5HIVX5$AS"$`NVM]M`X[FOO)]/'M?'_'[5'YX6->
M-B[F5>Y5.HZ]%IH!KI][\X4.27\.E6=H))I.W8=E_@T^ZQ9!5>")0Z:D8C7_
MI1-W*$9]O]XW"$Y+K82O9WE1QIKCCG4(+?ZOY8+]UH*?6!@?,18;JXA-8H]W
M1II$::2(<B;.E'0JMGY3X#[:IM\L2],CWVSDOT7=)32>P#L-IK4YRL0NRW+$
MTU'D97CO6(X@X#F[X_Q!_>L7J=51G?&"%$W/^CJJDA$?N"A2)]?PN)O)2K#!
M!,=,X'\87GZ?S-"TEK:Q_OON$0BN\1['B,-B4QNI#O'8]2EL'<V.)O,>`<!=
ML[4"S$49@B*K[;>K8U/5)Z*USW&'V@P9BU_6B^6/W?O[:0'J/0##,-NQD`"L
MF\QGX#S\'?<(#-893H%R^)=?Y+KZN+.KD+F,&A)89@3S+"(X!@6'(^,DUFE"
MF(\C8[U,4B'+RANO;\>Z*,3Y2.@>S[[`PJ(39R.>H+Y)/YU/X!2\QKY)C@1=
MRIJC+/H*.<,FD[8EB+N$A6/6:6JP-(IRBONY+"L6/RYW:E85QOQQP$OY*PX$
M+E5Q\K"BW"A)D$M\MYB#,D$LA<75RF"<;BO%J:9[M/A8<Y1!KK"=K`&%JN5+
M_OCK=/(%/F#TTGMH1(T#[:*F.B'"!!G9MZ!KJ]?9G,Z+2F6]6'V=G.>-[.WO
MN4-A*9SOA?'.@$OMZF)O]*CQ5!<A9YF"=-)7NPLBFY)(>4^$4#:-*7?*5466
M?=-Z48"Z0UFM5WB+4;[F+JOR_\_>M3ZW;23Y[U>U_P-*V4W%582,]\->IPH$
MR*QN;4LE*Y?;^^*"P)&(#4AP`5"/__ZZ9P8@^)`$/D""-"J)8Y+`S/1ONGNZ
M9WJZS;-?==,P[(7U8W[@E98+]!8PY.5S'/A1\<R>J:[J"H`+*2UM):Q#U3PD
MO\'T@\.$VVR#43@.TPS%_J'))]$&%69K7ON_04?5`YHK_[FIIS/T_IQN2A7/
M9S@E56X6-9%:;?DX8?7@=WL5,%?^Q7VWFSA#Z<F2<)R&0=T',"MR2U<+<06#
M2%\L\;L/+*J&!3'E<T7&?H1V!HAIGI2C=D6SLK"6JYN.)4FB95HF+*":*MJZ
M:HNVBUD@5=>6;'-I`=V"NDI%D7A-G<0+4Q!F>E:6/)<?6K<:\/8!UI5J`ZFX
MMZ'HBJV^71BI(HV5EFUWB(P\.R<IJC`C9S)>CZ+X<;VZJ'M<R6DQ$&O)B=F2
MU$K0T6/KXJOQ_45&1HTT=S!&LPI`*PFJI)RNF?,,^FXNCN^S/\%\\LYD$H4!
M+J1L2QF^^AR.PNP`+F#%`$:UBL[:ANA2GH[7+,\2JX)&G$4"-)'+`#-5TV;Y
M.C:AZVU85A[US.<0X@<_^8[%&E4L]JBW<-].MM]$:P-RYS%\\3B\H7&".D;2
MJW.XO$+"V_Q25O;-EA\,";1T_4V66$U1"8G/X7^F&!R$&U/XVQ<?C\.SY]S^
M[!(W\M,TO`LQO^+\D3&ON;BSV\\]5745Q?%$138<4;,-573`'@*_U`%(L%"Z
MQJMR7*E?.-T[&/]<57C<C;LG=/][5A$+,4T&V`#E,.P'S7*ZGY6F!PH,69V>
MSH$63$54^G)/U"SHQK;ZCN@I3L]T^JKCN7)A9==$\4)L'C0_P)M;X4,IZ+KW
M%$13:)XEH1E-IFREN[Q;O&N\G0$^JS6GF)*V035LI>=8'B;BMC59P3HQEFAW
M95>4NH[4D^R^)7D>RX^(6R2J#$:Z4@['VP7QS<33DA5E_3J&E?!4$4\+SQMD
MU3;KA7.GJ4^NP_3/?D)([HIN$_6Q;4&?*@E,=%Z=1E%JR@6S"I`])-[YGSB"
M9M"\:?X,R#@#AEG3!*Q&Y`A%8),:354F0,L+-+4B<+`9H"*@+Z8*V*<(@.F#
M1;BXZ0,S-JO*M7$@!\M_J>E/LJK+NHQ'Z"88(:Q`M"V_EMEKV2LP=54V'<44
MP16P8-VTP#)V'4FT7-O534O'2IG,#J'UV635F@OP>)&XP\*`Y176@Z'G*KHB
M.Z)I`U=IMNJ*MFR9HJ&:LB6I7<E4O!(,NJHU#P96JJ)^;E!XUF[I7-$:R`W+
M,-3##6H!@UPV<QH#0U%;JUYN4'E-+1"*<MWBYL)0#S=H!0R2T43=0*N2U`^#
MCC!H3"C4!L)`DVC7+Q0S&&!$F\!0:X+Q%>"L4YYS9461GMG7+<<6-94>:'BN
M:'EN7^QYDMOK]S3)[9NEC.P[3,7.L]QLFYUG?1A6G+!6`8'G69?R2J7GRQE[
M5N?I.01++%7D68,E^JYM2+9LBKH#&&BNVA,MPS1%4]4TTU,,RY%,%@359&ZH
MBL"JZY/5`,`D<(L9]QO'"%O4B'-ZGM57<.=8HN<.L()8BM,505>"KX;G#EV/
M!0GMK/!`;=Q0/PP2K8;3>';8O$"ZUN_9FN(Y8M=S95'S%$5T+-<2):_;4SVO
M[QF&FM?%:SX_U(X#/:!=+$;:4'Y8OY#ORI,FR78DU?9$U4)@:`7TO@M+J=EW
M>XK5M7I]A;GB6K.7CAU6-ZZ.":XF1A5VX6=TI9)VI6VPR[N[E&0W\>KCN'6K
M(.V!:<"ZM^6NXXJ&A?<23:,K6E;/%CVWYVF.HW55K5>4&YN=4&Y,?=VLLWF!
M34]U3-M5-5'VL+"-V05/109/Q?`<MZMU;8"=ZQ557T>M[)[&S0L:V8YN2*8#
MKJCJ@0]FZ)K8[6%P>4^U5%/K]5S+8<5[%FN]OTHBQMT%?IY[>VF;>,MS=Z1<
MDW7[";>^9;5*J?L5>9U<S51UO2^ZMJZ"%6$KHJU*MM@U3=?U)$N6%:?@<U6?
MS^A5C;Z#8:*;&^:ZJH*)PI6C+IE;8[*3)%>\')S,2+>JK`N;I_0!+6NLE_=J
MY\427R(>-V*4M8_[JQ*NTM!<G17HK*6$*7OGS62`QX`4WJPS)4,RRJ<;VY%]
MJ&3^^X1-KR'!?ZUI[5\!9_>J1Z5!IGKUI,0;5!#>%^O4@@XF;:Y>`6!+WCF$
MGJH%-<S6NI!H88?)6O<F?JJAUIO,S^15)G1#/TH)W`=`-&VZ7AV?8Y#!?>"F
M8!HXU:Q+")N:?'//,!\\&>?!#5];-HSU(X(K(BS9+*G?<@WZ/5B^>],'BQ#N
MG%$EED%=E#5MSXOR'OD0*TS4QH<RXT/P)$P-!G:B?+@`X>[Y4&9\J"PD$SDA
M/E3![-6,VOB0;02(L+1ING6:;+B$X.[9D+DHHGFRVA#PDN3:5F69:T-#-2Q9
M-HV39,,E"'=O/G)M6*.5?G`^M%5;KFU_3]*Y-I2A,T4]3>MP"<+=JT.=JT/Y
M9/6AKMN2HM7&AR;W4F3)UA68FY-DQ"4,=\^()G=36`K!6C@QKR?4CY.Y//#;
MX&-:JL2V5K4-#XX]37-T61>[DN2(&H`B6IJN@D2JB@)_,WL]%8/89;RVMIC@
M_B6*YNG&<D#IY1U/6H80QE$8/+,_;X#P;K1)XE[MA3O]CJQ95E>3Q:X.TZX9
MIBK:AF2)GF;+5E_7/*_?9T$`/T?9QT'X\/-]]A$&C)\F0IH]1^33V1?G^K>+
MKV+W\N;F\LL'09ID'X7^Y=<;\=O%__4^"/+LB[[SY>+SOSX(-^$(6/TK>12N
MXY$__BCP)FXNKSX(QB0[*W5SBW_'OX3X%XJ/$-\)5R"8&/5-\[7YXP%\$8Z#
M<!(1_!G>!29+`;4!?0+??Q_F+;TOVGP_V0]!'X6;WO_>B!=?O=[7FP^"]K><
MPILAW4+C(R4#X8YE>O8C&`Q\P5)<`&5XB5K(X&F?Y[-C5'[Q@R3^C8S#(.T(
M%^/@G&(1PL^/PSB*GH7X<0RMIM/;-!R$?@*"UBF_)/S^3VB%9K.!Q_#=\H]_
M`*/R9GMW=P33HA+!(P'!VM(_^Z/)QY^>'.FCHG2@$62SSDNO/_JI,"+)/73R
M&&9#-LIQ%L\1`(W0AYTHPA])$L2CB3]^GM&,KV6)/TY]EJU'&/HPHEM"QO`N
MB8",,44Q')=0A0?/*=`N;RY@F3\1'9K5E2#"0CPFT$A1ND](R3VB?RY<+GX%
MXT@(J`J:T4OP46F/)O!Z,2O^6"`X_DD2IC!CM_$T@_D(@R&T,/&Q1V'`$GX1
MZ/DN3D:,C\,47\[+A0GP`YWR8!B2N]+(4$FA)A5&_I\DZ0CP6/X5O`]?XD/W
M23R==)`P_`TK?PO#^%$`R'T>KB&`",73)"`,5S]-29K"<]`&=$5'-0[(/'0/
M(7E,*7_%L\2_^#8\Z]\3^A.\?SN%AJ`UCFL.7(>C`"(\8,%@.*Q1/(Z#"#=?
M*72P+L2#9Y%NNR+YB3\ATPSY"?$(<$Q`LS_-XG`TFD+CC)<H>\93[!VPI>GQ
MSY=$_#U783.U7$WA+MZO&8&\4$[`0AUYCHX`A`OSN$5Q.DW([I6UK'F&XYB8
M]5!187FV5;$KR[8HF9;L*(8JJ8JSD;+^XQ\7-SWQVY7C@G8;X[Q'7&'=7#M?
MO_4OK[_@]V,"CUY>>_3)BZ^_X=M/'P7W\O/E]0<AN;_]1>K`/^^8;F1Z4OC9
MG\3IQP7]R+Z<UY*RA4/YW+NYZ5W/>I@;3:X^:;?B([G],\Q$A%:$]33^DXB/
MX2`;TM^75A#[7"A-&^69N8G;=%UH!'9&K=`5B^],$;+R$]NOJD>&GO:WJN"5
M=69$P8*5X2X,F+;B$;-Q\BRD$S]@FAZ5ZI#X@_],_036#E1DH#VO08,\A%%$
M<&E-GB-X_7RV\EZ,^;*;#?V,=4276A^X?(#J,\9U\2DCW"B`=D?"71*/L#%0
MQ*K<P08L7!;^VQ]#S\_\.T6:ZP8U,S\CHVM*WNL"E8/B*3!@.,&40OK^OWV\
MJ(=]+=(*^CQ*8V@/%JW[87DHU+"8&TP9VB'2"DL,/4<&DWY`$H'X0!B#`GH*
M6`9W'`".%I:\";=CV".(_!U^?"9^DO(F\,D4,*1XK5A&FL_3LK(?IO9QX9_>
M^;E[!G]CB?K*K,M1]:$)/B_(K7$2WH.YAD8J>9J$"3`/S.&R=<EY5#L7F%-9
MF)IE[B-%O`2REB[B;,)DC\DC,B)C#_@77J$6TJHASQLZE!^I$4>XI>H+T!J\
M?0<V$VM_QD$EKF<"'=*^7N@)9;(PIQTP$J,9M06Q-T.PDE@/="SSK$X%.^=M
MVE7+SMNP,X6X@J*&>?T&UOQ0^.:C3NPGZ*RE09RS>)G!&5>GR'=]<IN@1BOY
M3!;3O.UL<-+1Z0._OF!EMA7F`^#HJPDD#?R(9V>/_&G*G1;P!?"97+,LO.3?
MYB[TN="GDI$[UPF98!%-$,K)-`$*"?4^64\\'!_$+QCZU&4%Z2^Y.[CA(&`^
M_?!^F(D1.#K"+=N6>"`)7V?H0ELF![Q:NF_QLGZC].".58>KJ=DB-Q`2GO$/
M>A[PI)%LM%&1&A4:_ZMR;@HC4+E\4P0:@:_L65_\MTYI'8Q`\5V7Z<Z]3J9!
MJ!T![;P\;OJGFH]>H?8']"JMZ!7'A_IW-L*Y(2\,JY4,1GI_"NL'K"7AF.;S
M9!IFPK<3N>(!PJAGS#8.9EL%3"K0^GJ3^Z`+'WUL3)R="K_0%0S\:9BD]-V'
M9LR%LLY<2+4X105P2XAD%'J.RNO;A:_2T`5$8,B`PF?GZALT$.`5NTE*UH!P
M9V2#@HTB7/J`F6BZ!OP\07.'?Z;/?CHSK+^=P2(:WH\_G074;#H3;E%C)?A4
M&:6D_&&0OV_Q+5&*:C:8?^:!-WP;9UD\*OJT7GYE-]^_GQ]LLO7D`B;W,)LQ
M@/*3Z_9Z_?[9:DJS>'*V2MBV8"LN&I][?9AZE8P6F$&4R2CO$O2!OKQU]L:L
M5)T]_/&OE::9?TQPF:6OJ1U;TRN].HX?$W_RZ8S]GXUM)KGS,ESSE#=T@HU:
M)_@UB*O,M-91#>W89OIHA-ML^-QK=BOENYEIJ^$SK=K&L<WTT4BYW>BYESN6
MJ1[;W!]FIN579_IF2!+BWX'%W>SYEAL@Z?.'6SL#9"UH5G$*=_FHVSIS>W&\
M`HUA6#4#ZTYTW7V^Q22'U\0-\6)DNR-;=BL,:S*F"HPYB*>W$=FC-&S>Z7KB
M\)YN'JT:V#ZWUZPF;Z\U?_.W'D2BQ2B,Y;"5-@1CY;8YACEDX8B&`>#_YT^,
M1_ZS<$LP,O+?)*!!"0]^@@%D0A1FX3T]Z\%]\S$>M$0TJG#D9QBL(,!S&">7
M'_+&R2#$LIU"$$^3E.`^>Q[_1L^42T<Y@QB0&,<9]!R%Y($(84;/F8J`Q-)P
MV""APY`&QN6=/Z*]1^/BZ!$5#_O(!%_`HFKQF.Y"`\)IR,^%Z%FDSUJ@C0D1
MIESB](=CVOE@_K2%_4N_6HJ86R_Z;3YR;K'HCX?U@C9(<E"$R*V*XOX^(<GW
MY9L#RG(\M^'(.M82=EV,=]>DOF@Y75<TC;YM>9[L.)[[76:%IN5SK13,_0(=
MKQ-;5Q"WUE=5R5,,T9&MKJBYKB/:GN**?<M5>QCAW=6[^P[BQK7D917VE60"
M2YHE_()IL]X)@)%`0=I>H=44J8V!H@&*"QUU1$<-C(:QOZ-X+%!^8X&M>/9+
M(X-O0>##!QI[^Y?_6G@5I)F6^*7B2N.46#-XA6(81P,4]=MG?A+\2-!Z)`/1
M?R")?T^$\11/\5#3E+M/A7B:I1FH+!HES().6`L3>A.C0X.O,1HY*)>3*[>#
M_0ND*,('&HSS]A(%2'Q!=4!+>\W33)4CX4+`WT*-6IGRE^B&1A8H+X]X#H3\
M,)O1GZOC#%7E%(,Z*+DCFMH4R9BF[+2_F$3Z<E[5C$?ML!COTEK"K1;<<_F8
M\C9YG,X]UO-,.Z"0,Q@;*E]>\9D(]+8,-'0U38(A'NEB/6C!QTHY++;AD54#
MY5'OT%UX)P;LZ@PN1OF@H8FJPWYQT,@A>2521L":I^_;J`KE%:GKEX(16"S"
MRV?82D<8@V)9XE)HAC$)1B8$?A1,V7(^"X[*'F,QP$*4.:KL)Q:L[D>X_,[X
M>!"FC('YA0EX=O;-.W:.GB=$Q$G!>$1H@+6_*&G8P,1/LC`()_D=@^(N&`N!
M9V%K(9)1BEZD_F2*[2>`!WY#Q0X@`I&]8(8)YN?,V/J/'[LQL!:3'2^$M[(X
M074%`TM88`EO`&,+J'#B+0H_'>+]@A@-#N`1C"R@`6QL5/C?6"P+7*Z(YNED
MIE<NW8P1H9%O!"^DS";2$6$F'1$FLML1W([@=2A`GJ@(P>S.V"*KHH*,I]$`
MS1D4LBQBP.?`T%LSK+(B]%S`5%)@5*`76F6X%0WGF'"Z(PP,`JNK4,0X"*"/
MO```"R%D#$4#5/..9]TBFV;,+L`^$5GLN)#X<[;5!QJ-6[(,/:$,&IJ:`%N!
M&O;Q$GN=ET.N2E.8BPNE8;,96H'F3'$MJ'QA.N&8XIHT'8WR)>DU'7MQ=8G<
M>0D\C/!C`-(6"HLJH`5/;EN/=`N%*+UIA2#D`VXZOVV1%&NSCWI^98"/0)X"
M`@X;>X<JI4(X!G[FKQL`M`-TUPBG64+SQ1":RO$LMK)=/(O^2G#*2_$L=MWQ
M+`<,I6EV%(_U%DM5V"E=>]^S\I[I_!9E+F<_L<(.@HQB2S?LEQ`&K@=6AR^P
M/-,\,^=04?_J7VA<]5X+]%SPQ;8\+VIG!#<C7ID0=/9W"WGS"59_-(*5O0O5
MVTMGS=$-+YD]5<ZYORZZ=AN=^VQS4+7A>=\OJM51Y8UC'=[5R.4[)%(QY-.F
M$";14#8EL<Z`E6H+X_X%]C-)TP_SNR.S792Y'9(Y#Q7=S\)'W:N,OS%Q&[2P
MS$4SGP?7^+J&NC=Y:B';]MW-M.U6RNA5?7LJD2,S4VU/,51;=UBS1=OBU^)W
M@`"^(W8PN)&R<$Q)M\8WLTM.SL\X+9]BPZZJ4==\,^?45O[]!8QNWV,SUZX6
MP1;!7:__35GMV4%J'F`DY`%&+X93U;KB;^L/*F9'M;2.;4OU+A&'I=+H6)K9
M,6SSE(F4.Y*E=A2S`;>ECMF8KQ*MV4@C'N.,&V;T;D..="YM?(^_>>0`-35K
MV--:9'=T9E<SC[9^<Y.I.9ISM^8NAAN>Q)7.X?["+D*Q*&!_,!!O_>!/&GV\
M%'%=FXC_R&=-+3Q-L,W;8[<?\-BCQ:_%[Y#XG;A'T!ZRM<Y">\AVM.O\*1UP
MM`BV"!X:P5/?BFB/W8[.ZVV/W9JVT]@48>X5>26*5!/;ANYOC_YIV(DM/"T\
MK9=Q>KLY+7XM?L>_F]A<_R)/*-AZ&$=D?+<>1KOT_PB;.RV"+8*'1O"T=B"\
M2DG0:EWBVT!?2DX;Z+O-.KU>_O^ZDJUB0626'A"C_U[*"`RV-2;<?0JB*:9C
MI=7D63K//+<J3RF<9RA<F925)Q>\)0$6\RTRG/)4M47:37^<A6*^N]@F(5PO
M":&AKI^$\)57=O7]C]AUF_*N34+8N!EIDQ`N$MPF(:Q=J(YZ>W&6<ENX*A)<
MTT3^F_D8]9P,;=!"`P^Q6LA.(%.9TI%UHR/+C2SFW-1=C4++**V6.2Z1:2$[
MB)91;:6CF$>A8QIOVW1;G7-<`M1"=A"=HW54U>A(:LV'UB=IV;BMCCDN@6DA
M.XB.T3NV9,-_#8@9.0'+QFNUSG&)4`O90;2.:=@=S;".0><T3<.T.S;')C`M
M9(?9L>FHMMRQ[8US#[26#78SNX'G%O556P7TPTF3K'9D"QP%Y3#7!%IF^5'L
MG#_RDO28*S"O6]\:/\>J>UK(#J.N+:EC6NUQU78N%XU+OIQ@M/%^ZP3N@@64
MCF1K'7OSF/ECY7T%TZ=U;/.H+)7=>#R*9G=,::^YC)?N%;P?A`_X\>_OIZEX
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M(L'MS8O:A>JHW;W?QV%&MY7`>$D+TP;-&;"%"@N'VC9[=P8WO@*N=L#PW=0?
MV.36]/^S=ZV_;2-)_OL`^1^(8!=P`-+#]V-S%X!Z,!?<Q`X<[\S-IX"FVA8W
M%*DA*3N:O_ZJJOF49$>6)4NRB=F9M22RN[JZJKJJN[I^>QCDYD<\QS%`5734
M+@?P41LW%'_X/Z"%$XP_(!8J];F(>#8$D=EC='^BB*:\<<K$,TOZ4P=KRLYN
M!?[PAJR(NGD4T&^'NX(/RJ.AQ@Z'/_K/+,LG6%;B656^._C8CY6T#>.5V,@3
M0]D?4M3Q.`.54<C(*[B*&.Y#\"W*?1F';4R_)LK:JSO;.='T9ZT!U1G_U^M-
M7+",^6DP%@*P'F$NXDG&T5F)$U54U=<2-9RHZL;W6#KK<(C6X5!LP67JQYD?
MT,%JD&2Y`"[$C#X>GT70K(UCZTY)#MG!>A4L>^E>QP.6IL'W:1HFJ3#'8]4Z
MACD^4V28G3=_('K5L>R5NSCGZ73LQ\(HG=T<=\2C:,?@WVQEJ+;^K#C!^QRJ
M+MK.;H*[E^Y1G.=CEF)!;'@1O`0AS-GD^+8[3S1[-[O=AS?4C77Z6'=UNT(`
MC[F0^]<LS.?2E9^Q$5;0GS*(%XYR)\(R=EQUYO"&K.H[OHY^@$/>?+NIVQ'`
M;CP_3+'[6?.\$E.:IFE]M(FW7^[XU5DA"OVK,`(C\:P6X56$?`>H7LJKRY0Z
M,783];PL/Z$/T?P-$\*8;`>_$^;CS2L_#IX_@?FI<Z[HQU9[8BNC%E5[/Y"5
M^W0+=SWDEP9@^7*P@SO^=?S;)_]>>BCQJ<Z+9C]PXX#]>O*T"Q$;&NKU;L(<
M;3S0<:7CRHMW.UX29G''P8Z#^^;@H^OJ/*54SGU%=ZA`3P_/%K[X<]QH=._\
M=$25L(I"6+^7NPENELTF_+L=E>%1=<_NZP-7LA3-D_2!ITJV8\A2S[8=6>M;
M2M_6-BK#\\?_?+H<2E^_N'TPNG&23ORH\)HN+]RSK][YQ6?\/F;P*,@`/?GI
M[".^_>.]T#__[?SB7T)Z<W4BB_#/.^ZA<6\-%IEIDKU?\-+XE^TJ-292\MOP
M\A)$K.J@14Q=Y^>](-VQJ^]A+B%CI2Q/D^],H@(G1%0IOH2O7.\7)]<"\X.Q
MD$SY]@_.)5;AJ6L!)3$5Z1GA;9CD&EJXH2WD65;6^>E%?O!=`@%)(A@0;TB:
MIB'6MQ$FR8A%]</PNE\+A1#RMFN\9Q+I1Q;ZV=54J8^9*GGMJ:)>UYNK!TS'
M(TH3/3B&>\L4/8*%6QOV<U5&,NQGP:0^Q*8VJGOS@`2MX8SNSB5872&E5N6U
MBJ08:]8E>GQ5HH[7[0W<G909VA?53ZL5M"^J'RSXL]G>UD,"N]M]KG46Y[7R
M97Y,P3<&#0?_,!RQ>"3,0Q:--MONVG338'G>Y'^^YDZW+XP'+7JW200AT_.G
M9"Q/AFGM0P3PP6L("DOV+SCUU4::H?VS[DNJ_RRIQC:>8PMLQ1`,Y5G$^#AL
MZD68?9>N4X;I!<`@"">?ORS:$\1,.;57RYEZJNU=T-8?A'K?(-2]#T(I:7C-
M5A^8,3G=MTZ8IZI!%P6S/71N[:_GNH5[2'A@NY7_C[Y^8--U&UNE"]NP58O]
M1EZWBUF=-PQ[Z,U7=UKT]Y&04S[%7U@:)J/-MV%G<<C?RK"W[*TP8D$X\:/L
MO]]^.O.6MFFMGNS*JN=*MC'H2;K6]Z1>7]8E6?%<5S-,U^H;WPSH[9OZ]H-C
MF;;I-/BYU3&OX.?5S]N^NJ?MWV%A8R,W'I4J?9G@5^>S/,O]&/>M_F!XO@C/
MW++4OV$7;.*'6.N^#ZQ/_2"?^=$E6`%E:UOBBF7IIJ=JDNZZJJ3W>IKDN+8C
M>?VAHMB6ZSF.^4U#7NMO/WRQ_E0_*^I@@=L'P9%'2G[V$S$8_F!I$&:LDH0%
M.LK?OZ1AP+:@&6&6Z*IB??OWU\&W*4N_+6N*NCQWKN)9NF%)NJZ;DFX;NN1:
MBB=IJCD<&K:LRTZA)]K;#\JIICQ"2[;*'SXW(Q;^:Y`$,VSJ<CY]`M<6^`!6
M0==E705[`2S0!\.!U-.]@320+=-5%=?LRQ8_UL%6_^O714)J\H9Q#C'5!;L)
MLQSMP)D_V1Z9\M#T-$U1I(%B@[ZILBPY0Q-4S1OTM&%/=8<JDJF\_?#9[5^<
M?QR>?>I_%3Z=]3G%JVA;I/P/%D7_"SY=_)7Y61*ST2=8*%CZW$,`4W&6-*F^
MAZZ:_,O41V7_.I]<)=%SDPN"\?GCV?]Q@EN4M(W*@HB?S7!_=Q!&,_B.E"5K
MV"VWOEJQBW5SQ6!-5S$LKR?U^YX")D'V)-OM]27+]!Q[,%!<=]"'P3IO/\BU
M'=AP2&V^-$W(!8OP'+"?9'FV@,NRM6DU3=<P+'C#-$W0=T\92JXY,*3!P-9Z
MICYT!CWUV=%4[`9&2+F%BG^$^`<Y<<45N_[B%;NPBJGJG=:-<$L>2;+Y`/Y+
MD^`IM_Z9`.(@^$&`@"[P]762XHDL?I&.\`Z`<!?FX^+8=IHFMV%&I[;)M>!^
M[=?NLZ78HE!QIL6-1CH5$0`-K>;6Z8J#Z6P5R6$&;52GT^+"\30_G!;O/9VF
MXVCJ"UKAN#7X8*/?,".8G)LX_)O7@`1O?"XDH$T%6,Y?,V!#CN]G++U%7V%*
MRZ4HW(W#8(P-W+`8*TG#>_C*+5(+G?#'"M0=>)V?E"^'?WN!!_)@[H%B`?C*
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M)E1.I*%KC`H2<-.(+@?[03H!'D>:3!K-P/N\H=,':8'FP&->[AX-TAL.4D<[
M>@*[/V]#0&FC_VI$,YZ-KZLOZXA^6V'X@SC['HP8-SK">`8V[GR*"Q?:"0BY
M(3`/`S<>-9WU/>U#]&7-[NFR"U&W9DJZ*?>DGJT/)<TP>IYEJ7UUX&!@"Y&M
MI)SJC?!CXY&N8MBE_V-G$8>LVYX#%F4HXT[+P-(DVU)TB"N!6<.>H_8\[[DM
MBOR002E,R"5"EARL!:DJJ1.N0I8QC#'B455O`"&Z4:I'#$\^P$<<57X6K7NP
MVJ8,W#]POUA^QUB1'AK&X!/"@EQ`59)K&O-.X/60(A+>6V&!6OW!9^QSPOQL
MEK9<1Q;[W"LK`"GI86@B\N^RIK6JG;<KNB[-N%=P-RX(;!(.;V"`TG@G91`\
M9(Q'.,6KX/*,5O,*NV]0CR,K3"EY+16E[3C%SRH$S;@,V'BX0</(9A"85+";
MI66FP7$6<.(*%I75(]`G7Z:2]SR:!1@1A-=@AF'8F9_.14(`K9TZG(OR-CD^
M&-*KX,$S&.%W1M$1^$YQ4H")9DA^Y5SS<(02CHG%RW3<A?``OGV%89F/OBH&
M&)6P4#5_'`N%>JT0P*=FIDG&O\G][XRZ7)AJ_GT1G1#[6#Y+8QS&"@F&5G%P
M$A^<A(.3^.#`WH(#BU-+*R>,M>KZBJ$P9K,,HR"D_Q-?6UOT31@*1SZFL*)J
M3J0':WQ6SH=*))#7I<C[W(F/_!3F'?G1!'&]=U*2)F>%V10H*6,:BG[S/"+^
MGC;#ACKD=]YG,`0TW]@%*0)N+-0)`5S:P?WT(Y+UE/N?^.@,9":EP+#)"`*'
M]<D126(NI#QB6+BRN,Y"?M\*<]^U!Q=6LA&N5[#N?V4!Q&](\[#P9/AB-X%8
MA$3__'H1T7C[*Y@WU!W7MEQ)M]`GEGNFU%,<1;(LUQ@,-;GO],R#0R"N,_V!
M^Q,0*!X@HH,(=H,V>.[8DH?(#5K@1\$LJJ"+1]QY6.$&@N43R,L!^0U\".RP
M`8I-2\--L,4@W!#1A5(YJZ\-7]A1GX@O_$#R^193WQ_[_6OLND.S[?"%#VY&
M.GSAQ0%W^,([5ZJC+K[Q%4(V>-F5%.%+5;F/SLV6'=I=)LMU=?HZEAU%(3!5
M5`Q35)0=H]R]K+)_E951.RMS7"K3L6PO5D9S5%&UCL+&'+QOT^MLSG$I4,>R
MO=@<7=0T4Y2U`RAT>G2>3;^S,<>E,!W+]F)C#-&1'?AWQQ@;K\2S&716Y[A4
MJ&/97JR.93JB;G:`3AM8F&['YM@4IF/9?G9L1,U11,?9,9362_=LAD6RXK70
M3^);EF*Z36>`7ITV*9JHV,ZQH>N\"F%Y67[.'QR>CI)%I[,T&/L9ZYR?H[4]
M'<OV8ZYM6;3L[KCJ:2$7Y247I5&>U=!L0P14479TT9%W+`2'.'`-O!7'.BI/
M93L1CZH[HB5OC("^B=H_"H%B6Q<H[KN@<<&R/)T%.=VLAP\LO66].58#.K_&
M*\W;OX$Q="Q-<0Q5TEW5E?2>UI=<RQA*LJ8:GN[)AF(.#NH&1K]]_3UBZ%^Q
M'V$#$)B7!,F*BQJ9<!+B/:Y\G,PR/QYE[U[;)0G3?MHE"5M__"4)ZP"N"QSU
MXNT&03KS(^'*C^CRH9_??PE\U:WO=>SUFL^M!TVV9,YK,A59E(\C]^A09O\+
M+`!!.(7Y+XL&[72&G[IRGYCJQOC<3P:K/B8TN0Y$]"7:7^V@E=,1==WHC._+
M-;Z*J&N=^>W,[VLUO_HA>K^V*!]"4MHQ:6<'<_JX3:!=EM5?*,%+/P[\G'E^
MF/Y.50/W4]7+]#S+Q'K"MMN7)7V@&Y+M#!7)LE5;-I2^HU,]8:RJ;9WJCZDM
MOEWV+-;`]L*(I7UXXB9)Y\]=2MIZ^\&M*XP*1$NS$':+N$7*L<A,.DUXY3,<
MX_EUZZNM#<88R$"OIDFJ*1M8.-Z0'--Q)=J$=-6!,W0*'%P8IRS)-K3?',7/
M"%T<V.])-(MS/^7#SYY[4LS%<N0+]"R4J_2SL1N/\/^&=:$9,A4A5GM:_3NO
M"[2UD<$[O8%B6)*F]SQ)5Q28(=TP)=?SY+XQL`=]5S^L$I8U@P1D#9G>0RPZ
MUZQ92[7)J#HLE9%"9`FJ(H75I,+K,*#2:5@\B%%-*2J`]897<J9M;]H?SK%X
M,U6WO?7!8,T0U)BJ%\8W?,^<%Y4KU8-J$T&'T%R`Z,E%0>WL5'"IRA:T&OE9
M!MWS2EQIS=<`^%K4&,9&P%2BOTN&IG3>LC$5_\)M^7]HLBSBTHN]_T.7#?X!
M!W"_?U=6M]2P;FXVY95QH_E:M2Z?H#=M#1Q.IE$R9^PKKYB]>CTYPQPS`@^A
M2LJ72>Y'S=]Q_3Y+\C]9?E%5.>,KBI>DC1K/VX-267/!!&OT1?^SYMOSCK;-
MZ3.6XWQ\P6KM(S;JS?\-_7Z*STL!=G'^Z>1M56W.[3HF36]$TI:XJVLF!$XF
M&$,-BXSV#$^R/=F2#,^2S9[<,X?]'A89A158TE3+<$#::R8_;:#W'2*N-75N
M!!YD<4RY.#E4/'G[1XV.T;<]%98+U;&`8;HQE&S+'4C#WF"@RY8A6XIU4$>-
M[6)O]Y9<]PL+247?&L4+ZTJ^O(PEGEF.R'R/\$CR%1](/A7[W-K@0-+87^FT
ME]QU5R.LJ]IV<#/256U;''!7M6WG2G74V^VXS>BGP9@BK1&#Z"J9X@[89COK
M3]@GWG"W71$-<\=I@P<S5G"47\E(=>M94T&/_=SZ(X?LXF@!HTD8$R8C[I4\
MNQH_.?]?-.VCT^<GYS\;.T[3.,`AF]T9Z2O-8.CXU_&ORZ#9G3=`N_$_!8K<
MS#/8K=N']X#V<^MKM^.R]Q2B['A4V@'4P3FF)?PEI3EU'.PXN&\./B'5;LM'
MI>T3V0MVR^(9:YQS[PH(4K6MP4#3>Y+IJ0@M:PXDUW95R;4TK6_T;,6UAX>6
MET.\V1L*)'>@U'\N9>@T26Y2V@3@7B#ZD'*':#,<#YKSA!_+7I59>AQ2,B`4
M<O\F98Q#T=^%^?C-+XUGDS2CM"$.6%AM!&/"T22)DR!*8MIBRL.K9#3GGN4;
M.N:&59W-\C"@TB=YRA`9'=-_TB:@+M`9,;`$849)2!QV#V$($1:08_*V"2S!
MU2<(VP?O`E%1B%F75XBFS>'J)_Z\Q*B&5D["QIV&8LB9B-"()88WT)=<4:OU
MST@S93"MQ`#,63".P<^_"0.\%A+Y.:*\PVN$2HG(E4"J%\#KF"XZ"?^NF3Z8
M^9'D7E^',5Y-OF#2)2(84B+6R<"]N'S7:)P1?/A)V!P!>5I$\_4LGR%D>(N6
M<#)-DUO.K.+EUMOW;.P+?I5;4H`D%LCU)9#I%1O[T74)D]R4#\*US(2IG^;+
M/Q/:/0=%/`EO&X3@8R#6LVL_H%'`F].424$$?,%Q0*/5WR5X>=;(H6A2<"H4
M";I9,6TUWGL\8NF2$+WYI2DBX(G&*;N&1RD)HE2*:T92PE'=^0?V@Z5!6/X&
MK93W@4A#UF"MV'Z#"]BCN2"6--++"#T94UI=V7:C%Q[H$<PE@<,'XY#=EF"H
MJ.<%(N4D!.W)D[A(`TR3>8%?"2^"/(UF02YD?H0*>DZ*6T!T$GAGF^6KE+8-
M&`_RBR]E+(J0A[QYRB%$G08]*`$2FW)T2SBS29IGI9"AP(5T\Q]:P2Q`3(84
M;EAR`Y8'[`":D30$\0A+NU*26!8"H%8PV2I#,U`9',%SO_8$]VL?8N8IM(/I
MQZHA+JT!;WYIK0*5@=#??RZ,DS3D:*)"(Z^\L<:19M0=07O4E;W<U;T=E?,F
M?&;Y.!DUVR:^%(F;Q-5D61-.A4\($DM*DI0/UT]B`]6S8FN:)[,L![\#?@BO
MY\7JT##$Q8RCWN.24E1GJ!JC@;-;@M5EA=5NO9^R*>I3S#-98:KQ.4S(X_#!
M]:@JI-IE^2ZE&^4<!`&51RP(PS?OQHQ$N4$[M,2*&1N#2<MR(%/R88E#3MS2
M-8="VMOFYY*^B3/@1[&\IBQ@T")!UOK<821F^+!H<J#FAT;%!8-&-)V"LI-A
M2BNI:R+_EB/C12[P:9XFS(`7I3RWNUI.D]U+-IU7.!5E,EPQWVS4EK.QSQE1
M)][E=S`%\RDK%+864.CP'4=912#[M@FFW.;)!.TWQ"M_EV#.Y7I/^+P<5/4G
M"_X<V_H5[7)A.LF1>?,+00!'$0,[CAY!BNG5L+Y#NP4='.(75AD0B!MX$=2G
M,%K<82(O(!-.JGIP\"JTS!"J.6L,JR3YW7N>!OVN<#*2^-=Z!:I-+QG:@-:6
M6`!;`:(49F-L'ITL7,1^RJ<6EQJ.76FZ4;_@14KRIF>:RB&!F2_PIXL1%OUA
M/OB\[6,)([KC!%24ZVX!^+V:*:@)N)A(>2*53*Y'_NY`Y/P2Z27MC)/2J<+E
M6N3><!053A+'WO9+I'#ND?#UL5B@"+6[6F$%O[&F<-3KRC<N/`5XN\:91_O$
M_IIQ1/?VFOTLG%H=8BV&A;1V#2MA_ZV0O`,,L5K+%?<S_7A93QMKW@T_CX_F
M9"UJCVCYG?;TM"T1Q@AH+VJ#A`ML>1&"EO':L%!@!OT6RL?7%?1]P8U,&F0L
MK+T59OG#P08VT`PWVBYPRY&]-]2@T*(5;#P0:I"[DB$L=D!75MK6`\<U]O'2
M2V4_L.@FNHEX?1_6O\(-"2I[47O"I9?;M&2H4]PKY2XI#^YJY^DP#,S'4JS$
MAZ2OCIS;X4X9:Z//5X4-P`,1[Q.QF#REPKNB1ROK4S8L<@M%H39QK+EZWX51
MU`[`BP>:L]J6;[SK!.N46)J^$5M3K#*^:9?QVT,QNTGRD.1XFM+7W,M$0UPI
M(G?:LAQ?)RVZPP&4*SJXK>FH"C,XP'HP1D42%V)RH"ZNN5>&6^1^KW)(&^&6
MN!B@4U,\_IHW(DRNN>T0.FSIP@W>.6TQOU(#'J2M4(2?+_T4D/(`K9S?AS0"
MA)<H%U+2(-3(6S^%)>N6E>%N,3:2IF496VGR5KI6Y>K/(]:F,U]M?A7A>D:K
MYH+2\ST)^')YS+S9=LB((RG%D6Q@8?_P$AR&"5B2`,B@*\O47<,^-VTD%S,>
M.+<WV0K?IU2TE5LIAV=\FCP:)=!(G.3"*(0()>?JE:=)A+,3%Y/0V#="XU#K
M2',/(L$-A@!E&XOX18SOKQ2"4ZK$@7#@#QP;[;/B]-%.JP_6YVYQYFIO#8=7
MNFCD#$R2$031A>?+?H!`T=_U&S\)O<F)7Q%\KQMZ+[Y?!=_KA][WV[JU0V]H
MXI[@^V>A-^XD0;.T8I"II]NPJ]RSYBR@2E]A_RD%ZK!N4A-D]24TEF!!4-]1
MMT_^G[U_;6[<2!*%X>\=H?^`IX_G#2D"H`G>:<\X@A));\^VW;VM]FSL)P=(
M%B6X08"#B]2<7_]F9E6A"B!(490H@13.V9EI24"A,BLK[Y>OGT<7Y#-VX!U`
M/_S'Q3/$3XG/\X^CH_-R=/T9GG;G!ECL,W@I]4X%D[]XM:JV]+^N/XTNT$\`
M5P?1>.>X'FZ;PZ;>@"_APO@D697<8&#"B^7RIBCR/#-"F"17#)!'H'JA>NC`
ME7(Y?Y$HUTA%>1<5T=SCB00>';?#SX8?#1"!"[QR)"U+1`1NDY3+N\"[(S'@
M.QSI6;[^5S*[T60/]Y]$J6L?M1+8,#!'G7863OB-D:TS<[G[7D@NA-5*,2W?
M3)5<SEP#]-[R/_%PVV+)E5U4C(3*(-FPYOHB3F_<PT&3<Q]ONT\*A#)FX1(S
M3RB-4JT&Z9`L>)"!W#:I7BV`");+((SQ;H'R-G,CNEJRAGJ./DHSI;19SE2?
M8JB1E*^)['.*M)A,X0)$J?\(W@7#D[$9?9>$CA)WL,%UO1>[U$<)Z1*!3@ZH
M>W,O&#XF<81';6H'K!VCO.13U:'U&UMQF2FQ@DZ7V3HY$YV3[LCU>2-R;WRJ
M=2>'(!,S/`1G2^.Q!99QSBTW8?$]8[ZX((4QI)HQ7&<=^55!RC_DF(3[E5%\
MLVY&X(D+9'-K?D7@[2#WPN)[)I1`?5E^C1&KVO8$_<'S4M<5;G?88LC`D/,Y
M,2);20-=V<V9\N<5<CW-;R&1C(C)0.-RG8:CF]1NI$Q/*$;)!(&)2>3IS*9(
MX>/KH.;`>>#F\^2W+3+F[G<412&!(3PI]&FN$0,^V'(3A>@>6GY''G+/9B2?
M&RI<Y@61V/X2==80C1'IQ,VX<(EST#92]RT2.3IP)7>FH(QX%1^$K83(T0"7
M6H4Q^@FUMY#U1>I8:\9OZIHJW5B[6HHAD]-<8E*7V(Y^5V@K64QQ8UJAJB1*
MV@<_`\W#_G>--/$LA+H49327=6L[U5O6U9:<OJ](*$O0@CZ!HN";&(IQIMS"
MP??=<)HLN+7!`XATVAHMUXRQDFWR'M)%H\N97@WZ5"8HMREV.7667+I0,'!>
M$'Q5H0JNN*2B*(5!+HZ(_(ZV&X90Q?7G@A!D\)0$C('%X<(?JFDPJ5#!<)(X
M`?@RVAIK/#:SMRFI/M*SGX9VB5&X,9?D6(J+0F^)N@%RIB")!5*FS%W&ZDPP
MV,JOMRXP\LX`?):?O'A1?A9U*&[PDHHLI5">D:9<?BMD^'_"3\&5S$@`FUJI
M14L#CN<YV@;<"F&1>F_6R#FCAHOS#AF@D4DC;L+D]>&=#I`7K;.&35<,_ZUS
M'.[:4ZI/5L6.\HBE`B?:!L\JV<JRU_1'$U@@V)Y.F!6B$3?JZ`)A1L0JZP_B
M#AE&G9I2K5-IK&DBR)KCK-##`?;6'7;ER7")K,%O$CT"X60<8*3[RA]B1I8C
MJ9KHHY'?S`=LUIR<XH*</93MLM)37;8`XTZE%$1?[U1D%8C?*Y-&+.*YWX!*
M;X-@)DAPBX^9:X439!PSML?K^%JZ!BF?/`A5#$G&0X/D(5@=<%"1K9%AGJD'
M<CV#1CBU><C2C7-+"[<\$2;WG.$5$F29+EOC.?PY72\K/URB.#^CT61BP?)N
M9',#R/B5DH=T&4M<.8N;E@M*+R#VL5DDS=QIC+<]923K$C+U$:%BCRITGKV8
M?/_I5I`WIV[I$%5H$0GD&]"4(DT1BF_#(+E)&;F((J(O4^FQ)=%,-)TL9&`9
ML4@$-HIWS3VIW)6=C7ZDX$<*1\ER'H(BG<EI$K3VC>+GSNPO,#@$=J.,IBH$
MM-@%_"3\Y\*>$W]'F9YRZ>(=P]$(9Y6+2N@'OBZ>&^BU>;6(@L7<P8'F,'4Y
M6DL\3`-<TZ+`C?3V&$C3&.&@T)?$@6E,$D0U^J8BX8A-4Y)V30'0HOH.9=EX
MY!`@&V!]/\*TBYQ%NAER)/%_XR5`X\B-DYAEI:((.=!($V<1@-Q17GE^Y$HC
M04>"ID#*DX<3-_".>UQDXV%HIEA&EA!'H,C<BJQ/GPO3=7B0@%Q*V!*?5P<O
M@1'+"P^0T"21"2IJR5$"\0PDA\)3X\V4.%N5.FP^4X2P=?9.703>F([S!WQ@
M"XKHZYAJPGUP4AQ[Z"%DE,V#25(S;45.1ZC293OAR;NG>),IK="9]!>B:I`+
M]PN.M:9H;L*FN)WW+NKKP;TR;*6^4!+V]H=`<LK#@X(8>21]L1H+QR":4K17
M>97/U>30`U+H[-T#"FV:;JBKR\*&!A5%NE15U%!:3H],Q5W7$Z0^L2T%5-?P
M,%8@LT!+<L!Z`$@30<K/H7()-D5Q<XY-I47Q:.-.L0B'AR<9'_:4:EXF7DDO
MH`<4!X0_1XD39=SPQ%*SJA5G+\@>-`]3QK]D"M\S!2<Y:Q%&G82;YP%*9XET
MB=4>0%O661S?/HK4]&"KDLUZ3%%+*I3.W?(14[Q:(FAPW<1I1AH%J0R2'8E)
MCR#PB\S)AFRX&[`X>?BN**/-S.:D(.T)K+%,U!:VYJVDJXA'W=?R%82%ADSH
M1L2IPN0FLV.NO7#%9)U3KE-.B`F%HN5@FG7*/1PIOE0"/0>04W)ZT92AHDE,
MY(I9<_1.F3KEHY>LKE:0_D*1A#3&G`HD\BBA8LM3^$E'0$+@_B!N<S@WL,R-
M"!/1A815C2EOD`U$^--9KLI$/\]<KD>F%N,F\5#K7>D/";+)^7\H^5Y[#*,4
M1=\0D0GM\C@KNN@\!%^@S6$=BLM["(-2.KLC(4I1,U+"YZ#.D/J6DG!(BN,M
M+]?Y4@3#QDU09@RH-`LWBJBL@B+A:/;2943K`ZX/SY'@#.R/VG7-&*-M3[4S
M>%D&6BL;6.-\/!Q<I.XP@R0"'HI.$'07THTZ"=BRH7!I4J1%\_0Y/,MD?5<R
M28I[XG@J+[Y.SB[AM20EC7IZHF.I9ESG3HWD"]MX.KZ/G^9''9+1+H/H'AYV
M643^H""HPCW1:;A8CX)J"#C3$YHRJ3IK#G9:4%U7\E^GRO"=\/F!>N!&W\@N
M@--/4[5$8)"'S`(9(./6Y`UN+^N_2;^"S!7>4"Q<"Z3Y/'`)YKFT0N5."SS0
M.8\,Q5S]*!&-M8F\F<M?=G(O<X]BSJ&F6=-4IL$39CA8Z>XI/>%\LK;>+;XG
M-YUW3J_%_<ZC"^Z[%6E>&7/;")*8TG*RM3I"YWG<UK6-G^5KW-:QR-4ARD%@
MWHJGLT5Q9GE99?;`2N0I<J+`%T45*@P*-W(-*SP(3'*<$ZYPYNJ9-7K\19-(
MF;A1D5LXFKK<+3(U-?9D:B%Z(0LX9T-2%THQ90!-N#.(SB.'6M45/4L@9$$A
M*Z$K2^54W)JGOMW"":5:S8LE4Y56+JK=RWSNG?I+'NO$@S?B_0%TI\ZF;)0;
M_5A<_<)(9'H[2\(G?P]\2\NTS2=;%HI_X0<A^8G!LJFP`29I<=,L?STW.JQ$
MO1P2L])2E8]NDVL!)90*'Q:QW6Q?:TUGW%QHF+WP/`6$I"O>.4[>!9%QO;@)
M*9G!#?MM'5?D4-8BGOJ&)VSJK(4WE!N:\@S<21++\D)I<.6RV?#>ZG<IRB42
MJ\.9QRS<C.FS=UE</XS.W$;6F'YJV(H2DR(GAN:JPR_Z02H.$^&^4_[EB>?>
M."(PMOF8SK94H>$QE:RBY(NL$Q):LS%(#8,2EI84WN8MI4Y:!GXVK$2:1J8J
M1=5%Y"K>>=*)\FIGD\')W:^J2HJ+;(N<\>OE7KG:;((B=??MENDOOP+_"]M8
M"*.XL!HM5U1,6J5XC9MV*'LH75F(O#.MEECXH-,*-@%`-@'U#U5B?I8MEZ5H
MB\PR52E>$OZ"L@CB#EM2E3)U<'#Q%85<_2S<V>I70R0GVH-6VG%1E*W``92!
M!0DV&3;\3!%=:Y4**;-/R^+)AZ:1F#,E78)6V;G*<`U(N7P!-.AS\=GL@N]5
M[105X4RI!-9)T.U83%*G^UQ3^$1LK"2*P]=;9N0*M[?=?C>;5B((*6OCR%87
M5"6BW(I94A:CS82TW2!0W;E9F%;GK.U1OPY9<P^U-6&[.>34U%5(?4]D+<$I
M36^#@-?%I<2F0Z6*7(M*/#:5LZILJ521R*1-*05>SX`+%)*R>-'2J5`O%PDI
M>OIV[CISG(A."FN@@XP'=-(2Q*C3*(66E"V2E01.I(HG=FB*)2-<9!/F<FF@
M\#_8)5#P$HT(5"</O@?E\-`K3!<+5P23W06ZSV8JRRF;,I;58(OW7Y++.'[@
M]MV3\E5(C8]A>Q&OW,R)MJU7,7NG=)66'DX-V<?L`.V,3(HG%=.M7?8,':9D
M(5+"*`3*BZX4(:4L._51<QLH#7V0#2<U7QG"$$JT,F'2S(>B/#\28QE2ET<R
M%ZG!NZ*"-(I(-2<0^=ZI8B!R:C;D:E&:C)/=(9>QY`',"-C\B9N$-YVQJ!8T
MALCB5!DPNN&0XLQSYSF^CR[4\&QKN7S&95><&6_FC:ALMMYZCEY!#<ZZ%<]3
MC[Y^'O&D"%Y0X,X-+(L153&YFI@\6]VQ*D:_+2A7'ED5LTVZ5>4Q;[<\9AM=
M4([+HRMF<!N9FID]*F:06VF)_8^HF,D+?5DSPUTXNU;,"*&1JYEY=,7,FGN:
M4C@>63&SYEYV"XI`'JR8D12J*4N/JYB!!0IJ9AY5,7.6*>S+YZH^IF(&F4=1
M1L..%3-(Y'J&*>?_.U?,Z+C,BHU'5,R<O<O6S.Q7,7.6J[1Y7,4,O*W5S)Q4
MQ<R:!J.7TTNEA/R7W,J/"-*4`8O0Q68SOTC=S=?=.+%PSD991P.E[,D[N+/!
ME\V=V*:]G+W+ZD\J>92<'G(?9IJVMT&$G[W+50NK/&N`F"01*8&%?6.XKA=-
M`0-(J1/0[TI"&W_H2-CL]7G,V10EOF*/&D4"!B<)Y<E.]6"E()O4(DG8ILK'
MH?$_[K=.DV0R.85)'BQ%`%H_T)V-B"RYQ13A)V85G67+3RW)>[:&0!Z_`2UV
MF%'CD7%2`K&YKD<\R'EY'0`YJ8"7I:6+^48J&\64)A.6U/Y8I%4DNR6*GJ,:
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MO:9/)S\X]`7(GCS\N<EC/O<5:-E^MC[[EW9W>-5HV%:S/ZI;K98]MGK]SJ75
M&=CM7G,\ML?=)DY[?__+Y\[_-7_+H?(@L#T3P8I($'#7.7,QCA1]\/F$@V<@
M46J2%>E$^N'W\1IRNY?U0;TQ'EB]]O#2:C6OQM;E5;UEU>WQ8-!L=P;=JS;0
M<MW^L_7^EV:G5V\_`ZENACN'6!RC=!MXR,Y'H.[&*V0E8<3H#]?`<>-GH[)!
MI][K->L]ZW+8!T1<#9M6[[+1M"X;W<[@LG4%]W7`ISG8%C!)R^[5NMUF7\/&
MPYO-0O=I*?+C/U)3_D_SCUB5R(:@>GE!!%AY_I$5K?Z@WN_6!Q:PH!&PHM$8
MF-*@:5U=#0'@07=D][LO/K)BJ^+!RS#0V%\D"\.C(CW5`I"<W7[@\QZO)+`#
MB57^<,2=IB"S"X>`&X@LGJ(0I0W+S\D7#1HE"+_HXJ?]53""3(>UKB7-;![%
M0K-4]AQ5)H;`7'WZ^''P^1I>(KF_C$!:81?<:.E@<?@_WM?YSTLTX\3/8GA]
MI_>W_)AG8T+-R_&IS$RH[(@:\7Y/G-Y.XZGD.YM?>9[?'__8N>;6L7-`QNV]
MA@CM^MS>0^7ZK0./5SVV:<(/'F3GH`?YU-FQ+;/9.?"8P#=P6;LE/^-6O[JU
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MF/`!Y!O3(,JT.ZPI`X*R42*6K_)9JCP7BV=WSE*:IR$!JB:?+RG">MJZE$/)
M42IR9R*>TQ%06B7F<10@%Y,<M!Q+S!JDUH\84<RDY.01DQD;*"%.!RJ(7.#"
M+QHW[AWEI21ZRKXC4U%D#Q8W7M6,3S[ES/@W@4B.<Z/-/8=QS^EVS;5\W4R+
MI8*0K&G,'3?D29.9PXO0_<\G]E*"L(R3\-$[,OV`GC+N*?\O3@]F1?N@TG/G
M.PTVU8OUHCB9K009Y!J'`#&'"7:BT8<`"R*8TG&KG#M884*S;3(8P,R06S?"
MFD-<EEH*N[R'$R6!W@&A!$F4ML?5DV=Y]B/6SGM85"LCZUIANIZFGKD9-6/`
M6X/(WJJ\YH!W2$FK<R*]ZU)9DB0R?96!A03AU@EC'SY_0D+_-(V#"8`&OVWF
M4V22V/4H@3)[C714N^LMMY$.SV3#^[0/ZF*!36&0RK+)`[)4C1-@6G9%`P!D
M@H"H-<`4`P^SZ>!\_?13FS\DD^O27!=1V7D9."%5;`\I7X%2Z_G`'G^9B)%'
MBJM@PHV6()KP>T1)\P'LG2$1IJU$""$"6X_#QT1N:B8WE<G2R?7YR@+.\]\T
MP-,\7,?P$PPZ\?1354\A4H_ECP45!J"!4'J_R-+/\[I(R`X)Y,0-]%E(_BR)
MXG`E,_#A;7F7Y6$6U6OPX@H>.):82EG4V3N!KG7%;DT3RVI466WK?QEJ^&PV
MP!2;&_8[X>?3G"+%GY*84LL!JDO@UM.!/QNZ7A*SPP3$UW6VJWJS=]FJ#ZS+
M5K-CM3KU2^NRUQI9S7;[<MSM-JX:PS[F&C3>_]+H-GNM?E]+W=@/,HZ=&7-_
M&@;`!X'&>2A\!$\\*5DE!]IX,&BUZJV&U6NW6U9K.!H"D..A-:QW.X.&/>A<
MU3'VBY#!(A8HJDW[[S]NW%?V4*^<Z!9`PO_!V#?<#!36N32?YPMC#SN7S3H<
MRV#0KENMR\NZ-1BB9MWIV9>M0;O?Z0_*I5DC8N@RTC\T%)5:Q5[/J<-:;M7&
MAKCM+1`]Z-&>"T!I6N(9ECP!#TID0W'>(P%8T(W+V5J<A*)>B'=Z`_89WU+A
M.0F9M"129F(NDW"*_="$-D'E24QALF:D2,8_(;M6?Y29LU+QI,*"6-;/+8/(
MS;?H$1//85-L)2NEYC17F$!1&7'`[/UO7##G@<=FP[Q%V55NL[Q,)R99@G8`
M;SM,;"["68\>-:DG+8ZWPV,A3FN4W:$Q/_"[T`B4*-J%,^]T4;-W>TC9\:08
M2),:#6S@9/J\]9SQ_7QW_;(Q'O=[?:M1;_>MUOBJ:_7ZPX;5K5_:PT[3[HXN
M&W#7F^]_&?+:55PKU_9,Z#&\GW+;6C$'.ZSX[!Y.3Z2U!W)0AFP12RT!G*G+
M+0G]-E#"/-.G%O!)=/,@"?G:/$TEU[(.4R^T@1Q%WQ$%9*@1#$!,>X9(4!$=
MT_BR]'FTM#+E`&D3;TJU3[\_Q[5P3_J()=XB&SL^U11A['7*64*1`B]]Z)H)
M<^_IPELL]5`Z6Z,_ZK6ZS4O+[M@C$'+VP.KWFEVKVV@-FNVK;N.R?26RN!3H
M&_>=!>^S&(GYV0.-&>X0WA]*DCV4F&N.KSIVJW-I]0:7EQ:\VK$N.^-+D'7C
MP14(\%9O]/+96EO%G$01<<,4/Z65<9GM,KG='&]&CESCQ3@AB\$XX#VB0JID
M-L]DWP4N6X1[9>9&HC'#/"V"E0X$8.K)(O'28EI0L*>NG%Y);<D#*IM)&U%P
MOY0P_:@=K6RV<\/])R@Q@X@ZE$R!)[DQ+SCD0W3)8R&2XD@4?6%+D!C2!81E
M/C'SR3=&Q;RT">%4FO$ZXVD24IG>4-^KF$.V6))VKBJNL&,H50IXF,W."UE4
MT3Q/L>--UY4U!3;=//$,S+J/WEJZ7;?SM'2[=OOQZ79;7BG^_?'']K='@J\X
M'8>*">P7$7Y"=*?)Q?2IQ]RO@WE\#RSFU/!;7MH>)Z%/2?8OCG*[_C9H^J.L
MJ^**1#"?8T.4UV,E[;=*ZF248`E&9E+#B^,?V=PM!O.T6H-@KOY-YIG6@`,L
M,>U![26N%VDONG/V#''R70V9K/GS/XF#('FKL?1R?/"I]P:J@\]O_'1:G>[@
M:CRV&KTKVVHUKMK6P+;[5N>R/1A?C5N=3G=8"N/';M2,%#=&BAQ#PXYQGOA.
M0HKYQ183Z/^S+./[)/3,23!;&9;U9G3@?N,A'5BBYY+=N+[QE7;[7\R99;'T
MC"IRY]`5*<^HG5>??B8;IK>GRK%WLN>C)$TV"4MR@/!F<EXWX?]?&/8R%FF(
M:TB&*PGWT*="Y>Q%D\CBO`S_%25%HKK7_MO/QK]&7[Y^N!I\M`8?/_SZ^T^&
M%/$15W+@S2Q$@B_F>-ZSY\R6#8V-/='HSRHT:FAL[HG&L$*CCL;6GFB,;U\0
MC4?/G3<>CMW:>CJ98F-T)[/OF)"(G>UX)@;&/YV\VOBLV$;%:@2&ZYI:5:1U
M7:[IIJ=G1RI&#O;)%H7]T(;DJSU7[;G:\]$YZ;:7[XDF1"]^A_<M?FF97?O`
MQ2^E`;9O-AKU-P*KW3.;O<8;`;9MMKHE*%XLMRZRG6_]CN/9@^CEO=A/+5L]
M;YIVO;?OX5^\+'T_&5B[83;:>_/K8X.V:?8;;^=H^Z9L[_#<T)Z6BB59E;)=
M32JZFE)8=,;3W8]%`3NOU^R]Q?0+D_C^(+;V;N5S-"#:IP]BI\S<Z3C</+QQ
M2N7FJ?;\UO9\6CK(L;EYZF:[OS?W/C)O`-I(_;?BTVK4S4;SK?AY[);9KU>.
MGB=;3Z+9PSE:41<OKX<\W2W0[.Q-!<?F%FCTC\6P>"JH';-3/W#+U_(!#<3<
MJ._=!/6->7TR?&O-_7,LRMAYH];?NX'FT3@+&L?"MO8$\2D>GR-3NP[GW7IS
MRI;.M([-4UVQK1,`L5ZKVQ7;>E:VE<UKU!(7^:.Y.JE7Z1FWA0^I8<DT=9$Z
M@_"N7/3\66XV\-()8W?J+GG?,YJ]QQL[9M@8_S_ZU5I9V&X%7MFBL"\L8DXX
MQ98R0S4U;L3;!_!RLN>;T-0;-#OCX:75;K>OK%9O.+0&5XVZ90^'E^W&<'`U
M[/5+41&&_Z!V%Q([%/_4\&-<8:<%.H4RML7(;%L?!DAM(69\8M?F/A';5N`M
M)I:ANW!"UUOI;9G88ND%*\;;:O)6&:JWJ>J+%SD>O"HZ(4Z8S^8N=MF4CYZ]
M2S<B.M[H8RIYYR8_#ITI3F44FPS"&\<7@PWYW%;J`N7>B-'9KFR\B+M-/!P[
M*7I<PB]H5F6F;:-@4')@>*8QI^@_FK8+H2&^");LQJ&W!<KU])2M3?6FGBD+
M.'NG84M.IITS)D<?SXR%ZP%0.+(]G9^E>IH2T)9X;R9G</(OI7T%J?WLIG:F
M:@.FP!4U$XFB`#N&L!E'OA_XJG^I@ZV.B$D)\$-V@XU1J)`:6UR!.-AQP.2#
M7.B9IAZ*R75:-[]<T[\O<G#RE2"SQ/%P9&#CV=B@W>VV.N-&TVH-!@UL?M>T
M^H->WQI?C6R[UQV,^_W.GTV<V-=X_\OG[O\U?[-[PV<8BK@_Z(^<EA@]?FQ@
M;B<CT?#K,[:Z?(;F4VX4M!IV]\\_KH=_@GS^<[V3Y/K\3WM@C[NM=M=JM5H=
MD%;MEC7HVF.KV>B,1NU>O57OJ\&*_5JW\XBYBL^,H8>&+OX>Q`>=2CCHC`97
M[6';JG?AM=;X<FQ=CH9`T:/&5?_JJMT8CYJE$.RMFJ%C1V?T!D=5R21YVA*O
MWB"F#/]H9GOCN5&$'09Q"'&,W?#F1K-E-II]L]EMP0*J%^PU(ZD[L&Q:*?V1
M&-L=ME1$)3O7T!I6.)=/YO]V09+I![M6KVM*KVINY?J&3WUO01!,&9OQIMJJ
M\R%H#S\T6[4Z"C8/9R*_&,8?Z@*M6CK7\YT(LUT#(XX:[(`)=SM">0BW%P6A
MXU)#K1^:]5I3`F@B/O!A*;8#[(E-B@+)6FHQG$-0H]DSZ_6ZJ=J)8=<R7*1K
MFZVZ#4?=S3;\A37$B5UN.]GT7"_7SE7,BH>7?480J5GUF]Y)03$-NXG1!K-N
M=S+DEVFO3//E,]:/N)&*4)65"!1[MMYIG?=/Q`'B%KE[<)L+YB"#*P\A_>:L
M%!Q`39TL-2&5`$`_M%JU_B8B.7NW3B9PZ?#D6YT"LK#MNMEO-TP0=PK[J!W"
MF^+TKG:BBZOUSM%$&=OHXFHS7<`:L#-D7Z#:[$,7.ET?)3'\,_&RU-`KY.1V
MPVQU.F:]V=]TKX<[G=]PG5^[7,F?WJ(>PNT*SY/]SP.E%QI39^G&-*"`L,LM
M)_E%6,,/T*(",X1/[)T;7YP[YAN76@]SLC4^^-.:<4Y_!-JY3B81^W<"/-1;
M<2L-+@C:;R"`;>*F<>SQ[HSW#AHWSO16VAV\]V"X`*Y,RTF2E/0Q02*3+0RY
M*-R$!XEH=Q.3X\"0:1>YLC^KW3)!#S0;#7FMRD-8USC_)#L9>9VZ)*]IM&J]
M/*_1+/8B7M/NF-U>;YW5@&AJ-KMFI]O+<'J-TPRW:Q>*5JW&.HN_*.C:*XYN
MP]@-O"-(U;C)M-DT[*AA]KIML]GHKJM#N,/<:NC_$/-I"C_"N93H24P7`!M`
MXS`9.,1T;@1=UX)SL>%<)@FY8ESR<6!?4F!>'SY_XG;WK8/:'&]?>I:?X4`'
M4J]UVJ1QB1W1G)2,J+$[U'>XGI]'H1HI.P9.:H![C(L">8\\U_CHXCR=]7$[
M8I'-&%/(3GTU9E81Y"O@Z=&J`$7'[,,N05KM=":\=RHL(0>LH,-4?K0-..W6
M>YE>S05KKE,8(>Z?CI\XH8X\WK39+KP_-V$013F=]@>[H;38`HG<,UN-KMF$
M*[2)H1<083FXRS`AZI`SD-"E`SQ1C.G0!/_&BR[Y='IP&H7P&479:R7F-,UX
MCWADT)X31>[<Y3Y*1TW6T2?@R$$U,^[5*QA+(Q;FPBVZU66-D'\.VM]R$PL0
M9)(/;*'*M7$_0G#A]:'FP\B0U*01?KUQLA+*E]E?222T'/T9/DV*41]"`T4@
M<6><+463K<@9H+7KY1X#"_T`^*O?J%^O&,?"!;UHA,^75WN+#&7^7OW\B;R1
M,I(A'($7ZHGAS^H:(WN@2\'EA#9B2IO:!9M738N%>Q!?"]DM+(UNV4S8I&9\
MWG'@#JR3';F#.DR\*[]&R&DOD::,\"<$_4KK;H.*NE%K@-V5Y=*Z=^Z,T:0#
MA,L/?-&P6@ZND6,)@LP='IBI@FTJWG1E*D5*^0T4MRQDUG#-@6'2U`=8"006
M:B/X/\V6+?[1:-%R^.]VHT'BS/']9$&"8\F;Z(.:*$Z+`)'ZYOTM7A^:HX0>
M/,\)MXTFJF4P@M*5CY](WXR"E&NLH4+!F<&)[D%9UR_%9EV:@^:YWYCUS?4E
MW:DP'Z.6Y33#CJ@^B-)91-N1G%XF;0+2[X$QRP!)/":%49]FQ>D72#W2)N_E
M8:")!!FRUX@>#Z1\9/]U$]]0GB]3_;NA4;NB==W(TL^XB/<S"O&"QD%'F#60
MB(/8M39:_.@@P__&J1;RWV`"X_+T#\YH<G1/9G]N&!<G43GO@I\;MW^XIJR=
M*O%=L8:0W<I7M<XH(SG+BLZ=FX<IN\>"C-C`O7$QS"UL8"6ZS\L(ICQH)T><
MI+,`MX36D';X$&?)J7(V/.@;,1,?`,7^[%WFDFY0$W$5DJTDW85`4310X$O2
M$,>U;,0(YQ)\&N(<^)E^%KHNB\\2P^.O*D\H*#H8\%/#UO*?X>>SS7TBQA90
MV'*QT$=E;D'I^E`ZLO(U\U[W"ZUA,(D#_-)4IVJNI2B)N"U<6D"RSG+IP8+(
MN_,TRB=I`JO"L6^4(K%&R^I(4-%N]D&`V+U:MPO_VZGUVWA5?NC6NG63_M[@
M-TO\$ZU!U*'$D63<X*;.!6`1G0]LY`);K%F3%#5UATO"%C^EU+!F'^9"":B>
M>2P68W;(((53H>L,Z[3)#UW/..\VJFKK7CV:3(?WA&A.FK)V)Q,]J!F#U(9#
MX8_K4Q+`?>C&PCW\`/$K/8]<1@F0/A]/*MZE48(XSL)"/R/G$8*EYBW6U()S
M?,VVA->[[?T0H;$)KABM@:\[/$!_8>X=#^8K6[/75/X;M"ZDM4G')5S'*<IH
MSJH;:?-'<#_`NC2EG.<AI'X?F82PF?4(5X6'F"CD*H_@*3D]9A>&(=D%2B;.
M,,IQSPH\XVH<+_(A<:D>F!F:)9]U=99/GM1=GSS3@G'_B&W!IRSBC\T^#;H-
M(R:0&P%2XQVH5=KLG!R+UIBP*8Z@4M.NZ*4B?Y=@-'"Q/>&5(0"4E%2S@Y5N
MNGUFL1#R,4^L"QE&"1S8`VJ\Q(+C,'`$#U96MO1V<P.:QF)&S!>2[09A8&*6
M<T`BR8V*(-<3F4(F?!,KGO\C^0PI];A&(,8&828.3=SQ4?L7AGA>N\-XHO)?
MH?5@<5.3N^)KV>FTKN;U7>?D!33$=8V=J`@!`3-"\XULE/5J$)_,:PQQIJOP
MF9N($4"-G#`,2/5O0-$5"B:-!F1SEX]?)CX+/T?NC4]'OTPFP`,48Z)SX<.5
MN,62DA#GJ,)S1!-GB7`)"FXN(6N7#M6MFR8G,]\?%R#`NFZ#D";[Z8-@-S@'
MB!NW&DI4HA6@?I36K+9HD51%]JW0D%?6:0XC-R05*:$9;><$B:95%Z]=H/T)
M_SI.B-8XNT.O#D$>96]W4XRW.Z,15G3/2\.+QVP2HE^W8)R@TG,<,<_*@A-D
ME/^AA5N5]K,^8M>N]10:I.<W[]W=+/N-'YH=,`ZW*CZP0('JHPOJPRLZ+:[H
M*%#WUW@X`UJ'^R&-A[3[3JV[CFZA^KB1=F(%"A`LL%4%VJ@`[9"WN'.JE9H1
M/)"\=>PY-R\]&]A^_\L<6!SC8X$S6U$[O$(['GX)4#C>_S$G?.Y!QO519]QL
MVK8UM'M-J]6HUZW^J-.WQN/A97-TV1B,&ET^$=32IQAOVM?Z_&7UR!A^\WRC
M3'?$<I-/8,[.7L[M::>1VF+`-*4*ZGF;+S1+N]X9V.WN^-*ZNAK;%D`^QD&6
M5U:W,^[WAD-[,!CB+$Z[_HA9VIM`RN)CY(28AQI]9J',DP15X'7R0'?$0@NH
MU:ZU-`P4`I&%\P.%0+XZWP^9G3EJMNS18'!E#>QFSVIU.B-KT*[WP4BX&HY:
M8[O5:5V5(CNS@THNQ80`(RS:DHKY'(-VGC%+<RQR#OB<7JYU;M:6N$4DTCGM
M!C=BT+]%B37&E+,Y%6OE<X`9R!C,[PRY)22C9S%BRICQ,"W7&N!79#EC7`W^
MQC48+O*Y:I?P0(/';ISIROC]TT<R,\)P!1_"(.A34EOV'%]TJ%.K/Q`O0%68
MC`$J;5DL`U\&+S?J-S.I,:=E7(!P.3?V7$:"719=B'2V2"B9\%=]5,!%-2CU
M68=$=>W'#XGJO=ZXI&XU+NF!=Y]ELDIGZ^R.0B:=DSM/;%52'<,.XY;6IW0\
M>X.8$L*<;UGYK)16S83)=8P89N6V)K77!?'Q-X4\QCV?5ENEL=#8_ZA=U[A?
MBJ?#@?E./;9UC?O%"7#?<1!ML]E^*]TNFQVSW3EP2X]3;]-S3;9JV:C_J:WE
MFF:WL7?#GF/MI]<TF_91=`@M"^UO[J$!6@B&DN%:'!WI=TV[VWU[I-_M'07I
MEU<0?`J7F`8Y"Y.;HZ9_NV\V>F_N`@#4O=Z!)=YI,?_4VD1?_M%1><NL=XZN
MS_M3@6Z;]J'[O9\ZE]>H_G6F.#Q=TO=[;X[P>]@LXA@(OSQDO@P9=D5S`__H
M2-S&HOVW1N*VV6H>V&]UZKR=*H2/CMK[G:,;X?(<M'Y@&;8+K2^_[Q"V?`%T
MYF^(".I1VD0FHO==1/0*SN"Q%'_H;SZ>3"HL/AZ+IZ6T_(J=2_+92UH4=#_6
M_E)LO&WVZZ_#R5\(PF[?['8K\_-))/XOQTMD'8\7W&-Y=JFI^KS?,AO]O97Q
M?>8BO!1D76Q`>AC(*N6CW&*SPN);5#ZV)U_AF(PC53ULL[/_&+ECT#R:_0.#
M=_QJQ^,S"[4Z@#W3"ZOGWF3:X&?L&>'.,J-:2LT?SY_$(,NLPSZ!,58*[!&K
M7A46RZ/`EM?9L-F?ILG^BG._.<Y=)E7C"4;9CVDIZVK/0?9['L!NV?JY%]=I
M`%_E)XG597MS[]<PZDX9*R>H^S1!@LZ"9.*Q%Q3;^W^TM-K/B>'QZ$;9YCHQ
M!3>^^Q]8ZFX]J$+-<:FO'5,"!"0'+"+Z((C>=Z(A%;77=B-C$82,&F)CRVM,
M!_>#6/39#1D<X7_X\%'L=(>M*](>]_2*>QL$,SX8"1]U>".\A9H!0*-(L1,3
M+''N:G)\GJ`5+=KYX?A-;*S_W8VH&DEVRXC9`KO`A=@!;.9B,RB&D/X,2Q6L
M)=\24I-]GWH)-;6G_5'#2NH\E:ZJK<F;4.G]-N@C^E>RRY_1J!S>PIO>FSC3
M;Z+9B#O7?@4H7K)PX<:Q&IZ:=M(\XXTJ/.?^9]K!N7N7_:*Q]!S?ITZ>,39O
MQQ$^M8U=M6$Y?YO^@)O!X]U\YK!"$KMTZEH#$]@@C8TRHF0^=Z<N]9X.DG#*
MVXYE\4^8H>\23E67^TD0?,LV0*$6D:H+RATU9L8%"(\<3I\/<P8"BV3_ZR+R
MQS^A^$008>-G::M'G/R:Z15WPWRL>J.$V`W%0*()ZUIY!.]-]ONGCUE24=VU
M:9>\^1L?LZ??1'X&'*H\1+GUS][EO\"H4_(<#U%TU9\QM<0LE^.;CGX5J,7Y
M,81)V<@&$:PV(5"5HO7LG4)L2;H'#C+M#@W5MT<_6NRQ3Z6]LC-/$2K7!Q[:
M[9Z:]<:'&.@/G&%3X'JSUE+C9-*./\1%[^'78G808OK.`:Z01)R(X>4)%O7[
MHK-?H]ZHPUMAD-S@C*UF*]=$-`M.1.#`&A(@)"-)*]BZK]%1HPP%&1;O1EZJ
MAW93CM/&*Y*HT0N%/7_R!\W'*J?X63MW`%<P*HX(,1@S#MUIK+B=&L^RK<EJ
M<`\\)+IUE^E'G1@6FB0TU'HJQ^4(Q&Y92!MH!OQN\$!/3Q.;JF.S?'GB6_%S
MG9:[`W8XO)X+@D@TW@7\GKU+F:Y`"KS;MH`JNJK/)DX-P=:PQ/[Q9]$<>!HD
MWBPG,OC8+)P9`E^=.)$;B4:HC73+@.,?;'67B!T2JQ)SCO$ZVJJ=-KY/VQ>B
M2T+`Y;6/:@IGB\BS;F")*#8*]8%\-\\<#^C6NEF\TD?I+DV84KW$P",Q(EV>
M,'X[7=P2?8(M.;"/1J.DNI0Q3D+,VC6QKRX\P!OG<D9%0!'U9FDWRQ86SHI+
M3D>#%-Y6`X\$+>-1`/L/?2Y_%X#?1;(@<E4,C%[5^O1&ZN372\2QK5E`YT"Z
MVMOH228.#)6FW/@Q.;<)"+JCTXZ4LC,U<$OW0:[$-(3L2S02*/N>IKE1)SI'
M2'1Y[[5CH_,60SJIJWF!CJ1=D9NLHU2%_8D)T3W'#TP<CY2KZ):Q6+3#HU=I
M2![-S/.%:?$?%@9%FF=J?_R8Z<-6(D&#Q^A/86.9AOI\O!?.`P*;9.'$674Z
M90"\,7G6JKHGSBB."K0UU/=7TF[*B"V\@TD<D(&#R])\)J&-"<47OPB\K^I8
M)]O#M0[:L:[3>7S'NH.WC=O\Z2V[/?I/5UW:L&.97=_:L@R;%Z,3BX1,U3KO
MA0ZE:IUW^-9Y1P%SXY"WJVH7F`N._N&3[4<-K**,3P2TKE27(BUJK_C$4P(J
M>S8T.[>;9LNN[_3R,P7\7P'(_MXMVXX#P(;9;U35^H^XR=?2^0`KG(L!(?(^
M"]MJSPR'5RSRI=R=O2O:7YC2GPILI_[F>G+89JNS-Z>NTO)_/MO0\#<=#+MG
M:MYA$F;V6*&$N3WENT7GO?:+YC>^)JAM>^_JX3>4\SA4\^Y0*P!KAJ:UD#/T
MM9C#<QQ_TZPW6V_N>C=;>\/\@M?[33#_4]<FTFZ^Q]R]]+QA-AIOQ6HX;S3V
M;MI;<8<R<H>R\(*OH>-'#A_J/`TB#**+&<_'QQ&:W;UMZ^J2E%G!>A,H.W6M
M8PNGT?#.4\,ISU;9,,?'BMJ=2ILOR;VJ4/;&59Q3F==P;N_?"_78[)U>:^\1
M#<<&:LOL]0]CW)VZ1D%MG*E,S,%9QX8;L\7QN3O/F[W#>+O+!^J;&S1V%'W:
MRW*=1_].W'AE3:@6$">8,[`7CM(3T6T?>,16^4!NM`X\7K*$(._O;JH\`OB9
ML>.&^/E$CU=B2M,R5*'-8/K-N'?"T/%C50GTHASA39A\);Q>]IO+E#IO'\;J
M.2T]X8IJC7F1]C,U27_%,[=;9K]QX/2X$D+]%D=/=@\-\@EVI#JI/I(5%BLL
ME@6+IVY<?%"9TM1_.F(_GC^M1&)/UGTJ[0XKK%18><.*R(FU=*SP6.&Q3'@\
MNA:C@PT-<%2C..Q6A',O\)^\S0T\0FV`X/7$UYIC::UQHJIKS<MUK>G6']^U
MIOUZK6-.^=-5@Y2J:TU)#Z7J6E-UK:FZUKRX`^<R5:1$.\6]%-NG:.)[=C6Q
MS>[^[2Q>*[:Q-ZSM_NO,LGX56`]=EWQL@=KM8Z4^B$;IT8_GLNMZ=$%-E#/]
MU*E??R"Z.;_X)7]ZXM/1T?^3@[?VFTMO:Q]%)F=Y)\QM9@5:P==Q,X+^4>4S
M5$EM%<I.7P,92E[#YP^H-O`TZ"/UV_(>F#2K@08E."_/@=X$<54HJU!6#A9V
M9,'GD\H\JK!88;$L6#Q^N^N!FCH>?WZ2!W7'Y_;N`5UOO8[E=%BX7L\+?&BX
M#N[Q/4$!?F+9.A4>*SR6"8_'ESWVP,A*2A[#,+LI\\KB`(<B/I@^MC:AT:YU
M,S-:X1?-,S6RD0]=FSMW00AX61GN8IF;_*N,.1R/R>9S-J6YB.E`9SF!S43_
MRI+_U5O5C(&'B6LWMZ8^$GG#_.49BW':L\]=,C0.C@_KW322F>];3F4^>[<V
MEUD;Q`TX0:I=FWU\KT9QRIF$-*DP9',:6DBS^6B>'$=*9D#=O1O?;I]VFD=5
MBJBMDZ@3V%D8.["T]I;TBFNS$''*[831B$PQ3I&&ZA5@C,\X%U.0B93TP:N9
MD9FP@)A36I)!@^-`'[/*&UQO&_2*5T;>G8:9/1U"&9*&/I84?NUBL@>+8ISN
MN62^X^&D17C(H^F%G&X?.IA(IW&:G4W#(--S<R,B,K7DQB/(#/G&W:YP=C4<
M])D:&)LA(&"I+!+#1?'VT1C+#'_(3)5,MP2[B("1NW-WZO@Q7)UT,K8B;:#^
M[T`S]\R[0Q0L`C^^?0II'-'XTDU7E$^BE"."D=1X^W7]CK,X"8$DYF&P@)4:
M];J-V":^S@?V`G5,_L*S@E^S[T[*^,2,<J*.!+AG2%,_:]NVPU=/9U';=7%7
MQ(<"H&B,L\$2VH=,`P>>&YP_TR>+7>!T9?A0[)F)W"7)S-E<FW*K)O%&1-0N
M'YJ,=*T-3X9M@8B2HD),K5_7`6;N'?[X]Q^3R+IQG.5/O*3KJ_-]Z$93^&(2
MLJ]`GY=>,/WV"[QE_%T^^2F\<8#V"8@K@`-=!_3#P)]]QOGU/@?PTWP,&/&G
MKN/1:!UJF%^PNC$%RH<?OK#Y/]ZSP/OS\\CN]AO]EF79+;MN_3<<0NO/ZZ_#
M/YN=]I]XT':C:?]9?V^XLW^\=V=_=GJM7J/3^7/<ZW7L=GMLM4;-H=6JCR^M
M2WC8NKP<U4?]*WO8O1S^B2_^@B@0&,C?@H43WKB^%0?+G_B-$K_@&ME/1-5S
MV+`5P?7_R58_SX$`O-5/6Z(UE-QFUPP=@72JOSLT,AG(XQ,_=!D@4>EPA3=6
MVVMGPU81L98+K-V/?VK];:^M_^9,P^!7YKM34("`3&K&.=*HNBE7/Z]=GN'/
M%SB:ERYNN`Q",:N6HD:><X]SOP'V07*31+'B35S(U.M9%HPY^\;4<V$#CF?!
M7;I!.I^XP?+6"1?.E`'GAK]05R-\?AY,DX@/_IX!M>$T<5DQ,(.;Z05+^)%N
MBA_<B3'4@1\`6?K$=&)W`EJM:)6$&HNSI$]$=,N(A0`KIWXJL`J.5D:%)S0Q
M#`;,W,/_%1/ND=$$[F*1^`SW0LGU_"*[/NDO\`S>?#>B0%H6[AO0.D.:*H<W
M?NDN&>"`\18N`79WQ0_/\.XQ7`09(G\R#);`'&(G7`$K=#G?05ECB14YV7$P
M@4"FMW[@!3<X[W<),A2`7$@YZ:)T]%S`6H1Z6@BX)`0`E>)CI.C!X@I]J./P
ME5W!L5)\`NB`ZAD\[+%IX@EH02(*:.!5!8\I-J"/MD9VZ2(A@U35)MD#R*1`
M(&ICA[OD8$\"IT@G"!Q'.IV$M0`>2@2Y`-CA)D:+"/DOSC!W9C/@8)%\VT(^
MBD+<@`<]C_DW3*(&21CU`I%MY2'Z)@P_OF`T89FFD8L)RT!"*&IV8,//S5RS
MK/MZ>LMF@/M/<SG?!!C^@$9AP_H?U2QLLNZ>GT/W[*M!X_*J8=D=^\IJ=8<#
M:S``#MT;UZ_HG<'E^$$._<)ZBJ;'$8L)?)I(+RS'0K4A9R<(,XZ/'#<R(\>!
M80`=525)LF:H\U!)4NJWS/I-Y/OVXVN.>J]7^'/P(=TG6F/R_^KT_W8J/.AL
M+3RHZGQ>X@Q.HLCG60%^Y@J?4X^T%HYH)'&Z+B$/GLKZ6L^5>L^GE=HH/5#D
MCEIWQF1\BB].@'O&EMMMLWGH3/O2`-OLF.W.@9OF'C_3W7X)^#SLLE'_4RL)
MFF:W\>9:I3?-YJ'+BDY+`*13'#6O(350/N89)UW3[AY5'<TSW??>49!^>07!
MJ<SXL?MOL3$N0-WK'5CBG1;S3ZW-\!C'X[7,>N?--7=OFW:S!(FSQ\SE-:J_
M8WYR?,W>FV:_]^8(OV<V[!(T/C\FYKX,V=0]SME'MMELOCT%QFPUJPX13]/@
M,0?AZ*B]WWE[W5^`UDLP^.H8"H!4/.Z%2B:?_,''$TB%O\?@[[04E5^Q&F5S
MD<:>'31>BG6WS7[]=;CW"T'8[9O=;F5R/HG$__5<(\9>Z,S/^RVSL7\KJGT&
M"K\49$#.S?V#`T\>D%<I')7"<7SX.S:%8WN2U>\L/E9UPS8[]?8I:QO-_H'!
M.WY5X_$9A%HB_IYIA-5S;S(]\'/(EHX[X[/O9BX6[Y6;/YX_B4&666]]`F.L
ME-:C5+HJ_)5!:2VO4V&SWTR3]Q6W?G/<NDSJQ1,,L1_3^M%5-6JW&BI;106+
MQ>?+]6![^A?+J?&<$@:SU+W6I6Z]#<.>C1(V=5L8.2$.VXH^L_#ZU@G9I1.Y
M4UAHZ'I)C&L?I-N"W>IVNJWZI56W[9'5NNPUK<OVU=BJ-QK]7M.&/XT>[H?S
M@MT6""N\XH+C10J_<RP[NL"N(]B!81'X1H18Q,XPV)&!'G6H!TI1%P4PTZ<,
MBW;I'5P>%^(_S9S8>7-=%OJ-IW59:&]IF;`FD>0W7Z_+PBLV>#CXIZOF`M58
MU]*=2-7N(0_P,0QT?5:`#SK-]1A]5@];_!E=9S_+_@D6P9YU]N?-GMFT]ZXN
MV\=7]0I`-O9O)7`<$,(A'CK7^K1<=!]9%/V$30?=2/09GAE,&'F4S#:5S8B7
M3AB[4W=)_1/@S8A-D_`)/NC#>(;V6*&$3JP*92=0`G'^)&94!76/,BA9X:_"
MWVOB[\T9&$))03<D*"FZ5_6PL?'CL3-.RZ;8\U-5>+.<DO^4@G,5!BL,OC8&
M3\L[P0.I]PSY+X9&[UCHW+"LE#>"));S$@XJ\9]J#S:Z9K/7,OO]^F%%Q.M"
MV3%[K:[9V;^X\!B`M,UZKVDVNE4_OF>XWMMS(TJIQ-NUUMZ7N(0J?+U6;YT.
M.`#-@3GL:0G99XK9'9A&*[NYS-`<3=RMO,)PSTB<%H<[>T=)@0'VR,(!8-;$
MF7ZCL:[^BUWQMQQKJM!3!MV\"KN]P;!'A;\*?Z^)OQ.W"*H@6V4L5$&VHY7S
MIQ3@J#!88?"U,7CJKH@J['9T5F\5=BN;I[$LEWDTG[-IC&/>J1C9O6-/3MU_
M.O9/0T^LT%.AI[(R3L^;4^&OPM_Q>Q/+:U^(;C&5A7%,RG=E852B_RTX=RH,
M5AA\;0R>E@=BN%,3M(.*^"K1E\"I$GV?(J<?U6[Q49T2-[5;'"?8DO\WUW<7
MR>(+\V/'^^RL%O"/:!R$G^`*40[@1^9$^0Z.S]9\<=0;]QMMV[:&S=[(:O7M
M2VM@C]K6Y7A\U>VVFF!:]%^Z^2)O5[BA^R)'FK$,@=^X2\<SE@)EF+LP8<;"
MF3',LP3^$]\RPT/D&<Y-R!@^Q?LO!O/B%FL&(LJ@]HM1<9/&-]>$L=-[6A/&
M7N?Q31C+T([PJ"UP(.-V&06N;79:1Y%'7J*#[!ST()]N4?<Z);"FC_RR=DM]
MQ@W3WC_;[HW>VE[)3[39*\&@MF/R@57AAZ?QTY)H(#VS7B^!O#HFRC]=S]NC
M+/XG&.N;[/__29P0#"IO-79]!ZQ9Q_O@SX-P0;.F#V3O7PT'S>[HJF5U[<'8
M:O4&`ZLW'@VLP;#=KMOU_K@U[&ZR]X]\'$#[\9;H%N/UN7Z_Z=-;=EM]>O_?
M5WWO'^B*3I4H45*D)O?:?_O9^-?HR]</5X./UN#CAU]__\F0`CZ*:;OP9A8<
MP>3HCY/#*;FEPF%C3QSZLPJ'$H?-/7$85CA,<=C:$X?Q[0OB\.@Y\L;#L5M;
M3R<36#!A/3$`*C?VZ<6Q?=3>-,6#U^>WO.2@BE=[KMISM>>C\Z=N'Y7\A=TQ
M/]DSA>0)Y[1OE*ME=NW^3N^6:!["GL#VS4;C=1)C7^%@>V:S=^#X96F`;9NM
M,N3)EEL7V<ZWL-$&9L.]O/+QQ/C0>=.TZ[U]#_^%9TD]&5B[83;:>_/K8X.V
M:?8;;^=H^Z:,Q3XWM*>E8DE6I8Q/TYCDYQP?BP)V7J_9AVD15R806R^:Z_LZ
MIWCZ(';*S)V.P\V3GUI;N7FJ/;^-/9^6#G)L;IZZV>[OS;V/S!N`-E+_K?BT
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MY88=_`I/QM$'_S,+W6"6VX38'OL<NE.V/\X3W^5ON5'0:MC=/_^X'OX)XN9/
MWL/PO3%C4W?A>!%E8N=/:&"/NZUVUVJU6AVKU6NWK$'7'EO-1F<T:O?JK7J_
M_6<;3ZCQ_I=&MU;OY([G9;"3.Q:XQ.[<G<+;@^DT2'PL:OL<>.[49='SEZ/U
M[,YXT!Y>6NW^J&>U1G7`4:=7MWK-9F\T:(^;P_[5B[>?Z6E]63P99ZH9U\EB
MX80K[!ZC8<E0:#(DGHAA%0>D#K7I3L&>\1\N_@.[$T6X[\]`M%BZB"1"D?W/
MO(V.A_TXY_`NW%DJ.:`G:/-N"L:+`[2Q!]#76[K38J=L9LPEXX?-P"]X/R"`
MS$MFC-H`.?R0!)2_.=,P^)7Y[C0RC0_^M$:X<.'/][>!Y\$1W_NP:I1,(G?F
M.B$<J:F_9/SQW[#*1W?A4GM3>%?_X_^R*!;+\N[LV)1]O=]0HX$Y_W@WS$VO
MWSN1L6#A#393=>-;ODL_#C(`P"+T\,#S\(]PLX%C./Y*P8RO`2<&)C(EWF#<
M.K"C"6,^O,L\`,-W>`<W#:OP8(T0?266FR9A"'A%[%"Q*T,,&X'/8)%`EK\:
M$;M![->,3_E?1=18:<;@K!!I$;:'6\+KZ:DXOD%5$LO0Q99-DR")X3S<Z2VL
ML'3PBZ#>1].0P3]<)>`-ET9CWCFN1_6I\`<Z\NFMR^;:SI!51_C\POG&0M.`
MQ^2OX'WX)3YT$P;)TD3`\&]8@FK<!O?86DK.Z#3@"@5).&4<KTX4L2B"YV`-
M^!3MRI^R+.KN7'8?$7V)[>`AX-OP++!C^A.\/TE@(5A-X%4BSA18@"L\8W?,
M"Y:XK47@!U,O\!V/4!>[DV"VLDA<(_B@<[$D1GI"?$QQ3P"SD\2!NU@DL#BG
M)2+/(,&O`VZI=KGV8E>\D-&F3.L/(`)@6:,H!@D;"Z9:5FZT##F)(GW!II'^
M-O`DNI;A#`^$+C4L<,-\."_D._`WMB2>HH3*4K'H\U\'@\\70('_3EQLH0R?
M(9[-J0R(%$G;8!)C=,9_);.;]-M`!+&#_^N&TV2![9>G-%@VOG5BP^&C)'#O
M`$T0TCX6DFT2I<?`!SW7F;@>S9<PX4&*V<KAM.P[ZBKX!_PI9![Q%;RU8*EC
MVS98!U4'@(LW8\,E\5EX7UNW!AQ-H!0Q`#N*=F#X)EUCO%#4Z>T6F2<V@\-[
M-P&D;$0,;HHC!L$0$`OI05QQTW&:QHU[1[PEP8/`';HS<<'Y<0`[@U?<>`4,
M$24NW.N;`-]`[RJ\'RLN@;P8C*B$<U;80;I=4VR&XR*(6(I9^(8X`7@[9-,`
MU!+\N&G,'3=$FRQAF<.+8M#>!)>8:IHEX@X0/F?`XV?\*9`^J&[&Z<&L3.EW
MB9WON"MXP9IZH.M/"2O);"7((/UEC-`C,8=@!$3:_.*4"*9TW+^EQX9L$+E0
M%@.`-N/6A6V%M"R2&0AEO$+`W.!O=T`HP,7XXKB)*$H67!'FM.W&0`*>"[B2
M?0)#8';`/5%BI-T"\0SUFP%"E<P7Y/F)%Z/(2CRD9[@IH3$/@P6G33PZN=47
M9)_;VB3"!<(6"IP8@(6@4`QT<A.*".@?_9\CX\/G3TCHGZ9Q`$H*:B5-,\=>
M0)IX[G]P;'7F&NFH)K$))+\@^X]?&Z!#6(0H$0G1)2SROK!(95E!>8,$EQ)@
M()9UD"J8L%D0&!2^?@"4B<(2SM=//[7Y0[SSH]P>?&.RHK<N`S":J",DL%0`
M/P3")F7+]9>@@-`A*ZY2(^TQY3$)OT>P9U!E8.\,B9!?8HD0@:W'X6,B-S63
MF])WSL]%'L,L!SCI/CK@_+:CPF_X">J@7-T*)G\)W12/$71=^>/<$6A07`=,
M/1:"J@&8"+^Q.,_K(B$[))`3-XC9]-8/O.!F!<O,DB@&PXGT4-J[O,OR,!VI
MZ6D$BK7/LW18`,=4RJ)@#8ZNDB@K5T[$U7/ZQPCD,YP'BHA2:RVI:B\.DR;1
MPWD!EXQ3G>'6O;D%U<1S`2A-\,(2K@_'FO`'A7T"_-B]<3FEQ#B%:L5),F0,
M-=;X-D*.3?>6;C6>-TIT?&H)6O4M=FOE#'J*F&0*DS4C13+^"6^`^B,'(8JE
M+"?C/.:$,P-E)@(!P#5>'394&$#17@FR-N8@"00H>(.0X0`D$\?_QGE='G@W
M3HC\Q=;T_:"M0XK"#(D;E`K8TW^(6:!UM_1(Y2;!2"H&7"\R^_@M<);+,/@N
MF*RZW64A]H$T++^`40L0HZ>VK&2>[C5,]\HU@IRFB(2(Q^!S.A$:#Y`B\3K/
M0\T8SS35C(5:F-%*)XY'>GUTRTBO10K7QIQ(W=(4%\`GH_*>7D$K#7M>Q?/$
M2RUW$@::"+Z'"T4T/0>=1>S*18@4<.C"8'QKGOL-5)[;()AQAB]?(),97ED`
MDRZ)MJ(S(Z4$<_S2IN5YH"I;<*)DPCOPFYO$<T*N7'-)FF(8Q!F\ZZ,2&PF1
MF"R5Z@CO"[F74;9UO1^.FBM41"&B[;0092N!8A!TH""'9``9P1V9=:BBNX`4
MLGWD$409)=97FJONM`&%W@\6(";EUH!(4-V/^=M380((PVU.'<HR!ZU_I6;\
M'F@$A[XEM!C"&??&T/ZW=,4.I%8H+HL\+KP\3@X+XON`P8!H/'L))'&7A)M]
M`<8+6@CB$KEX:3F9?D?H_I(38,;M3&!=CK#OBT0?<CQ4F5AXQ[CKS4,#$JB3
M&$]J/J7.,FJ;SHD02`1UVY@H"SX(RTU1.U5,:B!,YJD'Q@!\GA-4J/!*HCSP
MI8FUC64"B_VA6:^;V``'O_Y#J][F/\3;Z1,?Y@0*'UYR5=9;E87(QBC$_R55
M]#1."69:JD*5FO!("1%:DO(J9/FCK@[FO"?(70O])\*S*3SU>96/^TA10R/7
M#GU=DIVI:TGX#1?=G&&X0O(56]R=9F8)$_:QB[DD(.(M-+?HL[&8IIHU55-&
MC1<HQ)&KY*O")?W`M]+?D&!)[;,%W"M@TIN<@81111TJM`2K7",#A8L7"9/U
M?#RXOKS0PT_JB:M@QMD`2JOSP?75A=%KU$U!1'F*_$W?%`(P3!UV&E72.KC,
M!=QX_B\RJ-&?KVNI)EJF()5=N-(H&C3H;UW@+Z#DKPAIW"<E7$::]T\BB31G
M?5WN4Q2^3Q!L\#-9@LJ_&(FPP0:,\Q,4FU>[0=\9Z?B(_7\GCM0T0I:ZOL@`
M18=`1($#S>EA<B<`&1-DS0@[/?4%:WO)`*"<GSKPR!^!BMT\]-(HTEBLGWI6
M^3W#D`&_E$AS-+V"*S%H?*%(N`DPDK7_!(O.,0ZPL.OUOSVR4>C?'I.%C`EP
M\DVM0ZG'YK&^3*/>:.R^D/WX+>2_^Q%#18:MW'PM?N4Y-;GKSC`,/MV`7>',
M_@(M%G[W[R3`_Q$N&AXBP-$H::2-^\NYTXAS9\X-W1E<-G+4%M-X[='9/Q6%
MGBR%-AY+H9P-BS@".7\%J1<0+-(G!IW)BXJ1ZQ"]D>E/$U2(\>PQX$2K3F$Y
MJ8WPY2@P0@LB:4?NPD4+LYBPN43/W(<`C;KLQG:Y(K@2R!!:*]5]0'Y]$8$?
M5VW7\:)`RW7`\)"02,H3S;?!48:[X`'D&?,P))2@QRE*G5!&F/KV5R[S9ACX
MOU/XQ$^B(`K",)B074!GHW`I%35L7EC=].JFIS>]N?M-%^2=RIS$U^B+J]AQ
MG@25B4"49XC\`1X\%@NZ_EW@(3%'6@(7#S]K`1`5&=9&BL&N'.']HX@(7-]X
MM9:!B]8$8H75;FIF)AB&-Q4-%KA^:+!P*4L>)/3@D":'>KQP]9`&!VS"XVYW
MU$"!4013EX#ESG8,/C,?C/HI.=H/=]=>P-6GK,,-_%`<#W?(;C*H*,:E;#%R
M`R)Z4^(2RK%^$![1I@I`!5+'IO#@PF`._%:=^Y+R*6L$B!OEM'T],6,M+4,1
M&+RL2,R)9&!6T>24*7LC9>8Z,66BB(BJ>^#LC+-R\9KG<I-2^*G7C)XG>$9Z
M^_'>0Y%;?=NTP-WI:A-5P2KWK!H)^'R#&%K-QP]BZ+[>2(+JTP?Y]-&W_7YZ
M\_8'^H-O]-!M]VKFO,=/K+<^^F/:B/W&T[]</I+:/@_@?\@.59N@^H](_>SZ
M6>*9A,:/^9#&@.O(OW&+-/<4Z*P/K_`AM7T')).?EV!+?@1:Y8C:R2<TS!]&
MW*?4!LH]P9T7;Q:/#R+N#\U\W($^#X#-HV>CAS[/KT'L>&^*@J6#_NW!W'B#
M,.>;5!Z>GY2\R</V_IY<,UBWK`_>>NBUGJOV7.WYQ+I+9=*U];2>%[_5^[9&
M!).ZW3KPH.P*VB<8\P7[V`WZW(OKV%`.6`I7/><.*TP]+Z:.7Q?:SD=_6RM1
M>7FUZ(D=&1L=L]XZ<)/9"NK#L(FGK5!"?E&A[)58;%D8ZI=L9<+1<=-F_>@F
M[KTQD-\$4ZA0=A`^NOR^@Z/_!:YLGA\+!RFEJ2COZ'?A'2TXKL>RU(-^\/'D
M5.&OPE^%OV/!W_$[`;8'1"@^JB=,/%IAW?&Y?;V'[:[9Z[].&^0W#=DI>_8J
MK+P%);(),@%;GWCLI:30_E\LIQBO,%AAL,+@RRJ3V6X?`,4M]5C_QWN[LYF[
M:L]H:>";7JB2!@^3(O_RN5CE/J8MB6U/_G+Y2&J7%'F#9\8;54+\2R9R&U4>
M_%/0]S#BJCSXTI]GE0?_=F"N\N!?@I\<M=NWRH.O]OSV]GQ:Z49'GP??KYNM
MYEL9S'M\P)YRK*/"U'-&A<JM";V-+/CN,5V8MPGUFTA%K%!69<$?=19\JWY4
MM8IO$.0WP10JE+WY!*;3R:*M\%?AK\+?\>+O^)T`1YX%;W?,7N]U2K[?-&0O
MXMG+[OYQ_RJ7=GH*&"T1ED]-H3VE7-X*@Q4&*PP>.P9+/LE$B9_^SU$ZCTI,
M9L$Q$\O073BAZZVT0>6P1&Y&JKEE`F8F])4?#)T...&C1V!5&HLYTV=:T#R9
M.-W=V3M]?WRTEIA3=:Z&P%UL'5I%<VJVSK\JR_S5J\#'G+0PG<IXQ2?9?G&C
M;[3%,@Y>O4XF.#4Y=AT/"(?F*,_UT3)9JIMN2C,YXT/0Y)!@.3]HX?P%9YH=
MWRH'VLOIYG_X+A^!=HTS6X'LAGR@<&3<XF0P6F="HS,7SLI@WZ<,!Q+CV&T:
M"<RGV$1)B"-MSG"06G#GXE18.`.:52/F$\/"OS*?AF6O3#&Q2?Z)5IXPNBPS
MQA9R;O>,+6A0NS^C-T(&%,I,>-()#9R2LP"00CC=DDPX'Q>.R:4!5\L`Q\[S
M0T['T60&")W1T&1%P#1\5\QB1AA3I@*7%3ZRI*7P$9TD8!&-*/@TU8)9ZGQ&
M*OV:A4LGI'OMT%QQ.29:3H3FXT\W4!`N?X,3T'T$%6GPAL%C?'#P+=@"$@`Y
M&+PL!Q6$A/T5$%)D,!PQNV78!J\GDH.$&Z88,%5\07'0SD0@#H?",Q_8<D@3
M_6@(E',3,E'`A#<+18SSC<T<X_.M$RZ<*4LX]Y6$\=%=N,2O^6,7)O!VX._\
M&P$.HL*;R\([EX6TQ0_B@.#R&%_8%&[-%&?TRD?.Y>!VG)QMRE]?X-C@7UV/
M.3/C>DJCY.'4/_C3FG'.?PT?O@S8+<[<@E4^P'][M\Q=&+\N)O\%[YZK/\*3
MG^?N?U@H%^`_P:]'G@OP`-WFM"+\#P`,C\(3L!@]<T'0_`K8\H&1!Q$./`Z7
MN!_UJPO@*2$6E4A$TYBY4,Q/Q#%?`5ZGJ9"Q@"R&<[&,&WQ)7@B4H&&P,/ZH
M7>/(+T7/*37SZT*\5(P)1N+1Y]VKJR4Y,0Z;IF4W\_*45(*0[P]W4'R?GG!O
M]AP_]1J#O&@(N9II+.;/TM#+2$R]S"*-6&O(EGBPA*\%R`<^+]2N_XT.BIR)
MDCS@]/UT7KD8\Q;1M%`<G3Q[:T.^>JVG#?GJ=!X_Y*O_>N.N>B?\Z:KFZKU=
M+RI-T2V%_X/[K[8Q0K&O?BR4_SECX8GI']4A%9</9:RY'9W!-`5M5\?QLY[B
M7F^4"W/-"G-[8J[Q.I@[]9BO,$/V<EH^4PK7+M)\+<K5[-3V+B/YVZ&W^QP`
MMNW:WO'@HP#0[M::!P'PV!*)MU]09=X?W1UM]$Z<A!NM6N^D`;1[!^*RIRY6
MN<_PZ&ZLW2DQ0;^)[.T*4<^8%70\4IZ[^H^/7]@GKH7;S8HAGL(]+Z^FH$)S
MQW;YZ[5^::_&L]S]$^=MK=Z!#K"LZ63/'.$L2.\P')Y<,G-B]G:CF]W.TZ*;
MW?;CHYMP)J\68SQX9+4*7[WO;.U^5X40JQ#B6PF$O5((\=3U\*,-A#4/%$8I
MBYIZJ$#?:3F0CCE,9-<:)TW!=N-``)XZ3]82CH^.JNUNB=TCE>?PZ!C\*T0(
MW@25E$5(M)NEUG/**R1XD4MU,4[U8H#V]!)Y8B_GIMY:2OLY#)8LC%=4EC3Z
M=^(NL2")-EC&(MK,=IG<+M5A13'5@CFQ,0VBN&;\L:2ZO-CE8\2,`#B1XS&L
M?XNI)I+*MF7Q\\R-ED&$Q:QS6AL?D>5ESG2:+!+Z-[P\0Q_]U.5U?_AA6#](
M:\NH7%8ZZGE)ZPK+T1(OQD#`C>/ZL`;LQ<-"-S<2=9/XX="8WCKA#:]G0S!Y
M36;-^,*6CLLKQS`N@)6_#*LT.1!4SVFP[TOFX_X=+'.:)B$L2P6^:J]4,C<-
M%LL$/\=KQ'&[41PZ2/V6Y_K,6+#X-H#=W#%>.9D&,>!E58F>1&R>>(;GWK&"
M>195N&%;N*&]1[AARRO%OS]U*7S%Z3A43.#%+;8FKRH^=4/@.IC']\!B3@V_
MY:7M<1+Z;IR\`LKM^MN@:5E5'W)%(IC/79"FK\=*VF^5U#\R)V*W@3<SW`7V
M$^$-$UX<_\CF;H,PUB.ZP5S]V\-MJA^Q/8_VH/82UXNT%]TY.Q)+X,,"M4RN
M*L^-CX%_8WVDG@E:@\XRF@1:XR92YO'_A/H^12V6]S.B9@[8@,9#P#P"3*C^
MI)&CSA[.2*FF/CC4-@`;W$2R0\O@^DH+]W?JIK%F1)G&9\_A[1R*K:D:KF+`
MR[`Y^&O(1-[/^J9$CYP[E]VC:8']FM3YW-\RGZ&"CMT.J',3F@[^#>_9-'5#
ML%>P8\64FE3(O"#^*;)]G#!<H?JO&OLX/O\R->CQ@UAN0*`0.\E\6<,GKI7?
M.MHT"SZ]>69,5H@+,CJ<T(UXLZ8-.R#+B58`\V>>H/R#EQ/8?,3[U\P,'_Y(
M77#F8))$9/-,1?^/"3-NJ.E03)]5JW%KBR]\$P;)LF9\F*OOWU$W+=[KB)--
ME"QP._J'T6Y*/VMFV_G`4>0;=FEMNCA<'`X6>AQD?2\#6$,[60X)HOW&=_^#
M'2P4-F$5"1A'&OQT?^M.;Q_&*'T,#3@-SL*V8NMOU<3]YUM#^U>WE,G\72+G
MG,E<-,`14.:F<\8>8^I[IN'!?15F+'P@`HL+/XBO;V[3(PQAS$W('D9Z#K.4
MUF&#]_A??B#0K*X87^76F>$?Q>^P$98%M\U"5\$3>K'T2M>+90OC]^%^,N.K
M\YV5E\L/V9RA3\.(G>_:`6;ZU5$W'D4"$X>HU">:G</KU.P(B#B^QS`?W=2T
MVQ6G8J)4GW\$7G<CY2$23#WS/73O8"\VR>Z43X7Y#N=,L%!(':$XM7G.O6#Y
MTFFC,3#@W0SV.>4,GB=V:AOG;;OT=[#;31B))E_B56JF5HBKLVQW/X1,B`WJ
MDY/NU(UT!L3]24@@O)D.K,+;Z7`PJ/&;?#>50@0<1X%HJ<11)+4+A_QH^5WR
M+\^2*9N9ACL'=@]@1TX(<A58G4,L@UQ9>!;HE2)Q[:)<)SZ)";.>^XUY*YXW
MBV*,;Q*W3^>+$B@4S?>$([!@'_<N/,"%(&P(U,7_(!RJZ1NY&D7C)H$JV8G0
MH66HV1W^)G:^,?ID[JCY[['!(NX"T<=`X*&/KHB"854$SN+`60B<Q8$##0*U
M9Q1R<]E_3GQZPI`8HR3B;0))["&\F?TM&+'V6_(-ILMQKCH!>3IWM\LD)`]B
M^NBXC$CSX8R>]K+Q4`(=L[P#(#I(41R=82?+./8(O[7-;3F7@>=.5_@)N@BH
MO1GH&,4FG(+:ET""'M&ZUB@L`9H)$2491$0("%=4`I\3*6E.1/CXH/"OEJ4#
MYA?>Y^K5^#6W[1I_6V/@^I;UG9+V*.Y);M.O+5IT`X+<N<CQJ*6<WN&/,_\I
M$D%!:[]L+O]<=!V<87/68"FYWB+P@RGHR]ARU8_=23!;673%.2<*G27U!"2*
MCN%VH+*+U,I]%/@$$:C'OJ,2AB:I:%B'#".2/(!E-XB-\9#:%WC!X%W8%&KK
MI--'0G]$G5\4)\`JY^Z%;L`2R*#U`DS!DM\5C$],:%7U9]SSYFZ),9O>^H$7
MW%#+PR7<1L#1`EXC^8$R!K8ZGL+KG^`;"_<_"NG#Q/&LP1Q$-5H=7YCU%7D-
MB>KSX>#+UPMM<=@(`:!#0)&]2!D5N;WH?@?Q<N9MV4D0MZ*?)W7&Y9*4LS.0
MB@B35#DF[-;QYJD>K-$'MT<,[,:Y_F>`VA3LZ]R]TS824V-"/YG#AQ$*>',)
M(F'J`5X0#K0!Y;^1CX8@J(@2TWB7VD'-^.RL1,_2(*-!DYFR1D04=4I)!%BX
M'S+L7$QA&'DIYHRHA$A$_,"^LW#JRK\A1Y:?Q1NR`VK-[!N<P!Z-!5/N,1<]
MDVMK7^$2EP02C^3=NNQ.JBUXSX7L6+AP>^+`%UI@&*R$I($7@9Y`AXDIV@@7
M]!-=7"%,2<QF45YT:26FR8V!]"N-H[-W<OE(BRJFD4>-CNY((P2=)Y)$)MN_
MDK\C`G7$G;M3L)J#&^`\P`>0C80ND$?:"%-ND<<`HYQ3)&4XQGAP?4F>C:_!
M$M;IU-M6HVVNR8"S=QDIH&4;_":8DS7B<M\8A"%JDLH;2.OP-K?IAV`]^E1O
M_5,;/R3/S?B-XISZVJD?"/07PFJP?A-`BT)UCBY)(!]63^("Z;-9VW0!BICH
MN3U?">F@,6)QXGCO4:2(QI7I8CS>S15@)KAVYGV]<BQB<-3X7.*[_/@UJ%*=
M<IV^)74CG0,AX.4QQ<;P33!*B)2UO<-*3)S8+;`TZI)J.2#B>(-A]"@(:L^R
M']Z4V(\`'VD#7=&A%10ZU.VG(MH.ZJ0,4V^!RDQC]LYR"9>=&%.84IVNHTO(
MR$:AI[E>R``7DIZSGRI9*V/9S%2<-YMEZ0S]&9FXO1'?PQ&LEDQ<6$6@\,$+
M=`EY8+?>9;45:C,=+!;(OU%+EV:7E/>D24=L<\_;5,A2A.5'Y,N"=9(B0\IU
MS*A!<8(:@<SK@'7%/K@RCOWQ8<L.=J.63(LK3*0%1,9YF-IO@8'^'C2J(@TL
MN>6+GWECYPNA9`3^CTH"*=9+C'9*LL5''QF0DAO=XO*H9)EDN#Z`IPR6-,5.
MLFYR)_HS=R9;1>N7PP(V+RQ%`:'X7NK7/-,F!20A=UE(N2M,\V*DX$V@1(\X
ML"22%>07):'SK^2T<[C/3BA5**Y-K@T#IKB2Q*UD1]KT7",Y>Z=[[1'J5,+"
MDDJF</LTU8V%IH"^R=3(1_[$_IUPWTM69K\(IHI-K+Q92+)KE!+[1T%Y)32Q
M,N**ZYE`MVOW5)-Y-W**`#?%4XUH_9WL\60Y$=H(R"\40Z(`#]S])?7F!S&N
M&`L99C?H?*/+Q^4*ZKZ@1@;:-G*R-_4N;#<V<`'=W,BJP!E%=J.I0:9%QMC8
M8FJ0ND+>KZDCPF(:]T"X;AU`H^(?L'%2$W'L0"Q=?K"DE35EE1J:X62\A!VU
M4JZ2<N-.*4_E8##:<(HMU*<LYZRY(VUMU/E2LX'F5LS8DO$F\4*[HD=3[B,7
M-N7@##+,G.QT"/(\9@QP&;+33C5+WQA)!#EEGJ43.78DJP@K$,FQC!+)9S=!
M[!(=BR$Q7,M$1IQ>1#F:@H*0>(ON$0`IT4%M#6>IF7$?)-Y,I#2:.9L<V[,K
M[$ESB]3O(H54,[?,O(%.2W'[:Z59F/SF9DUH-W,7:#1`!OGI->!&6L%%>%CT
MDT'*#31YOMMN!!`O[5RXWO%&WCGA*DV_1)$MGD!J6J>Q0I97J%I)Z<\M5EV9
M3YU?PER/2&KF+CWW2<`OUV'FRV9-1H1$DB/Q0,'_G`CIA\QOW$9T2VHX!E(5
M?]9Y)"<S;CAGG6Q"]Y$7K="54C[FH^-H%L`BZ`^?N6"AQ/QZQ6'@\?@//P3-
M;X3,0=T1W0<1H(.!?-48X?'X>"A)./)*E`0#_XNPD9\5CX\\K0YPG_O\R2EM
M#<&3*AHI`XM@!D:TT'S9=R`H^K=ZXP'3FY3X`N-[5],[_WYJ?.]N>F_F=3N;
MWA@,+#:^'S*]T9/$,[H%JX?/%ZMG^BGPT4WP8$B&.@4[)=>WD%D"!\'[CG?[
M_.OGT07YC!UX!]`OLPWP4^+S_./HZ+P<77^^H)`?6.PS3-27WJF`!BB1,RM=
M^E_7GT87Z">`JX-HO'-<3\TZ4F_`EW!A$2)*PVK"BX4)?TZ<GF=&")/DB@'R
M"%0O5`\=C^*,I'P*E&NDHKR+BFCN\40PKXVB=W0V_&@HK%PS1M*R1$3@-DFY
MO`N\.Q(#OL.1GN7K?R6S&TWV</])E+KV*;5BBLQ1IQTQ:0X>G\E0%Y=<"*N5
M8EJ^F2JYG+EBHR+Q)^).;+'DRBXJ1D)ED&Q8<WT1IS?NX:!Y`!EP[Y,"H8Q9
MN,3,$TJC5*M!.B0+'F0XRXSW$4`$2XSBXMT"Y4U+#-*S<]*\EIRI3DDFI'Q-
MM!0F$,@89$[]1_`N&)Z,S>B[)'24N(,-KNN]QC()H\3AR3L:.:#NS;U@^)C$
M$1ZUJ1VP=HSRDFNI7-_8BLM,B15TNLS6R9GHG'1'KL\;D7OCX['R;#25&D#'
MQ-UKKLK&TF]YUBTGDB7$!2F,(6&5R1KKR*_*<Q>V<D>X7QG%-^MF!)ZX0#:W
MYE<$W@YR+RR^9T()U)=U94:6OKVT,Y<C=5WA=H<MBL@\$2.RE330E=V<*7]>
M(=?3_!82R8B8##2B'H>CF]1NI$Q/*$:9:8$:LRE2^/@ZJ#EP'KCY/&58?NY^
MIY(C`D-X4K1^8H`/MMQ$(;J'EM^1A]RS&<GGA@J7>4$DMK]$G35$8T0;K*9<
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M*V3X?\)/P97,2`";6JE%2Z=94XJV<7:G;.,H4U[SY)Q1P\5Y\YFFTHB;I&6B
M(KW;*6(-FZX8_EOG.&N3@C,J=I1'+"4NTC9X5LE6EKVF/YK``L'V=,*L$(VX
M44<7"#,B5EE_$'?(H`T6*ZU3::QI(LB:XZPX^PM3XX,DZQ7(&OPFT:,?9QU@
MI/O*'V)&EB.IFNBCD=_,!VS6G)SB@IP]E.VRTE-=M@#C3J441%_O5&05B-\K
MDT8L0NET[FT@<S"W^9BY5CA!QC%C>[R.KZ5KD/(I<M`?GG1Y]BYE=<!!1;9&
MAGFF'LCU#!KAU.8A2S<N&J(I")-[SO`*";),EP5M`H="YG2]K/QPB>+\C$:3
MB07+NY'-#5"9OE*7L<25L[AIR<NHB7UL%DDS=QIG"C/6)63J(T+%'E7H/'LQ
M^?[3K2!O3MW2H9;>RC>@*46:(A3?AD%RDS)R$45$7Z;28TNBF6@Z6<@R]3Z%
MN^:>U+1,0HM^I.!'"D?)<AZ"(IW):1*T]HT/?*5)Z@*[4493S<P:Q9^$_US/
ML:8-*"Y=O&,X&N&L<BEMEZ]+I3Z4+IP1:Q0LY@X.-(>1.I.UQ,,TP#4M"MQ(
M;X^!-(T1#@I]21R8QB1!5*-O*A*.V#0E:=<4`"VJ[_#L;7((D`VPOA]AVD7.
M(MT,.9+XO_$2H'&$HX]95BJ*D`-F1F+B",@=Y97G1ZXTDC0=7%QS<?)PX@;>
M<8^+;#P,S13+R!+B"!296Y'UZ7-AN@X/$I!+"5OB\^K@)3!B>>$!$IHD,D%%
M+3E*X$4$^'[1J?&B%Y%K+G38?*8(8>OLG;H(2-&2/^`#6U!$7^>E,S'1%!?'
M'GH(F2_RL;F%)5;D=(0JW=3#(`"/MJJ[IWB3F>EJS7TTM_EPO^!8:XKF)FR*
MVWGOHKX>W"O#5NH+)6%O?P@DISP\*(B11](7J[%P#*(I17N55_E<30X]((7.
MWCV@T*;IAKJZ+&QH4%&D2U5%#:7E],A4W'4]0>H3VU)`=0T/8P4R"[0D!ZP'
M@#01E!T@+ZI[-D1Q<XY-I45E6LAO]\@X/#S)5J0DI)J7B5<22SJ%*LXY(/PY
M2IPHXX8GEII5K3A[0?:@>9@R_B53^)[Y8'IB+<*HDW!KO>WQP\(E5GL`;5EG
M<7S[*%+3@ZU*-NLQ12VI4#IWRT=,\6J)H,%U$Z<9:12D,DAV)"8]@B`*:V5Q
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M>A140\"9GM"42=59<[#3@NJZDO\Z58;OA,\/U`,W^D9V`9Q^FJHE`H-IQ;-T
MOY.J@-O+^F_2KR!SA3<4"]<":3X/7()Y+JU0N=,"#W3.(T,Q5S]*0EX/2N3-
M7/ZRDWN9>Q1S#C7-FJ8R#9XPP\%*=T_I">>3M?5N\3VYZ;QS>BWN=QY=<-^M
M2//*F-M&D,24EI.MU1$ZS^.VKFW\+%_CMHY%K@Y1#@*5WF(Z6Q1GEI=59@^L
M1)XB)PI\452APJ"\C+HHH8;D."=<X<S5,VOT^(LFD3)QHR*W<#1UN5MD:FKL
MR=1"]$(6<,Z&I"Z48LH`FG!G$"_IS:)6)`.[=SD"(0L*60E=62JGXM:\?\>X
M&T@V<IEI2Z8JK5Q4NY?YW#OUESS6B0=OQ/L#Z$Z=3=DH-_JQN/J%D<CT=I:$
M3_X>^):6:9M/MBP4_X9LIG#V+E]C+TYCEK^>&QU6HEX.B5EIJ<I'M\FU@!)*
MA0^+V&Z8L=0UG7%SH6'VPO,4$)*N>.<X>1=$QO7B)J1D!C?LMW5<D4-9BWCJ
M&YZPJ;,6WE!N:,HS<"=)+,L+I<&5RV;#>ZO?I2B72*P.9QZS<#.FS]YE<?TP
M.G,;66/ZJ6$K2DR*G!B:JPZ_Z`>I.$R$^T[YER>>>^.(P-CF8SK;4H6&QU2R
MBI(OLDY(:,W&(#4,2EA:4GB;MY0Z:1GXV;`2:1J9JA15%Y&K>.=))\JKG4T&
M)W>_JBHI+K(M<L:OEWOE:K,)BM3=MUNFO_P*_"]L8R&,XL)JM%Q1,6F5XC5N
MVJ'LH71E(?+.M%IBX8-.*]@$`-D$U#]4B?E9MER6HBTRRU2E>$GX"\HBB#ML
M257*U,'!Q5<4<O6S<&>K7PV1G&@/6FG'15&V`@=0Z_A"8)-AP\\4T;56J9`R
M^[0LGO==4R3F3$F7$.UQ=JPR7`-2+E\`#?I<?#:[X'M5.T5%.%,J@742=#L6
MD]3I/M<4/A$;*XGB\/66&;G"[6VWW\VFE0A"RMHXLM4%58DHMV*6E#^)A[BT
MW2!0W;E9F%;GK.U1OPY9<P^U-6&[.>34U%5(?4]D+<$I36^#@-?%I<2F0Z6*
M7(M*/#:5LZILJ521R*1-*05>SX`+%)*R>-'2J:BO($](T=.W<]<YUY8HG^&S
M0'32$L2H53MVE90MDI4$3J2*)W9HBB6IC=$FS.720.%_8F"V@I=H1*`Z>?`]
M*(>'7F&Z6+@BF.PN1%,]F>6431G+:K#%^R_)91P_</ON2?DJI,;'L+V(5V[F
M1-O6JYAK%JBIM/1P:L@^9@=H9V12/*F8;NVR9^@P)0N1$D8A4%YTI0@I9=FI
MCYK;0&GH@VPXJ?FF[?JY$JU,&*U!Y'J>'XFQ#*G+(YF+U.!=44$:1:2:$XA\
M[U0Q$#DU&W*U*$W&R>Z0RUCR`&8$;/[$3<*;SEA4"QI#9'&J#!C=<$AQADUZ
MLWP?7:CAV=9R^8S+KC@SWLP;4=ELO?4<O8(:G'4KGJ<>??T\XDD1O*#`G1M8
M%B.J8G(U,7FVNF-5C'Y;4*X\LBIFFW2KRF/>;GG,-KJ@')='5\S@-C(U,WM4
MS""WTA+['U$QDQ?ZF0:C.U?,"*&1JYEY=,7,FGN:4C@>63&SYEYV"XI`'JR8
MD12J*4N/JY@Y>U=4,_.HBIFS3&%?/E?U,14SR#R*,AIVK)@Y>Y?-,.7\?^>*
M&1V76;'QB(J9LW?9FIG]*F;.<I4VCZN8@;>UFIF3JIA9TV#T<GJIE)#_<BI:
MOSLZ`Q:AB\UF?I&ZFZ^[<6+AG(VRC@9*V9-W<&>#+YL[L4U[.7N7U9]4\B@Y
M/>0^S#1M;X,(/WN7JQ96>=8`,4DB4@(+^\9P72^:`@:04B>@WY6$-O[0D;#9
MZ_.8LRE*?,4>-8H$#$X2RI.=ZL%*03:I19*P396/0^-_W&^=)LED<@J3/%B*
M`+1^H#L;$5ERBRG"3\PJ.LN6GUJ2]VP-@3Q^`UKL,*/&(^.D!&)S78]XD//R
M.@!R4E$[9%&ZF&^DLE%,:3*!MSP6:17);HFBYZ@&)E$D;\2%*$N.54KY%BMG
M2QJQ9M=PZMLCC?A,=$@1B<2/2B/&RU&82+QS&G%MW^@!:8P3EJW`FO%&;KQE
MT+HY^A:],_FP@_`*;`X^;BABS,NMAT3E)L=,5E%3,BO;ZD/PG*T<9U,T;Q?V
MD'VW]LB.,+F0%3=A4AY,>J1RX3S.NUN:UN9:2$M/VKM""[6T`RJ^;*H(IL[Q
M,YKGMF54Y[85^'@4H"(P\UW5A(L\P8NE%ZR8G@`MEL\X.2+'<T*9_2M;$9OI
MH]RID?`2*!5EU!HP$1FBVR<-.`;AC>,+&A)N$<R)H5@X6BFN&'I!NX5KY.A=
M%XDMQ)L+*+/)DYIGGEM)J"^)V/R9W@\:?Y?+NU29O$JXZ_UE%;8R-5]S4:>]
MGO^JN5T(:$N\-U.-F<E9HO<D!W(,IM]XKW=R+<$+4KL2&Y"9\33/-8J"*6_%
M1LCW`U\K;\BD<I]E$S5EZF59[C(>;LB`=9%2(@;-G'\,HNBBM!<YNV<Q`N(<
MQ_5>B-Q$N(EB_A&2)0ZERCQUIB>A:8XI3!2+5RIV1MH::C<4J5++H/N%%JIM
MW0LLAV2]]GFMYSL-%31XP?[F<4KTWTW>'+=N-\I".]?:G;G2[DQI"4??<*8$
M-UOHCQ;7^K"YLTSCVORXN:ZM]SC/8$-K;DX;$!2\CBVN:61G?45%6R9O5>HF
M-J435*K1%!$W-<O\TG-@D>OI;4#)VVCAR+"#EDVBOILM/08U!M0SU?&0)U2B
M^$"7+*^X$&$E45J&"ZA$,GSE3E2)J`PRCE$1S"F/YHT)%.A"M^2.G7L'ZU%$
MED$JD<GMQ0M8F396"C&2&=8MC7W-TN3?X<MFFAQ3:HKF9$TC'@]]%<D5]-]0
M=F0O^*;6;3]/5KJXDQ_BGLA,)_I,`Q#-8M27TJ$B(I4S@[",2,O]1.2NIW"6
MA`QT=1^0Z(E8;N$UXCUK^$V4E^CLG<(5JON$H'RZBDQ-42.S1#PI'[\J_*PI
MDYJ%P;1,2.^Z!;JC]HM@L<EHHA9H$1J,DG=$.OE`S)0*`U0W1\/AD19\F#9O
M$9_)LBEL1(AG+Z+,9]F6:-EA&=$W:X[51J%@5W(FE)F2"-JQ+I4QSHR5R[R9
M^I-Q%Z"7G:)?,N25_DT+$^,.:$,ED96_@Q*0T:Z,S\!-KV_EV.XRBLM+)W*G
M.=5ER4<<+;#JB3K#YN:AK?C)\5+O[*N2+?$FS4&Z#%X/G&F&?H2T?_X]0Q[*
M9I:#WH$;4.(2U(VH#:?V^0CK-RA"1O[3E*.<O5,22:04K76ETK]/JA]0,Z.6
MOT/72S@9K@.?0CWE\^TS,'-R=$+TYD::LKDSY)O@YJZ0#.*U'6>0('W`@J<*
M.8_3JJ($+!`.+A<+"$9Q\'6&&!`3:BC,*C/>"XU!G<-Q'H%QZ@!]IVCAC80)
M;$CUYW,"]BFV@,!AO%)H4-T%Q>1B%<UVYQ:<&Z`"$9UN&@7+CMO>N&E2YZ1#
MD@`HB?B14T30-'C(,FB8!=;%DLB%$PEU<W"\:<(M8M7Z,;X/+/+.2JSR/XF.
M*)3HI^AXAK6)%++@*3HT>5?^YD)F'6>[\TCO[]I-XZ4PLG$W^3[0><D-YH*@
M:EJBHPK&1;PC%1)14><-$IT!D!:_.T/RUU%;:@8;HVPC)65DU2)V]\54C+3X
M4NO-+7O&@[%GZ1=.,J(LG-PC(F]W*I2NF5;)"0<YL.`D!Q8<Y*5I7)G&D`OI
MH=4P!.&[N*\<J9[)9)^)J%'S9$,"CA@2[.F4X11-&@,3$P(RJW*\I0M+G`BX
MQ0!)Q8AQ$ZB3;$``+[?E!$7Q:/EA]5G2EO%1GNQ&`:4),](;7^.C1C`%CZ.3
M8\_0D8;6%*`MQ1HU2]A`7C5CD.9'ZSQ37A>"8;\3*L"F8EPYEJ^*BLCSMEA(
MD;2-QW[X_`FI\Q/0,*(?'0)/8%B-TDT_?D`+(8\K%\L[:"2I;'9XC3,?CG9.
M*F^01`[>!9RTO8S3_O8S[7*`@NM<_/3BV.7Z@?C&([%Y^>G+</3%NOKT\>/@
M\S6\1#&(9<3>&SB1)UHZV*CN'^_K_.<EAI3%S_?N++[]Q_M^XV_O@8V[-_X_
MWD^I4>![8T*#U/`I?9NA_L-,OM_N\2,CL.)9]ID[L?`DB.-@H;ZY^97G^OVF
M3V_9[=%_^L?L$84%--5[B*3>;P6%OINEY`>`S[VQ_5VQ7T'4\I[]OSK]/\/&
M:QMX[NS]&H:!ZH'4X1=V/4_,$E5D7_T?*E<CGX_S*U2O<K;8XZ"K3F3]1!I;
M#P3=H\^+\O(#W'QK`#=>_%(]+#I!R-T`!`%(N?]W=34:C<<;[ED<+/6_+/<4
MU)E*7YLM<GJ/!;]*J^WSIMV:QO"L!%#P[@\[B37Q(]EG]-IYLV<V!7D_]+(?
MW(?.\A_O^?_2ZQ<'I/)G!++1L4\;0CC$3F-?$'?;[_-<X;)<V(\LBG[*>D>4
M%R7C(<E8J!1&DS;JB][Q!PYNCQ76J4C9/!0"/=!67^P^52A[ZKO[<=LG,:.M
M_'87'K3\OH/V_0)HS/,RH:V1DT&I:M^%JE:`^,=REH-^\,`:;86_"G]/PM^;
M,S"$DI(+4Y)K?#^]Y.3LC-.R*?;\U&[0E5_-.37)WP1&.`L2N+XOQ7KW_V(Y
M95>%P0J#SRW_RR+M>2!5)A@9,L%H8SK5027^4^W!1M=L]EIFOU\_K(AX72@[
M9J_5-3O][BD#:9OU7M-L=#NO+^R/69G?)5NSE$J\76OM?8E+J,+7:_76Z8`#
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M;GGEN7[_%C]=M;RKFA"6[D2J)H1Y@*LFA`>_5$?M7E0MMXW/:8-K:N2_GXUQ
MF,C0'BN4,(A5H>P$.I4U3+O=,6U[;]OP+>95I%RF47&9X[HR%<I>A<LT^PVS
MT3T*'E-ZW>:RXCG'=8$JE+T*SVF9S6;'K#</'+0^2<WFJN(QQW5A*I2]"H]I
MF_UZ'_Y3@IR1$]!LAA77.:XK5*'L5;A.M],W6YW>,?"<LG&8RF-S;!>F0MGK
M>&S,9M\V^_V]>P]4F@U^1E7@7:7S52L&].9ND]TT[1X8"HW7*1.HB.6MZ#G_
M*T?28Z]`.;>^4GZ.E?=4*'L==MVKF]U>%:YZFLE%><F?EIAM_+)S`I^#!!IF
MO=\R^_OGS!\K[3>P?9K9[QZ5IO(\%D^CU3>[]1?M9?QR=04]+9_>$_F%^`\7
M__&%8?JAMS(^1%$"RL%@.@T2GWH,7V,9KA/.^!5VY6M:2N)>^?Z/W'YG2U7$
M!]_XS5D9*+U,K%,PQH/K2\,5D%S_8?P>U-2)X&-6O6\:&O!WS$\8%4K`<F"H
MQ:$SQ3H*-[XUKI((#IR%&OS&.:XJ%KJH&=I/\([GP2+,<Q>N[\3,@+7\")8#
M+FA1CV;7G\&2X<J*EFSJSMVI$8H-A&P:W/@N/@I+W"3NS/&G#/M"8[U4`FJ;
M'QN_#@:?:9V0+3T'_NS&?*..L0Q=?^HN/69-0.W#-&UGN0P#9WIKS(/0F+&8
MA;`K/-6"3Q;"$6)=28CE'TZ,!2=+QT=54KSV'Y8N1%\T`I\.`"X+_"J8PP($
MOE`Y;X)@%AFPDXB%=^X4UG$B?'YE!%,`#S!#;T_%`=2PW@66P&TY7A30GM(=
M834&;MOQC)D;3;T@2O"WDR"):15`/OS"1"0LD):!-/!(;@AW">`UC!W7CU=H
MFTL@\$]3)P)T><$]["YT(S[PEFIHIH(2T@U&)I;->,F,>G$#>\#3!.W;^"N9
MW2RH%`=6A-=!#?=O`%P`,/,G@#]BL89.4:TS#:(8GZ8SQ[[?L$8PP?TB]N:)
M-T=,.!JF]*-S(U&E@_U^\.`=WT\<?IK+(*1;O023``]CPFY<GRC"F0-U%.3U
MVVT35^[4C)$3>BO$YRP@H8X?\H,8UUJX<<QF\`CP#.PM!%CT^='3&:$U@F<2
M"5Z"%\2E5N4AB\,`+P)N%O@/[C9"R)(%%2H!!*+BR)G]!?A'U.$3G+9@R1G>
M,3A"N:D:\`+?N6'T(&Q07!M8&G$=X7D:]TC,?%FQ2@H2K)2_!<:M`[L0E'U%
M5V"E%.;^S]A['0Z",KVI3?L<+C[<0R!,@#=FVFE/^0U:X28`<RRJO1@#W5I7
M!ASTGXE'++2Y&PMM6K9M`B)=X"T.0,BK0@;75\;78`DLK=NJP]G>P%D3M84L
M`BRDA6=`'(FO$7WL?`=*]-G<Q0.YOV4^D`!6I05`6[S5/=:E&>>_?_IX`;05
MABN@ZWM8W80'([C7GA/2*O@8WGFD(_K%%"X0<$C]'8-]=^%^$7OAF^='!+<+
M0(67BX!5?,<W&%+YBDQL#E@10+".`(E3-.PCF:8(`&8LF")NDMB`N*H&P(@4
ME0$2>68.2OS=!@`1`8`VO%_`MWW^?<]U)JZ'^R;\GMM:42>>>,H2:=5E$$DY
MQ$O]:/M4!H@;Q(_S60,9Q'))A<_0+IU[A)67'H(D\ES>1OBO!/CJS.7(P'MQ
MWLCM12`8V#,<#ODR1`DB++0!<22@EDD(&V?\9)%L9P'C/$J>GL_NB0\B6T"R
M4J*#Z`$81DH0QKVC,]*ESJ=0)"`GAK?AFJ^8$SZ"E<(50ZAG+EX9W!PQ&,=8
M`+,(D6VXP"30:;R9Y2@>`TLH+E,2=O)5[1I@`R2B/D"LT0%VRND&3B>2#":^
M#8/DYC;EYX(I%S-54=XJ7D5$3D#9`@$><1H0Y*8Q=/@-4`^Q\@>Q3?I?`;X?
M9/#KJ/]QYM[ACW__,8FL&\=9_G2M5`2E8'^&9:<@,K^R[_&E!R;S+_"^\??T
MG602`>W")T9W^)WT,1+^\,,7-O_'>Q9X?WX>V=U^H]^R++MEUZW_KH,,^_/Z
MZ_#/9J?])PHTN]&T_ZR_-]S9/]Z[LS\[O5:OT>G\.>[8_7%KT+9&C7[=:O6&
M8^O2[G>M4;/=[W0'O59SW/P37_P%H1)`'9B\Z@7&BMVL&0H;!J&C?);(/QW0
MM4(2I6TA2ADP1:"5KZ$SHWNQ`-I%TKQ!3RV?]$(<A6OGCD:VP()<35W3^.M_
M.6%L74_!&+6^!"!C44,<(-<,04DR/BR`6]T)S6/`XT]PI!UN*`"O0T8FE#+2
M7CP/%.?023DRD"3SX=(X-R'CJA2]"<`!P^6/<'T."!$62#W-ZGENZ<"MC%&J
MY9;YY_#*.`?&,&/1-'0GI#N`X/D=5"*CAP85W`[2'+R5J?-`>>MML]]HFO5N
M-VT7-2<PM'IX`(X^PRVE*0.V/3-^Z+9K=0/DJ(>`DJI-#Z5X)6Z*KV^`*%T)
M-_5#NZZMEBQA/1_UEZ6SHA?X^@)EZN@V8AO9EOS:3NQD$VO@'&3&W)]('U]=
M,303O`^PA>__#=;6<W&.^J@S;C9MVQK:O:;5:M3K5G_4Z5OC\?"R.;IL#$:-
M+G".QOM?ZK"DW6@W6^V__[AQ7UG&-TPE\Z<Y'C]@B##VA7G(A*_01+K&T[]$
MR_,SQ_DAV&/[:GS9Z(VMJ_&P:[4NFV-KT!T/K7JKWVTTQ\-.]ZJ]%WO\W__Z
M\'5D77\>7`$7\H-PX7B"L7S],OC]>OSIRV_X>Y_!HY^^#.G)#[__BF]__]FX
M^O3QTY>?C/!F<EXWX?]?<![&^9GQ_W-`#_HYQ\?X+]?=0C\;'T=?OXZ^J"]D
M=B/9''W6NF>3;VYL(6JM"&RW;\RB$GWZ^QK/;M>X&Y@[)`S]'/=EW:5`6V=G
MK+7^MBO2OF[2]1I83*Q[TXEI?/#198>:Z6</=/QS?`I6P1_XS(Y[U%0"SG-(
MU)#A@7HZF3I2"G!SS+FY07,M%EX;NUDWNXVV8*_2T$.%V/7!X*##!`YKM^MF
MH]]-'TNU_0TZE,:?A:\'-KC`U]P4&BE3N/X&B\)96O].'`\T)S83;Z=_Y#^B
MFXN!0D;((8\N&8&PIS@$.R-]C;/PW"\3WQ7V.==,0=;BKM#UAAR9$`8B"85,
M<=L#X7E4')X.#`^"A%>(RY#.*G:=B<WF<`]BVNS6VTJN":RE@DEKC&B`MNNL
M-U)DWUDX=2.T6$"NX!(_U&L]&^'"57!A;B"EV^1*^O<E&$@S;IOX@3%/0CY,
MCE/,PEF!HHURFHM@!>T25@#\@'3.;UIL.4HF?PE]@R\&JQ0@BZOO?!MFJ@PQ
M,GZQ$PV=SKU+<C(BKPXL@1N>XE%Y^"\XMSES$1D!NI8DDF>D=J!C$'1_1-R$
M,<3H//&\58HO;F8#`(E'.I>+]VR5!67"Z"^$`J0P,BHFC%KG.'<.&.AHX.*M
MPV<T[RV'U&Z*>YQ>7G%C\?K"'_GE39:$*D/XA[%!3X)$AXCE*'ZDG5<*ELDM
MQF?FF:/4/!^S28B*M^ZXJ3=SVN-BZ9%V)10X?`(7^7>"WH8"ABI.A-\)EWL$
MA+>+._26I&>C^CI9;3;6B79N`P\(@5@OK-Q.KR#_!KFLW!N@>"3)Q[)OTAPU
M)M(PZVW;[+1:VI7<N#N=P&NPTB6+[^%^X-XZ!"4\5Z?7%\YW=Y$LUL@Q?^-Q
M.PE<N)#[P@+L$R781A9-63;`,8%()G-`RAEXQ3:[S;YIVQWY05BS:7;[(*0Z
M]9HQ3,B7@\N@*\9@VYK4(#@-<T=X4K:[/SS()3)R$UYIM]H88=6@X<5JW69=
M*$RIK!!&8IYE"EQQKBR=Z3DAFJY!")VQN>NK'7_`;B,8/)'1KZL`K-/S#U^N
M+H@/%DA=)90K_B-`?Z16T-2U`M()%$ZW:@5PH>L]L]5MJ4\\KX9@USJMK(;P
MQS*0X3ADF[I7XL/G3V;AI4V%]@-JQ!8E0FY@!S6B\$:@$H'AI8?5B`U*!'?M
M[JQ&%"D17/7<58TH5B*$AWF3&L'I:(NFD.*QNJO*.?=I&@>('A7GVJP:""1+
M.6TWI:J&(M^=`0AKTCG'=5.+(E(F<&I1F!B5N6<8QHTHYBQ,9,WZ2&T/BE-)
M=H`Q@P?D+]"<&[M<DRA42KG+#O^]Z3H)Z#&":IO]3MVT.SU)4"(L_^`N,#86
MW@DU)B5DD5@``A5./W:GM$TI'=$++SRH6M@$5V:8Q4#27:1IK#_&66X:3>`>
M2!F>+WZ\`60P68EX@\>BB`-T[ESH#V;A-XWSB?;G5JW^-\D8XR"FB,R#J-%Y
M-/RR2("H$#?:MHP>G6*#SQG@`!%!'.U\F@N=%7PZ[QJ5>2!*&;@,,'J'D@R8
M)MR1,%I3JI"GDMZ[3=@]H%3E-[*'4J6NX9HSH@'GU#4;W4;-^$`^#1$!XJ*`
MQTNE-(@$>\7E<05X;"?>[L[I%0X1RNYY@9,A9$J"T"&)M^B::7LP4SE%FX.K
M%K$X]C0Y0^$RC&13VH82P!LQ.@5K)%08Y%_,2ILH@8LD%G!(`<GRB*R]H9)L
M)#/Z+[!,X"-F%A%DNR/DN/5;YLV,<\HX\ES:T`6?7;_B?P9+B$C+^2Z.A?XF
MJ'U=.5%'B1_`$-[F'5/H;VW/CU/34AK3%;7=G#=FN]4T^\WN9BUF=^T,F72J
MGS5:M49#M>6MA+KF-%4=D35!2VJK]#6+%#`1.M:SK4A9(R8K$J)<.)HI17G/
MR449)!&<5G3QR-;&A\)XXS$8KQ_$MY_-;=VS&?-6&#8V9GX$"I\-[%U[0?=:
M3^L%W6T]OA=T^_4:,I_RI_?J/+R%HC>49+QFCUK%6MY,:^B3/J"3Z!3]W#`?
M0[/HYX:Y%/VBMUVUPQ:L[:(;[5*\]H5%P-.FW(LP`X/'"Y8+F7#VDG5L>\Y'
M`4ND<^!"IM+`VJZ_SERZEX>TU7W1XK3GN.YEO-R_,I\R,BF$.\.**%#[J=CD
MQ:_WDRN5S4[OZ.[YDRLUV^TW!W*G!"T&CV$L94:?>J&AP,_QS0,KGQ46*RP^
M&Q;?JE'P%<-[FYW,[#O^NY3#++&WP>MTLC@L7+U7,G(.#%6S!+T]CTS8O]P(
MX&?Y:&D%587'UP:IE'A\2M>:<D2?#U;H1"UA1HNE%ZP8*^AZI5KFO'KTN!0U
M3G/'#=,.,3RO2Z9W4+H*MB^)8G=!07B1@SI+*Y-XHD<2R=RD2\\!;>QZ>AMX
MF&U!"UF8-X$/+((9\]3#\+H31<E"9'*D)4@R?8"HN@KT2]"K0/]!`OWMWHL,
M?2[C4E7<-A_/:^\85W]\5+W"==:\.DA<_+5V_;3(]FOM>FML^JTZE4;?L8Z/
M83\@+"OP9\;*9=YL/R_2GG9-P;G5__:6/_HVXJ`IZ=T%V&L/FX.]-MEUNJ]!
M`OC@/`"[0J`_I]2GWK5V\V_J6Y;ZI]PUKO$2?K$"$-KVBY#Q<?#4+V[TS9J'
M8(YC"SFLT,!^>"\;W7\"F=FU7C&=-6K-5R>TW8%H;`*B\>I`V'(/;YGK8R52
M09^I%V;XM4:;-U!\A8]W7^_+:H4-6SA^C^LAZGU2<R*EXJ%4F_\O59LGVF'1
M3(M\0TH?*]B,&9MZ3D@YZT%H+!U7Z>"\>I<>#:@VG>J^9@'8/5KG(A8Q)FNU
M$^PV795E;3RF?V55S+4C4G]'![!C+)A##;U5`UDJX<+*1M%U6&O#>>>$+G=)
M8G$CM;NE,CE10'=+S0GF7C*->1O2\UL7^Q)B\;&F^UZ(*DR6,LA`O00+G+-U
M??G"F/$Z64=4D%&QH5Z]FK:@73%L3$#=1Z-D/L>FGP`/WPEU(<<V5,&]KZV>
MK5'G8"!]QJ(K!Y(Q@+!,)IX[Y5US75YS*+L%1^Y_F"E:.'Q'Y/*&Y%&,E8;P
MG);:3"0O/>^1MHM,;W=X6?M+VETU;0U?DBM0:O=Y^9G"[AC9@R>0=CY&[?R#
MU,Z_2.V\@'6[V">8+L(?M>N:\34DSK`BC?[L75H!?,_8MWQ`B0>+9ME*=E.6
M>#ND`9V)XN5%`/O`CI/8AAY9^V+BL4B4)(M[[[ESR9'$)TI"[F7D^%\!N0^?
MJ>ALBTB%G>LMG',=D*CX6V?-(5M@M_+$3^OS:S+NJG5-2KL]\ZX$>.+T,>9S
MW:^6Z5:MV!_?PY:3YTOQO@5*B<TNET14'$\MZI>BE=*"Q;<!`0#29XI##GA7
M=57^O54]?Z/D]<%/Z_KE,`D]E.M,@CN6E9;YHQ0M&5"G0,ZA";4D]`/2!YW8
MX0V*9=,B[/KMSAAOU8O!9_>.I=\'Y3%*.ZLQ$?\G/?'^-EAHE!+)3D^"*FNB
M:CV['W$?5.@;;@8:#$)0BZ74*ORJY-25"<LV+Y)=C0QJ&JH&@0#P+G:L1R66
MMQY"ALC;76#/9MAD17DW*F4AFR(`^MMBX6#CDBC3\Z>PO^C9.^HP:IQ_N?[C
MPL!!0'>H.:'80F98I1L\K"^]Z72#?N-IZ0:M+5'Z38']_NL5]V])CCCTIU\1
MZH-_NLH&>%PE-766CS3U]?$P'"'4_RMZ$5GTF]#X4>Q@P'73+#JTOVO*/U?%
M%2B?T0/SUO"X:XPDQ;>.X$Q89"NVOY`%!/+BX4?E4,,$!Y%D#;,-;YQC\E%T
M\=:.;B#[>>7P\@'PYX(U,,W]_E^8R+H#-EU?P::Z2CTO=M]JN/>3ZJEF;N[R
MUES3*TM?]&LVZG6SWSYP-5!YVAO4^F]NZG"GUC\ZD`_^W*D$XIO;VU!P1\[1
ML:5^MV/V.L='MD\$N]&MU0_<A.$8[^HQ[OET%:7M'$>:9\?'<\[;G9[9W__^
M71P7K[%K3;MB-:>PY[>ARHSUH).8)'9\/*8)>DU][]921\9B^K5NI<V<Q)Y/
ML)O'2;5+.D::JO9<GKM[G);(<[AL6_OI$"\D09MFN]O`J82O(D9?RA*Q:ZW7
M<<J^$(#=6K/,X.W;0JQEMNT#=TD]0;WCQ+HV':-$K/9\K)I'&?6,S:K%>N)E
M.<ZE>JYZ[K0M@YUB%%3N6F;MWS8[&)(H=P/:)YLXM4:IVP8_%;YVN97_)X/7
M-.U&-3+D&;C2OZ@HAI?(:O4V6"M3:B[5-)LMV[3[)\VE;+M6/^E[W*V=]/GU
MZF:S<>`#K-II%!5=B2'??`8R37U'#H>M^C*UE&(NM\C!,`W;;,`_ZZT^+($O
M]#H@:+H=PV?QAKG')M;%(=]T[YBW,@T7RRFG@?]7XD^I=([J+C/%=+*LE_?B
M^'+]AT&U6MD26U@%IZ.[.&9^ZD2WQC(,IHS-(AH3GQTHC6T1M`^(^=G.$E[Y
M3C67WLKXH5[K&@O7\^`!T_C!KMGR)]K%#ZVN6:_794DYX0W6R&`N"VI51RE`
M_THU^J+>018[4RVK1=V=LVVA@[5"[MEF4L51\#_8W1I(.L4"?NC4^C8_M'JM
MW\)RVC,QE3MW0K2UF&9[N#++?WTG:97YPWO)D93=JK4UFFK76K!$AJH:7=OL
M-_J;]Y5%CJPK3<N+J2$*K]M]$$_-6CW=#*SQ0ZO7-3MU_M0/O6[?K#=:^8T\
M.#_]C`_1YIM-?&W"=M&$%%C=<X0&!;1L\9WCZ62NI[CVD4E\!38@7]-*I],J
M;Q.A0WCL?JVCL,U1DZD+)_4MXAT$Q#8-JO]VX/4U"E7]";*G.@^24)3\KRN`
M,_<.?_S[CTEDW3C.\J>A&V%K"=CQI_F5AI$O'**K((HC*CF[Q*KTS\X*&[)$
M7^%"77J`DE]@8>/O<K$Q$,._D!8&4<3B:.#//KK.!!NRN"SZC??-F7V"M:=)
MB+0`#_P>X)GP'R^Q]OLKRK]T?>3$>'N_L/D_WK/`^_/SR.X"0;8LRV[9=>N_
MZW#(?UY_'?[9[+3_Q!.W&TW[S_I[PYW]X[T[^[/3:_4:G<Z?5YV&W1DW!E:O
MU[>M5GO<LP:C9M,:7@T'O5YW;-NMT9_XXB^()X&F7?CB=BT_Q],*JI5S3$LR
MI7':0L@A7!+->0J;1I1,_@)RH59`Z@Z*YD1T2$0T(;8C$&7BT=,FQ^N0$A_.
MP9(:09O#!(^HEU[#W,8:Z5(7+'=?KW2W^O1!/KU7P7*.FG<(/;YTK>+_J]/_
MVVWH>FMKI2**`5Y^:/RF\2/#B;?&/6BSD^<R[X[^F#9BO_'T+Y>/I+;7OOY/
M$F`]4KH)JMV.U,^NGR6>HD+7`2F-QF].^`WD:>XI4-P>7N$#-;C#UGQ<OWE>
M@BWY$5S#7]PY0._':B>?L!G1PXC[-(E8>"<#)YG:Y67RAO'X(.+^\(,,ZAZ@
MSP-@\^C9Z*'/DT9OOBD*_HB=.0W[#<*\=4S(B<+\M($N^_"3AXW!`R<,;#+:
M=TGKX9K!GBD\I4[+JO9<[?EY4X)V4Q,.<8>WA]2O,%R#_C:*V[!_)R[L!2W8
M%[_5>^98VV!2MUL'3K*NH'V",5^PC]V@S[VXC@WE@*6.QL^YPPI394A0*I,N
MM)V/_A;X;&4LR.%BS!-_]O(,]*D)((V.66\=7S7RFX/Z@7V<!K^H4/9*++8L
M#/6+ZN"-JNG1<=-F_<UUT3LRD-\$4ZA0]F8K:I5W](7:>#SY@X\GIPI_%?XJ
M_!T+_H[?";`]($+Q43UAXE`%2?MZ#]M=L]=_G9Z&;QJR4_;L55AY"TKDR_5D
M>?H7RRG&*PQ6&*PP^++*I%:HP:&XI<JB?[RW.YNYJ_:,E@:^Z84J:?`P*?(O
MGXM5[F/:DMCVY"^7CZ1V29$W>&:\427$OV0BMU'EP3\%?0\CKLJ#+_UY5GGP
M;P?F*@_^)?C)4;M]JSSX:L]O;\^GE6YT]'GP_;K9:KY.F\@*V+<=ZZ@P]9Q1
MH7)K0F\C"[Y[3!?F;4+])E(1*Y156?!'G07?VG^2X[&RTB,#^4TPA0IE;SZ!
MZ72R:"O\5?BK\'>\^#M^)\"19\';';/7*_6\T-.$[$4\>]G=/^Y?Y=).3P&C
M)<+RJ2FTIY3+6V&PPF"%P6/'X`/3G=8'<CS_#(WLC(X/BR5\`;/-/X5#-UH&
MD>-]FG\,_)N/.*N(?_4SZ/C3U?-/X1BV.Y?-]F7;NNQ<=:S6U;AK#?K#L=6&
M/XS&@_J@?]E[Z2D<=B];$3&1`LW%?RATX:051)-%>-)U>3<5@>F[^TW5>.3.
M.UOFAVB3J&B""/X?39O!T3(X089(:H5`N7%D>`B81X")>2,T!\N93H-PYOA3
MQL=@X0++,+AS(S&FRAA<7RGR;W;JII&B[G,8+%D8KTSCL^?X6-B`N22C?R?N
M$O&I4%?#50QX&38'?PUIITY<L*D).\.Q6G<NN^?3=@Q7G<_]+?,9CLN!_\):
M"OCK]-;Q;R@=WIBZX3191#$"@Z-17'_F3G&\$WT*`9LZ8;C""47.(DCX>3L^
M_[*Q<%:@9<5R`P*%'JL97];PB6OEMVZXD9S-,C,F.!S,H0%$3NA&@2_?*M@!
M_IJO@(->$APM!"\GL/EHBL_`<CB#B#)TYC3C19\".6'&#2`EI.%$DY5:#=8`
M]/"%;\(@6=:,#W/U_3NJ3&'?^<`R?"M*%K@=_<.PAOJLF1EE!/_VC1F+6;AP
M?4%XV4E1\!L.!PL]#K*^EP&.=E,GRR'19C=IV(15)&`<:?"3FJVT%:/T,7A?
MAU..;9JM[S>W14Z1M#588T:LE/%Y3"%N=AF$-)@S%@1Q#Y2YZ9QQ`)CZGFEX
M<%^!/B+^@8AYWL.CKO!VG?&);]G#2,]AEM)ZR/AH(#\0:%97C*]RZ\SPC^)W
MM\R;67#;+)`5;)>I4OL(F:R8`I8WF!*A`9Z`D_CPSRDODN+O'4I$]8;U4;W=
M&%C->OO*:O6[+:L_'K:L4?URV!KT.R.[4R^7B`(.!&CQ5L8'/@Q1X<VX!G8W
M<\)9>>74!]_X#7@K'PJ'5#L>7%_*L8Z#ZS^,WX.:HG5\S*KW-2'S!9D]7%$<
MJ@C+70$5A`Y.42-Y=95$H`:R4(/?.,=5Q4(7-4/["=[Q/.0'G@O7A61#Z/B1
M0W,@+9)>(#5@R7!EX1`Z+%]!:40;$-P)'X4E;A*7BTWB<`8J9\C(?AT,/M,Z
MP!X\!_[LQGRC#HA5UY^Z2X]9$X?/\J.Q;@XP,I1S\A+CJ19\LA`.(4WYK2=I
MX^/D,#5<3BY$7S0"GPY`LCQ8@,"?LQ#9PTT0S$BF8AT.U9@YQ#%!Y$T!/,/E
M;T_%`=",0%@"M^5X44![2G>$L[EPVXZ'C%,,H#.<29!P;@G(AU_@\#[.(8$T
M\$AN"'?(",+8<7TN;B40::(J%X,H6>$-9*PX;W,J*"'=8(2C/J=>@D/"C,A5
MM5Q_);,;48Q)K%#3(3)_DLQ1$TO\2\2V8>V$\!8'*&LGN%_$WCSQYH@)1\.4
M?G0@V=A\S@<<TL$[OI\X_#11HN!N^>0_U(9N7)\HPID#=13(!KM-LJ%3,T8.
MR%G$YTP,,84/H4*S1*J*05#!(\`S:+0<H($?/9T12B#2``0OP0OBH@R!'<5A
MH*8Q<HT"(4L6B><0!!P6^.I?@'^2Y8Z8;HI+TGA-%)AB4S7@!;YS0VP>-RBN
MC2=56`3U'HF9+RM624$B=31["T"0P2X$90N!J%QN_9]1$X2#H)@&E_KIW#V`
M-V;::4_Y#2*Y#9AC!>,5#\;_&]LYZ#\3;Z4)_H=8:-.R;3F`T@$(9\1N4`?_
M&BR!I75;J(G?P%D3M8$^#EAP)(J!.#)S-&/G.U"BS^8N'@@JX4`"-!=SB8HG
M+@'W.S+.?__T\8*K/D#7]["Z"0]&<*\])Z15\#%3:*;TBRE<(#?.O`/*F@OW
MBX\@I<WS(X+;!:#"RT7`*K[C&UBQ"HP#B%H`5@00*I4<)$[1L(]DFB(`F+%@
MBKA)KA7RJVH`C*06ZT`BS\Q!B;_;`"`B`-"&]POXML^_+P<_KCA^S^T+!2.>
M>,H2:550MZ0<N@\2;\:WSX@V8(/X\8`^D$$LEU0T+!5WZ=PK-1TD$2A;-+OQ
MKP3X*EA.L1P1>][([44@&-@S'`[IKTG$Q$(;$$<":IF$J$'SDT6RG06,\RAY
M>CZ[Y]87=W5HHH/H`1A&2A`T458QTJ7.I\ZHNAEN>H25RS0I=7=6"E<,H9ZY
M>&5P<\1@'`-MAA#9!NK3P/&VL!S%8\[>:5RF).Q$=QS<(A)1'R#6Z``[Y70#
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M[+0P#8-?F>].4>UHU>WS;Q<$GG&.?\9_77"G%@@T)O`0"<9\S8CGJF_R]U%<
M<J?"AR]7->,/P<2!%^)R)EU:M10ZU9@3Q4;#%HP/Y=D-73J<6>VY-RYR>92.
M#BB;8)"@BB9T>[XB`,754,'BYFX("\Z<%=\*0XME`8B\56<9D?^,%%YWDL""
MR1(_8=?K?Q.[=T%&.B`A5RC^M-'&-^A;\XFC+YSO[B)9;..3.GTV#D<#"BQ$
M&D$A1IQS1+FA@I7\I$*#1OQ)NV@3HTK?TE\R40O0W#C<X06K7`8HN=$M!*QD
M&@<A6C41"49D+V!@A6):^V;=MWB??&(Z?.N'IMTSF_VZ:?S0:#?,?K,N)L,#
MS=O]MA"F^!HG*%(GMTUDSXY^)W5''^F^`RO>EYGF6+)P3Y-S&M9*'=,'9</]
MQFA@CVRKV^BTK%9[>`D,>=2V>J/NH%_OV8-ZKU$*[U*S9D@$%;CMR^,_RFR2
MR4V2R$<[03)'/@`=N=8Y!3;>[A#T;N=I0]"[]N.'H/=?;QQXKQH'_L"[3V^?
MT=G:/J-0%.2XR!-+4*HS>*"%R?./5R\_P%7#ED=E**."F*#K@V4D_1%T>6B8
M[?Y1#:MZ$JS-;O^PL!Y;L>AVLKX.YO$]F&DO3LR/3.%=SULW.[WFL5'UTX%N
M=0]<<7_J?'R<A+X;4SC51]?`W)VR5^3I3Z6(;OMU!AB\(LB=0X-\6AS^HS,Y
M8OJVFV;?/JHF(\\"M6W:G0/K;*?.Z#\R)V*W@3?#(%@8W/%8U-%=`/0BOSD]
MIV7V^@=NU79JI5VG4^M<X:\,M>(OQ\:W=S,J#F#LQ\9?B'LU6J;=>IVQMB\%
M8=UL=RI#](GZ211AUB1/!F4S8\:6(9NZE$A8:OH^M[MFL[UWQZJ+\M+UN=TV
MV\W&02"K%(ZR"LP*?Y7"\9#"86+*]D&Y\IX1CX[9[;U.\\##PM4VZ\T#PW5J
M'/F4^@)4&'Q>KKS66>%5DN>'FHI+A=A^Q!Z;'WGV+ILA2:4,/]BUGK%P/0\6
M-O&GAOR)9V/:M7KZY[,],BH?D0N9S:*\OG5"=HGU@YA``/`2[(,PQ*(YRL=<
MJ4<^.RO\U0#K3?0^%\F"\OVCD2A=_U>`Y6-8[_(%TX_W3KY,?)>_M00`WH,!
M,G47CA=1\D@N,;-=[_9&H_;0JO=';:ME=WK6H-YL6:U1I]-K7C8N1ZW^G\T_
M[?>_U&N=KL+<"\#/$3YC[D_#`*PI6&!,I2N?J0QP#+^+GB\_=3!HM>JMAM5K
MMP'XX6AH7;;&0VM8[W8&#7O0N:IW_[3_;+W_9?Q_?_]QZYZR=/(U=&9,9NR*
M0HH(*Y==&NK&BR>>#8Q!_W)\V;O$0H<Z@-$;7UK]J\;0&HQ'_2LXX,M!?UR*
M-%O\!Y4E2Y08"B=T5<M8LYWN-4SWRLMW%JIZ\Y97!_,RL)A74(H2-JJ(Q;Q5
MJ@S5>R6H&F)5KS-Q/"JDCFX9DP-2@R2F:E350B$2/1.P8`XS?>D5JIL&V1//
M$X_J-_'!7`*^<1^Z,<,\86QN(79%-1`*N(A7W5$;!_<;\]S;()CQ*E;Y`B^H
M#=DBB`L:)+QZ(9<LXHH$?FG36LL2I^!$J7X02Q]O$BQ=G&!C(5%V*3%L&B[6
M@ZZHZ(`7D2=+0,6=`UP@P?J"N4-5"5JI-2\9D358<-2\$IPH9,GYHW'K1O#6
M2J!8UO!CY9U!O5:HDAR;P.#>U1'PWB>AR_#PL7P,><W9.P4=63SPR6#A3M.M
M!6G#&+USBL,+E]..*\5?J1F_!QK!H:3&0M)P1OTT^/ZW=.R`3XN2PBA3.'1+
M19]9+(CO\[H;*L73+X$D[AUD_4Z<.,N\KP(?DRQ#DFU?W.C;%=6MXK^>C65?
MC:YZ[5:]:5UUADVKU:GWK4&[-P`!W*W71W:_?S6PR\6R,UA!2N18,1`MI>7=
MU\D$J2:&RX=E]4A'\\V5JM--$\#.>,'8`KLP.%231&TL%LY?5%DKK[?K1[$;
MB^HBP=W_`*6,"LZOL?X26`HHS5BPS-O,\'4FCO^-%XWQWCQZ?Q_L6.6#1HHW
M#E:A=E0SWKXB2J:WZ&:FY6K&K]3Z".`T11FI_!.M+%HYS1@(+,&W9FQ!@LJ?
MF;Q+#D@08'(34-P-[+T!RJ,1PNF6A,./,W@.$UX)SXNI`Q2[_)#3<CJ]01.7
MP1H!4ZF,J$</Q<7&$AK9F(26PD=TDH!%-*(PTT8).5G"Q09O&Q5282&OG8/7
MA:B`/X:@!/"=F)LH")=7%8%(@S?`A5T2W\`N;VXE`)(QEN6@GE0AM[VTV?.<
MB4"<UAC&X\(>A---R$07"[Q9J!<XW]C,,3Z#5;)PIBSA`[PE87QT%W@]C7/^
MV(6)<1S,L<)O!-B;#6\NMH!A(6WQ@S@@N#RHN\*M@?]$Z2/G4G"A*6K*7U^@
MD?JKZS%G9EQ/293"J7_PIS7CG/\:/GP9L%NL\X=5/L!_>[?,71B_+B;_!>^>
MJS_"DY_G[G]8*!?@/\&O1YX+\`#=YMPJ^!\`&!Z%)S!2A<]<$#2_`K9\8.38
MH^$*2!+WHWYU`3PEQ!XQ$M%N1#R$Q[<`VVES&='D)X(#!Y9T@R_)"R'[Q/Q1
MNZ[!VUJ%JZ1F?EV(EVHMY71YK^FF@A//1`^D+;P\)174>G!_N(/B^_2$>[-G
M4=RA[F7]`0U9%0;RLCRNJ)*B'$0LAS1BK2$3C4-@A47`VROYL"]>RDQ]WB5Y
MP.G[RJR1;7MDY\'96RL][+6>5GK8Z52EAR7Y=%5Q]]ZN%U6@Z9;"_\']5]L8
MH=A7/U9ED:]6)9BQYHKV4O`OJJ#<\=GG/<6]WB@7YIH5YO;$7.-U,'?JN6G"
M#-DKZOF:>>/-3FWOM/&_'7J[SP%@VZ[M719R%`#:W=K>U0Y;`3RV)*7M%U29
M]T=W1QN]$R?A1JO6.VD`[=Z!N.RIBU7N,SRZ&VMW2DS0;V*P;H6H-UFZS5W]
MQ\<O[!/7PNUFQ1!/X9Z75U-0H;ECN_SUVM[]EX[C[I\X;VOU#G2`9<Q'/T"$
MLRA54,RXFO%>T6\TNOGDQJKMQT<WX4Q>+<9X\,AJ%;ZJ.JN6X`RJ$&(9,/=*
M(<13U\./-A#6/%`8I2QJZJ$"?:?E0#KF,)%=V[L/QU%0L-TX$("GSI.UA..C
MHVJ[6V+W2.4Y/#H&_PH1@C=!)641$NUFJ?6<\@H)7N1278Q3O1B@/;U$GMB:
MFWJ]7GA+\6^V2CCM:/%IGE8F?E"%B<_=XF'0K0]:PY;5:`_&5JO3P8&6S:;5
M:#4[K=YP=-D>C\I5+XSX,?XEIJMKQ9L:CN@$RE@V3($$W/_"";^Q&*DP86JZ
M6F$AJ@@TR/HG6*5H]JH<1"V>7JLTIDJU1>`SG"\IOBYC$"9.)@Z#[R[.@Y63
M%W&F,48[Q!:I8<26&GQ19MDTJ82.3T#$:92W01A;.'&1/ALG(<U&SPQ35+$0
M[#2AYA+CDG[@6^EO$'1$'FW)6#`'&^JD<ZMQE7#&&PA@\3.-\$XQI8;.GE')
M-,U@C\3DQW,<]7VA/:,]<17,:*0]58:>#ZZO+HQ>HVX*(LI3Y&_ZIA``U?E'
MHTI:!Y>YJ!GB7V<TU=GU`=4*1E.;?8JM##3H;UT68E'DBH_,QAG05,,(GY13
MKK&@5R!IAK$E?5U>5TGSH*D1@R.FEVNSH`UG$B3Q)HS+^=*T>;6;,YRZC47G
MB/U_)X[LC!$R-7N;*L^7"=(=W[KLVV/BB&ND\S,QUUZ,ZDP[`VA[R0#`P<\#
M?\8GB+MYZ)$Z)W!#/'@-CE9,4!:0\WL&]T2-[=8B?[=@4QH8EKL)8-UH_]A<
MYQA#<SBB]7'!.!F+VTV*H_HGWVRH**#'YK&^3*/>:.R^D/WX+>2_^Y'=,<^P
M=8UJK*B)BI>S4V63"*DE\9W97PD-M/UW$N#_+$-W*F=T8[6Q<^>XGH@FX^7E
M4]8Y=^;<T,4!NU197DSCM4=K)A6%GBR%-AY+H9P-BVGTE)T@2+V`8,]$@3Q-
M2,8>%B'E*,B?)A$+19.*#WS5*2PGM1&^W-D[N2"2=N0N7.R(5$S87*)G[D.`
M38BR&]OEBN!*($-HK53W`?GU1?0;<-5V'2\*TCWSO`XAD0B30@[A-CC*<!>(
MQT4P8QZ(+VJ<XD34K0OD4@RR$/M'X(96+G9E`47F3N$3/XF"*`C#@%)'^-DH
M7$I%;>;$3G73JYN>WO3F[C==D'<J<Q)?HR^N8L=Y$E0F`E&>\4<DU:&(R05=
M_R[PD)@CV"!IR+P_W5DZ>![O[E_)[$;TTR&E:^'`S8)=.:);'=X>O+YQOKD(
MP=9$K+#:3<U,@>*&`3=8X/JAP<*E++7^P$XMI,E1BR/>FNR,CU;'KIZ@+LY0
M`P5&$6![4=EOR3%N8+.^$:&E`0\<[JZ]0&LZ91UNX(=I(Z-@BT&%W=$T6XS:
MUB%Z4^(2RK%^$![1)M`9-T6QD0O7L5?X\,)@#OQ6G3MOY%$C0&#QK+:?ZO;9
M=DM`0-^81F#PLB(Q)Q*&IT:34Z;LC929Z\2$"#A[IUD5]]BQBK-R\9KG<I-2
M-"!9,WJ>T.:E=SQM7L:[T]4FJH)5[A&Y3B2,J@CGR+_A*?+]QM.2'5O-QR<[
M=E\OU['Z=)7A6?3N,W21:6U-\=SHH=ONU<QYC]]Z$NB6#,67B.Z\,$D5IEVF
M%/4_9(>J37PF@U3][/I9XIF$QH_YD,:`Z\B_<8LT]Q3HK`^O\"&U?0<DDY^7
M8$M^!-?*\%`[H7:\#R/N4VH#Y9[@SHLWB\<'$?>'9C[N0)\'P.;1L]%#G^=7
M;)[XIBA8.NC?'LR--PAS\\7YR5&G.''-8-VR/G@.[&L]5^VYVO/1Y>]N'S9X
MM6F`P(O?ZCW']-E@4K=;KS.`L()VSWWL!OT))*-6F#H976@['_T-$R!E;'.>
M^+/C*PUJ=,QZ:^_.B*_%2-\>U%6:?X6R4R@LV\Y0O[`H#EV:]H:JZ=%QTV:]
M?DPWY`V"_":80H6R-S^5'38KO*,%QW6(D>)[?_#QY%3AK\)?A;]CP=_Q.P$>
M:*].P^6TA(E'*ZP[/K>O][#=-7M]^U4TCC<-V2E[]BJLO`4EL@DR818D$X^]
ME!3:_XOE%.,5!BL,5AA\664RV^T#H+AE*"+^\=[N;.:NVC-:&OBF%ZJDP<.D
MR+]\+E:YCVE+8MN3OUP^DMHE1=[@F?%&E1#_DHG<1I4'_Q3T/8RX*@^^].=9
MY<&_'9BK//B7X"='[?:M\N"K/;^]/9]6NM'1Y\'WZV:KN7>KYM=*.7HSP)YR
MK*/"U'-&A<JM";V-+/CN,5V8MPGUFTA%K%!69<$?=19\JWY4M8IO$.0WP10J
ME+WY!*;3R:*M\%?AK\+?\>+O^)T`1YX%;W?,7N]U2K[?-&0OXMG+[OYQ_RJ7
M=GH*&"T1ED]-H3VE7-X*@Q4&*PP>.P9+/LE$B9_^SU$ZCTI,9L$Q$\O073BA
MZ]$,U,B-8B.8PQ)AU@=K;IF`F0E]T2!#>%_.&$D'G/#1([`JC<6<Z3,M:)Y,
MG.X.WM;VQT=KB3E5YVH(W,76H54TIV;K_*OU*2/K0V9WFAV;'3?[.0R6+(Q7
MGSW'CP?^;`086^+37]GW^-(+IM^>;=;L9:?3Z0\N&U:_/VY9K7:[9_4'P['5
M'HZ;]<&@/;P:-5]ZUNRV::T2-40Y3.)%DIT:VYK.ASP7HRO?ZCB3;N=IXTRZ
M]N/'F?1?;[!'KQKL\<"[3T^$[6Q-A"VL2Z*=3/8T`JHS>&PR\O,/2BD_P%7J
M]:-\C:A;)8!')43WTIN?HN7OZ:MKF.W^4;6=?!*LS6[_L+`>6]K'=K*^#N;Q
MO1.R%R?FIR8_V&:GUSPVJGXZT*WN@7/G3IV/CY/0=^,DY(,R@_D<[-E7Y.E/
MI8AN^W5:$;TBR)U#@WQ:'/ZC,SEB^K:;9M\^JG3A9X':-NW.@76V4V?T'YD3
ML=O`FQGN8AD&=[P7R-%=@+9I]]^<GM,R>_T#%UV=6I#V=+*6*OR5(>OKY=CX
M]KJ$X@#&?FS\A;A7HV7:K==I4/]2$-;-=J<R1)^HGT21X4RGR2+Q*#@[8\N0
M35TG=@._U/1];G?-9GOOVI.+\M+UN=TVV\W&02"K%(ZR"LP*?Y7"\9#"81H^
M.ZS6L6?$HV-V>Z]3!GA8N-IFO7E@N$Z-(Y]2AE^%P>?ERFLYDNN)=P]GT66S
M[JAB/)G&2>CZ-_#\%T9Z+#5`I?R_H1M-O0#;\#Y_'EYOV&HUV\TK:]QJ]*Q6
M"_/PNL.A->Z/^HW+RZO6E7WUTGEX=B_;!9IR*[HU[HDT1M_=V/@HLB-7=`0J
M^6*O_+IG3!/\Y!O_3+R5HB>[@[V1ZSV3T@-E8JDS!9H(P5;YXMPQW[AT@YA-
M;WTPL&[@O,TS[+DZK1GG].<+TW`P7_0.J,*X#I+XUKAV?&,<8DYG-`VL":!E
M!A3!UYX'TP1^AC4"GSXZP\S4@.<K!G-,>PV`G'S,-_5C=Q+,5O@8L'R6Q.Z4
MYZ3&(0/[R;^!5:;P&1;6Q%;OG8@G/<X8[M_15[>BV+EA!J7)P'[AK)P(%IBQ
MN>O#LZYO#*ZO%&KZ8"300;F(O*&VRVM:9P2[0_*G@Z5G:H`6W%'@^VR*YIUQ
M[P(V$$C":.3B+[.H=J,H@8_;#;/5Z8`L[,,"T:T3,LK9Q,S=:Q9BDNT0U[V#
MB^MBVB28D',6(HA1C/<--L^^3V\=_X92?F$1Q_-DUB><"8#N8PHDH&OI8C4=
M?XWZDVG+^G#0D;%T5LA%\(CF'*_K";VOG7MM)#X<<1P$WW@ZM610/!.9YR6'
MG%,9<8!H0)RH4U"@X:I`"QM7<?VIE\R(8@'?"1TLY3P#3N=S?-A#VN!)VXAN
M%P@,-@=:);("^(Z'C`'?GSM3D3-=,P9P/A&\B->$67*K@'K>R_P>Z)?NC,=B
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M8S3![@8SQOV.FFO%N0D9Y1QS;W(PWW(/"QPOE=ME?[=+Y_%NES+4P1^UW`$R
M;I=1G-AFI[5W0M=;5.+A(#NE5MMMLU?5QCSYC+NE/N.&:=L'KGHYN5O;*_F)
M-@^=IW9J:GUE=#^-GY9$`ZD,VLJ@+9E!BXD,RR2<WF8-52R3=6>BO9]C1$LV
M=><N)49@:A"8L%,6QHXKDIDP[0%?6[@>B^*`MQMT8C)F>6Z7R.1RIK<NXP6X
MV47@@Y@X8T0.K&"`@>?>89?",%BHY"B5;I;FFJTP2R8*3,-!P]IG,2!"VN3X
M@1_:M3KNRN/I)9Z7&ND\XX>O!^]2LA/6"+,P,I*EV*[KNS$OP\'%EO`O7'<6
M4%-$D3XQ=\,HAA4^$PH;QM2#M[`78ARZ'%68@R+A6X-,;D`0#DCOJY^O*&'-
MN([9PK@"RQ@ST6]"9U%3#PU_-GX/4DBC6T<#S94I*7)+?"=1C&DS,\S!@]]C
M(I<13*<)I8@A@"$L`,>-*36Y#,"VR=-7^!SV-'N.(T8D/T68XL="M-(Q]4UT
ML038$F:<L^_X#"679=Y%Z@I9Q!P@0$J.TC/]X&=8`_/NX]4%/#9EA+G)*I/<
M@TMX+GPV8H3K/*9AB2RN=\)T!M&X,4=2%]*JP'KH^#<($ZW_0T^C-""N'^R&
M]HL96V)&%KQ$M(74JNX4)8?AYCGQ(Z5Q&`HNPM[D\N*>HT.QL_H#W$QC1UEB
MD]??F4Z#Q*<FJ,C<@'!G,\H:<SP\7,D,J;\IG3V0'OJ<9O@L4'M([`LNE.M;
M<%!3K-[3B?CL78:,V?<E$>?]+=">&QLNGBHL,<-3GI![C7BE3&83NY]B8F&Z
MY1C9))O5\-*K[1K.`B&)X#[?`:-E1!GI;F<\=PZI!E,"HP=R`NT6#\0*$#;D
MQ*SEBN^3^YW-'K^>WK)9XK%/\S]\W/R-[_Z'S;XZWR^9S^9N''T)/&\<A/=.
M"+\%?#U_#KE]V>LWAO;(&E_VAU:KU[NT^H.K@37J#UJCRT9WV.CV7SR'?)O8
M'M`Q^Y@KFHHG/.@)`X[D4\HDUBSQA%Y.)?C(31A$Z().-$0;L?,=WN.H1NJL
MO,]:TMZ3&L#6'^]];K]>`]A3_G35]_2]7=_:!_3_,&M\Y/,L]JH3[4N<2-6)
M-@_P,W>B+3_`C1>_5$<=K;A,U1N1U+*7%^@I/JN]8X_=>N^PGK\2P=KN'SC.
M6B98FU56_B-Z*GQ`^QG,Z^C'\QD3_[P@0YP\46"F4/D:VB3+@!=S'5^GOL:A
M\PS*![)M'UUC\:>"W#XP0S]^8;XO*UB&+OSW"3""_E'UJWT3,\8KE+UQ#60H
M>0VY_M%SGWCD'&7?EVZ8>E.CV(F3F&)*GKMP8^?E.=";(*X*917*RL'"CBDM
MYG02PBK\5?A[3?P=OY6UW64ZXC'@)_E+=WQN[TE=]=;KV$F'A>OU?+Z'ANO@
M_MU3$]>GE,5:8;#"X&MC\-$=3??/,<OEJF&:\`=JR#BDC+?/+'2#V36U8Z0_
M?EJ2HV#TG853EW>UW#-'+?%=_A9O]OC>F+&INW"\Z!_O/_P^7LMAJ]M7S?&X
M95OMR]:EU>KV&M:@.;*M5GLPOJJW[6&[.^`Y;.U.KU_O:,AY-%`<*3/F_D0M
M+E=7/';SA2V#$-,7K]%Y$CU;>EY]U!DWF[9M#>U>TVHUZG6K/^KTK?%X>-D<
M738&HT870&N__^7_6/3W'Q_:5_9(_Y>A9&.S`39:O&&_)YCX\FG.H?^D^F)>
M.I$[/<AI%@#<&=CM[OC2NKH:PPFVZF.K-[B\LKJ=<;\W'-J#P1![VC;?_]+H
M-GNM?K^N3O-1\&11L>%NI([Z+^0K@W?'8;#XC$YZ3BGP[&?IHW\&#+E1T&K8
MW3__N![J:+*::WBZ:G0[K49[;/7[\('650<(HU[O6$#NXW&[4Q_:?<13X_TO
M_2YP)(6DYX!T)\[P+\=+&&CN])>71<[E^++9O^H-K>$`B:C>&UF];N/2:O::
MG>ZH-1CUZ\,_^W6[#Q]Z_TNWT[4[&1SM!%$."4AD5/"!Z?G,C\AK.@@Q4YZR
MIB]7ZI'//(U^@#Q7,)A_L0@H]X//OS1VW)"^9A\0;^TUO'7&8T`&7+[>X*IN
MM8:MMM7K`R,%CMH#PKKJM^3E:W)!IZ'L0/#GVVU36062YJ^P<OS"=Z[>[%VV
MZ@/KLM7L6*U._=*Z[+5&5K/=OAQWNXVKQK#/[UR[V<Q@9VW?6;!^9S'<OV#!
M/@91-+AS7(\$<0"H7`3^M5:@,W0]ZM+ZDF#OR)*[[W_!"V9G(7\T:%G,\'>!
M]WS))'T/5:_AE\1$9]P>M>W1V+KJC:^LUGC8L@:7[;YUU6HTQZ/^H&NW!UP:
M-[O]#!H>A"/'3;`<1A#-KT$PBP"-AX.T2*=J`P<8-(=MJ]_L-ZS6J#^V!L/+
ML=6I-^QV>]"X0A;:1%!U)E"P[2Q@'WF]TL"?7;/P#GZ0CY?Q(MOO?VEU&YU6
MYB0W0K!&N"1/9<SM@T\59)]DJ^1!%+$79E\`Z]45Z)-6JXE07X+RT!O7NU9[
MW*UW+NN7G='5)4(-(M&VU^EW!W"R*$C_J!A`&4^Y)_A6.P-PP>9WXDSPBZN0
MS="NDH51)>10+5"?&R#3=V!1ZP`]1.A4%^5.@9=?.=$MF):*2E3C^!(2?A\(
MP:ZW'Z#[7:![@FTA[+;CL"Z`03;0)MW7O-@(;(Z1(*OY/?"#[)T<B?+"$O(4
M(*4L6K:#4*CDEI)9-E$D=G,FI=QP%@RAY$=?@P$O8=\X6Z>,S,"&(VRVN]E3
MW!VD??7[YW*U/+MVWWBB=E_@<\F\7$9B1TWH(:`?$H8#7G(-?`^+^*FHLX34
M#K9;OVD_(/G607FD1I3V4"B;.@3@V\V=#+8<,%D$#&9_)5$L.41:J_[9<6<?
M_"L^6ZC83_*%\0$N3-@47")^X9(4'R!G2$E]:,0J&ZVLF71H7!3+&E&"_S6`
M<_I?-[Y%YH.Z1A#2MR[SWRKC76R`<F[W"^7.8\%[B#E]#MD2#N0U%*D=D=%#
MTEJ_FEOAR$(]U"9*P[\]1GY)?S988&#D/X<F@W4GZWA@VY?=7MOJ75T"^)>7
M'6LP'+2M=K][.6JW^NW+WIA'J^Q>SLFZ"RP/G?E0S$9[#;_+KKH7W(!FT^X^
M<.HY2';ROPB+0XX@+*DE:G?@\/.6U<X0K4VH)*L=R$0;TU=BVZG]_I=NW>YU
M<B;&%BAV<DC(1BVX4GA73KIOH@>B]2"[*X(GBP-T30"J\'_0)+ES/!0?7)+F
MURLC)AIP`5JV;6?9WV.@VDDU37\M"$EX*P;QF&'O)(^"YG$0KM3[V$.LA!HL
M6BIVLY5#V+."O0&CV37*B!N[D0E2;-CY!M_U1^&U2IG-02,Q!>I"S^XV[;$]
ML.Q^OPLW9M2P+CO#*\L>7PZZO7'K:MAL"5=</B:[%8C-6E(9&4(3M:%&8Z,V
MM.990";QF;=RG%VN_H@PMCQV?1R[JWMJKZCI6`*_$\AZ:4_KK@P1I6*WU;+S
MGH@GP)DSH;"?&YM%Z)?%!`?,F?XTUQPYI41+HRA]XT%0=A(.OP?8$@C#LQ-/
M.FJ+S:PK',-:0L8'=GFWW=E%(CP.UAU\7F'"9F57LH%V6LW6&GX>!&8G7O/!
MOV-1?)R\AMR>>=_WT^#<S&L.E3KZ_&@!&=3->;D>!"2GEG-;[<5UIZ($CX8]
M:H.A,;8Z5PV`>M`;6H/V>&PUF^W>\++>Z+?[P@VA:^!;`<@!"YPBPI@(?Z:4
M'O[N^U]Z'=O.4GI^XSM)"]29,2GD8S!UO/29%X9Z5X48C85.?:?P_R:XLDCY
M%0@`#`=T1<T6KN^"?0IOWY4Y1(LNEG:_D67_#\"Q:[#GL[,J:Z3'IL-OU]<,
MQ>V@%"2['H4SO540FMC%5U[\S'HZZ^6&=%8I`"*9T?H5N\=_\./0]2-W>NAP
MSMZIO:`3V:T\=;P$,G9-F>'\YS/S'0]U#;BI'["](.@@!^<U15)T<-7N#H"1
M6KUN#ZSS0:MI]=O-OM6_:MF=4?.J7^]WUZ3H$Z#+6^US[(V-"E?H3A)$-F8B
MC!9++UBQ$/M/AQ0C<,*5_M"`MT4^&*;6RSJ:PTZKVQ_UK/%5KVVU1MVF==F_
M:ECC7K\_;@_'EYU!_<\&99;;O68_8^4_!<:=9/?5+1*R"BC``SR?$2F3TSHV
MA:91HF44YS9>VGYC)]_?(V#="7<4@TA_Y=]\B-FBE$H/3_-<"ZGL#--.#.I+
MFL^=R7/[B,VW/\T'RZ7G3E&<<@\K_.JC:K!3Q@2_YBY\ZRE`<ZPN;OSO6J%B
ML;S1[2OJMB_S,.D/?P`.(F&#K@[4*W\,.G-G.!I8\%8/%`^0H?T.L/VK;LON
M-GNCRW9S6*I>^3@4@C>TIW$(O*5\LE@X(1QAQ">_&`&A5(Q[D#CE?SM[1[1E
MG'^Y_N/"<`1VJ5$=HNFM=<7O-Y[6%;_5?'Q7_/[KM:8_^#C84D)]\$]7[=\?
M:`[.ZW7IT\_6'KSD(,O*98M^$QH_BL^+2N8L+K2_IPM($TO!\1F'^+PI).(_
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M_:6,E5JC=<KPM<NMQC\9O*9I-THP;ZU,>L%V[L.G:%`N/_N^9)3)'P<&ENB7
MFALUS6;+-NU##]=[=:]"_:3O:[=VTN?7JYO-QH$/<.?Q;H<MF=+*LC:VN!Y%
ML;O`=J1_1&R>>!_=.3M0W56CWAV-L3MUMVX/K-9PW+$N1^VV51^V>O5ZIV-?
M=ILO77?5V5)V]06[D881L6',%8^9+VI'HQA^&S)BSC[V.7$BP_6GV%5C5B.[
M3FO#Y6))X&))\WZ2B"JX;K'X*720)"W/]9FQ8/%M,#.".Q;B7V$)5>_%Y`'!
MVWA"AN>"('AK15O=SM.*MMKMQQ=M;7GE5*VB[?Z**T['H<$D]]A/'7F"E&@:
M*RRM.'X-<#NFKX-Y?`\LYM3P6U[:'B<A"-+D%5!NU]\&37]T@&$[V)"41&HP
MG[L@35^/E;3?*JE3'U%L.F^XBV4(2@=UI7]Q_".;NPW"6/=_!W/U;P^WJ7Z,
ML?)./:B]Q/4B[47089^JD^^O+VM*][9F7%KG#A9I8Q;*V'0#&UHWZTW>?VEO
MR#3$;.\&PWL/IAU@?#]QO'_Q]H2?68C:GW/S'"U<EL#M'^H,M&/'&VRX5$NQ
M\PS@:<BZ1*N!1=%O++QAX6@^9VCLL>&3>ECGP!QU>G:GWFQ;PR9.,["[=:MO
M]UK6U6C0:_4'K6:_+1H@X2*6W;`:#0'LENUI0%RAPD_\G\\ZD/,7;T+&V0]V
M`/*""([D^2W/UJ#>['?J/:O>ZG8`NM;0&C3L$4`W[H[JXW[?[H]>O.-'3[.Z
M/%'LVJL9&421H!2H,A2NB%]-4AM$9]K_GV49WR>A9TZ"V<JPK)>QH=<`P7^X
M^(]_.GX4,=^X=(.836]-`SA'C7;MIOLOAN0U3/X/?AJ3I3"L2;8ZFCV.OS+(
M[`0[W/7CP'"X#:N?%"S@B;-RY%F!+1G?&H58,,[%KR^H%0NW^V=J+`(=/K#9
M!8:B0'R*(2?!W/CMUV'=MDW8`XAO[-IC3#$?;097#I:(;YT8W1%!N,3-`28T
M((24!.#Z/T?X^C)T6>R`3C8<?/EJX.Y\T%IN5KA08$3N(O%BQV=!$GDK`QZ\
M8;%Q-;3[M+NK85/NW5@":'X,&S7BD#G$\F$-V.VEA3:]L2`-`#M:LZA&/6TD
M7NF:+W"S\CLZIF$11_2X`88]O74RZ,5=N-2\%K:1_MHTF#.])=S#Z_\,;OTH
M\'.Z"OY'_@G.PP_N"+\*0:V?__G/X55Z5O#O"T"YC_L!U14E'D/PQ"&:(%=F
M0#;WMRY\&9_FVR'/?;IQV^PWFF:]VX55?*#/B)IDX#(;SVA*#:\%!N!D\=!1
M<89W?FCV0>C`4J"J\*5,(T3?4X0GX=_@^5)C6WJXVZ[5C87K>0`E'0"\R"2[
M1@XNMJ'C-S+NG<B(DLE?\!A"@ML$K=DC^@"-S/4%58KJB)1&\6"=M&D4+./R
M'5'GP(@C"];X+R>,K>LI:(76EV#F^H$Q@*W'(2@-Q@=-.S4&\'U8UL::2XYD
MI*XI=[H!">`Y)$C'@+:V<1XQ9OP.%&G8S8LLM;F1P8`2L46V0=05TB`T`-KX
MH5U7*#*2Y3S$/A1+W@K1@)\6Z4UVYG'JJUMC!`5L8,)088H4PFOI4O?P/5AE
MP@S0)X'XX?B6@1_1!O%R"9:`V.,77W,.PLDLW"CB.*>[SPS1R_G&X;.ZB`\.
MP^3&$#V\:)?GP/PN!"(1)4O03T!E(<\C\;YVS1A$4;+@7YE.@3[0^?@@?S+%
M+M3E3KQ9BN-DB43D`);266*`=9TRX2@1I9[KPU8]I.>;Q%-6XSH_A/?P]OM,
M'E0DB5MN8>$`1_$$`<^!\O`.X:@E3JDXC,N*N$XI/IMCQ$!=[/N46NX1>HCO
M8JMGNG/X9X3XC]IUC7-%QW=F#CJ"/\PS&V:SK$"Y)]S`P6L$*5&%6Z#T.FL&
M?XN-,%CQ;I(&T=C*N/&""6#/!WX<X<!N^C0P&?H"[P;&>?@TL&"["[P,^*=%
M`*A(\$KJDDF#X<4D\=:F9[\C)OAL*V1!JF6=,:.!.;1=-.!!6,S@MX6Y5+`.
M,G+!FN-;('1-1B#"?/P,C6.#$^=VB_Y=SA[0STQ.?J"6S3E;+XBX(MTQ5;F^
M.M_8S"FSCO6;LWI8O4IY*/J*)#GG]"H.:JJ"[*(\P2+$1>N%ZM,CE"<4NYO5
MIP+EB?DWR&-`9VI<"G7Q:MCM7THNC*PDO@^DO@2FT-P!.0\?B9GK`U?C^Z:`
M$F_@3E(8;BY(?$NRK@P2)&)2C8PD<Q('[F*1^,1CW(BFRM2,/T#H`)L#WB`9
M([ZI71>![(4S@U^C_A+X5LB0GY*$EV(250U;9^A":Q`XK,EU;NEV@2@0G0OA
ML6`2.RYR-V2W'MB5(#'N@]";W;OP34D0"!1'129.AM_`0!L?IT>`$F)FW!@W
M/G,%#'7)9+;*RP@4PH;''+CF\`])%QF"4E//$U!1/"(5Y+!P$6K(Z05<3+9)
M-EQ06SAP)OR;?\)!F<J4C,=A%"LA=><)^I_7J!@0F[DGZFH(S,V95/N!IKT`
M<$&7`]&(FEIFP51:FGP_,?9PA@/KU1";J7:XE^C/WJYXH\ZU31N`!7YH=7JU
MMJ8/Z%]>4PBX[$O!PEN9J@$[B5^Y&5W:(MO?0]YFI6V*BPRODH+6IZ)B<IC!
M3G'6#^A^V?V!WH(J^F;-A9-TTRB\^YK2(NC+`:$:PDX&@!%XW,]H,241^[JF
MSNZHF3&:4+>L0!X42P-B*OQD9HR;*+0"\O48*=%)!;RC>I_S%9!?N\!!2/_#
M.'N(K"TRT;P!RP60N*`4@&#B"?TZ:\KF!02HYU@JAOK^IO=3W:0(PHS$`ZGD
M)3.6\D9@''@;^$1%>DD__HB/W8V(,X1!<G-+W\AR0?$60;KB+%,P(9W9DLWK
MXM1>(+'T@\AK`]C\FBU/NQ08QT^FO%J<FAME\();2)]-/\M(H)!@29:$",E7
MI612J_D!6L7:@1EB-<`86VK2#-&I'3F_NZC`D]<]<F?B]03>"U$4Q2NUM?1$
ME-8NFXMD45!$>>2.2#TD>!^+>;W&W)1=DT48VA4##SOAP9'FN!]/2T%\2'BP
M![!ZE_C+"A]"XHQ1`&B*-2(:Q-RMR[C1+3&M=G+N2+G@D,T:T"AP>9U"-=S9
MF(;`WT(7Q3R<\82!B;%@\07:P4X2,8%XOA'0P?$2T/'!-H#A<9.?,,>QC?DT
M1/Q%W^)BF,Z)9+%^&/F#X/X-[2XB%-IM3-TGZ'0"0(D:7*XW\5D:5/:I@4&D
MF=Y(X,7TAUG`.&$2_%0O:J%L9A@)2T@*INP*64^0Q)M=0*16$H/'C"-@_X))
M:-23N^9;%)]R\/D!^4^`0@&A\Y74WW2F*_G=C/`CQ*9V??..!NVD4?&:`,FF
MN5-X?!$HU=PG!CPFK_X!.0=3$C4_V/5UW;7@@.$O\!GR@J4Z/V=E[&&F3'_X
MH:WK7/E/95DPYV:;.'!6;F9I1Z(E=<QM1XQ0%7:#`BQG5_(-S@K`Y'$]!QU[
M,1Q4Y$S7963F+<&E`U")G26H(\@FSUGMIF8J'CEUHEMC#EI^=(%(2L^97N:W
M23"J5"^6W#X.K`E>!,E:),9T-3FS<;E$#@#^Y,R=SQGY'EPP%Z>"8TS@YLJW
MN1>)U&`-81Q\36_#O29+B[L74=0I\N-4H%1')>4F#+^LL6O*%G3\E"X:+6L!
M"]X*'RMBD!N6*4^+!(6)E'+^'&Y(/UV-C9!O\U$650Y*6&`KG`_2N-@!G=D]
MR57AHY$F&-.OPP8WK%(]-(41%N/&KDBTUW>3$DQ)F&7V]J0$(&4A'@Q>GN]T
MI<'@^Z&IN[&%IUVI8AH:'N%+XSXN9-WQE@=,XX=NS4X_#EO3O7CR^)`N"EUR
M/^B.`WB9$S"^*EP>G',V:K;&.3//H5="/%N2T_O@&]>@AFZ**B)`RG4@"#)[
M`3:%%_)4+3U)I-N0P2LNX>ZB!`Q3:8X@FXTTS;G`$[1*);BPY8%YX#57SGVY
M<*38$?D=)DR/*D5LZ:"W;;/,P?A$E!-T1?9=&F[@EX0S/-BA,FE0L.`>(^/<
MUCI;<<XH\#\5';])C8[=.!'L,DJ<B/OF&8[/]'D8#AT8FEYBG#=RZ^H6EL9G
M]`"69$'*B"#?M*1ZY1W:J+K"=YNY[W+G3FK:<&=1D#4VN9-[[GX7F_CF!_>^
M-*!0G\9-HT*E7(-BK["9>R;,#=@RZ<$Q9R#2%RA("$P$S'6/.#L`,'SN?#]O
MY3:,HA[IA#O\T2W#;:N0P;99]MYHC/"'M?B19#J/Y6\:6]))?BV"Z'A10'05
M>UR822]2R-S%)`DC;L((;>IA36HIYK$JNT`&K]%3J,5>-]Y<<RU**\^+1^&=
M@DN&EZHL48M?7?2^ECEJH068F]LB%VM^*0Z:H`7^@^;M+G)UB^N2U\3-71-$
M.#.>!TG(XQ(RYH>>Q@"5`?)'I)%`L:?I;1"@WYJ4;/K*NA=7D7PF<BZYR0UV
M<B;^2AD'FAN7$C4`I"0D?5NZ@WF(<FMXN)$SR'YHK%WW3`!$]X;X,['F#XW6
M^C+:;W@@11=<FR+0>9<+CYQP!U4N=J(+!8%C(2_1`$)G0'H$A$^!=3IW+BMU
M]-_P+MER)87T=4]OEN7GCJ(D:M$V0<[YNQC0(>'DSBT`38L59+VT*HZF.QBY
MEB3=25)B"6P*]PNR1_D*^M'=B'P]NSGVD`#3Y"=IM*;DLZ.++^LMKCW*Q9=]
M5SGY=G;Q<66ZR,FWJXN/$E@V.OEV</'Q6[S-R:>[^.0=0#$L9"<)VX3:LJ6,
ML]`C@I5\(5YQ7E\M?L@HW%C@I_SRFAHP2!D$!FO$+E*'L-#&Z$`PZRL7N+MU
M\3BY4Y$G=<!#7G`O0D]&+M$#Y;:?AB*)#$IX=;-!FDW&>$8@P@KR_/8,U""]
MBE#-XP(URN67I8G'!&I<GA52"*B,T2CFS/V$.2^AOL`FG?"AN$J.^P$1Y?S-
MANYO3G5VKDBG+B'4<E&'F!#R-WJ\:\:0.ZW)='!PWN"<?X4^`JOPS^2M"S&.
M<#NDIO(U\6VL?]\XYSZS;$:>-)JD1VL;6K.*^44^J0C.#]"(1@QWJVG.L89M
MD%\M%3`I\MC:YS,F*ZU0PBN+J!$7D*B%N*A*5@4Q`*AP(Q2*?P4NT8AN;BS<
M.&9$#','*S]B1V26W2#J>(TTA3#AIP@5696:"`8(<C;][F7S*M98+J:].+[#
M[S[12!K7NK]E))MHT:F[%,H.=RK3QK7=HJ]BPO-6,H%"HI(UYL,=2;FH8LWX
M+]+B%^E^]-WLM`M8-K<#GAE"`B2]O;>DW:$O+T2-PH53P^177SIBU*V0UTWC
MCR6DMW67953@LVQGC05,!.GEW9@Y?V$*/Q7R<>/^;%M;-3IO;K\)NQK.P5O5
M,-M0T[!TA48H2[/"#90$V=L\L@#J#\U:9V^/+.F`!8Y8S!'B%WN;,UBXB>@Z
M:1I]/M5RP]?+XINX1D$%`);8.?$[)LH+![.]-:^2?`M6'%A"5JU[F+/>"P'\
MIB1++K>+:E0&C:Y-1K6'/L@$2][PXA//!D:KYT'!(CP3RA3)TZ;Q&_ON3@/3
M^*<#0)C&=9#`7OX;E!>'+O$'4/2=DER_!S,G)0IYZB2&*%3>Y-F[3.9DWMFA
M'>2.90S"W]&L9YPDZQX:P/4/K>ZFQ/N"M'IXWF[E5BTR9A5$(L[=J/>R;^5,
M6O6X.Y>X.GNG)5*J]!M3>,VBC%<&!<D=VMZ4K,3-89FVZ*VR.8"1H,P=U.OU
M-$ME?&=4[YW2C1Z;)"0\"6?O'N]+J-*%'I,N](%S(GPR3J]J418O3^]$S2O)
ME^JE#$^[[%C"A"Z`HGQ=$6>CC63EK7Q]W:E0Y%+`FB2DU+P3(49]9F;%B,A,
M)FO&G8!W42:QA'`"`7+HDC#5I_L8)"9?W,D@]\W-E7PZY..R(&4(B<BD1"F/
MJ>VMN<SGW"J<($-W!7^0+_`@E`:_EI1"T<6TRU4F'<DX=VMP6?Q`=W%J#EI2
M+6^P?O%B<R*NCNBS=SOX=Q[P[IR]TTL4UG+"-%^/J5+W3".:NMSW/Q5""AV1
M'F9WXV#II6@X`9M=8A*-%/Z98)UX<<W6=%+]XX[IYJ:OIQ*(EW6VE3ZZ0]+D
M%LSMEC2)1XCDF4VU>3A/4FD$>R=*IG#FD4=6#"@+MV8FNIIW-.4L)4=D(ZVE
M9`DO4MK(3>5F=1_*S<KYDC8D9XE;M\F-6>B$V.02$YJ[./\ACY2OYZ<4$$-N
M%;%57D+C@-3#Y#JIY(-,N>'%#>J.FY*.PT`9X<!)L%6(2-]4X.NB.\V=H^/1
M5&>R;%J-#))+(LB&V12$Z,$<!&ZV2U=%(WO>&_*_?JC7NFHEH6J#PMZP:\V\
M5Z6O\K.R;A"SV`@WOJ1&NO9QD9"[2U9%4Z7RHO<KFV&K"\$UBR#-`N'"9!8@
M=Q&^Q+D;DH(5NZ+:Q9$)B?@<W23'I\KH:7!+#)6\::)&B4R`<A#(UGPZS6,%
M9VQGPNGPB[X6O]8\.]S3HM>T%CMW,J>/C&V3LZ<<F,IGTC6V.CHB;$U$,8&<
MQV,W?P=B6`6)49K).'*:NL&SW=*\FK74;3V50HB-C"U*R1G6!/N]JA0-DRMF
MU`^(,[P@XN9&A/TSD$%.<@6!$25VUCOT!?IGU\3?WC.J.`1<P,&'Y!K5LT',
M';TSTC>#7*CRSFSTSGQ0^2,9NB3%A:<\;BZ"_*'3WN*O.7LG/3;]G"MEJ[^&
MLUVDHURM`7%30!6J9W"A2*%#*X,\$*+!3+UC"EH2>N0&&OJA6=_!*91Q":$0
MZ.0=5#LXA32K7#@4=).">YLRGA]Q]Z(BMQ%>2,UQ9*Y?STBK$.?\D_`C3@8/
M'-<01R[((=*D6+2>Z)M:]T@05'<)2W"QU:`'9$EG5DN/XFB;^TCZ,PH=2#NY
MCS()(#D'TL/NHVQ<;L]4%'6<^Z>BP!H/.9">/17ECR+)JKD?=G/D3%A\CYO&
M'!&+VU#(\\F90PVH"[TY6(Q<>71>TZ/#.>9>+AW]U?W=RMP8E5EM+MP743&W
M+:5MD_WX[&DP6]PD9^]V<Y1L=Y.<O2MVE&B)W]Q0($,E+_Q?SY^RI025#B^7
M]KVQPT<VD6=+Q>H#KA=R\&]VOCS"]4*1FT+GRV-<+UKXI<@)(PB#7O%6FUPP
MA!/D=W-TY@B6][__]>'KR+K^/+@"!J=-=FCTN?>`F"6^@+^4_IJTX]A&?TU!
MYL^:3T4SXW5E0.9$AZ*N;IV:98LB"O3AG[GE@9H8UWH<'97K6Q'E;KPZ`R-"
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MZ8U1U@6A"$5D/;298(2>T-IK;$IHC01`6Z1:YC9\X$PYG-&)T2G%^6+1ATU@
MD7`O)^AD:V'DI[[H^;M<RFR@.#&51_3NXPP*/26![S,JYY<;I1AH>O/N^#XL
MW!+'I=9ZA^<*RS:`#A<ZDJ=N";"(O=0>S=5S#B3U]6S2I*V1"&X,!>X\8G%^
M6VMZJE[AD,5#X&>S5GX/B"A)%M#2,G.:]L.E:=/@34,;(BMP"V!GV:X=MX1.
M6(QW1"-G578S_`QYKJQL5TK!4V&&*<4@TIZ5P2_T2P0>]?8#(]SQB%"C6\;(
M1N>1DUZY-8`#18SL3G'(J*>2166<[H>&(K-'A8R$&2;.?#?"%P<;42]$O;(W
MXZ-*O8/4E5?RE+2G2"XM29,5FO=*:=7T#OE#58O<2.-TFF,=70`><](3:M:M
MF;,B%1J.6O!(X:"GCK#CX2"77XP.8338=6=847;SK)`.SK9DW*I[6`Y*?JA5
MA-VM=??O%='48IN;>T78K5KK;$.S"`Q46ZB(U![,H>[G5RG:ZZ:=:G>*<YT-
M>]5XT::-EB0E^C)@MTB=Y<Z*_C2-`Q$KK&\+%3ZBE;\"G,P7]*J!?F7JALS9
MNYPI(WIC@!U:%/`3QQS!QO0&A.@2<)8,%.XIN@>=:%-OC@W*%BPA*X:U/>M&
MA:DJSDWA5UY9$\[;3`T#G*C=.-I@3FBZ1HH'*3H63O@-=`;NJ;AA/M8D:_=$
M1Z]H/*34:MI=23C9@U'$8KO8+\A5R3?(S1I&:$6R?R<,N_NJA<C?0\863HO)
MC*/,=#W'\%/!W\B_7&`BI'E**OVN,.\H[P27;4^UF0\!-ILMZL9>4.K3LC/1
M2$T.9_R<9"T5.#V1H?8WK5`4?!1YZ#V]+9)XA=O`:X$M/1B*@%+,$V"`&[6(
M-C0)D2DQ4X>[)#`$J3$"&9G$/Z51"%R7PDT4P]D:Y-L2XCNK<L0/G".N<U"]
MYGRGBO.S=P_4G,N1LMR4#W$D7I@)$VK:/`8",S7DF].[2\(Z'XJ$9&)>2C`H
ME)\5=<'5''3F0VF.:9L=D9W,O4QKB32FEEZ9MG$&:O@1X$WF#D@]TL<?4:"M
MKX*'KTI=R0#@#DM!%?0;K8>/B`H@,;,;6('K)G2A0N0"//5TK0@F&U99WX/@
M[R*'7+>B,^$,Y7T[2Q,\D1XYZA0.RD=B!2GW!:P@[T'*.4A2BL%:W+GCAMP%
M^(BBH:PS4;2I]&F4D:R:-T`1A'.@?I>&,XFX$L2X/+AS(TW1>+"&_B);X8_@
MR`UD/*(R5ZVHQ']KH%OCLL8,I\FHF0FWHEIZQ6)BRPJ7LN-ZVJF&I!\PY]2A
MJC'6K$\5GD\XB6^`7*\;3\=J"WFJ.\?5B!MM6D,^=^NC^XW=8WP#8V-J2].T
M,!NK$C*@4)\B+JS0C[LRS@M]PIQST?92J;']1!5<9ZH7J_:AB[6.:#*XION(
M=VPRP;D.C8>0KLU,%P9NK6J!-ZY1%"B0ZXQ#L`WDWE$4X#ATF9FP$T5+>X#B
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M\;KP9W7T"4;`:\`S8UCY7+C=R(A?N70R,C__7(60_B7N\#LK[!JYYO#C32/7
MJP&4'UFX__32A$R$RZ3>LQG:=#5)[*U$9?,R"2F=7-;Z*\<'#840B9]:Y\P-
MY?3I1S)-E%]R8.:NW`>OWWZU"5*"G&Q'RYVS$7>;?I/QJ6H^V@?'B14[8V5.
MQ2XNU<T.54+#`R[5#1O0:J%V<*H>ETNU@)BS?M$TS5NQXK-WNJMU)X^/,NES
M/K0"*GC(S7KV[F%'ZW8WZP9;.N=HW>YF)>FT[F@=`_7H_:@U@>LJ2`MZ#/'P
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MP\)S79MWZ-FL";`M<^[*<=@/>,3S;90+X3WC\[1R1-$UZ_7ZP]4:6@=GDC/&
MYA[.I>[@_&N(='$5!E%49G_Y/Q.?J4-XT&N>L=1UOZZ8.Z6`+NS>G+83*'0@
MH._`^J_1EP;]:Q+,<"!]>`.J"U+1!'45/&G%(,]$PG&4^?`FOP'V9B)7%;`*
M/@^)6I_`(K;6"*6A(E34OBLJ\/CKN^)Q5*T=$3G=?B.I73QZ4=^K0"^9\&(.
M%0`VDQ7+I/&+=G9Z:`D%HF2:,C%;R/KUQT4.FA1"<!<7P8P04!*>LR'362(B
MBT'4!A9L0R?JS,@-,9<J4^B'ORIH?J/')<6IBR9)F1D!JK]549+P6;[?UH:X
MJAP/I@N91[OD"ULSY"L!MGCE<P&0S'3!L\R$M+7V+]R/CSG%V6N0N00%NJ].
M]R0Y14JD4'>!\AB?=:S7^M*]#<(9CI/6]%M4OY0"BP66Z?"R*7V26\V*7;$B
M+;<D]+_=';RU=1SA%"E'<+[G=05O]01K5?N*^Z2:+F<QO*Y-<C+]L^X:CSS3
MZP?!)&11)#M>\&FJN=>+RX!O$I?_+IUO">;SX/K*Z-3;5J-M&JF`_DU"/!).
MPX%:'VGG7"9<?%'!FPLERF5Z30&_)>6':_9,#F%<@J5+$65GA@YCH/+!]1\`
M?+UOV<UT3S5M?8TJ\KG=C_.T%Z0R.WQZ8+%S73G,7#2S=\AR-@L*^*D]YJ:+
MG6=X6]RM,A*4G:8D`M0/^X[T&56%*;&P"O?5YIVL#V:RGND96"5B);*O3:94
M>T?O$KJ/"Z5Q`9F[T9H;RLDT%'C(#95Q0FGN*]I$H2=SF]-!4EG&1G_`JUG@
MTQ2-$\^*JY:0KZ[W=)*>+E2FX4XWZBC^QCST`S:3FF.&09P=G9XJ.#[#KY"+
MJ+A+A)GR=8Y7;$6K!:FB6]D.KM!=RWEK,5SGFN=5@G:1Y_PIMY8*:99/BUNB
M<VJ='>NJ'2_S5Z4HO.2?,RO>^(<;$?S4*2`A8_Z;Q`Y0E<>FTA6_J6$/AX7-
MR%TCL1*O>&UV&AD16TOU.`4&+PF/;]<[IV4F.9+O07QL?;(T;[:0'41K9^J-
MS]:F3)?(<;!'JJ661BFJ_NUZ';T$SU6<ONOT+>02*IGDV6KCU>=+<D8/I%FF
MCA?LKM2&V\F/8@)GQ&3"F6A1*_M:%&<^IE$V/2[-(U?(*F*1.\*UVTW=,A[.
MSNRTB5K.,HVH=RF.EV16G!8J7)3M]6=(WKU\@^JM?J:1YQH?X8169?8RB:Q,
MW=&$#:,W.YH*7#BI>5UL#IW'P0WC`A>7':21C`LN=`!/L`)A"@4#Z0RJ7V^!
MDR=FP/S_DX!M"^JM<0O_((Y&VXA=ZVK8Q)Y&P=03R1_<8T72$;44*0#41DPC
M/2MB-E+0W>I]O,4<=J$OR!S2DO"/8D=-(82[]+9NV=M[6__FK#(4TS,SIT@C
M7S+.M8)V_I0(6\]EPI)6DEL='9^PNOJ5]I&L5%8?$5FV9\_1T(_PKI]$7;OU
MZ:9>C`[J6\C@4]&%[IDBYYKC#3-%YD)W2@\(\,63MV9LRK-@J$D%NBID,%-K
ME#J/>;XF=KF!-Q'AHJ6J[JX#R>$H_>MS&,1B4Z/^SS?JGV(6`\BAKZLE36QP
MG0F+24,6$QVBU%#@_H3T_M>,:S!IQ)<<U^/::3HU1]1/@EX3`AN;H_HY17X&
MU@H9)B(*%<7)C-/UF$U"&:BV"WP?.F?0G'G%K('#KMV+1W?^:A01/AH.@):(
MSI`&DJF@:JZ+$;I8R1T8^-0M$=,X!4;/WFENM\UG@W=RY$\#LM70^[IYLM)9
M-N53#D>;I398?EQ#X=`;<LIX.,,L6>K53<P/`U)V4I+():+F]S)W>>([4D(Z
M/4%`D0UN<+4_$K8N-XS/WNE\)>N!EO[-E89!Q5T5SZ6L&O3P\5.).&FB+U1@
M,@UXJ[<EUB+I/1>NE<QE17P4'"FI<G`5T\Q=DF7DBJ(OED14/=#1K#B,G'6$
M;)Q[T]*"VWK_)-(;FW:MH5=-[=*[;-T:26V1L^)>5+HUHBI9=HF=9\^'_Q_]
M:N;>X2___N/BQO_^TY6N9@W\V4>NA"FZ&[H1J#Y1$K*O['M\Z073;[_`4L;?
MZ?4OO'(E?;S@::)"^.$+F__C/0N\/S^/[&Z_T6]9EMVRZ]9_UV&W?U[__]F[
MTMTVDB3]!/L.@@8-S`"3FKP/#]Q`G@LO[+9@NP>87P);HMQ$2Z*7E-SV/OU&
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MZ6`M6K8%M$?><NX#=N7O-S>AWN_Y4!?RK6=6<D*@7#48#SDEZNS7C^&XA"K7
M(,>OCQ%;,#V<2>^C3(@S)A%W(B&=L$(B*2P==C)Z!Z:'B..?$64<5$M-\<,T
MM(A]_Z7PU<WGM\/QV/=&H^_@E_W9&UV,WPZN<PUHUA'O;WX%TWQ=QI/NCGRQ
M0'ZP*22E#.*1,,23]LCY0!'!2M"@O#945997$8RGU#^6J!8>;P?`\Q=O;K[V
MJVS`NUX^%7/[_;0X\9^&KN^O>N-QB3TM_/;X]P@7?`56S=_]-KB^N]Z:XQ$9
M\Y3:@"B1%G$C&;(L`!](*TADE&-.*_)/V;N:]"VLOX6&+XX\R-VM;^N@#[7:
ML^/"9_D^O:LW-^!_Y'9P'VI%"%Y=F*K!6.O`G?'/FU_2(@,9"QZXHH@F$A'7
M<!NCDT6!VJAL8A8\N@I!//%+MTWQK&897O<_];[%;[VR)P&__&^XLIQJ;+WW
M(>>W/M[F7;YM\9(4F&G+#,(I4<1M2LAXK9&5#K[AJ4_15$B`2T2F6N21ZUU+
ML^2?W"ZU'14'R=02\6BM,5EPBUQ`R8-Z'=RVKP06&(PFL.W@L0)EFAGAD><2
MJ*58($N]1BX*'15S0FD&A(I,*&UX_%%+78/$6/:ZGY1`F0ED_)$$PD+79MAM
M$MF176EYBFHM=ITE]6WV"68!V1HQ(@42O%&(,="TW`J.+'%@M;@RW$H-?T*C
M:8ANS-;B@M;5F]M\,!VU9J5'^#I:<_:Y?,PAUILR\:S:8*K,]K]R&4;Y[/2J
M=V.;C;NG]$1=<@Q(#PAX-6^"Z(BTH@XQS:2*W$:#PYG!Q)Q18%-%Q=0;>Q11
M;>>CC$EZ`Q\U!32Q/GM7!QP9U#=5SZHG]4HE]59CBIP%CXQS"?P034`ZZ@A^
M.O@5#8,SU?9*'T%/A<+=&'WN];Z\LO#EB\%5&53SL7^>_3F(G>*W*O>=(&;*
M@=!=)?+O+R/$PO#C8X#Y8X[B-W/<SPC-,JN^$:H)I:(%6;5'L,H'H]'JP()!
M!GX1?+"HD7'$(^PLCM@DC0/<$^Y^IK,8&6XP2-)6:9^%LWQ0>NCD2\%%J_8@
MIU5%[OOT*_4.FIVU(!4';P*I$90!I$H8KA>%C:@`GC]!S$0,'$8@[#/2(6F)
MT"PEDA08O0Q9]OT)_O<4KZT1MP0SM_IGW?S/IMY@5"3=YEXIU53;#X/Q'PE"
M\3=E5VY\^R$GY[:&Y80]OT!\OXHY!58Z1A$0-E$@3K(L@Q\!AEA*S1QUD8-&
MRY87GV#*YG#>)2`M16@_?Q[U\P;*:5.>GTK#'#^$K\Z<2-@2B/!:4:SH-XB=
ML,9B+349L?8F^P$8M",`2C72$'8A'H)PL"AAL)@PL1!M3=F9X&?(I`"PW`63
MDII)LTOUQ$S:W`XBYG/XA3IBAJ^#)LEO]#[WR;:@RZRI,*?Y-34$/P`E70"2
M@3>GM`"O)2AP394C2$M!LW]JDO4LZ#AE27Q"\!3*AVC;+PJ":OHH%`Q)A`H?
MD%4&!-/!W9VF#+&$E;-.*N;]QBA\S'T^<W>Z]Y<S%[V_S)>Y[X6;P-,9CC9.
MV%7:BHL"!M=DT9SBQ(/G`B7A/.),.>02.+`D1:])`AD2864"[PGK7W)M0I5#
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MU\?9)LXR\WRM0(XSI\N(.54X?;DT8SA7*/`X@G\\I,6'1%<]HZ5K6?*O;`:[
M?G>[3W&M*PX+.?8#N361H_M!KH/F6.TR@''_#*`,P;K_Q?L84[I'F=P.O[0_
M^;*F@U*[0V]C`B^/]*_G_#X$;S6WJ:=^+M8S;%-[;<RM#1N5@N%R/9,GO-.5
M-\,_1[TOKX^KO\NU/^UZN=L@4)`3^:()).J$[83`[8CLH0CHW)#0YR2C5+]P
M%J;\1+]H`HG>D99]Z6;U4^^/_D7OV4DLD0?,T,MNNMDO+`(PW33*8<[:SV+%
M4G\`M3E0+\O*__?@JM^[>'[Z@KQP+YRP'PKQ)<CYX7H*L]T.GI/PXQ-SL**Q
M%=E_X;J-ZQT]P%F1_4=)M;7?F!R5V2!U>Q"Y7X758MVB3"X:'QPB,FC$74S(
MV600A?\I1YSTD3YU[G=EGZ,M)W_K#F3C5HN=HV92>:YJ^8]-_"JY6>)7B<<G
M?N&9["W]NO.D\X_,WK%<EF7)OUZ2(#^RJS^RJ_\I.<(]95=?>HCR;'.$;$<9
MID/QX'>5`WU9>VO/.8-&3NB+YF!"=T3@2]?)\\-8GA-7$W7`.T<_-E6?G8+?
M0_+D/X)+#L5("';0?L[A&HEJ-N,/P7BI@@'>TU.4T#W%#OZ.SK#56_5,$$'H
M(T[R+6[K*\&(LE0A)XQ&7&N&K+<8Y2.G0FD1I+?5&396SK`1?D!'^1H8RMG:
M1QSE6P)#]+D[I47*B("X81X9HA623!&-F<.*AK/<T*<Z'`H+/#P8!&;D4><Z
MU^2&`@/),%`MGP,,N^$&-H6!T`.$@6F)]>ZY@4W.MS)Y@+IA$8;=<`.?PL#8
M`<(@!3S,W7,#GZI(J0\1!B.(VCT,(L/`2QL!O):EJ$?:M2;:37H1O^O?_CZ\
MF/U";GV]$3B/:5&QK+,"BRH);0WB#.[(??!(!Y]0#-C'%#GV*3?>RHTU,2E-
M`M>G=!:INM_UN!D"^&0P+.G4\1@40%>0IJO1/;3,](]\N,MWK/HRA\UZ:\PA
M,-\]0TH1B73(IB00SX09FOMH"".-$U+[J*L*D+HC-,$=>Y2W5M_NUC*9)/9I
M6"-2.G]-VSY]+,,!1Q=CWYXFMD\.\(%$HZU#"6NP%4Z9W,U*H.!YY#+&$"FO
M,")LIE'+>K2VT/JU&L27^GT`^+0]?:\E6O%FMRP2?(B6.(H"P01QF_LM11(1
M<R%1SK@F1IW1JF4=Q0C+FOS'+'[_BI)SKI5<3U$F;R0V1"%A07ZX9Q%IJ112
MC',5J-06UPTU#UE'=D5@B81T!*#=RNC`U&-#_'QS%(J]-D0@Z:D$"T`%TL#S
MR`7MG<+42QPJWO^?WDTS589MI"%KL:D;#K788^.V:BM(M0+<:"<09J#;X!DJ
M\(A#0![<(2H\9DK4S_"4DG>S,G[?8O<OUE7@N!93VQATHKD],DX>\03!@J9@
M!<`?E)H9JXC+C7%X:0H\R]0')]N[AZ%8O^Z^SR]WN=#K_:6]`;&Y>M<;`($W
M>83!E)6J";G;)[T9^[&R/;:V$L/ER$7,$)<2[%Y(&D4NDI5@^2G%E59O!+XK
M4?M2<@T4\SZ@X#A:JI%,,8*!QP%9;"4RCEJN<VBMZN[7]>"QS=W`IB?X^\DT
MJ=R#[:J?_[536A7#3C'@84H2>/,JTYJ\1^#C>,458>#33_KO@BXTS9"$%0O>
MM?R6'8^UY)>G:#@-%FQ6'M`3*$56>XUP<)&%D(*4K!X3<)BFN:%]7B]Y[`.H
M()!,>)S<.XC9@]`H.Z2:):54T[W^E^'7R=@I<MBV^1Y:::`LX<B1Q\DA'AU!
MUF"#!#$8"W!(;#"-;5:/LLU/259^S1CCWW*_/DF6S)+J1&:]17O*Z;.A-+\V
M!FMPOIC1:LD#-LYQHBQ*SH):,L$AYR&82DSP%.!'14I3RI5X/O[7!(]9^M?I
M+(V-Q<P$Q'169-&D2G5KE7RDVNF8Z`0C<?@NV3Z0R5Z:[*[G/Y3YGQ4ON>\?
M)C.S[!T@-MJ@R_IJ&-8FD>6!+SA,[/8*"NZU:M,^L.\O+\?]LH>S;)!);KL[
M/BAVP%P8XJQ'4AL%/HYT2.MH4/`Q<&NY8SQ.!(7@]I;5!A#LUSU8R4`J"N8@
M[D6.$0AC+)/@S0>/*,/:!YNBDG8B([-C3#=R&9J88*)MQK89=+][GIG<=&6L
MTUF\\IB-N7!GD;3]6-S-+2QMNL93\WC?XGWI!!V_Y8'!XW[J]_=';'<-`(_S
M5$\<J=4D'(!'P86DZTZ\8E89SS@B@:7<XEHA1PP$OL%ZQYT!?-GA;]1V16"9
MI]`-`-S8A<=LY9R.AI]'O>MMV,)Y`NN?7O5XG0],&D)14#E^4"(BC4'D78P6
MFR@#SY,A,L^3.176K+U-5LY37-[=7.2"LE^_I)86V.LC="9P[Y-`E`@P9!%"
M7I=S=TX"A<)$[90XF_6!5]&S-]-=HS!'H?8)M!>PIB9&(IXX@7\)G'\U&VL9
MA*/5IOO6]J-:5WV=?K=2>:5,\':TP2"=;5&<8S_V[T5"'UCRT^ZY+:>NHUBR
M:DX4F@S8Z[;GMH=$Z7UT=I',.E':IG/]1.GV34LI*5JO3L)$9@,/2.D$IB5:
MAJP#ZH.*C$E"C'%U_HC-Q^:'LM%8$S^_/>X"A:"9(RJSS11"@F],3<Z$J\"X
MD1!'5,+YKE?R?_S`]QB7DTDMLUE2D8T.I)0+`J%2X`AB`1<4E9ZYV.PQ\K5W
MWC*37UT-2T.-3\/IS.A]<JZVC@<9/0*7&B@G!"BWSJ(H35#`UD2)&:=H8E(?
MINE)1'4:"DBXPO#UTO>81^E#1$H1C;@G$!M;07.FRS.&?8IB&ALO[*P=E/0N
MXK%0JI"\3=B`#.=J%N-RX6>B$!8ZP;P')>7Y\GV`K8CUCOE_*^S021[HHH?Y
M&''82^18"D77BQR-%1)\%HL4RYV2I.#@OO"(6&2:*1ZCU_:,'7SDV!&!)4S1
M$0`0&MX]<MQIB+4^K4$HFI1(*-"8<D+<090,KBNXJY$(RJ(RO%7RR<G!!UHU
M%O.%C:`RF`42J<W%GQ:#\4_P3`GA&APVZUV4\XE_K-95@Y/S5\LGGI99:^-?
M^G^6C[:PBR"Q$*:]&]IM(J<(@G!O`^(:G"%0A!9`,009FS2C"?S:G,\KFPB&
M,JQ4ZV19)\HZH?&O/%]NEV!TEX:.@(#J4PN^02?J=JSTNI*^C!GR/&:.K4%1
ME0KPJ)&&]Q#Q8&<35C(X44G(X3E$#=WK/4X@J6G'M;GS8R\NBOGK74UF5OJK
MP<W@O'<U3<E!<'^=-YY[5X/_JT:MUH5:5='T]EREW<N"`-=(S3I'VX1@3F!F
MIX-GZ#<Z5</@OV^$&2Y5.7]IF,:YGLJ`LENL+G(T):,-HEB`@"2OD#:!(H4=
M"9(1%5V=.%+52'.$*:*M4T3+5O\4]`$3*(FW0U^3-JKH8XB1+O15;`'/\Z)_
ML>1;!T@B:4K\22%Q!0&S3W$R]ST[NS?G@ZM!]<7^Q=UYF:"Z(;VYUD;!.[2#
M7"]KA"JB(.`)>5V*7`-'U@$:GE.68BYR;2)@":(M^8R16TG:W,#R)CA:/H`6
M0,P:=1,X.!&FE!X1QM:"`WNNF``'V!L!:BX9BH!U#')*>1\P.(?43BL(I*8S
M>'0C<&^@"-4E\;(F*(TJ('F'>%-03D?#+_W1[??3J][-+1C;^+]W@U)P\>L8
M`HRKMX/+C1"1A,DL-1POV2>!",C[Y`G*,]41Y]PBC6T":K5)0O/`P[0B8';*
M>H=E[X5.P=F:=$[J`MA.R(SC6V`[X(WFRJ^;N?P-P8KKQ0''G0AF]5G7C[\/
M1^#0Y3[)5UG#'\&+ZZ/AZ.BNK/3H"HCL@,@R`O?"`LJH1:>N$R*\*;[<#0ML
MDTRN#!=+2M^[D"F:$CJQ&9G]R_X(XH`2_X7!U\$%>`EY)CK$?R&'$"-[G<]`
M;D0L/)*JP/:^4VMGL.JS;E&_DX)KQA/",9]@8Q8<`!\5`J6!I7#<.(-;8[^Q
M;J/3D=C]8:2,D/?D1K:-$9VTE<&,\K51JH/-FZ_`=X/?KOJSEU<?C'.`-((`
M]&`0XM+8&$&Z'/P@XE%&9(@@*`G&HXE1<8$G5:KJ1$V+%KH1NC\.`N]&W+.9
MNFT.8I-V$YAQ\FPX:#L(=>*@IF>1/#'B67'0/9LNV^8@/NW4(2A]5ART.4*=
M.*CQ[W)/V_64T!.#DPN(Y.9FOA,XC:M'](E2SP$<KDG9V'D*<$03X-(39IZ+
M\I$$3,D]6R';5CX%(/'<E,^6$.K$0K)&:'WETV#Z2_^VVGQ[.QQO%C%S3*K-
M(=TE,;"X.>228\;K@()-!'&L(]**.L0TDRIR&PT.9P83?4;E\<_Y[=(K9LH>
M,Z0\=<*T)C_WSZ*/3IAV)9V=T;R!3$6G%.%^DZ;W`+)]?@!0<N*`KILU+<+S
MT/?+9SEPM^>WH',V.[+WE+!D_W::/GL4B:NAJ;CK*;!9E*$EA</=46$Y_:`Q
M)P_C<@]]LU+T:=3OC>]&W\O7JBL^]&\'H\UJK1H<&,=F9[H$;@H&!!;#="M"
MO)^@!PBOOW':&Q5FJ@JSMN)X+(-A^Z("-P9''@D]HT*ZDKA/+?(4T-#,)>8Y
MZI&5\K.^'A%%CV@IMJ!$GLP4,\G6R]MU14454_S_[%UI<]M&TOXK6_F.>`9S
M8&8KFRH<1,K[.K'+]NY6/J5H$K*P2Y$*0,I6?OT[/0`/@)`X)`%H**(V52M+
MX-']]/0U?7B<2WIN#=-V\E_^>;%3^3%.IV_GX?@^78YGFKM?ZO>`'Y,_5VF>
M+A.]R&J2%)^U4T&J/_9"^(GE#S\3EU;9V35O7E#5]R"A2M5?HJ;O@3-*TWM$
MG*7I-Z%Z6745+[*/2;[,5I.E?H=S6.$)@@KW\*DP^U#Y042ISS!S`H1\ARKZ
M'4$9<3Q,7%?]Y*FX^P]OG=>C1%:DY"F2ZJ56>9XD4,NC_K0S_B%_?Y]`8<_\
MJZ[SR3\GV5T[;9%%91+'RJ,]L3*)E-F$#_3WW:JK4PC9.2+ZSYN"N[>@7UJI
MS&J)7K[N(=QI(WSN*Y\&\\=DGGP;SX!)+="LQ-P[D>;U!/+*K?0)5'1;6-@2
MG;3$%KO'%!)NB5[D>3C.LL>;1?8-9@MO7_-[,L[.(%`@SC`(+V%L7S_%(A1$
MLM`)*5<$*C(=WPV%$XR8&'DD8$H#;D>(H$WFS_2+OQRM#4UD)K2N;\)=1.CI
MM#:7B^V(>_"X?:34\CZ\Y7JT0>'%E_.._DJF_LTRR=[.)YFNYSF'0Y+3[Y@H
M!^^$0%]B&@8C5_<8N@Z5RK#[V*6*C1%%-$(T*.J&7<U!R3W76X^=Z98C.ZS?
M#O)?OP9,Q=W]>/Z80Z7V8J[]B/>K90YSO!6LRKJNW^?M?)V`R)6WFDSA3\H9
M@6F@NIA[XX)T`,'AA0?F["\NXNGZM/;#DTN2?\XX]XZ6?Y]0$D+[@/`)S-WG
MQ)%>&#H>8P$)`\8#3K85M@RYTNM1_-<V9S3.Y@K"7*&N7Q6EL]7RN/0@!ZZY
M!=>.NE[:KUQ$W,<,1DB$(00#%,6*>X'B&5>&-8JP[T<A]&#B8D?'UG0^04:5
MUO\DL*M,L>-!Z>BO2<&M\LE2TK="O0UB6^"%26K'D'99:40ZD:2FPGTP6'&V
MN`-7.9VOU/.E+5O,@:U*V-()#(7;>?,7DI(0$1%0%2(%*D9R*(?F30&-JNID
MQ9[GAFXD&Z7D9$)K";%3SV<Q?"O_13VXS-^6$Q1J$.H_@NL7C]/LZ%10BUSF
M<>QQD$?AATCI+\J4.SO"CB>48F0XE%3+HRZ6E#ME@#US9^^Z.!SGMQ^R!5R^
M3X/'?ZD/>3O?>&5E-B!-\B;TV^7T@6A?R6X8CCA4&8`4!TR=]QAY#HL]Q`,4
M\%$8@!1[/_SL<%9KP#B/SI;$>8.!KTS\78$>=#E,%%Z[U0\ML+7N[^R+*T.>
M&(U8Y"`)RVTP%XZOW'*H4.""!&XPHO(/KZSM12V(JRGU#<S>RWON?]R78SX.
M`M^CXMHJET_C))20>[_7&-D)91V*J]X$FB7*;X6FUGS9D;CNGWY#)A>^^>ZB
MPL[)-_"92@]SQ[6H&<V>7"931P`Z^9$@KL</>$X'"3-BSE/^EUV.)$;F7'F*
MHN=C"<T[NR,)>BB0T#3T8"__O9BIMYFERT?;+*;VHAGNV&)6Z3^B.JY(1JS?
MK!AKVXW^:0KR$0Y)#,,<64!A\*%P'9\H)YDR/PZ5EQPQKYR9(R`#S`V+XAJ)
M,E?,>5V!V:5YR)'J>(^<EERJDL'_5H8/G.<"@(V0GN%0'8H&]CEG&&PI=24\
MB=QZN-4!]8W#O"!L+N*S7D,E0SOOPJ`FT;@48OO%&T?1*`-?5AR<,I2F+_I@
M')ODE#?-WMJG8"_'H[-_4;).U+Y?WJH3M@D8\SSI&573`!A!@5=]'(,!,>95
M3%W9D):K("C"$E1`30*.IJS*F`W73JNS[TOXA5)]+F(5RAN^^B&IUZ41*7@<
MD#^)%UE#RL3&4R#A$'C>@6-@0EV50_^:9YO1A)_'WX-DGMRDD'XKWA(N<E8S
M>`.=,5UEV68"M7KZPR)/^T^<A5!UY"H^2:G7-7/D2(2XH^QD'#..(BS#4EM6
MZZC:H;5V>D#Q_+:8+ZJB>,(TD[X.DH3;IJH@/4]$HR=@I8Y0CB4GZ@5-'D!]
M&D59+?5YX4_^7*59\N0$!!NU`91=ZAK6AOJOPQ2UU&'5F]L#T1/A>PEP<Z5?
MKN/.B^V<,+331E`AT8\)<P_H^'UBC,9PJ5^$63)5^DZ?]EX98#1[2S.`"LE-
M)F_5J+&W-KM'SQ`*_HEXP4KL?5G]D"7WZK->PAH:'CKE5LI#P465BBK-47*O
MG(KU.+AR=852MO[=(EN6(QX[I+MATKN/<>`)YH@P4,0'`7?\R&<.DUXP8E2R
M0,1%1FHST_@86@XA'I6=O2\11IL:3ZH#2H'1`=QKM-3]H*8]>1;[?4QI5Z8X
M4W..GJ'"*)9:EYF7%5]6`DZ@>X[LC70T(*?N-&XVM\R_?DHFZDF(J*(4HJXO
M<$.B^/BO^73[[_5U`G@I'5R''&HH,,O'\@;_J@52J[R#@%2]!/X/'-&'\0RL
M4F%6ZEC8*$2ZJ=^C7C4#<0Q557YL+T,V-OK]S7_&6?_954,&Z&Y<5K65SQ)A
MY)9N?EWJG#(H]Y=Q,E7!Z.S3<KQ<P>#D[>O;N1]KW7N%)G_I[F5HVB/Z"7Y6
MW\-&SL#]>Q-3JM_\B:SDIL-C;954Y->K0R6P1W",?0=+V+09C%PGX%'HX#CP
M/1'3,"*T2#>Y];7+SQ+QM!]IX^E7)E1'9D^XBT95>'$Z'ZM#<(E5>#"+@'KU
M#,091-:SL$\8TITU.T]89&N]"MS@59Q+IY%)^6T!X\IA,/>7V3J'V5RS`%NM
M;528$G2)-+$DQ]%JD"?+5LGT73K^`J48EEZ%Z'(NP0ZGR6JT&.FHM_,'%09<
MIHZ"B])Z5O@\,O=&&T^29*J+YU_^RM24*V1/<Q^DHQ:Y%#=!O3M<3?5&+AXQ
MI1ABAX>N(MH7D>.S.'8(82(*D"N9++,[NT'*LP34B%5J(H?+@N(9*R\$O!]^
M9HR[U5"D_L6-3`4XVE`Z\4X9G]GFF9ZI-O6BH>>?[^6LCB&KRI-?%/XJV(`$
MW_0NG8-AUIN&+<YA<<A:8E%-<A^@P_1RZ,/XT=:;(>AD<E048GHU5))B4K9J
M([ET_R*C^<NWVY:U5O^;WJ//BR4<'^6OSI7OV?'5S\DU@3KPQ.H[M->"9<()
MTS*20O=\2.;C&7@9ZI2NFPTZUS.-7;DA\WPE6X[PA(KF?4H<R8AT9$@Q'Y%0
M(NGM&=`SJ*M'^3?I'%"9%T$0S#R=C>>CN_O9XA$:-W-UE/4='6P*VSYT_`2C
M<X6/1)QZ<B2<.!3,H2./.($,72<64L8LB@/NHS^H;MUW&88AY>W0:&2VPUL0
MY.T%C7J@*/D#R2QD7<63WZ#KW$I+#HL4A5&F\`A*C3BG;\LWOYI_?;M,[JST
M=J#<SX1!C009Z::/F^5=E;JO=^/[/'E_X]_?S]()6-$B&:M^]2Z]2Y<O$/X9
MUKL1$Y5U#M$[(QN>`*/Q.J`Z[+F\'%B'Y4?-'NOM?")]7[@=--8>N54>/GG?
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M*J23*!M(>3?L9,!.%2`0Z;K>=7"3%A/XNN`F!VY2F/DL*1?7P$UER!'N2'-Z
MP$WE!!(BL93X*M@I%:T=F74![(2F5>5U(^)=`SL9@^[E;M@I@9VP/4,B*1'O
ME)W*E84AB:4KF^;_VTY-/+EO'`;,NH@R6.-.L.1ZIC2B+OB6KL3'S9?Q&,&>
M[WJ."F:$XI@@CA_ZR!&A#)DG6,1#O_`K]7P'O.M6/D=<KVP@@B/1/1M(Z<$H
M-GC$0C9PR6#4?M=L8*6M1#^JL.X4-I1U\CM-(K^FLR1?+N;EF/KJ`W^=7C!0
M,,=SUT?EI,(^?Q2)V(50%NG0'_N.</W`4?S@@D#H'T3%;91;[Y0XGM+&L0/G
M#AOHDPW0,(+K!8XU.KHF4NN#DXBD\4A2-_*=(`JQ0R/7=7P1"@=%P8A$41QQ
M3@HB)3Z&QA<1^8U:5&9.?(=%`,(S8$MC.@=)'Q$9.40`7T8R=OPX#!WAQ>'(
M%8$8Q7I*<*$8;#X`)S*E05;,>8(:5$.CN)2)L-EL_&61U2]CW]_<Y,GR\Z(Y
MYZ7K6NP2&F65)`[\T.$"*J(]'CA"C*03A:.(^CX-"!T5#,*[:<"3J;?@R%'&
MW=/*QR/B>S(DU,$1B16S`F6$L3+"//+#@`92(4/*:076&YG.N8"@LNME;8QV
MMDZB4?J,(\_W'8]$RLGBC#K!"&J81D00CXY&H5`N-]!85/(8$[DICFZNZSCS
M'@!HIYA)O1P5DQ-7UX34(XS%3B@944Z$=!U)D'0"SPO#"`F,77^C$@BO]GB;
MT?=B/&'>B77R)CQQ2SM"/?=LGK0RR:&_7;D4=N4V]1Z>NBBWU9KD?I;F4ECY
M"=>J4NQ&X.<.!^QMV%5_*\`HK`!K??B5K:,B>N;KBX^..'OEQ?8;UI=?G`%!
MN0!$;TX__KHG<L7(8\QSHLB'QD$>.5(Y"`XD6SP9$4R]N+")D+14/K77QECR
MPPRQ<O7*"W&>%MEWCZ`7V+W2]M9W187V)RHJ!&E#SKWCN3@*N51N<>A$)&0.
M)7ZDPCQ"E,\>X"@,L(!UA'J!#;BTU"62>*8V[(FMJKN=.>N]07IYWT.2Z1:W
M:G55!ZPQ=_?-V0,N+ZWG"8XDM>6M/1+8@0DB+8S:#JA/0N0C!X5PVI!/'8F$
M<`+)1SR.(D_$X1]Z3YKC_BAW$NQ&2WO.'"K^`H2Z!PEMZ&4]?JR>`66'_`,S
M>O2H("9%4W)BOZGRE`BD-U*@CX;4P\_G1\EUO1FIH)VV(J"8"&_D1<+QB=)+
M-!A)Q\=2.@PS%,I8QE&`2@%%/^XNE6AI,=*I0OPL]0>0-Z09A)AZ6'8MQ#V0
MHH48(V$JQ.<;"UP<3Q6']*-#]4I():*[<\Y[,1;]$^H>)+0=8W&8LC8TK,YN
M8M>579ZSODB!<^9*:I.MP(6*:4,^C93-6CXIM<%6'*:^#06K95BZ;N-E3)LB
MW`,E(,)02"W[LQ5N<3IE7RJT:'SZ$>&>347_=.I=8+AS2W&8L#;4:WEY[A*W
MPV/6%RGJF*F8PBI+X18:I@WQ--(U9!U56&$I#E/?AGXMBJ($$9W+<`^DZ*A"
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MTCEWUBZ25=RA#O*,9`=)!ZZ@NY,=&[E#S+A#NN1.)1-C%7>44%`SV>'=<H?8
MR!UBQAW2)7<J%SY6<0=88R8[I#.M7+G3M8H[Q(P[I$/N'*A'Z9I=P)'DJ]X%
M]]/W+]ELFOX]^0ZSG]+EKPG4,?UMFJJ_YLKM_L</VX(>Q03=E#$;Y_G[&UV7
MXG]/\Q]^WCRB.)/D?K5TI7C'G]XT?M#/"H7RFQR/)'*-D$1=>A\'2M>L1!+F
M\?TVODL*\'3=&VPO6<*^"7C_AP2>`,9UAQTVPTX]UB-VU9I;*[';G,(",:A2
M7,RA2K=Z$I^HV+U6/'4%_R7CJ7Y_!X.=.]6G5F-8=*-<,H8?D^481J.N<['7
M!F2EH\I*((O\U09.F)^NR[]K,#XSF^YJ,87.P<O%],`,^6M#M=(+:R6J(<SD
M2;)[Q;/'NBL[2]^EL]GCE8)6-&E?&F@?;M*_=)_,E:+6/)[ATE#4'7])=@!#
MXT_Z_'@/4ZFWS5>5CU),GWY,O]XN/R]*.UR9,7'-@O1*!>>U8E8,;[HTS()%
M<@M]?:"VOR:SVR2]NS[\GAG09BF>M6ENP6.0S">W=^.LGLL=SS;S2'Y+EFWI
M](8O`&I^\-^>'WHX"--IPG2UAN69.:*#+)TF2X/!JT[QM5*.SASV&SPVOT%5
MI<"ZU"=;]:]3)LI!V5<M$\$@$TVSZ*]:)B)W$(JF=0_7+12#3#0M5+EJF?`'
M1=&XM.BZA0(/0M&T&.SZA*(R5JT8:GFE$E`LVKM>"2AWBEX3^G;5CUO!'K;3
M,+>M.E:_Y]S2DHV&JN,=9596'*,.Q=JX*^(%<",N1?*R<*L5B^,NB\7MA(XS
M#(7^]L:SFRW%Y3S:Y>/N/=M\JHS/[\FXR]L1VX&SNFCQ">`^`2NO$#=/$H$4
M;B[V/%MM7+90E"\?/ZV^_#>9+#\OWF?^PSB=C57X%B^R<IC!_.L[F`:]`^FO
MX_GJ9CQ9ZD')G^['DRY+3FW&%B-J:\GIJ=AN6W$&E#U!4-&/0RW5O!^3?)FM
M2HQ@_90_GT+%?_:0U#MRX+)8R4&2W:7SKDL.K41SZ)9[I7A:&XL8XOD9MBVL
MLL>N$Z56HSCT/%X\AD//XRL`$I7#`"QU>)X9ZU`I8^CM]LEB'*G`!%D:GICA
MZ.,!1TB32\PMK3<PQ'$XCTC?!F-FNX$\-"XG&I`LD;P\S5I%,AB0A,!#,HXO
M',EP0'(81O8JD%2^CO);/4F9I4BNT^IPBPS)5H@G]425O?Z;=T5O]R)[5(^]
MO[E))\GFX>O$U?4\Z5E:#6>$Z^:L+FZ6W\99HIY;_[@S6P?2\->7.5@C3(6E
M:;RC$-:W8K>+V?3MW7VV>-"Z^VHQ99186C%R%*9%,6.27;T6IDB^!CSC539/
MERNMAN/T._QT=4=T&%+WBC$=AM2](E0)(124K_J-I0[2!L]/DV0^5BRH.;WE
M;U6$^I`N5OGL\6-RO\B6R?0*H23?,4?,XSO%8`R65EB:$SRU&*P(6]41W@:S
M)H5@QXO<+\GB:S:^OTTG2F-L/__C8O*_AW0V2WX=9X_*)[A242.2<H\-HM:E
MJ'U:K):WG\;S.!O/)VD^65R;J!73W9168]+2.ZIGIKO]<SS/\V0>I(ME,KGM
M=C"GQ>@-,W`O$C3&U&\VTU2Y>H6M`?HS('X>_R^9CMM2U\\-4UU'BY4!JF`Y
ME`%1D471H>=_S9+D&K,\NT+U.H7HM4(VS,*^1-2&6=@7-`O[(@2I3!5QR3$:
M!.ND))4__>\J7QJ8_T&B^Y;H08+;E>!7+3RO5%A>*V;#:H"+QH]2*FPMH7P&
MOU_263*^NJN!`C+B(8$LK:E[#K(L2>9AMLCS<)'=7ZV7-.SC.-)YLF(?A]7"
MM,XE#\+4@C!=:SJR>;4+<VVM[347)7\R`:NDI&F2I`]P*=V?-%UM;#!L"AID
MJ559VML4-*BF\\1I"(&')52#7'4H5T6</JBL]D1K2"%LA8MAAMU!:;4E63J?
M^&F2JN^5Y%=9V0!2!=+D6=J!\BR(FX>R9)HN]QZ]5C09%=86A)F@N<J7B[LD
MNW8\N60NT:>3#3'0$9-RH6ZC^F&_IO/T;G5M#NF3\C/X#(/P'"4\=@K+@%4=
M*R:IN,H;X[-D9OS]VF7&3AD9L!IV#+[`CD'K),"N+7/VL(<,^SO.%G9BAB;I
M%<UBRCQC$KF6=D<>F#*_,Q`Y#%]@4:[%J%)))+8T>V&.:C"@6D75Q0A;ZIJ8
MHQJ]R*ISBV$E&"%J:?1O#NO+;+"W&%:;-]@?`>N+[*"W&E;,^>4KX0'688_=
MZ\9SV(!V\1@.&]`N'<AAH.XKQG08J/N*4!TFWETN:,.DJTM$;9AT=4%S@:P7
MI%<J.*\5LV&TRT7C-XQVN3C(KJA0[Q4B.(QV:;TOZWJ#)BU,.F@:&C[:DZ<K
MCN>&`2^7.93CHL1I,':#+)TH2\.`EXL>Q'%1HC6HJ4&NSI>K_1D<@\JZG#$<
M%R58@\(:I.IDJ1HZN"\0JZ$;UWZLAF[<'KMQ;98`9::YI15)O4C`4*AO77>V
M#>S!NG<=L6%/I0EBU$',J)]>/=8I8F@?L:'BLADS9(89ZAHS*!L8,#/"#`DC
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MZR"<\\RB/J];J:);I;`C599&ZL9`!KT!28W40_%85T`BT.XNDNJ'H5OR0KLE
M70=)`S.C'R.H.SE29F8C1X5"X/_?WMGVMFT#`?@7&24IB;*'8H#;H%B&=C;0
M=E\#S58:`8J5Z26K__V.DN57.:;34#I*MP^#&U&TJ>=(W1WOCK!"8*U>^L*"
M<%`_K\UU70-CU<PD1LZ8/%P.*)E+UX4N]5SHTNP\]+8`*6"F>:YY6JBJ9FVC
MHG@9E*@X_->D)>%$U6DI`#[B.KZFLIDA9&)<[=@+^(`LGL$=,:&W.RY&8FSD
MZ?"QD)5;IX[_`=5-NAN%#>F+8AX'J^,]UK(<W&T9-AL]AZH%+`6.V9TZ'=%F
M!H-1.*!">Y2"Z/XHA<U&)BS7^Y%MF,MY&XULZ[P8N)('6.DUMB&K9J9$P@$!
MD/4NY%@E(\"BYR+-<E%;>8`T2-<JV:#1734#DM,X3G+5=0M!JVI1DQI1>%6S
M]BCZ\."1:F$:%&_GL^%0P_6N0O)PF&`3X2%[.*ST%@KODMFU;69*<ESFU_.]
M\BFZ$\XETNWB2S[%LZ_?S?O9;$RNKR'LVV:F>(*E?LB3?,37N1@]#8K;9@8H
MLL.#_,AP/$LN6@$E:+UO[]1_,P[$D9[$FLG3`&0O\VH#@_4)AB-<-K$+QM'D
MX#V9'-+CI>7G>DAMAJJ<^K?@Y[3('Q*PY->'!L,-7,WR:%%Z>-,W3B_HEHHO
M':Q!2)>HE)K"=+54U>_C/XLTRI;1XNU-\F[XT%FD^!$-,X[/$C9TZ)5%D-!J
M:IJ0OJ5AD!7IVH`MVC$:.F0,)Q@Z.0PK'?*OX8;CCKG#D'II].!,>6_A@"[-
M)5*?IB:<_LX<1YT-[-H)Y_MJ&6;1#[`^PV5O`54I9M8!:C&KJWL\]KUY6LS5
MZA8/%5!!B@?4`A5-"*V0+F[S-(%QYVNU;Z/<H,KR*4M2G)23_52`M9,7J7)<
MS^[OHT6X;=LC5L+W)S[2R$\M5MM)E=SG_P4EK?KC0<&1+.^)W5IC<['6(+\*
MV^<PR,*')%[>/CZER7.Y<O8+E.<Z2#7QJT!50=9AVL]%T)G(/D#J%YPJD4PR
MS\.Z:_=2^:M@E67;3;N^;-91:5=4'*@X%!H45!0$=U$0!-+14VFP"@159L,'
MA:I2XN!`E6QP83FH3W,\77:JAB>9$$@W*WYU^I@OE/,FNLP\#1<Q?-TBB+_`
ML+(\686]\&*]*((D<JW49D)`'B?I@0!0):_(T#14?(M,V3>11Y*_=HJ_H4)/
MBBBZE:C_BFB3")+(#6_Q&9"S@@2!:L#B`,"<\GPJX3"DT1*?@BC].XB+\,-Z
M^_$/Z#-(%P_KSTHS/Z2S;72[>BKRK&S!K6?5>;&L-L>\.Z:9,O%?)Y9.BX@H
MV]LF2)3MC14-97OC!$/9WECI4%HD:D"4.609*\H<LA4;90[9`8HRARR`1)E#
M".%0>@0V%!2U8DU,25?2T5-IL`H$I4?@@]+G&`>;.`PHXL`*++0=;0DK3-O1
MQL<L:#OZ%\52M(BHVK7QO`D32)>0"[LV>_4L/WYLY_S*3E&Y$V?"D;HO]5%]
M&`0JQ(?*ZJ-J[5C83EDYG#&L)Y3ILYH.@I682,F0NC6O8,6'P8I+:?\:.`Q6
M%)1H!20*2L2*AH(2<8*AH$1T=##YQ(R/F9/#Y8W$D[>.BAPN]J`BAXLUK,CA
M8@\K<KC8Q(H<+M:P(H>+%9#(X8(5#3E<<((AAPLZ.I@<+J;'S$XR7T$B)=88
MTA<R7P]/S)NVHPDQXS%B+@.]!Y=(NB,F1PXS&0O(N*Q$DCMCH<[89!,7Z]NK
M^">+EE$`.D,0AXTB.0/U?!K'2:ZZGCV9#JIE(R[;A./#\\3Z!KL,YW8^LQ8&
M@WFA5@<ZI/X52_=XQ"8FES&`XV]F"A7(/@/`-SP[3@!0/<`.`"!27LR/63*/
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M\YO2Y$<:/)[Y2=7%,]U4<QX^_`]02P,$%`````@`:89C1D3XH<U#%```!RH!
M`!4`'`!M9VYX+3(P,30Q,C,Q7V-A;"YX;6Q55`D``]8L]E36+/94=7@+``$$
M)0X```0Y`0``[5WK;^.XM?]>H/^#FP(7O4#SGIGM#G9:.*]%@"1V':>[]WXI
M%(EV>$<FLZ24Q/O7WT/J:5O4PY),,@VPV$D4/L[OZ(@\+Q[^](^WA3]X08QC
M2K[M'1\<[0T0<:F'R?S;WL/]_O#^_/IZ[Q]__^,??OK3_OY@,AE<4$*0[Z/E
MX%<7^8@Y`1I,G3=*Z&(Y.'=\-_2=`$8;W&#R_='AZ*\#\7]O`(]^/9O<#$X.
MC@>#IR!X_GIX^/KZ>L"8EPQYX-+%X6!_/YGN7Q%A7P=?#DY.#C[E_C*A(?&^
M#OZ6>W3.4#2Q!R1]'9P<'7_>/SJ%_Z;'7[X>G7P]^?*_^=;T><GP_"D8_,7]
M;VA\]'D?>IP.)@>3@QS&_QK<4\*A]>+9(<O!T/<'$]&+#R:((_:"O(-X4#^&
M.P".$OYM+X?P[9'Y!Y3-#V&:T\.DX=X?_S"(&G]]XWBEP^MITOSX\-?;FWOW
M"2V<?4QXX!!WI:,8K*CK\8\__G@H_QJUYO@KEZ/<4%=RJ0:!`V4+\=M^TFQ?
M/-H_/MD_/3YXX][>W\6$/S'JHPF:#20-7X/E,_JVQ_'BV4=[\;,GAF;?]A9S
M\B8X_^GX).K_YPOJA@M$`*IW20(<+*_)C+*%I'IO(,9]F%ROD+]P7$;GB&"7
M2PD*8G$\%(T/2\<[;$OM!'K^^SX`D1-SC&97F,`[PHX_IAR+*<Y]AW,\P\C;
MAOB:(^\2QMAA:*L7T6#XX`D%V'7\[H%=P^JV0$,_0(R`"+R@ED@VQ^N<Y/LG
M8,D3]3U8#2]_"T&"A\0;`8N86);@3XAPF#BBI"6<9G-U#O7<X4]7/GWEU\3#
M#+E!2SB;X[4F^0)SUZ<\9&C$Y@[!O\N%!+ATYP3BX6ST+#9%>,:'GB>%V_';
M+F%MY^P0]7VX6#AL":*"YP2^6-<AP=!U83\.0&D84Q^[&/4!O<W$.\>?MKIR
M,/N7XX?H%CFBNY#+=/4;<HX">(TWV'G$/M"-^"YXM#UQ^OAX3GW?>:0@Y93Q
MZ9,33!`L1QP(OJ4,P0-R?#2:36G@^!/T@DB(+AU&MMMT=T^DZ7R-!^`3Y"+\
MXCSZ6^TSNR=RYWR]Y`&&-0=Y#QS-0O\&]LJ=?-*%\^X<O=`1PD`NN:/9F<.Q
M"^O'!?9#("Q2&6XHYV.I3"PHD<K&+KBS%5V[_R;!0/-"'[;S(3SW!'GP&N^1
M&S*Y^EZ^N7[H(>^*T<7T">5L[=&L",S.V-L/X1WR?\PH*$A2EQ5*[;/8YS*B
MB_[:CFU;S-<SVA[TL?K3=/DE!=3]OFJ?]*!IUIRD:UQGPD\FUBHPLB(-OR=L
M-2?J'5_V313__?)-_-AV#6LU]0YYD&KCHV?Y3EX=YJ7[^HC`RGD!/XUF/S-8
MA1\X+,#PZ,QWW.\P!M#'HWYC!HLRF=]2#_G]<JX/@G<M<S'IQ)L@'@`A0+E\
M_D`P['2PC\'7OP/YJT5&A[R)]MNI\]:+J5XY>C](!'\I@6V(@Y$%>D;DM.<7
M:(880QZTD38M[\S<;CEW/UP`\X>"`>_C6,,"6XDRD*?TRTS;GB&"9KBEKM-J
MYMUP0*PZ:(X)@55&:"M$A+>&"Z'%BL4)E,X'PJ`/J+B_RU<5D]>=='1'48<<
MNT&P*%V^X2"1R3YTJ;J3](KK_,DA<\2OR>:?ND97-E6O&*_"0"KE&.3LV?''
MSE(HY"!'H,7*UL,Y0ZB];=-JY@XYD/F$HHWS!KM"84OG*MYYCMN!WW92[;A/
M=.`^T8_[5`?N4_VX/^G`_4D_[L\Z<'_6C_N+#MQ?]./^00?N'[K%O5C@()J,
M@(DH/:N(]!1$;3S;;I!FUO`M)G@1+B*=0FH/B3[1&_!:DW?KG_5"-[C%/MCZ
M8#,F<PCKGRX='U3D<OEK[;=M.7V'O+B$YG2)4&S?C'VG#Z=G[5DZ1/;/T`';
ME_G+-*">FRAQ#X`<<NICD;'HI1TFB(>^\"-D61WMX'=+2J=QL4>.?@M!TBY?
M^@E2U)JAFS2F.QH@/J4IC],T))Y/VLG8'.TXXRB.'?L%"CIG6*;H+3CSJ?M]
M&Y;LD+J^V5D:B^R)237G-`-Z\D`'"]*YS6#%5*2!:&%$/'/?;$BBL&)/"_*A
MV-[7C48SF\2&/F1BB_E[_T`VHMBB;>]B47_:OAF0RYJ=Y4-O$^0+)>><<J!6
MI)K(X%RB!O?$EK;$&,ZL/KZI;DCJFW%IE*?W+ZMT)ITP^WCY->;K&[(,Q8.E
M'+(H2A?+71R.A[V^]S>^%04FLJ4/"6E!1]\LJG0K]BXY6U'0/UN4/K@=,*31
MW&:QHH_/9RL*>E];UAR0_:^P-2;LW7819^KD5RH/VHU!KV$HP-%QG"3QHW]S
M;ELJ^F9/J?>R)V;4G-,,Z'VL#HUF[MV2777B]N;C4TX3`W2S@PLW`&<%*+1%
MQ!/GS:*G8JZN#JE'LQ^N3=\[337/GDLZ@!+@U,KLOJ@T0-GJNX\GE^4$9@Y_
ME#4%0KX_=YSG0R$3A\@/>/)$2LG^T7%<6N#/\>-_)R>]P.83$G@>,B;SFJ*9
M0/%!_K>]BL:'&NG.3JC=H:`>]85=-&%@(<J?"JT$H&BOA?HT`#1VL'=-SIUG
M'#B^BG9%:RV4R_1A%:'1'_7152$#*VUT4"D*`0@U%_X13LD7QY>*;W#N,+8$
MQ5<>8U!07Z^O%E31<47A<2T%L-Y,!ZU))OP$F'<._^+@CA*W5&Q*N^C%(`]O
MEPN]HK$!=#=@_'I['=2O'-<HI'?S4(4V"F&AV(R`5)-=W$TSEG+Y-F1'E]9J
MM,%4RG5Q6VU4UV:UJK4.RL<,/8,R%)^/+*>[N*T>JA7Q6="FE<27=-&!(3L:
M6*R1*'!4=M.&)7'>QZ7TRF6IK(<I""H7H(I.>G`$#B;($Y5H@"@.]EJX"&4H
M!=0`[&(UELJ..O#4WGT-V6^G3-9>6E9J\04-4WIS7J`A6R7=86XR(/RXX0):
M+>P8MSCDHNZ'&&T?!VB1])\QNMBP.9/)J,K<&U`&+);%13\='>T-7I$HH"E_
MA]^>&:8,>/]M[V1O$'(@CCY')K>IZ*J7X0SPY_<`N'SOS,!^>0]@%>IDAO('
MVU"N;:MYL#6](AGXXW<$OMP9FV$^>4>8%<I[!O;4'K`%;H$\U"+C*L5Y_'YP
M5NFA&6:+=M\*S.6^Q`RQ1=MO;<0;'KP,KD4;<%V/F>*+SJ.V:$/>!G51JQ3\
MB46;D]K;5;0KKX=VLRWJ;^\0LBJBFJ'^\;VA+O4`95_WT7O#K8HA99`M4K+K
M058ZNS/,%JUC]9;MS=!L!M:B%:P>V"(?5@9W9>G:?P]XE5DDV<9LT;I5#W,=
M/W$&?YLUS-0,M]4;2?23NGGEB);4$RX3QV-7@BKXM-%,AXO]9T00<WP@8^@M
M,,&@>$B^I>5E"TFOZJ4G.!\=XP#C`?0E^(7':H0R1J]JKX/Z.Q1D=;X5%*^V
MT1*:CTI=D'DEK44MM243W,%BL4I/N7A7=-(44D6P<0F7]`6(J4]EE*$<1GD?
M/2CD%R:*W<O"Q^JX_'H[C=16$,GU:BBJS6;-GBP3'BN#D'5P5VYN5D8C"[>*
M%9NR:)6V,DI7#;5B>;?2-5:RRZY^U<GR9&6,JB;*S>]<$54WW'I>WTQ6O?=*
MU=7*^'(9U@(5H%T\6:N]V>Q.2/WT;E[Z:,R!DS&"-RW*X`N'&;I`T;\JV[G)
M$'J.%<#;=W%<IJ\0PTH3'32F=Y0,O?\+>1!)R"\.*]/,R_OH0+'^NJ_)6IQ,
M@:2ZGUEH\O<+-@2T<>N?`9C6PGI-,*UW;89I\XBU>%(P4SZ38HV\.CW,X/1:
M2*TVF]?[F8$FVEFC$-DVPJ/J;Q"Z5"TN/=1:L[,9N%8SZVHC6NMF!I;5#.<K
MFF-Y6ERI-L):@QF$>RTEH1G.]<Z:O.R"TV-&7S#HTV?+!RYN7HH#7'FV1T5_
M0GB6KS2M<LNW&=0@/ER3%WA3'?.A[J`&\:'@,VS/A[J#?D2?E`<5XS*6<36[
M*9TZ;[_@X$G8W\!#6#^SDI?YHI@*0%L/I^F0IHN0QX7?Y)KS$):6J/1GDDFC
M`EG93S>:W!V/_/(-,1?SS--1@J:XGY9C=4VDKDJFM,12MG#(Y'UZ;9=1*[/2
M>V):[3W8RBSOGIA66X%KEX6E+PK6@=:Z=FRQ:C>Q,B6S7TXI=BI%-N=_'*>V
MULX4F:&&!_2ZL1W6%K?BB+W]:U4+KJQ&4JP\>]H]4RH_)9LR`;IG3T5DR\J$
MI^ZY5"_6I,B1^H];G:O]VG8FINR"4_6\YHH4M0_^*2)#BN2V#WYM9@!8>5AT
M1YS:B,1;><)T9\O81A#,RM.INV#71NZ!E6=:N^-4K3P3*^NP[&P/+,K]:%?%
M9??IF+F[VW+7RPZ)=^<$\D*WC#/%=_)JI_M>B`1;CF:EUWU:37S:*C4E;^4Y
M;IE'FQZ(E9J8O$(JDT=M=>932C.LBAB4NKTY]>?KHZG?OY-$P5M*T/+68=]1
M<!42KP:AM;N]R\JY^HJ]E;R9ZDI_A9VM=,G68D9]T;;2`]M(()I4,=U&2;-H
M]\ON2J2,3Y^<8"*\\>+>^UO*$#P@QT>CV90&CA]K^:(&1G+ST;L#6N`?M03H
M)0_P0L3E0#.?A?X-?DE4%?-I%R&.,)"DC&9G#L>N.,B,_3`01D82,!O+,U<B
M@"UB(SK4,#NRZ%8H&+XXV!=R/*6YZ']\H$VRN@Z.&J.8C306IM98DW'T9$>R
M`#Z79VEPWR,W9,E-O["9/0JRX*MY(%[V>U*N2,`J>]==C*R#(TJ2AKZ<520I
M*+"5L:/UL#IX\8M44>!-O2#FS-%=N'A$+!97N6#R41AP<<>B<->D45,%"[8=
MS1CDHYF*VB:(2T8Q".D&<67"W6P,W4[';3:R=YAQTY8-[1=*A5%H?BAR.P6A
ME@S9Y;]OSXA.%!!%:H[A@K3E'I/G7L/%V\K*17VQJ8X>T^XN%O.-Y'OW"7FA
MCT:S(3SW!$?`QL\^P\LWUP^!')'(/'U"YQGEZ0M8L:5S5K1.\,D%._F[=3*H
M17_5=.EV5O`U2U>%GWT4!_>&"PK+8Q3K4]X:I(K7=#6\4=<+_LS4;I**3D;A
M:'M-HHZ5N`Z86O=<Q2_1RJ!`4R9T]Y4KE,2Z6HYI"[*ID?Z-XMTF$[J1S6\5
ML=F>7/SW)$G:>/+3&&%TT&OXZC`O#9Z,"*A.%_#3:":+USUPT,#@T9GON-]A
M#)B*1_W&#(MC5+?40]KJHC=\9S%@XF7Q3_G\@>`@3N!:ZH<2*:E3Y\W8!*,<
MA8+;E(B8\6@FE&[XU2%+GF3\09LH,*TY?RBA)Z6\NK92:1<]!??6>+I*804,
M52\CD)0IRHK&1M"=$PFUCES5RP@D#<@WAN8T^588]/+64E@CQ6[&+T"R84=3
MA0"V&<EPQ+("JLC3I.*:DM:P5X<S`[O(CJZ-3#8V@NZFKI`&`QB!#WZ(;N%<
M$:!&;ZML"(,Q)I<.M(.9CF(*TN19;-#$IX!$A7)YE,KQ^>IYCMK@&PYL!#^$
MH139JKY/7T45D;J`"WIJ]065*UU%EQ0VVFBMC"SWPI.UK=A*QV$+QE2ME5:&
MCSOG1[P_6EFGH1TSFFXO5L:!6[!HW:IO%]:U#W^MH()%!>':[#'KBX1%A<IJ
M^DI*\<MV5AX^;X&^V$6I.#1M>-90F9NI],UO!%TM*FJQ->@B6T-1J<*&.&HN
M2C!!+B4N"'.<CC-!SY2)]+@D[)2V/4,$S;"6%)>4AE@S24@IMO=4K345LX]H
M6>7S^9-#YKGR"\V-V@X&-H@?%\@+7?%#R?T%%?VZNHBE>)J,FVE:WSJI6PS0
M)\V%9>C&+"9$!E?CHG3);K9L`&B;T0V2-\42,0RND"=N[12.@A!(6F;]82UL
M)IM;SF$0E^ZHV&W$!_;H)]=:%A=_%!<E-N-.P[$-XHI4_=-'9'X-ZD;#9:MX
M"(,PKCC*<MI",YC*4?I<]^2DN?56I&ILLV27CV/0NTJ]6*61G9J=C<15$<VI
MWU^K\5&AQ*X5H.IRU[(R`-">7>I%S$K'?PV&;*/#6NGT;\F+BCW"SG-@[3^8
MHA77S@K,[7F1MTCMK*W<I3QLN+MM*I+<GA$*E=]*[W][;C0U"ZUT%;?<8;;R
MOEA9^[B]/#5RAK:+.1GJ=!>G.-`<$W$@7<15HP/$"W'*5ASVH)P_$`9]Y@3_
M+OD3,]F`*EHWHD#NY1O.Y-C0DQ&;A$9RQZ_)YI],)/<J#.01.$Q$G0,_N?+H
M`:9CLO5PSA#2=0HY2[H2I/"(V%M,\")<)*1>*.\`K]M;AWNB)FUQ=>AV`)-!
M#,9Y3:YHR/X'S`.5-W"+@8S&.X5942>`<R.9C?B5=H,W&4>KAM)P:<IK+$V_
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MWM$`\2E-&2US9:44YV\,SG@=.9O&T7UU<3Y+0><,_!0(/`,]^[MY"$N+W%M/
M=_+`5OJGXEX0`ZE7EL6P0N:;4&_J&]@LMBW:6L'^W(7LLWSJ[`3)6N\B@Y9G
MR;6)DO%^`9DJ8FGVIA5254:MJ1R6E;]!HPY9E`4;"TQ<_3NZS,E\SF^#PM0W
M4AE1M.*-E`3KWB']ILK2NDUL!>O'(.Z1Z,L30&/8NQ@*,)-_37+PK4!2:D!;
M3[>I0K]FY]=1VWXZ%"0\@FX$O_P_4$L#!!0````(`&F&8T8UFK-VR30``%K-
M`P`5`!P`;6=N>"TR,#$T,3(S,5]D968N>&UL550)``/6+/94UBSV5'5X"P`!
M!"4.```$.0$``.U]ZW/CN'+O]U3E?_!UJF[E5F4>]NSNR9DZFY3\FOB4;2FR
M9_?D?MFB24CB#D5J`=)C[5^?!DGQ(1$@0(("2+,J=3)KX='=Q*,?OV[\[3]?
MU][)"\+$#?R?3\_>?SP]0;X=.*Z__/GTZ^.[R>/E[>WI?_['/__3W_[/NW<G
M\_G)5>#[R//0]N0?-O(0MD)T\F2]!GZPWIY<H87KNR$,=G+G^M^>+8+^[83^
MKW,"?_K'Q?SNY/S]V<G)*@PWGS]\^/[]^WN,G=V([^U@_>'DW;O=;+\D='T^
M^>G]^?G['PJ_S(/(=SZ?_'OA3Y<86?'$#E#T^>3\X]F/[SY^@O][.OOI\\?S
MS^<__?]BZV"SQ>YR%9[\J_W_H/''']]!CT\G\_?S]P46_^_)8^`3:+W>6/[V
M9.)Y)W/:BYS,$4'X!3GOTT&]E-T3$*A/?CXM</CZC+WW`5Y^@&D^?=@U//WG
M?SI)&G]^)6ZIP_=/N^9G'_YQ?_=HK]#:>N?Z)+1\N]21#E;5]>RO?_WKA_C7
M8FN@PPFSYD6R?OR0_)BT)NYG$L]Y%]BQ3`78.6&VH/_U;M?L'?W3N[/S=Y_.
MWK\2Y_0_Z(1_PX&'YFAQ$E/\.=QNT,^GQ%UO/'2:_FV%T>+GT_72?Z7?Z8>S
M\Z3_OUP%=K1&/@C&N?9#-]S>^HL`KV.J3T_HN%_GMR7RUY:-@R7R79O$ZRU,
MU^X'VO@#=[P/;:F=0\_?'D-8H'2.Z>+&]>&+NI8W"TB\:RX]BQ!WX2*G"?&"
M(Q^3C9F%4:,/(3%\N$*A:UN>>L9NX2A<HXD7(NS#$GA!+3DY'$\YR8\K$,DJ
M\!PX.Z__B&`%3WQG"B+"]!"#GY!/8.*$DI;LR,VEG-5+BZQNO.`[N?4=%R,[
M;,G.X7BM2;YRB>T%),)HBI>6[_X9'R0@I0<KI']<3#?T!H6_D8GCQ(O;\MH>
M86WG5,CU8[1>6W@+2\5=^K!C;<L/)[8-MW<(&L8L\%S;15VPWF;BH_.?M;JQ
M7/R+Y47H'EFT.UV7V>DW(02%\!GO7.O9]8!N1(XAH^;$Z9/C9>!YUG,`JSS`
MY&EEA7,$QQ$!@N\#C.`/_MG'Z>(I""UOCEZ0'Z%K"_O-+MWC$VFZ7-,!R!S9
MR'VQGKU&]\SQB3RZ7*])Z,*9@YRO!"TB[P[NRJ-LZ<IYC\X]U1&B,#YRIXL+
MB[@VG!]7KA<!88G*<!<0,HN5B77@Q\K&,:33B*[C[TDPT)S(@^M\`G]W*'GP
M&1^1'>'X]+U^M;W(0<X-#M9/*W1I>7;DI4Q5,7,T\79#N$+YSW``"E*LRU*E
M=D/ON9SHJE_;B:W!?!USVX$^)CZ-RIT4!O:WLGW2@:8I.(EJOBZH5XV>56!D
M)1I^1[P)3M0Y?_F>J/[]^I7^L^T9UFKJ(\H@T\:GF_B;?+>PD]WK4Q].SBOX
MUW3Q!<,I_)7``0Q_NO`L^QN,`?21I-\,PZ'L+^\#!WG=2JX+@H^]YE+2?6>.
M2`B$`.7QW[_Z+MQT<(_![C_"^A,B0Z%LDOOVR7KMQ%2O';T;3JA\`Q^N(0)&
M%N@9B8N?7*$%PA@YT":V:8DR<[OEW-U(`<R?``QXSTTU++"5`@SK*=N96=L+
MY*.%VU+7:37S<21`3QVT='T?3AFJK?@T%C994RV6'DZ@='[U,?0!%??/^%.E
MY*E;'>HH4BBQ.P2'TO6K&^[69!>ZE.@DG?)UN;+\)2*W_N%/JKGC3=4ICS=1
M&"OE+JRSC>7-K"U5R&$=@18;MYXL,4+M;9M6,RN40.X32B[..]>F"ELV5_7-
M<]:.^::3:N?[7`??Y_KY_J2#[T_Z^?Y!!]\_Z.?[1QU\_ZB?[Y]T\/V3?K[_
MHH/OOZCE>[UVPV0R'TS$V+.*_(Z"J-*S'8?3W!J^=WUW':T3G2+6'G;Z1&>,
M"TVNUC_K1'9X[WI@ZX/-N)N#6O_!UO)`1>:OO]9^VY;3*Y3%-30/M@BE]LW,
ML[IP>@K/HI"S_XXLL'VQM\T"ZH6)=NX!6(<D\%R*;W2R#G-$(H_Z$7)41SOV
MU9*B-"[V3-`?$:RTZY=N@A1",ZB!,3T$(2)/02;C#(9$BJ"=7,S)C3-+XMBI
M7Z"B<\[+$WH-+[S`_M9$)$>DKFMQ<F.1'0E)<$XS6-_]08<(LKG-$,43A8%H
M$40Z<]=BV$5AZ9T6%D.QG9\;4C.;)(8NUD2#^3O?(`=1;-JV\V4A/FW7`BB@
M9A?%T-L<>53)N0P(4$NA)G%P;J<&=R26ML08+JPN]I0:DKH67!;EZ7QG<6?2
MR687'U]@OJY9CD/Q8"E'.(G2I>LN#<?#7=_Y%V]$@8EBZ6*%M*"C:Q'5NA4[
M7SF-*.A>+$P?W!$$(C6W6:+H8OLTHJ#SLV7/`=G]"2LP8>>V"\VIBW=IG&@W
M`[T&H]!-TG%VP(_NS;FF5'0M'J[WLB-A",YI!NM=G`Y2,W=NR9:=N)WY^)C3
MI`Q:V!;ED9$ZOTO*ISGS/\:L6YYW>I(.7&0DZ^7ZX0?'77](VWR@'3JD!Z9*
M#H)W#EI8D1?*47?8_3BT!FO+]1N3FO3NDM)XAG=KM'Y&6)+,4M<.:5S!$-B.
MGM&[3#)RE%8-D-+K9$5$[H"R$LVPR9#OT$3-Y*]T*%75'9+)/Y1G[YHBP9(-
M!M-6+L&@F]##"@NZ*9(KDA`3!J3!35*BQZ.56`)<N5OC/;:PR'.\T2+R;FE9
MFP_TSOR`O)#L_A+?HN\^GJ6E5_XE_?-O>9AS9KG.K7]I;=S0\N[3XR>9$.Q#
MY/U\*M;G@Q8N?H](8J$\!0SRXD_QO)]<,8=KW(55C1X1?@'+=X:P&SCS!%!-
M&\19*TQ!=#RM#EFFB:W4-\]=!8?M=%";;*HLI>(JO=TK*:YNVTNJ?SO70O<#
M"O/T6P:]Y38ZJ)RC$$2$'%HQP?67A+N,&8WEZ#ZT4^A??H/-3=%R9Y>!_X)P
MZ(()-,-IF@][@TEU54GG>7,Z:[LJI/.B,9FU/152>=F8RMJ>"JF\:KXVZ[NJ
MI+/YVJSOJN.,BM4"<DM(E*N9>R=3J8D6&G=Z[-X51":O+NOTY_?1R@6H^>@6
M_EE+>MY0*[U/2?$</JU/A>(UQZ9S'[W!I/6@H39ZD]UT%0<"$YT[V67)$4%B
M[&+AN,@+D_!X:SZH<7)X0-_CGQKQFW<VCJ]"YCRY?D78=@G[W)4?2,U-5SMO
MC$;/*@U47'AR(QCTE6)S5_$F%!S3-"DTW()[?4WC2L$&Y(S3Y?[+IVVX_1@#
MZ/A"3SBNWKBM]^Y4M=1.\3R.,E.G<UJ*,EP%3E(+080-7G?MO"6'=$JB"#?E
M#AG]N5M[@LN<6-C>C9O&861#2FGO!0[6=5ZUW<R!I#_C),"@)])B]&=_^?CQ
M]&0#.P@.ZNW/I^>G)Q$!DH--XF7M"\OUEFO.\K\/@N5Z!TW.\5\'P7&]LR?C
M^/SC(#@6<!SE+)\-@V6)G7Q^WE^6.8&@G+]/_>>O4AG*.?RA_QS6!'=S7G_L
M/Z^LH$_.Y$^:F#R$254Q*N1L+3+,D$S&[T==%\T!U*H[=G\[-X#A&)?'Y?'`
M\UQD;-_?N^/GX\>4HP1]]9FB:9'S\VF(8SQ"^L?`#]%K>.W%(_Q\2M`RJ=ME
MY&86%<BA8SG_R.;J$H+<E0(_.5_F*@QB?'4/P<EE9:[R(;'"Z]U_.</FZB*M
M&#Z(.>0<FZN1\#ENXDG,N=:EHAQC80MX]W-!F.O[:?[YF8&<G&US_3\*]KG4
M`C#7+R0F"7&_=>X+,]<SU'[W,^(_.?.]U^L:A)]S[ONN_?%"&3F7?=?;]N"O
M.6.:]+/*/!PN>R5,4:456FV/RQK9&E,N#A]RU$)1ZX<8-5/=Y@U%'1D@!R^Z
M\5-86,VU9*]XL%SIX\XW`;X*HN=P$7E5S^A5<R+660E"XB(B<#P2<H_P$N'K
MQ0)1'39^NJ4*#\%KKB>S!<3DA\FNF[ODVP7R[16L\F_<!(S:;@/B15->R2%9
MVXPP#MBXMIL1O(`B2/]@+=&9*!_%+EKRD^+\V%]=!Z6/C]Y;OP?X,B(A*#_X
M0$?:SU@2[*WD3+IS06%Q;L&<3+R/]_1ZA>D3]?LIN$!YMNJ$4.6`:C@OEA>W
M?:5%G*O.+A7#ZOAR:5UJ[N57;J/D*SQ$=*SI(GFYZ+^0Y\!U]&@=W%HUC972
M<KO>6-0"2:;A$;+74DMF74I*JA7ZR\<DDL/,LF.VUY)Q1U^RX1S4^>_:J.,G
M`19:Z,E8W#WE1D\26F2I=*`PQ5K730L*&.8FZ<$/!C-7[M5MM5"=5?8_N+TN
MMJ7[BUQLD]?*"IN.FZJC8&1]CA%1/;/D2ZA>`7UP[C9AEVUZZO=NBF%/1-7O
M,CJL3E+:@1EB2)0NF#<;ER*IW9>VMHIC<L`(EP:BK?>L]`'\TF)-<53?/L!C
MFGYR)89K'S`Q+9:&J&>T#TB9%F*H-P_Z`)QI(0"^3ZT/^)FFIP3+F=$'J$Q;
MGBN<2?JA,D(ZY8$_I+2;B^X([5JBP'>L\)\4^=ES.6K'LXA'Q=79_`??MUG8
M?'"RJ#>N4A&=FXHLD(V(9ZUNX+Q.X5X4&A.;+UDES?AHBXOM)R]C4_2;CLAS
M?,)FE.:\LH+-S/9:XN8L:B;/H"]9-BLIO+Z?EKAAI6HG_FW$^^O@+J,C$7YY
MZ:<[Q)GZ<PH&35_I>`A\O/O/"XNXI"[NJ':.ODJ)YXM6-[Y6Z5QLLW_^EXLP
M7':K[1U<5AXG!"7862M?M_XF"DE,S!DW;L+KH96#PEU'#L7,A:;(C?$FN)1&
MXS`BXO>!CT")P]]0>!/YCL"E(MQMD-'2HUM8PII,2;<65QCZX":4DH'XLNZ#
M:[#1YQ^&4[`1ZQRS1;LOD!EUZT0#+DI%H?(XX`A=YY]!8$5K#VL)NX64&R25
M"[9&G]?N11.$4<C9)Y62$-,L31((QPM^)'D8`;:0.7EDS(=*J539B;(@@=[X
M4?/W20-,GE96.$<;C`B-@@<8P1_\LX_3Q5,06E[JL*8E@';/)K7->`G0BAYD
M"-_"_W@KY%9#JVL:&Y&',*ALEP'EAUQLGV!..3:R'D9P4.>8Y70P@OX>9N@<
M$,1S^S(:FT$WS"AW(!5Z*/&.77ONG>MY6_;!OM="R:Q?7`]9SB-<=<`>?<.>
M/3VKZ5M`][-?A7D!A8G[]DNA@9(YGZQOR+'84Y9^[Q>$O1:QKPM^J0W!;8))
MT93Y?76"RW?Q_-7.,M-Y5J]R\)D<O%NKI8`8>$I->'-A]Q1?"VH$1.H!5JL5
MU_GA((N\,F)9'ZJ+Q2K=19V@#S$O&?8XKH@^Q+AD6"UK6GT(8\EPQ]3\M<>N
M%#.Z;UC)8M8'YJ*L2%QY,X621O?JZ%X=W:NC>W5TKP[7O6H@!ZH`E$=WUK+H
MP`CYES@@Y#+`FR!AF4,+I[D2>F8+]T]Z'7/DL=]$J_M7O[JLII[(Z(\U%P4T
M*(?LL7W01F!Y1B_TZ(76YX\=N@.Z9?ZO$<MZ]$*_`2\T5]D>G=(]9?3`9!F:
M5_J:A.[:"I'SE:!%Y-VY+WIJ"]`G)*(089J2M(D+7/'\S*S66O(\(PR?DF9L
M^,Z-^TK_1;C$<SJHJ7&]"RYL88+I`KX\XDM5M)<.Z=XABR#ZO./M>H.#EP0&
MSQ4OKX<.#F8X`$4IW-)7O&@1CTRJM:YFD9Y&<51YF$CR5CF&45S6.=@%.AK%
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M6#\R4K:6_-)'I%4'0`P9R;OWO2M-'S5C:RFZVH[RBVWU`!RG69<S]E""=<XJ
M9<.;(YL':\WW9]5VTX1D?(%[S85K;P;#(HR1$[^/7A,(X??2Z\1JN;C$7%U*
M)E&%,Z0GQ9G<IY3JJI+.\^9TUG952.=%8S)K>RJD\K(QE;4]%5)YU?R;UW=5
M26=S,HT\$>G\TPT3?LUNIX/:7RV,K9H`?+F-5H?[$53,$MZZ5N<PUTNO6I>L
M]N6KN?4'[/'O\C,H,D/[X#P6U?Z+8$LQ_:P/3N.FW-=K`'WP'3?DOEZ7[(/S
MN"'S]2JJ=@]R=\S7:Y1]")8V95YFTYL;(97A7MBMHO^-P&X8W]/B^_"<>A,V
M*TRK/CXIJ-)3IE`=Y!M'_8FR[8*&Q7CA81"R^*NF8BO1FD:WD'-%2\+8;OQ9
MX-\>BM>F[X!^#H?9G_'?F9%0EMM;U?!ZW.-]S0\0H[@=I0QG6A$A(IP(4-]I
MS`,8\P"X='VA:7"RS"2=C.*C+GC:-Z3_`V+=#=PN1O$PO&P%%1Q)EZX9\Q7>
M4KX"KP+)H!,6=.=LF%VA9,S:,"5M(=68^N"#;,:Y.MNV#YY*Q:LCUMOZX*@<
M<UC&'!;Q9`X!]T0?8I$-%\"8MV)*U'',6U'C49\XCIN0=^LO`KR.;W+M:2@T
M0$27'L*$4@HDL\DT`;X^)D>\S02`CGC1Y!FZB`BHNH1,;-AS)#FJZ3\QXK-3
MW\\4;MB[C-7:$,J34_`6K&V,0,N\)21"SA33_T\OKX>(7LO31;SCTU_%&6TR
MN)9XHF<1`G30VX%?+_RPH6YZZ\(2U6TU4IUB4:9X[BY7X?4K:%LN`14"-/[L
M1Y+^2IA5_QN-90S7V<K/SNA+R_.0<['=)UJ&?XE1-47M:3HR78C)CI]$X0I4
MVC^91PJOAY*8.!,0EOQ`8N<3+*:JT+AP7Z,2"(MG[==-X.?$,K^!_$@Z.+Z=
M3;D1F/QW'=1-0303SPM":AH))/^PV^N)5A8__)7[XCI@C\VM$($Q<$5?L,+<
ME'7Q_OJYFUEXBA]#ZIO^Q?(BE)41$&&-V5D_7X)';DTG4_C@:J*<#J;0/XU"
M$EJ^`P:U!!/%7II0"S9"#J&^@5B)]VUT2WTVEC>+GCW7GBZ`9AY/HOU-X8X^
MT,>X_R1XY(UB#*>8ON0]720VFPQSY8Y*]+*Y]8+\"S<(D;WR`R]8NC5/)_$[
M:$&,Q$*)OS'UOTP73Z"!$\N.`YT\&U.@X\#XT8Y7BHF[V,9&E1A$Z;"'TJ(1
MLI4BNB\/(5L3HG.*IKYLG0I6#RUK+R%)HK@+KX<^#BZD.:CNH8^#2VD.JGN\
MQ<(<DJ<"H[V^;W\E_>VK>VCA@%H$5<ZIB@;:Z./;:=HML]A2CQ$V!2<Y)Y;#
M;J^MD$PIF#U'U`.71+D?-Y[+\L>(]%1S3M#Q=H9"#&.J/!T.6VF39[(:KR)J
MA<Y@RP=.LDH?T/?X)_;2$.JL5JI5<ST%7WWXKM^Q&\(7O0GP+BHR750X%;F?
M0\'P6KYC]$Q<Q[7PMF!Z\'8UL[V2KT7E1=RE3YV"HO=E;1^]60)CE:5!5*<R
M(A_!C$(7Y^8B2H7!,QG[-=ZSG&FCGX*N@=D4%[J`B/JPSMDPE!)6G.<ZR+^M
MN1AY/IL"?K"<27,K$XDSR3"B<R;-S6R16;`,3U'.IKF)+#)L,MQ).9OF5MR1
M89/A.<G8_-374U;`O94SV>LSMMXNR1DU-]5(_)QE!@QR-C4I@<R47"[.LSH+
MMR*4->#$6W$!"?IV^I!C*,RT-*"A#[F%XI^\X"#O0^9@+6-,CVH?<@7E/EL6
M-]">#JB2-57I%WTH#"`LE-;X^#Z4`&@GC?H<B3Z4`VAW;>VAT_I0P52"86%X
MM?9RIDH7>Y,DA5P"/=;0))-/<IX'H)=)@(ASOGNLMDF%ZW..!Z#*<1.^<DX'
MH-G5I5KDS`Y`8Q/-E\F9'H!BQDM"R1D=A/95DZV2<]MCU4L]CB;W\)NKF8EC
M^(LKHI!9F3-I[O74C$E.@F;.M*;#NT%)(F9&0UDC8<(?M8?+N^+Y&&\@G`].
M:AQ(7<KSI\'QS,2?I!S_8#C8K!;<7.%W*H71M)\!@FC$6KQG:24+W`XF,<[[
MP&KY;H(&U%S)[<(BR*'G-4@K/K`55'-C5@K);-E+:^.&EI>HB??`Z3I:W_HV
MIF4-;_WDSW-$$'Z!"R7`-Q&M:KGS=.PF*U<2432VEA=-UALOV"*X"_&+:Z/D
MEMS_+@_4HT7`1)Q\M[`#NC7P6/R=!K(>@O!_4#A'=K#T.04*NIMO4-)+3!E8
M(NF?:#M6,:4C$Z$$5;\+G-EPP8$F1@MI@N'UB0VIYW?0\>WOK5>ZO;E99^4V
M2B0''X7*P%JB75R18@+6&\O?DL))5+#YX0-RSJ#=Z1.;RXE+"&1;]0F.-+.6
MB@HP,;U7>0_W%)OHI)'_O$BY44_HU%1!H!C*2)9NK!Z1G:N(7:"FKI\.;N:6
MO^0MX/QW;=1QS\IB"\WU)"IOT`D-VR^3<M<7V[S-S-K&!9/IO2I8?:+E^-KR
M@9\Y-*<D/^^3?/VZ<7'R#D2L3K"DHVS\7DGGQG)Q''>9P&6XWATC&V2#IO:$
M\)JE\W4XH3;Y\78$:T,<1`>JY-1NX%[)8X>\RBUIP<)Q7<[82PD>2V[=5$95
M3M9D$:),F:^R#CJ>L5=K:$\?)+?IW11;W;=^B%V?N'9\#*M>5C)3]U&F7V+L
MY(ZK7Q&%4,):>4$8[-+XQRLK1-DMUY%X9:GHHZ0+=GRR13N2Y>$\/9?6WG(H
MP7^[ER%W]E[IQBEOO\1NR]U>R_:4<LVX;CJ%M5_*7LPSCMN3V]ZX*CLR3I0&
M`ZG[`LG0J1/Y8XWX*QMK?N>UPE]90H'M^>!Z$A*58ZLO]4^J':)E&%OU@NP#
M!+.&NYI`3Q_0B"+?CWFDZ\<5"NV\`^=Q<=N5?+=]V'$5SN8B/WN1.^WXWR80
M*#4NZJK#M<<(0O5"*>P+[>A`9IT!==Y31E&"MG(=<`F#CF2OWGO9A]((:H5Y
M%$=H'VHN&+9&V?ZE/M1Y,%Z8?/=3'XI-&"9BD9A:'PI=='"ZJH/5]J$H1@<"
M/!::KP]5-CK<]FJ`*WTHTV&8$`7P+7VH!=*15!OXTOM00:0;:0F@-?M07,0P
MY:9I6+T/-4W,%+48*J0/M5,,NVMJX\5]J,[2C4P[S/+J0R&8G@F5D?PE6X7&
MM.S._03N_=^I7N@3))?OJ0;50$M'V+0&3O5'W%%6C600[&QL?F)*OTL+)NPO
MPKA$Z<$N:)*`*#&+#DE]03[H.M[$=R;.&C8(":GM]X+2K\?-7!'KJX.K6Q^V
M*<I*"=RE7X"3)<3K81`'W.0R?I]!<*$I8XYZFN#>7<%2OT(OR`LVE#21/2+2
M4V_6EYI33"P#3.5<YJ!EI<"M1X^2=W075H?,E2ZF`8?/C_!11'6[/@0?C[&&
M&5M;?^!0#!HKH/*4JN/Q;V;M,"@Q^)Y*IOL"JQ72J4I8+A'EI0\P&6G.!8T;
M[5B6!IB_#K0V@9W2#"-IKD,F\Y(F/M0D_DE"=TWOS:G_M$+4_3]=Q)&`K\3U
ME_"G"\^RO\$8,!5)\>O8M>&W^\!!G@XW3M<E>111F8`C^%26VHSE1,9R(@,L
M)]+$(\\#%!2?WI"R157.VZL4R['\2'>KXI?`@V$\^E#$D=?CWLR]E^C<)=]N
M,$*[=[:.)<_*>7LES;K(C8*!Q[2UHZ6ME?7&/EBJ#1/Q>F1_'B7G3-^J'7/.
M#-Q5AN':Q%7R/KC8>R3<?0U3OXM^$.*M5C??7H;/<<'_@\"TI>Y3..]@W6"7
M,AK__2M0-[%#.`S#[:EF1A*7]I/UBHB"]Q;4&#B7$<:P:C+2TL#$!?)!(%F@
M;\]XJ>FDPU"[2A]?`VI@S:.0?,$!(0^!;R>T,CBI[68$+W>N]4QO&Q>1!R3,
MREXO(SB9@IH/:]U?WH&8+RV,M[#Z8WSN8_3\.YQ/3T&>_27*J-R@FN50^"KQ
M6KL479^LCEKX@7U/0M>^I(\KXRTW'%#=5LU;%G%>YO\@"W.>K]AOHP^%2!=L
MDKD<;FN!H`>-S:!;`#A9T;S'M$OC/1EK-1L_UP=8/L+Z]EU15!7VXK=52\GU
MJ[5V_?B<ICLVSJ4N_"WVS\"&YE(H.L;Q*7\,+;Q_T#<=98CO[O0CR,]8"6PE
M9.+[D>7=N6LW>1QSLJ8W8=4ZD!ZC8\ISK8FN1CF*]_IV3&DN&3+UOQ+41,:,
M,8Y,.946XXB3'T0#[<Q#KLDP'=/_$(29A9`3(4<\8XP1.'1,X!"SXC`L(KYY
ML-]$3V5G*T03WZ$81^_O$7:)X\;OBW*E5==+!R>@PER"M>J&Q2U2>1:+]%"R
M!BHG*%]./+52IOM1Z66>LW(#Z%@E7WV<08&!VM1M2#(M>(9\RXL?!_>=72B`
MGPC<9D0E7XU!P!R1R*/7QJW_@,+2)8)*UTC5AVP]ID'?]FEEA;\&D>?<KC>6
M'5XO%H@ZY>FWX6"*&@YF0AH,R]=S"'&O\E!H1Q_()+^T8;5?*2]L9U*15X9S
M5'\]<K5LUFHM.</F%BH28;A:E<RY,S?D+\S=H2,]9T]3T/T`_R3L1<VX8CLX
M!PA1DA*/:/379*1C(X;;!B2U`R55"432\V<R?JS10N!:JB;#N>2_LJ1%:3+<
MJCOF8_/?Y%+(*G<WRUMN<JWB+ODO^*U-KC3<M0CV]H!Y18%5"H`5E3.YS*]*
M_EFQ#Y,K^<KSW]XO9W*YW;8J,!.+9G(-7#5Z_P$\U.02M6I8WD>1FEP_MA''
M37W/LN5=^RH(L0"+R4]?MO`!20"TM#]+J$\"9150U].@M=F@0OA%?OS!D#1/
M]:R:]'#BF$M^P`\KE_S</'6[92[YN9CN:$0^%LTL"WR:W#Q=/*W09?H0%$^'
M,BB;C%96\VV@*ZNTM@EPB/)"8EG;G6=?2?;%3I'*1J?J5)F6@VNIE)HA-8":
MC!&!*9D@>/'.6O,=A%+X3,K=R\59$N7EBIX[M_[!)J29K5EUP>_)*W9\)IL/
M;)`\KI`3Q0'VVL0A9C^U.0_[T^32='Z/2!C7BJC:1W(#=$ESGB>=33A=S'!*
M2)Q`_*M%TZW#W<&_E6"HR>@&K3?&$3$);Y!#BYI2`$@$)&U+QZ'<VFPXAT%2
M>@CH;4XW&!S\*1?5U0!HO5,YZ4B.;9!4IN$*X>Q/_I)7"DMJ"(-X+`&@"MJ8
M')O,4;H\]^))"^<M+4C0Y,CFCV/0M\K"P"1>5G*?:+^SD7SM:FPW92WKKZ=D
M*_(M,!3A<GQQ@XAXVYT)PT^!J.NFDY>O/MD@VUVXR.$F'K/;:\M%H=MW1Q8G
MGZBZ[5'Q@(ULT!SV*&X-#A4QV%B`'2F/Q@/LNA(86YLP'GO7;A-*FI/&8_,Z
MD4:-PF8\9J^K75.E_QB/XNM*&$4'D?%0ONY71*KI&X_HZTH2#!O<>(!?5_*0
M]=08CP3LY*9IY!(U'C38U9J2BE$8#R54)R5F(I$N0*$8SD(Z/'B0$'EH.O<!
MLU#KLRB7"J]SUNA/&Q/"G7!]'54<5XBG/R^1<?`"]$DQM'1]'[0$,$&3;-`$
M$$]?'@L(82`*=6,@[A!<W=>O;GX7F5-8U[,(28L3<_U_%0UU./Y:T*NJ1.)E
MX%,4/FQ(^!=Q'93D:-'5"KO,F5``*XXW+/VZ,QS8B!#NVY)5H8P.9E'%_0O"
ML7):5K<>$781N6+7,!+LJ83*=,?5U86K:C:6+#2M9*&/0K@H[UT/D3#P45I!
M_BFX@'^Z3@P0GBPQ0NO#`L4-!C@^S5\W@?^XN['OZ+Z%<\NBCV:"11-04[`R
MV*E\CK$87/]>D8S?$8"O%V&X+*A#('E;`.$79MU>J:YZ7\8LD1B3YU&<Z.&3
MO,RW+^M'T!J^+&HI(B',@_9ZJ(?9;PF)P+Z(Y9H\E!P[J<C$_B-RB<L#`(KW
MUV=JLO7,S#,EJ@GI=_2/Z0W[_#"?RC,O#-$RO4%7.('Y,)S,C57]])O`K3!`
M'$1K^8F?VOH=8^K%P#8+3<9RM.)6TG`R&<!Q/#D(&6,FHSM:B:H+WY9VU$>#
M5UN%#8_*R,JA5J]=93J6#`Q-Z^55PJTUQDJE""OL`NT?5S*.U(S/)C5P30JY
M)#%P.,`.?](2>(&3%EMV2-^Y3$L;<!U-[/8Z7`#I%4IN`EPZ)AC$,YL;YC+C
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M1&&&^<ET4XFI<MF>EA+0@+U3XF)KJI'UP6/5F12*M[EV)Y9F0104N3[`NCH4
M14&'[P-JJS-)R..P]+GX+@,/M-L@P9[18E.N3:%DF1N/5*;/GBDI%YX//0,E
MU`]=R[N$7JYM>7.TC#PZT/8R6*]!,X#?W#_CN4OW&3<93>GX2JR-"HH*,+Z<
M*/@0,1`RPU$V8K;1T#ILR`FM'K),UYOO/``7^5^>X%_$2JH8<6$[LJ.\&4[5
M96/SSXKK^.$@Y^JPYK-T=RWY[K2Z`<(;"X?;!VO-0RA5-M5!\Z[*S!RVNL_T
MA.ZW,H!2OF>3T=@`NHL/Q(F07FBO9`_^'38WR=PV7$\5JZF:K/]T\_I.>5MG
M>@,KW"#;^SC4,D,]@CUUK,R4-,+?^_NME,CS@>8I+"+?H<Q_W=S@P`]3O:E*
MB+SF7="S*$PP1S9R7UB?5ZRC$AHSM2S](M/8!+A!=&U=6]C;%M2U3#F#GZO(
M;CR6'ICI)L+VJ@@.V+\_N?%L\?Z#YDZ5%K=+(6*H8\E2RFCA!$*:C*,%,FQ1
MW%*<7C'#0-P,X3@3DX4/9C4W+O__`7V/?VJ4_)]W-HBON,QD0[;V^BK9*T_6
M-^18[#U0^ET?W+I@#W*,ENJV2N24WIST`O+B?LAY"KCNBIH>*JG*[W-:KBYV
M\<0+AD,6LXL^;V5#ST$>[6UT[.M_^E<L",RSW<M`5.';6GM,4"P2K)QS(\+!
MU6][R!N=>3D"00MP@#'1MJ*3<ON9'!9M(0A)O<7DF&AW4CC02DV.AZH0`].P
M,#G\V?8X$/2U:"]%T:$(U`8N]0/M.MTE!VY*DRN`*>#W("2CO3[8\0Z#LB/8
M^'=%6C#>W)MK_",B:@_&9O@&XY\/:2&D.F>)\8^"M.>=[9+1_BS(42^'0S3I
MV:`41H$@>LZYJ27+&D20RYG`50X:[1Z6KMEF>*;U5RH32?27#.EEQQL3G9&O
M<O-T_/9LE\,D.:^Z]%TQGS$W=E)<RM*N=^V;6\QUW)4`^E6^KAD"^EPQ`CJ=
M]0M]1@\T0RET<TW?KI#+.Y?'?K'7=LCLNM&ZXH9CG+3B2W[<-X-+'E');P.5
M?`2L+V-M?(&M9CEL_$;I]Q$7.^)BCTOI^!89#],;T;&FBWM0U^P(KDQ:1#[U
M)B(G7GAY@(6F[\T0+JW%RAVF8%0U:&",['V-I_IRK6T^OB76P[?$9"C45*]K
MZ+CM^-PON*"SC76/PE7@E!O\B?;Q@BT&&I&B(R:S]A+0'P+3@S\TP'TVH@^-
MB!Z-Z,.B(%3HPP/%)4KZ4@<*2VSMIQTR:E&-QW?(H$9Q:,:(4QP"OTT,H(%"
M&871.;J`C"-&Y4UA5+KF^_#EP$\F0!6XK_'TZ,ELI6^`&Y&.U]TKX`:"H$4Y
M8KP";B!PM3W"JQQ(U8]0UHIO&CZZZ9-B=-.A";HSPII@:Z1'ZPHSU`:T)3I(
M5[0?V+IY\AY]E_L!?;_"T7*RV7@@ZGCQV#;:A)9O5^(!%,_0/<I+-;I+%VY-
M(51M1*=U@$Z+GT*^I6N;WK2NO[PFH0NG[,ZZI`63;]<;F+H2G2;1O0,T7:XE
ME%^HYU14DQM@V`A`(7KS-3A=+`@*GX)=J1:@I9`]%[^P5T^_W'`CHG&LLSK6
M61UQG"..TV0<)PLA:5H5UEV$.L.R3.R5"]^E$M;#::V$FB0C__J5AL0)JY#J
M8:-NYA8".@GT&K&>/<1ZCCA*(W"4C+T*P[KH>[*_+K8%4$`$DU*O7M56K>^D
MI:HJ7(46D#1Q?H](&)<>X6T,9G.=M'_UR0;9[L(%BXNW*]CM>TV]JBK/C[!+
M?&?N+E=@`:9F7TG#8^<:B'951">&G81YU!0;Z*E5#)8_W1W9?F'?A=5M1[SW
MB/>6VI19?.E<%Q)OQ'Z/V&_MD,01^RU79F_(H&[AH.O;0'?+1]3?++K[3:.Z
M&T>,!XKVEH6Z#Q+ZS8&Z#Q+7W0[J/JCBM<)0=P.!F1V<A:U04/HS=#M4O65P
M*_KQH-T)HB*,9#+45ZW))8E-&6@56^&0GO9:MD=;&+7`,),+GBK+Q*Z(<^M_
M,*L[O@4B9?IKOVIZV^'L+6B)E76[SP>:)/=&<R(/<P.'FP?)B.QISXG4F_?Z
MPT`R)PW8K-UE&9Z;9VFUSS+<`P/DS)IG7PL#/TKG#1.?D[.JRZ042\/F8B&J
M6*V0B_Y=*73,M&?5C-3M,56VTU39'Q2GR@Z^O/Z8>'F,Q$L&'Q<!6M$'6Q&^
MA?_Q5LBMSEJH:3SLM+TQS6U,<QO3W,8TM^.LB&.DN?4L@6SB^Q&H*J"MP@5)
M8ZVE]Z7YZ62U?<?'"52O8%,3G)@)/TD(<_KLN<M8;"#6C8?HOUC*1FV?-YMZ
M->+.1]SYB#L?*NY\K#FN`I<_/)B0N*;VQF#G#8JM#P\KI`J./SSHD`(X_A!Q
M174*^<#QZ1P\_EN`%0T6=2X.MA^4ZBB#'AL68EQ)PHDN5/D;!=1UBFCAQ-MD
MP?)]"XS_.`;&A;@I6-`[`2L,+3<>?M@AWGIZ7_)I$L3[='$)UCUF%>H5ZSD&
MHDT-[XX!TC%`VIL`:<_#CC7<S4`KP5;UCCIHHV3FV0(8`Q7-YKS`OM=D#+2.
M@=;>U+A,"U[<('K`S^!;N[:[V>5L[DBY]IF*F%3_,30\AH;'T/#00\.BIM*@
MP[]*P^,#C!*+A<?'P/`;#@PW]W\-.4Y\:`J-`>`!!H`;*.<##PVS0^'##`VW
MBQ0.2JT4CY9KTB3'`*GZ`.F!YTTV#-ZWL.A/78=%2V:'VABIU-"*`J:[2@FT
M]%Q\'B339&4)'T,+[`OLD,O`<1=IE<9JOIH-I8:/)<@%5)N\3/--%,9KB(1S
MY*Z?(TS87T2X\["#MF,X=,S+?2-YN5]@L_B7."!P%N%-[9,]O.9C&'P,@Q^7
MTK?V'.;XS.)^BS$X_G9#T&KX_>H_NYZ'G%T@B<Q9K\Z+]!B#Z&,0?0RBF^#D
M&X/HI7B8N%M@R'%T9=ZL(0?3FX:)AA==%X05##%\WM`;.M!0N4#^[*""Y4J"
MAL.*H->G%`\S3LZUCP8>,Q_3J8U+IWZCH?&W]!C'^#C#`3^LQQD,?/ZL/5*#
M&Y(:.FKC+TI0&V-D76%DG2'C:\^]`\UHRPZ6[K48XZ-C?/2-1Q['R-E8)7>,
MXHQ1G#&*TZ4_>E!Q&S6NR$%%:02\T9KLPC?JG>G4'-ZW,V3C3CHMX/7:#1-;
MUX\=R+1`G6^[J-KV59RP<&_YT<*RPXC6Q7O<6'8UK$RTEQIX_CH6[1V"A7#]
MNG&3E<^RPSFM]4*78?'"_W?K,<M90SWT$AN[\6Z8+NX0(0A14<)W+3XN.-W$
MK\K[RUC,+#]"L['4&-&H>&K<TEW+737<]EH,YL/U>\:RFJN:ZJ%9[!/#$D??
M+>\)X363)?F13.:8$L@L4=AR,"7[1>;<[_:TGRX6H.I0BR51<@*\K:&GIH>.
M=5'^8LX$/BS;RRC823\?=+N%<-!01?0!L98QOX\.+F8X`)K"[6/T_#NRPZ=@
MBB<OENM1C?DFP&6".7YQ^7&,YY;K.FPRTIOC^+=S1?7X`OO;"T6-W%MXZUF^
MPS[P6$UUR/[17B$G\M!T47E\5<4JI+IJX2GQ"'Y!M+S+9D61KMQ5PV[?:^I5
MK>S'(`I7CY9_`QJ-#89NP%[9K*9:Y+A[8KXH&<[MP&Y_+'>[G/91]!&)[>(!
MNMF;BZS:0#/9DR[/:ZW[Q63_>9M/V\".-=EOWEP4#=U!VIWJ6M?%OK5O<M9#
MPT.![U\S.:.AS5XX=.6:G,O0G-,:LU]_MD(.L4`+*_+":L8;V_U%630R+O5'
MUX1`*+H$!):%`2*JWSDM'`O925GGSS0Y'42E'-@>9I,S0U1*0"3*:OX[<TT<
M/XV/"T.P"IT+A>-KT)]:4K\[:EU.>3%AEI?3Y(Q`>3:9+B_MN6""JE.M\ZNT
M>MERT;YUQ10A->PV46N,1!KEQ]@]D+&.UDGAB_@HVU5W.-5,/MPC3F2'!U4G
M@)=YL+6\<%N3-:2ZU&LR_]<-K%M[Y:*7>&HJP91`/H2JOKLB+!4%T$T7^<3P
MX8GKH,2K-[-<1Z`(K?0@0RQTIXC*9(/QJ2RU4?N:6_;0_<K"R1,IMX1$5&%A
M?-WDRU)U9K8/SJQ:*]U,-)8`/&8)0&;$NGS,'KB4RC%K5N-.:&'FR%4W5$E#
M>I+'[PG9\`]K"??H`PKC=U/B19U@N:D/F;=SV@RG)5Y*"4IA]5^"P"%LB%!E
MTS$S_FB9\>4[IP_>^H:Y_KJ\\M69<+4'9L%,KCS.!AB`EQ2,E+YM<C!>DN^.
M]#63X_?-MDRSV]?DX+WL#I&W\$R.UHMSS]=#M,?@Q=+\N'HLO_A0#UQ.U^N-
M%VP1ND`^S!;./,OGN&;TT?G?D85#A+WMC>M3!VZ)./KZG>5O"=U6@><Z5HB<
MK,,<D0ATY<S_3U\1U<S,8_1,T!\1C>&_T).QO2]L0`5I_F[Y<#7Z%R[<J_:*
M^\8\JZD:.H(5K"::J)_^*WVH-LEY%7AD1&Z`+@JK+`J9]<QZ\!(=QV(KRBWT
M,+"_)>KB51QZ3AZ$3E3)!_0]_HD-;Q;J;!!?OUA>A!JRM==7"U?E<YOE7:MM
M;@#M7+]D=5L#J.;FKE0U-8%FF(^7H\!H;0CE_#P59OM>4U_,LAD+4?6@MHBD
MJF:R<:U`&"S]6;M3F9D=57>OEGP)E3?"`-VPC80CJ$Z:[(95R/>^NFFR;U6&
M;1E;3[L?51RIR='U>"=`IE]IO^24L\HM%&9$:7,N8I&O"-=\4W-4%S&\H@)F
M^Y*$4:MI<[CM2_VW!U"?R%.0N9LS/"J9XJ7ENW^FGN>=Q]F-]<\9W+,TQ)5D
M9U9TSIW`3T#@!9A#W_1XH]G\/;I+/WX+R0_SAY)FP"7%H?:<ZMT?^DE]?$\0
M/9$!GX9N$SMJ[I)O%]L:OP:OAYYB^WOTU/H'>#VT<!`GN!Y0Q?7D\?MHX2(B
M8;!&6)*/FEXZ.+FQ7!Q;&$DF45S1V7IV/3@Z$+E'%CWDG2E];3#"U":!!J"S
MX]U_7EC$3=*/\C.UFOD.)E(2;=KEC=&@<0B37O\1N;'/Y9J$[IH&8;\2L%"\
M.W>!N(RV'4UOE:4)'-:.ZT6A^X(>J=#C[W+]:GL17!4WH#G1^'2T4PJN+>S#
M5Z%HF-@NK_OZ'4RD5U[[=-'U:<,'OZ*L(4=H2S0=32?G)"Y`D1]?TT5R+=+_
MO;%LF%V4:YF1M-9IJHV0'3;42B\WOE1NI#E"4*N.E=T('-VG#P:G@/)6XK=.
MQ]#N"N^`9[YV:![^NOZPJ$S'?@,.?R&!=*%]]B(L(+9<FMRYO0@/<-EOK99K
MCQ8H7P'2^F8?HL.R(E!GHI@/VN8K=5RUJ*A%F0[A9OL2F?N_![YG&=J+WE!S
M.(A#T:O`@]5#*/7AEK;M@>AS$NF=N::UY9*-@3QZ9UP&!)A+ST_D[&H[#)4=
M,Q?7K0^MX=)^[<%ZXM%JIG3GB(#9D-8`HT5+DJ4RL>':C"_,'DB]"0]F?HW:
MAZ=[\#4X!7T&1[V9JV@_>Z\'8I\E6BV(?!JN$)[!3851Z.+XUS1/KP_+AYNR
MUW.JS5SL>U`;`>7L;Q\H!<^@`L%__"]02P,$%`````@`:89C1I1K"B4AC```
MG=D'`!4`'`!M9VYX+3(P,30Q,C,Q7VQA8BYX;6Q55`D``]8L]E36+/94=7@+
M``$$)0X```0Y`0``Y;UK<^0XFA[ZW1'^#SCC$]Z>"%5W)O/>WK5#)57U:JTN
MR9)ZQG,Z'!,4B90XPR1S2*:J-+_^X,(["1(@00!9WK"GU!+YWO@^#^XO_O5_
M?#OXX`U&L1<&__:'^8^S/P`8.*'K!2__]H??'C]</E[=W/SA?_SW__R?_O7_
M^?`!/#R`ZS`(H._#=_"_'>C#R$X@>+*_A4%X>`>W]C/T8W#K!7]_MF-X`?#_
MNB`,P/_^^'`+K!_G`+PFR?'GGW[Z^O7KCU'D9M)^=,+#3^##ATS3GZA-/X/U
MCY;UX[+TEX?P%+@_@VWI5U<1M!/T-'"1-3\#:S9??9@MT/][FJ]_GED_6^O_
MK_QT>'R/O)?7!/S@_!$]/%M]0&\LP,./#S^6W/NOX#$,8O3TX6@'[^#2]\$#
M?BL&#S"&T1MT?TR%^JF[``4SB/_M#R4/OSU'_H]A]/(34K/X*7OP#__Y/P'Z
M\,_?8J_RPM=%]OC\I__]Z^VC\PH/]@<OB!,[<"HO8F%MK\YWN]U/Y*_TZ=C[
M.292;D.'1(G#0,!\`O_7A^RQ#_A7'^;6A\7\QV^Q^X?_CA7^:Q3Z\`'N`;'A
MY^3]"/_M#[%W./KP#^GO7B.X;[?"CZ*?\/L_!?`%?4L7:]AA#?,UUO!?TE^3
M//L#P$_^]G##=&A7D45?^HD:Z>/_P'E:,1-^2V#@0C<S%+_>$2XBG42:",5B
M0Z<BT,<Q#Z-6QXFLO1T_$X&G^,.+;1^1X/GR)^@G<?8;G)S+#[-Y&N3_DO[Z
MKY>.@Y"0(*3>A[[G>#"^?(Z3R':23!OQ\=_^P/'"3[G]^)6*!Q&,PU/D0*&0
MT,\C:,5?_6?\TL%'KV#Z@<&'WQ[_`#SWW_[@N7]=;Y=;:[W^Z]S:K+?;U5_G
M?YW_X;\7PD`F#?R>R?L__TH-D>M;@H@)WBIPT!KFX&54S4`[<C)#T8\]'J9/
M_.2$B&R.R8?*A]Q'X8$KFS+](7=0?M*'G_C>?K>??7AUBB(8]&"G_K!ZW-0L
MX$VIK;7;6!7,Q""5=`%265KA,LHOJ^+7D4HR`!R,W&H!1IO[.D'Q`!WHO6&+
M?H6'9QCU?+S&XQJ`4;>!FVU7*(MJT"AD@=^I-+V-R4CGK"'.J<8**^7:T-(:
M#C/P\@4F?$U)ZRM:<5/8P4V_6VNS8V+G`B")AC0OX[VL@BC*Y9F%G6;Z=>.G
M%@U-&(I.:'CFV<^>[R6H;]@+(,;S:M'3;@1W4BV6LWD.'2P+E(3I1XT,[ZRR
M=_#;$08QC#7CI3O5:F#I"((FI)P.)Q]/9ES#(Z(@CTSHH)]]B'^X#-S+0Q@E
MWC_)[^^C\`BCY/T>?:L$_>W3/T[>\=`)+#GBU>)0BLW\`X[9LH!MIAJ4=5^`
M7#NP`Q>4]5^`S`+T$[;A@CR2FR$7[FWS7T:%<8GC>`OC&-BE8+HE"S2SA52X
MU<A%7L#%N.CP$GPC##.W4G[!O_GKI>MZ6)7M7Z&'/<?V?_5\&"=A`._#!*GR
M;!^-4K'2^+?`A='E2P1A"YV,E2:9/=P011K))7&4:RIGMJ]VJ]EV]=<%(8U<
M&<BT@5P=R/6!3"$@&D&N<I+^0!O!*@W-W-C0,+M*2N-#.E)Y4`YY4(ZI;!TL
M*8DT,"G*B*5D#KSU'-Q;_25"?/L90B'&ZWE7'[]U&\:=DM9ZM6BPF4]E@Q<L
M'.R1=(!:+'`B&+4S'3_JXB^9KM?9*I4-B'"`I1M%33)=)T1TV_C4!O`/'V!;
MV(8C/)*YY5<[..UM)SE%7O#R>+2=]DEVWK?T\0G+),Z<6L_1(&#38))#62J(
ML5AMM"''PSIA5*0"(E;3.L,D[EHCW57,''UP;.&,SCAIF1G*3;NW/?<FN+*/
M7F(S1_N,IU7.V[2;P#^_N%TUAPU8%/`"D`K3-'<JP[,ZA(Y(U`?DF</V3-FL
M2'>J528Y.D)A$$JZE[@[W]&/&,'UX,5Z,6O%S8<"-[K7O.4Y6H<1<?2&SU'-
M>.I8!.^-C^3^:CKJ_NT8!I?.JP??2,_X;I^/S[L[%?VOZ^O!]MK&F6_+V7:W
MV3:ZLNG\##@=\5I`H0"$^V(61UOG5K+S35:ASF/YH*0`W.V+>3VMW5W)`:BS
M#0)_[+EXBSQ>"D*?W(YCF(`C<N<5;[*VNZ8'%'>"N3'>TAOF"Z-L4LKF!+/9
MPLO`O0H/!Q@Y7GGJ<,"*Q3C1&LELC-T"0[Q9MI;Q@E[&2XO@F$_..]DD-5[6
M='+E+7/6P'ZS/9]L0TM"\`P!M*,`NNF,H1/ZZ&]ABAW]\X<*8]O@T3RX^0H`
M4@X*[>55$A/71A3&KKI0TIN#)A"O#!YK(^7109^:L.5R]!G1LIR,7RQF\\66
M@XF_.^J5&C\.MCTW>I4:GS-8>A[*+#RL:0)1/L`7O%,HC-X+`L_V!<F@3G'Y
M!I&IL/'\'8H%^K<QHF_R:Y1;4.ILI"84E&O*0KCJ`'+P:V$!:)AP)I0[<1`K
M)'Q1SKAJ%S<+VGG0]&!>XR'N85]D,BJOVX!ZXX\V^DB2.L%#Q9M`Y`-M%QD8
M+MG=Y`@>;)0QP4L+C#"X8FS*=]2'5A+M#M)O!!G/91`+SJ>?K22&E/-Y<M(L
M<A_)=)W</B;P4U'[-7R#?D@VXQ=M3L.P0;0^2+0!E#[$;NY]B//YW&+3N5NH
MKG>3AC&Y0=P]?5C9O%W27>ZOMY&WD9P]?>P(7Y?4-+KIK/PSB;W'D%D7<P\.
M_U2L/69_/Z\0`YA8SM[OY6(S[^A"MVS]/\_.L<QHL:G4\.,"DT2COC6BF3(F
ML>#@LP0BL9N*V1I]X:+8`]ZA\05^O8Y.+Y?'(_H&M!/MX/B0\H)\B3%&@P&<
M.,)\WOU`F_5NUS5WW-()+0J*T-UB`?P*7&0'L`M#\"GIU!+]9*DLC&PF;9DP
M*!4W(OO.D!D`VP%*AH#"$C.85EDH^Q;SZF,>DTA9`J]U,?;8;S`5G7=TET=-
M&8O+-8"ZA8WFA<=ZL5UONB:))<PD&-OMG3BJ;/[NF4@P>Q9XXJ@1JG[HS#N3
MV'DP375Q\K`03\_$LAGXK)A74I9O=ZL=U[)<B7N%YV[KG!NA\=B+<:PK-:)<
M;'M^'"LU1G5N-7M.5IAW^"A5)Y5*[,>>2]=59@]ANYPO.GNK&7=^9QU5^3%D
ML^5Y=4;E1X9PY.,9+%G)ZFQ.U+^4=7+];Z<X(18]A8P#P(^O=@3)A3OXSAH8
MQ`2_#_`?)R_V$O@(HS?/@?<P\D+W`3KA2T"D_,GV3_697V5JE9Z?G]87[@(/
MR\TLG]3,3<(\S*YD<0&(91_H=4IEVRY`;AU(S0/4/E`R4-=!?I,B3@FM%$:G
MI%!O`0`UV*[6$%#P:;03);8J<#Q2Y?PF0-\;WH8Q^OV5';_>1^&;YT+WX_MO
MR,.;X.Y(#FH'+Y=.XKUY"<=]2E.HTD6(DNSG+L^Q7:V7K228&X(O#P#4%/`#
M-N:/^,_8'I`9!)[?P0_8)D25?P2Y6:"P2_]M4-J#;+4$.<J#'*`@>VF0_2S(
M^)<.#O2)QA:$>6CMW)J?C>%,R3!G\J3,SR=I9)U9AXU[@\$IW4*5W[;UF-B!
M:T=N?!6ZWCY=N6H?4PP3I7YD/<A.D:U\>:7F3!-XPK1$=&6CO^):MEP=*.M3
M/516$)2YF4'I&RHKB$R-82G!TLA@UL)U8`CPP<%&UI+]'SU14326'L4>I;'T
M\!C+H<%L#BP?RW\^):<(7H5Q\@"]P_,)I0AS2I'[9>54QVN92+8VEER*&2\J
M'6#QH")?,9E-X_;<#+=[Z&H:WRW63/&>^NY@WZ,^W]60DBB6"QH2BIV6L:E/
MA$.7C*P_UD?6G^@%2:R!!-_+*L>/7!9Q3]*L+"L[@)()9LYZ@52XIC'=!([3
MV:DD=/[>,CN5W9VE=<0EE+R5,11_N'2A\BO>QO<YC*[#TW.R/_G->_(Z4H'C
M9<6H[+>(_YZFU7Q>H)((!OLP`IGHK-=?WGFK#Y6R';>JCN-IDP@-\G7CD#]=
MZSCD#)"<;CEJ;%&P;B%"/`*Y1]>3KQ$3M'9]V$\K[W@S3>'M=LU6R\4N[6E3
M88!(`X4X@.4I[EE+\FNNQZ^>KK,DYZRR<SYQ#A;.N0SGU/2->P%5=(:[HS&\
MG8VA\^-+^/:3"SW:Q*(?ZBTK^A4U`*/LLV^_U+Y7\^\*VL>&4NY9]/4J7Z_-
MW@=8@-HD'VF_Q6?_U'G,3`V<N>TN2FJ+<#-WMR^6.J_*Q9GQNB?'[C-A(>I;
M+D$+>?<$[>:;O!@:T4'*6;-*7>/;*G273Y@V$O-2).[VY9T;%35T'X<!.\:F
MC08AEWR#7`3I-:Y)"))7R,P2C9O(AI)!J7D=$D\MH]L@\5S//R7>&WR$SBDB
M2Y&?OCG^"?4//J.@X+'XB5+*W?Z3'>&-H_$]C,AHG3K*&G%)D:UR;"S#8.X1
MY&R^SE;-2GI!H1ADFNDR44DW9M=,.][.12?"+@"U0-/X6GWPK$;PXB)XL!(\
MIQH\F`4/WT$9T^"1?_1>/R\3C)6AO;1O<X8<]?&]7<#E-R^>)I<[-9X/GW6Y
MP0O4]7:]W72SW.]8GJ[M5Z9$J$EE7!$Z$V;B@:!$ONK]+&?(8K=>`&\2>)B(
ML@KQY\-/N<T"&QZW2ZE=+O`[-@(0*\Z3P@8&L9.O9`?Q3%BN`5&)E%;]3.;P
MUQ?[`*]#?)Y0*#U+KVGGF\(6D29[V\DC%P!+!;]3N48QPU!WNQ#/X:Y>##?3
MM!^;M4!IP5Q1D""^#-PO85`J4?"$?HKQ?OLPB+NOJ!64HA*18J9QMU&KQ3P#
M:$D#*9*"='PH*0%E+;H!.V4T++G14(;G81"HP'M`6+6@'5__R>S?TS^JQ";1
MR#TCM]GL%BGDR(O30"A,;+\30@.,7F.CG[!D>@.KWCG`2A)4TKAP35]V]IUY
MK#ZD/%N%C\`MUNMM.6OU'P@<X8?5C3ZU*=QY;*[II+Z4OCI%47-%O_T9Y0F=
M*N8FM.TV+]-/WK\`J02==#S(B1(K._1]8]BYEC'-S"X[K#VQN2B[_JRN1!<F
MOO7.FK<FO"%,/LHO6H^WDOUZCU5WY143!H;P_&?;BTCQB6LO=OPP/D7,7?O,
MYY7#HL4(_H,CF]6F"@TL#1!QH)"GLV48[5ZIE3"EX].19TV(L`)@%$RX6I"N
M]TR`C3`#SZR\7&87?`QI9Z1Y7!I$&-#6<&0C%ZBTMT$?[=B+[_;%H??[T/><
M=_J_3_!;\A$I_SOC$W.^K!!F?!;QKS#D5^(0P7B=L!!]`:A8\'OZ+Y8/B`)-
MD)O">ZOB_3VR.]O)329J[R,O<+PCKK>(_HRWDR)EKO;B9&)I78:J0`RE;/'_
M&,)7%,,7&-V@__%?H7=H737I>5CUEGVF)=S'EA;S[*Z90A;(A:&?4+H'=KH%
M^Y?#\[\KWHHOR<,YT\/?J3C%7"'3-ZOF6Y='2K;(]X(IWPK?'0$M+?$I]@(8
MQY<.K53HX;M:T(\1[-[)T/^>RO:WSQB!QF<Q2\&3R@0EH1<@$ZMY;52RP]9(
MAY6UK[S)6FE:N6)E"O;8V[!93VO&F<#FWLUZM^Y`E]:]SU)<8^+(@$W+/<G6
MAQB=FX5;[/F$?DK>26\-QDE\$\<GZ-Y%^%]<E^'+"3>J=WNR6S#]*_^''R)<
M+PH'6"RP7V;5V212W2!3#JAX$$8@4W\!J`%XK/;(/%>D!>.3!ZXHI!T#CT8F
M"8%-&R"`2V\E[X;1P@AL];#(T&C+&?*F]OP*(]3__K3?0UQL%K)*K'0]KGS8
MR[:%,QL7B]5Z8]&!;_X^*="!07D@<O%/\>DY]ES/CMZ!%Z!$/=J1^N/HTMRM
MLA85!PKW-15?D>:>U?4U]8V&^W%6C(=[0J&CMX$+5%\&+OX'\]6;[9.MDLF5
M'47O:.S>=04(W[L*^PI<!@D4WUNGH"*5Y?%,+/FA)/H"V`G(I-/EH4D@=B0W
M*7P*W*X&?P+OEQ7O2=UW6(C&SD/T>X1":N"$OC\F=I0H]G[5Z_TS?/$"<IW6
MM#'H[>Q-X+W5Z;W.7IP09Y4[:?Q1,H>*^;>N\+^OG9+'[/W8;!?K7EI6N-ME
M&#1'1^#<X,FY-48L6N;`E-YU=!,X$:ZK=PWIOT(IP1"A':SM=G%GZ]K:S7KQ
MFMY+EBD!/V1J_JAGB]ITD2"[UO#]1<XK/H>$K]!QS@?%W6G>#^2."!J$9:Z-
M.7SOZD?OL(TIF]5BM^F'K6&;<R8(@=49`@,1VK_]AC]*YF#R`<9)Y#D)=+NL
M%TH+3I':$<QG)W=6X[#W`KO0"<X>_E/$+[TFOA(D\[A`##3]%"$022F+&%>D
MBW03%!L%/\6)AZ_*2H^7_`7:T<WAV-R?+ORZZD4.`=LX,W-MS3>;=+=?:8MZ
MN">E5B&9;2:E>4L]3[NXEPVFZD$8Y(?NWI$-V06/81`K7AB9+$24_&@0;H+R
MY729@OP@&58!J`X-:R>31<`J1:`]#2ZJ2>`Q0Z!DE64`$>2K+J)!U-+G\>TX
MOMN32WXZ-R*V/*BR?]+0SMUJ;F;S;#B!A9#-$5B,YJV%8SVR!#U2UA]@)E2E
ME6_W7C<";GOJ';8_JPD'N0$"FU#S";%:XMSJ+B@HP;%61/0XI@,5C21C`:,:
M!XW8^#,I793<10_>RVORZ1N,'"^&]ZA##O,_QNE?XWGW%Q:4I1Y;8@;R3^DL
MYW7LI<+P%CXB[0)DV@!15WHFSA_2M*=/07#H-ILL`D<LTP#(#LO]%D@/")TQ
MD,]W#.9U"J]LW\<7R]<-%TD?`:FZ:8#?5(%>7%9#I(,02AMZBTJW5#5X?C>;
M'::*&;W8!?GP2NXDU7^#@B3(]'*&8$#E3(2%/O(\I/,P^<TQE8MEF/>1#A"@
M?#),Q#K>XY.K->J1TNFPBOSBMJ7:A4P3WU+*GN>:SONY,=[W3'1-%P*K&8(H
M%W4!O""M5UY,@\6E!_3->`U!?#'G)1S/"6@J<&]1KRJ(86[`)W(6PF4=0A!Y
M72]%==K&FY_68KG9M!$47FSSJ?SBDCQ\>@9K(!O?5<_$3^5\"S]AYU/Y):Y*
M->@ZQ#!9`%K8J?CB6F^4'8!E!OWTATL)^<3%HAAK:\]P.:;149N1O,=MEMO5
M=L?-2S%P<U6&T=+X(+3UG]KX*:X4!=.V#T)15-I(JS4JQI)7%Q=PLQ@SD!/0
M65&T_FZ_CV'R%#[`&*)PX%T8U_`-^N&1=O'BQNS/:'%ZR4W(5N[+:=?K];R5
MXTH7(H1$'S[!'*4:29Z[A4[@8*5::6_"\+2Q7RD\=WEX'LKA*>D$1*EV#IPP
M1(0*[SCS)+WWVF$EG"%T.8AK&*PI'GK9Y/E6$#;=?'ZW1^/@MIJF(F]JI,0.
ML_AG1M;+68/]WLJC37J8$4]Y.ZEP?2PGS>,ZH;V5AYCI$90[4F&1"-=+7-*\
MIC/U^??,O[$)=,.!SC9FZ8N-EB6[\'#PDNRF(6P.+GT7.!Z,N<LIB\E0N1PG
M8IC`5FHK'V/E\NE>\[(&DRHN3Q@(2V(@E"VZ#4GZRA*;<#R-Q7;O@3$Q(::A
M>T!MX^UL)0IO_6=()HQ%/\*-QW+WP3+QV$GJ[A\.84!VZUW91R^Q?5I4ZU<O
M\`ZG0W;<]":@O\9#D.@-NI_#Z/,I02:1DER!PUB4DB1;_9!!CN'<59J6ZWF^
MG(55IYL_4^5I+3R0JB^.>M\$V9\R$P"R`5`C0&:%ZL&'CMC-SREV?>,8'0&D
MY0=)Y*(L'GL4CSV-A]<1#T4#'[D\51H:20RWK@Y6ZD#G?<;-YQ1WDRK*^6]7
M65I6"[SU5*>7Y(XEY([*3DQK(M7[*4W/->?]O1W=18^H/8<N*75S#R."UOZO
MQWQ3#S98YG"GUW:]6371<@'N\6G4"%#1:74G))PV@=HQ),?M,JIBZO81N?W&
M*BVH`5=]B<I`6F=\-&./-HN7I^0UC+Q_,JMG=[VA!VMU,T0H?-&&L;0[64C4
MCJMQ+K;@B6Y5!W:GBQIPQ4I"!IY:XV($CNY.29S8@8L&_[R?M_R*3B25[!"9
MVMFQH70!2C(-`=-@+]EH"KN=U`:GEESLQ%,]-)H!U5E^N?Z8'N"(E9:U\CN;
MJV`A4B[2ZQ2TPV2`3RW0^']G/\[F1??MP]Q:7<QF,_S_FXW0!;`V%[O=ZF*]
MV))Y8?3P?+.Y6.TV+1C#Q8>OH4,&+V`Q1R^C5**OS>:+"SS]<:35Q7VM%RZP
M4IF!0<T%>,/#$09QMM_O`29>1-:81=9ON26H12NO6=R]J\5FE9\O*J23%"SD
M&[9R.TT0+&E!4(A*T42O`58HDKJQ_`!]/.HD>\PX:WMROJT)PQTF"8R.9K,6
M_*:BZ<Y-`RO\31&%8MG@PS,YS%S68@I..9*8A=&^0.G"9QC@E>*[_37<PRB"
M[I/]C5[BS='*]K^K&)N]!@F,M.;%]&<J%V_<RR0#)!I0V48TJI(])VC,??4"
M)SQ`D""7;?T7TPME;1V.?'$R"(RWGOWL^:3$P3!$M@G0#\L6J[B'>C-KN^[%
M9DF!J0`='0,F2OU"LHE0[<AI#KRRPJ8+M!%\18T\&N7?D`]`&W?^+B[7ZXH!
MRV.32/>NU)3FH@&5;6;W5GX`+%8`P`^W81RW7K&A$J8B65P'*7>T=$'TA#XZ
M+I%-CCGU[6UI?5HQ`%M,$*@@MU@6>,.20"Y*_VZ7\:Y9`UQ3B:2.9*L#AQ4+
M/3A!WN'C.V2TZL5__P@#Y_5@1SW%D/M>4XJ<;EM$&#M?32R)!%@FR(7J+ILL
MU5MKE+?J\,67I%6@<<3)#,2]YZ9=?O.8!23[7M.*N*HM`N4,EQ8/XK!08_`V
MQE<.O#%]U8>V]@3M1EM+E`Q!VQ/2*0:T_`V]&,O,$#C;N%PQX86EF8:L81ZR
M0-7CH48\U5.P!TJ5L!B!HJL(NEZ"?^+]N*4W=**H,$-@TFVS9:'H`E"!Z7^8
M-ZDAR?T6B(7[LN]&`:R9G9T`JP7%"(#=]EW$P7Y!)[QN16^NP-TB=AMEP+4<
MDCQDM5'&W,_1FX"=$+K5?U-'W:1[&.%?V"^0>2%'URLZ452R0V`_U)J)(W+)
M<RK1$!@-=C$KJ9.^3<KJ^#Z(O9?`VWL.OCT@@F\P.$$`[2B8:$?K&XR>0U4N
MS^DNF9*'EUFY[.[2X=K(HP5[G?11#XT1!/+44M&_YV&=I/$D4*`=[_<H#B$U
M&R4BRY06=X!CS-:6[9@VK#S5R\AS!,(,?""-8HL$I3>T(B4W0V"R?,X<`Z;S
M#&:M"@SUL7LNQ<2U@&8:=H.H&AA)17#2<CN->Q["R(7N94RJ0)"2,?Y-<!^%
M#HSC]FJ<G[[AO:.,<CC2M:@OC"/;!=XJ)=LYOCDI+9&3&8$+;);N88E2,X`=
MXVU5F2'X?I(C-85=9192<Y17ZM0;SWDMGE?U>VUH/"]C4#($E\Y)32G*%U_6
MRA>GYFBIGZ,WIH2!+UW7PUI1M.Q#?C,.,4!C"9VI6*Y43&>2V&OJ+I%-BD\P
M.G@!<:-G"Q+K>;5=I78C!#H1RV)<062!DC#M&Y&DN&<-<D]A!ZD[\6K=HXZ(
M:,+-&_J.R)#T$N!+PG_TUPET.R;S>MY3BZ-N8[A77S:+5;[K/9.9W^Y\`:A<
MD`O6ABN9[EI-=X]1MM^='/#6C"^^!*WAC"-"L@8C6*;W[,/[+&JT/%UN`[ES
ME]'WX7M7P\"!RS#>KM9FC?XO'PYDHNMIAL<'61*2ZYC5=^\G\'I>]SJ7G96^
M++R^9UU"/7TG?`+/Z\1RS"X9-X!>!F&WW''FCY>^9KW%P+Y.<>=;RIMTIBD"
M/<CUIA^"VOO)\GREM]KO]]!)R)Z1@5ZK;=Y[$[79N'>':]JF_1%&N-!W*Y9$
MWC2F6:^8Q7TOU'R^GO4WZC&1#:Y-:<Q'^-K+(X^IKYH(93+'Z8IXYIRIG#(`
MM/TM>C-J1K7GM)8;+2;VVS$,B@Z(:&/3(<F$=I]MGD#9V>*B4V8&YX5!J2IP
M0KI*773#>@BRHF+QL;B1/85^"'#U'GI"J0?U,;E?))U<9V].K3VF%*]5W?Q3
M3]NB]'6<7A"3"9D&9&%B^]T@&^/*&KORA'6D5V!BAV"'0^IPTYY$55"TN&Y"
MQO=68V$\KA$!PJ7U5LO5AH4$`ZJJR/#.JGJ7P4)SV93N5.O"AP$E44X!^G9'
M.TK>O]B'[@-V+8\JQ4=3O\"!LTU^8K40`[`<S8?IQCIEB3JE#A?LU*IB@A$"
M+7@@9XH:N\^Z9SL[WU&)D"Y#!,Z];+*M`/2<6-N&7+WSG/+\I!,2I\/!CM[)
M^FSW;GTC9CIY4K0"L-YP#4=:#)T?7\*WGUSH49"A'^K80K_ZZ]4)C8^"Y+,7
M.[;_%VA'GP+WVD[JJYF=CRI`4I=^[L1:KV;9IF,J"E!9``L#G_"..21.+73D
M.68-<6QJ;/"D&(9$;QBTM#G4(%J.Z\G^EG8./\(`[CWFB*7[)96M3J<E(H/?
M914U:<4U7!\RE0E^2*6V%F!3T/!(=)4>B(O"-X^L:9-+%R'>.>GC&[MB?.M3
MJ4BDYJ$_5X96VIS^2.F!6IP@@R+!#E[/6TK!UFF*P&AZFVT#3R4:V,V3Z6M7
M1^\A/7AJ1.^.+T.K6.N/DPZP955@<Q(HU8)E?/+.5Q3"K,L.;II?;+9IB\:J
M=7P!?HG"6/(T]8ZZ%\`77,*^"V`2O5QB-XDSP.TN<:P37#P96496;X!TPNH!
M'[<@0[N>SUMZ4`.$"NW<*;5<+W8UX#R08TI$C)[&:*P[U>K?I'^;@4+K=5/L
M;&H#0LU[,]+_"_*2=C>YOUWI%:V0*.P0R*;EC`V."U"(-`4H0YT\'\@T,[`;
M/+6(Z(41Z?OV?DSZE!:P$-4BJ3-OX(.(T(V'`7[4(<#T0WWN5]*F/=T+APW(
M\"O.)J+RL+Y\OQ)E3*NEST0D78"K"=N#8QA[^-),`0@,<FW1"H5I?1/%]B#'
MN"$^VAV.XE=2DK#5(]#1*=%$7E<\378C#@90F4"'M_Z\/D(;T`N<[[+:>$U.
MF[B;.X#6ACK(8K8`DH,WJ4QP#"/6Y8K*B6ZHJ^W,$(3!ARF_I3CO#<Y5QJ>\
M#8.7#RC(!],FPIB$TD&&!@U>\OL`JQ-U/1^9]98&;F28PIUUZWSS<\M5EQ?%
M'7M4K%[ND.*KL0.BGE1LPU-70(Q`%9G/Y_VJ]&&=&"(6<*?3:KOL@LX$"S.\
MYP=D.+;N7H^A%\,:A9M*LG7"I0B'.2CA[I(S7]..G`&=GO5BL>W#D#DSTG+<
M)2U0\7(!KQQ7YL&*KW_7&1\CH%9:?OT"N9%6>TLGT*JF"&P8VRTZ</:E/><T
M(&N,?Q18,&$W6#_]D*__3+0!4+AI'N/P>K3#VEBE'8B=I-(2*2,X18!(=+.'
M8(9U=6^_T,FE/]G^B>[WN_3]\*L=3%4U2AA8PK[VH\FL_BXO;HP"R]V1E'8-
M7O`MV%=V%+WOP^BK';GQ-0IUG'@.[_?ED*03:OWF"<Q;;.L;-LI(S#4!K`I4
M=%V`3)LA[;OLL)`V_W.Z[?VW'Q]_I+/>>4A\'!*GI,<H"/.CH1/AG$$UG``>
M\8F%R\"]1=9(R*>J.#.IH&(C=^)O=]9Z,!\0E>3L.U%J/"V,"!'=L4_\_3Y(
MH14A`YFA&5?3Z>'T_#?H)$_AIV]'+VJK+"=)J*%4T;14H+CR;G@'(E4,DA`4
MJLVGC;'ARB<3.FC#K/'`(.@,90]&>,W@D.25>1*/\;!6S&,+!*:0&[NW*UC&
MPDQ!I[AC!'5,'_1!JYQ1W9#)?38""O<1IJ_D_1X%/\%E@_YQ\L@M*;S?D"U`
M)V285HEP?'V3=QE&F0+T$U9!*V%E2@R!EZ0@I!LBCA%T/&;;K@UYO0G<B<;N
M$!F!4/1#6EZEW+X*-6%=(G2BM,,ND9G9^J[T,D[QSUF1H6JWU:2&4%H@:/,8
M'5_M`+C1Z04X$3VS%1BV:,R1U9W`[8N8P=#-;B4;EQRY%/,`G)DF,E';=HR]
M'\.9)J-A/"P<!,D/K$LESPO6]8P?@.Q*$$T!=_:[M/0,MC%Z@[CZYJ7C1"?;
MS_==/@CTJ,4%:Z8`,6M%.I]6#ROD?TA54T;`R@EB,O6E;<H/YG3/)XY<\VRS
M:4PQ##Y]Y#$@ID;P2;Y1(M\GP9M(+6_J9(2F.2)'7+IVH4V^ET2\L(T\KTE]
MF\)#N\M#;:AE)VDG+!G!T8R[TGXQLA^5[_QVQXMZ4,>P1J2\4MM,5[.(E"%'
MH66Y7"DS6MEC;50-D/Y$94"O*TCF(.\^@D?;Z[LWA.]=[?BK&232`O1",)4]
MT<TC@UH^:9XO::52ZB"Y<@&-_TZ1&2=8N?*U'X-M$=($0R^`+KG?VWL^X5;Y
M'EF$&^?`)1-H]V&<1##Q(HCG&O#4>'SMQ8X?QNB3]%QS(DNZ6BC+,)F[6.AB
MNRIV9V'-H*P:I+K)`)9H!U7U9,$I!H4!VB]>T1)`2UD`%?*-3&#6&$G:%Y)R
M7VF;04CGI\/1#]\AC,M_N`P"-&K_$]ZF&KS<PPA7H+5?6F\IER%6]4VG$FSF
MO>MZOEJLTKO-,^0X9>0<T>L7`&::*W^\0'C"RL$;U0Z.N7K%UZ4J#U@'5Y.`
MY9HK?[P`5#E(M8-"O8:K5I4'C1:?SU_&1X&RQ"(I5,L];9>P2F2B_(966<$V
MI7M8V![A1@&W$V%@1^\5/P[X)AN!'H*`4,V=07Y+!;:?ETI(]O!*!"I:JT]2
MO>;T^Z:*E<77:$7`K<2J\J3-C)7.+IXXN/IZ=H+?P""6^=7^YAU.!\J)Y3_&
MB!DS^DQ)4BPIA23KYQL1<_DO\YLO5KVDDVK..B\5W;@+D_=V+K(.C5'D,UW@
MNCHT%9I)0A#;/L*;@4PS!&`<=",<=3V<4VQA9295Z1&E+%#HY=\FM)OEI7&Z
M-^>J0.-0!QJ[B[,K=_6BIYDJ51C4W-6=S^AG']+AA(N:]BCQ_LF;Y\Q7->4_
MRQ[^ZF2+U;*)"[P'*!5,]P:51.O'C!RGFUC"GMHE>::!JR]O6:#KC)<>,**.
MMG?$-MSM;V$<0W@+[1B-Z2^C"'TZ,JU:.B^'_M:QV#E$EE*X#C"0_S*U5;$8
MFNO!W2VJ":2J0%E7Y8PJ4:<+TY-'AH"<O`CLEPC2)0VWT*L7VB-04,7ZT#AJ
M`7^^4G*WOPH/F&'I#7G0QZOI5V&<Q(^O=@2?D9GNO?U.K.];21TG5"4=C+*4
M?]EO-\M.^A1+=X@6RBI!JA,0I1>`J/U`](),L?[U4H7QLB:/ES)ND0*R"LF,
M_PY&L\W'LME/\%OR$5GU][%)R9!J(M^TF\H-H.UV8<DA'*P;$.6F4XZ,D*5E
M==![:2#*&L^"0KJ1,XA#.@(K9T=%NL\`'V(.$B]YOPGV872@NZ[;>QK\[RG?
M$\%A%&=.+A>S#;[<B<`X%4N&Q9`(!EXA6?4^!NE.SBM.7N*2!-3)DF1MO9^)
M?+;&^ZQFGX$`/HN-!+SA&MX/B:'SXTOX]I,+/=H%03_4>Q[H5[DIGQ'AV?X]
MC+S0_8Q^5Y_$Z'Y602^ATP#NAFRWWFQJ>*+"`)4&B#BU")+HF37$LZEQPI5F
M&!O]@5"-A[]`.^)#0_&D%BSDZKGS9;V:S]J1@&69@8.!7K6BH-LK]1AHI%8[
M`JHA4)?_%'F?`O<:]7<[/E3U.<6Y7U'.G2/+[;;>ITHI$DD"6)2^O!_AD27J
MD<J<;TVG>L8WG5>7[T](;,=W(7]6G-U8)V\*K'?;=;UC@]_7E\GBUEM<UJO,
MVG)2U),U]T_+7&%:WOL*[_:+WG^%AV=VV;#69U7.Z[49P+T"/ENNLNTPJ1Q:
M.^"4O(81'A#^3@7JFH$;[QS)>U+"/JMG_TOX!J.`P*#+.V7S:UW95IDU8P9#
M!T@^V5'@!2]XKUHV5<>\9:+]684@:36`NP.`MS)2D&1RR)Y.(ND"$%EZX"'!
M+0(/\EYV+\L/N"#S'_%))8#^^Q`&(,:R=5T!+./3Y56GFR[&]",^LSZB*A;H
MA%.9!=CQ,($%KCW_E$"7\UMF3VMD@M0$[K[4%G6FV%R02C.##0:YEBY]DS?/
MA!&&?<)^3G#9'U,7*]3@U<4+Y:B8P`SWH>\Y[WT+ZGUO:62*FBDBZ;9E,P:5
M"GY/_]6^YBW5ZQQC-RG&;@G&<O=-@A8C/[L@UA8;*<O2G_9[Z"3>&Z1Q0R.R
M!SN!#Q"[Y?ET,^^M%\";!![JD^<#!*A>J!:RCC/C5JL9OFV0K%CG\K.\PT-:
MK`)4=8#?L19`U$P#-^8R]H0AF)L5@NZE[0GC8$F-@Y+E[D&XS]>]Q6.IC*R>
M[&>_M?8(_\LFDA2QC'?GQ7*VF&]$"8IH,)";!G@NR$L3>CZ>D@:X+TA';/>-
M8:(*J(58J`B?'`;RO5O/]]LGZMN>4,XE%?6\S=AZM\H)P_<`D0#^JWTX_C=P
M%2K>=C?&@WG5`STK"J.]L/B]4(/0UJ0O8-AT50[6LG(\2,&+AV!\^0*?PGL[
M2CS'.R*DWP0?80#W'BF'UOH1Q"0HQZJ0>;QMP-Q:6=GH)"]\!5,-`%=&2$)P
M+)0`+P#/5`VIU:(:[A,&85X-0J8!(!7@*00E):B1!*D:4F=#!V-,&(B,49!<
M4C>Y4ARCR(6LRH@^IAD$^8*)Q$.H9;XR-?,11F^>`XOC!^4#"K@2NV/3`Y:X
M2_,2>/^$+MU90TXML&9EIM*B<CY4KNG<2WBS=;:5LGQ,J'*<J'2\%3R_MQTG
M`I?X0IR+ZFO8((T3($8$UBJS,4A-`*Q(7X#"#DQ7A279ECABB_;9E(E!79D4
MGN#K&<M_7\*`EJ$D<(J?P@17+BK^CGWY$B9_@4GAY9BL'Z3/-$X<X@3_K46[
MY;+:I>(`<6X1I<6XC1>11>`=)B6(&\R.TX>8;B,+HH+PG'+('!RR*#W5BKKR
M01A\2$,<E\YT5MZQ2T49C"?),<@7ILO!G_.[(L[L>$Z4_@H_-U>-DG8CO@>*
M;?6,O[JAM9HKXMV+K&^U#R-0,O8[XV,)WZ.'I-,R7B`J%.#]/DCK=TF_G?RA
MA)/9GU3.7&3@>L$+/L/5,?-??T;Y?&+-`,Z,7L\7J]4RG3$D(N@9NTEGS]GS
M@:.<F"MUHF=";Y0GEH@G:B;G&!@HIM_:')[^Y!<]>7^%D!'9_DW@PF__$[[7
M/@C[.45GP5J5\Y=MF<^SV6Q:/"$5!(@D@$2I/Q\FP2-+U",59\8ZTRD[/,9V
M7EF^D^W1I(H/:47CNU,2)S:!(/MK=;VD%@D=EH@<$E]484'WC!.Q::VG&)0D
M:T.)-&^MD=XJ1!!'@M;@U!<E9=BB-W$^P".N7!N\/*(^5VOIB,['U>*IU0;^
M:QX7\WD52>F]J[E`0"5J0Y`$_ZR!_BG$3&?BU=#"CH@JG'SV?!A=V0E\"2-V
MCZOZE%)45%1S$^U\50,#$0,R.;H@,,(92\@9=?G>FD#5-&]ZK2J[\:[""(&+
M%C1'%MSM*[]B?JC>%Y5BH,\:D4RR*K"HB+D@Y4GP2FWEU[K`(M=K@I]?;939
MO\#`<V)RDH_*@BYP-=9E$4O5*K2X8J0*;?>G9]]S/ONA72^#V?Z,4@R5%'-W
M.98;:UV!"Q4"B!1=L!CLB"7@B+J\;TF::HK7_565S0_PQ</E'X/DBWUHJT?4
M^IC2G*[J%JCPLZE.115R`!:D*[/'N&.)N:,NO]O3J)KB+8ZKRO(_A?XI2.R(
M=M+8`^3Z<TKSO*9<H.&WJJ.`7!#M0FL;"H]RR!)T2%VN,Y*IFNQMOJO*]C]#
MW_^?0?@U>(1V'`;0O8GC4V,IL/]YI=G/,$*$'ZN]&"SPP]^Q1)")!%2F+CQ(
M<=$:[*(ZA/0D8!4I75'1LG>)6N6Y\`&^P>`$?[7_%D97IS@)#S"Z[=O,SOFV
MRMU"?"8)U(]:I.O7J3Q\URN2"#*1)NP?G\)G:XS/RK;.B*5O9<^+0-"T(/,?
M)^^(-Y9T5I^L/Z42:575`A<LK;,=(9D$S44F1WE"+Y:SGP&?-\J0T9X^%02T
MN*TKTY/WGGO=:@\ISO-",W__99;/RQ(!VN]/&^.'Q>V'ROQN)DT]O6O^ZLMN
MO%$2=?>"Y#H\V![K@N'V9Y7G>LT`D2VXVTK*YX+`[U24UM0?Y98E[)9:)#`2
MK`F(MBC(V8Q+Q-\$^+9Z[PWBL[S8E8Z=N9TO*-^FVV4-]R;1V6*Y3O?LTES)
M!9(CW`"+U+6%5YZ#<YT.]FSOE>>E-<)+-5M_>1!7[`/NC8R.YO&S[45_LOT3
MO'3_AL9>&*)W^S^3DW$):]JA^QV%S66G(=PK>>ME=D,OE@>(0%!(Q(OWF4P]
MS:=$-ZW<S3?BIEUQ\RN5"7S/IA4Q=+:K7)E9;E_[PZ078'$,D_@R<&_3Z'HP
M_A7:^!).]RYX@,XIBO!-X8'[)<0GJ.A_XNKBO44MY.K0`F`)A@M<2[%;U`%_
M`:@)Y)+-DA$@LP*06W-3Q>2ILB7D$H+^L@LJN4)Y1"T=$57/1A)AW,Y>LC[<
MN;)=6ZU2^?+/C.5$"E[B%83LU%^I2Y-J(N4.+KJ0IZ7TI^9@61,$ZYRXJ5%+
M=)KO<=:<U'=WP@2*SI&EA.\JV&QWL^U8NM)_<X/N`!(*>SP=#GCO$AK-M<<2
M?/8".W`\VZ?]LWKW[+L@LLY;)";Z3EJI[>-[_N._>S!",7]]OX5OZ--]\WI'
MC=TOZZ"@3HL$ELX6#5JY`+E`\#N6IILL)+K:&(#QN*H<VURIVHK7_E!IQ>!-
M<#PE,3%HWKEII.L-'6AKFL&_-K>8-08:%X`*O`!$))AKWEXBS4^"K_]U"O'I
MIOO(<R`^\00NZ7T"O]K1W_%L!ZX1=>/B.7XG:V)CKD`H!R([7UO1QXB>5LB5
M^XA-;NA<ZQ>3H0.6/(8)U)K=S1M=[%+[H'5_P(0NU\?U?"XKQZ)((K>BDSMR
M6O%ZM\]''S=!G$1D2T!,KW'KRXW.=W7@L\L@_IGSU<)JX!(/WO)16DFV>;<5
M3A",.F)9P3`"MSP)W8K7WGAIP>DI"KP$T0@:\G[VON&?XNZ>+/L%E8AD6L'=
M5BQGNZP?FPDC$R.9.-U=6$D>6E4/C>B.]N9<!3_=@9"RD:ZLXVZ_1_W\[K,`
MG"^IWE#7:Q'O92G6<C[;TDUU57"$1"J`F5C%=^1(=K"&?B044*F<)PNF8X$I
MO+6:GU/(6R4;[+B1F&^RXXN2))K`>G[U`N]P.MRB[C>,T[M.XM\"%T;T5\R+
M-T5>5T\=W+9Q9MUBMEW/K(Q$2,H=J'C@$V'@F"H`)ZPA_:UR1IG([WG)[U0\
MH,*R^W%B0#1DO]5W^^9D,;`DQD`1^P@#O,1#8E'4T=O_!08PLGW$E)<N!B,^
MJ(.G,C_1*NV,KFC?6PK[_3VF<`\[T4_I)9FI1-(<5F6"5*B>_K]43ZVZIW9%
MIL[!`&=*ED<$/*$Q$%V=PVJ^=\U!FMA0=+V;+Q:\>-,\\)[`\0;\:HZ;,"@7
M2EX!-,KN@__BH7ZBRQZ55_ZNNA==5LY]5?D2EUTAW63ZNJ;#:L-MGZNRO;L;
M.]P!B],!)7W0M@3/.YD-'R5BZM'Q(#(MO@F</G@U']6#M(8=O..3%:EF6@9=
M)@IO97`4#T*E.#-O<0;[HA^2(QTS$)U,J-2`VNZY',Q&$`9741C'5T6AV@[<
M=CRN'+ML6W@S8S/;SM*[W8DT0,2!DCS5$);ET[S#)ZU0EN6@57=0/Z;[H53@
MNB<,.L:=-X>C[47D\&MT[<7',+;]N_UM&+S<HGZX2S>DT77FOO,,@T0I')4.
ML8][O70W6Z6#U$(-"".0*<+[$K"J#T17NM'/O`T:T\?(JL>H)2XZQ[)C`%$>
MV@Z.I!86")SP`&\1,WU&P;@*@\0+3E[P<G>$E*7B>QCADPP.&JI?>_XI@2ZY
M78B51H/EJ>2#H4;R;RG<SM-M(E07^`%K^R/`&0<*A:#02.Z.)6>9'3+9DZJE
M]U)IH@0U82*\4#CNIHX',"'W1.#@^21X2"V^)A9?VA5/%I4W&#V'1L1E3@+S
MI34,Q/\+\%R/FE;^'$LE%1(=%6-]3(JOD2*;:WO*)+*>5LZ"#1/XCSHLLUF\
ME.-R4=I+*$IQS1K@FEJL,9.MB:3V6!B`DUNL">&YX_QAUQOZ\%(V@W]SY7RU
M8V`FDZ?UM*$T']O!P^&C)@2UI6$'BAJ!,0A)G:>9NM_1CR;1HSM;:]F+)ZU'
MEB3ZV8<I`\XI<:4D!ZXTGT.B5CW9WRY/R6L8X?+$?<U3XV'E6*I;P'^:9KV:
M5T"$)(%<E`'MT3C/K`&>J<4+*]&:0&F-A!D(X6AV6A[7BA)!$M[-UNLNG!C0
MSHSUK@,KQK0N[*3KQHLI;<JU%SM^B`_A<LT1M+^A`S=-,T0&U-L&=`IYADP8
M2/"Q#B!N'Y5CB)V&K3!B!$;*KH06);>,2K;]SZO>E]!E#&?NK%;SF;6C&Q,8
MN7,[<;U8YA8%>>YUP7]J][IW*<CSL0O^/3XJV;3`@[1\UT)O6*8"/_,L'/-9
M`T`O=-)I,9]MMYV`G_!<EPC6!WC5A7-MI]7DN-8%;\V'T/I@U(5JO<?+V@SJ
MVW#4]8K>KK'XYIC-<K[I!HWVO4'2W*P!2&\549[$Z^D+C]G`T]<>?OIF'[R`
M-$%_@79$CH.6?O>`P@T_!6XGV_'*T-9^<AK(VPM;KS>K5:5=31"8WI'D&,2G
MY[]!)P%)"&"A`3R_XV=(P>!TIL##^_DCK!G`P%6\)7C:R-1IIB008"WIP>KR
MKXDB@#3I;+4G"8952Y-R5N"4863,17=(U+;V@B31[`6(1%8]OSTF=E2?'ALJ
MQ6B.(R;RGC^;H>[H0B++Q5BYR3PW(#J#F8[H,IWK!@1D)-O%K+"8QW<5TAC&
M>$5\M8Z(TM/0'V$`]U[O,D'M:1WCH*H)`E?.;9LKT-G!_A]2:7^<!I1A8OM<
M@Y\QOJT;X".R?OKAN<,WY>.@]G1K'0*U!$,K4C@/*K$>UX&5H8=I9ENK,5]@
MX'DB*6Z:.5_`<PBHRWVM2'F`V%7/]TAK=_6*F[N;X!KN811!%R^8DP-*N/@L
MW>+H^^%7.W#J$_(2!>M`WV!KN8E_-UND>Q,_[?>0%O\O-6\/=@)!U8H+0.W`
MMP5DEM!M&/1V@-P8D%MS`2X/X2E0W&'5%4U"!T6,WO)XV)D\(_AA-,1:F61<
MC`WBG&OHGAQRAD<LK4KOZ6>,PACN%)YO%QM10LC53`/T'?4_@"](N3L`ZH/#
ML,1Q>(KL(+;)^\`)XP2XF3@#<=Q,6PZ8UN(C=P:MKJI@@OQBZ^[],UP"M,V;
M\5C'745B/=]9C2FSJ*(!95_:YN*_%3>>JZXN.V$`ZF/LJH9:IZ-0HG,Z3'X0
M2"\B=]4KTL'N]ECM3)<(N)N37-Q1FY*1B@L4<Z5W^_LH->8Q0>.A/]L1:@.2
M[&+%^N4NLJ4;PF4#3.>NH;S>6O,^HMOC6U/>R*TI1<[C@AS'S`808R/`5VH%
M\#,SS*#"R>/7PY.E6V<*"\#='N0V`&($2*W([TU]-X=))X]A<3_/H$PSC8%'
MD%D?/0_]%`:-Z1@3PY?)9^CB0J_XA-\)F?1>O(]&'&)CC8$Z](\5AQDNLL(P
M$QM7`CL!J6Z0*Z^_8^34DHI0$N+Z+?!(^1U\,C4&^S18I)>8X,70-&81^K.!
M8]5Q<.08UX[X#@:QUI<P2&<<GOVL]#2I(O/1CJ%[%1[P;^AT6QCWKK^.DJV?
MI<0,YH;49C6?B\YZ54S)%H(O:"VL#\_8'%"V!V"#C*2K*6-*:`K?6I2\IS%Q
M2O(,)*5A:.,@HP%1-HB$[I)7&.6_"E[:CKT-$J&?4EKM$ECR65JBS$$T@I)*
M>N+*2'*0$!W"`=3G(XP.=H!'5QZ68R#^.Q.=`^;L>!F$9M)AO`Q<7,G$SY^!
M@H!F2M&/:99I_'<+S>9;45@3I:30(5%;>AZ:B6TY42+PIKXG^&WP`ZZ*&>[S
M\8A1V\?$@,`!^,X@3CEQ3127)LUA/&Q%K5N.(9/1G49R3_DM9\OFEO3:M'-,
M,KF\RH92VKAU-HGQZ)E&IL@N+[JA>$RV[-:_UJ\J*LO*`AS-"M1SQYUX,J%B
M\D(<%S7T3?CV!].@'@WZQ14RTTMBT@$3:P?K+^OOO]0LXFZ0EZOE2K3;@O]`
ME:4C$T-W\8R+"8'S771\M0/@1J<7X*0NH\Z*@1T31CYS]$?:PF0D4!]@#%&@
M7H=F0?Z^27#-C.+.SH4U%UP7J2(V4V@\:`=&AN`V>_=L0%O/;2'<5B*E";H1
MOM+Y&M)_;X)+Q\')A:]];BE[P_^>6JAV&\,_REW-BT/I1!;X(9/Z1[S%.Q,,
M4LG:!ODR'2;#^MRS(]LSA:#CR\H:V#B"8A;($"]`[VT0SDJO&@&UPAZ1[MJ"
M#VV%<(V-GFS'EQ7819TNZD=>,U7YP%<+CS'XBT[H@Z?;E[RN^?#^5W7CKV:/
MR+)M+_ZP;%`2;E"#-\KMK,TC_J7'GW4O4G$G:2_RVD(C:X*ZIBV;-GJ``:LR
M2M<;&B:=.\SAWKB_V*R+NDX4.FXJ$0,GGU..D%#UT\C2/*R20R81C5J+66(L
M5,\N8FE>5@]@1`R'5,WR<N"K/)_;%P4S&MS"K#<8G/A[N_7WM#:U-6.X&YS5
M<KGI;&=+8"*236ED1SE<1Q73,WTM+",KNYO7MJ"8`;+T,L+@Y<H^>HGM]]?S
MYQ6@%78LJP2NDMC-.O&7:P"I"A,N`)@D"J6*!3'V/,P]MVE-![RGQ2]ZCC^;
M!=B^#.]&;F<(#8$P7LBY.D6X$S)D=,IZ7R^`VXT2:$Y*%T*UXI?L.$PUF#A:
ME1*!TN9*O]M%C0#MSM\>?'9$R2!XYC1""YR()4']9?W`K%G$G9/69F-QH+)H
M6ZE\<R9P)7B_+"!I,[W3C$9&NG)`L2TV9N#P/H)'VW/3LQ7<7[SVFE;L56WA
M7SK8;7:=J$OE9J>4S(';*(<)T#+7S)RN;<_);IBUQ,0,@#U`U#7V'/21K^SX
M]7-8X@*\<46L4\HE3"L8>2SDW\VR7JT[(5IH`U@=V(>59C+7:`YV)XA/MMLG
MBX2#!)L%:!$,=,.<.WP&@?_D)*<(68BW*$5O_&ULZ\OZP5VSB'_DM>N9.ZI(
M!ZEX4\:=XUTG@\Y;XC?\YFFNAS(L93FPV18B+5B\O_L5'I[9N]KSOZM$5*:4
M_^K1U2*[=^W^#OQ.W]8UDSK,>HO'>F7Y7D^+2DI7')2RRO\?=H!&?,%'+TR@
M\XHPTYJ4G8^J7M=GV,'YT=>SU6J77H"82@*I*+Q%^\=I<YBYE"_%J3G#*4VX
ME.>8->AK*5G&[P%0OG[?%0<Y2`Y?@S@,+@,W_>D:OD$_/&(L7871,8P(HCKP
M+21`.>I%K./=%#+?K=<9%U"I`"D`V<\E%:"D0Q=%3!>!N5$1Z"&4Z<)@E</P
M7^W#\;_E@;@)@O"-^OX?_W%]=8'9Y\(`]AD"^H*3A$,IA:G0I\62P^@=:;[;
M[ST'XF)"1"V;GCC>4LU)_2;Q7I2UV2U7:TI$A5"R0A\2L0!F<A5O,93MXKS%
M12H6Y')ULHML?ZVQ_BJA$7Y$YMS!&2@YA(''[Y<O$818^DW@)6EQZ68AS_[G
ME9-$AS&\N;3:S&=I#7DZ09/+`X5`<,VH"#DA.TCS;:[+MQXZD.8@W=(1>2_9
MS8<N/@2,UP-LU_7P;VP?Q$?;(;O*#W9PVMO95"/Z26]A8AX`%LS0%S,=TVW$
MJ$_?CEZ4VS)G3".U/JIP$JY-/_=,[FQC+<I@*N1H@)`\CRIST[E'KN82N%U)
M59ZW8_HOKW4LI..;19E45GM,2UM8M8'WXFS\?YMR$UC*`WR)K.I^\5A/VC&*
MY>AJYL9X0UNW?&&;R-/;6K4#HMI(M7BLK6UZ#7WWYG",PC?2;,:=BT-=;ZAN
MJ=K-X%Z"V:"?2F#`TD!9G.8U)6DN6@-=5-J6=2=AHTGKB(L>',4QA-@RO-TB
M(C?,$[MR8B)6QP\P@%]M_PE&!^97%Y>D%'?"YG$GZVJ[WF5XQ%I`J@:4]5R`
M&M?'N&8140:P-EU8G3@L5BDL?AH6NQ*6XI"-GX8E2L.2,,*B#M^#P5'%_;`8
MF\P'V,B[_548=!VA&RC,0%:H6LB-@*65W4XE2`Q8'ZX<G&DTFQS&1(?P0^9N
M8UK'U]4IEH.'(2S0$DPM1-![O$[3`;HA!\26>>&RR4^_A8GM=V)JJ/EK`A0L
MWI3S;3TGV$PXHU:RX3*@=[/A#C@B/GH52_]':G]-3[ZWVB*PL7PQ:X"`+*Y1
M0=KQ(,&]=I`0)^.2Z'\A:\-Z=^GRIB8#4NQ@F8BSGEH+W*\;A#OA"@.K[6;>
MA3_M516F\=AJ\_C<P-A524$H;)K!F1X?[T^`[$$]@$NU\Q\WMK9-:%UD)0^T
M-VR#W"DU94Y:NL&\?E\MGQBP*/MO!@#XVZ/Z"UH!(<S`UFK='/CDP#"IQ1GE
M(:W;TT2)UOH\_5G7#9<1[09KU=MS\$%JU$I=A;Y/-Z-Y89#O.XEOO0"V76@H
M^K;R-7)NTWB7:!?+Q3+=Y9X*)_T6IRP>V+E\U2OI$_D[+_N+][17Q!>[S&+P
M.]9`;VO4LN5TH@!8T@*@9M5>&-#%8KY8!-7PSU-+K7>1-XWCG2>!PN>+Y6JQ
M.6/.&>"K`-\0Z492S0"_!6B&[;<9#/-4KWDO&C0]`X+,O$<8O:'_B+LK[[*?
M5SH<8!@A4)5KL:QB#O-+)DUO>5U)WEFT;@IY$^`\+M/G&P11>J60WH%!3_95
MQP5=<=$('C[(:`3*D`1:5>!A!B2&^9$"P0E?`N^?185I<`I<7(XO(V(#<,"1
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M>*:$'/JPDR.^,Q`ZQ@DIC70>RJD^HW",4%',OZ%AETV2I^]K/FDSP@N+UPM5
MHX'6="F/!9K.:LEJ+^C/ZLHS*K.ZK)C_K-5JEQ892=_7G=7#O;!XO5"6U6WI
M4LGJAK-RNEQA`-]_M:._P^0S&O+'GVTO^I/MG^"U%SM^&)^BUG46GM>4=\3Z
M;>(=%RS6F]T\[9-AJ6A0@,6"/98+]D@P>,.2@9N+5MU1D^WLO'"6B@5$+L""
M`9$,"M$Z^F^R';;:OZZ^#AP_$HN^'&=0=#2`7V""AXOW4?CFN=#]^/Y;#-%`
M\S,=4I=K=N,S+%YP0K]+C[B$`>LLR4BA"IO8<9;RW\([GZ?810KI)$ZF$CR_
M@Q^P5N`%?P2YXE)E_`M0Z`:%<CW[(%4&;)T%C,P3'DL!V^=ALCLO$%#5+Y"#
MHG)'0D*<SX].>O9Q2A)^-O0BNGMRO5NL5K)I1ONN4ATQI#M0R74E?O@UIDO/
MWQ?I=.U>E1AR@TB(3I]+[M/P"M5/.IR6\C?1JQT?V>2*=?5I!C+,)`&S*GV:
M$XU1NFYJ/+4((HB#4D1B?'Y4,JP_(RK\;*A%^#0(0LQ.-L68VI^9-(:M_9GO
MBW0&]&>&A-P@$FJY5VU\?X97J'[2X;24_^@9^IF+;-IN+SR'.9I)`K9N[<\4
M1<",IA9!!'%0BDB,SX]*AO5G1(6?#;4,F5M8RZ884_LSD\:P5FSW>R"9`?V7
M(2'61#HW@1,>X&T8=W1'2L^HI8!",7\-KV6V@0XCF0H`/V`1?P2721)YSZ<$
MGXG"VY[O[>G*5G"`<ZAW^4R%EWKG8^^T]6B&NE%T4,+#,8*O,(CQR:'IG7J#
MT7,XV=>9\W\>A?S7A'F-QFKN:F>CRS?;\S%0G\*K\'`(@W+!GX]V[#D\GXY#
MBBY&ZS=-)._63,[+U&#"HXI`6=,%(+H,8`_9`5FWXA#8/D[A-"`.#4C\BEH"
MW5V4(;G/!#%G,,V&^;7GGQ+HCDZ>3(Z14$^-X\[M^6:Y&P[V5)OI<!\4E.\4
M\#44#(-\.:!Z0/_UTG'"$QX$O:#A4H!^=&B)@OO0]YQW^K]/\%OR$9GQ=V8&
M"8I1"GDQV[BG\W;6*I___`H*':"JY`)0!>#W]%^L"1!5VB8@IHQ(=O(:B?/?
MP4T<G_!)S"(ZCXD=N':D9TOJV+ROHGQ`&+6`',7#CE^+U9O`S7>FD!)'?=.4
MW.^KA#6O40+3\[L,SU1V:944%PHI]H`1^?KG$:>)@%6.0-L6+JU5!85SN8)8
MH8A).8B"5#Y`O`,?]P!^.WY&-)'<V^^'9A7:WL=5'SSIL(7W'M/=,K^$%DG[
M$.7BP.F(U]2#!!RI1,7G3*3YEO$%*,2!WXZ`"`2I1`W'2J3YE[%!Y=-5OIRV
MDR4<T,I/E/3%8PJL[TM*<'_(>V.5]^-[43/^VZWB/6<^GRW62\H$]'I?'^PA
MKD>5"6I4JT*8"B/@9Y6ZLHH]>HE"1A#:*6-?9@Q0R-9/'C)\[J>14BJ8PBC=
M`&9Q2T>XY+#,"1^5O=M?!L')]G^UO2"!N`\#*SH;TW-B[RKG&D[#>+NRN]EZ
ME=82I:+)]5I$.#@4TFO)!UW5[#*)V_.2VW=[0(6#DO0:S4PU[]A-,I.X;O%^
M\3C_Y/K81A#(!>&(A$XNY\0Q3.)_A[[[.8P>;49OAOFP-E:I6\)?%7NUWC1H
MA$@#KT@<V*,N2HP$ZN*-<8[5B8(ZAL4!)`]@@3J989QS=2HHOMH']-4^Q`SG
MU$*?A:<FUEN#(17<-X>C[46X'AI6U?5E:D_J@G75#-[LL'9X@W\-TUXJ*DT3
M37`>XU`-RYFH%-0:83S&*:OS*VF';SMB&MAMB8!4X/[J^3!.P@#&E\ZK!WOZ
M_BU/ZP)PTQ3>]%C.E[-9'<0.4N0YN+^7RP5V*ABXM*P=+:ZJ"=]C_:UAO!`'
M,GD:<3[6N1K66[ZA=KRS@=;`/",:<G&/;'=.2`^N9WJ-=/CA$;$,OG3@<(`1
M+O"*:U]?QO<PJMQ#T-FXCY"JC4<&F\S='*VMC57GFT.F-JW5[&::TWM+RKIQ
M]6;$/=4)3EW]#%7QJO-5'B]:J3G7G-X!4HG798S+.E=O!M'9C5$5,WKRM"0S
MG0HOI9M^'AQ-/$V^'!=>+=LJ4M/S4R6/\(5,+;'6ZYG/J]PVP3*">Y/`>C:K
M(ANE9G&R*!.G:4N$'.]J79'B<&;<X9VR'1!]:5?9\=`9$*F]D?LP08(13A_)
M)DZ,8[KYZS*^=%T/8]7VKQ!@/3<]:/4;OHN##(KN42:\VC',+TCJ8F*YBG3U
M6:1ZP=O$K':KS;+>C3EFEJ3;;]/>C$=W[J%^BYW;@[HO)8.RRU2P2>"8VJ1O
MI59_8&O]G=P20$U)NSW9ED@T:BL"6S$($(OHU`W(;"JN1=/8"](8W+QCA/>)
MXRW4&G>+3T]\C0Z2_,C+9?\H?(GL]IMS&\]HX]S4`-Z*NK--R_+/,16".)),
M*)TB`F?*A8S+*G51X2!_ZRR6"M').H/\((1Q??GPE'TR_4Q1`TD3Y&5'I>#S
M;K_W''Q]WBU-RS!Z[[F!IN<-U=CM-H>W"9GM4%)0)%.!9(K&ST5JN95&IFOS
MDFMX-J40J?^.&IE^6K5/*.2G$K#S(2Z'/D=PY!!!`!/O`/-YZ72O".Y'W-N>
M2SL+7<,O,0'*:4+$.NX9.6NY6J6L$<`/6$&Q+I'O':/#I2/24K]=4C6?3!>#
M>1H#$H)<0;Z/C`YLL))LZ*)QK#)A&*QR&/(1;Y8(].LW!\+ZJ&@(Y@MF$HZC
M>J+Z[1@&CT?HD(O\;O&T\=T>[XZ)25_*/3GM&UFDZS":[C@<X.U9K^>+W7($
M(X+3$0_?,V.`CZW!HRJ\'2M.AU?$(I.Y4WI`!],KP*:`W!9`C,&C-F)..GPC
M!IE.Q-)C6N7J-)*EG,Q.EA0Y=QX\+4!YPZB<]TOH6'/+US%ZZZ.U/:EPG:U%
M/7?5C,7<2B^_*=;5*@5%])0)&>W2FI[^*A<!(8>^PL[RKZK6U3I2J[RBQHJ"
M5C3<0M3A3/<7WGH!)(>9^SYC^TLZ,-)J"7=NS7;Y_$<.%RHQV]'^.Q9*3^UK
M.JLOTU5KC*O*T=29FJW`8H=(/\;BSZ?D%,'TULJT&8VO3_6#,*)O:T,=TR1^
M:E^M&ZT5%7T!J'"0W4B:B0=(ON8V3*;SI%U[PJK-05QOHK*AUQT5@S%X=8JB
MYN3E0"'F(3*UC+_:XC:[UU@(F!?@"RY0]?05^F_HB3!(7C7MYIHR+J011>FV
M.@/(UO)Z`'++(3(8P/C&M#?X%VA'?)U7+D'F`;EDG4A#8PF"^0*C&5\N@;4!
MHLYH'`\.2X;EW1E@N27%!^"Y'BJS,8TR2@ZF<T%&8CJS3F129#48TTC;>6!Z
M6%@R3&_/`]/U%!^&Z4JHC,;T$](JIZ$N23(1U85Y(FW2<BBLB;JSP/70P&3`
MWIP%L)MY/@C9M6"9#>VOH1Q@9W*,A'5JG,#5!>O=8%!_#<\#TH."D@%Z?1Z`
MKF7W,#B7`V4PF)]>803M?=+8Z#M<CGE@+HSCSEO+6@SK>!>ZC(;RT)`0*'?[
M:!B@FQD^`-"U<!D`Z+O]+8QC"*^]V/'#&%G==P.#@`!]$.ZPBON`[G*Q833$
M>"</E0\*!>#W)U)M5/NE"U.%@F#VT7F%[LDGFYDRYDJ)C*C+:<P@2'/D>`>6
M^^)G`(@?4,`_?3OB369?(.>J5.T=?5"M&L+=C*Q7&^9B,!8)4IEXD4G3#8\2
M'4VO.D%N02K!('BU9U\'HEH"(6<_=ZXFC.,K.XK>]V'T%5\`0^N7WGH'CVYT
MOCS@RU1:=Y**RE"^'UO00-XB_*OU?),6*RP`A;?.`:>L)"MTZ^=J@$WTJ-Y%
M/6D8ZKR"PU!1DI4Z+M0`JD?'YN=)0Y%?9AI6L@)U@D@*0%J9]H1:_E/BT8)*
M.">"+%&>[=C3=W)^*"44^YF'!'=B-D/<Z=%MK'AN0"PE:N^:PUY5P[@/2\UG
MFTV=M5K@6D@G\V.F<-48I_LY2H730ZEIC.<,2JHU5+#P'@8N?NB=$03-3-0.
M9PX&:HGAQ,Q3L%U\%_P6PR']*(8,<YBHW4#>(T&;S6JYY.A'%1VH&#>8N`$U
MK",E(P[])%72`NX"\!LN/V1>3TI&+!BT92`C=<.<@YDZPJ68H3`S?@I:RU2+
M"S&7HU(+N2M<+%:+^3"2PHTH;E"-I:E!H1C$4U@30*J,9JI!X>`;])%4.-C?
M\"3P&;!8C0H&T%@YEAIX[#&QHY&=K4*,V5Q&;.2=J%BN5S.>J2L6F\58F=%\
M-B`<PQF-*#.>TP:$1(35Z-+6F;!:A1@&\EH1SXF9[4N8/)Z>_P:=Y"DL#!%+
M"(8,<SBMW4#>=+4V>,VGG]"",`$Q58,KH13\9@R9R8A#/Y,A+2!5@RN8%(J,
M8C$9L4C7`?$U@S@6QS#*:O8'+;QF('UUHY^#NSJB*(FXL+Q/W_!-`#'\#%LO
M'FP^I)YZ:A9P5RQ=[N8IMV1%?VKW(>/E'%SK!Z;":6%ZDF>(9-*K1YH7CV2U
M;91SSZA`I.1"O,N$`"1%"W.,\L0J>9)_NGV[)XI(@(&D$LK;/)X&Q@_0"5\"
M4KWZGMS,Q?4)FF]I!WK#)/[[L9=6WJMHI`F^I3:3J^?N,MF>LJ`-2G(!%6P"
MVD=ZRX)_RW<UAQ&8H&131'N8M&S"BU[L(+TU"9?##WW/I3L!`O<>)4R&ZKO]
M9P]?FHPKZJ/?D,IG\>5SG$2VP]RL)T6VRDU],@P6N#O'2N\H+.N]`!7-I(M2
MUHT[,KEV4*@'OV<&Z-JQJSYXEJ+@*=N3*!.,E;V+TK[-V7&4P)D`V6K.A;G&
M;*K?K%>61!*KG$30?@9!:U`;Y$:B^,4FQQ2*2^1TEX&<")O2V,NH$P_):WK%
M4/P%A;:[_E;KLRHII<T`[@W_V_5\F_("EI/66[P`A2A-F![OE55XI>]B=:Z4
MJH"(Z;@V)-QZ]K/GHU$0C'MJT3&>5HV&I@G<F3/?S)=E/)1$H<92.R+&>E;"
MA%^(T@X,=H8UH,&(@#9P()#F*R&T=G)ZVJCK,[)?4@T5IB7\U1)FLWD9,66)
M>7WO5.A$);ZYH"/)TQ*"O-0YV.&<4ACUYF(#3=U!T0*J-]3\^7Z8X%XAG9!K
MO=2M_WF54&(9(5`">YF-SY"L#[DPD,ZRZKGG3+)_UC#_E&&H+_4J\.D,B0[D
MW-M1XCG>D8#Y$:*N(VDET<`JB;SG4T+NG?\M<(O__F1'>&4_QNO>'^W8<QB?
M7X9DA6B48"[_@>GY+*U&7-$*"K47H*28S`U45(-,=WH)Q@4@!LC%^8X&+8`O
M:+CM=B%=?>R6.'BXZL'/^`:;4F!@%AC;)ZA!OTI"<*R$.<XM))$-Z6C/=3\\
MV\[?R97?>*N*5[Z<0R?#2(1HF8MD?30]K$5+>'P.HP>([#LY"3(_>&'F)^-Q
MI?S2;@-_Q<#9=I.11EJA'&\&K0C31P!2G".HOD<OXK3TLXNJM(XT^S*MBJB.
M*.B$R0/T\1=\"I_L;W_VDM?7T,?'39&=Y`+UC_B.D:OP@/OP;;L\1HO3`#-1
M&P4JYF=][AR&J2[<<"!MH*2.()0H1&T+OIFFK%(W6"<.$05S=@%HN`=)!.WX
MA.^73D+G[R:`>B@NVD`_*)HZ2>$IO'3^<?(B>!_AT7SR?H\^:X+:_$_HM\<#
M>\)60(`&X/=;)5#2<[&L01U!/!4/,OD7@&BX('W)7(EN<$L/0P7.V>VD1#)Q
M''8YKAK7_*G=AF3.T&G!+F(/NC1*)N+N0]3+@`DR%5OU$09P[XELBA@L3B6N
M!]K(O1Z_6RRR?C551?*93M96M8%,G5D[&=1$B$S#?3H<_?`=PBP2A/JT(GXD
M("KX'Q-'*5O"[R'*C2"Q7^#=GO0:XKL][C/8P7N,_CV$P2/N.MV=DCBQ@[1[
M<1,XN&,%;P+Z"AIZP.@-NOA/<7RR40S)G;;D5?R]VO;Z*M*L>FNZ&K=X3T%L
MY[-%6@JJ,(Q<^$WTX)\<:MR_Q.3D"KX>'"L!86$@&5)XJ8FXHGKZ<I1:2?^>
MVIE>[TR%')%UBC?,FQC_>2W^^()P&D+T4V8<H-8!H@.4[`/("I!9B'[(WLV,
MI'_/PD]O**="6%0Y70-A[">PFA"HI#M)Z7+2:SL/H):1\S,%"C^:G(9K[_T3
M8@-:5UU;'U'>%%3U\U8;6:[6UBSE;"(!@U\UBXXQ?5XU7=.:\'@_K)(?.M=]
MN_*]P&^+IUK&BRBR7^P#O/SFL>ZPJ3RB<EQ7TBNP(2"[3@J_#O#[X'<L0=?0
M:[`3%J\3RD92+:E2&1W57=69S]<AKB_0\U'2AS3D--4L,KZ>-;*:RM"<UT,<
MJ6=VAR.J<[N:-FW977)83L<H3%"GQ,-5F!V\0X[N^?D,(9Y.M"/__9H6*\!=
MEU\]'Z+^;\`JZ3!8EO*NUD!#>3L$N_D\+Q"1J0(^U975@<#GBLF\--:7E80@
MDWB'3"-^1G5/3DEDYM7(I+JR37/X?/EE0+80H<B4%()<HZ;R$FJB0_CI5CA;
M]/4U1U)(T2D=$UXY;!A!!SWE.;:?*X@[AHP=CROG-+8MO.FWGEE6-OU72"LR
M+%9-1K)<FM==*L1I'6[*\L]*_?MP)>B@&G[H!U5!`3TAT=*G1[)@%$&7S$M=
M>V^>"P/WP4[@/8RN<<VGJ+6(N_C[*D<"O$8)C!HWJQQI5#:=6,9;A:EX@.5?
MX((Q'ZB*#SKJE$\<`@+&2\>)3B@``3[L>#CYB+;?('!3':1VZC&/DO[M1J(9
M7AF9"(51/X#O[>@N(B>TW3_9_@E;2::CN;*$^;(VZ+(L$DG:-0.W2#8((UHA
MP05$/`8O75(R`;1RG">(Q2L/L?<2$%=KV+S`^_/!&]9@#DS[\IB-T<ZHZ0<H
M71RZ/"6O880OP^+*A,9+V@!9MT1@<BJ[[:,!Q'0-MQ!J`OC&.<H!NG3C@-WI
MM1[PL7*4#;K6:)D"-KS\*@2T]`7-(*-6")#]=M8-,"K0''`-<9`?6![36YV@
MJN9B'Z!*$3(%3*5-#P*?NOR69EB53.&OB%><&&5@ZZY[MXP>@`UVE1]EFG<)
M"69J'][J`=,$NJ/MN6E-A^[B/>W/J@58TP!N1M_-2TT6EE/<R:VU;(\$KZRR
M5VFQ$;TG*;O2JH8+AO-ZT!`Z$+KQ9^1,MHWN!E?WM?W[T[/O.7=[A.*NQHCW
M?:6HX31*H'C:-EMX3&73HOWY5MA4/*#R0:9`%[XF\=]J^N^E;A^IVV$JEUZ&
ML3<$F((97@6K2"1-`3#939OMHA7(D>I[F@%;,88[43?S[;83J.&^LOG='(".
M\+<-F"5_RYO/+S)HYE!UPEAS#0+>#.X#9C.")@$R>(-1XCW[L-HQ%LP0EA0#
MP,HPC3^5UYM%/W1S+:`V5#0+R5*"T8OK(AA&K0<.`@`/NKNB:@S6HT?;1];B
MX]3)NTC:5%_4C>B*-0)YN]YT@S@"6##.7RK:(-R.<+D%JG'J)IW),0Z1K6G:
M"\)FB'3CCAX5(YO]XNR:&O9B1-][FE#7:HQ`!N[6;:!+CW=2L?D53-I6**2Z
M2P!W9<>ON%!'R>?RI7GIZ>(C\Z:!T5ZC]N@Y5.KWO(UI2G[F`3"&<3H!RB(<
M=J0T\4U[J92>6Z3ZWU/+-]W&\-_QL5D6LV'E*D'5(D':KW62[+$UUF.%Z.-+
MUQKZ.()E%/H^OC\AW5VG/SG>-`&!A3D"ZXB+-0<&+P"6K/<4J6RO^W'8Z[5V
M)#93EPN+M9`9A4:!PEPB(DS`Y[CR4J5IK8ZFPZRB6Y-%H@+>_J*"VH'*6UU+
M-&"23IPQM'Z*$^^`-Y;\%L/]R;_U]O#)?O:9R!PK3?UYM:&F\F;K;K68+;/C
M;&FV'G/8YO4@`<P4@A/1"'RD4OE1-S71J+!82F*7%1++%0*J$6"5@.C4R&I*
M@T0K"3;C\*9G1"Z))TIG[$:%T:@>2\-D](U$&\16&2;T6=H,$VFJEURC"_Y$
MU]AI&1\*>JH>EQ_#A:^!=SA&X1O47[Y_2&9S=5N8(3,*P+]$82R,6/J2"1`E
MEO!/_UJS#1<FB5C#(#C`U>9(P8PJW%S)R`6R(BA&H>K6"^!-`@_"R"I>-`%=
MN36\:;?>K686U[PV%@V(;-/&YP.=YIG:[G%:._X::<N%P6K`C,+A%RB\KH1?
M,0%[R`YNLE^M+;Z9;"34,+0)N]G1II&=F=/X%R:VK\:_]0#_M!-'"6=<E)%%
MQ2BRN`]]SWD?//->?]T$$JG9)+!(M.29<4>_)`K`[^F_YLZZCXK$N<VX,S*9
M"YIM@3(*IH,!:A8TA5-Q.Y_-=EQ]:SI9;"X6![I.4/CHO$+W1+>%GA$BAV'1
M9!0BS=U%ECG>-`*'N3G<;<)RN>/9O)5MH=!;J%FVW_Q;1TRHZ\R?OGR`K`;-
M*$06BT:BJ5!ZTP1$%N:(]-+X%EM*:ZJ&X7&HUX8ME@Y(4R[DU<*C$WF/I^>_
M02=Y"N^BRS?;\W%OZW,8W:$_DJO2R2(7QY9*?CD:4,EMG,`J8%%*(^VWI4KP
MI:EA!'(]Y(:R7!,@JHS8?SE14*P)@J(:Y\*@:$.]6'R-YP"N_K&()%-Y0+`?
MN=DL5V.8P(@.]62!&<$&!O6X!P!D,"-H[I'_KY,=H;3QWS][@1TXGNW?!.CS
M',C6RV+S:L]!)U$I"KE`T#2!=-^DB\6Y!I"K`"4=E9W=FD]$31H,2VHP5&%^
M(`#*>!\25>.PWC<SS?FR*<@>LEBR7O$!6O_YC"E<YX&OL4#MG*(6B)8.6#Z@
MC],UY"[^KA!<N5*!C416NNQ*WM4ZYAUHO<5CO:I\;Z1%.:6K#FK+VM;;K=J>
M4)VY0A<A69O=,MOYEWY]K:.TP1Y8?!XHS>#F74TL-Z4<B7NPWV#PT0L3Z+P&
MH1^^>##NO+F[^P75!]LZK>&]AGZQWNVV].P:D0=J`B\TW/(MT;$YTS'=5X!+
M=-+J=/)'_1>S<0$M/S;6'QDM;1@\H@1XQ?.R+Q$DYWFN\&53,#JB'N-[[UW,
M_.^K;/]XC>(?'ECSM'4L"S+A)N>)?+7$?576IHJF;*7%%0J7'D3&$$7C]3)P
M2_>UIL72F4G0]8Y2Y'48(K"1>IUN!\CDD7T`Y:N,4Y&Z,"?-2ZOA9>ER8KTH
MXTC#*K+Z@F(<FKK';AQOFH(LL9$2&NEO9GSXTM25G,SI)MS*3NOL40Y(6&[T
M:>]C=MA&]ZL/^?[IFZ9@D)HCTLO:\F'0O%,:TN/0#<LKW?7Y!1*8&Y.E,,F9
M]4F57>$;@Y_#B,RO(,VWGH/5T4*B>9^W8S)HB!SE<T0#C.3,R/5L-M^E98_R
MC*SH(05_4DUI:6&0ZYJVP63/+4T>D+F1`>F9C)H\*M8445$S>36"+XHYK:$!
MEDIY=\^^]T)47X6'HP_)G@,[J0^6^=[1164L@SCS<;6V9LMMC;;"7":^`2<5
M"EPD5?74MU0GJU14R`2%4("E:F0<.8Y:G%]3.XGT(;!!&)WQT31&22+/2:"+
M*^HC"L/_X-,+;[:/:URQ>\+=KZD=G73:PCTQM9YOUSG(4I&`7#2`>^;DAY)8
M;4,0B<X2H%T>\$1P#!S?CF-O[R&G[1A$10@<I$+7'0J2/ZY5^[HLUQ2.L+C@
M5QM>]8=$&Y><G.2$;Y=#=CU`'Y_MNG02[\U+/!CW;"7F?U\UN_`8)7`H?+,L
MT4PFFY!,*AT4XK5O')XH`):D`"A%JDAR-R#+'4,CL<M?XWV0*),0/:+2.<[M
ME0"XC2K]/GU@BF*JX-,W+P&WGOWL^8RKX(Q!-F<A^,'ATXYW/-%,#(YA]-:Y
M'[GG+5TH;IK"?WYENYBU`5;[Y2E2'6QI;0VY)X4S$9E`8T3&,$S=]A16Y7K5
M#'3=BM89W2Q7ZT4;Q+#<M&$DD@VHKBK?[Q;D"?MM`!8;"<P)R%OM158KQJ56
M\7S][%%=J$OU<W>PK+EEM:$LE3,)GHXP\D+W4^!R8VJ05TLR3>4XT<GV`=*&
MW?IH^_A:V@G=>DSL*)G6L579L8_PQ0N"'M^T4$$--4SHEV-@"M2O3E$$`ZXI
MI]H;FH&?FL&?4*M=%_XO0"K0@(9UC(>E(23$0TC?N"%D>^+U@:8<#%.P\P5Y
M+@R?TDN:$518PIUBR\5FVPFB0J8Y.!KJ)Q-*I&`WKE2:B@7',-)]!IPO/_M0
M5@N5'J`E-NH4NY_L"#?V,6K^3X<3F2JZAGO/\=A@ZWU1*>#ZK.%.QL7,FF>@
MHT)!)A7\4)(+4L%_U`4]N1Y;:><O=\^E4O2BC#<YJTCCBHP):.LY^M#ZL$94
M">_UWVY92-)]HF&\8PW`I,EER/F%KD3K0HOV4PIO,#C!S\B;7R*[:\M/_3FE
MN*@IYU]W6EOY:CN1`?!W`U2*+BR,<H;`@+P((BI);]XSTJ>:\FT>:\SV!^B$
M+X&'.[6_>C[J*(8!_!4FKZ%;?>"?T.W^B"*"U.-%P#J!B:OYJ@JHDI8+D.L!
M5-$%J#V&=$TS:1?&R(0W'N1-%I8%P68N,P:V\^HAD=-XS$LTD[E;]79:9[GV
M"DZ<]#5_C_:[_M/*0^FLA9Y%`V<&?_-=?]7_GE9V'GK-D[5;+SO(V+P#E%(=
MMTJ.:SXHR9F5W:@SY0ZK+*3=7U''`("_J[Q<;!859.CM[`L:7LYL/3=##K.;
MW`+YA&5G8Q,3<-DU)M$^%.G?%5][3`/JA*M"XSG.*OH,V,<^QI=*4_.S"3G=
MO=^\Q5=)9T_?//CUGFR0^/C^`%_P5%P8O5^>4#\Q\I)Z10O.E]2?/NVQB+=D
MWWRY6&RRXZ=8)J";1\#S.V+`3"RP,[G*#Z!*]7->\I,*!1_?02$6Y'*UG$&5
MZJO5^*8:CYMR@JYTWI0G%G(8`?54WSS?A[_:T3L*K-M18X/QJ'+TM]O!70)A
MM5G/4LQGDD`F2E<A#!DNS76XU`-J&7Y9%;\N^!Q3@^QN\!1X[@B#)!2_VW[R
MGM>LZ#_NQ?V:>G3WVL3;$JQ7,SRK2].'2`5V7LK$S>6J;M1E.S@O.UC4:C'B
M<-HT'F>75;DG)RDM6=S3&=V8[LZO!T3+4%84G27*X(O9)/1QRSCOTO.P;JJX
M%3SCL5RO=XMEE2!*M8YN)S[.PLT0`_UB\(*^8SHRG;.&.:<%[PTX,5%^.^*\
M#2>VG_!E=CP?ACZH&]/$"M[4L-:;+:O!U]S*#_"#A5\BR@3H#O")!5NV3UH0
M6P$)$ZV%_S*1FO9B+F,T_G<P5%[@W?X+3!YMU,_Y+7!A1.O4X6/JF24=7VN0
M.$VH'V(K;_[MUK/%K,H-Z0X`7"_IF"O$&^?Q_OD8ZP0GK!3XF5;==#)]@"JD
MDZH#ES$H%(*[/4`J`=$)B%*0:RTPK8^?I@\2W4EB?_,.IP.(JME4SB7=?#:&
M2NJL-SBJ.A;GL%%W^\<$C9+PW1AW^Z?(#F+;(07[NBZ&X7A1X0)>OS4"UXQE
MU7"Q4$QR1*SF:V!D.VB).:AJT8\_'<O+@)S!T8RO^PC!'G'"XZL=L4[F,Q_7
M@Z6*#0(ED';K%@1=`"(.-Y"`"-2.I!'NI?<G'0YA`&("GR-Q#C5I(&8YIP%%
MK4G'P$XS'+H0$Z<+^[^$H1NCIK/C4S8>58R4NGZ!K;:S$DKB;/OX!2"2+G#/
M41]`QGE5WD1"CZ$<TREH,E;0#0U6=M5AT1H$W9!`=G2>[6M_5A,H<@,$]KO.
M9ZVHP`,IO4?[)#AF#7!,!S(:2<:"1C4.6K"!AE)VY(67[M].<<*\^Z3W<94(
M8=C`?TITG8,D%74!"F&Z82+%.VN0=\JPTI-T%;ATQ4,G8NXC^.:%I]A_?X"X
M\`5LW]'$_9H&!+%L$=CSNK#J2"J$@DRJ(9"2XVZZ)\`+(_`7:$>F8JLO/=LP
MUAD@G5C[+8B/T"&7#G3/JC&?UX"NAA$BG9UE'58E:;KGTN3X9PWS3S6.F*G7
M!J#VD.A!SBMT3WANXC)(/-?S3_C0\R-T3A$I,OWIF^.?7.CBL_;XCID373.[
MVV?E)K*)C+9E_(F4*,6H3,M%^F9Y>TD-P--[91-`80/(C*!S`"4S\$MYP99\
M/E#/@KT)$;4T1%0=#TT!Y"IY2?]RY\UX/6?$)U!TELPG?!@;=9]74[.?_L/K
MN@,\D`R35PBN;-_!)X#2(%_CE]#?;P(G/$#PPVT8QW_L7G\Z/U;L.GH_T:?4
MRX[7<`^C"+I/]K?+.(9)3"XDI24]D4\$1?P4*"9-"\\)F2AP7\9RUR2S3!=`
MR@#51@X)E/092%031BA;Z#V&`=FSA&)$F`;]Q@[>_R4N(I:R3"EP/Y1L:"WF
MJ9YM!H&GG5+$@ZZ7-^J<]M&./0??W4Y;"4'>$).FA3>$3!1`Q6K1Y(UF?^8"
M$'V$/;*&V#SFF#!&.7.4NGW-D#3[)NFN$H.Z*(.0TTX:XO'63!K[/<07FT'Z
MG1#7/=@)J644.(CHR(<590YQD7KH0]A.@4D/:]G"(9G"<E.*=8*J4A-I9.)8
MI3MJ*E%`$<O7IS[%B7>PDVHOY",,X%YOG6T90&(0R;"(:V:3P]$/WR$:@45O
MG@,S!H0N;B9@$!.K+WUB"QF'%94(:8T+?.E4S#>C+5.7'OZ1YP!WP[VVMBTS
M/)DE(#6%MLT?GK$QH&S-!2CLH?C,+,K*R!";3)GHUA;AQA2/R@AKX#[YL&>0
MHN0/^EVP)7_'3+*^<V;-`85*%RW321/AVJBNG\Z`-XB4;.3_\+$17_#I&_[9
ME`'E-,B>E!1-ZD8&B9>\_]ES8;H-]^/[K_;?PNCJ%">H+QS%']/]3VBD_0A?
MR&%+SD[C8,EZR&ZHN2(S.=LFK65G&Y[?`=$'<H47^'>Y3I`I-:;'IR9@#5J2
M&C`-?#46<`QF&O4U]'+0YU-RBN"O7H"/=C_@8\Y^5E7J<QC='6%D8[/)M7NB
M:W)C9&OAH1$&"P!KO6XR$=4,4M6`ZB[J>^T1U'+U@.HWL`^E+'Z$F-*8W4=>
MX'C'<KC2&@WDJLC.^@SJ*4@"WMI):&SL]=)0U3Z7+D3R]74Z7M5"(FQ[^"=7
M%K.6M;D:`;C9\K0A?1)9?C<Z'0/\5H_K_@1NAVU/U/2B\CX*D7G)^SWZ;LEE
MX'[ZQ\D[LFJJ";^N!9W=-@F,VC?IRE<F\`(0D611.!=J"C9E>FV-\EH],OF2
MN!V='''3B]#_=;(CE`?^^V<OL%$WR/9O`M19/`Q9T!:1I06[`@8*="=W+?.=
MN2:0JP(E709VO2>+3;[]A6Z3NPJ#./0]ERQ2%V%Z@/')I]OJTA8-/6<&_@=`
MI)T,1$.LEQDJU\DCZGJ`Y!)B@97G?@E:6*#7+.[\7JZ7F[9)P9)\6EF;:C!K
MT5=R&%JF^@:'03W&N9.]'=E\L30(S^@_8/0&/[X_(0/N]MA0_G:>7Y)^?'>9
M)W`<9=-RVK&:X*DB/(N-5>$'L#(#6_J)XD/;^5?T)(R!%Z2S9Y^^>4E^:*#U
MEB3-8.=!`@?H>^.H%_R,Q<XHPI^+S/%]?"^>R2J7?K4CEZ^I'RM?"U&,-%H$
M'BTS]JP=$*!L`*:3\H-Y?6%LA2D]":5Q;.YTF#2.ZME)$E3;.4O&IY)2NKW/
M)+)_Y>Y(AH&D0X6XUG-0GXK\X;?`2^)+O.T7-2J=LQ03*U-=]GTR3WA!N%O-
M%VM:%#X'X5T*0M"RW8B6%$XM`I=D%)#9E/Z16`4RLP#M+TU^`5-;$V%2B.?G
M'^+NVO.&Q+E]YUP:SG38VA+-/)C:*M9/SJ!Y/?MIOY0I'>-R8U?VZ$^V?Z*M
M9!R?#O1W@A/C4I1H[B(/MUS@A-.J99C-[+9=5)GO`N2F@)(M!@[`U0>UL],\
M(*BF]93'8[>ONSSR2VDF.6SPQ_<KWXXYI^Z;;^BAG[H9_,7YYXN6'3`TM]%8
MD$@T9OP\SDM&#X;'2PV89:4B`X"MH=&+IM^"*#\8\&1_2T_7Q@^A[W\.HWRL
MS-\]$!:H!8NB5HHD<<LJ6EE=^11S#+!&D*HTL'6?-DZ,`^"X%,U'^.(%0;;8
M]BEPR>UBA_"$VG;TR"]1&,?LL)I!#T.QU<X>@SZ%3G*)\<I!@"\+B[(S2%Z,
M^`__[V?;0=IY645$D@8Z$3!/8'/9KM;DQW05KJ2'K-LA'?2T"?H!4&W&\<AD
M`:*]A=/A8$?O.!KWE7L<LQ,GU:B9P`T#H-%&"J)QE3/9C?G:??!>7I.G\!J^
M03\\7B$2LI]#:D5KP7VA5Y5/1//9Q7M+Y&*WW6S3:64B&418-$A"X%+AP"E+
M5WR9Z"3>SDO>$M'@*02I<%"1KNG:@>E<MQJN)T-<5S//*@;>8M94('!:^AST
M(.$O,'R)[..KY]A^]Y4$S.=5]A]81@@<$<D65\I"=-]$(,<M2\@M92UX7Z)5
MVNG.2$AJC2,/QI=SU`]X@U'BH7[??936L"3S#5VM,=^KZEMC+KNX5\;6Z]DL
M:XVQ9'`Y1^UO+AL<,^'TSDOEK?$$WLZKWI9D@UQX=D&NSM9X`M>MLNL?AONN
MJ#D60F^I.>:/G%2:$>46HPAE1'(MM_/%;%-E$91<9E#'>+\J?`'F)I+$>"?K
MS&`L&PA1@!+<6\.[%[VO:F*#/KLX<VLQG\V6ZRHQ6.9U+^1Z.Z]Z:W;W0J[K
M51(9[KM*0N%%;YU;N"(GE69$N<4H0AF37.O=?%UC$91<9E#'>+^JW0O+1)(8
M[V2=&8QE`R$*4(+[NT"T5\%Z0Q/V&>;P]D^MS6YEU=`/#!E=2'%M7G4-R320
M`Z1X>BZ#C![(U7F@*S9ZYON)61RLP?.&TCE_IAD"NV`W]3;5##1)=](:[*2Z
M]8#>1*RN"'1'1F*K^G'PF+WW33VM;)]9O$2]6^SFU=;VHW$#=KF^SBN^&CU<
ME^NX)<5QA>TR+VAK[3-7U/2UTQ^%V^GV-Y2WTZUF".QQ76UJV#,#;]*=M`8[
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M,62OC0R_YC6_#"2)\4[6F<%8-A"B`"6X']Z[,+1S(6E[YW*Q6E5G&Z_-ZUI(
M];7"%(9W+*0Z;DEQ7"6/#.Q4F#W;>"T\V]C^AO+9QE8S1!;,MC7LF8$WZ4Y:
M@YU4.]O8F8C-V49V9&2UTV\>C#J;X](#&EK=0COO*L]BNY[E%3'(^^K;SZ%6
MSTM6:VX)A[I@\;J@JDUK)GBYZ:JYJ:6%:JT-S"+,]H=5MDNM%G"S]7:SR@:.
MC/L'-+5$$MRRZFXY4[N%NES/X?2.S:EGN`EJ\0S`;_AGJ+5U[011I6%EQT,;
M^I\[+I9([Y5XKA?3_?3MZ-%Z./>HJQ"Z79]?BGS5'"/#:.XEZ\7,VG;34OE:
ME,Y;42Y`806@9FBD-/51)%R1W:KP@I0E$,7D8'_#]Z,#9/5!.U'(Q%N#6Z1%
MW)S.2-.#1FWOS[87X9K>L%3/&WD%\74&U]Z;Y\+`?;`39@7MR?5J[R))=$8$
MD#MIM(:M(V7M8;FD/:$[8B'(3`381I.Z<=I"3[@PCX^;Q>?=@WYKHZ"WNS0!
MS/M[7K*_S5EUXKH\>T(MY5QVT]ZO\!RZ>;U>"*!T,5-'D$^,SH_!?4')H:X2
MHN_M2?7DD%X:Q>H;*ALF&Q"@>35"9]M=YF8V*?UGOH_PW72H_Q3Z2`R^&%AU
ME[JF^=P[U55W!#:X;S?J6HW"R.^M8STF_%6>?,LE:6=+-6"?O&/=\FW.GC_)
M9041A#<!RG<8)ZK8LU7ON7)GFS/<T%UN9M-/2-#[29")(+/Q>R'.\;&G]R`A
M,1_V.$!>%J"($:"SI,XNG$]&G,QO<U:T>>L%\":!AUAV.A>"SX'X<FL%B@CM
M+$G,!G['Z@'1KVMCEN+`-9;.IPF<\6S6@)\4NJI^E+/BHR\GO#GG;G_INAY^
MQ?;)<_'E*7D-(WQ!G>P,YM!X#@S6[X9`QV$^E]9IHW;A6;_",OI\#`K;SHSU
M9`>;T.%-X$00:4*=-&"_O$3P!?4H0)#'+Z9!LSN#9CSC\0-<"A5R?JFSY$A5
MS'C6?#@8F.O%2M[0M6#![X7ZQL6U<^ODQ7=+>DJH3@+!L<X/R#;M<H\2-6OW
M6G>F3ZM1^0F'2=WA/:JV6*-/FQZ9P/)`RQY?NTIM<>FY8TIM-AF"=4`5V-@Z
MU)VAYJD^EV%0K(MF!'SL;D8^ILU(^EQUN)NV(G<MK0@@UH',/!V'2`R*=Z4_
MW9FC^HZJ*.'2XNS+]%_GK'9BW66K7S!RO!C?:7X3))$7Q)Y#)GJE[\3J5W@.
M.[%ZO>`^:+*QUK+F3R_`7;&(GAMV`7+3Z*+1F>W$DAQJ0HF7^;1"+3:5R&GO
M8D\*:"D;D/@^SEG-*C1=HM0O>P#)U',.LPHLXT4V_2TGICUJT9E-*\@);#&M
M$)O%:%,`4LJD06?<SYR__@R]E]<$=57?8&2_P/0O\#[R'.G;@`2UGR?7=;DD
M`M35Q`R8V0E20[._XBH\R-2SIT9YWX$09B;N0WNXOD<FY:&&B?BU]^.=^3BZ
MYM\#/-A>X`4O5R'J(=M.<K+]28XZC;#D/$?>O.YQ,\)FMY*W[L_)S+G5H&3V
M.1Z<4O5]VAF;'4:SV%L/Q4PTY!?ZP&?<EX;Q35JGX"E,;+\ZTS%M;Z=;]?GU
MHCO]$2C2LY9WBK5.U##&&Y"HD2;-H1H5_,[]"ZV+IQ]:%D\OTI.P*/BP'/QC
M&GPO#_X;*_AGUO?FHI().M[]G_X<^?ES&.VAEYRBPKV)$-2FZ8S8M\5\D7&R
MO,.?.=F6+"KH5BZ[[FA<`[+@XT[)K^/#NRQ/W*;B4/3""!>;\Z(SW?;5#U.9
M5,?Z"N?(;+_@.F)3DUI-R1GQ6=5RD:,W$RP^46/*G<8O,,&;;4H)>9[]QC%A
MKBQ%_4++XITSB;4C4B9_M43[_*FK-D=`_GB-VN/\1*F2U.VWXFS)K]<U[I[(
M?"&Q)F@'.S;F0,DC`!M=.N+^/3"FY&]3G?JTT^B1DJ,?7!R]/8X>&2H75:;R
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MG_S[B&^C+YFDG;WU4(S,;?1#/_`YCO'^!&/L7N#F5Y2$^%>E$.0S\4J6G(;;
M<T;CP,%.<D\'K:W9!/L%J-T`F5C<")*$Y->U1H"Y?'.>?7%%'ZQOY:L4?UB*
M_QOZM7;:U\E!,KOQXS[U]]D$3+J@QJW^NR)XL>E]O&US@HW^_'Q^SG5;IOD8
ME3VT_]<2\W3+*$)?[?ND70V++B.-^JXH6LJL*[X@3B=Q?Y?E9E1^.[XJ-/_7
M-@"J9]DE?/ISG'P7=EMU:1N)!I[15+T\KT4ZGV8U*-_;]+ZN;RH^ZV]RHV/$
M!YAB<4!R>IQO8Y0=M\F/U4S;M+2H.[N&HND#__[.]6R"K5XI@Y0.`!IQR$][
MH`D7?ZZ<V"/;96-"K@:<UYL0O?+)DO$UC)RTB45K]DPQ22/7"),F9:1ZQM^_
MVLP$#O#%HXJ2G>>$B\;O(E3FUP#J5<X>0M,G\C_D6=)T2[TA'40M:L8Y4;6@
M;R);X`26.KG)NK6HV?=*UY-^&S["/KM":1-1BE3V'O)=SY*_.RMZ**%N`0O.
MB;7YW1)8)A.I^,M-V!S%B;X+KI[JB_#1]#E4?Y-/%E))6?`#:N/C7KK4PV:B
M-\-4[H'0COP!UA-@DO=P,6TZL:@=?]WP,"![XYLX/L'.<JO9(ZHS.-4KD@7E
M0UBHK:,"-!^F'N0&.?%</<-\D=X`K?TL\R"'R('CQA'B27WB8YI!WI1VJ>)%
M#"<\'%!W+$Y"Y^_`]@EF#6C\:]ANT$_9=2T$Y+T$WMYS4#M_Z3CA*4A0:MR'
MON=X,'Z"WY*/2/G?61^/[V65I,5ED4!O<Y/=EEP(!H5DD(D&OV/A@$C_/YJ0
M-('K%&.GP\&.WC'(>J*@%6U"B5S!(7_@M"`TW">H2PXO`S?[\1J^03\\XM[Z
M51@G\:^PZQ`+]_LJ<<IKE$B^9O=;I@+)[J'\/TKB`9$/?J<:=,%UF@A8E0AT
MN:@,F*+Y6\&F4)3$X'EX";X1T,VM%'+X-TCE*7E]M(//:.R+AK=.V(JNSD<E
M`\D-G1-VEXS>!>S@S)S%;KE&F;.@F8,D`20*Y+*FQ4D;2<CS::[%)R;VY3EF
M#7%L:L3SP`>#NS<,<G",!U)_@7;4@=_:(\IQ6]7/F0+K^6*%QC\4KU@"P")T
MP72,"W.5+O2@<HP?EH`?:D#8GOL%^%J\U=*W1=C`;?LM4N'_QRGR8M=S,%JZ
M>[0];ZGLQW:;(K#ZG!]]P!))UY7(!&6ANKNL,IVU1CFKK//*EZ"5+BM'E+1A
MC?2:?3N.[_:/>*;L\IL7=WWMUN=5XZO-"/YD6V:[RXD(,HM!Y@A_QV)T(FF\
M6Y:06THQTY5H#;0P(Z$5)Y_^<?*2=[QR&@9XK90'*ZWOZ,!+FR$BR96N1%(Q
MH)!C!FS&>V>)>J<</5WIUXH@9E"THN@7&+Y$]O'50ZTA#X(:S^M`3]T(_I4I
M]'\4.6419H!FG%.6@%/*L<)*LE:<M,9!*T9NO0#>H!][P5$\J`,5N7;NS-FM
M=KO2L(9,OO^.Q0`B1S<B!CIDB3FD'`V-=&J%0=5YK?E_M[^RX]?/?O@UOGR.
MR4GBOD_7]HH.3+38P7\>TYHOZ^A`_7@L$!")B&)3F;J1,MI-:[B;RO'3D8ZM
M2&(%1S.F/GL!GEJW_?LP]LC&3VYLL5_5@S&F/0)7!*P7+5C+!8-,LDF8D^1V
M$WO";FO`8&_Z,K#8'33-F"33&Z^A[Z(LH.,U?E!VO*L'E6R#1-J&50LLRY+_
M!:3#=(.`*<OS)C('>*X!F_UIS`!G3^"THO/1@8$=>2'/+$7E61WH*QL@,I#/
M.ISIZV;,3`QWQN)T1CE&VI*I%1,-W[5BX,E^]ID'::H/Z<AZHID[0Y:;1://
M]SL1H3OA!_A1GW1@^Z$\URM)TYKDA;]ZLKO>Z#"_3^-!I5E>U\[=F5@L%]G1
ML;;^PV621-[S*<%?`9?1N[<C]%$TGLD9Z6G+R1RM)W)&NM-^+F<:B@H3VY_2
MES7VY0EKH4=Q\E2$1)A>OF+10)6S6@-@!F_U#A;-&"&.'1QMULOY0IC/#!@@
MRG'<:CI.T?.S6?#I'O,9.-"KF_0E3."U%SM^&)\BV'O:C?M]K6!C&"62@LL.
M[&'QH)!OPL&W:4+0@L)/!K9A/3G<C<FN0)D!T0?XAK\_^</CT??XF[[FFUIA
MV3!'9*)CQP;D!4@EI_O_B&Q3@#C2:0+!S#UZLCMFN:</@<P4[<9>>VPD'7U!
M,F^0*T'BO<%[%&KTS*+K'$S'\^H/Q;"-X3TDM;"6LUUV0@:G32X/8($`2]1V
M8$:6>W.-[O4=II'EHS7<1T4';?J15CIUTQ,6B>"/XQ.>1"`G9-F?J/*4'J"7
M3>#,C=5Z/=]N*+SI4>X(^G9Z143R"H&7"L7U&</]'D9X6@47.L<:?]2!]^%>
MEE&>N47$:,/U<%_2]IQ^J_S#."QO%"*X#2XUW#;<UM9!IB5CKD\X>K0R&RTE
M<^F@C@7=\\!>P.1]7W5GF<<HD6TONSIR4,I1Z7G1Q:Q$55F%QIZS_`B42R1Y
M-`1>@/`6!)`>L?OJ):_`+N1K[UB+I':C>\T=0..0>Q4&>#"`#+S;TY\3[]F'
MC]!!CR8>'`3G?J&F8+S74O[]V>O9G!_XA5ZR(;70#`K5!A*"Y'#14X254!Q1
MXL,H0I&CHV[4KRK75^LJ&6<$77#CB9M#^&)N'+%\@5_)GP812/&R*4216R2R
M=T*@)X#DTR<FJO!(=J2^#4?^0/\7I6%TV@]P:0#P:(FN<H,]&BP%R'_R@(&L
M-]!WXGH^<JH5BKQ`'I-ME]7!R*0E,1%U/(?JXS`G@:`7BY<N_4K3`7W[./3U
MELL4XC%NXJZ&RSB")G^L76##K`0L+L@4XFZU3F"OM+64?T-@RQU7!M*>A,BE
M';PR[570;R3-R<B84K,7$DD`9M]\&HK?4=\#^(*GN+3ZOBP7X3;CBK'!/,A-
M]NS`R9U:9^K&D_J7#NKC-3>9#I&@;4J>RSS>(FG6;+-;TNEZ5O_#/9&-7'2T
M><3K.]F4OITJTS5M/T$D>H8C*3.EZ_EDL2O3HW/.?X)`E/BY]9MSM%-JUPB$
M<-]</^`/X?1T]13^%K@P^AIY^/M_#J.,+^_V=ZCMOO3],"%GMHZ#R$)0O%%$
M)V8[[X+VW%IN*GL2JB/Q8SH5D68\(L-3R0@R.L\Z+V3`B@PAUQPD].0@,<4D
MCIPRB)P$^A2"L@WXWK[BDJB[/<!V@-R0=&!@&L5.&4?"OY>N2Y9&\(Y]&C<\
M$T"SCZ39ASS-XJP;7<U.,WEY&,'QD?:`CV+0S`.YJ%SRDA.G3/WS$7R&<@^V
MEHOEMG]^F2@]P_6F*8(EOMQDX*!5#$(<XU>!2)O&)`/7F&KO&L(,PK/KV_EJ
M9W$SP,0+3*-P/M#U(0LLALTXCOKRS+6U=%WMC7[Y?&G-Q%7S=ASSTI:Q2RS$
M.@DK+!UR#*&M<3/&BQG/KIF4PN@CJ:[NF66]?"8A)AT+"*:B>.Q$>D_HIIR8
M*E0/G$9G"#!D<JG=.I$9T_32%R+H?.?09<2A;P:(ALCH&7098>B?0']KS173
M9FRZD=\W)],126V=$4J>/=?8U)]3W9DH*Q=97EY5+@>@4K3?33/*GQ*0LIZ-
M&=?/,%*IT9`W7)?74%/1]+C:;-9SBK3U82T-<)LEO-/CZ]5ZO2FOU:2]OR,]
M>3B;Z6A)QSLTKV=Y=I1R-M-^7'2\=PT,<WJGKN'K0E*UD6-&0TN#=GJ.X3].
M^(J1-Y[;"EB/JVS>&#;PM@KKW2:_GS`7!8@L$RXPD.*=-<@[94U?3])56L"N
M>!B`F.YN8.NS^K`B>)G?8K&:L8"BMT<XWBT&0DSH&'8E6`<TS&I)>F_[8#VN
M#QW"UU_@,W;K=H`8<+^'%.=:86+,K1X]*=<!%@-N\Z@9U%NBCOF\1L2(UU_;
MSF:,-B4VH=Z<'/]:46,24KIKR74&P0"L=%8R;WM4'T+$JH&CGHG%ZG!I+6X^
MVBE&=\N`2N<=J=4!"LU5SVO&('U=-ULPGM:(BM0$@9(GFRT#&%B6WJLN9/C6
MCH\>WW1AI)9N73`I!\,0I%R'!]NKSRWW/Z\7+=0(D7N0-YUXH?+,0<P0_[HP
MT^&?1M144Z\'-Z60Z$*.YWIV]/YH^[#EJO>6C]K^O&+DM!HAP,;;K`N&).37
M=FEO821X98EXI1(EG6E61PD[$%*619_LOT/79J^$5OZN>O&SK)R[/.-JM9C3
M]4[ZNJ;BN,-MGZNRO7LI<[@#%J<#2E8KVQ(\7Z!L^*BCY7FROUU%T/62*SN*
MWO=AA(M[7!["4\":3.YZ0V'KTV$&]Y:5K;7:9!G_#5!QH"SO`E")>IHB:2X2
M3/SV"#Y#%T:V#["W#I$<`P?+!JEPG8T31R:6FZ>^X$AJH%J4?/IV]"+2;/P%
MVM$#+I?S*:COA!=^77WSQFT;+P'/%O/=)FO]L@RC"9;*!S!7`-Z1!D"*#0$8
MN(HW`DWF?1>;@$(!P!H`40&0#BTM[$01(&339)KRIX?TRCF<`1J;9F%HEUIN
ML=@IY2)RS=Z8+TX%F,I'Q#K.C%RNY^CG(8P48RV&<M*`"`Q@):+%8%X:$`4.
M9B+?_3R(J8)S86HJPJ=EU)&M<O9L7&D^IW*$45<N,&-JI<55BD5V[7M41KIC
M";FC;-#`2J3*4*'5<RUY']DNO`S<N^051I>.@T<K\0-TH/>&USCO0]]S6)<J
M\[VK$A\\!O'O@-KN,LQ@N<`.7$`D@TPT*&1?`"H=_)[^JWTSRP3!H%6%FLYK
MQ9M(`E<PR!V?X;B,H?/C2_CVDPL]"DGT0QV)Z%?$%C3^>'P_/(?U[]G\NP)$
M-93R;T#?;F<%:O"@B@I0"X*1]EM\]D^=X\S4P'G<[J*>-@3:\2EZ)^LQG3OB
MVYY4VCXTU//O8\HOYLND9(MH6O?"CW;)$G1)':\SDZK*XNW^:\<!K8=[MZ=E
MY?X=^JS*)'UOZ<)'TQ2!:PEVLS:L7("B2G!:R1'+-0`Y8YVMHJA2BMT8$+$S
MD@DH1EBT@^L!)EX$W7L[(A4"?H7):]BS1LC[NBZX==C$O;2VL;+=*W7<I=+1
M*,6.TA(:5,,TZXG\U?(GBL&2WD>)Q=$JNGN05-!I#"HY4ID)S[YX:<<IY8W4
M3)X,J+Z@"XL5*P1VNN\8Z,LN:T@E&M#>C?#0ZH.6"7?(]6<A$U3-T&B'$4$W
MSV>E#^J"#='.OP]DL]VVPX7(,:)!&N+1LJTK:">D/.9_`]OUBDPDSI<7B^T\
MJ]V$_GP-'3)Z`8OY!;X"?4D>P]>(7P#TR!'?Z_H&_=8R5UI054E*)IJ*"&I!
M$5)PMR_=(-6Q@[G]6958:C.`?X)V-\O@A+?`(U8N7YR%<^E+&'RP2[][0C_&
MMI/61-*XP5F"X]8$CBM#55>25H#%C),^;#W`.(E.3D**MG6>K6$_KQQC+4;P
MG_!=+&=5G%6D:3Y;(\D_:YA_:A'3D7I-U+!"H@,YOP7/GN]#]RH,R.)O:=6)
M\5F[WE"(G@XS1#I)Z2@IDP9R<3U+BM/#1YJ#5L7!*)<"GFT?5U/7B1Z.]"OC
MIR\F4K82XDM78N\EP+WS^^S."/9Z$M\[JC<,]AG$?X7/;I[N$2R+!+E,%2M/
M;3PP@9=SO5YV[_R3ZZHURE4E._UX89AO[N.*D)XVUO50B^\]GY!EG^PH0,U^
M?!O&,;[!R<'F/H7W=I1XCG=$@`Y>BJM8/MJQYS`;B)%BE;;6XVP5F7)?Y$`N
M5(),)_@!:_TCR/7B8N85S:5;DBX`4:YK^D=QT,ADT2V,XY_QM6NEV,$L=G8Y
M:,=*T.+.JZ74=2?D(*W:YY#P%?30#NKKA2^!]T]DHOWM(PS@WDM84TZLIY62
M1*L)`A=_S7<9]@M)9"][)FN2AIM>P?,IZ`&S!.<(1#_1\T$=O7=)'I%=\)/[
MM,(^?80O7A#TN*6.13J!4R4'=@0,POQ-X(0'B'YQ#P/;Q]1T&;@W`>IQPCCY
M].T(@Y@]W!\N43]W\)@I,II>]?#+!:`:R2]SG63F-],*4K6Z9A44Q<EJQ,G+
M`A!&X)BI,1#G(F#AX`+NT)K%%WCA#"\]QR<?=VH^H\A=G="(*DCH=2C8H3`F
M=_H*=BE$A1O!(B(6\]_^A7K>/(1"E(-<.<!I#%+UV5U$A'`R"TSCENFB1^^%
MS#3\](,+TQ__2"XS=](@D<.K"0K1L2M$^HEG".KX.$CX$QA/1_?([&@:,F*)
M-I6*&/8*W#&ZYNK9M!(147ZN-"0E<CTD="0!.F,*ZD':8`+J"KY!]/,`W1/=
MH5&Q_M8^QG@/Q/'H>PY>@D+CY>24H%_=>@>/+LT(LM$H3?K):8SYW(C;6=MU
M+U?EEM3)BMA"-N;DUH#4'/S;DD'Z9GUUQY;,,EUG'`9L]/_PMC^D%(>H5`\"
M7_A8Q,[OCIUF9I,!8@ZB&_V9)"UA,XQ+3;H)OL#D[@@C,F&-)[-A7"Z)T;X`
M.5*F^B7P<0;S7I(Z6VZVNVR)O,1(N*U_3I6F^,$TY`7TMOI,,?")YDK='<6U
M==1&JIN[2X1]$P"D%^2*`=5<J<^C925>9;1(W_)+2\+@K=AY!`E'I\D&DM<H
M/+V\`MMU28?*]C\<;<_]X`4?'/N(V$;+`7*IQ%1:])?P,0SJ:SZ]VLF?PY/O
MWAR.MI-\VN_I9GOTR`/J.8CU&?J$Z>\Q]EC(W7&Q5LN^`2R"A9T`H@Q0;2!7
M1Q[$"HT:L4H-#N&17R($`'!BM5(&=MLX\<#1,^.)IIS.UQ%Y%B2?(2SM$+A\
MB2#9)]_:HG2_H;SCU&D.=_,UG\W6M%MT'T;9>.%$98,]A-7M)'8F7W7?1Z*S
ME(!2#Y'$TBZCIQ#D0G7T621Z22LOD9.]C$^HKWO!!;VB\]`?%=F,$+BEO4)A
M\$"9"O_X*7"OFRV\^/L:V:+7.-Y:N3OTCY4.J<J$$;CE;6>(4:)"!:Z;"URD
M1!^!2/:_22?(PXH&4%*!*R6#:^5]F(ECD!96C`[D;/<K-(MDN-'<1CE\D9))
M0/?V.XY<21.=?._XI,Q7--$,RQ[>K%KMUHOT/$.Z8A6^P0A\??6<U[QS<J1*
M@!?C9NT9ED;:>LA%CM<5/DE%5AB$"M7''W+<))2!-]8XN%]R3+_R'KCP#?KA
MT03NZ`-BG2XZ`Z-E]@+/9G^*$^^`>(JYR%5]2.5L0T4S?_FL;597[S>Z2)2+
M,*^DZA@7K387M0[^6].I,JAONJLC[_],SNXGG84EJ\\HS/J*8H'*B\NTJYF^
MK[F*Y`@O+%XO5.5U:[J4T[KIK):LAM[+*VHL+U%7R'Z!M-+>M>?C$R^T!-'=
M*8D3FQP\N'3_=HJ3EJFLL=)4(F68B=S9.)NMT@(HF2:0JLJJ3J;*LM*3)76@
MT*<)@"J"0SMI9`Z6],VP>#P1;\8YLI&`J"!\1#2-X8*[/<MBD1SJD*(;^VS3
M^.^!V,QGW9@O*LV6Y%]D5#`-V,/$]H7!+BL::[*1*&6ZKUE4[#0J3G@XX$ME
M:$C"0HEQR.]/_U[$]X34(*03`TOVD4.LEX&;VB^61WW"]..^QT*!@96U&`1_
MHI!,;4]*!(-:?<GA(8U^X:_+8H8@#UB%(PSD!4ZP<-`#3Z!-8XFX;N^`W&K*
M,(03&H8)G`E8K893@7GP'QF)$NK']0%&1P$I?0ZUQ6$N+1`FD!X3^[Q<UQY-
M"O[4Z5LD#_TW^B_TP[,=0_0?_S]02P,$%`````@`:89C1EV]N"1<2P``ZR`&
M`!4`'`!M9VYX+3(P,30Q,C,Q7W!R92YX;6Q55`D``]8L]E36+/94=7@+``$$
M)0X```0Y`0``[7U9D^,VEN[[1,Q_R%L3<9>(*9<K[7:W'=US0[EY<B8KI5%F
MV=/WQ<$D(0E=%"ESR4KYUU\`I,1%Q$I0H"!$3$R74P!XSH?M[/CK_WU;AQ>O
M($EA'/WMW<=OOGUW`2(_#F"T_-N[ST_O)T_7]_?O_N^__?,__?5_O']_,9]?
MW,11!,(0;"_^VP<A2+P,7#Q[;W$4K[<7LP2D(,J\#`UW\0"C+R]>"O[U`O__
MX`+]Z;^OY@\7E]]\O+A89=GFIP\?OG[]^DV2!+LQO_'C]8>+]^]WW_NEH.RG
MBQ^^N;S\YOO:+_,XCX*?+OY2^]-U`HH/!XBFGRXNO_WXI_???H?^[_GC#S]]
M>_G3Y0__K]XZWFP3N%QE%__;_S^H\;=_>H]Z?'<Q_V;^38W)_WGQ%$<I:KW>
M>-'V8A*&%W/<*[V8(U:35Q!\4PX:ENQ>($BC]&_O:AR^O23A-W&R_(`^\]V'
M7<-W__Q/%T7CG]Y2V.CP];M=\X\?_OO3PY._`FOO/8S2S(O\1D<\6%?7CS_^
M^.,'\FO1.H4_I624A]@G*`D0>$%M@?_K_:[9>_RG]Q\OWW_W\9NW-'CW;_B#
M?TWB$,S!XH+0\%.VW8"_O4OA>A."=^7?5@E8_.W=>AF]8>2__WA9]/^7F]C/
MUW@51<%ME,%L>Q\MXF1-J'YW@<?]/+]OD+_V_"1>@@CZ*5E!6;D>/^#&'YCC
M?>A+[1SU_.T)+7F`OS%=W,$(S1'TPEF<0OR)Z]!+4[B`(%`A7G#D8[(Q\Q*@
M-!$2PV<KD$'?"_4S=H^.MS68A!E((K0$7D%/3@['TT[RTPI!LHK#`)V&M[_G
M:`5/HF"*($KPL81^`E&*/EQ0TI,=N6]I9_7:2U=W8?PUO8\"F``_Z\G.X7B]
M2;Z!J1_&:9Z`:;+T(O@'.4@02H]>AO^XF&[PK8C^EDZ"@"QN+^Q[A/7]ID:N
MG_+UVDNV:*G`981VK.]%V<3WT7V<(:EA%H?0AV`(UOM\^.C\[UO=>3#YQ0MS
M\`EXN#M>E_O3;Y*F($/3^`"]%Q@BND%Z#(S4B3.'XW4<AMY+C%9YG*3/*R^;
M@TTA;7Z*$X#^$'W\=KIXCC,OG(-7$.7@UDLBM4OW^$2.'==R@'0.?`!?O9=0
MZ9XY/I%'Q_4VS2`Z<T#P.06+/'Q`=^51MG3G=X_./981\D+]FRZNO!3ZZ/RX
M@6&.""M$AH<X36=$F%C'$1$VCH&.$EW'WY-(00OR$%WG$_3W`).'IO$)^'E"
M3M_;-S_,`Q#<)?'Z>06NO=#/PY*I+F:.!N\PA&O$?Y;$2$`BLBP6:C?XGJN(
M[OJU'VP*WQN8VP'D,?'/Z-Q)6>Q_:>HG`TB:@A_1S=<5MI/ALPHI686$/Q!O
M@A\:G+]J3W3_?ON&_]GW#.OUZ2-BL)?&IQLR)U^])-C?Z],(G9PWZ%_3Q<\)
M.H4_I^@`1G^Z"CW_"QH#T9<6_68).I2CY:<X`.&PR`U!\+'77$EZ%,Q!FB%"
M$.7D[Y\CB&XZ=(^AW7^$]2=$AD9LBOOVV7L;1%7GCCX,)QC?.$+74(J4+"1G
M%$;[]`8L0)*``+4A.FVJ3=WN^>UA4$#J3XP4^!"6$A;2E>($K:?]SMRWO0(1
M6,">LDZO+Q\'`7SJ@"6,(G3*8&DEPOZMR1I+L?AP0D+GYRA!?9"(^P>9JI(\
M?:M#'T4:$7L`Z%"Z?8/9;DT.(4N)?F10OJY77K0$Z7UT^)-N[EB?&I3'NSPC
M0CE$ZVSCA3-OBP5RM(Z0%$M:3Y8)`/UUFUY?UHA`91,J+LX'Z&.!;?^M[IOG
M8S_F53]JG.]+$WQ?FN?[.Q-\?V>>[^]-\/V]>;[_9(+O/YGG^P<3?/]@GN\_
MF^#[SWKY7J]A5GPL0BHBL:R":"`GJO37CL-II0U_@A%<Y^M"IB#2PTZ>&(QQ
MH8_KM<\&N9]]@B'2]9'.N/L&UO[CK1<B$9F]_GK;;7M^7B,6MZAYO`6@U&]F
MH3>$T5/X*QHY^Z_<0[IO$F[W#O7:AW;F`;0.TSB$.&(QV'>8@S0/L1VABNKH
MQ[Y>4K3ZQ5Y2\'N.5MKMZS!."J$OZ`EC>HPSD#['>XSW84AI/6BG@KFX<>HA
ML[6XN*ISQ<LS>,NNPMC_H@+)$:D;&DZF+W(@D`2_.0[6=W\P`<'^V^.`XAF'
M@1@!HOSRT##LO+#X3LOJKMC!SPVI+X\)AB'6A,+W!]\@!UYLW';P92'^V:$!
MJ$7-+NJNMSD(L9!S':>(6AQJ0IQS.S%X(%CZ$C-RL(;84WI(&AJXO9=G\)W%
M_)))-H>8?('O#<TR<<4C33E/"B]=N>Y*=SRZZP>?<24*Q@C+$"ND!QU#0\0U
M*PZ^<I0H&!X6J@WN"(!(?7M<4`RQ?90H&/QL:1D@AS]A!3XXN.Z"<^K(+B6)
M=C,DUR0@@T4ZSB[P8WAU3I6*H>%A6B\'`D/PF^-@?8C30>K+@VNR32/N8#8^
MZF=*!C<U:^@#XJ?!*6H,H@`GG!5_Q1_3E:5./H\(0,0TOAGB9/XX:<);?I)D
M[*?`_V89OWX(`/R`$<?_(-"___9CF:__+^A/OTW0IP.2_1=ZR]UP2(``X=_>
M'?[^87!ZKO,D(;F(J>^%?P=><AL%.):X@S1J4SDJ#Q<E_LMONVF9=$S+Y`4=
MD1[.46X0)=YO>!QW9!3HS$`"X^`._2WM`)+>]MATXED4H[)J>3P:"V3H"[*[
MW?'H>T;#,L@B/P]/3;'JK]$'$WQW!.#M/\&V@ZSN=D>CK\CWPR9+8DE*IWF&
MBZS@<%PZL:Q.1Z.\./:*$&OT87R-=6X89O-C47L'0Y!<HWVPC!/Z*FBV.A9M
ML_PEA/Y=&'OMD[R[S;'HFH,EQ!=%E#UZZZX=W=GL6-3]$H<YDE:28M+H"Z_=
M[ECT_0K"\#^C^&OT!+PTCD!PGZ8Y2*ATTMH/3^]SXN&3XVF[?HG##OJ:O^_I
MJ0NCDZ1)FY?XNX'0/P\DT68QI[+%APTIO//>7\%P+\0NDG@M(]'LJ(@[[IR+
M.`E`0JJ,??SVVW<7B($B-^:AX)5*(*$.*2,I("UQ3Q@GB(*_O;M\=Y&GB+EX
M4T1UG!8\+:F[PN?2X<.0N"J<OG,X,:7G"JGO'5(<?:C"ZD\.JXY[J<+G!X</
M74JK8/JS@XFA"%8X_<7AQ#9Y55#]Z*`2D/#W>"$QT^'%M1A4<#FQG*&XUG!R
MXCG5:%-#R0GGHC;#&FA.3J=8W6H8#2V?__5#V]$WO/M/M()T^4F8X=$_8K7N
MVXOW%_O>C7_'BXO]6!>[P?[UHC:<LFUKX:4O!.(\?;_TO$UAX`)AEN[^TK9T
ME7_^;5>D<>9ML?.XO)1:9B].8W6;7'^ZJ^*2CR`3H[ZSBR$>DAS4"[IR&:"T
M-T+]/G=KYL'@/KKV-C#SVA937FLCE)/*/S1"BQ_-T45Q8U,:F:.3LU8;;8Q3
M*01JNZT)JG&%=!S_A_X'9VN\>B'`$8'9M9<D6R2<D/IN%"[$^AKAJA*WF`RT
MFYF@=5<B;([`NT;_"[/'./*9BYW9Q2P/I*HU>ZM2&H^`;@G@V^U-4-^H8]=)
M[V&U.6,4HH/B,#6,3W9WMS'RPCGRA;L;YHV]=T<B"QZ2(8[^&&Y=$F)="`'<
M,Z>[K3&JA9<*K;4)RF<)V"`UH"SJRZ:[NZT9JBE)Q4B/I!+/Z&*"AZJ>;;>T
M2.&#V\T8+[N,L_+]-_9:8O48"P?<`XC3R0P?F0<C$.#G4Q!1Z<3W\W5.\O^0
MB`9]2.>%V]$$/RSS'^=F$^IJAB=!:6\D\IVT1#<R&>XY(8\X;;E:;T=#$\X!
MMA4*>P(XEA5;XPG%@>%?KKUB"E]!\A*?/DIL,<K6:$)Q?"C*B*W!@[+G3M_0
M0/S:VRD@05&DZX`(&HLK5ZU=L5W2>+&=AA5,=L5U2<-$T<[W^%S:%<<EOXR:
M_J\*%Q6Y9_S'D:RAM0X5RS!H:P2S#MQXA@%;PYIU8,=VX-D:Z*P7N0/W6Z^@
MYPVQ?[Q:C%S#]=<OX-GN"X'5VM;(9\T+C.*Y[1</?5*K3D+4;\<U5L*:75'C
MRBC1(A`KH.RTP\@!Q70U55#9:9F1@XH6>U2A9%="IQI*5-]]!9/U6I$`3&R$
M5'2?\5]T,L['0[-$ASAU::>FHXJ3N!A6(6BG15!.!#T,XK4UN4P-GRZ'KUHF
MV8\%0A%8XD`(FS"B)HT<+YWL%&`2B:>I$+-34.AK5Z@C-+2@,-X4Q1G!>04R
MZ"-JS:9^(%JF"2$[(,?C#"0D^982%R/2TW`R2Y$[/,FS%5H??U132>?DH,<H
M.*"7613JXD+T!@@9>\S7+R"9+@JX_QV$M-7%ZW6*,KK0J6%[P)D&\`X/*%NK
MVFD'K;LBA*51::JH<4^LXT6M&9;!B@>2)B&B.?*PLW,/5UD<XO+[C^SB$,4(
M9F2TE+PZ4D;\T))`#IJ9D5V:1'#N>FIS$[3_#"*0>"$B9Q*L840*U>&E4A)'
M88'7RP0GQ5I]B-/T#ITCQ6LU.3HIJW>)T35]Y:701V3?P#!'MS=+UE<?SQSW
M^\W+68*TUF82-8MWIZ+@"22OZ#_2TDU#H9W>W@3UCR"K%@J%XF8;(VF9Q9J-
MEEQ:NUH:2R1]1/=:DQ[VL<3I9"B=#B"9!\=$WZ!E&L8DK8#-!KN/&2[(#L,'
MX<^XD"D])[/=SB"U'"+-TL8YH`^:F:#U5P"7*_Q>XBO:3DO0D*5KJDCK#J1P
MI#B820V$)]>UHC%8^]QVNX`,5%R1TW9[@`Q8AWI0/[U__+$&'$FVN>G:AZGM
M0>@2X-!7F>WQYA(@=0K&_:II6[7#>&*XK86T%:!J:8+](L>M6D0]+#.V5M16
M0%%5&K<](HJF437CZZ@V)MMSV$7@Z5#O;7WK1@&6!AHJ@4TG%+9#3I-FA%/Y
MVO=UO$8TK/`3X*^@]`NUW$G?_^4'MCNI/OK_NBACHL93)_H3P$<JQ7[![F.F
MVO4_\C0C[U(_QQ3R".(O7@H"/']H\L@"F@,$?0HS4)Z&Q2M7<^#'RXB,PJH-
M-/AG#8<?,5?!83L3U!8[!T,;1V@>;N*U!R,*Q=UMG:M$M&X<<SE0&LO137E7
M'&T2G`[P$<G+2.++X$L(9KM[A[Y0I;KJI/-2G4YN5XUT7BF3R>VID<IK92JY
M/352>:.^-OE===*IOC;Y78T$FI)H)O*8&<W=TFAR`C3^=FDV9+=U3::3-TB[
MH]A]C'*!-`-PC_[));UJ:#A06J&DIDA?HUP]X_1^'OE%HW%4,:72.M*JJ\+T
M&CM5$"'%N79#TO,+3:<X[XH+)47JSG11NUR>@(^:,AYJZ#GHZ'!X!%_)3TK\
M5IU'QQ?Y<4JL.NGM&TA\F-)O0/F!],A%W._B2J@3/X.OA]M-9801S1(Q,FC>
MA()CC@T%Q2W8ZCLVKC1L0,8X0^Z_ZK.*VX\R@/'$,:81I:NE<8KG((,)R54E
MF'X"V2H.)FM<P$F$#59WX[P5AW1)H@@WS0XFW39,RR?VW<B9SOJE8X_?RR4%
M%]]*8GO59AFX^(9$VXLWRZ#%-VC:7LI9!BT!PVJ_"L^6P25Q<EE:8Y$+%\/1
M:7M916%L.D56VRLI"J/#"9JPO9:B,$XT![+M512%7"EUH"B(5K%6=@H"=&>-
M</$HE22B36&?R[PDLP*?AGNQ5\:09<@,'Q9V-I5'^#N4;UBU/;ZX%U@'GB#;
MPX[9:*G8AFU_LJ;_9A3P]=B>-JB^[*@N0=N3"#6<:U(+STX;H1B*XIX7M7S#
MTRI>W/>\H_@_;7_*1L.&Y2*GH%V<Q`NY"MNTY42T/<M0#"%J#O#9R_[ML+Q^
MU=4+E?TVLN,L;X9!]ZNB?FK(B$0`-Q=3,\CV;*R%C:#B3D2Z[:X[@+YU"-6W
MX1Z6(^!B.*<7O\5]%\9?T_LH0)=U;5^5>;M_PDY15MXN'N&"#&$F6[=FT,36
MR,B'Y)GLZJI]CC&)LR1^A0BRJ^UG)+?=1_OB+J76"KEEUP;YE)%\5K%GV#M!
M$.MK)5>&\@6Z:2LT$[3RL-@-;D#QOU+L488PDV%=&4/(E5^H]*5=!`0?:8QQ
M^YG@Y@:@P]N'Y.BF$-YH8H+&.P\6)I3J5)LN?D7+G5'`D]W'4&'CQN*]CUKO
MJ%(XX?<;%S?HM@%HVZHP5.LZ&IY:;[C*\-3NJB7B_O!+]3?9NT+L.3W&@73K
M95-AF-O]QL'-7HHJW=3\*N:B`XR$/U)(IW@T5&5ST/J/B+M*$"9/?\JQUNX\
M#KYF"=AX,&#7[.9V&P<OY-%HZ".YB6B%<=*AN`AS*#38B/AN/98MQV>[LZ$*
M.EW*9_D\3AWVKB*+%'Y[#GIZ.'!N%4V#CPB7>Z0JI9GF]2$ZZ.GAH+8^9`<?
M$2X=QW;_]2$ZZ.GAH+8^9`=W%=JH5,:1CP"N-EP4[`]G8MWG39!P?Q/<S;PM
ML3_/`7E;^3E^]MY^A=D*>\@0@4C*(O["JW;P+H59Y>%,\OX<3_S?<Y@`M(G0
MSLBV./0LP[7LT5_)PQH<;@4&,,)?$OL`!*0,-O;WHC4'<&C8/B6+QA:WGVEN
M9&HN\/L9JU<FNJM&M&>Z''WB);0.NYATY0[IZ:L[A)O6>]O?YCD6JK0=9/MS
M/L?"E^//L3TK1]Y<W'J#0L#QHI:L<TKAQ;I1;!M'U1)XSAE!,9.L6IK/.>/:
M[8Y0R_0Y9QP/W.VV9_X,`."!-]SVO)]!#LD#_\T9O#ZF%<6#:`';<X+4`!0*
M&#F#E\GT7\==L0^V9P[I=5;6018P)]J>@70<<+EY@0HI3">1%S@@O,IN#K7T
MJ%.2X(=#O6\`2;]ZJ>-_U%1OX$#7>A=Q;:F56;5@A6O`N6\(C.U%6_6&/HCD
M/EM:SW4X((?Q)]A>,':X^9#1A&RO,RL=>].L/<M-`=OC]YV=JU3$6R]PG4FO
M:MMK_!X7U[Y5@<<O"&O"4UJ@L[V*L"9<I57!LRD^+(BK7,9UA9Z=:J\>]`[R
M\"O8%!R%IU>55R=XC3I`EPJJZ.G5`1([#\7ESTJ4M+&^RPU,_3!.\P1,DZ47
MP3^*68N"1R_#?US4;H%]#>C[:!$GZ\*.JARJF@+_FV7\^B$`L(A21?]H!Z>B
M/_UVB^ZC;(MUUF03%Z3<H,F>+AI_:H6H2G0T$6Q;QQI=N&D<PF`'_*PVV]-%
MN2J]<+_">5&Y>L8VN9FUHH-WO<PR.EX4K]GM_I2OUUZR11HT7$9P`7UL/BY"
M='`U2X2YC^T^>O=\C^)-AZ1Q2C#1.YC8\8=1HLRW#*G-C=`>HNL4.X7OXN0F
MSE^R11X*EQL1[*RE.,=5GL((I.DGD"Q!<KM8`*S6`+S/6]1QFQLJ;>2CC5^<
M1'.8?KD"D;]"N_1+\Y68P\I&[&[CX&6[)ZO^D`N7EU:W4?""]#O\!V\)&-6F
MZ%U,\%!<?[\BY;\,VOKD_2-.KO,TB]<@>6C7%6VQ(]I;RRY^@$B="0K1'%_I
MG[`DBCY?:-7/\16X#KTT17<6""9I4__YY+W!=;[NVNTZAC4Q<Y]@A+_-O"Z:
M;;3,PF..QYHNBH#G?P=A@&,IO(-SGM-8*RWWZXV'RT1WUH1AM3227ER2LK<%
M/X$ED5`I<TAO;X+ZN1<M`>.@KGXW1AUS1]1;&*&PD8UQ:*>AD<WK9B0U%'T[
M+0_^1Y`Q<>]N:X1J?P6"/$0:WL'M=;5MW%_IU78.D`98WW3/#)%6Q\A&$PVY
MNE0C'5,'CK:7UQ85W1O`=F\KVU,Z5*"B:\^V9QZ(ZE&M^`@.PK9O1TEM9Y^L
MP30@V)[?KP":@*QK>]:^ZE+3HN7:GJO?8TF*&BUM?U>S!X1\'<;V9S9[@,<V
M&MK^VJ;JJ4BS]-C^L&9?O#JL=+:GUQ]8J!I'5]U`9+NTVV$-JV/1,B#;GNRN
MT>YSL*+.Y2FL82#DZ[([9*W=J@,A*WQ]V/Y<F6Q\R[[5OBC:)_(V*8DEVD<7
MD=L5R;_U>@,N!D:>?B*D[)&NYHI&/K7]J*CG30*WWWB>"A.?&_'^9I^L(N`W
MMVZYPX-I-,<OJ"=%^.]C'"6[_[SR4ICR8B+T?N-446+YR?2-;Q2=J^W^G_\.
M08(N^]7V`5VS(<,]+MC9*%_WT2;/4D+,1Z9/E]7#*`>UNSH]A)D9-"<WAI8H
MED]Q!)",EWP!V5T>!0*'K7`W*R,<1N\9UWA^VFZB$!:>^!E.G=O&=D>(%'[B
MIXWMS@^E93>PV^,D"G8I`<?0[_KY.\:?^3J(PB&$;4>BHJ6>=NWJ2N==SI'V
MK;?]'@=E/=ODF-9,P[,AI(1V0BVF)-DN@"KIC)UX=JG-+FFTTZA^'8=(^\.I
MM7&2/J^\;`Y*.C_%"4!_B#Y^.UT\X^N]]%O<>DF$Z#PKXSHMF3$&*WSH@>0>
M_;]P!6!W#A"G\2@2YEPBXS@3&:^VS^B;<FSL>XR"`YZ5GM%A%/2?8"KI`4$L
M'P"E\3CH1E^4.Y!J/;2<\;<A?(!AN*4?[*T66K[Z,PR!%SRA*PNQE]Y'/OWS
MM*;GD(9&0>\))*](7*1CUFR@Y9O/WA<0>/1/-GX_'0,Z[22Q71D9)%O,3J./
MRW_2A%I;T&/OP]K->'98,>VPHF']=J:(L44_M5A/:VUWO<"JMJOU,;$]<#HK
M6["`_K+W_K:$5-O=XS+0,.QJMKO#96!JJARV)_K)($-5GVU/ZI,!J6W9.%X"
MGX4>DHZ\Y;/RD)QR"4[GW7'>'>?=<=X=Y]TY.^_.T?TL-#H2`*+K)$[3ZZK2
M.8,61G,M],P6\`]\E3'P:#<QZKEQ?I1344CTE))SKA3G2G&NE%-VI9Q$CH5F
M_\`9V;U=@1'G3''.E#%`XYPI8BX#E@;F?"O.MR(%TH'^[)PK=4WY-LW@VLM`
M\#D%BSQ\@*^N7).:16V]R='JP*G/&U*BF.4NH;4V4B`D3R*(GZ\DSWJ^X7^E
M[`HG]`YZGC3:^?BVZ`/3!5JY@(VJ:"\3Z#[@QXQ7<1C<KS=)_%JDTC'A9?4P
MP<$LB3<@R;:S$!\@4;!'E>LQ$>DY*HXZ#T-)WCK'&!67/#^10,=1\</U78CT
M'!5'NZ6SH+F21'J:?4:(CKG06T&<[D9XBQ?95X_<>KM_WN"\YIC0=1VGG'-=
MO/_I^%+$Y]MV:Z[$+5D'4.A0.UOLF!9QH=/3=DU8,W3=`I#M[PE(2!9-FS!%
MY;,]L441+XD+U';OLB*"+%7==D.[)&3"E@3;+>^*2XUIM[#=""^KQ@C=K6?E
MAAX$04,^UU,PXQ>R""%ENL"5WWP$W`T,D7P2W$=H?/`0I^D,)*CA.HZ>5F@&
MG9E?GGY<<@O1@I$D&!*H*:1WMQT#U>7"$*1[U]K(N_`@JY8OA=YFFY.@\K=+
M\W1.7CT8XC/X.2X/A2SVO^`K'[^GPUC7LJ.,FU/V7I`?QX@AV4LR=#9NO.+]
M(Q^_C8I.2G2)9`E\P62AV^!S%%3_O=OCF"W67.L8V00B5)+P2Z<^MG`\QQ3>
M6'#T'M8$%K\"N%SAF7H%B;<$Q2N(Y7(E!WPZS;,T\Q!OT7(2_",OWMBE0*`Z
MVF@XGRYHU,IPS!AE1)P>$,=:W')CG`67]7MZ],Z8EA1BNQ52#IS^%X*:3?+'
M`L\(+/$W;$)46ICL9Z$<_[,&<O!)GF6VFRGEP*.HX;;;)7ML4'23]7.&GD26
MD!Q`6M0F->>HNQ9JFG>_Q]?/^F)H;NL?W;;NH^_:_MB[EG5(5YXK^%04#MNV
M,=7F7L$T=&S#*3BN*D?A!/T]P"#!5U!=QK=O?I@C<N[05#ROP+47^GE8^KFZ
M_%O.LZ5*/Q?^AH^QO;PG:\P,C54M8Y\@*E?;[@$821-#?O$$$7S@)"MH&WX\
MV#QZ:W8^`[>;H9)22%#((!+V9[LKC4C[G$0X=B^S20P]%Y=8JH.6C^@J^81/
MBH]R4RG552>=E^IT<KMJI/-*F4QN3XU47BM3R>VID<H;]3GG=]5)ISJ9HSP1
M\?>G&VHE/'H[(UY"+TD\3@)VL\WI:)6Z[R;;4XN.(+\WZN5Q!3H'N)RXST=7
M6D6UWC$NJ%742S:)R7VVI^6H(L>72FS/SE%$CB\;6^_W5@..+ZY;[PM7`XXO
MF=N>,JP*G,PA9V>>L`QRPF:Q?LYO.T%K:7"]'-R60M2ADMONOA[&+JM1P6!K
MBV>4\SG2^7DXQ_S1739M/9'V,#NW_JLA[WF^QHY]$-S@1[U\2&!!_PX!6<)1
M@-1W=(_^0?Y.31&F^]KU#.]*2TKEG0I1W(]2BAV^7BI#N(8DOY,K(:FUT!TG
M1(;?;U3<V%<0\^>$GM#,Z30J/GA1)*=6\O(12&\9W&54/)QLV4Y7Y/+4BUP*
MWT>NUJ44?*[6Y;$+-I87M.TV:S74]"F5]B=Y:5Z71$"Q/:_+U0UU=4-'C:"H
M)<3VZ`3%A>=JA;I:H:Y6Z&DBZ'P].Y4V"&!!XGVTB),U(<&$BT=$!*=8%82Z
MCLJXI<^P/:9K@&4>$9O>XXFXAI.?:W4N,'QH3XYE'[J45I>V6?%RE:?HIDS3
MB8]6:4I6*/EG`MC,\/N-A1OZNJ2U'@GEQ;EQ'Z%C#R`=]SY-<Q!,$_R_6!QJ
M%H8I?A5G5&5P(\$/H9>FB`Y\GC(79$=#T_3RO([=;0U27<9=3I,Y+OUR^P82
M'Z9(JH0^V/^8EK^F']E<28XU&J[W*W]_0E][80B"JVV;:!G^)48U%&*T*\Y5
M[/A)GJV0?/4']4AA]=`2P$,-G"Y^2(G!'BVFKC@>X;ZC*I10/VL_;^*H(I8Z
M!_(CF0H#0P(P6R5J-3)!Y_ULRG1N5[^;H&Z*IA`7JR7%R@22L>GMS6C*]05Z
M`U]A@#2MN9<!).;?Q&'H)<P20N+]S7,W\Y)I\I1AI]\O7IB#?5DJ$=:HG<WS
M)7@U<#J-A0^FQ,SH,!;Z^87K>;T,6<Q\`((4:_U$V8A\<!\AB<@+9_E+"/WI
M`M',XDFT_UBXFRZH][0$CZQ11L-I\N1A,WYQE<LPU^RH17Z<>Z\@NH)Q!OQ5
M%(?Q$LG<]Y%/#_YF=S`2C$=`(7.,K433Q3/2%%(D'6$3*TL7%NAH-G"2D':U
M):J26*SD80^M):]DZUP-7]Q*MJ+5X!1-(]DJ6[0>1M9>09)$:3I6#W,<7$ES
MT-W#'`?7TAQT]SC'LF*2IP*EO;FYOY&>^^X>1CC`\G.7R:FC@3'ZV%J-<3V&
MZ+4D:J]F^F9X:.CMC97!:SAUYP#;U0IO[],FA#3KA4A//><$'F\G5I/0R,[3
MX;"5,3R+U7B38YUMAK9\7):6?P1?R4_TI2'462^J7=]ZCC]':%Z_)A#')]S%
MR<[7,5UTF."8TZ%A>"/SF+^D,(!>LJTI'JQ=36VO9;8P7BE<1MB$)GI?<ON,
MKSZ(*V(XBH(LBB62+NV,M!8.)]E#Q['35(#9&='/B5BI[TL!;&W?F/1HD$;"
M"$O7KQ:4G4DV;(@$C%X50'8&[(L#1-&V*X#L+',GL\DHYJ@*(CN+VLE`1+%W
M51#96=1.!B**66@/T7?G>)L)V/TJ@,[V+N,K>Q5(=DJ0XO<9U8-3062G5L(,
MRCVHJBE@D>J5QG(23VX*0R8=\F![CK;X8JLY%&S/P.:"0K5>VYYS+;=<]OX=
MV].JA6'1E3AC>PD=84![9T787@:^'Y+\K!K;*\+W$RU:,8:VUX:7`$LXP-[V
M0O'B&U0E%:??,^<6H">9GG6\]\Y'BI="Z'N%V9FJ`U(A-Q5:9ZXB,-,X*Y3.
M7&/@)3550)VY)B":U58!=N8"/RO-K`+I[*5Z3BY;A=29BO3Z8PXK9Z.=$G]W
MAGEW]>Z.W"/;PV;$$\GJD-72X:OU8Z>$I080(R._`LQ.&4(@E:\IQE/C_L^H
MO*405$=Y@\[>DTYR7=(CUW=073JHV(&J.Z"^<T"QQ+MC5J$UA!,ON8N&TKE$
M+W/S9!I'DX!(<CS`1E!-]<I+08#O/H!@(+/6OZ(JM?;8WHYV[6U@YH6%VO4)
M1G"=K^\C/\$ES^^CXL]SA$'RBB[G.+G+<:7]G75W][%F;3)-8YO(]*JF!(?X
M5%,Q!^25%1*R0>A^P9,U\[:D%#RG\E?/08U4-%MOPG@+D'R5O$(?%))7>WT^
M8D](BCB8?/62`.GL:*[KOV/&'N/L[R";`S]>1HR22L-]SRKT"A,)VBKEGW`[
M6IG*(Q.A);-Q%]CBHPV`I'M<GQN?Y_2T1G8'$W/_R7O#QQPS\[_91@MR:%(P
M!MX2[.)^BK/&B[9I[42NV2'1!#+.XMTI3,QPA7D<8=LU!4?ZLI$:4.C#6#9A
MO7A:;V*21O9+D\U&INMI%0N""&#ISK!++U3'ZV>"F[D7+5G+HOK=&'7,$ZC>
MPG"EK,Y[:8*#QI;%0SM7VZI-*1R1VTJPKE;/\8U5.GEAT%R2_-(F^?9M`Y/B
MK3]R2=/0T3;^2:%SY\&$>'8GZ(I9[XZ1#?"1_/,,DC5-DAKP@\;P8^T(VH8X
M\.5UX=1OX)/"8Q<S7.GI@@5DA_SB22)X+-R&J>2NG:S)(@-[$;E+YA[XBR>U
MAEKR8'I?WDU$E[V/L@1&*?3),:Q[6<E\^A0Q_9E$[N^X^A7@`'ZT5EY!@K0]
M\N.-EX']+3<0O+)4G"+2->VXV*(#87GXG1-'J[4<&LDGPV/(_/I)R<8E;[\0
M8^!NK^WWE';)F/<YC57MFK;!CPQC(K/]Z.H'RAA1%`;2-P/%T*5I]EL._)V-
M3?HT]7B$*)%Z?6T?MCN4NPRPC5#;EO'S7/"@E<&@;S?;0]@YR'`<2[9'9(NL
M&^I%:7ML]8$MOW["-$SIMA\O'7Z#.A8MUZ;M"1_:?11=-]?YQ0CKQ[*V@<\I
M_E<_D#H\`V<0!JK-?Z(%>[H-_7AOT=LP$4<QY=M>&VQD>X-N7;6]'MGH)X)M
MN+6]*-K(ID?$DVU[0;8!;A-]8?:V%V\;`/QC1<3:7@UNP*-*3XB;[>7D1C8!
M`E%TMM>L&VA&%+Q]ME>Z&P9I@5ATVXO@C4P`50TXLKWVWCBG22S6SO8:?R.[
ME[D1/+97$1QF/@;,A+6]8.&)30@EN?9XU1+'6(.@71ND_3N6_*,4R%4ET!,=
MARM3^3@&JWL)["CKCH@3[.QJ$(R\!D$YCQ"7BFIO9<+4P5FBDB8O\1432/T,
M(B0AAY,HF`1K&$$\:3B2IUS%S$Q0L;XFN+J/T'$%]D5W'LH98&3=LGJ,B`-F
MJC:[CY%L8G3[H$M_A9;(#7@%8;S!A(FL+9&>9K./]>Q^L4QDG=\:3]:&5)*%
MM9'<6M>1[6&&`UWLC2*3@K*A[6$`1X":=BST<N&?Q!."`@)*H]PP6QJP?=<+
M"4.-L$X1N</V&#=IU`1U`>L#T884\01V]=G%=0\,L_:+[)AQRN,V[.U]!(4'
MH8BR2#.XQO+3-'I>`>QTFRZ(_^US"J,E^M-5Z/E?T!CH4VF9<99`'_WV*0X0
M)LYL9LQL-G0!0DU4%B%P;"H;;5R9-U?FS<(R;RK^,58(5OUA3"G;C,[OGE3I
M"U<6;KA5\4N,[DD8XF<-C[P>6U\^>43G,/UREP"P>_7[6'AV?O>DT.1Y`#4,
M;*M9VQ4HX8#O:@<PA-%&[8"FO&^[V4ZQDH+UQKCC9/^?@;G-9?];%=1X!%70
M=E?G"4U,6RMRV<[&IZ9;O7(YS^--+52(QI:,*ABWVZ:6N#9!9SQ:LPG$0)&_
M?XY@-O$S=`%D6^>,,>>,Z9O-4V9:89&MF5XU5$5>Q@=/RNASR,Z@=;4/OW/B
M:!FHJRWZ]1/?QRW>Y@!'\L!H>1U'Y)S*O7`0KT,/2DYQ+=_%R0)`7$5EGZ4Z
MT+KM^M(I(M9,OAX(K-9'3A&G6L68HSPO0O_>B:/G7KH8+UJ_79XZ7NYED/-#
MUN2J[2&3T;FCR627`TF'*I2<XFHNJF1,HF!O7HKQGVKL3Y;+!"R]#!SECE>G
MQT[T![WLA#]O)[8&CN^>1)WBF2[-\K$-`1H)'.4^H3K`:46LAM@7>HDX29P[
MS",FD)8EXR2Q9M;/.PK,$A2<[8MZ=@2)ZK=L]`H*W!3X9UZ2C=OG/KZI:!M^
M;0]''&`&^I3NE8K'^K%`.2*J8'!V.`_A%%*+OG(3H=O>W"_:JCC_;R,W%?U#
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M9+H!N`9ZM'Q`,%][2;)%JY^\"_>4O_P#G1O/<?6JM"BC<H,:QJ$V*V2M78NN
M3UI'(_R@?9]FT+^.<W26;YF%;[O;RE&-7Y$GM'R\+"DA[\K?DGOE[\!+.BGH
M;F/N]2F\8/-L1:XH[M-9!XW'0;?`@UD=S8W27EW`G*(6K!Y:UFO'!QXH%3'Y
M[8>BJ*O(,[NM7DINW[PUC,A9C7?M9R1Z);6_D1IS:%,S*10=X_B4$Z]R;]J+
M45Q)>U,E[2DK@2Z(3*(H]\('N(:EFKC&MV'7.I`>8V#**\D)KT8YBEM]!Z:T
M0B:=1I]3H((Q98PC4X[1HAQQ\H,8H)UZR*D,,S#]CW&VUQ(J(N2(IXSAGLDX
MYC,9E)DGBXBM(K2;F,F&\3(PB0+\:%7X'WD"TP#Z>!4QT>+U,L$)$F&ND<8*
ML_H6Z3R+17IH60.='VA>3BRQ4J;[4>FEGK-R`YA8)9^C9/\J&**V-!VF>REX
M!B(OQ+8.M+IWA4#9S\CW&5'+K%$(F(,T#S/B,7H$6>,2`8UKI&LB>X\YHKE]
M7GG9KW$>!O?K#5*I;Q<+@,MBXKEAO*"A.)CYAR)IUI[#%PN[["NVOU'`LRS5
M4:)8&X_G-AH_1%SQH0++SD1"$;"ZY<$*&3LCRH21.;2F5]#8&<4E8"+>HT.W
ME-IZ5`N;K.L'$<^?;.MK,TI@]76/VIH=+@6FI/W2UK<WE!8@4U>W]2D,^=4E
MJ8_;^E3%<,`1PXNMJ<XZ3S.:C\/65.0AL:MY*GJE"Y\Q?*U]:U>LK4[P:/Y?
M6Q-L=6)'\]#9FO@JCUU_RW.O/%5;L)2)UK0U<U2/'GL0?&UKVJ8>N-KQW;9F
M3RJAI>I-LC6W42>(8NY66_,,Y2]:E5!/6Q,#!T:OJ5I8EL8G%'O-=A1;_LRV
M-$(=;X^?C4?F`!2!O6G_\^`'H9`'R^7`SVDS$LU`PCH6K6CYRNMKEUXMBD8S
MPZ%"8VA%;S3)R3@!/(YPPOAT\;P"^#^]:)NRU!8CJ<LU,@]HXZ1ZB?4U$3Q'
MH:R&M1IK70.83(7=K[?Z*NKFB-EE%&G-30HY;-!ZC8(38KD19:!H/`JZ[4F1
MER!_-#33C?>[V$U1E@1&&CG'C5#,_FPWAQL'[]F*GNW?W7@4=,^2&,&<;6>A
M%V6X4LWO.=RL)8J#T`<8!7^=T19RL\4:8L0\SI&$C!2`53\V]Z.,A=/=WTI+
M+*8O>24VVHGO)[D7[D6(N<0JEA]X%'C@8E&%FAB&\5<OHCZ<)=)S/$5@9@G8
M>'`W$P*B%Z.O164V#-@%I/1)Q3#>2ARR-1#ZF&BV1"U;PZ'U0\J[16T-DCX6
MDJ7,96L$]2`PR@H[MD99ZP>W;9VR-=!:/W(,C='6B.L![N_V86A7'(1^P$H;
M;+^XZCCSPG,!K$LU5(NL/J6G)/7AUPHZ5%%(3G:Y,1QK_)C@`^5=+8[:@E4G
M"6.W]T\MJ/K\T!,('%91.,:_AP43]B5/2%O#K?6BUKE&CQ=D/9KHF#GPX\A'
M2)!/3A=SL(D3=/#<IAE<XQ-HWW97]$!+J>M=?/M^=!SEWJ3E@55+6&X`/>6Y
M!3Y)K38LWMDBJ[<)#H1>?!C34P_5@F@LANL5CNN[C]0=1QH&'A$>-R#(20DH
M;IUY:C^]Y;';GZG0#/Z1IQEYH:;K))`;8$B:[SR8D#=KJ@].%[/=G?>4Q?Z7
M7SW\8DZVNRRW$@RIC#ZB]48Y(B;9'4`R@A=B9TV.2-HV#G2YM:GXC1&A]!AC
M>01O,'1UE5QT/[V$WW"20T=R[!&A0DR$^S]%RRXI1FF($?'8<%;6Y$DY-JFC
M#'GND8_6SEO\?I7*D<T>9T1SM??J,:.G!#N/DB].Q)1X?R/%LGT0>4AA1)?C
M*XSS--SNE#!VM6Q>-Y.\?([2#?#A`H*`^<8.O;VQLN5X^^[(8I2>[VYK+(].
M2:/NS,G4(P?9&KTR*-CT2]76$)9^<*IH9+9&L0R')$=>4HM<.04WQZ![O4MX
M40ME.7LHZ[8AM4"6LX?P0$50BV\Y>QPIJK_5106'PE+6N&1U]<%!;G8E"[#5
MA0J'6LM2[ARKRQ?J0YA:C%^IB.%XPT74O,\'[ZD<VC7L+K>DA)C*$K6_]I#,
MRR(2L-M>J(AK#&WL4:X5V/8<.Z;UM0NJ#ER/MZ1&&\'UO$)7XA)&$5(_<)('
M>0>IJ-`]79!@?$KY3!-5CTX_\H@&9C?UM-8G2_EOEV.B'2V.!"#M,-T7"[]#
M1TQ9YGH&T)[&K6=Q"EFA1)H&'STN,WS&#8,*;>@183+?6PT;E#]XFQ1,%Y/-
M)H0^EE,*#Q?Z4^W)"#F(>GWI!.0^[H'22W+9D%5$R@^/6W[1@Y;T$6:KI_48
ML%)/0%O]K7I![7>$JGEB3\'%H!=E)&+U*P]0G*!($3@-W>8![]/;-U@9G2=!
M``L"[Z-%G*P)`4:*M(9>FDX7Q#+.C&OJ:*@EI/$ZCO`N0Y.`_I7"`!1/SV$=
M$*V08%*<<UB)QEC-DM@'Z=[!C+3!&_`*PI@D_7>_/S_45W1Q_PH2X@]J>BF>
MT`H'Z4UGO)Q,3RU4ENNW^5#G(4E=S4R(QZT*T9W+N=G&")7-JM[=5#;::)G+
M:00RN`:?8`C2+([`S-OB5?T<7Z%_PH"\]3!9)@!T%%Y4&.#X-'_>Q-'3SHKV
M@/<M.K4\U!,[`F-\O7>&1&O_AHDU=5!2O[6>JM^-4<=<[_461BA$<Y^@V<N3
MPM0X!R&6R2;8_"]2VUN\OW'N<(0!H9"4<3KP3[(8HW4U$YZ]0B)["'">;R?V
MF-BT*XM5902C(=QU"4PDC/N@O1GJT=?OTS0'P0W!M=!-2=1+.O%_SR';1B?>
MWVC9"*H4O?<BBDIZMA?_<J^^,*Y#D5=?+*UGIOCJBZ7%RJ0%D:8W6>).M'Z7
M20@]S0@CX8O+]C`&60CI-@/;+?M*2$EJY+8;\H?'4,A"8&M652^8AS#6VEXG
M6$%#[8QT/53_K(UVU03=.3PYJ@LJH=/`_KA@KK&E48BO0^L_EW#-0Y=FD1""
M;H##G\R\/AD1!>D9)+MWJYFF9WI[$V:S4GY)[^*DL34IQ%.;&S<SGY,1G>5X
MX?0:&2<GZPYH$%92),+#KND)TFPH7ME^Q\LS^D"+-F:$#+W]:/0\9TD<1F.F
M28B,)73&:#'MKMVGX7G$6ZMB1I<6U0RNIQ21JG.=->-2%<RKTG&IMAD+G&'*
M65O$8>1*6,UG#Z@*_?%L]6,SNMSE"#8P0\CY<..%NXN`^#M(Z\IQ9$""OLI3
MM)S3NKN4_!.1Q)2D^?U,Z`-=5-$U?EIK+0&QQ;27$2)DGM/#J>]4OJ2[FT"Z
M>E$6$Q+LWM)AVR0XG<SSD39@WP%^D]/T8]'>(^:L3/+KQ^!ND!'S>1_=Q7F"
M8QS$5J?00*/F]QE]%6AAN#;2N#G^&NOA=S>.EIM@[KV"Z`K&&?!741S&2XA=
M,#X];XC=P;C]\SC^`@.RKK`LM`^VX$RM[8'"''&KKAH(8&NKN4U5'.3!9[<>
MKP,UGI!JO_HN)J;3,>.+C;9'U@Z&8%U<L3WH=D@0:U*N[7&W`\)84XYL#ZL=
M#,6^@;+CK0;;RU,M?Y.?2X3>=1PB12DN(K3Q$RS0QP'7>X-PVEF#Y*.6UW"K
MH6=(?8DRZ(77J!?TO7`.EGF(!]I>Q^LU2'ST&_R#?+LQ9\P:!%K'UZ*'=U!4
M"W:OB$(305(-]ID*2LPJ#6U"MY_@6NO+<KU%P2/BHOK+,_I7ZA7EEIBQF;*C
M:"K-PMX_MQ$Z#$!P<_A(IG1W$S-SC<NG@@0=R]GVT5NS@A<[FYJ@>5=K?HZ6
M?T2UF[=;C8!2MAV<TG@$=*.=YLN07FNO90_^!]K:Z=X(QK1KTIKJ*8!4;MXH
M:&[K_5U*<T[)]CX.M53'H&!/$RNS)"UE[_UV*RUX/N(,MT4>!9CYSYN[)(ZR
M4I;H`I'5?`AZ%K4/S($/X"MM>L4Z&O'")$LO*L4TG%H8AS#8W9RSFK@\7=S!
MR(NP4+=/U>'Y!_2,K67F]@)<N4ZG1&&X`WC'W7I)N*T)=GLQ#OW<-9G*8YGQ
M\6SRQ%_5`U+:4@4S(D2\OQZO6IFR2A'B"JCWE#"<;2KC&(GF]W`P&\EDFR6(
MN!E(2*4#6N@^K?GH2@P]@J_D)Z7Z0E7G$?%%GK=29*O55\M>>?:^@,"C[X'&
M[^;R.&HZ)$/5Z6ZK!:?ROL4'=$CZ@>`Y9BK^G!XZJ:JD`%RMEQA+R()AD$7M
M8M*&J&AOJ'SN2@=_]4Z7G;696+:"9ERS\"UOM3]>7EVL5=B0L#K9ZA[M`:+D
MY=G+-_H*DI?X_#`\$*SZI<R0)PI>+4:1*EK;Z@OM>P8*VC=L+1S4%SZ]SC=;
MPPPU[.P#DZ2M-3HU8'7@NK&U@J?FPZ]I;+;ZU?4>H*G;5:U^8EWO):(6SV#U
MX^H]`.:9@ZQ^,KT_;G2#5;]'TZT$CA>54$&FH(C8K@4S0B(JW,Y1`Z%F1G2;
M"^U.)E%'B^*>L+9BJ2)<TCOY#/)O=`9-B&-\-N6^)$,6]@A2H]:J^\(N6TI_
MR)I.Y`HGNVP#0A[I^MT@[<YTR0VLY(9+S<D-Y5=_1A.!%3FIQ`5.WZ&2$G:6
MX/9+"?V2+GBC#<4-PP[1BR_Y<5URA4NNL"JYX@@I"Y2U\3/::EY`#RAK_.["
M^UUX_W$I=:]+LU(3<CS6=/$)B6M^CJY,_`)3Z3@``5EXE=\9IT?/0-)8BYT[
M3,.H+JEAN*2&!/AM.;!;Y.`V=V]FG^*;V>-,[=#%';EI:GZF_:+]!+)5'#0;
M_`':(=,]!G+!\BXLG7]F6NMA=]'G+OK\%$'4(0/;6K-+7U@2S_9J:[FN`:.#
MN;93%[`NC*F"9=K%L_>-^'(AZFV9R(6HBV.EHNJY*';U8$.5&'8;LL5<W)R+
MFSL^7!V/H5\ZB%QHH0LM-!`GUW8Y'&S4X\=S&43BT.A)\6+:FJPEBD;3\VQK
MHDO_:-)F!(FMF50NFM1L-.EWFJ-)#\UP.V.22BRC]&A#Q6CV"9(5'60HV@]L
M=E7]B<^;.'H$7V^2?#G9;$($-5D\O@\V&1*(.N.O-']A^*A:W=&TIN*$-88&
MNVC@`:*!5_@+]WAMXPL>1LO;-(/HE-U9C?#C(??KS6$XE'3W`:*7*^$D2F$`
MBK^R"_'*#6!WQ+40O=4:G"X6*<B>XUVE/D1+K3`!>7>;3[_<<"Z"W)7G=^7Y
M7=R\BYL?<]P\+2)];,7[=]%!^SB^"=+MT;QT!C4R6FNAIBB4=/N&PY%26J7Y
MPT;#?%LHS%.@EXOU[Q_K[V+K76R]BZWG/A/Q"L'7XM2YVM9"OG+T46SO[#K`
M^)V,/#:`!`0/D30)_I&G&:F3Q]H8U.8F:?\<I1O@PP5$>BAK5]#;:UD53VB5
M1<$<+E=(KRR5R8;<2,^-$NVJB<X$K<2$14V]@9DG,,IK;+_>Z'=)=UN70^-R
M:.3V5N7UNK0KRMGET[A\FE,$4;`BLEW._0%2$ES&3%\HY3WT+F-&(6/&9<KH
M0U4V]<AET-0!E4@]<NDT+?&1D7KD<F4.1.T^J4<*>31G5K2[H]*Y@J)B0_*1
MU.71*_S-UK(4O75"F6`G6V.7^X+8X;>T-1Q>KPU",I"JU\L0%H,JXKL^[]<A
M1!<D-WK2UJ+IVLK,=`22V/H@<5_,!!RVMM:>UR]4U[%RS]&QL>I\->A200>Q
M0'%S]0^&2N@_4_\;%2)*^("K?Z!44>,[!Y<K%]$=4N#*1;AR$4=#0KY`PJ5=
MQK/^!1):H7\54':9:H4#1!M"`S42MH+)+@NC4+1E%T0=>-I^`KEB&^5?CUQL
MXWO-Q3:L?Q#-E6XX1ND&"A]7,5@E$&WVY![]OW`%8'?>(Z>QW8G_+E'>)<J[
M1'F7*'^<%7&,1/D32T&?1%&.1!4DMZ,+$@?M5'&.`'(2TKE]W7-RNE>P2S$_
MI11I:LIP$6TS?0GALH1[O0D!_A=-!./V.=OD;9<]-V:;B<N>&P&([C4JXYF)
M=EF+=2U(OO3IDN>&?,++!:5R,%5*2'0QJAQ491,270!K'5"^^N"R[%0R$EW\
M:@LK1JRO4U+86'4D&RJH)-8F&\I$2*MDO5D0(<W$K5>NL$ING`6`NI!S%_'J
M(EY/!UWUR$9&Y,7Q<EE/,<#J3R[`2HB;FK5T![#&$"7EX>T.%>+3^UI]IDCO
MG"[0L=SE\I3IZ0*:QAHFY`)M7*#-R03:G'CX"H>[&9)*$J][1QVT<8$S_0-G
M*/,Q6Z#I1F*O3P\U;C=Q`3LN8.=D7ELHBS'>`7SMS=!<0Q]N=N5B=J3<1E3Q
M5*J_"S$Z"8.!"S$:%XA,-<R%$1TC1,M%&S6P%0O1<@%&G+`-%V`T`*;*MD07
M;\0^22N5U`42N4`BO<C)J2$NQ$@A',N%&.D-^G#A1]SPHXZ@K7-44ER@C`N4
M<8$RIX.N>J#,@;?@>/7S3S$\YH>APV,:9AZ]L3)20VL*G-G53L/O"Y`+MOC,
M_LT+M,>CP$N"]#H.X*)\/J2;+[6A]/"Q1+@@]:AZZ.TNS\@:2K,Y@.N7'"U[
MZHP(=[8[>,>%Q;@Z/V=2Y^=GM%FBZR1.T5F4;+C/?;.:NW`H%PYU7$I;U7,[
MZ6RV.>V@+1=<-&"P2;MD=3N&9/^[,>J8Z[S>P@5)Z>?N5$*1]/#[.7J!80B"
M72A$6G_?JI,Q5@\73.6"J<9F57?!5-KB!,1-#BZ>2CI\1<[*YH*J]+K`7915
M'47!T#071M7<VXJ691<RI5(7QP5-Z0S$4(FD.K=`#!<RQ<"*J4BZ\"E7H6E(
MU%R%)A<GY=ZP=:%D+I3,2G3=*Z,,]Y#(*Z.#EY4ZM1!#9C2$"S=DA1O^64NX
MH0L)TQ@21L'X-H0/2"?;TJ-\6BU<8(\+['$A,]KD.'M"9ES(AWLNRH4?N/"#
M4W!*NH`#K7ZA\ZS*KNJ4M$O/=@9G9TUUUE3;T%6WFK4-"L>+!#)M*%NO85:L
MKHAXN'$9?[3N0+>)3'-"[B<ORA=H1>?X]8"GC>=W)PB(]M*3?KHFT#X`M(QN
MWS:PV$LT<QVCM1GK''4^JTGG:/-R8YA-0$0;'/TOY&<>[AN:H3?U$[@I#O8'
MD*8`X`6#8)TD"?9[$+"G&X!73[0DBXEF5%4;2X]%$=1/UGLL<3/W!K.]$>OA
MX2[]2#,A=C4U0[/8%*,E#KYZX3-(UE26Y$<:,\>80.J#$ST'T[)?9&ZW8>^T
MZ6*!1$1LGBF$PSC9<NCA]#!BP6[,6#!!$TMWN0AV,L\'WFX9.FBP`/\(J!9V
M9A\37,R2&-&4;9_REW\`/WN.I\GDU8,AUC3NXJ1),,-)*#_.Z+EE>@Q41M)3
M4S_VO[SB0-9/7K(-O2B@;WY:4Q/(/_DK$.0AF"XZMW*7$U.JJQ&>P!+?03\#
M7#!UL\(Y4LPU0V^O964\Q7FV>O*BNP1;'%(_IJ\,6E,C*.X,(W5<&"<-O;U9
M7Y6"QE:W18IM$-M-/V+"0</6W:D,V.JBDL>):PRQU3'59TDIZ&JVYKNJPZAH
M+K'55S7\>FQKTK;FP2H>@FR[EZTYKGWV[Z%YUM;L5G64.&8`6U\"Z&T_J&.H
MI);;+@KWL%7LCSR>P=#6M%>=&-+-O[TR8,\$/1$G\?'26<S@*&/[4CX6+8]=
MZHLEP\ID;?9L7\QXPI#]<5Y<"V_U)A3-+&]K10YYB*CV:5N?C1&V<#<.*CJ>
MQY-X1QO-5AUEGV"$,XF+`G_D@-I5HI,+;G,!6\HN[P+[<B)VZ-]0T_E$>X^8
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MD:003%!9ON;G.`Y2>DY=9U/[BH-0%J7M47"NLC+C4&Y45FY*1+9KAHIUIBT+
M6Q:[.KL>=^.K7;;:P"4Q&TCDM]4:+HEN+S''5MNW[*Z6-T[8:N`61XXM:-IJ
MJ^:K-YP79JR+]!1#A+>NCAD):]9^?+O>A/$6@"L0@07,9J$7:3`3:ZLGAJ:D
M>.`-ON3D\,.7!M&\IMD*)+,8:5<@@PF90$R\>'B>KM&UF`>ZB$'?V\U.6O]A
M$D6Y%_Z"Y#IT?587;)>90,>PABK),>A.\"S@B4%K--DV>"!7I\2$2PPZ(AQ*
M;:B8L?J/6-[:36XYA7)@2(VLY\V0W5J\#>$2HG-ZL@3/<?60,KB/:F=3UR*7
M',&DEJOY1*OJI$J":*LN."#.6K>DK=KBT.M<RS5IJYII;O$+W\O'TU/-2M7_
ME:.C%R3A=N\1J(G2U_%ZXT7;M/(E@&#?80[2'`D&^]0^U,:$Z'WK)1':-OCP
M(O:Q*R^%/D64Z&YK0EQJ4W(#PSRCOIY#:VV"\OL(+2?P$*?I'=K+16!4CHBK
M5@&BD@"+]G!)*"&:PIOZ>":X?P1913"%HV8;$U0R-[6PVBD[BL$'JJC!#+N?
M3=YRBK/1\4Y-:K\\K`&LUAZU78+5@!CE#K7WI2.-V/6X#WO)F.>"+U52ZN4I
MD43/K(S^E+^DX/<<?>CV%?LJQV+U'L5+OO^!5$(T!U<PSH"_0KN17GN8UE0/
M'?$**4E8<2W_=8/N[##>%&\('3RDW4&=U`!#O$B[J#T;.`<^@*^T\$.QCNX]
M5MW</66Q_Z4(_K@AU:S0J0CCXCY)'\%7\A.]?+50YQ'Q]8L7YD"1K59?(UPU
MS^V#:(`V([3F(Z"=&9+=W78$5/.B^*G-1T`[\UV"KJ9CH!E]CU4_G])Z))2S
M7U"@MG?O5)^4NJS^Q*.DA&=KI)L&(&DBN^VAXSR!H%DV4DS4ZV40W,0I4B5?
M[8>M+4GV,@J>A.E%!#09)=!V7S1/=&PLLDY1S?:;DR6@LM#9"X76AO+*(L1^
M_=TM(.K1=09U?]D:%6>?G8L0S]7>&#B=QPOMCTBV3I_CCCS?7DG"E5/B&1%X
MA13T+R8\#Q/?QT<H%N\0^>2Q>;:EA]'AY$I3=,U!-]?:/V-RS_/GO%%^23O"
MQXN\&-=Y\027$5Q`WXNRPREPIT`?&Z08LA2#I%CGT]FQHFBX?<C"9_<'MQ_E
MZ<=1.NETT:)J6_Q_WGX4[&R"KVLO7>$BANA_;G_/X:L7XO4DQI98W_%P-0=H
M`4$_`P&+<BEF!8<T@D&\Q@_^D9-H#D(<GW\=I\)S*]C;%&<)6.%LD%=0Q-C)
M[$;A[F9XBW"*3^$NFL/T2_'&)?X7E1UZCS&D+XA-"J^7"4[N/)@0YT!-$;B/
MT(;/U]SC0JROD22-]0;11@KKX%2G39QZX73Q$$?+![0?RO>TQ"9-:2ASB2G/
MWIL@7[3F9M)*OM8$AP3)@SG:\+55),:3]#`F>-V]+8C3\3)TF^*;E/C0Q7@4
M[FXF^C`%2#_"0D(M.*!\E9=YEHCT-)A@,P=^O(Q(V+'8-/'[F>#F.?$"L,LM
M+;=*6GDYF3,DUM<$5Y]3=`/=IAE<(Q&.%GS5:G0Z=@%1K<SVS"@YU-IKPO8L
M*#ET!#5BVV,>Y$`3/#QMCWO3L=)$K12V5H-3PU)05[,]BE!R`;*,#;96IU6#
M2EPSJ7#[B\--T=I@^_/4DAA2K1?5&]5VQO+(X22@CU:`.45`T"1A^SOHLE>F
MJ.^APLTI"!+>J`HVIR((.%,JN)P6H&(KK_`;6B$XQ8@1$H;MXD5T^'&OMIP,
M6%:/47#`S8-E]3#"`=%F#ZABYJNS^QCA(D\S)&4DDGQP>AGUIQ=:'Y(Z'Z#W
M`D,DJH/T$_!P4&TP1>*!GR<X/0\U>(RC9/>?Q-A/3B2>@VF`#VFIJ4(U(NR,
M\<'G%"SR\`$N`)/1OJ,9B6CU5R#(0S!=3-`Q'>!234B$?L*@DWFY??/#'%UU
M1:FL]2;?!6&W92!N]*O^#YG%J[,$6U4Q3&A+J(YFDO-TNF@<7]-%<2WB_W^'
M+O8X$>5:9B0S-6Y*N>R!5P?FL*%1>IF52)J-3D>+:'-G>\:<@*S*]!J<4W:A
M@%3<P(HGO-GND)+%BRVRV^Z3HM\#G;Y.C7*T[1$R8L@J21ZVA\^PH>NMV-@>
M2".W\J2E?=M#:F3ATZ=<VAY@TRW$,R6]NF!HNZ3'AZ=K:=K^YB+=HT"]`T92
M%X)*'\>QP.\WJDP)\0H04D.8W(G",R<4L.4*."AN6G/.P#/9NLH;UL9MZC9G
M2NI5KN(0<9]B7+(M;CN2Z[0@B+,!6XV,E8\7`I%FQ1;M;W+O=<_&0?%3,1S.
M=;]58&#S3W>\VDXE!T%9!]5LF2-ADE_J)//>%.\WJ)$GIGM.74\@**,:?3]5
MR\IH/)O:%V-WKB@!9T[N=J?+@7&V?*/Y"22OT`?5K-4YF82$EL)O4"0C_($X
M(<7&"7L2P1J:OZ<EC*DBKYL>(FI,R8[$SJDJH9'\\#F":#K]#+ZB'<R/<AKN
M8V97TL&&GWSUDJ#.#7;Q%?.;IOFZ^)MDK(^6C]AUBPVXEVWWH0XY&7JV@^VN
M6'TS,/1!?CRO[KADO7VNYDC,-!WT<.0S5@^CM;O$;3;,+B;WK\!L=";^.C.-
MX!8SIRN=_D:K;H.;<B4AVKI"S"2%4+G1#.MWBP7`-QK83\X<+3LL^*%%&$*R
MTF7C[>6'-(O!9QPJ6`JZB-HK$($%NNGG<1C>Q0D6RR01D![PA(YHY4UCN[*@
MC*/*%K1=[E<&4WXOGZO@3I2;W,_R,F*Z5*E*_09MX)$(]%PZ.5*'>']#15+E
M9T&1T;$I!](SVRKEH@#<N:H0*FB94RWLWO+59767(Q+!)QC!=;Z>XU41[DQ8
MZ+*:;@`.1(Z6#\!+I960/F.;1:4Q>[AB4_(*BCAL;`-,N5%C*B.=[#&H!)OM
MHK@F1'MMS^-)Z..Z::Z1I.V]E,^_$XW0Q\75]L^B]Q<K*4Y:I0]W^%^5QC%2
MOWWW=<YM>-C.Y-ZD4KUWTJA-Y+E*=M?Q>@VSPNT5!=<Q2?H'D3\>!4Z(0LX:
MEAO#T!M-,O/0@\UQ2"U*L]HJD"@%F-O@(CB94]K.8YNWI+[IX@&D*9`(KY<8
MX*2WMPQ0Y[JUY_'6"[/M7K(92C06^4Z')"S2S0F^^@1?H6DZU[TRPQ6HB3Y`
MGER9Q0A$D,&$_+IS\XQ'XJWB*;'Y84>GS$4H/(*1E$[5V>AF5WDXPU>D["PW
M$D&5(3S7(^"_<B]!Y(?;VH,WBSA9%QYRDQN>29GPII<=Q<3&%YP#!0;'L:D5
M9[*^L44A<MN8A8\Y1?9\-G/EZF#/B9SG46:L$]_JB@">Z\Y_RE]2\'N._GG[
M:CR3O$T,9S]3FQO9N%0@Q8@?QP;DS4!CI]$Y-KR;_OH!$XOSC]!__']02P,$
M%`````@`:89C1F4](5DA&```.@T!`!$`'`!M9VYX+3(P,30Q,C,Q+GAS9%54
M"0`#UBSV5-8L]E1U>`L``00E#@``!#D!``#M76UOXSB2_K[`_@=>@+OM`=9Q
MG'1ZMAO=L\CK;!9))^LDLW/W9<!(M,T=F?*0DA//K[\JZOV-EF0G+0\$-!J.
MQ"I6L1Z2Q6*1^OSWE[E#EDPJ[HHO>Z/]@SW"A.7:7$R_[#W>#T[NSZZN]O[^
MPY__]/F_!@,R'I-S5PCF.&Q%?K:8PR3U&'F@+ZYPYRMR;\W8G/Z5/%'%;.(*
M\O/I^)H<[H\(F7G>XM-P^/S\O"^E'3'9M]SYD`P&404_!:)\(A_V#P_WWZ?>
MC%U?V)_(WU*/SB2C'I0F-@CQB1P>C(X'!T?P[V'TX=/!X:?##_^7+NTN5I)/
M9QYY9WT'A0^.!T!Q1,;[X_V45O]#[EVAH/1\0<6*G#@.&2.5(F.FF%PR>S]D
MJK2R!%I0J"][*?V>C_9=.1U"%:/ASS?70:/L_?E/)"C[Z>5).CQ#@4\BFJ,A
M%\JCPF(I$H>+7PT4^!K;/%U)@204:_3QX\>A?ILJ[:O!E-)%7'Y"U9,N';Z`
M:D;O!P>CP=$H2^6M%DR5DNDWY73SJ7C)B#:GEG2G3'!+:40@U>@P0R/`0OZ\
MO`UL3PZQNB$4&D`I)KF5)EU/5Z#!,K87DZ6;^W@8O$R5M@"<GEQEBRMF[4_=
MY3!\B4H=%9K"\J6$'E=%&KXM;T:;\7(R>%%.P5ZL63D)OBFGX6+)E%=.%;PK
MUTQ0L&8YF7Z%5*,"E>)6.0V\J*#P%K*"!-[D:3PJI\S[2N=,+:C%ZJ,0QKHY
M$]ZE*^?G;$)]!YKD-Y\Z?,*9O4>HYTG^Y'LL4\`729$?D,MG*H3KZ5%+_XU/
M%@LN)F[X)SS`KOE)N@Y[`&@2_/$XOC(*ZH7C[Q`+#\]=RT=1J;`OA,>]U16P
MEW-=Z1[A]I<]8XE8D$@4FTVXX%KDT<&(#$A$GOX)K$C`BZ28?1[F.>29^S!1
MW(H?]&^+.I;O:,)K^#LD#DN8"!<2AF;AM:!,)*NF"Y]&%MF>H>Y!8@VJV\DE
M%S#B<^K<N4J+<^90I4)LH<G&0/!+30*S!8_`;#$C@O.B4*[#<0ZUR2EU<.8A
M]S/&/-6;;W/SW5$8P;T9\SBT3V-;:NHU!GU?WZ#D74:<[WH#US3P%3C%<W;B
M>$P*4&/)RBU9+&8VW;')=/$+1=P)N5V@K\W1-\6Q%OU3R69,**B%!/62=]>N
M4KU1ZQKU?@:=8>8Z-BPZ+G[S8>XZ$?8M=`Z9:=V@<<L-WHR%&0P?ZH/AWG.M
M7\-J_T*"BLD[<#NXQ;T>`'4!<$;5[-)QG]65L+EDEE=NY&(QLR&_KV](9$TT
M[]YH)J-]=3VF'MQXIDQ:\59.J>"_:X62AH8_H"/>I91-3;,)\3E7EN,J7[('
M]N*=.M"K4A!XPTK-@/H;>MHQ%?R1KE]/!U^IAV\R\T2/J':(NN=3`<Z7185W
M8NG%.Q?3.S"QQ8&B$4YJLC);_V/>^O?^?$[E2D\$204DJ8%$5?00:`>!.^E"
M-_)6=PY:#E;),,,N\$W;`:,10R,<1@=Y.$2\@S5XQ+@W?<O>GW*M`L<*R[:U
M>WUN9J./"F-`B0?8F[R=R9.&!5\/W';PV;5R8^:@RW;F*C`D.OJGN*UQ1U>:
MJAD0-JW##(_#4G@,@FV8='4]1-I!)%C`/="7M@.!D8'9N$=YXX:K?6#6S_!M
M#3IFRI.^!5XS^$LP(8?]\,3R^!*D9:V7!JT8FP'P/@^`:P8=FUR\<(]<<_K$
MG7[P;PV$,]=QZ),KH^7;-;=@L&0G4\DV6R.V8FP&PG$>")DZM/\7UD*2:GI@
MM`7&?,X]_1.L!ZM\7%DQ86TP-C1D:0;#AR(88NYAB#C%OT=!RWG"75''6\7=
MJ?6T4(./V=[?EZS[;)AHR`UW8,YQ!2.1VZC-'];8CP2;1P,PB*_'<!W9OP-?
M73*/2_WVE`F0NOTTT9JY&2V%D.'%?.&X*\9(R)-@**)'1#M$_,NGTF/26<7O
M4DD/S>Q?DY79VH408<R5Q&S[O(PM!(?\)\5^\^'GQ;)Y#*":VFC=PT+$+V%$
M-*?>G*\9Z8\>;#'B'[,T&[X8]:L=^2?OHE_]=O"KHN.!/CE;Q4;(T(R,8L"O
M`3*"&GI<O,'F4`-TM&!KQD@A;EB^4=3CX=MN'S2`R'9J,J.F$&RLVDKH<?.*
M>PH-0%&#C=GBA:AB>G^AM_(WV&AH8/T-V)M140@OEFTZ].AXTR!S`URT8FQ&
M1"$`:0PX]]!XDQA3`T@T8FB&0B&ZN";>U(.AWLFMQ+]+)7A"_PW2.V\G27+G
MB6UK*3-&#$]W;<K%;/M"K+%6,BJ42RK+0N.<>93W9U'J0B-<Z=].C.&$6OC8
MA)41)$<E(<O:\8D>*6^*E+C4)>7R)^KX[`8\/3_8@(I'\Q.EF*>S&`+7+XZ'
MOEUU9L1M$BO-%$:YB!:,I"1+S6M:MC#9(I:N!^?K@C/)='&E>IA1;\S")KAQ
MP9&=43$ZN)T\N!YUQFS)A,\NJ!31Z=FWK]8,UDW"MYG"&?F(!P*26$*"(A*4
MD8P._AM+:SE)*"@)).V!VP7@A@Q@.6\QOD1?^4V`6U*M&;B%F/+;`#>2DR2"
M]KA]%=Q>*(_/,8+TJ-C$=Z[YLNU$7\K)C*YB[+D)NN(*25`CT57V.'D5G.!.
M@!\=<CREBEO@K9USQX?V#^+'>!;]3I^#GKM"[TJTPU&KFLPX*T2\&^$L)1`2
M:)&T.Q@*E3V-3T`R$HA&M&P](%]GPK5FS/8=!I,:/+?1%-#][YGE2^V@7[Q8
MCF\S^U*Z\X<9.TN:\W92AJ8-$/LZHI@A70C7-YN80XGU7)N2F21"DTAJ,@&Q
M8<9F)"4X$E;#O\=]&]Q'V_7I7(`$6F5O\W!MP<&,LK(<Y+*4@BRBJO(.>CQL
MC(=:8;[ZA&;K%Z+^E=;O`WC;F?D*IX?KA75KDIFM7;QVH.S2F=[6V[2USMM)
M)]G4MW=-4J/-WQ?#]CKYAY1D__2&?U7#)]-T^?N+%_Q9=%`W8F8&1_D=!!7@
M2,__0;G38K&PWAXR6X9,O+5RN]`CP3.5=AP=N16PYCB'7[>3'R4L"1X5+`;@
MT:E#K5^!!U2E`KH[">L#,;UQ;>8T!=IKB&"&9\4=".OAF=KP"2HE6MI4/`D>
MX7H')48"+3/10NOG6NQ!*'?(8Q!*3K3H/<)?8U`,H85);\J#Y@93Z>>/H$"8
M`+=J-4#68FQ&8S%0WF2PC("HSW'&,H3O4`H2B=$CJR&RXG39FCD2:\N;<5`(
M:6>2:WLG:OM6Q;[E"DQXNYU@="VXR%^=LPF3DME01F_@*T,FPX;<S(@PIUL'
MX>6@1AP.=)PMJ/0OBD358N$@#T&1=ZFJO^N!TQXX8V:YPH*6#$.Q8[9P)0R[
ML1\0EPV/4!M@TYR7&32%\&X.--GZ$#A1C2DW)J&)#X'W<-D:7-!_95,N1)"(
M?R'P(RHG<XRVHYOK*O4H)-!,!?]=#QS1X?X&,&I?AQE>A;CN6GAIOS<2);S]
M'X4A@32!FPSRD+1`:>CU&[--L:</8.#YB_CX12T'IBZ9&2&%V&_I<9#>GWDU
M6Y_-J)@R=26*K]9;W$1LMGLA"EQA][`&PD7%0:$>`!L"X-+W]%X.AX%X09WH
M=.>CL)G4I>.+?M;CH0$O(SR."P'C"G@$%9*XQN2J(EUG2!;7VL.E(5S67C97
M.N:/\DAIR\8,DD+@N,ZU==5SR:A'QYN@XW`[Z#A<@XY"W'8S=!SVZ'@3=!QM
M!QU':]!1B*-NAHZC'AUO@H[WVT''^S7H*$17-T/'^QX=;X*.X^V@XW@-.EI=
MEUN-CN,>'6^"C@_;0<>'->@HN3]W$W1\Z-'Q)NCX?COH^'X-.DHNN]@$'=_W
MZ&B,CLH+3&J%/1O3F_%0B'^:+S_I`Z&O#X,D:>,&))W[\R#(I$-)47BI`2IJ
ML3.#I!`L70>2=.)'6&L4*@LB8G&8K,=-XV1YO!P]OAL]:DA,ZLE=Q5YO/-F<
MH1$['\H^Z]7L>O=^T-D6>**[TL.M2KR1LQ9&:M.9H5"(EY;>W=Z;>UOF-EZ,
M%67\I#_B&A.,F?(=3`U*+CK*8V*[S,W`*812UUW+-4CE%F6^4IL0AE+D;G/J
M(=;T#&OFZO>:MS/5H#$#HN2ZANS-\?T@`H_Q/\S+';,)>=%//"CT94]Q&'?9
M7OB,2@OI,^9_/MIWY70X^OCQXU"7&BZ"(W'@W@TCMA&#`O7+DW0T_>'!P5&`
MF%S[A5)%'&:23;[LS:?B97!X,'H_.CP:_0(4^R]S)RKB<0]K21_-14;JKX0Z
MSMZPNYIGS5A#<2`H4?P\9K,C>COTB3DU58:R)2I?(X<=T3;?S6LH#20E2J>_
MLEVF^^<A72PXC&?Z;_A+"#<H'3P`U5WI$4'G3"VH91*<"^7!W`EZ*EBNS>FU
M:VE&!A+\:Q#1#?#18'0X.!KMOR@[%+&)!$E+-Y,@HFLJP82J)\W*5P.$BAJB
M-08'(V!0*8.N/TTYI72A"8<,'(B8UR#AU;PY;$\.D<M0N&(@_#F3W*K7*FG*
MKP$A-LM';);1ATTD:2=%.Q'21C[6?]E>;51$!%CI<6,@Q.;<'`?XI"D,-%O%
MK/VINQSJ.RSD"KD>U1&GC"[Z8Y`P:2&(+R43UJIVPY02QG]MU"@VXXW%B&CP
MQT:5LQ=KUKCVF$C_VJA^+I9,>8T!D2(+?V\$!T%A(8#<1DV$2*B"GX.$07,1
M%+<:"Q#1X(_-*O<6LGGM$9'^55$_<X+$0!3@RUZR9CF#.8Z##YS$Y5P/RO%<
M4F,N-Q(]C%\V81(X4*@&_S0'`H_*U97'YKBZV"/T27F26MZ7O0EUM(.D"X+C
MQ%W[09,&SH$7O7JB#KH*7_9L]H0'2P3'W29T=#SIX[P/ZS;P?'R4]T?I^HNH
M<@Z5KFNC<*-*'UN]9*Q.BZPCV2G];ZCP)S3\1L(]HO>&S9^8+-6\NG"@,[@/
M,'=_LMTYY:),Y4#@HL:V+\-E_E:5"Q'ZN'#%B37C;*F+X29&B.52+6M0O9J)
M+<GLK=LX[K%17];;.W-PLC#H58C:U^@"&W+<J1Y2T'4K#?8';Z,QFV*(Q96K
M!!;A-?B;M%H+MANW8S(VO6U?S2L(7>R>`F@V@U]KKKN)QW,8O1U77[V58*>@
M<Y,6;,=Q-UNOA7-4FW8W6Z3039)+E]%?^,J>SZ4_/5DL'!ZX]2>6Q19AB,S4
M7!LQWLVV-'2?-D-;"W:[WFY;:J\_:#MM#JD_$(K^XRN=:_7@AI\X"+2(;[R]
M!PEL*FUUYMKZ/MQDUS5LG98<=L/_FH(YI]1+@AM!IAE^-73,^/S)EZJ`E_HT
MK]<&6X0(_+:9'9Z'7?"@0KS6*ZVSH5!:24R4:*G@5E0)+GU(!;%<H;@=9FC<
M46Y7CP+-:7?!NJ<NFV'0ALDK^,^9`3X+<1Y#F2Z%=TY]Q053ZH9)$/5B,F%X
MW1?+(=58JCM0#:X&N!+),!I=27.FMSV\_V547LT7(%)*N494.S$`9P\J1'TK
MT_7RGW\)6J(9W0Y,U>N.;%P(CT&[Y^#>B"IHA6C/6?>`>P][_C?L!^L.JI1\
MF+6!^N7DF5'-BYYWI1&DQ$X>A)XGBFF_2T&_MF;XC8\D"J&_;%[9%@VY[-I@
ML4QL?*>EP*\["2UD>9,8"3+S0JC(MX2#_F8+WFMY1A?<@_4(?BM"A8<AK@0T
M*?AA5\%G7?!KUTPNF7WIRL`1O5+*SP4>ML<RW51*%VXWCFZEG<*#(X5QWY7@
MK)XHK1828'KHG70M\`O*>T'FYNBPQ;;/?!<<1M!VB;ELP.5.AC<K!KC1+Q0/
M[A_.-55-DG#@A5%W$7[!Y5OVL@JI[Z%&ILX+;G)=@B[YS#KSD^DS79(_:4H\
M)A&=G5#I%R<@,'5^8DI_MH=)"[$]31MZ*]PR&,"GWPX"YZ[EXY_ZUD"@7:5R
MO4]"6=+JURJ>&2`KO:LWL7Z\^HEO3QR#RY>]M_`:+(H"ICV)AG0[IO%#;BG1
M@.:--;6]3[,5]A+_2;=UA<X.OP9^J\*`E7_1I8$I'C-`R"D.J2=3]N#>41A?
M\2XT6)J+U(&QM%(-";OEV@7W@>(JO6BMPJM.V4M_V09Z"$8\EPS;%O.GBUJ8
MRW5)I4M?"H[.+8SGL$8"!R7^6E-!K1IENZ4:RAHZ]SIHJXK7&:K\0-B(JI-#
MX8_<8=0N6"_[N$N&"B2[MSB#'H-+B@K92TIT2@U868LSO-KXS)6+,`115,54
MJDOJQ(Y`ZKK0$C?)7*Q#7E&)H/F^7UVDDQT]%O?BA<ZYT%7@U*G'J=2S,0;!
M8&8MT[0V:;H%]`3][?R'1L+?>^`5M=4\).ZB[EG7//W5B7BONK2;UJ/;A2!-
MA4KQ]Z42A?"+INE8Q;\I!H;SUV2;VJD5TQUN1`"^QU+@P*N1&L!J#?E.Q-FC
M</`YB\+"D4+C[*;YNH*[`(-_4J$4$Z?<]9@U*W/!*DMTR6?YISL32N^!A;\R
M>SS53EE#NBZI?!UL[02)?^M6<'4*=TJYS(WS5WA\ORPQQURL._D.N<PA]"3R
M6N3?=LCUB+:5\;!+6=Z!*EL>-"'JT&)AK=CYI4-=@DXN)*XY#`+VE3[EJH<"
MBH?<O%6P1_S@GK(SARK%)QSW_,ZHFN&HL:2.+ON"D9),4VR!6[<BEC7.">[&
MZ<`;\#]6-U3^RKQ+7]@J]FN3%6]:ISJE=R"KZ"MN64]`@^!`P:5TA1<&]5+:
M&DOM@A.74V"24J`T?:QF^5TPL(]=[782[+?>0`_S&-YJQC+JL'0$I#Y)6G\L
MA2FBWVPDBL76GWC\!W,P/04S]<M4*Y;95)=M9JY$8F*J)I<X%Z"X)7KD"W11
MB?B<A`I/39=AK:Q0)]%UXSK,\D%8G*W#M1"T?_J8,WZU[T3!G)[Q=\K,MPFS
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M`+'PQ0MZ_(I=,I91N/!N-^:XG-CCX(/F^#2(=IIT+"G<K:AGDK`./HA>..!Q
MH>A>^O@LS:WO84MCXN:E*PVG:*+S,]KCT:2YM-:WJC#TP;N0?7\W@;6O+-MP
M+;SITLHA?]%-`&X`-1X+H-)9I3908\<WV^?;L]B!P>Y.,BM_UYDJFMA4JE/F
M#N[V7F'WT2<_HDWCZ.2U#=/PQ`=33H*,N;)CJILPR31&!PZKCNDRSH40KN-.
M>7GBZIIR7;)Q=&ROXC1QT#WC=6I1TU;D76R`VR>'3S5;G'L<5I)PL+YHP1&]
M<84W^X:`94O.G@,_XW25NBW*]V:NS.;`U2C;+4=E#&/!$MBP&Y@)8'0I)K]7
MEN@4`'-?"S.?^J]5NG/C9D[HLI010YD.98CDI<PGA%2\[V3^1RAK&)C4&S&Q
M'_Z5>3K^&!Q^T8,Y"%T6%=Z(2X=<\N1SCWI!<0IK"]RJPN/K87(KKD'T?*:_
M\<?0CI87I@$_PHI.G>!12A@H*WVA5ZRC:UW^'C.#[3&?SKP'-_3I,TY"8;"N
M3=&EP3LX_WXRJCP@7Z)F38HNJEE3MYU1Z+"QW=93=%'-FKKMC$*WHJ:Y*@MV
M3ZG3IEA<3]`])<^:*KF>H'M*GC>>#FI0=%#-QJ-G#8HNJEE3MYU1J+'9=LUJ
M2\Z*ETSDGG=*Y-+50.H>N]-54B1::>'.8)0^%>R!A)$:S*J;>"S>(DFWP2M7
MM&'2V78;U04I[ZFXE/BA8V6Y1414E>@4-G"+N_36E,*;;HF-R\_L72BCXITI
MYF+=4RC<6LS?/UGV<A>R5&*YF7VNC[`$X=^@E\=;IU',H4SAFH2=&AA,LC^X
M.ECU+(%>JDM71EOWMY-;F`-/',<-SH$O<MD;6^6Z`\VE3P2U@$@5W>MUERVF
M?J0"=.'U3@?E0UIYF2Z-9P_T5V;3@O39Q]T2^.5,6S*=&I5-B2RY\J0158?R
MR.K*G<^?:TC7(8UQA%1\*C`E8,VR9'W1+@'W4<@@Y^MW?2M&>$4?9BSY#J;[
M78FOS,LD_[%,^E]&\4U9[4`637@F$7."8%ZTT,@/;MG6T[J"N^"!I700=G*5
M(P^N6PX3!6%PRJ4B-"/K6EI"X=1I9?KDVI+?-"7A\S#XGC'\_']02P$"'@,4
M````"`!IAF-&A3\C!Y-P`0!XIPX`$0`8```````!````I($`````;6=N>"TR
M,#$T,3(S,2YX;6Q55`4``]8L]E1U>`L``00E#@``!#D!``!02P$"'@,4````
M"`!IAF-&1/BAS4,4```'*@$`%0`8```````!````I('><`$`;6=N>"TR,#$T
M,3(S,5]C86PN>&UL550%``/6+/94=7@+``$$)0X```0Y`0``4$L!`AX#%```
M``@`:89C1C6:LW;)-```6LT#`!4`&````````0```*2!<(4!`&UG;G@M,C`Q
M-#$R,S%?9&5F+GAM;%54!0`#UBSV5'5X"P`!!"4.```$.0$``%!+`0(>`Q0`
M```(`&F&8T:4:PHE(8P``)W9!P`5`!@```````$```"D@8BZ`0!M9VYX+3(P
M,30Q,C,Q7VQA8BYX;6Q55`4``]8L]E1U>`L``00E#@``!#D!``!02P$"'@,4
M````"`!IAF-&7;VX)%Q+``#K(`8`%0`8```````!````I('X1@(`;6=N>"TR
M,#$T,3(S,5]P<F4N>&UL550%``/6+/94=7@+``$$)0X```0Y`0``4$L!`AX#
M%`````@`:89C1F4](5DA&```.@T!`!$`&````````0```*2!HY("`&UG;G@M
M,C`Q-#$R,S$N>'-D550%``/6+/94=7@+``$$)0X```0Y`0``4$L%!@`````&
-``8`&@(```^K`@``````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EUUAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Document and Entity Information (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Feb. 27, 2015</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_DocumentAndEntityInformationAbstract', window );"><strong>Document And Entity Information [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
        <td class="text">10-K<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
        <td class="text">false<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
        <td class="text">Dec. 31,  2014<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
        <td class="text">2014<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
        <td class="text">FY<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
        <td class="text">MGNX<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
        <td class="text">MACROGENICS INC<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
        <td class="text">0001125345<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
        <td class="text">--12-31<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
        <td class="text">No<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
        <td class="text">Yes<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
        <td class="text">No<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
        <td class="text">Accelerated Filer<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="dei_EntityCommonStockSharesOutstanding" onclick="toggleNextSibling(this);">29,968,476</a><span style="display:none;white-space:normal;text-align:left;">dei_EntityCommonStockSharesOutstanding</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="dei_EntityPublicFloat" onclick="toggleNextSibling(this);">$ 437,213,185</a><span style="display:none;white-space:normal;text-align:left;">dei_EntityPublicFloat</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_AmendmentFlag</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:booleanItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>End date of current fiscal year in the format --MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gMonthDayItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:fiscalPeriodItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_DocumentType</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:submissionTypeItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:centralIndexKeyItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityFilerCategory</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:filerCategoryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityPublicFloat</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityRegistrantName</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Trading symbol of an instrument as listed on an exchange.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_TradingSymbol</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_DocumentAndEntityInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_DocumentAndEntityInformationAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Quarterly Financial Information<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationTextBlock', window );">Quarterly Financial Information</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>12. Quarterly Financial Information (unaudited)</b></p>
 <!-- xbrl,body -->
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"><!-- Begin Table Head -->
 <tr>
 <td width="55%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>1<sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top">st</sup>&#xA0;Quarter</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2<sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top">nd</sup>&#xA0;Quarter</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>3<sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top">rd</sup>&#xA0;Quarter</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>4<sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top">th</sup>&#xA0;Quarter</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="14" align="center"><b>(in thousands,
 except per share data)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 <b>2014</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Revenue</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">14,719</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">9,220</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">18,382</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">5,476</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Net loss</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(3,108</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(12,259</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(3,928</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(19,018</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Net loss per share, basic and diluted</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.12</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.44</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.14</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.68</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 <b>2013</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Revenue</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">10,598</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">12,299</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">20,232</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">14,906</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Net income (loss)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(3,366</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(294</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,604</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(3,205</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Net income (loss) per share, basic</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(2.93</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.24</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">0.14</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.14</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Net income (loss) per share, diluted</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(2.93</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.24</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">0.01</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.14</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <!-- End Table Body --></table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Net income (loss) per share includes the effects of income
 allocated to participating securities.</p>


 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the quarterly financial data in the annual financial statements.  The disclosure may include a tabular presentation of financial information for each fiscal quarter for the current and previous year, including revenues, gross profit, income or loss before extraordinary items and earnings per share data. It also includes an indication if the information in the note is unaudited, comments on the aggregate effect of year-end adjustments, and an explanation of matters or transactions that affect comparability or are pertinent to an understanding of the information furnished.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 270<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6372559&amp;loc=d3e765-108305<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 270<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6372559&amp;loc=d3e725-108305<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 270<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)-(j)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35737889&amp;loc=d3e1280-108306<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 6<br><br> -Section G<br><br> -Subsection 1<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-K (SK)<br><br> -Number 229<br><br> -Section 302<br><br> -Paragraph a<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EPWAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Income (Loss) (USD $)<br>In Thousands, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicenseAndServicesRevenue', window );">Revenue from collaborative research</a></td>
        <td class="nump"><a title="us-gaap_LicenseAndServicesRevenue" onclick="toggleNextSibling(this);">$ 47,264</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LicenseAndServicesRevenue</span><span></span></td>
        <td class="nump"><a title="us-gaap_LicenseAndServicesRevenue" onclick="toggleNextSibling(this);">$ 56,753</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LicenseAndServicesRevenue</span><span></span></td>
        <td class="nump"><a title="us-gaap_LicenseAndServicesRevenue" onclick="toggleNextSibling(this);">$ 59,646</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LicenseAndServicesRevenue</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromGrants', window );">Grant revenue</a></td>
        <td class="nump"><a title="us-gaap_RevenueFromGrants" onclick="toggleNextSibling(this);">533</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RevenueFromGrants</span><span></span></td>
        <td class="nump"><a title="us-gaap_RevenueFromGrants" onclick="toggleNextSibling(this);">1,282</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RevenueFromGrants</span><span></span></td>
        <td class="nump"><a title="us-gaap_RevenueFromGrants" onclick="toggleNextSibling(this);">4,180</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RevenueFromGrants</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
        <td class="nump"><a title="us-gaap_Revenues" onclick="toggleNextSibling(this);">47,797</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Revenues</span><span></span></td>
        <td class="nump"><a title="us-gaap_Revenues" onclick="toggleNextSibling(this);">58,035</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Revenues</span><span></span></td>
        <td class="nump"><a title="us-gaap_Revenues" onclick="toggleNextSibling(this);">63,826</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Revenues</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
        <td class="nump"><a title="us-gaap_ResearchAndDevelopmentExpense" onclick="toggleNextSibling(this);">70,186</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ResearchAndDevelopmentExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_ResearchAndDevelopmentExpense" onclick="toggleNextSibling(this);">46,582</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ResearchAndDevelopmentExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_ResearchAndDevelopmentExpense" onclick="toggleNextSibling(this);">45,433</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ResearchAndDevelopmentExpense</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
        <td class="nump"><a title="us-gaap_GeneralAndAdministrativeExpense" onclick="toggleNextSibling(this);">15,926</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_GeneralAndAdministrativeExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_GeneralAndAdministrativeExpense" onclick="toggleNextSibling(this);">11,087</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_GeneralAndAdministrativeExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_GeneralAndAdministrativeExpense" onclick="toggleNextSibling(this);">10,188</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_GeneralAndAdministrativeExpense</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total costs and expenses</a></td>
        <td class="nump"><a title="us-gaap_CostsAndExpenses" onclick="toggleNextSibling(this);">86,112</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CostsAndExpenses</span><span></span></td>
        <td class="nump"><a title="us-gaap_CostsAndExpenses" onclick="toggleNextSibling(this);">57,669</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CostsAndExpenses</span><span></span></td>
        <td class="nump"><a title="us-gaap_CostsAndExpenses" onclick="toggleNextSibling(this);">55,621</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CostsAndExpenses</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
        <td class="num"><a title="us-gaap_OperatingIncomeLoss" onclick="toggleNextSibling(this);">(38,315)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingIncomeLoss</span><span></span></td>
        <td class="nump"><a title="us-gaap_OperatingIncomeLoss" onclick="toggleNextSibling(this);">366</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingIncomeLoss</span><span></span></td>
        <td class="nump"><a title="us-gaap_OperatingIncomeLoss" onclick="toggleNextSibling(this);">8,205</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingIncomeLoss</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense)</a></td>
        <td class="nump"><a title="us-gaap_OtherNonoperatingIncomeExpense" onclick="toggleNextSibling(this);">2</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherNonoperatingIncomeExpense</span><span></span></td>
        <td class="num"><a title="us-gaap_OtherNonoperatingIncomeExpense" onclick="toggleNextSibling(this);">(627)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherNonoperatingIncomeExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_OtherNonoperatingIncomeExpense" onclick="toggleNextSibling(this);">157</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherNonoperatingIncomeExpense</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net comprehensive income (loss)</a></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (38,313)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (261)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="nump"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ 8,362</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare', window );">Basic and diluted net income (loss) per common share</a></td>
        <td class="num"><a title="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" onclick="toggleNextSibling(this);">$ (1.40)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare</span><span></span></td>
        <td class="num"><a title="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" onclick="toggleNextSibling(this);">$ (0.04)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare</span><span></span></td>
        <td class="nump"><a title="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" onclick="toggleNextSibling(this);">$ 0.00</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Basic and diluted weighted average number of common shares</a></td>
        <td class="nump"><a title="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" onclick="toggleNextSibling(this);">27,384,990</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</span><span></span></td>
        <td class="nump"><a title="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" onclick="toggleNextSibling(this);">6,847,697</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</span><span></span></td>
        <td class="nump"><a title="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" onclick="toggleNextSibling(this);">1,083,276</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total costs of sales and operating expenses for the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income (loss) from continuing operations per each basic and diluted share of common stock or unit when the per share amount is the same for both basic and diluted shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LicenseAndServicesRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revenue from multiple-deliverable arrangements that include licensing fees and services revenue. Licensing revenue is consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Services revenue may be derived by providing other, nonspecified, services during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.1(d),(e))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LicenseAndServicesRevenue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Other Comprehensive Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Net Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br><br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 9<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net result for the period of deducting operating expenses from operating revenues.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net amount of other income and expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income (expense) recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) net gains or losses on securities, (d) unusual costs, (e) gains or losses on foreign exchange transactions, and (f) miscellaneous other income and expense items.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 9<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 985<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 730<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromGrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revenue earned during the period from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in grant agreements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.1(e))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RevenueFromGrants</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_Revenues</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Income Taxes<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>6. Income Taxes</b></p>
 <!-- xbrl,body -->
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 For the years ended December&#xA0;31, 2014, 2013 and 2012 there was
 no current provision for federal or state income taxes due to the
 taxable losses which resulted or use of legacy NOL
 carryforwards.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%">
 The significant components of the Company&#x2019;s deferred income
 tax assets (liabilities) were as follows (in thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"><!-- Begin Table Head -->
 <tr>
 <td width="71%"></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Deferred income tax assets:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Federal U.S. net operating loss carryforward</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">55,358</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">36,561</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 State net operating loss carryforward</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,723</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,316</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Research and development credit, net</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7,177</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,786</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Orphan drug credit, net</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">19,287</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">19,883</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Deferred rent</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,069</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,132</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Deferred revenue</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,989</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8,217</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Depreciation</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,337</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,438</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Other</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">962</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,439</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Gross deferred income tax assets</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">95,902</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">79,772</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Valuation allowance</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(94,297</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(79,377</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Net deferred income tax assets</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,605</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">395</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Deferred income tax liabilities:</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Prepaid expenditures</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(1,605</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(395</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Gross deferred income tax liabilities</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(1,605</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(395</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Net deferred income tax asset/(liability)</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <!-- End Table Body --></table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The Company recognizes valuation allowances to reduce deferred tax
 assets to the amount that is more likely than not to be realized.
 In assessing the likelihood of realization, management considers
 (i)&#xA0;future reversals of existing taxable temporary
 differences; (ii)&#xA0;future taxable income exclusive of reversing
 temporary difference and carryforwards; (iii)&#xA0;taxable income
 in prior carryback years if carryback is permitted under applicable
 tax law; and (iv)&#xA0;tax planning strategies. The Company&#x2019;s
 net deferred income tax asset is not more likely than not to be
 utilized due to the lack of sufficient sources of future taxable
 income and cumulative book losses which have resulted over the
 years. The net increase in the valuation allowance in 2014 is due
 to the fact the Company generated research and development and
 orphan drug credits and NOL carryforwards which increased the net
 deferred tax asset. The increase in the credits and NOL
 carryforwards were offset by the decrease in deferred revenue and
 resulted in a net current year increase to the valuation
 allowance.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 As of December 31, 2014, the Company had U.S. federal NOL
 carryforwards of approximately $158.9 million and approximately
 $103.4 million for state that will expire in various years
 beginning in 2020 through 2034. In addition, the Company has U.S.
 federal tax credits of $26.3 million which will expire in various
 years beginning in 2020 through 2034.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The use of the Company&#x2019;s U.S. federal NOL and tax credit
 carryforwards in future years are restricted due to changes in the
 Company&#x2019;s ownership and tax attributes acquired through the
 Company&#x2019;s acquisitions. As of December&#xA0;31, 2014, $7.1
 million of the Company&#x2019;s US Federal NOLs are limited for use
 over the years 2015-2027 in which a range of such amounts could be
 utilized on an annual basis of $0.2 million to $1.4 million. The
 remaining $151.8 million of NOLs is not limited and can be offset
 against future taxable income. Additionally, approximately $7.7
 million of NOLs will be recognized as a benefit through
 additional-paid-in-capital when realized. Further, despite the NOL
 and credit carryforwards, the Company may have a future tax
 liability due to an alternative minimum tax or state tax
 requirements in which net operating losses do not exist.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%">
 Furthermore, the Company recorded $1.6 million of current deferred
 tax liability and $1.6 million of noncurrent deferred tax asset as
 a result of the requirement to allocate its valuation allowance
 against gross deferred tax assets. As such the balance sheet was
 grossed up but nets to zero deferred income tax
 assets/(liabilities).</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The reconciliation of the reported estimated income tax benefit to
 the amount that would result by applying the U.S. federal statutory
 tax rate to the net income is as follows (in thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"><!-- Begin Table Head -->
 <tr>
 <td width="66%"></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="10" align="center"><b>Year Ended
 December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 United States federal tax at statutory rate</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(13,410</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(91</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,927</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 State taxes (net of federal benefit)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(1,608</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">609</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,460</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Deferred income tax adjustments</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(855</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(512</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Deferred state blended rate adjustments</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,034</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(344</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Research credit, net</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(2,228</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(226</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Transaction cost deduction</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(379</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Transaction cost deduction&#x2014;prior year adjustment</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(564</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Orphan drug credit, net</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(139</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(843</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(4,896</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Other permanent items</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(382</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Equity-based compensation</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">756</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">241</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">279</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Fair value adjustment of preferred stock warrant liability</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">219</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(53</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Change in valuation allowance</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">14,920</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,287</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">787</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Income tax expense/(benefit)</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <!-- End Table Body --></table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 A reconciliation of the beginning and ending amount of gross
 unrecognized tax benefits is as follows (in thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"><!-- Begin Table Head -->
 <tr>
 <td width="70%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="10" align="center"><b>Year Ended
 December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Beginning balance</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,708</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,592</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,534</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Increases/(decreases) for current year tax positions</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">242</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">116</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">58</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Increases/(decreases) for prior year tax positions</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">97</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Decreases as a result of expiration of statute of limitations</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Ending balance</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,047</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,708</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,592</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <!-- End Table Body --></table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 As of December&#xA0;31, 2014 and 2013, of the total gross
 unrecognized tax benefits, approximately $1.7 million and $1.3
 million would favorably impact the Company&#x2019;s effective income
 tax rate, respectively. Although, due to the Company&#x2019;s
 determination that the deferred income tax asset would not more
 likely than not be realized, a valuation allowance would be
 recorded, therefore, zero net impact would result within the
 Company&#x2019;s effective income tax rate. The Company&#x2019;s
 uncertain income tax position liability has been recorded to
 deferred income taxes to offset the tax attribute carryforward
 amounts.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 For the years ended December&#xA0;31, 2014, 2013 and 2012, the
 Company has not recognized any interest or penalties related to the
 uncertain income tax positions due to the fact such position is
 related to tax attribute carryforwards which have not yet been
 utilized. The Company does not expect its unrecognized income tax
 position to significantly decrease within the next twelve
 months.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%">
 The Company&#x2019;s U.S. Federal and state income tax returns from
 2001 to 2014 remain subject to examination by the tax authorities.
 The Company&#x2019;s 2001 through 2010 years remain open for
 examination, even though the statute of limitations has expired,
 due to the net operating losses and credits carried forward for use
 in prospective years.</p>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32718-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock-based Compensation<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-based Compensation</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 <b>5. Stock-based Compensation</b></p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 The Company&#x2019;s 2000 Stock Option and Incentive Plan (2000
 Plan) allowed for the grant of awards in respect of an aggregate of
 130,725 shares, which was increased to 150,297 shares, of the
 Company&#x2019;s common stock in the form of incentive stock
 options, non-qualified stock options, stock appreciation rights,
 restricted stock and restricted stock units and other performance
 awards. As of December&#xA0;31, 2014, under the 2000 Plan, there
 were options to purchase an aggregate of 19,705 shares of common
 stock outstanding at a weighted average exercise price of $0.81 per
 share. The 2000 Plan has expired, and no further awards may be
 issued under the plan. Any shares of common stock subject to awards
 under the 2000 Plan that expire, terminate, or are otherwise
 surrendered, canceled, forfeited or repurchased without having been
 fully exercised, or resulting in any common stock being issued,
 will become available for issuance under the 2013 Stock Incentive
 Plan (2013 Plan) up to a specified number of shares.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 Effective February&#xA0;2003, the Company implemented the 2003
 Equity Incentive Plan (2003 Plan), and it was amended and approved
 by the Company&#x2019;s stockholders in 2005. The 2003 Plan
 originally allowed for the grant of awards in respect of an
 aggregate of 2,051,644 shares of the Company&#x2019;s common stock.
 Between 2006 and 2010 the maximum number of shares of common stock
 authorized to be issued by the Company under the 2003 Plan was
 increased by 1,739,116 shares to 3,790,760. During the year ended
 December&#xA0;31, 2012, the maximum number of shares of common
 stock authorized to be issued by the Company under the 2003 Plan
 was increased by 545,970 shares to 4,336,730. Stock options granted
 under the 2003 Plan may be either incentive stock options as
 defined by the Internal Revenue Code (IRC), or non-qualified stock
 options.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 As of December&#xA0;31, 2014, under the 2003 Plan, there were
 options to purchase an aggregate of 2,008,474&#xA0;shares of common
 stock outstanding at a weighted average exercise price of $1.64 per
 share. Upon the completion of the IPO, the 2003 Plan was
 terminated, and no further awards may be issued under the plan. Any
 shares of common stock subject to awards under the 2003 Plan that
 expire, terminate, or are otherwise surrendered, canceled,
 forfeited or repurchased without having been fully exercised, or
 resulting in any common stock being issued, will become available
 for issuance under the 2013 Plan, up to a specified number of
 shares.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 In October 2013, the Company implemented the 2013 Plan. The 2013
 Plan provides for the grant of stock options and other stock-based
 awards, as well as cash-based performance awards. The aggregate
 number of shares of common stock initially available for issuance
 pursuant to awards under the 2013 Plan is 1,960,168 shares. The
 number of shares of common stock reserved for issuance will
 automatically increase on January&#xA0;1 of each year from
 January&#xA0;1, 2014 through and including January&#xA0;1, 2023, by
 the lesser of (a)&#xA0;1,960,168 shares, (b)&#xA0;4.0% of the total
 number of shares of common stock outstanding on December&#xA0;31 of
 the preceding calendar year, or (c)&#xA0;the number of shares of
 common stock determined by the Board of Directors. During the year
 ended December&#xA0;31, 2014, the maximum number of shares of
 common stock authorized to be issued by the Company under the 2013
 Plan was increased to 2,967,272. If an option expires or terminates
 for any reason without having been fully exercised, if any shares
 of restricted stock are forfeited, or if any award terminates,
 expires or is settled without all or a portion of the shares of
 common stock covered by the award being issued, such shares are
 available for the grant of additional awards. However, any shares
 that are withheld (or delivered) to pay withholding taxes or to pay
 the exercise price of an option are not available for the grant of
 additional awards. As of December&#xA0;31, 2014, under the 2013
 Plan, there were options to purchase an aggregate of 1,543,937
 shares of common stock outstanding at a weighted average exercise
 price of $24.22 per share.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 The following stock-based compensation amounts were recognized for
 the periods indicated (in thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <tr>
 <td width="74%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="10" align="center"><b>Year Ended
 December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Research and development</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,562</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">507</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">472</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 General and administrative</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,682</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">355</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">366</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Total stock-based compensation expense</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">3,244</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">862</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">838</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 <i>Employee Stock Options</i></p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 The fair value of each option award is estimated on the date of
 grant using the Black-Scholes option-pricing model using the
 assumptions in the following table:</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <tr>
 <td width="58%"></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="5" align="center"><b>Year Ended December&#xA0;31,</b></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" align="center"><b>2014</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" align="center"><b>2012</b></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Expected dividend yield</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">0%</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">0%</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">0%</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Expected volatility</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">67%</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center"><font style="WHITE-SPACE: nowrap">53%&#xA0;-&#xA0;67%</font></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">51%</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Risk-free interest rate</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center"><font style="WHITE-SPACE: nowrap">1.8%&#xA0;-&#xA0;2.3%</font></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center"><font style="WHITE-SPACE: nowrap">1.2%&#xA0;-&#xA0;2.2%</font></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">1.2%</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Expected term.</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">6.25 years</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">7 years</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">7&#xA0;years</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 <b>Expected Dividend Yield</b>&#x2014;The Company has never declared
 or paid dividends and has no plans to do so in the foreseeable
 future.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 <b>Expected Volatility</b>&#x2014;Volatility is a measure of the
 amount by which a financial variable such as a share price has
 fluctuated (historical volatility) or is expected to fluctuate
 (expected volatility) during a period. As the Company does not yet
 have sufficient history of its own volatility, the Company has
 identified several public entities of similar size, complexity and
 stage of development and estimates volatility based on the
 volatility of these companies.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 <b>Risk-Free Interest Rate</b>&#x2014;This is the U.S. Treasury rate
 for the week of each option grant during the year, having a term
 that most closely resembles the expected life of the option.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 <b>Expected Term</b>&#x2014;This is the period of time that the
 options granted are expected to remain unexercised. Options granted
 have a maximum term of ten years. The Company estimates the
 expected life of the option term to be 6.25 years. The Company uses
 a simplified method to calculate the average expected term.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 In addition to the assumptions above, the Company estimates the
 forfeiture rate based on turnover data with further consideration
 given to the class of the employees to whom the options were
 granted. The forfeiture rate is the estimated percentage of options
 granted that is expected to be forfeited or canceled on an annual
 basis before becoming fully vested.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 The following table summarizes stock option and restricted stock
 unit (RSU) activity for 2014:</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0">
 <tr>
 <td width="43%"></td>
 <td valign="bottom" width="9%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="9%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="9%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Shares</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Weighted-<br />
 Average</b><br />
 <b>Exercise&#xA0;Price</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b><font style="WHITE-SPACE: nowrap">Weighted-Average</font></b><br />
 <b>Remaining</b><br />
 <b>Contractual Term</b><br />
 <b>(Years)</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Aggregate<br />
 Intrinsic<br />
 Value</b><br />
 <b>(in&#xA0;thousands)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Outstanding, December&#xA0;31, 2013</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,200,958</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">4.90</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6.9</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Granted</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">976,869</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">27.06</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Exercised</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(568,906</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1.31</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Forfeited or expired</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(36,805</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">9.76</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Outstanding, December&#xA0;31, 2014</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,572,116</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">11.40</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7.3</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">84,515</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 December&#xA0;31, 2014:</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Exercisable</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,668,962</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3.24</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5.3</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">53,122</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Vested and expected to vest</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,341,192</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">11.03</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7.2</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">80,323</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 During 2014, 2013 and 2012 the Company issued 568,906, 1,268,049
 and 863,176 net shares of common stock, respectively, in
 conjunction with stock option exercises and RSU lapses. The Company
 received cash proceeds from the exercise of stock options of
 approximately $0.7 million, $1.1 million and $47,000 during 2014,
 2013 and 2012, respectively.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 The weighted-average grant-date fair value of options granted
 during 2014, 2013 and 2012 was $17.41,&#xA0;$6.91 and $0.94 per
 share, respectively. The total intrinsic value of options exercised
 during 2014, 2013 and 2012 was approximately $14.5 million, $5.4
 million and $271,929, respectively. The total fair value of stock
 options which vested during 2014, 2013 and 2012 was $3.0 million,
 $487,603 and $879,024, respectively. As of December&#xA0;31, 2014,
 the total unrecognized compensation expense related to non-vested
 stock options and RSUs, net of related forfeiture estimates, was
 $19.6 million, which the Company expects to recognize over a
 weighted-average period of approximately four years.</p>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 50<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6406099&amp;loc=d3e25284-112666<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 40<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6418621&amp;loc=d3e17540-113929<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5444-113901<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EKH">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock-based Compensation (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-Based Compensation Expense</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The following stock-based compensation amounts were recognized for
 the periods indicated (in thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <tr>
 <td width="74%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"><b>Year Ended
 December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Research and development</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,562</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">507</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">472</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 General and administrative</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,682</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">355</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">366</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Total stock-based compensation expense</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">3,244</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">862</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">838</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 The fair value of each option award is estimated on the date of
 grant using the Black-Scholes option-pricing model using the
 assumptions in the following table:</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <tr>
 <td width="58%"></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="5" align="center"><b>Year Ended December&#xA0;31,</b></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" align="center"><b>2014</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" align="center"><b>2012</b></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Expected dividend yield</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">0%</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">0%</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">0%</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Expected volatility</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">67%</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center"><font style="WHITE-SPACE: nowrap">53%&#xA0;-&#xA0;67%</font></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">51%</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Risk-free interest rate</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center"><font style="WHITE-SPACE: nowrap">1.8%&#xA0;-&#xA0;2.3%</font></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center"><font style="WHITE-SPACE: nowrap">1.2%&#xA0;-&#xA0;2.2%</font></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">1.2%</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Expected term.</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">6.25 years</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">7 years</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">7&#xA0;years</td>
 </tr>
 </table>


 </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of Stock Option and Restricted Stock Unit Activity</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The following table summarizes stock option and restricted stock
 unit (RSU) activity for 2014:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0">
 <tr>
 <td width="43%"></td>
 <td valign="bottom" width="9%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="9%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="9%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Shares</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Weighted-<br />
 Average</b><br />
 <b>Exercise&#xA0;Price</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b><font style="WHITE-SPACE: nowrap">Weighted-Average</font></b><br />
 <b>Remaining</b><br />
 <b>Contractual Term</b><br />
 <b>(Years)</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Aggregate<br />
 Intrinsic<br />
 Value</b><br />
 <b>(in&#xA0;thousands)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Outstanding, December&#xA0;31, 2013</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,200,958</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">4.90</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6.9</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Granted</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">976,869</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">27.06</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Exercised</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(568,906</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1.31</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Forfeited or expired</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(36,805</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">9.76</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Outstanding, December&#xA0;31, 2014</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,572,116</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">11.40</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7.3</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">84,515</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 December&#xA0;31, 2014:</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Exercisable</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,668,962</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3.24</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5.3</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">53,122</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Vested and expected to vest</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,341,192</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">11.03</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7.2</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">80,323</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Schedule Of Share Based Compensation Stock Options And Restricted Stock Units Activity Table [Text Block]</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.F)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section F<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (h)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Subsequent Event<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Event</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 <b>13. Subsequent Event</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 In January 2015, the Federal Trade Commission granted early
 termination of the waiting period under the Hart-Scott-Rodino
 Antitrust Improvements Act of 1976 with respect to the
 collaboration and license agreement with Janssen and the stock
 purchase agreement and investor agreement with JJDC (as described
 in Note 8). Accordingly, the Company issued 1,923,077 shares of
 common stock to JJDC and received $75.0 million from JJDC under the
 stock purchase agreement and received the $50.0 million upfront
 payment from Janssen under the collaboration and license
 agreement.</p>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 <b>9. Commitments and Contingencies</b></p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 <b><i>Operating Leases</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 The Company leases office and laboratory space for its headquarters
 in Rockville, Maryland.&#xA0;In 2014, that lease was amended to
 extend its term from March 31, 2018 to January 31, 2020.&#xA0;In
 addition, in 2014, the Company leased additional office space
 adjacent to its headquarters, also through January 31,
 2020.&#xA0;The Company has an option under each lease to continue
 the respective lease for five years under the same terms.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 The Company leases a manufacturing facility in Rockville under a
 lease that originally expired on December&#xA0;31, 2014. During
 2014, the Company exercised its 5-year renewal option on the
 manufacturing facility. The Company also entered into a new
 four-year lease for additional space in the manufacturing facility
 effective April&#xA0;1, 2014. This lease also has an option to
 continue the lease for five years under the same terms.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 The Company also leases office and laboratory space in South San
 Francisco under a lease that expires on February&#xA0;28, 2018.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 All of the leases contain rent escalation clauses and certain
 leases contain rent abatements. For financial reporting purposes,
 rent expense is charged to operations on a straight-line basis over
 the term of the lease. As of December&#xA0;31, 2014 and 2013, the
 Company had recorded a deferred rent liability of $2.7 million and
 $2.9&#xA0;million, respectively. Rent expense for the years ended
 December&#xA0;31, 2014, 2013 and 2012 was $2.0&#xA0;million, $2.7
 million and $2.7 million, respectively.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 Future minimum lease payments under noncancelable operating leases
 as of December&#xA0;31, 2014 are as follows (in thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="68%" align="center" border="0">
 <tr>
 <td width="84%"></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 2015</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">3,945</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 2016</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,364</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 2017</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,495</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 2018</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,396</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 2019</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,873</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Thereafter</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">116</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF">
 <td valign="top"></td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">19,189</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 18pt 'Times New Roman'; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 <b><i>Contingencies</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 From time to time, the Company may be subject to various litigation
 and related matters arising in the ordinary course of business. The
 Company does not believe it is currently subject to any material
 matters where there is at least a reasonable possibility that a
 material loss may be incurred.</p>


 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for commitments and contingencies.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.25)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 460<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6398077&amp;loc=d3e12565-110249<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 450<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 440<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394976&amp;loc=d3e25287-109308<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EXNAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Employee Benefit Plan - Additional Information (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 25, 2002</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract', window );"><strong>Defined Contribution Pension and Other Postretirement Plans Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan', window );">Eligibility of employee participation Plan</a></td>
        <td class="text">21 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Percentage of employee contribution to salary</a></td>
        <td class="nump"><a title="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" onclick="toggleNextSibling(this);">100.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_DefinedContributionPlanEmployeesContributionAnnualVestingPercentage', window );">Percentage of employee vested contribution</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="mgnx_DefinedContributionPlanEmployeesContributionAnnualVestingPercentage" onclick="toggleNextSibling(this);">100.00%</a><span style="display:none;white-space:normal;text-align:left;">mgnx_DefinedContributionPlanEmployeesContributionAnnualVestingPercentage</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Defined contribution plan, employer discretionary contribution amount</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" onclick="toggleNextSibling(this);">$ 318,390</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</span><span></span></td>
        <td class="nump"><a title="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" onclick="toggleNextSibling(this);">$ 252,930</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</span><span></span></td>
        <td class="nump"><a title="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" onclick="toggleNextSibling(this);">$ 225,195</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_DefinedContributionPlanEmployeesContributionAnnualVestingPercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Defined contribution plan, employees contribution, annual vesting percentage.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_DefinedContributionPlanEmployeesContributionAnnualVestingPercentage</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Employees eligible age to participate in benefit plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Lease Exit Liability<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Lease Exit Liability</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>7. Lease Exit Liability</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 On July&#xA0;16, 2008, the Company acquired Raven Biotechnologies,
 Inc. (Raven), a private South San Francisco-based company focused
 on the development of monoclonal antibody therapeutics for treating
 cancer. Raven was considered a development-stage enterprise as
 defined in ASC&#xA0;915, <i>Development Stage Entities</i>. In
 connection with the acquisition, the Company issued 12,466,039
 shares of its Series D convertible preferred stock in exchange for
 all of the outstanding capital stock and convertible notes payable
 of Raven.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The Company undertook restructuring activities related to the
 acquisition of Raven. These restructuring activities included
 reductions in staffing levels and the intended exit of leased
 facilities. All severance-related payments were completed in the
 year ended December&#xA0;31, 2009.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 In connection with these restructuring activities, as part of the
 cost of acquisition, the Company established a restructuring
 liability attributed to an existing operating lease. The terms of
 the operating lease extend through 2018.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Changes in the lease exit liability are as follows (in
 thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0">
 <tr>
 <td width="84%"></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Accrual balance at December&#xA0;31, 2012.</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">&#xA0;10,074</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Principal payments</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(629</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Accrual balance at December&#xA0;31, 2013</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">9,445</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Principal payments</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(1,439</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Accrual balance at December&#xA0;31, 2014</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">8,006</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Future principal payments to be made under the lease agreement as
 of December&#xA0;31, 2014 are as follows (in thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0">
 <tr>
 <td width="86%"></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 2015</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,642</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 2016</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,866</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 2017</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,113</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 2018</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,385</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top"></td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">8,006</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The purchase agreement provides for a specified total of certain
 contingent milestones that are based on the achievement of certain
 product sales derived from the acquired Raven technology. Also, a
 onetime payment of $5.0 million will be made to the Raven
 stockholders upon the initiation of patient dosing in the first
 Phase 2 clinical trial of any product derived from the Raven
 &#x201C;Cancer Stem Cell Program.&#x201D; No payment shall be made if
 the Phase 2 trial start date has not occurred on or before
 July&#xA0;15, 2018. Other consideration includes a percentage of
 revenue (excluding consideration for research and development and
 equity) received by the Company for license of a product derived
 from the Raven &#x201C;Cancer Stem Cell Program&#x201D; and a onetime
 payment ranging from $8.0 million to $12.0 million dependent upon a
 specified level of sales of products derived from the Raven
 &#x201C;Cancer Stem Cell Program.&#x201D;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%">
 The contingent consideration will be accounted for as additional
 purchase price and recorded as incremental in-process research and
 development expense when it is deemed probable that the
 contingencies will be attained. No additional amounts have been
 recorded during the years ended December&#xA0;31, 2014, 2013 and
 2012.</p>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 420<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 5.P.3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140864-122747<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 5<br><br> -Section P<br><br> -Subsection 3, 4<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 420<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 420<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 5.P.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Collaboration and License Agreements<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock', window );">Collaboration and License Agreements</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>8. Collaboration and License Agreements</b></p>
 <!-- xbrl,body -->
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 <b><i>Janssen Biotech, Inc.</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 In December 2014, the Company entered into a collaboration and
 license agreement with Janssen Biotech, Inc. (Janssen) for the
 development and commercialization of MGD011, a product candidate
 that incorporates the Company&#x2019;s proprietary DART technology
 to simultaneously target CD19 and CD3 for the potential treatment
 of B-cell malignancies. The Company contemporaneously entered into
 a stock purchase agreement and investor agreement, each with
 Johnson&#xA0;&amp; Johnson Innovation&#x2014;JJDC, Inc. (JJDC), an
 affiliate of Janssen, under which JJDC agreed to purchase 1,923,077
 new shares of the Company&#x2019;s common stock at a price of $39.00
 per share, representing proceeds of $75.0 million. The
 effectiveness of these agreements was subject to the early
 termination or expiration of any applicable waiting periods under
 Hart-Scott-Rodino Antitrust Improvements Act of 1976, which
 occurred in January 2015 (see Note 13). The Company is eligible to
 receive a $50.0 million upfront payment from Janssen after the
 collaboration and license agreement becomes effective. Janssen will
 be fully responsible for developing MGD011 following submission of
 the Investigational New Drug Application (IND), which is planned
 for 2015. Assuming successful development and commercialization,
 the Company could receive up to an additional $575.0 million in
 clinical, regulatory and commercialization milestone payments. The
 Company may elect to fund a portion of late-stage clinical
 development in exchange for a profit share in the U.S. and Canada.
 If commercialized, the Company would be eligible to receive
 double-digit royalties on any global net sales and has the option
 to co-promote the molecule with Janssen in the U.S.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 No revenue was recognized during the year ended December&#xA0;31,
 2014 under this agreement, and no related deferred revenue was
 recorded as of December&#xA0;31, 2014.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Takeda</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 In May 2014, the Company entered into a license and option
 agreement with Takeda for the development and commercialization of
 MGD010, a product candidate that incorporates the Company&#x2019;s
 proprietary DART technology to simultaneously engage CD32B and
 CD79B, which are two B-cell surface proteins. MGD010 is currently
 in pre-clinical development for the treatment of autoimmune
 diseases. Upon execution of the agreement, Takeda made a
 non-refundable payment of $15.0 million to the Company. Takeda has
 an option to obtain an exclusive worldwide license for MGD010
 following the completion of a pre-defined Phase 1a study. The
 Company will lead all product development activities until that
 time. If Takeda exercises its option, it will assume responsibility
 for future development and pay the Company a license option fee
 that, along with an early development milestone, will total $18.0
 million. Assuming successful development and commercialization of
 MGD010, the Company is eligible to receive up to an additional
 $468.5 million in development, regulatory and sales milestone
 payments. If commercialized, the Company would receive double-digit
 royalties on any global net sales and has the option to co-promote
 MGD010 with Takeda in the United States. Finally, the Company may
 elect to fund a portion of Phase 3 clinical development in exchange
 for a North American profit share.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The Company evaluated the license and option agreement with Takeda
 and has determined that it is a revenue arrangement with multiple
 deliverables, or performance obligations. The Company&#x2019;s
 substantive performance obligations under the license and option
 agreement include exclusivity, research and development services
 through the Phase 1a study and delivery of a future license for an
 initial research compound. The Company concluded that the MGD010
 option is substantive and that the license fee payable upon
 exercise of the option is not a deliverable at the inception of the
 arrangement as there is considerable uncertainty that the option
 would be exercised. The Company has determined that each potential
 future development and regulatory milestone is substantive.
 Although sales milestones are not considered substantive, they are
 still recognized upon achievement of the milestone (assuming all
 other revenue recognition criteria have been met) because there are
 no undelivered elements that would preclude revenue recognition at
 that time. The Company determined that these performance
 obligations represent a single unit of accounting, because the
 exclusivity clause does not have stand-alone value to Takeda
 without the Company&#x2019;s technical expertise and development
 through the pre-defined Phase 1a study.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 After identifying the deliverables included within the arrangement,
 the Company determined its best estimate of selling price. The
 Company allocated $10.0 million to the exclusivity clause to its
 technology and the research and development services and $5.0
 million to the exclusive license for the initial research compound.
 The Company&#x2019;s determination of best estimate of selling price
 for the research and development services relied upon other similar
 transactions. The Company relied upon the income approach (e.g.,
 future cash flows) to determine the value of the license of the
 to-be-delivered compound along with other similar license
 transactions with differing indications but similar stage of
 development. The portion of the up-front fee allocated to the
 MGD010 option is being recognized over an initial 24-month period,
 which represents the expected period of development through the
 completion of a pre-defined Phase 1a study. The portion of the
 up-front fee allocated to the license for the initial research
 compound was deferred until the research collaboration and license
 option agreement was executed and the license delivered.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The Company recognized revenue of approximately $3.0 million under
 the MGD010 agreement during the year ended December&#xA0;31, 2014.
 At December&#xA0;31, 2014, $7.1 million of revenue was deferred
 under this agreement, $5.0 million of which was current and $2.1
 million of which was non-current.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 In September 2014, the Company and Takeda executed a research
 collaboration and license option agreement, which formalized the
 license for the initial research compound. Under the terms of the
 agreement, Takeda may identify up to three additional compounds,
 which will be subject to separate research and development plans.
 The Company determined that it could recognize the entire license
 fee as (1)&#xA0;the executed contract constituted persuasive
 evidence of an arrangement, (2)&#xA0;the delivery of the license
 occurred and the Company had no current or future performance
 obligations, (3)&#xA0;the total consideration for the license was
 fixed and known at the time of its execution and there were not any
 extended payment terms or rights of return, and (4)&#xA0;the cash
 was received. Therefore, the Company recognized $5.0 million in
 revenue during the year ended December&#xA0;31, 2014 under this
 agreement. The Company is also entitled to receive reimbursements
 for research and development services provided to Takeda with
 respect to the initial research compound, subject to the execution
 of a separate research plan.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Gilead</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 In January 2013, the Company entered into an agreement with Gilead
 for Gilead to obtain exclusive worldwide rights for the research,
 development and commercialization of up to four DART molecules. For
 each molecule Gilead chooses to develop, the Company is entitled to
 receive a license grant fee of $7.5 million and is further eligible
 to receive up to an additional $20.0 million to $25.0 million in
 pre-clinical milestones and up to $240.0 million to $250.0 million
 in additional clinical, regulatory and sales milestones. Upon
 execution of the arrangement, Gilead identified one molecule to
 develop for which the Company granted Gilead a license in exchange
 for consideration of $7.5 million.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The Company determined that any remaining licenses are conditional
 deliverables, which are substantive options that were not granted
 with a substantial discount. The Company has determined that each
 potential future clinical, development and regulatory milestone is
 substantive. Although sales milestones are not considered
 substantive, they are still recognized upon achievement of the
 milestone (assuming all other revenue recognition criteria have
 been met) because there are no undelivered elements that would
 preclude revenue recognition at that time. Gilead also provides
 funding for the Company&#x2019;s internal and external research
 costs under the agreement. Additionally, Gilead would be obligated
 to pay the Company high single digit to low double digit royalties
 on product sales.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The Company evaluated the research collaboration agreement with
 Gilead and has determined that it is a revenue arrangement with
 multiple deliverables, or performance obligations. The
 Company&#x2019;s substantive performance obligations under this
 research collaboration include a license to its technology and
 research and development services. The Company concluded that the
 deliverables do not have stand alone value and therefore, represent
 a combined single unit of accounting. Due to the lack of standalone
 value for the license and research and development services, the
 combined unit of accounting (the upfront payment and the expected
 research and development reimbursements) was recognized ratably
 over a period of 21 months, which represented the expected
 development period.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The Company and Gilead have also agreed to establish a joint
 research committee to facilitate the governance and oversight of
 the parties&#x2019; activities under the agreements. Management
 considered whether participation on the joint committee may be a
 deliverable and determined that it was not a deliverable. Had
 management considered participation on the joint committee as a
 deliverable, it would not have had a material impact on the
 accounting for the arrangement.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The Company recognized revenues of approximately $5.5 million and
 $8.0 million under this agreement for the years ended
 December&#xA0;31, 2014 and 2013, respectively. No milestones have
 been achieved under this agreement.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 At December&#xA0;31, 2013, $3.6 million of revenue was deferred
 under this agreement, all of which was current. As of
 December&#xA0;31, 2014, there was no remaining deferred revenue
 under this agreement.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Servier</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 In November 2011, the Company entered into a right-to-develop
 collaboration agreement with Servier for the development and
 commercialization of MGA271 in all countries other than the United
 States, Canada, Mexico, Japan, South Korea and India.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Upon execution of the agreement, Servier made a nonrefundable
 payment of $20.0 million to the Company. The Company is eligible to
 receive up to $30.0 million in license grant fees, $47.0 million in
 clinical milestone payments, $140.0 million in regulatory milestone
 payments and $208.0 million in sales milestone payments if Servier
 exercises the option, obtains regulatory approval for and
 successfully commercializes MGA271. The Company concluded that the
 license option fees are not deliverables at the inception of the
 arrangement. The Company has determined that each potential future
 clinical, development and regulatory milestone is substantive.
 Although sales milestones are not considered substantive, they are
 still recognized upon achievement of the milestone (assuming all
 other revenue recognition criteria have been met) because there are
 no undelivered elements that would preclude revenue recognition at
 that time. In the event Servier exercises its option to continue
 development of MGA271, Servier must pay a license option fee. Under
 this agreement, Servier would be obligated to pay the Company from
 low double digit to mid-teen royalties on product sales in its
 territories.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The Company evaluated the research collaboration agreement with
 Servier and has determined that it is a revenue arrangement with
 multiple deliverables, or performance obligations. The Company
 concluded that the option is substantive and that the license fees
 for this option is not a deliverable at the inception of the
 arrangement as there is considerable uncertainty that the option
 would be exercised and the additional fee to be paid upon exercise
 of the option represents its estimated selling price (i.e. no
 substantial discount was given). The Company&#x2019;s substantive
 performance obligations under this research collaboration include
 an exclusivity clause to its technology, technical, scientific and
 intellectual property support to the research plan and
 participation on an executive committee and a research and
 development committee. The Company determined that these
 performance obligations represent a single unit of accounting,
 since the license does not have stand-alone value to Servier
 without the Company&#x2019;s technical expertise and committee
 participation. As such, the initial upfront payment was deferred
 and was being recognized ratably over the initial 27-month period,
 which represented the expected period of development and the
 Company&#x2019;s participation on the research and development
 committee. During 2014, the Company determined that the development
 period will last longer than originally estimated, and
 prospectively adjusted its period of recognition of the upfront
 payment to a 42-month period.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 During the years ended December&#xA0;31, 2014, 2013 and 2012 the
 Company recognized revenue of $0.7&#xA0;million, $21.3 million and
 $9.1 million, respectively, under this agreement. Revenue
 recognized in the year ended December&#xA0;31, 2013 included a
 $10.0 million substantive milestone payment received upon dosing
 the first patient in a Phase 1 dose expansion cohort trial of
 MGA271.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 At December&#xA0;31, 2014 and 2013, $0.1 million and $0.9 million
 of revenue remained deferred under this agreement, respectively,
 all of which was current.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 In September 2012, the Company entered into a second
 right-to-develop collaboration agreement with Servier and granted
 it options to obtain three separate exclusive licenses to develop
 and commercialize DART-based molecules, consisting of those
 designated by the Company as MGD006 and MGD007, as well as a third
 DART molecule, in all countries other than the United States,
 Canada, Mexico, Japan, South Korea and India.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Upon execution of the agreement, Servier made a nonrefundable
 payment of $20.0 million to the Company. In addition, the Company
 will be eligible to receive up to $65.0 million in license grant
 fees, $98.0 million in clinical milestone payments, including $5.0
 million upon IND acceptance for each of MGD006, MGD007 and a third
 DART molecule, $300.0 million in regulatory milestone payments and
 $630.0 million in sales milestone payments if Servier exercises all
 of the options and successfully develops, obtains regulatory
 approval for, and commercializes a product under each license. In
 addition to these milestones, the Company and Servier will share
 Phase 2 and Phase 3 development costs. The Company has determined
 that each potential future clinical, development and regulatory
 milestone is substantive. Although sales milestones are not
 considered substantive, they are still recognized upon achievement
 of the milestone (assuming all other revenue recognition criteria
 have been met) because there are no undelivered elements that would
 preclude revenue recognition at that time. Under this agreement,
 Servier would be obligated to pay the Company between high-single
 digit and mid-teen royalties on net product sales in its
 territories.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The Company evaluated the research collaboration agreement with
 Servier and has determined that it is a revenue arrangement with
 multiple deliverables, or performance obligations. The Company
 concluded that each option is substantive and that the license fees
 for each option are not deliverables at the inception of the
 arrangement and were not issued with a substantial discount. The
 Company&#x2019;s substantive performance obligations under this
 research collaboration include an exclusivity clause to its
 technology, technical, scientific and intellectual property support
 to the research plan during the first year of the agreement and
 participation on an executive committee and a research and
 development committee. The Company determined that the performance
 obligations with respect to the pre-clinical development represent
 a single unit of accounting, since the license does not have
 stand-alone value to Servier without the Company&#x2019;s technical
 expertise and committee participation. As such, the initial upfront
 license payment was deferred and initially recognized ratably over
 a <font style="WHITE-SPACE: nowrap">29-month</font> period, which
 represented the expected development period. During 2014, the
 Company and Servier further refined the research plan related to
 the three DARTs and as such, the development period was extended.
 Based on this revised development period, the Company prospectively
 adjusted its period of recognition of the upfront payment to a
 75-month period. The impact of this change in accounting estimate
 reduced revenue that would have been recognized in 2014 by $3.7
 million.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 During the year ended December&#xA0;31, 2014, Servier exercised its
 exclusive option to develop and commercialize MGD006. As a result
 of the exercise, the Company received a $15.0 million payment from
 Servier for its license to develop and commercialize MGD006 in its
 territories. Upon exercise of the option, the Company evaluated its
 performance obligations with respect to the license for MGD006. The
 Company&#x2019;s substantive performance obligations under this
 research collaboration include an exclusive license to its
 technology, technical, scientific and intellectual property support
 to the research plan and participation on an executive committee
 and a research and development committee. The Company determined
 that the performance obligations with respect to the clinical
 development represent a single unit of accounting, since the
 license does not have stand-alone value to Servier without the
 Company&#x2019;s technical expertise and committee participation. As
 such, the $15.0 million license fee was deferred and is being
 recognized ratably over a period of 82 months, which represents the
 expected development period for MGD006. In accordance with the
 agreement, the Company and Servier will share costs incurred to
 develop MGD006. Reimbursement of research and development expenses
 received in connection with this collaborative cost-sharing
 agreement is recorded as a reduction to research and development
 expense. During the year ended December&#xA0;31, 2014 the Company
 recorded approximately $1.0 million as an offset to research and
 development costs under this collaboration arrangement. No such
 offset was recorded in 2013 or 2012. As of December&#xA0;31, 2014
 the Company has a corresponding collaboration receivable, which is
 included in accounts receivable on the consolidated balance sheet,
 of $0.8 million.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 During the years ended December&#xA0;31, 2014, 2013 and 2012 the
 Company recognized revenue of $16.7&#xA0;million, $8.6 million, and
 $2.0 million, respectively, under this agreement. Revenue during
 the year ended December&#xA0;31, 2014 includes two $5.0 million
 milestone payments from Servier upon the achievement of clinical
 milestones related to the IND applications for MGD006 and MGD007
 clearing the 30-day review period by the U.S. FDA. No milestones
 were recognized under this agreement during the years ended
 December&#xA0;31, 2013 or 2012.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 At December&#xA0;31, 2014, $17.7 million of revenue was deferred
 under this agreement, $3.3 million of which was current and $14.4
 million of which was long-term. At December&#xA0;31, 2013, $9.4
 million of revenue was deferred under this agreement, $8.6 million
 of which was current and $0.8 million of which was long-term.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Boehringer</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 In October 2010 the Company entered into a collaboration and
 license agreement with Boehringer to discover, develop and
 commercialize up to ten DART-based molecules which span multiple
 therapeutic areas. Under the terms of the agreement, the Company
 granted Boehringer an exclusive, worldwide, royalty-bearing,
 license under its intellectual property to research, develop, and
 market DARTs generated under the agreement throughout the
 world.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Upon execution of the agreement, the Company received an upfront
 payment of $15.0 million. The Company subsequently received three
 annual maintenance payments. These maintenance payments are being
 recognized over the estimated period of development. The Company
 has the potential to earn milestone payments of approximately $41.0
 million related to pre-clinical and clinical development, $89.0
 million related to regulatory milestones and $83.0 million related
 to sales milestones for each of the DART programs under this
 agreement in the case of full commercial success of multiple DART
 products. The Company has determined that each potential future
 clinical, development and regulatory milestone is substantive.
 Although sales milestones are not considered substantive, they are
 still recognized upon achievement of the milestone (assuming all
 other revenue recognition criteria have been met) because there are
 no undelivered elements that would preclude revenue recognition at
 that time. Boehringer also provides funding for the Company&#x2019;s
 internal and external research costs and is required to pay the
 Company mid-single digit royalties on product sales.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The Company determined that the deliverables under the Boehringer
 agreement include the license, the research and development
 services to be performed by the Company, and the
 co-promotion/manufacturing services. The Company concluded that the
 co-promotional activities were optional and were subject to further
 negotiation upon reaching regulatory approval. As such, the
 co-promotional period is not included in the expected obligation
 period to perform services.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The Company concluded that the undelivered element of research and
 development services had fair value. The Company concluded that the
 license does not have value on a standalone basis (e.g. absent the
 provision of the research and development services) and therefore
 does not represent a separate unit of accounting. The Company
 concluded that because the drug candidate has not yet been
 developed, the license is of no value to Boehringer without the
 ensuing research and development activities using the DART
 technology, which is proprietary to the Company. Likewise,
 Boehringer could not sell the license to another party (without the
 Company agreeing to provide the research and development activities
 for the other party). Therefore, the upfront license fee and
 research and development services were treated as a combined unit
 of accounting and recognized over the expected obligation period
 associated with the research and development services through
 September 2015, which represents the estimated period of
 development.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The Company and Boehringer have also agreed to establish a joint
 research committee to facilitate the governance and oversight of
 the parties&#x2019; activities under the agreements. Management
 considered whether participation on the joint committee may be a
 deliverable and determined that it was not a deliverable. However,
 had management considered participation on the joint committee as a
 deliverable, it would not have had a material impact on the
 accounting for the arrangement as the period of participation in
 this committee matched the obligation period for the research and
 development services.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The Company recognized revenues of approximately $13.7 million,
 $14.4 million and $11.7 million during the years ended
 December&#xA0;31, 2014, 2013 and 2012, respectively, under this
 agreement. Revenue recognized in the years ended December&#xA0;31,
 2014, 2013 and 2012 included milestone payments of $2.0 million,
 $5.0 million and $2.0 million, respectively, for the achievement of
 clinical milestones. At December&#xA0;31, 2014, $5.8 million of
 revenue was deferred under this agreement, all of which was
 current. At December&#xA0;31, 2013, $12.8 million of revenue was
 deferred under this agreement, $7.0 million of which was current
 and $5.8 million of which was long-term.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Pfizer</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 In October 2010, the Company entered into a three year agreement
 with Pfizer to discover, develop and commercialize up to two
 DART-based molecules. The Company granted Pfizer a non-exclusive
 worldwide, royalty-bearing license and received an upfront payment
 of $5.0 million and has received milestone payments and funding for
 the Company&#x2019;s internal and external research costs under the
 agreement.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The Company is eligible to receive milestone payments of
 approximately $17.0 million related to pre-clinical and clinical
 development and $195.0 million related to commercialization and
 sales milestones for each DART program under this agreement. The
 Company has determined that each potential future technical and
 development milestone is substantive. Although sales milestones are
 not considered substantive, they are still recognized upon
 achievement of the milestone (assuming all other revenue
 recognition criteria have been met) because there are no
 undelivered elements that would preclude revenue recognition at
 that time. Pfizer is responsible for all pre-clinical and clinical
 development costs for the program. In addition, Pfizer is required
 to pay the Company mid-single digit to low-teen royalties on
 product sales. Under this collaboration, one DART program is
 currently being pursued and the Company completed its research
 obligations under this program in January 2014.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The Company has evaluated the research collaboration agreement with
 Pfizer and has determined that it is a revenue arrangement with
 multiple deliverables, or performance obligations. The
 Company&#x2019;s substantive performance obligations under this
 research collaboration include an exclusive license to its
 technology, research and development services and manufacturing
 services. The Company concluded that the manufacturing services
 were optional and were subject to further negotiation upon reaching
 regulatory approval. As such, the manufacturing services are not
 included in the expected obligation period to perform services.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The Company determined that it had fair value of the undelivered
 element of the research and development services. However, the
 Company concluded that the license does not have value on a
 standalone basis (e.g. absent the provision of the research and
 development services) and therefore does not represent a separate
 unit of accounting. Facts that were considered included the
 development of the candidate noting that because the drug candidate
 has not yet been developed, the license is of no value to Pfizer
 without the ensuing research and development activities using the
 DART technology, which is proprietary to the Company. Likewise,
 Pfizer could not sell the license to another party (without the
 Company agreeing to provide the research and development activities
 for the other party). Therefore, the upfront license fee and
 research and development services were treated as a combined unit
 of accounting and recognized over the expected obligation period
 associated with the research and development services through
 January 2014, which represents the estimated period of
 development.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The $5.0 million upfront payment received by the Company is
 non-refundable; therefore, there is no right of return for the
 license. The Company recognized revenue associated with this
 non-refundable up-front license fee through the expected obligation
 period associated with the research and development services, which
 ended in January 2014.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The Company and Pfizer have also agreed to establish a joint
 research committee to facilitate the governance and oversight of
 the parties&#x2019; activities under the agreements. Management
 considered whether participation on the joint committee may be a
 deliverable and determined that it was not a deliverable because it
 is a participating right and not an obligation of the Company.
 However, had management considered participation on the joint
 committee as a deliverable, it would not have had a material impact
 on the accounting for the arrangement.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The Company recognized revenues of approximately $0.1 million, $3.5
 million and $5.5 million during the years ended December&#xA0;31,
 2014, 2013 and 2012, respectively. Included in the 2012 revenues
 are milestone payments totaling $0.5 million. No additional
 milestones have been achieved under this agreement through
 December&#xA0;31, 2014.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 At December&#xA0;31, 2013, deferred revenue under this agreement
 was approximately $7,000. As of December&#xA0;31, 2014, there was
 no remaining deferred revenue under this agreement.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Green Cross</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 In June&#xA0;2010, the Company entered into a collaboration
 agreement with Green Cross for the development of the
 Company&#x2019;s anti-HER2 antibody margetuximab. This arrangement
 grants Green Cross an exclusive license to conduct specified Phase
 1 and Phase 2 clinical trials and commercialize margetuximab in
 South Korea. In March 2014, the Company and Green Cross entered
 into an amendment to the original agreement, causing the terms of
 the original agreement to be materially modified.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Upon execution of the amendment, the Company became eligible to
 receive reimbursement for costs incurred for Phase 2 and Phase 3
 clinical trials up to $5.5 million as well as clinical development
 and commercial milestone payments of up to $2.5 million. The
 Company has determined that each potential clinical development and
 commercial milestone is substantive. The Company is also entitled
 to receive royalties on net sales of margetuximab in South Korea.
 The Company and Green Cross have formed a joint steering committee
 to coordinate and oversee activities on which the companies
 collaborate under the agreement.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The Company has evaluated the collaboration agreement with Green
 Cross and has determined that it is a revenue arrangement with
 multiple deliverables or performance obligations. As a result of
 the material modification to the arrangement in March 2014, the
 Company reassessed the entire arrangement in accordance with the
 guidance provided by ASC 605-25, <i>Multiple Element Arrangements
 (Revenue Recognition)</i> as the original agreement was accounted
 for prior to adopting ASU 2009-13<i>.</i> The Company&#x2019;s
 substantive performance obligations under this agreement include an
 exclusive license to its technologies, research and development
 services, and participation in a joint steering committee. The
 Company concluded that the license and the reimbursements for
 research and development services do not have value on a standalone
 basis and therefore do not represent a separate unit of
 accounting.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The initial $1.0 million upfront payment received by the Company
 upon execution of the original agreement is non-refundable; as
 such, there is no right of return for the license. Therefore, the
 upfront license fee and participation on the joint steering
 committee were treated as a combined unit of accounting and will be
 recognized over the term of the agreement through June 2020.
 Further, due to the fact the research and development services are
 not deemed to have stand-alone value, revenue for those services
 should be recognized over the entire term of the agreement (through
 June 2020). As a result of reassessing the arrangement in
 accordance with ASC 605-25, the Company was required to record an
 adjustment on the date of the material modification to reflect the
 revenue that would have resulted had the entity applied the
 requirements of ASC 605-25 from the inception of the agreement. As
 a result, the Company recorded an additional $1.3 million of
 revenue during 2014.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The Company recognized revenues of approximately $1.7 million and
 $100,000 under this agreement during the years ended
 December&#xA0;31, 2014 and 2013, respectively. No milestones were
 achieved under this agreement during the years ended
 December&#xA0;31, 2014 and 2013.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 At December&#xA0;31, 2014, there was a $525,000 unbilled receivable
 balance under this agreement, which is included in other assets on
 the consolidated balance sheet. At December&#xA0;31, 2013, $650,000
 of revenue was deferred under this agreement, $100,000 of which was
 current and $550,000 of which was non-current.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Eli Lilly</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 In October&#xA0;2007, the Company entered into an exclusive license
 and collaboration agreement (together, the Agreements) with Eli
 Lilly to jointly develop and commercialize teplizumab, a humanized
 anti-CD3 monoclonal antibody. As part of the Agreements, Eli Lilly
 acquired the exclusive rights to the molecule.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Upon execution of the Agreements, Eli Lilly made a nonrefundable
 payment of $41.0 million to the Company. In May&#xA0;2008, Eli
 Lilly paid the Company a milestone payment of $50.0 million and in
 May&#xA0;2010, Eli&#xA0;Lilly paid an additional milestone of $5.0
 million.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%">
 On October&#xA0;28, 2010, Lilly notified the Company of its
 decision to terminate the agreement after review of one year of
 clinical data from the Prot&#xE9;g&#xE9; trial in Type 1 diabetes
 patients treated with teplizumab. Such data failed to support the
 primary efficacy end point in the study. In February 2011, the
 Company reacquired the commercial rights to the molecule from Eli
 Lilly. During the year ended December&#xA0;31, 2012, Eli&#xA0;Lilly
 satisfied its obligation related to the cost of monitoring patients
 under the Prot&#xE9;g&#xE9; and Encore trials. The Company&#x2019;s
 obligations continued through September 2012, which represented the
 follow up period for enrolled patients and the Company&#x2019;s
 final reporting of the trial&#x2019;s results. There is no
 additional clinical trial activity under the Eli Lilly Agreements
 as it relates to such trials. However, Eli Lilly continues to
 reimburse the Company for monitoring patients in one currently
 active trial.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 During the years ended December 2014, 2013 and 2012, the Company
 recognized revenue of $0.4 million, $0.8 million and $31.2 million,
 respectively, under this agreement. No milestones were achieved
 under this agreement during the three years ended December&#xA0;31,
 2014.</p>


 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Collaboration and license agreements disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Product Milestone Payments and Royalty Agreements<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_RoyaltyAgreementDisclosureTextBlock', window );">Product Milestone Payments and Royalty Agreements</a></td>
        <td class="text"><div>
 <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <b>10. Product Milestone Payments and Royalty Agreements</b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 In connection with an Asset Purchase Agreement with Tolerance
 Therapeutics, Inc. (Tolerance) entered into during June 2005, the
 Company may be required to issue Tolerance additional consideration
 as follows: (i)&#xA0;$10,950,000 if certain milestones are met,
 including the initiation of Phase 3 trials and filing of various
 regulatory product license applications; (ii)&#xA0;36,135 shares of
 common stock; and (iii)&#xA0;royalty payments between 1.75% and
 4.0% of net sales of products acquired from or patented by
 Tolerance or other product fees earned by the Company. Any
 additional consideration required to be paid under the Asset
 Purchase Agreement will be recorded as research and development
 expense when incurred. No payments related to the additional
 consideration have occurred during the three years ended
 December&#xA0;31, 2014. Additionally, certain agreements require
 the Company to pay royalties. Currently, the Company is not
 obligated to pay royalties, as no revenue from product sales is
 being generated by the Company.</p>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_RoyaltyAgreementDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Royalty agreement disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_RoyaltyAgreementDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E1UBG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Computation of Basic and Diluted Income (Loss) Per Common Share (Detail) (USD $)<br>In Thousands, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="8">3 Months Ended</th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2013</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (19,018)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (3,928)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (12,259)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (3,108)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (3,205)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="nump"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ 6,604</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (294)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (3,366)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (38,313)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (261)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="nump"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ 8,362</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic', window );">Less: undistributed earnings allocated to participating securities</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num"><a title="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" onclick="toggleNextSibling(this);">(8,362)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net income (loss) allocable to common shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" onclick="toggleNextSibling(this);">(38,313)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" onclick="toggleNextSibling(this);">(261)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic weighted average common shares outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" onclick="toggleNextSibling(this);">27,384,990</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</span><span></span></td>
        <td class="nump"><a title="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" onclick="toggleNextSibling(this);">6,847,697</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</span><span></span></td>
        <td class="nump"><a title="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" onclick="toggleNextSibling(this);">1,083,276</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic income (loss) per common share</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num"><a title="us-gaap_EarningsPerShareBasic" onclick="toggleNextSibling(this);">$ (0.14)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareBasic</span><span></span></td>
        <td class="nump"><a title="us-gaap_EarningsPerShareBasic" onclick="toggleNextSibling(this);">$ 0.14</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareBasic</span><span></span></td>
        <td class="num"><a title="us-gaap_EarningsPerShareBasic" onclick="toggleNextSibling(this);">$ (0.24)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareBasic</span><span></span></td>
        <td class="num"><a title="us-gaap_EarningsPerShareBasic" onclick="toggleNextSibling(this);">$ (2.93)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareBasic</span><span></span></td>
        <td class="num"><a title="us-gaap_EarningsPerShareBasic" onclick="toggleNextSibling(this);">$ (1.40)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareBasic</span><span></span></td>
        <td class="num"><a title="us-gaap_EarningsPerShareBasic" onclick="toggleNextSibling(this);">$ (0.04)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareBasic</span><span></span></td>
        <td class="nump"><a title="us-gaap_EarningsPerShareBasic" onclick="toggleNextSibling(this);">$ 0.00</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareBasic</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">(19,018)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">(3,928)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">(12,259)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">(3,108)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">(3,205)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="nump"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">6,604</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">(294)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">(3,366)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">(38,313)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">(261)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="nump"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">8,362</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic', window );">Less: undistributed earnings allocated to participating securities and other add-backs to net income (loss)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num"><a title="us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic" onclick="toggleNextSibling(this);">(8,362)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net income (loss) allocable to common shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" onclick="toggleNextSibling(this);">$ (38,313)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" onclick="toggleNextSibling(this);">$ (261)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic weighted average common shares outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" onclick="toggleNextSibling(this);">27,384,990</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</span><span></span></td>
        <td class="nump"><a title="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" onclick="toggleNextSibling(this);">6,847,697</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</span><span></span></td>
        <td class="nump"><a title="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" onclick="toggleNextSibling(this);">1,083,276</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Effect of dilutive securities</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</span><span></span></td>
        <td class="nump"><a title="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</span><span></span></td>
        <td class="nump"><a title="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted weighted average common shares outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" onclick="toggleNextSibling(this);">27,384,990</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</span><span></span></td>
        <td class="nump"><a title="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" onclick="toggleNextSibling(this);">6,847,697</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</span><span></span></td>
        <td class="nump"><a title="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" onclick="toggleNextSibling(this);">1,083,276</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted income (loss) per common share</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num"><a title="us-gaap_EarningsPerShareDiluted" onclick="toggleNextSibling(this);">$ (0.14)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareDiluted</span><span></span></td>
        <td class="nump"><a title="us-gaap_EarningsPerShareDiluted" onclick="toggleNextSibling(this);">$ 0.01</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareDiluted</span><span></span></td>
        <td class="num"><a title="us-gaap_EarningsPerShareDiluted" onclick="toggleNextSibling(this);">$ (0.24)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareDiluted</span><span></span></td>
        <td class="num"><a title="us-gaap_EarningsPerShareDiluted" onclick="toggleNextSibling(this);">$ (2.93)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareDiluted</span><span></span></td>
        <td class="num"><a title="us-gaap_EarningsPerShareDiluted" onclick="toggleNextSibling(this);">$ (1.40)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareDiluted</span><span></span></td>
        <td class="num"><a title="us-gaap_EarningsPerShareDiluted" onclick="toggleNextSibling(this);">$ (0.04)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareDiluted</span><span></span></td>
        <td class="nump"><a title="us-gaap_EarningsPerShareDiluted" onclick="toggleNextSibling(this);">$ 0.00</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareDiluted</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1252-109256<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 52<br><br> -URI http://asc.fasb.org/extlink&amp;oid=32703322&amp;loc=d3e4984-109258<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.21)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-04.23)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 18<br><br> -Article 7<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 21<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1252-109256<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.21)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 18<br><br> -Article 7<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 21<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1377-109256<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Net Income or Loss Available to Common Stockholders plus adjustments resulting from the assumption that dilutive convertible securities were converted, options or warrants were exercised, or that other shares were issued upon the satisfaction of certain conditions.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 16<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1505-109256<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1377-109256<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of earnings (loss) distributed and earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two-class method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 60B<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=SL5780133-109256<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of undistributed earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two-class method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 60B<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=SL5780133-109256<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 16<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1505-109256<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 10<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1448-109256<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Weighted-Average Number of Common Shares Outstanding<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6528421<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EIZAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Collaboration and License Agreements - Additional Information 2 (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jan. 31, 2013

</div>
          <div>Molecule</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue, Current</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DeferredRevenueCurrent" onclick="toggleNextSibling(this);">$ 14,248,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredRevenueCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredRevenueCurrent" onclick="toggleNextSibling(this);">$ 20,267,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredRevenueCurrent</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=mgnx_GileadMember', window );">Gilead [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CollaborationAndLicenseAgreementEnteredDate', window );">Collaboration agreement date</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">January 2013<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedAsPerCollaborations', window );">Commercialization of molecules</a></td>
        <td class="nump"><a title="mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedAsPerCollaborations[us-gaap_CounterpartyNameAxis=mgnx_GileadMember]" onclick="toggleNextSibling(this);">4</a><span style="display:none;white-space:normal;text-align:left;">mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedAsPerCollaborations<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_GileadMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_AdditionalLicenseGrantFeesUnderAgreement', window );">License grant fees</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="mgnx_AdditionalLicenseGrantFeesUnderAgreement[us-gaap_CounterpartyNameAxis=mgnx_GileadMember]" onclick="toggleNextSibling(this);">7,500,000</a><span style="display:none;white-space:normal;text-align:left;">mgnx_AdditionalLicenseGrantFeesUnderAgreement<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_GileadMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_UpfrontPaymentRecognitionPeriod', window );">Expected period of development</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">21 months<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicensesRevenue', window );">Recognized revenue under agreement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_LicensesRevenue[us-gaap_CounterpartyNameAxis=mgnx_GileadMember]" onclick="toggleNextSibling(this);">5,500,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LicensesRevenue<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_GileadMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_LicensesRevenue[us-gaap_CounterpartyNameAxis=mgnx_GileadMember]" onclick="toggleNextSibling(this);">8,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LicensesRevenue<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_GileadMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized', window );">Milestone achieved</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized[us-gaap_CounterpartyNameAxis=mgnx_GileadMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_GileadMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized[us-gaap_CounterpartyNameAxis=mgnx_GileadMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_GileadMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue, Current</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DeferredRevenueCurrent[us-gaap_CounterpartyNameAxis=mgnx_GileadMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredRevenueCurrent<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_GileadMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredRevenueCurrent[us-gaap_CounterpartyNameAxis=mgnx_GileadMember]" onclick="toggleNextSibling(this);">3,600,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredRevenueCurrent<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_GileadMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=mgnx_GileadMember', window );">Gilead [Member] | Minimum [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_AdditionalPotentialRegulatoryAndSalesMilestonePaymentsUnderAgreement', window );">Regulatory and sales milestone</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="mgnx_AdditionalPotentialRegulatoryAndSalesMilestonePaymentsUnderAgreement[us-gaap_CounterpartyNameAxis=mgnx_GileadMember;us-gaap_RangeAxis=us-gaap_MinimumMember]" onclick="toggleNextSibling(this);">240,000,000</a><span style="display:none;white-space:normal;text-align:left;">mgnx_AdditionalPotentialRegulatoryAndSalesMilestonePaymentsUnderAgreement<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_GileadMember<br>/ us-gaap_RangeAxis<br>= us-gaap_MinimumMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=mgnx_GileadMember', window );">Gilead [Member] | Maximum [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_AdditionalPotentialRegulatoryAndSalesMilestonePaymentsUnderAgreement', window );">Regulatory and sales milestone</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="mgnx_AdditionalPotentialRegulatoryAndSalesMilestonePaymentsUnderAgreement[us-gaap_CounterpartyNameAxis=mgnx_GileadMember;us-gaap_RangeAxis=us-gaap_MaximumMember]" onclick="toggleNextSibling(this);">250,000,000</a><span style="display:none;white-space:normal;text-align:left;">mgnx_AdditionalPotentialRegulatoryAndSalesMilestonePaymentsUnderAgreement<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_GileadMember<br>/ us-gaap_RangeAxis<br>= us-gaap_MaximumMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=mgnx_GileadMember', window );">Gilead [Member] | Pre-Clinical Milestones [Member] | Minimum [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_AdditionalPotentialClinicalMilestonePaymentsUnderAgreement', window );">Clinical milestone payments</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="mgnx_AdditionalPotentialClinicalMilestonePaymentsUnderAgreement[us-gaap_CounterpartyNameAxis=mgnx_GileadMember;us-gaap_RangeAxis=us-gaap_MinimumMember;us-gaap_TypeOfArrangementAxis=mgnx_PreclinicalMilestonesMember]" onclick="toggleNextSibling(this);">20,000,000</a><span style="display:none;white-space:normal;text-align:left;">mgnx_AdditionalPotentialClinicalMilestonePaymentsUnderAgreement<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_GileadMember<br>/ us-gaap_RangeAxis<br>= us-gaap_MinimumMember<br>/ us-gaap_TypeOfArrangementAxis<br>= mgnx_PreclinicalMilestonesMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=mgnx_GileadMember', window );">Gilead [Member] | Pre-Clinical Milestones [Member] | Maximum [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_AdditionalPotentialClinicalMilestonePaymentsUnderAgreement', window );">Clinical milestone payments</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="mgnx_AdditionalPotentialClinicalMilestonePaymentsUnderAgreement[us-gaap_CounterpartyNameAxis=mgnx_GileadMember;us-gaap_RangeAxis=us-gaap_MaximumMember;us-gaap_TypeOfArrangementAxis=mgnx_PreclinicalMilestonesMember]" onclick="toggleNextSibling(this);">$ 25,000,000</a><span style="display:none;white-space:normal;text-align:left;">mgnx_AdditionalPotentialClinicalMilestonePaymentsUnderAgreement<br>/ us-gaap_CounterpartyNameAxis<br>= mgnx_GileadMember<br>/ us-gaap_RangeAxis<br>= us-gaap_MaximumMember<br>/ us-gaap_TypeOfArrangementAxis<br>= mgnx_PreclinicalMilestonesMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_AdditionalLicenseGrantFeesUnderAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Additional license grant fees per under agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_AdditionalLicenseGrantFeesUnderAgreement</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_AdditionalPotentialClinicalMilestonePaymentsUnderAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate potential clinical milestone payments available to be earned under collaboration agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_AdditionalPotentialClinicalMilestonePaymentsUnderAgreement</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_AdditionalPotentialRegulatoryAndSalesMilestonePaymentsUnderAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate potential regulatory and sales milestone payments available to be earned under collaboration agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_AdditionalPotentialRegulatoryAndSalesMilestonePaymentsUnderAgreement</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborationAndLicenseAgreementEnteredDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Collaboration and license agreement entered date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_CollaborationAndLicenseAgreementEnteredDate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>us-types:dateStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_LicenseAndCollaborationAgreementsLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_LicenseAndCollaborationAgreementsLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedAsPerCollaborations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of molecules to be developed and commercialized as per collaborations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedAsPerCollaborations</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_UpfrontPaymentRecognitionPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Period over which upfront payment is to be recognized.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_UpfrontPaymentRecognitionPeriod</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 8<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 13<br><br> -Section A<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LicensesRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LicensesRevenue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of consideration recognized during the period for the milestone or milestones.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 28<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=19771982&amp;loc=SL6892177-166501<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=mgnx_GileadMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=mgnx_GileadMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EIIAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Summary of Fair Value Measurement Financial Asset and Liabilities</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%">
 Financial assets and liabilities subject to fair value measurements
 were as follows (in thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0">
 <tr>
 <td width="43%"></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"><b>Fair Value Measurements at
 December&#xA0;31, 2014</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Quoted&#xA0;Prices&#xA0;in</b><br />
 <b>Active Markets<br />
 for</b><br />
 <b>Identical Assets</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Significant&#xA0;Other</b><br />
 <b>Observable<br />
 Inputs</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Significant</b><br />
 <b>Unobservable</b><br />
 <b>Inputs</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Total</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Level 1</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Level 2</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Level 3</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Assets:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Cash and cash equivalents</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">131,545</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">131,545</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Money market funds</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">26,046</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">26,046</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Restricted cash</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">300</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">300</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Total Assets</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">157,891</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">157,891</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1pt">
 <td height="16"></td>
 <td height="16" colspan="16"></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"><b>Fair Value Measurements at
 December&#xA0;31, 2013</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Quoted Prices in</b><br />
 <b>Active Markets<br />
 for</b><br />
 <b>Identical Assets</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Significant Other</b><br />
 <b>Observable<br />
 Inputs</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Significant</b><br />
 <b>Unobservable</b><br />
 <b>Inputs</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Total</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Level 1</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Level 2</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Level 3</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Assets:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Cash and cash equivalents</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">90,434</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">90,434</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Money market funds</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">26,047</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">26,047</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Restricted cash</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">405</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">405</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Total Assets</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">116,886</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">116,886</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock', window );">Estimated Useful Lives</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Repairs and maintenance costs are expensed as incurred.
 Depreciation is computed using the straight-line method over the
 following estimated useful lives:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="55%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Computer equipment</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">3 years</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Software</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">3 years</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Furniture</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">10 years</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Laboratory and office equipment</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">5 years</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Leasehold improvements</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 Shorter&#xA0;of&#xA0;lease&#xA0;term&#xA0;or&#xA0;useful&#xA0;life</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Computation of Basic and Diluted Income (Loss) Per Common Share</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%">
 Basic and diluted income (loss) per common share is computed as
 follows (in thousands except share and per share data):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0">
 <tr>
 <td width="58%"></td>
 <td valign="bottom" width="9%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"><b>Year Ended
 December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Net income (loss)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(38,313</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(261</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">8,362</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Less: undistributed earnings allocated to participating
 securities</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(8,362</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Net income (loss) allocable to common shares</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(38,313</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(261</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Basic weighted average common shares outstanding</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">27,384,990</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,847,697</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,083,276</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Basic income (loss) per common share</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(1.40</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.04</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">0.00</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Net income (loss)</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(38,313</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(261</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">8,362</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Less: undistributed earnings allocated to participating securities
 and other add-backs to net income (loss)</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(8,362</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Net income (loss) allocable to common shares</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(38,313</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(261</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Basic weighted average common shares outstanding</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">27,384,990</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,847,697</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,083,276</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Effect of dilutive securities</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Diluted weighted average common shares outstanding</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">27,384,990</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,847,697</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,083,276</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Diluted income (loss) per common share</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(1.40</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.04</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">0.00</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from the Calculation of Diluted Income (Loss) Per Share</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The following common stock equivalents were excluded from the
 calculation of diluted net income (loss) per share because their
 effect would be anti-dilutive:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0">
 <tr>
 <td width="63%"></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"><b>Year Ended
 December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Series A-1 Preferred Stock</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,156,114</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Series A-2 Preferred Stock</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">392,274</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Series B Preferred Stock</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,336,037</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Series C Preferred Stock</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,909,906</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Series D Preferred Stock</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">769,468</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Series D-2 Preferred Stock</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,391,991</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Effect of Converted Preferred Stock</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">13,189,920</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Warrants to purchase Series D-2 Preferred Stock</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">180,784</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Stock Options</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,094,904</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,313,970</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,249,702</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Summary of Significant Revenue [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Summary of Percentage of Customer Concentration</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%">
 The following table includes those collaborators that represent
 more than 10% of total revenue earned in the periods indicated:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <tr>
 <td width="66%"></td>
 <td valign="bottom" width="9%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center">
 <b>Year&#xA0;Ended&#xA0;December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">
 <b>&#xA0;&#xA0;&#xA0;&#xA0;2014&#xA0;&#xA0;&#xA0;&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">
 <b>&#xA0;&#xA0;&#xA0;&#xA0;2013&#xA0;&#xA0;&#xA0;&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">
 <b>&#xA0;&#xA0;&#xA0;&#xA0;2012&#xA0;&#xA0;&#xA0;&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Servier</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">36.4</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">51.6</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">17.3</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Boehringer</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">28.6</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">24.8</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">18.4</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Takeda</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">16.8</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Gilead</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">11.4</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">13.8</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Eli Lilly</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.9</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1.4</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">48.9</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CreditConcentrationRiskMember', window );">Summary of Significant Accounts Receivable[Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Summary of Percentage of Customer Concentration</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The following table includes those collaborators that represent
 more than 10% of accounts receivable at the date indicated:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="75%"></td>
 <td valign="bottom" width="10%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="9%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">
 <b>&#xA0;&#xA0;&#xA0;&#xA0;2014&#xA0;&#xA0;&#xA0;&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">
 <b>&#xA0;&#xA0;&#xA0;&#xA0;2013&#xA0;&#xA0;&#xA0;&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Servier</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">33.3</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6.4</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Boehringer</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">21.2</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">12.2</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Green Cross</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">17.9</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Gilead</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">53.4</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Pfizer</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">12.3</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Property plant and equipment estimated useful life.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19279-110258<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a,b,bb)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2C<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=SL7498348-110258<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19190-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 16<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6327-108592<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6404-108592<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13531-108611<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 18<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6351-108592<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 21<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13537-108611<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 21<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6442-108592<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CreditConcentrationRiskMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CreditConcentrationRiskMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock', window );">Schedule of Minimum Future Lease Payments</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Future minimum lease payments under noncancelable operating leases
 as of December&#xA0;31, 2014 are as follows (in thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0">
 <tr>
 <td width="84%"></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 2015</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">3,945</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 2016</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,364</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 2017</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,495</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 2018</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,396</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 2019</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,873</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Thereafter</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">116</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top"></td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">19,189</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of a lessee's leasing arrangements including: (1) the basis on which contingent rental payments are determined, (2) the existence and terms of renewal or purchase options and escalation clauses, (3) restrictions imposed by lease arrangements, such as those concerning dividends, additional debt, and further leasing, (4) rent holidays, rent concessions, or leasehold improvement incentives and unusual provisions or conditions.  Disclosure may also include the specific period used to amortize material leasehold improvements made at the inception of the lease or during the lease term. Additionally, for operating leases having initial or remaining noncancelable lease terms in excess of one year: (a) future minimum rental payments required as of the date of the latest balance sheet presented, in the aggregate and for each of the five succeeding fiscal years, (b) the total of minimum rentals to be received in the future under noncancelable subleases as of the date of the latest balance sheet presented, and (c) for all operating leases, rental expense for each period for which an income statement is presented, with separate amounts for minimum rentals, contingent rentals, and sublease rentals. Rental payments under leases with terms of a month or less that were not renewed need not be included.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 460<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6851643&amp;loc=d3e12069-110248<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6452660&amp;loc=d3e36991-112694<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41499-112717<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 1,3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EDAAE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Lease Exit Liability - Future Principal Payments Under Lease Agreement (Detail) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">2015</a></td>
        <td class="nump"><a title="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" onclick="toggleNextSibling(this);">$ 3,945</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2016</a></td>
        <td class="nump"><a title="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" onclick="toggleNextSibling(this);">4,364</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2017</a></td>
        <td class="nump"><a title="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" onclick="toggleNextSibling(this);">4,495</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">2018</a></td>
        <td class="nump"><a title="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" onclick="toggleNextSibling(this);">4,396</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total</a></td>
        <td class="nump"><a title="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" onclick="toggleNextSibling(this);">19,189</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mgnx_RavenBiotechnologiesIncMember', window );">Raven Biotechnologies Inc. [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">2015</a></td>
        <td class="nump"><a title="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent[us-gaap_BusinessAcquisitionAxis=mgnx_RavenBiotechnologiesIncMember]" onclick="toggleNextSibling(this);">1,642</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent<br>/ us-gaap_BusinessAcquisitionAxis<br>= mgnx_RavenBiotechnologiesIncMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2016</a></td>
        <td class="nump"><a title="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears[us-gaap_BusinessAcquisitionAxis=mgnx_RavenBiotechnologiesIncMember]" onclick="toggleNextSibling(this);">1,866</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears<br>/ us-gaap_BusinessAcquisitionAxis<br>= mgnx_RavenBiotechnologiesIncMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2017</a></td>
        <td class="nump"><a title="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears[us-gaap_BusinessAcquisitionAxis=mgnx_RavenBiotechnologiesIncMember]" onclick="toggleNextSibling(this);">2,113</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears<br>/ us-gaap_BusinessAcquisitionAxis<br>= mgnx_RavenBiotechnologiesIncMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">2018</a></td>
        <td class="nump"><a title="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears[us-gaap_BusinessAcquisitionAxis=mgnx_RavenBiotechnologiesIncMember]" onclick="toggleNextSibling(this);">2,385</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears<br>/ us-gaap_BusinessAcquisitionAxis<br>= mgnx_RavenBiotechnologiesIncMember</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total</a></td>
        <td class="nump"><a title="us-gaap_OperatingLeasesFutureMinimumPaymentsDue[us-gaap_BusinessAcquisitionAxis=mgnx_RavenBiotechnologiesIncMember]" onclick="toggleNextSibling(this);">$ 8,006</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue<br>/ us-gaap_BusinessAcquisitionAxis<br>= mgnx_RavenBiotechnologiesIncMember</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasedAssetsLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingLeasedAssetsLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=mgnx_RavenBiotechnologiesIncMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=mgnx_RavenBiotechnologiesIncMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E6UAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock- based Compensation - Schedule of Fair Value Option Award Estimated on the Date of Grant Using the Black-Scholes Option-Pricing Model (Detail)<br></strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" onclick="toggleNextSibling(this);">0.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" onclick="toggleNextSibling(this);">0.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" onclick="toggleNextSibling(this);">0.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" onclick="toggleNextSibling(this);">67.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" onclick="toggleNextSibling(this);">51.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" onclick="toggleNextSibling(this);">1.20%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
        <td class="text">6 years 3 months<span></span></td>
        <td class="text">7 years<span></span></td>
        <td class="text">7 years<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate[us-gaap_RangeAxis=us-gaap_MinimumMember]" onclick="toggleNextSibling(this);">53.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate<br>/ us-gaap_RangeAxis<br>= us-gaap_MinimumMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate[us-gaap_RangeAxis=us-gaap_MinimumMember]" onclick="toggleNextSibling(this);">1.80%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate<br>/ us-gaap_RangeAxis<br>= us-gaap_MinimumMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate[us-gaap_RangeAxis=us-gaap_MinimumMember]" onclick="toggleNextSibling(this);">1.20%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate<br>/ us-gaap_RangeAxis<br>= us-gaap_MinimumMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate[us-gaap_RangeAxis=us-gaap_MaximumMember]" onclick="toggleNextSibling(this);">67.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate<br>/ us-gaap_RangeAxis<br>= us-gaap_MaximumMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate[us-gaap_RangeAxis=us-gaap_MaximumMember]" onclick="toggleNextSibling(this);">2.30%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate<br>/ us-gaap_RangeAxis<br>= us-gaap_MaximumMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate[us-gaap_RangeAxis=us-gaap_MaximumMember]" onclick="toggleNextSibling(this);">2.20%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate<br>/ us-gaap_RangeAxis<br>= us-gaap_MaximumMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.D.2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section D<br><br> -Subsection 2<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(iv)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ET3AK">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity (Deficit) (USD $)<br>In Thousands, except Share data</strong></div>
        </th>
        <th class="th">
          <div>Total</div>
        </th>
        <th class="th">
          <div>Series A-1 Convertible Preferred Stock [Member]</div>
        </th>
        <th class="th">
          <div>Series A-2 Convertible Preferred Stock [Member]</div>
        </th>
        <th class="th">
          <div>Series B Convertible Preferred Stock [Member]</div>
        </th>
        <th class="th">
          <div>Series C Convertible Preferred Stock [Member]</div>
        </th>
        <th class="th">
          <div>Series D-1 Convertible Preferred Stock [Member]</div>
        </th>
        <th class="th">
          <div>Series D-2 Convertible Preferred Stock [Member]</div>
        </th>
        <th class="th">
          <div>Common Stock [Member]</div>
        </th>
        <th class="th">
          <div>Treasury Stock [Member]</div>
        </th>
        <th class="th">
          <div>Additional Paid-In Capital [Member]</div>
        </th>
        <th class="th">
          <div>Accumulated Deficit [Member]</div>
        </th>
      </tr>
      <tr class="rc">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2011</a></td>
        <td class="num"><a title="us-gaap_StockholdersEquity" onclick="toggleNextSibling(this);">$ (17,484)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=mgnx_SeriesA1ConvertiblePreferredStockMember]" onclick="toggleNextSibling(this);">$ 269</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= mgnx_SeriesA1ConvertiblePreferredStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=mgnx_SeriesA2ConvertiblePreferredStockMember]" onclick="toggleNextSibling(this);">$ 74</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= mgnx_SeriesA2ConvertiblePreferredStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=mgnx_SeriesBConvertiblePreferredStockMember]" onclick="toggleNextSibling(this);">$ 714</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= mgnx_SeriesBConvertiblePreferredStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=mgnx_SeriesCConvertiblePreferredStockMember]" onclick="toggleNextSibling(this);">$ 1,110</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= mgnx_SeriesCConvertiblePreferredStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=mgnx_SeriesD1ConvertiblePreferredStockMember]" onclick="toggleNextSibling(this);">$ 144</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= mgnx_SeriesD1ConvertiblePreferredStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=mgnx_SeriesD2ConvertiblePreferredStockMember]" onclick="toggleNextSibling(this);">$ 637</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= mgnx_SeriesD2ConvertiblePreferredStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">$ 10</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="num"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember]" onclick="toggleNextSibling(this);">$ (58)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_TreasuryStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">$ 163,450</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="num"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember]" onclick="toggleNextSibling(this);">$ (183,834)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_RetainedEarningsMember</span><span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning Balance, Shares at Dec. 31, 2011</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_SharesIssued[us-gaap_StatementEquityComponentsAxis=mgnx_SeriesA1ConvertiblePreferredStockMember]" onclick="toggleNextSibling(this);">26,874,792</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharesIssued<br>/ us-gaap_StatementEquityComponentsAxis<br>= mgnx_SeriesA1ConvertiblePreferredStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_SharesIssued[us-gaap_StatementEquityComponentsAxis=mgnx_SeriesA2ConvertiblePreferredStockMember]" onclick="toggleNextSibling(this);">7,364,582</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharesIssued<br>/ us-gaap_StatementEquityComponentsAxis<br>= mgnx_SeriesA2ConvertiblePreferredStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_SharesIssued[us-gaap_StatementEquityComponentsAxis=mgnx_SeriesBConvertiblePreferredStockMember]" onclick="toggleNextSibling(this);">71,401,237</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharesIssued<br>/ us-gaap_StatementEquityComponentsAxis<br>= mgnx_SeriesBConvertiblePreferredStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_SharesIssued[us-gaap_StatementEquityComponentsAxis=mgnx_SeriesCConvertiblePreferredStockMember]" onclick="toggleNextSibling(this);">110,952,217</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharesIssued<br>/ us-gaap_StatementEquityComponentsAxis<br>= mgnx_SeriesCConvertiblePreferredStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_SharesIssued[us-gaap_StatementEquityComponentsAxis=mgnx_SeriesD1ConvertiblePreferredStockMember]" onclick="toggleNextSibling(this);">14,446,227</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharesIssued<br>/ us-gaap_StatementEquityComponentsAxis<br>= mgnx_SeriesD1ConvertiblePreferredStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_SharesIssued[us-gaap_StatementEquityComponentsAxis=mgnx_SeriesD2ConvertiblePreferredStockMember]" onclick="toggleNextSibling(this);">63,681,176</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharesIssued<br>/ us-gaap_StatementEquityComponentsAxis<br>= mgnx_SeriesD2ConvertiblePreferredStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_SharesIssued[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">1,049,030</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharesIssued<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_SharesIssued[us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember]" onclick="toggleNextSibling(this);">14,381</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharesIssued<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_TreasuryStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
        <td class="nump"><a title="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" onclick="toggleNextSibling(this);">838</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">838</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock option exercises</a></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" onclick="toggleNextSibling(this);">46</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">46</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock option exercises, Shares</a></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" onclick="toggleNextSibling(this);">863,176</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">49,884</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
        <td class="nump"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">8,362</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_NetIncomeLoss[us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember]" onclick="toggleNextSibling(this);">8,362</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_RetainedEarningsMember</span><span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2012</a></td>
        <td class="num"><a title="us-gaap_StockholdersEquity" onclick="toggleNextSibling(this);">(8,238)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=mgnx_SeriesA1ConvertiblePreferredStockMember]" onclick="toggleNextSibling(this);">269</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= mgnx_SeriesA1ConvertiblePreferredStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=mgnx_SeriesA2ConvertiblePreferredStockMember]" onclick="toggleNextSibling(this);">74</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= mgnx_SeriesA2ConvertiblePreferredStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=mgnx_SeriesBConvertiblePreferredStockMember]" onclick="toggleNextSibling(this);">714</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= mgnx_SeriesBConvertiblePreferredStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=mgnx_SeriesCConvertiblePreferredStockMember]" onclick="toggleNextSibling(this);">1,110</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= mgnx_SeriesCConvertiblePreferredStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=mgnx_SeriesD1ConvertiblePreferredStockMember]" onclick="toggleNextSibling(this);">144</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= mgnx_SeriesD1ConvertiblePreferredStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=mgnx_SeriesD2ConvertiblePreferredStockMember]" onclick="toggleNextSibling(this);">637</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= mgnx_SeriesD2ConvertiblePreferredStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">10</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="num"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember]" onclick="toggleNextSibling(this);">(58)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_TreasuryStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">164,334</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="num"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember]" onclick="toggleNextSibling(this);">(175,472)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_RetainedEarningsMember</span><span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending Balance, Shares at Dec. 31, 2012</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_SharesIssued[us-gaap_StatementEquityComponentsAxis=mgnx_SeriesA1ConvertiblePreferredStockMember]" onclick="toggleNextSibling(this);">26,874,792</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharesIssued<br>/ us-gaap_StatementEquityComponentsAxis<br>= mgnx_SeriesA1ConvertiblePreferredStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_SharesIssued[us-gaap_StatementEquityComponentsAxis=mgnx_SeriesA2ConvertiblePreferredStockMember]" onclick="toggleNextSibling(this);">7,364,582</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharesIssued<br>/ us-gaap_StatementEquityComponentsAxis<br>= mgnx_SeriesA2ConvertiblePreferredStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_SharesIssued[us-gaap_StatementEquityComponentsAxis=mgnx_SeriesBConvertiblePreferredStockMember]" onclick="toggleNextSibling(this);">71,401,237</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharesIssued<br>/ us-gaap_StatementEquityComponentsAxis<br>= mgnx_SeriesBConvertiblePreferredStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_SharesIssued[us-gaap_StatementEquityComponentsAxis=mgnx_SeriesCConvertiblePreferredStockMember]" onclick="toggleNextSibling(this);">110,952,217</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharesIssued<br>/ us-gaap_StatementEquityComponentsAxis<br>= mgnx_SeriesCConvertiblePreferredStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_SharesIssued[us-gaap_StatementEquityComponentsAxis=mgnx_SeriesD1ConvertiblePreferredStockMember]" onclick="toggleNextSibling(this);">14,446,227</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharesIssued<br>/ us-gaap_StatementEquityComponentsAxis<br>= mgnx_SeriesD1ConvertiblePreferredStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_SharesIssued[us-gaap_StatementEquityComponentsAxis=mgnx_SeriesD2ConvertiblePreferredStockMember]" onclick="toggleNextSibling(this);">63,681,176</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharesIssued<br>/ us-gaap_StatementEquityComponentsAxis<br>= mgnx_SeriesD2ConvertiblePreferredStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_SharesIssued[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">1,098,914</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharesIssued<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_SharesIssued[us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember]" onclick="toggleNextSibling(this);">14,381</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharesIssued<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_TreasuryStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
        <td class="nump"><a title="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" onclick="toggleNextSibling(this);">862</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">862</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of offering costs</a></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueNewIssues" onclick="toggleNextSibling(this);">83,623</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueNewIssues</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueNewIssues[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">58</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueNewIssues<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueNewIssues[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">83,565</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueNewIssues<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of offering costs, Shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesNewIssues[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">5,750,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesNewIssues<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of preferred stock to common stock</a></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" onclick="toggleNextSibling(this);">1,860</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</span><span></span></td>
        <td class="num"><a title="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities[us-gaap_StatementEquityComponentsAxis=mgnx_SeriesA1ConvertiblePreferredStockMember]" onclick="toggleNextSibling(this);">(269)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities<br>/ us-gaap_StatementEquityComponentsAxis<br>= mgnx_SeriesA1ConvertiblePreferredStockMember</span><span></span></td>
        <td class="num"><a title="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities[us-gaap_StatementEquityComponentsAxis=mgnx_SeriesA2ConvertiblePreferredStockMember]" onclick="toggleNextSibling(this);">(74)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities<br>/ us-gaap_StatementEquityComponentsAxis<br>= mgnx_SeriesA2ConvertiblePreferredStockMember</span><span></span></td>
        <td class="num"><a title="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities[us-gaap_StatementEquityComponentsAxis=mgnx_SeriesBConvertiblePreferredStockMember]" onclick="toggleNextSibling(this);">(714)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities<br>/ us-gaap_StatementEquityComponentsAxis<br>= mgnx_SeriesBConvertiblePreferredStockMember</span><span></span></td>
        <td class="num"><a title="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities[us-gaap_StatementEquityComponentsAxis=mgnx_SeriesCConvertiblePreferredStockMember]" onclick="toggleNextSibling(this);">(1,110)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities<br>/ us-gaap_StatementEquityComponentsAxis<br>= mgnx_SeriesCConvertiblePreferredStockMember</span><span></span></td>
        <td class="num"><a title="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities[us-gaap_StatementEquityComponentsAxis=mgnx_SeriesD1ConvertiblePreferredStockMember]" onclick="toggleNextSibling(this);">(144)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities<br>/ us-gaap_StatementEquityComponentsAxis<br>= mgnx_SeriesD1ConvertiblePreferredStockMember</span><span></span></td>
        <td class="num"><a title="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities[us-gaap_StatementEquityComponentsAxis=mgnx_SeriesD2ConvertiblePreferredStockMember]" onclick="toggleNextSibling(this);">(637)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities<br>/ us-gaap_StatementEquityComponentsAxis<br>= mgnx_SeriesD2ConvertiblePreferredStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">171</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">4,637</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of preferred stock to common stock, Shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num"><a title="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities[us-gaap_StatementEquityComponentsAxis=mgnx_SeriesA1ConvertiblePreferredStockMember]" onclick="toggleNextSibling(this);">(26,874,792)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities<br>/ us-gaap_StatementEquityComponentsAxis<br>= mgnx_SeriesA1ConvertiblePreferredStockMember</span><span></span></td>
        <td class="num"><a title="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities[us-gaap_StatementEquityComponentsAxis=mgnx_SeriesA2ConvertiblePreferredStockMember]" onclick="toggleNextSibling(this);">(7,364,582)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities<br>/ us-gaap_StatementEquityComponentsAxis<br>= mgnx_SeriesA2ConvertiblePreferredStockMember</span><span></span></td>
        <td class="num"><a title="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities[us-gaap_StatementEquityComponentsAxis=mgnx_SeriesBConvertiblePreferredStockMember]" onclick="toggleNextSibling(this);">(71,401,237)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities<br>/ us-gaap_StatementEquityComponentsAxis<br>= mgnx_SeriesBConvertiblePreferredStockMember</span><span></span></td>
        <td class="num"><a title="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities[us-gaap_StatementEquityComponentsAxis=mgnx_SeriesCConvertiblePreferredStockMember]" onclick="toggleNextSibling(this);">(110,952,217)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities<br>/ us-gaap_StatementEquityComponentsAxis<br>= mgnx_SeriesCConvertiblePreferredStockMember</span><span></span></td>
        <td class="num"><a title="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities[us-gaap_StatementEquityComponentsAxis=mgnx_SeriesD1ConvertiblePreferredStockMember]" onclick="toggleNextSibling(this);">(14,446,227)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities<br>/ us-gaap_StatementEquityComponentsAxis<br>= mgnx_SeriesD1ConvertiblePreferredStockMember</span><span></span></td>
        <td class="num"><a title="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities[us-gaap_StatementEquityComponentsAxis=mgnx_SeriesD2ConvertiblePreferredStockMember]" onclick="toggleNextSibling(this);">(63,681,176)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities<br>/ us-gaap_StatementEquityComponentsAxis<br>= mgnx_SeriesD2ConvertiblePreferredStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">17,060,634</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock option exercises</a></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" onclick="toggleNextSibling(this);">1,068</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">13</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">1,055</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock option exercises, Shares</a></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" onclick="toggleNextSibling(this);">1,268,049</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">1,268,049</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">(261)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss[us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember]" onclick="toggleNextSibling(this);">(261)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_RetainedEarningsMember</span><span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2013</a></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity" onclick="toggleNextSibling(this);">78,914</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">252</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="num"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember]" onclick="toggleNextSibling(this);">(58)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_TreasuryStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">254,453</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="num"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember]" onclick="toggleNextSibling(this);">(175,733)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_RetainedEarningsMember</span><span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending Balance, Shares at Dec. 31, 2013</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_SharesIssued[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">25,177,597</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharesIssued<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_SharesIssued[us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember]" onclick="toggleNextSibling(this);">14,381</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharesIssued<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_TreasuryStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
        <td class="nump"><a title="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" onclick="toggleNextSibling(this);">3,244</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">3,244</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of offering costs</a></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueNewIssues" onclick="toggleNextSibling(this);">76,716</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueNewIssues</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueNewIssues[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">22</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueNewIssues<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueNewIssues[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">76,694</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueNewIssues<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of offering costs, Shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesNewIssues[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">2,250,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesNewIssues<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_StockIssuedDuringPeriodValueStockPlanActivity', window );">Stock plan related activity, value of shares issued</a></td>
        <td class="nump"><a title="mgnx_StockIssuedDuringPeriodValueStockPlanActivity" onclick="toggleNextSibling(this);">725</a><span style="display:none;white-space:normal;text-align:left;">mgnx_StockIssuedDuringPeriodValueStockPlanActivity</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="mgnx_StockIssuedDuringPeriodValueStockPlanActivity[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">6</a><span style="display:none;white-space:normal;text-align:left;">mgnx_StockIssuedDuringPeriodValueStockPlanActivity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="num"><a title="mgnx_StockIssuedDuringPeriodValueStockPlanActivity[us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember]" onclick="toggleNextSibling(this);">(19)</a><span style="display:none;white-space:normal;text-align:left;">mgnx_StockIssuedDuringPeriodValueStockPlanActivity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_TreasuryStockMember</span><span></span></td>
        <td class="nump"><a title="mgnx_StockIssuedDuringPeriodValueStockPlanActivity[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">738</a><span style="display:none;white-space:normal;text-align:left;">mgnx_StockIssuedDuringPeriodValueStockPlanActivity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity', window );">Stock plan related activity, shares issued</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="mgnx_StockIssuedDuringPeriodSharesStockPlanActivity[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">568,041</a><span style="display:none;white-space:normal;text-align:left;">mgnx_StockIssuedDuringPeriodSharesStockPlanActivity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="mgnx_StockIssuedDuringPeriodSharesStockPlanActivity[us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember]" onclick="toggleNextSibling(this);">865</a><span style="display:none;white-space:normal;text-align:left;">mgnx_StockIssuedDuringPeriodSharesStockPlanActivity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_TreasuryStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockRetiredParValueMethodAmount', window );">Retirement of treasury stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_TreasuryStockRetiredParValueMethodAmount[us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember]" onclick="toggleNextSibling(this);">58</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_TreasuryStockRetiredParValueMethodAmount<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_TreasuryStockMember</span><span></span></td>
        <td class="num"><a title="us-gaap_TreasuryStockRetiredParValueMethodAmount[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">(58)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_TreasuryStockRetiredParValueMethodAmount<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock option exercises, Shares</a></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" onclick="toggleNextSibling(this);">568,906</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesRetired', window );">Retirement of treasury stock, Shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num"><a title="us-gaap_TreasuryStockSharesRetired[us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember]" onclick="toggleNextSibling(this);">(14,381)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_TreasuryStockSharesRetired<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_TreasuryStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">(38,313)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss[us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember]" onclick="toggleNextSibling(this);">(38,313)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_RetainedEarningsMember</span><span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2014</a></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity" onclick="toggleNextSibling(this);">$ 121,286</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">$ 280</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="num"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember]" onclick="toggleNextSibling(this);">$ (19)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_TreasuryStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">$ 335,071</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="num"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember]" onclick="toggleNextSibling(this);">$ (214,046)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_RetainedEarningsMember</span><span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending Balance, Shares at Dec. 31, 2014</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_SharesIssued[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">27,995,638</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharesIssued<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_SharesIssued[us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember]" onclick="toggleNextSibling(this);">865</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharesIssued<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_TreasuryStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued due to stock plan related activity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_StockIssuedDuringPeriodSharesStockPlanActivity</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_StockIssuedDuringPeriodValueStockPlanActivity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of shares issued due to stock plan related activity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_StockIssuedDuringPeriodValueStockPlanActivity</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represents the amount of recognized equity-based compensation during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized). Alternate captions include the words "stock-based compensation".</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 35<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415241&amp;loc=d3e4534-113899<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 20<br><br> -Section 55<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=32706628&amp;loc=d3e11149-113907<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 20<br><br> -Section 55<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=32706628&amp;loc=d3e11178-113907<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SharesIssued</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 4.E)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section E<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued during the period as a result of the conversion of convertible securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-30)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of new stock issued during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of share options (or share units) exercised during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The gross value of stock issued during the period upon the conversion of convertible securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of stock issued as a result of the exercise of stock options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockRetiredParValueMethodAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of decrease of par value, additional paid in capital (APIC) and retained earnings of common and preferred stock retired from treasury when treasury stock is accounted for under the par value method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_TreasuryStockRetiredParValueMethodAmount</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesRetired">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of common and preferred stock retired from treasury during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_TreasuryStockSharesRetired</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>4. Stockholders&#x2019; Equity</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 During 2002 and 2003, the Company issued a total of 34,239,374
 shares of Series A-1 and Series A-2 convertible preferred stock
 (Series A preferred stock) for $1.00 per share resulting in net
 proceeds of approximately $34.0 million.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 In October 2004, the Company entered into a series of transactions
 raising $30.3 million, net of related offering costs of
 approximately $238,000, from the sale of 71,401,237 shares of its
 Series B convertible preferred stock (Series B preferred stock). In
 connection with the Series B preferred stock offering, 13,604,016
 shares of common stock were allocated to holders of Series&#xA0;A-1
 preferred stock as an anti-dilution measure.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 In May&#xA0;2006, the Company raised $44.9 million, net of related
 offering costs of $101,246, from the sale of 110,952,217 shares of
 its Series C convertible preferred stock (Series C preferred
 stock). In connection with the Series C preferred stock offering,
 10,003,300 shares of common stock were allocated to holders of
 Series B preferred stock as an anti-dilution measure.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 In July&#xA0;2008, the Company issued 12,466,039 shares of its
 Series D convertible preferred stock (Series D preferred stock) in
 exchange for all of the outstanding capital stock and convertible
 notes payable of Raven Biotechnologies, Inc. (Raven). Subsequently,
 in March 2011 a settlement was reached with the former Raven
 stockholders bringing the total Series D preferred stock issued in
 connection with the Raven acquisition to 14,446,227 shares.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 In September&#xA0;2008, the Company raised $24.8 million, net of
 related offering costs of $156,788 from the sale of 38,337,678
 shares of its Series D-2 convertible preferred stock (Series D-2
 preferred stock). The Company also issued preferred stock warrants
 for the purchase of 2,875,327 shares of Series D-2 preferred stock.
 The preferred stock warrants were exercisable at any time prior to
 September&#xA0;2018, but expired upon an IPO, and had a stated
 exercise price of $0.65 per warrant. On May&#xA0;16, 2010, the
 Company exercised a put notice to Eli Lilly in accordance with the
 Series D-2 preferred stock purchase agreement, resulting in the
 issuance of 6,916,110 shares of Series D-2 preferred stock and a
 warrant to purchase 518,708 additional shares of Series D-2
 preferred stock. On January&#xA0;11, 2011, the Company raised gross
 proceeds of $12.0 million from the sale of 18,427,388 shares of its
 Series D-2 preferred stock.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Due to certain provisions in the Series D-2 convertible preferred
 stock warrant agreement, these warrants were required to be
 classified as a liability. Management believed that the
 circumstances requiring cash settlement of the award were remote.
 The Series D-2 preferred stock warrant liability was recorded at
 fair value and has been adjusted to fair value at the end of each
 reporting period using the Option-Pricing Method, with changes in
 value recorded as &#x201C;Other income (expense)&#x201D; in the
 accompanying consolidated statements of operations and
 comprehensive income (loss). Prior to the Company&#x2019;s IPO in
 October 2013, all the preferred stock warrants were exercised and
 subsequently were converted into shares of common stock in
 connection with the IPO.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Dividends were noncumulative and accrued on the Series A, Series B,
 Series C, Series D and Series&#xA0;D-2 preferred stock at a rate of
 $0.08, $0.0341, $0.0324 and $0.0522 per annum, respectively, and
 were payable when and as declared by the Board of Directors.
 Dividends had to be declared so that the Series A, Series&#xA0;B,
 Series C and Series D preferred stock were paid in like-kind and
 participated equally to those of the Series&#xA0;D-2 preferred and
 common stock. No dividends had been declared prior to the
 conversion of the preferred stock to common stock in connection
 with the IPO.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The Company&#x2019;s Series A-1, Series A-2, Series B, Series C,
 Series D and Series D-2 preferred stock were initially convertible
 into 1.506, 1.00, 1.14, 1.00, 1.00 and 1.00 shares, respectively,
 of common stock at the option of the holder. The conversion ratio
 of certain series of preferred stock was subject to change in the
 event specified dilutive transactions occurred, which included the
 Company&#x2019;s IPO. There were no anti-dilution protections for
 the Series A-2 preferred stock and no adjustment to the Series A-1
 preferred stock conversion price was to be made if a common stock
 issuance was at a price per share greater than the conversion price
 of the Series C preferred stock. Upon consummation of the
 Company&#x2019;s IPO in October 2013, all outstanding shares of
 preferred stock automatically converted to shares of the
 Company&#x2019;s common stock at the applicable conversion ratios
 then in effect. The conversion price was $12.39, $18.77, $6.95,
 $7.70, $12.20 and $12.20 for each share of Series A-1, A-2, Series
 B, Series C, Series D and Series D-2 convertible preferred stock,
 respectively.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 On October&#xA0;16, 2013, the Company completed its IPO, in which
 5,000,000 shares of the Company&#x2019;s common stock were sold at a
 price of $16.00 per share. Additionally, the underwriters of the
 Company&#x2019;s IPO exercised the full amount of their
 over-allotment option resulting in the sale of an additional
 750,000 shares of the Company&#x2019;s common stock at a price of
 $16.00 per share. The Company received proceeds of $83.8 million
 from the IPO, net of underwriting discounts and commissions and
 other offering expenses. Upon consummation of the IPO, all
 outstanding shares of preferred stock automatically converted to
 common stock at the applicable conversion ratios then in
 effect.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 In connection with preparing for its IPO in October 2013, the
 Company&#x2019;s Board of Directors and stockholders approved a
 1-for-18.7739 reverse stock split of the Company&#x2019;s common
 stock. The reverse stock split became effective on
 September&#xA0;26, 2013. All share and per share amounts in the
 consolidated financial statements and notes thereto have been
 retroactively adjusted for all periods presented to give effect to
 this reverse stock split, including reclassifying an amount equal
 to the reduction in par value of common stock to additional paid-in
 capital. In addition, in September 2013, the Company&#x2019;s Board
 of Directors and stockholders approved an amendment of the
 Company&#x2019;s certificate of incorporation to, among other
 things, change the definition of a designated public offering to
 remove the per share price requirement. The amended and restated
 certificate of incorporation also changed the authorized number of
 shares of common stock from 425,000,000 to 125,000,000, and
 authorized 5,000,000 shares of undesignated preferred stock with a
 par value of $0.01 per share. There were no shares of undesignated
 preferred stock issued or outstanding as of December&#xA0;31, 2014
 or 2013.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 In February 2014, the Company completed a follow-on equity
 offering, in which the Company sold 1.8&#xA0;million shares of its
 common stock at a price of $36.50 per share. Additionally, the
 underwriters of the offering exercised the full amount of their
 over-allotment option resulting in the sale of an additional
 450,000&#xA0;shares of the Company&#x2019;s common stock at a price
 of $36.50 per share. The Company received proceeds of
 $76.7&#xA0;million from this offering, net of underwriting
 discounts and commissions and other offering expenses.</p>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(d),(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 4<br><br> -Subparagraph (SAB TOPIC 4.C)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 4.E)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section C<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section E<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Article 4<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Preferred Stock<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br><br><br>Reference 17: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br><br><br>Reference 18: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph d<br><br> -Article 4<br><br><br><br>Reference 19: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ENFAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Minimum Future Lease Payments (Detail) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">2015</a></td>
        <td class="nump"><a title="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" onclick="toggleNextSibling(this);">$ 3,945</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2016</a></td>
        <td class="nump"><a title="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" onclick="toggleNextSibling(this);">4,364</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2017</a></td>
        <td class="nump"><a title="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" onclick="toggleNextSibling(this);">4,495</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">2018</a></td>
        <td class="nump"><a title="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" onclick="toggleNextSibling(this);">4,396</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears', window );">2019</a></td>
        <td class="nump"><a title="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" onclick="toggleNextSibling(this);">1,873</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter', window );">Thereafter</a></td>
        <td class="nump"><a title="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" onclick="toggleNextSibling(this);">116</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total</a></td>
        <td class="nump"><a title="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" onclick="toggleNextSibling(this);">$ 19,189</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Quarterly Financial Information (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock', window );">Company's Consolidated Quarterly Results of Operations</a></td>
        <td class="text"><div>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0">
 <tr>
 <td width="55%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>1<sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top">st</sup>&#xA0;Quarter</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2<sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top">nd</sup>&#xA0;Quarter</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>3<sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top">rd</sup>&#xA0;Quarter</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>4<sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top">th</sup>&#xA0;Quarter</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="14" align="center"><b>(in thousands,
 except per share data)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 <b>2014</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Revenue</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">14,719</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">9,220</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">18,382</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">5,476</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Net loss</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(3,108</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(12,259</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(3,928</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(19,018</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Net loss per share, basic and diluted</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.12</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.44</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.14</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.68</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 <b>2013</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Revenue</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">10,598</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">12,299</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">20,232</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">14,906</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Net income (loss)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(3,366</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(294</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,604</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(3,205</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Net income (loss) per share, basic</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(2.93</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.24</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">0.14</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.14</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Net income (loss) per share, diluted</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(2.93</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.24</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">0.01</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.14</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the quarterly financial data in the annual financial statements. The disclosure includes financial information for each fiscal quarter for the current and previous year, including revenues, gross profit, income (loss) before extraordinary items and cumulative effect of a change in accounting principle and earnings per share data.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 270<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)-(j)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35737889&amp;loc=d3e1280-108306<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<FilingSummary xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <Version>2.4.1.9</Version>
  <ProcessingTime />
  <ReportFormat>Html</ReportFormat>
  <ContextCount>249</ContextCount>
  <ElementCount>326</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>83</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>10</UnitCount>
  <MyReports>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>101 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/DocumentandEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
    </Report>
    <Report>
      <IsDefault>true</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>103 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/StatementOfFinancialPositionClassified</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>104 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>105 - Statement - Consolidated Statements of Operations and Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/StatementOfIncomeAlternative</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Income (Loss)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>106 - Statement - Consolidated Statements of Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity (Deficit)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>107 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/StatementOfCashFlowsIndirect</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>108 - Disclosure - Organization and Nature of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</Role>
      <ShortName>Organization and Nature of Operations</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>109 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>110 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock</Role>
      <ShortName>Property and Equipment</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>111 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock</Role>
      <ShortName>Stockholders' Equity</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>112 - Disclosure - Stock-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</Role>
      <ShortName>Stock-based Compensation</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>113 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock</Role>
      <ShortName>Income Taxes</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>114 - Disclosure - Lease Exit Liability</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsRestructuringAndRelatedActivitiesDisclosureTextBlock</Role>
      <ShortName>Lease Exit Liability</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>115 - Disclosure - Collaboration and License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsCollaborationAndLicenseAgreementsDisclosureTextBlock</Role>
      <ShortName>Collaboration and License Agreements</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>116 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock</Role>
      <ShortName>Commitments and Contingencies</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>117 - Disclosure - Product Milestone Payments and Royalty Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsRoyaltyAgreementDisclosureTextBlock</Role>
      <ShortName>Product Milestone Payments and Royalty Agreements</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>118 - Disclosure - Employee Benefit Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsPensionAndOtherPostretirementBenefitsDisclosureTextBlock</Role>
      <ShortName>Employee Benefit Plan</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>119 - Disclosure - Quarterly Financial Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlock</Role>
      <ShortName>Quarterly Financial Information</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>120 - Disclosure - Subsequent Event</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock</Role>
      <ShortName>Subsequent Event</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>121 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>122 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>123 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>124 - Disclosure - Stock-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables</Role>
      <ShortName>Stock-based Compensation (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>125 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>126 - Disclosure - Lease Exit Liability (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsRestructuringAndRelatedActivitiesDisclosureTextBlockTables</Role>
      <ShortName>Lease Exit Liability (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>127 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>128 - Disclosure - Quarterly Financial Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlockTables</Role>
      <ShortName>Quarterly Financial Information (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>129 - Disclosure - Organization and Nature of Operations - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformation</Role>
      <ShortName>Organization and Nature of Operations - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>130 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>131 - Disclosure - Summary of Significant Accounting Policies - Summary of Fair Value Measurement Financial Asset and Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfFairValueMeasurementFinancialAssetAndLiabilities</Role>
      <ShortName>Summary of Significant Accounting Policies - Summary of Fair Value Measurement Financial Asset and Liabilities (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>132 - Disclosure - Summary of Significant Accounting Policies - Summary of Collaborators that Represent More Than 10% of Total Revenue Earned (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfCollaboratorsThatRepresentMoreThan10OfTotalRevenueEarned</Role>
      <ShortName>Summary of Significant Accounting Policies - Summary of Collaborators that Represent More Than 10% of Total Revenue Earned (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>133 - Disclosure - Summary of Significant Accounting Policies - Summary of Collaborators that Represent More Than 10% of Accounts Receivable (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfCollaboratorsThatRepresentMoreThan10OfAccountsReceivable</Role>
      <ShortName>Summary of Significant Accounting Policies - Summary of Collaborators that Represent More Than 10% of Accounts Receivable (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>134 - Disclosure - Summary of Significant Accounting Policies - Estimated Useful Lives (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLives</Role>
      <ShortName>Summary of Significant Accounting Policies - Estimated Useful Lives (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>135 - Disclosure - Summary of Significant Accounting Policies - Computation of Basic and Diluted Income (Loss) Per Common Share (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesComputationOfBasicAndDilutedIncomeLossPerCommonShare</Role>
      <ShortName>Summary of Significant Accounting Policies - Computation of Basic and Diluted Income (Loss) Per Common Share (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>136 - Disclosure - Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from the Calculation of Diluted Income (Loss) Per Share (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromTheCalculationOfDilutedIncomeLossPerShare</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from the Calculation of Diluted Income (Loss) Per Share (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>137 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipment</Role>
      <ShortName>Property and Equipment - Schedule of Property and Equipment (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>138 - Disclosure - Property and Equipment - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformation</Role>
      <ShortName>Property and Equipment - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>139 - Disclosure - Stockholders' Equity - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/DisclosureStockholdersEquityAdditionalInformation</Role>
      <ShortName>Stockholders' Equity - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>140 - Disclosure - Stock- based Compensation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformation</Role>
      <ShortName>Stock- based Compensation - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>141 - Disclosure - Stock- based Compensation - Schedule of Stock-Based Compensation Expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpense</Role>
      <ShortName>Stock- based Compensation - Schedule of Stock-Based Compensation Expense (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>142 - Disclosure - Stock- based Compensation - Schedule of Fair Value Option Award Estimated on the Date of Grant Using the Black-Scholes Option-Pricing Model (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/DisclosureStockBasedCompensationScheduleOfFairValueOptionAwardEstimatedOnTheDateOfGrantUsingTheBlackScholesOptionPricingModel</Role>
      <ShortName>Stock- based Compensation - Schedule of Fair Value Option Award Estimated on the Date of Grant Using the Black-Scholes Option-Pricing Model (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>143 - Disclosure - Stock- based Compensation - Schedule of Stock Option and Restricted Stock Unit Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockOptionAndRestrictedStockUnitActivity</Role>
      <ShortName>Stock- based Compensation - Schedule of Stock Option and Restricted Stock Unit Activity (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>144 - Disclosure - Income Taxes - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation</Role>
      <ShortName>Income Taxes - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>145 - Disclosure - Income Taxes - Components of the Company's Deferred Tax Assets (Liabilities) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/DisclosureIncomeTaxesComponentsOfTheCompanysDeferredTaxAssetsLiabilities</Role>
      <ShortName>Income Taxes - Components of the Company's Deferred Tax Assets (Liabilities) (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>146 - Disclosure - Income Taxes - Reconciliation of Reported Estimated Income Tax Benefit (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/DisclosureIncomeTaxesReconciliationOfReportedEstimatedIncomeTaxBenefit</Role>
      <ShortName>Income Taxes - Reconciliation of Reported Estimated Income Tax Benefit (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>147 - Disclosure - Income Taxes - Reconciliation of the Beginning and Ending Amount of Gross Unrecognized Tax Benefits (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/DisclosureIncomeTaxesReconciliationOfTheBeginningAndEndingAmountOfGrossUnrecognizedTaxBenefits</Role>
      <ShortName>Income Taxes - Reconciliation of the Beginning and Ending Amount of Gross Unrecognized Tax Benefits (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>148 - Disclosure - Lease Exit Liability - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/DisclosureLeaseExitLiabilityAdditionalInformation</Role>
      <ShortName>Lease Exit Liability - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>149 - Disclosure - Lease Exit Liability - Changes in Lease Exit Liability (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/DisclosureLeaseExitLiabilityChangesInLeaseExitLiability</Role>
      <ShortName>Lease Exit Liability - Changes in Lease Exit Liability (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>150 - Disclosure - Lease Exit Liability - Future Principal Payments Under Lease Agreement (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/DisclosureLeaseExitLiabilityFuturePrincipalPaymentsUnderLeaseAgreement</Role>
      <ShortName>Lease Exit Liability - Future Principal Payments Under Lease Agreement (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>151 - Disclosure - Collaboration and License Agreements - Additional Information 1 (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformation1</Role>
      <ShortName>Collaboration and License Agreements - Additional Information 1 (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>152 - Disclosure - Collaboration and License Agreements - Additional Information 2 (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformation2</Role>
      <ShortName>Collaboration and License Agreements - Additional Information 2 (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>153 - Disclosure - Collaboration and License Agreements - Additional Information 3 (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformation3</Role>
      <ShortName>Collaboration and License Agreements - Additional Information 3 (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>154 - Disclosure - Collaboration and License Agreements - Additional Information 4 (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformation4</Role>
      <ShortName>Collaboration and License Agreements - Additional Information 4 (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>155 - Disclosure - Collaboration and License Agreements - Additional Information 5 (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformation5</Role>
      <ShortName>Collaboration and License Agreements - Additional Information 5 (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>156 - Disclosure - Collaboration and License Agreements - Additional Information 6 (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformation6</Role>
      <ShortName>Collaboration and License Agreements - Additional Information 6 (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>157 - Disclosure - Collaboration and License Agreements - Additional Information 7 (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformation7</Role>
      <ShortName>Collaboration and License Agreements - Additional Information 7 (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>158 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>159 - Disclosure - Commitments and Contingencies - Schedule of Minimum Future Lease Payments (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMinimumFutureLeasePayments</Role>
      <ShortName>Commitments and Contingencies - Schedule of Minimum Future Lease Payments (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>160 - Disclosure - Product Milestone Payments and Royalty Agreements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/DisclosureProductMilestonePaymentsAndRoyaltyAgreementsAdditionalInformation</Role>
      <ShortName>Product Milestone Payments and Royalty Agreements - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>161 - Disclosure - Employee Benefit Plan - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/DisclosureEmployeeBenefitPlanAdditionalInformation</Role>
      <ShortName>Employee Benefit Plan - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>162 - Disclosure - Quarterly Financial Information - Company's Consolidated Quarterly Results of Operations (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/DisclosureQuarterlyFinancialInformationCompanysConsolidatedQuarterlyResultsOfOperations</Role>
      <ShortName>Quarterly Financial Information - Company's Consolidated Quarterly Results of Operations (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>163 - Disclosure - Subsequent Event - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/DisclosureSubsequentEventAdditionalInformation</Role>
      <ShortName>Subsequent Event - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Info">Element us-gaap_DeferredRevenue had a mix of decimals attribute values: -5 0.</Log>
    <Log type="Info">Element us-gaap_DeferredRevenueCurrent had a mix of decimals attribute values: -5 -3 0.</Log>
    <Log type="Info">Element us-gaap_DeferredRevenueNoncurrent had a mix of decimals attribute values: -5 -3 0.</Log>
    <Log type="Info">Element us-gaap_LicensesRevenue had a mix of decimals attribute values: -5 0.</Log>
    <Log type="Info">Element us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate had a mix of decimals attribute values: 0 2.</Log>
    <Log type="Info">Element us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate had a mix of decimals attribute values: 0 3.</Log>
    <Log type="Info">Columns in Cash Flows statement 'Consolidated Statements of Cash Flows (USD $)' have maximum duration 365 days and at least 25 values. Shorter duration columns must have at least one fourth (6) as many values. Column '1/1/2013 - 3/31/2013' is shorter (89 days) and has only 2 values, so it is being removed.</Log>
    <Log type="Info">Columns in Cash Flows statement 'Consolidated Statements of Cash Flows (USD $)' have maximum duration 365 days and at least 25 values. Shorter duration columns must have at least one fourth (6) as many values. Column '4/1/2013 - 6/30/2013' is shorter (90 days) and has only 1 values, so it is being removed.</Log>
    <Log type="Info">Columns in Cash Flows statement 'Consolidated Statements of Cash Flows (USD $)' have maximum duration 365 days and at least 25 values. Shorter duration columns must have at least one fourth (6) as many values. Column '7/1/2013 - 9/30/2013' is shorter (91 days) and has only 1 values, so it is being removed.</Log>
    <Log type="Info">Columns in Cash Flows statement 'Consolidated Statements of Cash Flows (USD $)' have maximum duration 365 days and at least 25 values. Shorter duration columns must have at least one fourth (6) as many values. Column '10/1/2013 - 12/31/2013' is shorter (91 days) and has only 2 values, so it is being removed.</Log>
    <Log type="Info">Columns in Cash Flows statement 'Consolidated Statements of Cash Flows (USD $)' have maximum duration 365 days and at least 25 values. Shorter duration columns must have at least one fourth (6) as many values. Column '1/1/2014 - 3/31/2014' is shorter (89 days) and has only 2 values, so it is being removed.</Log>
    <Log type="Info">Columns in Cash Flows statement 'Consolidated Statements of Cash Flows (USD $)' have maximum duration 365 days and at least 25 values. Shorter duration columns must have at least one fourth (6) as many values. Column '4/1/2014 - 6/30/2014' is shorter (90 days) and has only 1 values, so it is being removed.</Log>
    <Log type="Info">Columns in Cash Flows statement 'Consolidated Statements of Cash Flows (USD $)' have maximum duration 365 days and at least 25 values. Shorter duration columns must have at least one fourth (6) as many values. Column '7/1/2014 - 9/30/2014' is shorter (91 days) and has only 1 values, so it is being removed.</Log>
    <Log type="Info">Columns in Cash Flows statement 'Consolidated Statements of Cash Flows (USD $)' have maximum duration 365 days and at least 25 values. Shorter duration columns must have at least one fourth (6) as many values. Column '10/1/2014 - 12/31/2014' is shorter (91 days) and has only 2 values, so it is being removed.</Log>
    <Log type="Info">'Monetary' elements on report '139 - Disclosure - Stockholders' Equity - Additional Information (Detail)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">'Monetary' elements on report '140 - Disclosure - Stock- based Compensation - Additional Information (Detail)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">'Monetary' elements on report '148 - Disclosure - Lease Exit Liability - Additional Information (Detail)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">'Monetary' elements on report '151 - Disclosure - Collaboration and License Agreements - Additional Information 1 (Detail)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">'Monetary' elements on report '157 - Disclosure - Collaboration and License Agreements - Additional Information 7 (Detail)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">'Monetary' elements on report '163 - Disclosure - Subsequent Event - Additional Information (Detail)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">Process Flow-Through: 103 - Statement - Consolidated Balance Sheets</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2012'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2011'</Log>
    <Log type="Info">Process Flow-Through: 104 - Statement - Consolidated Balance Sheets (Parenthetical)</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2012'</Log>
    <Log type="Info">Process Flow-Through: 105 - Statement - Consolidated Statements of Operations and Comprehensive Income (Loss)</Log>
    <Log type="Info">	Process Flow-Through: Removing column '3 Months Ended
Dec. 31, 2014'</Log>
    <Log type="Info">	Process Flow-Through: Removing column '3 Months Ended
Sep. 30, 2014'</Log>
    <Log type="Info">	Process Flow-Through: Removing column '3 Months Ended
Jun. 30, 2014'</Log>
    <Log type="Info">	Process Flow-Through: Removing column '3 Months Ended
Mar. 31, 2014'</Log>
    <Log type="Info">	Process Flow-Through: Removing column '3 Months Ended
Dec. 31, 2013'</Log>
    <Log type="Info">	Process Flow-Through: Removing column '3 Months Ended
Sep. 30, 2013'</Log>
    <Log type="Info">	Process Flow-Through: Removing column '3 Months Ended
Jun. 30, 2013'</Log>
    <Log type="Info">	Process Flow-Through: Removing column '3 Months Ended
Mar. 31, 2013'</Log>
    <Log type="Info">Process Flow-Through: 107 - Statement - Consolidated Statements of Cash Flows</Log>
  </Logs>
  <InputFiles>
    <File>mgnx-20141231.xml</File>
    <File>mgnx-20141231.xsd</File>
    <File>mgnx-20141231_cal.xml</File>
    <File>mgnx-20141231_def.xml</File>
    <File>mgnx-20141231_lab.xml</File>
    <File>mgnx-20141231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles />
  <BaseTaxonomies />
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ES3FM">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stockholders' Equity - Additional Information (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="1">24 Months Ended</th>
        <th class="th" colspan="4">1 Months Ended</th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Oct. 16, 2013</div>
        </th>
        <th class="th">
          <div>Feb. 28, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Jan. 11, 2011</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2003</div>
        </th>
        <th class="th">
          <div>Oct. 31, 2004</div>
        </th>
        <th class="th">
          <div>May 31, 2006</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2011</div>
        </th>
        <th class="th">
          <div>Jul. 31, 2008</div>
        </th>
        <th class="th">
          <div>May 16, 2010</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2008</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued or sold</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesNewIssues" onclick="toggleNextSibling(this);">1,800,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Price per share</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_SharePrice" onclick="toggleNextSibling(this);">$ 36.50</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharePrice</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from sale of shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" onclick="toggleNextSibling(this);">$ 76,700,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from initial public offering net of expenses</a></td>
        <td class="nump"><a title="us-gaap_ProceedsFromIssuanceInitialPublicOffering" onclick="toggleNextSibling(this);">83,800,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">1-for-18.7739<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesAuthorized" onclick="toggleNextSibling(this);">125,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesAuthorized</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesAuthorized" onclick="toggleNextSibling(this);">125,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesAuthorized</span><span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesAuthorized" onclick="toggleNextSibling(this);">425,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesAuthorized</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption', window );">Additional shares sold under over-allotments option to underwriter</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="mgnx_StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption" onclick="toggleNextSibling(this);">450,000</a><span style="display:none;white-space:normal;text-align:left;">mgnx_StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued or sold</a></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesNewIssues[us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember]" onclick="toggleNextSibling(this);">5,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesNewIssues<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= us-gaap_IPOMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Price per share</a></td>
        <td class="nump"><a title="us-gaap_SharePrice[us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember]" onclick="toggleNextSibling(this);">$ 16.00</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharePrice<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= us-gaap_IPOMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued or sold</a></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesNewIssues[us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember]" onclick="toggleNextSibling(this);">750,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesNewIssues<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= us-gaap_OverAllotmentOptionMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Price per share</a></td>
        <td class="nump"><a title="us-gaap_SharePrice[us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember]" onclick="toggleNextSibling(this);">$ 16.00</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharePrice<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= us-gaap_OverAllotmentOptionMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=mgnx_SeriesD2ConvertiblePreferredStockMember', window );">Series D-2 Convertible Preferred Stock [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued or sold</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesNewIssues[us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=mgnx_SeriesD2ConvertiblePreferredStockMember]" onclick="toggleNextSibling(this);">18,427,388</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesNewIssues<br>/ us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis<br>= mgnx_SeriesD2ConvertiblePreferredStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from sale of shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromIssuanceOrSaleOfEquity[us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=mgnx_SeriesD2ConvertiblePreferredStockMember]" onclick="toggleNextSibling(this);">12,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity<br>/ us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis<br>= mgnx_SeriesD2ConvertiblePreferredStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued or sold</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesNewIssues[us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember]" onclick="toggleNextSibling(this);">34,239,374</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesNewIssues<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_SeriesAPreferredStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from issuance of convertible preferred stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock[us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember]" onclick="toggleNextSibling(this);">34,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_SeriesAPreferredStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Price per share</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_SharePrice[us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember]" onclick="toggleNextSibling(this);">$ 1.00</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharePrice<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_SeriesAPreferredStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePerDollarAmount', window );">Accrued noncumulative dividends on preferred stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_PreferredStockDividendRatePerDollarAmount[us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember]" onclick="toggleNextSibling(this);"> 0.08</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockDividendRatePerDollarAmount<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_SeriesAPreferredStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=mgnx_SeriesA1PreferredStockMember', window );">Series A-1 Preferred Stock [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Convertible preferred stock series</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion[us-gaap_StatementClassOfStockAxis=mgnx_SeriesA1PreferredStockMember]" onclick="toggleNextSibling(this);">1.506</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion<br>/ us-gaap_StatementClassOfStockAxis<br>= mgnx_SeriesA1PreferredStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ConvertiblePreferredStockConversionPrice', window );">Conversion price of preferred stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="mgnx_ConvertiblePreferredStockConversionPrice[us-gaap_StatementClassOfStockAxis=mgnx_SeriesA1PreferredStockMember]" onclick="toggleNextSibling(this);"> 12.39</a><span style="display:none;white-space:normal;text-align:left;">mgnx_ConvertiblePreferredStockConversionPrice<br>/ us-gaap_StatementClassOfStockAxis<br>= mgnx_SeriesA1PreferredStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=mgnx_SeriesA2PreferredStockMember', window );">Series A-2 Preferred Stock [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Convertible preferred stock series</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion[us-gaap_StatementClassOfStockAxis=mgnx_SeriesA2PreferredStockMember]" onclick="toggleNextSibling(this);">1.00</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion<br>/ us-gaap_StatementClassOfStockAxis<br>= mgnx_SeriesA2PreferredStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ConvertiblePreferredStockConversionPrice', window );">Conversion price of preferred stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="mgnx_ConvertiblePreferredStockConversionPrice[us-gaap_StatementClassOfStockAxis=mgnx_SeriesA2PreferredStockMember]" onclick="toggleNextSibling(this);"> 18.77</a><span style="display:none;white-space:normal;text-align:left;">mgnx_ConvertiblePreferredStockConversionPrice<br>/ us-gaap_StatementClassOfStockAxis<br>= mgnx_SeriesA2PreferredStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued or sold</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesNewIssues[us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember]" onclick="toggleNextSibling(this);">71,401,237</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesNewIssues<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_SeriesBPreferredStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from issuance of convertible preferred stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock[us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember]" onclick="toggleNextSibling(this);">30,300,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_SeriesBPreferredStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_StockIssuanceCosts', window );">Related offering costs</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="mgnx_StockIssuanceCosts[us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember]" onclick="toggleNextSibling(this);">238,000</a><span style="display:none;white-space:normal;text-align:left;">mgnx_StockIssuanceCosts<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_SeriesBPreferredStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares of common stock allocated</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_SharesIssued[us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember]" onclick="toggleNextSibling(this);">10,003,300</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharesIssued<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_SeriesBPreferredStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePerDollarAmount', window );">Accrued noncumulative dividends on preferred stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_PreferredStockDividendRatePerDollarAmount[us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember]" onclick="toggleNextSibling(this);"> 0.0341</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockDividendRatePerDollarAmount<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_SeriesBPreferredStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Convertible preferred stock series</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion[us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember]" onclick="toggleNextSibling(this);">1.14</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_SeriesBPreferredStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ConvertiblePreferredStockConversionPrice', window );">Conversion price of preferred stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="mgnx_ConvertiblePreferredStockConversionPrice[us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember]" onclick="toggleNextSibling(this);"> 6.95</a><span style="display:none;white-space:normal;text-align:left;">mgnx_ConvertiblePreferredStockConversionPrice<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_SeriesBPreferredStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued or sold</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesNewIssues[us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember]" onclick="toggleNextSibling(this);">110,952,217</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesNewIssues<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_SeriesCPreferredStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from issuance of convertible preferred stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock[us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember]" onclick="toggleNextSibling(this);">44,900,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_SeriesCPreferredStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_StockIssuanceCosts', window );">Related offering costs</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="mgnx_StockIssuanceCosts[us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember]" onclick="toggleNextSibling(this);">101,246</a><span style="display:none;white-space:normal;text-align:left;">mgnx_StockIssuanceCosts<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_SeriesCPreferredStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePerDollarAmount', window );">Accrued noncumulative dividends on preferred stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_PreferredStockDividendRatePerDollarAmount[us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember]" onclick="toggleNextSibling(this);"> 0.0324</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockDividendRatePerDollarAmount<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_SeriesCPreferredStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Convertible preferred stock series</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion[us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember]" onclick="toggleNextSibling(this);">1.00</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_SeriesCPreferredStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ConvertiblePreferredStockConversionPrice', window );">Conversion price of preferred stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="mgnx_ConvertiblePreferredStockConversionPrice[us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember]" onclick="toggleNextSibling(this);"> 7.70</a><span style="display:none;white-space:normal;text-align:left;">mgnx_ConvertiblePreferredStockConversionPrice<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_SeriesCPreferredStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember', window );">Series D Preferred Stock [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePerDollarAmount', window );">Accrued noncumulative dividends on preferred stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_PreferredStockDividendRatePerDollarAmount[us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember]" onclick="toggleNextSibling(this);"> 0.0522</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockDividendRatePerDollarAmount<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_SeriesDPreferredStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Convertible preferred stock series</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion[us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember]" onclick="toggleNextSibling(this);">1.00</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_SeriesDPreferredStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ConvertiblePreferredStockConversionPrice', window );">Conversion price of preferred stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="mgnx_ConvertiblePreferredStockConversionPrice[us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember]" onclick="toggleNextSibling(this);"> 12.20</a><span style="display:none;white-space:normal;text-align:left;">mgnx_ConvertiblePreferredStockConversionPrice<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_SeriesDPreferredStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember', window );">Series D Preferred Stock [Member] | Raven Biotechnologies Inc. [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Shares issued to acquire entity</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued[us-gaap_BusinessAcquisitionAxis=mgnx_RavenBiotechnologiesIncMember;us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember]" onclick="toggleNextSibling(this);">14,446,227</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued<br>/ us-gaap_BusinessAcquisitionAxis<br>= mgnx_RavenBiotechnologiesIncMember<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_SeriesDPreferredStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued[us-gaap_BusinessAcquisitionAxis=mgnx_RavenBiotechnologiesIncMember;us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember]" onclick="toggleNextSibling(this);">12,466,039</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued<br>/ us-gaap_BusinessAcquisitionAxis<br>= mgnx_RavenBiotechnologiesIncMember<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_SeriesDPreferredStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=mgnx_SeriesD2PreferredStockMember', window );">Series D-2 Preferred Stock [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued or sold</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesNewIssues[us-gaap_StatementClassOfStockAxis=mgnx_SeriesD2PreferredStockMember]" onclick="toggleNextSibling(this);">6,916,110</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesNewIssues<br>/ us-gaap_StatementClassOfStockAxis<br>= mgnx_SeriesD2PreferredStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesNewIssues[us-gaap_StatementClassOfStockAxis=mgnx_SeriesD2PreferredStockMember]" onclick="toggleNextSibling(this);">38,337,678</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesNewIssues<br>/ us-gaap_StatementClassOfStockAxis<br>= mgnx_SeriesD2PreferredStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from issuance of convertible preferred stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock[us-gaap_StatementClassOfStockAxis=mgnx_SeriesD2PreferredStockMember]" onclick="toggleNextSibling(this);">24,800,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock<br>/ us-gaap_StatementClassOfStockAxis<br>= mgnx_SeriesD2PreferredStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_StockIssuanceCosts', window );">Related offering costs</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="mgnx_StockIssuanceCosts[us-gaap_StatementClassOfStockAxis=mgnx_SeriesD2PreferredStockMember]" onclick="toggleNextSibling(this);">$ 156,788</a><span style="display:none;white-space:normal;text-align:left;">mgnx_StockIssuanceCosts<br>/ us-gaap_StatementClassOfStockAxis<br>= mgnx_SeriesD2PreferredStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Purchased shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights[us-gaap_StatementClassOfStockAxis=mgnx_SeriesD2PreferredStockMember]" onclick="toggleNextSibling(this);">518,708</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights<br>/ us-gaap_StatementClassOfStockAxis<br>= mgnx_SeriesD2PreferredStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights[us-gaap_StatementClassOfStockAxis=mgnx_SeriesD2PreferredStockMember]" onclick="toggleNextSibling(this);">2,875,327</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights<br>/ us-gaap_StatementClassOfStockAxis<br>= mgnx_SeriesD2PreferredStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1[us-gaap_StatementClassOfStockAxis=mgnx_SeriesD2PreferredStockMember]" onclick="toggleNextSibling(this);"> 0.65</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1<br>/ us-gaap_StatementClassOfStockAxis<br>= mgnx_SeriesD2PreferredStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePerDollarAmount', window );">Accrued noncumulative dividends on preferred stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_PreferredStockDividendRatePerDollarAmount[us-gaap_StatementClassOfStockAxis=mgnx_SeriesD2PreferredStockMember]" onclick="toggleNextSibling(this);"> 0.0522</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockDividendRatePerDollarAmount<br>/ us-gaap_StatementClassOfStockAxis<br>= mgnx_SeriesD2PreferredStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Convertible preferred stock series</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion[us-gaap_StatementClassOfStockAxis=mgnx_SeriesD2PreferredStockMember]" onclick="toggleNextSibling(this);">1.00</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion<br>/ us-gaap_StatementClassOfStockAxis<br>= mgnx_SeriesD2PreferredStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ConvertiblePreferredStockConversionPrice', window );">Conversion price of preferred stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="mgnx_ConvertiblePreferredStockConversionPrice[us-gaap_StatementClassOfStockAxis=mgnx_SeriesD2PreferredStockMember]" onclick="toggleNextSibling(this);"> 12.20</a><span style="display:none;white-space:normal;text-align:left;">mgnx_ConvertiblePreferredStockConversionPrice<br>/ us-gaap_StatementClassOfStockAxis<br>= mgnx_SeriesD2PreferredStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=mgnx_UndesignatedPreferredStockMember', window );">Undesignated Preferred Stock [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Undesignated preferred stock, shares authorized</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_PreferredStockSharesAuthorized[us-gaap_StatementClassOfStockAxis=mgnx_UndesignatedPreferredStockMember]" onclick="toggleNextSibling(this);">5,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesAuthorized<br>/ us-gaap_StatementClassOfStockAxis<br>= mgnx_UndesignatedPreferredStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Undesignated preferred stock, par value</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_PreferredStockParOrStatedValuePerShare[us-gaap_StatementClassOfStockAxis=mgnx_UndesignatedPreferredStockMember]" onclick="toggleNextSibling(this);"> 0.01</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockParOrStatedValuePerShare<br>/ us-gaap_StatementClassOfStockAxis<br>= mgnx_UndesignatedPreferredStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Undesignated preferred stock, shares issued</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_PreferredStockSharesIssued[us-gaap_StatementClassOfStockAxis=mgnx_UndesignatedPreferredStockMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesIssued<br>/ us-gaap_StatementClassOfStockAxis<br>= mgnx_UndesignatedPreferredStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_PreferredStockSharesIssued[us-gaap_StatementClassOfStockAxis=mgnx_UndesignatedPreferredStockMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesIssued<br>/ us-gaap_StatementClassOfStockAxis<br>= mgnx_UndesignatedPreferredStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Undesignated preferred stock, shares outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_PreferredStockSharesOutstanding[us-gaap_StatementClassOfStockAxis=mgnx_UndesignatedPreferredStockMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesOutstanding<br>/ us-gaap_StatementClassOfStockAxis<br>= mgnx_UndesignatedPreferredStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_PreferredStockSharesOutstanding[us-gaap_StatementClassOfStockAxis=mgnx_UndesignatedPreferredStockMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesOutstanding<br>/ us-gaap_StatementClassOfStockAxis<br>= mgnx_UndesignatedPreferredStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=mgnx_SeriesAOnePreferredStockMember', window );">Series A-1 Preferred Stock [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares of common stock allocated</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_SharesIssued[us-gaap_StatementClassOfStockAxis=mgnx_SeriesAOnePreferredStockMember]" onclick="toggleNextSibling(this);">13,604,016</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharesIssued<br>/ us-gaap_StatementClassOfStockAxis<br>= mgnx_SeriesAOnePreferredStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ConvertiblePreferredStockConversionPrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Convertible preferred stock conversion price.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_ConvertiblePreferredStockConversionPrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_StockIssuanceCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Costs related to the issuance or offering of stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_StockIssuanceCosts</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Stock issued during period, shares to underwriters for exercise of over allotment option.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">mgnx_StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of equity interests issued or issuable to acquire entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)(4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Exercise price per share or per unit of warrants or rights outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(i)(4))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(i)(2))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph i<br><br> -Subparagraph 2<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued for each share of convertible preferred stock that is converted.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendRatePerDollarAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount per share used to calculated dividend payments on preferred stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PreferredStockDividendRatePerDollarAmount</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Price of a single share of a number of saleable stocks of a company.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SharePrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SharesIssued</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 4<br><br> -Subparagraph (SAB TOPIC 4.C)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section C<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of new stock issued during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=mgnx_SeriesD2ConvertiblePreferredStockMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=mgnx_SeriesD2ConvertiblePreferredStockMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=mgnx_SeriesA1PreferredStockMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=mgnx_SeriesA1PreferredStockMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=mgnx_SeriesA2PreferredStockMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=mgnx_SeriesA2PreferredStockMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=mgnx_SeriesAOnePreferredStockMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=mgnx_SeriesAOnePreferredStockMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=mgnx_SeriesD2PreferredStockMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=mgnx_SeriesD2PreferredStockMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=mgnx_UndesignatedPreferredStockMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=mgnx_UndesignatedPreferredStockMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EPCAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation and Principles of Consolidation</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 <b><i>Basis of Presentation and Principles of
 Consolidation</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The consolidated financial statements include the accounts of
 MacroGenics, Inc. and its wholly owned subsidiaries, MacroGenics UK
 Limited and MacroGenics West, Inc. Effective December&#xA0;22,
 2014, MacroGenics West, Inc. was merged with and into MacroGenics,
 Inc. All intercompany accounts and transactions have been
 eliminated in consolidation. The Company currently operates in one
 operating segment. Operating segments are defined as components of
 an enterprise about which separate discrete information is
 available for the chief operating decision maker, or decision
 making group, in deciding how to allocate resources and assessing
 performance. The Company views its operations and manages its
 business in one segment, which is developing monoclonal
 antibody-based therapeutics for cancer, autoimmune and infectious
 diseases.</p>
 </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Use of Estimates</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The preparation of the financial statements in accordance with
 generally accepted accounting principles (GAAP) requires the
 Company to make estimates and judgments in certain circumstances
 that affect the reported amounts of assets, liabilities, revenues
 and expenses, and related disclosure of contingent assets and
 liabilities. In preparing these consolidated financial statements,
 management has made its best estimates and judgments of certain
 amounts included in the financial statements, giving due
 consideration to materiality. On an ongoing basis, the Company
 evaluates its estimates, including those related to revenue
 recognition, fair values of assets, stock-based compensation,
 preferred stock warrant liability, income taxes, pre-clinical study
 and clinical trial accruals and other contingencies. Management
 bases its estimates on historical experience or on various other
 assumptions that it believes to be reasonable under the
 circumstances. Actual results could differ from these
 estimates.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 In addition, prior to the Company&#x2019;s IPO in October 2013, the
 Company utilized estimates and assumptions in determining the fair
 value of its common stock. The Company granted stock options at
 exercise prices not less than the fair value of its common stock as
 determined by the Board of Directors, with input from management.
 Management used contemporaneous valuations in estimating the fair
 value of its common stock. The board of directors determined the
 estimated fair value of the common stock based on a number of
 objective and subjective factors, including external market
 considerations affecting the biotechnology industry and the
 historic prices at which the Company sold shares of its preferred
 stock.</p>
 </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Cash and Cash Equivalents</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The Company considers all investments in highly liquid financial
 instruments with an original maturity of three months or less at
 the date of purchase to be cash equivalents. Cash and cash
 equivalents consist of certificates of deposit and investments in
 money market funds with commercial banks and financial
 institutions. Cash equivalents are stated at amortized cost, plus
 accrued interest, which approximates fair value.</p>
 </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Accounts Receivable</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Accounts receivable that management has the intent and ability to
 collect are reported in the consolidated balance sheets at
 outstanding amounts, less an allowance for doubtful accounts. The
 Company writes off uncollectible receivables when the likelihood of
 collection is remote.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The Company evaluates the collectability of accounts receivable on
 a regular basis. The allowance, if any, is based upon various
 factors including the financial condition and payment history of
 customers, an overall review of collections experience on other
 accounts and economic factors or events expected to affect future
 collections experience. No allowance was recorded as of
 December&#xA0;31, 2014 or 2013, as the Company has a history of
 collecting on all outstanding accounts.</p>
 </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Restricted Cash</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The Company is required to maintain certificates of deposit that
 serve as collateral for various operating leases and corporate
 credit card accounts. Amounts classified as restricted cash on the
 consolidated balance sheets are $300,000 and $405,000 at
 December&#xA0;31, 2014 and 2013, respectively.</p>
 </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Fair Value of Financial Instruments</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The fair market values of the financial instruments included in the
 financial statements, which include cash equivalents and money
 market accounts, approximate their carrying values at
 December&#xA0;31, 2014 and 2013, due to their short-term
 maturities. The Company accounts for recurring and non-recurring
 fair value measurements in accordance with the Financial Accounting
 Standards Board (FASB) Accounting Standards Codification (ASC) 820,
 <i>Fair Value Measurements and Disclosures</i> (ASC 820). ASC 820
 defines fair value, establishes a fair value hierarchy for assets
 and liabilities measured at fair value, and requires expanded
 disclosures about fair value measurements. The ASC 820 hierarchy
 ranks the quality of reliability of inputs, or assumptions, used in
 the determination of fair value and requires assets and liabilities
 carried at fair value to be classified and disclosed in one of the
 following three categories:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr>
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">Level 1&#x2014;Fair value is
 determined by using unadjusted quoted prices that are available in
 active markets for identical assets and liabilities.</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr>
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">Level 2&#x2014;Fair value is
 determined by using inputs other than Level 1 quoted prices that
 are directly or indirectly observable. Inputs can include quoted
 prices for similar assets and liabilities in active markets or
 quoted prices for identical assets and liabilities in inactive
 markets. Related inputs can also include those used in valuation or
 other pricing models, such as interest rates and yield curves that
 can be corroborated by observable market data.</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr>
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">Level 3&#x2014;Fair value is
 determined by inputs that are unobservable and not corroborated by
 market data. Use of these inputs involves significant and
 subjective judgments to be made by a reporting entity&#xA0;&#x2013;
 e.g., determining an appropriate adjustment to a discount factor
 for illiquidity associated with a given security.</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The Company evaluates financial assets and liabilities subject to
 fair value measurements on a recurring basis to determine the
 appropriate level at which to classify them each reporting period.
 This determination requires the Company to make subjective
 judgments as to the significance of inputs used in determining fair
 value and where such inputs lie within the ASC 820 hierarchy.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 18pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%">
 Financial assets and liabilities subject to fair value measurements
 were as follows (in thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0">
 <tr>
 <td width="43%"></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"><b>Fair Value Measurements at
 December&#xA0;31, 2014</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Quoted&#xA0;Prices&#xA0;in</b><br />
 <b>Active Markets<br />
 for</b><br />
 <b>Identical Assets</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Significant&#xA0;Other</b><br />
 <b>Observable<br />
 Inputs</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Significant</b><br />
 <b>Unobservable</b><br />
 <b>Inputs</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Total</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Level 1</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Level 2</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Level 3</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Assets:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Cash and cash equivalents</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">131,545</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">131,545</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Money market funds</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">26,046</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">26,046</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Restricted cash</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">300</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">300</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Total Assets</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">157,891</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">157,891</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1pt">
 <td height="16"></td>
 <td height="16" colspan="16"></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"><b>Fair Value Measurements at
 December&#xA0;31, 2013</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Quoted Prices in</b><br />
 <b>Active Markets<br />
 for</b><br />
 <b>Identical Assets</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Significant Other</b><br />
 <b>Observable<br />
 Inputs</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Significant</b><br />
 <b>Unobservable</b><br />
 <b>Inputs</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Total</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Level 1</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Level 2</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Level 3</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Assets:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Cash and cash equivalents</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">90,434</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">90,434</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Money market funds</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">26,047</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">26,047</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Restricted cash</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">405</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">405</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Total Assets</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">116,886</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">116,886</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The Company&#x2019;s Level 1 securities primarily consist of
 restricted cash, cash equivalents and money market funds. The
 Company determines the estimated fair value for its Level 1
 securities using quoted (unadjusted) prices for identical assets or
 liabilities in active markets.</p>
 </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Concentration of Credit Risk</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Substantially all of the Company&#x2019;s cash and cash equivalents
 are maintained with major financial institutions in the United
 States. Deposits held with banks may exceed the amount of insurance
 provided on such deposits. Generally, these deposits may be
 redeemed upon demand and, therefore, bear minimal risk.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Financial instruments that potentially subject the Company to
 concentrations of credit risk consist principally of cash and cash
 equivalents, and accounts receivable. The counterparties are
 various corporations, financial institutions and government
 agencies of high credit standing.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 For the years ended December&#xA0;31, 2014, 2013 and 2012, the
 Company&#x2019;s collaboration revenue relates to agreements with
 Takeda Pharmaceutical Company Limited (Takeda), Les Laboratoires
 Servier and Institut de Recherches Servier (collectively, Servier),
 Gilead Sciences, Inc. (Gilead), Boehringer Ingelheim GmbH
 (Boehringer), Pfizer, Inc. (Pfizer), Eli Lilly&#xA0;&amp; Co. (Eli
 Lilly) and Green Cross Corp. (Green Cross). Grant revenue is
 related to contracts and research grants received from U.S.
 government agencies. The majority of the outstanding receivables
 are due from the Company&#x2019;s collaborators and U.S. government
 agencies.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%">
 The following table includes those collaborators that represent
 more than 10% of total revenue earned in the periods indicated:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <tr>
 <td width="66%"></td>
 <td valign="bottom" width="9%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center">
 <b>Year&#xA0;Ended&#xA0;December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">
 <b>&#xA0;&#xA0;&#xA0;&#xA0;2014&#xA0;&#xA0;&#xA0;&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">
 <b>&#xA0;&#xA0;&#xA0;&#xA0;2013&#xA0;&#xA0;&#xA0;&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">
 <b>&#xA0;&#xA0;&#xA0;&#xA0;2012&#xA0;&#xA0;&#xA0;&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Servier</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">36.4</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">51.6</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">17.3</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Boehringer</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">28.6</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">24.8</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">18.4</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Takeda</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">16.8</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Gilead</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">11.4</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">13.8</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Eli Lilly</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.9</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1.4</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">48.9</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The following table includes those collaborators that represent
 more than 10% of accounts receivable at the date indicated:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="75%"></td>
 <td valign="bottom" width="10%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="9%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">
 <b>&#xA0;&#xA0;&#xA0;&#xA0;2014&#xA0;&#xA0;&#xA0;&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">
 <b>&#xA0;&#xA0;&#xA0;&#xA0;2013&#xA0;&#xA0;&#xA0;&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Servier</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">33.3</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6.4</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Boehringer</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">21.2</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">12.2</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Green Cross</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">17.9</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Gilead</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">53.4</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Pfizer</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">12.3</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Property and Equipment</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Property and equipment are stated at cost. Upon retirement or sale,
 the cost of assets disposed of and the related accumulated
 depreciation are removed from the accounts and any resulting gain
 or loss is credited or charged to operations. Repairs and
 maintenance costs are expensed as incurred. Depreciation is
 computed using the straight-line method over the following
 estimated useful lives:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="55%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Computer equipment</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">3 years</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Software</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">3 years</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Furniture</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">10 years</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Laboratory and office equipment</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">5 years</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Leasehold improvements</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 Shorter&#xA0;of&#xA0;lease&#xA0;term&#xA0;or&#xA0;useful&#xA0;life</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Impairment of Long-Lived Assets</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The Company assesses the recoverability of its long-lived assets in
 accordance with the provisions of ASC&#xA0;360, <i>Property, Plant
 and Equipment</i>. ASC 360 requires that long-lived assets be
 reviewed for impairment whenever events or changes in circumstances
 indicate that the carrying amount of an asset may not be
 recoverable. Recoverability of the long-lived asset is measured by
 a comparison of the carrying amount of the asset to future
 undiscounted net cash flows expected to be generated by the asset
 or asset group. If carrying value exceeds the sum of undiscounted
 cash flows, the Company then determines the fair value of the
 underlying asset group. Any impairment to be recognized is measured
 by the amount by which the carrying amount of the asset group
 exceeds the estimated fair value of the asset group. Assets to be
 disposed of are reported at the lower of the carrying amount or
 fair value, less costs to sell. As of December&#xA0;31, 2014 and
 2013, the Company determined that there were no impaired assets and
 had no assets held-for-sale.</p>
 </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 <b><i>Income Taxes</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Deferred tax assets and liabilities are determined based on
 differences between the financial reporting and tax basis of assets
 and liabilities and are measured using the enacted tax rates and
 laws that are expected to be in effect when the differences are
 expected to reverse. The effect on deferred tax assets and
 liabilities of a change in tax rates is recognized as income in the
 period that such tax rate changes are enacted. The measurement of a
 deferred tax asset is reduced, if necessary, by a valuation
 allowance if it is more likely than not that some portion or all of
 the deferred tax asset will not be realized. Financial statement
 recognition of a tax position taken or expected to be taken in a
 tax return is determined based on a more-likely-than-not threshold
 of that position being sustained. If the tax position meets this
 threshold, the benefit to be recognized is measured as the largest
 amount that is more likely than not to be realized upon ultimate
 settlement. The Company&#x2019;s policy is to record interest and
 penalties related to uncertain tax positions as a component of
 income tax expense.</p>
 </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenues</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Revenues</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 2%; MARGIN-TOP: 6pt">
 <i>Revenue Recognition</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The Company enters into collaboration and license agreements with
 collaborators for the development of monoclonal antibody-based
 therapeutics to treat cancer and other complex diseases. The terms
 of these agreements contain multiple deliverables which may include
 (i)&#xA0;licenses, or options to obtain licenses, to the
 Company&#x2019;s technological platforms, such as its Fc
 Optimization and Dual-Affinity Re-Targeting (DART) technologies,
 (ii)&#xA0;rights to future technological improvements,
 (iii)&#xA0;research and development activities to be performed on
 behalf of the collaborator or as part of the collaboration, and
 (iv)&#xA0;the manufacture of pre-clinical or clinical materials for
 the collaborator. Payments to the Company under these agreements
 may include nonrefundable license fees, option fees, exercise fees,
 payments for research and development activities, payments for the
 manufacture of pre-clinical or clinical materials, license
 maintenance payments, payments based upon the achievement of
 certain milestones and royalties on product sales. Other benefits
 to the Company of these agreements include the right to sell
 products resulting from the collaborative efforts of the parties in
 specific geographic territories. The Company follows the provisions
 of the FASB ASC Topic 605-25, <i>Revenue
 Recognition&#x2014;Multiple-Element Arrangements</i>, and ASC Topic
 605-28, <i>Revenue Recognition&#x2014;Milestone Method</i>, in
 accounting for these agreements. In order to account for these
 agreements, the Company must identify the deliverables included
 within the agreement and evaluate which deliverables represent
 separate units of accounting based on the achievement of certain
 criteria, including whether the delivered element has stand-alone
 value to the collaborator. The consideration received is allocated
 among the separate units of accounting, and the applicable revenue
 recognition criteria are applied to each of the separate units.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 For the periods presented, the Company had the following two types
 of agreements: 1) exclusive development and commercialization
 licenses to use the Company&#x2019;s technology and/or certain other
 intellectual property to develop compounds against specified
 targets (referred to herein as exclusive licenses); and 2)
 Option/research agreements to secure on established terms,
 development and commercialization licenses to therapeutic product
 candidates to collaborator-selected targets developed by the
 Company during an option period (referred to herein as
 right-to-develop agreements).</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 There are no performance, cancellation, termination or refund
 provisions in any of the arrangements that contain material
 financial consequences to the Company.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 2%; MARGIN-TOP: 18pt">
 <i>Exclusive Licenses</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The deliverables under an exclusive license agreement generally
 include the exclusive license to the Company&#x2019;s DART
 technology with respect to a specified antigen target, and may also
 include deliverables related to rights to future technological
 improvements, research and pre-clinical development activities to
 be performed on behalf of the collaborator. In some cases the
 Company may have an option to participate in the co-development of
 product candidates that result from such agreements.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Generally, exclusive license agreements contain nonrefundable terms
 for payments and, depending on the terms of the agreement, provide
 that the Company will (i)&#xA0;at the collaborator&#x2019;s request,
 provide research and pre-clinical development services at
 negotiated prices which are generally consistent with what other
 third parties would charge, (ii)&#xA0;earn payments upon the
 achievement of certain milestones, (iii)&#xA0;earn royalty
 payments, and (iv)&#xA0;in some cases grant the Company an option
 to participate in the development and commercialization of products
 that result from such agreements. Royalty rates may vary over the
 royalty term depending on the Company&#x2019;s intellectual property
 rights and whether the Company exercises any co-development and
 co-commercialization rights. The Company may provide technical
 assistance and share any technology improvements with its
 collaborators during the term of the collaboration agreements.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The Company does not directly control when any collaborator will
 achieve milestones or become liable for royalty payments.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 When entering into a new collaboration arrangement or materially
 modifying an existing arrangement, the Company must identify the
 deliverables included within the agreement and evaluate which
 deliverables represent separate units of accounting based on the
 achievement of certain criteria, including whether the delivered
 element has stand-alone value to the collaborator. The selling
 prices of deliverables under an arrangement may be derived using
 third-party evidence (TPE), or a best estimate of selling price
 (BESP), if vendor specific objective evidence (VSOE) is not
 available. The objective of BESP is to determine the price at which
 the Company would transact a sale if the element within the license
 agreement was sold on a standalone basis. Establishing BESP
 involves management&#x2019;s judgment and considers multiple
 factors, including market conditions and company-specific factors,
 including those factors contemplated in negotiating the agreements,
 as well as internally developed models that include assumptions
 related to market opportunity, discounted cash flows, estimated
 development costs, probability of success and the time needed to
 commercialize a product candidate pursuant to the license. In
 validating the BESP, management considers whether changes in key
 assumptions used to determine the BESP will have a significant
 effect on the allocation of the arrangement consideration between
 the multiple deliverables. Deliverables under the arrangement are
 separate units of accounting if (i)&#xA0;the delivered item has
 value to the customer on a standalone basis and (ii)&#xA0;if the
 arrangement includes a general right of return relative to the
 delivered item, delivery or performance of the undelivered item is
 considered probable and substantially within the Company&#x2019;s
 control. The arrangement consideration that is fixed or
 determinable at the inception of the arrangement is allocated to
 the separate units of accounting based on their relative selling
 prices. The appropriate revenue recognition model is applied to
 each element and revenue is accordingly recognized as each element
 is delivered. Management exercises significant judgment in
 determining whether a deliverable is a separate unit of
 accounting.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 In determining the separate units of accounting, the Company
 evaluates whether the exclusive license has standalone value to the
 collaborator based on consideration of the relevant facts and
 circumstances for each arrangement. Factors considered in this
 determination include the research and development capabilities of
 the collaborator and the availability of relevant research
 expertise in the marketplace. In addition, the Company considers
 whether or not (i)&#xA0;the collaborator could use the license for
 its intended purpose without the receipt of the remaining
 deliverables, (ii)&#xA0;the value of the license was dependent on
 the undelivered items and (iii)&#xA0;the collaborator or other
 vendors could provide the undelivered items. If the Company
 concludes that the license has stand-alone value and therefore will
 be accounted for as a separate unit of accounting, the Company then
 determines the estimated selling prices of the license and all
 other units of accounting based on market conditions, similar
 arrangements entered into by third parties, and entity-specific
 factors such as the terms of the Company&#x2019;s previous
 collaboration agreements, recent pre-clinical and clinical testing
 results of therapeutic product candidates that use the
 Company&#x2019;s technology platforms, the Company&#x2019;s pricing
 practices and pricing objectives, the likelihood that technological
 improvements will be made, the likelihood that technological
 improvements made will be used by the Company&#x2019;s collaborators
 and the nature of the research services to be performed on behalf
 of its collaborators and market rates for similar services. Total
 arrangement consideration is then allocated to each of the units of
 accounting using the relative-selling-price method. If facts and
 circumstances dictate that the exclusive license does not have
 stand-alone value, then the related payments are deferred and
 revenue is recognized throughout the period of performance.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Management reassesses the period of performance over which the
 Company recognizes deferred upfront license fees and makes
 adjustments as appropriate in the period in which a change in the
 estimated period of performance is identified. In the event a
 collaborator elects to discontinue development of a specific
 product candidate under a single target license, but retains its
 right to use the Company&#x2019;s technology to develop an
 alternative product candidate to the same target or a target
 substitute, the Company would cease amortization of any remaining
 portion of the upfront fee until there is substantial pre-clinical
 activity on another product candidate and its remaining period of
 substantial involvement can be estimated. In the event that a
 single target license were to be terminated, the Company would
 recognize as revenue any portion of the upfront fee that had not
 previously been recorded as revenue, but was classified as deferred
 revenue, at the date of such termination or through the remaining
 substantial involvement in the wind down of the agreement.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Upfront payments on exclusive licenses may be recognized upon
 delivery of the license if facts and circumstances dictate that the
 license has stand-alone value from the undelivered elements, which
 generally include rights to future technological improvements,
 research services and the manufacture of pre-clinical and clinical
 materials.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The Company recognizes revenue related to research and pre-clinical
 development services that represent separate units of accounting as
 they are performed, as long as there is persuasive evidence of an
 arrangement, the fee is fixed or determinable, and collection of
 the related receivable is probable. The Company recognizes revenue
 related to the rights to future technological improvements over the
 estimated term of the applicable license.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The Company typically performs research activities and pre-clinical
 development services, including generating and engineering product
 candidates, on behalf of its licensees during the early evaluation
 and pre-clinical testing stages of drug development under its
 exclusive licenses. The Company records amounts received for
 research materials produced or services performed as revenue from
 collaborative research.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The Company&#x2019;s license agreements have milestone payments
 which for reporting purposes are aggregated into three categories:
 (i)&#xA0;development milestones, (ii)&#xA0;regulatory milestones,
 and (iii)&#xA0;sales milestones. Development milestones are
 typically payable when a product candidate initiates or advances
 into different clinical trial phases. Regulatory milestones are
 typically payable upon submission for marketing approval with the
 U.S. Food and Drug Administration (FDA) or other countries&#x2019;
 regulatory authorities or on receipt of actual marketing approvals
 for the compound or for additional indications. Sales milestones
 are typically payable when annual sales reach certain levels.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 At the inception of each agreement that includes milestone
 payments, the Company evaluates whether each milestone is
 substantive and at risk to both parties on the basis of the
 contingent nature of the milestone. This evaluation includes an
 assessment of whether (i)&#xA0;the consideration is commensurate
 with either (a)&#xA0;the entity&#x2019;s performance to achieve the
 milestone, or (b)&#xA0;the enhancement of the value of the
 delivered item(s) as a result of a specific outcome resulting from
 the entity&#x2019;s performance to achieve the milestone,
 (ii)&#xA0;the consideration relates solely to past performance and
 (iii)&#xA0;the consideration is reasonable relative to all of the
 deliverables and payment terms within the arrangement. The Company
 evaluates factors such as the scientific, regulatory, commercial
 and other risks that must be overcome to achieve the respective
 milestone, the level of effort and investment required to achieve
 the respective milestone and whether the milestone consideration is
 reasonable relative to all deliverables and payment terms in the
 arrangement in making this assessment.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Non-refundable development and regulatory milestones that are
 expected to be achieved as a result of the Company&#x2019;s efforts
 during the period of substantial involvement are considered
 substantive and are recognized as revenue upon the achievement of
 the milestone, assuming all other revenue recognition criteria are
 met. Milestones that are not considered substantive because the
 Company does not contribute effort to the achievement of such
 milestones are generally achieved after the period of substantial
 involvement and are recognized as revenue upon achievement of the
 milestone, as there are no undelivered elements remaining and no
 continuing performance obligations, assuming all other revenue
 recognition criteria are met.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 2%; MARGIN-TOP: 18pt">
 <i>Right-to-Develop Agreements</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The Company&#x2019;s right-to-develop agreements provide
 collaborators with an exclusive option to obtain licenses to
 develop and commercialize in specified geographic territories
 product candidates developed by the Company under agreed upon
 research and pre-clinical development product programs. The product
 candidates resulting from each program are all directed to a
 specific target selected by the collaborator. Under these
 agreements, fees may be due to the Company (i)&#xA0;at the
 inception of the arrangement (referred to as &#x201C;upfront&#x201D;
 fees or payments), (ii)&#xA0;the selection of a target for a
 program, (iii)&#xA0;upon the exercise of an option to acquire a
 development and commercialization license (referred to as exercise
 fees or payments earned) for a program, or (iv)&#xA0;some
 combination of all of these fees.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The accounting for right-to-develop agreements is dependent on the
 nature of the options granted to the collaborator. Options are
 considered substantive if, at the inception of a right-to-develop
 agreement, the Company is at risk as to whether the collaborator
 will choose to exercise the options to secure development and
 commercialization licenses. Factors that are considered in
 evaluating whether options are substantive include the overall
 objective of the arrangement, the benefit the collaborator might
 obtain from the agreement without exercising the options, the cost
 to exercise the options relative to the total upfront
 consideration, and the additional financial commitments imposed on
 the collaborator as a result of exercising the options.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 For right-to-develop agreements where the options to secure
 development and commercialization licenses to a product program are
 considered substantive, the Company does not consider the
 development and commercialization licenses to be a deliverable at
 the inception of the agreement, and therefore defers any upfront
 payments received and recognizes this revenue over the period
 during which the collaborator could elect to exercise options for
 development and commercialization licenses. These periods are
 specific to each collaboration agreement. If a collaborator selects
 a target for a product program, any substantive option fee is
 deferred and recognized over the life of the option. For
 right-to-develop agreements that include multiple deliverables, the
 Company determines the selling prices of deliverables under the
 arrangement using TPE or a BESP, if VSOE is not available. The
 objective of BESP is to determine the price at which the Company
 would transact a sale if the element within the right-to-develop
 agreement was sold on a standalone basis. Establishing BESP
 involves management&#x2019;s judgment and considers multiple
 factors, including market conditions and company-specific factors,
 including those factors contemplated in negotiating the agreements,
 as well as internally developed models that include assumptions
 related to market opportunity, discounted cash flows, estimated
 development costs, probability of success and the time needed to
 commercialize a product candidate pursuant to the right-to-develop
 agreement. In validating the BESP, management considers whether
 changes in key assumptions used to determine the BESP will have a
 significant effect on the allocation of the arrangement
 consideration between the multiple deliverables. Deliverables under
 the arrangement are separate units of accounting if (i)&#xA0;the
 delivered item has value to the customer on a standalone basis and
 (ii)&#xA0;if the arrangement includes a general right of return
 relative to the delivered item, delivery or performance of the
 undelivered item is considered probable and substantially within
 the Company&#x2019;s control. The arrangement consideration that is
 fixed or determinable at the inception of the arrangement is
 allocated to the separate units of accounting based on their
 relative selling prices. The appropriate revenue recognition model
 is applied to each element and revenue is accordingly recognized as
 each element is delivered. Management exercises significant
 judgment in determining whether a deliverable is a separate unit of
 accounting.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 If a collaborator exercises an option and acquires a development
 and commercialization license to a product program, the Company
 attributes the exercise fee to the development and
 commercialization license. The Company determines the selling price
 of the option license, upon exercise, through management&#x2019;s
 best estimate using the process for an exclusive license as
 described above.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Upon exercise of an option to acquire a development and
 commercialization license, the Company would also attribute any
 remaining deferred option fee, in addition to the consideration
 received for the license upon exercise of the option, to the
 development and commercialization license. The Company then applies
 the multiple-element revenue recognition criteria to the
 development and commercialization license and other deliverables,
 if any, to determine the appropriate revenue recognition method.
 This model is consistent with the Company&#x2019;s accounting policy
 for upfront payments on exclusive licenses (discussed above). In
 the event a right-to-develop agreement were to be terminated, the
 Company would recognize as revenue any portion of the upfront fee
 that had not previously been recorded as revenue, but was
 classified as deferred revenue, at the date of such termination.
 The Company&#x2019;s right-to-develop agreements have been
 determined to contain substantive options.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 For right-to-develop agreements where the options to secure
 development and commercialization licenses to product programs are
 not considered substantive, the Company considers the development
 and commercialization licenses to be a deliverable at the inception
 of the agreement and applies the multiple-element revenue
 recognition criteria to determine the appropriate revenue
 recognition. The Company does not directly control when any
 collaborator will exercise its options for development and
 commercialization licenses.</p>
 </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Research and Development Costs</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Research and development expenditures are expensed as incurred.
 Research and development costs primarily consist of employee
 related expenses, including salaries and benefits, expenses
 incurred under agreements with contract research organizations,
 investigative sites and consultants that conduct the
 Company&#x2019;s clinical trials, the cost of acquiring and
 manufacturing clinical trial materials and other allocated
 expenses, license fees for and milestone payments related to
 in-licensed products and technologies, stock-based compensation
 expense, and costs associated with non-clinical activities and
 regulatory approvals.</p>
 </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Income (Loss)</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Comprehensive Income (Loss)</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Comprehensive income (loss) is comprised of the net income (loss)
 and other changes in equity that are excluded from net income
 (loss). Comprehensive income (loss) equals net income (loss) for
 the years ended December&#xA0;31, 2014, 2013 and 2012.</p>
 </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-based Compensation</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Stock-based Compensation</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Stock-based payments are accounted for in accordance with the
 provisions of ASC&#xA0;718, <i>Compensation&#x2014;Stock
 Compensation</i>. The fair value of stock-based payments is
 estimated, on the date of grant, using the Black-Scholes model. The
 resulting fair value is recognized ratably over the requisite
 service period, which is generally the vesting period of the
 option.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 For all time-vesting awards granted, expense is amortized using the
 straight-line attribution method. For awards that contain a
 performance condition, expense is amortized using the accelerated
 attribution method. Recognition of stock-based compensation expense
 is based on the value of the portion of stock-based awards that is
 ultimately expected to vest during the period.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The Company utilizes the Black-Scholes model for estimating fair
 value of its stock options granted. Option valuation models,
 including the Black-Scholes model, require the input of highly
 subjective assumptions, and changes in the assumptions used can
 materially affect the grant-date fair value of an award. These
 assumptions include the risk-free rate of interest, expected
 dividend yield, expected volatility and the expected life of the
 award.</p>
 </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Income (Loss) Per Share</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Net Income (Loss) Per Share</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Basic income (loss) per common share is determined by dividing
 income (loss) attributable to common stockholders by the
 weighted-average number of common shares outstanding during the
 period, without consideration of common stock equivalents. Diluted
 income (loss) per share is computed by dividing the earnings (loss)
 attributable to common stockholders by the weighted-average number
 of common share equivalents outstanding for the period. The
 treasury stock method is used to determine the dilutive effect of
 the Company&#x2019;s stock option grants, potential Employee Stock
 Purchase Plan awards and warrants and the if-converted method is
 used to determine the dilutive effect of the Company&#x2019;s
 preferred stock.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 For the year ended December&#xA0;31, 2012, net income (loss) per
 share was calculated under the two-class method under which all
 earnings (distributed and undistributed) are allocated to each
 class of common stock and participating securities based on their
 respective rights to receive dividends. In the event that the Board
 of Directors declared a dividend payable in cash or other property
 on the then-outstanding shares of common stock, the holders of the
 Series&#xA0;A-1, A-2, B, C, D, and D-2 convertible preferred stock
 would be entitled to receive the amount of dividends per share of
 preferred stock that would be payable on the largest number of
 whole shares of common stock into which each share of preferred
 stock could then be converted. Therefore, the Series A-1, A-2, B,
 C, D and D-2 are participating securities. All of the outstanding
 shares of Series&#xA0;A-1, A-2, B, C, D, and D-2 convertible
 preferred stock converted to common stock upon the consummation of
 the Company&#x2019;s IPO in October 2013.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%">
 Basic and diluted income (loss) per common share is computed as
 follows (in thousands except share and per share data):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0">
 <tr>
 <td width="58%"></td>
 <td valign="bottom" width="9%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"><b>Year Ended
 December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Net income (loss)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(38,313</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(261</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">8,362</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Less: undistributed earnings allocated to participating
 securities</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(8,362</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Net income (loss) allocable to common shares</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(38,313</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(261</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Basic weighted average common shares outstanding</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">27,384,990</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,847,697</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,083,276</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Basic income (loss) per common share</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(1.40</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.04</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">0.00</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Net income (loss)</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(38,313</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(261</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">8,362</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Less: undistributed earnings allocated to participating securities
 and other add-backs to net income (loss)</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(8,362</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Net income (loss) allocable to common shares</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(38,313</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(261</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Basic weighted average common shares outstanding</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">27,384,990</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,847,697</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,083,276</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Effect of dilutive securities</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Diluted weighted average common shares outstanding</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">27,384,990</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,847,697</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,083,276</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Diluted income (loss) per common share</p>
 </td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(1.40</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.04</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">0.00</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The following common stock equivalents were excluded from the
 calculation of diluted net income (loss) per share because their
 effect would be anti-dilutive:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0">
 <tr>
 <td width="63%"></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"><b>Year Ended
 December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Series A-1 Preferred Stock</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,156,114</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Series A-2 Preferred Stock</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">392,274</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Series B Preferred Stock</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,336,037</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Series C Preferred Stock</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,909,906</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Series D Preferred Stock</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">769,468</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Series D-2 Preferred Stock</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,391,991</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Effect of Converted Preferred Stock</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">13,189,920</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Warrants to purchase Series D-2 Preferred Stock</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">180,784</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Stock Options</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,094,904</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,313,970</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,249,702</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Standards</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Recently Issued Accounting Standards</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 In May 2014, the FASB issued ASU No.&#xA0;2014-09, <i>Revenue from
 Contracts with Customers</i> (ASU 2014-09). ASU 2014-09 will
 eliminate transaction- and industry-specific revenue recognition
 guidance under current GAAP and replace it with a principle-based
 approach for determining revenue recognition. ASU 2014-09 will
 require that companies recognize revenue based on the value of
 transferred goods or services as they occur in the contract. The
 ASU also will require additional disclosure about the nature,
 amount, timing and uncertainty of revenue and cash flows arising
 from customer contracts, including significant judgments and
 changes in judgments and assets recognized from costs incurred to
 obtain or fulfill a contract. ASU 2014-09 is effective for annual
 reporting periods beginning after December&#xA0;15, 2016. Early
 adoption is not permitted. Entities can transition to the standard
 either retrospectively or as a cumulative effect adjustment as of
 the date of adoption. Management is currently assessing what effect
 the adoption of ASU 2014-09 will have on the Company&#x2019;s
 consolidated financial statements and accompanying notes.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 In July 2013, the FASB issued ASU No.&#xA0;2013-11, which amended
 ASC Topic 740 regarding presentation of an unrecognized tax benefit
 when a net operating loss (NOL) carryforward, a similar tax loss,
 or a tax credit carryforward exists. The amendments in ASU
 No.&#xA0;2013-11 require an entity to present an unrecognized tax
 benefit as a reduction of a deferred tax asset for an NOL
 carryforward, or similar tax loss or tax credit carryforward,
 rather than as a liability when (1)&#xA0;the uncertain tax position
 would reduce the NOL or other carryforward under the tax law of the
 applicable jurisdiction and (2)&#xA0;the entity intends to use the
 deferred tax asset for that purpose. The ASU does not require new
 recurring disclosures. This amendment was effective prospectively
 for fiscal years beginning after December&#xA0;15, 2013, and did
 not have a material impact on the Company&#x2019;s financial
 statements.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The Company has evaluated all other ASUs issued through the date
 the consolidated financials were issued and believes that the
 adoption of these will not have a material impact on the
 Company&#x2019;s consolidated financial statements.</p>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 305<br><br> -SubTopic 10<br><br> -Section 05<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Financial Reporting Release (FRR)<br><br> -Number 203<br><br> -Paragraph 02-03<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 305<br><br> -SubTopic 10<br><br> -Section 05<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Financial Reporting Release (FRR)<br><br> -Number 203<br><br> -Paragraph 02-03<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-03.1(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Subparagraph a<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18726-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (b),(f(1))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for comprehensive income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for credit risk.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 825<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28088331&amp;loc=SL29635902-196195<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13531-108611<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 21<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13537-108611<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6875567&amp;loc=d3e14489-108613<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 825<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6480020&amp;loc=d3e61082-112788<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 825<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6480020&amp;loc=d3e61044-112788<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for determining the fair value of financial instruments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13279-108611<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 60<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 5<br><br> -Section CC<br><br> -Subsection 3<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 05<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6390181&amp;loc=d3e202-110218<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 19<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32840-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 30<br><br> -Section 05<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6423966&amp;loc=d3e40913-109327<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 954<br><br> -SubTopic 740<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 17<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32809-109319<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e32247-109318<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e32280-109318<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 13<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Research and Development<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6523717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18726-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 13<br><br> -Section B<br><br> -Paragraph Question 1<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 13.B.Q1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18823-107790<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for trade and other accounts receivables. This disclosure may include the basis at which such receivables are carried in the entity's statements of financial position (for example, net realizable value), how the entity determines the level of its allowance for doubtful accounts, when impairments, charge-offs or recoveries are recognized, and the entity's income recognition policies for such receivables, including its treatment of related fees and costs, its treatment of premiums, discounts or unearned income, when accrual of interest is discontinued, how the entity records payments received on nonaccrual receivables and its policy for resuming accrual of interest on such receivables.  If the enterprise holds a large number of similar loans, disclosure may include the accounting policy for the anticipation of prepayments and significant assumptions underlying prepayment estimates for amortization of premiums, discounts, and nonrefundable fees and costs.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 3, 4<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6378556&amp;loc=d3e10133-111534<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35738203&amp;loc=d3e5093-111524<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15<br><br> -Subparagraph (d)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35738203&amp;loc=d3e5212-111524<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6143-108592<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6132-108592<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6061-108592<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
